id|nct_id|intervention_type|name|description
79803047|NCT02628470|Procedure|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
79309172|NCT04786431|Other|Blood collection for lipid profiling by LC-MS|Blood withdrawal
79638210|NCT03536871|Dietary Supplement|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
79638211|NCT03536871|Other|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
79638212|NCT03487471|Diagnostic Test|Real-time elastography|Breast ultrasound with real-time elastography
79638213|NCT03487471|Diagnostic Test|Shear wave elastography|Breast ultrasound with shear wave elastography
79803048|NCT02628470|Procedure|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
79803049|NCT02628470|Procedure|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
79803050|NCT00855894|Drug|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
79803051|NCT00855894|Drug|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
79309173|NCT03232697|Diagnostic Test|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
79638214|NCT03428932|Device|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
79638215|NCT03428932|Other|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
79638216|NCT03417531|Dietary Supplement|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
79803052|NCT02566096|Drug|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
79473895|NCT02240485|Behavioral|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
79473896|NCT00003039|Drug|alvocidib|
79473897|NCT04246203|Other|Liquid Biopsy|17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.
79473898|NCT02534649|Procedure|Newly obtained biopsy and Blood samples collection|"For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
79638217|NCT03417531|Dietary Supplement|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
79638218|NCT03417531|Procedure|Active Exercise|Program includes five strength exercises that can be easily performed at home
79638219|NCT03417531|Procedure|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
79638220|NCT03386487|Drug|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
79803053|NCT02622594|Drug|Aminolevulinic Acid (ALA)|
79803054|NCT02622594|Device|Environ Cosmetic Roller|
79638221|NCT03386487|Drug|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
79803055|NCT02622594|Device|BLU-U IIlluminator|
79803056|NCT02628860|Drug|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
79803057|NCT04874272|Other|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
79967496|NCT04904718|Device|DreaMed Advisor Pro|Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
79473899|NCT00003045|Device|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
79473900|NCT00003045|Radiation|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
79638222|NCT03375918|Other|CONSULT-BP Educational Intervention|"The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias."
79638223|NCT03361345|Drug|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
79638224|NCT03361345|Drug|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
79638225|NCT03312686|Diagnostic Test|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
79638226|NCT03256201|Behavioral|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
79638227|NCT03256201|Behavioral|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
79638228|NCT03256201|Behavioral|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
79638229|NCT03245866|Other|Observational/ no intervention|
79638230|NCT03216187|Drug|Pregabalin|pregabalin 150 mg capsules
79638231|NCT03216187|Drug|Placebos|capsules identical to pregabalin but without active drug
79803058|NCT00674726|Other|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
79803059|NCT00855816|Behavioral|Breathing training|relaxation training
79803060|NCT04061668|Other|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
79984296|NCT03206944|Drug|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
79473901|NCT02490813|Dietary Supplement|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
79473902|NCT02490813|Dietary Supplement|Placebo|Placebo will be starch with colorings
79473903|NCT00003063|Biological|recombinant interferon alfa|
79473904|NCT00003063|Drug|fluorouracil|
79473905|NCT00003063|Drug|leucovorin calcium|
79473906|NCT00003063|Drug|levamisole hydrochloride|
79473907|NCT03793881|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
79473908|NCT03793881|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
79473909|NCT00003075|Drug|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
79473910|NCT00003075|Other|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
79473911|NCT00383175|Other|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
79473912|NCT00003081|Biological|filgrastim|
79473913|NCT00003081|Drug|busulfan|
79473914|NCT00003081|Drug|melphalan|
79638232|NCT03195270|Drug|[18F]FDG|10 mCi of [18F]FDG via the antecubital vein in a bolus injection
79813578|NCT01565785|Behavioral|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
79638233|NCT03195270|Device|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
79638234|NCT03172754|Drug|Nivolumab|PD-1 inhibitor
79813579|NCT00818038|Drug|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
79638235|NCT03172754|Drug|Axitinib|Tyrosine kinase inhibitor
79309174|NCT03232697|Diagnostic Test|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
79473915|NCT00003081|Drug|thiotepa|
79473916|NCT00003081|Procedure|peripheral blood stem cell transplantation|
79473917|NCT00003081|Radiation|radiation therapy|
79473918|NCT02348385|Drug|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
79473919|NCT00003087|Drug|cisplatin|
79473920|NCT00003087|Drug|paclitaxel|
79638236|NCT03123913|Drug|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
79638237|NCT03123913|Drug|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
79473921|NCT00003087|Procedure|surgical procedure|
79473922|NCT00003087|Radiation|radiation therapy|
79473923|NCT00003093|Biological|filgrastim|
79473924|NCT00003093|Biological|sargramostim|
79473925|NCT00003093|Drug|carboplatin|
79473926|NCT00003093|Drug|cyclophosphamide|
79473927|NCT00003093|Drug|doxorubicin hydrochloride|
79473928|NCT00003093|Drug|etoposide|
79473929|NCT00003093|Procedure|conventional surgery|
79473930|NCT00003093|Procedure|neoadjuvant therapy|
79473931|NCT04149535|Device|Sentinel® Cerebral Protection System|cerebral embolic protection system
79473932|NCT00003099|Drug|Fenretinide|Daily for 14-28 days.
79473933|NCT00003099|Drug|Tamoxifen Citrate|Daily for 14-28 days.
79473934|NCT00003099|Other|Placebo|Daily for 14-28 days
79473935|NCT04137445|Other|Baby Foods|Commercially available baby foods
79473936|NCT04137445|Other|Foods from the home|Caregiver will provide participant with usual foods from the home
79473937|NCT02294799|Other|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization
79473938|NCT02294799|Other|Placebo group|Nonspecific Mandibular Movement.
79473939|NCT00003105|Biological|filgrastim|
79473940|NCT00003105|Drug|cisplatin|
79473941|NCT00003105|Drug|doxorubicin hydrochloride|
79473942|NCT00003105|Drug|gemcitabine hydrochloride|
79473943|NCT00003105|Drug|ifosfamide|
79473944|NCT00003105|Drug|paclitaxel|
79473945|NCT05228197|Diagnostic Test|Biopsy & Imaging|H&E stained prostate biopsy slides from standard of care treatment
79473946|NCT00003111|Drug|carboplatin|
79473947|NCT00003111|Drug|cisplatin|
79473948|NCT00003111|Drug|irinotecan hydrochloride|
79473949|NCT00003111|Drug|paclitaxel|
79473950|NCT00003111|Procedure|neoadjuvant therapy|
79473951|NCT00003111|Procedure|surgical procedure|
79473952|NCT00003111|Radiation|radiation therapy|
79473953|NCT04329897|Behavioral|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
79473954|NCT00003117|Drug|carboplatin|
79473955|NCT00003117|Drug|paclitaxel|
79473956|NCT02240329|Behavioral|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
79473957|NCT02240329|Behavioral|Respiratory measures|We will collect measures of cough airflow and breathing strength.
79813580|NCT00482053|Procedure|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
79473958|NCT02240329|Drug|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
79473959|NCT04329741|Behavioral|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
79638238|NCT03067467|Drug|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
79638239|NCT03067467|Drug|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
79638240|NCT03066258|Genetic|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
79813581|NCT00482053|Procedure|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
79473960|NCT03751605|Procedure|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
79638241|NCT03054155|Device|Alexandrite Laser|Alexandrite 755nm hair removal laser
79473961|NCT02241811|Drug|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
79473962|NCT02241811|Drug|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
79473963|NCT00003123|Drug|amifostine trihydrate|
79473964|NCT03739905|Device|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
79473965|NCT03981523|Drug|Benznidazole|50 mg and 100 mg tablet taken orally
79473966|NCT03981523|Drug|Nifurtimox|120 mg tablet taken orally
79638242|NCT03039985|Device|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
79638243|NCT03039985|Device|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
79638244|NCT03028831|Dietary Supplement|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
79638245|NCT03028831|Dietary Supplement|Resistant starch|70g high-amylose maize starch
79638246|NCT03024255|Drug|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
79638247|NCT03024255|Drug|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
79638248|NCT03024255|Drug|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
79638249|NCT03024255|Drug|Vehicle (Placebo)|Placebo, applied once to each axilla daily
79638250|NCT03007238|Biological|Aldesleukin|Given SC
79813582|NCT00482053|Procedure|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
79813583|NCT00482053|Drug|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
79309175|NCT04793997|Biological|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
79473967|NCT03965923|Drug|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
79473968|NCT03965923|Drug|Truvada Tablet|Tablet taken orally
79473969|NCT03962725|Drug|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
79473970|NCT03962725|Drug|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
79473971|NCT03820219|Device|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
79638251|NCT03007238|Procedure|Extracorporeal Photopheresis|Undergo ECP
79638252|NCT03007238|Other|Laboratory Biomarker Analysis|Correlative studies
79638253|NCT03007238|Other|Quality-of-Life Assessment|Ancillary studies
79638254|NCT02902198|Dietary Supplement|Placebo|Tap water 200ml
79309176|NCT04793997|Biological|Placebo spray|Throat spray
79309177|NCT03107351|Device|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
79309178|NCT03107351|Device|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
79309179|NCT04786509|Diagnostic Test|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
79309180|NCT03107273|Other|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
79309181|NCT04800003|Diagnostic Test|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
79309182|NCT03202823|Procedure|blood samples|3 tubes (5 ml volume) collected during surgery
79309183|NCT03202823|Procedure|recover samples of atheromatous plaque|a carotid sample collected during surgery
79309184|NCT04794465|Diagnostic Test|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
79309185|NCT03203057|Other|coronary occlusion|percutaneous coronary intervention
79309186|NCT03202745|Other|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
79309187|NCT03202745|Other|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
79309188|NCT04799457|Other|Suture technique|We wil apply additional sutures to classical caesarean procedure.
79309189|NCT03202589|Other|FOCUS Echocardiography|FOCUS Echocardiography
79473972|NCT03820219|Other|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
79309190|NCT04799613|Other|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
79309191|NCT04799613|Other|visual loading|visual loading (walking through narrow pathway using VR)
79473973|NCT03775837|Dietary Supplement|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
79473974|NCT03775837|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks
79473975|NCT02251561|Device|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
79638255|NCT02902198|Dietary Supplement|Glucose|25g Glucose in 200ml tap water
79638256|NCT02902198|Dietary Supplement|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
79638257|NCT02902198|Dietary Supplement|Quinine|17mg quinine in 200ml tap water
79638258|NCT02858869|Biological|Pembrolizumab|Given IV
79638259|NCT02858869|Radiation|Stereotactic Radiosurgery|Undergo SRS
79638260|NCT02852031|Other|Collaborative Learning Network|
79638261|NCT02849717|Behavioral|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
79638262|NCT02811523|Drug|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
79638263|NCT02800551|Radiation|dose-intensified image-guided SBRT using simultaneous integrated boost|
79638264|NCT02800551|Radiation|External 3-dimensional conformal radiotherapy (3D-CRT)|
79638265|NCT02774694|Device|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
79638266|NCT02751138|Procedure|Surgery|Tumor resection
79638267|NCT02750319|Drug|Amiodarone|
79638268|NCT02750319|Drug|N-Acetylcysteine|
79638269|NCT02750319|Drug|Placebo|
79803061|NCT04061668|Other|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
79803062|NCT00708357|Drug|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
79803063|NCT00664976|Procedure|Electroconvulsive therapy|Electroconvulsive therapy
79803064|NCT00664976|Other|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
79803065|NCT00855738|Drug|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"Gabapentin: up to 3.600 mg/d~Lamotrigine: up to 400 mg/d~Levetiracetam: up to 3.000 mg/d~Pregabalin: up to 600 mg/d~Oxcarbazepine: up to 2.400 mg/d~Tiagabine: up to 30 mg/d~Topiramate: up to 400 mg/d~Zonisamide: up to 500 mg/d"
79638270|NCT02690766|Behavioral|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
79803066|NCT02628158|Procedure|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
79803067|NCT02628002|Device|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
79309192|NCT04799613|Other|dual task|dual task (serial subtraction using VR)
79309193|NCT04799613|Other|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
79309194|NCT03202433|Device|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
79309195|NCT03232619|Biological|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5*10~6/KgBW.
79309196|NCT04261959|Other|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
79473976|NCT02251561|Device|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
79473977|NCT02251561|Device|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
79473978|NCT02210559|Drug|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
79638271|NCT02688699|Procedure|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
79638272|NCT02669056|Other|5-HT measurement|
79638273|NCT02669056|Other|cerebral MRI|
79638274|NCT02669056|Other|Video recording|
79638275|NCT02669056|Other|EEG|
79638276|NCT02669056|Other|growth curves|
79638277|NCT02669056|Other|ASQ questionnaire|
79638278|NCT02637102|Other|Not applicable - observational study|
79638279|NCT02611258|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
79638280|NCT02529033|Device|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
79473979|NCT02210559|Drug|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
79473980|NCT02210559|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
79803068|NCT02628002|Device|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
79473981|NCT02991001|Procedure|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
79638281|NCT02512939|Procedure|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
79803069|NCT00665054|Drug|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
79803070|NCT00665054|Drug|Placebo|Matching placebo tablets orally prior to sexual activity
79803071|NCT02566798|Drug|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
79803072|NCT02566798|Drug|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
79803073|NCT00674960|Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
79803074|NCT02622516|Other|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
79803075|NCT02622516|Other|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
79803076|NCT00675038|Procedure|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2* MRI
79803077|NCT02622672|Dietary Supplement|water-soluble ubiquinol|100 mg/d
79803078|NCT02622672|Dietary Supplement|Placebo|glycerin.soy-lecithin, and water
79803079|NCT06157489|Other|Kinesio tape|Kinesiotape is applied on masseter muscle, orbi and infrahyoid muscles for facilitating suprahyoid muscle
79803080|NCT06157476|Other|Stretch-shortening exercise|The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
79309197|NCT04261959|Other|Physiotherapy|Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
79309198|NCT03232385|Device|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
79473982|NCT02991001|Procedure|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
79803081|NCT06157476|Other|Standard exercise program|The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
79803082|NCT06157450|Drug|ZSP1273|Participants receive ZSP1273 orally.
79309199|NCT03232385|Procedure|Renal Biopsy or Ablation|Standard of Care
79309200|NCT04793763|Other|traditional therapeutic exercises|group A will receive traditional exercises
79309201|NCT04793763|Other|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
79309202|NCT04793763|Other|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
79309203|NCT03232307|Drug|Dexamethasone|Given PO
79309204|NCT03232307|Drug|Ibrutinib|Given PO
79309205|NCT03232307|Drug|Lenalidomide|Given PO
79309206|NCT03232307|Biological|Rituximab|Given IV
79309207|NCT05615727|Drug|Dexmedetomidine|2 mcg/kg of undiluted dexmedetomidine [= 0.02 ml/kg] and oral placebo tablet
79309208|NCT05615727|Drug|Zolpidem|zolpidem 10 mg and intranasal saline 0.02 ml/kg
79309209|NCT05615727|Other|Placebo|a placebo oral tablet and intranasal saline at 0.02 ml/kg
79473983|NCT02991001|Device|Ultrasound|
79473984|NCT02991001|Drug|Normal Saline|
79490226|NCT03510481|Drug|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
79490227|NCT03510481|Drug|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
79490228|NCT03172520|Device|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
79473985|NCT03724357|Drug|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
79473986|NCT00003135|Drug|fluorouracil|
79473987|NCT00003135|Drug|pegylated liposomal doxorubicin hydrochloride|
79309210|NCT03202355|Device|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
79309211|NCT03202355|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
79473988|NCT00003135|Procedure|hyperthermia treatment|
79638282|NCT02497261|Procedure|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
79803083|NCT06157437|Device|Focal Pulse field Ablation|Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
79473989|NCT02135679|Radiation|Radiotherapy|
79473990|NCT03546205|Drug|JNJ-64565111|All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
79309212|NCT04785729|Drug|Almonertinib combine with Pyrrolitinib|110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
79638283|NCT02478853|Other|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
79638284|NCT02230124|Device|MRE|
79309213|NCT04785885|Diagnostic Test|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
79638285|NCT02218996|Other|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
79638286|NCT02172651|Drug|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
79638287|NCT02172651|Drug|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
79638288|NCT02144857|Drug|etanercept|50 mg
79638289|NCT02144857|Drug|ustekinumab|45 mg
79638290|NCT02144857|Drug|cyclosporine|Cyclosporine 2.5-3 mg/kgr
79638291|NCT02144857|Drug|Secukinumab|300 mg
79309214|NCT04785885|Diagnostic Test|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
79309215|NCT02450279|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
79309216|NCT02450279|Device|Vibrating-mesh nebulizer|
79309217|NCT02450279|Device|Jet Nebulizer|
79309218|NCT02450279|Other|Planar scintigraphy|
79309219|NCT02450279|Other|Preoperative spirometry|
79309220|NCT04793607|Other|Pleural procedures|Any pleural procedure that removes fluid
79309221|NCT03231839|Behavioral|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
79473991|NCT03731559|Drug|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
79473992|NCT03731559|Drug|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
79473993|NCT03728127|Dietary Supplement|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
79473994|NCT03728127|Dietary Supplement|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
79473995|NCT03507673|Diagnostic Test|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
79473996|NCT04943575|Dietary Supplement|EZC Pak|After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
79473997|NCT04943575|Dietary Supplement|EZC Pak +D|After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
79473998|NCT04943575|Dietary Supplement|Placebo|After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
79473999|NCT00003141|Biological|filgrastim|Given IV
79474000|NCT00003141|Drug|carboplatin|Given IV
79474001|NCT00003141|Drug|cisplatin|Given IV
79474002|NCT00003141|Drug|cyclophosphamide|Given IV
79638292|NCT02144857|Drug|Apremilast|30mg
79638293|NCT02095184|Drug|Anastrozole|1 mg daily
79638294|NCT02095184|Drug|Letrozole|2.5 mg daily
79638295|NCT02081157|Device|GalaFlex Mesh|
79638296|NCT01950234|Drug|ACTH|Acthar gel
79638297|NCT01950234|Drug|Placebo|Placebo
79803084|NCT06157398|Other|Increased EPA, DHA, fruit, and vegetable intake|Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
79474003|NCT00003141|Drug|etoposide|Given IV
79474004|NCT00003141|Drug|thiotepa|Given IV
79474005|NCT00003141|Drug|vincristine sulfate|Given IV
79474006|NCT00003141|Procedure|conventional surgery|
79474007|NCT00003141|Procedure|peripheral blood stem cell transplantation|
79803085|NCT06157385|Behavioral|Culinary Medicine|The CM group will receive virtually-delivered cooking demonstration videos every week and nutrition education videos every other week. The cooking demonstrations will provide them with visual instructions on how to incorporate lean beef into their diet. The nutrition education videos will be developed using the Nutrition Care Manual from the Academy of Nutrition and Dietetics and will cover the importance of maintaining adequate protein intake and ways to enhance it in the diet.
79309222|NCT03231839|Behavioral|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
79474008|NCT00003147|Biological|Ad5CMV-p53 gene|
79474009|NCT04867135|Drug|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
79474010|NCT02249455|Device|Acapella|Treatment time for 20 min twice daily
79309223|NCT03231839|Behavioral|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
79474011|NCT02249455|Other|ELTGOL|ELTGOL technique 20 min twice daily
79474012|NCT02249455|Other|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
79474013|NCT01738321|Other|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
79638298|NCT01555905|Device|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
79638299|NCT01252953|Drug|Anacetrapib|tablet, 100mg daily
79638300|NCT01252953|Drug|Placebo anacetrapib|tablet, 1 tablet daily
79638301|NCT01234480|Device|BD SurePath Plus Pap test|BD SurePath Plus Pap test
79638302|NCT01234480|Device|BD SurePath Pap test|BD SurePath Plus Pap test
79638303|NCT01234480|Procedure|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
79309224|NCT03231761|Other|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
79309225|NCT03231761|Other|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
79638304|NCT01234480|Device|HPV DNA test|digene HC2 HPV DNA test
79638305|NCT01183078|Procedure|free-hand|Free-hand technique utilizes x-rays to find screw holes.
79638306|NCT01183078|Procedure|Wand technique|Wand technique is utilized to find screw holes.
79638307|NCT00957489|Other|Dynamax appliance|
79638308|NCT00957489|Other|Twin-block appliance|
79309226|NCT04786041|Procedure|laparoscopic appendectomy|laparoscopic appendectomy
79474014|NCT01740817|Drug|Intralipid 20%|30 ml/h for 48 h
79474015|NCT01740817|Drug|Saline|30 ml/h for 48 h
79474016|NCT01742065|Other|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
79474017|NCT04806295|Other|any/all treatments for blood cancer|Following people undergoing any/all treatments for blood cancer.
79474018|NCT05642065|Other|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
79474019|NCT04633993|Behavioral|PCSMP|This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
79474020|NCT04581343|Drug|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
79474021|NCT04565743|Behavioral|Support on dentification and treatment of patients with high risk of osteoporotic fractures|Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
79474022|NCT01743859|Drug|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
79474023|NCT01743859|Drug|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
79474024|NCT01743859|Other|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
79474025|NCT01746043|Drug|Armodafinil|150 mg by mouth once a day for 6 weeks.
79474026|NCT01746043|Other|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
79474027|NCT01746043|Drug|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
79474028|NCT01746043|Behavioral|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
79474029|NCT05635903|Procedure|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
79474030|NCT05635903|Procedure|Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser|Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
79309227|NCT03231683|Drug|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
79803086|NCT06157385|Behavioral|Control|The CN group will receive virtually-delivered recipes every week centered on lean beef intake.
79309228|NCT03231683|Drug|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
79474031|NCT05635903|Procedure|Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
79474032|NCT01746511|Procedure|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
79638309|NCT00937131|Drug|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
79803087|NCT06157372|Diagnostic Test|targeted next-generation sequencing (tNGS)|To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
79803088|NCT06157359|Procedure|scalp nerve block|In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
79803089|NCT06157333|Device|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
79803090|NCT06157320|Drug|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
79803091|NCT06157320|Drug|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
79803092|NCT06157307|Device|Aortic compression|Aortic compression with four different methods on each participants
79309229|NCT03231683|Drug|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
79309230|NCT03231683|Drug|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
79309231|NCT04346979|Other|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
79309232|NCT04346979|Other|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
79309233|NCT03202277|Behavioral|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
79309234|NCT03202277|Behavioral|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
79309235|NCT03231605|Biological|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
79490229|NCT03172520|Device|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
79638310|NCT00877851|Behavioral|Computer-based Program|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
79655521|NCT04549636|Other|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
79655522|NCT04549636|Other|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
79655523|NCT04549636|Other|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
79655524|NCT04549636|Other|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
79655525|NCT04549636|Other|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
79655526|NCT04549441|Procedure|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
79638311|NCT00837616|Drug|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
79638312|NCT00837616|Drug|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
79638313|NCT00610051|Drug|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
79803093|NCT06157294|Procedure|Intra-articular pulsed radiofrequency|Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
79638314|NCT00476060|Procedure|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
79638315|NCT00176254|Radiation|Radiotherapy|80 centigray (cGy) on Day 1 & 2 and 22 & 23 of chemotherapy
79638316|NCT00176254|Drug|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
79638317|NCT00176254|Drug|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
79638318|NCT02950090|Behavioral|MobilWise|see arm description for MobilWise above
79638319|NCT02950090|Behavioral|Fitbit Only|see arm description for Fitbit above
79803094|NCT06157294|Procedure|Median branch pulsed radiofrequency|Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
79638320|NCT02950285|Other|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
79638321|NCT00166608|Procedure|Blood sampling|
79638322|NCT02949895|Drug|BMS-986012|
79803095|NCT06157281|Behavioral|Connect|A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
79803096|NCT06157268|Other|Natural history and non therapeutical therapy|"This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation."
79474033|NCT01746511|Drug|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
79474034|NCT01746745|Drug|[^14C]-LY2940680|Administered as solution by mouth
79474035|NCT01746979|Drug|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
79474036|NCT01746979|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
79638323|NCT02949895|Drug|Cisplatin|
79474037|NCT01746979|Drug|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
79474038|NCT04552171|Behavioral|Access to Game Plan app and 24-hour helpline|Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
79638324|NCT02949895|Drug|Etoposide|
79490230|NCT03109418|Drug|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
79490231|NCT03109418|Procedure|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
79490232|NCT03404167|Drug|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
79490233|NCT03771560|Drug|folinic acid|subject will take folinic acid daily for 12 weeks
79490234|NCT03404401|Drug|BLI4700|Oral bowel preparation
79490235|NCT03404401|Drug|Polyethylene glycol bowel preparation|Oral bowel preparation
79490236|NCT03767738|Drug|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
79638325|NCT02949622|Behavioral|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
79638326|NCT02949622|Other|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
79638327|NCT02949544|Other|water immersion|warm water immersion
79638328|NCT02949661|Procedure|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
79638329|NCT02949661|Procedure|Local wound infiltration|Patients will receive local wound infiltration
79638330|NCT02949583|Drug|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
79638331|NCT02949583|Drug|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
79638332|NCT00516841|Drug|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
79309236|NCT04798599|Other|Telemonitoring and teleorientation|"Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject."
79309237|NCT04798599|Other|Control Group - Waiting list|No intervention (at least, until the time frame for outcome assessment)
79474039|NCT05631535|Other|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
79638333|NCT04694599|Device|Low flow oxygen|Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
79309238|NCT03202199|Device|PET/MRI|2 PET/MRI examinations
79309239|NCT04793451|Behavioral|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
79638334|NCT00516880|Drug|rosiglitazone|
79638335|NCT02949739|Behavioral|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
79638336|NCT04694716|Other|No intervention|No intervention will be applied.
79638337|NCT04694677|Drug|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
79638338|NCT04694677|Drug|women receiving misoprostol|women receiving misoprostol in myomectomy
79638339|NCT00516958|Drug|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
79638340|NCT00516958|Drug|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
79638341|NCT00516958|Drug|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
79638342|NCT00517036|Dietary Supplement|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
79638343|NCT00517036|Dietary Supplement|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
79638344|NCT00517036|Dietary Supplement|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
79638345|NCT00517114|Drug|Rabeprazole 20mg twice daily|
79638346|NCT00517270|Drug|Rabeprazole 20mg twice daily|
79638347|NCT00517309|Biological|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
79638348|NCT00517309|Biological|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
79638349|NCT00517348|Biological|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
79638350|NCT00517387|Drug|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
79638351|NCT00517426|Drug|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
79638352|NCT00517465|Drug|Placebo|po bid
79638353|NCT00517465|Drug|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
79638354|NCT00517504|Drug|Methylphenidate|"1-week single blind placebo lead-in phase.~step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
79638355|NCT00517582|Drug|HOE-140|Subcutaneous at time 0 and 6 hours
79309240|NCT04793451|Behavioral|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
79638356|NCT00517582|Other|Placebo|Subcutaneous at time 0 and 6 hours
79309241|NCT03202121|Other|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
79309242|NCT03202121|Other|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
79309243|NCT03202121|Other|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
79309244|NCT03231449|Other|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
79309245|NCT03201887|Behavioral|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
79309246|NCT03201887|Behavioral|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
79309247|NCT02593773|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
79309248|NCT01526681|Other|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
79309249|NCT01526681|Other|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
79309250|NCT01526681|Other|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
79309251|NCT01526681|Device|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
79309252|NCT01526681|Procedure|Autologous Breast Reconstruction with Neurotization|
79474040|NCT05631535|Other|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
79474041|NCT01748227|Behavioral|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
79474042|NCT01748695|Drug|V158866|
79309253|NCT01526681|Procedure|Autologous Breast Reconstruction without Neurotization|
79474043|NCT01748695|Drug|Placebo|
79474044|NCT05614453|Drug|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
79474045|NCT05614453|Drug|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
79474046|NCT01750255|Other|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
79490237|NCT03989570|Procedure|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
79490238|NCT03989570|Procedure|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
79490239|NCT03989570|Other|control group|placebo
79490240|NCT03273673|Other|Biofeedback Intervention|Visual and Tactile Biofeedback
79490241|NCT04331990|Other|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
79474047|NCT01750255|Other|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
79638357|NCT00517621|Drug|Paclitaxel|
79638358|NCT00517621|Drug|EPO|
79638359|NCT00517738|Other|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
79638360|NCT00517738|Other|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
79638361|NCT04481165|Other|Survey|Oral interview and written questions
79638362|NCT02949856|Device|Mallinckrodt, COVIDIEN|
79638363|NCT02949856|Device|Endotracheal tube, Unomedica|
79638364|NCT02949817|Device|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
79638365|NCT02949817|Other|Conventional OT group|2. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
79803097|NCT06157229|Other|MAT|"The protocol consists of four phases: 1) immobilization phase, 2) early protective phase, 3) intermediate phase and 4) late phase. The detailed guideline can be found in the following article:~Gaunt, B. W., Shaffer, M. A., Sauers, E. L., Michener, L. A., McCluskey, G. M., & Thigpen, C. A. (2010). The American Society of Shoulder and Elbow Therapists' Consensus Rehabilitation Guideline for Arthroscopic Anterior Capsulolabral Repair of the Shoulder. Journal of Orthopaedic & Sports Physical Therapy, 40(3), 155-168. https://doi.org/10.2519/jospt.2010.3186"
79474048|NCT04339933|Diagnostic Test|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
79803098|NCT06157229|Other|CABRR|"The protocol consists of four phases: 1) immobilization phase, 2) early phase, 3) intermediate phase and 4) advanced phase.~The protocol comprises education, modified cognitive behavioral therapy, neuromuscular control exercises, kinetic chain exercises, range of motion enhancing exercises, strength and conditioning exercises, and sport-specific exercises. The protocol is currently unpublished."
79803099|NCT06157216|Drug|MRD-guided therapy|MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
79474049|NCT05605015|Behavioral|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
79474050|NCT01751971|Drug|Inspired oxygen (40%)|Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
79474051|NCT01751971|Other|Sham|Medical air with 21% oxygen via venturi mask (15 L/min).
79474052|NCT01754389|Drug|Tacrolimus|
79474053|NCT01754389|Drug|Methotrexate|
79474054|NCT01754389|Drug|Bortezomib|
79474055|NCT01754389|Drug|Sirolimus|
79474056|NCT04288453|Behavioral|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
79474057|NCT01754623|Drug|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
79474058|NCT01754623|Drug|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
79638366|NCT00166647|Procedure|Blood Sampling|
79638367|NCT00517777|Device|continuous positive airway pressure ventilation|nighttime
79638368|NCT00517777|Behavioral|dietary and life style recommendations|
79638369|NCT00517777|Behavioral|dietary and life style recommendations|
79638370|NCT00517816|Drug|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
79638371|NCT00517855|Biological|PRTX-100 (Staphylococcal protein A)|
79638372|NCT00151515|Drug|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
79638373|NCT00517894|Drug|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
79638374|NCT00517972|Drug|Omacor (omega-3-acid ethyl esters)|
79638375|NCT04478981|Other|No intervention|This concerns a natural history study; no interventions will be used
79638376|NCT00518050|Behavioral|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
79638377|NCT00518050|Behavioral|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
79638378|NCT00166686|Drug|Clonidine|
79638379|NCT00518128|Procedure|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
79638380|NCT00518128|Procedure|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
79638381|NCT02949778|Procedure|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
79638382|NCT02949778|Drug|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
79638383|NCT02949778|Drug|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
79638384|NCT00518245|Drug|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
79803100|NCT06157203|Device|Uterine electromyography|electromyographic and fetal electrocardiographic recordings will be obtained during threatened labor
79474059|NCT01754623|Drug|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
79474060|NCT01754623|Radiation|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
79638385|NCT00518362|Drug|TW|TW,120 mg/d
79638386|NCT00151554|Behavioral|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
79638387|NCT00518401|Biological|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
79638388|NCT02957903|Drug|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
79638389|NCT02957903|Drug|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
79638390|NCT00518479|Drug|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
79638391|NCT00518479|Drug|Valsartan 160mg OD; Moxonidine 400mcg OD|
79638392|NCT04694755|Drug|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
79638393|NCT04694755|Drug|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
79638394|NCT00166725|Drug|Octreotide LAR|
79638395|NCT00518518|Drug|Staloral 300|Staloral 300
79638396|NCT00518518|Drug|placebo|placebo
79638397|NCT00518557|Procedure|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
79638398|NCT00518596|Dietary Supplement|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
79803101|NCT06157190|Other|Unsupervised monitoring|"This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data."
79474061|NCT01754623|Other|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
79638399|NCT00151593|Other|Celsior®|Graft preservation solution
79638400|NCT00518635|Drug|Nutropin|Nutropin 0.1 mg/day self-administered once a day
79638401|NCT00518674|Procedure|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
79967497|NCT03913871|Behavioral|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
79309254|NCT04798443|Procedure|subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
79309255|NCT04798443|Procedure|open ureteral reimplantation (Lich-Gregoir)|The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
79309256|NCT04793139|Drug|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
79309257|NCT04793061|Other|blood sample collection|Blood is samples from peripheral vein during routine care
79474062|NCT01754623|Procedure|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
79474063|NCT01754623|Drug|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
79474064|NCT01755169|Drug|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
79474065|NCT01755169|Drug|Placebo|
79474066|NCT02073279|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
79474067|NCT02073279|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
79474068|NCT01755949|Drug|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
79474069|NCT01755949|Drug|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
79474070|NCT01756885|Drug|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
79474071|NCT01756885|Drug|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
79474072|NCT01756885|Behavioral|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
79474073|NCT04209907|Other|retrolaminar block tecnique|By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
79474074|NCT04172701|Drug|Long-acting Muscarinic Antagonists (LAMA)|drug
79474075|NCT04172701|Drug|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
79309258|NCT05234333|Drug|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
79309259|NCT02450045|Procedure|Continuous femoral nerve block|
79474076|NCT04151875|Device|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
79474077|NCT04151875|Device|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
79638402|NCT02949505|Behavioral|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
79638403|NCT00518752|Procedure|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
79638404|NCT00518752|Procedure|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
79803102|NCT06157164|Other|UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)|Simultaneous UroLift™ and Holmium Laser Enucleation of the Prostate (HoLEP) for the Treatment of BPH in Men with Prominent Median Lobe Desiring Preservation of Ejaculation
79638405|NCT00151632|Drug|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
79803103|NCT06157112|Other|Lifestyle behaviour (exposure in a observational study)|Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
79803104|NCT06157099|Drug|Atorvastatin|Given PO
79803105|NCT06157099|Drug|Placebo Administration|Given orally (PO)
79803106|NCT06157099|Procedure|Computed Tomography|Undergo CT
79803107|NCT06157099|Procedure|Magnetic Resonance Imaging|Undergo MRI
79803108|NCT06157099|Other|Electronic Health Record Review|Ancillary studies
79803109|NCT06157073|Device|Closed-loop ventilator|Fully automated closed-loop ventilator using the INTELLIVENT software
79638406|NCT00151632|Drug|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
79638407|NCT00518791|Other|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
79803110|NCT06157073|Device|Open-loop ventilator|Conventional closed-loop ventilator with manual adjustments by the physician in charge
79803111|NCT06157060|Diagnostic Test|circulating tumor DNA|blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
79803112|NCT06157047|Procedure|Crestal Bone Expansion obtained with the Magnetic Mallet®|A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
79309260|NCT02450045|Drug|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
79638408|NCT00518791|Other|Usual Care|No altered organisation of care
79803113|NCT06157034|Other|Placebo|Inert Material
79803114|NCT06157034|Dietary Supplement|Zingier officinale powder|The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.
79803115|NCT06157034|Dietary Supplement|Carum carvi, L powder|The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.
79803116|NCT06157034|Dietary Supplement|Mentha spicata oil|Mentha spicata L will be extracted in the form of oil and will be encapsulated.
79309261|NCT03201653|Procedure|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
79803117|NCT06157021|Procedure|Rotary pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby* rotary files and Endo Radar* rotary device).
79309262|NCT02593539|Drug|Nemiralisib|Participants will be administered nemiralisib
79309263|NCT00919763|Drug|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
79309264|NCT00919763|Drug|Vehicle Ointment, twice daily|Topical Ointment
79340333|NCT02440789|Drug|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
79638409|NCT00518830|Other|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
79638410|NCT00518830|Other|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
79638411|NCT02949232|Drug|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
79638412|NCT02949232|Drug|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
79803118|NCT06157021|Procedure|Manual pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani*)
79803119|NCT06156995|Device|Deep Acupuncture at Zhongliao Point to Stimulate Sacral Nerve|Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.
79803120|NCT06156995|Drug|Oral Mosapride Tablets|Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
79638413|NCT00151671|Drug|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
79803121|NCT06156969|Device|Robot-Assisted Gait Training|"Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes."
79803122|NCT06156956|Procedure|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation in capsules or suspension obtained from healthy unrelated donor introduced two times per treatment:~for capsules - FMT administration: day 7 (full dose) and days from 9 to 14 (prolonged intake regimen)~for suspension - FMT administration: day 7 and day 14"
79803123|NCT06156943|Device|individualized goal-directed fluid therapy by Starling device|For patients in optimized group, fluids will be managed by Starling device during the thoracic cancer surgery.
79638414|NCT00151671|Drug|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
79803124|NCT06156943|Device|group managed by standard of care|Patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols
79803125|NCT06156917|Diagnostic Test|diagnostic accuracy|Aims of the present project are: to investigate the relationship between incident PD dementia and multimodal parameters as cardiovascular autonomic dysfunction, altered cerebral glucose metabolism, and genetic biomarkers; development of an algorithm predictive for PD-related dementia, combining the rele- vant multidimensional parameters under study; longitudinal follow-up of clinical and cognitive status in PD patients with and without dementia along four years.
79803126|NCT06156891|Procedure|Toxicities reduced treatment|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
79803127|NCT06156891|Procedure|Conventional treatment|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
79803128|NCT06156878|Combination Product|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
79638415|NCT04694326|Diagnostic Test|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
79803129|NCT06156865|Behavioral|Intervention to address late talking|this intervention is designed to support both speech and language development in children who are toddlers. Given the age group of children their parents are part of the intervention program. Importantly the frequency of the intervention can range from once to twice per week, with timing also designed to complement the particular agency
79803130|NCT06156852|Other|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
79967498|NCT03913871|Behavioral|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
79309265|NCT05615571|Genetic|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
79309266|NCT05615571|Genetic|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
79309267|NCT00306917|Device|non-coated femoral hip stem|total hip replacement
79638416|NCT04694170|Other|additional therapy|Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.
79309268|NCT00306917|Device|coated femoral hip stem|total hip replacement
79638417|NCT04694170|Other|conventional physiotherapy|Using conventional physiotherapy only.
79638418|NCT00518908|Drug|Sevoflurane|3.2 Vol % for postconditioning
79655527|NCT00268398|Drug|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1&2) continuous 5FU 600mg/m² (day 1 to 2)
79655528|NCT00268398|Drug|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
79655529|NCT00235313|Procedure|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
79655530|NCT00235313|Drug|nicotine patch|normal following with a nicotine patch
79655531|NCT04549285|Biological|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10^6 cells/kg (up to a maximum dose of 100x10^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
79803131|NCT06156852|Other|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
79803132|NCT06156813|Diagnostic Test|Diagnostic test|Measurements for validity and reliability
79803133|NCT06156774|Other|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
79803134|NCT06156761|Drug|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m^2, 18 mg/m^2, 20 mg/m^2 and 22 mg/m^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
79803135|NCT06156761|Drug|Capecitabine|Capecitabine (1000 mg/m^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
79803136|NCT06156761|Drug|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m^2, 18 mg/m^2, 20 mg/m^2 and 22 mg/m^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
79803137|NCT06156761|Drug|Capecitabine|Capecitabine (825 mg/m^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
79803138|NCT06156748|Procedure|postoperative adjuvant transarterial chemoembolization|HCC patients received hepatectomy and PA-TACE.
79803139|NCT06156735|Other|Passive Music Therapy (P)|Music Therapy Intervention
79803140|NCT06156735|Other|Active Music Therapy (A)|Music Therapy Intervention
79803141|NCT06156735|Other|Standard Care Control Condition (C)|Without any intervention
79803142|NCT06156709|Procedure|Group I: Lower Volume with Higher Anaesthetic Concentration|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
79803143|NCT06156709|Procedure|Group II: Higher Volume with LowerAnaesthetic Concentration|20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
79803144|NCT06156683|Other|Multiple sclerosis disease modifying drug|There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.
79803145|NCT06156670|Device|PFO closure|"The operation of endovascular closure of PFO is performed on X-ray angiographic devices with digital processing of X-ray images. Endovascular closure of a PFO will be performed by femoral venous access using the following instruments: diagnostic catheter, diagnostic guidewire, high-stiffness guidewire for delivery system, interatrial septum occluders of PFO, UNI, ASD types.~Preoperative preparation and control of device implantation will be performed using modern echocardiographic equipment."
79803146|NCT06156657|Other|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
79803147|NCT06156631|Behavioral|DASH-ExMAMI|The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
79803148|NCT06156618|Dietary Supplement|Nitrate|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.
79803149|NCT06156605|Procedure|Sidelying lumbar manipulation|R sided lumbar manipulation
79803150|NCT06156592|Procedure|Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia|Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
79803151|NCT06156579|Drug|Decitabine|Decitabine 20 mg/m^2, i.v., once daily, 10 days
79803152|NCT06156579|Drug|Venetoclax|Venetoclax, 400 mg, p.o., once daily, 28 days
79803153|NCT06156566|Drug|Tecovirimat Oral Capsule|600 mg, twice daily, 14 days.
79340334|NCT02462083|Drug|IDP-118 Lotion|IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
79340335|NCT02538341|Biological|Herpes Zoster (HZ) Vaccine|
79803154|NCT06156566|Drug|Placebo|3 capsules, twice daily, 14 days.
79340336|NCT02538341|Drug|Placebo|
79340337|NCT05446181|Behavioral|Postoperative delirium|Postoperative delirium
79340338|NCT05446181|Procedure|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
79803155|NCT06156553|Behavioral|PULSE school-based intervention|"PULSE - School-based intervention is a feasibility study designed to support active travel among adolescents. The curricular intervention is designed to increase the students' health literacy as well as their autonomous motivation for active travel. The intervention will last for 6 weeks during fall 2023. The first session will be delivered by a science and education center, and the consecutive sessions will be delivered by teachers. PULSE sessions will contribute to the attainment of specific competence aims related to two interdisciplinary topics, Health and life skills and Sustainability, as defined in PE, social science, and science. The research question is the following: Can increased attention to the barriers and benefits of active travel increase physical activity for youths?"
79638419|NCT00518947|Drug|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
79803156|NCT06156527|Drug|Lazertinib|Lazertinib 240mg, QD, daily
79309269|NCT05615493|Device|radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session
79309270|NCT05615493|Device|sham radial extracorporeal shock wave therapy|Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), & frequency 4 Hz every week for one month without operating the machine .
79638420|NCT00518947|Drug|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
79638421|NCT00518947|Drug|verapamil plus lithium|
79803157|NCT06156527|Drug|Bevacizumab Injectable Product|Bevacizumab: 15mg/kg IV every 3 weeks
79803158|NCT06156501|Procedure|ACL Reconstruction|Reconstruction of the anterior cruciate ligament
79638422|NCT02949466|Drug|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
79803159|NCT06156488|Procedure|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone + polynucleotides and hyaluronic acid
79803160|NCT06156488|Procedure|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone
79638423|NCT02949466|Device|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
79638424|NCT00519064|Biological|Adjuvanted influenza vaccine|
79638425|NCT00151710|Drug|Pioglitazone|
79803161|NCT06156397|Other|Standard Physiotherapy Exercise Group|At the beginning of the treatment, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions. Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks.
79803162|NCT06156397|Other|Telerehabilitation Based Supervised Exercise Group|Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks. In the telerehabilitation group, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks at the beginning of the treatment, through a meeting with the patients via zoom application. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights.
79803163|NCT06156397|Other|Mobile Application Supported Exercise Group|With the videos uploaded to the Becure application, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied in the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. Between weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weight. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions.
79638426|NCT00519103|Other|exercise|
79638427|NCT00519181|Drug|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
79813584|NCT00482053|Drug|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
79813585|NCT00482053|Drug|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
79813586|NCT00482053|Drug|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
79803164|NCT06156384|Device|FITBONE® Lengthening Nail|"The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation."
79803165|NCT06156358|Other|No intervention|No intervention
79803166|NCT06156332|Drug|surufatinib、serplulimab|"surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment."
79803167|NCT06156319|Other|No intervention|No intervention
79803168|NCT06156306|Behavioral|CBT-I|The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
79803169|NCT06156306|Behavioral|CBT-I combined ACT|In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
79638428|NCT02949388|Drug|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
79803170|NCT06156293|Behavioral|Cognitive behavioral prevention program for insomnia (CBP-I)|CBP-I will be provided to participants once their districts are exposed.
79803171|NCT06156267|Drug|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
79803172|NCT06156267|Drug|mRNA tumor vaccines|neoantigen personalized mRNA vaccines
79803173|NCT06156254|Behavioral|Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
79803174|NCT06156241|Biological|Stem Cell|Stem cells derived from human cord tissue.
79803175|NCT06156228|Behavioral|Multilevel Intervention|Clinic patients from the randomly assigned intervention clinics will be provided with additional vaccine information and will have the opportunity to ask any questions they might have about any of the 4 study focused vaccines (COVID-19, Shingles, Pneumococcal, Influenza). Health educators will provide them with additional information, address any misinformation and disinformation and will offer to schedule their vaccine appointment(s) for them.
79984297|NCT03209596|Dietary Supplement|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
79984298|NCT03209596|Dietary Supplement|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
79638429|NCT02949388|Drug|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
79638430|NCT02949388|Drug|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
79638431|NCT00166803|Drug|Rosiglitazone|Rosiglitazone , 4 mg daily
79984299|NCT04454567|Drug|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
79638432|NCT02949310|Drug|Nefopam|
79309271|NCT03119129|Behavioral|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
79638433|NCT02949310|Drug|Normal Saline|
79638434|NCT00519220|Other|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
79638435|NCT02949349|Drug|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
79638436|NCT02949349|Drug|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
79638437|NCT02949349|Drug|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
79638438|NCT00166842|Drug|sirolimus, cyclosporine, tacrolimus|
79638439|NCT02949193|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
79638440|NCT02949193|Drug|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
79638441|NCT00519259|Drug|Lobeline|
79638442|NCT00519298|Drug|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
79638443|NCT00519298|Other|placebo|placebo
79638444|NCT00519298|Drug|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
79803176|NCT06156189|Dietary Supplement|Enteral Feeding|Feeding via Nasogastric tube in intubated and ventilated patients
79803177|NCT06156176|Other|COVIDEx|The program is delivered by physiotherapists and comprises of two 50-minute sessions each week for eight weeks. It is designed to be delivered by a physiotherapist either face-to-face or remotely in groups of 6 patients. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min).
79803178|NCT06156150|Biological|tumor vaccine|DC vaccine produced by the Team
79803179|NCT06156137|Other|Glucose variability|A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.
79309272|NCT02593305|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
79309273|NCT02593305|Dietary Supplement|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
79638445|NCT00519337|Drug|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
79803180|NCT06156124|Diagnostic Test|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
79803181|NCT06156111|Device|Transepithelial abutment group|Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm
79803182|NCT06156111|Device|Direct to implant group|It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
79638446|NCT00519337|Drug|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
79803183|NCT06156098|Other|No Intervention|No Intervention
79803184|NCT06156085|Drug|Vonoprazan and Amoxicillin|vonoprazan 20 mg and amoxicillin 1000 mg b.i.d. PC for 14days
79803185|NCT06156085|Drug|Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole|lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
79803186|NCT06156059|Drug|Oral Bedtime Melatonin|100 mg oral suspension or capsule given at bedtime
79803187|NCT06156059|Drug|Placebo suspension or capsule|Indistinguishable suspension or capsule
79803188|NCT06156046|Diagnostic Test|skin prick test|Skin prick test for bee venom
79803189|NCT06156046|Diagnostic Test|Blood tests|IgE/G and T cell tolerance studies
79638447|NCT00151749|Drug|Colesevelam hydrochloride|
79638448|NCT00519415|Other|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
79803190|NCT06156020|Procedure|Endoscopic endonasal surgery|Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas
79803191|NCT06155994|Drug|68Ga-DOTA-MGS5|intravenous administration
79803192|NCT06155955|Drug|"Emicizumab, HEMLIBRA®"|low dose
79803193|NCT06155942|Procedure|7 Tesla MRI|Patients will have a 7T MRI and questionnaires
79803194|NCT06155929|Behavioral|Flight|The participants are flying to turkey and back home. The flights are the intervention.
79803195|NCT06155916|Drug|Pregabalin|Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
79813587|NCT00482053|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
79813588|NCT00482053|Drug|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
79813589|NCT00482053|Drug|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
79813590|NCT00482053|Drug|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
79813591|NCT00482053|Drug|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
79309274|NCT03118973|Procedure|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
79309275|NCT02593149|Device|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
79340339|NCT02538107|Drug|Methoxy-polyethyleneglycol epoetin beta|
79803196|NCT06155903|Procedure|Spinal anesthesia|Spinal anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients in the lateral position with the fractured side up. A small dose of local anesthetic will be injected into the skin at the planned site of insertion. More local anesthetic will be then administered along the intended path of the spinal needle insertion to the estimated depth of the supraspinous ligament. This serves a dual purpose: additional anesthesia for the spinal needle insertion and identification of the correct path for spinal needle placement. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will be received Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg and will be maintained the lateral position for 15 min. At the end of these they will be gently placed in supine position.
79803197|NCT06155903|Procedure|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% (dose 9.375 mg) plus Mepivacaine 1% (dose 25 mg).~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
79803198|NCT06155903|Drug|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures were injected into the subarachnoid space for spinal anesthesia. It consisted of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg.
79803199|NCT06155903|Drug|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures were injected into selected peripheral nerves . It consisted of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
79803200|NCT06155877|Behavioral|Activité Vaccins et Vaccination - LAMAP|Two activities created by the La Main a la Pate foundation
79803201|NCT06155877|Behavioral|Kidivax Chatbot|A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
79474078|NCT04113421|Diagnostic Test|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
79803202|NCT06155851|Procedure|Upper Endoscopy|Endescopy
79803203|NCT06154161|Dietary Supplement|Whey protein supplement|A monthly supply of 35 g of whey protein isolate will be provided to participants in individual sachet packets with instructions of preparation. Every month, participants will come to the center to provide the standard monthly blood sample. At this time, the PI will have participants complete the quality-of-life instrument, ask if there have been any changes in their dietary habits, and collect weights for up to 6-months. Additionally, participants will indicate if they had consumed the protein daily and/or bring back their empty/full satchel packets. As this is a feasibility trial, it is necessary to determine the compliancy of consuming protein daily and the amount. Furthermore, understanding how protein markers may be affected by consumption of the protein daily vs less frequently throughout the week is important to establish improved recommendations for consumption of protein supplements.
79803204|NCT06152952|Procedure|The rhomboid flap approach|"The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed"
79803205|NCT06152341|Device|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
79474079|NCT01760239|Behavioral|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
79803206|NCT06151171|Dietary Supplement|CoQ10|"Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day."
79803207|NCT06150118|Behavioral|CBT+VR (Cognitive behavioral therapy and virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
79803208|NCT06150118|Behavioral|VR (Virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
79803209|NCT06150118|Behavioral|CBT (Cognitive behavioral therapy)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
79803210|NCT06150118|Behavioral|Control|The investigators are testing whether the placebo control protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
79803211|NCT06149650|Device|Shockwave Medical IVL System|Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.
79803212|NCT06149442|Other|Dose of five-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (five incisions).
79638449|NCT00519415|Other|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
79803213|NCT06149442|Other|Dose of ten-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (ten incisions).
79638450|NCT00519454|Other|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
79638451|NCT00519493|Procedure|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
79309276|NCT02448173|Biological|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
79803214|NCT06149442|Other|Dose of fifteen-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (fifteen incisions).
79813592|NCT00482053|Drug|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
79813593|NCT00482053|Drug|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
79967499|NCT03914027|Behavioral|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
79967500|NCT03243084|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
79309277|NCT02448173|Procedure|Surgery|Surgical resection of Stage II colon cancer
79309278|NCT04389411|Drug|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
79638452|NCT00519493|Device|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
79638453|NCT00519571|Device|ImplantLock device|dental implant
79638454|NCT00166881|Drug|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
79638455|NCT00519610|Other|Chart Review|Patients' charts will be reviewed for relevant medical information.
79638456|NCT02948998|Drug|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
79638457|NCT00151788|Drug|Pactimibe sulfate|
79638458|NCT00519688|Drug|Thalidomide|100 mg, BID
79638459|NCT00519688|Drug|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
79638460|NCT02948803|Behavioral|smartphone based intervention with Active Coach app|
79638461|NCT02948920|Drug|Ephedrine|9 mg of ephedrine (3 ml)
79638462|NCT02948920|Drug|NSS|3 ml of normal saline
79638463|NCT02948764|Device|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
79638464|NCT00519727|Drug|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
79638465|NCT00151827|Drug|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
79309279|NCT03231527|Procedure|coronary artery bypass grafting (CABG)|myocardial revascularization
79309280|NCT02448251|Drug|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
79803215|NCT06146231|Device|Motiva Flora® Tissue Expander|"This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant.~Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication.~To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study."
79967501|NCT03243084|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
79309281|NCT04792593|Biological|Senl-h19 CAR-T|Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
79309282|NCT03195569|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
79967502|NCT04353817|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
79967503|NCT04353817|Drug|IVA|Tablet for oral administration qd in the evening.
79474080|NCT01760473|Drug|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
79638466|NCT00151827|Drug|Losartan|Medications are taken once daily before breakfast with water.
79638467|NCT00151827|Drug|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
79984300|NCT04454567|Drug|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
79309283|NCT03195569|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
79638468|NCT00519805|Drug|dalteparin|
79638469|NCT00519805|Procedure|quality-of-life assessment|
79638470|NCT00519844|Drug|somatropin|
79638471|NCT00519883|Other|Exercise|
79638472|NCT00519883|Other|Supportive Care|
79638473|NCT00519922|Other|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion & agility, dynamic proprioception,functional strength & endurance.~Kinesthesia & Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability & confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia & balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
79638474|NCT00519922|Other|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal & external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
79638475|NCT02948881|Drug|ibandronate|
79638476|NCT00151866|Procedure|platelet transfusion|
79638477|NCT04457180|Drug|Apatinib Mesylate|Apatinib will be administered daily from on D5 through D16
79638478|NCT04457180|Drug|Repaglinide|Repaglinide will be administered daily on D1 and D12
79638479|NCT04457180|Drug|Bupropion|Bupropion will be administered daily on D2 and D13
79638480|NCT00519961|Device|Elecsys®proBNP|
79638481|NCT00520000|Drug|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
79638482|NCT00520000|Drug|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
79309284|NCT03195569|Drug|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
79309285|NCT03195569|Drug|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
79309286|NCT04792671|Behavioral|Sociodemographic variables|age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
79309287|NCT04792671|Behavioral|Family affluence scale (FAS)|a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
79803216|NCT06145620|Other|Physiotherapy|The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
79803217|NCT06139380|Drug|Ketamine|This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
79803218|NCT06139380|Drug|Sterile water|Intranasal sterile water was administered via syringe.
79803219|NCT06135740|Device|Fitbit wearing, with notification for sleep, activity and nutrition based fitbit data|Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data, and Nutritional supplementation and Promotion of Exercise
79803220|NCT06135740|Device|Routine care|Regular Care on sleep, activity and nutrition
79803221|NCT06134752|Other|Pulse field ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
79803222|NCT06134752|Other|Radiofrequency ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
79803223|NCT06134375|Drug|Tetrathiomolybdate|Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
79803224|NCT06134375|Drug|Capecitabine|1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
79803225|NCT06134375|Drug|Pembrolizumab|If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
79803226|NCT06124248|Behavioral|RISE intervention|"The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention (see image 1)."
79638483|NCT00520000|Drug|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
79803227|NCT06123325|Procedure|Clipping|Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
79803228|NCT06123325|Procedure|Endovascular embolization|Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.
79803229|NCT06112054|Device|Clotild Smart Guidewire System (CSGS)|In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
79803230|NCT06109506|Procedure|Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess|Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses > 4-5 cm, percutaneous image-guided drainage.
79803231|NCT06106503|Radiation|chest x-ray|chest x-ray after rigid bronchoscopy for patient with foreign body inhalation
79803232|NCT06106503|Other|clinical examination|no investigations well be done unless needed
79813594|NCT00482053|Drug|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
79309288|NCT04792671|Behavioral|Edinburgh postnatal depression scale (EPDS)|s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
79813595|NCT00455923|Drug|Seretide|Seretide
79813596|NCT00455923|Drug|Flixotide|Flixotide
79309289|NCT04792671|Behavioral|"Symptom Checklist 90 SCL 90:"|is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
79340340|NCT02538029|Behavioral|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
79340341|NCT02538029|Behavioral|Single Task Group|Performing motor or cognitive tasks alone.
79638484|NCT00520000|Drug|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
79638485|NCT00151905|Drug|3 % hypertonic saline|
79638486|NCT04453982|Other|Human milk donors|Human milk donors for the Rogers Hixon Ontario Human Milk Bank
79638487|NCT00520156|Device|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
79638488|NCT00520195|Behavioral|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
79638489|NCT02949115|Dietary Supplement|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
79309290|NCT03195881|Other|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
79309291|NCT04785495|Other|Quality-of-life assessment|Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
79309292|NCT02448017|Device|The Herbst appliance|Orthodontic functional appliance
79309293|NCT02448017|Device|Twin block appliance|Orthodontic functional appliance
79309294|NCT02447939|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
79309295|NCT02447939|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
79309296|NCT04785183|Dietary Supplement|Melatonin drops|Melatonin oral administration
79309297|NCT04785183|Other|Placebo|Oral 5% glucose
79309298|NCT03195725|Other|Review of notes|No intervention will occur
79309299|NCT04297917|Biological|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
79309300|NCT03195803|Behavioral|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
79638490|NCT02949115|Dietary Supplement|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
79638491|NCT02949115|Dietary Supplement|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
79638492|NCT02949115|Dietary Supplement|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
79638493|NCT00520273|Device|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
79638494|NCT00151944|Drug|SPD476 (mesalazine)|
79638495|NCT02949037|Other|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
79638496|NCT00520390|Drug|EZN-2208|
79967504|NCT04353817|Other|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
79638497|NCT00520429|Behavioral|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
79638498|NCT00520507|Drug|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
79638499|NCT00520507|Drug|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
79638500|NCT04694404|Drug|S-1,Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-10, q2w)
79638501|NCT04694365|Drug|Fluzoparib|A single oral dose of 50 mg Fluzoparib will be administered.
79967505|NCT04353817|Other|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
79967506|NCT05206760|Procedure|Brain biopsy|Biopsy of brain tissue
79309301|NCT03195491|Biological|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
79309302|NCT03195413|Procedure|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
79309303|NCT03195413|Drug|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
79309304|NCT03195413|Device|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
79309305|NCT03195335|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
79309306|NCT04792983|Other|No intervention|This is an observational study with no interventions.
79638502|NCT04406597|Device|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
79638503|NCT00151983|Drug|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
79638504|NCT00520585|Drug|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
79638505|NCT04392674|Device|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
79638506|NCT00520624|Device|inspiratory muscle strength training|
79340342|NCT05445401|Behavioral|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
79638507|NCT00520624|Procedure|Surgery|
79638508|NCT00520663|Drug|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
79803233|NCT06103019|Other|conventional complete denture|conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
79638509|NCT00152022|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
79638510|NCT03459001|Other|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
79638511|NCT00520702|Procedure|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
79638512|NCT00520702|Procedure|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
79638513|NCT00520780|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
79309307|NCT02447783|Dietary Supplement|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
79309308|NCT02447783|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
79309309|NCT04792905|Device|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
79638514|NCT00520780|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
79638515|NCT04723797|Other|Physical activity|Physical activity program consisting of running and/or cycling
79638516|NCT00520819|Drug|Antioxidant-rich food items|
79638517|NCT00520858|Other|Resistance Exercise (RE)|
79638518|NCT00520858|Other|Aerobic Exercise (AE)|
79638519|NCT00520858|Other|Resistance and Aerobic Exercise (RAE)|
79638520|NCT00152061|Drug|3TC and FTC|
79638521|NCT00520897|Drug|Raltegravir (MK0518)|400mg BID; 48 weeks
79638522|NCT00520897|Drug|Placebo|400mg QD
79638523|NCT00520897|Procedure|Leukopheresis|pack of cells as per protocol
79803234|NCT06103019|Other|3D complete denture|3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
79309310|NCT02447705|Drug|telbivudine|telbivudine replace Lamivudine
79638524|NCT00520897|Procedure|Sigmoid Biopsy|gut samples as per protocol
79340343|NCT05445401|Behavioral|Standard medical care|Traditional care
79638525|NCT00521092|Drug|sunitinib malate|Given orally
79803235|NCT06099184|Drug|EYP-1901|Intravitreal Injection
79803236|NCT06099184|Drug|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
79813597|NCT00642616|Drug|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
79340344|NCT05401331|Device|Treadmilll|Hemodynamic changes before and after treadmill use
79340345|NCT05401331|Other|mask|mask
79340346|NCT02272413|Drug|BI 695502|
79340347|NCT02272413|Drug|Avastin|
79340348|NCT02396381|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
79340349|NCT02396381|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
79638526|NCT00521092|Procedure|laboratory biomarker analysis|Correlative study
79638527|NCT00521092|Procedure|pharmacological study|Correlative study
79638528|NCT04376606|Procedure|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
79638529|NCT04376606|Procedure|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
79638530|NCT04376606|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
79638531|NCT00521131|Drug|Levocetirizine dihydrochloride|
79638532|NCT04694092|Drug|Intensive heart rate control with landiolol|Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
79638533|NCT04694092|Drug|Standard approach to heart rate control|Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
79638534|NCT00521170|Drug|Levocetirizine|
79803237|NCT06097689|Device|Lab Demo 1.0|"Lowering of the participants blood glucose with the application of insulin to induce hypoglycaemia, followed by the application of glucose to induce hyperglycaemia and finally insulin to restore euglycemia.~During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)."
79803238|NCT06096272|Device|Augment Reality Exergames|Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
79803239|NCT06094660|Procedure|Diagnostic genicular nerve block|Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.
79803240|NCT06094660|Procedure|Genicular nerve block with Radiofrequency Ablation (RFA)|"Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds."
79803241|NCT06094660|Procedure|Genicular nerve block with Phenol 6%|"Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary."
79803242|NCT06093945|Drug|SHR2554 tablet dosing|SHR2554 350mg taken on Day 1 and Day 10
79803243|NCT06093945|Drug|Omeprazole tablet dosing|Omeprazole taken from Days 5 to Day 10
79803244|NCT06092528|Other|Inspiratory muscle training|Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.
79803245|NCT06092528|Other|Upper extremity aerobic exercise training|Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.
79803246|NCT06092528|Other|Lower extremity aerobic exercise training|Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.
79803247|NCT06092528|Other|Resistant exercise training|Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.
79803248|NCT06092528|Other|Thoracic expansion exercises|The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.
79803249|NCT06090799|Drug|SHR-3032|Single dose at varying dosage levels depending on treatment assignment
79803250|NCT06090799|Drug|SHR-3032 Placebo|Single dose at varying dosage levels depending on treatment assignment
79803251|NCT06090396|Diagnostic Test|cardiac output monitoring with electrical cardiometry|comparison of limits of agreement between the two monitoring modalities
79803252|NCT06087198|Diagnostic Test|T-TAS 01 HD Assay|Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
79803253|NCT06087146|Other|Sauerkraut (Brassica oleracea v. capitata)|The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
79638535|NCT04376489|Behavioral|Messages (participants experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they experiencing negative affect & cigarettes are available.
79803254|NCT06086964|Other|therapeutic diet.|gluten and casein free diet.
79803255|NCT06086964|Other|physiotherapy|specific physiotherapy developmental program according to the pre evaluation of gross motor status.
79803256|NCT06085053|Drug|TQA3038 injection|TQA3038 is an injection.
79638536|NCT04376489|Behavioral|Messages (participants not experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they cigarettes are available.
79638537|NCT04376489|Behavioral|Messages (participants experiencing negative affect & cigarettes are not available)|Participants receive messages tailored for situations when they experiencing negative affect.
79638538|NCT04376489|Behavioral|Messages (participants not experiencing negative affect & cigarettes are not available)|Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
79638539|NCT04376489|Behavioral|Moodsurf|"Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood."
79638540|NCT04376489|Behavioral|Meditate|Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
79638541|NCT04376489|Behavioral|Joy|Smart phone app that teaches participants to practice breathing exercise.
79803257|NCT06085053|Drug|TQA3038 injection matching placebo|Placebo injection contains no active substance.
79803258|NCT06083493|Device|LIFUP excitation|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
79803259|NCT06083493|Device|LIFUP inhibition|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
79803260|NCT06083272|Device|Vitalthings Guardian M10 fixed and M10 mobile|VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
79638542|NCT04376489|Behavioral|Imagine|Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
79803262|NCT06076174|Other|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
79803263|NCT06071351|Other|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
79803264|NCT06071351|Other|Routine practice|An informative brochure prepared by the researcher was given.
79803265|NCT06070116|Drug|Ivermectin w/ Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
79803266|NCT06070116|Drug|Ivermectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
79803267|NCT06070116|Drug|Moxidectin + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
79340350|NCT05426291|Other|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
79803268|NCT06070116|Drug|Moxidectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
79803269|NCT06066749|Other|NIOSH certified N95 personal face covering (mask)|During the this final exposure session, participants will be randomly assigned to wear an N95 respirator (3M cat. #: 9205+). Participants will be instructed on how to wear the mask to ensure a proper fit before entering the chamber.
79803270|NCT06066749|Other|Surgical Mask|During the this final exposure session, participants will be randomly assigned to wear an ear loop style surgical mask. Participants will be instructed on how to wear the mask to ensure a proper fit before entering the chamber.
79803271|NCT06061978|Procedure|left bundle branch of His pacing|left bundle branch of His pacing
79803272|NCT06061978|Procedure|right ventricular pacing|right ventricular pacing
79803273|NCT06061068|Procedure|Hernia belt compression|Use the hernia belt to compress the inguinal region
79803274|NCT06057233|Diagnostic Test|mqMRI and GABA-MRS|multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
79803275|NCT06056180|Other|Balance Training|Participants will be given static and dynamic balance training with a balance platform game console (20 minutes) containing interactive video games based virtual reality for a total of 6 weeks.
79803276|NCT06056180|Other|Motor İmagery Training|For motor imagery training, two visualization scenarios will be created: anterior and posterior motor imagery. One of the visualization scenarios appropriate to each individual's needs will be used. Participants will be asked to perform kinesthetic or visual motor imagery in accordance with the scenario they listened to (10 minutes).
79803277|NCT06056180|Other|Action Observation Training|Action observation training will be done using video modeling method. The video content will include Nintendo Wii games in which the games that the person will play in that session are played by someone else and successful scores are achieved (10 minutes).
79803278|NCT06053125|Procedure|Adipose Tissue Biopsy|Fat sample collected from abdomen before exercise, immediately after exercise, and 3 hours after exercise
79984301|NCT04454567|Drug|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
79340351|NCT05648877|Device|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
79340352|NCT05424809|Behavioral|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
79803279|NCT06053125|Behavioral|Exercise|30 minutes of exercise on a cycle ergometer exercise machine
79803280|NCT06042400|Behavioral|Written Exposure Therapy|An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
79803281|NCT06038734|Diagnostic Test|gastric ultrasound|Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
79803282|NCT06038513|Device|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 24 hours
79803283|NCT06037915|Device|low flow oxygen with nasopharyngeal tube|low flow oxygen with nasopharyngeal tube
79803284|NCT06037915|Device|high flow oxygen with OptiflowTM Nasal High Flow|high flow oxygen with OptiflowTM Nasal High Flow
79309311|NCT04792125|Behavioral|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|"Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week."
79309312|NCT04792125|Behavioral|External electrical stimulation|Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
79638543|NCT04376489|Behavioral|Notice|Smart phone app that teaches participants to accept their thoughts and feelings.
79340353|NCT05648799|Drug|GP30341 capsules 200 mg|orall take of capsules twice a day
79340354|NCT05648799|Drug|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
79340355|NCT02120807|Drug|Certolizumab|
79638544|NCT04424147|Combination Product|HVA Regimens as Salvage Treatment|venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
79638545|NCT00521248|Drug|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
79638546|NCT00521248|Drug|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
79638547|NCT00167115|Drug|Alcohol|
79638548|NCT00521287|Other|Immune profiling and DC vaccine|"For observational study (immune profiling): blood sampling 3-5 mL~For DC vaccine: one dose of DC vaccine(~10 million cells)/2 week for at least 6 month or until progression."
79638549|NCT04370990|Device|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
79638550|NCT02948491|Other|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
79638551|NCT00521443|Procedure|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
79638552|NCT00167154|Drug|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
79638553|NCT04320563|Procedure|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
79638554|NCT00521482|Drug|Temozolomide|
79638555|NCT00521482|Drug|Temozolomide plus Thalidomide|
79638556|NCT00521521|Drug|docetaxel and cisplatin|
79638557|NCT00521521|Drug|docetaxel|
79638558|NCT00521560|Drug|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
79638559|NCT00152100|Procedure|Stem cell transplant|
79803285|NCT06036511|Drug|Ketamine Hydrochloride|"This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI."
79813598|NCT00642616|Drug|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
79967507|NCT01254695|Device|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
79340356|NCT02120807|Drug|cisplatin|
79340357|NCT02120807|Drug|pemetrexed|
79340358|NCT04457531|Drug|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
79638560|NCT00152100|Drug|Filgrastim, Alemtuzumab|
79638561|NCT00152100|Device|Miltenyi CliniMACS|
79655532|NCT04549753|Device|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
79655533|NCT02214316|Other|Hypertonic Saline|
79655534|NCT00235352|Drug|CX516 (Ampakine)|
79655535|NCT04555876|Device|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
79655536|NCT02212444|Device|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
79474081|NCT01760785|Drug|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
79474082|NCT01760785|Drug|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
79474083|NCT01761019|Drug|Taclonex Topical Suspension|topical medication for psoriasis
79638562|NCT04694209|Procedure|maxillary and mandibular telescopic retained overdentures supported by 4 implants|The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
79655537|NCT02212444|Device|Off -the-shelf triplanar orthoses|
79655538|NCT00235469|Drug|SPM 927|
79803286|NCT06035822|Other|Debriefing with TeamGAINS|The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
79655539|NCT04549012|Drug|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
79655540|NCT04549012|Drug|Oxytocin|Oxytocin
79803287|NCT06034912|Device|Low-Intensity Red Light Therapy|myopia and amblyopia comprehensive treatment instrument red light feeding treatment
79803288|NCT06033079|Behavioral|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
79803289|NCT06030206|Behavioral|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.
79803290|NCT06030206|Behavioral|Publicly available transplant education resource (Attention-control)|Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
79813599|NCT00816478|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
79967508|NCT03903575|Procedure|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
79655541|NCT04555954|Other|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
79655542|NCT02214394|Other|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
79340359|NCT04457531|Other|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
79340360|NCT02532647|Drug|Remimazolam|
79340361|NCT02532647|Drug|Midazolam|
79340362|NCT02532647|Drug|Placebo|
79340363|NCT02537015|Drug|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
79340364|NCT05397119|Biological|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
79340365|NCT05397119|Biological|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
79340366|NCT05397119|Biological|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
79340367|NCT05397119|Biological|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
79340368|NCT05397119|Biological|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
79803291|NCT06025435|Other|SAIA-HIV-SSP|The Systems Analysis and Improvement Approach (SAIA) is an evidence-based, multicomponent implementation strategy for improving the delivery of appropriate clinical services for HIV prevention and treatment. It involves five cyclical steps including (1) analyzing service delivery data to identify priority areas for system improvements, (2) mapping processes and building consensus around programmatic modifications to address priority areas, (3) implementing programmatic modifications, (4) assessing effects of programmatic modifications on improving delivery of services across the cascade, and (5) repeating steps 1-4 as needed.
79803294|NCT06019728|Drug|AGALSIDASE BETA (GZ419828)|Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
79803295|NCT06019728|Drug|Acetaminophen|Tablet or solution; Oral
79803296|NCT06019728|Drug|Diphenhydramine|Tablet or solution; Oral
79803297|NCT06019728|Drug|Dexamethasone|Tablet or solution; Oral
79803298|NCT06019728|Drug|Montelukast|Tablet or chewable tablet or oral granules; Oral
79803299|NCT06012305|Other|Taping|Taping has the effect of accelerating the flow in the tissue by increasing the epidermal dermal distance. The muscle technique used in the study will be applied to the trapezius muscle and aims to reduce the working level of the muscle. The EDF technique, which will be used in another group, aims to create a stronger base taping effect.
79803300|NCT06007183|Biological|PXVX0317 vaccine booster|PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
79803301|NCT06007183|Biological|Placebo booster|Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
79803302|NCT06005662|Drug|Psilocybin|The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
79803303|NCT06003634|Behavioral|Peer Coaching - Peer Participants A|Peer participants in group A will self select a peer coach and will be contacted weekly by peer coaches.
79803304|NCT06003634|Behavioral|Peer Coaching - Peer Participants B|Peer participants in group B will self select a peer coach and will be contacted bi-weekly by peer coaches.
79803305|NCT06003634|Behavioral|Peer Coaching - Peer Participants C|Peer participants in group C will be matched with a peer coach and will be contacted weekly by peer coaches.
79655543|NCT02214394|Device|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
79803306|NCT06003634|Behavioral|Peer Coaching - Peer Participants D|Peer participants in group D will be matched with a peer coach and will be contacted bi-weekly by peer coaches.
79803307|NCT05996471|Biological|VH3810109|VH3810109 will be administered.
79340369|NCT05397119|Biological|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
79655544|NCT00261105|Drug|telithromycin|
79803308|NCT05996471|Drug|Cabotegravir|Cabotegravir will be administered.
79803309|NCT05996471|Drug|Standard of care (SOC)|Pre-baseline SOC antiretroviral therapy (ART) will be administered.
79803310|NCT05996471|Biological|rHuPH20|rHuPH20 will be administered.
79803311|NCT05994248|Device|Enform Mesh|Use of absorbable mesh in umbilical hernia repair
79803312|NCT05994248|Device|Marlex|Use of non-absorbable mesh in umbilical hernia repair
79340370|NCT02271945|Drug|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
79984302|NCT03206632|Drug|BI 690517|single dose
79984303|NCT03206632|Drug|Placebo|single dose
79984304|NCT03206554|Drug|Ropivacaine|Large volume local anaesthetic intraarticularly
79984305|NCT03206554|Other|Saline|sham injection
79984306|NCT03751319|Other|CGA|Comprehensive Geriatric Assessment
79984307|NCT03209284|Procedure|transcrestal sinus floor elevation|augmentation procedure with xenograft
79340371|NCT02271945|Drug|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
79340372|NCT02271945|Drug|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
79340373|NCT05555199|Radiation|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
79340374|NCT05555199|Drug|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
79655545|NCT00235508|Drug|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
79655546|NCT04548856|Procedure|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
79655547|NCT04548856|Procedure|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
79803313|NCT05989750|Device|Ultrasonic scaler|Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
79803314|NCT05989750|Device|Air-Flow Prophylaxis Master|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
79803315|NCT05986929|Other|focus group|Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
79803316|NCT05986929|Other|electronic survey|An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
79803317|NCT05986916|Diagnostic Test|Liverscope® exam|Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).
79803318|NCT05986916|Diagnostic Test|MR exam|Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.
79803319|NCT05986916|Diagnostic Test|FibroScan® exam (optional)|Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.
79803320|NCT05986916|Other|Blood draw|Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.
79803321|NCT05986916|Other|Body measurements|Participants will have their height, weight, waist circumference, and hip circumference measured.
79803322|NCT05986916|Other|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications
79803323|NCT05986526|Procedure|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
79803324|NCT05986526|Procedure|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
79803325|NCT05976919|Diagnostic Test|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
79803326|NCT05975905|Biological|Dose A KER-012|Dose A KER-012 (Q4W);
79803327|NCT05975905|Biological|Dose B KER-012|Dose B KER-012 (Q4W);
79803328|NCT05975905|Biological|Dose C KER-012|Dose C KER-012 (Q4W);
79803329|NCT05975905|Biological|Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks|Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
79474084|NCT01761175|Procedure|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
79803330|NCT05974345|Drug|Inclisiran sodium|Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
79803331|NCT05974345|Drug|Placebo|Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
79803332|NCT05974345|Drug|Ezetimibe|Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
79803333|NCT05974345|Drug|Evolocumab|Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
79474085|NCT01761175|Procedure|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
79474086|NCT04769089|Procedure|Treatment with Pulse Dye Laser|Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.
79803334|NCT05963542|Behavioral|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
79803335|NCT05963542|Other|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
79803336|NCT05959486|Drug|BR6002A|One tablet administered alone
79803337|NCT05959486|Drug|BR6002B|One tablet administered alone
79803338|NCT05959486|Drug|BR6002|One capsule administered alone
79803339|NCT05952557|Drug|Camizestrant|Camizestrant. Experimental. Administered orally
79803340|NCT05952557|Drug|Tamoxifen|Tamoxifen. Comparator. Administered orally
79803341|NCT05952557|Drug|Anastrozole|Anastrozole. Comparator. Administered orally
79803342|NCT05952557|Drug|Letrozole|Letrozole. Comparator. Administered orally
79803343|NCT05952557|Drug|Exemestane|Exemestane. Comparator. Administered orally
79967509|NCT03903575|Procedure|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
79803344|NCT05952557|Drug|Abemaciclib|Abemaciclib adjuvant treatment Administered orally
79803345|NCT05952024|Drug|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule of X.
79803346|NCT05952024|Biological|Rituximab|Patients will receive rituximab via IV infusion on Cycle 1 Day 15 and via SC injection on Day 1 of Cycle 2 through Cycle 8.
79803347|NCT05950022|Procedure|Endoscopic tenotomy surgery of the iliopsoas tendon|The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
79803348|NCT05949905|Behavioral|Stage-matched interventions|The intervention would be using the Processes of Change that match each Stage of Change.
79803349|NCT05946395|Device|Hearing aid|Fitting a hearing aid
79803350|NCT05946395|Other|Speech therapy session|As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
79803351|NCT05946057|Diagnostic Test|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
79803352|NCT05945290|Procedure|Biospecimen Collection|Undergo blood and leftover tissue sample collection
79803353|NCT05945290|Other|Electronic Health Record Review|Medical records are reviewed
79803354|NCT05938777|Behavioral|Non-Stage-Matched Intervention|The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
79803355|NCT05938725|Biological|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
79803356|NCT05938725|Drug|Standard lymphodepletion regimen|Standard lymphodepletion regimen
79803357|NCT05938634|Behavioral|Stage-matched interventions|Precontemplation-based intervention Contemplation-based intervention Preparation-based intervention Action-based intervention Maintenance-based intervention
79803358|NCT05937009|Other|Orienteering exercise program|Orienteering exercise program running for 12 weeks (30-45 minutes, 3 sessions/week). Sessions will have 4 phases: 1) Signature of attendance sheet; 2) warm-up exercises for 5 minutes; 3) Start of orienteering proofs, where the departs will occur individually, with 3 interval minutes between participants; 4) stretches session, to return to a calm state.
79803359|NCT05935995|Other|microscopy confocal (Histolog Scanner)|"Surgical margins of tumor samples will be examined by conventional histopathology (H&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland).~Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve).~A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase."
79803360|NCT05933161|Device|Freestyle Libre 3 Continuous Glucose Monitor (CGM)|Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
79803361|NCT05930028|Drug|Fimasartan|Subjects take the investigational products once a day for 8 weeks.
79803362|NCT05930028|Drug|Ezetimibe/Atorvastatin|Subjects take the investigational products once a day for 8 weeks.
79803363|NCT05930028|Drug|Fimasartan Placebo|Subjects take the investigational products once a day for 8 weeks.
79803364|NCT05930028|Drug|Ezetimibe/Atorvastatin Placebo|Subjects take the investigational products once a day for 8 weeks.
79309313|NCT04792125|Behavioral|Pelvic floor muscle training (PFMT)|While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
79309314|NCT03195257|Other|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
79309315|NCT03195257|Other|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
79340375|NCT01660763|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
79803365|NCT05926063|Other|Comparison short vs extended EBAT treatment group|This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
79803366|NCT05925920|Drug|ENT-03|single dose of active drug
79803367|NCT05925920|Drug|Placebo|single dose of placebo comparator
79803368|NCT05925660|Diagnostic Test|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
79803369|NCT05925569|Other|Best Practice Advisory Computerized Alert|For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
79803370|NCT05923827|Device|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
79803371|NCT05915455|Other|HCP-facing Portfolio Diet Infographic + Informative Video|Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video
79803372|NCT05915455|Other|Portfolio Diet Application|Resource to evaluate includes the Portfolio Diet mobile application
79803373|NCT05915195|Other|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
79803374|NCT05915195|Other|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
79803375|NCT05909605|Device|sphygmomanometer|Comparison to the ultrasound sensor
79803376|NCT05909605|Device|Arterial Line|Comparison to the ultrasound sensor
79803377|NCT05900700|Behavioral|eYST website|The website is a psychoeducational, social support program for adolescents at risk for suicide
79803378|NCT05900076|Diagnostic Test|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
79803379|NCT05899140|Drug|Clindamycin|Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
79803380|NCT05899140|Other|Standard of care|Standard of care
79803381|NCT05898191|Other|vaginal laser treatment|non-ablative vaginal laser application
79803382|NCT05893108|Drug|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
79803383|NCT05893108|Drug|triamcinolone acetonide 10 mg/ml|intralesional injection
79803384|NCT05885516|Procedure|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
79803385|NCT05885152|Other|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
79803386|NCT05881681|Behavioral|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
79803387|NCT05880836|Device|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
79803388|NCT05880836|Device|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
79803389|NCT05880212|Other|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
79340376|NCT01660763|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
79638563|NCT04694209|Procedure|maxillary and mandibular screw retained hybrid prostheses supported by 4 implants|Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
79638564|NCT00521638|Biological|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
79638565|NCT00521677|Procedure|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
79638566|NCT00521677|Procedure|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
79638567|NCT00521716|Device|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
79638568|NCT00521716|Device|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
79638569|NCT00521755|Device|Seraffix LTB|laser soldering for soft tissue wounds
79638570|NCT00521833|Procedure|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
79340377|NCT04875273|Device|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
79638571|NCT00521872|Procedure|STARR Operation|
79638572|NCT00521911|Behavioral|Cognitive Behavioural Therapy|
79638573|NCT04273412|Behavioral|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
79638574|NCT00522067|Biological|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
79638575|NCT00522106|Behavioral|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
79813600|NCT00809068|Drug|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
79813601|NCT00809068|Drug|tibolone|tibolone 2.5 mg daily 23 weeks
79340378|NCT04875273|Device|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
79340379|NCT04859049|Procedure|infromedial single injection|"Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin."
79803390|NCT05880212|Other|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
79803391|NCT05879185|Biological|XmAb23104|XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
79803392|NCT05878093|Drug|Dupilumab|solution for subcutaneous injection
79803393|NCT05878093|Drug|Placebo|solution for subcutaneous injection
79474087|NCT04769089|Procedure|Treatment with CO2 Laser|CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
79474088|NCT04769089|Procedure|Treatment with combination of pulse dye laser and CO2 laser.|Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
79803394|NCT05878093|Drug|Budesonide|nasal spray (suspension)
79803395|NCT05874921|Drug|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
79803396|NCT05873699|Drug|Hyperpolarized 13-C-pyruvate|Given by Injection
79803397|NCT05870046|Procedure|Power training in women older than 65 years with pre-sarcopenia|resistance training based on muscle power training, perform the exercises at high speed.
79803398|NCT05870046|Procedure|Multimodal and nonspecific exercises in women older than 65 years with pre-sarcopenia|different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
79803399|NCT05869331|Procedure|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
79803400|NCT05869331|Procedure|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
79803401|NCT05867238|Other|Training stress management|The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
79803402|NCT05866679|Drug|Hyperpolarized 13-C-pyruvate|Given by PO
79803403|NCT05857930|Drug|OM-85|OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
79803404|NCT05857930|Drug|Placebo|Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
79803405|NCT05856123|Device|SimPull Lateral Transfer Device|Automated lateral transfer device
79813602|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
79340380|NCT04859049|Procedure|medial canthus injection|": We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection"
79474089|NCT04769089|Other|Control|One area will be randomized to receive no laser treatment.
79638576|NCT00522106|Other|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
79638577|NCT00522184|Procedure|intra-articular injection of etanercept|
79638578|NCT00522184|Procedure|intra-articular injection of steroid|
79474090|NCT04062097|Drug|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
79638579|NCT00522223|Behavioral|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
79340381|NCT05420675|Other|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
79638580|NCT00522262|Behavioral|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
79803406|NCT05855694|Device|THOR LED Photobiomodulation Helmet - Therapeutic|"Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2"
79803407|NCT05855694|Device|THOR LED Photobiomodulation Helmet - Control|"Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2"
79803408|NCT05854407|Other|skim milk|pasteurized or high-pasteurized skim milk
79803409|NCT05849831|Diagnostic Test|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography will be performed by single skilled examiner with patients placed in supine position with closed eyes. A layer of ultrasound gel will be applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine is placed on temporal area of eyelid with the hand holding it resting on forehead of patient. ONSD is measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. An average ONSD greater than 5 mm is considered abnormal and elevated intracranial pressure should be suspected. all enrolled subjects will be eligible for ONSD measurements, SOFA score calculation, as well as GCS assessment on daily basis for up to 10 consecutive days, until ICU discharge or death.
79803410|NCT05843318|Behavioral|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
79803411|NCT05843318|Behavioral|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
79803412|NCT05843318|Behavioral|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
79803413|NCT05842330|Drug|Concerta|"Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release."
79803414|NCT05842330|Drug|Placebo|"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm."
79803415|NCT05841953|Device|Transcutaneous neuromuscular electrical stimulation|Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
79803416|NCT05838677|Behavioral|Pain at Work Toolkit|Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.
79803417|NCT05838677|Other|Active control|Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
79803418|NCT05835440|Other|no intervention|interviews
79803419|NCT05829655|Drug|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
79803420|NCT05829655|Drug|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
79803421|NCT05829655|Drug|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
79813603|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
79803422|NCT05829655|Drug|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
79803423|NCT05829655|Drug|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
79803424|NCT05829655|Drug|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
79803425|NCT05827146|Drug|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
79803426|NCT05827146|Drug|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
79474091|NCT04062097|Drug|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
79803427|NCT05820308|Behavioral|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
79803428|NCT05820308|Behavioral|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
79803429|NCT05813457|Other|PRESTO Early Identification Program|"The program combines :~A population-based information component (information campaign aimed at the general population).~A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
79803430|NCT05810714|Other|Best Practice|Receive usual care
79803431|NCT05810714|Other|Fecal Immunochemical Test|Receive FIT kit
79474092|NCT04062097|Drug|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
79803432|NCT05810714|Behavioral|Health Education|Receive audio brochure
79474093|NCT02241655|Device|a pragmatic EEG-guided anesthetic protocol|
79474094|NCT04005079|Drug|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
79474095|NCT04005079|Drug|Ofloxacin|Standard of care
79638581|NCT00522340|Behavioral|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
79638582|NCT03458923|Drug|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
79638583|NCT03458923|Drug|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
79638584|NCT00522535|Procedure|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
79638585|NCT00522535|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
79638586|NCT04186013|Drug|Atezolizumab Injection [Tecentriq]|intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
79638587|NCT04186013|Radiation|External Beam Radiation Therapy (EBRT)|60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
79638588|NCT00152139|Procedure|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
79638589|NCT00152139|Drug|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
79638590|NCT00522574|Drug|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
79638591|NCT00522613|Behavioral|Recovery Group Project|Recovery Group Workbook & Group Sessions
79638592|NCT00522652|Drug|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
79638593|NCT04725162|Radiation|18F-FDG|All subjects received 18F-FDG PET examination.
79638594|NCT00522691|Procedure|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
79638595|NCT00405431|Drug|Restasis|1 drop in study eye twice a day X 6 months
79803433|NCT05810714|Behavioral|Health Education|Receive video brochure
79474096|NCT04005079|Drug|Prednisolone|Standard of Care
79474097|NCT01761643|Device|SoC + iTab|Text messaging reminders to improve adherence to PrEP
79474098|NCT01762501|Drug|Azilsartan|Azilsartan 20mg/day
79474099|NCT01762501|Drug|Amlodipine|Amlodipine 5mg/day
79474100|NCT02990221|Drug|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
79474101|NCT02990221|Procedure|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
79638596|NCT00405431|Drug|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
79638597|NCT00522730|Other|Parenteral nutrition|Duration : 5 days
79638598|NCT00522730|Other|Enteral nutrition|Duration : 5 days
79638599|NCT00167232|Drug|Naltrexone|
79803434|NCT05810714|Other|Scheduled Notification|Receive scheduled reminder
79803435|NCT05810714|Other|Survey Administration|Ancillary studies
79813604|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
79813605|NCT03844945|Other|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
79813606|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
79803436|NCT05807867|Behavioral|WMM-based intersectional stigma intervention|"Intervention components consist of:~psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total)."
79803437|NCT05807867|Behavioral|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
79803438|NCT05807321|Device|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
79803439|NCT05806255|Device|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
79803440|NCT05805527|Diagnostic Test|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
79803441|NCT05802550|Other|Ocular Surface Disease Index|Questionnaire on ocular surface disorders
79803442|NCT05802550|Other|Interferometry|Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement
79803443|NCT05802550|Other|Oxford score|Investigation and quantification of superficial corneal punctate keratitis using the Oxford score
79803444|NCT05802550|Other|Conjunctival collection|Two conjunctival prints: one for metabolomic and one for lipidomic
79803445|NCT05802550|Other|Aqueous humor collection|Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.
79803446|NCT05802550|Other|Quantification of Tyndall and flare|Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
79803447|NCT05798338|Diagnostic Test|Blood sample|Analysis of plasma in order to quantify and characterize EVs
79803448|NCT05796531|Behavioral|Therapeutic Evaluative Conditioning|"Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me)."
79803449|NCT05796531|Behavioral|Neutral comparison condition|Match neutral pictures to account for doing an intervention.
79803450|NCT05794230|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
79803451|NCT05794230|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
79803452|NCT05794230|Biological|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
79803453|NCT05794230|Biological|Pneumoccocal Vaccine|Suspension for injection - intramuscular
79803454|NCT05794230|Biological|Measles, Mumps, and Rubella Vaccine live (MMR) - TRESIVAC®|Lyophilized powder for injection - subcutaneous
79803455|NCT05794230|Biological|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
79803456|NCT05794230|Biological|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
79803457|NCT05794230|Biological|Hepatitis A vaccine - HAPIBEV™|Suspension for injection - intramuscular
79803458|NCT05794230|Biological|Rotavirus vaccine|Oral solution - oral
79803459|NCT05794230|Biological|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
79803460|NCT05794230|Biological|Measles vaccine - MeasBio®|Freeze-dried powder for reconstitution and injection - subcutaneous
79803461|NCT05794230|Biological|Varicella vaccine live - VARIPED®|Sterile powder and diluent for injection - subcutaneous
79803462|NCT05794230|Biological|Varicella vaccine live - Onvara|Lyophilized powder for injection - subcutaneous
79803463|NCT05794230|Biological|Measles, Mumps, and Rubella Vaccine live (MMR) - OMZYTA®|Lyophilized powder for injection - subcutaneous
79803464|NCT05794230|Biological|Hepatitis A vaccine - Avaxim 80 U|Suspension for injection - intramuscular
79803465|NCT05793944|Behavioral|SmartMom text messaging|SmartMom is a mobile health program delivered via text messaging that guides participants through each week of pregnancy. Participants receive three messages per week with links to content focused on improving knowledge, providing information about prenatal assessments and screening, and encouraging the adoption of behaviours to support healthy pregnancy and physiologic birth. Messages are consistent with current professional guidelines and peer reviewed prenatal education curricula. SmartMom provides optional supplemental streams for individuals who wish to have additional messages addressing topics such as reducing use of tobacco, alcohol or illicit drugs, depression, obesity, and maternal age over 35.
79803466|NCT05793944|Behavioral|Control text messaging|Control arm participants will receive weekly text messages with accurate, general-interest information about pregnancy and about progress of the trial. Content is not geared to decision-making during pregnancy that may affect health outcomes.
79803467|NCT05788679|Drug|Azacitidine|Azacitidine
79803468|NCT05788679|Other|Donor lymphocytes|Donor lymphocytes in patients without immune suppression
79803469|NCT05788679|Other|Tapering of immune suppression|Tapering of immune suppression in patients who are on immune suppressive drugs
79803473|NCT05787639|Drug|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
79803474|NCT05784298|Device|low-intensity rTMS|40 hz, 150 gauss, 1 session that lasts 45 minutes.
79803475|NCT05782088|Procedure|Single Piezocision|Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
79803476|NCT05782088|Procedure|Repeated Piezocision|Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
79803477|NCT05777759|Device|New Dermal Filler|hyaluronic acid
79803478|NCT05777759|Device|FDA appoved Dermal Filler|hyaluronic acid
79803479|NCT05776095|Procedure|Cataract surgery|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
79803480|NCT05776095|Device|Eyedeal® Model PX65AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
79803481|NCT05774639|Drug|Omalizumab Injection|ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
79474102|NCT01764607|Drug|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
79474103|NCT01764685|Drug|Topiramate|Max therapeutic dose of 150mg/day
79474104|NCT01764685|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
79803482|NCT05774639|Drug|Xolair Prefilled Syringe|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
79803483|NCT05770414|Behavioral|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
79803484|NCT05770193|Other|Pursed lip breathing|The position for every patient will be long sitting, and then he will be instructed to breathe in through the nose for 2 seconds. Purse the lips as if about to blow out the candles on a cake. Breathe out very slowly through pursed lips for 4 to 6 seconds, and then repeat for 5 to 10 minutes. The intervention will be done two days a week, through six weeks for all participants by a physiotherapist.
79474105|NCT01764685|Drug|Placebo|Placebo
79803485|NCT05770193|Other|Cognitive Behavior Therapy|A structured, 6-session psycho-therapeutic intervention, occurring once weekly, will be performed According to the CBT session structure provided by Cully and Teten, with some modifications, Each session will be approximately 1 hour.
79813607|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
79813608|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
79967510|NCT00159588|Drug|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
79967511|NCT04166942|Drug|KD025|Single dose of 200 mg KD025 orally
79967512|NCT03265938|Device|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
79803486|NCT05770193|Other|Diaphragmatic breathing exercise|"The patient will lie in supine position, and then he will be asked to rest for 5 min and lay on their back on a flat surface with pillows under their head and knees for support. One hand will be placed on the abdomen and the other on the upper part of the chest wall. When inhaling, the hand on the abdomen will move upward, while the other hand will remain as still as possible. When exhaling, the hand on the abdomen will move downwards, while the other hand will remain as still as possible again. Breathing will be performed quickly, deeply and without causing tiredness. The breaths should be inhaled through the nose and exhaled through the mouth.~The diaphragmatic breathing exercise will consist of three sets of 10 repetitions, with 30 seconds of rest between each set"
79803487|NCT05770193|Other|Kinesio tape|"The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 _75% tension and the tails will be applied toward the ribs."
79803488|NCT05765175|Device|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
79803489|NCT05765175|Procedure|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
79803490|NCT05762887|Other|Probiotic Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
79803491|NCT05762887|Other|Placebo Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
79803492|NCT05756738|Diagnostic Test|Dried blood spot testing|To evaluate the efficacy defined as the rate of diagnostic tests against hepatitis C virus (HCV) performed with a dried blood spot test
79803493|NCT05747638|Behavioral|Revised Children's Manifest Anxiety Scale (RCMAS)|All participants will be invited to complete a paper questionnaire.
79803494|NCT05734768|Behavioral|State-Trait Anxiety Inventory - Y ou STAI-Y|Questionnaire
79803495|NCT05733559|Device|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
79803496|NCT05732454|Drug|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
79803497|NCT05732454|Drug|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
79803498|NCT05725746|Diagnostic Test|Point of care device to measure HbA1c|After consent the participant will meet with the research team virtually to obtain HbA1c. The HbA1c self check equipment will be sent to the participant. During the video call the research team will talk the participant through obtaining their HbA1c with the point of care device.
79803499|NCT05721521|Other|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
79803500|NCT05721521|Other|Control|30 minute completing seated activities (e.g., wordsearches)
79803501|NCT05715970|Diagnostic Test|PoCT+questionnaire administration|"In Sicily, screening will be carried out in the general practitioner's clinics (GPs). GPs will have to submit the patients attending their clinics to the PoCT + software tools questionnaire. Subjects who are PoCT positive and/or who reach the minimum score in the questionnaire will be considered 'patients at risk of CD' and must be subjected, with prior consent, to in-depth diagnostics using standard serological methods. The subjects resulting positive in the serological investigations will then undergo the appropriate endoscopic and biopsy investigations to ascertain the presence of CD. In Malta the recruitment will exactly repeat the modalities already carried out in the ITAMA project, through the schools of Malta (Maltese takers), while the laboratory and endoscopic examinations of the subjects who tested positive for the PoCT and/or who will reach the minimum score in the software tools questionnaire will be centralized at the Mater Dei hospital."
79967513|NCT04353037|Drug|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
79474106|NCT01764919|Radiation|[124I]FIAU|A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
79474107|NCT01765465|Drug|Rowachol|
79803502|NCT05710549|Device|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to <30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
79803503|NCT05710549|Device|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
79803504|NCT05708001|Device|transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
79803505|NCT05708001|Device|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of <30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
79803506|NCT05708001|Diagnostic Test|Montreal Cognitive Assessment (MoCA)|Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline, after 4 weeks and 12 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
79803507|NCT05705999|Device|transcranial magnetic stimulation|The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% RMT. The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10-minute break in between each session
79803508|NCT05702853|Drug|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
79803509|NCT05702853|Drug|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
79803510|NCT05702853|Biological|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
79803511|NCT05695391|Biological|Coagulation Factor VIIa (Recombinant)|LR769
79803512|NCT05688280|Drug|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
79803513|NCT05682625|Other|No intervention|No intervention
79803514|NCT05680727|Procedure|transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
79803515|NCT05676710|Drug|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
79803516|NCT05674812|Diagnostic Test|Comprehensive evaluation|Non-ultrasound parameters:oxygenation index;arterial blood gas analysis;Type of surgery;ultrasound parameters:Diaphragmatic displacement, Mitral Annular Plane Systolic Excursion,Triscuspidal annular Plane Systolic Excursion, Lung score
79803517|NCT05674526|Biological|WU-NK-101 - Dose Escalation|WU-NK-101 administered on Days 1, 15, 30 and 44
79803518|NCT05674526|Drug|Cetuximab - Dose Escalation|Cetuximab 500mg/m2 administered on Days 29 and 43
79309316|NCT03195257|Other|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
79474108|NCT01765465|Drug|Placebo|
79803519|NCT05674526|Biological|WU-NK-101 - Cohort Expansion|WU-NK-101 administered on Days 2 and 16
79803520|NCT05674526|Biological|Cetuximab - Cohort Expansion|Cetuximab 500mg/m2 administered on Days 1 and 15
79803521|NCT05665543|Behavioral|GLAm app|Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
79474109|NCT02989831|Device|Vibrating insoles 'on'|Duration: 30-60 seconds
79474110|NCT02989909|Device|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
79803522|NCT05664776|Device|Dynamic office chair|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
79803523|NCT05664451|Behavioral|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
79803524|NCT05664451|Other|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
79803525|NCT05664412|Device|at-home tACS using Starstim-Home tES|We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
79803528|NCT05648344|Behavioral|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
79803529|NCT05648344|Behavioral|Control|Usual care with information from myplate.gov
79803530|NCT05641350|Behavioral|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
79803531|NCT05625373|Drug|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
79803532|NCT05619679|Other|Kidney Transplantation|Kidney transplantation
79803533|NCT05618717|Device|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
79803534|NCT05614583|Device|MORT-PFPS app|The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
79803535|NCT05614583|Other|treatment as usual (TAU)|In the control group, psychoeducation is delivered and self-exercise is recommended.
79803536|NCT05609305|Other|Discharge|observational study, not intervention
79803537|NCT05605366|Drug|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
79803538|NCT05605366|Drug|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
79803539|NCT05597007|Behavioral|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
79803540|NCT05596331|Other|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
79803541|NCT05588388|Drug|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
79474111|NCT02989909|Device|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
79803542|NCT05575167|Drug|Zoledronate or Alendronate|infusion (for zoledronate) or oral digestion (for alendronate)
79803543|NCT05571293|Drug|Botensilimab|Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
79803544|NCT05571293|Drug|Balstilimab|Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
79474112|NCT05115409|Drug|Anti-PD-1 Antibody Plus Chidamide and Rituximab|Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
79474113|NCT02249533|Other|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
79474114|NCT01766713|Drug|Ezetimibe|10mg daily oral dose of ezetimibe
79803545|NCT05571124|Behavioral|Therapeutic Exercise Intervention|Participants will perform stretching and mobility exercises in short bouts of time.
79803546|NCT05569759|Drug|zetomipzomib|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
79803547|NCT05569759|Drug|placebo|Subcutaneous injection of placebo
79803548|NCT05569759|Drug|zetomipzomib in open-label extension|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
79803549|NCT05569265|Procedure|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
79803550|NCT05564637|Drug|Treprostinil|30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.
79803551|NCT05564637|Diagnostic Test|Right Heart Catheterization (RHC) while exercising|A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.
79803552|NCT05564637|Diagnostic Test|Optional Muscle Biopsy|A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.
79803553|NCT05560763|Device|FlowTriever2 Catheter|The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism
79803554|NCT05551364|Device|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~Telephone contact phase (1 session)~Inclusion Phase (1 session)~Signing of informed consent (1 session)~Initial Evaluation Phase (1 session)~Treatment Phase (1st part) (7 sessions)~Monthly Evaluation Phase (1 session)~Treatment Phase (2nd part) (7 sessions)~Monthly Evaluation Phase (1 session)~Treatment Phase (3rd part) (7 sessions)~Final Evaluation Phase and results (2 sessions)"
79803555|NCT05543577|Other|Questionnaire|Questionnaire
79803556|NCT05538728|Device|poly-l-lactic acid (Sculptra)|Sculptra
79803557|NCT05535387|Behavioral|FamilyNet smart speaker/mobile application|In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
79803558|NCT05534581|Device|PVI using the Arctic Front Cryoballoon (Medtronic)|Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
79803559|NCT05534581|Device|PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)|Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
79803560|NCT05532137|Behavioral|e-12HR app|"The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~Evaluation of the user's MDSS index.~Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups)."
79803561|NCT05526937|Other|Bread|Bread portions of 50 gram available carbohydrates.
79803562|NCT05514821|Dietary Supplement|Beet It Sport Shot|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing ~400mg dietary nitrate
79803563|NCT05514821|Dietary Supplement|Beet It Sport Shot Placebo|Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing ~ 0 mg dietary nitrate
79803564|NCT05510817|Other|Multiparametric assessment|neuropsychological assessment, PRO measures, non-conventional MRI metrics
79803565|NCT05506683|Other|MotoMeds pediatric telemedicine and medication delivery service (TMDS)|The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.
79803566|NCT05499637|Drug|[68Ga]Ga-PentixaFor PET/CT|[68Ga]Ga-PentixaFor PET/CT
79967514|NCT04353037|Drug|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
79638600|NCT00522769|Behavioral|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
79638601|NCT00522808|Drug|A-831|
79803567|NCT05499377|Device|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
79803568|NCT05498376|Device|Conventional pacemaker DDD|Implantation of a conventional cardiac pacemaker
79803569|NCT05498376|Device|Leadless pacemaker Micra AV|Implantation of a leadless cardiac pacemaker
79803570|NCT05495061|Drug|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
79638602|NCT00522886|Drug|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
79638603|NCT00167271|Behavioral|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
79803571|NCT05495061|Drug|Latanoprost ophthalmic solution 0.005%|1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
79803572|NCT05487131|Behavioral|electrical stimulation|different types of weak electrical stimulation will be used
79803573|NCT05479565|Diagnostic Test|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
79803574|NCT05473416|Other|McKenzie back extension exercise|McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
79803575|NCT05473416|Other|Pilates pelvic tilt exercise|Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
79803576|NCT05473416|Other|Baseline treatment|Postural guidelines + proper lifting technique + stretch break Rest
79803577|NCT05472155|Device|Bulb syringe|Suctioning with a bulb syringe
79803578|NCT05472155|Device|Suction catheter|Suctioned with a suction catheter
79803579|NCT05470114|Drug|LEO 138559|LEO 138559 is an antibody given by subcutaneous injection.
79803580|NCT05470114|Drug|Dupixent®|Dupixent® is an antibody given by subcutaneous injection.
79803581|NCT05468333|Other|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
79803582|NCT05464810|Drug|Letrozole|Given PO
79803583|NCT05464810|Drug|Simvastatin|Given PO
79309317|NCT03195101|Procedure|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
79309318|NCT02447393|Drug|levocetirizine|levocetirizine
79803584|NCT05464758|Other|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
79803585|NCT05464355|Procedure|Intraoperative electroencephalography recording|Intraoperative electroencephalography measurements, a non-invasive routine monitoring device used during anaesthesia to measure the brain's electrical activity
79803586|NCT05464355|Procedure|Neurofilament light chain measurement|Measurement of the level of neurofilament light chain in a blood sample
79803587|NCT05464355|Procedure|Tau protein measurement|Measurement of the level of tau protein in a blood sample
79803588|NCT05462925|Device|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
79803589|NCT05452889|Diagnostic Test|18F-FGLN PET Imaging|PET/CT Imaging: The duration of PET will be around 90 minutes. Women should have negative pregnancy test prior to the study. An arterial line will be placed in the radial artery for arterial blood sampling and this will be performed by an experienced anesthesiologist. An intravenous catheter will be placed in the subject's opposite arm, which will be used for radiotracer administration. A low-dose helical CT scan will be performed during a ~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses. Blood Sampling: For the PET scan, the amount of blood will not be more than 43 arterial samples and a blood volume loss of no more than 60 ml (4-5 tablespoonfuls). Participants will be retained in the PET facility following the PET scan to evaluate for bleeding from the arterial puncture site and/or to promote urination to increase elimination of the radiotracer.
79803590|NCT05452889|Drug|(18F)FPGLU|[F-18]FGln is a natural glutamine derivative was synthesized to explore its potential application of imaging glutamine uptake for cancer diagnosis. The proposed research study will provide preliminary evidence of the potential to utilize [F-18]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
79803591|NCT05450042|Device|SELUTION SLR DCB|Sirolimus DCB
79803592|NCT05450042|Device|Paclitaxel DCB|Paclitaxel DCB
79803593|NCT05447052|Device|Bio-MIMICS 3D Stent|Bio-MIMICS Stent implantation
79803594|NCT05447052|Device|Innova Stent|Innova Stent implantation
79803595|NCT05445856|Drug|Methadone|Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
79803596|NCT05445856|Drug|Fentanyl|Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
79803597|NCT05443711|Other|No intervention, observational study|No intervention, observational study
79803598|NCT05436860|Device|liver ultrasound|"At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group."
79803599|NCT05430490|Procedure|MRI|Multimodal neuroimaging on 3T Prisma Fit MRI
79803600|NCT05430490|Other|NeuroPsychological Testing|A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.
79803601|NCT05430490|Procedure|Blood Draw|Laboratory reports (CMP, CBC, Lipids)
79803602|NCT05430490|Other|Questionnaires|Life history, current behaviors, and substance use surveys
79803603|NCT05430490|Procedure|Lumbar Puncture|Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
79803604|NCT05424250|Behavioral|occasional aversive imagination|During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
79803605|NCT05424250|Behavioral|Exposure|• All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
79803606|NCT05423093|Behavioral|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
79803607|NCT05421598|Drug|Amlitelimab|Injection solution Subcutaneous injection
79803608|NCT05421598|Drug|Placebo|Injection solution Subcutaneous injection
79803609|NCT05421429|Biological|KN057 doseⅠ|KN057 subcutaneous (SC) injection
79803610|NCT05421429|Biological|KN057 dose Ⅱ|KN057 SC injection
79803611|NCT05421429|Biological|KN057 dose Ⅲ|KN057 SC injection
79803612|NCT05410002|Dietary Supplement|Dietary Supplement: N-111|Dietary supplement N-111
79803613|NCT05410002|Other|Placebo|Dietary placebo
79803614|NCT05404295|Other|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
79803615|NCT05403983|Behavioral|Yoga movement intervention|Mixture of yoga, tai chi, pilates. Will be delivered in person (experimental) and online (active comparator)
79803616|NCT05403983|Other|Education booklet|Recently published postpartum physical activity guidebook through the Sport Information Resource Center of Canada
79803617|NCT05402358|Other|Acceptance and Commitment Therapy Group Intervention|The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
79474115|NCT03821467|Device|Dual beam Doppler Fourier-domain OCT (DOCT)|Retinal blood flow will be assessed using DOCT.
79474116|NCT03821467|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
79803618|NCT05401838|Behavioral|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
79803619|NCT05401838|Behavioral|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
79803620|NCT05400538|Other|Biorepair Toothpaste + Mousse|Domiciliary application of the products twice a day.
79803621|NCT05400538|Other|Biorepair Toothpaste|Domiciliary application of the product twice a day.
79474117|NCT03821467|Device|Optical coherence tomography (OCT)|Retinal morphology will be imaged using OCT.
79803622|NCT05397821|Procedure|UNC technique|In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
79803623|NCT05389683|Behavioral|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
79474118|NCT01767103|Drug|Ferriprox®|
79803624|NCT05388240|Other|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
79474119|NCT02243449|Procedure|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
79474120|NCT02243449|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
79803625|NCT05388240|Other|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
79474121|NCT01767415|Drug|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
79803626|NCT05380726|Behavioral|Patient education|The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
79803627|NCT05379686|Drug|GlucaGen|150 ug glucagon will be administered to the participants before exercise.
79803628|NCT05376293|Behavioral|Behavioral Internet program|The 12-week behavioral Internet program is designed to increase physical activity to recommended levels. Participants will be asked to plan and report aerobic exercise weekly, watch weekly video lessons, and complete brief weekly homework assignments.
79803629|NCT05376293|Behavioral|Informational newsletter condition|Newsletters will focus on the health benefits of regular physical activity, exercise safety, and will provide information on national exercise guidelines.
79474122|NCT01769209|Drug|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
79803630|NCT05361486|Other|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
79803631|NCT05361486|Other|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
79803632|NCT05361486|Other|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
79803633|NCT05361486|Diagnostic Test|G6PD testing|G6PD test after Malaria Vivax diagnosis
79803634|NCT05361486|Drug|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
79803635|NCT05361486|Drug|Primaquine|0.5mg/kg/7 days
79803636|NCT05361486|Other|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 [+2 days] after treatment start
79803637|NCT05345561|Other|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
79803638|NCT05344261|Procedure|Targeted Muscle Re-innervation|Targeted Muscle Re-innervation involves re-routing transected nerve ends to functional motor nerves proximal to the site of amputation.
79803639|NCT05344261|Procedure|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface involves placing transected nerve ends in harvested muscle grafts.
79803640|NCT05344261|Procedure|Standard Post-Amputation Surgical Care|Standard post-amputation surgical care involves placing transected nerve ends into muscle/soft tissue proximal to the site of amputation.
79803641|NCT05343988|Device|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
79638604|NCT00522964|Behavioral|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
79803642|NCT05304767|Drug|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
79803643|NCT05293444|Dietary Supplement|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
79803644|NCT05293444|Other|overnight fasting|no intervention
79638605|NCT04083560|Drug|Vit B12|Vitamin B12 250mcg
79803645|NCT05292664|Drug|Venetoclax|Tablet taken orally
79803646|NCT05292664|Drug|Azacitidine|Taken intravenously
79803647|NCT05292664|Drug|Cytarabine|Lumbar Puncture
79803648|NCT05292664|Drug|Methotrexate|Lumbar Puncture
79803649|NCT05292664|Drug|Hydrocortisone|Lumbar Puncture
79803650|NCT05292664|Drug|Leucovorin|Taken Orally or intravenously
79638606|NCT00511966|Other|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
79638607|NCT00511966|Drug|Rabeprazole|As prescribed
79803651|NCT05292664|Drug|Dexamethasone|Taken Orally or intravenously
79803652|NCT05292664|Drug|Vincristine|Taken intravenously
79803653|NCT05292664|Drug|Doxorubicin|Taken intravenously
79803654|NCT05292664|Drug|Dexrazoxane|Taken intravenously
79803655|NCT05292664|Drug|Calaspargase Pegol|Taken intravenously
79803656|NCT05292664|Drug|Erwinia asparaginase|Given as intramuscular injection
79803657|NCT05291689|Drug|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
79803658|NCT05287230|Behavioral|CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)|Investigators will use concepts from the LIFT and REFLECT interventions.
79803659|NCT05287230|Behavioral|Control|Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
79474123|NCT01769209|Drug|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
79474124|NCT01769209|Drug|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
79474125|NCT01769209|Drug|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
79803660|NCT05274919|Device|Philips Achieva 7T MRI|Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
79803661|NCT05274919|Device|X-ray (optional)|Optional X-ray scan to assess the safety for undergoing an MR examination.
79803662|NCT05274919|Combination Product|Additional contrast injection|Contrast agent administration for the additional 7T scan (optional).
79803663|NCT05274919|Other|Question list|Questionnaire for contra-indications for an MR examination.
79803664|NCT05268341|Behavioral|My Sentence Builder|computer-assisted treatment program for expressive grammar
79803665|NCT05257590|Drug|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
79803666|NCT05257590|Drug|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
79803667|NCT05246618|Drug|TUM012|Ex-vivo infusion
79638608|NCT00152178|Drug|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
79803668|NCT05246618|Drug|Placebo|Ex-vivo infusion
79803669|NCT05244057|Drug|Hepalatide|4.2mg, s.c., qd for 48 weeks
79803670|NCT05244057|Drug|Placebo of Hepalatide|s.c., qd for 48 weeks
79803671|NCT05244057|Drug|Tenofovir Alafenamide Tablets|25mg, p.o., qd for 48 weeks
79803672|NCT05244057|Drug|Pegylated Interferon alfa 2a|90ug, s.c., qw for 48 weeks
79803673|NCT05242978|Other|Nutrition|acute single dose nutrition intervention
79803674|NCT05239533|Drug|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. >/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
79803675|NCT05239533|Drug|Nivolumab|Nivolumab 240mg q2wk
79803676|NCT05239533|Diagnostic Test|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
79803677|NCT05239533|Diagnostic Test|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
79803678|NCT05236725|Device|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
79803679|NCT05236725|Device|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
79803680|NCT05236725|Behavioral|Instructions|Verbal and written instructions to conduct BP checks at home
79803681|NCT05229822|Diagnostic Test|LBP|Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
79803682|NCT05229822|Diagnostic Test|sCD14-ST|Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
79803683|NCT05229822|Diagnostic Test|16s rRNA|Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
79803684|NCT05229705|Behavioral|Resistance exercise|Participants in this exercise group will receive progressive resistance training.
79803685|NCT05229003|Drug|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
79803686|NCT05229003|Drug|Penpulimab|Penpulimab 200mg, d6, q2w
79803687|NCT05229003|Drug|Irinotecan|Irinotecan 180mg/m2, d6, q2w
79803688|NCT05227430|Other|Educational video tutorials|Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
79803689|NCT05225727|Behavioral|Me & You - Tech|The 13 MYT lessons will train youth to adopt a zero tolerance approach to dating violence (DV) and contain activities to enable youth to recognize healthy (non-abusive) and unhealthy (abusive) relationships, assess their own relationships, and adopt and practice a lifestyle paradigm of select-detect-protect informed by SCT self-regulatory frameworks. Within this lifestyle paradigm, youth select their personal rules to have only healthy (non-abusive) relationships, detect unhealthy (abusive) relationships that might threaten their rules, and learn to protect their rules using communication, management, and avoidance skills. MYT will tailor content by gender, relationship status, and the youth's DV profile of perpetration or victimization based on the Conflict in Adolescent Dating and Relationship Inventory (CADRI).
79803690|NCT05220462|Drug|Remimazolam|As per Remimazolam arm
79803691|NCT05220462|Drug|Midazolam|As per Midazolam arm
79638609|NCT00152178|Drug|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
79638610|NCT02948140|Procedure|MRI|
79638611|NCT02948140|Procedure|Abdominal scanner|
79638612|NCT02948179|Procedure|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
79803692|NCT05210985|Behavioral|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
79803693|NCT05210985|Behavioral|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales | Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
79309319|NCT02447393|Drug|cetirizine|cetiridine
79803694|NCT05210985|Behavioral|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
79803695|NCT05205603|Drug|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
79803696|NCT05205603|Drug|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
79803697|NCT05205603|Drug|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
79803698|NCT05198739|Other|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
79803699|NCT05196581|Drug|Dispersible NaCl powder 10 sessions|Dispersible NaCl powder 10 sessions
79803700|NCT05196581|Drug|Dispersible NaCl powder 5 sessions|Dispersible NaCl powder 5 sessions
79803701|NCT05196568|Dietary Supplement|Fasting mimicking diet|Women will be given three administrations of fasting mimicking diet once a month
79803702|NCT05196074|Other|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
79803703|NCT05181527|Drug|Selective Serotonin Reuptake Inhibitors|Patients in both the study arms will receive SSRI for 8 weeks.
79803704|NCT05181527|Drug|Dextromethorphan|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
79803705|NCT05181527|Drug|Placebo|Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
79803706|NCT05174208|Other|CTE examination|each patients should have undergone CTE examination
79803707|NCT05173194|Other|Exercise|Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
79803708|NCT05171777|Drug|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
79803709|NCT05162547|Device|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
79803710|NCT05153980|Device|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
79803711|NCT05153980|Other|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
79803712|NCT05148715|Drug|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
79803713|NCT05148715|Drug|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
79803714|NCT05147961|Other|Digital Health|Automated behavioral intervention via e-mail, web, and mobile phone
79803715|NCT05147961|Other|Standard care|Conventional recommendations on diet and exercise
79803716|NCT05146609|Behavioral|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
79803717|NCT05146609|Behavioral|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
79309320|NCT02447393|Drug|placebo|placebo
79803718|NCT05146609|Behavioral|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
79803719|NCT05146609|Behavioral|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
79813609|NCT03995563|Drug|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
79813610|NCT03995563|Drug|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
79813611|NCT00445549|Drug|Vandetanib|300 mg daily dose, 28 day cycle
79813612|NCT00445003|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
79813613|NCT00445003|Drug|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
79309321|NCT04785105|Other|No intervention|No intervention
79309322|NCT02447549|Radiation|WBRT|One RT plan with whole bladder treated to standard dose.
79309323|NCT02447549|Radiation|SART|Three plans (small, medium & large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
79803720|NCT05140226|Behavioral|Physical Training|Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.
79803721|NCT05140226|Behavioral|Cognitive-Physical Training|Eight weeks of home-based cognitive and physical training. Cognitive training sessions will be performed 5 times per week using the Brain HQ platform (Posit Science; San Francisco, CA, USA) and will have a duration of approximately 60 minutes. The cognitive training program will be tailored by using the Personal Trainer function which presents an automated sequence of exercise levels to participants based on selected exercises. Participants will have identical sessions initially, but schedules will diverge as participants progress and as the algorithm considers their individual performance history. The Personal Trainer program will be customized to the abilities of each user and will include a focus on the following domains: sustained attention, executive function, short and long-term memory, and anxiety and depression. Participants in this group will also engage in the same exercise training intervention as participants in the Physical Training group.
79803722|NCT05128149|Other|no intervention|no intervention
79474126|NCT01769209|Drug|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
79803723|NCT05115825|Behavioral|Behavioral Intervention|Attend Mobile Pain Coping Skills Training
79803724|NCT05115825|Other|Quality-of-Life Assessment|Ancillary studies
79803725|NCT05115825|Other|Questionnaire Administration|Ancillary studies
79474127|NCT01769209|Drug|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
79474128|NCT01769209|Drug|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
79803726|NCT05108818|Biological|Seasonal influenza vaccine|The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
79803727|NCT05107518|Behavioral|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
79803728|NCT05095350|Biological|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
79803729|NCT05095350|Biological|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
79803730|NCT05094271|Other|Supplemental Oxygen|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
79803731|NCT05094271|Device|Continuous Positive Airway Pressure Machine|Continuous positive airway pressure is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of a person.
79474129|NCT01769365|Drug|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
79474130|NCT01769365|Drug|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
79474131|NCT01769365|Drug|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
79474132|NCT02327143|Drug|LY2835219|Administered orally
79803732|NCT05094271|Other|Room Air|Subjects will be instrumented with a nasal cannula to receive 2L/min pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
79803733|NCT05093790|Drug|Ticagrelor|Specified dose on specified days
79803734|NCT05093790|Drug|BMS-986141|Specified dose on specified days
79474133|NCT02327143|Drug|¹³C₈-LY2835219|Administered IV
79474134|NCT01770691|Device|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
79474135|NCT01771627|Drug|varenicline|Given PO
79474136|NCT01771627|Drug|nicotine patch|
79474137|NCT01773187|Drug|Pacritinib|
79474138|NCT01773187|Drug|Best Available Therapy|
79474139|NCT01774045|Drug|PDC-1421|
79474140|NCT01774045|Drug|Placebo|
79474141|NCT01775371|Device|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
79474142|NCT01775371|Other|Usual Care|Usual opioid analgesia determined by the provider
79474143|NCT03749629|Other|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
79474144|NCT03749629|Other|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
79803735|NCT05093790|Drug|Aspirin|Specified dose on specified days
79803736|NCT05090800|Drug|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
79803737|NCT05081895|Device|Electrical Impedance tomography|Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
79803738|NCT05081895|Other|Lung mechanics and gas exchange|Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
79803739|NCT05079594|Other|Mother voice|"Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale."
79803740|NCT05079594|Other|White noise|"Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed."
79803741|NCT05076292|Drug|GlucaGen|150 ug or 75*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
79803742|NCT05076292|Drug|Saline|Saline will be used as placebo before and after exercise.
79803743|NCT05074485|Drug|anakinra|intravenous injection of 100 milligrams anakinra
79803744|NCT05074485|Drug|Placebo|intravenous injection of 1 milliliter normal saline
79803745|NCT05074485|Other|Nociceptive pain challenge|The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
79803746|NCT05071807|Drug|Pecans|Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
79803747|NCT05071807|Other|Usual Care|Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.
79803748|NCT05067140|Drug|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
79474145|NCT03723811|Drug|SJP002 BID|1 drop b.i.d for 12 weeks
79638613|NCT00523081|Behavioral|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
79803749|NCT05067140|Drug|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
79803750|NCT05063760|Behavioral|aerobic-strength exercise intervention (6-months)|6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
79803751|NCT05063240|Behavioral|Mobile phone text messaging plus prospective motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits
79638614|NCT00523081|Behavioral|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
79638615|NCT00523120|Drug|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
79984308|NCT03209206|Drug|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
79474146|NCT03723811|Drug|SJP002 QID|1 drop q.i.d for 12 weeks
79474147|NCT03723811|Drug|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
79474148|NCT03723811|Drug|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
79474149|NCT03719755|Procedure|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
79474150|NCT03719755|Procedure|Normal Saline|Cystoscopic distention media of normal saline
79803752|NCT05063240|Behavioral|Standard infant feeding counselling|Standard infant feeding counselling as part of routine practice at primary healthcare facility
79803753|NCT05047120|Behavioral|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
79803754|NCT05047120|Behavioral|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
79803755|NCT05044039|Drug|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
79803756|NCT05038709|Device|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
79803757|NCT05027035|Other|"surgical plication or nocturnal non-invasive ventilation"|10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.
79803758|NCT05019027|Drug|Beta blocker|"The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and will be subsequently discontinued.~Other Names:~acebutolol~atenolol~betaxolol~bisoprolol~carvedilol~labetalol~metoprolol succinate~metoprolol tartrate~nadolol~nebivolol~penbutolol~pindolol~propranolol~sotalol"
79803759|NCT05018221|Drug|Vitamin K1|Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.
79803760|NCT05018221|Drug|Magnesium citrate|Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
79803761|NCT05018221|Drug|Sodium Thiosulfate|Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
79803762|NCT05018221|Device|High Flux Dialyser|Hemodialysis using a high flux dialyser.
79803763|NCT05018221|Device|Medium Cut-off Dialyser|Hemodialysis using a medium cut-off dialyser.
79803764|NCT05018221|Drug|Placebo injection (normal saline)|Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
79803765|NCT05018221|Drug|Placebo capsule (Vitamin K1)|Placebo to be administered 3 times per week following the subject's hemodialysis session.
79803766|NCT05018221|Drug|Placebo tablet (Magnesium citrate)|Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
79309324|NCT02447549|Radiation|DART|Three plans (small, medium & large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
79803767|NCT05017935|Device|Renal Denervation|Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
79803768|NCT05014958|Other|Exercise training on whole body vibration|Participants will be included in the 6-week exercise training on whole body vibration
79803769|NCT05011331|Device|MedCline Shoulder Relief System|Patients will receive a customized pillow to aid with sleep
79803770|NCT04996875|Drug|bezuclastinib|Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
79803771|NCT04994418|Dietary Supplement|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
79803772|NCT04994418|Dietary Supplement|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
79803773|NCT04994418|Dietary Supplement|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
79803774|NCT04984837|Drug|Lacutamab|750 mg/IV
79803775|NCT04984837|Drug|Gemcitabine|1000 mg/m²
79803776|NCT04984837|Drug|Oxaliplatine|100 mg/m²
79803777|NCT04983095|Radiation|stereotactic body radiotherapy|30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
79803778|NCT04983095|Drug|androgen deprivation therapy|Medical castration
79803779|NCT04983095|Radiation|Radiotherapy|RT to the prostate for de novo patients
79803780|NCT04977362|Other|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
79803781|NCT04977362|Other|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
79803782|NCT04975685|Behavioral|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
79803783|NCT04975685|Behavioral|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
79813614|NCT00445003|Behavioral|Sham injection|Sham injection at baseline and 4 weeks
79309325|NCT04792359|Device|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
79309326|NCT04792437|Procedure|surgery|surgery
79309327|NCT02447471|Device|Nexfin|Nexfin cuff placed on finger to measure blood pressure
79967515|NCT05206214|Procedure|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
79967516|NCT05206214|Procedure|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
79967517|NCT01149161|Procedure|Routine central neck dissection|Level VI neck node dissection during thyroid operation
79967518|NCT04704804|Diagnostic Test|Synthetic CT Scan|method of generating CT-synthetic image from MRI
79967519|NCT05205902|Other|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
79967520|NCT05205902|Other|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
79967521|NCT05558423|Behavioral|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
79967522|NCT04893954|Diagnostic Test|Full Spine Radiography|Full Spine Radiography
79967523|NCT04893954|Diagnostic Test|Lumbar spine MRI|Lumbar spine MRI
79967524|NCT04349917|Drug|Methylphenidate|A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
79967525|NCT04349917|Other|Placebo|A matching placebo pill will be administered on the placebo day.
79967526|NCT03903029|Drug|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
79803784|NCT04965142|Behavioral|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
79803785|NCT04953286|Other|Measure of visual acuity|ETDRS and Parinaud scale
79967527|NCT02986620|Genetic|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
79967528|NCT04775654|Dietary Supplement|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
79474151|NCT03717103|Drug|IBI188|Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
79474152|NCT03682393|Drug|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
79474153|NCT03682393|Drug|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
79803786|NCT04953286|Other|Interferometry|Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
79803787|NCT04953286|Other|Samples of basal tears|Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
79803788|NCT04953286|Other|Central corneal sensitivity|Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
79967529|NCT04775654|Other|Placebo|Two capsules containing an inert material.
79803789|NCT04953286|Other|Slit lamp examination and undilated fundus|Slit lamp examination and undilated fundus
79803790|NCT04953286|Other|Conjunctival impression|Conjunctival impression with anesthetic instillation
79967530|NCT02527889|Other|Exercise training|8-week resistive exercise training
79967531|NCT04747730|Other|Transcendental Meditation training|The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
79967532|NCT04691856|Drug|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
79309328|NCT02447315|Drug|Pilocarpine|oral
79474154|NCT03499483|Drug|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
79474155|NCT04350931|Biological|intradermal injection of BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
79803791|NCT04953286|Other|Evaluation of the corneal innervation|Contact corneal confocal microscopy
79803792|NCT04948268|Behavioral|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
79803793|NCT04948268|Behavioral|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
79803794|NCT04948268|Behavioral|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
79984309|NCT03209206|Drug|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
79967533|NCT04691856|Drug|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
79803795|NCT04948268|Behavioral|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
79984310|NCT04449341|Device|Oculus Go headset with Ocean Rift application|Information already included in arm description
79638616|NCT00523120|Drug|dexotc|aural drops
79638617|NCT04694053|Procedure|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
79803796|NCT04940052|Drug|Dabrafenib|Dabrafenib will be administered orally twice daily
79803797|NCT04940052|Drug|Trametinib|Trametinib will be administered orally once daily
79638618|NCT04725279|Procedure|Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home|The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
79638619|NCT00523159|Drug|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
79803798|NCT04940052|Drug|Trametinib placebo|Trametinib will be administered orally once daily
79803799|NCT04940052|Drug|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
79803800|NCT04936282|Drug|Grafalon|When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
79803801|NCT04936282|Drug|Normal Treatment|When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
79803802|NCT04928599|Other|Electronic Health Record Review|Review of medical records
79803803|NCT04928599|Other|Interview|Complete interview
79803804|NCT04928599|Other|Survey Administration|Complete survey
79309329|NCT02447315|Drug|Placebo|oral
79340382|NCT02268045|Biological|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
79803805|NCT04922736|Device|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
79474156|NCT04350931|Other|placebo|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
79803806|NCT04920539|Drug|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
79803807|NCT04915612|Drug|Gemtuzumab Ozogamicin|Given IV
79803808|NCT04915612|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79803809|NCT04898595|Procedure|Discontinuation of CRRT|Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
79803810|NCT04894994|Drug|FLX475|Tablet
79803811|NCT04894994|Drug|Ipilimumab|IV infusion
79803812|NCT04887116|Behavioral|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks
79803813|NCT04885101|Procedure|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
79803814|NCT04885101|Procedure|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
79803815|NCT04885101|Procedure|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
79813615|NCT00445003|Procedure|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
79813616|NCT00811070|Drug|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
79813617|NCT02609594|Other|Weekly application of Amnioband|Weekly application of Amnioband.
79638620|NCT00523159|Drug|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
79638621|NCT00152217|Drug|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
79638622|NCT00152217|Procedure|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
79638623|NCT04693897|Drug|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
79638624|NCT04693897|Drug|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
79638625|NCT00424242|Drug|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
79813618|NCT02609594|Other|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
79803816|NCT04879940|Device|Merit Medical Embospheres|Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
79967534|NCT04691856|Drug|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
79967535|NCT04691856|Drug|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
79967536|NCT04156399|Other|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
79967537|NCT01254929|Device|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
79967538|NCT01254929|Device|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
79803817|NCT04879940|Radiation|Radiation Therapy|Patients will undergo standard of care definitive radiation therapy.
79967539|NCT03749395|Procedure|Erector Spinae Plane Block|The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
79967540|NCT03902795|Diagnostic Test|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
79967541|NCT03902795|Diagnostic Test|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
79967542|NCT03300570|Drug|Dolcanatide|Given PO
79803818|NCT04875078|Device|UVA-1 Phototherapy|UVA-1 Phototherapy treatments
79803819|NCT04870307|Other|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
79340383|NCT02268045|Biological|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
79967543|NCT03300570|Other|Laboratory Biomarker Analysis|Correlative studies
79967544|NCT03300570|Other|Placebo Administration|Given PO
79967545|NCT03300570|Other|Questionnaire Administration|Ancillary studies
79967546|NCT04154605|Device|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
79967547|NCT04154605|Device|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
79340384|NCT02536781|Drug|Anthocyanin|Anti-inflammation gel
79803820|NCT04865718|Diagnostic Test|ICGA imaging|subjects undergoing intraoperative ICGA imaging
79803821|NCT04864847|Diagnostic Test|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
79803822|NCT04859153|Diagnostic Test|central nerve sensory, motor control and various muscle mechanical characteristic and sport-related fitness test|To explore the sports performance of the adolescent sprinters, including analyzing the correlations between the results and central nerve sensory, and also between motor control and various muscle mechanical characteristic and sport-related fitness factor.
79803823|NCT04856072|Device|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
79813619|NCT02609594|Other|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
79813620|NCT04029896|Biological|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
79967548|NCT03902561|Device|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
79967549|NCT03264456|Diagnostic Test|[18F] Fluciclovine PET/MRI|[18F] fluciclovine PET/MRI
79967550|NCT03264456|Drug|[18F] fluciclovine|[18F] fluciclovine
79340385|NCT02536781|Drug|Placebo|Blank gel
79340386|NCT05440253|Device|dry needling|Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.
79638626|NCT04726553|Drug|Anifrolumab|Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.
79813621|NCT00642460|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (patients>=30kg) or 12mg/kg (patients <30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
79813622|NCT00642460|Drug|Placebo|iv every 2 weeks for 12 weeks
79813623|NCT00642460|Drug|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
79813624|NCT00642460|Drug|methotrexate|as prescribed
79813625|NCT00642460|Drug|corticosteroids|orally, as prescribed
79967551|NCT03902327|Dietary Supplement|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
79967552|NCT03902327|Dietary Supplement|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
79309330|NCT04792515|Drug|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
79309331|NCT04792047|Diagnostic Test|HRP frequency, plaque compostion and local immune-inflammatory activation|HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
79309332|NCT02447237|Other|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
79309333|NCT04791657|Procedure|Appendectomy|Surgical treatment for appendicitis
79309334|NCT03118193|Other|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
79309335|NCT03118193|Biological|blood test|one sample of 4mL
79309336|NCT03118193|Biological|Collection of faeces|Collection of faeces by patient at home - optional
79309337|NCT03118193|Device|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
79638627|NCT04726553|Drug|Standard of Care|Standard of Care treatments for Systemic Lupus Erythematosus
79803824|NCT04838210|Behavioral|EleVATE Group Care|10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
79803825|NCT04838210|Behavioral|Individual Prenatal Care|The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
79967553|NCT03853694|Drug|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
79967554|NCT03853694|Drug|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
79967555|NCT03853694|Drug|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
79638628|NCT02947945|Drug|Reslizumab|All subjects will receive Reslizumab
79638629|NCT02948101|Biological|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
79638630|NCT02948101|Drug|Cyclophosphamide|Given PO
79638631|NCT02948101|Other|Laboratory Biomarker Analysis|Correlative studies
79309338|NCT04784793|Other|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
79340387|NCT05440253|Procedure|ischemic compression|Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
79638632|NCT00167466|Device|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
79638633|NCT00167466|Device|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
79638634|NCT02952157|Drug|Lidocaine jelly application|
79638635|NCT02952157|Drug|Normal saline application|
79967556|NCT01255007|Other|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
79638636|NCT02951728|Drug|Rituximab|
79638637|NCT02951728|Drug|Cyclophosphamide|
79638638|NCT02951728|Drug|Doxorubicin|
79638639|NCT02951728|Drug|Vincristine|
79638640|NCT02951728|Drug|Prednisone|
79638641|NCT02951728|Drug|Decitabine|
79638642|NCT04726046|Drug|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
79803826|NCT04837495|Procedure|right stellate ganglion block|The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
79967557|NCT03902405|Behavioral|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
79803827|NCT04836910|Other|Dietary recommendations|"Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day."
79474157|NCT03406429|Device|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
79803828|NCT04836910|Drug|Oral contraceptive pills|Hormonal treatment
79803829|NCT04836910|Drug|Metformin|Insulin resistance treatment
79967558|NCT03902405|Behavioral|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
79967559|NCT04154293|Drug|Isotretinoin|Topical Isotretinoin ointment
79474158|NCT03406429|Device|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
79967560|NCT04154293|Other|Vehicle|Topical Vehicle Ointment
79967561|NCT01148147|Drug|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
79967562|NCT01148147|Drug|Placebo|Intracoronary Placebo administration
79967563|NCT05205824|Other|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
79967564|NCT03902249|Drug|Dexamethasone|
79967565|NCT05761652|Other|Observe and record|The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
79967566|NCT03908489|Procedure|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
79967567|NCT03908489|Procedure|vital pulpotomy using mta|mta vital pulpotomy
79967568|NCT01149317|Procedure|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
79967569|NCT03901937|Drug|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
79967570|NCT03901937|Procedure|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
79967571|NCT04342897|Drug|LY3127804|Administered IV
79967572|NCT04342897|Drug|Placebo|Administered IV
79967573|NCT03902171|Device|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
79967574|NCT05205590|Other|Non|Non
79967575|NCT03629444|Radiation|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
79967576|NCT03908723|Other|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
79967577|NCT03263767|Drug|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
79967578|NCT03263767|Drug|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
79967579|NCT03263767|Radiation|Full body irradiation|2 grays at Day-1
79967580|NCT03263767|Drug|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
79967581|NCT03263767|Drug|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
79967582|NCT03263767|Other|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
79967583|NCT03263767|Other|nuclear cells|CD3+ cells if needed after transplantation
79967584|NCT03263767|Drug|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
79967585|NCT03908411|Procedure|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
79967586|NCT03908411|Procedure|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
79967587|NCT04603742|Drug|Anakinra|100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
79967588|NCT04603742|Drug|0.9% Saline|The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
79967589|NCT03902015|Device|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
79803830|NCT04826757|Other|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
79803831|NCT04803955|Drug|16mg，KB|16mg,Q8h±3min,Day1-Day7
79967590|NCT03908333|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
79967591|NCT03908333|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
79967592|NCT03908333|Drug|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
79967593|NCT03908333|Drug|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
79967594|NCT04340557|Drug|Losartan|Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
79967595|NCT01255085|Dietary Supplement|yellow pea protein|Served in a tomato soup
79967596|NCT01255085|Dietary Supplement|yellow pea fiber|Served in a tomato soup
79967597|NCT01255085|Dietary Supplement|Control Tomato Soup|Served in a tomato soup
79967598|NCT04549376|Drug|Povidone-Iodine 0.4% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
79967599|NCT04549376|Drug|Povidone-Iodine 0.5% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
79967600|NCT04549376|Drug|Povidone-Iodine 0.6% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
79967601|NCT04549376|Drug|Povidone-Iodine 0.5% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
79967602|NCT04549376|Drug|Povidone-Iodine 0.6% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
79309339|NCT04784793|Other|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
79309340|NCT02447159|Behavioral|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
79309341|NCT04784949|Procedure|portland cement|pulpotomy with PRF and white Portland cement
79309342|NCT04784949|Procedure|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
79474159|NCT02243215|Other|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
79638643|NCT00167505|Behavioral|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
79803832|NCT04803955|Drug|Placebos|16mg,Q8h±3min,Day1-Day7
79803833|NCT04802512|Procedure|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
79813626|NCT00814658|Drug|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
79813627|NCT00814658|Drug|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
79813628|NCT00814658|Drug|Placebo|Matching placebo three times a day (tid).
79813629|NCT00816634|Drug|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
79813630|NCT00642304|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
79813631|NCT00814580|Drug|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
79967603|NCT04549376|Other|Placebo comparator: DW-NI|Nasal irrigation will be provided by Distilled water
79967604|NCT04549376|Other|Placebo comparator: DW-NS|Nasal spray will be provided by Distilled water
79967605|NCT03746197|Device|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
79967606|NCT03901703|Other|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
79967607|NCT03713060|Diagnostic Test|Mixed meal test|All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
79967608|NCT03901625|Device|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
79967609|NCT03901625|Device|Dental floss|A dental floss is used to clean inter-proximal areas.
79803834|NCT04802499|Procedure|Turkish Reliability and Validity of TESS|Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
79967610|NCT03901625|Device|Waterjet|A waterjet is used to clean inter-proximal areas.
79967611|NCT03901625|Device|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
79967612|NCT01149395|Drug|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
79967613|NCT04001192|Behavioral|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
79967614|NCT02527733|Drug|Ranibizumab|
79967615|NCT02527733|Drug|Ranibizumab and laser|
79967616|NCT04382053|Drug|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
79967617|NCT04382053|Drug|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
79967618|NCT03907865|Drug|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
79967619|NCT04135495|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
79967620|NCT04135495|Drug|Ivacaftor|CFTR potentiator
79967621|NCT01148303|Drug|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
79967622|NCT01148303|Drug|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
79309343|NCT04784949|Procedure|Biodentine|pulpotomy with PRF and Biodentine
79309344|NCT02446535|Other|achievement of the DW by means of the BIA DW (RE.S.T.)|
79309345|NCT02446379|Drug|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
79309346|NCT02446379|Device|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
79309347|NCT02446379|Device|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
79309348|NCT03818139|Other|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
79309349|NCT03194945|Drug|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
79309350|NCT03194945|Drug|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
79474160|NCT03403153|Behavioral|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
79967623|NCT01148303|Drug|Placebo|Placebo
79967624|NCT03901157|Dietary Supplement|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
79309351|NCT03194945|Drug|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
79309352|NCT03194945|Drug|CSII alone|No OHA is given after short-term intensive CSII
79967625|NCT03901157|Dietary Supplement|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
79967626|NCT03907709|Behavioral|In-Home Addiction Treatment Program|"Treatment was delivered per treatment protocol~Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~Urine drug screens administered randomly~Appointments were scheduled per protocol for 52 weeks~Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
79309353|NCT04791501|Device|Mechanical ventilation|Ventilatory support
79309354|NCT03195023|Drug|Lisinopril|
79309355|NCT03195023|Drug|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
79309356|NCT03194711|Device|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
79967627|NCT03907787|Dietary Supplement|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
79967628|NCT03900611|Device|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
79967629|NCT03066830|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79967630|NCT03066830|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79967631|NCT03066830|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79474161|NCT03377647|Behavioral|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
79803835|NCT04800510|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
79309357|NCT02446301|Drug|Bain®|Nalbuphine HCl 20mg, IM injection
79309358|NCT02446301|Drug|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
79803836|NCT04797273|Behavioral|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
79803837|NCT04797273|Behavioral|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
79803838|NCT04785820|Drug|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
79309359|NCT04791345|Drug|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
79309360|NCT04791345|Drug|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
79309361|NCT04791345|Drug|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
79474162|NCT03377647|Behavioral|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
79474163|NCT01673867|Biological|Nivolumab|
79474164|NCT01673867|Drug|Docetaxel|
79638644|NCT00167505|Behavioral|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
79803839|NCT04785820|Drug|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
79803840|NCT04785820|Drug|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
79803841|NCT04777097|Other|Blood sample|Two blood sample will be drawn. On the day of operation and the first postoperative day.
79803842|NCT04776252|Drug|MK-8591A|FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
79803843|NCT04774419|Radiation|Intensity modulated radiation therapy (IMRT)|To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
79309362|NCT04791345|Drug|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
79309363|NCT04791345|Drug|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
79309364|NCT02445989|Drug|NuvaRing|Provide NuvaRing to women seeking contraception
79309365|NCT04483895|Procedure|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
79638645|NCT00523354|Drug|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
79967632|NCT03066830|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
79967633|NCT03907553|Diagnostic Test|targeted genome sequencing|
79967634|NCT03900455|Device|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
79967635|NCT03900455|Procedure|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
79967636|NCT05205278|Other|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
79967637|NCT01149629|Drug|Droxidopa|One capsule containing 300 mg droxidopa, given once
79967638|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
79967639|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
79967640|NCT03900143|Device|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
79967641|NCT05667311|Device|ECG|Finapres electrocardiography machine
79803844|NCT04774419|Drug|Dostarlimab|IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
79967642|NCT05205122|Procedure|Combined trabeculotomy-trabeculectomy with mitomycin C|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases
79638646|NCT04725968|Procedure|Urgent major general surgery|All geriatric patients (75 years and over) going under urgent major general surgery during 2018 in our centre
79638647|NCT02276794|Other|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
79967643|NCT03907085|Other|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
79967644|NCT03907085|Other|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
79803845|NCT04773392|Drug|Twice-daily Tacrolimus|Within 48 hours of transplantation, immediate release tacrolimus (IRT) (0.1 mg/kg /day) will be administered twice a day.
79803846|NCT04773392|Drug|Once-daily envarsus XR|Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.
79803847|NCT04773392|Drug|Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)|Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.
79803848|NCT04773392|Drug|Methylprednisolone, prednisone|Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.
79803849|NCT04773392|Drug|Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)|Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.
79638648|NCT02276794|Other|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
79638649|NCT00512005|Device|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
79638650|NCT00523393|Drug|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
79803850|NCT04773392|Drug|Azathioprine|Azathioprine (1-3 mg/kg) will be administered once a day.
79803851|NCT04769167|Other|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
79967645|NCT04379336|Biological|Bacille Calmette-Guérin (BCG)|BCG vaccine will be given intradermally in the upper arm after randomization.
79967646|NCT04379336|Other|Placebo Comparator|Placebo injection will be given intradermally in the upper arm after randomization.
79967647|NCT03900065|Procedure|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
79967648|NCT05208632|Other|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
79967649|NCT03907007|Device|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
79967650|NCT03907007|Device|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
79967651|NCT04360616|Diagnostic Test|imaging|perform US and mammography examination
79967652|NCT03907163|Drug|Dronabinol|Capsules containing 5 mg Dronabinol
79967653|NCT03907163|Other|Placebo|capsules identical in appearance to dronabinol
79967654|NCT04330274|Other|Bipedal with open eyes|Standing bipedal with open eyes on force platform
79309366|NCT03231137|Combination Product|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
79638651|NCT00523393|Drug|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
79803852|NCT04769167|Other|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
79803853|NCT04765813|Behavioral|Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year)."
79803854|NCT04765813|Behavioral|Cognitive-behavioral treatment to quit smoking along with a control App|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks)."
79803855|NCT04765189|Dietary Supplement|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
79638652|NCT04725734|Other|Pregnant women|The patients will complete a questionnaire for each quarter
79638653|NCT00523432|Drug|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
79638654|NCT00523432|Drug|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
79967655|NCT04330274|Other|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
79967656|NCT04330274|Other|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
79967657|NCT04330274|Other|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
79967658|NCT01149707|Drug|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
79967659|NCT01149707|Drug|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
79967660|NCT01149707|Drug|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
79967661|NCT01149707|Drug|Placebo Enema|Placebo Enema, once-daily, intrarectally
79967662|NCT04320680|Other|description of a lupus patient cohort|description of a lupus patient cohort
79967663|NCT05761496|Device|Biliary stents insertion|Endoscopic placement of plastic and metal biliary stents
79967664|NCT01253681|Drug|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
79309367|NCT03231137|Drug|ATV gel|Atorvastatin gel
79638655|NCT00523471|Procedure|Blood test|
79638656|NCT00523510|Procedure|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
79309368|NCT03231137|Biological|PRF|Platelet rich fibrin
79309369|NCT03231137|Biological|PRGF|plasma rich in growth factor
79309370|NCT03674853|Drug|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
79803856|NCT04765189|Dietary Supplement|Verum A|Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
79803857|NCT04765189|Dietary Supplement|Verum B|Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
79803858|NCT04765189|Dietary Supplement|Verum C|Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
79803859|NCT04764292|Device|Contrast-enhanced mammography|supplemental breast cancer screening with contrast-enhanced mammography
79803860|NCT04764292|Drug|Iodinated Contrast Media (ICM)|supplemental breast cancer screening with contrast-enhanced mammography
79638657|NCT00512044|Procedure|Local anesthesia (pudendal block)|local anesthesia as indicated
79638658|NCT00512044|Procedure|general anesthesia (spinal and general)|general according to guidelines
79803861|NCT04754425|Procedure|Biopsy|Undergo biopsy
79803862|NCT04754425|Procedure|Biospecimen Collection|Undergo collection of blood and bone marrow
79803863|NCT04754425|Drug|Erdafitinib|Given PO
79803864|NCT04747418|Procedure|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
79803865|NCT04747418|Procedure|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
79803866|NCT04746859|Other|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
79803867|NCT04746859|Behavioral|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
79803868|NCT04739306|Biological|CT-P42|2mg/0.05 mL by Intravitreal injection
79803869|NCT04739306|Biological|Eylea|2mg/0.05 mL by Intravitreal injection
79309371|NCT03674853|Drug|Oryzanol|take oryzanol in active comparator group for 2 months
79340388|NCT05544747|Other|Action Observation Therapy|"following phases will be included in action observation therapy group:~upper limb active range of motion (AROM) exercises.~reaching movement or object manipulation.~upper limb functional tasks."
79638659|NCT00523588|Procedure|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
79638660|NCT00512083|Drug|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
79638661|NCT04726007|Drug|Antithrombotic Agents|Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
79803870|NCT04732533|Other|tDCS (transcranial direct current stimulation)|"Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tDCS. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tDCS sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tDCS. The participant can complete up to 5 tDCS sessions per week over 52 weeks."
79967665|NCT05204966|Diagnostic Test|AI analysis|"Bottle feeding filming~- With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~Evaluate NOMAS with bottle feeding video by certified evaluators.~NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input."
79967666|NCT01149941|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
79967667|NCT01253759|Procedure|TTT + ICG-based PDT|
79967668|NCT01589549|Biological|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
79967669|NCT03906773|Other|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
79474165|NCT03005977|Procedure|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
79474166|NCT03003169|Other|Medical questionnaire|"quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~Hospital Anxiety and Depression scale~satisfaction care questionnaire (IN-PATSAT32)"
79803871|NCT04726085|Drug|Indomethacin 150mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
79474167|NCT01777945|Drug|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
79474168|NCT01777945|Drug|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
79638662|NCT00521950|Genetic|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT*2, *3A, *3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
79803872|NCT04726085|Drug|Ibuprofen 2400mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
79803873|NCT04724213|Other|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
79803874|NCT04713514|Drug|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
79803875|NCT04713514|Drug|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
79638663|NCT00521950|Drug|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
79638664|NCT00523666|Drug|Galantamine (Reminyl®)|8mg - 24mg
79813632|NCT00814580|Drug|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
79813633|NCT00643162|Drug|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
79813634|NCT00643162|Behavioral|Light touch|Light touch twice a week, for 8 weeks
79813635|NCT00643162|Behavioral|Massage|Massage twice a week, for 8 weeks.
79813636|NCT00643006|Behavioral|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
79474170|NCT01778179|Drug|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
79474171|NCT01778179|Procedure|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
79474172|NCT02994017|Other|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
79803876|NCT04711031|Other|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
79302435|NCT03224065|Diagnostic Test|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
79302436|NCT02489513|Drug|[14C]-AG-120|Labeled investigational drug
79309372|NCT02446067|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
79309373|NCT03231215|Drug|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
79309374|NCT04784481|Drug|Ivermectin|Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
79474173|NCT02917915|Other|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
79474174|NCT02917915|Other|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
79638665|NCT00523666|Drug|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
79638666|NCT00167583|Drug|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
79638667|NCT00167583|Drug|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
79638668|NCT03943511|Other|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
79803877|NCT04703686|Drug|Obinutuzumab|1000mg - prephase - one infusion at D-3
79302437|NCT02451397|Other||This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
79302438|NCT03317015|Drug|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
79302439|NCT03317015|Drug|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
79638669|NCT03943511|Other|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
79638670|NCT00523822|Other|Spinal Manipulative Therapy|
79638671|NCT00523861|Dietary Supplement|Moderate alcohol consumption|
79638672|NCT02951923|Dietary Supplement|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
79803878|NCT04703686|Drug|RO7082859|2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
79813637|NCT00643006|Behavioral|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
79302440|NCT03204487|Drug|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp & Dohme, Wien)
79302441|NCT03316937|Procedure|Types of scalers|Scaling
79638673|NCT02951923|Dietary Supplement|Soy|
79967670|NCT03899675|Dietary Supplement|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
79967671|NCT03899675|Other|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
79967672|NCT03899909|Drug|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
79967673|NCT03899909|Drug|Placebo SAD|Placebo oral suspension
79967674|NCT03899909|Drug|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
79967675|NCT03899909|Drug|Placebo MAD|Placebo oral suspension, daily for 13 days
79967676|NCT03906383|Other|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
79967677|NCT01150019|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
79967678|NCT04380961|Drug|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
79967679|NCT04380961|Drug|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
79967680|NCT04380961|Other|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
79967681|NCT01253837|Drug|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
79967682|NCT03906305|Other|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
79474175|NCT05451043|Biological|Durvalumab|It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
79638674|NCT03922802|Device|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
79638675|NCT03922802|Other|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
79638676|NCT03922802|Other|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
79638677|NCT00172809|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
79803879|NCT04693988|Behavioral|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
79803880|NCT04680910|Drug|Propofol|Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
79803881|NCT04680910|Diagnostic Test|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
79803882|NCT04680910|Diagnostic Test|Slow-Wave Activity|Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.
79967683|NCT03906305|Other|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
79967684|NCT03899441|Other|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
79803883|NCT04677595|Drug|Capmatinib|400 mg of capmatinib tablets, administered orally twice daily
79803884|NCT04672733|Biological|Hizentra|Solution for injection for subcutaneous use
79967685|NCT01562197|Drug|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
79302442|NCT03204565|Procedure|coronally advanced flap|coronally advanced flap alone (CAF- control)
79967686|NCT01562197|Drug|Axitinib plus Lomustine|Lomustine 90mg/m²
79967687|NCT01253915|Drug|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
79967688|NCT01253915|Drug|Placebo|10 sec/nostril up to 4 times to treat a migraine
79967689|NCT03749239|Dietary Supplement|Collagen protein|Collagen protein
79967690|NCT01255397|Procedure|Male Infertility Protocol|"Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~If the follicle has collapsed than IUI will be performed~It the total motile sperm count is above 5 million sperm/ml then IUI will be done~If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
79803885|NCT04665505|Behavioral|Educational Workshop|The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).
79803886|NCT04665505|Behavioral|Optimizing Staff Scheduling|This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
79967691|NCT03899363|Procedure|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
79967692|NCT04331899|Drug|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
79803887|NCT04650425|Behavioral|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
79803888|NCT04634084|Procedure|Experimental group(Bursa Implantation)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.
79967693|NCT04331899|Other|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
79967694|NCT03905915|Device|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
79967695|NCT03905837|Drug|Lidocaine|Intravenous or paravertebral lidocaine
79967696|NCT03905837|Drug|Remifentanil|intravenous remifentanil
79803889|NCT04634084|Procedure|Control Group(Standard of Care)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
79967697|NCT03899129|Procedure|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
79967698|NCT03899129|Procedure|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
79803890|NCT04628780|Biological|PF-07209960|PD-1 targeted IL-15 mutein
79967699|NCT04328467|Drug|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
79967700|NCT04328467|Other|Placebo|Placebo; tablet; oral
79967701|NCT04254770|Device|ADA approved Manual Toothbrush|ADA approved Manual Toothbrush
79967702|NCT04254770|Device|Marketed Power Toothbrush|Marketed Power Toothbrush
79967703|NCT03899207|Other|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
79803891|NCT04626362|Other|Cranberry juice|Cranberry juice cocktail will be provided by Ocean Spray Cranberries, Inc.
79803892|NCT04626362|Other|Placebo juice|Apple juice added with flavor and colorants will be provided by Ocean Spray Cranberries, Inc.
79803893|NCT04622007|Drug|Tomivosertib|Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
79803894|NCT04622007|Biological|Pembrolizumab|Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
79803895|NCT04622007|Drug|Pemetrexed|Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
79967704|NCT03899207|Other|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
79967705|NCT04232618|Diagnostic Test|Multi-biomarker point-of-care test|Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
79967706|NCT01148615|Drug|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79967707|NCT01148615|Drug|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79309375|NCT02446145|Drug|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
79967708|NCT04227470|Drug|HBM9161 Injection|Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
79967709|NCT01150175|Procedure|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
79967710|NCT01150175|Procedure|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
79967711|NCT03905447|Drug|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
79967712|NCT03905447|Drug|Standard of Care|Standard of Care antifungal medication
79967713|NCT03905681|Device|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
79967714|NCT03905759|Drug|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
79967715|NCT03905759|Drug|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
79967716|NCT03905759|Drug|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
79967717|NCT05204498|Behavioral|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~It will be recorded in an Excel table each time the patient is called.~A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
79967718|NCT01255475|Drug|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
79967719|NCT01255475|Drug|Placebo|Patients will receive placebo
79474176|NCT05451043|Drug|Gemcitabine|Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
79967720|NCT05204420|Procedure|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
79967721|NCT01255553|Radiation|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
79638678|NCT00172809|Drug|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
79803896|NCT04620759|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.
79803897|NCT04620759|Drug|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
79803898|NCT04613492|Biological|MEDI9253|Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab
79803899|NCT04613492|Biological|Durvalumab|Durvalumab treatment will be started sequentially or concurrently with MEDI9253
79967722|NCT05208398|Drug|Apixaban|5 mg twice daily, on top of standards of care.
79967723|NCT05208398|Drug|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
79967724|NCT05593991|Other|Elevated heels|"Each subject will undergo the following evaluations:~neutral barefoot position;~neutral barefoot position (re-test);~3 cm rise of both heels, made with plastic spacer;~7 cm rise of both heels, made with plastic spacer."
79967725|NCT04117802|Other|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
79967726|NCT04117802|Other|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
79967727|NCT05593601|Drug|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
79309376|NCT02446145|Drug|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
79638679|NCT04696120|Drug|Apixaban|Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
79803900|NCT04601805|Device|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
79967728|NCT05207930|Device|GAmified HOme-based COgnitive-Nutrition training (GAHOCON)|"A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp."
79967729|NCT05207930|Device|Centre-based online open-source cognitive games|During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
79967730|NCT04109690|Drug|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
79967731|NCT03899051|Procedure|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
79967732|NCT03899051|Procedure|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
79967733|NCT03629210|Drug|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
79967734|NCT03629210|Biological|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
79967735|NCT05560061|Other|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
79967736|NCT05560061|Other|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
79967737|NCT04007198|Drug|EQ001|Itolizumab [Bmab 600]
79967738|NCT04007198|Drug|EQ001 Placebo|EQ001 Placebo
79967739|NCT03899285|Drug|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
79638680|NCT04696120|Drug|Placebo|All patients who are assigned to placebo group will receive placebo
79638681|NCT00523900|Dietary Supplement|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
79309377|NCT04790877|Other|Sub-study 1|Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
79967740|NCT04328077|Drug|TERN-101|Investigational drug
79967741|NCT04328077|Other|Placebo|Matching placebo
79967742|NCT01254071|Drug|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
79967743|NCT03898739|Other|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
79638682|NCT00512356|Biological|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
79638683|NCT04694014|Behavioral|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
79967744|NCT05761418|Drug|Dinoprostone|prostaglandin (PG) E2 analog
79967745|NCT05761418|Drug|Misoprostol|prostaglandin (PG) E1 analog
79474177|NCT05451043|Drug|Nab paclitaxel|Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
79638684|NCT04694014|Behavioral|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
79638685|NCT04694014|Behavioral|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
79803901|NCT04594603|Other|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
79638686|NCT04693741|Procedure|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
79309378|NCT04790877|Other|Sub-study 2|Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
79638687|NCT04693741|Procedure|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
79967746|NCT05207774|Drug|Oxytocin|8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
79967747|NCT05207774|Drug|placebo|8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
79302443|NCT03204565|Device|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
79302444|NCT03321227|Other|Snack skipping|No snack provided
79302445|NCT03321227|Other|Whole eggs|2 whole large eggs scrambled, provided as a snack
79302446|NCT03321227|Other|Egg whites|2 egg whites scrambled, provided as a snack
79309379|NCT04791111|Other|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
79967748|NCT03905291|Drug|MT921|Formulated as an injectable solution
79302447|NCT03321227|Other|Egg yolks|2 egg yolks scrambled, provided as a snack
79803902|NCT04592120|Behavioral|Coalition Check-Up|The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
79967749|NCT03905291|Drug|Placebo|normal saline
79474178|NCT05451043|Biological|Tremelimumab|Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
79474179|NCT05451043|Drug|Propranolol|Competitively blocks both β1 and β2 adrenergic receptors.
79967750|NCT03905213|Device|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
79803903|NCT04591119|Procedure|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
79803904|NCT04591119|Procedure|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
79474180|NCT05451043|Drug|Cisplatin|cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
79474181|NCT02713399|Device|Optical Coherence Tomography|
79638688|NCT04693741|Procedure|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
79638689|NCT02951845|Drug|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
79638690|NCT02951845|Drug|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 1.
79803905|NCT04589624|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
79803906|NCT04589624|Procedure|Magnetic Resonance Imaging|Undergo MRI
79803907|NCT04589624|Procedure|Magnetic Resonance Imaging|Undergo hpMRI
79803908|NCT04580888|Procedure|early transthoracic echocardiography|In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
79967751|NCT03905213|Device|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
79967752|NCT03905213|Device|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
79967753|NCT05742932|Device|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
79967754|NCT03905057|Device|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
79967755|NCT03905057|Device|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
79967756|NCT03629132|Procedure|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
79967757|NCT03629132|Procedure|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
79967758|NCT03904901|Dietary Supplement|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
79474182|NCT02700295|Device|Orthokeratology lens|
79474183|NCT02652169|Drug|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
79474184|NCT02652169|Drug|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
79474185|NCT02652169|Drug|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
79474186|NCT02652169|Other|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
79638691|NCT02951845|Drug|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 2.
79638692|NCT00167622|Procedure|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
79302448|NCT03321227|Other|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
79302449|NCT02451319|Procedure|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
79309380|NCT02445833|Behavioral|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
79309381|NCT03230825|Drug|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
79309382|NCT03230825|Other|Expectant management|No intervention and a follow up visit a wewk later
79638693|NCT00167622|Procedure|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
79638694|NCT00512395|Drug|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
79638695|NCT02276833|Other|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
79638696|NCT00512434|Procedure|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
79309383|NCT05473221|Biological|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
79309384|NCT05234489|Biological|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
79340389|NCT05544747|Other|Mirror Therapy|"following phases will be included in mirror therapy group:~AROM exercises),~reaching movement or object manipulation, and~functional task practice"
79340390|NCT05439863|Device|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
79340391|NCT05392283|Device|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
79638697|NCT00512473|Drug|Saline infusion|0.9 % NaCl
79638698|NCT00512473|Drug|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
79309385|NCT02445677|Device|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
79967759|NCT03904901|Dietary Supplement|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
79967760|NCT02528123|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
79803909|NCT04580888|Procedure|standards of care|In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
79803910|NCT04578249|Other|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
79967761|NCT02528123|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
79967762|NCT02528123|Drug|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
79967763|NCT02528123|Drug|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
79967764|NCT02528123|Drug|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
79967765|NCT05214248|Other|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
79967766|NCT03992612|Other|control group: usual medical care|The patients received usual medical care.
79967767|NCT03992612|Behavioral|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
79967768|NCT02527811|Drug|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
79967769|NCT03691831|Drug|Active|A-101 45% (hydrogen peroxide 45% topical solution)
79967770|NCT03691831|Other|Vehicle|Vehicle solution containing isopropyl alcohol and water
79967771|NCT01254383|Drug|Sildenafil Tablet|Tablet, 50 mg, Single Dose
79967772|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
79967773|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
79967774|NCT03700970|Drug|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
79967775|NCT03700970|Drug|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
79967776|NCT01256021|Drug|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
79474187|NCT02478775|Drug|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
79803911|NCT04578249|Other|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
79967777|NCT01256099|Behavioral|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
79967778|NCT01256099|Behavioral|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
79967779|NCT01256099|Behavioral|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
79967780|NCT04320745|Drug|Androderm®|Androderm® transdermal dose.
79638699|NCT00512473|Drug|Pegvisomant|30 mg Somavert administered at t = - 36 hours
79638700|NCT00512512|Procedure|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
79638701|NCT00524095|Drug|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
79638702|NCT00524095|Drug|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
79803912|NCT04558788|Diagnostic Test|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
79803913|NCT04547153|Drug|5-fluorouracil|200mg/square metre/day civ D1-D21
79803914|NCT04547153|Drug|Docetaxel|25mg/square metre ivdrip D1, D8, D15
79803915|NCT04543877|Dietary Supplement|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
79803916|NCT04543877|Dietary Supplement|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
79803917|NCT04543877|Biological|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
79967781|NCT01254461|Drug|AZD1981|100 mg per oral, twice daily for 8 days
79967782|NCT01254461|Drug|AZD1981|4x100 mg per oral, twice daily for 8 days
79967783|NCT01254461|Drug|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
79967784|NCT03904511|Other|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
79967785|NCT03904511|Other|Placebo|Placebo
79967786|NCT05712746|Drug|Samtasu for I.V. infusion|"Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour."
79967787|NCT03747523|Drug|Ergocalciferol|Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
79474188|NCT02478775|Drug|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
79803918|NCT04537403|Drug|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
79803919|NCT04537403|Drug|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
79803920|NCT04537026|Drug|Amniotic Fluid Allograft|Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach
79803921|NCT04537026|Drug|Dexamethasone sodium phosphate|Dexamethasone phosphate mixed with sterile water will be injected by transforaminal approach
79803922|NCT04527445|Procedure|Reduced radiation fluoroscopy|See previous information about each arm
79309386|NCT02445677|Device|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
79309387|NCT03526185|Drug|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
79309388|NCT03526185|Drug|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
79474189|NCT02478775|Drug|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
79474190|NCT02451995|Device|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
79803923|NCT04527445|Procedure|Conventional fluoroscopy|See previous information about each arm
79967788|NCT03898505|Dietary Supplement|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
79967789|NCT03898505|Dietary Supplement|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
79967790|NCT03898505|Other|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
79967791|NCT03904667|Other|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
79967792|NCT03747445|Procedure|Roux-en-Y gastric bypass|laparoscopic surgical procedure
79967793|NCT01150253|Dietary Supplement|L. paracasei fermented milk|
79309389|NCT02445599|Drug|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
79309390|NCT02445599|Drug|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
79638703|NCT00167700|Behavioral|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
79967794|NCT05293171|Drug|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
79967795|NCT05293171|Drug|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
79967796|NCT05293171|Drug|BL-8040-matching placebo|Administered subcutaneous (SC) injection
79967797|NCT05293171|Drug|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
79967798|NCT03904433|Other|Coconut oil|Coconut oil given in coffee with cream
79967799|NCT03904433|Dietary Supplement|Caprylic acid|Caprylic acid given in coffee with cream
79967800|NCT03904433|Other|Sunflower oil|Sunflower oil given in coffee with cream
79967801|NCT03904433|Other|Glucose|Glucose dissolved in water
79967802|NCT03063086|Drug|QVM149 150/50/80 μg o.d.|A
79967803|NCT03063086|Drug|QVM149 150/50/160 μg o.d.|B
79967804|NCT03063086|Drug|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
79967805|NCT03749161|Device|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
79967806|NCT03749161|Device|Monofocal IOL|Lentis L-313, monofocal IOL
79967807|NCT03904745|Drug|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
79967808|NCT03749083|Other|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
79967809|NCT05191160|Other|Soy Milk|250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein
79967810|NCT05191160|Other|Cow's Milk|250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein
79967811|NCT05191160|Other|Sugar Sweetened Beverages|355 mL, single-serve cans 130-140 Kcal, 0g of protein
79967812|NCT05213702|Device|Renal Calyx punture with traditional free hand or ANT-X device|ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
79967813|NCT02528045|Procedure|Vitrectomy with scleral shortening|
79967814|NCT04128007|Drug|Roflumilast foam 0.3%|experimental
79967815|NCT04128007|Drug|Vehicle foam|experimental
79967816|NCT05187338|Drug|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
79309391|NCT02445599|Drug|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
79309392|NCT02445599|Drug|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
79967817|NCT03898583|Drug|Microarray patch A|Microarray patch
79967818|NCT03898583|Drug|Microarray patch B|Microarray patch
79309393|NCT02445599|Drug|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
79309394|NCT02445599|Drug|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
79309395|NCT02445599|Drug|Metamizole-sodium|Additional rescue analgetic 2g intravenously
79309396|NCT02445599|Drug|Tramadol|Additional rescue analgetic 100mg intravenously
79967819|NCT03898583|Drug|Placebo|Microarray patch vehicle
79967820|NCT03898583|Drug|Daivobet|Daivobet Gel
79967821|NCT05213546|Other|Aerobic exercise training|bicycle ergometer exercise training
79967822|NCT03898193|Drug|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
79967823|NCT03898193|Drug|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp & Dohme B.V., the Netherlands
79967824|NCT03321188|Procedure|HIPEC|HIPEC with cisplatin
79967825|NCT03321188|Drug|Carboplatin|Adjuvant IV chemotherapy
79967826|NCT03321188|Drug|Paclitaxel|Adjuvant IV chemotherapy
79967827|NCT03904355|Drug|Gonadotropins|Gonadotropin stimulation of follicular growth
79309397|NCT03515733|Drug|PF-04995274|PF-04995274 tablets
79803924|NCT04526730|Drug|Tavo|Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume <0.4 cm3
79803925|NCT04526730|Drug|Nivolumab|Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions
79474191|NCT02451995|Device|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
79474192|NCT01783561|Drug|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
79474193|NCT02452931|Drug|Leuprolide Acetate 45 mg|Subcutaneous injection
79813638|NCT00814502|Drug|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
79813639|NCT00814502|Drug|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
79813640|NCT00653224|Drug|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
79813641|NCT00653224|Drug|placebo|0 mg daily (matching oral tablet) for 14 days
79813642|NCT00444925|Drug|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
79309398|NCT03515733|Drug|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
79309399|NCT03194633|Drug|Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Nifedipine GITS 60 mg (once per day)
79309400|NCT03230903|Other|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
79309401|NCT03230903|Other|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
79309402|NCT03194399|Behavioral|Personalized health care service|Physical activity coaching, other functional outcome observation
79309403|NCT04791189|Other|questionnaire|questionnaire to survey the needs of adolescents with juvenile idiopathic arthritis and the views of their parents in the area of sexual health.
79309404|NCT03194555|Drug|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
79309405|NCT03194555|Drug|Placebo|Twice daily
79309406|NCT03230669|Other|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
79474194|NCT01783639|Procedure|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
79474195|NCT04744727|Drug|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
79474196|NCT02243527|Other|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
79813643|NCT00444925|Drug|placebo|once daily (OD)for 12 weeks
79813644|NCT00444925|Drug|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
79813645|NCT00641056|Drug|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
79813646|NCT00641056|Drug|Insulin Glargine|subcutaneous injection, variable dose, QD
79967828|NCT03904355|Drug|human chorionic gonadotropin|HCG triggering of ovulation
79309407|NCT05473065|Device|Multiaxial Prosthetic Foot Emulator|Participants will walk in the laboratory with the multiaxial Prosthetic Foot Emulator (PFE) in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.
79309408|NCT05473065|Device|Commercially available prosthetic feet|"Participants will walk in the laboratory with the commercial prosthetic study feet in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.~Additionally, participants will be fit with one of the commercial prosthetic study feet and wear it at home and in the community for approximately one week. Participants will return to the laboratory to follow-up testing, and will complete the community trial with each of the three commercial prosthetic study feet."
79309409|NCT04346121|Other|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
79309410|NCT03230591|Other|Echocardiography|LV vortex flow in Echocardiography
79967829|NCT03904355|Procedure|Ovum pick up|34 to 36 hours after oocyte retrieval
79967830|NCT03904355|Procedure|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
79967831|NCT03748849|Procedure|Physiotherapy|
79967832|NCT03747367|Behavioral|Insufficient Sleep|
79967833|NCT03898427|Device|Wrist Actigraphy Devices|A watch-like wearable sensor
79967834|NCT03898427|Device|Polysomnography|Sleep Monitor
79967835|NCT03898427|Device|Videography|Thermal Camera
79967836|NCT05187260|Drug|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
79967837|NCT01254539|Procedure|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
79967838|NCT01254539|Procedure|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
79967839|NCT01254539|Procedure|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
79967840|NCT03628664|Radiation|CT scan|Assessment of the actual posterior condylar angle using the CT scan
79967841|NCT04318093|Drug|BMS-986259|Specified dose on specified days
79967842|NCT04318093|Other|Placebo|Specified dose on specified days
79967843|NCT01254617|Biological|Cetuximab|Given IV
79309411|NCT04790643|Other|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
79309412|NCT04790643|Other|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
79474197|NCT02243527|Other|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
79474198|NCT02454179|Drug|pembrolizumab|
79638704|NCT00167700|Behavioral|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
79638705|NCT00167700|Dietary Supplement|Placebo capsules|Placebo capsules
79474199|NCT02454179|Drug|Acalabrutinib|
79638706|NCT00167700|Dietary Supplement|Probiotics|
79638707|NCT00167700|Dietary Supplement|Prebiotics|
79638708|NCT00512551|Procedure|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
79813647|NCT00814346|Drug|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
79813648|NCT00814346|Drug|Placebo|Placebo 1 tablet BID
79813649|NCT00569374|Drug|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
79813650|NCT00828464|Drug|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
79813651|NCT00816712|Drug|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Testosterone 300 mg, Intramuscular injection."
79967844|NCT01254617|Other|Laboratory Biomarker Analysis|Correlative studies
79967845|NCT01254617|Drug|Lenalidomide|Given PO
79967846|NCT05187026|Other|electronic PROMs questionnaire|Patients are asked to complete EPIC-26 questionnaire in paper and electronically
79967847|NCT01150331|Drug|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
79967848|NCT01150331|Drug|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
79967849|NCT03747289|Other|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
79967850|NCT03747289|Other|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
79474200|NCT01395641|Drug|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
79474201|NCT02041533|Biological|Nivolumab|
79474202|NCT02041533|Drug|Gemcitabine|
79803926|NCT04526730|Device|OncoSec Medical Electroporation Therapy System|"The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence."
79967851|NCT01256489|Drug|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
79309413|NCT03230513|Other|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
79309414|NCT03230513|Other|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
79638709|NCT00512590|Behavioral|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
79967852|NCT03746119|Other|E-cigarette vapor containing nicotine|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
79967853|NCT03746119|Other|E-cigarette vapor, nicotine free|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
79474203|NCT02041533|Drug|Cisplatin|
79638710|NCT00512629|Drug|Omegaven|Omegaven is a fish based intravenous fat emulsion
79638711|NCT00512629|Drug|Intralipid|Intralipid is a plant based intravenous fat emulsion
79967854|NCT03160118|Drug|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
79967855|NCT01150565|Drug|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
79638712|NCT00512668|Drug|leuprolide acetate|Given intramuscularly
79638713|NCT00512668|Drug|goserelin acetate|Given subcutaneously
79309415|NCT02445209|Other|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
79474204|NCT02041533|Drug|Carboplatin|
79638714|NCT00512668|Drug|bicalutamide|Given PO
79638715|NCT00512668|Drug|nilutamide|Given PO
79967856|NCT01149005|Drug|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
79967857|NCT01149005|Drug|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
79967858|NCT01256645|Other|blood transfusion|application of single units of red blood cell transfusions
79967859|NCT03903887|Biological|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
79967860|NCT01150643|Genetic|gene expression analysis|
79309416|NCT02445209|Other|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
79474205|NCT02041533|Drug|Paclitaxel|
79474206|NCT02041533|Drug|Pemetrexed|
79638716|NCT00512668|Drug|flutamide|Given PO
79638717|NCT00512668|Drug|temsirolimus|Given IV
79638718|NCT00512668|Other|laboratory biomarker analysis|Optional correlative studies
79638719|NCT00167739|Drug|Quinine plus sulfadoxine-pyrimethamine|
79967861|NCT01150643|Genetic|microarray analysis|
79967862|NCT01150643|Genetic|polymerase chain reaction|
79967863|NCT01150643|Genetic|polymorphism analysis|
79967864|NCT01150643|Other|immunohistochemistry staining method|
79967865|NCT01150643|Other|laboratory biomarker analysis|
79967866|NCT05212844|Procedure|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
79967867|NCT03903419|Diagnostic Test|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
79967868|NCT05122130|Drug|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
79474207|NCT02907203|Device|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
79967869|NCT05122130|Drug|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
79967870|NCT03898271|Other|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
79967871|NCT03897803|Diagnostic Test|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
79967872|NCT05212532|Drug|EOM613|peptide nucleic acid (PNA)
79967873|NCT01258205|Drug|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
79967874|NCT03893981|Other|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
79967875|NCT03893981|Other|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
79967876|NCT02898506|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
79967877|NCT02898506|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
79967878|NCT03897959|Device|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
79967879|NCT03897647|Device|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
79967880|NCT04123405|Drug|acetylcysteine|600 mg tablet
79967881|NCT04123405|Drug|Placebo|Placebo to acetylcysteine
79638720|NCT00512746|Other|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
79967882|NCT02611232|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
79967883|NCT02611232|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
79967884|NCT01258283|Other|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
79967885|NCT05076734|Diagnostic Test|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
79967886|NCT01150877|Drug|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
79638721|NCT00512746|Other|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
79638722|NCT00512746|Procedure|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
79638723|NCT00512746|Procedure|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
79638724|NCT00524251|Drug|esomeprazole|
79638725|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
79638726|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
79638727|NCT00512824|Dietary Supplement|low calcium milk of 180 ml|twice daily for 24 weeks
79638728|NCT00512824|Dietary Supplement|regular milk of 180 ml|twice daily for 24 weeks
79638729|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
79638730|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
79967887|NCT03893591|Diagnostic Test|Anti Xa levels|one Blood sample
79474208|NCT02887157|Device|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
79474209|NCT02887157|Other|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
79474210|NCT02887157|Other|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
79803927|NCT04524442|Drug|arginine/lysine|1000 milliliters (mL) administered at a constant rate of 250 mL per hour
79813652|NCT00816712|Drug|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 & 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Testosterone 100 mg, Intramuscular injection."
79813653|NCT00816712|Drug|Comparator: Placebo given by Intramuscular Injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Placebo given as intramuscular injection."
79813654|NCT00818194|Drug|extended release tacrolimus|oral
79967888|NCT01256801|Biological|cytokine|interleukin 2 2 million unit every week
79967889|NCT02519738|Drug|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
79967890|NCT02519738|Drug|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
79474211|NCT02883335|Other|Observational registry|
79474212|NCT04743869|Device|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
79474213|NCT04743869|Device|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
79638731|NCT00512863|Drug|Humira (adalimumab)|
79967891|NCT02519738|Other|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
79967892|NCT03747211|Behavioral|Aerobic exercise|High Intensity Interval Training (HIIT)
79474214|NCT02260531|Drug|Cabozantinib|
79474215|NCT02260531|Drug|Trastuzumab|
79474216|NCT02458235|Drug|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
79474217|NCT02458235|Biological|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
79474218|NCT04744103|Drug|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
79474219|NCT02140723|Radiation|preoperative short course radiation|
79474220|NCT02115997|Drug|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
79638732|NCT00524407|Drug|Epoetin alfa|
79638733|NCT00525889|Drug|IL-2|Administered by subcutaneous injection at a dose of 4.5x10^6 IU/day, three times weekly for 28 days starting on day 0.
79638734|NCT00525889|Drug|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
79813655|NCT00818194|Drug|cyclosporine A microemulsion|oral
79813656|NCT00816010|Behavioral|telephone contact|for lifestyle and compliance counseling
79813657|NCT02552914|Device|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
79813658|NCT02610686|Drug|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
79813659|NCT00816790|Drug|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR < 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
79474221|NCT02115997|Drug|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day [mg/kg/day]) at the discretion of investigator given daily until participants are off the drug.
79803928|NCT04524000|Drug|Alpelisib|"[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~[Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1."
79803929|NCT04524000|Drug|Fulvestrant|Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
79474222|NCT02115997|Drug|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
79474223|NCT01302197|Other|No intervention|longitudinal follow-up after stroke
79474224|NCT01805323|Drug|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
79474225|NCT01641055|Dietary Supplement|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
79474226|NCT01641055|Dietary Supplement|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
79638735|NCT00524446|Dietary Supplement|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
79638736|NCT00524446|Dietary Supplement|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
79638737|NCT00524446|Dietary Supplement|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
79638738|NCT00524524|Drug|ARQ 501|Weekly IV Infusion; 450 mg/m2
79803930|NCT04512235|Drug|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
79803931|NCT04512235|Other|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
79967893|NCT01256957|Device|HEPA filter|
79474227|NCT01641055|Dietary Supplement|Cod protein|2.5g cod protein per day for 8wk.
79967894|NCT03893669|Biological|NBP607|1 dose, 0.5ml, Intramuscular (IM) injection
79967895|NCT03893669|Biological|Agrippal|1 dose, 0.5ml, Intramuscular (IM) injection
79967896|NCT03893747|Biological|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
79474228|NCT01641055|Dietary Supplement|Milk protein|2.5g milk protein per day for 8wk.
79474229|NCT02459795|Drug|Ingenol Mebutate (Perrigo)|
79474230|NCT02459795|Drug|Ingenol Mebutate (Reference)|
79474231|NCT02459795|Drug|Placebo gel|
79474232|NCT01787383|Drug|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
79474233|NCT01787383|Drug|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
79474234|NCT02461433|Device|Prevena|Prevena Incision Management system
79474235|NCT02461433|Device|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
79638739|NCT03879122|Drug|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
79803932|NCT04512235|Drug|cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen|According to institutional standard of care.
79803933|NCT04509115|Drug|Short-acting opioid prescription for acute pain|Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
79803934|NCT04506073|Drug|MSC+placebo|2 infusions of 10 X 10^6 MSC/kg and 1 placebo every 3 months.
79803935|NCT04506073|Drug|MSC|3 infusions of 10 X 10^6 MSC/kg every 3 months.
79803936|NCT04506073|Drug|Placebo|3 infusions of placebo every 3 months. Placebo will be identical to the investigational product but will not contain MSCs.
79803937|NCT04505865|Behavioral|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
79967897|NCT03893747|Biological|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
79967898|NCT03893747|Biological|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
79967899|NCT03893747|Biological|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
79803943|NCT04484987|Other|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
79803944|NCT04484987|Other|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
79803945|NCT04469075|Drug|Clindamycin Phosphate|phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
79803946|NCT04469075|Drug|Triamcinolone Acetonide|triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
79803947|NCT04467333|Other|All lung cancer patients.|There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
79803948|NCT04467255|Other|Rehabilitative training|4 weeks aerobic treadmill training compared to endurance training with elastic thera band
79474236|NCT02462291|Other|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
79474237|NCT02463227|Biological|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
79803949|NCT04463615|Drug|Leflunomide|Given PO
79803950|NCT04450732|Drug|GQ1001|anti-HER2 antibody drug conjugate
79813660|NCT00816790|Drug|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
79813661|NCT00818350|Drug|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
79803951|NCT04448483|Device|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
79967900|NCT03893747|Biological|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
79967901|NCT03893747|Biological|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
79967902|NCT02343224|Drug|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
79967903|NCT01257035|Other|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
79967904|NCT04314037|Drug|Cesol (Test)|Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.
79638740|NCT03879122|Drug|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
79803952|NCT04448483|Device|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
79967905|NCT04314037|Drug|Biltricide (Reference)|Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
79967906|NCT03893357|Other|Data extraction from medical files|Retrospective data extraction from the medical files
79967907|NCT02248688|Device|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
79638741|NCT03879122|Drug|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
79803953|NCT04444492|Drug|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
79638742|NCT03879122|Drug|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
79967908|NCT02248688|Procedure|Left Gastric Artery Embolization|
79967909|NCT03897569|Other|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
79967910|NCT03745963|Behavioral|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
79967911|NCT03745963|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
79967912|NCT01257113|Other|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
79967913|NCT01257113|Other|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
79967914|NCT05737862|Dietary Supplement|Moringa oleifera capsules|In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
79803954|NCT04444492|Device|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
79803955|NCT04442490|Drug|SAGE-217|SAGE-217 oral capsules.
79803956|NCT04442490|Drug|Placebo|SAGE-217 matched-placebo oral capsules.
79803957|NCT04393350|Drug|Lenvatinib|Given PO
79803958|NCT04393350|Drug|Lenvatinib Mesylate|Given PO
79803959|NCT04393350|Biological|Pembrolizumab|Given IV
79803960|NCT04393350|Other|Quality-of-Life Assessment|Ancillary studies
79803961|NCT04393350|Other|Questionnaire Administration|Ancillary studies
79474238|NCT00984269|Procedure|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
79803962|NCT04375761|Procedure|Collection of Biological Samples|Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
79638743|NCT00524602|Procedure|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
79803963|NCT04375761|Procedure|Symptom and Exposure Surveys|Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
79967915|NCT05737862|Dietary Supplement|iron and folic acid supplements|In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
79638744|NCT00525928|Drug|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
79638745|NCT00167817|Drug|Aripiprazole|
79638746|NCT03868982|Device|Neurally adjusted ventilatory assist|NAVA uses the diaphragm activity to deliver mechanical ventilation
79638747|NCT02948023|Biological|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
79638748|NCT02952079|Device|Blephex|Lid margin exfoliation
79638749|NCT02952079|Device|MiboFlo|Lid warming treatment
79638750|NCT02948218|Device|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
79638751|NCT00173082|Procedure|Glucose tolerance test|
79803964|NCT04361058|Drug|Nivolumab|At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
79803965|NCT04357912|Behavioral|Activity Tracker Group|In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
79803966|NCT04357912|Behavioral|Standard of Care Group|Participants will receive standard of care exercise education.
79803967|NCT04341155|Drug|Dexamethasone|Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
79803968|NCT04341155|Drug|Placebo|Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
79803969|NCT04339036|Drug|Capecitabine Oral Product|Capecitabine 750 mg/m2 twice daily orally for 14 days
79803970|NCT04339036|Drug|Temozolomide Oral Product|temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
79803971|NCT04339036|Combination Product|transarterial radioembolization|Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
79967916|NCT03745885|Drug|Supaglutide injection|Administered SC in the Supaglutide arms.
79967917|NCT03745885|Drug|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
79967918|NCT02101970|Dietary Supplement|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
79967919|NCT02101970|Other|Placebo Capsule|
79638752|NCT02947906|Other|No intervention|No intervention
79638753|NCT02947711|Drug|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
79638754|NCT02947711|Drug|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
79638755|NCT02946736|Behavioral|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
79638756|NCT02946736|Behavioral|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
79638757|NCT03845348|Other|TD03|Shampoo TD 3 days
79638758|NCT03845348|Other|TD07|Shampoo TD 7 days
79638759|NCT03845348|Drug|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
79638760|NCT04723563|Drug|Heparin|25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
79638761|NCT04723563|Drug|0.9%sodium chloride|5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
79638762|NCT00525967|Drug|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
79638763|NCT00524719|Procedure|Open Reduction and Internal Fixation|Fixation with volar locked plate
79638764|NCT00524719|Procedure|Non-Spanning External Fixation|Radio-radial external fixation
79638765|NCT00524719|Procedure|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
79474239|NCT01788631|Drug|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
79309417|NCT05613699|Behavioral|Exercise - Social Media|The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.
79967920|NCT02101970|Other|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
79967921|NCT01258361|Procedure|echocardiography|Echocardiography is performed for all patients
79967922|NCT05211830|Drug|SXR1096 cream|Skin cream to be applied twice a day to a predefined area of the skin
79638766|NCT03817307|Diagnostic Test|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
79638767|NCT02947789|Procedure|Emergency surgery|Patients undergoing emergency surgery
79638768|NCT00167856|Drug|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
79638769|NCT04693273|Other|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
79638770|NCT00524758|Device|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
79638771|NCT00524758|Drug|MMC in Trabeculectomy|MMC in Trabeculectomy
79638772|NCT00526006|Drug|esomeprazole|40 mg od for 8 wks
79803972|NCT04327700|Device|TheraBionic|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
79803973|NCT04327700|Drug|Regorafenib|Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
79309418|NCT05613699|Behavioral|Exercise - App|Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.
79309419|NCT05613699|Behavioral|Exercise - closed to patients residence|The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
79474240|NCT01788631|Drug|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
79638773|NCT04693117|Other|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
79638774|NCT02947477|Behavioral|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
79638775|NCT00167895|Procedure|Adding platelet concentrate to the wound|
79967923|NCT05211830|Drug|Placebo cream|Skin cream to be applied twice a day to a predefined area of the skin
79309420|NCT02445365|Device|AutoRIC device|
79309421|NCT02444975|Dietary Supplement|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
79309422|NCT02444975|Other|Coaching program|Coaching program to support increased water intake
79309423|NCT02444975|Other|No intervention|No intervention
79803974|NCT04325022|Device|Primary Total Hip Arthroplasty|Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
79474241|NCT00907283|Drug|Deferiprone|15 mg/Kg/twice for 1 year
79967924|NCT03893201|Other|Questionnaires|Questionnaires to assess quality of life
79967925|NCT02097680|Drug|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
79967926|NCT02097680|Drug|Placebo|One placebo capsule every two days during four months
79967927|NCT01150955|Dietary Supplement|Resveratrol|500 mg three times a day for five weeks.
79967928|NCT01150955|Other|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
79967929|NCT03897413|Drug|S-888711|Administered orally as three 0.25 mg tablets
79474242|NCT01789255|Drug|vorinostat|Given PO
79474243|NCT01789255|Drug|tacrolimus|Given IV or PO
79474244|NCT01789255|Drug|cyclosporine|Given IV or PO
79967930|NCT03897413|Dietary Supplement|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
79803975|NCT04325022|Device|Revision Total Hip Arthroplasty|Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
79474245|NCT01789255|Drug|methotrexate|Given IV
79967931|NCT03986372|Biological|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
79474246|NCT01789255|Other|laboratory biomarker analysis|Correlative studies
79967932|NCT01258439|Drug|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
79638776|NCT02946346|Other|vaginal sampling|
79638777|NCT02946814|Drug|essential oils|
79638778|NCT02946814|Drug|essential oils without mouthwash|
79638779|NCT02946814|Drug|sterile water|
79967933|NCT01258439|Drug|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
79967934|NCT05011448|Other|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
79967935|NCT01258517|Device|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
79967936|NCT03628820|Behavioral|Dog Therapy|5 minutes spent with therapy dog during shift
79967937|NCT03628820|Behavioral|Coloring|5 minutes spend coloring mandalas during shift
79967938|NCT01257191|Drug|Carbon Black|source: commercial
79967939|NCT01257191|Drug|Diesel Exhaust Particles|source: diesel engine
79967940|NCT01257191|Drug|Fine Concentrated Ambient Particles|source: concentrated ambient air
79967941|NCT01257191|Drug|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
79967942|NCT01257191|Drug|Saline|Saline solution
79967943|NCT05507021|Dietary Supplement|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
79967944|NCT05507021|Dietary Supplement|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
79803976|NCT04321512|Other|There is no intervention given to the subjects|Not appicable
79803977|NCT04315558|Drug|Revefenacin Inhalation Solution [Yupelri]|nebulized drug comparison
79803978|NCT04315558|Drug|Ipratropium Bromide|nebulized drug comparison
79803979|NCT04307849|Behavioral|Adolescent Health Club|Sexual health/HIV-related evidence-based interventions
79967945|NCT05211674|Other|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
79967946|NCT03893513|Device|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
79474247|NCT01789255|Other|pharmacological study|Correlative studies
79474248|NCT02464163|Biological|Panblok|Intramuscular injection
79474249|NCT02464163|Biological|rHA adjuvant|Intramuscular injection
79474250|NCT02465099|Device|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
79474251|NCT02465099|Device|Electrocautery Dissection (ED)|Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
79638780|NCT00524797|Dietary Supplement|Profonycia|
79967947|NCT03893513|Device|Pulse Contour Analysis|Invasive hemodynamic monitor
79967948|NCT05751824|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
79967949|NCT05751824|Other|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
79474252|NCT01807585|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
79803980|NCT04307849|Other|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
79967950|NCT01151033|Device|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
79309424|NCT03230357|Device|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
79309425|NCT04790331|Drug|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
79309426|NCT04790331|Drug|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
79309427|NCT04790331|Drug|Placebo|Placebo oral tablet
79309428|NCT03230201|Procedure|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
79638781|NCT02946619|Behavioral|Self-Regulation Condition|
79638782|NCT02946619|Behavioral|Enhanced self-Regulation Condition|
79638783|NCT00524836|Drug|levocetirizine dihydrochloride|
79638784|NCT03660449|Combination Product|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
79638785|NCT04692883|Procedure|Percutaneous suturing|
79638786|NCT02946307|Device|Restore DEB（dimeter>2.00 mm）|
79638787|NCT02946307|Device|Resolute DES|
79638788|NCT02946307|Device|Restore DEB（dimeter:2.00 mm）|
79638789|NCT00524875|Drug|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
79967951|NCT01151969|Behavioral|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
79967952|NCT01151111|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
79638790|NCT00524914|Drug|apomorphine|Acute apomorphine subcutaneous 3 mg
79638791|NCT00524914|Drug|placebo|placebo subcutaneous
79638792|NCT02957864|Drug|tenofovir alafenamide|
79803981|NCT04303650|Device|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
79803982|NCT04297761|Other|Filtered Air|Ambient air will be filtered and used for control exposure.
79803983|NCT04297761|Other|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m^3 for 2 hours.
79803984|NCT04292873|Other|Vitamin D supplement|Enteral supplement of 569,600 IU vitamin D
79803985|NCT04286386|Other|Hyperpolarized Carbon C 13 Pyruvate|Given IV
79803986|NCT04286386|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
79803987|NCT04286386|Procedure|Surgical Procedure|Undergo standard of care surgery
79967953|NCT00647036|Dietary Supplement|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
79967954|NCT00647036|Drug|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
79309429|NCT05613465|Drug|Codonopsis|Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
79967955|NCT03893123|Other|Observational study, prostate cancer is outcome of interest|Observational study
79309430|NCT05613465|Drug|Placebo|Placebo is packaged in the same package as the drug
79309431|NCT03230279|Procedure|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
79474253|NCT01807585|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
79638793|NCT02957864|Drug|abacavir|
79638794|NCT00524953|Device|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last ~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
79638795|NCT00168012|Drug|Immunoglobulins Intravenous (Human)|
79638796|NCT02946541|Drug|evogliptin 5mg|evogliptin 5mg, QD
79638797|NCT02946541|Drug|Placebo|Placebo, QD
79638798|NCT00526201|Behavioral|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
79638799|NCT00526201|Behavioral|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
79638800|NCT00525109|Other|No Intervention|No intervention
79638801|NCT03585452|Drug|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
79638802|NCT03585452|Drug|Propofol based general anesthesia|Patients with typical anaesthetic regimens
79638803|NCT02946502|Procedure|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
79309432|NCT03230279|Procedure|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
79309433|NCT03230123|Dietary Supplement|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
79474254|NCT01807585|Device|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
79474255|NCT01808755|Dietary Supplement|D Mannose|1 gr. every 8 hours
79474256|NCT01808755|Drug|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
79474257|NCT02694809|Drug|Conjugated Estrogens/Bazedoxifene|Given PO
79474258|NCT02694809|Other|Laboratory Biomarker Analysis|Correlative studies
79474259|NCT02694809|Other|Pharmacological Study|Correlative studies
79638804|NCT02947867|Drug|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
79638805|NCT02947672|Drug|Intravenous Dexamethasone|
79638806|NCT02947672|Drug|Intraperitoneal Dexamesathone|
79638807|NCT02947555|Other|Non interventional|
79803988|NCT04286191|Combination Product|Operant Conditioning|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
79803989|NCT04286191|Combination Product|Control Group|This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
79803990|NCT04275557|Other|Blood Sample collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).
79967956|NCT00394550|Procedure|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
79638808|NCT04693546|Diagnostic Test|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
79967957|NCT00394550|Procedure|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
79309434|NCT04790097|Radiation|Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost|"78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide"
79309435|NCT03230045|Device|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
79309436|NCT03230045|Device|no treatment|electrodes are attached, but no stimulation is given
79309437|NCT04789941|Drug|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
79309438|NCT02445053|Drug|ivacaftor|
79309439|NCT02444819|Drug|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
79474260|NCT02694809|Other|Placebo|Given PO
79474261|NCT02694809|Procedure|Quality-of-Life Assessment|Ancillary studies
79474262|NCT02694809|Other|Questionnaire Administration|Ancillary studies
79474263|NCT01790581|Behavioral|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
79474264|NCT01790581|Behavioral|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
79474265|NCT02648165|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
79474266|NCT02648165|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
79474267|NCT02648165|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
79474268|NCT00362687|Drug|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
79474269|NCT00362687|Drug|FTC alone|emtricitabine 200 mg
79638809|NCT04693546|Diagnostic Test|FIT Test|Procedure: Colonoscopy
79309440|NCT03079089|Drug|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
79309441|NCT03079089|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at DO
79309442|NCT03079089|Drug|Prevention of GVHD|"Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
79474270|NCT00362687|Procedure|No HAART|No HAART
79474271|NCT02469389|Behavioral|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
79474272|NCT02469389|Behavioral|Health & Wellness (H&W)|"Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session)."
79803991|NCT04275557|Other|Tissue sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
79967958|NCT01560572|Drug|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
79638810|NCT02947360|Other|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
79967959|NCT03897023|Biological|Gut Microbiota|Status of microbiota
79967960|NCT01258673|Drug|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
79803992|NCT04275557|Other|Data collection|Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
79803993|NCT04269200|Drug|olaparib|Olaparib tablets
79803994|NCT04269200|Biological|durvalumab|Durvalumab by intravenous infusion
79967961|NCT01258673|Drug|Fimasartan|Fimasartan 60mg, 120mg
79967962|NCT05209256|Drug|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
79967963|NCT05209256|Drug|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve [AUC] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
79967964|NCT01258751|Drug|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
79967965|NCT01258829|Other|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
79803995|NCT04269200|Drug|durvalumab placebo|Matching placebo for intravenous infusion
79967966|NCT01258829|Other|ECHO optimisation|Standard ECHO optimisation method
79967967|NCT05211128|Procedure|Robotic Surgery|Surgical procedure using robotic technologies.
79967968|NCT05211128|Procedure|Open Surgery|Surgical procedure using a large, open cut in the skin.
79967969|NCT05211128|Procedure|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
79967970|NCT05211050|Drug|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
79967971|NCT05211050|Drug|Sumatriptan|10 min infusion of 4 mg sumatriptan.
79967972|NCT05211050|Drug|Saline|10 min infusion of isotonic saline (placebo).
79967973|NCT03892733|Behavioral|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
79967974|NCT05210894|Biological|Anti-IL8|
79967975|NCT04883138|Drug|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
79309443|NCT03079089|Drug|Care supports|According to the protocols of each center
79474273|NCT01790659|Drug|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
79803996|NCT04269200|Drug|olaparib placebo|Placebo tablets to match olaparib
79803997|NCT04269200|Drug|Carboplatin|Standard of care chemotherapy
79803998|NCT04269200|Drug|Paclitaxel|Standard of care chemotherapy
79474274|NCT01790659|Drug|Paromomycin|Paromomycin alone
79474275|NCT00681655|Other|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
79638811|NCT03539627|Drug|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
79638812|NCT02947399|Radiation|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
79474276|NCT00681655|Other|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
79638813|NCT02946268|Drug|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
79474277|NCT01811875|Biological|Optivate 500IU|
79474278|NCT02469701|Drug|nivolumab and ablation|
79474279|NCT01733407|Drug|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
79638814|NCT00168051|Drug|ReFacto|
79638815|NCT00168051|Drug|Advante|
79474280|NCT01733407|Drug|placebo|400mg/kg/d divided TID for year 1 only.
79474281|NCT00422045|Device|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
79474282|NCT01733953|Drug|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
79967976|NCT03892811|Other|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
79803999|NCT04265794|Behavioral|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
79474283|NCT01733953|Drug|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
79967977|NCT05210738|Device|Single incision sling|Single incision sling is used to treat occult SUI
79967978|NCT05210738|Drug|Bulkamid bulking agent|Urethral bulking by Bulkamid is used to treat occult SUI
79967979|NCT02527655|Behavioral|Choice-Based Physical Activity and Active Transportation|
79804000|NCT04262089|Drug|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
79967980|NCT05209022|Dietary Supplement|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
79804001|NCT04235231|Device|Bed tilting|15° lateral tilt, original product brand name LINET Eleganza 5
79804002|NCT04235231|Other|Body positioning|Manual positioning of body by nurse: left side, back, right side, using positioning pillows
79804003|NCT04225598|Drug|CAM2038|Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
79967981|NCT03892499|Drug|Olinciguat|Oral Tablet
79474284|NCT00362921|Drug|Gliadel wafers in combination with O6-benzylguanine|
79474285|NCT01734889|Drug|Nitisinone|Oral suspension
79638816|NCT00526318|Biological|filgrastim|
79967982|NCT03892499|Drug|Itraconazole|Oral Capsule
79967983|NCT05732558|Procedure|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system|The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
79967984|NCT03896243|Diagnostic Test|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
79967985|NCT01152047|Drug|oxytocin|40mU/min as infusion of oxytocin
79967986|NCT01257659|Procedure|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
79813662|NCT00810602|Procedure|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
79474286|NCT01735981|Other|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
79474287|NCT01735981|Other|hand-held video game|hand-held video games
79967987|NCT01257659|Procedure|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
79967988|NCT01151267|Other|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
79967989|NCT01151267|Device|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
79967990|NCT03056300|Device|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
79474288|NCT01736527|Drug|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
79302450|NCT02486159|Drug|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
79302451|NCT02486159|Procedure|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
79302452|NCT03224377|Diagnostic Test|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
79474289|NCT01796665|Drug|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
79474290|NCT01796665|Drug|Acanya Gel|
79638817|NCT00526318|Drug|carboplatin|
79813663|NCT00810602|Drug|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
79813664|NCT00810602|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
79967991|NCT01152125|Other|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
79984311|NCT03223636|Device|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
79967992|NCT05210426|Other|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
79967993|NCT01259141|Drug|Moxifloxacin|0.4 Qd for 7days
79967994|NCT01259141|Drug|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
79967995|NCT03896087|Diagnostic Test|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
79967996|NCT03896087|Diagnostic Test|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
79967997|NCT03896087|Diagnostic Test|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
79967998|NCT03896087|Diagnostic Test|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
79638818|NCT00526318|Drug|cisplatin|
79302453|NCT02489435|Drug|VM-1500|VM-1500
79638819|NCT00526318|Drug|cyclophosphamide|
79638820|NCT00526318|Drug|dacarbazine|
79638821|NCT00526318|Drug|doxorubicin hydrochloride|
79638822|NCT00526318|Drug|etoposide phosphate|
79638823|NCT00526318|Drug|ifosfamide|
79638824|NCT00526318|Drug|isotretinoin|
79638825|NCT00526318|Drug|melphalan|
79638826|NCT00526318|Drug|topotecan hydrochloride|
79638827|NCT00526318|Drug|vincristine sulfate|
79638828|NCT00526318|Drug|vindesine|
79638829|NCT00526318|Procedure|autologous hematopoietic stem cell transplantation|
79638830|NCT00526318|Radiation|iobenguane I 131|
79967999|NCT05210192|Drug|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
79968000|NCT05210192|Drug|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
79474291|NCT01796665|Drug|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
79804004|NCT04225598|Drug|Buprenorphine Sublingual Product|"COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS >≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD."
79804005|NCT04219189|Other|Vaping condition|Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with ~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.
79968001|NCT01152203|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle
79309444|NCT03079089|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II."
79309445|NCT02444897|Drug|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
79309446|NCT02444897|Drug|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
79474292|NCT01796977|Device|OxyGenesys Dissolved Oxygen Dressing|
79474293|NCT01796977|Device|Standard Gauze Dressing|
79968002|NCT01152203|Drug|Bevacizumab|10 mg/kg by vein on Days 1 & 15 of every 28 day cycle
79968003|NCT05210036|Device|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~Hot Pack at 60 degrees Celsius for 20 minutes~TENS at 80 Hz for 20 minutes~Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
79309447|NCT03193775|Biological|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
79474294|NCT02989987|Behavioral|Narrative Exposure Therapy|
79474295|NCT02989987|Behavioral|Social Support|A local counselors provides social support on demand.
79474296|NCT01798225|Drug|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
79474297|NCT01798225|Drug|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
79474298|NCT01800877|Drug|Vasopressors|
79474299|NCT00363623|Device|Silicone hydrogel contact lens|
79638831|NCT00526318|Radiation|radiation therapy|
79968004|NCT05210036|Device|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~Hot Pack at 60 degrees Celsius for 20 minutes~TENS at 80 Hz for 20 minutes~Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
79804006|NCT04219189|Other|Control condition|Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
79804007|NCT04217694|Behavioral|Cogstate Assessment Battery|Complete CogState testing
79804008|NCT04217694|Drug|Memantine|Given PO
79804009|NCT04217694|Drug|Memantine Hydrochloride|Given PO
79804010|NCT04216524|Drug|Cyclophosphamide|Given IV
79968005|NCT01257815|Drug|Ranibizumab|
79968006|NCT04638920|Other|No intervention|No intervention
79968007|NCT03892421|Drug|Rituximab|Rituximab 375 mg/m²
79968008|NCT03892421|Drug|Carboplatin|Carboplatin AUC5
79968009|NCT03892421|Drug|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
79302454|NCT02489435|Drug|Placebo|Placebo
79804011|NCT04216524|Drug|Cytarabine|Given IT or IV
79804012|NCT04216524|Drug|Dexamethasone|Given PO or IV
79804013|NCT04216524|Drug|Doxorubicin|Given IV
79804014|NCT04216524|Drug|Mercaptopurine|Given PO
79804015|NCT04216524|Drug|Methotrexate|Given IT, IV, or PO
79804016|NCT04216524|Drug|Methylprednisolone|Given IV
79804017|NCT04216524|Drug|Prednisone|Given PO
79804018|NCT04216524|Biological|Rituximab|Given IV
79804019|NCT04216524|Biological|Tagraxofusp-erzs|Given IV
79804020|NCT04216524|Drug|Venetoclax|Given PO
79804021|NCT04216524|Drug|Vincristine|Given IV
79968010|NCT03892421|Drug|Dexamethasone|Dexamethasone 40 mg
79968011|NCT03892421|Drug|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
79968012|NCT03892109|Other|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
79968013|NCT03892109|Device|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
79968014|NCT03892109|Other|Gingitrac|packed into the sulcus
79968015|NCT01152281|Behavioral|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
79968016|NCT01152281|Behavioral|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
79968017|NCT01152281|Behavioral|Minimal Control|Control messages to increase awareness of HIV risk
79968018|NCT01152281|Behavioral|Instrumental|Instrumental messages with stories of people living with HIV
79968019|NCT01152281|Behavioral|Empowering|Empowering messages with stories of people living with HIV
79968020|NCT03895619|Other|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
79474300|NCT02470949|Behavioral|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
79474301|NCT02470949|Behavioral|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
79804022|NCT04214626|Drug|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles)."
79804023|NCT04214626|Drug|Lenalidomide|Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79968021|NCT05546567|Dietary Supplement|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
79309448|NCT03229733|Device|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
79309449|NCT03229733|Behavioral|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
79309450|NCT03229655|Procedure|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
79638832|NCT00526357|Drug|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
79638833|NCT04693312|Drug|Depo medrol|local injection
79309451|NCT05472285|Dietary Supplement|Verum|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
79309452|NCT05472285|Dietary Supplement|Placebo|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
79638834|NCT04710381|Drug|IMUNOR|The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
79309453|NCT03229889|Drug|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
79309454|NCT03229889|Drug|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
79309455|NCT03229889|Combination Product|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
79638835|NCT00525304|Behavioral|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
79804024|NCT04214626|Drug|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79804025|NCT04214626|Drug|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79968022|NCT03895229|Drug|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
79968023|NCT03892343|Diagnostic Test|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
79968024|NCT03895073|Other|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
79968025|NCT01257893|Drug|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
79302455|NCT02451787|Dietary Supplement|Vitamin D|2400 units per day for 3 months
79302456|NCT03321149|Other|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
79302457|NCT03224221|Drug|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
79302458|NCT03224221|Drug|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
79309456|NCT03229889|Drug|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
79804026|NCT04214626|Drug|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79804027|NCT04214626|Drug|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79804028|NCT04214626|Drug|Methotrexate|Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
79309457|NCT04789785|Diagnostic Test|ultrasound|observation with usg
79804029|NCT04214210|Other|Adapted Family Gene Toolkit|Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).
79804030|NCT04214210|Other|Targeted intervention|The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
79968026|NCT01257893|Drug|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
79309458|NCT04789629|Device|low level laser therapy|3 session per week laser with exercises
79309459|NCT02444585|Drug|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
79968027|NCT01152593|Drug|Mupirocin|Intranasal cream given to patient after confirmation of colonization
79309460|NCT03120221|Diagnostic Test|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
79309461|NCT05472129|Other|self-administered questionnaires|The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
79309462|NCT03193073|Diagnostic Test|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
79309463|NCT03193073|Diagnostic Test|serum fibroblast growth factor-23|serum levels of FGF-23
79309464|NCT03193073|Diagnostic Test|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
79309465|NCT02444507|Drug|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
79474302|NCT02471651|Drug|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
79474303|NCT02471651|Drug|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
79474304|NCT02473991|Radiation|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
79474305|NCT02476565|Device|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
79804031|NCT04213859|Behavioral|VRET - Virtual Reality Exposure Therapy|VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum & Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
79804032|NCT04209725|Drug|CPX-351|Given during the induction and consildation phase and will consist of 44 mg/m^2 daunorubicin with 100 mg/m^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
79804033|NCT04209725|Drug|Quizartinib|Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
79804034|NCT04201821|Biological|fecal microbial transplantation (FMT)|Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
79804035|NCT04196868|Drug|Metformin treatment|1500 mg once a day, per os, during six months
79309466|NCT02444507|Drug|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
79309467|NCT03118271|Device|lumbar traction|
79474306|NCT02476565|Device|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
79804036|NCT04196868|Other|Placebo|per os, during six months
79804037|NCT04196868|Drug|Methotrexate treatment|per os
79804038|NCT04193189|Biological|HEPLISAV-B|Administered by IM injection
79804039|NCT04193189|Biological|ENGERIX-B|Administered by IM injection
79309468|NCT03118271|Procedure|spinal manipulation|
79309469|NCT03118271|Procedure|surgery|
79309470|NCT03118427|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
79474307|NCT02477423|Drug|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
79309471|NCT03118427|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
79804040|NCT04192097|Other|Professionalism curriculum|"One year training program including ten two-hours sessions about~Knowing yourself~Interaction with patients and their families~Teamwork and organization with colleagues"
79804041|NCT04179162|Drug|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
79804042|NCT04179162|Drug|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
79984312|NCT03223636|Device|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
79302459|NCT03204253|Drug|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
79302460|NCT03204253|Drug|rFSH alone|32 women who were stimulated with recombinant FSH alone
79302461|NCT03204175|Other|FIT Plus|"Group handwashing facilities~Daily group handwashing and toothbrushing activities~Sanitation operation and maintenance manuals for school officials~Toilet cleaning consumable~Toilet and handwashing station maintenance kits~Soap, toothbrushes, and toothpaste"
79302462|NCT03204175|Other|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
79302463|NCT02486081|Device|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
79302464|NCT03204097|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
79804043|NCT04173702|Diagnostic Test|balance analysis|Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
79984313|NCT03749603|Device|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
79984314|NCT03223558|Behavioral|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
79984315|NCT03223402|Other|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
79984316|NCT03208972|Drug|low dose hCG|
79984317|NCT03208972|Drug|hp-FSH|
79302465|NCT03204097|Drug|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
79302466|NCT03204097|Drug|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
79804044|NCT04171323|Behavioral|Cognitive Training|Participants will be completing a total of 40 computerized sessions.
79804045|NCT04171323|Behavioral|Computerized Cognitive Stimulation|Participants will be completing a total of 40 computerized cognitive stimulation sessions.
79804046|NCT04164901|Drug|Vorasidenib|Vorasidenib oral film-coated tablets
79968028|NCT01259219|Drug|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
79804047|NCT04164901|Drug|Matching Placebo|Matching Placebo oral tablets
79804048|NCT04160221|Other|12 hours interval|Time interval between treatments
79804049|NCT04160221|Other|24 hours interval|Time interval between treatments
79804050|NCT04142307|Device|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
79804051|NCT04142307|Device|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
79968029|NCT03895151|Dietary Supplement|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
79474308|NCT02477423|Drug|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
79474309|NCT02477423|Drug|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
79474310|NCT02478671|Device|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
79474311|NCT02479763|Procedure|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
79474312|NCT00363701|Drug|esomeprazole|
79804052|NCT04140162|Drug|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
79804053|NCT04140162|Drug|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
79968030|NCT03895151|Other|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
79968031|NCT03891407|Diagnostic Test|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
79968032|NCT03895385|Drug|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
79984318|NCT03208972|Drug|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~<60 kg: Elonva 100 MCG > 60 kg: Elonva 150 MCG"
79984319|NCT03206866|Diagnostic Test|serum regucalcin antibody|serum regucalcin antibody
79804054|NCT04140162|Drug|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
79474313|NCT04744493|Device|ExaBlate 4000|The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
79804055|NCT04140162|Drug|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
79804056|NCT04132492|Other|no intervention|there is no intervention
79984320|NCT02450500|Behavioral|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
79984321|NCT03223324|Device|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
79984322|NCT03206398|Device|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
79984323|NCT02451748|Other|Lab Work|Lab work to measure IL-7 and IL-7R
79968033|NCT03891719|Procedure|Unilateral cleft lip rhinoplasty|"Perform marking with methylene blue tattoo marks~Inject Local anesthetic solution with epinephrine~Harvest auricular cartilage~Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~Dorsal augmentation~Lip reconstruction and alar base repositioning.~Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
79984324|NCT02451748|Drug|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
79804057|NCT04115098|Drug|Drug order 1|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
79804058|NCT04115098|Drug|Drug order 2|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
79655548|NCT04548895|Device|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
79984325|NCT02451748|Drug|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
79340392|NCT05647941|Diagnostic Test|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
79984326|NCT02451748|Drug|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
79984327|NCT02451748|Drug|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
79474314|NCT04744571|Drug|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
79474315|NCT04744571|Device|coronary wires. or coronary balloons|all species of coronary wires, or plain balloons
79474316|NCT04744571|Other|drug-coated balloon|Drug-coated balloon including all sizes and all brands
79474317|NCT04744571|Device|drug-eluting stent|Drug-eluting stent including all sizes and all brands
79804059|NCT04115098|Drug|Drug order 3|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
79804060|NCT04115098|Drug|Drug order 4|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
79968034|NCT01151501|Device|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) >92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2>92%.
79968035|NCT03891095|Drug|Oxytocin|intranasally administrated
79968036|NCT03891095|Drug|L-DOPA|orally administered
79968037|NCT03891095|Drug|Placebos|intranasally administrated and orally administered
79968038|NCT05667077|Drug|Amantadine|The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
79968039|NCT03891017|Other|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
79968040|NCT03891017|Other|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
79968041|NCT03890939|Device|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
79968042|NCT03890939|Device|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
79984328|NCT02451748|Drug|Medrol|some patients are on 8mg/day of medrol
79984329|NCT02451748|Drug|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
79984330|NCT02451748|Drug|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for ~ 3 months) some patients are on Triamcinolone 40mg IM monthly
79984331|NCT02451748|Drug|Naproxen|some patients are on 1000 mg/day of naproxen
79984332|NCT02451748|Drug|Leflunomide|some patients are on 20mg/day of leflunomide
79984333|NCT02451748|Drug|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
79984334|NCT02451748|Drug|humira|some patients are on Humira 40mg q2weeks
79984335|NCT03223168|Device|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
79984336|NCT03208894|Drug|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
79984337|NCT02450656|Drug|Afatinib|Tablet
79984338|NCT02450656|Drug|Selumetinib|Capsule
79984339|NCT02450656|Drug|Docetaxel|
79984340|NCT03208816|Behavioral|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
79309472|NCT05472051|Other|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~HIV screening, including pre- and post- counseling~Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
79309473|NCT02444195|Behavioral|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
79474318|NCT00363155|Drug|KRN7000|
79474319|NCT02518997|Other|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
79474320|NCT02519387|Drug|Buprenorphine Transdermal Patch|
79474321|NCT02521181|Drug|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
79474322|NCT02521181|Drug|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
79804061|NCT04115098|Drug|Drug order 5|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
79804062|NCT04115098|Drug|Drug order 6|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
79804063|NCT04111107|Drug|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
79968043|NCT03890939|Device|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
79968044|NCT01589627|Device|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
79968045|NCT01152671|Drug|Placebo|single oral dose
79968046|NCT01152671|Drug|RO5024048|single oral dose
79804064|NCT04111107|Other|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
79968047|NCT03894839|Other|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
79968048|NCT03894839|Other|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
79968049|NCT03894839|Other|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
79968050|NCT03894839|Other|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
79968051|NCT03894839|Other|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
79968052|NCT03894839|Other|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
79968053|NCT03894761|Other|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
79474323|NCT02521181|Drug|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
79309474|NCT02177812|Drug|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
79804065|NCT04111107|Diagnostic Test|Next Gen Sequencing Report|1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
79309475|NCT02177812|Drug|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
79309476|NCT02203305|Device|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
79309477|NCT02203305|Other|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
79309478|NCT01626352|Drug|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m^2 Days 1 and 2 of Cycles 1 through 6.
79968054|NCT01152749|Drug|Nicotine|Single-dose of new NRT product
79474324|NCT02521259|Device|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
79804067|NCT04079855|Other|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
79804068|NCT04079855|Other|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
79804069|NCT04079855|Other|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
79804070|NCT04078477|Other|Body positioning|Comparison lateral tilt bed to standard patient´s body positioning in the bed.
79804071|NCT04072354|Drug|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
79804072|NCT04072354|Drug|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
79804073|NCT04072354|Drug|Placebo|Placebo tablet dosed once daily
79804074|NCT04050202|Behavioral|Attachment and Biobehavioral Catch-up (ABC) Intervention|ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
79804075|NCT04050189|Biological|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
79804076|NCT04050189|Other|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
79968055|NCT01152749|Drug|Nicotine Gum|Single-dose of marketed nicotine gum
79968056|NCT03894683|Drug|Melatonin 10 mg|Melatonin tablets (10 mg)
79968057|NCT03894683|Drug|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
79968058|NCT01259453|Biological|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
79968059|NCT01151657|Dietary Supplement|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
79968060|NCT01151657|Dietary Supplement|Placebo|Placebo capsules containing maltodextrin
79309479|NCT01626352|Drug|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
79309480|NCT02080767|Drug|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
79309481|NCT04789473|Genetic|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
79309482|NCT01626118|Drug|Indomethacin|capsules, 40 mg, TID
79309483|NCT01626118|Drug|Indomethacin|capsules, 40 mg, BID
79474325|NCT02257957|Drug|PRP injection|
79804077|NCT04039581|Other|Kinesio Taping|Kinesio Taping relaxation technique (muscle inhibition technique)
79804078|NCT04039581|Other|Conventional treatment|Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications
79804079|NCT04038346|Drug|Naproxen|Patients will be randomized to an NSAID (naproxen)
79804080|NCT04038346|Drug|Acetaminophen|Patients will be randomized to acetaminophen
79968061|NCT03894527|Behavioral|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (~70% VO2peak). Time will vary based upon individual fitness levels to burn ~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
79309484|NCT01626118|Drug|Indomethacin|capsules, 20 mg, TID
79309485|NCT01626118|Drug|Placebo|capsules
79309486|NCT05471583|Other|Main group|no intervention; observational only
79655549|NCT04548934|Device|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
79655550|NCT04548934|Device|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
79655551|NCT00268515|Drug|cyclosporine|
79655552|NCT00268515|Drug|tacrolimus|
79655553|NCT00268515|Drug|prednisone|
79655554|NCT00268515|Drug|azathioprine|
79474326|NCT02257957|Drug|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
79474327|NCT02524769|Drug|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
79804081|NCT04037176|Drug|Omalizumab|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
79804082|NCT04037176|Other|Placebo|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
79804083|NCT04036305|Drug|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
79804084|NCT04036305|Drug|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
79804085|NCT04036305|Drug|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
79804086|NCT04020874|Behavioral|HuTT-2x|tackling and blocking training twice/week
79968062|NCT03894527|Behavioral|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
79968063|NCT03890783|Other|Evaluation of phonation quality|"Evaluation of phonation quality by :~Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
79968064|NCT03890783|Other|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~Self-evaluation: completion of the Deglutition Handicap Index questionnaire~Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
79968065|NCT03890783|Other|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H&N35 questionnaires
79968066|NCT01259531|Drug|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
79968067|NCT03894137|Dietary Supplement|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
79968068|NCT01586351|Device|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
79968069|NCT03894371|Device|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
79968070|NCT01151735|Drug|C-1-esterase|1000 units of C-1-esterase inhibitor
79968071|NCT01151735|Drug|C-1-esterase|1500 units of C-1-esterase inhibitor
79968072|NCT01151735|Drug|placebo|placebo
79968073|NCT03890393|Device|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
79474328|NCT01815229|Procedure|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
79804087|NCT04020874|Behavioral|HuTT-4x|tackling and blocking training four times/week
79804088|NCT04016896|Behavioral|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
79804089|NCT04016896|Other|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
79804090|NCT04012710|Procedure|Laparoscopy|Conventional abdominal laparoscopy
79968074|NCT03061214|Drug|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
79309487|NCT04789005|Drug|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
79309488|NCT04789005|Drug|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
79309489|NCT04788849|Diagnostic Test|BD Onclarity™ HPV assay|Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
79309490|NCT02152384|Drug|Insulin Peglispro|Administered SC
79309491|NCT02152384|Drug|Insulin Lispro|Administered SC
79309492|NCT02152384|Drug|Insulin Glargine|Administered SC
79474329|NCT01877161|Device|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
79474330|NCT01877161|Device|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
79474331|NCT01877161|Device|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
79474332|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel|
79474333|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel (Reference)|
79474334|NCT02525549|Drug|Placebo gel|
79474335|NCT01877941|Device|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
79474336|NCT01877941|Device|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
79474337|NCT01877941|Device|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
79474338|NCT01878799|Drug|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
79474339|NCT02527265|Biological|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
79474340|NCT01879345|Drug|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
79474341|NCT01879345|Drug|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
79474342|NCT01879345|Drug|Placebo|placebo tablets
79804091|NCT04012710|Procedure|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
79804092|NCT04009928|Device|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
79804093|NCT04009928|Device|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
79968075|NCT03061214|Drug|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
79968076|NCT03061214|Drug|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
79968077|NCT03061214|Drug|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
79968078|NCT03061214|Drug|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
79968079|NCT03061214|Drug|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
79309493|NCT05469243|Drug|Psychedelic|retrospective survey of previous use
79309494|NCT02177266|Drug|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
79309495|NCT02177266|Drug|Placebo|The placebo will match the study drug.
79309496|NCT05468229|Drug|Dorzagliatin|single oral dose of dorzagliatin 50 mg
79309497|NCT05468229|Drug|Placebo|Matching placebo
79309498|NCT04788381|Drug|Bevacizumab|Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
79340393|NCT05647785|Device|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
79340394|NCT05647785|Device|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
79340395|NCT02267187|Procedure|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
79340396|NCT02267187|Drug|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
79474343|NCT05329207|Behavioral|Experimental group|Web Based Adolescent Health Promotion Education Program
79655555|NCT04548700|Drug|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
79968080|NCT01152827|Drug|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~progression of disease~the subject develops unacceptable toxicity~consent to participate in the study is withdrawn"
79474344|NCT05329051|Biological|SCTV01E|intramuscular injection
79474345|NCT05329051|Biological|Comirnaty|intramuscular injection
79474346|NCT01804075|Drug|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
79474347|NCT01804075|Drug|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
79474348|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
79474349|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
79474350|NCT02530151|Drug|Morphine with clonidine|see arm description
79309499|NCT05475249|Other|Implant placement and prothesis made with different types of abutment|Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
79309500|NCT05466591|Diagnostic Test|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
79474351|NCT02530151|Other|Normal saline|see arm description
79968081|NCT03890471|Behavioral|Preoperative telephone call three days before surgery|Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
79474352|NCT02530541|Drug|CHG|Varied application times
79968082|NCT03890549|Diagnostic Test|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
79968083|NCT01259921|Behavioral|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
79968084|NCT01153373|Behavioral|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
79968085|NCT01153373|Behavioral|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
79968086|NCT03889301|Behavioral|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
79638836|NCT04692571|Device|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist [hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
79968087|NCT03889301|Behavioral|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
79968088|NCT01259999|Dietary Supplement|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
79968089|NCT05209958|Diagnostic Test|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
79968090|NCT03889145|Drug|Telmisartan 80mg|Telmisartan 80mg
79968091|NCT03889145|Drug|Amlodipine10mg|Amlodipine 10mg
79968092|NCT03889145|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
79968093|NCT05209724|Behavioral|Provider supervision/ feedback|Provider supervision/ feedback provided before and after walking sessions
79638837|NCT00526435|Behavioral|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
79638838|NCT00526435|Behavioral|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
79804094|NCT04008576|Behavioral|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
79968094|NCT04299776|Device|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
79968095|NCT04299776|Device|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
79968096|NCT01153451|Other|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
79968097|NCT03889223|Procedure|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
79968098|NCT03888677|Drug|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
79968099|NCT01153607|Drug|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
79968100|NCT01153607|Drug|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
79968101|NCT01153607|Drug|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
79968102|NCT04208126|Device|ECMO|ECMO implantation immediately after ICU admission
79968103|NCT01260155|Drug|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
79968104|NCT01260155|Drug|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
79968105|NCT01260155|Drug|E5501|Treatment C: 40 mg new tablet formulation administered with food
79968106|NCT04655690|Drug|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
79968107|NCT04655690|Drug|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
79968108|NCT03912545|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79968109|NCT04107662|Device|Tbit system|Suspected traumatic brain injury with head CT
79968110|NCT01251341|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
79968111|NCT01251341|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
79968112|NCT01251341|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
79968113|NCT01260233|Other|Smoking cessation program|"Smoking cessation program includes:~brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~smoking cessation brochures~referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
79968114|NCT03888521|Behavioral|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
79968115|NCT03888833|Device|ECMO|ECMO installation
79968116|NCT01251419|Other|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
79968117|NCT03912623|Other|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
79968118|NCT03912623|Other|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
79474353|NCT02416973|Device|Provant|
79804095|NCT03993197|Behavioral|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~First week a session of Body Strategy ©~Second week a psychological session with group of speech (Photolanguage ©).~Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
79804096|NCT03983837|Other|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
79804097|NCT03980509|Drug|Curcumin|Curcumin is an extract from turmeric
79804098|NCT03972384|Behavioral|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
79804099|NCT03970499|Procedure|brain tumor resection|Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
79309501|NCT04342377|Diagnostic Test|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
79804100|NCT03969264|Other|High Carbohydrate or Tree Nut Food Snacks|Snack consumption
79309502|NCT04342377|Diagnostic Test|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
79968119|NCT04435964|Drug|Immunotherapy|Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
79968120|NCT03912779|Behavioral|C2Hear RLOs|Freely available online RLOs
79474354|NCT01804465|Drug|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
79804101|NCT03967977|Drug|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
79804102|NCT03967977|Drug|Placebo|Tislelizumab placebo to match
79804103|NCT03967977|Drug|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
79968121|NCT03912779|Behavioral|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
79968122|NCT04040426|Other|Human split thickness skin allograft|Application of a fenestrated human skin graft
79968123|NCT04040426|Other|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
79968124|NCT04040426|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
79968125|NCT04040426|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
79968126|NCT01153919|Biological|romiplostim|Given subcutaneously
79968127|NCT01153919|Drug|ribavirin|Given orally
79968128|NCT01153919|Other|placebo|Given subcutaneously
79474355|NCT01804465|Drug|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
79968129|NCT01153919|Biological|PEG-interferon alfa-2a|Given subcutaneously
79968130|NCT01153919|Other|laboratory biomarker analysis|Correlative studies
79968131|NCT03912701|Diagnostic Test|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
79968132|NCT01260389|Behavioral|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
79984341|NCT03206242|Other|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
79984342|NCT03206320|Drug|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
79984343|NCT04448561|Drug|ASP8082|oral
79309503|NCT04787913|Behavioral|herdimm|In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
79474356|NCT02531321|Drug|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
79474357|NCT02531867|Biological|Asfotase Alfa|
79984344|NCT04448561|Drug|morphine|oral
79984345|NCT04448561|Drug|Placebo|oral
79984346|NCT03208660|Drug|Fycompa|Oral suspension
79474358|NCT01805089|Drug|Melatonin 3 mg|Melatonin vs. Placebo
79638839|NCT00168090|Drug|Blood coagulation Factor VIII and vWF, human|
79804104|NCT03967977|Drug|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
79968133|NCT03888443|Device|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
79474359|NCT01409629|Behavioral|Computer game|Participants will play a computer game
79638840|NCT00525382|Drug|levocetirizine dihydrochloride|
79804105|NCT03967977|Drug|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
79804106|NCT03945760|Drug|Baricitinib|Baricitinib 2 mg
79804107|NCT03945760|Drug|Placebo|Placebo
79968134|NCT03941444|Drug|ANAVEX2-73|Liquid oral solution
79474360|NCT02417129|Drug|Rituximab|BI 695500 375 mg/M2
79474361|NCT02417129|Drug|BI 695500|BI 695500 375 mg/M2
79474362|NCT01879735|Drug|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
79474363|NCT01879735|Drug|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
79474364|NCT02417831|Drug|tamsulosin capsules|
79474365|NCT02417831|Drug|tamsulosin HCl|
79638841|NCT04692805|Device|coils|EUS-guided injection of coils
79638842|NCT04692805|Drug|cyanoacrylate glue|EUS-guided injection of cyanoacrylate glue
79638843|NCT00526513|Drug|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
79638844|NCT03432299|Procedure|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
79638845|NCT00525460|Behavioral|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
79968135|NCT03941444|Drug|Placebo|Liquid oral solution
79968136|NCT03912389|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
79968137|NCT03912389|Drug|Pemetrexed|IV infusion
79968138|NCT03912389|Drug|Cisplatin (or carboplatin)|IV infusion
79968139|NCT03912389|Other|Placebo|IV infusion
79968140|NCT05703464|Drug|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
79968141|NCT03934658|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
79968142|NCT03934658|Device|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
79968143|NCT01147757|Drug|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
79968144|NCT01251497|Behavioral|diabetes self-management education|
79968145|NCT01153997|Drug|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
79804108|NCT03914508|Behavioral|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
79804109|NCT03896269|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79804110|NCT03861065|Procedure|Tertiary Wound Closure|The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
79804111|NCT03861065|Procedure|Historical Wound Closure|Participants wounds are left partially open to heal.
79804112|NCT03856879|Behavioral|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
79968146|NCT01153997|Drug|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
79968147|NCT01153997|Drug|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
79474366|NCT02271451|Device|Q collar|collar worn around neck
79638846|NCT00525538|Radiation|conformal radiotherapy|
79638847|NCT00168129|Procedure|Helical tomotherapy|
79474367|NCT02419547|Drug|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
79638848|NCT02946151|Device|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
79638849|NCT02946190|Biological|Pertagen® aP + Td-pur®|see arm/group descriptions
79638850|NCT02946190|Biological|Boostrix® dTpa|see arm/group descriptions
79638851|NCT03346694|Device|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
79638852|NCT03346694|Device|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
79638853|NCT03346694|Device|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
79309504|NCT04787913|Behavioral|guardianmeasles|A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
79474368|NCT02419547|Drug|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
79474369|NCT02419547|Drug|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
79474370|NCT02419547|Drug|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
79474371|NCT02273323|Other|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
79474372|NCT02273323|Other|Placebo|Placebo: tea flavour, colouring and sugar
79474373|NCT02274649|Behavioral|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
79474374|NCT02274649|Behavioral|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
79474375|NCT02533427|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
79474376|NCT02533427|Drug|VOX|100 mg tablet administered orally once daily
79474377|NCT02533427|Drug|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
79474378|NCT05328817|Drug|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
79474379|NCT05328739|Other|home care|home care program
79474380|NCT05328661|Diagnostic Test|Blink reflex|The stimulator is directly connected to the right side of the frontal board. The sponge must be soaked in water or saline before being inserted into the stimulator. Dry them a bit to avoid leaking on the stimulator (it could create a bridge between the two poles). We want to stimulate the supraorbital nerve at its emergence from the eyebrow arch (the supraorbital foramen in the supra-orbital margin bone is easy to palpate 1 cm laterally to the root of the nose). We place the stimulator above the emergence of the supraorbital nerve, with the distal pole placed below. The final intensity of stimulation is generally between 5 to 10 mA, but higher intensities sometime are required.
79638854|NCT02945995|Procedure|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
79638855|NCT00168168|Drug|G-CSF/Filgrastim|
79638856|NCT02945761|Procedure|High concentration of sugar solution|
79638857|NCT02945761|Procedure|conventional surgical dressing change|
79638858|NCT02945683|Dietary Supplement|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
79638859|NCT02945683|Dietary Supplement|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
79968148|NCT01153997|Drug|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
79474381|NCT05328583|Drug|HRS5685；Placebo|"Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H"
79804113|NCT03839394|Behavioral|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
79474382|NCT05328427|Other|Stopping|Discontinuation of nucleoside analogue
79638860|NCT02947321|Procedure|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
79804114|NCT03839394|Other|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
79309505|NCT04787913|Behavioral|theotheredmundmeasles|A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
79309506|NCT04787913|Behavioral|sbsnewsgeneric|A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
79309507|NCT04787913|Behavioral|publichealthagencycanadaflu|A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
79309508|NCT04787913|Behavioral|robertkochgeneric|A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
79309509|NCT05613231|Behavioral|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
79804115|NCT03833726|Procedure|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
79804116|NCT03833726|Procedure|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
79804117|NCT03820193|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
79804118|NCT03820193|Drug|Hydrocodon/Acetaminophen|Traditionally used narcotic pain control
79804119|NCT03820193|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
79638861|NCT02947321|Procedure|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
79804120|NCT03820193|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
79638862|NCT02947009|Behavioral|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
79804121|NCT03820193|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
79638863|NCT02947204|Other|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
79638864|NCT02947204|Other|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
79804122|NCT03820193|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
79804123|NCT03780881|Behavioral|Expectation confirmation|Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
79638865|NCT03225755|Drug|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
79804124|NCT03780881|Behavioral|Expectation disconfirmation|Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
79804125|NCT03778931|Drug|Elacestrant|400 mg/day once daily oral dosing
79804126|NCT03778931|Drug|Standard of Care|"Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~Anastrozole 1 mg/day on a continuous dosing schedule~Letrozole: 2.5 mg/day on a continuous dosing schedule~Exemestane: 25 mg/day on a continuous dosing schedule"
79804127|NCT03776799|Device|Stent-avoiding|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
79309510|NCT05613231|Behavioral|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
79638866|NCT00526786|Device|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
79638867|NCT00525577|Drug|Placebo|Placebo tablet, once daily
79638868|NCT00525577|Drug|AGI-1067|75 mg AGI-1067 tablet, once daily
79638869|NCT00525577|Drug|AGI-1067|150 mg AGI-1067 Tablet, once daily
79638870|NCT00407238|Device|Multi-purpose solutions (polyquaternium-1 and PHMB)|
79804128|NCT03776799|Device|Stent-based|Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
79804129|NCT03763643|Drug|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
79804130|NCT03763643|Procedure|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
79984347|NCT03208738|Behavioral|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
79984348|NCT03208738|Behavioral|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
79984349|NCT03751241|Device|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
79984350|NCT03206008|Drug|Magnesium Sulfate|
79984351|NCT03206008|Drug|Normal saline|Placebo
79984352|NCT04978259|Drug|Remdesivir|Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
79638871|NCT03186755|Drug|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
79638872|NCT03186755|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
79638873|NCT00525616|Drug|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
79638874|NCT00525655|Behavioral|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
79638875|NCT00525655|Behavioral|Questionnaire|Questionnaires taking 10-15 minutes to complete.
79638876|NCT00525694|Other|Glucose tolerance test|10 ounces glucose tolerance test solution
79638877|NCT00525694|Other|glucose tolerance test solution|75 grams glucose load
79638878|NCT00525694|Other|Diet Coke|10 ounces of Diet Coke
79804131|NCT03753204|Drug|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
79638879|NCT00525694|Other|Coke Zero|10 ounces of Coke Zero
79638880|NCT00526903|Behavioral|Elimination Diet|Daily diet change for 8 days.
79638881|NCT00405470|Device|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
79638882|NCT00173472|Drug|Chemotherapy|
79638883|NCT00526942|Behavioral|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
79638884|NCT02947243|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
79638885|NCT02947243|Drug|Morphine|As per unit's protocol
79638886|NCT02947282|Other|Educational Workshop|They will attend a 2 hour class on pelvic floor health
79309511|NCT05474937|Drug|Sevoflurane Inhalation Solution|Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
79340397|NCT02267187|Device|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
79638887|NCT04693000|Drug|Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
79804132|NCT03751709|Drug|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
79804133|NCT03751709|Other|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 & Day 15
79340398|NCT02267187|Other|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
79638888|NCT00173511|Device|24 hr Holter monitor|
79638889|NCT03177863|Procedure|Expectancy|Clinical monitoring. See arm description
79968149|NCT03619928|Device|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
79968150|NCT03619928|Device|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
79968151|NCT04184726|Behavioral|Mindfulness Based Cognitive Therapy|mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
79968152|NCT01154309|Behavioral|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
79638890|NCT02946970|Other|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
79340399|NCT02532179|Biological|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
79340400|NCT04422977|Diagnostic Test|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
79968153|NCT01586429|Other|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
79968154|NCT01251731|Drug|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
79638891|NCT02946970|Other|Control|Intragastric administration of distilled water
79968155|NCT01251731|Drug|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
79638892|NCT04692727|Other|Exercise program|"Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~Isometric exercises of vastus medialis, gluteus medius and external rotators~Isotonic exercises of vastus medialis, gluteus medius and external rotators~Closed kinetic chain exercises~Balance and coordination exercises~Core stabilization exercises"
79340401|NCT05389241|Other|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
79340402|NCT05389241|Other|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
79638893|NCT04692727|Other|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
79309512|NCT05474937|Drug|Midazolam, Ketamine and Propofol|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
79638894|NCT04692727|Other|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
79309513|NCT04788225|Other|Balance assessment|"Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test."
79638895|NCT00526981|Other|Prone position|Prone position during spontaneous breathing.
79804134|NCT03739762|Behavioral|i-STAND|Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)
79804135|NCT03739762|Other|Healthy Living control|In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
79804136|NCT03735979|Drug|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
79804137|NCT03735979|Drug|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
79804138|NCT03735979|Drug|Placebo|IV placebo solution
79968156|NCT01251731|Drug|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
79968157|NCT01251731|Drug|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
79804139|NCT03732352|Other|Fludeoxyglucose F-18|Given IV
79804140|NCT03732352|Drug|Osimertinib|Given PO
79804141|NCT03732352|Procedure|Positron Emission Tomography|Undergo fludeoxyglucose F-18 PET scan
79968158|NCT01260545|Drug|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
79968159|NCT01147913|Behavioral|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
79804142|NCT03725605|Combination Product|LTX-315 and TILs|Intratumoural injection of LTX-315 and infusion of TILs
79804143|NCT03713671|Diagnostic Test|gait analysis|Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
79968160|NCT01147913|Behavioral|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
79968161|NCT03888209|Device|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
79968162|NCT01251809|Drug|Oncaspar|2000 U/m2 BSA, single infusion
79968163|NCT01251809|Drug|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
79968164|NCT03912077|Behavioral|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
79968165|NCT01154387|Drug|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
79968166|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
79968167|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
79968168|NCT01154387|Drug|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
79309514|NCT04788225|Other|Functionality assessment|Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
79638896|NCT00527020|Drug|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
79638897|NCT00527020|Drug|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
79638898|NCT00527020|Drug|Placebo|Placebo tablets will be given to the subjects.
79638899|NCT00407277|Drug|Nicotine patch|21 mg of nicotine via a dermal patch
79638900|NCT00407277|Other|placebo|placebo via a dermal patch
79968169|NCT01154387|Drug|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
79968170|NCT01154387|Drug|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
79309515|NCT04788225|Other|Performance assessment|Performance evaluation will be made with a single leg jump test and time up and go test.
79309516|NCT04788225|Other|ROM assessment|Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
79309517|NCT04787601|Other|Exercise|Cognıtıve-based neuromuscular exercıses will be applied.
79309518|NCT04787601|Other|Classic Training|Classic match preparation training
79309519|NCT05474781|Drug|Epclusa|HCV treatment
79638901|NCT00407277|Behavioral|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
79804144|NCT03707366|Behavioral|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
79804145|NCT03707106|Behavioral|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
79804146|NCT03707106|Behavioral|virtual reality based cue exposure|smoking cue exposure in virtual reality
79804147|NCT03707106|Behavioral|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
79968171|NCT03911765|Behavioral|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
79804150|NCT03705715|Drug|PET with radiotracer [11C]PBR-28 ( or [11C]ER176)|[11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
79804151|NCT03705715|Other|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
79804152|NCT03687593|Device|Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts|Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert
79804153|NCT03676764|Drug|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
79804154|NCT03676764|Drug|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
79968172|NCT01154465|Procedure|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~Rinse with sterile water and then drying.~First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
79968173|NCT01154465|Device|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
79968174|NCT03887975|Procedure|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
79968175|NCT03887975|Procedure|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
79968176|NCT03911921|Drug|RSYRT decoction|Compound granules of traditional Chinese medicine
79968177|NCT03911921|Drug|Astragalus membranaceus|One herb
79968178|NCT01260623|Drug|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
79968179|NCT03887897|Procedure|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
79968180|NCT03890315|Diagnostic Test|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
79968181|NCT01259609|Procedure|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
79309520|NCT05474547|Behavioral|Meditation|Students will meditate for 30 min every day for 10 days
79309521|NCT02177032|Biological|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
79309522|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
79804155|NCT03674944|Behavioral|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).
79968182|NCT01147991|Biological|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
79968183|NCT01147991|Other|laboratory biomarker analysis|
79340403|NCT05438615|Other|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
79638902|NCT00527059|Drug|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
79638903|NCT00527059|Drug|spironolactone, beta-blockers,ecc|
79968184|NCT01147991|Other|pharmacological study|
79638904|NCT04693078|Device|AI polyp detection system based on deep learning|A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
79638905|NCT00173550|Procedure|Hysterectomy and Bilateral salpingo-oophorectomy|
79804156|NCT03674944|Behavioral|Behavioral Weight Loss (BWL)|All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
79638906|NCT03156452|Drug|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
79638907|NCT03156452|Drug|Prednisolone|5mg tablets for oral administration
79804157|NCT03674138|Diagnostic Test|DNA-guided choice of therapy|Buccal swab for DNA genotyping to identify best antidepressant therapy
79804158|NCT03674138|Other|Clinical management|Clinical management to identify best antidepressant therapy
79968185|NCT03887585|Procedure|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
79968186|NCT04115839|Drug|Filgotinib|Tablets will be administered orally once daily with or without food.
79968187|NCT04115839|Drug|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
79638908|NCT00525772|Drug|ciclesonide|low dose- 50ug and 200ug
79968188|NCT01152983|Device|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
79968189|NCT01252121|Other|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
79968190|NCT01252121|Other|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
79638909|NCT00525772|Drug|ciclesonide|high dose- 100ug and 400ug
79638910|NCT00525811|Other|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
79638911|NCT00525811|Other|patient information|Information on acute low back pain, information on depression
79638912|NCT00525850|Other|high fat diet|high saturated fat no starch diet
79638913|NCT00525850|Other|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
79968191|NCT01252121|Other|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
79968192|NCT01260779|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
79968193|NCT03911609|Other|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
79968194|NCT03911609|Other|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
79309523|NCT02177032|Biological|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
79638914|NCT02945956|Drug|Entecavir|The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
79638915|NCT02945956|Drug|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
79804159|NCT03672539|Drug|Gemtuzumab Ozogamicin|Given IV
79804160|NCT03672539|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79804161|NCT03672539|Other|Quality-of-Life Assessment|Ancillary studies
79804162|NCT03667482|Drug|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
79638916|NCT04692610|Behavioral|Stoma prehabilitation|A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
79968195|NCT01148069|Procedure|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
79968196|NCT01153061|Device|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
79968197|NCT01153061|Device|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
79968198|NCT03890159|Behavioral|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
79804163|NCT03667482|Drug|Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
79804164|NCT03660124|Device|Deep Brain Stimulation|DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
79968199|NCT03890159|Behavioral|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
79804165|NCT03655808|Biological|Bronchial basal cells (BBCs)|Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.
79968200|NCT01260857|Drug|Aldazide|Aldazide 25 mg OD
79968201|NCT03889847|Device|Fibreoptic intubation with silicone double lumen tube|Fibreoptic intubation with silicone double lumen tube
79968202|NCT03889847|Device|Fibreoptic intubation with PVC double lumen tube|Fibreoptic intubation with PVC double lumen tube
79968203|NCT03890003|Device|AID System|AID system
79968204|NCT03890003|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
79804166|NCT03655808|Procedure|Bronchoscopic airway clearance treatment （B-ACT）|The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
79804167|NCT03650387|Device|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
79804168|NCT03638141|Drug|Durvalumab|Durvalumab IV
79804169|NCT03638141|Drug|Tremelimumab (Cohort A dose)|Tremelimumab IV
79804170|NCT03638141|Drug|Tremelimumab (Cohort B dose)|Tremelimumab IV
79804171|NCT03636412|Other|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
79968205|NCT01252199|Drug|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
79968206|NCT01252199|Drug|Placebo|Placebo administered over 1 hour + standard of care
79968207|NCT05484245|Device|Sonography|Surgeon detects brain mass lesion and assesses extent of it's resection with sonography
79804172|NCT03629171|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79804173|NCT03629171|Drug|Venetoclax|Given PO
79804174|NCT03620721|Behavioral|mindfulness|8-week mindfulness based group intervention
79804175|NCT03618758|Drug|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
79804176|NCT03618758|Drug|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
79804177|NCT03618550|Drug|pembrolizumab|Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
79804178|NCT03618550|Drug|gemcitabine|1000mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
79804179|NCT03618550|Drug|vinorelbine|20mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
79309524|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
79309525|NCT05187273|Behavioral|Elastance Group|Fluids are given based on dynamic elastane value
79309526|NCT05135325|Behavioral|Patient portal message|Portal message encourages patients to donate blood
79309527|NCT05135325|Behavioral|Social responsibility|Message specifies that there is a shortage of the patient's blood type
79804180|NCT03618550|Drug|liposomal doxorubicin|15mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
79309528|NCT04426305|Other|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
79309529|NCT04426305|Other|care as usual|care as usual is provided by professional primary care provider
79309530|NCT05474157|Other|Standard care treatment for COVID-19 in Intensive Care Unit|Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
79309531|NCT05316753|Procedure|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
79309532|NCT05316753|Procedure|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
79309533|NCT02176642|Drug|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
79309534|NCT02176642|Device|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
79309535|NCT02176642|Drug|Placebo|Tablet taken by mouth daily for 6 weeks
79309536|NCT05612997|Other|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
79309537|NCT05473845|Procedure|Acupressure intervention|Acupressure
79804181|NCT03618550|Procedure|Stem cell mobilization and collection|Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
79804182|NCT03611738|Drug|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
79804183|NCT03611738|Drug|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
79804184|NCT03600233|Drug|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
79804185|NCT03596268|Diagnostic Test|Imaging|3T Prisma MRI
79638917|NCT04692610|Behavioral|preoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
79638918|NCT04692610|Behavioral|postoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
79804186|NCT03596268|Diagnostic Test|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
79309538|NCT05473845|Procedure|Reiki intervention|Reiki
79804187|NCT03596268|Diagnostic Test|Lumbar Puncture|CSF will be collected
79804188|NCT03595917|Drug|ABL001|•ABL001 is administered daily per 28 day cycle
79309539|NCT02116660|Drug|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
79309540|NCT02116660|Drug|Nevirapine|Nevirapine (NVP) 200 mg tablets
79309541|NCT02116660|Drug|Lamivudine|Lamivudine (3TC) 150 mg tablets
79309542|NCT02116660|Drug|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
79968208|NCT01259687|Device|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
79309543|NCT02116660|Drug|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
79638919|NCT04692610|Behavioral|Postoperative stoma care|Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
79638920|NCT04692454|Other|Modern acupuncture|use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
79638921|NCT00527137|Drug|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
79804189|NCT03595917|Drug|Dasatinib|Fixed doses oral once a day per 28 day cycle
79968209|NCT03889769|Diagnostic Test|OSNA test|Analysis of lymph node with OSNA
79968210|NCT01154621|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
79968211|NCT01154621|Drug|Placebo|Sterile 5% dextrose solution
79968212|NCT03889691|Procedure|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
79309544|NCT02116660|Drug|Lopinavir|Lopinavir (LPV) 200 mg tablets
79309545|NCT02116660|Drug|Ritonavir|Ritonavir (r) 100 mg tablets
79309546|NCT02116660|Drug|Atazanavir|Atazanavir (ATV) 300 mg tablets
79309547|NCT02116660|Drug|Darunavir|Darunavir (DAR) 400 mg tablets
79804190|NCT03595917|Drug|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
79804191|NCT03595917|Drug|Blinatumomab|By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
79309548|NCT02589405|Drug|Benzoyl Peroxide|
79309549|NCT02589405|Other|Dermotivin® Soft Liquid cleanser|
79309550|NCT02589405|Other|Cetaphil® Dermacontrol Moisturizer SPF30|
79309551|NCT05022225|Other|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where participants will take part in focus group discussions.
79309552|NCT02176018|Drug|Dextromethorphan and quinidine|
79309553|NCT02176018|Drug|Placebo|
79309554|NCT05612919|Other|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of <106/mm3.~Product validation is currently under development."
79474383|NCT05748535|Device|Auricular Vagus Nerve Stimulation|First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
79474384|NCT01816945|Behavioral|MOMBA web-based application|Web-based, interactive, social network application.
79474385|NCT02533505|Drug|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
79474386|NCT02533505|Drug|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
79804192|NCT03584490|Other|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
79638922|NCT00527137|Drug|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
79804193|NCT03584490|Other|Phone Administration of Questionnaires|This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
79804194|NCT03582800|Drug|STS|"M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation."
79474387|NCT01817491|Other|American Heart Association Diet|
79968213|NCT01260935|Procedure|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
79474388|NCT01817491|Other|Reduced Fat Vegan Diet|
79309555|NCT05612919|Other|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
79309556|NCT05612841|Other|data collection|data collection from drug-drug interaction between anti-cancer treatment and and other medications
79309557|NCT05612763|Device|Self fitting hearing device|comparison of outcomes when device is fit by clinician or self fit
79309558|NCT05465967|Procedure|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
79309559|NCT05465889|Drug|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
79309560|NCT05465889|Drug|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
79309561|NCT02116582|Drug|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
79309562|NCT05611827|Dietary Supplement|Quercetin LipoMicel (250 mg)|Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin
79474389|NCT05328271|Dietary Supplement|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
79638923|NCT02945839|Drug|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
79638924|NCT02945839|Behavioral|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
79638925|NCT02945839|Behavioral|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
79309563|NCT05611827|Dietary Supplement|Quercetin LipoMicel (500 mg)|Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin
79309564|NCT05611827|Dietary Supplement|Quercetin LipoMicel (1000 mg)|Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin
79638926|NCT02957786|Drug|Cytisine|Cytisine tablets
79968214|NCT01260935|Procedure|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
79309565|NCT05611827|Dietary Supplement|Regular/standard Quercetin (500 mg)|Total dose of 500 mg of quercetin
79309566|NCT04936425|Device|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
79474390|NCT02481557|Device|Oxalate Salt Solution|Applied by dentist
79474391|NCT01818427|Biological|infusion of 2 units of plasma|infusion of 2 units of plasma
79474392|NCT05328193|Behavioral|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
79474393|NCT05328193|Behavioral|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
79638927|NCT02957786|Behavioral|Behavioural support|Withdrawal-orientated cessation support
79638928|NCT02957786|Drug|Varenicline|Varenicline tablets
79638929|NCT00407394|Drug|Amoxycillin|
79638930|NCT00173628|Procedure|blood drawing|
79309567|NCT05187351|Procedure|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-99% de novo SVG lesion SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
79309568|NCT05612607|Drug|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are < 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
79638931|NCT03109964|Device|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
79968215|NCT01153139|Device|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
79638932|NCT03109964|Device|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
79638933|NCT03083873|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
79638934|NCT03083873|Biological|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
79638935|NCT00407433|Drug|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
79638936|NCT02484430|Other|Laboratory Biomarker Analysis|Correlative studies
79309569|NCT02589639|Drug|Empagliflozin|
79309570|NCT02589639|Drug|Placebo|
79309571|NCT02589639|Drug|Placebo|For blinding purposes
79309572|NCT05611749|Drug|Duloxetine 60 MG|Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
79309573|NCT05611749|Other|Placebo|Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
79309574|NCT05611593|Drug|FOL100|FOL100 lotion
79309575|NCT05611593|Drug|Propecia 1Mg Tablet|Oral Finasteride
79309576|NCT05614713|Procedure|Selected physical therapy program|Gait training and balance training
79309577|NCT05614713|Procedure|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
79638937|NCT02484430|Other|Pharmacological Study|Correlative studies
79638938|NCT02484430|Drug|Sapanisertib|Given PO
79638939|NCT00516412|Drug|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
79804195|NCT03570463|Behavioral|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
79638940|NCT00516412|Genetic|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
79638941|NCT00407472|Device|ATS-1 needle free device|
79638942|NCT03058835|Drug|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
79638943|NCT00516451|Drug|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
79638944|NCT00516490|Drug|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
79638945|NCT00516490|Drug|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
79638946|NCT00516607|Drug|enzastaurin hydrochloride|
79638947|NCT00516607|Drug|temozolomide|
79638948|NCT00516607|Other|pharmacological study|
79655556|NCT04548700|Drug|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
79655557|NCT02214433|Drug|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
79804196|NCT03566966|Biological|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
79804197|NCT03566966|Biological|Non-organ-specific Ab negative|direct-acting antiviral agents
79968216|NCT01261091|Procedure|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
79804198|NCT03555422|Drug|Selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
79968217|NCT01261091|Procedure|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
79804199|NCT03555422|Drug|Matching placebo for selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
79804200|NCT03536754|Other|Placebo|Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
79804201|NCT03536754|Drug|CCX140-B|One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
79804202|NCT03536754|Drug|CCX140-B|Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.
79804203|NCT03536754|Drug|CCX140-B|Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
79804204|NCT03535922|Other|PROMs Assessment|Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
79804205|NCT03535545|Drug|[68Ga]CBP8|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
79968218|NCT03889457|Other|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
79968219|NCT01153217|Drug|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
79968220|NCT01561430|Drug|LY2886721|
79968221|NCT01561430|Drug|Placebo|
79968222|NCT03887507|Other|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
79968223|NCT03887507|Other|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
79984353|NCT03747185|Other|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
79804206|NCT03535545|Diagnostic Test|PET Imaging|All subjects will undergo PET imaging after administration of [68Ga]CBP8.
79309578|NCT05611515|Procedure|TORS|"Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~Arm 2: Trans-oral Laser Microsurgery (TLM)~Arm 3: Trans-oral Robotic Surgery (TORS)"
79309579|NCT05614635|Device|Plastalgin and Plastalgin Fast|Plastalgin and Plastalgin Fast are potassium alginate-based powders designed for dental impression. The powder is mixed with water to obtain an impression material paste, used to imprint the teeth and mouth of the patient. The product is available under two presentations: Plastalgin and Plastalgin Fast. Plastalgin Fast has a shorter mixing time.
79309580|NCT05612451|Procedure|Regenerative Endodontic Procedures|Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
79309581|NCT05612451|Other|non-setting calcium hydroxide|non-setting calcium hydroxide
79309582|NCT05612451|Other|modified triple antibiotic paste|modified triple antibiotic paste
79804207|NCT03524235|Radiation|Total Body Irradiation|Pre-Transplantation Total Body Irradiation
79804208|NCT03524235|Procedure|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation
79804209|NCT03524235|Biological|CD56-Enriched Donor Lymphocyte Infusion|CD56-Enriched Donor Lymphocyte Infusion
79804210|NCT03524235|Drug|Bendamustine|Pre-Transplantation Bendamustine
79804211|NCT03524235|Drug|Fludarabine|Pre-Transplantation Fludarabine
79804212|NCT03524235|Drug|Rituximab|Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
79804213|NCT03521921|Device|Mitraclip|Edge-to edge mitral valve repair
79309583|NCT05611359|Procedure|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
79309584|NCT05611359|Drug|Chemotherapy|Chemotherapy
79804214|NCT03517904|Procedure|IVUS-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
79804215|NCT03517904|Procedure|Angiography-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
79804216|NCT03491176|Procedure|Biospecimen Collection|Undergo collection of blood samples
79804217|NCT03491176|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79309585|NCT04334811|Radiation|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
79804218|NCT03491176|Other|Quality-of-Life Assessment|Ancillary studies
79309586|NCT02151682|Drug|Tapentadol prolonged release|
79309587|NCT02151682|Drug|Morphine prolonged release|
79804219|NCT03491176|Other|Questionnaire Administration|Ancillary studies
79309588|NCT04331691|Drug|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
79309589|NCT04331691|Drug|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
79309590|NCT04756635|Other|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values <135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
79309591|NCT02174848|Drug|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
79309592|NCT05612217|Other|to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD|to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.
79309593|NCT02151058|Drug|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
79309594|NCT02151058|Drug|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
79309595|NCT02151058|Other|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
79309596|NCT04744389|Device|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
79340404|NCT05438615|Other|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
79804220|NCT03462342|Drug|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
79474394|NCT05327881|Diagnostic Test|Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.|"Measurement of Whole Blood Lactate Concentrations:~Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes.~Measurement of Plasma Renin Concentrations:~Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.~Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)"
79340405|NCT04422665|Other|Resistance exercise|Single-legged resistance exercise
79474395|NCT02420015|Drug|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
79474396|NCT02420015|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
79655558|NCT02214433|Drug|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
79655559|NCT02214433|Drug|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
79655560|NCT02214433|Drug|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
79340406|NCT05388539|Procedure|Theta Burst Stimulation|3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.
79340407|NCT05388539|Procedure|Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
79655561|NCT02214433|Drug|Debio 1450 Capsule|Debio 1450 40 mg capsules
79655562|NCT02214433|Drug|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
79655563|NCT02214433|Drug|Pantoprazole|Pantoprazole 40 mg orally
79655564|NCT04710407|Drug|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
79309597|NCT04744389|Device|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
79309598|NCT04699695|Other|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
79309599|NCT05614479|Other|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
79309600|NCT02149810|Behavioral|Automatic Self Transcending Meditation|as above
79309601|NCT05205759|Drug|Bamlanivimab Etesevimab|Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together [1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
79309602|NCT05205759|Drug|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
79309603|NCT05205759|Drug|Casirivimab-Imdevimab|Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
79309604|NCT05558163|Procedure|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
79474397|NCT02420015|Behavioral|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
79474398|NCT02420015|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
79474399|NCT02420015|Behavioral|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
79474400|NCT02420015|Behavioral|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
79309605|NCT05558163|Procedure|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
79309606|NCT04971447|Drug|gender affirming hormonal treatment in transgender men|testosterone enanthate
79309607|NCT04971447|Drug|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
79340408|NCT05416853|Procedure|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
79340409|NCT05416775|Drug|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
79340410|NCT05416775|Drug|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
79340411|NCT05416775|Drug|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
79340412|NCT05388227|Other|Pole Walking|Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
79309608|NCT04394715|Other|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
79309609|NCT02149420|Drug|VAY736|
79309610|NCT02149420|Drug|Placebo|
79309611|NCT05557773|Other|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
79309612|NCT05557773|Other|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
79638949|NCT04695145|Behavioral|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
79638950|NCT04695145|Behavioral|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
79340413|NCT02409667|Biological|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
79309613|NCT04337307|Biological|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
79309614|NCT05557383|Behavioral|use peanut ball|The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
79309615|NCT02149264|Drug|Testosterone gel (FE 999303)|
79309616|NCT05557149|Device|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
79309617|NCT05557149|Behavioral|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
79309618|NCT05557149|Device|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
79309619|NCT04417738|Device|unilateral transcranial photobiomodulation, near infrared mode|The investigators are applying a supra luminous LED at 810 nm and 250 mW/cm2 to the forehead of the participant at F3 and F4.
79474401|NCT05748379|Procedure|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper.
79474402|NCT05748379|Procedure|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment.
79309620|NCT04417738|Device|Sham treatment|The sham treatment is identical to the active treatment except that the sham treatment has a piece of aluminum foil covering the led so that the participant will experience warmth but receive no photons.
79309621|NCT02115256|Drug|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
79309622|NCT02115256|Drug|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
79309623|NCT02173054|Other|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
79309624|NCT02173054|Other|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
79309625|NCT02173054|Other|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
79474403|NCT05748301|Other|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
79638951|NCT00516646|Drug|ALT-711|200 mg bid
79638952|NCT00516646|Drug|Placebo|bid
79968224|NCT03887195|Other|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~2 lectures (optional)~6 supervision sessions by Balint type groups (5 of which are mandatory);~5 role-plays (all required);~2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
79474404|NCT02481713|Behavioral|motivational interviewing|motivational interviewing
79474405|NCT02481713|Behavioral|learning style interviews|interview and feedback about learning style
79638953|NCT00173667|Drug|Nifedipine 30 mg GITS|
79638954|NCT00516685|Biological|Recombinant Human rEGF-P64K/Montanide Vaccine|
79638955|NCT03458689|Procedure|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
79968225|NCT03931070|Drug|Ramelteon|Nightly administration of Ramelteon 8 mg
79968226|NCT03931070|Drug|Placebo - Cap|Nightly administration of Placebo capsule, which is indistinguishable from Ramelteon
79638956|NCT00173706|Drug|L-Carnitine Injection|
79309626|NCT04741906|Procedure|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
79309627|NCT04741906|Procedure|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
79309628|NCT04741828|Drug|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
79638957|NCT00527215|Drug|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
79638958|NCT00527254|Device|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
79638959|NCT00527293|Procedure|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
79638960|NCT00527293|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
79638961|NCT00527293|Radiation|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
79638962|NCT00173745|Drug|botulinum toxin A injection|
79655565|NCT00261144|Drug|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
79309629|NCT04225221|Drug|Estradiol|During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
79638963|NCT04692142|Other|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
79638964|NCT00527371|Device|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
79309630|NCT04225221|Drug|Micronized progesterone|During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
79309631|NCT04225221|Drug|Leuprolide Acetate|Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
79309632|NCT04225221|Drug|Placebo Oral Capsule|Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
79309633|NCT04187625|Biological|endothelial progenitor cell|Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.
79309634|NCT04024371|Behavioral|Self-rating Questionnaires|"Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~Behavioral avoidance/inhibition Scales (BIS/BAS)"
79309635|NCT04024371|Behavioral|Measures of Reward processing/reinforcement learning|"Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
79968227|NCT01153295|Procedure|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
79309636|NCT04024371|Behavioral|Additional Schizophrenia-specific Questionnaires and Interviews|"Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
79309637|NCT04675593|Behavioral|iTAB-CV|Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention
79309638|NCT04675593|Behavioral|Self-Monitoring|The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
79309639|NCT05556213|Procedure|laparoscopic examination|laparoscopic examination for staging of endometriosis
79309640|NCT05556213|Diagnostic Test|Blood sampling|Blood sample to detect endometriosis
79638965|NCT00527371|Procedure|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
79638966|NCT00168285|Behavioral|Pulmonary Rehabilitation|
79638967|NCT02516540|Behavioral|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
79638968|NCT02489422|Other|Laboratory Biomarker Analysis|Correlative studies
79638969|NCT02489422|Other|Questionnaire Administration|Ancillary studies
79638970|NCT02489422|Other|Daily Survey Administration|Ancillary studies
79638971|NCT02489422|Behavioral|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
79638972|NCT02489422|Behavioral|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
79968228|NCT01153295|Procedure|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
79309641|NCT05556135|Diagnostic Test|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
79309642|NCT04425993|Drug|Isosorbide Dinitrate 5 MG|All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
79968229|NCT03773120|Device|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
79309643|NCT04425993|Drug|Indomethacin 100 MG|All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
79309644|NCT04425993|Drug|Sublingual Placebo|All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
79309645|NCT04425993|Drug|Rectal placebo|All patients without contraindications should receive rectal placebo within 30 min before ERCP.
79309646|NCT03971643|Drug|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
79638973|NCT02489422|Other|Actigraphy Assessment|Ancillary studies
79638974|NCT02945644|Drug|Trazodone|take at bedtime for 14 days
79968230|NCT01259765|Drug|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
79309647|NCT03971175|Procedure|Forceps biopsy|Endobronchial biopsy with the forceps
79638975|NCT02945644|Drug|Placebo|take at bedtime for 14 days
79638976|NCT02945488|Other|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
79804221|NCT03462342|Drug|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
79804222|NCT03461445|Drug|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
79968231|NCT01259765|Drug|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
79968232|NCT05683886|Drug|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
79968233|NCT01261169|Drug|Myfortic|Myfortic in uveitis
79984354|NCT03747185|Other|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
79984355|NCT03208582|Drug|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
79984356|NCT03208582|Dietary Supplement|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
79984357|NCT03205930|Biological|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
79309648|NCT03971175|Procedure|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
79309649|NCT03961113|Other|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
79309650|NCT04739007|Procedure|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
79309651|NCT04739007|Device|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
79309652|NCT04512885|Other|Survey|Survey via questionnaire
79309653|NCT04480749|Diagnostic Test|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
79638977|NCT02945488|Other|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
79655566|NCT00261144|Biological|Biological|Collagenase injection
79655567|NCT04555681|Diagnostic Test|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
79474406|NCT01819597|Procedure|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
79474407|NCT02482025|Other|SMMRT|Includes My HealtheVet registration and enrollment
79474408|NCT05748223|Other|Mindfulness Meditation|Mindfulness meditation has been reported to produce beneficial effects on a number of psychiatric, functional somatic, and stress-related symptoms and has therefore increasingly been incorporated into psychotherapeutic programs
79474409|NCT05327179|Other|Action Observation Treatment|Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.
79309654|NCT04480749|Diagnostic Test|Syphilis Self-Test|Rapid Treponemal Test kit
79309655|NCT02149108|Drug|Nintedanib (BIBF 1120)|
79309656|NCT02149108|Drug|Placebo|
79309657|NCT02149108|Drug|BSC|
79309658|NCT02149108|Drug|BSC|
79474410|NCT05327179|Other|Virtual Rehabilitation|Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
79638978|NCT02945488|Other|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
79309659|NCT02148952|Behavioral|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
79309660|NCT04421859|Other|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
79309661|NCT03569007|Drug|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
79309662|NCT03569007|Drug|Matching Placebo|enteric-coated beads in gelatin capsules
79474411|NCT02420639|Device|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
79474412|NCT02989753|Dietary Supplement|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
79804223|NCT03461445|Drug|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
79309663|NCT02148718|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79309664|NCT03397953|Drug|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
79309665|NCT05549973|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
79309666|NCT02148250|Drug|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
79309667|NCT02148250|Drug|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
79309668|NCT03321747|Radiation|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
79309669|NCT03285789|Other|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
79340414|NCT01641939|Drug|Taxane|Standard taxane (docetaxel 75 mg/m^2 IV every 3 weeks or paclitaxel 80 mg/m^2) IV once a week according to investigator choice.
79804224|NCT03460067|Radiation|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
79804225|NCT03436862|Drug|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
79804226|NCT03426943|Biological|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
79804227|NCT03426943|Biological|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
79804228|NCT03426943|Device|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
79804229|NCT03426943|Device|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
79804230|NCT03421574|Device|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
79340415|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
79340416|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
79340417|NCT01641861|Device|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
79340418|NCT01641861|Procedure|Conventional method|caries removal by using rotary instrument.
79340419|NCT05511285|Behavioral|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
79340420|NCT02409355|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
79638979|NCT02945605|Other|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~Eye-Head coordination, gaze stability and convergence exercises~Sitting balance~Standing static balance (i.e. feet-in-place)~Dynamic balance (feet moving, but not walking)~Ambulation (gait exercises)~Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
79804231|NCT03417635|Behavioral|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
79638980|NCT02945605|Other|Standard of Care|Standard care as directed by a physician.
79638981|NCT02945527|Drug|Acetazolamide|As described above
79638982|NCT02945527|Drug|Dexamethasone|As described above
79804232|NCT03417635|Behavioral|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
79340421|NCT02409355|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
79638983|NCT02945371|Behavioral|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
79638984|NCT02945371|Behavioral|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
79638985|NCT00168363|Drug|brimonidine|
79638986|NCT02448095|Drug|Ponatinib|Observation of tolerability and safety profiles
79638987|NCT03458650|Drug|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
79638988|NCT03458650|Drug|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
79638989|NCT03458650|Drug|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
79638990|NCT03458650|Drug|Placebo|matching placebo tablets
79638991|NCT00168402|Drug|Botulinum Toxin Type A|
79638992|NCT00529477|Other|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
79309670|NCT03285789|Other|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
79309671|NCT02147626|Behavioral|Web-based educational and motivational modules|
79638993|NCT00529477|Other|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
79638994|NCT00529477|Other|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
79638995|NCT02444000|Drug|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
79309672|NCT02147626|Behavioral|Information and Screening Group|
79309673|NCT04870359|Procedure|Pre-emptive increase of immunosuppressive treatments|"Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~Adjustment of the 2nd agent would be as follows:~For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.~For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day."
79309674|NCT04870359|Drug|Prednisolone and/or AZA/MMF|Prednisolone and/or AZA/MMF
79309675|NCT05549817|Other|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
79340422|NCT02409355|Drug|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
79638996|NCT02444000|Drug|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
79804233|NCT03416894|Device|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
79474413|NCT02989753|Dietary Supplement|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
79474414|NCT02989753|Dietary Supplement|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
79474415|NCT05326867|Device|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
79968234|NCT03747848|Behavioral|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
79968235|NCT03911063|Behavioral|CBT sessions|weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.
79968236|NCT03911063|Behavioral|Talking Sessions|20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
79968237|NCT03939962|Drug|SHR1210 combined with FOLFOX|"SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
79984358|NCT04308239|Behavioral|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
79984359|NCT04308239|Behavioral|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
79638997|NCT00529594|Drug|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
79804234|NCT03399396|Behavioral|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
79804235|NCT03386578|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
79804236|NCT03386578|Behavioral|Behavioral HIV risk reduction package|HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
79984360|NCT03201328|Other|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
79984361|NCT03201328|Other|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
79638998|NCT00529594|Drug|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
79968238|NCT02527499|Behavioral|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
79968239|NCT02527499|Behavioral|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
79309676|NCT05549817|Other|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
79309677|NCT05549583|Drug|Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
79309678|NCT05554809|Other|Strecthing|Comparing the crossover-effect of dynamic versus static stretching
79309679|NCT02172664|Procedure|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
79309680|NCT02172664|Procedure|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
79309681|NCT02172664|Device|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
79968240|NCT02527499|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
79309682|NCT05554731|Device|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
79309683|NCT05554731|Device|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
79309684|NCT02659449|Device|made to measure compression gloves|Patients achieve tests with compression glove
79309685|NCT02659449|Device|Compression bandaging|Patients achieve tests with compression bandaging
79309686|NCT02659449|Other|Free Hands|Patients achieve tests without device
79309687|NCT02172040|Drug|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
79309688|NCT02172040|Drug|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
79309689|NCT02172040|Drug|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
79968241|NCT03889379|Drug|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
79968242|NCT03911219|Other|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
79984362|NCT03201328|Other|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
79309690|NCT02172040|Drug|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
79309691|NCT02367105|Drug|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
79309692|NCT02367105|Other|Lifestyle Therapy|Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week
79309693|NCT02367105|Drug|Placebo|Placebo gel for testosterone
79309694|NCT05554575|Biological|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
79309695|NCT05549349|Procedure|Cholecystectomy|Gallbladder removal
79804237|NCT03334617|Drug|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
79804238|NCT03334617|Drug|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
79804239|NCT03334617|Drug|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
79804240|NCT03334617|Drug|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
79804241|NCT03334617|Drug|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
79804242|NCT03334617|Drug|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
79804243|NCT03334617|Drug|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only & trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
79984363|NCT03205774|Behavioral|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
79984364|NCT03201172|Device|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
79984365|NCT03208114|Other|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
79638999|NCT00529672|Procedure|crossectomy and short stripping|under spinal or complete anaesthesia
79639000|NCT00529672|Procedure|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein>
79639001|NCT00529672|Procedure|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
79639002|NCT00173862|Drug|Gemcitabine, Ifosfamide|
79639003|NCT00529711|Drug|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
79639004|NCT00529711|Drug|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
79639005|NCT00529750|Drug|IRBESARTAN|Tablets
79639006|NCT00529750|Drug|Atenolol|Tablets
79639007|NCT02387606|Drug|Placebo|Participants will receive placebo once daily.
79639008|NCT02387606|Drug|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
79639009|NCT00529828|Procedure|Consumption of CLA enriched food|
79968243|NCT05168228|Procedure|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
79968244|NCT03887039|Other|clinical examination|clinical examination for all the oral findings
79968245|NCT03910829|Behavioral|Action Observation|Action observation training
79968246|NCT03910829|Behavioral|Motor Imagery|Motor imagery protocol
79968247|NCT03910829|Behavioral|Placebo Action Observation|Placebo Action Observation
79968248|NCT05159102|Other|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)
79968249|NCT05159102|Behavioral|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
79968250|NCT01252433|Other|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
79968251|NCT03361982|Other|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
79968252|NCT03886337|Device|Germicidal lighting|Germicidal ambient lighting
79968253|NCT01586507|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
79968254|NCT01586507|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
79968255|NCT03574727|Procedure|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
79968256|NCT05152394|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79639010|NCT00529867|Drug|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
79639011|NCT00529867|Drug|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
79639012|NCT00168441|Drug|Botulinum Toxin Type A|
79639013|NCT02944708|Drug|Conventional chemotherapy|
79639014|NCT02944708|Drug|Maintenance chemotherapy 1|
79639015|NCT02944708|Drug|Maintenance chemotherapy 2|
79639016|NCT02376686|Other|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
79639017|NCT02944630|Behavioral|Psychotherapy|Individual psychotherapy
79968257|NCT03910595|Other|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
79968258|NCT01154777|Behavioral|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
79968259|NCT01252511|Procedure|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
79639018|NCT02944591|Device|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
79639019|NCT00168480|Biological|Botulinum Toxin Type A|100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period
79639020|NCT02944435|Drug|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
79968260|NCT03910517|Other|No intervention|No intervention
79340423|NCT02409355|Drug|Gemcitabine|Gemcitabine will be administered at 1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
79639021|NCT02944435|Drug|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
79639022|NCT01708538|Drug|CXL|corneal crosslinking
79968261|NCT03910361|Drug|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
79968262|NCT03910361|Drug|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
79968263|NCT03910205|Diagnostic Test|ELISA|Enzim linked immunoabsorbant assay
79968264|NCT03700658|Drug|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
79968265|NCT03700658|Drug|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
79968266|NCT03700658|Drug|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
79968267|NCT03910127|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79968268|NCT03910127|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
79968269|NCT03910127|Drug|Anlotinib|matching placebo
79968270|NCT03886103|Drug|14C labeled PXL770|Single administration
79639023|NCT02945449|Biological|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
79639024|NCT00527449|Drug|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
79804244|NCT03334617|Drug|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
79804245|NCT03334617|Drug|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
79804246|NCT03334617|Drug|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
79804247|NCT03334617|Drug|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
79804248|NCT03334617|Drug|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
79804249|NCT03329313|Drug|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
79804250|NCT03329313|Drug|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
79804251|NCT03298802|Drug|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
79804252|NCT03298802|Drug|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
79804253|NCT03291496|Other|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
79804254|NCT03291496|Other|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is >24 hours old.
79804255|NCT03291496|Other|Adult Blood collection|One Time 1 ml of whole blood collected
79804256|NCT03282968|Device|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
79804257|NCT03282968|Other|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
79968271|NCT03031964|Device|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
79968272|NCT03885947|Biological|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
79968273|NCT03885947|Drug|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
79309696|NCT05549271|Procedure|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
79968274|NCT03885947|Drug|Fludarabine|Fludarabine 150 mg/m2
79639028|NCT00168519|Drug|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
79639029|NCT00144521|Drug|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
79639030|NCT00144521|Drug|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
79968275|NCT03885947|Drug|cytoxan|Cytoxan 50 mg/m2
79968276|NCT03885947|Drug|Thiotepa|Thiotepa 10 mg/m2
79968277|NCT03885947|Biological|TBI|TBI 400cGy
79968278|NCT04653272|Other|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
79968279|NCT01155557|Device|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
79639031|NCT00144521|Drug|MTX|8mg/week(p.o.) for 24 weeks
79639032|NCT00144521|Drug|MTX placebo|0mg/week(p.o.) for 24 weeks
79639033|NCT04692376|Biological|Mesenchymal stem cells|Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
79804258|NCT03280836|Behavioral|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
79804259|NCT03271814|Biological|LPS|0.6 by/kg LPS single dose iv
79804260|NCT03271814|Other|Placebo|Sterile Water
79804261|NCT03258580|Device|Medoc thermal stimulator|Heat pain stimulation for substudy 1
79804262|NCT03258580|Device|Electric shock stimulator|Electric pain stimulation for substudy 1
79804263|NCT03258580|Device|Cold water bath|Cold pain stimulation for substudy 1
79968280|NCT01155557|Behavioral|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
79984366|NCT04302545|Procedure|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
79639034|NCT04692376|Drug|Glucocorticoids|Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
79639035|NCT04692376|Drug|cyclosporine|Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
79639036|NCT00527527|Procedure|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
79639037|NCT00527527|Other|placebo control|Placebo for comparison with flexion distraction treatment
79639038|NCT00527683|Drug|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
79804264|NCT03258580|Behavioral|Pain assessment performance feedback|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
79804265|NCT03202316|Drug|Atezolizumab|Given IV
79804266|NCT03202316|Drug|Cobimetinib|Given PO
79804267|NCT03202316|Drug|Eribulin|Given IV
79804268|NCT03202316|Other|Laboratory Biomarker Analysis|Correlative studies
79804269|NCT03202316|Other|Pharmacological Study|Correlative studies
79804270|NCT03164616|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
79804271|NCT03164616|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
79984367|NCT04484896|Other|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
79984368|NCT04484896|Other|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
79984369|NCT04484896|Other|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
79309697|NCT05549271|Procedure|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
79309698|NCT05549193|Other|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
79309699|NCT04426227|Other|Gaze training|A training module in gaze training for peripheral nerve blockade
79309700|NCT04426227|Other|Discovery learning|A phase of discovery learning guided by novice operators themselves
79309701|NCT05554185|Dietary Supplement|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
79309702|NCT05554029|Diagnostic Test|Coronaphobia|Coronophobia will be assessed with COVID-19-phobia scale.
79639039|NCT00527683|Drug|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
79309703|NCT05548959|Diagnostic Test|Pneumatonometry after microshunt implantation|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
79309704|NCT05548959|Diagnostic Test|Pneumatonometry after ab interno trabeculectomy|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
79309705|NCT02112994|Drug|Sebelipase Alfa|IV infusion of sebelipase alfa
79639040|NCT00527683|Behavioral|Group therapy|Participants attend group sessions once a week
79639041|NCT00173901|Drug|ceftazidime|
79639042|NCT00527761|Drug|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
79639043|NCT00527761|Drug|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
79340424|NCT04874259|Procedure|Living donor liver transplantation|Living donor liver transplantation
79340425|NCT05647707|Dietary Supplement|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
79340426|NCT02408887|Procedure|Total Thyroidectomy (TT)|Total removal of thyroid
79340427|NCT02408887|Procedure|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
79340428|NCT02266875|Drug|hypertonic saline|
79340429|NCT02266875|Drug|standard saline|
79639044|NCT00527761|Drug|Temodar|150 mg by mouth (PO) on Days 1 - 5.
79639045|NCT00144560|Drug|MRA(Tocilizumab)|
79639046|NCT00527800|Drug|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
79639047|NCT00527800|Drug|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
79639048|NCT00527800|Drug|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
79639049|NCT04692064|Other|There is no intervention|There is no intervention
79639050|NCT00168558|Biological|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
79639051|NCT00144599|Drug|MRA(Tocilizumab)|
79639052|NCT00144599|Drug|placebo|
79639053|NCT02945293|Other|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
79984370|NCT03205852|Other|questionnaire|fulfillment of questionnaire
79984371|NCT03200938|Device|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
79984372|NCT03200938|Device|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
79984373|NCT04297241|Drug|Isosorbide Dinitrate|All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
79984374|NCT03205618|Other|Non-Interventional|Non-Interventional
79984375|NCT03749525|Drug|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
79984376|NCT03201016|Diagnostic Test|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
79984377|NCT03205540|Procedure|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
79804272|NCT03164616|Drug|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
79804273|NCT03164616|Drug|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
79804274|NCT03164616|Drug|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
79804275|NCT03164616|Drug|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.
79968281|NCT03885869|Other|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
79984378|NCT03205540|Procedure|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
79309706|NCT04325841|Biological|Murine autologous anti-CD19 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
79639054|NCT02945332|Behavioral|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
79309707|NCT05558397|Device|Interventional Group (Epidural morphine)|Implantation of an epidural catheter for administration of morphine and ropvacaine
79639055|NCT02945332|Behavioral|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
79639056|NCT02945332|Device|Fitbit Flex|
79639057|NCT04692415|Drug|Degludec|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
79804276|NCT03164616|Drug|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.
79968282|NCT03885869|Other|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
79309708|NCT05558397|Drug|Control Group (Oral morphine)|Oral administration of morphine, pregabalin or duloxetin
79804277|NCT03160131|Device|Neuro Vision Technology|Training using Neuro Vision Technology
79309709|NCT05558319|Drug|Bortezomib|Bortezomib
79309710|NCT05558319|Drug|Isatuximab|Isatuximab
79309711|NCT05558319|Drug|Iberdomide|Iberdomide
79309712|NCT05558319|Drug|Lenalidomide|Lenalidomide
79309713|NCT05558319|Drug|Dexamethasone|Dexamethasone
79309714|NCT05548725|Other|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
79309715|NCT05700825|Behavioral|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
79309716|NCT05700513|Combination Product|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
79309717|NCT05700513|Drug|Placebo capsules|Placebo capsules containing maltodextrin
79639058|NCT04692415|Drug|Glargine U300|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
79639059|NCT00527917|Device|placebo|bladder instillation
79639060|NCT00527917|Device|Uracyst|20 ml sterile solution for weekly intravesical instillation
79639061|NCT02945176|Device|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
79639062|NCT02945215|Drug|IBI301|IBI301 375mg/㎡
79639063|NCT02945215|Drug|Rituximab|Rituximab 375mg/㎡
79639064|NCT00144677|Drug|sirolimus|
79968283|NCT03885869|Other|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
79968284|NCT03885869|Other|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
79639065|NCT00144677|Drug|tacrolimus|
79639066|NCT00531076|Biological|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
79639067|NCT00531115|Drug|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
79639068|NCT00144716|Device|Insect Repellent plus Insecticide Treated Net|
79639069|NCT00531193|Drug|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
79474416|NCT05326867|Device|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
79968285|NCT03885869|Other|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
79639070|NCT00531193|Other|[11C]SCH442416|11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
79968286|NCT03885869|Other|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
79968287|NCT03886883|Other|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
79968288|NCT03886883|Other|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
79968289|NCT03886883|Other|Rest|The participants rested in a seated position for 10 minutes
79968290|NCT03886883|Other|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
79639071|NCT02943616|Device|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~Scaffold diameters: 2.5, 3.0, and 3.5 mm~Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
79968291|NCT03885791|Device|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
79968292|NCT01252589|Other|HRQOL questionnaire|
79968293|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
79474417|NCT05326789|Device|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
79309718|NCT05543343|Drug|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
79309719|NCT05543343|Drug|Placebo|8 placebo tablets 3 times daily
79309720|NCT05553717|Drug|Carvedilol|Carvedilol 12.5mg\12hr
79309721|NCT05543031|Other|Music-Integrated Phonological Awareness training program|We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
79474418|NCT05324995|Drug|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
79474419|NCT05324995|Drug|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
79968294|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
79968295|NCT01261637|Drug|Saline placebo|20ml saline
79474420|NCT05324995|Drug|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
79474421|NCT05318521|Drug|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
79639072|NCT02943421|Procedure|Transverse B-Lynch suture|
79639073|NCT00144755|Drug|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
79309722|NCT05543031|Diagnostic Test|Spectral-Temporally Modulated Ripple Test (SMRT)|Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
79309723|NCT05543031|Diagnostic Test|The Phonological Awareness Scale of Early Childhood Period (PASECP)|The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
79639074|NCT02943382|Other|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
79968296|NCT01261637|Drug|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
79968297|NCT03910049|Drug|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
79968298|NCT03885635|Procedure|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
79639075|NCT00531271|Drug|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
79639076|NCT00531310|Drug|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
79639077|NCT00407862|Drug|Telmisartan 80 mg|
79474422|NCT05318521|Drug|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-[4-(2-methylpropyl) phenyl] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
79474423|NCT05312905|Other|Mirror Therapy|Mirror Therapy applied alone
79804280|NCT03156335|Device|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
79474424|NCT05312905|Other|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
79474425|NCT02420873|Drug|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
79474426|NCT02534129|Drug|Difinsa53|Difinsa53 cream is applied to one half of radiation field
79474427|NCT02534129|Drug|Aquaphor|Aquaphor is applied to one half of radiation field
79474428|NCT02420951|Drug|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
79474429|NCT02420951|Other|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
79474430|NCT02267083|Drug|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
79474431|NCT02534285|Device|hearing protection|Attenuation of hearing during surgery
79474432|NCT05747911|Other||Groups will not be intervened. Only observational data will be used.
79639078|NCT00407862|Drug|Losartan 50 mg|
79309724|NCT05543031|Diagnostic Test|Mismatch Negativity Test|Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
79309725|NCT05543031|Diagnostic Test|Early Language Development (TELD-3)|Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
79968299|NCT03885635|Procedure|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
79474433|NCT02422511|Genetic|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
79474434|NCT02422511|Other|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
79804281|NCT03149081|Drug|Boswellia|Boswellia is an extract from frankincense
79804282|NCT03131765|Biological|YS-0N-001|Cancer vaccine
79968300|NCT01262183|Drug|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
79968301|NCT01262183|Drug|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
79968302|NCT03885479|Diagnostic Test|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
79968303|NCT03885557|Other|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
79968304|NCT03885557|Other|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
79309726|NCT05553483|Other|pranayama plus acupoint stimulation by laser|"This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )."
79474435|NCT05747833|Other|Children Preparation With a Toy IV Catheter Before Peripheral Cannula application|THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
79474436|NCT02989675|Drug|10% dextrose|Bolus of 10% dextrose 5mls/kg
79474437|NCT05747677|Drug|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
79474438|NCT02535611|Drug|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
79474439|NCT02535611|Drug|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
79804283|NCT03118752|Behavioral|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
79968305|NCT03886805|Other|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
79474440|NCT01823497|Drug|Morphine|Morphine will be used to control pain post-surgery.
79804284|NCT03115710|Diagnostic Test|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
79474441|NCT00363935|Drug|Dexmedetomidine|
79474442|NCT02423447|Device|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
79474443|NCT02423447|Device|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
79474444|NCT05747521|Drug|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
79968306|NCT03886805|Other|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
79968307|NCT01154855|Procedure|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
79968308|NCT03884933|Other|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
79639079|NCT00527995|Drug|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
79968309|NCT03885323|Device|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
79968310|NCT03885323|Device|Control placebo with no RF|Placebo control, with no RF
79968311|NCT01154933|Drug|exenatide 5 mcg|exenatide 5 mcg
79968312|NCT01154933|Drug|exenatide 10 mcg|exenatide 10 mcg
79968313|NCT01154933|Drug|placebo|saline sq
79968314|NCT01155635|Drug|Carvedilol|Use of Carvedilol with any dose
79968315|NCT01155635|Drug|No Carvedilol|No use of Carvedilol
79968316|NCT01155089|Drug|Anastrozole|1 mg tablet
79968317|NCT03886727|Device|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
79968318|NCT03886727|Device|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
79968319|NCT01261949|Device|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
79968320|NCT01261949|Device|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
79968321|NCT01155245|Drug|Forteo|Forteo pen
79968322|NCT03884699|Procedure|Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant|"Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique."
79968323|NCT01155713|Drug|TKI258|
79474445|NCT02537717|Device|Sapphire Lens|Each subject randomized to wear either the test or control in either the left of right eye.
79474446|NCT02537717|Device|enfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
79474447|NCT05234047|Procedure|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
79474448|NCT05234047|Procedure|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
79474449|NCT02537873|Drug|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
79639080|NCT00144833|Drug|fosamprenavir/ritonavir (700mg/100mg BID)|
79639081|NCT00144833|Drug|fosamprenavir/ritonavir (1400mg/100mg BID)|
79639082|NCT00144833|Drug|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
79639083|NCT00528034|Procedure|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
79639084|NCT02944864|Drug|TQ-B3395|TQ-B3395 p.o. qd
79639085|NCT02944942|Procedure|General anesthesia|Patients undergoing general anesthesia
79639086|NCT02964000|Device|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
79639087|NCT02964000|Device|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
79474450|NCT02537873|Drug|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
79474451|NCT02537873|Drug|Placebo comparator|Dextrose in gelatin capsule
79474452|NCT01823653|Device|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
79474453|NCT05118763|Drug|INNA-051|Liquid for intranasal administration
79474454|NCT05118763|Other|Placebo|Liquid for intranasal administration
79804285|NCT03109444|Diagnostic Test|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be >50%.
79968324|NCT01157039|Dietary Supplement|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
79968325|NCT03881735|Drug|Enasidenib|Given PO
79968326|NCT03881735|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
79968327|NCT01262417|Procedure|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
79968328|NCT01262417|Procedure|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
79639088|NCT02964000|Device|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
79639089|NCT02944903|Other|Audit|Questionnair
79639090|NCT00144872|Drug|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
79639091|NCT02945020|Drug|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
79968329|NCT01157195|Behavioral|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
79474455|NCT02537951|Device|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
79474456|NCT02537951|Device|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
79474457|NCT02537951|Device|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
79474458|NCT01824589|Device|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
79639092|NCT02945020|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
79639093|NCT02945020|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
79639094|NCT00528073|Drug|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
79639095|NCT00528151|Drug|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
79804286|NCT03100747|Procedure|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
79804287|NCT03100747|Procedure|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
79804288|NCT03100747|Procedure|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
79804289|NCT03095781|Drug|XL888|Given PO
79639096|NCT00144911|Drug|Salmeterol|
79639097|NCT00144911|Drug|Fluticasone Propionate/Salmeterol Combination Product|
79639098|NCT00528229|Radiation|Computer Tomography|
79639099|NCT00528307|Device|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
79639100|NCT00168597|Drug|Vitamin A|
79639101|NCT00528346|Behavioral|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
79639102|NCT00528346|Behavioral|placebo|Some participants will see simulated data that does not come from their own brains.
79639103|NCT00528385|Drug|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
79639104|NCT00528463|Procedure|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
79639105|NCT02945098|Other|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
79639106|NCT02945098|Other|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
79639107|NCT00407940|Device|Lower extremity Atherectomy and Cryoplasty|
79804290|NCT03095781|Biological|Pembrolizumab|Given IV
79804291|NCT03094715|Device|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
79804292|NCT03094715|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
79804293|NCT03088098|Device|LAAO|Left atrial appendage occlusion for stroke prevention
79804294|NCT03064490|Drug|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
79804295|NCT03039751|Drug|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
79804296|NCT03039751|Drug|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
79804297|NCT02960555|Biological|Isatuximab|Given IV
79804298|NCT02960555|Other|Laboratory Biomarker Analysis|Correlative studies
79804299|NCT02918565|Behavioral|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
79804300|NCT02918565|Behavioral|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
79804301|NCT02918565|Behavioral|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
79804302|NCT02918565|Behavioral|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
79804303|NCT02917421|Radiation|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
79968330|NCT01157195|Behavioral|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
79968331|NCT03884621|Other|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
79968332|NCT01155791|Drug|Docetaxel|IV 75 mg/m2
79968333|NCT01155791|Drug|Biosyn|IV dosage varies
79968334|NCT01155791|Drug|Prednisone|5mg, orally
79968335|NCT01263743|Behavioral|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
79968336|NCT01263743|Behavioral|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
79968337|NCT03881657|Behavioral|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
79968338|NCT03881657|Behavioral|Usual Care|Behavioral health services without primary care or integrated care services
79968339|NCT03881813|Device|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
79968340|NCT01589783|Other|completion of a questionnaire|Completion of a questionnaire
79968341|NCT01589783|Other|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
79968342|NCT03881969|Behavioral|Financial Payment of £100|No financial payment
79968343|NCT01157507|Drug|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
79804304|NCT02905422|Behavioral|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
79804305|NCT02887248|Drug|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
79804306|NCT02887248|Drug|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
79804307|NCT02878850|Other|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
79804308|NCT02873962|Drug|Bevacizumab|"Bevacizumab will be given intravenously at a pre-determined dosage~One dose reduction will be allowed for Bevacizumab"
79968344|NCT01157507|Procedure|Bladder overdistension|Bladder overdistension
79804309|NCT02873962|Drug|Nivolumab|"Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~No dose reductions or escalations will be allowed for Nivolumab"
79968345|NCT01157507|Drug|Placebo|One single injection of placebo
79968346|NCT03881267|Other|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
79968347|NCT03881267|Other|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
79968348|NCT03881267|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
79968349|NCT01263821|Procedure|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
79968350|NCT01263821|Procedure|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
79309727|NCT05553483|Other|acupoint stimulation by laser|This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
79804310|NCT02873962|Drug|Rucaparib|"Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~Up to three dose reductions will be allowed for Rucaparib (depending on cohort)."
79804311|NCT02871856|Diagnostic Test|Low dose CT|low-dose screening CT of chest for lung cancer detection
79968351|NCT01263821|Procedure|Functional magnetic resonance imaging|Undergo functional MRI
79968352|NCT01263821|Procedure|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
79968353|NCT01263821|Procedure|Therapeutic conventional surgery|Undergo maximal surgical resection
79968354|NCT01263821|Procedure|Quality-of-life assessment|Ancillary studies
79968355|NCT01263821|Procedure|Radiation therapy treatment planning/simulation|Undergo IMRT planning
79968356|NCT01263821|Procedure|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
79968357|NCT01263821|Other|Questionnaire administration|Ancillary studies
79968358|NCT01262495|Other|cryopreservation|cryopreservation of testicular tissue
79804312|NCT02859064|Drug|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
79968359|NCT01263899|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
79968360|NCT03881423|Drug|Rocuronium Bromide|DEEP block to PTC 1-3
79968361|NCT03884465|Drug|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
79968362|NCT01263977|Device|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
79968363|NCT01155947|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
79968364|NCT03881189|Device|SUNEKOS® 200|The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
79968365|NCT03884309|Other|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
79968366|NCT01157585|Drug|paliperidone ER|8 week prospective study
79309728|NCT05542953|Drug|[18F]APN-1607|In this study, all patients will receive one injection of [18F]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
79309729|NCT05553249|Behavioral|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
79968367|NCT01264133|Drug|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
79968368|NCT02527577|Drug|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
79474459|NCT01824589|Device|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
79474460|NCT02486939|Drug|CHS-0214|Open label
79804313|NCT02859064|Device|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
79968369|NCT02527577|Drug|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
79968370|NCT03883841|Drug|Iron Sucrose Solution for Injection|intravenous infusion of iron sucrose
79968371|NCT03881111|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
79968372|NCT03881111|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
79968373|NCT03881111|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
79968374|NCT03881111|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
79968375|NCT01157663|Other|Adapted balance training|during 8 weeks
79804314|NCT02843074|Drug|elotuzumab|Given intravenously (IV)
79804315|NCT02843074|Drug|Lenalidomide|Given by IV
79804316|NCT02843074|Drug|Dexamethasone|Given orally (PO) or by IV
79804317|NCT02843074|Procedure|autologous stem cell transplantation|
79968376|NCT01157663|Other|Balance Training|Balance training with unipedal standing during 8 weeks
79968377|NCT03884387|Other|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
79968378|NCT03883997|Other|No intervention|Cross-sectional
79968379|NCT01264211|Drug|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
79639108|NCT02944786|Behavioral|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
79639109|NCT00144950|Drug|insertion of a chest drain with urokinase instillation|
79639110|NCT00144950|Procedure|primary video-assisted thorascopic surgery|
79804318|NCT02795156|Drug|Afatinib|40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
79804319|NCT02795156|Drug|Regorafenib|160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
79968380|NCT01264211|Drug|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
79639111|NCT02944981|Drug|Gabapentin|Single oral dose
79639112|NCT02944981|Drug|Placebo|Single oral dose
79804320|NCT02795156|Drug|Cabozantinib|60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
79804321|NCT02777762|Behavioral|Fun First|8 weekly interactive small-group sessions with a health coach
79804322|NCT02777762|Behavioral|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
79804323|NCT02707042|Drug|Amoxicillin|7-day therapeutic oral course of twice daily amoxicillin
79804324|NCT02707042|Drug|Azithromycin|5-day oral course of once-daily azithromycin
79804325|NCT02707042|Other|Control|A group of volunteers will receive no antibiotics and will serve as study controls.
79804326|NCT02649673|Drug|LCL161|
79804327|NCT02649673|Drug|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
79804328|NCT02649673|Drug|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
79804329|NCT02642094|Drug|Rapamycin|Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
79804330|NCT02636582|Other|Laboratory Biomarker Analysis|Correlative studies
79804331|NCT02636582|Drug|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
79804332|NCT02636582|Biological|Sargramostim|Given ID
79804333|NCT02636582|Procedure|Surgical Procedure|Undergo surgery
79804334|NCT02627443|Drug|Berzosertib|Given IV
79804335|NCT02627443|Drug|Carboplatin|Given IV
79804336|NCT02627443|Drug|Gemcitabine Hydrochloride|Given IV
79968381|NCT03881033|Other|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
79968382|NCT03881033|Other|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
79968383|NCT03880877|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
79968384|NCT03880877|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
79639113|NCT02944669|Device|ReWalk Personal Device|
79639114|NCT00168636|Drug|Vitamin A|
79639115|NCT00144989|Drug|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
79639116|NCT00144989|Drug|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
79639117|NCT04692025|Drug|ASC41 tablet|Oral tablet
79639118|NCT00528502|Drug|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
79804337|NCT02627443|Other|Laboratory Biomarker Analysis|Correlative studies
79804338|NCT02627443|Other|Pharmacological Study|Correlative studies
79804339|NCT02616666|Drug|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
79968385|NCT03880877|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
79309730|NCT05542875|Procedure|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
79474461|NCT02487485|Drug|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
79804340|NCT02616666|Drug|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
79804341|NCT02615054|Device|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
79968386|NCT03880877|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
79968387|NCT03880877|Drug|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
79968388|NCT01157741|Behavioral|C-C|Mx as H-C plus positioning follow up in the community clinic
79968389|NCT01157741|Other|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
79968390|NCT01157741|Other|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
79968391|NCT01157741|Other|As C-C but with both SF & PS (C-SF+PS)|Giving both SF & PS
79309731|NCT05542875|Procedure|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
79474462|NCT02487485|Drug|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
79804342|NCT02615054|Device|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
79804343|NCT02613546|Behavioral|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~evaluation session;~sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
79968392|NCT01157741|Other|H-C|Follow-up at Hospital
79968393|NCT05666999|Device|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
79968394|NCT05666999|Device|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
79474463|NCT02487485|Drug|Placebo|Placebo oral dose
79474464|NCT02487563|Drug|Decitabine|Decitabine
79474465|NCT02487563|Drug|rhTPO|rhTPO
79474466|NCT02487563|Other|Conventional Treatment|immunoglobulin, glucocorticoid etc
79639119|NCT00528502|Drug|Saline|Saline is misted into the air that you breathe during the surgery.
79804344|NCT02613546|Behavioral|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
79804345|NCT02598726|Drug|Curcumin|Given PO
79968395|NCT05666999|Device|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
79639120|NCT00528619|Drug|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.
79804346|NCT02598726|Other|Laboratory Biomarker Analysis|Correlative studies
79309732|NCT05542875|Procedure|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
79309733|NCT05700123|Procedure|In-Office Hysteroscopy|In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
79639121|NCT00168714|Drug|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
79804347|NCT02598726|Dietary Supplement|Piperine Extract (Standardized)|Given PO
79309734|NCT05542797|Drug|Duphastone|dydrogesterone hormone
79309735|NCT02147158|Drug|Ulipristal acetate (UPA)|Ulipristal acetate (UPA) tablet.
79309736|NCT02147158|Drug|Placebo|Matching placebo tablet.
79309737|NCT05553093|Drug|Tirzepatide|Tirzepatide ih qw
79309738|NCT05553093|Drug|Insulin Glargine|6 IU ih qd
79309739|NCT05542719|Other|application|"Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk"
79309740|NCT04757740|Biological|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
79309741|NCT04757740|Drug|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
79309742|NCT05552937|Drug|Tafasitamab and Lenalidomide|"Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles."
79309743|NCT02112448|Drug|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
79639122|NCT00528658|Drug|Paracetamol|1g qid
79639123|NCT00528658|Drug|Ibuprofen|400mg tid
79804348|NCT02598726|Other|Quality-of-Life Assessment|Ancillary studies
79804349|NCT02578914|Drug|NS2 Ophthalmic Drops (0.5%)|
79639124|NCT00528658|Drug|Paracetamol Placebo|equivalent to 1g qid
79639125|NCT00528658|Drug|Ibuprofen placebo|Equivalent to 400mg tid
79639126|NCT04691674|Procedure|Endoscopy|Endoscopic removal of the pancreatic stent
79639127|NCT00145028|Drug|Carboplatin|
79639128|NCT00528814|Other|Active Hand Sanitizer|Active Hand Sanitizer
79639129|NCT04691752|Other|Audit|Audit from clinical records
79639130|NCT00145067|Behavioral|Disease Management Assessment|
79804350|NCT02578914|Drug|NS2 Ophthalmic Drops Vehicle (0.0%)|
79804351|NCT02577731|Other|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
79309744|NCT02112448|Drug|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
79309745|NCT02112448|Drug|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
79309746|NCT02112448|Drug|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
79309747|NCT02171260|Drug|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
79309748|NCT02110732|Dietary Supplement|Lactobacillus rhamnosus GG|
79309749|NCT02109562|Drug|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
79309750|NCT02109562|Drug|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
79639131|NCT01580527|Procedure|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
79639132|NCT01580527|Procedure|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
79639133|NCT05647603|Other|data collection|Information about contraception
79804352|NCT02577731|Other|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
79309751|NCT02109562|Drug|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
79309752|NCT02109484|Biological|P2-VP8 Subunit Vaccine 10mcg|10 mcg
79309753|NCT02109484|Biological|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
79309754|NCT02109484|Biological|P2-VP8 Subunit Vaccine 60mcg|60 mcg
79309755|NCT02109484|Other|Placebo|
79309756|NCT05134792|Drug|intravenous immunoglobulin|All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
79309757|NCT05177692|Device|Vguard|VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
79309758|NCT04737850|Drug|Hetrombopag|Thrombopoietin receptor agonist
79309759|NCT04737850|Drug|Placebo|Placebo with no active pharmaceutical ingredient
79309760|NCT02105974|Drug|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
79639134|NCT00168753|Drug|Alefacept|IM
79639135|NCT00528892|Drug|Raltegravir|switching PI to raltegravir
79639136|NCT00528892|Drug|boosted PI|continue on boosted-PI
79639137|NCT00405626|Drug|Bellis Perenis ,Arnica montana|
79639138|NCT04691401|Device|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
79639139|NCT00531349|Procedure|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
79804353|NCT02577731|Other|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
79804354|NCT02564848|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
79968396|NCT03880799|Behavioral|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
79968397|NCT01262729|Procedure|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
79474467|NCT02423993|Behavioral|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
79639140|NCT00531349|Drug|Sevoflurane|General anesthesia
79639141|NCT00531466|Drug|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
79804355|NCT02544035|Other|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
79804356|NCT02544035|Other|Play Partner|Each child will first play alone then play with parent.
79804357|NCT02540109|Device|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
79474468|NCT02423993|Device|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
79968398|NCT01262729|Drug|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
79639142|NCT00531466|Drug|Placebo|One tablet orally three times a day for 28 days
79474469|NCT02423993|Device|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
79639143|NCT00168792|Drug|Tenecteplase|
79639144|NCT00168792|Procedure|PCI|
79804358|NCT02540109|Device|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
79804359|NCT02509546|Drug|8-Chloroadenosine|Given IV
79804360|NCT02509546|Other|Laboratory Biomarker Analysis|Correlative studies
79474470|NCT02423993|Procedure|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
79804361|NCT02509546|Other|Pharmacological Study|Correlative studies
79968399|NCT01156025|Drug|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
79968400|NCT01156025|Drug|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
79968401|NCT03880721|Procedure|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
79474471|NCT02423993|Procedure|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
79968402|NCT01264289|Drug|Finasteride|Finasteride Tablets 5 mg
79968403|NCT03883451|Other|Helmet Model|helmet model worn by football players
79968404|NCT01156103|Behavioral|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
79474472|NCT02423993|Procedure|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
79474473|NCT02423993|Procedure|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
79968405|NCT03880487|Drug|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
79968406|NCT03880487|Drug|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
79968407|NCT03880487|Drug|Oxycodone oral capsule|10 mg Oxycodone Capsules
79968408|NCT03880409|Drug|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
79968409|NCT03880409|Drug|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
79968410|NCT01262807|Other|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
79968411|NCT01157819|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
79309761|NCT02105974|Drug|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
79968412|NCT01157819|Drug|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
79309762|NCT02105662|Drug|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
79309763|NCT02143024|Behavioral|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
79309764|NCT02143024|Behavioral|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
79309765|NCT02142712|Drug|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
79309766|NCT02142712|Drug|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
79309767|NCT02142712|Drug|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
79309768|NCT02142712|Drug|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
79309769|NCT02105272|Drug|OPC-1085EL ophthalmic solution|
79309770|NCT02105272|Drug|Latanoprost ophthalmic solution|
79968413|NCT03883373|Procedure|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
79968414|NCT03883373|Procedure|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
79968415|NCT01264367|Drug|Clevudine|30mg,QD
79309771|NCT02141854|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
79474474|NCT02427737|Behavioral|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
79968416|NCT01264367|Drug|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
79968417|NCT01262885|Drug|GSK2251052|500 mg tablet, dose levels detailed in Arm description
79474475|NCT02489123|Drug|Enzalutamide|Given PO
79968418|NCT01262885|Drug|Placebo|matching placebo tablet
79804362|NCT02508571|Other|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
79474476|NCT02489123|Other|Laboratory Biomarker Analysis|Correlative studies
79804363|NCT02508571|Other|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
79968419|NCT05666921|Other|psychological assessment|The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
79968420|NCT01262963|Drug|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
79968421|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
79968422|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
79968423|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 0
79474477|NCT02489357|Procedure|Cryosurgery|Undergo whole gland cryoablation
79474478|NCT02489357|Drug|Degarelix|Given SC
79474479|NCT02489357|Other|Laboratory Biomarker Analysis|Correlative studies
79474480|NCT02489357|Biological|Pembrolizumab|Given IV
79968424|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
79968425|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
79968426|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 4
79804364|NCT02508571|Other|Sham intervention|The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
79804365|NCT02501954|Drug|Cisplatin|Given IV
79804366|NCT02501954|Drug|Carboplatin|Given IV
79804367|NCT02501954|Drug|Paclitaxel|Given IV
79804368|NCT02501954|Radiation|Radiation Therapy|Undergo Radiation Therapy
79968427|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
79968428|NCT01264445|Biological|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
79968429|NCT01263041|Drug|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
79968430|NCT01263041|Drug|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
79968431|NCT03883685|Dietary Supplement|Probiotane|probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
79968432|NCT03883685|Dietary Supplement|Placebo|Placebo
79968433|NCT03883295|Procedure|Control|The specimens will be root canal treated conventionally
79968434|NCT03883295|Procedure|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
79968435|NCT03880331|Procedure|Debridement|Aggressive vs Minimal Debridement
79968436|NCT01261715|Procedure|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
79968437|NCT01156181|Procedure|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
79968438|NCT01156181|Procedure|control|Embryo transfer without any intervention
79968439|NCT01264523|Other|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
79968440|NCT03880253|Drug|CTP-692|Placebo or CTP-692
79968441|NCT03880097|Procedure|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
79968442|NCT01157975|Drug|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
79968443|NCT01157975|Drug|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
79968444|NCT01158053|Device|FFR and VH-IVUS|"Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) >48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~FFR followed by VH-IVUS of study lesion(s)~Any additional PCI based on routine clinical practice and FFR/IVUS data?~If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
79968445|NCT01158053|Device|IVUS and FFR|
79804369|NCT02473497|Drug|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
79968446|NCT03060512|Drug|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
79968447|NCT03060512|Drug|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
79804370|NCT02422667|Other|Patient Registry|Orthopedic Data Registry
79804371|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79474481|NCT02490293|Drug|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
79804372|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79804373|NCT02356822|Other|Patient registry|Oncology data registry
79968448|NCT01263275|Device|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
79474482|NCT02490293|Drug|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
79474483|NCT02538419|Behavioral|CPAP + Peer Support|
79474484|NCT02538419|Behavioral|CPAP + Individual Education|
79474485|NCT02539511|Drug|CI-581a|
79474486|NCT02539511|Drug|CI-581b|
79474487|NCT02539511|Behavioral|Motivational Enhancement Therapy (MET)|
79474488|NCT02540447|Procedure|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
79804374|NCT02318784|Drug|Carfilzomib|
79804375|NCT02311062|Other|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
79804376|NCT02311062|Other|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
79804377|NCT02311062|Other|Control|Only soccer training
79804378|NCT02276417|Other|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
79968449|NCT01263353|Drug|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
79968450|NCT01263353|Drug|Everolimus followed by Pasireotide LAR + Everolimus|
79309772|NCT02141854|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
79309773|NCT02141854|Drug|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
79804379|NCT02276417|Other|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
79804380|NCT02276417|Other|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
79968451|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
79968452|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
79474489|NCT02428595|Device|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
79474490|NCT02493257|Drug|Capsaicin|
79474491|NCT02493257|Drug|Placebo|
79474492|NCT02430389|Drug|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
79968453|NCT01158131|Behavioral|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
79968454|NCT02622542|Device|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
79968455|NCT02622542|Other|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
79309774|NCT02141854|Drug|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
79309775|NCT02587221|Biological|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|1 dose approximately 0.5 mL of aQIV
79309776|NCT02587221|Biological|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
79309777|NCT02141620|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
79309778|NCT02141620|Drug|n-Acetylcysteine|
79309779|NCT02141620|Drug|Placebo|
79474493|NCT02430389|Drug|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
79804381|NCT02276417|Other|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
79804382|NCT02276417|Other|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
79804383|NCT02276417|Other|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
79804384|NCT02276417|Other|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
79968456|NCT01158209|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
79804385|NCT02201758|Dietary Supplement|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
79804386|NCT02201758|Other|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
79804387|NCT02195011|Device|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
79804388|NCT02195011|Drug|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
79804389|NCT02170090|Drug|Gemcitabine|Gemcitabine 1000mg/m2
79804390|NCT02170090|Drug|Cisplatin|Cisplatin 25mg/m2
79804391|NCT02170090|Drug|Capecitabine|Capecitabine 1250mg/m2
79804392|NCT02143466|Drug|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
79474494|NCT02431637|Biological|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
79474495|NCT02431637|Drug|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
79804393|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
79804394|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
79804395|NCT02143466|Drug|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
79804396|NCT02143466|Drug|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
79804397|NCT02143466|Drug|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
79804398|NCT02143466|Drug|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent [4 days on/3 days off]) to further investigate the safety and tolerability of this combination.
79804399|NCT02143466|Drug|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
79968457|NCT03882983|Drug|Antria Cell Preparation Process|"Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~Stromal Vascular Fraction~Adiployx Biological/Vaccine:"
79968458|NCT03883061|Other|regular medical treatment|regular medical treatment
79309780|NCT02106910|Device|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
79309781|NCT05698953|Other|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
79309782|NCT05698953|Other|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
79309783|NCT01664949|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
79309784|NCT01664949|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
79340430|NCT04135443|Behavioral|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-17. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
79968459|NCT03882593|Procedure|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
79968460|NCT01158287|Drug|sorafenib tosylate|
79968461|NCT01158287|Other|laboratory biomarker analysis|
79968462|NCT01158365|Drug|LACTIC ACID (Dermacid)|Route of administration: local
79968463|NCT01158365|Drug|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
79968464|NCT01158443|Behavioral|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
79968465|NCT01158443|Behavioral|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
79968466|NCT03882515|Other|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
79968467|NCT03882515|Other|Continuous Surface Slip Technique|"Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
79968468|NCT03882515|Other|Without intervention|Evaluation and re-evaluation without intervention
79968469|NCT01156493|Other|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
79309785|NCT05548101|Procedure|ICSI|Using the injecting pipet, one sperm will be isolated. Using the tip of the injecting pipet, the sperm tail will be broken by trapping it between the pipet and bottom of the dish. The sperm will be picked up in the pipet. The oocyte will be positioned so the polar body is at the 12 o'clock or 6 o'clock position. The sperm injecting pipet will be positioned at the 3 o'clock position of the oocyte. The injecting pipet will be advanced into the oocyte cytoplasm and the cytoplasm will be gently aspirated until the oocyte membrane breaks. The sperm will then be injected into the cytoplasm of the oocyte. The pipet will then be withdrawn from the oocyte.
79309786|NCT02587143|Drug|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
79309787|NCT02587143|Drug|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
79804400|NCT02143466|Drug|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
79309788|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
79309789|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
79309790|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
79639145|NCT00405665|Drug|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
79804401|NCT02143466|Drug|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
79804402|NCT02143466|Drug|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
79804403|NCT02089607|Device|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
79804404|NCT02089607|Device|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
79309791|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
79804405|NCT02087501|Device|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
79804406|NCT02076074|Radiation|accelerated partial breast irradiation|Undergo HG-PBI
79804407|NCT02070809|Procedure|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
79804408|NCT02070809|Procedure|split-thickness skin graft method|This method is traditional split-thickness skin graft
79804409|NCT02003976|Procedure|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
79804410|NCT02003976|Other|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
79309792|NCT05542329|Device|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
79309793|NCT05547945|Behavioral|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
79309794|NCT05547945|Behavioral|Control group|The control group received as usual care.
79309795|NCT05552703|Procedure|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
79309796|NCT05698797|Other|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
79309797|NCT05698797|Other|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
79474496|NCT02494817|Behavioral|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
79804411|NCT01947023|Drug|Dabrafenib|Given PO
79968470|NCT01264757|Behavioral|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
79968471|NCT01264757|Behavioral|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
79968472|NCT01263431|Procedure|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
79968473|NCT01263431|Procedure|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
79968474|NCT05064683|Other|white noise|Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
79968475|NCT03880175|Behavioral|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
79968476|NCT03880175|Behavioral|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
79968477|NCT03880175|Behavioral|Anti Stigma Information|Adults in the households are provided anti-stigma information
79968478|NCT03880175|Behavioral|HIV/AIDS Information|The households receive information about HIV infection and AIDS
79968479|NCT03880175|Behavioral|ART Information|The households receive information about antiretroviral therapy.
79804412|NCT01947023|Drug|Dabrafenib Mesylate|Given PO
79968480|NCT03880175|Behavioral|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
79804413|NCT01947023|Drug|Lapatinib|Given PO
79804414|NCT01947023|Drug|Lapatinib Ditosylate|Given PO
79804415|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|"individualized α frequency~left DLPFC 110% motor threshold (MT)~13-15 sessions for 3 weeks"
79804416|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|- placebo treatment: sham coil
79968481|NCT03880175|Behavioral|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
79804417|NCT01937949|Device|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
79804418|NCT01918839|Device|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
79968482|NCT01264913|Behavioral|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
79804419|NCT01918839|Device|Restylane-L|Restylane-L injected into wrinkle treatment area
79804420|NCT01897454|Drug|Fluorouracil|Given IV
79804421|NCT01897454|Drug|Gemcitabine Hydrochloride|Given IV
79968483|NCT01264991|Procedure|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
79804422|NCT01897454|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79309798|NCT05698797|Other|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
79804423|NCT01897454|Drug|Irinotecan Hydrochloride|Given IV
79804424|NCT01897454|Drug|Leucovorin Calcium|Given IV
79968484|NCT01264991|Procedure|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
79968485|NCT01158599|Biological|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
79309799|NCT05552625|Drug|TADIOS|TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
79309800|NCT05552625|Drug|Placebo|Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
79804425|NCT01897454|Drug|Oxaliplatin|Given IV
79804426|NCT01865110|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
79968486|NCT01156649|Device|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
79968487|NCT01156649|Device|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
79804427|NCT01865110|Drug|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
79804428|NCT01865110|Drug|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
79804429|NCT01865110|Drug|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
79804430|NCT01856023|Drug|High Dose Interleukin-2|
79804431|NCT01856023|Drug|Ipilimumab|
79804432|NCT01815359|Procedure|Cytoreductive Surgery|Optimal Surgical Debulking
79309801|NCT05552391|Drug|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
79309802|NCT05552391|Drug|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
79309803|NCT05552391|Drug|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
79309804|NCT02106442|Drug|Sodium risedronate|Sodium risedronate tablets
79309805|NCT05552313|Procedure|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
79309806|NCT05552313|Procedure|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
79309807|NCT05552079|Other|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
79309808|NCT05551923|Other|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
79309809|NCT02105116|Drug|fludarabine phosphate|Given IV
79309810|NCT02105116|Drug|cytarabine|Given IV
79309811|NCT02105116|Biological|donor lymphocytes|Undergo infusion of donor lymphocytes
79309812|NCT02105116|Other|laboratory biomarker analysis|Correlative studies
79309813|NCT02105116|Drug|G-CSF|Given IV
79309814|NCT05551767|Drug|Pembrolizumab|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
79309815|NCT05551689|Drug|Psychostimulant|All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
79309816|NCT05551689|Device|FOCUS ADHD App|FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)
79309817|NCT05547789|Drug|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
79804433|NCT01815359|Drug|HIPEC with Mitomycin-C|
79804434|NCT01815359|Drug|EPIC with FUDR and Leucovorin|
79309821|NCT05547711|Diagnostic Test|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
79309822|NCT05547555|Diagnostic Test|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
79309823|NCT05542095|Drug|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride & Sodium Bicarbonate Mixture (pH balanced, Isotonic & Preservative & Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
79309824|NCT05542017|Procedure|Surgical Ablation for Atrial Fibrillation|Surgical ablation in combination with other cardiac procedures through a median sternotomy or thoracotomy. Main procedures were valve surgery (i.e. repair, replacement) and/or coronary artery bypass grafting (CABG). Surgical ablation procedures for atrial fibrillation were divided into three different groups according to Heart Rhythm Society (HRS) expert consensus 2017: (1) Pulmonary vein isolation alone; (2) Pulmonary vein isolation combined with left atrial lesion sets; (3) and biatrial procedure.
79309825|NCT05551221|Drug|Silodosin Capsules|Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
79804435|NCT01791478|Drug|PI3K inhibitor BYL719|Given PO
79804436|NCT01791478|Drug|letrozole|Given PO
79804437|NCT01791478|Other|laboratory biomarker analysis|Correlative studies
79804438|NCT01791478|Other|pharmacological studies|Correlative studies
79804439|NCT01787487|Drug|Azacitidine|Given SC or IV
79804440|NCT01787487|Other|Laboratory Biomarker Analysis|Correlative studies
79804441|NCT01787487|Drug|Ruxolitinib Phosphate|Given PO
79804442|NCT01751425|Drug|Dasatinib|Given PO
79804443|NCT01751425|Drug|Imatinib Mesylate|Given PO
79309826|NCT05551221|Drug|Ningmitai capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
79309827|NCT05551221|Drug|Tamsulosin|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
79804444|NCT01751425|Drug|Nilotinib|Given PO
79804445|NCT01751425|Drug|Ruxolitinib|Given PO
79804446|NCT01655030|Dietary Supplement|creatine monohydrate|
79639146|NCT00405665|Drug|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
79804447|NCT01655030|Dietary Supplement|placebo|
79804448|NCT01624220|Radiation|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
79804449|NCT01624220|Radiation|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
79804450|NCT01624220|Procedure|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
79804451|NCT01624220|Behavioral|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
79804452|NCT01612949|Other|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
79804453|NCT01538056|Device|Fenestrated Endovascular Graft|Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
79804454|NCT01393756|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
79968488|NCT01158755|Drug|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
79968489|NCT01158833|Other|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
79340431|NCT04135443|Behavioral|General Health App|The control group will download a mobile app that addresses general health behaviors, specifically drinking more water.
79639147|NCT03458572|Device|Seirin Pyonex press needle acupuncture|Acupuncture
79639148|NCT00531544|Drug|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
79639149|NCT00531583|Drug|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
79639150|NCT00531700|Other|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
79639151|NCT00531700|Other|Health messages|community level health messages unrelated to the study originating exposures
79639152|NCT00145106|Drug|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
79639153|NCT02943538|Device|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
79639154|NCT02943538|Device|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
79639155|NCT02943538|Other|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
79309828|NCT05551143|Other|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~Simple Strap - A sling to lift a seated patient~Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~Drag Straps - straps with handles that can be clipped on tarps used to drag patients~The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
79309829|NCT05551065|Device|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
79309830|NCT02104804|Drug|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
79309831|NCT02104804|Drug|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
79309832|NCT05541783|Procedure|laparoscopy-assisted distal gastrectomy Group|LADG
79309833|NCT05541783|Procedure|Totally laparoscopic distal gastrectomy|TLDG
79639156|NCT00145184|Dietary Supplement|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
79639157|NCT00145184|Drug|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
79340432|NCT05647395|Behavioral|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
79340433|NCT02438371|Drug|Nifedipine|
79340434|NCT02438371|Drug|Indomethacin|
79340435|NCT04419987|Genetic|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
79340436|NCT05647239|Device|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
79639158|NCT02944357|Drug|Cisplatin|Given IV
79639159|NCT02944357|Drug|Gemcitabine Hydrochloride|Given IV
79639160|NCT02944357|Procedure|Radical Cystectomy|Undergo cystectomy
79639161|NCT02944357|Biological|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
79639162|NCT02944474|Drug|Lucerastat|Capsule for oral administration containing lucerastat
79639163|NCT02944474|Drug|Placebo|Placebo capsules matching lucerastat capsules
79639164|NCT02944396|Drug|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
79639165|NCT02944396|Drug|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
79804455|NCT01364597|Drug|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight >40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights >50kg) is reached.
79968490|NCT03879785|Other|Screening|Screening and validation of assessment tool translated into Spanish
79639166|NCT02944396|Drug|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
79639167|NCT02944396|Drug|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
79804456|NCT01311648|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
79968491|NCT03879707|Drug|Melatonin 5 mg|Melatonin is known to induce sleep
79968492|NCT03879707|Drug|Placebo Oral Tablet|Placebo
79968493|NCT03879707|Drug|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
79639168|NCT02944396|Drug|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
79639169|NCT00529945|Device|PFx Closure System|
79968494|NCT01265069|Drug|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
79968495|NCT01265069|Drug|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
79639170|NCT00174174|Drug|Modafinil|
79639171|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
79639172|NCT00529984|Biological|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
79968496|NCT01158989|Device|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
79968497|NCT01265147|Drug|Cisplatin|40mg/m2/w
79968498|NCT01265147|Drug|Nedaplatin|40mg/m2/w
79968499|NCT03882281|Drug|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
79968500|NCT01159145|Drug|D961H|Oral, capsule
79639173|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
79639174|NCT00529984|Biological|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
79639175|NCT00529984|Biological|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
79968501|NCT01159145|Drug|Omeprazole|Oral, tablet
79968502|NCT01156883|Drug|asparaginase|
79968503|NCT01156883|Drug|cyclophosphamide|
79968504|NCT01156883|Drug|cytarabine|
79968505|NCT01156883|Drug|daunorubicin hydrochloride|
79968506|NCT01156883|Drug|dexamethasone|
79968507|NCT01156883|Drug|doxorubicin hydrochloride|
79968508|NCT01156883|Drug|ifosfamide|
79968509|NCT01156883|Drug|mercaptopurine|
79309834|NCT05547009|Other|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).
79309835|NCT05547009|Other|Face-to-face learning group|The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
79309836|NCT02075008|Drug|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
79309837|NCT05541549|Biological|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
79309838|NCT05550441|Drug|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
79309839|NCT05550441|Drug|Placebo|The Placebo group received placebo for 1 year.
79309840|NCT05550285|Device|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
79309841|NCT04321941|Diagnostic Test|Lumentin|Contrast agent used in combination with CTE
79309842|NCT04321941|Diagnostic Test|Movprep|Contrast agent used in combination with MRE
79309843|NCT05540925|Procedure|Liver resection|"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (<1cm) resection margin in different groups."
79309844|NCT05546775|Diagnostic Test|DHR|"To describe the clinical characteristics and pattern of presentation of patients diagnosed as CGD in Assiut, and to find the most common presenting symptoms.~To mention the immunological profile of patients diagnosed with CGD (Immunogloulins level - B, T, natural killer cells enumeration with flow cytometry- DHR123)~To assess the growth parameters in patients with CGD."
79309845|NCT05535699|Other|exercises|scapular exercise
79309846|NCT05540769|Procedure|catheter guided ASD closure|transcatheter secundum ASD device closure
79309847|NCT05535543|Procedure|Prone Positioning|Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
79474497|NCT02543723|Behavioral|Nurse Coach Intervention|Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
79474498|NCT02545907|Drug|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
79804457|NCT01311648|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
79804458|NCT01146249|Other|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
79309848|NCT05546619|Drug|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
79309849|NCT05540379|Device|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
79309850|NCT05535465|Other|Public health intervention|additional trained mobile health workers are hired to support and supervise the activities of community health workers
79309851|NCT05540301|Other|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
79309852|NCT05540301|Other|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
79474499|NCT02545907|Drug|Thalidomide|50mg capsule.
79474500|NCT02545907|Drug|Dexamethasone|2mg tablet.
79968510|NCT01156883|Drug|methotrexate|
79968511|NCT01156883|Drug|methylprednisolone|
79968512|NCT01156883|Drug|prednisone|
79309853|NCT05698017|Drug|hOMSC300|Human Oral Mucosa Stem Cells
79309854|NCT05698017|Other|Sham Procedure|Lumbar Puncture Only
79309855|NCT05546463|Behavioral|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
79474501|NCT04340999|Diagnostic Test|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
79474502|NCT02495831|Drug|Diclofenac sodium|Diclofenac sodium 50 mg single dose
79474503|NCT02495831|Drug|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
79309856|NCT05699577|Diagnostic Test|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
79309857|NCT05699421|Other|screening programme|CMV screening during the first trimester of pregnancy and neonatal
79309858|NCT05592327|Procedure|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
79309859|NCT05539755|Procedure|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
79309860|NCT05592171|Procedure|Microwave ablation + Occlusafe + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
79309861|NCT05592171|Procedure|Microwave ablation + Occlusafe|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time."
79968513|NCT01156883|Drug|thioguanine|
79309862|NCT05592171|Procedure|Microwave ablation + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
79309863|NCT05546307|Other|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
79309864|NCT05546307|Other|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
79309865|NCT05539521|Drug|Remimazolam Besylate|sedation drugs
79309866|NCT05539521|Drug|Propofol|Propofol
79309867|NCT05546229|Procedure|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
79474504|NCT02497235|Drug|TAK-935|TAK-935 oral solution.
79639176|NCT00530101|Drug|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
79968514|NCT01156883|Drug|vincristine sulfate|
79968515|NCT01156883|Drug|vindesine|
79968516|NCT03882125|Behavioral|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
79968517|NCT01156961|Drug|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
79474505|NCT02497235|Drug|[18F]MNI-792 (tracer)|[18F]MNI-792 injection.
79474506|NCT02497937|Drug|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
79639177|NCT00145262|Procedure|Autologous Bone Marrow Mononuclear Cell Implantation|
79968518|NCT01156961|Drug|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
79968519|NCT01265303|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
79968520|NCT01159457|Biological|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
79968521|NCT01159457|Biological|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
79968522|NCT01159223|Drug|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
79309868|NCT05591937|Behavioral|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
79804459|NCT00962728|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
79804460|NCT00962728|Device|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
79804461|NCT00869804|Behavioral|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
79804462|NCT00869804|Behavioral|Attention control|
79309869|NCT05591937|Behavioral|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
79639178|NCT00530140|Biological|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
79309870|NCT05591937|Behavioral|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
79639179|NCT02944552|Drug|bicyclol tablet 25mg|Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
79639180|NCT02944552|Drug|bicyclol tablet 50mg|Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
79309871|NCT05591781|Device|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
79804463|NCT00759096|Device|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
79968523|NCT01159301|Drug|entinostat|Given orally (PO)
79968524|NCT01159301|Drug|sorafenib tosylate|Given PO
79968525|NCT01159301|Other|pharmacological study|Correlative studies
79968526|NCT01159301|Other|laboratory biomarker analysis|Correlative studies
79968527|NCT03610334|Drug|IFB-088 (2.5-60.0mg) oral capsule|SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
79309872|NCT05591781|Device|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
79309873|NCT05538975|Other|Physiotherapy Treatment|Pulmonary Rehabilitation Techniques
79309874|NCT05545995|Other|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
79639181|NCT02944552|Drug|polyene phosphatidylcholine capsule 456mg|Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
79639182|NCT00145301|Drug|Lumiracoxib|
79639183|NCT00530179|Procedure|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
79804464|NCT00758342|Drug|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
79804465|NCT00758342|Drug|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
79804466|NCT00572481|Procedure|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
79804467|NCT00470704|Drug|Lapatinib|
79804468|NCT00470704|Drug|Herceptin|
79804469|NCT00385697|Biological|Teplizumab|Daily IV dosing for 14 days, repeated at Week 26
79968528|NCT03610334|Drug|Placebo (2.5-60.mg) oral capsule|SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
79968529|NCT03610334|Drug|IFB-088 (15.0-50.0mg) oral capsule|MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
79804470|NCT00385697|Drug|Placebo|Daily IV dosing for 14 days, repeated at Week 26
79804471|NCT00144196|Drug|tiotropium (Spiriva)|
79804472|NCT04152122|Diagnostic Test|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
79804473|NCT04118400|Procedure|NIV-NAVA|NAVA mode during Non-invasive ventilation
79804474|NCT04118400|Procedure|Nasal CPAP or NIMV mode|Nasal CPAP or NIMV mode during Non-invasive ventilation
79968530|NCT03610334|Drug|Placebo oral (15.0-50.0mg) capsule|MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
79968531|NCT01265771|Device|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
79968532|NCT01265771|Device|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
79968533|NCT01159613|Other|Responders|Responders
79309875|NCT05545917|Other|Experimental: APP care|The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
79309876|NCT05545917|Other|Control - Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
79309877|NCT04426149|Dietary Supplement|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
79474507|NCT02497937|Drug|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
79474508|NCT02498483|Drug|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
79474509|NCT02547623|Drug|Dexamethasone|depot intracameral
79968534|NCT01159613|Other|Non Responders|Non Responders
79474510|NCT02547623|Drug|Prednisolone|Prednisolone eye drops 1%
79474511|NCT02433665|Drug|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
79968535|NCT01159379|Drug|ertapenem|intravenous, 1 gram, once
79968536|NCT01159847|Drug|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
79968537|NCT01159847|Drug|Insulin|
79968538|NCT02539160|Drug|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
79968539|NCT04988906|Device|Zoll Accuvent Ventilation Monitor|Provides real-time ventilation quality monitoring (rate and volume)
79968540|NCT01265927|Drug|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
79968541|NCT01266005|Drug|Clevudine|30mg,QD
79968542|NCT01266005|Drug|Entecavir|0.5mg QD
79968543|NCT04292899|Drug|Remdesivir|Administered as an intravenous infusion
79968544|NCT04292899|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
79968545|NCT02530112|Other|Survey|
79474512|NCT02433665|Device|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
79474513|NCT02547779|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
79474514|NCT02547779|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
79968546|NCT03876899|Dietary Supplement|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
79968547|NCT03876899|Dietary Supplement|Placebo|Pill
79968548|NCT03490604|Device|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
79968549|NCT03490604|Other|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
79968550|NCT03241173|Drug|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
79968551|NCT03241173|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
79968552|NCT03241173|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
79968553|NCT01159925|Procedure|Serum sample|Serum samples collected
79968554|NCT01267877|Other|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
79968555|NCT01267877|Other|read favorable article prior to answering questions|"read A Backlash of Mistrust"
79474515|NCT02433977|Dietary Supplement|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
79474516|NCT02433977|Drug|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
79639184|NCT00530179|Drug|R-CHOP|6 - 21 DAY Cycles of R-CHOP
79968556|NCT01161719|Behavioral|parent training|Behavioral management skill training
79804475|NCT02567734|Procedure|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
79474517|NCT02433977|Drug|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
79639185|NCT00530296|Behavioral|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
79804476|NCT04152356|Drug|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
79968557|NCT01266083|Biological|WT1 peptide vaccine|Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, and 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Patients who are clinically stable and have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month.
79968558|NCT05571501|Device|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
79968559|NCT01266239|Procedure|kissing balloon inflation|Kissing balloon inflation following the MV stenting
79968560|NCT01266239|Device|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
79968561|NCT01562431|Other|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
79968562|NCT01161875|Device|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:~facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation~helmet use with non-invasive pressure support ventilation mode to define adequate settings~helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
79968563|NCT03264066|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
79968564|NCT03264066|Drug|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
79968565|NCT03264066|Drug|Atezolizumab Cohort 7|Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
79968566|NCT03759041|Drug|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
79968567|NCT03759041|Drug|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
79968568|NCT03759041|Drug|SER-287|Once-daily dosing of SER-287
79968569|NCT03759041|Drug|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
79968570|NCT04110145|Drug|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
79968571|NCT04110145|Drug|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
79309878|NCT05591469|Device|IR Camera|the respiration parameters are measured using an IR camera.
79639186|NCT02944318|Behavioral|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
79639187|NCT00168870|Drug|Gemcitabine|
79639188|NCT00168870|Drug|Treosulfan|
79968572|NCT02477618|Drug|SAGE-547|
79968573|NCT02477618|Drug|Placebo|Placebo
79639189|NCT02944201|Drug|Carvedilol|Carvedilol will give twice daily until prostatectomy
79639190|NCT02944162|Biological|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
79804477|NCT04152356|Drug|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
79968574|NCT04102501|Drug|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
79968575|NCT04102501|Drug|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
79968576|NCT03879083|Other|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
79968577|NCT03879083|Other|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
79309879|NCT05591469|Device|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
79309880|NCT05591391|Other|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
79639191|NCT00145340|Drug|pioglitazone|30 Mg/day
79968578|NCT01266473|Other|Physiotherapy|Physiotherapy for Airway Clearance
79639192|NCT02943343|Other|No intervention|
79968579|NCT01268033|Drug|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
79968580|NCT01268033|Drug|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
79968581|NCT01162031|Drug|Velcade|IV
79968582|NCT02879162|Drug|Durvalumab|
79968583|NCT02879162|Drug|Tremelimumab|
79968584|NCT01266551|Device|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
79968585|NCT03285477|Drug|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
79639193|NCT00168909|Drug|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
79639194|NCT00168909|Drug|placebo|placebo once daily, oral, for 3 years
79804478|NCT04271956|Biological|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
79968586|NCT03285477|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
79804479|NCT04271956|Drug|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
79804480|NCT00911924|Device|iStent|Glaukos iStent, medication
79968587|NCT01160003|Drug|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
79968588|NCT01160003|Drug|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
79968589|NCT03748693|Procedure|Hysterectomy|Surgery performed on women with a variety of gynecological indications
79968590|NCT03748693|Procedure|Colporrhaphy|Surgery performed on women with POP
79804481|NCT02628080|Drug|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
79309881|NCT05591391|Other|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
79804482|NCT00490945|Drug|VEC-162|
79309882|NCT05538507|Drug|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
79968591|NCT02285504|Drug|SAGE-547|Intravenous injection
79968592|NCT01160081|Other|Serum sample|Serum samples collected
79309883|NCT05538507|Drug|Donepezil|Severe AD and mild or moderate AD will be given donepezil
79968593|NCT04289623|Behavioral|Email|Email
79309884|NCT05538507|Drug|Memantine|Severe AD will be given memantine
79309885|NCT05538507|Drug|Placebo|patients with MCI will be given placebo
79309886|NCT05538429|Procedure|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
79309887|NCT05591235|Drug|Metformin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with metformin for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
79309888|NCT05591235|Drug|Dapagliflozin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with dapagliflozin (100mg one day) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
79309889|NCT05591235|Drug|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with fixed-dose combination of metformin and pioglitazone (two tablets of 500mg metformin plus 15mg pioglitazone) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
79309890|NCT04425837|Biological|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
79309891|NCT04425837|Other|Standard care|Standard care according to guidelines and national regulations
79309892|NCT05589519|Device|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
79474518|NCT00559585|Drug|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
79968594|NCT04289623|Behavioral|Loss frame|Email
79968595|NCT04289623|Behavioral|Testimonial (medical expert)|Email
79968596|NCT04289623|Behavioral|Testimonial (rank-and-file)|Email
79968597|NCT04289623|Behavioral|Social norms (percentage)|Email
79968598|NCT04289623|Behavioral|Social norms (number)|Email
79968599|NCT03248037|Drug|Netarsudil|netarsudil opthalmic solution 0.02%
79968600|NCT03248037|Drug|Placebo|Placebo eye drops
79968601|NCT02227394|Drug|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
79968602|NCT02227394|Drug|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
79968603|NCT04287517|Device|Capacitive-Resistive Therapy|Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
79968604|NCT03284229|Device|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
79968605|NCT03242928|Drug|AFQ056|50 mg and 100 mg tablets taken orally
79309893|NCT05538195|Biological|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
79309894|NCT05538195|Biological|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
79309895|NCT05697081|Other|Medical doctors infected with COVID-19|web-based survey
79309896|NCT05523063|Other|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
79309897|NCT05537805|Procedure|Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction|The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
79309898|NCT05537649|Dietary Supplement|Oatmeal porridge|Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
79309899|NCT01666119|Drug|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
79309900|NCT05389839|Device|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
79309901|NCT05361993|Drug|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
79474519|NCT00559585|Drug|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
79474520|NCT01824901|Drug|docetaxel|Given IV
79474521|NCT01824901|Drug|AZD4547|Given PO
79639195|NCT00531739|Other|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
79639196|NCT00145379|Drug|Tablet Metformin 500 mg|
79639197|NCT00145379|Drug|Placebo|
79639198|NCT00530374|Dietary Supplement|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
79639199|NCT00530374|Dietary Supplement|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
79639200|NCT00168948|Drug|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
79639201|NCT00530452|Drug|CG100649|Dual-acting COX-2 inhibitor & carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
79639202|NCT00530452|Drug|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
79968606|NCT03242928|Drug|Placebo|Matching placebo tablets taken orally BID
79309902|NCT05361993|Device|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
79309903|NCT04425681|Drug|Osimertinib|Treatment of LM With osimertinb
79309904|NCT04425681|Drug|Bevacizumab|Treatment of LM With Bevacizumab
79309905|NCT05545059|Drug|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
79309906|NCT05545059|Drug|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
79309907|NCT05536947|Other|Bread product (standard milled)|Bread rolls made from standard milled flour.
79309908|NCT05536947|Other|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
79309909|NCT05536947|Other|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
79639203|NCT00530491|Procedure|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
79639204|NCT00168987|Drug|oral nutritional supplement rich in eicosapentanoic acid|
79639205|NCT00530530|Drug|ASP8825|oral
79639206|NCT00530530|Drug|Placebo|oral
79639207|NCT00530413|Drug|Phenobarbital|Phenobarbital will be given based on weight range
79968607|NCT03876353|Other|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
79804483|NCT00678158|Radiation|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
79804484|NCT00678236|Other|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
79804485|NCT00678236|Other|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
79639208|NCT00530413|Other|Placebo|Placebo group
79639209|NCT00145457|Procedure|Blood sample|
79309910|NCT05536947|Other|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
79474522|NCT01825057|Behavioral|See One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
79309911|NCT05696925|Other|Motor Imagery|Motor imagery (MI) is a cognitive process that involves the ability to perform an action mentally, without the need to perform the movement itself. The perspective that the person uses to imagine can be: internal perspective (first person - imagines himself/herself), which relates to the person's view of the content of the images or to his/her kinesthetic sensation - the person imagines the movement being performed, as if feeling the movement of the action; or external perspective (third person - imagines another person), which relates to the visual imagination of scenes outside the person.
79639210|NCT00145457|Procedure|Radiography|
79639211|NCT00530569|Procedure|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
79639212|NCT00174330|Drug|atorvastatin|
79639213|NCT00174330|Drug|amlodipine|
79804486|NCT04279093|Other|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
79804487|NCT00678314|Drug|Ropivacaine 0.2%|10 ml
79804488|NCT00678314|Drug|Ropivacaine 0.75%|3 ml
79804489|NCT00678314|Drug|Normal saline|10 ml
79804490|NCT02566720|Drug|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
79804491|NCT02566720|Procedure|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
79804492|NCT04151576|Other|aromatherapy massage|aromatherapy massage
79804493|NCT00675194|Drug|Cisplatin, Irinotecan, Capecitabine|
79804494|NCT00665522|Drug|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
79639214|NCT00530686|Drug|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
79639215|NCT00531856|Drug|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
79804495|NCT00665522|Drug|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
79804496|NCT00675272|Drug|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
79639216|NCT00531856|Drug|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
79639217|NCT00531856|Drug|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
79639218|NCT00531856|Drug|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
79639219|NCT00531856|Drug|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
79804497|NCT00675272|Drug|sodium chloride|sodium chloride every 6 hours iv
79804498|NCT02566642|Other|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
79804499|NCT00912080|Genetic|genomic signature|genomic signature analysis
79804500|NCT00678548|Behavioral|Pleasant guided imagery|CD with pleasant guided imagery
79804501|NCT00678548|Behavioral|Pain diary|Filling out a pain diary
79804502|NCT02627612|Behavioral|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
79639220|NCT04691479|Behavioral|Motivational Interview (MI) & Adherence Follow-Up|"MEntA: Educational & Training Program~Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~Identification of Care plan and Schedule next visits~Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
79804503|NCT02627612|Behavioral|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
79639221|NCT04691479|Behavioral|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
79639222|NCT00174369|Drug|PD-0325901|15 mg BID
79639223|NCT00531895|Drug|duloxetine|duloxetine 60 mg/d
79639224|NCT00145535|Device|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, ~50 spots over 180°
79804504|NCT05324956|Other|No intervention|Individuals will not receive any interventions
79968608|NCT03747055|Behavioral|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
79474523|NCT01825057|Behavioral|Do One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
79474524|NCT01825057|Behavioral|Order One|"A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians."
79474525|NCT05747209|Other|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
79474526|NCT00559507|Drug|saracatinib|
79474527|NCT00559507|Other|laboratory biomarker analysis|Correlative studies
79474528|NCT05027113|Behavioral|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
79968609|NCT03747055|Behavioral|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
79968610|NCT05158491|Drug|JK-1201I|JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
79968611|NCT03876665|Other|No intervention|No intervention
79804505|NCT00678626|Drug|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
79309912|NCT05696925|Other|Action Observation|Action observation consists of watching another person acting, or doing a motor task, on video or in real-time.
79309913|NCT05696925|Other|Exoskeletons|The term Brain-Machine Interface (BMI) refers to systems that capture brain activity signals, translating them into computer commands to control external devices, with the robotic exoskeletons. The electrodes are positioned on the skull cap.
79474529|NCT04993651|Device|CPAP|CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
79639225|NCT00145535|Device|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, ~50 spots over 180°
79639226|NCT02943148|Other|Davey score for striae gravidarum|
79804506|NCT00678626|Drug|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
79804507|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
79804508|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
79474530|NCT01826227|Procedure|Positron Emission Tomography|
79474531|NCT01826227|Radiation|18F-Fluoro-2-deoxy-D-lucose|
79474532|NCT01826227|Procedure|Cytoreductive surgery|
79639227|NCT02943109|Other|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
79639228|NCT02943109|Other|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
79804509|NCT00678704|Drug|Placebo|Placebo tablet prior to intercourse on demand
79804510|NCT00678782|Drug|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
79804511|NCT00678782|Drug|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
79804512|NCT04707352|Drug|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
79968612|NCT03300024|Device|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
79309914|NCT05696925|Other|Execution of the Action|In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.
79309915|NCT05536869|Procedure|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
79309916|NCT05128773|Drug|Amcenestrant|tablet, oral
79309917|NCT05128773|Drug|Tamoxifen|tablet, oral
79309918|NCT05128773|Drug|Amcenestrant-matching placebo|tablet, oral
79309919|NCT05128773|Drug|Tamoxifen-matching placebo|tablet, oral
79474533|NCT04970563|Other|Body odor samples|Participants will provide six body odor samples (mask and sweat samples) at inclusion
79639229|NCT02943109|Other|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
79639230|NCT02943109|Other|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
79639231|NCT02942914|Drug|LY3209590|Administered SC
79639232|NCT02942914|Drug|Placebo|Administered SC
79639233|NCT02942914|Drug|Insulin Glargine|Administered SC
79639234|NCT00169026|Drug|Clozapine versus typical (conventional) and atypical antipsychotic medications|
79639235|NCT00145613|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
79804513|NCT04152590|Device|Uincare|Interactive digital healthcare system
79804514|NCT00678938|Behavioral|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
79804515|NCT00678938|Behavioral|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
79804516|NCT04061278|Drug|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
79804517|NCT04061278|Drug|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
79804518|NCT00679094|Drug|Bowman-Birk inhibitor concentrate|Given orally
79804519|NCT00679094|Other|placebo|Given orally
79804520|NCT00679094|Other|pharmacological study|Correlative studies
79804521|NCT00679094|Other|laboratory biomarker analysis|Correlative studies
79968613|NCT03300024|Device|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
79968614|NCT01162577|Behavioral|Weight Concerns|Standard Quitline plus weight coaching
79968615|NCT04276207|Drug|LY900014|Administered by CSII
79309920|NCT05536635|Behavioral|breathing techniques|Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
79309921|NCT05699187|Procedure|Face allotransplantation|Facial allotransplantation
79309922|NCT05536479|Procedure|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
79309923|NCT05536479|Procedure|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
79309924|NCT05536245|Other|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
79309925|NCT05544435|Behavioral|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak & Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller & Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
79309926|NCT04744467|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
79309927|NCT04731129|Device|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
79309928|NCT04677855|Drug|PCUR-101|50 mg capsules
79309929|NCT04677855|Drug|Dutasteride 0.5 mg|0.5 mg capsules
79309930|NCT04677855|Drug|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
79309931|NCT05696223|Other|Ultrasound|Doppler mesure
79309932|NCT05544279|Behavioral|Education|Education is given about the focused disease and its nursing care management
79474534|NCT04970563|Other|Body odor samples|Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
79474535|NCT04969627|Drug|Metformin|Use Metformin for 3 months to treat PCOS
79474536|NCT04969627|Drug|Exenatide|Use Exenatide for 3 months to treat PCOS
79968616|NCT04276207|Drug|Insulin Lispro|Administered by CSII
79309933|NCT01665807|Biological|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
79309934|NCT01665807|Biological|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
79309935|NCT04585113|Radiation|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
79309936|NCT04425759|Diagnostic Test|Blood sample|Blood sammples for the serological analysis will be collected at 0/90/180/270/360 days.
79309937|NCT04448535|Dietary Supplement|Gingko Biloba|oral intake of Gingko Biloba, 240mg/day for 4 weeks
79309938|NCT05695989|Device|Dual Robotic Arm Accessory (DRAA)|Dual Robotic Arm Accessory (DRAA)
79309939|NCT02584959|Drug|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor [Human] Liquid administered Subcutaneously as specified on specified days
79474537|NCT04953325|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
79474538|NCT04953325|Biological|23-valent pneumococcal polysaccharide vaccine|25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
79474539|NCT04953325|Biological|Inactivated Hepatitis A Vaccine|500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
79474540|NCT04928131|Other|No intervention - retrospective observational cohort study|
79639236|NCT00145613|Device|Miltenyi Biotec CliniMACS|stem cell selection device
79968617|NCT01162655|Behavioral|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
79309940|NCT02584959|Drug|Placebo|Placebo
79309941|NCT05543889|Other|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
79309942|NCT05695833|Device|Radiofrequency|Device emitting electric waves generating heat
79309943|NCT02584257|Other|methacholine chloride|
79309944|NCT02584257|Drug|placebo ProAir HFA|
79309945|NCT02584257|Drug|ProAir HFA|
79968618|NCT03748615|Device|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
79474541|NCT01826851|Drug|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
79804522|NCT04061200|Drug|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
79968619|NCT03876587|Drug|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
79968620|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
79968621|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
79968622|NCT01162811|Behavioral|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
79309946|NCT02584257|Drug|Lupin albuterol HFA MDI|
79309947|NCT02584257|Drug|placebo Lupin albuterol HFA MDI|
79309948|NCT05543655|Other|high fidelity simulation|"Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing."
79309949|NCT05543421|Device|TMS|rTMS (30sessions) or iTBS (40sessions)
79474542|NCT01826851|Drug|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
79309950|NCT04272099|Other|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
79474543|NCT04893967|Device|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
79639237|NCT00145613|Drug|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
79804523|NCT04061200|Other|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
79804524|NCT04061200|Drug|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
79474544|NCT04893967|Device|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
79804525|NCT00675350|Drug|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
79804526|NCT02565862|Drug|Daclatasvir|
79804527|NCT02565862|Drug|Metformin|
79474545|NCT02499497|Drug|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
79804528|NCT04152278|Diagnostic Test|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
79474546|NCT02499497|Drug|Placebo|The participants will receive pills containing no active drug.
79474547|NCT01827475|Drug|Ibuprofen|single dose
79474548|NCT01827475|Drug|Acetaminophen|single dose
79474549|NCT01827475|Drug|Ibuprofen-acetaminophen combination|single dose
79474550|NCT02434523|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
79474551|NCT02434523|Other|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
79474552|NCT05746741|Behavioral|Telehealth solution|Video conferencing
79474553|NCT02501135|Procedure|Femoral nerve block with ropivacaine or bupivacaine|
79474554|NCT04828837|Device|bubble PEP|Using the bubble positive expiratory pressure (Bubble PEP) for breathing training of inpatients with COPD. The training course for one day of three times. Every time needs about 20 mins. Huff and cough after the breathing training the end.
79474555|NCT04809493|Procedure|Conventional dialysis treatment|Conventional dialysis treatment
79474556|NCT04809493|Procedure|Isonatremic dialysis treatment|Isonatremic dialysis treatment
79804529|NCT00912314|Procedure|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
79474557|NCT02550743|Drug|BYL719|
79804530|NCT04060888|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
79804531|NCT04060888|Drug|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
79804532|NCT04060888|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
79804533|NCT00879398|Drug|Toviaz treatment|4 mg starting then can be followed by 8 mg
79804534|NCT04061122|Diagnostic Test|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
79474558|NCT02550743|Drug|Capecitabine|
79474559|NCT02550743|Radiation|Radiation|
79804535|NCT04031534|Drug|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
79474560|NCT02502461|Procedure|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
79639238|NCT02943187|Behavioral|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
79639239|NCT02943187|Dietary Supplement|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
79804536|NCT00679250|Drug|levocetirizine|5 mg once nightly before visit
79804537|NCT00679250|Drug|placebo to levocetirizine|1 tablet once nightly before visit
79804538|NCT00679328|Device|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
79639240|NCT00531973|Drug|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
79639241|NCT00531973|Drug|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
79639242|NCT00174408|Drug|Genotropin|
79639243|NCT00145652|Drug|Neo-Recormon and Venofer|
79804539|NCT00679406|Behavioral|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
79804540|NCT04150952|Other|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
79804541|NCT04150952|Other|TRAD training|Traditional endurance training
79968623|NCT04646343|Other|administration of F-CISS and F-PWES pre version|the CISS questionnaire is a 6 items questionnaire, the PWES is a 3 items questionnaire. Only 10 minutes are required to fulfilled the questionnaires.
79968624|NCT04646343|Other|administration of definitive version of F-CISS and F-PWES plus F-DASH, F-HFS and F-SF 36|The administration will required 25 minutes
79804542|NCT02627768|Drug|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
79804543|NCT00675662|Behavioral|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
79968625|NCT01162889|Drug|Placebo SC Injection|Single injection
79968626|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
79804544|NCT00675662|Behavioral|waiting list control|waiting list control
79968627|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
79968628|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
79968629|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
79968630|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
79968631|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
79968632|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
79968633|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
79968634|NCT01162889|Drug|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
79968635|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
79804545|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
79804546|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
79968636|NCT05666843|Behavioral|Personalized Dietary Advice|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
79968637|NCT03876431|Device|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
79639244|NCT02942992|Behavioral|Resistance exercise|resistance exercise
79639245|NCT05319769|Procedure|Atrial fibrillation ablation|Pulmonary vein isolation
79639246|NCT02942836|Device|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
79639247|NCT00174486|Drug|UK0369,003|
79639248|NCT00174486|Drug|Cialis (Tadalafil)|
79639249|NCT05319418|Behavioral|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
79804547|NCT00696436|Drug|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
79968638|NCT03876431|Other|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
79968639|NCT03282357|Device|Radiesse injectable implant (dermal filler)|Subdermal injection.
79968640|NCT03282357|Device|Restylane injectable implant (dermal filler)|Subdermal injection
79309951|NCT04272099|Device|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
79309952|NCT04272099|Other|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
79309953|NCT04254783|Drug|Risankizumab|Intravenous (IV) infusion
79309954|NCT04254783|Drug|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
79474561|NCT02437253|Drug|Adalimumab|Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
79474562|NCT02437253|Other|Placebo|Saline placebo
79639250|NCT00145691|Drug|Oxcarbazepine|
79639251|NCT05319340|Other|prescribing anticoagulant therapy|Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
79639252|NCT05319301|Dietary Supplement|Melatonin|A single dose of melatonin (1.9 mg)
79639253|NCT00169065|Drug|Clozapine|
79639254|NCT00169065|Drug|Olanzapine|
79639255|NCT00145730|Drug|Ibuprofen|
79639256|NCT02943031|Other|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
79639257|NCT05319223|Behavioral|patient blood management|three pillars of patient blood management will be applied
79804548|NCT00696436|Drug|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
79804549|NCT00696436|Drug|Placebo|Matching placebo, orally, once daily for up to six weeks.
79804550|NCT00878072|Drug|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
79804551|NCT00617435|Dietary Supplement|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
79804552|NCT00617435|Dietary Supplement|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
79804553|NCT00617435|Dietary Supplement|control diet|Mixed of different oil
79804554|NCT02627378|Other|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
79804555|NCT02627378|Other|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
79804556|NCT00680420|Procedure|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
79804557|NCT04150484|Other|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
79804558|NCT00675740|Drug|rosiglitazone|tablets 4 mg daily
79804559|NCT00675740|Behavioral|physical exercise|stationary bike 5-6 times a week
79474563|NCT02551757|Device|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
79474564|NCT02551757|Device|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
79804560|NCT00675740|Other|control|control without intervention
79804561|NCT03045341|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
79804562|NCT03045341|Behavioral|Behavioral Weight Loss (BWL) counseling|BWL counseling
79804563|NCT03045341|Other|Placebo|Placebo
79804564|NCT00675818|Device|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
79474565|NCT02437487|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
79804565|NCT00675818|Device|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
79804566|NCT00679484|Drug|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
79804567|NCT00679484|Drug|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
79804568|NCT04214483|Other|No intervention|There is no intervention for this study.
79804569|NCT00679562|Drug|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
79804570|NCT00679562|Other|Distilled water|Application of patches containing distilled water for 24 hours
79804571|NCT00679640|Drug|Candesartan|Oral tablets
79804572|NCT02523287|Biological|Fluad|Randomized assignment
79804573|NCT02523287|Biological|Saline|Randomized assignment
79968641|NCT03876509|Diagnostic Test|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
79968642|NCT01162967|Drug|Benznidazole|Standard dosage
79639258|NCT02942875|Other|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
79309955|NCT04090203|Drug|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
79309956|NCT04062201|Drug|Bedaquiline Oral Tablet|Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - >50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
79309957|NCT04062201|Drug|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - >50kg: 600mg daily
79309958|NCT04062201|Drug|Delamanid in Oral Dosage Form|Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - >50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
79474566|NCT02437487|Drug|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
79639259|NCT02942875|Other|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
79639260|NCT00169143|Drug|Rituximab + ACVBP regimen plus Pegfilgrastim|
79639261|NCT00169143|Procedure|Autologous stem cell transplant|
79804574|NCT00921388|Other|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
79804575|NCT00921388|Behavioral|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
79968643|NCT01162967|Drug|Posaconazole|
79968644|NCT01268423|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
79968645|NCT01268423|Procedure|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
79968646|NCT01163045|Procedure|thyroidectomy|total thyroidectomy and lobectomy
79968647|NCT01268657|Behavioral|Education|Learning about anxiety
79309959|NCT04062201|Drug|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - >50kg: 100mg daily
79309960|NCT04062201|Drug|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group >50kg:1000mg daily
79309961|NCT04062201|Drug|Isoniazid Oral Product|Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group >50kg: 600mg daily
79474567|NCT01828255|Device|SENSIMED Triggerfish®|
79474568|NCT02247427|Device|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
79474569|NCT02438423|Biological|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
79474570|NCT02438423|Other|Placebo|
79474571|NCT02553395|Device|Phenacite (Test) contact lens|
79474572|NCT02553395|Device|comfilcon A contact lens|
79474573|NCT01829503|Drug|decitabine and cytarabine|
79474574|NCT01829503|Other|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
79309962|NCT04062201|Drug|Ethambutol Oral Product|Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group >50kg: 1200mg daily
79309963|NCT04062201|Drug|Pyrazinamide Oral Product|Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group >50kg: 2000mg daily
79309964|NCT04062201|Drug|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - >50kg: 600mg daily
79309965|NCT04062201|Drug|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - >50kg: 100mg daily
79639262|NCT00145769|Drug|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
79639263|NCT00145769|Drug|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
79639264|NCT00145769|Radiation|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
79639265|NCT00145769|Radiation|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
79639266|NCT00145769|Drug|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
79804576|NCT04672564|Drug|Carrimycin|Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
79804577|NCT04672564|Drug|Placebo|Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
79804578|NCT04212065|Drug|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
79804579|NCT02627534|Procedure|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
79968648|NCT01268657|Behavioral|Relaxation Training|Learning skills to reduce tension
79968649|NCT01268657|Behavioral|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
79968650|NCT01268657|Behavioral|Behavioral Activation|Learning to initiate healthy activity
79968651|NCT01268657|Behavioral|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
79968652|NCT01268735|Drug|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
79309966|NCT04062201|Drug|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group >50kg:1000mg daily
79309967|NCT05696457|Behavioral|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
79309968|NCT02583711|Device|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
79309969|NCT02583477|Drug|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
79309970|NCT02583477|Drug|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
79309971|NCT05696379|Other|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
79309972|NCT02583399|Drug|Ibuprofen|Ibuprofen, 10 mg/kg
79639267|NCT00145769|Procedure|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
79968653|NCT04272775|Drug|Ixazomib|Ixazomib capsules.
79968654|NCT04272775|Drug|Lenalidomide|Lenalidomide capsules.
79309973|NCT05468463|Behavioral|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
79639268|NCT02942953|Device|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
79639269|NCT02942680|Drug|acetylsalicylic acid started for 24 hours before surgery|
79639270|NCT02942680|Drug|acetylsalicylic acid stayed for 5 days before surgery|
79639271|NCT00174525|Drug|AAB-001|
79968655|NCT04272775|Drug|Dexamethasone|Dexamethasone tablets.
79639272|NCT00529009|Drug|UDCA|
79309974|NCT05679297|Diagnostic Test|Quantitative sensory testing (QST)|"The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~Thermal pain threshold~Mechanical detection thresholds for touch~Mechanical pain threshold for pinprick stimuli~Stimulus-response functions~Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~Vibration detection threshold~Pressure pain threshold"
79968656|NCT03876197|Biological|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
79968657|NCT03876197|Other|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
79968658|NCT03232983|Drug|LY900014 (SC)|Administered SC
79968659|NCT03232983|Drug|LY900014 (IV)|Administered IV
79968660|NCT01163201|Biological|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10^6/kg, 10 x 10^6/kg, 30 x 10^6/kg, 100 x 10^6/kg and 300 x 10^6/kg)
79968661|NCT01163201|Biological|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10^6 cells/kg, 6 x 10^6 cells/kg, 9 x 10^6 cells/kg, 12 x 10^6 cells/kg, and 15 x 10^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
79968662|NCT01163201|Drug|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m^2 over 1 hour
79309975|NCT05679297|Diagnostic Test|Magnetic resonance imaging (MRI)|"Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups"
79309976|NCT05679297|Other|Clinical interview/exam|The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
79309977|NCT05679297|Other|Follow-up interview|"Structured telephone interview with 3 Questionnaires~The german pain questionnaire~Questionnaire regarding clinical development since the last visit designed by the investigators~German translation of 12-item-allodynia symptom checklist (ASC-12)"
79474575|NCT04691167|Device|repetitive trans magnetic stimulation|Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
79639273|NCT00529048|Other|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
79639274|NCT00529048|Other|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
79639275|NCT00529048|Other|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
79639276|NCT00145808|Device|Given® Diagnostic System|
79639277|NCT00174564|Drug|oxaliplatin|
79804580|NCT02627534|Procedure|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
79804581|NCT02566330|Device|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
79804582|NCT04213235|Behavioral|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
79804583|NCT02627456|Biological|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
79804584|NCT02627456|Biological|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
79804585|NCT02627456|Drug|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
79968663|NCT01163201|Drug|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
79968664|NCT01163201|Radiation|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
79968665|NCT01163201|Biological|Umbilical cord blood transplantation|Infusion given on day 0
79968666|NCT03876041|Drug|solumedrol|intravenous solution for injection
79968667|NCT03876041|Drug|Dexamethasone phosphate|intravenous solution for injection
79968668|NCT04102345|Other|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
79968669|NCT04102345|Drug|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
79804586|NCT02627456|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
79804587|NCT02627456|Drug|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
79968670|NCT01163435|Drug|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
79968671|NCT01163435|Drug|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
79968672|NCT01163435|Drug|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
79804588|NCT02627456|Drug|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
79804589|NCT02566408|Other|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
79639278|NCT00529165|Procedure|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
79804590|NCT02566408|Other|Survey Questions|Complete survey
79804591|NCT00617513|Drug|Prucalopride|0.5 mg once daily
79804592|NCT00617513|Other|Placebo|o.d.
79968673|NCT01163435|Drug|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
79474576|NCT04675957|Other|cardiac rehabilitation|stationary or ambulatory cardiac rehabilitation
79474577|NCT02504645|Drug|IPP-201101|
79968674|NCT04271605|Behavioral|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
79474578|NCT02504645|Drug|Placebo|
79474579|NCT02504645|Other|Standard of Care|
79474580|NCT02267629|Drug|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
79639279|NCT02276911|Drug|Ibuprofen|
79639280|NCT02276911|Other|normal saline|
79639281|NCT00145847|Drug|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
79804593|NCT00617513|Drug|Prucalopride|1 mg o.d.
79804594|NCT00617513|Drug|Prucalopride|2 mg o.d.
79804595|NCT02627222|Other|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
79804596|NCT02627222|Other|White cassava|Conventional white cassava
79968675|NCT03299244|Drug|Etelcalcetide|Administered intravenously three times per week.
79968676|NCT03299244|Drug|Cinacalcet|Cinacalcet administered orally once a day.
79968677|NCT03757715|Drug|Bupivacaine|20 mL of 1.3% bupivacaine
79968678|NCT03757715|Drug|Dexamethasone|2 mg dexamethasone
79968679|NCT01163825|Drug|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
79474581|NCT05744089|Device|PCA pump|simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
79474582|NCT05742763|Combination Product|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
79804597|NCT00619463|Behavioral|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
79804598|NCT00619463|Behavioral|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
79968680|NCT01163903|Drug|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
79968681|NCT01163903|Drug|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
79804599|NCT02566486|Device|Reciprocating system|Different root canal instrumentation systems
79804600|NCT02566486|Device|Rotational system|Different root canal instrumentation systems
79968682|NCT01163981|Other|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
79968683|NCT03281577|Drug|TAK-954|TAK-954 IV infusion.
79639282|NCT00169182|Drug|DOCETAXEL|75 mg/m 2 on day 1
79968684|NCT03281577|Drug|Placebo|TAK-954 placebo-matching IV infusion.
79639283|NCT00169182|Drug|Cisplatin|75 mg/m 2 on day 1
79804601|NCT00684476|Drug|venom immunotherapy|
79804602|NCT04214015|Other|No intervention|There is no intervention for this study
79804603|NCT02466737|Procedure|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
79804604|NCT02466737|Procedure|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
79804605|NCT00594854|Drug|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
79804606|NCT00594854|Drug|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
79804607|NCT02566564|Drug|Lopain|intra-articular injection
79968685|NCT04098367|Device|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
79309978|NCT05679219|Procedure|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
79309979|NCT05679219|Procedure|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
79474583|NCT05742763|Combination Product|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
79639284|NCT00169182|Drug|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
79804608|NCT00679718|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
79804609|NCT00684632|Drug|Placebo|Placebo
79639285|NCT02944825|Drug|Ciprofloxacin|first line prophylactic oral antibiotic
79804610|NCT00684632|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
79804611|NCT00855582|Drug|Tadalafil|tablet once daily by mouth for 12 weeks.
79968686|NCT04098367|Device|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
79968687|NCT04098367|Device|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
79968688|NCT04098367|Procedure|Cataract surgery|Cataract removal by routine small incision surgery
79804612|NCT00855582|Drug|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
79804613|NCT00619541|Drug|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
79804614|NCT00619541|Drug|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
79804615|NCT00680498|Drug|Ranibizumab|Ranibizumab 0.5 mg
79804616|NCT00680498|Drug|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
79804617|NCT04211597|Other|Control|No scar prevention or treatment.
79804618|NCT04211597|Other|Silicone gel|Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
79968689|NCT03745807|Biological|NKTR-214|Specified dose on specified days
79968690|NCT03745807|Biological|Nivolumab|Specified dose on specified days
79968691|NCT01164059|Drug|Olanzapine|Olanzapine 10, 15, or 20 mg / day
79309980|NCT05679219|Procedure|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
79639286|NCT02944825|Drug|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
79309981|NCT05695755|Diagnostic Test|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
79309982|NCT05454657|Device|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
79639287|NCT02944825|Drug|No Intervention|No intervention
79968692|NCT01164059|Drug|Flupentixol|Flupentixol 6, 9, or 12 mg / day
79968693|NCT01164059|Drug|Quetiapine|Quetiapine 400, 600, or 800 mg / day
79968694|NCT01164059|Drug|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
79968695|NCT01164059|Drug|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
79968696|NCT04091659|Other|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
79309983|NCT05454657|Behavioral|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
79309984|NCT05678985|Behavioral|Choose to Move|As described under study arm description.
79309985|NCT02580591|Drug|Empagliflozin|
79639288|NCT02942758|Drug|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
79804619|NCT04211597|Other|microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg|4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
79639289|NCT02942758|Drug|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
79804620|NCT04151030|Procedure|PEG placement|Push PEG placement
79804621|NCT00679796|Procedure|Varicella (chickenpox) lesion sampling|
79309986|NCT02580591|Drug|Placebo|For blinding purposes
79639290|NCT02942758|Drug|ATRA|ATRA *45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; *this regimen will be chosen for the first dose to be evaluated.
79639291|NCT02942758|Drug|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
79639292|NCT00145886|Drug|rhPTH|Subjects will be treated with rhPTH for 12 months.
79639293|NCT00174603|Drug|quetiapine|
79804622|NCT04211519|Diagnostic Test|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
79804623|NCT00680576|Behavioral|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
79309987|NCT05695677|Procedure|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
79309988|NCT05688501|Other|descriptiv group|no intervention
79968697|NCT04091659|Other|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
79804624|NCT00680576|Behavioral|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
79804625|NCT02369471|Drug|GWP42006|
79804626|NCT02369471|Drug|Placebo|
79309989|NCT05561439|Other|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
79309990|NCT05557461|Device|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
79309991|NCT05556057|Other|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
79639294|NCT02942563|Drug|FOLFOXIRI|"Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
79639295|NCT02942446|Device|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
79804627|NCT00679874|Other|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
79804628|NCT01793129|Device|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
79804629|NCT01793129|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
79804630|NCT00684710|Drug|PAZ-417|
79804631|NCT00684710|Drug|Placebo|
79804632|NCT01788683|Procedure|Regenexx SD|stem cell treatment
79804633|NCT01788683|Other|Exercise Therapy|exercise therapy control
79804634|NCT00684866|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
79639296|NCT05318950|Behavioral|E-learning|8 lessons about nutrition and lifestyle
79639297|NCT05318950|Dietary Supplement|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
79639298|NCT00145925|Drug|Perindopril-indapamide|
79639299|NCT00145925|Drug|Gliclazide MR-based glucose lowering|
79639300|NCT00529321|Biological|MVA-HCV (Immunotherapy)|MVA-HCV
79639301|NCT00169221|Drug|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
79639302|NCT00169221|Radiation|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
79639303|NCT00529360|Drug|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
79639304|NCT00529360|Drug|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
79309992|NCT05556057|Other|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
79309993|NCT05555043|Device|Irrisafe ip|This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.
79309994|NCT05555043|Device|GentleWave System|Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.
79309995|NCT05555043|Device|Waterlase iPlus|Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
79309996|NCT04261725|Genetic|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
79639305|NCT00174642|Drug|Insulin Glargine|One daily injection in the evening. 100 U/ml
79639306|NCT00174642|Drug|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
79309997|NCT02580357|Procedure|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
79309998|NCT02580357|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
79309999|NCT05680311|Biological|measurement of serum autotaxin serum level|autotaxin expression
79310000|NCT05678751|Diagnostic Test|lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)|Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
79310001|NCT04097535|Other|PET/MRI|Imaging scan
79639307|NCT00174642|Drug|Metformin|At same dosages as the previous treatment
79310002|NCT05404191|Device|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
79639308|NCT00174642|Drug|insulin secretagogue|sulfonylurea or glinide
79310003|NCT05678517|Drug|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
79310004|NCT04079439|Behavioral|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
79310005|NCT04425369|Procedure|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
79310006|NCT05542563|Behavioral|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
79639309|NCT05318014|Dietary Supplement|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
79639310|NCT05318014|Other|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
79639311|NCT02942056|Drug|Cinnamon|Cinnamon tablets to treat type 2 DM
79639312|NCT02942056|Drug|placebo|placebo
79804635|NCT00684866|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
79804636|NCT00854724|Drug|Puerarin, Placebo|400 mg, three times a day for 7 days
79804637|NCT00619697|Drug|biphasic insulin aspart|
79804638|NCT00619697|Drug|insulin glargine|
79639313|NCT00146003|Drug|Efalizumab treatment|
79639314|NCT00174681|Drug|Insulin Glargine|
79804639|NCT00619697|Drug|metformin|
79804640|NCT00619697|Drug|glimepiride|
79310007|NCT04012749|Behavioral|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
79639315|NCT05317897|Diagnostic Test|Lung ultrasound examination|45 pediatric patients who will go elective repair of congenital acyanotic heart diseases will be included and will be examined with Lung ultrasound together with arterial blood gases preoperative and postoperative and given a score range from 0-3 according to number of B lines in each region and sensitivity of post-operative lung ultrasound score to extubation within 6 hours was examined.
79310008|NCT04012749|Behavioral|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
79310009|NCT04012749|Behavioral|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
79639316|NCT00146042|Drug|Docetaxel|
79310010|NCT04716777|Behavioral|Brief Transdiagnostic group-based Cognitive-Behavioral Treatment|Weekly group-based transdiagnostic CBT sessions for eight weeks.
79310011|NCT05319249|Biological|NK cells|NK cells will be given as a single intravenous infusion.
79310012|NCT05319249|Drug|Talazoparib 1 MG [Talzenna]|Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
79310013|NCT05539131|Device|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
79310014|NCT05678361|Behavioral|Sleep/Nap|Participants sleep after a maximum of three sessions of exposure therapy.
79310015|NCT03849885|Drug|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
79310016|NCT05678283|Drug|[14C]CC-90010|Specified dose on specified days
79310017|NCT05678283|Drug|CC-90010|Specified dose on specified days
79310018|NCT01664091|Radiation|post-mastectomy radiation therapy (PMRT)|
79639317|NCT00146042|Drug|Trastuzumab|
79639318|NCT00146042|Procedure|Erythromycin Breath Test (ERMBT)|
79639319|NCT00169260|Behavioral|motivational counseling|behavioral motivational counselling
79639320|NCT00169260|Behavioral|placebo|
79639321|NCT05318911|Dietary Supplement|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
79639322|NCT05318911|Other|Placebo Drink|Placebo drink (skimmed milk)
79639323|NCT05318833|Drug|HRS7415|Drug: HRS7415
79639324|NCT03458494|Other|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
79639325|NCT03458494|Other|Low-fat diet|Participants will receive meals with a low content of total fat.
79639326|NCT00169299|Drug|Black cohosh|
79639327|NCT00169299|Drug|Multibotanical preparation|
79639328|NCT00169299|Drug|Multibotanical preparation + dietary soy counseling|
79310019|NCT01664091|Device|tissue expander (TE)|
79310020|NCT01664091|Device|acellular dermal matrix (ADM)|
79310021|NCT02577315|Drug|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
79310022|NCT02577315|Drug|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
79310023|NCT02577315|Drug|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
79310024|NCT02577315|Drug|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
79639329|NCT00169299|Drug|Conjugated equine estrogen +/- medroxyprogesterone acetate|
79310025|NCT05535777|Behavioral|Enhanced texts with Callback by a Person|"Enhanced texts - Callback by a person: Patient randomized to this study arm will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
79310026|NCT05535777|Behavioral|Enhanced Bidirectional Texts|"Patients randomized to this study arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient."
79310027|NCT05220657|Diagnostic Test|Maximal incremental exercise test|Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
79310028|NCT05220657|Diagnostic Test|Submaximal exercise test|A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
79310029|NCT05210283|Device|MRD|ctDNA MRD test
79639330|NCT02942602|Drug|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
79639331|NCT02942602|Drug|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
79639332|NCT02942602|Drug|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
79639333|NCT02942602|Drug|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
79639334|NCT02942602|Behavioral|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
79310030|NCT05678049|Diagnostic Test|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
79310031|NCT05695365|Behavioral|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last ~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
79310032|NCT05509413|Device|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
79639335|NCT00146081|Behavioral|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
79804641|NCT00680654|Drug|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
79804642|NCT00698568|Biological|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
79804643|NCT00698568|Biological|Placebo|Intramuscular injection, 3 doses
79804644|NCT00616733|Drug|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
79804645|NCT00616733|Drug|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
79804646|NCT00616733|Drug|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
79804647|NCT00680108|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
79804648|NCT02945969|Behavioral|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
79804649|NCT00680732|Dietary Supplement|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
79310033|NCT03526887|Drug|Pembrolizumab|200 mg, Q3W
79310034|NCT03526887|Drug|Pembrolizumab|200 mg, Q3W
79639336|NCT02942524|Other|Communication Intervention|Complete TEPID
79639337|NCT02942524|Other|Questionnaire Administration|Ancillary studies
79639338|NCT02942524|Other|Survey Administration|Ancillary studies
79804650|NCT00680732|Dietary Supplement|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
79804651|NCT00680732|Drug|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
79804652|NCT00680732|Drug|Sulphadoxyne-pyrimethamine (SP)|Tablets
79804653|NCT04210193|Drug|ALK Alutard 5-grasses|0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
79804654|NCT04210193|Drug|ALK Diluent|0.1 mL of ALK Diluent as an intralymphatic injection
79804655|NCT04653766|Drug|Ir-CPI - Dose 1|6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
79804656|NCT04653766|Drug|Ir-CPI - Dose 2|6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
79804657|NCT04653766|Drug|Ir-CPI - Dose 3|6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
79804658|NCT04653766|Drug|Ir-CPI - Dose 4|6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
79804659|NCT04653766|Drug|Placebo|For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
79804660|NCT00620243|Procedure|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
79310035|NCT03505983|Device|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
79639339|NCT02942329|Drug|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
79639340|NCT02942329|Drug|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
79310036|NCT03505983|Device|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
79310037|NCT03505983|Device|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
79310038|NCT03496779|Drug|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
79310039|NCT03496779|Drug|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
79310040|NCT03496779|Drug|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
79639341|NCT02958176|Behavioral|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
79310041|NCT03496779|Procedure|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
79310042|NCT02711345|Drug|LTT462|ERK Inhibitor
79310043|NCT03398655|Drug|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
79310044|NCT03398655|Drug|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
79310045|NCT05695287|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
79310046|NCT05695287|Drug|Isoflurane|Isoflurane
79310047|NCT05695287|Drug|Sevoflurane|Sevoflurane
79639342|NCT02958176|Behavioral|Autogenic Training|Autogenic training recording provided on a CD
79639343|NCT00174720|Drug|Ciclesonide (XRP1526)|
79639344|NCT02942641|Procedure|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
79639345|NCT02942641|Procedure|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
79639346|NCT02942641|Device|Foley|
79310048|NCT03772691|Procedure|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
79310049|NCT03772691|Procedure|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
79310050|NCT05501067|Other|tai chi exercise|specific tai chi exercise
79310051|NCT05501067|Other|no intervention|no intervention
79310052|NCT03118115|Device|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
79310053|NCT05097495|Procedure|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~Materials shall be prepared (napkins, non-sterile gloves, pacifier)~Hands shall be washed; gloves shall be worn.~The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~The diapers shall be changed.~Hands shall be washed after the procedure.~The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
79310054|NCT05097495|Procedure|NNS Combined with Breast Milk|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~Hands shall be washed; gloves shall be worn.~The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~The diapers shall be changed.~Hands shall be washed after the procedure.~The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
79310055|NCT03662009|Other|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
79310056|NCT05497869|Other|active release group|Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.
79310057|NCT05497869|Other|active control group|Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
79639347|NCT05318716|Device|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
79310058|NCT00591227|Drug|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
79639348|NCT05318716|Device|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
79310059|NCT00591227|Drug|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
79310060|NCT00408473|Drug|Flecainide|
79310061|NCT00328601|Drug|Thioctic Acid|
79310062|NCT03193697|Device|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
79310063|NCT03193697|Device|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
79639349|NCT02942212|Behavioral|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
79310064|NCT00189293|Drug|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
79310065|NCT00189293|Other|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
79310066|NCT03194009|Drug|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
79310067|NCT03194009|Behavioral|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
79639350|NCT02942212|Behavioral|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
79639351|NCT02942212|Other|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
79310068|NCT03192761|Procedure|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
79639352|NCT02942212|Drug|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke >10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
79310069|NCT03192761|Procedure|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
79310070|NCT03192761|Procedure|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
79310071|NCT02581995|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
79639353|NCT02942212|Behavioral|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
79639354|NCT02942212|Behavioral|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
79639355|NCT02942212|Behavioral|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
79639356|NCT00146120|Drug|Idarubicin|
79639357|NCT00146120|Drug|Cytosin-Arabinosid|
79639358|NCT00146120|Drug|Etoposide|
79310072|NCT03193385|Procedure|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
79310073|NCT03192605|Other|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
79310074|NCT03192605|Other|Placebo|Placebo - matched for calories and fiber
79310075|NCT03192683|Device|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
79310076|NCT03192683|Device|Regular sling|
79639359|NCT00146120|Drug|All-trans Retinoid acid|
79310077|NCT03193307|Drug|Microgynon|Run in period & Treatment Period
79310078|NCT03193307|Drug|BI 409306|Day 18 & 29 (Treatment Period)
79639360|NCT00169338|Procedure|Deep brain stimulation|internal pallidal deep brain stimulation
79310079|NCT02910843|Drug|Regorafenib|"Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
79310080|NCT02910843|Drug|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
79639361|NCT02942251|Other|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
79639362|NCT02942251|Other|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
79639363|NCT02942251|Other|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
79639364|NCT02942251|Other|Laboratory abnormality|This group will be suggested to more safety antidepressants.
79639365|NCT02942251|Other|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
79639366|NCT02942251|Other|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
79639367|NCT00169377|Procedure|deep brain stimulation|Stimulator on followed by off
79639368|NCT00169377|Procedure|No stimulation|Stimulator off followed by on
79639369|NCT00146159|Drug|Mitoxantrone|dosage
79310081|NCT02910843|Radiation|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
79474584|NCT05742763|Combination Product|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
79310082|NCT02910843|Procedure|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
79310083|NCT03192527|Drug|KN015|experimental drug
79310084|NCT03192527|Drug|Placebo|Comparator.
79968698|NCT02814708|Biological|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 binding Ab titer .
79968699|NCT01268813|Other|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
79310085|NCT03192527|Drug|Triptorelin|The drug is used for down-regulation of endogenous FSH.
79310086|NCT02444351|Drug|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
79310087|NCT02444351|Other|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
79310088|NCT03193463|Drug|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
79310089|NCT03193463|Drug|Topotecan (>8cc)|In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
79474585|NCT02504723|Drug|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure >90 mm Hg.
79968700|NCT03879005|Other|renal scintigraphy|"99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each."
79968701|NCT04256785|Dietary Supplement|VSL#3|sachets containing probiotic
79968702|NCT04256785|Dietary Supplement|Placebo|sachets containing placebo
79968703|NCT03878771|Biological|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
79310090|NCT03193463|Device|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
79310091|NCT03193463|Diagnostic Test|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
79310092|NCT03193463|Drug|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
79310093|NCT02444273|Procedure|Exercise|Subjects will be given and individualized exercise program.
79310094|NCT02577003|Drug|Ipragliflozin|50 mg tablet administered orally
79310095|NCT02577003|Drug|Placebo|Placebo to ipragliflozin tablet administered orally
79310096|NCT02577003|Drug|Sitagliptin|Background medication; 50 mg tablet administered orally
79639370|NCT02276989|Drug|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only."
79968704|NCT03878771|Drug|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
79968705|NCT02959918|Drug|SEL-212|SEL-212, biologic
79310097|NCT03193229|Behavioral|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
79310098|NCT03193229|Device|Fitbit|Fitbit
79310099|NCT05487417|Drug|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
79968706|NCT02959918|Drug|SEL-037|SEL-037, biologic
79310100|NCT03471611|Drug|Autologous CD34+ Cells|The dose will be 1x10^5 cells/kg, injected at the rate of 10 ml/min
79310101|NCT03471611|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
79968707|NCT02959918|Drug|SVP-rapamycin (SEL-110)|SVP-rapamycin, biologic
79968708|NCT01160159|Other|Tests|Arterial parameters
79968709|NCT01160159|Other|Healthy volunteers|Arterial parameters and blood test
79968710|NCT01266707|Biological|antiangiogenic paptide vaccine|for drugs include administration time frame
79968711|NCT03263442|Drug|Thiamine|200 mg IV three times daily for seven days
79968712|NCT03263442|Drug|Normal saline|Normal saline IV three times daily for seven days
79968713|NCT01164215|Drug|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
79968714|NCT01164215|Drug|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
79310102|NCT03281057|Behavioral|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
79310103|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
79968715|NCT01164215|Drug|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
79310104|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
79639371|NCT02276989|Drug|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
79310105|NCT03200327|Procedure|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
79310106|NCT03200327|Procedure|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
79310107|NCT03192839|Other|Low dose PUFA|Low dose PUFA
79310108|NCT03192839|Other|High dose PUFA|High dose PUFA
79310109|NCT03192839|Other|Placebo|Placebo
79310110|NCT05174741|Other|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT *3 sets/session*TD Walk (10-15 minutes) * BD
79474586|NCT02504723|Drug|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
79639372|NCT02276989|Drug|Riboflavin|"All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
79310111|NCT05174741|Other|Aerobic training Group|"Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day"
79310112|NCT03098693|Behavioral|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
79310113|NCT03098693|Behavioral|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
79310114|NCT03098693|Behavioral|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
79310115|NCT02866487|Procedure|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
79474587|NCT05738941|Procedure|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
79474588|NCT05738941|Procedure|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
79310116|NCT05470335|Procedure|nurse-led sheath insertion|radial sheaths for coronary examination and intervention are performed by experienced nurses
79310117|NCT05674305|Drug|Radiotherapy|IMRT for primary and regional field
79310118|NCT05674305|Drug|Cisplatin|Cisplatin 80mg/m2, 21days/cycle, 2 cycles
79310119|NCT02443649|Behavioral|Sleep hygiene program|Sleep hygiene program
79968716|NCT04245709|Drug|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
79968717|NCT03878693|Drug|Fomepizole|IV 4-MP.
79474589|NCT02439281|Drug|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
79474590|NCT02439281|Drug|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
79474591|NCT01830205|Drug|Daclatasvir|
79474592|NCT02505269|Drug|Brentuximab Vedotin|
79474593|NCT02505269|Drug|Adriamycin|
79474594|NCT02505269|Drug|Dacarbazine|
79639373|NCT00174759|Drug|Clopidogrel|
79639374|NCT00146198|Drug|ALGRX 4975|
79968718|NCT03878693|Drug|APAP|Oral APAP
79968719|NCT05305495|Drug|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output < 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
79310120|NCT02443649|Behavioral|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
79310121|NCT03192449|Drug|Albendazole.|Single dose 400mg orally
79474595|NCT02440139|Device|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
79474596|NCT02554799|Drug|MMV390048 formulation A|MMV390048 formulation A, tablet
79474597|NCT02554799|Drug|MMV390048 formulation B|MMV390048 formulation B, tablet
79474598|NCT00422123|Drug|Quetiapine fumarate (Seroquel) SR|
79474599|NCT04743713|Other|UWRI-Tr|Questionnaire
79474600|NCT00559273|Drug|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
79474601|NCT00559273|Drug|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
79474602|NCT02506673|Device|Zeiss, Cinema ProMED (audiovisual equipment)|
79474603|NCT02506673|Drug|Midazolam|
79474604|NCT02506673|Device|Skin Conductance Monitor|
79474605|NCT02508077|Drug|Fluorouracil|Given IV
79474606|NCT02508077|Drug|Irinotecan Hydrochloride|Given IV
79474607|NCT02508077|Other|Laboratory Biomarker Analysis|Correlative studies
79310122|NCT05666973|Procedure|Open Mesh Hernioplasty|"Steps of surgery:~Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~Incision:~Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~bleeding controlled by forcep coagulation.~Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~Nerve Iliohypogastric & ilioinguinal will be preserved (by taking aside from the field)~Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~Sac ligated with Polygalactin 2-0 suture.~Lichtenstein method of repair~Mesh type: large pore polypropylene mesh~Mesh size: 3 x 6 inches(7.5 x 15 cms)~Mesh Fixation: polypropylene 2-0~External oblique closure~Skin closure: Ethilon 2 - 0 suture"
79310123|NCT04308057|Procedure|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
79310124|NCT05691933|Procedure|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
79310125|NCT05691933|Procedure|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
79310126|NCT02443493|Device|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
79310127|NCT02443493|Device|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
79310128|NCT02443493|Radiation|radiotherapy|
79474608|NCT02508077|Drug|Leucovorin Calcium|Given PO
79804661|NCT04151186|Biological|TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy|"Specification: 30 mL-100 mL, cell density of about (1-10) x10^6 cells/ml in each bag, number of T-cells about (1-10) x10^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)<71> and <85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min."
79804662|NCT00698932|Drug|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
79804663|NCT00698932|Drug|Placebo|oral tablet, once daily for 24 weeks
79804664|NCT02566252|Drug|PUL-042 Inhalation Solution|PUL-042
79804665|NCT02566252|Drug|Cromolyn Sodium|Pre-treatment
79310129|NCT00977483|Drug|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
79310130|NCT00977483|Drug|Placebo|1 tablet once daily 4 years double-blind treatment period
79310131|NCT02439905|Drug|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
79310132|NCT02439905|Drug|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
79310133|NCT03190421|Diagnostic Test|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
79474609|NCT02508077|Biological|Panitumumab|Given IV
79474610|NCT02268877|Other|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
79474611|NCT02268877|Device|Ultrasound|An ultrasound will be performed by a radiology department technician
79474612|NCT04580095|Other|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
79804666|NCT02566252|Drug|Albuterol sulfate|Pre-treatment
79310134|NCT03190421|Diagnostic Test|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
79310135|NCT03192371|Biological|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
79310136|NCT02439983|Dietary Supplement|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
79310137|NCT02439983|Dietary Supplement|Placebo|2 capsules taken by mouth with morning and evening meals.
79310138|NCT02446899|Biological|Anifrolumab|Intravenous infusion (IV)
79310139|NCT02446899|Drug|Placebo|Intravenous infusion (IV)
79310140|NCT02709785|Drug|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
79310141|NCT02709785|Drug|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
79310142|NCT02709785|Drug|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
79310143|NCT02440061|Drug|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
79310144|NCT02440061|Drug|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
79310145|NCT02440061|Drug|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
79310146|NCT03190343|Procedure|cholangio-pancreatoscopy|
79310147|NCT02439827|Behavioral|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
79639375|NCT02941978|Behavioral|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
79310148|NCT02442947|Other|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment [charcoal base], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
79310149|NCT02443025|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
79310150|NCT05632341|Dietary Supplement|Lactococcus lactis|1 capsule once a day
79639376|NCT02941978|Behavioral|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
79310151|NCT05632341|Other|maltodextrin|1 capsule once a day
79310152|NCT02439671|Behavioral|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~Social communication (e.g. listening, perspective taking)~Self-determination (e.g. problem-solving, self-advocacy)~Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
79310153|NCT04852653|Procedure|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
79310154|NCT02442791|Drug|Byetta (Lilly, Exenatide)|See description of Arms
79310155|NCT02442791|Other|20% Human Albumin|See description of Arms
79639377|NCT02941042|Drug|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
79639378|NCT02941042|Drug|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
79639379|NCT00146237|Drug|phenytoin|
79968720|NCT01164293|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
79310156|NCT03190655|Device|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
79310157|NCT03190655|Device|Hydrogel|Hydrogel based wound dressing
79310158|NCT04771221|Diagnostic Test|pH metry|The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.
79639380|NCT02963727|Biological|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
79639381|NCT02277067|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
79474613|NCT04561297|Diagnostic Test|TDC differential value|TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
79639382|NCT02277067|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
79639383|NCT02940964|Behavioral|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
79639384|NCT02940964|Behavioral|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
79639385|NCT00146276|Drug|gemcitabine|
79639386|NCT00174798|Drug|SSR240600C|once daily
79639387|NCT00174798|Drug|Placebo|oral
79639388|NCT00174798|Drug|Tolterodine|once daily
79968721|NCT03748537|Drug|Hydrocortisone|After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP <65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP < 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
79968722|NCT04091581|Drug|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
79968723|NCT02527109|Drug|Nifedipine|
79968724|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
79639389|NCT05200975|Diagnostic Test|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
79968725|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
79310159|NCT04771221|Diagnostic Test|Filling out the questionnaire|Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem
79310160|NCT04771221|Device|Endoscopic laryngoscopy|Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem
79804667|NCT00823719|Drug|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m^2 on days 1, 2 and 3 of dosing cycle."
79310161|NCT04771221|Device|Acoustic voice analysis|acoustic analysis of the voice was performed in singers with voice disorders before and after treatment using program of the Lingwaves
79310162|NCT02442557|Biological|recombinant human alpha B-crystallin|intravenous injection
79804668|NCT00823719|Drug|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m^2 q12 hrs (2 doses) on day 2 of dosing cycle."
79804669|NCT03953170|Drug|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
79474614|NCT05006963|Other|manual therapy and therapy by exercise|In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
79474615|NCT04479085|Other|nursing intervention|"It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets."
79639390|NCT00146315|Behavioral|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
79474616|NCT05726851|Drug|E2025|E2025 IV infusion.
79474617|NCT05726851|Drug|Placebo|E2025 matched placebo IV infusion.
79474618|NCT01831921|Behavioral|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
79474619|NCT01831921|Behavioral|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
79474620|NCT00558259|Drug|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
79474621|NCT00558259|Drug|matching placebo twice daily (BID)|Matching placebo BID
79639391|NCT00146315|Behavioral|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
79639392|NCT05187520|Device|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
79804670|NCT03953170|Drug|Placebo|Placebo
79968726|NCT03878615|Procedure|elective surgery, according to deprtement routine|none, descriptive study
79968727|NCT01266785|Drug|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
79310163|NCT02442557|Other|placebo comparator|intravenous injection
79474622|NCT02508389|Drug|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
79639393|NCT05187520|Drug|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
79639394|NCT02940808|Dietary Supplement|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
79639395|NCT02940808|Other|Placebo|Oral consumption of capsule containing a placebo substance.
79340437|NCT02438137|Drug|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
79474623|NCT02508389|Drug|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
79474624|NCT02508389|Drug|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
79639396|NCT00169416|Drug|valaciclovir HCl granules|
79639397|NCT00146354|Behavioral|Hospitalists Results Manager|
79639398|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
79639399|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
79639400|NCT02941003|Device|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
79639401|NCT02941003|Other|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
79639402|NCT02941003|Device|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
79639403|NCT00146393|Behavioral|People with Arthritis Can Exercise program|
79804671|NCT02565550|Dietary Supplement|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
79340438|NCT02438137|Drug|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
79639404|NCT02963805|Behavioral|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
79639405|NCT02963805|Behavioral|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
79639406|NCT02963805|Behavioral|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
79639407|NCT02941081|Dietary Supplement|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
79639408|NCT02941081|Dietary Supplement|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
79639409|NCT02941081|Other|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
79968728|NCT03875807|Procedure|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
79968729|NCT03875807|Procedure|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
79639410|NCT02940613|Behavioral|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
79639411|NCT00146432|Procedure|Immunoadsorption of LPS, IL-6 and C5a|
79804672|NCT02567500|Behavioral|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with DSM-IV criteria:~MINI-Kids~Psychosis section of Kiddie-SADS"
79804673|NCT02567500|Behavioral|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with DSM-IV criteria:~MINI-Kids~Psychosis section of Kiddie-SADS"
79804674|NCT00708591|Drug|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
79804675|NCT00708591|Drug|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
79804676|NCT04595266|Drug|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
79310164|NCT04756557|Other|Experimental.|Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
79310165|NCT04756557|Other|Active comparator|Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
79310166|NCT02442635|Behavioral|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
79310167|NCT02442713|Drug|fluvoxamine|fluvoxamine: 50-300mg/day
79310168|NCT02410473|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
79310169|NCT02410473|Other|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
79804677|NCT04595266|Biological|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
79968730|NCT02526719|Procedure|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
79968731|NCT03746977|Dietary Supplement|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
79310170|NCT03190187|Other|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
79310171|NCT03190187|Other|Sham manipulation|Patients will receive simulated spinal manipulation without force application
79310172|NCT03189953|Radiation|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
79804678|NCT04595266|Drug|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
79804679|NCT00708669|Device|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
79968732|NCT03746977|Behavioral|Walking|Walking with a volume corresponding to 250 kcal/d
79968733|NCT03746977|Behavioral|WB-EMS application|WB-EMS application 1.5x 20 min/week
79968734|NCT03262038|Drug|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
79968735|NCT03262038|Drug|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
79968736|NCT01268969|Procedure|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
79968737|NCT01268969|Procedure|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
79474625|NCT02508389|Radiation|Intensity-Modulated Radiation Therapy|Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
79804680|NCT00708669|Device|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
79804681|NCT02565940|Other|biopsy|
79804682|NCT04062604|Other|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
79968738|NCT03745573|Behavioral|Empateach|Empateach is a behavioural intervention for teachers.
79968739|NCT01266863|Other|E test method|E test strips directly applied to BAL
79968740|NCT03746821|Dietary Supplement|Biotin|Biotin supplements (2) to be taken daily
79968741|NCT01266941|Drug|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
79968742|NCT02472964|Biological|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
79968743|NCT02472964|Biological|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
79968744|NCT02472964|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
79968745|NCT02472964|Drug|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
79968746|NCT01160315|Drug|Triptorelin|Triptorelin: intramusculAR injection every 3 months
79968747|NCT01160315|Drug|Norethisterone acetate|5 mg/day per os until during chemotherapy
79310173|NCT02356887|Diagnostic Test|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
79310174|NCT02442479|Behavioral|resistance training|
79310175|NCT02204085|Drug|GO-203-2c|
79474626|NCT02508389|Drug|Cisplatin|"Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor"
79474627|NCT02509481|Drug|Ivermectin|
79968748|NCT03875417|Procedure|liver resection|resection of one or more HCC nodules within the liver
79968749|NCT03875417|Procedure|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
79310176|NCT02204085|Drug|GO-203-2c + Decitabine|
79310177|NCT02439593|Other|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
79474628|NCT02509481|Drug|Albendazole|
79310178|NCT02439593|Other|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
79310179|NCT02067741|Drug|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
79639412|NCT04691440|Drug|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
79968750|NCT03875417|Procedure|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
79968751|NCT01160393|Device|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
79968752|NCT03385252|Other|Eggs|Eggs provided as complementary food for the infant
79968753|NCT03385252|Behavioral|Visits|Twice weekly household visits by study staff
79968754|NCT01164449|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
79310180|NCT02442401|Device|The negative pressure wound therapy|
79310181|NCT02439359|Drug|CF-301|Dose escalation
79474629|NCT02511587|Biological|FSME-Immune vaccination|booster vaccination with FSME-Immune
79474630|NCT02560493|Behavioral|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
79639413|NCT02940652|Radiation|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
79639414|NCT00174876|Drug|Drug Abilify|
79968755|NCT03878225|Dietary Supplement|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
79968756|NCT03878225|Other|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
79968757|NCT03385174|Other|Carbon monoxide|Carbon monoxide inhalation
79968758|NCT03878303|Drug|AC0058TA|25 mg capsules
79968759|NCT03878303|Drug|Placebo AC0058TA|equivalent dose of investigational product
79968760|NCT01164605|Drug|Raltegravir|60 tablets (30-day supply)
79804683|NCT00708747|Drug|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
79804684|NCT00708747|Drug|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
79310182|NCT02439359|Drug|Placebo|
79310183|NCT02442323|Behavioral|Walking Intervention|12-week walking program
79968761|NCT03380806|Drug|LHRH agonist|Standard LHRH agonist for 3 years
79968762|NCT03380806|Radiation|Pelvic Radiation|Pelvic Radiation
79968763|NCT03380806|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
79968764|NCT03380806|Radiation|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
79968765|NCT03746743|Diagnostic Test|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
79968766|NCT03875261|Drug|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
79310184|NCT04314843|Drug|Cyclophosphamide|Administered according to package insert
79310185|NCT04314843|Drug|Fludarabine|Administered according to package insert
79310186|NCT04314843|Biological|Lenzilumab|Administered as an IV infusion
79968767|NCT03748459|Other|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
79310187|NCT04314843|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
79310188|NCT02439437|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
79968768|NCT03748459|Other|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
79968769|NCT03380728|Drug|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
79310189|NCT03192293|Drug|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
79310190|NCT02442089|Behavioral|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
79474631|NCT04950881|Procedure|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
79968770|NCT03874949|Device|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
79804685|NCT00875420|Drug|RAD1901|10 mg Oral once a day for 28 days.
79804686|NCT00875420|Drug|RAD1901|25 mg Oral once a day for 28 days
79804687|NCT00875420|Drug|RAD1901|50 mg Oral once a day for 28 days.
79804688|NCT00875420|Drug|RAD1901|100 mg Oral once a day for 28 days
79804689|NCT00875420|Drug|Placebo|Placebo Oral once a day for 28 days
79804690|NCT02567344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
79968771|NCT03874949|Device|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
79310191|NCT02442245|Dietary Supplement|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
79310192|NCT02442245|Other|Placebo: Microcrystalline Cellulose|
79310193|NCT02442245|Other|Control: No supplementation|
79310194|NCT02439515|Device|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
79310195|NCT02439515|Device|Balance|Balance control exercises with visual biofeedback
79310196|NCT02439515|Other|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
79310197|NCT02439203|Drug|JM-010|
79310198|NCT02439203|Drug|Placebo|
79310199|NCT02439125|Drug|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
79310200|NCT02439125|Drug|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
79310201|NCT02439125|Drug|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
79310202|NCT02439125|Drug|Placebo|b.i.d. orally for 3 weeks
79310203|NCT02441933|Drug|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
79968772|NCT03877835|Procedure|Peripheral nerve blocks|LSIB + SSNB
79310204|NCT02441933|Drug|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~Paclitaxel (80 mg/m2) IV weekly for 12 doses"
79474632|NCT04950881|Drug|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
79474633|NCT04341077|Drug|SHR3162|A single oral dose of fluzoparib on Day 1
79310205|NCT01604265|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
79639415|NCT00146471|Drug|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
79310206|NCT01604265|Drug|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
79310207|NCT02439047|Procedure|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~- Adipose tissue samples : will be collected during surgery for breast reconstruction"
79474634|NCT04914767|Drug|Nigella|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
79474635|NCT04914767|Drug|Placebo|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
79639416|NCT00146471|Drug|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
79968773|NCT01104922|Drug|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: * Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) * Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
79474636|NCT02561585|Drug|LEO 124249|
79968774|NCT01104922|Device|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
79968775|NCT01164683|Behavioral|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
79968776|NCT01164683|Other|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
79968777|NCT04079803|Drug|Placebo oral tablet|Oral placebo tablet
79968778|NCT04079803|Drug|Simufilam 100 mg tablet|Simufilam 100 mg oral tablet
79968779|NCT04079803|Drug|Simufilam 50 mg oral tablet|Simufilam 50 mg oral tablet
79310208|NCT02441855|Device|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
79310209|NCT03190031|Other|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
79310210|NCT03190031|Other|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
79310211|NCT04705233|Other|sputum colour chart|5-point Sputum Colour Chart plus best standard care
79474637|NCT02561585|Other|Vehicle|
79474638|NCT02561897|Drug|Edoxaban|
79474639|NCT02561897|Drug|Warfarin|
79474640|NCT02512679|Drug|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
79474641|NCT02512679|Drug|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
79474642|NCT02512679|Drug|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
79639417|NCT04691245|Device|3D US|3D US guided access to femoral artery
79639418|NCT04691245|Device|2D US|2D US guided access to femoral artery
79474643|NCT02512679|Drug|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
79474644|NCT02562521|Behavioral|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
79474645|NCT02562521|Drug|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
79474646|NCT02562521|Drug|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
79804691|NCT02567344|Device|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
79968780|NCT00894244|Device|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
79968781|NCT03278613|Device|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
79968782|NCT03761147|Other|Paula exercises|structured exercises aimed to stimulate ring muscles
79968783|NCT03389152|Device|Elastography|liver stiffness measurements by shear wave-based elastography
79968784|NCT00560716|Drug|CYC116|Dose escalation of CYC116
79968785|NCT03909659|Behavioral|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
79474647|NCT02562521|Behavioral|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
79639419|NCT04691713|Drug|Targeting CD276 autologous chimeric antigen receptor T cells|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
79655568|NCT04548622|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
79804692|NCT00685022|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~Arm #A~Xopenex HFA MDI, albuterol HFA MDI"
79968786|NCT03380650|Device|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
79968787|NCT03380650|Device|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
79968788|NCT01164761|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
79474648|NCT04887779|Behavioral|Pathologist intervention|viewing explanted organ and microscopy
79474649|NCT02562755|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
79804693|NCT00685022|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~Arm #B~albuterol HFA MDI, Xopenex HFA MDI"
79310212|NCT04483427|Combination Product|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
79310213|NCT02438735|Procedure|laparoscopic endometrioma excision|
79474650|NCT02562755|Drug|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
79474651|NCT04796129|Other|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
79968789|NCT01164761|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
79474652|NCT02562989|Drug|[18F]MK-6240, ~185 MBq|IV dose of ~185 MBq [18F]MK-6240
79474653|NCT02562989|Drug|[18F]MK-6240, ~160 MBq|IV dose of ~160 MBq [18F]MK-6240
79310214|NCT02438735|Other|Conservative follow up|
79310215|NCT01664247|Drug|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
79310216|NCT01664247|Drug|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
79310217|NCT01664247|Drug|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
79655569|NCT04710251|Device|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
79968790|NCT03748381|Procedure|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
79968791|NCT03385096|Drug|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4."
79474654|NCT05446883|Drug|QL1706|Intravenous Infusion
79968792|NCT03385096|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
79474655|NCT05446883|Drug|Placebo|Intravenous Infusion
79474656|NCT05446883|Drug|Paclitaxel injection|Intravenous Infusion
79474657|NCT05446883|Drug|Cisplatin/Carboplatin|Intravenous Infusion
79474658|NCT02565485|Drug|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
79655570|NCT02212561|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
79968793|NCT03385096|Drug|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2."
79968794|NCT03385096|Drug|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
79968795|NCT01252823|Device|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
79968796|NCT03746665|Biological|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
79984379|NCT02449876|Other|Neuroscience Education|"The following topics will be discussed in the education~Basic structure of the nervous system~Basic physiology of the nervous system~The function and importance of pain~Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
79310218|NCT02441699|Behavioral|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
79310219|NCT02441465|Drug|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
79310220|NCT02441465|Drug|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters [mL], which corresponds to a dose of 20 micrograms [mcg] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
79474659|NCT00363857|Drug|Ropinirole|
79474660|NCT02515253|Other|Bra prescription|
79474661|NCT02515253|Other|Standard Care|
79474662|NCT02566265|Biological|Fluzone High Dose Vaccine|
79474663|NCT02566265|Biological|Standard of care/Placebo|
79655571|NCT02212561|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
79655572|NCT02212561|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
79804694|NCT04209881|Other|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
79968797|NCT04445974|Behavioral|Expand your horizons: More than my skin|'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.
79310221|NCT02438657|Procedure|median nerve block|
79984380|NCT04292171|Drug|Gabapentin|Preoperative treatment with Gabapentin
79310222|NCT02441621|Other|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
79474664|NCT04561973|Behavioral|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
79474665|NCT02516579|Drug|Siklos|
79984381|NCT04292171|Drug|Placebos|Preoperative treatment with Placebo
79984382|NCT03200782|Drug|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
79310223|NCT02441621|Other|premedication|patients receive premedication with midazolam 7.5 mg p.o.
79310224|NCT02441621|Other|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
79984383|NCT03200782|Drug|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
79984384|NCT03200782|Other|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
79984385|NCT03200782|Other|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
79984386|NCT02449954|Drug|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
79984387|NCT02449954|Drug|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
79984388|NCT02449954|Drug|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
79984389|NCT02448160|Device|alfapump|Implantation of alfapump
79310225|NCT02441621|Other|central venous catheter|a central venous catheter in the right or left internal jugular vein.
79310226|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
79310227|NCT02441621|Other|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
79474666|NCT02517047|Device|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
79310228|NCT02441621|Other|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
79310229|NCT03189797|Other|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
79310230|NCT02441387|Drug|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
79310231|NCT02441387|Other|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
79310232|NCT02441387|Other|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
79310233|NCT01441947|Drug|Cabozantinib|Part of combination arm
79310234|NCT01441947|Drug|Fulvestrant|part of combination arm
79310235|NCT03192059|Drug|Pembrolizumab|Efficacy of the combined treatment
79310236|NCT03192059|Radiation|Radiation|Efficacy of the combined treatment
79310237|NCT03192059|Drug|Vitamin D|Efficacy of the combined treatment
79310238|NCT03192059|Drug|Aspirin|Efficacy of the combined treatment
79310239|NCT03192059|Drug|Lansoprazole|Efficacy of the combined treatment
79310240|NCT03192059|Drug|Cyclophosphamide|Efficacy of the combined treatment
79310241|NCT03192059|Dietary Supplement|Curcumin|Efficacy of the combined treatment
79310242|NCT02441075|Other|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
79968798|NCT04445974|Behavioral|Creative writing activities|In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
79310243|NCT02441153|Other|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
79968799|NCT02526875|Drug|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
79968800|NCT05570877|Device|ChitoCare medical Wound Healing Gel|ChitoCare medical Wound Healing Gel is a CE-marked medical device.
79968801|NCT03380494|Other|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
79984390|NCT02448160|Drug|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
79340439|NCT02437903|Device|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
79984391|NCT04393493|Drug|Furosemide intravenous solution|Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
79984392|NCT04393493|Drug|Chlortalidone|One 50 mg pill administrated every 24 hours in group B
79984393|NCT04393493|Drug|Spironolactone|One 50 mg pill administrated every 24 hours in group B
79340440|NCT02437513|Device|NewBreez|Intralaryngeal prosthesis to protect the airways
79340441|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
79340442|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
79968802|NCT03380494|Other|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
79340443|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
79340444|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
79340445|NCT04909021|Other|Placebo (single-dose)|Single dose administered intranasally on Day 1
79340446|NCT04909021|Other|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
79340447|NCT02460991|Device|DEB-TACE|
79340448|NCT02460991|Drug|Sorafenib|
79340449|NCT02460679|Drug|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
79340450|NCT02459899|Drug|Placebo|Placebo, once daily, before the first meal of the day
79804695|NCT00822237|Biological|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
79968803|NCT01267097|Behavioral|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
79968804|NCT01267097|Behavioral|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
79310244|NCT04687683|Other|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
79655573|NCT02212561|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
79310245|NCT04687683|Other|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
79340451|NCT02459899|Drug|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
79655574|NCT00268554|Drug|dipyridamole|
79655575|NCT00268554|Drug|caffeine|
79340452|NCT02436889|Drug|Mirabegron|
79340453|NCT02436889|Drug|Tolterodine Tartrate|
79340454|NCT02436811|Behavioral|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
79340455|NCT02436811|Behavioral|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
79340456|NCT02436811|Behavioral|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
79340457|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
79655576|NCT04555993|Procedure|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
79655577|NCT04555993|Other|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
79804696|NCT00822237|Biological|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
79804697|NCT00822237|Biological|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection ~6 weeks apart
79804698|NCT02626286|Other|HIV quarterly global care|
79804699|NCT00617747|Drug|Zolmitriptan|5mg Nasal Spray
79804700|NCT00617747|Drug|Placebo|
79474667|NCT04768933|Dietary Supplement|Toddler Milk|At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
79968805|NCT03389074|Procedure|Radiofrequency catheter ablation|minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.
79968806|NCT04222699|Drug|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
79655578|NCT04555993|Other|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
79340458|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
79340459|NCT02436577|Drug|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
79340460|NCT02265705|Drug|Baricitinib|Administered orally
79474668|NCT00558103|Drug|lapatinib|Oral administration
79474669|NCT00558103|Drug|Pazopanib|Oral administration
79340461|NCT02265705|Drug|Placebo|Administered orally
79340462|NCT02459665|Biological|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
79655579|NCT00235586|Procedure|10 vit. D deficient subjects take vit. D for 3 months.|
79340463|NCT02459665|Drug|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
79340464|NCT02459665|Biological|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
79340465|NCT02265237|Drug|ombitasvir/paritaprevir/ritonavir|tablets
79474670|NCT02974361|Drug|Ibuprofen|
79474671|NCT02974361|Drug|Ibuprofen Lysine|
79474672|NCT02974361|Drug|Ibuprofen-LDH|
79655580|NCT00268593|Drug|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
79655581|NCT00268593|Drug|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
79340466|NCT02265237|Drug|ribavirin|tablets
79340467|NCT04874025|Drug|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
79639420|NCT04690933|Other|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
79639421|NCT00174993|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
79639422|NCT00174993|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
79804701|NCT04560400|Diagnostic Test|Conventional King-Devick test|Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function
79340468|NCT05484219|Device|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
79639423|NCT00146510|Behavioral|HealtheLifestyle Program|
79639424|NCT00146510|Behavioral|step counters with monthly feedback on logs|
79639425|NCT04690894|Procedure|erector spinae block - caudal block|the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
79655582|NCT00268593|Drug|prednisone|5 mg twice a day orally
79340469|NCT02263365|Drug|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
79340470|NCT05647083|Other|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
79655583|NCT04555525|Drug|sarecycline|sarecycline tablet
79655584|NCT04555525|Dietary Supplement|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
79655585|NCT00235625|Drug|Curcuminoids C3 Complex®|
79655586|NCT02212600|Other|Observational|observational cohort of proximal humerus fractures
79655587|NCT04555486|Drug|DCR-PHXC|Intervention, drug, DCR-PHXC
79655588|NCT04555486|Drug|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
79804702|NCT04560400|Diagnostic Test|Reverse King-Devick test|Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
79804703|NCT04041531|Other|blood sampling|venous blood sampling for oxygen affinity in-vitro test
79804704|NCT00619775|Device|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
79804705|NCT00685100|Other|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
79804706|NCT00708903|Drug|neratinib|HKI-272
79474673|NCT05690815|Drug|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
79310246|NCT04687683|Other|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
79474674|NCT04282603|Combination Product|Weight Loss and Weight Maintenance|Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
79474675|NCT02569541|Drug|sodium fusidate|
79639426|NCT04691830|Behavioral|Prosody treatment program|"The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section."
79968807|NCT04222699|Drug|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
79310247|NCT02438579|Other|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
79968808|NCT03637179|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
79968809|NCT03637179|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
79968810|NCT01269203|Drug|Curcumin|1000 mg per day
79968811|NCT01269203|Other|Placebo|Administered daily same as Curcumin.
79310248|NCT04664751|Other|Nil-per-Oral|NPO details
79310249|NCT02441231|Drug|Visbiome|Visbiome probiotic
79310250|NCT02441231|Other|Placebo|Placebo
79310251|NCT02438501|Radiation|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
79310252|NCT02438501|Radiation|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
79310253|NCT02440997|Other|aromatherapy|
79310254|NCT02440997|Other|foot bath|
79310255|NCT02438345|Biological|PRO 140|Humanized monoclonal antibody to CCr5
79310256|NCT02438189|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
79310257|NCT05245851|Device|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA [investigational testing authorization] from Health Canada, to screen for low bone mineral density (low BMD).~This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
79310258|NCT03191981|Drug|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
79310259|NCT03191981|Drug|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
79310260|NCT03191981|Drug|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
79310261|NCT05534997|Other|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
79639427|NCT04691830|Behavioral|Traditional auditory and language rehabilitation|Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
79639428|NCT02940379|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79639429|NCT02940379|Drug|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
79639430|NCT02940379|Drug|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
79639431|NCT00146549|Drug|Trastuzumab|
79310262|NCT05640219|Device|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
79310263|NCT05530941|Behavioral|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
79310264|NCT05428761|Other|TP1|Participants will receive TP1 during one experimental visit.
79310265|NCT05428761|Other|TP2|Participants will receive TP2 during one experimental visit.
79310266|NCT05428761|Other|Placebo|Participants will receive placebo during one experimental visit.
79639432|NCT00146549|Drug|Vinorelbine|
79639433|NCT00146549|Drug|Paclitaxel|
79639434|NCT00146549|Drug|Docetaxel|
79340471|NCT02261493|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
79340472|NCT02261493|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
79340473|NCT05646849|Other|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
79639435|NCT02940535|Drug|Diphereline (Triptorelin embonate)|
79639436|NCT02940535|Drug|Decapeptyl (Triptorelin)|
79639437|NCT02940535|Drug|human menopausal gonadotropin|
79639438|NCT02940535|Drug|human chorionic gonadotropin|
79639439|NCT00169494|Biological|HPV-16/18 L1/AS04|
79639440|NCT04690972|Procedure|Blood sample during surgery|During the hepato-bilio-pancreatic surgery, blood is drawn.
79639441|NCT04690972|Procedure|Taking an additional biopsy|As part of the treatment, an additional biopsy is executed and blood is drawn.
79474676|NCT04198675|Behavioral|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
79310267|NCT05530785|Combination Product|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
79310268|NCT05425173|Other|Conventional treatment|Chest Physical Therapy as required
79310269|NCT05425173|Other|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
79310270|NCT05530629|Device|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
79310271|NCT05530629|Device|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
79474677|NCT04198675|Behavioral|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
79474678|NCT04198675|Behavioral|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
79474679|NCT04093297|Procedure|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
79474680|NCT04477733|Drug|Butorphanol Injection|Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
79474681|NCT04477733|Drug|Saline|Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
79474682|NCT01833403|Other|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------"
79639442|NCT04690972|Diagnostic Test|Blood sample during diagnostic test|Blood sample as part of the care
79639443|NCT05157802|Behavioral|Physical activity coaching|Physical activity coaching over 5 sessions
79639444|NCT00146588|Drug|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
79639445|NCT00146588|Drug|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
79655589|NCT04555213|Drug|NOX66|NOX66 Suppository
79804707|NCT00708903|Other|Placebo|Placebo
79310272|NCT04655703|Device|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
79804708|NCT00708903|Drug|Moxifloxacin|
79474683|NCT01833481|Radiation|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
79474684|NCT00558025|Drug|Pramipexole Extended Release|
79310273|NCT05637255|Drug|SYL1801|1 drop in the eligible eye
79474685|NCT00558025|Drug|Pramipexole Immediate Release|
79474686|NCT04125251|Behavioral|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
79310274|NCT04692441|Dietary Supplement|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
79310275|NCT05530395|Diagnostic Test|Testosterone levels|Blood sample to determine testosterone levels
79474687|NCT01834027|Behavioral|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
79474688|NCT01834027|Behavioral|No music|In this group no music will be played in PACU
79474689|NCT02576249|Drug|Ropivacaine|4cc 0.5% ropivacaine
79474690|NCT02576249|Drug|Normal saline|4cc of sterile normal saline (0.9%)
79474691|NCT02576249|Drug|Methylprednisolone|1cc 40mg methylprednisolone
79474692|NCT03868657|Drug|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
79474693|NCT03868657|Drug|Placebo|Placebo
79968812|NCT05569083|Genetic|Genetic analysis of APOE and BDNF genes.|The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
79310276|NCT05407701|Dietary Supplement|Cranberry Juice|100% cranberry juice
79310277|NCT05407701|Dietary Supplement|Placebo|Placebo juice
79310278|NCT03191903|Combination Product|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
79310279|NCT03191903|Device|Monovisc|Hyaluronic acid
79310280|NCT03191903|Drug|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
79310281|NCT05530239|Other|Blood sample collection|Blood sample collection
79310282|NCT05530161|Other|hypocalcemia|hypocalcemia or normocalcemia
79474694|NCT01834261|Drug|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
79474695|NCT01834261|Drug|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
79474696|NCT05670925|Drug|Camrelizumab plus Famitinib with/without nab-Palitaxel|After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
79474697|NCT04707989|Other|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
79639446|NCT00146588|Drug|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
79639447|NCT05146843|Drug|Mitoquinone|Mitoquinone pill, 20 mg/day
79804709|NCT00619853|Behavioral|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
79804710|NCT00619853|Behavioral|treatment approach - HABIT|HABIT-2 months, 2Hr per day
79474698|NCT04707989|Other|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
79639448|NCT05146843|Other|Placebo|Placebo pill, 20 mg/day
79310283|NCT05534685|Other|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
79474699|NCT04707989|Other|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
79474700|NCT04707833|Diagnostic Test|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
79474701|NCT02578199|Behavioral|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
79474702|NCT02578745|Device|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
79474703|NCT02578745|Other|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
79639449|NCT00175032|Drug|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
79474704|NCT01834651|Drug|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
79474705|NCT00557323|Drug|Lanthanum carbonate|
79474706|NCT02578901|Drug|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
79639450|NCT00175032|Drug|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
79639451|NCT05139355|Combination Product|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
79639452|NCT00146627|Drug|Eflornithine|
79639453|NCT00146627|Drug|Nifurtimox|
79639454|NCT04691050|Procedure|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
79968813|NCT05569083|Diagnostic Test|EEG recording|The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
79968814|NCT05569083|Diagnostic Test|CSF collection and AD biomarker measurement|The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
79639455|NCT00175071|Behavioral|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
79310284|NCT05534685|Other|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
79310285|NCT05530083|Behavioral|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
79310286|NCT05530083|Behavioral|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
79639456|NCT02940418|Biological|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
79639457|NCT00146666|Device|Intermittent compression|
79474707|NCT02578901|Drug|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
79474708|NCT03832439|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
79474709|NCT03832439|Dietary Supplement|microcrystalline cellulose|Placebo
79474710|NCT02579057|Drug|Furosemide Injection Solution (SCP-101)|
79474711|NCT02579057|Drug|Furosemide Injection Solution, USP|
79474712|NCT00364325|Other|Acute Decompensated Heart Failure|Standard of Care
79474713|NCT02579135|Behavioral|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
79474714|NCT02579135|Behavioral|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
79474715|NCT00557245|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
79474716|NCT00557245|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
79474717|NCT00557245|Drug|Placebo|Placebo TDF & Placebo FTC/TDF, 1 tablet each daily.
79474718|NCT00364091|Drug|R89674 0.025% ophthalmic solution|
79474719|NCT03583541|Behavioral|HIV Risk Reduction|This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
79639458|NCT02940457|Device|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
79639459|NCT02940457|Device|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
79639460|NCT00169533|Drug|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
79639461|NCT00424229|Drug|LENALIDOMIDE|
79310287|NCT03191825|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
79639462|NCT00530725|Procedure|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
79804711|NCT00708981|Other|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
79804712|NCT00637091|Drug|Cetuximab, irinotecan|cetuximab, irinotecan
79310288|NCT03191825|Other|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
79310289|NCT03191825|Other|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
79639463|NCT00530725|Other|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
79804713|NCT04138784|Other|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
79639464|NCT00175110|Behavioral|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
79639465|NCT02944123|Drug|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
79804714|NCT04138784|Other|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
79804715|NCT00922857|Procedure|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
79804716|NCT04213391|Dietary Supplement|sulforaphane|Sulforaphane take 2550mg once a day.
79804717|NCT04213391|Dietary Supplement|Placebo|Placebo take 2550mg once a day.
79310290|NCT02437955|Other|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
79639466|NCT02944123|Drug|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
79310291|NCT02437955|Other|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
79310292|NCT02437955|Other|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
79310293|NCT02437955|Other|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
79639467|NCT02944123|Drug|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
79639468|NCT02944045|Drug|Methylprednisolone|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
79310294|NCT05530005|Other|Manual Therapy|Manual Therapy according to Kaltenborn Evjenth method. Exercises with PT resistance, massage.
79639469|NCT02944045|Drug|Placebo|saline serum
79639470|NCT00146705|Procedure|blood samples are taken once|
79804718|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
79804719|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
79804720|NCT00709137|Drug|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
79639471|NCT02944084|Dietary Supplement|Rice bran extract|
79639472|NCT02944084|Dietary Supplement|Porridge in water|
79639473|NCT02944084|Dietary Supplement|Porridge in milk|
79639474|NCT02943889|Biological|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
79639475|NCT00169572|Drug|Aprepitant|
79639476|NCT00169572|Drug|Ondansetron|
79639477|NCT00169572|Drug|GW679769|
79639478|NCT00169572|Drug|Dexamethasone|
79639479|NCT02943694|Device|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
79639480|NCT00146744|Biological|Mtb72F/AS02A|
79639481|NCT02943850|Biological|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
79639482|NCT02943850|Device|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
79639483|NCT02943967|Procedure|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
79639484|NCT02943967|Procedure|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
79639485|NCT00530881|Drug|PHX1149|
79639486|NCT00175149|Drug|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
79639487|NCT00530998|Procedure|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
79639488|NCT00530998|Procedure|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
79639489|NCT00146783|Drug|Sulphadoxine-pyrimethamine|
79639490|NCT00146783|Drug|Sulphadoxine-pyrimethamine, amodiaquine|
79639491|NCT00169611|Drug|methylphenidate|
79474720|NCT03583541|Behavioral|Financial Literacy|This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 & 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 & 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
79474721|NCT03583541|Behavioral|Mentorship|Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (e.g., referral and linkage, coaching, exchange visits to model farmers) from income-generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
79639492|NCT02943772|Other|Local hypothermia|Cooled brick
79804721|NCT00709137|Drug|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
79639493|NCT02943772|Other|Control|Control brick
79804722|NCT00617825|Other|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
79639494|NCT02943811|Device|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
79639495|NCT00146822|Device|ENDOTAK RELIANCE G lead|
79639496|NCT02943655|Drug|combined contraceptive pills (microcept)|oral combined contraceptive once daily
79639497|NCT02943655|Drug|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
79639498|NCT02943655|Drug|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
79639499|NCT00175188|Device|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
79639500|NCT00146861|Device|sensor programming|
79639501|NCT00175227|Drug|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
79639502|NCT00175227|Drug|intravenous saline hydration|500 mls half-normal saline
79639503|NCT02940262|Radiation|Gallium Ga 68 Gozetotide|Given IV
79639504|NCT02940262|Other|Laboratory Biomarker Analysis|Correlative studies
79639505|NCT02940262|Procedure|Positron Emission Tomography|Undergo PET imaging
79639506|NCT00146900|Procedure|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
79639507|NCT00146900|Procedure|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
79639508|NCT00146900|Drug|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
79639509|NCT00146900|Other|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
79804723|NCT04150406|Dietary Supplement|Flexofytol|Curcuma extract
79804724|NCT04150406|Other|Placebo|placebo
79310295|NCT03191435|Device|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
79310296|NCT03191435|Device|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
79310297|NCT03191591|Behavioral|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
79804725|NCT03659266|Other|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
79804726|NCT03659266|Other|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
79804727|NCT04150172|Drug|Rebamipide SR 150mg|Test drug
79804728|NCT04150172|Drug|Rebamipide IR 100mg|Reference Drug
79984394|NCT02448238|Other|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
79639510|NCT02940145|Other|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
79639511|NCT02940067|Other|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
79474722|NCT03583541|Behavioral|Matched savings individual development account|A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
79639512|NCT00169650|Other|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
79639513|NCT02940028|Behavioral|Expressive writing|Brief expressive writing intervention
79639514|NCT02940028|Behavioral|Control writing|Brief fact-based writing exercise.
79968815|NCT05569083|Diagnostic Test|Neuropsychological evaluation|"For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL)."
79310298|NCT02438033|Device|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
79310299|NCT02437799|Other|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
79639515|NCT02939482|Drug|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
79639516|NCT00405782|Behavioral|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
79639517|NCT02939521|Procedure|Surgery|
79639518|NCT00175266|Drug|alemtuzumab|
79639519|NCT00175266|Procedure|islet transplant|
79984395|NCT02448082|Other|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
79984396|NCT02448082|Other|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
79984397|NCT03205228|Drug|Omeprazole|A capsule of Omeprazole 20 mg & 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
79984398|NCT03205228|Behavioral|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
79984399|NCT03205228|Drug|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg & a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
79984400|NCT04568681|Device|Deep brain stimulation (DBS)|Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
79310300|NCT05534217|Biological|corneal debridement of corneal abrasion|Surgical debridement for traumatic corneal epithelial abrasions
79310301|NCT02437643|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
79310302|NCT02437643|Dietary Supplement|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
79804729|NCT02611245|Drug|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
79639520|NCT00175266|Drug|infliximab|
79804730|NCT02325011|Drug|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
79804731|NCT02325011|Drug|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
79984401|NCT03195946|Drug|Lu AF35700|tablets for oral use, 10 mg/day
79804732|NCT00690404|Drug|AZD2066|single oral dose
79984402|NCT03195946|Drug|Midazolam|syrup for oral use, 4mg/day
79310303|NCT02437643|Behavioral|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
79310304|NCT05534139|Diagnostic Test|7T MRI-scan|MRI-scanning of the brain using a 7T-MRI scanner
79310305|NCT05534139|Diagnostic Test|CSF collection via lumbar puncture|CSF is collected by doing a lumbar puncture
79474723|NCT04743011|Drug|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
79474724|NCT04743011|Drug|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
79474725|NCT03528941|Drug|Lamivudine|Patients who received lamivudine to prevent hepatitis B
79474726|NCT03528941|Other|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
79310306|NCT05534139|Diagnostic Test|Blood withdrawal|Blood is collected by doing a blood withdrawal
79310307|NCT05534139|Diagnostic Test|Clinical measures|UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
79474727|NCT02989363|Procedure|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
79474728|NCT02989363|Procedure|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
79310308|NCT02437721|Other|infant formula containing folic acid|
79310309|NCT02437721|Other|infant formula containing MTHF|
79310310|NCT02437565|Other|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
79474729|NCT02989363|Procedure|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
79474730|NCT02989363|Procedure|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
79474731|NCT00364403|Behavioral|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
79984403|NCT03195946|Drug|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
79310311|NCT02437565|Other|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
79310312|NCT05533983|Other|fecal microbiota transplantation with Nivolumab|This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
79310313|NCT02437019|Drug|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
79310314|NCT02436863|Procedure|Surgical performance|Two different surgical performances
79474732|NCT00364403|Behavioral|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
79639521|NCT02939443|Radiation|supine- and prone-position Computed Tomography|
79984404|NCT03205462|Drug|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
79984405|NCT03205462|Drug|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
79804733|NCT00620009|Behavioral|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
79804734|NCT02625584|Behavioral|Reading Together - Pausing for Reading|
79804735|NCT02625584|Behavioral|Reading Together - Dialogic Reading|
79310315|NCT05533905|Diagnostic Test|Lumbar puncture|A thin needle is inserted between the bones in the spine.
79310316|NCT05533905|Diagnostic Test|MRI|A scan of the head.
79310317|NCT05533827|Other|Kaleidoscope|Kaleidoscope
79310318|NCT05533827|Other|Music|Music
79310319|NCT05533827|Other|Virtual reality glasses|Virtual reality glasses
79474733|NCT01835743|Device|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
79804736|NCT02625584|Behavioral|Reading Together - Shared Reading Control|
79804737|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
79804738|NCT00577096|Behavioral|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
79804739|NCT00577096|Biological|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
79639522|NCT05013892|Radiation|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
79804740|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
79804741|NCT00577096|Drug|Thalidomide|Fifty percent of the participants received 400 mg daily
79804742|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
79804743|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
79804744|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
79984406|NCT03205462|Drug|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
79984407|NCT02448004|Drug|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
79984408|NCT02450422|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
79984409|NCT02450422|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
79984410|NCT03747029|Other|No intervention is provided|No intervention is provided
79984411|NCT02447770|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
79984412|NCT03118882|Behavioral|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
79804745|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
79474734|NCT01835743|Device|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
79474735|NCT02579915|Behavioral|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
79804746|NCT00577096|Drug|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
79804747|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
79474736|NCT02579915|Behavioral|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
79474737|NCT03580031|Drug|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
79474738|NCT03580031|Drug|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
79804748|NCT00577096|Drug|Thalidomide|Fifty percent of participants received 400 mg daily
79804749|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
79804750|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
79804751|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
79804752|NCT04211285|Diagnostic Test|e-GAB|android application for comprehensive geriatric assessment
79968816|NCT05569083|Diagnostic Test|Assessment of cognitive reserve, depression, personality traits and leisure activities|"In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS)."
79474739|NCT02581475|Procedure|Extending withdrawal time in the proximal colon|
79474740|NCT02581475|Procedure|Segmental examination twice of the proximal colon|
79639523|NCT05013892|Radiation|HA-WBRT (hippocampal avoidance whole brain radiation therapy)|Radiation
79639524|NCT05013892|Drug|Memantine|Capsule, taken orally
79639525|NCT02939248|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
79639526|NCT02939248|Drug|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
79474741|NCT03607357|Device|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
79639527|NCT00146978|Procedure|intra-arterial treatment|
79474742|NCT03607357|Device|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
79474743|NCT05665621|Other|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
79474744|NCT01836133|Drug|Erlotinib 150 mg|
79474745|NCT02989051|Other|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
79474746|NCT02989051|Other|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of >85% of normal fluid recommendations (for a healthy child).
79474747|NCT02581865|Drug|NBI-98854|
79474748|NCT02581865|Drug|Placebo|
79639528|NCT02939053|Device|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
79639529|NCT00169689|Procedure|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
79639530|NCT00169689|Other|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
79655590|NCT04555369|Genetic|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
79474749|NCT00365027|Procedure|Delayed embryo transfer|
79474750|NCT00365183|Drug|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
79474751|NCT00556075|Drug|Proellex 25 mg|1 capsule daily for 4 months
79474752|NCT00556075|Drug|Placebo|1 capsule daily for 4 months
79474753|NCT00556075|Drug|Proellex 50 mg|2 capsules daily for 4 months
79474754|NCT03441503|Other|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
79655591|NCT00261183|Drug|Melatonin|
79655592|NCT00235664|Procedure|Collection of stool and endotracheal aspirate samples|collection of samples
79804753|NCT04211285|Diagnostic Test|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
79804754|NCT02625506|Drug|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
79474755|NCT03376451|Other|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
79474756|NCT01837069|Drug|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
79968817|NCT05569083|Diagnostic Test|Clinical-neuropsychological follow-up|For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
79474757|NCT01837069|Drug|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
79474758|NCT01837069|Drug|Atorvastatin|80mg PO QD at preadmission testing
79474759|NCT01837069|Behavioral|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
79474760|NCT03323489|Radiation|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
79639531|NCT02938975|Other|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
79655593|NCT04555447|Dietary Supplement|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
79474761|NCT03193619|Device|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
79639532|NCT02938975|Other|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
79310320|NCT05533749|Device|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
79474762|NCT02289690|Drug|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
79474763|NCT02289690|Drug|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL*minute.
79474764|NCT02289690|Drug|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
79474765|NCT02289690|Drug|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
79474766|NCT02584673|Device|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
79474767|NCT02268955|Drug|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
79639533|NCT02938975|Other|Placebo lotion|A liposome lotion with no DEET
79639534|NCT02938975|Other|Army combat uniform|Army combat uniform with no permethrin
79639535|NCT00169455|Biological|Live attenuated human rotavirus vaccine|
79639536|NCT02939092|Drug|Pomegranates peel extract|Pomegranate is antimicrobial
79310321|NCT03189407|Dietary Supplement|Moringa oleifera tea|
79474768|NCT02268955|Drug|Saline|Saline will be administered to the placebo group
79474769|NCT02585843|Drug|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
79474770|NCT02585843|Drug|Spironolactone 25mg|25mg/day of spironolactone
79474771|NCT04350385|Other|Agility training|In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd & 6th week.
79474772|NCT04350385|Other|Conventional|In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd & 6th week
79474773|NCT02463305|Drug|Creatine monohydrate|21 grams creatine monohydrate total per day
79474774|NCT02463305|Other|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
79474775|NCT03032471|Other|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
79474776|NCT01838317|Drug|Pioglitazone|
79639537|NCT02939092|Drug|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
79655594|NCT04555447|Dietary Supplement|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
79655595|NCT00268632|Drug|risedronate|
79474777|NCT05249231|Drug|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
79474778|NCT05249231|Device|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
79474779|NCT05249153|Drug|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
79474780|NCT05249153|Drug|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
79474781|NCT05248685|Biological|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10^6 (±20%) to dose 2: 5×10^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10^5 (±20%)
79474782|NCT02961257|Drug|cabazitaxel|"Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~Standard cabazitaxel premedication will be used"
79474783|NCT02961257|Drug|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
79474784|NCT02961257|Drug|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
79474785|NCT02271217|Drug|Placebo|
79968818|NCT05569083|Diagnostic Test|ERP recording|For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
79474786|NCT02271217|Drug|dalfampridine-ER 7.5mg|
79474787|NCT02271217|Drug|dalfampridine-ER 10mg|
79474788|NCT02989519|Drug|dydrogesterone|
79474789|NCT02989519|Drug|Micronized progesterone|
79968819|NCT01160627|Other|Hydration|Saline hydration
79968820|NCT01160627|Drug|Acetylcysteine|Acetylcystein tablets for 2 days
79310322|NCT02437097|Other|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
79310323|NCT02437097|Other|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
79310324|NCT02437097|Other|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
79310325|NCT02437097|Other|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
79310326|NCT02436551|Other|Observation|
79310327|NCT02436629|Dietary Supplement|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
79310328|NCT02436629|Dietary Supplement|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
79310329|NCT02436785|Other|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
79474790|NCT02429375|Drug|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
79474791|NCT02289456|Drug|nab-Paclitaxel|
79474792|NCT02289456|Drug|Carboplatin|
79968821|NCT01160627|Drug|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
79968822|NCT01160627|Drug|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
79968823|NCT03985813|Behavioral|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
79968824|NCT02731690|Drug|Aceneuramic Acid Extended-Release|oral tablets
79968825|NCT03909581|Procedure|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
79310330|NCT02436785|Other|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
79310331|NCT02436473|Drug|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
79474793|NCT02588573|Device|etafilcon A (control)|contact lens
79474794|NCT02588573|Device|somofilcon A (test)|contact lens
79474795|NCT01838785|Drug|18F-DTBZ AV-133|
79474796|NCT02589977|Drug|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
79474797|NCT02274948|Drug|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
79474798|NCT02274948|Drug|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
79474799|NCT01838863|Biological|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
79474800|NCT01838863|Drug|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
79474801|NCT05248451|Other|Not an Interventional Study|Not an Interventional Study
79474802|NCT02274792|Drug|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
79968826|NCT03909581|Procedure|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator (50 participants)
79968827|NCT05568849|Diagnostic Test|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
79474803|NCT05248217|Behavioral|healthcare workers|healthcare
79968828|NCT05567211|Other|Free use of the virtual platform.|Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
79474804|NCT02591537|Device|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
79639538|NCT02938936|Other|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
79639539|NCT00175305|Drug|Sandostatin LAR|
79639540|NCT00147056|Device|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
79474805|NCT05649930|Other|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
79474806|NCT02592629|Drug|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
79474807|NCT02592629|Drug|ethyl chloride|topical spray
79474808|NCT02592629|Drug|Kenalog|used with lidocaine in shoulder injection
79474809|NCT05247983|Procedure|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
79310332|NCT02436473|Other|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
79310333|NCT02436473|Drug|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
79639541|NCT02938897|Behavioral|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
79310334|NCT02436473|Drug|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
79310335|NCT02436161|Behavioral|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
79310336|NCT05233553|Other|control of liver enzymes|follow-up with clinical and laboratory measurements
79310337|NCT02436395|Procedure|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
79310338|NCT02436395|Procedure|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
79310339|NCT02436317|Device|Point Of Care Ultrasound|Examination with an ultrasound machine
79310340|NCT02436083|Drug|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
79310341|NCT03189017|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
79310342|NCT03189017|Drug|Placebos|The placebo is a white, round, uncoated tablet.
79310343|NCT05599815|Drug|ADX-629|ADX-629 (250 milligrams) administered twice daily
79639542|NCT02938897|Behavioral|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
79639543|NCT02938897|Behavioral|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
79639544|NCT02938819|Other|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
79310344|NCT03189095|Behavioral|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
79310345|NCT03189251|Other|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
79310346|NCT05207631|Other|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
79310347|NCT03117647|Procedure|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
79639545|NCT02938819|Other|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
79310348|NCT03117335|Drug|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
79310349|NCT03117335|Drug|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
79639546|NCT02938741|Drug|Anti-human Thymoglobulin|r-ATG 2.5MG/KG*4days were used in the conditioning
79639547|NCT02938741|Drug|Placebo|r-ATG 2.5MG/KG*4days were not used in the conditioning
79474810|NCT05372471|Other|mHealth|ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
79474811|NCT05372471|Other|Usual Care|They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
79474812|NCT02274558|Drug|NBI-98854|NBI-98854 40 mg capsules
79474813|NCT02274558|Drug|Placebo|NBI-98854 placebo capsules
79474814|NCT05247749|Device|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
79968829|NCT05567211|Other|Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
79968830|NCT05567211|Other|Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
79474815|NCT05247671|Genetic|ERCC1|ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
79474816|NCT05247671|Genetic|OCT2|OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
79474817|NCT05247515|Device|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
79474818|NCT00311909|Device|Thalamic deep brain stimulation|
79474819|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
79968831|NCT01252979|Dietary Supplement|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
79474820|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
79474821|NCT00284063|Procedure|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
79474822|NCT02595983|Drug|Revusiran|500mg Revusiran by subcutaneous (sc) injection
79968832|NCT04446208|Procedure|Endoscopy|Endoscopic treatment will consist in placement of a metal stent in a patient with early fistula (< 15 days) and/or a large fistula orifice, and no abscess, or double pigtail plastic stents if the fistula is older than 15 days and the orifice is small.
79968833|NCT04075513|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
79474823|NCT02287896|Drug|ROLEDUMAB|See Arm description
79474824|NCT02596451|Drug|Diclofenac Sodium gel, 1%|
79474825|NCT02596451|Drug|Voltaren® Gel|
79474826|NCT02596451|Drug|Placebo|
79968834|NCT04075513|Drug|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
79310350|NCT05533515|Diagnostic Test|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
79474827|NCT01839799|Drug|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
79474828|NCT01839799|Drug|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
79474829|NCT01839799|Drug|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
79310351|NCT05533437|Device|dry needling|the dry needle inserted to area of pain
79310352|NCT05533437|Other|kinesio taping|kinesio taping
79474830|NCT01839799|Radiation|Chemoradiation|
79474831|NCT03062059|Drug|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
79474832|NCT03062059|Other|Normal saline|Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
79474833|NCT02597543|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
79474834|NCT02597543|Drug|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
79474835|NCT02597543|Procedure|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
79474836|NCT00364169|Procedure|Degree of constipation|
79474837|NCT02598089|Biological|Trivalent Seasonal Influenza Vaccine|
79474838|NCT02598089|Other|Placebo|0.5 mL of phosphate buffered saline
79474839|NCT05371769|Other|chronic pain management education program|The chronic pain management training program will be applied for 2 weeks. The training consists of 15 videos about theory and practice topics in chronic pain management. There are evaluation questions at the end of each video.
79474840|NCT05371769|Other|No intervention|No intervention will be made.
79474841|NCT00553501|Biological|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, & 36: 360mg/sq m IV
79968835|NCT04075513|Drug|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
79968836|NCT03874871|Procedure|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
79968837|NCT03874871|Procedure|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
79968838|NCT04619823|Other|Blood sample collection|Blood sample collection Mosquito collection at home
79968839|NCT03388996|Diagnostic Test|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
79968840|NCT03877523|Dietary Supplement|Cocarnit|a metabolic complex
79474842|NCT00553501|Biological|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, & 36: 375mg/sq m IV
79968841|NCT01313715|Biological|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
79310353|NCT02435927|Drug|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
79310354|NCT02435927|Drug|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
79310355|NCT02435771|Drug|Ergocalciferols|Treatment 1- 400,000 IU
79474843|NCT02599649|Drug|Lirilumab|3 mg/kg by vein every 4 weeks.
79310356|NCT02435771|Drug|Ergocalciferols|Treatment 2- 800,000 IU
79310357|NCT02435693|Other|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
79310358|NCT02435693|Other|Without PHARMACEUTICAL CARE programe|
79310359|NCT02440607|Other|Electronic Cognitive Aid|
79310360|NCT02440607|Other|Static Cognitive Aid|
79474844|NCT02599649|Drug|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
79968842|NCT01313715|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
79968843|NCT01313715|Biological|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
79968844|NCT01313715|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
79968845|NCT03388918|Device|Telerehabilitation|Blood pressure (A&D Medical UA 767PBT), weight (A&D Medical UC-321PBT), step counters(Fitbit Zip & Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) & transmitter (Qualcomm Life, QWH-HUB-V1.0E)
79310361|NCT02440841|Drug|fedovapagon|
79310362|NCT02440841|Drug|Itraconazole|
79310363|NCT02440841|Drug|rifampicin|
79474845|NCT02599649|Drug|Azacitidine|75 mg/m^2 by vein for 7 days of a 28 day cycle.
79968846|NCT03877679|Drug|Triamcinolone|Triamcenolone +napolycarboxylate
79968847|NCT03877679|Drug|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
79968848|NCT03330249|Drug|Split Cisplatin|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
79968849|NCT03330249|Drug|Cisplatin|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
79474846|NCT01840345|Drug|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
79474847|NCT02287584|Drug|DSP-5423P Placebo|DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
79474848|NCT02287584|Drug|DSP-5423P 40mg|DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
79474849|NCT02287584|Drug|DSP-5423P 80mg|DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
79474850|NCT02287584|Drug|DSP-5423P Placebo-to-Flex|"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
79639548|NCT00407589|Drug|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
79474851|NCT02287584|Drug|DSP-5423P Active-to-Flex|"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
79310364|NCT02435615|Device|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
79310365|NCT02576145|Biological|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
79474852|NCT05654909|Procedure|Prehospital assessment unit|The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
79474853|NCT00364481|Drug|omeprazole|
79474854|NCT00364481|Behavioral|Tongue exercises|
79639549|NCT02938546|Radiation|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
79474855|NCT04741529|Behavioral|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
79474856|NCT01841047|Radiation|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
79968850|NCT03330249|Radiation|Radiotherapy|70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
79968851|NCT04652206|Drug|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
79804755|NCT02625506|Drug|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
79310366|NCT02576145|Drug|Daclizumab|The fifth dose (1 milligram per kilogram [mg/kg]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
79310367|NCT02576145|Biological|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
79804756|NCT00620399|Other|lumbar corset|
79310368|NCT02435537|Drug|Dexmedetomidine (Precedex)|intrathecal administration
79310369|NCT02435537|Drug|Bupivacaine|intrathecal 10 mg bupivacaine
79310370|NCT02435537|Drug|Morphine|intrathecal 0.5mg morphine
79310371|NCT02440685|Drug|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
79310372|NCT02440685|Drug|ASN002 RD|Recommended dose of ASN002 from Part A
79310373|NCT03191513|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
79310374|NCT03191513|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
79310375|NCT03191513|Dietary Supplement|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
79474857|NCT02601833|Device|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
79474858|NCT02601833|Procedure|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
79474859|NCT00553267|Drug|fixed dose combination of telmisartan+amlodipine|
79474860|NCT00553267|Drug|amlodipine|
79310376|NCT02576067|Drug|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
79310377|NCT02576067|Drug|Placebo|
79310378|NCT02435459|Procedure|No lining|No lining material placed under amalgam dental restorations
79310379|NCT02435459|Procedure|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
79310380|NCT02435459|Procedure|RMGI cement|placement of lining material under amalgam dental restorations
79310381|NCT02435459|Procedure|Resin Bonding Agent|placement of lining material under amalgam dental restorations
79310382|NCT05199909|Drug|zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
79310383|NCT02435303|Drug|Sildenafil|
79310384|NCT02435303|Drug|Placebo|
79310385|NCT05529615|Procedure|detection of ctDNA|the ctDNA will be detected during the treatment and served as the andomization basis
79474861|NCT02602223|Device|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
79968852|NCT04652206|Drug|Gemcitabine|Used according to marketing authorisation
79310386|NCT02435225|Behavioral|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
79310387|NCT05533047|Procedure|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
79310388|NCT02434991|Device|Barostat|"During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~A urine pregnancy test for females of childbearing years.~Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~At this point healthy controls have completed the study.~Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~Patients will be contacted to complete a phone survey 3 & 6 months and 2 & 4 years after treatment."
79310389|NCT05363787|Other|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
79639550|NCT00175344|Procedure|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
79639551|NCT00147134|Procedure|open colectomy|Procedure/Surgery: open colectomy
79310390|NCT02434835|Drug|[14C]KWA-0711|
79310391|NCT02434913|Device|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
79310392|NCT02575911|Device|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
79310393|NCT02575911|Procedure|LASIK surgery|
79639552|NCT00147134|Procedure|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
79639553|NCT04891393|Dietary Supplement|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
79639554|NCT04891393|Dietary Supplement|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
79968853|NCT04652206|Drug|Nab paclitaxel|Used according to marketing authorisation
79639555|NCT03458065|Device|ICD|Implantable Cardioverter Defibrillator
79639556|NCT02938663|Behavioral|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
79639557|NCT00147329|Drug|MM-093|
79639558|NCT02938780|Other|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
79968854|NCT01269281|Drug|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
79984413|NCT03118882|Behavioral|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
79639559|NCT02938780|Other|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
79639560|NCT04690543|Procedure|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
79310394|NCT02434757|Drug|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
79310395|NCT03189329|Drug|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
79310396|NCT03189329|Drug|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
79639561|NCT04690543|Procedure|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
79310397|NCT03188939|Procedure|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
79639562|NCT00175383|Drug|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
79639563|NCT02938468|Drug|Dexamethasone|
79639564|NCT02938468|Procedure|Any surgical intervention aim at treating chronic subdural hematoma|
79968855|NCT03385018|Procedure|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~The number of trocars is 6 or less~Roux-en-Y esophagojejunostomy with any stapling method~Enough(negative) margin from tumor~LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~Washing cytology~Frozen biopsy for surgical margin at surgeons discretion~Complete omentectomy for grossly serosa-involved tumor~Combined organ resection only in cholecystectomy and splenectomy~Indwelling nasogastric tube and drainage catheter at surgeons discretion~D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
79639565|NCT02938507|Drug|Formulation 1 solabegron|
79639566|NCT02938507|Drug|Formulation 2 solabegron|
79639567|NCT02938429|Other|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
79639568|NCT00147368|Drug|intravenous (IV) arginine|
79639569|NCT00407667|Device|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
79639570|NCT02938390|Procedure|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
79639571|NCT02938312|Behavioral|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
79984414|NCT03118882|Behavioral|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
79984415|NCT03205384|Procedure|surgery|
79984416|NCT03204994|Drug|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
79984417|NCT03118648|Diagnostic Test|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
79984418|NCT03204760|Drug|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
79310398|NCT03188939|Procedure|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
79310399|NCT03188939|Procedure|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
79310400|NCT02575833|Drug|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
79310401|NCT02575833|Drug|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
79310402|NCT03188783|Drug|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
79474862|NCT02602223|Device|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
79310403|NCT03188783|Drug|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
79310404|NCT05532969|Other|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
79310405|NCT02709083|Drug|Dasatinib|Given orally
79639572|NCT02938312|Behavioral|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
79984419|NCT03204760|Drug|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
79474863|NCT00365963|Device|Comprehensive Health Enhancement Support System|computer based support and education
79474864|NCT00364559|Drug|Rosuvastatin|20 mg 10 days daily
79474865|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
79310406|NCT02709083|Drug|Imatinib Mesylate|Given orally
79310407|NCT02709083|Drug|Nilotinib|Given orally
79310408|NCT02709005|Drug|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
79310409|NCT02709005|Other|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
79474866|NCT02271984|Drug|Cysticide|Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
79474867|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
79474868|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
79655596|NCT04554979|Drug|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
79655597|NCT00235703|Device|Antimicrobial Prescribing Decision Support|
79984420|NCT03200470|Other|No intervention: sample collection study|Sample collection and collection of laboratory values
79984421|NCT03200392|Device|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
79984422|NCT03200392|Device|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
79984423|NCT03200392|Procedure|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
79984424|NCT03204838|Genetic|IDH mutation test performed at diagnosis|Observation of the test result
79474869|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
79474870|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
79474871|NCT03833011|Procedure|Osteopathic Manipulation|Osteopathic manipulation
79968856|NCT03385018|Procedure|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~Roux-en-Y esophagojejunostomy with any stapling method~Enough(negative) margin from tumor~LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~Washing cytology~Frozen biopsy for surgical margin at surgeons discretion~Complete omentectomy for grossly serosa-involved tumor~Indwelling nasogastric tube and drainage catheter at surgeons discretion~D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
79474872|NCT00366041|Drug|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
79474873|NCT00366041|Device|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
79310410|NCT03188315|Genetic|HPV oncogenes|PCR and oncogenes detection
79968857|NCT04073407|Dietary Supplement|AXA1957|Amino acids, food study
79968858|NCT04073407|Dietary Supplement|Placebo|placebo
79310411|NCT03188471|Drug|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
79474874|NCT05371535|Device|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
79310412|NCT03188471|Drug|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
79474875|NCT02604173|Drug|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
79474876|NCT02604173|Drug|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
79474877|NCT02604173|Drug|Placebo|Placebo pill and sham inhaler
79639573|NCT02938351|Behavioral|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
79639574|NCT00169728|Biological|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
79310413|NCT03188549|Other|AniosGel 85 NPC|Hand hygiene formula
79310414|NCT03188549|Other|Softa-Man (Braun)|Hand hygiene formula
79310415|NCT03188549|Other|Septol|alcohol-based hand rub
79310416|NCT05528679|Drug|610 100mg|100mg administered subcutaneously Q4W
79639575|NCT00169728|Biological|heptavalent pneumococcal conjugate vaccine, Prevenar|
79474878|NCT01841281|Drug|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
79310417|NCT05528679|Drug|610 300mg|300mg administered subcutaneously Q4W
79310418|NCT05528679|Drug|placebo|administered subcutaneously Q4W
79474879|NCT01841281|Drug|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
79474880|NCT02287038|Drug|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
79310419|NCT02434601|Procedure|Treatment of Dentin Surface|"Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
79474881|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
79474882|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
79474883|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
79474884|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
79310420|NCT02434601|Procedure|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
79310421|NCT02434601|Procedure|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
79474885|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
79474886|NCT02815033|Drug|Enzalutamide|
79474887|NCT02815033|Procedure|11C or 18F-Choline PET/CT|
79474888|NCT02815033|Procedure|Whole body MRI|
79474889|NCT02815033|Procedure|Bone scan|
79474890|NCT04340687|Device|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
79310422|NCT04650087|Drug|Apixaban 2.5 MG|Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
79310423|NCT04650087|Drug|Placebo|Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
79474891|NCT02286960|Drug|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
79474892|NCT02286960|Dietary Supplement|Lactose Pills|4 day course 2 x 20mg per da
79474893|NCT01842061|Behavioral|Active Living Program|
79474894|NCT01842061|Behavioral|Education|
79474895|NCT00365495|Procedure|Physical training (aerobic training)|
79474896|NCT05371379|Biological|CM338 Injection|A humanized monoclonal antibody.
79474897|NCT02286102|Device|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
79474898|NCT02286102|Device|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
79474899|NCT00366119|Drug|Ramipril|
79474900|NCT05371301|Drug|Paclitaxel, Carboplatin|Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
79474901|NCT05371301|Procedure|debulking surgery|"Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver"
79474902|NCT02285166|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
79474903|NCT02285166|Drug|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
79474904|NCT01842841|Drug|velaglucerase alfa|15-60 U/kg, EOW
79474905|NCT02605187|Other|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
79474906|NCT02605187|Other|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
79474907|NCT02605187|Drug|Ibuprofen|Ibuprofen 600mg po q6h
79474908|NCT02605187|Drug|Acetaminophen|Acetaminophen 650mg po q6h
79474909|NCT02605187|Drug|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
79474910|NCT02605187|Drug|Morphine (low)|Intrathecal morphine dose 50mcg
79474911|NCT02605187|Drug|Morphine (med)|Intrathecal morphine dose 150mcg
79968859|NCT02778204|Drug|Maraviroc|8 mg/kg oral solution as a single dose.
79968860|NCT02778204|Drug|Maraviroc|8 mg/kg oral solution given twice daily.
79968861|NCT03874403|Procedure|DSA|The changes on DSA on NIVATS and VATS
79968862|NCT01160705|Drug|docetaxel|
79968863|NCT01160705|Genetic|RNA analysis|
79968864|NCT01160705|Genetic|reverse transcriptase-polymerase chain reaction|
79968865|NCT01160705|Other|circulating tumor cell analysis|
79968866|NCT01160705|Other|laboratory biomarker analysis|
79968867|NCT04578028|Drug|ONO-2808|Investigational drug
79968868|NCT04578028|Drug|Placebo|Placebo drug
79968869|NCT04072159|Behavioral|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
79968870|NCT03232281|Drug|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
79968871|NCT03232281|Drug|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
79968872|NCT04572126|Behavioral|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
79968873|NCT04572126|Behavioral|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
79968874|NCT04071301|Device|TENA SmartCare Change Indicator|"Each participating subject will be provided with a Change Indicator and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration."
79968875|NCT03261336|Drug|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
79310424|NCT02434367|Behavioral|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
79310425|NCT02434289|Dietary Supplement|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
79310426|NCT02434289|Other|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
79474912|NCT02605187|Drug|Morphine (high)|Intrathecal morphine 300mcg
79474913|NCT05371067|Other|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
79474914|NCT02606903|Drug|BI 695501 prefilled syringe|
79474915|NCT02606903|Drug|BI 695501 autoinjector|
79474916|NCT04350619|Other|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
79474917|NCT05592197|Drug|Lenvatinib|Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients < 60 kg, and 12 mg qd for patients ≥ 60 kg)
79474918|NCT05592197|Procedure|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
79968876|NCT03388840|Biological|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
79968877|NCT03388840|Biological|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
79968878|NCT03745417|Biological|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
79968879|NCT01269359|Procedure|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
79968880|NCT03960255|Other|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
79968881|NCT03384862|Dietary Supplement|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
79310427|NCT02434211|Other|Questionnaire and focus group|
79474919|NCT05592197|Radiation|External beam radiation (RT)|RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
79310428|NCT03188159|Drug|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
79310429|NCT05528601|Behavioral|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
79310430|NCT05532579|Other|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
79310431|NCT05532579|Other|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
79310432|NCT03191669|Other|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
79310433|NCT05532501|Drug|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
79310434|NCT05532501|Drug|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
79310435|NCT05532501|Drug|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
79474920|NCT02989207|Procedure|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
79474921|NCT02989207|Device|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
79310436|NCT05532501|Drug|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
79968882|NCT03384862|Dietary Supplement|Placebo|Placebo pills, with same appearance as intervention pills.
79474922|NCT02989207|Drug|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
79968883|NCT03384862|Dietary Supplement|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
79968884|NCT03909191|Diagnostic Test|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
79968885|NCT05513235|Other|Digital personal health record|The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
79968886|NCT01269437|Drug|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
79968887|NCT03636867|Other|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
79968888|NCT03909269|Device|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
79968889|NCT03909269|Diagnostic Test|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
79968890|NCT03909269|Radiation|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
79968891|NCT03909269|Device|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
79968892|NCT00462748|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
79968893|NCT00462748|Drug|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
79968894|NCT00462748|Drug|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
79968895|NCT03948789|Procedure|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
79310437|NCT03188237|Behavioral|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
79310438|NCT05524857|Drug|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
79310439|NCT05524857|Drug|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
79474923|NCT05591729|Other|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
79310440|NCT05524857|Drug|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
79310441|NCT05524779|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
79655598|NCT04555057|Procedure|Music therapy|Music selected according to the patient's individual preferences.
79310442|NCT03191357|Other|n/a observational|Observational study
79310443|NCT05528523|Other|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
79310444|NCT03188003|Other|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
79310445|NCT03188003|Other|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
79474924|NCT05591729|Other|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
79968896|NCT03948789|Procedure|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
79968897|NCT04206085|Device|Viveve - Active|Radiofrequency and Cryogen-Cooling
79968898|NCT04206085|Device|Viveve - Cryogen-Alone|Cryogen-Cooling
79968899|NCT04206085|Device|Viveve - Sham|Sham
79968900|NCT01160939|Other|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
79310446|NCT05528445|Device|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
79310447|NCT02440529|Behavioral|Intervention|Discussion
79310448|NCT02440529|Behavioral|Verbal Group|Detailed Discussion
79804757|NCT04209959|Drug|nifekalant|Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
79804758|NCT04209647|Other|REHIT Exercise|"-Start with warm-up period --> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~15 seconds exercise period: %100 of maximum work rate~15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
79804759|NCT04209647|Other|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
79804760|NCT02565472|Other|White grape juice|
79804761|NCT02565472|Other|Apple juice|
79804762|NCT04209803|Drug|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
79804763|NCT02567032|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
79310449|NCT05524701|Behavioral|Sleep Restriction and Normal Sleep|The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.
79310450|NCT02434133|Procedure|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
79310451|NCT03191045|Diagnostic Test|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
79310452|NCT05327439|Other|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
79474925|NCT04340219|Other|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
79310453|NCT05327439|Other|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
79655599|NCT00261222|Drug|Amodiaquine|
79655600|NCT04554628|Diagnostic Test|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
79655601|NCT00235781|Drug|Thymoglobulin|
79655602|NCT04554823|Behavioral|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
79655603|NCT04554823|Behavioral|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
79655604|NCT04554589|Drug|Glycopyrrolate 0.2 MG|injections
79655605|NCT04554589|Drug|normal saline|normal saline
79655606|NCT00268671|Drug|Docetaxel|
79804764|NCT02567032|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
79804765|NCT00618059|Drug|Pilocarpine|
79804766|NCT04701047|Device|vaginal pessary|insertion and follow up of a vaginal pessary
79804767|NCT04701047|Procedure|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
79474926|NCT02409589|Device|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
79310454|NCT03187847|Device|Actigraph GT3X|"The primary outcomes are measured by the Actigraph GT3X (step counts) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).~The secondary outcomes are emotional status, measured by the hospital anxiety and depression scale (HADS) and quality of life, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS)."
79310455|NCT05528367|Drug|Nab-PTX,S-1,Tirelizumab|"S-1:BSA <=1.25 m2 ,80 mg daily; 1.25 m2 <BSA <1.5 m2,100 mg daily; BSA>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
79310456|NCT05528367|Radiation|Chemoradiation|45-50Gy/25F
79804768|NCT05118334|Drug|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
79310457|NCT03191279|Procedure|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
79310458|NCT05528289|Device|AIRVO 2, with conventional symmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 30 L/min with the standard cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 91 and 94%."
79310459|NCT05528289|Device|AIRVO 2, the new asymmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 30 L/min with the new asymmetric nasal cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 91 and 94%."
79310460|NCT02433821|Other|Pilates|
79804769|NCT05118334|Drug|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
79804770|NCT00863304|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
79804771|NCT00863304|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
79804772|NCT00863304|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
79804773|NCT00863304|Other|placebo|placebo to match tanezumab and naproxen dosing
79804774|NCT04210973|Drug|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
79804775|NCT04210973|Drug|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
79804776|NCT00695110|Drug|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
79804777|NCT00695110|Drug|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
79310461|NCT03187691|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
79310462|NCT02433899|Procedure|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
79310463|NCT02433899|Procedure|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
79310464|NCT02433899|Drug|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
79310465|NCT02433899|Drug|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
79310466|NCT02433899|Drug|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
79310467|NCT03191123|Procedure|hepatic resection|The aim of this intervention is to reach curative resection.
79968901|NCT01161017|Drug|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
79310468|NCT03191123|Procedure|TACE|The aim of this intervention is one of the palliative treatment.
79310469|NCT05184855|Dietary Supplement|Blueberry|Blueberry powder intake
79310470|NCT05184855|Dietary Supplement|Placebo|Placebo powder intake
79310471|NCT05532267|Drug|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
79310472|NCT05532267|Drug|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
79310473|NCT03191201|Drug|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
79310474|NCT03191201|Drug|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
79310475|NCT02434055|Device|AVERT PLUS|
79310476|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
79804778|NCT00695110|Drug|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
79968902|NCT01161017|Drug|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
79968903|NCT03874559|Diagnostic Test|Blood Draw|Serum samples will be obtained from each patient enrolled
79968904|NCT04202497|Drug|TAK-418|TAK-418 orally.
79310477|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
79968905|NCT04202497|Drug|[18F]MNI-1054 (radiotracer)|[18F]MNI-1054 injection.
79310478|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
79474927|NCT02409589|Procedure|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
79474928|NCT01843465|Other|Maneuvers for documenting the disconnection|
79474929|NCT01843621|Biological|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
79804779|NCT00695110|Drug|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
79968906|NCT03935685|Drug|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
79968907|NCT01164917|Drug|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
79968908|NCT01164917|Drug|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
79968909|NCT03297294|Drug|EMA401|capsules, oral
79968910|NCT03297294|Drug|Placebo|Placebo to EMA401 capsules, oral
79474930|NCT02608229|Drug|BVD-523|
79474931|NCT02608229|Drug|Nab-paclitaxel|
79474932|NCT02608229|Drug|Gemcitabine|
79474933|NCT02608229|Procedure|Tumor biopsy|
79474934|NCT00555061|Drug|Retapamulin Ointment, 1%|1% Ointment
79968911|NCT03874637|Device|Treament|Placement of the FemPulse System with therapy delivery
79968912|NCT03874637|Device|Sham Control|Placement of the FemPulse System without therapy delivery
79968913|NCT01161095|Device|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
79474935|NCT01844479|Device|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
79639576|NCT04823455|Procedure|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
79968914|NCT03238911|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
79310479|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
79310480|NCT03187457|Other|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
79310481|NCT03187457|Other|Control: no treatment|Healthy women without Bacterial Vaginosis
79474936|NCT01844479|Other|Standard innersole|
79639577|NCT02938195|Radiation|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
79639578|NCT02938195|Procedure|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
79639579|NCT00147524|Drug|quinapril|
79639580|NCT00147524|Procedure|Laser Doppler imaging|
79639581|NCT00175422|Behavioral|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
79310482|NCT05524155|Drug|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
79310483|NCT05524155|Drug|Sintilimab|200mg IV d1,Q3W
79968915|NCT03238911|Drug|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
79310484|NCT05524155|Drug|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
79310485|NCT03187223|Drug|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
79310486|NCT03187223|Drug|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
79639582|NCT04773106|Device|ARGOS-SC suprachoroidal pressure sensor|The ARGOS-SC pressure sensor was additionally used implanted during routine local intraocular pressure lowering procedures in patients in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
79639583|NCT00147563|Drug|Eplerenone|
79310487|NCT05184075|Procedure|Standard hybrid coronary revascularization|Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
79639584|NCT03457870|Behavioral|Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet.
79639585|NCT03457870|Behavioral|Chewing|Asked to chew 1 piece of gum for 10 minutes 3 times a day.
79474937|NCT01642212|Drug|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
79639586|NCT03457870|Behavioral|Chewing + Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
79804780|NCT04211051|Device|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
79474938|NCT01642212|Drug|Placebo|
79968916|NCT03909113|Dietary Supplement|amino acid based formula|amino acid based formula
79474939|NCT02608463|Behavioral|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
79474940|NCT02608463|Behavioral|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
79639587|NCT00175461|Procedure|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
79639588|NCT02938273|Drug|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
79804781|NCT04213313|Drug|Treatment of bacterial keratitis|0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
79804782|NCT04213313|Drug|Treatment of fungal keratitis|1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
79804783|NCT04213313|Drug|Treatment of viral keratitis|0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
79804784|NCT04213313|Diagnostic Test|corneal scraping|culture and sensitivity of corneal ulcerated infiltrating edge tissue
79968917|NCT01269515|Drug|Etoricoxib|90 mg QD
79968918|NCT00418834|Drug|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
79968919|NCT00418834|Drug|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
79968920|NCT00418834|Drug|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
79968921|NCT03908957|Drug|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
79968922|NCT03908801|Behavioral|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
79968923|NCT01267331|Procedure|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
79968924|NCT01267331|Procedure|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
79968925|NCT01269671|Drug|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
79968926|NCT01269671|Other|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
79474941|NCT02608463|Behavioral|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, & recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), & verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
79804785|NCT04213313|Other|Sequencing|polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
79968927|NCT04407286|Dietary Supplement|Vitamin D3|Oral vitamin D3 capsules
79968928|NCT03276975|Drug|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
79968929|NCT03380416|Other|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
79639589|NCT02938273|Radiation|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
79639590|NCT02938273|Drug|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
79639591|NCT02941939|Other|Hyperbaric chamber|
79968930|NCT03380416|Other|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
79639592|NCT02941939|Other|Ambient pressure|
79968931|NCT01267409|Other|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
79474942|NCT02608463|Behavioral|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock & Erbaugh, 1961).
79639593|NCT02941861|Other|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
79639594|NCT02941861|Other|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
79639595|NCT00147602|Drug|atorvastatin|
79639596|NCT00169767|Other|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
79804786|NCT04187963|Other|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
79639597|NCT02941588|Procedure|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
79968932|NCT03125746|Drug|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
79968933|NCT03125746|Drug|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
79968934|NCT03877601|Drug|Bevacizumab-IRDye800CW|Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
79639598|NCT02941744|Drug|nivolumab|low fixed dose ipilimumab in combination with nivolumab
79639599|NCT02941744|Drug|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
79639600|NCT02941822|Drug|Ambroxol|Details outlines in the intervention description.
79639601|NCT02941471|Device|Interferential Stimulation|Transabdominal interferential electrcial stimulation
79639602|NCT02941471|Device|TENS stimulation|Transabdominal standard electrical stimulation
79968935|NCT03877601|Diagnostic Test|Fluorescence endoscopy|Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
79310488|NCT05184075|Procedure|Reverse hybrid coronary revascularization|Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
79474943|NCT02608463|Behavioral|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
79474944|NCT02608463|Behavioral|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
79639603|NCT02941510|Drug|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
79804787|NCT00742534|Drug|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
79804788|NCT04210817|Other|No Intervention|There is no intervention for this study
79804789|NCT03264352|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
79968936|NCT03380338|Behavioral|Combined aerobic and strength exercise|
79968937|NCT03297216|Drug|17P|Synthetic progestin
79804790|NCT03264352|Drug|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
79968938|NCT03297216|Other|Placebo|Non-active placebo comparator
79968939|NCT03388684|Procedure|Conjoined twin separation surgery|This study included 4 case reports on conjoined twins (CT), 2 male and three female patients; 3 of them were parasitic and one was conjoined. We operated upon 2 parasitic and one conjoined. The 1st case died preoperatively.
79984425|NCT03204682|Device|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
79984426|NCT04484662|Other|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
79984427|NCT03195556|Device|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
79310489|NCT05532111|Drug|Rituximab combined with tacrolimus induction + rituximab maintenance|RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.
79639604|NCT02941510|Other|Placebo|Subject(s) will participate in all study activities but will receive placebo.
79639605|NCT00147680|Drug|Paclitaxel, Carboplatin|
79639606|NCT05037877|Dietary Supplement|HUM supplement|HUM supplement - 1 capsule per day
79639607|NCT05037877|Dietary Supplement|Placebo|Placebo supplement - 1 capsule per day
79474945|NCT02608463|Device|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
79474946|NCT05649618|Biological|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
79968940|NCT03908645|Device|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
79474947|NCT05649618|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
79474948|NCT05649618|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
79474949|NCT05649618|Drug|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
79474950|NCT00552175|Drug|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
79474951|NCT00552175|Drug|placebo|placebo taken orally every day
79474952|NCT00552175|Drug|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
79639608|NCT02940184|Drug|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
79639609|NCT02940184|Other|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
79474953|NCT05357183|Drug|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
79474954|NCT05649384|Diagnostic Test|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
79639610|NCT03458377|Other|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
79639611|NCT03458143|Drug|Ketamine 150 ng/ml|conscious sedation in TCI-mode
79639612|NCT03458143|Drug|Remifentanil|conscious sedation in TCI-mode
79474955|NCT05649384|Diagnostic Test|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
79474956|NCT04741763|Dietary Supplement|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
79474957|NCT04743089|Device|ERCP using SpyGlass™ DS Direct Visualization System|Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
79474958|NCT04743089|Other|PTCS|A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
79639613|NCT03458143|Procedure|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
79639614|NCT03458143|Drug|Ketamine 200 ng/ml|conscious sedation in TCI-mode
79639615|NCT00147485|Drug|AG-024322|
79639616|NCT00175500|Device|Large Diameter Femoral Head|
79984428|NCT03204604|Dietary Supplement|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
79984429|NCT03204604|Dietary Supplement|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
79474959|NCT02974205|Procedure|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
79474960|NCT02974205|Device|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
79639617|NCT02939911|Device|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
79639618|NCT02941354|Drug|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
79639619|NCT04723992|Other|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
79804791|NCT03264352|Other|Standard treatment by current guideline|No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
79804792|NCT04897919|Drug|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
79804793|NCT04897919|Drug|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
79804794|NCT00921544|Other|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
79804795|NCT00921544|Other|Sterile water|Sterile water administered 2 mins prior to eye exam
79968941|NCT03908645|Device|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
79804796|NCT04060732|Device|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
79968942|NCT03125668|Behavioral|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
79968943|NCT03125668|Behavioral|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
79968944|NCT03125668|Behavioral|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
79968945|NCT01165073|Dietary Supplement|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
79968946|NCT01165073|Dietary Supplement|Normal oral intake & supplementation if necessary|Enteral nutrition
79968947|NCT03872219|Combination Product|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
79968948|NCT05174104|Procedure|Vestibular Rehabilitation|The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
79968949|NCT01165151|Behavioral|behavioral weight loss program|weekly, group-based lifestyle weight loss program
79968950|NCT03388528|Dietary Supplement|Low Residue Diet Intervention|All patients will be provided with a LRD plan (< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
79968951|NCT03260868|Drug|Insulin glargine, 300 units per milliliter (U/mL)|Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
79968952|NCT03260868|Drug|Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)|Subcutaneous injection.
79968953|NCT01165385|Drug|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
79804797|NCT00594386|Drug|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
79968954|NCT01165385|Drug|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
79968955|NCT03380260|Behavioral|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
79968956|NCT03380182|Other|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
79968957|NCT03380182|Other|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
79474961|NCT02974205|Device|össur brace|Rehabilitation after acute isolated PCL rupture
79474962|NCT01644474|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
79639620|NCT02941432|Other|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
79310490|NCT05532111|Drug|Rituximab combined with tacrolimus induction + tacrolimus maintenance|RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).
79474963|NCT01644474|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
79639621|NCT05301946|Other|Outcome Measurements|The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
79639622|NCT02941393|Device|Intrauterine pressure catheter|
79639623|NCT02941393|Device|External tocodynamometry|
79804798|NCT03893812|Device|MRI|diffusion weighted MR
79474964|NCT01644474|Drug|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
79474965|NCT01644474|Drug|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
79639624|NCT02941198|Device|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
79639625|NCT02941198|Device|Cu T380 A|Cu T380 A will be inserted into the uterus
79310491|NCT05532111|Drug|Glucocorticoid combined with cyclophosphamide induction + maintenance|PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
79804799|NCT03893812|Device|Ultrasound|Color Doppler ultrasound
79804800|NCT00685256|Other|counseling intervention|subjects and parents will receive genetic counseling
79310492|NCT03187067|Device|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
79474966|NCT02614469|Drug|Inosine|Inosine, 1000 mg
79474967|NCT02989129|Behavioral|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
79474968|NCT02989129|Drug|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
79639626|NCT00147719|Drug|Colesevelam hydrochloride|
79639627|NCT02941159|Biological|SF2000SD|This is an intergrase inhibitor
79639628|NCT02941159|Biological|Placebo|
79639629|NCT05273671|Drug|Nalbuphine|will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
79310493|NCT03186599|Behavioral|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
79474969|NCT02615717|Behavioral|Attention Bias Modification|comparison of treatment versus control
79474970|NCT05302115|Device|S-ICD|Implantation of an S-ICD
79639630|NCT05273671|Drug|Dexmedetomidine|will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
79804801|NCT00685256|Other|educational intervention|subjects and parents will receive education re: genetic testing
79310494|NCT05527899|Drug|Zinc gluconate|30 and 60 mg/d of zinc gluconate
79804802|NCT00685256|Other|survey administration|surveys will be administered to subjects and parents
79310495|NCT03117959|Device|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
79310496|NCT03117959|Device|Stryker Triathlon Custom Fit Knee|
79474971|NCT01847131|Drug|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
79474972|NCT01847131|Drug|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
79639631|NCT05273671|Drug|normal Saline|will receive with a saline solution 10 min before the end of surgery
79639632|NCT00408018|Drug|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
79639633|NCT00147758|Drug|Colesevelam hydrochloride|
79474973|NCT02285010|Drug|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
79474974|NCT02285010|Drug|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
79474975|NCT02617667|Drug|Cyclosporine A|topical ocular, eye drops
79474976|NCT02617667|Drug|Placebo|topical ocular, eye drops
79804803|NCT00685256|Behavioral|psychosocial assessment and care|psychosocial assessment and counseling will be provided
79804804|NCT00685256|Behavioral|supportive care|parents and children will be provided with supportive care
79804805|NCT00742612|Drug|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
79804806|NCT00742612|Drug|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
79968958|NCT03872141|Diagnostic Test|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
79968959|NCT03384628|Device|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
79310497|NCT05524077|Procedure|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
79474977|NCT05154773|Behavioral|Kidney donation and transplant information made easy|Same as arm description
79474978|NCT05533411|Drug|Donanemab|Administered IV.
79474979|NCT05533411|Drug|Placebo|Administered IV.
79474980|NCT05525195|Procedure|Congenital cardiac surgery|All children who underwent congenital cardiac surgery with cardiopulmonary bypass between 2008 and 2018
79474981|NCT04742855|Dietary Supplement|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
79474982|NCT01848067|Drug|Alisertib|Given PO
79474983|NCT01848067|Drug|Abiraterone acetate|Given PO
79968960|NCT03384628|Device|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
79968961|NCT03384628|Device|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
79639634|NCT05229484|Other|an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
79639635|NCT02931409|Procedure|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
79639636|NCT02931409|Procedure|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
79639637|NCT02931448|Device|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
79804807|NCT00680966|Behavioral|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
79804808|NCT02565394|Other|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
79804809|NCT04138862|Behavioral|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
79804810|NCT04150016|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
79804811|NCT03893266|Other|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
79804812|NCT00690560|Biological|rituximab|
79968962|NCT03293394|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
79968963|NCT03293394|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
79968964|NCT01267487|Drug|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT <480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
79804813|NCT00690560|Drug|cyclophosphamide|
79968965|NCT01267487|Drug|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
79804814|NCT00690560|Drug|doxorubicin hydrochloride|
79804815|NCT00690560|Drug|prednisone|
79804816|NCT00690560|Drug|vincristine sulfate|
79804817|NCT00690560|Radiation|yttrium Y 90 ibritumomab tiuxetan|
79474984|NCT01848067|Drug|Prednisone|Given PO
79639638|NCT02931526|Drug|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
79639639|NCT00169845|Dietary Supplement|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
79639640|NCT00169845|Dietary Supplement|Placebo|Provided by Roche Vitamins Inc
79639641|NCT02931487|Behavioral|Attentional Bias Modification|Computerized
79474985|NCT05068349|Drug|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
79474986|NCT01848847|Procedure|Hysteroscopy|
79968966|NCT01267487|Drug|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
79474989|NCT04591717|Biological|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
79474990|NCT05731583|Device|Home pulse oximetry monitoring|A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
79474991|NCT05460793|Device|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
79474992|NCT05731427|Other|Pseudomonas aeruginosa colonization infection|With or without airway Pseudomonas aeruginosa colonization infection
79474993|NCT05731427|Drug|Macrolides|Before or after 6 months of treatment with macrolides for patients with bronchiectasis
79474994|NCT01850485|Device|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
79474995|NCT00365651|Procedure|Youth Soccer|
79474996|NCT00364871|Drug|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
79474997|NCT00551161|Drug|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
79474998|NCT04660019|Other|the scalp and ear acupuncture|Some stimulation areas with outstanding effects on certain symptoms are selected for acupuncture
79474999|NCT04660019|Other|sham acupuncture|Some stimulation areas with outstanding effects on certain symptoms are selected for acupuncture, and change acupuncture to auricular points sticker.
79475000|NCT05429177|Drug|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
79475001|NCT02277925|Other|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
79475002|NCT02277925|Other|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
79475003|NCT02988037|Behavioral|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
79475004|NCT01851655|Behavioral|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
79475005|NCT05442151|Drug|PET/CT ([F-18]FAPI-74)|PET/CT using [18F] FAPI-74 injection
79475006|NCT00365729|Behavioral|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
79475007|NCT00365807|Behavioral|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
79639642|NCT02931487|Behavioral|Sham Comparator|Computerized
79968967|NCT05173948|Other|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
79475008|NCT00365807|Other|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
79475009|NCT00365885|Other|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
79475010|NCT04741373|Dietary Supplement|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
79475011|NCT04741373|Behavioral|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
79475012|NCT04741373|Other|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
79475013|NCT01852201|Device|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
79475014|NCT04433195|Diagnostic Test|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
79475015|NCT05363813|Device|M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)|Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
79475016|NCT05730959|Device|Sacral nerve modulation|Implant of nerve stimulator
79475017|NCT00550771|Drug|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
79968968|NCT05173948|Device|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
79968969|NCT01267565|Other|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
79968970|NCT03380104|Device|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
79639643|NCT02931370|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
79639644|NCT00169884|Behavioral|cognitive-behavioural therapy|
79639645|NCT04597684|Procedure|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
79639646|NCT04597684|Procedure|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
79804818|NCT00742690|Drug|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
79804819|NCT00742690|Drug|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
79804820|NCT00690638|Drug|PHX1149T|200 mg
79804821|NCT00690638|Drug|PHX1149T|400 mg
79804822|NCT00690638|Drug|Placebo|Placebo
79804823|NCT00742768|Dietary Supplement|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
79804824|NCT00742768|Dietary Supplement|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
79639647|NCT00147836|Drug|Human Insulin (Novolin-R, Novo Nordisk)|
79639648|NCT00147836|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
79639649|NCT00147836|Other|Pre-meal|
79639650|NCT00147836|Drug|Novolin-R|
79639651|NCT00147836|Drug|Human Insulin NPH (Novolin-N, Novo Nordisk)|
79639652|NCT00147836|Drug|Gliclazide (Diamicron, Servier)|
79639653|NCT00147836|Drug|Diamicron and Glucophage|
79804825|NCT03195400|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
79804826|NCT03195400|Diagnostic Test|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
79804827|NCT03195400|Diagnostic Test|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
79310498|NCT05524077|Drug|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose <300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be <2% (VANISH trial)."
79310499|NCT03186833|Other|no intervention|no intervention
79310500|NCT02433743|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
79804828|NCT03195400|Diagnostic Test|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
79804829|NCT00685412|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
79968971|NCT03380104|Behavioral|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
79968972|NCT01267643|Drug|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
79804830|NCT04656431|Drug|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
79804831|NCT04656431|Procedure|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
79804832|NCT04210895|Other|Ginger powder footbath|40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
79804833|NCT04210895|Other|Warm water only footbath|40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
79804834|NCT00862992|Drug|Cariprazine 3 mg|
79968973|NCT03620604|Device|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
79968974|NCT03388450|Drug|Omega 3|Enteral 1000 mg omega 3 fatty acid.
79804835|NCT00862992|Drug|Cariprazine 6 mg|
79804836|NCT00862992|Drug|Cariprazine 12.5 mg|
79804837|NCT02565316|Drug|Nepeta menthoides Boiss & Bohse freeze dried extract|
79804838|NCT02565316|Drug|Sertraline|
79804839|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
79804840|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
79475018|NCT00550771|Drug|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
79804841|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
79804842|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
79804843|NCT00620087|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
79804844|NCT00620087|Procedure|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
79804845|NCT04123860|Other|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
79804846|NCT04123860|Other|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
79804847|NCT04209413|Procedure|Patients referred for a knee ligamentoplasty|knee ligamentoplasty
79804848|NCT00685490|Procedure|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
79475019|NCT04340765|Drug|18F-fluorocholine|Dual phase 18F-fluorocholine PET/CT
79475020|NCT02278237|Behavioral|VME Group|Received inhaler education through VME (virtual education module)
79475021|NCT05730803|Other|dietary intervention|During the iodine balance period of pregnant women, seaweed was added to lunch on the 4-6 days of the experiment, and the iodine content was about 200 μg.
79475022|NCT01852513|Drug|QNASL|
79475023|NCT01852513|Drug|Placebo nasal spray|
79804849|NCT04135560|Drug|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
79804850|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
79804851|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
79804852|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
79804853|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
79475024|NCT01852669|Procedure|Inversion|Patients inverted 30 degree head down in Trendelenburg position
79475025|NCT01852669|Procedure|Shock Wave Lithotripsy|Shock wave lithotripsy
79475026|NCT01852669|Drug|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
79475027|NCT05730647|Other|None intervention (observational study)|None intervention (observational study)
79475028|NCT05271383|Device|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
79475029|NCT01853215|Device|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
79804854|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
79804855|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
79804856|NCT00690872|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
79804857|NCT00690872|Drug|carboplatin|
79804858|NCT00690872|Drug|gemcitabine hydrochloride|
79804859|NCT00690872|Genetic|polymerase chain reaction|
79804860|NCT00690872|Other|fluorescence activated cell sorting|
79804861|NCT00690872|Other|immunoenzyme technique|
79968975|NCT03388450|Drug|Placebo|Enteral nutrition without omega 3 fatty acid.
79968976|NCT03874481|Other|Observation|follow up regularly for MACE
79968977|NCT05173402|Device|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
79475030|NCT04741295|Drug|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
79475031|NCT05729867|Procedure|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
79310501|NCT04299867|Procedure|Bowel Surgery with Metronidazole|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
79475032|NCT05729321|Combination Product|neutrox|Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
79804862|NCT04842227|Procedure|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
79968978|NCT05173402|Device|face mask|orthopedic treatment was performed using a face mask.
79475033|NCT04828577|Behavioral|Real Time Neurofeedback|Participants receive feedback from own brain activity.
79310502|NCT05531877|Diagnostic Test|Penile Prosthesis Implantation|Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
79310503|NCT05527821|Drug|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
79475034|NCT04828577|Behavioral|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
79475035|NCT00550537|Drug|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
79310504|NCT05527821|Drug|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
79310505|NCT05527821|Radiation|Short course radiotherapy|5Gy*5F short course radiotherapy will be delivered
79475036|NCT00550537|Drug|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
79475037|NCT00550537|Drug|erlotinib hydrochloride|150 mg taken by mouth daily
79475038|NCT00550537|Drug|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
79475039|NCT00550537|Genetic|gene expression analysis|Blood and tissue collection.
79475040|NCT00550537|Genetic|protein expression analysis|Blood and tissue collection.
79475041|NCT00550537|Genetic|proteomic profiling|Blood and tissue collection.
79475042|NCT00550537|Other|laboratory biomarker analysis|Blood and tissue collection.
79475043|NCT04801043|Drug|XNW4107|XNW4107 250mg IV over 60 minutes as a single dose
79475044|NCT04801043|Drug|Imipenem/Cilastatin|500mg/500mg IV over 60 minutes as a single dose
79475045|NCT04801043|Drug|placebo|"Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose"
79475046|NCT04425577|Diagnostic Test|Transabdominal Ultrasound|Transabdominal Ultrasound
79804863|NCT00694096|Drug|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
79804864|NCT04123080|Device|Endoscopic band ligation assisted polypectomy|A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
79804865|NCT04150094|Other|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
79804866|NCT04150094|Other|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
79804867|NCT04808531|Drug|NanaBis™|NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC & CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
79804868|NCT04808531|Drug|Oxycodone CR|Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
79804869|NCT04808531|Drug|Placebo Spray|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
79968979|NCT01269827|Drug|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
79475047|NCT04795505|Behavioral|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
79475048|NCT04795505|Behavioral|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
79475049|NCT01853371|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
79475050|NCT01853371|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
79475051|NCT04734197|Drug|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
79475052|NCT04734197|Drug|Mycophenolic Acid 0.1%|topical immunosuppressant
79475053|NCT04734197|Drug|Mycophenolic Acid 0.3%|topical immunosuppressant
79475054|NCT04734197|Drug|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
79475055|NCT04734197|Drug|Placebo Comparator: Vehicle|topical vehicle solution
79475056|NCT04734197|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
79804870|NCT04808531|Drug|Placebo Tablet|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
79475057|NCT04734197|Drug|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
79475058|NCT00550147|Drug|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~Visit 2 dose of 18 mg QAM~Visit 3 dose of 36mg QAM~Visit 4 dose of 54mg QAM."
79310506|NCT05527743|Other|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
79475059|NCT00550147|Drug|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~Visit 5 dose of 25mg BID~Visit 6 dose of 50mg BID~Visit 7 dose of 100mg BID~Visit 8 dose of 200mg BID~Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
79475060|NCT01853605|Device|Anatomically shaped silicone gel-filled breast implants|Surgical implant
79804871|NCT04808531|Drug|Oxycodone IR|Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
79804872|NCT02613780|Procedure|Crosslinking|corneal collagen crosslinking with riboflavin
79804873|NCT02613780|Procedure|Photorefractive keratectomy|
79968980|NCT01269827|Drug|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
79968981|NCT03388372|Biological|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
79968982|NCT03388372|Drug|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
79968983|NCT03388372|Radiation|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
79968984|NCT01161485|Behavioral|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
79475061|NCT04741685|Device|TTSX2|Treatment with Tandem T Slim X2 with Basal IQ
79475062|NCT04741685|Device|MM640G|Treatment with Medtronic Minimed 640G with Smartguard
79475063|NCT04740983|Other|Heliotherapy (a sole sun-bathing)|16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
79968985|NCT01161485|Behavioral|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
79310507|NCT05527743|Other|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
79310508|NCT02433587|Drug|Aspirin|Patients will take Aspirin 81 mg
79310509|NCT02433587|Drug|Clopidogrel|Patients will take Clopidogrel 75 mg
79310510|NCT04299009|Device|Bright light therapy glasses|Bright light therapy delivered through glasses
79310511|NCT02433431|Behavioral|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
79310512|NCT02433431|Behavioral|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
79310513|NCT02433431|Behavioral|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
79310514|NCT05527665|Procedure|Midurethral sling surgery|This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
79310515|NCT02433353|Drug|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
79310516|NCT02433353|Behavioral|EMDR|psychotherapy
79310517|NCT02433353|Drug|Placebo|Look-alike venlafaxine XR tablets containing no active drug
79475064|NCT01856491|Device|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
79475065|NCT00366353|Other|Sedation during SBT|
79475066|NCT00366353|Other|No sedation|
79475067|NCT00366431|Drug|MOA-728|
79475068|NCT00557401|Drug|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
79475069|NCT00557401|Drug|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
79475070|NCT00557401|Drug|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
79804874|NCT02613780|Device|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
79804875|NCT00690950|Drug|Dutasteride|0.5mg capsule, taken once daily for 12 months
79968986|NCT01161485|Behavioral|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
79968987|NCT03379948|Diagnostic Test|blood culture|blood culture to diagnose blood stream infection
79804876|NCT04118244|Diagnostic Test|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
79968988|NCT03259308|Drug|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
79968989|NCT03259308|Drug|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
79968990|NCT01280279|Other|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
79804877|NCT02625194|Drug|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
79968991|NCT05173246|Drug|JS001|JS001 240mg, ivdrip, d1, Q3w
79968992|NCT05173246|Drug|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
79968993|NCT05173246|Drug|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
79968994|NCT05173246|Drug|Carboplatin|Carboplatin AUC 5,d1,Q3w
79968995|NCT01167101|Drug|Rebamipide|Rebamipide 100mg Tid for 28days
79968996|NCT01167101|Drug|pantoprazole|pantoprazole 40mg qd for 28days
79968997|NCT01165463|Behavioral|SOPT basic training|10 hours of basic training
79310518|NCT03190733|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
79310519|NCT04648605|Other|Post traumatic stress disorder questionnaire|Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
79310520|NCT03190499|Other|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
79310521|NCT02433119|Drug|OROSARTAN® 5/160mg|
79310522|NCT02433119|Drug|CODIOVAN® 160/12.5mg|
79968998|NCT01165463|Behavioral|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
79968999|NCT01165463|Behavioral|SOPT booster training|4 hours of subsequent booster-training
79310523|NCT05178459|Diagnostic Test|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
79475071|NCT00557401|Drug|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
79475072|NCT00557401|Drug|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
79475073|NCT02617901|Radiation|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
79475074|NCT04685213|Device|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
79969000|NCT03388216|Biological|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
79969001|NCT03388216|Biological|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
79969002|NCT03388216|Biological|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
79969003|NCT03388216|Other|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
79969004|NCT01267721|Procedure|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
79969005|NCT05173090|Drug|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
79475075|NCT04685213|Device|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
79475076|NCT03832777|Device|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
79969006|NCT03384550|Behavioral|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
79969007|NCT03384550|Behavioral|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
79475077|NCT02278783|Drug|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
79475078|NCT02618915|Genetic|DTX101|solution for IV infusion
79969008|NCT03384550|Behavioral|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
79969009|NCT03384550|Behavioral|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
79969010|NCT03877367|Other|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
79969011|NCT03877445|Device|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
79969012|NCT03388060|Procedure|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
79969013|NCT03388060|Procedure|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
79969014|NCT03388060|Procedure|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
79969015|NCT02526953|Drug|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
79969016|NCT02526953|Drug|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
79475079|NCT04768699|Drug|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
79804878|NCT02622126|Drug|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
79804879|NCT02622126|Drug|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
79804880|NCT02622126|Drug|Morphine|Sub arachnoid 200 meg morphine
79804881|NCT02622126|Drug|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
79804882|NCT02622126|Drug|Ephedrine|If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
79639654|NCT02931292|Procedure|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
79804883|NCT02622126|Drug|Atropine|Bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
79804884|NCT02625272|Procedure|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
79969017|NCT02526953|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
79969018|NCT02526953|Drug|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
79969019|NCT02526953|Drug|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
79969020|NCT02526953|Radiation|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
79969021|NCT04343638|Device|conventional nociception control|While Intraoperative opioid will be administered by conventional clinical practice in control arm.
79969022|NCT04343638|Device|ANI monitor guided nociception control|The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
79969023|NCT03874247|Drug|pelubiprofen 45mg|bid for 3 days after meal
79969024|NCT03874247|Drug|pelubiprofen placebo|bid for 3 days after meal
79969025|NCT01269983|Other|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
79969026|NCT03258762|Drug|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
79310524|NCT04425135|Drug|Camrelizumab|200mg,D1,ivgtt, Q3w.
79639655|NCT02931136|Drug|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
79639656|NCT02931136|Drug|Placebo|The participants will treatment by the placebo in 52 weeks.
79969027|NCT03258762|Drug|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
79310525|NCT04425135|Drug|Apatinib|250mg,Qd,Q3W.
79310526|NCT04425135|Drug|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
79310527|NCT04425135|Drug|Carboplatin|AUC=5~6,D1,ivgtt, Q3w.
79310528|NCT03186911|Behavioral|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
79310529|NCT02429999|Drug|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
79475080|NCT04768699|Drug|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
79475081|NCT04768699|Drug|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
79639657|NCT00175539|Behavioral|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
79310530|NCT02429999|Drug|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
79310531|NCT02430155|Device|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
79310532|NCT02430155|Device|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
79310533|NCT02573883|Device|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
79639658|NCT02931175|Drug|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
79639659|NCT00147875|Drug|Prednisone|
79639660|NCT00147875|Drug|Vinblastine|
79984430|NCT03204604|Procedure|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of [11C]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using [11C]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post [11C]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
79639661|NCT00147875|Drug|Doxorubicin (Adriamycin)|
79639662|NCT00147875|Drug|Gemcitabine|
79310534|NCT02573883|Drug|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
79310535|NCT02432885|Drug|Enalapril|up to 20mg bid
79639663|NCT04690036|Drug|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
79639664|NCT02931214|Drug|GMI-1359|
79639665|NCT02931214|Drug|Placebo|
79639666|NCT02931019|Procedure|Intubation|
79639667|NCT00169923|Drug|rosiglitazone|
79310536|NCT02433041|Drug|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
79639668|NCT00147914|Drug|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
79639669|NCT00147914|Drug|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
79984431|NCT03204604|Behavioral|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
79310537|NCT02433041|Drug|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
79310538|NCT02433041|Drug|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
79310539|NCT02433041|Drug|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
79310540|NCT02429921|Dietary Supplement|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
79310541|NCT02429921|Dietary Supplement|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
79310542|NCT02575365|Drug|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
79639670|NCT02930746|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-092)
79639671|NCT02930863|Other|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
79639672|NCT02930863|Behavioral|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
79804885|NCT00620633|Biological|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
79969028|NCT03871985|Procedure|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
79969029|NCT03871985|Procedure|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
79969030|NCT03379714|Device|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
79969031|NCT05427669|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
79969032|NCT05427669|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
79969033|NCT01280513|Dietary Supplement|High protein intake|30% of energy intake coming from proteins
79310543|NCT02707991|Behavioral|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
79310544|NCT05527431|Device|high flow nasal cannula|high flow nasal cannula
79310545|NCT05527431|Device|noninvasive ventilation|noninvasive ventilation
79310546|NCT02432807|Drug|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
79310547|NCT02432807|Drug|Placebo|Placebo
79310548|NCT02429843|Drug|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
79639673|NCT00147953|Drug|Rituximab|
79639674|NCT00147953|Procedure|Total nodal irradiation|
79639675|NCT02930785|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-104)"
79310549|NCT05527275|Drug|Mitoxantrone liposome combine with Chidamide|"Mitoxantrone Hydrochloride Liposome Injection： Grade 1: 14mg/ m2, D1; Grade 2: 17mg/ m2, D1; Grade 3: 20mg/ m2, D1; Chidamide：20mg twice a week (D1 and D4 or D2 and D5 or D3 and D6) Every 28 days for a cycle, a maximum of 6 cycles of treatment. Mitoxantrone Hydrochloride Liposome Injection RP2D was determined in the phase I trial, and the combination regimen will be used to in the phase II study, with a cycle of every 28 days and a maximum of 6 cycles of treatment.~Subsequently, maintenance treatment was performed: Chidamide, 20mg twice a week, for 1 year."
79310550|NCT02429765|Drug|ACL/FOR|
79310551|NCT02429765|Drug|Placebo|
79310552|NCT03186053|Drug|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
79310553|NCT03186053|Drug|saline|.Loading dose followed by continuous infusion in operation
79310554|NCT02429219|Drug|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
79639676|NCT02930551|Drug|Lidocaine|
79639677|NCT02930551|Drug|Isotonic Saline|
79804886|NCT04140188|Diagnostic Test|Senti-Scint (99mTc- pertechnetate combined with human albumin)|Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
79804887|NCT00314015|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
79804888|NCT00314015|Procedure|Questionnaires|Questionnaires will be used
79804889|NCT02622282|Other|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
79310555|NCT02429219|Procedure|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
79475082|NCT04749277|Other|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
79310556|NCT02429219|Procedure|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
79310557|NCT05531409|Behavioral|Responsible Behavior for Younger Children (RBYC)|RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
79804890|NCT02622282|Other|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
79969034|NCT01280513|Dietary Supplement|Low Protein intake|9% of energy intake coming from proteins
79804891|NCT02622282|Other|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
79969035|NCT03379636|Device|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
79969036|NCT03379636|Device|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
79310558|NCT02429531|Biological|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
79310559|NCT02429531|Biological|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
79310560|NCT04483193|Diagnostic Test|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
79969037|NCT01270373|Drug|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
79804892|NCT00685568|Drug|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
79475083|NCT04749199|Behavioral|Enhanced mirror therapy|Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
79639678|NCT02930356|Other|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
79639679|NCT02930356|Other|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
79804893|NCT00685568|Other|placebo|Orally, twice daily for 3 months
79639680|NCT00175617|Drug|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
79804894|NCT00306059|Procedure|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
79804895|NCT04121988|Diagnostic Test|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~Coronal T2 weighted imaging~Dynamic contrast enhanced T1 weighted imaging~Coronal contrast enhanced T1 weighted imaging"
79310561|NCT02429141|Procedure|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
79475084|NCT04749199|Behavioral|Standard mirror therapy|Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
79475085|NCT04749121|Device|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
79804896|NCT02626208|Device|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
79310562|NCT02429141|Procedure|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
79310563|NCT05273463|Behavioral|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
79310564|NCT05273463|Behavioral|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
79475086|NCT04749121|Drug|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
79969038|NCT01270373|Drug|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
79969039|NCT03669237|Procedure|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
79969040|NCT03713086|Biological|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
79475087|NCT04749121|Device|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
79639681|NCT00175617|Drug|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
79969041|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 1|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
79310565|NCT02429453|Drug|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
79310566|NCT02429453|Biological|Fresh Frozen Plasma|A pooled collection of plasma from donors
79310567|NCT02429297|Other|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
79804897|NCT04210739|Drug|Betamethason Sodium Phosphate|Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
79969042|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 2|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
79639682|NCT02930707|Drug|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
79639683|NCT02930707|Drug|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
79310568|NCT02429297|Other|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
79310569|NCT05526963|Other|Medication plan review|Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
79310570|NCT05526963|Behavioral|Adherence support|Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
79310571|NCT02428751|Drug|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
79310572|NCT02428751|Drug|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
79310573|NCT02428751|Drug|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
79475088|NCT04749121|Device|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
79475089|NCT02264353|Drug|Donepezil|Donepezil 10mg before sleep
79639684|NCT00148031|Drug|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
79804898|NCT00696540|Drug|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
79804899|NCT00696540|Drug|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
79804900|NCT04212845|Drug|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
79310574|NCT02428751|Drug|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
79310575|NCT02428751|Drug|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
79310576|NCT02428751|Drug|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
79475090|NCT02264353|Drug|placebo|One piece of placebo before sleep
79310577|NCT05526807|Drug|Ursodeoxycholic acid|Oral
79310578|NCT02428829|Procedure|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
79310579|NCT02428829|Procedure|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
79804901|NCT04212845|Device|Fluoroscopy|Fluoroscopy-guided transforaminal injection
79804902|NCT04212845|Device|Ultrasound|Ultrasound-guided erector spinae plane block
79475091|NCT02622191|Device|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
79475092|NCT02265913|Drug|Acyclovir 5 percent (Perrigo)|
79804903|NCT00620165|Drug|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
79804904|NCT00620165|Drug|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
79804905|NCT00685646|Drug|antiandrogen therapy|Up to 24 courses of therapy
79804906|NCT00685646|Drug|zoledronic acid|Up to 24 courses of therapy
79475093|NCT02265913|Drug|Acyclovir 5 percent (Reference)|
79475094|NCT02265913|Drug|Placebo cream|
79475095|NCT02624375|Drug|Zoster Vaccine Live|
79475096|NCT01858753|Biological|Autologous fibroblasts|
79475097|NCT01858753|Biological|placebo sterile saline|
79475098|NCT02624843|Drug|Benzyl Alcohol Lotion 5%|White topical lotion
79475099|NCT02624843|Drug|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
79804907|NCT04209257|Device|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
79804908|NCT00685724|Behavioral|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
79804909|NCT00685724|Behavioral|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
79804910|NCT04139720|Behavioral|e-book|sexual harassment prevention via education e-book
79804911|NCT00284297|Procedure|History taken and clinical examination|History is taken and clinical examination is followed
79475100|NCT02624843|Drug|Placebo|White topical lotion
79475101|NCT00422357|Drug|Urtica Dioica (Tea bag)|
79475102|NCT05106101|Drug|L-glutamine|L-glutamine oral powder in 5 gram packet
79475103|NCT04741217|Other|Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.
79475104|NCT04600973|Behavioral|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
79475105|NCT02625545|Device|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
79969043|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 3|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
79969044|NCT05172856|Drug|IBI321|IBI321 at a dose no higher than RP2D, D1 IV Q3W.
79475106|NCT02279641|Drug|RDEA3170 10 mg|
79969045|NCT01271231|Drug|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
79804912|NCT00685958|Drug|enoxaparin (XRP4563)|14 days of treatment
79475107|NCT02279641|Drug|allopurinol 300 mg|
79475108|NCT02988505|Other|Standard care|
79475109|NCT04339985|Drug|ATx201|Topical
79475110|NCT04339985|Drug|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
79475111|NCT01859611|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
79475112|NCT04135807|Combination Product|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
79475113|NCT05215093|Other|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
79475114|NCT05215093|Other|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
79804913|NCT04784507|Procedure|En Bloc Resection|En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
79310580|NCT05531331|Behavioral|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
79310581|NCT03184961|Diagnostic Test|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
79475115|NCT01862419|Other|Alert|
79804914|NCT04784507|Procedure|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
79804915|NCT04138472|Drug|dexmedetomidine|intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
79804916|NCT04138472|Drug|fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
79804917|NCT04138472|Drug|lidocaine|intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
79804918|NCT00620789|Drug|Escitalopram + CBT-I|"Escitalopram, 10 mg daily for the duration of the study (6 months)~CBT-I, four biweekly sessions during eight week Treatment phase."
79804919|NCT00620789|Behavioral|CBT-I plus placebo antidepressant medication|"CBT-I, 4 biweekly sessions, eight week Treatment phase.~Placebo,daily for duration of study(6 months)."
79804920|NCT00620789|Drug|Escitalopram|"Escitalopram, 10 mg daily for the duration of the study (6 months)~SH, four biweekly sessions during eight week Treatment phase"
79804921|NCT00691184|Drug|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
79804922|NCT00691184|Drug|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
79969046|NCT01271231|Drug|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
79804923|NCT00691184|Drug|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
79804924|NCT00691184|Drug|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
79804925|NCT00854100|Drug|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
79969047|NCT01271231|Drug|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
79969048|NCT04575285|Diagnostic Test|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
79475116|NCT00553813|Drug|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
79969049|NCT04132596|Device|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
79475117|NCT02629991|Drug|Intranasal Oxytocin (IN-OXT)|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
79639685|NCT00148031|Behavioral|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
79475118|NCT02629991|Other|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
79475119|NCT00553657|Drug|DETROL LA (drug)|
79639686|NCT00148031|Behavioral|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
79639687|NCT00148031|Behavioral|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
79639688|NCT02930473|Behavioral|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
79639689|NCT02930473|Drug|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
79639690|NCT02930434|Dietary Supplement|cholecalciferol|Administration of vitamin D3
79639691|NCT00175656|Procedure|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
79639692|NCT02930512|Procedure|DXA scan|
79639693|NCT02930512|Procedure|pQCT scan|
79969050|NCT04132596|Other|Activity Based Therapy|Physical therapy
79969051|NCT03384394|Device|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
79969052|NCT03384394|Device|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
79310582|NCT04644783|Diagnostic Test|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
79639694|NCT00148070|Drug|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
79969053|NCT03379558|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
79969054|NCT01169909|Drug|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
79969055|NCT03379480|Behavioral|Yoga arm|Yoga module developed for patients with Schizophrenia
79804926|NCT00854100|Drug|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
79804927|NCT00854100|Drug|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
79804928|NCT00509899|Drug|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
79804929|NCT04212767|Procedure|Alveolar socket preservation with Platelet-rich fibrin|The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
79804930|NCT00691262|Drug|tacrolimus ointment|transdermal
79639695|NCT00148070|Procedure|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
79310583|NCT03184883|Procedure|single conventional denture|mandibular conventional denture with soft liner
79310584|NCT03184883|Procedure|single flexible denture|mandibular flexible compete denture
79310585|NCT04639947|Device|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
79310586|NCT04639947|Device|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
79310587|NCT03185195|Drug|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
79310588|NCT03185195|Drug|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
79804931|NCT00620867|Drug|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
79804932|NCT00620867|Drug|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
79804933|NCT00620867|Other|placebo|matched placebo orally for 6 weeks
79804934|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
79804935|NCT00922688|Drug|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
79804936|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
79804937|NCT02622204|Procedure|Corrective osteotomy|corrective osteotomy for varus alignment
79310589|NCT03185195|Drug|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
79310590|NCT03185039|Procedure|Blood and tumor samples|Blood and tumor samples
79310591|NCT03186365|Drug|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
79310592|NCT05531175|Other|Reiki apply|The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
79310593|NCT02428907|Behavioral|simulation training|teamtraining of endoscopy staff
79310594|NCT02432651|Drug|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
79310595|NCT02432651|Drug|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
79310596|NCT02432651|Drug|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
79310597|NCT02432651|Drug|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
79310598|NCT04628091|Other|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~Occipital hair sample (without roots)~Venous blood sample (3 tubes of 7mL)~During the surgery:~Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
79310599|NCT02428517|Procedure|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
79475120|NCT05157529|Device|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
79804938|NCT04271917|Drug|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
79804939|NCT04271917|Drug|placebo|Inactive placebo oil to imitate CBD oil
79804940|NCT04271917|Drug|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
79804941|NCT04643639|Device|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
79310600|NCT02428517|Procedure|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
79310601|NCT02428517|Procedure|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
79310602|NCT02428517|Procedure|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
79475121|NCT05157529|Device|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
79475122|NCT02633735|Other|Appy CDS|See description under arm/group section
79804942|NCT04122222|Biological|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
79804943|NCT00686114|Drug|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
79969056|NCT04502589|Drug|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
79804944|NCT00686114|Drug|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
79804945|NCT00686114|Drug|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
79969057|NCT04502589|Drug|Disulfiram|Disulfiram will be kept at 250mg daily
79310603|NCT05522985|Drug|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
79310604|NCT05526339|Device|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
79310605|NCT05526339|Device|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
79310606|NCT02707757|Drug|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
79969058|NCT01586663|Device|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
79969059|NCT01586663|Drug|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
79969060|NCT05172622|Drug|JP-2266|"Single Ascending Dose: Single administration on Day 1~Food effect cohort: Single administration on Day 1 of each period~Multiple Ascending Dose: Repeated administrations from D1 to D15"
79310607|NCT02707757|Drug|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
79310608|NCT02432573|Behavioral|Delayed rounds|
79310609|NCT05522829|Biological|SCTV01E-1 on D0|Day 0; intramuscular injection
79969061|NCT05172622|Drug|JP-2266 Placebo|"Single Ascending Dose: Single administration on Day 1~Food effect cohort: Single administration on Day 1 of each period~Multiple Ascending Dose: Repeated administrations from D1 to D15"
79969062|NCT03387904|Drug|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
79310610|NCT05522829|Biological|SCTV01E-1 on D28|Day 28; intramuscular injection
79310611|NCT05522829|Biological|SCTV01E-1 on D150|Day 150; intramuscular injection
79310612|NCT05522829|Biological|SCTV01E on D0|Day 0; intramuscular injection
79310613|NCT05522829|Biological|SCTV01E on D28|Day 28; intramuscular injection
79310614|NCT05522829|Biological|SCTV01E on D150|Day 150; intramuscular injection
79310615|NCT05522829|Biological|SCTV01E-1 on D120|Day 120; intramuscular injection
79310616|NCT05522829|Biological|SCTV01E on D120|Day 120; intramuscular injection
79804946|NCT00686114|Radiation|Radiotherapy|Enlarged field radiotherapy
79310617|NCT02432495|Other|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
79310618|NCT02432495|Other|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
79310619|NCT02432339|Drug|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
79310620|NCT02432339|Drug|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
79310621|NCT03184805|Drug|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
79310622|NCT03184805|Drug|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
79310623|NCT05518383|Drug|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate|For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
79639696|NCT02930629|Device|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~The TOF force transducer will be placed on the volar aspect of the thumb.~The TOF Watch leads will be attached to the ECG electrodes.~A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
79639697|NCT02930395|Procedure|serum S100B assay|
79804947|NCT00686114|Radiation|Radiotherapy|Conventional field radiotherapy
79804948|NCT01015729|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
79804949|NCT01015729|Drug|Esomeprazole|oral, single dose
79804950|NCT01015729|Drug|ASA|Tablet, oral, single dose
79310624|NCT05518383|Drug|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine|R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
79804951|NCT00698724|Drug|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
79804952|NCT00698724|Drug|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
79804953|NCT00686192|Dietary Supplement|Calcium Carbonate|1500 mg per day
79310625|NCT05518383|Drug|Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
79639698|NCT00175695|Drug|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
79639699|NCT02930317|Drug|Recombinant Factor VIII (50 IU/kg)|
79639700|NCT02930317|Drug|Recombinant Factor VIII (On-demand treatment)|
79639701|NCT00148148|Drug|caspofungin|
79639702|NCT00148148|Drug|liposomal amphotericin B|
79639703|NCT02929966|Other|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
79639704|NCT02929966|Other|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
79804954|NCT02622048|Behavioral|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
79804955|NCT05299190|Other|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
79804956|NCT05299190|Other|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
79969063|NCT03387904|Drug|Irinotecan|Irinotecan Day 1,8 ivgtt
79804957|NCT04117776|Other|Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
79804958|NCT04117776|Other|Skin microbiological sampling (wash with mild soap)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
79804959|NCT00922610|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
79639705|NCT04438135|Other|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
79804960|NCT04135170|Combination Product|ALBC vs plain bone cement|The patients undergoing full-cemented primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to PJI one year after primary TKA surgery.
79804961|NCT00686270|Drug|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
79310626|NCT05518383|Drug|Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin|Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
79639706|NCT00169962|Drug|rhDNAse (pulmozyme)|
79310627|NCT02432027|Drug|C-82 Topical Gel, Placebo|placebo
79310628|NCT02432027|Drug|C-82 Topical Gel, 1%|active
79310629|NCT02432027|Drug|Daivonex cream|comparator
79310630|NCT02432027|Drug|Diprosis gel|comparator
79639707|NCT02930239|Other|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
79639708|NCT02930239|Other|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
79639709|NCT02930161|Drug|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
79639710|NCT02930161|Other|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
79639711|NCT00170001|Drug|Nexium|40 mg bid dosing
79639712|NCT00170001|Drug|Sugar Pill|40 mg BID
79639713|NCT02930200|Behavioral|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
79639714|NCT02930200|Behavioral|QuitGuide|NCI QuitGuide Treatment App
79639715|NCT02930200|Behavioral|Smart-T|Smart-Treatment App
79639716|NCT00148226|Behavioral|Decision Aid|
79639717|NCT02929732|Other|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
79639718|NCT04426201|Drug|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
79639719|NCT04426201|Drug|Placebo|Same number, volume and frequency of IM administration of saline
79804962|NCT04117698|Drug|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~associated with a treatment similar to the control group."
79969064|NCT01283165|Behavioral|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
79475123|NCT05018663|Other|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
79969065|NCT03291288|Drug|Tolbutamide|Commercially available tolbutamide
79969066|NCT03291288|Drug|Midazolam|Commercially available midazolam
79804963|NCT04117698|Drug|Ethambutol|Ethambutol
79804964|NCT04117698|Drug|RIFINAH ©|RIFINAH ©
79804965|NCT04210271|Behavioral|Buddy self-testing condition|
79804966|NCT04210271|Behavioral|Control self-screening condition|
79804967|NCT04118322|Other|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
79310631|NCT05526261|Procedure|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
79310632|NCT02428439|Drug|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
79475124|NCT03949231|Drug|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
79804968|NCT04031612|Drug|Neoadjuvant therapy|Neoadjuvant therapy
79804969|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
79969067|NCT03291288|Drug|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules
79310633|NCT05526183|Biological|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
79310634|NCT03186443|Drug|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
79310635|NCT03186443|Drug|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
79804970|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
79804971|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
79310636|NCT05526027|Diagnostic Test|CFQ-R questionnaire, SNOT-22 questionnaire, fecal elastase measurement|cf supra
79310637|NCT02428361|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
79804972|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
79804973|NCT05662709|Procedure|Tooth extraction|Tooth extraction in the most atraumatic way
79804974|NCT05662709|Procedure|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
79804975|NCT00698802|Drug|EX1000|Treat-to-target titration scheme, s.c. injection
79804976|NCT00698802|Drug|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
79804977|NCT00686426|Dietary Supplement|Dairy Foods|Adequate dairy (> 3 standard daily servings)
79804978|NCT00686426|Dietary Supplement|Dairy Foods|< 1 standard dairy serving/day
79310638|NCT05517993|Drug|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
79310639|NCT02428673|Other|Assisted Standing Treatment Program|
79310640|NCT03186131|Drug|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
79310641|NCT03186131|Drug|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
79969068|NCT05172310|Drug|68Ga-FAPI-46|"[68Ga] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~Depending on the labelling yield 50 - 370 megabecquerel (MBq) of [68Ga] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
79969069|NCT05172310|Device|PET/CT|"Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~At 60 minutes post injection, a whole-body PET will be acquired."
79969070|NCT03636711|Other|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
79969071|NCT03869801|Procedure|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
79310642|NCT02572401|Behavioral|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
79310643|NCT02572401|Behavioral|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
79310644|NCT03186287|Other|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
79310645|NCT03186287|Other|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
79310646|NCT03186287|Other|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
79310647|NCT03185975|Behavioral|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
79969072|NCT03869801|Procedure|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
79969073|NCT03869723|Procedure|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
79969074|NCT03869723|Procedure|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
79639720|NCT00148265|Drug|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
79969075|NCT04084626|Drug|PD1 antibody|2mg/kg ivgtt on day 1(age<18 years); 200mg ivgtt on day 1(age >=18 years).
79475127|NCT04992143|Procedure|TACE|TACE first ,and more TACE could be performed when it is necessary.
79475128|NCT04992143|Drug|Tilelizumab|Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
79804979|NCT00618215|Behavioral|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
79804980|NCT00698880|Procedure|Right hepatic vein embolization|Embolization of the right hepatic vein
79475129|NCT04992143|Drug|Sorafenib|Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
79475130|NCT01866163|Drug|LEO 90100|
79475131|NCT01866163|Drug|Vehicle|
79804981|NCT02626988|Behavioral|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
79804982|NCT04213001|Diagnostic Test|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
79804983|NCT00691418|Dietary Supplement|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
79804984|NCT00691418|Dietary Supplement|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
79804985|NCT00691496|Behavioral|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
79804986|NCT02626442|Other|Exercise|6 month group exercise class
79804987|NCT00618293|Drug|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
79969076|NCT04084626|Drug|lenalidomide|5mg orally once a day（age<18years) ,day 1-14; 10mg orally once a day(age>=18years), day 1-14.
79969077|NCT03387826|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
79969078|NCT03387826|Drug|Prasugrel 5mg|Prasugrel 5 mg once daily
79969079|NCT03869411|Behavioral|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
79969080|NCT04016454|Procedure|Intervention|There will be one complete handover
79969081|NCT03387748|Behavioral|Gesture elicitation|"Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~Participants retell a cartoon to the researcher~The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded."
79969082|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
79475132|NCT04485065|Drug|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
79969083|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
79475133|NCT04969289|Behavioral|Dr. Eric Digital Health Intervention|Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
79475134|NCT03769129|Drug|Pembrolizumab|Pembrolizumab
79475135|NCT03769129|Procedure|microwave ablation|microwave ablation
79804988|NCT00618293|Other|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
79804989|NCT02627066|Behavioral|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
79804990|NCT02627066|Behavioral|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
79969084|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
79969085|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
79639721|NCT00170079|Behavioral|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
79804991|NCT00621569|Behavioral|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
79804992|NCT00621569|Behavioral|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
79804993|NCT00862836|Drug|Vandetanib|100mg doses orally, once daily
79804994|NCT00621647|Drug|Quetiapine Fumarate|
79804995|NCT00621647|Drug|Quetiapine Fumarate|
79804996|NCT00621647|Drug|Placebo|
79804997|NCT02625350|Other|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
79969086|NCT03379324|Biological|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
79969087|NCT03379324|Biological|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
79969088|NCT03953742|Drug|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
79969089|NCT01167335|Drug|BGG492|
79969090|NCT01167335|Drug|Placebo|
79969091|NCT03943914|Combination Product|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio < 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate < 25/min and SpO2 > 92% under FiO2 < 30% for at least 6 hours.
79310648|NCT03185975|Behavioral|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
79969092|NCT03943914|Combination Product|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 > 92%. NIV is initiated only in patients having PaO2/FiO2 ratio < 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
79804998|NCT02625350|Other|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
79310649|NCT03184649|Drug|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
79310650|NCT03184649|Drug|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
79475136|NCT04957589|Dietary Supplement|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
79804999|NCT02625350|Other|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
79805000|NCT04209179|Drug|PCO371|PCO371 capsule
79969093|NCT03872063|Other|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
79805001|NCT04209179|Drug|Placebo|Placebo capsule
79805002|NCT00681356|Drug|4975, 15 and 5 mg|Direct instillation into the surgical site
79805003|NCT00681356|Drug|Placebo Comparator|Direct instillation into the surgical site
79805004|NCT00681356|Drug|4975 - 5 mg|Direct instillation into the surgical site
79805005|NCT02621970|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
79805006|NCT02621970|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1
79310651|NCT03184649|Dietary Supplement|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
79310652|NCT05517915|Other|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
79310653|NCT05517915|Other|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
79310654|NCT02432261|Drug|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
79310655|NCT02432261|Drug|Testosterone only gel|Testosterone only gel
79310656|NCT03184415|Drug|DWC20155|tablet
79639722|NCT02929771|Device|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
79639723|NCT02929771|Device|iPad|iPad with headphones. Control
79805007|NCT02621970|Drug|Docetaxel|Docetaxel 60mg/m2, D1
79805008|NCT02621970|Drug|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
79969094|NCT03872063|Other|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
79969095|NCT03930966|Diagnostic Test|PDEQ, PCL-5 and demographic survey|Questionnaires
79969096|NCT03871517|Drug|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
79969097|NCT03871517|Drug|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
79969098|NCT03387592|Drug|CPT-11|180 mg/m2
79969099|NCT03387592|Drug|Calcio levofolinate|200 mg/m2
79969100|NCT03387592|Drug|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
79969101|NCT03387592|Drug|Capecitabine|1500 mg/m2
79969102|NCT03387592|Drug|Temozolomide|200 mg/m2
79969103|NCT01281059|Device|BreathID - Breath Test - 13C Octanoate|
79969104|NCT02501226|Other|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
79969105|NCT02501226|Behavioral|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
79969106|NCT01587053|Other|therapeutic education program|
79969107|NCT03384160|Diagnostic Test|Group 1 -Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
79310657|NCT03184415|Drug|DWC20156|tablet
79310658|NCT03184415|Drug|placebo of DWC20155|tablet
79310659|NCT03184415|Drug|placebo of DWC20156|tablet
79310660|NCT05522595|Device|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
79310661|NCT02431949|Other|Admission to BCPP|There is no intervention associated with this study.
79310662|NCT02428283|Drug|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
79310663|NCT02428283|Drug|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
79310664|NCT02428283|Drug|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
79310665|NCT02428127|Dietary Supplement|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
79639724|NCT02929615|Other|Hematopoietic stem cell transplantation|
79639725|NCT04395703|Other|Interviews and focus groups|Unstructured and semi-structured interviews with open ended questions.
79639726|NCT02929693|Drug|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
79805009|NCT02621970|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
79310666|NCT02428127|Dietary Supplement|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
79310667|NCT02428127|Other|Water|lukewarm water
79805010|NCT00820755|Drug|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram*hour/milliliter (mg*hr/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
79310668|NCT03185585|Other|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
79969108|NCT03384160|Diagnostic Test|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
79805011|NCT00820755|Drug|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
79969109|NCT01587131|Biological|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
79969110|NCT03387436|Behavioral|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
79969111|NCT03387436|Behavioral|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
79969112|NCT04445818|Behavioral|More appreciation|
79310669|NCT03185585|Other|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
79639727|NCT02929693|Drug|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
79639728|NCT02929693|Drug|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
79639729|NCT00175734|Procedure|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
79969113|NCT04445818|Behavioral|Less criticism|
79639730|NCT00175734|Procedure|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
79639731|NCT00148382|Drug|ATL-962|
79639732|NCT00170118|Behavioral|motivational interviewing|
79969114|NCT04445818|Behavioral|More Fruit and Vegetable|
79639733|NCT02929654|Device|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
79639734|NCT02929654|Device|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
79639735|NCT02929654|Device|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
79969115|NCT03384082|Procedure|hysteroscopic treatment|treatment
79969116|NCT04445506|Drug|Dexamethasone|4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
79969117|NCT01283243|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
79969118|NCT03387358|Device|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
79639736|NCT04689841|Other|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
79639737|NCT04689841|Other|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
79639738|NCT00148421|Drug|Darbepoetin alfa and Epoetin alfa|
79639739|NCT02929888|Drug|Lysine Acetilsalicilate|
79639740|NCT02929888|Drug|Aspirin|
79310670|NCT02427893|Drug|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
79475137|NCT04957589|Other|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
79805012|NCT00820755|Drug|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
79310671|NCT02427893|Drug|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
79310672|NCT03184493|Drug|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
79310673|NCT03184493|Drug|Celebrex|This group patients will receive celebrex.
79310674|NCT03184493|Drug|Metformin|This group patients will receive metformin.
79310675|NCT03184337|Behavioral|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
79310676|NCT03184337|Behavioral|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
79969119|NCT03869489|Device|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
79310677|NCT02431481|Drug|LEE011|400 mg
79475138|NCT04482569|Drug|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
79805013|NCT04671173|Device|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
79310678|NCT02431403|Drug|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
79310679|NCT02431325|Drug|Teduglutide|
79310680|NCT02431325|Drug|Placebo|
79310681|NCT03184103|Diagnostic Test|anti streptolysin o titre and serum complement test|diagnostic lab test
79310682|NCT03184025|Other|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
79310683|NCT02103478|Drug|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
79310684|NCT02103478|Drug|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
79310685|NCT02103478|Drug|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
79310686|NCT02431013|Drug|Simvastatin|Simvastatin 40 mg on Day 1 & Day 8.
79475139|NCT00367367|Procedure|Hysteroscopy and Curettage|
79805014|NCT00700128|Drug|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
79805015|NCT00700128|Drug|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
79805016|NCT00700128|Drug|placebo|placebo
79805017|NCT04212689|Device|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
79805018|NCT04212689|Other|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
79805019|NCT04135326|Other|Quality-of-Life Assessment|Ancillary studies
79805020|NCT04135326|Other|Questionnaire Administration|Ancillary studies
79475140|NCT05075551|Device|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
79475141|NCT05075551|Device|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
79805021|NCT04135326|Procedure|Transcranial Direct Current Stimulation|Undergo tDCS
79969120|NCT03869489|Device|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
79805022|NCT04117542|Other|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
79969121|NCT03869489|Device|Sham tDCS stimulation|Sham tDCS stimulation will be applied
79310687|NCT02431013|Drug|Pravastatin|Pravastatin 20 mg on Day 1 & Day 8.
79310688|NCT02431013|Drug|Cilostazol|Cilostazol 100 mg twice a day for 6 days & on Day 8 with statin.
79310689|NCT02427503|Procedure|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
79310690|NCT02430857|Other|OMT|Manuel osteopathic treatment of the spine
79475142|NCT05075551|Other|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence [repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
79984432|NCT03204604|Behavioral|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
79475143|NCT02988739|Biological|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
79805023|NCT04660097|Drug|Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer|This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
79310691|NCT02427659|Behavioral|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
79475144|NCT02988739|Device|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
79475145|NCT00367445|Drug|Inhaled Human Insulin (Exubera)|
79475146|NCT00367445|Drug|Insulin Glargine (Lantus)|
79475147|NCT05044585|Other|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
79475148|NCT01866943|Drug|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
79475149|NCT01866943|Drug|Normal Saline Solution|
79310692|NCT02427659|Behavioral|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
79310693|NCT02427659|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
79310694|NCT02427425|Device|TENS|
79639741|NCT04689763|Behavioral|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
79639742|NCT04689412|Drug|Resveratrol|Nasal administration of resveratrol
79310695|NCT02102464|Device|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
79310696|NCT02427347|Other|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
79475150|NCT04436081|Drug|THC-free CBD Oil|Hemp-based CBD oil Gelcaps
79475151|NCT04436081|Drug|Placebo|Placebo Gelcaps
79639743|NCT00148460|Drug|TNK-tPA|
79639744|NCT00148460|Drug|rt-PA|
79639745|NCT00170196|Drug|prednisone|
79639746|NCT02929459|Dietary Supplement|Riboflavin Dose 1|
79805024|NCT04117464|Behavioral|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
79639747|NCT02929459|Dietary Supplement|Riboflavin Dose 2|
79475152|NCT05003557|Other|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~concerning the current health situation~the SF 36~the IPQ-R questionnaire"
79475153|NCT01868425|Drug|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
79475154|NCT01868425|Drug|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
79639748|NCT02929459|Other|Placebo|
79639749|NCT02929576|Drug|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
79639750|NCT02929576|Drug|Placebo|
79310697|NCT02427347|Other|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
79310698|NCT03183947|Procedure|fMRI|collection of functional brain data for 1 hour per day
79475155|NCT01869439|Device|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
79475156|NCT01869439|Device|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
79639751|NCT02929576|Drug|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
79639752|NCT02929420|Drug|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
79639753|NCT02929420|Drug|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
79805025|NCT04117464|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
79805026|NCT04117464|Behavioral|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
79310699|NCT03183947|Behavioral|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 & 4; controls: Days 2 & 3)
79310700|NCT03183947|Other|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
79310701|NCT03183947|Other|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
79639754|NCT00175812|Drug|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
79639755|NCT00175812|Drug|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
79805027|NCT04117464|Other|Wait List Group|No psychological intervention
79310702|NCT03183947|Other|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3&4; controls: day 2&3) and after 4 weeks during a telephone interview
79310703|NCT02430935|Behavioral|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
79475157|NCT01869439|Device|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
79475158|NCT01869439|Device|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
79475159|NCT00550459|Drug|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
79969122|NCT03384004|Device|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
79475160|NCT00550459|Drug|Placebo|Placebo tablet given once daily for 21 days
79475161|NCT04916587|Other|Implementation Strategy of ACEs Screenings|We will use implementation mapping, guided by the EPIS framework, to promote a co-created process and refine the strategy comprised of online training videos, a customized ACEs algorithm and use of technology to improve workflow efficiency, implementation technical assistance/coaching, and written implementation protocols.
79475162|NCT04916587|Other|Usual Care|"The ACEs Aware policy goal is to equip providers with training and clinical protocols to screen children and adults for ACEs, detect ACEs early, and connect patients to interventions, resources, and other support to improve patient health and well-being. ACEs screenings are comprised of: a) a 2-hour on-line provider training; b) the Pediatric ACEs and Related Life-events Screener or PEARLS tool; c) an ACEs associated health conditions checklist; and d) complete a wellness exam. The primary care provider uses multiple sources of information to identify a child's need for follow-up services."
79475163|NCT04901611|Behavioral|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
79475164|NCT03545971|Drug|IBI310|IBI310 is anti CTLA-4 antibody
79475165|NCT03545971|Drug|Sintilimab|PD-1 monoclonal antibody
79805028|NCT00820599|Device|Sapien XT™ transcatheter heart valve and delivery system|
79475166|NCT01871077|Drug|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
79475167|NCT03436069|Other|Conventional treatment protocols of breast cancer|
79475168|NCT03426709|Behavioral|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
79475169|NCT02988583|Device|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
79475170|NCT02988583|Device|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
79475171|NCT04894045|Other|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
79639756|NCT00175812|Drug|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
79639757|NCT00148499|Drug|Ambroxol hydrochloride (Mucoangin?)|
79805029|NCT00700206|Drug|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
79805030|NCT00621101|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
79805031|NCT00621101|Drug|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
79475172|NCT01872325|Behavioral|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
79475173|NCT01874119|Drug|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
79475174|NCT02280655|Biological|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
79475175|NCT02280655|Biological|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
79475176|NCT02987881|Behavioral|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
79475177|NCT02823145|Drug|ZX008 (Fenfluramine Hydrochloride)|
79475178|NCT02721589|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
79805032|NCT00621101|Drug|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
79805033|NCT00709215|Drug|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
79805034|NCT04622657|Other|dubousset functional test|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
79969123|NCT03384004|Device|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
79310704|NCT02430935|Behavioral|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
79310705|NCT02430779|Procedure|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
79310706|NCT02430779|Device|NanoKnife|
79310707|NCT03185429|Biological|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7 TSA-DC on week 1,3,5,11,17,23,35,47.
79969124|NCT01587365|Biological|BMS-962476|
79969125|NCT01587365|Biological|Placebo matching with BMS-962476|
79969126|NCT04445272|Drug|Tocilizumab|Treatment with Tocilizumab
79969127|NCT03383926|Procedure|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
79969128|NCT03383926|Procedure|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
79969129|NCT01587287|Device|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
79475179|NCT02657707|Device|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
79475180|NCT02657707|Device|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
79475181|NCT02280811|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m^2/day for 5 days.
79969130|NCT03379012|Drug|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
79310708|NCT03185429|Drug|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
79475182|NCT02280811|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
79475183|NCT02280811|Biological|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
79639758|NCT00148499|Drug|benzocaine|
79639759|NCT02929342|Drug|Pitolisant|
79805035|NCT00698958|Procedure|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
79805036|NCT00698958|Procedure|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
79805037|NCT00699036|Drug|avandia|4 mg twice daily
79805038|NCT00699036|Drug|metformin|500 mg twice daily for 48 weeks
79805039|NCT00699036|Drug|losartan|losartan 50 mg once daily
79969131|NCT03869255|Procedure|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
79969132|NCT03839667|Behavioral|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
79969133|NCT03839667|Behavioral|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
79475184|NCT02280811|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
79639760|NCT02929342|Radiation|[14C]-Pitolisant|
79475185|NCT02263963|Drug|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
79639761|NCT02929381|Device|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
79805040|NCT00709293|Drug|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
79805041|NCT00709293|Drug|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
79310709|NCT02427191|Other|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
79310710|NCT02427191|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
79969134|NCT03839667|Behavioral|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
79310711|NCT03185507|Device|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
79310712|NCT03117413|Other|Positron emission tomography scan|"Binaural hearing assessments: speech recognition in noise and sound source localization~Voice perception assessment: voice/non-voice discrimination task, free categorization task~Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
79310713|NCT03184259|Device|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
79310714|NCT03184259|Device|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
79310715|NCT03117491|Procedure|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
79310716|NCT03117491|Procedure|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
79310717|NCT03117491|Procedure|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
79310718|NCT02430701|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
79310719|NCT02430701|Device|NanoKnife|
79310720|NCT02430545|Drug|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
79310721|NCT02430545|Drug|Rifampin|Subjects receive rifampin 600 mg oral dose daily [Day -6 to day 4]
79310722|NCT03117725|Drug|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
79475186|NCT02263963|Procedure|TAP Block|no intervention will be done to this arm.
79639762|NCT02929381|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
79969135|NCT01271777|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
79639763|NCT00175851|Drug|Seletracetam (ucb 44212)|
79639764|NCT00148538|Behavioral|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
79639765|NCT03457597|Drug|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
79639766|NCT03457597|Drug|Metoprolol tartrate|Metoprolol tartrate 100 mg
79639767|NCT03457597|Drug|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
79639768|NCT03457597|Drug|Tolbutamide|Tolbutamide 500 mg
79639769|NCT03457597|Drug|Omeprazole|Omeprazole 20 mg
79639770|NCT03457597|Drug|Relacorilant|Relacorilant 350mg
79639771|NCT02929147|Drug|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
79969136|NCT01271777|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
79984433|NCT03204604|Behavioral|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
79984434|NCT03204604|Behavioral|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
79984435|NCT03204370|Drug|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
79984436|NCT03200158|Other|Endoscopy biopsy and blood|Medical operation
79984437|NCT03204448|Device|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
79984438|NCT03200080|Drug|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
79984439|NCT03200080|Drug|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
79984440|NCT03200080|Drug|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
79475187|NCT03029923|Behavioral|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
79475188|NCT03029923|Behavioral|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
79475189|NCT01930435|Device|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
79475190|NCT01930747|Drug|rocuronium|measure effect on laparoscopic workspace
79475191|NCT01930747|Drug|Sevoflurane|1 MAC sevoflurane inhalation is given
79475192|NCT01930747|Drug|remifentanyl|remifentanyl is given in infusion
79969137|NCT03387202|Procedure|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
79310723|NCT03117725|Drug|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
79310724|NCT03185351|Drug|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
79475193|NCT01931527|Drug|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
79475194|NCT01933243|Drug|Fish oil|Participants will take 4 capsules daily
79475195|NCT01933243|Drug|Placebo pill|Participants will take 4 capsules daily
79475196|NCT01933399|Other|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
79475197|NCT01933399|Other|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
79969138|NCT03387202|Diagnostic Test|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
79969139|NCT01281215|Behavioral|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
79475198|NCT01933399|Other|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
79475199|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
79475200|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
79475201|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
79475202|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
79639772|NCT02929147|Drug|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
79639773|NCT02929147|Drug|Placebo|In the Group 3 the PCA will contain placebo.
79639774|NCT02929264|Drug|ABX-1431|Capsules, 40 mg, single dose
79639775|NCT02929264|Drug|Placebo|Capsules, single dose
79969140|NCT05181501|Drug|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
79310725|NCT03185351|Drug|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
79310726|NCT03185351|Drug|Midazolam|0.03 mg/kg of midazolam by I.V. route
79310727|NCT02427035|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
79310728|NCT02427035|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
79310729|NCT02427113|Other|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
79310730|NCT02427113|Other|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
79310731|NCT02707601|Drug|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
79310732|NCT02707601|Drug|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
79310733|NCT02707601|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79310734|NCT02426957|Behavioral|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
79310735|NCT02430623|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
79310736|NCT02430623|Device|NanoKnife|
79310737|NCT02707055|Drug|PF-05190457|Ghrelin Receptor Inverse Agonist
79310738|NCT02707055|Other|Placebo|Placebo
79310739|NCT03183635|Procedure|Balance training|Improvement of balance ability in stroke patients
79310740|NCT03183557|Drug|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
79310741|NCT03183557|Drug|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
79310742|NCT03183479|Drug|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
79310743|NCT03183479|Drug|Normal saline|100mL normal saline will be administered to patients in control group as placebo
79310744|NCT02425397|Genetic|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
79639776|NCT02929186|Behavioral|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
79969141|NCT03573154|Other|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
79310745|NCT02425397|Genetic|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
79310746|NCT02425475|Device|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
79475203|NCT02639351|Biological|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
79475204|NCT02639429|Drug|Vaginal Misoprostol|
79475205|NCT02639429|Device|Foley Balloon + Vaginal Misoprostol|
79475206|NCT01936363|Drug|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
79475207|NCT01936363|Drug|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
79475208|NCT01936363|Drug|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
79639777|NCT02929186|Behavioral|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
79969142|NCT03573154|Other|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
79969143|NCT01283477|Device|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
79969144|NCT01283477|Device|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
79969145|NCT03387124|Other|Breastfed infants|Breastmilk
79969146|NCT03873779|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
79969147|NCT03383848|Device|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
79969148|NCT01167413|Device|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
79475209|NCT01936363|Drug|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
79475210|NCT01936363|Drug|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
79475211|NCT04894097|Device|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
79475212|NCT04893629|Biological|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
79475213|NCT04893629|Drug|Digoxin+furosemide+captopril|classical heart failure medical treatment
79475214|NCT04892849|Other|Conventional Therapy acc. to prevailing clincal approved schemes|The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
79475215|NCT00366587|Device|Cataract surgery and IOL implantation|
79475216|NCT00366665|Device|Legacy 20000|
79475217|NCT00366665|Device|Infinit system|
79475218|NCT01936519|Drug|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
79475219|NCT01936519|Drug|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
79475220|NCT00366743|Procedure|Conventional LASIK|
79475221|NCT00366743|Procedure|Wavefront-guided LASIK|
79475222|NCT04509557|Drug|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
79969149|NCT01167413|Other|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
79310747|NCT05526495|Behavioral|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
79310748|NCT02426723|Drug|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
79310749|NCT02426723|Drug|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
79310750|NCT03182699|Diagnostic Test|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
79310751|NCT03182699|Diagnostic Test|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
79310752|NCT03182699|Diagnostic Test|Laboratory tests|drawing blood from dialysis machine
79310753|NCT03182699|Diagnostic Test|Body composition monitoring|Measurement with BCM (Fresenius) machine
79310754|NCT03182699|Diagnostic Test|lung ultrasound|ultrasound
79310755|NCT02426879|Procedure|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
79310756|NCT02426801|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
79310757|NCT02426801|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
79310758|NCT02426567|Other|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
79310759|NCT02426567|Other|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
79310760|NCT03183011|Other|MRI|Cardiac MRI
79310761|NCT03182777|Procedure|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
79310762|NCT02425085|Procedure|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
79310763|NCT02425085|Procedure|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
79310764|NCT02425241|Biological|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
79310765|NCT02425241|Biological|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10^10 vp at week 12.
79310766|NCT02425241|Biological|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10^8 pfu at week 20
79310767|NCT02425241|Drug|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
79310768|NCT02425241|Other|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
79310769|NCT02425007|Device|Incentive spirometry|
79310770|NCT02426411|Drug|EMA401 200 mg|
79310771|NCT02426411|Drug|EMA401 600 mg|
79475223|NCT04507841|Drug|Niraparib|Niraparib was used as 100mg capsules once a day since cycle 1 / day 1. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors (the best in the morning). The patient must swallow all the capsules completely and do not chew the capsules. You may drink water or eat when taking medicine.
79475224|NCT01936909|Drug|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
79475225|NCT01936909|Drug|Anakinra (weeks 3-12)|
79475226|NCT01936909|Drug|Placebo|
79969150|NCT03383302|Radiation|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
79310772|NCT02426411|Drug|Placebo|
79310773|NCT02425163|Device|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
79310774|NCT02425163|Procedure|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
79310775|NCT02426489|Device|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
79310776|NCT03182855|Drug|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
79310777|NCT03182855|Drug|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
79310778|NCT02426333|Other|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
79310779|NCT02424929|Procedure|Sedation|Propofol anesthesia administered during entire surgery.
79310780|NCT02424929|Procedure|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
79310781|NCT02426177|Drug|Labetalol|anti-hypertensive agents
79310782|NCT02426177|Drug|Nifedipine|calcium channel blocker ,for lowering blood pressure
79310783|NCT02426099|Drug|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
79310784|NCT02426099|Other|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
79475227|NCT01938079|Drug|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
79310785|NCT03182621|Behavioral|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
79310786|NCT03182621|Behavioral|SPARK|traditional YMCA program
79310787|NCT02426021|Drug|MLN1202|Subcutaneous administration of MLN1202
79639778|NCT00175890|Drug|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
79805042|NCT04116216|Combination Product|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
79969151|NCT03383302|Drug|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
79969152|NCT01165697|Other|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
79969153|NCT03493126|Drug|Estradiol|17β-estradiol vaginal cream
79310788|NCT02426021|Drug|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
79969154|NCT03493126|Other|Placebo|Compounded placebo cream
79310789|NCT03182543|Dietary Supplement|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
79310790|NCT03182543|Dietary Supplement|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
79310791|NCT03182543|Dietary Supplement|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
79310792|NCT02425709|Drug|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
79310793|NCT02425709|Drug|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
79310794|NCT02425709|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
79310795|NCT03182153|Device|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
79310796|NCT03183089|Drug|Rohto Dry-Aid®|
79310797|NCT03183089|Drug|Systane® Ultra|
79310798|NCT03183167|Other|No intervention|
79310799|NCT02073682|Drug|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
79310800|NCT02073682|Drug|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
79310801|NCT02073682|Drug|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
79639779|NCT00175890|Other|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
79639780|NCT00148577|Device|Transcutaneous Electrical Nerve Stimulation|
79639781|NCT02929030|Device|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
79639782|NCT02929303|Drug|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
79639783|NCT02929225|Drug|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
79639784|NCT02929225|Other|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
79639785|NCT00148616|Drug|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
79969155|NCT01167491|Biological|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
79969156|NCT03488758|Other|CMF|Taking a infant formula based on cow milk protein fractions, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
79969157|NCT03488758|Other|GMF|Taking a infant formula based on whole goat milk, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
79639786|NCT00148616|Drug|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
79639787|NCT02928835|Device|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
79639788|NCT00175929|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
79639789|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
79639790|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
79805043|NCT04116216|Combination Product|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
79969158|NCT01283633|Device|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
79310802|NCT03181919|Drug|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
79310803|NCT02072980|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses
79310804|NCT02706899|Drug|vadastuximab talirine|Intravenous (IV) push every 4 weeks
79310805|NCT02706899|Drug|Azacitidine|75 mg/m^2 given intravenously or subcutaneously for 7 days every 4 weeks
79310806|NCT02706899|Drug|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
79310807|NCT03107039|Behavioral|Exercise|A 12 week resistance exercise curriculum
79475228|NCT01938079|Other|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
79969159|NCT01283711|Device|apollo device|RF treatments for wrinkles and rhytides reduction
79969160|NCT03257358|Drug|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
79969161|NCT03386656|Drug|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
79969162|NCT03386656|Other|Saline Solution|Placebo
79969163|NCT03871439|Drug|PF-05221304 Formulation A|50mg
79969164|NCT03871439|Drug|PF-05221304 Formulation B|50mg
79969165|NCT03125278|Other|Medication knowledge|Participants will be asked questions over the phone about their medications
79969166|NCT01165853|Other|Glucose|25% dose at 8-week intervention assigned to subjects.
79969167|NCT01165853|Other|Fructose|25% dose at 8-week intervention assigned to subjects.
79969168|NCT03378778|Procedure|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
79969169|NCT01281527|Drug|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
79969170|NCT03378700|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
79984441|NCT03200080|Drug|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
79310808|NCT03107039|Behavioral|Health Education|A 12 week health education curriculum
79310809|NCT03106883|Behavioral|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
79310810|NCT03106883|Behavioral|Sham training|3 sessions of sham attention training using non-affective stimuli
79310811|NCT03181997|Device|Native aortic valve|Native valve, with any transcatheter heart valve type
79310812|NCT03181997|Procedure|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
79310813|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
79310814|NCT02425553|Other|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
79310815|NCT02425553|Other|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
79310816|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
79310817|NCT02424773|Device|High Flow Nasal Canula (HFNC)|
79310818|NCT02424773|Device|Venturi mask|
79310819|NCT02424773|Drug|Oxygen|
79310820|NCT02425631|Device|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
79310821|NCT02421575|Drug|Hydroxychloroquine|Given PO
79310822|NCT02421575|Other|Laboratory Biomarker Analysis|Correlative studies
79310823|NCT02424695|Drug|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
79310824|NCT02424695|Drug|Placebo|
79639791|NCT02928796|Behavioral|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
79639792|NCT02928874|Behavioral|% COMPX (low ED vs. high ED preload)|
79639793|NCT02928874|Behavioral|EAH (low ED vs. high ED snacks)|
79639794|NCT02928913|Other|No intervention|
79639795|NCT02928679|Drug|Liraglutide 3 mg (Saxenda)|
79639796|NCT02928679|Drug|Liraglutide 3 mg placebo|
79969171|NCT03378700|Other|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
79475229|NCT02641067|Drug|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
79475230|NCT01939405|Behavioral|built environment use counseling|
79475231|NCT02329015|Behavioral|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
79805044|NCT04116216|Combination Product|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
79805045|NCT04208711|Other|biological sample|whole blood sample
79805046|NCT04212455|Other|Non-interventional study|This is an observational, non-interventional study
79969172|NCT03378622|Other|Anchor|Anchor technique for mesh attachment
79475232|NCT02329015|Behavioral|Physical Education Class|Standard physical education
79475233|NCT02641691|Radiation|Radiation|
79475234|NCT02641691|Drug|Oxaliplatin|
79475235|NCT02641691|Drug|Leucovorin|
79475236|NCT02641691|Drug|Fluorouracil|
79475237|NCT02642237|Biological|Fluenz|intranasal inoculation with Fluenz
79475238|NCT02642237|Other|placebo|
79475239|NCT02642237|Other|LPS|
79639797|NCT02928640|Device|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
79639798|NCT02928445|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
79639799|NCT02928445|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
79639800|NCT02928562|Other|exercise|cyclic exercise, aerobic exercise and resistant training exercise
79639801|NCT02928601|Drug|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
79639802|NCT02928601|Drug|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
79639803|NCT02928484|Dietary Supplement|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
79639804|NCT02928484|Dietary Supplement|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
79639805|NCT02928523|Drug|Autologous Fecal Microbiota Transplantation|
79969173|NCT03378622|Other|Suture|Suture technique for mesh attachment
79969174|NCT03871127|Procedure|Percutaneous coronary intervention|Using sirolimus eluting stent
79969175|NCT03871127|Procedure|coronary artery bypass graft|coronary artery bypass graft
79969176|NCT03378544|Behavioral|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
79969177|NCT01313832|Other|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
79969178|NCT03385876|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
79984442|NCT03200314|Other|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
79475240|NCT01941745|Drug|Half normal saline|2 ml/kg
79475241|NCT01941745|Drug|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
79475242|NCT01941745|Drug|High dose rhCC10|5 mg/kg in 2 ml/kg
79475243|NCT01943227|Other|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
79639806|NCT02928367|Other|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
79639807|NCT02928367|Other|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
79639808|NCT02928367|Other|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
79639809|NCT02928328|Drug|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
79639810|NCT02928328|Drug|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
79639811|NCT02928328|Drug|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
79639812|NCT02928250|Dietary Supplement|Carnosine|Patients in intervention group received carnosine capsules orally daily
79639813|NCT02928250|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
79639814|NCT02928211|Device|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
79639815|NCT02928211|Drug|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
79639816|NCT02928211|Radiation|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
79639817|NCT00148655|Device|Decision Board|Decision board that explains the risks and benefits of treatment options
79639818|NCT00175968|Procedure|bed rest, hypocaloric nutrition|
79639819|NCT02927977|Other|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
79310825|NCT02422277|Device|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
79310826|NCT02422277|Drug|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
79639820|NCT02927977|Other|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
79639821|NCT02928016|Other|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
79639822|NCT02928016|Other|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
79639823|NCT02928016|Other|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
79639824|NCT02928016|Other|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
79639825|NCT02928016|Other|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
79805047|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
79805048|NCT00819741|Drug|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
79805049|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
79805050|NCT04208555|Drug|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
79805051|NCT04208555|Drug|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
79805052|NCT00621725|Drug|AZD2171|Oral dose
79969179|NCT01281605|Behavioral|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(<110mg/dl).
79805053|NCT00862134|Drug|PR104|770 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
79805054|NCT00862134|Drug|docetaxel|75 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
79310827|NCT02422121|Drug|RNS60|
79969180|NCT01281605|Behavioral|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG < 70 mg/dL.
79969181|NCT03386422|Behavioral|MSC|Mindfulness and Self-Compassion training
79969182|NCT03386422|Behavioral|CBT|Cognitive-behavioural techniques training
79310828|NCT02422121|Drug|Placebo|
79310829|NCT02424305|Drug|LEO 43204 gel 0.018%|
79310830|NCT02424305|Drug|LEO 43204 gel 0.1%|
79310831|NCT02424305|Drug|LEO 43204 gel 0.037%|
79310832|NCT02421107|Other|Glysure CGM|
79805055|NCT00862134|Drug|docetaxel|60 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
79310833|NCT02421107|Other|iStat intermittent testing|
79969183|NCT03871205|Biological|Neoantigen loaded DC vaccine|Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
79310834|NCT02424461|Drug|Ceftriaxone|1 injection 1 g per day for 2 days
79969184|NCT01170143|Drug|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
79310835|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
79310836|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
79310837|NCT02424461|Drug|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
79310838|NCT02072824|Drug|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
79310839|NCT02072824|Drug|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
79310840|NCT02072824|Drug|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
79310841|NCT04440605|Procedure|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
79475244|NCT01943227|Other|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
79475245|NCT02642393|Drug|Inosine|capsules containing 500 mg of inosine
79475246|NCT02642393|Drug|Placebo|capsules containing ~500 mg of lactose and appearing indistinguishable from inosine capsules
79475247|NCT02642627|Device|Bellafill|
79475248|NCT04272593|Device|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
79475249|NCT04740749|Device|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
79475250|NCT04741061|Biological|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
79475251|NCT04741061|Other|Placebo|Placebo
79475252|NCT04221737|Device|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
79805056|NCT00862134|Drug|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
79969185|NCT05171530|Drug|Lenvatinib plus taxane drugs|"Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
79969186|NCT02936037|Drug|MD1003 100mg capsule|
79969187|NCT02936037|Drug|PLACEBO|an inactive substance
79969188|NCT03288714|Device|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
79969189|NCT03288714|Device|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
79969190|NCT03869099|Other|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
79310842|NCT02421185|Drug|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
79310843|NCT03117257|Drug|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
79310844|NCT03117257|Drug|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
79475253|NCT04221737|Device|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
79475254|NCT00367757|Procedure|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
79475255|NCT00367757|Procedure|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
79475256|NCT00367757|Procedure|Combined approach for AF ablation|Combined trigger and substrate based approach
79639826|NCT02928016|Other|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
79639827|NCT02927899|Other|Survey Administration|Ancillary studies
79639828|NCT02927899|Dietary Supplement|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
79969191|NCT05171452|Biological|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
79969192|NCT02526251|Other|observational|No intervention
79969193|NCT03386188|Device|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
79475257|NCT05588999|Procedure|Cryotherapy Alone|"Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe"
79805057|NCT04188197|Other|JUUL|Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
79805058|NCT04120428|Other|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
79805059|NCT00621803|Drug|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
79805060|NCT02614014|Behavioral|Cognitive-behavior interventional program|
79805061|NCT04527029|Other|No interventions|It is an observational study. No interventions.
79475258|NCT05588999|Combination Product|Cryotherapy plus Salicylic Acid|Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
79475259|NCT04339283|Dietary Supplement|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
79475260|NCT01643928|Biological|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion [IV] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
79805062|NCT00700284|Drug|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
79969194|NCT03386188|Device|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
79639829|NCT02927860|Other|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
79639830|NCT00148694|Drug|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
79639831|NCT00176007|Procedure|Hypoxia|
79639832|NCT02927704|Other|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
79805063|NCT00700284|Drug|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
79805064|NCT04187885|Behavioral|Group/Cohort 2: PAP|"Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program."
79805065|NCT00618527|Drug|mycophenolate mofetil (Cellcept)|1 gram po, bid
79805066|NCT00618527|Drug|human interferon beta 1a (Rebif)|44mcg sq injection every other day
79805067|NCT02691533|Drug|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
79805068|NCT02691533|Drug|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
79805069|NCT02691533|Drug|No Lipid Emulsion/Placebo|
79805070|NCT00848484|Drug|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
79805071|NCT00848484|Drug|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
79805072|NCT00621881|Drug|naproxcinod|750 mg bid
79805073|NCT05214053|Device|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
79805074|NCT04115982|Drug|Cholecalciferol|One vial every 15 days during 2 months
79805075|NCT04115982|Drug|Placebos|One vial every 15 days during 2 months
79475261|NCT01643928|Biological|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
79805076|NCT05662631|Device|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
79475262|NCT01643928|Biological|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
79805077|NCT03904121|Procedure|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
79310845|NCT02072668|Drug|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
79969195|NCT03868865|Behavioral|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
79969196|NCT03256578|Device|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
79969197|NCT04933071|Behavioral|Podcast|A list of podcasts that are specified for each rotation
79475263|NCT03750071|Biological|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
79805078|NCT00622037|Drug|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
79805079|NCT00622037|Drug|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
79805080|NCT04208789|Diagnostic Test|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
79805081|NCT04208789|Other|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
79805082|NCT04208789|Diagnostic Test|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
79805083|NCT02691377|Device|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
79805084|NCT02691377|Device|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
79805085|NCT00618605|Biological|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
79475264|NCT03750071|Biological|Avelumab|Monoclonal anti-PD-L1 Antibody
79475265|NCT03631979|Other|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
79310846|NCT02072668|Drug|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
79310847|NCT03179267|Device|SNAP40|SNAP40 ambulatory monitoring device
79310848|NCT04750876|Other|Conventional support|"Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support."
79639833|NCT02927782|Procedure|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
79639834|NCT02927782|Procedure|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
79639835|NCT02927665|Device|Reshape Integrated Dual Balloon|
79805086|NCT00509821|Drug|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
79310849|NCT04750876|Other|Specific care, including the intervention of a psychologist and a physical therapist.|"In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~consultations with a psychologist~The patient will also be cared for on a daily basis by a physical therapist."
79475266|NCT05588765|Other|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
79310850|NCT03181841|Drug|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
79310851|NCT03181841|Drug|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
79310852|NCT03116789|Dietary Supplement|probiotics|Two capsules for daily
79969198|NCT01283789|Drug|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
79969199|NCT03383068|Drug|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
79969200|NCT03383068|Drug|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
79969201|NCT03383068|Drug|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
79969202|NCT03383068|Drug|Metformin|metformin effective subjects,act as control group
79969203|NCT03873701|Diagnostic Test|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
79310853|NCT03181685|Drug|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
79475267|NCT04339829|Drug|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
79475268|NCT04740281|Behavioral|Footwear|Assessment of footwear
79475269|NCT05588531|Drug|Group 1:YK-1169|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
79475270|NCT05588531|Drug|Group 2:YK-1169/Placebo Injection|YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
79639836|NCT03457480|Other|Computer-Assisted Intervention|Read computer messages
79639837|NCT03457480|Behavioral|Focus Group|Attend focus group
79639838|NCT03457480|Other|Informational Intervention|Receive text messages
79639839|NCT03457480|Other|Survey Administration|Complete surveys about experience
79639840|NCT00148772|Drug|Erlotinib (Tarceva)|
79310854|NCT03181685|Drug|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
79310855|NCT03181685|Drug|recombinant FSH|Controlled ovarian stimulation (COS)
79310856|NCT03181685|Drug|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
79310857|NCT03116711|Other|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
79310858|NCT03116711|Other|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
79310859|NCT03116711|Other|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
79639841|NCT02927743|Behavioral|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
79639842|NCT02927626|Drug|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
79639843|NCT02927626|Drug|Routine medical care|Routine medical care
79639844|NCT00176046|Drug|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
79639845|NCT00176046|Drug|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
79639846|NCT02927587|Drug|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
79805087|NCT00509821|Drug|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
79805088|NCT04208165|Other|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
79639847|NCT00148850|Drug|Pioglitazone|
79639848|NCT02927353|Drug|DMB-3113|subcutaneously injected in a single dose of 40 mg.
79639849|NCT02927353|Drug|Adalimumab|subcutaneously injected in a single dose of 40 mg.
79805089|NCT04208165|Other|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
79475271|NCT05588531|Drug|Group 3:YK-1169/Placebo|On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
79475272|NCT05588531|Drug|Group 4:YK-1169/Placebo|On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
79805090|NCT01010581|Drug|SC12267 (4SC-101)|oral administration
79475273|NCT05588531|Drug|Group 5:YK-1169/Placebo Injection|YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
79969204|NCT03227445|Device|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
79969205|NCT03227445|Device|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
79969206|NCT03227445|Device|HandiHaler placebo DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
79969207|NCT03227445|Other|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
79969208|NCT03869021|Other|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
79639850|NCT02927509|Drug|TNF alpha blockers|
79639851|NCT02927314|Drug|CF102|orally q12h
79639852|NCT02927314|Drug|Placebo|orally q12h
79639853|NCT00148889|Device|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
79639854|NCT02927275|Behavioral|Experimental: Standing Modality|Cognitive performance when standing
79639855|NCT02927275|Behavioral|Experimental: Biking Modality|Cognitive performance when biking slowly
79805091|NCT01010581|Drug|Placebo|oral administration
79805092|NCT01010581|Drug|Methotrexate|oral administration
79805093|NCT01010581|Drug|Folic Acid|oral administration
79805094|NCT04382885|Drug|Cariprazine|Oral Solution
79805095|NCT01010659|Device|Lacrimal Tube|Lacrimal Tube
79805096|NCT04208867|Behavioral|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
79310860|NCT03116711|Other|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
79475274|NCT05588531|Drug|Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection|YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
79639856|NCT02927275|Behavioral|Experimental: Walking Modality|Cognitive performance when walking at 1mph
79639857|NCT02927275|Behavioral|No Intervention: Seated Modality|Cognitive performance when sitting.
79639858|NCT00176124|Procedure|leukocyte depletion of whole blood|
79639859|NCT00176124|Other|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
79805097|NCT01015963|Other|laboratory biomarker analysis|Perform DNA sample analysis
79805098|NCT04208945|Drug|Colistin|500000 units of inhaled colistin three times daily for 10 days
79805099|NCT01016041|Device|everolimus stent|stenting
79805100|NCT01016041|Device|paclitaxel stent|stenting
79805101|NCT03820661|Device|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
79805102|NCT05662475|Diagnostic Test|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Gingival fluid collection strips were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument. Then, the strips were sealed into sterile tubes before freezing at -80 °C. The readings were converted to an actual volume (μl) by reference to the standard curve.
79475275|NCT05588375|Behavioral|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
79475276|NCT05588297|Drug|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
79805103|NCT05662475|Procedure|Non-surgical periodontal treatment completed in 24 hours|After clinical periodontal parameters were recorded and GCF samples were obtained, non-surgical periodontal treatment was started under local anesthesia. All periodontal treatments were performed by a single investigator. Local infiltrative anesthesia was applied to the buccal and palatal/lingual areas of the maxilla and mandible of the patients. After anesthesia was achieved, scaler and ultrasonic tips of various thicknesses were used together to remove supragingival and subgingival hard attachments. Root surface smoothing was performed with region-specific periodontal curettes. The roughness of the surfaces was controlled using a periodontal probe. Polishing was performed. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning is explained. The patient was told not to use any chemical agent for plaque removal.
79639860|NCT02927470|Device|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
79805104|NCT05662475|Diagnostic Test|HbA1c level determination in blood serum|Blood samples were taken from the patients and HbA1c concentration was measured in serum.
79805105|NCT02697305|Dietary Supplement|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
79805106|NCT02697305|Dietary Supplement|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
79805107|NCT02697305|Other|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
79805108|NCT00622115|Drug|Enoxaparin|
79475277|NCT05588297|Drug|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
79475278|NCT05588297|Drug|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
79805109|NCT04208633|Procedure|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
79805110|NCT04208633|Procedure|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
79475279|NCT04339673|Procedure|masseteric nerve block|regional bloc of masseter
79475280|NCT04339673|Procedure|trigger point injection|trigger point injection with local anesthetic
79475281|NCT04339673|Procedure|dry needling|needling with acupuncture needles of trigger points in masseter
79475282|NCT00366977|Behavioral|Multi-session telephone counseling|
79805111|NCT00508651|Biological|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
79805112|NCT00508651|Biological|Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
79805113|NCT02696837|Device|ETT|
79805114|NCT02696837|Device|Proseal LMA|
79310861|NCT03181373|Other|Cognitive rehabilitation program|Rehabilitation
79475283|NCT00366977|Drug|NRT patches|
79969209|NCT03869021|Other|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
79475284|NCT02303405|Drug|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
79475285|NCT02303405|Drug|Pioglitazone|Anti-hyperglycemic agent
79475286|NCT02164955|Drug|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
79475287|NCT05587907|Device|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
79310862|NCT02140762|Biological|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
79310863|NCT02140762|Other|Placebo|0.5 mL saline solution (IM)
79310864|NCT02140762|Biological|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
79310865|NCT03106961|Device|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
79310866|NCT03106727|Behavioral|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
79310867|NCT02424071|Drug|Melatonin|
79310868|NCT02424071|Drug|placebo|
79310869|NCT02101294|Device|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout [actual home row placement order: asdeihotlrn], plus substitutions on the upper row [qwfgjyuk;p] and bottom row [zxcvb'm,.] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
79310870|NCT02101294|Device|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
79310871|NCT03179111|Procedure|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
79310872|NCT03178955|Drug|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
79475288|NCT05587829|Other|• Diaphragmatic breathing technique|In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
79310873|NCT01598506|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
79310874|NCT02423915|Drug|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
79310875|NCT02423915|Drug|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
79475289|NCT05587829|Other|basic breathing technique|Deep Breathing for 15 minutes
79475290|NCT04740203|Drug|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
79969210|NCT04067401|Behavioral|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
79310876|NCT02423915|Drug|Cyclophosphamide|50 mg/kg by vein on Day -8.
79310877|NCT02423915|Radiation|Total Body Radiation|2 Gy delivered on Day -4.
79310878|NCT02423915|Procedure|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Fucosylated T-reg cells on Day -1."
79310879|NCT02423915|Procedure|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
79310880|NCT02423915|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
79310881|NCT02423915|Drug|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
79310882|NCT02423915|Procedure|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
79475291|NCT01943461|Drug|Avelumab 3 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
79475292|NCT01943461|Drug|Avelumab 10 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
79475293|NCT01943461|Drug|Avelumab 20 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
79475294|NCT01397669|Procedure|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
79475295|NCT00786539|Device|Diffuse Optical Spectroscopy|mitochondria
79805115|NCT02696837|Drug|Rocuronium|
79310883|NCT02423915|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
79310884|NCT02423915|Procedure|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1."
79310885|NCT02423837|Drug|Rituximab, bendamustine|
79310886|NCT03178877|Other|No intervention|
79310887|NCT02140060|Drug|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
79310888|NCT02140060|Drug|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
79310889|NCT02140060|Drug|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
79310890|NCT02140060|Drug|Brinzolamide 1% ophthalmic suspension AZOPT®|
79310891|NCT02140060|Drug|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
79969211|NCT04067401|Behavioral|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
79310892|NCT02140060|Drug|Travoprost solution vehicle|Inactive ingredients used for masking purposes
79310893|NCT02140060|Drug|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
79310894|NCT03181295|Behavioral|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
79310895|NCT03178721|Diagnostic Test|blood sample|study B regulatory in blood and its correlation with atherosclerosis
79310896|NCT02421029|Drug|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
79805116|NCT02696837|Other|No Muscle Relaxant|
79805117|NCT02696837|Drug|Rocuronium|
79805118|NCT03753893|Other|No intervention used|no intervention used
79805119|NCT03997045|Behavioral|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
79805120|NCT03996889|Device|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~Number of GORE VIABAHN® stent used (length and diameter of each)~Embolization of collaterals and other related actions~Operative complications~Intraoperative fibrinolysis~Collar cover> 2 cm~Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~Arteriography in profile, kink"
79805121|NCT01016119|Drug|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
79969212|NCT03378310|Drug|BMS-986205 reference tablet|Single, 100 mg oral dose.
79969213|NCT03378310|Drug|BMS-986205 tablet with free base|Single, 100 mg oral dose.
79969214|NCT01283867|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
79969215|NCT03382990|Device|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
79969216|NCT03378232|Dietary Supplement|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
79310897|NCT03181217|Other|water 0|300 ml tap water at 0 ºC
79310898|NCT03181217|Other|water 22|300 ml tap water at 22 ºC
79310899|NCT03181217|Other|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
79310900|NCT03181217|Other|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
79310901|NCT02139982|Procedure|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
79310902|NCT02139982|Drug|ropivacaine|Different concentration of ropivacaine
79310903|NCT03181139|Other|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
79310904|NCT03178643|Drug|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
79310905|NCT03178643|Drug|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
79310906|NCT03178643|Drug|Dihydroartemisinin-Piperaquine (DP)|"3) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
79310907|NCT03180983|Behavioral|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
79310908|NCT02139826|Drug|IX-01|
79310909|NCT02420561|Behavioral|Motivational Interviewing|"One in-person motivational interviewing session intervention that lasts for 45-minutes~Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
79310910|NCT02420561|Behavioral|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
79475296|NCT00422435|Device|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
79475297|NCT03679247|Other|Intervention|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations)."
79969217|NCT03378232|Dietary Supplement|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
79969218|NCT03378232|Dietary Supplement|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
79969219|NCT01170299|Dietary Supplement|dietary intervention|
79969220|NCT01170299|Other|laboratory biomarker analysis|
79969221|NCT01170299|Procedure|gastrointestinal complications management/prevention|
79969222|NCT01170299|Procedure|management of therapy complications|
79310911|NCT02420483|Other|Cardiopulmonary resuscitation chest compressions|
79310912|NCT02139592|Drug|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
79310913|NCT02139280|Drug|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
79310914|NCT02072434|Drug|Edoxaban|Edoxaban 30 mg tablets for oral administration
79310915|NCT02072434|Drug|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
79310916|NCT02072434|Drug|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
79310917|NCT04725994|Drug|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
79310918|NCT04725994|Drug|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
79310919|NCT02101060|Other|exercise|16-week progressive aerobic and resistance exercise training
79310920|NCT02139124|Drug|Placebo|Oral placebo capsule
79310921|NCT02139124|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
79310922|NCT02139124|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
79310923|NCT02139124|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
79310924|NCT02139124|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
79310925|NCT02139046|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
79310926|NCT02139046|Drug|Febuxostat XR|Febuxostat XR over-encapsulated capsules
79310927|NCT02139046|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
79310928|NCT02139046|Drug|Colchicine|Colchicine tablets
79310929|NCT02139046|Drug|Naproxen|Naproxen tablets
79310930|NCT02139046|Drug|Lansoprazole|Lansoprazole capsules
79310931|NCT02138890|Device|APS|Intra-articular Injection
79310932|NCT02138890|Device|Saline|Intra-articular injection
79310933|NCT04725526|Device|Mobile phone compatible with iOS or Android|MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
79310934|NCT02100670|Drug|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
79475298|NCT03679247|Other|Control|Usual Care, PCP will receive an email with general information about CKD guidelines
79310935|NCT02100670|Drug|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
79310936|NCT02100670|Drug|3% menthol|To be applied four times daily for 10 days.
79475299|NCT00540683|Device|Diffuse Optical Spectroscopy|Muscle properties
79969223|NCT01170299|Radiation|selective external radiation therapy|
79310937|NCT02100670|Drug|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
79310938|NCT02070484|Biological|NuCel|
79310939|NCT02070484|Biological|Demineralized Bone Matrix|
79805122|NCT01016119|Drug|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
79310940|NCT02100514|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
79310941|NCT02100514|Other|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
79310942|NCT02069392|Behavioral|Cognitive remediation training|
79310943|NCT02069392|Drug|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
79310944|NCT02047318|Drug|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
79805123|NCT01016197|Procedure|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
79805124|NCT01016197|Procedure|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
79805125|NCT01016275|Device|Misago (stent placement)|Misago iliac stent
79805126|NCT00490555|Drug|Testosterone gel|Testosterone gel 10 g
79805127|NCT00490555|Drug|Dutasteride|dutasteride 0.5 mg orally
79805128|NCT00490555|Drug|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
79805129|NCT00490555|Other|Placebo Testosterone gel|Place gel applied daily for 12 weeks
79310945|NCT05517759|Other|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
79310946|NCT05517681|Other|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
79310947|NCT05517681|Drug|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
79969224|NCT03378154|Procedure|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
79969225|NCT03378154|Procedure|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
79310948|NCT05525793|Other|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
79805130|NCT00490555|Other|Placebo dutasteride|placebo pill for 12 weeks
79805131|NCT00490555|Other|Placebo DMPA|placebo DMPA injection Once
79805132|NCT00501085|Device|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
79805133|NCT01014247|Drug|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
79805134|NCT01014247|Drug|Placebo|Single dose of matching tablet
79805135|NCT01014325|Biological|Allergen extract|sublingual application
79969226|NCT04194151|Drug|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
79310949|NCT05525715|Drug|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
79310950|NCT05525715|Drug|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
79310951|NCT05525715|Drug|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
79310952|NCT05525715|Drug|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
79310953|NCT05525715|Drug|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
79310954|NCT05525715|Drug|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
79310955|NCT05525715|Drug|5mg QY201 tablets，BID|5mg QY201 tablets，BID
79310956|NCT05525715|Drug|10mg QY201 tablets，BID|10mg QY201 tablets，BID
79475300|NCT00540371|Other|Port wine stain Birthmark|Port wine stain Birthmark
79310957|NCT05525715|Drug|20mg QY201 tablets，BID|20mg QY201 tablets，BID
79310958|NCT05525715|Drug|QY201 placebo，BID|QY201placebo，BID
79310959|NCT02100124|Behavioral|Reproductive Life Planning (RLP)|
79310960|NCT02100124|Behavioral|Contraceptive Action Planning|
79310961|NCT02100124|Behavioral|Contraception information|
79310962|NCT05522283|Diagnostic Test|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
79310963|NCT02068768|Device|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
79310964|NCT02046616|Drug|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
79310965|NCT02046616|Drug|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
79475301|NCT03029767|Other|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
79475302|NCT03029767|Other|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
79475303|NCT03029767|Other|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
79805136|NCT01014325|Biological|Placebo|sublingual application
79310966|NCT02046616|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
79805137|NCT01010737|Biological|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
79310967|NCT05525559|Drug|ET0038|ET0038 for oral administration
79310968|NCT04425057|Other|Interval training|
79310969|NCT05525481|Drug|Tamoxifen|Hormone therapy
79310970|NCT02099344|Device|Artegraft|Surgical placement of graft for hemodialysis access
79310971|NCT02099344|Device|Propaten|Surgical placement of graft for hemodialysis access
79310972|NCT02068222|Drug|ABT-450/ritonavir (r)|Tablet
79310973|NCT02068222|Drug|ABT-530|Tablet
79310974|NCT02068222|Drug|Ribavirin (RBV)|Tablet
79310975|NCT05517213|Drug|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
79969227|NCT01281761|Drug|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
79969228|NCT04280328|Drug|Ciforadenant|100 mg orally twice daily for 28-day cycles
79969229|NCT04280328|Drug|daratumumab|"16 mg/kg administered intravenously as follows based on 28-day cycles:~Cycles 1 - 2: Days 1, 8, 15, and 22~Cycles 3 - 6: Days 1 and 15~Cycles 7 - 24: Day 1"
79969230|NCT03385954|Other|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
79969231|NCT03385954|Other|Control|will receive a lecture of 30 minutes.
79310976|NCT05517213|Drug|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
79969232|NCT03820323|Diagnostic Test|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL>1000 copies/mL) is detected.
79310977|NCT05517135|Other|Arm 1|Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC) with capecitabine (physician's choice of 650 mg/m2 bid or 1000 mg/m2 bid oral, d1-21, q3w)
79310978|NCT05517135|Other|Arm 2|IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT
79969233|NCT03820323|Diagnostic Test|SOC VL testing|SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
79969234|NCT03748147|Drug|Misoprostol|prostaglandin e1
79969235|NCT01580813|Drug|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
79969236|NCT01580813|Drug|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
79969237|NCT05002504|Diagnostic Test|A series of questions were asked to the children's parents in a virtual questionnaire|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
79310979|NCT05517135|Other|Arm 3|CCRT + metronomic capecitabine (650 mg/m2 bid oral, d1-21, q3w)
79969238|NCT05002504|Diagnostic Test|"neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)"|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
79969239|NCT05002504|Procedure|Therapy sessions|Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
79310980|NCT05517135|Other|Group 1|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
79310981|NCT05517135|Other|Group 2|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
79310982|NCT05516901|Procedure|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
79310983|NCT05516901|Procedure|Control group|Patients in this group will receive general anesthesia alone.
79310984|NCT05516823|Other|Usage of drugs|Self-reported past usage of drugs belonging to different chemical groups.
79310985|NCT05512299|Diagnostic Test|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
79805138|NCT01010737|Biological|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
79805139|NCT01010737|Biological|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
79475304|NCT03676283|Other|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
79475305|NCT03642821|Device|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
79475306|NCT00702481|Drug|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
79310986|NCT05521971|Other|multifaceted pharmacist-led intervention|"Educational sessions were provided to the physicians and nursing staff.~Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~The patient's primary care physician and, if applicable, the nursing home were informed by phone."
79310987|NCT05521971|Other|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
79475307|NCT00702481|Drug|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
79475308|NCT00702481|Radiation|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
79475309|NCT02643875|Device|Orthokeratology|It is a kind of rigid permeable lens.
79475310|NCT02645123|Device|TENS|Enraf-Nonius Sonopuls 692
79475311|NCT02645123|Procedure|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
79805140|NCT01010737|Biological|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
79475312|NCT02645123|Procedure|swedish type massage|petrissage, effleurage, tapotement
79805141|NCT01010737|Biological|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
79805142|NCT01010737|Biological|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
79805143|NCT01010737|Biological|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
79805144|NCT00873860|Other|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
79805145|NCT00873860|Biological|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
79475313|NCT02645123|Procedure|static hamstring stretch|static hamstring stretching
79475314|NCT02645123|Procedure|sham treatment|touching of the skin overlying the lumbar area
79475315|NCT00367211|Drug|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
79475316|NCT00367211|Drug|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
79475317|NCT02646371|Biological|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
79475318|NCT02646371|Biological|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
79475319|NCT02646449|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
79805146|NCT00873860|Biological|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
79805147|NCT00873860|Biological|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
79805148|NCT03854227|Drug|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
79805149|NCT03854227|Drug|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
79805150|NCT03854227|Drug|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
79805151|NCT04350905|Other|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
79805152|NCT05368961|Behavioral|Distraction|Distraction (interactive tablet)
79639861|NCT02927470|Device|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
79310988|NCT05521893|Other|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
79639862|NCT02927470|Device|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
79639863|NCT02927197|Behavioral|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
79805153|NCT05368961|Other|Usual care|Anxiolytic ordered by anesthesiologist is usual care
79310989|NCT05521893|Other|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
79805154|NCT03853291|Behavioral|PICT Workbook|PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.
79969240|NCT01314183|Other|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
79475320|NCT02646449|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
79475321|NCT02646761|Device|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
79639864|NCT02927002|Device|Noninvasive brain stimulation|
79805155|NCT03853291|Behavioral|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
79805156|NCT00622271|Behavioral|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
79805157|NCT04207853|Other|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
79805158|NCT04207853|Other|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
79805159|NCT04207853|Other|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
79475322|NCT02646761|Other|Standard of Care Physical Therapy|Physical therapy rehabilitation program
79639865|NCT02927119|Dietary Supplement|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
79639866|NCT02927041|Device|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
79969241|NCT01314183|Other|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
79639867|NCT00170235|Other|Prehabilitation|Exercise class pre-surgery
79639868|NCT00170235|Other|Usual care|Exercise booklet, physiotherapy if needed
79639869|NCT00148928|Biological|P501-AS15 vaccine|
79639870|NCT02926885|Device|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
79639871|NCT02926885|Device|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
79639872|NCT02926885|Procedure|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
79639873|NCT02926963|Other|samples collection : hair and skin biopsy|
79639874|NCT02926807|Other|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
79969242|NCT04446364|Other|Ethanolic extract of Aloe vera gel cavity disinfectant|Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
79969243|NCT04446364|Other|Chlorohexadine|2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
79639875|NCT02926807|Other|MDCT|a MDCT to calculate the Agatston score
79805160|NCT04207853|Other|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
79805161|NCT03853213|Behavioral|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
79805162|NCT03853213|Behavioral|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
79805163|NCT00691730|Other|laboratory biomarker analysis|Only sample collection, no other intervention - Correlative studies
79969244|NCT01588535|Drug|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
79969245|NCT01588535|Drug|placebo|placebo solution, five drops in affected ear canal each hour as needed
79475323|NCT02646917|Procedure|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
79639876|NCT02926807|Other|biopsy and blood collection|biopsy and blood collection to assess biomarkers
79639877|NCT00170274|Device|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
79639878|NCT00170274|Device|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
79639879|NCT00148967|Device|Implantable Cardioverter Defibrillator|
79639880|NCT02926846|Drug|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
79639881|NCT02926846|Drug|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
79639882|NCT02926612|Other|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
79639883|NCT02926495|Device|eCoin System|Median nerve neurostimulator.
79639884|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
79639885|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
79639886|NCT02926300|Biological|stem cells|IV infusion
79639887|NCT02926378|Procedure|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
79639888|NCT00149006|Procedure|Cell therapy|
79639889|NCT02926183|Drug|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
79639890|NCT00170352|Procedure|Hyperbaric Oxygen Treatment (HBOT)|
79639891|NCT00170352|Procedure|Enhanced Oxygen Treatment (Enhanced FiO2)|
79639892|NCT02926261|Other|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
79639893|NCT02926339|Behavioral|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
79639894|NCT02926105|Behavioral|T&E Home-based exercise programme|"T&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
79639895|NCT02926105|Behavioral|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
79805164|NCT04138160|Other|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
79805165|NCT04138160|Other|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
79805166|NCT04274231|Genetic|different effection|Analysis of the reasons for treatment
79310990|NCT05077761|Device|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~Wavelength- 980 nm~Intensity/Power density- 3W/cm2~Emission mode- Continuous Emission~Energy (Joules)- 490 J~Irradiation time- 70 Sec on each point~Peak power- 15 Watt~Irradiation points- 09"
79310991|NCT05077761|Device|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
79310992|NCT05516745|Device|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
79969246|NCT03637101|Diagnostic Test|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
79969247|NCT03287622|Behavioral|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
79639896|NCT02926105|Behavioral|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
79639897|NCT00170391|Behavioral|Quarter of an Hour rule|
79639898|NCT02925832|Procedure|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
79639899|NCT02925832|Drug|Ropivacaine|0.75% ropivacaine soaked sponges
79639900|NCT02925832|Drug|Bupivacaine|0.5% bupivacaine soaked sponges
79639901|NCT02925832|Drug|Proparacaine|For anaesthetising conjunctiva
79969248|NCT03287622|Behavioral|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
79969249|NCT04063657|Procedure|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
79805167|NCT04031378|Radiation|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
79805168|NCT04031378|Drug|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
79805169|NCT02626052|Behavioral|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
79969250|NCT04063657|Procedure|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
79805170|NCT02626052|Behavioral|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
79805171|NCT02626052|Behavioral|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
79310993|NCT05516745|Other|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
79310994|NCT02099110|Drug|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
79475324|NCT02650193|Drug|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
79475325|NCT04339361|Drug|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
79475326|NCT04339361|Drug|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
79475327|NCT04339361|Drug|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
79475328|NCT02652221|Device|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
79805172|NCT02626052|Procedure|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
79475330|NCT04340297|Drug|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
79475331|NCT04340297|Drug|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
79475332|NCT04340297|Drug|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
79475333|NCT02653391|Drug|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
79475334|NCT02653391|Drug|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
79475335|NCT02653391|Drug|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
79475336|NCT02653391|Drug|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
79805173|NCT02626052|Procedure|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
79969251|NCT01165931|Drug|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
79969252|NCT03636945|Other|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
79475337|NCT05288309|Other|RAINSTİCK|When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.
79639902|NCT02925988|Device|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
79639903|NCT02925910|Device|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
79310995|NCT02099110|Drug|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
79310996|NCT02099110|Drug|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
79310997|NCT02099110|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
79310998|NCT02099110|Drug|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
79805174|NCT02626052|Procedure|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
79310999|NCT02099110|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
79311000|NCT02099110|Drug|Metformin >= 1500 mg/day|Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
79311001|NCT02099110|Biological|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
79805175|NCT00686504|Drug|AZD2066|single dose of oral dose, 3 times per subject
79969253|NCT02970136|Device|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
79311002|NCT02099110|Drug|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
79311003|NCT02098876|Device|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
79311004|NCT02098876|Device|Xience Xpedition everolimus eluting stent|PCI with Xience stent
79311005|NCT02098876|Device|Optical Coherence Tomography (OCT)|Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
79969254|NCT02970136|Device|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
79311006|NCT02098876|Device|Intravascular Ultrasound (IVUS)|Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.
79311007|NCT01624090|Drug|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
79311008|NCT02571777|Drug|QVM149 150/50/160|
79311009|NCT02571777|Drug|QVM149 150/50/80|
79639904|NCT00170430|Drug|Fluconazole|
79311010|NCT02571777|Drug|QMF149 150/320|
79311011|NCT02571777|Drug|QMF149 150/160|
79311012|NCT02571777|Drug|salmeterol/fluticasone|
79311013|NCT05516355|Behavioral|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn,1990).~During the retreat, participants will receive intensive training during 3 days (from 4:00pm to 9pm the first day and from 7 am to 10 pm including breaks, the second and third days), including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga. Training is delivered by certified instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
79475338|NCT05288309|Other|KALEİDOSCOPE|The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
79639905|NCT00170430|Drug|Metronizadole|
79639906|NCT00149084|Drug|Lansoprazole, clarithromycin, amoxicillin|
79639907|NCT00170469|Biological|AVA|
79639908|NCT00170469|Biological|rPA vaccine containing alhydrogel|
79805176|NCT00686504|Drug|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
79805177|NCT02626754|Drug|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
79805178|NCT00691886|Drug|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
79969255|NCT02970136|Device|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
79969256|NCT02970136|Other|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
79969257|NCT02970136|Device|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
79969258|NCT02970136|Other|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
79969259|NCT05181111|Device|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
79969260|NCT05181111|Other|Usual Care|Usual Care Monitoring
79969261|NCT03377998|Other|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
79311014|NCT05516355|Behavioral|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of daily formal and informal practices.~Training will be conducted during 3 days of the retreat (same schedule as the MBSR training). The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering. CCT program is delivered by certified instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
79311015|NCT05521659|Other|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
79311016|NCT05521581|Other|Hand massage|Hand massage will be applied to primiparous mothers who gave birth by cesarean section and its effect on pain, comfort and gas release times will be evaluated.
79311017|NCT05511831|Drug|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
79311018|NCT05511831|Drug|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) [19], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
79805179|NCT04148456|Procedure|Covered Endovacular Reconstruction of Aortic Bifurcation|"The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation."
79805180|NCT04138004|Drug|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
79311019|NCT02571075|Other|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
79311020|NCT02705105|Biological|Mogamulizumab + Nivolumab|i.v. administration
79311021|NCT05521425|Device|"Helping Hands for CAPD bag exchange procedures"|"Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home."
79311022|NCT05511753|Device|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
79311023|NCT05521347|Behavioral|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
79311024|NCT02097472|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
79311025|NCT02097472|Biological|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
79311026|NCT02097472|Biological|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
79475339|NCT04339205|Other|Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|"The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.~At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.~The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.~We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not."
79475340|NCT02654483|Drug|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
79475341|NCT02654483|Other|Placebo|Matching tablets to VPD-737 tablets without active drug
79475342|NCT03237845|Drug|Rimegepant|75 mg tablet QD
79475343|NCT03237845|Drug|Placebo|Placebo tablet to match rimegepant dose QD
79805181|NCT04138004|Drug|polyethylene glycol alone|4-litre polyethylene glycol split-dose
79311027|NCT02097472|Other|Saline|0.9% Sodium Chloride Injection, USP
79311028|NCT03180671|Device|Deprogramer Sliding Guide|Use of the intraoral device.
79311029|NCT03180671|Device|Deprogrammer Dawson B-Splint|Use of the intraoral device.
79311030|NCT03180671|Device|Deprogrammer Kois|Use of the intraoral device.
79805182|NCT04236635|Drug|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
79805183|NCT04236635|Drug|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
79805184|NCT04138082|Other|Exposition to high-dB soundtrack|Already stated
79805185|NCT00621491|Drug|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
79805186|NCT00686660|Behavioral|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
79475344|NCT02655653|Drug|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
79805187|NCT00686660|Behavioral|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
79805188|NCT00686660|Behavioral|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
79805189|NCT00686660|Behavioral|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
79805190|NCT00622349|Drug|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
79805191|NCT00622349|Drug|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
79805192|NCT00622349|Drug|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
79805193|NCT00681434|Behavioral|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
79969262|NCT01274273|Drug|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
79969263|NCT01274273|Drug|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
79969264|NCT01274273|Drug|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
79969265|NCT03377920|Device|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
79805194|NCT00681434|Behavioral|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
79969266|NCT04058353|Drug|ELX/TEZ/IVA|FDC tablet for oral administration.
79969267|NCT04058353|Drug|IVA|Mono-tablet for oral administration.
79969268|NCT04058353|Drug|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
79969269|NCT01170455|Device|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
79969270|NCT01170455|Device|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
79969271|NCT03226353|Device|somofilcon A|contact lens
79969272|NCT03226353|Device|omafilcon A|contact lens
79969273|NCT01274507|Other|Medical tests|All participants will undergo medical tests and will be observed.
79805195|NCT00686816|Dietary Supplement|Low calorie diet|low calorie diet
79805196|NCT00686816|Dietary Supplement|Olestra|low calorie Olestra diet
79639909|NCT02925715|Procedure|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
79639910|NCT00149123|Drug|hydrocortisone 200 mg/day|
79311033|NCT02420249|Behavioral|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong [in Chinese]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
79639911|NCT02925676|Device|hyposafe H02|hypoglycaemia notification device
79311034|NCT02420171|Other|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
79311035|NCT05516121|Drug|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
79311036|NCT03180593|Drug|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
79311037|NCT03180437|Procedure|IRE surgery|IRE surgery will be used in local tumor
79475345|NCT02655653|Drug|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
79639912|NCT02928289|Device|VISCO360 ab interno canaloplasty surgery|360 degrees of viscodilation of Schlemm's canal
79639913|NCT02928289|Device|Selective Laser Trabeculoplasty (SLT)|360 degrees of selective laser trabeculoplasty
79639914|NCT04689607|Other|Mulligan Traction Straight Leg Raise (TSLR)|The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.
79969274|NCT02730598|Device|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to ~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
79311038|NCT03180437|Biological|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
79311039|NCT05516043|Procedure|Implantation with POLYTHESE®|thoracic vascular surgery, abdominal vascular surgery and peripheral vascular surgery
79639915|NCT04689607|Other|Post Isometric Relaxation technique (PIR):|The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
79311040|NCT02423759|Drug|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
79311041|NCT02423759|Drug|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
79311042|NCT02423759|Drug|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
79311043|NCT02420405|Procedure|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
79311044|NCT02420405|Procedure|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
79311045|NCT02419781|Procedure|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
79311046|NCT02419781|Procedure|No endovascular therapy|
79311047|NCT01623310|Drug|Fluticasone Propionate|Using Optinose Exhalation Delivery System
79311048|NCT03178565|Other|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
79311049|NCT03178565|Other|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
79311050|NCT03180125|Drug|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
79311051|NCT03180125|Device|ultrasound|ultrasound guided injection
79311052|NCT03180125|Drug|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
79969275|NCT02730598|Device|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
79639916|NCT04689217|Drug|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
79639917|NCT00170508|Biological|Fluzone®|
79969276|NCT04874415|Behavioral|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
79969277|NCT04874415|Behavioral|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
79311053|NCT03180125|Drug|Corticosteroid and 1%lidocain|injection in the carpal tunnel
79311054|NCT02046226|Device|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
79311055|NCT02423603|Drug|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
79311056|NCT02423603|Drug|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
79311057|NCT02423603|Drug|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
79311058|NCT03178409|Procedure|Hepatectomy|Removal of a part of the liver
79311059|NCT03180203|Device|INTELLiVENT-ASV|"After ICU admission:~The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if >10minutes PEEP:<9cmH2O,FiO2:<41%,VT/IBW<5ml/kg and RSB:<106l/l*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate >35b/min or increases >100% since start of SBT, FiO2 >50%, PeTCO2 increases >8mmHg.~Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
79311060|NCT03180203|Device|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if >10min PS<11cmH2O,PEEP<9cmH2O,FiO2<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate >35b/min or increases >100% since the start of SBT, saturation <92% or the PeTCO2 increases >8mmHg.~Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
79475346|NCT02656745|Device|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones & engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
79475347|NCT03081143|Drug|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
79969278|NCT04874415|Behavioral|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
79475348|NCT03081143|Drug|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
79475349|NCT03081143|Drug|Paclitaxel|80 mg/m2 on day 1, 8, 15
79475350|NCT02657915|Drug|Placebo|Administered as specified in the treatment arm.
79969279|NCT04874415|Behavioral|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
79475351|NCT02657915|Drug|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
79639918|NCT00149162|Drug|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
79969280|NCT04874415|Behavioral|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
79969281|NCT04874415|Behavioral|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
79969282|NCT04874415|Behavioral|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
79969283|NCT04874415|Behavioral|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
79639919|NCT04689334|Other|Outcome|The number of surgeries
79639920|NCT02925637|Other|FaCoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
79639921|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
79311061|NCT03180281|Drug|DPP4|sitagliptin phosphate 100mg qd
79311062|NCT03180281|Drug|Insulin|Insulin Glargine or detemir 0.2U/kg qd
79311063|NCT03180281|Drug|SU|Glimepiride 1-2mg qd
79311064|NCT02419703|Device|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
79311065|NCT03178175|Procedure|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
79311066|NCT03178175|Procedure|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
79311067|NCT03116945|Drug|68Gallium Citrate|Procedure: PET/CT Imaging
79311068|NCT03117023|Drug|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
79311069|NCT02046148|Biological|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
79311070|NCT02046148|Biological|Placebo|Intramuscular injection - Normal saline
79805197|NCT02625896|Behavioral|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
79311071|NCT03117101|Drug|Lucitanib|
79969284|NCT04874415|Behavioral|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
79969285|NCT04874415|Behavioral|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
79311072|NCT03178019|Other|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
79311073|NCT03107585|Procedure|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
79311074|NCT02097238|Drug|Eribulin Mesylate|Given IV
79311075|NCT02097238|Other|Pharmacological Study|Correlative studies
79311076|NCT04703764|Drug|HSG4112|Once-daily, 14-day multiple oral administration
79475352|NCT02658461|Drug|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed >1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
79475353|NCT02658851|Device|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
79475354|NCT00367913|Drug|Addition of clarithromycin to rifampicin and ethambutol|
79475355|NCT00367913|Drug|Addition of Ciprofloxacin to rifampicin and ethambutol|
79475356|NCT00367913|Biological|Vaccination with M.vaccae|
79475357|NCT03069521|Device|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
79969286|NCT04874415|Behavioral|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
79639922|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
79639923|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
79805198|NCT02625038|Device|EUDAMED CIV-14-03-011940|
79311077|NCT04703764|Drug|Placebo|Once-daily, 14-day multiple oral administration
79969287|NCT04874415|Behavioral|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
79311078|NCT02704091|Drug|Smecta|
79969288|NCT04874415|Behavioral|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
79311079|NCT02704091|Drug|Smecta placebo|
79311080|NCT03179813|Procedure|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
79311081|NCT03179813|Procedure|Control|During the third molar extraction the saline solution will be used in the control group
79969289|NCT04874415|Behavioral|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
79969290|NCT04874415|Behavioral|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
79311082|NCT02419625|Behavioral|questionnaires|questionnaires , serum samples will be used
79969291|NCT04874415|Behavioral|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
79311083|NCT03179735|Drug|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
79311084|NCT03179735|Drug|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
79969292|NCT01167725|Biological|bevacizumab|Given IV
79969293|NCT01167725|Biological|cetuximab|Given IV
79969294|NCT01167725|Drug|FOLFIRI regimen|Given IV
79311085|NCT03179735|Drug|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
79311086|NCT02419859|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
79311087|NCT02419859|Drug|Insulin, Asp(B28)-|a fast-acting analog of human insulin
79969295|NCT01167725|Drug|FOLFOX regimen|Given IV
79969296|NCT01167725|Drug|capecitabine|Given IV
79969297|NCT01167725|Drug|fluorouracil|Given IV
79969298|NCT01167725|Drug|irinotecan hydrochloride|Given IV
79311088|NCT02419391|Biological|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
79311089|NCT02419391|Other|Placebo|Tris Buffered Saline, sterile
79311090|NCT03116867|Other|sonosalpingography|transvaginal ultrasound with saline infusion
79475358|NCT02974127|Radiation|Radiotherapy|Multisession radiosurgery
79969299|NCT01167725|Drug|leucovorin calcium|Given IV
79969300|NCT01167725|Drug|mitomycin C|Given intraperitoneally
79969301|NCT01167725|Drug|oxaliplatin|Given IV
79969302|NCT01167725|Procedure|therapeutic conventional surgery|Patients undergo cytoreductive surgery
79969303|NCT03815695|Drug|FT-4202/Placebo|Healthy volunteer subjects will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
79969304|NCT03815695|Drug|FT-4202|Healthy volunteer subjects will receive FT-4202 with or without food and undergo pharmacokinetic studies
79969305|NCT03815695|Drug|FT-4202/Placebo|SCD subjects will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
79969306|NCT03815695|Drug|FT-4202|SCD subjects will receive FT-4202 and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
79805199|NCT05368181|Drug|Methylprednisolone|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
79805200|NCT02626676|Other|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
79969307|NCT04446130|Drug|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1~5, intravenous infusion; Homoharringtonine :1mg/d,d3~16,intravenous infusion; Aclarubicin :10mg/d, d3~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection
79475359|NCT02653079|Other|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
79475360|NCT04739501|Procedure|TACE|Trans-arterial chemoembolization in patients with hepatocellular carcinoma
79805201|NCT05662163|Procedure|TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
79969308|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
79969309|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
79969310|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
79969311|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
79969312|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
79969313|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
79969314|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
79311091|NCT03177941|Other|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
79311092|NCT02423681|Device|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
79311093|NCT02423681|Device|Without ThermoSmart|ThermoSmart is switched off
79639924|NCT02925520|Drug|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
79639925|NCT00149201|Drug|5-FU continuous infusion|
79639926|NCT00149201|Drug|MTX + 5-FU sequential therapy|
79805202|NCT05662163|Procedure|GENERAL ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
79969315|NCT03226275|Drug|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
79969316|NCT03226275|Drug|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
79969317|NCT03226275|Drug|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
79311094|NCT02423369|Procedure|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
79311095|NCT02423369|Other|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
79475361|NCT02659709|Device|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
79639927|NCT02925559|Drug|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
79969318|NCT04189081|Device|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
79969319|NCT04189081|Other|Water Control|negative control
79969320|NCT03382756|Dietary Supplement|High fat diet|A diet consisting of more than 900kcal and 35% of fat
79969321|NCT03382756|Drug|CKD-337|Test Drug
79969322|NCT01274819|Other|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
79311096|NCT02423369|Other|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
79311097|NCT02419157|Drug|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
79311098|NCT02419157|Drug|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
79311099|NCT02419157|Device|Clearfil SE Bond|
79311100|NCT02419157|Device|Xeno V|
79311101|NCT02419235|Other|20% ethanol|Unmedicated 20% ethanol.
79311102|NCT02419235|Other|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
79639928|NCT02925559|Drug|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
79805203|NCT02624960|Device|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
79805204|NCT02687633|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
79311103|NCT02423135|Biological|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
79311104|NCT02422901|Drug|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
79311105|NCT02418767|Drug|MOD-4023|
79311106|NCT02418767|Drug|Placebo|
79475362|NCT02659787|Drug|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
79475363|NCT02659787|Drug|Placebo|Placebo
79475364|NCT02660801|Procedure|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
79805205|NCT00687050|Dietary Supplement|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
79969323|NCT04187989|Behavioral|Social Media Intervention|Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
79969324|NCT03868553|Other|No intervention|observational study
79969325|NCT01170611|Device|PACEMAKER SYMPHONY 2550|
79969326|NCT01166087|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
79969327|NCT01170767|Drug|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
79969328|NCT01170767|Drug|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
79639929|NCT02925325|Behavioral|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
79969329|NCT01170845|Drug|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
79311107|NCT02422823|Drug|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
79639930|NCT02925325|Other|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
79639931|NCT02925286|Other|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
79311108|NCT02422823|Drug|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
79311109|NCT02422823|Drug|Epinephrine|
79311110|NCT02418923|Other|Procedure: Blood specimen collection|Blood specimen collection
79311111|NCT03179501|Drug|NP001|NP001
79639932|NCT00170586|Device|Underglove coating (skin barrier)|
79639933|NCT00149240|Biological|Botulinum toxin type A|
79639934|NCT02925247|Behavioral|Adherence to oral anticoagulant treatment|The adherence will be evaluated by biological results
79639935|NCT02925481|Behavioral|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
79639936|NCT02925481|Behavioral|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
79639937|NCT02925481|Behavioral|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
79475365|NCT02660801|Procedure|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
79969330|NCT01150890|Biological|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
79969331|NCT01150890|Drug|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
79969332|NCT04057573|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79969333|NCT04057573|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
79311112|NCT03179501|Drug|Placebo|Normal saline
79969334|NCT01167803|Drug|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
79311113|NCT03179423|Drug|GNbAC1|Monthly IV repeated dose
79311114|NCT03179423|Drug|Placebo|Monthly IV repeated dose
79311115|NCT03179579|Procedure|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
79475366|NCT02661737|Device|YVOIRE volume s|
79475367|NCT05044871|Drug|Pamiparib|40mg PO. bid.
79475368|NCT05044871|Drug|Bevacizumab|7.5mg/kg IV. D1 (q3w.)
79475369|NCT05044871|Drug|Tislelizumab|200mg IV. D1
79969335|NCT01167803|Drug|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
79969336|NCT01167959|Procedure|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
79969337|NCT01167959|Behavioral|Prodimed dietary intervention|3 months of using the prodimed diet
79969338|NCT01168037|Device|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
79969339|NCT01168037|Procedure|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
79311116|NCT03179579|Procedure|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
79311117|NCT02422589|Drug|ceritinib|
79311118|NCT02422589|Drug|warfarin|
79311119|NCT02422589|Drug|midazolam|
79311120|NCT02422199|Drug|pyrotinib|
79311121|NCT02422199|Drug|Lapatinib|
79311122|NCT02422199|Drug|capecitabine|
79311123|NCT02421965|Behavioral|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
79311124|NCT02421965|Behavioral|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
79475370|NCT05044871|Drug|Nab paclitaxel|125mg / m2 IV. D1, 8 (q3w).
79475371|NCT05044871|Drug|Bevacizumab + Nab paclitaxel (intense dose-dense)|Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
79639938|NCT02925442|Procedure|t-RFA|standard thermal genicular radiofrequency ablation
79639939|NCT02925442|Procedure|C-RFA|Cooled radiofrequency ablation
79639940|NCT02925442|Procedure|Control|Simulated radiofrequency ablation for placebo controlled group
79639941|NCT02925598|Device|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
79639942|NCT02925598|Device|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
79639943|NCT02925598|Device|ETT insertion|'ETT insertion' was done following anesthesia induction.
79639944|NCT00170664|Drug|Paclitaxel|
79969340|NCT01275521|Drug|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
79969341|NCT01275521|Drug|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
79969342|NCT01275911|Drug|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
79311125|NCT02421653|Dietary Supplement|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
79311126|NCT02421653|Dietary Supplement|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
79311127|NCT02421653|Dietary Supplement|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
79311128|NCT02421653|Dietary Supplement|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
79311129|NCT02421653|Dietary Supplement|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
79311130|NCT02421653|Dietary Supplement|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
79311131|NCT02416739|Drug|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
79969343|NCT01275911|Drug|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
79969344|NCT01170923|Device|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
79969345|NCT01170923|Device|CT|CT performed after 3 cycles of chemotherapy
79311132|NCT02416583|Drug|Oxytocin|
79311133|NCT02416583|Drug|Dinoprostone|
79639945|NCT00170664|Drug|Carboplatin|
79639946|NCT02917954|Device|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
79639947|NCT02917837|Other|Usual QCNL DI utilization report|See arm descriptions.
79639948|NCT02917837|Other|New DI utilization report|See arm descriptions.
79639949|NCT02917837|Other|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
79639950|NCT04689022|Behavioral|Mississippi Scale for Combat-Related PTSD (M-PTSD)|The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
79639951|NCT04689022|Diagnostic Test|visual analogue scale (VAS)|pain intensity
79639952|NCT04689022|Diagnostic Test|Douleur Neuropathique 4 questions (DN4)|neuropathic pain component
79639953|NCT00170703|Device|Cortical Electrical Stimulation|
79639954|NCT00149279|Procedure|Surgery: D2 dissection|
79639955|NCT00149279|Procedure|Surgery: D2+paraaortic dissection|
79639956|NCT02917681|Other|Two intrathecal MSC injections|
79639957|NCT02917486|Other|blood sample|
79969346|NCT04054765|Device|videogame|Invite Only VR videogame
79969347|NCT04054765|Other|treatment as usual|treatment as usual
79969348|NCT01166165|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
79969349|NCT01166165|Drug|Placebo|3 placebo tablets daily for 20 weeks
79311134|NCT02416583|Procedure|Membrane sweeping|
79311135|NCT02416427|Drug|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
79311136|NCT02416349|Other|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
79311137|NCT02416349|Other|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
79311138|NCT02416271|Drug|Teriparatide|Administered SC
79311139|NCT02416271|Drug|Alendronate|Administered orally
79311140|NCT02416271|Dietary Supplement|Calcium|Administered orally
79311141|NCT02416271|Dietary Supplement|Vitamin D|Administered orally
79311142|NCT02416271|Drug|Placebo-Oral|Administered orally
79311143|NCT02416271|Drug|Placebo-SC|Administered SC
79311144|NCT02702609|Device|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
79969350|NCT01168193|Other|No intervention|
79969351|NCT03873155|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
79311145|NCT02702609|Device|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
79311146|NCT02416505|Behavioral|Verbal+Anatomic Model|
79311147|NCT02416505|Behavioral|Verbal+Video|
79311148|NCT02416115|Drug|Ramosetron|Ramosetron was given iv.
79311149|NCT02416115|Drug|Naloxone|Naloxone added to PCA was given iv.
79639958|NCT03315403|Diagnostic Test|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
79805206|NCT00687050|Dietary Supplement|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
79805207|NCT00681512|Dietary Supplement|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
79805208|NCT00639041|Dietary Supplement|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
79805209|NCT00639041|Dietary Supplement|Placebo|dairy products without special oils
79311150|NCT02416115|Drug|saline|Saline was given iv.
79639959|NCT00170742|Drug|Octreotide, 30 mg i.m. LAR formulation|
79969352|NCT04179721|Behavioral|PES-4-BPSD Model|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
79969353|NCT04179721|Behavioral|The attention control condition|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
79969354|NCT01171079|Device|application of oxidized regenerated cellulose|
79969355|NCT03286218|Drug|Lasmiditan|Administered orally
79639960|NCT00149318|Other|Biochemical analyses.|Biochemical analyses.
79639961|NCT02917525|Dietary Supplement|Vitamin K2|
79969356|NCT03286218|Drug|Alprazolam|Administered orally
79639962|NCT02917525|Other|Placebo|
79805210|NCT00687128|Behavioral|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
79805211|NCT00687128|Behavioral|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
79969357|NCT03286218|Drug|Placebo|Administered orally
79311151|NCT02416115|Drug|Morphine|Morphine in the PCA was given iv.
79311152|NCT02416037|Device|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
79639963|NCT03457441|Other|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
79639964|NCT03457441|Device|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
79805212|NCT00687128|Behavioral|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
79311153|NCT02416037|Device|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
79311154|NCT02415881|Drug|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
79311155|NCT02415881|Device|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
79311156|NCT02415881|Device|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
79311157|NCT02415803|Drug|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
79311158|NCT02415803|Drug|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
79311159|NCT02415803|Drug|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
79311160|NCT02415725|Drug|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
79311161|NCT04482881|Drug|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
79805213|NCT00692042|Drug|AZD1704|One dose, by mouth
79805214|NCT02666105|Drug|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
79805215|NCT04138238|Device|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
79969358|NCT01171157|Other|Routine sample collection|Collection of routine nasal/throat swab samples
79311162|NCT04482881|Drug|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
79311163|NCT04482881|Drug|Misoprostol|Giving women misoprostol
79311164|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
79311165|NCT02415569|Drug|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
79311166|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
79311167|NCT02415491|Other|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
79311168|NCT02415335|Drug|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
79311169|NCT02415335|Drug|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
79311170|NCT02415257|Drug|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
79311171|NCT02415179|Drug|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
79311172|NCT02415179|Drug|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
79311173|NCT02415101|Procedure|Resective surgery|
79311174|NCT02415023|Drug|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
79311175|NCT02414945|Drug|Cyclophosphamide|
79311176|NCT02414945|Drug|Fludarabine|
79311177|NCT02414945|Biological|Autologous tumor infiltrating lymphocytes (TILs)|
79639965|NCT02917330|Other|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
79969359|NCT03745261|Drug|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
79311178|NCT02414945|Biological|Interleukin-2|
79311179|NCT02414555|Drug|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
79639966|NCT00170781|Drug|Lumiracoxib|
79311180|NCT02414555|Drug|fluid bolus|
79311181|NCT02414555|Device|oesophagus doppler (CardioQ)|
79311182|NCT02414555|Drug|Normal Saline|
79311183|NCT02414555|Device|arterial cannulation|
79311184|NCT02414555|Device|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
79311185|NCT02414555|Drug|Elo-Mel Isoton (balanced acetat-based infusate)|
79311186|NCT02414711|Other|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (<1.75)
79311187|NCT02414711|Other|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
79311188|NCT02414087|Device|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
79311189|NCT02046070|Drug|Cyclophosphamide|Cyclophosphamide tablets
79311190|NCT02046070|Drug|Ixazomib|Ixazomib capsules
79639967|NCT00149357|Other|Thrombophilia Testing|TP testing in Group 1 and 3 only
79639968|NCT02917369|Other|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
79639969|NCT02917252|Other|3-hydroxybuturate|Drink of ketone bodies
79639970|NCT02917252|Other|Placebo|Drink of saline
79311191|NCT02046070|Drug|Dexamethasone|Dexamethasone tablets
79311192|NCT04483037|Drug|Bowklean|assigned intervention
79311193|NCT01663857|Drug|LY2228820|Administered Orally
79639971|NCT02917291|Drug|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)
79311194|NCT01663857|Drug|Carboplatin|Administered IV
79311195|NCT01663857|Drug|Placebo|Administered Orally
79311196|NCT01663857|Drug|Gemcitabine|Administered IV
79311197|NCT02414165|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
79311198|NCT02414165|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
79311199|NCT02414165|Drug|Lomustine|
79639972|NCT02917291|Other|Control group|(Ph 2) No treatment will be administered
79639973|NCT02917291|Drug|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
79311200|NCT02414165|Drug|Temozolomide|
79311201|NCT02414165|Biological|Bevacizumab|
79311202|NCT02094898|Drug|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
79311203|NCT02414009|Drug|Capecitabine|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
79311204|NCT02414009|Drug|Temozolomide|Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
79639974|NCT00170820|Drug|Everolimus|
79639975|NCT02917174|Behavioral|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
79969360|NCT03745261|Drug|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
79969361|NCT03745261|Drug|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
79969362|NCT03745261|Drug|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
79805216|NCT00622817|Drug|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
79311205|NCT02414009|Drug|Irinotecan|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
79311206|NCT02414009|Drug|Fluorouracil|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
79311207|NCT02414009|Drug|Leucovorin|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
79311208|NCT02413697|Device|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
79311209|NCT02413697|Device|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
79639976|NCT02917174|Behavioral|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
79639977|NCT02917018|Drug|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
79805217|NCT00622817|Drug|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
79311210|NCT02413853|Drug|CBP/beta-catenin Antagonist PRI-724|Given IV
79311211|NCT02413853|Biological|Bevacizumab|Given IV
79311212|NCT02413853|Drug|Leucovorin Calcium|Given IV
79311213|NCT02413853|Drug|Oxaliplatin|Given IV
79311214|NCT02413853|Drug|Fluorouracil|Given IV
79311215|NCT02413853|Other|Laboratory Biomarker Analysis|Correlative studies
79639978|NCT02917135|Device|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
79639979|NCT00149474|Behavioral|Peak Flow Monitoring|
79639980|NCT00170859|Drug|Everolimus|
79639981|NCT02917057|Drug|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
79639982|NCT02917057|Drug|basal insulin|basal insulin tretament in the customary clinical care in USA
79639983|NCT02916940|Drug|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
79639984|NCT00149513|Behavioral|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
79639985|NCT00149513|Behavioral|Usual care|Participants will receive usual care.
79639986|NCT02916901|Drug|CKD-519 200mg|
79639987|NCT02916901|Drug|Placebo|
79639988|NCT00170898|Drug|Lumiracoxib|
79969363|NCT03745261|Drug|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
79969364|NCT01166243|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
79639989|NCT02916355|Drug|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
79639990|NCT02916355|Drug|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
79639991|NCT00149552|Dietary Supplement|zinc|supplementation with zinc gluconate
79639992|NCT02916589|Dietary Supplement|Diet|
79639993|NCT02916628|Behavioral|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
79639994|NCT02916628|Device|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
79639995|NCT02916628|Device|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
79639996|NCT00163722|Other|Culture and histology|
79639997|NCT00163722|Other|Aspergillus galactomannan and PCR|
79805218|NCT04146740|Other|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
79969365|NCT01166243|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
79969366|NCT03744949|Drug|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
79805219|NCT04146740|Behavioral|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
79805220|NCT04033913|Other|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
79969367|NCT03744949|Drug|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
79969368|NCT03744949|Drug|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
79969369|NCT03744949|Drug|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
79639998|NCT02916667|Other|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
79639999|NCT00149591|Procedure|coronary balloon-angioplasty with stenting|
79640000|NCT02916394|Radiation|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
79640001|NCT02916277|Biological|endocan|to look series Endocan level for 5 days in intubated patients
79640002|NCT00170937|Drug|valsartan plus hydrochlorothiazide|
79640003|NCT02915965|Drug|DCX|docetaxel, cisplatin and capecitabine
79640004|NCT02915965|Procedure|surgery|Ivor Lewis Esophagectomy
79640005|NCT02916238|Drug|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
79640006|NCT02916238|Behavioral|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
79640007|NCT00149708|Drug|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
79640008|NCT02916082|Procedure|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
79640009|NCT00163761|Drug|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
79640010|NCT00163761|Drug|gemcitabine, vinorelbine, filgastrim|Drug
79640011|NCT02916043|Procedure|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
79640012|NCT02916160|Drug|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
79640013|NCT00149786|Behavioral|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
79640014|NCT00149786|Behavioral|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
79311216|NCT05515965|Other|Kinesiotaping|The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
79311217|NCT05515965|Other|Sham|Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
79311218|NCT02413931|Other|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
79311219|NCT04598295|Drug|DS-01|synbiotic
79640015|NCT02916121|Dietary Supplement|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
79640016|NCT02916121|Other|Placebo|placebo
79640017|NCT02916199|Device|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
79640018|NCT00170976|Drug|valsartan + amlodipine|
79805221|NCT04137926|Diagnostic Test|MicRNAs battery|for MCI due to AD diagnosis
79311220|NCT02413619|Procedure|Vitrectomy|Vitrectomy
79640019|NCT03266302|Device|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
79640020|NCT00149864|Drug|Mycophenolate sodium (enteric coated)|
79640021|NCT03254212|Device|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to > 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to < 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
79805222|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
79311221|NCT02413619|Procedure|Cataract surgery|Cataract surgery
79311222|NCT02413619|Procedure|Combined surgery|Combined vitrectomy and cataract surgery at the same time
79311223|NCT00704483|Drug|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
79311224|NCT00704483|Drug|Sevelamer HCl|0.8 g tid
79311225|NCT00704483|Drug|SBR759|1.5 g tid
79311226|NCT00704483|Drug|Sevelamer HCl|1.6 g tid
79640022|NCT02915848|Device|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
79640023|NCT00149903|Drug|Mycophenolate sodium (enteric coated)|
79640024|NCT04688632|Drug|Ampreloxetine <Dose A>|Ampreloxetine <Dose A> will be administered as 1 tablet of <Dose A> and 3 tablets of Ampreloxetine Placebo.
79640025|NCT04688632|Drug|Ampreloxetine <Dose B>|Ampreloxetine <Dose B> will be administered as 4 tablets of <Dose A>
79805223|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
79805224|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
79805225|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
79805226|NCT00692120|Dietary Supplement|Placebo|oral placebo capsule once daily for 12 months
79805227|NCT02429609|Device|Moorfields Acuity Chart|
79640026|NCT04688632|Drug|Ampreloxetine Placebo|Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine <Dose A> tablet.
79640027|NCT04688632|Drug|Moxifloxacin|Moxifloxacin will be administered orally as a single tablet.
79640028|NCT04688632|Drug|Moxifloxacin Placebo|Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
79640029|NCT05786690|Other|Interventions|the temporospatial and kinematic gait characteristics
79640030|NCT05786677|Other|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~Suboccipital release~Diaphragm release~Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
79640031|NCT05786677|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
79640032|NCT05786664|Procedure|Biospecimen Collection|Undergo collection of blood samples
79805228|NCT04137848|Procedure|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
79805229|NCT04137848|Procedure|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
79805230|NCT00819585|Drug|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
79969370|NCT03870581|Behavioral|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
79969371|NCT03870581|Behavioral|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
79969372|NCT03224325|Drug|TAK-831 Tablet T2|Tak-831 tablets.
79311227|NCT04596189|Drug|Dupilumab 300 MG in 2 ML Prefilled Syringe|"The Dupilumab will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
79640033|NCT05786664|Other|Electronic Health Record Review|Review of records
79969373|NCT03224325|Drug|Placebo|TAK-831 placebo-matching suspension.
79969374|NCT03224325|Drug|TAK-831 Suspension|TAK-831 Suspension.
79969375|NCT04016779|Drug|Placebo|Placebo will be administered once daily
79640034|NCT05786664|Other|Quality-of-Life Assessment|Complete quality-of-life questionnaires
79640035|NCT05786664|Other|Survey Administration|Complete surveys
79640036|NCT05786651|Behavioral|Experimental: Within-Subjects Attentional Information|Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
79640037|NCT05786495|Other|Early Discontinuation of Antibiotics|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
79640038|NCT05786495|Other|Standard of Care|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
79969376|NCT04016779|Drug|SPN-812|SPN-812 will be administered once daily and compared to Placebo
79640039|NCT05786430|Drug|Lazertinib/Pemetrexed/Carboplatin|Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
79640040|NCT05786391|Other|Flat position|Flat patient position during the cystoscopy
79640041|NCT05786391|Other|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
79640042|NCT05786391|Device|Insufflation|Insufflation to 15 mm Hg
79640043|NCT05786352|Procedure|ERAS protocol|The combination of interventions explained in arm descriptions.
79640044|NCT05786339|Drug|Tested Irbesartan Tablet|T
79640045|NCT05786339|Drug|Reference Irbesartan Tablet|R
79969377|NCT03870503|Drug|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
79969378|NCT03870503|Drug|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
79969379|NCT03870503|Drug|Carbetocin|The patient received Carbetocin 100 mic gm
79969380|NCT02857426|Drug|Nivolumab|
79640046|NCT05786313|Procedure|Centerpiece titanium plate|All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
79311228|NCT04596189|Other|Placebo|"The Placebo will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
79969381|NCT05181033|Drug|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
79311229|NCT04596189|Drug|Mometasone Furoate nasal spray|On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert & SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.
79311230|NCT03176537|Drug|Testosterone gel|Androgel (50mg testosterone), gel, daily
79311231|NCT03176537|Drug|Placebos|Placebo, gel, daily
79311232|NCT05511441|Procedure|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
79311233|NCT03176147|Other|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
79311234|NCT05515809|Drug|parasternal block|"Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery"
79311235|NCT05515809|Drug|Standard pain management|Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
79311236|NCT02413307|Other|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
79969382|NCT05181033|Drug|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
79969383|NCT05666765|Drug|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
79969384|NCT01127256|Drug|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
79475372|NCT05009849|Other|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
79475373|NCT01643850|Drug|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
79475374|NCT01643850|Drug|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
79475375|NCT04931693|Drug|paracetamol|iv post operative analgesia
79475376|NCT04931693|Procedure|modifiedPECs block|sonar guided pectoral nerve block
79475377|NCT03662633|Diagnostic Test|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
79475378|NCT03662633|Diagnostic Test|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
79640047|NCT05786248|Other|Impedancemetry|the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
79640048|NCT05786170|Diagnostic Test|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
79805231|NCT00819585|Drug|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
79805232|NCT00819585|Drug|Allopurinol|100-300 mg orally once daily for 24 weeks.
79969385|NCT01127256|Drug|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
79311237|NCT05515731|Biological|Autologous platelet-rich plasma (PRP) eye drops|Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.
79805233|NCT00819585|Drug|Placebo Matching Canakinumab|Subcutaneous injection.
79311238|NCT02413385|Behavioral|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
79311239|NCT05520957|Procedure|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
79311240|NCT02413541|Procedure|Polymyxin-B Hemoperfusion|Endotoxin removal
79311241|NCT02413541|Procedure|Standard treatment|
79311243|NCT02412995|Other|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
79311244|NCT02412995|Other|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
79805234|NCT00819585|Drug|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
79311245|NCT02412995|Other|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
79490242|NCT04331990|Other|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
79640049|NCT05786092|Device|Telemonitoring|Monitoring of the required parameters by means of the data provided by the devices used by patients. The data (weight, body composition, blood pressure, oxygen saturation, physical activity, heart rate and blood glucose) collected according to the predetermined schedule are then saved in a cloud accessible to researchers.
79805235|NCT00687206|Drug|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
79805236|NCT00687284|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79805237|NCT02358395|Drug|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
79805238|NCT02358395|Drug|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
79805239|NCT00508261|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
79805240|NCT00508261|Biological|Infanrix™ hexa|Single dose intramuscular injection
79805241|NCT00508261|Biological|Meningitec™|Single dose intramuscular injection
79805242|NCT04146350|Procedure|PPV+/-Cat|pars plana vitrectomy+/-cataract
79805243|NCT04146350|Procedure|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
79805244|NCT04146350|Procedure|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
79805245|NCT04146350|Procedure|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
79805246|NCT04146350|Procedure|PSR|posterior scleral reinforcement
79805247|NCT04146350|Procedure|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
79805248|NCT04146350|Procedure|Gas|gas tamponade alone
79969386|NCT01277471|Behavioral|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
79311246|NCT02412995|Other|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
79475379|NCT04340453|Other|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
79475380|NCT04340453|Other|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
79475381|NCT04340453|Other|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
79475382|NCT04866641|Drug|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
79640050|NCT05786053|Procedure|graded recession of inferior oblique muscle|. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
79640051|NCT05785923|Diagnostic Test|Point-of-Care Echocardiogram|Four view ultrasound of the heart performed at the bedside by trained emergency medicine physicians.
79640052|NCT05785910|Diagnostic Test|IUDS|a battery of neuropsycological test
79640053|NCT05785572|Procedure|supraescapular nerve radiofrequency|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
79640054|NCT05785572|Procedure|interescalenic braquial plexus|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
79640055|NCT05785559|Procedure|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
79640056|NCT05785520|Device|ST500 SINGLE-DOSE GEL|ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
79640057|NCT05785494|Other|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
79805249|NCT00692354|Drug|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
79805250|NCT03928847|Drug|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
79805251|NCT02624726|Drug|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in <5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
79640058|NCT05785481|Diagnostic Test|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
79640059|NCT05785468|Drug|Caplacizumab|description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
79640060|NCT05785416|Other|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
79311247|NCT02412995|Other|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
79311248|NCT02412995|Other|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
79311249|NCT03176069|Other|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
79311250|NCT03176069|Other|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy~Manual therapy~Electrotherapy (electric electrostimulation, ultrasound)~Behavioral therapy"
79640061|NCT05785416|Other|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
79640062|NCT05785403|Other|No intervention|No intervention
79640063|NCT05785364|Device|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
79311251|NCT02045836|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79311252|NCT02045836|Biological|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79311253|NCT02413073|Procedure|Whole Body Vibration|We wil use vibration in patients with kidney disease
79311254|NCT02412917|Drug|FV-100|antiviral nucleoside analog
79311255|NCT02412917|Drug|valacyclovir|antiviral nucleoside analog
79311256|NCT02412683|Other|oxaliplatin|
79640064|NCT05785351|Procedure|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
79640065|NCT05785312|Device|Online EMDR Therapy System|Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
79311257|NCT02412605|Procedure|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
79640066|NCT05785312|Other|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The Face to Face Eye Movement Desensitization & Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
79640067|NCT05785273|Device|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
79805252|NCT02624726|Drug|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
79969387|NCT01277471|Behavioral|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
79805253|NCT02624726|Drug|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
79311258|NCT02412527|Other|Patch III heart rate sensor|
79311259|NCT04482101|Other|Root canal obturation|Root canal filling
79311260|NCT02569437|Drug|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
79969388|NCT03059472|Behavioral|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
79475383|NCT02271594|Behavioral|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
79475384|NCT02271594|Behavioral|Standard education on injection technique|Usual and customary education and training normally provided injecting patients at the center
79475385|NCT04879212|Other|PCIA +Acupuncture group:|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6)
79475386|NCT05649228|Drug|Capsaicin 0.025% Cream|A small amount of cream about the size of a U.S. half dollar containing 0.25% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
79311261|NCT02569437|Drug|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
79311262|NCT02569437|Drug|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
79311263|NCT02569437|Drug|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
79311264|NCT02569437|Drug|sugar pill|placebo pill to match doxycycline
79311265|NCT02412449|Drug|AKB-6548 tablet, reference formulation given in the fasted state|
79311266|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fasted state.|
79311267|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fed state|
79311268|NCT02412293|Behavioral|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
79311269|NCT02412293|Other|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
79311270|NCT02412293|Behavioral|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
79311271|NCT02412059|Drug|Prednisolone acetate|
79311272|NCT02045212|Drug|RPh201|SC injection twice a week during 13/26 weeks
79311273|NCT02045212|Drug|Placebo|SC injection twice a week during 13/26 weeks
79311274|NCT02412215|Procedure|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
79475387|NCT05649228|Drug|Capsaicin Palmitate|A small amount of cream about the size of a U.S. half dollar containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
79475388|NCT05649228|Drug|Placebo Cream|A small amount of topical cream about the size of a U.S. half dollar will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
79475389|NCT02664311|Device|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
79311275|NCT02412215|Device|NanoFlex toric Intraocular Lens|
79311276|NCT02412137|Other|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
79311277|NCT03175991|Diagnostic Test|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
79311278|NCT03175679|Biological|iNKT cells|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of iNKT cells."
79311279|NCT03175679|Drug|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
79311280|NCT03175679|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
79311281|NCT05520645|Drug|etomidate|use etomidate for anesthesia induction in hysteroscopic surgery
79311282|NCT05520645|Drug|propofol|use propofol for anesthesia induction in hysteroscopic surgery
79311283|NCT03175757|Dietary Supplement|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
79475390|NCT02664311|Device|Conventional ventilation|Conventional ventilator - control arm
79640068|NCT05785260|Behavioral|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
79640069|NCT05785234|Drug|sufentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
79475391|NCT02535923|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
79490243|NCT04331990|Other|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
79640070|NCT05785234|Drug|remifentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
79640071|NCT05785208|Drug|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
79640072|NCT05785156|Other|quick tests|"New quick tests are~Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and~Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing"
79311284|NCT03175757|Dietary Supplement|Placebo|Placebo
79311285|NCT03175835|Drug|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1~Day5
79311286|NCT03175835|Drug|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9~Day21
79311287|NCT03175835|Drug|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22~Day26
79311288|NCT05515185|Drug|KT095 CAR-T injection|Clearance of lymphocytes
79311289|NCT02044822|Drug|Idelalisib|150 mg tablets administered orally twice daily
79490244|NCT02973620|Drug|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
79490245|NCT03512041|Behavioral|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
79490246|NCT03512041|Behavioral|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
79805254|NCT02624726|Drug|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
79805255|NCT02687555|Behavioral|Cognitive Bias Modification of Appraisals (CBM-App)|
79311290|NCT02044822|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly x 8 weeks
79311291|NCT05511051|Drug|Fruquintinib|Fruquintinib
79311292|NCT05511051|Drug|HAIC|HAIC
79311293|NCT03116555|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
79311294|NCT03116555|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC
79311295|NCT03175913|Device|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
79640073|NCT05785143|Procedure|Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.
79490247|NCT03512041|Behavioral|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
79640074|NCT05785117|Device|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
79805256|NCT02687555|Behavioral|Peripheral Vision Task (control condition)|
79805257|NCT00681746|Drug|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
79969389|NCT03059472|Behavioral|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
79805258|NCT00681746|Drug|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
79805259|NCT02687399|Other|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
79969390|NCT03873233|Device|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
79969391|NCT03873233|Device|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
79969392|NCT03377842|Drug|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
79311296|NCT03175913|Drug|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
79311297|NCT03175445|Other|CBCT scan by planmeca promax|software measurement tool of CBCT
79311298|NCT02044510|Drug|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
79311299|NCT02044510|Drug|Placebo|Matched placebo capsules to the intervention arm
79311300|NCT02411981|Other|Autogenic drainage|
79311301|NCT02411903|Drug|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
79490248|NCT03512041|Behavioral|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
79490249|NCT03512041|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
79805260|NCT02687399|Biological|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
79311302|NCT02411903|Drug|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
79311303|NCT02411669|Other|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
79475392|NCT02535923|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
79640075|NCT05785117|Other|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
79640076|NCT05785078|Behavioral|Educational session about vaccinations|An educational session about maternal and childhood vaccinations was held in the context of the Childbirth Preparation Course held monthly at the FPG. In this occasion, on-site flu vaccination was offered to pregnant women attending the course and their partners, if present.
79640077|NCT05785026|Other|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
79640078|NCT05785026|Other|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
79640079|NCT05785000|Other|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
79640080|NCT05785000|Other|Control patients receiving usual care|No exercise intervention
79805261|NCT02624882|Procedure|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
79805262|NCT02624882|Procedure|Negative rapid GAS test|Usual care
79969393|NCT03377842|Drug|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
79969394|NCT03377764|Procedure|Landmark Technique Control group|Spinal Anesthetic
79969395|NCT03377764|Procedure|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
79311304|NCT02411825|Drug|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79311305|NCT02411825|Drug|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79311306|NCT02411825|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79640081|NCT05784987|Drug|Rituximab|375 mg/m2, d0, Cycle 1~4
79640082|NCT05784987|Drug|Mitoxantrone hydrochloride liposome|20 mg/m2, d1, Cycle 1~4
79640083|NCT05784987|Drug|Isophosphamide|1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1~4
79640084|NCT05784987|Drug|Etoposide|65 mg/m2, d1-3, Cycle 1~4
79640085|NCT05784987|Drug|X: Orelabrutinib|MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2~4
79805263|NCT04265911|Biological|ASP3772 (subcutaneous)|Subcutaneous injection
79805264|NCT04265911|Biological|ASP3772 (intramuscular)|Intramuscular injection
79805265|NCT04265911|Biological|PPSV23 (subcutaneous)|Subcutaneous injection
79805266|NCT04265911|Biological|PPSV23 (intramuscular)|Intramuscular injection
79969396|NCT04016311|Behavioral|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
79969397|NCT01277705|Biological|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
79311307|NCT02411513|Device|CEFALY|
79969398|NCT01277705|Biological|Boostrix™|Intramuscular, single dose
79969399|NCT01277705|Biological|GSK Biologicals' IPV vaccine|Intramuscular, single dose
79969400|NCT01277705|Biological|Revaxis®|Intramuscular, single dose
79640086|NCT05784987|Drug|X: Chidamide|EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2~4
79640087|NCT05784987|Drug|X: Penpulimab|TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2~4
79475393|NCT04769921|Device|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
79640088|NCT05784987|Drug|X: Lenalidomide|Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2~4
79640089|NCT05784974|Drug|Cadonilimab|15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
79640090|NCT05784935|Device|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
79640091|NCT05784922|Other|Educational Lung Cancer Screening (LCS) Video|An educational video on lung cancer screening tailored to Hispanic current and former smokers.
79640092|NCT05784909|Device|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
79640093|NCT05784896|Diagnostic Test|v/Q scanning & CT pulmonary angiography & Echocardiography|"Echocardiography ( comparative follow up of the RVSF PASP TAPSE IVC).~CT pulmonary angiography with assessment of the following parameters :~Intravascular web. dilated bronchail arteries. Arterial retraction. dilated pulmonary arteries. RV/LV diameter more than 1. Flattening of interventricular septum. V/Q scanning Following ESC/ERS Guideline recommendations, V/Q is the preferred and recommended test for CTEPH. It has a sensitivity of >96% and normal V/Q scan can rule out CTEPH . V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE."
79640094|NCT05784831|Device|Reappraisal training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
79640095|NCT05784831|Device|Ecological Momentary Assessment|The EMA tested here collects data on participants' mood and behavior.
79969401|NCT03377686|Diagnostic Test|inflammation markers in exhaled breath|non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)
79969402|NCT04757337|Drug|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
79969403|NCT04757337|Drug|Cyclophosphamide|Until progression up to 24 months
79475394|NCT02350517|Drug|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
79475395|NCT02270736|Drug|NT 201 Placebo|NT 201 placebo matching injection.
79475396|NCT02270736|Drug|NT 201|NT 201 injection.
79475397|NCT04672031|Other|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
79640096|NCT05784818|Behavioral|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
79969404|NCT03868241|Device|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
79311308|NCT02411435|Drug|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
79311309|NCT02411435|Drug|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
79311310|NCT05520489|Device|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
79640097|NCT05784818|Behavioral|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
79655607|NCT04554433|Drug|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~Inhaling alcohol vapor through nostrils .~Inhalation of Alcohol vapor driven by Oxygen .~Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
79969405|NCT03868241|Device|Control|Devices without coating available at each participating intensive care unit
79969406|NCT03921970|Other|ESP block (Group ESP)|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
79969407|NCT03946527|Drug|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
79969408|NCT03377608|Drug|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
79311311|NCT05520489|Device|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
79490250|NCT03512041|Behavioral|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
79490251|NCT03512041|Behavioral|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
79490252|NCT03053960|Device|Computed Tomography|Undergo helical CT scan
79490253|NCT03053960|Device|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
79490254|NCT03053960|Device|Cone-Beam Computed Tomography|Undergo CBCT scan
79490255|NCT03053960|Device|Magnetic Resonance Imaging|Undergo MRI scan
79490256|NCT03053960|Procedure|Therapeutic Conventional Surgery|Undergo resection of tumor
79490257|NCT03053960|Procedure|Histopathologic Examination|Correlative studies
79490258|NCT05313386|Drug|BXCL501|BXCL501 is given in a film form
79490259|NCT05313386|Drug|Placebo film|Placebo is given in a film form
79311312|NCT05520489|Other|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
79640098|NCT05784649|Other|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
79311313|NCT02411279|Other|Equiped group with telemedicine systems|
79805267|NCT02687477|Procedure|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
79311314|NCT02411123|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
79805268|NCT02687477|Procedure|Sham procedure|patient in the sham group will receive sham procedure
79805269|NCT00819039|Drug|Aprepitant|Aprepitant administered orally or intraveously.
79311315|NCT03175289|Other|Best Practice|Undergo therapy session conducted by a speech pathologist
79805270|NCT00819039|Drug|Ondansetron|Ondansetron administered intravenously.
79805271|NCT04187261|Procedure|hip fracture surgeries|fixation or replacement
79805272|NCT00692510|Drug|AZD3480|Capsule, oral, dose once daily, 7 days
79805273|NCT00692510|Drug|Placebo|Capsule, oral, dose once daily, 7 days
79805274|NCT00692510|Drug|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
79969409|NCT03377608|Drug|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
79969410|NCT01282073|Drug|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 ~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
79969411|NCT01282073|Drug|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
79969412|NCT04052425|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79311316|NCT03175289|Other|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
79311317|NCT03175289|Other|Exercise Intervention|Perform prescribed home exercises
79311318|NCT03175289|Other|Expiratory Muscle Strength Training|Participate in EMST
79311319|NCT03175289|Other|Quality-of-Life Assessment|Ancillary studies
79311320|NCT03175289|Other|Questionnaire Administration|Ancillary studies
79311321|NCT02411045|Behavioral|Take and send a selfie|Direction to take and send a selfie.
79311322|NCT02411045|Behavioral|Workout gears|Direction to wear workout gears.
79311323|NCT02411045|Behavioral|Exercise|Direction to complete a 30 minute workout.
79311324|NCT02410889|Other|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
79311325|NCT03175211|Drug|BI 456906|single dose
79311326|NCT03175211|Drug|Placebo|single dose
79311327|NCT03175055|Device|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
79490260|NCT03274999|Device|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
79490261|NCT04018664|Drug|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
79490262|NCT04018664|Drug|Placebo solution|Placebo
79805275|NCT02687321|Other|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
79805276|NCT05758623|Device|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
79311328|NCT03174899|Radiation|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
79640099|NCT05784649|Behavioral|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
79640100|NCT05784636|Device|Non-invasive BiPAP ventilation|Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
79969413|NCT04052425|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
79311329|NCT03175133|Other|Strength exercise|Strengthening exercises performed with physical therapist.
79311330|NCT02410655|Drug|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
79311331|NCT02410655|Drug|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
79311332|NCT02410499|Drug|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
79311333|NCT02410499|Drug|MLN1202|MLN1202 solution for SC injection
79311334|NCT04859127|Other|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
79640101|NCT05784636|Device|HFNC|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
79640102|NCT05784623|Other|User experience|User experience is assessed by validated scales
79640103|NCT05784610|Device|Monitorage by TOF/PTC|Installation of TOFscan® and monitoring by MAR appreciation on one of the patient's wrists and installation of TOFscan® and monitoring by ATP mode (MAR blind) on the other wrist Installation of TOFscan® and monitoring by ATP mode
79640104|NCT05784610|Device|Monitorage by ATP|Installation of TOFscan® and monitoring by ATP mode on one of the patient's wrists
79311335|NCT02410421|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
79640105|NCT05784584|Procedure|Blood samples collection|The study population will take blood samples for virological and immunological measurements.
79805277|NCT00500539|Drug|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
79969414|NCT03235089|Device|Test Lens|Daily disposable contact lens
79969415|NCT03235089|Device|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
79969416|NCT03377530|Diagnostic Test|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
79969417|NCT03873077|Procedure|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
79640106|NCT05784558|Device|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
79311336|NCT05514249|Drug|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
79805278|NCT00687518|Drug|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
79311337|NCT05510505|Drug|CD20 monoclonal antibody|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）~ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）~ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
79640107|NCT05784558|Other|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
79805279|NCT00687518|Drug|Placebo|Intravenous injection of equivalent volume of saline serum
79311338|NCT05510505|Drug|ATG|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）~ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）~ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
79311339|NCT05514171|Procedure|Neoadyuvant therapy|Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
79475400|NCT02269098|Other|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
79640108|NCT05784558|Device|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
79640109|NCT05784519|Drug|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10^5 /50μl in each eye, twice a day for 2 weeks.
79805280|NCT02303795|Drug|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
79805281|NCT02303795|Drug|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
79805282|NCT04139408|Device|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
79805283|NCT04187417|Drug|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
79805284|NCT04187417|Drug|Placebo|Placebo
79805285|NCT01010815|Procedure|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
79640110|NCT05784506|Other|Macronutrients|Three successive food tolerance tests (glucose, protein and fat) at one-week intervals.
79640111|NCT05784506|Other|Mixed meal tolerance test (MMTT)|Mixed meal tolerance test (MMTT)
79640112|NCT05784493|Other|Study group|Washing by heated saline group
79640113|NCT05784467|Behavioral|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
79805286|NCT01010815|Other|stool collection|Stool will be collected from participants at study entry
79805287|NCT01010815|Procedure|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
79805288|NCT01010815|Other|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
79805289|NCT01016431|Other|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
79805290|NCT01016431|Other|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
79805291|NCT00818883|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
79640114|NCT05783700|Diagnostic Test|BIOIMPEDANCEMETRY|The impedance of cellular tissue can be modeled as a resistor (representing the extracellular path) in parallel with a resistor and capacitor in series (representing the intracellular path, the resistance that of intracellular fluid and the capacitor the cell membrane). This results in a change in impedance versus the frequency used in the measurement. Whole body impedance measurement is generally measured from the wrist to the ipsilateral ankle and uses either two (rarely) or four (overwhelmingly) electrodes. In the 2-elctrode (bipolar) configuration a small current on the order of 1-10 μA is passed between two electrodes, and the voltage is measured between the same whereas in the tetrapolar arrangement resistance is measured between as separate pair of proximally located electrodes. The tetrapolar arrangement is preferred since measurement is not confounded by the impedance of the skin-electrode interface
79311340|NCT04987385|Dietary Supplement|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
79640115|NCT05782699|Device|BP monitoring during tilt testing|BP measure at various times during tilt testing
79640116|NCT05782660|Other|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
79640117|NCT05782660|Other|No Cash Benefit|No monthly cash benefit.
79640118|NCT05781802|Other|Level of pressure support|"Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~In case of P0.1<2, the clinically selected level of pressure support will be considered High Pressure support.~In case of P0.1>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored."
79640119|NCT05781776|Other|Otago exercises and core strengthening|"Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times."
79655608|NCT04721054|Drug|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
79311341|NCT04987385|Dietary Supplement|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, …) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
79311342|NCT05510349|Other|Sonographic measure of placental elasticity and viscosity|Sonographic measure of placental elasticity and viscosity
79655609|NCT04721054|Drug|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
79311343|NCT05514015|Drug|Rituximab|"Induction therapy:~Rituximab iv infusion 1g, d1, d15, additional glucocorticoid treatment, oral methylprednisolone, initial dose 0.5mg/(KGD), once a day, after 8 weeks of treatment, reduced by 5mg every 2~4 weeks, until 0.25mg/kg, this dose was maintained for 8 weeks, then reduced by 2.5mg every 2~4 weeks, until drug withdrawal, The course of treatment was about 24 weeks; Maintenance therapy after 6 months Patients who achieved CR did not need maintenance therapy; Patients whose 24-hour proteinuria decreased by >25% but did not achieve CR were given an additional course of rituximab 1g, D1, D15 (independent of CD19+ cell count).~Patients whose 24-hour proteinuria decreased less than 25% did not need to continue drug treatment, and were considered as treatment failure and withdrawn from the trial."
79655610|NCT02212639|Drug|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
79805292|NCT00818883|Drug|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
79805293|NCT04049708|Other|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
79311344|NCT05514015|Drug|Cyclophosphamide|"Control group (treated with Italian protocol, namely cyclophosphamide-steroid alternating cycle treatment) :~- Treatment regimen: Methylprednisolone 0.5-1.0 g/d was given intravenously for the first 3 days of month 1, 3, and 5, followed by oral prednisone 0.5mg/(kg·d) for 27 days, and cyclophosphamide 2.0mg/(kg·d) for 30 days at month 2, 4, and 6.~-Maintenance therapy after 6 months: Patients who achieved CR or whose 24h urinary protein decreased by >25% but did not achieve CR did not need maintenance treatment, and were followed up.~Patients with 24h proteinuria decreased less than 25% did not need to continue to use drugs, and were considered as treatment failure and withdrawn from the trial."
79311345|NCT03174821|Device|Insulin pump|Blood glucose management device
79311346|NCT05520021|Drug|Nifedipine|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
79311347|NCT05520021|Drug|Magnesium sulfate|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
79311348|NCT02410031|Drug|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
79640120|NCT05781776|Other|Gaze stability exercises and core strengthening|"The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing."
79640121|NCT05781672|Diagnostic Test|cardiac ultrasound with speckle tracking analysis|"Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography."
79640122|NCT05781568|Diagnostic Test|Biomarker dosage|The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
79640123|NCT05781516|Drug|Prednisolone|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
79640124|NCT05781516|Drug|Baricitinib|Oral Baricitinib 2mg daily for 12 months.
79640125|NCT05781282|Device|Atrial fibrillation ablation|Pulmonary vein deconnection. PV antra visualization by ICE
79655611|NCT02212756|Drug|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
79655612|NCT02212756|Drug|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
79655613|NCT02212795|Drug|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
79655614|NCT02212795|Drug|Levofloxacin 250mg|Levofloxacin 250mg single dose
79805294|NCT01014481|Drug|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
79805295|NCT02167763|Device|VeraCept Intrauterine Copper Contraceptive|
79805296|NCT02167763|Device|TCu380 IUD|
79805297|NCT02624648|Behavioral|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
79805298|NCT02624648|Behavioral|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
79805299|NCT02624648|Behavioral|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
79805300|NCT02624648|Drug|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
79805301|NCT02624648|Drug|Placebo|They will receive a capsule of Placebo twice a day for 120 days
79805302|NCT00508027|Drug|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
79805303|NCT02626598|Device|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
79805304|NCT01986101|Drug|Placebo|Placebo comparator
79311349|NCT02410109|Behavioral|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
79655615|NCT02212795|Drug|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
79655616|NCT00261261|Behavioral|ADVANCE|
79655617|NCT00261261|Drug|Midazolam|
79655618|NCT00261261|Procedure|Parental presence|
79655619|NCT00235820|Drug|adalimumab|40 mg every other week following an 80 mg dose
79655620|NCT00235820|Drug|MTX|MTX 7.5 to 25 mg once weekly
79655621|NCT00235820|Drug|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
79655622|NCT04554199|Device|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
79655623|NCT04554355|Behavioral|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
79805305|NCT01986101|Drug|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
79805306|NCT01986101|Drug|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
79805307|NCT00500149|Drug|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
79805308|NCT00500149|Drug|Placebo|Placebo
79805309|NCT04139330|Drug|NPC-06|Infuse NPC-06 intravenously
79805310|NCT04185779|Diagnostic Test|Colonoscopy|Diagnostic colonoscopy
79640126|NCT05780437|Biological|AZD7442|AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
79640127|NCT05780437|Biological|Placebo|Commercially available 0.9% sodium chloride solution
79640128|NCT05780437|Biological|Remdesivir|Antiviral agent
79640129|NCT05780333|Procedure|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
79311350|NCT02410187|Radiation|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
79311351|NCT02410187|Drug|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
79311352|NCT02410187|Radiation|palliative RT|fraction size of RT = < 3 Gy
79311353|NCT02410265|Behavioral|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
79969418|NCT03377374|Dietary Supplement|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
79969419|NCT03377374|Other|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
79311354|NCT02410265|Behavioral|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
79311355|NCT05055453|Device|MyPhonak Junior App|The primary objective is to evaluate the effects on speech intelligibility of resulting from the changes that children and adolescents (aged 7 to 17 years) make to the volume control, directionality and noise reduction of the hearing of the hearing aids using the myPhonak app. First, in a controlled laboratory environment under the guidance of the principal investigator is tested. Then, using sound scenarios, the child is allowed to try out two programs with the aid of using the app and the volume control, respectively. After this, the speech comprehension of sentences in noise is tested in the individual programs using the Oldenburg Sentence Test (OLSA).
79311356|NCT02409953|Other|Lying in a bath during 2 hours|
79311357|NCT02409953|Other|Lying in a bed during 2 hours|
79311358|NCT04842981|Drug|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
79311359|NCT04842981|Drug|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
79311360|NCT03174587|Biological|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10^6cells/kg Step 1 dose : 2.0x10^6cells/kg Step 2 dose : 3.0x10^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
79640130|NCT05780333|Procedure|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
79311361|NCT03174509|Procedure|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
79311362|NCT03174509|Procedure|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
79311363|NCT02409641|Drug|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
79311364|NCT04839705|Device|WEB|"Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device"
79311365|NCT02409797|Other|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
79640131|NCT05779839|Behavioral|Algorithm|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.
79311366|NCT05519943|Behavioral|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
79311367|NCT05519943|Behavioral|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
79640132|NCT05779839|Behavioral|Random Match|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
79805311|NCT03997591|Other|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
79805312|NCT00681902|Drug|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
79969420|NCT03870347|Diagnostic Test|Endoscopic ultrasound|Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
79969421|NCT02736526|Procedure|recession or resection of the horizontal extraocular muscles|
79640133|NCT05779293|Device|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
79311368|NCT02067676|Biological|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
79311369|NCT02067676|Drug|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
79311370|NCT03174665|Other|No intervention|
79640134|NCT05779293|Other|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
79969422|NCT02526173|Procedure|RALP using full nerve sparing technique|RALP using full nerve sparing technique
79805313|NCT00681902|Drug|Placebo|Jet saline
79805314|NCT04185857|Drug|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
79311371|NCT03174743|Procedure|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
79311372|NCT03174743|Procedure|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
79311373|NCT03174743|Procedure|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
79311374|NCT03174743|Procedure|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
79311375|NCT05519787|Device|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement…). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
79311376|NCT01623154|Other|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
79311377|NCT03174431|Device|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
79969423|NCT02526173|Other|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
79969424|NCT03125512|Device|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
79969425|NCT03125512|Device|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
79969426|NCT01166477|Drug|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
79969427|NCT01166477|Drug|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
79969428|NCT02714920|Other|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
79969429|NCT02526641|Procedure|Functional Hepatic Nitrogen Clearance (FHNC)|
79969430|NCT02526641|Procedure|Galactose Elimination Capacity (GEC)|
79640135|NCT05778266|Dietary Supplement|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
79640136|NCT05778266|Dietary Supplement|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
79311378|NCT03174431|Device|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
79969431|NCT02526641|Procedure|Liver vein catheterization|
79969432|NCT01282151|Drug|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
79969433|NCT01282151|Drug|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
79311379|NCT04417816|Other|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
79969434|NCT03377218|Dietary Supplement|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
79969435|NCT03377218|Dietary Supplement|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
79311380|NCT04417816|Other|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
79475401|NCT04651595|Procedure|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
79969436|NCT01168505|Drug|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
79640137|NCT05778266|Other|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
79640138|NCT05774405|Drug|Climara 0.1Mg/24Hr Transdermal System|Transdermal estradiol patch is used.
79969437|NCT01282307|Behavioral|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
79805315|NCT04185857|Drug|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
79969438|NCT03377140|Dietary Supplement|Hesperidin|2 capsuls
79969439|NCT03377140|Other|control|2 capsuls
79311381|NCT02409407|Drug|Misoprostol , Prostaglandins E1 analogue|
79311382|NCT05510037|Other|no intervention|no intervention was needed
79311383|NCT02409563|Drug|Budesonide nasal spray (100 mcg bid)|
79969440|NCT03868319|Procedure|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
79311384|NCT02409563|Drug|Budesonide nasal spray (50 mcg bid|
79640139|NCT05774405|Other|Hydrogel patch|Adhesive Hydrogel patch
79969441|NCT03868319|Procedure|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
79969442|NCT04013191|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
79969443|NCT03872765|Device|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
79969444|NCT01171391|Drug|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
79969445|NCT01171391|Other|Placebo|Placebo on Day 1
79969446|NCT03898726|Biological|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
79969447|NCT03867929|Other|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
79969448|NCT03285594|Drug|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
79969449|NCT03285594|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79969450|NCT03285594|Drug|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
79311385|NCT02409485|Behavioral|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
79311386|NCT02409017|Procedure|Insulin drip|
79475402|NCT04651595|Drug|Morphine|morphine to control pain and avoid using muscle relaxant
79475403|NCT04645511|Procedure|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
79640140|NCT05768776|Procedure|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
79640141|NCT05768776|Procedure|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
79640142|NCT05764941|Drug|Inetetamab|8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
79640143|NCT05764941|Drug|Pyrotinib|400mg, oral, every day.
79640144|NCT05764941|Drug|Vinorelbine|25 mg/m2, D1, D8, every 3 weeks for one cycle.
79640145|NCT05761782|Behavioral|Education|To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
79640146|NCT05754658|Other|Standard of Care|Drugs routinely administered for breast cancer per local standard.
79640147|NCT05754658|Other|Standard of Care|Drugs routinely administered for prostate cancer per local standard.
79805316|NCT01016509|Drug|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl.
79311387|NCT05513079|Behavioral|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
79640148|NCT05750017|Biological|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
79640149|NCT05750017|Biological|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
79969451|NCT03285594|Drug|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
79969452|NCT01171469|Biological|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
79640150|NCT05750017|Drug|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
79640151|NCT05745675|Device|Pulse oximeter|OLV-4202 pulse oximeter SW version: 01-15)
79640152|NCT05745662|Device|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
79640153|NCT05730153|Biological|advanced PRF|advanced PRF+ surgery
79640154|NCT05723705|Other|European Multicentre Training Program for Robotic Liver Surgery|LIVEROBOT is a pan-european multicentre training program for robotic liver surgery involving simulation training, a procedure video-library, on and off-site proctoring, and video-assessment.
79311388|NCT05519553|Other|Peer support|: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
79640155|NCT05700734|Drug|MK-8510|Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
79640156|NCT05686226|Biological|E7 TCR-T cells|Participants will receive a conditioning regimen (cyclophosphamide and fludarabine), E7 TCR-T cells as a single infusion, and adjuvant high-dose aldesleukin.
79311389|NCT05512845|Procedure|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
79311390|NCT00702689|Drug|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
79311391|NCT02409251|Behavioral|Education and feedback|
79311392|NCT02409095|Biological|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
79311393|NCT02409095|Device|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
79311394|NCT02409095|Other|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
79311395|NCT05512533|Device|Linear Ultrasound Bronchoscope BF-UC290F (Olympus)|A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
79311396|NCT02409173|Device|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
79640157|NCT05685082|Behavioral|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
79640158|NCT05685082|Behavioral|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
79640159|NCT05667506|Biological|single dose of CNCT19|"Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide"
79640160|NCT05656313|Device|Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)|"The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB."
79655624|NCT04554238|Device|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
79805317|NCT01016509|Drug|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of <200 mg/dl.
79805318|NCT02626832|Other|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
79969453|NCT01171469|Drug|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
79655625|NCT04554238|Other|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
79655626|NCT00268710|Drug|docetaxel|
79805319|NCT00639119|Drug|Ropinirole|8 + 8 weeks cross-over placebo controlled
79969454|NCT03872921|Drug|norUrsodeoxycholic Acid|oral treatment
79311397|NCT02409173|Procedure|Bariatric Surgery|Standard Roux-en-Y gastric bypass
79640161|NCT05656313|Device|Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)|The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
79640162|NCT05656313|Device|Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)|This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
79311398|NCT02065570|Drug|Adalimumab|
79311399|NCT02065570|Drug|Placebo|
79311400|NCT02408705|Drug|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
79311401|NCT02408705|Drug|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
79311402|NCT02408705|Drug|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
79311403|NCT02408627|Device|EEG|
79311404|NCT05507697|Biological|HUC-MSCs|5 × 10^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
79805320|NCT01010893|Biological|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
79311405|NCT05507697|Biological|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
79311406|NCT04292223|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
79311407|NCT03174119|Device|Light therapy - active|Active light will be used for one week, as compared to placebo light.
79805321|NCT01010893|Biological|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
79805322|NCT01011127|Drug|pravastatin, rosuvastatin|
79311408|NCT03174119|Device|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
79311409|NCT05509491|Behavioral|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
79311410|NCT03116321|Drug|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
79475404|NCT04645511|Procedure|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
79311411|NCT03174041|Drug|Midazolam|Single dose midazolam
79311412|NCT03174041|Drug|GDC-0853|Multiple doses GDC-0853 for 6 days
79311413|NCT03174041|Drug|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
79311414|NCT03174041|Drug|Rosuvastatin|Single dose rosuvastatin
79311415|NCT03174041|Drug|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
79311416|NCT03174041|Drug|Simvastatin|Single dose simvastatin
79311417|NCT03174041|Drug|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
79311418|NCT03174041|Drug|GDC-0853|Single dose GDC-0853
79311419|NCT03174041|Drug|Itraconazole|Multiple doses itraconazole for 6 days
79311420|NCT03174041|Drug|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
79311421|NCT02566005|Device|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
79640163|NCT05656313|Device|Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)|"In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension."
79640164|NCT05649852|Other|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
79640165|NCT05649852|Other|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
79640166|NCT05643079|Procedure|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with metal/Bio-Tenodesis screws|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by~10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Metal/Bio-Tenodesis screw(MBS). The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with an MBS in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
79655627|NCT02212873|Other|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
79311422|NCT02566005|Device|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
79655628|NCT04554082|Procedure|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
79805323|NCT00639197|Procedure|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
79805324|NCT00639197|Procedure|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
79311423|NCT02408393|Drug|Saline|
79805325|NCT00912548|Drug|goserelin|"Zoladex™ administration:~Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~Sequence of administration Zoladex depot:~The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~Dosage:~Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
79805326|NCT00912548|Drug|tamoxifen|"Dose and period of Tamoxifen therapy:~Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
79805327|NCT01016665|Drug|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
79805328|NCT00681980|Drug|Valproic acid|15 mg/kg/day
79805329|NCT00681980|Drug|costicosteroids|metypredsolone 1 g/day
79805330|NCT00681980|Drug|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
79311424|NCT02408393|Drug|Ropivacaine|
79311425|NCT02408237|Device|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
79311426|NCT02408237|Device|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
79311427|NCT02408237|Device|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
79311428|NCT02408237|Device|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
79311429|NCT03173885|Diagnostic Test|Preimplantation Genetic Screening|"laser assisted hatching~trophectoderm biopsy~next generation sequencing"
79311430|NCT03173807|Behavioral|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
79311431|NCT02408159|Drug|Varicella Zoster Vaccine|
79969455|NCT03234465|Biological|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
79311432|NCT02408159|Drug|Placebo|
79311433|NCT05507619|Other|Acupuncture with Heat Therapy + Standard Care|Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
79311434|NCT05507619|Other|Standard Care|Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
79311435|NCT02408081|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
79311436|NCT02407925|Behavioral|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
79311437|NCT05507463|Drug|KBP-7072|KBP-7072
79655629|NCT02212912|Behavioral|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
79655630|NCT02212912|Behavioral|no intervention|No intervention indicated that the physicians among control hospital provide routine
79969456|NCT03234465|Other|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
79311438|NCT05507463|Drug|Placebo|Placebo
79969457|NCT03290131|Drug|Arbaclofen|Arbaclofen Extended Release Tablet
79969458|NCT03290131|Drug|Placebo|Placebo comparator
79640167|NCT05643079|Procedure|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with Shark Screws®|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by approx.10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Shark Screw®. The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with the Shark Screw® in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
79640168|NCT05634577|Drug|Mitotane|Given by PO
79311439|NCT03173963|Drug|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
79311440|NCT03173963|Other|Placebo|1placebo tablet per day
79311441|NCT02407847|Other|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
79311442|NCT05507229|Biological|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
79640169|NCT05634577|Drug|Pembrolizumab|Given by vein (IV)
79311443|NCT05507229|Biological|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
79311444|NCT03173651|Device|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
79311445|NCT03173651|Device|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
79311446|NCT03173651|Device|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
79311447|NCT03173417|Biological|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
79640170|NCT05633628|Behavioral|Periodic CGM group with data analysis report- Intervention group|The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
79640171|NCT05632471|Behavioral|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
79640172|NCT05632471|Other|The control group was not trained|The control group was not trained
79640173|NCT05621564|Drug|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
79969459|NCT03870191|Other|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
79969460|NCT03746353|Procedure|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
79311448|NCT03173417|Drug|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
79311449|NCT03173573|Drug|FDL176|CFTR modulator
79311450|NCT03173573|Drug|Placebo|Placebo for FDL176
79311451|NCT03173495|Dietary Supplement|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
79475405|NCT04630067|Drug|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
79475406|NCT04630067|Drug|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
79311452|NCT03173495|Dietary Supplement|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
79475407|NCT04586387|Device|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
79311453|NCT03173495|Dietary Supplement|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
79311454|NCT05508945|Device|Dermabond Prineo Skin Closure System|synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
79311455|NCT05508945|Device|silk|SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
79311456|NCT05508945|Device|3M Steri-Strip|non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
79655631|NCT00261300|Drug|Pantoprazole|Long term Pantoprozole trial
79311457|NCT03173339|Procedure|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
79969461|NCT02526485|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
79969462|NCT02695992|Drug|Metoprolol|Dosage 100 mg o.d.
79311458|NCT03173339|Drug|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
79311459|NCT03173339|Drug|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
79311460|NCT03173339|Drug|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
79311461|NCT03173339|Drug|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
79475408|NCT04586387|Device|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
79969463|NCT02695992|Drug|Diltiazem|Dosage 360 mg o.d.
79969464|NCT05180643|Behavioral|Mindfulness-Based Stress Reduction-based program (MBSR).|The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.
79311462|NCT03173261|Diagnostic Test|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
79311463|NCT03173183|Drug|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
79311464|NCT04757805|Diagnostic Test|Ultrasound|Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
79311465|NCT03172871|Drug|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
79311466|NCT03172871|Drug|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
79311467|NCT02065336|Drug|ARC-520|
79311468|NCT02065336|Drug|Placebo|
79311469|NCT02065336|Drug|entecavir|
79311470|NCT02065336|Drug|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
79311471|NCT02408003|Drug|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
79311472|NCT02408003|Drug|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
79311473|NCT02407769|Dietary Supplement|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
79311474|NCT04790409|Drug|sintilimab and anlotinib|This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
79311475|NCT02407535|Device|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
79311476|NCT02407379|Procedure|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
79311477|NCT02407379|Procedure|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
79311478|NCT02407301|Other|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
79311479|NCT02407301|Other|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
79311480|NCT02407301|Other|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
79311481|NCT02407301|Other|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
79311482|NCT02407301|Other|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
79640174|NCT05619952|Dietary Supplement|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
79640175|NCT05617183|Biological|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
79640176|NCT05617183|Biological|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
79969465|NCT04050865|Drug|Dexamethasone, 0.4mg|Ophthalmic Insert
79640177|NCT05616260|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
79640178|NCT05616260|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
79655632|NCT02212990|Other|Acetaminophen Arm|Blinded Therapy
79311483|NCT05506917|Procedure|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
79640179|NCT05616260|Device|Continuous Positive Airway Pressure|Standard CPAP device
79640180|NCT05615753|Behavioral|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
79640181|NCT05611034|Drug|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
79640182|NCT05592509|Dietary Supplement|Ozonized vegetable oil with vitamines|"description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day.~The time of administration is two months."
79640183|NCT05582213|Diagnostic Test|induction of anesthesia|This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
79311484|NCT05506761|Procedure|ultrasound-guided erector spinae plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
79311485|NCT05506761|Procedure|ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
79640184|NCT05579080|Device|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
79805331|NCT01016743|Device|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
79805332|NCT00692900|Drug|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
79311486|NCT02407067|Device|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
79969466|NCT04050865|Device|Placebo plug with no drug|Ophthalmic Insert
79969467|NCT01168661|Behavioral|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) >= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
79969468|NCT01168661|Behavioral|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
79969469|NCT01168661|Behavioral|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
79640185|NCT05550922|Behavioral|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
79640186|NCT05550597|Drug|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
79640187|NCT05550597|Drug|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
79640188|NCT05548140|Device|Novel Motorized Spiral Enteroscopy|This study involves performance of spiral enteroscopy in one arm and single balloon enteroscopy in the other arm in patients who satisfy inclusion criteria
79640189|NCT05537662|Device|Standard of care neuromodulation therapy (SCS or DRG)|Standard SCS or DRG therapy
79640190|NCT05535842|Other|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
79969470|NCT03283566|Drug|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
79969471|NCT03283566|Drug|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
79311487|NCT02407067|Device|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
79640191|NCT05522855|Device|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
79311488|NCT02406989|Drug|MS-553|Study Drug
79311489|NCT02406989|Drug|Placebo|Matching placebo to MS-553
79311490|NCT05508711|Device|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
79969472|NCT03210519|Dietary Supplement|Eleutherococcus senticosus|taken orally once/day for 90 days
79311491|NCT02406911|Drug|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
79311492|NCT02406833|Drug|TGF-β2 antisense oligonucleotide|intravitreal injection
79311493|NCT02406833|Procedure|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
79311494|NCT03173027|Drug|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
79311495|NCT03173105|Device|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
79311496|NCT03173105|Device|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
79311497|NCT03173105|Other|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
79311498|NCT03173105|Other|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
79311499|NCT03172793|Drug|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
79311500|NCT03116087|Drug|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
79311501|NCT03116087|Drug|Placebo|Placebo patch
79311502|NCT03116165|Behavioral|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
79640192|NCT05495269|Drug|QLS-101 ophthalmic solution, 2.0 %|ophthalmic solution in a single use dropper vial
79640193|NCT05494229|Other|Pars-plana vitrectomy|Pars-plana vitrectomy
79655633|NCT02212990|Other|Placebo Arm|Blinded Therapy
79655634|NCT02212990|Other|Ibuprofen Arm|Open Label Therapy
79655635|NCT00235859|Drug|adalimumab|
79655636|NCT00235859|Drug|methotrexate|
79969473|NCT03210519|Other|Placebo|taken orally once/day for 90 days
79969474|NCT01171547|Drug|Daptomycin|once daily over 5 days
79655637|NCT02213029|Drug|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
79655638|NCT02213029|Drug|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
79655639|NCT02213029|Drug|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
79311503|NCT03116165|Behavioral|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
79311504|NCT04968821|Behavioral|Physical activity intervention|Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
79640194|NCT05474638|Device|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
79640195|NCT05468112|Behavioral|SKY Meditation and Mindfulness|The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
79640196|NCT05451953|Procedure|Apneic Oxygenation|Nasal cannula at a rate of 6L/min with 100% FiO2 during laryngoscopy and intubation attempt(s)
79311505|NCT04968821|Other|Usual care|Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
79640197|NCT05451953|Procedure|Standard of Care|No respiratory support during laryngoscopy and intubation attempt(s) (current standard of care)
79655640|NCT02213029|Drug|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson & Johnson
79655641|NCT02213146|Drug|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
79655642|NCT02213146|Drug|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
79805333|NCT00692900|Drug|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
79311506|NCT03116009|Drug|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
79311507|NCT03115931|Other|no intervention|no intervention
79311508|NCT02406755|Other|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
79311509|NCT02406755|Other|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
79311510|NCT02406755|Other|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
79311511|NCT02406599|Device|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
79311512|NCT02406599|Other|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
79311513|NCT04482023|Behavioral|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
79311514|NCT03172559|Radiation|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
79311515|NCT02701985|Drug|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
79311516|NCT02701985|Drug|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
79311517|NCT03172169|Other|no Intervention|no Intervention
79311518|NCT02064868|Drug|Serelaxin|30 µg/kg/day IV infusion
79311519|NCT02064868|Drug|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
79655643|NCT02213146|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
79655644|NCT00268749|Drug|glycine|0.8 g/kg/day
79655645|NCT04553887|Drug|Almonertinib|single agent, 110mg p.o once daily until disease progressed
79311520|NCT03171935|Device|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
79640198|NCT05435443|Device|PowerBreathe and PEP Therosold tools|"Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM."
79640199|NCT05425719|Drug|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
79311521|NCT03171935|Device|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 >92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 >96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
79311522|NCT03171935|Device|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
79311523|NCT03172013|Diagnostic Test|Platelet indices|MPV, PDW
79311524|NCT03172091|Device|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
79311525|NCT03172091|Device|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
79311526|NCT02406521|Drug|Pazopanib|
79311527|NCT02406521|Drug|Sorafenib|
79311528|NCT02406521|Drug|Radium-223|
79311529|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
79311530|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
79311531|NCT02406365|Device|Diagnostic imaging aid for one-visit management of cervical lesions|
79311532|NCT02406131|Other|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
79311533|NCT02405975|Other|SCRIPT|An online tool designed to train doctors in all areas of prescribing
79311534|NCT02405897|Device|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
79311535|NCT02405897|Device|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
79311536|NCT02406053|Genetic|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
79311537|NCT02064166|Drug|Intranasal Insulin|"treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~placebo arm: normal saline, daily, intranasally, for 4 weeks."
79311538|NCT04482335|Other|No intervention|No intervention
79311539|NCT02405741|Device|Hyperbaric chamber treatment|
79311540|NCT02405819|Other|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
79311541|NCT02405819|Other|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
79311542|NCT02405663|Procedure|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
79311543|NCT02405663|Procedure|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
79311544|NCT03171467|Procedure|Salpingectomy|
79311545|NCT03171779|Other|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
79311546|NCT03171623|Drug|globalagliatin hydrochloride|orally administration, single dose
79311547|NCT03171623|Drug|placebo|orally administration, single dose
79311548|NCT03171389|Drug|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
79311549|NCT02405507|Dietary Supplement|wheat bread with wheat germ|
79311550|NCT02405507|Dietary Supplement|wheat bread without wheat germ|
79655646|NCT00235898|Drug|CoFactor|
79655647|NCT00235898|Drug|5-FU|
79655648|NCT00235898|Drug|Leucovorin|
79655649|NCT02213185|Other|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
79311551|NCT02405273|Procedure|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
79311552|NCT02405273|Procedure|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
79311553|NCT02565615|Other|No intervention|Because this is a non-interventional study, there is no intervention here.
79311554|NCT02405117|Behavioral|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
79311555|NCT03170999|Other|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
79311556|NCT03170999|Other|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
79311557|NCT03170999|Other|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
79311558|NCT03171077|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
79969475|NCT03745183|Other|Senna alata leaf decoction|"Preparation of the akapulko decoction~Remove the leaflets from the rachis of a mature leaf.~Wash the mature leaflets thoroughly to remove dust, dirt and debris.~In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~Cook the leaves and bring to a rolling boil.~When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
79969476|NCT03872687|Device|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
79969477|NCT03872687|Device|interdental brushes|Subjects in this group will only receive interdental brushes
79969478|NCT01166555|Drug|PF-04236921|single subcutaneous dose
79311559|NCT03171077|Other|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
79311560|NCT03171077|Other|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
79311561|NCT05508633|Drug|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
79311562|NCT04482257|Drug|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
79311563|NCT02701361|Behavioral|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
79805334|NCT00682058|Other|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
79311564|NCT02701361|Behavioral|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
79311565|NCT02701361|Behavioral|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
79311566|NCT05506527|Other|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~- Children of the study group B will receive sensorimotor program alone."
79311567|NCT02404727|Procedure|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
79311568|NCT02404727|Device|Avantage® Cup|
79311569|NCT05508555|Procedure|hyperthermic intrathoracic chemotherapy|application of chemotherapeutic agent intrathoracic under hyperthermic conditions
79805335|NCT00489853|Drug|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
79969479|NCT03737305|Device|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
79969480|NCT03737305|Device|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
79969481|NCT01283945|Drug|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
79969482|NCT04048681|Behavioral|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
79969483|NCT04048681|Behavioral|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
79969484|NCT04048681|Behavioral|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
79311570|NCT02404883|Other|Online Decision-Aid Tool|
79311571|NCT05502705|Drug|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
79475409|NCT02667821|Other|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
79640200|NCT05425719|Device|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have a transdermal sensor placed on their chest in the area between the shoulders (including the pectoralis and sternum area), and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. After collection of background fluorescence, participants will then receive a single dose of MB-102.
79640201|NCT05423496|Diagnostic Test|KidneyCare|Using KidneyCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
79311572|NCT05502705|Other|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
79640202|NCT05423496|Drug|steroid|optimization of steroids
79311573|NCT05508477|Biological|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
79640203|NCT05423496|Drug|MMF|optimization of MMF
79311574|NCT05508477|Biological|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
79640204|NCT05401318|Procedure|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
79640205|NCT05366686|Behavioral|NICE Support Program|Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
79640206|NCT05355935|Drug|Brensocatib|Oral tablet.
79640207|NCT05355935|Drug|Moxifloxacin|Oral tablet.
79640208|NCT05355935|Drug|Placebo|Oral tablet.
79640209|NCT05350397|Other|How Important Is Acupress Applyıng In Atrıal Fıbrılatıon Treatment?|The acupressure wristband was correctly attached to the Experimental Group and acupressure was applied. The placebo group was fitted with an inverted and loose acupressure wristband. No intervention was applied to the control group.
79805336|NCT00489853|Drug|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
79805337|NCT00489853|Other|Placebo|Placebo, 1 inhalation twice daily
79311575|NCT02404961|Other|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
79311576|NCT02405039|Drug|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
79640210|NCT05334017|Drug|Xylometazoline 0,1%|1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
79640211|NCT05334017|Drug|Cocaine 4%|2 ml of 4% cocaine given as a nasal spray
79640212|NCT05330104|Behavioral|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
79640213|NCT05326971|Procedure|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
79640214|NCT05307822|Other|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
79640215|NCT05307822|Other|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
79640216|NCT05307822|Other|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
79640217|NCT05307822|Other|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
79655650|NCT02213224|Drug|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
79655651|NCT02213224|Drug|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
79655652|NCT02213224|Drug|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
79655653|NCT00268788|Drug|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
79655654|NCT00268788|Drug|Intravenous immunoglobulin|Individual dose and frequency
79655655|NCT00235937|Drug|Anastrozole and goserelin|
79655656|NCT02213341|Procedure|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
79311577|NCT02405039|Drug|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
79311578|NCT03171233|Other|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
79311579|NCT03171233|Other|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
79311580|NCT05506293|Procedure|percutaneous paravalvular leak closure|"the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~Amplatzer vascular plug 3~occlutech paravalvular leak device~amplatzer vascular plug 2~amplatzer muscular ventricular septal defect~amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design."
79311581|NCT05508321|Diagnostic Test|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
79311582|NCT05508321|Diagnostic Test|Sniffin' Sticks|Assessment of olfactory function
79311583|NCT05502627|Drug|0.25% lemon grass oil mouthwash|0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
79311584|NCT05506137|Drug|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
79311585|NCT05506137|Other|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
79311586|NCT04742283|Drug|DE-126 Ophthalmic Solution 0.002% QD|DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
79640220|NCT05302700|Behavioral|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
79640221|NCT05292339|Drug|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
79311587|NCT04742283|Drug|Timolol Maleate Ophthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution BID (morning and evening)
79311588|NCT04289805|Drug|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
79311589|NCT04289805|Other|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
79311590|NCT05508165|Device|Stream Dx|home uroflowmetry device
79311591|NCT05508165|Device|DFree|at home wearable bladder scanner
79311592|NCT05508165|Device|TestCard|mobile urinalysis reader
79311593|NCT05505981|Other|Immediate PT|Patients will start PT immediately
79311594|NCT05505981|Other|Rest until pain resolves|Patients will wait to start PT until their pain resolves
79640222|NCT05292339|Drug|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
79655657|NCT02213341|Procedure|Blood draw|
79969485|NCT01171703|Device|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
79969486|NCT01171703|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
79969487|NCT03737227|Radiation|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
79640223|NCT05291650|Drug|Glucocorticoids|The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
79969488|NCT03870113|Biological|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
79969489|NCT01282385|Drug|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
79311595|NCT04782921|Device|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
79311596|NCT05502471|Diagnostic Test|Zonulin|Serum zonulin level
79311597|NCT05502471|Diagnostic Test|Occludin|Serum occludin level
79311598|NCT05502393|Drug|JS107|JS107, i.v., q3w
79311599|NCT05502393|Drug|Toripalimab|Toripalimab i.v., q3w
79311600|NCT05449431|Other|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
79475410|NCT02669615|Drug|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
79311601|NCT05449431|Other|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
79311602|NCT05505591|Drug|Cangrelor|Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
79311603|NCT05448807|Drug|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
79311604|NCT05402631|Procedure|Epidural Injection|patient receives an epidural injection due to lower back pain
79311605|NCT05402631|Procedure|Periradicular Injection|patient receives a periradicular injection due to lower back pain
79311606|NCT01662999|Drug|Saxagliptin|
79311607|NCT01662999|Drug|Dapagliflozin|
79311608|NCT05366283|Biological|sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
79311609|NCT05319951|Drug|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
79475411|NCT04739579|Diagnostic Test|C-Reactive Protein|C-Reactive Protein trend in post-operative course
79475412|NCT02670629|Procedure|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
79475413|NCT02670629|Procedure|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
79475414|NCT02672111|Drug|CAM2038 q1w or q4w exposure to SL BPN/NX|
79969490|NCT01282385|Drug|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
79311610|NCT05319951|Dietary Supplement|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
79311611|NCT05319951|Dietary Supplement|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
79475415|NCT02672111|Drug|CAM2038 q1w or q4w new to BPN treatment|
79475416|NCT01456013|Device|RenalGuard Therapy|Induced Diuresis with matched replacement
79475417|NCT01456013|Drug|Standard Therapy|Standard of care for patients at risk of CIN
79475418|NCT02675543|Device|Vitreous Tamponade with Silicone Oil|
79311612|NCT02565381|Drug|Transdermal nicotine patch|"≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
79311613|NCT02565381|Behavioral|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
79311614|NCT02565381|Behavioral|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide <8ppm
79311615|NCT02565381|Behavioral|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
79311616|NCT02063854|Drug|NE-58095 IR|NE-58095 IR tablets
79311617|NCT02063854|Drug|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
79311618|NCT02063854|Drug|NE-58095 DR|NE-58095 DR tablets
79311619|NCT02063854|Drug|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
79475419|NCT02684435|Drug|Perflutren lipid microsphere|Dosing per approved package label
79969491|NCT04007107|Drug|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
79969492|NCT04007107|Drug|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
79311620|NCT02063698|Drug|auranofin|Given PO
79311621|NCT02063698|Other|placebo|Given PO
79311622|NCT02063698|Other|questionnaire administration|Ancillary studies
79311623|NCT02062450|Device|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
79311624|NCT02062450|Device|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
79311625|NCT02561247|Device|Prismaflex HF20 CRRT Filter|
79311626|NCT02561247|Device|Prismaflex® System 7.10 and 7.20|
79311627|NCT02061592|Device|etafilcon A|
79311628|NCT02061592|Device|etafilcon A|
79311629|NCT04701034|Drug|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
79311630|NCT04701034|Drug|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
79311631|NCT04701034|Drug|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
79311632|NCT04701034|Drug|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
79311633|NCT04700956|Procedure|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
79311634|NCT04700956|Device|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
79311635|NCT01663623|Biological|Placebo|Placebo
79805338|NCT04137146|Device|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
79311636|NCT01663623|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg
79311637|NCT01663623|Drug|Azathioprine|Azathioprine
79311638|NCT02042950|Drug|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
79311639|NCT02042404|Device|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
79475420|NCT02684591|Drug|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
79805339|NCT04185467|Other|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
79311640|NCT04582305|Drug|Bleomycin|Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
79311641|NCT04582305|Drug|Normal saline|Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
79311642|NCT02042014|Drug|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
79311643|NCT04700410|Device|Pure-Vu System|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
79475421|NCT02684591|Drug|Placebo|Placebo
79475422|NCT02685293|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
79475423|NCT02685293|Drug|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
79311644|NCT05504967|Drug|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
79475424|NCT00782249|Procedure|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
79984443|NCT03200002|Drug|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
79311645|NCT05504967|Drug|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
79311646|NCT05504967|Drug|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
79311647|NCT02041702|Diagnostic Test|Non-Diagnostic Cardiac MRI scan|
79311648|NCT02565147|Procedure|PPCI|PPCI for treatment of participants presenting with large STEMI.
79311649|NCT02565147|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
79475425|NCT00782249|Procedure|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
79475426|NCT00782249|Procedure|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
79475427|NCT04339127|Other|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
79805340|NCT00682136|Procedure|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
79311650|NCT02565147|Drug|Heparin|Heparin is an anticoagulant.
79311651|NCT02061280|Drug|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
79311652|NCT02061280|Drug|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
79311653|NCT02061280|Drug|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
79311654|NCT05150925|Other|Cast treatment|Dorsal cast placed in OR
79311655|NCT05150925|Other|Immediate mobilization|Immediate mobilization postoperatively without casting
79311656|NCT05150925|Procedure|Volar plating|Volar plating of distal radius fracture
79311657|NCT02061202|Drug|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
79475428|NCT04340375|Dietary Supplement|AP green tea extracts|AP green tea extracts
79475429|NCT05436275|Biological|CM310|300 mg every two weeks
79475430|NCT05436275|Biological|Placebo|once every two weeks
79475431|NCT04707755|Other|Motor imagery technique|"The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs."
79475432|NCT04707755|Other|Conventional Physical Therapy|It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
79805341|NCT00693056|Drug|Placebo|Placebo (w/o API)
79805342|NCT00693056|Drug|RX-10100 5mg|5 mg/dose of RX-10100
79805343|NCT00693056|Drug|RX-10100 10mg|10 mg/dose of RX-10100
79805344|NCT00693056|Drug|RX-10100 15mg|15 mg/dose of RX-10100
79805345|NCT04137302|Drug|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
79805346|NCT04145336|Device|5cm 5-Fr PDS|High-risk patients receive 5cm 5-Fr PDS
79311658|NCT02061202|Drug|Placebo|placebo training inhaler with the same instructions as the experimental group.
79311659|NCT05112172|Other|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
79311660|NCT02059408|Other|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
79311661|NCT02059408|Other|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys <45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
79311662|NCT05504811|Device|FitMi AD|Exercise using the motion sensing devices and a tablet computer
79311663|NCT05504811|Other|Conventional exercise program|Exercise following printed sheets or booklet
79311664|NCT05504733|Device|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.
79805347|NCT04145336|Device|7cm 5-Fr PDS|High-risk patients receive 7cm 5-Fr PDS
79805348|NCT04145336|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
79969493|NCT01166711|Device|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"standard techniques will be used~maximal vasodilatation after nitro application~baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~6 French guiding catheter at least~target lesion will be crossed with standard guidewire~direct stenting at the discretion of the investigator~if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~full lesion coverage will be ensured (with one or more stents)~only insert assigned stent type~BMS needs to be fully embedded in vessel wall~post-dilation with high pressure is required before treatment with DEB~DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~length of DEB should exceed the BMS by 2-3 mm on each side~if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
79311665|NCT05504733|Device|Combat Application Tourniquet|The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
79311666|NCT04698850|Drug|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
79311667|NCT04698850|Drug|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
79311668|NCT04698850|Drug|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
79311669|NCT04698226|Procedure|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
79311670|NCT04698226|Procedure|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
79311671|NCT05504577|Drug|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
79311672|NCT05504577|Device|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
79311673|NCT05504577|Device|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
79311674|NCT05504499|Device|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
79475433|NCT05432843|Drug|Pregabalin|Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
79969494|NCT01166711|Device|Coroflex Please (DES)|"standard techniques will be used~maximal vasodilatation after nitro application~baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~6 French guiding catheter at least~target lesion will be crossed with standard guidewire~direct stenting at the discretion of the investigator~if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~full lesion coverage will be ensured (with one or more stents)~only insert assigned stent type"
79805349|NCT03686423|Procedure|Exercise Program|The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
79805350|NCT00499681|Drug|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
79805351|NCT00499681|Drug|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
79311675|NCT05501535|Device|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
79475434|NCT05432843|Drug|Placebo|Patients receive a treatment with placebo for 8 weeks
79475435|NCT02678039|Device|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
79805352|NCT00499681|Other|placebo|Given once daily for 2 weeks
79805353|NCT02687009|Drug|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
79311676|NCT05501457|Device|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
79311677|NCT05016297|Drug|Baricitinib|baricitinib 4mg per day
79805354|NCT00693212|Drug|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
79969495|NCT04046341|Behavioral|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
79311678|NCT05016297|Drug|Hydroxychloroquine|Hydroxychloroquine 200mg twice a day
79311679|NCT05504265|Drug|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
79311680|NCT05504265|Drug|Postoperative flurbiprofen axetil|50mg bid
79311681|NCT05504265|Device|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
79311682|NCT01625338|Drug|SOF|SOF 400 mg tablet administered orally once daily
79311683|NCT01625338|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79311684|NCT01625338|Drug|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
79311685|NCT05504109|Procedure|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
79311686|NCT05504109|Procedure|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
79311687|NCT05504031|Procedure|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
79475436|NCT02678039|Procedure|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
79475437|NCT02679911|Drug|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
79311688|NCT05504031|Procedure|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
79311689|NCT05503953|Drug|AGSAVI|Uptitation
79475438|NCT02679911|Drug|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
79311690|NCT05503953|Drug|AGLS|Uptitration
79311691|NCT04698148|Other|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
79475439|NCT02680145|Device|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
79640224|NCT05291650|Drug|Saline|A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
79805355|NCT00693212|Drug|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
79805356|NCT00693212|Drug|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
79805357|NCT03673943|Drug|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
79805358|NCT00693290|Other|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
79805359|NCT04471285|Procedure|acupuncture|acupuncture
79805360|NCT04471285|Procedure|Sham acupuncture|Sham acupuncture
79311692|NCT04698148|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
79311693|NCT04698148|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
79311694|NCT02560623|Procedure|Biopsy|Undergo biopsy
79311695|NCT02560623|Procedure|Biospecimen Collection|Undergo collection of blood sample
79311696|NCT02560623|Procedure|Endoscopic Procedure|Undergo endoscopy
79311697|NCT02560623|Device|Swallowable Sponge Cell Sampling Device|Undergo swallowable sponge cell sampling assessment
79969496|NCT01168739|Dietary Supplement|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
79311698|NCT05501223|Other|Medication review|30-60 minutes extra consultation regarding the patients drugs
79311699|NCT05501223|Other|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
79311700|NCT05501145|Procedure|cesarean section and aortic repair|The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.
79311701|NCT04740099|Other|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
79311702|NCT04740099|Other|Standard of Care|A handout including a map and list of locations offering this service.
79311703|NCT05503563|Procedure|terta modal bladder preservation|neoadjuvant chemotherapy, partial cystectomy, radiotherapy
79640225|NCT05291650|Drug|Hyaluronic acid|After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
79311704|NCT04535115|Procedure|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
79311705|NCT04535115|Procedure|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
79311706|NCT02560389|Drug|Placebo|Sugar pill packaged to resemble levodopa
79640226|NCT05285059|Behavioral|ASRT task|"The ASRT (Alternating Serial Reaction Time) task is a computerized behavioral task measuring implicit learning. This task consists of 20 series of trials lasting 2 minutes each.~In each trial, a stimulus is displayed on the screen in one of the four possible predefined locations. The participant must press a button to indicate the position of the stimulus on the screen. Response content and response time are recorded.~At the end of every trial, the participant can take a break and resume the task whenever ready. The task lasts about 45 to 50 minutes."
79640227|NCT05272046|Procedure|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
79969497|NCT01168739|Dietary Supplement|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
79311707|NCT02560389|Drug|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
79311708|NCT05500989|Other|Venepuncture|The only invasive procedure is a venepuncture where 100 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
79311709|NCT05500911|Procedure|sinus lift|when residual bone height is >4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
79969498|NCT03869879|Other|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
79311710|NCT05500911|Procedure|implant placement|Implant will be placed in edentulous area
79311711|NCT02564211|Drug|Ipragliflozin|one 50 mg tablet QD
79311712|NCT02564211|Drug|Sitagliptin|one 50 mg tablet QD
79640228|NCT05272046|Device|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
79969499|NCT03869879|Other|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
79311713|NCT04596579|Diagnostic Test|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
79311714|NCT04596579|Diagnostic Test|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
79640229|NCT05266950|Biological|CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)|Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
79805361|NCT00688298|Device|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
79805362|NCT00688298|Device|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
79805363|NCT02687087|Device|Visco-ease|19.6 mg/mL of LMS-611
79311715|NCT04596579|Behavioral|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
79805364|NCT02687087|Device|Placebo|Physiological Saline
79805365|NCT02686775|Behavioral|Patient coach|
79805366|NCT02686775|Behavioral|Standard care|
79969500|NCT01171781|Drug|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
79969501|NCT01171781|Drug|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
79969502|NCT01284023|Other|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
79969503|NCT03233529|Drug|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
79311716|NCT04465461|Procedure|Video-assisted thoracoscopic surgery (VATS) fissure completion|Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.
79311717|NCT04465461|Device|Zephyr Valve insertion|Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
79805367|NCT00499603|Drug|Paclitaxel|80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
79311718|NCT05503329|Diagnostic Test|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
79311719|NCT04619901|Other|Semi-structured interviews|Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
79311720|NCT04619901|Other|Questionnaire|Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
79969504|NCT03233529|Drug|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
79805368|NCT00499603|Drug|5-Fluorouracil|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
79805369|NCT00499603|Drug|Epirubicin|100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
79969505|NCT04006171|Diagnostic Test|C type natriuretic peptide|Serum level of CNP in PCOS and healthy women
79311721|NCT04619901|Other|following Scales|Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
79311722|NCT04465383|Device|Aqua© 30 on Oncomfort SedakitTM|Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
79311723|NCT04465383|Drug|Propofol|Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
79805370|NCT00499603|Drug|Cyclophosphamide|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
79969506|NCT01171859|Drug|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
79969507|NCT01284101|Device|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
79969508|NCT01284101|Device|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
79311724|NCT04388865|Behavioral|Control|Subjects will engage with their providers as is standard of care.
79311725|NCT04388865|Behavioral|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
79311726|NCT05500677|Drug|Lidocaine topical|Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
79311727|NCT04331535|Diagnostic Test|Polygenic risk score (PRS)|Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
79311728|NCT04411563|Other|Taking biological samples|Taking blood samples for biochemical and epigenetic analysis
79311729|NCT02093026|Drug|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
79311730|NCT02093026|Drug|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
79969509|NCT02652468|Drug|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
79969510|NCT02652468|Drug|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
79969511|NCT02652468|Drug|Cyclophosphamide|Given IV for 2 days
79969512|NCT02652468|Radiation|Total nodal irradiation|Undergo total lymphoid irradiation
79969513|NCT02652468|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
79311731|NCT02093026|Drug|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
79311732|NCT02093026|Drug|Folic Acid|Participants will receive folic acid >= 5 mg/week or equivalent.
79475440|NCT02680301|Drug|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
79475441|NCT02680301|Drug|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
79475442|NCT02680457|Drug|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
79475443|NCT02680457|Drug|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
79805371|NCT00499603|Drug|RAD001|30 mg by mouth weekly on Days 1, 8, & 15 for 12 cycles.
79805372|NCT04144868|Other|Normobaric Oxygen|
79805373|NCT00639353|Device|senofilcon A toric soft contact lens|contact lens
79969514|NCT02652468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
79969515|NCT02652468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
79969516|NCT02652468|Drug|Mycophenolate Mofetil|Given PO
79969517|NCT02652468|Drug|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10^5 cells/kg ideal BW of the patient
79969518|NCT02652468|Biological|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the patient
79969519|NCT03737071|Behavioral|Low Carbohydrate Diet|Ketogenic dietary intervention
79969520|NCT04673877|Drug|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
79969521|NCT04673877|Procedure|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
79969522|NCT04673877|Drug|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
79311733|NCT04698070|Dietary Supplement|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC < 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
79475444|NCT02689973|Behavioral|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
79475445|NCT02689973|Behavioral|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
79640230|NCT05266027|Drug|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
79640231|NCT05266027|Drug|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
79640232|NCT05258669|Biological|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
79640233|NCT05248867|Drug|AGN-151586|Intramuscular Injection
79805374|NCT00639353|Device|senofilcon A sphere soft contact lens|contact lens
79805375|NCT04144556|Other|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
79805376|NCT04144556|Other|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
79805377|NCT01946711|Drug|Budesonide|Inhalation
79805378|NCT01946711|Drug|Budesonide|Nasal spray
79805379|NCT00693446|Drug|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
79805380|NCT00693446|Drug|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
79969523|NCT01284179|Behavioral|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
79805381|NCT00693524|Drug|tacrolimus|oral
79805382|NCT00693524|Drug|Anti-IL2R AB|i.v.
79640234|NCT05248867|Drug|Placebo|Intramuscular Injection
79640235|NCT05245266|Diagnostic Test|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
79640236|NCT05236465|Behavioral|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
79969524|NCT01284179|Behavioral|Educational|Educational recordings regarding FCP and FGIDs.
79969525|NCT05179590|Other|Quality of Dream|"Patients frequently report having dreams during general anesthesia, and the dreams are often reported to be pleasant dreams.~However, factors associated with the quality of dreams during general anesthesia have not been clarifed. The aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.~This prospective observational study included patients scheduled for elective surgery under general anesthesia."
79969526|NCT01166789|Drug|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
79969527|NCT01166789|Drug|Placebo|2 capsules daily, taken in morning and evening
79311734|NCT04698070|Dietary Supplement|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC < 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC > or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC > or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
79311735|NCT04698070|Other|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~SAM: Children with MUAC<115 or WHZ<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
79311736|NCT02040844|Drug|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
79311737|NCT02040844|Drug|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
79805383|NCT00693524|Drug|Mycophenolate mofetil|oral
79805384|NCT00693524|Drug|prednisone|oral
79969528|NCT01314339|Drug|Desloratadine|Desloratadine Tablets, 5 mg
79969529|NCT03736915|Procedure|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
79805385|NCT00693602|Drug|Erwinase|Chemotherapy
79311738|NCT02040844|Drug|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
79311739|NCT02059174|Drug|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
79311740|NCT02059174|Drug|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
79969530|NCT03736915|Other|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
79640237|NCT05236465|Behavioral|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
79969531|NCT03736915|Other|Questionnaires|Patient is asked to answer questionairres at the end of each injection
79969532|NCT01168817|Drug|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
79805386|NCT00682214|Drug|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
79805387|NCT00682214|Drug|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
79805388|NCT00693680|Dietary Supplement|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
79805389|NCT00693680|Dietary Supplement|Placebo|placebo + imipramine (100-200mg/day)
79805390|NCT00682292|Drug|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
79969533|NCT01168817|Drug|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
79969534|NCT01168817|Drug|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
79311741|NCT02059174|Drug|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
79311742|NCT02092324|Other|Laboratory Biomarker Analysis|Correlative studies
79311743|NCT02092324|Other|Quality-of-Life Assessment|Ancillary studies
79311744|NCT02092324|Other|Questionnaire Administration|Ancillary studies
79311745|NCT02092324|Drug|Ruxolitinib Phosphate|Given PO
79311746|NCT04417582|Procedure|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
79311747|NCT02040766|Drug|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
79311748|NCT02040766|Drug|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
79311749|NCT02040766|Drug|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
79311750|NCT02040766|Drug|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
79311751|NCT02040766|Drug|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
79311752|NCT02040532|Drug|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
79311753|NCT02039908|Drug|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
79640238|NCT05228886|Behavioral|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
79805391|NCT00682292|Drug|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
79805392|NCT02624336|Other|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
79805393|NCT02624336|Other|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
79805394|NCT02624336|Other|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
79311754|NCT04695730|Other|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
79475446|NCT02689973|Behavioral|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
79475447|NCT02691143|Other|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
79475448|NCT02283762|Drug|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
79805395|NCT00810069|Drug|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
79805396|NCT00810069|Drug|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
79805397|NCT00693758|Drug|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
79805398|NCT00693758|Other|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
79805399|NCT00693758|Other|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
79805400|NCT00693758|Device|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
79805401|NCT00693758|Device|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
79805402|NCT00693836|Genetic|genetic linkage analysis|
79805403|NCT00693836|Genetic|loss of heterozygosity analysis|
79805404|NCT00693836|Genetic|mutation analysis|
79805405|NCT00693836|Genetic|polymerase chain reaction|
79805406|NCT00693836|Genetic|polymorphism analysis|
79805407|NCT00693836|Other|biologic sample preservation procedure|
79805408|NCT00693836|Other|medical chart review|
79805409|NCT00693836|Other|questionnaire administration|
79805410|NCT00693836|Procedure|evaluation of cancer risk factors|
79311755|NCT04695730|Other|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
79311756|NCT04417270|Device|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
79311757|NCT04417270|Device|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
79311758|NCT04417348|Drug|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
79311759|NCT02058940|Drug|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
79311760|NCT02058628|Drug|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
79311761|NCT02058628|Drug|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
79969535|NCT04523649|Device|Remote atrial fibrillation screening with handheld single lead ECG recorder|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
79969536|NCT03639961|Behavioral|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
79311762|NCT02058160|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
79311763|NCT02058160|Drug|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
79311764|NCT02058160|Drug|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
79311765|NCT02090764|Drug|Ozenoxacin|
79311766|NCT02090764|Drug|Placebo|
79311767|NCT04718506|Behavioral|Exercise|Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises [squat, bench press, deadlift and bench pull]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
79640239|NCT05228886|Behavioral|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
79640240|NCT05228886|Other|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
79640241|NCT05201508|Procedure|Polyglactin mesh|Polyglactin mesh is used in keyhole manner to enforce hiatal closure
79640242|NCT05201508|Procedure|Sutures only|Traditional hiatal closure with non-absorbable sutures.
79311768|NCT04718506|Behavioral|Inspiratory muscle training|Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
79311769|NCT04718506|Behavioral|Controls|Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
79311770|NCT04730830|Other|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
79640243|NCT05200624|Device|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
79640244|NCT05172726|Drug|tapinarof cream, 1%|applied topically once daily
79640245|NCT05168046|Behavioral|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
79640246|NCT05159466|Procedure|Kidney transplant|Participants will be recruited at the Tulane Abdominal Transplant Institute site where they are evaluated and followed for organ transplantation as part of standard of care. HIV-positive adult candidates on the wait list or referred for organ transplantation evaluation willing to accept an HIV positive organ will be recruited.
79640247|NCT05157867|Other|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
79640248|NCT05157867|Other|Placebo|Intraduodenal administration of placebo (physiological saline).
79640249|NCT05131581|Other|Changed clinical context|Changed clinical context: from midwifery clinic to youth clinic
79311771|NCT02057692|Drug|LUM001|LUM001 administered orally
79311772|NCT02057692|Drug|Placebo|Placebo administered orally
79640250|NCT05131581|Behavioral|Extra time allotted|Extra time allotted for each visit for CST
79640251|NCT05131581|Behavioral|RLP-information|Midwife-initiated discussion of the Reproductive Life Plan
79969537|NCT03639961|Behavioral|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
79640252|NCT05131438|Drug|sugemalimab|sugemalimab (Anti-PD-L1 antibody)
79640253|NCT05131386|Drug|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
79640254|NCT05129332|Other|Vaginal Moisturizer|Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
79640255|NCT05129332|Device|Vaginal Dilator|Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
79640256|NCT05118282|Behavioral|Combined coping skills + asthma management|This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
79311773|NCT02038036|Drug|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
79311774|NCT02038036|Drug|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
79311775|NCT02037568|Behavioral|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
79311776|NCT02088034|Behavioral|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
79640257|NCT05118282|Behavioral|Standard Asthma Management (AM)|This arm includes a curriculum teaching standard asthma management skills.
79311777|NCT02088034|Drug|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
79311778|NCT02088034|Other|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
79805411|NCT00688610|Other|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
79805412|NCT00682370|Drug|saline solution|intravenous infusion, single dose
79805413|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~0.3 mg/kg heme arginate"
79805414|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~1 mg/kg heme arginate"
79311779|NCT02037256|Drug|bortezomib|Given IV
79311780|NCT02037256|Biological|filgrastim|Given SC
79311781|NCT02037256|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
79311782|NCT02035696|Biological|Trivalent influenza vaccine (TIVc)|
79311783|NCT02035696|Biological|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
79311784|NCT02057458|Drug|Sildenafil (Acute-1 hour)|Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
79805415|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~3 mg/kg heme arginate"
79311785|NCT02057458|Drug|Sildenafil (Subchronic-4 weeks)|Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
79640258|NCT05111262|Drug|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
79805416|NCT02625740|Device|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
79805417|NCT02625740|Device|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
79805418|NCT02625740|Device|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
79475449|NCT02283762|Drug|Placebo|Sham-titration
79311786|NCT02057458|Drug|Placebo|Sugar pill designed to mimic the sildenafil treatment
79475450|NCT02692391|Drug|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
79640259|NCT05098613|Drug|CD19x22 CAR T Cells|Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
79640260|NCT05098431|Other|Quadriceps and Rectus Femoris MEP Recording|Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
79640261|NCT05091242|Drug|Clonidine|Clonidine injection 3 mcg/kg once
79640262|NCT05091242|Drug|Sodium chloride|Sodium chloride 0.9 % injection 0.2 mL/kg once
79805419|NCT02625740|Drug|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
79805420|NCT02625740|Procedure|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
79805421|NCT00688922|Drug|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
79969538|NCT01279811|Other|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
79805422|NCT00693914|Behavioral|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
79311787|NCT02057068|Behavioral|SLEEP-E Dyads Intervention|Described in arm/group description
79311788|NCT02056834|Device|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
79311789|NCT02087176|Drug|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
79311790|NCT02087176|Drug|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
79311791|NCT02087176|Drug|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
79311792|NCT02087176|Drug|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
79311793|NCT02056288|Drug|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
79311794|NCT02056288|Drug|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
79311795|NCT02086162|Behavioral|Web-based motivational decision support system|
79311796|NCT02086162|Behavioral|NCI Education|
79311797|NCT02404571|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
79311798|NCT03115697|Drug|Lactulose|Lactulose 20 mL
79969539|NCT04043143|Other|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
79969540|NCT04043143|Other|Arm 2 Prescription Tool Intervention|The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
79969541|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
79311799|NCT03115697|Drug|Rifaximin|Rifaximin 550 BD
79311800|NCT03115697|Biological|Plasmapheresis|Plasmapheresis 8 hrly duration
79311801|NCT03115775|Dietary Supplement|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
79311802|NCT03115775|Dietary Supplement|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
79311803|NCT03115775|Dietary Supplement|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
79311804|NCT03115775|Other|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
79311805|NCT02404259|Drug|TDF (Tenofovir)|
79311806|NCT02404259|Drug|Efavirenz|
79311807|NCT02404259|Drug|lopinavir/ritonavir, atazanavir/ritonavir|
79311808|NCT03171155|Device|XPro System|Implantation of the XPro System
79311809|NCT03170921|Other|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
79311810|NCT03170921|Other|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
79311811|NCT03170921|Other|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
79311812|NCT03170765|Biological|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
79311813|NCT03170687|Device|short foot cast|metatarsal foot cast
79311814|NCT03170687|Device|short leg cast|full short leg cast
79311815|NCT03170531|Diagnostic Test|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
79311816|NCT03170531|Diagnostic Test|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
79640263|NCT05085535|Other|Manual Therapy|Exercises for body mobility and muscle toning, Sophrology, musculoskeletal oscillatory manual therapy
79805423|NCT02609373|Behavioral|Sleep intervention|"Session 1: Intervener & participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 & 10 months: reinforcement, question answering, encouragement and monitoring."
79311817|NCT02403947|Drug|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
79805424|NCT00694148|Drug|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
79805425|NCT02609217|Other|Questionnaires and interviews|
79805426|NCT00694226|Behavioral|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
79969542|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
79969543|NCT01169129|Other|surgery|resection of brain metastases
79311818|NCT02403947|Drug|Suspension media|injection suspension media
79311819|NCT04481633|Diagnostic Test|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
79311820|NCT04481633|Other|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
79311821|NCT03170063|Procedure|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
79311822|NCT03169907|Radiation|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~Middle cerebral artery (MCA) peak systolic velocity (PSV):~Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~Ductus venosus (DV) Doppler:~Cardiac functions:~Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
79311823|NCT03169751|Device|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
79640264|NCT05085535|Other|Exercise|Exercises for body mobility and muscle toning, Sophrology
79640265|NCT05077865|Drug|MYMD-1|150 mg capsule
79969544|NCT01169129|Radiation|radiosurgery|radiosurgery to brain metastases
79969545|NCT03736837|Drug|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
79969546|NCT02526407|Behavioral|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
79640266|NCT05077865|Drug|Placebo|Matching in appearance to MyMD-1 150mg capsule
79640267|NCT05052138|Other|Tactile massage|Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
79969547|NCT02526407|Behavioral|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
79969548|NCT04041895|Other|Audio speech recording|Audio recording of speech sample from subject description of Cookie-Theft image.
79655658|NCT04553614|Behavioral|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
79655659|NCT04553614|Other|Control|Usual exercise referral scheme procedure.
79655660|NCT04553224|Other|Clinical evaluations|SCORAD and target SCORAD
79655661|NCT04553224|Other|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
79655662|NCT04553224|Other|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
79655663|NCT00261339|Drug|Pantoprazole|
79640268|NCT05045976|Other|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
79311824|NCT03169829|Dietary Supplement|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~Animal only Protein~Refined only Grains~Limit Dairy~Low-k only"
79311825|NCT03169829|Dietary Supplement|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~Limit Dairy, provide Soymilk Dairy~Low-k only Fruit and Vegetables"
79640269|NCT05032859|Drug|tapinarof cream, 1%|applied topically once daily
79640270|NCT05032859|Drug|vehicle cream|applied topically once daily
79640271|NCT05029128|Behavioral|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
79969549|NCT03523806|Behavioral|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
79640272|NCT05027516|Drug|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
79640273|NCT05027516|Drug|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
79640274|NCT05025670|Behavioral|Supportive psychotherapy|Participants will receive monthly 30-45 minute supportive psychotherapy sessions. Supportive psychotherapy is an integrative and eclectic psychotherapeutic approach, based upon the individual's needs and symptoms. It draws from elements of a variety of psychotherapeutic disciplines, including cognitive-behavior, psychodynamic, and interpersonal therapies.
79640275|NCT04992013|Drug|Niraparib|Capsule taken by mouth
79640276|NCT04975789|Other|InfoViz|The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
79640277|NCT04957953|Other|Patient's consent|Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.
79640278|NCT04957953|Other|Inclusion form|"This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate."
79640279|NCT04957953|Other|Adverse reaction report form.|One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,
79311826|NCT03169829|Dietary Supplement|Standard|"•¼ Animal, ¾ Plant Proteins~Refined, ½ Whole Grain~•Limit Dairy, provide Soymilk Dairy~Low-k, Fruit and Vegetables~High-k Fruit and Vegetables"
79311827|NCT04481867|Procedure|densah bur|osseodensification densah bur
79311828|NCT02403791|Device|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
79311829|NCT02403791|Device|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
79311830|NCT02403713|Drug|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
79311831|NCT02403713|Drug|Formoterol|Formoterol
79655664|NCT04553653|Other|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
79969550|NCT03745105|Drug|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
79311832|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
79311833|NCT02403713|Drug|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
79311834|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
79311835|NCT02700815|Drug|Diclofenac|
79311836|NCT02700815|Drug|Capsaicin|
79311837|NCT02700815|Drug|Placebo|
79311838|NCT02403557|Behavioral|Waitlist|Weekly check up.
79311839|NCT02403557|Behavioral|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
79475451|NCT02692391|Drug|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
79640280|NCT04957953|Diagnostic Test|Follow-up report form.|In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
79640281|NCT04947124|Drug|QLS-101ophthalmic solution 1%|QLS-101ophthalmic solution 1.0%
79640282|NCT04947124|Drug|QLS-101ophthalmic solution 2%|QLS-101ophthalmic solution 2.0%
79640283|NCT04938908|Drug|Ophthalmic Probiotic|Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
79640284|NCT04938908|Drug|Opthalmic Placebo|Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
79640285|NCT04938908|Dietary Supplement|Oral Probiotic Capsule|Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
79640286|NCT04938908|Dietary Supplement|Oral Placebo Capsule|Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
79640287|NCT04933630|Drug|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
79640288|NCT04923841|Other|High intensity light box for bright light therapy and single vision spectacle lenses|High intensity light box for bright light therapy and single vision spectacle lenses
79640289|NCT04923841|Other|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
79640290|NCT04923841|Other|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
79640291|NCT04923841|Other|Atropine 0.01% eye drop and and single vision spectacle lenses|Atropine 0.01% eye drop and and single vision spectacle lenses
79640292|NCT04906642|Device|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
79640293|NCT04906642|Other|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
79640294|NCT04898127|Diagnostic Test|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
79805427|NCT00694226|Behavioral|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
79475452|NCT02692859|Biological|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
79475453|NCT04878120|Device|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI
79475454|NCT04878120|Device|Standard Hybrid Closed Loop Control (USS Virginia)|Standard Hybrid Closed Loop Control (USS Virginia)
79640295|NCT04888832|Other|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
79640296|NCT04880629|Behavioral|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
79475455|NCT02694029|Device|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
79475456|NCT02694029|Device|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
79655665|NCT00235976|Drug|Gantacurium Chloride for Injection (AV430A)|
79655666|NCT04553380|Drug|basic insulin|"Initial dose of basic insulin: 0.2U/kg/d.~Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~Injection time: subcutaneous injection before going to bed every night."
79655667|NCT04553302|Other|This study does not contain any intervention.|This study does not contain any intervention.
79475457|NCT04739033|Behavioral|VIVIR MEJOR EXPERIMENTAL|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
79655668|NCT00236015|Drug|Gabitril|
79655669|NCT00261378|Device|Transarterialchemoembolisation (TACE)|
79655670|NCT00261378|Device|DC Bead with Doxorubicin|
79640297|NCT04880629|Behavioral|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
79640298|NCT04875338|Drug|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
79640299|NCT04875338|Drug|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
79640300|NCT04875338|Drug|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
79640301|NCT04869098|Dietary Supplement|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
79311840|NCT03170297|Other|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
79311841|NCT03169595|Procedure|Surgery|Patients affected by epithelioid hemangioma treated with surgery
79311842|NCT02403401|Drug|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
79311843|NCT02403245|Other|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
79311844|NCT02403011|Other|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
79805428|NCT04029051|Other|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
79805429|NCT02626364|Drug|crenolanib|single-agent crenolanib at 100 mg PO TID
79805430|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
79805431|NCT02609139|Drug|PF-06650833|100mg modified release tablet administered under fasted conditions
79311845|NCT02403011|Other|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
79475458|NCT02696291|Drug|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
79805432|NCT02609139|Drug|PF-06650833|20mg modified release tablet administered under fasted conditions
79311846|NCT02402855|Other|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
79475459|NCT02696291|Drug|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
79475460|NCT02696291|Drug|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
79640302|NCT04869098|Dietary Supplement|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
79640303|NCT04861792|Behavioral|Michigan SPARC Quality Improvement Intervention|Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
79805433|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
79311847|NCT02402855|Other|Interview with a sociologist|For a sub-group of 40 womens
79311848|NCT02402855|Other|No intervention|
79805434|NCT02609139|Drug|PF-06650833|100mg modified released tablet administered with high fat meal food intake
79805435|NCT02609139|Drug|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
79311849|NCT02402621|Drug|fentanyl|fentanyl with antiemetic drug
79311850|NCT04481789|Drug|MT-1186|Suspension
79311851|NCT04481789|Drug|Rosuvastatin|Tablets
79311852|NCT04481789|Drug|Sildenafil|Tablets
79311853|NCT04481789|Drug|Furosemide|Tablets
79311854|NCT02402387|Procedure|Neutral head position|
79311855|NCT02402387|Procedure|Flexed head position|
79475461|NCT02696291|Drug|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
79311856|NCT02402387|Procedure|Extended head position|
79311857|NCT02402387|Procedure|Rotated head position|
79475462|NCT02696291|Drug|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
79475463|NCT02696291|Drug|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
79475464|NCT05406245|Dietary Supplement|Carbohydrate drinking|Administration of carbohydrate fluid
79475465|NCT02682563|Drug|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
79640304|NCT04855006|Biological|Vaginal Microbiome Transplant|Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
79640305|NCT04855006|Biological|Vaginal Microbiome Transplant Placebo|Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
79640306|NCT04855006|Other|No intervention|Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
79640307|NCT04838808|Drug|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
79640308|NCT04838808|Drug|Placebo|Placebo tablet twice daily for 90-days
79805436|NCT00682526|Device|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
79805437|NCT02609295|Dietary Supplement|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
79805438|NCT02609295|Dietary Supplement|ALA group|1.2 g (two capsules) of perilla oil
79311858|NCT02402387|Device|Air-Q SP Airway|
79311859|NCT02402465|Drug|Placebo|Patients will be treated by placebo
79311860|NCT02402465|Drug|Fluticasone propionate|Patients will receive fluticasone nasal spray
79311861|NCT02402465|Drug|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
79311862|NCT02402465|Procedure|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
79311863|NCT04481711|Procedure|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
79311864|NCT02402231|Drug|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
79311865|NCT02402543|Drug|Gabapentin|
79311866|NCT02402543|Drug|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
79311867|NCT02402543|Drug|Acetaminophen|
79311868|NCT02402543|Drug|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
79311869|NCT02402543|Drug|Placebo|
79311870|NCT02401841|Drug|Two different types of drug for resolution of neuro-muscular blockade|
79475466|NCT02682563|Drug|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
79640309|NCT04834726|Behavioral|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
79805439|NCT04136834|Biological|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
79805440|NCT00694460|Biological|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
79805441|NCT00694460|Biological|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
79969551|NCT03745105|Drug|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
79640310|NCT04834726|Behavioral|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
79640311|NCT04834726|Behavioral|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
79805442|NCT00694460|Biological|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
79311871|NCT02401919|Behavioral|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
79311872|NCT04481477|Other|Nursing care to reduce anxiety, fear and loneliness|Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
79805443|NCT00694460|Biological|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
79311873|NCT02401607|Other|Karasek questionnaire and Saliva prelevement|Karasek questionniare and Saliva collection will be assessed on any health care worker working in any emergency department in France at day 1 and at 5 years
79311874|NCT02401373|Biological|Ad5-EBOV|intramuscular injection
79311875|NCT05232305|Dietary Supplement|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
79311876|NCT02401295|Drug|ATRA|
79311877|NCT02401295|Drug|Celecoxib|
79311878|NCT02401295|Drug|Itraconazole|
79311879|NCT02401451|Device|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
79311880|NCT02400983|Device|Pacemaker, ICD|
79311881|NCT04897763|Drug|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
79311882|NCT03169439|Procedure|Irreversible electroporation|minimal invasive ablative technique for tumors
79640312|NCT04834726|Behavioral|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
79640313|NCT04834726|Behavioral|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
79805444|NCT00694460|Biological|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
79805445|NCT04776525|Drug|Ifosfamide|3 g/m2 each day for three days
79311883|NCT03169205|Other|observation registry|observation registry
79311884|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
79311885|NCT02401217|Other|Phase 1- Arm 1 Infant Formula|Powder infant formula
79640314|NCT04834726|Behavioral|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
79311886|NCT02401217|Other|Phase 2- Arm 2 Infant Formula|Powder infant formula
79311887|NCT02401217|Other|Phase 2- Arm 3 Infant Formula|Powder infant formula
79311888|NCT03106649|Device|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
79805446|NCT04776525|Drug|Doxorubicin|80 mg/m2 over four hours day 1
79805447|NCT00689000|Drug|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
79805448|NCT00489541|Device|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
79311889|NCT03106649|Device|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
79311890|NCT00708305|Drug|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
79311891|NCT00708305|Drug|Placebo|Fluoride free toothpaste (0ppmF)
79640315|NCT04834726|Behavioral|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
79805449|NCT00689156|Drug|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
79640316|NCT04805658|Diagnostic Test|Clinical examinations|Clinical examinations
79640317|NCT04781842|Other|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
79640318|NCT04770363|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique which has been utilized in examining cortical function in healthy subjects and also showed significant outcome in neurological rehabilitation. A safe, portable, noninvasive painless, reversible, selective and focal brain stimulation technique, applied by sponge electrodes over the scalp. tDCS is capable of modulating the excitability of targeted brain zones through delivering a sustained direct current (DC), showed altering neuronal membrane potentials based on the polarity of the current. Researchers demonstrated modulating effects of anodal (increases cortical excitability) and cathodal (decreases cortical excitability) tDCS on brain tissue. The expected effects of tDCS brain stimulation exceeds the duration. Animal studies showed neuronal depolarization and increasing neuronal excitability of the anodal stimulation, and opposite results with cathodal stimulation.
79640319|NCT04762251|Other|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
79640320|NCT04762251|Other|Current Best Practice|Best practice guidelines to improve diet quality
79640321|NCT04748276|Drug|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
79640322|NCT04732949|Drug|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
79640323|NCT04732949|Drug|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
79640324|NCT04685239|Device|dual mobility cup|The use of a Sunfit dual mobility cup
79475467|NCT02697071|Drug|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
79640325|NCT04685239|Device|unipolar cup|The use of a TMT cup
79475468|NCT02697071|Drug|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
79640326|NCT04684147|Biological|single dose of CNCT19|Dose: 0.5 x 10^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
79475469|NCT02683421|Drug|Tilmanocept|
79640327|NCT04659811|Drug|Pembrolizumab|200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity
79475470|NCT02683577|Drug|telotristat etiprate|
79475471|NCT05369897|Device|VR training|The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.
79640328|NCT04659811|Procedure|Stereotactic Radiosurgery|Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
79805450|NCT00689156|Drug|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
79805451|NCT00689234|Procedure|diaphragm plication 6 months after inclusion|thoracotomy
79805452|NCT00689234|Procedure|diaphragm plication at time of inclusion|thoracotomy
79805453|NCT01016821|Drug|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
79475472|NCT05369897|Device|VR activity|High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
79475473|NCT02283294|Drug|Apixaban|
79640329|NCT04637776|Other|Hospitalization|Hospitalization for any reason
79640330|NCT04625504|Behavioral|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
79640331|NCT04610658|Drug|Nivolumab|Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.
79805454|NCT04139174|Procedure|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
79805455|NCT01011205|Drug|Advagraf|Capsule
79475474|NCT02283294|Drug|Warfarin|
79640332|NCT04610658|Drug|Ipilimumab|Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.
79640333|NCT04610658|Drug|Lurbinectedin|Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m^2 and increasing to 3.2 mg/m^2 or the Maximum Tolerated Dose (MTD)
79805456|NCT01011205|Drug|Mycophenolate Mofetil|Solution for infusion
79805457|NCT01011205|Drug|Basiliximab|IV infusion
79805458|NCT01011205|Drug|Corticosteroids|IV bolus
79969552|NCT03745105|Drug|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
79969553|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
79311892|NCT03169049|Device|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
79311893|NCT03169049|Device|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
79311894|NCT03169127|Drug|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
79311895|NCT03115307|Drug|Triptorelin|Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
79311896|NCT03169283|Other|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
79640334|NCT04593264|Other|Self-guided pre-habilitation exercise program|A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery
79311897|NCT03169283|Other|Cereal without B glucan|Cereal without B glucan
79311898|NCT02418533|Drug|menotropin|Menopur is used for controlled ovarian stimulation (COH)
79311899|NCT02418533|Drug|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
79311900|NCT03168893|Device|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
79311901|NCT03168893|Device|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
79311902|NCT02400593|Behavioral|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
79311903|NCT02418299|Device|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
79311904|NCT02418221|Dietary Supplement|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
79311905|NCT02418221|Procedure|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure & pulse
79640335|NCT04593264|Other|Traditional pre-habilitation|Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
79640336|NCT04586478|Biological|single dose of CNCT19|Dose: 2.00 x 10^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
79640337|NCT04538066|Drug|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
79969554|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
79969555|NCT03744325|Dietary Supplement|Hen's egg OIT|Increasing doses of egg white protein administered orally
79311906|NCT02400827|Other|malignant cells|
79311907|NCT02401997|Behavioral|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
79311908|NCT02417909|Other|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
79311909|NCT02418065|Other|training on ergonomic bicycle|
79311910|NCT02418065|Drug|Testosterone|
79311911|NCT02418065|Drug|Oral nutritional supplementation|
79311912|NCT02418065|Drug|n3 polyunsaturated fatty acid|
79311913|NCT02417987|Other|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
79311914|NCT02417987|Drug|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
79311915|NCT02417987|Biological|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
79311916|NCT02400515|Other|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
79311917|NCT03168581|Drug|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
79311918|NCT05058443|Drug|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
79640338|NCT04538066|Other|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
79640339|NCT04532918|Drug|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
79640340|NCT04532918|Drug|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
79969556|NCT01169363|Genetic|proteomic profiling|
79311919|NCT05058443|Drug|Placebo|placebo subcutaneously every 6 months (Q6M)
79311920|NCT02400281|Drug|Crenolanib besylate|
79311921|NCT02400281|Drug|Idarubicin|
79311922|NCT02400281|Drug|Cytarabine|
79311923|NCT02400281|Drug|Azacytidine|
79311924|NCT02400281|Drug|Mitoxantrone|
79969557|NCT01169363|Other|flow cytometry|
79969558|NCT01169363|Other|laboratory biomarker analysis|
79311925|NCT02400281|Drug|Etoposide|
79311926|NCT02400281|Drug|Fludarabine|
79311927|NCT02400281|Drug|G-CSF|
79311928|NCT02417519|Other|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
79640341|NCT04532918|Drug|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
79969559|NCT03745027|Diagnostic Test|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
79640342|NCT04532918|Drug|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
79311929|NCT02417519|Other|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
79311930|NCT02417519|Other|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
79311931|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
79311932|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
79311933|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
79640343|NCT04511247|Device|MagicTouch PTA Sirolimus drug coated balloon|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
79311934|NCT02055976|Drug|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
79311935|NCT02055976|Drug|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
79311936|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
79311937|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
79311938|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
79311939|NCT02055976|Drug|Placebo|Placebo Q14D SC for 16 week
79311940|NCT02055898|Drug|Sodium Oxybate|
79640344|NCT04511247|Device|POBA balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
79640345|NCT04487860|Drug|AS012|oral administration
79640346|NCT04487860|Drug|Placebo|oral administration
79640347|NCT04423913|Other|Administration of embolization beads|Patients will receive embolization beads, loaded with doxorubicin or not.
79640348|NCT04414163|Drug|IMC-001|Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
79640349|NCT04396899|Biological|EHM implantation|Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF <35%).
79640350|NCT04394585|Behavioral|smart phone app based human coaching program|"experimental arm~1:1 coaching using smart phone app~Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~Patients are encouraged to report their diet diaries and exercise everyday by the coach.~Patients can ask to the coach using the app and the coach answer when they check them.~Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
79805459|NCT04143698|Device|endoscopic retrograde cholangiopancreatography|The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
79969560|NCT03744247|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79969561|NCT03744247|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
79311941|NCT02055898|Other|placebo (fresh potable water)|
79311942|NCT02564055|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
79311943|NCT02564055|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
79311944|NCT02564055|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
79311945|NCT02563899|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
79311946|NCT02563899|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
79640351|NCT04387084|Drug|Atezolizumab|Given IV
79640352|NCT04387084|Drug|Avelumab|Given IV
79640353|NCT04387084|Biological|Cemiplimab|Given IV
79640354|NCT04387084|Biological|Durvalumab|Given IV
79640355|NCT04387084|Biological|Nivolumab|Given IV
79640356|NCT04387084|Biological|Pembrolizumab|Given IV
79311947|NCT04406259|Drug|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
79640357|NCT04387084|Other|Quality-of-Life Assessment|Ancillary studies
79640358|NCT04387084|Other|Short-Term Fasting|Undergo STF
79640359|NCT04351334|Drug|Alectinib|Observational treatment based on physician choice
79640360|NCT04347798|Other|Hydroxychloroquine/Chloroquine|Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
79640361|NCT04335669|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
79640362|NCT04335669|Drug|epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
79640363|NCT04332939|Other|transcranial direct current stimulation|real tDCS sessions
79640364|NCT04332939|Other|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
79640365|NCT04332055|Other|ERVIN|ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.
79640366|NCT04298983|Drug|Abemaciclib 150 MG by mouth twice daily|Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
79640367|NCT04298983|Drug|Androgen deprivation therapy (ADT)|ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
79311948|NCT05500521|Diagnostic Test|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
79311949|NCT05500521|Diagnostic Test|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
79969562|NCT03744247|Drug|Placebo|Intravenously every 2 weeks
79969563|NCT01282619|Drug|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
79969564|NCT01282619|Drug|huperzine A|Tablet, 200µg twice a day, 24 weeks
79640368|NCT04298983|Radiation|Radiation Therapy|RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
79640369|NCT04290403|Device|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
79640370|NCT04290403|Device|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
79640371|NCT04285463|Diagnostic Test|Transbronchial Lung Cryobiopsy (TBLC)|TBLC is a relatively new endoscopic technique used to obtain lung parenchyma specimens. It is a minimally invasive technique performed with a flexible or rigid bronchoscope under deep sedation or general anesthesia. Flexible cryoprobes of either 1.9 or 2.4 mm in diameter are introduced into a bronchoscope and a compressed gas, most commonly carbon dioxide or nitrous oxide, is released at high flow at the tip of the probe. As the tissue rapidly freezes, it adheres to the probe and is avulsed and extracted with a quick pullback movement followed by immediate extraction of samples.
79640372|NCT04255043|Device|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
79640373|NCT04255043|Device|Angiography guidance|DCB (Sequent® Please) treatment
79640374|NCT04254419|Biological|NK cells|"Natural killer cells will be taken from the patients peripheral blood cell collection. The administration of the cells will be done via an Ommaya intra-cavitary/intra-tumoral device.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya in approximately 2 milliliters over approximately 2 minutes; followed by 1 milliliter preservative-free normal saline flush over approximately 1 minute."
79805460|NCT00694538|Device|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
79805461|NCT00809835|Drug|Galantamine|Daily 8 mg galantamine capsule
79969565|NCT01282619|Drug|Placebo|placebo orally twice a day
79640375|NCT04241809|Diagnostic Test|Bioaerosol Sampling|Cyclone collection of exhaled bioaerosol
79969566|NCT01282697|Drug|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
79969567|NCT03283098|Drug|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
79969568|NCT03283098|Drug|Placebo|Placebo supplied to match active intervention.
79969569|NCT03655951|Behavioral|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
79969570|NCT03655951|Behavioral|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
79969571|NCT01169597|Drug|prednisone|prednisone 12.5 mg daily po
79640376|NCT04241120|Behavioral|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
79805462|NCT00809835|Behavioral|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
79640377|NCT04241120|Behavioral|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
79640378|NCT04240574|Device|Debritom|hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
79640379|NCT04238689|Biological|TB31F|Monoclonal antibody
79640380|NCT04236609|Device|Abluminus DES+ Sirolimus Eluting Stent System (SES)|The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
79640381|NCT04236609|Device|XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
79311950|NCT05500521|Diagnostic Test|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
79640382|NCT04235504|Other|MDI|Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
79640383|NCT04235504|Device|AHCL|"Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment."
79640384|NCT04232774|Device|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
79640385|NCT04232657|Drug|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
79640386|NCT04232657|Drug|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
79805463|NCT00694616|Device|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
79805464|NCT00694616|Device|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
79805465|NCT01014559|Drug|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
79805466|NCT01014559|Drug|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
79311951|NCT05500287|Other|Virtual Care|Children in the virtual care group had distance asthma education, case management and virtual care
79640387|NCT04232657|Drug|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
79640388|NCT04232566|Procedure|Bariatric surgery|Evaluate liver fibrosis by elastography before gastric bypass surgery.
79640389|NCT04216277|Diagnostic Test|Procalcitonin|"In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml"
79640390|NCT04199780|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
79640391|NCT04199780|Behavioral|Cognitive-Behavioral (CB) intervention|CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
79805467|NCT04027023|Drug|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
79969572|NCT02527798|Drug|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
79311952|NCT03972111|Drug|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
79640392|NCT04195737|Procedure|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
79311953|NCT02699099|Dietary Supplement|Vitamin A|Oral administration of Vitamin A (1 dose)
79640393|NCT04195737|Procedure|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
79311954|NCT02699099|Biological|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
79311955|NCT02699099|Biological|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
79311956|NCT02699099|Biological|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
79311957|NCT04284189|Other|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
79311958|NCT03928587|Dietary Supplement|2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.|One lozenge once daily for 12 months
79311959|NCT03928587|Dietary Supplement|Placebo|Placebo once daily for 12 months
79311960|NCT02399969|Other|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
79640394|NCT04173585|Drug|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
79640395|NCT04173585|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
79311961|NCT05500131|Behavioral|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
79311962|NCT02399891|Other|Quality Assurance Implementation|
79311963|NCT02399891|Other|Standard of Care|
79640396|NCT04172987|Drug|Tirzepatide|Administered SC
79640397|NCT04172987|Drug|EE/NGM|Combination oral contraceptive administered orally
79640398|NCT04138381|Drug|Selinexor|oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)
79640399|NCT04138381|Drug|Imatinib|imatinib 400 mg, once daily (Cohort A)
79640400|NCT04049331|Drug|Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]|first two doses four weeks apart; following three more doses every ten weeks.
79640401|NCT04049331|Other|placebo|first two doses four weeks apart; following three more doses every ten weeks.
79655671|NCT04555408|Device|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
79805468|NCT00853242|Drug|Placebo|
79969573|NCT02527798|Drug|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
79311964|NCT02417597|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
79311965|NCT05497479|Drug|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
79311966|NCT05497479|Drug|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
79311967|NCT05497479|Drug|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
79311968|NCT05497479|Drug|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
79311969|NCT03177785|Behavioral|EverydayMatters|
79311970|NCT02400047|Drug|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
79805469|NCT00853242|Drug|Genz-644470|
79805470|NCT00853242|Drug|Sevelamer carbonate|
79805471|NCT04143230|Other|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
79969574|NCT02527798|Drug|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
79805472|NCT00912470|Procedure|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
79311971|NCT02400047|Drug|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
79311972|NCT02400047|Drug|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
79311973|NCT02698865|Device|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
79311974|NCT02698865|Device|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
79311975|NCT03842319|Other|Microbiota analysis|From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
79969575|NCT02527798|Other|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
79969576|NCT01282775|Behavioral|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
79311976|NCT03842319|Other|Immunological analysis|A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
79311977|NCT03842319|Other|Proteome analysis|A study of host and microbiota proteome will be carried out from samples using mass spectrometry
79311978|NCT03842319|Other|Metabolome analysis|A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
79311979|NCT03842319|Other|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies
79311980|NCT03842319|Other|Diet evaluation|Biochemical analysis and questionaries for diet adherence and exercise registration
79311981|NCT03842319|Other|MedDiet|The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (>40 g/d) for cooking and dressing dishes; b) consumption of >2 daily servings of vegetables; c) >2-3 daily serving of fresh fruits; d) >3 weekly servings of legumes; e) >3 weekly servings of fish or seafood; f) >1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
79311982|NCT02698787|Device|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
79311983|NCT02698787|Device|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
79311984|NCT03755349|Device|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
79475475|NCT02700425|Device|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
79475476|NCT02701049|Other|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
79475477|NCT05648994|Biological|TCR-T cells|patients will be administration of TCR-T cells
79805473|NCT04701801|Diagnostic Test|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
79969577|NCT01282775|Behavioral|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
79969578|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
79969579|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
79969580|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
79969581|NCT03382444|Procedure|Cognitive Assessment|Each patient with have a 2 hour cognitive assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therapy
79969582|NCT03382444|Diagnostic Test|Depression and Quality of Life Assessment|Each patient with have a 2 hour depression and QOL assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therpay
79969583|NCT05331911|Drug|Propofol|total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
79969584|NCT05331911|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
79311985|NCT03755349|Other|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
79311986|NCT02417051|Behavioral|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
79311987|NCT05499897|Procedure|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
79640402|NCT04033055|Procedure|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
79311988|NCT05499897|Procedure|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
79969585|NCT03188991|Drug|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
79969586|NCT03857542|Drug|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
79969587|NCT03857542|Other|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
79311989|NCT02417675|Other|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
79311990|NCT02417675|Other|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
79311991|NCT02417675|Other|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
79311992|NCT02417207|Drug|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
79475478|NCT05648994|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regime
79475479|NCT05648994|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regime
79475480|NCT05648994|Drug|Albumin-bound paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regime
79475481|NCT05648994|Drug|IL-2|Following cell infusion, the patient will be administration high-dose IL-2.
79475482|NCT04869384|Other|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
79969588|NCT01172717|Drug|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
79475483|NCT04869384|Other|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
79475484|NCT04869306|Device|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
79640403|NCT04033055|Procedure|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
79969589|NCT01172795|Behavioral|Relaxation session|30 minutes relaxation session (audiotape)
79969590|NCT01172795|Behavioral|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
79969591|NCT03382366|Diagnostic Test|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
79969592|NCT03209973|Drug|Tislelizumab|Administered as specified in the treatment arm
79969593|NCT03751631|Drug|Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)|Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
79311993|NCT02417207|Drug|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
79311994|NCT02399501|Procedure|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
79311995|NCT02399501|Device|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
79805474|NCT00689312|Drug|Enfalyte|Each patient will receive one 250 ml dose.
79805475|NCT00689312|Drug|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
79311996|NCT02399501|Device|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
79805476|NCT00689312|Drug|Pedialyte|Each patient will receive one 250 ml dose.
79311997|NCT02399501|Device|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
79311998|NCT02698475|Drug|Ustekinumab 0.75 mg/kg|Participants weighing less than (<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
79311999|NCT02698475|Drug|Ustekinumab 45 mg|Participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
79312000|NCT02698475|Drug|Ustekinumab 90 mg|Participants weighing >100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
79312001|NCT02399657|Drug|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
79312002|NCT03177707|Other|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
79805477|NCT04117386|Diagnostic Test|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
79805478|NCT04117386|Diagnostic Test|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
79805479|NCT02609061|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
79805480|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
79805481|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
79805482|NCT04136678|Other|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
79805483|NCT02608983|Dietary Supplement|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
79312003|NCT02399579|Other|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
79312004|NCT03177629|Drug|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
79312005|NCT02559687|Biological|pembrolizumab|IV Q3W
79640404|NCT04015596|Drug|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
79640405|NCT04015596|Other|Placebo|Participants take placebo pills twice daily, for 8 weeks.
79805484|NCT02608983|Dietary Supplement|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
79805485|NCT02608983|Dietary Supplement|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
79805486|NCT00848250|Drug|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
79805487|NCT00848250|Other|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
79805488|NCT00912626|Behavioral|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
79805489|NCT04116294|Other|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
79969594|NCT03751631|Drug|Tropicamide 1% ophthalmic solution (TR)|Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
79640406|NCT03985722|Drug|Olaratumab and Trabectedin|"Dose escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. * Dose starting level is 0.~LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1.~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1.~LEVEL 3**: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~**In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles."
79805490|NCT00694694|Drug|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
79805491|NCT00694694|Drug|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
79969595|NCT03751631|Drug|Phenylephrine 2.5% ophthalmic solution (PE)|Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
79969596|NCT03736525|Behavioral|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
79312006|NCT04279119|Drug|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
79312007|NCT02399735|Biological|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
79312008|NCT02399735|Biological|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
79312009|NCT02399735|Biological|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
79312010|NCT03177317|Drug|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
79312011|NCT03177239|Drug|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
79312012|NCT03177239|Drug|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
79312013|NCT02399267|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
79312014|NCT02399267|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
79640407|NCT03966105|Diagnostic Test|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
79640408|NCT03939416|Other|Experimental|"STANDART~Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~Sophrology: mental control of insomnia and painful perception~Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~Rhythmic transversal muscle mobilization in posterior chain musculature.~General vertebral decompression from the sacrum and pelvis~Metameric subcutaneous mobilization~Rhythmic vertebral mobilization from the spinous processes."
79640409|NCT03939416|Other|Control|"STANDART~Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~Sophrology: mental control of insomnia and painful perception~Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
79640410|NCT03929523|Device|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
79640411|NCT03929523|Device|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
79640412|NCT03890432|Device|GLUCOSAFE 2|Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
79640413|NCT03890432|Device|Local protocol control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
79640414|NCT03890432|Device|Historical control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
79969597|NCT03736525|Behavioral|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
79969598|NCT01172951|Other|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
79312015|NCT02399267|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =< 8 cm H2O with PEEP =< 5 cm H2O.
79312016|NCT02399267|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
79312017|NCT04480775|Drug|Triamcinolone|transversus abdominis plane block with bupivacain and triamicinolone
79312018|NCT04480775|Drug|Methylprednisolone|transversus abdominis plane block with bupivacaine and methylprednisolone
79312019|NCT04480775|Drug|bupivacaine|transversus abdominis plane block with bupivacaine alone
79312020|NCT02399033|Drug|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
79312021|NCT02416817|Other|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
79312022|NCT02416817|Other|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
79312023|NCT02399189|Drug|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
79475485|NCT04869306|Device|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
79640415|NCT03885908|Other|in-person geriatric co-management|"The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
79640416|NCT03885908|Other|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
79312024|NCT03106493|Other|None (observational)|None (observational)
79312025|NCT03177161|Other|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
79475486|NCT02702921|Device|Surgeon's 'standard of care' stapler|
79475487|NCT02702921|Device|Ethicon Powered Vascular Stapler|
79475488|NCT05648760|Behavioral|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
79640417|NCT03840746|Other|Tomato, onion and lovage soup (TOL)|Soup
79640418|NCT03840746|Other|TOL soup with inulin|Soup
79640419|NCT03762096|Dietary Supplement|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
79640420|NCT03762096|Dietary Supplement|Placebo|Placebo
79640421|NCT03758638|Behavioral|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an ~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
79312026|NCT03176849|Dietary Supplement|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
79640422|NCT03758638|Behavioral|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
79312027|NCT03176849|Dietary Supplement|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
79640423|NCT03705832|Drug|Ginger Extract|2gm Capsule of Ginger extract
79805492|NCT00700362|Procedure|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
79969599|NCT01172951|Other|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
79969600|NCT03688711|Drug|Dasiglucagon|Glucagon analogue
79312028|NCT03106571|Drug|Pomaglumetad methionil|Tablets twice daily
79805493|NCT00700362|Procedure|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
79969601|NCT03688711|Drug|Placebo|Placebo for dasiglucagon
79969602|NCT03866681|Drug|sirolimus|The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
79312029|NCT03106571|Drug|Placebo|1-4 tablets twice daily
79805494|NCT00682682|Other|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
79805495|NCT00682682|Other|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
79312030|NCT03106571|Drug|Methamphetamine|intravenous methamphetamine
79312031|NCT02398955|Device|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
79312032|NCT03177083|Drug|peginterferon beta-1a|SC every 2 weeks
79640424|NCT03705832|Drug|Placebo|Matching Placebo
79640425|NCT03613987|Device|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
79640426|NCT03602677|Device|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
79640427|NCT03579901|Device|Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants|Breast augmentation
79969603|NCT03188055|Other|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
79312033|NCT03177083|Drug|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
79312034|NCT03177083|Drug|interferon beta-1b|Per SMPC
79312035|NCT02398721|Other|Fine Needle Aspiration Cytology|
79312036|NCT02398643|Other|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
79312037|NCT02398643|Other|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
79312038|NCT02398799|Behavioral|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
79312039|NCT03629925|Drug|Sintilimab|200mg, Q3W, day1, I.V.; consecutive cycles
79312040|NCT03629925|Drug|Gemcitabine|1000mg/m^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
79312041|NCT03629925|Drug|Cisplatin|75 mg/m^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
79312042|NCT03629925|Drug|Placebo|NA, Q3W, day1, I.V.; consecutive cycles
79312043|NCT03629925|Drug|Carboplatin|AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
79475489|NCT05648682|Other|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
79475490|NCT05648682|Other|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
79475491|NCT05648682|Other|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
79475492|NCT05648682|Other|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
79475493|NCT02702999|Device|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
79475494|NCT02702999|Device|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
79475495|NCT02268864|Drug|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
79475496|NCT02268864|Drug|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
79475497|NCT02268786|Other|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
79475498|NCT02703779|Drug|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
79475499|NCT02703779|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
79655672|NCT04555408|Device|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
79475500|NCT02703779|Drug|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
79655673|NCT04555408|Device|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
79655674|NCT04553458|Device|Radiofrequency ablation|Radiofrequency ablation of the tumour
79655675|NCT04553458|Drug|Trance-arterial chemoembolization|Trance-arterial chemotherapy
79655676|NCT04553458|Procedure|Liver resection|non-anatomical or anatomical liver resection
79312044|NCT04295811|Device|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
79312045|NCT04295811|Diagnostic Test|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
79312046|NCT04294719|Other|Cognitive Adaptation Training (CAT)|Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
79312047|NCT02703311|Device|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
79312048|NCT02416895|Other|In vivo immunity model|A measure of in vivo immune function.
79312049|NCT04280133|Behavioral|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
79312050|NCT02398565|Other|No intervention|
79640428|NCT03509571|Other|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
79640429|NCT03509571|Other|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
79312051|NCT05499819|Other|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
79312052|NCT05499819|Other|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
79312053|NCT05499819|Other|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
79312054|NCT02398877|Other|stress|
79312055|NCT03595995|Biological|UB-621|Monoclonal antibody by SC injection
79312056|NCT03595995|Other|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
79312057|NCT02398487|Device|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
79312058|NCT02398487|Device|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
79312059|NCT02396927|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
79312060|NCT02396927|Device|2D HD laparoscopy|Placebo
79312061|NCT05497245|Other|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
79312062|NCT04480619|Diagnostic Test|Ga-68-PEG-Αvβ3-IAC PET/CT|PET Diagnostic Agent
79640430|NCT03493516|Diagnostic Test|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer [18F]-LMI1195
79805496|NCT04136600|Drug|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
79640431|NCT03460379|Drug|Escitalopram|Patients are tested for their normal prescription escitalopram medication
79640432|NCT03460366|Drug|Enalapril|Patients are tested for their normal prescription enalapril medication
79805497|NCT04136600|Drug|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
79805498|NCT00809757|Drug|Levalbuterol|90 ug Levalbuterol (2 actuations)
79805499|NCT00809757|Drug|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
79805500|NCT00809757|Drug|Placebo|Placebo (2 actuations)
79969604|NCT03866915|Diagnostic Test|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
79312063|NCT03371745|Procedure|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
79312064|NCT03371745|Procedure|Cryopreservation|Rapid freezing using vitrification
79312065|NCT03371745|Procedure|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
79312066|NCT02398253|Behavioral|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
79312067|NCT02398253|Behavioral|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
79640433|NCT03460353|Drug|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
79312068|NCT05497167|Other|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
79312069|NCT02398097|Biological|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
79475501|NCT04738955|Drug|Micafungin Sodium|micafungin sodium ≥ 100, <200mg/time, once a day, intravenous drip. Low dose group
79969605|NCT03866915|Diagnostic Test|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
79312070|NCT02398097|Biological|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
79312071|NCT02398097|Biological|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
79312072|NCT03348345|Behavioral|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
79312073|NCT02396615|Dietary Supplement|SATIN pineapple|Active juice with added fibre and ginseng
79640434|NCT03460327|Drug|Candesartan|Patients are tested for their normal prescription candesartan medication
79312074|NCT02396615|Dietary Supplement|SATIN pineapple control|Control products without active ingredients
79312075|NCT03250299|Drug|Microtubule-Targeted Agent BAL101553|Given PO
79312076|NCT03250299|Radiation|Radiation Therapy|Undergo radiation therapy
79312077|NCT03250299|Other|Laboratory Biomarker Analysis|Correlative studies
79312078|NCT03250299|Other|Pharmacological Study|Correlative studies
79312079|NCT02697617|Drug|Pioglitazone|Pioglitazone
79312080|NCT02697617|Drug|Placebo|Placebo
79312081|NCT05499429|Device|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
79312082|NCT02398331|Other|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~Educational footage~Clinical neurological examination with educational aim~Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
79312083|NCT02396771|Procedure|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
79312084|NCT02396771|Procedure|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
79312085|NCT02396693|Device|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) < 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) < 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
79475502|NCT02268396|Drug|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
79475503|NCT04859400|Dietary Supplement|Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)|The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.
79640435|NCT03460314|Drug|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
79640436|NCT03460210|Drug|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
79640437|NCT03449472|Drug|Quetiapine|Patients are tested for their normal prescription quetiapine medication
79640438|NCT03447743|Drug|XR-NTX community location|XR-NTX will be administered at the local health care clinic
79640439|NCT03440879|Drug|Zoladex|Patients currently treated with Zoladex
79640440|NCT03433755|Drug|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
79640441|NCT03433755|Drug|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
79312086|NCT02396693|Device|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
79312087|NCT02396693|Device|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
79312088|NCT05496699|Behavioral|Mckenzie Exercises|"Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~Cervical Rotation Exercise in Sitting Position~Cervical Retraction Exercise in Supine Position~Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~Cervical Lateral Flexion Exercise~Cervical Flexion Exercise in Sitting Position"
79640442|NCT03430674|Behavioral|Exercise|Exercise, questionnaires and blood draws.
79312089|NCT05496699|Behavioral|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
79312090|NCT02396225|Drug|Voriconazole|
79312091|NCT02398175|Other|reanimation/intubation|
79312092|NCT02396303|Drug|Carbetocin|
79475504|NCT04859400|Behavioral|Standardized nutritional program|During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.
79640443|NCT03406507|Biological|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
79640444|NCT03283150|Drug|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
79640445|NCT03283150|Drug|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
79312093|NCT05496621|Other|Questionnaire|1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
79640446|NCT03283150|Drug|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
79640447|NCT03249792|Drug|MK-2118 (IT)|IT injection
79475505|NCT04859400|Behavioral|Standardized exercise program|In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
79475506|NCT05648526|Drug|ACTH4-10Pro8-Gly9-Pro10|ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
79640448|NCT03249792|Drug|MK-2118 (SC)|SC injection
79640449|NCT03249792|Biological|Pembrolizumab|IV infusion
79312094|NCT05564247|Behavioral|Wheelchair Skills Training Program (WSTP)|Participants will complete customized MWC skills training based on the evidence-based wheelchair skills program. Lessons plans will be created by the clinicians, children and parents participants based on goals, age, skills and interests, and used to customize the training.
79312095|NCT02698241|Device|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
79475507|NCT05648526|Drug|Ketamine|negative-positive control (ketamine 40 mg/kg BW subcutaneously)
79475508|NCT02268084|Device|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
79640450|NCT03218917|Drug|Brensocatib 10 mg|Administered once per day for 24 weeks
79805501|NCT00594464|Drug|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
79805502|NCT00694772|Procedure|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
79805503|NCT00694772|Procedure|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
79312096|NCT01292421|Biological|hepatitis B antigen peptide|Given PO
79312097|NCT01292421|Other|placebo|Given orally (PO)
79312098|NCT01292421|Other|immunoenzyme technique|Correlative studies
79475509|NCT02268084|Device|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
79475510|NCT05320601|Device|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
79475511|NCT05320601|Procedure|Dry needling|Dry needling at trigger point of upper trapezius muscle
79475512|NCT04420338|Biological|Blood sample|rapid serological tests carried out
79475513|NCT04420338|Biological|Serum tube collection|SARS-COV2 seroconversion assay
79640451|NCT03218917|Drug|Brensocatib 25 mg|Administered once per day for 24 weeks
79640452|NCT03218917|Drug|Placebo|Administered once per day for 24 weeks
79312099|NCT02396069|Drug|JPI-289|PARP-1 inhibitor
79312100|NCT02396069|Drug|Placebo|Placebo
79312101|NCT04440215|Other|Telerehabilitation and team meetings and team care plans|A mix of home or rehabilitation center visits and telerehabilitation will be planned by the rehabilitation team for a maximum of 16 weeks. Moreover, for each participant enrolled, a multidisciplinary meeting will be organised. The patient/family will participate in the meeting and the decision making process using the telerehabilitation platform. The team will generate an interprofessional individualized treatment plan, aiming for an interprofessional shared decision making process.
79312102|NCT04440215|Other|Usual care|Rehabilitation teams will be instructed to provide care as they have been doing previously. Currently, this translates into no telerehabilitation, and interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals.
79640453|NCT03207841|Other|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake.
79640454|NCT03204240|Other|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
79312103|NCT03168503|Dietary Supplement|LGG+Promitor™|synbiotic
79312104|NCT03168503|Dietary Supplement|Promitor™|Soluble Corn Fiber
79312105|NCT03168503|Dietary Supplement|LGG-PB12+Promitor™|synbiotic
79312106|NCT03168503|Dietary Supplement|Maltodextrin|Control
79312107|NCT02397941|Other|Ultrasound|ultrasound measures
79312108|NCT02397863|Drug|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
79312109|NCT05496387|Other|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
79312110|NCT02395757|Device|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
79312111|NCT02398019|Device|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
79312112|NCT01097733|Other|Randomization of Pre-knowledge of CT coronary venography|
79475514|NCT04015817|Other|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
79312113|NCT03168269|Diagnostic Test|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
79312114|NCT04480229|Behavioral|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
79312115|NCT03168035|Drug|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
79475515|NCT05558748|Procedure|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
79640455|NCT03177681|Other|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
79312116|NCT02397395|Drug|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
79475516|NCT05558748|Procedure|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
79805504|NCT00682760|Drug|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
79312117|NCT02397395|Drug|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
79312118|NCT02397551|Procedure|IVF/ICSI|
79312119|NCT02397551|Drug|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
79312120|NCT02395913|Drug|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
79312121|NCT02395913|Drug|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
79312122|NCT02395913|Drug|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
79312123|NCT02395913|Drug|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
79312124|NCT02395679|Biological|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
79312125|NCT03168191|Drug|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
79475517|NCT05557968|Other|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
79312126|NCT03168191|Other|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
79312127|NCT03168191|Other|Menthol Flavor|Menthol flavored e-cigarette for lab session
79475518|NCT05557968|Other|Action Observation Therapy (AO)|"The video consists of :~Ascending and descending the step box.~Ascending and descending the stairs in the treatment room.~Holding the handrails to climb and descend the stairs inside and outside the building.~Climbing and descending the stairs inside and outside the building without holding the handle.~Climbing and descending the sidewalk block"
79475519|NCT02705807|Drug|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen [pH] 10.2 - 10.8 diluent) for Injection.
79475520|NCT02705807|Drug|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
79475521|NCT05648370|Genetic|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
79475522|NCT02706041|Procedure|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
79475523|NCT02706041|Procedure|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
79475524|NCT01643772|Drug|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
79475525|NCT02707523|Drug|Azithromycin 10 mg|
79475526|NCT02707523|Drug|Azithromycin 20mg|
79475527|NCT02707523|Drug|Placebo|
79475528|NCT05299853|Other|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
79475529|NCT05299853|Other|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
79640456|NCT03177681|Other|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
79640457|NCT03177681|Behavioral|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
79312128|NCT04440293|Other|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
79312129|NCT04440293|Other|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
79312130|NCT02395445|Device|orotracheal intubation|
79312131|NCT02397317|Radiation|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
79312132|NCT02395523|Radiation|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
79312133|NCT05564013|Device|Virtual reality|Up to 25 minutes of virtual reality exposure in supine position
79312134|NCT05563935|Device|Repetitive transcranial magnetic stimulation|The OCD group will receive rTMS treatment for 6 weeks. There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total. Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil. Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
79640458|NCT03177681|Device|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
79640459|NCT03177681|Other|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
79312135|NCT05496153|Behavioral|Adaptive posture-balance cardiac rehabilitation exercise|The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
79640460|NCT03132675|Biological|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks
79312136|NCT05499351|Biological|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
79475530|NCT04738721|Behavioral|Evaluation|"Within the scope of the course, the demographic information of the students (such as height, weight, body mass index) is recorded and the physical activity status is recorded with International Physical Activity Questionnaire Short Form (UFAA). Cardiovascular endurance with 6-Minute Walking Test, flexibility and circumference of waist, hip and neck with the Sit and Lie Test and body composition and Body Fat Ratio will be evaluated. After a full year of quarantine, the same students who were previously evaluated and accepted to participate in the current study will be evaluated with online remote video viewing methods (Teams, Zoom, etc.) and, with the same tests and measurements under supervision by the researchers."
79640461|NCT03132675|Biological|Pembrolizumab|Intravenous 3 weekly treatments
79640462|NCT03132675|Device|ImmunoPulse|Device that electroporates the tavokinogene telseplasmid
79640463|NCT03122925|Device|MR|MR
79475531|NCT02712047|Drug|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
79475532|NCT02712047|Drug|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
79475533|NCT02712047|Drug|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
79475534|NCT02712359|Other|Blood sample collection|A blood sample (~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
79640464|NCT03110744|Drug|Palbociclib|application on 21 consecutive days of a 28 days cycle
79640465|NCT03056040|Biological|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
79640466|NCT03056040|Biological|Eculizumab|All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
79640467|NCT03021499|Drug|Voclosporin|calcineurin inhibitor
79640468|NCT03021499|Drug|Placebo Oral Capsule|matching placebo capsule
79640469|NCT02973828|Procedure|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
79640470|NCT02924038|Biological|IMA950|IMA950 vaccine
79640471|NCT02924038|Biological|poly-ICLC|poly-ICLC vaccine
79640472|NCT02924038|Biological|Varlilumab|Intravenous solution
79640473|NCT02913222|Other|Rehabilitation|Comparison of two rehabilitation approaches
79640474|NCT02798458|Device|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
79640475|NCT02798458|Procedure|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
79640476|NCT02726581|Biological|Nivolumab|Specified dose on specified days, IV (intravenous)
79640477|NCT02726581|Biological|Elotuzumab|Specified dose on specified days, IV
79640478|NCT02726581|Drug|Pomalidomide|Specified dose on specified days, PO (by mouth)
79640479|NCT02726581|Drug|Dexamethasone|Specified dose on specified days, PO
79640480|NCT02700048|Drug|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
79640481|NCT02700048|Drug|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
79640482|NCT02683447|Other|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
79640483|NCT02678429|Device|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
79640484|NCT02638766|Drug|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
79312137|NCT05499351|Biological|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
79312138|NCT05499351|Biological|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
79312139|NCT05499351|Biological|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
79312140|NCT05495919|Other|Control|No intervention was perfomed to reduce anxiety in control group
79312141|NCT05495919|Other|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
79312142|NCT05495919|Other|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
79312143|NCT04280055|Drug|Psilocybin|0.14 mg/kg p.o. in three sessions spaced by one week
79312144|NCT05495607|Device|CARPEDIEN|Continuous renal replacement therapy
79312145|NCT04424823|Procedure|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
79312146|NCT04265781|Drug|BAY1817080|Three different doses over the course of study
79312147|NCT04265781|Drug|Matching Placebo|Matching Placebo to BAY1817080
79312148|NCT05495529|Procedure|Thermal Ablation|Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
79312149|NCT05499117|Device|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
79312150|NCT05499117|Device|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
79312151|NCT05563311|Other|Exercise on High-intensity interval training|3 times a week, for 8 weeks
79475535|NCT00368693|Device|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
79475536|NCT02716727|Device|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
79475537|NCT02716727|Device|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
79312152|NCT05499039|Device|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
79475538|NCT02717273|Drug|standard|peri-operative antibiotic regimen only
79640485|NCT02599116|Other|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
79475539|NCT02717273|Drug|extended|extended three-day course of antibiotics
79475540|NCT02717273|Other|liver transplant|orthotopic liver transplantation
79475541|NCT00369239|Drug|risperidone long acting injectable|
79475542|NCT05215925|Drug|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
79475543|NCT05215925|Drug|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
79475544|NCT05215925|Drug|HLX07|HLX07 1500mg q3w
79475545|NCT03815357|Other|Referral to Immunology|Screening for primary immunodeficiency including splenic dysfunction
79475546|NCT02719535|Other|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
79640486|NCT02599116|Other|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
79640487|NCT02535832|Drug|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
79969606|NCT04035577|Behavioral|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
79969607|NCT02416492|Biological|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
79475547|NCT05159687|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
79640488|NCT02535832|Drug|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
79640489|NCT02428712|Drug|FORE8394|
79640490|NCT02425904|Drug|Clofarabine|second-generation purine nucleoside analog
79640491|NCT02406209|Drug|NS2|NS2 ophthalmic drops (0.5%)
79640492|NCT02406209|Drug|Prednisolone acetate ophthalmic suspension (1%)|
79640493|NCT02313428|Device|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
79640494|NCT02295722|Drug|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
79640495|NCT02295722|Drug|Melphalan|200 mg/m2
79640496|NCT02295722|Other|ASCT|Day 0 - Stem cell infusion
79640497|NCT02282059|Drug|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
79640498|NCT02066285|Drug|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79969608|NCT02416492|Procedure|Sham Control|Sham Surgery
79969609|NCT01284569|Biological|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
79475548|NCT05159687|Drug|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
79969610|NCT01284569|Biological|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
79969611|NCT01172015|Other|blood samples|
79969612|NCT03736369|Drug|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
79475549|NCT02720627|Drug|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
79640499|NCT01964989|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
79640500|NCT01964989|Biological|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
79640501|NCT01934309|Behavioral|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
79475550|NCT02721017|Device|Cryoanalgesia|
79475551|NCT02721017|Drug|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
79475552|NCT02721641|Drug|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
79475553|NCT02722577|Procedure|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
79475554|NCT02724449|Device|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
79475555|NCT03754127|Device|tDCS|Transcranial direct current stimulation
79640502|NCT01575860|Drug|Lenalidomide|Lenalidomide, 10mg, oral tablets, daily
79640503|NCT01558804|Other|Identifying group A strep carriers|At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
79640504|NCT01416831|Other|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
79969613|NCT03736369|Drug|DWP14012 40mg placebo|DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
79969614|NCT03736369|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
79969615|NCT03736369|Drug|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
79969616|NCT03867695|Drug|Ropivacaine|At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
79640505|NCT01416831|Drug|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
79640506|NCT00635700|Drug|ziprasidone|20-160 mg/d
79640507|NCT00635700|Drug|placebo|placebo
79312153|NCT05499039|Device|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
79312154|NCT05495295|Drug|PhOx430|"Dose Escalation Phase: A standard 3 + 3 design will be followed for the escalation phase. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval."
79312155|NCT05495217|Device|Conventional Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.
79312156|NCT05495217|Device|Gasless Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
79312157|NCT05495139|Device|Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
79312158|NCT05498805|Radiation|Radiation|According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
79312159|NCT05562921|Behavioral|Controls-ususal care|Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases
79640508|NCT00634257|Behavioral|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
79805505|NCT00689468|Procedure|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
79805506|NCT00689468|Dietary Supplement|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
79805507|NCT00689468|Procedure|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
79805508|NCT00689468|Dietary Supplement|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
79969617|NCT03867695|Drug|sterile saline|Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
79969618|NCT02412046|Procedure|Muscle biopsy|
79969619|NCT03124654|Behavioral|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
79969620|NCT01172171|Drug|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
79969621|NCT01172171|Drug|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
79312160|NCT05562921|Behavioral|Cases-remote patient monitoring prescribed|Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
79312161|NCT05494827|Other|Regular consumption of natural mineral water Borjomi® with high bicarbonate content|"Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) <0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities."
79805509|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
79805510|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
79805511|NCT00809445|Behavioral|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
79969622|NCT03655717|Drug|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
79969623|NCT03655717|Drug|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
79312162|NCT05494827|Other|Regular consumption of processed drinking water Smart Spring®|Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
79312163|NCT05494827|Other|Regular consumption of still drinking water|Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
79969624|NCT03655717|Drug|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
79312164|NCT05562843|Biological|Autologous Cellular Therapy with PRP-PC|In this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using centrifugation, then returned to the patient same day via the peripheral circulation.
79312165|NCT05562765|Other|Survey|A descriptive characteristics form, the General Comfort Scale and Quality of Life Index Cardiac Version-IV was used to collect data.
79312166|NCT04424433|Drug|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
79312167|NCT05494515|Procedure|the early swallowing rehabilitation program|the early swallowing rehabilitation program based on the HRIM evaluation
79312168|NCT05494359|Diagnostic Test|The nitrogen isotope|The nitrogen isotope of various mass in oral gas were detected.
79312169|NCT05498337|Other|calcium hydroxide|Dental pulp medicament material
79312170|NCT05498337|Other|MTA|Dental pulp medicament material
79312171|NCT05498337|Device|Diode Laser|Device used in pulp therapy
79969625|NCT03655717|Drug|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
79969626|NCT03382288|Device|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
79312172|NCT01663233|Drug|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
79312173|NCT01663233|Drug|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
79312174|NCT01663233|Drug|Placebo|Matching placebo to LCZ696
79312175|NCT04064151|Behavioral|My Guide|12-week long health promotion Smartphone application
79312176|NCT04046055|Device|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
79312177|NCT04046055|Device|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
79805512|NCT00809445|Behavioral|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
79805513|NCT00809445|Behavioral|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
79969627|NCT03382210|Other|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
79312178|NCT04046055|Device|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
79475556|NCT03754127|Device|sham tDCS|Sham transcranial direct current stimulation
79312179|NCT05494281|Procedure|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
79312180|NCT05494281|Procedure|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
79312181|NCT05494203|Diagnostic Test|questionnaire survey|All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
79312182|NCT05486091|Behavioral|App-Enhanced Brief Cognitive-Behavioral Therapy|BCBT is a cognitive-behavioral intervention designed to target core skills deficits among suicidal individuals. App-enhanced BCBT incorporates the use of a SmartPhone app during the therapy sessions.
79475557|NCT03730883|Procedure|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
79475558|NCT03730883|Procedure|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
79475559|NCT03649061|Drug|Etanercept 50 MG/ML|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
79805514|NCT00682994|Behavioral|Interview|Interview lasting about 5-10 minutes.
79805515|NCT00682994|Behavioral|Questionnaire|Questionnaires taking 20-30 minutes to complete.
79805516|NCT00695006|Other|Sham Traction|Traction <5lbs
79805517|NCT00695006|Other|Traction|Standard supine intermittent traction
79805518|NCT05326269|Drug|Terbutaline|Subcutaneous injection
79312183|NCT05494047|Drug|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
79475560|NCT03649061|Drug|Leflunomide 10 milligram (MG)|Leflunomide 10mg PO daily added to the COBRA-Slim scheme
79475561|NCT02265744|Drug|BMS-931699|
79475562|NCT02265744|Drug|Placebo matching BMS-931699|
79475563|NCT03647891|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
79475564|NCT03624725|Procedure|modified BII+Braun|modified BII+Braun digestive tract reconstruction
79475565|NCT05109143|Drug|Indomethacin suppository|100mg Indomethacin Suppository administered at the time of Induction
79475566|NCT05109143|Other|Standard Medical Treatment|Standard Medical Treatment
79475567|NCT03614663|Drug|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
79475568|NCT03614663|Other|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
79475569|NCT05648136|Biological|blood sample|"Blood sampling by venipuncture will be performed :~for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~for patients and controls undergoing embryo transfer: on the day of embryo implantation"
79475570|NCT00085735|Drug|Cisplatin|Given IV
79475571|NCT00085735|Radiation|Craniospinal Irradiation|Undergo craniospinal Irradiation
79475572|NCT00085735|Drug|Cyclophosphamide|Given IV
79475573|NCT00085735|Radiation|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
79475574|NCT00085735|Other|Laboratory Biomarker Analysis|Correlative studies
79475575|NCT00085735|Drug|Lomustine|Given orally
79475576|NCT00085735|Other|Quality-of-Life Assessment|Ancillary studies
79475577|NCT00085735|Radiation|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
79475578|NCT00085735|Drug|Vincristine Sulfate|Given IV
79475579|NCT03578783|Drug|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
79640509|NCT00582075|Drug|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
79805519|NCT02624570|Drug|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
79805520|NCT04665453|Diagnostic Test|Electroencephalography|Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
79805521|NCT04665453|Diagnostic Test|Monitoring of vital functions|Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.
79640510|NCT00558961|Drug|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
79475580|NCT03578783|Drug|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
79640511|NCT00507923|Device|Actigraph|Wear actigraph
79640512|NCT00507923|Other|Best Practice|Receive usual care
79640513|NCT00507923|Other|Quality-of-Life Assessment|Ancillary studies
79640514|NCT00507923|Other|Questionnaire Administration|Ancillary studies
79640515|NCT00507923|Other|Sleep Diary|Complete sleep diary
79640516|NCT00507923|Other|Stretching|Participate in stretching sessions
79640517|NCT00507923|Procedure|Yoga|Participate in Tibetan yoga
79969628|NCT03124498|Biological|CIK Cell|Autologous cytokine-induced killer (CIK) cell
79969629|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
79640518|NCT00382070|Drug|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
79640519|NCT00382070|Other|Placebo|Placebo tablet taken orally once daily for 5 years
79640520|NCT00368524|Behavioral|contingency management and behavioral day treatment|
79640521|NCT00326456|Drug|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
79805522|NCT04665453|Drug|Melatonin 0,1mg/kg oral syrup|Melatonine in the form of syrup will be given orally to child.
79805523|NCT04665453|Drug|Dexmedetomidine 3 mcg/kg sublingually|Dexmedetomidine in the form of a solution will be given to child sublingually.
79805524|NCT04665453|Drug|Dexmedetomidine 3 mcg/kg intranasally|Dexmedetomidine in the form of nasal spray will be given to child intranasally.
79969630|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
79984444|NCT03200002|Drug|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count <1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count <1000/mm3.
79984445|NCT02447536|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
79984446|NCT02447536|Biological|BCG-Russia-I (Serum Institute of India)|See above
79475581|NCT04338737|Other|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
79475582|NCT05544786|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
79640522|NCT00326456|Drug|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
79640523|NCT00326456|Drug|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
79640524|NCT00244842|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
79640525|NCT00244842|Drug|Placebo|Placebo
79640526|NCT04688827|Other|Exercise therapy|15 weeks of resistance training (additional to endurance training)
79640527|NCT00149942|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
79640528|NCT04688437|Radiation|standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination|Routine examination
79640529|NCT02915887|Other|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
79640530|NCT02915926|Behavioral|occupational performance coaching|
79640531|NCT02915926|Behavioral|standard OT|
79640532|NCT03171259|Other|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
79640533|NCT03160378|Behavioral|Organizational skills training|10 sessions of parent and child training in a group format.
79805525|NCT00695084|Behavioral|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
79805526|NCT00695162|Other|quiet|no noise
79805527|NCT00695162|Other|non-speech noise|noise without speech
79805528|NCT00695162|Other|speech noise|noise with speech present
79805529|NCT00695240|Device|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
79984447|NCT03203980|Other|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
79984448|NCT02447380|Drug|AZD6094|AZD6094 600MG qd
79984449|NCT02447380|Drug|Docetaxel|Docetaxel 60 mg/m2
79984450|NCT02447224|Drug|1 gm IV ertapenem at enrollment|
79312184|NCT05493969|Drug|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
79475583|NCT05544786|Drug|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
79312185|NCT05491629|Other|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
79312186|NCT05491473|Device|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
79640534|NCT03160378|Other|Treatment as usual|Treatment as usual in the outpatient clinic
79640535|NCT03142984|Other|Cosmetic Products|"Phase 1:~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
79475584|NCT05544786|Drug|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
79640536|NCT00149981|Drug|everolimus (RAD)|Everolimus
79640537|NCT02915770|Procedure|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
79640538|NCT02915770|Procedure|hepatectomy|
79640539|NCT02915770|Device|T-tube|T-tube Drainage
79475585|NCT05544786|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
79475586|NCT05544786|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
79640540|NCT02915731|Dietary Supplement|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
79640541|NCT02915653|Other|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
79640542|NCT02915809|Biological|GC3110B vaccine|0.5mL, Intramuscular
79640543|NCT02915809|Biological|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
79640544|NCT02915497|Behavioral|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
79640545|NCT02915692|Device|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
79475587|NCT02726789|Drug|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
79475588|NCT02726789|Drug|pegylated interferon|immunotherapy
79475589|NCT02726789|Drug|entecavir|local generic entecavir
79640546|NCT02915692|Device|Comparator Silver Coated Catheter|Foley catheter coated with silver
79312187|NCT05493813|Behavioral|Cognitive function and delirium evaluation|Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
79312188|NCT05493813|Behavioral|Neurological functional assessment|National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
79312189|NCT05491395|Radiation|Hypofractionation|Hypofractionation scheme will comprise 40 Gy in 15 fractions
79312190|NCT05493579|Other|Implant supported overdenture|Implant supported overdenture compared to complete denture
79475590|NCT05544396|Other|probiotic|probiotic group give probiotics (2 packs per day) for 6 months.
79640547|NCT02915536|Other|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
79805530|NCT00689702|Drug|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
79984451|NCT02447224|Drug|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
79984452|NCT02447224|Procedure|Appendectomy|
79475591|NCT04420104|Procedure|erector spinae plane block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
79475592|NCT04420104|Drug|iv analgesia|iv contromal
79475593|NCT02731313|Biological|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
79475594|NCT02281591|Drug|BIA 2-093|Tablets containing 900 mg
79475595|NCT02281591|Drug|S-licarbazepine|capsules containing 225 mg
79475596|NCT02281591|Drug|R-licarbazepine|capsules containing 225 mg
79475597|NCT02987101|Procedure|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
79475598|NCT02987101|Other|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
79475599|NCT02987101|Drug|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
79655677|NCT04553458|Combination Product|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
79655678|NCT04553458|Drug|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
79655679|NCT04553458|Drug|Systemic chemotherapy|Systemic chemotherapy
79655680|NCT04553458|Drug|Sorafenib|Sorafenib
79655681|NCT04553458|Dietary Supplement|Viscum|Viscum for HCC
79655682|NCT04553458|Drug|Symptomatic treatment|Symptomatic treatment
79655683|NCT00236054|Drug|Gabitril|
79655684|NCT00268827|Drug|Kaletra soft-gel capsules switched to Kaletra tablets|
79312191|NCT05485545|Other|Electrophysiological exploration of the right ventricle|"CARTO electrophysiological mapping system~3D echocardiography~High Resolution MRI"
79312192|NCT05485389|Other|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
79312193|NCT05493345|Behavioral|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
79312194|NCT04277091|Other|High-intensity interval training|Arm-cranking exercise
79312195|NCT04277091|Other|Moderate-intensity continuos training|Arm-cranking exercise
79312196|NCT05493267|Drug|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
79312197|NCT05493267|Drug|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
79312198|NCT04239261|Dietary Supplement|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
79312199|NCT04239261|Dietary Supplement|Placebo|Hydrolyzed gelatin 10.0 g once daily
79312200|NCT05485311|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
79475600|NCT01880047|Drug|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (> 50,000 and increase by > 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
79984453|NCT03199690|Drug|Dolutegravir|Antiviral (integrase inhibitor)
79312201|NCT02556255|Device|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
79475601|NCT01880047|Drug|Placebo|
79475602|NCT01881373|Other|CHL program|Multiple component environmentally focused program designed with community engagement.
79475603|NCT01881373|Other|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
79475604|NCT02731469|Biological|BCD-131|
79312202|NCT05485233|Device|REDSCAR App|"Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge."
79312203|NCT05490849|Drug|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
79475605|NCT02731469|Biological|Mircera®|
79475606|NCT02731469|Biological|Aranesp®|
79475607|NCT03493217|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
79475608|NCT01882543|Drug|AQX-1125|Synthetic SHIP1 activator
79475609|NCT01882543|Drug|Placebo|Double blind placebo capsule
79475610|NCT01944319|Drug|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
79475611|NCT01944319|Drug|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
79655685|NCT00268827|Device|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
79805531|NCT00683150|Other|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
79805532|NCT00689780|Drug|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
79805533|NCT00689780|Drug|Midazolam|Oral solution given orally once daily on day -1 and day 14
79805534|NCT00689858|Drug|Cilostazol, Ginkgo biloba and placebo|dosing time
79805535|NCT00683228|Behavioral|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
79984454|NCT03199690|Drug|Rifampicin|Antibiotic
79984455|NCT03203902|Other|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
79984456|NCT03204058|Drug|Placebos|Oral prophylaxis followed by placement of placebo gel
79984457|NCT03204058|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
79984458|NCT03204058|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
79312204|NCT05492487|Drug|Mirena|Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.
79312205|NCT05492487|Drug|Megace|Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
79312206|NCT02556801|Biological|SUBLIVAC FIX Phleum Prat.|sublingual daily administration
79312207|NCT02556177|Procedure|MRI|MRI scanning
79640548|NCT02915380|Biological|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.~When available, the following hormones will be tested:~FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.~Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
79984459|NCT03199846|Other|Non-Interventional|Non-Interventional
79312208|NCT05492019|Drug|Doxycycline|Doxycycline 50 mg capsule twice daily for 8 weeks.
79312209|NCT05492019|Drug|Placebo|Oral placebo identical to Doxycycline
79312210|NCT05484843|Behavioral|telenursing training based on self-care theory|"A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~Identification of the study/control group (randomization)~Patients were informed and consents were obtained.~Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~All patients included in the sample group were pre-tested before discharge.~Training was offered for the study group patients in line with the guide prepared based on self-care theory.~Tele-nursing training was applied to the study group patients.~Control group patients were followed up~Post-tests were administered at the end of the 12-week period~The training of the control group patients was completed~Your data has been evaluated"
79312211|NCT05484843|Behavioral|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
79312212|NCT05491941|Other|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
79312213|NCT05491863|Other|conservative physiotherapy plan|Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
79312214|NCT05491863|Other|trunk stability exercise plan|"trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)"
79312215|NCT05491785|Drug|Cebranopadol 600 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets
79312216|NCT05491785|Drug|Cebranopadol 800 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet
79312217|NCT05491785|Drug|Cebranopadol 1000 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets
79312218|NCT05491785|Drug|Oxycodone 30 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets
79312219|NCT05491785|Drug|Oxycodone 60 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets
79312220|NCT05491785|Drug|Placebo|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
79640549|NCT02915380|Behavioral|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
79312221|NCT05490147|Procedure|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 10~12.
79312222|NCT05490147|Procedure|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 6~8.
79312223|NCT05484609|Other|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
79312224|NCT05484609|Other|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
79805536|NCT00695630|Drug|Flumazenil|2 mL, 0.2 mg SM
79312225|NCT04424589|Other|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
79312226|NCT04424589|Other|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
79312227|NCT05484531|Device|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
79984460|NCT03203824|Dietary Supplement|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
79312228|NCT05484453|Diagnostic Test|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
79312229|NCT05484375|Drug|Capecitabine plus toripalimab|Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
79312230|NCT05480007|Drug|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
79312231|NCT05480007|Drug|Sitagliptin|sitagliptin treatment (100mg per day)
79312232|NCT05480007|Drug|Metformin|metformin group who received metformin (500mg three times per day)
79984461|NCT03203824|Other|non dark chocolate|No dark chocolate will be given to this group during the procedures.
79312233|NCT05479929|Other|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
79312234|NCT05484063|Other|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
79312235|NCT05489601|Drug|Oxycodone|Oxycodone in 5mg increments up to a maximum of 10mg
79312236|NCT05489367|Biological|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
79805537|NCT00695630|Drug|Placebo|2 mL sterile saline SM
79984462|NCT03118414|Other|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
79805538|NCT01614899|Drug|SM-13496 40mg|once daily orally
79805539|NCT01614899|Drug|SM-13496 80mg|once daily orally
79805540|NCT01614899|Drug|Placebo|once daily orally
79805541|NCT00695708|Behavioral|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
79805542|NCT00695708|Behavioral|Cogpack|Computer-aided cognitive program for cognitive abilities
79805543|NCT00690014|Drug|probenecid|500 mg q 6 hrs
79805544|NCT00683306|Drug|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
79805545|NCT00690092|Biological|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
79805546|NCT01475123|Drug|Nicorandil|15mg per day
79805547|NCT04208399|Drug|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
79312237|NCT05483985|Device|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
79312238|NCT05483829|Behavioral|Adhera® Fatigue for Long COVID program|"Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information."
79312239|NCT04424121|Diagnostic Test|CCTA|Coronary Computed Tomography Angiography
79312240|NCT05479695|Device|Spinal Orthoses and Insoles|Evaluation of scoliosis treatment in people using spinal orthoses and insoles
79312241|NCT05479695|Device|Spinal Orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
79312242|NCT05479539|Behavioral|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
79312243|NCT05489289|Biological|AK104|Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
79312244|NCT05489289|Biological|placebo|Subjects will receive placebo until disease progression or for a maximum of 16 cycles
79312245|NCT05479227|Procedure|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
79312246|NCT05479071|Diagnostic Test|Blood test|Screening of antibodies against LDL
79312247|NCT02554929|Behavioral|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
79312248|NCT02554929|Behavioral|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
79312249|NCT05489055|Drug|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
79312250|NCT04423965|Drug|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day *2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
79312251|NCT04423965|Combination Product|Chemoradiotherapy|Capecitabine based chemoradiotherapy
79312252|NCT03766035|Device|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
79640550|NCT02915380|Behavioral|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
79640551|NCT02915146|Radiation|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
79312253|NCT03972501|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
79312254|NCT03972501|Drug|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
79312255|NCT05488899|Diagnostic Test|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
79312256|NCT05488899|Diagnostic Test|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
79312257|NCT05483439|Drug|cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
79312258|NCT05483439|Drug|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
79312259|NCT05483439|Drug|traditional herbal medicine|traditional herbal medicine
79312260|NCT03748095|Drug|pipéracilline/tazobactam|There is not intervention description
79312261|NCT04275375|Other|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
79312262|NCT04058691|Device|Surgical repair|Open surgery
79312263|NCT04058301|Other|Text message information|Geographically proximate resources delivered by text message
79312264|NCT05488821|Drug|QLH11906|QLH11906 only
79312265|NCT05488743|Behavioral|educational intervention|The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
79640552|NCT02915419|Biological|PRP|platelet rich plasma
79640553|NCT02915419|Biological|PRF|PLATELET RICH FIBRIN
79640554|NCT00163839|Behavioral|Dietary Therapy|
79640555|NCT02915107|Device|BioFreedom|PCI with BioFreedom
79640556|NCT02915107|Device|Orsiro|PCI with BioFreedom
79640557|NCT00405860|Drug|CellCept (mycophenolate mofetil)|
79640558|NCT02914990|Drug|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
79475612|NCT03424499|Procedure|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
79312266|NCT05478057|Device|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
79312267|NCT05488587|Diagnostic Test|magnesium and zinc levels|measuring magnesium and zinc levels
79312268|NCT05488353|Drug|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
79312269|NCT05488275|Procedure|Surgery|MPFL reconstruction
79312270|NCT04543305|Drug|PRT1419|PRT1419 will be administered orally
79312271|NCT05488197|Other|uterine artery doppler at 18-23 weeks of pregnancy|uterine artery doppler at 18-23 weeks of pregnancy
79969631|NCT03744169|Diagnostic Test|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
79805548|NCT02624258|Biological|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
79312276|NCT05483205|Drug|Normaderm Phytosolution Double-Correction Daily Care Moisturizer|Normaderm Phytosolution (NP) was to be applied for up to 90 days once or twice daily, according to the investigator's prescription.
79475613|NCT03424499|Procedure|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
79475614|NCT03424499|Diagnostic Test|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
79805549|NCT00912392|Drug|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
79312277|NCT05488041|Procedure|Performing anorectal manometry|"Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~Bionda M, Lenglinger J, … AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165."
79805550|NCT00912392|Drug|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
79312278|NCT05477745|Procedure|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
79312279|NCT05487963|Drug|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
79312280|NCT05487963|Other|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
79312281|NCT05487729|Other|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
79312282|NCT05477667|Diagnostic Test|real time pcr|Detection of expressin level of MiRNA-124 and let-7a using real time pcr
79475615|NCT02284165|Other|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
79475616|NCT00368303|Drug|Paroxetine CR|
79805551|NCT00683462|Drug|Placebo|
79475617|NCT00368303|Drug|Paroxetine IR|
79805552|NCT00683462|Drug|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
79805553|NCT00683462|Drug|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
79805554|NCT04135820|Drug|BPI-7711|BPI-7711 180 mg
79805555|NCT04135664|Procedure|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
79312283|NCT05487495|Biological|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
79312284|NCT05477433|Behavioral|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
79312285|NCT05477355|Behavioral|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
79312286|NCT05482659|Behavioral|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
79312287|NCT04274985|Other|Questionnaire application|Patients will complete the mentioned questionnaires.
79312288|NCT05477043|Diagnostic Test|Transabdominal ultrasound and cistoscopy|Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
79312289|NCT04274595|Drug|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
79312290|NCT04274127|Diagnostic Test|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
79475618|NCT00368381|Drug|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
79640559|NCT02915068|Behavioral|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
79805556|NCT04135664|Combination Product|chemoradiation|concurrent chemotherapy and radiotherapy
79805557|NCT04135664|Other|active surveillance|No further adjuvant therapy
79805558|NCT00690170|Drug|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
79805559|NCT00690170|Drug|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
79805560|NCT00690170|Drug|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
79805561|NCT00690170|Drug|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
79312291|NCT05486871|Procedure|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group [A] : 15 patients with T1 RCC (≤ 7 cm). Group [B] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
79475619|NCT02733653|Device|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
79475620|NCT02734355|Drug|Telmisartan 80 mg and amlodipine 5 mg|
79805562|NCT02623868|Drug|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
79805563|NCT02623868|Drug|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
79805564|NCT02623868|Drug|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
79805565|NCT00689624|Drug|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
79805566|NCT00689624|Drug|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
79805567|NCT00689624|Drug|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
79805568|NCT00689624|Drug|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
79475621|NCT02734355|Drug|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
79312292|NCT05476965|Combination Product|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
79969632|NCT03744169|Diagnostic Test|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
79312293|NCT05482503|Device|12-Lead ECG(I-lead)|All participants will simultaneously record 12-lead ECGs(I-lead)
79312294|NCT04424043|Procedure|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
79312295|NCT04424043|Procedure|Surgery alone|hepatic resection remove the liver tumors
79312296|NCT05486715|Drug|Vit D|Vit D
79312297|NCT03560895|Device|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
79312298|NCT03560895|Device|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
79312299|NCT05486637|Behavioral|Perception of acoustic cues to emotion|Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
79312300|NCT05486637|Behavioral|Production of acoustic cues to emotion|The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
79312301|NCT05476731|Diagnostic Test|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
79312302|NCT05482113|Drug|Liposomal bupivacaine|Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
79312303|NCT05482113|Drug|Bupivacaine Hcl 0.25% Inj|Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
79312304|NCT05482035|Device|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
79312305|NCT05476653|Other|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
79312306|NCT05476575|Other|hydrogen inhalation, 4% concentration, given via nasal cannula|4% hydrogen inhalation via nasal cannula perioperatively
79312307|NCT05486325|Device|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~To evacuate gastric contents~During construction of the gastric sleeve~To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~To evacuate gastric contents~During construction of the gastric pouch~To calibrate closure of the gastrojejunal anastomosis~To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
79312308|NCT05481957|Drug|Vortioxetine|5-10mg for 16 weeks
79312309|NCT05481957|Drug|valprote|500~1000mg for 16 weeks
79312310|NCT05475561|Procedure|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
79475622|NCT00369395|Drug|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
79475623|NCT04984109|Procedure|Sham PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.
79640560|NCT02914678|Other|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
79640561|NCT00163878|Procedure|Sensory Stimulation|
79640562|NCT00163878|Device|Sesnory Modality Assessment and Rehabilitation Technique|
79805569|NCT00689624|Drug|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
79969633|NCT03744169|Diagnostic Test|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
79312311|NCT05475561|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
79312312|NCT05475561|Drug|Bupivacain|local anesthetic
79312313|NCT05475405|Other|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
79312314|NCT05475405|Other|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
79312315|NCT05476341|Drug|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
79312316|NCT05476341|Drug|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
79312317|NCT05481723|Drug|noradrenaline and vascular filling|In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
79312318|NCT05481723|Procedure|pulmonary ultrasound after vascular filling|In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
79312319|NCT05481567|Other|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
79312320|NCT05474703|Other|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
79312321|NCT04272021|Drug|Methylphenidate|standard therapy for ADHD
79312322|NCT04423887|Other|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
79312323|NCT04423887|Other|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
79312324|NCT04423887|Device|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
79312325|NCT04423887|Procedure|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
79640563|NCT00405977|Drug|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
79312326|NCT04423887|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
79312327|NCT05474313|Behavioral|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
79312328|NCT05474313|Behavioral|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
79312329|NCT02697773|Other|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
79312330|NCT02697773|Biological|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
79312331|NCT02697773|Biological|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
79312332|NCT02395289|Behavioral|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
79805570|NCT05298800|Biological|Vaccine|Different arms were administrated different vaccines
79805571|NCT05298488|Behavioral|Home office|Working from home
79805572|NCT05298488|Behavioral|Office|Working at the office
79805573|NCT02621528|Device|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
79312333|NCT02395289|Behavioral|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
79312334|NCT02395211|Behavioral|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
79312335|NCT02395211|Device|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
79312336|NCT02394977|Device|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
79312337|NCT02394977|Other|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
79312338|NCT02394899|Behavioral|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
79640564|NCT00405977|Drug|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
79312339|NCT02394899|Other|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
79312340|NCT02397005|Drug|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
79640565|NCT02914288|Other|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
79312341|NCT02397005|Drug|Placebo matching ZL-2102|
79312342|NCT02394821|Drug|Polihexanide 2%|
79312343|NCT02394821|Drug|Metronidazole 0.8%|
79640566|NCT02914327|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
79312344|NCT02394587|Behavioral|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
79312345|NCT02394743|Radiation|18FDG-PET|
79312346|NCT02397161|Other|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
79312347|NCT02397161|Other|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
79312348|NCT02397161|Other|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
79312349|NCT02394509|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
79490263|NCT03763058|Other|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
79805574|NCT02621684|Other|Community Health Activities Model Program for Seniors (CHAMPS)|"Physical activity questionnaire for older adults~Asks about activities in the past 4 weeks~41 questions and asks to notate how long the activity took"
79805575|NCT02621684|Other|Lifetime Total Physical Activity Questionnaire|"Questions about leisure time (27) and household activities (5)~Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
79805576|NCT02621684|Other|Expanded Prostate Cancer Index Composite (EPIC)|"Measures urinary and sexual function before and after prostate cancer treatment~7 questions about urinary function~9 questions about sexual function"
79805577|NCT02621684|Other|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
79805578|NCT02621684|Other|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
79805579|NCT02621684|Other|Questionnaire regarding behavior/lifestyle changes since diagnosis|
79805580|NCT02621684|Other|12 week Walking Program|
79969634|NCT03867461|Procedure|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
79312350|NCT02394431|Other|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
79312351|NCT02394431|Other|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
79312352|NCT02394431|Other|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
79805581|NCT02621684|Other|12 week Resistance Training Program|
79805582|NCT02623790|Other|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
79805583|NCT02623790|Other|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
79805584|NCT02623790|Other|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
79805585|NCT00696098|Other|sodium butyrate|1 enema (60 ml) once daily containing 100mM
79312353|NCT05745857|Drug|Avastin|Orally administered
79312354|NCT05745857|Drug|Erbitux|Orally administered
79805586|NCT00696098|Other|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
79312355|NCT05745857|Device|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
79805587|NCT02623634|Behavioral|Position, waveform|different positions and waveform
79312356|NCT05476185|Behavioral|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
79969635|NCT03867461|Other|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
79312357|NCT02394353|Device|Transient hepatic elastography|
79312358|NCT05745779|Diagnostic Test|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
79312359|NCT02394197|Drug|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
79312360|NCT02394197|Drug|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
79312361|NCT02394119|Drug|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
79312362|NCT02394119|Drug|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
79805588|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
79805589|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
79805590|NCT00684008|Drug|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
79312363|NCT03167333|Drug|platelet rich plasma|The amount of PPR was about 4-5 cc
79969636|NCT03867461|Other|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
79312364|NCT03167333|Drug|Hyaluronic acid|HA was 2.5cc
79312365|NCT02394041|Device|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
79969637|NCT03867461|Other|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
79969638|NCT03867461|Other|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
79969639|NCT05153733|Device|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
79969640|NCT03385642|Device|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
79969641|NCT03621813|Behavioral|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
79969642|NCT03621813|Other|Control|Participants are instructed to maintain current activity level and are monitored for changes.
79312366|NCT02394041|Device|Sham acupuncture|Sham acupuncture with sham needles
79312367|NCT02393729|Behavioral|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~Intellectual ability~Laterality~Reading Skills~Motor skills~Oral Language~Attention~Child's behaviour"
79312368|NCT02393729|Other|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
79312369|NCT03167567|Behavioral|Presence of a medical clown during labor|Presence of a medical clown during labor
79312370|NCT02393963|Drug|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
79805591|NCT00684008|Drug|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
79312371|NCT02393963|Other|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
79805592|NCT00696176|Drug|STAT 3 DECOY|single administration to a head and neck tumor
79805593|NCT05326724|Device|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
79805594|NCT02623478|Drug|Insulin Lispro|Administered subcutaneously (SC)
79805595|NCT02621450|Biological|standart dialysis|dialysate sodium consentration 140 mEq
79805596|NCT02621450|Biological|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
79805597|NCT04139954|Other|There is no intervention in the study|There is no intervention in the study
79805598|NCT00696254|Behavioral|Nerve excitability measurement|
79805599|NCT02623088|Other|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
79805600|NCT04135040|Dietary Supplement|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
79805601|NCT00684086|Behavioral|Diabetes Self Management Program|
79312372|NCT03115385|Dietary Supplement|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
79312373|NCT03115385|Dietary Supplement|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
79312374|NCT02393807|Drug|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
79312375|NCT02393807|Drug|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
79312376|NCT02393651|Device|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
79312377|NCT03115619|Drug|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
79312378|NCT05745623|Drug|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
79312379|NCT02393495|Device|intrauterine device TCu 380A|
79312380|NCT02393573|Drug|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
79312381|NCT02393573|Drug|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
79312382|NCT02393261|Other|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
79312383|NCT02393261|Other|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
79805602|NCT04135430|Other|Survey|practice of an updated questionnaire at D0, D2 and D7
79805603|NCT00684164|Drug|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
79969643|NCT03867071|Other|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
79969644|NCT03867071|Other|placebo injection|Intravenous injection 0,9% saline solution.
79312384|NCT02693171|Drug|Dinutuximab|Unituxin was administered along with cytokines according to the prescribing information
79312385|NCT02392949|Behavioral|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
79312386|NCT02392949|Other|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
79312387|NCT03167021|Other|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
79312388|NCT02393027|Drug|[18F] LBT-999 PET|
79312389|NCT02392793|Drug|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
79490264|NCT03031340|Drug|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
79805604|NCT00684164|Other|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
79805605|NCT04135508|Drug|BAT1406|40mg/0.8ml
79805606|NCT04135508|Drug|Humira|40mg/0.8ml
79805607|NCT02621372|Other|platelet count|Correlation of esophageal varices with platelet count
79805608|NCT04135196|Other|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
79969645|NCT03382132|Behavioral|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
79969646|NCT03382132|Behavioral|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
79969647|NCT04032613|Other|Vascular Access Navigation and Education Quality Improvement Program|A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
79475624|NCT04984109|Procedure|Real PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
79312390|NCT02392793|Drug|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
79475625|NCT01947907|Drug|ACP-001|Once weekly subcutaneous injection
79805609|NCT02621294|Other|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-[1-13C] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
79312391|NCT02392793|Drug|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
79312392|NCT02392793|Drug|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given.
79312393|NCT02392793|Drug|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given.
79312394|NCT05745155|Device|Senti Wear device system with Senti-AI subsystem|"This device is a smart garment, with a similar form to a T-Shirt, jacket or tabard, embedded with ten sensor modules (nine acoustic sensors, one kinetic sensor - all able to detect signals from the chest wall and underlying structures, including the lungs) encased in silicone; the device is charged via a charging port in the garment. The device has two modes of operation: recording mode and charging mode. The device is internally (battery) powered during recording mode and mains-powered during charging mode. The device is accompanied by cloud-based software to listen to both contemporaneous and historically recorded breath sounds, for each Senti patient. To use the device, the user puts the garment on (overhead, like a T-Shirt, before joining the back piece to the front like a tabard).~Additionally, Senti-AI adds an anomaly burden score and an alert flag for review against each acoustic record for each patient."
79475626|NCT01947907|Drug|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
79475627|NCT05735665|Diagnostic Test|bowel ultrasound|Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
79475628|NCT05735665|Diagnostic Test|colonoscopy|Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
79805610|NCT04134962|Diagnostic Test|3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
79805611|NCT02622932|Drug|Anlotinib and 14C-labeled Anlotinib|oral
79805612|NCT02617238|Other|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
79312395|NCT03166943|Procedure|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~by biplane Simpson's method.~by speckle tracking:"
79312396|NCT03166943|Procedure|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~Left atrial Volume~Mitral Inflow Patterns~Pulsed wave Doppler~Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~Tissue Doppler Annular Early and Late Diastolic Velocities~Pulsed wave tissue doppler imaging~Primary measurements include the systolic , early diastolic, and late diastolic velocities."
79312397|NCT02392715|Device|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
79312398|NCT02392715|Device|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
79312399|NCT02692703|Drug|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
79312400|NCT02392325|Biological|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10^3.0 plaque-forming units (PFU)
79312401|NCT02392325|Biological|Placebo|Administered subcutaneously in 0.5 mL
79312402|NCT02392325|Biological|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10^3.0 PFU
79312403|NCT03167177|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79312404|NCT03167177|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
79312405|NCT03167177|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79312406|NCT03167177|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79312407|NCT03167177|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79312408|NCT03167177|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79312409|NCT03167177|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79312410|NCT03167177|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79312411|NCT03167177|Biological|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
79312412|NCT03167177|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
79312413|NCT03167177|Radiation|Stereotactic Body Radiation Therapy|radiation
79312414|NCT03167177|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79312415|NCT03167177|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79312416|NCT03167177|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79312417|NCT03167177|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
79312418|NCT03167177|Biological|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
79312419|NCT03167177|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
79312420|NCT03167177|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
79475629|NCT02737397|Drug|JMI-001 (SJP-304 and SJP-223)|
79475630|NCT02737397|Drug|SJP-304|
79475631|NCT02737397|Drug|SJP-223|
79475632|NCT02737397|Drug|placebo|
79475633|NCT02737631|Device|"Chameleon Personal Lubricant"|
79475634|NCT01948141|Drug|nintedanib|Given PO
79475635|NCT04938323|Drug|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
79490265|NCT03031340|Other|placebo|placebo
79805613|NCT04135274|Diagnostic Test|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
79805614|NCT02620982|Device|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
79312421|NCT03166709|Behavioral|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
79312422|NCT03166709|Behavioral|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
79312423|NCT02392169|Drug|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
79312424|NCT02392013|Other|Home Modification|Removal of home barriers or hazards.
79312425|NCT02391857|Procedure|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
79312426|NCT03166865|Biological|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10~7 diluted on 5 mL of Platelet Rich Plasma
79312427|NCT03166865|Other|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
79312428|NCT03166787|Other|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
79312429|NCT03166787|Other|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
79805615|NCT02617394|Other|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
79312430|NCT03166787|Other|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
79475636|NCT04938323|Drug|Placebo|.1 mL of diluent (saline) given intradermally at baseline
79475637|NCT05446493|Drug|Tadalafil 5mg|"Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~Penile color Doppler ultrasound examination before and after treatment"
79490266|NCT03760796|Device|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
79490267|NCT03405259|Device|Super Seal® Desensitizer|Single dose professional application.
79490268|NCT03405259|Device|Acclean® Fluoride Varnish|Single dose professional application.
79490269|NCT03513757|Drug|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
79475638|NCT01948375|Device|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
79475639|NCT01948375|Device|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
79490270|NCT03513757|Drug|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
79805616|NCT02617394|Other|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
79805617|NCT02622776|Other|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
79969648|NCT01172327|Behavioral|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
79969649|NCT01172327|Behavioral|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
79969650|NCT03375502|Drug|Varicella Vaccine|The subject will receive investigational product or comparator.
79805618|NCT02617316|Other|Barefoot|barefoot running test was 20 minutes.
79805619|NCT02617316|Other|In shoes|In shoes test was 20 minutes.
79969651|NCT01284413|Drug|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
79969652|NCT03867149|Other|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
79969653|NCT03867149|Other|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
79969654|NCT05152017|Biological|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
79312431|NCT03166787|Drug|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
79312432|NCT03166787|Other|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
79312433|NCT03166787|Drug|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
79312434|NCT03166787|Drug|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
79312435|NCT02692235|Dietary Supplement|carnitine|1500 mg/d l-carnitine-l-tartrate
79312436|NCT02692235|Dietary Supplement|placebo|isonitrogenous
79475640|NCT05446103|Other|Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM"
79475641|NCT05446103|Other|Sham Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An <20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM"
79475642|NCT04934033|Other|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
79969655|NCT05152017|Biological|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
79969656|NCT05152017|Biological|Placebo|solution for intramuscular injection, 0.5 ml
79969657|NCT03866993|Biological|AK105|IV infusion
79969658|NCT03866993|Drug|Paclitaxel|IV infusion
79969659|NCT03866993|Drug|Carboplatin|IV infusion
79969660|NCT03866993|Drug|Placebo|IV infusion
79312437|NCT03166241|Diagnostic Test|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
79312438|NCT03166241|Diagnostic Test|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
79312439|NCT03166241|Diagnostic Test|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
79312440|NCT03166241|Diagnostic Test|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
79475643|NCT01885117|Biological|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
79312441|NCT03166241|Diagnostic Test|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
79475644|NCT04895501|Other|running flexible shoes|21kms of running flexible shoes followed by a time-to-exhaustion run.
79805620|NCT02616770|Drug|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
79312442|NCT03166241|Diagnostic Test|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
79969661|NCT03376906|Procedure|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
79312443|NCT03167645|Drug|Human albumin|Substitution according to pre-specified dosage
79312444|NCT03166553|Drug|Elemene|
79312445|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
79312446|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
79805621|NCT02616770|Drug|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
79805622|NCT02616770|Drug|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
79805623|NCT02616770|Drug|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
79312447|NCT03166397|Drug|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
79312448|NCT03166397|Drug|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
79312449|NCT03166397|Biological|TIL|TIL administration
79312450|NCT03166397|Drug|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
79312451|NCT03166397|Drug|Nivolumab|Nivolumab 480 mg fixed dose
79312452|NCT03166397|Drug|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
79312453|NCT03166397|Drug|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
79805624|NCT02616770|Drug|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
79312454|NCT05744609|Other|exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports|epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
79475645|NCT02905721|Procedure|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
79475646|NCT04879355|Device|Spinal needle (25G)|Fine needle aspiration from thyroid nodules using a 25G spinal needle.
79475647|NCT04879355|Device|Conventional fine needle (25G)|Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
79805625|NCT02616770|Drug|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
79805626|NCT00499369|Drug|irinotecan hydrochloride|Given IV
79805627|NCT00499369|Drug|leucovorin calcium|Given IV
79805628|NCT00499369|Drug|fluorouracil|Given IV
79805629|NCT00499369|Biological|cetuximab|Given IV
79312455|NCT04480073|Procedure|Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges|"Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications."
79312456|NCT05744531|Other|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
79312457|NCT05746169|Other|Health Questionnaires|A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.
79312458|NCT05746169|Other|Specimen sample collection|Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
79312459|NCT04480151|Other|standard of care|retrospective study: standard of care
79312460|NCT05744453|Dietary Supplement|Olive Leaf Extract|experimental arm
79312461|NCT05744453|Dietary Supplement|Cellulose|placebo comparator arm
79805630|NCT00499369|Biological|bevacizumab|Given IV
79805631|NCT02622464|Other|micro injection of SVF in vocal cords|
79969662|NCT03376906|Procedure|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
79312462|NCT03166475|Procedure|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
79490271|NCT03513757|Drug|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
79805632|NCT02622698|Dietary Supplement|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
79805633|NCT02622698|Other|Placebo|Placebo- Patients did not take any protein supplementation after surgery
79805634|NCT02616692|Drug|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
79969663|NCT03376906|Procedure|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
79969664|NCT01172405|Drug|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
79312463|NCT05746013|Dietary Supplement|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
79805635|NCT02620592|Drug|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
79969665|NCT01172405|Drug|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
79490272|NCT03513757|Drug|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
79805636|NCT02620592|Drug|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
79805637|NCT02620514|Behavioral|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
79969666|NCT03381976|Other|Intervention 2X/week (G2X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
79312464|NCT03115229|Behavioral|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
79312465|NCT03106259|Drug|FURESTEM-RA Inj.|Non-interventional observational study
79312466|NCT02552121|Drug|Tisotumab vedotin (HuMax-TF-ADC)|
79805638|NCT02620514|Behavioral|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
79805639|NCT02620514|Behavioral|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
79805640|NCT02620514|Behavioral|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
79307767|NCT02419976|Other|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
79312467|NCT03488355|Other|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
79312468|NCT03484143|Device|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
79312469|NCT03484143|Device|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
79312470|NCT05473611|Procedure|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
79312471|NCT05476107|Drug|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
79312472|NCT05476107|Drug|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
79969667|NCT03381976|Other|Intervention 3X/week (G3X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
79307768|NCT02419976|Device|Aeonose|
79307769|NCT02296125|Drug|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
79307770|NCT02296125|Drug|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79312473|NCT05476107|Other|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
79312474|NCT02552355|Drug|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
79640567|NCT02914249|Other|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
79640568|NCT00150020|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
79640569|NCT02914015|Procedure|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
79969668|NCT02966691|Other|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
79969669|NCT01166867|Device|Photo-plethysmography monitoring|monitoring vital sign in infant
79969670|NCT04000165|Drug|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
79640570|NCT02914015|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
79307771|NCT02296125|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79312475|NCT02552355|Drug|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
79312476|NCT02552355|Dietary Supplement|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
79312477|NCT02552355|Dietary Supplement|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
79312478|NCT02551731|Drug|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
79312479|NCT04479657|Drug|QingFei Granule|QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
79312480|NCT04479657|Drug|Cefuroxime|30mg/kg/d,bid, used until to the normalization of blood routine。
79312481|NCT05476029|Diagnostic Test|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
79312482|NCT05475951|Diagnostic Test|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
79312483|NCT05475795|Other|Metapex|obturation of root canals of primary molars with Metapex
79312484|NCT05475795|Other|Endoflas|obturation of root canals of primary molars with Endoflas
79312485|NCT04270305|Other|Orientation|In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
79640571|NCT02914015|Drug|Ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
79640572|NCT02914015|Drug|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
79640573|NCT02914093|Other|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
79640574|NCT00171093|Drug|valsartan + simvastatin|
79640575|NCT02914054|Drug|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
79805641|NCT02620670|Behavioral|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
79805642|NCT02622308|Device|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
79805643|NCT02622152|Procedure|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
79805644|NCT02622152|Procedure|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
79969671|NCT03376828|Device|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
79969672|NCT03376828|Device|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
79969673|NCT02526563|Procedure|ropivicaine|Blood draws to measure serum ropivicaine
79969674|NCT03375424|Biological|vedolizumab|duration of disease and kind of therapy
79312486|NCT04270305|Other|walking|In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
79312487|NCT05481099|Behavioral|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
79805645|NCT02622152|Procedure|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
79805646|NCT02622152|Procedure|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
79312488|NCT05480787|Drug|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
79312489|NCT05480787|Drug|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
79312490|NCT05480787|Drug|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
79312491|NCT05471661|Biological|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
79640576|NCT02914054|Drug|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
79312492|NCT05480631|Procedure|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
79312493|NCT05480631|Procedure|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
79312494|NCT05480631|Procedure|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
79312495|NCT05471193|Diagnostic Test|Machine Learning Prediction|Machine Learning Prediction
79640577|NCT00150059|Drug|Pimecrolimus Cream 1%|
79805647|NCT02622152|Procedure|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
79640578|NCT02913976|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
79640579|NCT02913976|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
79805648|NCT02622230|Drug|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
79805649|NCT02622230|Drug|Placebo|Placebo to match with experimental groups
79805650|NCT01014637|Drug|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
79805651|NCT01014637|Drug|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
79640580|NCT00171132|Drug|valsartan|
79805652|NCT02616926|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
79805653|NCT02616926|Procedure|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
79312496|NCT05480397|Other|TENS, Distractive techniques, cryotherapy|"Group (1): Will receive (TENS , cryotherapy and conventional physical therapy ) Massage with ice was done by the researcher over the AVF puncture site . After that, the TENS electrodes will be applied by the researcher 6 centimeters apart closely up and down the skin area for insertion of the needle.~Group (2): Will receive (Distraction techniques ,cryotherapy and conventional physical therapy ) Initially five minutes before starting hemodialysis, Distraction techniques will be applied. Natural and eye-catching images were broadcasted through a video display device on a laptop monitor in a manner that was easy for the older patient to watch while they were lying on the bed. Massage with ice was done by the researcher over the AVF puncture site~Group (3): Will receive (cryotherapy and conventional physical therapy )"
79312497|NCT05458869|Procedure|HPV Self-Collection|Use HPV self-collection kit
79312498|NCT05458869|Other|Interview|Attend interview
79312499|NCT05458869|Other|Survey Administration|Complete surveys
79805654|NCT02616926|Procedure|RFA|RFA will be performed 1 week after TACE.
79312500|NCT02542605|Drug|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
79312501|NCT02542605|Drug|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
79312502|NCT02542605|Drug|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
79312503|NCT05480241|Drug|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
79312504|NCT05480241|Drug|Placebo|Placebo + Omeprazole 20mg once daily on fasting
79312505|NCT02550873|Biological|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
79312506|NCT02550873|Other|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
79312507|NCT05480163|Other|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
79312508|NCT02702115|Biological|SB-318|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
79312509|NCT05455905|Diagnostic Test|Patient Health Questionnaire-9|The Patient Health Questionnaire-9 is a nine question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Patient Health Questionnaire-9 is scored from 0 to 27 where higher scores are associated with more severe depression.
79312510|NCT05455905|Diagnostic Test|Generalized Anxiety Disorder-7|The Generalized Anxiety Disorder-7 is a seven question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Generalized Anxiety Disorder-7 is scored from 0 to 21 where higher scores are associated with more severe anxiety.
79312511|NCT05455905|Diagnostic Test|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is administered by a mental health profession and includes twenty-one questions asking about how the participant has been feeling in the past week. The Hamilton Depression Rating Scale is scored from 0 to 45 where higher scores are associated with more severe depression.
79312512|NCT05455905|Diagnostic Test|Hamilton Anxiety Rating Scale|The Hamilton Anxiety Rating Scale is administered by a mental health profession and includes fourteen questions asking about how the participant has been feeling in the past week. The Hamilton Anxiety Rating Scale is scored from 0 to 56 where higher scores are associated with more severe anxiety.
79312513|NCT02550795|Drug|Dexmedetomidine|administration of dexmedetomidine only
79312514|NCT02550795|Drug|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
79312515|NCT02550795|Drug|Control|administration of normal saline
79312516|NCT02541903|Drug|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
79312517|NCT02541669|Drug|TAK-491|TAK-491 tablets
79312518|NCT02541669|Drug|TAK-491 placebo|TAK-491 placebo-matching tablets
79312519|NCT05455047|Diagnostic Test|PET-CT at 18F-FDG|PET-CT at 18f6FDG in nuclear medicine departement of Nancy's hospital
79312520|NCT04423809|Other|clinical assessment|assessment of caregivers suffering when a family member is hospitalized
79312521|NCT02549859|Device|Deep Brain Stimulation (DBS) at 60 Hz|Bilateral subthalamic nucleus deep brain stimulation at 60 Hz
79312522|NCT02549859|Device|Deep Brain Stimulation (DBS) at 130 Hz|Bilateral subthalamic nucleus deep brain stimulation at 130 Hz
79312523|NCT02549859|Device|Deep Brain Stimulation (DBS) Off (Sham)|Deep Brain Stimulation (DBS) Off (Sham)
79312524|NCT02688647|Drug|Belumosudil|
79312525|NCT02688647|Other|BSC|Treatment/drug as determined by each subject's prescribing physician
79490273|NCT03513757|Drug|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
79490274|NCT03513757|Drug|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
79805655|NCT01014715|Other|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
79312526|NCT04469127|Drug|Lutetium-177-DOTAGA-PEG-IAC|Study participants be administered therapeutic doses of Lutetium-177-PEG-DOTAGA-PEG-IAC up to three treatments spaced 6-8 weeks apart and a CT scan immediately after. A Ga-68-PEG-αvβ3-IAC PET/CT scan will be performed four weeks before and four weeks after the initial dose of the Lutetium-177-DOTAGA-PEG-IAC.
79312527|NCT02687607|Device|WEB Aneurysm Embolization System|
79312528|NCT04479839|Diagnostic Test|Ultrasound of the airway|Placing ultrasound on the neck after intubation
79312529|NCT03165851|Other|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
79312530|NCT05453799|Drug|Vudalimab|Given IV
79312531|NCT05453487|Biological|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
79312532|NCT05453487|Biological|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
79312533|NCT05453487|Biological|rabies vaccine|received three dose of rabies vaccine
79312534|NCT05032053|Drug|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
79312535|NCT03968601|Other|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
79312536|NCT05738525|Device|APD-RPM|"APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day."
79312537|NCT01662063|Drug|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
79312538|NCT05627999|Procedure|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
79312539|NCT05431725|Biological|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
79312540|NCT05431725|Biological|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
79312541|NCT02548455|Device|Quartet 1457Q LV Lead|
79312542|NCT02691455|Device|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
79969675|NCT01172483|Procedure|general practice in primary care and education|education of chronic disorders in PC
79312543|NCT02691455|Procedure|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
79312544|NCT02691455|Device|Ahmed Model FP7 Flexible Plate|
79312545|NCT02691455|Device|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
79490275|NCT03760640|Drug|LY900014|Administered SC
79640581|NCT00171132|Drug|atenolol|
79312546|NCT04264845|Other|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
79312547|NCT04264845|Other|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
79312548|NCT04264845|Other|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
79475648|NCT00368771|Behavioral|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
79805656|NCT02621996|Device|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
79312549|NCT05451615|Drug|Janus Kinase Inhibitor|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
79312550|NCT05451615|Drug|Abatacept|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
79805657|NCT02621996|Device|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
79475649|NCT00368771|Behavioral|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
79490276|NCT03760640|Drug|Insulin Lispro|Administered SC
79490277|NCT03407053|Dietary Supplement|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
79490278|NCT03407053|Dietary Supplement|Unprocessed diet|Consuming unprocessed diet over a 2-week period
79640582|NCT00171132|Drug|hydrochlorothiazide|
79805658|NCT00696566|Drug|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
79312551|NCT03166007|Behavioral|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
79475650|NCT00368771|Behavioral|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
79475651|NCT05445479|Drug|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
79475652|NCT02711735|Biological|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
79475653|NCT02711735|Biological|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
79475654|NCT04864145|Device|Transcatheter Aortic Valve Implantation|The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
79475655|NCT04864145|Drug|Medical therapy|Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
79475656|NCT04738565|Dietary Supplement|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
79475657|NCT04738565|Dietary Supplement|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
79475658|NCT05445011|Drug|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg * 3d on day-7~-2; Cyclophosphamide 250 mg/kg *3d on day-7~-2; TAA05 Cell Injection on day 0.
79475659|NCT02380781|Behavioral|Information in the form of a video|see intervention description
79640583|NCT02913898|Behavioral|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
79805659|NCT01017133|Radiation|fludeoxyglucose F 18|Given IV
79312552|NCT03166007|Behavioral|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
79312553|NCT02534883|Drug|Misoprostol|To be place vaginally
79969676|NCT01172483|Other|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
79312554|NCT02534883|Drug|Placebo|To be placed vaginally
79312555|NCT05626439|Drug|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
79969677|NCT03187197|Drug|Pradaxa®|Dabigatran etexilate
79969678|NCT03375346|Device|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
79312556|NCT05626439|Drug|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
79312557|NCT02685995|Device|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
79312558|NCT02685995|Device|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
79312559|NCT02548143|Biological|Coagulation Factor VIIa (Recombinant)|LR769
79312560|NCT03165149|Drug|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
79312561|NCT03165149|Drug|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
79312562|NCT03165149|Drug|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
79312563|NCT03165227|Drug|BI 685509|Taken orally
79312564|NCT03165227|Drug|Placebo|Taken orally
79312565|NCT03165305|Other|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
79312566|NCT02547441|Drug|CLS001 (Omiganan)|Topical gel
79312567|NCT02547441|Drug|Vehicle|Vehicle Gel
79312568|NCT05430009|Radiation|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
79312569|NCT05430009|Drug|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
79312570|NCT05429697|Drug|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
79312571|NCT05429697|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
79312572|NCT02540265|Drug|N1539|
79312573|NCT02540265|Drug|Intravenous Placebo|
79969679|NCT03375346|Other|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
79969680|NCT01284647|Drug|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
79475660|NCT05444621|Radiation|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
79475661|NCT04744181|Drug|Ferric carboxymaltose|administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
79312574|NCT05450601|Drug|HCP2102-1|Take once daily for 2 weeks orally
79805660|NCT01017133|Radiation|Fluorine F 18 EF5|Given IV
79475662|NCT04744181|Drug|B vitamin|administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
79969681|NCT01284647|Drug|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
79805661|NCT01017133|Procedure|Positron emission tomography|Undergo scan
79969682|NCT04000009|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
79969683|NCT03381898|Behavioral|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
79312575|NCT05450601|Drug|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
79312576|NCT05450601|Drug|HCP2102-2|Take once daily for 6 weeks orally
79805662|NCT04031066|Drug|Velmanase Alfa|infusion i.v. treatment
79805663|NCT04031066|Drug|Placebo|infusion i.v. treatment
79805664|NCT01017211|Other|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
79805665|NCT01017289|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
79805666|NCT00869258|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
79805667|NCT00869258|Radiation|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
79805668|NCT01011517|Dietary Supplement|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
79805669|NCT03996811|Other|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
79805670|NCT00696644|Drug|Teriparatide|20 mcg daily subcutaneous for 18 months.
79969684|NCT01280045|Procedure|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
79312577|NCT05450601|Drug|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
79312578|NCT05450601|Drug|RLD2106-1|Take once daily for 2 weeks orally
79312579|NCT05450601|Drug|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
79312580|NCT05450601|Drug|RLD2106-2|Take once daily for 6 weeks orally
79312581|NCT05450601|Drug|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
79312582|NCT02547363|Drug|LEO 43204 gel|
79312583|NCT02547363|Drug|Vehicle gel|
79805671|NCT01017367|Drug|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
79805672|NCT01017367|Drug|Placebo|Placebo
79805673|NCT00696722|Drug|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
79805674|NCT00696722|Drug|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
79969685|NCT03282240|Biological|QIV-HD|0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.
79969686|NCT03282240|Biological|Licensed TIV-HD1|0.5 mL-dose was administered IM into the upper arm area.
79969687|NCT03282240|Biological|Investigational TIV-HD2|0.5 mL-dose was administered IM into the upper arm area.
79969688|NCT01177865|Other|informational intervention|
79969689|NCT01177865|Other|questionnaire administration|
79969690|NCT03185949|Device|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
79312584|NCT02539797|Device|tDCS|comparing anodal, cathodal, and sham tDCS
79312585|NCT02684357|Drug|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
79312586|NCT02684357|Drug|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
79312587|NCT02684357|Drug|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
79312588|NCT02684357|Drug|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
79475663|NCT04744181|Drug|Folic acid|administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
79969691|NCT03185949|Behavioral|Behavioral therapy|Healthy diet and exercise
79969692|NCT01284725|Drug|mycophenolate mofetil or azathioprine|
79475664|NCT05444387|Other|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
79969693|NCT01284725|Other|immunosuppressive treatment discontinuation|
79969694|NCT03655405|Other|Individual Deprescribing Intervention|The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
79969695|NCT03510598|Device|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
79969696|NCT03510598|Drug|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
79969697|NCT01173107|Drug|colchicine|colchicine 1T tid
79969698|NCT03376750|Behavioral|CO - OP|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
79969699|NCT03860441|Other|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
79969700|NCT04656210|Radiation|MRI|Non conventional MRI (35 minutes)
79969701|NCT04656210|Other|neuropsychological tests|Standardized and quantified neuropsychological assessment
79969702|NCT03736291|Device|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
79312589|NCT05586191|Other|Action observation at home|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
79475665|NCT01887041|Procedure|Stent|Endoscopically inserted biliary tract drainage
79475666|NCT01887041|Procedure|Biliodigestive anastomosis|Biliodigestive anastomosis
79475667|NCT04717115|Genetic|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
79475668|NCT00619931|Drug|APD791|APD791 or matching placebo in escalating doses
79640584|NCT02913898|Behavioral|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
79969703|NCT03381820|Other|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
79969704|NCT03222141|Device|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
79475669|NCT05452655|Behavioral|Multidisciplinary Intensive Rehabilitation|"The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim)."
79475670|NCT05452655|Behavioral|Muscle-stretching and active mobilization exercises|The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
79640585|NCT02913937|Device|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
79640586|NCT02913937|Device|Endodontic needle|Endodontic irrigation
79640587|NCT00150098|Behavioral|Enhanced HIV risk reduction and HIV vaccine education|
79640588|NCT02913859|Radiation|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
79640589|NCT02913859|Drug|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
79805675|NCT02620436|Other|Core Mother Shelter Model|"Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
79805676|NCT00696956|Device|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
79805677|NCT00696956|Device|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
79640590|NCT02913820|Other|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
79640591|NCT02913742|Procedure|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
79640592|NCT00150137|Drug|Methimazole|
79640593|NCT04688281|Device|Medicurtain®|Medicurtain® 5ml prefilled syringe
79805678|NCT02616848|Drug|Everolimus|
79969705|NCT01313598|Drug|GLPG0187|continuous IV infusion
79640594|NCT04688281|Device|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
79640595|NCT00163917|Device|Virtual reality relaxation|
79640596|NCT02913781|Procedure|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
79640597|NCT02913781|Procedure|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
79640598|NCT02913625|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
79640599|NCT02913625|Other|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
79805679|NCT02616848|Drug|Eribulin|
79805680|NCT02621918|Other|Progressive resistance training|
79805681|NCT02621918|Other|Aerobic training|
79805682|NCT02621918|Other|Placebo training|
79805683|NCT02620124|Drug|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
79805684|NCT02620124|Drug|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
79805685|NCT02617160|Device|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
79969706|NCT03744091|Drug|P1|10 mg or 20 mg of THC:THCa
79969707|NCT03376594|Drug|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
79805686|NCT02617160|Other|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
79805687|NCT04134650|Combination Product|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
79805688|NCT04134650|Drug|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
79805689|NCT02621762|Device|Magnesium|Magnesium in dialysate increased
79805690|NCT02621762|Device|Bicarbonate|Bicarbonate in dialysate increased
79805691|NCT02621840|Behavioral|Mandatory On-Site Pre-Admission Testing|
79640600|NCT02913547|Device|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
79640601|NCT00150215|Drug|PF-00184562|
79640602|NCT00150215|Drug|Olanzapine|
79640603|NCT02913703|Drug|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
79640604|NCT02913703|Other|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
79640605|NCT00171171|Drug|deferasirox|
79805692|NCT02620358|Other|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
79805693|NCT02620358|Other|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
79805694|NCT02999074|Other|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
79805695|NCT02999074|Other|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
79969708|NCT03376594|Drug|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
79969709|NCT03863873|Procedure|Platelet-Rich Plasma Injection Group|Platelet-Rich Plasma Injection Group
79969710|NCT05572164|Procedure|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
79307772|NCT02296125|Drug|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
79640606|NCT02913430|Drug|Fulvestrant|500mg IM Q28 days
79640607|NCT02913430|Drug|Tamoxifen|20mg PO Qdaily
79640608|NCT02913430|Drug|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
79969711|NCT05572164|Procedure|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
79969712|NCT03381664|Drug|AVP-923|capsule
79969713|NCT04029961|Other|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
79969714|NCT04029961|Other|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
79969715|NCT03863561|Behavioral|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
79969716|NCT05126979|Biological|Inactivated Split Influenza Vaccine|
79640609|NCT02913469|Drug|Morphine|The patients in group A would be administrated intravenous morphine 5mg
79969717|NCT05126979|Biological|Placebo|
79969718|NCT04060758|Drug|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
79969719|NCT03484455|Device|Hypothermic machine perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
79969720|NCT03484455|Device|Static cold storage|Static cold storage (standard of care)
79969721|NCT03863405|Drug|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
79969722|NCT03863405|Drug|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
79969723|NCT03863405|Drug|Placebo Oral Tablet|oral tablet
79969724|NCT03637218|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
79640610|NCT02913469|Drug|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
79312590|NCT05586191|Other|Action Observation therapy at hospital|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
79805696|NCT02999074|Other|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
79805697|NCT00693784|Biological|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
79805698|NCT00693706|Biological|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
79969725|NCT03637218|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
79969726|NCT03997825|Device|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
79969727|NCT03866369|Drug|Moxifloxacin|Single oral dose at D-8
79969728|NCT03866369|Drug|Placebo|Single oral dose at D-1
79312591|NCT02684279|Drug|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
79312592|NCT05578703|Procedure|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
79312593|NCT05578703|Device|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
79312594|NCT05578703|Device|Apollo ESG|Using only Apollo ESG as approved per label
79312595|NCT03115073|Drug|Candiplus|Administration of Candiplus
79312596|NCT03115073|Drug|Clotrimazole|Administration of Clotrimazole
79312597|NCT03166163|Drug|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
79640611|NCT02913469|Drug|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
79640612|NCT00150254|Drug|CP-526,555 (varenicline)|
79805699|NCT00693706|Biological|Fluarix|IM injection on Day 0
79640613|NCT02913352|Procedure|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
79640614|NCT02913352|Procedure|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
79805700|NCT03891394|Diagnostic Test|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
79969729|NCT03866369|Drug|Lanifibranor|Single daily oral dose during 14 days
79969730|NCT03866369|Drug|Placebo|Single daily oral dose during 14 days
79969731|NCT05178264|Drug|SARS-CoV-2 vaccines|All patients treated at least with 1 SARS-CoV-2 vaccine
79969732|NCT01284803|Behavioral|an educational intervention|To elaborate an educational program for the management of depression in primary care
79969733|NCT05177952|Other|Blood Flow Restriction|Resistance training with BFR
79969734|NCT05177952|Other|Standard of Care|Resistance Training with no BFR
79969735|NCT03124576|Device|Implantable loop recorder|Continuous rhythm monitoring Medtronic
79969736|NCT03860675|Diagnostic Test|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
79969737|NCT04024891|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
79312598|NCT03166163|Drug|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
79312599|NCT03165929|Drug|Flurbiprofen|oral flurbiprofen spray
79312600|NCT03165929|Drug|placebo|oral placebo spray
79475671|NCT04739111|Drug|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
79969738|NCT04024891|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
79805701|NCT00488683|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
79805702|NCT00488683|Biological|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
79805703|NCT00488683|Biological|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
79969739|NCT03381586|Drug|ALT-803|Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
79969740|NCT01178021|Drug|Chloroquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
79969741|NCT01178021|Drug|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
79969742|NCT03250182|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
79969743|NCT03381508|Device|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
79969744|NCT01173263|Other|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
79969745|NCT01173263|Other|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
79640615|NCT02913508|Drug|Vedolizumab intravenous injection|Vedolizumab intravenous injection
79640616|NCT02913508|Drug|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
79475672|NCT05444075|Other|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
79969746|NCT01173263|Other|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
79969747|NCT05177874|Device|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
79969748|NCT05177874|Device|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
79969749|NCT03381430|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
79969750|NCT01288157|Drug|Golimumab|Single dose of 100 mg subcutaneously
79312601|NCT03165773|Other|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
79312602|NCT03165773|Other|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
79969751|NCT01288157|Drug|Golimumab|Single dose of 50 mg subcutaneously
79312603|NCT03165695|Drug|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
79475673|NCT05443997|Behavioral|MIYCN capacity building|"MIYCN knowledge, skills, and motivation of FLWs~Supportive supervision~Decentralized programmatic decision-making using data~PRI member involvement~Availability of THR~IYCF knowledge and practices"
79475674|NCT01885897|Biological|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
79475675|NCT04621331|Drug|Roxadustat|HIF-PH inhibitor for treatment of anemia in CKD
79969752|NCT03993379|Drug|CX-072|CX-072 in combination with ipilimumab
79969753|NCT03993379|Drug|Ipilimumab|CX-072 in combination with ipilimumab
79969754|NCT01284881|Device|MRA|daily wear overnight
79312604|NCT03165695|Drug|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
79312605|NCT02534493|Device|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
79312606|NCT02547129|Device|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
79312607|NCT02547129|Device|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
79312608|NCT05448729|Diagnostic Test|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
79312609|NCT04423653|Behavioral|Telehealth home exercise program|The intervention will include videos of exercises and also live coaching using telehealth system.
79312610|NCT05446935|Procedure|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
79475676|NCT04768231|Drug|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
79475677|NCT02987725|Behavioral|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
79475678|NCT02987725|Behavioral|Attention Control|A 30-minute historical story read by a research clinician.
79969755|NCT03376282|Other|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
79969756|NCT03866291|Other|No intervention, observational|See above
79969757|NCT01173419|Device|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
79969758|NCT01173419|Device|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
79969759|NCT03866447|Drug|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
79969760|NCT03866447|Drug|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
79969761|NCT03370120|Drug|Padsevonil|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
79969762|NCT03247686|Drug|RSLV-132|RNase Fc fusion protein
79969763|NCT03247686|Drug|Placebo|Placebo
79969764|NCT05160324|Procedure|Removal of axillary lymph nodes.|Axillary dissection in patients with positive sentinel lymph node
79969765|NCT05160324|Procedure|Preservation of axillary lymph nodes|Preservation of axillary lymph nodes in patients with positive sentinel lymph node
79969766|NCT03990649|Drug|Soticlestat|Soticlestat tablets
79475679|NCT05452421|Dietary Supplement|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
79640617|NCT02913235|Procedure|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
79475680|NCT05452421|Dietary Supplement|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
79475681|NCT01889563|Other|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
79475682|NCT04608851|Drug|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
79640618|NCT02913157|Drug|Hydroxychloroquine|Orally administered Hydroxychloroquine
79969767|NCT03990649|Drug|Placebo|Soticlestat matching placebo tablets
79307773|NCT02296125|Drug|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
79307774|NCT02296125|Drug|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79475683|NCT04608851|Other|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
79475684|NCT04599491|Device|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
79640619|NCT00150293|Drug|Pregabalin|
79640620|NCT02913118|Drug|Andrographolid Sulfonate Injection (AS Injection)|
79640621|NCT02913118|Drug|Cephalosporin|
79640622|NCT02913118|Drug|Azithromycin, Minocycline or Doxycycline|
79640623|NCT02913118|Drug|Amoxicillin-clavulantic acid|
79640624|NCT02913118|Drug|Fluoroquinolones|
79640625|NCT02913118|Drug|Placebo|
79640626|NCT02913391|Other|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
79969768|NCT01175291|Drug|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + MK-0646 (Investigational).
79969769|NCT01175291|Drug|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
79312611|NCT05465811|Other|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
79312612|NCT02546193|Device|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
79312613|NCT02546193|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
79312614|NCT02538471|Radiation|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
79312615|NCT02538471|Drug|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
79969770|NCT03863717|Other|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
79969771|NCT03863717|Other|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
79984463|NCT03118414|Other|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
79984464|NCT03118414|Other|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
79984465|NCT03203746|Drug|Lycopene + SRP|
79984466|NCT03203746|Procedure|SRP only|
79984467|NCT02447068|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
79984468|NCT02447068|Device|Luma Light|NBUVB light
79312616|NCT05465421|Other|bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation|"Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later"
79312617|NCT01661595|Drug|Sildenafil|50 mg/day for 4 weeks
79312618|NCT01661595|Drug|tadalafil|10 mg/day for 4 weeks.
79805704|NCT00488683|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
79312619|NCT01661595|Drug|Placebo|Placebo 1 capsule per day for four weeks.
79805705|NCT00488683|Biological|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
79805706|NCT00746200|Procedure|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
79805707|NCT00746200|Procedure|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
79984469|NCT02447068|Device|Occlusive Dressing|Off-the-shelf occlusive dressing
79805708|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
79805709|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
79984470|NCT02447146|Other|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
79984471|NCT02447146|Other|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
79312620|NCT02213133|Drug|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
79312621|NCT02146833|Drug|Selinexor|Comparison of different dosages and dosing schedules of drug.
79312622|NCT05445999|Device|High-Definition transcranial electrical stimulation|According to the results of structural phase magnetic resonance and electroencephalogram, four optimal stimulation parameters will be determined.Transcranial electrical stimulation devices (Sorterix)will be used for intervention.In each cycle, the stimulation will be performed every night during weekdays,a total of 10 times.A maximum of four cycles of intervention will be performed for each patient, depending on the efficacy and the their wishes.
79312623|NCT04262661|Drug|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
79312624|NCT04262661|Drug|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
79312625|NCT04262661|Drug|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
79312626|NCT02957097|Drug|Gabapentin|Medication used for management of neuropathic pain conditions
79640627|NCT02913391|Other|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
79312627|NCT02957097|Drug|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
79312628|NCT05443659|Device|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
79312629|NCT02690207|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
79805710|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
79312630|NCT02689349|Device|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
79312631|NCT03165383|Drug|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
79805711|NCT00746434|Drug|Roflumilast cream|Roflumilast cream 0.5%
79805712|NCT00746434|Drug|Placebo cream|Placebo cream
79312632|NCT03165383|Drug|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
79312633|NCT03114839|Dietary Supplement|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of LcS.
79312634|NCT03165539|Device|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
79312635|NCT03162575|Behavioral|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
79805713|NCT02563366|Other|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
79805714|NCT02563366|Other|Saline|Saline is the placebo of MSCs in this study.
79805715|NCT02563132|Procedure|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
79805716|NCT02563288|Drug|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
79805717|NCT02563288|Drug|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
79805718|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
79805719|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
79805720|NCT00711269|Drug|Placebo|
79805721|NCT00711269|Drug|Risperidone|
79805722|NCT01017445|Other|Boonme stick exercise|individual exercise daily
79312636|NCT02679287|Device|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
79312637|NCT05357261|Behavioral|Wellness Check and Socialization|In-home delivery with driver observation and interaction
79312638|NCT05357261|Other|Prepared Meals|Prepared meals compliant with Older Americans Act nutrition programs guidelines
79312639|NCT03162185|Drug|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
79312640|NCT03162185|Drug|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
79312641|NCT03162029|Other|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
79640628|NCT02913079|Behavioral|Sit-stand desk|
79640629|NCT02913079|Behavioral|Sitting desk|
79640630|NCT02912962|Behavioral|Self-Regulation Intervention adapted from the Alert Program ®|
79640631|NCT00150332|Drug|linezolid|
79640632|NCT02913040|Other|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
79312642|NCT02544633|Drug|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
79312643|NCT03162263|Device|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
79312644|NCT02678351|Drug|68Ga-PSMA-11|Undergo 68Ga-PSMA-11 PET/MRI
79312645|NCT02678351|Procedure|Magnetic resonance imaging (MRI)|Undergo 68Ga-PSMA-11 PET/MRI
79312646|NCT02678351|Procedure|Positron Emission Tomography (PET)|Undergo 68Ga-PSMA-11 PET/MRI
79312647|NCT05426265|Device|MEL-T01|A 12 week intervention with MEL-T01.
79312648|NCT05426265|Device|MEL-S01|A 12 week intervention with MEL-S01.
79312649|NCT05286437|Drug|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
79312650|NCT03161717|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
79312651|NCT03161717|Device|Loss of resistance (LOR)|Using loss of resistance technique only
79312652|NCT04440527|Device|Preserflo / Innfocus Microshunt|The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
79312653|NCT04440527|Other|Trabeculectomy|Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
79312654|NCT03161639|Other|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
79312655|NCT05442099|Behavioral|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
79312656|NCT05442099|Behavioral|Generic calm music playlist|Participants listen to the calm music playlist for 30 minutes.
79312657|NCT03161561|Other|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
79312658|NCT05554289|Device|Depression Auxiliary Intervention Treatment Software|Depression Auxiliary Intervention Treatment Software
79312659|NCT03160937|Other|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
79312660|NCT02683187|Drug|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
79475685|NCT04599491|Device|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
79640633|NCT02913040|Other|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
79640634|NCT02912923|Other|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
79640635|NCT02912923|Other|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
79640636|NCT02912884|Drug|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
79805723|NCT01014793|Drug|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
79805724|NCT00286169|Drug|Amrubicin Hydrochloride|
79805725|NCT02697461|Other|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
79805726|NCT02697461|Other|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
79312661|NCT02683187|Drug|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
79312662|NCT05515601|Drug|Mirikizumab|Administered SC.
79805727|NCT00693472|Drug|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
79312663|NCT02683109|Drug|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
79312664|NCT02683109|Drug|Placebo|
79312665|NCT02683109|Drug|Tiotropium|
79312666|NCT02683109|Drug|Olodaterol|
79312667|NCT02544321|Drug|Bromocriptine|
79312668|NCT02544321|Other|Placebo|
79312669|NCT05195723|Drug|WP1122|Oral solution
79312670|NCT05195723|Drug|Placebo|Oral solution
79312671|NCT02533401|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
79475686|NCT05452343|Biological|CM310|600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
79640637|NCT02912728|Behavioral|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
79640638|NCT02912728|Device|Standard CGM|use of CGM alone to assess CGM adherence
79640639|NCT00150371|Drug|atorvastatin|
79312672|NCT02533401|Drug|Fludarabine|Fludarabine will be administered IV at 25 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
79312673|NCT02533401|Drug|Rituximab|Rituximab will be administered IV at 375 mg/m^2 on Day 1 of Cycle 1 and then at 500 mg/m^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
79640640|NCT02912767|Behavioral|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
79640641|NCT02912845|Drug|KamRAB - HRIG|wound infiltration or IM injection
79312674|NCT05497037|Device|PRF stimulation|One time 500 kHZ stimulation for 15 min
79984472|NCT03199456|Device|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
79640642|NCT00407706|Procedure|blood test|
79640643|NCT02912689|Device|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
79640644|NCT02912689|Device|Pressure support ventilation|PS during Non-invasive ventilation
79640645|NCT02912806|Procedure|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
79640646|NCT02912611|Procedure|Education and Protocol based management|
79805728|NCT00693472|Drug|Placebo|Matching placebo capsule administered orally every 12 hours
79805729|NCT00693472|Drug|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
79312675|NCT05497037|Device|Sham stimulation|Sham stimulation for 15 min
79312676|NCT05441709|Behavioral|Ci-BPC with Standard of Care (SOC)|"Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day."
79312677|NCT03164837|Drug|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
79312678|NCT02370927|Other|Control|Non pulse extruded cereal
79640647|NCT02912416|Dietary Supplement|Probiotics|
79640648|NCT02912416|Dietary Supplement|Placebo|
79640649|NCT02912377|Biological|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
79640650|NCT02912494|Drug|JR-131|
79640651|NCT02912494|Drug|Darbepoetin alfa|
79640652|NCT00150410|Drug|Inhaled insulin|
79640653|NCT02912221|Other|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
79640654|NCT02912260|Drug|MGL-3196|
79640655|NCT02912260|Drug|Placebo|
79640656|NCT00171288|Drug|fluvastatin, ezetimibe|
79640657|NCT02912533|Drug|JR-131|
79640658|NCT02912299|Procedure|Skin biopsies|2 3mm skin biopsies will be taken
79640659|NCT02912299|Other|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
79640660|NCT02912299|Other|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
79640661|NCT02912338|Behavioral|Resistant Training|
79640662|NCT02912338|Other|Control Group|
79640663|NCT00163995|Drug|urotensin II|
79640664|NCT00150449|Drug|Pregabalin|
79984473|NCT03199456|Device|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
79984474|NCT03203668|Radiation|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
79984475|NCT02446678|Device|PillCam ESO2|Capsule endoscopy
79984476|NCT03203434|Diagnostic Test|Urinary volatile organic compound analysis|
79984477|NCT02446756|Other|acupuncture|
79984478|NCT02446756|Other|physiotherapy|
79984479|NCT03199534|Drug|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
79984480|NCT03199534|Drug|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
79640665|NCT02912182|Drug|Betamethasone|Betamethasone intravenous
79312679|NCT02370927|Other|Pea protein|Pulse extruded cereal
79312680|NCT02370927|Other|Pea Starch|Pulse extruded cereal
79475687|NCT05452265|Procedure|Endoscopic resection|Complete resection of gastric SETs was recommended if the tumor size was >2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
79475688|NCT04594031|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ >1x10E6/kg)
79640666|NCT02912182|Drug|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
79640667|NCT02912182|Drug|Prednisolone|Oral tablets
79640668|NCT02912026|Drug|IV F901318|Metabolic profile AUC 0 to infinity
79640669|NCT02912026|Drug|Oral F901318|Metabolic profile AUC 0 to infinity
79640670|NCT02911987|Other|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
79640671|NCT02911987|Other|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
79969772|NCT05572008|Behavioral|Protein nutrition in paediatric Crohn's disease|"All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17"
79312681|NCT02370927|Other|Pea fibre + pea starch|Pulse extruded cereal
79312682|NCT02370927|Other|Pea protein + pea starch|Pulse extruded cereal
79312683|NCT02370927|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
79312684|NCT05441475|Drug|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w|All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).
79475689|NCT05452187|Drug|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
79475690|NCT05452187|Drug|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
79640672|NCT00164034|Device|Real time computer prompted trauma algorithms|
79312685|NCT03164915|Biological|LIV-GAMMA SN Inj.|
79312686|NCT05462379|Procedure|Ovarian graft|Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
79312687|NCT04440137|Behavioral|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
79640673|NCT02911870|Drug|SNAC|Oral administration
79640674|NCT02911870|Drug|Placebo|Oral administration
79640675|NCT02911870|Drug|Moxifloxacin|Oral administration
79640676|NCT02892214|Procedure|Pelvic floor physical therapy|
79640677|NCT02892214|Drug|estriol cream (ovestin)|
79640678|NCT02892214|Procedure|Low-level-laser therapy|
79805730|NCT00693472|Drug|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
79640679|NCT02872402|Behavioral|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
79640680|NCT02872402|Behavioral|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
79640681|NCT00164073|Procedure|Liver biopsy|
79969773|NCT03230266|Procedure|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
79969774|NCT03732469|Drug|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
79969775|NCT03732469|Drug|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
79969776|NCT03732469|Drug|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
79969777|NCT01175447|Drug|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
79969778|NCT02519998|Other|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
79969779|NCT01313988|Dietary Supplement|Plant sterols and fish oil|4 weeks intervention, 3 times daily
79640682|NCT02843230|Radiation|Avastin|
79640683|NCT02843230|Radiation|Lomustine|
79640684|NCT02843230|Radiation|Temozolomide|
79640685|NCT02843230|Device|MRI|
79640686|NCT02843230|Device|MRS|
79969780|NCT01313988|Dietary Supplement|Plant sterols|4 weeks intervention, 3 times daily
79969781|NCT01313988|Dietary Supplement|Placebo|4 weeks, 3 times daily
79969782|NCT03743857|Procedure|Manual Therapy|AP ankle mobilization
79969783|NCT03863327|Other|No intervention|There will be no intervention as a part of this protocol.
79969784|NCT03381352|Radiation|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
79969785|NCT03381352|Drug|Capecitabine|Capecitabine 825mg/m2 PO BID
79969786|NCT03381352|Drug|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
79312688|NCT04777565|Other|Robotic surgery|Cochlear implant surgery with HEARO procedure
79312689|NCT02536833|Drug|SM04690|
79312690|NCT02536833|Drug|Placebo|
79312691|NCT02680847|Drug|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
79312692|NCT03164525|Diagnostic Test|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
79312693|NCT03164603|Drug|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
79312694|NCT05146973|Biological|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
79312695|NCT03164213|Device|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
79312696|NCT03164213|Device|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
79969787|NCT05571930|Procedure|Secondary TEVAR after initial FET procedure|Under general anesthesia, via percutaneous femoral access, the investigators implant a TEVAR in the endovascular part of a FET. This secondary connexion is indicated in case distal thoracic aortic involvement such as aneurysm or dissection.
79312697|NCT02532855|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet
79312698|NCT02532855|Drug|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
79312699|NCT02532855|Drug|Metformin|This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
79312700|NCT02532855|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
79312701|NCT02532855|Drug|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
79640687|NCT02843230|Device|DSC|
79640688|NCT02712814|Drug|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
79312702|NCT02532855|Drug|Sulfonylurea|This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
79969788|NCT01175525|Drug|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
79969789|NCT01175525|Drug|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
79969790|NCT05571852|Device|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
79969791|NCT03375190|Other|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
79640689|NCT02712814|Procedure|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
79640690|NCT02712814|Procedure|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
79805731|NCT02697149|Radiation|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
79969792|NCT03375190|Other|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
79969793|NCT03375190|Other|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
79984481|NCT03199534|Drug|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
79984482|NCT03203356|Drug|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
79984483|NCT04280705|Other|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
79984484|NCT04280705|Drug|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
79984485|NCT03199378|Other|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
79475691|NCT05452187|Other|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of <0.05.
79475692|NCT01889797|Biological|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
79969794|NCT03375190|Other|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
79640691|NCT00150527|Drug|Citalopram|40 mg, pill, single dose
79640692|NCT00150527|Drug|Escitalopram|20 mg, pill, single dose
79475693|NCT01889797|Biological|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
79640693|NCT00150527|Drug|Dexamethasone|1 mg, pill, single dose
79640694|NCT00150527|Behavioral|Cold Pressor Test|single test
79640695|NCT02911636|Radiation|Pelvic SABR with intra-prostatic SABR|described elsewhere
79640696|NCT00171327|Drug|valsartan, fluvastatin|
79640697|NCT02911597|Drug|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
79640698|NCT00150566|Drug|Lanthanum carbonate|
79640699|NCT02911441|Behavioral|Cognitive Behavioral Therapy|
79640700|NCT02911363|Device|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
79640701|NCT02911363|Other|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
79640702|NCT02911480|Drug|Oxytocin|
79640703|NCT00171366|Drug|amlodipine/benazepril|
79969795|NCT03375190|Other|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
79640704|NCT00150605|Drug|Extended-release carbamazepine|
79640705|NCT02911207|Behavioral|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
79640706|NCT02911168|Procedure|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
79805732|NCT02697149|Radiation|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
79805733|NCT00622661|Other|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
79805734|NCT00622661|Other|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
79805735|NCT02565238|Device|BioMonitor 2|Implantation of BioMonitor 2
79805736|NCT03882736|Procedure|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
79969796|NCT03375190|Other|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
79969797|NCT03735355|Procedure|Surgery|Surgical resection of fibrostenotic area
79969798|NCT03735355|Procedure|TTS balloon dilation|Dilation of a stricture using TTS balloon
79640707|NCT02911168|Procedure|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
79969799|NCT01175603|Behavioral|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
79312703|NCT05438667|Biological|TCR-T therapy|"1.Preprocessing strategy：~Cyclophosphamide: 500mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 14 days (24 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed ."
79312704|NCT04262427|Drug|Cyclophosphamide 50mg|cytotoxic chemotherapy
79312705|NCT04262427|Drug|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
79640708|NCT02911051|Device|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
79640709|NCT00171405|Drug|aliskiren|
79640710|NCT00150644|Drug|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
79640711|NCT00150644|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
79640712|NCT00150644|Drug|Placebo|Placebo Tablet, oral Daily for 12 weeks
79640713|NCT02910778|Drug|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
79969800|NCT04818424|Device|Soft exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
79969801|NCT04818424|Behavioral|Gait training without exosuits|Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
79969802|NCT03185481|Drug|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
79969803|NCT03185481|Drug|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
79312706|NCT04262349|Behavioral|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
79312707|NCT02530125|Other|Laboratory Biomarker Analysis|Correlative studies
79312708|NCT02530125|Biological|Pidilizumab|Given IV
79312709|NCT05436873|Device|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
79312710|NCT05421819|Dietary Supplement|Calcium and vitamin D supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 plus flavonoids once per day.
79475694|NCT00369551|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
79640714|NCT02910778|Drug|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
79640715|NCT02910778|Drug|Ticagrelor|
79640716|NCT00164112|Drug|Cooperstown 5+1 alone|
79640717|NCT00164112|Drug|Azithromycin plus Cooperstown 5+1|
79640718|NCT00164112|Drug|Telithromycin plus Cooperstown 5+1|
79969804|NCT03185481|Drug|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
79969805|NCT03185481|Drug|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
79475695|NCT00369551|Drug|paclitaxel|Given IV
79475696|NCT00369551|Biological|bevacizumab|Given IV
79475697|NCT00369551|Drug|carboplatin|Given IV
79475698|NCT00369551|Other|laboratory biomarker analysis|Correlative studies
79640719|NCT00164112|Drug|Levofloxacin plus Cooperstown 5+1|
79640720|NCT02910817|Drug|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
79640721|NCT02910817|Other|Placebo|Placebo
79640722|NCT00150683|Device|vibration and passive standing versus passive standing alone|
79640723|NCT02910934|Other|Actellic CS|Indoor residual spray with Actellic CS
79640724|NCT02910505|Device|enLighten Laser|Laser for tattoo removal
79640725|NCT02910622|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
79640726|NCT00171444|Behavioral|Medical education|
79640727|NCT00150722|Drug|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
79805737|NCT00498433|Drug|Aliskiren|300 mg tablet once daily
79640728|NCT02910661|Other|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last ~90 min. and be audio-recorded. An observer will take field notes.
79640729|NCT02910388|Device|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
79640730|NCT02910388|Other|LLETZ without colposcopy|Loop procedure without using a colposcope
79640731|NCT02910427|Other|Regular salt|Participants eat a regular salt diet.
79640732|NCT02910427|Other|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
79475699|NCT01890031|Other|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
79475700|NCT01890031|Other|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
79475701|NCT04537793|Drug|ELX/TEZ/IVA|Fixed dose combination granules for oral administration.
79475702|NCT04537793|Drug|IVA|Granules for oral administration.
79640733|NCT02910427|Other|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
79640734|NCT04687930|Drug|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
79640735|NCT04687930|Drug|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
79640736|NCT00164151|Drug|HalfLytely|
79640737|NCT00164151|Drug|Visicol|
79640738|NCT00150761|Drug|Levocetirizine (drug)|
79805738|NCT00498433|Drug|Amlodipine|5 mg capsule once daily
79640739|NCT00171483|Drug|Tegaserod|
79640740|NCT03777904|Diagnostic Test|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
79640741|NCT03777904|Diagnostic Test|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
79805739|NCT00498433|Drug|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
79805740|NCT00498433|Drug|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
79805741|NCT02565160|Procedure|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
79805742|NCT02565160|Procedure|Joint irrigation washout|Procedural washout for treatment purposes
79640742|NCT03777904|Diagnostic Test|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
79640743|NCT03777904|Diagnostic Test|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
79640744|NCT03759925|Other|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
79640745|NCT00150839|Drug|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
79969806|NCT03185481|Drug|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
79969807|NCT03185481|Drug|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
79969808|NCT03185481|Drug|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
79805743|NCT02565160|Procedure|Total Joint Arthroplasty|
79805744|NCT02565160|Procedure|Revision Joint Arthroplasty|
79640746|NCT00150839|Drug|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
79640747|NCT04723914|Biological|dual target CAR-T cell therapy|CD19/CD20 dual target CAR-T cell therapy
79805745|NCT02689583|Biological|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin > Clarithromycin > Levofloxacin >Tetracycline > Furazolidone > Metronidazole.
79969809|NCT03185481|Drug|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
79969810|NCT03863249|Procedure|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
79640748|NCT00150878|Other|Conditioning therapy|Preparation before allogeneic transplantation
79640749|NCT03782740|Drug|Melatonin 10 mg|Melatonin capsule
79640750|NCT03782740|Drug|Placebo|Sugar pill manufactured to mimic Melatonin capsule
79640751|NCT03782740|Drug|Melatonin 20 mg|Melatonin capsule
79640752|NCT00164190|Procedure|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
79640753|NCT00150917|Behavioral|Supportive-Expressive Group Therapy|
79312711|NCT05421819|Dietary Supplement|Calcium, vitamin D and prebiotic supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
79312712|NCT05421819|Dietary Supplement|Calcium, vitamin D and flavonoid supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
79805746|NCT02689583|Genetic|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
79969811|NCT03863249|Drug|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
79312713|NCT05421585|Other|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
79312714|NCT01661205|Device|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
79312715|NCT05436171|Other|No intervention|No intervention
79312716|NCT02055820|Drug|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
79640754|NCT00164229|Behavioral|math|
79640755|NCT00164229|Behavioral|behavior regulation|
79640756|NCT00150956|Procedure|Daily home hemodialysis|
79640757|NCT00532168|Drug|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
79640758|NCT00532168|Drug|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
79312717|NCT02055820|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
79312718|NCT02055820|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
79805747|NCT02689583|Dietary Supplement|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
79312719|NCT02055820|Drug|Rituximab|Rituximab 375 mg/m^2 dose will be administered IV on Day 1 of every 21-day cycle.
79312720|NCT02055820|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
79312721|NCT02055820|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
79312722|NCT02055820|Drug|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
79312723|NCT04258215|Device|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
79312724|NCT01975233|Device|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
79312725|NCT02055352|Drug|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
79640759|NCT00532168|Drug|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
79640760|NCT00532207|Drug|teriparatide|subcutaneous 20 micrograms
79640761|NCT04723836|Dietary Supplement|Riboflavin (5mg)|From 16th week gestation until end of pregnancy
79640762|NCT04723836|Dietary Supplement|5-methyltetrahydrofolate (400µg)|From 16th week gestation until end of pregnancy
79640763|NCT04723836|Dietary Supplement|Placebo|From 16th week gestation until end of pregnancy
79640764|NCT00150995|Drug|Tetrathiomolybdate|
79640765|NCT00532246|Drug|raloxifene|
79640766|NCT00532246|Drug|Placebo|
79805748|NCT00746746|Biological|HyperAcute vaccine|1.8 mL weekly
79805749|NCT00746746|Drug|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
79805750|NCT00498355|Drug|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
79805751|NCT03439475|Biological|AMG 714|
79805752|NCT02564302|Device|MUSE Headband|MUSE Headband will help patients with mindfulness.
79312726|NCT02055352|Drug|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
79312727|NCT02055352|Drug|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
79640767|NCT00532285|Drug|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
79640768|NCT00164268|Behavioral|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
79640769|NCT00151034|Drug|Trastuzumab|
79640770|NCT00151034|Drug|Paclitaxel|
79312728|NCT02055352|Drug|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
79312729|NCT02034916|Drug|talazoparib|
79640771|NCT00151034|Drug|Carboplatin|
79640772|NCT00151034|Drug|Gemcitabine|
79640773|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
79640774|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
79640775|NCT00171522|Drug|Tegaserod and Polyethylene Glycol 3350|
79640776|NCT05467696|Drug|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
79640777|NCT00151073|Drug|Zoledronic acid|
79640778|NCT00151073|Drug|Estramustine|
79640779|NCT00151073|Drug|Docetaxel|
79640780|NCT05467618|Procedure|Maxillofacial surgery|An incision on the skin over the mandible versus incision on the gingivae inside the mouth
79640781|NCT05467579|Device|Device: orthodontic - mandibular advancement clear aligner|Intervention orthodontic - mandibular advancement: mandibular retrognathia correction with a mandibular advancement using a step-wise approach with clear aligner.
79640782|NCT00171561|Drug|valsartan/hydrochlorothiazide|
79640783|NCT05467540|Device|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
79640784|NCT00151112|Procedure|Positioning and plexus anesthesia|positioning during plexus anesthesia
79640785|NCT05467501|Device|Theraputic ultrasound|Therapeutic ultrasound
79805753|NCT01011595|Procedure|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
79640786|NCT00532324|Other|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
79640787|NCT00171600|Drug|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
79640788|NCT05467384|Drug|Amlodipine|5mg/day in two divided doses
79640789|NCT00151151|Behavioral|Computer-Assisted Motivational Intervention|
79640790|NCT00151151|Behavioral|Didactic Educational Counseling|
79640791|NCT05467267|Procedure|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
79640792|NCT00164307|Behavioral|Parent assisted social skills training|
79640793|NCT05467189|Drug|Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)|As part of routine treatment.
79640794|NCT00151190|Behavioral|Education for diabetes self-management|
79640795|NCT05466760|Radiation|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
79640796|NCT00151229|Other|target blood pressure|
79640797|NCT00171639|Drug|zoledronic acid|
79640798|NCT05466604|Drug|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
79640799|NCT05466604|Drug|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
79640800|NCT00164346|Behavioral|neurocognitive habilitation|
79640801|NCT00151307|Device|INVOS cerebral oximeter|
79805754|NCT01011595|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
79984486|NCT03199222|Device|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
79984487|NCT03203590|Drug|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
79984488|NCT03203590|Drug|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
79640802|NCT04723875|Drug|Paclitaxel or docetaxel + Cisplatin or carboplatin|Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
79640803|NCT05466019|Drug|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
79312730|NCT01374425|Drug|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m^2) by IV bolus and subsequent 2400 mg/m^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
79475703|NCT01949389|Behavioral|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
79640804|NCT05465902|Biological|Recombinant COVID-19 variant Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
79640805|NCT05465902|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
79640806|NCT05465902|Biological|mRNA COVID-19 vaccine (Moderna)|1dose, Intramuscular Injection
79640807|NCT05465902|Biological|Viral Vector COVID-19 vaccine (AstraZeneca)|1dose, Intramuscular Injection
79640808|NCT00151346|Drug|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
79640809|NCT00151346|Drug|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
79805755|NCT01011595|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
79969812|NCT03863249|Diagnostic Test|MICROBIAL SAMPLING|"Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
79312731|NCT01374425|Drug|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
79312732|NCT01374425|Drug|Irinotecan|Irinotecan 180 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
79640810|NCT00164385|Behavioral|Adolescent Impact|
79640811|NCT05465863|Biological|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
79640812|NCT05465785|Biological|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
79312733|NCT01374425|Drug|Leucovorin|Leucovorin 400 mg/m^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
79312734|NCT01374425|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
79312735|NCT01374425|Drug|Capecitabine|Capecitabine 850 or 1000 mg/m^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
79312736|NCT03161015|Drug|GBT440|Oral
79640813|NCT04687462|Device|1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
79969813|NCT03652675|Behavioral|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
79969814|NCT03381118|Drug|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
79969815|NCT03381118|Drug|Nivolumab|Nivolumab 40 mg IV infusion on D+5
79969816|NCT03381118|Drug|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
79969817|NCT03381118|Drug|Nivolumab|Nivolumab 40 mg IV infusion on D+1
79969818|NCT03381118|Biological|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
79969819|NCT03863171|Diagnostic Test|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
79312737|NCT02085460|Drug|Placebo|
79312738|NCT02085460|Drug|2% Rebamipide liquid|
79312739|NCT02085460|Drug|4% Rebamipide liquid|
79312740|NCT03161171|Other|This is an observational study|This is an observational study
79312741|NCT03164291|Drug|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
79312742|NCT02084134|Drug|hydrocortisone|100mg at the time of surgery
79312743|NCT02084134|Drug|dexamethasone|0.5mg every 6 hours for a total of four doses
79312744|NCT03164135|Genetic|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
79312745|NCT03163901|Other|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
79312746|NCT02034058|Device|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
79312747|NCT01374269|Other|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
79640814|NCT00151385|Procedure|single blood draw|
79640815|NCT00164424|Drug|Acyclovir|
79969820|NCT03863171|Diagnostic Test|Fundus fluorescein angiography|Fundus fluorescein angiography test
79969821|NCT03241368|Device|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
79640816|NCT05465746|Diagnostic Test|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
79969822|NCT01286597|Dietary Supplement|dietary restriction|restrict intake of lactose
79640817|NCT05465746|Diagnostic Test|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
79805756|NCT04327271|Behavioral|Text-based VMMC follow-up|2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
79475704|NCT04529291|Other|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
79969823|NCT03220581|Behavioral|Referral for care|referral for addictions support
79475705|NCT04529291|Other|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
79640818|NCT00532519|Drug|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
79805757|NCT02564224|Procedure|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
79805758|NCT02564224|Procedure|Conventional Wound Closure|Procedure: Conventional Wound Closure
79969824|NCT03220581|Behavioral|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
79969825|NCT02954575|Drug|Wilate|
79969826|NCT02997358|Drug|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
79969827|NCT02997358|Drug|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
79640819|NCT04687618|Device|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
79640820|NCT04687618|Device|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
79640821|NCT00171678|Drug|Diclofenac Topical Sodium Gel 1%|
79969828|NCT01175681|Procedure|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
79969829|NCT03375034|Drug|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
79475706|NCT04480307|Drug|temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
79969830|NCT03375034|Drug|NDMC60mg|Oral administration of three NDMC 20mg capsules
79475707|NCT04480307|Drug|temelimab 36 mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
79969831|NCT03375034|Drug|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
79969832|NCT03375034|Drug|Placebo|Oral administration of three Placebo capsules
79969833|NCT03184701|Other|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
79475708|NCT04480307|Drug|temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
79640822|NCT00151463|Drug|sildenafil citrate|
79640823|NCT05465707|Biological|CM313 2 mg/kg|Once 1 week, intravenous infusion.
79640824|NCT05465707|Biological|CM313 4 mg/kg|Once 1 week, intravenous infusion.
79312748|NCT01374269|Drug|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
79312749|NCT03163823|Other|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
79312750|NCT03163823|Other|Standard of Care|Standard of Care communication methods
79312751|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
79312752|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
79312753|NCT03163979|Biological|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
79312754|NCT03163979|Biological|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
79312755|NCT03114761|Radiation|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
79312756|NCT03114605|Behavioral|Mindfulness-based Intervention|
79312757|NCT03160781|Biological|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
79312758|NCT03163745|Procedure|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
79312759|NCT03163589|Drug|Erythropoietin|injection
79312760|NCT03163589|Drug|normal saline|injection
79312761|NCT03163277|Drug|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
79312762|NCT05419817|Drug|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
79312763|NCT05419817|Drug|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
79312764|NCT03160625|Device|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
79312765|NCT03160391|Behavioral|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
79312766|NCT03160391|Behavioral|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
79312767|NCT03163355|Other|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
79312768|NCT05676905|Device|Neocement|Bone graft substitutes
79475709|NCT04480307|Drug|Placebo|Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
79805759|NCT02564224|Device|prolene|
79312769|NCT03163433|Behavioral|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
79312770|NCT05392205|Diagnostic Test|18F-FDG|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.
79312771|NCT02679755|Drug|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
79312772|NCT02679755|Drug|Letrozole|2.5 mg/d tablets orally on a continuous regimen
79475710|NCT05450939|Diagnostic Test|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
79969834|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
79969835|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
79969836|NCT03376204|Other|No intervention|No intervention
79969837|NCT03247530|Drug|Placebo|Placebo was administered once daily
79969838|NCT03247530|Drug|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
79475711|NCT05450861|Other|SF DNA extraction composition|the composition of small fragments of DNA from fish
79969839|NCT03247530|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
79969840|NCT03735277|Biological|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
79969841|NCT01175837|Other|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
79969842|NCT01175837|Other|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
79969843|NCT01175837|Other|laboratory biomarker analysis|Correlative studies
79969844|NCT03381040|Device|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
79969845|NCT03381040|Device|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
79969846|NCT01175915|Other|Western therapy|"Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
79312773|NCT05676671|Procedure|Applications of self-etching adhesives and dental restorations|
79312774|NCT05231759|Device|L'DISQ|
79969847|NCT01175915|Other|Reduning Injection|"Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~Reduning Injection, 0.5~15ml, depending on patient's condition, IV per day, or according to the instruction;~Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
79640825|NCT05465707|Biological|CM313 8 mg/kg|Once 1 week, intravenous infusion.
79640826|NCT05465707|Biological|CM313 16 mg/kg|Once 1 week, intravenous infusion.
79969848|NCT01175915|Other|Reduning Injection plus western therapy|"General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
79969849|NCT03376048|Procedure|Wound infiltration plus TAP|"TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
79475712|NCT05450861|Other|Placebo|the scalp conditioning solution without SF DNA extraction composition
79475713|NCT00369005|Procedure|Red blood cell transfusion guidelines|
79475714|NCT05450783|Other|Biocollection|serum
79475715|NCT05450627|Drug|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
79640827|NCT05465707|Biological|Placebo|Once 1 week, intravenous infusion.
79640828|NCT05462431|Behavioral|Deep relaxation exercises intervention|Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
79640829|NCT00171717|Drug|Cyclosporine - cyclosporine microemulsion|
79640830|NCT05460481|Drug|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
79640831|NCT00151502|Drug|Atorvastatin|
79640832|NCT05451433|Drug|Saccharomyces Boulardii 250 MG|Normagut capsule twice a day
79312775|NCT03163121|Biological|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
79312776|NCT03163121|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
79312777|NCT03163121|Other|Normal Saline|0.9% sodium chloride
79312778|NCT03163121|Biological|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
79312779|NCT03114449|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
79312780|NCT03114449|Device|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
79312781|NCT03114293|Behavioral|Smartphone App|The app includes an EBPI and physical activity feedback
79312782|NCT03114371|Drug|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
79312783|NCT03114371|Drug|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
79312784|NCT03114371|Drug|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
79312785|NCT03162887|Other|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
79640833|NCT05451433|Drug|Placebo|Placebo capsule twice a day
79640834|NCT00164463|Drug|Moxifloxacin|400 mg po qd 5/7 days per week
79312786|NCT03162887|Other|Counseling|Undergo a web-based decision counseling session
79312787|NCT03162887|Other|Informational Intervention|"Receive a next steps document"
79312788|NCT03162965|Other|Oraquick HIV Self Test|This is an oral swab in home HIV test.
79312789|NCT03162965|Other|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
79312790|NCT03163043|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
79312791|NCT03162419|Drug|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
79312792|NCT03162419|Biological|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
79312793|NCT03162419|Biological|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
79312794|NCT04703387|Diagnostic Test|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
79312795|NCT03114215|Drug|MD1003|capsules 100mg 3 times per day
79640835|NCT00164463|Drug|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
79640836|NCT05404360|Device|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
79640837|NCT05404360|Device|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
79312796|NCT03114215|Drug|Placebo oral capsule|capsules 100mg lactose 3 times per day
79312797|NCT04439981|Dietary Supplement|Ice cream|Curcumin extract was added into ice cream
79312798|NCT03374267|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
79312799|NCT04665479|Other|Web-based legacy-making intervention through digital storytelling|A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
79312800|NCT03186989|Drug|IONIS MAPTRx|"Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48 weeks."
79312801|NCT03186989|Other|Placebo|A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks in Part 1. No placebo is given in Part 2.
79312802|NCT05620043|Device|Sculptra|Biostimulator
79640838|NCT00171756|Drug|valsartan/atenolol|
79640839|NCT00406016|Drug|ATI355|
79640840|NCT05392738|Device|I-Stent implantation|I-Stent implantation
79640841|NCT00164502|Behavioral|Community-based eight session group self-management program|
79312803|NCT05620043|Device|Radiesse Plus|Semi-permanent filler
79640842|NCT00406055|Device|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
79640843|NCT00532558|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
79640844|NCT00532558|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
79640845|NCT05386849|Device|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
79969850|NCT03376048|Procedure|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
79969851|NCT03743779|Behavioral|Mastering Diabetes|"The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered."
79312804|NCT03113825|Device|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
79312805|NCT03113825|Drug|AVB-620|AVB-620 will be administered IV before the surgical procedure.
79312806|NCT03113903|Behavioral|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
79475716|NCT05450471|Drug|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
79475717|NCT05450471|Other|Placebo|Placebo
79640846|NCT00171795|Drug|Rivastigmine|
79475718|NCT05437601|Drug|Astaxanthin Oral Capsule|12 mg oral astaxanthin daily for 8 weeks
79640847|NCT00151541|Drug|Dapsone Topical Gel + adapalene gel 0.1%|
79640848|NCT00151541|Drug|Dapsone Topical Gel + benzoyl peroxide gel 4%|
79640849|NCT00151541|Drug|Dapsone Topical Gel + vehicle control|
79640850|NCT05385601|Other|eVOG (Mobile VideoOculoGraphy)|"Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
79640851|NCT05377099|Diagnostic Test|CORVIS|Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.
79969852|NCT03374878|Other|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
79805760|NCT04539223|Drug|Evolocumab|Autoinjector 1-mL deliverable volume of 140 mg/mL
79969853|NCT03374878|Other|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
79475719|NCT05437601|Other|Placebo|Oral placebo identical to astaxanthin
79312807|NCT03113747|Biological|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
79312808|NCT02742935|Biological|camrelizumab|A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)
79312809|NCT02673515|Behavioral|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
79312810|NCT02667275|Drug|A-101 Solution|
79640852|NCT05364268|Device|Diagnostic Test: Diagnostic Software as Medical Device|AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
79640853|NCT04687384|Procedure|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
79312811|NCT02667275|Other|Vehicle Solution|Placebo
79312812|NCT04364789|Drug|TT-00920|Tablets
79312813|NCT04364789|Drug|Placebos|Tablets
79312814|NCT02672423|Drug|Abemaciclib Capsules (Reference Formulation)|Administered orally
79312815|NCT02672423|Drug|Abemaciclib Tablet (Test Formulation)|Administered orally
79312816|NCT04205903|Drug|Nilotinib|Given PO
79312817|NCT04205903|Drug|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
79312818|NCT04205903|Drug|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
79312819|NCT04205903|Other|Placebo|Given PO
79312820|NCT04205903|Other|Questionnaire Administration|Ancillary studies
79312821|NCT05566691|Other|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
79312822|NCT05566691|Other|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
79312823|NCT05566691|Other|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
79312824|NCT05566691|Other|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
79312825|NCT02670551|Drug|Cariprazine|
79312826|NCT02670551|Drug|Placebo|
79312827|NCT01478477|Dietary Supplement|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
79312828|NCT01478477|Other|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
79312829|NCT01478477|Other|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
79312830|NCT01478477|Other|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
79312831|NCT01478477|Procedure|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
79312832|NCT01478477|Procedure|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
79312833|NCT00893399|Drug|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
79640854|NCT04687384|Procedure|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
79640855|NCT00164541|Behavioral|Arts Based Program|
79312834|NCT00893399|Drug|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
79312835|NCT05675267|Other|data collection|HEART score calculation
79312836|NCT04439591|Other|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
79312837|NCT05675033|Drug|Serplulimab and Bevacizumab injection|"Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles."
79312838|NCT02391935|Drug|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
79312839|NCT02391935|Drug|Placebo|Cryomedium
79640856|NCT00164541|Behavioral|Curriculum|
79640857|NCT00151580|Drug|Ribavirin|18 months of oral ribavirin maintenance treatment
79640858|NCT00151580|Drug|Placebo|18 months oral placebo treatment
79640859|NCT00532597|Procedure|On-line hemodiafiltration|
79969854|NCT01285037|Drug|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
79969855|NCT01285037|Drug|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
79312840|NCT02391935|Device|Sham injection|skin penetration of the needle without injection of liquid
79312841|NCT02391779|Dietary Supplement|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
79640860|NCT00532597|Procedure|Low flux hemodialysis|
79969856|NCT01285037|Drug|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
79312842|NCT02391779|Behavioral|Walking training|30-60 minutes walking training, 5 days/week.
79312843|NCT02391779|Behavioral|Flexibility training|5 days/week; e.g. stretching training at home
79312844|NCT02391779|Dietary Supplement|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
79312845|NCT02391779|Behavioral|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
79312846|NCT05545085|Device|Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device|Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
79805761|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
79805762|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
79805763|NCT03382769|Device|Cochlear implantation|Unilateral implantation with a commercially approved Nucleus cochlear implant
79969857|NCT01285037|Drug|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
79312847|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
79312848|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
79312849|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
79805764|NCT00746824|Drug|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
79805765|NCT01011751|Drug|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
79805766|NCT01011751|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
79805767|NCT01011751|Drug|Venlafaxine|Venlafaxine capsule.
79969858|NCT01285037|Drug|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
79969859|NCT03743701|Diagnostic Test|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
79969860|NCT03743701|Diagnostic Test|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
79969861|NCT03380884|Device|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
79475720|NCT05437445|Diagnostic Test|Plasma amino acid assay|Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
79640861|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
79640862|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
79312850|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
79312851|NCT02670473|Device|fanfilcon A (test)|contact lens
79312852|NCT02667119|Behavioral|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
79312853|NCT02667119|Behavioral|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
79640863|NCT00171912|Drug|imatinib mesylate|
79312854|NCT02391389|Procedure|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
79312855|NCT02391233|Behavioral|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
79640864|NCT05338567|Diagnostic Test|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
79640865|NCT05332015|Other|Hypotonic (distilled) water|orally given daily two liters of distilled water
79640866|NCT05332015|Other|Normal water|orally given daily two liters of normal water
79640867|NCT00151619|Drug|Amlodipine|
79640868|NCT00532675|Drug|LBH589|PAN 5 mg and PAN 20 mg capsules
79640869|NCT00532675|Combination Product|Lenalidomide|Lenalidomide 5mg or 25 mg
79640870|NCT00164580|Behavioral|Community-Level Intervention|
79640871|NCT05308030|Drug|Rivaroxaban and Aspirin|After the endovascular intervention, Anticoagulant therapy plus Antiplatelet therapy will be maintained (Aspirin 100 mg once daily and Rivaroxaban 2.5 mg twice daily) for 3 months, and then Aspirin alone indefinitely
79640872|NCT00151658|Device|Coronary Drug Eluting Stents for PCI|
79312856|NCT02391233|Behavioral|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
79805768|NCT01011751|Drug|Leuprorelin|Leuprorelin injection.
79805769|NCT01011751|Drug|Flutamide|Flutamide tablet
79805770|NCT01011751|Drug|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
79475721|NCT04339907|Other|Sampling of tears|Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.
79640873|NCT05300659|Other|Action for Rehabilitation for Neurological Injury (ARNI)|If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
79969862|NCT03441126|Other|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
79969863|NCT01287767|Behavioral|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
79969864|NCT03732391|Drug|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
79969865|NCT03374722|Drug|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
79969866|NCT03246672|Behavioral|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
79969867|NCT01285115|Drug|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
79640874|NCT00164619|Behavioral|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). [see Brief Summary above]
79640875|NCT00164619|Biological|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
79655686|NCT04552756|Diagnostic Test|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
79969868|NCT01285115|Drug|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
79969869|NCT01285115|Drug|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
79969870|NCT03983317|Device|Empower Neuromodulation System|Transcutaneous electrical nerve stimulation
79475722|NCT04339907|Other|Sampling of aqueous humor|Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.
79969871|NCT01285193|Behavioral|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
79969872|NCT03374644|Device|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
79655687|NCT04553029|Other|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
79969873|NCT03207243|Drug|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
79969874|NCT03207243|Drug|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
79969875|NCT03207243|Drug|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
79969876|NCT03207243|Drug|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
79475723|NCT05447975|Other|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
79655688|NCT04552951|Drug|Cholecalciferol|Single doe of 100.000 IU
79969877|NCT01285271|Drug|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
79969878|NCT01285271|Drug|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
79969879|NCT03982069|Biological|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
79969880|NCT03982069|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
79969881|NCT04434586|Device|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
79969882|NCT03863015|Drug|Tocilizumab 20 Mg/mL Intravenous Solution|Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
79969883|NCT03863015|Drug|isotonic saline|A one hour infusion of 100mL isotonic saline
79969884|NCT02937870|Device|Test Product 1|Test adhesive 1 with a thin nozzle
79969885|NCT02937870|Device|Test Product 2|Test adhesive 2 with a thin nozzle
79655689|NCT02213419|Drug|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
79805771|NCT02686619|Drug|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
79805772|NCT02686619|Drug|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
79969886|NCT02937870|Device|Reference Product|Adhesive Cream
79969887|NCT02937870|Other|Negative Control|No adhesive
79969888|NCT03125434|Other|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
79475724|NCT05450315|Behavioral|Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors|
79475725|NCT05450315|Behavioral|Canadian Physical Activity Guidelines|
79655690|NCT00268866|Behavioral|Education|
79655691|NCT00236093|Drug|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
79655692|NCT04552483|Drug|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
79655693|NCT04552483|Drug|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
79655694|NCT02213536|Radiation|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
79655695|NCT00261417|Drug|Tesaglitazar|
79640876|NCT05299957|Diagnostic Test|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
79640877|NCT05293600|Drug|Placebo|Placebo capsule 30 min before bedtime
79640878|NCT05293600|Drug|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
79969889|NCT03375970|Other|TCM|oral chinese herb, chinese topical ointment
79475726|NCT05449925|Procedure|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
79475727|NCT05449847|Biological|Blood Sampling|Blood sampling under a complete aseptic conditions
79640879|NCT05293600|Drug|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
79969890|NCT03375970|Other|Western medicine|oral steroid, oral antihistamine, topical steroid
79969891|NCT03862937|Dietary Supplement|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
79969892|NCT03862937|Other|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
79969893|NCT03743623|Device|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
79969894|NCT03743623|Device|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
79969895|NCT03862703|Device|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
79969896|NCT02519920|Drug|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
79475728|NCT04287101|Other|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
79475729|NCT05449613|Drug|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
79475730|NCT05449613|Other|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
79640880|NCT05293600|Drug|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
79640881|NCT00151697|Drug|Novomix 30|
79969897|NCT02519920|Drug|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
79969898|NCT02519920|Drug|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
79969899|NCT02519920|Drug|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
79640882|NCT00151697|Drug|Novorapid and Amaryl|
79640883|NCT00151697|Drug|Lantus|
79475731|NCT05447429|Procedure|Transversus abdominis plane block|TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
79475732|NCT05447429|Drug|Placebo|20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
79475733|NCT00369083|Procedure|Hospital at home treatment|
79475734|NCT04743557|Drug|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
79475735|NCT05447039|Drug|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
79475736|NCT05446961|Dietary Supplement|LCLT : 68% elemental L-carnitine and 32 % Tartric acid|3 g orally capsules
79640884|NCT00532714|Drug|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
79640885|NCT00164658|Behavioral|Familial risk assessment and personalized prevention messages|
79640886|NCT00532753|Behavioral|Community Empowerment|
79312857|NCT04479527|Drug|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
79312858|NCT02391077|Other|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
79805773|NCT02686619|Drug|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2*500mg tablets or 4*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
79805774|NCT02686619|Drug|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
79805775|NCT02686619|Drug|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
79805776|NCT00688636|Drug|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
79805777|NCT00688636|Drug|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
79805778|NCT00870740|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
79805779|NCT00870740|Drug|Placebo|Placebo SC injection
79805780|NCT02563210|Other|airway resistance measurement|assessment of airway resistance
79312859|NCT02391077|Other|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
79312860|NCT02391077|Other|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
79312861|NCT02391155|Procedure|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
79312862|NCT02391155|Procedure|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
79312863|NCT02390999|Procedure|48 hours of therapeutic hypothermia|
79312864|NCT02390921|Drug|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
79805781|NCT01017523|Behavioral|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
79805782|NCT01017523|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
79805783|NCT02686853|Drug|Liposomal amphotericin B|
79312865|NCT02390921|Drug|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
79805784|NCT02565082|Other|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
79805785|NCT02565082|Other|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
79312866|NCT02390609|Drug|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
79312867|NCT02390609|Drug|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
79312868|NCT02390609|Drug|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
79655696|NCT02213614|Dietary Supplement|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
79312869|NCT02390609|Drug|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
79655697|NCT02213614|Dietary Supplement|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
79655698|NCT02213614|Other|natural spring water|A group will drink natural spring water for 4 months
79655699|NCT02213653|Drug|ARM A : IV iron + epoietin zeta|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
79312870|NCT02390609|Drug|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
79312871|NCT02390609|Drug|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
79805786|NCT02565082|Other|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
79805787|NCT02565082|Other|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
79969900|NCT05666479|Device|Dexcom G6 Pro Continuous Glucose Monitor (CGM)|"A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery."
79969901|NCT01286675|Drug|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
79969902|NCT04525690|Behavioral|Nudge|Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
79969903|NCT04176952|Drug|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
79969904|NCT04176952|Drug|AG|"nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
79805788|NCT02689505|Drug|BI 836880|
79805789|NCT01017679|Drug|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
79969905|NCT05571774|Other|collection data|collection data
79969906|NCT03629041|Device|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
79805790|NCT00743236|Procedure|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
79805791|NCT00743236|Procedure|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
79805792|NCT01017757|Procedure|High-resolution CT scanning|High-resolution CT scanning
79312872|NCT02390687|Drug|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
79312873|NCT02390687|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
79805793|NCT04187339|Biological|NGM395|NGM395 Dose 1
79805794|NCT04187339|Biological|NGM395|NGM395 Dose 2
79805795|NCT04187339|Biological|NGM395|NGM395 Dose 3
79805796|NCT04187339|Biological|NGM395|NGM395 Dose 4
79805797|NCT04187339|Biological|NGM395|NGM395 Dose 5
79805798|NCT04187339|Biological|NGM395|NGM395 Dose 6
79805799|NCT04187339|Other|Placebo|Placebo
79312874|NCT02390843|Drug|Simvastatin|The starting dose of simvastatin will be 140 mg/m^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m^2/dose BID, 225 mg/m^2/dose BID, and 290 mg/m^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
79312875|NCT02390843|Drug|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
79312876|NCT02390843|Drug|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
79805800|NCT00746902|Device|nCPAP|Active nCPAP
79805801|NCT04130672|Procedure|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
79805802|NCT04130672|Procedure|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
79805803|NCT00743314|Other|screening questionnaire administration|
79312877|NCT02390843|Drug|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm^3
79312878|NCT02390375|Drug|DW-0929|5/10mg
79312879|NCT02390375|Drug|DW-0929|10/10mg
79312880|NCT02390375|Drug|DW-0929|20/10mg
79312881|NCT02390375|Drug|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
79312882|NCT02390375|Drug|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
79312883|NCT02390375|Drug|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
79312884|NCT02670083|Drug|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
79312885|NCT02670083|Drug|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
79805804|NCT00743314|Procedure|computed tomography|
79475737|NCT05446961|Drug|Placebo|orally capsules
79312886|NCT02669849|Drug|VX-210|
79640887|NCT05283070|Other|Questionnaires, physical tests, and heart rate variability measures|"The 2MWT will be conducted in an unobstructed hallway with patients being asked to walk at moderate intensity (brisk walk) for the duration of the activity (2 minutes). The amount of distance in metres will be recorded.~The EMLi movement consists of pushing a 2kg weighted ball from the chest level forward, and then raising the ball overhead, before returning it to the starting position (Figure 1). The number of repetitions done at moderate intensity will be recorded after 60 seconds.~HRV and questionnaires previously listed"
79640888|NCT00151736|Drug|Chlorambucil|Chlorambucil 2mg tablets
79312887|NCT02669849|Drug|Placebo|
79475738|NCT05446805|Drug|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for [18F] AV-1451. A PET-certified medical professional will prepare and administer the [18F] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of [18F] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
79475739|NCT05446805|Drug|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for [11C] PIB. A PET-certified medical professional will prepare and administer the [11C] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of [11C] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
79475740|NCT05446649|Other|dry needling|the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
79475741|NCT05446649|Other|instrumented assisted soft tissue mobilization|the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
79312888|NCT02390141|Drug|ZP4207|
79312889|NCT02390141|Drug|Placebo|
79640889|NCT00151736|Drug|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
79640890|NCT00171990|Drug|Famciclovir|
79312890|NCT03836963|Behavioral|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
79312891|NCT03836963|Behavioral|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
79640891|NCT05242939|Other|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
79640892|NCT05242939|Other|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
79805805|NCT00743314|Procedure|lymphoscintigraphy|
79805806|NCT00743314|Procedure|single photon emission computed tomography|
79805807|NCT00743314|Radiation|intensity-modulated radiation therapy|
79805808|NCT00743314|Radiation|technetium Tc 99m sulfur colloid|
79969907|NCT03629041|Device|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
79969908|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
79312892|NCT03836963|Behavioral|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
79312893|NCT03836963|Behavioral|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
79312894|NCT03806309|Drug|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m^2, irinotecan 180 mg/m^2, 5-FU bolus 400 mg/m^2 and continuous infusion 2,400 mg/m^2
79312895|NCT03806309|Drug|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
79312896|NCT03781583|Device|No HMD used|Participants will use their existing mobility skills and strategies to navigate toward a goal. If the participant cannot perform this task, the participant will not be forced to.
79312897|NCT03781583|Device|HMD worn but not active|Participants will wear the HMD, but the HMD will not be active. This will test whether or not the HMD physical components obscure the participants remaining vision and reduce the participants ability to navigate toward a goal.
79969909|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
79969910|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
79312898|NCT03781583|Device|HMD worn and active|Participants will wear the HMD and the HMD will be active. This will test the HMD function for navigation toward a goal.
79475742|NCT05446649|Other|conventional therapy|patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
79475743|NCT05446415|Other|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
79312899|NCT03758105|Other|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
79312900|NCT03758105|Other|Usual care|Medication and psychotherapy as prescribed in usual care
79312901|NCT03741023|Procedure|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
79312902|NCT03489629|Drug|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if < 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
79640893|NCT00164697|Behavioral|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
79640894|NCT04725578|Behavioral|Telehealth Single Session Consultation|A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
79640895|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
79640896|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
79969911|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
79969912|NCT04171570|Procedure|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
79969913|NCT03735043|Device|cardiac output by ccNexfin ©|Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
79969914|NCT03860363|Device|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
79969915|NCT03219723|Drug|Vonoprazan|Vonoprazan tablets
79969916|NCT03219723|Drug|Amoxicillin hydrate|Amoxicillin hydrate (potency)
79312903|NCT03489629|Drug|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if < 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
79640897|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
79640898|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
79640899|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
79640900|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
79969917|NCT03219723|Drug|Clarithromycin|Clarithromycin (potency)
79969918|NCT03219723|Drug|Metronidazole|Metronidazole
79640901|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
79312904|NCT03489629|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
79312905|NCT03489629|Drug|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
79805809|NCT02686541|Device|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
79312906|NCT03489629|Behavioral|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
79640902|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
79640903|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
79640904|NCT00532792|Biological|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
79640905|NCT04687423|Drug|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
79805810|NCT02686463|Procedure|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
79312907|NCT02388503|Dietary Supplement|no added fruit extract|
79312908|NCT02388503|Dietary Supplement|fruit extract|
79312909|NCT02388503|Dietary Supplement|fruit extract|
79312910|NCT02388503|Dietary Supplement|fruit extract|
79312911|NCT02388503|Dietary Supplement|fruit extract|
79312912|NCT05345015|Device|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
79312913|NCT05345015|Device|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
79312914|NCT05231291|Other|hand grip strength|Observational study
79312915|NCT04479293|Other|Post COVID-19 Functional Satus Scale|scale from 0-64 assessing functional limitation
79475744|NCT05448365|Dietary Supplement|Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol|The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
79475745|NCT05448365|Dietary Supplement|Placebo|Maltodextrines
79475746|NCT05448053|Procedure|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
79475747|NCT04728347|Biological|ARCT-021|ARCT-021 single dose
79805811|NCT02686463|Procedure|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
79805812|NCT00639899|Procedure|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
79312916|NCT02389751|Drug|Carboplatin|Given IV
79312917|NCT02389751|Drug|Ganetespib|Given IV
79312918|NCT02389751|Drug|Paclitaxel|Given IV
79312919|NCT02389751|Radiation|Radiation Therapy|Undergo radiation therapy
79312920|NCT04740047|Diagnostic Test|Ion Endoluminal System|Robotic bronchoscopy with c-arm imaging.
79312921|NCT02390063|Biological|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
79312922|NCT02390063|Biological|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
79312923|NCT02390063|Drug|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
79312924|NCT02388113|Behavioral|accumulated exercise|
79312925|NCT02388113|Behavioral|traditional exercise|
79312926|NCT02389673|Device|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
79312927|NCT02388035|Drug|Cefotaxime|
79312928|NCT02387723|Biological|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
79312929|NCT02389439|Drug|Pyronaridine-artesunate|
79475748|NCT03183791|Behavioral|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
79312930|NCT02663687|Drug|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
79312931|NCT02663687|Drug|Placebo|Subjects will receive matching placebo
79312932|NCT02663687|Drug|SHP623|SHP623
79312933|NCT02663687|Drug|Placebo|Placebo
79312934|NCT02389205|Other|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
79312935|NCT02387645|Procedure|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
79312936|NCT02388971|Drug|MLN1202|MLN1202 solution
79312937|NCT02388971|Drug|Placebo|MLN1202 placebo-matching solution
79312938|NCT03113591|Procedure|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
79475749|NCT03183791|Behavioral|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
79475750|NCT04713995|Other|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in ~3 months survey after following recommendations.
79475751|NCT03175523|Device|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
79312939|NCT03113591|Procedure|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
79312940|NCT03106025|Device|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
79312941|NCT03106025|Other|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
79312942|NCT02663453|Drug|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
79312943|NCT02663453|Drug|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
79312944|NCT02387489|Behavioral|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
79312945|NCT02387489|Behavioral|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
79969919|NCT03375814|Drug|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
79312946|NCT05225207|Other|Non-interventional|No intervention will be administered.
79312947|NCT02055118|Biological|idursulfase-IT|10mg
79312948|NCT02055118|Other|No IT treatment|Standard of Care
79312949|NCT04439825|Drug|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
79312950|NCT04439825|Drug|Placebo|Saline solution (preservative free)
79312951|NCT04439747|Other|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
79312952|NCT02388581|Drug|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
79312953|NCT02387411|Other|High-intensity interval exercise training|High-intensity interval exercise training [4 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)]
79969920|NCT03375814|Drug|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
79969921|NCT03866213|Diagnostic Test|BiliSpec|BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
79475752|NCT03175523|Device|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
79475753|NCT04687553|Diagnostic Test|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
79969922|NCT03628417|Procedure|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
79312954|NCT02387411|Other|Combined exercise training|High intensity [2 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
79969923|NCT03628417|Procedure|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
79312955|NCT02387333|Procedure|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
79312956|NCT02387333|Procedure|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
79312957|NCT02387567|Drug|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
79312958|NCT02387567|Drug|Sham Lidocaine|Sham injection, without lidocaine.
79312959|NCT02387567|Other|Standard treatment|Standard treatment only, without lidocaine or sham injection.
79475754|NCT03034421|Behavioral|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
79475757|NCT02971787|Dietary Supplement|Probiotics|Day 1-21: 2 capsules per day
79475758|NCT02971787|Dietary Supplement|Salt|Day 8-21: 10 tablets à 600 mg per day
79969924|NCT03375736|Device|whole body vibration|The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
79312960|NCT02387177|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
79312961|NCT02387177|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
79312962|NCT02389127|Device|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
79312963|NCT02383121|Drug|Midodrine|Not appliciable
79312964|NCT02387021|Procedure|Continuous femoral nerve block|
79969925|NCT04948905|Other|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
79312965|NCT02387021|Procedure|Continuous adductor canal block|
79312966|NCT02387021|Procedure|infragluteal Sciatic nerve block|
79312967|NCT02387021|Drug|Ropivacaine 0.2%|
79312968|NCT02387021|Drug|Saline|
79312969|NCT02386943|Drug|Sitagliptin|100mg po once.
79475759|NCT00370799|Drug|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
79805813|NCT00869024|Biological|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
79312970|NCT02386943|Drug|Saxagliptin|5mg po once.
79312971|NCT02386943|Drug|Blank control|No medication is taken.
79312972|NCT02084056|Drug|Linagliptin|Linagliptin
79312973|NCT02084056|Drug|Metformin|Metformin
79312974|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
79312975|NCT02386787|Device|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
79312976|NCT02386631|Device|Custom Made Orthotic|Provides longitudinal arch support
79312977|NCT02383277|Other|Stretching|Stretching of the rib cage muscles
79312978|NCT02383277|Other|Control|Rest without stretching (sham)
79312979|NCT02383277|Other|Exercise|Constant load exercise on a bike
79640906|NCT04687189|Device|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
79805814|NCT02685449|Drug|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
79969926|NCT03369964|Drug|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
79969927|NCT03369964|Drug|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
79475760|NCT00370799|Drug|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
79475761|NCT00370799|Drug|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
79640907|NCT00406094|Drug|montelukast|10mg
79805815|NCT02685449|Drug|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
79475762|NCT00370799|Drug|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
79475763|NCT04593953|Procedure|TLIP|Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
79475764|NCT04738253|Diagnostic Test|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
79640908|NCT00406094|Drug|placebo|placebo
79640909|NCT00532870|Other|laparoscopic|
79805816|NCT02685449|Drug|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
79805817|NCT00697034|Drug|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
79475765|NCT05445089|Drug|Carvacrol|Carvativir 6 mg/ml diluted for oral solution.
79475766|NCT05445089|Other|Control group|Placebo
79640910|NCT00164736|Drug|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
79640911|NCT00164736|Drug|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
79640912|NCT00164736|Dietary Supplement|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
79640913|NCT05163730|Device|COVID-19/ Flu A&B Rapid Panel|Rapid Diagnostic Device
79805818|NCT00506779|Drug|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
79805819|NCT00506779|Drug|Paclitaxel|175 mg/m^2 by vein over 3 Hours every 21 Days
79805820|NCT02689193|Other|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
79805821|NCT02616458|Other|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
79969928|NCT03369964|Drug|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
79969929|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
79312980|NCT02382887|Procedure|tracheal intubation|tracheal intubation with the Airtraq
79969930|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
79312981|NCT02382887|Device|Airtraq|
79312982|NCT02382887|Device|fiberscope|
79312983|NCT02386397|Drug|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
79312984|NCT02386397|Drug|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
79312985|NCT02386475|Other|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
79969931|NCT03375658|Other|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
79969932|NCT02525705|Biological|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
79312986|NCT02386475|Drug|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
79312987|NCT02386475|Drug|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
79312988|NCT02382731|Behavioral|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
79312989|NCT02382731|Behavioral|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
79312990|NCT02386163|Biological|MSC from synovial membrane and infrapatellar Fat Pad|
79312991|NCT02386241|Other|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
79312992|NCT02382653|Drug|oral perixicam|Oral adminstration of buccal perixicam
79312993|NCT02386085|Procedure|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
79312994|NCT02382809|Drug|DC071|Mouthwash, twice daily
79312995|NCT02382809|Drug|Placebo|Mouthwash, twice daily
79312996|NCT02382263|Drug|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
79969933|NCT03184077|Procedure|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
79969934|NCT03184077|Procedure|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
79969935|NCT03245736|Drug|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
79969936|NCT03369886|Diagnostic Test|Optical Coherence Tomography Angiography (OCTA)|The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
79969937|NCT03375411|Device|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
79969938|NCT01173809|Drug|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
79969939|NCT01173809|Drug|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
79969940|NCT03375580|Dietary Supplement|TLC|transform life custom (TLC)
79969941|NCT03375580|Drug|metformin|0.5g metformin group，PO tid
79969942|NCT03375580|Drug|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
79969943|NCT03375580|Drug|Simvastatin|20mg simvastatin, PO qn
79969944|NCT01286831|Drug|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
79969945|NCT02855710|Other|Rhythm workers training Perceptive timing|Perceptive timing training
79969946|NCT02855710|Other|Rhythm workers training sensorimotor timing|Sensorimotor timing training
79969947|NCT02855710|Other|No Rhythm workers training|No training
79969948|NCT01286909|Dietary Supplement|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
79312997|NCT02382263|Drug|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
79312998|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
79312999|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
79313000|NCT02386007|Drug|DW-3101_150mg|
79313001|NCT02386007|Drug|DW-3101_300mg|
79313002|NCT02386007|Drug|DW-3101_600mg|
79313003|NCT02386007|Drug|Placebo|
79313004|NCT02382419|Drug|carrageenan-containing gel|Applied vaginally
79313005|NCT02382419|Other|Placebo|Applied vaginally
79313006|NCT02382419|Other|Laboratory Biomarker Analysis|Correlative studies
79313007|NCT02382419|Other|Questionnaire Administration|Ancillary studies
79313008|NCT02382341|Device|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
79313009|NCT02382185|Other|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
79313010|NCT02382185|Drug|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
79313011|NCT02382185|Device|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
79313012|NCT02382107|Other|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
79313013|NCT02385851|Drug|CHS-1701|
79969949|NCT02954887|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
79313014|NCT02385851|Drug|Pegfilgrastim|
79313015|NCT02385773|Dietary Supplement|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
79313016|NCT02385773|Dietary Supplement|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
79313017|NCT02385929|Behavioral|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
79313018|NCT02385695|Procedure|Posterior Dynamic Stabilization|
79313019|NCT02385695|Procedure|Internal Fixation and Fusion|
79313020|NCT02382029|Drug|Clonazepam|Active medical treatment for burning mouth syndrome
79313021|NCT02382029|Other|acupuncture|Traditional chinese acupuncture
79475767|NCT00370877|Drug|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
79475768|NCT00370877|Procedure|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
79475769|NCT04515953|Drug|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
79640914|NCT05142046|Drug|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
79640915|NCT00532909|Drug|Vandetanib|100mg or 300mg By mouth every day continuous
79969950|NCT03183063|Device|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
79969951|NCT03183063|Device|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
79475770|NCT04515953|Drug|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
79475771|NCT00370955|Procedure|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
79640916|NCT00532909|Drug|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
79640917|NCT00532909|Drug|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
79969952|NCT03183063|Device|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
79984489|NCT02446522|Procedure|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
79475772|NCT02665247|Behavioral|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
79805822|NCT02616458|Other|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
79475773|NCT02665247|Other|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
79475774|NCT02661971|Drug|Docetaxel|Docetaxel 50 mg/m², d1
79475775|NCT02661971|Drug|Oxaliplatin|Oxaliplatin 85 mg/m², d1
79475776|NCT02661971|Drug|Calciumfolinat|Leucovorin 200 mg/m², d1
79475777|NCT02661971|Drug|5-Fluorouracil|5-FU 2600 mg/m², d1
79475778|NCT02661971|Biological|Ramucirumab|Ramucirumab 8mg/kg, d1
79805823|NCT02685371|Behavioral|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
79805824|NCT01017913|Other|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
79969953|NCT05155722|Drug|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
79640918|NCT00532909|Drug|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
79640919|NCT00172068|Drug|Zoledronic acid + Calcium/Vitamin D|
79640920|NCT00151931|Drug|Lanthanum carbonate|
79640921|NCT05119816|Other|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
79640922|NCT05117164|Other|enteral feeding as per predefined protocol|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
79640923|NCT05095987|Procedure|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
79805825|NCT01017913|Other|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
79805826|NCT02619968|Other|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
79969954|NCT03860129|Drug|Isoflurane|Group A: Isoflurane (0.5 MAC)
79475779|NCT01949545|Drug|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
79475780|NCT05442905|Drug|propofol|Anesthesia will be induced with propofol 2-3mg/kg
79475781|NCT05442905|Drug|Atracurium Besylate|Atracurium 0.15mg/kg used for muscle relaxation before intubation
79640924|NCT00151970|Drug|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
79640925|NCT00151970|Drug|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
79640926|NCT00151970|Drug|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
79640927|NCT05077501|Drug|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
79640928|NCT05077501|Drug|Placebo|Placebo oral solution
79640929|NCT05075317|Behavioral|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
79640930|NCT05075317|Behavioral|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
79655700|NCT02213653|Drug|ARM B: IV iron + epoietin zeta sequence|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~carboxymaltose ferric (Ferinject ®) at week 1~Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
79655701|NCT02213653|Drug|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
79655702|NCT02213731|Other|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
79655703|NCT00268944|Biological|Myozyme|20 mg/kg qow
79805827|NCT00639977|Other|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
79805828|NCT00639977|Other|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
79969955|NCT03860129|Drug|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
79969956|NCT03860129|Drug|Desflurane|Group C: Desflurane (0.5 MAC)
79313022|NCT02385539|Drug|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
79313023|NCT02385461|Drug|Low Molecular Weight Heparins (LMWHs)|
79640931|NCT05074771|Device|ARC intellicare|ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
79640932|NCT00152048|Drug|Eflornithine hydrochloride|
79805829|NCT04130360|Behavioral|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
79805830|NCT01017991|Other|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
79640933|NCT03457246|Other|D-Pigment rich texture|
79640934|NCT03457246|Other|Hydrance optimale riche|
79640935|NCT05062876|Drug|AD-214|1 tablet administered before the breakfast during 7 days
79805831|NCT01017991|Other|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
79805832|NCT04185233|Other|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
79313024|NCT02381717|Other|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
79805833|NCT04185233|Drug|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
79805834|NCT04130048|Diagnostic Test|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
79313025|NCT02381717|Drug|bupivacaine|
79313026|NCT02381717|Drug|morphine|
79475782|NCT05442905|Drug|sevoflurane|sevoflurane(1%-2%) used during anesthesia
79475783|NCT00369863|Drug|Triamcinolone acetonide|
79805835|NCT00639431|Behavioral|direct observation|direct observation of another person's foot moving
79475784|NCT04338425|Behavioral|Voice call|Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
79475785|NCT04338425|Behavioral|Video call|Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
79640936|NCT05062876|Drug|AD-2141|1 tablet administered before the breakfast during 7 days
79640937|NCT00152087|Device|Brachytherapy|
79640938|NCT04687111|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
79475786|NCT01949779|Device|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
79475787|NCT01890343|Drug|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
79475788|NCT01890343|Drug|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
79640939|NCT04687111|Drug|Valsartan|Valsartan is an Angiotensin Receptor Blocker
79640940|NCT00532987|Behavioral|Questionnaire|Questionnaire form to be completed by patient
79313027|NCT02381951|Device|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
79313028|NCT02381639|Behavioral|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
79313029|NCT02385383|Drug|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
79313030|NCT02385383|Other|Standard Care|Standard Care in a historical control cohort
79313031|NCT02385305|Device|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
79313032|NCT02385227|Other|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
79313033|NCT02385227|Other|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
79313034|NCT02385227|Other|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
79313035|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
79969957|NCT03374098|Behavioral|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
79313036|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
79313037|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
79969958|NCT03374098|Behavioral|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
79313038|NCT02385227|Other|Nicotine product cessation C|Nicotine cessation
79313039|NCT02385149|Other|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
79313040|NCT02385149|Other|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
79313041|NCT02381171|Device|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
79475789|NCT02588027|Drug|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
79640941|NCT00164775|Drug|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
79969959|NCT05240703|Device|Stabilization splint treatment|The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
79313042|NCT02381171|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
79313043|NCT02381171|Device|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
79313044|NCT02381171|Device|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
79313045|NCT05003687|Drug|Lu AG06474|solution, orally (Parts A and B)
79313046|NCT05003687|Drug|Placebo|solution, orally (Part A only)
79313047|NCT02381327|Device|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
79640942|NCT00164775|Drug|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
79805836|NCT00639431|Behavioral|mental visualization|mentally imagining moving one's phantom foot/feet
79313048|NCT03113669|Behavioral|CBT-GSH|
79313049|NCT02381483|Other|Cold exposure|
79475790|NCT02588027|Drug|Placebo|Pharmacy formulated placebo
79805837|NCT04130282|Biological|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
79475791|NCT05441189|Procedure|Resection|radical R0 resection of pancreatic adenocarcinoma
79805838|NCT00488293|Procedure|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
79805839|NCT02614430|Other|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
79969960|NCT03865901|Diagnostic Test|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
79475792|NCT01894087|Behavioral|TBI - Cohort 1|
79475793|NCT01894087|Behavioral|TBI - Cohort 2|
79475794|NCT04449965|Drug|Povidone-iodine|This will be performed twice daily for two weeks.
79475795|NCT04449965|Drug|Placebo|This will be performed twice daily for two weeks.
79969961|NCT03369808|Biological|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
79475796|NCT05433389|Behavioral|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
79475797|NCT05433389|Behavioral|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
79475798|NCT05433389|Behavioral|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
79640943|NCT00533026|Drug|Duloxetine|
79313050|NCT02385071|Drug|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
79640944|NCT00533026|Drug|Warfarin|
79805840|NCT04185077|Drug|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
79475799|NCT05433389|Behavioral|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
79640945|NCT00152126|Procedure|Stem Cell Transplantation|Autologous stem cell transplantation
79805841|NCT04185077|Drug|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
79805842|NCT04527965|Other|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
79805843|NCT04527965|Other|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
79805844|NCT04527965|Other|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
79805845|NCT01018069|Drug|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
79805846|NCT02686307|Procedure|ICD Implant|Implantation of an implantable cardioverter/defibrillator
79805847|NCT02686385|Drug|Prednisolone|
79805848|NCT02686385|Drug|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
79969962|NCT03369808|Biological|Phosphate Buffer Solution|0.5ml phosphate buffer solution
79969963|NCT03369808|Biological|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
79969964|NCT03369808|Biological|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
79969965|NCT03369808|Biological|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
79475800|NCT05433389|Behavioral|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
79640946|NCT00152126|Drug|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
79969966|NCT03734575|Device|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
79969967|NCT04630626|Device|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
79640947|NCT05043883|Device|CathVision Cube® system|Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
79805849|NCT04417777|Genetic|Blood Test|Blood analysis
79805850|NCT02686151|Drug|Letrozole|used after oocyte retrieval
79805851|NCT02686151|Drug|Polygeline|used after oocyte retrieval
79805852|NCT02686151|Drug|Sodium Chloride|used after oocyte retrieval
79805853|NCT02686151|Drug|dexamethasone|used after oocyte retrieval
79805854|NCT00868790|Drug|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
79805855|NCT00868790|Drug|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
79805856|NCT00868790|Drug|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
79805857|NCT00868790|Drug|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
79969968|NCT01178255|Drug|homeopathic q-potencies|individualised homeopathic medicines
79969969|NCT01178255|Drug|Placebo|placebo
79969970|NCT01178255|Other|homeopathic case history taking type I|one special homeopathic technique for case history taking
79969971|NCT01178255|Other|homeopathic case history type II|another type of homeopathic case history taking
79969972|NCT03374020|Device|Notal OCT|Imaging using Notal OCT
79969973|NCT03182829|Diagnostic Test|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
79969974|NCT03363724|Other|HaGuide version 1.0 software module|
79969975|NCT02525237|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
79475801|NCT05431673|Drug|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
79805858|NCT00496483|Drug|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
79805859|NCT00496483|Drug|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
79805860|NCT00697580|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
79969976|NCT02525237|Drug|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
79969977|NCT03369652|Behavioral|Medication review|Conducted by the pharmacist and discussed with hospital physician
79969978|NCT01173887|Drug|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
79969979|NCT01173887|Biological|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
79969980|NCT04524052|Drug|DWRX2003|Intramuscularly injection at pre-defined injection sites
79969981|NCT04524052|Drug|Placebo|Intramuscularly injection at pre-defined injection sites
79969982|NCT02525159|Dietary Supplement|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
79969983|NCT02525159|Other|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
79969984|NCT03373942|Other|Choroidal thickness measurements with SD-OCT device|
79475802|NCT05431673|Drug|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
79475803|NCT05431673|Drug|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
79475804|NCT01951651|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
79969985|NCT03865823|Procedure|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
79969986|NCT03369574|Drug|Reslizumab|reslizumab administration
79969987|NCT03278028|Drug|A-101 Topical Solution|A-101 Topical Solution
79969988|NCT03278028|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
79969989|NCT01176149|Behavioral|SMBG plus intensive education|
79969990|NCT02651740|Drug|Rifaximin|400mg tid* 3d
79969991|NCT02651740|Procedure|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
79969992|NCT03862547|Diagnostic Test|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
79969993|NCT03181503|Drug|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
79969994|NCT03181503|Drug|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
79969995|NCT03363568|Behavioral|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
79805861|NCT00697580|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
79640948|NCT05039593|Other|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
79640949|NCT00425451|Drug|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
79640950|NCT00152165|Procedure|Radiostereometric Analysis beads inserted during surgery|
79640951|NCT05001451|Biological|GDX012 Suspension for IV Infusion|"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"
79640952|NCT00152204|Drug|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
79640953|NCT00152204|Drug|IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
79640954|NCT00533065|Drug|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
79805862|NCT00697580|Behavioral|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
79640955|NCT04686877|Procedure|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
79805863|NCT04403893|Other|HANARO biliary stent placement|HANARO biliary stent placement
79640956|NCT00152243|Drug|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
79640957|NCT00152243|Procedure|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
79969996|NCT03363568|Behavioral|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
79969997|NCT03277794|Behavioral|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
79640958|NCT00172107|Drug|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
79640959|NCT00172107|Drug|placebo|placebo powder for subcutaneous injection
79640960|NCT00172107|Drug|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
79805864|NCT02614352|Drug|Atorvastatin + Candesartan|
79805865|NCT02614352|Drug|AG1502|
79805866|NCT02616536|Other|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
79805867|NCT02619890|Other|Brain Glioma Registry|
79805868|NCT01018147|Procedure|4-dimensional computed tomography|Undergo 4-D CT imaging
79805869|NCT04133246|Behavioral|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
79805870|NCT04133246|Behavioral|Individual interview|Interview led by the psychologist about the patient's parenthood
79805871|NCT01018225|Drug|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
79805872|NCT01018225|Drug|Placebo|Placebo pill, once a day, for six weeks
79475805|NCT01951651|Drug|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
79640961|NCT00172107|Drug|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
79475806|NCT02466581|Drug|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
79475807|NCT02466581|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
79805873|NCT00698438|Device|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
79805874|NCT00698438|Procedure|Trabeculectomy|standard trabeculectomy
79475808|NCT02466581|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
79640962|NCT04945837|Other|self administered questionnaire|longitunidal descriptive study
79640963|NCT04686955|Drug|Xiao-Xian-Gui-Fu-Tang|The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
79805875|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
79805876|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
79805877|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
79805878|NCT01018303|Dietary Supplement|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
79805879|NCT03996343|Device|Endotracheal intubation|COMPLETE
79640964|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
79805880|NCT03996343|Device|Laryngeal mask airway|COMPLETE
79805881|NCT00487981|Device|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
79805882|NCT01014949|Other|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine [140 ug/kg/min] to induce steady state maximal hyperemia."
79313051|NCT02385071|Drug|Treatment B|Treatment B (3*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
79313052|NCT02385071|Drug|Treatment C|Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions).
79313053|NCT02385071|Drug|Treatment D|*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions.
79475809|NCT02466581|Biological|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
79805883|NCT02685137|Drug|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
79805884|NCT02685137|Other|Sham Injection|nothing
79969998|NCT03277794|Behavioral|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
79313054|NCT02385071|Drug|Treatment E|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
79475810|NCT01951963|Drug|Ketamine|
79475811|NCT01951963|Drug|Morphine|
79475812|NCT02377271|Drug|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
79475813|NCT02377271|Drug|placebo|treatment by bosentan or placebo is randomized
79475814|NCT01894555|Drug|Aspirin|81 mg daily for 4 weeks
79805885|NCT01015027|Biological|REGN668|4 IV Cohorts (Dose 1, 2, 3, & 4)
79805886|NCT01012063|Drug|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
79805887|NCT01012063|Drug|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
79313055|NCT02385071|Drug|Treatment F|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
79313056|NCT02381405|Dietary Supplement|Enterade beverage|
79313057|NCT02381093|Other|Modified BLS course|BLS using CI
79313058|NCT02381093|Other|Standard BLS Course|Usual BLS teaching
79313059|NCT02384681|Other|Exposure to auditory fatigue|12-hour auditory exposure
79313060|NCT02384915|Drug|prilocaine|
79313061|NCT02384915|Drug|mepivacaine|
79313062|NCT02384915|Procedure|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
79313063|NCT02384915|Procedure|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
79313064|NCT02384915|Device|Sonoplex, Pajunk|
79805888|NCT02689115|Other|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
79805889|NCT00861744|Biological|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
79313065|NCT04875377|Dietary Supplement|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
79313066|NCT04875377|Dietary Supplement|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
79805890|NCT00861744|Biological|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
79475815|NCT02330471|Procedure|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
79475816|NCT02330471|Procedure|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
79313067|NCT04875377|Dietary Supplement|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
79313068|NCT04875377|Dietary Supplement|Control capsule|Empty capsules (placebo)
79475817|NCT04421495|Drug|Delamanid|the eligible patients will be give damanid-containing regimen
79475818|NCT01895647|Device|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
79475819|NCT02034461|Device|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
79475820|NCT01896115|Device|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
79475821|NCT01953211|Drug|combined oral contraceptives|
79805891|NCT00861744|Biological|Varivax®|Subcutaneous injection, one dose
79969999|NCT03862391|Drug|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
79805892|NCT00861744|Biological|Havrix®|Intramuscular injection, one dose
79805893|NCT00861744|Biological|Prevnar®|Intramuscular injection, one dose
79805894|NCT00638417|Behavioral|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
79805895|NCT00638417|Behavioral|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
79970000|NCT03862391|Drug|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
79970001|NCT03369496|Other|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
79970002|NCT03862313|Device|active-rtACS treatment|For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
79970003|NCT03862313|Device|sham-rtACS treatment|For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
79805896|NCT02685059|Drug|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
79970004|NCT03363490|Behavioral|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
79970005|NCT03363490|Behavioral|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
79970006|NCT03363490|Behavioral|Health education|All four groups of patient will receive two times of health education in the first week.
79970007|NCT02509702|Behavioral|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
79970008|NCT03859583|Dietary Supplement|Capsaicin|4 tsp of cayenne in a breakfast omelette
79970009|NCT03859583|Dietary Supplement|Control|breakfast omelette without cayenne pepper
79313069|NCT04733495|Other|Counseling|Receive group-based behavioral counseling
79475822|NCT02028221|Drug|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
79475823|NCT02028221|Drug|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
79640965|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
79805897|NCT02685059|Drug|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
79805898|NCT02685059|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
79970010|NCT03369262|Drug|OBE022|Oral
79970011|NCT03369262|Drug|Placebos|Oral
79970012|NCT03369262|Drug|Atosiban|I.V.
79970013|NCT03862235|Diagnostic Test|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
79640966|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
79640967|NCT00152282|Drug|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
79805899|NCT02685059|Drug|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
79805900|NCT02685059|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
79970014|NCT03862235|Diagnostic Test|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
79313070|NCT04733495|Behavioral|Dietary Counseling and Surveillance|Receive dietary counseling
79313071|NCT04733495|Other|Quality-of-Life Assessment|Ancillary studies
79313072|NCT04733495|Other|Questionnaire Administration|Ancillary studies
79475824|NCT02987569|Behavioral|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
79640968|NCT04916041|Device|Cataract surgery with bilateral implantation of the same type of intraocular lens|Cataract surgery with bilateral implantation of the same type of intraocular lens
79640969|NCT00152321|Behavioral|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
79805901|NCT00640055|Other|Coordinator|Coordinator (non-physician) assigned cause of death
79475825|NCT02987569|Behavioral|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
79640970|NCT00152321|Behavioral|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
79640971|NCT00152321|Other|Usual Care|
79640972|NCT04914364|Other|Balance assessments|There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
79640973|NCT00164853|Procedure|endoscopic balloon dilatation|Refer to description under arms
79640974|NCT00164853|Procedure|Standard sphincterotomy|Refer to under arms
79805902|NCT00640055|Other|Physician-assigned cause of death|Physician (gold standard) cause of death
79805903|NCT00603239|Drug|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
79805904|NCT00603239|Drug|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
79970015|NCT03276078|Drug|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
79640975|NCT04687150|Other|Fecal microbiota transplantation|Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
79640976|NCT04687150|Other|Colored water|Colored water (placebo)
79805905|NCT00700986|Drug|AZD9056|Oral tablet, 800mg, one single administration
79805906|NCT00700986|Drug|Placebo|Single dose
79970016|NCT01288547|Dietary Supplement|theobromine|700 mg theobromine in gelatin capsules given one time only
79475826|NCT05735197|Drug|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
79475827|NCT05735197|Drug|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
79640977|NCT00152360|Drug|Orlistat|See Detailed Description.
79805907|NCT04119726|Behavioral|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
79970017|NCT01288547|Dietary Supplement|Caffeine|120 mg caffeine in capsules given one time only
79640978|NCT00533104|Procedure|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
79640979|NCT00533104|Procedure|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
79640980|NCT00164892|Drug|Oral Vioxx (Rofecoxib)|
79640981|NCT00533143|Other|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
79805908|NCT04119726|Behavioral|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
79970018|NCT01288547|Dietary Supplement|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
79970019|NCT01288547|Dietary Supplement|placebo|cellulose in capsules given one time only
79970020|NCT03180801|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
79970021|NCT03180801|Biological|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
79970022|NCT03180801|Other|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
79970023|NCT03373864|Procedure|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
79970024|NCT03373864|Procedure|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
79970025|NCT03373786|Drug|RG012|RG012 in 0.3% sodium chloride
79970026|NCT01176227|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
79970027|NCT01176227|Dietary Supplement|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
79970028|NCT04597320|Drug|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
79970029|NCT04597320|Drug|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
79475828|NCT00370097|Drug|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
79640982|NCT04686994|Drug|ASC 41|Oral tablets
79970030|NCT04597320|Drug|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
79970031|NCT03373708|Drug|Epirubicin|100mg/m2
79970032|NCT03373708|Drug|Cyclophosphamide|600mg/m2
79970033|NCT03373708|Drug|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
79970034|NCT03373708|Drug|Goserelin acetate|3.6mg every month
79970035|NCT03373708|Drug|Tamoxifen|10mg twice daily oral
79970036|NCT03373708|Drug|Letrozole|2.5mg every daily oral
79970037|NCT01173965|Device|MEA|Microwave endometrial ablation device
79970038|NCT01173965|Device|Novasure|Bipolar impedence control system
79970039|NCT03363412|Device|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
79970040|NCT03363334|Drug|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
79970041|NCT03363334|Drug|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
79970042|NCT03742271|Device|senofilcon A|TEST Lens
79970043|NCT03214224|Device|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
79313073|NCT04733495|Other|Resistance Training|Undergo personalized resistance exercises
79313074|NCT04872101|Drug|Delgocitinib cream|Cream for topical application
79313075|NCT04872101|Drug|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
79313076|NCT02384837|Device|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
79313077|NCT03113357|Other|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
79313078|NCT03113357|Other|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
79313079|NCT03105791|Other|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
79313080|NCT02384291|Device|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
79475829|NCT00370097|Drug|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
79805909|NCT04119726|Behavioral|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
79313081|NCT02384291|Device|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
79313082|NCT04729439|Behavioral|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
79313083|NCT04729439|Device|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
79313084|NCT03105947|Other|Coconut oil|50g extravirgin coconut oil daily for four weeks
79313085|NCT03105947|Other|Butter|50g butter daily for four weeks
79313086|NCT03105947|Other|Olive oil|50g extra virgin olive oil daily for four weeks
79313087|NCT03105869|Diagnostic Test|fluorocholine PET/CT|standard diagnostic PET/CT procedure
79475830|NCT01897285|Device|AQUACEL® foam adhesive dressing|
79475831|NCT00370253|Drug|Terlipressin|1mg/4 h per day
79313088|NCT02380937|Procedure|ablation for typical atrial flutter|ablation for typical atrial flutter
79313089|NCT02380937|Device|Vision Ablation Catheter|
79313090|NCT02384369|Drug|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
79313091|NCT02380547|Other|Sonographic diaphragmatic measurements|
79475832|NCT00370253|Drug|Noradrenalin|0,1 mcg/kg/min
79475833|NCT01800539|Behavioral|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
79475834|NCT04412525|Device|vitrectomy (27G gauge or larger needle)|vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
79475835|NCT01618565|Procedure|Hands-On Training|one-time, 30 minute hands-on training
79475836|NCT01618565|Procedure|Demonstration|30 minutes passive training
79640983|NCT04686994|Drug|ASC 41 Placebo|Oral tablets
79640984|NCT02938117|Other|cycling exercises|
79805910|NCT04119882|Diagnostic Test|Blood collection|New biomarker test
79475837|NCT01491815|Drug|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
79475838|NCT01491815|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
79640985|NCT00152399|Drug|Somatostatin UCB (drug)|
79805911|NCT04186715|Device|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
79640986|NCT02277145|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
79805912|NCT00699114|Drug|Placebo|Lactose as powder in gelatine capsules, single dose
79970044|NCT03214224|Device|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
79805913|NCT00699114|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
79805914|NCT00699114|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
79805915|NCT00699114|Drug|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
79970045|NCT03123562|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
79970046|NCT05280353|Other|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
79970047|NCT03369184|Drug|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
79970048|NCT03369184|Other|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
79970049|NCT01174277|Other|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
79640987|NCT02938078|Device|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
79640988|NCT02938039|Device|Ambu LMA|Ambu Laryngeal Mask Airways
79640989|NCT02938039|Device|I-Gel LMA|I-Gel Laryngeal Mask Airways
79805916|NCT00699114|Drug|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
79805917|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
79805918|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
79805919|NCT00639587|Drug|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
79805920|NCT00639587|Drug|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
79805921|NCT00700518|Drug|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
79805922|NCT00700518|Drug|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
79970050|NCT03123952|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
79970051|NCT03865745|Dietary Supplement|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
79970052|NCT03373630|Device|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
79970053|NCT03180645|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
79475839|NCT01491815|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
79640990|NCT02938234|Dietary Supplement|High caloric, high protein ONS|
79805923|NCT00700518|Drug|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
79640991|NCT02938000|Device|Theraband with exercise video|Theraband exercise band for resistance training
79805924|NCT00700518|Drug|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
79805925|NCT00700518|Drug|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
79970054|NCT03180645|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
79970055|NCT03180645|Other|No treatment|No treatment
79475840|NCT01491815|Biological|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
79475841|NCT04359953|Drug|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
79475842|NCT04359953|Drug|Azithromycin|Azithromycin 2 x per day during 14 days
79475843|NCT04359953|Drug|Telmisartan|Telmisartan 2 x per day during 14 days
79640992|NCT02938000|Other|usual care with advice to exercise|advice to exercise
79640993|NCT00164931|Drug|Intravenous omeprazole infusion|
79640994|NCT00164931|Procedure|Scheduled second endoscopy|
79640995|NCT00152438|Drug|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
79805926|NCT00852930|Procedure|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
79805927|NCT00852930|Procedure|laser alone|The intervention is therapist administered laser
79805928|NCT00852930|Procedure|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
79805929|NCT00852540|Drug|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
79970056|NCT03124030|Procedure|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
79970057|NCT03750695|Behavioral|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
79970058|NCT03750695|Behavioral|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
79805930|NCT00852540|Drug|Linezolid|Adult and adolescent (=>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects <5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
79970059|NCT03750695|Behavioral|Rest|40 minutes of quiet rest in semi-recumbent position
79475844|NCT01470677|Drug|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
79475845|NCT05364515|Drug|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
79805931|NCT00701142|Biological|Haemocomplettan® P|Single intravenous infusion
79475846|NCT05364515|Drug|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
79475847|NCT01438073|Drug|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
79475848|NCT01438073|Drug|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
79475849|NCT04334369|Device|Proclear Single Vision Contact Lenses manufactured by CooperVision|FDA approved single vision contact lenses.
79475850|NCT04334369|Device|Proclear Multifocal Contact Lenses manufactured by CooperVision|FDA Approved Multifocal Contact Lenses
79970060|NCT02519530|Behavioral|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
79313092|NCT02384525|Procedure|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
79475851|NCT05295095|Procedure|positive pressure during extubation procedure|positive pressure during extubation procedure
79475852|NCT05454917|Device|Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)|Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
79640996|NCT00152438|Other|Placebo|3 identical placebo pills daily, no active ingredient.
79640997|NCT02937961|Biological|Early SLED|withing 6 to 12 hours
79640998|NCT02937961|Biological|Late SLED|when absolute indications will meet
79640999|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
79641000|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using standard care bougie|After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
79641001|NCT02937922|Other|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
79655704|NCT04721093|Device|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
79655705|NCT04552444|Drug|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
79970061|NCT05010213|Other|Educational intervention|Educational intervention
79970062|NCT03373474|Other|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
79970063|NCT03373474|Other|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
79641002|NCT02937922|Other|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
79641003|NCT02937922|Other|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
79641004|NCT00164970|Dietary Supplement|Vitamin B12|
79970064|NCT02518906|Behavioral|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
79641005|NCT00164970|Dietary Supplement|folate|
79970065|NCT02518906|Behavioral|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
79970066|NCT02519608|Drug|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
79970067|NCT02519608|Drug|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
79970068|NCT02519608|Drug|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
79970069|NCT03699930|Device|tDCS|Anodal or sham tDCS will be applied to the scalp.
79970070|NCT03699930|Behavioral|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
79970071|NCT03363178|Biological|GC3107|BCG Vaccine, 0.1mL
79970072|NCT05181852|Drug|IP2015, dose 1|Active
79970073|NCT05181852|Drug|IP2015, dose 2|Active
79655706|NCT04552600|Drug|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
79805932|NCT00701142|Biological|Saline solution|Single intravenous infusion
79970074|NCT05181852|Drug|Placebo|Placebo
79970075|NCT05181852|Drug|Pregabalin|Comparator
79970076|NCT03373396|Diagnostic Test|Blood samples|Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
79970077|NCT04584684|Other|Saline|Saline placebo rinse
79970078|NCT04584684|Drug|1.5% w/v Hydrogen Peroxide|Over-the-counter antiseptic mouth rinse
79970079|NCT04584684|Drug|0.12% Chlorohexidine Gluconate|Dentist prescribed antimicrobial mouth rinse
79655707|NCT04552600|Other|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
79655708|NCT04552561|Behavioral|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
79970080|NCT04584684|Drug|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
79313093|NCT02384525|Procedure|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
79313094|NCT02384603|Other|Global postural reeducation|
79313095|NCT02384603|Other|Segmental muscle stretching exercises|
79313096|NCT02384603|Other|Cognitive behavioral therapy|
79313097|NCT02384135|Other|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
79313098|NCT02380625|Drug|Azithromycin|Adults (>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to <18 yrs): 30mg/kg (oral suspension) daily for 5 days
79805933|NCT00861198|Other|ERCP as per medical indication|ERCP as per medical indication
79805934|NCT00847704|Device|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
79805935|NCT02613702|Procedure|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
79970081|NCT04584684|Drug|0.5% w/v Povidone-iodide|Over-the-counter antiseptic mouth rinse
79970082|NCT04584684|Drug|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
79970083|NCT03369106|Other|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
79970084|NCT03369028|Other|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
79641006|NCT04725461|Device|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
79313099|NCT02380625|Drug|Sunitinib and Erlotinib|Sunitinib - Adults (>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to <18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to <20kg): 3.5 mg/kg daily for 7 days; Children (>20kg to <30kg): 3.0 mg/kg daily for 7 days; Children (>30kg to < 18 yrs): 25 mg/kg daily for 7 days
79641007|NCT02937844|Biological|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
79641008|NCT02937844|Drug|Cyclophosphamide|250 mg/m^2, d1-3
79970085|NCT03373318|Drug|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
79970086|NCT03373318|Drug|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
79313100|NCT02380625|Drug|Atorvastatin and Irbesartan|Atorvastatin - Adults (>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to <18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to <18 yrs): 1 x 75mg tablet daily until discharge.
79313101|NCT02380625|Other|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
79970087|NCT03124420|Drug|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
79970088|NCT03124420|Drug|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
79313102|NCT02383979|Device|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
79313103|NCT02383979|Device|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
79313104|NCT02380313|Drug|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
79313105|NCT02380313|Drug|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
79313106|NCT02380313|Drug|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
79970089|NCT03124420|Drug|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
79313107|NCT02380313|Drug|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
79313108|NCT02380157|Drug|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
79313109|NCT02380157|Drug|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
79641009|NCT02937844|Drug|Fludarabine|25mg/m^2, d1-3
79641010|NCT02937883|Other|Empowerment intervention|Empowerment intervention for persons with young onset dementia
79475853|NCT05454761|Behavioral|Group-based Lifestyle Medicine Program|Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.
79475854|NCT00371033|Drug|Pregabalin|dosage
79641011|NCT02937727|Device|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
79641012|NCT00172263|Procedure|blood sampling|
79641013|NCT00152555|Behavioral|Physical Therapy or Relaxation Therapy|
79475855|NCT00371033|Drug|Placebo|dosage
79475856|NCT00371111|Drug|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
79475857|NCT00371111|Drug|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
79313110|NCT02380235|Biological|PEG-somatropin|0.20mg/kg/w
79313111|NCT02380235|Biological|PEG-somatropin|0.12mg/kg/w
79475858|NCT00371189|Drug|Placebo|Normal saline.
79475859|NCT00371189|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
79475860|NCT05286203|Device|Metagenomic Deep Sequencing (MDS)|MDS is an RNA-seq based testing of ocular fluid or tissue to identify potential infectious pathogens including bacteria, fungi, parasites, and DNA and RNA viruses.
79475861|NCT05286203|Diagnostic Test|Standard of Care (SOC)|SOC includes any available diagnostic tests, such as Gram stain, cultures, PCRs, that are considered the appropriate testing based on the clinical findings.
79475862|NCT05275361|Behavioral|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
79475863|NCT05242523|Other|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
79475864|NCT05242523|Other|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
79641014|NCT02937805|Device|Moisturizing vaginal and vulvar sea buckthorn oil cream|
79641015|NCT02937805|Device|Moisturizing vaginal and vulvar cream|
79641016|NCT02937610|Procedure|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
79970090|NCT03231228|Drug|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to <60 kg
79970091|NCT03231228|Drug|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
79970092|NCT01176383|Genetic|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
79970093|NCT03363100|Behavioral|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
79970094|NCT03363022|Drug|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
79475865|NCT05233943|Device|Spinal Mouse and Digital Inclinometer|"The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded."
79641017|NCT02937532|Behavioral|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
79641018|NCT02937532|Behavioral|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
79641019|NCT02937493|Behavioral|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
79641020|NCT02937415|Procedure|Breath carbon monoxide|Breath carbon monoxide measurement.
79641021|NCT02937415|Procedure|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
79641022|NCT02937415|Procedure|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
79641023|NCT00165009|Device|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
79641024|NCT00152594|Drug|voriconazole|
79641025|NCT02937337|Device|Laryngeal mask insertion with videostylet guided technique|
79641026|NCT02937337|Device|Laryngeal mask insertion with standard blind technique|
79970095|NCT03363022|Other|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
79475866|NCT05229887|Procedure|Nostril-Tragus-Length|"Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear."
79641027|NCT02937220|Procedure|monolithic zirconia crown|New crown material used as final restoration for dental implants
79641028|NCT02937220|Procedure|metal ceramic crown|Conventional crown material used as final restoration for dental implants
79641029|NCT02937259|Other|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
79970096|NCT03363022|Other|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
79641030|NCT00407199|Drug|quetiapine|
79641031|NCT02937298|Dietary Supplement|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
79641032|NCT02937298|Dietary Supplement|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
79805936|NCT02613702|Procedure|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
79805937|NCT02613702|Procedure|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
79475867|NCT05229887|Procedure|Vocal cord marking|The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.
79641033|NCT02937298|Dietary Supplement|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
79641034|NCT02937298|Dietary Supplement|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
79805938|NCT00701298|Biological|peginterferon alfa-2b|Given SC
79805939|NCT00701298|Drug|decitabine|Given IV
79805940|NCT00701298|Other|laboratory biomarker analysis|Correlative studies
79805941|NCT00860574|Drug|treosulfan|Given IV
79641035|NCT02937103|Biological|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
79641036|NCT02936908|Other|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
79641037|NCT00172302|Drug|vitamin C, intravenous injection|
79641038|NCT00152633|Drug|Losartan|
79805942|NCT00860574|Drug|fludarabine phosphate|Given IV
79805943|NCT00860574|Radiation|total-body irradiation|Low dose starting at 2Gy
79805944|NCT00860574|Procedure|peripheral blood stem cell transplantation|Given IV per institutional standard practice
79805945|NCT00860574|Drug|tacrolimus|Given IV or PO
79805946|NCT00860574|Procedure|allogeneic bone marrow transplantation|Given IV per institutional standard practice
79805947|NCT00860574|Procedure|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
79641039|NCT00152633|Drug|Metoprolol|
79641040|NCT00152633|Drug|Losartan|Treatment with Losartan
79805948|NCT00860574|Drug|methotrexate|Given IV
79805949|NCT00496015|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
79970097|NCT01178645|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
79805950|NCT00496015|Biological|Infanrix hexa.|1 intramuscular injection.
79805951|NCT00496015|Biological|Meningococcal vaccine GSK134612.|1 intramuscular injection.
79805952|NCT00496015|Drug|Paracetamol.|Body weight of < 7 kg: none; Body weight of ≥ 7 kg to < 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
79805953|NCT01018381|Procedure|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
79313112|NCT02380469|Behavioral|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
79313113|NCT01625182|Drug|Fingolimod|Fingolimod 0.5 mg capsules
79313114|NCT01625182|Drug|Placebo Comparator|Matching placebo capsules
79313115|NCT02383901|Drug|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
79641041|NCT02937181|Drug|Ceftaroline|IV Ceftaroline will be given for 72 hours
79313116|NCT02383823|Drug|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
79313117|NCT02383823|Other|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
79313118|NCT02380001|Drug|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
79313119|NCT02380001|Drug|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
79313120|NCT02384057|Other|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
79313121|NCT02384057|Other|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
79313122|NCT02383745|Other|Acute EEG with fast EEG electrode|
79313123|NCT04799717|Behavioral|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
79313124|NCT02379767|Device|Electroconvulsive therapy|
79313125|NCT02379767|Other|Positron emission tomography of the brain using [11C]harmine|
79641042|NCT02937025|Device|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
79641043|NCT00425490|Drug|sitagliptin|
79970098|NCT03674892|Device|TrueTear™ intranasal neurostimulator (ITN)|Subject will place the tips of the ITN into both nostrils simultaneously. Subject will be asked to apply it for 3 minutes [could be modified if need be], daily.
79313126|NCT02379767|Other|Structural magnetic resonance imaging|
79313127|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
79313128|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
79970099|NCT02525315|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
79475868|NCT05454683|Dietary Supplement|melatonin plus zinc|One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
79475869|NCT05454683|Other|isomaltose and magnesium stearate|One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
79970100|NCT05181774|Diagnostic Test|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
79970101|NCT05181774|Diagnostic Test|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
79970102|NCT03368872|Other|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
79970103|NCT03368872|Other|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
79313129|NCT02383511|Drug|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
79313130|NCT02661815|Drug|Paclitaxel|Please see arm/group description.
79475870|NCT04175249|Other|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
79313131|NCT02661815|Drug|Ricolinostat|Please see arm/group description.
79313132|NCT02661815|Drug|Bevacizumab|Please see arm/group description.
79313133|NCT02379845|Device|NBTXR3|One intratumor implantation by injection
79313134|NCT02379845|Device|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
79313135|NCT02379689|Drug|Injectable placental tissue extract called BioDGenesis (Active Product)|
79313136|NCT02379689|Drug|Placebo|
79313137|NCT02377193|Drug|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
79313138|NCT02377193|Drug|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
79313139|NCT02053792|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
79313140|NCT02379455|Other|Comprehensive drug review|1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
79313141|NCT02379533|Other|Aerobic exercise|
79313142|NCT02377115|Other|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
79641044|NCT02936674|Device|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
79641045|NCT02936674|Device|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
79641046|NCT02936713|Other|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
79641047|NCT00172341|Drug|Staloral TM|
79641048|NCT03457753|Drug|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
79475871|NCT04146857|Other|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
79475872|NCT04146857|Other|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
79475873|NCT04146857|Other|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
79475874|NCT05186051|Drug|ZYIL1 capsule|NLRP3 inflammasome inhibitor
79475875|NCT04707521|Behavioral|3M tape ship-shaped combined with strap fixing method|During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
79641049|NCT03457714|Behavioral|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
79641050|NCT03457714|Other|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
79641051|NCT02936830|Drug|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
79641052|NCT02936830|Drug|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
79475876|NCT04145453|Behavioral|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
79641053|NCT02936830|Drug|Glycerol|Glycerol with water in a 1: 1 ratio
79641054|NCT00165048|Drug|Vioxx (Rofecoxib)|
79641055|NCT04756414|Behavioral|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
79970104|NCT03368872|Other|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
79970105|NCT01178723|Dietary Supplement|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
79970106|NCT04525768|Diagnostic Test|JAK2 mutation test|Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
79641056|NCT00152711|Device|nCPAP|
79970107|NCT01174355|Drug|ND0801|Confidential
79970108|NCT03213366|Behavioral|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
79970109|NCT03213366|Behavioral|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
79970110|NCT04525924|Device|bright light therapy|please see arm description
79970111|NCT01285505|Drug|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
79970112|NCT01285505|Drug|alprazolam test sublingual tablet|0.5 mg tablet, single dose
79970113|NCT01285583|Drug|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
79641057|NCT04690270|Drug|Sumatriptan 100 mg|Single dose Sumatriptan 100 mg
79970114|NCT04525612|Diagnostic Test|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
79641058|NCT04690153|Other|Patients with three vertical Hayman Sutures|Patients who are referred to our clinic due to postpartum hemorrhage between the ages of 18-45 and who need to undergo a surgical procedure (not responding to medical treatment) due to abnormal uterine bleeding in our clinic will be included. Patients with a previously known diagnosis of bleeding and coagulation disorders will not be included in the study. Considering that we are one of the primary referral centers in Istanbul in terms of deliveries and post-partum bleeding in our hospital, it is aimed to terminate the study with approximately 50 participants.
79641059|NCT00165087|Drug|asparaginase (E. Coli)|
79970115|NCT04523896|Radiation|Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy|"- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian)."
79475877|NCT04145453|Behavioral|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
79475878|NCT04145453|Behavioral|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
79475879|NCT05454059|Procedure|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
79475880|NCT05454059|Diagnostic Test|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
79475881|NCT05454059|Other|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
79641060|NCT00165087|Drug|asparaginase (Erwina)|
79641061|NCT00165087|Drug|dexrazoxane|
79641062|NCT00165087|Drug|doxorubicin|
79641063|NCT00165087|Procedure|cranial radiation (once daily fractionation)|
79641064|NCT00165087|Procedure|cranial radiation (twice-daily fractionation)|
79970116|NCT01287299|Other|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
79475882|NCT05454059|Other|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
79475883|NCT05454059|Diagnostic Test|HbA1c Level|Measurement of HbA1c levels from blood tests
79970117|NCT01287299|Other|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
79641065|NCT00165087|Procedure|Intrathecal chemotherapy without radiation|
79641066|NCT02936518|Procedure|Lingual frenotomy and/or maxillary labial frenectomy|
79641067|NCT00152750|Drug|APO-clonidine|
79641068|NCT02936362|Other|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
79641069|NCT02936362|Other|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
79641070|NCT02936557|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-054)"
79313143|NCT04356287|Biological|UCMSC|Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
79313144|NCT04356287|Other|Placebo|Each infusion will consist of 50 mL of PlasmaLyte A.
79313145|NCT04688021|Drug|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
79641071|NCT02936401|Behavioral|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
79641072|NCT02936245|Other|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
79641073|NCT00152789|Procedure|Oxygen measurement - Eppendorf machine|
79641074|NCT02936128|Other|TruSkin|
79641075|NCT02936128|Other|Wound Cover|
79641076|NCT02936284|Behavioral|Music Enhancement|
79805954|NCT01018381|Procedure|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
79970118|NCT03637140|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
79313146|NCT04688021|Drug|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
79313147|NCT04688021|Drug|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
79313148|NCT04688021|Drug|Me-CCNU|250mg/m2 once administered orally on day -3.
79313149|NCT04688021|Drug|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
79313150|NCT04688021|Drug|Tocilizumab|8mg/kg administered IV on day -1.
79641077|NCT02936284|Behavioral|Play Date|
79970119|NCT03637140|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
79313151|NCT04688021|Procedure|Allogeneic HSCT|Day 0
79313152|NCT04688021|Drug|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
79313153|NCT04688021|Drug|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
79313154|NCT04688021|Drug|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
79313155|NCT02082340|Behavioral|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
79313156|NCT02082340|Other|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
79641078|NCT02936167|Biological|Ringer Lactate|
79805955|NCT01018381|Procedure|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
79970120|NCT03372850|Drug|HIP1601|Test Drug
79970121|NCT03372850|Drug|HGP1705|Reference Drug
79313157|NCT02082340|Other|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
79313158|NCT02082340|Behavioral|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
79641079|NCT02936167|Biological|Plasmalyte|
79641080|NCT00152828|Drug|Celecoxib|
79641081|NCT02935933|Drug|bupivicaine|Paravertebral block
79641082|NCT02935933|Drug|morphine|
79641083|NCT02935933|Drug|Dexmedetomidine|
79641084|NCT02936011|Device|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
79641085|NCT02935777|Dietary Supplement|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
79641086|NCT02935777|Dietary Supplement|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
79641087|NCT00152867|Drug|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
79805956|NCT01018381|Procedure|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
79805957|NCT01018381|Dietary Supplement|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
79313159|NCT02082340|Behavioral|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
79313160|NCT04349969|Drug|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
79313161|NCT04349969|Drug|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
79313162|NCT04712968|Behavioral|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
79475884|NCT05139095|Drug|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO [etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
79475885|NCT05139095|Drug|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO [etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine]; or EMA/EP [etoposide, methotrexate and actinomycin-D/etoposide, cisplatin]; or FAEV [floxuridine, actinomycin-D, etoposide, vincristine]). The observation period is 21 days.
79641088|NCT02935816|Radiation|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
79805958|NCT01018381|Drug|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
79805959|NCT00487825|Drug|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
79805960|NCT00487825|Drug|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
79805961|NCT00487825|Drug|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
79641089|NCT02935972|Drug|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
79641090|NCT02935972|Drug|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
79641091|NCT02935972|Drug|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
79641092|NCT02935855|Drug|Dabigatran|
79641093|NCT02935855|Drug|Apixaban|
79641094|NCT02935855|Drug|Rivaroxaban|
79641095|NCT02935855|Drug|Edoxaban|
79641096|NCT02935855|Drug|Warfarin|
79641097|NCT02935855|Drug|Acenocumarole|
79970122|NCT01178879|Behavioral|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
79313163|NCT04327505|Drug|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
79970123|NCT04525066|Drug|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
79313164|NCT02053246|Drug|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
79313165|NCT02053168|Device|Resorbable Mesh|Phasix Mesh
79313166|NCT02379299|Device|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
79313167|NCT02379299|Device|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
79313168|NCT03112967|Other|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
79313169|NCT03112967|Other|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
79475886|NCT05453669|Biological|CD19-CAR-DNT cells|Lentiviral vector-transducted DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
79970124|NCT04525066|Other|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
79475887|NCT04108247|Drug|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
79475888|NCT01955473|Drug|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
79970125|NCT01178957|Other|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
79475889|NCT05453435|Drug|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 12 months after completing CD20 monoclonal antibody therapy.
79970126|NCT03362788|Drug|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
79970127|NCT03362788|Drug|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
79970128|NCT03859505|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
79313170|NCT02379065|Device|The Aerogen Aeroneb Solo©|
79313171|NCT02379065|Device|Phillips Respironic© mask|
79475890|NCT05453279|Combination Product|Delcetravir dry powder inhaler|Placebo dry powder inhaler
79641098|NCT00152906|Procedure|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
79641099|NCT04702555|Drug|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
79313172|NCT02377037|Other|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
79475891|NCT05453123|Behavioral|telerehabilitation|examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
79475892|NCT03029845|Drug|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
79475893|NCT03029845|Drug|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
79475894|NCT03029845|Drug|Placebo|Participants will take placebo twice a day for 2 weeks
79641100|NCT02935504|Behavioral|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~Engage clinic leaders and staff~Identify leadership group and prepare for change~Assess readiness to implement PRISM~Identify steps to achieve goals~Implement PRISM components into the clinic~Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
79970129|NCT03859505|Device|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
79970130|NCT03368794|Behavioral|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
79970131|NCT03368794|Behavioral|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
79641101|NCT02935504|Behavioral|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
79641102|NCT02935582|Drug|Enstilar® aerosol foam|Treatment according to local labelling
79475895|NCT05451719|Drug|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
79475896|NCT05451719|Drug|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
79475897|NCT01955629|Drug|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
79475898|NCT01955629|Drug|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
79475899|NCT01955629|Drug|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
79970132|NCT03862001|Behavioral|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
79970133|NCT02518828|Other|High SpO2|SpO2 range ≥96%
79970134|NCT02518828|Other|Low SpO2|SpO2 range 90-92%
79641103|NCT02935582|Drug|Other topical|Treatment according to local practise
79641104|NCT00406172|Drug|Bevacizumab|
79970135|NCT03862079|Other|Best Practice|Given standard of care
79970136|NCT03862079|Procedure|Fecal Microbiota Transplantation|Undergo FMT
79641105|NCT02935660|Device|enLighten Laser|Laser tattoo removal treatment
79641106|NCT02935465|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
79970137|NCT03862079|Drug|Nystatin|Given PO
79641107|NCT02935465|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
79970138|NCT03862079|Drug|Piperacillin-Tazobactam|Given PO
79970139|NCT03362632|Drug|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
79970140|NCT03213210|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
79970141|NCT01179035|Other|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
79970142|NCT01179035|Other|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
79970143|NCT03372772|Drug|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
79641108|NCT02935621|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
79641109|NCT02935621|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
79641110|NCT02935426|Device|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
79641111|NCT02935426|Device|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
79641112|NCT00152945|Drug|Intravenous Intralipid|intravenous infusion
79641113|NCT00152945|Drug|Intravenous leucine, glycerol|intravenous infusion
79970144|NCT01235494|Other|polarised 3 helium|1 inhalation (= 1 litre)
79970145|NCT01174433|Device|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
79970146|NCT02932878|Drug|DSXS topical|topical treatment
79970147|NCT01093066|Drug|optimal TURB|The TURB will always try to be optically complete.
79970148|NCT03859271|Behavioral|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
79970149|NCT03859271|Behavioral|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
79641114|NCT02935153|Biological|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
79641115|NCT02935114|Drug|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
79805962|NCT00487747|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
79641116|NCT02935114|Drug|35% hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
79641117|NCT02935231|Drug|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
79970150|NCT03368638|Other|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
79641118|NCT02935231|Behavioral|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
79970151|NCT01179269|Drug|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
79970152|NCT03230292|Drug|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
79313173|NCT02376881|Drug|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
79313174|NCT02376881|Other|placebo|100 ml normal saline in 2 hr for 3 successive days
79313175|NCT02032888|Drug|Daclatasvir|
79313176|NCT02032888|Drug|Sofosbuvir|
79641119|NCT02935231|Other|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
79805963|NCT01012141|Dietary Supplement|phytochemical|
79641120|NCT00172380|Drug|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
79805964|NCT01012141|Drug|Docetaxel|
79805965|NCT00487435|Drug|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
79805966|NCT00487279|Device|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
79805967|NCT00487279|Other|Control|No Intervention
79970153|NCT01174511|Drug|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
79475900|NCT05127317|Diagnostic Test|Mechanical power|"In our study, mechanical power (MP) will be calculated during mechanical ventilation in patients who will be operated under general anesthesia.~MP will be calculated with the simplified formula applied by Gattinoni et al. MPvcv: RR x Tv x (PIP-[(Pplat-PEEP)/2]) x 0.098(2) In pressure-controlled ventilation, the simplified MP formula of Becher et al. well be used.~MPpcv: RR x Tv x (ΔPinsp + PEEP) x 0.098 (11)~For MP calculated according to the weight of the patients; Indexed MP: MP /kg according to IBW. For the force applied to the lungs in each inspiration; Dynamic power (mJ/min): Vt x RR x [(Pplato+ tPEEP)/2]. For the driver power that provides the gas flow; Driving power (mJ/min): Vt x RR x [ (Pplat - tPEEP) / 2]. Calculating mechanical energy; Mechanical energy (mJ/kg): 0.098 x (V x kg ) x (PIP - [(P plateau- PEEP) / 2]) formulas were used"
79641121|NCT02935348|Radiation|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
79970154|NCT00165724|Drug|Donepezil Hydrochloride|
79970155|NCT01287455|Drug|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
79475901|NCT01898611|Drug|Ghrelin|Ghrelin
79970156|NCT01287455|Other|placebo|drops, 70 placebo drops, once weekly for 6 weeks
79475902|NCT01898611|Drug|Placebo|Saline will be used as a placebo
79641122|NCT00152984|Drug|Tiotropium inhalation capsules|
79641123|NCT00152984|Drug|Placebo inhalation capsules|
79641124|NCT02935387|Other|Taper|Taper
79475903|NCT05110703|Dietary Supplement|Supergut|Meal replacement shake
79475904|NCT05110703|Dietary Supplement|Placebo|Placebo
79475905|NCT05110703|Other|Dietary guidelines|Dietary guidelines
79475906|NCT01898689|Drug|Ropivacaine 0.1%|A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
79641125|NCT02935075|Drug|Tenofovir disoproxil fumarate|Oral daily
79641126|NCT02935075|Drug|Lamivudine|Oral daily
79641127|NCT02935075|Drug|Efavirenz|Oral daily
79641128|NCT02934919|Drug|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
79641129|NCT00172419|Drug|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
79970157|NCT04527172|Diagnostic Test|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
79970158|NCT03865433|Other|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
79641130|NCT02934880|Other|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
79970159|NCT03865433|Other|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
79805968|NCT04385875|Biological|Vaccine + extension of the ATI period|During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
79641131|NCT02934880|Other|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
79641132|NCT02934802|Device|Total Knee prothesis e motion PS Pro|
79641133|NCT00153023|Drug|Telmisartan|
79641134|NCT00153023|Drug|Valsartan|
79641135|NCT00152672|Device|nCPAP vs oral appliance|
79641136|NCT00165126|Procedure|Radiation therapy|Given as standard therapy
79641137|NCT02934958|Behavioral|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
79641138|NCT02934958|Behavioral|Standard of Care|Patients will be tracked to compare how effective are usual care methods
79641139|NCT02934997|Other|Observational study|
79641140|NCT00165204|Drug|Tibolone|
79641141|NCT02934763|Drug|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
79641142|NCT02934763|Drug|Saline|Saline as placebo
79641143|NCT04689958|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
79475907|NCT01898689|Drug|Ropivacaine 0.4%|A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
79475908|NCT05090267|Dietary Supplement|Probiotic Supplement|Participants will take a probiotic supplement or placebo for 90 days.
79475909|NCT05090267|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
79641144|NCT04689958|Drug|Vitamin D 5,000IU Oral Tablet|Vitamin D 5000 IU oral tablet once daily
79641145|NCT02934841|Drug|Conbercept|
79641146|NCT02934841|Drug|sham|
79641147|NCT00153140|Drug|polyethyleneglycol3350|
79805969|NCT04385875|Other|Placebo + extension of the ATI period|During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
79641148|NCT02934724|Procedure|Self sample from vagina|Self sample using The Rover's Evalyn Brush
79641149|NCT02934724|Procedure|Self sample from the oral cavity|Self sample using COPAN FloqSwab
79641150|NCT02934724|Other|Questionnaire|Questionnaire about vaccination status and sexual behaviour
79641151|NCT00165243|Procedure|Tangential radiation|Radiation given over 6 1/2 weeks
79641152|NCT02934412|Drug|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
79641153|NCT02934412|Drug|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
79641154|NCT02934607|Drug|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
79641155|NCT02934607|Drug|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
79641156|NCT02934685|Radiation|hypofraction|70 Gy in 28 fractions over 5.6 weeks
79641157|NCT02934685|Radiation|convention|80Gy in 40 fractions over 8 weeks
79641158|NCT00153257|Device|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
79805970|NCT00495625|Drug|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
79805971|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
79805972|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
79805973|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
79475910|NCT04350697|Procedure|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
79475911|NCT00370409|Procedure|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
79475912|NCT05062577|Drug|ASP8062|oral
79475913|NCT05062577|Drug|Placebo ASP8062|oral
79475914|NCT05062577|Drug|buprenorphine/naloxone|sublingual
79475915|NCT01956097|Dietary Supplement|HX106 590mg|
79475916|NCT01956097|Dietary Supplement|HX106 1180mg|
79475917|NCT01956097|Dietary Supplement|Placebo|
79641159|NCT02934334|Other|Observational|
79641160|NCT02934490|Device|Mesh|Meshes were made by Gynemech TM PS, (Johnson & Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
79641161|NCT00165282|Behavioral|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
79641162|NCT00165282|Behavioral|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
79641163|NCT02934646|Device|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
79641164|NCT00153296|Drug|Carbamazepine|
79641165|NCT02934373|Device|A New Sound Processor|
79641166|NCT02934139|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
79641167|NCT02934139|Other|Placebo|Matched placebo
79805974|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
79805975|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
79313177|NCT02376959|Behavioral|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
79313178|NCT02376803|Drug|Warfarin|Morning vs Evening administration
79475918|NCT05449379|Other|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
79641168|NCT02934100|Device|Shock Master 300|"Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
79805976|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
79805977|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
79313179|NCT02379143|Other|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
79313180|NCT02082262|Drug|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
79313181|NCT04697069|Biological|Imsidolimab|Humanized monoclonal antibody
79313182|NCT04697069|Biological|Placebo|Placebo
79475919|NCT05449379|Other|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
79475920|NCT05448989|Drug|1% atropine 5+3|A method for myopia control using high-concentration atropine
79970160|NCT03368560|Other|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
79970161|NCT03859817|Other|Comparison of eGFR values and ketonemia in diabetic patients|To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
79970162|NCT03865511|Drug|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
79970163|NCT03865511|Genetic|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~C797S testing (digital PCR)~MET amplification (dPCR/FISH)~Histological examination of the tissue sample (to identify small cell transformation)~Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
79970164|NCT03865511|Genetic|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~Kinetics studies of the alterations"
79970165|NCT03368482|Behavioral|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
79313183|NCT04247243|Device|Rapid testing|Abbott ID NOW Strep A testing
79475921|NCT05447195|Drug|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
79475922|NCT05447195|Drug|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
79475923|NCT00370565|Drug|Inhaled Human Insulin|
79475924|NCT05049161|Drug|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
79313184|NCT04247243|Diagnostic Test|Reference testing|Culture-based testing
79313185|NCT02082184|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
79475925|NCT05049161|Drug|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
79475926|NCT05049161|Drug|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
79475927|NCT05039723|Drug|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
79475928|NCT05391191|Device|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
79475929|NCT05370989|Other|Technology-Based Parent School Program|The program will be continued for 10 weeks in the intervention group and will be included five web-based modules, five online group interactions after each module, and consultation throughout the program and the follow-up period.
79475930|NCT05370989|Other|ongoing treatment|Health service of the control group will ongoing.
79970166|NCT03368482|Behavioral|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
79313186|NCT02082184|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
79970167|NCT03865355|Other|Non- interventional|Translational, observational study
79970168|NCT03362398|Drug|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
79970169|NCT03362398|Drug|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
79475931|NCT05356247|Behavioral|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
79641169|NCT02934100|Device|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
79655709|NCT04552678|Behavioral|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79970170|NCT03865199|Behavioral|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
79970171|NCT01287533|Drug|Ibandronate|monthly dosage of ibandronate 150mg
79970172|NCT01287533|Drug|Placebo|monthly dosage of placebo
79313187|NCT02378909|Device|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
79655710|NCT04552678|Behavioral|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
79313188|NCT04057157|Device|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
79655711|NCT04552678|Behavioral|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79805978|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
79805979|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
79805980|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
79805981|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
79805982|NCT04115904|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
79805983|NCT05297994|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
79313192|NCT04132427|Combination Product|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
79313193|NCT04132427|Combination Product|placebo vancomycin, real magnsium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
79313194|NCT02378675|Other|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
79313195|NCT02376491|Device|Transcranial magnetic stimulation|
79475932|NCT00370019|Drug|Estradiol/Medroxyprogesterone acetate|
79475933|NCT05286281|Drug|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
79313196|NCT02378597|Behavioral|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
79313197|NCT02031640|Drug|Beclomethasone dipropionate|
79313198|NCT02031640|Drug|Placebo|
79641170|NCT02934100|Device|EVO US13 CosmoGamma|"Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
79641171|NCT02934100|Device|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
79641172|NCT00172536|Behavioral|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
79641173|NCT00172536|Other|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
79970173|NCT03859349|Diagnostic Test|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
79313199|NCT02031640|Drug|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
79313200|NCT02376725|Procedure|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
79313201|NCT02376725|Procedure|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
79313202|NCT03105635|Other|Mixed method feasibility study|"Participating practices will receive the following:~Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~Navigator: The services of a Navigator"
79313203|NCT02378363|Other|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
79313204|NCT02376413|Procedure|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
79313205|NCT02376413|Drug|Chemotherapy or endocrine therapy or Trastuzumab therapy|
79313206|NCT02376413|Radiation|Radiation therapy|
79313207|NCT02376023|Other|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
79313208|NCT02376101|Procedure|Surgery less than 60 minutes|
79313209|NCT02378285|Device|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
79313210|NCT02378285|Other|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
79313211|NCT02378441|Drug|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
79313212|NCT02378441|Drug|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
79313213|NCT02378519|Behavioral|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
79313214|NCT02378519|Behavioral|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
79313215|NCT04600427|Procedure|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
79313216|NCT02378129|Drug|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
79313217|NCT02378129|Drug|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
79313218|NCT02375945|Device|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
79313219|NCT02375945|Device|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
79313220|NCT02376335|Biological|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
79313221|NCT02376335|Other|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
79313222|NCT02375789|Device|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
79313223|NCT02375789|Device|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
79475934|NCT03904823|Drug|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
79970174|NCT03859349|Diagnostic Test|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
79313224|NCT02375867|Drug|prednisolone|Oral administration of 1 mg/Kg/day
79641174|NCT02934295|Biological|Determination of Anti-Rubella Antibody, E1|
79641175|NCT00153335|Behavioral|patient-provider interaction|
79641176|NCT02934022|Drug|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
79641177|NCT02934256|Drug|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
79641178|NCT02933983|Other|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
79805984|NCT05297994|Biological|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
79805985|NCT00851682|Device|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
79313225|NCT02375867|Drug|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
79475935|NCT03904823|Drug|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
79475936|NCT03888131|Drug|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
79475937|NCT03888131|Drug|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
79641179|NCT04651543|Other|X-Ray|X-ray obtained at one-week of the fracture
79641180|NCT00153374|Behavioral|Women's health|
79641181|NCT02934061|Device|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
79641182|NCT02934061|Drug|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
79641183|NCT02934217|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
79641184|NCT02934217|Drug|Placebo|One single intravenous bolus injection of Placebo
79641185|NCT02934217|Procedure|Echocardiography|3 years after AMI
79475938|NCT01900249|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
79313226|NCT02378051|Behavioral|Staying Strong with Schools Intervention|"On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
79313227|NCT02378051|Other|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
79313228|NCT02377739|Other|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
79313229|NCT02375633|Drug|DW-330SR2|
79313230|NCT02375633|Drug|Pelubiprofen|
79475939|NCT01900249|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
79641186|NCT00153413|Behavioral|Women's health|
79970175|NCT03372616|Diagnostic Test|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
79970176|NCT03372616|Diagnostic Test|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
79970177|NCT03372616|Diagnostic Test|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
79313231|NCT02375711|Biological|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
79313232|NCT02375477|Other|Educational Intervention|Given educational presentation
79313233|NCT02375243|Drug|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
79313234|NCT02375321|Behavioral|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
79313235|NCT03113045|Other|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
79475940|NCT01900249|Drug|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
79475941|NCT02987647|Other|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
79475942|NCT02987647|Other|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
79475943|NCT02987647|Other|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
79641187|NCT00165360|Drug|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
79641188|NCT02933905|Drug|Intravitreal Ranibizumab injection|
79641189|NCT02933515|Other|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
79970178|NCT03372616|Diagnostic Test|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor [AtCor Medical, Australia], PulsePen [DiaTecne SRL, Italy], and Mobil-O-Graph [IEM, Germany] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
79970179|NCT01179425|Other|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
79641190|NCT02933788|Drug|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
79641191|NCT02933788|Drug|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
79641192|NCT00153452|Behavioral|perpetration of intimate partner violence|
79641193|NCT00165399|Drug|Docetaxel|Given intravenously on day 2 of four three-week cycles
79641194|NCT00165399|Drug|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
79313236|NCT03105401|Other|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
79313237|NCT03105557|Device|Urinary collecting device|Urinary collecting device
79313238|NCT02375009|Procedure|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
79313239|NCT02374931|Drug|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
79313240|NCT02374931|Procedure|Positron Emission Tomography|Undergo 18F-FES PET/CT
79313241|NCT02374931|Procedure|Computed Tomography|Undergo 18F-FES PET/CT
79313242|NCT02374931|Other|Laboratory Biomarker Analysis|Correlative studies
79313243|NCT02374697|Device|During tele-expertise|
79313244|NCT02374619|Dietary Supplement|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement [Resoferon Ferrous Sulfate 125 (37) mg]
79313245|NCT02374619|Dietary Supplement|Placebo|
79313246|NCT02377661|Drug|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up
79313247|NCT02377505|Device|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
79313248|NCT02377505|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
79641195|NCT00165399|Drug|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
79641196|NCT00165399|Drug|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
79313249|NCT02372357|Drug|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
79641197|NCT02933593|Drug|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
79313250|NCT02372357|Procedure|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
79313251|NCT02374541|Behavioral|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
79313252|NCT02374385|Biological|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
79313253|NCT02374385|Other|Placebo|Normal saline
79313254|NCT02374229|Procedure|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
79313255|NCT02374229|Procedure|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
79313256|NCT02374151|Device|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
79313257|NCT02374073|Other|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
79313258|NCT02374073|Other|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
79313259|NCT02371967|Drug|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
79641198|NCT02933593|Drug|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
79641199|NCT02933593|Drug|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
79313260|NCT02373839|Other|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
79313261|NCT02371811|Device|uterine manipulator (v care)|
79313262|NCT02373761|Device|Stryker Triathlon Tritanium primary knee|
79313263|NCT02373995|Biological|LAB4|Additional treatment with the specific LAB4 probiotic preparation
79805986|NCT04116138|Dietary Supplement|Salovum|Egg yolk powder enriched for anti secretory factor
79970180|NCT03372538|Procedure|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
79655712|NCT04552678|Behavioral|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
79475944|NCT02987647|Other|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
79970181|NCT01176539|Device|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
79970182|NCT03368404|Device|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
79313264|NCT02371655|Procedure|Diet|A low-fibre diet for three days before the examination
79475945|NCT05269745|Other|Stretching through immobilisation (IG)|The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)
79475946|NCT05269745|Other|Stretching through immobilisation and activity (IAG)|The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).
79475947|NCT05269745|Other|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
79970183|NCT03368404|Device|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
79970184|NCT03859037|Other|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
79970185|NCT03362320|Procedure|double layer fixation|
79313265|NCT02371655|Drug|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
79313266|NCT02371655|Drug|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
79313267|NCT02371655|Procedure|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
79475948|NCT05267171|Other|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
79475949|NCT01900561|Behavioral|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
79970186|NCT03362320|Procedure|single layer fixation|
79970187|NCT01287689|Other|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
79805987|NCT04116762|Device|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
79475950|NCT01900561|Behavioral|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
79475951|NCT03789617|Biological|EBViNT Cell|"Dosage: 1 bag containing 1.4x10^9 cells/100mL~Administration: Inject intravenously over 30 minutes~Dosing schedule: Single dose"
79475952|NCT05166473|Other|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
79475953|NCT05166473|Other|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
79475954|NCT01957657|Drug|BI 207127|oral administration
79475955|NCT01957657|Drug|faldaprevir|oral administration
79970188|NCT03228420|Device|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
79970189|NCT03228420|Other|CMM|Conventional Medical Management
79970190|NCT03368326|Diagnostic Test|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
79475956|NCT01957657|Drug|BI 207127|oral administration
79970191|NCT03859115|Procedure|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
79970192|NCT03859115|Procedure|sham intervention|sham stimulation without electrical pulse generation
79970193|NCT03362242|Drug|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
79970194|NCT03362242|Other|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79475957|NCT01957657|Drug|BI 207127|oral administration
79475958|NCT01957657|Drug|BI 207127|oral administration
79641200|NCT02933632|Other|Physical Therapy-SAP|"Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~Day 4 and other days) Patients repeated the gait training until the discharge date."
79970195|NCT05181306|Procedure|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
79970196|NCT05181306|Procedure|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
79641201|NCT02933632|Other|Physical Therapy-ARP|"Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~Day 2) Patients repeated three times the day 1-3°approach;~Day 3) Patients repeated three times the day 1-3°approach."
79805988|NCT04116762|Device|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
79805989|NCT00860262|Drug|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
79475959|NCT01957657|Drug|faldaprevir|oral administration
79475960|NCT01957657|Drug|faldaprevir|oral administration
79475961|NCT01957657|Drug|faldaprevir|oral administration
79475962|NCT05734963|Genetic|DNA sequencing, RNA gene expression analysis, molecular profiling|Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
79475963|NCT02987491|Behavioral|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
79805990|NCT00860262|Drug|telmisartan|telmisartan 80mg for the 8w, no titration required
79475964|NCT04969211|Drug|VHX-896 and iloperidone|oral tablet
79475965|NCT04969211|Drug|Iloperidone and VHX-896|oral tablet
79475966|NCT05734885|Other|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
79475967|NCT01901575|Drug|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
79475968|NCT05049005|Behavioral|Simplified dietary tracking|Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
79475969|NCT01901809|Drug|Furosemide|
79475970|NCT01901809|Drug|Dopamine|
79475971|NCT01902901|Genetic|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
79475972|NCT01902901|Genetic|Carrier status testing|Carrier status testing
79313268|NCT02371577|Drug|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
79641202|NCT00153491|Drug|artemether-lumefantrine|
79641203|NCT00165438|Procedure|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
79475973|NCT05740189|Device|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
79475974|NCT04929743|Device|BTI Implant|Placement of dental implants of 5.5 vs >6.5 mm length
79475975|NCT02284399|Other|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
79641204|NCT00165438|Procedure|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
79313269|NCT02373449|Other|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
79641205|NCT02933749|Device|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
79641206|NCT02933749|Device|BIS|Bispectral index
79641207|NCT02933398|Procedure|Robotic Assisted Nephrectomy|Robotic (Davinci)
79641208|NCT02933398|Procedure|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
79641209|NCT02933437|Drug|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
79641210|NCT00153530|Drug|methotrexate|"chemotherapy with radiotherapy~chemotherapy without radiotherapy"
79641211|NCT00153530|Radiation|radiotherapy|whole-brain irradiation
79313270|NCT02373449|Drug|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
79313271|NCT02371733|Other|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
79313272|NCT02371733|Other|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
79313273|NCT02371499|Dietary Supplement|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
79475976|NCT05441423|Radiation|CBCT|CBCT Scans. conventional & ultra low dose
79475977|NCT05734651|Device|PROMIS Stem|Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
79641212|NCT04690075|Dietary Supplement|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
79313274|NCT02371499|Dietary Supplement|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
79475978|NCT05740111|Other|Annual surveillance|Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.
79475979|NCT03029533|Drug|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
79475980|NCT03029533|Drug|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
79475981|NCT04921007|Procedure|Sacral ESP block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
79641213|NCT04690075|Dietary Supplement|Nutrition Management|Routine nutrition management for 12 weeks.
79641214|NCT02933164|Device|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
79641215|NCT02933125|Behavioral|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
79313275|NCT02371421|Drug|Allopurinol|
79313276|NCT02373527|Other|No Fasting prior to catheterization|No restriction for oral intake
79475982|NCT04921007|Procedure|Caudal block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
79475983|NCT04921007|Drug|Bupivacaine Hydrochloride|Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
79475984|NCT01904071|Procedure|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
79475985|NCT01904071|Procedure|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
79475986|NCT01904071|Drug|IVMS (IV Morphine)|Intravenous Morphine
79475987|NCT01905241|Device|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
79475988|NCT01905241|Procedure|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
79475989|NCT01907113|Drug|BI 10773|oral administration
79475990|NCT01907113|Drug|BI 10773|oral administration
79475991|NCT01907113|Drug|BI 10773|oral administration
79475992|NCT01907113|Drug|BI 10773|oral administration
79475993|NCT01907113|Drug|BI 10773|oral administration
79475994|NCT03535337|Behavioral|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
79475995|NCT03535337|Behavioral|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
79475996|NCT01907269|Behavioral|Video-based Intervention|Video clips delivered by DVD and Internet
79475997|NCT00370643|Drug|human regular insulin|
79475998|NCT01908127|Behavioral|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
79313277|NCT02373605|Other|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
79313278|NCT02373605|Other|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
79313279|NCT02371343|Dietary Supplement|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
79313280|NCT02371343|Dietary Supplement|Sunflower Oil|
79313281|NCT02371109|Other|selftaken versus clinically taken swabs|
79475999|NCT01908127|Behavioral|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
79476000|NCT01908127|Drug|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
79641216|NCT02933125|Behavioral|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
79476001|NCT01908127|Procedure|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
79476002|NCT04679831|Dietary Supplement|Ujiplus®|Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
79476003|NCT04679831|Drug|Praziquantel 400mg|400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,
79313282|NCT02371031|Drug|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
79313283|NCT02371031|Device|PET/MRI|
79313284|NCT02371031|Procedure|Surgical resection (standard of care)|
79313285|NCT03959891|Drug|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
79313286|NCT03959891|Drug|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
79313287|NCT03959891|Drug|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
79313288|NCT03959891|Drug|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
79476004|NCT02980471|Device|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
79476005|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
79476006|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
79476007|NCT04882397|Other|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
79641217|NCT00165477|Drug|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
79313289|NCT02370953|Device|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
79313290|NCT02370953|Procedure|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
79313291|NCT02373215|Drug|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
79313292|NCT02370719|Behavioral|Mobile application for diabetes self-management|
79313293|NCT02370563|Drug|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
79313294|NCT02373059|Other|Diabetes Issue Cards Decision Aids|
79313295|NCT02373059|Other|Usual Pharmaceutical Care|
79313296|NCT02372981|Device|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
79313297|NCT02370485|Drug|LY2801653|Administered orally
79641218|NCT00165477|Radiation|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
79641219|NCT02933086|Other|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
79641220|NCT02933086|Other|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
79641221|NCT00153569|Biological|Tyrosinase, MAGE-3, GnTV|
79641222|NCT02932930|Procedure|QLB bloc|
79641223|NCT02932930|Drug|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
79641224|NCT02932930|Drug|0.9% normal saline|0,2ml/kg of 0.9% normal saline
79641225|NCT02932813|Behavioral|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
79641226|NCT02932969|Drug|BMS-986231|
79641227|NCT02932969|Drug|BMS-986231 Placebo|
79641228|NCT00165516|Drug|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
79313298|NCT02370173|Device|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
79313299|NCT02370173|Device|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
79313300|NCT02372903|Drug|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
79313301|NCT02372825|Procedure|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
79313302|NCT02372591|Drug|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
79313303|NCT02372591|Drug|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
79313304|NCT02372591|Drug|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
79476008|NCT04882397|Other|Sham|Bilateral sham Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
79476009|NCT01908751|Procedure|Sliding Hip Screw|
79641229|NCT00165516|Drug|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
79641230|NCT00153608|Biological|WT1 126-134 peptide|
79641231|NCT04647409|Other|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
79641232|NCT00172653|Procedure|functional tasks|
79641233|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
79313305|NCT02372669|Device|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
79476010|NCT01908751|Procedure|Cancellous Screws|
79476011|NCT01908751|Drug|Vitamin D|
79476012|NCT01908751|Drug|Vitamin D Placebo|
79476013|NCT04873115|Other|Placebo|Sialanar placebo
79476014|NCT04873115|Drug|Sialanar|Sialanar - a licensed glycopyrronium bromide product
79641234|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
79641235|NCT04642378|Drug|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
79313306|NCT02372669|Procedure|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
79970197|NCT03372694|Behavioral|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
79313307|NCT02370017|Biological|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
79313308|NCT02372747|Procedure|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
79313309|NCT02372747|Procedure|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
79313310|NCT02369861|Drug|ST266|Topical ocular application 4 times per day
79476015|NCT04873115|Other|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
79476016|NCT00370721|Drug|bevacizumab|
79476017|NCT03459521|Biological|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
79476018|NCT01909141|Drug|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
79641236|NCT04642378|Drug|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
79641237|NCT04608136|Behavioral|Diet intervention|Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
79313311|NCT02369861|Drug|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
79313312|NCT02369783|Other|Questionnaire and interview|The aim is to detect social fragility.
79313313|NCT02369939|Radiation|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
79313314|NCT02369939|Drug|Mitomycin C|MMC w1, w5
79313315|NCT02369939|Drug|5-Fluorouracil|5-FU w1, w5
79476019|NCT01909141|Drug|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
79313316|NCT02369939|Procedure|Hyperthermia|6x deep regional hyperthermia
79313317|NCT02372435|Procedure|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
79476020|NCT01909141|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of > 18 mm or till day 20 of the cycle
79313318|NCT02369627|Device|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
79476021|NCT01909141|Other|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
79476022|NCT01909141|Other|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
79476023|NCT01909141|Other|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
79476024|NCT01909141|Other|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
79641238|NCT02933047|Procedure|Total laparoscopic hysterectomy|
79641239|NCT02933047|Procedure|Total laparoscopic hysterectomy|
79641240|NCT02932852|Procedure|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
79641241|NCT02932852|Procedure|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
79641242|NCT00407784|Drug|eplerenone|
79641243|NCT00153686|Procedure|capsule endoscopy|capsule endoscopy of small intestine
79641244|NCT00153686|Procedure|Mesenteric Angiogram|Mesenteric Angiogram
79641245|NCT02932774|Drug|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
79313319|NCT02369627|Device|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
79641246|NCT02932774|Drug|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
79970198|NCT03372694|Drug|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
79313320|NCT02369627|Other|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
79313321|NCT02369549|Drug|Micro-particle Curcumin|as described in Arm
79476025|NCT01909141|Other|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
79970199|NCT03372694|Other|Rehabilitation Education|General health education
79970200|NCT03372694|Drug|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
79970201|NCT01179503|Dietary Supplement|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
79970202|NCT01179503|Dietary Supplement|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
79313322|NCT02369549|Drug|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
79313323|NCT02372123|Other|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
79313324|NCT02372123|Other|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
79313325|NCT02660489|Drug|OC459|
79313326|NCT02660489|Drug|Placebo|
79313327|NCT02660489|Other|Rhinovirus|Inoculation with rhinovirus serotype 16
79313328|NCT02372201|Other|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
79313329|NCT02369315|Behavioral|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
79313330|NCT02369315|Behavioral|Control (Invited entry 2013)|Entry to music program offered in September 2013
79313331|NCT02365259|Device|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
79313332|NCT02365415|Drug|Sirolimus|8 weeks oral sirolimus, following drug levels
79476026|NCT01909141|Other|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
79476027|NCT04486859|Drug|LMWH/Rivaroxaban|combined prevention
79476028|NCT04486859|Device|IPC|mechanical prevention
79476029|NCT01910311|Drug|Baricitinib|Administered orally
79476030|NCT01910311|Drug|Rifampicin|Administered orally
79641247|NCT02932774|Other|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
79805991|NCT00860262|Drug|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
79313333|NCT02369081|Drug|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
79313334|NCT02369081|Drug|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
79313335|NCT02369081|Drug|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
79476031|NCT04404959|Other|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
79313336|NCT02369081|Drug|Placebo|Placebo treatment for 12 weeks.
79313337|NCT02368769|Device|During Tele-expertise|
79313338|NCT02365493|Drug|Beta-Lactam|
79476032|NCT04404959|Other|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
79641248|NCT02932696|Other|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
79641249|NCT02932657|Other|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
79641250|NCT00180063|Drug|L-NMMA(drug)|
79641251|NCT00153725|Drug|Aspirin and Pantoloc|
79641252|NCT02932423|Other|Control product E|Plain water
79970203|NCT03368248|Other|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
79970204|NCT03372304|Drug|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
79313339|NCT02368925|Device|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
79313340|NCT02365103|Other|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
79313341|NCT02365103|Other|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
79313342|NCT02365103|Other|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
79476033|NCT05739877|Drug|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
79476034|NCT05739877|Drug|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
79476035|NCT05734573|Behavioral|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
79641253|NCT02932423|Other|Test product A|Beverage with no sugar but sweetener
79641254|NCT02932423|Other|Test product B|Beverage with 22 g/L sugar and sweetener
79641255|NCT02932423|Other|Test product C|Beverage with 33 g/L sugar and sweetener
79641256|NCT02932423|Other|Test product D|Beverage with 47 g/L sugar and sweetener
79641257|NCT02932423|Other|Comparative product F|Beverage with 98 g/L sugar
79805992|NCT00701454|Other|No intervention|No intervention
79970205|NCT02525081|Drug|Ramipril (ACE-inhibitor)|up to 10 mg
79970206|NCT02525081|Drug|placebo|up to 10 mg
79641258|NCT02932384|Behavioral|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
79313343|NCT02365103|Other|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
79313344|NCT02365181|Procedure|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
79313345|NCT02365181|Procedure|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
79313346|NCT02365181|Drug|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
79476036|NCT04403711|Other|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
79641259|NCT02932384|Behavioral|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
79641260|NCT02932540|Other|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
79641261|NCT00153764|Drug|Cooper Complete One-A-Day Vitamin Supplement|
79641262|NCT00180102|Drug|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
79641263|NCT00180102|Procedure|early allogeneic PBSCT within induction therapy|
79641264|NCT00180102|Procedure|autologous PBSCT|
79641265|NCT04690309|Drug|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting < 100 mg/dl (5.5 mmol/L) and postprandial < 140 mg/dl (7.8mmol/L)
79641266|NCT02931955|Other|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
79641267|NCT02932189|Device|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
79641268|NCT02931994|Other|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
79970207|NCT05566548|Diagnostic Test|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
79970208|NCT02525003|Dietary Supplement|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
79641269|NCT00153881|Drug|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
79641270|NCT00180141|Drug|Elidel-Creme|
79970209|NCT02525003|Dietary Supplement|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
79313347|NCT05653895|Dietary Supplement|Resveratrol|Resveratrol
79313348|NCT05653895|Drug|Metformin|Metformin
79313349|NCT05653895|Combination Product|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
79313350|NCT02368847|Device|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
79313351|NCT02368847|Device|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
79313352|NCT02368535|Other|Survey|25-item questionnaire on pereception of interdisciplinary rounds
79476037|NCT04403711|Other|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
79313353|NCT02365025|Other|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
79313354|NCT02364869|Dietary Supplement|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
79641271|NCT02932033|Procedure|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
79641272|NCT02932033|Procedure|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
79641273|NCT02931799|Behavioral|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
79641274|NCT02931799|Other|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~PRO-2 Scale for patients with Crohn's Disease~6-Point Mayo Score for patients with Ulcerative Colitis~Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
79970210|NCT02525003|Other|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
79970211|NCT03367936|Behavioral|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
79313355|NCT02364869|Dietary Supplement|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
79313356|NCT02368613|Drug|DW-3102|
79313357|NCT02364479|Drug|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
79313358|NCT02364479|Drug|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
79313359|NCT02364479|Drug|Placebo|The injection method and frequency of placebo is the same as the other arms.
79641275|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
79313360|NCT05653817|Drug|Carrilizumab|Carrilizumab 200mg Q3W d1
79970212|NCT03367936|Behavioral|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
79313361|NCT05653817|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
79641276|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
79641277|NCT02931799|Other|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
79641278|NCT00153959|Behavioral|acute psychiatric day care|
79641279|NCT02931760|Device|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
79313362|NCT05653817|Drug|Apatinib|Apatinib mesylate tablets for treatment: 250mg
79313363|NCT02364635|Drug|icosabutate|Single dose at each dose levet
79313364|NCT02052310|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
79641280|NCT02931760|Device|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
79641281|NCT02931643|Other|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
79641282|NCT02931643|Other|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
79641283|NCT02931877|Drug|sevoflurane|
79313365|NCT02052310|Drug|Epoetin Alfa|Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
79313366|NCT02364245|Device|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
79476038|NCT01911169|Drug|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
79641284|NCT02931877|Drug|propofol|
79641285|NCT00153998|Drug|Cetuximab|
79641286|NCT00153998|Procedure|Liver resection|
79641287|NCT00153998|Drug|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
79641288|NCT00153998|Drug|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
79641289|NCT02931604|Device|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
79641290|NCT02925208|Other|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
79313367|NCT02364245|Other|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
79641291|NCT02925130|Drug|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
79641292|NCT02925130|Drug|Placebo|Acute oral intake of a placebo drug
79641293|NCT00407823|Procedure|Central venous oxygen saturation continuous monitoring|
79641294|NCT02924974|Drug|Morphine|mixed with bupivacaine
79641295|NCT02924974|Drug|Lidocaine|sham procedure (s.c. lidocaïne)
79641296|NCT02924896|Dietary Supplement|Palm olein|60g of palm olein will be given in a milkshake at breakfast
79641297|NCT02924896|Dietary Supplement|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
79313368|NCT02364245|Other|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
79313369|NCT02368379|Other|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
79641298|NCT02924896|Dietary Supplement|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
79641299|NCT00154037|Drug|Pioglitazone (drug) and/or candesartan (drug)|
79970213|NCT03367936|Behavioral|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
79970214|NCT03464448|Drug|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
79970215|NCT01179581|Drug|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
79313370|NCT02368379|Other|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
79313371|NCT02368067|Procedure|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
79313372|NCT02368067|Procedure|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
79313373|NCT02051764|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
79641300|NCT00180258|Device|Cardiac Resynchronization Therapy with & without defibrillator|
79641301|NCT02925169|Device|CT Scan|CT imaging
79641302|NCT02925052|Device|Gastric Tube Guide|
79641303|NCT02925052|Device|Conventional placement|
79970216|NCT01179581|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
79313374|NCT02051764|Drug|Florbetapir F 18|370 megabecquerel (MBq) IV single-dose
79313375|NCT02051764|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
79313376|NCT02364401|Device|Ablation|Catheter ablation for atrial fibrillation
79313377|NCT02368223|Device|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
79313378|NCT02051296|Drug|Minocycline|RCT blinded placebo trial
79313379|NCT02051296|Drug|placebo|RCT blinded placebo trial
79313380|NCT02364167|Drug|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
79641304|NCT00154076|Drug|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
79641305|NCT00154076|Drug|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
79641306|NCT02924779|Other|No intervention|Retrospective observational study
79641307|NCT02924740|Behavioral|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
79313381|NCT02364167|Device|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
79313382|NCT02364167|Other|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
79313383|NCT02367677|Other|Method comparison|
79313384|NCT02367755|Drug|Propofol|Propofol use during therapeutic hypothermia
79313385|NCT02367755|Drug|Lorazepam|Lorazepam use during therapeutic hypothermia
79476039|NCT04403087|Drug|Trimebutine 100 MG|Trimebutine 100mg three times a day
79641308|NCT02924740|Behavioral|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
79641309|NCT00154115|Drug|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
79641310|NCT00154115|Drug|placebo|Placebo
79970217|NCT01179581|Drug|GLPG0634|multiple dose, capsule, 10 days
79970218|NCT01179581|Drug|placebo|multiple dose, capsule, 10 days
79970219|NCT03362008|Drug|Zeropix|administration of Zeropix
79970220|NCT03362008|Drug|Champix®|administration of Champix®
79970221|NCT03858959|Device|topical agent|"HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe."
79970222|NCT03123406|Drug|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
79970223|NCT03361930|Device|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
79970224|NCT01179659|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
79805993|NCT04119492|Behavioral|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
79970225|NCT03858725|Drug|D569 Tab.|D569 Tab. 1T single oral administration under fasting condition
79313386|NCT02050048|Other|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
79313387|NCT02363777|Procedure|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
79313388|NCT02363777|Procedure|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
79313389|NCT02363699|Drug|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
79641311|NCT00180336|Device|CRT-D|
79641312|NCT02924662|Other|There is no intervention.|
79641313|NCT02924506|Device|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
79641314|NCT02924506|Device|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
79805994|NCT00700830|Drug|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
79970226|NCT03858725|Drug|CKD-374 5mg Tab.|CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
79970227|NCT03361774|Drug|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
79805995|NCT02613000|Other|No intervention|
79805996|NCT00860028|Drug|Extended Varenicline Pretreatment|4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
79805997|NCT00860028|Drug|Short-term Varenicline Pretreatment|3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
79805998|NCT00701532|Drug|Modafinil and PET (brain imaging)|duration 90 days
79805999|NCT00701532|Drug|placebo|duration 90 days
79641315|NCT00154154|Behavioral|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
79641316|NCT00154154|Behavioral|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
79970228|NCT03361774|Drug|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
79970229|NCT03746483|Drug|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
79970230|NCT03746483|Drug|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
79970231|NCT04523740|Drug|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
79970232|NCT04523740|Drug|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
79970233|NCT03410706|Drug|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
79970234|NCT04523662|Drug|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
79970235|NCT04266522|Other|Informational Intervention|Receive printed materials
79641317|NCT02924194|Device|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
79806000|NCT00859638|Behavioral|Physiotherapy|group self-management classes
79806001|NCT00859638|Behavioral|Occupational Therapy|group self-management classes
79806002|NCT00859638|Behavioral|Capacity Building|workshops and case reviews with primary health care team members
79806003|NCT00700908|Behavioral|automated telephone intervention vs. usual care|
79476040|NCT03374891|Other|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
79476041|NCT01911403|Procedure|Manual compression|Closure procedure by Manual compression
79476042|NCT01911403|Device|Angio-Seal|Closure procedure by angio-Seal
79476043|NCT04387253|Diagnostic Test|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
79476044|NCT04375241|Other|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
79476045|NCT01912495|Drug|Boceprevir|
79476046|NCT05739799|Procedure|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
79476047|NCT05739799|Procedure|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
79313390|NCT02363699|Drug|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
79313391|NCT02049814|Drug|Metformin|Metformin tablets
79476048|NCT04354727|Drug|APG-1252|infusion once weekly
79313392|NCT02049814|Drug|Voglibose|Voglibose tablets
79313393|NCT02049814|Drug|Acarbose|Acarbose tablets
79476049|NCT04354727|Drug|Ruxolitinib|taken orally twice a day
79476050|NCT05739721|Behavioral|Attractiveness|Visual attractiveness scale 0-7
79313394|NCT02363855|Drug|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
79313395|NCT04059809|Device|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 ~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
79641318|NCT02924194|Device|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
79641319|NCT02924467|Behavioral|1 Notice|1 Reminder notification via autodialer
79806004|NCT00846846|Device|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
79313396|NCT02363543|Device|Hyalomatrix|
79313397|NCT02363543|Device|Integra|
79806005|NCT00846768|Drug|BI 1744 CL|
79970236|NCT04266522|Other|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
79313398|NCT02363387|Behavioral|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
79313399|NCT02363387|Behavioral|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
79313400|NCT03458975|Radiation|MRI|Magnetic Resonance Imaging
79641320|NCT02924467|Behavioral|2 Notices|2 Reminder notifications via autodialer
79641321|NCT02924467|Behavioral|3 Notices|3 Reminder notifications via autodialer
79313401|NCT03458975|Radiation|Perfusion CT scan|Perfusion Computerized tomography scan
79313402|NCT03458975|Other|Contrast enhanced ultrasound|Contrast enhanced ultrasound
79313403|NCT03458975|Drug|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
79313404|NCT03344159|Drug|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
79313405|NCT03344159|Drug|Placebo|Placebo daily for a total of duration of 12 weeks
79313406|NCT03344159|Radiation|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
79476051|NCT05739721|Behavioral|Self-Esteem|Self Esteem scale
79476052|NCT05739721|Behavioral|Trustworthiness|Trustworthiness scale 0-7
79476053|NCT04330859|Other|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
79641322|NCT02924233|Drug|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
79641323|NCT02924233|Drug|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
79641324|NCT00180375|Device|Prizm, Vitality, Renewal|Follow-up during 2 years
79641325|NCT02923999|Drug|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
79641326|NCT02923999|Drug|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
79641327|NCT02923999|Drug|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
79806006|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
79806007|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
79806008|NCT00863798|Drug|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
79806009|NCT00697658|Drug|Paliperidone ER|6 mg tablet once daily, variable treatment length.
79970237|NCT04266522|Other|Questionnaire Administration|Ancillary studies
79970238|NCT03746405|Device|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
79970239|NCT03746405|Device|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
79970240|NCT02518672|Dietary Supplement|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
79970241|NCT02518672|Dietary Supplement|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
79970242|NCT03372226|Behavioral|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
79970243|NCT03226392|Drug|QAW039|QAW039 once daily
79970244|NCT03226392|Drug|Placebo|Placebo once daily
79970245|NCT03372070|Device|cNEP|soft silicon collar applied to anterior neck with negative pressure
79970246|NCT03371992|Drug|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
79313407|NCT03344159|Diagnostic Test|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
79313408|NCT02363465|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
79313409|NCT03324113|Drug|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79313410|NCT03324113|Drug|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
79313411|NCT03324113|Drug|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
79313412|NCT03324113|Drug|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
79313413|NCT02079844|Drug|Roflumilast|Roflumilast tablets
79476054|NCT04330859|Other|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
79641328|NCT02923960|Other|Standard ONS|One serving (237 ml) standard oral nutritional beverage
79970247|NCT03371992|Diagnostic Test|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
79970248|NCT03371992|Other|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
79970249|NCT03371914|Behavioral|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
79970250|NCT03371758|Other|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
79970251|NCT03205371|Biological|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
79970252|NCT03205371|Biological|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
79641329|NCT02923960|Other|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
79476055|NCT04748887|Other|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
79313414|NCT02079844|Drug|Placebo|Roflumilast placebo-matching tablets
79313415|NCT02079844|Drug|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
79313416|NCT02367365|Other|No Intervention|No intervention
79970253|NCT03205371|Biological|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
79313417|NCT02367365|Other|No Intervention|No intervention
79313418|NCT02363153|Other|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
79313419|NCT02363075|Drug|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
79313420|NCT02363075|Drug|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
79313421|NCT02367443|Radiation|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
79970254|NCT03205371|Biological|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
79970255|NCT03205371|Biological|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
79970256|NCT03371680|Drug|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
79970257|NCT03371524|Other|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
79970258|NCT03371446|Genetic|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
79313422|NCT02362763|Procedure|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
79476056|NCT04748575|Dietary Supplement|Acai smoothie|Smoothie containing 150g acai pulp
79476057|NCT04748575|Dietary Supplement|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
79641330|NCT02923960|Other|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
79641331|NCT00154193|Drug|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
79970259|NCT03371290|Other|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
79476058|NCT05739487|Procedure|selective intra-arterial thrombolysis|IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
79476059|NCT01916629|Drug|Photocil for Psoriasis|Photocil for Psoriasis
79476060|NCT01916629|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
79476061|NCT01916941|Drug|Prazosin|
79476062|NCT01916941|Drug|Placebo|
79476063|NCT02987413|Biological|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart
79806010|NCT00859014|Biological|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
79313423|NCT03097757|Radiation|Ultrasound - guided fracture reduction|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
79313424|NCT03097757|Procedure|Standard of care fracture reduction|Closed reduction of a fractured bone.
79313425|NCT02367053|Drug|ZP4207|
79313426|NCT02367053|Drug|Glucagon|
79313427|NCT02048722|Drug|regorafenib|Given PO
79313428|NCT02366897|Device|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
79313429|NCT04417114|Drug|Rosuvastatin|Statin
79313430|NCT02366975|Drug|Testosterone gel 2%|testosterone gel 2% (50mg/die).
79313431|NCT02366975|Other|Placebo|placebo gel
79476064|NCT01918189|Behavioral|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
79476065|NCT04780685|Biological|hMSC|IV administration
79476066|NCT05739409|Biological|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
79970260|NCT03371290|Other|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
79970261|NCT03367858|Behavioral|Motivational Interviewing (MI)|Motivational interviewing introduced a conversation about alcohol use, and the personally-experienced consequences of problem drinking. The MI sessions explored youths' stories around their substance use, the factors in youths' lives that support problem drinking (e.g., what they like about drinking), and the consequences of their recent or previous problem drinking (e.g., getting in trouble). Youth were provided personalized feedback about how their problem drinking compared to age-matched norms in the U.S. The ultimate goal of the MI sessions was to engage youth in a thoughtful conversation about their problem drinking with an eye to bolstering and supporting youths' own inherent drive for behavior change.
79970262|NCT03367858|Behavioral|Brief Adolescent Mindfulness (BAM)|Brief Adolescent Mindfulness introduced a conversation about what mindfulness is, and ways that it might be personally-relevant to adolescents' current experiences. This manualized treatment introduced concepts of eastern thought in a manner articulated to adolescents. Treatment included a discussion of factors in the youth's life that could be positively impacted by using or engaging mindful approaches (e.g., current experiences of stress) and a link to how mindful approaches might be applicable or relevant to the adolescent's problem drinking. The ultimate goal was to engage youth in a thoughtful conversation about BAM and how eastern thought and mindful approaches could unburden some aspects of their current lived experiences.
79641332|NCT02923843|Other|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
79641333|NCT00187863|Behavioral|pain perception|pain perception
79970263|NCT03682705|Drug|Elsubrutinib|Elsubrutinib capsule will be administered orally.
79970264|NCT03682705|Drug|Upadacitinib|Upadacitinib tablet will be administered orally.
79970265|NCT03682705|Drug|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
79970266|NCT03682705|Drug|Placebo for upadacitinib|Placebo tablet for upadacitinib will be administered orally.
79313432|NCT04417504|Other|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.
79313433|NCT04417504|Other|Control isocaloric breakfast|White bread, butter and milk.
79970267|NCT03361618|Dietary Supplement|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
79476067|NCT04768985|Drug|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
79641334|NCT04046848|Drug|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
79806011|NCT00701688|Drug|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
79970268|NCT01314495|Drug|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
79970269|NCT01314495|Drug|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
79970270|NCT03367780|Device|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
79970271|NCT03361540|Drug|ASP8302|ASP8302 will be administered orally.
79970272|NCT03361540|Drug|Placebo|Placebo will be administered orally.
79313434|NCT03009539|Behavioral|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
79313435|NCT04711486|Drug|Contraloid acetate|Oral administration of drug substance capsules
79313436|NCT04711486|Drug|Placebo|Oral administration of placebo without any exipients.
79313437|NCT01696721|Other|No intervention|
79476068|NCT04768985|Drug|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
79476069|NCT05739253|Procedure|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
79476070|NCT04210037|Drug|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
79476071|NCT04210037|Drug|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
79806012|NCT00699426|Drug|nexium|40 mg once daily is tested together with Yoghurt
79806013|NCT00699426|Drug|nexium|nexium and placebo are tested
79313438|NCT04686292|Diagnostic Test|urine flow cytometry|Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
79313439|NCT01288235|Radiation|Proton radiotherapy|5 days a week
79476072|NCT05739175|Device|Mobile Application with Interactive Nurse Support|"A mobile application containing an interactive nurse support program will be applied to the patients in the experimental group and its effect on patient outcomes will be evaluated through scales.~The mobile application consists of three modules. The first part is a learning module with videos on Covid 19, breast cancer and chemotherapy related side effects management. Second part is ask the nurse/doctor. Third part is patient experiences module.~After the participants download the mobile application to their phones, they can log in to the application with a valid e-mail address and password."
79476073|NCT05739097|Diagnostic Test|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
79476074|NCT01923805|Device|Vitagel|Vitagel
79476075|NCT01923961|Procedure|HDF NaCl|
79806014|NCT00699426|Dietary Supplement|Yoghurt|Yoghurt
79806015|NCT00699426|Drug|placebo+placebo|placebo and placebo are tested.
79806016|NCT00593606|Drug|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
79806017|NCT04119102|Drug|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
79970273|NCT04943367|Device|TEAS|Transcutaneous electrical acupuncture stimulation
79970274|NCT04539561|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of hand pigmentation
79970275|NCT03123484|Drug|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
79970276|NCT03123484|Drug|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
79970277|NCT02519764|Other|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
79641335|NCT00154232|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79641336|NCT00180453|Device|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
79970278|NCT02519764|Other|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
79970279|NCT03179787|Drug|Aripiprazole oral product|oral administration of aripiprazole
79970280|NCT03367468|Other|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
79476076|NCT01923961|Procedure|Hemodialysis|
79641337|NCT00180453|Device|Coronary artery stent placement|Coronary artery stent placement
79476077|NCT01923961|Procedure|Standard Predilution Hemodiafiltration|
79476078|NCT04116281|Other|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
79476079|NCT04750733|Other|Assessment|Assessment of core strength and endurance, muscle strength, postural sway in different condition, physical capacity and fatigue
79476080|NCT01924975|Procedure|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
79476081|NCT01924975|Device|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
79476082|NCT01924975|Device|A 22 or 24 G intravenous catheter|
79476083|NCT00371501|Drug|Rosuvastatin|10mg/day
79476084|NCT00371501|Drug|placebo|one tablet/day
79476085|NCT00371501|Drug|aspirin|80mg/day
79476086|NCT00371501|Drug|placebo|placebo
79641338|NCT00154271|Drug|Valsartan, Valsartan HCT|
79641339|NCT04024423|Other|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
79641340|NCT04018846|Procedure|Revascularization using a BIOPROTEC Graft|It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.
79641341|NCT00154349|Drug|Imatinib Mesylate|
79641342|NCT02923804|Dietary Supplement|Omega-3|3x 1g capsules taken daily for 6 months
79970281|NCT03367468|Other|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
79970282|NCT03745937|Drug|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
79970283|NCT03745937|Drug|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
79970284|NCT02956057|Drug|Polyethylene Glycols|
79970285|NCT02956057|Drug|Natrium picosulfate / Magnesium citrate|
79476087|NCT03251651|Drug|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
79476088|NCT03251651|Drug|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
79970286|NCT02956057|Drug|Polyethylene glycol / Ascorbic acid|
79641343|NCT02923804|Dietary Supplement|Olive oil|3x 1g capsules taken daily for 6 months
79476089|NCT01925677|Device|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
79806018|NCT02614118|Drug|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
79806019|NCT02614118|Drug|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
79970287|NCT03179319|Behavioral|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
79970288|NCT04526392|Other|Questionnaire|Pubertal course questionnaire
79970289|NCT04526470|Drug|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
79970290|NCT04526470|Drug|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
79970291|NCT01314651|Behavioral|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
79970292|NCT01314651|Behavioral|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
79313440|NCT02030002|Device|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
79313441|NCT02030002|Device|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
79641344|NCT02923765|Other|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
79641345|NCT00187941|Drug|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
79806020|NCT02614118|Drug|Placebo|placebo 45 minutes before root canal treatment
79970293|NCT03361384|Drug|Alcohol|
79641346|NCT02923687|Drug|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
79641347|NCT02923687|Drug|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
79641348|NCT02923492|Behavioral|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
79970294|NCT03361384|Other|Placebo (non-alcoholic beverage)|
79970295|NCT02519374|Drug|Placebo (including Maltodextrin)|
79970296|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 1
79970297|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 2
79970298|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 3
79970299|NCT01176695|Drug|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
79970300|NCT01176695|Drug|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
79970301|NCT03361150|Procedure|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
79970302|NCT03361150|Procedure|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
79970303|NCT04526626|Device|Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)|Thermal injury to long saphenous vein
79970304|NCT03367390|Device|AID System|AID system
79970305|NCT03367390|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
79970306|NCT01179893|Biological|IVIG|Intravenous immunoglobulin
79641349|NCT00154388|Drug|Imatinib mesylate|
79970307|NCT01179893|Procedure|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
79970308|NCT04526080|Device|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
79970309|NCT04526080|Device|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
79313442|NCT04479371|Drug|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
79641350|NCT02923414|Device|Standard escalating shocks|125 J, 150 J, 200 J
79641351|NCT02923414|Device|High energy shock protocol|360 J, 360 J, 360 J.
79970310|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
79970311|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
79970312|NCT01176851|Drug|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
79970313|NCT02519218|Device|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
79970314|NCT01176929|Other|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~A systematic telephone contact with the referring physician~A telephone helpline for people who made a suicide attempt and referring physicians."
79970315|NCT01176929|Other|Usual Treatment|Usual Treatment
79970316|NCT03627091|Drug|Ontamalimab|SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
79970317|NCT03627091|Other|Placebo|SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
79970318|NCT01179971|Dietary Supplement|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
79970319|NCT04526314|Other|observational|observational
79970320|NCT04237584|Drug|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
79970321|NCT04237584|Drug|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
79970322|NCT04237584|Drug|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
79641352|NCT00180492|Device|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
79970323|NCT04237584|Drug|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
79476090|NCT05349461|Procedure|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
79313443|NCT04479371|Drug|Bupivacaine|Standard bupivacaine
79313444|NCT02079610|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
79313445|NCT02079610|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
79313446|NCT03112733|Diagnostic Test|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
79641353|NCT02923375|Biological|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
79313447|NCT02366741|Radiation|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
79313448|NCT03112655|Diagnostic Test|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
79313449|NCT02366585|Drug|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
79476091|NCT05349461|Procedure|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
79476092|NCT05738863|Device|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
79641354|NCT02923453|Dietary Supplement|CNT 2000 American ginseng extract|
79641355|NCT02923453|Dietary Supplement|Placebo|
79641356|NCT00154427|Drug|activated recombinant human factor VII|
79641357|NCT02923258|Drug|Docetaxel|20mg/m2/w
79641358|NCT02923258|Drug|Cisplatin|100mg/m2/q3w
79641359|NCT02923258|Radiation|IMRT|a total dose of 60Gy in 30fractions over 6 weeks
79641360|NCT02923297|Other|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
79970324|NCT04237584|Drug|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
79970325|NCT04237584|Drug|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
79970326|NCT02893787|Other|Speckle Tracking Echocardiography|Echocardiography analyses
79970327|NCT02519296|Behavioral|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
79476093|NCT05738863|Device|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
79476094|NCT04023461|Device|PVAC GOLD catheter ablation|Isolation of pulmonary veins using PVAC GOLD catheter.
79970328|NCT02519296|Behavioral|Observation|fMRI.
79476095|NCT02287675|Drug|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
79476096|NCT02287675|Drug|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
79641361|NCT02923336|Drug|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
79806021|NCT04127942|Procedure|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
79806022|NCT04134416|Drug|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
79476097|NCT02973893|Biological|Placebo|Placebo
79476098|NCT02973893|Biological|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
79313450|NCT02362685|Device|functional test|subjects perform a metabolic exercise testing
79476099|NCT02973893|Biological|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
79476100|NCT05738707|Biological|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
79476101|NCT05349305|Drug|continuous renal replacement therapy|continuous renal replacement therapy
79476102|NCT05738629|Drug|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
79476103|NCT05349149|Drug|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
79476104|NCT05349149|Drug|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
79806023|NCT04134416|Behavioral|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
79970329|NCT02519296|Device|fMRI|Functional Magnetic Resonance Imaging of the brain
79970330|NCT01177085|Behavioral|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
79970331|NCT04525378|Other|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
79970332|NCT03858803|Behavioral|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
79970333|NCT03858803|Behavioral|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
79970334|NCT03371134|Biological|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
79970335|NCT05180916|Device|TVNS|Cerbomed NEMOS
79313451|NCT02362685|Genetic|matching genotype with phenotype|
79313452|NCT02366429|Behavioral|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
79313453|NCT02366429|Other|TAU|Treatment as usual provided at antenatal clinics and other health care instances
79313454|NCT02079532|Drug|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
79313455|NCT02372279|Other|Embryo observation|In EO group, conventional observations will be made.
79313456|NCT02366351|Drug|SHR3824|Once daily, 12 weeks
79313457|NCT02366351|Drug|Placebo|Once daily, 12 weeks
79313458|NCT02366117|Behavioral|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
79641362|NCT02923219|Biological|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
79970336|NCT03360994|Other|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
79313459|NCT02038673|Drug|ASP5878|oral
79313460|NCT02958917|Drug|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
79313461|NCT02958917|Other|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
79970337|NCT03360994|Other|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
79970338|NCT01177163|Drug|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
79313462|NCT02362529|Drug|Minocycline|50 mg and 100 mg capsule, oral administration
79313463|NCT02362529|Drug|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
79313464|NCT02362529|Drug|Celecoxib|100 mg and 200 mg capsules, oral administration.
79313465|NCT02362607|Behavioral|Integrated Diabetes Management Protocol|
79313466|NCT02362607|Behavioral|Standard Diabetes Management Protocol|
79313467|NCT02362295|Other|qualitative interview|some patient are interviewed.
79970339|NCT01177163|Drug|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
79970340|NCT01177163|Drug|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
79970341|NCT05180604|Behavioral|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
79313468|NCT02769689|Drug|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
79313469|NCT02769689|Drug|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
79476105|NCT04337645|Procedure|surgical treatment of peri-implantitis|resective surgical treatment of peri-implantitis
79476106|NCT01928797|Device|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
79970342|NCT03367234|Behavioral|Individual Therapy Sessions|One-on-one sessions with a counselor
79970343|NCT03367234|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
79970344|NCT03367234|Behavioral|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
79970345|NCT03367234|Behavioral|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
79970346|NCT03367234|Behavioral|Group Therapy Sessions|Group therapy sessions
79970347|NCT03367234|Behavioral|Psychiatric Consultation|Access to psychiatric consultation
79313470|NCT02769689|Drug|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
79313471|NCT02769689|Drug|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
79313472|NCT02362061|Radiation|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
79313473|NCT02362139|Drug|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
79313474|NCT02365571|Drug|LY3154207|Administered orally
79313475|NCT02365571|Drug|Placebo|Administered orally
79313476|NCT02365571|Drug|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
79313477|NCT02362217|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
79313478|NCT02362217|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
79313479|NCT02362217|Biological|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
79313480|NCT02362217|Biological|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
79476107|NCT03702413|Procedure|Endovascular treatment|Acute thrombectomy
79641363|NCT00180531|Device|Renewal TR2|
79641364|NCT02923141|Behavioral|Neutral Writing|
79313481|NCT02361983|Device|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
79476108|NCT04338035|Behavioral|Expectant management|Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
79476109|NCT05349071|Drug|methylprednisolone|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
79970348|NCT03367234|Behavioral|Contingency Management|Rewards for engagement in specified recovery behaviors
79476110|NCT05349071|Drug|physiological saline|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
79476111|NCT01929889|Drug|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
79641365|NCT02923141|Behavioral|Expressive Writing|
79970349|NCT02524925|Procedure|fast track protocol|Evaluation of postoperative stress
79970350|NCT03370978|Behavioral|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
79970351|NCT03858881|Behavioral|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
79970352|NCT03858881|Behavioral|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
79970353|NCT03858881|Behavioral|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
79970354|NCT04524988|Procedure|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
79476112|NCT05738473|Drug|antibiotic|For pregnant women with GBS colonization, antibiotics are used to prevent infection
79476113|NCT05738395|Diagnostic Test|Questions|Questions
79641366|NCT02923141|Behavioral|Contingency Management|
79970355|NCT03224598|Drug|A-101 Topical Solution 40%|A-101 Topical Solution 40%
79970356|NCT03681691|Drug|Estradiol patch|transdermal 17β-estradiol patch
79970357|NCT03370822|Device|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
79970358|NCT01177319|Drug|Glutathione|
79476114|NCT03452033|Drug|H-1337 Placebo|H-1337 Placebo Vehicle
79476115|NCT03452033|Drug|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
79476116|NCT03452033|Drug|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
79641367|NCT02922907|Dietary Supplement|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
79641368|NCT02922907|Dietary Supplement|Placebo for arabinoxylan rice bran|inactive product
79641369|NCT02923102|Dietary Supplement|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
79641370|NCT02923102|Dietary Supplement|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
79641371|NCT02923024|Behavioral|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
79313482|NCT02361827|Procedure|Embryo transfer|For patients in each group after oocyte retrieval, they will have embryo transferred 3 or 5 days after oocyte retrieval. For FET cycles, they will have ET with an euploid blastocyst.
79313483|NCT02365727|Drug|Liposomal bupivacaine|
79476117|NCT03452033|Drug|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
79641372|NCT02922946|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
79641373|NCT00188019|Procedure|diagnosis methods|
79641374|NCT02922595|Device|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
79970359|NCT03360760|Drug|Doxorubicin|60mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
79970360|NCT03360760|Drug|Cisplatin|100mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
79970361|NCT03360760|Drug|Methotrexate|High dose of methotrexate (8-12g/m^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
79970362|NCT03360760|Drug|Ifosfamide|12g/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
79641375|NCT02922595|Device|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
79970363|NCT03360760|Procedure|definitive surgery|Including limb-sparing procedure and amputation
79970364|NCT03360760|Other|pre surgical chemotherapy|chemotherapy that given before definitive surgery
79313484|NCT02365727|Drug|Ropivacaine|
79313485|NCT02365727|Drug|Epinephrine|
79313486|NCT02365727|Drug|Clonidine|
79476118|NCT05725135|Drug|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
79476119|NCT05718271|Other|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
79476120|NCT05718271|Other|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
79970365|NCT01285661|Drug|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
79970366|NCT02935842|Other|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
79970367|NCT02935842|Other|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
79970368|NCT03360682|Drug|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
79970369|NCT03360682|Drug|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
79970370|NCT03360682|Drug|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
79970371|NCT03360682|Drug|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
79970372|NCT03360682|Drug|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
79313487|NCT02365727|Drug|Saline|
79313488|NCT02361593|Procedure|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
79313489|NCT02361593|Procedure|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
79313490|NCT02365805|Drug|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
79641376|NCT02922712|Drug|NISE|Nise 200mg Max per day in 2 divided doses
79641377|NCT00180570|Device|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
79641378|NCT02922790|Behavioral|standard health information|Subjects will review standard health information
79641379|NCT02922790|Behavioral|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
79641380|NCT02922790|Behavioral|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
79641381|NCT02922673|Drug|Aspirin|
79641382|NCT02922673|Drug|Placebo|
79641383|NCT02922556|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
79970373|NCT01180205|Drug|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
79970374|NCT01180205|Drug|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
79970375|NCT01180205|Drug|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
79970376|NCT01180205|Drug|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
79970377|NCT04523506|Biological|Botulinum toxin(Botox)|This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
79313491|NCT02365805|Drug|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
79313492|NCT02365805|Drug|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
79806024|NCT04134416|Device|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
79970378|NCT01174589|Other|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
79970379|NCT03370744|Diagnostic Test|Neuropsychological scale|Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
79970380|NCT01180283|Drug|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
79970381|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
79970382|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
79970383|NCT01177475|Other|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
79313493|NCT03112889|Drug|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
79313494|NCT04478825|Drug|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
79970384|NCT01177475|Other|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
79313495|NCT04479059|Other|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
79313496|NCT04438889|Other|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
79313497|NCT03112577|Drug|REGN3500|Intravenous (IV) use
79313498|NCT03112577|Drug|Dupilumab|Subcutaneous (SC) use
79476121|NCT05738317|Drug|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
79476122|NCT02284555|Drug|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
79313499|NCT03112577|Drug|Placebo|Matching placebo
79313500|NCT03112577|Drug|Fluticasone propionate|Inhalation use
79313501|NCT02361905|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
79970385|NCT04525846|Other|PFMT|"program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
79806025|NCT04134182|Drug|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
79641384|NCT02922556|Other|Commercially available computerized training|
79641385|NCT02922478|Radiation|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
79641386|NCT02922478|Procedure|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
79806026|NCT04134182|Drug|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
79806027|NCT00870584|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
79476123|NCT02987179|Other|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
79970386|NCT04525846|Other|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
79970387|NCT05179980|Other|Assessment|Evaluation of clinical-surgical competencies with a previously validated instrument.
79970388|NCT01287845|Drug|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
79970389|NCT01287845|Drug|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
79970390|NCT03360604|Dietary Supplement|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
79970391|NCT03360604|Dietary Supplement|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
79641387|NCT02922478|Radiation|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
79806028|NCT00870584|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
79806029|NCT02616224|Other|No intervention|No intervention was administered in this study.
79970392|NCT03867084|Biological|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
79970393|NCT03867084|Drug|Placebo|IV infusion of 0.9% normal saline.
79970394|NCT03860831|Drug|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
79970395|NCT03360526|Device|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
79970396|NCT03360526|Procedure|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
79970397|NCT01180439|Device|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
79313502|NCT02361905|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
79313503|NCT02361749|Drug|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
79313504|NCT02361749|Procedure|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
79313505|NCT02361203|Behavioral|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
79313506|NCT02361359|Other|Psychological questionnaires|
79313507|NCT02361437|Dietary Supplement|Vasculera|Vasculera 630 mg b.i.d.
79313508|NCT02359409|Device|goggle balloon|Colonoscopy will be performed using the water immersion technique.
79313509|NCT02359409|Other|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
79313510|NCT04349735|Other|Assessment of inhalation technique|Assessment of inhalation technique by 3 methods in every patient
79806030|NCT02614508|Drug|Buparlisib|Given PO
79806031|NCT02614508|Drug|Ibrutinib|Given PO
79806032|NCT02614508|Biological|Ofatumumab|Given IV
79806033|NCT02613806|Drug|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
79970398|NCT03639883|Drug|AIV001|Intradermal injection
79476124|NCT02753699|Drug|Alisporivir|Intervention of interest; follow-up after ALV-active study
79970399|NCT01177631|Procedure|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
79970400|NCT03360448|Drug|Ad5.hAC6|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
79970401|NCT03360448|Drug|Placebo|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
79313511|NCT03160469|Device|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) & class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
79476125|NCT04335617|Drug|MMPF (Micronized purified Flavonoid-Fraction)|500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
79970402|NCT01288001|Drug|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
79970403|NCT03732313|Procedure|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
79970404|NCT03732313|Procedure|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
79313512|NCT02358941|Behavioral|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
79313513|NCT02358941|Behavioral|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
79476126|NCT04335617|Other|Placebo|4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
79806034|NCT02613806|Drug|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
79806035|NCT04134338|Other|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
79806036|NCT02616068|Drug|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
79806037|NCT02616068|Drug|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
79806038|NCT02616068|Drug|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
79806039|NCT02616068|Drug|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
79970405|NCT03360370|Other|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
79970406|NCT03667326|Drug|Aspirin tablet|Low dose aspirin, 81mg tablets, PO
79970407|NCT03667326|Drug|Placebo oral capsule|Placebo oral capsule, PO
79970408|NCT03860519|Behavioral|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
79970409|NCT03860519|Behavioral|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
79970410|NCT03860519|Behavioral|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
79970411|NCT03860519|Behavioral|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
79970412|NCT03860519|Behavioral|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
79970413|NCT03860519|Behavioral|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
79476127|NCT05717413|Device|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
79476128|NCT05736601|Device|focus motion knee brace|knee brace that captures knee motion
79476129|NCT03133247|Drug|SHR-1316|PD-L1
79641388|NCT02922478|Procedure|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
79641389|NCT02922205|Device|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
79806040|NCT04127084|Drug|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
79970414|NCT03860519|Behavioral|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
79970415|NCT03860519|Behavioral|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
79806041|NCT04126928|Diagnostic Test|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
79970416|NCT03370666|Other|HFNT|High flow nasal therapy
79970417|NCT03370666|Other|NIV|Noninvasive ventilation
79970418|NCT03734341|Device|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
79970419|NCT03734341|Device|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
79970420|NCT05163132|Device|Shearwave elastography|Shear wave elastography is an ultrasound applied technique used to measure tissue stiffness as a result of a disease. So, it can be used to evaluate liver stiffness as a result of liver cirrhosis
79970421|NCT03261323|Procedure|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
79313514|NCT03160313|Behavioral|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
79476130|NCT03029689|Drug|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
79476131|NCT03029689|Drug|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
79476132|NCT03029689|Drug|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
79476133|NCT03085277|Dietary Supplement|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
79313515|NCT03160313|Behavioral|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
79313516|NCT02358785|Device|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
79313517|NCT02358707|Other|Ibuprofen phonophoresis|
79313518|NCT02358551|Device|Placement of electrode lead through axillary vein puncture|
79313519|NCT02358551|Device|Placement of electrode lead through subclavian vein puncture|
79313520|NCT02358317|Behavioral|Video Game Motor Training|
79313521|NCT02358317|Behavioral|Sedentary Video Game Training|
79313522|NCT02360969|Other|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS <50 Deep anesthesia and muscle relaxation: BIS <50 and TOF 0/4"
79313523|NCT02361047|Behavioral|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
79313524|NCT02358239|Procedure|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
79970422|NCT03261323|Procedure|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
79970423|NCT03261323|Other|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
79313525|NCT02360813|Behavioral|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
79313526|NCT02360813|Other|Treatment as usual|Keep getting usual care.
79313527|NCT02360657|Drug|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2*5 mg tablet) orally once daily for 4 weeks.
79476134|NCT03085277|Dietary Supplement|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
79476135|NCT00372047|Device|multiphoton laser imaging|
79476136|NCT02287909|Drug|Clopidogrel|Swiching from ticagrelor to clopidogrel
79476137|NCT02287909|Drug|Ticagrelor|Continue treatment with ticagrelor
79476138|NCT00371579|Drug|rosuvastatin|
79641390|NCT04705610|Other|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~Neurological evaluation~Neuropsychological evaluations~Social cognitions tasks~Behaviour assessment"
79641391|NCT00188058|Device|Setting of positive end-expiratory pressure|
79970424|NCT04525300|Drug|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
79641392|NCT02922088|Device|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
79970425|NCT04525300|Drug|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
79970426|NCT03865121|Drug|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
79970427|NCT03680911|Drug|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
79641393|NCT02922283|Device|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
79641394|NCT02922283|Procedure|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
79641395|NCT02922283|Device|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
79970428|NCT03680911|Drug|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
79970429|NCT03370588|Drug|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
79970430|NCT03370588|Drug|Normal saline|Group B: Saline infusion during same time period.
79970431|NCT05156814|Drug|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
79313528|NCT02360657|Drug|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
79476139|NCT02935907|Drug|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
79313529|NCT02360657|Drug|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
79313530|NCT02360735|Other|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
79313531|NCT02360735|Other|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
79313532|NCT02358005|Procedure|Extracorporeal shock wave therapy 60mj|
79641396|NCT02922283|Procedure|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
79641397|NCT02922049|Other|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
79313533|NCT02358005|Procedure|Extracorporeal shock wave therapy 120mj|
79641398|NCT04705454|Biological|Loncastuximab Tesirine|
79641399|NCT02922400|Behavioral|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
79641400|NCT00180609|Device|Automatic threshold test in Insignia Pacemakers from Guidant|
79313534|NCT02358005|Procedure|non extracorporeal shock wave therapy|
79313535|NCT02360501|Drug|Docetaxel|75mg/㎡,d1
79313536|NCT02360501|Drug|Cisplatin|25mg/㎡,d1-3
79641401|NCT02922244|Other|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
79641402|NCT02922244|Other|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
79641403|NCT02922244|Other|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
79970432|NCT05156814|Drug|Duphaston|Duphaston®, 10 mg
79313537|NCT02360501|Drug|Capecitabine|2000mg/㎡,d1-14
79313538|NCT02358629|Device|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
79313539|NCT02360423|Device|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
79313540|NCT02360423|Device|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
79313541|NCT02358161|Drug|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
79313542|NCT02357927|Behavioral|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
79313543|NCT02357927|Behavioral|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
79641404|NCT02922244|Other|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
79641405|NCT02922166|Drug|SRX246|oral capsule
79641406|NCT02922166|Drug|Placebo|oral capsule
79641407|NCT04705493|Other|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
79641408|NCT02922127|Drug|Ulipristal Acetate|Daily use of Ulipristal Acetate
79641409|NCT02922127|Drug|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
79970433|NCT05156814|Drug|Klimadynon|Cimicifuga racemosa rhizomatum extract
79970434|NCT05156814|Drug|Divigel|Divigel, 0.1%
79970435|NCT03250013|Drug|ADHD medications|
79970436|NCT03367078|Device|Anodal tDCS|Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
79313544|NCT02360345|Drug|ONX-0801|
79313545|NCT02357849|Drug|Aripiprazole|see arm description
79641410|NCT02922322|Other|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
79641411|NCT02921854|Other|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
79641412|NCT02921659|Dietary Supplement|Niagen™|nicotinamide riboside chloride, 250mg capsules
79641413|NCT02921659|Dietary Supplement|Placebo|silicified microcrystalline cellulose, vegetarian capsule
79641414|NCT00406211|Biological|MMRV|
79641415|NCT00406211|Biological|MMR (Priorix®)|
79970437|NCT03367078|Other|Usual care|Usual care of DOC patients
79313546|NCT02357849|Drug|Fluoxetine|see arm description
79313547|NCT02357693|Drug|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
79313548|NCT02360033|Behavioral|Systemic Therapy for Social Anxiety Disorder|
79313549|NCT02360033|Behavioral|Cognitive Behavioral Therapy for Social Anxiety Disorder|
79970438|NCT03370432|Other|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
79970439|NCT01174667|Procedure|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
79641416|NCT00406211|Biological|Varicella (Varilrix®)|
79313550|NCT02357771|Drug|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
79313551|NCT02357771|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
79313552|NCT02357537|Behavioral|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
79313553|NCT02357615|Drug|nifedipine CR tablets (Xin Ran)|
79641417|NCT00188097|Behavioral|Diagnosis of variceal bleeding and dits control in cirrhosis|
79641418|NCT02921932|Dietary Supplement|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
79641419|NCT02921932|Other|Cognitive Training, Memory Card Game|Preoperative memory card game
79313554|NCT02357615|Drug|Adalat|
79313555|NCT03160001|Drug|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
79641420|NCT02921932|Device|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
79641421|NCT04689100|Drug|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
79970440|NCT01174667|Other|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
79970441|NCT03224130|Other|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
79476140|NCT02284867|Other|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
79476141|NCT02833805|Drug|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
79476142|NCT02833805|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
79476143|NCT02833805|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
79476144|NCT02833805|Radiation|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
79476145|NCT02833805|Drug|Tacrolimus|Start on Day 5 through Day 365
79970442|NCT03224130|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
79476146|NCT02833805|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
79476147|NCT02327195|Drug|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
79313556|NCT03160001|Drug|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
79313557|NCT03160001|Drug|Etanercept|Etanercept 50mg weekly
79641422|NCT04689100|Drug|JMT101|IV infusion Q2W (28-day cycles)
79641423|NCT00188136|Drug|Melphalan, ATG, Fludarabine|allo Tx during aplasia
79970443|NCT03858413|Diagnostic Test|No intervention|No intervention
79970444|NCT03864887|Procedure|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
79476148|NCT02327195|Drug|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
79641424|NCT02921698|Device|FRED®|Flow Re-Direction Endoluminal Device
79641425|NCT00406250|Drug|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
79641426|NCT00406250|Drug|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
79641427|NCT03878056|Device|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
79970445|NCT03864887|Procedure|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
79641428|NCT00180726|Procedure|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
79641429|NCT02921620|Biological|PRX-102|Intravenous
79641430|NCT02921620|Other|Placebo|Intravenous
79970446|NCT03864887|Device|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
79970447|NCT03370354|Behavioral|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
79970448|NCT03367000|Dietary Supplement|Ceprolac|The supplement was packed into two ~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
79970449|NCT03367000|Other|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
79970450|NCT03366922|Dietary Supplement|Artemisia Annua, Moringa oleifera|As described above
79970451|NCT03370198|Biological|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
79641431|NCT02921347|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
79641432|NCT00406289|Procedure|18F-FDG-PET radiotherapy|
79641433|NCT00188175|Radiation|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
79641434|NCT02921269|Drug|Atezolizumab|Given IV
79641435|NCT02921269|Biological|Bevacizumab|Given IV
79641436|NCT02921269|Other|Laboratory Biomarker Analysis|Correlative studies
79641437|NCT00406406|Drug|SKI-606|
79641438|NCT02921542|Device|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
79641439|NCT00180765|Procedure|Up to 100ml blood will be taken by venupuncture.|
79641440|NCT00406484|Behavioral|Standard drug counseling|Individual drug counseling
79641441|NCT00406484|Behavioral|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
79313558|NCT02359643|Drug|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
79313559|NCT02038985|Other|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
79313560|NCT02359721|Drug|tablet clarithromycin 500 mg (Clarino-500) orally|orally
79476149|NCT04768465|Drug|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
79476150|NCT04768465|Drug|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
79476151|NCT02756351|Device|CytaCoat Nasal Prong|
79476152|NCT02756351|Device|Inspiration Healthcare Inspire nCPAP Nasal Prong|
79641442|NCT03835585|Device|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
79641443|NCT03835585|Other|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
79313561|NCT02359487|Behavioral|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
79476153|NCT01744223|Biological|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
79476154|NCT01744223|Drug|Rimiducid|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
79476155|NCT01744223|Biological|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
79476156|NCT01744223|Biological|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
79806042|NCT00697736|Procedure|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
79806043|NCT02615834|Procedure|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
79970452|NCT01289405|Device|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
79806044|NCT00870194|Drug|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
79970453|NCT03366688|Drug|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
79970454|NCT03366688|Drug|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
79970455|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
79970456|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
79476157|NCT01744223|Biological|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
79476158|NCT01744223|Procedure|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
79806045|NCT00870194|Drug|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
79806046|NCT00690430|Drug|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
79970457|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
79970458|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
79970459|NCT01180517|Procedure|Percutaneous coronary intervention (PCI)|balloon angioplasty
79970460|NCT01180517|Procedure|PCI|balloon angioplasty
79970461|NCT03358420|Diagnostic Test|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
79806047|NCT00690430|Drug|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
79476159|NCT01614665|Drug|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
79641444|NCT03835585|Behavioral|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley & Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
79806048|NCT02619656|Procedure|CO2 insufflation|Patients were randomized to insufflation with CO2.
79806049|NCT02619656|Procedure|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
79806050|NCT02619734|Biological|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
79970462|NCT03864809|Behavioral|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
79970463|NCT03358342|Other|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
79970464|NCT03858257|Device|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
79970465|NCT03858257|Device|Standard oxygenation|Supplemental oxygen through a facemask.
79970466|NCT03679741|Device|CONTROL Lens|Acuvue OASYS
79970467|NCT03679741|Device|TEST Lens|senofilcon A
79970468|NCT03360058|Behavioral|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
79970469|NCT03360058|Behavioral|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
79641445|NCT03835585|Behavioral|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
79313562|NCT02359487|Behavioral|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
79313563|NCT02357303|Drug|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
79313564|NCT02357303|Drug|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
79313565|NCT02357303|Other|Placebo|100mL of water
79313566|NCT03112811|Device|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
79313567|NCT03112811|Device|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
79806051|NCT04060186|Procedure|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
79313568|NCT02352857|Other|Sugar|100g of sponge cakes made with 24g of dextrose.
79641446|NCT02921464|Other|none - registry clinic followup only|
79806052|NCT02619500|Other|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
79806053|NCT02619500|Other|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
79313569|NCT02352857|Other|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
79313570|NCT02352935|Device|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
79313571|NCT02357225|Drug|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
79313572|NCT04478903|Other|Questionnaire|Zarit Burden Inventory French version and SF12
79313573|NCT02357381|Device|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
79313574|NCT02356991|Drug|Famitinib|
79313575|NCT02356991|Drug|Placebo|
79313576|NCT03112265|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
79806054|NCT02619500|Other|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
79476160|NCT01614665|Drug|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
79641447|NCT00188214|Procedure|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
79970470|NCT01289327|Drug|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (~2 minutes) or according to clinical judgment.
79641448|NCT00406523|Device|JANUS Stent|
79970471|NCT03359980|Drug|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
79970472|NCT03857789|Other|Questionnaire|A 40 question frailty questionnaire.
79970473|NCT02446405|Drug|Enzalutamide|
79641449|NCT02921503|Other|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
79970474|NCT02446405|Drug|NSAA|
79970475|NCT02446405|Drug|LHRHA or Surgical Castration|
79641450|NCT02920840|Device|Intermittent theta-burst stimulation|see associated arm/group description
79806055|NCT02619500|Other|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
79806056|NCT04126304|Drug|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
79970476|NCT03858023|Other|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
79970477|NCT03366610|Other|Non-interventional|Non-interventional
79970478|NCT01181063|Drug|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
79970479|NCT03359824|Other|Exercise|
79806057|NCT04126304|Drug|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
79970480|NCT03678103|Device|INVSENSOR00029|Noninvasive pulse oximeter sensor
79970481|NCT03358264|Dietary Supplement|L-citrulline|Amino acid supplement
79641451|NCT02920840|Device|Negative-peak-triggered-TMS|see associated arm/group description
79984490|NCT02446522|Procedure|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
79984491|NCT03203278|Behavioral|Web-based exercise programme|Aerobic, resistance and balance exercises
79641452|NCT02920840|Device|Open-loop replay TMS|see associated arm/group description
79641453|NCT02920801|Drug|saxagliptin|5mg per day for 12 weeks
79641454|NCT02920801|Drug|Metformin|1500mg per day for 12 weeks
79641455|NCT00154505|Device|Lateral trunk support of wheelchair seating|
79641456|NCT00180843|Drug|salbutamol + ipratropium bromide nebules|
79641457|NCT00180843|Drug|nebulized saline|
79641458|NCT02921152|Procedure|bone marrow aspiration /trephine biopsy|
79641459|NCT02921074|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
79641460|NCT02921074|Other|Commercially available computerized training|
79984492|NCT02450344|Behavioral|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
79984493|NCT02450344|Behavioral|Passive health promotion|An electronic package of information related to alcohol
79970482|NCT03858179|Device|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
79970483|NCT03858179|Device|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
79970484|NCT03366532|Other|Dietary assessments|We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
79970485|NCT03639805|Other|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
79970486|NCT03639805|Other|standard care of vaso-occlusive crises|administration of standard care only
79970487|NCT01180595|Device|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
79970488|NCT01180595|Device|Trabecular Metal Monoblock Tibial Total Knee Component|
79970489|NCT03358186|Procedure|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
79970490|NCT02596997|Drug|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
79970491|NCT04522258|Dietary Supplement|Dietary fiber|Fermentable cereal bran
79970492|NCT04522258|Dietary Supplement|Placebo|Refined cereal flour
79970493|NCT03649477|Drug|3.2 mg intranasal carbetocin|three times per day with meals
79970494|NCT03649477|Drug|9.6 mg intranasal carbetocin|three times per day with meals
79970495|NCT03649477|Drug|placebo|three times per day with meals
79806058|NCT04126304|Diagnostic Test|Mycoplasma detection|"common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
79970496|NCT01181219|Procedure|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
79970497|NCT01181219|Procedure|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
79970498|NCT03359746|Drug|Grazoprevir/Elbasvir|Medication for treatment of patient
79970499|NCT03359668|Diagnostic Test|Use of IV contrast during head and neck CT|Use of IV contrast during head and neck CT
79970500|NCT01180673|Behavioral|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
79641461|NCT02920879|Procedure|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
79641462|NCT02920762|Other|on-interventional study - retrospective database review|
79641463|NCT02920567|Drug|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
79313577|NCT03112265|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
79313578|NCT03112265|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
79313579|NCT03112343|Device|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
79313580|NCT03112343|Device|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
79641464|NCT02920567|Drug|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
79641465|NCT02920723|Other|Training|
79970501|NCT01180673|Behavioral|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
79641466|NCT02920723|Other|Control|
79313581|NCT02357069|Drug|Enbrel|Etanercept
79313582|NCT02357069|Drug|LBEC0101|Etanercept
79313583|NCT02356913|Drug|Nicotine gum|
79313584|NCT02352545|Drug|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
79641467|NCT00180882|Drug|rituximab|
79641468|NCT02920606|Procedure|Pulpotomy|
79984494|NCT04362449|Combination Product|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
79984495|NCT04362449|Combination Product|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
79984496|NCT02446210|Device|Magstim 200|Transcranial Magnetic Stimulation
79984497|NCT02446210|Device|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
79641469|NCT02920606|Procedure|Endodontic treatment|
79641470|NCT02920645|Other|AVM-related ICH|
79641471|NCT02920684|Other|Passive legs mobilisation|A physiotherapist performs a passive leg movement
79641472|NCT02920684|Other|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
79641473|NCT02920684|Other|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
79641474|NCT02920684|Other|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
79641475|NCT02920411|Other|Pediatopic Treatment Cream|Applied twice a day minimum.
79641476|NCT02920411|Other|Pediatopic Body lotion|Applied at libitum.
79641477|NCT00154622|Behavioral|work hardening program|
79641478|NCT00180921|Drug|Imatinib|
79984498|NCT02077166|Drug|Ibrutinib|
79984499|NCT02077166|Drug|Lenalidomide|
79984500|NCT02077166|Drug|Rituximab|
79984501|NCT05186350|Procedure|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
79984502|NCT05186350|Procedure|ESWL+ ERCP|ESWL + Stone removal through ERCP
79984503|NCT03198832|Procedure|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
79984504|NCT04273217|Drug|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
79984505|NCT04273217|Drug|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
79641479|NCT02920489|Drug|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
79313585|NCT02356835|Device|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
79641480|NCT02920489|Drug|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
79641481|NCT02920372|Drug|EPOETIN ALFA|
79641482|NCT02920255|Other|Diagnostic|Measurement of spinal tilt
79641483|NCT00188331|Behavioral|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
79641484|NCT02920294|Dietary Supplement|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
79641485|NCT02920294|Dietary Supplement|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
79641486|NCT02920294|Dietary Supplement|Placebo|Acidified dairy drink without ferments
79806059|NCT04126304|Other|Data collection|"Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
79806060|NCT04126304|Other|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
79806061|NCT02677792|Behavioral|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
79641487|NCT02919904|Device|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~NREM and REM sleep frequency and duration~Duration and number of arousal~Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~Apnea/hypopnea index and respiratory disturbance index"
79313586|NCT02356835|Device|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
79313587|NCT02352701|Drug|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
79641488|NCT00154661|Drug|pentoxifylline|
79641489|NCT00180960|Drug|Oxaliplatin and irinotecan|
79970502|NCT01310101|Drug|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
79313588|NCT02352701|Drug|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
79641490|NCT02919943|Procedure|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
79313589|NCT02352701|Drug|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
79313590|NCT02352623|Radiation|DXA scan|DXA scan
79476161|NCT02285023|Other|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
79641491|NCT00154700|Drug|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
79806062|NCT00746980|Drug|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
79313591|NCT02352623|Procedure|Clinical examination|Clinical examination
79313592|NCT02352467|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
79313593|NCT02356445|Other|Cytotoxic drug|Observe patients versus treatment type
79641492|NCT02920099|Other|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
79806063|NCT00863330|Biological|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
79806064|NCT02563054|Drug|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
79806065|NCT02563054|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
79806066|NCT02563054|Drug|Cisplatin|Participants will receive cisplastin, 80 mg/m^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
79806067|NCT02614040|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
79641493|NCT04688983|Drug|Ponatinib|30 mg QD starting day 1, given continuously unless interruption required for toxicity
79641494|NCT04688983|Drug|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
79806068|NCT02614040|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
79806069|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
79806070|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
79806071|NCT00698594|Biological|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
79806072|NCT00743470|Drug|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
79313594|NCT02356679|Drug|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
79313595|NCT02356679|Drug|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
79313596|NCT02352233|Procedure|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
79313597|NCT02356289|Drug|Placebo|
79313598|NCT02356289|Drug|MYK-461|
79313599|NCT02356367|Other|telemonitoring|
79313600|NCT02351999|Device|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
79641495|NCT04688983|Drug|Imatinib|starting day 1, given orally at 400mg BID continuously for 8 weeks
79641496|NCT00188370|Procedure|high frequency ultrasound imaging|
79641497|NCT02919865|Device|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
79641498|NCT02920060|Drug|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
79641499|NCT02920060|Drug|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
79641500|NCT03740815|Procedure|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
79641501|NCT03740815|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
79313601|NCT02352155|Procedure|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
79313602|NCT02352155|Other|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
79806073|NCT00743470|Drug|rifabutin|rifabutin capsule; see arms for intervention description
79806074|NCT02613962|Procedure|biopsy or surgical resection of tumor and blood sampling|
79806075|NCT00688324|Drug|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
79970503|NCT03864497|Procedure|Myocardial perfusion imaging|
79313603|NCT02355899|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
79641502|NCT03740815|Procedure|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
79970504|NCT03359512|Device|qCON monitor|supervision by qCON monitor of the depth of anesthesia
79806076|NCT02619578|Other|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
79806077|NCT02619578|Other|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
79970505|NCT03639727|Diagnostic Test|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
79806078|NCT02619578|Drug|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
79313604|NCT02351921|Device|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (~1 hour) in neural activity in the brain. The delivery of cTBS requires ~ 40 seconds in total.
79313605|NCT02352311|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
79313606|NCT02352311|Drug|AVODART|Dutasteride 0.5 mg
79313607|NCT02352311|Drug|CIALIS|Tadalafil 5 mg
79313608|NCT02352077|Biological|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
79313609|NCT02356055|Behavioral|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
79641503|NCT00154739|Drug|Gemcitabine|
79641504|NCT00154739|Drug|Cisplatin|
79641505|NCT00154739|Drug|Epirubicin|
79641506|NCT00180999|Drug|Erythropoiétine|
79641507|NCT02919553|Procedure|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
79806079|NCT02619578|Other|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
79806080|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Ketamine
79970506|NCT03639727|Diagnostic Test|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
79970507|NCT01180751|Radiation|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
79970508|NCT01181297|Other|Extensively Hydrolyzed Formula with a Probiotic|
79970509|NCT01181297|Other|Extensively Hydrolyzed Formula without a Probiotic|
79970510|NCT01180829|Behavioral|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
79641508|NCT02919553|Procedure|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
79806081|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Normal Saline
79806082|NCT02615912|Other|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
79806083|NCT02615912|Other|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
79806084|NCT02615912|Other|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
79806085|NCT02615912|Other|Silwet* DA-63 (Momentive) 1.5%|
79806086|NCT02615912|Other|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
79806087|NCT02615912|Other|Water (control)|
79806088|NCT02615756|Behavioral|Exercise|
79970511|NCT01180829|Behavioral|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
79970512|NCT03677869|Device|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
79970513|NCT04523272|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79970514|NCT04523272|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
79970515|NCT04523272|Drug|Sunitinib|A multi-target receptor tyrosine kinase inhibitor.
79970516|NCT01289561|Drug|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
79970517|NCT01289561|Drug|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
79806089|NCT04133090|Procedure|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
79970518|NCT03366376|Radiation|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
79313610|NCT03153215|Other|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
79313611|NCT03153215|Other|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
79641509|NCT02919709|Biological|blood taking|
79641510|NCT02919514|Other|Physical training on hard surface.|Physical training on hard surface.
79641511|NCT02919514|Other|Physical training on sand surface.|Physical training on sand surface.
79476162|NCT05348135|Other|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
79476163|NCT05348135|Other|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
79313612|NCT02355431|Drug|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
79641512|NCT02919514|Other|Physical training on soft surface.|Physical training on soft surface.
79641513|NCT00154778|Drug|Taxol, UFT,Leucovorin|
79641514|NCT00188409|Procedure|CT scan|
79641515|NCT02919631|Drug|Triheptanoin|Anaplerotic dietary oil
79313613|NCT02355431|Drug|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
79313614|NCT02355431|Drug|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
79313615|NCT02355353|Other|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
79313616|NCT02351687|Dietary Supplement|Lipid Nutrient Supplement|
79313617|NCT02351687|Drug|Sulfadoxine-pyrimethamine|
79476164|NCT05348135|Other|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
79476165|NCT02330341|Dietary Supplement|Artemisia dracunculus|
79641516|NCT02919631|Drug|Placebo oil|Safflower oil
79313618|NCT02351687|Drug|Albendazole|
79313619|NCT02351687|Drug|Zinc|
79313620|NCT02351687|Other|Insecticide-treated bednet|
79313621|NCT02351843|Device|MECTA Spectrum 5000Q|
79476166|NCT02330341|Other|Placebo|
79641517|NCT02919748|Other|Choral Singing|Weekly sessions at 1 hour of choral singing.
79641518|NCT02919748|Other|Health Education Program|Weekly session at 1 hour of health education talk and group activities
79641519|NCT00154817|Procedure|radiotherapy|
79641520|NCT00188448|Device|MRI|
79641521|NCT03670147|Device|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
79641522|NCT02919319|Drug|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
79641523|NCT02919319|Drug|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
79641524|NCT02919319|Drug|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
79641525|NCT02919319|Drug|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
79641526|NCT02919319|Drug|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
79313622|NCT02355509|Drug|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
79313623|NCT02355509|Drug|Placebo|Placebo pills are given instead of acarbose in this group
79313624|NCT02355197|Drug|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
79313625|NCT02351609|Behavioral|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
79970519|NCT03855527|Drug|Silver Diamine Fluoride|SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
79313626|NCT02351609|Other|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
79641527|NCT02919319|Drug|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
79970520|NCT03855527|Drug|Chlorhexidine|Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
79970521|NCT03855527|Procedure|Atraumatic Restorative Treatment without Disinfection|Atraumatic Restorative Technique will be performed without cavity disinfection
79970522|NCT03864263|Other||
79313627|NCT02351531|Dietary Supplement|Extensively Hydrolyzed formula|
79313628|NCT02351297|Dietary Supplement|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
79313629|NCT02351297|Dietary Supplement|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
79313630|NCT02351297|Dietary Supplement|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
79313631|NCT02355119|Drug|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
79313632|NCT02355119|Drug|Gemcitabine|
79313633|NCT02355041|Behavioral|Meal Replacement-based Weight Loss Diet|
79313634|NCT02355041|Behavioral|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
79641528|NCT00154856|Behavioral|Detect the variation of limb lengthening|
79641529|NCT00181038|Device|Peri-Neuronal Catheter|
79970523|NCT03366064|Biological|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
79970524|NCT03677401|Drug|5mg Serlopitant Tablets|Serlopitant Tablets
79970525|NCT03677401|Drug|Placebo Tablets|Placebo Tablets
79970526|NCT02525393|Device|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
79970527|NCT02525393|Device|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
79970528|NCT02525393|Device|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
79970529|NCT03359278|Procedure|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
79970530|NCT03357874|Drug|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
79313635|NCT03149939|Drug|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
79313636|NCT03149783|Drug|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
79641530|NCT02919202|Procedure|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
79641531|NCT02919202|Procedure|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
79641532|NCT02919358|Other|Music|
79641533|NCT02919358|Other|No music.|This is the control group.
79313637|NCT03149783|Drug|sodium chloride|Placebo
79313638|NCT02354885|Drug|Tranexamic Acid|Coagulation Management / Efficiency
79313639|NCT02354807|Drug|Mirabegron|One-time dose of 100mg of Mirabegron
79313640|NCT02354807|Other|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
79641534|NCT00154895|Drug|intrapleural minocycline instillation|
79313641|NCT03159845|Drug|Zinc Sulfate Oral Product|
79313642|NCT03159845|Drug|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
79313643|NCT03159845|Drug|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
79313644|NCT03159845|Drug|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
79313645|NCT02351375|Other|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
79313646|NCT02351375|Device|IntelliCap® system|
79641535|NCT02919397|Device|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
79641536|NCT02919397|Behavioral|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
79641537|NCT02919397|Behavioral|Motivational messaging|Messages sent via smartphone application
79641538|NCT02919124|Device|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
79641539|NCT00181077|Drug|2% buffered hypertonic saline administration|
79641540|NCT02919085|Procedure|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
79970531|NCT03357874|Drug|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
79313647|NCT03159065|Other|Bilberry|Fruit beverage with bilberry and fermented oatmeal
79313648|NCT03159065|Other|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
79313649|NCT03159065|Other|Mango|Fruit beverage with mango and fermented oatmeal
79313650|NCT03159065|Other|Beetroot|Fruit beverage with beetroot and fermented oatmeal
79313651|NCT03159065|Other|Rose hip|Fruit beverage with rose hip and fermented oatmeal
79313652|NCT03159065|Other|Glucose drink|A reference glucose drink
79970532|NCT03855293|Procedure|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
79970533|NCT01286051|Drug|Follistim administration|adminstation of FSH for ovulation induction
79970534|NCT01286051|Drug|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
79970535|NCT03357796|Drug|LY03005|80 mg, oral tablets, single dose
79970536|NCT03357796|Drug|Pristiq|50 mg, oral tablets, single dose
79970537|NCT02359513|Drug|Antidepressants|bulimic patients are treated during 3 months
79313653|NCT02351219|Drug|FOLFOXIRI|
79313654|NCT02350751|Drug|MEDI8852|
79313655|NCT02350751|Drug|Placebo|
79313656|NCT02350829|Other|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
79313657|NCT02354729|Other|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
79313658|NCT02354573|Drug|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
79313659|NCT02350985|Drug|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
79313660|NCT02350985|Drug|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
79313661|NCT02354495|Dietary Supplement|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
79313662|NCT02354261|Drug|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
79313663|NCT02350439|Drug|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
79970538|NCT02359513|Drug|Positron Emission Tomography (PET)|PET scan using [18F]MPPF is performed before and after (3 months)antidepressant treatment
79970539|NCT01184495|Drug|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
79970540|NCT01184495|Drug|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
79970541|NCT04522024|Procedure|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
79970542|NCT04522024|Procedure|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
79970543|NCT03218787|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
79641541|NCT02919046|Biological|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
79806090|NCT04133090|Procedure|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
79641542|NCT02918929|Drug|EDP 305|
79806091|NCT02619422|Other|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
79970544|NCT03218787|Drug|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
79970545|NCT03639649|Diagnostic Test|STHLM3|
79970546|NCT03365986|Diagnostic Test|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
79970547|NCT03640039|Procedure|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
79970548|NCT03864575|Drug|Celecoxib 400 mg|Celecoxib 400 mg/day in combination with nivolumab fixed dose
79970549|NCT03357718|Drug|Precedex|2 µg/kg oral
79313664|NCT02350673|Drug|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
79641543|NCT02918929|Drug|Placebo|placebo to match EDP 305
79641544|NCT00181116|Drug|Levetiracetam|
79970550|NCT03357718|Drug|Midazolam|0.5 mg/kg
79641545|NCT02918812|Drug|Intracervical lidocaine|Intracervical lidocaine injected at four different points
79641546|NCT02918812|Drug|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
79641547|NCT00188487|Device|magnetic resonance imaging (MRI) of the thorax|
79641548|NCT02918539|Drug|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
79313665|NCT02350673|Drug|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
79641549|NCT02918422|Other|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
79641550|NCT00188526|Device|lung biopsy|
79641551|NCT02918461|Behavioral|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
79641552|NCT02918383|Diagnostic Test|Indocyanin Green Dye (ICG)|
79806092|NCT04123652|Drug|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
79806093|NCT00862940|Drug|Memantine|10 mg tablets twice daily
79970551|NCT01184651|Behavioral|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
79641553|NCT02918578|Other|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
79641554|NCT02918578|Other|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
79641555|NCT02918578|Other|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
79641556|NCT02918188|Drug|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
79641557|NCT00181194|Device|Asthma Control and Communication Instrument|
79806094|NCT00862940|Drug|Placebo|Tablets twice daily
79806095|NCT04122716|Drug|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
79313666|NCT02350361|Drug|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
79313667|NCT02350361|Drug|Placebo|Placebo
79313668|NCT02353949|Drug|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
79313669|NCT02354027|Drug|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
79641558|NCT02918344|Other|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
79641559|NCT02918344|Procedure|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
79641560|NCT02918227|Procedure|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
79641561|NCT02918110|Drug|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
79641562|NCT00181272|Drug|azithromycin|
79476167|NCT04337801|Other|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
79476168|NCT04337801|Other|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
79641563|NCT02910544|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
79970552|NCT01184651|Behavioral|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
79970553|NCT04521790|Other|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
79476169|NCT02958839|Procedure|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
79476170|NCT05348057|Drug|Ivabradine|The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
79476171|NCT05735977|Diagnostic Test|Indocyanine Green (ICG)|Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
79641564|NCT02910310|Other|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
79970554|NCT05239923|Biological|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
79970555|NCT04521400|Drug|High dose Interferon-beta 1a|High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
79970556|NCT04521400|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir (Kaletra) [IFN-β1a group] (400mg/100 mg twice a day for 10 days
79970557|NCT04521400|Drug|Low dose Interferon-beta 1a|Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
79476172|NCT00371735|Drug|chlorproguanil-dapsone-artesunate|
79476173|NCT00371735|Drug|chlorproguanil-dapsone|
79970558|NCT01184807|Drug|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
79970559|NCT01184963|Dietary Supplement|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
79641565|NCT02910154|Dietary Supplement|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
79313670|NCT02354183|Behavioral|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
79313671|NCT03149471|Diagnostic Test|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
79313672|NCT02353793|Device|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
79641566|NCT02910154|Behavioral|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
79970560|NCT01184963|Dietary Supplement|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
79970561|NCT01348087|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
79970562|NCT01185041|Dietary Supplement|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
79307775|NCT02287311|Biological|MABEL CTLs|"Dose escalation:~DL1:2x10^7 cells/m2+2x10^7 cells/m2~DL2:2x10^7cells/m2+5x10^7 cells/m2~DL3:5x10^7 cells/m2+1x10^8 cells/m2~*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
79313673|NCT02353793|Device|Cotton wool blanket|Using cotton wool blanket for patient warming
79313674|NCT02350283|Device|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
79970563|NCT03864185|Biological|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
79970564|NCT03864185|Other|Placebo|Administer placebo IV infusion once weekly for 4 doses.
79313675|NCT03149627|Other|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
79313676|NCT03149393|Drug|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
79313677|NCT03149393|Drug|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
79307776|NCT02287311|Drug|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
79307777|NCT02287311|Drug|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
79307778|NCT02286089|Biological|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
79307779|NCT02276443|Drug|Chemotherapy|Receive standard chemotherapy
79307780|NCT02276443|Other|Immunotherapy|Receive standard immunotherapy
79307781|NCT02276443|Other|Laboratory Biomarker Analysis|Correlative studies
79307782|NCT02276443|Procedure|Lymph Node Biopsy|Undergo baseline lymph node evaluation
79307783|NCT02276443|Procedure|Ultrasonography|Undergo standard ultrasound
79313678|NCT03149315|Drug|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
79313679|NCT02353559|Behavioral|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
79313680|NCT02353637|Dietary Supplement|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
79313681|NCT02353715|Drug|Enzalutamide|
79313682|NCT02353715|Drug|Abiraterone acetate|
79313683|NCT02353715|Drug|Sipuleucel-T|
79641567|NCT02910154|Drug|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure > 130 and/or low density lipoprotein (LDL) > 2.0.
79641568|NCT00181311|Procedure|hysterectomy|
79641569|NCT02910076|Drug|Hydroxychloroquine|200 MG Plaquenil three times a day
79641570|NCT02910115|Other|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
79641571|NCT02910115|Drug|Pitocin|Pitocin is administered intravenously according to the usual protocol.
79641572|NCT02910232|Device|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
79641573|NCT00188565|Drug|Celecoxib|
79655713|NCT04552678|Behavioral|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79970565|NCT03365830|Diagnostic Test|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
79970566|NCT01347931|Device|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
79313684|NCT02353403|Other|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
79970567|NCT01347931|Device|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
79313685|NCT02353403|Other|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
79970568|NCT01174979|Drug|Caroverin|treatment with eardrops 2 times for 48 hours
79970569|NCT01185119|Drug|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
79313686|NCT02349737|Other|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
79313687|NCT02353325|Dietary Supplement|non-encapsulated FeSO4|
79313688|NCT02353325|Dietary Supplement|encapsulated FeSO4, before cooking|
79970570|NCT03357640|Drug|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
79307785|NCT02152254|Drug|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration [FDA]-approved for another indication), patients can receive the FDA-approved drug.
79307786|NCT02152254|Drug|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
79313689|NCT02353325|Dietary Supplement|encapsulated FeSO4, after cooking|
79313690|NCT02353325|Dietary Supplement|non-encapsulated FeSO4 + ascorbic acid|
79313691|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, before cooking|
79313692|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, after cooking|
79313693|NCT02353481|Other|Heart Failure Management|
79970571|NCT01185197|Drug|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
79970572|NCT01185197|Drug|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
79970573|NCT03733873|Drug|Desmopressin|take desmopressin for 3 months
79970574|NCT03733873|Drug|Suoquan|take Suoquan mixture for 3 months
79806096|NCT04122716|Behavioral|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
79970575|NCT03365674|Device|Vibration|Vibration applied with vibrator switch-on state (100Hz)
79970576|NCT03365674|Device|Placebo vibration|Vibrator applied with switch-off state
79806097|NCT00868166|Drug|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
79970577|NCT02524691|Device|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
79970578|NCT03733795|Other|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
79970579|NCT03357484|Procedure|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH & Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
79970580|NCT03357484|Procedure|Blood clot|Natural blood clot formed within extraction socket
79313694|NCT03157895|Behavioral|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
79970581|NCT01290965|Drug|Placebo|Oral tablet given once or three times daily for 15 consecutive days
79970582|NCT01290965|Drug|SCY-635|oral capsule
79970583|NCT03733639|Drug|Tisseel|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
79970584|NCT03733639|Device|No Tisseel|No reinforcement of esophagojejunal anastomoses after total gastrectomy
79307787|NCT02135744|Behavioral|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
79307788|NCT02119065|Procedure|positron emission tomography|Undergo PET/CT scan
79307789|NCT02119065|Procedure|computed tomography|Undergo PET/CT scan
79307790|NCT02096601|Drug|Levodopa and carbidopa SC solution|Levodopa and carbidopa SC solution
79307791|NCT02096601|Drug|Oral levodopa and carbidopa|Oral levodopa and carbidopa
79313695|NCT02349503|Drug|NBI-77860|
79313696|NCT02349503|Drug|NBI-77860|
79313697|NCT02349503|Drug|NBI-77860|
79313698|NCT02349659|Device|Implantation with the commercially available Axium neurostimulator|
79970585|NCT03357406|Procedure|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
79970586|NCT03357406|Procedure|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
79970587|NCT01291043|Other|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
79313699|NCT03157505|Drug|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
79806098|NCT00868166|Drug|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
79313700|NCT03157505|Other|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
79806099|NCT00868166|Drug|Riluzole|Riluzole given as add-on therapy 50mg bid
79806100|NCT00698672|Device|charnley OGEE|charnley OGEE
79806101|NCT00698672|Device|Spectron Reflection CoCr|Spectron Reflection CoCr
79313701|NCT03157193|Drug|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
79313702|NCT03157193|Drug|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
79313703|NCT03149159|Drug|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
79313704|NCT03149159|Drug|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
79313705|NCT03149159|Radiation|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
79313706|NCT03156959|Behavioral|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
79806102|NCT00698672|Device|Spectron XLPE CoCr|Spectron XLPE CoCr
79806103|NCT00698672|Device|Spectron Reflection Oxinium|Spectron Reflection Oxinium
79806104|NCT00698672|Device|Spectron XLPE CoCR|Spectron XLPE CoCR
79806105|NCT00858780|Drug|Etanercept|50 mg etanercept once weekly + methotrexate
79806106|NCT00858780|Drug|Etanercept|25mg etanercept once weekly + methotrexate
79806107|NCT00858780|Drug|Placebo|Placebo comparator once weekly + methotrexate
79806108|NCT04132856|Other|Psychosocial Navigator|Services of psychosocial navigator
79806109|NCT04132856|Other|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
79806110|NCT02619188|Other|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
79806111|NCT02619188|Other|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
79970588|NCT03358966|Other|Doubly-labelled water technique|
79806112|NCT02619188|Other|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
79806113|NCT02619188|Other|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
79806114|NCT02615678|Device|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
79806115|NCT02613234|Device|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
79970589|NCT03358966|Other|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
79970590|NCT03733561|Drug|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
79970591|NCT03733561|Drug|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
79313707|NCT03156959|Behavioral|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
79313708|NCT03156803|Behavioral|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
79806116|NCT02613234|Device|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
79313709|NCT03156569|Diagnostic Test|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
79313710|NCT03155477|Dietary Supplement|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
79313711|NCT03155477|Dietary Supplement|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
79313712|NCT03148925|Biological|SELA-070|Sub-cutaneous injection, multiple dose
79313713|NCT03148925|Biological|Saline|Sub-cutaneous injection, multiple dose
79313714|NCT03148847|Other|Baseline care|
79313715|NCT03148847|Other|Referential's dissemination|
79313716|NCT02349581|Procedure|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
79313717|NCT02349581|Drug|Bupivacaine|
79313718|NCT03155633|Other|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
79313719|NCT03155633|Other|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
79313720|NCT03155711|Procedure|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
79313721|NCT03155711|Procedure|Standard group|Supplemental oxygen through venturi mask
79313722|NCT03155165|Device|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
79313723|NCT02349191|Procedure|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
79313724|NCT03154385|Drug|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
79655714|NCT04552678|Behavioral|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
79313725|NCT03154463|Procedure|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
79313726|NCT03154463|Procedure|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
79313727|NCT03112187|Drug|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
79313728|NCT02353013|Dietary Supplement|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
79313729|NCT02353013|Dietary Supplement|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
79313730|NCT03147677|Drug|Alfacalcidol|
79313731|NCT03147677|Drug|Irbesartan|
79313732|NCT03148535|Drug|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
79313733|NCT03148535|Drug|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
79313734|NCT03148301|Other|Survey|Survey
79313735|NCT03147599|Drug|Coloverin|Mebeverine hydrochloride 135 mg
79313736|NCT03147599|Drug|Placebo|Placebo
79313737|NCT03147443|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
79970592|NCT03358888|Drug|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
79313738|NCT03147443|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
79313739|NCT03147443|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
79313740|NCT03147521|Other|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
79806117|NCT02619266|Other|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
79806118|NCT02619266|Other|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
79806119|NCT02619266|Drug|Megestrol Acetate|Megestrol Acetate 160mg tablet
79806120|NCT02619266|Drug|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
79970593|NCT03358888|Drug|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
79970594|NCT03358888|Drug|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
79970595|NCT03733405|Behavioral|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
79970596|NCT03733405|Behavioral|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
79806121|NCT00850200|Radiation|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
79806122|NCT00850200|Radiation|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
79806123|NCT00850200|Radiation|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
79806124|NCT02618954|Other|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
79313741|NCT03148223|Device|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
79655715|NCT04552678|Behavioral|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79806125|NCT02619110|Other|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
79970597|NCT03864029|Drug|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
79970598|NCT03365518|Behavioral|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
79806126|NCT02619110|Other|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
79806127|NCT02612766|Dietary Supplement|Pure, uncontaminated oats|
79806128|NCT04122092|Diagnostic Test|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
79970599|NCT03365518|Behavioral|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
79970600|NCT01291121|Procedure|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
79970601|NCT03357328|Other|Therapy light room|See group description
79313742|NCT03148145|Behavioral|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
79313743|NCT03148145|Behavioral|Message Delivery by Smartphone|Message Delivery by Smartphone
79970602|NCT03357328|Other|Standard light|See group description
79313744|NCT02348411|Device|ExAblate|
79641574|NCT04688086|Diagnostic Test|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
79970603|NCT01185275|Device|Alair system|Bronchial thermoplasty
79970604|NCT03365440|Device|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
79970605|NCT01185431|Dietary Supplement|Ficus carica (Fig paste)|Ficus carica paste 300g/day
79970606|NCT01185431|Dietary Supplement|Placebo (Placebo paste)|Placebo composition 300g/day
79970607|NCT01187849|Drug|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
79970608|NCT01187849|Drug|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
79313745|NCT03147365|Behavioral|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
79641575|NCT02909998|Other|Blood sample|Conservation at the end of the blood sample
79641576|NCT02909803|Other|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
79970609|NCT03358810|Device|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
79970610|NCT02524535|Other|Therapeutic alliance|
79313746|NCT03147365|Behavioral|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
79313747|NCT02348879|Drug|AMG 403|AMG 403 is for treatment of subjects with chronic pain
79313748|NCT02348879|Drug|Placebo|contains no active drug
79313749|NCT03147209|Behavioral|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
79641577|NCT02909803|Other|White Bread|Participants will consume white bread on at least two different test days
79641578|NCT00181350|Device|Relocatable fixation system|
79655716|NCT04552678|Behavioral|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
79970611|NCT03358732|Device|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
79970612|NCT03358654|Drug|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
79970613|NCT04927871|Behavioral|Total Diet Replacement (TDR)|The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
79313750|NCT02349035|Device|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
79476174|NCT03833245|Behavioral|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
79641579|NCT02909725|Other|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
79970614|NCT04927871|Behavioral|Medical Nutritional Therapy (MNT)|The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
79970615|NCT04927871|Behavioral|Diabetes Prevention Program 4 months|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
79970616|NCT04927871|Behavioral|Diabetes Prevention Program|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
79970617|NCT03365284|Device|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
79307792|NCT02087423|Drug|MEDI4736|MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
79307793|NCT02031419|Drug|CC-122|2mg or 3 mg administered orally once daily
79307794|NCT02031419|Drug|CC-223|20mg or 30mg administered orally once daily.
79970618|NCT03365284|Other|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
79970619|NCT01187927|Biological|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
79970620|NCT04522882|Device|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
79970621|NCT04522882|Other|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
79476175|NCT04337411|Other|Follow-up assessments|Longitudinal evaluation of recovery
79476176|NCT04337333|Device|Two-in-one stent|Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
79970622|NCT04522882|Other|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
79970623|NCT01185665|Device|TENS|Transcutaneous Electrical Nerve Stimulator
79476177|NCT00425399|Procedure|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
79476178|NCT04337567|Procedure|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
79476179|NCT04337567|Procedure|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
79476180|NCT03029377|Other|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
79476181|NCT00372125|Drug|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
79970624|NCT01185665|Device|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
79970625|NCT03123718|Drug|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
79970626|NCT03123718|Drug|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged >70 years."
79970627|NCT01185743|Drug|olanzapine|olanzapine 10mg od + placebo od
79970628|NCT01185743|Drug|ziprasidone|ziprasidone 40mg td
79970629|NCT01185743|Drug|placebo|placebo td
79970630|NCT04445038|Drug|610|Recombinant anti-IL-5 Humanized Monoclonal Antibody
79970631|NCT04445038|Drug|Placebo|Placebo
79476182|NCT05028439|Device|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
79806129|NCT02613156|Procedure|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson & Johnson, USA), a laparoscopic linear cutter stapler (Johnson & Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
79970632|NCT01188005|Device|n-CPAP|administration of continuous positive airway pressure through a nasal device
79476183|NCT05028439|Drug|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
79476184|NCT02761967|Behavioral|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
79476185|NCT03029299|Device|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
79970633|NCT01188005|Device|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
79970634|NCT01188005|Drug|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
79970635|NCT03645421|Drug|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
79970636|NCT03645421|Drug|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
79476186|NCT05012605|Other|Observation|Observe physical function and sleep disorder symptoms following stroke
79476187|NCT05009797|Procedure|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
79806130|NCT00698906|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
79806131|NCT00698906|Biological|Engerix™-B|3-dose intramuscular injection
79970637|NCT03645421|Drug|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
79476188|NCT05417659|Dietary Supplement|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
79970638|NCT03645421|Drug|PlaceboA|1.0 mL liquid formulation per Vial
79970639|NCT03645421|Drug|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
79970640|NCT03645421|Drug|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
79970641|NCT04445194|Biological|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79970642|NCT04445194|Biological|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79970643|NCT04445194|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79970644|NCT03853031|Procedure|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
79970645|NCT03853031|Procedure|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
79970646|NCT04445350|Other|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
79970647|NCT04445350|Other|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
79806132|NCT04118946|Biological|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
79806133|NCT00698984|Dietary Supplement|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
79970648|NCT01291199|Drug|vardenafil|10 mg p.o. bid for 6 weeks
79970649|NCT01291199|Drug|Placebo|Placebo p.o. 6 weeks bid
79970650|NCT04521010|Other|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
79970651|NCT02524613|Other|Pelvis CT scan|
79476189|NCT05417659|Dietary Supplement|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
79806134|NCT00698984|Dietary Supplement|Placebo|2 capsules per day over a period of 6 months
79806135|NCT04116060|Dietary Supplement|Dietary Nitrate|Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
79806136|NCT04116060|Dietary Supplement|Control|Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
79806137|NCT00699062|Drug|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
79970652|NCT04444726|Device|Ultra Violet A Device.+ Topical medical treatment|"Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule."
79970653|NCT04444726|Device|Iontophoresis device + Topical medical treatment|Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
79970654|NCT04444726|Drug|"Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )"|thin film of the cream is being applied to the affected areas for 2 times per day.
79970655|NCT03733327|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
79970656|NCT03733327|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79970657|NCT03733327|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
79970658|NCT01188083|Dietary Supplement|Fructose Drink|Fructose Based beverage 8 oz
79641580|NCT02909725|Other|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
79476190|NCT05417659|Other|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
79476191|NCT02762513|Drug|Axitinib|
79476192|NCT04996225|Other|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
79476193|NCT02958761|Biological|intraarticular injections of platelet lysate|
79476194|NCT02958761|Drug|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
79641581|NCT02909725|Other|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
79641582|NCT02522260|Other|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
79641583|NCT02522260|Other|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
79476195|NCT02764385|Other|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
79476196|NCT02764385|Other|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
79490279|NCT03756506|Device|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
79641584|NCT02522260|Other|Standard supportive care|Standard supportive care
79641585|NCT00155246|Drug|pentoxifylline (drug)|
79641586|NCT02909920|Other|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
79970659|NCT01188083|Dietary Supplement|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
79970660|NCT03365206|Other|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
79970661|NCT03733171|Drug|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
79970662|NCT03733171|Drug|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
79970663|NCT03733171|Device|hemoclips|diluted epinephrine was injected followed by application of hemoclips
79970664|NCT03207750|Biological|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
79970665|NCT03207750|Biological|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
79970666|NCT03207750|Biological|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
79970667|NCT03207750|Biological|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
79970668|NCT04444570|Device|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
79307795|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
79307796|NCT02031419|Drug|CC-122|2mg or 3mg administered orally once daily.
79307797|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
79307798|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
79307799|NCT02031419|Drug|CC-223|20mg or 30mg per day administered orally daily.
79307800|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
79307801|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
79307802|NCT01954979|Drug|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
79307803|NCT01883505|Drug|Levodopa and carbidopa|Subcutaneous continuous administration
79307804|NCT01883505|Drug|Placebo|Subcutaneous continuous administration
79970669|NCT03854981|Behavioral|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
79970670|NCT03854981|Procedure|Standard Care|Standard preoperative care of bariatric surgery
79970671|NCT04521322|Drug|Iota-Carrageenan|Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
79970672|NCT03674281|Device|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
79970673|NCT03674281|Device|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
79970674|NCT04523038|Diagnostic Test|S-Albumin|Preoperative serum albumin levels
79806138|NCT00699062|Drug|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
79641587|NCT02909920|Other|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
79641588|NCT00181506|Procedure|dose escalation (radiotherapy treatment schedule)|
79641589|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
79641590|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
79970675|NCT01188161|Device|Rotating Chair|Subjects will be spun in rotating chair
79970676|NCT03365050|Other|No Intervention Given|No Intervention to be given
79970677|NCT01185977|Drug|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
79641591|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
79641592|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
79641593|NCT02909881|Behavioral|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
79970678|NCT01185977|Drug|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
79641594|NCT02909842|Dietary Supplement|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
79641595|NCT02909842|Dietary Supplement|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
79806139|NCT02619032|Drug|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
79806140|NCT02619032|Drug|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
79806141|NCT00858234|Drug|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
79806142|NCT00858234|Drug|Bortezomib|Bortezomib (1.0 or 1.3 mg/m^2) intravenous infusion.
79806143|NCT00697814|Drug|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
79806144|NCT04116450|Procedure|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
79806145|NCT00701844|Behavioral|Writing A (Experimental informative writing)|Experimental informative writing
79806146|NCT00701844|Behavioral|Writing B (Experimental noninformative writing)|Experimental noninformative writing
79641596|NCT02909842|Biological|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
79476199|NCT05215535|Radiation|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
79641597|NCT02909530|Device|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
79806147|NCT00701844|Behavioral|Writing C (Control informative writing)|Control informative writing
79806148|NCT00701844|Behavioral|Writing D (Control noninformative writing)|Control noninformative writing
79970679|NCT03673345|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
79641598|NCT02909530|Device|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
79641599|NCT00155285|Procedure|computed tomography|
79641600|NCT02909608|Other|No interventions / observations only|This is an observational study only
79806149|NCT04115592|Other|Cocoa butter|Consumption of cocoa butter made with chocolate confectionery
79970680|NCT04521244|Other|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
79641601|NCT02909569|Drug|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
79641602|NCT02909413|Drug|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
79641603|NCT02909413|Drug|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
79970681|NCT04521244|Other|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
79806150|NCT04115592|Other|Cocoa butter oleogel|Consumption of cocoa butter oleogel made with chocolate confectionery
79970682|NCT03854825|Procedure|Cardiac surgery|
79806151|NCT04115592|Other|Sal seed oil|Consumption of sal seed oil made with chocolate confectionery
79806152|NCT04115592|Other|Sal seed oleogel|Consumption of sal seed oleogel made with chocolate confectionery
79641604|NCT00155324|Device|Extracorporeal Shock Wave Therapy (Device)|
79806153|NCT00862082|Drug|PR104 550 mg/m^2 + sorafenib|550 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
79806154|NCT00862082|Drug|PR104 770 mg/m^2 + sorafenib|770 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
79806155|NCT00692770|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
79806156|NCT00692770|Drug|Placebo|Placebo 2 tablets twice daily (BID)
79313751|NCT02349035|Procedure|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
79313752|NCT03147053|Drug|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
79313753|NCT03147053|Drug|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
79313754|NCT03147131|Procedure|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
79313755|NCT03146975|Procedure|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
79313756|NCT02349113|Drug|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
79490280|NCT03275623|Drug|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
79490281|NCT03275623|Other|Standard Prenatal Care|Continued surveillance of urinary cultures
79970683|NCT03223662|Other|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
79970684|NCT03223662|Procedure|Esophagectomy|Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
79970685|NCT03364972|Device|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
79970686|NCT03852641|Other|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
79970687|NCT03357172|Biological|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
79970688|NCT03357172|Biological|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
79476200|NCT05215535|Radiation|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
79313757|NCT02348801|Behavioral|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of ~90 min duration 15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and, after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
79313758|NCT02348801|Behavioral|Healthy lifestyle|Diabetes support and education
79313759|NCT02348567|Other|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
79313760|NCT02348567|Other|announced hospital surveys|
79313761|NCT04151849|Drug|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
79476201|NCT05649397|Other|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
79313762|NCT04151849|Drug|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
79476202|NCT05649397|Other|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
79476203|NCT04336709|Drug|Calcipex II|Water based intracanal medicament
79476204|NCT04336709|Drug|Metapex|Oil based intracanal medicament
79641605|NCT02909374|Other|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
79641606|NCT02909257|Drug|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
79806157|NCT00849108|Drug|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~Doses at rest were to range between 2.9 and 3.4 mCi.~Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
79806158|NCT00867308|Drug|Lenalidomide 50 mg|
79806159|NCT00867308|Drug|Lenalidomide 15 mg|
79806160|NCT00849186|Drug|sunitinib malate|oral
79806161|NCT00849186|Procedure|neoadjuvant therapy|IV
79806162|NCT00849186|Procedure|therapeutic conventional surgery|Surgery
79806163|NCT04119908|Device|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
79806164|NCT04119908|Biological|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
79313763|NCT03147989|Drug|MultiHance|gadolinium contrast agent
79806165|NCT02613078|Behavioral|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
79970689|NCT03357172|Biological|Blood sample|Before donation
79970690|NCT03357172|Biological|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
79970691|NCT01181453|Device|Dermagraft|Weekly application of Dermagraft(R) with standard care
79970692|NCT01181453|Other|Comparator|Weekly application of standard care
79313764|NCT02348177|Drug|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
79313765|NCT02348177|Drug|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
79313766|NCT02348255|Procedure|Electric Field Therapy|Undergo NovoTTF-100A
79313767|NCT02348255|Biological|Bevacizumab|Given IV
79970693|NCT01291355|Other|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
79970694|NCT03358498|Other|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
79970695|NCT01186055|Behavioral|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
79313768|NCT02348255|Drug|Carmustine|Given IV
79313769|NCT02348255|Other|Quality-of-Life Assessment|Ancillary studies
79806166|NCT02613078|Dietary Supplement|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
79313770|NCT02348333|Drug|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
79313771|NCT02348333|Drug|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
79313772|NCT02348021|Procedure|Percutaneous coronary intervention (PCI)|
79313773|NCT02348021|Drug|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
79313774|NCT03147755|Other|No intervention|No intervention
79970696|NCT03857399|Drug|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
79984506|NCT05234086|Combination Product|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
79984507|NCT05234086|Procedure|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
79806167|NCT02613078|Behavioral|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
79806168|NCT02618876|Drug|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
79970697|NCT04520620|Drug|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between < 30 kg/m² and > 30 kg/m² without added thrombotic risk factor:~Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~if weight > 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI > 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen > 8 g/L or D-Dimer > 3 μg/ml or 3000 ng/ml)~* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
79970698|NCT04520620|Device|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
79970699|NCT03857633|Diagnostic Test|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
79970700|NCT03857633|Diagnostic Test|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
79970701|NCT03857633|Diagnostic Test|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
79970702|NCT03857633|Diagnostic Test|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
79806169|NCT02618876|Drug|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
79806170|NCT04132700|Device|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
79970703|NCT03857633|Diagnostic Test|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
79970704|NCT03357016|Other|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
79970705|NCT03857711|Procedure|Conventional CABG|Coronary artery bypass grafting
79313775|NCT03147833|Dietary Supplement|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
79806171|NCT04120142|Other|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
79806172|NCT04120142|Other|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
79806173|NCT00743548|Device|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
79970706|NCT03857711|Procedure|CABG+ PVI|CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
79970707|NCT03857711|Procedure|CABG+ PVI+amiodarone|CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
79970708|NCT03857711|Procedure|CABG+amiodarone|
79970709|NCT04524676|Procedure|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
79313776|NCT03147833|Dietary Supplement|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
79970710|NCT03364816|Procedure|TDR|total artificial disc replacement
79970711|NCT03672097|Drug|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
79970712|NCT04520542|Other|Acupressure Application|Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
79307805|NCT01878617|Radiation|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
79307806|NCT01878617|Drug|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
79307807|NCT01878617|Drug|Cisplatin|ROA: IV
79307808|NCT01878617|Drug|Vincristine|ROA: IV
79641607|NCT02909257|Drug|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
79307809|NCT01878617|Drug|Vismodegib|ROA: Orally (PO)
79806174|NCT00743548|Device|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
79806175|NCT04132622|Drug|Levothyroxine Sodium|Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
79307810|NCT01878617|Drug|Pemetrexed|ROA: IV
79307811|NCT01878617|Drug|Gemcitabine|ROA: IV
79476205|NCT02767271|Drug|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
79490282|NCT04735237|Procedure|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
79806176|NCT04132622|Drug|Traditional therapy|including steroids, vitamin C, hemodialysis and blood perfusion.
79806177|NCT00743626|Other|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
79806178|NCT02562976|Other|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
79806179|NCT04119752|Dietary Supplement|Curcumin powder|10g of curcumin powder
79806180|NCT04119752|Dietary Supplement|Placebo|1g of sucralose
79806181|NCT00747058|Drug|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
79476206|NCT04928677|Drug|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
79476207|NCT02741297|Device|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
79476208|NCT05375071|Other|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
79641608|NCT02909218|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
79806182|NCT00747058|Drug|Placebo|Placebo
79313777|NCT05255627|Other|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
79806183|NCT00866918|Drug|Arsenic Trioxide|Given IV
79970713|NCT04444960|Procedure|percutaneous coronary intervention|Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
79313778|NCT05255627|Other|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
79313779|NCT05255549|Procedure|ESWT + Stretching|"3 weeks intervention:~3 sessions of ESWT, once a week~6 sessions of passive stretching, twice a week"
79313780|NCT05255549|Procedure|ESWT and SHAM + Stretching|"3 weeks intervention:~1 sessions of ESWT + 2 sessions of Sham, once a week~6 sessions of passive stretching, twice a week"
79476209|NCT05375071|Other|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
79476210|NCT05647993|Drug|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
79476211|NCT05647993|Drug|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
79641609|NCT02908945|Drug|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
79641610|NCT02908945|Device|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
79970714|NCT03847896|Combination Product|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
79641611|NCT02909296|Procedure|Endoscopic drainage|
79806184|NCT00866918|Drug|Cytarabine|Given IT or IV
79806185|NCT00866918|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79806186|NCT00866918|Drug|Idarubicin|Given IV
79806187|NCT00866918|Drug|Mercaptopurine|Given orally
79806188|NCT00866918|Drug|Methotrexate|Given orally
79806189|NCT00866918|Drug|Mitoxantrone Hydrochloride|Given IV
79806190|NCT00866918|Drug|Tretinoin|Given orally
79806191|NCT03158285|Drug|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
79806192|NCT03158285|Drug|Placebo|Participants will receive matching placebo as SC injection.
79806193|NCT00861692|Drug|argatroban|
79970715|NCT03847896|Combination Product|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
79970716|NCT03847896|Drug|Budesonide metered dose inhaler / BD MDI 160 µg|Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
79641612|NCT04688008|Drug|Hetrombopag|"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"
79641613|NCT02939833|Procedure|Scalp Nerve Blocks With Ropivacaine|
79641614|NCT02939833|Procedure|Scalp Nerve Blocks With Saline|
79970717|NCT03847896|Drug|Albuterol sulfate metered dose inhaler / AS MDI 180 μg|Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
79970718|NCT03847896|Other|Placebo metered-dose inhaler / Placebo MDI|Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
79641615|NCT02939677|Other|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
79641616|NCT02939794|Drug|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
79970719|NCT01186289|Drug|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
79641617|NCT02939794|Drug|Placebo|Saline (normal saline, sodium chloride)
79970720|NCT04444648|Combination Product|No intervention|No intervention
79970721|NCT03670537|Diagnostic Test|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
79970722|NCT03364504|Other|urine collection|3 urine collections during 24 hours
79970723|NCT04509388|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
79970724|NCT01291823|Drug|gefitinib|gefitinib 250mg/day
79307812|NCT01878617|Other|Aerobic Training|
79307813|NCT01878617|Other|Neurocognitive Remediation|
79307814|NCT01874353|Drug|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
79970725|NCT01291823|Radiation|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
79476212|NCT05647993|Drug|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
79476213|NCT02741687|Drug|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) > 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
79806194|NCT03157973|Other|Education intervention|eHealth tool and standardized nurse-led follow-up.
79806195|NCT02684747|Other|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
79476214|NCT02741687|Drug|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
79806196|NCT02684747|Other|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
79476215|NCT02741687|Drug|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
79641618|NCT03458104|Other|Cone Beam Computed Tomography|Cone Beam CT of the larynx
79641619|NCT03458104|Diagnostic Test|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
79806197|NCT04422821|Device|Flash Glucose Monitoring|Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
79806198|NCT04422821|Device|Self-Monitoring of Blood Glucose|Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.
79970726|NCT03354676|Other|MetS+|Data processing from Patient Medical Files
79806199|NCT02689271|Other|MRI|VERDICT diffusion-weighted microstructure imaging sequence
79806200|NCT02685917|Procedure|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
79806201|NCT02685917|Procedure|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
79806202|NCT02689037|Procedure|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
79970727|NCT03354676|Other|MetS-|Data processing from Patient Medical Files
79970728|NCT01181765|Biological|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
79806203|NCT02689037|Drug|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
79806204|NCT04184921|Drug|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
79970729|NCT04509310|Device|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
79970730|NCT01186445|Drug|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
79806205|NCT04184921|Drug|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
79970731|NCT01186445|Drug|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
79806206|NCT00639665|Other|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
79970732|NCT03356938|Behavioral|Sleep restriction|Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
79806207|NCT00602927|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
79806208|NCT00602927|Drug|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
79806209|NCT00639743|Drug|placebo ( group B)|placebo ( group B)
79806210|NCT00639743|Drug|tenecteplase (group A)|tenecteplase (group A)
79970733|NCT03356938|Behavioral|Sleep deprivation|Sleep deprivation during first night of sleep laboratory examination
79641620|NCT03458104|Diagnostic Test|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
79641621|NCT00188604|Drug|sodium selenite|
79641622|NCT00155363|Device|conventional artificial kidney (AK) vs. high flux AK|
79641623|NCT04853173|Other|Assess pain management modalities in adult outpatient tonsillectomy surgery|use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
79641624|NCT00181545|Procedure|escalation of dose (radiotherapy treatment)|
79641625|NCT00155402|Drug|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
79641626|NCT04838587|Other|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
79806211|NCT02684513|Dietary Supplement|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
79806212|NCT02684513|Dietary Supplement|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
79641627|NCT04833400|Device|ICRS|Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
79806213|NCT02685683|Drug|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of >50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI <7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
79806214|NCT00602537|Drug|Venlafaxine|75 to 375 mg
79806215|NCT00602537|Drug|Lithium Carbonate|300 to 2400 mg
79806216|NCT02685839|Device|Intelligent POWER Rehabilitation Cluster Machine|
79806217|NCT02685839|Other|general physical therapy|
79806218|NCT02688803|Drug|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
79806219|NCT02688803|Drug|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
79806220|NCT02688803|Drug|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
79806221|NCT00638495|Drug|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
79970734|NCT03739333|Other|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
79806222|NCT00638495|Drug|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
79806223|NCT03041363|Drug|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
79806224|NCT02688725|Device|post mastectomy ultrasound|post mastectomy ultrasound
79806225|NCT02976935|Other|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
79970735|NCT05183100|Procedure|Tibial Nerve Neurodynamics|The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
79313781|NCT02343653|Behavioral|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training."
79313782|NCT02343653|Behavioral|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
79313783|NCT02343497|Dietary Supplement|Astaxanthin|
79313784|NCT02343497|Dietary Supplement|Placebo|
79313785|NCT02343419|Other|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
79313786|NCT02343341|Behavioral|Preschool Health Promotion Education Program|
79641628|NCT04833400|Device|TAET|Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
79806226|NCT00861614|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
79641629|NCT00188643|Drug|Venlafaxine and Lamotrigine|
79641630|NCT00155441|Behavioral|cognitive-behavioral therapy|
79313787|NCT02343107|Behavioral|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
79313788|NCT02348099|Other|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
79806227|NCT00861614|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
79806228|NCT00485173|Device|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
79806229|NCT00495469|Drug|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
79806230|NCT00495469|Drug|Placebo|Available as Placebo matching tablet to GSK189075
79313789|NCT02343029|Other|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
79641631|NCT00533299|Drug|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
79641632|NCT00533299|Drug|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
79641633|NCT04785391|Diagnostic Test|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
79806231|NCT00861380|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
79806232|NCT00861380|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children < 12 months of age at the time of first study vaccination."
79806233|NCT00861380|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children >= 12 months of age at the time of first study vaccination.
79806234|NCT00495391|Drug|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
79970736|NCT05183100|Procedure|Lying in supine|Lying in supine position for about 13 minutes.
79970737|NCT04520464|Diagnostic Test|Cervical samples for identification of HR-HPV DNA via real-time PCTR.|Identification of HR-HPV DNA via real-time PCTR.
79970738|NCT04520230|Drug|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
79641634|NCT00181584|Drug|Zoledronic acid|Given intravenously once.
79641635|NCT00181584|Other|Placebo|Given intravenously once.
79641636|NCT04769440|Drug|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
79806235|NCT00495391|Drug|Placebo|One oral placebo tablet twice daily for 52 weeks.
79806236|NCT00495391|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
79806237|NCT00495391|Drug|Ribavirin|1000 mg (if <75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
79806238|NCT04378621|Drug|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
79806239|NCT04378621|Other|Hand training|Physical hand training 10 min twice daily while on stable treatment
79806240|NCT00869960|Drug|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
79806241|NCT00869960|Drug|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
79806242|NCT00869960|Drug|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
79970739|NCT04520230|Drug|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
79313790|NCT02343029|Other|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
79313791|NCT03146897|Dietary Supplement|Supplementary Food|Supplementary food for treating MAM
79313792|NCT02343185|Other|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
79641637|NCT00155480|Procedure|computed tomography|
79490283|NCT04735237|Procedure|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
79970740|NCT04520230|Drug|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
79970741|NCT05155410|Dietary Supplement|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
79970742|NCT05155410|Dietary Supplement|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
79970743|NCT03619837|Drug|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
79970744|NCT03619837|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
79970745|NCT03852485|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
79970746|NCT03364426|Other|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
79970747|NCT03852563|Drug|BAY207543 (Bepanthol)|Product is applied to one hemiface.
79970748|NCT03852563|Other|Semisolid vaseline|Product is applied to one hemiface.
79490284|NCT03756038|Drug|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
79641638|NCT04762693|Device|Hyfe cough tracker|A mobile app that runs in the background of smartphones and detects putative cough sounds.
79970749|NCT03356782|Biological|Sarcoma-specific CAR-T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
79970750|NCT03739255|Device|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
79970751|NCT03739255|Device|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
79641639|NCT00533338|Behavioral|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
79806243|NCT00869960|Drug|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
79970752|NCT01188317|Drug|aleglitazar|repeated daily doses
79970753|NCT01188317|Drug|placebo|repeated daily doses
79302078|NCT03319823|Drug|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~If sleep systolic blood pressure is > 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
79641640|NCT00533338|Behavioral|Questionnaire|Packet of questionnaires will be completed.
79806244|NCT02618486|Procedure|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
79806245|NCT02615444|Dietary Supplement|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
79970754|NCT01188317|Drug|ibuprofen|repeated daily doses
79806246|NCT02615444|Dietary Supplement|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
79806247|NCT02618564|Drug|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
79806248|NCT02615366|Drug|Tranexamic Acid|
79806249|NCT02615366|Drug|Placebo|
79806250|NCT00699296|Drug|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
79806251|NCT00494299|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
79970755|NCT03356704|Other|no intervention|Observational study
79970756|NCT03739177|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
79970757|NCT03206970|Drug|Zanubrutinib|Administered as specified in the treatment arm.
79970758|NCT04520386|Drug|OMT-111|Pre-filled Syringe
79970759|NCT03739021|Drug|Exparel|Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
79490285|NCT03756038|Drug|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
79490286|NCT03276637|Genetic|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
79641641|NCT04716283|Other|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
79806252|NCT00494299|Drug|Placebo|Placebo: matching placebo
79970760|NCT03739021|Drug|Ropivacaine|Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
79970761|NCT01588145|Drug|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
79806253|NCT02618330|Device|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
79970762|NCT03363958|Procedure|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
79970763|NCT03363958|Procedure|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
79970764|NCT03738943|Drug|Adenosine Triphosphate|See arm/group descriptions
79970765|NCT03738943|Drug|Acetylcholine|See arm/group descriptions
79970766|NCT03738943|Drug|Sodium Nitroprusside|See arm/group descriptions
79313793|NCT02343185|Other|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
79313794|NCT02342951|Other|Lung clearance index determination|Lung clearance index determination
79313795|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
79313796|NCT02342717|Drug|Itraconazole|multiple doses of Itraconazole capsules
79313797|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
79313798|NCT02342795|Other|e-cigarette|
79313799|NCT02342795|Other|cigarette substitute|
79313800|NCT02342873|Procedure|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
79313801|NCT02342873|Procedure|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
79313802|NCT02347553|Other|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
79313803|NCT04478435|Other|glucose loaded clear fluid|Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
79313804|NCT04478357|Drug|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
79970767|NCT03738943|Drug|Adenosine Diphosphate|See arm/group descriptions
79313805|NCT04478357|Drug|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
79313806|NCT04478357|Drug|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
79313807|NCT04478357|Drug|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
79313808|NCT04478513|Drug|AZD4635|During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
79313809|NCT04478513|Drug|Fluvoxamine|Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
79313810|NCT02342483|Dietary Supplement|MSM|
79970768|NCT03738943|Drug|Adenosine Monophosphate|See arm/group descriptions
79970769|NCT03738943|Drug|Uridine Triphosphate|See arm/group descriptions
79313811|NCT02342405|Other|80% oxygen|
79313812|NCT02342405|Other|30% oxygen|
79313813|NCT04478591|Other|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
79970770|NCT03738943|Drug|Adenosine|See arm/group descriptions
79970771|NCT03738943|Drug|Vitamin B 6|See arm/group descriptions
79970772|NCT03738943|Drug|Pyridoxal 5'-Phosphate|See arm/group descriptions
79970773|NCT01588223|Other|Lipid identification|The lipids are identified using Mass Spectrometry
79970774|NCT01588301|Behavioral|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
79970775|NCT01588301|Behavioral|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
79970776|NCT04520308|Drug|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
79806254|NCT05298176|Drug|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
79806255|NCT00593684|Device|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
79806256|NCT02615288|Dietary Supplement|Vitamin D3|
79970777|NCT03644173|Behavioral|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
79970778|NCT04509154|Other|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
79806257|NCT02618096|Drug|Oxytocin|
79970779|NCT04509154|Other|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
79806258|NCT02618096|Drug|Dinoprostone|
79806259|NCT02618096|Procedure|Membrane sweeping|
79806260|NCT04134026|Drug|HIF-PHI|Drug will be dosed orally three times a week.
79806261|NCT04134026|Drug|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
79313814|NCT02347475|Other|Observational Study|Ultrasound and NIRS
79641642|NCT04678141|Other|Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)|compomer (Dyract XP,R&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
79641643|NCT00181662|Drug|Curcumin|
79641644|NCT00533416|Drug|ON 01910 Na|
79641645|NCT00155558|Drug|5-Fluorouracil, Leucovorin|
79641646|NCT00533455|Drug|Gabapentin|
79641647|NCT00533494|Behavioral|physician feedback (A)|Feedback information to physicians
79641648|NCT00533533|Drug|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
79641649|NCT00155597|Behavioral|home physical therapy|
79641650|NCT04658914|Biological|Rotarix|Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10^6 CCID50(median cell culture infective doses) of G1P[8] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
79806262|NCT02963831|Biological|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
79806263|NCT02963831|Drug|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
79806264|NCT02963831|Drug|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
79806265|NCT00859898|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
79490287|NCT03754556|Device|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
79490288|NCT03276871|Procedure|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
79490289|NCT03276871|Device|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
79806266|NCT00859898|Drug|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
79313815|NCT02342093|Drug|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
79313816|NCT02342093|Drug|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
79313817|NCT02347319|Drug|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
79806267|NCT00859898|Drug|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
79806268|NCT00859898|Drug|dapagliflozin matching Placebo|Tablets
79806269|NCT00859898|Drug|metformin HCl Modified Release matching Placebo|Tablets
79970780|NCT03854669|Device|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
79806270|NCT02685761|Procedure|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
79806271|NCT02685761|Procedure|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
79806272|NCT02683967|Procedure|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
79970781|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
79970782|NCT03178851|Drug|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
79970783|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
79970784|NCT03178851|Biological|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
79302079|NCT03207919|Behavioral|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
79302080|NCT03323333|Behavioral|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
79302081|NCT04961151|Other|Multimodal therapeutic warming w/ esophageal d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
79313818|NCT02347319|Drug|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
79313819|NCT02347319|Drug|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
79313820|NCT03146351|Other|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
79806273|NCT00859586|Device|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
79806274|NCT00638729|Drug|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
79806275|NCT00638729|Drug|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
79806276|NCT00638729|Drug|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
79806277|NCT00697892|Drug|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
79806278|NCT00697892|Drug|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
79806279|NCT00697892|Drug|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
79970785|NCT03733015|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
79970786|NCT01291979|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
79970787|NCT01291979|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
79970788|NCT04443634|Procedure|Ultrasound Guided Adductor Canal Block|It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
79313821|NCT02341937|Other|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
79313822|NCT02347397|Device|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head & SL-TWIN Stem
79313823|NCT02347397|Device|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head & SL-PLUS Stem
79641651|NCT04658914|Biological|Trivalent P2-VP8|Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P[4] (DS-1), P[6] (1076), and P[8] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
79641652|NCT04658446|Device|Augmented Reality-Assisted Indirect Bonding|Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.
79641653|NCT04658446|Device|Digitally-Asssited Indirect Bonding|3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
79641654|NCT04628104|Radiation|cardiac magnetic resonance|"o CMR protocol:~Cine imaging to assess regional & global ventricular function according to the AHA 16-segment model.~T2-weighted imaging to detect extent & distribution of myocardial edema.~Early Gd enhancement imaging to detect extent & distribution of myocardial hyperemia.~Late Gd enhancement imaging to detect extent & distribution of myocardial necrosis.~Single-short sequences & other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~Post-processing analysis will be done on a dedicated workstation"
79641655|NCT00533611|Drug|MK0524A, /Duration of Treatment : 4 Weeks|
79641656|NCT00533611|Drug|Comparator : niacin /Duration of Treatment : 1 Weeks|
79970789|NCT04443634|Procedure|Ultrasound Guided Saphenous Nerve Block|"It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected."
79970790|NCT04443634|Procedure|General anesthesia|"General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization."
79970791|NCT04443634|Drug|Bupivacaine 20 ml|20ml bupivacaine 0.5%
79970792|NCT04443634|Drug|Bupivacaine 30ml|30ml bupivacaine 0.5%
79970793|NCT04443634|Drug|Bupivacaine 10ml|10ml bupivacaine 0.5%
79970794|NCT03643159|Combination Product|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
79970795|NCT03643159|Drug|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
79970796|NCT03205566|Drug|Raltegravir 400Mg Tab|bd for 7 days
79970797|NCT03205566|Drug|Lamivudine 150Mg Tablet|+ Raltegravir 400Mg tablet bd for 7 days
79970798|NCT01181999|Drug|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
79641657|NCT00533650|Drug|MK0429|
79313824|NCT03146273|Dietary Supplement|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
79313825|NCT02347241|Other|Educational intervention|Educational Debriefings and High frequency training and team reflection
79641658|NCT00533689|Procedure|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
79806280|NCT02683811|Behavioral|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
79970799|NCT03363880|Other|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
79970800|NCT03363880|Other|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
79313826|NCT02347163|Drug|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
79313827|NCT02341703|Drug|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
79806281|NCT00699452|Drug|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
79806282|NCT00699452|Drug|placebo|placebo
79970801|NCT03732937|Diagnostic Test|Ultrasonography|Ultrasonography with biometry and TCD measurement
79641659|NCT04589923|Device|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
79970802|NCT04523974|Procedure|Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT|"Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~Rapid immunoreactive parathyroid hormone detection technology during peri-operative period."
79970803|NCT03854435|Other|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
79970804|NCT03854435|Other|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
79806283|NCT02683733|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
79970805|NCT04509232|Procedure|Silver diamine fluoride|"Group A~Excavation of soft carious dentin will be done to minimize the staining.~The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~38% Silver diamine fluoride will be applied to carious lesions by microbrush~Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
79970806|NCT04509232|Procedure|Silver diamine fluoride and glass ionomer|"38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
79970807|NCT02935452|Behavioral|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
79476216|NCT02741687|Drug|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
79476217|NCT02741687|Drug|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
79806284|NCT02683733|Drug|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
79806285|NCT02683655|Drug|Apatinib|Apatinib 500mg qd p.o.
79806286|NCT02683655|Drug|Apatinib|Apatinib 750mg qd p.o.
79970808|NCT03732235|Device|TACE+ systemic Bevacizumab|PEG embolics
79970809|NCT03732235|Drug|FOLFIRI+Bevacizumab|antiangiogenic factor
79970810|NCT03732235|Device|TACE|PEG embolics
79970811|NCT01289951|Drug|Raltegravir 400 mg/12hours|
79806287|NCT00494221|Drug|AZD2171|oral tablet
79970812|NCT01289951|Drug|Raltegravir 400 mg/12hours|
79970813|NCT03178773|Behavioral|TExT-MED|messages designed to inspire motivation and behavior change
79970814|NCT03178773|Behavioral|FANS|SMS delivered messages to family members to improve social support
79970815|NCT04508920|Other|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
79970816|NCT01188473|Other|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
79970817|NCT03738787|Procedure|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
79970818|NCT03738787|Procedure|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
79970819|NCT01186523|Other|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
79984508|NCT02450188|Drug|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
79476218|NCT02741687|Drug|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
79476219|NCT05361499|Biological|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
79476220|NCT05361499|Drug|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
79806288|NCT00494221|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
79970820|NCT04508608|Diagnostic Test|Stress Gated blood pool SPECT|"After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
79970821|NCT04508608|Diagnostic Test|Dynamic SPECT|"The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
79970822|NCT03732157|Procedure|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
79970823|NCT03732157|Procedure|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
79970824|NCT01182077|Drug|ASP015K|Oral
79970825|NCT01182077|Drug|Midazolam|Oral
79970826|NCT03356314|Other|MRI between 30-35 GA|MRI between 30-35 GA
79970827|NCT03356314|Other|Pediatric surgeon meeting|Pediatric surgeon meeting
79970828|NCT03356314|Other|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
79970829|NCT03356314|Other|+/- prophylactic surgery|+/- prophylactic surgery
79476221|NCT02742077|Device|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
79476222|NCT00372203|Procedure|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
79476223|NCT02768129|Device|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
79806289|NCT00494221|Drug|Placebo Cediranib|oral tablet
79806290|NCT00909935|Drug|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
79806291|NCT00857948|Drug|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
79806292|NCT00857948|Drug|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
79806293|NCT02618174|Behavioral|Neutral Control Condition|Message about age of University of Birmingham
79313828|NCT02341703|Drug|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
79313829|NCT02341703|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
79313830|NCT02341703|Other|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
79313831|NCT02346851|Procedure|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
79476224|NCT02768129|Device|sham transcranial direct current stimulation|sham stimulation
79476225|NCT02980549|Other|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
79476226|NCT04337099|Drug|MBM-02 (Tempol)|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
79476227|NCT05637151|Other|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
79970830|NCT03854513|Device|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
79970831|NCT02519062|Other|No intervention|This is a retrospective study
79970832|NCT03218397|Device|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
79476228|NCT02768753|Procedure|The Axillary Bilateral-breast Approach|
79476229|NCT02768753|Procedure|The bilateral Axillo-breast Approach|
79476230|NCT05635513|Device|Owlet OSS V3|A wearable pulse oximeter designed for monitoring infants and children in a home environment
79970833|NCT03218397|Device|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
79476231|NCT05162807|Behavioral|Psychoeducational Video on Palliative Care|The intervention is a psychoeducational video introducing palliative care and discussing its purpose, structure, benefits, and efficacy.
79476232|NCT05162807|Behavioral|Educational Video on Nutrition|The attention control is a video on nutrition and healthy eating during cancer survivorship.
79476233|NCT05630677|Drug|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
79476234|NCT05630677|Drug|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
79476235|NCT05630677|Drug|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
79476236|NCT05630677|Drug|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
79476237|NCT05630677|Drug|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions [Study Day 10 to 18].
79476238|NCT05630677|Drug|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
79970834|NCT03618823|Drug|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
79970835|NCT03618823|Drug|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
79970836|NCT03618823|Drug|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
79970837|NCT01188629|Behavioral|Safety Training|IT intervention focuses on safety in the home.
79313832|NCT02341469|Other|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~The training of nurses on IMCI and REC.~A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~A supervision system conducted implemented by district managers to provide support and guidance to health centres.~A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
79313833|NCT02341547|Drug|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
79970838|NCT01188629|Behavioral|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
79641660|NCT04589923|Device|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
79970839|NCT04504786|Other|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
79970840|NCT04504786|Other|Control|Participants maintained their daily activities.
79970841|NCT01188707|Drug|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
79970842|NCT03356158|Biological|CPGJ602|Injection, q.w., 20 mg: 100 ml
79970843|NCT03356158|Biological|Cetuximab|Injection, q.w., 20 mg: 100 ml
79970844|NCT05048706|Device|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
79641661|NCT00533728|Drug|Soluble beta-glucan (SBG)|
79970845|NCT05048706|Device|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
79970846|NCT03738709|Behavioral|Falls prevention and education giving a demonstration of the usage of technical assistance.|"Ecological trail to work on balance and walking.~Technical assistance presentation and try-outs within the therapeutic apartment.~Discussion on the perceived feelings over the exercises and the technical assistance submitted.~Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
79970847|NCT03854591|Other|No intervention|No intervention
79970848|NCT05239689|Biological|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
79476239|NCT05129735|Dietary Supplement|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
79476240|NCT05354323|Biological|NECVAX-NEO1|Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes
79476241|NCT02770625|Drug|ISU302|60 U/kg given intravenously
79476242|NCT05350657|Behavioral|Ketogenic Diet|2 week isocaloric, high protein and low carbohydrate ketogenic diet
79476243|NCT05124041|Diagnostic Test|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
79476244|NCT05627791|Drug|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
79476245|NCT05627791|Drug|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
79476246|NCT00372281|Drug|Cliavist|Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
79476247|NCT02986945|Behavioral|Resiliency App|
79476248|NCT04337879|Drug|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
79476249|NCT04337879|Drug|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
79476250|NCT04337879|Drug|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
79476251|NCT04337879|Drug|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
79476252|NCT04337879|Drug|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
79476253|NCT05613049|Other||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
79806294|NCT02618174|Behavioral|Food-based Control Condition|Message about variety of vegetables in the world
79806295|NCT02618174|Behavioral|Health Condition|Message about the health benefits of eating vegetables
79806296|NCT02618174|Behavioral|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
79476254|NCT05294419|Device|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
79970849|NCT03356080|Drug|Decitabine|Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
79970850|NCT03356080|Drug|Cytarabine|cytarabine, iv,15mg/m2 q12h, Day1-Day10
79970851|NCT03356080|Drug|All-transretinoic acid|All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
79476255|NCT04336631|Behavioral|Intervention on DCP3 based strategies for Hypertension Management and Control|Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
79806297|NCT02618174|Behavioral|Liking Social Norm|Message suggesting most people like eating vegetables
79476256|NCT05456945|Other|acupressure application|Acupressure will be applied to the UB32 point
79476257|NCT05456945|Device|Shotblocher|Shotblocher will be administered during injection
79476258|NCT02774213|Other|Questionnaires completion|
79476259|NCT02774213|Other|Clinical Pain Assessments|
79476260|NCT05456789|Device|combined catheter-thrombectomy and local fibrinolysis|combination of catheter-based thrombectomy with local pulmonary fibrinolysis plus conventional treatment
79476261|NCT05456789|Other|conventional treatment|conventional treatment of pulmonary embolism
79476262|NCT02745353|Drug|naloxegol|
79806298|NCT04183751|Other|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
79806299|NCT02618018|Procedure|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
79970852|NCT03356080|Drug|G-CSF|G-CSF 300ug,sc,Day 0 until CR is achieved
79970853|NCT01290107|Genetic|DNA analysis|
79970854|NCT01290107|Genetic|gene rearrangement analysis|
79970855|NCT01290107|Genetic|microarray analysis|
79970856|NCT01290107|Genetic|polymerase chain reaction|
79970857|NCT01290107|Other|immunological diagnostic method|
79970858|NCT01290107|Other|laboratory biomarker analysis|
79970859|NCT03640507|Drug|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
79970860|NCT03640507|Drug|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
79313834|NCT02347007|Dietary Supplement|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
79313835|NCT02347007|Dietary Supplement|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
79313836|NCT02346929|Other|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
79476263|NCT04778839|Drug|Paclitaxel Micelles for Injection|Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
79970861|NCT03640507|Drug|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
79970862|NCT02467413|Drug|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
79313837|NCT02341391|Biological|TissueGene-C(Low dose)|3.0 x 10^6 cells
79313838|NCT02341391|Biological|TissueGene-C(Medium dose)|1.0 x 10^7 cells
79313839|NCT02341391|Biological|TissueGene-C(High dose)|3.0 x 10^7 cells
79313840|NCT02341235|Behavioral|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
79476264|NCT04778839|Drug|Paclitaxel injection|Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
79476265|NCT05456711|Diagnostic Test|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
79641662|NCT04575844|Drug|Liraglutide|24 weeks of Liraglutide
79970863|NCT02467413|Other|BAC Matched Vehicle|BAC Matched Vehicle
79641663|NCT04575844|Other|Exercise training|24 weeks of Exercise training
79970864|NCT02937636|Other|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride & 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
79970865|NCT02937636|Other|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
79970866|NCT03356002|Device|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~To evaluate the safety of the C-Scan Capsule System procedure"
79970867|NCT05212259|Drug|Collagen type II (40 mg/day)|4 capsules per day
79970868|NCT05212259|Drug|Collagen type II (80mg/day)|4 capsules per day
79970869|NCT05212259|Drug|Collagen type II (120 mg/day)|4 capsules per day
79970870|NCT05212259|Drug|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
79313841|NCT02341235|Behavioral|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
79476266|NCT05602207|Drug|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
79476267|NCT02746991|Drug|Sham Injection|Placebo
79476268|NCT02746991|Drug|FAI Insert|Fluocinolone Acetonide
79476269|NCT04738357|Drug|HSK21542|HSK21542：1 µg/kg
79641664|NCT04575844|Drug|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
79641665|NCT00155675|Drug|GUSUIBU|
79806300|NCT02688491|Drug|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
79970871|NCT05212259|Drug|Placebo|4 capsules per day
79476270|NCT04738357|Drug|Placebo|Placebo
79476271|NCT02289157|Device|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
79806301|NCT00866606|Biological|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
79970872|NCT05239611|Drug|Exercise|The intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
79970873|NCT02518360|Other|Osteopathic|Body adjustment in three sessions (20 minutes/session).
79476272|NCT02747615|Other|transfused pre-operatively donated autologous blood.|Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
79806302|NCT02615132|Behavioral|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
79970874|NCT02518360|Other|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
79970875|NCT03732079|Diagnostic Test|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
79806303|NCT02614976|Device|Padding|"Padding webrill (Covidian) TM 6"
79970876|NCT03354442|Device|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
79970877|NCT03638635|Drug|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
79970878|NCT03638635|Drug|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
79970879|NCT03854279|Device|tonsillar dissection|The tonsils will be removed by bizact device
79970880|NCT03204981|Device|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
79970881|NCT03204981|Procedure|Ablation|standard ablation
79970882|NCT03354364|Dietary Supplement|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
79970883|NCT03354364|Dietary Supplement|Control|Snacks without added fiber.
79313842|NCT02346773|Dietary Supplement|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
79313843|NCT02346773|Other|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
79313844|NCT03146429|Diagnostic Test|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
79313845|NCT02346617|Biological|IFN-γ positive selected T-cells|No intervention
79476273|NCT02747615|Drug|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
79313846|NCT02341079|Drug|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
79313847|NCT02341079|Drug|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
79313848|NCT02346539|Drug|Nicotine polacrilex|Single Acute dose
79313849|NCT02340689|Other|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
79476274|NCT02747615|Other|transfused only allogeneic blood.|
79476275|NCT04336319|Biological|Fecal Microbial Transplantation|"At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline)."
79476276|NCT02775617|Drug|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
79476277|NCT02775617|Drug|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
79313850|NCT04018859|Device|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
79970884|NCT03354286|Behavioral|Developmental & Technological Demands|Education and training related to use of CGM in this age group
79313851|NCT04018859|Drug|Saline|intradermal injections to the eyebrows
79313852|NCT02346149|Other|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
79313853|NCT05254691|Procedure|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
79476278|NCT02775617|Drug|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
79476279|NCT04336007|Device|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
79970885|NCT03354286|Behavioral|Distress Reduction|Education and training on reducing distress
79970886|NCT03354286|Behavioral|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
79970887|NCT03354286|Behavioral|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
79970888|NCT03354286|Behavioral|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
79970889|NCT03205488|Drug|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
79970890|NCT03205488|Drug|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
79970891|NCT03205488|Drug|Placebo|2 capsules taken once daily
79970892|NCT01662609|Procedure|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
79970893|NCT01587755|Other|TTOP|Patient is taken care of in an intensified, optimised manner
79970894|NCT01587755|Other|non-TTOP|Standard medical care
79970895|NCT02518516|Drug|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed >120 days of the index date (i.e. no exposure within 120 days of the index date)."
79806304|NCT02617940|Other|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
79476280|NCT04336007|Device|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
79476281|NCT04336007|Other|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
79806305|NCT02617940|Other|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
79476282|NCT04719403|Other|HealthPAL|Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
79806306|NCT00857792|Drug|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
79806307|NCT02613494|Drug|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
79806308|NCT02613494|Drug|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
79806309|NCT02613494|Other|Placebo|Placebo twice daily, increasing to placebo three times daily
79806310|NCT00699530|Other|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
79806311|NCT04119128|Device|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
79970896|NCT02518516|Drug|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79970897|NCT02518516|Drug|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79970898|NCT02518516|Drug|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79806312|NCT04119128|Device|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
79806313|NCT02617862|Procedure|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
79806314|NCT02617862|Device|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
79476283|NCT05456633|Device|Capri Cervical Static|When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
79806315|NCT02617862|Device|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
79806316|NCT00697970|Biological|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
79806317|NCT00697970|Biological|Engerix™-B|Intramuscular injection, 3 doses
79806318|NCT02617706|Device|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
79970899|NCT02518516|Drug|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79806319|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
79970900|NCT02518516|Drug|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79970901|NCT02518516|Drug|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79476284|NCT05456633|Other|CAPRI Static Expandable|When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
79641666|NCT00533806|Behavioral|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
79970902|NCT02518516|Drug|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
79970903|NCT00454467|Procedure|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
79970904|NCT00454467|Procedure|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
79970905|NCT00454467|Procedure|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
79970906|NCT00454467|Procedure|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
79970907|NCT00454467|Procedure|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
79970908|NCT00454467|Procedure|Cost Data|Cost Data will be collected via hospital billing databases.
79970909|NCT00454467|Procedure|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
79302082|NCT04961151|Other|Multimodal therapeutic warming w/ conductive d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
79302083|NCT02487953|Drug|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
79970910|NCT04508686|Drug|Capecitabine, camrelizumab|This is a single-arm study with all patients receiving these two drugs.
79302084|NCT02487953|Other|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
79302085|NCT02487953|Other|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
79476285|NCT05456633|Device|Capri Thoracolumbar|Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
79476286|NCT00371813|Drug|Varenicline tartrate|
79476287|NCT00371813|Drug|Placebo|
79476288|NCT05456009|Other|No intervention|No intervention
79476289|NCT02748785|Drug|Methotrexate|Methotrexate will be continued
79641667|NCT00533806|Behavioral|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
79806320|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
79806321|NCT02617472|Device|Pelvic floor exerciser|Daily exercise using the study device
79806322|NCT00640367|Other|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
79806323|NCT00640367|Drug|Alteplase IV|intravenous recombinant tissue plasminogen activator
79806324|NCT04133714|Device|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
79806325|NCT04133714|Device|single-channel tDCS|single-channel transcranial direct current stimulation
79302086|NCT02487953|Other|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
79970911|NCT03852095|Other|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
79476290|NCT02748785|Biological|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
79476291|NCT02750267|Device|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
79476292|NCT02295553|Drug|Ketamine|
79970912|NCT03852173|Behavioral|Wasserschulen|"Schools receive following materials and trainings:~one training sessions for teachers (at the beginning of the intervention)~refillable water bottles for each school student~drying rack for water bottles for each classroom~educational material for each class and for school events~informational material for parents"
79970913|NCT02518438|Drug|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
79476293|NCT02295553|Drug|Propofol|
79806326|NCT00697424|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
79970914|NCT04521556|Procedure|Epidural anesthesia with light general anesthesia|"Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8."
79970915|NCT04521556|Procedure|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
79476294|NCT05455151|Procedure|Conservative therapy|Conservative therapy to which the patients were subjected was the effect of an electrical impulse
79476295|NCT05455151|Biological|PRP injection|This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
79476296|NCT05455151|Biological|Injection of PRP after conservative therapy|This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
79641668|NCT04545346|Other|Low Glutamate diet|Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
79806327|NCT00640445|Behavioral|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
79806328|NCT00640445|Behavioral|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
79806329|NCT04133558|Other|tracheal aspirate during routine care|tracheal aspirate during routine care
79806330|NCT02688413|Device|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
79302087|NCT03207607|Other|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
79302088|NCT03207607|Other|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
79302089|NCT03207607|Other|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
79302090|NCT03207607|Other|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
79302091|NCT03207607|Other|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
79302092|NCT03207607|Other|Snack skipping|no snack
79302093|NCT03091569|Other|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
79302094|NCT03091569|Other|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
79302095|NCT03226951|Device|Subthreshold 532nm laser|Subthershold 532nm laser
79302096|NCT03323255|Device|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
79302097|NCT03323255|Device|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
79302098|NCT05005767|Procedure|scaling and root planing|will receive scaling and root planing only
79302099|NCT05005767|Procedure|Frankincense extract gel natural herbal product|will receive Scaling and root planing then. Subgingival application of Frankincense extract gel
79302100|NCT03323177|Dietary Supplement|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
79302101|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
79302102|NCT03226873|Behavioral|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
79302103|NCT03226717|Drug|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
79302104|NCT03319589|Dietary Supplement|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
79302105|NCT03222193|Device|TRP|3 months of TRP tongue retraining
79307815|NCT01874353|Drug|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
79313854|NCT02346227|Drug|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
79313855|NCT02346227|Drug|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
79806331|NCT02688413|Other|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
79313856|NCT03146039|Radiation|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
79806332|NCT00697502|Drug|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
79806333|NCT02617082|Radiation|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
79806334|NCT04183829|Procedure|induced termination of pregnancy|Medically, induced termination of pregnancy (I-TOP) is defined as an intervention to voluntarily terminate a pregnancy (ie, induced abortion) by either surgical or medical means so it does not result in a live birth.
79806335|NCT04118816|Diagnostic Test|Polysomnography|overnight polysomnography recording at least six hours
79806336|NCT04118816|Diagnostic Test|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
79313857|NCT03146195|Other|Dynamic Magnetic resonance imaging|
79806337|NCT04118816|Other|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
79806338|NCT04183517|Drug|PXS-5382A|Orally once daily or twice daily
79806339|NCT02688257|Other|MRI|Functional magnetic resonance imaging
79806340|NCT02688257|Other|Ultrasound|Optoacoustic imaging
79806341|NCT02688335|Device|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
79806342|NCT00640913|Procedure|Reversal of defunctioning stoma|Reversal of defunctioning stoma
79970916|NCT04521556|Procedure|General anesthesia|"Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally."
79476297|NCT05455151|Biological|Injection of PRP with endometrial cells|This intervention consisted of injecting endometrial cells suspended in prp
79641669|NCT04535635|Other|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
79970917|NCT04521556|Drug|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
79806343|NCT00857246|Drug|Cetuximab|
79806344|NCT00857246|Drug|Irinotecan|
79806345|NCT00857246|Drug|Cisplatin|
79313858|NCT05254223|Other|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
79313859|NCT05254223|Other|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
79476298|NCT02296099|Drug|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
79806346|NCT00857246|Procedure|Surgery|
79806347|NCT00857246|Drug|5-FU|
79806348|NCT00857246|Radiation|Radiation|
79806349|NCT02683499|Procedure|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
79806350|NCT04184531|Other|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
79806351|NCT04118582|Other|Body composition and resting metabolic rate analisys|
79806352|NCT00699686|Drug|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
79970918|NCT03204279|Drug|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
79970919|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
79970920|NCT03204279|Drug|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
79970921|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
79970922|NCT02524301|Drug|Positron Emission Tomography using [11C]diprenorphine|PET using [11C]diprenorphine
79970923|NCT03122782|Drug|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
79313860|NCT05254145|Diagnostic Test|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
79313861|NCT02345915|Other|Blood sample|
79313862|NCT02345915|Other|Electrocardiogram|
79313863|NCT02341001|Other|Daily text message of support|
79313864|NCT02340845|Biological|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
79313865|NCT02340533|Procedure|hysteroscopic endo-myometrial biopsy|
79476299|NCT02296099|Drug|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
79970924|NCT03122782|Drug|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
79313866|NCT02340533|Device|ultrasound|two dimensional trans-vaginal ultrasonography
79313867|NCT02340455|Drug|Pregabalin_male|Pregabalin 150mg bid 1day Men
79313868|NCT02340455|Drug|Pregabalin_female|Pregabalin 150mg bid 1day Women
79313869|NCT02340455|Drug|Placebo_Men|Placebo durg
79313870|NCT02340455|Drug|Placebo_Women|Placebo_Women
79313871|NCT02345837|Device|endometrial sampling|injury to the endometrium
79313872|NCT02345837|Drug|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
79313873|NCT02346071|Behavioral|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
79313874|NCT02346071|Other|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
79313875|NCT02345993|Drug|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
79313876|NCT02345447|Drug|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
79313877|NCT02345447|Drug|Placebo|Aqueous ethanol solution non-distinguishable from verum
79476300|NCT05455073|Dietary Supplement|Weekly Iron and Folic Acid Supplementation (WIFA)|Weekly school provision of WIFA tablets to adolescent girls
79476301|NCT05455073|Combination Product|WASH|Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
79476302|NCT05455073|Combination Product|Menstrual Hygiene Management|Support for adolescent girls' menstrual hygiene
79476303|NCT05455073|Behavioral|Nutrition Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
79806353|NCT00699686|Drug|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
79970925|NCT04938414|Diagnostic Test|Lumbar puncture|Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
79970926|NCT01291433|Drug|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
79970927|NCT01291433|Drug|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
79970928|NCT01291433|Drug|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
79313878|NCT05253989|Device|VR Intervention|VR Device that allows a patient to play games based on the EMG activity in the upper limb.
79313879|NCT05253989|Device|FES|Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
79313880|NCT05253599|Device|Isokinetic training|The knees were flexed slightly at 15 degrees, and the fixation straps were tied around the popliteus, thigh, pelvis, chest and scapula to prevent the tricky movements.
79313881|NCT05253599|Device|Virtual reality training|"Training was given in the sitting position which provides challenges to the balance activities of the participant. The game which was used in the current study was a shooting game, which consists of the subject sitting on the virtual platform and visualizing the game on the display screen. The game was executed and controlled by moving the trunk back and forth and left and right according to the signs. Participants can perform all the six movements of their spine within their pain limits.~The level of difficulty of the exercises was increased by graded activity, in which the activities were gradually getting difficult and harder as participants required more muscle activity and movement."
79313882|NCT05253599|Other|Exercises|They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
79313883|NCT02345681|Drug|Furosemide|
79313884|NCT02345525|Behavioral|mCIMT|"This intervention is based on 3 main aspects:~intensive training of functional tasks with the affected arm (massed practice)~constraint of the un-affected hand through a mitt~shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
79313885|NCT02345525|Behavioral|hCIMT|"This intervention is based on 3 main aspects:~intensive training of functional tasks with the affected arm (massed practice)~constraint of the un-affected hand through a mitt~shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
79313886|NCT02345291|Drug|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
79313887|NCT02345291|Drug|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
79313888|NCT02340611|Drug|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
79476304|NCT05455073|Behavioral|MHM & WASH Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
79476305|NCT04334993|Drug|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
79476306|NCT04335071|Drug|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
79476307|NCT04335071|Drug|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
79476308|NCT05349929|Drug|Gelofen (generic name of Ibuprofen in Iran)|Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
79476309|NCT05349929|Drug|Anahil ( generic name of Bromelain in Iran)|Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
79476310|NCT05349929|Procedure|Root Canal Therapy|all the participants go under RCT.
79806354|NCT02688101|Drug|DpC|iron chelator
79806355|NCT04184063|Drug|NBMI|NBMI active treatment
79806356|NCT04184063|Other|Placebo|Placebo for comparison
79641670|NCT04535635|Other|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
79641671|NCT00155714|Drug|type-5 phosphodiesterase Inhibitor (Sildenafil)|
79641672|NCT00181740|Drug|atomoxetine (Strattera)|
79641673|NCT04686721|Diagnostic Test|Chest CT scan + baseline spirometry|Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
79641674|NCT00181779|Drug|aripiprazole (Abilify)|
79641675|NCT04475809|Procedure|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
79970929|NCT01291433|Drug|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
79641676|NCT04475809|Procedure|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
79970930|NCT01291433|Drug|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
79313889|NCT02340611|Drug|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
79476311|NCT04335227|Other|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
79806357|NCT04183985|Device|Total knee arthroplasty prosthesis|In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
79806358|NCT00640679|Drug|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
79806359|NCT00640679|Drug|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
79806360|NCT02682953|Drug|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
79970931|NCT01291433|Drug|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
79970932|NCT04832841|Diagnostic Test|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
79970933|NCT04517422|Dietary Supplement|Probiotics|Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
79313890|NCT02340377|Device|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
79476312|NCT04335227|Other|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
79313891|NCT02345603|Procedure|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
79313892|NCT02340143|Other|Control|Marketed partially hydrolyzed cow's milk protein infant formula
79641677|NCT04475809|Procedure|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
79806361|NCT02682953|Procedure|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
79970934|NCT04517422|Other|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
79970935|NCT01314144|Drug|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
79970936|NCT01182155|Procedure|Exhaled Breath Sampling|Standard of care
79970937|NCT04516798|Other|vibration|local and whole-body vibration were applied
79970938|NCT01186601|Drug|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of </= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
79476313|NCT04335227|Other|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
79476314|NCT04335227|Other|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
79476315|NCT00371891|Procedure|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
79970939|NCT03354208|Other|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
79970940|NCT03173547|Drug|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
79970941|NCT03173547|Drug|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
79970942|NCT01314378|Behavioral|Mindfulness Training|Eight session intensive behavioral training program for smokers
79970943|NCT01314378|Behavioral|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
79970944|NCT01182233|Radiation|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
79970945|NCT03350308|Other|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
79970946|NCT02954653|Biological|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
79970947|NCT02954653|Drug|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
79970948|NCT02954653|Drug|Daunorubicin|60-90 mg/m2 daily for 3 days
79970949|NCT02954653|Drug|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
79970950|NCT02954653|Drug|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
79476316|NCT04737941|Procedure|Endothermal Ablation|Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
79313893|NCT02340143|Other|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
79313894|NCT03145883|Other|Home-Based Aerobic Exercise|
79313895|NCT02340065|Procedure|standard colonoscopy|examination of the colon with a conventional colonoscope
79970951|NCT04504084|Other|Decision aid|Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
79476317|NCT04737941|Procedure|Foam Sclerotherapy|Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
79476318|NCT00371969|Behavioral|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
79970952|NCT01186679|Procedure|laminectomy|surgical laminectomy with glial scar resection
79970953|NCT01186679|Procedure|Intrathecal|direct into the CSF through lumbar puncture
79970954|NCT03173313|Device|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
79970955|NCT04508374|Procedure|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
79970956|NCT04508374|Procedure|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
79313896|NCT02340065|Procedure|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
79313897|NCT03145649|Other|Dietary therapy or insulin injection|
79313898|NCT04086329|Device|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
79313899|NCT02345213|Drug|E2020|E2020 tablets will be orally administered once daily after breakfast
79313900|NCT02345213|Drug|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
79313901|NCT02339753|Drug|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
79313902|NCT02345135|Procedure|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
79476319|NCT00371969|Behavioral|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
79476320|NCT05455307|Device|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
79806362|NCT02682953|Drug|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
79970957|NCT01182389|Procedure|Robotic VT Ablation|Robotic VT Ablation
79970958|NCT01182389|Other|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
79970959|NCT05218473|Diagnostic Test|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
79970960|NCT05218473|Diagnostic Test|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
79806363|NCT02683031|Other|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
79806364|NCT04183907|Behavioral|Transform|"The Partner, Blue Mesa Health, has developed a lifestyle intervention program for pre-diabetics that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. Transform is based on the CDC's National Diabetes Prevention Program (DPP). Blue Mesa Health adapted the National DPP into a digital experience by combining the use of technology- an app, wearable activity trackers (Fitbit) and digital scales- with the professional guidance of remote health coaches.~It is a 6-month intervention that helps individuals establish healthier lifestyle habits. Each participant strives to achieve 2 primary goals:~Attaining 5 to 7 percent weight loss from their starting bodyweight Engaging in at least 150 minutes of weekly physical activity"
79476321|NCT04335851|Other|Video based aerobic exercise|"During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videoswalk at home which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes."
79476322|NCT04334447|Other|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
79476323|NCT04334447|Other|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
79806365|NCT04184141|Drug|Hydroxyzine Hydrochloride|Hyroxyzine hydrochloride is given to the patient one hour before surgery.
79806366|NCT04184141|Drug|Alprazolam tablet|Alprozolam is given to the patient one hour before surgery.
79970961|NCT01182467|Radiation|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
79970962|NCT04508452|Drug|Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
79970963|NCT02524223|Other|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
79806367|NCT04184141|Drug|Placebo|Placebo candy
79806368|NCT02682407|Biological|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
79806369|NCT02682251|Other|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
79806370|NCT02682329|Other|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
79806371|NCT02682329|Other|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
79806372|NCT00640991|Drug|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
79806373|NCT04102709|Device|Health Tag|Health Monitoring Device
79806374|NCT00640757|Dietary Supplement|Methionine deficient diet|Hominex with a low protein diet
79806375|NCT00640757|Dietary Supplement|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
79806376|NCT00638807|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
79970964|NCT02524223|Other|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
79970965|NCT02524223|Other|systematic HPV Status in newborns in case of pregnancy|
79970966|NCT03355846|Drug|Centella|after meals twice a day for 15 days
79970967|NCT03355846|Drug|Proctocella|after hygiene treatment for 4 weeks;
79970968|NCT03355846|Drug|Flavonil® cps|after meals twice a day for 15 days
79970969|NCT03355846|Drug|Flavonil® Cream|"treatment for 4 weeks;~."
79970970|NCT03355846|Drug|Rectalgan Mousse|for 4 weeks
79970971|NCT03215667|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
79970972|NCT03856853|Drug|Pirfenidone|pirfenidone for SSc-ILD treatment
79970973|NCT03856853|Other|placebo|as control
79313903|NCT02345135|Procedure|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
79313904|NCT02345135|Behavioral|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
79313905|NCT02345057|Drug|CS-3150|
79313906|NCT02345057|Drug|placebo|
79313907|NCT02339597|Procedure|Automatic Positive Airway Pressure (APAP) initiation|
79313908|NCT02339675|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
79313909|NCT02339519|Device|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
79476324|NCT04334447|Other|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
79970974|NCT03732703|Drug|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
79313910|NCT02339519|Device|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
79313911|NCT02339519|Device|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
79313912|NCT02339441|Drug|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
79313913|NCT02339441|Drug|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
79313914|NCT02339441|Drug|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
79313915|NCT02344823|Drug|Vardenafil|per oral intake of 10mg Vardenafil once daily
79313916|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
79313917|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
79476325|NCT04336085|Procedure|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
79641678|NCT04475809|Procedure|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
79806377|NCT00638807|Other|Placebo|Matched oral placebo for 6 weeks
79806378|NCT00856856|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
79313918|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
79806379|NCT00782327|Drug|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
79806380|NCT00782327|Drug|Placebo|Daily placebo capsule
79970975|NCT03732703|Drug|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
79970976|NCT03732703|Drug|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
79313919|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
79313920|NCT02344823|Drug|Placebo intake once daily|
79970977|NCT03732703|Drug|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
79476326|NCT04336085|Procedure|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
79476327|NCT05349695|Device|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
79476328|NCT04335695|Behavioral|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
79641679|NCT00533884|Other|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
79970978|NCT03732703|Drug|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
79970979|NCT03732703|Drug|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
79307816|NCT01802632|Drug|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
79476329|NCT04822883|Drug|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
79970980|NCT03732703|Drug|Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
79970981|NCT03732703|Drug|Selinexor, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
79641680|NCT00533884|Other|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
79641681|NCT00533884|Other|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
79641682|NCT00533923|Drug|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
79970982|NCT03636555|Drug|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
79970983|NCT03636555|Drug|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
79970984|NCT03636984|Drug|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
79970985|NCT01186757|Drug|PF-03715455|PF-03715455 1.6 mg BID
79313921|NCT03145961|Drug|Pembrolizumab|200mg intravenous infusion
79476330|NCT04822883|Drug|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
79307817|NCT01782131|Drug|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
79307818|NCT01782131|Drug|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
79313922|NCT02339207|Drug|AL-335 matching placebo|
79313923|NCT02339207|Drug|AL-335|
79313924|NCT02339363|Behavioral|Sitting Meditation|4 weeks Sitting Meditation
79476331|NCT02331589|Drug|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
79476332|NCT02331589|Drug|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
79476333|NCT05439083|Biological|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
79476334|NCT04669171|Biological|EO2463|Multiple dose of EO2463
79476335|NCT04669171|Drug|lenalidomide|D1-21 of 4-weekly cycles
79476336|NCT04669171|Biological|rituximab|Multiple doses of rituximab
79641683|NCT00409227|Drug|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
79970986|NCT01186757|Drug|PF-03715455|PF-03715455 4mg BID
79970987|NCT01186757|Drug|PF-03715455|PF-03715455 10 mg BID
79970988|NCT01186757|Drug|Placebo|Placebo
79970989|NCT03123016|Drug|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
79970990|NCT03123016|Procedure|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
79313925|NCT02339363|Behavioral|Hatha yoga|4 weeks of Hatha yoga
79313926|NCT03145727|Device|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
79641684|NCT00409227|Drug|placebo|placebo once a day for 3 months or stone free
79641685|NCT04475380|Device|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
79641686|NCT00533962|Drug|Anterior Juxtascleral Depot of Anecortave Acetate|
79970991|NCT01182545|Procedure|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
79970992|NCT03636477|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
79970993|NCT03636477|Drug|veledimex|"2 doses (10mg/day, 20mg/day)~15 oral daily doses of veledimex"
79970994|NCT03636477|Drug|Nivolumab|"2 doses (1mg/kg, 3mg/kg)~Every 2 weeks"
79970995|NCT03123094|Drug|BI 655130|single dose
79970996|NCT03123094|Drug|Placebo|single dose
79970997|NCT03732001|Drug|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
79970998|NCT03732001|Drug|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
79970999|NCT01186835|Procedure|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
79971000|NCT01186835|Procedure|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
79971001|NCT03649464|Drug|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
79971002|NCT04812951|Drug|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
79806381|NCT00559091|Drug|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
79313927|NCT03145727|Device|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
79313928|NCT03145727|Device|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
79313929|NCT02339051|Behavioral|Jumping on one leg|
79313930|NCT02338895|Device|Ultrasound|Ultrasound of inferior vena cava and kidneys
79313931|NCT02344511|Drug|Dalbavancin|Drug
79971003|NCT04812951|Device|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
79971004|NCT04508296|Diagnostic Test|Goal directed de-escalation therapy|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI > 650 mL/m2 or EVLWI > 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 or EVLWI < 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
79313932|NCT02344511|Drug|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
79313933|NCT02344589|Drug|Lidocaine|used for the active blocks
79806382|NCT00641615|Biological|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
79971005|NCT01290185|Device|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
79313934|NCT02344589|Drug|Saline|used for the placebo-block
79313935|NCT02344667|Radiation|Stereotactic Body Radiotherapy|
79313936|NCT02338583|Device|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
79313937|NCT02338661|Device|SBG hip stem|
79641687|NCT04473781|Procedure|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
79641688|NCT00406562|Biological|Boostrix|
79806383|NCT04108949|Behavioral|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
79806384|NCT04108949|Behavioral|Treatment as usual|See description included in arm/Group description.
79806385|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
79806386|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
79806387|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
79806388|NCT05664035|Biological|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
79971006|NCT05666089|Drug|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
79971007|NCT05666089|Drug|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
79313938|NCT02338739|Behavioral|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
79313939|NCT02338739|Behavioral|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
79313940|NCT02338739|Behavioral|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
79313941|NCT02338739|Behavioral|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
79313942|NCT02338739|Behavioral|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
79313943|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
79313944|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
79476337|NCT05427227|Device|EV-array detection|Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
79971008|NCT04508218|Dietary Supplement|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
79476338|NCT05421455|Drug|Group A|treat participants with biologics
79313945|NCT02338739|Behavioral|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
79313946|NCT02338739|Behavioral|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
79476339|NCT05421455|Procedure|Group B|treat participants with surgery
79476340|NCT05414591|Drug|DWP16001 drug A|1 tablet, Oral, once daily single dose
79476341|NCT05414591|Drug|DWP16001 drug B|3 tablet, Oral, once daily single dose
79476342|NCT04814225|Other|Test Product 1|Pea Protein powder
79476343|NCT04814225|Other|Test Product 2|Pea & Oat Protein Powder
79313947|NCT02338739|Behavioral|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
79313948|NCT02338739|Behavioral|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
79313949|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
79313950|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
79313951|NCT02338739|Behavioral|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
79313952|NCT02338739|Behavioral|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
79313953|NCT02338817|Device|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
79806389|NCT04182581|Biological|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.
79971009|NCT04508218|Other|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
79971010|NCT04508218|Other|traditional burn care|ROM exercises, stretching, ADL activities and scar management
79313954|NCT03145337|Biological|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
79313955|NCT03145337|Biological|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
79476344|NCT04814225|Other|Test Product 3|Oat Protein Powder
79476345|NCT04814225|Other|Comparator|Whey Protein Isolate
79806390|NCT00641069|Device|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
79313956|NCT02344433|Behavioral|VICKY|Relational agent/virtual counselor
79313957|NCT02344433|Behavioral|MFHP|US Surgeon General's family history tool
79476346|NCT00372671|Behavioral|Survey|
79476347|NCT00372671|Behavioral|Survey and videotape|
79476348|NCT02986867|Radiation|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
79476349|NCT05146999|Biological|QM1114-DP|QM1114-DP
79806391|NCT02682173|Other|MR Abdomen|
79806392|NCT02682017|Other|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
79313958|NCT02338505|Device|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
79313959|NCT02338427|Other|Immunohistochemistry|
79476350|NCT05146999|Biological|Placebo|Placebo
79476351|NCT03029221|Other|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
79641689|NCT00181818|Drug|bupropion SR (sustained-release)|
79806393|NCT02682017|Other|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
79806394|NCT01015105|Other|observation|observation
79476352|NCT03029221|Other|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
79971011|NCT01188785|Drug|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
79971012|NCT03732625|Drug|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
79971013|NCT03555006|Other|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
79971014|NCT03555006|Other|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
79971015|NCT03123172|Diagnostic Test|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
79971016|NCT04694157|Device|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
79476353|NCT03029221|Other|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
79476354|NCT04787939|Behavioral|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
79476355|NCT04757675|Drug|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
79476356|NCT04757675|Drug|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
79476357|NCT04757675|Drug|S-ketamine 2|2 μg/kg intranasal s-ketamin
79476358|NCT04757675|Drug|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
79806395|NCT04033835|Other|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
79806396|NCT04033835|Other|Treatment as usual|Treatment as usual
79806397|NCT00856778|Device|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
79806398|NCT02680925|Procedure|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
79476359|NCT04757675|Drug|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
79490290|NCT03521089|Device|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
79313960|NCT02338427|Other|Proteomic analysis|
79490291|NCT03410797|Device|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
79806399|NCT02680925|Procedure|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
79806400|NCT05663879|Drug|ID120040002|Drug: ID120040002
79806401|NCT05663879|Drug|Compound-X|Drug: Compound-X
79806402|NCT05663879|Drug|Placebo comparator|Placebo comparator
79806403|NCT02680769|Dietary Supplement|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
79806404|NCT02680769|Other|Placebo|This group will take a placebo
79806405|NCT04049903|Drug|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
79313961|NCT02344277|Device|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
79476360|NCT04731311|Device|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
79476361|NCT04730063|Device|VQm PHM™|Procedure: Non-invasive measurements obtained with the VQm PHM™
79476362|NCT04726163|Device|Continuous blind glucose measurement device (Free style Pro)|A continuous blind glucose measurement device (Free style Pro) will be set up on the first day and throughout the entire hospital stay
79971017|NCT03636828|Diagnostic Test|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
79971018|NCT03738319|Genetic|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
79971019|NCT04503928|Drug|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
79971020|NCT04684875|Device|Radiofrequency Stylus|Low power radiofrequency energy delivered to the posterior nasal nerve area
79971021|NCT04597476|Dietary Supplement|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
79641690|NCT04462627|Diagnostic Test|Blood group determination|Determination of the blood group (ABO/LE)
79313962|NCT05002595|Drug|H. pylori eradication|Antimicrobial agents for H. pylori eradication
79476363|NCT05288075|Drug|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
79476364|NCT04424251|Drug|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
79971022|NCT04597476|Other|Placebo( Potato starch)|Potato starch 4.4gram
79307819|NCT01782131|Drug|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
79971023|NCT01188863|Drug|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
79971024|NCT01188863|Drug|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
79971025|NCT01188863|Drug|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
79971026|NCT03634579|Device|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
79307820|NCT01725802|Drug|levodopa and carbidopa solution for SC administration|
79307821|NCT01725802|Drug|Placebo|
79307822|NCT01653093|Procedure|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
79307823|NCT01653093|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
79476365|NCT04424251|Drug|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
79476366|NCT04424251|Drug|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
79476367|NCT04424251|Drug|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
79476368|NCT04424251|Drug|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
79476369|NCT04424251|Drug|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
79476370|NCT04424251|Drug|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
79476371|NCT05272787|Other|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
79806406|NCT05664503|Other|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
79806407|NCT02687945|Procedure|Outpatient physiotherapy|
79806408|NCT02687945|Procedure|Self-guided physiotherapy|
79806409|NCT02687789|Other|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
79806410|NCT02687789|Other|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
79806411|NCT05664347|Behavioral|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
79313963|NCT02343965|Other|Touch-massage|
79313964|NCT03145493|Device|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
79476372|NCT05272787|Other|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
79476373|NCT05272787|Other|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
79313965|NCT02338271|Other|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
79313966|NCT02344043|Device|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
79984509|NCT02450188|Behavioral|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
79313967|NCT02343887|Other|neuropsychological tests|
79313968|NCT02343887|Other|STAI-Y scale for anxiety|
79313969|NCT02343887|Other|Beck scale for depression|
79313970|NCT02343887|Other|without intervention|
79313971|NCT02338115|Drug|Paclitaxel 80mg/m2 weekly x 12 weeks|
79313972|NCT02343809|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
79313973|NCT02343809|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
79476374|NCT05272787|Other|Sunscreen|Auxiliary product
79971027|NCT01188941|Behavioral|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
79971028|NCT02730208|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
79971029|NCT02730208|Drug|Ivacaftor|IVA 150 mg tablet.
79971030|NCT02730208|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
79971031|NCT02730208|Drug|Placebo|Placebo matched to IVA tablet.
79313974|NCT02343809|Other|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
79313975|NCT03112109|Other|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
79476375|NCT05272787|Other|Facial wash|Auxiliary product.
79641691|NCT04462627|Diagnostic Test|Antibody titration|Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
79641692|NCT04462627|Dietary Supplement|Probiotic|Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
79641693|NCT00406601|Drug|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
79641694|NCT00409305|Drug|Betahistine|
79971032|NCT01291511|Drug|Iloperidone|Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
79971033|NCT01291511|Drug|Placebo|Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
79971034|NCT03354130|Other|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
79971035|NCT01292213|Procedure|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
79971036|NCT01292213|Procedure|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
79971037|NCT01292213|Procedure|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
79971038|NCT01292213|Procedure|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
79307824|NCT01653093|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
79307825|NCT01653093|Procedure|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
79307826|NCT01653080|Procedure|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
79971039|NCT01292213|Procedure|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
79307827|NCT01582191|Drug|Everolimus|Given PO
79307828|NCT01582191|Other|Laboratory Biomarker Analysis|Optional correlative studies
79307829|NCT01582191|Other|Pharmacological Study|Optional correlative studies
79307830|NCT01582191|Drug|Vandetanib|Given PO
79307831|NCT01486628|Drug|ND0612|levodopa and carbidopa solution for subcutaneous administration
79307832|NCT01486628|Drug|Placebo|Saline solution for SC continuous administration
79641695|NCT00409305|Behavioral|Dietary counseling|
79971040|NCT01292213|Other|Data collection|Questionnaire completion.
79971041|NCT01292291|Other|biologic sample preservation procedure|
79971042|NCT01292291|Other|laboratory biomarker analysis|
79971043|NCT01292291|Other|study of socioeconomic and demographic variables|
79971044|NCT01292291|Procedure|diffusion-weighted magnetic resonance imaging|
79806412|NCT05664347|Behavioral|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
79971045|NCT01292291|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79971046|NCT01292291|Procedure|multiparametric magnetic resonance imaging|
79313976|NCT02039297|Other|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
79313977|NCT02343731|Other|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
79971047|NCT01292291|Procedure|quality-of-life assessment|
79313978|NCT02337803|Behavioral|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
79971048|NCT01292291|Procedure|transperineal prostate biopsy|
79313979|NCT02337803|Behavioral|Usual Care|Will continue daily physical activity and complete surveys online
79313980|NCT02337881|Drug|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
79313981|NCT02337881|Drug|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
79313982|NCT02337257|Drug|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
79971049|NCT01292291|Procedure|transrectal prostate biopsy|
79971050|NCT01292291|Procedure|ultrasound-guided prostate biopsy|
79313983|NCT02337257|Drug|Placebo|subjects will receive placebo one pill per day for 16 weeks
79313984|NCT02337569|Drug|NPC-02|
79313985|NCT02337569|Drug|Placebos|
79313986|NCT02337179|Procedure|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
79313987|NCT02337101|Other|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
79641696|NCT04442347|Biological|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
79641697|NCT04442347|Other|Placebo|The placebo for this study is 0.9% sterile saline.
79971051|NCT03349918|Behavioral|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
79971052|NCT04507984|Diagnostic Test|Genetic analysis|After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
79971053|NCT04507984|Diagnostic Test|Lipid levels measurement|Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
79971054|NCT03201900|Drug|E2007|Oral tablet
79971055|NCT01314729|Device|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
79971056|NCT01314729|Device|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
79476376|NCT05215145|Behavioral|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
79476377|NCT05215145|Behavioral|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
79971057|NCT03122938|Dietary Supplement|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
79313988|NCT02337101|Behavioral|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
79313989|NCT02337413|Drug|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
79313990|NCT02337413|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
79313991|NCT02337413|Behavioral|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
79641698|NCT00406679|Drug|Paracetamol (acetaminophen) solution experimental|1 gm IV
79641699|NCT00406679|Drug|paracetamol (acetaminophen) solution commercial|1 gm IV
79641700|NCT00406679|Drug|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
79641701|NCT04441216|Other|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae|granule
79641702|NCT04441216|Other|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix|granule
79641703|NCT04431154|Behavioral|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
79971058|NCT03122938|Dietary Supplement|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
79971059|NCT01587833|Drug|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
79971060|NCT05208723|Behavioral|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
79971061|NCT01587911|Other|Whey|Preload containing complete whey protein.
79476378|NCT04349683|Drug|Jinshuibao|6 capsules at a time, 3 times a day (tid).
79971062|NCT01587911|Other|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
79971063|NCT01587911|Other|Control|Preload control matched for energy to the other 5 preloads.
79476379|NCT04349683|Drug|Placebo|6 capsules at a time, 3 times a day (tid).
79476380|NCT05145569|Drug|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
79971064|NCT01587911|Other|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
79971065|NCT01587911|Other|MPI|Preload containing whole milk protein.
79971066|NCT01587911|Other|CPI|Preload containing sodium caseinate.
79476381|NCT05145569|Drug|Bintrafusp alfa (M7824)|"Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human TGF-β receptor II (TGF-βRII or TGF-β trap) fused via a flexible linker to the C-terminus of each heavy chain of an IgG1 antibody blocking programmed death ligand 1 (anti-PD-L1); it is designed to target tumors via colocalized, simultaneous inhibition of 2 key mechanisms of immunosuppression in the tumor microenvironment."
79971067|NCT03800862|Device|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
79971068|NCT01572207|Behavioral|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
79971069|NCT01572207|Behavioral|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
79476384|NCT05136833|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
79476385|NCT05136833|Biological|Placebo|Normal saline will be used as a placebo.
79476386|NCT04547725|Other|CRS followed by IP and systemic chemotherapies|Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
79971070|NCT04444258|Other|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
79971071|NCT04444258|Other|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
79971072|NCT04971005|Drug|Autologous Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
79971073|NCT04971005|Drug|Ocrelizumab|600 mg every 6 months continuously
79971074|NCT04971005|Drug|Alemtuzumab|12 mg/day for 5 consecutive days and again after 365 days for 3 days
79971075|NCT03782532|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79313992|NCT02332265|Other|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed & implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, & Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission & partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices & sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings & Loans Groups, 3) building capacity of local governance structures & 4) integrating HIV education & gender empowerment into programs through training & education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
79641704|NCT04423159|Biological|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
79806413|NCT05663723|Device|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
79971076|NCT03782532|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79971077|NCT03782532|Drug|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
79971078|NCT03782532|Drug|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
79984510|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
79984511|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
79984512|NCT03198676|Drug|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
79984513|NCT03198676|Drug|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
79984514|NCT03749369|Drug|Salvadora Persica Root|Salvadora Persica Gel
79984515|NCT03749369|Procedure|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
79984516|NCT03202966|Other|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
79971079|NCT01187069|Behavioral|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
79476387|NCT05088265|Device|Bigfoot Unity Diabetes Management System|The Bigfoot Unity System is a wirelessly connected set of hardware and software that is intended for use by people with diabetes mellitus who use disposable insulin pens for self-injection of insulin. Bigfoot Unity consists of the Abbott FreeStyle Libre 2 Sensor, two durable insulin pen caps (one each for specific rapid-acting and long-acting insulin pens) and an iOS-specific mobile App.
79971080|NCT03854201|Behavioral|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
79313993|NCT02332109|Device|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
79313994|NCT02332343|Other|No intervention - Natural history study|
79313995|NCT02337023|Radiation|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
79476388|NCT04622345|Drug|VSJ-110|ophthalmic solution
79476389|NCT04622345|Drug|Placebo|ophthalmic solution
79971081|NCT03355768|Drug|Romidepsin|Intravenous administration on a 28 day cycle
79971082|NCT03355768|Drug|Pralatrexate|Intravenous administration on a 28 day cycle
79313996|NCT04477811|Drug|Vitamin K1|vitamin k1 tablets
79971083|NCT04804800|Other|Experimental group 1 : Virtual Reality|Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
79313997|NCT04477811|Drug|Vitamin k2|vitamin k2 45 ug tablets twice daily
79313998|NCT04477811|Other|placebo|placebo tablets
79313999|NCT02332031|Drug|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
79476390|NCT04608617|Device|Viz LVO (De Novo Number DEN170073)|"Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application."
79314000|NCT02332031|Drug|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
79314001|NCT03112031|Drug|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
79314002|NCT03112031|Drug|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
79314003|NCT03112031|Drug|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
79314004|NCT03111797|Drug|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
79314005|NCT03111797|Other|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
79971084|NCT04804800|Other|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
79314006|NCT03111953|Procedure|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately ~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
79314007|NCT03111953|Procedure|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, ~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, ~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
79476391|NCT02292433|Drug|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
79476392|NCT02292433|Drug|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
79314008|NCT02336867|Device|Closure clip (OTSC® Proctology)|
79314009|NCT02938013|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
79314010|NCT02938013|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
79314011|NCT02331875|Drug|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
79314012|NCT02331875|Procedure|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
79314013|NCT02331875|Radiation|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
79476393|NCT02292433|Drug|Placebo|tablets, breakfast plus lunch, 7 days
79476394|NCT03907631|Other|Standard of care|care decisions driven by local physicians; this is an observational cohort
79476395|NCT04939805|Device|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
79476396|NCT04334213|Drug|CKD-501|QD, PO
79476397|NCT04334213|Drug|D745, D150|QD, PO
79314014|NCT02331797|Device|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
79314015|NCT02331797|Device|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
79476398|NCT04334213|Drug|CKD-501, D745, D150|QD, PO
79476399|NCT04885595|Procedure|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
79476400|NCT02986477|Other|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
79476401|NCT04873271|Device|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
79476402|NCT03812549|Drug|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
79971085|NCT01182701|Behavioral|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
79971086|NCT03349840|Drug|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
79476403|NCT03812549|Radiation|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
79476404|NCT03812549|Radiation|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
79476405|NCT03763175|Drug|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
79971087|NCT03349840|Drug|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
79971088|NCT04786236|Device|"Physiological Control Module for the Medtronic -HVAD Left Ventricular Assist Device"|Software, which sets the device speed according to physiological demand, is activated for the duration of the tests (up to 4 hours). Every patient provides his/her own control, because sequences with active control and with standard pump operation are subsequently performed in randomized order (determined by permutated blocks).
79971089|NCT01187147|Dietary Supplement|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
79476406|NCT03763175|Drug|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
79476407|NCT03763175|Drug|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
79314016|NCT02336945|Device|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
79476408|NCT04737863|Procedure|Endodontic retreatment|Root canal retreatment in cases with secondary root canal infection
79314017|NCT02336711|Radiation|dose escalation|molecular imaging based radiotherapy dose escalation
79314018|NCT02820311|Drug|TD-4208 175 mcg|via nebulizer
79314019|NCT02820311|Drug|TD-4208 700 mcg|via nebulizer
79314020|NCT02820311|Drug|Placebo for TD-4208|via nebulizer
79314021|NCT02820311|Drug|Moxifloxacin 400 mg|oral
79971090|NCT01182779|Radiation|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
79971091|NCT01182779|Radiation|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
79314022|NCT02336633|Dietary Supplement|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
79314023|NCT02336633|Other|Placebo|
79314024|NCT02336477|Drug|Mexiletine|"Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~Patients will receive gradual dose of the treatment as it would be done in clinical practice.~Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~The duration of each treatment period is 18 days minimum (maximum 22 days)."
79314025|NCT02336477|Drug|placebo|
79314026|NCT02336789|Other|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
79314027|NCT02336789|Other|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
79314028|NCT04700891|Diagnostic Test|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
79314029|NCT04700891|Diagnostic Test|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
79641705|NCT04724954|Device|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
79971092|NCT03353896|Device|Wear novoTTF-200A|Wear novoTTF-200A device
79971093|NCT03353896|Procedure|Quality-of-Life Assessment|Ancillary studies
79971094|NCT03170271|Drug|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
79971095|NCT03170271|Drug|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
79971096|NCT03613129|Drug|CT38|Infusion
79971097|NCT04504006|Procedure|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
79314030|NCT04700891|Diagnostic Test|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
79314031|NCT02331485|Device|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
79314032|NCT03111563|Other|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
79971098|NCT01187225|Drug|Fibrinogen concentrate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
79971099|NCT01187225|Drug|Cryoprecipitate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
79971100|NCT04664166|Other|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
79971101|NCT03353818|Behavioral|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
79971102|NCT03353818|Behavioral|No intervention|Patients acting as controls will not be restricted in any ways.
79314033|NCT04624451|Drug|Dalbavancin|Dalbavancin 1500 mg intravenously x 1 dose
79314034|NCT03105167|Procedure|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
79971103|NCT03851939|Combination Product|Transarterial Chemoinfusion (TAI) Combine Toripalimab|Transarterial Chemoinfusion (TAI) Combine Toripalimab
79971104|NCT03355612|Drug|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
79971105|NCT03355612|Drug|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
79476409|NCT04365049|Radiation|Radiotherapy|Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
79971106|NCT03235284|Other|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
79971107|NCT03235284|Other|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
79971108|NCT03235284|Other|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
79971109|NCT03732547|Drug|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
79971110|NCT03732547|Drug|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
79971111|NCT04503850|Drug|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
79971112|NCT04503850|Drug|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
79971113|NCT03349684|Drug|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
79971114|NCT03349684|Drug|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
79971115|NCT03349684|Drug|Placebo|Acarbose matching placebo, oral
79971116|NCT03856385|Behavioral|Mindful Walking|Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
79971117|NCT03856697|Drug|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
79476410|NCT04365049|Drug|Nab-paclitaxel|Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
79971118|NCT03856697|Drug|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
79971119|NCT03856697|Drug|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
79971120|NCT03856697|Drug|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
79813665|NCT00810602|Drug|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher [probably or definitely related to the drug] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
79476411|NCT04365049|Drug|Gemcitabine|Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
79476412|NCT04365049|Drug|Camrelizumab|Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
79476413|NCT03092011|Drug|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
79476414|NCT03092011|Drug|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
79476415|NCT04589585|Device|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
79476416|NCT03088033|Device|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
79476417|NCT03088033|Other|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
79476418|NCT04572035|Behavioral|Behavioural Coaching|behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
79476419|NCT04572035|Behavioral|Self-compassion psychoeducation|self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
79476420|NCT04572035|Other|Exercise|aerobic exercise program either delivered in a laboratory setting or via Zoom
79314035|NCT03105167|Procedure|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
79314036|NCT02642315|Drug|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
79314037|NCT02518139|Drug|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
79314038|NCT02518139|Drug|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
79314039|NCT02336321|Device|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
79314040|NCT04477655|Procedure|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
79314041|NCT04477655|Procedure|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
79314042|NCT02709889|Drug|Rovalpituzumab tesirine|
79314043|NCT02709889|Drug|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
79813666|NCT00816868|Drug|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
79813667|NCT00791700|Drug|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
79314044|NCT03189901|Drug|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
79476421|NCT04554173|Procedure|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
79971121|NCT03355378|Procedure|gum chewing|chewing gum orally for 30 minutes
79971122|NCT03856541|Drug|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
79971123|NCT03353662|Other|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
79971124|NCT03353662|Other|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
79971125|NCT03353662|Other|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
79314045|NCT02711995|Drug|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
79971126|NCT03353662|Other|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
79971127|NCT03353662|Other|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
79971128|NCT03353662|Other|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
79984517|NCT04484506|Drug|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
79984518|NCT02449564|Drug|sirolimus|sirolimus 1mg daily
79984519|NCT05668871|Drug|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
79984520|NCT02449720|Drug|Ropivacaine|Intraperitoneal instillation and infusion
79984521|NCT02449720|Drug|0.9% Saline|Intraperitoneal instillation and infusion
79984522|NCT03194620|Other|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
79984523|NCT03194620|Other|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
79314046|NCT02711995|Drug|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
79314047|NCT02438605|Device|Nellix|
79314048|NCT02438449|Procedure|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
79314049|NCT02443051|Behavioral|Attention Bias Modification|Computer delivered modification in 80% of trials
79314050|NCT02443129|Device|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
79314051|NCT02438215|Drug|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
79314052|NCT03193723|Procedure|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~Subdermic infiltration. Approximately 8 milliliters~Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
79314053|NCT03193723|Procedure|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
79314054|NCT04483609|Other|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
79314055|NCT04483609|Other|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
79476422|NCT00372749|Behavioral|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
79476423|NCT02986165|Dietary Supplement|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
79641706|NCT04724954|Genetic|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
79641707|NCT04422457|Other|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
79476424|NCT02986165|Dietary Supplement|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
79476425|NCT02986165|Dietary Supplement|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
79314056|NCT03194035|Biological|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
79476426|NCT00372515|Drug|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
79476427|NCT04333979|Other|Drainage|Using drain after operation
79971129|NCT05195229|Device|COVID-19 Aerosol Collection|"Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator."
79314057|NCT04483453|Other|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
79314058|NCT04483453|Other|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
79314059|NCT02438293|Other|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
79314060|NCT03193411|Device|Visumax femtosecond laser|
79971130|NCT03349606|Drug|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
79813668|NCT00816946|Behavioral|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI & protection against ARI"
79314061|NCT03193411|Device|Moria M2 microkeratome (MK)|
79314062|NCT02437825|Drug|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
79314063|NCT02437825|Other|placebo|placebo ( saline) act as comperator in this study.
79314064|NCT03192319|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection
79314065|NCT02442583|Other|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
79971131|NCT03349606|Radiation|[C-11]FLB 457|PET radiotracer
79971132|NCT02843451|Drug|Milk Thistle|
79971133|NCT02843451|Drug|Placebo|
79314066|NCT02438059|Behavioral|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
79314067|NCT03193489|Other|Follow-up|
79314068|NCT03193489|Other|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
79314069|NCT03193489|Other|Control Parkinson group|No treatment.
79314070|NCT03192163|Other|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
79314071|NCT03193255|Device|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
79813669|NCT00810368|Drug|Carnosine|500mg Carnosine x2 daily
79971134|NCT03353506|Biological|LFMT|Lyophilized fecal microbiota transplant
79971135|NCT03353506|Biological|LSFF|Lyophilized sterile fecal filtrate
79971136|NCT03854045|Other|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
79971137|NCT03349372|Procedure|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
79971138|NCT01183091|Procedure|Ablation of atrial fibrillation|Ablation of atrial fibrillation
79813670|NCT00810368|Drug|Placebo|Microcrystalline cellulose placebo tablets x2 daily
79813671|NCT02610608|Other|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
79813672|NCT02605200|Behavioral|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
79971139|NCT01292525|Drug|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
79971140|NCT01292525|Drug|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
79971141|NCT03355222|Behavioral|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
79314072|NCT02442817|Drug|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
79806414|NCT05663723|Device|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
79984524|NCT03194620|Other|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
79314073|NCT02437747|Drug|SRP + Aloe|Scaling and root planing along with aloe vera application was done
79314074|NCT02437747|Procedure|SRP|Scaling and root planing was done
79314075|NCT02437357|Other|Metacognitive Training|8 group sessions á 60 min
79314076|NCT02437357|Other|Positivity Training|8 group sessions á 60 min
79314077|NCT03193177|Other|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
79314078|NCT03503617|Device|RehabTouch|Exercise using the motion sensing devices and a computer
79314079|NCT03503617|Other|Conventional tabletop exercise program|Exercise following printed sheets of exercises
79314080|NCT02437591|Drug|fidaxomicin|oral
79314081|NCT02442739|Drug|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
79314082|NCT02442739|Other|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
79314083|NCT02442505|Device|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
79314084|NCT03189667|Device|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~All lesions to be predilated with high pressure balloons until waist is obliterated.~At least two minutes dilatation.~Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~Multiple lesions:~To be treated with single balloon if possible.~To be treated with multiple inflation if cannot be covered with single balloon."
79476428|NCT04448119|Drug|Favipiravir|Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
79476429|NCT04448119|Drug|Favipiravir Placebo|Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
79476430|NCT04342429|Radiation|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
79314085|NCT03189667|Device|Plain balloon angioplasty|"Plain balloon angioplasty~Vessel treatment with additional Plain balloon angioplasty:~Inflation to nominal pressure for at least 1 minute.~Balloon size: similar to predilation balloon."
79984525|NCT03194620|Other|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
79984526|NCT03194620|Other|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
79984527|NCT03194620|Other|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
79314086|NCT03189667|Device|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~Inflation to nominal pressure for at least 1 minute.~Balloon size: similar to the predilation balloon.~New drug coated balloon will be required for each lesion."
79314087|NCT02437201|Behavioral|Liberty Program|
79314088|NCT02437123|Behavioral|The Cedar Project mHealth intervention|
79314089|NCT03022903|Procedure|Aminolevulinic Acid (ALA)|Photosensitizing
79314090|NCT02442037|Biological|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10^6/kg) ,once every week，a total of three times.
79314091|NCT02442037|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
79314092|NCT02442427|Drug|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
79314093|NCT02442427|Other|Placebo|An equal volume of 0.9% normal saline
79314094|NCT02442193|Other|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
79314095|NCT03189511|Drug|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
79314096|NCT04483687|Drug|Filgotinib|Tablets administered orally once daily
79314097|NCT04483687|Drug|Placebo to Match Filgotinib|Tablets administered orally once daily
79314098|NCT02065141|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
79314099|NCT03189043|Device|Antimicrobial Surface|Antimicrobial Surface
79476431|NCT02986633|Other|Echocardiography|
79806415|NCT05663723|Device|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
79971142|NCT03851861|Other|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
79302106|NCT05019807|Other|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
79476432|NCT04502615|Other|Sand|sand surface
79476433|NCT04502615|Other|artificial grass|grass surface
79476434|NCT04502615|Other|firm ground|firm surface
79476435|NCT02986555|Device|Existing Biofeedback|Using relaxing assisted biofeedback approach
79476436|NCT02986555|Device|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
79476437|NCT00372983|Drug|NOV-205|
79806416|NCT02680535|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
79806417|NCT02680691|Other|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
79971143|NCT01189019|Drug|ranibizumab|2mg intravitreal injection monthly
79806418|NCT02680691|Other|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
79314100|NCT01654315|Device|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
79806419|NCT02680613|Behavioral|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
79806420|NCT02680613|Behavioral|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
79806421|NCT00603473|Drug|gabapentin|Orally administered gabapentin
79971144|NCT01189019|Drug|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
79971145|NCT04515862|Other|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
79971146|NCT01183247|Drug|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
79806422|NCT02688023|Drug|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
79971147|NCT01183247|Drug|Everolimus|Add everolimus de novo to tacrolimus and MMF
79314101|NCT01654315|Behavioral|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
79314102|NCT03188575|Behavioral|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
79314103|NCT03188575|Other|Waiting List|8 week waiting list period.
79314104|NCT05233735|Other|Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel|Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
79314105|NCT05233735|Other|Topical treatment|betamethasone ointment treatment once per day
79476438|NCT03047473|Biological|avelumab|add on of avelumab 10mg/kg IV to standard therapy
79806423|NCT02680223|Device|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
79806424|NCT02680223|Device|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
79806425|NCT00910013|Drug|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
79806426|NCT04182503|Other|No intervention|This is a multi-city observational cohort study without intervention.
79971148|NCT01183247|Drug|Prednisone|Add prednisone de novo to tacrolimus and MMF
79806427|NCT00486889|Biological|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
79806428|NCT04182191|Drug|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
79806429|NCT02680379|Drug|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
79806430|NCT02680379|Drug|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
79302107|NCT05019807|Other|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
79302108|NCT03323021|Other|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
79302109|NCT03323021|Other|Standard of Care|Standard of Care
79302110|NCT05012553|Other|education of self and peer assesment|Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
79302111|NCT05012709|Behavioral|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
79302112|NCT03119935|Device|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
79302113|NCT03119935|Device|Ambu bag|Participants ventilated the simulated patients by ambu bag
79302114|NCT03109145|Other|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
79302115|NCT03207217|Other|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
79302116|NCT02487719|Drug|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
79302117|NCT03207295|Drug|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
79302118|NCT03207295|Drug|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
79302119|NCT03322787|Device|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
79302120|NCT03207061|Diagnostic Test|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
79302121|NCT04940871|Drug|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
79302122|NCT04940871|Drug|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
79302123|NCT03319511|Other|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
79302124|NCT03319511|Other|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
79302125|NCT03226561|Procedure|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
79302126|NCT03322709|Procedure|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
79302127|NCT03091335|Other|Music-listening|Patients listen to music on headphones
79302128|NCT03226405|Other|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
79476439|NCT03043963|Behavioral|Sleep Extension|Lengthen the duration of sleep time.
79476440|NCT03043963|Behavioral|Sleep Timing|Regularize the timing of the sleep period.
79476441|NCT03020251|Other|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
79806431|NCT03996421|Dietary Supplement|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
79971149|NCT04515082|Diagnostic Test|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
79971150|NCT04515082|Diagnostic Test|FIT|Fecal immunochemical test
79302129|NCT03226405|Other|Usual Care|the standard of care provided by the institution
79314106|NCT03188341|Other|vascular surgery procedure|"an elective open vascular surgery procedure~ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
79314107|NCT02441959|Procedure|Lumbar discectomy Open|Open Discectomy
79971151|NCT03853967|Other|Low dose CT scan|low dose CT scan
79476442|NCT03020251|Other|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
79476443|NCT04707365|Biological|Tumor samples|for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
79476444|NCT02990845|Drug|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
79476445|NCT04310449|Procedure|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
79476446|NCT04310449|Procedure|Dual zone concept and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
79476447|NCT04480931|Behavioral|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
79476448|NCT04480931|Behavioral|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
79476449|NCT01987219|Drug|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
79806432|NCT03996421|Dietary Supplement|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
79806433|NCT00641693|Drug|Budesonide|16mg Nasal Spray
79806434|NCT00641693|Drug|Budesonide|32mg Nasal Spray
79806435|NCT00641693|Drug|Budesonide|64mg Nasal Spray
79806436|NCT00641693|Drug|Placebo|
79971152|NCT04514146|Other|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
79971153|NCT03853889|Procedure|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
79813673|NCT02605200|Behavioral|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
79813674|NCT00628108|Drug|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
79813675|NCT00628108|Other|Placebo|Placebo oral liquid once a day for two weeks
79971154|NCT03353428|Biological|LC-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, chest or tumor injection each time
79971155|NCT01183325|Device|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
79971156|NCT03170193|Drug|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
79971157|NCT03170193|Drug|Placebo|Single doses of matching placebo by SC or IV injection
79971158|NCT03349216|Procedure|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
79813676|NCT00915330|Procedure|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
79813677|NCT00915330|Procedure|TBNA|transbronchial needle aspiration
79971159|NCT03349216|Drug|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
79314108|NCT02441959|Procedure|Lumbar discectomy Endoscopic|Endoscopic Discectomy
79314109|NCT02436499|Drug|Botulinum Toxin-A|
79314110|NCT02434315|Device|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
79314111|NCT02434315|Device|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
79971160|NCT04507750|Drug|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
79971161|NCT03355144|Dietary Supplement|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
79971162|NCT05173077|Procedure|Identification of specific VOCs in CRC tissue surgery material|Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
79476450|NCT01987219|Drug|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
79314112|NCT02434315|Device|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
79314113|NCT02514239|Drug|BI 836909|Intravenous Infusion of BI 836909.
79314114|NCT02436421|Other|Best Practice Alert based in the Electronic Medical Record|
79476451|NCT01987219|Other|placebo|Saline solution 3 cc NA
79971163|NCT05173077|Other|Secondary validation study in general CRC screening settings|"Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results."
79476452|NCT03027245|Drug|Eribulin|
79476453|NCT04768387|Dietary Supplement|Personalized microbiome diet|The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
79476454|NCT02758223|Biological|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
79476455|NCT04265053|Drug|L-NMMA|L-NMMA is a modified amino acid which competitively inhibits Nitric Oxide Synthase (NOS). It is infused acutely (~5 min) via IV catheter. Metabolized via normal metabolic (amino acid) pathways in ~24 hours.
79476456|NCT04265053|Drug|Ketorolac Tromethamine|Ketorolac is an NSAID which competitively inhibits Cyclooxygenase (COX). It is infused acutely (~5 min) via IV catheter. Metabolized in <24 hours.
79971164|NCT05173077|Device|Breath sampling for VOC detection|Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
79641708|NCT04420429|Procedure|Descemet membrane endothelial keratoplasty (DMEK)|All participants underwent DMEK surgery
79971165|NCT05173077|Other|Blood sample collection|Serum, plasma sampling for group description and stratification.
79971166|NCT05173077|Diagnostic Test|Microbiota testing|Faecal samples for microbiota testing.
79971167|NCT05173077|Diagnostic Test|Colonoscopy|Colonoscopy will be used only according to the clinical indications.
79971168|NCT03633331|Drug|Palbociclib|Given PO
79971169|NCT03633331|Drug|Letrozole|Given PO
79314115|NCT03189355|Procedure|Blood sampling|"D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~D4 zonulin"
79314116|NCT03189355|Procedure|Bioelectrical impedance vector analysis|"D1~D4"
79314117|NCT03189355|Procedure|Muscular echography|"D1~D4"
79314118|NCT02441881|Device|Venefit|Endovenous radiofrequency device
79314119|NCT02441881|Device|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
79314120|NCT02441881|Device|Endovenous Radiofrequency|Endovenous radiofrequency device
79314121|NCT02441647|Device|KL029 Intimate Lubricant Gel|
79314122|NCT02441725|Other|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
79314123|NCT04483271|Dietary Supplement|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
79314124|NCT02336009|Device|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
79314125|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
79971170|NCT03633331|Drug|Fulvestrant|Given IM
79971171|NCT03633331|Other|Questionnaire Administration|Ancillary studies
79971172|NCT03633331|Other|Quality-of-Life Assessment|Ancillary studies
79971173|NCT01292681|Other|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
79971174|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
79971175|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
79971176|NCT02524457|Other|This is an observational study. There are no interventions|
79971177|NCT02518204|Other|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
79641709|NCT00181896|Drug|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
79641710|NCT04686448|Drug|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
79971178|NCT02518204|Other|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~HRB: Halstead-Reitan Battery~MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~WAIS-IV: Weschler Adult Intelligence Scale - IV"
79971179|NCT01187303|Drug|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
79971180|NCT03856151|Device|"HEALTHY BOX Powered heating pad (electronic moxibustion)"|Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
79971181|NCT02518282|Other|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
79971182|NCT02518282|Other|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
79971183|NCT02518282|Other|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
79971184|NCT01187459|Dietary Supplement|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
79971185|NCT01187459|Dietary Supplement|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
79971186|NCT03354988|Other|Physical exercise group|For the exercise group, systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital
79971187|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
79971188|NCT01189175|Drug|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
79971189|NCT01189175|Drug|BI 113823|single oral dose
79971190|NCT03201003|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
79971191|NCT03201003|Other|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
79971192|NCT04503538|Other|Telemedicine visit|Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
79314126|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
79314127|NCT02331329|Device|NICOM cardiac output measurement|
79813678|NCT00628030|Behavioral|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
79314128|NCT02331329|Device|Cardiac MRT cardiac output measurement|
79314129|NCT02331563|Drug|Dexmedetomidine|ultrasound guided transvers abdominis plane block
79314130|NCT02331563|Drug|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
79971193|NCT01187537|Procedure|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to < 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
79971194|NCT03349138|Device|Conventional Therapy|
79314131|NCT03188107|Other|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
79314132|NCT02336243|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
79314133|NCT02336243|Dietary Supplement|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
79641711|NCT04686448|Drug|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
79813679|NCT00628030|Other|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
79314134|NCT02331641|Procedure|Hepatectomy|Removal of a part of the liver
79314135|NCT02436343|Other|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
79314136|NCT02330939|Other|Low fat- Low glycemic index meal|
79971195|NCT03349138|Device|Robotic Glove|
79971196|NCT03349138|Device|Electrical Stimulation|
79971197|NCT03851315|Device|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
79971198|NCT03348982|Behavioral|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
79971199|NCT03856073|Behavioral|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
79971200|NCT03354832|Other|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
79971201|NCT03354832|Other|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
79971202|NCT03354832|Other|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
79971203|NCT03354832|Other|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
79314137|NCT02330939|Other|MUFA- Low glycemic index meal|
79314138|NCT02330939|Other|SAFA- Low glycemic index meal|
79641712|NCT00181935|Drug|risperidone (Risperdal)|
79641713|NCT00181935|Drug|olanzapine (Zyprexa)|
79984528|NCT03194620|Other|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
79984529|NCT03194620|Other|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
79984530|NCT03203122|Other|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
79984531|NCT03203122|Other|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
79984532|NCT04384523|Drug|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
79984533|NCT04384523|Drug|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
79984534|NCT04384523|Drug|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
79984535|NCT04384523|Drug|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
79984536|NCT04384523|Drug|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
79984537|NCT04384523|Other|Placebo|Normal Saline (0.9% Sodium Chloride)
79476457|NCT04265053|Drug|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
79806437|NCT04183361|Diagnostic Test|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
79314139|NCT02330939|Other|Low fat- High glycemic index meal|
79314140|NCT02330939|Other|MUFA- High glycemic index meal|
79806438|NCT02681861|Drug|ASP6294 Intravenous|Intravenous (IV)
79971204|NCT05115357|Procedure|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
79971205|NCT05115357|Procedure|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
79476458|NCT04265053|Drug|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
79476459|NCT04265053|Drug|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
79476460|NCT04332497|Other|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
79806439|NCT02681861|Drug|ASP6294 Subcutaneous|Subcutaneous (SC)
79806440|NCT02681861|Drug|Placebo Intravenous|Intravenous (IV)
79806441|NCT02681861|Drug|Placebo Subcutaneous|Subcutaneous (SC)
79806442|NCT02687867|Drug|Dabigatran (Pradaxa)|As prescribed by treating physicians
79971206|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
79971207|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
79971208|NCT04507672|Drug|Fluid resuscitation|Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
79971209|NCT01291589|Behavioral|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
79971210|NCT01183793|Radiation|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
79971211|NCT04507516|Other|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
79971212|NCT03738007|Device|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
79971213|NCT03738007|Device|Perlane|Treatment with Perlane
79971214|NCT03855839|Device|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
79806443|NCT02687867|Drug|Vitamin K antagonist|As prescribed by treating physicians
79806444|NCT00743704|Other|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
79314141|NCT02330939|Other|SAFA- High glycemic index meal|
79476461|NCT04332497|Other|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
79806445|NCT02681939|Drug|Tulsi(Ocimum sanctum Linn.) capsules|
79476462|NCT02840383|Other|Delayed Intervention|Schools not receiving intervention until two years after implementation.
79476463|NCT02840383|Other|Intervention|intervention at the beginning of study.
79476464|NCT04322981|Behavioral|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
79476465|NCT04322981|Behavioral|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
79806446|NCT02681783|Drug|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
79806447|NCT00486811|Drug|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
79476466|NCT02746159|Device|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
79476467|NCT04307225|Device|Zenicor|Handheld Thumb ECG monitoring device
79806448|NCT00486811|Drug|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
79806449|NCT00486811|Drug|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
79476468|NCT02548715|Drug|Levothyroxine|
79476469|NCT02548715|Drug|Placebo|
79476470|NCT02611687|Drug|pitolisant|Tablet
79476471|NCT02611687|Drug|Placebo|Tablet
79806450|NCT04183127|Other|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
79806451|NCT04060810|Other|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
79971215|NCT03855839|Device|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
79971216|NCT03353038|Device|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
79971217|NCT03855761|Behavioral|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
79971218|NCT03855761|Behavioral|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
79476472|NCT04258397|Drug|Pirfenidone|Pirfenidone vs. matching placebo
79476473|NCT04258397|Drug|matching placebo|matching placebo
79476474|NCT01988857|Biological|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
79476475|NCT04707209|Drug|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~Injections will be repeated every eight weeks. A total of 3-6 injections will be given per eye, over 6-12 months. The current treatment plan is for a maximum of six injections per eye, which may be amended to accommodate more in the future."
79476476|NCT04295213|Other|oligosaccharides|1 dose a day of oligosaccharides or placebo
79476477|NCT01989793|Drug|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
79476478|NCT01989793|Drug|Placebo|Placebo will be given to those in placebo arm
79971219|NCT03348826|Drug|Sodium Bicarbonate 8.4% Solution for Injection|3 mL injection into line with up to 2 injections administered
79806452|NCT04182347|Other|Health Research ToolKit Development|"The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."
79806453|NCT00921700|Drug|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
79806454|NCT00921700|Drug|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
79806455|NCT00921700|Drug|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
79971220|NCT03348826|Drug|Alteplase Injectable Solution|2 mL injection into line with up to 2 injections administered
79971221|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
79971222|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
79971223|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
79476479|NCT02422745|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
79476480|NCT02422745|Dietary Supplement|Multivitamin|Multivitamin
79476481|NCT02422745|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
79806456|NCT00921700|Drug|Placebo|Single oral dose of lactose as placebo in gelatine capsules
79806457|NCT02678195|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
79806458|NCT02678195|Drug|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
79971224|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
79971225|NCT01290419|Biological|Placebo|Placebo; Day 0 and Day 30
79971226|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
79971227|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
79971228|NCT04507282|Drug|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
79971229|NCT03737773|Other|glasses (prismatic lenses)|
79971230|NCT03737773|Other|glasses (neutral)|
79971231|NCT04507048|Other|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
79971232|NCT04507048|Other|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
79314142|NCT02331017|Behavioral|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
79476482|NCT02422745|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
79476483|NCT01991821|Drug|APD421|
79476484|NCT01991821|Drug|Placebo|
79476485|NCT04197635|Diagnostic Test|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
79476486|NCT04197635|Diagnostic Test|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
79476487|NCT04197635|Behavioral|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
79641714|NCT04402840|Procedure|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
79806459|NCT02681627|Other|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
79806460|NCT02681627|Other|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
79971233|NCT01183871|Procedure|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
79971234|NCT01060579|Drug|AR-12286 0.5% ophthalmic solution|q.d. PM
79971235|NCT01060579|Drug|AR-12286 0.25% Ophthalmic solution|q.d. PM
79971236|NCT01060579|Drug|Latanoprost ophthalmic solution|q.d. PM
79971237|NCT04443946|Drug|Propofol|5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
79971238|NCT04443946|Drug|1% Sevoflurane|add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
79971239|NCT04443946|Drug|1% Sevoflurane continue|1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
79971240|NCT04443946|Drug|Sufentanil|0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
79971241|NCT04443946|Drug|2% Sevoflurane|2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
79971242|NCT04443946|Drug|Propofol half|2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
79971243|NCT01184027|Behavioral|nutrition /swallowing counseling|general nutrition and swalling information
79971244|NCT01184027|Behavioral|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
79971245|NCT01184027|Behavioral|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
79314143|NCT02331173|Drug|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~Topical dorzolamide 2% three times per day~Topical brinzolamide 1% three times per day"
79476488|NCT04197635|Diagnostic Test|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
79806461|NCT03996577|Drug|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
79971246|NCT03730129|Drug|Hizentra|Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
79314144|NCT02709109|Drug|VX-371 + HS|
79806462|NCT03996577|Drug|placebo|the control group will be given the same volume of saline.
79806463|NCT02681705|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
79806464|NCT02681705|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
79314145|NCT02709109|Drug|Hypertonic saline|
79314146|NCT02709109|Drug|Placebo|
79314147|NCT02709109|Drug|Orkambi|
79314148|NCT02709109|Drug|VX-371|
79314149|NCT04337489|Device|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
79314150|NCT01979003|Drug|Fluorescein|
79314151|NCT02436109|Device|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
79476489|NCT04197635|Other|Clinical evaluation|Evaluation of signs and symptoms of heart failure
79641715|NCT04390087|Other|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
79806465|NCT00921622|Dietary Supplement|Vitamin D|1000 IU twice daily for up to 10 days
79806466|NCT00921622|Dietary Supplement|Vitamin C|500 mg twice daily for up to 10 days
79971247|NCT03348592|Dietary Supplement|Oligofructose-enriched inulin (p-inulin)|
79971248|NCT03348592|Other|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
79971249|NCT03729973|Drug|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
79971250|NCT03729973|Drug|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
79971251|NCT03729973|Drug|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
79476490|NCT01992523|Drug|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
79476491|NCT01992523|Drug|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
79806467|NCT02681471|Other|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
79806468|NCT02681471|Other|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
79314152|NCT01827761|Behavioral|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
79314153|NCT03188029|Diagnostic Test|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
79806469|NCT02681471|Device|monopolar resectoscope|
79806470|NCT02681471|Device|bipolar resectoscope TURis|
79314154|NCT02441569|Behavioral|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
79314155|NCT02441569|Behavioral|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
79314156|NCT04289051|Device|HYDRAL Oral Rinse|Application 4 times a day for two weeks
79314157|NCT04289051|Device|BIOTENE® Oral Rinse|Application 4 times a day for two weeks
79314158|NCT04289051|Device|Placebo Oral Rinse|Application 4 times a day for two weeks
79806471|NCT00747292|Procedure|epidural|Patients in this limb receive epidural analgesia
79806472|NCT00747292|Procedure|PCA|Patients in this limb receive a PCA for their pain control
79806473|NCT00747292|Procedure|Spinal|Patients in limb will receive spinal analgesia
79806474|NCT00642395|Drug|Bortezomib|bortezomib-Melphalan
79806475|NCT03880552|Other|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
79971252|NCT03729973|Drug|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
79314159|NCT02441413|Radiation|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
79314160|NCT03117595|Drug|Bupivacaine-fentanyl|Dosages as previously written
79314161|NCT03117595|Drug|Bupivacaine-fentanyl morphine|Dosage as previously written
79314162|NCT02434159|Other|Heart scan|
79314163|NCT02039531|Biological|Plasma rich in growth factors|
79314164|NCT02039531|Drug|Hyaluronic Acid|
79314165|NCT02435875|Other|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
79314166|NCT02331251|Drug|Pembrolizumab|
79314167|NCT02331251|Drug|Gemcitabine|
79314168|NCT02331251|Drug|Docetaxel|
79314169|NCT02331251|Drug|Nab-paclitaxel|
79314170|NCT02331251|Drug|Vinorelbine|
79314171|NCT02331251|Drug|Irinotecan|
79314172|NCT02331251|Drug|Liposomal Doxorubicin|
79314173|NCT02435953|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
79314174|NCT02435953|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
79806476|NCT00486265|Drug|AZD4877|intravenous infusion administered on days 1, 2 and 3
79806477|NCT00747370|Procedure|movement of midurethra, bladder neck, cervix and rectum|
79806478|NCT02679989|Behavioral|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
79806479|NCT02679989|Behavioral|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
79971253|NCT01189253|Drug|doxorubicin hydrochloride|
79971254|NCT01189253|Drug|trabectedin|
79971255|NCT01189253|Other|laboratory biomarker analysis|
79971256|NCT01189253|Procedure|quality-of-life assessment|
79971257|NCT04443790|Drug|Leptin Human|
79971258|NCT03166215|Drug|TAK-935|TAK-935 tablets.
79314175|NCT02335619|Behavioral|Early palliative care|
79314176|NCT02435797|Drug|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
79314177|NCT02435797|Drug|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
79314178|NCT02330861|Device|combowire and IVUS|
79314179|NCT02335697|Behavioral|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
79314180|NCT02335697|Other|No intervention|
79971259|NCT03166215|Drug|Placebo|TAK-935 placebo-matching tablets.
79314181|NCT04477967|Other|No intervention|There are no interventions because it is a protocol study
79641716|NCT00406757|Drug|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
79971260|NCT03851549|Device|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
79971261|NCT04443868|Drug|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
79314182|NCT02330705|Drug|HCG|Women will be given HCG before IUI
79971262|NCT03851393|Other|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
79971263|NCT03851393|Procedure|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
79641717|NCT00406757|Drug|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
79641718|NCT00406757|Drug|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
79314183|NCT04174625|Dietary Supplement|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
79641719|NCT00406757|Drug|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
79806480|NCT01018459|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10^9 viral particles (vp)/mL, 10^10 vp/mL, 5 x 10^10 vp/mL, and 10^11 vp/mL.
79641720|NCT04361929|Device|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
79314184|NCT02330783|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
79971264|NCT03851393|Diagnostic Test|Peptest™|The Peptest™ lateral flow device
79314185|NCT02330783|Drug|Sorafenib|400mg twice daily by oral of each 4-week cycle
79641721|NCT04342195|Procedure|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
79641722|NCT00409383|Drug|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
79806481|NCT01018459|Drug|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
79806482|NCT03888976|Procedure|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
79806483|NCT01018615|Drug|silymarin|capsules, 700 mg, twice daily, 12 days
79806484|NCT01018615|Dietary Supplement|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
79971265|NCT04443556|Drug|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
79971266|NCT04443556|Other|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
79314186|NCT03105089|Procedure|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
79476495|NCT04057391|Diagnostic Test|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
79476496|NCT00373373|Drug|Sorafenib|2 x 400 mg/d
79476497|NCT00373373|Drug|Placebo|Chemotherapy + Placebo
79971267|NCT05054985|Device|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
79971268|NCT01187615|Drug|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
79971269|NCT01187615|Drug|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
79971270|NCT05375097|Other|Erenumab|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
79314187|NCT02330315|Device|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
79476498|NCT00373451|Drug|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute [maximum of 10 µg/minute] infusion for 12 hours)
79476499|NCT00373451|Drug|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
79971271|NCT04509934|Other|Connective Tissue Manipulation|The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
79476500|NCT00373451|Drug|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
79641723|NCT00409383|Drug|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
79641724|NCT00409383|Drug|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
79641725|NCT04312906|Other|no intervention|No intervention
79971272|NCT01189331|Device|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
79971273|NCT01184105|Drug|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
79971274|NCT01184105|Drug|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
79971275|NCT02752191|Drug|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
79971276|NCT02752191|Drug|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
79971277|NCT03853577|Other|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
79971278|NCT01290497|Drug|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
79971279|NCT01290497|Drug|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
79971280|NCT01290497|Drug|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
79314188|NCT02330315|Device|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
79314189|NCT02335307|Genetic|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
79314190|NCT02335307|Other|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
79476501|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
79476502|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
79971281|NCT03352804|Other|Screening of MDR Bacteriae|questionnaire will be filled by every patient
79971282|NCT03853265|Behavioral|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
79971283|NCT04509778|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
79971284|NCT01184183|Procedure|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
79476503|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
79476504|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
79641726|NCT00409422|Behavioral|weight management program|
79641727|NCT00534079|Drug|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
79641728|NCT00534079|Drug|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
79476505|NCT01387763|Drug|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
79476506|NCT01719497|Drug|[C-11]OMAR|PET radioligand
79641729|NCT00533221|Drug|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
79314191|NCT02335307|Other|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
79314192|NCT02335385|Procedure|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
79314193|NCT02335385|Procedure|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
79314194|NCT02335151|Drug|Desflurane|Apply desflurane as anesthetic
79314195|NCT02330237|Drug|natural gels|whole fruits and vegetables
79314196|NCT02330237|Drug|Placebo|
79314197|NCT03890237|Behavioral|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
79314198|NCT03890237|Behavioral|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
79314199|NCT03890237|Behavioral|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
79314200|NCT03890237|Behavioral|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
79314201|NCT02330003|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
79971285|NCT04509466|Drug|Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
79476507|NCT02514187|Drug|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
79476508|NCT02514187|Drug|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
79476509|NCT00373061|Drug|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
79971286|NCT04509466|Drug|Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
79971287|NCT04509466|Drug|Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
79971288|NCT03352726|Drug|DBV712 IHRP|DBV712 Solution for Skin Prick Test
79971289|NCT03122626|Behavioral|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
79971290|NCT03168711|Drug|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
79971291|NCT03168711|Drug|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
79984538|NCT02446054|Dietary Supplement|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
79984539|NCT03202888|Behavioral|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
79984540|NCT02446288|Device|TMJ Next Generation|
79984541|NCT02446288|Device|DSG Relaxer|
79314202|NCT02330003|Biological|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
79314203|NCT02335073|Other|Venous blood|
79984542|NCT02445976|Drug|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
79984543|NCT03198442|Procedure|F-18 FDG breast PET scan|
79984544|NCT03198364|Behavioral|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
79984545|NCT03198364|Behavioral|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
79984546|NCT03198208|Drug|Fentanyl dose administration|
79984547|NCT01044056|Drug|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
79476510|NCT03936257|Other|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
79641730|NCT00533221|Drug|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
79641731|NCT00155870|Behavioral|questionnaires|
79641732|NCT00188799|Procedure|daily Xray volume imaging for planning radiotherapy|
79641733|NCT04893148|Drug|IGlarLixi|Changing to iGlarLixi from insulin glargine
79813680|NCT02550964|Procedure|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
79476511|NCT03936257|Other|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
79641734|NCT04893148|Drug|Dulaglutide|Add dulaglutide to insulin glargine
79476512|NCT03936257|Other|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
79476513|NCT02500381|Drug|SRP-4045|SRP-4045 solution for IV infusion
79476514|NCT02500381|Drug|SRP-4053|SRP-4053 solution for IV infusion
79476515|NCT02500381|Drug|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
79476516|NCT03871907|Behavioral|Digital technology|Lifestyle-Focused Text Messaging
79476517|NCT03865979|Device|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
79641735|NCT04883632|Combination Product|Saypha Volume Lidocaine|correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma
79641736|NCT04878874|Device|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
79641737|NCT04878874|Device|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
79641738|NCT00181974|Drug|Tisseel Fibrin Sealant|
79641739|NCT02569645|Drug|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
79641740|NCT02500147|Drug|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
79813681|NCT00821392|Drug|Febuxostat|
79971292|NCT04509856|Behavioral|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
79971293|NCT03738215|Drug|Cariprazine|Cariprazine supplied in capsules
79314204|NCT02330159|Procedure|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
79476518|NCT00707213|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar ([18F]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
79971294|NCT03738215|Drug|Placebo|Placebo supplied in capsules
79971295|NCT03122704|Procedure|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
79476519|NCT01993849|Drug|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
79476520|NCT01993849|Other|Placebo|Placebo, designed to match in appearance to NAC
79641741|NCT02500147|Drug|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
79476521|NCT02308189|Behavioral|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
79641742|NCT00182013|Drug|Risperidone|Open treatment with Risperidone
79641743|NCT00182013|Drug|Olanzapine|Open treatment with Olanzapine
79641744|NCT00182013|Drug|Quetiapine|Open treatment with Quetiapine
79641745|NCT00155987|Procedure|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
79641746|NCT04686370|Other|laser treated implant surface|Better marginal bone stability is expected for this type
79641747|NCT00182052|Drug|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
79641748|NCT00182052|Other|Placebo|Given orally twice daily.
79641749|NCT00156026|Procedure|loop electrosurgical excision procedure (LEEP)|1. loop electrosurgical excision procedure
79641750|NCT00188838|Behavioral|Psychoeduction|
79641751|NCT00188838|Behavioral|Cognitive-Behavioral Therapy|
79971296|NCT04506580|Procedure|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
79641752|NCT01715974|Drug|GM-CSF group|30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
79641753|NCT01715974|Drug|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
79641754|NCT00156143|Procedure|Blood sample|
79641755|NCT00156143|Procedure|Radiography|
79641756|NCT00182130|Procedure|Quality Initiative in Rectal Cancer (QIRC) strategy|
79971297|NCT05352321|Drug|Gemcitabine|for induction chemotherapy
79971298|NCT05352321|Drug|Cisplatin|for induction and concurrent chemotherapy
79476522|NCT02308189|Behavioral|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
79971299|NCT05352321|Radiation|regular intensity-modulated radiotherapy|in active comparator arm
79476523|NCT04231591|Diagnostic Test|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
79476524|NCT02778113|Drug|Nasal Glucagon|Administered intranasally.
79971300|NCT05352321|Procedure|surgery|in experimental arm
79641757|NCT00535717|Procedure|uttarbasti (per urethral administration of medicated oil )|
79641758|NCT00535756|Drug|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
79641759|NCT00535756|Drug|Placebo|Placebo
79641760|NCT00156182|Drug|Asoprisnil|10mg Tablet, oral Daily for 6 months
79641761|NCT05471479|Drug|Activated Charcoal|Activated charcoal administered as per Clinical Toxicology Recommendations Collaborative or as per current practices
79806485|NCT05663021|Diagnostic Test|Ultrasound-guided core needle biopsy in breast|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
79806486|NCT00743782|Drug|Synthetic Human Parathyroid Hormone 1-34|
79806487|NCT02678117|Drug|Pregabalin & Placebo|
79806488|NCT02678117|Drug|Magnesium sulphate & Placebo|
79971301|NCT05352321|Radiation|Target-reduction intensity-modulated radiotherapy|in experimental arm
79476525|NCT02778113|Drug|Glucagon|Administered SC.
79476526|NCT01994785|Diagnostic Test|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
79806489|NCT02678117|Drug|Pregabalin & Magnesium sulphate|
79971302|NCT01290575|Drug|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
79971303|NCT01290575|Drug|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
79971304|NCT01290575|Drug|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
79971305|NCT01290575|Drug|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
79971306|NCT01290575|Drug|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
79476527|NCT04982237|Biological|AK104|IV infusion
79476528|NCT04982237|Drug|paclitaxel|IV infusion
79476529|NCT04982237|Drug|carboplatin|iv infusion
79476530|NCT04982237|Drug|cisplatin|iv infusion
79476531|NCT04982237|Drug|bevacizumab|iv infusion
79641762|NCT00188877|Procedure|intensity modulated radiation therapy|
79641763|NCT00188877|Drug|cisplatinium and fluorouracil - standard treatment|
79641764|NCT00535795|Radiation|Radiation Therapy|Radiation Therapy
79641765|NCT05471362|Device|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
79641766|NCT05471284|Behavioral|Proximal|The first factor tested framing of the near, proximal threat of continued smoking.
79641767|NCT05471284|Behavioral|Distal|The first factor tested framing of the long-term, distal threat of continued smoking.
79806490|NCT02678117|Drug|Placebo|
79806491|NCT01018849|Dietary Supplement|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
79971307|NCT01290575|Drug|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
79971308|NCT01290575|Drug|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
79971309|NCT01290575|Drug|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
79971310|NCT01290575|Drug|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
79971311|NCT03352570|Device|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
79971312|NCT01290653|Other|Dry needling|Deep dry needling until achieving twitch response of the muscle
79971313|NCT01290653|Other|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
79971314|NCT01290653|Other|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
79971315|NCT03348436|Procedure|radiofrequency ablation|
79971316|NCT05031741|Other|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
79314205|NCT02334839|Other|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
79314206|NCT02329769|Drug|PRO044 SC 6 mg/kg|
79314207|NCT02329769|Drug|PRO044 IV 6 mg/kg|
79314208|NCT02329769|Drug|PRO044 IV 9 mg/kg|
79314209|NCT02334917|Procedure|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
79806492|NCT01018849|Dietary Supplement|Placebo|placebo by mouth every 2 months for 1 year
79314210|NCT02329457|Biological|Zostavax|varicella zoster vaccine
79476532|NCT04982237|Drug|Placebo|iv infusion
79806493|NCT04102319|Diagnostic Test|serum hepcidin|it is a serum marker
79806494|NCT00743860|Drug|darapladib|experimental drug
79806495|NCT01018693|Drug|VAK694; Alutard Avanz SQ|
79314211|NCT02329457|Biological|Normal Saline|normal saline placebo vaccine
79476533|NCT02780765|Device|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
79806496|NCT01018693|Drug|VAK694 placebo infusion; Alutard Avanz SQ|
79806497|NCT01018693|Drug|VAK694 placebo infusion; Saline|
79806498|NCT00747526|Drug|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
79971317|NCT03199911|Drug|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
79314212|NCT02709655|Drug|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
79971318|NCT03199911|Drug|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
79984548|NCT01044056|Drug|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
79984549|NCT01044056|Drug|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
79984550|NCT03198286|Other|Informational Intervention|Receive treatment summary and survivor care plan
79314213|NCT02709655|Drug|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
79476534|NCT02780765|Device|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
79314214|NCT02709655|Drug|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
79314215|NCT02709655|Other|Placebo|Encapsulated tablet, orally
79314216|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
79314217|NCT02334605|Device|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
79314218|NCT02334605|Device|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
79314219|NCT02329613|Other|Standard evening meals.|Patients will receive usual evening meals.
79314220|NCT02329613|Other|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
79971319|NCT05511532|Other|Orthopaedic treatment|"Female and male patients aged between 6 and 12 years are included in the study. Initially, the values of dorsiflexion of the tibio-fibular-talar joint and dorsiflexion of the first metatarsophalangeal joint will be measured to rule out hallux rigidus and ankle equinus, respectively.~Those patients who do not present hallux rigidus or equinus ankle, will be included in the study and will have their computerized foot pressures taken."
79314221|NCT02334449|Drug|LML134|LML134 will be administered first as single doses and then as multiple doses
79476535|NCT01995487|Device|BioNIR|drug-eluting stent
79806499|NCT00747526|Drug|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
79806500|NCT01018771|Procedure|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
79806501|NCT01018771|Procedure|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
79806502|NCT01025011|Device|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
79314222|NCT02334449|Drug|Placebo|All study cohorts (except food effect cohort) are placebo controlled
79314223|NCT02329535|Drug|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
79314224|NCT03187795|Drug|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
79314225|NCT03187795|Drug|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
79476536|NCT01995487|Device|Resolute|drug-eluting stent
79476537|NCT02783027|Behavioral|SleepTrackTXT2|Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
79476538|NCT01996657|Drug|Warfarin|
79476539|NCT02462629|Drug|BLZ-100|
79806503|NCT00747604|Biological|mecasermin [rDNA origin] injection|As prescribed by the physician.
79971320|NCT03853421|Drug|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
79314226|NCT02329379|Drug|Levothyroxine|
79314227|NCT02334293|Drug|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
79314228|NCT02441257|Procedure|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
79314229|NCT02441257|Procedure|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
79476540|NCT01996813|Device|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
79476541|NCT02784275|Drug|Cyclo-Z|
79476542|NCT02784275|Drug|Placebo|
79314230|NCT02329067|Other|walnuts|consumption of 43 g walnuts per day
79314231|NCT02334137|Behavioral|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
79314232|NCT02334137|Behavioral|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
79314233|NCT02334137|Behavioral|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
79314234|NCT03189199|Other|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
79314235|NCT02329145|Procedure|renal denervation|
79314236|NCT02435563|Drug|ticagrelor 180 mg administrated alone|
79314237|NCT02435563|Drug|Ticagrelor adjusted dose + ritonavir 100mg|
79314238|NCT02329301|Drug|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
79476543|NCT04229563|Device|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
79476544|NCT02784587|Procedure|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
79314239|NCT02329301|Drug|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
79476545|NCT01997125|Device|Neural Bridge System|Implanted device
79476546|NCT01997437|Device|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
79971321|NCT03352492|Procedure|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
79314240|NCT03187639|Diagnostic Test|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or > 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
79314241|NCT03187639|Diagnostic Test|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
79314242|NCT02328989|Device|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
79476547|NCT02316379|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
79476548|NCT02316379|Device|MRI|
79476549|NCT03764501|Device|Image fusion system|Image fusion system for the 3D preoperative planning
79641768|NCT05471284|Behavioral|Cost|Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
79971322|NCT03352492|Procedure|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
79971323|NCT02517814|Dietary Supplement|Vitamin D|
79971324|NCT05349201|Other|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
79971325|NCT05349201|Other|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL])
79971326|NCT05303727|Drug|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
79971327|NCT05303727|Drug|Fludarabine|30 mg/m2/day for 5 days
79971328|NCT05303727|Drug|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
79641769|NCT05471284|Behavioral|Benefit|Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
79476550|NCT03701165|Device|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
79476551|NCT02303743|Device|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
79971329|NCT05303727|Drug|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
79971330|NCT05303727|Drug|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
79476552|NCT02303743|Device|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
79641770|NCT05471284|Behavioral|Loss|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
79641771|NCT05471284|Behavioral|Gain|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
79641772|NCT05471284|Behavioral|Control|Does not include any of the three message factors.
79641773|NCT00182169|Drug|Human recombinant growth hormone|
79641774|NCT05471167|Biological|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
79641775|NCT05471050|Drug|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
79971331|NCT05303727|Drug|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
79971332|NCT05303727|Drug|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
79971333|NCT05303727|Drug|Cyclosporine|2.5~4 mg/kg/dose every 12 hours orally；1.5~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150~250ng/ml
79971334|NCT05303727|Drug|Tacrolimus|0.02~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
79476553|NCT04964375|Drug|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
79476554|NCT02303977|Drug|Abraxane|
79476555|NCT02303977|Drug|Gemcitabine|
79476556|NCT01997515|Drug|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
79476557|NCT01997515|Drug|placebo|Group P (placebo) will receive the same amount of saline.
79476558|NCT02786771|Device|Spire|
79476559|NCT02786771|Device|Muse headband|
79476560|NCT01997905|Device|AtriClip LAA Exclusion Device|
79641776|NCT05471050|Drug|Danazol|Danazol is given at 200mg bid for 12 weeks.
79641777|NCT00156260|Procedure|Ductal lavage|
79641778|NCT00535834|Procedure|diagnostic procedure|
79641779|NCT00535834|Procedure|molecular diagnostic method|
79641780|NCT00535834|Procedure|protein expression analysis|
79641781|NCT00182208|Device|Veno-device (Venowave)|
79806504|NCT02151604|Drug|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
79806505|NCT00466921|Drug|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
79806506|NCT02563912|Other|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
79971335|NCT05303727|Drug|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
79971336|NCT05303727|Drug|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
79971337|NCT04506658|Device|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
79971338|NCT04506658|Device|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
79971339|NCT05495074|Other|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
79971340|NCT04503525|Other|Nutritional assessment|Nutritional assessment in COVID patients
79971341|NCT05011929|Behavioral|Cognitive behavioral therapy|refer to the arm description
79971342|NCT04502368|Procedure|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
79476561|NCT04938089|Other|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking > 9 cigarettes per day.
79971343|NCT04502368|Procedure|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
79971344|NCT04502368|Diagnostic Test|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
79971345|NCT04502368|Diagnostic Test|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
79971346|NCT03348358|Behavioral|quiet music|playing quiet music during labor
79476562|NCT02788019|Drug|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
79806507|NCT02563912|Other|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
79476563|NCT02788097|Procedure|Progesterone supplementation|artificial frozen embryo transfers
79476564|NCT01999231|Biological|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
79806508|NCT02073292|Procedure|c-RFA|
79806509|NCT02073292|Procedure|tRFA|
79971347|NCT03348358|Behavioral|Rhythmic music|playing rhythmic music during labor
79971348|NCT03348358|Behavioral|control|No music during labor
79971349|NCT04984083|Dietary Supplement|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
79971350|NCT03736967|Drug|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
79971351|NCT03736967|Drug|Dupilumab|Administered SC q2w
79971352|NCT03736967|Drug|REGN3500 + Dupilumab Combo|Administered SC q2w
79971353|NCT03736967|Drug|Placebo|Administered SC q2w
79971354|NCT04506502|Device|The ZELTIQ System|The MMS device will be used to perform the treatments.
79971355|NCT04938219|Other|Gloves filled with warm tap water|The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
79971356|NCT04506346|Diagnostic Test|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
79971357|NCT03352258|Radiation|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
79971358|NCT01581203|Drug|Asunaprevir (ASV)|
79476565|NCT02789033|Drug|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
79641782|NCT05470972|Drug|Ethanol Injection|The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
79806510|NCT00601523|Drug|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
79806511|NCT00601523|Drug|Pramipexole|ER 0.375-4,5 mg
79971359|NCT01581203|Drug|Daclatasvir (DCV)|
79806512|NCT00466687|Biological|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
79806513|NCT00466687|Drug|erlotinib hydrochloride|150mg PO qd
79806514|NCT00466687|Genetic|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
79806515|NCT00466687|Genetic|gene expression analysis|gene expression analysis
79971360|NCT01581203|Drug|Pegylated-interferon alfa 2a (PegIFN)|
79971361|NCT01581203|Drug|Ribavirin (RBV)|
79806516|NCT00466687|Other|immunologic technique|immunologic technique
79806517|NCT00466687|Other|laboratory biomarker analysis|laboratory biomarker analysis
79806518|NCT00466687|Procedure|biopsy|biopsy
79806519|NCT01759459|Drug|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
79806520|NCT01759459|Drug|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
79806521|NCT01759459|Drug|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
79806522|NCT00747838|Procedure|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
79806523|NCT02537795|Device|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
79806524|NCT02537795|Procedure|anterior capsulotomy|
79806525|NCT02562742|Drug|SOF|SOF 400 mg tablets administered orally once daily
79971362|NCT04506268|Behavioral|Opt-out Recruitment Email|Behaviorally informed, opt-out framed recruitment email
79971363|NCT04506268|Behavioral|Opt-in Recruitment Email|Standard, opt-in framed recruitment email
79971364|NCT03168555|Drug|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
79971365|NCT03352180|Procedure|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
79971366|NCT03352180|Procedure|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
79971367|NCT03235050|Drug|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
79971368|NCT03235050|Drug|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
79971369|NCT03235050|Drug|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
79971370|NCT03235050|Drug|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
79971371|NCT03235050|Drug|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
79971372|NCT01184339|Device|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
79971373|NCT03636399|Behavioral|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
79971374|NCT03636399|Behavioral|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
79971375|NCT03348124|Behavioral|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
79971376|NCT01187693|Other|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
79971377|NCT04933149|Drug|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
79971378|NCT03855683|Behavioral|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
79476566|NCT02789033|Drug|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
79971379|NCT03853499|Other|No intervention (observational study)|No intervention (observational study)
79971380|NCT03004365|Drug|C16G2 Varnish|Antimicrobial Peptide
79971381|NCT03004365|Drug|Placebo Varnish|Placebo
79314243|NCT03187873|Behavioral|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
79314244|NCT02435485|Device|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
79314245|NCT02435485|Other|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
79314246|NCT02334371|Radiation|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
79476567|NCT02789033|Drug|Placebo|placebo
79476568|NCT01999777|Drug|USL261|
79476569|NCT01999777|Drug|Placebo|
79971382|NCT04502212|Device|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
79314247|NCT02435641|Other|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
79314248|NCT02708485|Other|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
79476570|NCT02790281|Procedure|Blood sampling|Blood sample collected at a single visit
79476571|NCT04913519|Drug|TDM-105795|TDM-105795 topical solution
79971383|NCT01293617|Other|Blackberries|300 g blackberries daily for 5 days
79971384|NCT01293617|Other|Gelatin|300 g gelatin per day for 5 days
79476572|NCT04913519|Drug|Placebo|Placebo for TDM-105795 topical solution
79971385|NCT03851471|Drug|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
79971386|NCT03352102|Procedure|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
79476573|NCT00372827|Drug|Brinzolamide 1% added to Travoprost 0.004%|
79476574|NCT02278315|Drug|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
79476575|NCT02278315|Drug|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
79971387|NCT01189721|Drug|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
79971388|NCT04503070|Behavioral|Motion capture participant|"Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~15 dry swings with a wiffle bat at low, medium and high effort~15 dry swings with a weighted bat at low, medium and high effort~15 swings off of a tee at low, medium and high effort~15 swings at an underhand toss at low, medium and high effort~15 swings from a pitching machine at low, medium and high effort"
79971389|NCT03847883|Drug|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
79971390|NCT03492216|Behavioral|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) <300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
79476576|NCT02278315|Drug|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
79476577|NCT02188147|Device|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
79476578|NCT02794727|Device|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
79476579|NCT02794727|Device|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
79476580|NCT02795117|Drug|Ivermectin|
79476581|NCT02795117|Drug|Ivermectin (reference)|
79476582|NCT02795117|Drug|Placebo|
79476583|NCT02333071|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
79476584|NCT02333071|Other|Placebo|Placebo
79476585|NCT02795819|Drug|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
79971391|NCT03492216|Behavioral|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
79971392|NCT03167619|Drug|Olaparib Oral Product|olaparib 300mg twice daily
79971393|NCT03167619|Drug|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
79971394|NCT03578809|Biological|MEDI6012|MEDI6012
79971395|NCT03578809|Other|Placebo|Placebo
79971396|NCT01189877|Procedure|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
79971397|NCT03850925|Procedure|Laser therapy|4 consecutive sessions of laser therapy
79476586|NCT02795819|Drug|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
79476587|NCT02882633|Drug|30ml bolus of bupivacaine|Local anesthetic
79476588|NCT00373607|Drug|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
79971398|NCT03198507|Drug|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
79971399|NCT03198507|Drug|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Amoxicillin 3000 mg~Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
79307833|NCT01406184|Other|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
79476589|NCT00373607|Drug|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
79806526|NCT02562742|Drug|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
79971400|NCT01184261|Behavioral|behavioral intervention|8 session behavioral intervention.
79476590|NCT02797613|Behavioral|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
79476591|NCT02882711|Drug|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
79476592|NCT02884427|Device|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
79806527|NCT04182971|Other|Fruit|Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
79806528|NCT04182971|Other|Fruit juice|Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
79476593|NCT02884427|Device|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
79476594|NCT02884427|Device|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
79476595|NCT02798627|Drug|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
79476596|NCT02798627|Drug|placebo|Placebo pills identical in appearance to the NS2359 will be provided
79476597|NCT02794337|Radiation|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
79476598|NCT02794337|Procedure|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
79476599|NCT02794337|Drug|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
79971401|NCT01189955|Procedure|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
79307834|NCT01189786|Device|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
79476600|NCT02886923|Device|Hioxifilcon A Test|contact lens made with hioxifilcon A material
79476601|NCT02886923|Device|Hioxifilcon A With Cosmetic Ring Control|contact lens made with hioxifilcon A material with a cosmetic ring on the lens
79476602|NCT02888093|Device|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
79476603|NCT02590523|Drug|Vancomycin|Intracameral vancomycin injection during cataract surgery
79476604|NCT02590523|Drug|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
79307835|NCT00938145|Procedure|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
79307836|NCT00938145|Drug|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
79806529|NCT04182971|Other|Fruit juice plus fiber|Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
79806530|NCT00305851|Procedure|Music Therapy|Undergo therapeutic music video therapy
79314249|NCT02435407|Behavioral|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
79314250|NCT02435407|Other|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
79806531|NCT00305851|Procedure|Psychosocial Assessment and Care|Undergo books on tape therapy
79314251|NCT02333903|Other|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
79314252|NCT02441023|Behavioral|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
79806532|NCT00305851|Other|Quality-of-Life Assessment|Ancillary studies
79806533|NCT04183283|Drug|LY3526318|Administered orally.
79806534|NCT04183283|Drug|Placebo|Administered orally.
79806535|NCT00744016|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
79984551|NCT03203044|Other|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
79984552|NCT01005056|Drug|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
79984553|NCT04796714|Drug|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
79806536|NCT00744016|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
79984554|NCT04796714|Drug|Aspirin|One sachet of aspirin 160 mg per day during 3 months
79984555|NCT04796714|Device|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
79984556|NCT04796714|Other|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
79984557|NCT04382651|Drug|MAS825|MAS825 liquid solution for intravenous infusion
79476605|NCT02590523|Drug|Placebo|Intracameral placebo injection with BSS during cataract surgery
79806537|NCT05664269|Dietary Supplement|drink ingestion|drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
79476606|NCT02519309|Other|Virta Program|
79476607|NCT02895035|Drug|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
79971402|NCT01189955|Procedure|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
79971403|NCT04738344|Device|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
79971404|NCT03610165|Device|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
79971405|NCT03610165|Device|Control|Arterial waveform and pressures
79476608|NCT02895035|Drug|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
79476609|NCT02802449|Drug|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
79476610|NCT02802449|Drug|Placebo|
79476611|NCT02803229|Drug|Adderall-XR|
79476612|NCT02803229|Drug|Matched placebo|matched placebo provided for placebo arm
79476613|NCT01938001|Drug|Rituximab|Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
79806538|NCT05664269|Behavioral|resistance-type exercise|Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
79806539|NCT00744094|Dietary Supplement|protein drink|250 ml protein hydrolysate solution
79806540|NCT00744094|Behavioral|Resistance training|12 weeks resistance training, 3 days per week
79314253|NCT02441023|Behavioral|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
79314254|NCT02333981|Device|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
79314255|NCT02433847|Drug|Mosapride|
79806541|NCT01018927|Device|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
79314256|NCT02328833|Other|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
79314257|NCT02435329|Other|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
79314258|NCT02435251|Device|dual energy X-ray absorptiometry|
79314259|NCT03187483|Procedure|orthodontic treatment|orthodontic treatment in maxillary crowding
79314260|NCT02328911|Device|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
79314261|NCT02328911|Device|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
79314262|NCT02435095|Drug|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
79314263|NCT02435095|Drug|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
79314264|NCT04477421|Procedure|FS-SMILE|Femtosecond small incision lenticule extraction
79806542|NCT02677883|Other|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
79806543|NCT02677883|Other|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
79314265|NCT04477421|Procedure|S-LASIK|Femtosecond laser Insitu keratomileusis
79314266|NCT01307813|Device|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
79476614|NCT01938001|Drug|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
79476615|NCT01938001|Drug|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
79806544|NCT04182893|Diagnostic Test|ctDNA and Exosome Combined Detection|Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
79806545|NCT00641303|Procedure|acupuncture therapy|Given weekly for 8 sessions
79806546|NCT00641303|Procedure|sham intervention|Given weekly for 8 sessions
79806547|NCT04182737|Drug|IgM-enriched polyclonal immunoglobulins titer-based treatment|Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
79806548|NCT04182737|Drug|IgM-enriched polyclonal immunoglobulins Flat treatment|Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
79806549|NCT02681393|Behavioral|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
79984558|NCT04382651|Other|Placebo|Placebo liquid solution for intravenous infusion
79984559|NCT04382651|Drug|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
79476616|NCT04349293|Procedure|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
79806550|NCT02681393|Behavioral|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
79806551|NCT02679599|Other|B-MOBILE-CARDIAC smartphone application|
79806552|NCT02679599|Behavioral|Cardiac rehabilitation as usual|
79314267|NCT03111251|Behavioral|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
79476617|NCT04349293|Procedure|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
79476618|NCT02805179|Radiation|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
79476619|NCT02805179|Drug|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
79476620|NCT02003053|Device|Inspiratory Muscle Trainer|
79806553|NCT02537639|Device|Transesophageal echocardiography simulator|
79971406|NCT03850769|Drug|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area < 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 < 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
79971407|NCT04663464|Combination Product|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
79476621|NCT02896595|Device|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
79476622|NCT02896595|Device|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
79476623|NCT02003911|Drug|Azithromycin|Azithromycin suspension (200mg/5mL)
79314268|NCT03111251|Behavioral|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
79314269|NCT03111251|Behavioral|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
79314270|NCT03111251|Behavioral|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
79476624|NCT02003911|Drug|Placebo|
79806554|NCT00641849|Behavioral|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
79806555|NCT00641849|Behavioral|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
79806556|NCT05663489|Behavioral|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
79813682|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
79476625|NCT04147351|Drug|Atezolizumab Injection; bevacizumab Injection|a PD-L1 inhibitor; anti-angiogenesis
79806557|NCT04181645|Drug|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
79476626|NCT02004613|Drug|Dexmedetomidine|Dexmedetomidine
79476627|NCT02004613|Drug|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
79476628|NCT02806895|Drug|JZP-110|
79476629|NCT02806895|Drug|Placebo|
79476630|NCT01754779|Drug|Placebo|Matching placebo for both aims.
79476631|NCT01754779|Dietary Supplement|Citric Acid|
79476632|NCT01754779|Dietary Supplement|Potassium Citrate|
79476633|NCT02298361|Other|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
79476634|NCT02149277|Drug|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
79476635|NCT02005393|Device|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
79476636|NCT02896907|Drug|Oxaliplatin|Given IV
79476637|NCT02896907|Drug|Irinotecan Hydrochloride|Given IV
79476638|NCT02896907|Drug|Leucovorin Calcium|Given IV
79476639|NCT02896907|Drug|Fluorouracil|Given IV
79476640|NCT02896907|Dietary Supplement|Ascorbic Acid|Given IV
79476641|NCT02005549|Drug|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
79806558|NCT02679833|Dietary Supplement|Placebo|Toothpaste not containing the vitamin.
79806559|NCT02679833|Dietary Supplement|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
79971408|NCT04663464|Combination Product|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
79971409|NCT05671601|Diagnostic Test|Automatic picture recognition|A machine that processes photographs automatically taken
79971410|NCT05671601|Diagnostic Test|Manual Assessment Group|Manual recognition of pictures
79971411|NCT03729895|Device|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
79971412|NCT01190033|Device|Neurotome OFF|In this intervention the neurotome will be unconnected.
79971413|NCT01190033|Procedure|neurolysis|In this procedure the neurotome will be connected
79971414|NCT01190111|Biological|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
79307837|NCT00938145|Procedure|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
79307838|NCT00579124|Device|CliniMACs|T and B Cell depletion
79307839|NCT00102544|Device|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
79307840|NCT01903733|Drug|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
79307841|NCT03253055|Radiation|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are ~8uSv and ~4uSv respectively.
79307842|NCT03253055|Radiation|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
79307843|NCT03253055|Other|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
79307844|NCT03253055|Other|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
79307845|NCT03253055|Other|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
79307846|NCT03253055|Biological|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
79314271|NCT03111251|Behavioral|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
79314272|NCT02333669|Other|no intervention|no intervention
79314273|NCT02333747|Device|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
79476642|NCT02005549|Drug|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
79476643|NCT02005549|Drug|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
79476644|NCT02897141|Device|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
79641783|NCT04686019|Other|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
79641784|NCT04686058|Drug|Propofol 10 MG/ML Injection|
79641785|NCT04686058|Drug|Midazolam injection|
79641786|NCT04686058|Drug|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
79641787|NCT04686058|Device|target controlled infusion pump|
79641788|NCT04686058|Device|patient-controlled sedation pump|
79641789|NCT00156299|Drug|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
79641790|NCT00156299|Drug|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
79971415|NCT03609619|Drug|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
79971416|NCT03609619|Drug|Placebo|Oral doses of Placebo will be administered twice daily, during the treatment period.
79971417|NCT01292993|Drug|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
79971418|NCT01292993|Drug|1000 mg metformin|1000 mg metformin given as a solid oral dose form
79314274|NCT02333591|Drug|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
79314275|NCT02333591|Drug|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
79314276|NCT02333591|Drug|Saline|Infused intravenously for 2,5 hours.
79314277|NCT02709577|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
79476645|NCT02897141|Device|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
79476646|NCT03645356|Device|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
79476647|NCT03645356|Device|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
79476648|NCT04349696|Drug|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
79641791|NCT04685863|Other|Mobilizing the knee with active neurodynamic sliding technique (active Slump slider)|60 physiotherapy students perform measurements during three tutorials. The first involves training in evaluation techniques. The second involves mobilizing the knee, out of the SLUMP position. The third tutorial includes neuronal mobilization in SLUMP.
79641792|NCT00535912|Procedure|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
79641793|NCT00535951|Drug|LBH589|
79641794|NCT00156338|Procedure|fluid management|volume and sodium restriction
79641795|NCT00156338|Procedure|fluid management|volume restriction
79641796|NCT00156338|Procedure|fluid management|liberal fluid management
79971419|NCT04892355|Device|Root canal irrigation|Devices used during root canal irrigation
79314278|NCT02709577|Other|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
79314279|NCT02328521|Drug|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
79314280|NCT02328521|Drug|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
79314281|NCT03192241|Other|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
79314282|NCT03192241|Other|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
79314283|NCT03187093|Drug|Vortioxetine|10-20 mg once daily for 8 weeks
79314284|NCT03187093|Drug|Escitalopram|10-20 mg once daily for 8 weeks
79476649|NCT03028675|Other|MRI Scan|MRI scans will consist of a 1-hour brain scan for both patients and controls.
79476650|NCT00373997|Procedure|Esophageal and Laryngeal biopsies|one day procedure
79641797|NCT00188955|Drug|sirolimus|
79314285|NCT02039999|Other|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
79314286|NCT02039999|Other|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
79476651|NCT00373997|Procedure|egd with biopsy|standard of care procedure with biopsy
79476652|NCT03582020|Dietary Supplement|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
79476653|NCT01529983|Procedure|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
79476654|NCT01808183|Device|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
79314287|NCT02039999|Other|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
79314288|NCT02078752|Drug|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
79476655|NCT02809859|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
79641798|NCT00536068|Drug|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
79641799|NCT05470660|Procedure|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing.
79641800|NCT05470660|Procedure|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
79806560|NCT00641927|Drug|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
79806561|NCT00641927|Drug|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
79641801|NCT05470582|Biological|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
79314289|NCT02078752|Drug|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
79971420|NCT03737617|Drug|Cuvitru 20 % Injectable Solution|Active
79314290|NCT03187249|Behavioral|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
79314291|NCT03187249|Behavioral|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
79314292|NCT03187249|Behavioral|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
79314293|NCT03191851|Device|standard device|paracentesis using standard
79476656|NCT04116619|Other|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
79476657|NCT02810327|Genetic|Genetic Sequencing|Sequencing of the SERPINA1 gene
79971421|NCT01293773|Device|Taxus Element stent|paclitaxel-eluting stent
79971422|NCT01293773|Device|Integrity Resolute stent|ABT 578-eluting stent
79641802|NCT05470582|Biological|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
79641803|NCT05470582|Biological|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
79641804|NCT05470582|Biological|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
79641805|NCT00156377|Drug|Mupirocin|
79641806|NCT00182247|Procedure|venogram|
79641807|NCT05470426|Other|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
79971423|NCT01293773|Device|Xience Prime stent|Everolimus-eluting stent
79971424|NCT05196477|Drug|Olokizumab|The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
79971425|NCT05196477|Drug|Standard therapy|Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
79971426|NCT03849833|Dietary Supplement|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
79971427|NCT03849521|Diagnostic Test|MRI|Enhanced carotid calcification presented by UTE MR.
79971428|NCT03167151|Drug|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial
79971429|NCT01191125|Other|medical food with AN777|Two(220 mL)servings every day for six months
79971430|NCT01191125|Other|oral nutritional formula|Two (220 mL) servings daily for six months
79971431|NCT03660943|Drug|Placebo|Receiving Placebo Injection
79971432|NCT03660943|Drug|CNTX-4975-05|Receiving CNTX-4975-05 Injection
79314294|NCT03191851|Device|Melody Device|paracentesis using Melody Device
79314295|NCT03191851|Device|Melody Device with Pump|paracentesis using Melody Device with Pump
79314296|NCT03145571|Procedure|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
79314297|NCT02434627|Drug|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
79314298|NCT03145103|Device|CT ASPHINA 409|intraocular lens
79971433|NCT03167073|Other|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
79971434|NCT03167073|Other|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
79971435|NCT03731767|Procedure|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
79971436|NCT01191203|Drug|Copper IUD|Copper IUD (CuT360)
79971437|NCT01191203|Drug|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
79971438|NCT03657277|Device|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
79971439|NCT03197883|Other|Test Product|Restoring lipid balm
79971440|NCT03197883|Other|Cleanser|Moisturizing facial cleanser
79971441|NCT03197883|Other|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
79314299|NCT03187171|Other|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
79314300|NCT03187171|Device|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
79641808|NCT05470231|Dietary Supplement|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
79641809|NCT00536185|Dietary Supplement|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
79806562|NCT04033523|Behavioral|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
79806563|NCT00641459|Other|Observational BPSD treatment study|Observational BPSD treatment study
79806564|NCT02677571|Procedure|Paravertebral Thoracic block|
79971442|NCT03849677|Other|Endothelial function and inflammation|Analysis of endothelial function, oxidative stress
79971443|NCT03729661|Behavioral|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
79971444|NCT03849599|Biological|PRV-300|Treatment
79314301|NCT02434861|Drug|Rolapitant|
79641810|NCT00536185|Dietary Supplement|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
79641811|NCT00156416|Behavioral|Mindfulness Meditation|8 weeks of meditation training
79806565|NCT02677571|Procedure|Pectorals nerve block|
79806566|NCT02677571|Drug|Levobupivacaine 0.25%|
79806567|NCT02677571|Drug|Morphine|
79971445|NCT03849599|Biological|Placebo|Control
79971446|NCT03731689|Drug|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
79971447|NCT03731689|Drug|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
79314302|NCT02434861|Drug|Digoxin|P-gp substrate
79806568|NCT04182269|Other|Measurement of functional exercise capacity|The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
79971448|NCT03729583|Behavioral|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
79476658|NCT04349462|Diagnostic Test|VideoFlurosocopy Swallow Study|VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.
79476659|NCT04349462|Diagnostic Test|Water Sip Test|The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
79476660|NCT02810873|Device|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
79641812|NCT00188994|Drug|Insulin Cardioplegia|
79806569|NCT02681315|Device|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
79806570|NCT02681315|Device|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
79806571|NCT04181567|Other|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
79806572|NCT04181567|Drug|agomelatine|agomelatine
79806573|NCT04181567|Drug|Placebo|placebo
79806574|NCT02681081|Other|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
79806575|NCT02681081|Other|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
79971449|NCT01191281|Behavioral|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
79314303|NCT02434861|Drug|Sulfasalazine|BCRP substrate
79314304|NCT02434861|Drug|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
79806576|NCT02681081|Other|Control|Normal food intake
79806577|NCT00642005|Procedure|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
79314305|NCT02328365|Other|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
79314306|NCT03187015|Drug|Entinostat|HDAC (histone deacetylase inhibitor)
79314307|NCT03187015|Drug|Midazolam|benzodiazepine central nervous system (CNS) depressant
79314308|NCT02328053|Procedure|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
79314309|NCT02328053|Drug|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
79806578|NCT00642005|Procedure|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
79806579|NCT02679521|Device|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
79971450|NCT01191281|Other|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
79806580|NCT02679521|Device|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
79314310|NCT03186937|Dietary Supplement|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
79476661|NCT02810873|Device|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
79971451|NCT03729505|Procedure|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
79476662|NCT02810873|Radiation|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
79971452|NCT03729505|Procedure|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
79476663|NCT02810873|Drug|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
79971453|NCT03234036|Drug|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
79971454|NCT03234036|Drug|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
79971455|NCT03234036|Drug|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
79971456|NCT03234036|Drug|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
79971457|NCT03849365|Drug|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
79971458|NCT03847805|Other|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
79971459|NCT03847805|Other|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
79971460|NCT03606109|Drug|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
79971461|NCT01191359|Biological|oral immunotherapy|orally applied specific immunotherapy
79971462|NCT01293071|Other|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
79971463|NCT01193855|Drug|dutasteride|
79476664|NCT04492358|Drug|Colchicine|Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
79476665|NCT04492358|Drug|Prednisone tablet|Prednisone 60 mg/day, in a single dose, during 3 days
79476666|NCT04492358|Drug|standard of care|The standard treatment used in each site will be administered to the patients assigned to the control group.
79641813|NCT00536224|Behavioral|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
79641814|NCT00536224|Behavioral|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
79314311|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
79314312|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
79641815|NCT05470192|Other|Qigong exercise training|"Before and after the qigong exercises, 10-minute exercises will be done to stretch the large muscle groups for warm-up-cooling purposes.~The entire Baduanjin exercise consists of 8 postures:~preparation position~Raising arms with palms up,~Shooting arrows left and right like an archer in a semi-crouching position~Keeping one arm up~Looking back with trunk rotations in a semi-crouching position~Nodding the head and lowering the body to relieve stress,~Fisting and staring~Touching feet with hands touching back and legs~Raising and lowering heels"
79806581|NCT02677727|Other|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
79813683|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
79813684|NCT00591578|Drug|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
79314313|NCT02022748|Drug|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
79314314|NCT02333513|Drug|Lomustine/Vincristine/Procarbazine|
79314315|NCT02434549|Drug|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
79314316|NCT02434549|Drug|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
79476667|NCT04480970|Device|Nasogastric tube placement|All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
79476668|NCT04470128|Drug|Stage I: HSK21542 0.5 μg/kg|intravenous injection
79476669|NCT04470128|Drug|Stage I: HSK21542 1 μg/kg|intravenous injection
79806582|NCT00642083|Device|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
79314317|NCT03191773|Combination Product|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
79476670|NCT04470128|Drug|HSK21542 0.5 μg/kg|intravenous injection
79476671|NCT04470128|Drug|HSK21542 1 μg/kg|intravenous injection
79476672|NCT04470128|Drug|HSK21542 2 μg/kg|intravenous injection
79476673|NCT04470128|Drug|Placebo|intravenous injection
79806583|NCT02676011|Drug|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
79476675|NCT03447704|Drug|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
79314318|NCT02328287|Drug|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
79476676|NCT03447704|Other|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
79476677|NCT01661426|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
79476678|NCT01661426|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
79806584|NCT02676011|Drug|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
79806585|NCT02676011|Drug|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
79971464|NCT01193855|Drug|gadolinium-chelate|
79971465|NCT01193855|Other|active surveillance|
79971466|NCT01193855|Procedure|diffusion-weighted magnetic resonance imaging|
79314319|NCT02328209|Drug|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
79314320|NCT02022670|Drug|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
79314321|NCT02022670|Drug|Sodium Nitrite|80 mg/d or 160 mg/d
79806586|NCT02676011|Drug|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
79971467|NCT01193855|Procedure|functional magnetic resonance imaging|
79971468|NCT01193855|Procedure|prostate biopsy|
79971469|NCT01193855|Procedure|ultrasound imaging|
79314322|NCT02433769|Device|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
79314323|NCT02433769|Device|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
79314324|NCT02328443|Drug|Midazolam|
79476679|NCT02811419|Device|i-scan|examination will be performed with i-scan digital enhancement
79314325|NCT02328443|Drug|itraconazole|
79314326|NCT02328443|Drug|rifampicin|
79314327|NCT02076334|Other|Far Infrared Fabric|
79476680|NCT02811419|Device|standard high-definition white light|examination will be performed with high-definition white light
79806587|NCT02676011|Drug|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
79314328|NCT02076334|Other|Spandex|
79314331|NCT02039765|Drug|Brimonidine tartrate|
79314332|NCT03191539|Drug|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
79476681|NCT02811965|Other|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
79476682|NCT02811965|Other|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
79476683|NCT02811965|Device|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
79476684|NCT02811965|Device|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
79806588|NCT02676011|Drug|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
79813685|NCT00817024|Drug|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
79813686|NCT00817024|Drug|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
79813687|NCT00817024|Drug|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
79813688|NCT00797862|Drug|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
79813689|NCT00797862|Drug|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
79813690|NCT00797862|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
79813691|NCT00817102|Procedure|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
79813692|NCT00818428|Behavioral|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
79971470|NCT03771144|Procedure|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
79971471|NCT03849755|Device|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
79971472|NCT01294475|Behavioral|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
79971473|NCT01193933|Procedure|autologous HSCT|T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
79971474|NCT01190345|Drug|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
79971475|NCT01190345|Drug|no bevacizumab|no bevacizumab
79971476|NCT01194011|Behavioral|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
79971477|NCT02729896|Drug|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
79971478|NCT02729896|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
79971479|NCT02729896|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
79971480|NCT02729896|Drug|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
79476685|NCT02811965|Device|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
79806589|NCT00643253|Behavioral|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
79806590|NCT02677649|Other|cranberry|the effect of cranberry on the gut microbiota
79806591|NCT02677649|Other|placebo|the effect of placebo on the gut microbiota
79806592|NCT00465985|Drug|ACZ885|
79971481|NCT04698174|Procedure|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
79971482|NCT04698174|Procedure|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
79971483|NCT04698174|Procedure|Standard Photorefractive keratectomy (PRK)|Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
79971484|NCT03847727|Drug|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
79971485|NCT01190423|Behavioral|Family Based Therapy for young adults|Individual and Group Therapy Sessions
79971486|NCT01190501|Device|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
79476686|NCT02811965|Device|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
79490292|NCT03410953|Biological|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
79641816|NCT00536302|Dietary Supplement|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
79806593|NCT00465985|Drug|Placebo|
79806594|NCT00643331|Behavioral|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
79806595|NCT02679365|Procedure|lower segment cesarean section and double lock closure of rectus sheath|
79806596|NCT02679365|Procedure|lower segment cesarean section and continuous non-locking closure of rectus sheath|
79806597|NCT01025167|Dietary Supplement|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
79971487|NCT04506034|Drug|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
79971488|NCT04506034|Drug|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
79641817|NCT00536302|Dietary Supplement|Placebo|Matching placebo solution per day by mouth for 48 weeks.
79806598|NCT01025167|Dietary Supplement|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
79806599|NCT02679443|Dietary Supplement|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
79806600|NCT01019005|Device|Catheter|Catheter inserted into either perineural tibial nerve or wound
79806601|NCT05663255|Drug|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
79806602|NCT02678975|Drug|Disulfiram|Disulfiram 400 mg daily
79307847|NCT03253055|Other|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
79307848|NCT03252899|Other|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
79307849|NCT03252899|Other|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
79307850|NCT03229421|Other|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
79307851|NCT01375205|Other|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
79307852|NCT01375205|Other|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
79307853|NCT03234959|Device|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
79307854|NCT03234959|Other|Infant Massage|Infants will received IM by their parents
79307855|NCT03229577|Behavioral|Sudarshan Kriya Yoga|Yoga-based breathing program.
79307856|NCT03229577|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness program.
79806603|NCT02678975|Dietary Supplement|Copper|nutritional supplement with copper, 2 mg daily
79806604|NCT02678975|Drug|Alkylating Agents|Alkylating antineoplastic agent
79806605|NCT02677415|Other|Intravenous anesthetics|
79806606|NCT02677415|Other|local anesthesia|
79806607|NCT02677415|Other|Controlled ventilation|
79806608|NCT02677415|Other|Spontaneous breathing|
79806609|NCT00454051|Drug|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
79971489|NCT04506034|Drug|IV saline infusion|received i.v. saline infusion.
79307857|NCT03229577|Behavioral|Emotional Intelligence|Emotional Intelligence program.
79806610|NCT00454051|Drug|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
79971490|NCT01294631|Drug|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
79984560|NCT02445898|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
79476687|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
79476688|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
79476689|NCT01066663|Drug|pyrimethamine|Taken orally once a day
79806611|NCT04179851|Diagnostic Test|Thermal imaging of neck veins|Thermal imaging of neck veins
79984561|NCT02445898|Drug|Isotonic Sodium Chloride|Placebo
79984562|NCT03202576|Device|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
79806612|NCT04181489|Drug|Sintilimab|Sintilimab 200mg d0
79806613|NCT04181489|Drug|Rituximab|Rituximab 375 mg/m2 d0
79806614|NCT04181489|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
79806615|NCT04181489|Drug|Doxorubicin|Doxorubicin 50 mg/m2 d1
79806616|NCT04181489|Drug|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
79806617|NCT04181489|Drug|Prednisolone|Prednisolone 60mg/m2 d1-5
79806618|NCT02537561|Drug|Cisplatin|
79806619|NCT02537561|Drug|Gemcitabine|
79314333|NCT03188809|Procedure|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
79314334|NCT03188809|Procedure|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
79476690|NCT00804427|Dietary Supplement|Fish oil (90% triglycerides)|
79476691|NCT00804427|Dietary Supplement|Fish oil (60% triglycerides)|
79476692|NCT00804427|Dietary Supplement|Fish oil (ethyl esters)|
79476693|NCT00804427|Dietary Supplement|Soy oil|
79806620|NCT02537561|Drug|Talazoparib|
79490293|NCT03521479|Drug|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
79490294|NCT01495988|Drug|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
79490295|NCT01495988|Drug|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
79476694|NCT04349527|Procedure|Round-block Oncoplastic Breast Conserving Surgeries|We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
79476695|NCT04349527|Procedure|Retroglandular Oncoplastic Breast Conserving Surgeries|We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
79476696|NCT01959685|Drug|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
79307858|NCT03235037|Drug|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
79307859|NCT03229343|Other|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
79476697|NCT01959685|Drug|Placebo|Placebo, single dose
79476698|NCT04333589|Drug|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
79476699|NCT02902913|Other|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
79476700|NCT02902913|Other|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
79476701|NCT02902913|Other|D2i0|No oleocanthal and no oleacein
79806621|NCT04179773|Other|Current care study|"Observational study in two parts:~Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
79476702|NCT02902913|Drug|Ibuprofen|400 mg of Ibuprofen
79476703|NCT04737161|Biological|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
79806622|NCT02676089|Drug|CHF 5993 200/6/12.5 µg|
79806623|NCT02676089|Drug|CHF 1535 200/6 µg|
79806624|NCT02676089|Drug|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
79806625|NCT02679053|Behavioral|Aerobic exercise|
79476704|NCT03002753|Behavioral|detached mindfulness|Please see detailed study description.
79476705|NCT03002753|Behavioral|cognitive restructuring|Please see detailed study description.
79490296|NCT01495988|Drug|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
79490297|NCT04735003|Device|Transcatheter tricuspid valve interventions|Transcatheter repair or replacement to treat tricuspid regurgitation
79490298|NCT02934932|Drug|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
79806626|NCT02679053|Behavioral|Placebo control|
79476706|NCT03417986|Drug|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
79476707|NCT02906813|Drug|TAK-935 Tablets|Tablets
79476708|NCT02906813|Drug|TAK-935 Oral Solution|Oral solution
79476709|NCT04349228|Drug|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200mg/day
79476710|NCT04349228|Drug|Placebo oral tablet|Placebo of Hydroxychloroquine (HCQ) without any active substance
79476711|NCT02301416|Drug|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
79476712|NCT02301416|Other|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
79476713|NCT02815709|Drug|Oliceridine|
79476714|NCT02815709|Drug|Placebo|
79641818|NCT05469880|Other|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
79641819|NCT05469880|Other|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
79641820|NCT00408525|Drug|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
79641821|NCT05469763|Other|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~Duration: 25 to 30 minutes of continuous aerobic activity.~Frequency: three to five days per week."
79971491|NCT03849209|Device|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
79476715|NCT02815709|Drug|Morphine|
79476716|NCT02816723|Behavioral|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
79476717|NCT02816723|Behavioral|Brain Health|Brain Health Education
79476718|NCT02912195|Drug|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
79476719|NCT02912195|Drug|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
79476720|NCT01960075|Drug|Fosphenytoin|
79476721|NCT01960075|Drug|Levetiracetam|
79476722|NCT01960075|Drug|Valproic acid|
79476723|NCT01988246|Drug|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
79476724|NCT01988246|Drug|Sham|Sham injection. No actual injection. No medication is used.
79476725|NCT02821403|Device|clear lens with regular coating|
79476726|NCT02821403|Device|regular coating lens with yellow tint|
79476727|NCT02821403|Device|clear lens with blue-light blocking coating|
79971492|NCT03849209|Device|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
79641822|NCT05469724|Other|Role of ct pulmonary angiography in diagnosis of pulmonary embolism|Role of ct pulmonary angiography in diagnosis of acute pulmonary embolism as filling defect in pulmonary artery
79641823|NCT05469529|Drug|Dexmedetomidine|5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
79641824|NCT00189033|Drug|psyllium fibre (dietary supplement)|
79641825|NCT00189033|Drug|wheat bran (dietary supplement)|
79641826|NCT00189033|Drug|rice wheat (placebo)|
79641827|NCT05469217|Other|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
79641828|NCT05469100|Drug|Selpercatinib|Administered orally
79641829|NCT05469061|Drug|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
79641830|NCT05469061|Drug|5-FU|A FP regimen with 5-Fu 850mg/m^2 d1-4 + cis-platinum 850mg/m^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
79476728|NCT01990820|Device|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
79971493|NCT05342662|Device|Blue light-blocking glasses|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
79806627|NCT02679209|Biological|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
79971494|NCT05342662|Device|Glasses with clear lenses|Non-blue light-blocking glasses
79971495|NCT03847571|Drug|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
79476729|NCT01990820|Procedure|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
79806628|NCT02679209|Biological|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
79806629|NCT02679131|Drug|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
79971496|NCT01293149|Drug|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
79806630|NCT02675777|Other|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~Identification of a clinical champion and Local Implementation Team.~Participatory Design.~Training primary care providers and Medical Assistants.~EHR clinical decision support tools~Weekly facilitated Local Implementation Team meetings.~Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~Learning sessions for primary care providers during implementation.~Social worker use of an EHR registry with weekly supervision.~Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
79806631|NCT00484939|Drug|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
79971497|NCT01293149|Drug|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
79971498|NCT03575065|Drug|BGB-290|Administered orally
79971499|NCT03636672|Procedure|perturbation training|perturbation training during stationary bicycle riding
79307860|NCT03229265|Drug|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
79307861|NCT03234803|Other|poly-amide|new denture base material
79307862|NCT03234803|Other|poly-methyl methacrylate|gold standard for denture base materials
79307863|NCT02452853|Procedure|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
79307864|NCT02452853|Drug|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
79307865|NCT00700271|Drug|Amlodipine|5 mg or 10 mg tablets.
79307866|NCT00700271|Drug|Valsartan|160 mg capsules.
79307867|NCT03228797|Procedure|an ultrasound guided rectus sheath block|
79307868|NCT03228797|Procedure|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
79307869|NCT03228797|Procedure|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
79307870|NCT03234647|Device|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
79307871|NCT02452541|Other|Prognostic tests|"Brain CT-Scan on day 1, 3 and 7~Brain MRI on day 7~SomatoSensory Evoked Potentials on day 7~Electroencephalogram on day 7~Serum biomarkers on day 1, 3 and 7~Daily clinical exams"
79307872|NCT03046095|Other|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
79314335|NCT02327975|Other|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
79314336|NCT02327975|Other|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
79314337|NCT02327975|Other|Control group|No received intervention.
79314338|NCT02433925|Dietary Supplement|Resveratrol|
79314339|NCT02433925|Dietary Supplement|Placebo|
79314340|NCT02332967|Other|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
79314341|NCT02332967|Other|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
79314342|NCT02332967|Other|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
79314343|NCT02433691|Other|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
79314344|NCT02433691|Other|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
79476730|NCT01990898|Drug|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
79476731|NCT02822885|Radiation|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
79314345|NCT02433691|Other|stretching and toning|anaerobic stretching and toning followed by memory training.
79314346|NCT02327663|Drug|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
79476732|NCT01960387|Drug|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
79641831|NCT05469061|Drug|cis Platinum|A FP regimen with 5-Fu 850mg/m^2 d1-4 + cis-platinum 850mg/m^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
79806632|NCT00484939|Drug|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
79971500|NCT03847961|Device|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
79971501|NCT04454424|Drug|BAY1817080|Study intervention BAY1817080 will be administered orally with tablet(s).
79476733|NCT01960387|Drug|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
79476734|NCT01991522|Behavioral|Curriculum Group|
79806633|NCT02677337|Other|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
79806634|NCT02677337|Other|Educational Program|
79806635|NCT02677025|Behavioral|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
79806636|NCT02677025|Behavioral|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
79806637|NCT02675855|Other|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
79806638|NCT02675855|Procedure|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
79806639|NCT02675855|Device|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
79806640|NCT02675621|Other|Phenolic Beverage|
79806641|NCT00642161|Drug|budesonide|
79806642|NCT05663177|Drug|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
79806643|NCT00642551|Dietary Supplement|menaquinone-7|180 µg menaquinone-7 daily for three years
79806644|NCT00642551|Dietary Supplement|placebo|1 placebo capsule daily for three years
79476735|NCT01991522|Behavioral|Self-directed learning group|
79476736|NCT02823431|Drug|lidocaine gel|
79476737|NCT02823431|Other|Plain aqueous gel|
79476738|NCT01960465|Device|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
79314347|NCT02440867|Device|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
79314348|NCT02440867|Device|Sham TBS|Sham stimulation
79314349|NCT02021812|Device|GORE® TAG® Thoracic Branch Endoprosthesis|
79314350|NCT03191929|Other|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
79314351|NCT03191929|Other|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
79314352|NCT02333123|Drug|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
79476739|NCT01991990|Drug|placebo|Single i.v. infusion
79476740|NCT01991990|Drug|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
79971502|NCT04454424|Drug|Midazolam|Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
79971503|NCT02518126|Other|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
79971504|NCT01194167|Drug|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
79971505|NCT05313802|Drug|LY3502970|Administered orally.
79971506|NCT03521310|Procedure|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
79806645|NCT02678897|Drug|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
79806646|NCT02678897|Drug|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
79806647|NCT04181957|Drug|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
79806648|NCT04181957|Drug|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
79806649|NCT02678741|Drug|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
79806650|NCT02678819|Device|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
79806651|NCT02678663|Procedure|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
79307873|NCT03046095|Procedure|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
79307874|NCT03228641|Device|micro-excisional skin removal with coring needle|
79307875|NCT03045939|Device|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
79307876|NCT03228485|Device|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
79307877|NCT04864197|Biological|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
79307878|NCT02452619|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
79806652|NCT02678663|Procedure|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
79806653|NCT00643409|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
79806654|NCT00643409|Other|placebo|placebo
79476741|NCT02824913|Drug|P-321 Ophthalmic Solution|
79476742|NCT02824913|Drug|P-321 Ophthalmic Solution placebo|
79641832|NCT00408642|Behavioral|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
79806655|NCT00643409|Drug|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
79806656|NCT00643409|Other|placebo|placebo
79806657|NCT04180007|Drug|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
79806658|NCT02675309|Drug|MT-8554|
79806659|NCT02675309|Drug|rosuvastatin|
79806660|NCT02675309|Drug|simvastatin|
79971507|NCT03521310|Procedure|Conventional care|Neonates will get Conventional care the first 72 hours after birth
79806661|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
79971508|NCT01293227|Procedure|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
79314353|NCT02333123|Drug|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
79806662|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
79971509|NCT03348046|Drug|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
79314354|NCT03188887|Drug|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
79971510|NCT03514134|Behavioral|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
79971511|NCT03514134|Behavioral|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
79971512|NCT03849287|Drug|CKD-333, formula I|Test drug
79476743|NCT01961089|Device|Galilei Lens Professional|Measurement device
79641833|NCT00408642|Behavioral|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
79641834|NCT05469022|Drug|Neoadjuvant lazertinib|Lazertinib 240mg p.o once daily.
79806663|NCT05662085|Other|No intervention|According to clinical practice.
79806664|NCT05662007|Other||no intervention
79971513|NCT03849287|Drug|CKD-333, formula II|Test drug
79971514|NCT03849287|Drug|CKD-330, D090|Reference Drug
79806665|NCT01025245|Drug|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ & Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
79314355|NCT03188887|Drug|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
79476744|NCT01961089|Device|IOLMaster|Measurement device
79806666|NCT05661929|Other|Questionnaire CMQ|The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
79806667|NCT01025323|Behavioral|Lifestyle modification|DASH diet and exercise advice
79314356|NCT02332811|Drug|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
79314357|NCT02332811|Drug|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
79314358|NCT02433457|Drug|CC-292|
79314359|NCT02433457|Drug|Oral Omeprazole (OMP)|
79314360|NCT02021656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
79314361|NCT03188653|Other|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
79476745|NCT01961089|Device|Lenstar|Measurement device
79971515|NCT03352024|Other|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
79806668|NCT01025323|Behavioral|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
79806669|NCT02677259|Drug|17-beta estradiol|
79806670|NCT02677259|Drug|Micronized progesterone|
79806671|NCT00465361|Procedure|performance feedback with an educational module|individual performance feedback with an educational module
79806672|NCT05484479|Behavioral|Baduanjin training/exercise|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
79806673|NCT02677103|Device|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
79806674|NCT02677103|Procedure|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
79971516|NCT03352024|Other|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
79971517|NCT03188718|Device|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
79971518|NCT05584930|Other|Collection of blood sample|"Visit 1 : At inclusion (day 1 of chemotherapy treatment)~Visit 2 : Onset of aplasia~Visit 3a : day 1 of the 1st febrile aplasia~Visit 3b : day 3 of the 1st febrile episode~Visit 3c : day 8 of the 1st febrile episode~Visit 4a : second febrile episode (after 7 days)~Visit 4b : day 3 of the second febrile episode (after 7 days)"
79806675|NCT02677103|Procedure|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
79971519|NCT01294943|Device|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
79806676|NCT00464815|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
79971520|NCT04505644|Drug|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
79971521|NCT04505644|Drug|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
79806677|NCT00464815|Biological|Mencevax™ ACWY|One subcutaneous dose
79806678|NCT02675387|Device|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
79806679|NCT02675387|Drug|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
79806680|NCT00642239|Drug|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
79806681|NCT00642239|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
79476746|NCT02825849|Biological|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
79476747|NCT02057042|Behavioral|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
79971522|NCT04505644|Drug|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
79971523|NCT03574753|Drug|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
79971524|NCT03850613|Behavioral|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
79971525|NCT04505800|Dietary Supplement|Tryptophan supplement|"Pure L-tryptophan in capsules (500mg/capsule)~3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
79971526|NCT04505800|Dietary Supplement|Maltose|Maltose
79806682|NCT01022437|Other|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
79971527|NCT03725839|Device|F&P Interface|F&P Interface to be used for OSA therapy
79971528|NCT05200156|Dietary Supplement|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
79971529|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
79971530|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
79971531|NCT01310257|Other|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
79971532|NCT03347968|Biological|MEDI0382|All participants will receive MEDI0382
79971533|NCT03347968|Drug|Warfarin|All participants will receive Warfarin
79971534|NCT03347968|Drug|Esmolol|All participants will receive Esmolol
79641835|NCT05468944|Procedure|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
79641836|NCT05468944|Procedure|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
79314362|NCT03188653|Other|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
79314363|NCT03188653|Other|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
79641837|NCT00189072|Drug|gabapentin|
79641838|NCT05468905|Other|None of intervention|None of intervention
79641839|NCT00156572|Procedure|Sodium supplementation|
79641840|NCT00156572|Procedure|Fluid restriction|
79641841|NCT05468866|Genetic|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
79971535|NCT03848975|Other|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
79971536|NCT03848975|Other|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
79971537|NCT03731533|Behavioral|WellStart|"Five weekly automated text messages linked to an online article on health and wellness.~Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~Three group (up to 20 participants) health coach online visits (60 minutes).~Two online group visits with a dietitian in groups of 10-12 participants.~Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
79971538|NCT05179720|Other|puncture stent-assisted transperineal prostate biopsy|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
79971539|NCT01191515|Device|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
79971540|NCT03346954|Other|[11C]-Methionine PET/MRI|Implementation [11C]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The [11C]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
79971541|NCT01194557|Device|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
79314364|NCT03188653|Other|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
79314365|NCT03188653|Other|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
79971542|NCT01194557|Drug|Lumartem|Presumptive treatment of malaria/fever
79314366|NCT03188653|Other|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
79314367|NCT03188653|Other|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free & Clear Liquid Cleanser
79314368|NCT03145025|Device|Retisert|Intravitreal Implant
79641842|NCT05468788|Behavioral|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
79641843|NCT05468788|Behavioral|Control: Improvisational Theatre|Participants play improvisational theatre games.
79641844|NCT00156611|Procedure|Balloon Angioplasty|
79641845|NCT00156611|Drug|ReoPro|
79641846|NCT00189111|Procedure|Cardiac Imaging + Treatment|
79641847|NCT00156650|Drug|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
79641848|NCT00156650|Drug|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
79641849|NCT00156650|Drug|Depo-Medroxyprogesterone|300 mg IM every 3 months
79314369|NCT03145025|Drug|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
79314370|NCT03144947|Biological|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
79641850|NCT00536419|Drug|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
79641851|NCT00536419|Other|Placebo|Placebo, daily dose, 4 days, oral administration
79641852|NCT00189150|Drug|Mycophenolate mofetil|
79641853|NCT00189150|Drug|Valganciclovir|
79641854|NCT00536458|Procedure|radiotherapy|mini chep+ radiotherapy
79641855|NCT00536458|Drug|MINI CHEP|chemotherapy minichep 6 courses
79641856|NCT00536497|Drug|GW842166X|
79806683|NCT00642317|Behavioral|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
79806684|NCT04181021|Behavioral|Values Clarification and Attitudes Transformation (VCAT) Workshop|VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
79806685|NCT02678507|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
79641857|NCT00536536|Behavioral|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
79641858|NCT00156689|Drug|levetiracetam|
79641859|NCT00536614|Genetic|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
79641860|NCT00182286|Behavioral|Assessment of continuity of care from the patient perspective|
79806686|NCT02676947|Drug|Tocilizumab|
79806687|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
79641861|NCT00182286|Behavioral|Relationship between continuity of care, patient outcomes, and costs|
79641862|NCT05468164|Drug|Selpercatinib|Administered orally
79641863|NCT05468164|Drug|Omeprazole|Administered orally
79641864|NCT00156728|Device|Vitatron biventricular pacemaker|
79641865|NCT05468086|Device|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
79641866|NCT00189189|Behavioral|parent management training|
79806688|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
79806689|NCT00464737|Other|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
79641867|NCT05468047|Drug|Ketamine hydrochloride injection|Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
79641868|NCT04686214|Procedure|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
79806690|NCT00642629|Drug|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
79806691|NCT00642629|Drug|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
79641869|NCT05467969|Behavioral|Teleteaching of procedural skills through the online multiscreen display teleconference platform|Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
79641870|NCT05467930|Other|Survey|Survey completion by the participant to collect information about health and social experience
79641871|NCT05467930|Other|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
79641872|NCT05467930|Other|Sample Collection|Collection of nasal and blood samples
79641873|NCT00182364|Drug|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
79641874|NCT00156806|Procedure|Aloe barbadensis topical application in a moisturizing cream vehicle.|
79641875|NCT00536653|Drug|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
79641876|NCT00536653|Drug|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
79641877|NCT00536653|Drug|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
79641878|NCT05467852|Drug|didroxyprogesterone|Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
79641879|NCT00536692|Drug|mecamylamine|topical ocular drops
79641880|NCT00156845|Procedure|AI-700 contrast-enhanced echocardiography|
79641881|NCT00189345|Biological|anti-EpCAM x anti-CD3 (removab)|
79641882|NCT05466058|Diagnostic Test|palpation - ultrasonography|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
79641883|NCT00156884|Drug|strontium-89|
79641884|NCT00156884|Drug|cisplatin|
79641885|NCT00182403|Drug|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
79806692|NCT02678585|Drug|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
79971543|NCT03729193|Behavioral|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
79971544|NCT03346876|Procedure|Nuss surgery|surgical correction for pectus excacatum
79314371|NCT03144947|Biological|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
79806693|NCT02678585|Drug|Lidocaine|53 patients received intravenous regional lidocaine
79806694|NCT00453349|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
79806695|NCT00453349|Drug|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
79971545|NCT03848897|Other|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
79314372|NCT03144947|Biological|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
79314373|NCT03144947|Drug|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
79314374|NCT02440555|Other|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
79314375|NCT02433535|Drug|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
79806696|NCT02675153|Drug|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
79806697|NCT04033601|Behavioral|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
79806698|NCT01025401|Device|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
79806699|NCT02673437|Other|This is a non-interventional study|This is a non-interventional study
79806700|NCT02676557|Device|Exposed to the high pressure during the surgery|
79806701|NCT02676713|Drug|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
79971546|NCT03731455|Device|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
79971547|NCT03351946|Procedure|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
79971548|NCT03351946|Procedure|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
79971549|NCT03847259|Diagnostic Test|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
79971550|NCT03351868|Genetic|Gene-modified autologous stem cells|Infusion for 5x10^6~1x10^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
79971551|NCT01191593|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
79641886|NCT05464693|Diagnostic Test|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~Its macroscopic appearance will be analyzed: yellow, black, or purulent.~Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
79641887|NCT00156962|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
79641888|NCT00156962|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
79806702|NCT02676713|Drug|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
79314376|NCT02433535|Other|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
79314377|NCT03191695|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
79641889|NCT00182442|Drug|Olanzapine & Quetiapine|
79641890|NCT05468983|Procedure|surgical ( implants placement)|4 implants were placed interforamen of the mandibular arch by using the surgical guide
79641891|NCT00536770|Drug|placebo + gemcitabine + erlotinib|
79641892|NCT00536770|Drug|Placebo + gemcitabine|
79641893|NCT00536770|Drug|calcitriol + gemcitabine|
79641894|NCT00536770|Drug|calcitriol + gemcitabine + erlotinib|
79641895|NCT00157001|Procedure|Photopheresis Post Angioplasty|
79641896|NCT00182481|Procedure|Induced sputum cell counts|
79806703|NCT02676713|Drug|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
79806704|NCT02676713|Drug|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
79806705|NCT02673593|Drug|DS102|
79806706|NCT02673593|Drug|Placebo|
79806707|NCT04178525|Device|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
79806708|NCT04178525|Device|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
79971552|NCT01191593|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
79314378|NCT03144713|Drug|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
79314379|NCT03144713|Drug|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
79314380|NCT03144713|Drug|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
79314381|NCT03191617|Dietary Supplement|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
79314382|NCT02076022|Device|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
79641897|NCT00182481|Drug|inhaled corticosteroids and other asthma drugs|
79641898|NCT04685512|Drug|tenofovir disoproxil and emtricitabine|Experimental drugs administration of 7-day short course TDF/FTC
79641899|NCT00157040|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
79641900|NCT00189384|Drug|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
79971553|NCT03347890|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo|Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
79971554|NCT03848819|Device|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
79641901|NCT00536848|Dietary Supplement|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
79971555|NCT03347812|Procedure|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
79971556|NCT03347812|Procedure|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
79971557|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 14 days
79971558|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 56 days
79971559|NCT04505488|Behavioral|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
79641902|NCT00536848|Dietary Supplement|Placebo|
79641903|NCT00536848|Drug|Metronidazole|
79641904|NCT00157079|Biological|Immune Globulin Intravenous (Human), 10%|
79641905|NCT00189501|Drug|Sensipar®|
79971560|NCT03351790|Other|Questionniare only|A pre-procedure questionnaire will be completed by all participants
79806709|NCT04181099|Other|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
79971561|NCT04505332|Procedure|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
79641906|NCT05592691|Procedure|Fascial block|The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
79641907|NCT00157118|Drug|Protein C Concentrate (Human) Vapor Heated|
79641908|NCT00189579|Drug|Herceptin|
79641909|NCT00157235|Drug|Tiotropium bromide|
79641910|NCT04293328|Device|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
79806710|NCT04178369|Other|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
79971562|NCT03573505|Drug|BG00011|Administered as specified in the treatment arm.
79641911|NCT04293328|Device|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
79314383|NCT02076022|Procedure|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
79641912|NCT04271215|Other|Chemotherapy protocol used|Chemotherapy protocol used in each participating hospital
79641913|NCT00182520|Drug|Topiramate|25 mg - 400 mg/day x 12 weeks
79641914|NCT00182520|Drug|placebo|25 - 400 mg/day x 12 weeks
79641915|NCT00157274|Drug|alemtuzumab|
79641916|NCT04257487|Drug|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
79314384|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79971563|NCT03573505|Drug|Placebo|Administered as specified in the treatment arm.
79971564|NCT01296425|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
79971565|NCT01293383|Drug|LEO 90105|Ointment
79476748|NCT02057042|Behavioral|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
79641917|NCT04257487|Drug|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
79971566|NCT01296503|Drug|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
79641918|NCT04257487|Drug|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
79641919|NCT00182559|Drug|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
79971567|NCT01296503|Drug|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
79476749|NCT01961167|Device|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
79476750|NCT03008213|Drug|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
79476751|NCT01959542|Device|MRI|
79641920|NCT00182559|Drug|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
79971568|NCT01376908|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
79971569|NCT01376908|Other|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
79971570|NCT03850457|Other|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
79971571|NCT03729037|Other|CPR self-training|
79971572|NCT01295099|Drug|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
79476752|NCT01959542|Other|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
79476753|NCT03008837|Device|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
79476754|NCT03008837|Other|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
79641921|NCT04247347|Behavioral|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
79476755|NCT01962025|Procedure|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
79476756|NCT01992380|Drug|Flortaucipir F18|IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
79476757|NCT01992380|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
79476758|NCT02059070|Drug|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
79476759|NCT02059070|Drug|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
79476760|NCT04348994|Device|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
79971573|NCT01295099|Radiation|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
79476761|NCT01962961|Dietary Supplement|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
79476762|NCT01962961|Dietary Supplement|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
79476763|NCT03010631|Drug|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
79314385|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79476764|NCT03010631|Drug|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
79476765|NCT03010631|Drug|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
79476766|NCT03010631|Drug|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
79314386|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79476767|NCT01993238|Device|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
79971574|NCT01295099|Drug|Triamcinolone|TAC 10mg in 1ml injected intralesional
79971575|NCT01310335|Device|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
79476768|NCT01993238|Drug|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
79476769|NCT01965067|Drug|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
79971576|NCT01426529|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
79314387|NCT03191383|Drug|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79314388|NCT03111641|Diagnostic Test|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
79314389|NCT02332733|Biological|TV003|10^3 plaque forming units (PFU) of rDEN1 delta 30, 10^3 PFU of rDEN2/4 delta 30(ME), 10^3 PFU of rDEN3 delta 30/31-7164, and 10^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
79971577|NCT01426529|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
79476770|NCT00374621|Drug|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
79641922|NCT04247347|Other|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
79641923|NCT04247347|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
79641924|NCT00157313|Behavioral|Integrated treatment, family involvement|
79641925|NCT00157313|Behavioral|Social skills training|
79641926|NCT04242121|Diagnostic Test|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
79641927|NCT00425568|Drug|AndroGel (Transdermal Testosterone Gel)|
79641928|NCT04232254|Behavioral|Animal-based Protein Foods|Participants will consume animal-based protein foods.
79641929|NCT04232254|Behavioral|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
79641930|NCT04232254|Behavioral|Plant-based Protein Foods|Participants will consume plant-based protein foods.
79641931|NCT04232254|Behavioral|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
79971578|NCT01426529|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
79641932|NCT00534274|Other|3'-deoxy-3'-[18F]fluorothymidine|
79641933|NCT00157508|Drug|nitroaspirin|
79641934|NCT00189618|Drug|Aspirin|100mg p.o. OD
79641935|NCT00189618|Drug|Clopidogrel|75mg p.o. OD
79806711|NCT04178369|Other|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
79641936|NCT04177030|Behavioral|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
79314390|NCT02332733|Biological|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
79476771|NCT01960400|Device|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
79806712|NCT04179617|Other|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
79806713|NCT04179617|Other|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
79806714|NCT00464269|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Film-coated tablet~Concentration: 2.5 mg, 10 mg and 25 mg~Route of Administration: Oral use"
79806715|NCT00464269|Drug|Brivaracetam 2.5 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
79971579|NCT03346798|Behavioral|Food Photography|Participants will engage in food photography on their smart phones while eating
79971580|NCT03346798|Behavioral|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
79971581|NCT03346798|Behavioral|No Phone Use|Participants will not use their smart phones while eating
79971582|NCT03728959|Other|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
79806716|NCT00464269|Drug|Brivaracetam 10 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg~Route of Administration: Oral use"
79971583|NCT03728959|Other|GIP|Subcutaneous injected GIP
79314391|NCT03191071|Diagnostic Test|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
79314392|NCT03191071|Diagnostic Test|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
79971584|NCT03728959|Other|GLP-2|Subcutaneous injected GLP-2
79971585|NCT03728959|Other|Placebo (saline)|Subcutaneous injected Placebo (saline)
79971586|NCT03849053|Other|Mézières Therapy for Low back pain|Spinal muscular global stretching
79806717|NCT00464269|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 25 mg~Route of Administration: Oral use"
79641937|NCT04177030|Behavioral|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
79641938|NCT04175548|Other|Data extraction from medical files|Data extraction from medical files
79641939|NCT00406796|Drug|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
79641940|NCT00182598|Procedure|computer-based psychoeducational intervention|
79641941|NCT00182598|Procedure|community-based substance abuse counseling|
79641942|NCT00534391|Drug|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
79806718|NCT00642863|Dietary Supplement|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
79806719|NCT00642863|Dietary Supplement|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
79641943|NCT00534391|Drug|Artificial tear|4 times daily
79641944|NCT00534508|Drug|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
79641945|NCT00406835|Procedure|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
79806720|NCT00642863|Dietary Supplement|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
79806721|NCT02674763|Drug|IMGN779|
79806722|NCT02674997|Biological|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
79303492|NCT04442321|Other|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz~TENS Pulse width - 250 microseconds~Duration - 30 minutes.~TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
79641946|NCT00534547|Procedure|Duodenal Exclusion|duodenal-jejunal bypass
79641947|NCT00182715|Biological|cetuximab|
79641948|NCT00182715|Drug|capecitabine|
79641949|NCT00182715|Drug|fluorouracil|
79641950|NCT00182715|Drug|leucovorin calcium|
79641951|NCT00182715|Drug|oxaliplatin|
79641952|NCT00534586|Drug|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
79641953|NCT00534586|Drug|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
79641954|NCT00534586|Drug|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
79641955|NCT00534586|Drug|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
79971587|NCT03728803|Device|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
79971588|NCT03122392|Device|AMS 800|AMS 800 Artificial Urinary Sphincter
79641956|NCT00534625|Drug|zileuton|Single injection of zileuton 150 mg
79641957|NCT00534625|Drug|placebo|Single injection of placebo
79641958|NCT00534625|Drug|zileuton|Single injection of zileuton 300 mg
79641959|NCT00406874|Drug|omega 3 fats|1,000 mg daily
79971589|NCT03847415|Diagnostic Test|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
79641960|NCT00406874|Drug|folic acid|800 micrograms daily
79641961|NCT04134208|Procedure|Computed Tomography|Undergo PET-CT scan
79641962|NCT04134208|Drug|Fluciclovine F18|Given IV
79641963|NCT04134208|Procedure|Positron Emission Tomography|Undergo PET-CT scan
79641964|NCT04110769|Diagnostic Test|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
79641965|NCT04110769|Diagnostic Test|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
79641966|NCT04106830|Drug|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
79641967|NCT00189657|Procedure|5FU/LV Mayo Clinic or LV5FU2|
79641968|NCT00189657|Procedure|LV5FU2 + irinotecan|
79641969|NCT00406913|Drug|mupirocin ointment|
79641970|NCT00406913|Other|SOC sterilization|
79641971|NCT00406952|Procedure|electronic diary|
79641972|NCT00406952|Drug|Sertraline|
79641973|NCT00406952|Drug|Placebo|
79641974|NCT00406952|Procedure|voice acoustics|
79641975|NCT04722900|Other|intrauterine exposure to elevated glucose levels|intrauterine exposure to elevated glucose levels
79641976|NCT04076800|Procedure|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
79641977|NCT04071340|Device|non-contrast MSCT|non-contrast multi-slice computed tomography
79314393|NCT03191071|Diagnostic Test|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
79314394|NCT03191071|Diagnostic Test|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
79314395|NCT03111329|Other|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
79476772|NCT01960400|Device|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
79314396|NCT03188497|Drug|Lobaplatin|Lobaplatin for Injection
79314397|NCT03188497|Device|linear accelerator|Medical linear accelerator
79314398|NCT02332421|Device|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
79314399|NCT02075632|Drug|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
79314400|NCT02430259|Drug|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
79314401|NCT02332499|Drug|Anlotinib|Anlotinib p.o. qd
79314402|NCT02332499|Drug|Placebo|Placebo p.o. qd
79314403|NCT02075554|Device|CALIBER|Expandable interbody spacer
79314404|NCT02327819|Dietary Supplement|Branched-chain amoni acids (BCAA)|
79314405|NCT02327819|Dietary Supplement|non-BCAA protein supplement|
79476773|NCT03012191|Drug|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
79476774|NCT01994486|Drug|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
79476775|NCT01997216|Device|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
79476776|NCT01997216|Device|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
79476777|NCT02059928|Device|Intraosseous Device|
79641978|NCT04071340|Device|Abdominal ultrasonography|Abdominal ultrasonography
79641979|NCT04071340|Diagnostic Test|Urine analysis|Urine analysis
79641980|NCT04071340|Diagnostic Test|Urine culture|Urine culture
79641981|NCT00189696|Drug|YM060|
79314406|NCT02075476|Procedure|Hemiarthroplasty|
79314407|NCT02075476|Procedure|reverse arthroplasty|
79314408|NCT02327585|Behavioral|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
79314409|NCT02326961|Device|Celution Device|ADRCs Prepared using the Celution Device
79314410|NCT02326961|Other|Placebo|Inactive Placebo
79314411|NCT02075320|Device|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
79476778|NCT01967641|Drug|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
79314412|NCT02327273|Drug|BMS-963272|
79314413|NCT02327273|Drug|Placebo|
79314414|NCT02327507|Behavioral|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
79314415|NCT03144869|Behavioral|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
79314416|NCT02708095|Drug|Baricitinib|Administered orally
79314417|NCT02708095|Drug|Placebo|Administered orally
79314418|NCT02327039|Drug|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
79314419|NCT02327039|Drug|Placebo|Tables of Dapagliflozin placebo
79314420|NCT03142607|Drug|Metronidazole gel|1% Metronidazole gel
79314421|NCT03142607|Drug|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
79314422|NCT03144557|Other|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
79314423|NCT03186547|Drug|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
79314424|NCT03186547|Procedure|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
79314425|NCT03144323|Behavioral|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
79314426|NCT02440477|Other|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
79314427|NCT05077475|Drug|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
79314428|NCT05077475|Drug|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
79314429|NCT02433067|Other|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
79314430|NCT02433067|Other|Control Group|standard oncologic care
79314431|NCT02326727|Drug|Ropivacaine|Epidural analgesia
79314432|NCT02326727|Drug|Fentanyl|General Anesthesia
79314433|NCT02326727|Drug|Propofol|General Anesthesia
79314434|NCT02326727|Drug|Isoflurane|General Anesthesia
79314435|NCT02326727|Drug|Nitrous Oxide|General Anesthesia
79314436|NCT02432911|Drug|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
79314437|NCT02432911|Drug|low dose cytarabine|cytarabine 20mg bid for 10 days.
79314438|NCT03588767|Drug|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
79314439|NCT03588767|Other|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
79314440|NCT02440321|Behavioral|Parent-child interactive program|
79314441|NCT02440321|Other|written materials|
79476779|NCT03017261|Device|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
79971590|NCT03728725|Device|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
79971591|NCT03122158|Drug|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
79971592|NCT03728647|Behavioral|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
79971593|NCT03728647|Behavioral|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
79971594|NCT03122236|Behavioral|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
79314442|NCT02440399|Drug|Tramadol hydrochloride|Please see arm description
79476780|NCT01968421|Drug|OM-85 BV|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
79314443|NCT02440399|Drug|Morphine|Please see arm description
79476781|NCT02314520|Device|peripherally inserted central catheter|Any complication associated with central access
79314444|NCT02440399|Drug|Paracetamol|
79314445|NCT02440399|Drug|Diclofenac|
79314446|NCT02440399|Drug|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
79314447|NCT02432989|Behavioral|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
79314448|NCT03186625|Drug|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
79314449|NCT03186625|Drug|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
79314450|NCT03184909|Drug|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
79971595|NCT03122236|Behavioral|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
79314451|NCT03184909|Drug|Placebo|Placebo capsules of look alike inert substance for control
79476782|NCT02314520|Device|centrally inserted central catheter|Central access not associated with any complication
79476783|NCT02913521|Drug|Diclofenac Sodium Gel 1%|
79971596|NCT03122236|Device|Transcranial Direct Current Stimulation (tDCS) dosage A|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
79476784|NCT02913521|Drug|Voltaren Gel|
79641982|NCT00157547|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
79476785|NCT02913521|Drug|Placebo|
79476786|NCT01969201|Drug|Urofollitrophin|
79476787|NCT01969201|Drug|Follitrophin alpha|
79476788|NCT02062502|Biological|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
79476789|NCT02062502|Biological|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
79641983|NCT00534664|Device|TheraBionic device|Daily outpatient treatment with theraBionic device
79641984|NCT04061161|Drug|Tiotropium Bromide|Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
79641985|NCT04049149|Other|Biogenetic explanation and endocrinologist intensive managment|"JADE report and JADE APP~Biogenetic explanation~First-year intensive management by endocrinologists~Follow up by their usual care doctors for continue treatment regimen maintenance.~Yearly DM nurses follow up for blood taking and questionnaires"
79641986|NCT04049149|Other|Usual care management|"JADE report and JADE APP~Attend their usual care clinic for ongoing treatment~Yearly DM nurses follow up for blood taking and questionnaires"
79641987|NCT00189735|Drug|FK778|
79314452|NCT02429635|Behavioral|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
79641988|NCT00157586|Drug|Delapril, Delapril-Manidipine Fixed combination|
79641989|NCT04008940|Device|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
79314453|NCT03110939|Other|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
79641990|NCT03966586|Behavioral|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
79314454|NCT02429713|Procedure|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
79314455|NCT02429713|Procedure|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
79641991|NCT03966586|Behavioral|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
79641992|NCT03966586|Behavioral|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
79314456|NCT03144479|Procedure|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
79314457|NCT03186703|Behavioral|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
79314458|NCT03142529|Drug|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
79641993|NCT03966586|Behavioral|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
79641994|NCT03966586|Behavioral|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
79641995|NCT03966586|Behavioral|Usual clinical care and counseling|Usual clinical care and counseling
79641996|NCT00157625|Behavioral|Automatic stop order|
79641997|NCT00182832|Behavioral|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
79641998|NCT00182832|Behavioral|Standard Care|Standard care for hospitalized older patients with cognitive impairment
79971597|NCT03122236|Device|Transcranial Direct Current Stimulation (tDCS) dosage B|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
79314459|NCT03191305|Drug|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
79314460|NCT03191305|Drug|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
79314461|NCT03144401|Drug|Misoprostol|mesotac
79314462|NCT03144401|Other|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
79314463|NCT04483765|Procedure|spinal anesthesia|patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
79314464|NCT05054231|Other|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
79314465|NCT03186391|Other|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
79314466|NCT03186469|Behavioral|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
79641999|NCT03943654|Other|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
79314467|NCT03186469|Behavioral|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
79314468|NCT03142217|Other|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
79642000|NCT04724993|Other|Online Aerobic Dance Exercises|Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
79642001|NCT04724993|Other|Physical Activity Counseling|Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
79642002|NCT03920800|Other|Data extraction from medical files|Data extraction from medical files
79314469|NCT02326415|Other|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
79314470|NCT02326415|Other|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
79314471|NCT02429245|Other|Retrospective study|
79314472|NCT03142295|Procedure|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
79314473|NCT03186313|Drug|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
79314474|NCT03186313|Drug|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.
79642003|NCT03920800|Biological|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
79642004|NCT00182871|Drug|testosterone|
79971598|NCT03728569|Other|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
79971599|NCT03728569|Other|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
79314475|NCT03186313|Drug|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
79314476|NCT03186313|Drug|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks
79642005|NCT00189774|Drug|nateglinide|
79642006|NCT00157703|Drug|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
79642007|NCT04686643|Drug|AGSAVI|S-amlodipine, Valsartan, Indapamide
79642008|NCT04686643|Drug|AGLS|S-amlodipine, Valsartan
79642009|NCT00534781|Device|plasma microdebrider|Coblation of the Achilles
79971600|NCT03736031|Behavioral|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
79476790|NCT02062502|Biological|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
79476791|NCT01962428|Drug|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
79476792|NCT01999400|Drug|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
79642010|NCT00534781|Procedure|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
79971601|NCT04503304|Other|Exercises|already included in arm/group descriptions.
79476793|NCT01999400|Drug|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
79476794|NCT01999400|Drug|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
79476795|NCT01999400|Drug|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
79476796|NCT02000180|Behavioral|Progressive Group|
79476797|NCT01969435|Drug|Carmustine|
79476798|NCT01969435|Drug|Etoposide phosphate|
79314477|NCT03144245|Biological|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
79476799|NCT01969435|Drug|Cytarabine|
79476800|NCT01969435|Drug|Melphalan HCl (propylene glycol-free)|
79476801|NCT01965002|Device|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
79476802|NCT01965002|Drug|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
79476803|NCT01965002|Drug|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
79476804|NCT02304757|Drug|99Tc-MDP|99Tc-MDP, H20000218
79476805|NCT02304757|Drug|Fosamax|H20080172
79476806|NCT02002208|Drug|OC000459|Oral CRTH2 antagonist
79476807|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
79642011|NCT00534820|Procedure|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
79642012|NCT00157742|Procedure|Spinal Cord Stimulation (SCS)|
79642013|NCT00157742|Procedure|Percutaneous Myocardial Laser Revascularisation (PMR)|
79642014|NCT00534859|Device|High Risk PCI|High Risk Percutaneous Coronary Intervention
79642015|NCT00534898|Drug|Bexarotene|
79642016|NCT00534898|Drug|Fenretinide|
79642017|NCT00534898|Drug|Placebo|
79642018|NCT00189813|Drug|YM060|
79971602|NCT01296659|Drug|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
79971603|NCT03122080|Device|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
79314478|NCT03144245|Combination Product|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
79476808|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
79476809|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
79806723|NCT02676635|Behavioral|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
79476810|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
79476811|NCT01969747|Drug|Empagliflozin medium|Empagliflozin medium
79314479|NCT02326493|Device|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
79314480|NCT04996199|Drug|Oxcarbazepine|oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
79476812|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
79476813|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
79642019|NCT00157781|Device|Medtronic AT500|
79476814|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
79476815|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
79314481|NCT04996199|Drug|Carbamazepine|carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks & 10weeks
79476816|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
79642020|NCT03750448|Other|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
79642021|NCT03750448|Other|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
79971604|NCT03122080|Device|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
79314482|NCT02432833|Drug|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
79314483|NCT02432833|Drug|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
79314484|NCT02432833|Drug|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
79314485|NCT02326337|Device|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
79476817|NCT01969747|Drug|Empagliflozin low|Empagliflozin low
79476818|NCT01969747|Drug|Empagliflozin high|Empagliflozin high
79476819|NCT02002832|Drug|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
79476820|NCT02002832|Drug|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
79476821|NCT02010151|Other|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
79476822|NCT01966718|Drug|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
79806724|NCT04178291|Device|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
79971605|NCT03122080|Other|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
79971606|NCT03725683|Device|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
79971607|NCT03725683|Device|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
79314486|NCT02326337|Device|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
79476823|NCT02010697|Behavioral|Messages targeting nonsmokers|
79806725|NCT04178291|Device|Air polishing with erythritol powder|Air flow PLUS
79314487|NCT02429323|Drug|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
79314488|NCT02326103|Drug|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
79314489|NCT02326103|Drug|Placebo|
79314490|NCT02707861|Drug|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
79476824|NCT02010697|Behavioral|Messages targeting smokers|
79476825|NCT02004158|Behavioral|Positive psychology intervention|
79476826|NCT02308501|Drug|Lastacaft ®|
79476827|NCT02308501|Drug|Tears Naturale ® (Placebo)|
79476828|NCT02005016|Behavioral|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
79971608|NCT04502992|Behavioral|Acceptance and Committment Therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles & McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
79971609|NCT01194635|Genetic|fluorescence in situ hybridization|
79314491|NCT02707861|Drug|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
79971610|NCT01194635|Genetic|gene expression analysis|
79971611|NCT01194635|Genetic|polymerase chain reaction|
79314492|NCT04908137|Drug|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet No. 2. It is provided as a single use applicator in a blister package
79314493|NCT02432599|Radiation|F18-choline PET examination|F18-choline PET examination will be performed before surgery
79314494|NCT02326181|Device|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
79971612|NCT01194635|Genetic|protein analysis|
79971613|NCT01194635|Genetic|protein expression analysis|
79971614|NCT01194635|Other|enzyme-linked immunosorbent assay|
79971615|NCT01194635|Other|immunohistochemistry staining method|
79971616|NCT01194635|Other|laboratory biomarker analysis|
79971617|NCT04313361|Other|No intervention|No drug will be administered as part of this study.
79971618|NCT01190735|Drug|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
79971619|NCT01296893|Behavioral|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
79971620|NCT05097118|Drug|Ketamine Versus Bupivacaine|Drugs Ketamine versus Bupivacaine
79971621|NCT03847103|Other|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
79314495|NCT02326181|Device|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
79314496|NCT02432755|Behavioral|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
79971622|NCT03847103|Other|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
79971623|NCT03847103|Other|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
79642022|NCT03750448|Other|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
79642023|NCT03748810|Drug|Empagliflozin|Empagliflozin 25 mg once daily add on the background OADs for 3 years
79642024|NCT03748810|Drug|Dapagliflozin|Dapagliflozin 25 mg once daily add on the background OADs for 3 years
79642025|NCT00157859|Drug|Chloroquine and sulphadoxine-pyrimethamine|
79642026|NCT00183027|Behavioral|Dietary composition and energy intake|
79642027|NCT00157898|Drug|MK0826; ertapenem sodium|
79642028|NCT00157898|Drug|Comparator: ceftriaxone + metronidazole|
79642029|NCT03669523|Drug|Denosumab-nivolumab combination|"Denosumab: 120 mg every 4 weeks subcutaneously~Nivolumab: 240mg intravenously on day 1 every 2 weeks"
79642030|NCT00535015|Drug|Betamarc|2 tabs BID
79642031|NCT00157976|Drug|Photrex (rostaporfin)|
79642032|NCT00535054|Drug|Tears Again|Liposome Eye Spray
79971624|NCT03602053|Biological|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
79314497|NCT02432755|Behavioral|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
79314498|NCT02432755|Behavioral|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
79476829|NCT02311309|Other|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration >8 g/dL.
79476830|NCT02311309|Other|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration < 8 g/dL.
79642033|NCT00535093|Device|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
79971625|NCT03602053|Biological|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
79971626|NCT03602053|Biological|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
79642034|NCT00189852|Device|Chronic heart failure monitoring system|
79642035|NCT00189852|Device|Lifestyle monitoring system|
79642036|NCT03493750|Other|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
79642037|NCT00158093|Drug|Nebivolol|
79642038|NCT00158093|Drug|Atenolol|
79642039|NCT00158093|Drug|Moxifloxacin|
79642040|NCT00183105|Behavioral|Brief Intervention (adaptation of motivational interviewing)|
79642041|NCT00535210|Behavioral|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
79806726|NCT04178681|Other|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
79806727|NCT04178681|Other|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
79971627|NCT03351634|Device|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
79971628|NCT01194713|Behavioral|Sleep deprivation|subjects will undergo one night of full sleep deprivation
79971629|NCT05584306|Drug|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
79314499|NCT04904705|Other|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
79314500|NCT04904705|Other|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
79314501|NCT02429401|Behavioral|Non-adapted brief motivational interview|1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
79806728|NCT04178681|Other|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
79314502|NCT02429401|Behavioral|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
79314503|NCT05076851|Other|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
79642042|NCT00535210|Behavioral|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
79642043|NCT03429946|Drug|Spironolactone|Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
79806729|NCT04016675|Other|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery|After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
79642044|NCT03429946|Drug|Placebo|Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
79642045|NCT03429946|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
79971630|NCT05584306|Drug|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
79971631|NCT05584306|Drug|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
79971632|NCT05584306|Other|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
79971633|NCT05584306|Other|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
79971634|NCT05584306|Other|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
79971635|NCT01190969|Dietary Supplement|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
79971636|NCT03351400|Biological|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
79971637|NCT01194791|Drug|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
79971638|NCT01194791|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
79971639|NCT01194791|Drug|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
79971640|NCT04831515|Device|Lens A|daily disposable soft contact lens - test lens
79971641|NCT04831515|Device|Lens B|daily disposable soft contact lens - control lens
79971642|NCT03351322|Drug|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
79971643|NCT03351322|Drug|Regaine|Regaine are applied for treatment of hair loss.
79971644|NCT01296971|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
79971645|NCT01296971|Drug|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
79971646|NCT01296971|Drug|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
79971647|NCT04697667|Other|Exercise|Supervised exercise program
79971648|NCT04697667|Biological|PRP|Intra-articular PRP injections to knee joint
79971649|NCT03554629|Device|Capnography CO2 cannula sampling Flexiterline (CCSF) designs with supplemental O2|Use of 8 post-market nasal CO2 cannula sampling filterlines; 4 nasal only sampling ports manufactured by Medtronic, Salter, Hudson/Teleflex and FlexiCare) and 4 post-market oral/nasal sampling ports manufactured by Medtronic, Salter, Dispo-Med and Westmed during scripted activity with supplemental O2.
79971650|NCT03849989|Procedure|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~Skin desinfection with chlorhexidine digluconate 1% solution~Local anaesthesia with lidocaine hydrochloride 1%~Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
79971651|NCT04691661|Drug|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
79971652|NCT04691661|Drug|Placebo|Placebo
79971653|NCT01194947|Device|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
79314504|NCT05076851|Drug|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
79314505|NCT04890509|Drug|Bemcentinib|Bemcentinib capsules will be administered orally.
79642046|NCT03429946|Other|Euglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
79806730|NCT04016675|Other|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy|After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
79971654|NCT04655001|Behavioral|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
79314506|NCT04890509|Other|SoC|The SoC will be administered based on local guidelines.
79314507|NCT02432521|Other|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
79806731|NCT04180631|Diagnostic Test|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
79806732|NCT02673125|Genetic|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
79314508|NCT03185143|Drug|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
79806733|NCT00644267|Behavioral|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
79806734|NCT00643643|Drug|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
79806735|NCT00643643|Drug|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
79476831|NCT01967342|Behavioral|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
79476832|NCT01967342|Behavioral|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
79314509|NCT03185143|Drug|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
79314510|NCT03185143|Drug|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
79476833|NCT01967342|Other|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
79314511|NCT05076773|Procedure|Ultrasound guided block|Giving one regional block
79314512|NCT05076773|Drug|IV morphine|given when VAS>3
79314513|NCT02432677|Drug|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
79476834|NCT02006108|Drug|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
79476835|NCT02006108|Other|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
79642047|NCT00189930|Biological|MVA-nef|3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm
79642048|NCT00189930|Biological|IMVAMUNE|3 immunizations: 1E8_TCID50 IMVAMUNE
79642049|NCT00158132|Drug|Propranolol|Propranolol 100mg/day in 3 divided doses
79642050|NCT00158132|Drug|Amantadine|Amantadine 100mg three times daily
79476836|NCT02006264|Drug|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
79642051|NCT00158132|Drug|Placebo|Placebo pills
79642052|NCT04686409|Biological|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
79642053|NCT00189969|Biological|Elstree-BN|
79971655|NCT01297049|Behavioral|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
79971656|NCT03846869|Diagnostic Test|major cations|blood sample
79314514|NCT02432677|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
79314515|NCT02432677|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
79314516|NCT02432677|Drug|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
79314517|NCT03144167|Other|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
79314518|NCT02432443|Behavioral|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, & Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice & McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
79314519|NCT02432443|Other|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
79314520|NCT03442673|Drug|Vinorelbine|Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
79314521|NCT03442673|Drug|Gemcitabine|Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
79314522|NCT03442673|Drug|G-CSF|Cytokine stimulation with G-CSF for mobilization of autologous stem cells
79314523|NCT03184831|Procedure|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
79314524|NCT03184831|Procedure|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
79314525|NCT03185299|Other|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
79642054|NCT00158171|Drug|Nicotine Replacement Therapies|Nicotine gum 2 & 4 mg dependent on baseline smoking rate
79642055|NCT00158171|Drug|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
79642056|NCT00158171|Dietary Supplement|Folic Acid|400 mg
79642057|NCT03457207|Procedure|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
79642058|NCT03370783|Drug|Ethanol|Moderate alcohol consumption
79642059|NCT00183144|Behavioral|Contingency management|
79642060|NCT00158210|Drug|Rivastigmine|
79642061|NCT04723017|Other|Retrospective analysis cohort|We analyze pre-existing data base and develop machine-learning-based system that predicts the risk of hypoxemia
79971657|NCT03196791|Drug|Sugammadex Sodium|"INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
79971658|NCT03347734|Behavioral|Eye exercises group|"20 times hot water, 20 times cold water washing face in the morning and evening.~Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~20 blinks~Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
79971659|NCT03347734|Behavioral|Convergence exercise group|"Close eyes for 15 s,~Focus on a point 1 to 1.5 ft away for 10 s,~Close eyes for 5 s,~Focus on a point 20 ft away for 10 s,~Close eyes for 5 s,~Focus on a point 1 to 1.5 ft away for 10 s,~Blink for 5 s,~Close eyes for 5 s."
79971660|NCT03347734|Behavioral|Oculomotor Exercise Group (OMEG)|"The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
79314526|NCT03185299|Other|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
79314527|NCT03117673|Other|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
79314528|NCT04741841|Dietary Supplement|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
79806736|NCT00643643|Drug|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
79476837|NCT02006264|Drug|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
79476838|NCT02006342|Drug|Insulin Glargine|
79314529|NCT04741841|Dietary Supplement|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
79476839|NCT02006342|Drug|Regular Insulin|
79476840|NCT02006420|Device|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
79476841|NCT02062580|Biological|BCG|
79476842|NCT01968356|Drug|3M CHG/IPA Prep Colorless|Apply topically.
79476843|NCT01968356|Drug|3M CHG/IPA Prep Tint|Apply topically.
79476844|NCT01968356|Drug|ChloraPrep|Apply topically.
79642062|NCT04723017|Other|Prospective validation cohort|We validate our model to predict the risk of hypoxemia to prospective cohort
79476845|NCT01968356|Drug|Saline|Apply topically.
79642063|NCT00158288|Behavioral|LAAM|
79642064|NCT00535522|Drug|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
79806737|NCT00643643|Drug|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
79806738|NCT00643643|Other|Placebo|Matching placebo oral tablet twice daily for 10 days
79806739|NCT04179227|Other|Questionnaire Administration|Ancillary studies
79806740|NCT04179227|Other|Survey Administration|Ancillary studies
79806741|NCT04180787|Dietary Supplement|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
79806742|NCT02676869|Drug|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
79971661|NCT03846011|Other|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
79971662|NCT05670899|Procedure|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
79971663|NCT05023174|Procedure|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
79314530|NCT04741841|Dietary Supplement|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
79642065|NCT00535522|Drug|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
79642066|NCT00535561|Drug|Ferrous sulfate tablets 325 mg, po, TID|
79642067|NCT00535561|Drug|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
79971664|NCT05023174|Procedure|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
79971665|NCT03196635|Device|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC & MLO.
79971666|NCT03196635|Device|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
79642068|NCT00183183|Behavioral|Screening and Brief Intervention|
79314531|NCT02432365|Drug|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
79314532|NCT02432365|Drug|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
79314533|NCT02432365|Procedure|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
79314534|NCT05076695|Drug|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
79314535|NCT05076695|Drug|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
79314536|NCT05076695|Drug|pyrotinib|Pyrotinib 400mg, PO daily, continuously
79642069|NCT00158327|Behavioral|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
79642070|NCT00158327|Behavioral|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
79642071|NCT00535639|Drug|Betula Verrucosa allergen extract|
79642072|NCT00190008|Drug|piracetam|
79642073|NCT00158366|Behavioral|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
79642074|NCT00158366|Behavioral|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
79642075|NCT00158366|Behavioral|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
79971667|NCT01195181|Drug|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
79314537|NCT05076695|Drug|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
79314538|NCT03143933|Drug|Propofol|I.V propofol
79314539|NCT03143933|Drug|Fentanyl|
79642076|NCT03139318|Radiation|GRID radiotherapy|Patients will be treated with GRID radiotherapy
79642077|NCT00183222|Drug|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
79642078|NCT00158405|Procedure|Structured Treatment Interruption|
79642079|NCT00158405|Drug|Zidovudine (ZDV)|
79642080|NCT00158405|Drug|Lamivudine (3TC)|
79642081|NCT00158405|Drug|Efavirenz (EFV)|
79642082|NCT00158405|Drug|Ritonavir (NRV)|
79642083|NCT00158405|Drug|Indinavir (IDV)|
79971668|NCT05065437|Other|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
79971669|NCT05441943|Procedure|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
79642084|NCT02884765|Procedure|Non-surgical|Non-surgical treatment in both condylar fractures
79314540|NCT02440243|Drug|Purethal|prerseasonal course of SCIT - three years
79314541|NCT02440243|Drug|Purethal -placebo|preseasonal course of SCIT - three years
79314542|NCT04723043|Device|mechanical ventilation modes|ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
79971670|NCT05600699|Device|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
79971671|NCT05047341|Drug|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi [14C]SHR0302, once, D1
79971672|NCT03845855|Other|virtual reality|Virtual reality with a game
79642085|NCT02884765|Procedure|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
79642086|NCT02884765|Procedure|Surgical|Surgical treatment in both condylar fractures
79642087|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
79642088|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
79642089|NCT00158483|Drug|Acyclovir (ACV)|
79642090|NCT05265481|Device|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
79971673|NCT03845855|Other|robotic gait|robotic gait therapy
79642091|NCT05265481|Device|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
79642092|NCT05265481|Device|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
79642093|NCT05256667|Combination Product|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
79642094|NCT05256667|Other|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
79642095|NCT05256667|Other|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
79642096|NCT00183300|Behavioral|Prolonged Exposure Therapy|
79971674|NCT01196897|Device|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
79971675|NCT01197053|Biological|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
79971676|NCT01197053|Biological|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
79642097|NCT00158522|Drug|pegylated interferon alpha2a|
79642098|NCT05250544|Other|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
79642099|NCT00190047|Drug|DP-b99|
79642100|NCT05195047|Dietary Supplement|1 week placebo(Week 1)|1 week of consecutively consuming oral placebo (1 time/day)
79476846|NCT02063516|Device|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
79971677|NCT03845699|Device|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
79971678|NCT05671133|Diagnostic Test|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
79642101|NCT05195047|Dietary Supplement|1 week of probiotics(Week 1)|1 week of consecutively consuming oral probiotics (1 time/day)
79642102|NCT05195047|Dietary Supplement|1 week placebo(Week 2)|1 week of consecutively consuming oral placebo (1 time/day)
79476847|NCT02063516|Device|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
79971679|NCT03845777|Diagnostic Test|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
79971680|NCT03846713|Procedure|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
79971681|NCT03846713|Procedure|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
79971682|NCT03194217|Drug|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
79971683|NCT03194217|Drug|Placebo|Placebo
79971684|NCT00709618|Drug|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
79971685|NCT01195259|Drug|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
79971686|NCT05584228|Drug|Azathioprine + infliximab|Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
79476848|NCT02006888|Drug|IBI-10090|
79476849|NCT02006888|Drug|Placebo|Placebo
79476850|NCT02007200|Other|Laboratory Biomarker Analysis|Correlative studies
79476851|NCT02007200|Drug|Soy Isoflavones|Given PO
79476852|NCT02007200|Other|Survey Administration|Ancillary studies
79476853|NCT01969214|Device|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
79476854|NCT02008682|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
79476855|NCT02008682|Drug|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
79971687|NCT05584228|Procedure|Intestinal resection|Ileocolonic or small bowel resection
79476856|NCT01969448|Procedure|Inframammary Fold Incision or Lateral Radial Incision|
79476857|NCT01969448|Procedure|Lateral Radial Incision|
79476858|NCT01969448|Procedure|Inframammary Fold Incision|
79642103|NCT05195047|Dietary Supplement|1 week of probiotics(Week 2)|1 week of consecutively consuming oral probiotics (1 time/day)
79642104|NCT05195047|Dietary Supplement|1 week placebo(Week 3)|1 week of consecutively consuming oral placebo (1 time/day)
79314543|NCT02440165|Behavioral|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
79476859|NCT01969448|Device|Laser-assisted fluorescence angiography|
79476860|NCT01969448|Drug|Indocyanine Green|
79476861|NCT01969916|Drug|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
79806743|NCT02676869|Drug|Pembrolizumab|Administered according to the approved label.
79971688|NCT03193047|Drug|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
79476862|NCT02011490|Drug|sugammadex|sugammadex 4 mg/kg IV bolus
79476863|NCT00373763|Procedure|Fetoscopic tracheal balloon occlusion|
79476864|NCT00373919|Drug|intravenous (IV) administration of erythromycin|
79642105|NCT05195047|Dietary Supplement|1 week of probiotics(Week 3)|1 week of consecutively consuming oral probiotics (1 time/day)
79642106|NCT00158561|Drug|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
79642107|NCT05169229|Drug|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
79642108|NCT05169229|Drug|Saline|As a placebo added to the allograft.
79642109|NCT00158639|Behavioral|Home BP;secure messaging;pharmaceutical care;|
79642110|NCT00538018|Drug|Telithromycin|
79642111|NCT00183378|Behavioral|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
79642112|NCT00183378|Behavioral|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
79806744|NCT02676245|Behavioral|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
79806745|NCT02676245|Behavioral|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
79971689|NCT03193047|Other|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
79314544|NCT04705259|Behavioral|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs [7], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~Education and engagement of prescribers, nurses, pharmacists and residents and family members~Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~Guideline development specific to antibiotic use in RACF residents~Antimicrobial stewardship team creation in RACF with GP involvement~EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~Telehealth support for key intervention components"
79314545|NCT05076461|Drug|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
79314546|NCT02428933|Drug|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
79314547|NCT05076305|Other|No specific intervention; cases are retrospective and patients have already been treated.|To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.
79314548|NCT02428777|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
79314549|NCT02428777|Drug|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
79314550|NCT02428777|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
79314551|NCT03142373|Other|CV4 technique|
79314552|NCT03142373|Other|RR technique|
79314553|NCT03142373|Other|Placebo treatment|
79476865|NCT02916407|Drug|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
79971690|NCT03193047|Drug|evolocumab|Monthly PCSK9i (evolocumab) background therapy
79971691|NCT01197209|Biological|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
79971692|NCT03346720|Other|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
79476866|NCT02916407|Drug|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
79476867|NCT02916563|Device|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
79806746|NCT02674841|Other|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
79806747|NCT02674841|Other|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
79314554|NCT05076071|Genetic|NGS|Next Generation Sequencing
79314555|NCT05233657|Drug|JX11502MA|Oral capsule
79314556|NCT05233657|Drug|Placebo|Oral capsule
79314557|NCT03142139|Biological|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
79642113|NCT00183378|Behavioral|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
79642114|NCT00183378|Behavioral|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
79806748|NCT02674841|Other|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
79314558|NCT03142139|Biological|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
79806749|NCT02673047|Biological|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
79971693|NCT03346720|Other|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
79971694|NCT04970212|Device|BioTraceIO Lite|The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
79971695|NCT01195337|Behavioral|PA Prescription Plan|Exercise program and instructions.
79971696|NCT01195337|Device|Pedometer|Step monitor for individual PA progress.
79971697|NCT01195337|Behavioral|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
79971698|NCT04504552|Drug|Avelumab|Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
79971699|NCT01197287|Drug|QAK423A|
79971700|NCT01197287|Drug|QAK423A|
79314559|NCT03142139|Biological|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
79314560|NCT02432053|Drug|Advagraf|
79314561|NCT04624919|Other|Hot/Dry|Work is completed in a hot/dry environment.
79314562|NCT04624919|Other|Warm/Humid|Work is completed in a warm/humid environment
79314563|NCT03186157|Procedure|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
79314564|NCT03186157|Procedure|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
79642115|NCT00538057|Drug|GW685698X & GW642444M|study drug
79971701|NCT01197287|Drug|QAK423A|
79971702|NCT03351166|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
79642116|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
79314565|NCT02429089|Drug|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
79314566|NCT03141827|Drug|Insulin|Insulin 40 IU, nasal spray, single dose
79642117|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
79314567|NCT03141827|Drug|Placebo|Placebo, nasal spray, single dose
79314568|NCT03190681|Drug|Ritalin 10Mg Tablet|ingestion of an oral single-dose
79314569|NCT03143777|Device|Sara Combilizer|Combined tilt table and stretcher chair
79314570|NCT04604405|Radiation|photobiomodulation|650nm low energy red light eye irradiation
79314571|NCT03186235|Other|Flow cytometry|Isolation of T regulatory cells from blood
79314572|NCT05068115|Procedure|Clinical characteristics, diagnosis and treatment, survival status|Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
79314573|NCT03186001|Drug|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
79642118|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
79642119|NCT00538135|Behavioral|Cognitive Behavioural Therapy|
79642120|NCT00538135|Other|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
79642121|NCT00158678|Procedure|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
79806750|NCT02672813|Procedure|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
79806751|NCT00643019|Behavioral|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
79806752|NCT00643019|Other|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
79806753|NCT00643721|Other|dehydration|dehydration to 3% and 5% loss of total body water
79971703|NCT01197365|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
79314574|NCT04593563|Drug|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
79314575|NCT03185923|Drug|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical & Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
79314576|NCT03185923|Drug|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
79642122|NCT00158678|Procedure|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
79971704|NCT01197365|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
79971705|NCT05584150|Other|Deep Cleansing Gel|daily use
79971706|NCT03351088|Procedure|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
79971707|NCT03845387|Drug|KDT-3594|oral administration, dose titration
79971708|NCT03845387|Drug|Pramipexole|ER formulation, oral administration, dose titration
79971709|NCT05584072|Diagnostic Test|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
79971710|NCT01197443|Behavioral|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
79971711|NCT01197443|Behavioral|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
79642123|NCT00158678|Drug|concomitant cisplatin|100 mg/m2 D1, D22, D43
79642124|NCT00538174|Drug|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
79642125|NCT00538174|Drug|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
79806754|NCT02676167|Behavioral|PrEP Intervention|
79314577|NCT04551911|Drug|Rayaldee 30Mcg Extended-Release (ER) Capsule|Rayaldee 30Mcg Extended-Release (ER) Capsule
79314578|NCT04551911|Drug|Placebo|0Mcg Extended-Release (ER) Capsule
79314579|NCT02428465|Behavioral|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
79971712|NCT03351010|Behavioral|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
79314580|NCT03143387|Other|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
79314581|NCT03143387|Other|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
79314582|NCT02431975|Drug|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
79314583|NCT02431975|Drug|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
79314584|NCT02431975|Drug|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
79314585|NCT02431975|Drug|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
79314586|NCT03143465|Drug|Calcitonin Gene-Related Peptide|
79314587|NCT03143465|Drug|Sildenafil|
79476868|NCT02828267|Behavioral|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
79314588|NCT03143465|Drug|Placebo|
79642126|NCT05139823|Procedure|geriatric follow-up home visit after discharge|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
79314589|NCT02431819|Device|contention socks|Patients wear contention socks during 15 days.
79642127|NCT05120479|Procedure|Kinesiotape|"Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension). The measure determined in the measurement with a tape measure is cut. The anchor of the KT is placed on the medial epicondyle with the body segments in a neutral position (anchor length: 5 cm). Placement of the active zone of the bandage with the flexor muscles of the fingers in elongation. Origin-insertion placement. Distal anchor in neutral position. Material: Kinesiotape: Kinesiology Tape TEMTEX ® Beige (Towatek Korea Co .; South Korea)."
79314590|NCT05034809|Drug|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
79971713|NCT03351010|Device|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
79476869|NCT02828267|Behavioral|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
79476870|NCT02828267|Behavioral|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
79971714|NCT01295177|Drug|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
79971715|NCT02918019|Drug|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
79971716|NCT02918019|Drug|Placebo|Placebo matched with MSTT1041A.
79971717|NCT03350932|Behavioral|Sensory imagination about foods|In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
79971718|NCT01295333|Drug|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
79971719|NCT01295333|Drug|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
79971720|NCT04848454|Drug|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
79971721|NCT04842292|Drug|Heparin|Nebulized heparin 25,000 units every 6 hours
79971722|NCT04842292|Drug|Placebo|Sodium chloride 0.9% every 6 hours
79971723|NCT01191905|Drug|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
79314591|NCT02428543|Drug|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
79314592|NCT04428203|Drug|Epidiolex Oral Liquid Product|patients with rising PSA after failure of localized therapy will receive Epidiolex PO once daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients receive an Epidiolex taper for 7-10 days after withdrawing from study for any reason or completion of the study period.
79314593|NCT04381325|Drug|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
79476871|NCT02918357|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
79476872|NCT02829983|Drug|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
79476873|NCT02829983|Drug|Placebo|Use of placebo tablets twice a day for 3 days.
79476874|NCT02829983|Other|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
79476875|NCT02014129|Drug|LY2835219|Administered orally
79642128|NCT05120479|Procedure|Sham tape|Sham tape: exactly the same procedure is followed as above, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain).
79642129|NCT00538330|Drug|Tamoxifen|Tamoxifen
79642130|NCT00538369|Other|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
79642131|NCT00538369|Device|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
79971724|NCT01191905|Drug|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
79971725|NCT01191983|Drug|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
79971726|NCT03350854|Behavioral|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
79642132|NCT00158717|Drug|Hepsera|
79642133|NCT00538408|Procedure|Whole body magnetic resonance angiography (dotarem)|
79642134|NCT00538408|Device|Whole body magnetic resonance angiography (vasovist)|
79971727|NCT03055988|Drug|Tiotropium|Fixed Dose Combination
79642135|NCT00183417|Behavioral|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
79642136|NCT00183417|Behavioral|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
79642137|NCT00183417|Behavioral|Bibliotherapy|Participants will be given a book on how to increase their mood.
79642138|NCT00538447|Other|Database|data base for CML
79642139|NCT00538486|Drug|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
79642140|NCT00538486|Drug|Telmisartan|Telmisartan 80mg 1/d
79642141|NCT00538486|Drug|Candesartan|Candesartan 8mg daily
79642142|NCT00538486|Drug|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
79314594|NCT02431663|Drug|Ketamine|Intravenous administration in continuous
79642143|NCT00538486|Drug|Amlodipine|Amlodipine 5mg 1/d
79642144|NCT00538486|Drug|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
79642145|NCT00158795|Biological|Haemophilus Influenza type b vaccine|
79642146|NCT00538525|Drug|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
79642147|NCT00538564|Drug|tadalafil|10mg oral tablets taken 3 times a week for 2 months
79971728|NCT03055988|Drug|Olodaterol|Fixed Dose Combination
79971729|NCT03055988|Drug|Fluticasone propionate|Fixed Dose Combination
79971730|NCT03055988|Drug|Salmeterol|Fixed Dose Combination
79314595|NCT05014217|Behavioral|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
79476876|NCT02918669|Radiation|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
79476877|NCT04333355|Biological|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
79476878|NCT02012192|Drug|Ganetespib|
79642148|NCT00538564|Drug|placebo|Placebo tablets taken orally 3 times a week for 2 months
79642149|NCT04685161|Procedure|Surgical extrusion|Invasive treatment option for fractured tooth
79642150|NCT04685161|Device|Fibre post|Easy approach for treatment
79642151|NCT00538603|Drug|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
79971731|NCT03346642|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
79971732|NCT03346642|Drug|GVD chemotherapy|GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
79642152|NCT00538603|Drug|Paclitaxel & Carboplatin|Chemotherapy
79971733|NCT03346642|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
79971734|NCT03636321|Procedure|living donor liver transplantation with internal biliary stent|living donor liver transplantation without internal biliary stent
79971735|NCT01192217|Procedure|Modified thoracoscopic technique|Two-port thoracoscopic technique
79971736|NCT01192217|Procedure|Axillary mini-thoracotomy|Axillary mini-thoracotomy
79971737|NCT02473107|Other|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
79971738|NCT02473107|Other|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
79971739|NCT05583916|Procedure|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
79971740|NCT04809844|Other|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
79971741|NCT05668325|Other|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
79971742|NCT05668325|Other|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
79971743|NCT02912949|Drug|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
79971744|NCT03496636|Procedure|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
79476879|NCT02012192|Drug|Paclitaxel|
79476880|NCT02066792|Drug|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
79476881|NCT02066792|Drug|Placebo|Sugar pill
79642153|NCT00158834|Drug|Salmeterol/Fluticasone propionate combination product|
79642154|NCT00158834|Drug|Fluticasone propionate|
79642155|NCT00538720|Drug|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
79642156|NCT00538720|Device|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
79642157|NCT00538798|Drug|[18F]SP203|
79642158|NCT05553886|Drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
79642159|NCT00536887|Drug|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
79642160|NCT00158873|Drug|midazolam|
79642161|NCT00158873|Drug|lorazepam|
79314596|NCT05014217|Behavioral|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. & Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
79314597|NCT02428621|Device|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
79314598|NCT02428621|Device|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
79314599|NCT04956029|Other|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
79314600|NCT02428387|Behavioral|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
79314601|NCT02431585|Dietary Supplement|gluten|
79314602|NCT02431585|Dietary Supplement|placebo|
79314603|NCT03143231|Other|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
79314604|NCT03143231|Other|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
79314605|NCT03185845|Drug|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
79642162|NCT00158873|Drug|fentanyl|
79642163|NCT00158873|Drug|morphine|
79642164|NCT00158873|Drug|remifentanil|
79642165|NCT00158873|Drug|propofol|
79642166|NCT00536926|Device|Home spirometry with data transfer via cell phone|home spirometry recording
79642167|NCT00536926|Device|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
79642168|NCT00536926|Device|Home spirometer w/o BT|Standard home spirometry
79642169|NCT00190164|Procedure|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
79971745|NCT01250912|Drug|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
79971746|NCT05583682|Other|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
79971747|NCT03350776|Behavioral|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
79971748|NCT04780724|Other|Hypoxic gas mixture|Gas mixture of 12% O2 and 88% N2 for five minutes.
79971749|NCT04780724|Other|Hypercapnic and hypoxic gas mixture|Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.
79971750|NCT04780724|Other|SpO2 measurement|Two SpO2 measuring devices are active simultaneously during measurement.
79971751|NCT05216276|Procedure|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
79971752|NCT05216276|Procedure|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
79971753|NCT03636087|Procedure|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
79971754|NCT03636087|Procedure|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
79971755|NCT03636087|Procedure|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
79806755|NCT02672735|Other|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
79806756|NCT04178447|Drug|Glepaglutide|Single dose of Glepaglutide 10 mg
79806757|NCT04180553|Diagnostic Test|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP <90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
79806758|NCT04180553|Other|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
79806759|NCT05277155|Dietary Supplement|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~Zingiber officinale var. rubrum (Rhizome extract) 80 mg~Foeniculi vulgare Fructus (Fennel) 25 mg~Menthae arvensis Folium (Mint) 5 mg~Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~Honey 7500 mg"
79806760|NCT05277155|Other|Placebo|Placebo composition: Substance without active ingredient
79806761|NCT02674919|Other|Nordic Hamstring|
79642170|NCT00190164|Procedure|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
79971756|NCT03636087|Procedure|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
79971757|NCT03636087|Procedure|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
79642171|NCT00537121|Drug|fluorouracil|Given IV
79971758|NCT03636087|Other|Changing gloves before obturation|The treating dentist will change gloves before obturation
79806762|NCT02674919|Other|Control|
79806763|NCT05584319|Drug|Empagliflozin 10 Mg|subjects in Empagliflozin group takes Empagliflozin 10mg per day
79642172|NCT00537121|Drug|irinotecan hydrochloride|Given IV
79642173|NCT00537121|Drug|leucovorin calcium|Given IV
79642174|NCT00537121|Drug|vorinostat|Taken Orally
79642175|NCT00537121|Other|pharmacological study|Correlative Study
79642176|NCT00406991|Drug|aspirin|
79642177|NCT00406991|Drug|clopidogrel|
79642178|NCT00537160|Behavioral|Behavior modification, Nutrition Education, Exercise|
79642179|NCT03457090|Other|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
79642180|NCT05432947|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
79642181|NCT05432947|Drug|18F-FDG|Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
79642182|NCT00158951|Device|CONTAK RENEWAL 2/4/4HE CRT-D|
79642183|NCT00158951|Device|EASYTRAK 2 Lead|
79642184|NCT00190203|Procedure|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
79642185|NCT00190203|Procedure|hemicraniectomy|hemicraniectomy
79806764|NCT02674607|Dietary Supplement|Spirulina|
79642186|NCT00158990|Drug|triiodothyronine|
79642187|NCT00158990|Drug|sertraline|
79642188|NCT03457051|Procedure|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint. The device that will be used is: Stryker TKA Triathlon system implant Cruciate retaining radius femur design. This device has been approved for use by Health Canada.
79642189|NCT03457051|Procedure|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced. The device that will be used is: Stryker PKR implant cemented and fixed bearing design. This device has been approved for use by Health Canada.
79642190|NCT04685434|Other|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
79314606|NCT04336787|Other|Survey|A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.
79314607|NCT03184597|Diagnostic Test|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
79314608|NCT04327193|Procedure|Titrated PEEP based on driving pressure|Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
79314609|NCT04327193|Procedure|Conventional PEEP|Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
79314610|NCT04293029|Drug|SHR0302|SHR0302
79314611|NCT03184753|Biological|OC-IgT cells|Autologous human OC-IgT cells.
79314612|NCT03185767|Other|blood sampling|blood sampling
79642191|NCT04685629|Diagnostic Test|25 post ICU-patients|patients who were hospitalized in an intensive care unit
79642192|NCT04685629|Other|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
79806765|NCT02676323|Drug|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
79314613|NCT03184675|Other|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
79314614|NCT03184675|Other|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
79806766|NCT02676323|Drug|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m^2/dose over 30 minutes, daily for 5 days (days 8-12).
79806767|NCT02676323|Drug|Cytarabine|Cytarabine will be given IV, 2 gram/m^2/dose over 4 hours, daily for 5 days (days 8-12).
79314615|NCT04747457|Device|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~Standard examination [Reference CE-marked FibroScan]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~Standard examination [Research FibroScan]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~Exploratory examination [Research FibroScan]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
79314616|NCT03182803|Biological|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
79642193|NCT00537355|Biological|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
79642194|NCT00537355|Drug|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
79642195|NCT00183612|Drug|Olanzapine|
79806768|NCT02676323|Drug|Intrathecal Triples|Given intrathecally (IT).
79806769|NCT02676323|Drug|Leucovorin|Leucovorin (5 mg/m^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
79806770|NCT00643799|Drug|Celecoxib|200 mg oral capsule once daily for 6 months
79806771|NCT00643799|Drug|Naproxen|500 mg oral capsule twice daily for 6 months
79806772|NCT00643799|Drug|Placebo|Matched oral placebo for 6 months
79314617|NCT04596917|Behavioral|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
79314618|NCT04596917|Behavioral|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
79314619|NCT03185689|Behavioral|Effectiveness of an intensified DSME in T2D adult patients|
79314620|NCT04199897|Dietary Supplement|Succrose rinsing|Sucrose rinsing 7-8 times a day for 14 days
79314621|NCT04199897|Dietary Supplement|Probiotic lozenges|Probiotic lozenges 2 times a day for 35 days
79314622|NCT04199897|Other|xylitol rinsing|Xylitol rinsing 7-8 times a day for 14 days
79314623|NCT04199897|Other|Placebo tablets|Placebo lozenges 2 times a day for 35 days
79314624|NCT03185611|Drug|Rifaximin|Antibiotics
79314625|NCT03185611|Drug|Azathioprine|immunomodulator
79314626|NCT03185533|Behavioral|Quality improvement (QI) interventions|"1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~The ED director created QI education sessions and reported monthly QI outcomes.~The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~The ED patients could be admitted before 8 a.m. if the bed was vacant.~The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~Monthly QI outcomes were reported in the hospital affairs meeting."
79314627|NCT03182959|Drug|Avmacol®|Avmacol® tablets
79314628|NCT02431429|Drug|Miltefosine|
79314629|NCT04158245|Drug|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
79314630|NCT03182881|Other|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
79314631|NCT03182881|Other|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
79314632|NCT03143543|Drug|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
79314633|NCT03143543|Drug|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
79806773|NCT02672891|Device|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
79314634|NCT03143543|Other|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
79314635|NCT03143543|Other|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
79314636|NCT02428075|Behavioral|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
79314637|NCT02428153|Other|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
79314638|NCT03142061|Procedure|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
79314639|NCT04402307|Other|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
79314640|NCT02427919|Drug|G-CSF|Comparison of the effect of G-CSF use
79314641|NCT03110783|Biological|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
79806774|NCT02676401|Drug|MT-3995 Low|
79314642|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
79314643|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
79314644|NCT02027428|Drug|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
79806775|NCT02676401|Drug|MT-3995 Middle|
79806776|NCT02676401|Drug|MT-3995 High|
79642196|NCT05402995|Drug|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
79642197|NCT05402995|Drug|Saline|Saline irrigation
79642198|NCT00183651|Behavioral|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
79642199|NCT00183651|Behavioral|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
79642200|NCT00183651|Behavioral|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
79642201|NCT00537433|Other|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
79642202|NCT00537472|Drug|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
79642203|NCT00537472|Drug|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
79642204|NCT00183690|Procedure|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
79642205|NCT00183690|Procedure|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
79642206|NCT00159107|Drug|Acamprosate|Acamprosate
79303493|NCT04442321|Other|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
79303494|NCT03306563|Diagnostic Test|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
79303495|NCT02468297|Device|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
79303496|NCT02468297|Drug|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
79303497|NCT03304925|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
79303498|NCT03306407|Other|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
79303499|NCT03304769|Device|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
79303500|NCT02468375|Drug|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
79314645|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
79314646|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
79314647|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
79314648|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
79314649|NCT03182647|Procedure|Surgically treatment of the ACL|Surgical initial ACL treatment
79314650|NCT03182647|Other|Non surgical initial ACL treatment|Non surgical initial ACL treatment
79314651|NCT03143699|Other|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
79314652|NCT04016363|Other|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
79476882|NCT02066792|Behavioral|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
79642207|NCT00159107|Behavioral|Integrative behavior therapy|Integrative behavior therapy
79642208|NCT00159107|Drug|Placebo|Placebo
79642209|NCT05357365|Other|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
79642210|NCT00190242|Drug|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
79642211|NCT00190242|Drug|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
79642212|NCT05355259|Device|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
79642213|NCT00537550|Drug|Vincristine|Steroids pre-treatment
79971759|NCT03636087|Other|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
79971760|NCT03636087|Other|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
79806777|NCT02672969|Device|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
79806778|NCT05348213|Drug|Zanubrutinib plus R-ICE|Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
79806779|NCT05348213|Drug|Decitabine plus R-ICE|Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
79806780|NCT05348213|Drug|Chidamide plus R-ICE|Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
79642214|NCT00537550|Drug|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
79642215|NCT00159146|Drug|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
79303501|NCT02468453|Device|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
79314653|NCT04016363|Other|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
79314654|NCT03399071|Drug|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
79642216|NCT00537667|Drug|anakinra|anakinra
79642217|NCT00537667|Drug|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
79642218|NCT00538876|Drug|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
79806781|NCT05348213|Drug|Tofacitinib plus R-ICE|Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
79642219|NCT00538954|Drug|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
79642220|NCT00538954|Dietary Supplement|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
79642221|NCT00538954|Other|Standard ERAS group|
79642222|NCT00538993|Behavioral|Stage based counseling|
79806782|NCT05348213|Drug|Pomalidomide plus R-ICE|Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
79971761|NCT03636087|Radiation|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
79971762|NCT03636087|Radiation|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
79971763|NCT03733301|Drug|Baricitinib|Administered orally.
79971764|NCT03733301|Drug|Topical corticosteroid|Administered as standard-of-care.
79971765|NCT03733301|Drug|Placebo|Administered orally.
79314655|NCT02425033|Procedure|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
79314656|NCT03857165|Drug|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
79314657|NCT03184363|Drug|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
79642223|NCT00539071|Drug|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
79314658|NCT02431039|Device|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
79806783|NCT02674451|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
79314659|NCT02431039|Device|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
79314660|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
79314661|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
79314662|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
79476883|NCT02922959|Behavioral|Peer Intervention|The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
79476884|NCT02922959|Drug|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
79642224|NCT00539071|Drug|long acting injectable risperidone|Study dose remains 50 mg for the length of the study.
79806784|NCT00643877|Procedure|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
79806785|NCT00643877|Procedure|surgery|radical surgery only
79971766|NCT04767334|Device|Anti-Gravity Treadmill|"Each participant will started with a 5 - 10 minute warm-up on a standard cycle ergometer, manual and therapeutic therapy for upper extremity, and gait training using LBPP. Manual and therapeutic therapy will consist of passive and active ROM, joint mobilization, passive and active stretch, manual resistance exercise, and activities of daily life (ADL). All participants will walk in Alter G one session a day (for 40 min), three days a week, for six weeks. On session one, the Alter G pressure chamber will be set to unload 50% of patient's body weight. On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
79971767|NCT05583214|Drug|Ondansetron 8mg|8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
79971768|NCT05583214|Drug|Dexamethasone 8mg|8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
79971769|NCT05583214|Drug|Normal saline|Normal saline will be given IV stat to the group after induction of spinal anesthesia
79314663|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
79314664|NCT02430805|Other|dna extraction and genotyping|blood and urine sample
79476885|NCT02922959|Behavioral|Personally-tailored opioid overdose prevention education (information packet)|"Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder."
79476886|NCT02014363|Drug|ETS6103 (low dose)|
79476887|NCT02014363|Drug|ETS6103 (high dose)|
79476888|NCT02014363|Drug|Amitriptyline|
79476889|NCT02833337|Radiation|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
79476890|NCT02067806|Drug|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
79476891|NCT02833415|Drug|[U-13C3] glycerol|Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
79476892|NCT02833415|Drug|Empagliflozin|Active drug
79476893|NCT02833415|Drug|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
79476894|NCT02014519|Procedure|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
79476895|NCT02014519|Other|Data collection|Active questioning
79476896|NCT04737551|Other|Follow-up only|Only routine follow-up but no treatment
79476897|NCT04737551|Drug|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
79476898|NCT04737551|Radiation|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
79476899|NCT04737551|Radiation|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
79971770|NCT04502680|Drug|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
79971771|NCT04768478|Drug|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
79971772|NCT04768478|Drug|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
79971773|NCT05578924|Other|" women group "|women aged more than 18 years old
79971774|NCT02871297|Drug|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
79971775|NCT04758104|Radiation|Yttrium90|Intracystic implantation of 90yttrium colloid
79314665|NCT01995136|Drug|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
79806786|NCT02676479|Device|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~Use of a tenaculum or cervical stitch is required~Use of saline to wash the cervix is required~Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
79314666|NCT04290299|Other|Data collection|Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes
79806787|NCT00643175|Behavioral|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
79314667|NCT04483141|Diagnostic Test|Abbey Pain Scale|Hetero-assessment of pain
79314668|NCT02430883|Procedure|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
79314669|NCT03141593|Drug|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
79314670|NCT03141593|Drug|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
79806788|NCT02674295|Drug|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
79314671|NCT03141593|Drug|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
79314672|NCT03141593|Drug|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
79314673|NCT04680832|Diagnostic Test|Electronic nose|First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow <0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
79806789|NCT02674295|Drug|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
79314674|NCT03183973|Biological|PRF|patients who will receive PRF suspension
79314675|NCT03183973|Biological|placebo group|patients who will receive Placebo
79314676|NCT03143309|Behavioral|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
79642225|NCT00539071|Drug|long acting injectable risperidone|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
79806790|NCT04179071|Drug|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
79314677|NCT03143309|Other|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
79314678|NCT04102241|Drug|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
79314679|NCT04102241|Drug|Placebos|Placebos are the same as drugs, but contain no Hemay005.
79314680|NCT01994902|Device|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
79314681|NCT01994902|Device|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
79642226|NCT00539149|Drug|Amoxycillin|50 mg/kg/day twice daily
79806791|NCT04179071|Drug|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
79806792|NCT02672501|Drug|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences
79806793|NCT02673983|Procedure|Endoscopic full-thickness biopsy|
79314682|NCT03111095|Other|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
79314683|NCT02425267|Other|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
79314684|NCT03777137|Behavioral|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
79314685|NCT02026258|Procedure|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
79314686|NCT02026258|Device|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
79476900|NCT04737395|Device|"upper extremity training program (Meditouch,MSQUARE)"|40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
79476901|NCT02012348|Other|Antibacterial soap with triclocarban|
79476902|NCT02012348|Other|Antibacterial soap + benzalkonium chloride|
79476903|NCT02012348|Other|Control soap|
79476904|NCT02016235|Drug|Phosphorus Supplement|250 mg po qid
79642227|NCT00539149|Drug|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
79806794|NCT02675933|Behavioral|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
79806795|NCT02674139|Device|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
79806796|NCT00910169|Other|inpatient treatment|Hospitalisation modalities are described but are naturalistic
79806797|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
79314687|NCT03576443|Drug|Idelalisib|Idelalisib 150 mg x 2 p o
79314688|NCT03141515|Device|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
79314689|NCT02427685|Device|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
79314690|NCT02427529|Drug|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
79314691|NCT02427529|Drug|Placebo|
79476905|NCT02016235|Other|Observation|Baseline blood and urine measurements only
79476906|NCT02834663|Drug|Lucentis|Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
79642228|NCT00539227|Procedure|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
79642229|NCT00539227|Behavioral|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
79642230|NCT00539266|Biological|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
79642231|NCT00539266|Biological|placebo|40 IM injections (calf muscle) of placebo suspension
79806798|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
79314692|NCT02427529|Other|Low calorie diet|
79314693|NCT03336671|Procedure|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
79806799|NCT02672267|Biological|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
79314694|NCT03336671|Procedure|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
79314695|NCT03552341|Other|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
79314696|NCT02427763|Device|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
79314697|NCT02427763|Other|collect saliva|the patient spit during 30 seconds in a small bottle
79314698|NCT02427763|Other|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
79314699|NCT02427763|Other|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
79314700|NCT04438733|Drug|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
79314701|NCT04438733|Drug|reference-anastrozole tablet (Arimidex)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
79314702|NCT04438811|Other|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
79314703|NCT04438811|Other|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
79314704|NCT02427295|Drug|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~Frequency: every 4 weeks.~Route of administration: IM injection."
79314705|NCT01994590|Drug|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
79314706|NCT01994590|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
79314707|NCT01994590|Drug|Prednisone|5 mg by mouth twice daily.
79314708|NCT02427373|Dietary Supplement|fish oil ethyl ester|
79314709|NCT02427373|Dietary Supplement|fish oil triglyceride|
79314710|NCT02427373|Dietary Supplement|krill oil|
79971776|NCT03121924|Procedure|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
79314711|NCT02427061|Behavioral|Intervention Program (Manhood 2.0)|
79314712|NCT02427061|Behavioral|Control Program (Job Skills Training)|
79314713|NCT05387603|Drug|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
79314714|NCT05387603|Drug|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
79314715|NCT03182569|Device|FLEXIBLE CATHETER|
79314716|NCT03182569|Device|hourly rigid needle puncture|
79806800|NCT02672267|Other|Placebo|Lactated Ringer's Solution
79314717|NCT03306173|Other|Commercially available cigarette|Commercially available cigarette with either ~0% or ~25% filter ventilation. Menthol flavor will be available in both types.
79314718|NCT02019550|Device|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
79314719|NCT02019550|Device|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
79971777|NCT03628430|Procedure|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
79314720|NCT03182413|Drug|Placebo|
79971778|NCT03628430|Procedure|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
79971779|NCT03628430|Procedure|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
79971780|NCT03121846|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
79971781|NCT03628352|Drug|Tricaprilin|Tricaprilin with flavoring agents added
79971782|NCT03122314|Drug|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
79971783|NCT03122314|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
79971784|NCT03554005|Drug|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
79971785|NCT03554005|Drug|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
79971786|NCT01314573|Behavioral|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
79971787|NCT01314573|Behavioral|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
79971788|NCT00709228|Drug|PegIntron|1.5 ug/kg/week
79971789|NCT00709228|Drug|Rebetol|800-1200 mg/day
79971790|NCT01584557|Drug|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
79971791|NCT01584557|Drug|placebo or sugar pill|sugar pill
79971792|NCT03728491|Device|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
79971793|NCT03728491|Device|Healthy figurants|Medical students or volunteers without any pathology in thorax
79971794|NCT01587599|Behavioral|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
79971795|NCT05215964|Procedure|Renal artery embolization|After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
79984563|NCT03749291|Other|Obemat2.0 therapy|"Lifestyle (diet & physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month & 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight & physical activity are defined to be accomplished until the next visit."
79314721|NCT03182413|Drug|Modafinil|
79314722|NCT03182413|Drug|THN102|
79314723|NCT02430649|Procedure|Irreversible electroporation (IRE)|
79314724|NCT02430649|Device|NanoKnife|
79314725|NCT03182257|Drug|ONO-7579|ONO-7579 Tablets
79314726|NCT03166631|Drug|BI 891065|Part A, B & C
79314727|NCT03166631|Drug|BI 754091|Part B & C
79314728|NCT05117827|Device|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
79476907|NCT01973036|Device|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
79314729|NCT03159377|Device|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
79642232|NCT00539344|Drug|ANG1005|IV infusion once every 21 days
79971796|NCT03728413|Biological|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
79971797|NCT01192373|Other|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
79314730|NCT02980367|Other|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
79314731|NCT02980367|Procedure|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
79642233|NCT00539383|Drug|ANG1005|IV infusion once every 21 days
79642234|NCT00183768|Behavioral|Cognitive Behavioral Therapy|
79642235|NCT00183768|Behavioral|Psychopharmacology|
79642236|NCT00539422|Genetic|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
79642237|NCT00183807|Drug|irinotecan, cisplatin, celecoxib|
79314732|NCT03185221|Device|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
79314733|NCT03185221|Device|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
79314734|NCT03184129|Device|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
79314735|NCT03184129|Device|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
79314736|NCT02507765|Other|Laboratory Biomarker Analysis|Correlative studies
79642238|NCT00539578|Drug|MK0777|Duration of Treatment: 4 weeks
79971798|NCT01192373|Other|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
79971799|NCT01310491|Behavioral|Health coaching|Telephone based health coaching supported by tele-monitoring.
79314737|NCT02507765|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79314738|NCT02507765|Procedure|Transarterial Chemoembolization|Undergo TACE
79642239|NCT00539578|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
79314739|NCT03184285|Procedure|baseline alert 1|measurement in supine position
79314740|NCT03184285|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
79314741|NCT03184285|Procedure|ATB in narcosis|measurement under ATB in narcosis
79314742|NCT03184285|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
79314743|NCT03184285|Procedure|passive leg raising|measurement under passive leg raising
79314744|NCT03184285|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
79314745|NCT03184285|Procedure|baseline in narcosis 2|measurement in supine position
79314746|NCT03184285|Procedure|start capnoperitoneum|measurement in supine position
79314747|NCT03184285|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
79642240|NCT00539773|Drug|BCG, Interferon|Chemotherapy
79642241|NCT00409461|Drug|ATG-Sirolimus-Tacrolimus|
79642242|NCT00539812|Behavioral|Standard Care|Standard 40 hour state mandated batterer intervention program
79642243|NCT00539812|Behavioral|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
79642244|NCT00539890|Drug|Technosphere Insulin|
79642245|NCT00539968|Drug|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
79642246|NCT00183846|Drug|irinotecan|
79642247|NCT00183846|Procedure|radiation therapy|
79642248|NCT00540085|Drug|Rocuronium|0.6 mg/kg given intravenously before intubation
79642249|NCT00190320|Procedure|Induction of labor vs waiting|
79642250|NCT00540202|Drug|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
79314748|NCT03184285|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
79314749|NCT03184285|Procedure|ATB loss of capnoperitoneum|measurement under ATB
79314750|NCT03184285|Procedure|baseline|measurement in supine position
79806801|NCT05313581|Behavioral|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
79806802|NCT04178759|Procedure|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
79806803|NCT02671799|Device|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
79314751|NCT03184285|Procedure|baseline alert 2|measurement in supine position
79314752|NCT03184285|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
79314753|NCT03184285|Procedure|torso position rising 30° at the end|measurement in the recovery unit
79314754|NCT03183817|Behavioral|Person-centred care at distance|Person-centred care at distance through an eHealth platform
79314755|NCT03183739|Drug|ASP8062|ASP8062 will be administered orally.
79806804|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
79806805|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
79806806|NCT01019083|Other|Control|Control will be selected from the Arsenic non contaminated Area
79806807|NCT01019083|Drug|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
79806808|NCT01019083|Drug|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
79314756|NCT03183739|Drug|Placebo|Placebo will be administered orally.
79806809|NCT01019083|Other|Arsenic|Participant will be selected from the Arsenic Contaminated Area
79314757|NCT05080361|Drug|BRAF inhibitor|Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
79314758|NCT02430415|Device|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
79314759|NCT02430415|Device|traditional lightwand intubation|traditional lightwand intubation
79314760|NCT05080205|Procedure|Bariatric surgery|Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
79314761|NCT03117439|Other|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
79314762|NCT02741141|Other|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
79314763|NCT02741141|Other|Classical partograph|Classical partograph used as standard care
79314764|NCT02616263|Other|Foot exercise|
79314765|NCT02616263|Other|Shoulder exercise|
79314766|NCT02427139|Device|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
79314767|NCT02426905|Drug|trientine dihydrochloride|A retrospective review of patients' medical records
79314768|NCT05079893|Other|Case control study|Observational case control study
79314769|NCT05079737|Other|Mutation Burden|Subjects will have their facial samples analyzed for DNA mutation burden.
79971800|NCT05215028|Device|web-application|web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
79971801|NCT03725527|Procedure|Rectus Sheath Catheter Block|Sonar guided RSC will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
79314770|NCT03181945|Other|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
79314771|NCT03181945|Other|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
79314772|NCT02031107|Device|cTBS|
79314773|NCT02031107|Device|cathodal tDCS|
79314774|NCT02031107|Device|sham stimulation|
79314775|NCT02421523|Procedure|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of ~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
79971802|NCT03725527|Procedure|Epidural Catheter Block|Sonar-guided epidurals will be performed with a 17-gauge Tuohy needle and 19 G flex-tip catheter. Using an LOR (loss of resistance) to saline technique, catheters will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection.
79314776|NCT02421523|Procedure|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of ~30% of the subject's MVC. Subjects will be asked to perform ~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (~50% MVC). Similarly, if no damage has occurred at ~50% MVC, four more subjects exercise at ~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
79971803|NCT05283317|Biological|Mesenchymal stem cells|Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
79971804|NCT05670665|Other|Threatened preterm labor|Presence of uterine contractions and cervical shortening between 24+0 and 36+6 weeks of gestation and/or rupture of the membranes between 24+0 and 36+6 weeks of gestation.
79314777|NCT02421523|Procedure|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
79314778|NCT02421289|Drug|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
79314779|NCT02421289|Drug|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
79314780|NCT02421289|Other|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
79314781|NCT03142997|Diagnostic Test|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
79314782|NCT02424643|Behavioral|Monetary Incentive|$20 Amazon.com gift card
79314783|NCT02424643|Behavioral|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
79642251|NCT00540202|Drug|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
79806810|NCT04098185|Device|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
79806811|NCT00463801|Drug|Daptomycin|
79971805|NCT02606799|Device|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
79971806|NCT05214872|Diagnostic Test|laboratory parameters - complete blood count|"the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~hemoglobin (HGB) [g/dl];~red blood count (RBC) [10^12/l];~hematocrit (HCT) [l/l];~white blood cells (WBC) [10^9/l];~platelet count (PLT) [10^9/l]"
79314784|NCT02424643|Behavioral|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
79314785|NCT03142685|Device|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
79314786|NCT02424877|Procedure|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
79314787|NCT05079503|Drug|GEN-001|GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
79314788|NCT02424487|Procedure|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
79314789|NCT03141125|Other|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
79314790|NCT03141125|Other|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
79314791|NCT02427217|Biological|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
79642252|NCT00540241|Drug|Pemetrexed|in-label use
79642253|NCT00159224|Drug|Lopinavir/ritonavir simplification strategy|Simplification
79806812|NCT04016519|Other|Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
79314792|NCT02426983|Device|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
79314793|NCT02426983|Drug|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
79314794|NCT02426827|Device|Spinal Cord Stimulation|
79314795|NCT05078801|Procedure|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
79314796|NCT05078801|Procedure|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
79314797|NCT03183583|Procedure|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
79314798|NCT03141047|Other|Lifespan Integration|A protocol based psychological treatment method
79314799|NCT03183349|Procedure|deprotienized bovine bone (tutogen)|
79314800|NCT03183349|Procedure|platelet rich fibrin|
79314801|NCT03142763|Other|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
79314802|NCT03142763|Dietary Supplement|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
79314803|NCT03183271|Radiation|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
79314804|NCT03183193|Other|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
79314805|NCT03183193|Other|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
79314806|NCT05653505|Other|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
79314807|NCT03179059|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
79806813|NCT02672345|Drug|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
79314808|NCT03179059|Diagnostic Test|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
79806814|NCT02537483|Drug|IDP-120 Gel|Investigational Product: IDP-120 Gel
79971807|NCT05214872|Other|body mass index (BMI) [kg/m^2] calculation|body mass index (BMI) [kg/m^2] was calculated by dividing a person's weight (post-HD weight in HD group) [kg] by the squared their body height [m]
79314809|NCT05078645|Device|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
79314810|NCT02426593|Device|IMED-4|Non-invasive novel lung hydration status sensor.
79642254|NCT00540280|Radiation|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
79806815|NCT02537483|Drug|IDP-120 Component A|Comparator Product: IDP-120 Component A
79314811|NCT05078567|Device|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
79314812|NCT02426515|Device|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
79314813|NCT05081765|Drug|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
79806816|NCT02537483|Drug|IDP-120 Component B|Comparator Product: IDP-120 Component B
79314814|NCT05081765|Device|Lynparza|correlation between C through and taken drug
79642255|NCT00540319|Behavioral|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
79806817|NCT02537483|Drug|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
79971808|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (1)|"Serum concentration of:~advanced glycation ends products (AGE) [µg/mg protein];~3-nitrotyrosine (3-NT) [µmol/mg protein];~advanced oxidation protein products (AOPP) [µmol/mg protein];~carboxymethyle(lysine) (CML) [µg/mg protein]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China."
79971809|NCT05214872|Diagnostic Test|metalloproteinases|"metalloproteinases in the serum [ng/ml]:~metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R&D Systems, Canada;~tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R&D Systems, Canada;~the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration."
79314815|NCT04482829|Drug|Jing-yan-kang Granule|Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
79314816|NCT04482829|Drug|PC chemotherapy and symptomatic treatment|"Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used."
79314817|NCT02426359|Drug|Q301 Cream|
79642256|NCT00540397|Drug|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
79642257|NCT00183924|Drug|Estramustine|
79642258|NCT00183924|Drug|Docetaxel|
79642259|NCT00183924|Drug|Carboplatin|
79642260|NCT00159302|Procedure|Induced Sputum|
79642261|NCT00159302|Procedure|Exhaled Nitric Oxide|
79642262|NCT00159302|Procedure|Nasal Nitric Oxide|
79642263|NCT00159302|Procedure|Blood Tests|
79642264|NCT00159302|Procedure|24hr Urine Samples|
79642265|NCT00159302|Procedure|Exhaled Breath Condensate|
79806818|NCT02537249|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
79806819|NCT02537249|Drug|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
79806820|NCT04100369|Diagnostic Test|laboratory|Arm
79806821|NCT00644111|Drug|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
79806822|NCT00644111|Drug|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
79806823|NCT04016441|Other|Survey|Participants will complete a survey online
79806824|NCT02673827|Other|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
79314818|NCT02426359|Drug|Placebo|
79314819|NCT05078177|Drug|Rituximab|All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
79806825|NCT00644891|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
79806826|NCT00644891|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
79806827|NCT02670863|Other|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
79806828|NCT02670863|Other|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
79806829|NCT04178057|Biological|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
79806830|NCT04178057|Biological|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
79806831|NCT04178057|Biological|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
79314820|NCT03183427|Diagnostic Test|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
79314821|NCT05387369|Drug|Paxlovid|The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
79806832|NCT04178057|Biological|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
79806833|NCT02672189|Behavioral|EVA-Online|Internet-based cognitive behavioral therapy
79314822|NCT05387213|Behavioral|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
79314823|NCT05387135|Device|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
79314824|NCT05080985|Procedure|TPVB|20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
79642266|NCT00159302|Procedure|Spirometry|
79971810|NCT05214872|Diagnostic Test|parameters of lipids metabolism in the serum|"total cholesterol (T-C) [mg/dl] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~low-density lipoprotein cholesterol (LDL-C) [mg/dl] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~high-density lipoprotein cholesterol (HDL-C) [mg/dl] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~triglycerides (TG) [mg/dl] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C [mg/dl] = total cholesterol (T-C) [mg/dl]- HDL-C [mg/dl]- TG[mg/dl]/5)."
79806834|NCT04177043|Diagnostic Test|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
79806835|NCT04177043|Drug|DAAs|Treatment with different regiments with DAAs
79806836|NCT04177979|Behavioral|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
79806837|NCT02671877|Procedure|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
79806838|NCT04097327|Other|Ectoin Dermatitis Cream 7% (EHK02)|Application of Ectoin Dermatitis Cream in accordance with the instructions for use
79314825|NCT05080985|Procedure|ESPB|20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
79806839|NCT04175951|Device|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
79806840|NCT04175795|Behavioral|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
79314826|NCT05080985|Drug|Bupivacain|20 ml 0.375 % bupivacaine was injected
79971811|NCT05214872|Diagnostic Test|parameters of iron metabolism|"iron concentration [mg/dl] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~total iron-binding capacity (TIBC) [mg/dl] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~the unsaturated iron-binding capacity (UIBC) [mg/dl] was determined by an equation in which iron concentration in plasma is subtracted from TIBC [mg/dl];~ferritin [ng/ml] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA."
79314827|NCT05080829|Diagnostic Test|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
79314828|NCT05258591|Device|Axem Home|Rehabilitation system comprised of functional near-infrared spectroscopy headband (measuring from the motor cortex), as well as tablet-based software application (guiding stroke survivors through rehabilitation exercises for their hands/arms).
79314829|NCT03139643|Other|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
79314830|NCT03139643|Other|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
79314831|NCT03139643|Other|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
79314832|NCT05072171|Procedure|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
79314833|NCT03139487|Drug|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
79314834|NCT03139487|Drug|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
79314835|NCT03139487|Drug|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
79314836|NCT03139253|Drug|amoxicillin|amoxicillin 1000 mg bid. for 14 days
79314837|NCT03139253|Drug|clarithromycin|clarithromycin 500 mg bid. for 14 days.
79314838|NCT03139253|Drug|tinidazole|tinidazole 500 mg bid. for 14 days.
79314839|NCT03139253|Drug|levofloxacin|levofloxacin 500 mg qd. for 14 days.
79314840|NCT03139253|Drug|furazolidone|furazolidone 100 mg bid. for 14 days.
79314841|NCT03139253|Drug|tetracycline|tetracycline 750 mg bid. for 14 days.
79314842|NCT03139253|Drug|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
79314843|NCT03139409|Procedure|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
79314844|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
79971812|NCT05214872|Diagnostic Test|selected inflammatory markers|"high-sensitivity C-reactive protein (hsCRP) [mg/l] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~neopterin [nmol/l] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~interleukin 18 (IL-18) [pg/ml] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R&D Inc., USA."
79971813|NCT05214872|Device|carotid intima-media thickness (IMT)|"carotid intima-media thickness (IMT) [mm] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC)."
79806841|NCT04175717|Other|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
79806842|NCT02671487|Behavioral|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
79806843|NCT04177667|Dietary Supplement|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
79642267|NCT00540553|Drug|placebo|
79806844|NCT04177667|Other|Placebo|Treatment with placebo for Placebo Arm
79806845|NCT04177745|Other|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
79806846|NCT04177745|Other|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
79806847|NCT02671955|Drug|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
79314845|NCT02019472|Biological|adalimumab 40 mg|SC injections
79806848|NCT02670785|Drug|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
79314846|NCT02019472|Biological|sirukumab 100 mg|SC injections
79314847|NCT02019472|Biological|sirukumab 50 mg|SC injections
79314848|NCT02019472|Drug|Placebo|SC injections
79476908|NCT01973036|Drug|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
79806849|NCT02670785|Drug|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
79806850|NCT04092413|Device|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
79971814|NCT05214872|Device|non-invasive cardiological examinations|"For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) [beats per minute [bpm]]; ejection duration (ED) [millisecons]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) [mm Hg]; peripheral mean arterial pressure (pMAP) [mm Hg]; peripheral end-systolic pressure (pESP) [mm Hg]; central systolic (cSBP) and diastolic blood pressure (cDBP) [mm Hg]; central mean arterial pressure (cMAP) [mm Hg]; central augmented pressure (cAP) [mmHg]; central mean pressure of diastole (cMPD)[mm Hg]; central mean pressure of systole (cMPS) [mm Hg]; central end-systolic pressure (cESP) [mm Hg]."
79642268|NCT00540553|Drug|GSK971086|
79642269|NCT00540631|Biological|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~to be det. A 0.1 100 TU~7 (+7) days later A 0.2 200 TU~7 (+7) days later A 0.4 400 TU~7 (+7) days later A 0.6 600 TU~7 (+7) days later B 0.1 1000 TU~7 (+7) days later B 0.2 2000 TU~7 (+7) days later B 0.4 4000 TU~7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~to be det. A 0.1 100 TU~7 (+7) days later A 0.2 200 TU~7 (+7) days later A 0.4 400 TU~7 (+7) days later A 0.6 600 TU~7 (+7) days later B 0.1 1000 TU~7 (+7) days later B 0.2 2000 TU~7 (+7) days later B 0.4 4000 TU~7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
79806851|NCT04176809|Other|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
79806852|NCT02670395|Drug|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
79806853|NCT02670395|Drug|Placebo|Placebo solution will be administered orally.
79806854|NCT02670317|Drug|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
79314849|NCT05095649|Biological|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
79314850|NCT03140891|Device|NHFOV|NHFOV is used as the noninvasive mode after extubation
79314851|NCT03140891|Device|NCPAP|NCPAP is used as the noninvasive mode after extubation
79314852|NCT04587245|Other|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
79314853|NCT05092061|Other|Moderate-repetition resistance training|Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
79806855|NCT02670317|Drug|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
79806856|NCT02670317|Drug|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
79971815|NCT05214872|Device|vessel stiffness assessment|"The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~reflection index (RI) [in percentages [%]];~vascular stiffness index (SI) [m/s];~peripheral pulse pressure (pPP) [mm Hg];~central puls pressure (cPP) [mm Hg]~peripheral pulse pressure/central pulse pressure (pPP/cPP ratio)."
79642270|NCT00540670|Drug|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
79642271|NCT00540670|Drug|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
79642272|NCT00540670|Drug|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
79314854|NCT05092061|Other|High-repetition resistance training|Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
79314855|NCT00157937|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
79314856|NCT00157937|Drug|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
79642273|NCT00540670|Drug|Placebo|Placebo (tablet) taken orally, once a day.
79971816|NCT05214872|Other|cardiovascular (CV)-related death recording during 2-year follow-up|During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
79314857|NCT03139565|Biological|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
79314858|NCT03139565|Biological|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
79314859|NCT04566185|Other|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
79476909|NCT02017093|Device|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
79642274|NCT00183573|Behavioral|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
79971817|NCT05214872|Diagnostic Test|glucose (Glu)|glucose (Glu) [mg/dl] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
79971818|NCT05214872|Diagnostic Test|klotho|klotho [ng/ml] - was analyzed in the serum by Human KL(Klotho) [ng/ml] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
79971819|NCT05214872|Diagnostic Test|fibroblast growth factor 23 (FGF-23)|FGF-23 [pg/ml] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
79642275|NCT00183573|Behavioral|Brief Informational Intervention|15 minute informational DVD on safer sex
79642276|NCT00183573|Behavioral|Intensive Informational Intervention|4-hour, information-only intensive group workshop
79642277|NCT00183573|Behavioral|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
79642278|NCT00183885|Drug|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
79642279|NCT05090293|Behavioral|Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)|A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.
79642280|NCT05090293|Behavioral|Lifestyle Intervention (LI)|A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
79314860|NCT04566185|Other|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
79642281|NCT00540709|Drug|Insulin Glargine|
79314861|NCT04566185|Other|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 *, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
79314862|NCT03139175|Device|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
79314863|NCT03139331|Drug|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
79314864|NCT03139331|Drug|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
79314865|NCT03139331|Drug|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
79314866|NCT04423601|Drug|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
79314867|NCT04423601|Drug|Itraconazole capsule|200 mg itraconazole was administered in the morning.
79314868|NCT04418141|Drug|CN1|Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
79642282|NCT00540748|Drug|oxytocin|5 U i.v. during surgical abortion
79642283|NCT00540787|Device|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
79642284|NCT00540787|Drug|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
79642285|NCT00540787|Device|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
79314869|NCT04345991|Drug|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
79314870|NCT03139019|Behavioral|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
79642286|NCT00159380|Drug|Aminoguanidine|500mg
79314871|NCT03139019|Behavioral|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
79314872|NCT03139019|Behavioral|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
79314873|NCT04085705|Diagnostic Test|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
79314874|NCT04902287|Behavioral|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
79314875|NCT04880759|Other|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
79642287|NCT00159380|Drug|Placebos|2ml
79642288|NCT00190398|Device|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
79642289|NCT00540826|Drug|Atomoxetine|in-label use
79642290|NCT00540826|Drug|stimulants (any approved ADHD medication)|in-label use
79642291|NCT00540865|Behavioral|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
79642292|NCT00540865|Behavioral|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
79642293|NCT00540904|Drug|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
79314876|NCT04877405|Other|No intervention|This observational study is not focused on therapeutic intervention
79314877|NCT03495479|Drug|OMN54|Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
79314878|NCT03140813|Drug|AZD7325 (High-Dose)|15mg PO BID
79314879|NCT03140813|Drug|AZD7325 (Low-Dose)|5mg PO BID
79314880|NCT03140813|Drug|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
79314881|NCT04792931|Other|description of adult autoimmune myopathies|description of adult autoimmune myopathies
79314882|NCT02936687|Drug|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure ~8-15 mmHg that is within the range observed during exercise.
79476910|NCT02017093|Device|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
79476911|NCT02835677|Behavioral|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
79642294|NCT00540904|Drug|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
79642295|NCT00540943|Drug|Pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
79971820|NCT05214872|Diagnostic Test|parameters of calcium and phosphate metabolism|"total and ionized calcium [mg/dl],~phosphate [mg/dl],~intact parathormone (iPTH) [mg/dl]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
79314883|NCT02936687|Drug|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
79642296|NCT00540943|Drug|Cetuximab|"Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline"
79971821|NCT05214872|Diagnostic Test|liver enzymes activity assessment|"activity of:~alanine transaminase (ALT) [U/l];~aspartate transaminase (AST) [U/l];~alkaline phosphatase (ALP) [U/l]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
79642297|NCT00540943|Drug|Irinotecan|Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
79642298|NCT00159458|Drug|Gemcitabine and oxaliplatin|
79642299|NCT02963259|Device|SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system|Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
79642300|NCT00541021|Drug|gemcitabine hydrochloride|
79971822|NCT05214872|Diagnostic Test|total protein and albumin|"total protein (TP) [g/dl];~albumin (ALB) [g/dl]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
79971823|NCT05214872|Diagnostic Test|creatinine and urea|"creatinine in the serum [mg/dl] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~urea [mg/dl] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
79971824|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (2)|myeloperoxidase (MPO) [ng/ml] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R&D Systems kit, Canada.
79971825|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (3) sRAGE|soluble receptor for advanced glycation end products (sRAGE) [µg/mg protein] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R&D Systems kit, Canada.
79971826|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups|"methylglyoxal (MG) [µg/mg protein];~carboxyethyle(lysine) (CEL) [µg/mg protein];~carbamyl protein groups [µg/mg protein] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA."
79971827|NCT05214872|Diagnostic Test|selected electrolytes assessment|"potassium (K) [mmol/l];~sodium (Na) [mmol/l];~magnesium (Mg) [mg/dL]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
79971828|NCT05214872|Diagnostic Test|NT-pro-brain natriuretic peptide (NT-proBNP)|NT-proBNP [fmol/ml] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
79642301|NCT00541021|Drug|sorafenib tosylate|
79642302|NCT00541060|Genetic|mutation|a mutation of a gene coding
79642303|NCT00541138|Drug|carboplatin|CBDCA AUC=3
79642304|NCT00541138|Drug|tamoxifen citrate|Tamoxifen 100mg bid
79642305|NCT00541138|Drug|topotecan hydrochloride|Topotecan 0.75 g/m2/d
79642306|NCT00541138|Other|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
79642307|NCT00159497|Device|porous coated Trilogy®|THA
79314884|NCT02936687|Drug|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
79314885|NCT02936687|Device|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
79806857|NCT04088825|Other|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
79806858|NCT04175561|Other|Green prescription|Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
79806859|NCT04033133|Device|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
79314886|NCT02936687|Device|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
79806860|NCT00644501|Drug|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
79806861|NCT00644579|Drug|bLAC|bLAC high and low dose and placebo
79806862|NCT00644579|Drug|Placebo|Placebo
79806863|NCT02670239|Procedure|normothermic ex vivo lung perfusion|
79314887|NCT02936687|Other|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
79642308|NCT00159497|Device|Trilogy Calcicoat®|THA
79806864|NCT04077593|Device|RRate Mobile app|Test respiratory rate with RRate application
79806865|NCT05143697|Behavioral|Wellness Coaching for Families and Kids|The investigators propose to conduct a cluster-randomized pragmatic trial in 50 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 25 intervention or 25 usual care + attention control (enrolling 10,800 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
79806866|NCT02671565|Drug|Hyaluronic Acid injections|
79806867|NCT04087889|Biological|HB-adMSCs|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
79314888|NCT02936687|Drug|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
79314889|NCT04728737|Other|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
79642309|NCT00541177|Drug|atropine|0.25% atropine
79642310|NCT00541177|Drug|tropicamide|0.5% tropicamide
79314890|NCT04728737|Other|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
79314891|NCT04728737|Other|neuromuscular electrical stimulation (NMES) therapy|"The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)"
79314892|NCT04722809|Drug|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
79314893|NCT04722809|Other|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
79314894|NCT04722809|Other|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
79806868|NCT00910325|Procedure|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
79314895|NCT04722809|Other|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
79806869|NCT02669927|Other|Observational|
79314896|NCT04722809|Other|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
79806870|NCT02671721|Other|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
79806871|NCT02671721|Other|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
79806872|NCT02537093|Behavioral|Psychiatric Consultation|
79806873|NCT02671409|Other|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
79806874|NCT05143463|Drug|NS101 IV infusion|Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
79806875|NCT02669771|Drug|enzalutamide|oral
79314897|NCT04722809|Other|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
79314898|NCT05083793|Drug|Pregabalin 150mg|The effect of pregabalin on post-operative pain
79314899|NCT05083793|Other|Placebo|patients will receive placebo one hour before operation
79314900|NCT03139097|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79642311|NCT02963298|Procedure|Continuous renal replacement therapy|
79642312|NCT00541216|Drug|Ephedrine|
79642313|NCT00541333|Drug|Copaxone Injection|
79806876|NCT02537405|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
79806877|NCT02537405|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
79806878|NCT02668445|Other|Standard meal containing low or high carbohydrate content|
79806879|NCT02668367|Drug|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
79642314|NCT00158912|Device|Implantable Cardioverter Defibrillator|
79314901|NCT04561193|Other|Observational|Observational
79314902|NCT03140657|Drug|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
79971829|NCT05214872|Other|estimated glomerular filtration rate (eGFR) calculation|eGFR [ml/min/1.73m^2] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x [creatinine concentration in mg/dl] - 1.154 x [age in years] - 0.203 x [0.724] for the female gender.
79642315|NCT00541372|Device|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
79971830|NCT01195571|Biological|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
79971831|NCT01330095|Dietary Supplement|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
79971832|NCT01197989|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
79971833|NCT01197989|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
79971834|NCT03219372|Drug|Pravastatin Pill|statin
79971835|NCT03219372|Drug|Placebo Oral Tablet|placebo
79971836|NCT02427867|Other|Remote ischemic preconditioning|
79971837|NCT02427867|Other|no ischemic preconditioning|
79971838|NCT05668247|Other|FOOT BATH|In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.
79971839|NCT03628040|Drug|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
79971840|NCT03628040|Drug|Normal saline|Normal saline will be injected in the erector spinae plane
79314903|NCT03140657|Drug|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
79314904|NCT04427345|Other|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
79642316|NCT00408759|Behavioral|hypnosis|
79642317|NCT00159536|Drug|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
79971841|NCT04715763|Drug|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
79971842|NCT04715763|Drug|Placebo|Gelatin capsules filled with an inactive ingredient
79971843|NCT04487210|Biological|MVC-COV1901|MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
79971844|NCT01295411|Device|Magnetic Resonance Imaging|
79971845|NCT01295411|Other|EVALUATION NEUROPSYCHOLOGICAL|
79971846|NCT01330173|Drug|Vismodegib|Given PO
79971847|NCT01330173|Other|Pharmacological Study|Correlative studies
79476912|NCT02310776|Device|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
79642318|NCT00159536|Drug|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
79642319|NCT00541411|Drug|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
79642320|NCT03456973|Behavioral|Nurse AMIE|Supportive care software platform
79314905|NCT03140501|Device|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
79314906|NCT04415021|Other|Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
79314907|NCT04415021|Other|Sham Comparator: Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
79971848|NCT01330173|Other|Laboratory Biomarker Analysis|Correlative studies
79314908|NCT05083013|Diagnostic Test|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
79314909|NCT05083013|Diagnostic Test|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
79314910|NCT05083013|Radiation|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
79314911|NCT05083013|Diagnostic Test|Routine Laboratory investigations|"Arterial blood gases (ABGs)~Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
79314912|NCT05083013|Diagnostic Test|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
79314913|NCT05082623|Other|Music|Music medicine
79314914|NCT05082623|Other|Earplug|Earplug with noise cancelling
79642321|NCT00541489|Drug|Naproxcinod|750 mg, bid
79314915|NCT04139837|Behavioral|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
79642322|NCT00541489|Drug|Naproxen|500 mg, bid
79642323|NCT00541489|Drug|Placebo|bid
79642324|NCT00190437|Drug|Amoxicillin-clavulanic|Amoxicillin-clavulanic
79971849|NCT03848741|Behavioral|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
79971850|NCT03848741|Behavioral|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
79314916|NCT03111017|Other|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
79642325|NCT00159575|Drug|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
79642326|NCT00541567|Drug|ibipinabant|oral, tablet, once daily
79642327|NCT00541606|Other|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
79642328|NCT00541606|Other|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
79642329|NCT00408798|Drug|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
79971851|NCT03848741|Dietary Supplement|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
79971852|NCT03848741|Dietary Supplement|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
79971853|NCT03356626|Device|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
79971854|NCT03356626|Device|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
79971855|NCT03356626|Device|Thunderbeat|to use Thunderbeat when performing gastrectomy
79971856|NCT04540458|Other|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
79971857|NCT04540458|Other|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
79314917|NCT02705755|Drug|TD-9855|Administered orally.
79314918|NCT02705755|Drug|Placebo|Administered orally.
79642330|NCT00541723|Drug|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
79642331|NCT00541723|Drug|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
79642332|NCT00159614|Drug|KW-3902IV|
79971858|NCT01295489|Other|Laboratory Biomarker Analysis|Correlative studies
79971859|NCT04361266|Device|Rotium nanoscaffold|Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
79971860|NCT04361266|Procedure|Control arm rotator cuff repair|Standard rotator cuff repair without Rotium
79971861|NCT04659746|Device|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
79971862|NCT04338828|Drug|Nitric Oxide Gas|Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
79314919|NCT05073653|Diagnostic Test|68Ga-PSMA PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
79806880|NCT02668367|Drug|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
79314920|NCT05073653|Diagnostic Test|68Ga-GRP PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
79314921|NCT02024932|Drug|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
79806881|NCT02671253|Procedure|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
79971863|NCT04338828|Other|Inhaled Supplemental Oxygen|2 L/min oxygen therapy
79971864|NCT01295567|Drug|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
79314922|NCT02024932|Drug|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
79314923|NCT02034149|Behavioral|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
79476913|NCT02310776|Device|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
79476914|NCT02017327|Drug|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
79476915|NCT02017327|Drug|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
79476916|NCT02017327|Drug|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
79476917|NCT02837237|Drug|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
79314924|NCT02034149|Behavioral|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
79476918|NCT02923271|Device|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
79314925|NCT02034149|Behavioral|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
79314926|NCT02420899|Drug|rosuvastatin|10mg/d or 20mg/d,po
79314927|NCT03179137|Other|Standard therapy|Patients with therapy prescribed independent of the study
79314928|NCT05042141|Dietary Supplement|KOVIR oral capsule|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
79314929|NCT05042141|Dietary Supplement|Placebo oral capsule|Placebo
79314930|NCT02426203|Procedure|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
79314931|NCT03194165|Biological|Dolutegravir|Dosage
79476919|NCT02018107|Diagnostic Test|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
79642333|NCT00541762|Dietary Supplement|Fat perfusion to the small intestine|"Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~Orlistat perfused to the small intestine~DEXLOX as CCK-1 receptor antagonist"
79642334|NCT00541801|Device|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
79642335|NCT00541840|Drug|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
79642336|NCT00190476|Drug|Weekly docetaxel alone|
79642337|NCT00190476|Drug|Weekly docetaxel + cisplatin combination|
79314932|NCT03194165|Biological|Raltegravir|Dosage
79314933|NCT03194165|Biological|Rilpivirine|Dosage
79314934|NCT03194165|Biological|Nevirapine|Dosage
79314935|NCT03194165|Biological|Atazanavir|Dosage
79476920|NCT02018107|Diagnostic Test|PET scan|PET scan
79476921|NCT02314598|Other|No treatment|
79476922|NCT02018653|Drug|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
79476923|NCT02018653|Other|Placebo|1 by mouth every 6 hours for up to 6 days.
79806882|NCT04175171|Drug|Coprelotamab Injection|The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
79806883|NCT04175171|Drug|Trastuzumab Injection|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
79971865|NCT01295567|Drug|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
79642338|NCT00159653|Drug|Xalacom|
79314936|NCT03194165|Biological|Darunavir|Dosage
79314937|NCT03194165|Biological|Ritonavir|Dosage
79314938|NCT02426437|Other|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
79314939|NCT02426437|Other|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
79314940|NCT03117205|Other|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
79314941|NCT03117205|Other|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
79314942|NCT04065113|Procedure|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
79314943|NCT04065113|Procedure|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
79314944|NCT03178903|Other|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
79314945|NCT03178903|Other|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
79314946|NCT03178903|Behavioral|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
79314947|NCT05005871|Other|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
79314948|NCT02425969|Procedure|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
79314949|NCT02425969|Drug|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
79314950|NCT04029155|Device|Lung biopsy|Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
79642339|NCT00159653|Drug|Xalatan|
79314951|NCT03116737|Drug|Benzocaine Otic Solution|
79314952|NCT03116737|Drug|Placebo|
79314953|NCT02426047|Dietary Supplement|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
79971866|NCT04656080|Behavioral|CPET exercise testing|"The cardiopulmonary exercise testing (CPET) is done.~EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
79314954|NCT04910243|Other|Questionnaire Survey|Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
79314955|NCT03116659|Drug|Doxycycline|Doxycycline 100 mg PO BID x 14 days
79314956|NCT03116659|Drug|Imiquimod|up to 2 packs 3/ week x 28 days
79314957|NCT04889573|Genetic|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
79314958|NCT01993888|Biological|EVARREST® Fibrin Sealant Patch|
79314959|NCT01993888|Other|Standard of Care (SoC)|
79314960|NCT02425813|Drug|Budesonide|Given PO
79314961|NCT02425813|Drug|Methylprednisolone Sodium Succinate|Given IA and IV
79642340|NCT00159653|Drug|Timolol|
79642341|NCT00541879|Behavioral|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
79642342|NCT00541879|Other|comparison|
79642343|NCT00541918|Drug|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
79642344|NCT00541918|Drug|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
79642345|NCT00541957|Behavioral|behavior therapy|10 sessions over 4 months
79642346|NCT00541957|Drug|Medication prescribed by PCP|Can include any antidepressant medication
79642347|NCT00190515|Drug|5FU+l-leucovorin|5FU+l-leucovorin
79642348|NCT00190515|Drug|UFT+Leucovorin|UFT+Leucovorin
79642349|NCT00541996|Drug|vabicaserin|
79642350|NCT00159692|Drug|Amlodipine|
79971867|NCT03474354|Device|chemoembolization|correlation of necrosis with the deposition of beads
79806884|NCT04175093|Diagnostic Test|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
79971868|NCT03848585|Device|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
79971869|NCT03848585|Other|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
79314962|NCT04862429|Other|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
79314963|NCT04862429|Other|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
79314964|NCT03181555|Other|Exploratory|
79314965|NCT04852133|Other|Burn subjects|see eligibility criteria
79314966|NCT04683562|Other|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
79806885|NCT02669693|Dietary Supplement|bread without olives|
79806886|NCT02669693|Dietary Supplement|bread with olives|
79806887|NCT04176653|Drug|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
79971870|NCT01192529|Dietary Supplement|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
79971871|NCT01192529|Dietary Supplement|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
79314967|NCT04683562|Other|at delivery|women delivered at term
79314968|NCT04804787|Diagnostic Test|Carrying out a tests and questionnaires battery|The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders
79971872|NCT02351284|Other|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
79971873|NCT01195649|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
79476924|NCT02018653|Behavioral|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
79476925|NCT02923895|Other|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
79476926|NCT02923895|Other|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
79476927|NCT01973348|Device|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
79476928|NCT01973348|Device|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
79476929|NCT01973348|Device|2-hour patching|2-hour patching for moderate amblyopia
79806888|NCT00645125|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
79476930|NCT01973348|Device|6-hour patching|6-hour patching for severe amblyopia
79476931|NCT02925143|Other|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
79971874|NCT02226796|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
79971875|NCT03056690|Drug|ASP0819|Oral capsule
79806889|NCT00645125|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
79806890|NCT04175405|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
79806891|NCT02669459|Drug|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
79971876|NCT03056690|Drug|Placebo|Oral capsule
79971877|NCT04895267|Device|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
79971878|NCT03846557|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
79971879|NCT03191799|Drug|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
79307912|NCT04874727|Procedure|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
79307913|NCT02452385|Drug|CM082 tablet|CM082 tablets taken orally
79476932|NCT02018809|Behavioral|Medication Adherence Partner|
79476933|NCT02018809|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
79476934|NCT02838407|Other|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
79476935|NCT02838407|Other|Nasopharyngeal swab sampling|1 swab, Day 0
79476936|NCT02020135|Drug|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
79806892|NCT02669459|Procedure|LLETZ|surgical treatment for CIN, current gold standard
79806893|NCT04176887|Drug|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
79971880|NCT03845309|Behavioral|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
79314969|NCT03116581|Other|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.~Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.~Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
79314970|NCT03116581|Other|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.~Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.~Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
79642351|NCT00542074|Other|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
79971881|NCT01195727|Drug|Apixaban|
79971882|NCT03848507|Drug|albumin 20%|Intravenous administration of 20% albumin during cystectomy
79642352|NCT00542074|Other|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
79806894|NCT04176887|Drug|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
79806895|NCT04174937|Drug|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
79806896|NCT04174937|Other|Placebo PA|Intervention is administered to patients in this Arm
79806897|NCT04085471|Diagnostic Test|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
79971883|NCT04958876|Drug|SP-104|oral capsule once daily
79971884|NCT04958876|Drug|Naltrexone immediate release oral capsules|oral capsule once daily
79971885|NCT01195805|Drug|Spironolactone|1 tablet twice a day for 28 days
79642353|NCT00542113|Behavioral|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
79642354|NCT00542113|Behavioral|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
79971886|NCT01195805|Other|Placebo|1 tablet twice a day for 28 days
79971887|NCT01195805|Drug|Amiloride|1 tablet twice a day for 28 days
79642355|NCT00542113|Behavioral|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
79971888|NCT03627962|Other|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell > 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
79971889|NCT01192607|Device|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
79971890|NCT04899986|Other|Chlorhexidine and Biorepair gel and toothpaste application|Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.
79971891|NCT04899986|Other|Standard oral hygiene|Use of standard toothpastes for home oral hygiene.
79971892|NCT01192685|Procedure|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
79971893|NCT01192685|Device|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
79971894|NCT04866758|Other|Survey|All data gathered will be quantitative in nature. In addition to participant completed surveys, additional demographic, and diagnosis/treatment related information will be collected from the patient's electronic medical record via Health Data Compass. Subsequent data collected as part of the patient's standard psychosocial and cancer related care (i.e., health outcomes, future utilization of UCCC psychosocial services) will also be gathered. This subsequent data collection will not include further participation, but continued access to the patient's medical record. Protected health information collected for this project will include dates (e.g., birth dates, date of diagnosis, date since last treatment, death dates) and participant zip codes. No other identifiable data will be collected. A separate survey emailed to the participant at the end of the study will collect information regarding the participant's completion status of the survey.
79971895|NCT04709679|Procedure|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
79971896|NCT03845231|Biological|Flucelvax(R)|Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
79476937|NCT02020369|Biological|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
79476938|NCT02839889|Drug|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
79476939|NCT02839889|Drug|Placebo|Placebo once daily for two weeks, followed by two week open-label period
79476940|NCT02012582|Drug|VAS203|i.v. infusion
79476941|NCT02012582|Drug|Saline|i.v. infusion
79476942|NCT01971385|Drug|Squaric Acid solution|
79476943|NCT01971385|Drug|Placebo solution|
79476944|NCT01971463|Other|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
79476945|NCT02925611|Drug|Isoflurane|
79476946|NCT02925611|Drug|Desflurane|
79476947|NCT00374153|Behavioral|Feedback|Online personal feedback report
79476948|NCT00374153|Behavioral|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
79476949|NCT00374153|Behavioral|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
79971897|NCT03845231|Other|Human Challenge virus|A dose of 10^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
79971898|NCT04773704|Diagnostic Test|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
79971899|NCT05126537|Other|no intervention|prospective and observational study with no intervention
79971900|NCT04746560|Device|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
79971901|NCT03845153|Drug|Metformin Retard 850 mg|tablet
79971902|NCT03845153|Other|Placebo|placebo tablet
79971903|NCT04619108|Biological|Thrombosomes®|
79971904|NCT00198718|Drug|Vitamin A (retinyl palmitate)|
79971905|NCT03951116|Drug|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
79971906|NCT04500808|Drug|Macitentan Dose 1|Participants will receive Dose 1 of macitentan tablet in Part 1.
79971907|NCT04500808|Drug|Macitentan Dose 2|Participants will receive Dose 2 of macitentan tablet in Part 1.
79476950|NCT00374309|Drug|VRC-EBOADV018-00-VP|
79476951|NCT02841449|Behavioral|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
79642356|NCT00542152|Drug|CYCLOSPORINE VS INFLIXIMAB|"Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~Infliximab 5mg/kg at weeks 0, 2 and 6"
79642357|NCT00159731|Drug|Pregabalin|
79476952|NCT02841449|Behavioral|Rehydrated|Participants rehydrate after the heat tent procedure
79476953|NCT01973335|Drug|Combination therapy with acetazolamide and low-dose loop diuretics|"Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~If diuresis <1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
79642358|NCT00408915|Drug|Continuous Subcutaneous Lisuride Infusion|
79642359|NCT00542347|Drug|Esomeprazole first|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
79642360|NCT00542347|Drug|Generic omeprazole first|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
79642361|NCT00542464|Biological|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
79642362|NCT00542581|Device|The Acrysof toric SN60T3 IOL|Intraocular Lens
79642363|NCT00190554|Drug|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
79642364|NCT00190554|Drug|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
79642365|NCT00159770|Drug|ziprasidone versus olanzapine , risperidone or quetiapine|
79642366|NCT00159770|Behavioral|Panss , CGI-C, UKU-SERS-Pa|
79642367|NCT00159770|Procedure|Blood tests|
79642368|NCT00542698|Behavioral|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
79642369|NCT00542737|Behavioral|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
79642370|NCT00542776|Other|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
79642371|NCT00190593|Drug|raloxifene|
79642372|NCT00190593|Drug|placebo|
79642373|NCT00542854|Device|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
79642374|NCT00542893|Drug|Genasense® (G3139, oblimersen sodium)|
79642375|NCT00542893|Drug|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
79971908|NCT04500808|Drug|Macitentan Dose 3|Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
79642376|NCT00542893|Drug|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
79806898|NCT02668523|Device|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
79806899|NCT02667899|Device|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
79971909|NCT04500808|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 13.
79971910|NCT03628274|Device|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
79971911|NCT03628274|Device|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
79971912|NCT01192763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
79971913|NCT01192763|Other|laboratory biomarker analysis|Correlative studies
79806900|NCT02667899|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
79806901|NCT02667899|Other|Routine treatment|Means without above additional treatment.
79806902|NCT02667977|Other|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
79806903|NCT02667977|Other|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
79806904|NCT05276999|Other|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
79971914|NCT01192763|Other|pharmacological study|Correlative studies
79971915|NCT01192763|Procedure|neoadjuvant therapy|
79971916|NCT01192763|Procedure|therapeutic conventional surgery|
79971917|NCT04097210|Diagnostic Test|POC|
79806905|NCT05276999|Other|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
79314971|NCT03116581|Other|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.~Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.~Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
79314972|NCT02024698|Device|omafilcon A|contact lens
79314973|NCT02024698|Device|etafilcon A|contact lens
79314974|NCT03106831|Drug|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
79314975|NCT03106831|Drug|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
79314976|NCT02425735|Biological|DC-CIK cells|DC-CIK cells will be used against tumor cells.
79314977|NCT02425735|Biological|γδ T cells|γδ T cells will be used against breast tumor.
79314978|NCT02425735|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
79642377|NCT00542932|Other|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
79642378|NCT00543010|Drug|MK0767|
79642379|NCT00184041|Drug|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
79806906|NCT00645203|Drug|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
79642380|NCT00543049|Drug|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
79642381|NCT00543049|Drug|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
79642382|NCT00190632|Drug|Duloxetine|
79806907|NCT00910403|Procedure|LASIK|Excimer Laser Ablation using LASIK
79642383|NCT00543166|Drug|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
79642384|NCT00543205|Drug|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
79642385|NCT00184080|Drug|Elsamitrusin|
79806908|NCT02669381|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
79806909|NCT02669303|Drug|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
79642386|NCT00159809|Drug|Viagra (Sildenafil citrate)|
79806910|NCT02669303|Drug|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
79971918|NCT04539548|Drug|Dextenza|Dextenza, dexamethasone ophthalmic insert
79971919|NCT04539548|Drug|Prednisolone|Prednisolone, acetate ophthalmic suspension
79476954|NCT01973335|Drug|High-dose loop diuretics|"Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~If diuresis <1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
79476955|NCT01973335|Drug|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
79806911|NCT02671019|Behavioral|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
79314979|NCT03106675|Device|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
79314980|NCT03106675|Device|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
79314981|NCT03138785|Drug|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
79314982|NCT03138785|Radiation|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
79314983|NCT02424331|Other|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
79806912|NCT00645281|Drug|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
79806913|NCT02668835|Device|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
79307914|NCT04874649|Other|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
79314984|NCT02424331|Other|Quiet Breathing|
79314985|NCT05393843|Dietary Supplement|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
79476956|NCT02844569|Device|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
79476957|NCT02844569|Device|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
79806914|NCT02668835|Genetic|Non intervention-Genetic testing|
79806915|NCT02668757|Behavioral|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
79476958|NCT02844569|Device|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
79476959|NCT01973413|Device|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
79476960|NCT01973413|Device|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
79476961|NCT01973413|Device|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
79314986|NCT05393843|Behavioral|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
79314987|NCT05393843|Other|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
79314988|NCT03106597|Drug|Manidipine 20mg|"After a 1~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
79476962|NCT02927327|Device|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
79476963|NCT02927327|Device|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
79476964|NCT02021461|Drug|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
79806916|NCT02668679|Procedure|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
79806917|NCT02668679|Device|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
79314989|NCT03106597|Drug|Amlodipine 10mg|"After a 1~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
79806918|NCT02668679|Biological|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
79314990|NCT03140267|Diagnostic Test|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
79642387|NCT04684888|Procedure|Visumax Femto-flap|"Under topical anesthesia [Tetracaine eye drop 0.5%]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy [Carl Zeiss, Meditec, Germany]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system [Carl Zeiss, Meditec, MEL 90, Germany]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards."
79642388|NCT04684888|Procedure|Sub Bowman's keratomileusis (SBK)-flap|"Under topical anesthesia [Tetracaine eye drop 0.5%] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system [Carl Zeiss, Meditec, MEL 90, Germany]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~."
79642389|NCT00543244|Drug|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: < 75 kg 1000 mg/day, >=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
79642390|NCT00190710|Drug|Gemcitabine|
79642391|NCT00190710|Drug|Carboplatin|
79642392|NCT00159848|Behavioral|Treatment Optimization Program (educational material)|
79307915|NCT04874649|Other|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
79307916|NCT03227627|Device|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
79314991|NCT03178825|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
79476965|NCT02021461|Drug|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
79642393|NCT03456661|Drug|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
79642394|NCT03456661|Drug|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
79642395|NCT05079295|Procedure|CSDH evacuation|Burr hole for chronic subdural hematomas
79806919|NCT02668679|Other|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
79806920|NCT00645437|Drug|Levofloxacin|
79806921|NCT02668133|Dietary Supplement|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
79806922|NCT02668133|Dietary Supplement|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS) added during manufacturing
79806923|NCT02668133|Dietary Supplement|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
79307917|NCT03227627|Other|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
79314992|NCT02018458|Biological|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
79314993|NCT02018458|Biological|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
79314994|NCT02017522|Device|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
79314995|NCT05393687|Other|Eccentric exercise|progressive eccentric exercise with elastic band
79314996|NCT03183505|Drug|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
79314997|NCT03183505|Drug|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
79314998|NCT02423083|Drug|Guanabenz|
79971920|NCT02517970|Behavioral|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
79971921|NCT01192841|Other|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
79314999|NCT05393531|Device|Mandibular advancement device (MAD)|Active therapy
79315000|NCT05393531|Device|Continuous positive airway pressure (CPAP)|Active therapy
79315001|NCT02017444|Drug|AZD4017|
79315002|NCT02017444|Other|Placebo|Matched placebo (matched to AZD4017 arm)
79971922|NCT00708916|Drug|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
79971923|NCT01196039|Drug|MEMP1972A|Intravenous repeating dose
79971924|NCT01196039|Drug|placebo|Intravenous repeating dose
79315003|NCT02423941|Procedure|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
79315004|NCT02423941|Procedure|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
79315005|NCT03138395|Diagnostic Test|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
79315006|NCT02421367|Biological|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
79315007|NCT05393063|Drug|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
79971925|NCT02352753|Drug|Denosumab|Subcutaneous (SC) injection.
79315008|NCT02420587|Drug|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
79315009|NCT02420587|Behavioral|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
79315010|NCT02425657|Behavioral|Training of junior doctors|Training program
79806924|NCT02668133|Dietary Supplement|1 mg isotopically enriched 68Zn|administered intravenously
79806925|NCT02668055|Biological|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
79315011|NCT03138551|Behavioral|Mealtime PREP (Promoting Routines of Exploration and Play)|
79315012|NCT03140111|Device|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
79315013|NCT03140111|Device|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
79315014|NCT02420743|Procedure|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
79315015|NCT02420743|Procedure|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
79315016|NCT02423863|Biological|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC [Hiltonol®]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
79806926|NCT02668211|Device|PROFEMUR Preserve Classic Femoral Components|
79806927|NCT02668913|Other|Diagnostic analysis|Molecular profiling
79806928|NCT04176341|Other|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
79806929|NCT02671331|Procedure|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
79806930|NCT02537171|Drug|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
79806931|NCT00645515|Drug|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
79971926|NCT01192997|Biological|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
79971927|NCT01192997|Biological|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
79971928|NCT04532294|Drug|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
79971929|NCT04532294|Drug|Placebo|Placebo to match BGB-DXP593
79971930|NCT02517736|Drug|Sorafenib at a dose of 800 mg / day|
79971931|NCT03347578|Diagnostic Test|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
79315017|NCT03178747|Diagnostic Test|Methylene blue|working solution methylene blue
79315018|NCT03178747|Diagnostic Test|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
79315019|NCT03181321|Behavioral|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
79315020|NCT02425423|Dietary Supplement|New thickened formula|
79806932|NCT00645515|Drug|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
79315021|NCT05392673|Other|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
79315022|NCT02425579|Drug|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
79315023|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
79315024|NCT02425579|Drug|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
79315025|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
79476966|NCT02021461|Drug|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
79642396|NCT03456544|Drug|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
79642397|NCT00159887|Drug|Sildenafil citrate|
79642398|NCT00543361|Drug|MK0767|Duration of Treatment: 52 Weeks
79642399|NCT00543361|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
79642400|NCT00543361|Drug|Comparator: metformin|Duration of Treatment: 52 Weeks
79642401|NCT00184158|Procedure|decompression|Conservative, simple decompression and nerve transfer
79806933|NCT00644735|Drug|Esomeprazole|
79642402|NCT00543478|Drug|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
79642403|NCT00543478|Drug|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
79642404|NCT00543517|Drug|MK0767|
79642405|NCT00159926|Procedure|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
79806934|NCT00644735|Drug|Lansoprazole|
79315026|NCT05392595|Other|Cawthrone and cooksey exercises,Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Epley repositioning maneuver will be performed, also cervical stretches and Basic Balance exercises Following Exercises will be performed by patient in next session. Caw-Thorne and Cooksey exercise program. Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
79971932|NCT03844841|Drug|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
79315027|NCT05392595|Other|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Conventional treatment: Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.~Frequency: Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
79315028|NCT03178591|Drug|vildagliptin|
79476967|NCT02927639|Other|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
79642406|NCT00159926|Procedure|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
79642407|NCT00190788|Drug|Drotrecogin Alfa (Activated)|
79971933|NCT03844841|Drug|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
79971934|NCT03197766|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
79971935|NCT03197766|Drug|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
79971936|NCT03704025|Behavioral|Current guidelines rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
79315029|NCT03178591|Drug|Dapagliflozin|
79476968|NCT02929667|Drug|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
79476969|NCT02929667|Drug|Placebo|Standard 6 weeks titration.
79476970|NCT02021929|Drug|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:~Unresectable hepatocellular carcinoma~Advanced renal cell carcinoma~Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
79476971|NCT02021929|Drug|Placebo|
79476972|NCT02848079|Drug|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
79642408|NCT00190788|Drug|placebo|
79642409|NCT00543556|Drug|MK0767|
79642410|NCT00543595|Drug|MK0916|
79642411|NCT00543634|Drug|Premarin/MPA|0.625 mg/2.5 mg X4
79971937|NCT03704025|Behavioral|Mobile device guided rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
79642412|NCT00543634|Drug|Premarin/MPA|0.625 mg/5 mg X 2
79642413|NCT00543634|Drug|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
79642414|NCT00160004|Behavioral|Intensive Controlled Exercise|
79642415|NCT00543673|Other|Milk based formula A|feed as per HCP directions
79642416|NCT00543673|Other|#2 Standard formula|Feed as per HCP directions
79642417|NCT00543673|Other|#3 Human Milk|Feed as per HCP directions
79642418|NCT00543673|Other|Milk based formula C|Feed as per HCP direction
79476973|NCT02022085|Device|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
79642419|NCT00184197|Drug|Botulinum toxin|
79642420|NCT00184197|Drug|Placebos|
79642421|NCT00543751|Drug|MK0767|
79642422|NCT00543790|Drug|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
79642423|NCT00543829|Drug|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
79806935|NCT04175015|Other|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
79806936|NCT04176263|Behavioral|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
79971938|NCT04501900|Drug|Clopidogrel|Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
79806937|NCT04176263|Behavioral|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
79971939|NCT03738332|Device|Low-Level Laser|Low-level laser therapy
79642424|NCT00543829|Drug|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
79642425|NCT00543868|Drug|MK0782|
79642426|NCT00190827|Drug|duloxetine|
79642427|NCT00190827|Drug|placebo|
79642428|NCT00543946|Drug|GAP-134|24-Hour IV infusion, SAD
79642429|NCT00160043|Drug|SH T00268C|1250 mg experimental drug od
79642430|NCT00160043|Drug|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
79642431|NCT00544063|Drug|irinotecan hydrochloride|
79642432|NCT00544063|Drug|oxaliplatin|
79642433|NCT00184236|Behavioral|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
79806938|NCT04175483|Other|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
79476974|NCT02929823|Drug|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
79476975|NCT02929823|Drug|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
79315030|NCT01993186|Drug|UX007|oral liquid
79315031|NCT01993186|Drug|Placebo|oral liquid
79315032|NCT03181243|Procedure|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
79315033|NCT03181243|Procedure|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
79315034|NCT03139955|Device|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
79315035|NCT03178435|Other|Measures to prevent AKI among critically ill patients|"Meticulous optimization of the fluid balance~Avoidance of nephrotoxic medications where possible~Optimisation of the hemodynamic status~Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~Optimization of the underlying medical condition~Seek expert renal advise when necessary"
79315036|NCT03110705|Behavioral|sport|recreaational sport : diving or multisport
79315037|NCT02420665|Drug|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
79315038|NCT02420665|Device|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
79642434|NCT00184236|Behavioral|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
79315039|NCT02420665|Behavioral|Phone Call|Study staff follow up with participant by phone one month after procedure.
79642435|NCT04684927|Device|MID-C System -Minimal invasive deformity correction system for the treatment of AIS|"A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS."
79315040|NCT02420665|Procedure|Colposcopy|Colposcopy performed after visual inspection of cervix.
79315041|NCT02420665|Drug|Acetic Acid|3 - 5% added to cervix before visual inspection.
79642436|NCT00160082|Drug|Xepol|
79642437|NCT00544180|Drug|Risedronate|
79642438|NCT00544219|Biological|rituximab|375 mg/m2 i.v. per cycle
79315042|NCT02016898|Procedure|Placement of the sponge|
79315043|NCT02016898|Drug|Mitomycin-C|
79315044|NCT04482907|Dietary Supplement|Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.|Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
79315045|NCT03110627|Device|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
79315046|NCT03110627|Device|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
79476976|NCT02929823|Drug|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
79642439|NCT00544219|Drug|cyclophosphamide|750 mg/m2 i.v. per cycle
79642440|NCT00544219|Drug|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
79642441|NCT00544219|Drug|prednisone|100 mg/day p.o. per cycle
79642442|NCT00544219|Drug|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
79642443|NCT00544219|Procedure|positron emission tomography|PET Scan during treatment
79642444|NCT00190866|Drug|Duloxetine|
79642445|NCT00190866|Drug|placebo|
79315047|NCT02416297|Procedure|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
79315048|NCT03110549|Drug|TMB-607|
79315049|NCT03110549|Drug|Placebo|
79315050|NCT02420509|Drug|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
79315051|NCT01993030|Device|HQ® Matrix Medical Wound Dressing|
79971940|NCT04501744|Drug|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
79971941|NCT04501744|Drug|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
79315052|NCT01993030|Device|Sidaiyi® wound dressing|
79315053|NCT02416531|Drug|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
79315054|NCT02416531|Radiation|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
79315055|NCT02416531|Radiation|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
79315056|NCT03138317|Biological|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
79315057|NCT03138317|Biological|Plasma|This group will receive a knee injection with 6 ml of plasma.
79315058|NCT03138317|Biological|Placebo|This group will receive a knee injection with 6 ml saline solution.
79315059|NCT04483063|Drug|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
79315060|NCT03110393|Device|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
79476977|NCT02929979|Behavioral|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
79642446|NCT00544258|Drug|PEP005|
79642447|NCT00160121|Drug|Lanthanum carbonate|
79971942|NCT04501744|Drug|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
79315061|NCT03110393|Device|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
79315062|NCT03181165|Behavioral|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
79315063|NCT05392049|Other|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
79315064|NCT05392049|Other|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
79315065|NCT02416141|Drug|fast release oro dispersible tramadol 50 mg|idem arm 1
79315066|NCT03138239|Radiation|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
79813693|NCT00818428|Behavioral|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
79315067|NCT02001233|Biological|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
79315068|NCT02420197|Behavioral|High-intensity resistance training|
79315069|NCT02420197|Behavioral|General physical activity|
79476978|NCT02929979|Behavioral|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
79476979|NCT04026529|Other|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 & 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or"
79476980|NCT02932787|Device|Height-adjustable workstation|
79476981|NCT02023411|Drug|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm
79476982|NCT02023411|Other|Placebo|Placebo
79476983|NCT02851823|Device|Periodontal curettes|
79476984|NCT02851823|Device|Er-YAG+Nd-YAG lasers|
79476985|NCT02023801|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
79476986|NCT02933879|Drug|NVXT topical|topical treatment
79476987|NCT02933879|Drug|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
79476988|NCT02068820|Device|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
79476989|NCT02068820|Device|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
79476990|NCT02855567|Device|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
79476991|NCT02856035|Other|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
79476992|NCT01975519|Drug|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
79971943|NCT04501744|Drug|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
79971944|NCT04501744|Drug|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
79476993|NCT02934191|Drug|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
79642448|NCT00544336|Other|questionnaire administration|no intervention
79642449|NCT00544336|Other|survey administration|no intervention
79315070|NCT02420197|Behavioral|Multidisciplinary rehabilitation program|
79315071|NCT05391659|Device|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
79315072|NCT05391659|Diagnostic Test|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
79315073|NCT05391659|Diagnostic Test|gold standard|examination by ophthalmologist
79315074|NCT02416219|Procedure|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
79315075|NCT02416219|Device|Ultrasound|
79315076|NCT02416063|Drug|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia"
79476994|NCT02934191|Other|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
79476995|NCT02934191|Drug|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
79642450|NCT00544336|Procedure|quality-of-life assessment|no intervention
79315077|NCT02416063|Drug|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia"
79315078|NCT02416063|Drug|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia"
79315079|NCT01828697|Drug|Low dose nadroparin|"Fixed low dose nadroparin:~< 100 kg: 2850 IU subcutaneously once-daily~100 kg and above: 3800 IU subcutaneously once-daily"
79642451|NCT00544375|Device|Optical measurement|Optical measurement neonatal tissues
79642452|NCT00160160|Drug|eprosartan/HCTZ|
79642453|NCT00544453|Drug|[123I] MNI-308|Injection of [123I] MNI-308 and SPECT scanning
79642454|NCT00544492|Device|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
79642455|NCT00544570|Biological|filgrastim|
79315080|NCT01828697|Drug|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~< 50 kg: 3800 IU subcutaneously once-daily;~50 to < 70 kg: 5700 IU subcutaneously once-daily;~70 to < 100 kg: 7600 IU subcutaneously once-daily;~100 kg or above: 9500 IU subcutaneously once-daily."
79315081|NCT01828697|Drug|Low dose enoxaparin|"Fixed low dose enoxaparin:~< 100 kg: 40 mg subcutaneously once-daily~100 kg and above: 60 mg subcutaneously once-daily"
79315082|NCT01828697|Drug|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~< 50 kg: 60 mg subcutaneously once-daily, or;~50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;~70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;~100 kg or above: 120 mg subcutaneously once-daily."
79642456|NCT00544570|Drug|carmustine|
79642457|NCT00544570|Drug|cyclophosphamide|
79642458|NCT00544570|Drug|etoposide|
79642459|NCT00544570|Drug|melphalan|
79642460|NCT00544570|Procedure|autologous hematopoietic stem cell transplantation|
79642461|NCT00544570|Procedure|peripheral blood stem cell transplantation|
79642462|NCT00544570|Radiation|radiation therapy|
79813694|NCT00818428|Behavioral|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
79813695|NCT00818428|Behavioral|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
79315083|NCT01828697|Drug|Low dose dalteparin|"Fixed low dose dalteparin:~< 100 kg: 5000 IU subcutaneously once-daily~100 kg and above: 7500 IU subcutaneously once-daily"
79315084|NCT01828697|Drug|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~< 50 kg: 7500 IU subcutaneously once-daily, or;~50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;~70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;~100 kg or above: 15000 IU subcutaneously once-daily."
79315085|NCT01828697|Drug|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~< 100 kg: 3500 IU subcutaneously once-daily~100 kg and above: 4500 IU subcutaneously once-daily"
79476996|NCT02934191|Drug|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
79476997|NCT02934347|Procedure|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
79476998|NCT01975909|Device|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
79476999|NCT02937623|Device|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight[w/w] calcium sodium phosphosilicate).
79477000|NCT01977547|Biological|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
79642463|NCT00544570|Radiation|total-body irradiation|
79642464|NCT00190905|Drug|duloxetine HCl|
79642465|NCT00544609|Drug|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
79642466|NCT00544609|Procedure|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
79642467|NCT00544687|Drug|CRx-191|topical (mometasone furoate + nortriptyline HCl)
79642468|NCT00544687|Drug|mometasone furoate|topical mometasone furoate
79642469|NCT00544687|Drug|nortriptyline HCl|topical nortriptyline HCl
79642470|NCT00544687|Drug|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
79642471|NCT00544687|Drug|Vehicle|topical (placebo)
79642472|NCT00544726|Behavioral|Physical training|
79642473|NCT00544726|Behavioral|No training|
79642474|NCT00160238|Drug|Betahistine 24 mg bid (Betaserc)|
79813696|NCT04025970|Genetic|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
79315086|NCT01828697|Drug|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~< 50 kg: 4500 IU subcutaneously once-daily, or;~50 kg to < 70 kg: 7000 IU subcutaneously once-daily, or;~70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;~100 kg or above: 12000 IU subcutaneously once-daily."
79315087|NCT02420275|Other|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
79315088|NCT02420275|Device|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
79477001|NCT02864069|Behavioral|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
79477002|NCT02864069|Behavioral|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
79477003|NCT02864069|Behavioral|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
79642475|NCT00544765|Drug|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
79642476|NCT00544765|Drug|NX|Vinorelbine 25 mg/m² as a < 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
79642477|NCT00544804|Drug|lapatinib ditosylate|
79642478|NCT00544804|Genetic|gene expression analysis|
79642479|NCT00544804|Other|diagnostic laboratory biomarker analysis|
79315089|NCT02419963|Procedure|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
79315090|NCT02419963|Other|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
79315091|NCT02419963|Other|Stool Sample|Stool sample to evaluate microbiome fingerprint.
79315092|NCT02415985|Drug|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
79477004|NCT02013050|Drug|SGX942|
79477005|NCT02013050|Drug|Placebo|
79477006|NCT01977781|Drug|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
79477007|NCT01977781|Drug|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
79813697|NCT00817180|Other|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
79971945|NCT04501744|Drug|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
79971946|NCT04501744|Drug|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
79971947|NCT01196195|Drug|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
79971948|NCT01196195|Drug|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
79642480|NCT00544921|Drug|GLY-230|
79971949|NCT01330329|Behavioral|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
79971950|NCT01330329|Behavioral|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
79971951|NCT03637556|Drug|DST-0509|Novel iron chelator with improved absorption characteristics
79642481|NCT00544921|Other|Placebo|No drug administered
79971952|NCT03637556|Drug|Jadenu|Commercial iron chelator with standard absorption characteristics
79813698|NCT00817180|Other|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
79971953|NCT03637556|Drug|Exjade|Commercial iron chelator with standard absorption characteristics
79971954|NCT04501510|Diagnostic Test|Ultrasonographic examination validation and testing|X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
79971955|NCT01330407|Procedure|cryopreserved skin allografts.|
79971956|NCT01330407|Procedure|Cultured Epidermal Autografts|
79971957|NCT04069910|Other|Quality-of-Life Assessment|Ancillary studies
79642482|NCT00160277|Drug|Moxonidine|
79642483|NCT02963181|Drug|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
79642484|NCT02963181|Drug|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
79642485|NCT00544999|Drug|cytarabine|
79642486|NCT00544999|Drug|daunorubicin hydrochloride|
79642487|NCT00544999|Drug|everolimus|
79642488|NCT00544999|Other|laboratory biomarker analysis|
79813699|NCT00817258|Drug|cisplatin|Cisplatin 40mg/m2,weekly
79971958|NCT04069910|Other|Questionnaire Administration|Ancillary studies
79315093|NCT02415985|Drug|Rifabutin|
79315094|NCT02415907|Drug|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 ([ethyl-1-14C]-idalopirdine) in one capsule for oral administration, single dose
79477008|NCT02938169|Behavioral|exercise|"stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise: treadmill gait with tolerable gait speed~flexibility exercise: stretching exercise(control)"
79477009|NCT04012411|Procedure|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
79642489|NCT00544999|Other|pharmacological study|
79642490|NCT00545116|Other|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
79642491|NCT04684771|Dietary Supplement|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
79642492|NCT04684771|Dietary Supplement|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
79642493|NCT00160316|Drug|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
79642494|NCT00545194|Drug|Prostaglandin E2|
79642495|NCT00190944|Drug|Teriparatide|
79813700|NCT00817258|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
79813701|NCT00794820|Drug|Fludarabine Phosphate|25 mg/m^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
79813702|NCT00794820|Drug|Cyclophosphamide|250 mg/m^2 by vein over 60 minutes daily for 3 days (days 2-4)
79813703|NCT00794820|Drug|Rituximab|375 mg/m^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m^2 on days 2-3
79971959|NCT04069910|Radiation|Stereotactic Radiosurgery|Undergo SRS/SRT
79971960|NCT04069910|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
79971961|NCT03347500|Other|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
79971962|NCT03759314|Other|Observation|to use a simple screening tool to find out the risk of falling, the nutritional status and the level of cognitive functioning activity
79642496|NCT00190944|Drug|placebo|
79971963|NCT04500730|Drug|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
79971964|NCT03346330|Drug|TRK-750|TRK-750 capsule
79971965|NCT03346330|Drug|Placebo|Placebo capsule
79971966|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
79971967|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
79971968|NCT05560594|Device|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
79315095|NCT02415907|Drug|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 ([benzyl-7-14C]-idalopirdine) in one capsule for oral administration, single dose
79315096|NCT03138083|Drug|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
79642497|NCT03456505|Behavioral|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
79806939|NCT05069519|Behavioral|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
79315097|NCT02415829|Drug|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
79315098|NCT03180931|Device|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
79315099|NCT04631393|Drug|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
79642498|NCT03456505|Behavioral|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
79642499|NCT03456466|Drug|TQB2303|375mg/m2 ，iv
79642500|NCT03456466|Drug|Rituximab|375mg/m2 ，iv
79642501|NCT03456388|Drug|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
79315100|NCT04482725|Other|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
79315101|NCT04482725|Other|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
79315102|NCT04482725|Other|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
79315103|NCT04482725|Other|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
79315104|NCT04482725|Other|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
79315105|NCT04482725|Other|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
79315106|NCT04482725|Other|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
79315107|NCT04482725|Other|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
79315108|NCT04482725|Other|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
79315109|NCT04482725|Other|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
79315110|NCT04482725|Other|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
79315111|NCT04482725|Other|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
79315112|NCT03180775|Other|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
79477010|NCT04012411|Procedure|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
79477011|NCT04012411|Genetic|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
79315113|NCT03180775|Dietary Supplement|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315114|NCT03180775|Dietary Supplement|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315115|NCT03180775|Dietary Supplement|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315116|NCT03180775|Dietary Supplement|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315117|NCT03180775|Dietary Supplement|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315118|NCT03180775|Dietary Supplement|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315119|NCT03180775|Dietary Supplement|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315120|NCT03180775|Dietary Supplement|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315121|NCT03180775|Dietary Supplement|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79477012|NCT04012411|Other|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
79315122|NCT03180775|Dietary Supplement|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
79315123|NCT03180697|Diagnostic Test|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
79315124|NCT03178357|Other|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
79315125|NCT03178357|Other|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
79806940|NCT05069519|Behavioral|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
79315126|NCT03180541|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
79315127|NCT05391425|Other|no intervention|no intervention planned, since it is an observational study
79315128|NCT02415673|Device|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
79315129|NCT05390099|Drug|Moringa oleifera leaf|Moringa toothpaste
79315130|NCT02415751|Behavioral|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
79806941|NCT04017299|Other|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
79806942|NCT02667743|Drug|Paclitaxel Micelles for Injection|
79806943|NCT02667743|Drug|Paclitaxel Injection|
79477013|NCT02070302|Drug|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
79477014|NCT02070302|Drug|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
79642502|NCT03456388|Drug|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
79806944|NCT02667743|Drug|Cisplatin|
79642503|NCT03456349|Drug|HTL0018318|HTL0018318
79642504|NCT03456349|Drug|Placebo|Placebo
79477015|NCT02938949|Drug|alirocumab|
79477016|NCT02938949|Drug|placebo|
79642505|NCT00160355|Procedure|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
79642506|NCT00160355|Device|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
79806945|NCT04176107|Behavioral|Informative video|Exposure to informative video before cesarean delivery
79806946|NCT04070885|Procedure|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
79806947|NCT04070885|Procedure|Urine sample|The urine will be taken from three 15 ml tubes.
79806948|NCT04173845|Drug|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
79806949|NCT04173845|Drug|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
79971969|NCT04479332|Procedure|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
79642507|NCT00160355|Drug|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
79315131|NCT03137927|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
79315132|NCT03137927|Other|Placebo|Placebo
79315133|NCT04482985|Drug|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
79315134|NCT05388305|Biological|CAR--γδT cells|Biological: CAR-γδT; Drug:
79315135|NCT03178513|Other|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~Medical assessment~Psychosocial assessment~Medication reconciliation~Follow-up of inpatient primary team's specific recommendations~Follow-up, as needed, with primary care team or inpatient team"
79315136|NCT03178279|Other|Physical Health Plan|Use of a Physical Health Plan by service users
79315137|NCT04286789|Drug|Low dose ORTD-1|Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
79315138|NCT04286789|Drug|Low dose vehicle control|Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
79971970|NCT01196273|Other|Comprehensive non invasive cardiovascular examination|"The examination includes:~Anamnesis incl. admission form~Physical examination~Documentation of the medical therapy (incl. HAART)~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~6 minute walk test~Blood collection~Questionnaire to quality of life and health economics"
79971971|NCT03346174|Other|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
79971972|NCT03346174|Other|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
79315139|NCT04286789|Drug|High dose ORTD-1|Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
79315140|NCT04286789|Drug|High dose vehicle control|Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
79315141|NCT02415517|Behavioral|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken & Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
79315142|NCT02415517|Behavioral|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
79315143|NCT05385263|Drug|Nivolumab Injection [Opdivo]|Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
79315144|NCT00706147|Drug|Arimoclomol|Drug: Arimoclomol capsules given three times per day
79315145|NCT00706147|Drug|Placebo|Drug: Placebo capsules given three times per day
79315146|NCT05384561|Other|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
79315147|NCT03180229|Drug|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
79806950|NCT02666651|Drug|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
79806951|NCT02666651|Other|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
79971973|NCT04467554|Device|T-chair|Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
79971974|NCT01198223|Drug|garlic , nystatin|mouthwash
79971975|NCT03346564|Behavioral|Ritual training program|Ritual training program including education and demonstration
79971976|NCT03346564|Behavioral|Routine care|
79642508|NCT03456310|Diagnostic Test|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
79315148|NCT03137849|Other|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
79315149|NCT03137849|Other|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
79315150|NCT03137849|Other|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
79315151|NCT05375435|Drug|triple therapy|high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
79315152|NCT05375435|Drug|dual-therapy|high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
79315153|NCT03178123|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
79315154|NCT03178123|Biological|high-dose recombinant interferon a-2B|15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
79642509|NCT00545311|Drug|NVA237|
79315155|NCT02423551|Other|MRE|MRE consumption
79315156|NCT03820817|Drug|Rifaximin|Given PO
79642510|NCT00545311|Drug|NVA237|
79642511|NCT00545311|Drug|NVA237|
79642512|NCT00545311|Drug|NVA237|
79642513|NCT00545311|Drug|Placebo|
79642514|NCT00545350|Other|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
79806952|NCT02666807|Dietary Supplement|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
79806953|NCT02666807|Dietary Supplement|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
79971977|NCT03346486|Other|Control diet|Regular diet
79971978|NCT03346486|Other|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
79971979|NCT01196351|Other|Dietary Supplement: water with noncalorie sweetener|
79971980|NCT01196351|Other|Activity: With noncalorie sweetener or glucose|
79971981|NCT05559424|Diagnostic Test|OCT|OCT will be used to assess results after intervention
79642515|NCT00160394|Drug|Duac® Gel / Differin® Gel|
79642516|NCT04684693|Device|Laser|Laser puncture and exercise
79642517|NCT04684693|Procedure|Control|Exercise
79642518|NCT00191022|Drug|LY686017|
79642519|NCT00191022|Drug|paroxetine|
79642520|NCT00191022|Drug|placebo|
79642521|NCT00545389|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
79642522|NCT00545428|Procedure|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
79813704|NCT00455533|Drug|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
79813705|NCT00455533|Drug|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
79315157|NCT05111197|Radiation|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
79806954|NCT02671175|Drug|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
79806955|NCT02671175|Drug|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
79806956|NCT02666573|Device|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
79806957|NCT02666573|Other|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
79315158|NCT05111197|Drug|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
79315159|NCT03138005|Other|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to ~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
79315160|NCT03138005|Other|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
79315161|NCT05106517|Drug|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
79315162|NCT05106517|Drug|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
79315163|NCT02415361|Other|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
79315164|NCT03140033|Drug|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
79315165|NCT03140033|Drug|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
79642523|NCT00545467|Drug|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
79642524|NCT00160433|Drug|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
79642525|NCT00160433|Drug|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
79806958|NCT00644813|Other|Scapular with glenoid neck fractures|
79806959|NCT02670941|Drug|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
79806960|NCT02670941|Drug|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
79813706|NCT00455533|Drug|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
79315166|NCT02415283|Device|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
79315167|NCT03622697|Behavioral|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
79477017|NCT01979029|Procedure|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
79806961|NCT02670941|Drug|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
79315168|NCT01992094|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
79971982|NCT05005988|Behavioral|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
79971983|NCT01193465|Device|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
79971984|NCT01193465|Device|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
79315169|NCT01992094|Biological|TIV1c|Licensed Influenza Vaccine
79971985|NCT01193465|Device|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
79971986|NCT01193465|Device|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
79971987|NCT03347344|Drug|Riluzole|50 mg will be administered (per os) twice a day
79315170|NCT01992094|Biological|TIV2c|Novartis Investigational Vaccine
79477018|NCT01979029|Procedure|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
79477019|NCT02939105|Device|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
79477020|NCT02025439|Device|rTMS|
79477021|NCT02025439|Drug|Amantadine|
79477022|NCT02939651|Drug|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
79477023|NCT02943941|Other|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
79813707|NCT00455533|Drug|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
79813708|NCT04037930|Behavioral|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
79315171|NCT05347043|Other|Montreal cognitive assessment|Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
79477024|NCT02026297|Drug|Tranexamic Acid|1 gram IV over 10 minutes
79813709|NCT04030208|Device|Umbulizer|Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
79813710|NCT04030208|Device|Traditional Mechanical Ventilator|A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
79813711|NCT00818584|Drug|Micafungin|IV Administration
79971988|NCT03347344|Drug|Placebo|50 mg will be administered (per os) twice a day
79477025|NCT02026297|Drug|Placebo; Normal Saline|0.9% Normal Saline
79315172|NCT03177967|Behavioral|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
79315173|NCT03177967|Other|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
79315174|NCT03177967|Other|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
79315175|NCT05338931|Drug|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
79806962|NCT02670941|Drug|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
79971989|NCT01193543|Dietary Supplement|calanus oil|1 gram twice daily
79971990|NCT01193543|Dietary Supplement|olive oil|1 gram twice daily
79971991|NCT03173456|Drug|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
79971992|NCT03173456|Drug|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
79971993|NCT03173456|Drug|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
79971994|NCT03173456|Drug|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
79971995|NCT03173456|Drug|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
79971996|NCT03846245|Other|No intervention|No intervention
79971997|NCT01193621|Drug|haloperidol, PET|"Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
79971998|NCT04501198|Device|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
79971999|NCT04501198|Device|Moxibustion combined with lifestyle intervention.|"The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
79972000|NCT04501198|Device|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
79972001|NCT02668874|Device|Isolite System|
79972002|NCT02668874|Other|Cotton Roll Technique|
79315176|NCT02414893|Procedure|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
79315177|NCT03507101|Other|No intervention|No particular intervention or exposure is of particular interest
79315178|NCT02706691|Drug|BGJ398|Given by mouth (oral)
79477026|NCT02070692|Drug|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
79477027|NCT02070692|Drug|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
79477028|NCT02026453|Other|Pharmacist obtains admission medication history|
79477029|NCT02026453|Other|Pharmacy technician obtains admission medication history|
79477030|NCT02026687|Drug|Epidural|
79477031|NCT02026687|Drug|Intrathecal|
79806963|NCT02667041|Device|NeuroQore rTMS Device|
79477032|NCT02015234|Drug|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
79477033|NCT01974050|Behavioral|Text message surveillance|
79972003|NCT05211479|Behavioral|educational intervention|"In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study."
79315179|NCT03504137|Other|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
79315180|NCT03177889|Combination Product|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
79315181|NCT02419729|Device|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
79315182|NCT02419729|Drug|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
79477034|NCT02028247|Behavioral|Personalized Cognitive-behavioral therapy|
79477035|NCT02028247|Behavioral|Standard Practice Cognitive-behavioral therapy|
79477036|NCT02028247|Behavioral|Treatment as Usual|
79315183|NCT02419729|Drug|Placebo of Estrogen|Placebo of topical estrogen cream.
79315184|NCT02419729|Device|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
79477037|NCT01975922|Behavioral|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
79477038|NCT02028325|Drug|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
79477039|NCT02016560|Drug|florbetapir F 18|
79477040|NCT02016560|Drug|Flortaucipir F18|
79477041|NCT02016560|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
79477042|NCT02017574|Behavioral|Reaching Task|Learn a reaching task that requires coordination of the arm segments
79477043|NCT02869295|Drug|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
79806964|NCT02671097|Drug|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
79972004|NCT02517424|Drug|High THC/Low CBD Cannabis|Dried cannabis
79972005|NCT02517424|Drug|High THC/High CBD Cannabis|Dried cannabis
79972006|NCT02517424|Drug|Low THC/Low CBD Cannabis|Dried cannabis
79972007|NCT03846323|Other|Visiting policies: 24 hours a day, 7 days a week|
79972008|NCT03846323|Other|Restriction of visiting policies < 6 hours|
79972009|NCT01567904|Drug|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
79477044|NCT02340104|Drug|Baricitinib|4 milligrams (mg) administered orally
79477045|NCT02340104|Drug|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
79477046|NCT02869451|Drug|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
79642526|NCT00160433|Drug|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
79972010|NCT02517346|Other|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
79972011|NCT02517346|Other|Telemonitoring|Follow up by telemonitoring system during 3 months
79315185|NCT03136757|Other|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~to identify new intracellular signaling pathways that could lead to new therapeutic"
79315186|NCT03176719|Other|Venipuncture|"Full blood count and leukocyte differentiation.~Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~Detection of anemia, thallasemia and sickle cell anemia (XN-20)~Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~Circulating cytokines and inflammatory markers (ELIZA)~DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~pan-Salmonella PCR~Gametocyte PCR"
79315187|NCT02414971|Other|There is no intervention|There is no intervention
79315188|NCT02729207|Drug|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
79315189|NCT02415049|Other|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
79315190|NCT02415049|Other|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
79806965|NCT02671097|Drug|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
79806966|NCT02665169|Behavioral|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
79806967|NCT02665169|Other|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
79972012|NCT01196507|Drug|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
79315191|NCT02709239|Dietary Supplement|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
79315192|NCT02709239|Dietary Supplement|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
79315193|NCT01991470|Device|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
79315194|NCT02419651|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
79315195|NCT02419651|Drug|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
79315196|NCT02419651|Drug|Placebo|Women will receive a placebo 1 hour before the procedure
79315197|NCT02488655|Device|Echopulse|HIFU Under ultrasound guidance
79315198|NCT02414815|Device|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
79315199|NCT05088239|Drug|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
79315200|NCT02419261|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
79315201|NCT02419261|Procedure|Arthroscopic surgical repair of the anterior cruciate ligament|
79806968|NCT00645983|Dietary Supplement|Chamomile Extract|220 mg - 1100 mg daily
79806969|NCT00645983|Other|Placebo|1 to 5 capsules daily
79806970|NCT02666495|Other|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement & stabilisation; phase 2 - developing trust & understanding; phase 3 - developing awareness & acceptance; phase 4 - testing change & strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
79806971|NCT02667197|Other|Algorithm to determine overdose from opioid abuse|
79972013|NCT01196507|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
79315202|NCT01991314|Drug|Ferrous sulphate|200mg tablets.
79315203|NCT03176641|Other|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
79315204|NCT03176641|Other|control|Meniscus repair surgery only
79477047|NCT02869451|Drug|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
79477048|NCT02869451|Drug|Nicotine polacrilex|Initiated at smoking quit date.
79315205|NCT03500471|Procedure|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
79972014|NCT02340884|Behavioral|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
79315206|NCT03500471|Procedure|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
79315207|NCT02414503|Drug|8IU intranasal oxytocin|
79315208|NCT02414503|Drug|24IU intranasal oxytocin|
79477049|NCT02869451|Drug|nicotine lozenge|Initiated at smoking quit date.
79972015|NCT03347266|Drug|VVZ-149 injections|•VVZ-149 injection
79972016|NCT03347266|Drug|Placebo|water for injection
79477050|NCT02869451|Behavioral|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
79972017|NCT04987970|Drug|CKD-386(2)|QD, PO
79972018|NCT04987970|Drug|D013, D326, D337|QD, PO
79972019|NCT02517190|Other|Parabolic flight|
79972020|NCT02517190|Other|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
79972021|NCT02517190|Other|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
79972022|NCT02517190|Other|cellular energy metabolism measurements|purines, lactate
79972023|NCT05180201|Dietary Supplement|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
79972024|NCT05180201|Dietary Supplement|Probiotic|Lactiplantibacillus plantarum ATCC 202195
79972025|NCT05180201|Other|Placebo|Maltodextrin
79315209|NCT02414503|Drug|Placebo|
79315210|NCT02414503|Device|OptiNose Breath Powered Bi|
79477051|NCT02869451|Behavioral|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
79477052|NCT02340338|Biological|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
79642527|NCT00160433|Drug|Placebo|Tablet, oral Daily for 12 weeks
79642528|NCT00184392|Procedure|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
79642529|NCT00545545|Biological|Safety and efficacy of escalating doses|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
79642530|NCT00545545|Biological|Safety and efficacy of escalating doses.|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
79642531|NCT00545701|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
79642532|NCT00545857|Drug|pioglitazone|Pioglitazone daily; dose varies with size
79972026|NCT03627650|Procedure|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
79972027|NCT03627650|Procedure|placebo injection|
79972028|NCT03143660|Behavioral|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
79315211|NCT03137615|Procedure|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
79315212|NCT03137615|Drug|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
79315213|NCT03137147|Behavioral|Intervention for Sleep and Pain in Youth|See arm description.
79315214|NCT03415061|Drug|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
79315215|NCT03415061|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
79642533|NCT00545857|Drug|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
79642534|NCT00160472|Procedure|removal of ovarian vessels|
79642535|NCT00545896|Procedure|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
79642536|NCT00184431|Behavioral|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
79642537|NCT00545935|Drug|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
79642538|NCT00545935|Drug|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
79642539|NCT00545935|Drug|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
79972029|NCT03143660|Behavioral|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
79806972|NCT02665091|Behavioral|Peer Education Program|
79972030|NCT02517112|Other|Parabolic flight|
79315216|NCT03136211|Behavioral|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
79806973|NCT05276921|Other|ultrasound|Quadriceps and abdominal muscle ultrasonography
79315217|NCT03275831|Device|PluroGel|Surfactant based gel
79315218|NCT03275831|Device|Intrasite gel|Hydrogel
79315219|NCT03160235|Radiation|Magnetic resonance imaging|
79642540|NCT05057260|Other|No drug invervention|No clinical trial
79642541|NCT00160511|Drug|Levetiracetam|
79806974|NCT02665325|Drug|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
79806975|NCT05257421|Device|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
79972031|NCT02517112|Other|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
79315220|NCT03160235|Device|EEG|
79315221|NCT03160235|Device|NIRS|
79315222|NCT05088083|Device|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
79315223|NCT03110159|Drug|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
79315224|NCT03110159|Drug|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
79315225|NCT05088005|Procedure|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
79315226|NCT01990768|Drug|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
79315227|NCT01990768|Drug|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
79315228|NCT01990768|Drug|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
79315229|NCT03002207|Device|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
79806976|NCT05257421|Other|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~Bridge~Plank~Squat~Push-ups~Back extension Each exercise will be done for 3-5 sets."
79806977|NCT05257421|Combination Product|shockwave and exercises|both types of interventions will be applied for the patient
79972032|NCT02517112|Device|3D-BCG sensor|
79972033|NCT03964246|Behavioral|Compassion Meditation (CM) intervention|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
79315230|NCT03002207|Procedure|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
79642542|NCT00191061|Drug|duloxetine hydrochloride|
79642543|NCT00160550|Drug|Levetiracetam|
79642544|NCT00160589|Drug|Levocetirizine|
79972034|NCT03964246|Other|Heathy Aging Psychoeducation|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
79315231|NCT05087459|Drug|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10^9/L < platelet count < 50×10^9/L patients received Avatrombopag 60mg/d, 50×10^9/L≤ platelet count < 75×10^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
79315232|NCT01990612|Procedure|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score < 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
79315233|NCT05086991|Other|Follow up|like group descriptions
79315234|NCT05228327|Device|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
79477053|NCT02305316|Drug|BIA 9-1067 non-micronized|
79477054|NCT02305316|Drug|BIA 9-1067 micronized|
79477055|NCT02944565|Biological|Daratumumab|Given IV
79972035|NCT05282771|Drug|Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
79972036|NCT05282771|Drug|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
79972037|NCT05282771|Drug|Placebo|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
79972038|NCT03954652|Genetic|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
79972039|NCT03848117|Other|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
79315235|NCT05228327|Procedure|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
79477056|NCT02870309|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
79477057|NCT01979276|Drug|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
79477058|NCT01979276|Drug|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
79477059|NCT01979276|Drug|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
79477060|NCT02871011|Drug|Nitric Oxide|Delivered as a footbath
79477061|NCT02871011|Drug|Water|Delivered as a footbath
79477062|NCT02343380|Other|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
79477063|NCT02871479|Drug|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
79477064|NCT02871479|Drug|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
79477065|NCT02871479|Drug|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
79477066|NCT02344238|Other|ID Capsule|Capsule containing ingestible sensor
79477067|NCT02344238|Dietary Supplement|Riboflavin|50mg
79477068|NCT02344238|Behavioral|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
79806978|NCT02665403|Other|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
79806979|NCT02665403|Other|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
79972040|NCT03848117|Other|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
79972041|NCT02512978|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
79972042|NCT05487833|Biological|insulin|5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours
79972043|NCT05487833|Other|standard treatment|infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
79972044|NCT03197376|Biological|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
79972045|NCT03197376|Biological|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
79972046|NCT01295957|Behavioral|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
79972047|NCT01295957|Behavioral|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
79315236|NCT05228327|Combination Product|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
79315237|NCT05086601|Procedure|colorectal cancer surgery|Any surgery for primary tumor of colorectal cancer, including palliative resection, simple bowel stoma and exploratory surgery.
79477069|NCT02344316|Drug|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
79477070|NCT02344316|Other|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
79315238|NCT05086367|Other|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
79315239|NCT05086367|Other|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
79315240|NCT05090189|Other|Exercise Training|"The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period."
79315241|NCT05086211|Other|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
79642545|NCT00546130|Drug|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
79477071|NCT02872103|Drug|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
79642546|NCT00546130|Drug|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79642547|NCT00546130|Drug|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
79972048|NCT01295957|Other|control|advise and informal counseling
79642548|NCT00191178|Drug|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
79642549|NCT00191178|Drug|insulin glargine|
79972049|NCT01196585|Procedure|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
79972050|NCT01196585|Procedure|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
79642550|NCT00546169|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
79972051|NCT01193699|Drug|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
79972052|NCT03600805|Drug|Sarilumab SAR153191|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79972053|NCT03600805|Drug|Sarilumab matching placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79315242|NCT05086211|Other|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
79315243|NCT05085587|Drug|Test|2 inhalations of Test and Reference product in each study period
79315244|NCT05085587|Drug|Reference|2 inhalations of Test and Reference product in each study period
79972054|NCT03600805|Drug|Prednisone|Pharmaceutical form: tablets or capsules Route of administration: oral administration
79972055|NCT03600805|Drug|Prednisone matching placebo|Pharmaceutical form: capsules Route of administration: oral administration
79972056|NCT01196663|Device|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
79972057|NCT01196663|Device|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
79972058|NCT05473247|Behavioral|Ring-Fit Adventure Group|Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
79477072|NCT02872103|Drug|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
79477073|NCT02344628|Drug|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
79315245|NCT01990534|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion
79315246|NCT05085509|Procedure|US guidance and MB staining|Ultrasound guidance and methylene blue staining
79315247|NCT05085431|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
79315248|NCT05085353|Procedure|non-obstetric acute general surgical disease|non-obstetric acute general surgical disease
79477074|NCT02345486|Other|0.9% sodium chloride|
79477075|NCT02345486|Other|Physiologically balanced fluid|
79806980|NCT00463567|Drug|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
79972059|NCT01198379|Drug|aspirin|aspirin 100 mg qd for 3 years
79972060|NCT01198379|Drug|Placebo|
79972061|NCT02729740|Device|Penumbra Smart Coil|
79972062|NCT02729740|Device|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
79972063|NCT05283005|Procedure|Grafting of the alveolar cleft|alveolar cleft grafting using either the conventional technique or the double cortex technique
79972064|NCT05433857|Drug|Lacteol forte capsules|probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
79972065|NCT03848039|Biological|Gardasil-9|administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
79972066|NCT03848039|Drug|Placebo|administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
79806981|NCT00463567|Drug|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
79477076|NCT02950025|Device|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
79477077|NCT02950025|Device|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
79642551|NCT04684342|Diagnostic Test|Routine Laboratory investigations|"Complete blood picture~Liver function test and prothrombine time & concentration.~Blood urea and creatinine~Blood glucose, serum Na and K~CRP and ESR~Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers"
79972067|NCT01296269|Drug|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
79642552|NCT00160628|Drug|Levetiracetam|
79806982|NCT00463567|Drug|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
79972068|NCT01296269|Drug|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
79972069|NCT01296269|Drug|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
79642553|NCT00546286|Drug|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
79477078|NCT02950025|Other|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"30 questions~28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
79477079|NCT02873585|Device|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
79477080|NCT02873585|Device|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
79477081|NCT02019758|Drug|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
79477082|NCT02019758|Drug|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
79477083|NCT02019758|Drug|Placebo slurry|Slurry of sucralose - 4 mL twice daily
79477084|NCT02019758|Drug|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
79642554|NCT00546286|Drug|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
79642555|NCT00184509|Behavioral|integrated psychosocial treatment (behavior)|
79315249|NCT05084807|Other|Endoscopy|"A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range."
79315250|NCT05089097|Other|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
79315251|NCT02414659|Procedure|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
79315252|NCT05085743|Diagnostic Test|Deep convolutional neural networks analysis|using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
79315253|NCT05084573|Drug|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
79642556|NCT00546325|Drug|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
79642557|NCT00546325|Drug|Placebo|Matching placebo tablets. Once daily before breakfast
79972070|NCT05595772|Drug|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
79315254|NCT05084573|Drug|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
79315255|NCT03136289|Behavioral|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
79315256|NCT05069753|Procedure|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
79315257|NCT05069753|Procedure|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
79477085|NCT02876159|Biological|2016-2017 Influenza Vaccine|Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
79477086|NCT02020304|Drug|combined spinal epidural|Combined Spinal Epidural
79642558|NCT00546403|Drug|Modafinil|Adjunctive treatment with titrated dose of modafinil
79642559|NCT00546403|Drug|Placebo|Adjunctive treatment with placebo
79642560|NCT00546442|Drug|Metformine|850-2550 mg/daily for 48 weeks
79642561|NCT00546442|Other|Placebo of metformine|850-2550 mg/daily for 48 weeks
79642562|NCT00191256|Drug|Gemcitabine|
79642563|NCT00191256|Drug|Carboplatin|
79642564|NCT00191256|Drug|Paclitaxel|
79477087|NCT04349384|Procedure|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
79642565|NCT00546520|Drug|Ciclesonide|
79642566|NCT00546559|Drug|statins (simvastatin, pravastatin)|
79642567|NCT00160745|Drug|Rosuvastatin|
79642568|NCT00546676|Drug|Telithromycin|
79642569|NCT00546832|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
79642570|NCT00546832|Drug|celecoxib|
79642571|NCT00546832|Other|placebo|
79642572|NCT02963532|Other|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
79642573|NCT00160784|Procedure|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
79642574|NCT00160784|Procedure|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
79642575|NCT00160784|Other|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
79642576|NCT00546949|Procedure|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
79642577|NCT00546949|Procedure|Interspinous Process Decompression (IPD)|Interspinous device
79642578|NCT00546988|Biological|allogeneic stem cell transplant|
79972071|NCT05595772|Drug|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
79972072|NCT05595772|Procedure|Surgery: Dental Implant surgery|Immediate implant following extraction
79972073|NCT05595772|Procedure|Tooth extraction|A Traumatic tooth extraction
79972074|NCT05595772|Procedure|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
79972075|NCT03844451|Drug|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
79642579|NCT00184587|Drug|candesartan cilexetil|
79642580|NCT00184587|Drug|placebo|
79642581|NCT00160823|Procedure|Self-administered leaflet|
79972076|NCT03844451|Drug|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
79972077|NCT01198457|Drug|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
79972078|NCT02516956|Other|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
79972079|NCT02516956|Other|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
79315258|NCT05088707|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
79477088|NCT01980589|Drug|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
79642582|NCT05015764|Other|Fluid Management|Removal of excess extracellular fluid using diuretics
79642583|NCT05015764|Device|Reprieve Cardiovascular System|System with Fluid Management Module
79642584|NCT05012956|Procedure|Laparoscopic sacrocolpopexy|During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
79642585|NCT05012956|Procedure|gynecologic laparoscopic surgery|Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
79972080|NCT02516956|Other|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
79972081|NCT02516956|Other|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
79477089|NCT01980589|Drug|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
79642586|NCT00547027|Behavioral|print-based physical activity intervention|individually-based, print-based physical activity intervention
79642587|NCT00547027|Behavioral|usual care|print-based materials of nutritional information
79642588|NCT00547144|Drug|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
79477090|NCT01980589|Drug|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
79477091|NCT02021942|Drug|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
79642589|NCT00547144|Procedure|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
79642590|NCT00547183|Drug|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
79315259|NCT05088707|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
79315260|NCT01967134|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
79315261|NCT05028257|Biological|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
79315262|NCT05075057|Biological|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
79315263|NCT05072639|Behavioral|Guided Meditation|23 minute audio recording
79315264|NCT03135977|Drug|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
79315265|NCT01966432|Behavioral|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
79315266|NCT01966432|Behavioral|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
79315267|NCT04937231|Other|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
79315268|NCT04937231|Other|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
79315269|NCT04937231|Other|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
79315270|NCT03136133|Dietary Supplement|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
79477092|NCT01981057|Other|Numeta|parenteral receipt prescribed with Numeta
79642591|NCT00547183|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
79642592|NCT00547183|Drug|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
79642593|NCT00547261|Drug|SSR97225|every 3 weeks
79642594|NCT00184626|Drug|biphasic insulin aspart|
79642595|NCT00184626|Drug|insulin glargine|
79642596|NCT00184626|Drug|metformin|
79642597|NCT04684186|Procedure|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
79642598|NCT04684186|Procedure|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
79477093|NCT01981057|Other|Individual|parenteral receipt prescribed individually
79477094|NCT02345642|Device|ActiveCare+SFT Supine|
79477095|NCT02345642|Device|VenaFlow Elite Supine|
79477096|NCT02345642|Device|ActiveCare+SFT Standing|
79477097|NCT02345642|Device|VenaFlow Elite Standing|
79477098|NCT02345720|Device|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
79477099|NCT01981759|Drug|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
79477100|NCT01981759|Other|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
79642599|NCT00547417|Drug|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
79642600|NCT00160862|Drug|SLV317|
79642601|NCT00191295|Drug|Atomoxetine|
79642602|NCT00191295|Drug|Placebo|
79642603|NCT00547495|Drug|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
79642604|NCT00547495|Drug|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
79972082|NCT02516956|Other|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
79477101|NCT01981759|Behavioral|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
79477102|NCT01980524|Drug|acipimox|
79806983|NCT00463567|Drug|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
79806984|NCT00463567|Drug|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
79806985|NCT00646061|Drug|buscopan|
79477103|NCT01980524|Drug|Placebo Oral Capsule|
79477104|NCT01982539|Drug|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
79642605|NCT00547495|Drug|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
79806986|NCT00646841|Drug|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
79813712|NCT02609516|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
79813713|NCT00821470|Procedure|core decompression|core decompression procedure only
79813714|NCT00821470|Procedure|Bone marrow implantation into the necrotic lesion|
79972083|NCT03386214|Drug|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a > 5% change in body weight from the weight used for the most recent BSA calculation.
79972084|NCT03386214|Drug|Ruxolitinib|-Standard of care outside of protocol
79972085|NCT03386214|Procedure|Peripheral blood draw|"Baseline or Cycle 1 Day 1 (prior to study treatment administration)~Cycle 2 Day 1 (prior to study treatment administration)~Cycle 4 Day 1 (prior to study treatment administration)~End of treatment"
79642606|NCT00547495|Drug|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
79477105|NCT01980914|Device|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
79477106|NCT01982695|Drug|Losartan|
79477107|NCT01982695|Drug|Lisinopril|
79642607|NCT02277223|Dietary Supplement|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
79642608|NCT02277223|Drug|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
79477108|NCT02347124|Behavioral|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
79813715|NCT05755490|Behavioral|PROWESS|Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
79813716|NCT00818740|Drug|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
79315271|NCT05002439|Other|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
79315272|NCT04928729|Other|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
79315273|NCT04928729|Other|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
79315274|NCT04928729|Other|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
79315275|NCT04850651|Drug|Pyrotinib；Fluconazole|"Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18."
79315276|NCT04837235|Drug|Hemay005|oral
79642609|NCT02277262|Device|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
79315277|NCT04767971|Device|Standard Colonoscopy|Colonoscopy with a standard colonoscope
79315278|NCT04767971|Device|G-EYE Colonoscopy|Colonoscopy with a G-EYE Colonoscope
79813717|NCT00821548|Procedure|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
79315279|NCT04829981|Device|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
79315280|NCT04829981|Behavioral|Behaviour change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
79315281|NCT02702401|Biological|Pembrolizumab|IV infusion
79315282|NCT02702401|Drug|Placebo|0.90% w/v sodium chloride IV infusion
79315283|NCT02702401|Other|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
79315284|NCT04736615|Device|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
79315285|NCT04736615|Behavioral|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
79477109|NCT02347124|Behavioral|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
79642610|NCT02277262|Procedure|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
79642611|NCT00547573|Drug|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
79642612|NCT00547573|Drug|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
79315286|NCT02423707|Drug|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
79315287|NCT02423707|Drug|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
79315288|NCT02423629|Device|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
79315289|NCT04729829|Behavioral|Social and behaviour change communication|Each SBC treatment community will receive nutrition content and learning through savings groups. The group members will participate in skill-building activities that promote five key behaviours about fish nutrition and household decision making on fish consumption as part of facilitated discussions, interactive learning sessions, and a video-based facilitated dialogue. Increased fish consumption through SBC mass attendance events through marketing of fish vendors, interactive learning, and edu-tainment competitions promoting fish consumption. SBC will raise awareness of the benefits of eating fish as part of a balanced diet, with a particular focus on pregnant and lactating mothers, and children under 5 years of age.
79315290|NCT04729829|Other|Fish aggregating device|This is a moored line attached to buoys in coastal waters that attracts oceanic fish to it, to make it easier for small-scale fishers to catch them using their existing gear and boats. This FAD will work to increase the catch rate and hence, the availability of fish for sale in upland community markets.
79315291|NCT04719533|Other|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
79315292|NCT02419183|Other|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
79477110|NCT01981772|Drug|4% lidocaine with 1:100,000 epinephrine|see arm/group description
79477111|NCT01981772|Drug|4% buffered lidocaine with 1:100,000 epinephrine|see arm/group description
79642613|NCT00547573|Drug|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
79642614|NCT00160901|Drug|two complex naturopathic add-on therapies, leaflet 5-a-day|
79315293|NCT02419183|Other|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
79315294|NCT02419027|Dietary Supplement|GI Flora|
79315295|NCT02419027|Dietary Supplement|Placebo|
79315296|NCT04708301|Diagnostic Test|T1 mapping|T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map
79315297|NCT03116971|Drug|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
79642615|NCT00191373|Drug|Gemcitabine|
79972086|NCT03386214|Procedure|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
79642616|NCT00191373|Drug|Trastuzumab|
79642617|NCT00547612|Other|high performance liquid chromatography|
79315298|NCT03116971|Drug|Cisplatin|Cisplatin 75 milligram per square meter (mg/m^2) was administered over a 60-minute intravenous infusion on Day 1.
79315299|NCT03116971|Drug|Etoposide|Etoposide 100 mg/m^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
79315300|NCT03135743|Other|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
79642618|NCT00547612|Other|pharmacological study|
79642619|NCT00547612|Radiation|[18F]-labeled substance P antagonist receptor quantifier|
79642620|NCT00547690|Other|Acupuncture and Strengthening|Acupuncture and strengthening
79315301|NCT02414581|Drug|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
79315302|NCT02414581|Drug|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
79315303|NCT02414581|Drug|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
79315304|NCT04700267|Drug|GLPG3970 film-coated tablet|GLPG3970 for oral administration
79315305|NCT04700267|Drug|Placebo film-coated tablet|Placebo for oral administration
79315306|NCT02419105|Drug|Testosterone|transdermal gel, 75 mg daily
79315307|NCT02419105|Drug|Colecalciferol|drink solution, 24000 IU once per month
79315308|NCT02419105|Drug|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
79315309|NCT02419105|Drug|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
79315310|NCT03136991|Drug|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
79315311|NCT03136991|Drug|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
79315312|NCT02414737|Drug|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
79315313|NCT04643249|Drug|KL1333|Tablet
79642621|NCT00547690|Other|Strengthening Alone|Strengthening training program
79642622|NCT00547768|Drug|Fexofenadine HCI|
79642623|NCT00547807|Other|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
79642624|NCT00547807|Other|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
79642625|NCT00184665|Drug|insulin detemir|
79642626|NCT00184665|Drug|insulin NPH|
79642627|NCT00184665|Drug|insulin aspart|
79642628|NCT00547846|Drug|PDC-748|
79642629|NCT00184743|Drug|somatropin|
79642630|NCT04982419|Device|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
79642631|NCT04982419|Device|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
79642632|NCT04974385|Drug|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
79642633|NCT04974385|Drug|Bupivacaine|Active comparator as standard of care.
79642634|NCT00547885|Drug|Dihydrocodeine|"Group 1: 2* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8*30 mg dihydrocodeine short acting"
79642635|NCT00161018|Drug|Quetiapine, Risperidone, Fluphenazine|
79642636|NCT00191412|Drug|Pemetrexed|
79972087|NCT01198535|Biological|Cetuximab|Given IV
79972088|NCT01198535|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
79972089|NCT01198535|Other|Laboratory Biomarker Analysis|Correlative studies
79972090|NCT01198535|Other|Pharmacological Study|Correlative studies
79315314|NCT04643249|Drug|Flurbiprofen|Tablet
79315315|NCT04643249|Drug|Dextromethorphan|Syrap
79642637|NCT00547924|Behavioral|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
79315316|NCT04643249|Drug|Bupropion|Tablet
79315317|NCT04643249|Drug|Midazolam injection|solution for injection
79315318|NCT04643249|Drug|Omeprazole|Capsule
79315319|NCT04643249|Drug|Caffeine|Tablet or capsule
79315320|NCT04643249|Drug|Repaglinide|Tablet
79315321|NCT04482517|Other|Density Gradient Centrifugation|Semen processing is done by double layer density gradient method.
79315322|NCT04482517|Other|Physiological ICSI|Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head
79315323|NCT04482517|Other|Magnetic activated cell sorting|Sperm selection by using Annexin V micro-beads and separation columns
79315324|NCT04482517|Other|Testicular sperm|Using testicular sperm retrieved by TESA or TESE
79477112|NCT01982240|Drug|Plecanatide|Plecanatide tablets QD for 12 weeks
79642638|NCT00547963|Behavioral|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
79642639|NCT00548002|Drug|trovafloxacin and levofloxacin|Trovafloxacin: <60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: < 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
79315325|NCT02418871|Device|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
79315326|NCT02418871|Procedure|Cataract surgery|Performed using standard microsurgical techniques
79315327|NCT02414425|Procedure|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
79315328|NCT02414425|Procedure|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
79315329|NCT02414425|Drug|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
79642640|NCT00191490|Drug|Gemcitabine|
79642641|NCT00191490|Drug|docetaxel|
79642642|NCT00191490|Drug|cisplatin|
79642643|NCT00548080|Drug|MK0991, caspofungin acetate / Duration of Treatment:|
79642644|NCT00548275|Behavioral|Enhanced Sexual Risk Management|management of sexual risk
79642645|NCT00548275|Behavioral|Standard Sexual Risk Management|management of sexual risk
79315330|NCT04524143|Other|cervical mobilization|"Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
79315331|NCT04524143|Other|control|There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
79315332|NCT02414191|Behavioral|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
79315333|NCT02414191|Behavioral|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
79315334|NCT05737589|Radiation|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
79315335|NCT03116893|Drug|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
79315336|NCT03116893|Drug|Itraconazole|Administration of itraconazole together with BI 685509
79315337|NCT03116893|Drug|Rifampin|Administration of rifampicin together with BI 685509
79315338|NCT03116893|Drug|BI 685509 Fasted Conditions|BI 685509, given alone
79642646|NCT00161096|Drug|pantoprazole 20 mg (drug)|
79642647|NCT00184782|Procedure|FDG-PET|
79477113|NCT01982240|Drug|Placebo|Matching placebo tablets QD for 12 weeks
79642648|NCT00548314|Other|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
79642649|NCT00548314|Procedure|Split skin graft|
79642650|NCT00548314|Device|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
79315339|NCT05737511|Drug|Hydroxyzine|Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
79477114|NCT01982240|Drug|Bisacodyl|Rescue medication
79477115|NCT02029495|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
79315340|NCT05737511|Drug|Escitalopram Oxalate|The treatment as usual can include first-line, second-line and third-line recommendations
79477116|NCT02029495|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
79477117|NCT02029495|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
79477118|NCT02348606|Drug|JZP-110|
79477119|NCT02348606|Drug|Placebo oral tablet|
79477120|NCT02348684|Radiation|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
79477121|NCT02312713|Behavioral|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
79642651|NCT00548353|Drug|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
79642652|NCT00548353|Drug|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
79642653|NCT00184821|Procedure|Ischemic preconditioning|
79642654|NCT00184821|Procedure|Forearm ischemic exercise|
79642655|NCT00184821|Procedure|Annexin A5 scintigraphy|
79642656|NCT00184821|Drug|Diazoxide|
79642657|NCT00184821|Drug|glibenclamide|
79642658|NCT00184821|Drug|adenosine|
79642659|NCT00548509|Drug|Menatetrenone (Vitamin K2)|
79642660|NCT02277301|Behavioral|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
79315341|NCT03117127|Behavioral|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
79315342|NCT03117127|Other|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
79315343|NCT03117127|Other|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
79315344|NCT03180073|Diagnostic Test|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
79315345|NCT03180073|Diagnostic Test|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
79315346|NCT03180073|Diagnostic Test|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
79315347|NCT05737277|Drug|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
79477122|NCT02312713|Behavioral|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
79477123|NCT02033083|Device|Laminaria|
79642661|NCT00548626|Procedure|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
79984564|NCT03749291|Other|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians & nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity [Spanish Ministry of Science and Innovation], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
79984565|NCT02445820|Drug|HES|2500 mL of balanced HES 130/0.4
79984566|NCT02445820|Drug|Crystalloid|2500 mL of balanced crystalloid.
79315348|NCT05737277|Drug|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
79315349|NCT02418637|Other|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
79315350|NCT04187027|Device|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
79315351|NCT03179839|Behavioral|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
79477124|NCT02033083|Device|Dilapan-S|
79477125|NCT01985425|Drug|Colchicine 0.6 mg|
79477126|NCT01985425|Drug|Placebo Colchicine|
79477127|NCT02348918|Drug|Luminate 1.0mg|
79477128|NCT02348918|Drug|Luminate 2.0mg|
79477129|NCT02348918|Drug|Luminate 3.0mg|
79477130|NCT02348918|Drug|Avastin|
79477131|NCT02348918|Drug|Luminate 0.5mg|
79477132|NCT01985581|Drug|Guanfacine extended release|
79477133|NCT01985581|Drug|Placebo|
79477134|NCT01985581|Drug|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
79315352|NCT03179839|Behavioral|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
79315353|NCT03179839|Drug|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
79315354|NCT05737043|Diagnostic Test|prenatal diagnose|we will do a fetal echo in pregnant women with polyhidramnios
79477135|NCT02024204|Drug|Fluticasone propionate 230mcg for 3 Months|
79477136|NCT02024204|Drug|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
79477137|NCT02024204|Drug|Salmeterol 21mcg for 3 Months|
79477138|NCT04349137|Device|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
79477139|NCT04349137|Device|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
79477140|NCT03019055|Biological|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10^5 CAR-20/19-T cells/kg (starting dose level)"
79477141|NCT03019055|Biological|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10^5 CAR-20/19-T cells/kg"
79477142|NCT03019055|Biological|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10^6 cells/kg (single infusion)"
79477143|NCT03019055|Biological|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
79477144|NCT03930745|Other|Placebo|Placebo vaginal inserts.
79477145|NCT03930745|Drug|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
79477146|NCT02033317|Drug|patiromer|15 grams/day (5 grams 3 times daily) administered orally
79477147|NCT02034019|Drug|Dexamethasone|
79477148|NCT02034019|Drug|Punctum Plug|
79477149|NCT02349152|Drug|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
79477150|NCT02349152|Drug|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
79477151|NCT02034175|Device|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
79315355|NCT03106909|Radiation|pulmonary computed tomography (CT)|Pulmonary CT imaging
79315356|NCT03135821|Diagnostic Test|TCM|
79315357|NCT02418793|Drug|MOD-5014|Long Acting Factor VIIa
79315358|NCT03136601|Other|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
79315359|NCT05736887|Drug|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
79315360|NCT05736887|Drug|Placebo|Placebo in 600mg tablets
79315361|NCT04074083|Behavioral|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
79315362|NCT04074083|Behavioral|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
79315363|NCT02703337|Drug|LY900014|Administered subcutaneously (SC)
79315364|NCT02703337|Drug|Insulin Lispro|Administered SC
79477152|NCT02034175|Device|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
79477153|NCT02035345|Drug|Carboplatin|
79642662|NCT00548626|Procedure|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
79315365|NCT03110081|Procedure|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
79315366|NCT03110081|Procedure|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
79477154|NCT01985971|Radiation|PET/CT Imaging|
79477155|NCT01986361|Drug|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
79477156|NCT01986361|Drug|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
79477157|NCT01983020|Drug|Lidocaine|
79477158|NCT01983020|Drug|Ketamine|
79642663|NCT00191529|Drug|somatropin|
79642664|NCT04953637|Other|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
79642665|NCT00548665|Device|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
79642666|NCT00548665|Behavioral|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
79315367|NCT05736809|Other|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
79315368|NCT05736809|Other|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
79315369|NCT05736809|Other|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
79315370|NCT02418715|Other|Water Aerobics Training|
79315371|NCT03976895|Procedure|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
79477159|NCT01983020|Other|Saline|
79477160|NCT02058511|Drug|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
79315372|NCT03976895|Procedure|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
79477161|NCT02058511|Procedure|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
79806987|NCT04173143|Device|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
79315373|NCT02413723|Device|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
79642667|NCT00184860|Procedure|PET-scan, MRI-scan|
79642668|NCT00548704|Drug|Dexrazoxane|
79642669|NCT00548743|Behavioral|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
79642670|NCT00548743|Behavioral|Usual care|usual care for identification and management of postpartum depression
79984567|NCT03749213|Drug|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
79315374|NCT02413723|Device|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
79315375|NCT03179683|Device|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
79315376|NCT02418559|Drug|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
79477162|NCT01983566|Drug|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
79477163|NCT01983566|Drug|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
79642671|NCT00184899|Drug|Intravenous infusion of Intralipid/heparin|
79642672|NCT00184899|Drug|Intravenous infusion of Glycerol/heparin|
79642673|NCT00548782|Other|Paleolithic diet|diet
79315377|NCT02418559|Drug|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2*300 mg) tablet orally once on Day 1 under fasted conditions.
79315378|NCT02418559|Drug|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4*300 mg) tablet orally once on Day 1 under fasted conditions.
79477164|NCT01983566|Drug|BI 207127|BI 207127 as a single dose in fasted state
79477165|NCT01983566|Drug|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
79477166|NCT02059057|Device|LVRC System|
79642674|NCT00548782|Other|ADA ( American Diabetes Association) recommended diet|diet
79642675|NCT00548821|Drug|Cisplatin|
79642676|NCT00161291|Drug|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
79642677|NCT00548899|Drug|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
79642678|NCT00191568|Drug|Gemcitabine|
79315379|NCT02418559|Drug|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
79642679|NCT00191568|Drug|Oxaliplatin|
79972091|NCT02516878|Procedure|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
79972092|NCT01198613|Biological|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
79972093|NCT01198613|Biological|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
79315380|NCT03135665|Device|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
79315381|NCT02413645|Biological|TriMix_100|100 μg of TriMix in
79972094|NCT02516644|Behavioral|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
79972095|NCT02516644|Behavioral|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
79972096|NCT05670977|Dietary Supplement|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
79315382|NCT02413645|Biological|TriMix_300|300 μg of TriMix in
79315383|NCT02413645|Biological|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
79315384|NCT02413645|Biological|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
79477167|NCT01983878|Drug|Ramucirumab|Administered IV
79477168|NCT01986686|Procedure|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
79477169|NCT02351258|Device|70% Isopropyl alcohol embedded caps|Protective cap on central lines
79477170|NCT02351258|Other|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~Daily assessment whether central line is needed~Central line Site Care~Central line Hub/Cap/Tubing Care"
79477171|NCT02029040|Drug|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
79642680|NCT00191568|Procedure|Radiotherapy|
79642681|NCT00548938|Drug|Gliadel wafer|Implanted at surgery
79642682|NCT00548938|Drug|Temozolomide|During External Beam Radiation
79642683|NCT00548938|Radiation|External Beam Radiation Therapy|60 Gy
79642684|NCT00161330|Drug|oral amoxicilline/clavulanic acid|
79972097|NCT05670977|Dietary Supplement|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
79642685|NCT00161330|Drug|iv ceftriaxone|
79972098|NCT03896620|Device|Preoperative RT|Radiation delivered before surgery.
79806988|NCT04173143|Other|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
79806989|NCT00646139|Drug|Src kinase inhibitor KX2-391|
79806990|NCT00646139|Other|immunoenzyme technique|
79972099|NCT03896620|Device|Postoperative RT|Radiation delivered after surgery.
79642686|NCT00548977|Other|Drawing blood to study genetic polymorphism|
79972100|NCT03896620|Drug|Chemotherapy|Physician's choice of chemotherapy.
79972101|NCT03896620|Other|Surgery|Surgical excision of tumor.
79972102|NCT04499404|Other|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
79972103|NCT04499404|Other|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
79972104|NCT03844685|Drug|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
79642687|NCT00184938|Drug|morphine|
79642688|NCT00184938|Drug|naloxone|
79972105|NCT03844685|Drug|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
79972106|NCT02942966|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
79972107|NCT04151069|Other|Procedure A|Up-dosing nut drink at home
79972108|NCT04151069|Other|Procedure B|Up-dosing nut drink at the hospital
79972109|NCT04151069|Other|Control group|Strict avoidance of tree nut consumption
79642689|NCT00184938|Drug|Technetium-TC99m-labeled Annexin A5|
79642690|NCT00184938|Procedure|forearm ischemic exercise|
79642691|NCT00184938|Procedure|ten minute forearm ischemia|
79972110|NCT03844763|Drug|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
79972111|NCT03844763|Drug|CTX|CTX: 50 mg Daily untill PD or major toxicity
79972112|NCT03844763|Radiation|RT|RT: 8 Gy single shot day 8
79972113|NCT02516566|Other|PEEP|Mechanical ventilation with PEEP 8 cmH2O
79984568|NCT04484116|Diagnostic Test|Intraoperative Paratohormone|Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values <150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
79984569|NCT04614428|Behavioral|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
79984570|NCT03198130|Drug|REGN2810|Intravenous (IV) use
79642692|NCT00549016|Device|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
79984571|NCT03202654|Other|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
79984572|NCT03202654|Other|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
79477172|NCT02029040|Drug|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
79477173|NCT02029196|Other|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
79477174|NCT02029196|Other|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
79477175|NCT02396732|Drug|Aspirin|Daily dose is 81 mg oral tablet
79477176|NCT02396732|Drug|Enoxaparin|Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
79477177|NCT02030288|Behavioral|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
79642693|NCT00549133|Drug|Irbesartan|
79642694|NCT00549211|Drug|GSK557296|
79806991|NCT00646139|Other|pharmacological study|
79806992|NCT00646919|Procedure|Nose swab|
79806993|NCT02665013|Behavioral|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
79315385|NCT02413645|Biological|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
79315386|NCT03116815|Other|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
79315387|NCT03200483|Other|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
79477178|NCT02031770|Drug|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
79477179|NCT02031770|Other|Control|subjects will receive no treatment
79642695|NCT00191607|Drug|Gemcitabine|
79642696|NCT00191607|Drug|liposomal doxorubicin|
79642697|NCT00549289|Drug|cyclosporine A|
79642698|NCT00549367|Behavioral|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
79642699|NCT00161408|Behavioral|cognitive behavioural therapy|
79806994|NCT02665013|Behavioral|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
79806995|NCT01323049|Procedure|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
79984573|NCT04238780|Procedure|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
79315388|NCT03200483|Other|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
79642700|NCT00161408|Behavioral|psychoeducation|
79642701|NCT00549406|Procedure|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
79642702|NCT00549406|Procedure|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
79642703|NCT00549406|Procedure|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
79642704|NCT00184977|Drug|N-acetylcysteine|
79642705|NCT00184977|Drug|fluticasone propionate|
79642706|NCT03456232|Other|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
79642707|NCT03456232|Other|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
79642708|NCT03456154|Drug|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
79642709|NCT03456154|Device|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
79642710|NCT00161447|Drug|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
79972114|NCT05018039|Other|Collaborarive Care Model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care)."
79315389|NCT03200483|Other|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
79315390|NCT02418403|Behavioral|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
79315391|NCT02418403|Behavioral|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
79315392|NCT02418247|Drug|I131|
79315393|NCT02418247|Drug|I123|
79315394|NCT04483219|Drug|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
79315395|NCT03975179|Procedure|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
79315396|NCT03975179|Procedure|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
79315397|NCT02413957|Other|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
79642711|NCT00161447|Drug|Testosterone Gel|Testosterone Gel (10 g daily
79642712|NCT00161447|Drug|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 & month 3
79642713|NCT00191685|Drug|duloxetine|
79642714|NCT00549523|Drug|Placebo|Capsules containing 0 mg bid (placebo)
79642715|NCT00549523|Drug|Low Dose|Capsules containing 400 mg bid of L. frutescens.
79642716|NCT00549523|Drug|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
79642717|NCT00549523|Drug|High Dose|Capsules containing 1200 mg bid of L. frutescens.
79642718|NCT00161486|Drug|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
79642719|NCT00161486|Drug|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
79642720|NCT00161486|Drug|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
79642721|NCT00161486|Drug|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
79642722|NCT00549796|Other|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
79642723|NCT02963571|Procedure|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
79972115|NCT03121300|Other|CT Scan|Quantitative lung SPECT-CT
79642724|NCT00549835|Procedure|Real Acupuncture|
79477180|NCT02032550|Other|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
79806996|NCT01323049|Procedure|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
79806997|NCT00645749|Biological|Helminth ova|2500 ova per dose (liquid form)
79972116|NCT03121300|Other|Lung CT|CT lung ventilation
79972117|NCT03121300|Other|MRI|DCE MRI
79972118|NCT03121300|Other|Walk Test|6 minute hall walk test
79972119|NCT03121300|Other|SGRQ|St. George Respiratory Questionnaire
79972120|NCT03121300|Other|Biological Sample Collection|Blood Draw
79972121|NCT03121300|Other|Toxicity|Toxicity Evaluation
79972122|NCT03121300|Other|Cardiac Assessment|Cardiac MRI Scan
79477181|NCT02352974|Drug|GAD-Alum|
79972123|NCT02512822|Procedure|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
79477182|NCT02352974|Drug|Vitamin D|
79477183|NCT02353754|Drug|Intrathecal morphine injection|0.2 mg
79477184|NCT02353754|Drug|EXPAREL|266 mg
79642725|NCT00549835|Procedure|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
79642726|NCT00549874|Drug|Rosiglitazone|oral 8 mg/once daily for 6 months
79642727|NCT00549874|Drug|Glyburide|20 mg/ once daily for 6 months
79806998|NCT03995797|Procedure|Laser therapy|Erbium YAG laser
79806999|NCT04167397|Other|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
79807000|NCT01019161|Drug|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
79807001|NCT01019161|Drug|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
79807002|NCT04173767|Device|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated & humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
79807003|NCT00646217|Behavioral|Self Care Talk|6 weekly telephone sessions
79807004|NCT01025557|Other|Dietary intervention|Dietary treatments with beverages
79807005|NCT00647075|Dietary Supplement|Yunzhi extract|3.5 g/day
79807006|NCT00647075|Dietary Supplement|Placebo|Placebo (starch)
79972124|NCT02516722|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
79972125|NCT03606616|Procedure|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
79984574|NCT04238780|Procedure|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
79984575|NCT03197974|Behavioral|Mindfulness for Bipolar|Brief online self-management program with email coaching support
79984576|NCT03197974|Behavioral|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
79984577|NCT00944216|Drug|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
79984578|NCT03202732|Other|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
79315398|NCT02413957|Other|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
79315399|NCT03176563|Drug|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
79315400|NCT03176563|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
79315401|NCT03176563|Drug|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
79315402|NCT03176563|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
79315403|NCT03955835|Device|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
79315404|NCT03925961|Other|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
79315405|NCT03176485|Other|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
79477185|NCT02354144|Other|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
79315406|NCT03176251|Other|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
79642728|NCT00161525|Procedure|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
79642729|NCT00185016|Behavioral|a training to improve recognition of partner abuse.|
79807007|NCT04172753|Radiation|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
79807008|NCT04172753|Diagnostic Test|Imaging on the MR Linac|Only imaging performed on the MR Linac
79807009|NCT01022515|Other|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
79315407|NCT03909503|Device|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
79477186|NCT02354144|Other|Control gel|A gel not containing carrageenan
79477187|NCT02397122|Biological|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
79477188|NCT02397122|Procedure|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
79807010|NCT01022515|Other|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
79984579|NCT00878462|Drug|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
79984580|NCT00878462|Drug|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
79807011|NCT04068389|Procedure|Pulmonary Tissue Collection|Pulmonary Tissue Collection
79984581|NCT00878462|Drug|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
79984582|NCT03197818|Drug|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
79315408|NCT05088551|Other|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
79315409|NCT02418325|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
79315410|NCT02418325|Other|Liberation therapy|
79315411|NCT03877133|Device|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
79315412|NCT02418481|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
79807012|NCT04068545|Device|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
79807013|NCT00484159|Procedure|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
79315413|NCT02418481|Biological|γδ T Cell|γδ T cells will be used against breast tumor.
79315414|NCT02418481|Biological|Combination|γδ T/DC-CIK cells will be used against breast tumor.
79315415|NCT03827447|Drug|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
79315416|NCT03827447|Drug|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
79807014|NCT00484159|Drug|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
79807015|NCT00484159|Drug|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
79315417|NCT01680497|Device|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
79315418|NCT02423473|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
79315419|NCT02423473|Procedure|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
79315420|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
79477189|NCT02397122|Procedure|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
79477190|NCT02354378|Drug|Dexmedetomidine|
79477191|NCT02354378|Other|Memory Test|
79807016|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
79807017|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
79807018|NCT00484159|Procedure|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
79807019|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
79807020|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
79807021|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
79807022|NCT00647153|Other|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
79807023|NCT00647153|Procedure|single photon emission computed tomography|One day post infusion
79807024|NCT00647153|Radiation|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
79807025|NCT00910637|Drug|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 13 cycles
79984583|NCT03197818|Drug|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
79984584|NCT00754520|Device|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
79984585|NCT00754520|Device|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
79984586|NCT01562249|Other|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
79315421|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
79315422|NCT02423395|Drug|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
79315423|NCT02423395|Drug|Placebo|calcium in muscle cramps in cirrhotic patients
79315424|NCT05712083|Drug|BCMA CAR-T cells|Each subject receive BCMA CAR T-cells by intravenous infusion
79477192|NCT02312726|Procedure|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
79477193|NCT02399228|Drug|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
79642730|NCT00549913|Biological|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
79642731|NCT00549913|Procedure|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
79642732|NCT00549952|Other|no intervention study|
79807026|NCT00462865|Drug|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
79972126|NCT01198847|Behavioral|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
79315425|NCT02418091|Behavioral|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
79315426|NCT05711147|Procedure|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
79315427|NCT05711147|Procedure|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
79315428|NCT05694689|Dietary Supplement|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
79315429|NCT05694689|Dietary Supplement|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
79315430|NCT05694689|Other|Usual Care|Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
79807027|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
79972127|NCT02512666|Device|AM4113-N5UT Dino-Lite|
79972128|NCT01198925|Drug|piperacillin continuous infusion|piperacillin continuous infusion
79642733|NCT00191763|Drug|Gemcitabine|
79642734|NCT00191763|Drug|cisplatin|
79642735|NCT00161564|Drug|Rituximab|
79642736|NCT00550030|Radiation|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
79642737|NCT00550030|Other|No treatment|no UV exposure
79642738|NCT00185055|Drug|Olmesartan medoxomil|
79642739|NCT00185055|Drug|Irbesartan|
79642740|NCT00185055|Drug|Valsartan|
79642741|NCT00161603|Behavioral|Semi-structured, open-ended interviews|
79642742|NCT00550108|Other|Ethanol lavage|Ethanol lavage of pancreatic cysts.
79642743|NCT00550186|Other|placebo|
79642744|NCT00550186|Drug|Ringers Lactate|
79642745|NCT00550186|Drug|HaemoHES 6%|
79642746|NCT00550225|Drug|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
79642747|NCT00550225|Drug|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
79642748|NCT00161642|Drug|CMD-193|
79972129|NCT01198925|Drug|piperacillin extended infusion|piperacillin extended infusion
79972130|NCT04501354|Drug|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
79972131|NCT03844139|Device|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
79972132|NCT03579862|Other|Blood Draw|
79972133|NCT03346408|Behavioral|Questionnaire|patient (self-questionnaire) and algologist physician (questionnaire)
79315431|NCT02423239|Drug|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
79315432|NCT02423239|Drug|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
79315433|NCT02423239|Drug|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
79642749|NCT00185094|Drug|Olmesartan medoxomil|
79642750|NCT00185094|Drug|Losartan potassium|
79642751|NCT00185094|Drug|Atenolol|
79642752|NCT00550264|Other|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
79642753|NCT00550303|Drug|bazedoxifene/conjugated estrogens combination|
79642754|NCT00550342|Drug|rituximab|375 mg/m2 intravenously for 4 doses
79972134|NCT04500496|Drug|INH|3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
79972135|NCT04500496|Drug|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
79315434|NCT02423239|Drug|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
79642755|NCT00550381|Drug|HKI-357|Single-dose capsule
79642756|NCT00161681|Drug|Levonorgestrel/Ethinyl Estradiol|
79642757|NCT02963454|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
79642758|NCT02963454|Drug|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
79972136|NCT01199627|Drug|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
79972137|NCT01199627|Drug|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
79972138|NCT01199627|Drug|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
79315435|NCT02449733|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
79972139|NCT02512744|Procedure|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
79315436|NCT02449733|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
79315437|NCT02449733|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
79315438|NCT02449733|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
79315439|NCT02449733|Other|HIV Testing|Rapid HIV testing at multiple time points
79315440|NCT02449733|Other|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
79477194|NCT02033174|Other|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
79972140|NCT02512744|Device|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
79477195|NCT02033174|Other|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
79477196|NCT02059213|Drug|Ibrance|
79477197|NCT02059213|Drug|Bicalutamide|
79477198|NCT02059213|Drug|Zoladex|
79477199|NCT02059213|Drug|Lupron Depot|
79972141|NCT03146507|Radiation|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
79315441|NCT02449733|Procedure|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
79315442|NCT02449733|Behavioral|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
79315443|NCT03176329|Other|Nursing 1 : INTELLIVENT-ASV|
79315444|NCT03176329|Other|Nursing 2 : INTELLIVENT-ASV|
79477200|NCT02037061|Drug|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
79477201|NCT02037061|Other|Normal Saline|
79477202|NCT02354534|Drug|Artesunate Suppositories|
79477203|NCT02059993|Device|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
79477204|NCT02060461|Device|FS200 femtosecond laser LASIK|
79972142|NCT03146507|Radiation|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
79315445|NCT03176329|Other|Nursing 1 : Conventional mode|
79315446|NCT03176329|Other|Nursing 2 : Conventional mode|
79972143|NCT03146507|Radiation|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
79972144|NCT02512588|Drug|BTD-001|
79972145|NCT02512588|Drug|Placebo|
79477205|NCT02060461|Device|IntraLase femtosecond laser LASIK|
79477206|NCT02354924|Device|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
79315447|NCT05082493|Drug|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
79972146|NCT01566617|Other|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
79972147|NCT01566617|Other|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
79315448|NCT02418013|Other|Fresh cord blood(experimental group A)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
79972148|NCT02516254|Dietary Supplement|fortified bread|50 g of fortified bread + placebo daily
79477207|NCT02354924|Device|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
79477208|NCT02060539|Device|Biofinity XR|
79972149|NCT02516254|Dietary Supplement|supplement|vitamin D supplement+ plain bread
79972150|NCT02516254|Dietary Supplement|placebo|plain bread+placebo
79972151|NCT02516176|Behavioral|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
79972152|NCT04810169|Device|Smart inhaler|"Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
79972153|NCT01199081|Drug|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
79315449|NCT02418013|Other|Frozen cord blood(experimental group B)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
79477209|NCT02355158|Drug|clonidine hydrochloride topical gel, 0.1%|
79315450|NCT02418013|Other|Frozen plasma(experimental group C)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
79477210|NCT02033876|Drug|Ursodiol|
79972154|NCT02512354|Other|Sample of a fragment of fetal tissue|
79972155|NCT02512354|Other|Parent's blood samples|
79972156|NCT02516020|Drug|Global|Embryos are cultured in single step culture from day 1 to day 5
79972157|NCT02516020|Drug|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
79315451|NCT02418013|Other|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
79477211|NCT02061397|Drug|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
79477212|NCT02061397|Drug|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
79477213|NCT02061397|Drug|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
79477214|NCT02400710|Behavioral|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
79477215|NCT02400710|Behavioral|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
79477216|NCT04349761|Drug|MyMD1|Isomyosamine 5mg capsules
79477217|NCT04349761|Drug|Placebo|Placebo
79477218|NCT02401022|Drug|AZD8529|comparison of different dosages of drug
79477219|NCT02062177|Drug|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
79477220|NCT02062177|Drug|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged < 70, 0.03 mg/Kg if aged > 70.
79477221|NCT02034578|Drug|Apixaban|
79477222|NCT02403830|Drug|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
79477223|NCT02403830|Other|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
79972158|NCT03841955|Device|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
79315452|NCT05377775|Device|Iliac Stenting|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
79315453|NCT02413411|Behavioral|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
79315454|NCT02413411|Behavioral|an educational program (an NIH-developed booklet)|
79315455|NCT01826591|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
79315456|NCT01826591|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
79315457|NCT01826591|Behavioral|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
79315458|NCT05377931|Diagnostic Test|Changes in heart pulse rate|Measuring heart pulse rate using a wrest smart watch.
79315459|NCT05377931|Diagnostic Test|Changes in eye strain|Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
79972159|NCT03841955|Device|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
79477224|NCT02403830|Drug|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
79642759|NCT02963454|Drug|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
79807028|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
79807029|NCT01025713|Drug|GS-9411|Inhaled GS-9411
79807030|NCT01025713|Drug|Placebo|Inhaled Placebo
79315460|NCT02417623|Behavioral|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
79807031|NCT04173455|Drug|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
79807032|NCT03839641|Other|High fat meal|60% fat meal
79807033|NCT03839641|Other|Low fat meal|20% fat meal
79315461|NCT02422849|Other|hospital specialist|
79315462|NCT02422849|Other|General Practitioner|
79315463|NCT02417467|Other|Nicotine E-Cigarette|
79315464|NCT02417467|Other|Non-Nicotine E-Cigarette|
79315465|NCT02417467|Behavioral|Counseling|
79315466|NCT02422771|Other|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
79315467|NCT03199937|Behavioral|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
79477225|NCT02403830|Drug|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
79972160|NCT04500886|Drug|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
79972161|NCT04500886|Drug|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
79972162|NCT03346018|Diagnostic Test|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
79315468|NCT03199937|Other|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
79315469|NCT02422927|Dietary Supplement|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
79315470|NCT02422927|Other|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
79315471|NCT02422927|Other|Placebo|placebo
79315472|NCT02423005|Device|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
79315473|NCT02423005|Device|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
79972163|NCT04800029|Other|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
79477226|NCT02036840|Drug|Antibiotic|
79477227|NCT02951195|Drug|VX-152|Tablet for oral administration.
79315474|NCT03199703|Device|Baylis transseptal system group|
79315475|NCT03199703|Device|Standard conventional transseptal group|
79315476|NCT05233501|Procedure|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
79315477|NCT05233501|Procedure|non-surgical periodontal treatment|standart periodontal therapy
79315478|NCT03199781|Device|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
79477228|NCT02951195|Drug|TEZ/IVA|Fixed-dose combination tablet for oral administration.
79477229|NCT02951195|Drug|IVA|Tablet for oral administration.
79477230|NCT02951195|Drug|Placebo|Placebo matched to VX-152.
79477231|NCT02951195|Drug|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
79477232|NCT02037230|Drug|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
79477233|NCT02037230|Drug|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
79807034|NCT02667353|Procedure|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) < 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
79807035|NCT02667353|Drug|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
79807036|NCT02667353|Drug|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
79315479|NCT02413177|Behavioral|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
79315480|NCT02413177|Behavioral|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
79315481|NCT02413099|Drug|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
79972164|NCT04800029|Other|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
79315482|NCT02607449|Drug|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
79315483|NCT02607449|Drug|Placebo|Placebo without any active pharmaceutical ingredients
79315484|NCT02417389|Drug|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
79315485|NCT02417389|Drug|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
79315486|NCT04928963|Dietary Supplement|Prolon - FMD|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
79315487|NCT02412943|Other|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
79315488|NCT03177655|Other|Guided Imagery|Guided Imagery meditation
79315489|NCT03177655|Other|Journaling|Keeping a journal
79315490|NCT02413021|Drug|Cytarabine|20 mg/m^2 , SC, two times a day for 10 days every 30 days for 1 cycle
79477234|NCT02037230|Radiation|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
79477235|NCT02312882|Drug|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
79477236|NCT03020537|Biological|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
79807037|NCT00462709|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
79807038|NCT02664857|Drug|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
79807039|NCT02664857|Drug|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
79477237|NCT02037776|Drug|Rikkunshito|- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
79477238|NCT02037776|Drug|Rikkunshito placebo|- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
79477239|NCT02877095|Drug|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
79972165|NCT04800029|Other|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
79642760|NCT00550498|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
79807040|NCT04066673|Diagnostic Test|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
79315491|NCT02413021|Drug|Deferasirox|20 mg/kg ,oral, per day
79315492|NCT01680341|Drug|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
79315493|NCT01680341|Drug|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
79315494|NCT03177811|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79315495|NCT03177811|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79642761|NCT00191802|Drug|teriparatide|
79642762|NCT00550576|Drug|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
79315496|NCT03177733|Procedure|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.~The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.~This is a purely observational study that assesses our current practice in this type of surgery."
79315497|NCT03175939|Radiation|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
79315498|NCT03175939|Drug|Cisplatin|cisplatin IV injection over 3 hours
79315499|NCT03175939|Drug|5-FU|5-FU IV 24 hours continuous infusion
79642763|NCT00550693|Device|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
79642764|NCT00550810|Drug|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
79642765|NCT00191841|Drug|gemcitabine|
79315500|NCT03176017|Procedure|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
79315501|NCT03176017|Procedure|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
79315502|NCT03199625|Behavioral|Cognitive therapy|
79315503|NCT03199625|Behavioral|Behavior therapy|
79315504|NCT03199625|Drug|SSRI antidepressants|
79315505|NCT02417077|Other|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
79315506|NCT02412865|Behavioral|Quit4Baby|
79315507|NCT02412865|Behavioral|Text4Baby|
79315508|NCT03199313|Drug|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
79315509|NCT03199313|Drug|Placebo|Matching Sutezolid placebo
79315510|NCT02412709|Device|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
79642766|NCT00191841|Drug|Cisplatin|
79315511|NCT03199235|Device|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
79642767|NCT00550888|Procedure|suture techniques|
79642768|NCT00550927|Biological|bevacizumab|
79642769|NCT00550927|Drug|enzastaurin hydrochloride|
79642770|NCT00550927|Other|diagnostic laboratory biomarker analysis|
79642771|NCT00550927|Other|pharmacological study|
79315512|NCT03199235|Other|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
79315513|NCT03179527|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
79642772|NCT00550966|Behavioral|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
79315514|NCT03179527|Drug|Lipid Regulating Drugs|Mainly including statins
79315515|NCT03179527|Drug|Coronary Vasodilator|Mainly including nitrates
79642773|NCT00161720|Drug|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
79642774|NCT00185133|Drug|Olmesartan medoxomil|
79642775|NCT00185133|Drug|Amlodipine|
79642776|NCT00551005|Drug|celecoxib|
79315516|NCT03179527|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
79642777|NCT00551005|Drug|etoposide|
79972166|NCT03345940|Drug|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
79315517|NCT02412475|Drug|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
79642778|NCT00551005|Other|immunoenzyme technique|
79642779|NCT00551005|Other|laboratory biomarker analysis|
79642780|NCT00551044|Drug|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
79477240|NCT02951273|Other|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
79477241|NCT02357264|Device|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
79477242|NCT02877485|Drug|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
79477243|NCT02877485|Drug|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
79477244|NCT02404532|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
79807041|NCT01019239|Procedure|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
79807042|NCT01019239|Procedure|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
79477245|NCT02879747|Drug|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
79477246|NCT02880137|Drug|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
79477247|NCT02880137|Procedure|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
79477248|NCT00374387|Drug|Nuvaring|
79477249|NCT00374387|Drug|low-dose combination pill|
79477250|NCT00374387|Drug|minipill|
79477251|NCT03023891|Drug|Prednisone|Prednisone 60 mg tablet once
79807043|NCT04172519|Other|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
79807044|NCT04172519|Other|Unsupervised PMFT|intervention after surgery, unsupervised exercises
79807045|NCT04172519|Other|Supervised PMFT|intervention after surgery and supervised exercise
79315518|NCT02412475|Drug|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
79315519|NCT02412475|Drug|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
79477252|NCT03026777|Drug|intravenous crystalloid fluid, 500 mL|
79807046|NCT03996031|Device|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
79807047|NCT00646295|Device|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
79807048|NCT00647465|Drug|vaccine|IFNalpha 2b
79315520|NCT02412475|Drug|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
79315521|NCT02412475|Drug|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
79315522|NCT02412475|Drug|Cytarabine|"Patient Age (years) IT Cytarabine Dose > 1 30 mg~2 and < 3 50 mg~3 and ≤ 18 70 mg > 18 100 mg~given IT on day 0 or -1"
79807049|NCT00647465|Drug|Placebo|Placebo
79807050|NCT04172207|Other|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
79807051|NCT02665793|Other|DBPCFC to peanut cookie|
79807052|NCT02665793|Other|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
79315523|NCT02412475|Drug|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
79642781|NCT00551083|Other|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
79807053|NCT02665793|Other|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
79807054|NCT02665871|Biological|one dose of Influenza Vaccine|
79807055|NCT02665871|Biological|one dose of Influenza Vaccine|
79807056|NCT02665871|Biological|placebo|
79315524|NCT02417311|Other|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
79972167|NCT03345940|Drug|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
79315525|NCT04543643|Drug|Carvedilol|As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
79315526|NCT04543643|Drug|Berberine|Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
79315527|NCT02417155|Behavioral|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
79315528|NCT02417155|Behavioral|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
79315529|NCT03177499|Procedure|Invasive PPG|Invasive PPG obtained by means of catheterization.
79807057|NCT02665871|Biological|placebo|
79807058|NCT02664779|Other|Arrhythmia diagnosis with the 10 steps method|
79807059|NCT02664779|Other|Arrhythmia diagnosis with the 6 steps method|
79807060|NCT02664779|Other|Arrhythmia diagnosis with the 4 steps method|
79807061|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
79807062|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
79807063|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
79315530|NCT05377619|Drug|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
79315531|NCT05377619|Drug|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
79807064|NCT04172285|Behavioral|Physical activity|Home-based physical activity program
79807065|NCT04172285|Dietary Supplement|Physical activity and supplementation|Home-based physical activity program and amminoacid supplementation
79807066|NCT04172285|Other|Control|No intervention
79972168|NCT05670353|Drug|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
79972169|NCT05670353|Drug|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
79972170|NCT05670353|Drug|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
79477253|NCT03028025|Device|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
79642782|NCT00551083|Other|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
79642783|NCT00161759|Drug|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
79642784|NCT00551122|Biological|filgrastim|
79807067|NCT00646373|Other|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
79807068|NCT00647621|Drug|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
79807069|NCT00647621|Drug|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
79642785|NCT00551122|Biological|lenograstim|
79642786|NCT00551122|Biological|pegfilgrastim|
79642787|NCT00551122|Drug|cisplatin|
79642788|NCT00551122|Drug|gemcitabine hydrochloride|
79807070|NCT00461305|Drug|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
79642789|NCT00551122|Drug|ifosfamide|
79642790|NCT00551122|Drug|paclitaxel|
79642791|NCT00551239|Biological|rituximab|Given IV
79642792|NCT00551239|Drug|fludarabine phosphate|Given IV
79642793|NCT00551239|Drug|pixantrone dimaleate|Given IV
79642794|NCT00191880|Drug|atomoxetine|
79642795|NCT00551278|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
79642796|NCT04724525|Other|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
79642797|NCT00551317|Drug|Darapladib (SB480848)|
79642798|NCT00551356|Drug|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
79642799|NCT00551356|Drug|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
79642800|NCT00551395|Procedure|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
79807071|NCT00461305|Drug|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
79807072|NCT04172129|Device|Total Hip Arthroplasty|
79807073|NCT04172051|Behavioral|Tony Robbins Date with Destiny|DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
79642801|NCT00551395|Procedure|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
79642802|NCT02963337|Drug|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
79642803|NCT02963337|Drug|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
79642804|NCT00551434|Dietary Supplement|Creatine|Creatine 21 g daily
79642805|NCT00551434|Dietary Supplement|L-arginine and creatine|L-arginine
79642806|NCT00551434|Dietary Supplement|l-arginine|l-arginine 9 g daily
79642807|NCT00551434|Dietary Supplement|placebo, double|placebo
79807074|NCT01022671|Drug|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
79807075|NCT01022749|Drug|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
79807076|NCT01022749|Biological|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
79642808|NCT00161798|Biological|Tick-borne encephalitis vaccine|
79642809|NCT00551473|Drug|Lavoltidine|
79315532|NCT05377619|Drug|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
79315533|NCT02412319|Drug|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
79315534|NCT02412319|Other|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
79315535|NCT04393337|Other|Gestational Age Chart Method|The endotracheal tube insertion depth is obtained by the gestational age chart
79315536|NCT04393337|Other|Nasal-Tragus Length Method|The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
79315537|NCT02412397|Procedure|Total Shoulder Arthroplasty|
79477254|NCT03028025|Device|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
79315538|NCT04322513|Diagnostic Test|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
79315539|NCT00703573|Drug|S-777469 400 mg|S-777469 400 mg BID
79315540|NCT00703573|Drug|S-777469 800 mg|S-777469 800 mg BID
79315541|NCT00703573|Drug|Placebo|Placebo BID
79315542|NCT02412241|Other|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
79315543|NCT02412241|Procedure|Technical measure|Undergo standard CT scan
79477255|NCT02955329|Drug|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
79315544|NCT02412241|Procedure|Technical measure|Undergo standard ultrasound
79315545|NCT03199157|Drug|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
79477256|NCT02955329|Drug|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
79477257|NCT02955329|Device|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
79315546|NCT02412163|Device|Ellipse IM HTO Nail|
79315547|NCT02422537|Dietary Supplement|Unmodified wheat bran|
79315548|NCT02422537|Dietary Supplement|Wheat bran with reduced particle size|
79315549|NCT02422537|Dietary Supplement|Destarched pericarp-enriched wheat bran|
79315550|NCT02422537|Dietary Supplement|No wheat bran fraction|
79315551|NCT02416999|Drug|Ultra-low dose Bevacizumab|
79315552|NCT02416999|Drug|Temozolomide|
79315553|NCT04194671|Biological|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
79315554|NCT04194671|Other|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
79315555|NCT02422693|Other|Aquatic Exercises|Exercises performed in the water.
79315556|NCT02422693|Other|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
79477258|NCT02359058|Drug|Ramucirumab|Administered IV
79477259|NCT02359058|Drug|Capecitabine|Administered orally
79477260|NCT02359058|Drug|Cisplatin|Administered IV
79477261|NCT02359058|Drug|S-1|Administered orally
79477262|NCT02359058|Drug|Oxaliplatin|Administered IV
79477263|NCT02404610|Procedure|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
79477264|NCT02404610|Procedure|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
79477265|NCT02404610|Drug|propofol|
79477266|NCT02359916|Other|Time delays on delivery of less healthy snacks|
79477267|NCT02359916|Other|25%/$0.25 discount on healthy snacks|
79642810|NCT03455803|Device|CPAP|Continuous positive airway pressure
79315557|NCT02412007|Other|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~Standing up from squatting position to catch an object of interest.~Squatting from standing position to pick an object of interest.~Walking to reach an object of interest.~Climbing up steps to get an object of interest.~Climbing down steps to keep the above object of interest.~Cycling~Kicking a football~Dancing"
79807077|NCT02664623|Procedure|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
79807078|NCT02664623|Procedure|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
79807079|NCT01022827|Other|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes [about 6 minutes for each muscle and order was random] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
79315558|NCT02412085|Drug|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~body weight < 80kg: 50 mg every 4 weeks~body weight ≥ 80 kg: 100 mg every 4 weeks"
79315559|NCT03176797|Diagnostic Test|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
79972171|NCT02512120|Device|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
79477268|NCT02359916|Other|25%/$0.25 tax on less healthy snacks|
79477269|NCT02405390|Procedure|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
79642811|NCT00191919|Drug|Duloxetine Hydrochloride|
79642812|NCT00191919|Drug|Placebo|
79807080|NCT01022905|Biological|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
79807081|NCT00645905|Drug|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
79807082|NCT00645905|Drug|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
79807083|NCT00647777|Drug|Olanzapine Tablets 5 mg|5mg, single dose fed
79807084|NCT00647777|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fed
79315560|NCT01679405|Drug|BIBW 2992|once daily per os
79477270|NCT02405390|Procedure|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
79477271|NCT02405390|Device|Storz C-Mac® laryngoscope|
79477272|NCT02881775|Device|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
79477273|NCT02881775|Device|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
79477274|NCT03109769|Behavioral|Mobile phone application|
79477275|NCT03109769|Behavioral|Verbal oral hygiene instructions|
79642813|NCT00161837|Biological|Vero Cell-derived Influenza Vaccine|
79642814|NCT00161837|Biological|Egg-derived Influenza Vaccine|
79807085|NCT04173611|Drug|EXPAREL|Injection into the Intrathecal space.
79807086|NCT04173611|Drug|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
79807087|NCT04173611|Other|Placebo|Injection into the Intrathecal space.
79807088|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
79642815|NCT00551512|Drug|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
79642816|NCT00551551|Other|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
79642817|NCT00551551|Other|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
79315561|NCT03175861|Other|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
79477276|NCT02957123|Drug|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
79477277|NCT03110003|Drug|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
79477278|NCT03110003|Drug|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
79642818|NCT00161876|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
79642819|NCT00424320|Drug|Sodium bicarbonate|
79642820|NCT00551590|Drug|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
79642821|NCT00551590|Drug|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
79642822|NCT00551590|Drug|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
79315562|NCT03175705|Biological|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
79315563|NCT03175705|Drug|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
79315564|NCT03175705|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
79315565|NCT00301457|Drug|Anastrozole|1 mg once daily oral dose
79315566|NCT03175783|Device|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
79315567|NCT03175393|Device|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
79315568|NCT02422459|Behavioral|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
79315569|NCT03270527|Other|High SFA diet (Diet 1)|'Diet 1' will contain ~18% of its total energy as SFA .
79315570|NCT03270527|Other|Low SFA diet (Diet 2)|'Diet 2' will contain ~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
79315571|NCT03198845|Other|video game|20-min per session for 3 times per week for a 4-week duration
79315572|NCT03198845|Other|exercise|20-min per session for 3 times per week for a 4-week duration
79315573|NCT02422225|Device|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention]~Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~Stimulation site <Experimental group>~Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit <Control group> Sham stimulation"
79315574|NCT02422225|Device|Sham Eldith DC-STIMULATOR|
79315575|NCT03177109|Drug|5% fluoride varnish|Applied topically as a coating at single point in time
79315576|NCT03177109|Drug|8% arginine containing paste|Applied topically as a coating at single point in time
79642823|NCT00551590|Drug|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
79642824|NCT00551629|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
79315577|NCT03177109|Drug|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
79642825|NCT00551629|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
79642826|NCT00551629|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
79972172|NCT02512120|Device|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
79642827|NCT00551629|Biological|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
79315578|NCT03198923|Biological|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
79315579|NCT03198455|Dietary Supplement|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
79315580|NCT03198455|Other|Placebo|Drinking water with food coloring and salt
79972173|NCT01202201|Other|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
79315581|NCT03198611|Diagnostic Test|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
79315582|NCT03176875|Other|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
79315583|NCT03176875|Other|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
79315584|NCT03185897|Other|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
79315585|NCT02421991|Behavioral|Telephone Delivered Intervention|
79642828|NCT00161915|Drug|Fibrin Sealant|
79642829|NCT00185172|Other|placebo|Placebo oral tablets for 2 weeks
79972174|NCT03345862|Behavioral|non-pharmacological multicomponent|Following the proposal of Nicholson & Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home [30-60 minutes] for 16 weeks (1 fortnightly session) and 5 telephone sessions [20 min.] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
79315586|NCT03175627|Device|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
79315587|NCT03175627|Device|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
79315588|NCT01603355|Drug|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
79642830|NCT00185172|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
79642831|NCT00185172|Drug|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
79655717|NCT04552678|Behavioral|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79642832|NCT04836286|Behavioral|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
79972175|NCT01199159|Drug|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
79972176|NCT01199159|Drug|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
79642833|NCT00191997|Drug|Olanzapine|
79972177|NCT05669963|Drug|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
79315589|NCT03177031|Device|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
79315590|NCT03177031|Device|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
79972178|NCT02507440|Drug|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
79315591|NCT02416843|Other|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
79315592|NCT02411851|Drug|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
79642834|NCT00551668|Procedure|proximal patellar surgery|Initial proximal patellar surgery
79642835|NCT00551668|Procedure|Nonoperative|Nonoperative without surgery
79642836|NCT00551824|Drug|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
79972179|NCT02507440|Drug|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
79972180|NCT02507440|Drug|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
79807089|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
79807090|NCT02665715|Other|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
79807091|NCT02665715|Other|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
79807092|NCT02665637|Drug|Trastuzumab|Each patient may receive single dose by intravenous infusion
79807093|NCT00647855|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
79807094|NCT00647855|Drug|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
79315593|NCT02411851|Other|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
79642837|NCT00161954|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
79807095|NCT04062539|Device|Sentinel and Spider|Dual filter and single filter
79807096|NCT02666729|Procedure|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
79807097|NCT02666729|Procedure|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
79807098|NCT00648011|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
79807099|NCT00648011|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
79807100|NCT04173299|Procedure|early tips|patients with early tips
79807101|NCT04171973|Device|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
79315594|NCT05094947|Procedure|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
79315595|NCT05094947|Procedure|trial without catheter|catheter Foley
79315596|NCT05094947|Drug|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
79315597|NCT02421913|Drug|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
79315598|NCT05094869|Behavioral|Use of mobile health application|The APP would regularly send messages including the medication reminder, health education knowledge, etc.
79315599|NCT05094869|Behavioral|Online interaction|The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
79315600|NCT05094869|Behavioral|Self follow-up reminders|The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)
79807102|NCT04171973|Device|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
79807103|NCT00646529|Drug|budesonide/formoterol (Symbicort)|
79807104|NCT00646529|Drug|budesonide (Pulmicort)|
79807105|NCT00648089|Drug|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
79807106|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
79972181|NCT04962659|Behavioral|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
79972182|NCT02507362|Radiation|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
79972183|NCT02507362|Radiation|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
79315601|NCT05094869|Behavioral|Intelligent follow-up reminders|The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
79315602|NCT03179293|Drug|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
79315603|NCT03179293|Drug|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
79315604|NCT02416765|Other|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
79315605|NCT02416765|Drug|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
79315606|NCT02416765|Drug|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
79315607|NCT02416765|Other|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
79315608|NCT05094479|Behavioral|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
79315609|NCT02703259|Drug|Gabapentin|
79642838|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
79807107|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
79807108|NCT02666885|Radiation|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
79807109|NCT02664389|Genetic|Genetic analysis|Sequencing of 200 selected genes in the different study populations
79807110|NCT00856544|Drug|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
79807111|NCT00856544|Drug|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
79807112|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
79807113|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
79315610|NCT02703259|Drug|Acetaminophen|
79315611|NCT02703259|Drug|Celecoxib|
79315612|NCT02366273|Other|PASI and HOMA index|
79315613|NCT05094167|Other|V9|one times a day during the whole treatment
79972184|NCT02507362|Drug|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
79315614|NCT05094167|Other|placebo|placebo
79315615|NCT02416687|Device|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
79315616|NCT05093465|Behavioral|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
79972185|NCT02507362|Procedure|epithelial debridement|corneal epithelium will be removed by a cottons swab
79972186|NCT04958369|Device|Ultrasound-guided axillary venous access|Venous access is obtained through ultrasound-guided axillary vein puncture and Seldinger technique.
79315617|NCT05093465|Other|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
79972187|NCT04958369|Device|Cephalic venous access|Venous access is obtained through cephalic vein cut-down.
79972188|NCT03196284|Drug|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
79972189|NCT03196284|Drug|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
79972190|NCT05640830|Drug|trastuzumab, bevacizumab with paclitaxel (triple combination)|Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
79315618|NCT02411695|Drug|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
79315619|NCT05093309|Behavioral|Educational Webinar|At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.
79315620|NCT05093309|Behavioral|Resources|After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.
79315621|NCT05093309|Behavioral|Reminders|Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
79642839|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
79642840|NCT00185250|Drug|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
79642841|NCT00185250|Drug|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
79642842|NCT04798066|Biological|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
79315622|NCT02416921|Behavioral|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
79642843|NCT00551863|Behavioral|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
79972191|NCT02512198|Behavioral|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
79642844|NCT00551902|Procedure|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
79315623|NCT02416921|Behavioral|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
79315624|NCT05093231|Drug|Pembrolizumab|Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
79315625|NCT05093231|Drug|Olaparib|Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
79807114|NCT02664233|Behavioral|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
79315626|NCT02411617|Device|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
79477279|NCT03110471|Behavioral|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
79315627|NCT02410525|Drug|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug [11C]PF-06427878 on Day 1 of all 3 Periods
79477280|NCT03110471|Behavioral|usual care|usual care
79477281|NCT03111407|Procedure|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
79642845|NCT00551902|Procedure|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
79807115|NCT00646685|Procedure|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
79807116|NCT00646685|Procedure|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
79315628|NCT02410525|Drug|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
79315629|NCT02410525|Drug|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
79477282|NCT02958995|Other|No Intervention|
79477283|NCT03032393|Other|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
79477284|NCT03032393|Other|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
79642846|NCT00161993|Drug|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
79807117|NCT02663921|Other|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~Immediately after the light exposure;~30 minutes after light exposure; and~1 hour after light exposure."
79807118|NCT02663921|Other|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~Visual Clinical Assessment~Spectroscopy~Colorimetry"
79807119|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
79807120|NCT00648245|Drug|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
79807121|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
79807122|NCT00648245|Drug|Placebo|Placebo given once daily for 21 days by nebulizer
79972192|NCT04938947|Device|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
79477285|NCT03114683|Drug|PD1|IBI308 200mg/3 weeks
79477286|NCT02959307|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
79642847|NCT00161993|Drug|Gammagard S/D (Solvent/Detergent)|
79642848|NCT00551941|Procedure|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
79477287|NCT02959307|Device|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
79477288|NCT03114995|Drug|Tirofiban|
79477289|NCT02959853|Drug|Anastrazole|
79477290|NCT02959853|Behavioral|weight loss|
79477291|NCT00374465|Drug|Verapamil|
79477292|NCT00374465|Drug|Carvedilol|
79477293|NCT03036215|Behavioral|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
79477294|NCT02962427|Drug|Sphenopalatine ganglion Block|
79972193|NCT04938947|Other|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
79315630|NCT03198377|Device|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
79972194|NCT04938947|Other|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
79477295|NCT02962427|Procedure|Epidural blood patch|
79807123|NCT00648245|Drug|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
79972195|NCT03636594|Other|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
79477296|NCT02039726|Drug|Quizartinib|20 or 30 mg quizartinib tablets administered orally once daily
79477297|NCT02039726|Drug|Salvage Chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
79477298|NCT03036293|Drug|Tenoten|Tablet for oral use.
79477299|NCT03036293|Drug|Placebo|Tablet for oral use.
79642849|NCT00551941|Procedure|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
79642850|NCT00185289|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
79972196|NCT04500262|Device|Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|Ultrasound-guided biopsy using 14G open-tip pulsed biopsy needle
79972197|NCT04500262|Device|Core needle biopsy (CNB)|Ultrasound-guided biopsy using standard of care core needle biopsy
79972198|NCT03730961|Drug|BMS-986231|Intravenous administration
79972199|NCT03730961|Drug|Furosemide|Intravenous administration
79972200|NCT03730961|Drug|Placebo|Intravenous administration
79972201|NCT01078454|Drug|melphalan|Given PO
79807124|NCT00648323|Drug|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
79807125|NCT00648557|Drug|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
79972202|NCT01078454|Drug|dexamethasone|Given PO
79972203|NCT01078454|Drug|bortezomib|Given IV
79972204|NCT02968602|Drug|Minocycline|Minocycline capsules taken twice daily for two weeks.
79972205|NCT02968602|Other|Placebo|Placebo capsules taken twice daily for two weeks.
79972206|NCT03345004|Biological|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
79807126|NCT00648557|Drug|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
79972207|NCT03345004|Dietary Supplement|Vitamin D|Oil suspension of Vitamin D
79477300|NCT02408198|Behavioral|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
79477301|NCT02040116|Drug|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
79642851|NCT00551980|Behavioral|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
79642852|NCT00552136|Procedure|Ankle Arthroplasty|
79642853|NCT00552136|Procedure|Ankle Arthrodesis|
79642854|NCT00162071|Drug|apadenoson|
79642855|NCT00552214|Device|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
79642856|NCT00185328|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
79642857|NCT04766164|Behavioral|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
79477302|NCT03037541|Drug|Carac Cream|Carac Cream will be used once daily for seven consecutive days
79477303|NCT03037541|Drug|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
79642858|NCT00552253|Drug|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1~0.3 mU/L. It will be discontinued for 3 months. Then
79477304|NCT02986256|Behavioral|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
79642859|NCT00162110|Drug|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
79642860|NCT00552331|Device|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
79972208|NCT03345004|Biological|Placebo for Diamyd|Alhydrogel® only
79642861|NCT00552331|Device|LISS|treatment of distal femur fractures with less invasive stabilization systems
79642862|NCT00552370|Drug|Lantus®|
79642863|NCT00552487|Drug|synacthen|1 µg synacthen in the vein
79642864|NCT00162149|Drug|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
79642865|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
79642866|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
79642867|NCT00162149|Drug|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
79807127|NCT04170569|Behavioral|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
79807128|NCT00856388|Drug|fludarabine phosphate|Given IV
79807129|NCT00856388|Drug|melphalan|Given IV
79807130|NCT00856388|Radiation|total-body irradiation|Undergo total-body irradiation
79477305|NCT02986256|Behavioral|Visit at home|Home visit by the referring nurse every 15 days
79477306|NCT02360774|Drug|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
79477307|NCT02360774|Drug|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
79477308|NCT02361476|Drug|Clonidine|Injection - during surgery
79477309|NCT02361476|Drug|Placebo|Injection - during surgery
79972209|NCT03345004|Dietary Supplement|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
79972210|NCT03552757|Drug|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
79972211|NCT03552757|Drug|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
79642868|NCT00552526|Dietary Supplement|Ketogenic diet|Ketogenic diet is a very strict high fat diet
79655718|NCT04552678|Behavioral|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
79807131|NCT00856388|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
79477310|NCT02363270|Procedure|Ketamine|IV Push or or IV Drip
79477311|NCT02042534|Drug|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
79477312|NCT02042534|Drug|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
79477313|NCT03038399|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
79477314|NCT03038399|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
79477315|NCT03038399|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
79477316|NCT03038399|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
79477317|NCT02043704|Drug|IV Acetaminophen|Details covered in arm description.
79477318|NCT03117569|Drug|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
79477319|NCT02363972|Device|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
79477320|NCT02963597|Device|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
79477321|NCT02963597|Other|Standard Medical Therapy|Standard medical therapy according to current guidelines.
79477322|NCT02410382|Drug|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
79477323|NCT02410382|Drug|Placebo|oral placebo
79477324|NCT04737005|Procedure|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
79477325|NCT03038867|Drug|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
79477326|NCT03038867|Drug|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
79477327|NCT03039179|Device|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
79477328|NCT02963987|Other|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
79477329|NCT03040427|Drug|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
79477330|NCT03119831|Drug|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
79477331|NCT03119831|Drug|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
79477332|NCT03119831|Drug|C31G|Rinsing with 15ml for one minute twice daily for 14 days
79477333|NCT02965781|Drug|SADBE|Topical solution
79477334|NCT02965781|Other|Placebo|Topical solution
79477335|NCT02968277|Device|LifeWalker Upright|LifeWalker (LW) upright walker
79477336|NCT02968277|Device|Predicate Device|Individual's personal walker
79477337|NCT02968277|Device|Standard Rollator|A control rollator device
79477338|NCT03124121|Drug|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
79477339|NCT04333277|Other|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
79807132|NCT00856388|Biological|anti-thymocyte globulin|Given IV
79807133|NCT00648401|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
79807134|NCT00648401|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
79807135|NCT04132154|Procedure|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
79972212|NCT03552757|Drug|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
79642869|NCT00552526|Drug|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
79642870|NCT00552565|Drug|Rezular 15mg|Oral Tablets
79642871|NCT00552565|Drug|Placebo|placebo
79477340|NCT04333277|Other|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
79477341|NCT03041441|Device|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
79642872|NCT00552565|Drug|Rezular|Rezular 37.5mg 3xday up to 12 weeks
79477342|NCT03041441|Procedure|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
79642873|NCT00552565|Drug|Rezular|Rezular 75mg 3xday up to 12 weeks
79642874|NCT00552604|Drug|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
79642875|NCT00552604|Drug|Placebo|Matching placebo capsules, twice daily
79642876|NCT00552643|Device|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
79477343|NCT03041441|Procedure|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
79477344|NCT03041909|Drug|GBT440|Oral drug
79477345|NCT03042299|Drug|TAK-536|TAK-536 granules.
79477346|NCT03042299|Drug|TAK-536|TAK-536 tablet.
79477347|NCT03043079|Diagnostic Test|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
79477348|NCT02971631|Other|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
79477349|NCT02971631|Other|Placebo|Infusion of 1% human albumin in normal saline
79477350|NCT00374699|Drug|Velcade|
79642877|NCT00552643|Device|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
79315631|NCT03198377|Device|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
79315632|NCT03198377|Device|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
79642878|NCT00162188|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
79972213|NCT03552757|Drug|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
79315633|NCT03198377|Device|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
79315634|NCT02411383|Device|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
79315635|NCT03198299|Device|MEI BIN insoles|wearing insoles for 12 weeks
79315636|NCT02421835|Dietary Supplement|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
79315637|NCT02421835|Dietary Supplement|Placebo|700 mg Maltodextrin per day
79315638|NCT04542395|Behavioral|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
79315639|NCT02410447|Device|Defocused shock wave therapy (DUOLITH® SD1)|
79315640|NCT02410681|Device|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~3 recordings after the baseline visit~3 recordings 6 weeks after the baseline visit~3 recordings one year after the baseline visit"
79315641|NCT02410681|Radiation|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
79315642|NCT02410681|Other|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~At the baseline visit~Three months after the baseline visit~One year after the baseline visit"
79315643|NCT03197909|Other|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
79315644|NCT02411227|Behavioral|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
79477351|NCT00374777|Drug|zolpidem MR|oral
79477352|NCT00374777|Drug|nitrazepam|oral
79477353|NCT00374777|Drug|placebo|oral
79477354|NCT03045809|Diagnostic Test|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
79477355|NCT02044796|Drug|Cladribine|Given IV
79477356|NCT02044796|Drug|Cytarabine|Given IV
79477357|NCT02044796|Biological|Filgrastim|Given SC
79642879|NCT00192153|Biological|CAIV-T or TIV|
79642880|NCT04755088|Drug|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
79477358|NCT02044796|Other|Laboratory Biomarker Analysis|Correlative studies
79972214|NCT03730103|Other|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
79477359|NCT02044796|Drug|Mitoxantrone Hydrochloride|Given IV
79477360|NCT03124823|Device|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
79477361|NCT03124901|Device|DCI pulse oximeter sensor|
79477362|NCT03124979|Device|LNCS DBI Sensor|Noninvasive Measurement of SpO2
79477363|NCT02045108|Behavioral|Active Retraining|
79477364|NCT02045108|Device|Sham TDCS|
79477365|NCT02045108|Device|Active TDCS|
79477366|NCT02045108|Behavioral|Sham Retraining|
79477367|NCT02973503|Drug|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
79477368|NCT03127943|Drug|Lidocaine|Efficacy for mandibular molar and canine anesthesia
79477369|NCT03047447|Behavioral|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
79477370|NCT02412098|Drug|Eleclazine|Eleclazine tablets administered orally
79477371|NCT03048383|Drug|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
79477372|NCT03048383|Drug|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
79477373|NCT03048383|Drug|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
79315645|NCT05093075|Other|Therapeutic Plasma Exchange|TPE procedures will be performed using a Spectra Optia ® apheresis machine (Terumo BCT, Lakewood, USA) according to usual-care procedures for apheresis. Venous access for the TPE procedures will be obtained through a double lumen dialysis catheter to provide adequate flow rates required for TPE. Regional citrate anticoagulation will be used for anticoagulation within the apheresis circuit. One to two grams of calcium chloride will be infused as per standard during TPE to prevent symptomatic hypocalcemia. Plasma volume will be calculated as per a standard formula whereby estimated plasma volume (in liters) = 0.07 x weight (kg) x (1 - hematocrit). In patients on dialysis, dialysis will be interrupted for the duration of the procedure. Antibiotics will be given after TPE to avoid clearance of the antibiotics. On the first day of TPE, a repeat dose of antibiotics will be administered after completion of TPE. Nurse clinicians trained in TPE will perform the TPE procedures.
79642881|NCT04755088|Drug|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
79972215|NCT03345706|Procedure|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
79642882|NCT04751890|Behavioral|Structured home-based exercise|Low-intensity interval walking program prescribed at hospital and performed at daily at home
79642883|NCT04751890|Behavioral|Walking advice|Walking advice according to the guidelines for peripheral artery disease patients
79315646|NCT02411149|Drug|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
79315647|NCT02411149|Drug|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
79315648|NCT02411149|Drug|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
79477374|NCT02045264|Drug|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
79477375|NCT02975297|Drug|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
79642884|NCT00162227|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
79642885|NCT04709926|Other|Survey|Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.
79972216|NCT03345706|Procedure|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
79972217|NCT03003468|Drug|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
79642886|NCT04709926|Other|Interview (optional)|Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
79972218|NCT03003468|Drug|MK-3475|200mg IV
79972219|NCT03003468|Drug|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
79807136|NCT02660099|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
79807137|NCT02663999|Drug|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
79315649|NCT04413227|Drug|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
79807138|NCT00648479|Device|The Guiding Star|
79315650|NCT03175315|Behavioral|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
79315651|NCT02410369|Drug|S-588410|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
79315652|NCT02410369|Drug|Placebo|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
79807139|NCT00648479|Device|fluoroscopy (OEC 9800 - General Electric)|
79807140|NCT04169087|Other|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
79807141|NCT04171427|Other|Lithium liposome|Cosmetic product
79807142|NCT04171427|Other|Placebo|Cosmetic product vehicle
79807143|NCT04171739|Drug|Itraconazole oral solution|200 mg once daily on Days 6 to 15
79807144|NCT04171739|Drug|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
79477376|NCT02975297|Drug|NRT|Nicotine Patch (21mg) / 24 hours.
79315653|NCT03198143|Drug|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
79972220|NCT02511808|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
79642887|NCT00425529|Device|Module AOX (attached to Sondalis ISO)|
79972221|NCT02511808|Behavioral|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
79315654|NCT03198143|Drug|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
79315655|NCT03179215|Diagnostic Test|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
79315656|NCT03198065|Procedure|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
79477377|NCT02975297|Behavioral|Counseling|Brief individual behavioral smoking cessation counseling.
79477378|NCT02975297|Drug|Placebo|Normal saline.
79477379|NCT02046200|Drug|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
79477380|NCT02046200|Drug|Placebo|Matched placebo
79477381|NCT02046200|Drug|Alcohol|
79807145|NCT04171739|Drug|Olorofim|Single oral dose on Days 1 and 11
79315657|NCT03198065|Procedure|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
79315658|NCT05233423|Device|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
79315659|NCT03197987|Device|Endocuff|Endocuff-assisted colonoscopy
79315660|NCT03197987|Device|cap|Cap-assisted colonoscopy
79315661|NCT03175237|Other|Mirror Therapy|
79315662|NCT02410993|Procedure|CABG surgery|
79807146|NCT02656043|Drug|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
79315663|NCT02410135|Drug|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
79315664|NCT05080127|Combination Product|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
79315665|NCT02410915|Device|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
79315666|NCT02410915|Other|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
79315667|NCT05054621|Biological|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
79315668|NCT05054621|Biological|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
79315669|NCT02410759|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
79642888|NCT04705012|Other|Submucosal supportive therapy|Increased frequency of submucosal cleaning using a rotating chitosan brush
79315670|NCT02410759|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
79315671|NCT04459091|Dietary Supplement|Amino Essential Acid|8 gr die in two administration
79315672|NCT04459091|Dietary Supplement|placebo|8 gr die in two administration
79315673|NCT03175081|Drug|Ropivacaine|Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
79315674|NCT03175081|Drug|Normal saline|Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
79315675|NCT05016479|Device|Accelerated repetitive Transcranial Magnetic Stimulation|arTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with a Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
79315676|NCT03175003|Other|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
79315677|NCT02406625|Behavioral|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
79642889|NCT04701580|Diagnostic Test|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
79807147|NCT02656043|Drug|Placebo|
79807148|NCT02656277|Other|Decision Tool|
79807149|NCT02656277|Other|Information on Shoulder Dislocation|
79972222|NCT02511808|Behavioral|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
79807150|NCT02656121|Drug|Vitamin D|6000 IU of vitamin D3
79972223|NCT02506972|Other|Classic Quaker Quick Oats|Various doses of oats without or with sugar
79315678|NCT02409979|Other|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
79315679|NCT02409979|Other|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
79315680|NCT02409979|Other|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
79315681|NCT02409901|Behavioral|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
79315682|NCT03171961|Behavioral|online visit group|subjects has online visit with dietitian every 2 weeks+diet
79315683|NCT03171961|Behavioral|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
79315684|NCT03171961|Behavioral|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
79315685|NCT02409823|Drug|Atypical Antipsychotics|any atypical antipsychotic
79315686|NCT02409511|Other|non intervention|
79315687|NCT02406469|Dietary Supplement|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
79477382|NCT02978339|Drug|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
79477383|NCT02367014|Drug|elamipretide (low dose)|elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
79315688|NCT02406313|Other|CTS|Standardized Thermal Cure
79315689|NCT02406313|Other|ETP|Patient Therapeutic Education
79477384|NCT02367014|Drug|elamipretide (intermediate dose)|elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
79315690|NCT04481269|Device|Surface-modified composite coated orthopedic implants|The surface-modified composite coated orthopedic implants have the capacity of high binding strength, high tissue-inducing activity and intelligent bacteria-resistance. The implant devices are expected to be used in the prevention and treatment of plant-related infections in orthopedic surgeries.
79315691|NCT04481269|Device|conventional orthopedic implants|conventional orthopedic implants
79315692|NCT02401477|Drug|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
79315693|NCT03174769|Other|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
79315694|NCT03174769|Other|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
79315695|NCT02401399|Dietary Supplement|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
79477385|NCT02367014|Drug|elamipretide (high dose)|elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
79477386|NCT02367014|Drug|Placebo|placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
79315696|NCT02401399|Dietary Supplement|High protein formula|The patients receive high protein formula during 15 days before surgery
79315697|NCT02401399|Dietary Supplement|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
79972224|NCT02506972|Other|Cream of Rice Cereal|Various doses of cereal without sugar
79477387|NCT02367872|Drug|TAK-272|TAK-272 tablet
79972225|NCT03727841|Drug|Marizomib|0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
79477388|NCT02979899|Biological|TRC105|TRC105 antibody
79477389|NCT02979899|Drug|Votrient|pazopanib
79477390|NCT00374855|Drug|PPAR alpha|
79972226|NCT03345628|Drug|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
79315698|NCT03174691|Diagnostic Test|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
79315699|NCT02406157|Device|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
79477391|NCT00374855|Drug|Hydrochlorothiazide|
79972227|NCT03552523|Device|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
79972228|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
79972229|NCT03345550|Drug|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
79972230|NCT03345550|Drug|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
79315700|NCT02406157|Device|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
79477392|NCT00374855|Drug|Placebo|
79972231|NCT03728101|Drug|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
79315701|NCT03174457|Drug|Micafungin|Intravenous
79477393|NCT02412644|Drug|apremilast|
79477394|NCT03134963|Other|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
79477395|NCT03134963|Other|Blood pressure monitoring|Continuous blood pressure recording
79477396|NCT03134963|Other|Heart rate monitoring|Continuous heart rate monitoring
79477397|NCT03134963|Other|End tidal CO2 monitoring|Continuous ETCO2 monitoring
79477398|NCT03134963|Other|Addenbrooke's cognitive examination|Performance of a memory test
79477399|NCT02980211|Drug|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
79477400|NCT02412956|Behavioral|SmokefreeMOM Text|
79477401|NCT03054077|Other|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
79477402|NCT02046980|Procedure|Gufoni|
79807151|NCT02656121|Drug|Ovulatory Agent|only Clomophine Citrate
79972232|NCT03186378|Combination Product|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
79972233|NCT02511964|Behavioral|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
79972234|NCT02511964|Behavioral|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
79972235|NCT03844217|Drug|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
79477403|NCT02046980|Procedure|Vibration|
79477404|NCT02046980|Procedure|Sham|
79477405|NCT02983877|Behavioral|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
79477406|NCT02413034|Drug|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
79477407|NCT02413034|Other|Control group|no antibiotic prophylaxis
79477408|NCT04737473|Drug|Opiod Free Anesthesia|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
79477409|NCT03136913|Device|Cytoplast® TXT-200|Non-resorbable membrane
79807152|NCT02659865|Drug|Placebo|Administered orally
79972236|NCT03844217|Drug|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
79315702|NCT00701701|Biological|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m^2 IV q4w after Myozyme infusion for 6 months.
79315703|NCT00701701|Biological|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
79972237|NCT04170972|Other|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
79315704|NCT02401711|Behavioral|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
79315705|NCT02401711|Behavioral|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
79315706|NCT02401711|Behavioral|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
79315707|NCT03174613|Drug|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
79315708|NCT03174613|Drug|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
79315709|NCT02409745|Procedure|endometrial scratch|local injury to the endometrium by Pipelle
79315710|NCT02401321|Behavioral|Telephone-Based Intervention|Complete Taking Care of Her program
79315711|NCT02401321|Other|Caregiver-Assisted Training|Complete Taking Care of Her program
79642890|NCT04701580|Diagnostic Test|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
79642891|NCT00552682|Drug|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
79642892|NCT00185367|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
79972238|NCT02515864|Drug|FYU-981|
79972239|NCT02515864|Drug|Placebo|
79972240|NCT02515864|Drug|Moxifloxacin|
79315712|NCT02401321|Other|Questionnaire Administration|Ancillary studies
79315713|NCT02401321|Other|Quality-of-Life Assessment|Ancillary studies
79315714|NCT03174145|Behavioral|Positive behaviour|Information about T4P1010 treatment
79315715|NCT03174145|Drug|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
79315716|NCT03174145|Genetic|Pharmacogenetic|Blood sample of 10 millilitres maximum
79315717|NCT03174145|Other|Questionnaires and diary completion|Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
79315718|NCT04480957|Biological|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
79315719|NCT04480957|Biological|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
79315720|NCT04480957|Biological|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
79315721|NCT04480957|Biological|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
79315722|NCT04480957|Biological|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
79315723|NCT04480957|Biological|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
79315724|NCT04480957|Other|Placebo|Sterile 0.9% saline
79807153|NCT02659865|Drug|LY3039478 original formulation|Administered orally
79972241|NCT02515864|Drug|Moxifloxacin Placebo|
79315725|NCT02401243|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
79477410|NCT03136913|Device|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
79477411|NCT03136913|Procedure|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
79477412|NCT03136913|Procedure|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
79477413|NCT02413580|Biological|IGIV-C|An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
79315726|NCT02406079|Procedure|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
79477414|NCT02985827|Drug|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
79807154|NCT02659865|Drug|LY3039478 new formulation|Administered orally
79972242|NCT00687596|Drug|TAC-101|Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
79972243|NCT00687596|Drug|Placebo|Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
79315727|NCT02406001|Device|Tigran PTG|Open Flap Debridement
79315728|NCT02406001|Procedure|Surgical intervention|Open Flap Debridement
79477415|NCT02985827|Drug|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
79477416|NCT04707287|Other|No Intervention|No intervention used. This is observational study
79477417|NCT02369900|Drug|Esmolol|
79477418|NCT02369900|Other|Saline|
79477419|NCT03054857|Drug|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
79477420|NCT03054857|Drug|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
79477421|NCT02370056|Diagnostic Test|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
79477422|NCT02370056|Diagnostic Test|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
79972244|NCT02507206|Drug|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
79315729|NCT02409433|Drug|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
79315730|NCT02409433|Drug|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
79315731|NCT01989754|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
79315732|NCT01989754|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
79315733|NCT01989754|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
79315734|NCT01619878|Drug|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
79477423|NCT02987231|Procedure|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
79315735|NCT02015104|Biological|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
79315736|NCT02015104|Biological|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
79477424|NCT02987231|Device|ES|Local electric stimulation for 120 seconds, once a day for a week
79477425|NCT02987231|Device|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
79477426|NCT02414204|Drug|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
79477427|NCT02414204|Other|Placebo|Placebo will be over encapsulated to identical to drug comparison
79807155|NCT02656355|Other|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
79807156|NCT02656355|Other|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
79807157|NCT04169555|Procedure|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
79807158|NCT04169555|Other|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
79315737|NCT04178746|Device|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
79807159|NCT02659553|Procedure|steatosis|Liver Transplantation with graft steatosis
79807160|NCT00648713|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
79315738|NCT01619800|Device|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
79315739|NCT01619800|Device|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
79315740|NCT01989208|Other|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
79315741|NCT01989208|Other|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
79315742|NCT01619410|Biological|Linezolid|Linezolid 600 mg every 12 hours for 7 days
79315743|NCT01619410|Biological|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
79315744|NCT01966042|Procedure|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
79315745|NCT01966042|Procedure|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
79315746|NCT01966042|Procedure|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
79315747|NCT01966042|Biological|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
79315748|NCT04416724|Procedure|Phacoemulsification|Lens removal by Phacoemulsification
79477428|NCT02987621|Device|tDCS|Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
79807161|NCT00648713|Drug|Lamisil® Tablets 250 mg|250mg, single dose fed
79807162|NCT02659319|Behavioral|Family Lifestyle (FL)|12-week Family Food & Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
79807163|NCT02659319|Behavioral|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
79807164|NCT02659319|Behavioral|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
79315749|NCT04416724|Device|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
79315750|NCT02014480|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
79972245|NCT02507206|Drug|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
79972246|NCT03844373|Dietary Supplement|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
79315751|NCT02014480|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
79315752|NCT02014480|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
79477429|NCT02989493|Drug|Doxazosin|Doxazosin
79477430|NCT02989493|Other|Placebo|Placebo
79477431|NCT02050334|Drug|CC100|CC100 reconstituted in diluent
79477432|NCT02050334|Drug|Placebo|Diluent. Amount to match CC100 dose.
79477433|NCT03062267|Other|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
79477434|NCT00355004|Other|counseling intervention|
79315753|NCT05016167|Procedure|Replacement every 24 hours|"Processing Steps:~The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~The data were recorded."
79315754|NCT05016167|Procedure|Replacement every 12 hours|"Processing Steps:~Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~Monitored again.~Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~Immediately after drying, skin moisture was measured from the monitored areas.~The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~The data were recorded."
79315755|NCT01261247|Drug|panobinostat|Given orally
79315756|NCT01261247|Other|laboratory biomarker analysis|Correlative studies
79477435|NCT00355004|Procedure|fecal occult blood test|
79315757|NCT01261247|Genetic|western blotting|Correlative studies
79315758|NCT01261247|Genetic|DNA analysis|Correlative studies
79315759|NCT01261247|Other|flow cytometry|Correlative studies
79315760|NCT01261247|Other|pharmacological study|Correlative studies
79315761|NCT01261247|Other|immunohistochemistry staining method|Optional correlative studies
79315762|NCT02449577|Other|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
79477436|NCT00355004|Procedure|screening colonoscopy|
79972247|NCT02892409|Drug|Clarithromycin|Clarithromycin tablets
79315763|NCT02449577|Other|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
79315764|NCT02449577|Other|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
79315765|NCT02449577|Other|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
79315766|NCT02449577|Other|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
79972248|NCT02892409|Drug|Amoxicillin|Amoxicillin capsules
79315767|NCT02449577|Other|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
79315768|NCT02449577|Other|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
79315769|NCT02449577|Other|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
79315770|NCT02449577|Other|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
79972249|NCT02892409|Drug|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
79477437|NCT02371850|Drug|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
79477438|NCT03141281|Behavioral|BrainHQ|BrainHQ
79642893|NCT00185367|Drug|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
79642894|NCT04663633|Other|Core stability training|Functional Rhythmic Core Stability exercises performed by the experimental group. 30 minutes insert included in the Gymnasts regular training.
79972250|NCT02892409|Drug|Lansoprazole|Lansoprazole capsules
79972251|NCT02892409|Drug|TAK-438|TAK-438 tablets
79315771|NCT02449577|Other|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
79315772|NCT02449577|Other|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
79315773|NCT03233243|Drug|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
79315774|NCT02449655|Drug|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
79315775|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
79315776|NCT02449655|Drug|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
79315777|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
79315778|NCT04400123|Drug|Famitinib malate|"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."
79315779|NCT03197753|Device|Laryngeal mask airway|Laryngeal mask airway
79972252|NCT03219216|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet
79984587|NCT01562249|Other|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
79984588|NCT01562249|Other|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
79984589|NCT03197896|Other|Educational Intervention|Review prostate cancer information
79984590|NCT03442088|Drug|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
79984591|NCT03202420|Other|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
79984592|NCT03746795|Device|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
79984593|NCT03746795|Device|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
79315780|NCT03197753|Device|Nasotracheal intubation|Nasotracheal intubation
79315781|NCT04916795|Drug|Vupanorsen|80 mg subcutaneous injection
79315782|NCT04916795|Drug|Vupanorsen|80 mg subcutaneous injection
79315783|NCT03197519|Behavioral|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
79315784|NCT03197519|Behavioral|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
79315785|NCT04897295|Device|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
79315786|NCT04897295|Device|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
79315787|NCT03189563|Drug|DA-9805 45mg|DA-9805 15mg tid
79315788|NCT03189563|Drug|DA-9805 90mg|DA-9805 30mg tid
79642895|NCT04652089|Drug|Simvastatin 20mg|Simvastatin 20mg once a day for 7 days
79642896|NCT04652089|Drug|Placebo|Placebo once a day for 7 days
79642897|NCT00192192|Biological|CAIV-T|
79642898|NCT00552721|Other|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
79315789|NCT03189563|Other|Placebo|Placebo, tid
79315790|NCT04254731|Drug|Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)|
79642899|NCT00552721|Other|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
79642900|NCT00407108|Procedure|Vitrectomy|
79642901|NCT00409032|Drug|Strontium malonate|
79642902|NCT04684303|Procedure|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
79642903|NCT04684303|Procedure|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
79984594|NCT03202498|Device|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
79315791|NCT01603277|Biological|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
79315792|NCT01603277|Other|Placebo|Normal Saline
79315793|NCT04192487|Drug|Crofelemer delayed-release tablets 125mg|1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
79315794|NCT04107623|Diagnostic Test|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
79642904|NCT04609306|Other|H2O2 application to incision|A lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes.
79984595|NCT03202498|Other|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
79807165|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
79315795|NCT03197597|Other|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
79315796|NCT04655027|Drug|Roxadustat|The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to < 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to < 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
79315797|NCT04655027|Drug|rHuEPO|The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU [dosing will BIW], and patients on weekly dose of >6000 IU [dosing will TIW]) and on patient's haemoglobin levels.
79315798|NCT04032743|Other|ICU treatment|any treatment available by ICU
79315799|NCT04631705|Biological|DZIF-10c|Inhaled administration of the human monoclonal antibody DZIF-10c
79315800|NCT04631705|Biological|DZIF-10c|Intravenous administration of the human monoclonal antibody DZIF-10c
79315801|NCT04631705|Drug|Placebo|Inhalation of DZIF-10c diluent as placebo
79642905|NCT00407147|Device|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
79642906|NCT00192231|Biological|CAIV-T|
79315802|NCT04631705|Drug|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
79477439|NCT03141281|Behavioral|Rise of Nations|Rise of Nations
79477440|NCT03141281|Behavioral|IADL Training|IADL Training
79477441|NCT03141281|Behavioral|Active Control|Puzzle solving
79642907|NCT04710680|Other|no intervention|no intervention
79315803|NCT03197285|Other|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
79477442|NCT02415608|Drug|Ibrutinib|Given orally in 28-day cycles
79642908|NCT04684498|Drug|Oseltamivir phosphate capsules|Treatment group vs. Control group
79984596|NCT03202498|Device|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
79984597|NCT03202498|Other|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
79477443|NCT03144089|Device|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
79477444|NCT03144089|Device|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
79477445|NCT02051426|Other|D-serine|single P.O. administration of D-serine (2.1g)
79477446|NCT02051426|Other|Placebo|single P.O. administration of Placebo
79477447|NCT03144635|Drug|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
79642909|NCT00552799|Drug|Penicillin VK|Biconcave tablet 250mg oral, b.d.
79642910|NCT00552799|Other|placebo|biconcave tablet matching active comparator as much as possible in size and shape
79642911|NCT00409071|Drug|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
79642912|NCT00409071|Drug|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
79315804|NCT03197285|Other|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
79315805|NCT03876977|Procedure|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
79315806|NCT04508933|Device|Extravascular Lung Water Index|Measurement of the EVLWI
79315807|NCT04508933|Device|Pulmonary Vascular Permeability Index|Measurement of the PVPI
79315808|NCT03197441|Other|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
79315809|NCT01678313|Drug|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
79315810|NCT01678313|Drug|Doxazosin 4 mg every day (QD)|Control group
79315811|NCT03197207|Procedure|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
79315812|NCT03197207|Procedure|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
79315813|NCT03409991|Behavioral|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
79315814|NCT04435379|Biological|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
79315815|NCT04435379|Biological|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
79315816|NCT03407495|Drug|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
79315817|NCT01603121|Drug|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
79315818|NCT04365803|Procedure|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
79315819|NCT04413383|Other|Traditional Curved Iris Scissors|Aesculap Curved Iris Scissors
79315820|NCT04413383|Other|Wuennenberg Modified Curved Iris Scissors|Modified Silent Curved Iris Scissors
79315821|NCT04413383|Other|Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors|Patients experience both types of scissors
79984598|NCT01562405|Drug|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
79984599|NCT01562405|Drug|Lenalidomide|15 to 25 mg days 1-21, given orally
79984600|NCT01562405|Drug|Dexamethasone|40 mg days 1,8,15,22; given orally
79984601|NCT01562405|Drug|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
79984602|NCT03194386|Other|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
79984603|NCT03194386|Other|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
79984604|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
79984605|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
79984606|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
79984607|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
79984608|NCT03298334|Biological|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
79315822|NCT03246425|Other|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
79315823|NCT03246425|Device|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
79315824|NCT03139721|Device|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
79315825|NCT02356757|Behavioral|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
79315826|NCT02356757|Behavioral|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
79315827|NCT03196895|Behavioral|Weight reduction training|6 one-hour sessions of conventional weight reduction training
79315828|NCT03196895|Behavioral|PPG training|Four 90-minute sessions of glycemic load and exercise training
79315829|NCT03196895|Behavioral|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
79315830|NCT03196895|Behavioral|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
79315831|NCT02449265|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
79315832|NCT02449265|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15~18 fractions of 2 Gy 5 days per week for partial response (PR)."
79315833|NCT02449265|Drug|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
79315834|NCT02449265|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
79315835|NCT02449265|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy.
79315836|NCT02449265|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy.
79315837|NCT05092685|Genetic|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
79315838|NCT04143035|Other|No Intervention|No Intervention
79315839|NCT05092217|Drug|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
79315840|NCT05092217|Procedure|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
79807166|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
79807167|NCT00648791|Drug|Finasteride Tablets 5 mg|5mg, single dose fasting
79315841|NCT04031807|Procedure|Single-Incision Sling|The women with stress urinary incontinence underwent single-incision sling procedure.
79315842|NCT04413305|Other|screen of CRKP and infection control measure|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
79315843|NCT03854747|Other|cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
79315844|NCT03196817|Drug|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
79315845|NCT03196817|Device|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
79315846|NCT03118661|Other|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
79315847|NCT03118661|Procedure|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
79315848|NCT01603043|Drug|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
79642913|NCT04524325|Other|Trans men|We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
79477448|NCT02313506|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
79315849|NCT01603043|Drug|Sham injection|Mock injection administered as an empty hub without needle
79315850|NCT05091515|Other|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
79315851|NCT05091359|Device|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
79642914|NCT00162305|Drug|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
79642915|NCT00162305|Drug|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
79642916|NCT00162305|Drug|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
79642917|NCT00162305|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
79642918|NCT00162344|Drug|Technetium Tc99m Sestamibi|
79315852|NCT03670745|Behavioral|An electronic self-administered pre-visit planning tool.|An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
79315853|NCT03670745|Behavioral|Control group|No planning tool
79315854|NCT03196739|Device|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
79315855|NCT05091125|Diagnostic Test|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
79477449|NCT02313506|Behavioral|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
79477450|NCT05719298|Device|Respiratory interface|Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
79477451|NCT03145259|Drug|Diclofenac Epolamine Patch|patch
79477452|NCT03145259|Drug|diclofenac sodium solution|solution
79642919|NCT04395625|Procedure|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
79642920|NCT04395625|Procedure|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
79642921|NCT00409149|Behavioral|CALM Approache|
79642922|NCT00409149|Behavioral|DASH approach|standard dietary DASH approach in hypertensive patients
79642923|NCT00162383|Drug|Debrisoquine|
79642924|NCT00162383|Drug|Mephenytoin|
79642925|NCT00162383|Drug|Dapsone|
79642926|NCT00162383|Drug|Caffeine|
79642927|NCT04683874|Device|3D printed tray|3D printed tray
79315856|NCT03196583|Device|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
79315857|NCT02014402|Biological|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
79972253|NCT05668169|Other|Family-centered support program for caregivers of stroke survivors|Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
79972254|NCT02507128|Drug|liraglutide|Liraglutide were taken 30 min before PCI.
79315858|NCT02014402|Biological|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
79642928|NCT00192270|Biological|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of ~3 x 10^7 TCID50 per dose.
79807168|NCT00648791|Drug|Proscar Tablets 5 mg|5mg, single dose fasting
79642929|NCT00162422|Drug|albuterol|
79642930|NCT04355143|Drug|Colchicine Tablets|COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.
79807169|NCT02655809|Radiation|Fluoroscopic examination|
79807170|NCT00649181|Drug|Metolazone Tablets 5 mg|2x5mg, single dose fasting
79807171|NCT00649181|Drug|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
79807172|NCT02659475|Drug|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
79807173|NCT04170257|Diagnostic Test|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
79807174|NCT02655731|Device|PVI with HeartLight|Catheter ablation
79807175|NCT02663843|Device|i-gel airway|Fibreoptic intubation via i-gel airway device
79807176|NCT02663843|Device|air-Q airway|Fibreoptic intubation via air-Q airway device
79807177|NCT04444427|Drug|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
79807178|NCT02655965|Drug|Ropivacaine|Ropivacaine 3.5 mg/ml
79807179|NCT02655965|Drug|Clonidine|Clonidine 5µg/ml
79807180|NCT02655965|Drug|Sodium Chloride|Sodium Chloride 0.9 %
79315859|NCT01988662|Procedure|Neovascular Age-related Macular Degeneration|Blood measurement
79315860|NCT02839343|Radiation|radiation therapy|
79315861|NCT02839343|Procedure|surgery|
79315862|NCT02839343|Drug|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
79315863|NCT02839343|Drug|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
79315864|NCT00127673|Drug|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
79315865|NCT00127673|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
79315866|NCT05377073|Other|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
79315867|NCT05377073|Other|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
79315868|NCT03196661|Biological|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
79315869|NCT05376995|Diagnostic Test|Graston technique|Graston technique among patient of knee osteoarthritis
79315870|NCT05376995|Diagnostic Test|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
79315871|NCT05090735|Procedure|SPIP and TAP Block|Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
79642931|NCT04355143|Other|Current care per UCLA treating physicians|Current care
79642932|NCT00185445|Drug|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
79642933|NCT00552838|Behavioral|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
79642934|NCT00192309|Biological|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
79642935|NCT00192309|Biological|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
79642936|NCT00192309|Biological|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
79807181|NCT04170179|Procedure|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
79807182|NCT04170179|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79807183|NCT04170179|Drug|Toripalimab|240mg intravenously every 3 weeks
79807184|NCT02659163|Behavioral|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
79315872|NCT05090735|Procedure|SPIP Block|Injection of Bupivacaine 0.25% for SPIP Block
79807185|NCT02659163|Behavioral|mHealth scale|A wireless scale used by participants to measure and record daily weight.
79807186|NCT02659163|Behavioral|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
79972255|NCT02507128|Drug|placebo|Placebo were taken 30 min before PCI.
79315873|NCT02379611|Procedure|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
79807187|NCT02659163|Behavioral|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
79477453|NCT05719220|Behavioral|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
79477454|NCT00354692|Drug|Sodium Ferric Gluconate and Iron sucrose|
79477455|NCT03146585|Device|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
79807188|NCT02659163|Behavioral|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
79807189|NCT02659163|Behavioral|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
79315874|NCT05376605|Other|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
79315875|NCT02449187|Drug|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
79477456|NCT05719142|Other|Picture exposure|Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.
79477457|NCT02375984|Biological|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
79477458|NCT02989727|Drug|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
79477459|NCT02989727|Drug|Placebos|Placebo tablets
79807190|NCT02655341|Device|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
79315876|NCT02449187|Drug|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
79315877|NCT02449343|Drug|Anlotinib|Anlotinib p.o. qd
79315878|NCT02449343|Drug|Placebo|Placebo p.o. qd
79315879|NCT05376527|Biological|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1*107 PFU (calculated at minimal ED on mice); 2*107 PFU; 4*107 PFU; 6*107 PFU; 8*107 PFU; 10*107 PFU;"
79315880|NCT05090579|Procedure|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
79315881|NCT05090579|Procedure|Active Comparator:Group ll (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
79315882|NCT05090579|Procedure|Active Comparator:Group lll (B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
79315883|NCT02449109|Procedure|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
79972256|NCT03731377|Drug|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
79315884|NCT05087537|Procedure|Valve ablation|Valve ablation
79477460|NCT02051816|Device|Video Laryngoscopy|
79477461|NCT02051816|Device|Apneic Oxygenation|
79477462|NCT02051816|Device|Direct Laryngoscopy|
79315885|NCT05087537|Procedure|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
79315886|NCT05095493|Dietary Supplement|Zinc Acetate|50 mg tablet
79315887|NCT05095493|Dietary Supplement|Placebo|Zinc Acetate matched placebo tablet
79315888|NCT05095415|Other|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
79315889|NCT05095415|Other|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
79477463|NCT02051816|Device|No Apneic Oxygenation|
79477464|NCT02039947|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
79477465|NCT02039947|Drug|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
79807191|NCT02655341|Procedure|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
79807192|NCT02655341|Procedure|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
79807193|NCT02655341|Procedure|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
79807194|NCT04170413|Drug|CeVUS|Contrast enhanced voiding urosonography
79807195|NCT02655497|Behavioral|Cognitive training|
79972257|NCT02507050|Drug|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
79315890|NCT01965652|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
79315891|NCT01965652|Drug|Placebo|Placebo tablet taken orally once a day
79315892|NCT02677181|Drug|ATG|rabbit ATG（Sanofi）
79315893|NCT02677181|Drug|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
79315894|NCT02677181|Drug|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
79477466|NCT02052752|Drug|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
79972258|NCT03844529|Device|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
79972259|NCT03728023|Drug|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
79477467|NCT02052752|Drug|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
79972260|NCT03728023|Drug|Placebo|Single dose in SAD and once daily for 14 days
79984609|NCT03298334|Other|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
79984610|NCT03194230|Other|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
79984611|NCT03746717|Device|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
79984612|NCT03746717|Device|conventional wound closure|wound closure with surgical staples
79984613|NCT03119194|Drug|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
79642937|NCT04297111|Dietary Supplement|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
79315895|NCT02677181|Drug|Methotrexate|short-term methotrexate
79315896|NCT01602965|Procedure|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
79315897|NCT01602965|Procedure|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
79315898|NCT05095025|Drug|Bupivacaine Hydrochloride 20ml injectate|Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
79315899|NCT03196271|Dietary Supplement|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
79315900|NCT05065073|Drug|Iodixanol|Iso-osmolar Contrast Media
79315901|NCT05065073|Drug|Iohexol|Low-Osmolar Contrast Media
79315902|NCT05059379|Radiation|Entire supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
79315903|NCT05059379|Radiation|Medial supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
79315904|NCT05056259|Device|18F-FDG PET/CT|"The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be <150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG & MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data."
79315905|NCT01987960|Drug|Placebo|Once daily, tablets, orally
79315906|NCT01987960|Drug|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
79315907|NCT05084027|Combination Product|venetoclax combining with fludarabine and melphalan|Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
79315908|NCT02013778|Drug|HCQ|
79315909|NCT05374889|Other|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
79315910|NCT04676308|Other|Artificial Intelligence|Artificial intelligence
79315911|NCT05074745|Diagnostic Test|ELISA POCT vs RT-PCR|3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
79315912|NCT02013622|Drug|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
79315913|NCT02448797|Drug|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
79477468|NCT02052752|Drug|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
79642938|NCT04297111|Other|Placebo|Maltodextrin capsule, no active ingredient
79315914|NCT02448797|Drug|Chemotherapy|Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles.
79315915|NCT05374733|Diagnostic Test|Coronary Physiology assessment|"Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
79477469|NCT03063437|Biological|Encapsulated fecal microbiota preparation|30 capsules
79477470|NCT03063437|Biological|Encapsulated placebo|30 capsules
79477471|NCT02042131|Behavioral|Treatment As Usual (TAU)|
79642939|NCT00552877|Device|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
79642940|NCT04233034|Device|HCL|Hybrid Closed Loop therapy
79642941|NCT04233034|Drug|verapamil 120mg tablet|verapamil tablet
79642942|NCT04233034|Device|non-HCL|Usual diabetes care
79642943|NCT04233034|Drug|placebo|placebo pill manufactured to mimic verapamil 120mg tablet
79807196|NCT02655497|Behavioral|Psychosocial education|
79315916|NCT04438421|Drug|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
79315917|NCT04438421|Drug|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
79315918|NCT04438421|Drug|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
79315919|NCT05099081|Procedure|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
79315920|NCT05099081|Procedure|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
79315921|NCT04438577|Drug|Lidocaine mucilage-ICG|Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
79315922|NCT04846439|Biological|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
79315923|NCT03196037|Behavioral|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
79315924|NCT05087615|Drug|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
79315925|NCT05087615|Drug|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
79315926|NCT05087615|Drug|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
79315927|NCT05087615|Drug|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
79315928|NCT01987102|Drug|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
79315929|NCT01987102|Drug|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug [6R] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate® dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
79315930|NCT02448953|Procedure|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
79315931|NCT02448953|Procedure|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
79315932|NCT04570007|Procedure|Pars Plana Vitrectomy|removal of vitreous with vitreous cutter
79315933|NCT02013544|Drug|Placebo|
79315934|NCT02013544|Drug|Prasterone (DHEA)|
79315935|NCT04284605|Other|Aerobic exercise combined with strength training|30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.
79315936|NCT04284605|Other|Yoga|60 minute yoga intervention including different asanas, breath control and meditation
79315937|NCT03968939|Drug|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
79315938|NCT03968939|Dietary Supplement|Melatonin|Oral Melatonin, 3 mg
79315939|NCT03968939|Behavioral|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
79315940|NCT03856619|Drug|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
79315941|NCT02448407|Biological|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
79315942|NCT02448407|Drug|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
79315943|NCT04484597|Diagnostic Test|Rt PCR|positive COVID-19 by PCR and tested for other ancillary tests and CT chest to compare them and analyse which is the most sensitive in both moderate and severe clinical condition
79315944|NCT03195647|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
79315945|NCT05374343|Drug|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
79315946|NCT05374265|Other|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
79315947|NCT02013388|Drug|N91115|Given PO daily for 14 days
79315948|NCT02013388|Drug|Placebo|Given PO daily for 14 days
79315949|NCT02013388|Drug|N91115|Given PO only on Day 1
79315950|NCT02013388|Drug|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
79315951|NCT05200715|Other|No intervention is foreseen by the protocol.|Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
79315952|NCT02012686|Device|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
79315953|NCT02012452|Behavioral|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
79315954|NCT02012452|Behavioral|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
79315955|NCT05098847|Drug|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
79477472|NCT02042131|Behavioral|Standard Crisis Response Plan (S-CRP)|
79477473|NCT02042131|Behavioral|Enhanced Crisis Response Plan (E-CRP)|
79477474|NCT02996591|Procedure|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
79315956|NCT05098847|Drug|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79315957|NCT05098847|Drug|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
79477475|NCT02996591|Procedure|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
79972261|NCT03344926|Behavioral|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~education about pain behaviors, exposure and acceptance and commitment therapy~education about pain physiology~exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~value based exposure in the participant's daily life"
79972262|NCT02878044|Other|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
79972263|NCT01199315|Drug|AZD1446|oral capsule, Moderate Release
79315958|NCT01676909|Behavioral|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
79315959|NCT01676909|Behavioral|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
79477476|NCT02996591|Drug|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
79477477|NCT02996591|Procedure|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
79477478|NCT02996591|Procedure|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
79642944|NCT00552916|Device|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
79972264|NCT01199315|Drug|Placebo|oral capsule
79315960|NCT04437953|Drug|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of > 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, … 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
79315961|NCT03051971|Device|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
79315962|NCT03051971|Device|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
79315963|NCT04517357|Drug|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
79807197|NCT02655263|Drug|Somatropin|Somatropin infusion (Genotropin®)
79807198|NCT02655263|Other|Ketone bodies|ketone bodies infusion
79315964|NCT04517357|Drug|Fluzoparib|Fluzoparib monotherapy
79315965|NCT04517357|Drug|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
79315966|NCT02012296|Drug|enzalutamide|Given PO
79315967|NCT02012296|Drug|mifepristone|Given PO
79315968|NCT02012296|Other|laboratory biomarker analysis|Correlative studies
79315969|NCT02012296|Other|pharmacological study|Correlative studies
79642945|NCT00552916|Device|Compex Motion Stimulator|'False' FES
79807199|NCT02659085|Drug|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
79807200|NCT02659085|Procedure|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
79315970|NCT02012218|Drug|ADT|
79315971|NCT02012218|Drug|Brexpiprazole|
79315972|NCT04658836|Drug|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
79315973|NCT01965262|Device|Hema-copolymer Lens|contact lens
79315974|NCT01965262|Device|etafilcon A Lens|contact lens
79315975|NCT01677377|Drug|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
79315976|NCT01677377|Drug|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
79807201|NCT02659007|Other|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
79807202|NCT04171271|Behavioral|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
79807203|NCT04171271|Behavioral|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
79807204|NCT04168697|Behavioral|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
79315977|NCT02893865|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
79315978|NCT02893865|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
79315979|NCT05104151|Dietary Supplement|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
79315980|NCT05104151|Behavioral|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
79477479|NCT02053376|Drug|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
79477480|NCT03065075|Drug|Phenazopyridine|Phenazopyridine 200 mg on morning of postoperative day 1
79642946|NCT00185484|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
79315981|NCT02492009|Behavioral|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
79315982|NCT02492009|Behavioral|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
79315983|NCT04458623|Diagnostic Test|Air Test|.The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
79315984|NCT05098691|Diagnostic Test|serum marker levels|two groups comparisons
79315985|NCT04430387|Device|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
79315986|NCT04430387|Device|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
79315987|NCT04430387|Device|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
79315988|NCT04066205|Behavioral|SLEEPSAMRT|SLEEPSMART will be designed to improve sleep by providing guidance and structure to assist JIA children and their parent in adhering to the intervention protocol. The intervention will be interactive and personalized; users will interface with three primary components:1) monitoring: daily records of sleep and symptoms; 2) skill building modules: sleep education, sleep skills training, relaxation techniques, positive coping skills, and reward systems for activity participation for reducing sleep deficiency; and 3) assignment review and personalized feedback via behavioral assignments for skill implementation and tailored feedback. Modules will take an estimated 30 minutes each week to complete and will include multimedia elements to enhance learning.
79315989|NCT05098535|Other|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
79642947|NCT04218721|Other|InvolveMe|An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
79642948|NCT04710290|Dietary Supplement|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
79642949|NCT04710290|Dietary Supplement|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
79315990|NCT05098535|Other|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
79477481|NCT03066947|Biological|SV-BR-1-GM|See above
79315991|NCT05103995|Other|no intervention|no intervention, just observation
79315992|NCT05103917|Drug|X4P-001|CXCR4 inhibitor
79315993|NCT03861221|Device|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
79477482|NCT03066947|Drug|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
79642950|NCT04710290|Dietary Supplement|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
79315994|NCT05098223|Behavioral|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
79315995|NCT05097911|Drug|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
79807205|NCT04170101|Procedure|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC < 3
79315996|NCT05097911|Drug|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
79315997|NCT05097911|Drug|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
79315998|NCT03732209|Behavioral|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
79315999|NCT03732209|Behavioral|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
79316000|NCT05097365|Dietary Supplement|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
79316001|NCT05097365|Dietary Supplement|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
79477483|NCT03066947|Biological|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
79477484|NCT02042911|Drug|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
79477485|NCT02043145|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
79477486|NCT02062801|Drug|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
79477487|NCT02062801|Drug|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
79477488|NCT03152591|Drug|LIK066|LIK066 tablets for oral administration
79477489|NCT03152591|Drug|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
79477490|NCT02063035|Drug|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
79477491|NCT02063035|Drug|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
79477492|NCT00375245|Drug|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
79807206|NCT04170101|Procedure|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
79642951|NCT04710290|Dietary Supplement|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
79642952|NCT00185523|Procedure|Allogeneic hematopoietic cell transplantation|
79642953|NCT00162461|Drug|Phenytoin single dose (300 mg)|
79972265|NCT03727945|Other|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
79642954|NCT04167124|Behavioral|multi-sensor lifestyle intervention|
79972266|NCT03727945|Other|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
79477493|NCT00375245|Other|Grapefruit Juice|Daily oral doses starting during the second week on study.
79477494|NCT05405933|Diagnostic Test|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
79642955|NCT00192348|Biological|CAIV-T|
79972267|NCT02506582|Dietary Supplement|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
79972268|NCT02506582|Dietary Supplement|placebo|40 g powdered rice flour
79316002|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
79477495|NCT05405933|Diagnostic Test|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
79642956|NCT00162500|Biological|Peptide Vaccine (MUC-1)|
79642957|NCT00185562|Drug|Adalimumab|
79642958|NCT00162539|Other|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
79807207|NCT02663375|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
79972269|NCT02292758|Biological|Bevacizumab|Given IV
79972270|NCT02292758|Biological|Cetuximab|Given IV
79972271|NCT02292758|Drug|Irinotecan|Given IV
79972272|NCT02292758|Other|Laboratory Biomarker Analysis|Correlative studies
79972273|NCT02292758|Other|Placebo|Given IV
79972274|NCT04721249|Dietary Supplement|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
79972275|NCT04721249|Dietary Supplement|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
79316003|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
79316004|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
79316005|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
79316006|NCT02659943|Biological|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.66x10^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
79316007|NCT02659943|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
79316008|NCT02659943|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
79316009|NCT03257969|Behavioral|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
79316010|NCT03257969|Behavioral|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
79316011|NCT05103371|Behavioral|"Experiment: Millie prevention program, adolescents and active parents"|"Prevention program: Millie, with the participation of adolescents and parents"
79972276|NCT02511652|Device|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
79316012|NCT05103371|Behavioral|"Experiment: Millie prevention program, adolescents only"|"Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program"
79972277|NCT02511652|Device|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
79972278|NCT02511652|Procedure|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
79316013|NCT05369663|Device|mask use|face mask use
79316014|NCT05083325|Drug|Oseltamivir 75mg Test Drug capsules|Investigational Medicinal Product
79316015|NCT05083325|Drug|Oseltamivir 75mg capsules Reference Product capsules|Tamiflu (Roche Pharma (Switzerland) AG, Basel)
79316016|NCT01677299|Drug|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
79316017|NCT01677299|Drug|EFB0026 (metformin immediate-release)|Active comparator
79316018|NCT05103059|Diagnostic Test|BMI|Patients with cancer cachexia will be enrolled in the study, and the following data will be collected: age, sex, total protein, albumin, hemoglobin (Hb), white blood cell (WBC) count, neutrophil count, lymphocyte count, red blood cell (RBC) count, platelet (PLT) count, body mass index (BMI), mid-arm circumference (MAC), thickness of triceps skinfold (TSF), handgrip strength (HGS), and calf circumference (CC)
79316019|NCT04436783|Device|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
79316020|NCT04436783|Other|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
79316021|NCT05102825|Diagnostic Test|1H and Xe-129 MRI|Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
79316022|NCT05012267|Other|16-hour PP|PP according to previous study
79316023|NCT04999631|Drug|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
79316024|NCT04999631|Drug|Ethanol Solution|Control
79316025|NCT05337761|Behavioral|Peer-led training on lifejacket wear|Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
79807208|NCT04171193|Drug|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
79316026|NCT04437875|Biological|Gam-COVID-Vac Lyo|adenoviral-based vaccine against SARS-CoV-2
79316027|NCT02718833|Drug|Elotuzumab|
79316028|NCT02718833|Drug|Pomalidomide|
79972279|NCT03727867|Drug|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Oral EGFR TKI begins on day 1 and continues until disease progresses.
79972280|NCT03727867|Device|Stereotactic Body Radiation Therapy|Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
79316029|NCT02718833|Drug|Bortezomib|
79316030|NCT02718833|Drug|Dexamethasone|
79316031|NCT04908293|Other|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
79316032|NCT04908293|Other|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
79316033|NCT04437797|Procedure|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
79477496|NCT02043379|Drug|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
79477497|NCT02043379|Other|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
79477498|NCT02054156|Drug|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
79972281|NCT03843983|Device|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
79477499|NCT02054156|Drug|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
79972282|NCT02832648|Dietary Supplement|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
79316034|NCT04437797|Procedure|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
79642959|NCT04684030|Device|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
79642960|NCT04684030|Device|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
79972283|NCT02506738|Device|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
79316035|NCT01964326|Drug|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
79316036|NCT04786457|Biological|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10^3 PFU/mL
79477500|NCT02054156|Drug|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
79972284|NCT03727711|Other|TPTNS|We will be comparing hospital treatment to TPTNS at home
79972285|NCT03195660|Device|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
79972286|NCT04497532|Other|Diet as suited for gestational diabetes mellitus|Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
79972287|NCT04497766|Drug|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
79972288|NCT04497766|Drug|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
79972289|NCT03841721|Drug|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
79972290|NCT03194490|Other|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
79477501|NCT03159143|Drug|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m^2.
79477502|NCT03159143|Drug|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m^2
79477503|NCT03159299|Behavioral|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
79477504|NCT02376530|Behavioral|Nutrient profiling|Nutrient profiling system will be present during shopping session.
79477505|NCT02376530|Behavioral|Price Changes|Price changes will be present during shopping session.
79477506|NCT02376998|Device|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
79477507|NCT03161327|Device|ABI using QuantaFlo™|"Perform Digital ABI:~Will be performed by the nurse/medical assistant with training to perform this test~The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~Usually each digit takes about 15 seconds to obtain a waveform~At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
79642961|NCT04114864|Behavioral|Psycho-educational sessions|"Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks."
79642962|NCT00192387|Biological|CAIV-T, Liquid|
79316037|NCT04436705|Other|Progressive Muscle Relaxation (PMR) technique|The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
79477508|NCT02377700|Device|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
79477509|NCT03028753|Device|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
79316038|NCT05102045|Device|Repetitive Transcranial Magnetic Stimulation|TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
79316039|NCT05102045|Other|Aerobic Exercise|Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
79972291|NCT03194490|Other|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
79316040|NCT05102045|Drug|Acetylcholinesterase Inhibitors|Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
79316041|NCT05102045|Drug|Memantine|Memantine were given for Alzheimer's disease. .
79642963|NCT00185601|Behavioral|Internet Diabetes Self-Management Program|
79477510|NCT03028753|Procedure|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
79477511|NCT03028753|Procedure|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
79477512|NCT03068897|Drug|Metaxalone|Metaxalone 400-800mg
79477513|NCT03068897|Drug|Tizanidine|Tizanidine 2-4mg
79477514|NCT03068897|Drug|Baclofen|Baclofen 10-20mg
79477515|NCT03068897|Drug|Ibuprofen 600 mg|Ibuprofen
79477516|NCT03068897|Behavioral|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
79477517|NCT05718986|Other|No intervention|No intervention
79642964|NCT00162617|Drug|Red blood cell transfusion|
79642965|NCT00192426|Biological|CAIV-T|
79642966|NCT00162656|Drug|half cyclophosphamide|
79642967|NCT00162656|Drug|without COPADM3|
79642968|NCT00162656|Drug|mini CYVE, without 3 maintenance courses|
79642969|NCT00162656|Drug|LMB B|
79477518|NCT02049476|Drug|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
79807209|NCT04171193|Drug|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
79477519|NCT02299297|Drug|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
79807210|NCT02663141|Drug|Losartan|
79642970|NCT00162656|Drug|LMB C|
79642971|NCT00424307|Device|HiResolution Bionic Ear System|
79807211|NCT02663141|Drug|Intravitreal bevacizumab|
79807212|NCT02663141|Drug|Placebo|
79807213|NCT04171349|Drug|Articaine|Vial
79807214|NCT04171349|Drug|Dexmedetomidine|Vial
79807215|NCT02536547|Device|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
79477520|NCT02055404|Device|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
79477521|NCT02055404|Device|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
79642972|NCT00185757|Drug|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
79642973|NCT00162695|Drug|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
79642974|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
79642975|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
79642976|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
79642977|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
79642978|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
79642979|NCT00162734|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
79642980|NCT00185796|Procedure|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
79642981|NCT00185796|Procedure|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
79642982|NCT00162812|Drug|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
79642983|NCT00162851|Drug|alemtuzumab|
79642984|NCT00162890|Behavioral|Therapeutic exercise|
79642985|NCT04025749|Behavioral|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
79316042|NCT04934267|Other|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
79477522|NCT03069677|Other|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
79477523|NCT03069677|Drug|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
79477524|NCT03820063|Drug|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
79477525|NCT03072953|Drug|APD334|APD334 active treatment
79642986|NCT04025749|Other|Care as usual|Care as usual
79642987|NCT00162929|Biological|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
79642988|NCT04015414|Drug|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
79642989|NCT04015414|Drug|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
79642990|NCT00185835|Drug|ZD-1839|
79642991|NCT00185835|Drug|Cisplatin|
79642992|NCT03985267|Behavioral|Mindfulness based Swinging Effect Intervention|Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
79642993|NCT03979495|Other|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
79642994|NCT00162968|Drug|escitalopram|
79316043|NCT04934267|Other|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
79316044|NCT04867655|Other|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
79316045|NCT04867655|Other|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
79316046|NCT04855019|Procedure|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
79316047|NCT04414241|Drug|Hydroxychloroquine|A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
79316048|NCT05101967|Procedure|Dynamic Cervical Implant|Cervical discectomy through anterior approach with replacement of disc by dynamic implant
79642995|NCT00192543|Behavioral|diet of fish and fruit|fish and fruit in specified quantities
79477526|NCT02044393|Drug|itraconazole|multiple doses of itraconazole given as capsules
79642996|NCT00192543|Behavioral|fruit and fish|no drugs
79642997|NCT00192543|Behavioral|diet only|Fish and fruit
79642998|NCT00192543|Behavioral|regular diet|no change in regular diet
79642999|NCT03970603|Other|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
79643000|NCT03970603|Other|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
79643001|NCT03970330|Drug|Naltrexone|4.5mg daily dose, taken orally
79643002|NCT03970330|Drug|Norethindrone Acetate|5 - 15mg daily dose, taken orally
79643003|NCT03970330|Drug|Placebo|daily placebo pill, taken orally
79643004|NCT00163007|Procedure|Nutritional support|
79316049|NCT05101967|Procedure|Anterior Cervical Discectomt and Fusion|Cervical discectomy through anterior approach with putting of cervical cage.
79477527|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
79477528|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
79477529|NCT05405465|Drug|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
79643005|NCT00185874|Biological|Intratumoral Dendritic Cell Immunotherapy|
79643006|NCT00185874|Biological|autologous dendritic cells|
79643007|NCT03911596|Device|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
79643008|NCT04724408|Device|VieScope|see above
79643009|NCT04724408|Device|Conventional|see above
79643010|NCT00192582|Behavioral|Motivational Interview with care plan and education|
79643011|NCT03788044|Other|Education|Education + Medication adherence monitoring + Feedback when low adherence
79643012|NCT04724174|Procedure|pancreaticogastrostomy|Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.
79643013|NCT04724174|Procedure|pancreaticojejunostomy|Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
79643014|NCT03757585|Drug|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
79643015|NCT03757585|Drug|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
79316050|NCT04779905|Diagnostic Test|urinary albumbin/creatinine ratio|detection of microalbuminuria in nafld patients
79316051|NCT04764773|Other|No intervention|No intervention
79316052|NCT04758377|Procedure|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
79316053|NCT05101889|Dietary Supplement|Oral Impact®|3 ready-to-drink bottles/day
79316054|NCT04531553|Procedure|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
79477530|NCT02378402|Other|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
79643016|NCT00163046|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
79972292|NCT03841643|Device|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
79972293|NCT03841643|Device|cement|norian cement for reconstruction of the cranial defect
79316055|NCT04531553|Procedure|ESPB with levobupivacaine and dexmedetomedine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
79316056|NCT04531553|Procedure|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
79972294|NCT02515786|Other|oxygen humidification|humidification for oxygen delivered by nasal catheter
79972295|NCT03843827|Device|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
79972296|NCT03843827|Device|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
79316057|NCT05101811|Drug|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
79316058|NCT05101811|Device|Vitamin D level assessment|Using lIAISON DEVICE
79316059|NCT04088123|Drug|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
79316060|NCT05307419|Procedure|Rectal suction biopsy.|Suction biopsy performed
79316061|NCT05307419|Procedure|Full-thickness rectal biopsy.|Full-thickness biopsy performed
79316062|NCT05199779|Behavioral|Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise|This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
79972297|NCT04500184|Other|cardiac rehabilitation|rehabilitation performed by professional trainers
79972298|NCT01203683|Behavioral|Active computer-based training|8 sessions across 4 weeks.
79477531|NCT00374933|Drug|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
79477532|NCT00374933|Drug|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
79643017|NCT00163046|Drug|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
79807216|NCT00650039|Drug|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
79316063|NCT05199779|Behavioral|Finger-Tapping Active Control|This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
79316064|NCT03847181|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
79316065|NCT03847181|Drug|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
79972299|NCT01203683|Behavioral|Inert computer training|8 sessions across 4 weeks.
79316066|NCT03847181|Drug|Warfarin|Warfarin dose as prescribed by medical practitioner
79316067|NCT03825107|Other|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
79316068|NCT03825107|Other|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
79316069|NCT05101499|Procedure|AKIN osteotomy with screw fixation|"A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific."
79316070|NCT05101499|Procedure|AKIN osteotomy without screw fixation|This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
79316071|NCT03477851|Drug|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
79316072|NCT03477851|Drug|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
79316073|NCT05101343|Behavioral|Breathing meditation|Daily, 5-minute breathing meditation for one week.
79316074|NCT04437407|Device|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
79316075|NCT04437407|Device|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
79316076|NCT04437407|Device|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
79316077|NCT04437407|Device|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
79316078|NCT04437407|Device|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
79316079|NCT04437407|Device|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
79316080|NCT04437407|Device|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
79972300|NCT04073238|Device|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
79316081|NCT05375045|Device|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
79316082|NCT04437251|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
79477533|NCT00374933|Drug|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
79477534|NCT02046265|Behavioral|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
79972301|NCT04500340|Behavioral|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond & Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
79972302|NCT05282303|Procedure|CABG operation|Efficacy of regional analgesia techniques in coronary artery bypass operations
79316083|NCT05094635|Diagnostic Test|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: < 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
79972303|NCT02515708|Device|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
79316084|NCT03310697|Other|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
79807217|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
79972304|NCT02515552|Behavioral|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
79316085|NCT03310697|Other|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
79316086|NCT02699749|Drug|TAK-931|TAK-931 oral capsules.
79316087|NCT02409199|Drug|Docetaxel|
79316088|NCT02409199|Drug|apatinib|
79477535|NCT02046265|Behavioral|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
79643018|NCT00185952|Drug|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
79807218|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
79807219|NCT00649259|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
79807220|NCT00649259|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
79807221|NCT02658773|Drug|lidocaine-Prilocaine cream|
79807222|NCT02658773|Drug|placebo cream|
79807223|NCT04170491|Diagnostic Test|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
79807224|NCT00648869|Drug|metformin tablet, metformin gum|500 mg, 250 mg
79807225|NCT02654951|Other|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
79807226|NCT02654951|Other|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
79807227|NCT04169945|Other|Ultrasonic instrumentation|Full mouth root surface debridement
79807228|NCT04169945|Other|Air polishing with erythritol powder|Air flow PLUS
79477536|NCT02046265|Behavioral|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
79807229|NCT04169867|Biological|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
79477537|NCT02046265|Behavioral|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
79477538|NCT02064907|Drug|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
79316089|NCT02405923|Other|HRF|The subject will take the formula for a period of 12 months.
79316090|NCT02405923|Other|eHF|The subject will take the formula for a period of 12 months.
79316091|NCT02409121|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
79316092|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
79477539|NCT02064907|Drug|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
79807230|NCT02536625|Other|prospective study|
79807231|NCT02655029|Drug|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
79316093|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
79316094|NCT02405611|Behavioral|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
79316095|NCT03169465|Procedure|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
79316096|NCT03169465|Procedure|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
79316097|NCT03169543|Behavioral|Sleep deprivation|36-hours total sleep deprivation
79316098|NCT03115489|Drug|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
79807232|NCT02662673|Device|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
79316099|NCT03115489|Drug|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
79316100|NCT02405533|Dietary Supplement|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
79477540|NCT03165617|Biological|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
79477541|NCT03165617|Biological|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
79316101|NCT02405533|Other|Placebo|Placebo supplementation x 12 months
79477542|NCT02064985|Drug|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
79807233|NCT02662595|Other|SMS reminder message|
79316102|NCT02409043|Other|Blood draw|Blood drawn for comparison with other groups
79477543|NCT00375089|Other|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
79477544|NCT00375089|Other|Group 2|Individuals with Early-onset Morbid Obesity.
79477545|NCT05396027|Other|Audio-guided deep breathing|2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
79477546|NCT02065453|Device|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
79643019|NCT03541447|Drug|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
79972305|NCT03620526|Drug|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
79643020|NCT03541447|Drug|Octreotide LAR|A single dose of two 20 mg i.m. injections.
79643021|NCT03541447|Other|Placebo|A single dose of two 20 mg i.m. injections.
79643022|NCT00163085|Drug|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
79643023|NCT00192621|Drug|Combivir (zidovudine [AZT] / lamivudine [3TC])|
79477547|NCT02065453|Device|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
79643024|NCT00192621|Drug|Kaletra (lopinavir [LPVr])|
79643025|NCT03516604|Drug|PF-04995274|PF-04995274 tablets
79807234|NCT02662595|Other|Voice call + SMS message|
79643026|NCT03516604|Drug|Citalopram|Citalopram capsule
79807235|NCT02654795|Radiation|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
79643027|NCT03516604|Drug|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
79643028|NCT03516604|Drug|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
79643029|NCT00163124|Procedure|spinal manipulation & patient education/nutrition|
79643030|NCT00185991|Drug|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
79643031|NCT00163163|Procedure|Echographic measurements|
79643032|NCT00163163|Procedure|Blood samples|
79643033|NCT00186030|Behavioral|HIV Skills-based Prevention|
79643034|NCT03434158|Drug|Olaparib|300 mg twice a day
79643035|NCT00552994|Device|Cypher Select plus|Drug eluting stent
79643036|NCT00552994|Device|Xience V stent|Drug eluting stent
79643037|NCT00186108|Drug|Oral Triamcinalone|
79807236|NCT04168853|Diagnostic Test|vascular reactivity of internal thoracic arteries|"Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~Blood sampling and biochemical analysis"
79807237|NCT02662829|Behavioral|Community-based intervention|
79807238|NCT02662829|Other|Standard of care|
79643038|NCT00163202|Procedure|Blood samples|
79643039|NCT00163202|Drug|Atorvastatin|
79316103|NCT02409043|Other|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
79316104|NCT02699593|Device|Test Contact Lens|
79316105|NCT02699593|Device|Control Contact Lens|
79316106|NCT02408731|Drug|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
79316107|NCT03169309|Device|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
79316108|NCT03168997|Drug|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
79316109|NCT02405767|Other|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
79316110|NCT02408809|Behavioral|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
79316111|NCT02408809|Behavioral|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
79972306|NCT03620526|Drug|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
79972307|NCT04499560|Dietary Supplement|Supplement Drink|Superfoods based nutritional supplement
79972308|NCT02850588|Procedure|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
79643040|NCT03318952|Drug|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
79972309|NCT02850588|Procedure|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
79972310|NCT02987153|Radiation|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
79643041|NCT03318952|Drug|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
79643042|NCT03455647|Behavioral|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
79643043|NCT00192660|Drug|Lamivudine|
79643044|NCT00192660|Drug|Stavudine|
79807239|NCT02536859|Drug|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
79307918|NCT03046329|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
79643045|NCT00192660|Drug|Didanosine|
79643046|NCT00192660|Drug|Zidovudine|
79643047|NCT00192660|Drug|Tenofovir|
79643048|NCT00192660|Drug|Abacavir|
79643049|NCT00192660|Drug|Efavirenz (EFV)|
79643050|NCT00192660|Drug|Nevirapine|
79972311|NCT03217968|Device|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
79643051|NCT00192660|Drug|Indinavir|
79643052|NCT00192660|Drug|Saquinavir|
79643053|NCT00192660|Drug|Amprenavir|
79643054|NCT00192660|Drug|Ritonavir|
79643055|NCT00192660|Drug|Nelfinavir|
79477548|NCT03077165|Drug|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
79643056|NCT00192660|Drug|Tipranavir|
79643057|NCT00192660|Drug|enfuvirtide (T20)|
79643058|NCT04684069|Device|Long-axis syringe free in-plane|Long-axis syringe-free in-plane catheter placement
79643059|NCT04684069|Device|Short-axis out-of-plane|Short-axis out-of-plane catheter placement
79643060|NCT00163241|Drug|celecoxib|
79643061|NCT00553033|Procedure|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
79643062|NCT03114397|Device|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
79643063|NCT03114397|Device|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
79643064|NCT00186225|Procedure|ablative allogeneic hematopoietic cell transplantation|
79643065|NCT00163280|Drug|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
79643066|NCT00186264|Drug|venlafaxine XR|
79643067|NCT00186264|Drug|hydrocortisone|
79807240|NCT02536859|Drug|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
79807241|NCT02536937|Drug|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
79972312|NCT03843749|Drug|Pyrotinib|Pyrotinib in Combination With Trastuzumab
79972313|NCT01199783|Drug|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
79972314|NCT01199783|Drug|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
79807242|NCT04169633|Diagnostic Test|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
79643068|NCT02890693|Behavioral|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
79643069|NCT00163319|Drug|Ciclesonide|
79807243|NCT00649337|Procedure|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
79807244|NCT02654405|Dietary Supplement|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
79807245|NCT02654405|Other|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
79807246|NCT04169789|Dietary Supplement|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
79477549|NCT03077165|Drug|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
79477550|NCT03077165|Drug|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
79643070|NCT02812420|Biological|Durvalumab|Given IV
79807247|NCT00649415|Drug|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
79807248|NCT00649415|Drug|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
79807249|NCT04171505|Drug|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
79807250|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
79643071|NCT02812420|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
79643072|NCT02812420|Biological|Tremelimumab|Given IV
79807251|NCT00650117|Drug|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
79807252|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
79807253|NCT00650117|Drug|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
79807254|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
79807255|NCT00650117|Drug|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
79807256|NCT02654249|Device|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
79807257|NCT02654249|Procedure|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
79316112|NCT02408575|Device|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
79316113|NCT02408575|Device|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
79316114|NCT03171727|Drug|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
79316115|NCT02401165|Other|Blood test|blood test
79807258|NCT02654249|Device|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
79807259|NCT02654249|Device|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
79807260|NCT02662751|Other|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
79807261|NCT02662751|Device|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
79807262|NCT00648947|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
79807263|NCT00648947|Drug|Plavix® Tablets 75 mg|75mg, single dose fasting
79807264|NCT00649493|Drug|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
79807265|NCT00649493|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
79316116|NCT02401087|Procedure|Anaesthesiological procedure|
79316117|NCT02400931|Procedure|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
79807266|NCT02654093|Drug|Cholecalciferol|
79316118|NCT02400931|Procedure|no mask ventilation|
79316119|NCT02400931|Drug|Rocuronium|
79316120|NCT02408653|Device|EEG|
79477551|NCT03077165|Drug|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
79807267|NCT02654093|Drug|Raloxifene|
79807268|NCT02654093|Drug|Cholecalciferol and Raloxifene co-administration|
79807269|NCT02662439|Device|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
79807270|NCT04168619|Drug|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
79807271|NCT04168619|Other|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
79807272|NCT00650195|Drug|Metolazone Tablets 10 mg|10mg, single dose fasting
79807273|NCT00650195|Drug|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
79807274|NCT04170959|Drug|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
79807275|NCT04170959|Other|No metformin|Standard of care without metformin.
79807276|NCT04169399|Drug|Toripalimab|240mg intravenously every 3 weeks
79972315|NCT03841877|Procedure|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
79972316|NCT03192306|Drug|Merlin|glycolic acid/ethanol solution
79972317|NCT03192306|Drug|Ethanol|Ethanol solution
79316121|NCT03169387|Behavioral|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
79807277|NCT04169399|Radiation|Stereotactic body radiotherapy|Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
79972318|NCT04066829|Behavioral|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
79972319|NCT01203995|Behavioral|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
79972320|NCT01203995|Behavioral|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
79972321|NCT03216954|Drug|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
79316122|NCT03169387|Behavioral|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
79316123|NCT03116191|Drug|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
79316124|NCT03116191|Drug|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
79316125|NCT03116503|Other|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
79477552|NCT03077165|Drug|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
79477553|NCT03077165|Drug|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
79477554|NCT03170219|Combination Product|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
79807278|NCT00848354|Biological|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
79972322|NCT03216954|Drug|Placebos|Subjects will receive placebo capsules
79972323|NCT03216954|Drug|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
79972324|NCT01200017|Biological|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
79972325|NCT04497922|Device|e-ink screen|A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
79972326|NCT04497922|Behavioral|Treatment as usual|Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
79972327|NCT03978702|Other|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
79972328|NCT03841487|Device|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
79972329|NCT05669807|Drug|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
79972330|NCT05669807|Drug|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
79972331|NCT05669807|Drug|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
79972332|NCT03599089|Drug|CA-008|single-dose wound infiltration prior to surgical incision closure
79972333|NCT03599089|Drug|Placebo|single-dose wound infiltration prior to surgical incision closure
79972334|NCT03599089|Drug|Ketorolac|30mg IV administered intraoperatively
79316126|NCT03171649|Device|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~anterior reaching (in a plane or in the space)~lateral elevation of the arm~hand to mouth movements with or without an object in the hand~moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
79807279|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
79316127|NCT03171649|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~Upper limb passive motion~Arm Cycle ergometer with or without FES~Neuro Muscular Electrical Stimulation~Upper limb exercises using augmented or virtual reality environment~Occupational therapy exercises~Constraint induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training~Mirror therapy~Writing training~Chemodenervation Therapy"
79316128|NCT03116269|Drug|Cilostazol 100mg|
79316129|NCT03116269|Drug|Aspirin|
79316130|NCT03168763|Behavioral|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
79316131|NCT03168763|Behavioral|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
79316132|NCT03174223|Drug|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
79316133|NCT03174067|Drug|Buprenorphine|The participant receives buprenorphine
79316134|NCT03174067|Drug|Clonidine|The participant receives clonidine
79972335|NCT03599089|Drug|Acetaminophen|1000mg IV administered intraoperatively
79972336|NCT03599089|Drug|Oxycodone|5mg PO prn post-surgery
79972337|NCT03599089|Drug|Bupivacaine Hydrochloride|0.5% infiltration pre-surgery
79972338|NCT01200173|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
79972339|NCT01200173|Other|2-Non fermented dairy product (control)|
79316135|NCT03171571|Other|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~survey like FFQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
79316136|NCT03168685|Device|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device [ActiGraph GT9X Link Actigraph Link] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
79316137|NCT03168607|Drug|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
79316138|NCT02408185|Drug|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
79316139|NCT02408185|Drug|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
79316140|NCT02400541|Behavioral|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
79316141|NCT02400541|Other|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
79316142|NCT02408419|Drug|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
79316143|NCT02408419|Drug|Saline|Saline is injected as a placebo
79316144|NCT00708097|Drug|NaF|Fluoride
79316145|NCT00708097|Drug|Placebo|Placebo
79316146|NCT00708097|Drug|NaMFP|Fluoride
79316147|NCT02400697|Other|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
79972340|NCT03192150|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
79972341|NCT03192150|Other|Vehicle|Vehicle twice daily for 16 days
79972342|NCT01204073|Drug|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~Continuous daily dosing on Days 8 through 28 in Cycle 1~In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
79972343|NCT03838523|Other|Open Label Placebo|See group description
79972344|NCT03597529|Drug|Melatonin|melatonin
79972345|NCT01204151|Behavioral|discrete-trial training|
79972346|NCT03906240|Behavioral|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
79316148|NCT02400775|Drug|Azilsartan|Azilsartan tablets
79807280|NCT00848354|Drug|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
79807281|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
79807282|NCT00848354|Drug|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
79316149|NCT02405689|Drug|Remifentanil|
79316150|NCT02405689|Drug|Dexmedetomidine|
79316151|NCT02405689|Drug|Sevoflurane|
79807283|NCT02614664|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
79807284|NCT00848120|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
79316152|NCT03173989|Device|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
79316153|NCT03173989|Behavioral|Orientation|Orientation for home.
79316154|NCT02405455|Procedure|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
79972347|NCT01202357|Behavioral|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
79316155|NCT02405455|Device|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
79316156|NCT02400619|Device|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
79316157|NCT02400619|Drug|Botulinum Toxin Type A|Botulinum toxin type A Botox
79316158|NCT02400853|Device|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
79807285|NCT00600821|Drug|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
79316159|NCT02400853|Procedure|Cord blood analysis|Cord blood will be collected during deliverance and analysed
79972348|NCT05420454|Drug|Docetaxel|75 mg/m2, d1, q3w,6 cycles
79972349|NCT05420454|Drug|Carboplatin|AUC 6, d1, q3w ,6 cycles
79316160|NCT02659631|Drug|PF-06671008|Dose Escalation Phase - Part 1
79972350|NCT05420454|Drug|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles
79972351|NCT05420454|Drug|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles
79316161|NCT02659631|Drug|PF-06671008|Dose Expansion Phase - Part 2
79316162|NCT03173833|Other|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
79316163|NCT02405143|Device|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
79316164|NCT02405143|Device|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
79316165|NCT03173911|Device|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
79477555|NCT00375557|Drug|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
79807286|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
79972352|NCT05420454|Drug|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
79972353|NCT05420454|Drug|Epirubicin|90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel
79972354|NCT05420454|Drug|Cyclophosphamide|600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
79972355|NCT05420454|Drug|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
79972356|NCT05420454|Drug|Epirubicin|90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel
79972357|NCT05420454|Drug|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
79972358|NCT05420454|Drug|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
79972359|NCT02961959|Procedure|Surgery|Arthrodesis of SI-joints, Physiotherapy
79972360|NCT02961959|Other|Non-surgery|Physiotherapy
79972361|NCT03180528|Drug|Remetinostat|Applied topically under bandage occlusion
79316166|NCT02408107|Behavioral|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
79316167|NCT04459247|Drug|Vit D|Oral liquid formulation of 60000 IU
79972362|NCT04667507|Drug|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
79972363|NCT03843905|Other|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
79972364|NCT03597295|Drug|Retifanlimab|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
79972365|NCT03180138|Behavioral|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
79477556|NCT00375557|Drug|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
79477557|NCT03177395|Drug|PP100-01 (calmangafodipir)|PP100-01
79477558|NCT03177395|Drug|Acetylcysteine|NAC
79807287|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
79807288|NCT00600821|Drug|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
79972366|NCT03180138|Behavioral|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
79807289|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
79972367|NCT04652921|Dietary Supplement|Creatine-guanidinoacetic acid|A dietary supplement provided as powder dissolved in a glass of water
79972368|NCT04652921|Other|Inulin|A dietary supplement provided as powder dissolved in a glass of water
79643073|NCT02789800|Behavioral|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
79643074|NCT02556931|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
79643075|NCT02556931|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
79643076|NCT02556931|Radiation|Total body irradiation|Day -1: 200 cGy in a single fraction
79807290|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
79807291|NCT00699764|Biological|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
79316168|NCT02405377|Procedure|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
79316169|NCT02405377|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
79643077|NCT02556931|Drug|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
79643078|NCT02556931|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
79643079|NCT00163358|Drug|Ciclesonide|
79807292|NCT00699764|Biological|Placebo injection|Intramuscular injection, 3 doses
79807293|NCT02658383|Other|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
79807294|NCT02658383|Other|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
79807295|NCT02653703|Other|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
79807296|NCT02653703|Other|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
79807297|NCT04168463|Device|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
79807298|NCT04168541|Other|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
79807299|NCT02653781|Behavioral|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
79316170|NCT02405377|Drug|0.9% sodium chloride ﬂuid administration|
79316171|NCT02405377|Device|5-French catheter|
79316172|NCT04402463|Other|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
79643080|NCT00186303|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
79643081|NCT00186303|Procedure|ablative allogeneic hematopoietic cell transplant|
79807300|NCT02653781|Behavioral|control group|The control group will have contents exposed solely from the dialogue-exhibition.
79807301|NCT02653781|Behavioral|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
79807302|NCT02653781|Behavioral|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
79643082|NCT02316184|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
79643083|NCT02316184|Behavioral|Brief Advice|
79643084|NCT04683952|Device|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
79807303|NCT00649571|Drug|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
79807304|NCT00649571|Drug|Adoxa Tablets 100 mg|100mg, single dose fasting
79807305|NCT02662283|Drug|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
79807306|NCT02662283|Drug|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
79807307|NCT04170803|Device|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
79807308|NCT04170803|Other|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
79807309|NCT02653937|Drug|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
79807310|NCT02657993|Behavioral|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
79972369|NCT01314612|Behavioral|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
79316173|NCT04402463|Other|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
79316174|NCT02405299|Other|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
79316175|NCT04342871|Behavioral|Fam-CT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
79972370|NCT01200251|Drug|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
79316176|NCT04480879|Drug|AZD8154 nebuliser|Nebuliser suspension
79316177|NCT04480879|Drug|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
79972371|NCT03597139|Drug|Voclosporin Ophthalmic Solution|Investigational Drug
79316178|NCT04480879|Drug|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
79316179|NCT02400229|Procedure|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
79316180|NCT02400229|Procedure|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
79316181|NCT02717663|Behavioral|Adaptive Goals|Prescribed goals change daily based on participant's performance
79316182|NCT02717663|Behavioral|Static Goals|Prescribed goals remain the same throughout study
79316183|NCT02717663|Behavioral|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
79316184|NCT02717663|Behavioral|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
79316185|NCT02699125|Drug|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
79316186|NCT02699125|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
79316187|NCT04279535|Drug|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
79316188|NCT05049317|Procedure|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
79316189|NCT02400151|Drug|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
79316190|NCT02400151|Drug|Placebo|Patients randomized to this group will receive placebo for 90 days.
79316191|NCT02400151|Other|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
79316192|NCT02400151|Other|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
79477559|NCT03078647|Device|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
79477560|NCT03083093|Diagnostic Test|The initial CTPA will be reviewed|The initial CTPA will be reviewed
79477561|NCT00375323|Drug|NovoSeven|
79477562|NCT03179345|Drug|Gabapentin|
79477563|NCT03179345|Drug|Pregabalin|
79477564|NCT03179345|Other|Placebo|
79477565|NCT03180515|Device|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
79972372|NCT03597139|Drug|Restasis®|Comparator
79972373|NCT01202435|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
79972374|NCT01202435|Drug|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
79316193|NCT02407951|Behavioral|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
79643085|NCT04683952|Other|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
79643086|NCT00186342|Procedure|ablative allogeneic hematopoietic cell transplantation|
79807311|NCT02657993|Behavioral|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
79477566|NCT03086213|Drug|Propofol|anaesthetic
79477567|NCT03086213|Drug|Sulfentanyl|anaesthetic
79477568|NCT03086213|Drug|Dexmedetomidine|anaesthetic
79643087|NCT02171104|Biological|Stem Cell Transplantation|Infusion given on Day 0
79643088|NCT02171104|Drug|IMD Preparative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan"
79643089|NCT02171104|Drug|Osteopetrosis Only Preparative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan~Thiotepa"
79643090|NCT02171104|Drug|Osteopetrosis Haploidentical Only Preparative Regimen|"Rituximab~Alemtuzumab~Busulfan~Fludarabine"
79316194|NCT02407951|Behavioral|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
79316195|NCT02400385|Drug|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
79316196|NCT02400385|Drug|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
79316197|NCT03173677|Dietary Supplement|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
79316198|NCT03173677|Dietary Supplement|Glucose intake|300 calories of glucose
79316199|NCT03173677|Dietary Supplement|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
79316200|NCT02405065|Drug|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
79316201|NCT03173599|Drug|PNA 40mg|The beginning dose is 40mg.
79316202|NCT03173599|Drug|PNA 80mg|The single dose is 80mg.
79316203|NCT03173599|Drug|PNA 160mg|The single dose is 160mg.
79316204|NCT03173599|Drug|PNA 240mg|The single dose is 240mg.
79316205|NCT03173599|Drug|PNA 360mg|The single dose is 360mg.
79316206|NCT03173599|Drug|PNA 480mg|The single dose is 480mg.
79477569|NCT03086213|Drug|Lidocaine|local anaesthetics
79477570|NCT03086213|Drug|Ropivacaine|local anaesthetics
79316207|NCT03173599|Drug|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
79316208|NCT03173287|Procedure|Quantification of liver fibrosis|Procedure MRI and liver biopsy
79316209|NCT02425787|Behavioral|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
79477571|NCT04737083|Genetic|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
79477572|NCT03089879|Biological|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
79477573|NCT02378714|Drug|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
79477574|NCT02378714|Behavioral|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
79643091|NCT02171104|Drug|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
79807312|NCT02653547|Other|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
79316210|NCT02425787|Behavioral|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews &/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
79972375|NCT03179202|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
79316211|NCT02425787|Behavioral|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
79972376|NCT03843671|Drug|Hyperbaric oxygen|Hyperbaric oxygen therapy
79972377|NCT03843671|Device|Hyperbaric chamber|Hyperbaric chamber
79972378|NCT05406102|Drug|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
79972379|NCT05406102|Drug|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
79316212|NCT03173365|Drug|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
79316213|NCT05100953|Behavioral|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
79316214|NCT03171337|Device|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
79316215|NCT03171337|Device|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
79316216|NCT03171337|Device|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
79972380|NCT01200563|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
79477575|NCT02378714|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
79316217|NCT05100719|Drug|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
79316218|NCT05100719|Drug|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
79477576|NCT03091361|Other|imaging, no intervention|no intervention
79477577|NCT05091047|Device|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
79477578|NCT03091673|Drug|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
79316219|NCT05100563|Drug|50 mg naltrexone|Medication combined with twice a week psychotherapy
79972381|NCT01200563|Device|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
79477579|NCT03091751|Drug|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
79972382|NCT01200563|Device|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
79316220|NCT05100329|Drug|Mitoxantrone Hydrochloride Liposome injection|20 mg/m^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
79316221|NCT04530539|Dietary Supplement|Vitamin C|1000mg Vitamin C, at bedtime
79316222|NCT04530539|Dietary Supplement|melatonin|10mg melatonin, at bedtime
79316223|NCT04530539|Dietary Supplement|Placebo|Placebo at bedtime
79316224|NCT04530539|Other|Symptom Survey|Daily symptom survey to be completed by patient electronically
79316225|NCT02698891|Drug|Paclitaxel|
79316226|NCT02698891|Drug|Neulasta|
79316227|NCT04719065|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
79316228|NCT03171181|Other|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
79316229|NCT04567745|Diagnostic Test|Retinal fundus photography|Fundus photographs
79477580|NCT02381288|Drug|TAK-448|TAK-448 solution for subcutaneous injection
79477581|NCT02381288|Drug|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
79316230|NCT03173443|Device|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
79316231|NCT03173443|Device|double lumen tube|fiberoptic intubation with double umen tube
79316232|NCT05087147|Device|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
79316233|NCT05087147|Device|Banded space maintainer|band and loop space maintainer
79316234|NCT03173209|Behavioral|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
79316235|NCT05099627|Other|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
79316236|NCT05099627|Other|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
79316237|NCT05099627|Other|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
79316238|NCT02399683|Biological|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
79316239|NCT02407873|Other|Non|
79316240|NCT02399605|Other|Stimulation|Subcutaneous abdominal electrical stimulation
79316241|NCT05076383|Other|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
79316242|NCT05076383|Other|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
79316243|NCT02408029|Other|Observational study - no intervention|
79316244|NCT05108207|Other|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
79316245|NCT05108207|Other|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
79316246|NCT05108207|Other|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
79316247|NCT02399059|Procedure|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
79316248|NCT02399059|Procedure|Normal saline lavage|Peritoneal irrigation with normal saline
79316249|NCT05108051|Drug|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
79316250|NCT05108051|Drug|Oseltamivir|Oseltamivir 75mg administered orally twice daily
79316251|NCT02404909|Other|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
79316252|NCT03765359|Drug|metforminhydrochloride|metformin 500 mg tablets and insulin
79316253|NCT03765359|Drug|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
79316254|NCT02407483|Device|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
79316255|NCT02407483|Device|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
79316256|NCT02404987|Other|Nutritional Supplement|
79316257|NCT04351295|Drug|Favipiravir|Favipiravir
79316258|NCT04351295|Drug|Chloroquine|chloroquine oral tablets
79316259|NCT05107895|Behavioral|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
79316260|NCT02407639|Other|CO2|gas
79316261|NCT02407639|Other|air|air
79316262|NCT04344587|Other|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~Welcome message~Educational review of the potential benefits of prone positioning~How-To guide to safely prone in a hospital bed~A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
79316263|NCT04344587|Other|Usual care|"The Qualtrics usual care website will include the following sections:~Welcome message~A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
79316264|NCT02399137|Drug|MM-141|
79316265|NCT02399137|Drug|Placebo|
79316266|NCT02399137|Drug|Gemcitabine|
79316267|NCT02399137|Drug|Nab-Paclitaxel|
79316268|NCT05236205|Procedure|Caries removal with a lowspeed drill|"Initial periapical and interproximal radiographs;~Prophylaxis with toothbrush and fluoride toothpaste;~Relative isolation with lip bumper, cotton roll, and aspirator;~Microbiological sampling with ear curette for standardization of volume of carious tissue;~Removal of carious dentin with carbide burs and manual instruments;~Additional microbiological sampling;~Clinical inspection of texture of remaining dentin with an exploratory probe;~Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months."
79316269|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement;~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
79477582|NCT05364359|Dietary Supplement|Taste-test|Patients will receive a dietary counseling based on a simple taste-test
79477583|NCT05364359|Other|Standard care|Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
79477584|NCT02381678|Device|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
79477585|NCT05363969|Device|Fractionated laser resurfacing|Patients will receive 3-4 treatments with fractionated laser resurfacing
79477586|NCT05363735|Other|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
79477587|NCT00355316|Other|Blood draw|
79807313|NCT02653547|Other|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
79477588|NCT05363657|Procedure|Partial Nephrectomy (PN)|Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
79477589|NCT05363657|Procedure|Radical Nephrectomy (RN)|Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
79643092|NCT02171104|Drug|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
79807314|NCT02653547|Other|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
79807315|NCT02653547|Other|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
79807316|NCT02657759|Dietary Supplement|CARDICHOL|
79807317|NCT02657759|Dietary Supplement|PLACEBO|
79316270|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~Irradiation of dental tissue for 1 minute on a single point;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement;~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
79316271|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~Irradiation of dental tissue for 1 minute on a single point;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
79316272|NCT05093387|Drug|Carboplatin|Given IV
79316273|NCT05093387|Biological|Pembrolizumab|Given IV
79316274|NCT05093387|Genetic|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
79807318|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (LAX)
79316275|NCT02399293|Behavioral|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
79316276|NCT02399293|Behavioral|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
79807319|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (SAX)
79807320|NCT02657603|Procedure|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
79807321|NCT02657603|Procedure|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
79807322|NCT02657447|Drug|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
79807323|NCT02657447|Drug|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
79807324|NCT02657681|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
79807325|NCT02657681|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
79807326|NCT00649649|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
79807327|NCT00649649|Drug|Accupril® Tablets 40 mg|40mg, single dose fed
79807328|NCT00592904|Drug|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
79807329|NCT02657291|Drug|Ropivacaine|Local anesthetic
79807330|NCT02657291|Device|Ultrasound|Ultrasound guided block
79807331|NCT02662205|Other|Psychotherapy Group|Traditional process group
79807332|NCT02662205|Other|Yoga class|Yin yoga class
79807333|NCT02662205|Other|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
79972383|NCT02821182|Radiation|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated >48h and <96h."
79972384|NCT01204229|Behavioral|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
79972385|NCT01204229|Behavioral|Brief Motivational Intervention (BMI)|Integrate drinking intervention
79972386|NCT01204307|Drug|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
79972387|NCT01204307|Drug|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
79316277|NCT03952793|Other|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
79316278|NCT02698423|Device|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
79316279|NCT02698423|Other|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
79316280|NCT02967965|Other|Imagery|MRI at year 3
79972388|NCT03725137|Other|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
79316281|NCT02850263|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
79316282|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
79316283|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
79316284|NCT04481815|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
79316285|NCT04481815|Drug|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
79316286|NCT04481815|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
79316287|NCT05107037|Drug|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
79316288|NCT02407093|Behavioral|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
79972389|NCT01204385|Procedure|Sample collection|Middle ear fluid and urine
79972390|NCT03727555|Genetic|Intracerebral LV gene therapy|Intracerebral LV gene therapy to deliver high levels lenvirus which carry normal ABCD1 gene at 1-2×10^9 multiplicity of infection/ml per site in multiple sites.
79972391|NCT01567241|Other|clinical hypnosis or relaxation music|25 minute tape recording
79972392|NCT05223296|Device|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
79972393|NCT03920111|Biological|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
79316289|NCT02407093|Behavioral|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
79316290|NCT05106959|Behavioral|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
79316291|NCT02404831|Other|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
79477590|NCT05363657|Procedure|Ablation therapy (AT)|The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.
79972394|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
79972395|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
79972396|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
79972397|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
79972398|NCT04906694|Biological|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
79972399|NCT04906694|Drug|Placebo|Diluent solution
79807334|NCT04118426|Radiation|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
79807335|NCT02662127|Device|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
79807336|NCT00699920|Drug|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
79316292|NCT02404831|Other|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
79316293|NCT05106803|Drug|ciprofloxacin|Antibiotics used in vitro n the study
79316294|NCT02404753|Drug|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
79316295|NCT02404753|Procedure|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
79316296|NCT02404753|Procedure|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
79316297|NCT02404753|Drug|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
79316298|NCT03780803|Other|home cardiac rehabilitation and respiratory rehabilitation|
79316299|NCT02404675|Drug|icotinib|
79316300|NCT05025761|Other|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
79316301|NCT03106441|Device|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
79316302|NCT03106441|Device|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
79807337|NCT00699920|Drug|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
79807338|NCT02661893|Drug|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
79477591|NCT05363657|Diagnostic Test|Active Surveillance (AS)|Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
79316303|NCT05017883|Drug|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
79807339|NCT02661893|Drug|Rifampin|Oral dose of rifampin 600 mg (2*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5 to 12.
79807340|NCT04131608|Diagnostic Test|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
79807341|NCT04170881|Other|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
79643093|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
79807342|NCT02653235|Biological|Salmonella typhi vaccination|
79972400|NCT05669495|Device|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
79807343|NCT02653235|Biological|Placebo|
79972401|NCT01568216|Drug|AMG 747|Three dose levels once-daily oral administration
79972402|NCT01568216|Drug|Placebo|Once-daily oral administration
79972403|NCT02749955|Behavioral|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
79972404|NCT02749955|Behavioral|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
79972405|NCT04894214|Diagnostic Test|Arterial blood gas (ABG)|Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.
79972406|NCT04894214|Other|Recording of hemodynamic monitoring|Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.
79807344|NCT02653469|Other|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
79807345|NCT02653469|Other|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
79807346|NCT00855920|Drug|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
79807347|NCT00855920|Drug|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
79807348|NCT00855920|Other|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
79807349|NCT00855920|Other|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
79807350|NCT04168307|Device|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
79807351|NCT04168307|Other|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
79807352|NCT02657213|Device|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
79807353|NCT02657213|Device|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
79807354|NCT00649727|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
79807355|NCT00649727|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
79807356|NCT00650273|Drug|Azithromycin Tablets 600 mg|600mg, single dose fasting
79972407|NCT04894214|Other|Recording of respiratory monitoring|Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
79643094|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
79972408|NCT02506894|Drug|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
79972409|NCT02506894|Other|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
79972410|NCT04891250|Drug|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
79972411|NCT04891250|Other|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
79807357|NCT00650273|Drug|Zithromax® Tablets 600 mg|600mg, single dose fasting
79972412|NCT03570697|Drug|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
79316304|NCT05008991|Device|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity [TLC]) to maximal expiration (residual volume [RV]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
79316305|NCT02700997|Device|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
79316306|NCT02407015|Other|Nintendo 3DS gameplay|
79643095|NCT00163397|Drug|Ciclesonide|
79643096|NCT00186381|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
79643097|NCT00163436|Drug|Ciclesonide|
79643098|NCT00186420|Drug|Taxotere|
79643099|NCT02086630|Behavioral|Heart to Heart|
79807358|NCT00848042|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
79807359|NCT02657135|Behavioral|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
79972413|NCT03570697|Drug|Placebo|Participants will receive matching placebo subcutaneous monthly.
79807360|NCT02657135|Other|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
79972414|NCT03570697|Drug|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
79972415|NCT03878381|Combination Product|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
79477592|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
79477593|NCT02382848|Drug|Placebo|Prazosin-matched placebo pill
79972416|NCT03878381|Drug|Placebo|The placebo will be a formula with no active ingredients
79477594|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
79643100|NCT01818661|Drug|AV-1451|This is used to assess Tau burden in the brain.
79972417|NCT02511574|Drug|natural progesterone|
79972418|NCT02511574|Device|cervical pessary|
79972419|NCT02506504|Device|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
79972420|NCT02506504|Device|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
79316307|NCT02404597|Device|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure <100 or mean arterial pressure <65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
79316308|NCT04481659|Procedure|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
79316309|NCT04481659|Combination Product|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
79643101|NCT00186459|Behavioral|Hypocaloric diet of varying macronutrient composition|
79643102|NCT00163475|Drug|Roflumilast|
79643103|NCT01626313|Behavioral|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
79643104|NCT00186576|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|
79643105|NCT00163514|Drug|Ciclesonide|
79643106|NCT00717652|Drug|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
79643107|NCT00717652|Drug|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
79972421|NCT01200641|Drug|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
79972422|NCT01200641|Drug|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
79972423|NCT01200641|Drug|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
79972424|NCT03731143|Procedure|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
79316310|NCT03115645|Other|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
79316311|NCT03218423|Device|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
79316312|NCT02398981|Other|Clinical decision support tool|
79316313|NCT04826081|Other|data collection|data collection
79316314|NCT02398903|Other|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
79316315|NCT02398903|Other|DXA and impedancemetry|Body composition by DXA and impedancemetry
79316316|NCT04923971|Other|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
79316317|NCT02398669|Drug|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
79316318|NCT05041751|Procedure|Acupuncture Point Injection|Receive trigger point injections
79316319|NCT05041751|Procedure|Massage Therapy|Perform myofascial release
79316320|NCT05041751|Other|Quality-of-Life Assessment|Ancillary studies
79316321|NCT05041751|Other|Questionnaire Administration|Ancillary studies
79316322|NCT02398591|Drug|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
79316323|NCT02398591|Drug|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
79316324|NCT02398357|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
79807361|NCT02657135|Other|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
79316325|NCT04437641|Other|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
79316326|NCT02398435|Biological|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
79316327|NCT02398513|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
79477595|NCT02382848|Drug|Placebo|Prazosin-matched placebo pill
79807362|NCT02657135|Other|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
79807363|NCT02657135|Other|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
79807364|NCT02657135|Other|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
79807365|NCT02657135|Other|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
79972425|NCT01856270|Drug|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
79972426|NCT02506270|Device|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
79316328|NCT04436939|Device|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
79316329|NCT02398279|Dietary Supplement|L-Arginine|Experimental supplement
79316330|NCT02398279|Other|Placebo|Placebo capsules in the same color and shape with the experimental supplement
79477596|NCT03094325|Device|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
79477597|NCT03094325|Device|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
79477598|NCT03094325|Device|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
79643108|NCT00461539|Other|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
79807366|NCT00698126|Drug|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
79972427|NCT02506270|Device|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
79972428|NCT03727321|Combination Product|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
79972429|NCT03727321|Dietary Supplement|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
79972430|NCT03727321|Dietary Supplement|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
79972431|NCT02511340|Drug|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
79972432|NCT02506348|Drug|Diclofenac|
79316331|NCT04611425|Drug|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
79316332|NCT04436471|Biological|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
79316333|NCT02398201|Drug|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
79316334|NCT05106179|Drug|Atenolol Pill|Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
79316335|NCT05106179|Drug|Propranolol Pill|Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
79972433|NCT02506348|Drug|Nepafenac|
79972434|NCT05223140|Behavioral|Birth within 7 minutes of rumping|Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus
79316336|NCT04480567|Drug|BMN 307|AAV Gene Therapy Infusion
79316337|NCT02406781|Drug|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
79316338|NCT02406781|Drug|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
79477599|NCT03094325|Device|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
79316339|NCT05106023|Drug|SHR-1701|SHR-1701 combined with temozolomide
79316340|NCT05106023|Drug|Temozolomide|SHR-1701 combined with temozolomide
79477600|NCT05718440|Other|Individualisation of uronephrological complications risk factors|description of pelvic disorders in terms of clinical presentation, electrophysiology/urodynamics/anorectal manometry patterns, urethrocystography/urinary ultrasound/defecography results and urinary complications (infections, vesicoureteral reflux), depending on the dysraphim's type and level of injury and to correlate these parameters to the uronephrological risk factors and complications recorded.
79643109|NCT00461539|Behavioral|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
79807367|NCT00698126|Drug|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
79972435|NCT05223140|Behavioral|Premature cord clamping|Umbilical cord clamping <1 minute following birth
79972436|NCT02511262|Device|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
79316341|NCT02398123|Other|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
79316342|NCT02398123|Other|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
79316343|NCT02398123|Drug|Bupivacaine|
79972437|NCT03569371|Drug|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
79316344|NCT05105945|Procedure|Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery|"Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
79316345|NCT05105945|Procedure|Thoracoscopy Combined With Laparoscopic Surgery|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
79972438|NCT02506426|Procedure|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
79972439|NCT02506426|Procedure|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
79316346|NCT04480801|Other|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
79316347|NCT04480801|Other|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
79316348|NCT02397967|Other|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
79316349|NCT04458077|Behavioral|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
79316350|NCT02404363|Drug|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --> clopidogrel 150 mg/d x 7days then 75mg/d"
79316351|NCT02404363|Drug|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --> placebo 150 mg/d x 7days then 75mg/d"
79316352|NCT02404519|Dietary Supplement|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
79316353|NCT02404519|Dietary Supplement|Placebo|1 tablet without MK-7 taken orally every day during 1 year
79477601|NCT02065687|Drug|Carboplatin|Given IV
79477602|NCT02065687|Other|Laboratory Biomarker Analysis|Correlative studies
79477603|NCT02065687|Drug|Metformin Hydrochloride|Given PO
79477604|NCT02065687|Drug|Paclitaxel|Given IV
79477605|NCT02065687|Other|Placebo Administration|Given PO
79316354|NCT03173131|Behavioral|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
79316355|NCT02398045|Other|Computerised CBT for OCD|Computerised CBT for OCD
79316356|NCT02658149|Drug|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
79316357|NCT02658149|Drug|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
79316358|NCT02658149|Drug|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
79316359|NCT02658149|Drug|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
79316360|NCT02658149|Drug|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
79477606|NCT02065687|Other|Quality-of-Life Assessment|Ancillary studies
79477607|NCT02065687|Other|Questionnaire Administration|Ancillary studies
79477608|NCT03095885|Other|Test Meal|
79477609|NCT02383706|Device|ApneaLink Air|Overnight, home polysomnography device
79972440|NCT02515396|Drug|MMI-0100|
79972441|NCT02515396|Drug|Placebo|
79972442|NCT03731065|Dietary Supplement|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
79972443|NCT03731065|Dietary Supplement|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
79972444|NCT03731065|Dietary Supplement|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
79807368|NCT02657057|Device|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
79972445|NCT01200719|Device|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: < 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity ~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
79477610|NCT02383706|Behavioral|Berlin Quesionnaire|OSA screening questionnaire
79807369|NCT02657057|Device|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
79477611|NCT02383706|Behavioral|Epworth Sleepiness Scale|OSA screening questionnaire
79316361|NCT03511079|Behavioral|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
79316362|NCT03458195|Other|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
79316363|NCT05111873|Other|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
79477612|NCT02383706|Behavioral|STOP-BANG questionnaire|OSA screening questionnaire
79477613|NCT02383706|Other|Physical exam|Physical exam of neck, mouth and upper airway
79477614|NCT03096353|Other|Placebo|saline
79477615|NCT03096353|Drug|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
79643110|NCT00186654|Procedure|Acupuncture|
79807370|NCT00701012|Procedure|preservation of nerve fibers around IMA|low ligation
79807371|NCT00701012|Procedure|resection of nerve fibers around IMA|high ligation
79807372|NCT02661659|Biological|Multipeptide vaccine S-588210|
79807373|NCT04168151|Other|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
79972446|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
79316364|NCT05105321|Drug|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
79316365|NCT05105321|Behavioral|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
79316366|NCT02698189|Drug|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
79316367|NCT03172663|Device|pure tone audiometry|for estimate the type and degree of hearing loss
79316368|NCT02397733|Radiation|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
79316369|NCT02397733|Radiation|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
79316370|NCT04482127|Other|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
79316371|NCT02397811|Dietary Supplement|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
79972447|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
79972448|NCT01318070|Drug|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
79316372|NCT02397811|Dietary Supplement|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
79316373|NCT02397811|Dietary Supplement|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
79316374|NCT02397811|Dietary Supplement|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
79316375|NCT02397811|Dietary Supplement|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
79316376|NCT02397811|Dietary Supplement|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
79316377|NCT04481971|Drug|Prednisolone|Tablets
79972449|NCT03345316|Drug|FFI-1010|Intravenous single dosing
79316378|NCT04481971|Drug|lactose in capsules gelatin|Tablets
79316379|NCT03170791|Device|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
79316380|NCT03172741|Drug|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
79316381|NCT03172741|Drug|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
79316382|NCT02702011|Drug|empagliflozin medium dose|
79316383|NCT02702011|Drug|empagliflozin low dose|
79316384|NCT02702011|Drug|empagliflozin high dose|
79316385|NCT02702011|Drug|placebo|
79316386|NCT03170713|Drug|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
79316387|NCT03170713|Drug|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
79643111|NCT00186654|Procedure|Perinatal massage|
79972450|NCT01202513|Drug|Bimatoprost 0.03% topical ophthalmic solution|
79972451|NCT03345238|Procedure|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
79972452|NCT03730909|Drug|Sodium Lactate|IV infusion
79972453|NCT03730909|Drug|Sodium chloride|IV infusion
79972454|NCT04497688|Drug|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
79972455|NCT03835715|Drug|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
79972456|NCT03727165|Other|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
79972457|NCT03727165|Other|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
79972458|NCT02510716|Behavioral|SGR|
79972459|NCT02510716|Behavioral|Support message only|
79972460|NCT03727087|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
79316388|NCT03170713|Other|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
79972461|NCT04877366|Dietary Supplement|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
79316389|NCT02404207|Other|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
79316390|NCT02404207|Other|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
79316391|NCT02404207|Other|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
79316392|NCT02404207|Other|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
79972462|NCT04877366|Other|Reference control|A placebo matching to the test product will be used as control
79972463|NCT04877366|Other|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
79972464|NCT01202669|Other|No intervention planned, observational study only.|No intervention planned, observational study only.
79972465|NCT02505802|Drug|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
79972466|NCT03627884|Drug|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
79972467|NCT03627884|Drug|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
79972468|NCT03835559|Procedure|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
79972469|NCT03835559|Procedure|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
79972470|NCT02505646|Other|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
79972471|NCT05222282|Other|Sexual Health|Prevention of sexual dysfunction
79972472|NCT02895295|Behavioral|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
79972473|NCT02895295|Behavioral|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
79316393|NCT02657369|Drug|Lenvatinib 24 mg|
79316394|NCT02397421|Drug|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
79972474|NCT02895295|Behavioral|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
79972475|NCT02505724|Behavioral|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
79316395|NCT02397421|Drug|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
79316396|NCT04862507|Other|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
79316397|NCT04862507|Diagnostic Test|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
79316398|NCT03168451|Behavioral|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
79643112|NCT00066040|Drug|Cervitec chlorhexidine varnish|
79316399|NCT05110859|Other|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
79316400|NCT02397343|Drug|Hyperbaric oxygen|
79316401|NCT04850339|Biological|ANXV|Intravenous infusion
79316402|NCT04850339|Other|Placebo|Intravenous infusion
79316403|NCT02403973|Other|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
79316404|NCT04832009|Drug|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
79477616|NCT02384096|Device|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
79477617|NCT02384096|Device|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
79477618|NCT03098615|Drug|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
79477619|NCT05363579|Other|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
79643113|NCT00066040|Drug|Duraphat fluoride varnish|
79643114|NCT00066040|Drug|xylitol gum from Fennobon, Finland|
79643115|NCT05454826|Other|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week * 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
79316405|NCT04832009|Drug|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
79316406|NCT04832009|Drug|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
79477620|NCT05363579|Other|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
79477621|NCT05363579|Other|Physio and Tuina therapy|Physiotherapy mixed with Tuina
79643116|NCT05454826|Other|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week * 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
79643117|NCT00163553|Drug|Pethidine|
79643118|NCT00163553|Drug|Placebo|
79477622|NCT05504798|Other|Selected physical therapy program|Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.
79477623|NCT05504798|Procedure|Interrupted serial casting|Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.
79316407|NCT04832009|Drug|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
79477624|NCT05504798|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
79807374|NCT02661425|Other|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
79477625|NCT05363501|Drug|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
79643119|NCT05420818|Procedure|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
79643120|NCT00192699|Device|Bimetric femoral stem|Cemented Bi-Metric femoral stem
79643121|NCT00163592|Drug|Tissucol®|
79643122|NCT00163592|Procedure|Control: Conventional treatment, i.e. compression with swabs|
79643123|NCT04683601|Other|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
79972476|NCT02505724|Behavioral|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
79316408|NCT03115957|Other|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
79477626|NCT05363501|Drug|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
79643124|NCT04683445|Drug|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
79643125|NCT04683445|Drug|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
79972477|NCT03843281|Drug|Paracetamol|s. above
79316409|NCT03129113|Drug|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
79316410|NCT03129113|Drug|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
79316411|NCT03116035|Other|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
79316412|NCT03116035|Other|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
79316413|NCT05105165|Diagnostic Test|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
79477627|NCT05363501|Drug|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
79477628|NCT05363501|Drug|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
79643126|NCT04683445|Drug|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
79643127|NCT04683445|Drug|Pyrotinib|Pyrotinib，400mg，oral，every day
79643128|NCT04683445|Drug|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
79643129|NCT04683445|Drug|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
79643130|NCT00192777|Drug|Xeloda|
79972478|NCT03843281|Drug|Placebo|s. above
79972479|NCT03843281|Drug|Morphine|s. above
79972480|NCT02515240|Biological|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
79972481|NCT03727009|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
79972482|NCT03843515|Drug|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
79316414|NCT03170635|Behavioral|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
79316415|NCT05110547|Biological|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
79316416|NCT02397577|Other|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
79316417|NCT05105009|Drug|Furosemide|"Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~Oral creatinine load using 5 grams of creatinine"
79316418|NCT03168529|Drug|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
79316419|NCT03168529|Drug|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
79316420|NCT03115879|Other|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
79316421|NCT03115879|Other|Hip manipulation simulation|Hip manipulation simulation
79643131|NCT00192777|Procedure|External Beam Radiotherapy|
79643132|NCT00553072|Drug|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
79643133|NCT00553072|Drug|Normal saline|1 ml/kg/dose
79643134|NCT05381194|Drug|BPaL regimen|"The regimen consists of only oral medication using bedaquiline, linezolid, and pretomanid for 26 weeks.~Bedaquiline (400 mg/day for the 2 weeks, 200mg/TIW afterward). Pretomanid 200mg/day. Linezolid 600mg/day for the 9 weeks, 300mg/day afterward."
79972483|NCT02515318|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
79972484|NCT02515318|Drug|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
79972485|NCT03776201|Other|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
79972486|NCT00245960|Drug|etanercept|
79972487|NCT00245960|Drug|etanercept|
79972488|NCT00245960|Drug|Placebo|
79972489|NCT04443322|Drug|Durvalumab Injection|Anti-PD-L1 Monoclonal Antibody
79972490|NCT04443322|Drug|Lenvatinib 4 MG|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
79316422|NCT05104931|Drug|Nanoformed Piroxicam IR Tablet|Orally delivered Nanoformed Piroxicam
79316423|NCT05104931|Drug|Felden (piroxicam) Tablets|orally delivered Felden (reference) tablets
79316424|NCT05104931|Drug|Brexidol (piroxicam) Tablets|orally delivered Brexidol (reference) tablets
79316425|NCT02397499|Drug|LIPO-202|
79316426|NCT02397499|Drug|Placebo|
79316427|NCT02847689|Behavioral|Language Treatment|Recording of a mother's voice reading a children's storybook.
79316428|NCT02847689|Behavioral|Control Treatment|Standard of Care
79316429|NCT02406703|Drug|Chloroprocaine|
79316430|NCT02406703|Drug|Mepivacaine|
79807375|NCT02656901|Device|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
79807376|NCT02656901|Device|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
79316433|NCT02397031|Behavioral|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
79316434|NCT02397031|Behavioral|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
79643135|NCT05808842|Other|CeraVe|"CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
79807377|NCT02656901|Device|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
79316435|NCT05110469|Drug|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
79316436|NCT05110469|Drug|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
79316437|NCT02404129|Other|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
79316438|NCT04831775|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
79477629|NCT05363501|Drug|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
79477630|NCT05363501|Drug|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
79316439|NCT04831775|Behavioral|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
79316440|NCT02404051|Drug|Everolimus|10 mg daily tablets
79643136|NCT05808842|Other|CeraVe and Calecim|"CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
79643137|NCT05808829|Other|Progressive Muscle Relaxation Exercise|University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
79643138|NCT05808816|Drug|Lactobacillus Crispatus M247|Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
79972491|NCT01202825|Drug|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
79643139|NCT05808790|Procedure|Minimally invasive pulmonary metastasectomy|Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection
79972492|NCT01202825|Drug|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
79643140|NCT05808790|Radiation|Stereotactic ablative radiotherapy|Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
79972493|NCT01202825|Drug|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
79643141|NCT05808777|Other|Phone interview|A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
79972494|NCT01202825|Drug|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
79316441|NCT02404051|Drug|Exemestane|25 mg daily tablets
79477631|NCT04736927|Drug|GLPG3667|From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
79972495|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
79972496|NCT01202825|Drug|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
79972497|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
79972498|NCT01202825|Drug|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
79972499|NCT01202825|Drug|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
79972500|NCT01202825|Drug|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
79972501|NCT02515162|Procedure|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
79972502|NCT02515162|Procedure|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
79972503|NCT03843203|Device|Transcranial Direct Current Stimulation - tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
79972504|NCT03725215|Behavioral|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
79316442|NCT02404051|Drug|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
79643142|NCT05808712|Other|validation|Translation and validation design
79807378|NCT02656901|Device|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
79807379|NCT00847886|Drug|LX3305|Daily oral intake of LX3305 for 14 days.
79316443|NCT05102357|Procedure|Conservative Treatment (splint)|splint 6 weeks
79316444|NCT02406547|Device|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
79316445|NCT02406547|Device|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
79316446|NCT04436549|Procedure|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
79972505|NCT02510872|Other|18F-FDG PET combined with CT with iodinated contrast injection|
79643143|NCT05808647|Behavioral|5-day controlled metabolic dietary intake|Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.
79643144|NCT05808634|Drug|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
79643145|NCT05808569|Behavioral|Test|A specific self-test composed by 16 questions , will be administered to BC patients undergoing adjuvant RT.
79807380|NCT00847886|Drug|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
79807381|NCT00847886|Drug|Methotrexate|Once weekly stable-dose methotrexate.
79316447|NCT04436549|Diagnostic Test|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
79316448|NCT03172585|Other|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
79316449|NCT03172585|Other|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
79316450|NCT05094323|Drug|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
79316451|NCT05094323|Drug|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
79316452|NCT05094323|Drug|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
79643146|NCT05808556|Device|Sticker pads containing lavender and ylang ylang oil|The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
79643147|NCT05808556|Device|Placebo|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
79807382|NCT04315649|Other|3D movie viewing|3D movie viewing
79807383|NCT02653157|Other|MDR-GNB|
79807384|NCT00847808|Drug|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
79972506|NCT02510872|Other|18F-FDG PET combined with CT without injection|
79972507|NCT05222204|Drug|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
79316453|NCT03170323|Drug|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
79316454|NCT03170323|Drug|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
79477632|NCT04736927|Drug|Midazolam|On Day 1 and Day 7 as liquid formulation, orally in fed state.
79477633|NCT02387294|Biological|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
79477634|NCT02387294|Biological|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
79972508|NCT02515006|Other|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
79477635|NCT05352269|Biological|XBI-302|Fecal Microbiota Transplantation Capsules
79477636|NCT05352269|Biological|XBI-302 Placebo|XBI-302 Placebo
79316455|NCT05087225|Biological|polyethelyene glycol|the excipients at covid-19 vaccines
79316456|NCT04480489|Other|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
79316457|NCT04480489|Other|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
79316458|NCT02396797|Behavioral|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
79477637|NCT05718206|Device|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
79477638|NCT02066857|Device|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
79477639|NCT02066857|Device|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
79477640|NCT04940585|Other|ROSE Program|The program includes 6 group sessions and an individual session 4-6 weeks after birth. Each session will last 60 minutes and will be conducted over Webex. The key areas that will be discussed during the sessions include: Psychoeducation, Adjusting to life with baby, Effective communication, Asking for what you need, and Planning for the future.
79807385|NCT02656979|Drug|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
79477641|NCT02388386|Device|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
79972509|NCT02558465|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
79477642|NCT03810703|Drug|Placebo oral capsule|Placebo oral capsule
79477643|NCT03810703|Drug|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
79972510|NCT02515084|Device|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
79972511|NCT02515084|Device|MRI imaging|
79316459|NCT02396797|Behavioral|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
79316460|NCT04788875|Procedure|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
79316461|NCT04788875|Procedure|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
79316462|NCT02396875|Procedure|Blood sampling and exercise protocol pre and post CRT implant|
79316463|NCT02396875|Procedure|Peripheral blood sampling|
79477644|NCT03810703|Drug|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
79477645|NCT04819997|Other|Educational Intervention|Participate in videoconference session
79477646|NCT05718050|Diagnostic Test|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
79807386|NCT02656667|Device|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
79316464|NCT02396875|Procedure|Central blood sampling pre and post CRT implant|
79477647|NCT04332965|Procedure|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
79316465|NCT02396875|Procedure|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
79316466|NCT02396641|Other|Best Supportive Care Checklist|
79477648|NCT02389088|Drug|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
79477649|NCT04747691|Diagnostic Test|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
79807387|NCT02656667|Device|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
79807388|NCT02656667|Other|Conventional pulmonary rehabilitation|excercise training on treadmill
79807389|NCT00701168|Device|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
79316467|NCT05109923|Dietary Supplement|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
79316468|NCT05109923|Dietary Supplement|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
79316469|NCT02396563|Procedure|epidural analgesia|
79316470|NCT02396563|Drug|Ropivacaine|
79316471|NCT05109767|Device|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
79316472|NCT05109767|Device|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
79316473|NCT03170245|Diagnostic Test|Interleukin-6|serum samples used for doing the test by ELISA
79316474|NCT03170245|Diagnostic Test|HsC-RP|serum samples used for doing the test by ELISA
79316475|NCT03170245|Diagnostic Test|Adiponectin level|serum samples used for doing the test by ELISA
79477650|NCT02068027|Drug|Clonidine Gel 0.1%|
79477651|NCT02068027|Drug|Placebo|
79807390|NCT04168229|Device|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
79807391|NCT04168229|Device|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
79807392|NCT04017455|Drug|Atezolizumab|3 cycles of atezolizumab 840 mg
79807393|NCT04017455|Drug|Bevacizumab|3 cycles of bevacizumab 5mg/kg
79807394|NCT05298020|Drug|Envafolimab|400mg,sc,d1,Q4W
79316476|NCT03170245|Diagnostic Test|Carotid intima media thickness|Done by carotid doppler
79316477|NCT05109689|Behavioral|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
79316478|NCT05109689|Behavioral|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
79316479|NCT02701777|Other|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
79316480|NCT02701777|Behavioral|Training|The participant will be asked to perform exercises using their hands and arms.
79477652|NCT05242055|Other|Integrated diagnosis and treatment for CKD|This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
79477653|NCT05717972|Other|Kombucha|"Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste."
79807395|NCT05298020|Drug|Endostar|210mg，CIV72h，d1-3，Q4W
79316481|NCT02701777|Other|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
79477654|NCT05717894|Drug|Vitex Agnus Castus Extract|The patient group received two pills containing 200mg of VAC daily for six months
79477655|NCT05231681|Dietary Supplement|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
79477656|NCT04661657|Other|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
79477657|NCT04661657|Other|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
79477658|NCT02391350|Behavioral|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
79807396|NCT05298020|Drug|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
79807397|NCT05298020|Drug|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
79807398|NCT02536469|Drug|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
79807399|NCT02661581|Behavioral|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
79807400|NCT02652845|Behavioral|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
79316482|NCT02701777|Other|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
79316483|NCT05109533|Other|Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1|Probiotics implementation
79316484|NCT05109377|Diagnostic Test|Endocan|Endocan will measured before and after treatment
79316485|NCT05109377|Drug|tadalafil|tadalafil
79316486|NCT05109299|Other|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
79316487|NCT05109299|Other|Fluoride toothpaste|1450 ppm fluoride toothpaste
79316488|NCT03172351|Device|EDoF1|extended depth of focus IOL - EDoF1
79477659|NCT02391350|Procedure|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
79316489|NCT03172351|Device|Monofocal|Monofocal IOL
79477660|NCT02392208|Drug|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
79477661|NCT02392208|Procedure|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
79477662|NCT05185583|Drug|Methylphenidate Hydrochloride|Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
79477663|NCT05185583|Drug|Placebo|Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
79316490|NCT03172351|Device|EDoF2|Comparison EDoF2 IOL
79316491|NCT05108753|Other|Procedure/Surgery|Transanal Total Mesorectal Excision
79316492|NCT03170089|Behavioral|Oral Health Educational Program|Oral Hygiene methods learned
79316493|NCT02396719|Device|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
79316494|NCT04673591|Drug|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
79316495|NCT04673591|Other|Placebo|Matched Placebo
79477664|NCT04645121|Device|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
79477665|NCT04645121|Device|Bioimpedance|Measures total volume, intra and extracellular volume.
79477666|NCT04645121|Radiation|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
79477667|NCT05462444|Other|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
79477668|NCT02392286|Drug|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
79316496|NCT05108597|Drug|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
79316497|NCT02397187|Behavioral|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
79316498|NCT02396485|Other|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
79316499|NCT03167593|Dietary Supplement|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
79316500|NCT03167593|Other|Control placebo|Maltodextrin
79316501|NCT02396173|Other|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
79972512|NCT03834467|Other|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
79972513|NCT03834467|Other|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
79477669|NCT04586153|Drug|Meplazumab for Injection|humanized antibody target CD147
79477670|NCT04586153|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
79477671|NCT05717816|Device|intramedullary nail and plate|fusing Charcot ankle using retrograde intrameudllary femoral nail and plate
79316502|NCT04524767|Behavioral|SBIRT|Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.
79316503|NCT04524767|Behavioral|Referral as Usual|We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
79316504|NCT02396407|Behavioral|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children < 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
79316505|NCT02403739|Other|No Intervention|No Intervention
79316506|NCT05080907|Other|Observational|Subjects for observational study Various conditions & healthy subjects
79477672|NCT02393378|Drug|Namilumab|Namilumab injection
79477673|NCT02393378|Drug|Adalimumab|Adalimumab SC injection
79477674|NCT02393378|Drug|Methotrexate|Methotrexate tablet
79972514|NCT03840785|Other|Argentine tango|"Argentine tango sessions will consist of:~Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
79477675|NCT02393378|Drug|Folic Acid|Folic Acid Tablet
79807401|NCT04170647|Drug|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
79972515|NCT04825184|Behavioral|Body image chatbot|See arm/group description.
79972516|NCT02729194|Drug|Pazopanib|
79972517|NCT02729194|Other|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
79972518|NCT05218616|Drug|Aviga, capsules 50 mg / Sutent®, capsules 50 mg|Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
79477676|NCT05443490|Dietary Supplement|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.|Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.
79477677|NCT05443490|Other|Placebo comparator with maltodextrin as a carrier.|Sachets containing maltodextrin
79477678|NCT04949477|Drug|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
79477679|NCT04949477|Drug|paracetamol|the patient will receive paracetamol orally [Rx paracetamol 250 mg/ml] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
79477680|NCT00354926|Biological|AME-133v (LY2469298)|IV 4X weekly X 4
79316507|NCT03170011|Behavioral|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
79316508|NCT05086913|Other|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
79316509|NCT05086913|Other|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
79316510|NCT05086913|Other|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
79316511|NCT05745805|Device|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
79807402|NCT02661347|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
79807403|NCT02661347|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
79807404|NCT02661269|Device|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
79316512|NCT03169855|Diagnostic Test|Slit lamp (LOCS III Score)|Diagnostic procedure only
79316513|NCT04436627|Device|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
79316514|NCT04436627|Device|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
79807405|NCT02661269|Device|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
79807406|NCT00649805|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
79316515|NCT04436627|Device|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
79316516|NCT02396329|Drug|Chlorhexidine|
79477681|NCT05717660|Combination Product|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
79655719|NCT04552678|Behavioral|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79807407|NCT00649805|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
79807408|NCT02652689|Radiation|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
79807409|NCT02656589|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
79807410|NCT02656589|Drug|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
79807411|NCT00600353|Drug|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
79807412|NCT00600353|Drug|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
79807413|NCT00600353|Drug|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
79972519|NCT05218616|Drug|Sutent®, capsules 50 mg / Aviga, capsules 50 mg|Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
79972520|NCT02505880|Other|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
79316517|NCT02396329|Drug|Povidone-Iodine|
79316518|NCT04964921|Other|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
79316519|NCT04053049|Other|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
79807414|NCT02661191|Drug|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
79477682|NCT05717582|Drug|apalutamide|Patients receive apalutamide 240mg,qd,po.
79477683|NCT05717582|Drug|androgen deprivation therapy|Patients receive systemic ADT.
79807415|NCT02660879|Other|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
79316520|NCT04648553|Behavioral|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
79972521|NCT02505880|Drug|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
79972522|NCT03840629|Other|No study intervention.|
79316521|NCT04648553|Behavioral|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
79316522|NCT03167515|Device|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
79316523|NCT03168139|Drug|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
79316524|NCT03168139|Drug|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
79316525|NCT02396017|Device|Capsule endoscopy|Endoscopic device
79316526|NCT02396017|Drug|Polyethylene Glycol|Bowel purgative
79316527|NCT02395939|Procedure|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
79316528|NCT02395939|Procedure|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
79316529|NCT02395783|Drug|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
79316530|NCT02395783|Drug|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
79477684|NCT05717582|Procedure|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
79316531|NCT02395783|Other|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
79316532|NCT04604015|Diagnostic Test|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
79316533|NCT04604015|Diagnostic Test|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
79316534|NCT04569383|Biological|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
79316535|NCT04569383|Biological|Comirnaty|Vaccination with Comirnaty (21 day interval)
79316536|NCT04555343|Drug|Tranexamic acid|1gm instilled instravesically
79477685|NCT05717582|Radiation|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
79477686|NCT03101033|Device|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
79655720|NCT04552678|Behavioral|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
79807416|NCT02660879|Other|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
79807417|NCT02652533|Device|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
79807418|NCT02660957|Behavioral|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
79807419|NCT02660957|Other|placebo comparator|suggest a healthy life style as a placebo comparator
79316537|NCT04450667|Dietary Supplement|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
79477687|NCT03101033|Drug|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
79807420|NCT00691210|Drug|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
79807421|NCT00691210|Drug|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
79807422|NCT00691210|Drug|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
79807423|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
79807424|NCT02536703|Device|Lotus Valve System|Lotus Valve System
79807425|NCT02652143|Device|AneVivo (Medical device for in vivo culture of embryos)|
79807426|NCT02652143|Other|comparator for embryo culture in vitro|
79807427|NCT02652065|Other|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
79807428|NCT02652065|Other|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
79807429|NCT02652065|Other|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
79316538|NCT04436237|Other|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
79807430|NCT02652065|Other|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
79316539|NCT04466657|Dietary Supplement|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
79316540|NCT04466657|Other|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
79807431|NCT00650429|Drug|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
79807432|NCT00691132|Drug|phenethyl isothiocyanate|Given orally
79807433|NCT00691132|Other|placebo|Given orally
79972523|NCT05218304|Biological|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
79972524|NCT02505490|Other|Television|The purpose is to determine whether television impacts liking of food.
79972525|NCT02505490|Other|No Television|The purpose is to determine whether the lack of television impacts liking of food.
79972526|NCT03840863|Dietary Supplement|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
79972527|NCT02510950|Biological|Personalized peptide vaccine|
79972528|NCT02510950|Drug|Poly-ICLC|
79972529|NCT02510950|Drug|Temozolomide|
79316541|NCT04392323|Diagnostic Test|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
79972530|NCT05670197|Other|No intervention. Participants will take part in a qualitative interview|No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
79316542|NCT04528667|Drug|STI-5656|STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
79316543|NCT04528667|Drug|Placebo|Placebo capsules
79316544|NCT04309877|Drug|Theophylline ER|Capsules of theophylline ER
79316545|NCT04309877|Other|PO placebo|Capsules of methylcellulose
79807434|NCT04262219|Behavioral|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
79807435|NCT02652299|Biological|Synovial biopsy|Synovial tissue for analysis and biobank.
79807436|NCT02651909|Other|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
79972531|NCT04499872|Other|Advance Care Plan with Trajectory Touchpoint Technique|Advance Care Plan with Trajectory Touchpoint Technique
79972532|NCT03840473|Behavioral|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
79972533|NCT03840473|Behavioral|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
79972534|NCT03840473|Behavioral|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
79972535|NCT05221814|Diagnostic Test|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
79972536|NCT02514928|Procedure|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
79972537|NCT02514928|Procedure|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
79316546|NCT04309877|Biological|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
79316547|NCT04309877|Other|IV placebo|Normal (0.9%) saline
79316548|NCT04367909|Drug|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
79316549|NCT04367909|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
79316550|NCT04367909|Drug|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
79807437|NCT04167839|Other|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
79972538|NCT05221736|Procedure|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) & surgical excision in management of warthin tumor of parotid gland.
79807438|NCT02564458|Behavioral|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
79972539|NCT02510560|Drug|NTRA-2112|
79316551|NCT04221425|Procedure|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
79477688|NCT03101033|Drug|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
79477689|NCT03101033|Drug|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
79477690|NCT02069041|Biological|Ramucirumab|Administered IV.
79477691|NCT02069041|Drug|FOLFOX4|Administered IV.
79477692|NCT03101111|Biological|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
79972540|NCT02510560|Drug|Placebo|
79477693|NCT03101111|Biological|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
79972541|NCT05361252|Procedure|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
79972542|NCT01204619|Behavioral|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
79972543|NCT03636750|Drug|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
79972544|NCT01982357|Device|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
79807439|NCT02651753|Drug|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
79807440|NCT02651753|Drug|CKD-337|Test Drug: CKD-337
79972545|NCT02510404|Biological|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
79316552|NCT04221425|Procedure|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
79316553|NCT04058873|Drug|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
79477694|NCT05423834|Drug|Tenofovir alafenamide|Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
79807441|NCT00855218|Drug|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. [twice daily], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
79972546|NCT01314456|Device|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
79316554|NCT04203953|Other|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
79316555|NCT04196075|Drug|Andrographis Paniculata|AP as palliative treatment
79807442|NCT00855218|Drug|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
79972547|NCT05218226|Drug|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
79316556|NCT04142255|Biological|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
79972548|NCT05282537|Behavioral|In person academic activities|All participants will perform academic activities in person from March to December, 2022
79316557|NCT03863483|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
79316558|NCT03863483|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
79807443|NCT00748150|Biological|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
79972549|NCT02514850|Drug|Biochaperone Combo|Injection of BioChaperone Combo
79972550|NCT02514850|Drug|Humalog Mix25|Injection of Humalog Mix25
79316559|NCT03863483|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
79316560|NCT03863483|Drug|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
79807444|NCT00744172|Procedure|laparoscopy|laparoscopic hysterectomy
79807445|NCT00744172|Procedure|vaginal|vaginal hysterectomy
79807446|NCT00744172|Procedure|abdominal|abdominal hysterectomy
79316561|NCT04010045|Device|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
79972551|NCT02514850|Drug|Humalog|Injection of Humalog
79972552|NCT02514850|Drug|Lantus|Injection of Lantus
79972553|NCT02514850|Drug|Placebo|Injection of saline 0.9% solution
79972554|NCT03178266|Device|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
79316562|NCT03871595|Drug|BI 894416|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
79316563|NCT03840005|Drug|Ursonorm|Ursodeoxycholic acid
79316564|NCT03780725|Drug|BI 754111|Solution for infusion
79316565|NCT03780725|Drug|[89Zr]Zr-BI 754111|Solution for infusion
79316566|NCT03780725|Drug|BI 754091|Solution for infusion
79316567|NCT03830411|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
79316568|NCT03830411|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
79316569|NCT03830411|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
79477695|NCT05423834|Drug|Entecavir|Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
79477696|NCT03102437|Device|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
79807447|NCT00650507|Procedure|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
79807448|NCT00650507|Procedure|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
79807449|NCT00748228|Dietary Supplement|dietary sodium|10 mEq/day
79807450|NCT00748228|Dietary Supplement|dietary sodium|300 mEq/day
79477697|NCT05717426|Other|Open chain exercises|An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.
79477698|NCT05717426|Other|Closed kinetic chain exercises|Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
79477699|NCT02069119|Drug|OPC-108459|
79316570|NCT03300479|Drug|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
79316571|NCT03300479|Drug|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
79316572|NCT04718987|Radiation|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
79316573|NCT04708379|Behavioral|Lifestyle intervention|Nutrition and physical activity education.
79316574|NCT03702569|Diagnostic Test|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
79316575|NCT04685447|Procedure|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
79477700|NCT02069119|Drug|Placebo|
79477701|NCT04139135|Drug|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
79477702|NCT04139135|Drug|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
79477703|NCT05406557|Procedure|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
79477704|NCT05406557|Procedure|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
79972555|NCT03837197|Device|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
79477705|NCT02069353|Device|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
79477706|NCT02069353|Device|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
79807451|NCT00748228|Dietary Supplement|dietary sodium|150 mEq/day dietary sodium
79807452|NCT02651519|Drug|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
79972556|NCT03837197|Device|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
79477707|NCT04899830|Device|Telepresence robot|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
79807453|NCT02651519|Drug|saline|stellate-ganglion block with saline
79807454|NCT00748306|Drug|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
79477708|NCT04011527|Procedure|Rotational Atherectomy in Coronary Lesion/s|
79477709|NCT05440877|Behavioral|VR materials|In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
79316576|NCT04685447|Procedure|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
79316577|NCT03012425|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
79477710|NCT05440877|Behavioral|Tutorial guide|A tutorial guide including description of the smokers' cases
79807455|NCT00748306|Drug|Placebo|Matching Intervention Drug
79316578|NCT03012425|Procedure|Acupuncture|
79316579|NCT03012425|Behavioral|questionnaires|
79972557|NCT05553028|Procedure|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
79316580|NCT03012425|Other|Diurnal Cortisol|saliva test
79316581|NCT03587675|Diagnostic Test|EVH test|
79316582|NCT03540875|Device|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
79807456|NCT02651441|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
79972558|NCT05221268|Other|Level walking exercise|treadmill exercise with 0 inclination
79807457|NCT02651441|Drug|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
79807458|NCT02651441|Biological|D-CIK|8×10^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
79807459|NCT01063348|Drug|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
79972559|NCT05221268|Other|Downhill exercise|treadmill exercise with -20 inclination
79972560|NCT04450511|Device|Magnetic stimulation -Armchair type (MS)|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
79972561|NCT04450511|Other|Bladder Training (BT)|Bladder Training (BT)
79972562|NCT02505568|Drug|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
79972563|NCT03627572|Other|No intervention|Not applicable (no intervention)
79972564|NCT05356728|Drug|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
79316583|NCT03540875|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
79316584|NCT03540875|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
79316585|NCT03536507|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79316586|NCT03536507|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79316587|NCT03220685|Biological|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
79477711|NCT03103061|Drug|Lexiscan|Coronary vasodilator
79477712|NCT03105479|Drug|Cadazolid|Granules for oral suspension to be administered twice daily
79972565|NCT02514694|Drug|LEO32731|
79972566|NCT02514694|Other|Placebo|
79972567|NCT05344482|Other|Secukinumab|Included all the patients treated with secukinumab
79807460|NCT01063348|Drug|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
79807461|NCT02651129|Other|Noise measurement|We will be measuring noise levels in the operating room
79807462|NCT00855062|Drug|minocycline|100 mg capsule every 12 hours by mouth
79807463|NCT00855062|Drug|minocycline placebo capsule|1 capsule every 12 hours by mouth
79807464|NCT00744250|Drug|Pancrelipase|PANCRECARB MS-16
79807465|NCT02651207|Other|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
79807466|NCT02564536|Drug|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
79807467|NCT02564536|Drug|Decitabine|-From commercial stock
79807468|NCT02651285|Other|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
79807469|NCT02651285|Other|Control|incubation of IVF embryos with a medium without G-CSF
79807470|NCT03887104|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
79807471|NCT00748462|Device|Fractional CO2 Laser|"the treatment settings:~Pulse duration : 5 to 7ms depending on skin reaction~Spot Density: 49 MTZ/cm2 (Low density)~Power: 15 W = (75 - 105) mJ/MTZ"
79807472|NCT00854828|Procedure|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
79316588|NCT04765787|Drug|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
79477713|NCT03105479|Drug|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
79477714|NCT03105479|Drug|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
79807473|NCT00854828|Other|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
79477715|NCT00355862|Drug|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
79477716|NCT00355862|Drug|Sirolimus|Sirolimus based immunosuppression
79807474|NCT02614820|Procedure|Remote Ischemic Preconditioning Training Apparatus|
79807475|NCT00847730|Device|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
79807476|NCT00600119|Drug|placebo|placebo, oral, once daily (QD)
79807477|NCT00600119|Drug|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
79807478|NCT02651051|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
79807479|NCT02651051|Other|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
79807480|NCT04032821|Drug|Alkotinib（300mg)|1. First empty stomach, after the meal.2. After eating first, after fasting.
79807481|NCT02650973|Drug|CHS-1701|
79807482|NCT02650973|Drug|Pegfilgrastim|
79807483|NCT02660567|Procedure|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
79807484|NCT00866294|Drug|paroxetine IR 10mg tablet|1 or 2 tablets once a day
79807485|NCT00866294|Drug|paroxetine IR 20mg tablet|1 tablet once a day
79316589|NCT05115539|Other|doppler US of portal vein, hepatic veins, intrarenal veins|"Hepatic Vein Doppler : To obtain the HV PW, a phased array transducer is used with cardiac pre-sets. ECG leads are placed to assist in the interpretation of HVD in sinus rhythm as well as atrial fibrillation. The middle hepatic vein is identified from mid-subcostal or lateral views during the end-expiratory phase of the patients respiratory cycle.~Portal vein Doppler: From a lateral costal or subcostal window, the portal vein is identified in the coronal plane using a phased-array transducer. The PV were considered abnormal if the pulsatilty index was greater than 30%. The portal pulsatility index was defined as: (VMax - VMin/VMax) * 100%. Here, VMax is the maximal velocity and VMin is the minimal velocity during the cardiac cycle.~Intra-renal venous Doppler: From lateral costal window, the kidney is located in the coronal plane and a color flow box placed over the distal renal calyceal junction to cortex."
79477717|NCT03106337|Device|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
79316590|NCT04672967|Diagnostic Test|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
79477718|NCT03772847|Drug|ginkgolide|ginkgolide plus alteplase
79477719|NCT05345834|Behavioral|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
79316591|NCT04663217|Other|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
79316592|NCT02749331|Drug|AdVince|Virus solution for infusion in intrahepatic artery
79807486|NCT00866294|Drug|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
79807487|NCT00866294|Drug|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
79316593|NCT05115149|Device|VIBRAINT RehUp robotic orthosis|VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
79477720|NCT05345834|Behavioral|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
79807488|NCT00866294|Drug|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
79807489|NCT00866294|Drug|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
79807490|NCT02660333|Dietary Supplement|Placebo|Maltodextrin - 11g/day
79807491|NCT02660333|Dietary Supplement|Prebiotic|Fructooligosaccharide - 11g/day
79807492|NCT02660333|Dietary Supplement|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
79807493|NCT00649103|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
79316594|NCT05115149|Procedure|tSCS during the exercise|"During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
79316595|NCT05115149|Procedure|tSCS prior to the exercise|"Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
79316596|NCT05115149|Device|Neostim-5|Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
79972568|NCT05217836|Diagnostic Test|ferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin|All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.
79316597|NCT05115149|Procedure|Exercise|The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
79316598|NCT05112341|Radiation|radiation therapy|the patient first is simulated then delineation is done
79316599|NCT04638803|Drug|PRX-P4-003, (-)-FCF|sequential study
79316600|NCT05114681|Other|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
79316601|NCT04592783|Drug|Antihypertensive Agents|Antihypertensive medications will be initialed once BP is at predetermined threshold
79316602|NCT05114525|Behavioral|Survey questionnaire|The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
79316603|NCT05112107|Behavioral|Culinary workshops|Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
79316604|NCT04521881|Drug|Tranexamic Acid 500 MG|given once as an intramuscular injection
79316605|NCT04570787|Procedure|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
79316606|NCT05114369|Procedure|Curative surgery|
79477721|NCT02049151|Drug|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
79807494|NCT00649103|Drug|Accupril® Tablets 40 mg|40mg, single dose fasting
79807495|NCT04131530|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
79807496|NCT02660177|Drug|Metamizole|metamizole IV administration
79807497|NCT00701246|Drug|ferrous sulfate|
79807498|NCT00701246|Drug|folic acid|
79972569|NCT02514616|Procedure|Laparoscopic IPG and lead implant procedure|EST placement
79972570|NCT02514616|Device|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
79972571|NCT02514616|Device|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
79316607|NCT04316585|Drug|GSK2982772|GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
79316608|NCT04316585|Drug|Placebo|GSK2982772 matching placebo tablets will be administered via the oral route.
79316609|NCT04305899|Drug|BMS-986165 Tablet formulation 1|Specified dose on specified days
79807499|NCT00701246|Drug|placebo (folic acid)|
79807500|NCT02648711|Drug|CRLX101|infusion CRLX101 weekly
79807501|NCT02648711|Drug|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
79316610|NCT04305899|Drug|BMS-986165 Tablet formulation 2|Specified dose on specified days
79316611|NCT01675661|Drug|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
79316612|NCT01675661|Drug|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
79972572|NCT03842735|Other|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
79477722|NCT02049151|Drug|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
79316613|NCT05113823|Procedure|Simulation Training|Simulation Training using High and Low Fidelity Simulator
79643148|NCT05808543|Other|Both EARS training package (BEARS)|The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.
79643149|NCT05808543|Other|Usual Care|This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
79643150|NCT05808517|Behavioral|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
79643151|NCT05808517|Other|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
79643152|NCT05808504|Other|Neuropsychological assessment|interview with a neuropsychologist and carrying out tests measuring overall cognitive abilities, depression, apathy and anxiety (respectively using the MOCA, MADRS, LARS, STAI scales)
79643153|NCT05808504|Other|Neurological assessment|Only for patients with Parkinson disease. Evaluation consisting in a disease severity assessment using the Hoehn and Yahr and Schwab and England scales, as a well as a measure of levodopa equivalent daily dose.
79643154|NCT05808504|Other|Cognitive task|"The task consists in pressing a left or right button as fast and as accurately as possible according to the direction of an arrow displayed at the center of a screen. On 25 % of the trials, a stop signal will occur right after the stimulus, indicating the participant to stop his impending button press. The delay between the presentation of the arrow stimulus and the stop signal will be adjusted to ensure a final 50% accuracy (decreased following an accurate response and increased after an error), which is necessary to comply with the assumptions for a robust calculation of the stop signal reaction time (SSRT)."
79643155|NCT05808504|Procedure|EEG|A high-resolution (256 channels) electroencephalographic recording will be done at rest and during the Stop task, before and after each real or sham stimulation.
79807502|NCT02648711|Drug|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
79807503|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
79807504|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 1)
79807505|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 15)
79972573|NCT03842735|Behavioral|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
79972574|NCT03833843|Diagnostic Test|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
79316614|NCT04003493|Other|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
79477723|NCT02049151|Drug|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
79477724|NCT02049151|Drug|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent [%] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
79477725|NCT03844295|Device|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
79643156|NCT05808504|Procedure|tACS (real or sham)|Real or sham tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz according to standard EEG position, and defined based on dosimetry analyses on averaged head models) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset.
79477726|NCT03844295|Device|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
79807506|NCT02648399|Procedure|surgery：BCND（bilateral central lymph node dissection）|
79477727|NCT00355550|Drug|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
79807507|NCT02648399|Procedure|surgery：UCND（unilateral central lymph node dissection）|
79807508|NCT02648555|Behavioral|Daily walking|Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
79477728|NCT00355550|Other|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
79807509|NCT02648555|Behavioral|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
79643157|NCT05808491|Radiation|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
79643158|NCT05808478|Behavioral|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
79972575|NCT05220644|Procedure|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
79972576|NCT02510482|Other|No intervention|
79643159|NCT05808478|Behavioral|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
79643160|NCT05808387|Dietary Supplement|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
79643161|NCT05808387|Dietary Supplement|Placebo|Starch, 1000 mg daily for 90 days
79643162|NCT05808348|Other|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
79807510|NCT00854360|Drug|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
79807511|NCT00854360|Drug|Placebo|HFA Vehicle Aerosol
79807512|NCT02650661|Behavioral|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
79972577|NCT02505178|Other|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
79972578|NCT05217524|Device|Galaxy BIA watch|Digital multifunction watch
79972579|NCT02510248|Drug|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
79972580|NCT02510248|Drug|Placebo|Placebo to match AL-704
79972581|NCT03833453|Behavioral|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
79972582|NCT03833453|Behavioral|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
79316615|NCT03956849|Other|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
79316616|NCT05113511|Drug|SCT510|Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
79316617|NCT05113511|Drug|Bevacizumab|Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
79316618|NCT04506515|Diagnostic Test|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
79316619|NCT05113433|Other|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
79316620|NCT05113433|Other|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
79316621|NCT05112887|Other|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
79316622|NCT01602341|Drug|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
79643163|NCT05808322|Drug|Ropeginterferon alfa-2b|A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
79972583|NCT03886064|Other|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
79972584|NCT02514538|Drug|Non- effervescent Paracetamol kern|1g
79972585|NCT02514538|Drug|Effervescent paracetamol termalgin|1 g
79807513|NCT02650661|Behavioral|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
79807514|NCT02650661|Behavioral|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
79807515|NCT02650661|Behavioral|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
79972586|NCT05219786|Behavioral|Appendicitis Decision Support Tool|Viewing of a decision support tool.
79972587|NCT05219786|Behavioral|Control Infographic|Viewing of a standardized infographic
79972588|NCT05281913|Other|Psychoeducational Game|Psychoeducational Game
79316623|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
79972589|NCT02510170|Other|no intervention|
79972590|NCT05202392|Other|Myofascial release with isometric exercises|Patients in group A will receive 40 minutes of combined therapy treatment session including myofascial release of muscles with trigger point release and 5 isometric exercises of neck at alternative 3 days/week for 4 weeks.
79316624|NCT01602341|Drug|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
79316625|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
79316626|NCT03539393|Drug|Fremanezumab|quarterly 675 mg dose (3 subcutaneous [SC] injections of 225 mg each).
79807516|NCT00650351|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
79807517|NCT00650351|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
79807518|NCT04117880|Drug|Ataluren|Oral
79807519|NCT02650739|Procedure|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
79972591|NCT05202392|Other|Myofascial release with scapular stabilization exercise|Patients in group B will get 40 minutes of myofascial therapy same as the first group combined with scapular stabilization exercise in 5 different positions and this treatment session will be at alternative 3 days/week for 4 weeks.
79972592|NCT04499794|Drug|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
79972593|NCT01566851|Other|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
79316627|NCT05111171|Device|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
79316628|NCT03330197|Biological|Ad-RTS-hIL-12|2.0 x 10^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
79316629|NCT03330197|Drug|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
79972594|NCT03840395|Device|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
79972595|NCT05707052|Other|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
79316630|NCT03330197|Drug|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
79316631|NCT03155399|Other|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
79477729|NCT03726359|Radiation|Fractionated Stereotactic Radiation Therapy|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
79477730|NCT02049307|Drug|Losartan 100mg daily|
79477731|NCT02049307|Drug|Matching placebo|
79643164|NCT05808322|Procedure|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
79807520|NCT02648633|Radiation|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
79972596|NCT05707052|Other|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
79972597|NCT02514460|Device|plaque excision system|
79972598|NCT02514460|Device|Stent|
79972599|NCT01567007|Behavioral|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
79972600|NCT01567007|Behavioral|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
79972601|NCT01567007|Behavioral|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
79972602|NCT05706896|Procedure|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
79477732|NCT05314556|Behavioral|Group psychotherapy|Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
79477733|NCT00355628|Drug|KW-2246 (fentanyl citrate)|KW-2246
79477734|NCT02049385|Drug|Diazoxide|A nondiuretic vasodilator thiazide-related agent
79477735|NCT02049385|Drug|Placebo|Placebo
79643165|NCT05808296|Other|Lavander oil Aromatherapy|Lavander oil Aromatherapy
79643166|NCT05808296|Other|Saline Solution|Saline solution application
79643167|NCT05808244|Behavioral|tgCBFI|Six weekly sessions CBT-based family intervention programme
79643168|NCT05808244|Behavioral|Usual psychiatric care|Integrated community psychiatric care with medical follow-up
79643169|NCT05808231|Drug|Standard of Care + Quinine Sulfate|Standard of Care + Quinine Sulfate
79643170|NCT05808231|Drug|Standard of Care|Standard of Care for COVID-19 mild and moderate symptom
79807521|NCT02648633|Drug|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
79807522|NCT02648633|Drug|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
79972603|NCT05281445|Behavioral|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
79972604|NCT05706818|Other|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
79643171|NCT05808205|Device|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~Temporal / frontal area~Orbital / Malar area~Perioral area~Lips."
79643172|NCT05808192|Drug|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
79643173|NCT05808166|Biological|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
79477736|NCT03717155|Drug|Avelumab|Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
79477737|NCT03717155|Drug|Cetuximab|Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m^2) body surface area on Day 1 and 500 mg/m^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
79477738|NCT03717155|Drug|Gemcitabine|Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
79477739|NCT03717155|Drug|Cisplatin|Participants received cisplatin intravenous infusions at a dose of 75 mg/m^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
79477740|NCT03717155|Drug|Carboplatin|In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
79643174|NCT05808166|Other|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
79643175|NCT05808114|Behavioral|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
79643176|NCT05808114|Behavioral|TAU|Individually tailored and delivered specialized child psychiatric care
79643177|NCT05808101|Other|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
79643178|NCT05808088|Other|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
79643179|NCT05808075|Other|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
79643180|NCT05808049|Other|MXP22 (Probiotic and antioxidant capsule)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
79643181|NCT05808049|Other|Placebo (Microcrystalline Cellulose)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
79807523|NCT00853970|Drug|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
79807524|NCT00853970|Drug|Placebo Comparator|sterile ophthalmic solution
79807525|NCT04131296|Diagnostic Test|influenza screening|positive influenza screening
79972605|NCT03343912|Drug|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
79972606|NCT03343912|Drug|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
79972607|NCT03343912|Drug|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
79807526|NCT04116008|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
79643182|NCT05808036|Other|Dietary intervention: DOMINO app|Life style intervention and diet low in FODMAPs.
79316632|NCT03155399|Other|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
79643183|NCT05808036|Other|Dietary intervention: low FODMAP diet|Strict low FODMAP diet.
79643184|NCT05808023|Other|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
79643185|NCT05807984|Radiation|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
79316633|NCT05065307|Diagnostic Test|Venipuncture|Diagnostic venipuncture
79316634|NCT01013129|Genetic|DNA analysis|saliva samples will be collected from men (probands) who join the study.
79316635|NCT01013129|Genetic|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
79643186|NCT05807958|Device|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
79643187|NCT05807945|Drug|Ropivacaine 7.5% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 7.5%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
79316636|NCT01013129|Other|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
79643188|NCT05807945|Drug|Ropivacaine 2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
79807527|NCT02652377|Drug|EDP-494|10, 100 and 200 mg capsules
79807528|NCT02652377|Drug|Placebo|placebo to match EDP-494
79807529|NCT02644733|Procedure|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
79807530|NCT02644733|Procedure|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
79807531|NCT02648321|Behavioral|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
79316637|NCT01013129|Other|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
79316638|NCT01013129|Other|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
79316639|NCT01013129|Procedure|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
79316640|NCT01013129|Procedure|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
79316641|NCT05103761|Other|Study diet|A low carbohydrate diet (<20g/day) is administered to achieve diet-induced ketosis.
79316642|NCT05103761|Other|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
79316643|NCT02700919|Drug|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
79316644|NCT02700919|Drug|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
79316645|NCT05103137|Other|Questionnaire|Questionnaires concerning assesment of quality of life with 3 different questionnaires ( SF36, HAQ and pre-established questionnaire for the study) during a phone interview
79316646|NCT05088473|Other|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
79643189|NCT05807893|Drug|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
79643190|NCT05807880|Drug|The combination treatment of anlotinib, penpulimab and capecitabine.|Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
79807532|NCT02648321|Behavioral|Health Education|General education about healthy lifestyle and diet.
79807533|NCT00651287|Drug|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
79807534|NCT00651287|Drug|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
79807535|NCT00651287|Drug|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
79972608|NCT03833219|Behavioral|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
79972609|NCT03833219|Behavioral|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
79972610|NCT03833219|Behavioral|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
79972611|NCT02509858|Drug|thyroxine|treatment with 50μg of thyroxine once daily for two months.
79972612|NCT02509858|Drug|Placebo|treatment with 50μg of placebo, once daily, for two months.
79643191|NCT05807828|Procedure|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup and stem implantation before actual implantation.
79972613|NCT02509858|Other|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
79972614|NCT05706662|Procedure|inguinal hernia repair with mesh|inguinal hernia repair with mesh
79972615|NCT01201187|Drug|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
79972616|NCT01201187|Drug|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
79316647|NCT05119127|Device|Alcon Vivity toric intra ocular lens|implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
79316648|NCT04161989|Drug|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% & Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
79316649|NCT04161989|Drug|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
79316650|NCT01986010|Biological|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
79316651|NCT01986010|Biological|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
79316652|NCT01986010|Biological|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
79316653|NCT01986010|Biological|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
79643192|NCT05807815|Procedure|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation <95 or PaO2<60 mmHg"
79643193|NCT05807776|Drug|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
79643194|NCT05807776|Drug|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
79807536|NCT02648243|Behavioral|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
79807537|NCT00910793|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
79807538|NCT02648087|Device|With and without SDB|Screening of sleep-disordered breathing (SDB)
79807539|NCT02647931|Behavioral|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
79316654|NCT01986010|Biological|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
79316655|NCT01986010|Biological|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
79807540|NCT02647853|Drug|TAT4 Gel concentration A|
79807541|NCT02647853|Drug|TAT4 Gel concentration B|
79807542|NCT02647853|Drug|Placebo|
79807543|NCT02650505|Drug|LEO 43204|
79807544|NCT02650505|Drug|LEO 43204 Vehicle|
79807545|NCT02650427|Drug|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
79316656|NCT01986010|Other|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
79807546|NCT02650583|Other|Educational Intervention|Receive Enhancing Connections Program
79807547|NCT02650583|Other|Questionnaire Administration|Ancillary studies
79477741|NCT05311046|Diagnostic Test|Pediatric sepsis screening tool (either algorithmic or manual)|All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
79807548|NCT02650349|Other|fMRI|
79807549|NCT00652613|Radiation|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
79807550|NCT00652613|Radiation|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
79807551|NCT02650037|Procedure|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
79807552|NCT00651365|Drug|JNJ-38877605|
79807553|NCT04166747|Other|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
79807554|NCT02647775|Procedure|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
79807555|NCT02647775|Procedure|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
79807556|NCT02644811|Drug|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
79972617|NCT05706584|Other|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
79972618|NCT03842579|Other|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
79316657|NCT01986010|Biological|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
79972619|NCT03842579|Other|High-protein diet|Daily supplementation with milk-based protein-rich products
79972620|NCT03842579|Other|Recommendations|Provided with the official national recommendations on nutrition
79972621|NCT05217290|Behavioral|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
79316658|NCT01986010|Other|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
79316659|NCT04160117|Drug|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
79316660|NCT04160117|Drug|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
79316661|NCT04414631|Drug|Conestat alfa|Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
79316662|NCT03115255|Drug|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
79316663|NCT02403583|Behavioral|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
79316664|NCT05042063|Device|Hyfe Cough Tracker|"Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough."
79316665|NCT05042063|Device|Hyfe Air|Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
79316666|NCT03168061|Drug|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
79477742|NCT02049931|Device|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
79807557|NCT02644811|Drug|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
79972622|NCT02505256|Other|No intervention|
79972623|NCT02510092|Device|Percutaneous coronary intervention with new generation fully resorbable scaffold|
79972624|NCT02505100|Other|Touching relaxant|
79972625|NCT02505100|Other|Hypnoses|
79972626|NCT02513992|Procedure|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
79972627|NCT02513992|Drug|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
79972628|NCT02513992|Device|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
79972629|NCT02513992|Device|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
79972630|NCT03832673|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
79972631|NCT03832673|Drug|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
79972632|NCT04499716|Procedure|IPACK|25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.
79807558|NCT02644811|Procedure|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
79807559|NCT02644811|Drug|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
79807560|NCT02644811|Drug|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
79316667|NCT01963780|Device|OCS Lung Preservation|
79643195|NCT05807763|Procedure|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
79807561|NCT02644811|Device|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
79972633|NCT04499716|Procedure|Femoral triangle block|25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.
79972634|NCT04499716|Procedure|Obturator nerve block|20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
79972635|NCT04499716|Procedure|Femoral nerve block|20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
79316668|NCT02009878|Drug|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
79316669|NCT04439968|Other|Clinical algorithm|In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
79316670|NCT02009722|Drug|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
79477743|NCT02049931|Device|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
79316671|NCT02009722|Drug|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
79477744|NCT02049931|Device|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
79477745|NCT03655613|Biological|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
79643196|NCT05807737|Device|Ultrasound scanning with artificial intelligence|Three residents who are eligible to perform ultrasound-guided regional anesthesia will scan volunteers in random order with artificial intelligence software (Nerveblox) fed by an FDA-cleared ultrasound device.
79643197|NCT05807685|Behavioral|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
79643198|NCT05807659|Drug|fractionated busulfan-based conditioning regimen|"Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation"
79643199|NCT05807633|Device|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
79972636|NCT04499716|Procedure|Sciatic nerve block|25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
79972637|NCT04499716|Procedure|Lateral femoral cutaneous nerve block|5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
79316672|NCT04416880|Device|Press Tack Needle Acupuncture|Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
79316673|NCT02655419|Drug|ATM-AVI|"Cohort 1:~(Creatinine clearance > 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance > 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
79477746|NCT03655613|Drug|APL-101|Oral specific c-Met inhibitor
79477747|NCT03655613|Biological|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
79477748|NCT00422747|Drug|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
79477749|NCT03766009|Other|Usual Care|Usual Care
79477750|NCT03766009|Other|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
79807562|NCT02644811|Device|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
79807563|NCT02647463|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|
79807564|NCT00651443|Drug|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
79807565|NCT02649881|Procedure|The heart subject will undergo OCT|
79807566|NCT00650897|Drug|Escitalopram|10-20 mg once daily
79807567|NCT02644655|Biological|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
79477751|NCT00355940|Device|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
79477752|NCT00355940|Device|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
79477753|NCT00356018|Behavioral|Compliance|
79316674|NCT02655419|Drug|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
79316675|NCT01962922|Drug|LCP-Tacro|once-daily extended release tablet
79316676|NCT01962922|Drug|Tacrolimus -IR|twice daily capsules
79643200|NCT05807607|Procedure|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
79643201|NCT05807607|Procedure|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation|SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
79643202|NCT05807607|Procedure|Change according to the scale of the PainDetect questionnaire|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
79972638|NCT03832283|Diagnostic Test|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
79316677|NCT04198961|Other|opioid prescribing|Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
79316678|NCT05118971|Diagnostic Test|muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles|understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
79316679|NCT04436315|Device|Motor-cognitive training device|Motor-cognitive training device
79316680|NCT04436315|Other|Active control condition|Physical activity program
79316681|NCT01984684|Drug|delafloxacin|
79316682|NCT01984684|Drug|vancomycin|
79316683|NCT01984684|Drug|aztreonam|
79316684|NCT05118659|Procedure|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
79316685|NCT05118659|Procedure|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
79316686|NCT04999553|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
79316687|NCT04999553|Device|Intermittent Theta Burst Stimulation (iTBS)|Intermittent Theta Burst Stimulation (iTBS)
79316688|NCT04999553|Device|Low Frequency Right (LFR)|Low Frequency Right (LFR)
79316689|NCT04657588|Device|myMiracle anal insert|The myMiracle device is a single-use, pre-lubricated, liquid-filled rectal insert with a plastic applicator. The insert is filled with liquid mineral oil. The primary advantage of this new instrument is the fact that the liquid-filled insert will move and adapt as the fluid is transferred throughout the device making it easy to insert/remove and comfortable to wear. The design is intended to adjust to the contours of the individual anatomy to prevent leakage.
79316690|NCT04657588|Other|Care as usual|Care as usual means participants are to continue their usual treatment for FI, like they would if they would not have participated in this study.
79316691|NCT05118347|Other|Buteyko Breathing Technique|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
79477754|NCT03286829|Drug|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
79477755|NCT03286829|Drug|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
79477756|NCT03286829|Drug|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
79807568|NCT02644499|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
79807569|NCT02644499|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
79807570|NCT02644499|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
79807571|NCT02644499|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
79807572|NCT02644499|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
79807573|NCT00652691|Biological|filgrastim|
79972639|NCT03832283|Diagnostic Test|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
79477757|NCT03286829|Drug|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
79972640|NCT03832283|Other|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (<50) will indicate that a patient's MDD is in remission.
79477758|NCT00421616|Behavioral|High protein diet study|
79477759|NCT02051335|Drug|Roflumilast|Roflumilast tablets
79477760|NCT02051335|Drug|Roflumilast placebo|Roflumilast placebo-matching tablets
79477761|NCT02051335|Drug|Donepezil|Donepezil overencapsulated tablets
79477762|NCT02051335|Drug|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
79477763|NCT02051335|Drug|Scopolamine|Scopolamine subcutaneous injection
79972641|NCT03832283|Other|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score < 5 will indicate that a patient's MDD is in remission.
79316692|NCT05109845|Diagnostic Test|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
79643203|NCT05807581|Other|physical activity|treadmill running 3 times weekly
79316693|NCT02694523|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
79972642|NCT04499638|Device|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
79316694|NCT02694523|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
79477764|NCT03289481|Dietary Supplement|Active lozenge|nitric oxide generating lozenge
79972643|NCT03548935|Drug|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
79316695|NCT02694523|Drug|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
79316696|NCT02694523|Biological|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
79807574|NCT00652691|Drug|carboplatin|
79972644|NCT03548935|Drug|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
79807575|NCT00652691|Drug|cyclophosphamide|
79972645|NCT04499014|Device|ultrasound|5 days a week, a total of 10 sessions
79316697|NCT04959617|Device|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
79477765|NCT03289481|Drug|Placebo|placebo tablet
79477766|NCT03290027|Drug|DFD-03|DFD-03 Lotion
79477767|NCT03290027|Other|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
79477768|NCT02979158|Procedure|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
79477769|NCT02979158|Procedure|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
79477770|NCT02979236|Device|STENTYS Xposition S|
79477771|NCT02300077|Drug|methadone|Escalating dose of methadone up to .3mg/kg.
79643204|NCT05807581|Other|iTBS|repetitive TMS stimulation 5 days weekly for two weeks
79643205|NCT05807542|Drug|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
79643206|NCT05807542|Drug|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
79643207|NCT05807542|Drug|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
79643208|NCT05807503|Drug|Cerebrolysin|Cerebrolysin administration in short period of time after TBI
79807576|NCT00652691|Drug|topotecan hydrochloride|
79477772|NCT02300077|Drug|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
79643209|NCT05807438|Other|Self myofascial Release|Myofascial release participants on their own will roll the foam roller in each area for two minutes.
79643210|NCT05807438|Other|myofascial release|Myofascial release will be applied to the participants by the physiotherapist.
79807577|NCT00652691|Procedure|autologous hematopoietic stem cell transplantation|
79807578|NCT00652691|Procedure|peripheral blood stem cell transplantation|
79807579|NCT02649725|Behavioral|patient's satisfaction|Questionnaire based measurement.
79807580|NCT02649803|Behavioral|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
79807581|NCT02647541|Dietary Supplement|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
79807582|NCT04166825|Diagnostic Test|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
79972646|NCT03832205|Device|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
79972647|NCT02513758|Other|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
79972648|NCT01485497|Device|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
79643211|NCT05807425|Procedure|Polidocanol foam sclerotherapy|The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
79643212|NCT05807373|Procedure|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
79643213|NCT05807347|Drug|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC >20×109/L
79316698|NCT05038475|Diagnostic Test|COVID-19 antibody test|FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
79316699|NCT02395861|Other|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
79316700|NCT04848935|Device|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
79316701|NCT04827095|Other|Web-Based Support and Education Program 1|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
79316702|NCT04827095|Other|Web-Based Support and Education Program 2|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
79643214|NCT05807334|Other|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
79643215|NCT05807334|Other|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
79316703|NCT01353703|Biological|Infanrix hexa™|Intramuscular, three doses
79643216|NCT05807308|Behavioral|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
79643217|NCT05807295|Other|Relaxation Program|The relaxation program will include progressive muscle relaxation exercises and videos for relaxation. Videos will be sent to caregivers' social media accounts. Initial applications will be implemented with caregivers. The relaxation program is planned to last 6 weeks. The program is planned to last 8 weeks in total, with pre-test and post-test applications.
79643218|NCT05807256|Other|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
79643219|NCT05807243|Other|Dietary intervention for healthy weight loss|Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
79972649|NCT02504944|Drug|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
79972650|NCT01201499|Drug|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or ~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
79972651|NCT01201499|Drug|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
79972652|NCT02504632|Other|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
79972653|NCT02504632|Other|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
79972654|NCT03473639|Drug|Entinostat|In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
79643220|NCT05807230|Behavioral|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
79316704|NCT04096703|Procedure|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is > 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
79643221|NCT05807191|Other|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
79643222|NCT05807165|Radiation|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
79807583|NCT00652769|Procedure|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
79972655|NCT03473639|Drug|Capecitabine|In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
79972656|NCT02504710|Device|Kinematic Real Time Feedback|
79807584|NCT00652769|Procedure|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
79807585|NCT02536157|Device|Thermoplastic splinting|
79807586|NCT02647697|Drug|Radiprodil oral|"Active Substance: Radiprodil~Pharmaceutical Form: dry granules for oral suspension~Concentration: 30 mg~Route of Administration: oral use"
79807587|NCT02647307|Drug|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
79807588|NCT03785327|Device|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
79807589|NCT03785327|Behavioral|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism & Developmental Disorders Lab at Simon Fraser University
79807590|NCT02649569|Device|Monitoring Device|Wear activity monitor
79807591|NCT02649569|Other|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
79807592|NCT02649491|Other|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
79807593|NCT00650975|Device|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
79807594|NCT00650975|Device|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
79807595|NCT02649179|Drug|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
79807596|NCT02649179|Drug|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
79807597|NCT02644577|Drug|Metformin|
79807598|NCT02644577|Other|Starch|
79807599|NCT02644421|Drug|VVZ-149|
79807600|NCT02644421|Drug|Lidocaine|
79807601|NCT02644421|Drug|Placebo|
79807602|NCT02649257|Procedure|cataract surgery|
79807603|NCT02649257|Device|intraocular lens (MC 6125 AS)|
79807604|NCT02649257|Device|capsular tension ring (CTR 13/11)|
79972657|NCT02504710|Other|Traditional systems of manual therapy teaching|
79972658|NCT03547687|Device|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
79972659|NCT03547687|Device|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
79972660|NCT03840317|Biological|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
79972661|NCT02509780|Other|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
79972662|NCT03121690|Drug|Prednisone|prednisone 40 mg/day for 7 days
79972663|NCT03121690|Drug|placebo|5ml saline / day for 7 days
79972664|NCT01483703|Device|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
79972665|NCT03730831|Behavioral|Narrative Exposure Therapy|8-10 sessions: 1 lifeline session, 6-10 sessions narrative exposure, 1-2 sessions of future-oriented counselling
79316705|NCT02009332|Drug|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
79316706|NCT02009332|Drug|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
79316707|NCT04480021|Behavioral|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
79807605|NCT04167449|Dietary Supplement|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
79316708|NCT04480021|Behavioral|EUC|Group education on depression by community health workers
79316709|NCT04480177|Device|foot insole|the subject was instructed to wear foot insole for 8 hours.
79807606|NCT04167449|Dietary Supplement|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
79807607|NCT04167449|Dietary Supplement|Placebo|Visually identical placebo capsule containing rice flour
79316710|NCT04480177|Other|short foot exercise|the subject was instructed to perform exercise once a day 30 repetitions.
79316711|NCT03166969|Procedure|Holter 21 days|
79316712|NCT01984294|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
79316713|NCT01984294|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79643223|NCT05807165|Radiation|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed [Week 1 -3]~5-mg twice a day in the following week [Week 4]~A morning dose of 10 mg and an evening dose of 5 mg in the following week [Week 5]~10-mg twice a day for the subsequent weeks up to Week 24 [Week 6 - 24]"
79807608|NCT02647229|Other|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
79316714|NCT01984294|Drug|GS-9669|GS-9669 tablet(s) administered orally once daily
79316715|NCT04932707|Other|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient head applying pressure up and backward, pressure was maintained till tissue relaxation was occurred flexes the head of the patient to get the chin to the manibiurim sternii, plus the passive stretch exercise
79316716|NCT04932707|Other|Neural slump sliding stretch|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot plus the passive stretch exercise
79316717|NCT04932707|Other|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
79807609|NCT02647229|Other|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
79807610|NCT00651599|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
79972666|NCT03840551|Other|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
79972667|NCT03724591|Procedure|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
79972668|NCT03724591|Procedure|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
79972669|NCT03831269|Drug|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
79972670|NCT03831269|Other|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
79807611|NCT00651599|Drug|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
79807612|NCT02647151|Drug|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
79972671|NCT02513836|Other|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
79643224|NCT05807152|Device|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
79477773|NCT04745546|Device|WeFlow-JAAA Stent Graft System|The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
79972672|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
79477774|NCT03291041|Drug|Tasimelteon|capsule
79972673|NCT02513680|Device|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
79477775|NCT03291041|Drug|Placebo|capsule
79477776|NCT02052661|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
79643225|NCT05807113|Other|Atopi intensive care BNO 3731|Crem twice daily
79643226|NCT05807113|Other|Benchmark product|Crem twice daily
79643227|NCT05807100|Diagnostic Test|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
79643228|NCT05807100|Diagnostic Test|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
79316718|NCT03170479|Dietary Supplement|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
79477777|NCT03291197|Drug|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
79316719|NCT03170479|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
79316720|NCT03953027|Other|Survey Administration|Ancillary studies
79316721|NCT05745493|Behavioral|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
79477778|NCT03411707|Diagnostic Test|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
79316722|NCT01962298|Drug|sugammadex 2mg/kg|
79316723|NCT01962298|Drug|neostigmine|
79316724|NCT01962298|Drug|sugammadex 4mg/kg|
79316725|NCT01962298|Drug|placebo|
79316726|NCT01962298|Drug|Single rocuronium dose|
79477779|NCT00356096|Drug|pramipexole|
79477780|NCT00375635|Procedure|mFPSA treatment|
79477781|NCT03275675|Drug|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
79477782|NCT03294629|Device|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
79477783|NCT04737044|Other|Study 1: MRBS|MRBS as added sugar based on their habitual diet
79477784|NCT04737044|Other|Study 2: White sugar & education module|White sugar for daily usage (<10% daily energy intake)
79316727|NCT01962298|Drug|Repeated rocuronium dose|
79316728|NCT01962298|Drug|Continuous rocuronium infusion|
79316729|NCT04418921|Behavioral|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
79316730|NCT04418921|Behavioral|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
79316731|NCT03169933|Radiation|Combined, intensified and modulated adjuvant radiotherapy|
79316732|NCT03169621|Procedure|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
79477785|NCT04737044|Other|Study 2: MRBS & education module|MRBS for daily usage (<10% daily energy intake)
79477786|NCT05230394|Diagnostic Test|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
79477787|NCT05230394|Diagnostic Test|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
79477788|NCT03243461|Drug|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
79477789|NCT03296345|Drug|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
79972674|NCT02513680|Device|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
79316733|NCT02403349|Drug|Fimasartan|
79316734|NCT02403349|Drug|Valsartan|
79316735|NCT02403349|Drug|Atenolol|
79316736|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence ABFCED|Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
79316737|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence BCADFE|Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
79643229|NCT05807087|Procedure|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
79643230|NCT05807087|Procedure|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
79643231|NCT05807035|Biological|Radvax|Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
79643232|NCT05806502|Diagnostic Test|Nω-hydroxy-nor-arginine|Arginase inhibitor
79316738|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence CDBEAF|Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
79316739|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence DECFBA|Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
79316740|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence EFDACB|Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
79316741|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence FAEBDC|Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
79316742|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence GHI|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
79316743|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence HIG|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
79316744|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence IGH|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
79316745|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence IHG|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
79972675|NCT03547531|Other|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
79316746|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence GIH|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
79316747|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence HGI|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
79316748|NCT02395393|Device|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
79316749|NCT02693743|Device|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
79316750|NCT02655887|Device|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
79643233|NCT05806281|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
79643234|NCT05799677|Other|Reflexology|Additive reflexology treatment
79972676|NCT03547531|Other|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
79316751|NCT02008318|Drug|Galunisertib|Administered orally
79316752|NCT02008318|Drug|Placebo|Administered orally
79316753|NCT04009265|Combination Product|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
79316754|NCT01982812|Drug|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
79316755|NCT01982812|Drug|Standard AED|Active comparitor, Standard AED
79316756|NCT03996785|Behavioral|Walking in Urban setting|Walking for 60 minutes as described above
79316757|NCT03996785|Behavioral|Walking in nature setting|Walking for 60 minutes as described above
79316758|NCT04541693|Device|Full revision|Both cup and stem require revision
79316759|NCT04541693|Device|Cup revision|Only the cup requires revision
79316760|NCT04541693|Device|Stem revision|Only the stem requires revision
79477790|NCT00421694|Drug|Bicalutamide|
79477791|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
79972677|NCT02513602|Procedure|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
79316761|NCT04910087|Diagnostic Test|Sonographic optic nerve sheath diameter measurement|With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
79316762|NCT02007070|Biological|Pembrolizumab|Intravenous infusion
79972678|NCT01333553|Device|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
79316763|NCT03906617|Drug|Intercostal nerve block and wound infiltration with liposomal bupivacaine|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
79972679|NCT02504476|Drug|AMG 581|Active drug
79316764|NCT03906617|Drug|Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
79643235|NCT05797675|Procedure|prf + osseodensification|prf+ osseodensification in close sinus lift
79643236|NCT05792098|Procedure|percutaneous dilatational tracheostomy (PDTS)|Tracheostomy made by percutaneous dilatational technique
79643237|NCT05792098|Diagnostic Test|Ultrasound examination|Ultrasound verification of guidewire position
79643238|NCT05792098|Diagnostic Test|Bronchoscopy|Bronchoscopic control of guidewire position
79643239|NCT05781698|Drug|Mesalamine|mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
79972680|NCT02504476|Drug|Placebo|Placebo
79972681|NCT02504476|Drug|Midazolam|Interaction
79316765|NCT03897725|Other|Telehealth Coaching|Telehealth coaching to promote adherence
79643240|NCT05781698|Drug|Fenofibrate|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
79643241|NCT05720650|Other|No intervention|No intervention
79972682|NCT04313855|Diagnostic Test|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
79972683|NCT02504398|Other|Fast injection speed by immunizer|
79972684|NCT02504398|Other|Slow injection speed by immunizer|
79643242|NCT05718193|Diagnostic Test|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
79316766|NCT03844919|Device|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
79316767|NCT03844919|Behavioral|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
79316768|NCT02006758|Device|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
79477792|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
79643243|NCT05718193|Diagnostic Test|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
79643244|NCT05718193|Diagnostic Test|conventional colonoscopy|conventional colonoscopy
79643245|NCT05709509|Drug|Colchicine|Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. commonly used as anti-inflammatory drugs.
79972685|NCT03842501|Dietary Supplement|Release Supplement|Calorie reduced diet plus Release supplement
79972686|NCT03842501|Dietary Supplement|Placebo|Calorie reduced diet plus Placebo
79972687|NCT02509390|Procedure|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
79972688|NCT01205009|Drug|Ovitrelle|One dose of Ovitrelle 250 mcg
79972689|NCT02504242|Device|Inject BMP|
79972690|NCT02504242|Procedure|Locally Harvested Bone|
79972691|NCT01297205|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
79972692|NCT02513524|Procedure|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
79316769|NCT01960816|Device|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
79316770|NCT01602419|Other|Patients using Wilate as standard of care|Patients with von Willebrand Disease using Wilate for a period of 2 years.
79477793|NCT00376181|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
79477794|NCT05607134|Other|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
79972693|NCT03830489|Drug|polyethylene glycol|The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
79972694|NCT03830489|Drug|polyethylene glycol plus ascorbic acid|The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
79643246|NCT05709509|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention: a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart)
79643247|NCT05709509|Other|Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.|The subjects just received optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.
79972695|NCT02509468|Drug|Sirolimus|"each patient will be followed during a 12-month-period~each patient will start by an observational period and end being treated by sirolimus~at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
79972696|NCT03344614|Drug|raltitrexed combined with apatinib|raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
79972697|NCT01205087|Drug|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
79643248|NCT05706909|Device|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
79972698|NCT02513368|Device|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
79643249|NCT05705193|Other|NeuroFlex (computerized gamified tasks)|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant."
79643250|NCT05693844|Biological|CD40 ligand expressing MSLN-CAR T cells|Dose escalation: Dose1 (1×10^6 cells/kg) . Dose 2 (3×10^6 cells/kg) .Dose 3 (6×10^6 cells/kg) Dose expansion: RP2D
79477795|NCT05607134|Device|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
79643251|NCT05693844|Drug|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
79643252|NCT05693844|Drug|Cyclophosphamide|Administered intravenously at dose of 15-30mg/kg on day -3 and day -2
79643253|NCT05693844|Drug|Fludarabine|Administered intravenously at dose of 30mg/m2 on day -3 and day -2
79643254|NCT05674513|Drug|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
79972699|NCT02513368|Procedure|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
79807613|NCT02647151|Drug|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
79807614|NCT04167293|Radiation|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
79477796|NCT05607134|Device|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
79477797|NCT04736693|Drug|Raloxifene|Raloxifene dispensing claim is used as the reference group.
79643255|NCT05665296|Other|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
79807615|NCT04167293|Drug|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
79807616|NCT04166357|Diagnostic Test|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
79477798|NCT04736693|Drug|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
79477799|NCT04655378|Other|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
79477800|NCT04652414|Drug|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
79477801|NCT04652414|Drug|Placebo|This is a matching placebo to prednisone.
79477802|NCT04736069|Other|Physical therapy program|In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
79807617|NCT02536391|Drug|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
79807618|NCT02536391|Drug|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
79807619|NCT00651053|Device|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
79972700|NCT01205243|Drug|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
79972701|NCT02504164|Drug|midazolam 0.02mg/kg|
79477803|NCT04630964|Drug|Psilocybin|psilocybin 25 mg Single Oral Dose
79477804|NCT04630964|Drug|Niacin|niacin 100mg Single Oral Dose
79807620|NCT02644187|Device|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
79972702|NCT02504164|Drug|No premedication|No premedication before sedation for endoscopic submucosal dissection
79643256|NCT05665296|Other|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
79643257|NCT05665036|Combination Product|SIG-005 (hIDUA Producing Spheres)|Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
79643258|NCT05657964|Device|Gokhale sensor|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
79643259|NCT05646173|Device|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
79643260|NCT05646173|Device|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
79643261|NCT05646173|Other|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
79807621|NCT02644187|Device|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
79807622|NCT02644187|Drug|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
79316771|NCT04655482|Drug|Aflibercept Injection|"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
79316772|NCT04866173|Other|Dog|Subjection to standardised stress situations in the presence of a dog and a person
79316773|NCT04866173|Other|No Dog|Subjection to standardised stress situations in the presence of a person
79807623|NCT02536235|Other|heat|activated heating pad to lower abdomen
79807624|NCT04166279|Other|Single rehabilitative treatment|The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
79316774|NCT03571841|Behavioral|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
79316775|NCT03571841|Behavioral|Telephone Booster|One month following the group session, women will receive a telephone booster session (<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
79316776|NCT04866095|Device|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
79972703|NCT02509234|Drug|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
79316777|NCT04866095|Device|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
79316778|NCT02184767|Drug|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
79643262|NCT05644340|Procedure|Speed 8 (Fast balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
79316779|NCT01981954|Drug|Solifenacin succinate|Oral suspension
79316780|NCT04248413|Device|Blood Flow Restriction Therapy|The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.
79807625|NCT04166279|Other|Group rehabilitative treatment|Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
79643263|NCT05644340|Procedure|Speed 4 (Medium speed balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
79316781|NCT04248413|Other|Standard physical rehabilitation|Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
79316782|NCT03727139|Drug|Rasagiline|Rasagiline Tablets
79316783|NCT05122403|Procedure|MRgFUS central lateral thalamotomy|MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
79807626|NCT00651131|Drug|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
79972704|NCT02504086|Behavioral|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
79972705|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
79643264|NCT05631977|Other|Point of care ultrasound cardiac examination|The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
79807627|NCT04167137|Drug|SYNB1891|Up to four 21-day cycles of escalating doses of SYNB1891 intratumoral injection on Days 1, 8 and 15 of Cycle 1 and Day 1 of cycles 2-4.
79807628|NCT04167137|Drug|Atezolizumab|Administered in accordance with its recommended dose and schedule (1200 mg IV Q3W) on Day 1 of each of the 4 planned 21-day cycles.
79807629|NCT00651677|Procedure|HAL proctectomy|Hand-assisted laparoscopic proctectomy
79807630|NCT00651677|Procedure|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
79807631|NCT00651677|Procedure|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
79972706|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
79316784|NCT05120687|Drug|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
79316785|NCT05120609|Device|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
79316786|NCT05120609|Device|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
79316787|NCT03416855|Drug|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
79316788|NCT05121779|Drug|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
79316789|NCT05121779|Drug|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
79316790|NCT02693119|Drug|elamipretide (MTP-131) 1% topical ophthalmic solution|
79807632|NCT00651677|Procedure|SL Proctectomy|Straight laparoscopic proctectomy
79316791|NCT02693119|Drug|Vehicle topical ophthalmic solution|
79643265|NCT05627947|Drug|Mitomycin c|Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
79807633|NCT02644031|Procedure|mtwo rotary system|post-treatment pain after using mtwo rotary system
79807634|NCT02644031|Procedure|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
79807635|NCT02644031|Procedure|hand files|post-treatment pain after using hand files
79807636|NCT02646995|Dietary Supplement|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
79807637|NCT02646995|Dietary Supplement|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
79807638|NCT00651833|Drug|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
79807639|NCT04167215|Procedure|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
79972707|NCT02504008|Drug|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
79972708|NCT02504008|Drug|Placebo|Once weekly for 6 weeks
79972709|NCT01203293|Behavioral|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
79972710|NCT01203293|Behavioral|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
79972711|NCT01297361|Other|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
79316792|NCT04224311|Biological|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
79643266|NCT05617118|Drug|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
79643267|NCT05617118|Drug|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
79972712|NCT03566485|Drug|Atezolizumab|Given by IV
79972713|NCT03566485|Drug|Cobimetinib|Given by mouth
79316793|NCT05121389|Drug|normal saline|Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
79316794|NCT02395549|Drug|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
79643268|NCT05614167|Other|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
79643269|NCT05611281|Drug|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
79316795|NCT02395549|Drug|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
79316796|NCT02395549|Drug|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
79316797|NCT02395549|Drug|Vehicle Control Gel|
79643270|NCT05609422|Other|Physical therapy program|"Stretching exercises~Strength Training Kneeling exercises~Standing exercises~Gait Training"
79643271|NCT05609422|Other|scooter board activities|"Scooter board bear walk.~Scooter board crab walk.~Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~Cross sitting on scooter board, pulls along the rope using his/her hands~Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~Supine flexion on scooter board, Clip clothespins to a rope hanging above."
79643272|NCT05606341|Drug|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
79807640|NCT04167215|Procedure|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
79316798|NCT05121233|Drug|Diclofenac|a single dose 75 mg IV diclofenac by infusion prior to the procedure
79316799|NCT05121233|Drug|Placebo|single dose iv placebo (saline ) by infusion prior to the procedure
79316800|NCT02403427|Device|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
79316801|NCT05121155|Device|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak [TTP] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care[B4c]). Intracranial hypertension was defined as an invasively measured ICP > 20 mmHg for at least five minutes
79316802|NCT06121401|Drug|Olaparib|Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
79316803|NCT06121401|Drug|Bevacizumab|Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
79316804|NCT06121375|Drug|OCA|OCA will be administered.
79316805|NCT06121375|Drug|Matching Placebo|Matching Placebo will be administered.
79316806|NCT06121336|Diagnostic Test|Plasma levels of BD-tau|Plasma levels of BD-tau will be assessed using a single-molecule array assay.
79316807|NCT06121323|Other|Sodium lactate infusion|Dosage of sodium-lactate: 0.5 mol/L; 3 mL/kg/time; maximal 300 mL/hour.
79316808|NCT06121323|Other|Sodium lactate ingestion|Oral dose is equal to the i.v. dose.
79316809|NCT06121310|Other|Survey|Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
79316810|NCT06121284|Drug|D-Cycloserine|Participants will orally ingest a capsule containing a weight-based dose (25mg/17.5kg) of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
79643273|NCT05606341|Drug|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
79643274|NCT05606341|Drug|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
79643275|NCT05606341|Drug|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
79643276|NCT05597241|Drug|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
79643277|NCT05597241|Drug|Placebo|Placebo
79643278|NCT05596513|Other|motor learning and occupational therapy|"Constraint-induced movement therapy (CIMT)~Hand-arm bimanual intensive training (HABIT)"
79316811|NCT06121284|Device|intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
79316812|NCT06121284|Drug|Placebo oral tablet|Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
79316813|NCT06121245|Other|Proton Pump inhibitor|A proton pump inhibitor will be used as a tool to study the effect of pH changes in the stomach lumen on the release of somatostatin (evaluated by measurements of somatostatin and pro-somatostatin 1-64)
79643279|NCT05596513|Other|Motor Learning Approaches From Working on a Vertical Surface|"Ball on wall, kneel to stand~Kneel walk cross over~Vertical playground puzzles and games~Color on big boxes~Fridge magnets~Erasing a whiteboard or chalkboard~Tactile feedback from textured walls"
79316814|NCT06121245|Other|Placebo|Placebo capsule
79316815|NCT06121232|Device|Abbott® DRG / Abbott®/Medtronic® SCS|Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
79643280|NCT05588687|Behavioral|Virtual reality|Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
79643281|NCT05588687|Device|Tablet|Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
79316816|NCT06121232|Other|Control Group|Participants will not receive any intervention
79477805|NCT04736459|Procedure|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
79643282|NCT05570734|Behavioral|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
79643283|NCT05570734|Behavioral|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
79643284|NCT05570734|Behavioral|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
79643285|NCT05570734|Behavioral|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
79643286|NCT05546658|Drug|Psilocybin|Psilocybin administration under supportive conditions
79643287|NCT05542277|Device|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
79643288|NCT05541705|Behavioral|Treadmill Oscillation Walking|Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
79643289|NCT05523479|Behavioral|Traditional online education|A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
79972714|NCT03566485|Drug|Idasanutlin|Given by mouth
79972715|NCT02503930|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
79972716|NCT02503930|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
79477806|NCT05605886|Drug|Solvazinc 50mg|Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
79477807|NCT05605886|Drug|placebo|placebo
79316817|NCT06121180|Drug|ZIV-Aflibercept|Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.
79643290|NCT05523479|Behavioral|Interprofessional education|Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
79643291|NCT05523479|Behavioral|Clinical protocol|"An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices."
79643292|NCT05523479|Other|Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
79643293|NCT05523479|Other|Preventive post-extubation high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation HFNC for all eligible patients (without risk stratification)
79643294|NCT05510882|Other|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
79643295|NCT05494580|Drug|Pamiparib|Oral
79643296|NCT05494580|Drug|Surufatinib|Oral
79807641|NCT04167215|Procedure|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
79807642|NCT02649413|Drug|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
79807643|NCT04167059|Behavioral|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
79316818|NCT06121180|Drug|Cemiplimab|"Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells."
79316819|NCT06121141|Drug|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
79316820|NCT06121141|Drug|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
79972717|NCT05281367|Procedure|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
79643297|NCT05491252|Behavioral|PAtient CEntered Self-Management Intervention (PACE-SMI)|"Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time."
79316821|NCT06121128|Procedure|Inspiratory Muscle Training (IMT)|"The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week."
79643298|NCT05480618|Behavioral|Slow Breathing|"On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~frequency (between 0.25 and 0.1 Hz)~Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~with and without ujjayi (yogic throat restriction)~with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on."
79972718|NCT05281367|Procedure|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
79972719|NCT05281367|Procedure|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
79316822|NCT06121128|Procedure|Normal Breathing|No IMT performed
79316823|NCT06121115|Drug|Norepinephrine|Norepinephrine administered in midline catheter according to clinical routine
79316824|NCT06121076|Other|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
79316825|NCT06121050|Other|Pet visit|Intensive care patients visited by their pets for 20 minutes
79316826|NCT06121011|Biological|Cipaglucosidase alfa|Enzyme Replacement Therapy (ERT) via intravenous infusion
79316827|NCT06121011|Drug|Miglustat|Participants received ATB200 co-administered with AT2221 (Miglustat)
79316828|NCT06121011|Biological|Alglucosidase alfa or Avalglucosidase alfa|Patients prescribed other commercially available ERT after local regulatory approval
79807644|NCT02643953|Behavioral|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
79316829|NCT06121011|Other|Untreated|Patients who are not currently receiving any medical therapy for Pompe disease.
79316830|NCT06120959|Other|Stabilization exercise|The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
79477808|NCT03298841|Device|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
79477809|NCT05169242|Procedure|Endoclip|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
79477810|NCT04736381|Drug|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
79477811|NCT02906657|Other|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
79972720|NCT05281367|Procedure|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
79477812|NCT03302741|Drug|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
79477813|NCT03302741|Other|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
79477814|NCT03302741|Device|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
79643299|NCT05465291|Procedure|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
79807645|NCT02643953|Behavioral|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
79807646|NCT02643641|Biological|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
79807647|NCT02643641|Biological|Placebo|Placebo contains aluminum hydroxide only
79807648|NCT02643563|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
79807649|NCT02643563|Drug|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
79807650|NCT02643563|Drug|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
79972721|NCT02513290|Drug|Bilastine|
79972722|NCT02513290|Drug|Loratadine|
79490299|NCT03415243|Drug|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters [mcL]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel [MBq] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
79807651|NCT02643797|Behavioral|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
79807652|NCT02647073|Device|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
79807653|NCT00651209|Drug|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
79807654|NCT00652925|Drug|Celecoxib|Higher dose, 6 mg/kg/dose BID
79316831|NCT06120959|Other|Pelvic floor exercise|The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
79643300|NCT05465291|Procedure|Neuromuscular Electrical Muscle Stimulation group|"Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
79807655|NCT00652925|Drug|Celecoxib|Active drug at lower dose
79807656|NCT00652925|Drug|Naproxen|Control comparator, 15 mg/kg/dy target dose
79643301|NCT05465291|Procedure|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
79643302|NCT05464654|Drug|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
79643303|NCT05464654|Drug|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
79643304|NCT05459480|Other|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
79807657|NCT00653003|Drug|Leflunomide|tablets, 20mg, single-dose
79807658|NCT00653003|Drug|ARAVA|Tablets, 20mg, single-dose
79807659|NCT02646605|Other|depression screening|Patient Health Questionnaire
79807660|NCT02643719|Behavioral|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
79807661|NCT02643719|Drug|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
79972723|NCT01297439|Procedure|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
79972724|NCT01297439|Procedure|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
79972725|NCT03839927|Other|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
79972726|NCT02508844|Dietary Supplement|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
79972727|NCT02508844|Dietary Supplement|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
79316832|NCT06120933|Dietary Supplement|Hair Nutra Growth Supplement & Hair Nutra Boost Supplement|"Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
79972728|NCT05669651|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
79316833|NCT06120933|Dietary Supplement|Hair Nutra Growth|"From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
79972729|NCT02501200|Drug|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
79807662|NCT02643719|Drug|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
79807663|NCT02643719|Drug|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
79643305|NCT05456750|Device|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
79972730|NCT02501200|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
79972731|NCT01205477|Drug|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
79972732|NCT01205477|Drug|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
79316834|NCT06120920|Other|Assigned Interventions|Conventional physical therapy consists of hot pack application and transcutaneous electric stimulation (TENS) and routine knee strengthening exercises in addition with core stability exercises in three sessions per week for 4 weeks. Core stability exercises include bent knee hollow hold, bridging, supine toe tap and knee strengthening exercises include knee flexion strengthening exercises and knee extension isometric exercises.
79316835|NCT06120920|Other|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|Conventional physical therapy consists of hot pack application, Tens and routine knee exercise program same as group A and in addition with hip strengthening exercises. Hip strengthening exercises include hip flexion and extension strengthening exercises and hip internal rotation and external rotation and hip adduction and abduction strengthening exercises.C
79316836|NCT06120894|Diagnostic Test|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
79316837|NCT06120894|Diagnostic Test|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
79316838|NCT06120894|Diagnostic Test|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
79643306|NCT05443503|Other|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
79643307|NCT05434650|Device|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
79643308|NCT05410600|Other|Arm ergometer smart trainer cycling program|Arm ergometer exercise training using the smart trainer.
79643309|NCT05357573|Drug|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
79643310|NCT05356793|Drug|SCH-1|Novel anti-infective eyedrop
79972733|NCT02501278|Biological|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
79643311|NCT05356793|Drug|Placebo|SCH-1 vehicle minus active components eyedrop
79316839|NCT06120894|Diagnostic Test|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
79316840|NCT06120894|Diagnostic Test|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
79643312|NCT05332873|Device|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
79643313|NCT05332678|Drug|SLS-005 - Once Weekly|Please see Arm description.
79643314|NCT05332678|Drug|SLS-005 - Twice Weekly|Please see Arm description.
79643315|NCT05323968|Diagnostic Test|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
79316841|NCT06120894|Diagnostic Test|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
79316842|NCT06120894|Diagnostic Test|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
79316843|NCT06120894|Diagnostic Test|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
79807664|NCT04166201|Procedure|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
79316844|NCT06120894|Diagnostic Test|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
79316845|NCT06120894|Other|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
79316846|NCT06120868|Other|Surefil one®|For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.
79807665|NCT00865904|Drug|VX-809|Capsules
79807666|NCT00865904|Drug|Placebo|Placebo matched to VX-809 capsules.
79807667|NCT02648867|Device|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
79807668|NCT02649101|Drug|Thalidomide|Thalidomide tablet 100mg qn po.
79807669|NCT02649101|Drug|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
79807670|NCT04117568|Other|Blood sampling|Blood sampling at 3-5 occasions per admission
79807671|NCT02648945|Other|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
79972734|NCT02501278|Radiation|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
79316847|NCT06120868|Other|Filtek One|Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
79316848|NCT06120829|Procedure|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
79316849|NCT06120829|Device|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
79643316|NCT05323968|Diagnostic Test|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
79643317|NCT05298553|Device|Group A|Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
79316850|NCT06120829|Procedure|Core Needle Biopsy|Core Needle Biopsy
79316851|NCT06120777|Device|INVSENSOR00069|Noninvasive pulse oximeter
79643318|NCT05298553|Device|Group B|they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
79643319|NCT05287958|Diagnostic Test|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
79316852|NCT06120764|Other|guided imagery|"The experimental group will listen to Guided Imagery CD prepared by the Turkish Psychological Association for relaxation 10 minute before the chemotherapy infusion. The remained part of CD, containing relaxing music and wave sound, will be played for 30 minutes after the chemotherapy infusion starts. When the chemotherapy infusion starts, the patients will be given imagery suggestions by a researcher, together with listening CD throughout first 30 minutes of chemotherapy infusion. Participants will be encouraged to think of various images: the patient will be asked to imagine that the treatment is over, that he/she is much healthier, that he/she heals very fast, that he/she returns to his/her old life in a short time, that he/she imagines himself/herself doing whatever he/she wants to do first after recovery, and that he/she imagines an object, person, event, situation, food or anything else that will make him/her feel good."
79807672|NCT02613260|Behavioral|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
79316853|NCT06120686|Other|Biofeedback method|Study group - implementing a conventional therapy program supplemented additionally with visual and auditory biofeedback training on a dynamic balance platform
79807673|NCT04166045|Device|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
79316854|NCT06120686|Other|Conventional therapy program|Control group - rehabilitation management aimed at improving cognitive and motor functions in children with mild intellectual disabilities.
79316855|NCT06120673|Drug|Obinutuzumab|"Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~IV methylprednisolone 80 mg,~Paracetamol 1,000 mg orally,~Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion."
79807674|NCT04166045|Device|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
79316856|NCT06120673|Drug|Oral prednisolone and cyclophosphamide|"Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~Oral cyclophosphamide will be given for 90 days, adjusted by age and weight"
79316857|NCT06120660|Other|Music Therapy|Music Therapy
79643320|NCT05282459|Drug|Enasidenib mesylat dose escalation|Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
79643321|NCT05267873|Drug|Duloxetine, Vortioxetine|
79807675|NCT00700154|Procedure|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
79807676|NCT00651911|Drug|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
79807677|NCT02643485|Procedure|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
79972735|NCT02501278|Drug|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
79807678|NCT00651989|Other|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
79972736|NCT03176238|Drug|everolimus|one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
79972737|NCT03176238|Drug|exemestane|25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
79972738|NCT03565315|Biological|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
79807679|NCT02643407|Drug|Docetaxel|60mg/m2
79972739|NCT03565315|Biological|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
79807680|NCT02643407|Drug|Nedaplatin|80mg/m2
79807681|NCT02643407|Drug|Cisplatin|75mg/m2
79807682|NCT02643329|Drug|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
79807683|NCT02643329|Drug|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
79972740|NCT03840161|Device|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
79972741|NCT01205555|Device|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (<8 IU\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\L) the insemination will be the next day."
79972742|NCT01957332|Procedure|Molecular imaging|On the day of FES-injection&scan or the day after FES-injection, 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
79807684|NCT04165655|Behavioral|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
79972743|NCT01957332|Procedure|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET.
79643322|NCT05259956|Behavioral|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
79972744|NCT03840083|Behavioral|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
79972745|NCT02509000|Other|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
79972746|NCT02501122|Other|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
79807685|NCT02643017|Drug|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
79972747|NCT01205633|Procedure|venous angioplasty|catheter venous angioplasty via femoral vein approach
79807686|NCT02643017|Drug|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
79807687|NCT02643173|Other|Volatile anesthetics|
79807688|NCT02643173|Other|Intravenous anesthetics|
79972748|NCT01923636|Other|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
79972749|NCT03565237|Biological|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
79972750|NCT03565237|Biological|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
79972751|NCT01205711|Drug|FOLFIRI regimen|
79972752|NCT01205711|Drug|fluorouracil|
79972753|NCT01205711|Drug|irinotecan hydrochloride|
79643323|NCT05259956|Behavioral|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
79643324|NCT05224037|Diagnostic Test|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
79807689|NCT02646215|Device|Threshold inspiratory muscle training|Inspiratory muscle training
79807690|NCT02646137|Drug|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
79807691|NCT02646137|Procedure|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
79807692|NCT02646137|Procedure|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
79807693|NCT04165421|Behavioral|Family intervention group|Education and Family conversations
79807694|NCT00653081|Procedure|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
79972754|NCT01205711|Drug|leucovorin calcium|
79972755|NCT01205711|Drug|zibotentan|
79316858|NCT06120634|Procedure|Open surgical method|After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
79643325|NCT05222295|Other|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
79643326|NCT05222295|Other|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
79643327|NCT05221281|Behavioral|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
79643328|NCT05221281|Behavioral|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~A written letter explaining the goals of transition to the patient and family.~Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
79972756|NCT01205711|Other|laboratory biomarker analysis|
79972757|NCT01205711|Other|pharmacogenomic studies|
79643329|NCT05205265|Device|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
79643330|NCT05183607|Other|Virtual Nutrition Education|4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
79643331|NCT05133141|Device|Echelon Contour|There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
79643332|NCT05129293|Behavioral|Prospective Memory Intervention|Cognitive remediation focusing on prospective memory
79643333|NCT05129293|Behavioral|Educational|Psychoeducation
79643334|NCT05117840|Device|Low-dose CT scan|Standard of care screening for individuals at high-risk of lung cancer
79643335|NCT05109065|Diagnostic Test|SCID (Standardized Clinical Interview for DSM-V)|The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
79807695|NCT00653081|Procedure|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
79807696|NCT00653549|Drug|Torsemide|Tablets, 20 mg, single-dose
79972758|NCT02508922|Dietary Supplement|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
79972759|NCT02508922|Dietary Supplement|Placebo|Matching placebo drops will be taken daily for 20 weeks
79972760|NCT02894437|Other|qualitative interviews|semi-structured interviews as a conceptual frame work
79972761|NCT03730675|Procedure|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
79807697|NCT00653549|Drug|Demadex|tablets, 20 mg, single-dose
79807698|NCT02642861|Drug|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
79807699|NCT02642861|Drug|Calcium Carbonate|Calcium carbonate for 2 weeks
79807700|NCT02641535|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
79972762|NCT03730675|Procedure|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
79643336|NCT05109065|Diagnostic Test|PSS (Perceived Stress Score)|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
79972763|NCT03730675|Drug|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
79316859|NCT06120634|Procedure|Plastibell method|The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
79972764|NCT04495738|Other|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
79972765|NCT04495738|Other|Control Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
79972766|NCT04495738|Other|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
79972767|NCT04495738|Other|Experimental Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
79316860|NCT06120621|Procedure|Arm 1 : VCST-phaco group , Arm 2 : phaco group.|Arm 1 : VCST-phaco group , Arm 2 : phaco group.
79972768|NCT04495738|Other|Supplemental Formula for HM Group|Ad libitum formula given up to 12 months of age if HM is supplemented
79972769|NCT04495738|Other|Toddler Drink for HM group|16 fl oz per day if weaned from HM feedings
79316861|NCT06120608|Behavioral|Novel dietary approach focused on restricting the intake of highly bioavailable potassium|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
79807701|NCT02641535|Device|BC membrane protective garment|
79972770|NCT01297673|Procedure|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
79972771|NCT03726853|Drug|CKD-497 200mg|CKD-497 200mg
79972772|NCT03726853|Drug|CKD-497 300mg|CKD-497 300mg
79972773|NCT03726853|Drug|CKD-497 placebo|Placebo of CKD-497
79972774|NCT03726853|Drug|Comparator|Comparator
79807702|NCT02641535|Device|NBC mask|
79807703|NCT02641457|Drug|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
79972775|NCT03726853|Drug|Comparator placebo|Comparator placebo
79972776|NCT01205867|Drug|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
79972777|NCT05219214|Other|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
79972778|NCT03343288|Device|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
79972779|NCT01345682|Drug|Afatinib|Once daily
79972780|NCT01345682|Drug|Methotrexate|Weekly
79972781|NCT05295264|Other|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
79972782|NCT03343210|Diagnostic Test|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
79972783|NCT03839849|Procedure|: i-PRF|The description of this intervention has been already given before
79972784|NCT03839849|Procedure|saline|The description of this intervention has been already given before
79972785|NCT02503696|Device|Stool Collection Kit|Stool Collection Kit.
79972786|NCT03562117|Drug|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
79316862|NCT06120608|Behavioral|Traditional approach|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
79316863|NCT06120595|Behavioral|REBECCA-assisted intervention|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis), dietary advice, referral to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
79316864|NCT06120582|Genetic|ANB-002, dose 1|Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.
79972787|NCT01314924|Dietary Supplement|Dark chocolate|70% cocoa
79972788|NCT02503462|Drug|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
79972789|NCT02503462|Drug|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
79972790|NCT02503462|Drug|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
79972791|NCT01203215|Behavioral|2 print based physical activity interventions|physical activity promotion
79972792|NCT03561883|Drug|IW-3718|oral tablet
79972793|NCT03561883|Drug|placebo|oral tablet
79972794|NCT03561883|Drug|Standard-dose PPIs QD|background therapy
79972795|NCT04495426|Other|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
79972796|NCT05217056|Other|measurements|All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
79972797|NCT02503306|Drug|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
79972798|NCT02503306|Drug|placebo|Pharmaceutical form:tablets Route of administration: oral
79972799|NCT02508766|Procedure|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
79972800|NCT05706350|Biological|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
79807704|NCT02641457|Drug|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
79643337|NCT05109065|Diagnostic Test|Urine Toxicology Screen|Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
79643338|NCT05109065|Diagnostic Test|Vitals|Height and weight will be measured in order to calculate BMI.
79643339|NCT05109065|Diagnostic Test|Blood Work|A venipuncture will be performed for the purpose of collecting blood tissue for study.
79643340|NCT05109065|Diagnostic Test|PQ-B|The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
79643341|NCT05109065|Diagnostic Test|COVID Screening|Questionnaire to assess risk of transmission of COVID-19.
79643342|NCT05109065|Diagnostic Test|Positive and Negative Syndrome Scale (PANSS)|Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
79643343|NCT05089864|Other|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
79643344|NCT05089864|Other|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
79807705|NCT02641223|Device|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
79807706|NCT02641613|Procedure|retroclavicular block|retroclavicular block for forearm or hand surgery
79316865|NCT06120582|Genetic|ANB-002, dose 2|Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.
79316866|NCT06120569|Device|Soleus ms exercise|Soleus muscle exercise before and after eating by half an hour
79316867|NCT06120530|Drug|Bupivacaine|Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
79316868|NCT06120530|Other|Saline|Placebo
79316869|NCT06120517|Combination Product|emg- biofeedback|EMG activity shows the electrical activity measured during striated muscle contraction. The electrical activity of the muscle is in microvolts (1 volt = 1,000,000μV). Biofeedback units usually produce audio or visual feedback depending on the amount of electrical activity. Recording the bio-electrical activity of the muscle is a practical indicator of its contractility.
79316870|NCT06120478|Other|observe|observational study
79316871|NCT06120465|Other|Yoga|Yoga classes
79316872|NCT06120452|Other|Rael Miracle Clear Complete Acne Serum|"This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid."
79643345|NCT05035589|Drug|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
79643346|NCT05031286|Other|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
79643347|NCT05012917|Other|Patient/Proxy-SSPedi|"SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age."
79807707|NCT02641613|Procedure|supraclavicular block|supraclavicular block for forearm or hand surgery
79807708|NCT04131452|Other|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
79807709|NCT02646059|Other|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
79807710|NCT02646059|Other|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
79972801|NCT05706350|Dietary Supplement|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
79972802|NCT05706350|Dietary Supplement|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
79972803|NCT05706350|Dietary Supplement|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
79972804|NCT05706350|Dietary Supplement|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
79972805|NCT03343678|Drug|Venetoclax|Venetoclax given alone and then in combination with BI 836826
79316873|NCT06120439|Combination Product|PECS II combined with intercostal nerve blockade;|The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
79643348|NCT05012917|Other|Co-SSPedi|"Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms."
79972806|NCT03343678|Drug|BI 836826|Venetoclax given in combination with BI 836826
79972807|NCT03724279|Device|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
79643349|NCT05009875|Other|Medical Food SBD111|Two capsules administered twice daily with morning and evening meals for 52 weeks
79643350|NCT05009875|Other|Placebo|Two capsules administered twice daily with morning and evening meals for 52 weeks
79972808|NCT02500966|Device|DUDA device|Insertion DUDA device
79972809|NCT02500966|Procedure|LEEP|Loop Electrosurgical Excision Procedure
79316874|NCT06120439|Combination Product|General anesthesia with laryngeal mask|The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
79316875|NCT06120400|Drug|Whole Egg|Whole Large, Grade A Egg
79316876|NCT06120387|Procedure|Radical surgery|Radical nephroureterectomy
79316877|NCT06120387|Radiation|Kidney sparing surgery+Postoperative radiotheray|Kidney sparing surgery+Postoperative radiotheray
79316878|NCT06120374|Radiation|Radiotherapy|"For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)"
79643351|NCT05007288|Other|Restorative Eye Treatment (RET) cream|RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
79643352|NCT05007288|Other|INhance with Trihex Technology|INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
79643353|NCT05000411|Drug|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
79972810|NCT05216822|Drug|Racecadotril|racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
79972811|NCT02508688|Procedure|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
79643354|NCT05000411|Drug|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
79972812|NCT04495036|Other|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~Demographic data of telemedicine users and non-users~Subjective disease perception of the dermatology patients~Use of internet, telemedicine and telemedicine insurance model~Patients´ willingness for additional features of telemedicine~Advantages and disadvantages telemedicine and face-to-face consultation~Suitable fields of dermatology for telemedicine from the patient's perspective~Recommended structure of telemedical services by users and non-users"
79972813|NCT04495036|Other|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
79972814|NCT05706194|Diagnostic Test|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
79316879|NCT06120374|Drug|Chemotherapy and immunotherapy|"For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.~Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year."
79316880|NCT06120374|Combination Product|Combined adjuvant therapy|For patients eligible for enrollment, sequential adjuvant radiotherapy (same as the radiotherapy group) and systemic drug therapy (same as the chemotherapy group; immunotherapy drugs can be PD-1 or PDL-1) can be started at about 4-6 weeks after surgery. The specific dose of drugs can be adjusted according to the actual tolerability of the patient, such as reducing or replacing the regimen, or interrupting the regimen.
79316881|NCT06120322|Other|Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies|During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
79643355|NCT04995601|Device|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
79972815|NCT02503072|Behavioral|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
79972816|NCT02503072|Behavioral|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
79643356|NCT04986475|Other|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
79643357|NCT04962503|Drug|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
79643358|NCT04960566|Other|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
79643359|NCT04960566|Other|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
79972817|NCT03627338|Diagnostic Test|questionaire, interview|questionaire, interview
79972818|NCT04498936|Drug|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
79316882|NCT06120309|Diagnostic Test|CRS scoring|For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines
79972819|NCT04498936|Drug|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
79972820|NCT02502994|Drug|GEN0101|
79972821|NCT03627260|Behavioral|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
79807711|NCT02642939|Drug|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
79643360|NCT04935424|Device|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
79316883|NCT06120309|Diagnostic Test|Routine blood laboratory testing before treatment|The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
79316884|NCT06120296|Device|Acumen Hypotension prediction Index software|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
79316885|NCT06120192|Behavioral|Piano|Receives the piano training
79477815|NCT03302741|Device|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
79643361|NCT04918329|Other|Observational study|Non interventional study
79643362|NCT04916080|Drug|N-acetyl cysteine|mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
79643363|NCT04858477|Other|Visual estimation of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size
79643364|NCT04858477|Other|Napoleon measurement of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
79316886|NCT06120179|Device|The Bashir™ Endovascular Catheter (BEC|To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
79316887|NCT06120166|Drug|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
79477816|NCT02803307|Drug|TLC599|Single dose via intra-articular injection
79316888|NCT06120153|Diagnostic Test|POC PCR-test device|"The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed."
79316889|NCT06120127|Radiation|SBRT|postoperative SBRT of liver lesions
79643365|NCT04855305|Drug|Hyperpolarized 129Xe|Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
79643366|NCT04854369|Drug|68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit|The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.
79643367|NCT04842032|Drug|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
79643368|NCT04842019|Drug|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
79643369|NCT04838782|Procedure|Repeat Surgical Management of Recurrent GBM|Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
79643370|NCT04833140|Drug|Estradiol patch|The patch will provide 100mcg of estradiol daily.
79643371|NCT04833140|Drug|Placebo|Placebo patch will contain no estradiol.
79807712|NCT02642549|Behavioral|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
79972822|NCT02503150|Biological|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
79972823|NCT02503150|Drug|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
79316890|NCT06120127|Drug|Chemotherapy|XELOX/FOLFOX/FOLFIRI
79316891|NCT06120127|Drug|PD-1 antibody|Sintilimab (200mg d1，q3w)
79316892|NCT06120114|Procedure|Modified percutaneous internal ring suturing|Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
79316893|NCT06120088|Drug|Bubpivacaine|Bupivacaine is a long-acting local anesthetic commonly used to provide pain relief by blocking nerve signals in a specific area. It's often utilized for various medical procedures and surgeries, offering prolonged numbing effects.
79643372|NCT04828070|Other|Observation|all participants followed for clinical data for one year, vital status check at 5 years
79643373|NCT04778618|Drug|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
79807713|NCT02641301|Drug|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
79807714|NCT02642783|Behavioral|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
79643374|NCT04775979|Drug|diphenylcyclopropenone (DPCP)|Depigmenting agent
79643375|NCT04773457|Other|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
79643376|NCT04767841|Drug|Metformin|Metformin 1000mg tablet plus celecoxib 200 mg capsule
79643377|NCT04767841|Drug|Placebo|Placebo tablet plus celecoxib 200 mg capsule
79643378|NCT04761861|Drug|Vildagliptin 50 MG|Vildagliptin 50 MG tablet once daily
79643379|NCT04761861|Drug|Placebo|Placebo one tablet daily
79316894|NCT06120088|Drug|dexamethasone|Dexamethasone is a potent corticosteroid with anti-inflammatory properties. It's frequently employed as an adjunct in medical treatments to reduce inflammation and swelling, and in some cases, to prevent nausea and vomiting associated with certain medications or procedures.
79477817|NCT02669537|Device|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
79643380|NCT04741919|Procedure|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
79972824|NCT05706038|Drug|Adalimumab|"Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.[4] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential."
79807715|NCT02642783|Behavioral|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
79807716|NCT04165187|Other|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
79316895|NCT06120088|Drug|fentanyl|Fentanyl is a powerful synthetic opioid pain reliever. It acts on the central nervous system to alleviate severe pain. Fentanyl is significantly potent and is used in medical settings for acute pain management, such as during surgeries or for chronic pain in cases where other opioids may not be as effective.
79316896|NCT06120062|Other|swaddled|the 1st experimental group were swaddled
79316897|NCT06120062|Other|mother's breast milk odor|the 2nd experimental group were made to inhale mother's breast milk odor
79316898|NCT06120062|Other|both swaddled and made to inhale mother's breast milk odor|the 3rd experimental group were both swaddled and made to inhale mother's breast milk odor
79316899|NCT06120062|Other|No procedure|No procedure was applied to the infants in the control group.
79972825|NCT02500810|Drug|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
79972826|NCT03546907|Drug|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
79972827|NCT03546907|Drug|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
79972828|NCT03546907|Drug|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
79972829|NCT03546907|Drug|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
79972830|NCT03546907|Drug|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
79972831|NCT03546907|Drug|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
79643381|NCT04735627|Device|Levodopameter|There are several minimally-invasive sensors being developed that can detect levodopa levels in the capillary blood, sweat, and interstitial fluid.
79972832|NCT02500888|Radiation|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
79972833|NCT05126264|Drug|Ibuprofen 400 mg|morning and afternoon
79972834|NCT05126264|Drug|Ibuprofen 400 mg|morning, afternoon and night
79316900|NCT06120049|Diagnostic Test|[18F]-MFBG PET CT|"[18F]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).~Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.~In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.~If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes)."
79643382|NCT04716699|Procedure|Biospecimen Collection|Undergo collection of blood and tumor samples
79643383|NCT04716699|Drug|Lidocaine|Given IV
79643384|NCT04716699|Procedure|Resection|Undergo surgical resection per standard of care
79643385|NCT04702191|Behavioral|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, & Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
79655721|NCT04552678|Behavioral|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79316901|NCT06120049|Diagnostic Test|[18F]-FE-PE2I PET CT or PET MRI|"[18F]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.~Injected activity: 120 MBq"
79807717|NCT04165187|Other|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
79807718|NCT02642471|Procedure|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
79807719|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
79316902|NCT06120049|Diagnostic Test|[123I]-MIBG SPECT CT|"[123I]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq"
79807720|NCT02640989|Biological|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
79807721|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
79316903|NCT06120049|Diagnostic Test|[18F]-MFBG PET dosimetry scans|"[18F]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation."
79316904|NCT06120036|Drug|Kybella|Injection into the cutaneous Neurofibromas lesion.
79316905|NCT06120036|Drug|Asclera|Injection into the cutaneous Neurofibromas lesion.
79316906|NCT06120010|Device|MRI|To detect prevalence of anatomical variants of dural sinuses by MRV
79316907|NCT06119984|Behavioral|Community mobilization|The intervention focused on creating awareness, challenging social norms, and promoting actions against violence. To achieve these, the following activities were undertaken: introductory meetings, selection and training of model couples, structured workshops and small group meetings.
79316908|NCT06119971|Device|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
79316909|NCT06119958|Drug|DWC202313|Experimental Drug 1
79807722|NCT02642705|Other|High intensity interval training N|Exercise training and ambient air breathing
79807723|NCT02642705|Other|High intensity interval training H|Exercise training and hypoxic breathing
79972835|NCT02508298|Procedure|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
79316910|NCT06119958|Drug|DWC202314|Experimental Drug 2
79807724|NCT02642705|Other|Constant load exercise training N|Exercise training and ambient air breathing
79807725|NCT02642705|Other|Constant load exercise training H|Exercise training and hypoxic breathing
79807726|NCT02642705|Other|Hypoxic conditioning at rest|Hypoxic breathing at rest
79807727|NCT02642705|Other|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
79807728|NCT00653627|Biological|BCG|Mycobacterium bovis Bacille Calmette-Guerin
79972836|NCT02508298|Drug|Indocyanine Green Retention test|As decribed in arm descriptions
79972837|NCT02508298|Device|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
79972838|NCT02508298|Device|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
79972839|NCT03730597|Device|reverse shoulder arthroplasty|prosthesis implantation
79316911|NCT06119945|Drug|DWJ1568|One tablet of DWJ1568
79316912|NCT06119945|Drug|DWC202215|One tablet of DWC202215
79316913|NCT06119932|Procedure|Evacuation for subdural hematoma by one burrhole|Evacuation for subdural hematoma by one burrhole
79316914|NCT06119906|Device|Hyper-Spectral Endoscopy|We have developed a custom hyperspectral endoscopy approach based around a commercially available endoscopy system. An Olympus gastroscope (GIF-H260) and video processor and display are used with a modified light source that incorporates a laser with tunable wavelength for illuminating the scene through the endoscope. A live video feed from the gastroscope is displayed on the endoscopy monitors and can be acquired and saved in the native video acquisition system. The spectral imaging data is also saved within this video feed, where imaging wavelength corresponds to a given timestamp in the video.
79972840|NCT02500654|Device|Emdogain®|Surgery and Emdogain®
79972841|NCT02500654|Device|Surgery alone|Surgery alone
79972842|NCT01318382|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
79316915|NCT06119880|Drug|Pancreatin Enteric-coated Capsules|pancreatic enzyme replacement therapy
79316916|NCT06119880|Other|Routine treatment plan|Routine treatment plan without PERT
79316917|NCT06119828|Behavioral|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
79316918|NCT06119828|Other|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
79316919|NCT06119815|Diagnostic Test|CO2 GAP|"CO2 gap will be measured by insertion of radial arterial cannula and internal jugular C.V.P~I.V.C collapsibility will be measured by abdominal us at the subcostal area and the IVC diameters will be measured in M-mode coupled to 2D mode 3 cm before the IVC joined the right atrium to ensure that IVC diameter measurements are accurate and that the inter- and intra-observer variability of IVC can be minimized. The IVC collapsibility index (IVCCI) will be calculated as follows: (maximum diameter on expiration (IVC max) - minimum diameter on inspiration (IVC min).~Echocardiography for all patients to asses cardiac index in a parasternal (2D) view. The aortic diameter (AoD) will be measured at the aortic valve annulus. The aortic area (AA) will be calculated using the formula: AA = π × (AoD2/ 4). We measured the aortic blood flow using pulsed"
79316920|NCT06119802|Diagnostic Test|atrial fibrillation|ECG of atrial fibrillation last more than 30 seconds.
79316921|NCT06119789|Drug|Imatinib|imatinib treatment based on molecular alterations
79316922|NCT06119776|Procedure|Whipple over the splenic artery|Treatment for pancreatic ductal cell adenocarcinoma
79316923|NCT06119776|Procedure|Total pancreatectomy|Treatment for pancreatic ductal cell adenocarcinoma
79316924|NCT06119763|Diagnostic Test|anti dfs70 antibodies|blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
79477818|NCT05573828|Procedure|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
79477819|NCT02769611|Drug|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
79972843|NCT04495114|Other|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
79972844|NCT03001817|Drug|K-877|
79972845|NCT03001817|Drug|Fenofibrate|
79972846|NCT03001817|Drug|Placebo (for K-877)|
79316925|NCT06119750|Device|NS Solution|This will be administered via skin patch.
79316926|NCT06119750|Other|Normal Saline|This will be administered via skin patch.
79316927|NCT06119750|Other|SLS|This will be administered via skin patch.
79316928|NCT06119737|Other|Exercise|Effects of exercises on TSH levels
79477820|NCT02512445|Behavioral|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
79477821|NCT02512445|Behavioral|Supportive Care Therapy|Supportive therapy
79477822|NCT04525820|Drug|Single high dose vitamin D|Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
79477823|NCT04525820|Drug|Placebo|Patient receives a single dose of a placebo solution
79477824|NCT04525820|Drug|Treatment as usual vitamin D|Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
79655722|NCT04552678|Behavioral|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
79972847|NCT03001817|Drug|Placebo (for Fenofibrate)|
79972848|NCT03726697|Other|Tahneek|A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
79972849|NCT02508376|Other|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
79807729|NCT02645747|Drug|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
79807730|NCT00653237|Device|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
79807731|NCT04165499|Combination Product|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
79316929|NCT06119724|Procedure|Bipolar enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar
79807732|NCT04165499|Combination Product|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
79807733|NCT00653315|Drug|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
79807734|NCT00653315|Drug|Ultracet|Tablets, 37.5mg/325mg
79807735|NCT00652223|Biological|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
79807736|NCT02640833|Drug|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
79807737|NCT02640833|Drug|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
79972850|NCT02508376|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
79972851|NCT02508376|Biological|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
79972852|NCT03560869|Other|Normal hydration|see description in 'arms'
79972853|NCT03560869|Other|Dehydration|see description in 'arms'
79972854|NCT04498624|Procedure|inverted flap|full thickness macular hole surgery
79972855|NCT04498624|Procedure|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
79972856|NCT02502682|Drug|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
79807738|NCT00653393|Drug|Tranylcypromine|Tablets, 10 mg, single-dose
79807739|NCT00653393|Drug|Parnate|Tablets, 10 mg, single-dose
79807740|NCT02640599|Other|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
79807741|NCT02640599|Other|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
79807742|NCT02645669|Procedure|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
79807743|NCT02645669|Procedure|Control site|Only Scaling and Root planing was done.
79807744|NCT02645903|Drug|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
79807745|NCT02645903|Drug|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
79807746|NCT02645981|Drug|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
79807747|NCT02645981|Drug|Sorafenib|Control
79972857|NCT03590743|Drug|Apixaban|Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
79972858|NCT03590743|Other|Placebo|apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
79972859|NCT03053102|Drug|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
79972860|NCT03726619|Behavioral|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
79972861|NCT03726619|Behavioral|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
79972862|NCT05705960|Other|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
79972863|NCT03343600|Drug|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
79972864|NCT03343600|Drug|Placebo|Placebos 2 tablets daily
79972865|NCT05705882|Other|Malnutrition|For the diagnosis of malnutrition, the investigators adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
79316930|NCT06119724|Procedure|Thulium laser enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
79316931|NCT06119711|Other|No intervention|No intervention
79316932|NCT06119698|Behavioral|GetActive+|This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
79316933|NCT06119672|Drug|Probiotic Blend Oral capsules|probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
79316934|NCT06119672|Drug|Corticosteroids for Local Oral Treatment|topical clobetasol probionate in orabase application 4 times daily
79316935|NCT06119659|Drug|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10^12 vg/kg.
79807748|NCT02535767|Drug|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
79643386|NCT04702191|Behavioral|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
79643387|NCT04685980|Procedure|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
79643388|NCT04673552|Procedure|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
79643389|NCT04657692|Procedure|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
79643390|NCT04627974|Device|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
79643391|NCT04626934|Other|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
79972866|NCT02502760|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
79972867|NCT02502760|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
79972868|NCT02502760|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
79316936|NCT06119659|Drug|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10^12 vg/kg.
79316937|NCT06119659|Drug|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10^13 vg/kg.
79316938|NCT06119646|Other|Warm Pads Applied to the Breast|Applying a warm pad to a breast during episiotomy repair
79316939|NCT06119633|Procedure|Immediate tissue expander and lipofilling after mastectomy|Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
79316940|NCT06119620|Device|intermitted theta burst stimulation|Participants receive intermitted theta burst stimulation for 3-4 minutes before completing the N-back task.
79316941|NCT06119594|Device|Body Comp Pro connected scale (Withings manufacturer)|Patients in the intervention group will use the connected scale at a minimum frequency of once a week from receipt of the scale and throughout their participation in the research (6 months)
79972869|NCT05085938|Procedure|gonadal vein embolization|"GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
79643392|NCT04626934|Other|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
79477825|NCT05570708|Drug|MDMA, LSD, psilocybin|"MDMA per os (2 x 100mg) in a group setting~LSD per os (75 and 150 mcg) in a 1:1 setting~Psilocybin per os (15 mg and 25 mg) in a group setting~Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
79477826|NCT04490330|Other|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
79643393|NCT04603209|Radiation|Intraoperative Radiation Therapy (IORT)|IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
79643394|NCT04598854|Device|Intravascular laser irradiation of blood|Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
79972870|NCT02502604|Behavioral|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
79316948|NCT06119516|Other|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
79316949|NCT06119477|Other|Bioceramic Putty Apical Plugs|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, then dried, and filled with Ca(OH)2 dressing. Afterward, the incisor will be temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger. The correct placement and thickness of the apical plug will be verified with a periapical radiograph. Afterward, the remainder of the root canal will be filled with gutta-percha with sealer. Finally, a suitable immediate final restoration was made for each case individually.
79477827|NCT03303911|Drug|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
79477828|NCT03305159|Drug|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
79477829|NCT03305159|Drug|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
79477830|NCT05552690|Procedure|blood draw|10 ml of blood will be draw to genetic analysis (sequencing)
79477831|NCT03306641|Device|Test Contact Lens|Daily disposable contact lens
79477832|NCT03306641|Device|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
79643395|NCT04598854|Device|Intravascular laser irradiation of blood (Sham)|zero intensity of the laser energy
79643396|NCT04577690|Drug|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
79643397|NCT04577690|Drug|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
79643398|NCT04549181|Behavioral|Phase II: Problem-Solving for Rural HF Dyads|Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
79477833|NCT04473326|Behavioral|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
79972871|NCT05152706|Other|Aerobic training|Cycling at the aerobic intensity
79972872|NCT05152706|Other|Photobiomodulation|Photons therapy
79972873|NCT04498702|Drug|APL-1202 treatment|A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
79972874|NCT03589885|Drug|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
79972875|NCT03589885|Drug|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
79972876|NCT03589885|Drug|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
79477834|NCT02163317|Radiation|stereotactic radiosurgery|Undergo MRI-guided focal SRS
79643399|NCT04547816|Procedure|Biofeedback therapy|Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands
79972877|NCT03589885|Drug|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
79972878|NCT03121222|Drug|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
79477835|NCT02163317|Device|magnetic resonance imaging|Undergo staging MRI with contrast
79643400|NCT04547816|Procedure|Tibial neuromodulation|TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
79316950|NCT06119477|Other|Single Cone Gutta-percha with Bioceramic Sealer|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. A large sized gutta-percha cone (GC) will be inserted to the working length, The GC was ensured to make tag-back with the apical third of the immature canal and confirmed with a periapical radiograph. Then the immature canal will be gently filled with Bioceramic sealer and the GC will be placed again and another apical radiograph will be taken to confirm that the canal was properly filled. Finally, a suitable immediate final restoration was made for each case individually.
79316951|NCT06119477|Other|Combination of Bioceramic Putty and Sealer|"Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried.~The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP (diameter of 1 mm) will be inserted into the canal orifice and gently plugged with hand pluggers. Afterward, an apical radiograph will be taken to confirm that the canal was properly filled without gaps and voids. Finally, a suitable immediate final restoration was made for each case individually."
79807749|NCT02640521|Behavioral|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
79807750|NCT04165265|Device|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
79807751|NCT02640443|Drug|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
79807752|NCT02640365|Drug|MM-398|unresectable Advanced non-colorectal cancer
79807753|NCT02640365|Drug|Irinotecan|unresectable metastatic colorectal cancer
79807754|NCT02640365|Drug|Leucovorin (LV)|unresectable metastatic colorectal cancer
79316952|NCT06119126|Drug|SDF1|Topical SDF application
79316953|NCT06119126|Device|Diode Laser|Irradiating Enamel by Diode laser
79807755|NCT02640365|Drug|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
79807756|NCT02640365|Drug|bevacizumab|unresectable metastatic colorectal cancer
79807757|NCT02640365|Drug|MM-398|unresectable metastatic colorectal cancer
79807758|NCT02645591|Procedure|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
79807759|NCT02645591|Biological|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
79807760|NCT02645591|Behavioral|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
79807761|NCT02645513|Behavioral|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
79807762|NCT02645513|Behavioral|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
79807763|NCT02645513|Behavioral|Control|No text message reminders
79807764|NCT02642003|Drug|Granulocyte Colony Stimulating Factor|
79807765|NCT00653705|Other|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
79807766|NCT00653705|Other|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
79807767|NCT02641925|Procedure|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
79807768|NCT02641925|Procedure|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
79807769|NCT02640287|Biological|Blood or bone marrow samples|
79316954|NCT06119126|Drug|Pit Fissure Sealant|Sealing occlusal pits and fissures
79316955|NCT06117748|Other|Pressure controlled ventilation-volume guaranteed|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is <45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
79316956|NCT06117748|Other|Volume controlled ventilation|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is <45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
79316957|NCT06117488|Device|endoscopy|gastro duodenal endoscoe
79316958|NCT06117228|Other|Data collection|Data collection
79807770|NCT02536001|Device|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
79807771|NCT02536001|Device|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
79972879|NCT03121222|Drug|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
79477836|NCT02163317|Other|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
79477837|NCT02163317|Procedure|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
79477838|NCT02163317|Procedure|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
79807772|NCT00653471|Device|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
79807773|NCT00653471|Device|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
79807774|NCT00653471|Device|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
79807775|NCT02641769|Biological|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
79807776|NCT02640131|Behavioral|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
79972880|NCT05074394|Biological|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
79972881|NCT05074394|Drug|Placebo|Diluent solution
79316959|NCT06117124|Radiation|Digital X-Ray Radiogrammetry|An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
79477839|NCT02163317|Behavioral|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
79477840|NCT05552144|Device|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
79477841|NCT05550428|Device|Pulse Electromagnetic Field device|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
79477842|NCT05550428|Device|Sham Pulse Electromagnetic Field device|Sham Pulse Electromagnetic Field Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with a total of 16 treatment sessions.
79643401|NCT04547816|Behavioral|Pelvic floor muscles training|"PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training."
79643402|NCT04547816|Behavioral|Diet modification|Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
79643403|NCT04531176|Other|Weight Management Program (WMP)|Weight Management Program (WMP)
79807777|NCT02640131|Behavioral|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
79477843|NCT03308669|Drug|Lasmiditan|Administered orally
79477844|NCT03308669|Drug|Placebo|Administered orally
79477845|NCT03308669|Drug|Topiramate|Administered orally
79643404|NCT04531176|Other|Traditional care|Traditional care
79643405|NCT04531176|Drug|Phentermine / Topiramate Extended Release Oral Capsule|Medication for chronic weight management (Rx)
79316960|NCT06117124|Diagnostic Test|Quantitative Ultrasound (QUS)|The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
79316961|NCT06116812|Other|the laughter therapy group|They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.
79477846|NCT00356252|Drug|mixed carotenoids|
79477847|NCT01386359|Drug|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
79643406|NCT04531176|Drug|naltrexone/bupropion extended-release|Medication for chronic weight management (Rx)
79643407|NCT04531176|Drug|liraglutide 3.0 mg|Medication for chronic weight management (Rx)
79643408|NCT04531176|Drug|Orlistat|Medication for chronic weight management (Rx)
79643409|NCT04472767|Drug|Nivolumab|Given IV
79643410|NCT04472767|Drug|Ipilimumab|Given IV
79643411|NCT04472767|Drug|Cabozantinib|Given PO
79972882|NCT05059964|Other|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
79477848|NCT05099042|Other|Recommendations and re-orientation towards appropriate physical, mental, and social health ressources|Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
79477849|NCT02055781|Drug|Pacritinib|
79316962|NCT06116812|Other|the mindfulness therapy group|Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.
79316963|NCT06116500|Device|Modified twin block appliance with expander|These appliances are myofunctional appliance used for treating class II division growing adolescents.
79316964|NCT06116500|Device|Conventional twin block appliance with expander|These appliances are myofunctional appliances used for treating class II division growing adolescents.
79972883|NCT05059964|Other|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
79972884|NCT03120988|Biological|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
79972885|NCT03639493|Drug|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
79316965|NCT06116396|Genetic|Genetic analysis on isolated cells|Isolation of cells from blood and urine
79316966|NCT06116383|Device|NIRS|Renal perfusion will be evaluated with NIRS
79316967|NCT06116370|Procedure|Rezum procedure|In Rezūm procedure, the Rezūm System (NxThera Inc., Maple Grove, MN, USA) consists of a radiofrequency (RF) power supply generator and single-use transurethral delivery device. Starting 1 cm distal to the bladder neck, injection was done at 3 and 9 o'clock sites. The needle was inserted for 9 s duration, retracted, and then delivered to another treatment site in 1 cm distance distal to the previous one.
79316968|NCT06116370|Procedure|B-TURP procedure|In B-TURP, Olympus SurgMaster™ UES-40 bipolar generator (Olympus Europe, Hamburg, Germany) was used. Current's settings used were cut/coag 200/120. Using continuous flow 26Fr resectoscope first resection of the median lobe from the level of the bladder neck to the apex of the prostate was done followed by resection of the lateral lobes. Using Ellic evacuator, Prostatic chips were extracted from the field. A 22 fr three-way silicon Foley catheter was placed with traction applied and the balloon inflated by normal saline of 30-80 cc according to the size of the prostate.
79316969|NCT06115668|Other|Positive end-expiratory pressure 5 (PEEP 5)|Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery
79477850|NCT02055781|Drug|Best Available Therapy|
79477851|NCT03309449|Device|Syringe and needle|Intramuscular administration of simulated naloxone
79477852|NCT03309449|Device|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
79972886|NCT03639493|Drug|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
79972887|NCT03120910|Device|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
79972888|NCT03724045|Dietary Supplement|Back Side of the Moon|"The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU."
79972889|NCT05150678|Procedure|removal of ceserean section scar|we will remove the previous scar in group A
79972890|NCT05150678|Procedure|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
79972891|NCT03344302|Drug|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
79972892|NCT02502292|Behavioral|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
79972893|NCT03545503|Drug|Etomidate|Etomidate will be administered as the sedative for RSI on even days
79316970|NCT06115668|Other|Individualized positive end-expiratory pressure (PEEPIND)|Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: [Cstat = VT/Pplat - PEEP] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O
79477853|NCT03309449|Device|Nasal spray|Nasal spray administration of simulated naloxone
79643412|NCT04472767|Procedure|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
79643413|NCT04456946|Device|Low Level Laser Therapy|Low Level Laser Therapy
79643414|NCT04456946|Device|Occlusal Splint Treatment|Occlusal Splint Treatment
79643415|NCT04409860|Radiation|CCRT|Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
79807778|NCT02640131|Behavioral|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
79807779|NCT00599027|Drug|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
79972894|NCT03545503|Drug|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
79316971|NCT06115395|Device|non- invasive ventilator|Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
79316972|NCT06115395|Device|fiber-optic bronchoscopy|Group 2 (hypoxemic patients who will undergo conventional bronchoscopy under conventional o2 therapy without NIV ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
79477854|NCT05094440|Behavioral|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
79643416|NCT04409860|Drug|Paclitaxel, Cisplatin|The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
79643417|NCT04360746|Other|Pharmaceutical intervention|Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.
79643418|NCT04360746|Other|Rehabilitation|A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
79972895|NCT01297829|Drug|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
79972896|NCT01297829|Other|IV Placebo|IV normal saline
79972897|NCT05685992|Other|no intervention|no intervention
79316973|NCT06115395|Device|non- invasive ventilator|Group 3 (non- hypoxemic patients who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
79316974|NCT06115395|Device|fiber-optic bronchoscopy|Group 4 (non- hypoxemic patients who will undergo conventional bronchoscopy without non- invasive ventilation{NIV) will be on conventional oxygen therapy throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
79643419|NCT04312867|Behavioral|Project STRONG|Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.
79643420|NCT04312867|Behavioral|Health Promotion|Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
79643421|NCT04303559|Drug|Eloctate Injectable Product|This is a factor VIII-Fc fusion protein.
79643422|NCT04303559|Drug|Emicizumab Injection [Hemlibra]|This is a bispecific monoclonal antibody FVIII mimic.
79643423|NCT04303390|Drug|Cefuroxime|second generation cephalosporin
79643424|NCT04303390|Drug|Cefazolin|First generation cephalosporin
79972898|NCT04496440|Other|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
79316975|NCT06115356|Diagnostic Test|Vitamin D Plasma Level|Blood test measured in ng/ml
79316976|NCT06115356|Diagnostic Test|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
79316977|NCT06115356|Diagnostic Test|Ferritin|Ferritin plasma levels were measured in μg/L
79316978|NCT06115356|Diagnostic Test|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
79316979|NCT06115356|Diagnostic Test|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
79316980|NCT06115356|Other|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
79643425|NCT04303390|Other|24 hours|Duration of antibiotic therapy
79643426|NCT04303390|Other|48 hours|Duration of antibiotic therapy
79643427|NCT04282967|Behavioral|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
79643428|NCT04234139|Procedure|liver transplant|solid organ transplant
79643429|NCT04230785|Genetic|Sequencing of circRNA/lncRNA/miRNA|Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
79972899|NCT03829943|Diagnostic Test|Vitamin D|Blood will be drawn for Vitamin D level
79972900|NCT03545113|Procedure|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
79972901|NCT03545113|Procedure|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
79972902|NCT02508142|Drug|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
79643430|NCT04185298|Behavioral|mSIM intervention plus activity monitoring|Participants will receive the full mSIM intervention and be monitored (via Fitbit)
79643431|NCT04185298|Behavioral|Activity monitoring|Participants will have activity monitored (via Fitbit)
79807780|NCT00599027|Drug|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
79972903|NCT02508220|Drug|Syntocinon|Oxytocin nasal spray
79807781|NCT02645357|Other|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
79807782|NCT02645357|Other|Control group|control group
79972904|NCT02508220|Drug|Placebo|distilled water in nasal spray
79972905|NCT01297907|Other|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
79972906|NCT01297907|Other|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
79972907|NCT01297907|Other|Blood Test|Blood Tests (Eosinophil Count)
79972908|NCT01297907|Other|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
79972909|NCT02508064|Drug|BMS-663068|BMS-663068
79972910|NCT05705570|Drug|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
79972911|NCT05705570|Drug|Fludarabine|Fludarabine 25mg/m^2 IV on days -5 to -3
79972912|NCT05705570|Biological|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 [Starting dose] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
79972913|NCT01206023|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
79316981|NCT06114927|Behavioral|Validation of a questionnaire|The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
79316982|NCT06114888|Diagnostic Test|MeMed BV + Usual Care|We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.
79643432|NCT04175691|Genetic|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
79316983|NCT06114888|Other|Usual Care Alone|Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
79643433|NCT04165746|Other|Foster Care|"Upon entry into the Child Protection System, if the child is assigned to one of the districts participating in the RCT, the court will notify the study team. Children that have been randomly assigned to Foster Care will be placed in a foster home within 48 hours of referral to the Family Court/Child Protection System.~Children and Foster Parents will receive biweekly visits from Social Workers. Children and Foster parents will also participate in the caregiving intervention described below. Children will remain in the placement until such time as the social workers, psychologists and Family Court Judge determine that one of the following outcomes is appropriate: reunification with biological family or adoption."
79655723|NCT04552678|Behavioral|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
79655724|NCT04552678|Behavioral|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
79655725|NCT00236171|Drug|Protopic, Advantan|
79655726|NCT00236171|Procedure|Blood and Urine Test|
79655727|NCT00236171|Procedure|coherence tomography|
79807783|NCT03272633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
79807784|NCT03272633|Biological|Irradiated Allogeneic Cells|Correlative studies
79807785|NCT00652379|Drug|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
79972914|NCT02502448|Procedure|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
79972915|NCT02502448|Drug|hydroxyethyl starch (HES 130/0.6)|
79972916|NCT03839615|Procedure|guided bone regenerations|"intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
79972917|NCT02502370|Drug|observation alone|
79972918|NCT02502370|Drug|LV5FU2|
79316984|NCT06114719|Drug|Silymarin|Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
79972919|NCT02502370|Drug|FOLFOX|
79477855|NCT04429100|Diagnostic Test|Magnetic Resonance Imaging|One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
79316985|NCT06114654|Behavioral|Physical Therapy|Specific physical tests to assess muscle strength, ankle stability and activation of the lower extremity musculature: Single Leg Stance Test, Hurdle Step test and Single leg vertical jump.
79316986|NCT06114160|Other|Data collection|Data collection
79316987|NCT06113575|Device|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
79316988|NCT06113549|Procedure|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
79316989|NCT06113549|Procedure|Knee Prosthesis|A total or unicompartmental knee prosthesis
79316990|NCT06113484|Other|DIET + EXERCISE|At first, a two-hour group session titled 'Discovering New Flavors' is conducted. This session aims to promote the consumption of healthy foods that should be included in the participants' daily diet. In order to create a different dynamic and enhance interaction, some recipe suggestions are prepared in a group setting. The intervention group is advised to have three (breakfast, lunch, and dinner) to four (breakfast, lunch, afternoon snack, and dinner) daily meals. Participants are encouraged not to count calories, thus emphasizing the importance of moderation. Regarding the main meals, legumes are recommended as a protein source for dinner. On the other hand, for lunch, the protein component can include white meats, fish, or eggs. Red and/or processed meats are excluded in this intervention. Moreover, all participants in this group are encouraged to practice a nightly fasting period of at least 12 hours.
79316991|NCT06113484|Other|WITHOUT DIET + EXERCISE|"An educational session titled Healthy Eating: Nutritional Recommendations for Individuals at Risk of Cardiovascular Disease will be conducted in a group setting.~The objective of this session is to raise awareness among participants about the importance of a healthy diet and lifestyle in the prevention of cardiovascular diseases."
79643434|NCT04165746|Behavioral|Caregiving Intervention|During AVI an intervenor meets with a caregiver (foster parent or caregiver at the institution) and child in the home environment. During each session, the intervenor videotapes the caregiver and child doing play-based activities. During that meeting, the intervenor reviews the videos with the caregiver and provides positive, constructive feedback to the caregiver. AVI is aimed at increasing sensitivity in parents/caregivers in order to encourage positive interactions. The guiding principles are to create a positive environment and to convey that the caregiver is the expert on their own child. The AVI methodology was selected to be used as a method of caregiving intervention with the study participants due to its demonstrated results in its use with children in contexts of social vulnerability, as well as families included in the child protection system. This will be the first time that AVI is being used in foster and institutional care in Brazil.
79316992|NCT06112964|Procedure|MRI/ Functional MRI|Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
79477856|NCT02056171|Drug|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
79477857|NCT02056171|Other|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
79316993|NCT06112964|Behavioral|Self-reported questionnaires|Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
79316994|NCT06112964|Behavioral|Computer based tasks|"Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake"
79316995|NCT06110858|Behavioral|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
79316996|NCT06108778|Device|MRI|Investigations as CT,MRI.serum ammonia and lactate
79316997|NCT06108063|Drug|Losartan|12.5 mg oral Losartan taken for 42 days total (2 weeks preoperative, 4 week postoperative).
79316998|NCT06108063|Drug|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 42 days total (2 weeks preoperative, 4 week postoperative).
79316999|NCT06105034|Procedure|interventional techniques, the severity of placental invasion, and various placental positions and suture techniques|Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion
79972920|NCT03829709|Other|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
79317000|NCT06103656|Drug|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
79643435|NCT04092946|Device|Digital intervention|"Individuals included will be offered a program based on three pillars: education, cognitive-behavioural therapy (CBT) and therapeutic exercise.~The therapeutic exercise component will be delivered in the form of exercise sessions to be performed independently by the individual at home using SWORD Phoenix. These programs will have a duration of between 8 and 12 weeks, according to the condition, following pre-defined protocols. These protocols can be adapted to the needs, performance and progress of each individual by their assigned physical therapist. Individuals will be asked to perform at least 3 exercise sessions per week, in different days, but will not be excluded in case of lower adherence.~In addition to the exercises, the individuals will also have access to educational articles written by the clinical team, as well as to a CBT program delivered through a combination of written articles and pre-recorded audio sessions."
79317001|NCT06103656|Drug|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
79643436|NCT04091165|Other|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
79643437|NCT04088149|Drug|GXNPC1|Autologous ADSCs
79643438|NCT04086849|Diagnostic Test|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
79643439|NCT04075110|Drug|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
79643440|NCT04075110|Drug|Placebo|Placebo tablet once daily
79643441|NCT04067479|Dietary Supplement|Amino Acids|Oral bolus of essential amino acids
79643442|NCT04063384|Other|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
79317002|NCT06103656|Drug|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
79317003|NCT06103643|Other|Using High Reality Simulator|Using High Reality Simulator will perform emergency breech birth.
79317004|NCT06103201|Drug|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) [13C]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize [13C]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and [13C]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as [1- 13C]pyruvate, [2- 13C]pyruvate and [1,2- 13C]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body [Koletzko et al., 1997]."
79477858|NCT03312023|Drug|Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|1 pill once daily for 12 weeks for Group A
79477859|NCT03312023|Drug|Sofosbuvir 400 MG [Sovaldi]|1 pill once daily for 12 weeks for Group C
79477860|NCT03312023|Drug|Ledipasvir 90 MG|1 pill once daily for 12 weeks for Group D
79477861|NCT04425122|Diagnostic Test|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
79972921|NCT02502136|Procedure|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
79643443|NCT04063384|Other|Placebo beverage|placebo beverage conditions.
79643444|NCT04055909|Drug|nangibotide low dose|nangibotide 0.3 mg/kg/h
79643445|NCT04055909|Drug|nangibotide high dose|nangibotide 1.0 mg/kg/h
79643446|NCT04055909|Drug|placebo|matching placebo
79643447|NCT04013711|Diagnostic Test|Thermography|Thermograms will be acquired of both treated and non-treated cancer site for comparison.
79643448|NCT03997708|Other|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
79643449|NCT03997708|Other|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
79643450|NCT03991234|Behavioral|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
79643451|NCT03991234|Behavioral|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge & counting strategies to build arithmetic skill.
79643452|NCT03991234|Behavioral|Coordinated Intervention|Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm & similar objectives as the math intervention arm.
79643453|NCT03989986|Behavioral|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
79643454|NCT03978689|Drug|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A&B and in combination in Parts C&D according to the schedule described in the protocol.
79972922|NCT02502136|Procedure|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
79972923|NCT01206179|Biological|cell injection|Injection of mesenchymal cells in fractured zone
79972924|NCT03214380|Drug|LY900014|Administered SC
79972925|NCT03214380|Drug|Insulin Lispro|Administered SC
79643455|NCT03978689|Drug|Keytruda|Keytruda is first-line therapy in HPV16 and HLA A*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C&D according to the schedule described in the protocol.
79317005|NCT06101225|Other|MindRegulation Intervention|The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.
79317006|NCT06101225|Other|Relaxation|The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.
79317007|NCT06101225|Other|Waiting List Control Group|No Intervention.
79317008|NCT06090058|Diagnostic Test|Measurement of neurofilament light chain|Serum samples will be collected into a serum gel with clotting activator tube (Sarstedt). After delivery to the laboratory, the serum samples were centrifuged at 2500 × g for 6 min at 4 Celsius degree, then aliquoted into at least three vials (0.3 mL per vial) and stored at -70 Celsius degree until the analysis.
79317009|NCT06085131|Device|Argos|Argos Biometer
79643456|NCT03915899|Behavioral|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
79643457|NCT03875768|Behavioral|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
79643458|NCT03856775|Device|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
79643459|NCT03816553|Drug|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
79643460|NCT03816553|Drug|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
79643461|NCT03784820|Behavioral|UNITE|UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.
79643462|NCT03784820|Behavioral|CBT-E|CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
79807786|NCT00652379|Drug|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
79807787|NCT00655187|Other|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
79317010|NCT06082752|Procedure|Massage session|Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
79317011|NCT06081361|Drug|Bedaquiline|Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week
79317012|NCT06081361|Drug|Delamanid|Oral, 100mg bid
79317013|NCT06081361|Drug|Contezolid|Oral, 800mg bid
79317014|NCT06081361|Drug|Levofloxacin|Oral, 400mg qd for weight <50kg, 600-750mg qd for weight ≥50kg
79972926|NCT03214380|Drug|Insulin Glargine|Administered SC
79972927|NCT03214380|Drug|Insulin Degludec|Administered SC
79972928|NCT03214380|Drug|Metformin|Administered orally.
79972929|NCT03214380|Drug|SGLT2 inhibitor|Administered orally.
79972930|NCT03344224|Diagnostic Test|laboratory test|laboratory test
79972931|NCT02502058|Device|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
79972932|NCT03819179|Other|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
79972933|NCT03819179|Other|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
79972934|NCT03819179|Other|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
79317015|NCT06081361|Drug|Moxifloxacin|Oral, 400mg qd
79317016|NCT06081361|Drug|Clofazimine|Oral, 100mg qd
79477862|NCT04425122|Diagnostic Test|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
79972935|NCT03819179|Other|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
79972936|NCT03819179|Other|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
79477863|NCT02056639|Device|Bioteque cup pessary|
79972937|NCT01206257|Drug|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
79317017|NCT06081361|Drug|Linezolid|Oral, 600mg qd
79477864|NCT03839420|Device|CZM IOL|implantation of CZM IOL
79477865|NCT03839420|Device|Competitor IOL|implantation of Competitor IOL
79477866|NCT04368806|Drug|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
79477867|NCT04368806|Other|Placebo Control|Normal Saline with autologous Serum
79477868|NCT02340091|Device|HA IDF plus|
79477869|NCT02340091|Device|HA IDF|
79972938|NCT03343444|Drug|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
79972939|NCT03343444|Drug|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
79972940|NCT03819023|Diagnostic Test|Respilife monitor|Respilife monitor
79972941|NCT04498390|Drug|LY3493269|Administered orally.
79972942|NCT04498390|Drug|Placebo|Administered orally.
79972943|NCT03819101|Drug|Acetylsalicylic acid|100mg
79972944|NCT03819101|Drug|Atorvastatin|80 mg
79643463|NCT03769675|Device|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
79477870|NCT02342197|Drug|Decapeptyl|half the dose of Gn agonist
79643464|NCT03729245|Biological|bempegaldesleukin|Specified dose on specified days
79477871|NCT03182933|Drug|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
79477872|NCT03182933|Behavioral|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
79477873|NCT03182933|Other|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
79477874|NCT03182933|Device|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
79643465|NCT03729245|Drug|sunitinib|Specified dose on specified days
79972945|NCT05705102|Other|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for <24h.
79972946|NCT02501746|Other|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
79317018|NCT06081361|Drug|Cycloserine|Oral, 250mg bid
79317019|NCT06081361|Drug|Prothionamide|Oral, 600mg qd for weight <50kg, 600-800mg qd for weight ≥50kg
79317020|NCT06081361|Drug|Pyrazinamide|Oral, 1500mg qd for weight <50kg, 1750mg qd for weight ≥50kg
79477875|NCT04324034|Device|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
79477876|NCT04324034|Procedure|laparoscopy|The surgery by conventional laparoscopy is used
79477877|NCT03183869|Drug|Fecal microbiota|fecal microbial transplantation
79477878|NCT02344225|Drug|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
79477879|NCT02344225|Drug|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
79477880|NCT02344225|Drug|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
79477881|NCT04319588|Procedure|Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage|After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
79477882|NCT04319588|Procedure|Infiltration with local anesthetic of access to thoracic drainage|Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
79643466|NCT03729245|Biological|nivolumab|Specified dose on specified days
79807788|NCT00655187|Procedure|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
79807789|NCT02639975|Drug|PBF-677|once daily oral administration
79643467|NCT03729245|Drug|cabozantinib|Specified dose on specified days
79643468|NCT03727737|Device|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
79643469|NCT03712397|Drug|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
79807790|NCT02639975|Drug|Placebo|once daily oral administration
79807791|NCT04164797|Drug|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
79807792|NCT04164797|Other|chemoradiotherapy|chemoradiotherapy
79807793|NCT00654017|Drug|placebo|Placebo comparator to be given per protocol.
79317021|NCT06081361|Drug|Para-Aminosalicylic Acid|8000mg qd for weight <50kg, 10000mg qd for weight ≥50kg
79807794|NCT00654017|Drug|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
79317022|NCT06081361|Drug|Ethambutol|750mg qd for weight <50kg, 1000mg qd for weight ≥50kg
79477883|NCT05078528|Device|Multimodal Mobile Colposcope (MMC)|Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
79807795|NCT02639819|Drug|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
79477884|NCT03314753|Other|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
79643470|NCT03660423|Other|Integrative Dance|Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
79807796|NCT02645201|Dietary Supplement|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
79807797|NCT02645201|Other|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
79807798|NCT02638025|Device|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
79807799|NCT02639741|Drug|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
79807800|NCT02639741|Drug|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
79807801|NCT02639741|Other|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
79807802|NCT04164719|Drug|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
79317023|NCT06077916|Drug|Azithromycin|azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution
79317024|NCT06077916|Drug|Saline solution|placebo consisting of saline solution 250 mL is administered
79807803|NCT02639663|Device|dental device|"Leboride~Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control~Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
79807804|NCT02639507|Procedure|Vitrectomy|
79807805|NCT00654173|Drug|Rosuvastatin|
79807806|NCT00654173|Drug|Simvastatin|
79807807|NCT00654173|Drug|Atorvastatin|
79317025|NCT06077838|Behavioral|RELAXaHEAD Smartphone App Version 1|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
79477885|NCT05060354|Other|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
79477886|NCT03318341|Device|Real Stimulation|The device applies wrist vibration at a subthreshold (imperceptible) level.
79477887|NCT03318341|Device|Sham Stimulation|The device applies no vibration.
79477888|NCT02300545|Drug|Pazopanib|
79807808|NCT02645435|Procedure|hip replacement|Total hip replacement
79807809|NCT02645279|Other|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
79807810|NCT02645279|Drug|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
79807811|NCT02639585|Drug|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
79317026|NCT06077838|Behavioral|RELAXaHEAD Smartphone App Version 2|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
79317027|NCT06076785|Device|OdySight|At home measurements of visual acuity through a mobile app.
79317028|NCT06076707|Drug|bupivacain-tramadol|Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
79643471|NCT03557918|Drug|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
79643472|NCT03557463|Dietary Supplement|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
79643473|NCT03544099|Drug|Pembrolizumab|Pembrolizumab 200mg Intravenous Solution
79972947|NCT02501746|Other|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
79317029|NCT06076525|Behavioral|Multidirectional Perturbations for Balance Control Assessment (60 perturbations)|The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
79477889|NCT05040464|Drug|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
79477890|NCT05040464|Drug|MTX|MTX 25 mg SC once a week
79477891|NCT05040464|Biological|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
79477892|NCT02979080|Other|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
79477893|NCT02346643|Device|Implantation with the commercially available Axium Neurostimulator|
79643474|NCT03528408|Drug|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle
79477894|NCT05032664|Other|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
79477895|NCT05032664|Other|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
79643475|NCT03528408|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
79643476|NCT03527199|Diagnostic Test|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
79643477|NCT03514602|Behavioral|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
79643478|NCT03514602|Behavioral|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
79643479|NCT03501381|Drug|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
79317030|NCT06076525|Behavioral|Multidirectional Perturbations for Balance Control Assessment (150 perturbations)|The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
79317031|NCT06072313|Other|Monopolar electrical diathermy plus therapeutic exercise|The Experimental Group will undergo two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device and one session of therapeutic neck exercise per week.
79477896|NCT03589651|Drug|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
79477897|NCT03589651|Drug|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
79807812|NCT04164251|Other|Screening mammography|The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
79807813|NCT04164953|Procedure|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
79477898|NCT03589651|Drug|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
79477899|NCT03186677|Biological|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
79643480|NCT03501381|Drug|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
79643481|NCT03478566|Device|Transcutaneous CO2 monitoring|The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
79643482|NCT03475264|Diagnostic Test|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
79807814|NCT02639195|Other|Treatment|Retrospective chart review of patients treated with manual therapy.
79477900|NCT03186677|Biological|BeneFIX|BeneFIX 75 IU/kg, intravenous administration
79477901|NCT03769844|Drug|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity < 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
79477902|NCT02347345|Drug|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
79477903|NCT03319277|Other|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
79807815|NCT02881151|Device|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
79807816|NCT04164329|Drug|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
79643483|NCT03465618|Drug|89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
79643484|NCT03465618|Other|Blood and Urine samples|Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
79643485|NCT03451786|Device|IOL|Intraocular lens
79477904|NCT03319277|Other|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
79643486|NCT03406299|Drug|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
79643487|NCT03406299|Drug|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
79643488|NCT03406299|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
79643489|NCT03406299|Drug|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
79643490|NCT03406299|Drug|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
79643491|NCT03396445|Drug|Boserolimab|IV infusion
79643492|NCT03396445|Biological|Pembrolizumab|IV infusion
79477905|NCT03767426|Behavioral|Sleep Deprivation|Subjects are sleep deprived for an entire night
79643493|NCT03396445|Drug|Pemetrexed|IV infusion
79643494|NCT03396445|Drug|Carboplatin|IV infusion
79643495|NCT03396445|Drug|Nab-paclitaxel|IV infusion
79317032|NCT06072313|Other|Therapeutic Exercise|The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Participants will be asked to focus on their posture, joint positions and muscle tension in each exercise posture.
79477906|NCT03767426|Behavioral|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
79477907|NCT03323723|Device|SUI Device|Pessary SUI device
79477908|NCT00356564|Biological|hepatitis B vaccine|
79477909|NCT04624295|Drug|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
79643496|NCT03355469|Drug|Low Intensity Exercise + Metformin|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
79643497|NCT03355469|Drug|High Intensity Exercise + Metformin|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
79643498|NCT03355469|Drug|Low Intensity Exercise + Placebo|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
79317033|NCT06070584|Procedure|aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
79317034|NCT06063629|Procedure|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
79317035|NCT06063629|Procedure|No drain|No drain will be inserted into patients allocated to this group
79643499|NCT03355469|Drug|High Intensity Exercise + Placebo|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
79972948|NCT02501746|Other|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
79317036|NCT06062849|Device|nephrostomy tube|we will investigate if a nephrostomy tube really necessary after PNL operations
79317037|NCT06062849|Device|double J stent|we will investigate if a JJ stent really necessary after PNL operations
79317038|NCT06062849|Procedure|totally tubless|we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
79972949|NCT05704010|Device|Video capsule endoscopy|Video capsule endoscopy every 2 years
79317039|NCT06062641|Drug|SR-GDP|Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
79317040|NCT06054529|Procedure|Surgical removal of the GBM tumor|Surgical removal of the GBM tumor
79317041|NCT06054529|Other|d4-NAM infusion|Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
79317042|NCT06050512|Drug|Mezigdomide|Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
79317043|NCT06050512|Drug|Ixazomib|Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
79317044|NCT06050512|Drug|Dexamethasone|Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
79317045|NCT06032416|Radiation|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
79317046|NCT06029920|Other|Overground Walking|Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
79972950|NCT02507674|Device|ultrasound|
79972951|NCT03818867|Procedure|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
79972952|NCT03343366|Drug|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
79317047|NCT06029244|Device|EyeControl-Pro|Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
79317048|NCT06029244|Other|Control|No intervention
79643500|NCT03330028|Drug|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
79643501|NCT03330028|Drug|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
79972953|NCT03343366|Procedure|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
79972954|NCT03343366|Behavioral|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
79972955|NCT05044416|Device|VieScope|intubation with VieScope laryngoscope
79972956|NCT05044416|Device|Videolaryngoscopy|intubation with videolaryngoscope
79317049|NCT06025448|Procedure|BIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using bony lateralization (BIO-RSA).
79317050|NCT06025448|Procedure|MIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using metallic lateralization (MIO-RSA).
79317051|NCT06025331|Procedure|BIO-RSA|Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
79317052|NCT06025331|Procedure|RSA|Conventional reversed shoulder arthroplasty(RSA) will be performed.
79317053|NCT06008977|Other|Exercise Test|Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
79807817|NCT02800655|Device|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS"
79807818|NCT04164095|Procedure|lappg|Preservation of pylorus and vagus nerve by laparoscopy
79317054|NCT05998954|Procedure|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
79972957|NCT05622773|Other|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
79317055|NCT05998954|Procedure|suprainguinal fascia iliaca block|Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
79317056|NCT05989126|Drug|aflibercept 8 mg PFS|Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
79317057|NCT05977946|Device|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
79972958|NCT02507518|Procedure|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
79972959|NCT01298297|Drug|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
79972960|NCT01298297|Drug|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
79972961|NCT04498312|Other|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
79972962|NCT01300715|Procedure|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
79972963|NCT02674464|Behavioral|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as <140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
79972964|NCT02674464|Behavioral|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
79317058|NCT05968105|Procedure|Lateral Sagittal Infraclavicular Block|Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.
79477910|NCT04624295|Drug|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
79477911|NCT02348593|Drug|JZP-110|
79477912|NCT02348593|Drug|Placebo oral tablet|
79477913|NCT03323801|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
79477914|NCT04197908|Device|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
79643502|NCT03330028|Drug|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
79317059|NCT05968105|Procedure|Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
79317060|NCT05968105|Diagnostic Test|Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
79972965|NCT02674464|Behavioral|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
79317061|NCT05965687|Procedure|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
79317062|NCT05965687|Procedure|Nasal oxygen|For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
79317063|NCT05965687|Drug|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
79477915|NCT03721640|Other|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
79477916|NCT04450355|Drug|Nefopam 80mg/day|continuous nefopam infusion
79477917|NCT04450355|Drug|Normal saline|continuous normal saline infusion
79643503|NCT03330028|Drug|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
79643504|NCT03330028|Drug|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
79317064|NCT05965193|Device|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
79643505|NCT03330028|Drug|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
79972966|NCT02674464|Behavioral|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
79317065|NCT05965193|Device|Nasal oxygen|For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
79317066|NCT05965193|Drug|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
79317067|NCT05961293|Device|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
79317068|NCT05955495|Other|Food|Post-operative feeding includes water, liquid diet, soft diet.
79317069|NCT05950867|Diagnostic Test|ECG + echocardiography|Electrocardiogram and echocardiography
79317070|NCT05950867|Other|Answering questionnaires|Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
79317071|NCT05945264|Behavioral|Music Intervention (MI)|The intervention will involve listening, playing and/or singing melodies or songs, that are meaningful to the participant, with interpretation/reflection on their relevance/capacity to alter stress.
79317072|NCT05945264|Other|Sham Control (SC)|The intervention will be to support a woman to talk about anything she wants that is important to her.
79317073|NCT05938465|Biological|EXE-346|EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.
79317074|NCT05938465|Other|Placebo|Placebo contains excipients maltose and silicon dioxide.
79317075|NCT05937685|Behavioral|BP REACH Intervention|Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
79317076|NCT05925530|Drug|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
79317077|NCT05904470|Drug|Bemnifosbuvir|550 mg administered orally once a day (QD) for 8 weeks
79972967|NCT02674464|Behavioral|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
79972968|NCT02674464|Behavioral|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
79317078|NCT05904470|Drug|Ruzasvir|180 mg administered orally once a day (QD) for 8 weeks
79643506|NCT03313011|Diagnostic Test|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
79972969|NCT05525338|Drug|Alectinib|In case of an alectinib plasmaconcentration Cmin <435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
79972970|NCT04302467|Procedure|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
79972971|NCT03818945|Drug|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
79972972|NCT03818945|Drug|Sodium fluoride varnish|5% sodium fluoride [22,600 ppm F-]
79972973|NCT02501824|Other|anthroposophic therapeutic speech|anthroposophic therapeutic speech
79317079|NCT05901753|Device|Laryseal pro supra glottic device|The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
79972974|NCT05281289|Other|kinesio-tape|KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
79972975|NCT05281289|Other|stretching exercise|15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
79972976|NCT05281289|Other|instructions about dealing with calf cramps|instructions about dealing with calf cramps by self low sustained stretch of calf muscle
79972977|NCT02631798|Dietary Supplement|Food grade dye mucosal staining|mucosal staining with food grade dye
79972978|NCT03344068|Radiation|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
79972979|NCT03344068|Drug|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
79643507|NCT03311711|Behavioral|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
79317080|NCT05901753|Device|Laryngeal Mask Airway- Proseal™|The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
79317081|NCT05891587|Drug|Semaglutide|Semaglutide pen injector
79317082|NCT05891587|Drug|Placebo|Saline solution
79643508|NCT03311711|Behavioral|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
79972980|NCT03344068|Dietary Supplement|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
79972981|NCT01330056|Procedure|FOPS|"Functional organ preservation (FOPS) as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group."
79972982|NCT01330056|Radiation|CRT|"Concurrent chemoradiotherapy as a first-line treatment modality~Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
79972983|NCT01206335|Drug|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
79972984|NCT02562612|Drug|SM-88|Daily SM-88 in multiple ascending doses over 6 months
79972985|NCT02501356|Dietary Supplement|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
79972986|NCT02501356|Dietary Supplement|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
79972987|NCT03636516|Device|SWL|extracorporeal shockwave lithotripsy apply
79972988|NCT05622695|Device|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
79317083|NCT05891496|Drug|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
79317084|NCT05891496|Drug|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
79317085|NCT05888090|Other|Prone, right lateral, and semi-elevated supine positions|Each participant will be followed during three feedings and the prone, right lateral, and semi-elevated supine positions will be applied once.
79317086|NCT05888090|Other|Semi-elevated supine, prone, and right lateral positions|Each participant will be followed during three feedings and the semi-elevated supine, prone, and right lateral positions will be applied once.
79317087|NCT05888090|Other|Right lateral, semi-elevated supine, and prone positions|Each participant will be followed during three feedings and the right lateral, semi-elevated supine, and prone positions will be applied once.
79643509|NCT03311711|Behavioral|Usual care|Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
79643510|NCT03311555|Drug|Apalutamide|240mg tablet daily for 36 weeks
79972989|NCT03343990|Procedure|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
79972990|NCT03343990|Procedure|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
79972991|NCT03842423|Procedure|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
79972992|NCT03172026|Drug|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
79972993|NCT03172026|Behavioral|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
79972994|NCT03172026|Drug|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
79972995|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536|2 capsules od
79643511|NCT03311555|Drug|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
79317088|NCT05885997|Behavioral|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Program:~Patients are loaned a wireless home BP device or use their own device~Navigator or app support for onboarding and engaging patients in HBPM~Nursing or app support for monitoring and triaging home BP data for extreme readings~EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~Prompts and reminders to increase clinician referrals~Instructional materials for patients and clinicians~Problem-solving meetings to tailor implementation for individual practices"
79317089|NCT05885997|Other|Usual care|Usual care
79317090|NCT05881031|Other|Home Initiation of NiPPV|Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
79317091|NCT05880134|Procedure|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
79807819|NCT02637869|Other|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
79807820|NCT02639039|Drug|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
79807821|NCT02639039|Procedure|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
79807822|NCT00689728|Biological|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
79807823|NCT00689728|Drug|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
79807824|NCT02639117|Drug|Vismodegib|Vismodegib 150 mgs po qd for 3 months
79807825|NCT04163939|Other|Vista Therapy Collar|The patient will wear the cervical collar
79807826|NCT04163939|Other|Placebo|The patient will not wear the cervical collar
79807827|NCT00655265|Drug|Colesevelam hydrochloride film-coated tablets|tablets
79972996|NCT01201577|Dietary Supplement|Active hexose correlated compound (AHCC)|One capsule tds
79972997|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
79972998|NCT01201577|Dietary Supplement|Corn starch placebo capsule|One capsule tds and two capsules od
79807828|NCT00655265|Drug|Placebo|Tablets
79807829|NCT04163861|Diagnostic Test|2d speckle tracking echocardiography|2d speckle tracking echocardiography
79807830|NCT04163861|Diagnostic Test|serum BNP level|serum BNP level of HFpEF study subjects
79317092|NCT05880134|Procedure|cartilage graft reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day"
79317093|NCT05869071|Device|Sensor analyzing software (own development)|A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
79317094|NCT05869071|Device|Body plethysmograph|Body plethysmograph measures specific airway resistance
79317095|NCT05859178|Other|Exercise group|Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.
79317096|NCT05848778|Device|Acute Intermittent Hypoxia|The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)
79317097|NCT05848778|Device|Normoxia|The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
79317098|NCT05847543|Other|Stool diaper data and sample collection|Stool diaper data and sample collection
79317099|NCT05845593|Other|Decision Support Test|LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
79317100|NCT05842044|Drug|Ketorolac|15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
79477918|NCT02349685|Procedure|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute [amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC > 1.0 μ g / ml; metronidazole (MET), MIC > 8 μ g / ml; tetracycline (TC), MIC > 4 μ g / ml; and moxifloxacin (MOX), MIC > 1 μ g / ml).
79643512|NCT03311555|Radiation|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
79643513|NCT03311555|Drug|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
79643514|NCT03278366|Behavioral|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
79643515|NCT03271866|Drug|metformin|metformin 1500mg per day
79643516|NCT03270891|Diagnostic Test|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
79643517|NCT03217565|Drug|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
79972999|NCT01201577|Drug|Azithromycin|250mg od
79973000|NCT02496520|Biological|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
79973001|NCT02496520|Procedure|Surgery as needed by the patient´s tumor and stage|
79973002|NCT02496520|Drug|Chemotherapy as needed by the patient´s tumor and stage|
79643518|NCT03217565|Drug|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
79643519|NCT03190382|Other|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
79317101|NCT05842044|Drug|Acetaminophen|1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
79317102|NCT05842044|Drug|Oxycodone|"Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization."
79317103|NCT05842044|Drug|Hydromorphone|Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
79317104|NCT05842044|Drug|Ibuprofen|400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
79317105|NCT05839951|Drug|Regorafenib (BAY73-4506, Stivarga®)|Oral multitargeted kinase inhibitor
79317106|NCT05839951|Drug|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Oral cytotoxic chemotherapy
79317107|NCT05839951|Drug|Bevacizumab|VEGFR inhibitor
79643520|NCT03019328|Other|Peanut in diet|
79643521|NCT02992743|Drug|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
79643522|NCT02992743|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
79643523|NCT02992743|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
79643524|NCT02927912|Radiation|Electron Beam Therapy|Undergo IOERT boost
79643525|NCT02927912|Procedure|Lumpectomy|Undergo lumpectomy
79643526|NCT02927912|Other|Quality-of-Life Assessment|Ancillary studies
79643527|NCT02927912|Other|Questionnaire Administration|Ancillary studies
79643528|NCT02927912|Radiation|Radiation Therapy|Undergo whole breast radiation therapy
79807831|NCT02638961|Other|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
79807832|NCT02638961|Other|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
79643529|NCT02927912|Procedure|Reconstructive Surgery|Undergo oncoplastic reconstruction
79807833|NCT02638961|Other|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
79807834|NCT02562586|Device|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
79973003|NCT02496520|Radiation|Radiation therapy as needed by the patient´s tumor and stage|
79317108|NCT05833373|Device|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
79317109|NCT05833373|Device|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
79317110|NCT05793320|Procedure|Carpal Tunnel Release Surgery|Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
79317111|NCT05786274|Diagnostic Test|Cerebral autoregulation monitoring|Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
79317112|NCT05785585|Dietary Supplement|Methylcobalamin|Treatment with Methylcobalamin during 12 weeks
79317113|NCT05785585|Dietary Supplement|Cyanocobalamin group|Treatment with Cyanocobalamin during 12 weeks
79477919|NCT02349685|Drug|14 day PBMT group|Rescue therapy using 14 day PBMT regimen [Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d]
79317114|NCT05785585|Dietary Supplement|Control group|Treatment with microcrystalline cellulose during 12 weeks
79477920|NCT02349685|Drug|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
79477921|NCT03676010|Other|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
79807835|NCT02562664|Drug|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
79973004|NCT03058770|Other|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
79973005|NCT03058770|Other|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
79973006|NCT01298609|Device|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
79643530|NCT02853344|Biological|Pembrolizumab|IV infusion
79643531|NCT02739620|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
79643532|NCT02738229|Drug|Valacyclovir|
79643533|NCT02738229|Drug|placebo|
79655728|NCT04552639|Behavioral|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
79655729|NCT04552639|Behavioral|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
79655730|NCT04552405|Dietary Supplement|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
79655731|NCT00269022|Drug|SB-705498|
79643534|NCT02722486|Device|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
79317115|NCT05780892|Behavioral|Emotional Wellbeing|Participants in this intervention will learn cognitive behavioral therapy tools to identify unhelpful beliefs and thought patterns, increase motivation through SMART goal making, and increase relaxation and stress management techniques through deep breathing, progressive muscle relaxation and pleasant activity scheduling. Additionally, participants will learn acceptance and commitment therapy tools to increase cognitive flexibility and resilience through acceptance and diffusion work, being present through contact with present moment and self as context and doing what matters through committed actions and value identification.
79317116|NCT05780892|Behavioral|EHR Skills Optimization|Participants in this intervention will learn how to better utilize the EHR by gaining knowledge and skills in the EHR. Session topics include, but are not limited to, understanding current usage patterns and behaviors in the EHR, optimization of the table of contents for easier chart navigation, integration of specialty-focused workflows with current EHR documentation and chart review tools, and recommendations to be more efficient and reduce amount of time spent in the EHR.
79317117|NCT05780892|Behavioral|Performance Improvement|This intervention focuses on improving participants perception of Keck Medicine as a positive workplace environment by supporting participants in gaining basic performance improvement knowledge and skills through didactic training, group discussions based on sociocultural learning theory, and hands on practice leading a performance improvement project. Sessions will review performance improvement concepts such as Lean wastes, systems thinking, change management and sustainability. Participants in this intervention will then identify a project area of focus that they want to improve and develop a project charter. Once a project area has been identified, participants will be put into breakout rooms to discuss successes and challenges as well as receive feedback on their project from peers.
79643535|NCT02722486|Other|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
79643536|NCT02675426|Drug|Placebo|Tablet; Oral
79643537|NCT02675426|Drug|Upadacitinib|Tablet; Oral
79317118|NCT05780892|Behavioral|control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
79317119|NCT05778760|Other|Retinol|Topical retinol (0.5%) applied to the face
79317120|NCT05778760|Other|Adapinoid|Topical Adapinoid (0.5%) applied to the face
79317121|NCT05777941|Other|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied.
79643538|NCT02656433|Device|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
79317122|NCT05762263|Behavioral|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
79643539|NCT02656433|Other|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
79643540|NCT02647294|Dietary Supplement|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
79477922|NCT03676010|Other|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
79643541|NCT02647294|Other|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
79807836|NCT02562664|Drug|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
79643542|NCT02631837|Procedure|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
79643543|NCT02631837|Procedure|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
79643544|NCT02579473|Drug|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
79643545|NCT02526511|Procedure|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
79317123|NCT05757908|Drug|Long-Acting Beta Agonist|The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
79317124|NCT05753891|Device|Suture Tape Reconstruction|This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
79317125|NCT05729256|Behavioral|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
79317126|NCT05729256|Behavioral|Brief Advice and Information|Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
79317127|NCT05727878|Drug|KPI-012|KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
79317128|NCT05727878|Drug|KPI-012 Vehicle|KPI-012 formulation with no active drug
79807837|NCT02562664|Drug|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
79973007|NCT04496050|Drug|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
79973008|NCT01300793|Drug|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 & 11 q. 28 days.
79807838|NCT02635919|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
79317129|NCT05720039|Device|Robotic NSM|Robotic-assisted Nipple sparing mastectomy procedures
79973009|NCT03342040|Procedure|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
79973010|NCT03342040|Procedure|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
79317130|NCT05720039|Procedure|Open NSM|open nipple-sparing mastectomy procedures
79807839|NCT02564614|Drug|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
79317131|NCT05704257|Device|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
79317132|NCT05697094|Behavioral|Meditation to Remove Stress and Create A Proper System in Mind|Meditation to Remove Stress and Create A Proper System in Mind is a guided meditation.
79973011|NCT02495974|Drug|enzalutamide|oral
79973012|NCT01206413|Dietary Supplement|Low glycemic index diet|
79973013|NCT01206413|Dietary Supplement|High glycemic index diet|
79973014|NCT01206413|Other|Home-based exercise intervention|
79317133|NCT05685368|Behavioral|ACT for Race Related Stress|This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
79317134|NCT05680597|Other|Balance Tele-Rehabilitation Agility Boot Camp (ABC)|The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
79317135|NCT05676593|Device|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
79807840|NCT04164017|Device|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
79973015|NCT01206413|Other|Non-exercisers|
79973016|NCT03818633|Device|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
79973017|NCT03818789|Behavioral|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
79973018|NCT03818789|Behavioral|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
79973019|NCT03337048|Device|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
79317136|NCT05676593|Other|Therapeutic education|Therapeutic education
79317137|NCT05667116|Drug|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
79317138|NCT05666258|Diagnostic Test|GEP|GEP before surgery to determine need for neoadjuvant chemotherapy
79317139|NCT05660265|Drug|GSK4172239D|Different strength of GSK4172239D will be administered in different cohorts.
79317140|NCT05660265|Other|Placebo|Matching placebo will be administered.
79317141|NCT05655312|Drug|[203Pb]VMT01|[203Pb]VMT01 IV administered as Image agent for SPECT/CT
79317142|NCT05655312|Drug|[212Pb]VMT01|Patients with positive uptake of [203Pb]VMT01 will receive a fixed dose of [212Pb]VMT01 IV administered every 8 weeks for a maximum of three doses. Doses range between 111 MBq to 555 MBq (3 mCi to 15 mCi)
79317143|NCT05655312|Drug|[212Pb]VMT01|Patients with positive update of [203Pb]VMT01 will receive a fixed dose of [212Pb]VMT01 IV administered every 8 weeks at the RPh2D and schedule determined in Phase I dose escalation
79317144|NCT05647850|Other|No intervention|No intervention
79317145|NCT05641311|Drug|ALXN1840|Tablet for oral use.
79477923|NCT03676010|Other|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
79973020|NCT03120364|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
79973021|NCT03120364|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
79973022|NCT01298843|Drug|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
79973023|NCT03336970|Other|EDTA|
79973024|NCT03336970|Other|NaOCl|
79973025|NCT03336970|Other|CHX|
79973026|NCT03336970|Other|Calcium hydroxide|
79807841|NCT04164017|Device|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
79807842|NCT04060576|Procedure|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
79807843|NCT04060576|Procedure|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
79807844|NCT04060576|Procedure|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
79973027|NCT01567319|Biological|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
79317146|NCT05639231|Behavioral|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:~PATIENTS:~Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).~Customizable diary to document mobility goals, results, difficulties and needs.~Exercise booklet with explanations & pictures of mobility exercises (supine, sitting, standing).~iPad 10.2'' with videos of the exercises.~HCPs (physicians & nursing staff):~E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication & interdisciplinary collaboration regarding mobility; implementation.~Oral presentation on the intervention.~Checklist to remind HCPs to address mobility.~ENVIRONMENT:~Posters in the wards about mobility and other topics of interest to older adults.~Walking itineraries in the wards."
79317147|NCT05638373|Other|One shade universal composite|A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
79317148|NCT05638373|Other|Nanohybrid resin composite|A conventional resin composite with multiple shades
79973028|NCT01567319|Biological|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
79477924|NCT03676010|Other|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
79973029|NCT01567319|Biological|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
79807845|NCT02635763|Procedure|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
79807846|NCT02635763|Procedure|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
79807847|NCT04060498|Behavioral|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
79807848|NCT04060498|Behavioral|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
79807849|NCT00654407|Drug|Rosuvastatin|
79807850|NCT00654407|Drug|Atorvastatin|
79477925|NCT03676010|Other|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
79643546|NCT02526511|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
79807851|NCT00654407|Drug|Simvastatin|
79807852|NCT00691054|Drug|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
79643547|NCT02526511|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
79643548|NCT02526511|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
79643549|NCT02503475|Other|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
79643550|NCT02503475|Behavioral|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
79807853|NCT00748696|Dietary Supplement|Fortimel Extra®|260kcal and 20g protein per day
79807854|NCT00748696|Other|resistance training|3 sessions of resistance training per week
79807855|NCT00748696|Other|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
79807856|NCT02563756|Procedure|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
79807857|NCT02563756|Procedure|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
79807858|NCT00598871|Drug|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
79807859|NCT00598871|Other|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
79643551|NCT02503475|Device|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
79643552|NCT02401035|Drug|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
79643553|NCT02313623|Procedure|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
79643554|NCT02153944|Drug|Propranolol|Propranolol 40 mg was given orally during study visit
79807860|NCT00744406|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
79807861|NCT00744406|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
79807862|NCT00744406|Drug|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
79807863|NCT00748774|Behavioral|Questionnaire|Two questionnaires taking about 10 minutes to complete.
79807864|NCT00748930|Other|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
79807865|NCT00741520|Device|CPAP|Control - no treatment
79973030|NCT03829163|Device|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
79973031|NCT03829163|Device|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
79477926|NCT03676010|Other|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
79477927|NCT03326843|Drug|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
79973032|NCT01343888|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
79973033|NCT01343888|Drug|BI 201335|BI 201335 once daily high dose
79973034|NCT01343888|Drug|BI 201335|BI 201335 once daily low dose
79973035|NCT01343888|Drug|Placebo|
79973036|NCT03336892|Behavioral|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
79973037|NCT03829085|Other|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
79973038|NCT02495740|Behavioral|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
79973039|NCT04185389|Other|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
79477928|NCT02352259|Procedure|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
79477929|NCT02352259|Device|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
79973040|NCT03336814|Drug|Terlipressin|Administration of terlipressine
79973041|NCT03336814|Other|Placebo|Administration of placebo
79477930|NCT02352259|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
79477931|NCT04155866|Other|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
79477932|NCT02354443|Biological|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
79643555|NCT02153944|Drug|Methylphenidate|Methylphenidate 20mg was given orally during study visit
79643556|NCT02153944|Drug|Placebo|Placebo was given orally during study visit
79973042|NCT03818555|Other|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
79973043|NCT02495584|Dietary Supplement|Fortified milk (10µg vitamin D3)|
79973044|NCT02495584|Dietary Supplement|Unfortified milk (placebo)|
79973045|NCT02495584|Dietary Supplement|10µg vitamin D3 supplement|
79317149|NCT05638204|Behavioral|Suicidal Crisis Intervention (SCI)|This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley & Brown, 2012) and continuity of care.
79643557|NCT02060721|Drug|Macitentan|Macitentan 10mg, oral tablet, once daily
79317150|NCT05635214|Procedure|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
79643558|NCT02060630|Procedure|Open surgical revascularization|
79973046|NCT02495584|Dietary Supplement|Placebo supplement|
79317151|NCT05634525|Drug|MRTX849|Given By PO
79973047|NCT03828851|Other|Domiciliary care - Activities of Daily Living|Home-based ADL training.
79973048|NCT03336736|Diagnostic Test|Exercise|"The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires."
79973049|NCT05623904|Procedure|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
79973050|NCT05623904|Drug|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP < 140 mmHg, HDL < 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
79643559|NCT02060630|Device|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
79643560|NCT01782027|Drug|3H-cholesterol bound to albumin|up to 100 uCi of [3H]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
79643561|NCT01565187|Behavioral|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
79643562|NCT01359956|Drug|Dacarbazine|900 mg / m2 every 3 weeks
79643563|NCT01359956|Drug|Fotemustine|100 mg / m2 every 3 weeks
79643564|NCT01359956|Drug|Interferon Alfa-2b|5 M units every 3 weeks
79973051|NCT03589807|Biological|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
79973052|NCT03589807|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
79973053|NCT03589807|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
79643565|NCT01306045|Drug|AZD6244|Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
79643566|NCT01306045|Drug|MK-2206|Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
79643567|NCT01306045|Drug|Lapatinib|Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
79643568|NCT01306045|Drug|Erlotinib|Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
79643569|NCT01306045|Drug|Sunitinib|Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
79643570|NCT01306045|Procedure|Molecular Profiling|Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
79643571|NCT01278303|Device|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
79317152|NCT05633225|Other|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
79317153|NCT05633082|Device|Lens 1 (omafilcon B)|Toric daily wear contact lens for 15 minutes
79317154|NCT05633082|Device|Lens 2 (fanfilcon A)|Toric daily wear contact lens for 15 minutes
79643572|NCT01196936|Drug|Tamoxifen Citrate|5 mg PO Daily
79973054|NCT03589807|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
79973055|NCT02495818|Procedure|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
79973056|NCT02495818|Procedure|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
79973057|NCT02495818|Other|Homemade exercises|Codman and Hughston exercises.
79973058|NCT01201733|Other|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
79973059|NCT01201733|Other|Ultrasound therapy and hot pack|
79973060|NCT02495662|Drug|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
79973061|NCT02495662|Drug|Placebo|0.9% normal saline
79317155|NCT05619237|Device|NanoSALV Catalytic|NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
79317156|NCT05613972|Other|Brief Suicide and Trauma Therapy|12-week trauma therapy
79317157|NCT05594147|Drug|Non-TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
79317158|NCT05594147|Drug|Other TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
79317159|NCT05594147|Drug|Regorafenib (Stivarga, BAY73- 4506)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
79317160|NCT05594147|Drug|Sorafenib (Nexavar, BAY43-9006)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
79643573|NCT01196936|Drug|Placebo|1 tablet daily
79643574|NCT01196936|Procedure|Digital mammography|Correlative studies
79643575|NCT01196936|Other|immunohistochemistry staining method|Correlative Studies
79643576|NCT01196936|Other|pharmacological study|Correlative Studies
79643577|NCT01196936|Other|laboratory biomarker analysis|Correlative Studies
79643578|NCT01196936|Genetic|protein expression analysis|correlative studies
79643579|NCT01196936|Other|pharmacogenomic studies|correlative studies
79643580|NCT01196936|Other|questionnaire administration|Ancillary studies
79973062|NCT03827915|Device|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
79973063|NCT05702060|Procedure|Radial Artery Puncture Method for Coronary Angiography and Intervention|Radial Artery Puncture Method for Coronary Angiography and Intervention
79807866|NCT00741520|Device|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
79807867|NCT00744562|Drug|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
79807868|NCT00690820|Drug|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
79807869|NCT00690820|Drug|Placebo Comparator|Placebo
79317161|NCT05592613|Device|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
79317162|NCT05592613|Drug|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
79317163|NCT05592613|Drug|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
79317164|NCT05592600|Behavioral|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
79317165|NCT05591105|Drug|Control Group|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
79317166|NCT05591105|Drug|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
79317167|NCT05590832|Behavioral|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
79317168|NCT05583435|Behavioral|One-on-one professional coaching|One-on-one professional coaching
79317169|NCT05583435|Behavioral|Small-group professional coaching|Small-group professional coaching
79317170|NCT05583006|Drug|tenofovir alafenamide (TAF)|TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
79317171|NCT05580107|Drug|MDPK67b|24 mg or 48 mg
79317172|NCT05573126|Drug|EP0062|EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
79317173|NCT05567601|Drug|DOXIL/CAELYX|40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
79477933|NCT03326999|Drug|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
79477934|NCT03326999|Drug|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
79807870|NCT00741676|Procedure|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
79807871|NCT00741676|Procedure|open distal gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
79973064|NCT02496052|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
79477935|NCT03326999|Drug|Saline|Saline as placebo comparator
79477936|NCT04146194|Other|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
79477937|NCT04952870|Other|Inhaled NO|Newborn or young infants (< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
79477938|NCT04952870|Other|routine care|Patients treated for respiratory failure
79477939|NCT02397265|Device|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
79973065|NCT02496052|Device|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
79973066|NCT02496052|Drug|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
79477940|NCT02397265|Device|Standard opened loop pump|Using a standard opened loop pump
79973067|NCT01206569|Drug|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
79643581|NCT01196936|Procedure|Fine needle aspiration|
79317174|NCT05567055|Drug|Capmatinib|Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
79973068|NCT03544333|Device|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
79317175|NCT05566002|Diagnostic Test|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP >20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
79317176|NCT05565586|Dietary Supplement|High-Fiber Diet (HFD)|Participants are assigned to the high fiber diet, all meals and snacks will be provided to participants during the study. This diet includes fruits, vegetables and whole grains, a maximum of 18 oz. cooked red meat (including beef, pork, and lamb) per week, and little or no processed meats or added sugars.
79317177|NCT05565586|Dietary Supplement|Prebiotic Food-Enriched Diet (PreFED)|Participants are assigned to the prebiotic food enriched diet, participants will receive 2 prepared snacks and 1 meal component (a key prebiotic ingredient to incorporate into meals and simple recipes) each day. Participants will also receive a handout that includes key prebiotic foods to incorporate into your own diet.
79973069|NCT01206647|Drug|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
79317178|NCT05558007|Drug|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
79317179|NCT05558007|Drug|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
79477941|NCT02397265|Device|Insulin closed loop|Using a closed loop
79477942|NCT04948580|Behavioral|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
79477943|NCT02959489|Behavioral|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
79477944|NCT02959489|Behavioral|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
79477945|NCT02979314|Device|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
79477946|NCT03328949|Device|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
79477947|NCT00356642|Drug|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
79477948|NCT00356642|Drug|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
79477949|NCT00356720|Drug|Azithromycin|
79643582|NCT01196936|Other|Quality of Life Assessment|Ancillary Studies
79643583|NCT01075971|Drug|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
79973070|NCT02495506|Other|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
79973071|NCT02495506|Other|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
79973072|NCT05599256|Drug|Ruxolitinib|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight > 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
79317180|NCT05558007|Drug|Oral Placebo|Oral administration of a placebo pill
79643584|NCT01075971|Drug|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
79317181|NCT05558007|Drug|Topical Placebo|Topical application of 1.5 mL of placebo
79317182|NCT05555550|Drug|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
79643585|NCT00775749|Drug|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
79317183|NCT05543187|Drug|TAK-625|TAK-625 orally, twice daily (BID)
79317184|NCT05543174|Drug|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
79643586|NCT00775749|Drug|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
79807872|NCT02562508|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
79317185|NCT05532007|Dietary Supplement|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
79317186|NCT05532007|Other|Habitual Diet|continue with habitual diet and abstain from eating peanuts
79807873|NCT02562508|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
79807874|NCT02562352|Other|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
79317187|NCT05528263|Device|Acupuncture|Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
79317188|NCT05528263|Other|Nature scenery with a relaxation exercise|Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
79317189|NCT05514587|Behavioral|Meaning of Life Questionnaire (MLQ)|Completion of questionnaires at crisis centre entry and 3 months later.
79643587|NCT00338065|Behavioral|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
79643588|NCT00338065|Behavioral|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
79643589|NCT00324922|Drug|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
79807875|NCT00749086|Device|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
79317190|NCT05502289|Device|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
79317191|NCT05502289|Device|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
79317192|NCT05497726|Procedure|Sentinel lymph node detection using intravenous bevacizumab-800CW|Sentinel lymph node detection using intravenous bevacizumab-800CW
79317193|NCT05494060|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
79317194|NCT05494060|Drug|Penpulimab Injection|Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
79317195|NCT05494060|Drug|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
79477950|NCT03330041|Device|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
79643590|NCT00324922|Drug|vancomycin|1g iv bid
79643591|NCT00192816|Behavioral|reaction to pain|
79643592|NCT05380102|Device|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
79655732|NCT00236210|Behavioral|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
79973073|NCT03336580|Drug|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
79477951|NCT04121780|Biological|Growth Hormone|"Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase"
79477952|NCT04121780|Other|Placebo|"Daily self-injections by subjects:~1-year double-blind phase"
79477953|NCT00375869|Drug|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
79477954|NCT00375869|Drug|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
79643593|NCT05380102|Device|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
79477955|NCT00356798|Biological|an inactivated whole virion H5N1 vaccine, adjuvanted|
79477956|NCT03198221|Drug|Golytely|bowel preparation
79477957|NCT03198221|Drug|Clenpiq|bowel preparation
79807876|NCT00749086|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
79477958|NCT05723120|Other|Assessment Respiratory and Neuromuscular|Comparative Score
79973074|NCT03726541|Other|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
79643594|NCT05380102|Device|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
79643595|NCT00163709|Procedure|BNP test|
79643596|NCT05377879|Device|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
79477959|NCT03674996|Other|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
79643597|NCT05356975|Behavioral|Superset|"A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~One leg squat, side plank, and push up.~Deadlift, lumbar extension stretch, and row.~Glute bridge, crunches, and front raise."
79643598|NCT05356975|Behavioral|Concurrent|Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
79973075|NCT03814655|Procedure|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
79973076|NCT03814655|Procedure|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
79477960|NCT03674996|Other|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
79477961|NCT03674996|Other|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
79477962|NCT03203681|Drug|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
79477963|NCT03207035|Procedure|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
79477964|NCT05993962|Dietary Supplement|Fortified yoghurt|Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
79477965|NCT05993962|Other|Control yoghurt|Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
79477966|NCT05993923|Other|GPOU|"Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure.~Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report"
79477967|NCT05993910|Other|Hyperthermie Register|"die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~die Dauer der Anwendung und~die simultane Therapie mit Chemo- und/oder Strahlentherapie"
79643599|NCT00192855|Drug|Entacapone|Entacapone 600mg BID
79643600|NCT00407186|Drug|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
79643601|NCT00407186|Radiation|radiotherapy|45 Gy in 25 fracions (5 days/week)
79317196|NCT05490121|Other|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
79317197|NCT05478707|Drug|Dulaglutide|GLP1-RA
79317198|NCT05478707|Drug|Placebo|Saline placebo
79317199|NCT05478707|Behavioral|exercise training|supervised high intensity interval training
79317200|NCT05476718|Other|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
79807877|NCT00749164|Procedure|MSC transplantation|1-2X10^6 MSC per kg
79317201|NCT05476718|Other|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
79317202|NCT05469347|Drug|Alirocumab|A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
79807878|NCT00689338|Drug|Anidulafungin|Anidulafungin Intravenous Administration
79807879|NCT00689338|Drug|Fluconazole|Oral Administration of Fluconazole
79477968|NCT05993897|Drug|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|10 mg of Dapagliflozin orally once daily
79807880|NCT00689338|Drug|Voriconazole|Oral Administration of Voriconazole
79807881|NCT00749242|Other|orthopedic brace|antalgic drugs and orthopedic brace
79807882|NCT00749242|Device|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
79807883|NCT00686998|Drug|AZD2624|Oral Suspension
79317203|NCT05469347|Drug|Placebo|A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
79317204|NCT05462938|Drug|Continuous infusion of propofol|Sedation under continuous infusion of propofol. Small doses of fentanyl will be administered if needed.
79317205|NCT05462938|Drug|Continuous infusion of dexmedetomidine|Sedation under continuous infusion of dexmedetomidine. Small doses of fentanyl will be administered if needed.
79317206|NCT05459935|Device|PBM Tonsil Arm|exposure of hypertrophic tonsils to photobiomodulation
79317207|NCT05459935|Device|Sham PBM Tonsil Arm|non-powered exposure of hypertrophic tonsils to photobiomodulation
79317208|NCT05456542|Diagnostic Test|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
79317209|NCT05456542|Drug|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
79317210|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of tobacco flavored protonated e-liquid
79317211|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of unflavored protonated e-liquid
79317212|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of tobacco flavored unprotonated cigarette
79317213|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of unfavored unprotonated cigarette
79317214|NCT05455086|Procedure|Computed Tomography|Undergo PET/CT
79317215|NCT05455086|Procedure|Positron Emission Tomography|Undergo PET/CT
79317216|NCT05455086|Other|Questionnaire Administration|Ancillary studies
79643602|NCT00407186|Drug|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
79643603|NCT00553111|Other|educational video|educational video
79807884|NCT00686998|Drug|Olanzapine|PO BID
79807885|NCT00686998|Drug|Placebo|
79973077|NCT03341884|Drug|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
79317217|NCT05453968|Drug|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
79317218|NCT05452239|Drug|Eptinezumab|Solution for infusion
79317219|NCT05452239|Drug|Placebo|Solution for infusion
79317220|NCT05445921|Drug|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
79317221|NCT05444478|Procedure|Microwave ablation|only microwave ablation for tumor
79317222|NCT05444478|Drug|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight >60 kg)
79807886|NCT00744640|Drug|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
79807887|NCT00749320|Other|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
79317223|NCT05436444|Biological|A/Mallard/Ohio-99/MM4/1989 H10N7|The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
79643604|NCT05335720|Drug|rhEGF|EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
79807888|NCT00848718|Drug|MK-2206|MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
79807889|NCT00848718|Drug|docetaxel|Administered as an IV infusion on Day 1 of each 21-day cycle
79807890|NCT00848718|Drug|erlotinib|Administered daily (QD) PO in each 21-day cycle
79807891|NCT00848718|Drug|carboplatin|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
79807892|NCT00848718|Drug|paclitaxel|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
79807893|NCT00848718|Drug|corticosteroid|Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
79807894|NCT02612844|Drug|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
79807895|NCT02612844|Drug|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
79317224|NCT05434637|Other|Physical Therapy|Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
79317225|NCT05434637|Other|Sound-based Therapy|Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
79317226|NCT05434637|Other|Combination Therapy|Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
79317227|NCT05424120|Procedure|Manual aspiration|One option from standard of care
79317228|NCT05424120|Procedure|Wall suction|One option from standard of care
79317229|NCT05424120|Procedure|Vacuum bottle drainage|One option from standard of care
79643605|NCT00163748|Drug|gemcitabine, vinorelbine|
79643606|NCT00192933|Procedure|NovoSeven treatment according to guideline|
79643607|NCT05298241|Other|Hand-grip Strength Game|Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
79643608|NCT00163787|Behavioral|outcome measures and self report|
79643609|NCT00192972|Procedure|Catheter ablation (pulmonary vein isolation)|
79643610|NCT05295199|Other|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
79643611|NCT05283343|Device|SP-1P|A subject undergoes corneal thickness measurement with pachymeter.
79807896|NCT00883337|Drug|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
79807897|NCT00883337|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
79807898|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
79807899|NCT00838110|Drug|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
79807900|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
79807901|NCT00838110|Drug|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
79807902|NCT04163783|Drug|[14C]-BGB-3111|20-mg capsule containing ~200 μCi of [14C]-BGB-3111,
79807903|NCT04163783|Drug|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
79807904|NCT00654485|Drug|Rosuvastatin|
79643612|NCT05277961|Radiation|Ultraviolet radiation|UV6 tubes
79643613|NCT00193011|Drug|Docetaxel|Docetaxel
79643614|NCT00193011|Drug|Cyclophosphamide|Cyclophosphamide
79643615|NCT00193011|Drug|Methotrexate|Methotrexate
79807905|NCT00654485|Drug|Atorvastatin|
79317230|NCT05419232|Other|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
79317231|NCT05419232|Other|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
79317232|NCT05384665|Drug|Remifentanil|REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
79317233|NCT05384665|Drug|Sufentanil|SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
79317234|NCT05384665|Drug|Placebo|PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
79643616|NCT00193011|Drug|5-Fluorouracil|5-Fluorouracil
79643617|NCT05276791|Other|EMR|Endoscopic mucosal resection, according to standard care
79643618|NCT05276791|Other|ESD|Endoscopic submucosal dissection, according to standard care
79643619|NCT05272228|Dietary Supplement|Dietary supplement - standard product|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
79643620|NCT05272228|Dietary Supplement|Dietary supplement - Investigational product IP1|Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10
79643621|NCT05272228|Dietary Supplement|Dietary supplement - Investigational product IP2|Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
79643622|NCT00193089|Drug|Docetaxel|Docetaxel
79643623|NCT00193089|Drug|Vinorelbine|Vinorelbine
79643624|NCT00193089|Drug|Trastuzumab|Trastuzumab
79807906|NCT00655343|Drug|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
79643625|NCT04724057|Device|AutocathFFR|The MedHub Autocath FFR device is a software only medical device. The FFR is computed from several standard DICOM format 2D angiography images retrieved from the C-arm imaging system, which display the structure of the vessels. The MedHub AutocathFFR device software analyzes these images and automatically (without the need for user selection or markings) and computes and displays the FFR on the viewed blood vessel.
79643626|NCT05260216|Combination Product|Comprehensive prevention and treatment|Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.
79317235|NCT05371886|Other|Dose-effect relationship of morphine +/- midazolam administration|Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
79317236|NCT05363904|Other|Observation|Questionnaires, Clinical Scores, Biomaterial Sampling
79317237|NCT05361382|Drug|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
79973078|NCT05358899|Device|accelerated theta burst stimulation|cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).
79317238|NCT05361382|Drug|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
79317239|NCT05361382|Drug|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
79317240|NCT05350696|Drug|Erector Spinae plane block (plain pubivicaine)|"The erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process .~The technique is performed under ultrasound guidance."
79317241|NCT05350696|Drug|Intravenous morphine group|patients will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
79973079|NCT05358899|Device|Sham stimulation|Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.
79317242|NCT05343182|Other|Modified Technique|This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
79317243|NCT05343182|Other|Traditional Technique|This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
79317244|NCT05339360|Procedure|Femoral fixation with intramedullary nails|Femoral fracture fixation Femoral Osteotomy
79973080|NCT02495194|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
79317245|NCT05337553|Drug|taldefgrobep alfa|DB Phase: 35 mg/50 mg weekly subcutaneous injection
79317246|NCT05337553|Drug|Placebo|DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
79317247|NCT05337553|Drug|taldefgrobep alfa|Extension Phase: 35 mg/50 mg weekly subcutaneous injection
79317248|NCT05336383|Drug|Radiation Therapy|Given by Infusion
79655733|NCT00236210|Behavioral|VIP program|Risk assessment, lifestyle counselling, exercise program
79973081|NCT03827837|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
79973082|NCT03827837|Drug|Famitinib|a small-molecule multikinase inhibitor
79973083|NCT03560245|Drug|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
79973084|NCT03560245|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
79973085|NCT03336424|Diagnostic Test|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
79973086|NCT03336424|Diagnostic Test|Invasive investigations|Cystomanometry, pressure flow study, EMG
79973087|NCT02495272|Drug|Oxytocin|Oxytocin 10IU Administered intramuscularly.
79973088|NCT03814811|Diagnostic Test|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
79973089|NCT03336346|Drug|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
79973090|NCT03336346|Device|ENG implant|Reversible contraception implant
79973091|NCT03336346|Drug|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
79973092|NCT03841292|Drug|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
79317249|NCT05336266|Drug|Ketorolac Tromethamine|Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
79317250|NCT05333939|Dietary Supplement|Moringa leaf powder|capsule ingestion
79317251|NCT05333939|Other|Placebo|capsule ingestion
79317252|NCT05329038|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
79317253|NCT05321394|Drug|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
79317254|NCT05321394|Drug|Tixagevimab Cilgavimab|"2 subsequent injections:~tixagevimab 300mg/3mL (100mg/mL)~cilgavimab 300mg/3mL (100mg/mL)"
79317255|NCT05321394|Drug|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
79317256|NCT05304065|Behavioral|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
79643627|NCT05260216|Combination Product|Routine prevention|Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
79643628|NCT05256082|Diagnostic Test|six-minutes-walking test|Patients conducting a six-minutes-walking test
79643629|NCT00193167|Drug|Topotecan|
79643630|NCT00163904|Behavioral|High mono-unsaturated fat/low carbohydrate diet|
79643631|NCT00163904|Behavioral|High carbohydrate/low fat diet|
79973093|NCT03841292|Device|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
79973094|NCT03841292|Device|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
79973095|NCT05659199|Device|extracorporeal shockwave|Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
79973096|NCT05659199|Behavioral|myofascial release|pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
79973097|NCT02495350|Other|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
79643632|NCT00193245|Drug|Topotecan|
79643633|NCT00193245|Drug|Docetaxel|
79643634|NCT00163943|Behavioral|Dietary weight loss +/- aerobic exercise|
79643635|NCT00193284|Drug|Gefitinib|
79643636|NCT00193284|Drug|Docetaxel|
79643637|NCT00193284|Drug|Carboplatin|
79643638|NCT00193284|Drug|Fluorouracil|
79973098|NCT04805996|Behavioral|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
79643639|NCT05167045|Behavioral|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
79643640|NCT00163982|Drug|Norfloxacin|
79643641|NCT05149690|Other|Experimental: monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
79643642|NCT05149690|Other|Active Comparator: Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
79973099|NCT05665231|Other|A - Bone defect (clinical variables)|At T0, the edentulous space to be rehabilitated will be characterized in terms of the morphometric level of the existing defect in the vestibular cortical, according to the classification by Caplanis N. in EDS-1 or EDS-2.
79643643|NCT00193323|Drug|Docetaxel|
79643644|NCT00193323|Drug|Gemcitabine|
79643645|NCT00164021|Procedure|Physiotherapy, exercise, percutaneous gastrostomy feeds|
79317257|NCT05304065|Behavioral|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
79643646|NCT00164021|Drug|Anti-reflux pharmacotherapy|
79643647|NCT00193362|Drug|Paclitaxel|
79643648|NCT00193362|Drug|Carboplatin|
79643649|NCT00193362|Drug|Gemcitabine|
79643650|NCT00193362|Drug|Vinorelbine|
79643651|NCT04683757|Other|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
79643652|NCT04683523|Other|Exercise|Resistance training using dumbbells and therabands
79317258|NCT05302752|Other|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
79643653|NCT00193401|Drug|Topotecan|
79643654|NCT00553189|Drug|ABT-888|
79643655|NCT00553189|Drug|Topotecan|
79643656|NCT00164099|Drug|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
79643657|NCT05093452|Behavioral|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
79643658|NCT05093452|Other|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
79317259|NCT05301595|Procedure|TAP block|Please see description of TAP block group.
79317260|NCT05301595|Procedure|QL Block|Please see description of QL block group.
79643659|NCT00193440|Drug|Rituximab|
79643660|NCT00193440|Drug|CHOP|
79643661|NCT00193440|Drug|CVP|
79643662|NCT00193440|Drug|Ibritumomab Tiuxetan|
79643663|NCT05077969|Drug|Famotidine|80 mg tablet, QID for 14 days
79643664|NCT05077969|Drug|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
79643665|NCT05077969|Drug|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
79643666|NCT00164138|Procedure|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
79643667|NCT05062564|Device|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
79643668|NCT05062564|Procedure|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
79643669|NCT00193518|Drug|Arsenic Trioxide|
79643670|NCT00164177|Drug|HalfLytely|
79643671|NCT04722510|Device|repeated transcranial magnetic stimulation|Transcranial magnetic stimulation is a non-invasive brain modulation technique that has proven to be a useful study and treatment tool in neuropsychiatric disorders. This technique allows to increase (with high frequency protocol, > 1 Hz) or decrease (with low frecuency protocols, 1 hz or less) neuronal excitability in a focused cortical area.
79643672|NCT00164216|Drug|mefloquine plus artesunate|
79643673|NCT00193557|Drug|Bortezomib|
79643674|NCT00164255|Drug|sulfadoxine/pyrimethamine|
79643675|NCT00164255|Drug|sulfadoxine/pyrimethamine plus artesunate|
79643676|NCT05023642|Other|resistance training|"Interventions will include a three-phase strengthening training protocol.~Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~Basic phase: 12 sessions, to increase muscle strength; and~Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus."
79643677|NCT00409500|Drug|AQW051|
79643678|NCT00164294|Behavioral|Brief intervention|
79643679|NCT00409656|Drug|Basiliximab|
79643680|NCT00164333|Behavioral|TAP: Treatment Advocacy Program|
79643681|NCT04683328|Biological|SCTA01|Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
79643682|NCT04683328|Biological|SCTA01 Placebo|The excipients of SCTA01
79643683|NCT04683016|Other|Questionnaires|"Patients will be asked two sets of questions:~questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
79973100|NCT05665231|Other|B- Bacterial plaque index (O'Leary index)(clinical variables)|At time T-1 and T4, the investigator will analyse the existing plaque on teeth adjacent to the surgical site using a dichotomous score (0 = no visible plaque at the soft tissue margin, 1 = visible plaque at the soft tissue margin). The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4, and compare the results between implants type.
79973101|NCT05665231|Other|C- Probing depth|At Time T-1 and T4, the investigators will analyse the probing depth of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in millimeters. The change between T-1 and T4 is also going to be analysed and compare implants results.
79973102|NCT05665231|Other|D- Bleeding on probing|At time T-1 and T4, the investigators will analyse the bleeding on probing of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings of bleeding on probing will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4 and compare between implants type.
79317261|NCT05295173|Drug|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
79973103|NCT05665231|Other|E- Gingival phenotype|At time T-1, the identification of the gingival phenotype is performed by clinical inspection with a periodontal probe. The gingival phenotype will be classified as thin, moderate or thick. The investigators will compare implant results.
79973104|NCT05665231|Other|F- Implant insertion torque (Clinical variables)|Recording of implant insertion torque, in Ncm during placement in T1, and compare implants results.
79973105|NCT05665231|Other|G- Implant stabilization quotient (ISQ) (clinical variables)|Determination of the implant stability coefficient at the time of implant placement (T1) and in the 2nd surgical phase (T3) using the Osstell® device (minimum 1; maximum 100; high stability when ≥70) and analysis of the change between T1 and T3 and different implants results.
79317262|NCT05295173|Drug|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
79643684|NCT04981405|Biological|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
79643685|NCT00409695|Drug|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
79643686|NCT00409695|Drug|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
79643687|NCT00164372|Behavioral|Peer Education Intervention|
79317263|NCT05274750|Biological|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre-filled syringe.
79317264|NCT05274750|Drug|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
79317265|NCT05268991|Other|Geriatric Assessments and Frailty Indices|Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
79317266|NCT05263934|Biological|Depemokimab|Depemokimab will be administered
79643688|NCT04977232|Drug|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
79317267|NCT05263934|Biological|Mepolizumab|Mepolizumab will be administered
79643689|NCT04977232|Behavioral|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
79317268|NCT05263934|Drug|Placebo matching mepolizumab|Placebo matching to mepolizumab will be administered.
79317269|NCT05263934|Drug|Placebo matching depemokimab|Placebo matching to depemokimab will be administered.
79317270|NCT05254158|Drug|NNC0174 0833|Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
79317271|NCT05208346|Dietary Supplement|Mixed meals|Mixed meals enriched with either 25 or 50 g of canola or coconut oil
79643690|NCT04974814|Drug|Rosuvastatin 40mg|patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
79807907|NCT04162379|Drug|Oral tablet|Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
79807908|NCT02637791|Device|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
79973106|NCT05665231|Other|Morphometric results (Direct measurements - millimeter)|"Compare Direct measurements (millimeters) at the different times intervention with periodontal probe or gauge and analyse the change between times and compare implant results.~In T-1, T2 and T3c and T4 the investigators will evaluate interdental distance; BPD, cortical bone, papilla and volume, corresponding of measurements: a,b,c and r.~In T0, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume corresponding to measurements: a, b, c, d, e, q, r, s, t, and u).~In T1 e T3, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume, implant parameter corresponding to measurements: a, b, d, e, f, g, h, I, j, k, l, m, n, p, q, r and ISQ value."
79807909|NCT02637635|Procedure|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
79973107|NCT05665231|Other|Morphometric results (plaster models measurements - millimeter)|"Preparation of plaster models at times T-1 and T4 and the following measurements (millimeter) will be evaluated with the use of periodontal probe or gauge and will analyse the change between T-1 and T4 and compare implants results:~interdental distance~bucco-palatal distance (BPD)~presence of papilla~r. global volume."
79317272|NCT05197647|Other|Patients with symptomatic COVID-19 disease not requiring hospitalization.|Patients with symptomatic COVID-19 disease not requiring hospitalization.
79317273|NCT05192980|Other|No Intervention NA|Additional blood sampling (not mandatory)
79317274|NCT05186428|Other|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
79317275|NCT05186428|Other|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
79317276|NCT05184634|Other|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
79317277|NCT05184634|Other|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
79317278|NCT05184634|Other|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
79317279|NCT05184634|Other|QUALITY OF LIFE|To determine the quality of life of MetS individuals
79477969|NCT05993897|Drug|Rhythm control and anticoagulation|"In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females."
79477970|NCT05993884|Drug|iEPCs|Given: IV
79973108|NCT05665231|Other|Imaging Results (X-ray) (millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of digital X-ray at times T-1, T1,T4 and analyse the variation and compare implants results. The measurements are:~a. interdental distance; i. implant - cemento-enamel junction (CEJ) of adject teeth distance; l. distance from the implant position depth to the buccal bone crest; n. implant diameter; o. implant length."
79643691|NCT04974814|Drug|Atorvastatin 80mg|patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
79807910|NCT02637635|Procedure|Expander prosthesis|breast reconstruction with expander prosthesis.
79477971|NCT05993884|Combination Product|Clinical standard treatment (CST)|Clinical standard treatment
79477972|NCT05993871|Diagnostic Test|Clinical Evaluation/Questionnaires|Anthropometric measures, somatosensory assessment (NPS, UENS, TCNS), autonomic assessment (COMPASS-31, Ewing battery), and severity and quality of life evaluation (NPS, TCNS, COMPASS-31, and EuroQOL-5D-5L index score)
79477973|NCT05993871|Diagnostic Test|Nerve Conduction Study|Routine Nerve Conduction Study.
79477974|NCT05993871|Diagnostic Test|Small fiber electrodiagnostic tests|R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.
79643692|NCT04974814|Drug|Control Test|patients in control arm will not preloaded with statin in ER before PCI
79643693|NCT00409734|Behavioral|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
79807911|NCT00837876|Drug|Sorafenib|400 mg taken by mouth 1 time per day.
79807912|NCT00837876|Drug|Erlotinb|150 mg taken by mouth 1 time per day.
79643694|NCT00409734|Behavioral|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
79807913|NCT00655421|Other|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
79807914|NCT00655421|Device|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
79807915|NCT00655421|Other|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
79317280|NCT05180552|Device|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
79317281|NCT05180552|Device|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
79317282|NCT05165979|Other|Hospitalization due to COVID-19|Hospitalization due to COVID-19
79643695|NCT00164411|Biological|Tetanus-diphtheria toxoids (Td)|
79317283|NCT05165511|Behavioral|PBT-EF|PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
79317284|NCT05158738|Other|Patients with inherited cardiac condition, onset <16 years old and Parents|Patients with a confirmed diagnosis of an inherited cardiac condition, onset <16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
79317285|NCT05157698|Drug|Naltrexone and Bupropion Combination|Participants in this intervention will take active naltrexone and bupropion pills.
79317286|NCT05157698|Behavioral|Behavioral Weight Loss|Participants in this intervention will receive behavioral weight loss treatment.
79973109|NCT05665231|Other|Imaging Results (CBCT)(millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of CBCT at times T-1 and T4, analyse the variation and compare implants results. The measurements are:~interdental distance;~bucco-palatal distance (BPD);~d. buccal cortical distance; e. palatal cortical distance; f. mesial cortical distance; g. distal cortical distance; h. jumping distance; j. buccal cortical wall-implant distance; k. jumping distance space depth; l. distance from the implant position depth to the buccal bone crest; m. distance from the buccal cortex to the center of the implant; n. implant diameter; o. Implant length; q. global bone volume; r. global volume; s. alveolus buccal-palatal distance; t. alveolus mesial-distal distance; u. alveolus depth."
79973110|NCT05665231|Other|Photographic results PES/WES index|The investigator will analyse the intraoral photographs to describe the Pes/Wes index, in time T-1 (initial) and T4 (final), and compare the PES/WES results between implants.The score will range on 0-10, the best score is ≥8.
79317287|NCT05157698|Other|Placebo|Participants in this intervention will take inactive (placebo) pills.
79643696|NCT00164411|Biological|7-valent pneumococcal conjugate vaccine|
79643697|NCT00164411|Biological|23-valent polysaccharide vaccine|
79643698|NCT04921345|Drug|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
79807916|NCT00911027|Drug|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
79807917|NCT00911027|Procedure|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
79643699|NCT04921345|Drug|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
79643700|NCT00193635|Drug|mycophenolate mofetil|oral drug administration
79643701|NCT04723979|Drug|Eptacog alfa|Recombinant coagulation factor VII activated
79643702|NCT04723979|Other|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
79807918|NCT00707070|Drug|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
79807919|NCT00707070|Drug|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
79973111|NCT02495428|Procedure|Kinesio Tape Method|
79643703|NCT00193674|Drug|Dydrogesterone|20 mg/day, oral
79643704|NCT00193674|Drug|Placebo|Placebo
79643705|NCT00164450|Drug|Rifapentine + isoniazid once weekly for 3 months|
79643706|NCT00193713|Drug|bifeprunox|
79643707|NCT00164489|Behavioral|Weight control and physical activity promotion|
79643708|NCT04861246|Device|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
79643709|NCT04861246|Device|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
79643710|NCT04861246|Device|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
79643711|NCT03455413|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
79643712|NCT00164528|Behavioral|Positive Behavior Support|
79973112|NCT05701514|Procedure|Elective surgical resection of CPAM between 6 and 9 months of age|Surgical resection of the CPAM between 6 and 9 months of age
79973113|NCT03726463|Procedure|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
79973114|NCT03814577|Diagnostic Test|Total Antioxidant Status|Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
79973115|NCT03814577|Diagnostic Test|Total Oxidant Status|Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
79643713|NCT04841356|Procedure|Immediate Compression Garment|"Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study."
79643714|NCT00193752|Other|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
79973116|NCT03814577|Device|Bispectral Index|Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
79643715|NCT04835545|Other|extreme hypercapnia induced by ventilation insufficiency|extreme hypercapnia
79643716|NCT00164567|Behavioral|Onsite IPV specialist|
79643717|NCT00164567|Behavioral|Empowerment focused intervention|
79643718|NCT04834453|Diagnostic Test|transcranial ultrasound|- Transcranial Doppler sonography will be performed with the patients in the supine position., using low frequency probe of 2 MHz will be placed on temporal bone- will be performed daily
79477975|NCT05993871|Diagnostic Test|Nerve Ultrasound|Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
79643719|NCT00193791|Other|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
79643720|NCT04832425|Drug|PRAX-114|40 mg once daily
79643721|NCT04832425|Drug|Placebo|Placebo once daily
79655734|NCT04552210|Diagnostic Test|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
79655735|NCT02213848|Drug|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
79643722|NCT04724135|Other|Survey|The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
79317288|NCT05151835|Device|K2 Robotic Surgical System|The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console [SGC], a Patient Side Robot [PSR], and a Vision Cart [VCT], and is used with an endoscope, Surgical Instruments [SGI], and Accessories [ACC]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
79317289|NCT05151653|Drug|BI 765250|BI 765250
79317290|NCT05151653|Drug|Placebo|Placebo
79317291|NCT05149911|Behavioral|Life Coaching|Sessions with a professional life coach.
79477976|NCT05993871|Diagnostic Test|Skin Biopsy|distal leg 3mm punch skin biopsy
79477977|NCT05993858|Drug|3cycles (Toripalimab + cetuximab)|"Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 9."
79477978|NCT05993858|Procedure|Surgery|After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.
79643723|NCT00193830|Procedure|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
79643724|NCT00164606|Behavioral|Positive Parenting Program (Triple-P)|
79643725|NCT04825639|Other|No intervention|no intervention
79643726|NCT00193869|Drug|Dexamethasone|
79477979|NCT05993858|Radiation|Radiotherapy or chemoradiotherapy|Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
79477980|NCT05993819|Other|pilates based core stability training and congnitive therapy|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.
79643727|NCT04818658|Other|Assessment of the stainless steel crown using the Hall Technique and Compomer Restoration on primary molars|Intra-oral clinical examination is performed and restorations are evaluated by the practitioner. Periapical radiography is taken according to national guidelines.
79643728|NCT04683484|Biological|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
79643729|NCT04683484|Biological|Placebo|0,5 mg Al PO4
79643730|NCT00164645|Behavioral|Problem Solving intervention|
79643731|NCT04683367|Procedure|laparoscopic surgery|laparoscopic repair of hernia
79807920|NCT04115670|Behavioral|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
79807921|NCT04115670|Behavioral|Control group|The control group will follow its normal course of activity
79643732|NCT00176163|Behavioral|Operant behavioral treatment; Drug: THC|
79643733|NCT04683211|Other|Evaluation of iodine supplementation|survey of iodine supplementation
79643734|NCT04683289|Procedure|trabeculotomy|performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
79643735|NCT00164684|Behavioral|Father Friendly Initiative|
79643736|NCT04683133|Diagnostic Test|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
79643737|NCT00193908|Drug|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
79643738|NCT00193908|Drug|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
79643739|NCT00193908|Radiation|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
79643740|NCT00164723|Procedure|Capsule endoscopy|Capsule endoscopy and colonoscopy
79643741|NCT04810117|Diagnostic Test|Serodiagnosis of IgG and IgM|IgG and IgM antibodies will be detected in COVID-19 patients
79643742|NCT02277340|Procedure|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
79317292|NCT05130008|Other|Digitally-enabled CHW Care|Patients will be paired with a CHW and be encouraged to wear the arm biosensor continuously, take blood pressure daily, respond to short symptom assessments daily or every other day, complete weekly life quality surveys, watch weekly HF educational videos and engage in digital (e.g., video visit) and phone-based, and in-person CHW interactions. Each participant will have access to the digital platform and CHW staff during their hospitalization and for the 30 days following discharge for a typical study duration of approximately 32-35 days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
79317293|NCT05130008|Behavioral|Usual CHW Care|Patients will be paired with a CHW for 30-days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
79643743|NCT00176241|Drug|gemcitabine|2000-3000mg/m2 IV on days 1 & 15
79643744|NCT00176241|Drug|paclitaxel|150 mg/m2 IV on days 1 & 15
79317294|NCT05111314|Radiation|Gallium Ga 68 Gozetotide|Given IA
79317295|NCT05111314|Procedure|Hepatic Artery Embolization|Undergo hepatic artery embolization
79643745|NCT00176241|Radiation|radiation|50-80 cGy on days 1,2,15,16
79643746|NCT04732897|Procedure|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
79643747|NCT04727203|Behavioral|AHAA|Multi-component healthy lifestyle program
79643748|NCT00164801|Drug|Baclofen, Diltiazem|
79643749|NCT00176280|Drug|Leukine|
79643750|NCT00176280|Drug|Dexamethasone|
79643751|NCT04719793|Biological|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
79643752|NCT04723940|Drug|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
79477981|NCT05993819|Other|Pilates based core stability training|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
79317296|NCT05111314|Procedure|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
79317297|NCT05110183|Device|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
79317298|NCT05110183|Other|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
79317299|NCT05110183|Other|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
79317300|NCT05100823|Procedure|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
79317301|NCT05100823|Procedure|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
79317302|NCT05096221|Genetic|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
79317303|NCT05096221|Genetic|placebo|Single IV infusion of matching placebo.
79317304|NCT05093439|Diagnostic Test|Heart Rate Variability|Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
79317305|NCT05085379|Device|Ossiview|Imaging of the ear using Optical Coherence Tomography
79477982|NCT05993806|Drug|L04RD1|1 tablet of L04RD1
79477983|NCT05993806|Drug|L04TD3|1 tablet of L04TD3
79643753|NCT04723940|Drug|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
79643754|NCT04723940|Drug|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
79807922|NCT02638727|Drug|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
79477984|NCT05993793|Device|Fototherapy|The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
79643755|NCT04723940|Drug|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
79643756|NCT04684849|Other|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
79317306|NCT05073835|Drug|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
79317307|NCT05073835|Drug|Placebo|Placebo
79317308|NCT05069467|Device|Acupuncture|For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
79317309|NCT05069467|Device|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
79317310|NCT05067933|Drug|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
79643757|NCT04684849|Other|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
79655736|NCT02213848|Drug|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
79655737|NCT00413855|Procedure|laparoscopic appendectomy or not (surgery)|
79807923|NCT02638727|Drug|placebo|This group treat with placebo dayley
79807924|NCT00686920|Drug|Rifaximin|Oral
79477985|NCT05993780|Other|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
79643758|NCT04680793|Other|Rehabilitation|The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
79317311|NCT05067933|Other|Placebo Tablets|Placebo tablets matching the active vaccine tablets
79317312|NCT05058677|Drug|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
79317313|NCT05058677|Drug|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
79643759|NCT04678570|Other|White Noise|"The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled."
79655738|NCT04548544|Behavioral|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
79807925|NCT02562118|Drug|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
79807926|NCT00741754|Other|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
79317314|NCT05058677|Drug|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
79477986|NCT05993767|Drug|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
79317315|NCT05058677|Procedure|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
79317316|NCT05058300|Device|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
79317317|NCT05052307|Drug|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
79317318|NCT05052307|Drug|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
79317319|NCT05052307|Drug|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
79973117|NCT03814577|Other|Invasive arterial monitorization|Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
79317320|NCT05052307|Drug|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
79317321|NCT05049538|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79317322|NCT05049538|Procedure|Liquid Biopsy|Undergo liquid biopsy
79477987|NCT05993741|Device|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
79477988|NCT05993715|Dietary Supplement|Nitrate supplementation|Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (~12.8 mmol/day nitrate) or nitrate-depleted (~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (~9 am) and one each evening (~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
79477989|NCT05993715|Dietary Supplement|Placebo supplementtaion|2 × 70 mL/day shots of concentrate nitrate-depleted (~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (~9 am) and one each evening (~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
79655739|NCT04548388|Other|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
79973118|NCT03730363|Drug|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
79973119|NCT02493166|Other|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
79973120|NCT01206725|Other|Exercise|"Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
79973121|NCT01206803|Drug|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg & daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
79973122|NCT00707434|Device|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
79317323|NCT05049538|Other|Pap Smear|Undergo Pap smear
79317324|NCT05048147|Behavioral|Community Mobilization|The Community Mobilization (CM) strategy will include: (1) Community advisory board [comprising local community-based organizations, government officials, and residents], that will provide leadership support and buy-in for adoption of Clean Fuel- Clean- Stove (CF-CS) use; (2) Trained MoH community health extension workers, community health officers, community mobilizers and health education officers, who will form community action teams (CAT) to facilitate the implementation of CF-CS use via provision of support, knowledge exchange and performance feedback to the primary cooks in participating households; (3) Community dialogues with residents and households focused on shared concerns on the significance and importance of CF-CS use.
79317325|NCT05040971|Drug|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
79317326|NCT05040971|Drug|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
79317327|NCT05037513|Behavioral|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
79317328|NCT05037513|Behavioral|CDC-PrEP|1 session PrEP education following CDC guidelines
79973123|NCT03818009|Other|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
79477990|NCT05993702|Drug|regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
79477991|NCT05993702|Drug|fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; or Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
79477992|NCT05993676|Behavioral|MeT4VeT mobile phone app: control|The control/ sham comparator arm of the Mental Health Toolkit for Veterans (MeT4VeT) smart phone app contains only signposting information around support services available to military veterans
79655740|NCT00261573|Drug|galantamine hydrobromide|
79655741|NCT04548466|Device|PEP bottle|
79807927|NCT00741832|Device|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
79807928|NCT00741832|Other|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
79807929|NCT00744718|Drug|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
79807930|NCT00744718|Drug|Carboplatin|Carboplatin AUC 5 every 5 weeks
79807931|NCT00845832|Drug|Placebo|iv on days 1 and 15 (Parts 1 and 2)
79807932|NCT00845832|Drug|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
79973124|NCT03054428|Drug|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
79973125|NCT03054428|Drug|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
79973126|NCT03335956|Drug|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
79973127|NCT03335956|Drug|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
79655742|NCT04548427|Drug|CKD-352|Eye Drop
79807933|NCT00845832|Drug|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
79973128|NCT03335956|Drug|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
79973129|NCT03335956|Drug|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
79973130|NCT03335956|Drug|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
79973131|NCT03335956|Drug|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
79973132|NCT03335956|Drug|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
79973133|NCT03335956|Drug|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
79973134|NCT03335956|Drug|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
79973135|NCT03335956|Drug|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
79973136|NCT03335956|Drug|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
79973137|NCT03335956|Drug|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
79317329|NCT05004662|Behavioral|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
79655743|NCT04548427|Drug|Diquafosol Sodium 3%|Eye Drop
79655744|NCT00413933|Procedure|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
79655745|NCT04548271|Drug|Camrelizumab|Anti-PD-1 targeted immunotherapy
79655746|NCT04548271|Drug|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
79655747|NCT04541719|Drug|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
79317330|NCT05004662|Drug|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
79317331|NCT05004662|Behavioral|Counceling|Phone counseling with the Florida Quitline
79317332|NCT05004662|Drug|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
79317333|NCT05002075|Other|m-health cardiac rehabilitation|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California). This app includes a patient-facing iOS and Android compatible smartphone app and an integrated hospital-facing online dashboard for remote monitoring and care coordination by a trained coach
79317334|NCT04984629|Device|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
79317335|NCT04979780|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using US Optum De-Identified EHR data.
79317336|NCT04979780|Drug|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
79317337|NCT04979780|Drug|Direct Oral Anticoagulants (DOAC)|Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
79317338|NCT04972513|Procedure|Biospecimen Collection|Undergo collection of blood
79317339|NCT04972513|Procedure|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
79317340|NCT04972513|Procedure|Oscillometry|Undergo airwave oscillometry
79317341|NCT04972513|Procedure|Spirometry|Undergo spirometry
79317342|NCT04972513|Other|Survey Administration|Complete survey
79317343|NCT04972513|Procedure|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
79317344|NCT04972110|Drug|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
79317345|NCT04951466|Behavioral|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
79317346|NCT04951466|Behavioral|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
79317347|NCT04941950|Behavioral|PlaySmart|PlaySmart is designed to provide players with behavioral skills and knowledge through repetitive and engaging videogame play to target adolescent perception of risk of harm from initiating opioid misuse.
79807934|NCT02562274|Dietary Supplement|Placebo|Subjects are received placebo treatments once daily for 8 weeks
79317348|NCT04941950|Other|Video Game Control|Participants in the control group will play another video game with no intended effect similar to PlaySmart.
79807935|NCT02562274|Dietary Supplement|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
79807936|NCT02562274|Dietary Supplement|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
79807937|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
79807938|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
79655748|NCT04541719|Drug|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
79807939|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
79317349|NCT04939051|Procedure|Biospecimen Collection|Undergo blood sample collection
79317350|NCT04939051|Procedure|Esophageal Biopsy|Undergo esophageal biopsy, brushings and gastric aspirate
79317351|NCT04939051|Procedure|Esophagogastroduodenoscopy|Undergo EGD
79317352|NCT04939051|Procedure|Liver Ultrasonographic Elastography|Undergo liver ultrasound with elastography
79317353|NCT04939051|Biological|Obeticholic Acid|Given PO
79317354|NCT04939051|Drug|Placebo Administration|Given PO
79317355|NCT04939051|Other|Questionnaire Administration|Ancillary study
79317356|NCT04934722|Biological|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
79317357|NCT04934722|Drug|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
79317358|NCT04934722|Drug|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
79317359|NCT04934722|Other|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
79317360|NCT04925375|Drug|Abatacept|Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
79317361|NCT04925375|Other|Placebo|The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
79317362|NCT04921384|Drug|Placebo|0.9% normal saline, intravenously
79317363|NCT04921384|Drug|Eptinezumab|Solution for infusion, intravenously
79807940|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
79807941|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
79807942|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
79807943|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
79973138|NCT03335956|Drug|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
79973139|NCT03335956|Drug|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
79643760|NCT04678570|Other|Swaddling Method|The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
79317364|NCT04910074|Device|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
79317365|NCT04910074|Device|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
79477993|NCT05993676|Behavioral|MeT4VeT mobile phone app: intervention|"The Mental Health Toolkit for Veterans (MeT4VeT) smart phone app has been developed through careful and close collaboration with military veterans and key providers of veterans' mental healthcare services. The aim of this app is to provide both a degree of education to support military veterans' understanding of mental health and foster self-recognition and management of mental health symptoms whilst also encouraging those who need it to seek more formal support.~The elements of the app have been chosen for inclusion as they represent the intersection between:~Core components of cognitive behavioural therapy, the theoretical framework underwriting the app~Behaviour change constructs"
79643761|NCT04644133|Other|Paper diary|Subjects will be asked to complete a 2 week paper stool diary.
79643762|NCT04644133|Other|Electronic APP diary|Subjects will be asked to complete a 2 week paper stool diary.
79317366|NCT04890938|Combination Product|Sputum-guided management and comprehensive care management|Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils >3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells >10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
79317367|NCT04890938|Other|Usual Care|As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
79477994|NCT05993663|Behavioral|Arts in health group intervention|12 sessions using the Arts in Health methodology with the aim of having a better understanding of the disease, developing healthy lifestyle habits and greater emotional intelligence. Visual thinking strategies, game based activities, mindfulness and dance will be used
79643763|NCT00193986|Device|Arbitrary Waveform Defibrillator|
79643764|NCT00164840|Drug|Esomeprazole|
79643765|NCT04641247|Drug|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
79973140|NCT03335956|Drug|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
79973141|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
79973142|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
79973143|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
79317368|NCT04840108|Behavioral|Support Person Coaching Intervention|The intervention condition will include, for the SPs, a manualized, 1-session coaching intervention delivered by a research coach. The call will be delivered by phone using VA-permitted remote audio or video communication technology (e.g., doximity dialer, Zoom, or VA Video Connect if a Veteran). Coaches will use behavior change strategies delivered with a MI style.
79643766|NCT04635007|Drug|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
79643767|NCT04635007|Drug|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
79643768|NCT04590898|Device|Peri-device leakage closure after left atrial appendage occlusion|Peri-device leakage closure after left atrial appendage occlusion
79643769|NCT00176319|Behavioral|Aerobic endurance exercise training (ergometer)|
79317369|NCT04840108|Behavioral|Support Person Written Materials|Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
79317370|NCT04830137|Drug|NX-2127|Oral NX-2127
79317371|NCT04824144|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
79317372|NCT04824079|Drug|Keynatinib|The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
79317373|NCT04817410|Drug|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
79317374|NCT04816877|Drug|Opioid|Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
79643770|NCT00164879|Procedure|Endoscopic stenting followed by elective laparoscopic resection|
79973144|NCT02494960|Behavioral|The brief smoking cessation AWARD model|"Ask whether or not the patient currently smokes~Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
79477995|NCT05993650|Other|Inspiratuar Muscle Training Group|Inspiratory muscle training will be done for 15 minutes/session, 2 times/day, or 30 minutes/day if tolerated, 5-7 days/week (one under supervision and others at home), for a total of 6 weeks. Applications made at home will be followed with a diary. Inspiratory muscle training will be performed using an inspiratory muscle training device (PowerBreathe®) working with the threshold loading principle.In the first week of the training, 30-50% of the maximal inspiratory pressure (MIP) measured in the initial evaluation of the individual will be adjusted according to the patient's tolerance, and inspiratory muscle training will be performed. Respiratory muscle strength measurement will be repeated every week in the individuals in the training group. 30-50% of the new MIP value obtained will be calculated and adjusted by calculating the new training workload for the application of inspiratory muscle training in the following weeks
79643771|NCT04546945|Diagnostic Test|CD56|detection of CD56 by flow cytometry
79643772|NCT00194064|Drug|Olanzapine|
79643773|NCT04503343|Other|non-drug intervention|mindfulness training, relaxation training, or electrical cerebellar stimulation
79643774|NCT00164918|Device|nasogastric tube|
79807944|NCT02562196|Device|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79317375|NCT04812067|Drug|TTHX1114|engineered FGF-1
79317376|NCT04807881|Drug|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is > 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
79317377|NCT04798781|Drug|Telatinib|900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
79317378|NCT04798781|Drug|Keytruda|200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
79317379|NCT04795531|Drug|Insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
79317380|NCT04795531|Drug|Placebo insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
79317381|NCT04795531|Drug|Insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
79317382|NCT04795531|Drug|Placebo insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
79317383|NCT04787575|Procedure|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
79807945|NCT00591864|Device|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
79317384|NCT04781933|Dietary Supplement|Treatment with Combo|Treatment with Combo
79317385|NCT04781933|Other|Treatment with placebo|Treatment with placebo
79807946|NCT00885755|Drug|Standard taxane therapy|As prescribed
79807947|NCT00885755|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
79807948|NCT00885755|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
79317386|NCT04778592|Drug|ETX-018810|Study Drug
79317387|NCT04778592|Drug|Placebo|Placebo
79317388|NCT04765267|Dietary Supplement|Zinc sulphate heptahydrate|Dietary supplements
79643775|NCT04467970|Procedure|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
79643776|NCT04467970|Procedure|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
79643777|NCT00176358|Device|PTCA and Stent Implantation|
79643778|NCT00176358|Behavioral|Exercise Training|
79643779|NCT04427917|Drug|PF-06835919|PF-06835919 300 mg repeated doses
79807949|NCT00749554|Device|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
79807950|NCT00749554|Device|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
79807951|NCT00749710|Procedure|clopidogrel|ORIF - surgical treatment
79807952|NCT00749710|Procedure|no antiaggregant therapy|ORIF - surgical treatment
79807953|NCT00913302|Behavioral|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
79317389|NCT04750902|Drug|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
79317390|NCT04750902|Drug|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
79317391|NCT04750902|Drug|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
79317392|NCT04750902|Drug|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
79317393|NCT04737265|Other|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
79317394|NCT04737252|Behavioral|Sage (formerly known as COMPASS)|Sage is a remote 12 session intervention for couples wherein one individual has Borderline Personality Disorder (BPD) and engages in self-injury thoughts and behaviours. The intervention consists of elements of Cognitive Behavioural Conjoint Therapy (CBCT) and has been adapted for this population. Couples will meet remotely with a clinician (registered psychologists and/or graduate level clinicians) for 8-12 sessions via Zoom Healthcare. The primary outcomes are self-injury thoughts and behaviours (as measured by the Suicide Attempt and Self-Injury Interview-modified, and the Beck Scale for Suicidal Ideation and ecological momentary assessment) and borderline personality disorder symptoms (as measured by the Borderline Symptom List-23).
79317395|NCT04737239|Other|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
79807954|NCT04058548|Diagnostic Test|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
79807955|NCT00749866|Drug|Gentamicin|Nebulised 80mg twice daily
79807956|NCT00749866|Drug|Saline|Nebulised 4mls 0.9% Saline twice daily
79807957|NCT00655577|Behavioral|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
79807958|NCT04058236|Other|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
79807959|NCT04058236|Other|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
79807960|NCT04164875|Diagnostic Test|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
79807961|NCT02638649|Procedure|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
79317396|NCT04730921|Device|Left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
79317397|NCT04730921|Device|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
79317398|NCT04728100|Other|LQT|Patients with LQT syndrome diagnosis.
79317399|NCT04725383|Drug|amitriptyline|Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
79317400|NCT04718389|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
79317401|NCT04718389|Biological|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
79317402|NCT04718389|Biological|Benralizumab|Benralizumab will be provided in a single-use PFS.
79973145|NCT02494960|Behavioral|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
79317403|NCT04718389|Biological|Placebo|Placebo will be a sterile liquid formulation.
79317404|NCT04718389|Drug|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
79317405|NCT04718389|Device|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
79317406|NCT04696237|Other|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
79317407|NCT04688775|Drug|Eptinezumab|Eptinezumab - concentrate for solution for infusion, intravenously
79317408|NCT04688775|Drug|Placebo|Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
79317409|NCT04688671|Drug|ETX-018810|Study Drug
79317410|NCT04688671|Drug|Placebo|Matching Placebo
79317411|NCT04677816|Drug|Standard of Care Neoadjuvant Chemotherapy|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
79317412|NCT04677816|Dietary Supplement|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
79317413|NCT04677816|Other|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
79317414|NCT04676737|Drug|TTHX1114(NM141)|TTHX1114
79317415|NCT04668209|Drug|Silmitasertib|Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
79317416|NCT04661878|Behavioral|Social Support|The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
79317417|NCT04661878|Behavioral|Informational Resources|The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
79317418|NCT04661878|Behavioral|Self-Monitoring and habit formation|The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
79317419|NCT04661878|Behavioral|Goal setting and action planning|The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
79317420|NCT04655196|Other|SOLUS-D + weekly feedback by a coach|internet-based self-help
79643780|NCT04427917|Drug|Placebo|Placebo repeated doses
79973146|NCT01206881|Drug|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
79317421|NCT04655196|Other|SOLUS-D + weekly automated messages|internet-based self-help
79317422|NCT04637581|Behavioral|Wraparound|Wraparound is a 12-month family-driven intensive care coordination model.
79317423|NCT04597697|Drug|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
79643781|NCT00164957|Device|continuous pump feeding|
79643782|NCT00164957|Other|intermittent bolus feeding|
79807962|NCT02638649|Device|ultrasound|
79807963|NCT00742066|Drug|Irbesartan|Single dose 600mg orally
79807964|NCT00742066|Drug|Felodipine|single dose 10mg Felodipine ER
79973147|NCT02494804|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
79317424|NCT04578951|Device|FHK® total knee prosthesis|FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
79317425|NCT04566653|Drug|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
79317426|NCT04566653|Drug|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
79317427|NCT04566653|Drug|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
79317428|NCT04566653|Drug|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
79973148|NCT02494804|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
79317429|NCT04566653|Drug|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
79643783|NCT00194103|Behavioral|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
79643784|NCT00194103|Behavioral|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
79317430|NCT04554277|Biological|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
79317431|NCT04551469|Behavioral|music|Music intervention for 30 minutes
79643785|NCT00164996|Procedure|Local pharyngeal anaesthesia|
79643786|NCT00164996|Device|Ultrathin endoscope|
79317432|NCT04540575|Behavioral|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
79317433|NCT04540575|Behavioral|Mother Provides MOM|Mother receives standard Rush NICU lactation care
79317434|NCT04537377|Genetic|VTX-801|"The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels."
79317435|NCT04515745|Behavioral|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
79317436|NCT04515745|Behavioral|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
79317437|NCT04484350|Drug|Labetalol|10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
79807965|NCT00742066|Drug|Placebo|Single dose tablet orally
79973149|NCT01299155|Device|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
79973150|NCT01299155|Device|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
79317438|NCT04484350|Drug|Hydralazine|10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
79643787|NCT04418557|Diagnostic Test|RT-PCR and antibody testing|Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.
79643788|NCT04682782|Drug|Esketamine|Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .
79643789|NCT04682782|Drug|Saline|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.
79317439|NCT04484350|Drug|Enalapril|1.25 - 2.5 mg IV bolus and then q6h PRN.
79317440|NCT04481113|Drug|Abemaciclib|Given PO
79317441|NCT04481113|Drug|Niraparib Tosylate Monohydrate|Given PO
79807966|NCT02635529|Procedure|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
79317442|NCT04456998|Drug|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
79317443|NCT04456998|Drug|Placebo|Matching capsule containing placebo
79317444|NCT04456998|Device|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
79317445|NCT04433897|Other|Questionnaire|"All women fulfilled 3 questionairres~TANGO~ICIQ -N~Perceived Stress Scale"
79317446|NCT04414696|Behavioral|Exercise intervention|eHealth exercise intervention for postpartum women at increased risk of depression
79317447|NCT04405089|Device|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
79643790|NCT00176397|Procedure|Percutaneous coronary intervention (left main)|
79643791|NCT00165035|Device|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
79643792|NCT00165035|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
79643793|NCT03455374|Device|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
79643794|NCT04330339|Behavioral|Fasting|Fasting
79643795|NCT00194181|Drug|TPA Infusion|
79643796|NCT00165074|Drug|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
79643797|NCT04322695|Behavioral|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
79317448|NCT04405089|Device|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
79317449|NCT04404530|Drug|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
79317450|NCT04403802|Device|Voxx Human Performance Technology Socks|"Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
79643798|NCT04307953|Drug|AZD0530 Difumarate|AZD0530 for the duration of the trial
79643799|NCT04307953|Drug|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
79643800|NCT04306861|Diagnostic Test|MRI|Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
79807967|NCT02635529|Procedure|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
79807968|NCT00837486|Device|Reclaim™ DBS System|
79807969|NCT00742144|Drug|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
79807970|NCT00742222|Radiation|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
79807971|NCT00742222|Radiation|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
79807972|NCT00845676|Drug|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
79807973|NCT00707148|Drug|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
79643801|NCT00165152|Procedure|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
79807974|NCT00707148|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
79807975|NCT00742300|Procedure|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
79973151|NCT02494726|Other|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
79643802|NCT00165152|Procedure|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
79643803|NCT04297267|Drug|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
79643804|NCT04297267|Drug|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
79807976|NCT02611908|Drug|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
79643805|NCT00176475|Biological|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
79807977|NCT02611908|Drug|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
79807978|NCT02561884|Drug|Olostar Tab.|
79807979|NCT02561884|Drug|Co-administration of Olmetec and Crestor|
79807980|NCT00655655|Drug|everolimus|Given orally
79807981|NCT00655655|Drug|vatalanib|Given orally
79807982|NCT00655655|Other|pharmacological study|Correlative study (Cohort IIA only)
79643806|NCT00176475|Biological|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
79643807|NCT04283968|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
79643808|NCT04283968|Biological|placebo fecal transplantation|placebo fecal transplantation
79643809|NCT00165191|Drug|Doxorubicin|
79643810|NCT00165191|Drug|Cisplatin|
79643811|NCT00165191|Drug|5-fluorouracil|
79807983|NCT00655655|Other|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
79807984|NCT00655655|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
79807985|NCT00655655|Procedure|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
79807986|NCT00845520|Device|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
79807987|NCT00845520|Device|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
79807988|NCT00845520|Device|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
79643812|NCT04231357|Drug|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
79317451|NCT04403802|Device|Placebo Socks|"Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
79317452|NCT04400760|Drug|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
79643813|NCT00176514|Drug|Administration of the antineoplastic|
79317453|NCT04378634|Behavioral|Exercise|Sub-maximal exercise test
79643814|NCT00165230|Drug|Thalidomide|
79317454|NCT04378634|Other|Mental Stress Test|Computerised mental arithmetic challenges and social evaluative threat tasks
79643815|NCT00165230|Drug|Temodar|
79643816|NCT04175041|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
79643817|NCT04166500|Procedure|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
79807989|NCT02638571|Other|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
79317455|NCT04366440|Behavioral|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
79317456|NCT04366440|Other|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
79317457|NCT04362657|Diagnostic Test|Computer Aided Diagnosis|Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
79317458|NCT04338776|Device|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
79643818|NCT00176553|Drug|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
79643819|NCT00165269|Procedure|Mantle irradiation|Limited to above the diaphragm
79643820|NCT00165308|Drug|Tamoxifen|Given orally, daily for one year.
79643821|NCT00194376|Procedure|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
79643822|NCT00165347|Drug|PTK787/ZK222584|
79643823|NCT00176670|Drug|midazolam or GameBoy or parental presence|
79643824|NCT00165386|Procedure|Magnetic Resonance Imaging|
79643825|NCT00165386|Procedure|Bone Marrow Biopsy|
79643826|NCT00176748|Drug|AG 6013736|5 mg po bid
79643827|NCT00165464|Drug|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
79643828|NCT00165464|Drug|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
79643829|NCT00165464|Drug|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
79643830|NCT04118140|Other|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
79643831|NCT04118140|Other|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
79643832|NCT04118140|Other|Usual care|Usual care only (an education booklet)
79643833|NCT00194415|Behavioral|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
79643834|NCT00194415|Procedure|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
79643835|NCT04082650|Drug|vitamin D|4000IU per day
79643836|NCT04082650|Other|Placebo|The same doses with vitamin D
79643837|NCT00165542|Other|A PROTEIN level|
79973152|NCT01301105|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
79317459|NCT04338776|Device|Rezum|"The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra."
79317460|NCT04302961|Other|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
79317461|NCT04302961|Other|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
79317462|NCT04287621|Drug|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
79317463|NCT04286308|Other|electrophysiological data collection|Electrophysiological data collection at the time of DBS surgery.
79317464|NCT04286243|Other|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
79317465|NCT04286243|Other|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
79643838|NCT00194454|Behavioral|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
79973153|NCT01301105|Behavioral|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
79643839|NCT00194454|Other|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
79643840|NCT04036942|Procedure|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
79643841|NCT04036942|Procedure|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
79807990|NCT00844896|Behavioral|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
79973154|NCT01299233|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
79973155|NCT03341650|Behavioral|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
79973156|NCT03341650|Behavioral|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
79973157|NCT03558997|Drug|Dupilumab|Dupilumab was administered SC in a single-use, pre-filled glass syringe
79973158|NCT03558997|Drug|Timothy Grass SCIT|Timothy grass extract was administered SC.
79973159|NCT03558997|Drug|Placebo matching dupilumab|Placebo matching dupilumab was prepared in the same formulation without the addition of protein
79973160|NCT03558997|Drug|Placebo matching SCIT|Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
79317466|NCT04283994|Behavioral|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
79477996|NCT05993650|Other|Thoracic Expansion Exercise Group|"Individuals in this group will be given thoracic expansion exercises and patient education. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of inhale a deep breathing + holding the deep breath for 3 seconds + slowly exhale all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
79477997|NCT05993637|Other|Examination of propriception|application of the tests used in proprioception assessment to patients by a physiotherapist
79317467|NCT04283994|Behavioral|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
79477998|NCT05993624|Device|virtual reality|The BeCure Balance Assessment System protocol used in this study; It was planned to determine the amount of change in the center of gravity in the x and y axes and the position of the center of gravity of the body with images during standing and balancing for 15 seconds on the board with eyes open. In order to support the balanced development of the participants with the Becure system; Balance surfing, balance adventure, balance bowling and traffic games were played. uBall, gates, smartclean and SmartBubblePop games with Kinect for the upper extremity; KneeUp game was played on the lower extremity.
79477999|NCT05993598|Other|hippotherapy|Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
79478000|NCT05993585|Other|Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control|(Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
79478001|NCT05993585|Other|Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT|(CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
79478002|NCT05993455|Drug|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (> 1,000 mg).
79317468|NCT04271202|Drug|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
79317469|NCT04253964|Drug|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
79478003|NCT05993416|Drug|Nedosiran|In adults and in adolescents (aged 12-17 years) weighing greater than or equal to (>=) 50 kilograms (kg), Nedosiran will be administered via subcutaneous (SC) injection once monthly at a dose of 170 milligrams (mg). In adults and adolescents weighing < 50 kg, nedosiran will be administered once monthly at a dose of 136 mg. The dose for participants aged 6 to 11 years will be 3.5 mg/kg monthly, not to exceed 170 mg.
79478004|NCT05993403|Other|Intercultural Sensitivity Education Program|The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
79478005|NCT05993312|Other|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
79478006|NCT05993299|Drug|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
79478007|NCT05993299|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
79478008|NCT05993299|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
79478009|NCT05993286|Behavioral|Exposure Therapy|"At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions."
79478010|NCT05993286|Other|Sound Therapy|Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.
79478011|NCT05993286|Other|Psychoeducation|A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
79807991|NCT00844896|Behavioral|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
79317470|NCT04253964|Drug|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
79643842|NCT00165581|Device|High Dose Intracavitary Brachytherapy|
79643843|NCT03997201|Procedure|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
79643844|NCT00176787|Drug|Capecitabine|
79643845|NCT00176787|Procedure|Radiation|
79643846|NCT00176787|Procedure|Surgery|
79643847|NCT00165620|Drug|Iomeprole|
79643848|NCT00176943|Drug|Aldara Cream 5%|
79807992|NCT00654719|Dietary Supplement|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
79317471|NCT04253964|Drug|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
79478012|NCT05993273|Procedure|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
79807993|NCT00654719|Dietary Supplement|Placebo|Nutritional supplementation containing only 12 kcal/day
79807994|NCT00654797|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
79807995|NCT00837330|Drug|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
79807996|NCT00703638|Drug|cisplatin|Cisplatin administered intravenously, 75 mg/m^2 over 1-2 hours on day 1 of a 21 day cycle
79807997|NCT00703638|Drug|pemetrexed disodium|Pemetrexed 500 mg/m^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
79807998|NCT00703638|Drug|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
79807999|NCT00837096|Device|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
79808000|NCT00837096|Device|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
79317472|NCT04253964|Drug|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
79317473|NCT04253964|Other|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
79808001|NCT00703794|Device|The AXIUM Progressive Coil System|Embolization of aneurysm
79808002|NCT05478564|Other|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
79808003|NCT00885677|Device|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
79808004|NCT02637479|Device|GammaKnife®|
79808005|NCT02637479|Device|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
79808006|NCT02637479|Device|MRI|
79808007|NCT04162301|Drug|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
79808008|NCT02637401|Behavioral|Dialectical Behaviour Therapy|
79808009|NCT00885365|Drug|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
79808010|NCT00885365|Drug|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
79808011|NCT00827112|Drug|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
79317474|NCT04253964|Other|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
79317475|NCT04253964|Other|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
79317476|NCT04253964|Drug|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
79317477|NCT04251221|Drug|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
79317478|NCT04248257|Behavioral|PeACE|3 session peer coaching intervention
79317479|NCT04248257|Behavioral|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
79317480|NCT04224727|Behavioral|Group Commitment Contract|A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
79317481|NCT04224727|Behavioral|Individual Monetary Rewards|Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
79317482|NCT04224727|Behavioral|Individual Commitment Contract|Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
79317483|NCT04224727|Other|Information|"In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates."
79317484|NCT04221451|Drug|venglustat GZ402671|"Pharmaceutical form: tablet~Route of administration: oral"
79317485|NCT04221451|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79317486|NCT04203238|Other|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
79317487|NCT04203238|Other|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
79478013|NCT05993273|Procedure|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
79317488|NCT04200313|Combination Product|Bionic Pancreas (BP) with Aspart or Lispro|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
79808012|NCT00827112|Drug|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
79808013|NCT00689104|Drug|Mirabegron|Tablets
79317489|NCT04200313|Combination Product|Bionic Pancreas with Fiasp (BPFiasp)|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
79808014|NCT00689104|Drug|Tolterodine|Capsules
79808015|NCT00689104|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
79317490|NCT04200313|Other|Usual Care (UC)|Using pre-study insulin regimen with the Dexcom G6 CGM
79808016|NCT00689104|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
79317491|NCT04200313|Other|BP Guidance Insulin Dosing|Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
79317492|NCT04198337|Procedure|Endoscopic Full Thickness Resection|Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
79317493|NCT04197180|Procedure|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
79317494|NCT04196062|Device|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
79478014|NCT05993273|Procedure|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
79478015|NCT05993260|Behavioral|Behavioural science-informed text messages|Behaviourally-informed content in vaccination eligibility reminder text messages
79478016|NCT05993260|Behavioral|Control|Control vaccination eligibility reminder text message
79808017|NCT02635217|Device|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
79808018|NCT02635217|Device|room air insufflation|using standard care room air will be infused on demand
79808019|NCT02635217|Procedure|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
79808020|NCT02635217|Procedure|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
79317495|NCT04194723|Procedure|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
79643849|NCT03978208|Drug|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
79808021|NCT00702078|Behavioral|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
79808022|NCT00702078|Behavioral|usual care|follow-up according to todays best practice
79808023|NCT00702156|Drug|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
79808024|NCT00702156|Drug|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
79808025|NCT00707382|Genetic|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
79317496|NCT04187326|Behavioral|Facial Microexpression Training|The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
79317497|NCT04184609|Other|Control|In this condition, the participants will not receive any medications or drugs before exercise
79317498|NCT04184609|Drug|Albuterol|180 mcg of Albuterol will be administered before exercise
79317499|NCT04182477|Diagnostic Test|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
79317500|NCT04174859|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
79317501|NCT04149600|Procedure|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
79317502|NCT04119804|Diagnostic Test|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
79317503|NCT04101851|Procedure|omission of SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
79317504|NCT04099524|Device|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
79317505|NCT04055844|Drug|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
79478017|NCT05993247|Combination Product|Probiotics capsule|Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
79478018|NCT05993247|Combination Product|Placebo capsule|Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
79478019|NCT05993195|Device|Conduit Titanium Interbody Graft|The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.
79478020|NCT05993195|Device|Concorde Bullet Device|This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
79478021|NCT05993156|Device|modified Fixed twinblock|modified fixed twin block functional appliance, with cemented bands on the first molars
79478022|NCT05993156|Device|removable twin block|Conventional Removable Clark twin block myofunctional appliance
79478023|NCT05993143|Drug|Ivermectin|Round and white tablets
79478024|NCT05993143|Drug|Placebo|Round and white tablets
79478025|NCT05993130|Other|The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study
79478026|NCT05992987|Diagnostic Test|Adenosine deaminase serum level|Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).
79317506|NCT04055844|Drug|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to >100 x 10^9/L.
79317507|NCT04055844|Drug|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
79317508|NCT04053322|Drug|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
79317509|NCT04053322|Drug|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
79317510|NCT04053322|Drug|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
79317511|NCT04050176|Behavioral|Hypnotic Medication Open-Label Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.
79317512|NCT04050176|Behavioral|Hypnotic Medication Blinded Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
79317513|NCT04049279|Procedure|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
79317514|NCT04049279|Procedure|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
79973161|NCT03814421|Drug|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
79973162|NCT02493244|Other|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
79973163|NCT03814343|Drug|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
79973164|NCT03814343|Drug|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
79973165|NCT03341572|Other|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
79973166|NCT04603274|Procedure|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
79317515|NCT04049279|Procedure|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
79478027|NCT05992987|Diagnostic Test|IgE antibodies serum level|Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
79478028|NCT05992948|Device|Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations
79478029|NCT05992883|Drug|Ketorolac|Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
79317516|NCT04042467|Behavioral|Greenlight Plus|Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
79317517|NCT04042467|Behavioral|Greenlight|All residents and families seen in the participating clinics will receive the basic Greenlight materials.
79317518|NCT04031820|Procedure|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
79317519|NCT04031820|Procedure|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
79317520|NCT04029025|Procedure|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
79317521|NCT04029025|Procedure|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
79317522|NCT04029025|Procedure|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
79478030|NCT05992883|Drug|Triamcinolone|Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
79478031|NCT05992870|Radiation|Neoadjuvant radiotherapy|"In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment."
79478032|NCT05992805|Other|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
79317523|NCT04028037|Procedure|FTPGT treated patients|"The recipient bed will be prepared according to Langer&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured."
79317524|NCT04028037|Procedure|CAF+SCTG treated patients|According to De Sanctis & Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
79317525|NCT04020744|Other|real-time fMRI based neurofeedback from the hippocampus|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
79317526|NCT04020744|Other|real-time fMRI based neurofeedback from another brain area|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
79317527|NCT04015973|Dietary Supplement|High energy diet|An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
79478033|NCT05992792|Behavioral|App message|Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.
79478034|NCT05992792|Behavioral|SMS message|Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
79478035|NCT05992792|Behavioral|Internet|Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
79478036|NCT05992792|Behavioral|Whithout internet|Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
79973167|NCT03817541|Device|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
79478037|NCT05992779|Other|Measuring the vocal audiometry of patients.|Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up
79478038|NCT05992779|Other|Measuring data loging|Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
79973168|NCT03341494|Drug|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
79317528|NCT04006210|Combination Product|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
79973169|NCT03814265|Behavioral|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
79973170|NCT03341416|Device|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
79317529|NCT04006210|Combination Product|Placebo for SC infusion|Placebo solution administered SC via infusion pump
79317530|NCT04006210|Drug|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
79317531|NCT04006210|Drug|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
79317532|NCT03963817|Diagnostic Test|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.
79317533|NCT03963817|Diagnostic Test|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
79317534|NCT03960177|Drug|Glucarpidase|Given IV
79317535|NCT03960177|Other|Quality-of-Life Assessment|Ancillary studies
79317536|NCT03939533|Drug|CUTAQUIG|Human normal immunoglobulin
79317537|NCT03932461|Procedure|Vacuum assisted closure|The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
79317538|NCT03932461|Procedure|"Relaparotomy on demand"|Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
79317539|NCT03931655|Diagnostic Test|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
79317540|NCT03905655|Drug|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
79317541|NCT03905655|Drug|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
79643850|NCT03978208|Other|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
79643851|NCT03978208|Drug|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
79643852|NCT03978208|Drug|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
79643853|NCT00165659|Drug|DONEPEZIL HYDROCHLORIDE|
79643854|NCT00176982|Drug|Hydroxychloroquine|
79317542|NCT03863730|Dietary Supplement|Profermin Plus, FSMP, probiotics|"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."
79643855|NCT00165737|Drug|Donepezil Hydrochloride|
79317543|NCT03863730|Dietary Supplement|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
79317544|NCT03862365|Genetic|Nerve conduction Studies|Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
79317545|NCT03851406|Device|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
79478039|NCT05992766|Other|Reformer Pilates|Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.
79317546|NCT03851406|Other|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
79317547|NCT03836950|Device|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
79317548|NCT03836950|Device|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
79317549|NCT03821129|Device|PFO closure with GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
79317550|NCT03814928|Behavioral|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
79478040|NCT05992766|Other|Hammock Yoga|Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.
79478041|NCT05992766|Other|Traditional mat exercises|The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
79973171|NCT03341416|Device|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
79643856|NCT00194493|Behavioral|ESRA-C|Graphical summary of patient symptoms and quality of life
79973172|NCT03827135|Other|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
79317551|NCT03794726|Procedure|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
79317552|NCT03794726|Procedure|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
79317553|NCT03761849|Drug|RO7234292|Intrathecal injection
79317554|NCT03761849|Drug|Placebo|Intrathecal injection
79317555|NCT03751800|Drug|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
79317556|NCT03737786|Other|Tight control of end-tidal CO2 levels|The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
79478042|NCT05992753|Other|Questionnaire application|The research data were collected from 455 mothers admitted to the postpartum and lactation unit of a city hospital in Istanbul between September and November 2022. The mothers to be included in the study sample were determined according to the non-probability sampling method, considering the inclusion criteria of the study. The research data were collected by the researchers face-to-face through a questionnaire that lasted about 10-20 minutes.
79478043|NCT05992727|Diagnostic Test|Galectin 3 measurement in serum and saliva by ELIZA|Galectin 3 measurement in serum and saliva by ELISA in the two groups
79478044|NCT05992714|Device|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
79643857|NCT04682899|Drug|procalcitonin-guided antibiotic therapy|In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
79643858|NCT04682899|Drug|guideline-guided antibiotic therapy|In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
79643859|NCT03789916|Drug|Ticagrelor|90 mg bis in die
79643860|NCT03789916|Drug|acetylsalicylic acid|100 mg die
79643861|NCT00165815|Drug|ARICEPT|
79973173|NCT03827135|Other|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
79317561|NCT03698994|Other|Pharmacokinetic Study|Ancillary studies
79643862|NCT00177021|Drug|Aldara Cream 5%|
79973174|NCT03723733|Behavioral|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
79973175|NCT01207037|Procedure|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
79973176|NCT03817619|Drug|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
79973177|NCT03817619|Drug|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
79973178|NCT05480774|Drug|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
79973179|NCT05480774|Drug|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
79973180|NCT03335410|Other|Non- interventional|Non- interventional
79317562|NCT03698994|Drug|Ulixertinib|Given PO
79317563|NCT03654508|Genetic|ADRB2-genotype guided treatment|This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
79317564|NCT03654508|Other|Randomisation|In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
79317565|NCT03613727|Drug|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
79317566|NCT03604432|Device|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
79317567|NCT03593525|Other|SPARK|see above
79317568|NCT03582930|Combination Product|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
79973181|NCT03725995|Drug|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
79317569|NCT03572335|Diagnostic Test|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
79317570|NCT03561441|Drug|Tailored aggressive hydration|"Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~At 8 hours, if pain (<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
79317571|NCT03561441|Drug|Tailored standard hydration|"Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~At 8 hours, if pain (<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
79317572|NCT03555149|Drug|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
79317573|NCT03555149|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
79317574|NCT03555149|Drug|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
79317575|NCT03555149|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
79317576|NCT03555149|Drug|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
79317577|NCT03555149|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
79317578|NCT03555149|Drug|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
79317579|NCT03555149|Drug|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
79973182|NCT03725995|Drug|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
79973183|NCT03725995|Drug|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
79973184|NCT01299311|Behavioral|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
79973185|NCT01299311|Behavioral|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
79973186|NCT03341260|Drug|Diclofenac Potassium 50mg Tab.|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
79973187|NCT03341260|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
79973188|NCT03052400|Drug|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
79317580|NCT03555149|Genetic|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
79317581|NCT03541512|Behavioral|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
79317582|NCT03541512|Behavioral|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
79973189|NCT03052400|Drug|Placebo|Matching placebo
79317583|NCT03530267|Drug|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
79973190|NCT01301261|Drug|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
79973191|NCT01301261|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
79973192|NCT01301261|Drug|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
79973193|NCT03723577|Device|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
79317584|NCT03530267|Drug|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
79317585|NCT03515811|Device|Signia™ Stapling System|Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
79317586|NCT03512418|Behavioral|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
79478045|NCT05992714|Device|white noise group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using phone
79478046|NCT05992636|Procedure|pneumoperitoneum insufflation (flow) rate|"Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)"
79478047|NCT05992623|Device|Zoll external defibrillator|Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator
79478048|NCT05992623|Device|Lifepak external defibrillator|Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
79973194|NCT03341182|Procedure|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
79317587|NCT03512418|Device|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
79317588|NCT03512418|Drug|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
79317589|NCT03463265|Drug|nab-sirolimus|nab-sirolimus, single agent
79317590|NCT03463265|Drug|nab-sirolimus + temozolomide|temozolomide, combination
79317591|NCT03463265|Drug|nab-sirolimus + bevacizumab|bevacizumab, combination
79973195|NCT03341182|Procedure|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
79808026|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
79808027|NCT00707382|Other|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
79317592|NCT03463265|Drug|nab-sirolimus + lomustine|lomustine, combination
79317593|NCT03463265|Drug|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
79317594|NCT03463265|Drug|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
79317595|NCT03459092|Drug|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
79808028|NCT02638415|Procedure|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
79317596|NCT03459092|Procedure|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
79317597|NCT03453931|Drug|Corticosteroid injection|Intravenous high dose corticosteroids
79973196|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
79317598|NCT03438552|Radiation|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
79317599|NCT03374800|Drug|Placebo (0.9% saline)|normal saline
79317600|NCT03374800|Drug|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
79317601|NCT03373968|Drug|Givinostat|suspension of givinostat (10 mg/mL)
79317602|NCT03329300|Behavioral|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
79317603|NCT03304210|Drug|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
79317604|NCT03297346|Other|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
79317605|NCT03289741|Drug|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
79317606|NCT03289741|Drug|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
79317607|NCT03289741|Behavioral|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
79808029|NCT02638415|Other|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
79808030|NCT02638415|Drug|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
79808031|NCT00703872|Drug|Oral HDV-Interferon + ribavarin|Naive pateints
79808032|NCT00703872|Drug|Injectable HDV-Interferon + ribavarin|Nonresponders
79808033|NCT00703950|Procedure|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
79808034|NCT00703950|Procedure|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
79973197|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
79973198|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
79317608|NCT03205657|Procedure|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
79317609|NCT03142711|Other|No Medical Intervention|Validation of phone ePRO
79643863|NCT03768310|Biological|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
79317610|NCT03125343|Procedure|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~PET-CT is optional, but can be performed at inclusion~Pelvic MRI including diffusion weighted imaging according to appendix C.~Clinical examination~Endoscopy (flexible sigmoidoskopy) with photodocumentation~CEA~After two years the patients will be followed every six month with:~Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~Clinical examination~Endoscopy with photodocumentation~CEA"
79317611|NCT03125343|Procedure|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
79317612|NCT03125343|Device|MRI|
79317613|NCT03109210|Behavioral|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
79317614|NCT03109210|Behavioral|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
79317615|NCT03086798|Procedure|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
79317616|NCT03086798|Procedure|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
79317617|NCT03083652|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
79317618|NCT03083652|Other|Sham|Conventional physiotherapy with NMES device NOT activated
79317619|NCT03035877|Behavioral|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
79317620|NCT03035877|Behavioral|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
79643864|NCT03768310|Biological|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
79643865|NCT03729154|Behavioral|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
79643866|NCT03697603|Drug|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
79643867|NCT03697603|Drug|Placebo|Tablets, Oral, once daily, 14 weeks
79643868|NCT00165854|Drug|E7070|
79643869|NCT00177060|Drug|hydromorphone|
79973199|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
79973200|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
79317621|NCT03017560|Behavioral|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
79478049|NCT05992610|Other|Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy|"Chemotherapy based on carboplatin 6 AUC + paclitaxel 75 mg/m2.~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
79643870|NCT03686644|Procedure|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
79973201|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
79478050|NCT05992480|Biological|rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)|It is an Ebola virus vaccine
79478051|NCT05992441|Other|SCALE DEVELOPMENT STUDY|"The study to be carried out is a scale development study. The steps to be followed for the scale development study are as follows;~Creating an item pool by making use of the literature review on the subject,~Questioning the relevance of the prepared question pool to the subject to be measured with the Expert Evaluation Form by experts in the field,~Pilot application,~Switching to the main study after the pilot application,~After the factor and item analyzes, the final arrangements regarding the item and form of the scale will be completed.~As a result of this study, an awareness scale related to physiotherapy will be created for individuals with breast cancer."
79643871|NCT03686644|Procedure|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
79643872|NCT00194571|Behavioral|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
79973202|NCT03730285|Device|Telemedicine|Installation of videotelephone with broadband in patient's home
79973203|NCT03335176|Behavioral|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
79973204|NCT03341104|Drug|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
79643873|NCT00165893|Device|Accu-Spina Device/IDD therapy|
79643874|NCT00165893|Procedure|Physical Therapy|
79643875|NCT03421639|Drug|GnRH analog (3,75mg Leuprolide)|3,75 Leuprolide monthly for 3 months
79973205|NCT03538951|Drug|10% VDA-1102|200 mg twice-daily for 12 weeks
79973206|NCT03538951|Drug|20% VDA-1102|200 mg once-daily for 12 weeks
79973207|NCT03335098|Drug|Bortezomib|Six 4-week cycles
79973208|NCT03341026|Other|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
79973209|NCT03341026|Other|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
79478052|NCT05992415|Other|Intervention Using Patient Navigators|Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
79478053|NCT05992415|Other|Usual Care Without Patient Navigators|Consented participants referred from the 5 developments randomized to the Usual Care Arm 2 who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
79478054|NCT05992363|Device|ureteral stent\s insertion|ureteral stent\s insertion in the operating room
79643876|NCT03421639|Drug|Aromatase inhibitor plus GnRH analog (3,75mg Leuprolide)|1mg/day of Anastrazole plus Leuprolide 3.75mg/monthly for 3 months
79643877|NCT00177099|Drug|FK506, GP11046, GP11511|
79643878|NCT03413800|Drug|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
79478055|NCT05992324|Device|Caption LungAI|Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
79478056|NCT05992298|Other|7 T MRI vs 3 T MRI|Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
79478057|NCT05992285|Device|transcranial magnetic stimulation|the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
79478058|NCT05992272|Biological|fMRI imaging (BOLD)|Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
79478059|NCT05992272|Biological|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
79643879|NCT00165971|Procedure|BIS monitoring|
79643880|NCT03303742|Other|deep chamfer|finish line marginal design of a full coverage crown preparation
79643881|NCT03303742|Other|feather edge|finish line marginal design of a full coverage crown preparation
79643882|NCT03207256|Drug|TGR-1202|Oral Daily TGR-1202
79643883|NCT03207256|Drug|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
79643884|NCT00166010|Drug|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
79973210|NCT03723499|Other|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
79317622|NCT03015805|Behavioral|Contingency Management|"Contingency Management (CM) utilizes behavior modification & cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
79317623|NCT03015805|Behavioral|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
79317624|NCT02975934|Drug|Rucaparib|Rucaparib will be administered daily.
79317625|NCT02975934|Drug|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
79317626|NCT02975453|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
79317627|NCT02911142|Drug|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
79317628|NCT02911142|Drug|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
79317629|NCT02911142|Drug|Prednisone|During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.
79317630|NCT02911142|Drug|Etopside|During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.
79317631|NCT02911142|Drug|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
79317632|NCT02911142|Drug|Vincristine|During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
79317633|NCT02911142|Drug|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
79478060|NCT05992272|Behavioral|Trier Social Stress Test|Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
79808035|NCT00702312|Behavioral|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
79973211|NCT03725917|Other|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
79973212|NCT03120598|Behavioral|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
79317634|NCT02864758|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
79317635|NCT02864758|Drug|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
79317636|NCT02864758|Drug|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
79973213|NCT03120598|Behavioral|ISF strategy|Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
79973214|NCT03817385|Device|repetitive TMS|rTMS x 10 times
79973215|NCT03817385|Device|robotic GT|robotic gait training for 20 times
79973216|NCT03639571|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
79973217|NCT03639571|Other|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
79973218|NCT03814031|Other|NO internvention|NO internvention
79973219|NCT03052322|Drug|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
79973220|NCT03052322|Drug|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
79973221|NCT05465512|Other|response to neoadjuvant chemotherapy|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
79973222|NCT05655455|Behavioral|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
79973223|NCT05655455|Behavioral|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
79973224|NCT03340948|Behavioral|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
79973225|NCT02493010|Device|Arousal-based biofeedback system|
79973226|NCT03521791|Drug|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% [Lagricel ofteno®] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
79973227|NCT03521791|Other|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
79973228|NCT01207193|Biological|cell injection|injection of mesenchymal cells to bone cyst defect
79973229|NCT02492698|Dietary Supplement|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
79973230|NCT02492698|Dietary Supplement|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
79973231|NCT03817697|Other|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
79973232|NCT03335020|Device|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
79973233|NCT03335020|Device|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
79973234|NCT03335020|Drug|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
79317637|NCT02847598|Drug|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
79317638|NCT02847598|Drug|Placebo|Administered as specified in the treatment arm.
79317639|NCT02834975|Drug|Pembrolizumab|Pembrolizumab on Day 1 of each cycle.
79317640|NCT02834975|Drug|Paclitaxel|"NACT: Paclitaxel on Day 1 of each cycle;~ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol."
79973235|NCT03335020|Other|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
79973236|NCT03335020|Device|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
79973237|NCT01207271|Behavioral|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
79317641|NCT02834975|Drug|Carboplatin|Carboplatin IV on Day 1 of each cycle.
79317642|NCT02822508|Drug|BLI801 Laxative|BLI801 oral laxative
79317643|NCT02822508|Drug|BLI801 Placebo|BLI801 oral laxative placebo
79317644|NCT02811198|Other|No intervention|
79317645|NCT02755272|Drug|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
79317646|NCT02755272|Drug|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
79317647|NCT02755272|Drug|Gemcitabine|IV infusion of 800 mg/m^2 given on days one and eight of each 21 day treatment cycle.
79317648|NCT02708940|Other|Participatory technology development|Creating mobile support tools by patients and their therapists
79317649|NCT02708940|Other|Usual Care|Usual care as part of the UCLA PHP and IOP programs
79317650|NCT02684123|Drug|Apremilast|Subjects will get drug or placebo
79317651|NCT02684123|Drug|Placebo|
79317652|NCT02621021|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
79317653|NCT02621021|Drug|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
79317654|NCT02621021|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
79808036|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
79808037|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
79317655|NCT02621021|Drug|Pembrolizumab|(Cohort 1, Arm 2 and Cohort 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes. (Cohort 1, Arm 1 Retreatment) 4 doses every 3 weeks (+/- 2 days): Pembrolizumab 2mg/kg IV over approximately 30 minutes.
79317656|NCT02621021|Biological|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
79317657|NCT02606448|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
79317658|NCT02606448|Procedure|Femoral nerve block|Pre-operative femoral nerve block
79317659|NCT02606448|Drug|Ropivacaine|Ropivicaine was used in all femoral nerve blocks
79317660|NCT02584309|Drug|Dexrazoxane|
79317661|NCT02584309|Drug|Doxorubicin|
79317662|NCT02576574|Drug|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
79317663|NCT02576574|Drug|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
79317664|NCT02576574|Drug|Paclitaxel|Participants received Paclitaxel 200 mg/m^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
79808038|NCT00742456|Dietary Supplement|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
79317665|NCT02576574|Drug|Gemcitabine|Participants received Gemcitabine 1250 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
79478061|NCT05992272|Behavioral|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
79973238|NCT01207271|Behavioral|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
79478062|NCT05992272|Behavioral|Counting Stroop task|Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
79808039|NCT00742456|Dietary Supplement|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
79973239|NCT03340870|Drug|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
79973240|NCT03521635|Drug|Pramipexole SR|Tablets
79973241|NCT03521635|Drug|Pramipexole IR|Tablets
79973242|NCT03813953|Procedure|Liver resection|Resection of diseased liver
79973243|NCT03340792|Device|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
79973244|NCT03813797|Device|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
79973245|NCT03813797|Device|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
79973246|NCT03120754|Procedure|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
79973247|NCT03120754|Procedure|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
79973248|NCT03723421|Other|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
79973249|NCT03723421|Other|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
79973250|NCT03817073|Device|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
79973251|NCT03170544|Drug|MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
79973252|NCT03170544|Drug|MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
79973253|NCT03170544|Drug|MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
79973254|NCT03170544|Drug|MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
79973255|NCT03170544|Drug|MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
79973256|NCT03170544|Drug|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
79973257|NCT03170544|Drug|Lispro 1.2 nmol/kg|Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting ~12 hours after MK-1092 administration.
79973258|NCT03170544|Drug|Placebo to glargine|Placebo to glargine, SC, as a single dose
79973259|NCT03170544|Drug|Placebo to MK-1092|Placebo to MK-1092, SC, as a single dose
79973260|NCT03170544|Other|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
79973261|NCT03170544|Biological|Insulin|Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
79973262|NCT03582943|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
79973263|NCT03582943|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
79478063|NCT05992272|Behavioral|No-go Simon task|Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
79317666|NCT02576574|Drug|Gemcitabine|Participants received Gemcitabine 1000 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
79973264|NCT03582943|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
79643885|NCT03183388|Behavioral|BE-SMART|Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
79973265|NCT03813563|Drug|RL|lactated Ringer's
79973266|NCT03813563|Drug|PLA|PlasmaLyte
79973267|NCT03334786|Drug|FLX-787-ODT|Oral Disintegrating Tablet
79317667|NCT02576574|Drug|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
79317668|NCT02576574|Drug|Cisplatin|Participants received Cisplatin 75 mg/m^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
79973268|NCT02494414|Other|Long-term follow-up|Vital and neurological follow-up
79973269|NCT03813641|Drug|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
79973270|NCT03813641|Drug|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
79973271|NCT02494492|Other|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
79973272|NCT05210478|Device|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
79973273|NCT03532009|Drug|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
79973274|NCT03532009|Drug|Placebo|Oral use for approximately 3 months
79317669|NCT02576574|Drug|Carboplatin|Carboplatin AUC 6 mg/mL*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
79317670|NCT02576574|Drug|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
79643886|NCT00166049|Behavioral|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
79973275|NCT05207046|Other|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely <72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
79973276|NCT03340558|Biological|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
79973277|NCT03340558|Drug|Cobimetinib|MEK inhibitor
79973278|NCT04905108|Drug|Riboflavin|Administration of riboflavin one drop every 2 minutes during UVA exposure
79973279|NCT04905108|Drug|Riboflavin|Administration of riboflavin one drop every 10 minutes during UVA exposure
79973280|NCT04443166|Combination Product|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
79973281|NCT04509570|Procedure|Biopsy|5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
79317671|NCT02540967|Drug|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
79478064|NCT05992272|Diagnostic Test|Stop Signal Task|"Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped."
79478065|NCT05992272|Diagnostic Test|blood samples|for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
79643887|NCT00166049|Behavioral|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
79973282|NCT01560221|Behavioral|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
79317672|NCT02439775|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
79317673|NCT02439775|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
79317674|NCT02403661|Procedure|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
79317675|NCT02389244|Drug|Regorafenib|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
79317676|NCT02389244|Drug|Placebo|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
79317677|NCT02257177|Drug|Inhaled TD139|DPI Galectin-3 inhibitor
79317678|NCT02257177|Drug|Placebo|DPI placebo
79478066|NCT05992272|Diagnostic Test|questionnaires for chronic stress|"Perceived Stress Scale~Social Readjustment Rating Scale~Trier Inventory for the Assessment of Chronic"
79478067|NCT05992272|Diagnostic Test|hair samples|Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
79478068|NCT05992272|Diagnostic Test|saliva samples|Assessing acute stress effects in AUD.
79643888|NCT00166049|Behavioral|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
79643889|NCT04685395|Drug|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
79478069|NCT05992272|Diagnostic Test|EMA assessment|We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
79317679|NCT02229656|Radiation|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
79317680|NCT02229656|Drug|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
79317681|NCT02207465|Radiation|Radiotherapy|
79317682|NCT02207465|Drug|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
79317683|NCT02203331|Drug|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
79973283|NCT01560221|Drug|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
79317684|NCT02203331|Drug|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
79317685|NCT02203331|Drug|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
79317686|NCT02203331|Drug|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
79317687|NCT02178436|Drug|gemcitabine hydrochloride|Given IV
79317688|NCT02178436|Drug|Selinexor|Given IV
79478070|NCT05992272|Diagnostic Test|clinical diagnostic|SKID-I Interview neurocognitive and psychopathological testing
79478071|NCT05992259|Device|TENS|TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
79478072|NCT05992233|Device|Dual wavelength low level laser|Application of double wavelength low level laser to the related area after tooth extraction.
79973284|NCT01560221|Drug|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
79973285|NCT03334474|Other||no intervention
79973286|NCT03813329|Dietary Supplement|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
79317689|NCT02178436|Other|Pharmacological Study|Correlative studies
79317690|NCT02178436|Other|Laboratory Biomarker Analysis|Correlative studies
79317691|NCT02178436|Drug|Nab paclitaxel|Given IV
79317692|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
79973287|NCT03813329|Dietary Supplement|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
79973288|NCT03813329|Dietary Supplement|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
79973289|NCT03723343|Drug|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1&d8 +Cisplatin 80 mg/m2 intravenously, d1 21~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
79973290|NCT03723343|Drug|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1~d521~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
79973291|NCT03340480|Drug|NVP-1402|Oral
79317693|NCT02170025|Drug|Placebo|Participants received matching placebo tid.
79973292|NCT03639415|Drug|Increasing the Controlled-Release Oxycodone dose frequency|Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
79973293|NCT03334240|Drug|CLS003|CLS003
79973294|NCT03334240|Drug|Vehicle|Vehicle
79973295|NCT03813485|Other|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
79317694|NCT02164578|Drug|Rivaroxaban|
79317695|NCT02164578|Drug|Aspirin|
79478073|NCT05992233|Device|Placebo|Only red light applied.
79643890|NCT04685122|Procedure|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
79643891|NCT00537784|Biological|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
79643892|NCT00537784|Biological|no injection|
79317696|NCT02107703|Drug|Abemaciclib|Administered Orally
79317697|NCT02107703|Drug|Fulvestrant|Administered IM
79643893|NCT04685278|Biological|Blood samples|Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization
79317698|NCT02107703|Drug|Placebo|Administered Orally
79317699|NCT02054247|Device|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
79317700|NCT02054247|Device|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
79317701|NCT02054247|Device|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
79317703|NCT01946100|Genetic|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
79317704|NCT01823198|Biological|Aldesleukin|Given SC
79317705|NCT01823198|Biological|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
79643894|NCT00166088|Dietary Supplement|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
79973296|NCT03813485|Other|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
79973297|NCT03340402|Radiation|Accelerated Partial Breast Irradiation|Proton radiation
79317706|NCT01823198|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
79973298|NCT03340402|Device|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
79317707|NCT01823198|Drug|Busulfan|Given IV
79317708|NCT01823198|Drug|Fludarabine Phosphate|Given IV
79317709|NCT01823198|Other|Laboratory Biomarker Analysis|Correlative studies
79317710|NCT01823198|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
79317711|NCT01823198|Other|Pharmacological Study|Correlative studies
79973299|NCT03721939|Device|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
79317712|NCT01761292|Drug|Givinostat|Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
79317713|NCT01725113|Drug|Calcitriol|3 times weekly
79973300|NCT01299623|Behavioral|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
79317714|NCT01725113|Drug|Paricalcitol|3 times weekly
79317715|NCT01580293|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
79317716|NCT01546766|Device|Pupillometry testing.|
79643895|NCT00166088|Dietary Supplement|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
79973301|NCT03334162|Behavioral|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
79317717|NCT01089933|Procedure|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
79317718|NCT01089933|Procedure|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
79317719|NCT00668772|Drug|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
79317720|NCT00668772|Drug|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
79317721|NCT00668772|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
79317722|NCT00668772|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
79317723|NCT00668772|Drug|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
79643896|NCT00537862|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79643897|NCT00537901|Radiation|First-Line Bevacizumab and Chemotherapy|Chemotherapy
79643898|NCT00537901|Drug|Bevacizumab|Chemotherapy
79973302|NCT02916953|Device|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
79973303|NCT02492542|Device|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
79973304|NCT03334084|Drug|ARGX-113|intravenous or subcutaneous administration
79478074|NCT05992220|Radiation|Atezolizumab plus bevacizumab, combined EBRT to vascular invasion|"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."
79478075|NCT05992220|Drug|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab q3w
79643899|NCT00166127|Drug|Levosimendan|
79643900|NCT00194649|Drug|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
79643901|NCT05425147|Other|Perioperative autonomic function assessment|Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
79643902|NCT05425069|Drug|Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P|We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
79973305|NCT03340324|Biological|V-Endo|V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
79973306|NCT03520387|Procedure|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
79478076|NCT05992207|Other|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
79973307|NCT03520387|Procedure|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
79973308|NCT03520387|Behavioral|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
79317724|NCT00595491|Biological|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
79317725|NCT00487305|Biological|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
79317726|NCT00382655|Procedure|Education and referral|
79317727|NCT00294827|Procedure|Liver transplantation and colo-rectal cancer|Liver transplantation
79317728|NCT00208507|Device|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
79317729|NCT00208507|Device|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
79317730|NCT00167219|Biological|Stem Cell Transplant|Transplantation on Day 0.
79317731|NCT00167219|Drug|Preparative Regimen|"Busulfan~Cyclophosphamide~Mesna~Melphalan~Anti-thymocyte Globulin (ATG)"
79808040|NCT00707460|Behavioral|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
79973309|NCT03520387|Behavioral|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
79317732|NCT05120921|Other|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
79317733|NCT05120921|Other|Self-management|Providing rehabilitative exercises to patients to do at home
79317734|NCT05120921|Other|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
79478077|NCT05992207|Other|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
79317735|NCT05120921|Other|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
79317736|NCT05745259|Drug|Alteplase|Alteplase 0.9mg/kg are being used.
79317737|NCT05745259|Drug|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
79317738|NCT05118581|Device|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
79317739|NCT02928107|Other|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
79317740|NCT02928107|Other|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
79317741|NCT02893241|Drug|Cafedrine/theodrenaline|
79317742|NCT02893241|Drug|Ephedrine|
79317743|NCT02395237|Drug|: Amaryl® M IR 2/1000|
79317744|NCT02394847|Drug|propofol|
79317745|NCT03167125|Other|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
79808041|NCT00689026|Drug|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
79317746|NCT03167125|Other|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
79317747|NCT04509479|Procedure|Valve replacement|Description of valve replacements
79317748|NCT05745181|Biological|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
79317749|NCT01960348|Drug|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
79317750|NCT01960348|Drug|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
79317751|NCT04508699|Other|semantic learning|Experimental semantic learning from linguistic context task
79478078|NCT05992142|Drug|5-ASA|Assessment of the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, who report to be in clinical remission during a routine follow-up visit
79808042|NCT00689026|Other|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
79973310|NCT02492386|Device|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
79973311|NCT03340168|Other|Bisphenol-S|Oral and dermal exposure in volunteers
79973312|NCT03170232|Drug|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
79973313|NCT03170232|Drug|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
79317752|NCT02395159|Device|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
79317753|NCT02395159|Other|sterile plaster dressings|standard wound management method of sterile plaster dressings
79808043|NCT04058002|Other|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
79973314|NCT03170232|Device|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
79973315|NCT03170232|Drug|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
79973316|NCT01299701|Drug|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
79317754|NCT05021861|Drug|Cyproterone Acetate, Ethinyl Estradiol Drug Combination|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
79973317|NCT03340090|Device|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
79973318|NCT03333850|Device|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
79973319|NCT03333850|Device|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
79317755|NCT05021861|Diagnostic Test|FEMALE PATIENTS WITH PCOS|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
79317756|NCT05021861|Diagnostic Test|Control group|SYSTEMICALLY HEALTHY FEMALES
79317757|NCT02403115|Other|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
79973320|NCT03333850|Device|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
79973321|NCT03721861|Device|Intra-operative neural cuff stimulation|A feasibility study consists of placing 2 electrodes around the radial or medial nerves intraoperatively. The movements caused by the electrical stimulation of these nerves are observed.
79973322|NCT01299779|Drug|PEG-SD|"PEG-SD~Bisacodyl: two 5-mg tablets at 3 pm day prior~1L sports drink* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~1L SD* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~Same flavor, non-red Gatorade® for all patients."
79973323|NCT01299779|Drug|PEG-ELS|"1L + 500 cc clear liquids at 6 pm night prior~1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
79973324|NCT02492620|Drug|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
79973325|NCT02426034|Drug|ApatinibTablets|Apatinib Tablets, recommended dose of 850mg
79973326|NCT03813251|Device|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
79973327|NCT03519919|Device|somofilcon A multifocal lens|contact lens
79973328|NCT03340012|Device|GTR + radiation-sterilize allogenic bone graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw
79973329|NCT03340012|Device|GTR + xenogenic graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
79973330|NCT01301417|Device|ColonRing™|Creation of a circular Compression Anastomosis
79973331|NCT03812939|Drug|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
79317758|NCT05230355|Device|360 degrees subthreshold diode laser cyclophotocoagulation|cyclophotocoagulation is applied along 360 degrees over pars plana
79317759|NCT05230355|Device|180 degrees subthreshold diode laser cyclophotocoagulation|cyclophotocoagulation is applied over one hemisphere only along 180 degrees in a double arc fashion
79317760|NCT04664062|Behavioral|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
79973332|NCT03333772|Behavioral|REAL-T Intervention|Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
79973333|NCT03813173|Procedure|lymph node dissection|The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
79317761|NCT02403037|Device|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
79317762|NCT02403037|Device|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
79973334|NCT03339856|Device|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
79317763|NCT02403037|Drug|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
79317764|NCT02653625|Drug|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning.
79317765|NCT05745025|Device|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor-evoked potentials (MEP) of the first dorsal interossei that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
79478079|NCT05992129|Other|foot exercise|These are foot and ankle muscle strengthening exercises described and evaluated by the literature
79973335|NCT03333694|Drug|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
79973336|NCT03333694|Drug|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
79973337|NCT05623631|Other|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
79973338|NCT03333538|Biological|GamEvac-Lyo (component A)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
79317766|NCT05745025|Device|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same methods as the active group, but a sham Air Film coil (Magstim Inc., Eden Prairie, MN) will be used. This coil looks and sounds like the active coil, but it does not deliver magnetic pulses.
79317767|NCT05745025|Other|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
79317768|NCT01981096|Behavioral|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
79317769|NCT01981096|Behavioral|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
79317770|NCT02394613|Drug|ANX776|Single intravenous injection
79973339|NCT03333538|Other|Placebo|Placebo vaccination
79973340|NCT03333538|Biological|GamEvac-Lyo (component B)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
79973341|NCT03333538|Biological|GamEvac-Lyo|Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
79973342|NCT03339700|Drug|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
79973343|NCT03339700|Drug|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
79973344|NCT03339700|Drug|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
79973345|NCT03339700|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
79973346|NCT05623553|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
79973347|NCT03813095|Drug|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
79973348|NCT03813095|Drug|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
79973349|NCT03333460|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
79317771|NCT02394691|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
79973350|NCT01301495|Device|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
79317772|NCT02652767|Biological|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
79973351|NCT03339622|Combination Product|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
79973352|NCT03339622|Combination Product|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
79317773|NCT02652767|Device|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
79317774|NCT04480333|Drug|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
79317775|NCT04480333|Drug|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
79317776|NCT04480333|Drug|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
79973353|NCT03333304|Diagnostic Test|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
79973354|NCT01299857|Drug|Rituximab|375mg/m2
79973355|NCT05465356|Other|Questionnaire|Questionnaires completed as part of routine care - this is an observational study
79808044|NCT04058002|Other|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
79973356|NCT05465356|Other|Semi-structured interview|Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
79973357|NCT03816371|Other|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
79973358|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
79973359|NCT03822923|Other|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
79973360|NCT03822923|Other|Control group|Conventional treatment
79973361|NCT02494024|Drug|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
79317777|NCT04480333|Drug|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
79317778|NCT04480333|Drug|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
79317779|NCT04480333|Drug|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
79317780|NCT04480333|Drug|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
79317781|NCT04480333|Drug|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
79317782|NCT04480333|Combination Product|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
79317783|NCT04480333|Combination Product|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
79317784|NCT04480333|Combination Product|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
79317785|NCT04480333|Combination Product|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
79317786|NCT03166891|Drug|Chiauranib|Take 50mg orally once daily
79317787|NCT04969601|Biological|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
79317788|NCT01980940|Drug|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
79317789|NCT01980940|Drug|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
79317790|NCT01980940|Drug|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
79973362|NCT02494024|Drug|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
79973363|NCT03478969|Device|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
79317791|NCT01980940|Drug|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
79973364|NCT03478969|Device|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
79973365|NCT03478969|Other|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
79973366|NCT03812783|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
79973367|NCT03812783|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
79973368|NCT03812783|Drug|Sorafenib|administration of Sorafenib
79973369|NCT03812783|Procedure|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
79973370|NCT03812783|Drug|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
79317792|NCT01980940|Drug|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
79973371|NCT02500498|Drug|Nulojix|
79973372|NCT03812861|Other|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
79317793|NCT01980940|Drug|Placebo|Placebo gel applied topically.
79808045|NCT00598559|Drug|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
79643903|NCT03455257|Behavioral|Cash Transfer|The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
79478080|NCT05992077|Drug|Sofosbuvir/Daclatasvir|Patients with a weight > 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
79478081|NCT05992051|Behavioral|Exercise Therapy|Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
79808046|NCT00686686|Biological|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
79808047|NCT02637167|Drug|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
79317794|NCT01980940|Drug|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
79808048|NCT02637167|Drug|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
79813718|NCT02609438|Behavioral|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
79317795|NCT01980940|Drug|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
79317796|NCT02394223|Procedure|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
79317797|NCT04857437|Drug|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
79317798|NCT04857437|Drug|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
79317799|NCT04857437|Drug|Placebo|Matching Placebo
79317800|NCT02394379|Device|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
79317801|NCT05229575|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
79317802|NCT04842929|Device|Transcranial magnetic stimulation|The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
79317803|NCT02699983|Behavioral|Behavioral Dietary Intervention|Use SparkPeople web-based program
79478082|NCT05992025|Behavioral|Physical activity|Intervention with physical activity more than 150 minutes of medium to high intensity per week.
79478083|NCT05992025|Behavioral|Sleep hygiene|Intervention with sleep hygiene to optimize sleep duration and quality.
79478084|NCT05991986|Other|somatic cell collection|One or more types of somatic cells will be collected from every participant by collecting approximately 100~500 ml of midstream urine, 20~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc.
79643904|NCT00166244|Drug|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
79478085|NCT05991973|Drug|Chidamide|In the time window of 30-180 days after transplantation: oral chidamide 10mg twice a week with a total of 96 courses(4 weeks as a course). If the MRD turns positive during treatment, the dose can be increased to a maximum of 20 mg twice a week, and donor lymphocyte infusion (DLI) is also permitted in the case of MRD positivity.
79317804|NCT02699983|Behavioral|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
79317805|NCT02699983|Device|Activity Monitoring Device|Wear Fitbit activity monitoring device
79478086|NCT05991947|Other|No intervention|No intervention measures are needed.
79478087|NCT05991895|Drug|Iruplinalkib|Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
79317806|NCT01960114|Drug|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
79317807|NCT01960114|Drug|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
79478088|NCT05991882|Behavioral|Condition 1: Craving daily+PBS daily|Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
79478089|NCT05991882|Behavioral|Condition 2: Craving daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
79478090|NCT05991882|Behavioral|Condition 3: Craving trigger+PBS daily|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
79643905|NCT00194688|Drug|H. pylori treatment|
79643906|NCT05311930|Drug|2.5mg/d Hetrombopag|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
79643907|NCT00177138|Drug|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
79643908|NCT00177138|Drug|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV >monthly for 1 year (only if ALC>200 mm, up to a total of 10 doses in year)
79643909|NCT04687891|Diagnostic Test|transabdominal ultrasound and transvaginal ultrasound|Within a week before scheduled delivery,antepartum transabdominal and transvaginal ultrasound will be performed with moderately full bladder.
79643910|NCT00166283|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
79643911|NCT00166283|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
79317808|NCT04752527|Drug|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
79317809|NCT05229497|Drug|AK112|IV infusion,Specified dose on specified days
79317810|NCT05229497|Drug|AK117|IV infusion,Specified dose on specified days
79317811|NCT05229497|Drug|Carboplatin|IV infusion,Specified dose on specified days
79317812|NCT05229497|Drug|Cisplatin|IV infusion,Specified dose on specified days
79317813|NCT05229497|Drug|5-Fluorouracil|IV infusion,Specified dose on specified days
79317814|NCT02005276|Behavioral|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
79973373|NCT02500342|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
79317815|NCT02005276|Behavioral|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
79317816|NCT02005276|Behavioral|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
79317817|NCT03169777|Biological|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
79643912|NCT02427997|Behavioral|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
79643913|NCT02427997|Behavioral|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
79643914|NCT02266615|Genetic|Biobanking of biomaterial for future genetic research.|
79643915|NCT00177177|Drug|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
79643916|NCT05311774|Drug|Duloxetine 30 mg|tablet
79643917|NCT05311774|Drug|Tramadol|tablet
79808049|NCT04057534|Behavioral|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
79808050|NCT04057534|Behavioral|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
79317818|NCT03169777|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
79317819|NCT03169777|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79317820|NCT03169777|Biological|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
79317821|NCT03169777|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79317822|NCT03169777|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79643918|NCT05311774|Drug|Placebo|tablet
79643919|NCT00166322|Procedure|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
79643920|NCT05307133|Other|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
79973374|NCT02500342|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
79973375|NCT02500264|Device|TENS|
79317823|NCT03169777|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
79643921|NCT05302102|Other|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
79808051|NCT04057534|Behavioral|Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
79973376|NCT03816215|Behavioral|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
79317824|NCT03169777|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79317825|NCT03169777|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79317826|NCT03169777|Biological|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
79317827|NCT03169777|Drug|Lovaza|Omega-3-acid ethyl esters
79973377|NCT02500186|Drug|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
79973378|NCT02500186|Other|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
79973379|NCT02500030|Procedure|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
79973380|NCT02500030|Procedure|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
79317828|NCT03169777|Drug|oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79317829|NCT03169777|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
79317830|NCT03169777|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
79317831|NCT03169777|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
79317832|NCT03169777|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
79317833|NCT03169777|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79317834|NCT03169777|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
79317835|NCT03169777|Biological|GI-4000|RAS yeast vaccine
79317836|NCT03169777|Biological|GI-6207|CEA yeast vaccine
79317837|NCT03169777|Biological|GI-6301|Brachyury yeast vaccine
79317838|NCT03169777|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
79317839|NCT02306915|Drug|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
79317840|NCT04105907|Device|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
79317841|NCT03167047|Procedure|Caudal block|Caudal epidural
79317842|NCT03167047|Procedure|Nerve Block|Peripheral nerve block
79317843|NCT03167047|Drug|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
79973381|NCT05623475|Behavioral|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
79973382|NCT05623475|Behavioral|Lecture|Face-to-face Education using Delirium Care Flip Chart
79973383|NCT05623475|Behavioral|E-learning|Including 7 parts of delirium care video
79973384|NCT02499874|Drug|Efavirenz|oral Efavirenz 400mg
79973385|NCT02499874|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
79317844|NCT01980706|Drug|Baclofen|Baclofen is a GABA-B agonist
79317845|NCT01980706|Drug|Placebo|Pill containing no pharmacologically active substance.
79317846|NCT02402803|Other|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
79317847|NCT02092571|Drug|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
79317848|NCT02402959|Other|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
79973386|NCT02499874|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
79973387|NCT02499874|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
79973388|NCT05093777|Other|Program Intensified Habilitation|The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.
79478091|NCT05991882|Behavioral|Condition 4: Craving trigger+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
79478092|NCT05991882|Behavioral|Condition 5: PBS daily+ PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
79973389|NCT05093777|Other|Habilitation as usual|"When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community."
79317849|NCT02085863|Drug|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
79317850|NCT02085863|Drug|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
79317851|NCT02402725|Drug|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
79317852|NCT02054351|Drug|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
79317853|NCT02394145|Drug|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
79973390|NCT04495192|Genetic|Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment|Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
79973391|NCT03816059|Diagnostic Test|Respiratory virus testing|All patients will be tested for respiratory viruses
79306723|NCT06080828|Device|Percutaneous Posterior Tibial Nerve Stimulation|20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.
79317854|NCT02394145|Drug|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
79317855|NCT03167827|Other|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
79317856|NCT03167827|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
79317857|NCT03167827|Other|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
79317858|NCT03166657|Procedure|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
79317859|NCT04103099|Dietary Supplement|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
79317860|NCT02692417|Device|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
79317861|NCT04091555|Dietary Supplement|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
79317862|NCT02393911|Dietary Supplement|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
79973392|NCT04495270|Diagnostic Test|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
79973393|NCT03815903|Drug|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
79973394|NCT03815903|Combination Product|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
79973395|NCT02499796|Device|Hygrovent Gold|
79317863|NCT02004886|Drug|MK-0893|10 mg and 100 mg tablets
79317864|NCT02004886|Drug|Metformin|500 mg metformin tablets
79317865|NCT02004886|Drug|Placebo|Placebo tablets matching MK-0893
79317866|NCT02004886|Drug|Placebo|Placebo tablets matching metformin
79478093|NCT05991882|Behavioral|Condition 6: Craving daily+Craving trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
79973396|NCT02499796|Device|Heated and moisture exchanger (HME)|
79317867|NCT02393989|Procedure|posterior restoration|restorations for caries effected teeth
79973397|NCT02499796|Device|Heated humidifier (HH)|
79973398|NCT03822299|Dietary Supplement|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
79973399|NCT03333226|Procedure|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
79973400|NCT03822221|Other|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
79317868|NCT04065893|Procedure|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
79317869|NCT04065893|Drug|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
79317870|NCT05744713|Other|Observational|Observational
79317871|NCT05228561|Other|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
79317872|NCT05228483|Device|CO2 fractional laser|CO2 fraction laser
79317873|NCT05228483|Combination Product|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
79317874|NCT05228483|Drug|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
79973401|NCT03822221|Other|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
79973402|NCT03822221|Other|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
79973403|NCT03822221|Other|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
79306724|NCT06080828|Device|Placebo Percutaneous Posterior Tibial Nerve Stimulation|placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.
79306725|NCT06080828|Behavioral|Home instructions|they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
79306726|NCT06080464|Other|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
79306727|NCT06080113|Radiation|Focal Brachytherapy|Targeted focal brachytherapy is an image-guided technique, where the radioactive source is placed only, and directly into the cancerous area of the prostate. The aim is to preserve the normal surrounding prostate gland tissue to limit treatment-related side effects to the adjacent anatomical structures. A multiparametric prostate MRI is used to identify, localize, and delineate the intraprostatic PCa tumour lesion and plan treatment. A specialized MRI-ultrasound image-fusion software combines the MRI-images with dynamic ultrasound performed in the operating room and is used to focally guide the placement of the radioactive source in the prostate cancer (PCa) tumour focus based on focal dosimetry calculations. A safety margin around the tumour is applied where it is possible to account for MRI tumour volume underestimation, microscopic spread, and treatment uncertainties.
79306728|NCT06078176|Other|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility and facilitate bowel emptying. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
79306729|NCT06075498|Procedure|transversus abdominis plane block,|2 different plan blocks; 1. transversus plane block 2. quadratus lumborum plane block
79306730|NCT06073899|Other|Leg Extension Exercise|Participants will perform a concentric quadriceps contraction into terminal knee extension with weight equivalent to 65% of a1-repetition maximum.
79306731|NCT06072170|Drug|Kratom|Single administration thirty minutes after the start of a high-fat breakfast
79306732|NCT06072170|Drug|Placebo|Single administration thirty minutes after the start of a high-fat breakfast
79306733|NCT06071117|Device|Virtual Reality Glasses (VR)|Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.
79973404|NCT03333148|Drug|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
79973405|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
79973406|NCT02492308|Procedure|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
79973407|NCT02492308|Drug|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
79808052|NCT04057534|Behavioral|Standard therapy for TUD|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week."
79973408|NCT03820895|Diagnostic Test|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
79973409|NCT01300169|Behavioral|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
79973410|NCT01300169|Behavioral|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
79973411|NCT05865470|Drug|Cannabis|smoked cannabis
79973412|NCT05865470|Drug|Dronabinol|Oral delta-9-THC
79306734|NCT06071117|Other|White noise|"Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter"
79808053|NCT04164485|Biological|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
79808054|NCT04164485|Biological|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
79973413|NCT05865470|Drug|Smoked Placebo|Placebo Cannabis
79973414|NCT05865470|Drug|Oral Placebo|Oral Placebo
79973415|NCT05865431|Drug|Zinc Oxide and Avobenzone|Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
79973416|NCT05865340|Behavioral|oral health + MED diet|oral health + MED diet education
79973417|NCT05865340|Behavioral|oral health|oral health education
79973418|NCT05865340|Behavioral|MED diet|MED diet education
79973419|NCT05865314|Other|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~Optimisation of nutrition therapy during ICU stay~Optimisation of physiotherapy during ICU stay~Better communication and closer collaboration between physiotherapy and nutrition teams.~Optimisation of continuity of the care."
79317875|NCT01959880|Device|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
79317876|NCT05228405|Other|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
79317877|NCT04255277|Drug|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
79317878|NCT04255277|Drug|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
79317879|NCT04255277|Drug|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
79317880|NCT04255277|Drug|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
79808055|NCT00750022|Behavioral|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
79317881|NCT04255277|Other|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
79317882|NCT04255277|Drug|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
79317883|NCT05228093|Procedure|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
79317884|NCT05228093|Procedure|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
79317885|NCT01980628|Drug|ibrutinib|
79317886|NCT01255943|Behavioral|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
79317887|NCT04007705|Behavioral|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
79317888|NCT04007705|Behavioral|General healthy eating|Healthy eating counseling according to the World Health Organization
79808056|NCT00750022|Behavioral|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
79808057|NCT02638181|Procedure|trabeculectomy|
79808058|NCT02561728|Device|Hangar Helmet|Child will be fitted with the Hangar Helmet
79808059|NCT02561728|Device|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
79808060|NCT00750100|Drug|human chorionic gonadotropin|hCG 200IU in the late follicular phase
79808061|NCT00750100|Drug|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
79643922|NCT05302102|Other|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
79643923|NCT05302102|Other|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
79643924|NCT00194727|Drug|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
79643925|NCT00194727|Drug|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
79643926|NCT00166400|Drug|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
79317889|NCT03978533|Behavioral|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
79317890|NCT03840707|Behavioral|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
79643927|NCT02042287|Device|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
79643928|NCT02042287|Drug|Metronidazole|Oral antibiotic
79643929|NCT05296213|Drug|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
79643930|NCT05296213|Drug|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
79973420|NCT05865314|Other|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
79317891|NCT03670121|Device|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
79973421|NCT05865288|Drug|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
79317892|NCT04435925|Drug|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
79643931|NCT05296213|Drug|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
79973422|NCT05865236|Procedure|Infra-red lamp therapy + Kegal Exercises|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
79643932|NCT00408057|Other|no intervention|no intervenion
79643933|NCT00166478|Drug|Exisulind Therapy|
79643934|NCT05282875|Drug|management of immunosuppressive therapy|"3 groups :~Discontinuation of immunosuppressive agents~Reduction of immunosuppressive agents~Maintenance of immunosuppressive agents"
79317893|NCT04435925|Drug|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
79317894|NCT03648281|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
79317895|NCT01979614|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
79317896|NCT01979614|Other|Placebo|5% v/v glucose solution
79317897|NCT05205707|Diagnostic Test|ACE serum levels|Circulating ACE2 level will be measured
79643935|NCT00194766|Drug|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
79643936|NCT00166556|Drug|Campath-1H and Tacrolimus|
79317898|NCT04649476|Drug|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
79643937|NCT05276089|Behavioral|Video message|"The five-minute video will be sent to the patient's mobile phone, outlining reasons to reduce opioid use and highlighting the support available. It invites patients to consider 3 responses:~I would like to reduce my opioid medication with support.~I understand this video but I want to continue my current dose.~I would like to speak to someone to understand more. Option 1) will enable the GP practice to initiate existing opioid reduction support, Option 2) will continue care and support as usual, and Option 3) will enable the team to offer more information."
79973423|NCT05865236|Procedure|Dry air heat group + Kegal Exercises|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
79643938|NCT00408096|Procedure|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
79973424|NCT05865223|Other|Mckenzie exercise program|MacKenzie extension exercise program for cervical spine
79973425|NCT05865223|Other|Conventional Physical therapy|hot pack for 15 minutes will be given followed by joint mobilization,and home exercise program.
79317899|NCT04649476|Drug|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
79317900|NCT04671784|Other|EUS-E|EUS-E
79317901|NCT05117957|Drug|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
79317902|NCT04671628|Behavioral|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
79973426|NCT05865210|Other|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
79317903|NCT04671238|Device|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
79317904|NCT02654717|Drug|DFD-07 Cream|
79317905|NCT02654717|Drug|Placebo Cream|
79317906|NCT05117879|Procedure|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove [small colonic polyps] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
79643939|NCT00166595|Drug|Risperidone|
79973427|NCT05865210|Other|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
79973428|NCT05865184|Other|Data collection|Data collection of clinically relevant signals using home-based sensor system
79973429|NCT05865145|Device|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
79973430|NCT05865132|Drug|Palbociclib|120mg/125mg po qd on day 1 to 21, every 28 days
79973431|NCT05865132|Drug|Afatinib|30mg/40mg po qd on day 1 to 28, every 28 days
79317907|NCT05117801|Device|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
79973432|NCT05865054|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Combined orbital and cranial vessel wall MRI
79973433|NCT05865015|Other||
79973434|NCT05864989|Procedure|Non-incised papila surgical approach only|Reconstructive periodontal surgery
79317908|NCT03094871|Behavioral|FACE-PC|
79973435|NCT05864989|Procedure|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
79317909|NCT05191043|Other|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
79317910|NCT05191043|Other|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
79317911|NCT05190029|Diagnostic Test|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
79317912|NCT05190029|Other|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
79317913|NCT05190029|Procedure|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
79643940|NCT05259631|Drug|Sevoflurane|Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
79808062|NCT00655031|Dietary Supplement|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
79317914|NCT05117645|Diagnostic Test|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
79643941|NCT05259631|Drug|Propofol|Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
79643942|NCT05220163|Diagnostic Test|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
79973436|NCT05864963|Procedure|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
79317917|NCT03297827|Other|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic & hemorrhagic stroke.
79317918|NCT05136365|Drug|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
79317919|NCT03251729|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
79317920|NCT03251729|Drug|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
79643943|NCT05220163|Diagnostic Test|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
79643944|NCT05205304|Drug|D'Oxyva|The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
79478094|NCT05991882|Behavioral|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
79478095|NCT05991882|Behavioral|Condition 8: No daily or trigger craving or PBS|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
79808063|NCT00655031|Dietary Supplement|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
79306735|NCT06071117|Behavioral|Basic behavior management techniques|Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
79306736|NCT06070779|Other|neuro linguistic programming|neuro linguistic programming
79808064|NCT00655109|Drug|Olopatadine|Ophthalmic solution
79808065|NCT00655109|Drug|Fluticasone|Nasal spray
79306739|NCT06063083|Behavioral|"Tell Me More (Dime Mas)"|Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.
79643945|NCT00194805|Behavioral|Telehealth for Diabetes Self Management|
79643946|NCT00194805|Other|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
79643947|NCT00166634|Procedure|Ambulatory Blood Pressure Monitoring (ABPM)|
79808066|NCT00655109|Drug|Saline|Nasal spray
79808067|NCT00655109|Drug|Artificial tears|Ophthalmic Solution
79808068|NCT00656045|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
79808069|NCT00656045|Behavioral|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
79808070|NCT00656045|Behavioral|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
79317921|NCT03248843|Drug|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
79317922|NCT02696785|Drug|Ixekizumab|Administered SC
79317923|NCT02696785|Drug|Placebo|Administered SC
79973437|NCT05864937|Other|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
79973438|NCT05864924|Biological|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
79973439|NCT05864924|Biological|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
79317924|NCT02696785|Drug|Adalimumab|Administered SC
79317925|NCT05117567|Combination Product|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
79478096|NCT05991869|Behavioral|Point-of-care decision support intervention|"PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly."
79478097|NCT05991856|Procedure|radiofrequency ablation|The subjects is placed in a prone or lateral position under local anesthesia, and the electrodes are placed in the adrenal nodules under ultrasound guidance. A rapidly alternating radiofrequency current (300-500khz) generated around the electrode propagates through the adrenal nodules, causing resistance heating (Joule effect) and inducing cell death through coagulation necrosis. The choice of ablation time and frequency depends on the size, shape and location of the nodules within the adrenal gland.
79478098|NCT05991856|Procedure|laparoscopic adrenalectomy|The subjects was placed in a lateral position under general anesthesia. Using harmonic scalpel carefully separates the adrenal vessels and lates them. The adipose tissue around the adrenal gland is dissected carefully, the surrounding tissue is bluntly separated, and the adrenal gland is fully exposed and dissected. After adrenalectomy was completed, hemostasis was rechecked and specimens were removed.
79478099|NCT05991856|Drug|Hypotensive Drugs|All subjects in the study selected appropriate antihypertensive drugs based on factors such as blood pressure level.
79973440|NCT05864924|Biological|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
79973441|NCT05864911|Device|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
79973442|NCT05864885|Drug|Minoxidil|Topical formulation applied once a day.
79973443|NCT05864781|Behavioral|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
79317926|NCT02004262|Biological|GVAX Pancreas Vaccine|
79317927|NCT02004262|Biological|CRS-207|
79317928|NCT02004262|Drug|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
79317929|NCT02004262|Drug|cyclophosphamide|
79317930|NCT05117411|Diagnostic Test|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
79317931|NCT01675427|Other|Interleukin 28B testing|Blood sampling for ILB28 genotyping
79317932|NCT02394067|Other|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
79317933|NCT03166267|Device|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
79478100|NCT05991830|Procedure|General anesthesia|Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken
79808071|NCT02632877|Drug|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
79973444|NCT05864768|Dietary Supplement|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths >3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values >20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
79973445|NCT05864768|Dietary Supplement|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths >3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values >20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
79973446|NCT05864729|Diagnostic Test|Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR).|Hemodynamic invasive study employing FFR (after intracoronary adenosine administration) and cFFR (after intracoronary lopamidol contrast media administration) measurements of hyperemic intravascular pressure.
79478101|NCT05991778|Device|Bioelectrical impedance vector analysis (BIVA)|BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
79478102|NCT05991778|Diagnostic Test|Blood and urine analysis|For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
79973447|NCT05864716|Biological|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
79478103|NCT05991778|Diagnostic Test|cumulative water balance|Cumulative balance is the sum of daily fluid balances during hospitalization.
79478104|NCT05991765|Other|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
79478105|NCT05991765|Other|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
79808072|NCT02632877|Drug|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
79808073|NCT04163705|Diagnostic Test|blood sample collection|Routine Laboratory Analysis
79808074|NCT00656123|Biological|Colon GVAX|Dose escalation: 1.4x10^8 to 7x10^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
79808075|NCT00656123|Drug|cyclophosphamide|200 mg/m^2 administered IV on Day 1 of Cycles 1-4
79317934|NCT02393833|Procedure|Blood samples collection|"Blood samples to be collected at the following time points:~Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~Months 12, 18 and 36 after start of induction chemotherapy~At time of confirmatory evidence of progression"
79317935|NCT02393599|Drug|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
79317936|NCT02393599|Drug|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
79973448|NCT05864664|Procedure|Wide awake local anaesthesia no tourniquet technique|"Patient awake with no form of sedation or analgesia~A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~Injection is performed around incision site - superficial to deep including periosteum~Incision is performed in the normal fashion~Plate and screws are removed and incision is closed"
79317937|NCT02393599|Drug|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
79478106|NCT05991752|Diagnostic Test|ROMA score evaluation|Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
79478107|NCT05991726|Other|Other: Survey|Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
79808076|NCT04032431|Behavioral|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
79808077|NCT04163471|Device|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
79808078|NCT00657449|Drug|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
79808079|NCT00657449|Drug|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
79317938|NCT02393365|Other|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
79317939|NCT02393365|Procedure|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
79317940|NCT02402491|Drug|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
79317941|NCT02402491|Drug|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
79973449|NCT05864586|Behavioral|Vaping study EC A|Vaping two puffs using the study EC device
79973450|NCT05864586|Behavioral|Vaping study EC B|Vaping two puffs using the study EC device
79973451|NCT05864586|Behavioral|Vaping study EC C|Vaping two puffs using the study EC device
79973452|NCT05864586|Behavioral|Vaping study EC D|Vaping two puffs using the study EC device
79973453|NCT05864586|Behavioral|Vaping study EC E|Vaping two puffs using the study EC device
79973454|NCT05864586|Behavioral|Vaping study EC F|Vaping two puffs using the study EC device
79317942|NCT02402491|Drug|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
79317943|NCT03166423|Drug|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
79317944|NCT03166423|Device|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
79317945|NCT02402569|Device|32 channels Deep Brain Stimulator|
79478108|NCT05991167|Device|EndeavorRx|EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
79478109|NCT05990894|Drug|Methylprednisolone|In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
79973455|NCT05864586|Behavioral|Vaping study EC G|Vaping two puffs using the study EC device
79973456|NCT05864586|Behavioral|Vaping study EC H|Vaping two puffs using the study EC device
79317946|NCT02402413|Procedure|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
79317947|NCT02402413|Procedure|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
79317948|NCT02402413|Device|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
79973457|NCT05864586|Behavioral|Vaping study EC I|Vaping two puffs using the study EC device
79973458|NCT05864586|Behavioral|Vaping study EC J|Vaping two puffs using the study EC device
79973459|NCT05864508|Drug|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
79973460|NCT05864430|Other|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
79973461|NCT05864430|Other|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
79973462|NCT05864430|Other|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
79478110|NCT05990335|Behavioral|mHealth application (custom)|Smartphone based application designed to engage user executive functions
79808080|NCT04160195|Biological|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10^6 CAR+ T cells/kg based on cohort) infuse on day 0
79973463|NCT05864339|Behavioral|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
79808081|NCT04160195|Drug|Cyclophosphamide|500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
79973464|NCT05864339|Behavioral|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
79973465|NCT05864313|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
79973466|NCT05864313|Behavioral|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
79973467|NCT05864313|Behavioral|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
79317949|NCT04440241|Procedure|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
79317950|NCT03166501|Drug|Lanicemine|Three 60 min parenteral infusions over a 5 day period
79317951|NCT03166501|Drug|Placebo|Three 60 min parenteral infusions over a 5 day period
79808082|NCT04160195|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
79808083|NCT04159883|Other|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
79808084|NCT04159883|Other|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
79808085|NCT00911261|Drug|Oxymorphone Extended Release|"Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
79973468|NCT05864313|Device|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
79478111|NCT05990257|Procedure|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
79478112|NCT05990257|Procedure|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
79478113|NCT05990257|Procedure|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
79317952|NCT02402257|Behavioral|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
79317953|NCT03166579|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
79317954|NCT01978912|Drug|KTP-001|KTP-001 is one time dose intradiscally.
79478114|NCT05989477|Other|At-home Breast Oncology care Delivered with E-health solutions - ABODE|The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
79808086|NCT00686374|Biological|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed < 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
79808087|NCT00750178|Drug|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
79808088|NCT04159961|Drug|DWJ211|Inject the Drug into submental fat and abdominal fat via subcutaneous
79973469|NCT05864287|Behavioral|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
79973470|NCT05864248|Device|Supira System|The Supira System is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
79317955|NCT02393443|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
79317956|NCT02393443|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
79317957|NCT01977898|Drug|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
79317958|NCT01977898|Drug|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
79317959|NCT02393287|Other|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
79808089|NCT00750256|Drug|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
79808090|NCT00750334|Drug|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
79808091|NCT00750334|Drug|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
79808092|NCT00750412|Behavioral|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
79973471|NCT05864183|Diagnostic Test|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
79973472|NCT05864183|Diagnostic Test|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
79317960|NCT02392975|Procedure|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
79808093|NCT04056832|Procedure|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
79317961|NCT02392975|Procedure|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
79317962|NCT02003638|Drug|Niacin|Niacin titrated to 6000 mg daily
79317963|NCT02003638|Drug|Placebo|Placebo provided in the same pill quantity as niacin arm
79317964|NCT05232253|Device|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
79317965|NCT02393131|Radiation|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
79317966|NCT02393131|Radiation|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
79317967|NCT02696317|Device|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
79478115|NCT05989438|Other|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
79478116|NCT05989438|Other|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
79478117|NCT05989425|Drug|surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
79478118|NCT05989386|Procedure|0.9% saline solution|During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
79808094|NCT04056832|Procedure|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
79808095|NCT02561416|Behavioral|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
79973473|NCT05864183|Diagnostic Test|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
79317968|NCT02696317|Device|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
79317969|NCT02393053|Procedure|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
79317970|NCT02393053|Procedure|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
79317971|NCT01959412|Drug|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
79478119|NCT05989386|Procedure|Povidone-iodine Swab|No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
79808096|NCT02561416|Behavioral|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
79478120|NCT05989360|Diagnostic Test|Lung Clearance Index|Normative values in healthy children from ethnic backgrounds
79478121|NCT05989321|Procedure|PVI alone|pulmonary vein isolation
79808097|NCT02561416|Drug|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
79317972|NCT01959412|Drug|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
79317973|NCT01959412|Drug|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
79317974|NCT01959412|Drug|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
79317975|NCT01959412|Drug|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
79317976|NCT01959412|Drug|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
79317977|NCT02402101|Device|Procedure: active tDCS|Intensity 2 mA during 20 minutes
79478122|NCT05989321|Procedure|PVI + SPs ablation|pulmonary vein isolation + SPs ablation
79478123|NCT05989295|Dietary Supplement|probiotic LRa05|treatment about 12 weeks
79317978|NCT02402101|Device|Procedure: sham tDCS|sham condition as delivered by the stimulator
79317979|NCT02402179|Other|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
79317980|NCT02401945|Drug|DE-120|
79317981|NCT02401945|Drug|Aflibercept|
79317982|NCT01977820|Drug|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
79478124|NCT05989243|Device|Conventional prosthetic socket|Participants will use their own conventional rigid socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for ~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
79478125|NCT05989243|Device|Adjustable Quatro socket|Participants will use an adjustable Quatro socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for ~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
79973474|NCT05864183|Diagnostic Test|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
79973475|NCT05864183|Diagnostic Test|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
79973476|NCT05864183|Diagnostic Test|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
79808098|NCT00571948|Other|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
79808099|NCT00571948|Other|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
79973477|NCT05864183|Diagnostic Test|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
79973478|NCT05864183|Diagnostic Test|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
79973479|NCT05864183|Diagnostic Test|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
79973480|NCT05864170|Biological|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
79973481|NCT05864131|Behavioral|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
79808100|NCT04054726|Device|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
79808101|NCT04054726|Device|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
79317983|NCT01977820|Drug|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
79808102|NCT00752284|Procedure|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
79317984|NCT02402023|Behavioral|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
79317985|NCT02402023|Behavioral|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
79317986|NCT02392897|Behavioral|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
79317987|NCT02392897|Behavioral|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
79808103|NCT00752284|Procedure|Total Excision|Total excision of lower third molar
79808104|NCT00752362|Device|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
79973482|NCT05864131|Behavioral|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
79973483|NCT05864092|Other|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
79973484|NCT05864053|Drug|Ketamine|Ketamine will be administered over a 45-minute period.
79317988|NCT02003014|Drug|Pioglitazone|Pioglitazone Tablets
79317989|NCT03166345|Other|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
79478126|NCT05989230|Behavioral|Emotional Awareness and Expression Therapy|The goal of EAET is to increase awareness of uncomfortable emotions that are often linked to stressful past experiences (e.g., anger, sadness, fear) and learn adaptive ways to experience and express those emotions, in a safe and controlled environment. Core treatment components include pain education, drawing associations between the experience of pain and emotion, and experiencing and expressing emotions via imaginary, in vivo, and real life exposures. EAET will be delivered via 8, 60-minute, weekly psychotherapy visits.
79808105|NCT00752362|Device|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
79973485|NCT05864053|Drug|(2R,6R)-hydroxynorketamine|(2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
79317990|NCT04411498|Diagnostic Test|Fibromyalgia diagnosis in patients with SSc|American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index [WPI] and symptom severity (SS) scale [19]. Diffuse pain index [WPI]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip [gluteal region], left hip [gluteal region], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale [SSS]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
79317991|NCT02392819|Dietary Supplement|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
79317992|NCT02392819|Dietary Supplement|Placebo|
79317993|NCT01977352|Drug|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
79973486|NCT05864053|Drug|Saline|Saline will be administered over a 45-minute period.
79317994|NCT01977352|Drug|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
79317995|NCT03166033|Other|the disease|Observation the patients and non-patients
79317996|NCT03166189|Biological|bone marrow-derived MSC and HRT|"Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~Three cycles of HRT following MSC transplantation;~Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~Frozen/thawed embryo transfer 3-6 months after transplantation."
79317997|NCT03166189|Other|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~Three cycles of HRT preceding frozen/thawed embryo transfer;~Frozen/thawed embryo transfer."
79317998|NCT03166111|Drug|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
79973487|NCT05864027|Behavioral|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
79317999|NCT03166111|Drug|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
79318000|NCT02001688|Drug|Kamada-AAT for Inhalation, 80mg|
79318001|NCT02001688|Drug|Placebo|
79318002|NCT02001688|Drug|Kamada-AAT for Inhalation, 160mg|
79478127|NCT05989061|Device|PEEK customized healing abutment|Guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery
79478128|NCT05989061|Device|Titanium customized healing abutment|Guided delayed implant and a customized Titanium healing abutment placed simultaneously with implant surgery
79318003|NCT05668507|Behavioral|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~Group support delivered via a 24/7 chat room~Face to face support delivered via virtual happy hours"
79318004|NCT02392741|Other|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
79318005|NCT03114943|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
79318006|NCT03114943|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
79318007|NCT05117021|Drug|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
79973488|NCT05864027|Behavioral|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
79973489|NCT05864014|Drug|Hetrombopag|Hetrombopag
79318008|NCT02001064|Behavioral|Care4Today v2.0 mobile application + electronic monitoring of adherence|Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
79318009|NCT02392585|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
79973490|NCT05864014|Drug|Hetrombopag plus Placebo|Hetrombopag plus Placebo
79973491|NCT05864014|Drug|Placebo|Placebo
79973492|NCT05863988|Other|Functional Electrical Stimulation|The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.
79973493|NCT05863988|Other|Upper Limb Loading Exercises|The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
79973494|NCT05863975|Drug|Human interferon alpha 2b vaginal Effervescent capsules|①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
79478129|NCT05989009|Other|Breastfeeding|Mothers will breastfeed their newborns
79478130|NCT05988853|Other|follow-up of patients|Follow-up of evidence of nosocomial infections of patients in music therapy
79478131|NCT05988840|Other|Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.|Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
79478132|NCT05988801|Other|Glass ionomer sealant|glass ionomer-based sealant material
79643948|NCT05181904|Other|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
79643949|NCT00408135|Drug|telithromycin (HMR3647)|
79643950|NCT00166673|Device|FreeStyle Navigator Continuous Glucose Monitoring System|
79318010|NCT02392585|Procedure|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
79318011|NCT03068273|Device|Real-time CGM data|
79318012|NCT02392663|Other|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
79318013|NCT02392663|Other|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
79318014|NCT02392663|Other|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
79318015|NCT02000752|Device|Acupuncture|
79318016|NCT02000752|Device|Sham acupuncture|Sham point acupuncture
79478133|NCT05988801|Other|Resin based sealant|resin-based sealant material
79478134|NCT05988788|Other|Epigallocatechin-3-gallate|to be used as a root canal irrigant
79478135|NCT05988788|Other|sodium hypochlorite|to be used as a root canal irrigant
79478136|NCT05988775|Behavioral|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
79643951|NCT05160376|Other|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
79318017|NCT02982941|Drug|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
79478137|NCT05988775|Behavioral|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
79478138|NCT05988775|Other|Nature movie watching|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
79643952|NCT05160376|Other|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
79643953|NCT00194844|Behavioral|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
79643954|NCT00194844|Behavioral|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
79318018|NCT02392117|Drug|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
79318019|NCT02812433|Drug|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
79318020|NCT02812433|Drug|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
79318021|NCT02392039|Drug|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
79318022|NCT02392039|Drug|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
79478139|NCT05988736|Device|MaCintosh Laryngoscope (DL)|A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.
79643955|NCT00194844|Behavioral|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
79643956|NCT00407225|Drug|Difluprednate Ophthalmic Emulsion|
79643957|NCT05133622|Other|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
79643958|NCT05133622|Other|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
79318023|NCT02392039|Other|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
79318024|NCT02392039|Behavioral|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
79318025|NCT03995693|Dietary Supplement|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
79478140|NCT05988736|Device|McGrath Laryngoscope (VL)|A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
79478141|NCT05988723|Other|ELISA kits|Making biochemical measurements with the ELISA kit
79808106|NCT00752362|Device|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
79973495|NCT05863962|Other|walking and Stretching|Stretching exercise will be given for 6 weeks (3 sessions per week). 15 minutes of moderate walking with stretching exercises 5 times a week with Warm up and Cool down. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed and frequency of each exercise
79478142|NCT05988645|Device|MiWEndo System|"All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
79643959|NCT05133622|Other|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
79643960|NCT05133622|Other|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
79643961|NCT05133622|Other|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
79643962|NCT05133622|Other|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
79973496|NCT05863962|Other|walking and Jacobsons relaxation technique|Jacobson's Relaxation Technique will be given for 6 weeks. 15 minutes of moderate walking with Jacobson's Relaxation Technique. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed. Participants will also bring their Pedometer
79973497|NCT05863949|Dietary Supplement|vitamin D +/- calcium|vitamin D 1000iU daily +/- calcium 500mg BID daily
79973498|NCT05863949|Other|Placebo|placebo pill x3 daily
79973499|NCT05863936|Drug|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
79973500|NCT05863936|Drug|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
79973501|NCT05863936|Drug|Immunosuppressive Agents|"Mycophenolate Mofetil, oral, 1.0-1.5g per day;~Tacrolimus, oral, 2-4mg per day."
79973502|NCT05863923|Behavioral|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
79973503|NCT05863923|Behavioral|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
79808107|NCT04054258|Device|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
79973504|NCT05863897|Behavioral|e-COGRAT (a blended eHealth intervention)|The blended eHealth intervention for fatigue complaints after ABI, e-COGRAT, is a cognitive behaviorial intervention. It consists of 12 weekly sessions, including 6 individual online sessions, 2 face-to-face group sessions and 4 online group sessions, in 4 groups of 4 patients.
79318026|NCT03995693|Behavioral|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
79808108|NCT00684424|Other|Non-Interventional Study|Observational Only
79318027|NCT03995693|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
79318028|NCT03995693|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
79318029|NCT03995693|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
79478143|NCT05988619|Device|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
79808109|NCT00752440|Other|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
79808110|NCT00745186|Drug|Glucagen|0.2 mg or 1 mg Glucagen single injection
79318030|NCT03995693|Behavioral|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
79808111|NCT00745186|Drug|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
79808112|NCT00750646|Device|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
79808113|NCT04056364|Biological|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
79808114|NCT00750724|Drug|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
79808115|NCT00750724|Drug|normal saline,2 ml., intraarticular weekly for 5 weeks|
79808116|NCT00685750|Procedure|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
79808117|NCT02561104|Procedure|Laser-assisted cataract surgery.|
79973505|NCT05863871|Drug|Linperlisib|80 mg, qd
79973506|NCT05863858|Drug|Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID|The eradication rate of H. Pylori with levofloxacin-based sequential therapy
79478144|NCT05988619|Behavioral|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
79973507|NCT05863858|Drug|Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID|The eradication rate of H. Pylori with moxifloxacin-based triple therapy
79318031|NCT03995693|Diagnostic Test|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
79318032|NCT03995693|Diagnostic Test|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
79318033|NCT03995693|Diagnostic Test|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
79318034|NCT03995693|Procedure|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
79318035|NCT02000440|Drug|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
79478145|NCT05988619|Behavioral|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
79808118|NCT02561104|Procedure|Traditional manual phacoemulsification|
79973508|NCT05863845|Drug|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
79318036|NCT02781701|Device|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
79318037|NCT03106363|Drug|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
79808119|NCT00752518|Drug|bortezomib|
79808120|NCT00752596|Drug|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
79808121|NCT00923728|Drug|AVN944|
79808122|NCT00745264|Drug|Diractin|100 mg Ketoprofen to 2 joints
79808123|NCT00745264|Drug|Diractin|400 mg ketoprofen to 4 joints
79318038|NCT03106363|Drug|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
79808124|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
79808125|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
79808126|NCT00752674|Other|Neuromuscular balance|
79808127|NCT00750802|Drug|AZD6280|10mg Capsule, oral, single-dose
79808128|NCT00750802|Drug|AZD6280|40mg Capsule, oral, single-dose
79808129|NCT00750802|Drug|Lorazepam|2mg tablet, oral single-dose
79808130|NCT00750802|Drug|Placebo|
79808131|NCT00750958|Procedure|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
79808132|NCT00745342|Behavioral|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
79973509|NCT05863845|Drug|Carmustine|300mg/m2 day -7, Given IV
79318039|NCT03106363|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
79318040|NCT03106363|Drug|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
79318041|NCT04413071|Other|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
79643963|NCT05133622|Other|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
79643964|NCT05124067|Drug|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
79643965|NCT05124067|Drug|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
79643966|NCT05124067|Drug|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
79643967|NCT05124067|Drug|normal Saline|patients will receive normal saline.
79808133|NCT02563444|Device|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
79973510|NCT05863845|Drug|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
79973511|NCT05863845|Drug|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
79973512|NCT05863845|Drug|Melphalan|140mg/m2, day -2, Given IV
79973513|NCT05863845|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
79318042|NCT03106519|Drug|Liposome bupivacaine + bupivacaine|
79318043|NCT05657587|Device|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
79318044|NCT02687815|Drug|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
79318045|NCT02687815|Drug|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
79318046|NCT05742451|Other|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
79808134|NCT00751192|Device|HIV-testing motivational videos|
79808135|NCT00751192|Device|Standard public health text|
79808136|NCT00751504|Drug|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
79808137|NCT00751582|Dietary Supplement|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
79973514|NCT05863832|Drug|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
79318047|NCT03916133|Diagnostic Test|Intervention group|6s PBV mapping will be conducted
79318048|NCT03915665|Drug|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
79318049|NCT03915665|Device|Air-powder|Erythritol powder using air-powder device
79643968|NCT00194883|Drug|Recombinant Human Growth Hormone|
79643969|NCT05109286|Behavioral|CrossFit|CrossFit training
79808138|NCT00751582|Behavioral|Nutrition education|Nutrition education for children for three months
79808139|NCT00751582|Other|Control Group|No Nutrition Education
79808140|NCT00751660|Other|laboratory biomarker analysis|
79808141|NCT00751660|Other|screening questionnaire administration|
79808142|NCT00751660|Procedure|bronchoscopic and lung imaging studies|
79973515|NCT05863832|Drug|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
79808143|NCT00751660|Procedure|computed tomography|
79808144|NCT00751660|Procedure|endoscopic biopsy|
79808145|NCT00751660|Procedure|quality-of-life assessment|
79808146|NCT00576628|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
79808147|NCT02561650|Drug|COV155|COV155 tablets
79643970|NCT02277184|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
79808148|NCT00752830|Drug|AZD0328|Oral capsule, single dose
79318050|NCT01959334|Drug|Nasal Glucagon (NG)|
79973516|NCT05863793|Other|Acupuncture|The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients' symptoms appear not only in the lower limbs but also in the upper limbs. After skin disinfection, disposable, stainless steel acupuncture needles will be inserted into the skin of acupoint (approximately 10-20 mm depth), and then manipulations of twirling, lifting, and thrusting will be performed on all needles for at least 10 s to reach De qi (a compositional sensation including soreness, numbness, distention, and heaviness), which is believed to be an essential component for acupuncture efficacy. Needles will be retained in these acupoints for 20 min.
79318051|NCT01959334|Drug|Glucagon IM|
79318052|NCT04722419|Other|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
79318053|NCT02687581|Device|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
79973517|NCT05863793|Other|Sham Acupuncture|Patients in the SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
79318054|NCT02687581|Device|patch|6-hour of eye patch on the fellow eye
79318055|NCT04173754|Procedure|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
79318056|NCT02248805|Drug|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
79808149|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
79973518|NCT05863780|Other|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
79318057|NCT02021279|Device|MatriStem Pelvic Floor Matrix|
79318058|NCT02021279|Procedure|native tissue repair|
79808150|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
79808151|NCT00683878|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
79808152|NCT00683878|Drug|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
79318059|NCT05652439|Other|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
79318060|NCT02392273|Drug|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
79318061|NCT04813705|Radiation|Reduced dose|The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
79318062|NCT04813705|Radiation|Conventional dose|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
79318063|NCT04813705|Drug|Chemotherapy|The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
79808153|NCT00884741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
79808154|NCT00884741|Biological|Bevacizumab|Given IV
79808155|NCT00884741|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
79973519|NCT05863780|Other|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
79478146|NCT05988606|Behavioral|15 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 1 round of high-intensity interval training
79478147|NCT05988606|Behavioral|43 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 5 rounds of high-intensity interval training
79478148|NCT05988606|Other|Hot environment|Participants exercised in a hot environment, ~ 35 °C, ~40% relative humidity.
79478149|NCT05988606|Other|Temperate environment|Participants exercised in a temperate environment, ~ 22 °C, ~40% relative humidity.
79318064|NCT01958476|Drug|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
79643971|NCT02277184|Drug|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
79318065|NCT01958476|Drug|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
79973520|NCT05863780|Other|Carpal bone mobilization and flexor retinaculum stretch|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
79973521|NCT05863767|Other|Baduanjin sequential therapy|Baduanjin sequential therapy consists of eight different movements including the preparatory phase till final movement (gathering the energy). The session will account for 30 minutes twice a day for four weeks.
79973522|NCT05863767|Other|Conventional Therapy|Neck stretches Arm circles Triceps stretch Calf stretch Forward step up Strengthening exercises Every exercise 5 repetitions three times a day
79318066|NCT01958476|Drug|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores <8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
79973523|NCT05863754|Device|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
79318067|NCT04809181|Drug|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
79318068|NCT05737381|Other|Differential oxygen tension|By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
79318069|NCT01057121|Drug|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
79318070|NCT02695537|Drug|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
79318071|NCT04692389|Device|Jalosome soothing gel|This study has not got other intervention
79318072|NCT04620941|Diagnostic Test|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
79318073|NCT04615871|Drug|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
79318074|NCT04991129|Drug|WJ01024|5mg: WJ01024, Q4W, twice per week
79318075|NCT04991129|Drug|WJ01024|10mg: WJ01024, Q4W, twice per week
79318076|NCT04991129|Drug|WJ01024|20mg: WJ01024, Q4W, twice per week
79318077|NCT04991129|Drug|WJ01024|40mg: WJ01024, Q4W, twice per week
79973524|NCT05863728|Procedure|Piezosurgery assisted group|apicectomy will be done using the Piezosurgery device
79973525|NCT05863728|Procedure|Trephine Bur assisted group|apicectomy will be done using the trephine burs
79973526|NCT05863715|Behavioral|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
79973527|NCT05863689|Diagnostic Test|Spectralis SD-OCT|Optical Coherence Tomography
79973528|NCT05863676|Procedure|Oophorectomy|Ovary will be removed for fertility preservation.
79973529|NCT05863676|Diagnostic Test|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
79973530|NCT05863663|Other|questionnaire|cross sectional questionnaire
79318078|NCT04991129|Drug|WJ01024|60mg: WJ01024, Q4W, twice per week
79318079|NCT04991129|Drug|WJ01024|80mg: WJ01024, Q4W, twice per week
79318080|NCT04991129|Drug|WJ01024|100mg: WJ01024, Q4W, twice per week
79318081|NCT04991129|Drug|WJ01024|120mg: WJ01024, Q4W, twice per week
79318082|NCT04991129|Drug|WJ01024|140mg: WJ01024, Q4W, twice per week
79318083|NCT04991129|Drug|WJ01024|1600mg: WJ01024, Q4W, twice per week
79318084|NCT04888793|Diagnostic Test|Serologic immune response evaluation|Detection of total and neutralizing antibodies against SARS-CoV-2
79318085|NCT04802447|Drug|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
79318086|NCT04746989|Drug|Probenecid|Probenecid claim is used as the exposure group.
79318087|NCT04746989|Drug|Allopurinol|Allopurinol claim is used as the reference group.
79318088|NCT04446221|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
79318089|NCT02691247|Biological|CLBS03 Low Dose|
79318090|NCT02691247|Biological|CLBS03 High Dose|
79318091|NCT02691247|Biological|Placebo|
79318092|NCT04412915|Other|Labor induction|Labor induction with oxytocin or prostagladin
79318093|NCT04383821|Device|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
79318094|NCT04383821|Device|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
79318095|NCT04520009|Behavioral|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
79318096|NCT04520009|Behavioral|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
79306740|NCT06063083|Behavioral|"Peer Ambassador Stories [Listen Miami (Oye Miami)]"|Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.
79306741|NCT06063083|Behavioral|Standard Community Outreach|Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
79306742|NCT06062888|Biological|Fresh Frozen Plasma (FFP)|Standard of Care + 2 units (400-500 ml) of fresh frozen plasma
79306743|NCT06059534|Dietary Supplement|Dietary supplementation with placebo.|Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
79306744|NCT06059534|Dietary Supplement|Dietary supplementation with DracoBelleTM Nu.|Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
79306745|NCT06058091|Drug|RY_SW01 cell injection|Administer basic treatment with an injection of RY_SW01 cell solution
79306746|NCT06058091|Drug|Basic treatment|Basic treatment for SSc
79306747|NCT06058078|Drug|RY_SW01 cell injection|Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
79306748|NCT06058078|Drug|Basic treatment|Drugs for LN treatment
79306749|NCT06056765|Device|"Minilith, Storz, Swiss"|shock waves
79306750|NCT06055452|Drug|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
79306751|NCT06055452|Drug|Placebo|Each participant in the placebo group takes matching placebo.
79306752|NCT06055439|Biological|CHM-2101 CAR-T cells|Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
79306753|NCT06053307|Behavioral|Acceptance commitment therapy|The baseline intervention will use ACT, a psychological intervention based on modern behavioral psychology, including relational frame theory, that uses acceptance and mindfulness strategies, along with commitment and behavior-change strategies to increase psychological flexibility. The proposed intervention will be delivered over a 6-week period, with each week including content related to one of the six tenets of ACT: cognitive defusion, acceptance, contact with the present moment, the observing self, values, and committed action. Each week will include educational material, skills work, and homework. The intervention will be delivered via a mobile application.
79306754|NCT06046729|Drug|Eltrekibart|Administered SC
79306755|NCT06046729|Drug|Placebo|Administered SC
79306756|NCT06044831|Behavioral|Expanded Population Health Model|This intervention includes the current population health model in addition to expanded programming from a local community organization. The current population health model with Baylor Scott & White Health and Wellness Center includes access to primary care, general wellness programs such as cooking classes and nutritional counseling, and evidence-based disease management and prevention. The additional programs from a local community organization focus on human essentials integral to improving health and quality of life and include: health and wellness, economic stability, safe and affordable housing, transportation, a sense of belonging, education, and access to fair credit.
79306757|NCT06044571|Other|Prescriptive|Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
79643972|NCT02277184|Radiation|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
79318097|NCT04349423|Behavioral|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
79318098|NCT04163393|Procedure|Percutaneous Coronary Intervention|PCI with robotic assistance
79318099|NCT04163393|Device|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
79318100|NCT04428749|Diagnostic Test|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
79478150|NCT05988476|Other|Exercise|5 day/week, two week, one session stretching exercises consisting of ten repetitions of one minute
79643973|NCT00166790|Drug|chemotherapy agents|
79478151|NCT05988476|Device|Pulsed Electromagnetic Field Therapy|5 day/week, two week,two sessions consisting of 180 minutes
79478152|NCT05988450|Device|SQ-Kyrin Transcatheter Mitral Valve Repair System|Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
79478153|NCT05988424|Other|Left atrial mapping|Creation of a left atrial voltage map
79643974|NCT00166790|Procedure|suction curettage|
79643975|NCT00194922|Dietary Supplement|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
79643976|NCT05093101|Other|case series review of clinical data|Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis
79643977|NCT00166829|Drug|sirolimus, tacrolimus, mycophenolate mofetil|
79643978|NCT00177333|Drug|Doxycycline|
79808156|NCT00884741|Other|Laboratory Biomarker Analysis|Correlative studies
79808157|NCT00884741|Other|Placebo|Given IV
79808158|NCT00884741|Other|Quality-of-Life Assessment|Ancillary studies
79973531|NCT05863650|Device|Digital based simulation|Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.
79973532|NCT05863650|Other|Face to face education|In the face-to-face education group, two case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
79973533|NCT05863611|Other|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
79973534|NCT05863585|Drug|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
79478154|NCT05988385|Device|Positive airway pressure|Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.
79478155|NCT05988385|Device|Oral appliance therapy|Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.
79478156|NCT05988385|Device|Positional therapy|A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
79478157|NCT05988359|Procedure|Caries treatment with a dental turbine|G1 (n=30) conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
79808159|NCT00884741|Drug|Temozolomide|Given orally
79318101|NCT04428749|Diagnostic Test|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
79478158|NCT05988359|Procedure|Caries treatment with Er:YAG laser|G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
79808160|NCT00656279|Behavioral|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
79808161|NCT02632799|Device|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
79973535|NCT05863559|Behavioral|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
79808162|NCT02632799|Device|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
79973536|NCT05863546|Device|therapeutic ultrasound|US treatment sessions will be performed for 6 min per session , once a day, three days a week, for a total of 4 weeks.
79808163|NCT02632799|Device|CPAP|Nsal CPAP 5cm H2o by face mask
79808164|NCT00657527|Drug|Rosuvastatin|
79808165|NCT00657527|Behavioral|Cholesterol lowering diet|
79808166|NCT04159649|Drug|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
79808167|NCT04159649|Drug|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
79318102|NCT04238585|Behavioral|Mobile messaging|Mobile health messages
79318103|NCT04677803|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
79318104|NCT04671953|Drug|BMS-986165|Specified dose on specified days
79478159|NCT05988333|Other|Psychoeducational Family Intervention|Supportive intervention administered to families with a member affected by MDD
79478160|NCT05988333|Other|Informative intervention|Informative intervention administered to families with a member affected by MDD
79478161|NCT05988307|Device|Percussion massage gun|Percussion massage gun on hamstrings flexibility in patients with knee Osteoarthritis.
79318105|NCT04671953|Drug|Metformin|Specified dose on specified days
79478162|NCT05988281|Procedure|Type I Dental implant placement.|Placement of dental implant.
79318106|NCT04616105|Drug|REGN6490|Single dose of REGN6490
79318107|NCT04616105|Drug|Placebo|Placebo matching single dose of REGN6490
79318108|NCT04585061|Drug|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
79318109|NCT04585061|Device|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
79318110|NCT04585061|Dietary Supplement|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
79318111|NCT04531007|Diagnostic Test|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
79478163|NCT05988281|Procedure|Type II Dental implant placement.|Placement of dental implant.
79808168|NCT04159649|Procedure|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
79318112|NCT03902717|Procedure|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
79318113|NCT03874091|Procedure|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
79318114|NCT03874091|Procedure|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
79318115|NCT03874091|Drug|Morphine PCA pump|Morphine given postoperatively.
79318116|NCT03786965|Other|On-pump CABG|On-pump CABG
79318117|NCT03786965|Other|Off-pump CABG|Off-pump CABG
79318118|NCT03786965|Other|Pump-assisted CABG|Pump-assisted CABG
79318119|NCT03786965|Other|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
79478164|NCT05988281|Procedure|Type III/IV dental implant placement.|Placement of dental implant.
79643979|NCT00166868|Drug|Lactobacillus casei rhamnosus (Lcr35)|
79643980|NCT00166868|Drug|Neomycin|
79808169|NCT00880763|Drug|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
79318120|NCT03786965|Other|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
79318121|NCT03735017|Other|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
79318122|NCT03735017|Other|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
79318123|NCT01362491|Drug|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
79318124|NCT01362491|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
79318125|NCT01362491|Drug|Placebo|Single-dose of placebo
79318126|NCT02687191|Biological|PF-05230907|PF-05230907 IV bolus injection
79318127|NCT02687035|Device|SAPIEN S3 valve|Transcatheter aortic valve replacement
79318128|NCT04515563|Behavioral|Stretching exercise|Control Group
79318129|NCT04515563|Behavioral|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
79643981|NCT00194961|Drug|Recombinant Human Growth Hormone|
79643982|NCT04943458|Other|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
79643983|NCT00166907|Behavioral|Balance and Exercise|
79643984|NCT00177372|Drug|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
79643985|NCT04892914|Device|Embr thermal device|Participants use the Embr thermal device for 4 weeks
79318130|NCT04515563|Behavioral|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
79318131|NCT04515563|Behavioral|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
79318132|NCT04515563|Behavioral|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
79808170|NCT00880763|Drug|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
79318133|NCT05746507|Behavioral|Night Respite Care|(see description above)
79318134|NCT03167749|Diagnostic Test|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
79318135|NCT03684473|Behavioral|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
79318136|NCT03560297|Behavioral|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
79808171|NCT00880763|Drug|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
79318137|NCT03560297|Behavioral|Delayed Intervention|Participants receive intervention after delay
79318138|NCT02691013|Drug|Ramelteon|
79808172|NCT00880763|Drug|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
79808173|NCT00657683|Biological|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
79808174|NCT00657683|Biological|Placebo|1 dose of placebo
79318139|NCT02691013|Drug|Placebo|
79318140|NCT03423407|Device|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
79478165|NCT05988268|Other|Vibration Foam Rolling|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
79808175|NCT04159727|Other|stool and blood analysis|High throughput sequencing and quantitative PCR
79808176|NCT00884273|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
79808177|NCT00884273|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
79808178|NCT00884273|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
79808179|NCT04159337|Other|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
79808180|NCT00657761|Drug|Enfuvirtide|90 mg/12h sc for 7 days
79318141|NCT03342989|Behavioral|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
79478166|NCT05988268|Other|Non-Vibration Foam Rolling|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
79478167|NCT05988255|Device|Static progressive stretching|A stretching technique applies a mechanical progressive stretch
79808181|NCT00657761|Drug|Placebo|0.9% saline solution/12h sc for 7 days
79808182|NCT04159493|Drug|Estriol|Vaginal Application
79808183|NCT04159493|Drug|Placebo|Vaginal Application
79808184|NCT00657839|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
79318142|NCT03342989|Behavioral|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
79318143|NCT03274505|Other|Questionnaires|"Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~Clinical evaluation~Routine neuropsychological evaluation (for stroke patients)~Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) > 10)"
79808185|NCT00657839|Drug|Placebo|Matching placebo
79973537|NCT05863494|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
79318144|NCT02690701|Drug|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
79318145|NCT02690701|Biological|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
79318146|NCT04122287|Drug|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
79318147|NCT04122287|Drug|tinidazole|tinidazole-tetracycline-containing quadruple regimens
79318148|NCT05746351|Drug|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
79973538|NCT05863494|Device|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
79318149|NCT05746351|Drug|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
79318150|NCT05746351|Drug|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
79318151|NCT05403437|Other|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
79478168|NCT05988255|Other|Cyclic manual stretching|A stretching technique applies an intermittent manual stretch
79808186|NCT00884117|Drug|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
79808187|NCT04159181|Other|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
79973539|NCT05863468|Device|ArchSinus implantation|Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
79973540|NCT05863455|Drug|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
79973541|NCT05863455|Drug|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
79973542|NCT05863429|Biological|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
79973543|NCT05863416|Drug|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
79318152|NCT05403437|Diagnostic Test|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
79318153|NCT05403437|Other|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
79318154|NCT02694757|Device|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
79318155|NCT05403281|Drug|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
79318156|NCT03158831|Drug|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
79318157|NCT03165877|Other|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (<55%),consisting of salad, main course and dessert, respectively.
79318158|NCT03165877|Other|Control|Subjects ate standard lunches and dinners (>60%),consisting of salad, main course and dessert, respectively.
79318159|NCT03115099|Drug|LY3325656|Administered orally
79318160|NCT03115099|Drug|Placebo|Administered orally
79318161|NCT03115099|Drug|Liraglutide|Administered subcutaneously
79318162|NCT03115099|Drug|Sitagliptin|Administered orally
79318163|NCT03165097|Drug|ACT-709478|Hard gelatine capsules for oral administration
79318164|NCT03165097|Drug|Placebo|Placebo capsules matching ACT-709478 capsules
79318165|NCT03165097|Drug|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
79318166|NCT03165097|Drug|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
79318167|NCT03165799|Behavioral|Mindfulness Education|Mindfulness Education
79318168|NCT03165643|Diagnostic Test|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
79318169|NCT04436003|Behavioral|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
79318170|NCT04436159|Procedure|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
79643986|NCT04834765|Other|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
79808188|NCT04159181|Other|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
79808189|NCT04159181|Other|Placebo (water)|oral administration of Water (200mL).
79808190|NCT00884039|Drug|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
79318171|NCT04436159|Procedure|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
79318172|NCT03165409|Biological|Nivolumab|Melanoma intervention
79318173|NCT03165409|Biological|Ipilimumab|Melanoma intervention
79808191|NCT00884039|Drug|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
79808192|NCT00657995|Device|Artificial Pancreas (STG-22)|safe tool
79318174|NCT05403125|Device|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
79318175|NCT05403125|Device|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
79318176|NCT05701423|Drug|Natalizumab|Administered as specified in the treatment arm.
79973544|NCT05863403|Diagnostic Test|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
79318177|NCT02795351|Drug|Sildenafil|Single oral administration of active or placebo one week apart
79318178|NCT02795351|Drug|Placebo|
79318179|NCT05403047|Drug|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
79318180|NCT04626713|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
79318181|NCT05399303|Procedure|obturation|obturation using different types of sealers
79318182|NCT03927443|Drug|SDP-133|one drop
79973545|NCT05863403|Diagnostic Test|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
79318183|NCT03927443|Drug|Lumigan|one drop
79318184|NCT02872493|Procedure|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
79318185|NCT05124353|Drug|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
79318186|NCT02222831|Procedure|Day 0 denudation and time lapse culture on IVF-oocytes.|
79318187|NCT05124197|Other|prone position|extension of prone position duration
79318188|NCT03805841|Drug|tarloxotinib bromide|weekly intravenous infusion
79318189|NCT02815943|Procedure|biliopancreatic diversion with duodenal switch|
79318190|NCT02815943|Procedure|sleeve gastrectomy|
79318191|NCT02815943|Other|liquid meal|will be consumed over 30 minutes with [U-13C]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
79318192|NCT02815943|Radiation|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
79318193|NCT02815943|Other|[7,7,8,8-2H]-palmitate|i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to 360 min.
79318194|NCT02815943|Device|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
79318195|NCT04440995|Procedure|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
79318196|NCT03563651|Procedure|Biopsy|Undergo biopsy
79318197|NCT03563651|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and stool
79318198|NCT03563651|Other|Laboratory Biomarker Analysis|Correlative studies
79318199|NCT03563651|Other|Questionnaire Administration|Ancillary studies
79808193|NCT02636621|Device|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
79973546|NCT05863390|Behavioral|McKenzie exercise|routine simple McKenzie exercise
79973547|NCT05863390|Diagnostic Test|Trochanteric belt|Trochanteric belt with conventional physical therapy
79973548|NCT05863338|Behavioral|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
79973549|NCT05863273|Drug|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
79973550|NCT05863260|Drug|Treatment Group|Treatment Group
79318200|NCT03560765|Device|MED|Training in the use of mainstream electronic devices with accessibility options
79318201|NCT03560765|Other|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
79318202|NCT04207073|Device|Mobilization of median nerve|Neural mobilization
79973551|NCT05863221|Drug|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
79318203|NCT04435847|Biological|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
79318204|NCT04435847|Other|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
79318205|NCT03057743|Device|Positron emission tomography (PET/CT) imaging|
79318206|NCT03057743|Device|radiotracer [18F]ISO-1|
79318207|NCT05123651|Biological|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
79318208|NCT02811887|Behavioral|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
79318209|NCT02811887|Other|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
79318210|NCT02811887|Behavioral|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
79318211|NCT03995303|Other|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
79318212|NCT03957707|Procedure|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
79318213|NCT02739659|Device|carbon-ion radiotherapy|
79318214|NCT05123261|Behavioral|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
79318215|NCT05123105|Other|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
79318216|NCT05123105|Other|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
79318217|NCT05123105|Other|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
79478169|NCT05988242|Other|Primrose oil|group A will take primrose oil
79973552|NCT05861024|Other|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
79973553|NCT05860998|Diagnostic Test|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
79318218|NCT05122949|Device|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
79973554|NCT05859425|Device|Real-time rehabilitative ultrasound imaging (RUSI)|Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation
79973555|NCT05859425|Other|Tactile feedback (control intervention)|Palpatory-guided (manual) feedback for TrA activation
79973556|NCT05856500|Dietary Supplement|basic nutrition|An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
79973557|NCT05856500|Dietary Supplement|oral supplement of creatine and curcumin|Creatine and curcumin are orally added other than basic nutrition treatment.
79318219|NCT05122949|Device|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
79318220|NCT02684617|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
79318221|NCT02684617|Drug|dinaciclib|dinaciclib 7 mg/m^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
79318222|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
79318223|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
79318224|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
79318225|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
79318226|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
79478170|NCT05988242|Other|Lavender oil|group B will take lavender oil
79808194|NCT02636621|Other|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
79318227|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
79318228|NCT04055389|Drug|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life ~4 days) at a weight-based dosage according to the following formula:~[Desired level of AT (100%) - Subject level of AT (%)] * subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
79318229|NCT04055389|Other|Placebo|No study drug
79318230|NCT03106207|Procedure|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
79643987|NCT04834765|Other|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
79643988|NCT04834765|Other|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
79808195|NCT02632565|Drug|Lidocaine|
79808196|NCT02632565|Drug|Saline|
79808197|NCT04158947|Drug|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
79808198|NCT04158947|Drug|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
79808199|NCT02632643|Behavioral|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
79808200|NCT00835770|Drug|dimethyl fumarate|BG00012 capsules
79808201|NCT00835770|Drug|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
79808202|NCT00658073|Procedure|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
79808203|NCT00658073|Procedure|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
79808204|NCT04163237|Drug|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
79318231|NCT05697055|Drug|Azvudine|5mg orally, once a day, for no more than 14 days
79318232|NCT05697055|Drug|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR < 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
79318234|NCT03162367|Biological|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
79318235|NCT03162367|Drug|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
79318236|NCT01999894|Drug|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
79643989|NCT00166946|Procedure|foreskin from healthy adults for organotypic culture|
79643990|NCT04819399|Drug|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~cohort 50 µg~cohort 70 µg~cohort 100 µg~Part II will be treated at recommended dose"
79643991|NCT04800172|Drug|Roflumilast|administration of roflumilast 500 mcg tablet once daily for 3 months.
79643992|NCT04800172|Drug|placebo|administration of placebo tablet once daily for 3 months.
79808205|NCT04163237|Drug|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
79808206|NCT04159259|Other|Low fiber diet|Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
79808207|NCT04159259|Other|Pea Fiber Bar|Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
79318237|NCT03165565|Behavioral|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
79318238|NCT03165565|Behavioral|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
79318239|NCT02679235|Drug|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
79318240|NCT01976806|Drug|Aspirin|
79318241|NCT01976806|Drug|Docosahexaenoic acid|
79318242|NCT01976806|Drug|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
79318243|NCT02679079|Drug|NBI-98854|
79318244|NCT02679079|Drug|Placebo|
79318245|NCT02678923|Drug|MDCO-216|
79318246|NCT02678923|Drug|Placebo|
79643993|NCT04769518|Procedure|Advanced Recovery Room Care (ARRC)|High acuity care
79808208|NCT04159259|Other|Low fiber diet|Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
79808209|NCT02636777|Other|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
79808210|NCT00658229|Behavioral|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
79973558|NCT05852457|Device|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
79643994|NCT00177411|Drug|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
79808211|NCT02636543|Other|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
79808212|NCT02636543|Other|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
79318247|NCT01976728|Drug|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
79318248|NCT01976728|Drug|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
79318249|NCT01976728|Drug|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
79318250|NCT01976728|Drug|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
79318251|NCT02689219|Drug|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
79318252|NCT03162133|Other|Baduanjin exercise|
79318253|NCT05673733|Other|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
79643995|NCT03457324|Drug|JCM-16021|This prescription with seven ingredients.
79318254|NCT05673733|Other|exergaming training|Group B will receive only exergaming training
79318255|NCT05673421|Other|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
79643996|NCT03457324|Drug|Placebo|Placebo
79643997|NCT00177489|Behavioral|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
79643998|NCT00177489|Other|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
79808213|NCT00880685|Drug|Memantine|10-30mg, daily for 8 weeks
79808214|NCT02636465|Other|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
79808215|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
79643999|NCT04716985|Dietary Supplement|MOLECULAR HYDROGEN|Magnesium Tablet
79318256|NCT05673421|Other|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
79644000|NCT04716985|Dietary Supplement|PLACEBO MAGNESIUM|Magnesium carbonate tablet
79808216|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
79808217|NCT00658307|Device|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
79973559|NCT05850806|Device|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
79973560|NCT05837182|Procedure|augmented fixation techniques|augmented fixation techniques like percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques
79318257|NCT03165253|Drug|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
79644001|NCT04711174|Behavioral|LMA removal|the timing when conducting LMA removal
79644002|NCT00195078|Drug|ZD1839 (IRESSA)|
79644003|NCT00195078|Drug|Cisplatin|
79644004|NCT00195078|Procedure|Radiation Therapy|
79808218|NCT00835380|Biological|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
79808219|NCT02612298|Drug|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
79808220|NCT02612298|Drug|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
79808221|NCT00880607|Drug|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
79973561|NCT05828303|Drug|TPX-0005|Oral TPX-0005 capsules
79973562|NCT05828303|Drug|Metformin Hydrochloride|oral solution
79644005|NCT04693819|Diagnostic Test|Somatic modulation|"Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application"
79973563|NCT05828303|Drug|Digoxin|oral tablet
79973564|NCT05828303|Drug|Rosuvastatin Calcium|oral tablet
79306758|NCT06044571|Behavioral|Behavioral|Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
79318258|NCT03165253|Drug|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
79644006|NCT00167141|Drug|injection of hormonal male contraceptive|testosterone injections 4 times
79644007|NCT04660045|Drug|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
79644008|NCT00177528|Drug|venlafaxine-XR|
79644009|NCT04612387|Behavioral|Mind-body therapy|Online yoga, meditation and nutrition tips.
79306759|NCT06041568|Drug|Imvotamab|Administered intravenously
79306760|NCT06033677|Procedure|Distal radial artery cannulation|Interventional application for invasive blood pressure monitoring
79306761|NCT06033677|Procedure|Forearm radial artery cannulation|Interventional application for invasive blood pressure monitoring
79306762|NCT06030037|Biological|Responder-Derived Fecal microbiota transplantation (R-FMT|R-FMT (induction) via colonoscopy on C1D1 and C3D1. R-FMT (maintenance) via sigmoidoscopy will be repeated every 9 weeks.
79306763|NCT06030037|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)
79306764|NCT06030037|Drug|Lenvatinib|Lenvatinib will be administered at 20 mg daily
79306765|NCT06029283|Dietary Supplement|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
79306766|NCT06029283|Other|Placebo chewing gum|placebo chewing gum
79973565|NCT05823571|Drug|Itacitinib|A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.
79318259|NCT03165253|Drug|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
79318260|NCT03165253|Drug|Omeprazole|1 mg/kg/day
79318261|NCT05543317|Diagnostic Test|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
79318262|NCT03114241|Behavioral|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
79318263|NCT03161977|Other|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
79478171|NCT05988242|Other|placcebo|this is the comparator group who will take the same bottle of oil which dosnt contain the active substances but have the sampe shape, same oder, same color
79808222|NCT00880607|Drug|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
79318264|NCT02683525|Drug|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
79318265|NCT01976338|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
79318266|NCT01976338|Other|Sham injection|Sham intravitreal injection
79318267|NCT02674633|Device|AKL-T01|Videogame-like digital therapy
79318268|NCT02674633|Device|AKL-T09|Videogame-like digital therapy
79478172|NCT05988190|Behavioral|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
79478173|NCT05988177|Drug|Carrimycin tablets|Carrimycin tablets are administered 400mg a day orally for 7 days.
79644010|NCT03457285|Other|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
79478174|NCT05988060|Other|Experimental Intervention|"Patients who were randomized in the PEI group and accepted the invitation to undergo the experimental intervention receive a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT. The PEI consists of a 60 minutes intervention twice a week and will be supervised by a physiotherapist specialized in oncology.~Patients who receive the intervention also have to do home-based aerobic and muscle strength exercises by themselves three times a week."
79644011|NCT00167258|Behavioral|Voucher Reinforcement|
79644012|NCT00167258|Behavioral|Extra Counseling Services|
79973566|NCT05821907|Behavioral|data collection group|The scale development process generally consists of three stages as item production, theoretical analysis and psychometric analysis. The researcher provides theoretical support to the item pool during item production. In the theoretical analysis stage, the content validity of the new scale is evaluated and the first item pool is ensured to reflect the desired structure. In the final stage of the psychometric analysis, the researcher evaluates whether the new scale establishes validity and reliability.
79478175|NCT05988034|Drug|Avacopan|Administered orally.
79478176|NCT05988034|Drug|Moxifloxacin|Administered orally.
79318269|NCT02651987|Drug|Lanreotide autogel 120 mg|
79318270|NCT05676307|Behavioral|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
79318271|NCT05115773|Procedure|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
79478177|NCT05988034|Drug|Placebo for avacopan|Administered orally.
79318272|NCT05115773|Procedure|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
79478178|NCT05988034|Drug|Placebo for moxifloxacin|Administered orally.
79478179|NCT05988021|Drug|CCX168|Administered orally.
79478180|NCT05988008|Drug|CCX168|Administered orally.
79478181|NCT05988008|Drug|Placebo|Administered orally.
79478182|NCT05987995|Procedure|Endometrial injury|A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity
79318273|NCT05108285|Diagnostic Test|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
79644013|NCT00167258|Behavioral|Voucher Reinforcement + Extra Counseling Services|
79973567|NCT05818761|Device|virtual reality|wearing virtual reality glasses
79973568|NCT05818761|Behavioral|stress ball|squeezing the stress ball during the attempt
79306767|NCT06014866|Device|Cardiac pacing|Patient's previously implanted with the INGEVITY+ lead located in the LBBA
79306768|NCT06014489|Drug|azacitidine|during run-in and extention phase: from Cycle 1 until relapse
79306769|NCT06014489|Drug|Venetoclax|during run-in and extention phase: from Cycle 1 until relapse
79306770|NCT06014489|Drug|Cobicistat|"during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse"
79306771|NCT06013852|Diagnostic Test|"processing the radiography with the Boneview software"|all X-Rays will be analysed with and without the software
79306772|NCT06007664|Behavioral|Tele-Video to Improve Daily Activity|Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
79318274|NCT02677987|Device|Intervention systematic light exposure|Bright light using Litebook device.
79318275|NCT02677987|Device|Comparison systematic light exposure|Dim light using modified Litebook device.
79973569|NCT05816941|Procedure|Conventional Periodontal Treatment (Complete Oral Disinfection)|"Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
79318276|NCT02463773|Device|Ultrasound|Diaphragmatic excursion ultrasound assessment
79973570|NCT05816941|Procedure|Adjunctive Photodynamic Therapy|"Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
79973571|NCT05801705|Drug|Aromatase inhibitor|Aromatase inhibitor includes Arimidex, Aromasin, Femara.
79973572|NCT05801705|Procedure|ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)|Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin
79973573|NCT05801705|Drug|Tamoxifen|tamoxifen,10mg, bid
79973574|NCT05801705|Drug|toremifene|toremifene, 60 mg, qd
79973575|NCT05798624|Diagnostic Test|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~Depth of isthmocele~Width of isthmocele~Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
79973576|NCT05798624|Diagnostic Test|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
79318277|NCT05676151|Behavioral|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
79318278|NCT04701853|Other|Specific abdominal muscle training|Specific abdominal muscle training
79318279|NCT04701853|Other|Usual care|Care according to each center.
79478183|NCT05987982|Procedure|Oral exercises and oral hygiene|The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
79318280|NCT03049397|Other|Communication Intervention|Complete Enhancing Connections program
79318281|NCT03049397|Other|Questionnaire Administration|Ancillary studies
79318282|NCT04657939|Drug|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
79318283|NCT04657939|Drug|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
79318284|NCT01999114|Drug|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
79318285|NCT01999114|Drug|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
79318286|NCT01999114|Drug|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
79318287|NCT01999114|Drug|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
79318288|NCT02968355|Other|Observational study|Observational study
79318289|NCT03161743|Procedure|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
79318290|NCT02783105|Other|Musical intervention|
79318291|NCT02783105|Other|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
79318292|NCT03161665|Other|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
79318293|NCT02666339|Other|Usual care|Usual care : drug therapy, nurse and physician consultations.
79973577|NCT05798624|Diagnostic Test|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
79318294|NCT02666339|Behavioral|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
79318295|NCT02382497|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
79318296|NCT02382497|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
79318297|NCT02382497|Device|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
79318298|NCT02382497|Device|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
79318299|NCT04503161|Device|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
79478184|NCT05987982|Procedure|Oral care|The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
79478185|NCT05987969|Other|"Alena mobile application"|This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
79478186|NCT05987878|Procedure|single minimal conjunctival incision|A 5-0 PGA traction suture was used near the corneal limbus corresponding to the operated muscle. A 3-4 mm single conjunctival incision posterior and parallel to the insertion in medial, lateral or superior rectus muscle was used. A hang-back recession of the muscle was done using 6-0 PGA suture. The conjunctiva was closed by an 8-0 PGA single stitch with knot burial
79478187|NCT05987839|Procedure|robotic system|Total knee arthroplasty assisted by knee navigation and positioning system
79478188|NCT05987800|Diagnostic Test|Titration procedure|"The NAVA level will be reduced to 0,5 cmH2O/microvolt (µV) for 3 minutes as a starting point. Limit peak pressure will be set to 35 cmH2O (the maxi-mum pressure that can be delivered to the patient is cut off at 30 cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 2,5 cmH2O/µV."
79478189|NCT05987800|Diagnostic Test|Electrical impedance tomography|This is a non-invasive technique consisting of the application of a non-adhesive single-use patient belt to monitor regional changes in lung aeration at the bedside.
79478190|NCT05987800|Diagnostic Test|Lung and diaphragm ultrasound|"Lung ultrasound is a non-invasive technique used to diagnose lung pathology and to monitor lung condition. This technique is part of the standard of care for preterm infants in our neonatal unit. Lung ultrasound scores are calculated at each time an ultrasound is performed.~Ultrasound of the diaphragm consists of a short additional measurement of diaphragm thickness and thickening fraction and will be done at the same time of the lung ultrasound following a standardized procedure."
79318300|NCT02214407|Drug|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
79318301|NCT02214407|Drug|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
79808223|NCT04158791|Procedure|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
79318302|NCT02682823|Device|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
79318303|NCT02682823|Drug|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
79318304|NCT01634711|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
79318305|NCT05008601|Device|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
79318306|NCT01478555|Drug|ISV 101|Bromfenac in DuraSite
79318307|NCT02261285|Drug|ONO-4538|
79644014|NCT00195117|Behavioral|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
79318308|NCT01422083|Procedure|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
79318309|NCT01288625|Drug|Amifostine|500 mg sc, qod, 3 times per week
79318310|NCT01288625|Radiation|Amifostine|500mg rinsing wash, qod, 3 times per week
79318311|NCT05041829|Other|Dietary sodium|Low sodium diet with sodium of <2.3 g/day (<100 mmol/day) and high sodium diet with sodium of ≥4 - <6 g/day (≥174 - <261 mmo/day)
79808224|NCT00656435|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
79808225|NCT02636231|Drug|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
79808226|NCT02636231|Radiation|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
79808227|NCT02632487|Behavioral|Exercise|Center-based walking + balance, stretching, and light resistance
79808228|NCT02632487|Behavioral|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
79808229|NCT02636309|Behavioral|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
79808230|NCT00835068|Other|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
79808231|NCT00658463|Drug|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
79808232|NCT00658463|Drug|Placebo|Placebo
79808233|NCT00656591|Drug|Methotrexate|Methotrexate
79808234|NCT00658853|Behavioral|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
79808235|NCT00658931|Drug|Drug treatment with Cymbalta|Drug treatment with Cymbalta
79808236|NCT00834912|Drug|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
79318312|NCT05129813|Behavioral|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
79318313|NCT05129579|Behavioral|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
79318314|NCT05129579|Other|no intervention|No intervention will be made in the control group.
79644015|NCT04566250|Combination Product|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
79644016|NCT04548583|Drug|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
79808237|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
79318315|NCT05129267|Other|Group B|Scaling and Root debridement + iPRF
79318316|NCT05129267|Other|Group C|Scaling and Root debridement + iPRF together with vitamin C
79318317|NCT01374451|Drug|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
79318318|NCT01374451|Drug|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
79478191|NCT05987787|Procedure|laparoscopic sleeve gastrectomy without suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
79644017|NCT04548583|Drug|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
79644018|NCT04548583|Other|Placebo|Normal saline
79644019|NCT00167297|Drug|Atomoxetine|
79644020|NCT04687579|Other|Screening|Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
79644021|NCT04687579|Procedure|Preoperative optimization|Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin < 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia < 150 10^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio > 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
79808238|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
79808239|NCT02535689|Drug|Tofacitinib|Oral administration of tofacitinib, 5 mg
79808240|NCT02535689|Drug|Placebo|
79306773|NCT05996315|Other|Hematoma block|A patient who presents to the emergency department with a suspected distal end radius fracture , will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give hematoma block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
79306774|NCT05996315|Other|Supracondylar radial nerve block|A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
79306775|NCT05989711|Drug|Pemvidutide|Administered by subcutaneous injection
79306776|NCT05989711|Drug|Placebo|Administered by subcutaneous injection
79306777|NCT05983367|Drug|Ompenaclid (RGX-202)|RGX-202
79306778|NCT05983367|Drug|Placebo|Placebo
79306779|NCT05983367|Drug|Bevacizumab|Bevacizumab
79306780|NCT05983367|Drug|FOLFIRI regimen|FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
79306781|NCT05982340|Diagnostic Test|Lithium clearance|Blood and urine samples
79306782|NCT05972044|Drug|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
79306783|NCT05972044|Drug|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
79306784|NCT05972044|Drug|Placebo|Placebo tablets, taken once daily
79306785|NCT05970185|Drug|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
79973578|NCT05797727|Device|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
79973579|NCT05797727|Device|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
79973580|NCT05785104|Other|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
79973581|NCT05785104|Other|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
79644022|NCT04687579|Procedure|Umbilical hernia repair|A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
79973582|NCT05778617|Drug|Ambroxol Hydrochloride (420mg)|Oral tablet
79644023|NCT00177567|Drug|lithium carbonate|
79973583|NCT05778617|Drug|Placebo|Oral tablet
79644024|NCT00177567|Drug|Depakote-ER|
79984614|NCT05582564|Other|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
79644025|NCT00177567|Drug|risperidone|
79808241|NCT02632331|Drug|ASP8825|Oral
79808242|NCT00707538|Drug|BMS747158|2 IV injection of ~11 mCi (total) F-18 labeled compound
79306786|NCT05970185|Drug|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
79306787|NCT05969665|Device|Fitbit Inspire 2|A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.
79306788|NCT05969665|Device|Abbott Freestyle Libre 3|A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
79644026|NCT00177567|Drug|olanzapine|
79808243|NCT04162535|Drug|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
79644027|NCT00177567|Drug|paroxetine|
79644028|NCT00177567|Drug|bupropion|
79808244|NCT04162535|Biological|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
79808245|NCT04162535|Drug|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
79306789|NCT05969041|Drug|MT-302 (A)|MT-302 is an investigational drug
79306790|NCT05967182|Drug|Pembrolizumab|Given by IV (vein)
79306791|NCT05967182|Drug|Gemcitabine|Given by IV (vein)
79306792|NCT05967182|Drug|Cisplatin|Given by IV (vein)
79306793|NCT05964413|Drug|vilobelimab|vilobelimab infusion
79306794|NCT05964413|Drug|Placebo|Placebo Infusion
79306795|NCT05958342|Drug|Calcium Gluconate|1 gram calcium gluconate provided intravenously over approximately 2-5 minutes
79490300|NCT03415243|Drug|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi[4MBq]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
79808246|NCT04162535|Drug|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
79808247|NCT05472324|Drug|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
79306796|NCT05958342|Drug|Vasopressin|4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
79306797|NCT05958342|Drug|saline placebo|saline placebo volume matched to prehospital or in hospital phase
79306798|NCT05955898|Behavioral|Parents THRIVE|Parents THRIVE is a digital, one-time intervention that will give parents strategies to cope with their emotions and improve their distress tolerance. Parents will learn how to increase their emotion awareness to better tolerate strong emotions, such as anxiety, sadness, anger, and frustration.
79306799|NCT05955898|Behavioral|Sharing Feelings Project|Sharing Feelings Project is a digital, one-time program that focuses on the benefit of sharing emotions with others and will be used as a control. Parents will read about how sharing their emotions can be helpful and anecdotes from others' experiences sharing emotions.
79306800|NCT05952869|Drug|MK-0616|Oral tablet
79306801|NCT05952869|Drug|Placebo|Placebo
79306802|NCT05951101|Device|Zenith LAA Occlusion System|LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
79306803|NCT05946876|Drug|XH-S003 (A)|IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
79644029|NCT00177567|Drug|lamotrigine|
79318319|NCT02674477|Device|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
79644030|NCT00177567|Drug|venlafaxine|
79644031|NCT00177567|Drug|tranylcypromine|
79808248|NCT05472324|Drug|Placebo|The drug is a placebo Comparator.
79808249|NCT02632019|Drug|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
79984615|NCT03194152|Dietary Supplement|Peanut|Dietary Supplement: Peanut
79984616|NCT03194152|Dietary Supplement|Control|Dietary Supplement: High carbohydrate snacks
79318320|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
79644032|NCT00177567|Drug|mirtazapine|
79644033|NCT04519684|Drug|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
79644034|NCT04519684|Other|Placebo|Normal Saline
79644035|NCT04441840|Dietary Supplement|Active Probiotic Culture|Both conditions matched in appearance and serving size
79644036|NCT04441840|Dietary Supplement|Inactive Probiotic Culture|Both conditions matched in appearance and serving size
79644037|NCT00195156|Drug|ATRA-IV|
79644038|NCT00195156|Drug|Depakote|
79984617|NCT03107338|Drug|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
79984618|NCT03107338|Other|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
79984619|NCT05581940|Combination Product|Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors|(CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
79984620|NCT04223687|Other|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
79984621|NCT04223687|Other|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
79984622|NCT02445742|Drug|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
79644039|NCT04369417|Behavioral|Relaxation Response Resiliency Program for Siblings of Children with ASD|Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
79644040|NCT00167375|Drug|eszopiclone 3 mg qHS|
79808250|NCT02632019|Biological|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
79808251|NCT00707616|Other|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
79808252|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
79984623|NCT03748589|Device|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
79644041|NCT00167375|Behavioral|General cognitive/behavioral interventions for insomnia|
79644042|NCT00195000|Drug|Mylotarg|6 mg/m2 on day 1
79644043|NCT00195000|Drug|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
79644044|NCT00195195|Drug|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
79984624|NCT02445508|Drug|Sevelamer|
79644045|NCT00583804|Device|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
79808253|NCT00659009|Other|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
79808254|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
79808255|NCT00659087|Procedure|Femoral Block|Those receiving femoral block postoperatively
79808256|NCT00659087|Other|Usual Care|Those receiving only usual pain management postoperatively
79808257|NCT00659243|Drug|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
79808258|NCT00659243|Drug|Placebo|One week treatment
79808259|NCT00883493|Drug|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
79808260|NCT00883493|Drug|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
79984625|NCT02445508|Drug|Cholecystokinin|
79644046|NCT04282330|Diagnostic Test|3D CEST imaging|Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
79644047|NCT00167453|Procedure|Exercise, Education|
79644048|NCT00195234|Biological|HIV CTL MEP 1000 micrograms, 19 months per subject|
79644049|NCT04248010|Device|neuroConn DC-Stimulator MR|standard tDCS, active & sham
79644050|NCT04248010|Device|Soterix MxN HD-tES|HD-tDCS, active & sham
79644051|NCT04122898|Other|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
79644052|NCT00177606|Behavioral|withdrawal of life sustaining treatments|
79644053|NCT00167492|Drug|Myfortic|720 mg by mouth every 12 hours
79984626|NCT02445508|Drug|Sevelamer placebo|
79984627|NCT02445508|Drug|Isotonic saline|
79318321|NCT03164863|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
79318322|NCT03164941|Procedure|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
79318323|NCT03164707|Diagnostic Test|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
79644054|NCT04687657|Drug|umbilical cord blood|During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
79808261|NCT00659321|Drug|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
79808262|NCT00659321|Drug|placebo|16 weeks treatment with placebo
79318324|NCT01352845|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
79318325|NCT01352845|Other|Placebo|0.5 mL dose, given at 0, 2 and 6 months
79318326|NCT02674399|Drug|JointStem|
79318327|NCT02674399|Drug|Synvisc-One|
79318328|NCT05675839|Other|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI_hzY&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY&t=284s)
79318329|NCT03161509|Drug|Paracetamol|single dose of 1 gr paracetamol
79318330|NCT03161509|Drug|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
79808263|NCT02636153|Other|normal diet|Diet containing 1500mg of phosphorus
79808264|NCT02636153|Other|restricted phosphate diet|Diet containing 500mg of phosphorus
79808265|NCT04158479|Device|ECMO|ECMO for circulatory and/or respiratory support
79808266|NCT04032353|Other|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
79808267|NCT00659399|Drug|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
79808268|NCT00659477|Drug|insulin glargine|once daily
79808269|NCT00911339|Drug|Atorvastatin|Atorvastatin 10 mg associated with stent genous
79808270|NCT00911339|Drug|Atorvastatin|Atorvastatin 80 mg associated with stent genous
79318332|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
79808272|NCT05863208|Device|Artificial intelligence|ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma
79808273|NCT05863208|Device|Endocuff vision|Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma
79478192|NCT05987787|Procedure|laparoscopic sleeve gastrectomy with suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
79644055|NCT04064593|Diagnostic Test|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
79644056|NCT00167531|Behavioral|treadmill walking with partial weight support|
79644057|NCT00167531|Behavioral|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
79808274|NCT05863208|Device|High-definition endoscope|High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
79306804|NCT05946876|Other|Placebo (B)|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
79644058|NCT04030234|Drug|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
79478193|NCT05987774|Device|AI Modules for Improving Social Conversation|"The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers."
79478194|NCT05987761|Behavioral|PRT for Adolescents|Clinician-led 70-minute PRT sessions targeting social skills once per week at Stanford.
79478195|NCT05987748|Behavioral|Exercise training|Mixed exercise training containing strength and endurance elements carried out under supervision
79478196|NCT05987735|Behavioral|BLAME-LESS|The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
79478197|NCT05987722|Other|Enoxolone|The experimental group returned home after the operation and used glycyrrhetinic acid toothpaste three times a day for oral cleaning.After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
79644059|NCT04030234|Drug|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP <140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
79644060|NCT00532012|Drug|RhuDex®|
79644061|NCT00177684|Drug|Amphotericin B|
79644062|NCT00167570|Device|Prosthetic socket fabricated using selective laser sintering|
79808275|NCT05863195|Biological|Bevacizumab|Given IV
79808276|NCT05863195|Biological|Cetuximab|Given IV
79808277|NCT05863195|Procedure|Computed Tomography|Undergo SPECT/CT and/or CT
79808278|NCT05863195|Drug|Floxuridine|Given via HAI pump
79808279|NCT05863195|Drug|Fluorouracil|Given IV
79808280|NCT05863195|Procedure|Implantation|Undergo surgery to place the HAI pump
79808281|NCT05863195|Procedure|Intrahepatic Infusion Procedure|Undergo HAI
79318333|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
79318334|NCT02676895|Biological|Menveo|One injection of Menveo was administered in subjects in the Control Group.
79318335|NCT02676895|Biological|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
79318336|NCT05235451|Other|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
79318337|NCT05675683|Drug|Capmatinib|Patients receiving Capmatinib
79318338|NCT04691999|Behavioral|Intermittent Fasting|16-18 hour fasting period four times per week
79318339|NCT01680809|Device|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
79318340|NCT01680809|Device|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
79318341|NCT04440085|Drug|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
79808282|NCT05863195|Drug|Irinotecan|Given IV
79318342|NCT04440085|Drug|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
79808283|NCT05863195|Drug|Leucovorin|Given IV
79808284|NCT05863195|Drug|Oxaliplatin|Given IV
79318343|NCT05129033|Drug|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
79318344|NCT05129033|Drug|itraconazole|Anti-fungal medication to reduce fugal load.
79318345|NCT05129033|Biological|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
79318346|NCT04780399|Drug|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
79808285|NCT05863195|Biological|Panitumumab|Given IV
79318347|NCT04780399|Drug|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
79318348|NCT04780399|Drug|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
79490301|NCT02892500|Drug|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
79490302|NCT02892500|Drug|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
79490303|NCT02904356|Device|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
79808286|NCT05863195|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
79808287|NCT05863169|Device|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
79808288|NCT05863156|Diagnostic Test|Right side lying position|In the study, 60 participants were placed in the right side lying position (intervention 1)
79808289|NCT05863156|Diagnostic Test|Semi Fowler|In the study, 60 participants in the semi-sitting position (intervention 2)
79490304|NCT00378872|Drug|IV Tranexamic acid 10mg/kg pt body weight|
79490305|NCT00378872|Drug|Quixil topical sealant|
79973584|NCT05774886|Combination Product|Implantable Microdevice (IMD)|"Small, implantable device with 30 reservoirs for drug and drug combinations.~Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
79973585|NCT05766592|Behavioral|LGBTQ-affirmative CBT|16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
79318349|NCT05404997|Device|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
79318350|NCT05404997|Other|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
79318351|NCT03114007|Behavioral|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
79318352|NCT03114007|Behavioral|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
79318353|NCT03114007|Behavioral|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
79318354|NCT04557709|Other|Medical Chart Review|Review of medical charts
79478198|NCT05987722|Other|Sensodyne|The Active Comparator group returned home after the operation and used glycyrrhetinic acid -free toothpaste(Sensodyne) three times a day for oral cleaning. After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
79644063|NCT03983590|Other|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
79973586|NCT05766592|Behavioral|ABFT-SGM|16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
79318355|NCT05128721|Biological|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
79318356|NCT03161119|Device|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
79318357|NCT03161119|Device|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
79478199|NCT05987709|Diagnostic Test|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
79478200|NCT05987696|Drug|CD33/CLL1 dual CAR-NK cell|NK cell therapy
79973587|NCT05764564|Diagnostic Test|Positive or negative pressure|Positive or negative pressure is applied via a closed chamber.
79808290|NCT05863156|Diagnostic Test|left side lying position|In the study, 120 participants in the left side lying position (control group).
79973588|NCT05756153|Drug|GFH925|GFH925 tablets administered orally daily.
79973589|NCT05756153|Drug|Cetuximab|Cetuximab administered intravenously Q2W.
79478201|NCT05987696|Drug|Cyclophosphamid|Lympho-conditioning Agent
79808291|NCT05863117|Diagnostic Test|Reveal Rapid TP (from MedMira)|Point of care tests for HIV and Syphilis
79808292|NCT05863091|Device|HiCardi+|A patch-type electrocardiogram device is attached to a patient undergoing pulmonary function tests.
79973590|NCT05749679|Other|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~Hygienic and dietary measures~Physical activity~Smoking cessation~Avoidance of nephrotoxic substances~Treatment of hypertension~Proteinuria reduction~Oral antidiabetics; choice~Optimal HBA1c~Statin~Compliance"
79808293|NCT05863091|Device|HiCardi+|A patch-type electrocardiogram device is attached to a patient on a ventilator in an intensive care unit.
79808294|NCT05863065|Other|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
79808295|NCT05863013|Other|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
79478202|NCT05987696|Drug|Fludarabine|Lympho-conditioning Agent
79478203|NCT05987696|Drug|Cytarabine|Lympho-conditioning Agent
79478204|NCT05987696|Drug|CD33 CAR-NK cell|NK cell therapy
79478205|NCT05987696|Drug|super NK cell|NK cell therapy
79478206|NCT05987618|Device|Oral appliance with elastic bands|"The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16)."
79478207|NCT05987618|Device|Oral appliance without elastic bands|The oral appliance without the elastic bands.
79644064|NCT03962023|Other|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
79644065|NCT00532090|Drug|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
79644066|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
79644067|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
79644068|NCT00195312|Biological|HIV-1 gag DNA (formulated with bupivacaine)|
79644069|NCT00195312|Biological|IL-15 DNA (formulated with bupivacaine)|
79644070|NCT00195312|Biological|IL-12 DNA (formulated with bupivacaine)|
79644071|NCT00195312|Biological|Sodium chloride injection USP (0.9%)|
79644072|NCT00167609|Drug|dehydroepiandrosterone 100 and 400 mg|
79318358|NCT04496609|Device|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
79318359|NCT04496609|Device|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
79644073|NCT03920176|Diagnostic Test|Computed tomography coronary angiography|CTCA >64 detector row scanner
79318360|NCT05128175|Drug|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
79318361|NCT05341427|Device|electromagnetic device|electromagnetic waves for burn wound
79644074|NCT03920176|Other|ASSIGN Score|ASSIGN Cardiovascular Risk Score
79644075|NCT03888079|Drug|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
79644076|NCT03888079|Drug|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
79644077|NCT00167648|Drug|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
79318362|NCT05119205|Diagnostic Test|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
79644078|NCT00167648|Drug|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
79644079|NCT03852706|Other|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
79644080|NCT03852706|Other|Treatment as usual|Treatment-as-usual
79644081|NCT02907034|Procedure|Virtual reality experimentation sequency (VR)|
79644082|NCT02907034|Procedure|Classical narrative approach (CN)|
79973591|NCT05749679|Other|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
79973592|NCT05743777|Drug|Pembrolizumab|400 mg IV q6 weekly for a maximum of 18 cycles
79644083|NCT00177762|Behavioral|behavior weight loss|
79644084|NCT02906722|Drug|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
79644085|NCT02906722|Drug|Intravenous placebo|administration once, twice or 3 times per day according to renal function
79644086|NCT02906722|Drug|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
79808296|NCT05863000|Other|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
79808297|NCT05862974|Drug|LPM3480392|Intravenous infusion of 30min duration
79808298|NCT05862974|Drug|Placebo|Intravenous infusion of 30min duration
79644087|NCT02906722|Drug|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
79644088|NCT00167687|Drug|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
79644089|NCT02906878|Procedure|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
79808299|NCT05862948|Device|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
79973593|NCT05743777|Drug|MET-4|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
79644090|NCT02906956|Behavioral|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
79973594|NCT05743777|Drug|Placebo|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
79973595|NCT05725811|Other|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
79306805|NCT05944120|Combination Product|Aromatherapy patches|This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
79306806|NCT05942586|Dietary Supplement|Probiotic capsule (L. reuteri PB-W1™), Placebo sachet|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
79318363|NCT04184453|Drug|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patients.
79644091|NCT02906995|Drug|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
79973596|NCT05713669|Behavioral|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
79973597|NCT05713669|Behavioral|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
79973598|NCT05705687|Drug|BEP Protocol|anticancer therapy
79318364|NCT05127707|Behavioral|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
79318365|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
79318366|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
79318367|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
79318368|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
79644092|NCT00195390|Biological|Prevenar|Prevenar 0.5ml/ Vial and PFS
79644093|NCT02906800|Drug|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
79644094|NCT02906683|Drug|TAS-303|Oral administration for 8 weeks, once daily.
79644095|NCT02906683|Drug|Placebo|Oral administration for 8 weeks, once daily.
79644096|NCT02906605|Drug|JNJ-809|JNJ-809 (1*10^9) colony forming units (CFU) given as an infusion.
79644097|NCT02906605|Drug|Apalutamide|Apalutamide 240 mg orally daily.
79644098|NCT00195468|Drug|CYCLOSPORINE|
79973599|NCT05705687|Drug|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
79973600|NCT05705687|Procedure|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
79318369|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
79318370|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
79644099|NCT02906527|Drug|Non-exposed group|Non-exposed group / Patients receiving VKA
79318371|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
79318372|NCT05018975|Drug|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
79644100|NCT02906527|Drug|Exposed group|Exposed group / Patients receiving DOAC
79644101|NCT00167765|Drug|Abciximab|
79973601|NCT05691803|Behavioral|Exercise intervention|"The 6 month intervention consists of usual care (PaP) plus an initial 12 weeks of instructor led exercise (described below) followed by a 12 week period in where the participant will have to conduct their physical activity on their own.~Exercise intervention:~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks in where a physiotherapist contact the participant and discuss how they will adhere to their Physical activity on prescription."
79318373|NCT03741881|Other|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
79318374|NCT02673697|Device|Perceval valve|Sutureless Aortic Biological Valve
79318375|NCT02673697|Device|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
79644102|NCT02906410|Other|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
79318376|NCT02891993|Other|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
79644103|NCT02906410|Other|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
79973602|NCT05676203|Drug|Standard ADT (androgen deprivation therapy)|as prescribed by the treating physician.
79644104|NCT02906449|Behavioral|Meditation Technique|Alertness training or relaxation training
79973603|NCT05676203|Drug|Standard Darolutamide|2x600 mg/d as prescribed by the treating physician
79973604|NCT05676203|Drug|Docetaxel|Docetaxel
79318377|NCT02891993|Other|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
79478208|NCT05987553|Other|e-learning program|All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.
79478209|NCT05987540|Device|Non-invasive brainstem stimulation|Study participants will self-administer ~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
79644105|NCT02906371|Drug|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
79644106|NCT02906371|Drug|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (~ Day -5 to -1) will follow the standard CRS Rx algorithm
79973605|NCT05675540|Device|Macusense Assessment Software|Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.
79973606|NCT05642663|Device|Stapler|Stapling performed with ALTUS Powered Stapler
79644107|NCT02906371|Biological|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of ~1.5 x107 - 5 x109 (~3x105 - 1x108/kg) T cells.
79973607|NCT05638516|Behavioral|Vira mobile app intervention|The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
79318378|NCT02433509|Other|HUCB monocyte cells|"The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
79318379|NCT04533919|Procedure|Biospecimen Collection|Undergo collection of dorsal root ganglia
79318380|NCT05168579|Behavioral|Deliberate practice|As above
79318381|NCT00719225|Drug|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
79318382|NCT05404607|Other|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
79318383|NCT05404607|Other|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
79318384|NCT05404451|Diagnostic Test|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
79318385|NCT05404451|Diagnostic Test|Mckenzie Exercises|Using Mckenzie Exercises
79318386|NCT05127239|Behavioral|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
79644108|NCT00167804|Behavioral|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
79973608|NCT05638516|Behavioral|Vira mobile app intervention + coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
79644109|NCT02906293|Other|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
79318387|NCT05127083|Radiation|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
79644110|NCT02906254|Other|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
79973609|NCT05634837|Behavioral|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
79973610|NCT05634837|Behavioral|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
79318388|NCT04566497|Other|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
79318389|NCT04566497|Procedure|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
79318390|NCT05134337|Drug|LOXO-305|Oral LOXO-305
79318391|NCT05134337|Drug|Itraconazole|Oral itraconazole
79318392|NCT05134337|Drug|Rifampin|Oral rifampin
79318393|NCT04499495|Other|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
79478210|NCT05987514|Diagnostic Test|multimodal ultrasound|contrast-enhanced ultrasound and shear wave elastography on liver target lesion
79644111|NCT02906254|Other|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
79478211|NCT05987501|Diagnostic Test|Multimodal ultrasound|Contrast enhanced ultrasound and shear wave elastography on target intestinal loop are perfomed before and at different timepoints after treatment induction
79318394|NCT05134181|Drug|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
79318395|NCT05323175|Drug|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
79478212|NCT05987462|Other|Green walking|The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
79478213|NCT05987436|Other|Supervised Aerobic Exercise|Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
79318396|NCT05323175|Other|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
79318397|NCT02673619|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
79644112|NCT02906098|Behavioral|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
79644113|NCT02906098|Behavioral|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
79644114|NCT00195546|Drug|DVS-233|
79644115|NCT00167843|Drug|sulfadoxine-pyrimethamine|
79318398|NCT02673619|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2
79478214|NCT05987397|Drug|idebenone 30 mg for 14 days|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
79478215|NCT05987397|Drug|idebenone 30 mg for 3 months|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
79478216|NCT05987384|Dietary Supplement|Arachidonic acid|D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study
79478217|NCT05987384|Dietary Supplement|Sunflower oil|The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
79644116|NCT02906059|Drug|AZD1775|
79644117|NCT02906059|Drug|Irinotecan|
79644118|NCT02906176|Drug|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
79644119|NCT02906176|Drug|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
79644120|NCT02905942|Drug|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
79644121|NCT02905942|Drug|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
79644122|NCT02905864|Drug|Liraglutide 3 mg (Saxenda)|
79644123|NCT02905864|Drug|Liraglutide 3 mg placebo|
79644124|NCT00177840|Procedure|acupuncture|
79644125|NCT00167882|Drug|5-aminosalicylate (Pentasa, Ferring)|
79973611|NCT05629039|Behavioral|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
79478218|NCT05987384|Biological|Rabies Vaccine (Vero Cell) for Human Use|Every participant will receive three doses of rabies vaccination.
79478219|NCT05987358|Drug|TQB3454 tablets|TQB3454 is a selective IDH1 mutant enzyme inhibitor.
79478220|NCT05987358|Drug|TQB3454 tablets matching placebo|Placebo tablets without active substance.
79478221|NCT05987345|Device|PEF|PEF device treated in the trial.
79973612|NCT05618561|Diagnostic Test|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
79478222|NCT05987345|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
79478223|NCT05987280|Other|eDelphi method|eDelphi method
79478224|NCT05987267|Other|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
79973613|NCT05603169|Other|High intensity resistance Exercise Training|The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks
79478225|NCT05987228|Dietary Supplement|Thymus vulgaris|500 mg of Thymus vulgaris (capsules) was given orally twice daily
79478226|NCT05987215|Combination Product|Radiologic diagnosis|Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis
79318399|NCT05279963|Procedure|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
79318400|NCT05279963|Drug|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
79318401|NCT05279963|Procedure|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
79478227|NCT05987215|Diagnostic Test|Artificial intelligence diagnosis|Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
79478228|NCT05987176|Drug|Lutathera|"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."
79808300|NCT05862922|Device|Analgesia Nosiception İndex Monitoring|"ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period."
79973614|NCT05603169|Other|High intensity aerobic Exercise Training|The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
79973615|NCT05601661|Device|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
79478229|NCT05987163|Device|GP0116|GP0116 is an injectable, sterile, transparent product.
79478230|NCT05987163|Device|Active Comparator: FDA approved dermal filler device|FDA approved dermal filler device
79478231|NCT05987150|Radiation|Variation in anisotropy of the Spinal Cord using diffusion tensor imaging|All examinations were performed on a 3.0-T MRI machine with a 12-channel spine special coil (Ingenia CX, Philips Healthcare, Best, the Netherlands). The multi-sequence MRI protocol included conventional T1-weighted (sag & tra), T2-weighted (sag & tra), and DTI sequence.
79808301|NCT05862883|Drug|Rutan 25 mg|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."
79478232|NCT05987111|Behavioral|Pilates|Pilates exercises were applied twice a week for 4 weeks in both groups. The sessions were supervised by an Australian Physiotherapy and Pilates Institute (APPI) certified physiotherapist as 5 minutes of warm-up, 45 minutes of exercise and 5 minutes of cool-down periods.
79478233|NCT05987098|Diagnostic Test|BBPA PET examination|A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
79644126|NCT02905708|Device|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
79973616|NCT05601661|Device|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
79318402|NCT03161197|Behavioral|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
79318403|NCT03160963|Other|Power Testing|Chair stand, vertical jump, computerized squat
79318404|NCT05158543|Other|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
79318405|NCT05158543|Other|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
79318406|NCT05158543|Other|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
79478234|NCT05987059|Behavioral|SBIRT Intervention|"Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies."
79478235|NCT05986994|Other|Metabolic acidosis|Metabolic acidosis at birth with umbilical cord arterial pH at birth < 7.12
79478236|NCT05986994|Diagnostic Test|microRNA|Evaluation of microRNA levels
79644127|NCT02905708|Device|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
79644128|NCT02905747|Behavioral|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
79644129|NCT04681885|Device|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
79478237|NCT05986994|Other|Hypothermia|Therapeutic induced hypothermia refers to a lowering of the central body temperature for therapeutic purposes
79644130|NCT04681885|Device|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
79644131|NCT04681885|Device|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
79644132|NCT00177879|Behavioral|website comparison|
79808302|NCT05862883|Other|Control group|Taking basic therapy without Rutan
79808303|NCT05862831|Biological|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
79478238|NCT05986981|Drug|Vaccine|"Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects)."
79644133|NCT00167921|Drug|Premarin® Vaginal Cream|
79644134|NCT00167921|Drug|Premarin® oral tablets|
79973617|NCT05601661|Other|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
79973618|NCT05591365|Other|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
79478239|NCT05986968|Drug|Ticagrelor|Ticagrelor monotherapy for 12 months
79478240|NCT05986968|Drug|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
79478241|NCT05986955|Other|Diet|Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.
79478242|NCT05986903|Drug|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and > 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
79478243|NCT05986877|Drug|STSA-1201 Subcutaneous injection|Subcutaneous injection
79478244|NCT05986877|Drug|Placebo|Subcutaneous injection
79478245|NCT05986799|Dietary Supplement|Amway Herbal Drink|1 sachet per time, 3 times daily, for 3 months period.
79644135|NCT04681924|Other|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
79644136|NCT04681690|Other|No intervention, observation only.|Observation only
79644137|NCT02905630|Other|Exercise training|high intensity aerobic interval training
79644138|NCT00167960|Drug|Piperacillin/tazobactam and other β-lactam/β-lactamase|
79644139|NCT02905786|Device|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
79644140|NCT02905786|Other|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
79644141|NCT02905786|Other|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
79644142|NCT02905513|Behavioral|Contraceptive app instant messages|
79318407|NCT05133869|Device|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
79318408|NCT05231863|Drug|TKIs|tyrosine kinase inhibitors based therapy
79318409|NCT03164317|Other|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
79644143|NCT02905513|Other|Mobile phone app|
79644144|NCT02905552|Other|No intervention|
79973619|NCT05591365|Other|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps*3sets*TD), Breathing Exercise (10 Reps*3sets*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
79318410|NCT03164317|Other|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
79644145|NCT00167999|Drug|piperacillin-tazobactam|
79973620|NCT05583669|Drug|DS-2325a|Subcutaneous injection (starting dose 300 mg)
79318411|NCT04442087|Biological|Serology SARS-CoV2|Collect serum for Serology SARS-CoV2 at inclusion
79973621|NCT05583669|Drug|Placebo|Subcutaneous injection
79478246|NCT05986799|Dietary Supplement|Placebo Drink|1 sachet per time, 3 times daily, for 3 months period.
79644146|NCT00177996|Drug|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
79644147|NCT02905474|Other|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
79318412|NCT04442087|Behavioral|Data collection|Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion
79318413|NCT03164239|Behavioral|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
79478247|NCT05986760|Behavioral|SPARK|Functional Motor training
79478248|NCT05986734|Drug|Cutaquig|Subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L.
79478249|NCT05986721|Drug|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
79644148|NCT02905474|Device|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
79644149|NCT02905474|Device|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
79644150|NCT02905279|Behavioral|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
79644151|NCT02905279|Behavioral|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
79808304|NCT05862818|Behavioral|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
79808305|NCT05862818|Behavioral|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
79808306|NCT05862818|Behavioral|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
79808307|NCT05862818|Behavioral|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
79808308|NCT05862805|Procedure|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
79808309|NCT05862779|Dietary Supplement|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
79318414|NCT05133635|Drug|Methylprednisolone|Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
79318415|NCT05133635|Drug|Tocilizumab|Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
79478250|NCT05986721|Drug|Placebo|Placebo oral tablet
79318416|NCT05133557|Other|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
79318417|NCT04253587|Device|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
79318418|NCT04253587|Device|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
79318419|NCT04253587|Device|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
79318420|NCT04253587|Device|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
79318421|NCT05133167|Procedure|Balloon Tamponade or B-Lynch|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
79318422|NCT05132777|Drug|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
79478251|NCT05986708|Other|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
79478252|NCT05986695|Behavioral|Alert|Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note
79478253|NCT05986695|Behavioral|Peer comparison report|Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
79478254|NCT05986578|Device|TMS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dmPFC, approximately 25% of the nasion-inion distance or Talairah coordinates X 0 Y+60 Z+60 will be measured. The first session will begin with the acquisition of the resting motor threshold (rMT) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last ~3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
79808310|NCT05862779|Dietary Supplement|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
79318423|NCT05132777|Drug|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
79318424|NCT02680639|Device|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
79808311|NCT05862779|Dietary Supplement|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
79318425|NCT05126615|Drug|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
79318426|NCT05126615|Behavioral|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
79318427|NCT05126069|Device|Ab interno gelatin microstent|Ab interno gelatin microstent
79318428|NCT05126069|Procedure|Trabeculectomy|Trabeculectomy
79318429|NCT05422027|Drug|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
79318430|NCT05422027|Drug|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
79644152|NCT02905279|Behavioral|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
79318431|NCT05422027|Drug|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
79644153|NCT02905279|Behavioral|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
79644154|NCT00168077|Drug|Prothrombin Complex Concentrate|
79808312|NCT05862779|Dietary Supplement|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
79808313|NCT05862753|Drug|induction by Etomidate bolus|General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
79644155|NCT00195585|Drug|Isovorin|
79644156|NCT00195585|Drug|UFT|
79318432|NCT05422027|Drug|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
79318433|NCT05132621|Diagnostic Test|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
79318434|NCT05080777|Behavioral|Tele-Savvy|A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
79644157|NCT02905396|Device|Spinal cord stimulation|implantation of spinal cord stimulator
79644158|NCT02905123|Behavioral|Check Your Drinking|
79644159|NCT02905045|Drug|Ketoprofen|
79644160|NCT02905045|Drug|placebo|
79808314|NCT05862740|Procedure|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
79973622|NCT05579951|Procedure|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
79318435|NCT05080777|Behavioral|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
79318436|NCT05132309|Combination Product|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
79318437|NCT01674725|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79318438|NCT01674725|Drug|Ribavirin|Tablet
79318439|NCT03164083|Biological|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
79318440|NCT03164083|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
79318441|NCT03164395|Procedure|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
79318442|NCT03164395|Procedure|External Cardioversion|External Cardioversion per institutional protocol
79490306|NCT03418051|Other|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
79490307|NCT03418051|Other|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
79973623|NCT05579951|Procedure|Conventional|Total knee replacement with conventional instrumentation
79973624|NCT05579951|Device|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
79973625|NCT05529966|Device|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
79973626|NCT05529966|Device|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
79973627|NCT05517304|Device|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
79973628|NCT05517304|Device|sham|sham stimulation
79973629|NCT05492227|Diagnostic Test|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
79973630|NCT05489796|Drug|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
79973631|NCT05489796|Drug|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
79973632|NCT05489796|Drug|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
79973633|NCT05487651|Genetic|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
79973634|NCT05480670|Dietary Supplement|Berberine|550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
79973635|NCT05448664|Behavioral|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
79973636|NCT05448664|Behavioral|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
79318443|NCT05404061|Other|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~0.9% saline,~GLP-1"
79318444|NCT03161041|Procedure|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
79318445|NCT03161041|Drug|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
79318446|NCT05123495|Behavioral|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
79318447|NCT05123495|Behavioral|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
79318448|NCT05120219|Drug|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
79808315|NCT05862740|Procedure|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
79973637|NCT05448664|Behavioral|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en_index.html) will be distributed in an electronic form and sent via a mobile message.
79973638|NCT05438238|Device|Oncomfort|Virtual Reality
79973639|NCT05435950|Device|Sono-Intruments|"Spirecut's single use, pre-CE Sono-Instruments (SI) allow the percutaneous treatment of Carpal Tunnel (CT) syndrome and Trigger Finger/thumb (TF) under sonography (instead of open or endoscopic approach).~Two models will be assessed:~The Carpal Tunnel Sono-Instrument® (CT-SI), for CT syndrome release, by progressively cutting the transverse carpal ligament.~The Trigger Finger Sono-Instrument® (TF-SI), for TF release by progressively cutting the A1 annual pulley."
79318449|NCT05120219|Drug|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
79318450|NCT05120219|Drug|FDC tablet|single and multiple doses of HR20033 FDC tablet
79973640|NCT05422131|Device|MyCare Insite Clozapine Test|The MyCare Insite Clozapine Test is a 2 reagent system designed to evaluate the level of antipsychotic drug clozapine in a patients blood using the near patient device the MyCare Insite Analyser.
79973641|NCT05415501|Behavioral|Sentence training|Participants will be trained to read, make, and recall sentences during each session.
79973642|NCT05415228|Drug|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
79973643|NCT05414357|Diagnostic Test|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~Biological and physiological measurements~Spatial memory task~Cognitive battery~Questionnaires (sleep, quality of life)"
79318451|NCT05119517|Other|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
79318452|NCT05119049|Other|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
79318453|NCT05113355|Drug|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
79318454|NCT05113355|Drug|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
79318455|NCT03163693|Drug|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
79318456|NCT03163693|Other|normal saline|receive equal volume of normal saline
79318457|NCT05054543|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
79318458|NCT05054543|Drug|Placebo|0.9% Sodium Chloride
79490308|NCT02818946|Device|MRI|Detection of cancer by MRI for pathologic nipple discharge
79973644|NCT05409638|Behavioral|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
79318459|NCT05044507|Device|BQ 2.0|frequency and intensity parameters will be set to zero so that no stimulation is delivered
79808316|NCT05862714|Drug|Fluconazole|400 mg stat. Follow up at 4 weeks
79490309|NCT00378404|Drug|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
79490310|NCT00378404|Radiation|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
79490311|NCT01440452|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
79318460|NCT05044507|Device|BQ 2.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
79644161|NCT04723329|Behavioral|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
79644162|NCT00168116|Procedure|radiation treatment and surgery|
79644163|NCT00168116|Procedure|radiation alone|
79644164|NCT02905162|Other|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
79644165|NCT02904772|Drug|alipogene tiparvovec|A dose of 1x10(*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
79644166|NCT02904772|Drug|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
79644167|NCT02904772|Drug|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
79644168|NCT02904772|Drug|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
79644169|NCT00195741|Drug|divalproex sodium|
79644170|NCT00168155|Drug|perioperative chemotherapy|
79644171|NCT02904889|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
79644172|NCT02904889|Other|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
79306807|NCT05942586|Dietary Supplement|Prebiotic sachet (Prebiotic Blend), Placebo capsule|Participants in this arm will consume one placebo capsule daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
79306808|NCT05942586|Combination Product|Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend)|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
79306809|NCT05942586|Dietary Supplement|Placebo sachet, Placebo capsule|Participants in this arm will consume one placebo capsule daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
79306810|NCT05941715|Drug|Aflibercept 40 MG/ML|treat-and-extend
79306811|NCT05941715|Drug|Faricimab 120 MG/ML|treat-and-extend
79306812|NCT05932225|Other|Propylene glycol solution/drops|commercially available eye drops
79306813|NCT05931913|Device|Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex|TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
79306814|NCT05931913|Behavioral|Exposure with Response Prevention|ERP will be delivered daily, immediately following TMS
79306815|NCT05931913|Device|Transcranial Magnetic Stimulation: Sham|Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (<3%) magnetic field is delivered to the cortex
79306816|NCT05931913|Device|Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area|TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
79306817|NCT05929612|Radiation|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
79318461|NCT05125757|Other|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
79318462|NCT05125757|Other|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
79318463|NCT04439617|Biological|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
79318464|NCT05030545|Drug|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
79318465|NCT03163927|Other|Simulation-based training|See arm description
79318466|NCT03106805|Procedure|early insertion|insertion at 4th postpartum week
79318467|NCT03106805|Procedure|late insertion|insertion at 6th postpartum week
79318468|NCT03164161|Device|Cold pressor test|Described before.
79318469|NCT03164161|Other|β-endorphins evaluation in saliva|Described before.
79318470|NCT03164161|Other|β-endorphins evaluation in blood plasma|Described before.
79318471|NCT02627183|Procedure|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
79318472|NCT02627183|Behavioral|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
79318473|NCT04960475|Other|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
79318474|NCT04960475|Other|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
79318475|NCT04960475|Other|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
79318476|NCT03163615|Drug|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
79318477|NCT03163615|Drug|Placebo oral capsule|4 capsules, po, from admission up to 84 days
79318478|NCT04439695|Biological|Low dose|Low dose of KBP-V001
79318479|NCT04439695|Biological|Intermediate dose|Intermediate dose of KBP-V001
79318480|NCT04439695|Biological|High dose|High dose of KBP-V001
79318481|NCT04439695|Biological|Placebo|Buffered Saline Solution
79318482|NCT05675215|Diagnostic Test|Psychopathology screening tests|"The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer & Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks & Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun & Kempenaers, 2007)."
79644173|NCT02904850|Biological|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
79644174|NCT02904733|Other|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
79973645|NCT05369741|Other|TIME™ at Home|"Components of each 1.5-hour session:~Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~Post-class social time (15 min): Structured and unstructured social interactions~Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators."
79973646|NCT05357079|Drug|Tranexamic Acid|Topical application
79318483|NCT03114787|Other|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
79644175|NCT00178035|Drug|paroxetine|
79644176|NCT00178035|Behavioral|One night of Total Sleep Deprivation|
79644177|NCT02904616|Device|mobile spectrofluorimeter|
79644178|NCT02904538|Drug|Dexamethasone|
79644179|NCT02904538|Drug|isotonic saline|
79644180|NCT02904655|Other|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
79973647|NCT05357079|Drug|Normal saline|Topical application
79973648|NCT05336279|Drug|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|TR Group: famitinib malate T on day 1, famitinib malate R on day 13.
79973649|NCT05336279|Drug|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
79644181|NCT02963103|Drug|Tacrolimus|Oral
79644182|NCT00407264|Drug|Fluticasone propionate|
79644183|NCT02904499|Drug|Dabigatran|
79644184|NCT02904343|Device|domestic hemodialysis machine|WEGO, DBB-27C
79318484|NCT05125445|Procedure|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
79644185|NCT02904343|Device|imported hemodialysis machine|Fresenius, 4008s
79644186|NCT00195780|Drug|Divalproex Sodium (Depakote ER)|
79644187|NCT00407342|Drug|Alefacept (drug)|alefaceptgiven iv
79318485|NCT05125445|Procedure|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
79318486|NCT03114475|Radiation|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
79318487|NCT03114475|Other|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
79318488|NCT00754949|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
79318489|NCT00754949|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
79318490|NCT00754949|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
79318491|NCT03114709|Other|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
79318492|NCT03114709|Other|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
79644188|NCT00407342|Procedure|Narrowband UVB phototherapy|
79644189|NCT00553423|Drug|Lactulose|Lactulose 30 ml q6h for 48 hrs
79644190|NCT00553423|Drug|Placebo|Placebo 30 ml q6hrly for 48 hrs
79644191|NCT02904148|Procedure|Shoulder mobilisation|early shoulder mobilisation
79808317|NCT05862714|Drug|Itraconazole|1000 mg stat. Follow up at 4 weeks
79808318|NCT05862701|Drug|Permethrin|5% permethrin cream
79318493|NCT05022121|Behavioral|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
79644192|NCT02904304|Drug|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
79644193|NCT02904304|Drug|Placebo|01 tablet, orally, every 12 hours.
79644194|NCT00407459|Drug|Bevacizumab, Pemetrexed, Carboplatin|"Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
79644195|NCT00178074|Behavioral|total sleep deprivation|
79644196|NCT00178074|Procedure|PET imaging|
79644197|NCT02904031|Drug|5-fluorouracil|
79644198|NCT02904031|Drug|oxaliplatin|
79644199|NCT02904031|Drug|l-leucovorin|
79644200|NCT02904031|Drug|panitumumab|
79644201|NCT02904109|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
79644202|NCT02904109|Drug|Placebo|Once daily oral administration of placebo mannitol for 8 days.
79644203|NCT02904070|Device|Vaginal swabbing|
79808319|NCT05862701|Drug|Sulphur|10% Sulfur ointment
79318494|NCT05022121|Drug|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
79318495|NCT05011045|Procedure|Magnetic Resonance Imaging|Undergo MRI
79318496|NCT05011045|Other|Neurocognitive Assessment|Undergo neurocognitive function assessment
79318497|NCT05011045|Other|Quality-of-Life Assessment|Complete questionnaires
79318498|NCT05011045|Other|Questionnaire Administration|Complete questionnaires
79478255|NCT05986578|Device|TMS to dlPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dlPFC, position F3 will be measured, using probabilistic EEG placement. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last 3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
79478256|NCT05986578|Device|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 3 sessions with a 15-20 min interval between sessions.
79478257|NCT05986448|Behavioral|Tai-chi exercise|Traditional Chinese Tai Chi Movement
79973650|NCT05326997|Device|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
79644204|NCT00178113|Drug|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
79644205|NCT00178113|Drug|- Certagen (multivitamins with minerals)|
79973651|NCT05326997|Other|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
79644206|NCT00407498|Drug|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
79644207|NCT04681456|Behavioral|There is no medical intervention for the purposes of this Registry.|There is no medical intervention for the purposes of this Registry.
79318499|NCT05675137|Device|mobile-based|Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
79318500|NCT05675137|Other|paper-based|Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
79318501|NCT04620707|Device|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
79644208|NCT04681495|Behavioral|STAC|STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
79973652|NCT05326438|Behavioral|CIRCLE mHealth app|For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
79318502|NCT04620707|Behavioral|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
79973653|NCT05325476|Other|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
79318503|NCT03160807|Drug|Levofloxacin|Levolet 500 mg OD for 5 days
79644209|NCT04681378|Procedure|double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
79318504|NCT03160807|Drug|Levofloxacin|Levolet 500 OD for 10 days
79318505|NCT01674569|Drug|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
79318506|NCT01674569|Drug|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
79318507|NCT03160729|Drug|Dexamethasone|pre-operative, single-shot injection
79478258|NCT05986409|Other|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
79478259|NCT05986396|Device|INSPIRIS Resilia (model 11500A)|Aortic Valve
79478260|NCT05986357|Diagnostic Test|maternal serum C reactive protein|maternal serum high sensitivity C reactive protein
79478261|NCT05986357|Diagnostic Test|total leucocytic count levels|total leucocytic count levels
79478262|NCT05986357|Diagnostic Test|differential leucocytic count levels|differential leucocytic count levels
79478263|NCT05986344|Device|Copper intrauterine contraceptive device|copper T-380 IUD
79478264|NCT05986344|Device|LNG-IUS|Levonorgestrel Intrauterine System
79478265|NCT05986305|Behavioral|GOACT|GOACT sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
79478266|NCT05986305|Behavioral|PEER|During PEER sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
79973654|NCT05325476|Other|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
79318508|NCT04589117|Behavioral|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to cultivate compassion & forgiveness~Week 3: Writing to nurture positive emotions~Week 4: Writing to invite insight, perspective, & growth"
79808320|NCT05862662|Other|MOVE Program|Mobility Opportunities Via Education functional therapy program.
79973655|NCT05315193|Other|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
79973656|NCT05315193|Other|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps*3sets*TD), Breathing Exercise (10 Reps*3sets*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
79973657|NCT05309629|Drug|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
79973658|NCT05309629|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
79973659|NCT05309629|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
79973660|NCT05307380|Diagnostic Test|"functional pain scale"|French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
79973661|NCT05307211|Procedure|Cervical Interlaminar Epidural Steroid Injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
79973662|NCT05307211|Other|Neck Stabilization Exercises|The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
79973663|NCT05307211|Other|Neck and Scapular Stabilization Exercises|The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
79973664|NCT05283044|Biological|biopsy liquid|Patient performs a blood test at treatment baseline
79478267|NCT05986227|Drug|toripalimab FOLFOX|Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
79808321|NCT05862610|Drug|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
79644210|NCT04681573|Diagnostic Test|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
79973665|NCT05271032|Diagnostic Test|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
79973666|NCT05269433|Behavioral|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
79973667|NCT05269433|Behavioral|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
79973668|NCT05269433|Other|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
79973669|NCT05269433|Other|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
79478268|NCT05986214|Other|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
79644211|NCT04681612|Diagnostic Test|MSNA|"Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm"
79644212|NCT04681612|Diagnostic Test|Heart Rate Variability|Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
79644213|NCT04681612|Diagnostic Test|Blood Pressure Variability|Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
79644214|NCT04681612|Diagnostic Test|CMR|Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
79973670|NCT05267912|Procedure|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
79973671|NCT05258578|Behavioral|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
79973672|NCT05258578|Other|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
79318509|NCT04439929|Biological|TUR01|Administered as a single 40 mg, subcutaneous dose
79478269|NCT05986201|Device|TachoSil®|TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
79478270|NCT05986175|Other|Motor Imagery Training|The motor imagery training will be given with an audio recording containing 15 minutes of motor imagery training. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
79318510|NCT04439929|Biological|Adalimumab-EU|Administered as a single 40 mg, subcutaneous dose
79318511|NCT05131841|Drug|Cipterbin Combined With Vinorelbine|"Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer"
79318512|NCT03163849|Drug|Sofosbuvir , daclatasvir|Tablets
79318513|NCT03163849|Drug|Placebos|oral tablets
79490312|NCT01440452|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
79808322|NCT05862610|Drug|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
79808323|NCT05862597|Diagnostic Test|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
79973673|NCT05245747|Device|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
79808324|NCT05862584|Other|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
79478271|NCT05986175|Other|Core Stabilization Exercises|Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
79808325|NCT05862558|Device|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
79478272|NCT05986162|Drug|Itolizumab|Patients to be treated with Itolizumab.
79808326|NCT05862532|Dietary Supplement|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
79808327|NCT05862532|Dietary Supplement|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
79808328|NCT05862532|Dietary Supplement|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
79808329|NCT05862519|Dietary Supplement|Reset|Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.
79808330|NCT05862519|Dietary Supplement|Stay Ready Fiber|Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds & Flaxseed. Taken from Day 7 through Day 21.
79973674|NCT05243537|Other|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
79973675|NCT05226091|Behavioral|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
79973676|NCT05212688|Other|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 & GV24 midline.
79973677|NCT05212688|Other|Active Control|Weekly contact once per week for 6 weeks for a semi-structured telephone consultation.
79318514|NCT04520867|Other|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
79973678|NCT05209620|Drug|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
79973679|NCT05209620|Drug|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
79318515|NCT04509947|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
79318516|NCT04509947|Biological|Placebo|Placebo will be administered as IM injection.
79318517|NCT05131763|Biological|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
79318518|NCT03160495|Other|All patients|All patients are scanned with PET/MR prior to surgery.
79318519|NCT04160039|Device|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
79478273|NCT05986123|Other|Topical cream Z for PIH|The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
79808331|NCT05862519|Dietary Supplement|Libido|Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.
79808332|NCT05862519|Dietary Supplement|Testosterone supplement|Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
79644215|NCT04681612|Diagnostic Test|History, Lab, clinical and hemodynamic parameters|1. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
79644216|NCT02904187|Other|Positron Emission Tomography (PET)|
79973680|NCT05204836|Drug|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
79644217|NCT02904187|Other|Electroencephalogram (EEG)|
79644218|NCT02903875|Other|Patient therapeutic education (PTE) programme|
79644219|NCT00168272|Device|Transcranial Magnetic Stimulation|
79644220|NCT00195858|Behavioral|aerobic and resistance exercise|aerobic and resistance exercise
79644221|NCT02903563|Other|observational|
79644222|NCT02903524|Drug|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
79644223|NCT02903524|Drug|pirarubicin and cyclophosphamide|
79644224|NCT00168350|Drug|memantine|
79644225|NCT02903602|Behavioral|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
79644226|NCT02903602|Behavioral|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
79644227|NCT02903485|Other|nurses perform presurgical assessement and surveillance during surgery|
79644228|NCT02903485|Other|the anesthetic team performs presurgical assessement and surveillance during surgery|
79808333|NCT05862480|Other|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
79808334|NCT05862480|Other|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
79973681|NCT05204836|Drug|Placebo|100 mL intravenous infusion
79318520|NCT05178641|Device|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
79808335|NCT05862441|Drug|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
79318521|NCT05178641|Other|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
79318522|NCT05676775|Other|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
79973682|NCT05184062|Drug|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
79318523|NCT04501913|Procedure|Patient Monitoring|Undergo remote perioperative telemonitoring
79318524|NCT04501913|Other|Questionnaire Administration|Complete questionnaires
79318525|NCT03163537|Device|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
79318526|NCT03163381|Drug|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
79318527|NCT05131295|Drug|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
79318528|NCT05131295|Drug|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
79318529|NCT04028167|Drug|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
79318530|NCT05130905|Dietary Supplement|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity [6, 7, 8]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
79318531|NCT03163459|Drug|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
79478274|NCT05986110|Procedure|A training intervention on clinical ultrasound|To train 20 primary care family doctors in clinical ultrasound so that they have greater power of resolution and allow them to limit the diagnostic and surgical times on the waiting lists of their patients.
79478275|NCT05986097|Behavioral|Breakfast|We will provide participants recipes and information to support this dietary change.
79478276|NCT05986071|Drug|M1774|• Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
79808336|NCT05862441|Drug|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
79973683|NCT05184062|Drug|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
79973684|NCT05182788|Dietary Supplement|Placebo pressed candy|consume 2 tablets per day for 8 weeks
79973685|NCT05182788|Dietary Supplement|CHOLESWISE pressed candy|consume 2 tablets per day for 8 weeks
79973686|NCT05160532|Drug|Placebo|5ml of normal saline (NS)
79973687|NCT05160532|Drug|Dextrose prolotherapy (DPT)|25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
79478277|NCT05986071|Drug|Fulvestrant injection|Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
79318532|NCT03163459|Device|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
79318533|NCT05130749|Other|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
79318534|NCT05130203|Behavioral|MouvMat Exergaming|Sessions engaging with exergaming device.
79808337|NCT05862428|Drug|Rectal misoprostol|This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
79973688|NCT05156346|Other|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
79973689|NCT05153304|Biological|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
79318535|NCT05130203|Behavioral|Standard Recreational Programming|Conducted by recreational therapists.
79478278|NCT05986058|Behavioral|Golden Circle|The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
79318536|NCT05124587|Other|No intervention group|No intervention group
79318537|NCT01374217|Drug|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
79318538|NCT01374217|Drug|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
79318539|NCT01374217|Drug|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
79318540|NCT01374217|Drug|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
79478279|NCT05986045|Other|Quality of Life|ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period
79644229|NCT05996081|Behavioral|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
79644230|NCT05996068|Device|arterial line|insert arterial line for patients who meet major trauma criteria
79644231|NCT05996055|Device|improved version_support device|designed the NTUH version_support device based on the clinical suggestion.
79644232|NCT05996055|Device|the NTUH version_support device|original designed by NTUH
79318541|NCT04494815|Drug|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
79644233|NCT05996042|Behavioral|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
79973690|NCT05153304|Drug|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
79318542|NCT04494815|Drug|active control|Each participant will receive 1 dose of 300 mg active control capsule.
79318543|NCT04494815|Drug|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
79318544|NCT04494815|Drug|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
79318545|NCT04494737|Behavioral|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
79318546|NCT04494737|Behavioral|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
79318547|NCT05676541|Other|Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements|The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
79318548|NCT03688763|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
79318549|NCT03906253|Device|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
79478280|NCT05986032|Diagnostic Test|Respiratory Oscillometry|Measurement of respiratory system reactance by respiratory oscillometry
79644234|NCT05996029|Combination Product|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
79644235|NCT05996016|Other||
79808338|NCT05862415|Other|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
79318550|NCT03278249|Other|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
79318551|NCT04941937|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
79318552|NCT04941937|Drug|Thalidomide|100mg/d, Po. on day1-28
79808339|NCT05862402|Drug|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
79318553|NCT04941937|Drug|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
79478281|NCT05986019|Device|transcranial focused ultrasound (tFUS)|Transcranial focused ultrasound (tFUS) is a promising new technology that is both noninvasive and may be focally applied to deep brain targets. tFUS utilizes transducers which contain piezoelectric elements to produce pulses of ultrasonic waves that summate deep in the brain. Transcranial focused ultrasound (tFUS) uses a single transducer fixed in a head-worn apparatus on the scalp to produce ultrasonic waves deep into the brain.
79478282|NCT05986006|Procedure|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
79644236|NCT05995990|Device|Raman Spectrometry|Laboratory technique of Raman Spectrometry
79808340|NCT05862350|Other|aromatherapy inhalation with lavender essential oil|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep
79478283|NCT05986006|Procedure|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
79808341|NCT05862350|Other|aromatherapy inhalation with coconut essential oil.|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
79808342|NCT05862337|Drug|Anlotinib hydrochloride capsules, Penpulimab injection|"Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1)."
79808343|NCT05862337|Drug|Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo|placebo control, no active substance.
79808344|NCT05862311|Diagnostic Test|ELISA|ELISA(enzyme-linked immunosorbent assay)
79808345|NCT05862246|Other|Clinical examination|No intervention, only clinical examination
79318554|NCT04941937|Drug|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
79318555|NCT04941937|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
79318556|NCT05124431|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
79318557|NCT05124431|Drug|everolimus|5mg po，qd
79808346|NCT05862220|Diagnostic Test|D-Dimer vs CTPA|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
79808347|NCT05862181|Procedure|DEB-TACE plus HAIC or HAIC alone|the patients received DEB-TACE plus HAIC or HAIC at least twice during this observational study
79808348|NCT05862142|Other|No intervention|No intervention
79318558|NCT04435613|Other|protective mechanical ventilation strategies|1. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
79318559|NCT04955249|Drug|Dexmedetomidine|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
79644237|NCT05995977|Behavioral|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
79318560|NCT04955249|Drug|Placebo|Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
79318561|NCT04876417|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
79318562|NCT04876417|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
79318563|NCT05097443|Drug|Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies|"Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD."
79478284|NCT05985980|Diagnostic Test|Exercise Treadmill Test (ETT)|Routinely ordered exercise treadmill test results will be reviewed in premenopausal women. ETT results and change in hs cTnI levels will be compared between the early and late follicular phases of menstrual cycle.
79478285|NCT05985967|Device|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
79478286|NCT05985967|Device|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
79478287|NCT05985967|Device|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
79644238|NCT05995951|Device|Deep Bran Stimulation (DBS)|Deep brain stimulation (DBS) surgery targeting the antero-medial Sub-Thalamic Nucleus (amSTN)
79808349|NCT05862129|Procedure|surgical operation|Radical operation for the perianal abscess
79808350|NCT05862116|Other|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
79478288|NCT05985967|Other|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
79478289|NCT05985902|Other|Core Stabilization Exercises|"Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma"
79644239|NCT05995951|Device|Sham-stimulation|Deep brain stimulation (DBS) surgery - Sham stimulation
79808351|NCT05862103|Other|Treatment Strategies|AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
79478290|NCT05985902|Other|Schroth Exercises|In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
79478291|NCT05985889|Other|Robot|You have to walk with a robot mounted on your lower limb. To move, to change direction.
79478292|NCT05985889|Other|Fizio|Patients do state-funded physical therapy.
79808352|NCT05862090|Drug|RLD2301|Take it once a day per period.
79478293|NCT05985889|Other|EXE1|Patients undergo intensive virtual reality therapy once a day.
79318564|NCT02285621|Other|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
79318565|NCT00197873|Dietary Supplement|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
79318566|NCT00197873|Other|Placebo administration.|Placebo is administered during chemotherapy.
79318567|NCT03114085|Drug|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
79318568|NCT03114085|Drug|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
79318569|NCT04854317|Procedure|Endoscopic gastroplasty or Intragastric balloon placement|Endoscopic bariatric procedures
79808353|NCT05862090|Drug|RLD2007|Take it once a day per period.
79973691|NCT05121844|Device|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
79318570|NCT04440553|Behavioral|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
79318571|NCT04440553|Behavioral|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
79318572|NCT03114631|Biological|Dendritic cells pulsed with tumor lysate|
79318573|NCT03114631|Biological|Dendritic cells pulsed with MUC-1/WT-1 peptides|
79318574|NCT03162835|Other|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
79478294|NCT05985889|Other|EXE2|Patients undergo intensive virtual reality therapy twice a day.
79808354|NCT05862064|Drug|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
79808355|NCT05862064|Drug|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
79973692|NCT05114252|Device|Vivid Vision Home|The study intervention consists of playing serious games (Vivid Vision, San Francisco, USA) embedded in a virtual reality headset in a home environment 5 days a week for 30 minutes over 8 weeks (20 h of total gaming).
79318575|NCT04918511|Drug|OPD5|OPD5 solution for i.v. infusion
79318576|NCT03162757|Procedure|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
79318577|NCT03162991|Other|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for ~30-55 minutes per exercise session.
79318578|NCT03163069|Combination Product|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
79318579|NCT03163069|Combination Product|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
79478295|NCT05985889|Other|EXE+ROB|The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.
79808358|NCT05861908|Other|Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
79973693|NCT05114252|Behavioral|Refractive error correction|The control intervention will be refractive error correction that consists of wearing the lenses with the prescribed correction for 2 months.
79318580|NCT03163069|Combination Product|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
79644240|NCT05995938|Behavioral|Mindfullnes-Based Cognitive Therapy|Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
79973694|NCT05078970|Behavioral|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
79973695|NCT05078970|Behavioral|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
79973696|NCT05078970|Behavioral|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
79318581|NCT05136599|Biological|Bordetella pertussis D420|Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
79318582|NCT03162679|Behavioral|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
79644241|NCT05995912|Drug|etoricoxib-tramadol|Oral administration (with or without food)
79644242|NCT05995912|Drug|Naproxen|Oral administration (with or without food)
79644243|NCT05995912|Drug|Tramadol|Oral administration (with or without food)
79644244|NCT05995821|Other|Collection of biological specimens|Collection of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of your cheek, urine, saliva, or other tissue samples.
79644245|NCT05995808|Procedure|Bone marow biopsy and aspiration|Bone marrow biopsy and biopsy aspiration
79644246|NCT05995808|Diagnostic Test|biochemical and heamatological tests|complete blood count ,serum urea and creatinine
79644247|NCT05995795|Device|ARTHROSCOY|arthroscopy
79644248|NCT05995782|Drug|FB418|Oral dose
79644249|NCT05995730|Other|Lavender oil inhalation|Lavender inhalation will be administered to this group. Participants will be asked to drop three drops of lavender oil solution on a small piece of cotton on the 1st, 2nd, and 3rd days of their first menstrual bleeding after enrollment in the study, hold it 7-10 cm from their noses, and sniff for 5 minutes. Participants will be asked to apply this application immediately after the onset of dysmenorrhea pain on the first day of their menstruation and to continue regularly every 8 hours for the first three days of menstrual bleeding. Participants will be asked to apply this application in the same way in two consecutive menstrual cycles and the participants will be followed in this process.
79318583|NCT03162601|Procedure|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
79318584|NCT05136521|Drug|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
79318585|NCT05136521|Drug|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
79644250|NCT05995730|Other|Placebo|Olive oil will be administered to the placebo group. The application will be similar to the experimental group.
79644251|NCT05995691|Drug|ABP 501|SC injection
79644252|NCT05995691|Drug|Adalimumab|SC injection
79808359|NCT05861908|Other|Heated Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
79808360|NCT05861908|Other|G-aenial™ BULK Injectable restoration|restoration of class II caries with different bulk-fill technique
79808361|NCT05861908|Other|Sonicfill3 restoration|restoration of class II caries with different bulk-fill technique
79478296|NCT05985876|Behavioral|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
79808362|NCT05861882|Other|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
79318586|NCT03162523|Radiation|High-Dose Rate Brachytherapy|
79318587|NCT03330067|Device|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
79318588|NCT03330067|Device|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
79318589|NCT05136209|Procedure|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
79808363|NCT05861882|Other|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
79318590|NCT05136209|Procedure|PCCC+A-Vit procedure|PCCC+A-Vit procedure
79318591|NCT05135897|Device|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
79808364|NCT05861882|Other|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
79808365|NCT05861882|Other|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
79318592|NCT05135897|Device|rTMS|repetitive Transcranial Magnetic Stimulation
79318593|NCT03850171|Other|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
79318594|NCT04937465|Other|No intervention done|No intervention was done. This was an observational study.
79318595|NCT04725877|Biological|VIR-1111|VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
79318596|NCT04725877|Drug|Placebo|A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
79318597|NCT02388529|Drug|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
79318598|NCT02388529|Drug|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
79318599|NCT02388529|Drug|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
79318600|NCT02388529|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
79808366|NCT05861817|Device|Laser theapy|participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
79490313|NCT01440452|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
79318601|NCT05343013|Drug|TAS-102|GIven by PO
79318602|NCT02388373|Drug|Fluticasone 250/formoterol 10|
79318603|NCT02388373|Drug|Fluticasone 250/salmeterol 25|
79318604|NCT02388373|Drug|Fluticasone 125/formoterol 5|
79318605|NCT05231239|Device|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
79318606|NCT02388451|Device|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
79808367|NCT05861791|Drug|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
79808368|NCT05861791|Drug|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
79478297|NCT05985876|Behavioral|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
79644253|NCT05995665|Device|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
79644254|NCT05995665|Other|Graded Repetitive Arm Supplementary Program (GRASP)|Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
79808369|NCT05861752|Behavioral|Treatment as usual|both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
79318607|NCT03239587|Behavioral|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
79318608|NCT03239587|Procedure|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
79318609|NCT03239587|Behavioral|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
79478298|NCT05985837|Device|KalobaGOLA spray (1)|Oral spray, 2-4 spray, till 8 times per day
79478299|NCT05985837|Device|KalobaGOLA spray (2)|Oral spray, 2-4 spray, till 4 times per day
79318610|NCT01674647|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
79318611|NCT01674647|Drug|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
79318612|NCT02669407|Procedure|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
79318613|NCT02669407|Drug|regional nerve block with a local anesthetic (Lidocaine)|
79318614|NCT02388139|Procedure|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
79318615|NCT02388139|Procedure|coronarography|
79478300|NCT05985837|Device|KalobaGOLA tablets|1 tablets, 6 times per day
79318616|NCT02388139|Procedure|coronary angioplasty|
79808370|NCT05861739|Behavioral|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
79973697|NCT05060653|Other|SBRT followed by surgical stabilization within 24-48 hours|In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
79973698|NCT05045079|Procedure|Inferior Vena Caval (IVC) Occlusion maneuver|During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
79318617|NCT02388139|Procedure|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
79973699|NCT05038813|Drug|Anlotinib+TQB2450|"Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months."
79973700|NCT05034159|Behavioral|Cognitive Behavioral Therapy for Insomnia|Same as is described previously.
79973701|NCT05004363|Drug|Lokelma Oral Product|Potassium binder
79973702|NCT04985903|Behavioral|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
79973703|NCT04985903|Other|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
79973704|NCT04982302|Procedure|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
79973705|NCT04973748|Behavioral|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
79318618|NCT02388139|Procedure|body composition monitoring|using Fresenius device
79478301|NCT05985798|Drug|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
79478302|NCT05985798|Drug|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
79478303|NCT05985785|Other|Autologous bone marrow aspirate concentrate (BMAC)|Bone marrow aspirate concentrate BMAC is a biologically substance harvested from a patient for autologous use. Bone marrow aspirate concentrate (BMAC) has been determined by the FDA to be a minimally manipulated biologic prepared for autologous use and does not require premarket FDA approval for clinical use.
79973706|NCT04973748|Behavioral|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
79808371|NCT05861726|Behavioral|Aerobic exercise|a moderate kind of physical activity with a heart rate between 65 & 70% maximum heart rate
79808372|NCT05861726|Other|None (control group)|None (the control group)
79973707|NCT04973189|Drug|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
79973708|NCT04973189|Drug|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
79973709|NCT04973189|Drug|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
79318619|NCT05135741|Device|pressure bio feedback|The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
79318620|NCT02667457|Radiation|99mTc-rhAnnexin V-128|
79318621|NCT05135507|Behavioral|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
79478304|NCT05985785|Drug|Corticosteroid injections|Current standard of treatment for OA of the knee is corticosteroid injection.
79808373|NCT05861713|Drug|Hydrating Cream|The experimental group will apply the Hydrating Cream to the affected skin area at least twice daily with a cotton swab, while the other limb was the control group.
79808374|NCT05861687|Drug|Esomeprazole|Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
79808375|NCT05861687|Drug|Lansoprazole|Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was <30 kg, and 30 mg if it was >30 kg
79973710|NCT04973189|Drug|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
79808376|NCT05861687|Drug|Amoxicillin|Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
79973711|NCT04967495|Procedure|TACE combined with lenvatinib and iodion-125 seeds brachytherapy|TACE will be performed for the patients after randomization. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight < 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 14 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
79973712|NCT04967495|Procedure|TACE combined with lenvatinib|TACE will be performed for the patients after randomization and it can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight < 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
79318622|NCT05135429|Other|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
79318623|NCT05403905|Procedure|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
79478305|NCT05985785|Other|Crossover Autologous bone marrow aspirate concentrate (BMAC)|Subjects who participate in this study and who are randomized to receive the BMAC may experience decreased pain and increased functionality after the injection compared to those that receive a corticosteroid injection. As such, participants who continue to have pain after a corticosteroid injection will be allowed to crossover to a BMAC injection at 24 weeks or 6 months post-surgery.(ARM 3)
79808377|NCT05861687|Drug|Clarithromycin|Administered twice a day per-oral with the dose of 7.5 mg/kg
79973713|NCT04965766|Drug|U3-1402|First infusion for 90 minutes and then infusion duration can be progressively decreased to 30 minutes if participant doesn't experience infusion related reactions (IRR)
79973714|NCT04933721|Drug|berotralstat|BCX7353 capsules administered orally once daily
79808378|NCT05861661|Other|The study do not include an intervention|The study do not include an intervention
79808379|NCT05861648|Drug|Folic Acid Oral Tablet|Dietary Supplement: Folic acid 2.5mg/day
79973715|NCT04928885|Behavioral|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
79973716|NCT04928885|Other|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
79318624|NCT05403905|Procedure|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
79318625|NCT04893707|Biological|CM310|"adults and teenagers (12 ~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 ~ 18 years) with weight ≥30 kg and <60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
79318626|NCT02669095|Device|Investigational Contact Lenses (Test)|
79318627|NCT02669095|Device|Marketed Contact Lenses (Control)|
79318628|NCT04637555|Drug|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
79318629|NCT02388061|Drug|Tenecteplase|
79318630|NCT02388061|Drug|Tissue Plasminogen Activator|
79318631|NCT04598789|Other|no intervention|no intervention, observational study
79808380|NCT05861648|Dietary Supplement|Placebo|Dietary Supplement: Placebo
79318632|NCT05134961|Procedure|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
79318633|NCT04587635|Dietary Supplement|PHGG|PHGG
79808381|NCT05861635|Drug|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
79318634|NCT04587635|Dietary Supplement|Placebo|Maltodextrin
79318635|NCT02387827|Behavioral|Diet+ short term versus long -term physical activity|
79318636|NCT04556357|Drug|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
79318637|NCT04556357|Drug|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
79318638|NCT02933281|Biological|MTBVAC|Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
79318639|NCT02933281|Biological|BCG|BCG 5 x 10^5 CFU
79318640|NCT05134883|Other|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
79318641|NCT05134883|Other|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
79318642|NCT05134805|Procedure|Bipolar hemiarthroplasty , proximal femoral nail|"Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
79318643|NCT02667301|Device|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
79318644|NCT02667301|Device|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
79318645|NCT02667301|Device|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
79318646|NCT02803333|Other|No Intervention|No intervention
79318647|NCT04553939|Drug|Toripalimab|Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
79318648|NCT04553939|Drug|Gemcitabine|Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
79808382|NCT05861622|Other|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
79808383|NCT05861609|Procedure|Usual care|Usual care with respect to Spinal Cord Stimulation implantation
79808384|NCT05861609|Procedure|Standardized pain medication tapering|A standardized pain medication tapering program before Spinal Cord Stimulator implantation.
79808385|NCT05861609|Procedure|Personalized pain medication tapering|A personalized pain medication tapering program before Spinal Cord Stimulator implantation.
79318649|NCT03113773|Drug|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10^6 - 3.0 X 10^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10^6 IU will be allowed per day.
79318650|NCT03113773|Drug|Placebo Injection|Dextrose 5%
79318651|NCT04874831|Drug|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
79318652|NCT04454879|Drug|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
79318653|NCT05122169|Drug|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
79318654|NCT05122169|Drug|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
79808386|NCT05861596|Device|Repetitive Transcranial Magnetic Stimulation|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
79973717|NCT04877444|Device|Duck Duck Punch|"Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions."
79973718|NCT04877444|Behavioral|Aerobic exercise|Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
79318655|NCT04387955|Diagnostic Test|Biological Sample Collection|"Diagnostic test : biological sample collection at Day 0~Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~Anal swabbing at Day 0~Blood test at Day 0~Blood test at Month 1~Blood test at Month 2"
79318656|NCT04359329|Drug|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
79318657|NCT04326101|Other|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
79318658|NCT04494035|Device|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
79318659|NCT03041285|Drug|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
79318660|NCT03041285|Radiation|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
79318661|NCT04794023|Device|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
79644255|NCT05995639|Procedure|Dry Needling|Dry needling is an evidence-based therapeutic procedure used primarily in musculoskeletal rehabilitation. It involves inserting thin needles into specific trigger points in muscles, tendons, or fascia, aiming to alleviate pain and improve musculoskeletal function. Unlike acupuncture, dry needling focuses on resolving myofascial pain and dysfunction by directly targeting trigger points, often identified through palpation and anatomical understanding. Academic exploration of dry needling delves into its physiological mechanisms, clinical effectiveness, and potential integration into comprehensive treatment strategies.
79973719|NCT04877444|Behavioral|Lower extremity stretching|Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
79973720|NCT04865341|Behavioral|IMB|Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
79973721|NCT04847037|Procedure|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
79973722|NCT04845347|Device|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
79973723|NCT04845347|Device|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
79973724|NCT04828135|Drug|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
79973725|NCT04823949|Device|Home blood pressure monitoring|See arm description
79318662|NCT04256681|Other|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
79318663|NCT04766645|Device|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
79318664|NCT04766645|Genetic|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
79318665|NCT04766645|Diagnostic Test|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
79318666|NCT05301725|Other|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
79318667|NCT05301725|Other|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
79318668|NCT05301647|Diagnostic Test|Nasal cytology|The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
79318669|NCT05301647|Other|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
79318670|NCT05301647|Other|Total symptom score (TSS)|Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
79318671|NCT05301647|Other|Visual analogic scale (VAS)|A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
79973726|NCT04817605|Other|Therapeutic Exercise|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
79973727|NCT04815720|Drug|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
79808387|NCT05861596|Device|Neuromuscular electrical stimulation combined with conventional swallowing training|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
79318672|NCT05403671|Other|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
79318673|NCT04412759|Other|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
79318674|NCT04203875|Drug|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
79318675|NCT05283785|Procedure|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
79318676|NCT04491461|Dietary Supplement|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
79318677|NCT04491461|Dietary Supplement|Warm water|1 cup of warm water
79318678|NCT04151927|Device|Normobaric Hypoxia|Low oxygen exposure to mimic ~8500 feet elevation.
79318679|NCT04151927|Device|Normobaric Normoxia|Normal oxygen exposure to mimic ~1000 feet elevation (sham comparator).
79478306|NCT05985772|Other|Non-Operative Pain Management|The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
79478307|NCT05985772|Procedure|Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment|The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
79808388|NCT05861557|Drug|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
79808389|NCT05861557|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy*5Fx), after 1 cycle of immunotherapy
79808390|NCT05861544|Dietary Supplement|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
79318680|NCT04142645|Device|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~an ICT platform:~automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
79318681|NCT05900687|Behavioral|Use of mHealth Question Prompt List app|mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
79318682|NCT05900674|Drug|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
79813719|NCT02609438|Behavioral|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
79973728|NCT04813484|Behavioral|Kickin it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
79973729|NCT04809740|Other|Evaluate implementation of navigator-delivered Home ePRO for all cancer patients|evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes
79644256|NCT05995639|Procedure|Ozone Injection|Intramuscular ozone injection is a therapeutic intervention utilized within the context of musculoskeletal care, particularly for individuals grappling with conditions such as myofascial pain syndrome and related neuromuscular issues. This technique involves the controlled introduction of ozone gas, a chemically reactive form of oxygen, directly into targeted muscle tissue through an injection. This intramuscular administration is guided by precise anatomical knowledge and is designed to harness the potential therapeutic benefits of ozone's reactive properties.
79973730|NCT04740879|Behavioral|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
79318683|NCT05900661|Drug|myo-inositol|myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .
79318684|NCT05900661|Drug|Somatropin|growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
79644257|NCT05995574|Behavioral|chatbot communication training|Artificial intelligence chatbot that simulates a mother and a daughter for the pediatrician to practice communication about contraception.
79644258|NCT05995561|Other|no intervention is planned.|no intervention is planned.
79644259|NCT05995522|Dietary Supplement|Vitamin K2|100 µg per day for 90 days
79644260|NCT05995522|Other|Cornstarch|500 mg per day for 90 days
79644261|NCT05995509|Procedure|Micro-osteo-perforations|small perforations drilled in Alveolar bone, adjacent to site of tooth movement.
79808391|NCT05861531|Behavioral|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
79813720|NCT00627094|Device|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
79318685|NCT05900661|Drug|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
79318686|NCT05900635|Drug|Lactoferrin|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
79318687|NCT05900635|Drug|Ferrous Glycine Sulfate|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
79318688|NCT05900622|Other|Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
79478308|NCT05985759|Drug|N acetyle cystiene|N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
79973731|NCT04737889|Drug|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
79973732|NCT04737889|Drug|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
79973733|NCT04737889|Drug|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
79318689|NCT05900622|Other|Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
79318690|NCT05900557|Diagnostic Test|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
79318691|NCT05900544|Other|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
79318692|NCT05900531|Drug|K-757|administered orally
79318693|NCT05900531|Drug|K-757 and open-label sitagliptin|both administered orally
79318694|NCT05900531|Drug|Matching placebo to K-757|administered orally
79318695|NCT05900531|Drug|Matching placebo to K-757 and matching placebo to K-833|both administered orally
79318696|NCT05900531|Drug|K-757 and K-833|both administered orally
79318697|NCT05900531|Drug|Matching placebo to K-757, open-label sitagliptin|both administered orally
79318698|NCT05900440|Other|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
79973734|NCT04737889|Drug|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
79973735|NCT04735354|Drug|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
79318699|NCT05900440|Other|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
79318700|NCT05900414|Behavioral|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
79808392|NCT05861531|Behavioral|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
79973736|NCT04725487|Other|Standard integration program with social and health promoting intervention|"Basic language course, internships, courses in Labour market knowledge and Danish culture~Physical activity workshops~Community gardening (garden workshops)~Entrepreneurship course~MindSpring course~Family excursions~Danish language workshops"
79318701|NCT05900414|Other|Information|Link to website with information about atrial fibrillation treatments
79973737|NCT04725487|Other|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
79973738|NCT04679740|Device|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
79973739|NCT04672291|Drug|Poly-ICLC (Hiltonol®) or Placebo|The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
79973740|NCT04672291|Drug|Poly-ICLC (Hiltonol®) or Placebo|The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
79808393|NCT05861531|Behavioral|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
79808394|NCT05861531|Behavioral|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
79318702|NCT05900349|Other|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
79973741|NCT04668365|Drug|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
79973742|NCT04668365|Drug|Zanubrutinib|160mg twice daily continuous oral administration.
79973743|NCT04668365|Drug|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79973744|NCT04668365|Drug|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79973745|NCT04668365|Drug|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79318703|NCT05900349|Other|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
79318704|NCT05900323|Combination Product|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
79644262|NCT05995483|Other|Early Diagnosis on BSE|the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
79644263|NCT05995431|Procedure|scaling and root planing|All the participants will undergo scaling and root planing
79808395|NCT05861531|Behavioral|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
79973746|NCT04668365|Drug|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79973747|NCT04616729|Drug|Triptorelin 3.75 MG Injection|Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.
79808396|NCT05861518|Behavioral|Hypnosis|In the hypnosis group, patients were given hypnosis sessions of approximately 30 minutes each, in groups of three, once a week. In this way, session standardization was achieved. Arm catalepsy was suggested in all patients. The first session was used as hypnosis induction, progressive muscular relaxation and introduction to hypnosis. In the second session, in addition to the first session, self-hypnosis training was given. The second session was applied as the same 3rd session. In these patients, in addition to analgesia suggestions, the feeling of worthlessness was especially studied with the recommendation of a psychiatrist.
79808397|NCT05861505|Drug|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
79813721|NCT00627094|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
79478309|NCT05985746|Other|Augmented reality group|"Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
79644264|NCT05995431|Procedure|Subgingival instrumentation|All the participants will undergo subgingival instrumentation
79973748|NCT04616729|Procedure|Transvaginal oocyte retrieval|Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
79808398|NCT05861505|Other|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
79808399|NCT05861492|Other|Fatigue Differential Diagnosis Aid|The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
79318705|NCT05900310|Diagnostic Test|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
79478310|NCT05985746|Other|Traditional learning group|"Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
79973749|NCT04616729|Drug|Triptorelin Injection|Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
79973750|NCT04594681|Drug|Placebo|Placebo is administered once daily or three times daily.
79478311|NCT05985733|Other|Biochemical analysis|Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
79478312|NCT05985629|Drug|IPACK|Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
79973751|NCT04594681|Drug|KHK4951|KHK4951 is administered once daily or three times daily.
79478313|NCT05985629|Drug|PLACEBO|The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
79478314|NCT05985577|Other|Without any intervention|There were no special interventions for the two groups.
79478315|NCT05985564|Other|imaging diagnosis|no intervention
79478316|NCT05985551|Other|SLND or TAD by the magnetic technique (SPIO)|All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.
79644265|NCT05995418|Other|There was no intervention as this was an observational study.|There was no intervention as this was an observational study.
79644266|NCT05995379|Diagnostic Test|Donor-derived cell-free DNA|"Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed."
79644267|NCT05995262|Other|Chart Review|Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
79644268|NCT05995210|Procedure|Kinesio taping|A corrective kinesio taping was applied to the patellofemoral joint for the knee. In addition, exercise therapy was taken.
79813722|NCT02610530|Procedure|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
79808400|NCT05859971|Drug|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
79808401|NCT05859971|Device|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
79808402|NCT05859724|Biological|NM26-2198|IL-4R/IL-31 bispecific antibody for subcutaneous administration
79808403|NCT05859724|Other|Placebo|Placebo for NM26-2198
79318706|NCT05900232|Diagnostic Test|Anti _KU antibodies|aim of the work is to determine the relationship between Anti_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
79318707|NCT05900219|Drug|HL-085+Vemurafenib|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
79318708|NCT05900206|Drug|Trastuzumab deruxtecan|Experimental drug. Provided in 100mg vials. IV infusion.
79808404|NCT05859685|Other|Experimental|"Manual therapy techniques:~Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
79808405|NCT05859685|Other|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
79318709|NCT05900206|Drug|Docetaxel|Active comparator. IV infusion.
79808406|NCT05859659|Diagnostic Test|This study does not intervene in this process.|This study does not intervene in this process.
79808407|NCT05859503|Other|Closure Strategy with Perclose-Proglide system|Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure
79808408|NCT05859503|Other|Closure Strategy with figure-of-8|Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
79813723|NCT02610530|Procedure|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
79318710|NCT05900206|Drug|Paclitaxel|Active comparator. IV infusion.
79813724|NCT02610530|Other|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
79318711|NCT05900206|Drug|Carboplatin|Active comparator. IV infusion.
79318712|NCT05900206|Drug|Trastuzumab|Active comparator. IV infusion.
79318713|NCT05900206|Drug|Pertuzumab|Active comparator. IV infusion.
79318714|NCT05900206|Drug|Ribociclib|Experimental drug. Tablets.
79318715|NCT05900206|Drug|Letrozole|Experimental drug. Tablets.
79318716|NCT05900206|Drug|Epirubicin|Active comparator. IV infusion.
79318717|NCT05900206|Drug|Cyclophosphamide|Active comparator. IV infusion.
79808409|NCT05859256|Other|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
79318718|NCT05900193|Dietary Supplement|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
79318719|NCT05900167|Behavioral|enteral nutrition|The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition
79318720|NCT05900089|Drug|SHR0302|SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
79318721|NCT05900024|Other|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
79318722|NCT05900011|Behavioral|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
79318723|NCT05899985|Combination Product|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
79808410|NCT05859256|Other|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
79808411|NCT05858931|Procedure|vaginal repair|vaginal repair
79808412|NCT05855031|Diagnostic Test|Transient Elastography|One transient elastography 1-2 weeks after randomization
79808413|NCT05853991|Other|osteopathic manipulative treatment|The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.
79808414|NCT05853991|Other|Active comparator|Application of affective touch
79318724|NCT05899959|Device|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
79318725|NCT05899946|Other|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
79318726|NCT05899920|Diagnostic Test|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
79318727|NCT05899907|Drug|Telitacicept|160mg once a week for 48 weeks
79318728|NCT05899907|Drug|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
79318729|NCT05899894|Device|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
79318730|NCT05899855|Other|No intervention|No intervention
79318731|NCT05899842|Drug|Protein pump inhibitor therapy systematically|Lansoprazole 30mg once per day
79318732|NCT05899803|Diagnostic Test|Posture Analysis|This analysis consists of 13 different body parts and evaluates the body in terms of current posture changes. Our study evaluated children from two angles: posterior (head, shoulders, back, hips, feet, and arches) and lateral (neck, chest, shoulders, upper back, trunk, abdomen, and waist). In the scoring system, correct posture was recorded as five points, a moderate amount of deformity posture as three points, and severe deformity posture as one point. The total score calculated at the end of the questionnaire was a maximum of 65 points and a minimum of 13 points. The results of the analysis were evaluated as follows: ≥ 45 points, very good, 40-44 points good, 30-39 points moderate, 20-29 points poor, and a total score of ≤ 19 points.
79808415|NCT05853991|Other|Placebo|Application of static touch
79318733|NCT05899803|Diagnostic Test|Physical activity level|This questionnaire, administered to children aged 4-14, evaluates the activities performed during a week. The questionnaire consisted of nine questions, each of which was evaluated on a 5 points. One point indicated a low physical activity level and five points indicated a high physical activity level. Dividing the total score of the selected items by the number of items gives a summary score for the PAQ-C questionnaire. In our study, we used the Turkish version of the questionnaire, which was found to be reliable and valid.
79318734|NCT05899803|Diagnostic Test|Muscle strength|"Our study objectively measured muscle strength using the JTech Commander PowerTrack Muscle Dynamometer.~Right and left muscle tests: Hip flexors/hyperextensors/adductors/abductors/internal rotators/external retractors, knee flexors/extensors, and foot plantar flexors/dorsiflexors were evaluated. The measurement results were recorded in Newtons, the measurements were repeated three times, and the average of these three repetitions was recorded."
79478317|NCT05985525|Device|Skeletal muscle and cerebral NIRS (research device)|NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
79813725|NCT00923000|Drug|Nalbuphine|Nalbuphine 10mg with oral administration
79813726|NCT00923000|Drug|Morphine|Morphine 10mg with oral administration
79813727|NCT00923000|Drug|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
79973752|NCT04586686|Procedure|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
79478318|NCT05985512|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
79644269|NCT05995210|Procedure|Orthosis|They were asked to use a knee orthosis for a minimum of 6 hours a day. They also received exercise therapy.
79813728|NCT00923000|Drug|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
79813729|NCT00923000|Drug|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
79813730|NCT04534972|Other|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 > 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air [no supplemental oxygen] for non-mechanically ventilated patients).
79813731|NCT01019863|Drug|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
79813732|NCT00642850|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
79813733|NCT00455455|Drug|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
79813734|NCT00455455|Drug|ReNu Multiplus Multipurpose Solution|lens care system
79813735|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
79813736|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
79813737|NCT00913952|Drug|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
79644270|NCT05995210|Procedure|Control|An exercise program focused on the knee and hip muscles was given two days a week.
79973753|NCT04586686|Procedure|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
79318735|NCT05899790|Other|VR|"The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones."
79318736|NCT05899777|Other|Yizhi Baduanjin|Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
79318737|NCT05899764|Drug|Brivaracetam|"Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12."
79318738|NCT05899751|Drug|High-dose methotrexate|High-dose methotrexate
79318739|NCT05899751|Drug|Glucarpidase|Glucarpidase
79318740|NCT05899712|Other|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
79318741|NCT05899686|Device|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
79644271|NCT05995197|Other|action observation|cartoon observation
79644272|NCT05995158|Procedure|Metagenomic testing of the subgingival plaque samples|sampling, extraction and sequencing of the oral microbiome in the samples
79644273|NCT05995080|Other|clorhexidine gluconate bathing|daily skin cleansing with chlorhexidine gluconate
79808416|NCT05852561|Other|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
79973754|NCT04577859|Device|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anaesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
79808417|NCT05852561|Other|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
79813738|NCT00818818|Drug|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
79813739|NCT02609282|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|
79813740|NCT03840811|Drug|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
79808418|NCT05852509|Behavioral|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
79808419|NCT05852509|Behavioral|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
79813741|NCT03840811|Drug|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
79813742|NCT03840811|Drug|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
79318742|NCT05899660|Dietary Supplement|Active Comparator: Omega-3|It is a dietary supplement made of fish oil rich in n-3 PUFA.
79318743|NCT05899660|Dietary Supplement|Placebo Comparator: olive oil|Refined olive oil is the usual placebo used in studies with n-3 PUFA.
79478319|NCT05985460|Device|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
79318744|NCT05899621|Drug|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
79318745|NCT05899621|Drug|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
79318746|NCT05899621|Drug|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
79318747|NCT05899621|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
79318748|NCT05899621|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
79318749|NCT05899621|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
79808420|NCT05845619|Behavioral|Enhanced virologic monitoring|"The pilot intervention will include the following components:~More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (>1000))."
79808421|NCT05844865|Other|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI PC, with a planned standard of care surgery.
79973755|NCT04577859|Device|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is normally used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches >38 degrees then it is widely recognised that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
79318750|NCT05899621|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
79318751|NCT05899517|Drug|oral lollipop with oxytocin (24IU)|For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.
79318752|NCT05899517|Drug|oral lollipop with placebo|For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
79808422|NCT05844293|Drug|FXI-GalNAc-siRNA|FXI-GalNAc-siRNA solution for injection
79808423|NCT05844293|Other|Placebo|Saline
79808424|NCT05842993|Device|Hydrogen generator|Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
79973756|NCT04526886|Other|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
79478320|NCT05985460|Device|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
79478321|NCT05985408|Device|left ventricular septal pacing|For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.
79478322|NCT05985408|Device|right ventricular apical pacing|For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
79318753|NCT05899504|Device|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
79478323|NCT05985369|Other|Controlled diet and resistance exercise|Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
79973757|NCT04517877|Behavioral|Caring Response App|Participants will receive the Caring Light mobile app containing the coping skills training.
79318754|NCT05899491|Procedure|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
79318755|NCT05899491|Procedure|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
79478325|NCT05985317|Procedure|Collagen membrane over BMAC/bovine graft in sinus lift|Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
79318756|NCT05899478|Device|Tyknot® Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
79318757|NCT05899478|Device|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
79318758|NCT05899452|Behavioral|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
79318759|NCT05899452|Behavioral|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
79318760|NCT05899400|Diagnostic Test|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
79318761|NCT05899374|Behavioral|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
79318762|NCT05899348|Behavioral|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
79478326|NCT05985317|Procedure|PRF membrane over BMAC/bovine graft in sinus lift|PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
79808425|NCT05842993|Device|Analogue machine|Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.
79808426|NCT05842941|Drug|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
79808427|NCT05842941|Drug|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
79973758|NCT04517877|Behavioral|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
79973759|NCT04499482|Other|Food|Soy-fiber containing food
79478327|NCT05985291|Combination Product|SCS in combination with CMM|Subjects receiving BurstDR spinal cord dorsal column stimulation in combination with conservative medical management for the treatment of painful diabetic neuropathy as part of regular medical care.
79973760|NCT04497857|Other|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
79478328|NCT05985278|Drug|[ Lu-177]-Catalase|[ 177Lu]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
79478329|NCT05985265|Procedure|Fat grafting|Nano fat grafting followed by fractional carbon dioxide laser resurfacing
79478330|NCT05985252|Procedure|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
79973761|NCT04496401|Drug|Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]|"Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml."
79973762|NCT04489303|Behavioral|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
79973763|NCT04489303|Behavioral|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
79973764|NCT04471064|Drug|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
79478331|NCT05985252|Procedure|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
79973765|NCT04470167|Biological|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
79973766|NCT04470167|Other|Placebo|Ultrasound-guided intratendinous placebo injection
79973767|NCT04437498|Device|sham stimulation|non invasive vagal nerve stimulation
79973768|NCT04437498|Device|nVNS|active vns stimulation
79478332|NCT05985226|Device|intraoral scan|All the experimental groups will be developed with an intraoral scanner, a device that emits light and collects the image projected by that light, to build a 3-dimensional digital model. It is more comfortable than conventional impressions and it is a harmless, non-intrusive, and painless procedure.
79973769|NCT04433156|Drug|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79318763|NCT05899322|Behavioral|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
79318764|NCT05899322|Behavioral|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
79644274|NCT05995054|Drug|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
79644275|NCT05995041|Biological|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
79973770|NCT04433156|Drug|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79973771|NCT04433156|Drug|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79973772|NCT04433156|Drug|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
79973773|NCT04433156|Drug|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
79973774|NCT04417231|Device|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
79973775|NCT04411381|Other|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
79318765|NCT05899309|Diagnostic Test|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
79318766|NCT05899296|Device|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
79318767|NCT05899296|Device|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
79644276|NCT05995015|Biological|Universal CD19-specific CAR gene-engineered T cells|Infusion of 4SCAR19U cells
79808428|NCT05826639|Procedure|Temperature-sensitive radiofrequency ablation|Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
79808429|NCT05825768|Device|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
79973776|NCT04408794|Drug|Zavegepant (BHV-3500)|10 mg IN up to 8 times per month, up to 1 year
79644277|NCT05994885|Procedure|Root surface debridement|the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
79644278|NCT05994872|Procedure|Reverse drilling technique|A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel.
79644279|NCT05994872|Procedure|Traditional extraction drilling|A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel.
79644280|NCT05994846|Device|RISES-T System|The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
79644281|NCT05994742|Drug|Rifampicin|Rifampicin is commonly used in the first-line management of paediatric tuberculosis, and is approved by the FDA (ID: 2862628) and the EMA (EMA/31710/2020).
79973777|NCT04406623|Drug|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
79973778|NCT04394754|Device|BodyPort|Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
79973779|NCT04394754|Other|Noom|Patients will receive a subscription to use Noom, a personalized diet and weight management application.
79973780|NCT04394754|Other|Conversa|patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
79973781|NCT04390451|Behavioral|Whole Health STEPS|A peer-delivered package of Whole Health services.
79318768|NCT05899283|Device|OCI-HF160|OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
79644282|NCT05994742|Drug|Azithromycin|Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
79644283|NCT05994742|Drug|Isoniazid|Isoniazid is an antibiotic commonly used in the firstline treatment of tuberculosis, and as tuberculosis prophylaxis.
79644284|NCT05994742|Drug|Pyridoxine Hydrochloride|Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
79808430|NCT05825768|Diagnostic Test|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
79973782|NCT04388176|Drug|C21|C21 as first treatment
79973783|NCT04388176|Drug|C21|C21 as second treatment
79973784|NCT04388176|Drug|Placebo|Placebo as second treatment
79318769|NCT05899283|Device|FX800HDF|FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
79973785|NCT04388176|Drug|Placebo|Placebo as first treatment
79808431|NCT05819684|Drug|SHR-4602 for injection|be administered via intravenous (IV) infusion
79318770|NCT05899270|Other|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
79318771|NCT05899270|Other|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
79808432|NCT05817370|Behavioral|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
79318772|NCT05899088|Other|Mindful Movement|Mindful Movement Program with Researcher Follow-up
79318773|NCT05899075|Other|xylitol wipes|group A will receive xylitol wipes and group B will receive placebo wipes
79318774|NCT05899075|Other|placebo wipes|group A will receive xylitol wipes and group B will receive placebo wipes
79318775|NCT05899062|Other|"Education with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp"|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
79644285|NCT05994742|Behavioral|The Friendship Bench|The Friendship Bench was developed in Zimbabwe as a low-cost psychological intervention utilising problemsolving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags).
79644286|NCT05994742|Behavioral|Care for Child Development|Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability.
79808433|NCT05809310|Procedure|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
79973786|NCT04354896|Drug|Levothyroxin|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
79973787|NCT04354896|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
79973788|NCT04354168|Behavioral|mHealth Application|Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
79973789|NCT04354129|Drug|Cutaquig®|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
79973790|NCT04311489|Drug|Ularitide|Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
79973791|NCT04311489|Drug|Placebo|Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
79973792|NCT04305405|Drug|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
79973793|NCT04263259|Behavioral|Attentional Bias Modification|Mobile-Delivered Cognitive Retraining Intervention
79973794|NCT04255134|Drug|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
79973795|NCT04255134|Drug|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
79973796|NCT04240639|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
79973797|NCT04217304|Drug|Definity® with High Mechanical Index Ultrasound|Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
79808434|NCT05808673|Biological|Post-change CMAB807X|for subcutaneous injection only
79808435|NCT05808673|Biological|Pre-change CMAB807X|for subcutaneous injection only
79973798|NCT04210947|Other|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
79973799|NCT04210947|Other|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
79973800|NCT04210947|Other|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
79973801|NCT04192370|Drug|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
79973802|NCT04189029|Other|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
79973803|NCT04183504|Behavioral|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
79808436|NCT05808673|Biological|Xgeva®|for subcutaneous injection only
79973804|NCT04180930|Diagnostic Test|CAPS-5|Clinician Administered PTSD Scale for DMS-5
79973805|NCT04180930|Diagnostic Test|PSSI-5|PTSD Symptom Scale Interview for DSM-5
79973806|NCT04180930|Diagnostic Test|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
79973807|NCT04180371|Drug|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
79973808|NCT04180371|Drug|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
79973809|NCT04160910|Drug|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
79973810|NCT04160910|Drug|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
79973811|NCT04090827|Other|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
79644287|NCT05994742|Behavioral|Educational and behaviour-change modules|Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma,HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. These have been developed with caregivers affected by SAM in a previous study, through a series of codesign workshops, ensuring these are contextually relevant.
79644288|NCT05994742|Dietary Supplement|Reformulated Ready to Use Therapeutic Food|A reformulated product designed to improve outcomes for children who have severe acute malnutrition.
79973812|NCT04067037|Drug|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
79973813|NCT04067037|Drug|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
79808438|NCT05806411|Diagnostic Test|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
79808439|NCT05793372|Other|Retrospective study of clinical features|Retrospective study of clinical features
79808440|NCT05785182|Procedure|Open Fracture|Patients 18 years of age or older with open fracture. Provision of informed consent.
79808441|NCT05785182|Procedure|Infected Fracture|Patients 18 years of age or older with infected fracture. Provision of informed consent.
79973814|NCT04067037|Drug|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
79973815|NCT04067037|Drug|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
79318776|NCT05899062|Other|Training and exercise practices with the telerehabilitation method.|The patients in this group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 6 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
79318777|NCT05899049|Biological|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
79318778|NCT05899049|Drug|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
79808442|NCT05776420|Behavioral|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
79318779|NCT05899049|Biological|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
79318780|NCT05899049|Drug|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
79973816|NCT04066699|Procedure|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
79808443|NCT05775003|Dietary Supplement|Exercise|8 week exercise training program - consisting of weight training and cardiovascular exercise
79973817|NCT04035980|Behavioral|Telemedicine based healthcare programme|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
79318781|NCT05898997|Behavioral|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
79478333|NCT05985213|Other|data collection and follow-up|"Main measures and data collection methods:~Recording of baseline demographic and clinical information of the participants.~Multimodal magnetic resonance imaging~blood pressure variability.~neuropsychological testing~Blood samples collection"
79808444|NCT05773326|Drug|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
79973818|NCT03996616|Device|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a <10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
79973819|NCT03996616|Device|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
79973820|NCT03996616|Device|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
79808445|NCT05766475|Behavioral|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
79318782|NCT05898984|Drug|Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI|"CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP [200 μg], FF [6 μg] and GB [12.5 μg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP [100 μg], FF [6 μg] and GB [12.5 μg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve)."
79808446|NCT05766475|Behavioral|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
79318783|NCT05898984|Drug|Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI|with HFA 134a propellant (fixed combination of BDP [100 μg], FF [6 μg] and GB [12.5 μg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
79318784|NCT05898984|Drug|Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)|pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
79973821|NCT03948256|Procedure|Control intervention|Prompt closure of EVD with subsequent observation period
79973822|NCT03948256|Procedure|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
79808447|NCT05765071|Biological|Botulinum toxin A|Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
79813743|NCT03840811|Biological|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10^5 - 10^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
79813744|NCT03840811|Biological|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10^5 - 10^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
79318785|NCT05898958|Procedure|thoracic paravertebral block|The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
79973823|NCT03867903|Device|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
79644289|NCT05994742|Other|Standard Care|All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
79644290|NCT05994690|Drug|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
79644291|NCT05994690|Drug|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
79808448|NCT05765071|Biological|Normal saline|A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
79808449|NCT05764460|Diagnostic Test|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
79808450|NCT05744232|Behavioral|Low calorie total diet replacement|"Summary~Weeks 1-12: TDR phase~Weeks 13-14: Food reintroduction phase I~Weeks 15-16: Food reintroduction phase II~Weeks 17 till 20: Food reintroduction phase III~Weeks 21 till 24: Maintenance phase"
79808451|NCT05744232|Other|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
79808452|NCT05736159|Diagnostic Test|Method of assessment of school maturity|Psychophysiological examination of the functional readiness of the child for admission to school.
79808453|NCT05736159|Diagnostic Test|Assessment of school adaptation|Psychophysiological examination of the success of school education of first graders.
79644292|NCT05994690|Drug|Standard Intervention Ri|No addition of GO to first induction course
79644293|NCT05994690|Drug|Investigational Intervention Ri|Addition of GO to first induction course
79306818|NCT05923853|Other|FiO2 titration using electronic alert system|In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted. Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined. E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator. Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen. Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
79808454|NCT05718180|Other|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
79973824|NCT03867903|Other|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
79973825|NCT03764878|Diagnostic Test|functional MRI|Participants will undergo a functional MRI using multiple imaging modalities.
79973826|NCT03669640|Drug|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
79973827|NCT03669640|Drug|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
79973828|NCT03668028|Biological|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
79973829|NCT03668028|Procedure|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
79973830|NCT03632941|Biological|VRP-HER2|VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
79318786|NCT05898958|Procedure|rhomboid intercostal and subserratus block|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
79973831|NCT03632941|Biological|Pembrolizumab|A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
79318787|NCT05898893|Device|Microport NeuroTech Tubridge Plus flow-diverter Stent|Intracranial stent for wide-necked aneurysms
79973832|NCT03623893|Procedure|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
79973833|NCT03601507|Drug|Alpelisib|Given PO
79973834|NCT03601507|Other|Laboratory Biomarker Analysis|Correlative studies
79973835|NCT03601507|Other|Pharmacodynamic Study|Correlative studies
79973836|NCT03601507|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79973837|NCT03596866|Drug|Brigatinib|Brigatinib Tablets.
79318788|NCT05898880|Other|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
79973838|NCT03596866|Drug|Alectinib|Alectinib Capsules.
79973839|NCT03543410|Drug|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
79808455|NCT05718141|Other|COMET-GB|"Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~Cognitive Restructuring (labelled Flexible Thinking)~Behavioural Activation (labelled Positive Activities)~Gratitude~Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only)."
79973840|NCT03543410|Drug|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets
79973841|NCT03543410|Drug|Placebo|Placebo (supplied in two tablets/day)
79973842|NCT03502785|Biological|INO-5401|INO-5401 (9 milligram [mg] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
79973843|NCT03502785|Biological|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
79644294|NCT05994625|Device|Stream™ Platform|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage."
79808456|NCT05716542|Other|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
79478334|NCT05985187|Drug|TQB2440 injection + Trastuzumab + Docetaxel|"TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
79813745|NCT00640510|Drug|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
79973844|NCT03502785|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
79813746|NCT00640510|Drug|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
79318789|NCT05898880|Other|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
79318790|NCT05898880|Other|Control group|No intervention will be made in the control group.
79318791|NCT05898867|Other|Saline|Open label intra-articular injection of isotonic saline.
79478335|NCT05985187|Drug|Perjeta + Trastuzumab + Docetaxel|"Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
79478336|NCT05985174|Diagnostic Test|CD64 , HLA-DR|"CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\macrophages , dendritic cells and plays a crucial role in adaptive immune response"
79478337|NCT05985161|Drug|Selinexor|This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .
79644295|NCT05994625|Device|Stream™ Platform with Risk Score Omitted|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform."
79808457|NCT05713695|Behavioral|Full MISSION|MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.
79973845|NCT03502785|Device|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
79973846|NCT03495960|Drug|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 & 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
79478338|NCT05985096|Diagnostic Test|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
79478339|NCT05985070|Dietary Supplement|Ferrous sulphate|Daily single oral dose of 30 mg
79478340|NCT05985070|Dietary Supplement|Ferric pyrophosphate|Daily single oral dose of 30 mg
79478341|NCT05985070|Dietary Supplement|Ferric sodium pyrophosphate|Daily single oral dose of 30 mg
79478342|NCT05985070|Dietary Supplement|Vitamin D3|Daily single oral dose of 200 IU
79973847|NCT03495960|Drug|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 & 30
79318792|NCT05898815|Diagnostic Test|Medical record collection|Medical record collection
79318793|NCT05898802|Dietary Supplement|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
79318794|NCT05898802|Dietary Supplement|Placebo|Lactose with kimchi flavor
79318795|NCT05898685|Behavioral|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
79318796|NCT05898685|Behavioral|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
79318797|NCT05898542|Procedure|Nature-based therapy|Therapy sessions conducted outdoors
79318798|NCT05898503|Behavioral|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
79318799|NCT05898503|Behavioral|Resistance training|Resistance training for 12 weeks
79973848|NCT03495960|Drug|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
79318800|NCT05898503|Behavioral|Walking exercise|Walking exercise for 12 weeks
79318801|NCT05898503|Behavioral|Health promotion|Health promotion for 12 weeks
79318802|NCT05898490|Behavioral|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
79973849|NCT03495960|Drug|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
79973850|NCT03495960|Radiation|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
79808458|NCT05713695|Behavioral|Linkage Only Delivered by a Peer Specialist|Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
79318803|NCT05898451|Drug|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
79318804|NCT05898451|Drug|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
79973851|NCT03495960|Drug|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
79973852|NCT03491683|Biological|INO-5401|INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
79973853|NCT03491683|Biological|INO-9012|INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
79318805|NCT05898373|Drug|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
79318806|NCT05898373|Drug|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
79318807|NCT05898373|Drug|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
79318808|NCT05898373|Drug|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
79318809|NCT05898360|Combination Product|Time Restricted Eating|time restricted eating
79318810|NCT05898360|Other|normal diet|normal diet
79318811|NCT05898347|Other|Active surveillance|"Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised."
79318812|NCT05898334|Device|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
79318813|NCT05898334|Device|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
79318814|NCT05898321|Drug|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
79318815|NCT05898321|Drug|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
79808459|NCT05705921|Radiation|Radiotherapy standard|Standard moderately hypofractionated radiotherapy in prostate cancer
79808460|NCT05705921|Radiation|Radiotherapy Hypo-FLAME|Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
79973854|NCT03491683|Biological|Cemiplimab|Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
79973855|NCT03491683|Radiation|Radiation Therapy|Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
79813747|NCT04889378|Other|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
79973856|NCT03491683|Drug|Temozolomide|Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m^2).
79973857|NCT03471234|Device|Angioplasty|Inspiron Drug Eluting stent implantation
79318816|NCT05898308|Drug|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
79318817|NCT05898295|Other|no intervention|No intervention: only observation of the child behavior
79813748|NCT01323127|Procedure|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
79813749|NCT00825838|Dietary Supplement|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
79813750|NCT00825838|Dietary Supplement|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
79813751|NCT00913718|Drug|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
79813752|NCT00913718|Drug|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
79813753|NCT00813800|Drug|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
79478343|NCT05985031|Diagnostic Test|Tendon tap|While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
79644296|NCT05994599|Combination Product|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
79478344|NCT05985031|Diagnostic Test|Tibial nerve stimulation|H-reflex responses were examined by tibial nerve stimulation
79478345|NCT05984563|Device|Cardiopulmonary bypass|CPB will be ensured as usual care: priming volume will be set as 1200 to 1500 mL. Patient blood management and hemodynamic management will be left at the discretion of the anesthesiologist in charge of the patient. Anticoagulation during CPB will be handled through an initial heparin bolus of 300-400 UI/kg followed by additional boluses to maintain ACT above 400 s. Non-heparin-coated bypass circuits incorporating an integrated phosphorylcholine-coated oxygenation system will be used.
79478346|NCT05984511|Procedure|I-125 Seeds Brachytherapy in PVTT|Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
79644297|NCT05994599|Combination Product|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
79644298|NCT05994586|Dietary Supplement|AP029 mix|Polyphenol-rich plant extracts Twice a day
79973858|NCT03438656|Behavioral|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
79973859|NCT03345823|Drug|Upadacitinib|Oral; Tablet
79478347|NCT05984511|Procedure|Transcatheter arterial chemoembolization|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
79644299|NCT05994586|Other|Placebo|Twice a day
79644300|NCT05994560|Other|With temporary occlusion|at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
79644301|NCT05994547|Drug|Byfavo|For induction and maintenance of sedation
79644302|NCT05994547|Drug|Midazolam|For induction and maintenance of sedation
79644303|NCT05994508|Other|Pickleball program|The intervention will be a 6-week pickleball program, at a frequency of two times a week. Each session will be one hour which will consist of dynamic warm-up drills, pickleball-related skill practice and game play, and a cool-down period.
79813754|NCT00627016|Drug|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
79813755|NCT00627016|Drug|Placebo|1 capsule, orally, once daily for 4 weeks
79973860|NCT03345823|Drug|Placebo for Upadacitinib|Oral; Tablet
79973861|NCT03282461|Drug|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
79973862|NCT03275454|Drug|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
79813756|NCT00794664|Drug|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
79813757|NCT00794664|Drug|Placebo|1 mL weekly subcutaneous injections for 26 weeks
79973863|NCT03275454|Drug|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
79478348|NCT05984511|Drug|Atezolizumab plus Bevacizumab|Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
79973864|NCT03263260|Device|implant|coronary stent implantation
79478349|NCT05983952|Drug|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
79973865|NCT03138161|Drug|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
79973866|NCT03138161|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
79973867|NCT03138161|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
79973868|NCT03093337|Other|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
79973869|NCT03031821|Drug|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
79973870|NCT03031821|Drug|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
79973871|NCT02908074|Drug|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
79973872|NCT02907359|Drug|Guadecitabine|
79973873|NCT02907359|Other|Treatment Choice|"BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~LDAC: 20 mg/m^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m^2/day) or idarubicin (9-12 mg/m^2/day) or mitoxantrone (8-12 mg/m^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
79973874|NCT02749981|Procedure|blood and tissue sampling|
79973875|NCT02714205|Drug|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
79973876|NCT02714205|Drug|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
79973877|NCT02666781|Other|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
79973878|NCT02611206|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
79973879|NCT02611206|Device|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
79973880|NCT02611206|Device|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
79644304|NCT05994469|Behavioral|Copenhagen Adduction Exercise|The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
79644305|NCT05994456|Drug|PD-1 inhibitor|240mg, Q3W. The opportunity for surgery was evaluated after 2 cycles of treatment and surgical treatment was performed after 2-4 cycles of treatment. Postoperatively, adjuvant therapy was continued according to the neoadjuvant regimen, and direct treatment met the criteria for termination of treatment.
79973881|NCT02477124|Device|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
79644306|NCT05994430|Other|End-of-life care awareness training in intensive care|End-of-life care awareness training in intensive care
79644307|NCT05994404|Procedure|ACDF|
79644308|NCT05994404|Procedure|Posterior Cervical Fusion|
79644309|NCT05994404|Procedure|Cervical Laminoplasty|
79644310|NCT05994391|Dietary Supplement|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin"
79973882|NCT02477124|Other|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
79973883|NCT02329080|Drug|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
79973884|NCT02329080|Drug|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
79973885|NCT02329080|Drug|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
79973886|NCT02329080|Drug|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
79973887|NCT02329080|Drug|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
79973888|NCT02329080|Drug|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
79973889|NCT02329080|Drug|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
79973890|NCT02329080|Drug|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
79973891|NCT02329080|Radiation|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
79973892|NCT02231515|Device|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
79973893|NCT02231515|Device|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
79973894|NCT02229331|Other|Gait analysis|
79644311|NCT05994391|Dietary Supplement|Placeo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose"
79973895|NCT02227927|Drug|Domperidone|10-30mg oral dose, four times daily.
79973896|NCT02025543|Device|MRI|R2 MRI scan
79973897|NCT01922635|Other|Valadation of the metrological properties of questionnaire of quality of life|
79973898|NCT01820910|Drug|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
79973899|NCT01808599|Drug|Chlorambucil|
79973900|NCT01808599|Drug|Rituximab i.v.|
79973901|NCT01808599|Drug|Rituximab s.c.|
79644312|NCT05994365|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
79973902|NCT00583752|Biological|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
79973903|NCT00071071|Drug|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
79973904|NCT00071071|Drug|HuMax-CD4|HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
79973905|NCT03333070|Dietary Supplement|probiotic - Lactobacillus reuteri|The treated arm will receive 5 drops per day for 48 weeks
79973906|NCT03333070|Other|placebo - with no active ingredient|The control arm will receive 5 drops per day for 48 weeks
79644313|NCT05994352|Other|virtual reality simulation|The effect of virtual reality simulation on therapeutic communication skill levels
79644314|NCT05994300|Radiation|Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy|"Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2"
79478350|NCT05983926|Procedure|Subtotal colectomy was performed|"Colonic subtotal resection, also known as subtotal colectomy, is a surgical procedure used to treat colonic diseases such asconstipation, colon cancer, ulcerative colitis, and others.~The purpose of this surgery is to remove a portion of the colon in the patient's body. Unlike a total colectomy, which involves removing the entire colon, a subtotal colectomy only removes a portion of the colon. The procedure typically involves removing the diseased part of the colon and reconnecting the remaining colon. This allows for the preservation of some normal colonic function, enabling the patient to have regular bowel movements."
79478351|NCT05983237|Drug|Fluzoparib Camrelizumab Temozolomide|Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w
79973907|NCT03332992|Behavioral|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
79318818|NCT05898282|Other|observation|since this is a cross sectional observational study any form of intervention was not applicable
79478352|NCT05983055|Drug|Dexamethasone 20mg|Periarticular dexamethasone injection
79973908|NCT03332992|Behavioral|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
79478353|NCT05982769|Behavioral|Endurance Training 3 times per week|endurance training will be performed from home 3 times per week under the supervision of the research team.
79973909|NCT03332992|Behavioral|General intentions|Question language asking about general interest in getting influenza vaccination
79478354|NCT05982769|Behavioral|Resistance Exercise|resistance training will be performed from home 2 times per week under the supervision of the research team.
79478355|NCT05982769|Behavioral|Standard of Care|continue usual activity
79973910|NCT03332992|Behavioral|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
79973911|NCT03332992|Behavioral|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
79973912|NCT05465278|Drug|Alirocumab|18 months treatment with alirocumab
79973913|NCT01302275|Drug|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
79973914|NCT03332914|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
79318819|NCT05898256|Drug|Cadonilimab|10mg/kg administered intravenously (IV)
79318820|NCT05898256|Drug|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
79318821|NCT05898256|Drug|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
79478356|NCT05982496|Drug|FES|16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
79478357|NCT05982496|Procedure|PET/MRI A|An additional FES PET/MRI will be performed before surgery.
79478358|NCT05982496|Procedure|PET/MRI B|Two additional PET/MRI will be performed before and after induction ET.
79478359|NCT05982496|Procedure|PET/MRI C|Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.
79478360|NCT05982496|Procedure|PET/MRI D|Two additional PET/MRI will be performed before and after two cycles of systemic therapy.
79478361|NCT05982496|Genetic|Translational analysis|Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
79490314|NCT01440452|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
79490315|NCT03742154|Drug|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
79973915|NCT03332836|Biological|HM12460A|HM12460A is a long-acting insulin
79973916|NCT03332758|Procedure|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
79973917|NCT03332758|Procedure|External drainage|Standard of care treatment for retinal detachment.
79973918|NCT01301573|Biological|rAAV-GAD|
79973919|NCT02263014|Behavioral|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
79973920|NCT03339544|Drug|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
79973921|NCT03339544|Drug|Placebo|placebo is given as a tablet before initiation of endodontic treatment
79973922|NCT03332680|Biological|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
79973923|NCT03332680|Biological|Standard control medium|Embryos placed in this medium prior to transfer
79318822|NCT05898204|Other|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
79318823|NCT05898204|Other|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
79318824|NCT05898178|Other|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
79973924|NCT05157594|Biological|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
79973925|NCT02499718|Device|BiPAP mode|Noninvasive ventilator
79318825|NCT05898152|Other|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
79318826|NCT05898087|Drug|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
79318827|NCT05898087|Drug|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
79318828|NCT05898074|Device|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
79318829|NCT05898074|Device|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
79478362|NCT05981937|Drug|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH & Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
79478363|NCT05981716|Other|No intervention|This is an observational study. There is no intervention.
79478364|NCT05979883|Radiation|Machine Learning Assisted Radiation (MLAP) RapidPlan|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist. The preliminary plan will be run through the RapidPlan module, which will give a list of possible improvements to the plan. The dosimetrist will then make an amendment to the plan according to RapidPlan suggestions, followed by plan change requests and approval by the physician.
79973926|NCT03815747|Device|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
79644315|NCT05994222|Other|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
79644316|NCT05994209|Device|quitSTART Mobile Application|Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
79644317|NCT05994209|Behavioral|Chatbot Feature in quitSTART Mobile Application|In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
79973927|NCT02526264|Other|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
79973928|NCT05123417|Diagnostic Test|Follow up|Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
79973929|NCT03332602|Dietary Supplement|free FeSO4|Testmeal with free FeSO4
79973930|NCT03332602|Dietary Supplement|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
79973931|NCT03332602|Dietary Supplement|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
79973932|NCT03332602|Dietary Supplement|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
79973933|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
79318830|NCT05898035|Procedure|Endodontic Microsurgery|Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
79318831|NCT05898009|Genetic|blood sample for BRCA2 mutation detection|blood sample
79318832|NCT05897970|Diagnostic Test|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
79318833|NCT05897944|Other|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
79318834|NCT05897918|Drug|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
79318835|NCT05897697|Other|Interview|Structured interview
79318836|NCT05897450|Other|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block: injection of a local anesthetic into a region between the internal oblique and transversus abdominis muscles.
79318837|NCT05897034|Drug|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
79318838|NCT05897034|Drug|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
79318839|NCT05897034|Drug|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
79478365|NCT05979883|Radiation|Radiation Therapy Standard of Care (SOC)|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist, followed by plan change requests and approval by the physician.
79973934|NCT03332602|Dietary Supplement|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
79973935|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
79318840|NCT05897008|Biological|CMAB007|for subcutaneous injection only
79318841|NCT05897008|Biological|Xolair|for subcutaneous injection only
79490316|NCT03284359|Behavioral|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
79973936|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
79973937|NCT03332602|Dietary Supplement|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
79973938|NCT01302353|Drug|Emulsified Isoflurane|
79973939|NCT03339310|Device|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
79973940|NCT03812315|Combination Product|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
79318842|NCT05896865|Radiation|Whole breast / chest wall & regional lymph node irradiation|Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
79973941|NCT03812315|Combination Product|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
79318843|NCT05896865|Radiation|Internal mammary or supraclavicular lymph node boost|Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
79973942|NCT03332524|Drug|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
79318844|NCT05896410|Device|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
79478366|NCT05979350|Diagnostic Test|Metagenomic next-generation sequencing|Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).
79973943|NCT03332524|Drug|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
79973944|NCT03332524|Drug|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
79973945|NCT01301651|Behavioral|balance training|30 minute each time, 2 times per week for 6 weeks.
79973946|NCT03332446|Other|cold water immersion|10 min at 12-15°C
79973947|NCT03815513|Other|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
79973948|NCT02499640|Other|immersion cold water|immersion cold water at different temperatures and exposure times
79318845|NCT05894304|Device|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
79318846|NCT05894304|Other|Scapular training exercises|Scapular muscle strength by resistance
79973949|NCT01302431|Other|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
79973950|NCT02499484|Drug|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
79973951|NCT02499484|Other|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
79973952|NCT02499484|Other|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
79973953|NCT03170154|Device|Clareon aspheric hydrophobic acrylic monofocal IOL|Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
79490317|NCT05313230|Other|CITRASATE SLED|Applying of CITRASATE SLED
79490318|NCT03738020|Device|HA IDF (YVOIRE classic)|Treatment with HA IDF
79318847|NCT05893667|Diagnostic Test|Inflammatory markers|analysis of inflammatory scores
79973954|NCT01302509|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
79973955|NCT03339232|Dietary Supplement|BCAA Supplement|Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
79318848|NCT05893251|Other|Manual therapy|"Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching"
79318849|NCT05893251|Other|Postural exercises|The treatment plan includes active postural exercises for the cervical spine.
79973956|NCT03339232|Other|Physical Activity|Supervised low impact aerobic physical activity for one hour each week.
79973957|NCT03812237|Other|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
79973958|NCT03339154|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
79490319|NCT03738020|Device|Restylane|Treatment with Restylane
79973959|NCT03812003|Drug|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
79973960|NCT03332368|Other|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
79318850|NCT05892939|Drug|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
79318851|NCT05892939|Drug|intranasal Placebo|Administration of intranasal Placebo
79973961|NCT04874610|Drug|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
79490320|NCT02734940|Drug|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
79318852|NCT05892861|Behavioral|cognitive stimulation|video education, board games, and 24-hour dietary recall record
79318853|NCT05892861|Other|as usual care|history taking, explain data, and discuss how to control healthy condition
79318854|NCT05890534|Drug|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
79318855|NCT05890534|Drug|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
79318856|NCT05888545|Device|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
79318857|NCT05885061|Device|Spinal cord stimulation turned on (suggestions: off)|Spinal cord stimulation turned on with verbal suggestions of treatment off
79318858|NCT05885061|Device|Spinal cord stimulation turned off (suggestions: on)|Spinal cord stimulation turned off with verbal suggestions of treatment on
79644318|NCT05994196|Behavioral|Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)|Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
79644319|NCT05994170|Radiation|Reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)
79973962|NCT03518125|Biological|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
79973963|NCT03518125|Biological|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
79973964|NCT03518125|Drug|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
79973965|NCT03812081|Device|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
79973966|NCT03812081|Device|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
79973967|NCT02492230|Device|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
79973968|NCT02492230|Drug|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
79973969|NCT03169530|Other|Alcohol|~15 gm daily of beer, wine, or spirits for ~6 years
79973970|NCT03339076|Device|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
79973971|NCT05623241|Diagnostic Test|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
79973972|NCT02499094|Other|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
79973973|NCT03819881|Biological|STMC-103H|Live bacterial product
79973974|NCT03819881|Biological|Placebo|Inactive placebo substance
79973975|NCT02513238|Drug|Mesenchymal stem cell|Stemcells injected into submandibularis
79973976|NCT02513238|Drug|Isotonic NaCl|
79973977|NCT03338842|Device|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
79318859|NCT05885061|Device|Spinal cord stimulation turned on with suggestions (suggestions on)|Spinal cord stimulation turned on with verbal suggestions of treatment on
79318860|NCT05880966|Behavioral|Functional Fitness|Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
79644320|NCT05994170|Radiation|Non-reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
79973978|NCT05659511|Diagnostic Test|MRI|MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
79318861|NCT05875454|Diagnostic Test|Histopathological examination of tru-cut needle biopsy|Renal biopsies fixed in formalin from patients with suspected medical renal disease will be processed and examined for histopathological diagnosis.
79318862|NCT05867836|Dietary Supplement|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
79318863|NCT05861765|Drug|Papaverine Hydrochloride|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
79318864|NCT05861765|Drug|normal saline|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
79318865|NCT05860595|Genetic|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
79318866|NCT05842304|Device|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
79318867|NCT05842304|Device|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
79318868|NCT05836454|Other|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
79318869|NCT05836454|Other|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
79478367|NCT05979350|Diagnostic Test|Standard work-up for pneumonia|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
79478368|NCT05976945|Behavioral|Imagery Rescripting|In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
79478369|NCT05976594|Diagnostic Test|serology and virology detection of hepatitis E virus|Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.
79478370|NCT05973929|Other|Screen for movement disorder and correlates it with MRI findings.|"To determine the prevalence of movement disorders in MS patients.~To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.~To find the correlation between the movement disorder and the different types of MS."
79490321|NCT02734940|Drug|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
79973979|NCT02440230|Drug|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
79318870|NCT05823259|Other|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
79644321|NCT05994144|Other|VIDEO OBSERVED THERAPY|Video-observed therapy is the usage of teleconferencing to observe anti-TB medication ingestion.
79478371|NCT05971732|Drug|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
79318871|NCT05823259|Other|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
79318872|NCT05818618|Drug|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
79318873|NCT05818618|Drug|Placebo|Placebo oral gel applied locally on OLP lesions.
79318874|NCT05814016|Drug|Danavorexton|Danavorexton IV infusion.
79318875|NCT05814016|Drug|Placebo|Placebo matching danavorexton IV infusion.
79318876|NCT05811702|Other|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
79318877|NCT05804513|Drug|Placebo|s/c injection
79318878|NCT05804513|Drug|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
79318879|NCT05799989|Procedure|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
79478372|NCT05971732|Drug|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
79478373|NCT05970744|Biological|RSV/Flu-01E low dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
79318880|NCT05799989|Procedure|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
79318881|NCT05794087|Other|Clean Air|Subjects will be exposed to clean air for 3 hours.
79318882|NCT05794087|Other|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
79478374|NCT05970744|Biological|RSV/Flu-01E high dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
79644322|NCT05994131|Drug|IN10018|orally taken once daily
79644323|NCT05994131|Drug|Furmonertinib|orally taken once daily
79644324|NCT05994118|Other|NaCl 0.9% (normal saline)|Subcutaneous normal saline injection
79644325|NCT05994118|Other|Magnetized Normal Saline|Magnetized Normal Saline
79644326|NCT05994105|Behavioral|Art based Augmented Reality|The participants will be provided 14 sessions management plan
79644327|NCT05994079|Device|High intensity focused ultrasound|"Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J"
79644328|NCT05994079|Other|topical firming creams|medical topical firming creams
79973980|NCT02440230|Drug|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
79973981|NCT02499250|Device|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
79973982|NCT02499250|Drug|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
79973983|NCT03036462|Drug|Iron|i.v. iron administration
79973984|NCT03036462|Drug|Saline|i.v. NaCl administration
79478375|NCT05970744|Biological|Placebo|Participants will receive single intranasal injection of Placebo
79318883|NCT05783219|Drug|Lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
79318884|NCT05783219|Other|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
79318885|NCT05771246|Diagnostic Test|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
79318886|NCT05766878|Device|implants placement|The intervention will consist of placement of two types of short implants (one with traditional machined collar and one with anodized collar). After their healing period, the prosthetic rehabilitation will be made.
79318887|NCT05759013|Device|Breath synchronized abdominal NMES|Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
79318888|NCT05759013|Device|Sham breath synchronized abdominal NMES|Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
79318889|NCT05756114|Behavioral|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
79318890|NCT05756114|Other|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
79318891|NCT05740124|Behavioral|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
79973985|NCT03332290|Behavioral|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
79973986|NCT01300325|Other|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
79318892|NCT05740124|Behavioral|alternative balance training|Participants practice standing and walking under varied sensory conditions.
79318893|NCT05709444|Drug|Bremelanotide|Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
79318894|NCT05709444|Drug|RAAS inhibition therapy|RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
79318895|NCT05682482|Drug|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
79318896|NCT05682482|Drug|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
79318897|NCT05672329|Other|0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
79318898|NCT05672329|Other|2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
79318899|NCT05672329|Other|4 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
79973987|NCT03332134|Behavioral|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
79318900|NCT05672329|Other|2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
79318901|NCT05667532|Diagnostic Test|Contrast Enhanced Mammography|Screening Modality
79318902|NCT05642611|Procedure|Biospecimen Collection|Undergo collection of blood, plasma, and serum
79318903|NCT05642611|Procedure|Cryocompression Therapy|Undergo cryocompression
79318904|NCT05642611|Procedure|Pneumatic Compression Therapy|Undergo continuous compression
79318905|NCT05642611|Procedure|Pneumatic Compression Therapy|Undergo low cyclic compression
79318906|NCT05642611|Other|Quality-of-Life Assessment|Ancillary studies
79318907|NCT05642611|Other|Questionnaire Administration|Ancillary studies
79318908|NCT05641948|Other|MRI scan|Participants will undergo brain MRI scan at 3 intervals
79318909|NCT05627102|Other|Experimental Group|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
79318910|NCT05627102|Other|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
79318911|NCT05612971|Behavioral|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
79318912|NCT05612971|Behavioral|Self-Guided|The Self-Guided group will receive newsletters for 3 months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
79318913|NCT05610176|Device|Amvia Sky pacemaker or CRT-P device|Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
79318914|NCT05606042|Device|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
79644329|NCT05994066|Other|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).
79318915|NCT05583110|Drug|Tucatinib|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
79318916|NCT05583110|Drug|Trastuzumab|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
79318917|NCT05583110|Drug|Vinorelbine|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
79318918|NCT05570604|Behavioral|Sweep Seeker|The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
79478376|NCT05970380|Other|Erector spinae plane block|Local anesthetic solution (40 mL 0.25% bupivacaine totally) will be given bilaterally between the processus transversalis of the fractured vertebra and the erector spinae muscle under ultrasound imaging by an anesthesiologist.
79644330|NCT05994053|Device|high definition transcranial alternating current stimulation|low intensity alternating current to OFC
79644331|NCT05994014|Diagnostic Test|PET/CT|Experimental test for detecting atherosclerosis
79644332|NCT05994001|Drug|cardonilizumab|cardonilizumab:PD1 and CTLA-4 bispecific antibody
79644333|NCT05994001|Drug|LM-302|LM-302 :ClAUDIN 18.2-ADC
79644334|NCT05993988|Other|Exercise|Muscle relaxing Technique
79644335|NCT05993520|Other|Assessment|Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
79808461|NCT05696730|Other|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
79318919|NCT05570604|Behavioral|Bird Safari|The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
79318920|NCT05570604|Behavioral|Jewel Diver|The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
79318921|NCT05570604|Behavioral|Master Gardener|The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
79318922|NCT05570604|Behavioral|Road Tour|The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
79318923|NCT05570604|Behavioral|Computerized Crossword Puzzles|The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
79318924|NCT05565937|Device|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
79973988|NCT03819725|Device|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
79973989|NCT03478891|Biological|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
79318925|NCT05565937|Device|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
79318926|NCT05537935|Drug|Low Dose Naltrexone|Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
79644336|NCT05992909|Procedure|Lymphovenous bypass procedure|Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
79808462|NCT05686681|Behavioral|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
79808463|NCT05686564|Drug|ALXN1840|bis-choline tetrathiomolybdate
79318927|NCT05461014|Behavioral|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
79644337|NCT05992337|Diagnostic Test|Blood sampling|Blood sample collection for mRNA determination
79644338|NCT05992337|Diagnostic Test|Echocardiography|Echocardiography for detection of ventricular dysfunction
79808464|NCT05685108|Device|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
79318928|NCT05456893|Procedure|Procedure: endoscopic biopsy|Per-endoscopic biopsies
79318929|NCT05456893|Procedure|Blood sampling|Blood sampling
79318930|NCT05456893|Procedure|stool sampling|stool sampling
79318931|NCT05440851|Other|Ultra-Protective Ventilation Facilitated by Extracorporeal Support|Patients randomized to the intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
79318932|NCT05440851|Other|Lung-Protective Ventilation (LPV)|Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
79490322|NCT02734940|Drug|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
79490323|NCT02734940|Drug|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
79808465|NCT05685108|Device|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
79644339|NCT05992337|Diagnostic Test|Cardio MRI|MRI for early detection of myocardial impairment caused by chemotherapy
79644340|NCT05992337|Diagnostic Test|24-hours monitoring of ECG|Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
79644341|NCT05992337|Diagnostic Test|24 hours monitoring of BP|Diagnostic test for detection of hypertension as a consequence of cardiotoxicity
79808466|NCT05671900|Drug|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
79808467|NCT05646368|Dietary Supplement|Formulation #1|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
79973990|NCT01585103|Device|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
79318933|NCT05440851|Other|Driving Pressure-Limited Ventilation (DPL)|Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
79318934|NCT05440851|Other|Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)|Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
79318935|NCT05440851|Drug|Early Cohort corticosteroid dose|Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
79318936|NCT05440851|Drug|Extended Cohort corticosteroid dose|Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
79318937|NCT05440851|Drug|Usual care without routine corticosteroids|Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
79973991|NCT03168906|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
79973992|NCT03168906|Drug|Placebo|Saline bag
79973993|NCT05281133|Other|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
79973994|NCT03811925|Procedure|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
79318938|NCT05440851|Drug|Usual care without extending corticosteroids|Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
79318939|NCT05419076|Radiation|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
79478377|NCT05970380|Other|Local anesthesia|Local anesthetic solution (20 mL 0.25% bupivacaine) will be given extrapedicular part of the fractured vertebra by the surgeon.
79808468|NCT05646368|Dietary Supplement|Formulation #2|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
79973995|NCT03811925|Procedure|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
79973996|NCT00706966|Drug|dutasteride|6 months of dutasteride 3.5 mg daily
79973997|NCT03478657|Drug|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
79973998|NCT03478657|Device|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
79973999|NCT03478657|Other|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
79974000|NCT01330524|Drug|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
79974001|NCT01330524|Other|placebo|2mg placebo
79318940|NCT05419076|Procedure|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
79318941|NCT05411679|Drug|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
79974002|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
79318942|NCT05411679|Drug|Olaparib tablets|Olaparib is a PARP inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor) Other names: Lynparza
79478378|NCT05969756|Drug|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
79478379|NCT05969756|Drug|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
79974003|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
79318943|NCT05409105|Dietary Supplement|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
79318944|NCT05409105|Dietary Supplement|Water|2 cups/day bottled water, 2 weeks
79974004|NCT03331900|Drug|COR388|Administered as oral capsule
79318945|NCT05406479|Drug|BE-PEP (Bedaquiline)|Single dose of Bedaquiline
79478380|NCT05969756|Drug|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
79478381|NCT05966870|Other|Unsweetened flavored sparkling water|Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
79318946|NCT05406479|Drug|SDR-PEP|Single dose of Rifampicin
79318947|NCT05406479|Drug|BE-PEP (Rifampicine)|Single dose of Rifampicin
79318948|NCT05400837|Combination Product|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
79318949|NCT05380505|Behavioral|Racially Congruent Ads|Facebook food ads that are racially congruent.
79318950|NCT05380505|Behavioral|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
79318951|NCT05325281|Drug|CPI-613® (Dose level -1.0 250 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
79318952|NCT05325281|Drug|CPI-613® (Dose level 1.0 500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
79478382|NCT05966324|Drug|baxdrostat|Baxdrostat is an aldosterone synthase inhibitor
79478383|NCT05965466|Procedure|Distal gastrectomy and radical resection|Distal gastrectomy and Roux-en-Y anastomosis
79478384|NCT05965466|Procedure|Total gastrectomy and radical resection|Total gastrectomy and Roux-en-Y anastomosis
79478385|NCT05963009|Drug|baxdrostat (formerly CIN-107) oral solution|5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
79974005|NCT03331900|Drug|Placebo|Administered as oral capsule
79490324|NCT02734940|Drug|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
79318953|NCT05325281|Drug|CPI-613® (Dose level 2.0 1,000 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
79318954|NCT05325281|Drug|CPI-613® (Dose level 3.0 1,500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
79478386|NCT05962762|Biological|Human Umbilical Cord Mesenchymal Stem Cells|"The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group."
79478387|NCT05962476|Device|Transcutaneous vibro-acoustic device|Wearable device which sends low-frequency sound vibrations through the skin.
79644342|NCT05991921|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|"TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section."
79478388|NCT05961397|Drug|baxdrostat|single oral dose of baxdrostat 10 mg
79478389|NCT05961384|Drug|baxdrostat|a blood pressure lowering drug, oral dose
79478390|NCT05961020|Device|Total body vibration|Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system
79478391|NCT05961020|Other|moderate restricted diet|moderate restricted diet
79318955|NCT05325281|Drug|CPI-613® Maximum Tolerated Dose (MTD)|MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m^2 and up to 1,500 mg/m^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
79478392|NCT05960552|Diagnostic Test|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
79478393|NCT05960552|Diagnostic Test|The conventional TEE group|Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
79478394|NCT05960448|Other|Transcutaneous Spinal Cord Stimulation (TSCS)|This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.
79478395|NCT05960448|Other|Sham Transcutaneous Spinal Cord Stimulation|This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
79644343|NCT05991921|Other|Plasebo-Fake TENS|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
79318956|NCT05325281|Drug|Gemcitabine|Subjects will be administered 400 mg/m^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
79318957|NCT05325281|Radiation|Intensity-modulated Radiation Therapy|1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
79318958|NCT05289934|Behavioral|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
79318959|NCT05289505|Device|MUSIC-CARE|This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
79318960|NCT05274165|Device|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
79318961|NCT05274165|Device|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
79318962|NCT05258916|Procedure|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
79644344|NCT05991557|Procedure|peroneus longus autograft|Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
79644345|NCT05991154|Behavioral|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
79808469|NCT05614661|Behavioral|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
79808470|NCT05604066|Diagnostic Test|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
79974006|NCT05664997|Behavioral|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
79318963|NCT05254275|Other|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
79318964|NCT05254275|Other|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
79318965|NCT05248438|Behavioral|Questionnaire|Questionnaire
79318966|NCT05244629|Device|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
79318967|NCT05242809|Behavioral|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
79318968|NCT05193994|Drug|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
79318969|NCT05193994|Drug|Placebo|Matching placebo.
79318970|NCT05191784|Drug|GX-I7|Administered by intramuscular (IM) injection
79318971|NCT05191784|Drug|Bevacizumab|Administered by intravenous (IV) injection
79318972|NCT05161715|Drug|Obicetrapib|10mg obicetrapib
79318973|NCT05147974|Behavioral|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
79318974|NCT05146024|Behavioral|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
79478396|NCT05955222|Device|PEEK|Participants receiving splints produced with CAD/CAM from PEEK blocks,
79478397|NCT05955222|Device|PMMA|Participants receiving splints produced with CAD/CAM from PMMA blocks,
79808471|NCT05604066|Diagnostic Test|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
79318975|NCT05145595|Device|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
79318976|NCT05145595|Device|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
79318977|NCT05145595|Device|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (<1 mm²) and texture.
79318978|NCT05145595|Behavioral|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
79318979|NCT05145595|Behavioral|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined [22; 55]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
79318980|NCT05145595|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
79808472|NCT05582850|Drug|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
79478398|NCT05955222|Device|Traditional|Participants receiving splints from vacuum forming system
79490325|NCT00378092|Drug|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
79490326|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
79808473|NCT05582850|Drug|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at the recommended clinical dose (RCD).
79808474|NCT05541055|Device|digital CBT-I|A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
79808475|NCT05541055|Other|Sleep hygiene education|Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.
79974007|NCT03121066|Device|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
79318981|NCT05145595|Behavioral|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
79318982|NCT05145595|Behavioral|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
79318983|NCT05145595|Behavioral|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms [41]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
79318984|NCT05145595|Behavioral|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
79318985|NCT05140434|Diagnostic Test|Exercise test|exercise test on an exercise bike with increasing load
79318986|NCT05140434|Diagnostic Test|Cardiac CT|cardiac CT scan
79318987|NCT05137717|Drug|Maribavir|Maribavir tablets
79318988|NCT05119179|Drug|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
79318989|NCT05091112|Procedure|Spinal surgery|In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.
79318990|NCT05091112|Other|Histology|The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
79318991|NCT05089084|Drug|ARO-APOC3|ARO-APOC3 injection
79318992|NCT05089084|Drug|Placebo|sterile normal saline (0.9% NaCl)
79490327|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
79644346|NCT05991050|Dietary Supplement|energy-restricted diet|Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.
79644347|NCT05991050|Device|Whole body vibration|"For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions."
79974008|NCT03121066|Device|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
79974009|NCT01302587|Drug|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
79644348|NCT05991024|Behavioral|the incisional hernia recurrent|Recurrence after repair was the main outcome
79644349|NCT05990049|Drug|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
79644350|NCT05990036|Other|Sports vision enhancement training curriculum|A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
79974010|NCT03723109|Procedure|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
79318993|NCT05077709|Drug|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
79490328|NCT00378170|Device|intubation of patients undergoing elective surgery|
79490329|NCT01347632|Drug|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
79490330|NCT02679560|Drug|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
79318994|NCT05073471|Behavioral|Patterned Sensory Enhancement (PSE)|"Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily."
79478399|NCT05952011|Procedure|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
79644351|NCT05988502|Other|auricular acupressure|"The well-trained researcher nurse in this study was performed the AA intervention. First of all, the participant was instructed to find a comfortable position. Disinfect the ears using cotton with 75 % alcohol was then provided and followed by placed vaccaria seeds (Beijing, China) with an adhesive patch onto the unilateral each selected auricular acupoint (left ear first) Participants were pressed each acupoint by thumb and index finger for one minute, four times a day, five days a week, remove the taped seeds on the 6th day, and then replaced the opposite ear two days after. They were noted that they experienced various sensations while pressing, including numbness, swelling, mild pain, or warmth. Seeds were taped on the other side of the ear weekly for two weeks.~Two TCM physicians verified the conduct of the AA protocol, which consisted of a selection of acupoints, length of stimulation time, finding location of acupoint, and procedure of practice."
79478400|NCT05947409|Drug|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
79478401|NCT05947396|Dietary Supplement|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
79644352|NCT05988294|Other|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
79644353|NCT05988294|Other|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
79644354|NCT05985863|Drug|standard medical treatment|standard medical treatment for ACLF
79478402|NCT05947396|Other|placebo|The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
79478403|NCT05942612|Drug|SHR-2001|Subcutaneous injection, single dose
79478404|NCT05942612|Drug|Placebo|Subcutaneous injection, single dose
79318995|NCT05073471|Device|Transcranial Direct Current Stimulation (tDCS)|"We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure."
79318996|NCT05071287|Other|mHealth + low-fat diet|A restricted total calorie and reduced total fat consumption.
79318997|NCT05071287|Other|mHealth + low-carb/ketogenic diet|A low-carb/ketogenic diet
79318998|NCT05047705|Behavioral|Distress Tolerance Skills Training|Individuals with TS will receive distress tolerance skill training. Therapeutic skill training will consist of 4 weekly 1-hour sessions. Skill training will occur either in-person or remotely via videoconferencing software. Sessions will focus on building participants' distress tolerance skills with strategies drawn from third-wave CBT.
79318999|NCT05020470|Device|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
79319000|NCT05020470|Other|In-Person Training|Participants will receive in-person training to self-administer APA.
79319001|NCT05020470|Other|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
79319002|NCT04996264|Drug|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
79319003|NCT04996264|Drug|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
79319004|NCT04996264|Drug|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
79319005|NCT04969822|Device|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
79490331|NCT02679560|Drug|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
79319006|NCT04957134|Device|Electro-acupuncture|The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
79319007|NCT04957134|Device|Sham electro-acupuncture|The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
79319008|NCT04931953|Other|Intermittent theta burst stimulation (iTBS)|The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
79319009|NCT04931953|Other|Sham Intermittent theta burst stimulation (iTBS)|The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
79974011|NCT03338608|Procedure|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
79974012|NCT03338608|Procedure|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
79319010|NCT04924712|Other|Measurement of blood immune populations and microbiota distribution.|Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
79974013|NCT03338608|Procedure|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
79319011|NCT04911062|Drug|Bupivacaine HCI without epinephrine|100 mg administered via injection into the surgical site.
79319012|NCT04911062|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
79319013|NCT04911062|Device|Luer Lock Applicator|Applicator for instillation.
79319014|NCT04818749|Drug|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
79319015|NCT04818749|Drug|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
79319016|NCT04818749|Drug|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
79319017|NCT04817137|Device|CareTaker PDA Device|Non-invasive blood pressure monitoring
79319018|NCT04815551|Drug|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
79319019|NCT04815551|Drug|Placebo|Placebo is sterile liquid for IV infusion.
79319020|NCT04813692|Procedure|Surgical repair|Surgical repair of post-infarction LVFWR or VSR
79319021|NCT04813692|Procedure|Percutaneous treatment|Percutaneous closure of post-infarction VSR (or treatment for LVFWR)
79319022|NCT04813692|Procedure|Mitral valve surgery|Mitral valve repair or replacement for post-infarction PMR
79319023|NCT04795960|Dietary Supplement|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
79319024|NCT04795960|Dietary Supplement|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
79974014|NCT03018288|Drug|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
79319025|NCT04790071|Other|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
79319026|NCT04790071|Other|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
79319027|NCT04776395|Drug|Dexamethasone|Given PO
79319028|NCT04776395|Drug|Iberdomide Hydrochloride|Given PO
79319029|NCT04776395|Other|Quality-of-Life Assessment|Ancillary studies
79319030|NCT04726748|Procedure|Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts|"Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~a linear regression model when it involves quantitative variables,~a logistic regression model adjusted on potential confounding when it involves qualitative variables."
79319031|NCT04726748|Procedure|Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts|"Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~a linear regression model when it involves quantitative variables,~a logistic regression model adjusted on potential confounding when it involves qualitative variables."
79319032|NCT04716036|Other|Alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
79319033|NCT04716036|Other|Placebo beverage|placebo beverage condition.
79319034|NCT04712552|Procedure|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
79319035|NCT04671771|Device|InnAVasc arteriovenous graft surgical implant|The InnAVasc AVG is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
79319036|NCT04657549|Procedure|Tonsillectomy|Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
79319037|NCT04657549|Procedure|Tonsillotomy|Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
79319038|NCT04612049|Device|Immersive virtual reality visuo-motor skill assessment|Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
79478405|NCT05939349|Other|Produce Prescription Group|"Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program."
79644355|NCT05985863|Drug|Placebo|5% human serum albumin in 0.9% saline (at week0, week1 and week2)
79319039|NCT04588688|Drug|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
79319040|NCT04587830|Drug|ADI-PEG20|Investigational Medicine
79319041|NCT04587830|Drug|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
79478406|NCT05938790|Other|Continuous Fetal Monitoring|Fetal doppler used to monitor fetal heart rate in triage
79478407|NCT05938790|Other|Point of Care Handheld Ultrasound|Point of Care Handheld Ultrasound
79974015|NCT03018288|Biological|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
79478408|NCT05938088|Drug|Arm I (mirogabalin group)|Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.
79478409|NCT05938088|Drug|Arm II (placebo group)|It is performed in the same way as Arm l.
79478410|NCT05933967|Drug|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
79644356|NCT05985863|Drug|hUC-MSC|hUC-MSC (1.5×10^8 cells/time, Peripheral IV, at week0, week1 and week2)
79644357|NCT05985863|Drug|hUC-MSC_Prolonged|hUC-MSC (1.5×10^8 cells/time, Peripheral IV, at week4 and week5)
79644358|NCT05985239|Procedure|VI|Laparoscopic or robotic surgery with virtual ileostomy
79644359|NCT05985239|Procedure|DI|Laparoscopic or robotic surgery with virtual ileostomy
79808476|NCT05527678|Other|Questionnaires|Written or by phone
79319042|NCT04558281|Drug|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
79319043|NCT04558281|Drug|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
79319044|NCT04510090|Drug|EP547|EP547
79319045|NCT04510090|Drug|Placebo|Placebo
79319046|NCT04498468|Drug|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
79319047|NCT04498468|Other|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
79319048|NCT04491006|Drug|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
79319049|NCT04491006|Drug|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
79319050|NCT04436510|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
79319051|NCT04436510|Drug|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
79478411|NCT05929352|Behavioral|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
79478412|NCT05928832|Other|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
79319052|NCT04433052|Behavioral|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
79319053|NCT04365400|Drug|DS102|DS102 Epeleuton capsules
79478413|NCT05927935|Other|Supervised strength exercise intervention|A 6 months exercise intervention of training 2 times a week. Patients will be instructed by a physiotherapist during the first session, in order to be able to perform the exercises at home or in a local gymnasium based on personal preference. Subsequently, there are supervised sessions once every second week (12 sessions in total). The intervention will consist of 6 exercises. 4 targeting planes of hip movement (i.e., flexion, extension, abduction and adduction), a general lower extremity- and a trunk exercise. Progression is made when an exercise is performed with the designated number of sets and repetitions, with good performance quality and tolerable pain. Progression is provided by 3 levels of difficulty and secondly by the number of repetitions or where possible by increasing the external load. In addition, patient information and education is identical to what is delivered in the usual care group.
79490332|NCT00378248|Behavioral|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
79490333|NCT00378248|Behavioral|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
79490334|NCT03734822|Other|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
79319054|NCT04365400|Drug|Placebo|Placebo capsules
79319055|NCT04343222|Drug|Bromfenac|An NSAID used to treat eye pain and swelling
79319056|NCT04343222|Drug|Artificial tears|eye drops to lubricate the eye and maintain moisture
79319057|NCT04342039|Drug|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
79319058|NCT04342039|Other|Placebo|2 sprays each nostril daily on days as indicated in the timeline
79319059|NCT04311671|Drug|Moxidectin|2 mg tablets, encapsulated for blinding
79319060|NCT04311671|Drug|Ivermectin|3 mg tablets, encapsulated for blinding
79319061|NCT04311671|Drug|Albendazole|400 mg tablets
79319062|NCT04281108|Drug|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
79319063|NCT04281108|Drug|Placebo oral tablet|Placebo orally disintegrating tablet.
79319064|NCT04281108|Procedure|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
79319065|NCT04268849|Drug|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
79319066|NCT04268849|Drug|Saline|Placebo for Ferumoxytol
79319067|NCT04268849|Drug|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
79478414|NCT05927935|Other|Minimal educational intervention (usual care)|Usual care varies slightly across regions in Denmark and between Denmark and Australia. The consensus is that the patient should be advised to remain physically active and reduce symptom provoking activities. Therefore, minimal educational intervention is provided as usual care. Patients allocated to the usual care group will receive written information in a leaflet on self-management of hip symptoms including advice about staying physically active in accordance with the World Health Organization guidelines on physical activity and sedentary behavior. Moreover, self-management of hip symptoms will include advice to reduce symptoms by focusing on symptom-lowering activities and sports. The content of the information provided as usual care will be identical to the information provided to the patients in the intervention group. Patients in the usual care group can continue to seek any additional treatment they would like and won't be prohibited from doing this.
79478415|NCT05916287|Biological|Blood and urine samples|Blood and urine samples
79478416|NCT05916287|Genetic|Blood samples|Blood samples
79319068|NCT04268849|Drug|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
79319069|NCT04258046|Drug|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
79478417|NCT05916287|Other|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
79319070|NCT04227587|Other|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
79319071|NCT04227587|Other|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
79319072|NCT04217161|Device|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
79319073|NCT04192227|Behavioral|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
79974016|NCT03018288|Drug|Temozolomide|Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m^2. Post RT: The starting TMZ dose will be 150 mg/m^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
79974017|NCT03018288|Other|Placebo|One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
79974018|NCT03018288|Procedure|Surgery|Tissue for vaccine production and neo-epitope monitoring.
79319074|NCT04189055|Drug|Cetuximab|Cetuximab 500mg/m² IV, day 1
79319075|NCT04189055|Drug|Irinotecan|Irinotecan 180mg/m² IV, day 1
79478418|NCT05916287|Behavioral|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
79478419|NCT05916287|Other|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
79644360|NCT05984121|Drug|Local ozon injections|"Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively."
79644361|NCT05984121|Drug|Local dextroz prolotherapy injections|Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
79644362|NCT05984121|Other|Exercise Group|Patients will receive a conventional therapy program consisting of exercises
79644363|NCT05983224|Dietary Supplement|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
79808477|NCT05496166|Combination Product|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
79974019|NCT03811613|Other|Transcranial photobiomodulation|Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
79974020|NCT03331822|Other|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day*Light Classic Light will be positioned at each nursing station in the ICU hallway.
79319076|NCT04162470|Drug|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
79319077|NCT04147806|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
79319078|NCT04147806|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
79319079|NCT04147806|Drug|Dexamethasone|4 mg by mouth on treatment days only
79319080|NCT04147806|Drug|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
79478420|NCT05916287|Other|Hemodynamic parameters|Systolic pressure index measurement
79478421|NCT05916287|Other|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
79478422|NCT05916287|Other|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
79478423|NCT05916287|Other|Hemodynamic parameters|Electrocardiogram
79478424|NCT05916287|Behavioral|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
79478425|NCT05916287|Other|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
79478426|NCT05916287|Biological|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
79808478|NCT05491642|Drug|BAY3283142|Oral administration
79319081|NCT04131361|Other|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
79478427|NCT05916287|Other|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
79478428|NCT05916287|Other|Women specific questionnaire|Women specific questionnaire
79478429|NCT05916287|Behavioral|Women specific questionnaire|Women specific questionnaire
79478430|NCT05916287|Diagnostic Test|NYHA dyspnea questionnaire|Determination of NYHA class.
79478431|NCT05916287|Behavioral|Anxiety questionnaire|Assessment of anxiety
79644364|NCT05983224|Other|Placebo|The control group will receive two placebo daily, after breakfast and lunch, for twelve weeks.
79478432|NCT05916287|Behavioral|Epworth Sleepiness Scale|sleep quality assessment
79478433|NCT05916287|Other|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
79478434|NCT05916287|Behavioral|A questionnaire on eating behaviors|Assessment of eating behaviors
79974021|NCT05035290|Device|Negative pressure ventilation|Negative pressure ventilation - cuirass will be applied on the patient´s ches and abdomen immediately after extubation
79319082|NCT04122625|Drug|Debio 1143|Administered as capsules.
79319083|NCT04122625|Drug|Nivolumab|Administered as IV infusion.
79319084|NCT04091984|Diagnostic Test|Prospera|No Interventions, this is an observational study.
79319085|NCT04077346|Device|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
79319086|NCT04077346|Other|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
79319087|NCT04076462|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
79478435|NCT05916287|Behavioral|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
79478436|NCT05916287|Dietary Supplement|A questionnaire on food supplements use|Evaluation od food supplements intake
79478437|NCT05916287|Other|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
79478438|NCT05916287|Other|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
79478439|NCT05916287|Biological|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
79478440|NCT05911698|Device|Fractional co2 laser|"The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes."
79644365|NCT05958056|Other|Resistance exercise|The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
79808479|NCT05491642|Drug|Placebo to BAY3283142|Oral administration
79319088|NCT04076462|Drug|Matching placebo|Matching placebo for CAM2029
79478441|NCT05911594|Drug|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
79478442|NCT05911594|Procedure|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
79478443|NCT05911594|Drug|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
79478444|NCT05911594|Combination Product|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
79478445|NCT05910879|Behavioral|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, …a time when you felt successful and proud of yourself. …You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will… a)…think about things I value about myself, b)…remember things that I have succeeded in, c) …think about what I stand for, or d)…think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
79319089|NCT04058288|Device|High-definition Transcranial Direct Current Stimulation|Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
79478446|NCT05910879|Behavioral|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
79478447|NCT05908396|Drug|IGM-2644|IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
79478448|NCT05900882|Drug|Selinexor|Selinexor 60 mg/day, orally on d1,8,15,22
79478449|NCT05900882|Drug|Bortezomib|Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
79478450|NCT05900882|Drug|Lenalidomide|Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
79319090|NCT04057105|Device|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
79319091|NCT04057105|Device|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
79319092|NCT04044313|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
79319093|NCT04044313|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79319094|NCT04044313|Drug|Toripalimab|240mg intravenously every 3 weeks
79974022|NCT03338530|Behavioral|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
79974023|NCT05013294|Other|Intervention|Text messages through a basic phone or smart phone
79974024|NCT02492152|Device|Study group|Dianatal
79319095|NCT04042337|Behavioral|Pivotal Response Treatment|PRT will target functional communication abilities
79319096|NCT04032990|Device|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
79319097|NCT03975634|Device|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
79974025|NCT03515941|Drug|Oxaliplatin|130 mg/m2 by IV (Arm 1)
79319098|NCT03968757|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
79319099|NCT03941756|Drug|Indocyanine Green|Given IV
79478451|NCT05900882|Drug|Dexamethasone|Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
79478452|NCT05899738|Drug|Iberdomide|Specified dose on specified days
79478453|NCT05896891|Diagnostic Test|esophagogastroduodenoscopy (EGD), buccal swab, blood withdrawal|During routine EGD, biopsy, blood and buccal saliva samples will be withdraw and stored at San Raffaele Hospital
79478454|NCT05896254|Drug|MAR001|Subcutaneous injection
79974026|NCT03515941|Drug|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
79974027|NCT03515941|Drug|Leucovorin|400 mg/m2 by IV (Arm 1 & Arm 2)
79319100|NCT03941756|Procedure|Lymphangiography|Undergo lymphangiography
79319101|NCT03941756|Procedure|Lymphovenous Bypass|Undergo LVB
79478455|NCT05896254|Drug|Placebo|Subcutaneous injection
79808480|NCT05489185|Drug|Tranexamic acid|Intravenous or topical administration
79974028|NCT03515941|Drug|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
79974029|NCT03515941|Radiation|radiation|45 Gy in 1.8 Gy/fraction
79974030|NCT01300403|Other|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
79974031|NCT01300403|Other|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
79974032|NCT01300403|Other|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
79319102|NCT03938922|Drug|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
79319103|NCT03887455|Drug|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
79974033|NCT03819647|Drug|stiripentol (Diacomit)|Administration of stiripentol per os
79974034|NCT02498782|Drug|Fexinidazole|
79974035|NCT02498782|Drug|Placebo|
79319104|NCT03887455|Drug|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
79319105|NCT03887455|Drug|Lecanemab|720 milligram (mg) weekly administered as subcutaneous injection.
79319106|NCT03836976|Other|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
79319107|NCT03828201|Drug|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
79490335|NCT03734822|Device|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
79974036|NCT05623085|Other|Aerobic exercise|Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
79974037|NCT05623085|Other|Yoga exercise|Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
79478456|NCT05893914|Procedure|Dry Needling and intramuscular electrical stimulation to trigger points|Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
79478457|NCT05883540|Drug|Lysergic Acid Diethylamide Tartrate|25 μg p.o.
79478458|NCT05883540|Drug|Lysergic Acid Diethylamide Tartrate|100 or 200 μg p.o.
79808481|NCT05489185|Other|Physiologic saline|Placebo
79478460|NCT05880576|Device|Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy|Infants will have monitoring three times a day with resonance Raman spectroscopy device during arch watch period. They will have continuous monitoring with pulse oximetry and near infrared spectroscopy. They will have intermittent blood pressure monitoring.
79974038|NCT03338452|Behavioral|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
79478461|NCT05878704|Drug|GBT021601|Oral
79478462|NCT05878301|Other|vegetable and protein first followed by carbohydrates (VPF) meal sequence|vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
79319108|NCT03828201|Drug|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
79319109|NCT03828201|Drug|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
79319110|NCT03828201|Drug|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
79319111|NCT03828201|Drug|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
79319112|NCT03824704|Drug|Rucaparib|Oral rucaparib will be administered twice daily
79319113|NCT03824704|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
79319114|NCT03800537|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
79319115|NCT03798106|Drug|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
79319116|NCT03767075|Drug|Atezolizumab|1200 mg, administered IV, once every 3 weeks
79319117|NCT03767075|Drug|Futibatinib|20 mg administered orally, once daily (QD) continuously in 28-day cycles.
79307979|NCT03225521|Behavioral|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
79319118|NCT03767075|Drug|Amivantamab|1050 mg administered IV for body weight < 80 kg and 1400 mg for body weight >= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
79319119|NCT03766581|Drug|BMS-986177|Oral administration
79319120|NCT03766581|Other|Placebo|Oral Administration
79319121|NCT03766581|Drug|Clopidogrel|Oral administration
79319122|NCT03766581|Drug|Aspirin|Oral administration
79478463|NCT05875857|Behavioral|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
79478464|NCT05873452|Device|Kaitoh Atherectomy System|The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
79644366|NCT05953246|Behavioral|Neutral labels|Participants view neutral labels (QR codes with and without neutral text) for menu items
79319123|NCT03743129|Drug|Anlotinib|Anlotinib 12mg p.o, qd
79319124|NCT03723850|Device|Active tDCS|The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
79319125|NCT03723850|Device|Sham tDCS|The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
79319126|NCT03716778|Other|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
79319127|NCT03675321|Device|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
79319128|NCT03675321|Device|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
79319129|NCT03638596|Behavioral|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
79319130|NCT03638596|Behavioral|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
79974039|NCT05623007|Dietary Supplement|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
79974040|NCT05623007|Behavioral|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
79478467|NCT05870943|Procedure|Hybrid Argon Plasma Coagulation|Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach.
79478468|NCT05870943|Procedure|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
79478469|NCT05865119|Device|OPTIMUS covered stent|The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.
79478470|NCT05865119|Procedure|Surgical correction of a SVD|Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
79478471|NCT05864300|Behavioral|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
79644367|NCT05953246|Behavioral|Numeric text-only sustainability labels|Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item
79644368|NCT05953246|Behavioral|Endorsement text-only sustainability labels|Participants view labels using text to endorse menu items as having low environmental impact
79644369|NCT05953246|Behavioral|Endorsement icon-only sustainability labels|Participants view labels using icons to endorse menu items as having low environmental impact
79644370|NCT05953246|Behavioral|Endorsement text-plus-icon sustainability labels|Participants view labels using text and icons to endorse menu items as having low environmental impact
79974041|NCT05623007|Dietary Supplement|Placebo probiotics|Maltodextrin
79478472|NCT05862857|Behavioral|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
79478473|NCT05862857|Behavioral|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
79478474|NCT05862233|Drug|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27
79478475|NCT05862233|Drug|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d in 2 divided doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks±3 days until the target blood concentration of 125~175 ng/ mL was reached.If the treatment is effective,cyclosporine would be reduced by about 1/2 of the original dose each month, and discontinued after 2 months.
79974042|NCT02499016|Procedure|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
79974043|NCT03815201|Dietary Supplement|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
79974044|NCT03815201|Other|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
79974045|NCT02493790|Other|Cognitive and motor performances|
79319131|NCT03613363|Device|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
79319132|NCT03527745|Drug|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
79319133|NCT03527745|Drug|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
79808482|NCT05469581|Other|A set of preventive interventions to improve adherence in vulnerable elderly people|"reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~a counseling about the importance of adherence;~handing over the medication dispenser (if the elderly person does not have one yet),~delivering of a personal medication card, which shows the timeline of taking prescribed medication."
79808483|NCT05465304|Drug|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
79808484|NCT05455450|Other|Eye movement desensitisation and reprocessing therapy|Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.
79478476|NCT05859815|Behavioral|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
79974046|NCT03819335|Device|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
79974047|NCT03819335|Other|Standard care|Face-to-face visits
79808485|NCT05455450|Other|Neuropsychiatric care|Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
79974048|NCT02498938|Genetic|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
79974049|NCT03811691|Diagnostic Test|MRI exam|Pacing system safety and stability under MRI scan environment
79974050|NCT02498860|Drug|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
79974051|NCT02498860|Drug|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
79974052|NCT03811457|Genetic|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
79974053|NCT02498704|Procedure|Dry Needling|Trigger point dry needling to hamstring muscle group.
79974054|NCT02498704|Other|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
79478477|NCT05856851|Drug|Alteplase|See arm/group descriptions.
79478478|NCT05856617|Drug|Remimazolam besylate|Remimazolam besylate anesthesia induction
79974055|NCT03011034|Drug|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
79974056|NCT03011034|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
79974057|NCT04984499|Device|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
79974058|NCT03815123|Diagnostic Test|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
79974059|NCT01330602|Behavioral|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy"
79307980|NCT04868487|Other|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
79307981|NCT04380753|Drug|AMG 510|Subjects will be enrolled and will receive AMG 510 PO QD.
79307982|NCT04379973|Drug|Lipiodol Ultra Fluide®|Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
79307983|NCT02453009|Drug|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
79808486|NCT05453370|Device|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
79808487|NCT05453370|Other|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
79808488|NCT05442333|Procedure|surgical resection with safety margin|"• The patients with preoperative radiotherapy:~will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~6 weeks post radiation for wound dehiscence~3 months post radiation for local swelling or recurrence~6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~6 weeks post radiation for wound dehiscence~3 months post radiation for local swelling or recurrence~6 months post radiation for local recurrence, joint stiffness or pathological fractures."
79808489|NCT05440240|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
79808490|NCT05440240|Drug|Corticosteroid injection|Depo-Medrol
79808491|NCT05440240|Other|Saline injection|Isotonic saline
79307984|NCT02453009|Drug|Prednisone|Pharmaceutical form:tablet Route of administration: oral
79319134|NCT03527745|Drug|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
79319135|NCT03527745|Drug|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
79319136|NCT03527745|Drug|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
79319137|NCT03524534|Other|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
79319138|NCT03524534|Other|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
79319139|NCT03522584|Biological|Durvalumab|Given IV
79307985|NCT02453009|Drug|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
79307986|NCT03044457|Procedure|TKA|"femoral and tibial positioning using the reversed gap technique"
79319140|NCT03522584|Other|Laboratory Biomarker Analysis|Correlative studies
79478479|NCT05851469|Device|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
79307987|NCT03225053|Device|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
79307988|NCT04868331|Behavioral|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
79307989|NCT03234101|Behavioral|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1) Healthy body weight (Minimum: BMI <30kg/m2 or WC of <88 in females or <92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits & vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation >12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (>6 hours)"
79307990|NCT03047811|Other|TCR - T cell therapy|Low dose group: 1 x 10 ^8 /kg T cell total reinfusion. High dose groups: 10 x 10 ^ 8 / kgT cell total reinfusion.
79307991|NCT03233789|Behavioral|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
79307992|NCT04868175|Drug|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
79307993|NCT04868175|Drug|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
79307994|NCT04868175|Drug|Hypromellose|Placebo eye drop, lubricant
79974060|NCT03331588|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
79490336|NCT03734822|Diagnostic Test|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
79974061|NCT03331588|Procedure|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
79974062|NCT01301885|Procedure|Laparoscopy/laparotomy|Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.
79974063|NCT03515629|Drug|REGN2810/ipi|REGN2810 plus ipilimumab
79319141|NCT03522584|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79319142|NCT03522584|Biological|Tremelimumab|Given IV
79319143|NCT03522584|Procedure|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
79319144|NCT03515083|Device|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
79319145|NCT03495115|Device|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
79319146|NCT03495115|Device|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
79478480|NCT05849935|Diagnostic Test|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
79808492|NCT05412524|Behavioral|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
79808493|NCT05412251|Radiation|health promotion program|Multi-domain intervention 120 minutes cognitive training, 120 ~180 minutes physical exercise per weeks, and 60 minutes diet nutrition education per month
79808494|NCT05391633|Behavioral|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
79974064|NCT03515629|Drug|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
79974065|NCT03515629|Drug|Pembrolizumab|Reference drug administered IV infusion
79319147|NCT03482557|Device|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
79808495|NCT05391633|Behavioral|Placebo Recording|60-minute blank recording played once daily for 14 total days.
79808496|NCT05375266|Other|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
79974066|NCT02498626|Other|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
79974067|NCT04581954|Drug|Ruxolitinib|Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
79974068|NCT04581954|Drug|Fostamatinib|Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
79974069|NCT04581954|Other|Standard of care|Standard of care treatment as per site-level policies and guidelines.
79974070|NCT05016089|Other|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
79319148|NCT03482557|Device|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
79319149|NCT03284463|Drug|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
79974071|NCT04494178|Device|2.0g G-PUR®|Oral administration (Intervention period I)
79478481|NCT05848973|Other|Healthy Diet|The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and <10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
79478482|NCT05848973|Behavioral|Mindfulness-based cognitive therapy (MBCT)|MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
79974072|NCT04494178|Device|2.0g G-PUR®|Oral administration (Intervention period II)
79478483|NCT05842460|Behavioral|Nutrient warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
79974073|NCT04494178|Other|Placebo|Intervention period I
79319150|NCT03284463|Drug|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
79478484|NCT05842460|Behavioral|Nutrient and ultraprocessed warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
79478485|NCT05842070|Procedure|Low-Intensity Egg Freezing Protocol|The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.
79974074|NCT04494178|Other|Placebo|Intervention period II
79319151|NCT03223103|Drug|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
79319152|NCT03223103|Device|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
79319153|NCT03223103|Biological|Peptides|synthetic long peptides (SLP) as vaccine substrate
79319154|NCT03208907|Drug|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
79319155|NCT03208907|Drug|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
79974075|NCT05002751|Other|UCSD Vaginal Dilator Questionnaire|14 question survey
79974076|NCT05002751|Other|EORTC Sexual Health Questionnaire|22 question survey
79974077|NCT04541940|Other|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
79974078|NCT04541940|Other|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
79974079|NCT02498470|Procedure|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
79974080|NCT01330680|Dietary Supplement|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
79974081|NCT01330680|Dietary Supplement|Decaffeinated coffee|40 mL dose of decaffeinated coffee
79974082|NCT03331510|Other|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
79319156|NCT03208907|Drug|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
79974083|NCT01330758|Drug|AZD8931|40 mg AZD8931 wet granulation tablet formulation
79319157|NCT03208907|Drug|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
79478486|NCT05842070|Procedure|High-Intensity Egg Freezing Protocol|The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
79478487|NCT05840887|Procedure|Knee osteotomy associated with meniscal allograft transplantation|Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
79974084|NCT01330758|Drug|AZD8931|40 mg AZD8931 roller compacted tablet formulation
79974085|NCT01302821|Biological|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
79974086|NCT01302821|Drug|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
79974087|NCT01302821|Radiation|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
79974088|NCT03331432|Dietary Supplement|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
79974089|NCT03331432|Dietary Supplement|Placebo|Taking daily placebo capsules for 4 weeks.
79478488|NCT05840887|Procedure|Knee osteotomy|Knee osteotomy
79478489|NCT05840861|Drug|Vortioxetine|All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
79319158|NCT03191058|Device|Magnetic Seizure Therapy|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
79478490|NCT05840861|Drug|Quetiapine|All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
79478491|NCT05839431|Behavioral|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
79478492|NCT05838911|Other|Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, calf muscles and anterior tibial group performed for 30 min /day for five days a week for three consecutive weeks.
79974090|NCT03512353|Drug|Dexamethasone|Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
79478493|NCT05838911|Other|Control Group Chest physical therapy|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
79808497|NCT05370313|Behavioral|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
79808498|NCT05370313|Behavioral|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
79490337|NCT03734822|Diagnostic Test|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
79490338|NCT02671136|Device|Hyperbaric Oxygen therapy|
79490339|NCT02671136|Other|Conventional Wound Therapies|
79808499|NCT05370313|Behavioral|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
79808500|NCT05370313|Behavioral|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
79808501|NCT05370313|Behavioral|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
79808502|NCT05366075|Other|Intervention 1 (simple exercise program)|Up to four sessions per day (total duration 20-30 minutes/day). Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week). At discharge, the participants will be encouraged to continue with the exercise program at home.
79307995|NCT03225209|Other|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
79307996|NCT03047889|Drug|standard therapy|standard therapy for advanced/metastatic breast cancer
79307997|NCT02452775|Biological|OC-L|
79307998|NCT02452775|Other|Montanide|
79307999|NCT02452775|Other|poly-ICLC (Hiltonol),|
79308000|NCT03224975|Other|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
79308001|NCT03045705|Behavioral|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman's wishes to receive analgesia by the medical team.
79308002|NCT03045705|Behavioral|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
79308003|NCT03224897|Device|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
79308004|NCT03224897|Device|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
79308005|NCT03224897|Device|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
79308006|NCT03045627|Drug|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
79308007|NCT03045627|Drug|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
79308008|NCT03045627|Drug|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
79308009|NCT03045627|Drug|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
79974091|NCT03512353|Drug|Carfilzomib|Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
79974092|NCT04959006|Dietary Supplement|Antioxidant supplement|Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
79319159|NCT03191058|Device|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
79319160|NCT03187860|Procedure|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
79319161|NCT03187860|Other|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
79478494|NCT05837715|Device|Chattanooga Stabilizer pressure biofeedback|"Stabilization exercises, which form the basis of spinal stabilization training, increase the strength and endurance of the postural and stabilizer muscles by using the basic principles of motor learning, and improve balance control in stable and unstable positions.~In addition, stabilization exercises include kinesthetic training and functional training.~Spinal stabilization training is very important for proper control of extremity movements.~It is also an important factor in the formation of proper spinal posture and the neutral position required for the spine.~In cervical region problems, cervical stabilization exercises that activate the deep neck flexors (longus colli and longus capitis) can be applied.~Cervical stabilization training improves the cervical proprioception sense as well as strength and endurance, thereby reducing joint position sense error."
79974093|NCT04959006|Dietary Supplement|Placebo|Placebo
79974094|NCT03331276|Other|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
79974095|NCT03331276|Other|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
79319162|NCT03174782|Drug|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
79319163|NCT03174782|Drug|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
79319164|NCT03145298|Biological|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
79974096|NCT02498314|Other|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
79974097|NCT02498314|Other|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
79319165|NCT03145298|Biological|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
79319166|NCT03115333|Diagnostic Test|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
79808503|NCT05366075|Other|Intervention 2 (comprehensive exercise program)|Two daily sessions (morning and afternoon) of 20 minutes' duration each. Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week).
79974098|NCT02498314|Other|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
79319167|NCT03110523|Drug|X0002|All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
79319168|NCT03090659|Biological|LCAR-B38M CAR-T cell injection|
79319169|NCT03081364|Other|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
79974099|NCT01974804|Procedure|MRI|
79974100|NCT01300637|Drug|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
79974101|NCT01300637|Drug|placebo|identical-appearing pill of placebo
79974102|NCT02493634|Procedure|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
79974103|NCT02493634|Device|MRWire|
79319170|NCT02973685|Procedure|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
79319171|NCT02973685|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
79319172|NCT02973685|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
79974104|NCT03819257|Diagnostic Test|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
79974105|NCT03819257|Diagnostic Test|High-resolution anorectal manometry|"rest - basal anal pressures at rest over 60 s~squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~cough - anorectal pressure changes during cough~push - anorectal pressure changes during simulated defecation~rectoanal inhibitory reflex - reflex anal response to rectal distension~rectal sensation - assessment of rectal sensitivity to distension."
79808504|NCT05357768|Other|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
79478495|NCT05837715|Device|VibraSens - Focal Vibration Therapy (TechnoConcept - France)|"Vibration applications have also started to be used for treatment purposes. Therapeutic vibration produces minor changes in skeletal muscle length. Vibrations elicit a response called the tonic vibration reflex, which includes activation of muscle spindles, neural signals by Ia afferents, and activation of muscle fibers via large α-motor neurons. The tonic vibration reflex can also cause an increase in activation of motor units through activation of muscle spindles and polysynaptic pathways. It is well known that the input of the proprioceptive pathways (Ia, IIa and possibly IIb) plays an important role in the production of isometric contractions. The increase in isometric strength after application of vibration with extensive sensory stimulation may be the result of more efficient use of the positive proprioceptive feedback loop. It can be predicted that the increased muscle strength after vibration application is due to neural adaptation."
79478496|NCT05837715|Other|Telerehabilitation|Telerehabilitation is a method that aims to provide rehabilitation to patients/clinicians by reducing obstacles such as distance, time and cost by using information and communication technologies. Telerehabilitation enables patients who cannot access rehabilitation due to geographic, economic or physical disabilities to benefit from rehabilitation services. The COVID-19 pandemic has highlighted the importance of telerehabilitation practices. In order to minimize the risk of transmission in the COVID-19 pandemic, the physical activity levels of individuals have decreased and their access to rehabilitation services has been restricted by the restriction of social life.
79478497|NCT05830344|Device|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
79308010|NCT03224663|Other|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
79308011|NCT03224663|Other|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
79308012|NCT04868019|Drug|Fenofibrate Capsules|Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
79308013|NCT03047967|Diagnostic Test|lung function tests|baby-body plethysmography
79308014|NCT03047967|Diagnostic Test|Nasal brushing|Epithelial sample collecting for in vitro study
79308015|NCT03224741|Behavioral|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
79308016|NCT03224741|Behavioral|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
79308017|NCT03224741|Behavioral|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
79478498|NCT05830344|Device|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
79478499|NCT05829642|Behavioral|Enhanced Care Management|"ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed"
79478500|NCT05825625|Drug|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
79974106|NCT03819257|Diagnostic Test|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
79478501|NCT05825625|Drug|Tiragolumab|Tiragolumab by IV infusion Q3W.
79478502|NCT05823558|Diagnostic Test|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
79478503|NCT05822843|Drug|ESG206|Administered via intravenous (IV) infusion
79478504|NCT05819515|Procedure|Tunneled coronally advanced flap|Describes the flap design for both treatment arms
79478505|NCT05815186|Drug|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
79644374|NCT05942430|Procedure|Autologous costal osteochondral transplantation|"Operating steps:~Arthroscopic examination of the size and location of the talar osteochondral lesion;~Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;~Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~Trim the autograft according to the size of the lesion;~Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;~Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
79974107|NCT03342820|Procedure|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
79974108|NCT04851522|Drug|Di-Dak-Sol|Topical solution applied externally.
79308018|NCT04863105|Drug|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
79478506|NCT05815186|Drug|Ladarixin|Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
79478507|NCT05814640|Drug|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
79478508|NCT05814640|Drug|Sertraline|Commonly used oral antipsychotics intervention therapy.
79478509|NCT05814640|Drug|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
79478510|NCT05814640|Drug|Duloxetine|Commonly used oral antipsychotics intervention therapy.
79974109|NCT04851522|Other|White Petrolatum|Topical ointment applied externally
79308019|NCT02179918|Drug|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
79308020|NCT02179918|Drug|MK-3475|2 mg/kg q3wks, IV
79308021|NCT03233321|Other|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
79308022|NCT03233321|Other|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
79308023|NCT04868253|Drug|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
79308024|NCT04486157|Drug|IN-A012|The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
79308025|NCT04486157|Drug|Akynzeo 300Mg-0.5Mg Capsule|The subjects will be administrated Akynzeo by Orally with water.
79308026|NCT02452073|Other|Thyroid function tests|
79319173|NCT02973685|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
79319174|NCT02919969|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
79974110|NCT03331120|Device|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
79974111|NCT03512275|Drug|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
79974112|NCT03809897|Drug|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
79974113|NCT03809897|Drug|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
79319175|NCT02905812|Other|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
79319176|NCT02840656|Other|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
79319177|NCT02840656|Other|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
79974114|NCT02491918|Procedure|cataract surgery|cataract surgery in children
79319178|NCT02837263|Radiation|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
79974115|NCT02491918|Procedure|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
79319179|NCT02837263|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
79319180|NCT02729350|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
79319181|NCT02729350|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
79319182|NCT02694055|Other|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
79319183|NCT02694055|Other|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
79319184|NCT02694055|Other|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
79478511|NCT05814640|Drug|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
79478512|NCT05814640|Drug|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
79478513|NCT05814640|Drug|Olanzapine|Commonly used oral antipsychotics intervention therapy.
79478514|NCT05814640|Behavioral|GCBT|Commonly used intervention therapy of psychotherapy.
79478515|NCT05810597|Drug|Tirzepatide|Administered SC
79478516|NCT05810597|Device|Test|Used to administer tirzepatide SC
79478517|NCT05810597|Device|Reference|Used to administer tirzepatide SC
79490340|NCT03728348|Diagnostic Test|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
79974116|NCT02491996|Behavioral|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
79974117|NCT03809195|Behavioral|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
79974118|NCT03473197|Drug|Diacerein 1% ointment|During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
79319185|NCT02694055|Other|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
79319186|NCT02694055|Other|Training of primary health centre staff|"Health center staff will receive targeted training in~Integrated management of childhood illness~Diagnosis and treatment of simple and severe cases of malaria~Helping babies breathe~Managing post-partum haemorrhage~Gestational dating using frontal height, last menstrual period and ultrasound~Family planning counselling and administration of long-acting contraceptives~Pharmacy stock management~Health center management"
79319187|NCT02416622|Biological|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
79974119|NCT02493556|Device|LLLT before muscle damage|
79974120|NCT02493556|Device|Placebo LLLT before muscle damage|
79319188|NCT02352883|Procedure|Magnetic Resonance Imaging|Undergo MRI
79319189|NCT02352883|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy
79490341|NCT03728348|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
79974121|NCT02493556|Device|LLLT after muscle damage|
79974122|NCT02493556|Device|Placebo LLLT after muscle damage|
79974123|NCT01560299|Drug|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
79974124|NCT01560299|Drug|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
79974125|NCT01560299|Drug|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
79974126|NCT02491762|Procedure|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
79974127|NCT03511105|Drug|GSK2798745|GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
79974128|NCT03511105|Drug|Placebo|Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
79490342|NCT02665988|Device|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
79974129|NCT03511105|Drug|Lipoplysaccharide from Escherichia Coli|LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
79974130|NCT03511105|Drug|Saline|Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
79319190|NCT02352883|Procedure|Therapeutic Surgical Procedure|Undergo wide local excision
79319191|NCT02352883|Radiation|Radiation Therapy|Undergo radiation therapy
79319192|NCT02352883|Drug|Endocrine Therapy|Undergo endocrine therapy
79319193|NCT02352883|Other|Quality-of-Life Assessment|Ancillary studies
79319194|NCT02352883|Other|Laboratory Biomarker Analysis|Correlative studies
79319195|NCT02352883|Other|Cytology Specimen Collection Procedure|Correlative studies
79319196|NCT02270632|Drug|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
79319197|NCT02270632|Drug|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
79490343|NCT02665988|Device|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
79644375|NCT05942430|Procedure|Autologous iliac osteoperiosteal transplantation|"Operating steps:~Arthroscopic examination of the size and location of the talar osteochondral lesion;~Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.~Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;~Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
79974131|NCT03811379|Drug|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
79319198|NCT02270632|Drug|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
79319199|NCT01891344|Drug|Oral rucaparib|600 mg BID
79319200|NCT01399138|Dietary Supplement|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
79644376|NCT05939024|Other|Muscle Energy Technique plus Conventional Physical Therapy|Post-Isometric Relaxation of the Muscle Energy Techniques will be applied to Spinal Stabilizers and Mechanoreceptors. Hold time will be 7 seconds with 5 seconds rest between two performance x 3 times /session. Whereas, Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
79319201|NCT01188096|Drug|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
79644377|NCT05939024|Other|Conventional Physical Therapy|Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
79644378|NCT05922527|Procedure|Combined regenerative technique|Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
79490344|NCT03726164|Device|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
79319202|NCT01094691|Procedure|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
79490345|NCT03726164|Device|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
79644379|NCT05922527|Procedure|Open flap debridement|Open flap debridement
79319203|NCT01005420|Dietary Supplement|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
79644380|NCT05911217|Drug|CT041 autologous CAR T-cell injection|Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
79319204|NCT01005420|Dietary Supplement|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
79974132|NCT03342742|Behavioral|Weight Loss|Weight loss behavioral intervention via one of two strategies.
79974133|NCT03807869|Procedure|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
79974134|NCT03807323|Behavioral|Lifestyle counselling and exercise|"The program consists of:~Instructor-led training twice a week,~One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
79319205|NCT00632853|Radiation|Standard Radiation Dose Therapy|45 Gy
79478518|NCT05806099|Drug|MBS303|"Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg ~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7"
79319206|NCT00632853|Drug|cisplatin|IV
79478519|NCT05804240|Diagnostic Test|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
79478520|NCT05804084|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
79478521|NCT05804084|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
79478522|NCT05799703|Device|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
79478523|NCT05799703|Other|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
79478524|NCT05798507|Drug|Avutometinib|Given PO
79319207|NCT00632853|Drug|etoposide|IV
79478525|NCT05798507|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
79478526|NCT05798507|Drug|Defactinib|Given PO
79974135|NCT03337828|Other|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
79478527|NCT05796206|Drug|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
79644381|NCT05895058|Device|Gastric bypass surgery with 2D 4K laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
79644382|NCT05895058|Device|Gastric bypass surgery with 3D HD laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
79644383|NCT05885594|Drug|[18F]NOS|[18F]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as [18F]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
79974136|NCT03337828|Other|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
79974137|NCT03510715|Drug|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
79974138|NCT03510715|Drug|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
79319208|NCT00632853|Radiation|High Radiation Dose Therapy|70 Gy
79319209|NCT00632853|Drug|carboplatin|IV
79974139|NCT03510715|Drug|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
79319210|NCT00579826|Drug|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
79319211|NCT00579826|Drug|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
79319212|NCT00106691|Drug|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
79319213|NCT00106691|Drug|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
79319214|NCT04089137|Behavioral|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
79478528|NCT05796206|Drug|placebo|An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
79478529|NCT05794243|Drug|LY3493269|Administered orally.
79644384|NCT05880758|Behavioral|Intermittent Short Sleep (ISS)|Restricted sleep duration of <5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
79644385|NCT05880758|Behavioral|Social Jetlag (SJL)|2-hour delayed sleep timing.
79644386|NCT05880758|Behavioral|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
79974140|NCT03510715|Drug|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
79478530|NCT05792306|Device|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
79644387|NCT05880459|Drug|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
79808505|NCT05344885|Behavioral|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q&A section that contains frequently asked questions.
79974141|NCT03510715|Drug|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
79974142|NCT03510715|Drug|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
79319215|NCT04004429|Drug|50 mg AP1189|50 mg AP1189 powder in bottle
79319216|NCT04004429|Drug|AP1189|100 mg AP1189 powder in bottle
79319217|NCT04004429|Drug|Placebo|Placebo powder in bottle
79319218|NCT03826901|Drug|delgocitinib|Cream for topical application
79319219|NCT04590443|Other|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
79319220|NCT03476759|Procedure|Tubal adhesiolysis|125 patients will undergo tubal adhesiolysis or tuboplasty
79974143|NCT03510715|Drug|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
79974144|NCT03510715|Drug|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
79974145|NCT03510715|Drug|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
79974146|NCT03510715|Drug|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
79974147|NCT03510715|Drug|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
79974148|NCT03510715|Drug|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
79974149|NCT03815279|Drug|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
79319221|NCT03476759|Drug|IVF/ICSI|125 patients will undergo IVF-ICSI procedures.
79319222|NCT04582643|Behavioral|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
79478531|NCT05792306|Device|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
79478532|NCT05789004|Procedure|Tooth Bleaching with Whiteness HP Automixx 35%|"Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~Prophylaxis with a Robson brush and prophylactic paste;~Application of lip balm on the patient's lips;~Placement of the labial retractor;~Application of the gingival barrier;~Application of Whiteness HP Automixx 35% whitening gel;~In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
79478533|NCT05789004|Procedure|Tooth Bleaching with Whiteness HP Automixx 6%|"Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~Prophylaxis with a Robson brush and prophylactic paste;~Application of lip balm on the patient's lips;~Placement of the labial retractor;~Application of the gingival barrier;~Application of Whiteness HP Automixx 6% whitening gel;~In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
79974150|NCT03815279|Drug|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
79478534|NCT05779449|Dietary Supplement|Prebiotics and Probiotics supplementation|"From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose)."
79478535|NCT05779449|Dietary Supplement|Placebo supplementation|1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.
79974151|NCT03815279|Drug|Dexamethasone|Dexamethasone will be administered weekly
79974152|NCT02498548|Behavioral|Trained SCI Knee or Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
79974153|NCT03342508|Device|Fetal Pillow|see arm description
79974154|NCT03814733|Drug|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
79319223|NCT04576325|Drug|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
79319224|NCT04576325|Drug|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
79974155|NCT03814733|Drug|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
79974156|NCT03814733|Drug|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
79974157|NCT03814733|Drug|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
79974158|NCT03814733|Drug|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
79319225|NCT05231993|Procedure|Conization|A cone biopsy to remove abnormal tissue.
79319226|NCT05231993|Procedure|Colposcopy|"Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~Colposcopy after 12 months if the first colposcopy and biopsies are normal~Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
79808506|NCT05344885|Behavioral|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
79974159|NCT03814733|Drug|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
79974160|NCT03721627|Drug|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
79644388|NCT05877222|Drug|Daridorexant 10 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
79319227|NCT05223257|Other|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
79319228|NCT04534361|Other|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
79319229|NCT03390491|Behavioral|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
79319230|NCT03390491|Behavioral|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
79808507|NCT05332236|Diagnostic Test|Parent-Adolescent Communication Scale (questionnaire)|Observational psychometric validation study
79808508|NCT05324449|Drug|Cannabidiol 100 MG/ML|pharmaceutical grade cannabidiol
79808509|NCT05315440|Other|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
79974161|NCT02498158|Device|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~anatomical scan according to standard protocol~functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
79478536|NCT05779449|Procedure|peripheral blood withdrawal|40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.
79478537|NCT05779449|Procedure|Transcranial Magnetic Stimulation (TMS)|Intermittent theta burst stimulation (iTBS) protocol
79644389|NCT05877222|Drug|Daridorexant 25 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
79974162|NCT03806855|Diagnostic Test|Bladder diary|3-day bladder diary
79974163|NCT02498080|Procedure|DEB PTA|paclitaxel drug eluting balloon PTA
79974164|NCT02498080|Procedure|Standard PTA|Standard PTA
79974165|NCT03508843|Behavioral|interactive virtual presence|installing the car seat with advice via interactive virtual presence
79974166|NCT03811223|Drug|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
79308027|NCT02452229|Other|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
79308028|NCT04862637|Procedure|pull through group|pull through method
79308029|NCT04862637|Procedure|mandibular-lip split group|traditional mandibular-lip split method
79308030|NCT03224273|Other|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
79308031|NCT04868097|Procedure|cervix biopsy|large loop electrosurgical cervix biopsy
79308032|NCT02153788|Drug|Temazepam|Temazepam 15 mg orally at bedtime
79308033|NCT02153788|Drug|Placebo|
79308034|NCT03224117|Drug|DWJ211|inject the Drug into submental fat via subcutaneous
79974167|NCT03811223|Drug|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
79319231|NCT03126617|Biological|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
79319232|NCT04422743|Dietary Supplement|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
79319233|NCT04421417|Procedure|Microfracture + Standard Arthroscopic Rotator Cuff Repair|drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair
79478538|NCT05773521|Procedure|SILAP (single incision laparoscopic appendectomy)|Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
79478539|NCT05770271|Device|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild senile groin eczema, neurodermatitis and psoriasis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
79478540|NCT05770258|Device|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild periodontitis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
79478541|NCT05770245|Device|The novel electrolyzed water spray|The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
79478542|NCT05766930|Device|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
79974168|NCT04915391|Diagnostic Test|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
79974169|NCT03508609|Biological|CLBS16|GCSF-mobilized autologous CD34 cells
79974170|NCT03639337|Dietary Supplement|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
79478543|NCT05765526|Device|A novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
79478544|NCT05764070|Device|non-invasive auricular vagus stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
79478545|NCT05764070|Device|Placebo Non Invasive Vagus Stimulation|Placebo Non Invasive Vagus Stimulation
79974171|NCT03508193|Other|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
79974172|NCT03723031|Drug|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
79319234|NCT04421417|Procedure|Standard Arthroscopic Rotator Cuff Repair|Standard Arthroscopic Rotator Cuff Repair
79319235|NCT05403515|Other|foot massage|foot massage
79319236|NCT05403515|Other|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
79808510|NCT05315440|Other|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
79808511|NCT05309915|Drug|STP707|STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
79308035|NCT03224117|Drug|Normal saline|inject the Drug into submental fat via subcutaneous
79308036|NCT04862793|Device|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
79308037|NCT04862793|Device|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
79308038|NCT04862559|Device|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
79308039|NCT02451761|Biological|Blood sampling|
79308040|NCT04867629|Dietary Supplement|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
79308041|NCT04867629|Dietary Supplement|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
79308042|NCT03224429|Other|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
79308043|NCT03224429|Other|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
79308044|NCT04862403|Procedure|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
79308045|NCT03224039|Drug|Sufentanil|Intranasal for one dose (experimental)
79308046|NCT03224039|Drug|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
79308047|NCT03224039|Drug|Morphine|intravenous push for one dose (active comparator)
79308048|NCT04862091|Drug|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
79308049|NCT04862091|Drug|ZYTIGA®|ZYTIGA®
79308050|NCT03119675|Device|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
79308051|NCT03119675|Device|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
79308052|NCT04873635|Other|Implant support prostheses|Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
79308053|NCT04485143|Device|Wisdom bracelet|routine medical
79308054|NCT03119441|Device|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
79308055|NCT03119441|Device|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
79308056|NCT03043833|Behavioral|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:~Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~Lesson 2 presents different strategies to generate realistic cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
79308057|NCT03223961|Drug|EPREX|60 000 U/week for at least 12 weeks
79644390|NCT05869552|Other|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
79644391|NCT05869552|Other|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
79319237|NCT05140421|Behavioral|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
79478546|NCT05763290|Other|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
79644392|NCT05864417|Other|Sunscreen Color tone 2.0|Participants will topically apply sunscreen color tone 2.0.
79644393|NCT05864417|Other|Sunscreen Color tone 3.0|Participants will topically apply sunscreen color tone 3.0.
79319238|NCT05127629|Procedure|Immediate implant placement|After tooth extraction, a dental implant is placed immediately.
79478547|NCT05759780|Device|Optical imaging of the tissues|OCT vibrography
79644394|NCT05856409|Diagnostic Test|68Ga-FAPI|[68Ga]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
79644395|NCT05856136|Drug|Fentanyl Injection|Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
79808512|NCT05304871|Drug|Cefazolin|infusion
79808513|NCT05304871|Other|saline|infusion
79974173|NCT03811067|Procedure|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
79808514|NCT05297604|Radiation|Non-Invasive Intravascular Laser Irradiation Of Blood|Participants will receive the treatment for 20 minutes. The laser to be used is infrared-red, power 100 mW ±20%, wavelength 660nm ±10 nm, energy parameter 60J, continuous application. The technique is not invasive, the irradiation point is by continuous and direct transcutaneous application to the radial artery by means of a bracelet that inserts the laser beam. One session will be performed.
79319239|NCT05127629|Procedure|Guided bone regeneration|After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.
79808515|NCT05297604|Radiation|Placebo application of laser|Simulated radiation. One session will be performed.
79974174|NCT03811067|Procedure|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
79319240|NCT05127629|Procedure|Wound closure with gelatin sponge|After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.
79319241|NCT05127629|Procedure|Wound closure with collagen matrix|After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
79319242|NCT02535221|Drug|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
79644396|NCT05853029|Combination Product|Combined shockwave therapy & conventional therapy , focused shockwave therapy& conventional therapy , conventional therapy|"The device used for management is from Storz-Medical company; Duolith-SD1 with focused and radial module.~- Conventional therapy in the form of eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007)."
79319243|NCT02535221|Drug|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
79644397|NCT05850390|Other|Respiratory-Responsive Vocal Biomarker application|"A smartphone app that allows participants to receive a respiratory-responsive vocal biomarker (RRVB) score by recording a 6-second held ahh vowel elicitation. The applications returns the RRVB score which has previously been validated to correspond to the likelihood that the user's voice is similar to those of people diagnosed with asthma. This study will examine if the RRVB scores correlate with respiratory function and symptoms in asthma patients."
79974175|NCT03722875|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
79974176|NCT03722875|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor
79974177|NCT03054350|Drug|Vadadustat|Daily oral dose
79974178|NCT03054350|Drug|Placebo|Daily oral dose
79974179|NCT04867733|Other|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
79974180|NCT03528577|Drug|Zero-dose|Treatment A
79319244|NCT01071941|Biological|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
79319245|NCT00000587|Procedure|erythropoietin, recombinant|
79319246|NCT05138237|Procedure|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
79319247|NCT05089253|Other|Dry Needling|"The subject will be in the supine position and receive dry needling. The first point will be at the medial femoral condyle of the knee joint line in vastus medialis muscles. The second point will be at the lateral femoral condyle of the knee joint line in vastus lateralis muscles. The third point will be above the base of the patella in the rectus femoris muscle. The fourth point will be 2cm above the third point in rectus femoris muscles. These four points were the most common places of trigger point at quadriceps muscles. Dry needling is affected on A-delta fibers. Therefore when superficial dry needling with a noxious stimulation leads to stimulation on A-delta fibers, the excitation remains almost 72 hours and gradually decreases.~The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks."
79319248|NCT05089253|Other|Kinesio tapping|"The subject will be in the supine position and receive Kinesio taping. The Kinesio tape application with no tension one Y strip with a length of 20 cm, an anchor of 2 cm.~The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks."
79319249|NCT04567121|Behavioral|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
79974181|NCT03528577|Drug|90 mcg of PROAIR® HFA|Treatment B
79319250|NCT04567121|Behavioral|standard intervention group|Conduct general health education without active management
79319251|NCT05083403|Device|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
79319252|NCT05083403|Other|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
79319253|NCT05081921|Drug|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
79319254|NCT05081921|Drug|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
79478548|NCT05758831|Drug|Perfusion of treatment Rituximab|Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
79478549|NCT05758831|Drug|Perfusion of treatment Ocrelizumab|Perfusion of treatment (Ocrevus®)
79478550|NCT05756426|Other|Prospective|Single arm, healthy adult volunteers for blood donation.
79478551|NCT05755971|Other|Combination taping|Elastic and rigid tapes applied together for six weeks
79644398|NCT05845632|Other|Treatment|Patients were treated with surgery, radiotherapy or surgery with postoperative radiotherapy.
79974182|NCT03528577|Drug|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
79974183|NCT03528577|Drug|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
79974184|NCT03796715|Diagnostic Test|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
79974185|NCT03796715|Diagnostic Test|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
79974186|NCT03626948|Drug|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
79644399|NCT05812300|Drug|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
79644400|NCT05806996|Drug|Magnesium|Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
79319255|NCT04492007|Behavioral|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
79319256|NCT05138159|Drug|Donafenib|Donafenib: 200mg po bid.
79478552|NCT05754580|Radiation|High Dose Brachytherapy|This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
79478553|NCT05754580|Radiation|Stereostatic Body Radiation Therapy|ultra-hypofractionation radiation therapy.
79644401|NCT05806996|Drug|Placebo|Equivalent volume of normal saline
79644402|NCT05788016|Behavioral|opioid taper|The participant will attempt to taper their opioid dose by ~50% during the 4-6 week preoperative period
79644403|NCT05769751|Other|Electronic medical record and hospital information system or other available resources|This is a non-interventional study. No study medication will be provided to the participants.
79319257|NCT05138159|Drug|S1|S-1 capsule: According to the body surface area <1.25m2 40mg/d, 1.25 ~ 1.5 m2 50 mg/d, > 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
79974187|NCT01303289|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
79974188|NCT01303289|Dietary Supplement|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
79974189|NCT05281055|Procedure|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
79974190|NCT05452226|Device|neuromuscular electrical stimulation (NMES)|Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
79974191|NCT03810989|Device|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
79974192|NCT03810989|Device|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
79319258|NCT04592159|Drug|Nabiximols|oromucosal spray
79319259|NCT04592159|Drug|Placebo|oromucosal spray
79319260|NCT05061485|Other|Sucrose|The participants consume A) water with 75 g sucrose
79319261|NCT05061485|Other|Sucrose + protein|The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
79319262|NCT05061485|Other|Sucrose + fat|The participants C) water with 75 g sucrose + approx. 100 kcal fat
79319263|NCT05138081|Other|PNF stretching|"Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion."
79644404|NCT05755048|Biological|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
79644405|NCT05755048|Biological|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
79644406|NCT05752994|Other|Training in the multisensory room environment|The children will start with the swing follow with the scheduled activities and tabletop activity. The session will end in the relaxation room such as bubble tube, fiberoptic cascade, fiberoptic carpet and aurora projector bundle while the therapist has the interactive communication with children
79319264|NCT05138081|Other|Stabilization|Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
79974193|NCT03810989|Device|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
79974194|NCT05432414|Drug|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
79644407|NCT05752994|Other|Home program|Home program
79644408|NCT05750199|Other|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
79974195|NCT05432414|Drug|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
79319265|NCT05137613|Other|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
79319266|NCT05137613|Other|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
79319267|NCT05137535|Other|Questionnaire|Family-based questionnaire
79490346|NCT03723980|Drug|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
79490347|NCT03723980|Drug|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
79490348|NCT02660528|Drug|Tocilizumab|Subcutaneous tocilizumab
79490349|NCT02633540|Radiation|IMRT Radiation|Radiation to Larynx
79644409|NCT05750199|Other|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course
79974196|NCT05432414|Drug|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
79974197|NCT03796403|Other|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
79974198|NCT03627182|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
79974199|NCT03627182|Drug|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
79974200|NCT01302977|Procedure|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
79808516|NCT05293314|Diagnostic Test|an exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant.
79974201|NCT03810833|Device|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
79974202|NCT00706654|Drug|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
79974203|NCT00706654|Drug|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
79808517|NCT05281978|Behavioral|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
79808518|NCT05281978|Behavioral|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
79808519|NCT05281406|Drug|Osimertinib|80 mg daily or reduced dose 40 mg daily
79808520|NCT05281406|Drug|Pemetrexed|500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
79808521|NCT05281406|Drug|Cisplatin|75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
79319268|NCT05137457|Other|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
79808522|NCT05281406|Drug|Carboplatin|AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
79808523|NCT05277350|Drug|SNIPR001|SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
79808524|NCT05277350|Drug|Placebo|Matching placebo
79808525|NCT05275582|Behavioral|CARE|"Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator"
79808526|NCT05265299|Drug|Aspirin 81mg|Aspirin 81mg once daily
79974204|NCT00706654|Drug|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
79974205|NCT00706654|Drug|Placebo depot|Placebo depot was supplied in lyophilized vials.
79319269|NCT05137457|Other|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
79319270|NCT05137145|Drug|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
79319271|NCT05137145|Drug|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
79319272|NCT05136911|Behavioral|SALT-Intervention|Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
79319273|NCT05121467|Other|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
79319274|NCT05121467|Other|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
79319275|NCT05121467|Other|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
79319276|NCT05121467|Other|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
79319277|NCT05306171|Behavioral|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
79319278|NCT05305937|Device|MRI scan|All patients will be scanned twice during the same MRI session, before and 2 hours after taking glucosamine orally. In addition to the CEST scans with glucosamine, patients will undergo MRI scans with the standard contrast agent of gadolinium. This procedure will be done following the CEST scan
79319279|NCT05305703|Other|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
79478554|NCT05754151|Behavioral|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
79478555|NCT05752916|Drug|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
79808527|NCT05265299|Drug|Aspirin 162 mg|Aspirin 162 mg once daily
79808528|NCT05265299|Drug|Aspirin 325mg|Aspirin 325mg once daily
79808529|NCT05262712|Device|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
79808530|NCT05262712|Other|Placebo Control|Devices mounted, no stimulation
79808531|NCT05256888|Behavioral|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
79808532|NCT05256888|Behavioral|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
79808533|NCT05255562|Procedure|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
79808534|NCT05255562|Drug|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
79974206|NCT00706654|Drug|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
79478556|NCT05752916|Drug|Antiplatelet Agents|Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.
79974207|NCT03811145|Biological|Tendoncel|Platelet lysate gel
79974208|NCT03811145|Other|Placebo control gel|Placebo control gel
79974209|NCT03471871|Drug|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
79974210|NCT03471871|Drug|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
79974211|NCT03471871|Drug|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
79808535|NCT05250414|Device|MED-EL Cochlear Implant System|Cochlear implant and audio processor
79974212|NCT03471871|Drug|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
79974213|NCT03471871|Drug|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
79974214|NCT04354922|Behavioral|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
79974215|NCT03627104|Dietary Supplement|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
79478557|NCT05752409|Drug|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
79319280|NCT05305703|Other|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
79319281|NCT05305625|Procedure|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
79808536|NCT05249036|Procedure|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
79319282|NCT05305625|Drug|standard therapy|received standardized treatment
79319283|NCT04938791|Other|Isometric activity|Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
79319284|NCT04457141|Combination Product|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
79319285|NCT05304845|Drug|DWP14012|Potassium-competitive acid blocker
79319286|NCT05304845|Drug|Aspirin|acetylsalicylic acid
79319287|NCT04407143|Diagnostic Test|IgG test|IgG+ blood test by ELISA method.
79319288|NCT04385927|Behavioral|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
79319289|NCT05304299|Dietary Supplement|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
79478558|NCT05752409|Drug|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
79478559|NCT05752409|Drug|Propofol|2mg•kg-1propofol for general anesthesia induction.
79808537|NCT05249036|Procedure|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
79808538|NCT05236075|Device|shearing wave collar|Collar inducing shearing wave to treat obstructive sleep disorders
79808539|NCT05233722|Other|Exercise|1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
79974216|NCT03627104|Dietary Supplement|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
79974217|NCT03627104|Dietary Supplement|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
79319290|NCT04924517|Behavioral|Extended Evening Fasting|Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
79319291|NCT04924517|Behavioral|Control|Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
79478560|NCT05749172|Other|Strength group|4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
79808540|NCT05233722|Procedure|Insulin infusion|2 hours of Euglycemic Hyperinsulinemic Clamp
79808541|NCT05233722|Drug|Placebo|Administration of 800 mg of calcium tablets
79974218|NCT03627104|Dietary Supplement|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
79319292|NCT05303597|Diagnostic Test|ultrasound-guided diagnostic nerve block with lidocaine|Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
79319293|NCT04892459|Biological|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
79319294|NCT04892459|Biological|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
79319295|NCT04890431|Drug|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
79319296|NCT04890431|Drug|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
79319297|NCT04881539|Dietary Supplement|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
79319298|NCT04854083|Drug|Semaglutide, 1.34 mg/mL|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
79319299|NCT04854083|Drug|Placebo|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
79319300|NCT05303441|Procedure|percutaneous coronary intervention|conventional coronary angiography
79319301|NCT03050879|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
79319302|NCT05303285|Drug|Secukinumab 300mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
79319303|NCT05303285|Drug|Secukinumab 150mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
79319304|NCT04288661|Procedure|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered
79478561|NCT05749172|Other|Controlled group|Two hours of parkour training for two days a week.
79808542|NCT05233722|Drug|Rapamycin|Administration of 16 mg of Rapamycin tablets
79974219|NCT04313153|Drug|Vadadustat|oral tablets
79974220|NCT04313153|Drug|Darbepoetin alfa|intravenous or subcutaneous solution
79319305|NCT04280939|Procedure|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
79319306|NCT04276571|Device|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
79974221|NCT03337750|Behavioral|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
79974222|NCT03804983|Device|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
79319307|NCT04831385|Behavioral|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
79319308|NCT04328441|Drug|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
79319309|NCT04328441|Drug|Placebo|Intracutaneously 0.1ml NaCl 0,9%
79319310|NCT05302739|Other|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
79319311|NCT05302661|Behavioral|re-education|Contact patients by phone or wechat and guide them
79319312|NCT04314713|Drug|Scopolamine Hydrobromide Trihydrate|Scopolamine Hydrobromide Trihydrate Intramuscular Injection
79319313|NCT05302193|Other|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
79319314|NCT05302193|Other|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
79319315|NCT05302193|Other|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
79319316|NCT04777253|Other|Biofeedback method|"Patients in the study group will participate in training with visual biofeedback, aimed to improve motor function of the arm. The exercise will be performed using a Biometrics device. The biofeedback training will be carried out for 30 minutes per day.~Health-resort based rehabilitation The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy."
79319317|NCT04777253|Other|Health-resort based rehabilitation|"The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy"
79319318|NCT04775771|Behavioral|Animal Assisted Practice|The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
79974223|NCT03804983|Device|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
79808543|NCT05233592|Device|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
79974224|NCT03330964|Other|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
79974225|NCT04312529|Other|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
79319319|NCT05302037|Biological|Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)|In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
79319320|NCT04121507|Drug|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
79319321|NCT04121507|Procedure|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
79808544|NCT05221892|Drug|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
79974226|NCT03337672|Drug|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
79974227|NCT03337672|Drug|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
79319322|NCT04121507|Diagnostic Test|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
79319323|NCT04121507|Diagnostic Test|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
79319324|NCT04762043|Device|MyoVoice|Person-centric AAC system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
79319325|NCT04762043|Device|Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
79808545|NCT05221892|Drug|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
79808546|NCT05216172|Drug|AZD1656|active drug
79808547|NCT05216172|Drug|Placebo|placebo
79808548|NCT05215847|Drug|ARD-101|Twice daily, oral administration
79974228|NCT03503591|Device|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
79974229|NCT04280393|Device|Colonoscopy procedure with endocuff|Colonoscopy procedure with the use of ENDOCUFF VISION
79974230|NCT03337516|Biological|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
79319326|NCT04261595|Other|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
79974231|NCT03337516|Genetic|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
79974232|NCT03330808|Other|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
79974233|NCT03330730|Other|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
79319327|NCT04261595|Behavioral|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
79319328|NCT04261595|Other|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
79319329|NCT04743167|Procedure|Surgery|Laparoscopic treatment of endometriotic lesions
79319330|NCT04743167|Procedure|IVF|Up to three completed cycles of IVF
79319331|NCT01449149|Radiation|Proton Therapy|
79808549|NCT05197348|Behavioral|Meaning-Centered Group Psychotherapy (MCP).|"The MCP program is divided into eight sessions:~Session1: Psychoeducation about Meaning in life, Sources of Meaning, etc. Session 2: Cancer illness and meaning. Session 3: Historical Sources of Meaning (the past) Session 4: Historical Sources of Meaning (present and future). Session 5: Attitudinal Sources of Meaning. Session 6: Creative Sources of Meaning. Session 7: Experimental Sources of Meaning. Session 8: End of psychotherapy, farewell, and facing the future with hope."
79319332|NCT00905957|Procedure|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
79974234|NCT03810599|Other|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
79319333|NCT00905957|Procedure|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
79319334|NCT04704479|Device|Russian current|For application of Russian current, 2 channels with 2 electrodes each will positioned on the oblique muscles and rectus abdominis motor points using wet spongy pads to enhance electrical activity. Russian current will be a carrier frequency 2500 Hz with frequency of 5 Hz for 5 minutes of muscular conditioning, 40 Hz for 10 minutes for training of slow contraction muscular fibers and 120 Hz for 5 minutes for training of fast contraction muscular fibers with On time (contraction time) 4 secs and Off time (relaxation time) 2 secs. The contraction phase will be at time of patient's expiration while relaxation will be at time of patient's inspiration
79478562|NCT05748457|Behavioral|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
79478563|NCT05748457|Behavioral|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock & Le Grange (2nd edition, 2015)."
79478564|NCT05746481|Drug|Tiragolumab|Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
79974235|NCT03810677|Device|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
79974236|NCT02497924|Drug|GBT440|GBT440 capsules followed by single dose of [C14] GBT440 oral suspension
79974237|NCT01303055|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
79974238|NCT01303055|Drug|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
79974239|NCT03810521|Biological|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
79319335|NCT04704479|Device|EMT|patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved
79319336|NCT04039763|Device|Dexcom G6|Realtime Continous Glucose Monitoring
79319337|NCT04039763|Device|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
79478565|NCT05746481|Drug|Atezolizumab|Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
79478566|NCT05746481|Drug|Pemetrexed|Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
79478567|NCT05746481|Drug|Carboplatin|Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.
79478568|NCT05738187|Procedure|local cryotherapy treatment|cryotherapy
79974240|NCT05484388|Device|SN2|Investigational device absorption level Normal
79974241|NCT05484388|Device|SP3|Investigational device absorption level Plus
79974242|NCT03796169|Behavioral|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
79974243|NCT03796169|Behavioral|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
79974244|NCT03796169|Behavioral|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
79319338|NCT03982043|Behavioral|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
79319339|NCT03982979|Device|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
79319340|NCT03948503|Procedure|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
79974245|NCT01957176|Drug|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
79319341|NCT03948503|Procedure|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
79319342|NCT03920189|Diagnostic Test|echocariographic ultrasound|left ventricular diastolic function description
79319343|NCT03867773|Behavioral|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
79319344|NCT03790397|Drug|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
79319345|NCT03780101|Diagnostic Test|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
79319346|NCT03800771|Device|Cycléo BRAU|Practice dual-task tests.
79319347|NCT03800771|Device|GAITRITE®|Routine practice dual-task tests.
79319348|NCT03428165|Other|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
79319349|NCT01171937|Drug|Risperidone|children get randomized to either placebo or active risperidone
79319350|NCT01171937|Drug|Placebo|Children get randomized to either placebo or risperidone
79319351|NCT03102905|Other|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
79319352|NCT03102983|Other|MRI functional|vowels records and MRI session
79319353|NCT05302349|Other|Core Exercise Group|"Core Exercise Group Procedure:~Weeks 1-4 (Five days a week)~Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Core stabilization exercise :~Active pelvic floor exercise (supine position)~Bridge exercise (supine position)~Back Extension and Ball Back Extension exercises (prone position)~Abdominal and Oblique Crunch exercises (supin position)~Leg lift exercise (prone position)~Plank and Side Plank exercise~Superman exercise~Weeks 5-8 (Three days a week)~Stretching exercises and strengthening exercises for low back pain.~Core stabilization exercise :~The same exercises as for Weeks 1-4 will perform."
79319354|NCT05302349|Other|Routine Therapy Group|"Routine Therapy Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Weeks 5-8 (Three days a week)~1.Stretching exercises and strengthening exercises for low back pain."
79319355|NCT04483349|Other|Survey Administration|Complete survey
79319356|NCT03350711|Other|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~Health history and physical examination~Urinalysis~Urine or serum pregnancy test~Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~Electrocardiogram (EKG or ECG)~Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
79319357|NCT00887783|Drug|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
79319358|NCT00887783|Radiation|66 Gy/33F|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
79319359|NCT00887783|Radiation|60 Gy/30F|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
79319360|NCT03287843|Procedure|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
79319361|NCT03287843|Procedure|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
79319362|NCT02156609|Device|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
79319363|NCT02047097|Drug|dimethyl fumarate|Provided under routine clinical care
79319364|NCT01125371|Behavioral|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
79319365|NCT01125371|Behavioral|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
79319366|NCT01125371|Behavioral|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
79644410|NCT05731999|Device|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
79644411|NCT05716191|Other|Naturally different iodine levels exposure|A cross-sectional survey of thyroid disease in elderly people in areas with different iodine nutrition backgrounds
79644412|NCT05711849|Biological|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.|Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
79644413|NCT05711849|Procedure|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).|These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
79644414|NCT05706779|Drug|Encorafenib Oral Capsule + Cetuximab|Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.
79644415|NCT05706623|Drug|Apraglutide|Single dose of apraglutide 5mg.
79974246|NCT03810443|Diagnostic Test|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
79319367|NCT03199547|Drug|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
79478569|NCT05728723|Device|Android Application|Android Application for 3 months
79478570|NCT05728723|Behavioral|Pharmacy education|Pharmacy education in hypertensive patients
79319368|NCT03199547|Drug|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
79478571|NCT05726487|Behavioral|ACTION Intervention|Participants in the ACTION Intervention arm of the study will have group sessions, physical activity self-monitoring, text-based support for goal setting. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
79644416|NCT05694559|Behavioral|Genetic Testing and Counseling|Participants will complete testing
79319369|NCT03180905|Device|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
79319370|NCT03180905|Device|ImPACT Online|ImPACT Online will be administered at 2 time points.
79319371|NCT04042571|Device|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
79319372|NCT04038593|Other|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
79319373|NCT04038593|Device|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
79319374|NCT00416351|Drug|clofarabine|
79319375|NCT03104777|Behavioral|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
79319376|NCT03105011|Behavioral|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
79478572|NCT05726487|Other|Education Control|Participants in the Education Control arm of the study will receive and individual asthma education session and text messages related to asthma education. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
79319377|NCT03965273|Behavioral|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
79478573|NCT05725395|Behavioral|Virtual Reality|During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.
79478574|NCT05725395|Behavioral|Standard of Care|For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
79478575|NCT05721937|Drug|Abrocitinib|taken by mouth
79478576|NCT05715411|Other|Placebo with light therapy glasses|Placebo
79478577|NCT05715411|Other|light therapy with light therapy glasses|light therapy
79974247|NCT03337438|Other|Personalized Feedback Intervention with Values|The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
79644417|NCT05694559|Behavioral|Screening Form|Participants will complete forms with demographics and history
79808550|NCT05197348|Behavioral|Cognitive Behavioral Psychotherapy (CBT).|"The CBT divided into eight sessions:~Session1: Presentation of psychotherapy, establishing the goals of psychotherapy. Presentation of the participants. Updated information about psychological consequences of cancer.~Session 2. Increase in enjoyable activities. Behavioral activation. Progressive muscle relaxation training. Slow breathing training.~Session 3. Cognitive model of coping with cancer. Psychoeducation on negative thoughts. Training in detecting negative thoughts. Presentation of cognitive distortions Session 4. Training in cognitive restructuring techniques. Session 5. Training in problem-solving skills. Session 6. Being aware of participants needs. Self-care. Assertiveness skills training.~Session 7. Setting goals for the future. Session 8. Summary, relapse prevention, and end of psychotherapy."
79319378|NCT03965273|Behavioral|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
79319379|NCT03102827|Drug|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
79319380|NCT03102827|Other|Placebo|Ambient air without high-flow therapy administered during first night
79319381|NCT03102515|Drug|USG-TAP block|
79319382|NCT03102515|Drug|CIC|
79478578|NCT05714384|Device|CeraSeal (Calcium Silicate-based Root Canal Sealer)|A calcium silicate-based root canal sealer will be used in cases requiring root canal retreatment.
79808551|NCT05194306|Drug|Perla® Cold Preservation solution|Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
79319383|NCT03102749|Other|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
79644418|NCT05658393|Behavioral|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
79644419|NCT05654857|Diagnostic Test|PCR test in the stool|Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
79974248|NCT03337438|Other|Personalized Feedback Intervention Traditional|This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
79319384|NCT03947333|Other|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
79319385|NCT03938831|Drug|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
79478579|NCT05711238|Other|Robotic rehabilitation|In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
79478580|NCT05711238|Other|Conventional rehabilitation|Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
79974249|NCT03636048|Drug|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
79319386|NCT03938831|Drug|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
79319387|NCT03875183|Drug|INL1|Capsules
79319388|NCT03875183|Other|Placebo|Capsules
79319389|NCT03872375|Dietary Supplement|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
79478581|NCT05707247|Device|software|"The experimental medical device is a prototype software. It is a patient interface.~The device comes in the form of a smartphone with a touch screen"
79478582|NCT05706766|Behavioral|PARE|Aerobic and resistance exercise program via Zoom platform.
79478583|NCT05706766|Behavioral|Waitlist Control Group|Normal Activities.
79478584|NCT05701644|Drug|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
79319390|NCT03872375|Behavioral|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
79319391|NCT03102671|Other|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
79319392|NCT03102671|Other|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
79319393|NCT02431091|Other|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
79319394|NCT03104621|Drug|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
79319395|NCT03104621|Drug|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
79319396|NCT03104387|Other|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
79319397|NCT03104387|Other|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
79808552|NCT05136105|Behavioral|Preventive Narrative Exposure Therapy (PreNET) family intervention|"Sessions: (1) Participants are invited to narrate the event in detail, in line with the protocol of the trauma-focused intervention NET. Furthermore, participants and caregiver(s) will receive a brief psychoeducation about expected symptoms and supportive behaviour in the aftermath of sexual violence.~(2) Two weeks after session 1, the second session focuses on caregiver only and their emotions. The narration of the event is read to the caregiver(s). Caregiver(s) receive assistance regulating their emotions. They receive psychoeducation on how to support their child.~(3) Two weeks after the second session, the children assisted by their caregivers lay a chronological lifeline of their most important life experiences. The chronology and the context of the traumatic events is reinforced. The narration of the sexual abuse is read again to the child and the caregiver(s). The caregiver(s) are encouraged to support emotionally their child during the renarration."
79319398|NCT03104465|Behavioral|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
79319399|NCT03102359|Drug|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
79319400|NCT03102359|Device|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
79319401|NCT03104231|Other|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
79319402|NCT03104309|Device|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
79808553|NCT05128019|Behavioral|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
79808554|NCT05107869|Other|High Saturated Fat|High saturated fat meal
79808555|NCT05096234|Drug|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
79808556|NCT05081804|Dietary Supplement|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
79808557|NCT05045794|Device|VitaSmart Liver Machine Perfusion System|Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
79319403|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses|0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
79319404|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses|0.5mL intramuscular dose - 2 doses (0 and 6 months)
79319405|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose|0.5mL intramuscular dose - 1 doses (0 months)
79319406|NCT02281175|Behavioral|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
79478585|NCT05701644|Drug|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
79478586|NCT05701644|Drug|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
79319407|NCT02281175|Behavioral|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
79319408|NCT02102477|Procedure|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
79319409|NCT02102477|Other|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
79478587|NCT05701644|Drug|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
79319410|NCT04482413|Drug|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
79478588|NCT05701644|Drug|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
79974250|NCT03636048|Drug|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
79319411|NCT04482413|Drug|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
79478589|NCT05701644|Drug|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
79478590|NCT05701644|Drug|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
79974251|NCT03804047|Other|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
79974252|NCT03527173|Biological|S.sonnei vaccine|Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
79974253|NCT03527173|Drug|Placebo|Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
79319412|NCT03103997|Procedure|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
79319413|NCT04435223|Biological|biological assays in particular on the lipid metabolism|bioassays carried out on samples already collected and conserved
79319414|NCT04412603|Other|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
79478591|NCT05701644|Drug|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
79478592|NCT05701644|Drug|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
79478593|NCT05694403|Other|Survey|Questionnaire
79478594|NCT05692960|Other|Hypnotic Relaxation Intervention (HRI)|HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
79478595|NCT05692960|Device|Vulvovaginal Atrophy (VVA)|VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
79478596|NCT05678010|Drug|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
79478597|NCT05678010|Radiation|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
79974254|NCT03527173|Biological|S. sonnei 53G challenge strain|Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
79974255|NCT01952262|Other|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
79974256|NCT04254302|Other|WECARE web platform|The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
79319415|NCT03103685|Drug|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
79974257|NCT04778436|Dietary Supplement|T7082|Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
79974258|NCT04718922|Drug|Chlorhexidine Gluconate 0.12 % Mouthwash|Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
79974259|NCT05344196|Behavioral|Modified EAET for prediabetes|Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
79319416|NCT00999011|Procedure|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
79319417|NCT00999011|Procedure|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
79319418|NCT03748433|Device|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
79319419|NCT03748433|Device|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
79319420|NCT03103529|Other|Active Rehabilitation|
79319421|NCT03103607|Diagnostic Test|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
79319422|NCT03103607|Diagnostic Test|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
79319423|NCT00418301|Other|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
79319424|NCT03101969|Other|Call|not called, not reached, and spoken to
79974260|NCT03722641|Other|Bread reference|Commercially available white wheat bread
79974261|NCT03722641|Other|Product 1: Milk|Developed reference product based on milk
79974262|NCT03722641|Other|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
79974263|NCT03722641|Other|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
79974264|NCT03722641|Other|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
79974265|NCT01303601|Drug|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
79974266|NCT01303601|Drug|Starch|
79319425|NCT03103451|Drug|BCD-121|
79319426|NCT03103451|Other|Placebo|
79319427|NCT03103295|Biological|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
79319428|NCT05103215|Drug|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
79319429|NCT05103215|Drug|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
79478598|NCT05669521|Drug|TK-112690|TK112690 treatment Post 5-FU chemotherapy
79478599|NCT05669521|Drug|Placebo|Placebo treatment Post 5-FU chemotherapy
79974267|NCT01330992|Other|Ocular light or darkness exposure|Ocular light or darkness exposure
79808558|NCT05045794|Other|Static cold storage|Donor liver retrieval and preservation using standard of care cold storage methods
79808559|NCT05044936|Drug|Cannabidiol Oil|"The dose that will be used for each administration of CBD will be 0.5mg/kg of body mass. As there are no recommendations for CBD from the FDA or through previous research in humans, and especially for CBD cream, the dosage is based on the United Kingdom's governing body recommending maximal amounts of CBD ingestion being 1 mg/kg per day. Further, the practical amount that companies recommend is anywhere from a pea size to a handful, which can range from high and low amounts. Using 0.5mg/kg of body mass allows for a moderate use of the lotion, as well as leaving extra quantities throughout the day should people want to use CBD outside of their post-workout recovery strategies outside of a laboratory setting. To convert the amount of CBD to the amount of lotion, we will divide the amount of CBD (0.5 mg/kg) by 4.85 (the amount of mg of CBD per gram of lotion). This will calculate the amount (in grams) of lotion each participant will receive."
79808560|NCT05044936|Other|Resistance Exercise|Participants will complete eccentric-based leg press (4-s lowering phase and 1-s upward phase) for 10 sets of 8 repetitions at 70% 1RM in order to induce muscle damage using a leg press machine. Three minutes of rest will be permitted between sets. Following the 10th leg press, participants will complete 4 sets of 20 consecutive plyometric lunges using only their body weight. Two minutes of rest will be permitted between sets. The muscle damaging protocol will be done upon completion of the 4th set of plyometric lunges.
79808561|NCT05021900|Drug|Tenalisib|Tenalisib will be administered 800mg BID, orally
79974268|NCT00707980|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
79974269|NCT03795935|Other|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
79974270|NCT04970459|Biological|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
79319430|NCT03656159|Behavioral|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
79319431|NCT03656159|Behavioral|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
79319432|NCT05001815|Device|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
79319433|NCT05001815|Device|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
79319434|NCT02644967|Drug|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
79319435|NCT02644967|Drug|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
79319436|NCT04435535|Procedure|PEP|Positive expiratory pressure 10 cmH2O 15 min
79319437|NCT04964453|Drug|BI 474121|BI 474121
79319438|NCT04964453|Drug|Placebo|Placebo matching BI 474121
79319439|NCT04945109|Other|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
79974271|NCT05330468|Device|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
79974272|NCT01304537|Drug|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
79974273|NCT01304537|Drug|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
79974274|NCT01304537|Drug|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
79974275|NCT03506425|Drug|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
79319440|NCT04945109|Other|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
79478600|NCT05667233|Other|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
79478601|NCT05661955|Drug|BGB-A445|administered intravenously
79478602|NCT05661955|Drug|Tislelizumab|administered intravenously
79974276|NCT03051620|Drug|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
79974277|NCT03337360|Dietary Supplement|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
79974278|NCT03337360|Other|Placebo|Inactive ingredients, placebo
79974279|NCT02861183|Device|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
79478603|NCT05658016|Drug|TK-112690|TK112690 treatment Pre & Post Radiation
79974280|NCT02861183|Device|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
79974281|NCT05290454|Other|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
79478604|NCT05658016|Drug|Placebo|TK112690 Placebo treatment Pre & Post Radiation
79808562|NCT05021900|Drug|Tenalisib|Tenalisib will be administered 1200mg BID, orally
79478605|NCT05657938|Device|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
79478606|NCT05657938|Other|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
79478607|NCT05654701|Drug|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
79478608|NCT05648773|Behavioral|Messaging|Booster reminder message
79644420|NCT05645640|Combination Product|Village doctor-led tailored health management|"Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life."
79478609|NCT05648773|Behavioral|Financial Incentive|Financial Incentive for getting boosted within 2-weeks of the message
79478610|NCT05648773|Other|Placebo|Treatment as usual; no additional message and no incentive.
79808563|NCT05014646|Drug|Cholestyramine|Given PO
79808564|NCT05014646|Drug|Leflunomide|Given PO
79478611|NCT05648630|Dietary Supplement|PB125|PB125 is a naturally-derived plant-based supplement that activates the Nuclear Factor Erythroid-2-like 2 (Nrf2) system to stimulate induction of endogenous antioxidants and anti-inflammatory pathways.
79478612|NCT05648630|Dietary Supplement|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
79478613|NCT05648630|Behavioral|Exercise Rehabilitation|A 12-week treadmill based supervised rehabilitation
79478614|NCT05646446|Behavioral|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
79478615|NCT05646082|Drug|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
79478616|NCT05645016|Behavioral|COEST|Adapted version of our COEST training, targeting Black church members.
79478617|NCT05640271|Drug|Tocilizumab|Tocilizumab 80 mg IV dose (one time per patient)
79478618|NCT05633862|Drug|BI 1015550|BI 1015550
79478619|NCT05632861|Drug|HuHuangLianzonggan capsule|HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
79478620|NCT05632861|Drug|HuHuangLianzonggan capsule placebo|HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
79478621|NCT05632133|Drug|Lacosamide 50 MG Oral Tablet|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
79319441|NCT04896749|Other|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
79478622|NCT05632133|Drug|Ibuprofen 400 mg|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
79478623|NCT05628597|Device|Fos Biomedical patch product|Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
79478624|NCT05628597|Device|Fos Biomedical patch product:placebo|Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
79478625|NCT05624047|Behavioral|Breastfeeding education using hybrid simulation method|In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
79478626|NCT05624047|Behavioral|Routine verbal breastfeeding education|Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
79478627|NCT05621811|Drug|Naronapride|Naronapride is a 5HT-4 agonist
79478628|NCT05621811|Drug|Placebo|Placebo
79478629|NCT05616858|Behavioral|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
79478630|NCT05615597|Procedure|Para-discal injection of corticoid|In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
79478631|NCT05615233|Behavioral|TACAD|"Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~2 sub-ethnic specific social media sites;~interactive online educational modules;~online resources; and~a VR component based on A Walk Through Dementia (WTD)"
79319442|NCT04896749|Other|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
79319443|NCT04890821|Device|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
79478632|NCT05615233|Behavioral|Alzheimer's Association website|The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
79478633|NCT05606380|Drug|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
79319444|NCT03594383|Device|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
79478634|NCT05605340|Behavioral|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
79478635|NCT05603429|Diagnostic Test|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
79478636|NCT05602961|Drug|GLB-COV2-043|COVID-19 vaccine, administered as a booster
79478637|NCT05602961|Drug|BNT162b2/COMIRNATY®|active control
79478638|NCT05594238|Behavioral|Telephone Engagement|Brief phone session with a study counselor.
79478639|NCT05594238|Behavioral|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
79478640|NCT05594238|Behavioral|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
79478641|NCT05593796|Behavioral|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
79478642|NCT05586776|Drug|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
79478643|NCT05586776|Drug|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
79808565|NCT04995666|Device|Phonak Audeo hearing aid|Rechargeable hearing aid
79644421|NCT05641532|Behavioral|Physical activity behavioral intervention in persons newly diagnosed with MS|"The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program."
79644422|NCT05631834|Procedure|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
79478644|NCT05586776|Drug|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
79644423|NCT05631834|Procedure|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
79808566|NCT04971954|Other|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
79808567|NCT04971954|Other|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
79974282|NCT03803189|Behavioral|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
79478645|NCT05586776|Drug|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
79478646|NCT05584800|Biological|ZGGS18 for Injection|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
79478647|NCT05584800|Biological|ZGGS18 for Injection|Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
79478648|NCT05584137|Drug|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
79478649|NCT05584137|Drug|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
79478650|NCT05583019|Device|GENEActiv Accelerometry Device|a watch like wearable sensor
79478651|NCT05583019|Device|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
79478652|NCT05583019|Device|Apple Watch Accelerometry Device|a watch like wearable sensor
79974283|NCT05050760|Drug|Camrelizumab|Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
79974284|NCT05050760|Drug|DCF|DCF:Oxaliplatin (85mg/ m^2, IV D1,Q3W.Docetaxel: 60 mg/m^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA<1.25^2,40 mg/time,1.25^2<BSA<1.5^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
79974285|NCT02498002|Device|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
79974286|NCT02498002|Other|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
79478653|NCT05583019|Device|Polysomnography|Sleep monitor
79478654|NCT05583019|Device|Videography|Thermal Camera
79478655|NCT05576831|Procedure|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
79478656|NCT05576207|Dietary Supplement|Balanced energy and protein supplement for pregnant women|A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
79478657|NCT05576207|Dietary Supplement|Multiple Micronutrient Supplement for pregnant women|"Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group."
79478658|NCT05567159|Drug|Donanemab|Administered IV.
79319445|NCT04771637|Drug|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
79319446|NCT04771637|Drug|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
79319447|NCT04771637|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
79319448|NCT04771637|Drug|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
79478659|NCT05565807|Biological|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.
79478660|NCT05556694|Diagnostic Test|calculation of cumulative fluid balance|- We will calculate cumulative fluid balance as daily fluid balance within four days of the event of interest. Cumulative fluid balance will be computed as the sum of daily fluid balances over the previous 24 hours, calculated by total fluid input minus total fluid output on a specific day of ICU admission over the first four calendar days of mechanical ventilation. Insensible fluid loss, such as perspiration or evaporative water loss related to respiration will not be routinely assessed and will not be included in the calculation of cumulative fluid balance. The cumulative fluid balance from day 0 to day 1 will be labelled as day 1, and the following days as day 2 and day 3. Cumulative fluid balance at day 3 refers to the cumulative fluid balance during the first four calendar days.
79974287|NCT02498002|Other|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
79974288|NCT02498002|Procedure|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
79319449|NCT04751591|Procedure|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
79319450|NCT04751591|Procedure|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
79319451|NCT04731389|Behavioral|internet-based cognitive-behavioral therapy|Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.
79319452|NCT04731389|Behavioral|Quality of life improving intervention|consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
79478661|NCT05554601|Behavioral|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration
79974289|NCT02498002|Procedure|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
79319453|NCT03588377|Device|Pulse Oximetry|"Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under <5 children with symptoms of cough or difficulty breathing~Case definition:~Birth - 6 days: Fast breathing +/- Low oxygen in blood <92% (Hypoxemia)~7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood <92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor."
79319454|NCT03103217|Behavioral|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
79644424|NCT05625516|Device|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
79808568|NCT04969471|Device|enVast stent|In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
79319455|NCT03103373|Device|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
79319456|NCT03103373|Device|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
79478662|NCT05554601|Behavioral|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
79319457|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
79478663|NCT05553041|Drug|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
79974290|NCT02498002|Drug|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
79974291|NCT02498002|Other|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
79974292|NCT02498002|Radiation|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
79319458|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
79319459|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
79319460|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
79319461|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
79478664|NCT05549934|Drug|PF-06651600|tablets containing active drug (a combined JAK3/TEC inhibitor)
79478665|NCT05549687|Other|Questionnaire Administration|Ancillary studies
79478666|NCT05549687|Procedure|Supportive Care|Participate in Pack Health, an electronic support program
79478667|NCT05549687|Procedure|Supportive Care|Access to telephone triage line for support care services
79478668|NCT05548231|Drug|LY3437943|Administered SC
79478669|NCT05548231|Drug|Placebo|Administered SC
79478670|NCT05547880|Drug|[11C]ER176|Brain PET with [11C]ER176. [11C]ER176 is a PET ligand that images TSPO.
79644425|NCT05622201|Drug|Rituximab|Infusion
79808569|NCT04969471|Procedure|conventional treatment|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
79808570|NCT04942340|Drug|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
79808571|NCT04942340|Drug|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex & Saline at 15 mg/kg across 5 minutes
79808572|NCT04932525|Procedure|Biopsy|Blood and tumor samples for Genetic Profiling research
79974293|NCT02498002|Other|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
79974294|NCT02498002|Other|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
79974295|NCT02498002|Other|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
79974296|NCT02498002|Other|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
79974297|NCT03810209|Drug|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
79974298|NCT03810209|Drug|Normal saline|adding normal saline to local anaesthetic in SAP block
79974299|NCT03053492|Device|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
79478671|NCT05546931|Behavioral|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
79478672|NCT05546931|Other|WebMD|Smartphone-based application for health education and/or monitoring.
79478673|NCT05546931|Behavioral|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
79478674|NCT05543850|Device|Bi-hormonal closed-loop control|During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
79478675|NCT05543850|Device|Open-loop control|During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
79478676|NCT05539989|Biological|VPM1002 Vaccine|0.1 mL (2-8x10^5 CFU)
79478677|NCT05539989|Biological|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
79478678|NCT05539989|Drug|Placebo|0.1 mL (sodium chloride for injection 0.9%)
79478679|NCT05538325|Device|Bubble Inclinometer and Digital Pelvic Inclinometer|They are valid and reliable devices to measure the range of motion of the lumbar spine
79974300|NCT03053492|Behavioral|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
79644426|NCT05615376|Device|ECG application|The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
79974301|NCT02497846|Device|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity [I]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
79974302|NCT04630925|Other|isCGM|As previously described
79974303|NCT03330340|Procedure|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
79974304|NCT05585879|Device|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~Boston Bowel Preparation Score (BBPS) < 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~Inability to identify > 5mm polyps"
79974305|NCT04186988|Drug|Fluorine F 18 Ara-G|Given IV
79974306|NCT02491294|Behavioral|School|students receive Cooking With Kids (CWK) - Colorado cooking & tasting lessons, SPARK active recess, and Cafeteria Connections
79478680|NCT05529147|Drug|Antihypertensive Agents|Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
79644427|NCT05615376|Device|12 lead ECG|The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
79644428|NCT05583708|Drug|Pembrolizumab|Pembrolizumab 400mg IV
79644429|NCT05583708|Drug|Lutetium Lu 177 dotatate|7.4GBq (200 mCi) IV
79974307|NCT02491294|Behavioral|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
79974308|NCT02491294|Behavioral|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
79644430|NCT05579314|Drug|XW014|Oral capsules
79644431|NCT05579314|Drug|Placebo|Matched oral placebo capsules
79974309|NCT03337282|Procedure|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
79644432|NCT05558020|Diagnostic Test|Continuous laryngoscopy during exercise (CLE), incremental exercise protocol|The incremental work rate exercise test will be performed using a cycle-ergometer. The exercise protocol is initiated by a five-minute warm-up at 50 Watts (W). Subsequently, they will complete a stepwise protocol, which will begin at 100 W and increase by 2 W every 6th second, until exhaustion or until the patient is unable to continue exercise, for any reason.
79478681|NCT05526690|Drug|Metformin|1000 mg dose of immediate-release metformin
79478682|NCT05526690|Drug|CIN-107|10 mg dose of CIN-107
79644433|NCT05558020|Diagnostic Test|Continuous laryngoscopy during exercise (CLE), continuous work rate protocol|"Within two weeks the participants will perform an additional CLE-test at various intensities. The new exercise protocol is designed to induce EILO at different exercise intensities. Using the participants' individually calculated exercise capacity, three different workloads (70 %, 80 % and 90 %) will be calculated.~The exercise protocol will be initiated with a five-minute warm-up at 50 W, then the workload will increase to the watt equivalent to 70 % of the participant's maximal exercise capacity. This workload will be fixed for ten minutes and only terminated if the participant feels the need to stop due to exhaustion or breathing difficulties. Next, the participant will have a five-minute resting phase with a set workload of 50 W. This protocol will be repeated at a workload equivalent to 80 % and 90 %"
79974310|NCT03801707|Drug|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
79974311|NCT03801707|Drug|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
79974312|NCT03337204|Behavioral|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
79974313|NCT03337204|Behavioral|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
79974314|NCT03330184|Drug|Berberine Hydrochloride group|
79974315|NCT03330184|Drug|Bifidobacterium group|
79974316|NCT03330184|Drug|Berberine Hydrochloride and Bifidobacterium group|
79974317|NCT03330184|Drug|placebo|
79974318|NCT04117490|Other|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast & dinner).
79478683|NCT05526430|Drug|Harmine Hydrochloride Capsules|capsules taken orally
79478684|NCT05523739|Drug|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
79478685|NCT05520528|Behavioral|Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia|The participants will read through a designated book incrementally across multiple weeks at home and complete reading, writing, and discussion related to weekly readings in a group setting.
79478686|NCT05520138|Drug|Enzalutamide|As provided in real-world setting
79478687|NCT05520138|Drug|Abiraterone acetate|As provided in real-world setting
79478688|NCT05517980|Drug|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
79974319|NCT04117490|Other|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
79974320|NCT03795779|Biological|CLL1-CD33 cCAR T cells|CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
79974321|NCT03329872|Other|Data collection|data collection about symptoms without any specific clinical or biological intervention
79974322|NCT04239872|Drug|Fluoride mouthwash|Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.
79319462|NCT04626869|Other|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
79974323|NCT04239872|Drug|Calcium and fluoride mouthwash|Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
79644434|NCT05557162|Other|AI ECG Amyloid algorithm|Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis
79974324|NCT03164772|Drug|Durvalumab|anti-PD-L1
79644435|NCT05542251|Behavioral|Parent Educational Program|The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
79808573|NCT04909723|Combination Product|NOV-001|NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
79974325|NCT03164772|Drug|Tremelimumab|anti-CTLA-4
79974326|NCT03164772|Biological|BI 1361849|mRNA Vaccine
79974327|NCT03164772|Device|PharmaJet Tropis® device|The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
79974328|NCT02497690|Behavioral|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
79974329|NCT02497690|Behavioral|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
79808574|NCT04909723|Biological|NB1000S|A recombinant live biotherapeutic product.
79974330|NCT03801317|Dietary Supplement|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
79974331|NCT03801317|Dietary Supplement|Control|15 grams corn-soya blend
79974332|NCT03801317|Dietary Supplement|multiple micronutrient|multiple micronutrient sprinkle powder
79974333|NCT02497768|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
79974334|NCT03795545|Procedure|SWL|Shock wave lithotripsy
79974335|NCT02493400|Other|No intervention in the follow up study.|
79974336|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
79974337|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
79974338|NCT03337126|Drug|Metronidazole Tablet|Comparator Drug
79974339|NCT01331226|Behavioral|telephone counseling 3 sessions|3 sessions of telephone counseling
79974340|NCT01331226|Behavioral|telephone counseling 1 session|1 session of telephone counseling
79974341|NCT01331226|Behavioral|written materials only|written materials only
79808575|NCT04909723|Drug|NB2000P|A botanically derived polysaccharide.
79974342|NCT05016050|Device|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
79808576|NCT04909723|Drug|Placebo|Placebo
79319463|NCT04435145|Behavioral|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
79319464|NCT04435301|Device|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
79319465|NCT03471221|Behavioral|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~Specific treatment goals are not planned for each visit.~Volunteers and treatment providers are not required to take detailed notes.~Visit content and activities are spontaneous.~Visit length can be as long or as short as needed."
79319466|NCT03464669|Other|Prenatal education|Observational study : natural distribution of participants between groups
79808577|NCT04905654|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
79808578|NCT04905654|Drug|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
79808579|NCT04890483|Device|Transcranial direct current stimulation|tDCS: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: five times, once per day.
79808580|NCT04887922|Device|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
79808581|NCT04887922|Device|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
79808582|NCT04887922|Device|Conventional spirometer|Will be provided to participants
79808583|NCT04878406|Drug|NNC0480-0389|A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
79808584|NCT04878406|Drug|Placebo (NNC0480-0389)|A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
79808585|NCT04878406|Drug|Semaglutide|A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
79808586|NCT04878406|Drug|Placebo (Semaglutide)|A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
79808587|NCT04877730|Device|Fully Closed Loop (FCL)|Closed loop without a meal anticipation module without announced carbohydrate
79808588|NCT04877730|Device|Fully Closed Loop with meal anticipation module (FCL+)|Closed loop with a meal anticipation module and without announced carbohydrate
79974343|NCT03325036|Diagnostic Test|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
79974344|NCT04710732|Drug|Standard Enoxaparin 40 mg once-daily before randomization|"Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~12 hours after the previous key injection 1 (key injection 2) on the POD 1~24 hours after the previous key injection 2 on the POD 2"
79974345|NCT04710732|Drug|Standard Enoxaparin 40 mg once-daily after randomization|Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
79319467|NCT05244863|Other|Test|Measurements
79319468|NCT03101735|Drug|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
79319469|NCT03446027|Device|NMES|NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
79808589|NCT04877730|Device|Hybrid Closed Loop (HCL)|Closed loop without a meal anticipation module with announced carbohydrate
79808590|NCT04868305|Procedure|Intramedullary nail|"Intertan nail (Smith & Nephew)* or Gamma 3 nail (Stryker)*~* All of the above-mentioned products are subjects to change into an equivalent product"
79808591|NCT04868305|Procedure|Hip arthroplasty|"Total hip arthroplasty:~Cemented: Lubinus (Link)*, Exeter (Stryker)*~Uncemented: Restoration Modular (Stryker)*~Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)*~Hemiarthroplasty:~Cemented: Lubinus (Link)*, Exeter (Stryker)*~Uncemented: Restoration Modular (Stryker)*~All of the above-mentioned products are subjects to change into an equivalent product"
79808592|NCT04857398|Drug|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
79808593|NCT04814407|Diagnostic Test|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
79808594|NCT04812548|Drug|sabatolimab|Sabatolimab will be administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2 and Expansion (Part 2)) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle.
79808595|NCT04812548|Drug|azacitidine|A standard dose of azacitidine will be given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 will be permitted (alternative schedule).
79808596|NCT04812548|Drug|venetoclax|Venetoclax film-coated tablets will be administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax is necessary.
79808597|NCT04803773|Device|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
79808598|NCT04794075|Other|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
79808599|NCT04783181|Biological|AAV BBP-631|intravenous
79808600|NCT04771403|Device|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
79974346|NCT04710732|Drug|Escalated Enoxaparin 30 mg twice-daily after randomization|Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
79974347|NCT04710732|Device|Anti-embolic elastic compression stockings|Applied before or just after the surgery and used around the clock until discharge
79808601|NCT04771403|Device|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
79808602|NCT04771403|Device|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
79974348|NCT04710732|Diagnostic Test|Thrombodynamic test (TD)|"Blood sampling for TD:~12 hours after key injection 1 (TD-12) on the POD 1~24 hours after key injection 2 (TD-24) on the POD 2~24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)"
79974349|NCT02497456|Behavioral|Follow-up counselling|
79974350|NCT05014334|Drug|Berberine|berberine 500 mg, twice daily for 14 days
79808603|NCT04749004|Behavioral|Promotion of physical activity|Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
79808604|NCT04704284|Diagnostic Test|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
79808605|NCT04702022|Diagnostic Test|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
79319470|NCT05244707|Behavioral|Mediterranean style diet|The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
79319471|NCT05244707|Behavioral|Standard of care|The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
79478689|NCT05516849|Drug|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
79644436|NCT05517408|Drug|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
79644437|NCT05514431|Procedure|Epidural|Traditional epidural catheter placement
79644438|NCT05514431|Procedure|Dural Puncture Epidural (DPE) technique|Epidural catheters placed via DPE technique
79644439|NCT05514431|Procedure|Combined Spinal-Epidural (CSE) technique|Epidural catheters placed via CSE technique
79808606|NCT04698525|Drug|Valproate Sodium|Comparison between two actives
79808607|NCT04698525|Drug|Memantine|Memantine
79808608|NCT04680845|Behavioral|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
79808609|NCT04678635|Other|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
79808610|NCT04672538|Procedure|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
79974351|NCT05014334|Drug|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
79319472|NCT05244317|Device|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
79478690|NCT05516849|Other|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
79478691|NCT05514834|Device|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
79478692|NCT05514834|Other|PRP Only|platelet rich plasma without hyaluronic acid
79478693|NCT05514834|Other|Placebo|Neither PRP nor hyaluronic acid
79644440|NCT05511480|Behavioral|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
79644441|NCT05511480|Behavioral|No interference|No interference through the continuation of learning same motor skill
79644442|NCT05504837|Biological|KB407 (Nebulization)|Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
79644443|NCT05473637|Diagnostic Test|MRI|Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
79644444|NCT05473312|Behavioral|Community Sensitization|One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
79319473|NCT05244317|Device|splint|Removable splint
79478694|NCT05510427|Drug|Infigratinib|Given by PO
79478695|NCT05510427|Drug|Atezolizumab|Given by (IV) vein
79478696|NCT05510427|Drug|Bevacizumab|Given by (IV) vein
79808611|NCT04672538|Procedure|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
79974352|NCT05014334|Drug|Amoxicillin|amoxicillin 1000mg, twice daily for 14 days.
79974353|NCT05014334|Drug|Rabeprazole|Rabeprazole 10mg, twice daily for 14 days.
79808612|NCT04667104|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
79808613|NCT04667104|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
79808614|NCT04667104|Drug|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
79808615|NCT04667104|Drug|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
79808616|NCT04667104|Drug|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
79808617|NCT04659369|Drug|CMAB819|for injection only
79808618|NCT04659369|Drug|Nivolumab|for injection only
79808619|NCT04651439|Drug|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~20 to < 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~30 to < 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~60 to < 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~90 to < 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
79808620|NCT04651439|Drug|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~20 to < 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~30 to < 60kg = 20mL of Glucose 5% solution (by IV)~60 to < 90kg = 20mL of Glucose 5% solution (by IV)~90 to < 120kg = 20mL of Glucose 5% solution (by IV)~120 to 150kg = 20mL of Glucose 5% solution (by IV)~> 150kg = 20mL of Glucose 5% solution (by IV)"
79808621|NCT04649801|Procedure|Atrial fibrillation ablation|Catheter ablation
79974354|NCT05014334|Drug|Bismuth|Bismuth 220mg, twice daily for 14 days.
79974355|NCT05014334|Drug|Clarithromycin|clarithromy 500mg, twice daily for 14 days.
79974356|NCT04337034|Behavioral|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
79808622|NCT04641663|Dietary Supplement|Multi-target Dietary Supplement (MTDS)|"The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components."
79808623|NCT04635774|Drug|Insulin|40 IU via four activations of an intranasal spray
79478697|NCT05509985|Biological|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
79808624|NCT04635774|Drug|Saline|Four activations of an intranasal spray containing placebo (normal saline).
79808625|NCT04634799|Drug|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
79808626|NCT04634799|Other|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
79974357|NCT04337034|Procedure|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
79974358|NCT02497378|Drug|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
79974359|NCT02497378|Drug|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
79974360|NCT02497378|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
79974361|NCT02497144|Other|NMES Group|Neuromuscular electrical stimulation
79974362|NCT02497144|Other|Control Group|Breathing exercises
79974363|NCT02497222|Drug|RNS60|
79644445|NCT05473312|Behavioral|28-day PD/Hearth Sessions|Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.
79808627|NCT04622930|Device|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
79808628|NCT04603365|Drug|Pamiparib|Given PO
79808629|NCT04603365|Drug|Temozolomide|Given PO
79319476|NCT05244161|Behavioral|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
79319477|NCT05243927|Other|Aerobic exercise program|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes 3 days a week for 8 weeks
79808630|NCT04591912|Behavioral|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
79808631|NCT04591873|Other|telemedicine|Using telemedicine system to communicate
79319478|NCT05243927|Other|Spinal stabilization exercise program|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes 3 days a week for 8 weeks.
79808632|NCT04591873|Other|traditional communication tools|Use telephone or direct verbal communication
79808633|NCT04587089|Procedure|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
79808634|NCT04587089|Procedure|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
79808635|NCT04587089|Procedure|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula & Ação (F&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
79808636|NCT04565015|Biological|GC5107|Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
79319479|NCT04961879|Procedure|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
79319480|NCT04961879|Procedure|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~- this flap is harvested from the same finger ."
79319481|NCT05243849|Device|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
79808637|NCT04560660|Drug|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
79808638|NCT04560660|Drug|Midazolam|FDA approved sedative medication with dissociative effects.
79808639|NCT04556526|Biological|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
79808640|NCT04556526|Biological|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
79974364|NCT02497222|Drug|Normal Saline|
79974365|NCT02491606|Drug|Tafenoquine|Tafenoquine 200mg and 400 mg
79319482|NCT04937075|Other|No intervention|No intervention
79319483|NCT05243771|Procedure|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
79319484|NCT05243771|Procedure|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
79319485|NCT05243771|Procedure|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
79974366|NCT02491606|Other|Placebo|Placebo
79974367|NCT05255354|Device|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
79644446|NCT05473312|Behavioral|Supplemental Print Information|The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
79319486|NCT04701593|Drug|Triamcinolone Acetonide 40mg/mL|Sub-tenon irrigation 1cc
79319487|NCT05243693|Drug|Brentuximab vedotin|3 cycles of Brentuximab vedotin and DHAP
79319488|NCT05243225|Procedure|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
79319489|NCT04640987|Biological|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
79319490|NCT04640987|Device|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
79644447|NCT05470699|Procedure|Computed Tomography|Undergo PET/CT
79808641|NCT04551638|Other|Psychological assessment with the Repertory Grid Technique|The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
79319491|NCT04640987|Drug|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
79319492|NCT02644343|Device|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
79319493|NCT04552847|Drug|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
79319494|NCT04552847|Device|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
79319495|NCT04552847|Device|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
79319496|NCT05167331|Drug|Nitrous Oxide inhalation|use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
79319497|NCT05167331|Device|Dispositif de RV - HYPNO VR|use of Virtual Reality on children's anxiety during a dental treatment
79644448|NCT05470699|Other|Fluorine F 18 Piflufolastat|Given IV
79644449|NCT05470699|Device|Positron Emission Tomography|Undergo PET/CT
79808642|NCT04517916|Device|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
79808643|NCT04510675|Device|Test Article|Omeza Collagen Matrix
79808644|NCT04510675|Other|Negative Control|Occlusive Patch of 0.9% sodium chloride, NaCl
79808645|NCT04493957|Behavioral|ACCOMPAGNE Education Program|"The following workshops will be organised :~Presentation workshop~Cognitive skills workshop~Perception and Environment workshop~Responsibilities workshop~Representation workshop -~Caregivers workshop,~Solutions workshop"
79974368|NCT03353753|Drug|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
79974369|NCT03353753|Drug|Placebo Oral Tablet|Placebo
79319498|NCT04509401|Drug|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
79644450|NCT05458453|Drug|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
79808646|NCT04493957|Behavioral|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
79319499|NCT04509401|Drug|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
79319500|NCT05155007|Drug|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
79319501|NCT05155007|Drug|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
79319502|NCT01641107|Drug|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
79319503|NCT04425317|Diagnostic Test|Blood sample|Blood sample and endometrial biopsy on the moment of oocyte retrieval
79808647|NCT04478617|Drug|Metronidazole Vaginal|Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
79974370|NCT03329638|Drug|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
79974371|NCT03329638|Drug|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
79974372|NCT03329638|Drug|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
79974373|NCT03329638|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
79974374|NCT03050450|Drug|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
79974375|NCT03050450|Drug|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
79319504|NCT04411511|Other|Exposure to the Dutch measures due to the Covid-19 pandemic.|Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
79319505|NCT03101423|Drug|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
79319506|NCT03101423|Drug|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
79319507|NCT04309799|Device|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
79319508|NCT05073029|Other|nutrition program and modification of physical activity|nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
79319509|NCT05073029|Dietary Supplement|synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)|one synbiotic sachet (3g), BID, for 3 month traetment
79490350|NCT01240304|Drug|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
79319510|NCT05073029|Dietary Supplement|vitamin D3|vitamin D3, oral, 2000IU BID, for 3 month treatment
79490351|NCT01240304|Radiation|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
79808648|NCT04462289|Behavioral|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
79974376|NCT03050450|Drug|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
79808649|NCT04452292|Other|Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma|Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
79808650|NCT04452292|Other|Treatment for Small Cell Lung Cancer|Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
79808651|NCT04432064|Device|Active TI-NDBS|In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.
79808652|NCT04432064|Other|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
79974377|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
79319511|NCT02644109|Dietary Supplement|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
79478701|NCT05505292|Drug|Lifitegrast 5% Ophthalmic Solution|Dosed twice a day for 8 weeks
79478702|NCT05505292|Other|Lifitegrast Ophthalmic Solution Vehicle|Dosed twice a day for 8 weeks
79478703|NCT05503238|Behavioral|Skin-to-skin contact|Preterm infants will receive maternal-infant skin-to-skin contact at least 1 continuous hour everyday from infant 3 days of life until discharge, and other nursing care will be same as the routine group. During skin-to-skin contact, place naked baby only with diaper on the mother's bare chest in an upright position and tilt the baby's head to one side in a slightly extended position to keeps the airway open, cover the infant with a blanket to keep them warm. A neonatal nurse will be stay with mother and infant to observe and support.
79478704|NCT05503238|Other|Routine care|Preterm infants will receive standard nursing care provided by neonatal nurses in accordance with hospital principles during hospitalization.
79478705|NCT05503212|Other|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
79478706|NCT05503212|Other|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
79478707|NCT05503212|Other|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
79478708|NCT05500820|Drug|CIN-107|A repeat oral dose of CIN-107 once daily for 10 days.
79808653|NCT04432064|Device|tDCS|This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
79974378|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
79974379|NCT03329560|Biological|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
79974380|NCT05463718|Device|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
79478709|NCT05500820|Drug|Matching Placebo|A repeat oral dose of matching placebo once daily for 10 days.
79808654|NCT04431999|Drug|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
79808655|NCT04431999|Drug|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
79808656|NCT04424966|Drug|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
79808657|NCT04401605|Other|Fermented Food-supplemented Diet|Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.
79808658|NCT04401605|Other|Regular Diet|No change in diet.
79808659|NCT04397159|Behavioral|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
79808660|NCT04361045|Behavioral|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
79808661|NCT04358276|Other|Computer-Assisted Intervention|Complete online course
79808662|NCT04358276|Device|Dermatoscope|Receive dermatoscope
79478710|NCT05497180|Device|passive myofunctional appliance|passive myofunctional appliance
79478711|NCT05497180|Device|standard oral appliance|standard oral appliance
79478712|NCT05495997|Behavioral|Mental Imagery Training|Participants will practice mental imagery of everyday tasks daily for 6 weeks.
79478713|NCT05495997|Behavioral|Psychoeducation|Participants will receive psychoeducation on cognition and brain health.
79478714|NCT05495633|Other|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
79808663|NCT04358276|Other|Educational Intervention|Receive study packet
79808664|NCT04358276|Other|Educational Intervention (Physician)|Receive physician directed letter and educational package
79808665|NCT04358276|Other|Questionnaire Administration|Ancillary studies
79808666|NCT04358276|Other|Text Message|Receive text messages
79319512|NCT02644109|Dietary Supplement|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
79319513|NCT05072951|Diagnostic Test|Urine Biomarker for Kidney Transplant Rejection|Biomarker for active kidney transplant rejection.
79319514|NCT02642159|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
79319515|NCT02642159|Drug|Statins|Statins at stable dose without other LMT as clinically indicated.
79319516|NCT02642159|Drug|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
79319517|NCT02642159|Drug|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
79319518|NCT02642159|Drug|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
79808667|NCT04340258|Device|Cesium-131|Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
79808668|NCT04340258|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
79974381|NCT03795077|Other|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
79974382|NCT03799679|Drug|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
79974383|NCT03329482|Other|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
79319519|NCT02642159|Drug|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
79319520|NCT02642159|Drug|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
79319521|NCT05072873|Drug|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
79319522|NCT05072873|Other|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
79319523|NCT05072405|Drug|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
79319524|NCT05072405|Drug|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
79319525|NCT05072327|Procedure|Mohs surgery|Mohs surgery of eyelid
79490352|NCT01240304|Procedure|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
79490353|NCT02614586|Drug|TAK-058|TAK-058 oral solution.
79319526|NCT05072327|Procedure|cryotherapy|cryotherapy of eyelid
79974384|NCT03329482|Other|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
79319527|NCT03101579|Drug|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
79974385|NCT03505021|Drug|Levosimendan|Levosimendan 1 mg capsule for oral administration
79974386|NCT03505021|Drug|Placebo for levosimendan|Placebo capsule for oral administration
79974387|NCT02497066|Other|Neuropathic pain cream|Subjects will apply the cream to the painful area.
79974388|NCT02497066|Other|Nociceptive pain cream|Subjects will apply the cream to the painful area.
79319528|NCT03101579|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
79319529|NCT03101579|Drug|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
79319530|NCT03101579|Drug|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
79319531|NCT05071547|Behavioral|Guided internet-delivered acceptance and commitment therapy (ACT)|ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility
79319532|NCT05071547|Other|Interdisciplinary Pain Rehabilitation Program (IPRP)|Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
79974389|NCT02497066|Other|Mixed pain cream|Subjects will apply the cream to the painful area.
79974390|NCT04217603|Device|Continuous positive airway pressure (CPAP) device|Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle
79974391|NCT04217603|Device|Sham-continuous positive airway pressure (CPAP) device|An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
79974392|NCT05463640|Biological|ADGRE2 CAR-T|ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
79319533|NCT05071625|Procedure|percutaneous vertebroplasty|percutaneous vertebroplasty under combined CT/fluoroscopy guidance for non-union after posterior fixation performed for a traumatic non-neurologic thoraco-lumbar vertebral fracture.
79319534|NCT03101345|Other|Peptamen® 1.5 vanilla|Administration orally
79319535|NCT05071391|Procedure|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
79319536|NCT05071781|Drug|Corticotropin-release hormone|intravenous CRH (100 µg)
79490354|NCT02614586|Drug|Ondansetron|Ondansetron capsule.
79974393|NCT05155358|Diagnostic Test|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
79974394|NCT03793283|Device|CSII|Currently receiving CSII therapy during 6 or more months.
79974395|NCT03793283|Drug|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
79490355|NCT02614586|Drug|TAK-058 Placebo|TAK-058 placebo-matching, solution.
79490356|NCT02614586|Drug|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
79490357|NCT01211756|Drug|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
79490358|NCT01211756|Drug|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
79974396|NCT02496988|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
79319537|NCT05071781|Drug|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
79974397|NCT02496988|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
79974398|NCT03050372|Device|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
79319538|NCT05071001|Procedure|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~a 3D-FLAIR imaging~a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~Magnetization transfer imaging providing information about integrity of membranes."
79974399|NCT03050372|Device|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
79974400|NCT01647971|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
79319539|NCT03882905|Drug|Ezetimibe|10 mg tablet, oral, once daily
79319540|NCT03882905|Drug|Placebo|one tablet, oral, once daily
79319541|NCT03882905|Drug|Simivastatin|Once daily administration at dose to be determined
79319542|NCT03882905|Drug|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
79319543|NCT03572543|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
79319544|NCT02669017|Drug|ADCT-402|intravenous infusion
79974401|NCT03329326|Other|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
79974402|NCT03721315|Behavioral|Intervention|"The health literacy enhancement will comprise of the following:~Practical day to day information to help manage the disease~Benefits of medication and adherence~Tips to improve managing shortness of breath~Proper use of inhalers (if applicable)~Managing daily activities"
79974403|NCT03793205|Drug|Long-acting G-CSF|Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
79974404|NCT03793205|Drug|Short-acting G-CSF|Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
79319545|NCT02387671|Behavioral|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
79808669|NCT04336683|Device|Interstitial and intracavitary brachytherapy|Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
79974405|NCT03324568|Behavioral|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
79974406|NCT03324568|Behavioral|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
79808670|NCT04301271|Drug|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
79974407|NCT03329248|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79974408|NCT03329248|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79974409|NCT03329248|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79974410|NCT03329248|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
79974411|NCT03329248|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
79974412|NCT03329248|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
79974413|NCT03329248|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79974414|NCT03329248|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79974415|NCT03329248|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79974416|NCT03329248|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79974417|NCT03329248|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
79974418|NCT03329248|Drug|lovaza|Omega-3-acid ethyl esters
79974419|NCT03329248|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79490359|NCT03591458|Drug|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
79808671|NCT04301271|Drug|Placebo oral tablet|12 weeks Placebo add-on
79974420|NCT03329248|Procedure|SBRT|Stereotactic Body Radiation Therapy
79974421|NCT03792893|Other|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
79808672|NCT04287218|Behavioral|TG-iConquerFear|The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance & mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.
79974422|NCT03792893|Other|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
79644451|NCT05454696|Other|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
79644452|NCT05454696|Other|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
79974423|NCT05482022|Device|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
79644453|NCT05450549|Drug|DNL919|Single doses
79644454|NCT05450549|Drug|Placebo|Single doses
79808673|NCT04287218|Behavioral|aTAU|Active control group
79808674|NCT04269655|Device|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
79808675|NCT04229134|Behavioral|Project CONNECT|Home based pain self-management intervention using peer reinforcement to promote engagement and skill uptake
79974424|NCT05482022|Other|control|no intervention
79808676|NCT04228783|Biological|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
79808677|NCT04228783|Biological|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
79974425|NCT03329014|Drug|Remimazolam|For induction and maintenance of sedation
79974426|NCT03329014|Drug|Placebo|Control arm
79974427|NCT03792971|Drug|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
79974428|NCT03792971|Drug|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
79974429|NCT03470545|Drug|mavacamten|mavacamten capsules
79974430|NCT03470545|Drug|Placebo|placebo oral capsule
79974431|NCT03163446|Biological|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
79974432|NCT03163446|Drug|Placebo|Placebo, given as a single 2 hour iv infusion
79974433|NCT03799133|Device|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
79478715|NCT05495633|Other|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
79808678|NCT04228783|Biological|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
79974434|NCT03328936|Other|Laboratory Biomarker Analysis|Correlative studies
79974435|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
79974436|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
79974437|NCT03328936|Other|Pharmacological Study|Correlative studies
79974438|NCT03626480|Other|No treatment|No treatment
79974439|NCT01303757|Behavioral|Dietary counselling|
79478716|NCT05493891|Other|Visual analogue scale (VAS)|VAS is a reliable and valid method for assessing the intensity of low back pain (LBP)
79478717|NCT05493891|Device|Pressure Biofeedback Unit (PBU)|PBU is a valid and reliable instrument for measuring the maximal voluntary isometric contraction of both lumbar multifidus and transversus abdominis muscles (core muscle strength)
79478718|NCT05493501|Drug|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
79974440|NCT02496754|Drug|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
79644455|NCT05438979|Dietary Supplement|Placebo|Placebo for comparison to CFB
79808679|NCT04188119|Drug|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
79644456|NCT05438979|Dietary Supplement|Calcium Fructoborate|216mg CFB
79644457|NCT05436080|Device|U/S|Epididymal Ultrasongraphic Findings by Scrotal U/S
79644458|NCT05390385|Dietary Supplement|KE1 5g|5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
79644459|NCT05390385|Dietary Supplement|KE1 10g|10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
79644460|NCT05390385|Dietary Supplement|KE4 5g|5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
79808680|NCT04188119|Drug|Aspirin|300mg tablets
79808681|NCT04188119|Drug|Lansoprazole|30mg
79808682|NCT04183218|Procedure|Biospecimen Collection|Undergo biospecimen collection
79808683|NCT04183218|Device|Cardiac Event Monitor|Receive cardiac monitor
79808684|NCT04183218|Other|Chemoradiotherapy|Undergo CRT
79974441|NCT02496754|Drug|GnRH-a|In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
79478719|NCT05493501|Drug|Osimertinib monotherapy|80 mg tablet administered orally, once daily
79478720|NCT05493501|Drug|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
79644461|NCT05390385|Dietary Supplement|KE 10g|10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
79808685|NCT04183218|Radiation|Radiation Therapy|Undergo RT
79808686|NCT04170023|Drug|ALXN2050|Oral FD inhibitor
79644462|NCT05390385|Other|Placebo drink|Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
79644463|NCT05379803|Drug|Furmonertinib|furmonertinib 160 mg orally QD
79644464|NCT05368844|Device|rTMS treatment using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of rTMS treatment
79808687|NCT04142658|Drug|Apixaban 5 MG|"For patients that do NOT meet the following criteria~age ≥ 80 years~weight ≤ 60 kilograms~creatinine ≥ 1.5 mg/dL (133 micromol/L)"
79808688|NCT04142658|Drug|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~age ≥ 80 years~weight ≤ 60 kilograms~creatinine ≥ 1.5 mg/dL (133 micromol/L)"
79808689|NCT04142658|Drug|Warfarin|Active Control Intervention
79478721|NCT05493501|Drug|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
79478722|NCT05493501|Drug|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
79478723|NCT05493501|Drug|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
79478724|NCT05493501|Drug|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
79478725|NCT05493501|Drug|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
79478726|NCT05492721|Device|2-Octylcyanoacrylate|Incisions on left will have one glue and on right will have the other glue
79478727|NCT05492721|Device|N-butyl-2-cyanoacrylate|Incisions on left will have one glue and on right will have the other glue
79644465|NCT05368844|Device|sham TMS using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of sham iTBS treatment
79644466|NCT05365451|Drug|MetFORMIN Oral Solution|liquid
79644467|NCT05365451|Drug|Cimetidine 400 MG|tablet
79644468|NCT05365451|Drug|Furosemide Oral Liquid Product|oral solution
79644469|NCT05365451|Drug|Probenecid 500 MG|tablet
79644470|NCT05364671|Drug|Raphamin|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
79974442|NCT03301337|Dietary Supplement|Meat protein absorption|Meat protein absorption when digested together with a full meal.
79974443|NCT02496910|Drug|YH22162|
79974444|NCT02496910|Drug|Telmisartan/Amlodipine 80/5 mg (FDC)|
79974445|NCT02496910|Drug|Chlorthalidone 25mg|
79974446|NCT01310959|Other|Database|Database
79478728|NCT05492474|Procedure|Cranial Point of Care Ultrasound|Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane using a 1-2 MHz probe through the thin temporal bone. Upload of cPOCUS images will occur over DICOM® based Health Insurance Portability and Accountability Act (HIPAA) compliant platforms accessible via Cloud. Currently all handheld machines use Tricefy® or their own cloud based remote image access application.
79974447|NCT01304615|Behavioral|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
79319546|NCT02387671|Behavioral|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
79974448|NCT01304615|Behavioral|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
79974449|NCT01304615|Behavioral|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
79974450|NCT03342352|Drug|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
79974451|NCT03342352|Drug|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
79974452|NCT03342352|Drug|Placebo|Matching placebo for epacadostat administered orally twice daily.
79974453|NCT03342352|Drug|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
79319547|NCT02387671|Behavioral|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
79319548|NCT02387671|Behavioral|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue & dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
79319549|NCT04479865|Drug|Aricept 5mg Tablet|1 tablet once daily
79319550|NCT04479865|Drug|Aricept 10mg Tablet|1 tablet once daily
79490360|NCT03591458|Drug|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
79490361|NCT03565328|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
79808690|NCT04142658|Device|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
79808691|NCT04138394|Drug|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
79808692|NCT04138394|Drug|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
79319551|NCT04479865|Drug|DA-5207 150mg|1 patch once weekly
79808693|NCT04129931|Drug|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
79319552|NCT04479865|Drug|DA-5207 170mg|1 patch once weekly
79319553|NCT02153047|Behavioral|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
79319554|NCT02387515|Other|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
79319555|NCT03113539|Other|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~Modified low-dose, EKG-gated CT without contrast~Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
79319556|NCT02668393|Drug|Docetaxel|
79319557|NCT02668393|Drug|Nintedanib|Low Dose
79319558|NCT02668393|Drug|Nintedanib|Medium dose
79319559|NCT02668393|Drug|Nintedanib|High dose
79319560|NCT02668393|Drug|Nintedanib|Continuous high dose
79319561|NCT03105739|Other|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
79319562|NCT03105895|Procedure|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
79808694|NCT04129931|Drug|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
79319563|NCT03473821|Behavioral|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
79319564|NCT05263843|Diagnostic Test|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
79808695|NCT04129931|Drug|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
79974454|NCT03342352|Drug|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
79319565|NCT02383147|Device|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
79319566|NCT02383147|Device|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
79319567|NCT05206591|Biological|Secukinumab|Secukinumab 300 s.c.
79319568|NCT05206591|Other|Placebo|Placebo
79319569|NCT02383069|Other|Intervention Group|Aerobic training
79319570|NCT02383069|Other|Control Group|Chest physiotherapy: Flutter and muscle stretching
79319571|NCT02387593|Device|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
79808696|NCT04129931|Drug|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
79808697|NCT04129931|Drug|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
79974455|NCT03342352|Drug|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
79974456|NCT03342352|Drug|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
79974457|NCT03722563|Procedure|total laparoscopic hysterectomy with sacrocolpopexy|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
79644471|NCT05364671|Drug|Placebo|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
79974458|NCT03722563|Procedure|total laparoscopic hysterectomy with lateral suspension|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
79319572|NCT02383303|Behavioral|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
79319573|NCT02383225|Behavioral|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
79319574|NCT02383225|Behavioral|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
79319575|NCT02383225|Behavioral|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
79319576|NCT02387437|Behavioral|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
79319577|NCT02387437|Behavioral|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
79319578|NCT02387437|Behavioral|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
79319579|NCT02383615|Procedure|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
79974459|NCT03636360|Device|Light|15 hours of light exposure
79974460|NCT03795389|Drug|DM199|Single SC dose
79974461|NCT03719443|Biological|VIS649|Single IV dose of study product on Day 1 of study
79974462|NCT03719443|Biological|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
79974463|NCT03636204|Biological|AL001|Active dose of AL001
79319580|NCT01226563|Device|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
79974464|NCT03636204|Other|Placebo|Saline solution administered as a single infusion as palcebo.
79974465|NCT03120442|Drug|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
79974466|NCT03120442|Drug|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
79974467|NCT03120442|Drug|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
79808698|NCT04129931|Other|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
79808699|NCT04103814|Drug|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
79644472|NCT05342064|Other|patient-centered TB preventive therapy|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
79808700|NCT04103814|Drug|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
79974468|NCT03722485|Device|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
79974469|NCT03722485|Biological|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
79319581|NCT01226563|Device|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
79319582|NCT02382757|Drug|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
79319583|NCT02382679|Dietary Supplement|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
79808701|NCT04097067|Radiation|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
79808702|NCT04096430|Behavioral|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
79808703|NCT04095442|Device|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
79808704|NCT04095442|Device|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
79808705|NCT04042610|Behavioral|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
79974470|NCT00852696|Drug|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
79974471|NCT00852696|Other|Placebo|Take orally once daily for 9 weeks.
79974472|NCT02496832|Drug|18F-Fluoroazomycin arabinoside|
79974473|NCT04640246|Biological|TBX-3400|Autologous transfusion
79974474|NCT03324490|Procedure|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) & 5 μg dexmedetomidine will be injected."
79974475|NCT03324490|Procedure|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle & a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose & continued throughout the procedure."
79974476|NCT03324490|Drug|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
79974477|NCT03324490|Drug|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
79974478|NCT03324490|Drug|Fentanyl|Neuro-axially injected
79974479|NCT03324490|Drug|Dexmedetomidine|Neuro-axially injected
79974480|NCT04286412|Biological|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
79974481|NCT03798899|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
79974482|NCT03798899|Drug|Normal Saline|Placebo
79974483|NCT03274661|Drug|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
79974484|NCT02496598|Procedure|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
79974485|NCT02496598|Drug|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
79319584|NCT02382679|Dietary Supplement|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
79319585|NCT02387125|Biological|CMB305|
79319586|NCT02387125|Biological|G100|
79319587|NCT02387125|Drug|Metronomic CPA|
79319588|NCT02386891|Other|Thermal Environment|
79319589|NCT02386969|Device|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
79319590|NCT02386969|Device|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
79319591|NCT02386657|Other|Satisfaction|Satisfaction questionnaire to be filled in
79319592|NCT02386657|Other|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
79319593|NCT02386657|Other|Pain management|Validated pain scale questionnaire to be filled in
79319594|NCT00916747|Drug|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
79319595|NCT05231317|Other|Plant-based diet|16 days with all foods provided
79319596|NCT05231317|Other|Western diet|16 days with all foods provided
79808706|NCT04027075|Behavioral|Rewire app users|Use of the Rewire app involves completing 12 modules and 12 practice sessions over 30 days.
79808707|NCT04016285|Device|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
79808708|NCT04016285|Device|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
79808709|NCT04007770|Other|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
79808710|NCT04007770|Other|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
79808711|NCT04007770|Other|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
79319597|NCT02391883|Drug|Clopidogrel|
79319598|NCT02386423|Device|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
79808712|NCT03977662|Combination Product|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
79808713|NCT03977363|Drug|Anticoagulant drugs|Anticoagulant drugs
79319599|NCT02386267|Drug|L-leucine|L-leucine pills per os for 6 months
79490362|NCT03534362|Device|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
79490363|NCT03534362|Device|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
79490364|NCT01206296|Drug|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
79490365|NCT02593682|Drug|suvorexant|
79808714|NCT03973502|Drug|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
79319600|NCT02382523|Drug|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
79808715|NCT03950674|Biological|Pembrolizumab 200 mg|IV infusion
79808716|NCT03950674|Drug|Cisplatin|IV infusion
79319601|NCT02386501|Drug|ADXS31-164|
79319602|NCT05547841|Device|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
79319603|NCT02391727|Biological|SYN004|subjects who have received effective treatment for their cancers are eligible
79319604|NCT02391805|Drug|Entecavir|Entecavir will be administered as per local labeling.
79319605|NCT02391805|Drug|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
79319606|NCT02391805|Drug|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
79319607|NCT02391805|Drug|Tenofovir|Tenofovir will be administered as per local labeling.
79808717|NCT03950674|Drug|Carboplatin|IV infusion
79808718|NCT03950674|Drug|Pemetrexed|IV infusion
79319608|NCT02391649|Behavioral|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the [psychosocial] effects of the illness; and Module 5:Dealing with [physical and mental health] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
79490366|NCT02593682|Drug|placebo|
79490367|NCT02461550|Device|Irreversible Electroporation Ablation|
79490368|NCT01200602|Drug|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
79808719|NCT03950674|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
79808720|NCT03950674|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
79808721|NCT03950674|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
79808722|NCT03950674|Drug|Saline solution|IV infusion
79808723|NCT03949972|Other|Biosampling|Biosampling at initial visit and follow-up visits
79808724|NCT03911661|Other|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
79808725|NCT03911661|Other|Usual care|Historical management of warfarin by patient's usual care providers
79319609|NCT02391649|Behavioral|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
79644473|NCT05342064|Other|TB preventive therapy adherence support|As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
79808726|NCT03909477|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
79808727|NCT03909477|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
79808728|NCT03909477|Diagnostic Test|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
79808729|NCT03909477|Diagnostic Test|Six Minute Walk Test (6MWT)|Participants >35 years of age will perform the six minute walk test as a measure of exercise capacity
79808730|NCT03909477|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|Participants <35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
79808731|NCT03909477|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
79319610|NCT02382289|Procedure|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
79319611|NCT02386579|Procedure|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
79319612|NCT02382367|Other|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
79319613|NCT02381977|Other|No intervention|
79490369|NCT01200602|Other|clinical observation|No treatment is given.
79644474|NCT05309603|Other|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
79808732|NCT03909477|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
79319614|NCT02391493|Device|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
79319615|NCT02391415|Biological|VPM1002|Tuberculosis vaccine
79319616|NCT02391415|Biological|BCG|commercially available live vaccine BCG
79478729|NCT05492240|Other|i-STRONGER|An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.
79808733|NCT03898856|Drug|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
79319617|NCT02391415|Biological|VPM1002(Hyg+)|Tuberculosis vaccine
79319618|NCT02382055|Behavioral|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
79644475|NCT05309603|Other|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
79644476|NCT05309603|Other|Walking|Walking three miles on a treadmill at a self-selected speed
79644477|NCT05296070|Drug|Loncastuximab tesirine 150 µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
79319619|NCT02382055|Behavioral|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
79319620|NCT02382055|Behavioral|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
79319621|NCT02391181|Drug|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
79319622|NCT02391181|Drug|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
79319623|NCT02381821|Other|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
79319624|NCT02381821|Drug|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
79319625|NCT02381899|Drug|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
79319626|NCT01998958|Drug|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
79319627|NCT01998958|Drug|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
79319628|NCT01998958|Drug|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
79319629|NCT01998958|Drug|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
79319630|NCT01998958|Drug|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
79644478|NCT05296070|Drug|Loncastuximab tesirine 75µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
79974486|NCT03636126|Device|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
79974487|NCT01560455|Device|single stent|single stent
79974488|NCT01560455|Device|two stent|culotte
79478730|NCT05492240|Other|Usual Care|Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.
79478731|NCT05488964|Behavioral|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
79808734|NCT03898856|Diagnostic Test|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
79974489|NCT02491372|Behavioral|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
79974490|NCT03324412|Drug|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
79808735|NCT03874923|Other|Fluid challenge|After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
79478733|NCT05483530|Biological|HLX60 combined with HLX10|five various doses of HLX60 combined with flat dose of HLX10
79808736|NCT03874052|Drug|Ruxolitinib|Given PO
79974491|NCT03324412|Drug|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
79974492|NCT03798821|Dietary Supplement|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
79974493|NCT03798821|Dietary Supplement|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
79974494|NCT03798821|Dietary Supplement|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
79974495|NCT03324334|Diagnostic Test|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
79974496|NCT03324334|Diagnostic Test|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
79319631|NCT02386111|Drug|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
79319632|NCT02381743|Behavioral|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
79319633|NCT02381743|Behavioral|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
79808737|NCT03874052|Drug|Venetoclax|Given PO
79808738|NCT03872414|Behavioral|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
79808739|NCT03872414|Behavioral|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
79319634|NCT02386033|Drug|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
79319635|NCT02386033|Drug|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
79319636|NCT05233345|Behavioral|Occupational Therapy|online occupational therapy sessions are based on the activity training
79808740|NCT03851159|Dietary Supplement|Nyaditum resae®|Heat-killed Mycobacterium manresensis
79808741|NCT03851159|Other|Mannitol|Placebo
79808742|NCT03837041|Other|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
79319637|NCT02385955|Procedure|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
79319638|NCT02381665|Device|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
79319639|NCT02381665|Device|Flexstim IF faked|Patient enrolled will receive a sham device.
79319640|NCT02381587|Other|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
79319641|NCT01958164|Drug|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
79319642|NCT01958164|Drug|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
79319643|NCT01958164|Drug|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
79319644|NCT01958164|Drug|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
79319645|NCT02381275|Drug|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
79319646|NCT02381431|Device|FLIR ONE|
79319647|NCT02385877|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
79319648|NCT02385877|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
79319649|NCT01976104|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
79808743|NCT03836755|Diagnostic Test|Metacos|Evaluation of stability of implant by RSA technique
79808744|NCT03826147|Dietary Supplement|Nitrate-rich beetroot juice|Daily supplementation with ~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
79808745|NCT03826147|Dietary Supplement|Nitrate-depleted beetroot juice|Daily supplementation with ~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
79319650|NCT01976104|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
79319651|NCT01976104|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
79808746|NCT03782623|Diagnostic Test|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
79319652|NCT01976104|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
79319653|NCT01372501|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
79808747|NCT03749538|Other|Transcranial direct current stimulation session.|Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
79808748|NCT03711604|Drug|Tenalisib|BID Orally
79808749|NCT03708627|Drug|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
79808750|NCT03702621|Drug|liposomal Bupivacaine|20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
79319654|NCT02391259|Drug|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
79319655|NCT02391259|Drug|Placebo|contains no active drug
79319656|NCT02385643|Behavioral|SmartPhone Support System|
79319657|NCT02385565|Other|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
79319658|NCT02385565|Other|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
79319659|NCT02391103|Device|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
79319660|NCT02391103|Device|sham-stimulation|no electricity applied
79319661|NCT01958008|Drug|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
79319662|NCT01958008|Drug|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
79478734|NCT05483231|Behavioral|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
79808751|NCT03702621|Drug|Bupivacaine Hydrochloride|"40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group"
79319663|NCT01958008|Drug|BI 113608 high dose b.i.d.|Film-coated tablet
79319664|NCT01958008|Drug|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
79319665|NCT01958008|Drug|BI 113608 low dose b.i.d.|Film-coated tablet
79319666|NCT01958008|Drug|BI 113608 medium dose b.i.d.|Film-coated tablet
79319667|NCT04479163|Biological|Convalescent Plasma|250 ml Convalescent plasma with an IgG titer against SARS CoV2
79319668|NCT04479163|Other|Placebo|Normal Saline 0.9%
79319669|NCT04645264|Device|Foley Catheter|The patient is catheterized during surgery.
79478735|NCT05483231|Behavioral|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
79319670|NCT02380963|Dietary Supplement|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
79319671|NCT02380963|Behavioral|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
79319672|NCT02381509|Device|IVC Filter|
79319673|NCT02381197|Device|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
79974497|NCT03798665|Drug|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
79319674|NCT04694287|Diagnostic Test|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
79319675|NCT02385253|Behavioral|Educational training program|"The educational training program (intervention) consists of four sequential phases:~Knowledge Acquisition~Skills Assessment~Deliberate Practice~Clinical Proficiency"
79319676|NCT02390947|Drug|Famitinib|25 mg p.o. qd
79319677|NCT02390947|Drug|Placebo|25 mg p.o. qd
79808752|NCT03691441|Procedure|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
79974498|NCT05434416|Other|mobile app|mobile app self-guided psychological interventions
79974499|NCT03792815|Drug|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
79974500|NCT03792815|Drug|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
79319678|NCT04693507|Drug|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
79319679|NCT04693507|Drug|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
79319680|NCT03105661|Drug|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
79319681|NCT03105661|Drug|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
79319682|NCT03105661|Drug|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
79319683|NCT03105817|Device|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
79319684|NCT02381119|Behavioral|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
79974501|NCT03792815|Drug|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
79808753|NCT03691441|Radiation|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
79319685|NCT02381119|Behavioral|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
79319686|NCT02385175|Other|Different objective clinical tests of Eustachian tube function|
79319687|NCT02385175|Other|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
79319688|NCT02384785|Device|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
79319689|NCT02390713|Device|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
79478736|NCT05483153|Behavioral|Infant-Directed Singing Coaching|At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
79478737|NCT05478278|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
79478738|NCT05478278|Drug|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
79808754|NCT03691441|Drug|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
79808755|NCT03691441|Procedure|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
79974502|NCT03328858|Other|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
79974503|NCT04381364|Drug|Ciclesonide Inhalation Aerosol|Ciclesonide 320 µg twice daily for 14 days.
79974504|NCT01331382|Dietary Supplement|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
79974505|NCT01331382|Other|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
79974506|NCT03328780|Device|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
79319690|NCT02380885|Behavioral|SCIT|psychosocial group intervention
79478739|NCT05478278|Drug|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
79478740|NCT05478239|Drug|ArtemiCoffee|3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
79478741|NCT05475782|Procedure|Spyglass-guided lithotripsy|Spyglass-guided lithotripsy
79478742|NCT05475782|Procedure|ESWL|ESWL+ERCP
79478743|NCT05475210|Drug|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
79478744|NCT05475210|Other|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
79974507|NCT03794765|Drug|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
79319691|NCT02380885|Behavioral|TAFT|psychosocial group intervention
79319692|NCT02380729|Genetic|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
79319693|NCT02380729|Genetic|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
79319694|NCT02390401|Device|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
79319695|NCT02390401|Device|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
79319696|NCT04903327|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
79974508|NCT03794765|Drug|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
79319697|NCT04903327|Drug|Placebo|Excipient solution
79319698|NCT02380807|Device|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
79319699|NCT02380807|Other|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
79319700|NCT02380651|Procedure|Limb salvage|Local or free flaps
79319701|NCT02390479|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of four clinical visits~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
79478745|NCT05472818|Drug|[11C]APP311|For each [11C]APP311 (UCB-J) PET scan, up to 20 mCi of [11C]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third [11C]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
79319702|NCT02380495|Other|Data Collection|
79478746|NCT05471908|Behavioral|As-needed follow up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
79478747|NCT05471908|Behavioral|Automatic follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
79974509|NCT03794765|Other|Placebo infusion|Similar placebo infusion
79319703|NCT01998880|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
79319704|NCT01998880|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
79319705|NCT01998880|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
79319706|NCT04747561|Drug|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
79319707|NCT04745221|Other|autologous fecal bacteria|autologous fecal bacteria transplantation
79319708|NCT02385019|Biological|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~- Negative selection of CD8 and CD19 cells~- Positive selection of CD25 cells"
79478748|NCT05470725|Drug|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
79478749|NCT05470283|Drug|OBX-115|Given by IV
79478750|NCT05470283|Drug|Acetazolamide|Given by PO
79319709|NCT02384629|Device|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
79478751|NCT05470283|Drug|Cyclophosphamide|Given by IV
79478752|NCT05470283|Drug|Furosemide|Given by IV
79478753|NCT05470283|Drug|Mesna|Given by IV
79478754|NCT05470283|Drug|Fludarabine Phosphate|Given by IV
79808756|NCT03689387|Other|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
79808757|NCT03688295|Other|No antibiotics|Patients will not receive antiobitherapy post surgery for CAA
79808758|NCT03688295|Drug|Antibiotics|Patients will receive antiobitherapy post surgery for CAA
79478755|NCT05469789|Other|No Intervention|As it is an observational study, no intervention is administered in this study.
79478756|NCT05468151|Other|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
79478757|NCT05468151|Other|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
79478758|NCT05468151|Other|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
79478759|NCT05466929|Behavioral|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
79644479|NCT05294146|Drug|Clofazimine|"All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored."
79319710|NCT02384629|Device|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
79319711|NCT02384629|Device|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
79319712|NCT02384629|Device|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
79319713|NCT02384707|Other|allegic food|"Reintroduction procedure for small doses :~Administration of the first dose~Clinical monitoring for 45 minutes~Administration of the second dose"
79319714|NCT02384707|Other|Placebo|
79319715|NCT02380417|Procedure|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
79319716|NCT02380417|Drug|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
79319717|NCT02380417|Device|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
79644480|NCT05293522|Combination Product|NTX-001|2 solutions plus a delivery device; one time use surgical product
79319718|NCT02380339|Behavioral|Psych-Educational session and virtual reality|Psych-Educational session and virtual reality
79319719|NCT02380339|Behavioral|Psych-Educational and BF sessions|Psych-Educational and BF sessions
79644481|NCT05284591|Biological|Daratumumab|intravenous or subcutaneous
79808759|NCT03684876|Procedure|diuretic use|use of diuretic
79808760|NCT03677544|Other|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
79808761|NCT03655665|Drug|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
79308058|NCT03045471|Drug|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
79308059|NCT03045471|Drug|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
79308060|NCT03045315|Other|IVF Procedure|
79308061|NCT03223571|Other|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
79308062|NCT04862169|Other|educational intervention (SPARK)|"There are 3 modules with 11 chapters. These topics were considered as the most relevant topics for implementation of palliative care for PHC nurses. Also, topics were selected based on our previous literature review of the previous study on the content of PHC nurses training program.~The first module is the introduction. This consists of three chapters: introduction, support system and effective communication. Total reading time is estimated to be one hour. The second module is about the nursing approach in palliative care. It is estimated to be completed in around 2 hours and 15 minutes. The last module is about end of life care.~The participants are expected to access this module before the scheduled synchronous mode. Modules will be provided in the electronic version, so that participants are able to download and read them on their own devices. We are also providing video as trigger for case study discussion"
79308063|NCT04862169|Other|electronic version of the modules|electronic version of the modules
79308064|NCT03045549|Device|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
79319720|NCT01975948|Other|Mental Health Practice Support Program|"training and (2) practice support.~Three half day workshop sessions over a 24 week period.~Practice support:~3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
79319721|NCT01975948|Other|Treatment as Usual|Physicians manage patients with depression as usual
79319722|NCT02380105|Behavioral|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
79319723|NCT02380105|Device|Interocclusal Appliances|Patients were treated using interocclusal appliances
79644482|NCT05265611|Behavioral|low intensity psychosocial intervention - Problem Management Plus (PM+)|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.
79644483|NCT05265611|Behavioral|Tutoring|Young adults will be trained to tutor students in elementary school.
79644484|NCT05263973|Other|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
79644485|NCT05263154|Other|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
79974510|NCT04280744|Other|Music therapy|Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
79319724|NCT04645030|Diagnostic Test|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI <25 and >25 to insure optimal ULD-CT image quality.
79319725|NCT04645030|Diagnostic Test|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
79319726|NCT02390089|Drug|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
79808762|NCT03648606|Other|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
79808763|NCT03641690|Other|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
79808764|NCT03633370|Other|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
79319727|NCT02390089|Other|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
79319728|NCT02390089|Radiation|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
79319729|NCT02390089|Device|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
79644486|NCT05263154|Other|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
79319730|NCT04644874|Diagnostic Test|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
79319731|NCT04644874|Diagnostic Test|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
79319732|NCT04644874|Diagnostic Test|30 second chair stand test|Repetitions within 30 seconds
79319733|NCT04644874|Diagnostic Test|Handgrip Strength Test|Measured in kilograms
79319734|NCT02379871|Other|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
79319735|NCT02379871|Other|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
79478760|NCT05465109|Other|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
79478761|NCT05461755|Combination Product|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
79478762|NCT05461755|Drug|Topical Tretinoin|Treatment of striae with topical tretinoin alone
79319736|NCT03521986|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
79319737|NCT03521986|Procedure|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
79319738|NCT02379793|Drug|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
79478763|NCT05461755|Device|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
79478764|NCT05450965|Drug|Onvansertib|Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
79478765|NCT05448833|Device|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
79478766|NCT05446909|Behavioral|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
79319739|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
79319740|NCT01975246|Drug|hydrochlorothiazide|tablet
79319741|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
79319742|NCT01975246|Drug|Placebo|placebo matching hydrochlorothiazide tablet
79319743|NCT02389933|Drug|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
79974511|NCT03723876|Behavioral|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
79974512|NCT03324256|Other|energy drink|16 oz cold commercially-available energy drink
79319744|NCT04669834|Other|a traditional therapeutic knee rehabilitation program|mini-squatting exercise and clamshell exercise
79319745|NCT04669834|Other|core stability exercise|the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
79319746|NCT01621126|Device|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
79319747|NCT02389855|Procedure|NeuroBlate® System Therapy|
79319748|NCT02389699|Radiation|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
79319749|NCT02389699|Radiation|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
79319750|NCT01973998|Drug|Roflumilast|PDE4 inhibitor
79974513|NCT03324256|Other|caffeinated drink|16oz cold commercially-available caffeinated drink
79974514|NCT03324256|Other|Energy gum|2 pieces of commercially-available energy gum
79974515|NCT03324256|Other|placebo gum|2 pieces of commercially-available placebo gum
79974516|NCT03324256|Other|Control drink|16oz cold control drink
79974517|NCT03324256|Other|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
79974518|NCT03792581|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
79974519|NCT01622712|Device|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
79319751|NCT01973998|Drug|Placebo|Inactive substance.
79319752|NCT02380027|Device|MRI|This will be a multi-parametric MRI of the prostate
79319753|NCT02380027|Procedure|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
79319754|NCT02380027|Procedure|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
79974520|NCT03342118|Drug|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
79974521|NCT03342118|Drug|Normal saline|The control group was treated with normal saline before endoscopy
79974522|NCT03324178|Behavioral|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
79974523|NCT03324178|Behavioral|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
79974524|NCT01331460|Behavioral|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
79319755|NCT02384161|Other|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
79478767|NCT05446909|Behavioral|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
79974525|NCT01331460|Other|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
79319756|NCT02384005|Other|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
79319757|NCT02379949|Behavioral|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
79319758|NCT02379949|Behavioral|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
79319759|NCT02379715|Drug|Remifentanil|
79808765|NCT03625752|Device|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
79319760|NCT02379715|Drug|Desflurane|
79319761|NCT02379559|Behavioral|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
79974526|NCT03798509|Drug|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
79974527|NCT02496364|Other|Observational|
79319762|NCT02379559|Behavioral|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
79319763|NCT02379481|Dietary Supplement|NS 550mg|
79319764|NCT02379481|Dietary Supplement|NS 1100mg|
79319765|NCT02379481|Dietary Supplement|placebo|
79808766|NCT03625752|Device|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
79319766|NCT02389153|Behavioral|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
79644487|NCT05245201|Other|Standard of care|Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
79319767|NCT04439773|Drug|placebo|the control group will be given the same volume of saline.
79319768|NCT04439773|Drug|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
79644488|NCT05245201|Other|Clinical decision support for PrEP|Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
79319769|NCT02664415|Biological|VRC01|40 mg/kg; administered IV
79319770|NCT02664415|Biological|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
79319771|NCT05387083|Drug|Low Dose TP-05|Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
79319772|NCT05387083|Drug|High Dose TP-05|Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
79478768|NCT05444582|Drug|Levonorgestrel 52 MG Intrauterine System|"Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - >7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days."
79478769|NCT05442034|Biological|growth factors to help in regeneration|regenerative therapy
79478770|NCT05440799|Drug|BI 1819479|BI 1819479
79319773|NCT05387083|Drug|Placebo Comparator|Healthy Volunteers will receive a single dose of placebo on Day 1.
79319774|NCT02389231|Drug|Interleukine-2|"Four courses of IL2 ( [Proleukin, Novartis]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
79319775|NCT02383927|Drug|Tipifarnib|FTase inhibitor
79478771|NCT05440799|Drug|BI matching placebo|BI matching placebo
79478772|NCT05437900|Procedure|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
79478773|NCT05437900|Procedure|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
79644489|NCT05227638|Other|exercise|participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
79808767|NCT03604627|Other|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
79319776|NCT02383693|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
79319777|NCT02379325|Behavioral|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
79319778|NCT02379325|Behavioral|pamphlets material|Given pamphlets material on smoking and complication
79974528|NCT01605552|Behavioral|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
79974529|NCT01605552|Other|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
79974530|NCT02496442|Device|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
79974531|NCT02496286|Drug|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
79974532|NCT01489176|Drug|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
79974533|NCT03792503|Drug|Apatinib|Apatinib 500 mg Po qd
79974534|NCT03792503|Drug|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
79319779|NCT02383771|Drug|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
79319780|NCT02383771|Drug|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
79319781|NCT02383771|Drug|Control|No Anti-platelet Therapy
79319782|NCT02383771|Drug|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
79319783|NCT02388919|Drug|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
79319784|NCT02388919|Drug|Placebo|Basic dosage, take once when limosis in the morning.
79319785|NCT02383537|Other|Diabetes|the trial is observational with no intervention
79319786|NCT04685317|Device|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
79319787|NCT04685317|Diagnostic Test|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
79319788|NCT02388841|Radiation|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
79319789|NCT02379013|Procedure|Volunteer with MRI|functional MRI
79319790|NCT02383381|Procedure|lateral rectus recession|typical surgery for correcting intermittent exotropia
79319791|NCT02377297|Procedure|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
79974535|NCT03047720|Device|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
79974536|NCT03047720|Device|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
79974537|NCT04494724|Drug|Clazakizumab|Infusion
79319792|NCT02377297|Procedure|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
79319793|NCT02377297|Procedure|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
79319794|NCT02377375|Procedure|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
79319795|NCT02377375|Procedure|Standard technique|Medtronic DBS lead 3391-28cm
79319796|NCT02379169|Dietary Supplement|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
79319797|NCT02379169|Dietary Supplement|Placebo|Triglycerides of medium chain fatty acids
79974538|NCT04494724|Drug|Placebo|Infusion
79319798|NCT02377219|Other|hormonal and blood analysis|
79319799|NCT02388607|Other|measurements|performance measurements
79319800|NCT02377141|Procedure|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
79306819|NCT05923203|Other|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
79319801|NCT02377141|Procedure|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
79319802|NCT02378623|Drug|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
79808768|NCT03577990|Behavioral|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
79319803|NCT02378623|Drug|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
79319804|NCT02372149|Drug|10% intravenous immunoglobulin (IVIg)|
79319805|NCT02372149|Drug|0.9% sodium chloride|
79319806|NCT02372305|Biological|FlexHD|Patients will be randomized to receive FlexHD.
79319807|NCT02372305|Biological|Alloderm|Patient will be randomized to receive Alloderm.
79319808|NCT02661061|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
79808769|NCT03577990|Behavioral|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
79319809|NCT02661061|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
79319810|NCT02371915|Other|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
79478774|NCT05437900|Procedure|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
79974539|NCT03794843|Drug|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
79974540|NCT03794843|Drug|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
79974541|NCT03635970|Procedure|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
79478775|NCT05437900|Procedure|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
79974542|NCT04220216|Other|H4H fitness program|4 weekly, 1 hour exercise sessions
79974543|NCT04494802|Behavioral|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
79974544|NCT04494802|Behavioral|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
79974545|NCT01333800|Drug|Beclomethasone|200 to 400 mcg per day for 6 months
79974546|NCT01333800|Drug|Ciclesonide|80 to 160 mcg per day for 6 months
79974547|NCT04926077|Device|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
79974548|NCT04494100|Procedure|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
79974549|NCT04494100|Procedure|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
79974550|NCT04494100|Procedure|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
79974551|NCT04494100|Drug|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
79974552|NCT04494100|Drug|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
79319811|NCT02371837|Other|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
79319812|NCT02376985|Procedure|Oral management|
79319813|NCT02376985|Drug|Everolimus|
79808770|NCT03565497|Behavioral|Wellness Education Control Condition|As per arm of the same name
79974553|NCT01333878|Biological|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
79974554|NCT03798431|Behavioral|M-ROCC|"LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks & 120 minutes/wk.~MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
79319814|NCT02376907|Procedure|Biliary drainage|EUS-BD or ERCP
79319815|NCT02376751|Drug|sebelipase alfa|
79808771|NCT03565497|Behavioral|Mindfulness Training|As per arm of the same name
79974555|NCT03328390|Other|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
79319816|NCT02371993|Dietary Supplement|Choline|
79319817|NCT02371993|Other|Placebo|
79478776|NCT05434754|Other|eHealth Tool|text messaging algorithm
79478777|NCT05431881|Procedure|Binaural beat|Different frequencies are transmitted in both ears, causing beats. The low frequency sound generated by beats induces brainwaves entrainment.
79808772|NCT03565497|Behavioral|Mindfulness Training Plus IE|As per arm of the same name
79808773|NCT03519581|Device|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
79808774|NCT03519581|Device|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
79808775|NCT03516656|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
79974556|NCT03328390|Other|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
79974557|NCT03167879|Behavioral|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
79974558|NCT03328312|Drug|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR >0.9
79974559|NCT03328312|Drug|neostigmine+atropine|Number and time of bradycardic episodes (HR<60 bpm) as well as that of tachycardic episodes (HR>100 bpm) before tracheal extubation
79974560|NCT03328312|Drug|neostigmine+atropine+sugammadex|4. Time of extubation
79319818|NCT02378779|Other|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
79644490|NCT05206734|Other|Exposure of mental health condition|"Primary:~Composite of all chronic psychological conditions (depression, anxiety, eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorder, acute stress disorder, and post-traumatic stress disorder).~Major recurrent depression or treated depressive episode. Non-phobia related anxiety episode or disorder.~Secondary:~Self-harm, suicide attempt or suicide related codes, other chronic psychiatric conditions (eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorders, acute stress disorder, schizophrenia, bipolar disorder and post-traumatic stress disorder. Problems with sleep."
79644491|NCT05195073|Biological|Laparoscopy|3 D laparoscopy
79644492|NCT05174572|Procedure|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
79974561|NCT04051580|Drug|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
79319819|NCT02378779|Other|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
79319820|NCT02378779|Other|Humour|Use the humour to approach the subject of premature ejaculation
79974562|NCT03328234|Radiation|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
79974563|NCT03328234|Drug|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
79319821|NCT02378779|Other|Take the drama out|Take the drama out to approach the subject of premature ejaculation
79319822|NCT02378779|Other|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
79974564|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
79974565|NCT03328234|Drug|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
79974566|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
79319823|NCT02378779|Other|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
79644493|NCT05152927|Device|Parathyroid Eye (PTeye)|Intraoperative Tool
79974567|NCT03328234|Other|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
79808776|NCT03516656|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
79974568|NCT03626168|Dietary Supplement|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
79974569|NCT03626168|Other|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
79319824|NCT02378779|Other|Help to verbalize|Help for the patient to speak about premature ejaculation
79319825|NCT02371603|Drug|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
79319826|NCT02371603|Drug|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
79644494|NCT05148000|Biological|QM1114-DP|QM1114-DP
79644495|NCT05131204|Drug|Cemdisiran|Administered per protocol
79644496|NCT05131204|Drug|Eculizumab|Administered per protocol
79808777|NCT03515603|Procedure|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
79808778|NCT03515603|Procedure|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
79974570|NCT03798275|Dietary Supplement|coffee|2 g Nescafe Clasico contains approximately 65 mg caffeine
79478778|NCT05431881|Procedure|Silent|Apply a wave file which is created in silence.
79974571|NCT05625035|Drug|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
79974572|NCT03323710|Drug|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
79478779|NCT05430451|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
79974573|NCT03323710|Drug|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
79974574|NCT04771676|Drug|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
79478780|NCT05430451|Behavioral|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
79644497|NCT05131204|Drug|Pozelimab|Administered per protocol
79644498|NCT05131204|Drug|Ravulizumab|Administered per protocol
79644499|NCT05128474|Other|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
79974575|NCT03328000|Radiation|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
79478781|NCT05430451|Behavioral|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
79478782|NCT05430451|Behavioral|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
79644500|NCT05128474|Other|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
79644501|NCT05121480|Drug|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
79974576|NCT03792269|Drug|Irinotecan|intraperitoneal
79974577|NCT03792269|Drug|Oxaliplatin|intravenous
79974578|NCT03792269|Drug|Capecitabine|
79478783|NCT05430451|Behavioral|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
79974579|NCT02488564|Drug|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
79478784|NCT05430451|Behavioral|SMS|SMS on follow-up survey reminders
79478785|NCT05428449|Drug|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
79478786|NCT05428449|Drug|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
79478787|NCT05425875|Procedure|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure <100 mmHg
79478788|NCT05425875|Procedure|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
79478789|NCT05425875|Procedure|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
79644502|NCT05121480|Drug|Placebo|Placebo oral capsule
79974580|NCT02488564|Drug|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
79974581|NCT02488564|Drug|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
79974582|NCT02488564|Drug|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
79644503|NCT05109819|Radiation|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
79644504|NCT05106335|Drug|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
79644505|NCT05106335|Drug|famitinib|famitinib malate capsules for oral administration
79644506|NCT05106335|Drug|docetaxel|docetaxel for intravenous injection
79974583|NCT02966873|Drug|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
79974584|NCT02966873|Behavioral|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
79808779|NCT03479905|Other|Salter nasal cannula|Oxygen will be delivered by using standard nasal cannula
79974585|NCT02966873|Drug|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
79478790|NCT05417490|Other|PRADO-IC|"The CAM (Health Insurance Advisor) are part of the staff of the Primary Health Insurance Funds (CPAM). They are physically present in the establishments participating in the PRADO.~They are facilitators between city health professionals and the patient for their return home.~They assist the patient in making appointments with their general practitioner, their cardiologist, and the IDE (general care nurses) trained at PRADO-IC who will make the home visits.~After returning home, the CAM verifies, by two telephone calls at 1 week and 2 months, that the patient has initiated his outpatient follow-up.~IDE, trained in the therapeutic education of the IC patient according to the PRADO-IC device, carry out:~for NYHA (New York Heart Association) 1-2 patients: 8 home visits in two months.~for NYHA 3-4 patients: 8 home visits in 2 months, upon confirmation and prescription from the physician, 8 visits in the following 4 months.~The doctor carries out a long consultation at 2 months."
79974586|NCT02966873|Other|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
79490370|NCT01194908|Drug|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
79490371|NCT01184456|Dietary Supplement|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
79974587|NCT02966873|Other|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
79974588|NCT03626636|Drug|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
79974589|NCT03626636|Other|Sham|Sham injection
79974590|NCT03323632|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
79974591|NCT04697186|Drug|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
79808780|NCT03479905|Other|Face mask|Oxygen will be delivered via face mask during colonoscopy
79808781|NCT03479905|Device|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
79808782|NCT03478462|Drug|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
79808783|NCT03476226|Other|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
79478791|NCT05417490|Device|Remote monitoring|"Chronic Care Connect is intended for remote medical monitoring of patients suffering from chronic heart failure.~It consists of a web application (named NOMHADChronic™) and non-medical remote human assistance performed by qualified personnel.~Non-medical human assistance allows the following steps to be carried out:~characterization of alerts~structured follow-up of remote patients.~This non-medical human assistance is provided by:~nurses trained in therapeutic education and cardiology, Customer Relations Advisors, and logisticians.~Weight and symptoms (listed in an 8-question questionnaire) are collected respectively using a connected scale and the mobile application.~It allows, via a web browser:~to the personnel constituting the non-medical human assistance, to have access to the health data of the patients~remote monitoring doctors, to have access to the health data of each of their own patients, and to carry out medical remote monitoring procedures."
79490372|NCT01184456|Drug|Placebo|1 capsule per day for 90 days.
79490373|NCT01163084|Drug|Goserelin Acetate|Given SC
79644507|NCT05102565|Behavioral|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
79490374|NCT01163084|Other|Laboratory Biomarker Analysis|Correlative studies
79490375|NCT01163084|Drug|Leuprolide Acetate|Given IM
79490376|NCT01163084|Drug|Vismodegib|Given PO
79490377|NCT01162382|Device|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
79808784|NCT03458884|Other|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
79974592|NCT04697186|Drug|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
79974593|NCT04697186|Drug|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
79974594|NCT04697186|Drug|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
79478792|NCT05416203|Behavioral|Brief Enhanced Anxiety Sensitivity Treatment|BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
79490378|NCT01155518|Drug|testosterone|intramuscular every 2 weeks
79490379|NCT01155518|Drug|clomiphene|thrice a week
79490380|NCT01155518|Drug|placebo|intramuscular saline injections every 2 weeks
79808785|NCT03416270|Drug|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
79808786|NCT03416270|Drug|Placebo|Placebo once daily for 12 weeks
79808787|NCT03362931|Device|XEN45|XEN45 unilaterally implanted in the study eye
79808788|NCT03360019|Device|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
79808789|NCT03360019|Other|Activlink Phone Application|Smartphone tool used for monitoring location
79808790|NCT03282097|Behavioral|DECAD decision aid|A mammography decision aid that will help caregivers of patients with Alzheimer's make decisions about stopping or continuing breast cancer screening.
79808791|NCT03282097|Other|Home safety guide|The home safety guide provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
79808792|NCT03245008|Drug|MT-5547|Solution for injection in pre-filled syringe
79808793|NCT03245008|Drug|MT-5547-matching placebo|Solution for injection in pre-filled syringe
79974595|NCT04697186|Drug|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
79974596|NCT04697186|Drug|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
79974597|NCT04697186|Drug|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
79974598|NCT02488642|Drug|Isosorbide Dinitrate|
79974599|NCT02488642|Drug|Misoprostol|
79974600|NCT02488642|Drug|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
79808794|NCT03203473|Drug|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
79974601|NCT03792425|Procedure|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
79974602|NCT03798197|Drug|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
79974603|NCT02488486|Device|Automated postoperative sedation|
79974604|NCT02488486|Drug|propofol|
79974605|NCT02488486|Drug|remifentanil|
79974606|NCT01389024|Drug|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
79974607|NCT01389024|Drug|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
79974608|NCT03327766|Diagnostic Test|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D < 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
79974609|NCT03798119|Drug|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
79319827|NCT02371603|Drug|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
79478793|NCT05414240|Drug|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
79478794|NCT05414240|Behavioral|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
79478795|NCT05414240|Drug|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
79478796|NCT05413434|Other|exercise|high-intensity interval training will be performed on the treadmill.
79974610|NCT03323554|Device|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
79490381|NCT01155518|Drug|placebo|oral
79808795|NCT03203473|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
79974611|NCT03323554|Device|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
79808796|NCT03201094|Device|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
79808797|NCT03201094|Dietary Supplement|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
79974612|NCT03794219|Other|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
79974613|NCT03794219|Drug|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
79974614|NCT03327688|Diagnostic Test|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
79974615|NCT01304771|Biological|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide [FOS], NutraFlora®).
79974616|NCT01334034|Drug|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
79974617|NCT01334034|Drug|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
79974618|NCT01334034|Drug|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
79974619|NCT03050060|Drug|Atezolizumab|Given IV
79974620|NCT03050060|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79974621|NCT03050060|Other|Laboratory Biomarker Analysis|Correlative studies
79974622|NCT03050060|Drug|Nelfinavir Mesylate|Given PO
79490382|NCT03490916|Drug|Acetazolamide|Administration of Acetazolamide
79974623|NCT03050060|Biological|Nivolumab|Given IV
79974624|NCT03050060|Biological|Pembrolizumab|Given IV
79974625|NCT01304849|Drug|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
79974626|NCT03327610|Other|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
79974627|NCT03327610|Other|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
79974628|NCT03327610|Other|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
79478797|NCT05413434|Device|inspiratory muscle training|Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.
79478798|NCT05412615|Procedure|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
79808798|NCT03185208|Drug|Lithium Carbonate|See lithium carbonate arm
79808799|NCT03185208|Drug|Placebo oral capsule|See placebo arm
79808800|NCT03158051|Behavioral|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
79478799|NCT05412615|Procedure|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
79478800|NCT05411146|Drug|[14C]-etrumadenant|Administered as specified in the treatment arm.
79490383|NCT03490916|Drug|Placebo|Administration of Placebo
79490384|NCT03333746|Other|Laboratory Biomarker Analysis|Correlative studies
79490385|NCT03333746|Drug|Lenalidomide|Given PO
79490386|NCT03333746|Biological|Nivolumab|Given IV
79974629|NCT03327610|Other|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
79319828|NCT02371603|Drug|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
79319829|NCT02371525|Behavioral|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
79319830|NCT02378545|Drug|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
79974630|NCT03327610|Other|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
79974631|NCT03327610|Other|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
79319831|NCT04149145|Drug|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
79319832|NCT04149145|Drug|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
79319833|NCT02378389|Drug|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
79319834|NCT02376595|Drug|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
79319835|NCT02371213|Other|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
79319836|NCT02378155|Device|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
79974632|NCT01334112|Drug|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
79319837|NCT02378467|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
79319838|NCT02378467|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
79974633|NCT03791957|Other|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
79974634|NCT01315314|Drug|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
79319839|NCT02371291|Behavioral|Memory Flexibility Training|As in experimental arm description.
79319840|NCT02371291|Behavioral|Psychoeducation|As in experimental arm description.
79319841|NCT02370979|Biological|Blood samples|
79319842|NCT02376517|Behavioral|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
79319843|NCT02378077|Procedure|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
79319844|NCT02378077|Procedure|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
79319845|NCT02378077|Dietary Supplement|Fish Oil Supplement|Fish Oil supplementation for three months.
79974635|NCT02491450|Drug|Heterosofir|1 tablet contains 400 mg sofosbuvir
79974636|NCT02491450|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
79974637|NCT03626090|Biological|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
79974638|NCT05624645|Device|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
79319846|NCT02376439|Other|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
79478801|NCT05405920|Behavioral|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
79490387|NCT03333746|Other|Pharmacological Study|Correlative studies
79974639|NCT01274442|Other|anamnesis|To update the anamnesis.
79974640|NCT01274442|Procedure|oral examination|A brief clinical oral examination will be performed.
79974641|NCT01274442|Procedure|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
79974642|NCT03320590|Diagnostic Test|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
79974643|NCT03792113|Procedure|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
79974644|NCT03792113|Other|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
79974645|NCT03792113|Other|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
79319847|NCT02377843|Behavioral|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~Practice using the communication strategy via role play~Discussion on applying the communication strategy to medical practice"
79478802|NCT05405920|Behavioral|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
79478803|NCT05404542|Drug|Tavapadon|Oral tablets
79478804|NCT05401227|Drug|Ketamine|Ketamine during an MRI
79478805|NCT05401227|Drug|Ts-134|4 days of TS-134 20 mg
79974646|NCT01304927|Drug|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
79974647|NCT01304927|Other|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
79974648|NCT05464940|Other|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
79974649|NCT05464940|Other|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
79974650|NCT01305551|Drug|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
79974651|NCT01305551|Drug|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
79478806|NCT05401227|Drug|Placebo|4 days of placebo TS-134
79478807|NCT05400941|Behavioral|Practice Led Intervention|This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.
79478808|NCT05398653|Drug|MIL62|An intravenous (IV) infusion of 600 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27.
79478809|NCT05398653|Drug|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125~175 ng/ mL was reached.Cyclophosphamide will be maintained for 12 months, after which the dose was reduced by about 1/3 to 1/2 of the original dose each month, and discontinued after 2 months.
79478810|NCT05396287|Device|MRI|Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
79974652|NCT01305551|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
79478811|NCT05386329|Behavioral|Mindset: Therapist-guided smartphone-delivered CBT|All participants will receive the app-delivered CBT, including modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., activity scheduling), and mindfulness. Therapists will also conduct brief weekly virtual appointments with participants.
79478812|NCT05378802|Other|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
79808801|NCT03158051|Behavioral|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
79808802|NCT03140644|Other|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
79808803|NCT03132831|Other|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
79808804|NCT03117179|Other|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
79808805|NCT03115567|Drug|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
79808806|NCT03114930|Other|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
79808807|NCT03103698|Device|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
79808808|NCT03103698|Other|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
79808809|NCT03092180|Drug|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
79808810|NCT02982902|Biological|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10^3 - 10^5 virus - specific, antigen selected T cells per kg of recipient weight.
79319848|NCT02377843|Behavioral|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~Practice using the communication strategy via role play~Discussion on applying the communication strategy to medical practice"
79974653|NCT03897296|Diagnostic Test|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
79974654|NCT03791879|Drug|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
79319849|NCT02376673|Other|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
79319850|NCT02376673|Other|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
79319851|NCT02370745|Drug|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
79319852|NCT02370745|Drug|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
79808811|NCT02976636|Behavioral|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
79808812|NCT02976636|Behavioral|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
79319853|NCT02370745|Dietary Supplement|Oral amino acids|Oral amino acids containing 15 g of amino acids
79319854|NCT02370745|Drug|GIP|This will be co infused with GLP-1 and intravenous amino acids
79319855|NCT02370745|Drug|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
79319856|NCT02377999|Drug|Picato|
79319857|NCT01995838|Drug|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
79319858|NCT01995838|Drug|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
79319859|NCT02377765|Device|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
79319860|NCT02377765|Procedure|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
79319861|NCT02370823|Procedure|Regenexx SD|stem cell treatment
79478813|NCT05378555|Drug|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
79478814|NCT05374317|Biological|Yellow Fever Vaccine|Administered subcutaneously once.
79808813|NCT02964559|Biological|Pembrolizumab|Given IV
79974655|NCT03896360|Behavioral|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
79319862|NCT04589377|Behavioral|Mindfulness Training|Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
79319863|NCT02376049|Drug|Pimecrolimus cream|
79319864|NCT02376049|Drug|Betamethasone dipropionate cream|
79319865|NCT02376049|Drug|Clobetasol propionate cream|
79319866|NCT02376049|Drug|Glaxal Base cream vehicle|
79808814|NCT02893293|Drug|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
79319867|NCT02376205|Drug|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
79319868|NCT02376205|Drug|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
79319869|NCT01957462|Device|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
79319870|NCT01957462|Device|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
79319871|NCT02370433|Drug|Intravenous Neostigmine and Glycopyrrolate|
79319872|NCT02370433|Drug|Transdermal Neostigmine and Glycopyrrolate|
79319873|NCT01957150|Drug|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
79319874|NCT01957150|Drug|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
79319875|NCT01955122|Device|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
79319876|NCT01995526|Drug|Insulin Peglispro|
79974656|NCT03896360|Behavioral|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
79490388|NCT01139996|Drug|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
79974657|NCT03799757|Drug|40ml of 0.25% bupivacaine|
79974658|NCT03799757|Drug|40ml of 0.9% normal saline|
79974659|NCT03844646|Device|CGM|Intermittent use of a continuous glucose monitor (CGM)
79974660|NCT03844646|Other|Dietitian|Monthly meetings with a dietitian
79974661|NCT04025255|Dietary Supplement|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
79974662|NCT04025255|Dietary Supplement|Placebo|Matched placebo
79319877|NCT01955044|Dietary Supplement|LCPUFA supplement|
79319878|NCT01955044|Dietary Supplement|placebo|
79319879|NCT01973218|Biological|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
79319880|NCT01973218|Biological|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
79319881|NCT01973218|Biological|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
79319882|NCT01972438|Drug|ASEDs|Experimental Intervention
79319883|NCT01972438|Drug|Saline|Control Intervention
79319884|NCT01946152|Drug|Dexamethasone|Given PO
79319885|NCT01946152|Biological|Filgrastim-sndz|Given SC
79319886|NCT01946152|Other|Laboratory Biomarker Analysis|Correlative studies
79319887|NCT01946152|Drug|Pomalidomide|Given PO
79490389|NCT01139996|Drug|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
79490390|NCT02417870|Biological|aldesleukin|
79490391|NCT01131884|Drug|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
79808815|NCT02893293|Device|Magentic Resonance Imaging|Both arms will receive MRI
79808816|NCT02770859|Procedure|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle [esophagus] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle & sphincter of the LES for the treatment of achalasia
79974663|NCT02960009|Device|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
79974664|NCT00706342|Drug|Fostamatinib Disodium / R935788|R935788 tablets
79974665|NCT01303991|Other|Hexvix PDT with Karl Storz T-Light|
79974666|NCT03327454|Biological|Benepali|Administered as specified in the treatment arm.
79319888|NCT01945996|Behavioral|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
79808817|NCT02725905|Behavioral|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
79319889|NCT01945996|Behavioral|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
79319890|NCT01971346|Drug|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
79974667|NCT05624411|Device|CU T380A IUD|post-placental insertion of intrauterine contraceptive device
79490392|NCT01131884|Drug|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
79974668|NCT05624411|Device|multiload 375 IUD|post-placental insertion of intrauterine contraceptive device
79974669|NCT03323242|Device|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
79974670|NCT03323242|Device|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
79974671|NCT01305629|Behavioral|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
79974672|NCT03049748|Device|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
79974673|NCT03049748|Other|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
79974674|NCT02491216|Other|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
79974675|NCT03794063|Other|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
79974676|NCT02491138|Behavioral|Appearance-based intervention|
79974677|NCT02491138|Other|Pamphlets|
79974678|NCT03320356|Other|the French version of the Oxford Shoulder Score|
79974679|NCT03792035|Drug|Tongxinluo|tid, po.
79974680|NCT03792035|Drug|Placebos|tid, po.
79319891|NCT01945216|Drug|Alogliptin|Alogliptin tablets
79319892|NCT02641379|Drug|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\n
79319893|NCT02641379|Drug|Ribavirin|Ribavirin is available as 200 mg tablets
79319894|NCT02660983|Drug|Donepezil hydrochloride|
79319895|NCT02660983|Drug|Donepezil matching placebo|
79319896|NCT02660983|Drug|Donepezil hydrochloride|
79319897|NCT05070611|Device|IPL-MGX|One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
79319898|NCT05070221|Drug|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|less than 8mL/time，Q2W，i.t.；
79319899|NCT05070221|Drug|Recombinant humanized anti-PD-1 monoclonal antibody for injection|200mg/time，Q3W，i.v.；
79319900|NCT05070221|Drug|Axitinib|5mg，bid，p.o.；
79319901|NCT05069909|Procedure|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
79319902|NCT02962115|Behavioral|Decision Aid Invitation|electronic invitation to complete web-based decision aid
79319903|NCT02370355|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
79490393|NCT01139294|Drug|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
79490394|NCT02402036|Drug|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
79808818|NCT02725905|Behavioral|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
79319904|NCT02370355|Other|Laboratory Biomarker Analysis|Correlative studies
79808819|NCT02691923|Drug|Fluorescein|
79490395|NCT05600504|Other|no intervention|no intervention
79306825|NCT05917353|Dietary Supplement|Hinex Jelly|"Name: Hinex Jelly~Dosage form: Semi-solid jelly/ A-114001297-00000-2~Dose(s): 300g/pack (per serving)~Dosing schedule: one pack (serving) per day~Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food."
79306826|NCT05917145|Drug|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
79306827|NCT05916664|Behavioral|Kinto Care Coaching|Describe the basics of the intervention
79306828|NCT05913479|Device|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
79808820|NCT02691923|Drug|Fluorescein + ALA|
79808821|NCT02600507|Drug|Lumateperone (ITI-007)|
79808822|NCT02600507|Drug|Placebo|
79808823|NCT02578680|Biological|Pembrolizumab 200 mg|IV infusion
79808824|NCT02578680|Drug|Cisplatin|IV infusion
79808825|NCT02578680|Drug|Carboplatin|IV infusion
79808826|NCT02578680|Drug|Pemetrexed|IV infusion
79974681|NCT02488252|Drug|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
79974682|NCT02488252|Drug|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
79974683|NCT03799913|Biological|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
79974684|NCT03799913|Drug|Fludarabine|30mg/m2/d
79478815|NCT05374109|Behavioral|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
79974685|NCT03799913|Drug|Cyclophosphamide|300mg/m2/d
79808827|NCT02578680|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
79974686|NCT03323008|Other|Prototype|Usability testing and System Usability Scale
79974687|NCT03814382|Device|Acupuncture needle|Acupuncture needle
79974688|NCT01304069|Drug|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
79974689|NCT01304069|Drug|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
79974690|NCT01304069|Drug|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
79974691|NCT03327298|Procedure|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
79478816|NCT05373771|Other|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
79974692|NCT03799601|Drug|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
79974693|NCT03799601|Drug|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
79974694|NCT03799601|Drug|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
79319905|NCT03099941|Other|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
79319906|NCT04479397|Procedure|Latarjet Surgery for anterior shoulder instability|Bone block procedure for anterior shoulder instability
79478817|NCT05365243|Device|AMMA Portalbe Scalp Cooling System|AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
79478818|NCT05364203|Device|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
79478819|NCT05361759|Device|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
79808828|NCT02578680|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
79808829|NCT02578680|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
79490396|NCT02389712|Drug|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
79808830|NCT02578680|Drug|Saline solution|IV infusion
79319907|NCT04479397|Procedure|No sling in postoperative care|No sling will be used in postoperative care.
79319908|NCT03099629|Behavioral|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
79974695|NCT03322852|Other|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
79974696|NCT03327142|Diagnostic Test|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
79974697|NCT03793985|Drug|T|CKD-391 40/10mg
79974698|NCT03793985|Drug|R|D086 and D337 co-administration
79974699|NCT03326908|Device|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
79319909|NCT02370277|Other|Cytology Specimen Collection Procedure|Undergo collection of stool samples
79319910|NCT02370277|Other|Laboratory Biomarker Analysis|Correlative studies
79808831|NCT02464072|Procedure|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
79974700|NCT03607526|Other|Barriers|NGT sessions identifying barriers to vegetable intake.
79974701|NCT03607526|Other|Facilitators|NGT sessions identifying facilitators to vegetable intake.
79974702|NCT03791801|Drug|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
79974703|NCT03791801|Drug|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
79974704|NCT03791801|Drug|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
79974705|NCT03791801|Drug|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
79974706|NCT03494192|Other|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
79319911|NCT02370277|Other|Questionnaire Administration|Ancillary studies
79319912|NCT05068895|Other|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
79319913|NCT02375815|Other|Statin Choice Implementation|
79490397|NCT02389712|Drug|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
79490398|NCT00378950|Behavioral|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
79974707|NCT03494192|Other|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
79974708|NCT01305083|Drug|Udenafil|Placebo-control
79974709|NCT01305083|Drug|Placebo|Placebo
79974710|NCT03319888|Device|CPAP|continuous positive pressure in the airway
79974711|NCT03319888|Other|conservative treatment|conservative treatment group with lifestyle modifications
79974712|NCT02490826|Other|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~Auditory Bombardment;~Auditory and discrimination;~Letter-sound knowledge;~Phoneme identity and phoneme matching;~Blending;~Segmentation;~Rhyme;~Phoneme manipulation."
79974713|NCT02490826|Other|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~Auditory Bombardment;~Auditory and discrimination;~Letter-sound knowledge;~Phoneme identity and phoneme matching;~Blending;~Segmentation;~Rhyme;~Phoneme manipulation."
79319914|NCT02375737|Behavioral|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
79808832|NCT02464072|Procedure|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
79974714|NCT03464396|Other|Bedside Physiology study|A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
79808833|NCT02464072|Procedure|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
79319915|NCT05067881|Procedure|Pulmonary resection|Resection of pneumohematocele
79319916|NCT04404439|Drug|Nortriptyline + topiramate|Treatment group 1
79319917|NCT04404439|Drug|Verapamil + paroxetine|Treatment group 2
79319918|NCT04404439|Other|Placebo|Placebo comparator
79319919|NCT01953328|Drug|Atorvastatin|Administered orally once a day
79319920|NCT01953328|Biological|Evolocumab|Administered by subcutaneous injection
79319921|NCT01953328|Other|Placebo to Evolocumab|Administered by subcutaneous injection
79808834|NCT02459171|Other|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
79808835|NCT02459171|Other|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
79319922|NCT05067959|Biological|Covid-19 vaccine|blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
79319923|NCT02375893|Other|No intervention|Collecting blood and feces samples
79319924|NCT02375893|Other|Healthy subject|Collecting blood and feces samples
79319925|NCT03100955|Drug|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
79490399|NCT00378950|Behavioral|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
79490400|NCT03530917|Drug|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
79808836|NCT02459171|Other|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
79319926|NCT03100955|Drug|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
79319927|NCT02377609|Drug|Tacrolimus|oral
79478820|NCT05360017|Device|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
79490401|NCT03530917|Drug|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
79490402|NCT02365688|Procedure|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
79490403|NCT05600348|Dietary Supplement|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
79490404|NCT02369744|Drug|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
79319928|NCT05067413|Procedure|Transanterior obturator nerve gateway approach|Distal rectal transection of cases in the experimental group will be performed using transanterior obturator nerve gateway approach
79974715|NCT03464396|Other|Carotid Body Function Test|Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
79974716|NCT03464396|Other|Room Air Challenge|Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate [HR] < 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
79319929|NCT05067413|Procedure|Total mesorectal excision approach|Distal rectal transection of cases in the control group will be performed using total mesorectal excision approach
79319930|NCT02375581|Drug|Icotinib|125mg, Po, TID during RT
79319931|NCT02375581|Radiation|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
79974717|NCT03464396|Other|Hypoxia Challenge Test|"A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge.~If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of > 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% < 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped."
79319932|NCT04435067|Genetic|Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia|The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
79478821|NCT05359666|Device|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
79478822|NCT05359666|Device|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline & Irrisept and Irrisept); Chloraprep; Gentamicin & saline; unknown; and none."
79478823|NCT05356377|Drug|Pegvaliase-Pqpz|Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. [Note that prescription and standard care are independent of the present study.]
79808837|NCT02459171|Other|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
79808838|NCT02385266|Drug|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
79808839|NCT02385266|Drug|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
79974718|NCT03464396|Other|Effects of Nasal Cannula Flow|"Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.~28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for 15 minutes. Infant on Bubble CPAP will be increased 1cm H2O to max 8 cm H2O for 15 minutes.~Infant's that fail the RAC or HCT at 36 weeks with periodic breathing, high flow at 3LPM will be started for 2 minutes or until periodic breathing stops. Infants on Bubble CPAP will not undergo the RAC or HCT. Their pressure is increased by 1cm H20 to max of 8 cm H2O for 15 minutes.~Infant on RA at 40 and 52 weeks PMA with periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started for 2 minutes or until periodic breathing stops."
79319933|NCT04435067|Other|Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor|This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D_average, Gray Level Co-occurrence Matrix 3D_combined, Gray Level Run Length 3D_average, Gray Level Run Length 3D_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
79319934|NCT02377531|Other|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
79490405|NCT02369744|Drug|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
79808840|NCT02379988|Radiation|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
79808841|NCT02351765|Drug|Acelarin|First-in-class nucleotide analogue
79808842|NCT02351765|Drug|Cisplatin|Platinum-compound chemotherapy drug
79808843|NCT02329652|Device|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
79808844|NCT02251431|Drug|BYDUREON|Exenatide-extended release, Cohorts A and B
79808845|NCT02251431|Drug|Placebo|Cohort A only
79808846|NCT02191488|Drug|5-aminolevulinic acid|
79319935|NCT02377531|Other|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
79808847|NCT02006069|Device|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
79808848|NCT01985867|Dietary Supplement|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10^8 CFU, twice daily, orally for 4 weeks)
79974719|NCT03464396|Diagnostic Test|Magnetic Resonance Imaging|A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
79974720|NCT03464396|Diagnostic Test|Echocardiogram|An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
79644508|NCT05089825|Other|Receive routine instructions|Study subjects randomized to this arm will receive a mailed myLab Box kit with instructions on HPV self-collection and postage to be shipped directly to the commercial lab. It should take less than 5 minutes to collect the sample.
79319936|NCT03101189|Drug|ACT-541468|Capsule
79319937|NCT03101189|Drug|placebo|Matching placebo capsule
79319938|NCT02377687|Other|observational study|
79319939|NCT02369965|Drug|albuvirtide|albuvirtide 320mg administered intravenously once a week
79319940|NCT02369965|Drug|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
79319941|NCT02369965|Drug|tenofovir|tenofovir 300mg administered orally once daily
79319942|NCT02369965|Drug|lamivudine|lamivudine 300mg administered orally once daily
79808849|NCT01985867|Dietary Supplement|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
79974721|NCT03464396|Other|Blood Sample|Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
79974722|NCT03791723|Drug|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
79644509|NCT05089825|Other|Telehealth-based instructional visit and receive routine instructions|"Study subjects randomized to this arm will similarly receive a mailed myLab Box kit and also undergo a brief 5-10 telehealth instructional visit via video conference."
79808850|NCT01837745|Drug|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
79808851|NCT01837745|Drug|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
79808852|NCT01837745|Other|Follow up|"10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~4 years (+/- 2 months) after randomization: a serum Tg/LT4~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
79808853|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
79808854|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
79808855|NCT01494493|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
79974723|NCT03791723|Drug|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
79974724|NCT05452070|Device|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
79974725|NCT03797885|Other|No treatment given|No treatment is administered to the participants for this study
79808856|NCT01494493|Procedure|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
79808857|NCT01494454|Device|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
79974726|NCT05410912|Procedure|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
79974727|NCT04442932|Device|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
79974728|NCT03920657|Drug|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
79974729|NCT03420950|Other|Rapid sequence intubation: sedative first|Sedative first
79974730|NCT03420950|Other|Rapid sequence intubation: paralytic first|Paralytic first
79319943|NCT02369809|Drug|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
79478824|NCT05356130|Behavioral|Written Educational Material on BLT|Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.
79974731|NCT03319654|Diagnostic Test|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
79319944|NCT02640755|Drug|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
79319945|NCT02640755|Drug|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
79319946|NCT02640755|Drug|Fulvestrant|Hormonal Agent
79319947|NCT02640755|Drug|Paclitaxel|Taxane
79319948|NCT02375425|Other|no intervention|no intervention-specimen collection study only
79478825|NCT05356130|Behavioral|Enhanced BLT Encouragement and Adherence Promotion|BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
79490406|NCT03577171|Drug|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
79490407|NCT03577171|Drug|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
79974732|NCT03501277|Drug|Alogliptin|Alogliptin tablets.
79974733|NCT03501277|Drug|Pioglitazone|Pioglitazone tablets.
79974734|NCT03501277|Drug|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
79974735|NCT04568850|Diagnostic Test|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
79974736|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
79319949|NCT04400539|Device|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
79974737|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
79319950|NCT04400539|Drug|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
79319951|NCT02369497|Device|HRA|Humeral head resurfacing with the HRA device
79319952|NCT03099785|Drug|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
79319953|NCT03099785|Drug|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
79319954|NCT03099785|Drug|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
79319955|NCT02389075|Procedure|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
79974738|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
79319956|NCT02389075|Procedure|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
79319957|NCT02375503|Dietary Supplement|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
79319958|NCT02375503|Dietary Supplement|Placebo|
79319959|NCT02375269|Device|RIPC with a tourniquet|
79319960|NCT00867191|Drug|Placebo|Placebo, 1 tablet daily, per os., 15 days
79319961|NCT00867191|Drug|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
79808858|NCT01494454|Device|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
79808859|NCT01494441|Procedure|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
79319962|NCT05066945|Other|Observation|observe the association of ctDNA with efficacy of treatment
79319963|NCT02640677|Biological|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
79319964|NCT05067023|Diagnostic Test|MRI scan|All participants will undergo 1 DCE-MRI scan.
79319965|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
79319966|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
79808860|NCT01494441|Device|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
79974739|NCT03447626|Device|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
79974740|NCT02488174|Other|PROOFcheck|
79974741|NCT02488174|Other|Standard Care|
79319967|NCT02643251|Drug|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
79319968|NCT02643251|Drug|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
79319969|NCT02375191|Drug|fentanyl|
79974742|NCT03870425|Other|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
79974743|NCT03322228|Other|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
79319970|NCT02375191|Drug|dexmedetomidine|
79319971|NCT02375191|Drug|Ropivacaine|
79319972|NCT02375035|Device|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
79319973|NCT03100877|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79319974|NCT03100877|Drug|Cyclophosphamide|Given IV
79319975|NCT03100877|Biological|Filgrastim|Given SC or IV
79319976|NCT03100877|Other|Laboratory Biomarker Analysis|Correlative studies
79974744|NCT03797729|Drug|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
79644510|NCT05088317|Diagnostic Test|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
79644511|NCT05073705|Behavioral|Empowerment and personal transformation intervention|The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
79644512|NCT05073679|Drug|Naltrexone Hydrochloride|25mg x 3 days then 50mg a day thereafter
79644513|NCT05073679|Other|Control|Methylcellulose and gelatin capsule only
79644514|NCT05071976|Diagnostic Test|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
79644515|NCT05056506|Procedure|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
79319977|NCT03100877|Drug|Lenalidomide|Given PO
79319978|NCT03100877|Procedure|pheresis|Undergo apheresis
79319979|NCT03100877|Drug|Melphalan|Given IV
79319980|NCT03100877|Biological|Palifermin|Given IV
79319981|NCT03100877|Radiation|Total Marrow Irradiation|Undergo TMI
79319982|NCT02374879|Device|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
79319983|NCT02369419|Other|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as <14/17 points using the ONCODAGE score
79319984|NCT03099551|Device|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
79319985|NCT03099551|Device|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
79319986|NCT03099473|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
79319987|NCT03099473|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
79319988|NCT03099473|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
79974745|NCT03797729|Drug|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
79974746|NCT03500419|Device|RestoreX|PTT - Penile traction therapy in the straight position.
79974747|NCT03500419|Other|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
79974748|NCT02487940|Drug|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
79974749|NCT02487940|Drug|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
79974750|NCT03625934|Biological|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
79319989|NCT02369107|Other|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
79319990|NCT02369107|Other|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
79319991|NCT00794495|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
79319992|NCT00794495|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
79974751|NCT03625934|Biological|Placebo|5 s.c. injections of matching Placebo four weeks apart
79974752|NCT03797573|Device|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
79974753|NCT03797573|Device|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
79319993|NCT02369029|Drug|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
79490408|NCT03577171|Drug|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
79490409|NCT02367170|Procedure|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
79644516|NCT05056506|Procedure|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
79319994|NCT03099317|Other|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
79808861|NCT01494441|Device|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
79808862|NCT01494428|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
79808863|NCT01494428|Device|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
79974754|NCT02488096|Device|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
79644517|NCT05036733|Drug|Dupilumab|"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
79974755|NCT02488096|Device|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy ~ 1 week after the MRI."
79974756|NCT03500341|Device|INVSENSOR00014|Noninvasive pulse oximeter sensor
79644518|NCT05031429|Other|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
79974757|NCT03365102|Device|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
79974758|NCT03365102|Device|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
79974759|NCT03365102|Device|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
79974760|NCT02487862|Behavioral|Stress Reduction Protocol|Stress Reduction Protocol
79974761|NCT03816293|Device|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
79974762|NCT02487628|Device|HQ® Matrix Soft Tissue Mesh|
79974763|NCT02487628|Device|ULTRAPRO® Partially Absorbable Lightweight Mesh|
79644519|NCT05027867|Drug|KRT-232|Administered by mouth
79644520|NCT05025748|Behavioral|Behavioral Intervention|Complete questionnaires
79644521|NCT05005234|Drug|GFH925|Administered as an oral tablet formulation
79644522|NCT04979793|Drug|L-citrulline|3 gram sachet, L-citrulline
79644523|NCT04979793|Drug|Placebo|Milk powder placebo
79644524|NCT04969653|Other|Exposure of venous thromboembolism|Composite of pulmonary embolism and deep vein thrombosis
79808864|NCT01491542|Device|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
79319995|NCT03099317|Other|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
79319996|NCT04529707|Behavioral|Transdiagnostic Behavioral Sleep Intervention|"The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention."
79319997|NCT03105973|Behavioral|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
79478826|NCT05338385|Behavioral|Mental Skills Coaching|Participants will partake in a 1-hour pre-op initial intake, followed by five 30-min follow-up sessions at 2 weeks, 6 weeks, 3 months, 6 months and 9-months post-op. All sessions will be one-on-one with the same master's-level mental skills coach. At each session, the provider will allow time for participants to share their current injury experience to date (i.e. how they are doing, challenges they have encountered). Following this, participants will be introduced to a series of mental skills tools, including but not limited to mindset awareness, motivation, cognitive restructuring, goal setting, and objective performance assessment. Participants will be provided with handouts outlining the strategies addressed to help maintain consistency of mental skills engagement between sessions.
79808865|NCT01491542|Device|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
79974764|NCT03719365|Device|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
79478827|NCT05334966|Other|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
79478828|NCT05329766|Drug|Domvanalimab|Administered as specified in the treatment arm
79974765|NCT02487706|Drug|Dolutegravir|Dolutegravir 50mg/day per 5 days
79478829|NCT05329766|Drug|Quemliclustat|Administered as specified in the treatment arm
79478830|NCT05329766|Drug|Zimberelimab|Administered as specified in the treatment arm
79974766|NCT04551950|Drug|M7824|Participants will receive bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
79974767|NCT04551950|Drug|Carboplatin|Carboplatin will be administered intravenously as per standard of care.
79478831|NCT05329766|Drug|Fluorouracil|Administered as specified in the treatment arm
79478832|NCT05329766|Drug|Leucovorin|Administered as specified in the treatment arm
79478833|NCT05329766|Drug|Oxaliplatin|Administered as specified in the treatment arm
79478834|NCT05324852|Drug|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
79644525|NCT04969419|Other|Exposure of skin cancer of interest|Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.
79319998|NCT04157075|Drug|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
79644526|NCT04964986|Drug|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
79644527|NCT04957251|Procedure|anterior approach to the hip|anterior hip hemiarthroplasty
79644528|NCT04957251|Procedure|posterior approach to the hip|posterior hip hemiarthroplasty
79644529|NCT04956094|Diagnostic Test|GGT/Uric Acid|Standard laboratory blood testing for GGT and uric acid levels.
79808866|NCT01491464|Device|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
79808867|NCT01491464|Device|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
79808868|NCT01491451|Device|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
79808869|NCT01491451|Device|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
79808870|NCT01491425|Device|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
79808871|NCT01491425|Device|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
79808872|NCT01491399|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
79808873|NCT01491399|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
79808874|NCT01491386|Device|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
79808875|NCT01491386|Device|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
79974768|NCT04551950|Drug|Paclitaxel|Paclitaxel will be administered intravenously as per standard of care.
79319999|NCT00763529|Drug|Mometasone|Mometasone furoate cream 0.1% applied once daily
79320000|NCT00763529|Drug|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
79320001|NCT03105505|Drug|Permethrin 5%|Facial skin application once a night for 3 months.
79320002|NCT03105505|Drug|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
79320003|NCT03105505|Drug|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
79320004|NCT03105193|Drug|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
79644530|NCT04929392|Drug|Carboplatin|Given IV
79644531|NCT04929392|Procedure|Endoscopic Biopsy|Undergo endoscopic biopsy
79644532|NCT04929392|Radiation|External Beam Radiation Therapy|Undergo EBRT
79644533|NCT04929392|Drug|Lenvatinib Mesylate|Given PO
79644534|NCT04929392|Drug|Paclitaxel|Given IV
79644535|NCT04929392|Biological|Pembrolizumab|Given IV
79974769|NCT04551950|Drug|Bevacizumab|Bevacizumab will be administrated as indicated for standard of care.
79644536|NCT04929392|Procedure|Resection|Undergo surgical resection
79974770|NCT04551950|Drug|Cisplatin|Cisplatin will be administered intravenously as per standard of care.
79974771|NCT04551950|Radiation|Radiotherapy|Participants will receive radiotherapy as per standard of care.
79644537|NCT04918771|Drug|Raphamin|"Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days."
79644538|NCT04918771|Drug|Placebo|Oral administration - not with food. Placebo using Raphamin scheme.
79974772|NCT02487784|Procedure|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
79974773|NCT02487784|Procedure|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
79974774|NCT03797339|Other|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
79974775|NCT03797339|Other|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
79974776|NCT03797339|Other|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
79644539|NCT04876742|Other|Beer|"As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment."
79644540|NCT04876742|Other|Water|For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
79644541|NCT04867278|Procedure|External Beam Radiation (XRT)|Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
79974777|NCT03797339|Other|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
79974778|NCT03319576|Other|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
79974779|NCT03326752|Drug|DV281|- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
79974780|NCT03326752|Device|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
79974781|NCT03326752|Drug|DV281 (RP2D)|- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
79478835|NCT05324852|Drug|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
79644542|NCT04867278|Procedure|Debridement|Gluteus minimus debridement in the OR
79644543|NCT04834505|Other|Diagnostic imaging modalities for validation sample|Endoscopic ultrasound and other imaging modalities such as CT, MRI, or PET-CT are performed.
79808876|NCT01367002|Drug|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
79974782|NCT03326752|Drug|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
79320005|NCT03105193|Drug|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
79320006|NCT03105193|Drug|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
79320007|NCT03105193|Drug|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
79320008|NCT05066633|Drug|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
79320009|NCT05066633|Drug|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
79320010|NCT02365129|Other|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
79320011|NCT03100799|Procedure|Arthroscopy|Arthroscopy of the target knee
79320012|NCT03100799|Procedure|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
79644544|NCT04834505|Other|EUS for derivation sample|Endoscopic ultrasound was performed.
79644545|NCT04831294|Drug|Cannabidiol|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
79644546|NCT04831294|Drug|Placebo|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
79974783|NCT01304303|Drug|SPARC1023 I|IV administration
79974784|NCT01304303|Drug|SPARC1023 II|IV administration
79974785|NCT03326674|Drug|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
79974786|NCT03326674|Drug|Capecitabine|Capecitabine alone at approved dose
79974787|NCT02491060|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
79974788|NCT02491060|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
79974789|NCT01316900|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
79974790|NCT01316900|Drug|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
79974791|NCT01316900|Drug|GW642444|25 mcg once-daily
79974792|NCT01316900|Drug|tiotropium bromide|18 mcg once-daily
79974793|NCT02490982|Drug|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
79974794|NCT03322150|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
79974795|NCT03322150|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
79974796|NCT03499873|Drug|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
79974797|NCT03499873|Drug|Placebos|Placebo
79974798|NCT03499873|Drug|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
79974799|NCT01305707|Device|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
79974800|NCT01305707|Drug|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
79320013|NCT03100799|Diagnostic Test|MRI|MRI with and without a gadolinium-based contrast agent
79320014|NCT04439305|Drug|Dasatinib|Given PO
79320015|NCT05066867|Other|Smart sharps bin - collects data on compliance|collects compliance data
79320016|NCT02368951|Drug|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
79320017|NCT03100643|Other|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
79320018|NCT02364973|Other|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
79320019|NCT03100721|Behavioral|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
79320020|NCT03100721|Procedure|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
79320021|NCT02368873|Procedure|Application of IPOM mesh|
79320022|NCT02368795|Device|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
79320023|NCT02368795|Drug|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
79478836|NCT05319756|Drug|gabapentin 600 mg|Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
79320024|NCT02368795|Drug|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
79320025|NCT02368795|Drug|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
79320026|NCT05066243|Other|questionnaire|this study is to develop a questionnaire for vulval conditions
79320027|NCT00650663|Drug|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
79320028|NCT00650663|Drug|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
79320029|NCT02374723|Device|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
79320030|NCT02374723|Device|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
79478837|NCT05319756|Drug|gabapentin 1200 mg|Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
79478838|NCT05319756|Drug|gabapentin 600 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
79478839|NCT05319756|Drug|gabapentin 1200 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
79478840|NCT05319756|Drug|oxycodone HCl 20 mg|Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
79644547|NCT04828694|Drug|BICX104|Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
79320031|NCT05065853|Diagnostic Test|urine self-sampling group|collection of urine and vaginal samples
79320032|NCT05065853|Diagnostic Test|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
79974801|NCT04493086|Diagnostic Test|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR < 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
79478841|NCT05319756|Drug|placebo|Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
79478842|NCT05319080|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
79320033|NCT02368717|Drug|Mesalazine Enema|
79320034|NCT02368717|Drug|Placebo Enema|
79478843|NCT05316350|Device|Electrocardiogram recording|ECG recording with investigational device
79320035|NCT04231565|Drug|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
79320036|NCT02364817|Behavioral|cognitive and psychiatric assessment|"Administered at baseline:~Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~administered at week 12: ASRS"
79320037|NCT05065931|Other|Auxiliary diagnostic system by AI-CDSS|Helping clinicians to make diagnoses by using CDSS based-on AI
79478844|NCT05316350|Device|Electrocardiogram recording|ECG recording with reference device
79478845|NCT05316337|Device|Electrocardiogram recording|ECG recording with investigational device
79644548|NCT04828694|Drug|Vivitrol|Intramuscular injection containing 380 mg of naltrexone.
79478846|NCT05316337|Device|Electrocardiogram recording|ECG recording with reference device
79478847|NCT05314985|Other|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
79490410|NCT02367170|Drug|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
79478848|NCT05314010|Drug|MIL62|"Phase 1b:participants will receive IV MIL62 500 mg or 1000 mg on Day 1 and Day 15.~Phase 3:Participants will receive IV MIL62 on Day 1, Day 15 and Day 183 of the RCP at the dose confirmed in the phase Ib. The participants who enter the OLP will receive IV MIL62 on Day 1 and matching placebo on Day 15, followed by a single IV dose of MIL62 every 6 months until maximum of 6 months after the last participant enters the OLP."
79478849|NCT05314010|Other|Placebo|Phase 3:Participants will receive IV placebo matched to MIL62 on Day 1, Day 15 and Day 183 of the RCP. The participants who enter the OLP will receive IV MIL62 on both Day 1 and Day 15, followed by a single IV dose of MIL62 every 6 months until maximum of 6 months after the last participant enters the OLP.
79320038|NCT02374801|Device|"SonR automatic optimization feature turned ON (AV+VV)."|
79808877|NCT01367002|Drug|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
79478850|NCT05313945|Procedure|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
79320039|NCT05065385|Diagnostic Test|INTER-NDA|Neurodevelopmental Screening Test at age 2 years.
79478851|NCT05313945|Procedure|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
79478852|NCT05308901|Drug|Pembrolizumab|200 mg IV every 3 weeks for a maximum of 2 years.
79478853|NCT05308901|Drug|Lenvatinib|20 mg daily for a maximum of 2 years.
79808878|NCT01124214|Procedure|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
79808879|NCT00858273|Dietary Supplement|Antioxidant supplement|1 capsule daily with dinner
79808880|NCT00858273|Other|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
79808881|NCT00858273|Drug|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
79320040|NCT02375113|Dietary Supplement|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
79320041|NCT02364895|Other|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
79320042|NCT02364895|Other|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
79320043|NCT02364895|Other|Males Group 2: New letter with neutral gender content|Unisex letter
79320044|NCT02364895|Other|Males Group 3: New letter with male-specific content|New letter tailored for men
79320045|NCT02364895|Other|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
79320046|NCT02364895|Other|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
79320047|NCT02364895|Other|Females Group 2: New letter with neutral gender content|Unisex letter
79320048|NCT03100565|Drug|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
79320049|NCT03100565|Other|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
79320050|NCT03113227|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
79320051|NCT03113227|Diagnostic Test|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
79320052|NCT05035277|Drug|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
79320053|NCT05035277|Drug|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
79320054|NCT05035277|Drug|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
79320055|NCT05035277|Drug|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
79808882|NCT00624234|Behavioral|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
79320056|NCT02374645|Drug|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79320057|NCT02374645|Drug|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79320058|NCT02368483|Other|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
79320059|NCT02368327|Biological|Fluad|
79320060|NCT02368327|Biological|Fendrix|
79320061|NCT02368327|Biological|Placebo|
79320062|NCT02368561|Drug|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
79320063|NCT04095845|Device|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
79478854|NCT05307224|Device|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
79320064|NCT04095845|Device|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
79478855|NCT05306665|Behavioral|ACT intervention|One day in person workshop + telephone booster
79478856|NCT05305105|Drug|Psilocybin|Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
79320065|NCT02368639|Device|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher & Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
79320066|NCT02374489|Drug|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
79320067|NCT02374567|Drug|Phenobarbital|
79320068|NCT02374567|Drug|Phenytoin|
79320069|NCT02374567|Drug|Carbamazepine|
79320070|NCT02374567|Drug|Oxcarbazepine|
79320071|NCT02374567|Drug|Valproic Acid|
79320072|NCT02374567|Drug|Lamotrigine|
79320073|NCT02374567|Drug|Topiramate|
79320074|NCT02374567|Drug|Gabapentin|
79320075|NCT02374567|Drug|Levetiracetam|
79320076|NCT02374567|Drug|Pregabalin|
79320077|NCT02374567|Drug|Lacosamide|
79320078|NCT02374567|Drug|Clonazepam|
79320079|NCT02374567|Drug|Biperiden|
79320080|NCT02374567|Drug|Levomepromazine|
79320081|NCT02374567|Drug|Fluphenazine|
79320082|NCT02374567|Drug|Perphenazine|
79320083|NCT02374567|Drug|Perazine|
79320084|NCT02374567|Drug|Thioridazine|
79320085|NCT02374567|Drug|Haloperidol|
79320086|NCT02374567|Drug|Melperone|
79320087|NCT02374567|Drug|Pipamperone|
79320088|NCT02374567|Drug|Bromperidol|
79320089|NCT02374567|Drug|Benperidol|
79320090|NCT02374567|Drug|Sertindole|
79320091|NCT02374567|Drug|Ziprasidone|
79320092|NCT02374567|Drug|Flupentixol|
79320093|NCT02374567|Drug|Chlorprothixene|
79320094|NCT02374567|Drug|Zuclopenthixol|
79320095|NCT02374567|Drug|Fluspirilene|
79320096|NCT02374567|Drug|Pimozide|
79320097|NCT02374567|Drug|Clozapine|
79320098|NCT02374567|Drug|Olanzapine|
79320099|NCT02374567|Drug|Quetiapine|
79320100|NCT02374567|Drug|Sulpiride|
79320101|NCT02374567|Drug|Tiapride|
79320102|NCT02374567|Drug|Amisulpride|
79320103|NCT02374567|Drug|Prothipendyl|
79320104|NCT02374567|Drug|Risperidone|
79320105|NCT02374567|Drug|Aripiprazole|
79320106|NCT02374567|Drug|Paliperidone|
79320107|NCT02374567|Drug|Diazepam|
79320108|NCT02374567|Drug|Oxazepam|
79320109|NCT02374567|Drug|Lorazepam|
79320110|NCT02374567|Drug|Bromazepam|
79320111|NCT02374567|Drug|Clobazam|
79320112|NCT02374567|Drug|Alprazolam|
79320113|NCT02374567|Drug|Hydroxyzine|
79320114|NCT02374567|Drug|Buspirone|
79478857|NCT05301608|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.
79478858|NCT05301608|Drug|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
79974802|NCT04051970|Drug|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load <500 cp/mL at W4 and <50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
79974803|NCT04442854|Other|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
79974804|NCT03722329|Drug|Eculizumab|Eculizumab Injection. 300 mg, single dose
79974805|NCT03791333|Other|injury severity score|injury severity score of multi trauma patients
79320115|NCT02374567|Drug|Chloral Hydrate|
79478859|NCT05301361|Drug|Methylphenidate Oral Solution|The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
79974806|NCT03326440|Other|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
79974807|NCT03791177|Other|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
79320116|NCT02374567|Drug|Flurazepam|
79320117|NCT02374567|Drug|Nitrazepam|
79478860|NCT05301257|Behavioral|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
79644549|NCT04820309|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
79644550|NCT04810299|Other|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
79320118|NCT02374567|Drug|Triazolam|
79320119|NCT02374567|Drug|Lormetazepam|
79320120|NCT02374567|Drug|Temazepam|
79320121|NCT02374567|Drug|Midazolam|
79320122|NCT02374567|Drug|Brotizolam|
79320123|NCT02374567|Drug|Zopiclone|
79320124|NCT02374567|Drug|Zolpidem|
79320125|NCT02374567|Drug|Zaleplon|
79320126|NCT02374567|Drug|Melatonin|
79320127|NCT02374567|Drug|Clomethiazole|
79320128|NCT02374567|Drug|Diphenhydramine|
79320129|NCT02374567|Drug|Promethazine|
79320130|NCT02374567|Drug|Imipramine|
79320131|NCT02374567|Drug|Clomipramine|
79478861|NCT05280340|Drug|Anakinra|Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
79320132|NCT02374567|Drug|Opipramol|
79320133|NCT02374567|Drug|Trimipramine|
79320134|NCT02374567|Drug|Amitriptyline|
79320135|NCT02374567|Drug|Nortriptyline|
79320136|NCT02374567|Drug|Doxepin|
79320137|NCT02374567|Drug|Maprotiline|
79320138|NCT02374567|Drug|Amitriptyline oxide|
79478862|NCT05279027|Drug|Zirconium Zr 89 Crefmirlimab Berdoxa|Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation
79320139|NCT02374567|Drug|Fluoxetine|
79808883|NCT00624234|Behavioral|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
79974808|NCT05420896|Other|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
79320140|NCT02374567|Drug|Citalopram|
79320141|NCT02374567|Drug|Paroxetine|
79320142|NCT02374567|Drug|Sertraline|
79320143|NCT02374567|Drug|Fluvoxamine|
79320144|NCT02374567|Drug|Escitalopram|
79320145|NCT02374567|Drug|Tranylcypromine|
79320146|NCT02374567|Drug|Moclobemide|
79320147|NCT02374567|Drug|Mianserin|
79320148|NCT02374567|Drug|Trazodone|
79478863|NCT05277012|Drug|Etrumadenant|Etrumadenant capsule and tablet formulations
79644551|NCT04810299|Other|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
79974809|NCT03467971|Drug|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
79320149|NCT02374567|Drug|Mirtazapine|
79320150|NCT02374567|Drug|Bupropion|
79320151|NCT02374567|Drug|Venlafaxine|
79320152|NCT02374567|Drug|Reboxetine|
79320153|NCT02374567|Drug|Duloxetine|
79320154|NCT02374567|Drug|Agomelatine|
79320155|NCT02374567|Drug|Pyritinol|
79478864|NCT05273567|Drug|guanfacine-ER|guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
79478865|NCT05273567|Other|Placebo|placebo will be dispensed similar to the active arm.
79320156|NCT02374567|Drug|Piracetam|
79320157|NCT02374567|Drug|Donepezil|
79320158|NCT02374567|Drug|Rivastigmine|
79320159|NCT02374567|Drug|Galantamine|
79320160|NCT02374567|Drug|Memantine|
79320161|NCT02374567|Drug|Nicergoline|
79320162|NCT02374567|Drug|Acamprosate|
79320163|NCT02374567|Drug|Lithium|
79320164|NCT04981535|Device|Head box during upper gastrointestinal endoscopy|"็Head box is an acrylic box over a patient's head who undergoing upper gastrointestinal endoscopy."
79320165|NCT04434989|Radiation|Stereotactic Body Radiation Therapy|SBRT for perivascular HCC
79320166|NCT04434989|Procedure|radiofrequency ablation|RFA for perivascular HCC
79320167|NCT05064215|Procedure|anatomical examination|After injection of dye, its distribution along lymphatic clearance paths was investigated
79320168|NCT03965741|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
79320169|NCT03965741|Drug|Apixaban(Eliquis)|Follow clinical administration
79478866|NCT05272176|Behavioral|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
79478867|NCT05269225|Other|Organic diet|Organically produced foods.
79478868|NCT05269225|Other|Conventional diet|Conventionally produced foods.
79478869|NCT05266729|Drug|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
79320170|NCT03965741|Drug|Pradaxa (Dabigatran etexilate)|Follow clinical administration
79320171|NCT02364505|Behavioral|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
79320172|NCT02364505|Behavioral|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
79320173|NCT02368171|Other|measure exhaled carbon monoxide and nitric oxide|
79320174|NCT04412447|Device|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
79320175|NCT02364739|Other|Written information|Brochure
79808884|NCT04158167|Drug|oxytocin|24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
79320176|NCT02364739|Other|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
79320177|NCT02374333|Biological|huCART19|
79320178|NCT05063669|Behavioral|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
79974810|NCT03138590|Device|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
79974811|NCT02487550|Biological|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
79320179|NCT02364583|Drug|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
79478870|NCT05266729|Drug|Placebo|Phosphate buffered saline placebo for injection
79974812|NCT02487550|Biological|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
79478871|NCT05266339|Other|Cross-education training|The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
79808885|NCT00659555|Drug|pazopanib eye drops|Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
79808886|NCT00659555|Drug|Ketoconozole tablets|Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
79808887|NCT02635997|Drug|antiresorptive therapy|
79808888|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
79478872|NCT05266339|Other|Standard exercise program|The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
79808889|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
79808890|NCT00660101|Biological|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
79808891|NCT02635607|Drug|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
79808892|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
79974813|NCT04442776|Behavioral|D-AIP|Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
79320180|NCT03100409|Other|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
79320181|NCT02368015|Other|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
79320182|NCT02368015|Drug|cefazolin|
79320183|NCT02364661|Behavioral|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
79974814|NCT03791021|Diagnostic Test|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
79320184|NCT02364427|Device|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
79320185|NCT02373943|Other|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
79320186|NCT02373943|Other|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
79320187|NCT02373943|Other|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
79320188|NCT05062499|Device|Active TENS|electrical stimulation
79320189|NCT05062499|Device|Sham TENS|no stimulation
79320190|NCT02364193|Device|MRI|"Cardiac MRI for LVEF and segmentation.~Phase-contrast MRI for CO in aorta and each pulmonary vein.~DCE-MRI for bolus kinetic parameter analysis."
79478873|NCT05263232|Other|Natural or artificial office light exposure|Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
79644552|NCT04801589|Drug|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
79974815|NCT03791021|Diagnostic Test|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
79974816|NCT03791021|Diagnostic Test|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
79974817|NCT03791021|Diagnostic Test|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
79320191|NCT02364193|Drug|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
79478874|NCT05258981|Diagnostic Test|MRI|Brain MRI
79644553|NCT04801589|Drug|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
79974818|NCT03049280|Device|Transoral robotic surgery|Transoral robotic surgery for T1 & T2 oropharyngeal cancers
79974819|NCT04442698|Procedure|Mini-Gastric Bypass Original Technique|Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
79974820|NCT03791099|Drug|Metronidazole|After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
79974821|NCT03326362|Other|Resistance training|Comparison between high and low intensities trainings described in arms
79974822|NCT03185000|Drug|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
79478875|NCT05257018|Drug|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~Rituximab 375 mg / m^2，D1~Cyclophosphamide 750 mg / m^2，D2~Doxorubicin Hydrochloride Liposome Injection 35mg / m^2，D2~Vincristine 1.4mg/m^2 (dose capped at 2 mg)，D2~Prednisone 50 mg， bid D2-6~Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
79478876|NCT05255445|Biological|Red Blood Cell (RBC) Transfusion|Simple RBC transfusion or partial manual exchange
79478877|NCT05254210|Device|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
79478878|NCT05243862|Drug|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
79974823|NCT02653313|Drug|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
79974824|NCT03322072|Device|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
79974825|NCT03791255|Drug|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
79478879|NCT05243862|Drug|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
79478880|NCT05242406|Other|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
79478881|NCT05239767|Drug|NSAID|We will administer oral NSAIDs
79478882|NCT05239598|Drug|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
79478883|NCT05236296|Behavioral|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
79320192|NCT02364193|Device|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
79478884|NCT05235308|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis is a minimally invasive technique which involves the use of a spring-wound catheter, ideally placed in the ventrolateral aspect of the epidural space for the lysis of adhesions.
79478885|NCT05232383|Device|polychromatic light|Application of polychromatic light at different times of day
79478886|NCT05232383|Device|polychromatic light|Application of polychromatic light for 2h30 at different times of day with sleep
79478887|NCT05232383|Device|red light|Application of red light at different times of day
79478888|NCT05232383|Device|red light|Application of red light at different times of day with sleep
79320193|NCT02364193|Device|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
79320194|NCT03100175|Behavioral|physiotherapy|strength training for upper and lower limbs fitness and balance work out
79478889|NCT05232383|Device|green light|Application of green light at different times of day
79478890|NCT05232383|Device|green light|Application of green light at different times of day with sleep
79478891|NCT05227196|Drug|Semaglutide D Dose 1|Tablet given orally
79478892|NCT05227196|Drug|Semaglutide D Dose 2|Tablet given orally
79478893|NCT05227196|Drug|Semaglutide D Dose 3|Tablet given orally
79478894|NCT05227196|Drug|Semaglutide Dose 4|Tablet given orally
79478895|NCT05227196|Drug|Semaglutide Dose 5|Tablet given orally
79478896|NCT05227196|Drug|Semaglutide Dose 6|Tablet given orally
79320195|NCT05231161|Diagnostic Test|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
79320196|NCT03100097|Device|Aspen Horizon 627 LSO|
79320197|NCT02368249|Drug|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
79478897|NCT05218525|Other|Algorithm|"Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter."
79478898|NCT05216380|Behavioral|ActivityLink|"ActivityLink is an implementation program using:~Didactic and experiential training sessions for clinic staff to conduct referrals~Secure electronic referral webform to refer patients using their email address and phone number~Messaging sent to the patient and provider that they have been referred to a program~Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
79478899|NCT05212753|Device|Conventional physical therapy|Hot packs or hot water bags are superficial warming agents that will be used to heat muscle tissue, reduce muscle spasms and pain sensation. TENS is a pain reliever application.
79478900|NCT05212753|Other|Lumbar stabilization exercises|Training about the concepts of stabilization and abdominal bracing is given before starting the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface. The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
79478901|NCT05212753|Other|Breathing exercises|Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During diaphragmatic breathing, attention is focused on the correct abdominal breathing. The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over-breathing. This intervention also includes Sleep Hygiene education to the subjects,
79808893|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels>600 pg/ml; and (iii) serum LH levels>10 IU/l.
79478902|NCT05211414|Behavioral|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
79808894|NCT02635607|Drug|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
79808895|NCT02635607|Drug|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
79808896|NCT04156841|Diagnostic Test|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
79974826|NCT03791255|Drug|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
79974827|NCT03326284|Other|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
79320198|NCT02368249|Drug|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
79320199|NCT04473443|Other|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
79320200|NCT02367937|Drug|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
79320201|NCT02364349|Drug|Bee Venom (BV)|Raw Bee Venom
79320202|NCT02364349|Drug|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
79320203|NCT02373787|Device|creos xenoprotect|Implant placement with simultaneous bone augmentation
79320204|NCT02373787|Device|Bio-Gide|resorbable collagen membrane
79320205|NCT05062187|Other|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
79320206|NCT02367547|Drug|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
79320207|NCT02367547|Drug|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
79320208|NCT02367547|Drug|Methylaminolevulinate cream|In the study we use Metvix.
79808897|NCT04156841|Procedure|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
79974828|NCT03326284|Other|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
79320209|NCT05061641|Drug|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (<37 weeks of gestation), the rate of early premature delivery (<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (<37 weeks), neonatal perinatal mortality and morbidity.
79808898|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
79974829|NCT03326284|Other|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
79974830|NCT03326284|Other|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
79320210|NCT02367625|Device|CryoPop|The new CryoPop device will be compared to standard cryotherapy
79320211|NCT02367625|Device|MedGyn MGC 200|Standard cryotherapy
79320212|NCT03055403|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
79320213|NCT03055403|Drug|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
79320214|NCT02367703|Procedure|laparoscopic hysterectomy|
79320215|NCT05060861|Other|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
79320216|NCT03100019|Dietary Supplement|Resveratrol|
79320217|NCT03100019|Drug|Placebo|
79320218|NCT02363725|Drug|Colchimax®|
79320219|NCT02363725|Drug|Conventional treatment|
79320220|NCT05060393|Behavioral|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
79808899|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
79808900|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
79808901|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
79808902|NCT00844428|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
79974831|NCT03794141|Behavioral|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
79306829|NCT05912595|Device|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
79478903|NCT05208437|Behavioral|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
79478904|NCT05208437|Behavioral|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
79478905|NCT05205031|Device|Intraosseous access|Needle placed in the bone marrow.
79478906|NCT05205031|Device|Intravenous|Needle placed in a vein.
79478907|NCT05203679|Genetic|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 1×10^13 vg/ kg
79306830|NCT05912166|Behavioral|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~Write what they observed during meditations.~Be guided by videos/audios through breathing exercises and gentle stretching.~See what others experienced and their tips for overcoming challenges.~Access videos/audios that explain how mindfulness benefits the body and mind.~Receive suggestions on meditations to do during the week~Set an intention for the week based on class content."
79478908|NCT05187442|Other|questionnaire, interview|The first stage is an online questionnaire survey. A total of 321 TMs were recruited. The time of online questionnaire is about 10-15 minutes to get a preliminary understanding of the erotic and sexual risk experience of TM in Taiwan. In the second stage, focus groups and in-depth interviews will be conducted, 2 hours of each group and interview. A total of 29 transgender man and women, and non-binary participants were recruited.
79478909|NCT05186779|Drug|Progestagen|Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
79808903|NCT00660335|Drug|RG1068 (synthetic human secretin)|Single-dose, IV infusion
79808904|NCT00660413|Device|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
79808905|NCT04156685|Drug|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
79974832|NCT03794141|Behavioral|life style advise|all test persons were given information on healthy diet and life style
79306831|NCT05910801|Procedure|Biopsy|Undergo biopsy
79808906|NCT04156685|Drug|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
79808907|NCT04156685|Drug|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
79808908|NCT04156685|Drug|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
79808909|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
79306832|NCT05910801|Procedure|Biospecimen Collection|Undergo blood sample collection
79306833|NCT05910801|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79306834|NCT05910801|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79306835|NCT05910801|Procedure|Computed Tomography|Undergo CT scan
79306836|NCT05910801|Drug|Lenalidomide|Given PO
79306837|NCT05910801|Procedure|Lumbar Puncture|Undergo lumbar puncture
79306838|NCT05910801|Procedure|Magnetic Resonance Imaging|Undergo MRI
79306839|NCT05910801|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79306840|NCT05910801|Biological|Tafasitamab|Given IV
79306841|NCT05910801|Drug|Venetoclax|Given PO
79306842|NCT05898269|Diagnostic Test|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
79306843|NCT05898269|Diagnostic Test|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
79974833|NCT03326206|Other|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
79478910|NCT05177146|Drug|Intravenous Ketamine (IV)|A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
79644554|NCT04801238|Procedure|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
79644555|NCT04801238|Procedure|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
79644556|NCT04796948|Drug|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
79644557|NCT04772755|Device|Buzzy® and Electronic Game|Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
79644558|NCT04765865|Other|SHAKE Package|The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
79644559|NCT04699617|Device|Dolphin 2.0|The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
79644560|NCT04692467|Drug|Amlodipine 5mg|Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
79808910|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
79974834|NCT03797105|Behavioral|School-Based Obesity Intervention (FLOW)|The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
79808911|NCT00660491|Other|exercise training|moderate intensity exercise group, and high intensity exercise group
79974835|NCT03319420|Drug|LO2A eye drops|Sodium hyaluronate
79974836|NCT03319420|Drug|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
79974837|NCT03794297|Drug|Dabrafenib Mesylate|Given PO
79320221|NCT02367235|Procedure|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
79320222|NCT02367235|Procedure|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
79320223|NCT02373631|Other|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
79320224|NCT02373631|Other|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
79320225|NCT02363413|Other|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
79478911|NCT05171712|Device|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
79320226|NCT02363413|Other|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
79320227|NCT03099239|Biological|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
79320228|NCT02373475|Other|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
79478912|NCT05168800|Behavioral|Dialogue-Based Webinar|One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
79478913|NCT05168800|Behavioral|Social Media Website|A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
79478914|NCT05168800|Other|Enhanced Usual Practice|COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
79974838|NCT03794297|Other|Quality-of-Life Assessment|Ancillary studies
79478915|NCT05168774|Drug|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
79974839|NCT03794297|Other|Questionnaire Administration|Ancillary studies
79974840|NCT03794297|Drug|Trametinib Dimethyl Sulfoxide|Given PO
79974841|NCT04531020|Diagnostic Test|PAED measurement|The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
79974842|NCT03321994|Device|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
79974843|NCT03321994|Device|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
79974844|NCT03048500|Other|Laboratory Biomarker Analysis|Correlative studies
79974845|NCT03048500|Drug|Metformin Hydrochloride|Given PO
79974846|NCT03048500|Biological|Nivolumab|Given IV
79974847|NCT01331772|Other|Control arm|Dietetic follow-up only
79974848|NCT01331772|Other|Intervention arm|Dietetic follow up + adapted physical activity
79974849|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to others
79974850|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to self
79974851|NCT03319342|Behavioral|Behavioral Intervention|Perform self-kindness meditation
79974852|NCT03319342|Behavioral|Behavioral Intervention|Keep track of daily activities
79974853|NCT03319342|Other|Questionnaire Administration|Ancillary studies
79974854|NCT01305161|Other|Blood simple|Single Blood simple at Day 1
79974855|NCT03790787|Drug|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
79974856|NCT03790787|Drug|Dorzagliatin|Glucokinase activator currently under development
79974857|NCT01334268|Device|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
79974858|NCT01334268|Device|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
79974859|NCT04493398|Procedure|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
79974860|NCT04493398|Procedure|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
79974861|NCT04493398|Procedure|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
79974862|NCT01304381|Other|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
79974863|NCT01304381|Other|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
79974864|NCT00908076|Drug|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
79320229|NCT02373475|Other|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
79320230|NCT05059613|Other|probiotics|one times a day during the whole treatment
79320231|NCT02373553|Other|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
79320232|NCT02373553|Other|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
79974865|NCT03319264|Other|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
79644561|NCT04692077|Drug|Cabotegravir (CAB) tablet|30 mg tablets
79974866|NCT03319264|Other|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
79974867|NCT03319264|Radiation|DXA measurement|DXA measurement will be performed to assess patient's body composition
79974868|NCT03319264|Other|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
79974869|NCT03319264|Behavioral|Life habits Questionnaire|Life habits Questionnaire
79974870|NCT02664740|Drug|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
79974871|NCT02664740|Drug|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
79974872|NCT03721237|Other|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
79974873|NCT03797027|Device|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
79974874|NCT03797027|Device|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
79974875|NCT03797027|Device|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
79974876|NCT03319186|Procedure|EDIT Management|"EDIT management~Volumetric Pleural MRI for pre-aspiration pleural cavity volume~Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~Volumetric Pleural MRI for post-aspiration pleural cavity volume~Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 < 14.5 cm H2O/L: allocated to 1st-line TP~EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
79478916|NCT05168124|Behavioral|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
79644562|NCT04692077|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.
79644563|NCT04692077|Drug|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet|300 mg/200 mg fixed-dose combination tablets
79974877|NCT03319186|Procedure|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
79644564|NCT04662099|Biological|Conditioning chemotherapy followed by CAR T cell infusion|Conditioning chemotherapy: Cyclophosphamide 250 mg/m^2 and fludarabine 30 mg/m^2 IV infusion on days -5, -4, and -3 CAR T cells infusion: 0.75x10^6-3.0X10^6 CAR+ T cells per kg of recipient bodyweight. if DLTs don't occur at the dose of 3.0X10^6 CAR+ T cells per kg, the investigators will discuss whether to try higher dose.
79974878|NCT01305317|Drug|Lipitor|Atorvastatin 20mg daily for 6 months
79974879|NCT02613416|Drug|Denosumab|monthly subcutaneous injections
79974880|NCT03326050|Drug|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
79974881|NCT03326050|Drug|Ciprofloxacin|cipro 750 tablet twice daily
79974882|NCT03326050|Drug|Rifampicin|Rifampicin 150Mg Capsule twice daily
79974883|NCT03614585|Behavioral|12 weeks of High-intensity Interval Training|Cardiovascular exercise
79974884|NCT03614585|Behavioral|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
79974885|NCT01334346|Other|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
79974886|NCT01334346|Other|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
79974887|NCT01334346|Other|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
79974888|NCT03467425|Drug|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
79974889|NCT03467425|Drug|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
79974890|NCT03467425|Drug|LAMA|LAMA as prescribed by the physician.
79974891|NCT03467425|Drug|LABA|LABA as prescribed by the physician.
79320233|NCT03098849|Other|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
79320234|NCT02373397|Device|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
79644565|NCT04661163|Other|Psychotherapy|Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
79644566|NCT04647396|Other|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"|"Implementation of the KDIGO bundle for at least 12 hours~discontinuation of all nephrotoxic drugs when possible~optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~close monitoring of serum creatinine, fluid balance and urinary output~avoidance of hyperglycemia~considerations of alternatives to radiocontrast agents~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~avoidance of HES, gelatin, and chlorid-rich solutions"
79320235|NCT02373397|Device|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
79320236|NCT05059847|Other|Training|Training routine assigned by randomized chart
79644567|NCT04643158|Drug|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
79644568|NCT04643158|Drug|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
79644569|NCT04643158|Drug|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
79644570|NCT04643158|Drug|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
79644571|NCT04627025|Drug|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
79320237|NCT03098927|Behavioral|Motor imagery training|Motor imagery training
79320238|NCT05060159|Other|Hemofiltration|Postdilutional Hemofiltration
79320239|NCT03098771|Procedure|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
79320240|NCT03098771|Drug|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
79320241|NCT03098537|Drug|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
79320242|NCT03098537|Other|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
79644572|NCT04590040|Other|Placebo|0% nano-HAP toothpaste
79644573|NCT04590040|Device|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
79644574|NCT04590040|Device|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
79644575|NCT04586296|Other|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
79644576|NCT04583098|Other|fecal microbiota transplantation|frozen or capsulized stool from donors who had already finished recommended blood & stool screening for stool donors
79644577|NCT04581993|Dietary Supplement|Super Cereal - wheat soya blend with sugar|Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.
79644578|NCT04581993|Dietary Supplement|Lipid-based nutrient supplement-medium quantity (LNS-MQ)|Children will receive LNS during 6-23 months of age.
79974892|NCT03467425|Drug|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
79320243|NCT05046665|Drug|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
79320244|NCT05046041|Drug|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
79320245|NCT01970878|Drug|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
79320246|NCT01970878|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
79644579|NCT04581993|Behavioral|Social and behavior change communication (SBCC)|SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.
79974893|NCT04490850|Procedure|Blood sample|Blood sample
79320247|NCT01970878|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
79320248|NCT01970878|Drug|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
79478917|NCT05168124|Behavioral|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
79478918|NCT05166421|Biological|AZD7442|AZD7442 will be administered via IM route.
79478919|NCT05166421|Biological|AZD8895 (clonal cell line material)|AZD8895 will be administered via IM route.
79478920|NCT05166421|Biological|AZD1061 (clonal cell line material)|AZD1061 will be administered via IM route.
79478921|NCT05166421|Biological|AZD8895 (cell pool material)|AZD8895 will be administered via IM route.
79478922|NCT05166421|Biological|AZD1061 (cell pool material)|AZD1061 will be administered via IM route.
79478923|NCT05156788|Drug|PD-1+Lenvatinib+GEMOX|Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
79644580|NCT04557488|Other|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
79974894|NCT03606941|Device|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
79974895|NCT03606941|Device|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
79320249|NCT05045651|Procedure|Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA|gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
79478924|NCT05154513|Other|Cohort 1|No intervention provided in this study
79320250|NCT05045417|Diagnostic Test|Serum level of IL-17|"Measurement of serum level of IL-17 :~To explore the role of IL-17 in systemic lupus erythematosus~To determine the relation between IL-17 and lupus disease activity~To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
79320251|NCT05045339|Procedure|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
79320252|NCT05059145|Drug|Chlorhexidine Gluconate|Vaginal cream 1%
79320253|NCT05059145|Drug|Fluconazole|150 mg oral capsule
79478925|NCT05154136|Drug|Etrumadenant|Capsule
79478926|NCT05154136|Drug|Itraconazole|Capsule
79478927|NCT05153746|Device|3D colonoscopy|3D colonoscopy is a new device to enhance endoscopic imaging.
79478928|NCT05152576|Drug|OnabotulinumtoxinA X|Intramuscular Injection
79478929|NCT05152576|Drug|Placebo|Intramuscular Injection
79644581|NCT04557488|Behavioral|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
79644582|NCT04542018|Other|a low FODMAP diet for 4 weeks|low FODMAP diet for 4 weeks
79644583|NCT04540874|Drug|BI 894416|BI 894416
79644584|NCT04540874|Drug|Placebo|Placebo
79644585|NCT04531982|Drug|Pimavanserin|Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
79974896|NCT05464108|Diagnostic Test|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
79320254|NCT05045105|Other|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
79320255|NCT05059067|Device|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
79320256|NCT05058599|Diagnostic Test|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
79320257|NCT01970488|Biological|Adalimumab|Administered by subcutaneous injection
79478930|NCT05148247|Behavioral|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
79478931|NCT05147350|Drug|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 (Oral) in combination with FOLFIRI (IV)
79478932|NCT05138588|Device|rTMS|For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
79644586|NCT04531982|Drug|Placebo|Placebo, taken as two blinded tablets once daily by mouth
79320258|NCT01970488|Biological|ABP 501|Administered by subcutaneous injection
79320259|NCT03097835|Drug|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
79320260|NCT03097835|Drug|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
79644587|NCT04505618|Device|Swept-Source OCT Angiography|Non-invasive, minimal risk, ocular imaging study
79644588|NCT04505618|Device|Spectral-Domain OCT Angiography|Non-invasive, minimal risk, ocular imaging study
79644589|NCT04505618|Device|Fundus Imaging|Non-invasive, minimal risk, ocular imaging study
79644590|NCT04505618|Device|Axial Length Measurement Device|Non-invasive, minimal risk, ocular imaging study
79644591|NCT04497961|Drug|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
79644592|NCT04497961|Drug|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
79974897|NCT01560611|Device|Near infrared spectroscopy|
79974898|NCT01334424|Drug|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
79308101|NCT04872933|Other|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
79644593|NCT04497961|Behavioral|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
79974899|NCT04493008|Behavioral|Experimental: Educational session|Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
79308102|NCT04867239|Other|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
79308103|NCT03222401|Drug|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
79308104|NCT03222401|Drug|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
79308105|NCT03222401|Drug|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
79308106|NCT04873011|Drug|Quinine Hydrochloride|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of the quinine hydrochloride solution will be infused into the stomach in a randomized, double-blinded fashion
79308107|NCT04873011|Drug|Placebo|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
79308108|NCT02451605|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
79308109|NCT02451605|Procedure|Total knee replacement surgery.|Total knee replacement surgery.
79308110|NCT04873089|Other|Cosmetic product|"It is a comparative study with two parallel groups of subjects:~Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~Comparative group: no application of study product or reference product"
79308111|NCT03222323|Drug|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
79308112|NCT03222323|Drug|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
79308113|NCT03222323|Drug|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
79308114|NCT03222323|Drug|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
79308115|NCT03222323|Drug|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
79308116|NCT04872699|Diagnostic Test|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
79308117|NCT03043677|Biological|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
79308118|NCT03222089|Drug|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
79320261|NCT03097835|Other|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
79320262|NCT03097601|Diagnostic Test|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
79320263|NCT05058755|Drug|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
79974900|NCT03789227|Procedure|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
79320264|NCT05058755|Drug|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
79320265|NCT05044247|Procedure|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
79320266|NCT05044169|Drug|Broncho-Vaxom|administration for 6 months after remmission
79320267|NCT05058365|Behavioral|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
79320268|NCT05044559|Other|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
79320269|NCT05044559|Other|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
79320270|NCT05058053|Other|Cold application|Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
79974901|NCT05083637|Drug|L- carnitine oral solution|The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
79974902|NCT05083637|Other|Placebo|The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
79320271|NCT03097679|Device|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
79974903|NCT04492696|Other|Education|Education
79974904|NCT02178072|Drug|5-Azacitadine|
79320272|NCT03097679|Device|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
79974905|NCT03722251|Behavioral|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
79974906|NCT03319108|Other|Exercise|Pulmonary Rehabilitation Program for 8 weeks
79974907|NCT01804998|Procedure|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
79974908|NCT01804998|Procedure|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
79974909|NCT05664685|Drug|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
79974910|NCT05664685|Drug|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
79974911|NCT03321838|Behavioral|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
79974912|NCT03793517|Drug|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
79320273|NCT05058209|Drug|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
79320274|NCT05058209|Drug|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
79974913|NCT03793517|Drug|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
79320275|NCT05057663|Drug|Bleomycin and 5-fluorouracil|"In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, >10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions"
79320276|NCT03097445|Drug|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
79320277|NCT03097367|Diagnostic Test|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at <2 cm below SMSP, and Level -2: bladder neck at >2 cm below SMSP.
79974914|NCT03793517|Drug|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
79974915|NCT04493944|Behavioral|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
79974916|NCT03789071|Diagnostic Test|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
79974917|NCT02490748|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
79974918|NCT02490748|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
79974919|NCT02886702|Drug|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
79974920|NCT02886702|Drug|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
79974921|NCT02886702|Drug|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
79974922|NCT03498313|Drug|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
79974923|NCT03498313|Drug|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
79644594|NCT04497961|Other|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by the company Plantable. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
79320278|NCT05057351|Other|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
79644595|NCT04464629|Drug|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
79320279|NCT05057351|Other|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
79320280|NCT03097523|Device|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
79320281|NCT03097211|Drug|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
79644596|NCT04464629|Drug|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
79974924|NCT03498313|Drug|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
79974925|NCT02569229|Other|Diagnostics for glucose tolerance with 3 different methods.|"A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~An oral glucose tolerance test done within the 7 day period of CGMS.~Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
79644597|NCT04459416|Other|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
79644598|NCT04459416|Drug|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
79644599|NCT04459416|Other|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
79308119|NCT03222089|Drug|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
79308120|NCT03222089|Drug|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
79308121|NCT03222089|Drug|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
79308122|NCT03222089|Drug|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
79308123|NCT03222089|Drug|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
79308124|NCT03043989|Drug|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
79308125|NCT03043989|Drug|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
79308126|NCT03043989|Drug|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
79308127|NCT02451371|Device|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
79808912|NCT02611284|Procedure|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
79320282|NCT03097211|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
79320283|NCT03097211|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
79320284|NCT03097211|Drug|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
79320285|NCT05056961|Other|Multiparametric mesurements|Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
79320286|NCT05044403|Procedure|Extracorporeal support with haemoperfusion|Use of extracorporeal support with haemoperfusion
79320287|NCT05044403|Procedure|Conventional treatment|Conventional treatment
79320288|NCT05044481|Procedure|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
79320289|NCT04434443|Other|trunk exercise on unstable exercise|Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
79320290|NCT04434443|Other|Upper limb range of motion exercise|Upper limb range of motion exercise with trunk fully supported
79320291|NCT05043935|Procedure|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
79320292|NCT05043935|Procedure|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
79320293|NCT05056571|Behavioral|Progressive muscle relaxation|Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
79320294|NCT03096977|Diagnostic Test|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
79808913|NCT02611284|Procedure|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2< 0.35; for a target Oxygen Saturation (SpO2) of >90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
79320295|NCT03096977|Device|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
79644600|NCT04456647|Other|Parenteral nutrition|Parenteral nutrition treatment in palliative care
79808914|NCT02535377|Other|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
79320296|NCT03096977|Device|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
79808915|NCT00834834|Drug|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
79320297|NCT03096977|Device|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
79644601|NCT04438551|Behavioral|Standard dietary counseling|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.
79808916|NCT00834834|Behavioral|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
79808917|NCT00834834|Drug|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
79808918|NCT02631863|Drug|Aminolaevulinic acid|Aminolaevulinic acid with illumination
79808919|NCT02631863|Drug|Placebo|Placebo with illumination
79808920|NCT00834366|Drug|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
79644602|NCT04438551|Behavioral|Mobile app|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection. Subjects will be given a mobile app to build grocery lists where the sodium level will be recorded and tracked in the app.
79808921|NCT04157933|Drug|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
79320298|NCT03096977|Device|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
79320299|NCT05056181|Other|Physical Activity|Physical activity
79320300|NCT05056337|Drug|Lenvatinib 4 MG Oral Capsule [Lenvima]|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
79320301|NCT05056337|Drug|Toripalimab|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
79320302|NCT05056337|Procedure|TACE|Hepatic arterial chemoembolization
79974926|NCT04494022|Diagnostic Test|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
79974927|NCT05464121|Behavioral|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
79808922|NCT04157933|Drug|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
79974928|NCT03721081|Drug|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
79974929|NCT03721081|Other|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
79974930|NCT04493554|Drug|Vasopressin|Administration of vasopressin (20 IU) intranasally
79974931|NCT04493554|Drug|Placebo|Administration of placebo intranasally
79320303|NCT05056025|Dietary Supplement|Postbotics and Vitamins|2 capsule 3 times a day, before meals
79320304|NCT05056025|Dietary Supplement|Vitamins|2 capsule 3 times a day, before meals
79808923|NCT04157933|Drug|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
79974932|NCT02601014|Biological|Ipilimumab|Given 1 mg/kg IV
79974933|NCT02601014|Biological|Nivolumab|Given 3 mg/kg IV
79974934|NCT02601014|Drug|Enzalutamide|given orally per standard of care
79974935|NCT03721003|Device|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
79478933|NCT05137938|Drug|Intranasal Ketamine (IN)|A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
79478934|NCT05134662|Drug|ALT-801|Injected subcutaneously (SC)
79320305|NCT03097055|Procedure|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
79320306|NCT03097055|Procedure|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
79478935|NCT05134662|Other|Placebo|Injected subcutaneously (SC)
79808924|NCT04157933|Drug|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
79808925|NCT04157933|Drug|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
79320307|NCT02661217|Drug|LCZ696|"LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient."
79320308|NCT05044091|Drug|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
79808926|NCT04157933|Drug|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
79974936|NCT01307046|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
79320309|NCT01952080|Drug|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
79478936|NCT05134454|Diagnostic Test|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
79320310|NCT05043779|Procedure|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
79320311|NCT05055791|Drug|SYHX1903|SYHX1903 tablets, orally, qd
79478937|NCT05132335|Other|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA([18F]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water([15O]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~[18F]-FTHA tracer injections [15O]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
79974937|NCT01307046|Drug|Losartan|Tablet containing losartan potassium (100 mg), once daily
79974938|NCT01307046|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
79974939|NCT01307046|Drug|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
79974940|NCT01307046|Drug|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
79644603|NCT04432935|Dietary Supplement|Bovine Lactoferrin|Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
79320312|NCT01951378|Device|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS > 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
79320313|NCT01951378|Device|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
79478938|NCT05130606|Behavioral|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
79320314|NCT01951378|Drug|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
79644604|NCT04432935|Other|Placebo Glucon D|This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
79644605|NCT04430335|Behavioral|Telephone interview|Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
79644606|NCT04430335|Behavioral|Cognitive Behavioral Therapy|Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
79974941|NCT03719209|Other|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
79974942|NCT03719209|Other|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
79974943|NCT03318796|Device|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB & SB
79974944|NCT05419115|Drug|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
79320315|NCT05055635|Radiation|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
79808927|NCT02631785|Other|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
79320316|NCT01944670|Device|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
79320317|NCT05043467|Drug|Duvie(Lobeglitazone) tab 0.5mg|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
79320318|NCT03096899|Other|Observational|Best Supportive Care
79320319|NCT03096821|Drug|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
79320320|NCT02363179|Behavioral|Live preferential music|Live preferential music will be performed for patients in the emergency department.
79320321|NCT05055245|Other|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
79644607|NCT04429568|Other|Smoked Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.
79808928|NCT00704574|Drug|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
79974945|NCT05419115|Device|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
79974946|NCT05664607|Other|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
79974947|NCT02490592|Other|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
79974948|NCT02490592|Other|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
79974949|NCT03790475|Other|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
79974950|NCT03790475|Other|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
79974951|NCT04492930|Behavioral|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
79974952|NCT04492930|Behavioral|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
79974953|NCT03075462|Drug|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
79974954|NCT03075462|Drug|Apatinib|Apatinib at 250mg once daily, tablet oral
79974955|NCT03788915|Behavioral|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
79974956|NCT03788915|Behavioral|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
79320322|NCT03096587|Device|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
79320323|NCT03096587|Device|ultrasonic activated irrigation|by Satelec,Acteon, France
79320324|NCT03096665|Diagnostic Test|blood test|Point of care blood analysis obtained from skin puncture
79478939|NCT05130606|Behavioral|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
79320325|NCT02373319|Behavioral|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
79320326|NCT02373319|Behavioral|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
79478940|NCT05121064|Behavioral|Alcohol Brief Intervention|The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
79478941|NCT05121064|Behavioral|Common Elements Treatment Approach|CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
79478942|NCT05121064|Behavioral|Standard of Care|Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
79478943|NCT05120063|Device|SPS monoblock stem, Symbios|hip prosthesis
79478944|NCT05120063|Device|Quadra-H, Medacta|hip prosthesis
79478945|NCT05120063|Procedure|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
79478946|NCT05120063|Procedure|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
79478947|NCT05119036|Radiation|44 doses of radiation|Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
79478948|NCT05119036|Radiation|54 doses of radiation|Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
79974957|NCT03325660|Other|whole body vibration|pelvic floor exercises
79974958|NCT01305395|Drug|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
79974959|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
79320327|NCT02373319|Behavioral|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
79320328|NCT02373319|Behavioral|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
79320329|NCT05055167|Drug|Envafolimab|single agent, 300mg Q3W IH until disease progressed
79320330|NCT05043233|Drug|Methimazole(MMI)|Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
79478949|NCT05117463|Other|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
79974960|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
79974961|NCT01305395|Drug|Sirolimus|Will start sirolimus after they develop CAV by angiogram
79320331|NCT02372929|Procedure|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
79320332|NCT05054855|Behavioral|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
79320333|NCT05054933|Other|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
79320334|NCT05054777|Procedure|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
79320335|NCT05054777|Procedure|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
79320336|NCT03112915|Procedure|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
79320337|NCT03112915|Procedure|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
79320338|NCT02367079|Device|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
79478950|NCT05117463|Other|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
79974962|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
79974963|NCT03495817|Drug|ATI-50002|ATI-50002 Topical Solution
79974964|NCT02490514|Other|No intervention|No intervention was administered in this study.
79974965|NCT02886624|Drug|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
79974966|NCT03790241|Procedure|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
79320339|NCT05054465|Drug|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
79320340|NCT05054465|Drug|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
79320341|NCT02367001|Other|Normal invitation|No modification and signed by the coordinating doctor as usual
79320342|NCT02367001|Other|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
79320343|NCT02367001|Other|Revised invitation signed by the attending physician|signature typed or typed + handwritten
79320344|NCT05054699|Device|Magnetic Seizure Therapy|Subjects will receive a train of magnetic pulses (between 600 and 1400 pulses) at 100Hz under general anaesthesia using a Magventure device with a Twin Coil
79320345|NCT05054699|Device|Electroconvulsive Therapy|Subjects will receive a brief-pulse electrical stimulus (between 25 and 1008mC) under general anaesthesia using a ECT device
79320346|NCT02367157|Procedure|Kenzo Kase Method|
79320347|NCT02367157|Device|Kinesio Taping|
79320348|NCT04059835|Other|OptiBra study|compare two different bra after breast cancer surgery
79320349|NCT02366455|Procedure|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
79320350|NCT02366455|Procedure|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
79320351|NCT03860233|Drug|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
79974967|NCT03717025|Procedure|SUCTION BLISTER EPIDERMAL GRAFTING|"Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~Blister formation is induced by using suction apparatus.~Recipient site is surgically prepared by doing dermabrasion.~After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~Donor area is dressed with dry sterile pads.~The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
79320352|NCT03860233|Drug|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
79320353|NCT02373007|Procedure|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
79320354|NCT02373085|Other|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
79320355|NCT02372851|Device|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
79478951|NCT05117125|Diagnostic Test|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
79974968|NCT03717025|Procedure|MINI PUNCH GRAFTING|"Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~The donor area is either upper lateral portion of thigh or gluteal region.~Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~For the donor area only surgipad and micropore are used.~Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
79478952|NCT05117125|Diagnostic Test|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
79320356|NCT01361009|Drug|pramipexole|as prescibed by the investigator
79320357|NCT02373163|Drug|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
79320358|NCT02373163|Drug|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
79320359|NCT02373163|Drug|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
79320360|NCT02372539|Other|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
79320361|NCT02372539|Other|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
79320362|NCT02366377|Drug|SHR3824|
79320363|NCT02366377|Drug|Placebo|
79320364|NCT02366377|Drug|Metformin|
79320365|NCT02362867|Device|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
79320366|NCT05053685|Diagnostic Test|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
79320367|NCT02366299|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
79320368|NCT02366299|Drug|Propofol|Treatment of delirium by Propofol i.v. infusion
79320369|NCT05042297|Procedure|Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention|Reduction of the posterior ring was either closed reduction in SI joint dislocations & fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral & completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
79478953|NCT05117125|Diagnostic Test|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
79644608|NCT04429568|Other|Vaped Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
79644609|NCT04429568|Other|Tobacco Cigarette|Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
79644610|NCT04414722|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
79644611|NCT04414722|Biological|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
79644612|NCT04414722|Other|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
79644613|NCT04410146|Device|SQUID Embolization|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent
79644614|NCT04410146|Device|SQUID Embolization and Surgical Evacuation|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical evacuation of the sub-dural hematoma
79984628|NCT03746639|Other|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
79644615|NCT04410146|Procedure|Surgical Evacuation|Surgical evacuation of the sub-dural hematoma
79644616|NCT04410146|Other|Other: Medical Management|Standard
79644617|NCT04404114|Diagnostic Test|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
79320370|NCT05053919|Device|Schumann resonance sleep device|"A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
79320371|NCT05053919|Device|Placebo sleep device|"A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
79320372|NCT02997553|Drug|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
79320373|NCT02997553|Drug|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
79478954|NCT05117125|Diagnostic Test|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
79478955|NCT05117125|Diagnostic Test|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
79478956|NCT05117060|Drug|LEO 152020 tablet|LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
79478957|NCT05117060|Drug|LEO 152020 placebo tablet|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except the medical ingredient LEO 152020.
79478958|NCT05116384|Device|catheter ablation|cryo energy via cryoballoon
79984629|NCT03197584|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79984630|NCT03197584|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
79984631|NCT03197584|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79320374|NCT02997553|Device|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
79320375|NCT02997553|Device|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
79478959|NCT05116384|Device|renal artery denervation|RF energy delivery to multiple sites within each major renal artery
79478960|NCT05116176|Device|Implantable cardioverter-defibrillators|500 patients age >65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).
79478961|NCT05114512|Other|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
79320376|NCT05041985|Drug|Diazepam Tablets|Diazepam 5 mg tablet once per day (bedtime) for 7 days
79320377|NCT02372695|Drug|Paricalcitol|
79320378|NCT05053841|Drug|Metformin|
79320379|NCT02372461|Drug|Placebo|This is an non inferiority trial, the intervention is a placebo
79320380|NCT02372461|Drug|Amoxicillin|Amoxicillin Liquid
79478962|NCT05114460|Drug|Naloxone|Intranasal Naloxone
79478963|NCT05114460|Drug|Marijuana|Vaped Marijuana
79984632|NCT03197584|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79984633|NCT03197584|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79984634|NCT03197584|Drug|Fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
79644618|NCT04404114|Diagnostic Test|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
79644619|NCT04404114|Diagnostic Test|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
79644620|NCT04392037|Drug|Iberdomide plus low-dose cyclophosphamide and dexamethasone|Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
79644621|NCT04333485|Other|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
79644622|NCT04333485|Other|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
79644623|NCT04289753|Behavioral|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
79644624|NCT04289753|Behavioral|Brief clinician education|Clinicians will be invited to view brief education material.
79644625|NCT04287062|Drug|Suvorexant|Dual orexin receptor antagonist
79644626|NCT04287062|Drug|Placebos|Weight and color matched placebo
79644627|NCT04280627|Other|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
79644628|NCT04249141|Other|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
79306844|NCT05898269|Diagnostic Test|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
79306845|NCT05898269|Diagnostic Test|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
79306846|NCT05898269|Diagnostic Test|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index > 15% will be identified as being fluid responders, and the others as non-responders."
79306847|NCT05898022|Drug|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.
79306848|NCT05898022|Drug|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
79306849|NCT05893888|Drug|PRV211 (Intraoperative Cisplatin System)|PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
79306850|NCT05889286|Drug|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) [F-18]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of [F-18]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
79306851|NCT05884957|Diagnostic Test|Nitric oxide synthase gene|Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
79644629|NCT04238520|Behavioral|Functionally Tailored Oral Care Intervention|Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
79644630|NCT04238520|Behavioral|Control Intervention|Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
79644631|NCT04229368|Dietary Supplement|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
79644632|NCT04148664|Procedure|Catheter ablation with Standard RF ablation settings|"Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard."
79644633|NCT04148664|Procedure|Catheter ablation with High Power Short Duration RF ablation settings|"High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard."
79644634|NCT04106544|Procedure|Investigational Procedures|The investigational assessments will be performed
79984635|NCT03197584|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79644635|NCT04095052|Dietary Supplement|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
79644636|NCT04095052|Dietary Supplement|Placebo|Microcrystalline Cellulose capsule
79644637|NCT04082533|Drug|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
79644638|NCT04082533|Drug|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
79644639|NCT04074356|Other|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
79644640|NCT04074356|Diagnostic Test|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
79644641|NCT04074356|Diagnostic Test|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
79644642|NCT04074356|Diagnostic Test|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
79974969|NCT03717025|Procedure|NON CULTURED EPIDERMAL CELL SUSPENSION|"About one-tenth the size of recipient area is selected as the donor site.~Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~The area is dressed with Bactigras gauze.~Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~Epidermal cell suspension is carefully transferred to a tuberculin syringe.~With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
79974970|NCT02487238|Biological|Fecal Microbiota Enema|Active intervention.
79644643|NCT04027426|Behavioral|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
79974971|NCT02487238|Biological|Normal Saline Enema|Placebo comparator.
79974972|NCT01305863|Device|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
79974973|NCT01305863|Device|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
79306854|NCT05867225|Procedure|Laparoscopic hiatal hernia repair|laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
79306856|NCT05845840|Drug|BRII-297|Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
79306857|NCT05845840|Drug|Placebo|Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
79306858|NCT05844735|Drug|SAR441566|Tablet
79306859|NCT05844735|Drug|Placebo|Tablet
79306860|NCT05844735|Drug|Ciprofloxacin|Tablet
79306861|NCT05844150|Drug|PM8002|IV infusion
79306862|NCT05844150|Drug|Platinum|IV infusion
79306863|NCT05844150|Drug|Atezolizumab|IV infusion
79306864|NCT05844150|Drug|Etoposide|IV infusion
79306865|NCT05841706|Biological|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb < 7 g/dL)
79644644|NCT04027426|Behavioral|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
79644645|NCT03991182|Other|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
79644646|NCT03991182|Other|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
79644647|NCT03991182|Behavioral|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
79644648|NCT03991182|Other|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
79644649|NCT03989271|Drug|Quercetin|Placebo
79644650|NCT03989206|Drug|Nemolizumab|Nemolizumab
79644651|NCT03961334|Drug|Dabigatran|150mg 2x/d
79644652|NCT03961334|Drug|Apixaban|5mg 2x/d
79320381|NCT05053529|Other|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
79644653|NCT03961334|Drug|Edoxaban|60mg 1x/d
79644654|NCT03961334|Drug|Aspirin|100mg 1x/d
79974974|NCT02280902|Biological|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
79974975|NCT02487316|Drug|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
79974976|NCT02490436|Drug|Cetuximab|Randomized cross-over between cetuximab and placebo
79974977|NCT02490436|Drug|Placebo|Randomized cross-over between cetuximab and placebo
79974978|NCT03793595|Device|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
79974979|NCT03793595|Device|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
79306866|NCT05841706|Biological|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb < 9 g/dL)
79306867|NCT05841706|Procedure|Computed Tomography|Undergo CT scan
79306868|NCT05841706|Procedure|X-Ray Imaging|Undergo x-ray imaging
79306869|NCT05841706|Procedure|Biospecimen Collection|Undergo blood sample collection
79974980|NCT03318718|Drug|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
79984636|NCT03197584|Drug|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79306870|NCT05841706|Other|Survey Administration|Ancillary studies
79306871|NCT05841706|Procedure|Pancreatectomy|surgical removal of all or part of pancreas
79306872|NCT05840250|Other|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
79320382|NCT05053529|Other|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
79644655|NCT03961334|Drug|Clopidogrel|75mg 1x/d
79644656|NCT03933163|Drug|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
79644657|NCT03913104|Drug|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
79644658|NCT03897218|Dietary Supplement|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
79974981|NCT03318718|Diagnostic Test|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
79974982|NCT03318718|Diagnostic Test|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
79984637|NCT03197584|Drug|omega-3 acid ethyl esters|omega-3 acid ethyl esters
79320383|NCT03096431|Behavioral|Physical Activity|"Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
79320384|NCT03096431|Behavioral|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
79320385|NCT02372617|Procedure|periacetabular osteotomy|
79644659|NCT03897218|Dietary Supplement|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
79644660|NCT03854370|Other|Baby shampoo|baby shampoo will be used to prepare the surgical site prior to incision
79644661|NCT03854370|Other|Betadine|Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision
79644662|NCT03854370|Other|Peridex|Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision
79644663|NCT03854370|Other|TechniCare|TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
79644664|NCT03809377|Procedure|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
79644665|NCT03757533|Behavioral|Health Coaching|10 phone calls with a trained health coach
79984638|NCT03197584|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79984639|NCT03197584|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
79984640|NCT03197584|Biological|ALT-803|Recombinant human super agonist IL-15 complex
79320386|NCT05053373|Device|Electroacupuncture group|
79320387|NCT05053373|Device|Sham electroacupuncture group|
79320388|NCT05053373|Behavioral|Pelvic floor muscle training|
79320389|NCT05053061|Behavioral|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
79974983|NCT03790319|Behavioral|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
79974984|NCT03790319|Behavioral|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
79320390|NCT04499131|Drug|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
79320391|NCT04499131|Other|Artificial Cycle (no intervention)|Control group of 15 subjects in the context of a natural cycle with only endogenous progesterone present
79320392|NCT03096119|Other|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
79320393|NCT02805595|Drug|23.4% Hypertonic saline|Saline Injections
79320394|NCT05053295|Drug|autologous activated T lymphocyte|"Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV"
79320395|NCT02372227|Drug|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
79320396|NCT03095963|Other|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
79320397|NCT03095963|Drug|levothyroxin|replacement therapy for hypothyroidism
79320398|NCT05653687|Device|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
79644666|NCT03757533|Other|Surveys|Surveys to assess Behavioural and Psychosocial measures
79644667|NCT03729349|Biological|Golimumab|Participants will receive golimumab as a part of clinical practice.
79974985|NCT03325348|Drug|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
79974986|NCT03325348|Drug|Labetalol|IV labetalol 20 mg & mint tablet will be given to patients every 15 min until one hour
79974987|NCT03790163|Drug|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
79974988|NCT01775657|Device|Thopaz (Digital drainage)|
79974989|NCT01775657|Device|Pleur Evac (Analogue drainage)|
79974990|NCT03321448|Drug|TMTP1-ICG|Detection of SLN
79974991|NCT03321448|Drug|ICG|Detection of SLN
79320399|NCT05053217|Procedure|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
79320400|NCT02366065|Drug|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
79320401|NCT05052593|Other|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
79320402|NCT05052593|Other|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
79320403|NCT02362945|Drug|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
79320404|NCT02365909|Drug|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
79974992|NCT03325270|Dietary Supplement|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
79306873|NCT05838573|Drug|Metformin treatment|Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
79644668|NCT03723226|Behavioral|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
79808929|NCT04157777|Other|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
79974993|NCT03325270|Dietary Supplement|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
79974994|NCT03325270|Dietary Supplement|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
79974995|NCT04493710|Diagnostic Test|Sarcopenia estimation|Analysis of pre-existing CT imaging
79974996|NCT04493788|Other|Blood test, ultrasound and egg retrieval|Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
79974997|NCT03318562|Drug|eFT508|200 mg eFT508 dosed BID for 3 week cycles
79808930|NCT04156529|Behavioral|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
79808931|NCT04156529|Behavioral|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
79808932|NCT00660647|Drug|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
79974998|NCT03318484|Drug|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
79974999|NCT03318484|Combination Product|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
79975000|NCT02963766|Drug|Dulaglutide|Administered SC
79975001|NCT02963766|Drug|Placebo|Administered SC
79975002|NCT02490280|Behavioral|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
79975003|NCT02487004|Device|hemodialysis|
79975004|NCT04493476|Drug|Chinese herbal formula|Chinese herbal formula
79975005|NCT03325192|Drug|Rapid pleurodesis protocol|"The pleural space will be evacuated completely through the newly placed IPC~20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~The patient will be transferred to the recovery unit~Two hours after instillation the pleural space will be drained~After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
79975006|NCT03325192|Other|Placebo|"The pleural space will be evacuated completely through the newly placed IPC~Only placebo (normal saline) will be instilled into the pleural space~The patient will be transferred to the recovery unit~Two hours after instillation the pleural space will be drained~After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
79975007|NCT01334502|Biological|rituximab|PO
79306874|NCT05838573|Drug|Placebo treatment|Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
79975008|NCT01334502|Drug|cyclophosphamide|IV
79644669|NCT03723226|Behavioral|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
79975009|NCT01334502|Drug|doxorubicin hydrochloride|IV
79975010|NCT01334502|Drug|everolimus|PO
79975011|NCT01334502|Drug|prednisone|PO
79975012|NCT01334502|Drug|vincristine sulfate|IV
79975013|NCT04839965|Biological|Ampion|Ampion administered via intravenous infusion
79975014|NCT04839965|Other|Saline|Placebo administered via intravenous infusion
79975015|NCT02490046|Dietary Supplement|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
79644670|NCT03710746|Behavioral|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
79644671|NCT03710746|Behavioral|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
79644672|NCT03690427|Other|Traditional hookah smoking|Charcoal-heated hookah smoking
79644673|NCT03690427|Other|Electronic hookah vaping|Electronic hookah bowl inhalation
79644674|NCT03679962|Behavioral|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
79975016|NCT05390333|Behavioral|Self-Care Sampler for Family Carer Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
79975017|NCT02487082|Drug|Melatonin and Donepezil|The duration depends on group assignment.
79644675|NCT03679962|Behavioral|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
79644676|NCT03658668|Device|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (<4 mA) to induce changes in cortical excitability.
79644677|NCT03658668|Device|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
79644678|NCT03658668|Other|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
79808933|NCT00660647|Drug|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
79808934|NCT02632097|Procedure|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
79320405|NCT02365909|Drug|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
79320406|NCT05052515|Dietary Supplement|Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts|Patients with NAFLD will be randomly allocated to receive Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts supplementation
79320407|NCT05052515|Other|Placebo|Patients with NAFLD will be randomly allocated to receive placebo
79975018|NCT02487082|Other|Placebo|The duration depends on group assignment.
79975019|NCT03788681|Drug|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
79975020|NCT03788681|Drug|Placebo Oral Tablet|placebo
79808935|NCT02632097|Procedure|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
79975021|NCT03788603|Drug|Rogaratinib (BAY1163877)|Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
79984641|NCT03197584|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2 vaccine
79320408|NCT02365675|Device|Cotton gauze with petrolatum|
79320409|NCT02365675|Device|Cellulose acetate with petrolatum|
79320410|NCT02365675|Device|Nanocrystalline silver (Acticoat)|
79320411|NCT02365675|Device|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
79320412|NCT05052437|Drug|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
79320413|NCT05052437|Drug|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
79320414|NCT02365753|Device|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
79320415|NCT05052359|Diagnostic Test|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
79320416|NCT02365831|Other|Observation of treatment management|Group/cohort
79320417|NCT05041517|Behavioral|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
79320418|NCT02365987|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
79320419|NCT02365987|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
79320420|NCT03095573|Device|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
79320421|NCT03095573|Device|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
79320422|NCT05051423|Diagnostic Test|Endoscopic ultrasound|"Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes."
79975022|NCT03789929|Behavioral|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
79808936|NCT04156451|Procedure|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
79320423|NCT02359201|Drug|V0018|Oromucosal - Single dose
79320424|NCT02359201|Drug|Placebo|Oromucosal - Single dose
79320425|NCT05041283|Other|Chatbot|A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.
79320426|NCT05041283|Other|Phone call|A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
79320427|NCT02363023|Procedure|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
79975023|NCT03789929|Behavioral|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
79975024|NCT03790085|Drug|Risperidone|Risperidone tablet
79975025|NCT03790085|Drug|Olanzapine|Olanzapine tablet
79975026|NCT03790085|Drug|Aripiprazole|Aripiprazole tablet
79975027|NCT01306097|Drug|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
79975028|NCT03466099|Drug|KVD001 Injection|Intravitreal KVD001 Injection
79320428|NCT05041205|Dietary Supplement|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
79320429|NCT05041205|Device|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
79320430|NCT02362711|Drug|NPC-16 Standard Dosing Regimen Group|
79320431|NCT02362711|Drug|NPC-16 Continuous Dosing Regimen Group|
79320432|NCT02362711|Drug|Placebo Group|
79808937|NCT04156451|Procedure|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
79320433|NCT04434677|Radiation|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
79320434|NCT04434677|Radiation|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
79975029|NCT03466099|Other|Sham Procedure|Sham Procedure
79975030|NCT01308281|Procedure|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
79975031|NCT01308281|Procedure|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
79975032|NCT03790007|Drug|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
79975033|NCT03716947|Procedure|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
79975034|NCT03716947|Procedure|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
79975035|NCT03716947|Procedure|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
79975036|NCT03789695|Drug|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
79984642|NCT03197584|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79984643|NCT03197584|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1 vaccine
79975037|NCT05693831|Other|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
79975038|NCT03720769|Behavioral|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
79975039|NCT03720769|Behavioral|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
79984644|NCT03197584|Biological|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
79306875|NCT05838573|Other|Baseline assessments|Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
79306876|NCT05838573|Other|Volunteer assessments|Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
79644679|NCT03584945|Behavioral|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
79644680|NCT03584945|Other|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
79644681|NCT03536897|Radiation|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
79644682|NCT03535298|Drug|Early Highly Effective Therapies Group|Highly Effective MS Therapy group of medications
79644683|NCT03535298|Drug|Escalation Therapies Group|Escalation MS Therapy group of medications
79975040|NCT03720691|Device|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
79975041|NCT03720691|Device|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
79975042|NCT05663437|Other|Core stabilization exercises|6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.
79975043|NCT05663437|Other|Core stabilization exercises + neural mobilization technique|"6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.~Neural mobilization technique (SLR intervention for first 2 weeks and slider intervention for last 2 weeks)."
79984645|NCT03197584|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
79984646|NCT03197584|Biological|haNK®|NK-92 [CD16.158V, ER IL-2]
79984647|NCT03722576|Drug|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
79984648|NCT02445664|Behavioral|Educational video|Video: Information on osteoporosis and alendronate treatment.
79644684|NCT03513705|Other|Best practices in pancreatic cancer care|All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
79975044|NCT03789851|Device|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
79644685|NCT03493178|Dietary Supplement|Glycine|Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
79644686|NCT03493178|Dietary Supplement|N-acetylcysteine (NAC)|Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
79644687|NCT03493178|Dietary Supplement|Alanine|Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
79644688|NCT03469934|Biological|Etokimab|Administered on Day 1 over 1 hour by IV infusion
79644689|NCT03469934|Drug|Placebo|Administered on Day 1 over 1 hour by IV infusion
79984649|NCT03416348|Drug|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
79984650|NCT03416348|Drug|Alcohol|Placebo
79478964|NCT05113264|Device|'Penny' via Memora Platform|"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."
79478965|NCT05107453|Drug|Levobupivacaine|"The IMP is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
79644690|NCT03424278|Other|Motor control exercises|Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
79302130|NCT04433793|Behavioral|Yoga therapy|"One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana)."
79644691|NCT03424278|Other|Resistance training exercises|A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
79478966|NCT05105841|Drug|Venetoclax|Oral Tablet
79478967|NCT05105841|Drug|Ibrutinib|Oral Capsule
79478968|NCT05105841|Drug|Obinutuzumab|Intravenous (IV) Infusion
79478969|NCT05103826|Drug|SHR6390、Famitinib|SHR6390, oral;Famitinib, oral.
79644692|NCT03422770|Diagnostic Test|Echocardiography|Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
79644693|NCT03422770|Diagnostic Test|MRI|Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
79644694|NCT03422770|Diagnostic Test|Blood test|Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
79644695|NCT03422770|Diagnostic Test|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
79984651|NCT03202342|Other|Water|Water, 300 ml, at room temperature
79478970|NCT05102812|Behavioral|Breakfast Group Intervention|An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
79644696|NCT03422770|Diagnostic Test|6 min walking test|6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
79644697|NCT03406650|Drug|Neoadjuvant and adjuvant durvalumab|Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles
79320435|NCT01944046|Drug|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
79320436|NCT01944046|Drug|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
79320437|NCT01944046|Drug|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
79320438|NCT05040737|Device|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
79320439|NCT02087891|Behavioral|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
79478971|NCT05099848|Drug|Camrelizumab|"Procedure:~Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
79644698|NCT03377725|Drug|Decitabine|20mg/m^2,d1-5,ivgtt,28days as a duration
79984652|NCT03202342|Other|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
79984653|NCT03202342|Other|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
79478972|NCT05099029|Biological|EV71 vaccine|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose) Two vaccinations at 28 days apart
79644699|NCT03377725|Drug|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
79644700|NCT03375853|Behavioral|Computer Based Response Training Weight Loss Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
79644701|NCT03375853|Behavioral|Generic Response Training Control Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
79644702|NCT03346135|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo standard of care ASCT with a conditioning regimen of melphalan
79478973|NCT05099029|Biological|Placebo|Placebo ([ adjuvant 150 μg AI(OH)3] per dose) Two vaccinations at 28 days apart
79478974|NCT05098860|Other|Home Exercise Program|Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
79644703|NCT03346135|Biological|Daratumumab|Given IV
79644704|NCT03346135|Other|Laboratory Biomarker Analysis|Correlative studies
79975045|NCT00739674|Drug|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~Losartan 50 mg~Losartan 100 mg~Losartan 100 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 25 mg~Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~Losartan 50 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 25 mg~Losartan 100 mg/HCTZ 25 mg + CCB~Losartan 100 mg/HCTZ 25 mg + increasing CCB"
79975046|NCT00739674|Behavioral|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension [DASH]) including:~Healthy diet~Reduction in sodium intake to less than 2300 mmol/day~Low alcohol consumption (less than 2 standard drinks/day)"
79975047|NCT03639181|Biological|GB226|3mg/kg treat every 2 weeks
79644705|NCT03346135|Drug|Melphalan|Undergo standard of care ASCT with a conditioning regimen of melphalan
79644706|NCT03282916|Drug|Valacyclovir|Valacyclovir hydrochloride 500mg caplet
79975048|NCT01306409|Drug|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
79975049|NCT01306409|Drug|ESA|Sequential application of three different ESA
79975050|NCT01331928|Drug|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
79975051|NCT03785795|Device|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
79975052|NCT01329822|Behavioral|Caloric restriction|Caloric restriction
79306877|NCT05833503|Behavioral|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
79644707|NCT03282916|Drug|Placebo|Placebo sugar pill 500mg caplet
79644708|NCT03267524|Behavioral|Exercise Intervention|Receive Walking for Recovery from Surgery prehabilitation intervention
79644709|NCT03267524|Other|Quality-of-Life Assessment|Ancillary studies
79644710|NCT03267524|Other|Survey Administration|Ancillary studies
79306878|NCT05833503|Behavioral|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
79306879|NCT05830721|Device|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
79306880|NCT05830721|Device|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
79306881|NCT05830721|Other|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
79320440|NCT02087891|Behavioral|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
79975053|NCT03494725|Dietary Supplement|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
79644711|NCT03229382|Drug|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
79644712|NCT03215693|Drug|X-396 capsule|225mg once daily
79644713|NCT03187106|Drug|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
79320441|NCT02087891|Behavioral|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
79320442|NCT00773695|Drug|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
79320443|NCT00773695|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
79320444|NCT00773695|Drug|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
79644714|NCT03187106|Drug|Placebo|Placebo representing standard of care
79644715|NCT03187106|Drug|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
79975054|NCT03494725|Dietary Supplement|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
79975055|NCT01306487|Procedure|Vitrectomy|Macular hole surgery
79975056|NCT01334580|Behavioral|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
79975057|NCT01334580|Behavioral|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
79975058|NCT00705718|Device|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
79320445|NCT00773695|Drug|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
79320446|NCT00773695|Drug|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
79320447|NCT00773695|Drug|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m^2 as IV infusion every week for 12 weeks.
79320448|NCT00773695|Drug|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
79320449|NCT02362633|Device|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
79320450|NCT02362633|Device|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
79320451|NCT03112525|Diagnostic Test|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
79320452|NCT03112525|Genetic|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
79975059|NCT05523713|Biological|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
79975060|NCT02694588|Drug|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
79644716|NCT03159702|Drug|Evomela|140 mg/m^2/day IV on Day -6 for patients who are < 60 years of age. 70 mg/m^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of >3
79644717|NCT03159702|Drug|Fludarabine|40 mg/ m^2/day intravenous on Days: -5 -4, -3, -2
79975061|NCT02694588|Drug|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
79644718|NCT03159702|Radiation|Total Body Irradiation|200 cGy on Day: -1
79975062|NCT03789539|Biological|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
79320453|NCT05040425|Drug|Zi-Yin-Liang-Ge-San|Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
79644719|NCT03143621|Dietary Supplement|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
79644720|NCT03143621|Other|Water|Tap water heated to same temperature as coffee
79320454|NCT03112837|Other|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
79320455|NCT01969084|Drug|Linagliptin|
79320456|NCT01969084|Drug|Placebo|
79478975|NCT05098860|Other|Manual Therapy Combined with Home Exercise Program|Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
79478976|NCT05098860|Other|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
79478977|NCT05098327|Drug|Pioglitazone 30 mg|pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
79478978|NCT05098327|Drug|Placebo|placebo pills containing cellulose 1 pill daily will be given for 12 weeks
79975063|NCT03789539|Biological|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
79975064|NCT03789539|Biological|Placebo|Placebo saline
79984654|NCT03202342|Other|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
79984655|NCT03202342|Other|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
79644721|NCT03096197|Device|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
79644722|NCT03096197|Device|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
79644723|NCT03073122|Diagnostic Test|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
79644724|NCT03054961|Device|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
79478979|NCT05095246|Biological|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
79320457|NCT01969084|Other|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
79320458|NCT01969084|Other|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
79320459|NCT01969084|Other|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
79320460|NCT05040347|Other|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
79478980|NCT05085795|Device|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
79320461|NCT02359123|Other|Cannabics capsules|Cannabis extract in an oil formulation
79320462|NCT02362477|Behavioral|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
79320463|NCT02362477|Behavioral|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
79320464|NCT05040191|Other|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
79478981|NCT05084937|Other|CeliCAT form|Systematic summary to support transition
79478982|NCT05082610|Drug|HMBD-002|IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.
79478983|NCT05082610|Drug|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
79644725|NCT03044977|Drug|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
79644726|NCT03044977|Drug|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
79644727|NCT03009201|Drug|Doxorubicin Hydrochloride|Given IV
79644728|NCT03009201|Other|Laboratory Biomarker Analysis|Correlative studies
79644729|NCT03009201|Other|Pharmacological Study|Correlative studies
79644730|NCT03009201|Drug|Ribociclib|Given PO
79478984|NCT05080673|Procedure|5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy|The five- and ten-year colonoscopies, in addition to any unscheduled colonoscopies, will be performed according to currently accepted guidelines for the performance of quality colonoscopy. Participants will be given the standardized colonoscopy preparation instructions per institutional standards.
79644731|NCT03004404|Drug|Placebo|Placebo
79644732|NCT03004404|Drug|BI 730357|powder for reconstitution of an oral solution (PfoS)
79644733|NCT03004404|Drug|BI 730357|BI 730357 film-coated tablet
79644734|NCT03002597|Device|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
79984656|NCT03236012|Drug|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
79984657|NCT02449486|Drug|Ropivacaine|
79644735|NCT02985749|Drug|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
79644736|NCT02905591|Drug|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
79644737|NCT02905591|Drug|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~the dose is 45 mg/m2 (standard dose)~Administered weekly~6 to 7 weeks of therapy, depending on when radiation starts~Standardized dose reductions are used"
79478985|NCT05079971|Diagnostic Test|Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology|In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.
79478986|NCT05074589|Drug|Irinotecan liposome、5-Fluorouracil、Leucovorin|Irinotecan liposome、5-Fluorouracil、Leucovorin
79644738|NCT02905591|Drug|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~Administered weekly~6 to 7 weeks of therapy, depending on when radiation starts~Standard dose reductions are used"
79320465|NCT05040191|Other|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
79320466|NCT05040191|Other|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
79320467|NCT02358577|Device|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
79478987|NCT05074589|Drug|Placebo、5-Fluorouracil、Leucovorin|Placebo、5-Fluorouracil、Leucovorin
79478988|NCT05069623|Biological|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
79478989|NCT05069623|Biological|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
79644739|NCT02905591|Drug|Ascorbic Acid|"Administered intravenously~75 grams per infusion; each infusion is about 2 hours~3 infusion per calendar week~The infusion is actively running for at least 20 minutes when radiation begins~May be given while chemotherapy is delayed due to low counts~Dose reductions are not used~Given for 6 to 7 weeks, depending on when radiation starts"
79644740|NCT02845063|Behavioral|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
79644741|NCT02845063|Behavioral|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
79644742|NCT02845063|Genetic|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
79644743|NCT02838069|Biological|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
79984658|NCT03625154|Procedure|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
79984659|NCT03625154|Other|non operative management|closed reduction and splinting followed by progressive weight bearing
79984660|NCT03202186|Drug|Progesterone oral capsule|Oral capsule treatment
79984661|NCT03202186|Drug|Placebo oral capsule|Oral capsule treatment
79320468|NCT02358577|Other|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
79320469|NCT04636840|Device|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
79320470|NCT05040035|Diagnostic Test|ACT measurement|Measurement of active clotting time (ACT)
79320471|NCT02353039|Drug|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
79320472|NCT02353039|Drug|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
79320473|NCT02353039|Drug|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
79644744|NCT02838069|Biological|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
79320474|NCT02353039|Drug|Placebo|Administer placebo t.i.d for 2 weeks
79644745|NCT02838069|Other|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
79644746|NCT02635672|Drug|VIP152 (BAY 1251152)|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
79644747|NCT02635672|Drug|VIP152 (BAY 1251152) 30 mg|30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
79644748|NCT02635672|Drug|Keytruda|200 mg IV fixed dose once every 3 weeks of a 21 day cycle
79644749|NCT02635672|Drug|VIP152 (BAY 1251152) 15 mg|The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
79644750|NCT02589600|Drug|Zoledronic acid|Annual intravenous 5.0 mg
79320475|NCT05039957|Other|joint preparation|fixation of fracture with joint preparation
79320476|NCT05039957|Other|without joint preparation|fixation of fracture without joint preparation
79478990|NCT05064241|Other|Access to Genetic Counselor for answering questions|A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
79644751|NCT02589600|Dietary Supplement|vitamin D|800 IU daily
79644752|NCT02589600|Dietary Supplement|calcium|approximately 1200 mg (dietary and supplement)
79644753|NCT02589600|Other|Saline|Annual intravenous saline placebo
79644754|NCT02565199|Device|rTMS over Premotor Cortex (Contralateral Hemisphere)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
79644755|NCT02565199|Device|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
79644756|NCT02565199|Device|rTMS (Control 1)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 400 milliseconds after the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
79644757|NCT02565199|Device|rTMS (Control 2)|"Location of rTMS: somatosensory cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
79644758|NCT02565199|Device|rTMS (Control 3)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
79644759|NCT02565199|Other|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
79644760|NCT02450604|Genetic|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
79644761|NCT02335268|Drug|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
79320477|NCT01942486|Device|Investigational Coating|
79320478|NCT03095729|Other|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
79478991|NCT05061654|Drug|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
79320479|NCT04660084|Diagnostic Test|Ultra-rapid molecular point-of-care testing|"Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is <2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs."
79320480|NCT02352805|Device|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
79975065|NCT01334658|Procedure|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
79320481|NCT02362399|Drug|sildenafil citrate|single oral dose of 50 mg
79320482|NCT02362399|Other|placebo|single oral dose of placebo tablet
79320483|NCT04410887|Drug|PIPAC+SOX+OLAPARIB|SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
79478992|NCT05060965|Drug|Nicotine lozenge|Nicotine replacement therapy
79478993|NCT05060965|Drug|Nicotine gum|Nicotine replacement therapy
79478994|NCT05060965|Drug|Nicotine patch|Nicotine replacement therapy
79478995|NCT05060965|Other|Maryland Quitline|Telephone-based tobacco cessation service
79478996|NCT05060965|Other|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
79975066|NCT01334658|Drug|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
79984662|NCT03625076|Drug|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
79320484|NCT02362555|Other|no intervention was used in this observational study|
79320485|NCT05050331|Procedure|Muscle Energy Technique|Muscle energy technique (MET) is an active manipulative technique that requires patient active muscle contraction of a respective muscle from a specific position in a specific direction with 10-20 percent force exerted by the patient which is resisted by the therapist in an attempt to relax and lengthen the muscle.
79478997|NCT05053126|Drug|Pregabalin 300mg|Participant will receive an oral dose of pregabalin 300 mg
79478998|NCT05053126|Drug|pregabalin 450 mg|Participant will receive an oral dose of pregabalin 450 mg
79478999|NCT05053126|Drug|Pregabalin 300 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
79479000|NCT05053126|Drug|pregabalin 450 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
79479001|NCT05053126|Drug|oxycodone 20 mg|Participant will receive an oral dose of oxycodone 20 mg
79479002|NCT05053126|Drug|Placebo|Participant will receive an oral dose of placebo
79479003|NCT05050123|Behavioral|iPhone Google Cardboard virtual reality meditation/relaxation app|Virtual reality meditation/relaxation app that has 6 scenes of 360° visual imagery with soothing music. The patient can spend about 15 minutes exploring the app.
79479004|NCT05050123|Behavioral|Standard relaxation training|"15 minute sessions of guided imagery using Mayo Clinic Patient Education CD-ROM Relaxation for Your Mind and Body"
79479005|NCT05049616|Drug|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
79479006|NCT05049616|Drug|NIFEdipine ER|Extended release nifedipine
79975067|NCT01334658|Drug|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
79320486|NCT05050331|Procedure|Trigger Point Release|In trigger point release, a vertical downward pressure toward the trigger point for 90 seconds is applied with the therapist's thumb. Three repetitions needed to be done with 30 seconds relaxation time. After that, 3 longitudinal strokes in caudal to cranial direction are given by therapist's thumb over the taut band.
79320487|NCT05050331|Procedure|Self-Stretching of Calf and Plantar Fascia|Self-stretching will be done 5 times twice a day with 20 seconds of intermittent stretch and 20 seconds relaxation time.
79320488|NCT02352961|Other|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
79644762|NCT02222155|Drug|CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
79975068|NCT01308359|Drug|IV glucose 5%|500 ml glucose 5% within 30 minutes
79975069|NCT01308359|Drug|saline|saline
79975070|NCT02490202|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
79644763|NCT02222155|Drug|CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids|
79644764|NCT02222155|Other|Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
79975071|NCT02490202|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
79975072|NCT01334736|Behavioral|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
79975073|NCT01334736|Behavioral|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
79984663|NCT03625076|Drug|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
79984664|NCT03197272|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
79984665|NCT02445352|Drug|Rosuvastatin 5mg|
79984666|NCT02445352|Drug|DP-R207 5/10mg|
79479007|NCT05049213|Drug|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~Intranasal spray 3 times/day, 2~3 spray/nostril/per time~Oral gargling 3 times/day, 15cc/per time"
79479008|NCT05041075|Device|Weighted Blanket|Weighted blankets provide Deep Pressure Stimulation (DPS) or Deep Touch Pressure (DTP) which has advantages in both physical and psychological domains.
79479009|NCT05039346|Other|Phone interviews|Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
79644765|NCT02020070|Drug|Degarelix|
79644766|NCT02020070|Drug|Ipilimumab|
79644767|NCT02020070|Procedure|Radical Prostatectomy|
79644768|NCT01936272|Device|Chhabra Shunt Placement|
79644769|NCT01936272|Procedure|ETV/CPC|
79808938|NCT00660725|Drug|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
79644770|NCT01823237|Device|Transcranial Magnetic Stimulation|
79320489|NCT05039333|Device|RUS(TM) software : surgical navigation|This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
79320490|NCT01941940|Drug|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
79644771|NCT01484093|Other|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
79975074|NCT01334736|Behavioral|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
79984667|NCT02445352|Drug|Rosuvastatin 10mg|
79984668|NCT02445352|Drug|DP-R207 10/10mg|
79984669|NCT02445352|Drug|Rosuvastatin 20mg|
79320491|NCT01941940|Drug|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
79984670|NCT02445352|Drug|DP-R207 20/10mg|
79984671|NCT02445352|Drug|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
79984672|NCT02445352|Drug|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
79984673|NCT02445352|Drug|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
79808939|NCT00660725|Drug|Gemcitabine|30-minute IV infusion of 1000 mg/m^2 gemcitabine on Day 1 of each 14-day cycle.
79975075|NCT01334736|Behavioral|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
79975076|NCT05654389|Other|Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital|Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
79975077|NCT02484586|Device|Etafilcon A|Prototype lens material
79975078|NCT02484586|Device|Etafilcon A|Control lens for presbyope group
79320492|NCT02358733|Procedure|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
79320493|NCT02358733|Procedure|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
79320494|NCT02358499|Drug|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
79975079|NCT02484586|Device|Nelfilcon A|Control lens for presbyope group
79975080|NCT02484586|Device|Nesofilcon A|Control lens for presbyope group
79320495|NCT02362087|Other|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
79320496|NCT03095807|Drug|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
79320497|NCT03095807|Drug|Placebo|Administered subcutaneously (s.c., under the skin)
79644772|NCT01465100|Radiation|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
79975081|NCT02484586|Device|Nelfilcon A|Control lens for non-presbyope group
79320498|NCT02358655|Other|Retrospective review of OAC prescription|
79320499|NCT02358655|Other|Prescription of OAC in ED|
79320500|NCT02358655|Other|Community AF clinic|
79320501|NCT02358265|Drug|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
79320502|NCT02358265|Drug|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
79320503|NCT02358265|Drug|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
79320504|NCT02358265|Drug|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
79320505|NCT05038397|Device|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
79644773|NCT01465100|Procedure|Hepatocyte Transplant|"Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient."
79320506|NCT03112213|Drug|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
79320507|NCT03112213|Drug|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
79320508|NCT01968694|Drug|IV Lidocaine|
79320509|NCT01968694|Drug|IV diphenhydramine|
79320510|NCT03097913|Device|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
79320511|NCT05049941|Diagnostic Test|lactat and blood gases|observational
79975082|NCT02484586|Device|Etafilcon A|Control lens for non-presbyope group
79975083|NCT02484586|Device|Somofilcon A|Control lens for presbyope group
79320512|NCT02362243|Other|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
79644774|NCT01465100|Drug|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
79320513|NCT02362243|Other|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
79320514|NCT05038007|Drug|Liposomal bupivacaine|As prior described
79320515|NCT05038007|Drug|Bupivacaine Hydrochloride|As prior described
79808940|NCT00660725|Drug|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m^2 oxaliplatin on Day 1 of each 14-day cycle.
79808941|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
79975084|NCT02484586|Device|58% Poly-HEMA|Control lens for presbyope group
79975085|NCT02484586|Device|Omafilcon A|Control lens for non-presbyope group
79975086|NCT00400218|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
79975087|NCT01332006|Procedure|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
79975088|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|
79975089|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
79975090|NCT02486848|Drug|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
79644775|NCT01465100|Other|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
79644776|NCT01465100|Behavioral|Neuro-psychological Assessment|Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
79808942|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
79808943|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
79306882|NCT05822518|Dietary Supplement|Neo-mune powder (otsuka pharmaceutical)|"Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible."
79975091|NCT02486848|Drug|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
79306883|NCT05822518|Drug|Dipeptiven solution (Fresenius Kabi pharmaceutical)|Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
79306884|NCT05821569|Other|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
79306885|NCT05821569|Other|Biological nurturing|Adoption of biological nurturing approach to breastfeed
79306886|NCT05810415|Diagnostic Test|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
79306887|NCT05799079|Drug|Venetoclax|Given by mouth
79306888|NCT05799079|Drug|Decitabine|Given by mouth
79306889|NCT05799079|Drug|Cedazuridine|Given by mouth
79306890|NCT05799079|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy
79306891|NCT05799079|Procedure|Biospecimen Collection|Undergo blood sample collection
79306892|NCT05789589|Drug|Azeliragon|"Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)"
79306893|NCT05789589|Radiation|Stereotactic radiosurgery|Patients will undergo standard of care SRS as per the treating facility's policies.
79306894|NCT05789589|Drug|Corticosteroid|"Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT)."
79306895|NCT05785169|Behavioral|TRAncenDS|The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To transform clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. TRAnscenDS is modeled on these principles and supports the development of multiple SRD-reduction strategies (instituting comprehensive anti-racist and Diversity, Equity and Inclusion policies, monitoring and feedback systems; workforce equity), at the top two levels of the socioecological model (organizational/policy and systems/providers/staff), to in turn impact individual-level out-comes.
79306896|NCT05779475|Other|No treatment given|Participants will not receive any investigational treatment in this study.
79306897|NCT05776121|Drug|ZB001 for injection|Dose Cohort1 (3 mg/kg) ZB001 four IV injections
79975092|NCT01334814|Device|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
79975093|NCT01306565|Drug|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
79320516|NCT04639102|Other|PATH Intervention|"Patients will receive an enhanced level of care and service:~Discharge planning- PATH clinicians will develop an individualized treatment plan at time of ED discharge. Each patient will receive next-day phone call to monitor status. There will be additional patient and family education, triage of new or worsening symptoms, and additional telephone contact as determined in treatment plan. There will be communication with home health teams as needed.~Care coordination- PATH clinicians will arrange necessary primary medical doctor and specialty appointments. They will also communicate treatment plan to outpatient provider and arrange transportation for patients.~Home monitoring/ Home Health Services- If patients are eligible and consent to home health services, they will be enrolled in Penn Medicine Home Health (PMHH). This will include virtual home monitoring, skilled nurse care, home physical and occupational therapists, social work services, and wound care."
79320517|NCT04479007|Device|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
79320518|NCT01968226|Drug|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis >50% who are undergoing planned carotid endarterectomy will be imaged under PET with [F-18] RDG-K5
79479010|NCT05036538|Device|Intervention with natural sounds administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
79644777|NCT01465100|Diagnostic Test|Whole body Phe oxidation testing|Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
79644778|NCT01465100|Procedure|Liver Biopsy|Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
79975094|NCT01306565|Drug|High dose atorvastatin|80mg daily atorvastatin for 72 hours
79975095|NCT03716791|Dietary Supplement|methylsulfonylmethane|3g per day
79975096|NCT03716791|Dietary Supplement|placebo|white rice flour
79975097|NCT05186610|Procedure|FDG PET/CT guided metabolic core needle biopsy|The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
79975098|NCT02486770|Biological|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
79644779|NCT01436656|Drug|LGX818|
79975099|NCT02486770|Biological|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
79975100|NCT02486770|Biological|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
79479011|NCT05036538|Device|Intervention with natural sounds and binaural beats administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
79479012|NCT05036538|Device|Intervention with natural sounds and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
79479013|NCT05036538|Device|Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
79644780|NCT01368588|Radiation|radiation therapy|Undergo RT using IMRT or 3D-CRT
79644781|NCT01368588|Radiation|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
79975101|NCT03786029|Drug|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
79644782|NCT01364857|Genetic|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
79644783|NCT01029002|Drug|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
79975102|NCT03786029|Drug|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
79644784|NCT01029002|Other|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
79975103|NCT03786029|Drug|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
79975104|NCT01334892|Drug|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
79306898|NCT05776121|Drug|ZB001 for injection|Dose Cohort2 (10 mg/kg) ZB001 four IV injections
79306899|NCT05772702|Device|Closed-loop tACS|Individual alpha tACS
79306900|NCT05758896|Drug|Isuzinaxib (APX-115)|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
79306901|NCT05758896|Drug|Placebo|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
79306902|NCT05756660|Drug|Sodium Thiosulfate|This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.
79306903|NCT05752279|Drug|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
79306904|NCT05752279|Drug|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
79306905|NCT05750498|Other|No interventions|There are no interventions
79306906|NCT05745285|Other|LLS Program|The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
79306907|NCT05743699|Behavioral|Bright Horizons|Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.
79306908|NCT05743699|Behavioral|Case Management|Placebo condition
79306909|NCT05740020|Device|virtual reality glasses|A specialized VR glasses will be used and VR games application in spider cage
79306910|NCT05740020|Other|The traditional exercise program|"The selected physical therapy program:~Neurodevelopmental approach: aims to facilitate typical motor development and function and to prevent secondary impairments (figure 4).~Approximation: aims to control spasticity and stimulate the joint mechanoreceptors (figure 5).~Stretching exercise: aims to maintain length and flexibility of shorten muscles (figure 6).~Strengthening exercise: aims to improve the functional ability (figure 7).~Spider suspension exercise for 30 minutes (figure 8).~5. Gait training activities: aims to improve balance (figure 9). 6. Balance training program: aims to improve balance (figure 10)."
79306911|NCT05731947|Drug|SNDX-5613|SNDX-5613 administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
79975105|NCT03435211|Device|INVSENSOR00006|Noninvasive pulse oximeter sensor
79975106|NCT02484508|Drug|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
79644785|NCT01011478|Drug|rosuvastatin|
79644786|NCT01011478|Other|placebo|
79644787|NCT00883207|Behavioral|Psychotherapy|Narrative and dialogical approach for couples
79975107|NCT02484508|Drug|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
79975108|NCT05186532|Radiation|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
79975109|NCT05186532|Other|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
79644788|NCT00876174|Procedure|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
79644789|NCT00876174|Procedure|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
79644790|NCT00799864|Drug|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged >=12 to <18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged >=6 to <12 years) or 25 mg once daily for up to 48 weeks.
79644791|NCT00799864|Drug|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
79644792|NCT00799864|Drug|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
79975110|NCT04730219|Drug|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
79644793|NCT00799864|Drug|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
79320519|NCT02358109|Behavioral|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
79975111|NCT04730219|Drug|Nab paclitaxel|Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
79320520|NCT05038319|Procedure|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
79644794|NCT00799864|Drug|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
79975112|NCT05654311|Other|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
79808944|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
79975113|NCT04492774|Combination Product|Goldic serum|epidural injections
79975114|NCT04492774|Drug|Steroid injections|epidural injections
79320521|NCT05049629|Device|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
79320522|NCT05049629|Device|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
79320523|NCT02362165|Drug|Cyclophosphamide|500mg/d,once-weekly,per oral.
79320524|NCT02362165|Drug|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
79644795|NCT00799864|Drug|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
79808945|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
79808946|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
79808947|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
79808948|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
79808949|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
79975115|NCT04492774|Procedure|Manual therapy|Veno-lymphatic drainage
79975116|NCT01332084|Other|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
79975117|NCT01928732|Behavioral|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
79320525|NCT02362165|Drug|Dexamethasone|40mg/d,once-weekly,per oral
79320526|NCT02362165|Drug|Doxorubicin|9mg/㎡,d1-4
79320527|NCT02352571|Biological|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
79479014|NCT05030467|Behavioral|REDUCE-BP Intervention|"Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits."
79644796|NCT00756795|Behavioral|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
79644797|NCT00695279|Procedure|Venipuncture|Blood draw
79644798|NCT00546260|Drug|placebo|administration of iv bolus prior to angiography
79320528|NCT03095495|Device|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
79320529|NCT03095495|Device|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
79320530|NCT02352649|Drug|Neovasculgen|
79320531|NCT05037773|Behavioral|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
79320532|NCT02357953|Other|Measurement of cardiac index|
79320533|NCT05049239|Behavioral|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
79479015|NCT05025605|Drug|BXCL501 80 Micrograms|Sublingual film containing 80 Micrograms BXCL501
79479016|NCT05025605|Drug|Placebo Film|Matching Sublingual Placebo film
79644799|NCT00546260|Drug|PRT060128 Potassium|administration of iv bolus prior to angiography
79644800|NCT00272714|Drug|Afimoxifene (0.057%) in hydroalcoholic gel|
79808950|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
79808951|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
79808952|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
79808953|NCT02632253|Procedure|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
79320534|NCT05049239|Behavioral|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
79975118|NCT01928732|Behavioral|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
79320535|NCT05049473|Drug|Rituximab|Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1*, B1/B1*, C1/A2*, A2/B2*, B2/A3*, C2/B3*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
79975119|NCT03321292|Drug|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
79975120|NCT03321292|Drug|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
79975121|NCT03785717|Procedure|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
79975122|NCT03785717|Procedure|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
79975123|NCT02484742|Behavioral|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
79975124|NCT01306721|Drug|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
79975125|NCT01306721|Drug|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
79975126|NCT01306721|Drug|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
79975127|NCT01306721|Drug|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
79975128|NCT01337466|Radiation|[124I]FIAU|This is a single dose study of 2 mCi [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
79975129|NCT02486926|Other|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
79975130|NCT02486926|Drug|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
79975131|NCT02486926|Drug|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
79975132|NCT02486926|Drug|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
79479017|NCT05025605|Drug|BXCL501 120 Micrograms|Sublingual film containing 120 Micrograms BXCL501
79479018|NCT05025605|Drug|BXCL501 60 Micrograms|Sublingual film containing 60 Micrograms BXCL501 Europe Only
79975133|NCT02486926|Drug|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
79975134|NCT01335048|Drug|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
79975135|NCT01335048|Drug|Clopidogrel|Clopidogrel 150 mg daily
79975136|NCT03318250|Device|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
79975137|NCT01335126|Other|Emulsion type artificial tear|2 types of artificial tears
79975138|NCT03465709|Drug|Pegcetacoplan|Study Drug
79975139|NCT02489812|Behavioral|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
79320536|NCT05049473|Drug|Methotrexate|Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1*, B1*, A2*, B2*, A3*, B3*
79320537|NCT05049473|Drug|Dexamethasone|Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1*, B1/B1*, C1/A2*, A2/B2*, B2/A3*, C2/B3*.
79479019|NCT05025241|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
79975140|NCT01567475|Drug|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
79320538|NCT05049473|Drug|Iphosphamid|"Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1*."
79320539|NCT05049473|Drug|Vincristine|Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1*, B2*, B3*
79320540|NCT05049473|Drug|Etoposide|Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1*, A2*, A3*.
79320541|NCT05049473|Drug|Cytarabine|Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1*, A2*, A3*
79320542|NCT05049473|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1*, B2*, B3*
79320543|NCT05049473|Drug|Doxorubicin|Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1*, B2, B2*, B3*
79320544|NCT05049473|Drug|Vindesine|Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
79320545|NCT05049473|Drug|Cytarabine|Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
79479020|NCT05020600|Drug|Duloxetine|First-line fibromyalgia treatment
79320546|NCT05049473|Drug|Methotrexate|Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1*, B1*, A2*, B2*, A3*, B3*
79320547|NCT05049473|Drug|Hydrocortisone|Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
79320548|NCT05049473|Drug|Prednisone|Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
79975141|NCT01337544|Other|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
79479021|NCT05020600|Drug|Pregabalin|First-line fibromyalgia treatment
79479022|NCT05020600|Drug|Amitriptyline|First-line fibromyalgia treatment
79479023|NCT05017480|Drug|CBP-201|CBP-201 subcutaneous(SC) injection.
79479024|NCT05017480|Drug|Placebo|subcutaneous(SC) injection
79479025|NCT05011799|Behavioral|Cancer Educational Materials|Receive prostate cancer educational materials
79479026|NCT05011799|Other|Questionnaire Administration|Ancillary studies
79479027|NCT05011799|Other|Educational Intervention|Attend peer-led education sessions
79479028|NCT05011266|Drug|Buprenorphine/naloxone|5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
79479029|NCT05011266|Drug|Placebo|placebo sub-lingual tablet daily
79479030|NCT05010070|Behavioral|diet and lifestyle program|See description of main arm.
79975142|NCT03716713|Device|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
79808954|NCT02632253|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
79479031|NCT05008198|Other|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
79479032|NCT05000450|Genetic|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
79479033|NCT05000450|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
79479034|NCT05000450|Drug|Fludarabine|Chemotherapy for lymphodepletion
79479035|NCT05000450|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
79479036|NCT04999917|Diagnostic Test|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
79306912|NCT05731947|Drug|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
79479037|NCT04998279|Drug|Granulocyte Colony-Stimulating Factor|Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
79306913|NCT05725603|Other|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
79975143|NCT03316144|Biological|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
79479038|NCT04998279|Other|placebo|mock test without injection of G-CSF
79479039|NCT04991753|Other|Placebo|Placebo infusion will be administered intravenously.
79479040|NCT04991753|Drug|Nipocalimab|Nipocalimab infusions will be administered intravenously.
79306914|NCT05724849|Drug|Venlafaxine|See arm/group description.
79479041|NCT04983420|Other|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
79306915|NCT05724849|Drug|Placebo|See arm/group description.
79479042|NCT04983420|Other|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
79479043|NCT04983420|Other|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
79808955|NCT04157387|Other|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
79984674|NCT03693989|Drug|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
79306916|NCT05723198|Drug|Baricitinib|Administered orally
79306917|NCT05723198|Drug|Placebo|Administered orally
79306918|NCT05722158|Dietary Supplement|Dietary supplementation with placebo.|Volunteers will be provided with the placebo. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
79306919|NCT05722158|Dietary Supplement|Dietary supplementation with the collagen-based product CP1.|Volunteers will be provided with the collagen-derived product CP1. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
79320549|NCT02361931|Drug|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
79320550|NCT02361931|Drug|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
79320551|NCT02361853|Other|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
79320552|NCT02361853|Other|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
79320553|NCT02361853|Other|Exposure: abundance of Immature monocytes counts in blood samples|
79320554|NCT02361853|Other|Exposure: abundance of Immature neutrophils counts in blood samples|
79320555|NCT05037695|Drug|empagliflozin 25 MG|empagliflozin 25mg - daily
79320556|NCT02361697|Other|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
79320557|NCT05049395|Device|High Flow Nasal Cannula oxygen (HFNO)|The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
79320558|NCT05049395|Device|Regular oxygen|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
79320559|NCT02357641|Other|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
79320560|NCT05048771|Other|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
79479044|NCT04983420|Other|lemonade|intake of 1 L lemonade per day for 2 weeks
79479045|NCT04979169|Behavioral|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
79975144|NCT05527028|Other|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
79479046|NCT04971148|Other|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level equal to patient peak tidal inspiratory flow
79644801|NCT02903641|Behavioral|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
79644802|NCT02903641|Behavioral|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
79975145|NCT01332162|Device|Biventricular pacing|All patients will be pacing during two years
79975146|NCT01332162|Device|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
79644803|NCT02903758|Other|cross sectional|
79644804|NCT02903719|Drug|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
79644805|NCT00178269|Drug|docetaxel|
79975147|NCT02484196|Behavioral|Questionnaires|Questionnaires
79644806|NCT00178269|Procedure|Radiation Therapy|
79644807|NCT02903251|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
79644808|NCT02903251|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
79644809|NCT00168467|Drug|Ramipril|
79975148|NCT03435055|Drug|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
79975149|NCT01337622|Procedure|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
79975150|NCT01337622|Procedure|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
79644810|NCT02903329|Other|Detoxification|Two ways of composing the detoxification protocol
79320561|NCT02352181|Procedure|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if fibrinogen <1gram per liter~Platelet concentrate :~if platelets <50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~if platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~if prothrombin<40% before transfusion at anhepatic phase or in case of bleeding.~if prothrombin<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
79320562|NCT02352181|Procedure|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM <8 mm~Platelet concentrate :~If MCF EXTEM <40mm or A10<35 mm and MCF or A10 FIBTEM >8mm.~If platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~2 Fresh frozen plasma if CT EXTEM >100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~if fibrinolysis in EXTEM~Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes >15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
79320563|NCT02357563|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
79644811|NCT04723589|Biological|Thawed plasma|"Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study."
79644812|NCT02903056|Other|Rett Syndrome|Diagnosis of Rett Syndrome
79644813|NCT00195936|Drug|Cinacalcet|Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
79644814|NCT02903095|Drug|TD-1439|
79644815|NCT02903095|Drug|Placebo|
79644816|NCT00168506|Drug|SSRI|
79644817|NCT00168506|Drug|CBT|
79975151|NCT02489656|Device|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
79975152|NCT03788447|Other|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
79975153|NCT03788447|Other|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
79644818|NCT00168506|Drug|CBT/SSRI|
79644819|NCT02902783|Other|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
79644820|NCT02902939|Device|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
79320564|NCT02357563|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
79320565|NCT04478929|Diagnostic Test|Gastroscopy|Routine gastroscopy
79320566|NCT02361541|Procedure|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
79320567|NCT03160105|Drug|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
79320568|NCT03160105|Other|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
79479047|NCT04971148|Other|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow
79479048|NCT04971148|Other|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow
79479049|NCT04971148|Other|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set 2 times of patient peak tidal inspiratory flow
79644821|NCT02902939|Procedure|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
79644822|NCT02902861|Drug|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
79644823|NCT02902861|Drug|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
79644824|NCT00168545|Biological|Measles vaccine|
79984675|NCT03693989|Drug|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic"
79984676|NCT02786186|Drug|Secikinumab|
79320569|NCT02640053|Procedure|Cryotherapy|Applied topically
79320570|NCT02640053|Drug|Paclitaxel|Given IV
79320571|NCT02640053|Other|Quality-of-Life Assessment|Ancillary studies
79320572|NCT02640053|Other|Questionnaire Administration|Ancillary studies
79320573|NCT03160261|Drug|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
79479050|NCT04965077|Drug|Recombinant Humanized Monoclonal Antibody MIL97 for Injection|"Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle."
79479051|NCT04960813|Behavioral|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
79644825|NCT02902705|Other|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
79644826|NCT02902978|Drug|E6130|
79644827|NCT02902978|Drug|Placebo|E6130 matched placebo
79644828|NCT02903017|Drug|Tranexamic acid 5%|Via nasogastric tube, 100 mL
79644829|NCT02903017|Drug|Placebo|Via nasogastric tube, 100 mL
79644830|NCT02902744|Drug|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
79644831|NCT00168584|Drug|Vitamin A|
79644832|NCT02902666|Drug|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
79320574|NCT05036837|Drug|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
79320575|NCT02361775|Device|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
79320576|NCT02361775|Device|opioid iv pca|opioid pca consisting of hydromorphone
79320577|NCT02361775|Drug|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
79320578|NCT02361775|Device|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
79479052|NCT04960813|Behavioral|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
79479053|NCT04958057|Behavioral|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
79479054|NCT04956120|Device|Citrate Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
79479055|NCT04956120|Device|Standard Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
79644833|NCT02902666|Drug|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
79808956|NCT04157387|Other|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
79320579|NCT05036759|Drug|68Ga-FAPI|intravenously injected with 68Ga-FAPI
79320580|NCT02361619|Drug|Caffeine|probe
79320581|NCT02361619|Drug|Diclofenac|probe
79320582|NCT02361619|Drug|Esomeprazole|probe
79320583|NCT02361619|Drug|Metoprolol|probe
79320584|NCT02361619|Drug|Midazolam|probe
79320585|NCT02361619|Drug|Dabigatran|probe
79808957|NCT00660803|Drug|Fulvestrant|
79320586|NCT02361619|Drug|Clarithromycin|perpetrator
79320587|NCT02361463|Device|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
79320588|NCT02361463|Device|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
79320589|NCT05048303|Procedure|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
79808958|NCT04157543|Other|electroacupuncture|acupuncture with electricity
79306920|NCT05722158|Dietary Supplement|Dietary supplementation with the collagen-based product CP2.|Volunteers will be provided with the collagen-derived product CP2. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
79306921|NCT05722158|Dietary Supplement|Dietary supplementation with the collagen-based product CP3.|Volunteers will be provided with the collagen-derived product CP3. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
79306922|NCT05722158|Dietary Supplement|Dietary supplementation with the collagen-based product CP4.|Volunteers will be provided with the collagen-derived product CP4. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
79306923|NCT05718557|Drug|PYX-106|Intravenous (IV) infusion
79306924|NCT05712798|Other|No intervention|No intervention
79306925|NCT05710848|Drug|STM-416|STM-416 monotherapy
79306926|NCT05694884|Drug|Placebo|Placebo Comparator
79320590|NCT02352025|Drug|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
79479056|NCT04955795|Behavioral|Alcohol Brief Intervention (BI)|The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
79808959|NCT00661115|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
79808960|NCT00661115|Drug|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
79808961|NCT04157699|Drug|TDF tablet|TDF tablet 300mg QD
79808962|NCT04157699|Drug|QL-007|QL-007 tablet
79808963|NCT00665717|Drug|Pravastatin|40 mg tablet; QD; 4 days
79808964|NCT00665717|Drug|Raltegravir|400mg tablet; BD 4 days
79306927|NCT05694884|Drug|ASLAN004|ASLAN004
79808965|NCT00665717|Drug|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
79808966|NCT02611596|Drug|Ranolazine|24 weeks of the assigned medication
79306928|NCT05692388|Other|Patient and Community Stakeholder Interviews|Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.
79306929|NCT05692388|Other|Cross-sectional Study Participants|Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.
79808967|NCT02611596|Drug|Placebo|Placebo for 24 weeks
79808968|NCT00661349|Drug|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
79808969|NCT00661349|Drug|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
79808970|NCT00702858|Drug|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
79808971|NCT00702858|Drug|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
79320591|NCT01950364|Drug|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
79320592|NCT01950364|Drug|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
79320593|NCT05047991|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
79320594|NCT05047991|Drug|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
79320595|NCT05047991|Drug|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
79320596|NCT05047991|Drug|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
79320597|NCT05047991|Drug|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
79320598|NCT05047991|Drug|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
79644834|NCT02902822|Procedure|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~fungal skin infections (tinea corporis, cruris, pedis);~pigmented tumors (melanoma);~non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
79320599|NCT00014443|Drug|thalidomide|
79320600|NCT00014443|Drug|topotecan hydrochloride|
79320601|NCT05035979|Drug|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
79320602|NCT05035979|Drug|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
79320603|NCT05035979|Drug|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
79320604|NCT05035979|Drug|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
79320605|NCT05047367|Behavioral|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
79808972|NCT04156607|Other|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
79320606|NCT05036057|Other|Questionnaire|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
79644835|NCT02902822|Device|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~fungal skin infections (tinea corporis, cruris, pedis);~pigmented tumors (melanoma);~non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
79644836|NCT02902354|Other|Nifedipine for tocolysis|observational
79644837|NCT02902393|Biological|Thromboelastography|
79320607|NCT02351635|Other|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
79320608|NCT05047133|Drug|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
79320609|NCT02357251|Other|Enhanced recovery protocol|
79320610|NCT05035355|Procedure|a weaning protocol|a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
79644838|NCT00168623|Drug|Vitamin A|
79644839|NCT02902510|Other|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
79644840|NCT02902315|Other|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
79320611|NCT04334863|Drug|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
79320612|NCT02357407|Drug|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
79320613|NCT02357407|Drug|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
79320614|NCT05035433|Procedure|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
79320615|NCT05035433|Procedure|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
79320616|NCT02038699|Drug|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
79320617|NCT05046743|Other|Colonic gas load|Colonic infusion of gas via an anal cannula
79320618|NCT05046743|Other|Sham load|Sham infusion of gas via an anal cannula
79975154|NCT03316066|Procedure|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
79975155|NCT03316066|Procedure|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
79975156|NCT03716635|Procedure|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
79975157|NCT03716635|Procedure|normal saline|a room temperature saline is used as a final flush after mechanical preparation
79320619|NCT03160651|Drug|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
79975158|NCT03315988|Other|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
79975159|NCT05186298|Device|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
79975160|NCT05186298|Device|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
79320620|NCT05046977|Procedure|Single osteotomy|Single tibial osteotomy
79975161|NCT05186298|Procedure|Cataract Surgery|IOL implantation will be performed
79320621|NCT05046977|Procedure|Double Osteotomy|Double Tibial Osteotomy
79320622|NCT02357095|Procedure|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
79320623|NCT05026307|Procedure|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
79320624|NCT02351713|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
79320625|NCT05034965|Drug|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
79320626|NCT03160339|Biological|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
79320627|NCT03160339|Biological|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
79644841|NCT02902315|Other|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
79320628|NCT03094091|Other|News items with spin|Interpretation of news items with spin
79320629|NCT03094091|Other|News items without spin|Interpretation of news items without spin
79644842|NCT02902315|Other|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
79644843|NCT02902315|Other|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
79644844|NCT00178347|Radiation|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
79644845|NCT02902588|Other|ICG-PULSION|Intravenous administration of indocyanine green
79644846|NCT02902588|Device|LiMON, Pulsion Medical Systems|Application of near infrared light
79644847|NCT02902588|Other|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
79320630|NCT05025839|Other|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
79320631|NCT05034887|Drug|Trastuzumab Deruxtecan (T-DXd)|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
79320632|NCT05035121|Dietary Supplement|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
79320633|NCT05035121|Dietary Supplement|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
79644848|NCT00168662|Biological|Measles and inactivated polio vaccine|
79644849|NCT02902627|Device|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
79644850|NCT02902432|Drug|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
79644851|NCT02902471|Other|Forced oscillations measure|
79644852|NCT02902276|Other|additional blood sample|Two blood samples will be taken at ICU admission
79644853|NCT02902042|Drug|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
79644854|NCT02902042|Drug|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
79644855|NCT02902042|Drug|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
79644856|NCT02902042|Drug|Pembrolizumab alone|200 mg q3w
79644857|NCT00178425|Procedure|Serial blood sampling as described in protocol|
79644858|NCT00178425|Procedure|Estimation of Creatinine Clearance at regular intervals|
79644859|NCT02902159|Other|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
79644860|NCT02902159|Other|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
79320634|NCT05035121|Behavioral|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
79320635|NCT05034653|Other|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
79320636|NCT05034653|Other|Healthy Plate|Quarter-quarter-half meal concept
79320637|NCT02357017|Dietary Supplement|NaCl tablets|
79320638|NCT05025917|Dietary Supplement|Shatavari|Shatavari root powder
79320639|NCT05025917|Dietary Supplement|Magnesium stearate|Magnesium stearate powder
79320640|NCT02039011|Drug|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
79320641|NCT02039011|Drug|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
79320642|NCT04449055|Device|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
79320643|NCT05025215|Behavioral|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
79320644|NCT05025215|Behavioral|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
79975162|NCT05695157|Device|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
79320645|NCT02361385|Other|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
79320646|NCT03093857|Diagnostic Test|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
79320647|NCT02356627|Other|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
79479057|NCT04955795|Behavioral|Common Elements Treatment Approach (CETA) via Telemedicine|CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
79975163|NCT03318016|Drug|Cyclophosphamide|"ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV dose along with Mesna (in subjects receiving >1000mg/m2 Cy) and hydration for a maximum of 6 doses in the following dose escalation schema:~Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2~Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2~Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2~Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2~Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2"
79479058|NCT04953962|Drug|CBP501 (16)|16 mg/m2
79479059|NCT04953962|Drug|CBP501 (25)|25 mg/m2
79479060|NCT04953962|Drug|Cisplatin|60mg/m2
79479061|NCT04953962|Drug|Nivolumab|240 mg
79644861|NCT00168740|Drug|rituximab|
79644862|NCT02901847|Other|PAD tailored care|PAD tailored care
79975164|NCT03434977|Drug|TAK-536|TAK-536 granule formulation
79644863|NCT00196053|Device|Archimedes Constant Flow Implantable Pump|
79644864|NCT02901925|Drug|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
79644865|NCT02901964|Other|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
79975165|NCT01308515|Device|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
79320648|NCT05025137|Other|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
79320649|NCT05025137|Other|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
79320650|NCT02351479|Behavioral|Hula|
79320651|NCT05024669|Combination Product|Gluma desensitiser|Gluma desensitiser was used before restoration.
79320652|NCT05024669|Combination Product|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
79320653|NCT05024669|Combination Product|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
79644866|NCT02901964|Other|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
79644867|NCT02901886|Behavioral|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
79808973|NCT04156607|Other|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
79320654|NCT02039167|Device|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
79320655|NCT05024825|Drug|Gabapentin|Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
79320656|NCT05024825|Drug|hydrocodone, acetaminophen and ibuprofen|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
79320657|NCT02361151|Behavioral|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
79644868|NCT00168779|Drug|telmisartan 80 mg / hydrochlorothiazide 25 mg|
79644869|NCT00168779|Drug|valsartan 160 mg / hydrochlorothiazide 25 mg|
79644870|NCT00168779|Drug|placebo|
79644871|NCT04681300|Other|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
79644872|NCT04681300|Other|Plastic surgery remnants|healthy skin from plastic surgery interventions
79644873|NCT04681222|Procedure|LFCN|LFCN block was performed in combination with PENG block
79644874|NCT04681222|Procedure|Wound infiltration|Wound infiltration was performed in combination with PENG block
79808974|NCT02631005|Other|"Walk With Ease"|Six-week walking program
79320658|NCT02361151|Behavioral|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
79320659|NCT05033795|Dietary Supplement|Water A|2 L of water A per day
79320660|NCT05033795|Dietary Supplement|Water B|2 L of water B per day
79479062|NCT04947709|Behavioral|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
79479063|NCT04939480|Drug|Atezolizumab|Atezolizumab 1200 mg intravenous solution
79479064|NCT04938960|Diagnostic Test|blood draw|blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.
79644875|NCT03455335|Drug|20 million hMSCs|
79479065|NCT04938492|Behavioral|Cognitive Behavioral Therapy for loneliness (CBT-L)|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
79644876|NCT03455335|Drug|40 million hMSCs|
79644877|NCT03455335|Drug|80 million hMSCs|
79644878|NCT00196092|Device|Roll-in|Proctored entry.
79644879|NCT00196092|Device|Surgical|Surgery
79644880|NCT00196092|Device|Standard Risk|Standard Endovascular repair
79644881|NCT00196092|Device|High Risk|High Risk Endovascular repair.
79644882|NCT00196092|Device|Compassionate Use|Endovascular repair for compassionate use patients.
79644883|NCT00196092|Device|Treatment for females|Endovascular repair in female patients
79644884|NCT00196092|Device|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
79644885|NCT00196092|Device|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
79644886|NCT02901613|Device|Negative-pressure wound therapy|
79644887|NCT02901652|Device|noninvasive respiratory support devices|
79644888|NCT02901691|Other|musical rhythmic stimulation|
79644889|NCT00178581|Drug|Glutamine|
79306930|NCT05692388|Other|Focus Groups and Intervention Mapping|A subsample of patient interview/cross-sectional study participants will be invited back to participate in four focus groups (five participants/group) to review components of the intervention, give feedback on appropriateness, feasibility, acceptability, and likelihood of having an impact based on their lived experiences.
79306931|NCT05683015|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
79306932|NCT05683015|Procedure|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
79306933|NCT05679674|Radiation|Stereotactic Ablative Body Radiation (SABR)|50 Gy in 5 fractions, once per day for 5 days
79306934|NCT05679674|Device|Tumor Treating Fields (TTF)|Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
79306935|NCT05674240|Device|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
79306936|NCT05674240|Combination Product|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
79320661|NCT03149965|Other|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
79320662|NCT02356549|Behavioral|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
79320663|NCT02356549|Behavioral|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
79644890|NCT02901730|Procedure|532nm laser group|LPI with 532nm laser.
79479066|NCT04938492|Behavioral|Physical Health Education Training (PHET)|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
79644891|NCT02901730|Procedure|561nm laser group|LPI with 561nm laser.
79644892|NCT02901535|Other|Spirometry|Spirometry in baseline
79644893|NCT02901535|Other|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
79644894|NCT02901535|Other|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
79644895|NCT02901535|Other|Spirometry - 20 weeks|Spirometry (20 weeks)
79975166|NCT01308515|Device|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
79975167|NCT02489578|Other|other|retrospective cohort study
79975168|NCT01335360|Drug|Nevirapine|200mg twice daily of nevirapine
79320664|NCT02356549|Behavioral|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
79320665|NCT05024435|Device|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
79320666|NCT02360917|Other|Emerging from the Haze|A 6 week psycho-educational class
79320667|NCT03093467|Behavioral|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
79644896|NCT02901769|Other|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
79644897|NCT00196131|Drug|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
79644898|NCT00168896|Drug|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
79808975|NCT00826176|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
79975169|NCT02489890|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
79984677|NCT02445274|Procedure|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
79479067|NCT04938349|Behavioral|Dual task perturbation training|Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
79479068|NCT04931849|Drug|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
79644899|NCT02901457|Other|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
79975170|NCT03788057|Other|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
79320668|NCT03093467|Drug|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
79320669|NCT03093467|Behavioral|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
79320670|NCT02356237|Other|No episiotomy|Avoidance of episiotomy
79320671|NCT03095261|Behavioral|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
79644900|NCT02901418|Biological|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
79644901|NCT02901379|Drug|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
79320672|NCT03095261|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
79320673|NCT03095261|Behavioral|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
79479069|NCT04927780|Drug|Leucovorin Calcium|IV
79479070|NCT04927780|Drug|Fluorouracil|IV
79644902|NCT02901379|Drug|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
79808976|NCT00665873|Device|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
79479071|NCT04927780|Drug|Irinotecan Hydrochloride|IV
79479072|NCT04927780|Drug|Oxaliplatin|IV
79479073|NCT04927780|Procedure|Resection|Open or minimally-invasive pancreatectomy.
79479074|NCT04927559|Other|Survey Administration|Complete survey
79975171|NCT01332240|Procedure|Endoscopic ultrasonography|in order to stage the mediastinum
79320674|NCT03095261|Behavioral|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
79320675|NCT03149653|Drug|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
79320676|NCT03149653|Drug|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
79320677|NCT03149653|Drug|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
79975172|NCT02489266|Biological|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
79320678|NCT03149653|Drug|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
79320679|NCT03149653|Drug|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
79320680|NCT03149653|Drug|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
79320681|NCT03093545|Biological|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
79479077|NCT04925557|Drug|Mayzent|PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
79975173|NCT02489266|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
79320682|NCT03093545|Biological|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
79320683|NCT02351401|Behavioral|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
79320684|NCT03093623|Behavioral|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
79644903|NCT00196170|Procedure|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
79644904|NCT00196170|Procedure|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
79320685|NCT02360761|Procedure|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
79320686|NCT02360761|Procedure|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
79644905|NCT00196170|Procedure|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
79644906|NCT00196170|Procedure|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
79975174|NCT02489266|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
79320687|NCT05024357|Drug|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
79320688|NCT03095183|Device|Grape flavored Puritan Junior tongue depressor|
79320689|NCT03095183|Device|Traditional unflavored Puritan Regular Tongue Depressor|
79320690|NCT02356315|Other|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
79320691|NCT03095339|Other|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
79320692|NCT03149731|Device|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
79320693|NCT03095105|Drug|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
79320694|NCT02351323|Drug|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
79479078|NCT04925557|Drug|Ocrevus|PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
79479079|NCT04908280|Drug|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
79644907|NCT00168935|Drug|Fresubin protein energy Drink (CAVE! nutritional intervention)|
79644908|NCT02901340|Dietary Supplement|one to two liters of water daily|
79644909|NCT02901106|Drug|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
79644910|NCT04723628|Behavioral|Intervention group (telephone counseling)|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
79644911|NCT02901223|Procedure|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
79975175|NCT02489266|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
79975176|NCT03785483|Behavioral|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
79975177|NCT03317938|Device|Fecobionics|Fecobionics is a new device for studying defecation
79984678|NCT03746561|Diagnostic Test|deep learning|detect and classify spinal stenosis by deep learning
79984679|NCT02445118|Other|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
79479080|NCT04903015|Diagnostic Test|MRI|"The following sequences of the MRI will be acquired during the inclusion visit:~3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~resting-state fMRI: functional connectivity;~64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~monovoxel spectroscopy of the mesencephalus with short echo time (TE)."
79320695|NCT02351323|Behavioral|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
79644912|NCT02901223|Procedure|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
79644913|NCT00196209|Procedure|catheter ablation|catheter ablation to treat persistent atrial fibrillation
79320696|NCT05024123|Dietary Supplement|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 ~ 180 min to measure 1) nitrate and 2) cGMP content."
79479081|NCT04899063|Device|ELIOS Procedure|Treatment with the ELIOS System
79479082|NCT04897711|Behavioral|Perceptual Training|Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
79479083|NCT04897074|Device|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
79479084|NCT04888585|Drug|ABBV-154|Subcutaneous Injection
79479085|NCT04888585|Drug|Placebo|Subcutaneous Injection
79479086|NCT04888169|Device|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
79644914|NCT00196209|Procedure|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
79644915|NCT02901145|Drug|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
79644916|NCT02901301|Drug|Pembrolizumab|200mg, IV, q3weeks, Day 1
79644917|NCT02901301|Drug|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
79644918|NCT02901301|Drug|Capecitabine|1000mg/m2, PO, BID, Day 1-14
79644919|NCT02901301|Drug|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
79644920|NCT02901028|Other|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
79644921|NCT02901028|Other|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
79644922|NCT02900989|Behavioral|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
79644923|NCT02900950|Procedure|Multicolour inking specimens|
79644924|NCT02900950|Procedure|Monocolour inking specimens|
79479087|NCT04888169|Device|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
79479088|NCT04888169|Device|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
79479089|NCT04888169|Device|SMART Mobile App - Control|Participants will only answer questions.
79479090|NCT04885179|Other|no intervention|No interventions are involved in this observational study.
79479091|NCT04878029|Drug|Cabozantinib S-malate|Given PO
79479092|NCT04878029|Drug|Enfortumab Vedotin|Given IV
79644925|NCT00169013|Drug|Gabapentin|
79479093|NCT04878029|Other|Quality-of-Life Assessment|Ancillary studies
79479094|NCT04878029|Other|Questionnaire Administration|Ancillary studies
79479095|NCT04871529|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79479096|NCT04871529|Drug|Avelumab|Given IV
79808977|NCT00665873|Drug|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
79808978|NCT05297916|Other|enteral feeding|to intake oral feeding or delay it
79808979|NCT04156061|Other|Delivery of CT scan results|Method of results delivery - verbal or visual.
79320697|NCT05024123|Dietary Supplement|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 ~ 180 min to measure 1) nitrate and 2) cGMP content."
79479097|NCT04871529|Drug|Gemcitabine Hydrochloride|Given IV
79479098|NCT04871529|Drug|Carboplatin|Given IV
79479099|NCT04865887|Drug|Pembrolizumab|200mg, every 3 weeks, IV infusion
79808980|NCT00707850|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
79808981|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
79808982|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
79479100|NCT04865887|Drug|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
79479101|NCT04864444|Drug|Dihydroartemisinin-piperaquine|DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
79644926|NCT02900911|Other|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
79644927|NCT02900911|Other|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
79644928|NCT02900716|Drug|DTRMWXHS-12|DTRMWXHS-12
79644929|NCT02900716|Drug|DTRM-505|DTRMWXHS-12 and everolimus
79644930|NCT02900716|Drug|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
79479102|NCT04864444|Drug|Primaquine|Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
79479103|NCT04854070|Device|IVUS|IVUS-guided approach in patients with complex coronary lesions undergoing PCI
79644931|NCT00169052|Behavioral|Health Care Management and Supported Rehabilitation|
79644932|NCT02900599|Other|Observationnal (no intervention)|
79644933|NCT02900677|Behavioral|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
79644934|NCT02900794|Device|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
79644935|NCT02900794|Procedure|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
79479104|NCT04854070|Device|Angio|Angio-guided approach in patients with complex coronary lesions undergoing PCI
79479105|NCT04854018|Drug|Indocyanine green|Intravenous or intraparenchymal injection
79644936|NCT00169091|Drug|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
79644937|NCT00169091|Drug|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
79644938|NCT02900755|Drug|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
79644939|NCT02900638|Behavioral|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
79644940|NCT02900209|Other|Influenza Vaccination|
79644941|NCT00169130|Drug|doxorubicin|
79644942|NCT00169130|Drug|cyclophosphamide|
79644943|NCT00169130|Procedure|Autologous stem cell transplantation|
79306937|NCT05670158|Biological|Blood sampling|Blood will be collected into 2 EDTA and 1 heparin tube. The 2 EDTA tubes (4ml of blood in each) will be transported on ice to the proteomics platform in the next three hours, centrifuged and stored on -80 degrees Celcius in low-binding tubes for further molecular analysis. 1 heparin tube (5mL) will be sent to the Bacteriology-Virology Department for the active PBMC counting.
79306938|NCT05670158|Procedure|Perilymph sampling|The perilymph collection will be performed during the cochlear implantation surgery at the same time as the round window opening. 5 to 15 microliters will be aspirated using an atraumatic spinal needle mounted onto 1 ml insulin syringe.
79306939|NCT05664555|Drug|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
79306940|NCT05664126|Drug|VST infusion|single intravenous (IV) infusion.
79306941|NCT05664126|Device|CliniMACS|Cells infusions are prepared using the ClinMACS
79306942|NCT05660395|Drug|Loncastuximab Tesirine|Intravenous (IV) Infusion
79320698|NCT02360449|Behavioral|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
79320699|NCT05033951|Other|Standard care|Both groups: standard care+ questionnaires
79320700|NCT01968070|Drug|LY3127760|Administered orally
79320701|NCT01968070|Drug|Celecoxib|Administered orally
79320702|NCT01968070|Drug|Placebo|Administered orally
79644944|NCT02900404|Other|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
79644945|NCT02900404|Other|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
79644946|NCT02900248|Other|Provider determined|Provider will treat patient as he/she feels best
79320703|NCT02351089|Dietary Supplement|Capsules placebo|Capsules
79320704|NCT02351089|Dietary Supplement|Capsules probiotic powder and corn starch|
79320705|NCT03093311|Other|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
79320706|NCT02351245|Other|observation|
79320707|NCT05033405|Behavioral|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
79320708|NCT02351011|Biological|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
79320709|NCT02351011|Biological|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
79320710|NCT02351011|Biological|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
79320711|NCT03093233|Other|no intervention|only descriptive data analysis
79320712|NCT02350855|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
79320713|NCT02350855|Other|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
79320714|NCT02350855|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
79644947|NCT00178620|Drug|Reteplase 10 Units (U) plus a second dose of reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
79644948|NCT00178620|Drug|Reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
79644949|NCT00178620|Procedure|Urgent Percutaneous Coronary Intervention (PCI)|
79644950|NCT00178620|Procedure|Primary Percutaneous Coronary Intervention (PCI)|
79644951|NCT02900365|Procedure|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
79644952|NCT02900365|Procedure|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
79644953|NCT00169169|Drug|ACVBP|
79644954|NCT00169169|Drug|ACE|
79644955|NCT00169169|Drug|rituximab|
79644956|NCT00169169|Procedure|Autologous stem cell transplant|
79808983|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
79479106|NCT04853043|Drug|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
79644957|NCT02900131|Drug|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
79644958|NCT02900131|Drug|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
79975178|NCT01337778|Behavioral|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
79479107|NCT04843501|Behavioral|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.
79479108|NCT04843501|Behavioral|Texas Education Agency (TEA) required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
79479109|NCT04837222|Other|No Intervention|This is a non-interventional study.
79644959|NCT04681261|Other|this study is not an intervention study|this study is not an intervention study
79644960|NCT00169208|Drug|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
79644961|NCT00169208|Drug|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
79644962|NCT00169208|Drug|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
79644963|NCT02899975|Other|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
79644964|NCT02899936|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
79644965|NCT02899936|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
79644966|NCT00178698|Other|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
79644967|NCT00178698|Drug|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
79644968|NCT00178698|Other|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
79644969|NCT02899897|Device|echocardiography in IV fluid therapy|
79644970|NCT00169247|Drug|cetuximab|
79644971|NCT00169247|Drug|Cisplatin|
79984680|NCT04944212|Diagnostic Test|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
79644972|NCT00169247|Procedure|Radiotherapy 70 Gy, 35 fractions|
79644973|NCT02899819|Other|meconium|The meconium will be sampled in the first 2 days of life
79808984|NCT02631707|Other|High protein diet|The intervention diet is higher in protein than the control diet.
79808985|NCT02631161|Other|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
79808986|NCT02631161|Other|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
79320715|NCT03093389|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
79320716|NCT03093389|Drug|Placebo|Matching placebo capsules
79320717|NCT05033249|Diagnostic Test|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
79320718|NCT05033249|Diagnostic Test|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
79320719|NCT02356081|Other|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
79644974|NCT02899702|Drug|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
79644975|NCT02899702|Drug|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
79644976|NCT02899780|Device|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
79644977|NCT00169286|Procedure|Telephone care management|
79984681|NCT05234242|Procedure|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
79320720|NCT01918774|Behavioral|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
79320721|NCT02355925|Drug|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
79320722|NCT02355925|Drug|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
79320723|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
79320724|NCT03092999|Drug|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
79320725|NCT02355847|Other|Lectures|Lectures
79320726|NCT03093077|Device|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
79644978|NCT00169286|Procedure|peer-led chronic disease self-management workshop|
79808987|NCT02631083|Other|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
79808988|NCT00661739|Drug|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
79808989|NCT00878969|Drug|valsartan (ARB)|
79320727|NCT02350933|Procedure|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
79808990|NCT00878969|Drug|ramipril (ACE inhibitor)|
79808991|NCT00878969|Drug|Placebo|
79320728|NCT03092921|Device|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
79320729|NCT03092921|Device|F&P Mask|Investigative Mask to be used for OSA therapy
79320730|NCT05024201|Behavioral|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
79320731|NCT04408183|Drug|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
79320732|NCT04408183|Drug|Placebo|Placebo is given as a nasal spray using an atomizer
79808992|NCT02630849|Procedure|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
79808993|NCT02630849|Procedure|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
79808994|NCT02630927|Drug|AG-519|AG519 will be tested.
79975179|NCT01337778|Behavioral|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
79975180|NCT03787979|Other|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
79302131|NCT03207139|Drug|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
79320733|NCT01949116|Drug|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
79320734|NCT01949116|Drug|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
79808995|NCT02630927|Drug|Placebo|Placebo will be tested.
79808996|NCT04057235|Device|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
79808997|NCT00843726|Radiation|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
79808998|NCT00843726|Radiation|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
79808999|NCT00661817|Behavioral|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
79320735|NCT01949116|Dietary Supplement|Folic acid|1-mg tablet of folic acid by mouth once a day
79320736|NCT01673009|Drug|Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
79320737|NCT02355535|Drug|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
79320738|NCT05033015|Procedure|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
79320739|NCT02350387|Procedure|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
79644979|NCT00169286|Procedure|professionally-led cognitive behavioral psychotherapy group|
79644980|NCT02899741|Drug|Omega-3|1000mg every day for 90 days
79644981|NCT02899624|Biological|Extra blood draw samples|
79320740|NCT02350387|Procedure|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
79320741|NCT05023499|Drug|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
79320742|NCT02350621|Procedure|ACDF|
79320743|NCT02350621|Procedure|minimal invasive Posterior Cervical Foraminotomy|
79320744|NCT05023421|Other|no intervention|no intervention
79320745|NCT02350543|Drug|Aspirin|
79320746|NCT05033093|Drug|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
79320747|NCT02359747|Genetic|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
79479110|NCT04826133|Drug|Calcitriol|Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
79479111|NCT04826133|Other|Placebo|Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
79479112|NCT04810624|Behavioral|Relapse Prevention and Changing Habits (REACH+)|Psychotherapy
79975181|NCT03787979|Other|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
79975182|NCT03434119|Drug|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter [U/mL]) and lixisenatide (33 micrograms per milliliter [mcg/mL]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter [mmol/L]) while avoiding hypoglycemia.
79320748|NCT05023577|Drug|Rabeprazole|20mg bid
79479113|NCT04797559|Procedure|SZMN Block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
79644982|NCT02899624|Biological|additional tissue samples|
79320749|NCT05023577|Drug|Bismuth potassium citrate|0.6g bid
79320750|NCT05023577|Drug|Metronidazole|0.4g qid
79320751|NCT05023577|Drug|Clarithromycin|0.5g bid
79320752|NCT05023577|Drug|Levofloxacin|0.5g qd
79320753|NCT03149497|Procedure|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
79320754|NCT05032625|Procedure|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
79320755|NCT03149419|Drug|Paroxetine|
79320756|NCT03149419|Drug|Placebo oral capsule|
79320757|NCT03092765|Drug|E6011|Intravenous administration
79320758|NCT03092765|Drug|Placebo|Intravenous administration
79320759|NCT02355223|Other|FAST|See information in arm description
79320760|NCT05032391|Biological|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
79320761|NCT05032391|Drug|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
79320762|NCT02359981|Behavioral|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
79479114|NCT04796961|Other|Implementation Intervention|The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
79479115|NCT04792645|Drug|Placebo|Pill that contains no medicine
79320763|NCT02359981|Behavioral|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
79479116|NCT04792645|Drug|Memantine|Cognition-enhancing medication
79479117|NCT04791228|Device|Magnetic Resonance-Guided High Intensity Focused Ultrasound|"Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy."
79644983|NCT00178737|Behavioral|Electronic reminder message|
79809000|NCT00661817|Behavioral|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
79809001|NCT02630771|Procedure|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
79809002|NCT00843492|Drug|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg [0.5mL] (1.5 mg [0.3mL] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
79320764|NCT02359981|Device|Smartphone|An Android Smartphone with operating system version higher than 2.2
79320765|NCT01939366|Drug|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
79644984|NCT00169325|Procedure|Magnetic resonance imaging|
79644985|NCT02899585|Other|Questionnaires|
79644986|NCT02899585|Other|Score|
79644987|NCT02899507|Drug|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
79809003|NCT00843492|Drug|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
79809004|NCT00666107|Biological|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
79809005|NCT02631629|Other|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
79320766|NCT01939366|Drug|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
79644988|NCT00178776|Behavioral|Transtheoretical Model Group Therapy|
79809006|NCT02631629|Other|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
79809007|NCT04156139|Device|HFNC|The gas flow rate was set at 45~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
79809008|NCT04156139|Device|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
79809009|NCT00666185|Drug|Micafungin|IV
79975183|NCT03434119|Drug|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
79975184|NCT03434119|Drug|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
79479118|NCT04791228|Drug|Lyso-thermosensitive Liposomal Doxorubicin|"LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence."
79479119|NCT04790968|Diagnostic Test|PSMA-PET|Prostate specific membrane antigen positron emission tomography
79302132|NCT03319433|Device|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
79644989|NCT00178776|Behavioral|Education & Advice|
79320767|NCT01939366|Drug|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
79479120|NCT04790968|Diagnostic Test|PSMA-PET/MRI|Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
79479121|NCT04790968|Diagnostic Test|PSMA-PET/CT|Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
79479122|NCT04786028|Other|Isatuximab|Brand name for interventional drug is Sarclisa
79479123|NCT04782167|Behavioral|BRACE|"Balance training,Static balance:~Romberg with eye open & eye close [30 sec repeat 3 times]~Tandem standing with eye open then with eye close. Right foot front first, then left foot front [10 Sec repeat 3 times]~Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~Sit to stand: 5 repetition~Functional reach test: forward, sideways & cross reach, practice 1 min for each~TUG test: with distance of 10 feet & time 10 sec. practice 2 min Cognitive exercises~1) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
79975185|NCT02484352|Drug|saline|different dosage of IV oxycodone was given before intubation
79975186|NCT02484352|Drug|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
79975187|NCT02484352|Drug|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
79975188|NCT02484352|Drug|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
79975189|NCT02484352|Drug|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
79320768|NCT01939366|Drug|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
79320769|NCT01939366|Drug|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
79320770|NCT04434365|Drug|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
79320771|NCT04434365|Drug|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
79320772|NCT04434365|Drug|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
79320773|NCT04434365|Drug|Statin|Statins once daily for 12±1 weeks.
79479124|NCT04782167|Behavioral|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
79479125|NCT04772469|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
79479126|NCT04772469|Other|Small monetary incentives|Use of small incentive voucher (~$5) to encourage linkage to confirmatory testing.
79809010|NCT00666185|Drug|Fluconazole|IV
79809011|NCT00833976|Drug|Lovaza|4 grams per day
79984682|NCT04206293|Device|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
79975190|NCT05186220|Procedure|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
79644990|NCT02899234|Other|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
79644991|NCT00169364|Device|positron emission tomography|
79809012|NCT00913224|Drug|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
79809013|NCT00913224|Drug|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
79975191|NCT05186220|Device|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
79975192|NCT02484274|Biological|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
79975193|NCT02489188|Procedure|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
79975194|NCT02489188|Other|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
79975195|NCT02489188|Procedure|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
79975196|NCT01308593|Device|Juvederm XC|Filler
79320774|NCT02359669|Behavioral|StimuLearn Intervention|"StimuLearn apps~Cognitive questionnaires"
79320775|NCT02359669|Behavioral|Without StimuLearn intervention|Cognitive Questionnaires
79320776|NCT02359591|Other|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
79320777|NCT05032469|Other|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
79320778|NCT02350075|Procedure|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
79320779|NCT02350075|Device|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
79809014|NCT00666341|Drug|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
79975197|NCT01308593|Drug|Botox|26 units dosed one time
79975198|NCT03716557|Device|Spinal Cord Stimulation 4000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
79975199|NCT03716557|Device|Spinal Cord Stimulation 10000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
79975200|NCT03716557|Device|Spinal Cord Stimulation 40Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
79975201|NCT01308671|Drug|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
79975202|NCT01308671|Behavioral|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
79975203|NCT02484118|Procedure|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
79975204|NCT00378378|Drug|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
79320780|NCT02359279|Device|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
79809015|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
79320781|NCT02359357|Drug|FDL169|
79320782|NCT02359357|Drug|Placebo|
79975205|NCT00378378|Drug|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
79320783|NCT05023265|Radiation|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
79320784|NCT05031923|Procedure|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
79320785|NCT05031923|Procedure|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
79975206|NCT03720457|Drug|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
79975207|NCT01306955|Drug|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
79975208|NCT01306955|Other|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
79975209|NCT03315676|Drug|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
79975210|NCT03315676|Drug|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
79320786|NCT02354755|Device|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
79320787|NCT02354989|Device|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
79320788|NCT02354989|Device|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
79320789|NCT05023187|Behavioral|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
79320790|NCT05023187|Behavioral|CON|"A 8-week active control intervention consisting of 2 sessions (~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
79320791|NCT05032001|Drug|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
79479127|NCT04772469|Behavioral|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
79809016|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
79975211|NCT03317782|Device|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index <20 indicates adequate analgesia.
79975212|NCT01335438|Device|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
79809017|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
79809018|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
79809019|NCT00666419|Other|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
79975213|NCT01335438|Device|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
79975214|NCT01307189|Drug|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
79644992|NCT02899390|Behavioral|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
79320792|NCT05022875|Device|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q&A
79320793|NCT05022875|Device|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
79320794|NCT03149263|Behavioral|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
79320795|NCT03149341|Other|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
79644993|NCT00178854|Drug|Risperidone|
79644994|NCT02899351|Device|Respiratory Volume Monitor|
79644995|NCT00169403|Procedure|Deep brain stimulation|
79809020|NCT04154657|Procedure|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
79975215|NCT01307189|Drug|Placebo|Placebo diskus inhalation powder, once daily
79975216|NCT03720379|Device|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
79975217|NCT03720379|Device|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
79975218|NCT02486458|Drug|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
79809021|NCT00833898|Device|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
79809022|NCT00833898|Behavioral|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development & application of various stress-mgmt techniques such as effective problem-solving, identifying & challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support & goal setting.
79975219|NCT02486458|Drug|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
79320796|NCT04963517|Behavioral|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
79809023|NCT00661973|Drug|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
79809024|NCT00666575|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
79975220|NCT01307345|Behavioral|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
79320797|NCT04963517|Other|Information|"Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations."
79644996|NCT02899468|Device|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
79809025|NCT00666575|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
79809026|NCT00666653|Drug|pramipexole|
79809027|NCT00707928|Drug|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
79809028|NCT00707928|Other|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
79809029|NCT00662285|Dietary Supplement|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
79975221|NCT03720301|Procedure|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~Soft tissue massage to the posterior cervical musculature for approximately 1 minute~Muscle energy to the muscles of neck extension approximately 1 minute~Muscle energy to the Occipital Atlanto (OA) joint 1 minute~Muscle energy to the jaw. Approximately 1 minute~Occipital decompression approximately 1 minute~With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~Myofascial Steering wheel Technique~Sibson's Fascia Release~Occipital decompression"
79975222|NCT03720301|Procedure|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
79975223|NCT02486614|Procedure|CRRT|citrate based continuous renal replacement therapy
79975224|NCT01335516|Other|Glypressin (terlipressin)|Study drug (without placebo)
79975225|NCT03317704|Behavioral|Speed endurance training|Speed endurance training
79479128|NCT04768296|Drug|Berzosertib|Participants with advanced solid tumors, for which no effective standard therapy exists, or standard therapy has failed will receive Berzosertib at a dose of 105 milligrams per square meter (mg/m^2) intravenously on Day 2 and Day 5 of each 21-day cycle in DL1 of safety run-in part.
79975226|NCT01335594|Procedure|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
79975227|NCT05694923|Drug|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
79975228|NCT03490981|Other|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
79479129|NCT04768296|Drug|Berzosertib|Participants with relapsed, platinum-resistant SCLC will receive Berzosertib at a dose of 210 mg/m^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
79320798|NCT03159715|Behavioral|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
79479130|NCT04768296|Drug|Topotecan|Participants who have advanced solid tumors, for which no effective standard therapy exists, or standard therapy has failed or who have relapsed, platinum-resistant SCLC will receive Topotecan at a dose of 1.25 mg/m^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
79644997|NCT02899117|Other|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
79644998|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
79644999|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
79645000|NCT02898844|Behavioral|Mixed Diet Condition|One roommate dieted and the other ate normally.
79645001|NCT02898844|Behavioral|Both Diet Condition|Both roommates dieted.
79975229|NCT03490981|Behavioral|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
79975230|NCT02483806|Procedure|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0->5->10, 0->10->5, 5->10->0, 5->0->10, 10->5->0, 10->0->5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
79645002|NCT00407576|Drug|[11C]MeS-IMPY|
79645003|NCT02898922|Biological|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
79809030|NCT00666809|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
79975231|NCT01332396|Drug|Lapatinib|
79975232|NCT03787667|Diagnostic Test|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
79645004|NCT02898961|Drug|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
79645005|NCT02898805|Other|Placebo|
79645006|NCT02898805|Other|Prescribed Diet|
79645007|NCT02898805|Dietary Supplement|LopiGLIK®|
79645008|NCT02898805|Dietary Supplement|Armolipid Plus|
79645009|NCT00196404|Drug|DR-3001a|4mg daily vaginally
79645010|NCT00196404|Drug|DR-3001b|6 mg vaginally daily
79645011|NCT00196404|Other|Placebo|Administered vaginally to match experimental arms
79645012|NCT02898883|Behavioral|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
79809031|NCT00666809|Drug|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
79809032|NCT00666887|Drug|Minocycline|100 mg twice daily to be taken for up to 2 years
79809033|NCT00666887|Drug|Placebo|placebo twice daily for 2 years
79809034|NCT02631473|Drug|50mg NANO-efavirenz|OD
79809035|NCT02631473|Drug|400mg NANO-Lopinavir|BID
79809036|NCT02631473|Drug|200mg NANO-Lopinavir|BID
79809037|NCT02631473|Drug|100mg Ritonavir|BID
79975233|NCT03321214|Other|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is < 20 ppm or a wheat icon for > 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
79975234|NCT01332474|Drug|BOTOX|BOTOX
79975235|NCT03787823|Procedure|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
79975236|NCT03719053|Drug|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
79975237|NCT03788135|Behavioral|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
79975238|NCT03526848|Drug|3BNC117|Intravenous infusion of 3BNC117
79975239|NCT03526848|Drug|10-1074|Intravenous infusion of 3BNC117
79320799|NCT03159715|Behavioral|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
79320800|NCT03159715|Behavioral|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
79320801|NCT05031689|Biological|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
79320802|NCT05031689|Biological|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
79320803|NCT03147469|Procedure|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
79975240|NCT03526848|Other|Analytical treatment interruption|Analytical treatment interruption
79975241|NCT02486536|Drug|polyethylene glycol|
79320804|NCT03147469|Procedure|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
79320805|NCT03147469|Procedure|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
79645013|NCT02898688|Behavioral|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
79809038|NCT02631473|Drug|300mg NANO-Efavirenz|OD
79809039|NCT02631473|Drug|600mg Sustiva|OD
79809040|NCT02631473|Drug|200mg NANO-Efavirenz|OD
79809041|NCT02631473|Drug|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
79975242|NCT02486536|Device|capsule endoscopy|
79320806|NCT05022953|Other|Education, dijital storytelling|Digital story
79320807|NCT03159013|Other|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
79320808|NCT05031377|Behavioral|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
79809042|NCT02631473|Drug|+/- 200mg NANO-Lopinavir|BID
79809043|NCT02631473|Drug|+/- 200mg ritonavir NORVIR|BID
79809044|NCT02631473|Drug|400mg Sustiva|
79320809|NCT05031377|Behavioral|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
79320810|NCT02350231|Drug|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
79320811|NCT02350231|Drug|Tonics group|Those patients will receive only tonics
79320812|NCT03092141|Other|Physical training|
79320813|NCT05031299|Behavioral|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
79809045|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
79809046|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
79809047|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
79809048|NCT00662441|Drug|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
79809049|NCT04154501|Drug|CNTX-6016|Oral Dose CNTX-6016
79809050|NCT04154501|Other|Other: Placebo|Oral Dose Placebo
79809051|NCT00708006|Drug|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
79809052|NCT00911573|Drug|Tigecycline|50 mg IV every 12 hours up to 14 days
79809053|NCT00911573|Drug|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
79320814|NCT05031299|Behavioral|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
79320815|NCT05031299|Device|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
79645014|NCT02898688|Behavioral|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
79645015|NCT02898688|Behavioral|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
79320816|NCT03147391|Device|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
79320817|NCT03147547|Other|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
79645016|NCT02898688|Behavioral|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
79645017|NCT02898766|Other|Enteral Nutrition Formula|
79320818|NCT03147547|Other|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
79645018|NCT02898571|Dietary Supplement|Placebo|Placebo comparitor
79645019|NCT02898571|Dietary Supplement|Vitamin C|Active treatment
79645020|NCT02898571|Dietary Supplement|epicatechin|Active treatment
79809054|NCT04155827|Other|SIT|Sprint interval training of 4*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
79975243|NCT03718975|Device|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
79645021|NCT02898649|Device|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
79975244|NCT03718975|Device|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
79645022|NCT00553618|Drug|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
79320819|NCT03147547|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
79479131|NCT04762706|Behavioral|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
79479132|NCT04760626|Drug|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
79645023|NCT02898337|Device|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
79645024|NCT02898376|Other|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
79975245|NCT03321136|Drug|LSD|0.025 mg LSD per os, single dose
79975246|NCT03321136|Drug|LSD|0.05 mg LSD per os, single dose
79975247|NCT03321136|Drug|LSD|0.1 mg LSD per os, single dose
79975248|NCT03321136|Drug|LSD|0.2 mg LSD per os, single dose
79975249|NCT03321136|Drug|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
79975250|NCT03321136|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
79975251|NCT01332552|Drug|GSK2485852 70 mg|single dose
79975252|NCT01332552|Drug|GSK2485852 420 mg|single dose
79975253|NCT01332552|Drug|placebo|single dose
79975254|NCT01332552|Drug|placebo|Repeat dose, once daily for 3 days
79975255|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
79975256|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
79975257|NCT01332552|Drug|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
79975258|NCT01332552|Drug|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
79975259|NCT01332552|Drug|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
79320820|NCT03147547|Other|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
79320821|NCT01918306|Drug|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------"
79320822|NCT01918306|Other|laboratory biomarker analysis|correlative studies
79320823|NCT01918306|Other|pharmacological study|correlative studies
79320824|NCT01918306|Procedure|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
79320825|NCT01918306|Drug|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
79645025|NCT02898376|Drug|Pentoxifylline|400 mg bid during at least 6 months
79975260|NCT01332552|Drug|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
79975261|NCT03720223|Drug|Liposomal Bupivacaine|20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
79320826|NCT05031611|Behavioral|Intuitive Eating Treatment|"Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details."
79320827|NCT05031533|Radiation|Dose-Painting Radiation|"Radiation therapy:~Delineation of target area:~The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
79320828|NCT02348515|Procedure|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
79320829|NCT02348515|Procedure|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
79320830|NCT02348515|Procedure|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
79479133|NCT04760626|Drug|Insulin Glargine 100U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
79320831|NCT02348515|Procedure|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
79320832|NCT02348515|Procedure|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
79320833|NCT05022797|Drug|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
79320834|NCT01917526|Device|oxygen mask|
79320835|NCT01917526|Device|oxygen cannula|
79320836|NCT05031143|Drug|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
79320837|NCT01948258|Device|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
79479134|NCT04760626|Drug|Insulin Degludec|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
79479135|NCT04760626|Drug|Insulin Glargine 300U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
79479136|NCT04757259|Drug|cerdulatinib|Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams [mg] twice daily [BID]).
79645026|NCT02898376|Drug|Tocopherol acetate|500 mg bid during at least 6 months
79645027|NCT00196443|Device|urea contained compressing stockings|
79645028|NCT00196443|Device|compressing stockings|
79975262|NCT03718897|Diagnostic Test|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
79320838|NCT02354677|Other|In vitro experiments on bronchial epithelial cells|
79320839|NCT02354521|Other|NO INTERVENTIONS|
79975263|NCT02486380|Device|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
79975264|NCT03160716|Device|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
79320840|NCT02348437|Procedure|Repair|An on-going suture technique with minimum four stitches.
79320841|NCT02348437|Procedure|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
79320842|NCT01916980|Drug|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
79975265|NCT03720145|Behavioral|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
79479137|NCT04753307|Diagnostic Test|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
79479138|NCT04751500|Procedure|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
79479139|NCT04751500|Behavioral|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
79320843|NCT05021627|Procedure|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP[LSGP]), the leftinfer oposterior area(left inferior GP[LIGP]), the right superoanterior area (rightanterior GP[RAGP]), the right inferoposterior area(right inferior GP[RIGP]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
79320844|NCT05021627|Procedure|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
79320845|NCT02348281|Drug|Bicalutamide|150mg, po, qd, d1-28
79320846|NCT05021783|Diagnostic Test|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
79479140|NCT04751500|Drug|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
79479141|NCT04751500|Drug|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
79479142|NCT04751500|Procedure|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
79479143|NCT04750486|Device|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
79479144|NCT04750265|Device|Robotic assisted early mobilization|Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
79975266|NCT03317626|Diagnostic Test|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
79320847|NCT05021783|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
79645029|NCT00169481|Biological|Pneumococcal (vaccine)|
79645030|NCT02898532|Behavioral|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
79645031|NCT02898415|Procedure|Liver transplantation|
79320848|NCT05021783|Other|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
79320849|NCT05021783|Diagnostic Test|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
79320850|NCT05021783|Diagnostic Test|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
79320851|NCT03147313|Device|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
79320852|NCT03147313|Device|Sham|Extracorporeal shock wave treatment will be faked.
79320853|NCT02354287|Procedure|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
79320854|NCT03094949|Procedure|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
79479145|NCT04742049|Other|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
79479146|NCT04742049|Other|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
79645032|NCT02898298|Behavioral|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
79645033|NCT00408174|Drug|Balsalazide disodium|
79975267|NCT01332708|Behavioral|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
79975268|NCT02483962|Other|Gelatine capsule|Gelatine capsules containing no active ingredients.
79975269|NCT02483962|Other|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
79975270|NCT00092664|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
79975271|NCT02483884|Drug|[68Ga]RM2|[68Ga]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
79975272|NCT02483884|Procedure|PET/CT|Patients received [68Ga]RM2 undergo PET/CT 60 min p.i. for at least 20 min
79975273|NCT03321058|Behavioral|Assessment|Assessment of patients' medication organisation and comprehension of generics
79975274|NCT03713021|Device|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
79645034|NCT00169520|Drug|docetaxel|
79645035|NCT00169520|Drug|SB-715992|
79975275|NCT02483494|Other|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
79975276|NCT01335828|Device|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
79975277|NCT03317548|Diagnostic Test|progesterone|according progesterone level to decide fresh or frozen embryo transfer
79975278|NCT03317548|Diagnostic Test|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
79975279|NCT00092586|Drug|MK0653, ezetimibe|
79975280|NCT00092586|Drug|Comparator: statins|
79645036|NCT02898064|Device|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
79645037|NCT02898064|Other|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
79645038|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Norway|
79975281|NCT03787199|Device|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
79645039|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
79975282|NCT03787199|Other|Treadmill|Bodyweight supported treadmill walking
79975283|NCT03320980|Procedure|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
79975284|NCT03320980|Procedure|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
79975285|NCT01335906|Other|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
79975286|NCT03787433|Device|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
79975287|NCT01337856|Other|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
79645040|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
79975288|NCT01337934|Drug|Lactated Ringer|Lactated Ringer
79975289|NCT01337934|Drug|Albumin|Albumin 4%
79320855|NCT03094949|Procedure|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
79320856|NCT02349919|Drug|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
79320857|NCT02349919|Drug|Placebo|Placebo twice daily for 4 weeks
79975290|NCT03786887|Drug|Nalbuphine|dosage of nalbuphine
79975291|NCT03787043|Drug|FDC(MP-513 10mg/Metformin XR 750mg)|
79975292|NCT00090168|Drug|MK0653A , ezetimibe (+) simvastatin|
79975293|NCT00090168|Drug|Comparator: atorvastatin|
79975294|NCT00090168|Drug|Duration of Treatment: 6 weeks|
79975295|NCT03786809|Drug|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
79975296|NCT03786809|Drug|Placebo|patients of the placebo group will use placebo once a day for 28 days
79975297|NCT01332786|Drug|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~Level 1: 50 mg daily x 10 doses; 1 week rest~Level 2: 100 mg daily x 10 doses; 1 week rest~Level 3: 150 mg daily x 10 doses; 1 week rest~Level 4: 200 mg daily x 10 doses 1 week rest~Level 5: 250 mg daily x 10 doses; 1 week rest~Level 6: 300 mg daily x 10 doses; 1 week rest~Level 7: 350 mg daily x 10 doses; 1 week rest"
79975298|NCT03786731|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
79975299|NCT03160560|Drug|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
79975300|NCT03160560|Drug|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
79975301|NCT03160560|Other|Placebo|Subjects in Placebo group will receive Placebo Rinse.
79975302|NCT05694377|Behavioral|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
79975303|NCT03786575|Diagnostic Test|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
79975304|NCT03489343|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
79975305|NCT01338090|Drug|89Zr-bevacizumab|Intravenous injection 120 MBq
79320858|NCT03091985|Device|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
79320859|NCT03091985|Device|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
79645041|NCT02897986|Drug|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
79479147|NCT04735874|Other|Evaluate vascular disease risk factors in children with Down Syndrome|We will determine CV disease risk profiles in children with DS at our centers. We will compare these data to published national norms of children without DS. Risk factor data will include: anthropometric measures; blood pressure; history of congenital heart disease and associated surgery, sleep apnea, hypothyroidism, and cancer; fasting blood draw [lipid panel with subfractions (NMR), insulin, glucose, and CRP].
79975306|NCT01338090|Drug|Everolimus|Oral use, 10 mg per day
79975307|NCT01307969|Drug|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
79645042|NCT00169559|Drug|GW590735|1µg to 20µg daily doses of GW590735
79645043|NCT00169559|Drug|fenofibrate|Marketed Drug
79320860|NCT03147235|Behavioral|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
79320861|NCT02349763|Drug|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
79320862|NCT02349763|Drug|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
79320863|NCT02349841|Drug|Meropenem|To administer 2g daily 8 hourly for 14 days
79320864|NCT02349841|Drug|Faropenem|To adminster 600mg 8 hourly daily for 14 days
79645044|NCT00408213|Drug|mycophenolate mofetil [CellCept]|1g po bid
79645045|NCT00408213|Drug|Placebo|po bid
79975308|NCT01332864|Procedure|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
79975309|NCT01332864|Procedure|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
79975310|NCT03786419|Drug|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
79975311|NCT01338324|Drug|Simvastatin|Simvastatin 20 mg single dose on day 1
79320865|NCT02349841|Drug|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
79320866|NCT02349841|Drug|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
79320867|NCT02349997|Other|no interventions|This is an observational study and no intervention applied.
79320868|NCT05020925|Drug|SHR-1701|Intravenous (IV) on Day 1 of each cycle
79320869|NCT05020925|Drug|Famitinib|Famitinib, po, qd
79320870|NCT02349373|Behavioral|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
79645046|NCT02898142|Other|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
79320871|NCT02349373|Behavioral|16 week training period|Receipt of a weekly running schedule through an online training diary.
79645047|NCT02898025|Device|Active Interferential Current|Involves the application of medium frequency alternating currents
79645048|NCT02898025|Device|Active Laser|Involves the application of low level laser over the knee
79645049|NCT02898025|Device|Placebo Interferential Current|It is a sham interferential therapy
79645050|NCT02898025|Device|Placebo Laser|It is a sham laser therapy
79302133|NCT03080415|Drug|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
79302134|NCT03206983|Device|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
79302135|NCT03091023|Procedure|Endometrial Biopsy and endometrial fluid collection|
79302136|NCT03206827|Other|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
79302137|NCT03206827|Other|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
79302138|NCT03206827|Other|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
79302139|NCT03091101|Device|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
79302140|NCT03226483|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
79302141|NCT03119779|Drug|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
79302142|NCT03119779|Drug|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
79302143|NCT03319355|Behavioral|cognitive behavioral therapy|exercise therapy
79302144|NCT03319199|Dietary Supplement|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
79302145|NCT03319199|Other|Placebo - water|for a duration of 16 weeks
79302146|NCT03221881|Drug|Pegylated Liposomal Doxorubicin and docetaxel|
79302147|NCT03091257|Drug|Dabrafenib|Administered Orally BID
79302148|NCT03091257|Drug|Trametinib|Administered Orally once daily
79302149|NCT04493255|Drug|[14C]E7090|[14C]E7090, oral capsule.
79302150|NCT03078387|Diagnostic Test|imaging|imaging before and after treatment
79320872|NCT02349529|Behavioral|Psychosocial Intervention Group|6 group sessions
79645051|NCT02897752|Device|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
79645052|NCT02897752|Other|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
79645053|NCT00196482|Drug|changing of fortifier|
79479148|NCT04735874|Other|Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome|We will perform PWV, CIMT, and CD studies in children with DS and compare these data to available data in children without DS. We will also perform multivariable analysis of the influence of combinations of CV disease risk factors on markers of early atherosclerosis in children with DS. Hypothesis: CV disease risk factors will correlate with markers of early atherosclerosis in children with DS but the associations between risk factors and markers of early atherosclerosis will differ between children with DS vs. the general population of children.
79645054|NCT00169598|Procedure|positron emission tomography|
79645055|NCT02897713|Other|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
79645056|NCT02897713|Other|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
79645057|NCT02897635|Behavioral|Individualized Integrative Medicine Intervention|
79645058|NCT02897674|Dietary Supplement|Palm olein|two thirds of the 30% fat calories will come from palm olein
79645059|NCT02897674|Dietary Supplement|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
79645060|NCT02897674|Dietary Supplement|soybean oil|two thirds of the 30% fat calories will come from soybean oil
79320873|NCT02349529|Other|Waiting list control|Treatment as usual
79479149|NCT04729725|Biological|Anti-TGF-beta Monoclonal Antibody SAR-439459|Given IV
79479150|NCT04729725|Biological|Cemiplimab|Given IV
79645061|NCT00408252|Other|biopsies|No intervention, only biopsy for translational project
79320874|NCT05021159|Other|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
79320875|NCT02353975|Drug|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
79320876|NCT05020613|Procedure|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
79320877|NCT05020613|Procedure|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
79645062|NCT00408252|Drug|SU011248|no intervention
79645063|NCT02897869|Drug|POL7080|7 doses of POL7080 alone over 2.5 days
79320878|NCT03159247|Behavioral|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
79479151|NCT04726449|Other|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
79645064|NCT02897869|Drug|Amikacin|3 doses of Amikacin alone over 2.5 days
79645065|NCT02897869|Drug|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
79645066|NCT00169637|Drug|rhGH|
79645067|NCT02897830|Drug|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
79320879|NCT03094559|Device|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
79320880|NCT02354053|Drug|Switch to Triumeq|
79320881|NCT02354053|Behavioral|Adherence support + current ART|
79320882|NCT05029037|Drug|High doses of intravenous vitamin C|Two (2) High doses of intravenous vitamin C for seven (7) days.
79975312|NCT01335984|Procedure|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
79975313|NCT01335984|Procedure|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring & Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
79975314|NCT01335984|Other|control group|"- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
79975315|NCT03489109|Behavioral|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
79320883|NCT05029037|Drug|Dextrose 500 mL|"Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days."
79320884|NCT05028959|Other|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
79320885|NCT02353741|Drug|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
79479152|NCT04723004|Combination Product|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
79479153|NCT04723004|Drug|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
79479154|NCT04719130|Other|Multimodal circuit exercise|A structured and supervised multimodal exercise circuit twice a week, under 12 weeks program. The circuit workout program consists of 8 exercises, divided into motor coordination, balance, strength, and aerobic exercises. The exercises will be employed in a reserved room inside of the Basic Health Units. The sessions of exercises will last approximately 50 minutes,
79479155|NCT04719130|Other|Multidisciplinary lectures|Multidisciplinary lectures on pain and usual care provided by the Basic Health Units. A cycle of multidisciplinary lectures on pain will be offered by professionals in physical education, nursing, physiotherapy, medicine, psychology and social work that will take place in the Basic Health Units every 15 days.
79479156|NCT04705649|Other|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
79479157|NCT04698603|Drug|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
79479158|NCT04697524|Behavioral|Support Group Therapy|Virtual group meetings
79479159|NCT04697524|Behavioral|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
79479160|NCT04697524|Other|Quality of Life (QOL) Questionnaires|Administered at each study visit
79479161|NCT04697524|Other|Interview|Virtual exit interview at end of study
79479162|NCT04691154|Combination Product|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
79479163|NCT04687475|Other|Clinical Tool (Mobile Spirometry and Survey)|The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
79479164|NCT04685798|Device|Diffusion-weighted imaging magnetic resonance imaging|The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
79479165|NCT04679909|Biological|AdCOVID|Administered intranasally
79479166|NCT04679909|Other|Placebo|Administered intranasally
79479167|NCT04678440|Drug|[18F]F-AraG Imaging|Total body PET imaging using [18F]F-AraG
79479170|NCT04676334|Drug|Rucaparib|Rucaparib will be administered daily.
79479171|NCT04676022|Device|WaveWriter|To receive Spinal Cord Stimulation programming
79479172|NCT04676022|Other|Conventional Medical Managament|To receive conventional medical management
79320886|NCT02353741|Radiation|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
79809055|NCT02630381|Device|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (~500 bar) and short rise time (~20 ns), which are followed by a longer low-magnitude negative wave (~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
79809056|NCT00667433|Drug|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
79975316|NCT03489109|Other|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
79975317|NCT01336062|Drug|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
79975318|NCT05694221|Drug|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
79320887|NCT03092063|Behavioral|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
79320888|NCT03092063|Behavioral|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
79479173|NCT04674267|Other|Phase 2 Intervention - Geriatric Co-Management|"Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year."
79479174|NCT04673292|Behavioral|Fixed site standard of care testing|This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
79479175|NCT04673292|Behavioral|Community-based, mobile van testing|This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
79809057|NCT00667667|Device|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
79809058|NCT00667667|Device|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
79975319|NCT05694221|Drug|Digoxin|Digoxin
79975320|NCT05694221|Drug|Metformin|Metformin
79975321|NCT03786341|Device|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
79320889|NCT03092063|Behavioral|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
79320890|NCT03092063|Behavioral|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
79320891|NCT02353663|Other|Echocardiography|Echocardiography examination
79645068|NCT02897830|Drug|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
79645069|NCT02897830|Drug|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
79645070|NCT02897518|Device|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
79645071|NCT02897518|Device|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
79320892|NCT02347969|Dietary Supplement|X34|Dietary supplement named X34
79645072|NCT00196521|Device|Tension-free vaginal tape obturator system|
79645073|NCT02897557|Device|Insulet Artificial Pancreas (AP) System|
79809059|NCT00667667|Behavioral|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
79809060|NCT00662519|Drug|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
79320893|NCT05028803|Drug|sodium phenylbutyrate|same as arm/group
79320894|NCT03146923|Other|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides <15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) in 2010 and includes following main components:~Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~Restricting dairy intake (1-1.5 portions per day)~Avoiding foods high in phosphate~Avoiding foods with phosphate additives"
79645074|NCT00169676|Other|observation|registry and database for surgery outcomes
79645075|NCT02897596|Drug|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
79645076|NCT02897596|Drug|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
79645077|NCT02897596|Drug|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
79645078|NCT02897596|Drug|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
79809061|NCT00662519|Drug|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
79809062|NCT00662519|Dietary Supplement|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
79809063|NCT00662519|Other|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
79320895|NCT03146923|Other|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~Increased focus on avoiding additives~Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~Avoiding over-prescription of protein which carries an obligatory phosphorus load.~Focus on high protein foods with a low phosphorus to protein ratio"
79320896|NCT05020223|Other|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
79320897|NCT03147001|Other|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
79320898|NCT03147001|Other|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
79320899|NCT03094481|Procedure|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
79320900|NCT03094481|Procedure|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
79320901|NCT03094481|Procedure|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
79320902|NCT03094481|Drug|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
79479176|NCT04673292|Behavioral|Self-collected, home-based testing|Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
79645079|NCT02897791|Behavioral|written evaluations|answering questions about pictures and stories
79975322|NCT03718819|Other|exercise|Pilates and aquaplyometric exercises will be done combinedly.
79320903|NCT04438837|Drug|Hydroxychloroquine|Hydroxychloroquine post exposure prohylaxis
79320904|NCT05020067|Radiation|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
79320905|NCT02348125|Drug|Mitochondrial Cocktail|
79479177|NCT04669197|Drug|Paclitaxel protein bound|combination therapy
79479178|NCT04669197|Drug|Gemcitabine|combination therapy
79479179|NCT04669197|Drug|Cisplatin|combination therapy
79479180|NCT04669197|Drug|Hydroxychloroquine|combination therapy
79479181|NCT04660812|Drug|AB680|AB680 is a cluster of differentiated CD73 Inhibitor
79479182|NCT04660812|Drug|Etrumadenant|Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
79320906|NCT05019911|Device|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
79320907|NCT05019911|Device|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
79320908|NCT02353273|Drug|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
79809064|NCT00662519|Other|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
79320909|NCT05028335|Other|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
79479183|NCT04660812|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclononal antibody
79479184|NCT04660812|Drug|Bevacizumab|Bevacizumab is administered as part of standard chemotherapy regimen
79479185|NCT04660812|Drug|m-FOLFOX-6 regimen|mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
79479186|NCT04660812|Drug|Regorafenib|Regorafenib is adminstered as part of standard chemotherapy regimen
79645080|NCT02897440|Procedure|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
79479187|NCT04641325|Other|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
79479188|NCT04640831|Drug|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
79479189|NCT04640701|Other||
79479190|NCT04634851|Behavioral|Virtual home visits|These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
79479191|NCT04621734|Device|AMT BridlePro Device|A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
79479192|NCT04621734|Device|Adhesive Tape|Adhesive tape used to secure nasoenteric tube
79645081|NCT02897440|Procedure|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
79645082|NCT04681027|Drug|Oxymorphone hydrochloride (HCl)|Opioid
79645083|NCT00408330|Drug|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
79645084|NCT00408330|Drug|Inactive 15% gel base|placebo, topically applied daily for six weeks
79645085|NCT00169715|Procedure|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
79302151|NCT03322553|Device|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
79645086|NCT02897245|Other|No intervention|
79302152|NCT05019573|Dietary Supplement|Black tea|Black tea twice a day for 4 weeks
79302153|NCT05019573|Dietary Supplement|Placebo|Placebo tea twice a day for 4 weeks
79302154|NCT03322475|Device|PiQo4 laser system|The PiQo4 laser system
79645087|NCT02897167|Genetic|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
79302155|NCT03078231|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
79302156|NCT03078231|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
79302157|NCT03322397|Behavioral|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
79645088|NCT02897167|Genetic|Prospective study of fresh samples|Samples of serum and cells will be drawn.
79645089|NCT02897128|Other|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
79645090|NCT00408369|Drug|DB289|
79645091|NCT00407615|Device|Flex Pad/Static Magnet|
79302158|NCT03322397|Behavioral|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
79302159|NCT03322397|Behavioral|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
79302160|NCT05005377|Procedure|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
79302161|NCT05005377|Procedure|Socket Preservation with Freeze-Dried Bone Allograft|The extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
79645092|NCT02897206|Drug|Imipenem|A wide-spectre antibiotic from the carbapenem group
79645093|NCT02897206|Drug|Placebo|An imipenem-matching placebo
79479193|NCT04617834|Other|Quality Surveillance Data Collection|Data will be retrospectively collected through EHR queries
79479194|NCT04616287|Other|Neuropsychological assessment and Multimodal brain MRI|Neuropsychological assessment and Multimodal brain MRI
79479195|NCT04611568|Other|Educational Intervention|Receive educational and training material
79479196|NCT04611568|Other|Educational Intervention|Receive educational lecture
79479197|NCT04611568|Behavioral|Health Education|Receive melanoma curriculum
79479198|NCT04611568|Behavioral|Media Campaign|View digital media strategies
79479199|NCT04611568|Other|Survey Administration|Complete survey
79479200|NCT04610398|Drug|Dexamethasone 4mg|s. arm/group description
79645094|NCT02897323|Other|description|
79809065|NCT00662753|Device|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
79809066|NCT00662753|Other|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
79809067|NCT00667901|Drug|riluzole|
79302162|NCT03077997|Behavioral|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, & diabetes distress in people with type 2 diabetes mellitus.
79302163|NCT03319121|Drug|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
79302164|NCT03319121|Drug|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
79302165|NCT02487407|Drug|ODM-109|ODM-109 1 mg capsule for oral administration.
79302166|NCT02487407|Drug|Placebo for ODM-109|Placebo capsule for oral administration.
79302167|NCT03221959|Device|Medical Device Vittamed 205|Intracranial pressure measurement
79479201|NCT04610398|Drug|NaCl 0.9%|s. arm/group description
79479202|NCT04607460|Device|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
79302168|NCT03078153|Behavioral|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
79302169|NCT03078153|Behavioral|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
79479203|NCT04607460|Device|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
79479204|NCT04607460|Device|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
79645095|NCT02897401|Biological|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
79645096|NCT02897401|Biological|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
79809068|NCT00667901|Genetic|protein expression analysis|
79809069|NCT00667901|Genetic|reverse transcriptase-polymerase chain reaction|
79809070|NCT00667901|Genetic|western blotting|
79809071|NCT00667901|Other|immunohistochemistry staining method|
79809072|NCT00667901|Other|laboratory biomarker analysis|
79809073|NCT00667901|Other|pharmacological study|
79809074|NCT00667901|Procedure|neoadjuvant therapy|
79809075|NCT00667901|Procedure|therapeutic conventional surgery|
79809076|NCT00667979|Drug|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
79809077|NCT00667979|Drug|Placebo|Matching placebo
79320910|NCT05028335|Other|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
79320911|NCT02353351|Device|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
79320912|NCT04434053|Device|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
79320913|NCT04434053|Device|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
79320914|NCT02348047|Device|Hamilton T1|
79320915|NCT03094403|Drug|Azelaic Acid 15% topical gel|Gel
79320916|NCT03094403|Drug|Finacea® (azelaic acid) Gel, 15%|Gel
79479205|NCT04606069|Drug|Regadenoson|Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
79320917|NCT03094403|Drug|Placebo|Gel
79320918|NCT03148873|Device|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
79320919|NCT02347735|Other|No interventions, only data collection|Only data is collected from the subjects in both groups.
79479206|NCT04606069|Other|Placebo Control|The same volume of saline will be given intravenously for 6 and half hours.
79809078|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
79809079|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
79479209|NCT04601506|Behavioral|Choice Architecture Nudge|"Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options.~PCPs will also be sent alerts when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order."
79479210|NCT04601506|Behavioral|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration & nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
79320920|NCT03091517|Behavioral|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
79645097|NCT02897401|Biological|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
79975323|NCT01338402|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
79975324|NCT01338402|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
79975325|NCT01338402|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
79975326|NCT01308047|Drug|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
79320921|NCT03147157|Other|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
79975327|NCT03716479|Other|Low Fiber|20 g of acacia gum will be added to orange juice
79975328|NCT03716479|Other|High Fiber|40 g of acacia gum will be added to orange juice
79975329|NCT03716479|Other|Placebo/Control|No acacia gum will be added to orange juice.
79975330|NCT05186142|Other|Ultrasonography / Ultrasound elastography|Ultrasonography / Ultrasound elastography
79975331|NCT05694143|Other|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~To know facts, statistics and harmful effects of obesity and overweight.~To know facts about physical activity and its importance.~To know facts about a healthy diet and its importance.~Definition of BMI and calculating the BMI.~To read the Nutrition Facts label.~To develop decision-making and self-care education."
79479211|NCT04601493|Behavioral|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
79975332|NCT05694143|Other|No Intervention|They will have their regular curriculums and normal physical activity routine
79975333|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
79645098|NCT02897401|Behavioral|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
79645099|NCT02897401|Procedure|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
79645100|NCT00196560|Device|Immobilization in External Rotation|
79645101|NCT00169754|Other|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
79645102|NCT02897089|Device|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
79645103|NCT02897284|Behavioral|Mindfulness 8 weeks|8 sessions of mindfulness
79645104|NCT02897284|Behavioral|Mindfulness 2 weeks|2 sessions of mindfulness
79645105|NCT00169793|Other|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
79645106|NCT00169793|Other|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
79809080|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
79809081|NCT00668057|Drug|Placebo|5 mg matching placebo
79975334|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
79975335|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
79975336|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
79975337|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
79975338|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
79809082|NCT00668057|Drug|Placebo|10 mg matching placebo
79809083|NCT00668057|Drug|Placebo|20 mg matching placebo
79809084|NCT00668135|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
79975339|NCT01308125|Procedure|PICSO|"Baseline (hemodynamic) measurement~Intra coronary~Blood sampling~LAD occlusion: for 3 min or until pain with and without PICSO~Break recovery: the patient can recover from pain for 3 min~CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.~PICSO: start automatically and continued for 10 min.~PCI/PICSO: concomitantly for the whole duration of the PCI intervention.~24h Follow up: additional blood samples every 6 hours (4 times)~30 days follow up."
79975340|NCT03785951|Dietary Supplement|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
79809085|NCT00668135|Drug|Placebo|Matching placebo
79809086|NCT04155905|Procedure|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\0 sutures
79975341|NCT03785951|Dietary Supplement|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
79479212|NCT04601493|Behavioral|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration & nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
79479213|NCT04600206|Other|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
79479214|NCT04596644|Drug|Cannabis|Investigates two strengths of cannabis.
79975342|NCT03785951|Dietary Supplement|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
79320922|NCT05028023|Biological|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
79320923|NCT03146767|Device|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
79320924|NCT02347501|Drug|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
79320925|NCT05020301|Device|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
79479215|NCT04595981|Drug|Cisplatin|Subjects will be admitted to the UAB Heart and Vascular Center, pre-medicated with 24 mg Ondansetron IV, 500 mg Prednisolone IV and 1.5 L NaCl with 20 meq KCl IV. The chemo-embolic agent is prepared in the HVC pharmacy by reconstituting 300 mg lyophilized Cisplatin in 60 mL 0.9% NaCl. Subjects are placed under anesthesia in the angiography suite. The access site is prepped and draped in sterile fashion then the femoral artery is catheterized using a 5-French catheter containing a coaxial microcatheter. After superselective visualization of the tumor-feeding vessel, a microcatheter is advanced into the target vessel and infused with 150 mg m2 cisplatin in 45-60 mL NaCl over 30-60 seconds. 10 seconds after the infusion starts, 9 gm sodium thiosulphate is administered IV to neutralize systemic Cisplatin. A post-infusion angiogram is then performed to assess the adequacy of embolization. The catheter is removed and the arteriotomy site closed with a subcutaneous suture.
79809087|NCT04155905|Procedure|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
79809088|NCT00911417|Device|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
79320926|NCT05020301|Device|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
79320927|NCT03155581|Behavioral|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
79975343|NCT03777449|Radiation|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
79809089|NCT02630303|Device|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
79320928|NCT03155581|Behavioral|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
79320929|NCT04130165|Other|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
79975344|NCT03777605|Drug|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
79975345|NCT03777761|Drug|tucatinib|300mg oral dose
79320930|NCT03148717|Drug|Misoprostol|Cytotec
79320931|NCT03148717|Other|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
79320932|NCT02349607|Drug|PF-05089771 300mg|PF-05089771 300 mg
79975346|NCT03777761|Drug|placebo|Matching placebo for tucatinib
79975347|NCT03777761|Drug|moxifloxacin|400mg single oral dose
79975348|NCT05185908|Procedure|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
79975349|NCT01316861|Drug|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
79320933|NCT02349607|Drug|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
79320934|NCT02349607|Drug|Placebo|Placeco
79320935|NCT02349607|Drug|pregabalin 300 mg|pregabalin 300 mg
79320936|NCT02349607|Drug|ibuprofen 600 mg|ibuprofen 600 mg
79320937|NCT05019755|Drug|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
79320938|NCT05019755|Drug|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
79479216|NCT04583644|Device|Fetoscopic Endoluminal Tracheal Occlusion Surgery|"Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation."
79975350|NCT01316861|Drug|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
79975351|NCT01338480|Other|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
79320939|NCT04478461|Drug|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
79320940|NCT02039089|Drug|E2006 2.5 mg|
79320941|NCT02039089|Drug|E2006 10 mg|
79320942|NCT02039089|Drug|E2006 25 mg|
79320943|NCT02039089|Drug|Placebo|
79320944|NCT02353507|Device|Opticell Ag+|
79320945|NCT02353507|Device|Aquacel Ag+|
79975352|NCT03777293|Device|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
79975353|NCT01336218|Drug|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
79975354|NCT01336218|Drug|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
79975355|NCT03776981|Other|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
79479217|NCT04583215|Device|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
79975356|NCT03776981|Other|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
79809090|NCT02630303|Device|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
79975357|NCT03776903|Other|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
79975358|NCT01318031|Drug|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
79975359|NCT01318031|Drug|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
79479218|NCT04575805|Behavioral|Internet-delivered Combined Cognitive Bias Modification (iCBM-C)|The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.
79320946|NCT03148561|Drug|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
79320947|NCT05027555|Other|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
79320948|NCT05027555|Other|Conventional training|Conventional training included strengthening, balance training and gait training
79320949|NCT05027321|Behavioral|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
79479219|NCT04575805|Behavioral|Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)|The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
79809091|NCT04155983|Drug|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
79809092|NCT00668369|Procedure|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
79975360|NCT03776825|Device|Permacol Paste|Permacol Paste Injection
79975361|NCT03776591|Procedure|Open surgery|
79975362|NCT03776591|Procedure|Right colectomy|
79975363|NCT03776591|Procedure|Laparoscopic surgery|
79975364|NCT03776591|Procedure|Central lymphadenectomy and vascular ligation|
79975365|NCT05097833|Behavioral|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
79320950|NCT05027321|Behavioral|Conversational Hypnosis|Conversational Hypnosis during examination
79320951|NCT05027321|Behavioral|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
79320952|NCT02348983|Behavioral|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
79320953|NCT02353429|Drug|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
79320954|NCT05019989|Behavioral|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
79479220|NCT04575805|Behavioral|Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)|The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
79645107|NCT04680754|Other|head-neck stretching exercises|Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
79645108|NCT02896894|Other|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
79975366|NCT05097833|Behavioral|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
79809093|NCT02631317|Behavioral|Advance hospital notification by EMS|Advance hospital notification by EMS
79809094|NCT02631317|Behavioral|stroke team notification|stroke team notification
79975367|NCT05038553|Other|No intervention|No intervention
79975368|NCT05029115|Drug|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
79975369|NCT01319123|Device|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
79975370|NCT03776435|Radiation|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
79479221|NCT04575311|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
79479222|NCT04575311|Other|Placebo|Matching Placebo
79479223|NCT04566562|Diagnostic Test|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
79479224|NCT04566562|Diagnostic Test|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
79479225|NCT04566562|Diagnostic Test|Blood Biomarkers|Inflammatory Markers
79809095|NCT02631317|Behavioral|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
79975371|NCT03776513|Behavioral|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
79645109|NCT02896816|Other|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
79479226|NCT04565730|Other|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
79645110|NCT02896816|Other|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
79645111|NCT02897011|Drug|Methotrexate|
79645112|NCT00169832|Drug|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
79645113|NCT00196599|Drug|emtricitabine, FTC (drug)|
79645114|NCT00196599|Drug|didanosine, ddI (drug)|
79302170|NCT05012085|Other|Investigation of Global Interest in Global Surgery|"The investigators searched the terms global surgery and global health on Google Trends (Google Inc., CA, USA) from January 2004 to May 2021. The investigators identified time trends and compared the two search terms using SPSS v26 (IBM, WA, USA) to run summary descriptive analyses and Wilcoxon rank-sum tests."
79302171|NCT03221569|Drug|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
79302172|NCT03221569|Drug|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
79302173|NCT03221569|Drug|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
79302174|NCT03221569|Drug|Normal saline|1ml intravenous push as placebo for double-blinding purposes
79645115|NCT00196599|Drug|efavirenz (drug)|
79645116|NCT02896972|Procedure|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
79645117|NCT02896543|Other|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
79975372|NCT03776279|Drug|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
79975373|NCT03776045|Other|Standard care plus exercise|The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted ~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
79975374|NCT03709823|Drug|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
79809096|NCT02631317|Behavioral|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
79479227|NCT04565730|Other|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
79479228|NCT04554316|Device|Steri-strip|Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
79809097|NCT02631317|Behavioral|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
79975375|NCT03709823|Drug|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
79975376|NCT03709823|Behavioral|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
79975377|NCT03488563|Biological|B244|B244 Suspension
79975378|NCT03488563|Biological|Vehicle|Vehicle Suspension
79975379|NCT03775889|Behavioral|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
79975380|NCT03718741|Radiation|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
79975381|NCT03775655|Drug|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
79975382|NCT03775733|Dietary Supplement|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
79975383|NCT03775733|Dietary Supplement|Placebo|Placebo for 12 weeks.
79645118|NCT02896660|Device|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
79645119|NCT00178971|Drug|adjunctive treatment with buspirone|buspirone 15-30 mg qd
79809098|NCT00668447|Dietary Supplement|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
79975384|NCT01320059|Drug|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
79975385|NCT01320059|Procedure|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
79975386|NCT03775031|Device|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
79975387|NCT03775499|Dietary Supplement|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
79975388|NCT03775499|Other|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
79975389|NCT03775499|Dietary Supplement|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
79975390|NCT03775499|Other|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
79975391|NCT01310465|Drug|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
79975392|NCT01310465|Drug|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
79975393|NCT03782441|Device|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
79975394|NCT03782285|Procedure|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
79984683|NCT04939532|Behavioral|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
79479229|NCT04554121|Behavioral|Brain Basics|"Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life."
79645120|NCT00178971|Drug|placebo|placebo
79975395|NCT05457179|Behavioral|Park-based physical activity|The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
79320955|NCT05019989|Behavioral|Control group: only public recommendation an lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~Dissemination of the information on the study by media~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
79320956|NCT04478305|Drug|Duavive 0.45Mg-20Mg Tablet|Duavee, marketed as Duavive in Canada.
79479230|NCT04554121|Behavioral|Brain Training|Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
79975396|NCT05457179|Behavioral|Active Control|The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
79479231|NCT04554004|Diagnostic Test|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
79479232|NCT04544280|Drug|Xeomin Injectable Product|Intramuscular injection
79645121|NCT02896621|Drug|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
79645122|NCT02896621|Drug|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
79645123|NCT02896504|Drug|Exposure: Adjuvant chemotherapy treatment|
79645124|NCT02896504|Drug|Exposure: Adjuvant hormonal therapy treatment|
79975397|NCT03782129|Biological|blood samples|Blood samples drawn during hospitalisations when needed
79320957|NCT05027243|Procedure|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
79320958|NCT05027243|Drug|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
79320959|NCT03147079|Behavioral|Lifestyle intervention|
79320960|NCT03148639|Behavioral|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
79320961|NCT03148639|Other|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
79320962|NCT05019599|Other|low protein diet|Low protein diet (<0.8g/kg/BW/day)
79320963|NCT03112135|Drug|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
79320964|NCT03112135|Drug|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
79320965|NCT03112135|Drug|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
79320966|NCT03090893|Drug|ATryn continuous infusion|replenish serum thrombin levels
79809099|NCT00668447|Dietary Supplement|Control protein|20 grams of powder mixed in beverages or food daily for one year
79809100|NCT00668447|Dietary Supplement|Novasoy isoflavones|3 tablets daily for one year
79975398|NCT03782129|Other|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
79975399|NCT03782051|Procedure|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
79320967|NCT03112759|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
79320968|NCT05019287|Biological|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
79320969|NCT05019287|Other|Intravenous saline injection|Intravenous saline injection in addition to standard care
79320970|NCT03094169|Drug|AVID100 IV|AVID100 is administered once every 3 weeks
79320971|NCT04477993|Drug|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils < 500/mm3 or platelets <50,000/mm3.
79320972|NCT04477993|Other|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
79320973|NCT03094013|Other|Assessment|Assessment
79320974|NCT03112447|Procedure|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
79645125|NCT02896582|Drug|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
79645126|NCT02896582|Drug|Dexamethasone|40 mg D1 to D4 in GA-DHAP
79809101|NCT00668447|Dietary Supplement|Placebo tablets|3 tablets daily for one year
79809102|NCT00668603|Drug|17-b-estradiol|2mg oral daily for 6 months
79975400|NCT03782051|Procedure|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
79975401|NCT03781895|Drug|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
79975402|NCT03781739|Drug|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
79975403|NCT03781661|Other|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
79975404|NCT00706030|Drug|neratinib|
79645127|NCT02896582|Drug|Aracytine|2g/m² D1 & D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
79809103|NCT00668603|Drug|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
79809104|NCT00668603|Drug|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
79809105|NCT00668603|Drug|placebo pill + gel|placebo daily for 6 months
79809106|NCT00662987|Drug|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
79809107|NCT00662987|Drug|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
79809108|NCT00663065|Drug|PAZ-417|
79645128|NCT02896582|Drug|Cisplatinum|100 mg/m² D1 in GA-DHAP
79975405|NCT00706030|Drug|vinorelbine|
79320975|NCT03112447|Procedure|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
79320976|NCT05019443|Device|Wedge Scoring Balloon|Scoring balloon
79320977|NCT05019443|Device|Conventional Balloon|Conventional balloon
79320978|NCT03146533|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
79479233|NCT04533386|Behavioral|Multi-component intervention strategy|Multi-component intervention strategy using a peer change agent and mobile application to record and review sexual risk behaviors
79479234|NCT04532151|Diagnostic Test|Non-invasive skin imaging assessment|"Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~an examination on LC-OCT~an examination on LC-OCT-doppler~a fluid silicone molding~an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable."
79975406|NCT01561001|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
79975407|NCT05409599|Other|Exercises|Exercises
79975408|NCT02484040|Radiation|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
79975409|NCT02484040|Drug|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
79320979|NCT03146533|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
79320980|NCT03146533|Biological|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
79320981|NCT03093935|Device|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
79320982|NCT03148483|Other|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
79320983|NCT03148483|Other|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
79320984|NCT03148483|Dietary Supplement|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
79320985|NCT03148483|Dietary Supplement|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
79645129|NCT02896582|Drug|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
79645130|NCT02896582|Drug|Melphalan|140 mg/m² D-2 in GA-BEAM
79320986|NCT02353117|Behavioral|Congenital Syphilis Intervention Group|
79320987|NCT03093779|Other|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
79479235|NCT04523480|Drug|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
79645131|NCT02896582|Drug|Carmustine|300 mg/m² D-7 in GA-BEAM
79645132|NCT00196638|Drug|Antiretroviral combination (drugs)|
79645133|NCT00196638|Drug|Pegylated Interferon alpha (drug)|
79645134|NCT00407693|Drug|[C-11]PRB28|
79645135|NCT02896426|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
79975410|NCT01312883|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
79479236|NCT04523480|Drug|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
79320988|NCT02353195|Other|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
79320989|NCT03090971|Drug|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
79479237|NCT04523480|Drug|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
79320990|NCT03090971|Drug|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
79320991|NCT03154177|Behavioral|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
79320992|NCT03154177|Procedure|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
79320993|NCT05018741|Procedure|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
79320994|NCT03146689|Drug|Topical NSAID|Applied four times daily
79479238|NCT04521621|Biological|Gebasaxturev|Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
79479239|NCT04521621|Drug|Pembrolizumab|Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
79479240|NCT04521569|Drug|Regadenoson|If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
79479241|NCT04521569|Drug|Placebo|If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
79479242|NCT04519853|Behavioral|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
79479243|NCT04518007|Device|hyperbaric oxygen therapy|"The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel."
79479244|NCT04513782|Diagnostic Test|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
79479245|NCT04506203|Diagnostic Test|Air test|Patients will breathe 0.21 < FiO2 < 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
79479246|NCT04501419|Procedure|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
79479247|NCT04501419|Other|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
79479248|NCT04497142|Drug|Perampanel|Tablet taken orally 1x daily.
79479249|NCT04497142|Drug|Standard of Care|Predetermined standard of care drug and dosing
79479250|NCT04495257|Drug|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
79479251|NCT04495257|Drug|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
79479252|NCT04495257|Drug|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
79479253|NCT04485767|Behavioral|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
79320995|NCT03146689|Drug|Topical Capsaicin|Applied four times daily
79320996|NCT02347267|Behavioral|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
79320997|NCT02347267|Behavioral|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
79320998|NCT05025995|Behavioral|Serious health game|Serious health game
79320999|NCT05255575|Drug|Ertapenem|Patients will receive ertapenem therapy.
79321000|NCT05026229|Drug|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
79321001|NCT05026229|Drug|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
79479254|NCT04485767|Behavioral|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
79479255|NCT04479020|Device|Mechanical Thrombectomy|Mechanical thrombectomy requiring the use an APERIO® or APERIO® Hybrid(17) Thrombectomy device due to an thrombotic occlusion in a distal vessel of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA)
79479256|NCT04477759|Radiation|50 Gy Radiation Therapy|Ionizing radiation
79479257|NCT04477759|Radiation|55 Gy Radiation Therapy|Ionizing radiation
79975411|NCT03781505|Drug|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
79479258|NCT04477759|Radiation|60 Gy Radiation Therapy|Ionizing radiation
79479259|NCT04477759|Drug|Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
79645136|NCT02896426|Behavioral|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
79321002|NCT02343679|Drug|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
79321003|NCT03148249|Other|interview|control group: interview, study group: explanation and exploration
79321004|NCT05026073|Behavioral|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
79321005|NCT05026073|Procedure|Blood and endometrial tissue sampling|"All women will undergo planned hysterectomy.~Venous blood sample will be collected prior to surgery.~Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
79321006|NCT05026073|Procedure|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
79479260|NCT04469712|Procedure|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
79479261|NCT04469712|Procedure|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
79479262|NCT04467853|Biological|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
79479263|NCT04466358|Procedure|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
79479264|NCT04466358|Procedure|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
79645137|NCT02896153|Other|Questionnaire|
79975412|NCT02483728|Other|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
79479265|NCT04454125|Behavioral|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
79321007|NCT03148171|Other|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
79645138|NCT02896270|Drug|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
79321008|NCT04478149|Device|SafelyYou|technology to detect and prevent falls
79321009|NCT04478149|Other|Control|technology present but not activated
79321010|NCT02347423|Biological|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
79321011|NCT02347423|Biological|IPV Vaccine SSI|
79321012|NCT05018429|Procedure|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
79321013|NCT03146611|Diagnostic Test|nCD64|neutrophil CD64
79645139|NCT00196677|Drug|Vitamins, minerals and medical herbs|
79479266|NCT04454125|Other|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
79645140|NCT02896465|Other|Oral rehydration solution|
79645141|NCT02896465|Other|Zinc|
79645142|NCT02896465|Other|Human milk oligosaccharides|
79321014|NCT03146611|Diagnostic Test|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
79321015|NCT03146299|Procedure|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
79321016|NCT05009693|Other|White Light Application|White Light Therapy
79321017|NCT02343601|Device|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
79321018|NCT03090815|Genetic|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
79321019|NCT02348905|Drug|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
79321020|NCT02348905|Drug|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
79321021|NCT04954157|Diagnostic Test|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
79321022|NCT04954157|Diagnostic Test|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
79479267|NCT04440891|Device|TMS stimulation with X-Torp task|TMS-Stimulation with X-Torp task
79479268|NCT04440891|Device|TMS-Stimulation with MindMotion Go|TMS-Stimulation with MindMotion Go
79645143|NCT02896465|Other|Breastfeeding|
79645144|NCT02896309|Dietary Supplement|Sodium bicarbonate|
79645145|NCT02896309|Dietary Supplement|Sodium chloride|
79645146|NCT02896231|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
79645147|NCT02895958|Drug|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
79645148|NCT02896192|Drug|Setmelanotide|Once daily SC injection
79479269|NCT04440891|Device|TMS-Sham with X-Torp task|TMS-Sham with X-Torp task
79479270|NCT04440891|Device|TMS-Sham with MindMotion Go|TMS-Sham with MindMotion Go
79479271|NCT04433949|Other|Best Practice|Receive standard of care
79479272|NCT04433949|Radiation|Low Dose Radiation Therapy|Undergo LDRT
79479273|NCT04433299|Other|no intervention, observational|no intervention, observational
79645149|NCT02896192|Drug|Placebo|Once daily SC injection
79645150|NCT00169949|Drug|aripiprazole|
79645151|NCT02896036|Procedure|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
79645152|NCT02896036|Procedure|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
79975413|NCT03781271|Device|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
79321023|NCT02347033|Drug|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
79975414|NCT05384327|Other|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
79321024|NCT02347033|Behavioral|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
79321025|NCT04949633|Drug|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
79321026|NCT04949633|Drug|Oxytocin|Induction of labor with oxytocin.
79321027|NCT02343367|Behavioral|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
79321028|NCT02343367|Other|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
79321029|NCT02343367|Behavioral|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
79321030|NCT02343367|Behavioral|Text messages|regularly scheduled cell phone text messages for 12 months
79321031|NCT02343367|Behavioral|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
79975415|NCT05384327|Other|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
79321032|NCT02343367|Behavioral|Newsletters|12 monthly newsletters mailed to participant homes
79975416|NCT03317470|Other|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
79321033|NCT03146377|Drug|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
79321034|NCT03146377|Drug|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
79321035|NCT03146377|Drug|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
79321036|NCT05018195|Procedure|Excise adipose tissue|Perform partial omentectomy to obtain one 5*5 cm omental fat and excise one 3*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
79479274|NCT04424199|Behavioral|Rightward Attentional Shift (R-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.
79479275|NCT04424199|Behavioral|Leftward Attentional Shift (L-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
79479276|NCT04418440|Dietary Supplement|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
79479277|NCT04414475|Drug|Selinexor|Participants will receive Selinexor oral tablets.
79479278|NCT04414475|Drug|Dexamethasone|Participants will receive Dexamethasone oral tablets.
79321037|NCT02343055|Other|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
79321038|NCT05009615|Dietary Supplement|Green coffee extract|150 mg polyphenols from green coffee, twice daily
79321039|NCT05009615|Dietary Supplement|Beta glucan|2.5 g BG twice daily
79321040|NCT05009615|Dietary Supplement|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
79321041|NCT02343133|Biological|HemaMax|
79321042|NCT02343133|Drug|Placebo|
79321043|NCT02349139|Drug|ASN001: Escalating dose Part A|Androgen inhibitor
79321044|NCT02348827|Behavioral|Family psychoeducation|
79479279|NCT04414475|Drug|Bortezomib|Participants will receive Bortezomib SC injection.
79645153|NCT02895997|Other|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
79321045|NCT02348827|Behavioral|Social support group|
79321046|NCT03090581|Procedure|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
79321047|NCT03090581|Procedure|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
79321048|NCT02348671|Other|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
79321049|NCT03079583|Dietary Supplement|Intervention-group|Biofortified Rice is grown by foliar Zn application
79321050|NCT03079583|Dietary Supplement|Control-group|Control Rice with normal zinc levels
79321051|NCT02346955|Biological|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
79321052|NCT02346955|Biological|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
79321053|NCT03079505|Drug|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
79479280|NCT04414475|Drug|Pomalidomide|Participants will receive Pomalidomide oral tablets.
79321054|NCT03079505|Drug|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
79321055|NCT02343211|Drug|Immunoglobulin|
79321056|NCT03090503|Drug|Aripiprazole|Initial dose: 10 mg.
79321057|NCT03090503|Drug|Risperidone|Initial dose: 2 mg.
79321058|NCT02343289|Drug|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
79321059|NCT02343289|Drug|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
79321060|NCT03090113|Drug|Shuxuetong Injection|intravenous drip
79321061|NCT03090113|Drug|Placebo Injection|intravenous drip
79321062|NCT02346799|Behavioral|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
79479281|NCT04410419|Dietary Supplement|Pre-operative carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
79809109|NCT00663143|Procedure|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
79975417|NCT03317470|Behavioral|Life Navigator|"The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
79975418|NCT03317470|Other|Follow-up survey|-5 questions about the acceptability of the basic needs survey
79975419|NCT03317470|Other|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
79975420|NCT03781193|Other|Questionnaires administration|Psychological and quality of life questionnaires
79975421|NCT03781193|Other|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
79321063|NCT02346799|Behavioral|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
79645154|NCT02895919|Other|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
79321064|NCT02346799|Behavioral|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
79321065|NCT02346799|Behavioral|Partner Assignment|"Participants will be required to have same workout window as partners."
79809110|NCT00668681|Device|EndoRefix|
79809111|NCT00668759|Drug|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
79321066|NCT03146221|Other|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
79321067|NCT03090269|Drug|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
79479282|NCT04390048|Device|Anodal tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
79479283|NCT04390048|Device|Sham tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
79479284|NCT04386005|Device|Continuous Glucose Monitoring Device|The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age >2 years).
79479285|NCT04369820|Other|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
79479286|NCT04369326|Other|Community-Based TPT Initiation|Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
79479287|NCT04337515|Device|CliniMacs®|CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
79479288|NCT04334135|Dietary Supplement|MitoQ|Four to eight 20mg capsules (depending on body mass)
79479289|NCT04333433|Device|PRESERFLO® MicroShunt|Device surgically implanted
79479290|NCT04333433|Procedure|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
79321068|NCT02342899|Device|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
79321069|NCT02342899|Device|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
79321070|NCT05008679|Drug|Oseltamivir|at a dose of 75 mg twice daily
79321071|NCT03090035|Drug|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
79321072|NCT03090035|Drug|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
79321073|NCT03147781|Device|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
79645155|NCT02895880|Behavioral|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
79975422|NCT03781193|Other|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
79975423|NCT03781193|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
79321074|NCT03147781|Device|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
79321075|NCT03147703|Behavioral|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
79321076|NCT03079349|Other|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
79321077|NCT03079349|Other|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
79479291|NCT04333303|Other|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book [SGB] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
79479292|NCT04318028|Radiation|7 Tesla Magnetic Resonance Imaging|Undergo 7 Tesla MRI
79645156|NCT02895880|Behavioral|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
79645157|NCT00196755|Drug|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
79975424|NCT03781193|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
79975425|NCT03781193|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
79975426|NCT03781193|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
79321078|NCT03147625|Behavioral|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
79975427|NCT03781193|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
79975428|NCT03781193|Other|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
79479293|NCT04316715|Behavioral|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
79479294|NCT04316715|Behavioral|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
79975429|NCT02488954|Other|Probiotics in the form of cheese portion|
79975430|NCT05380349|Drug|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
79975431|NCT02489032|Behavioral|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
79975432|NCT02489032|Other|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
79321079|NCT05008367|Drug|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
79479295|NCT04316702|Device|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
79645158|NCT00196755|Drug|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
79321080|NCT05008367|Drug|Isotonic saline|6 ml of isotonic saline
79321081|NCT02346175|Drug|SHR3824|
79321082|NCT02346175|Drug|Placebo|
79321083|NCT02342587|Drug|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
79321084|NCT02346331|Other|WHO algorithm of fluid boluses guided by physical examination|
79645159|NCT00169988|Drug|risperidone|
79321085|NCT02346331|Other|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
79321086|NCT02346331|Other|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
79321087|NCT02346331|Other|Oxygen delivery|
79479296|NCT04316702|Drug|Cymbalta / lyrica|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
79479297|NCT04315506|Behavioral|SGR|The SGR program will reduce smokeless tobacco use by 1/4 until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
79479298|NCT04315506|Behavioral|Control|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for five weeks.
79321088|NCT02346331|Other|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
79321089|NCT02346331|Other|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
79321090|NCT05017259|Dietary Supplement|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
79321091|NCT02342509|Drug|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
79321092|NCT02342509|Drug|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
79321093|NCT02342509|Drug|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
79321094|NCT02342431|Device|Forced air warming compressible|Warming with a compressible forced air mattress
79321095|NCT02342431|Device|Forced air non-compressible|Warming with a non-compressible forced air mattress
79321096|NCT03079271|Drug|Lacrisert, 5 Mg Ophthalmic Insert|
79479299|NCT04313751|Behavioral|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
79645160|NCT00169988|Drug|sertraline-primary|
79645161|NCT02895607|Procedure|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
79645162|NCT02895529|Drug|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters [mL]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
79645163|NCT02895529|Drug|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
79321097|NCT02342353|Drug|Pacritinib|
79321098|NCT02342353|Drug|Erlotinib|
79321099|NCT02337127|Drug|Lamivudine|Lamivudine, 100mg/day, per os
79321100|NCT02336971|Behavioral|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
79479300|NCT04313751|Other|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
79321101|NCT02336971|Behavioral|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
79321102|NCT02337205|Drug|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
79479301|NCT04313296|Device|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
79479302|NCT04307446|Device|Immersive Virtual Reality|Immersive Virtual Reality
79645164|NCT02895802|Behavioral|Verbal instructions with picture diagram|verbal instructions and picture diagram
79321103|NCT05007587|Drug|Lenvatinib|8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) QD
79479303|NCT04302051|Diagnostic Test|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
79479304|NCT04302051|Diagnostic Test|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
79479305|NCT04292457|Drug|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
79479306|NCT04292457|Drug|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
79479307|NCT04274179|Other|Modified Atkins Diet|Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
79479308|NCT04274179|Drug|Absence epilepsy medications|At neurologist's discretion. *OF NOTE< THIS ARM IS COMPLETED
79479309|NCT04273932|Drug|Lithium|Lithium aspartate of lithium carbonate will be administered by mouth.
79479310|NCT04273594|Device|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
79321104|NCT05007587|Drug|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
79321105|NCT05007587|Drug|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
79645165|NCT02895802|Behavioral|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
79645166|NCT02895802|Behavioral|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
79645167|NCT02895802|Behavioral|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
79645168|NCT00170027|Device|Magnetocardiograph|
79321106|NCT03078959|Other|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
79321107|NCT05015933|Procedure|Pump refill procedure at home|Implantable pump refill is performed at home
79645169|NCT00179088|Behavioral|Patient may be able to put weight on the operated leg|
79645170|NCT02895646|Other|Collection of blood sample|
79321108|NCT03146143|Procedure|ultrafiltration|ultrafiltration after cardiopulmonary bypass
79321109|NCT05015465|Diagnostic Test|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
79321110|NCT05015777|Other|Emil Jaques-Dalcroze's Eurhythimcs Exercise Program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
79321111|NCT02039323|Drug|Tenofovir|
79321112|NCT02039323|Drug|Maraviroc|
79321113|NCT05015699|Device|HT Supreme|HT Supreme ( R&D by Sinomed, Tianjin, China)
79479311|NCT04272086|Drug|Bupivacaine|0.25%
79479312|NCT04272086|Drug|Bupivacaine liposome|10mL
79645171|NCT00169910|Drug|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
79645172|NCT02895763|Other|Form administrations|
79479313|NCT04272086|Drug|normal saline|10ml
79479314|NCT04267705|Other|Control|This group will receive a cup of rice 7 days/week over a 12-week period
79479315|NCT04267705|Other|Black bean|This group will receive a cup of black bean7 days/week over a 12-week period
79645173|NCT02895490|Other|educational intervention|Receive a DVD containing educational information and communication skills
79645174|NCT02895490|Other|communication skills training|Receive a DVD containing educational information and communication skills
79645175|NCT02895490|Other|educational intervention|Receive information about the LINC group
79645176|NCT02895490|Other|questionnaire administration|Ancillary studies
79645177|NCT02895490|Other|quality-of-life assessment|Ancillary studies
79645178|NCT02895412|Biological|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
79321114|NCT04958161|Other|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
79321115|NCT02342119|Other|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
79479316|NCT04267705|Other|Chickpea|This group will receive a cup of chick pea 7 days/week over a 12-week period
79479317|NCT04264572|Other|Medically Tailored Meals|MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.
79479318|NCT04264572|Behavioral|Tele-Medical Nutrition Therapy (tele-MNT)|Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
79479319|NCT04263181|Procedure|Peripheral blood draw|"All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~Cohort 0 or 1 - peripheral blood draw on Day 2~Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
79479320|NCT04263181|Procedure|Bone marrow aspirate|"Cohort 0 or 1 - bone marrow aspirate on Day 14~Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
79645179|NCT00196794|Drug|Tolevamer potassium-sodium (GT267-004)|
79809112|NCT00668759|Drug|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
79809113|NCT00668837|Drug|Paliperidone|
79321116|NCT02342119|Other|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
79809114|NCT02630225|Behavioral|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
79321117|NCT03079115|Drug|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
79809115|NCT02630225|Other|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~All necessary medical care and scheduled follow-ups with subspecialty services~Evaluation by social work with referral to appropriate community services~Screening for alcohol use~Discharge planning services~Financial counseling"
79321118|NCT03079115|Drug|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
79321119|NCT02342041|Drug|SUVN-G3031|
79321120|NCT02342041|Drug|Placebo|
79975433|NCT03320746|Device|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to ~1h/day of jogging or ~2h/day of walking or ~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
79975434|NCT03781349|Device|MENS|
79975435|NCT03781349|Device|TENS|
79321121|NCT05014997|Other|no intervention|this study was designed as retrospective observational study
79321122|NCT05255185|Procedure|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
79321123|NCT05015075|Behavioral|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
79321124|NCT04919863|Drug|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
79321125|NCT04919863|Drug|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
79479321|NCT04263181|Procedure|Buccal swab|"Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
79321126|NCT05015231|Diagnostic Test|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
79321127|NCT04909177|Other|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
79321128|NCT05917483|Diagnostic Test|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
79321129|NCT05917431|Combination Product|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
79479322|NCT04261504|Behavioral|IBMT|mindful presence in a non-judgmental way
79479323|NCT04261504|Behavioral|RT|progressive muscle relaxation
79479324|NCT04259125|Diagnostic Test|Blood draw|Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
79479325|NCT04259125|Other|Survey|Regarding epilepsy and development.
79321130|NCT05917418|Dietary Supplement|nutritional support|nutritional support
79321131|NCT05917405|Drug|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
79321132|NCT05917405|Drug|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
79321133|NCT05917405|Drug|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
79321134|NCT05917405|Drug|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
79321135|NCT05917392|Dietary Supplement|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
79321136|NCT05917392|Dietary Supplement|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
79321137|NCT05917392|Dietary Supplement|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
79321138|NCT05917366|Other|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
79321139|NCT05917366|Other|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
79321140|NCT05917314|Other|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~Limosilactobacillus fermentum K7-Lb1~Limosilactobacillus fermentum K8-Lb1~Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
79321141|NCT05917314|Other|Placebo|The placebo capsule contains microcrystalline cellulose.
79321142|NCT05917288|Biological|Belimumab|Belimumab will be administered
79321143|NCT05917288|Drug|Standard of care|Standard of care will be administered
79321144|NCT05917236|Procedure|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
79321145|NCT05917197|Other|survey based information|Only survey based information collected
79321146|NCT05917184|Other|Telehealth|Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
79321147|NCT05917158|Drug|RC48-ADC and JS001|Patients in group will receive 6 x 2 week cycles of JS001 (Toripalimab) 3mg/kg in combination with RC48-ADC (Disitamab Vedotin) 2mg/kg intravenously.
79321148|NCT05991674|Diagnostic Test|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
79321149|NCT05991648|Procedure|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
79321150|NCT05991622|Drug|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
79321151|NCT05991583|Drug|IBB0979|IBB0979 should be subcutaneous injected，qw
79321152|NCT05991505|Other|Physical exercise|Multimodal exercises twice a week
79479326|NCT04258514|Procedure|Virtual Reality during vasectomy|Virtual Reality
79479327|NCT04258514|Procedure|Standard Vasectomy|No Virtual Reality
79479328|NCT04256707|Drug|Selinexor 100 mg|"100-mg 2 formulations:~5 × 20-mg tablets (Tablet A)~1 × 100-mg tablet (Tablet B)"
79809116|NCT02630225|Behavioral|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
79479329|NCT04256707|Drug|Docetaxel|75 mg/m^2 IV
79479330|NCT04256707|Drug|Pembrolizumab|200 mg IV
79479331|NCT04256707|Drug|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m^2~Leucovorin 400 mg/m^2~5-FU 400 mg/m^2 bolus~5-FU 2400 mg/m^2 IV"
79479332|NCT04256707|Drug|Selinexor 40 mg|- 2 × 20-mg tablets (Tablet A)
79479333|NCT04256707|Drug|Selinexor 80 mg|- 4 × 20-mg tablets (Tablet A)
79479334|NCT04256707|Drug|Selinexor 60 mg|- 3× 20-mg tablets (Tablet A)
79479335|NCT04249427|Drug|Erenumab Prefilled Syringe|140mg Erenumab, pre-filled syringe given by subcutaneous injection
79479336|NCT04249427|Other|Placebo|Placebo, pre-filled syringe given by subcutaneous injection
79321153|NCT05991466|Drug|Dexmedetomidine|"All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block."
79321154|NCT05991388|Drug|Odronextamab|CD20xCD3 bispecific antibody
79321155|NCT05991388|Drug|Loncastuximab tesirine|CD-19-directed antibody-drug conjugate
79321156|NCT05991388|Drug|Rituximab|Modified R-ICE chemotherapy
79479337|NCT04241588|Device|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
79479338|NCT04233229|Device|t:slim X2 with Control-IQ|closed-loop in patients at home for three months
79975436|NCT02483338|Behavioral|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
79321157|NCT05991388|Drug|Ifosfamide|Modified R-ICE chemotherapy
79321158|NCT05991388|Drug|Carboplatin|Modified R-ICE chemotherapy
79321159|NCT05991388|Drug|Etoposide|Modified R-ICE chemotherapy
79809117|NCT02630225|Other|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
79809118|NCT02631395|Other|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
79975437|NCT03781115|Drug|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
79975438|NCT03781115|Drug|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
79975439|NCT03781115|Drug|Placebo Comparator|A non drug oral placebo capsule will be given as a control
79975440|NCT03317236|Drug|Quetiapine|A fixed 50 mg exteded release formulation.
79975441|NCT02488798|Procedure|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
79975442|NCT02488798|Procedure|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
79975443|NCT02488798|Procedure|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
79321160|NCT05991388|Drug|Etoposide Phosphate|Modified R-ICE (Treatment Arm II)
79321161|NCT05991388|Drug|Dexamethasone|Modified R-ICE chemotherapy
79479339|NCT04233229|Other|home healthcare services|home healthcare services from Air Liquide in patients at home for three months
79479340|NCT04233229|Other|usual care for daily insulin treatment|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
79479341|NCT04230304|Biological|Daratumumab|Given IV
79479342|NCT04230304|Drug|Ibrutinib|Given PO
79975444|NCT01313429|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
79321162|NCT05991388|Biological|CAR T-cells (TBC)|Modified R-ICE chemotherapy
79321163|NCT05991375|Drug|DEXmedetomidine|28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
79321164|NCT05991375|Other|saline|28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
79479344|NCT04219215|Device|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
79645180|NCT02895685|Other|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
79645181|NCT02895724|Drug|Medical Oxygen|Hyperbaric oxygen therapy
79975445|NCT01313429|Biological|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
79321165|NCT05991336|Genetic|Gene therapy|Autologous edited hematopoietic stem cell transplantation
79321166|NCT05991297|Other|Deep sensory assisted rehabilitation|"A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs."
79645182|NCT00553774|Dietary Supplement|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
79645183|NCT00553774|Other|Placebo|Placebo (BD 21 - 28 Days)
79645184|NCT00170144|Drug|Branchamin 4%|
79645185|NCT00553852|Drug|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
79809119|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
79809120|NCT00663221|Dietary Supplement|Anthocyans, Calcium and Vitamin D|
79975446|NCT01313429|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
79975447|NCT03488251|Drug|MT-3724|MT-3724 will be administered.
79975448|NCT03488251|Drug|Gemcitabine|Gemcitabine will be administered.
79975449|NCT03488251|Drug|Oxaliplatin|Oxaliplatin will be administered.
79479345|NCT04219215|Device|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
79479346|NCT04210375|Drug|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
79479347|NCT04210375|Drug|Matching Placebo|Vehicle control
79479348|NCT04209673|Other|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
79479349|NCT04209673|Other|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
79479350|NCT04207801|Drug|AUR101|Inhibitor of RORγ
79479351|NCT04207801|Drug|Matching Placebo|Drug-Placebo of AUR101 tablet
79975450|NCT02727322|Drug|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
79975451|NCT02727322|Drug|Placebo|Placebo
79975452|NCT03716401|Diagnostic Test|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
79321167|NCT05991297|Other|classical rehabilitation|Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
79321168|NCT05991245|Other|Collecting datas|Blood, Tissue and Urine samples
79479352|NCT04206215|Device|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
79479353|NCT04206215|Device|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
79645186|NCT03455296|Other|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A & group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
79479354|NCT04205552|Drug|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
79321169|NCT05991141|Other|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
79321170|NCT05991141|Other|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
79645187|NCT02895061|Drug|Alfacalcidol|Alfacalcidol 1 microgram/capsule
79645188|NCT00170183|Drug|Nesiritide|
79479355|NCT04205552|Drug|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
79479356|NCT04192136|Dietary Supplement|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
79479357|NCT04192136|Dietary Supplement|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
79645189|NCT02895139|Device|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
79809121|NCT00663221|Dietary Supplement|placebo|
79809122|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
79809123|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
79975453|NCT03716401|Diagnostic Test|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
79975454|NCT03716401|Procedure|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
79975455|NCT03716401|Diagnostic Test|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
79321171|NCT05991115|Behavioral|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
79479358|NCT04192136|Other|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
79479359|NCT04191057|Device|Free light chains|Blood samples will be collected and analyzed
79479360|NCT04181996|Drug|Colchicine Oral Product|Patients will be randomized to receive either placebo or colchicine
79975456|NCT03716401|Diagnostic Test|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
79479361|NCT04181996|Drug|Placebo oral capsule|Patents will be randomized to receive either placebo or colchicine
79809124|NCT00668993|Behavioral|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
79975457|NCT03315520|Drug|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
79975458|NCT02483182|Drug|ZEP-3 ointment 1.0%|
79975459|NCT02483182|Drug|Acyclovir cream 5%|
79809125|NCT00596687|Drug|Insulin glargine|Insulin glargine once daily SQ
79321172|NCT05991037|Biological|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
79975460|NCT03780491|Other|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
79975461|NCT03431857|Device|TESS V2|Patients requiring the TESS V2 prosthesis.
79321173|NCT05991011|Other|Immersive and Interactive Wall Exergames|This intervention will be performed using the Neo One device. It was chosen because of the variety and quality of the games offered which are accessible to older people. The target intensity of core workout will be moderate. Five to 7 five-minutes games will be selected from 19 games. A variety of materials will be used (e.g., basketball, rugby, handball ball, balloon, chair, hoop, rhythm ladder, tennis racket). The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity. Interventions will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Neo One device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants.
79479362|NCT04180709|Device|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
79479363|NCT04174365|Drug|Brexpiprazole|Oral tablet; take once daily
79479364|NCT04174365|Drug|Placebo|Administered orally daily for up to Week 8.
79479365|NCT04173780|Drug|Atropine 0.01%|1 drop per day in both eyes for 1 year
79479366|NCT04173780|Drug|Placebo|1 drop per day in both eyes for 1 year
79479367|NCT04167111|Dietary Supplement|Cholecalciferol|Vitamin D
79321174|NCT05991011|Other|Complex Cognitive and Motor Activities program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving cooperation and opposition exercises inspired by team sports (basketball, volleyball, rugby) and individual sports (boxing, weight training), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants. The target intensity of body workout will be moderate. The first part will be focused on endurance and the second on muscle strengthening and coordination work in the form of circuit training. A variety of equipment will be used (e.g., tennis balls, basketballs, volleyballs, rugby balls, balloons, elastics, chairs, blocks). The number of partners and/or opponents will be changed regularly.
79321175|NCT05991011|Other|exergames program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, physically active (standing). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Nintendo Switch device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants. The games (Fitness Boxing 2, Switch Sport, Just Dance 2020, 2021, 2023, Let's Get Fit, Mario and Sonic at the Olympic Games Tokyo 2020, Instant Sport, Ring Fit, Zumba Burn It Up!) will be carried out in the form of circuit training, in pairs or groups of 4. The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity.
79975462|NCT02480062|Other|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
79321176|NCT05991011|Other|video games program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, while being inactive (sitting). The sessions will consist in one-hour single and multi-players games, using the Nintendo Switch device, in groups of 6 participants.
79321177|NCT05991011|Other|Bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this active comparator intervention, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike at about 50% of Heart Rate Reserve, and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
79321178|NCT05991011|Other|Video games + bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this experimental arm, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike (like BIKE program at about 50% of Heart Rate Reserve) and at the same time playing on a Nintendo Switch (like VG program), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
79809126|NCT00596687|Drug|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
79479368|NCT04144608|Drug|Toripalimab combination with platinum-containing dual-drug chemotherapy|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
79975463|NCT02480062|Other|Usual Care|Usual care at the community health centers
79975464|NCT03780647|Other|questionnaire|Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
79975465|NCT01338558|Drug|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
79809127|NCT00596687|Drug|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
79809128|NCT02631239|Drug|Methotrexate|1g/m2/d IV *1d
79809129|NCT02631239|Drug|Etoposide|200mg/d PO *3d
79809130|NCT02631239|Drug|Dexamethasone|40mg/d PO *3d
79809131|NCT02631239|Drug|Pegaspargase|2500IU/m2/d IM *1d
79809132|NCT02631239|Radiation|Radiotherapy|50-56Gy
79321180|NCT05990972|Procedure|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
79321181|NCT05990959|Other|No intervention for research purpose|No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
79321182|NCT05990946|Procedure|ePRO based Remote Symptom Management|Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management.
79975466|NCT01338558|Drug|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
79975467|NCT01338558|Drug|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
79975468|NCT05390866|Other|HIIT|A single HIIT on a bicycle ergometer
79321183|NCT05990933|Drug|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
79321184|NCT05990907|Procedure|Remote ischemic preconditioning|The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
79975469|NCT03780569|Device|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
79975470|NCT03780569|Radiation|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
79321185|NCT05990881|Drug|Botulinum toxin|Patients in this group will receive an injection of Botulinum toxin.
79321186|NCT05990881|Drug|Standard-of-care corticosteroid injections|Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
79321187|NCT05990868|Drug|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
79975471|NCT03780569|Drug|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m^2 in the absence of toxicity."
79321188|NCT05990842|Drug|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
79321189|NCT05990842|Other|placebo|the individual will receive 10 ml of saline during anesthetic induction
79479369|NCT04143009|Behavioral|Enhanced Friendship Bench|EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
79479370|NCT04143009|Other|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
79479371|NCT04143009|Behavioral|Adapted Friendship Bench|Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
79479372|NCT04139304|Drug|Cyclophosphamide|Given IV
79645190|NCT02895139|Device|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
79321190|NCT05990829|Drug|Ozurdex|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
79321191|NCT05990829|Drug|Aflibercept|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
79479373|NCT04139304|Biological|Daratumumab|Given IV
79479374|NCT04139304|Drug|Doxorubicin|Given IV
79479375|NCT04139304|Drug|Doxorubicin Hydrochloride|Given IV
79479376|NCT04139304|Drug|Etoposide|Given IV
79321192|NCT05990725|Biological|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
79321193|NCT05990712|Dietary Supplement|Omega-3|Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.
79321194|NCT05990712|Drug|Trehalose|Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
79479377|NCT04139304|Drug|Prednisone|Given PO
79479378|NCT04139304|Drug|Vincristine|Given IV
79479379|NCT04139304|Drug|Vincristine Sulfate|Given IV
79479380|NCT04136288|Device|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
79975472|NCT03316846|Behavioral|Internet-Delivered Cognitive Behavioral Therapy|
79975473|NCT05512559|Device|body composition analysis|Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
79645191|NCT02895139|Device|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
79321195|NCT05990712|Drug|Zocular Eyelid System Treatment|A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
79321196|NCT05990712|Other|Blephadex cleansing eyelid wipes|Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
79479381|NCT04135690|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
79479382|NCT04135690|Drug|Toripalimab|240mg intravenously every 3 weeks
79479383|NCT04135690|Drug|Sorafenib|400mg bid po
79479384|NCT04135690|Drug|systemic treatment|atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on
79975474|NCT01333020|Other|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
79975475|NCT03780413|Behavioral|PR-ESSENCE treatment|
79975476|NCT03780413|Behavioral|Control (TAU)|
79975477|NCT01338714|Other|Compound Herbal Formula (RHD-1)|100 ml/per day
79975478|NCT01338714|Other|dilute RHD-1|100 ml/per day
79321199|NCT05990673|Drug|Remimazolam|remimazolam is given intravenously
79321200|NCT05990647|Diagnostic Test|Dynamometric tension assessment|"Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR."
79479385|NCT04131426|Drug|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
79479386|NCT04131426|Other|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
79479387|NCT04130646|Device|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
79479388|NCT04130646|Device|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
79975479|NCT03487549|Combination Product|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
79975480|NCT03487549|Combination Product|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
79479389|NCT04128215|Behavioral|Control Period|Subjects will complete an 8-week control period of normal lifestyle, followed by the 8-week exercise period.
79479390|NCT04128215|Behavioral|Exercise Period|Subjects will complete an 8-week non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT will consist of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax will be included.
79479391|NCT04126317|Drug|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
79479392|NCT04126317|Drug|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
79975481|NCT02486068|Device|ABSORB scaffold|
79975482|NCT02486068|Device|Xience|
79975483|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
79975484|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
79975485|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
79975486|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
79321201|NCT05990647|Diagnostic Test|Postural balance|"Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR."
79321202|NCT05990647|Diagnostic Test|Assessment of the hernia defect size|"Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)"
79321203|NCT05990647|Diagnostic Test|Physical activity of patients|"To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR."
79809133|NCT00663299|Device|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
79479393|NCT04123314|Drug|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
79809134|NCT00663377|Drug|losartan|losartan 50-100mg for 16 weeks
79809135|NCT00669149|Drug|clopidogrel + aspirin|
79809136|NCT00669149|Drug|heparin + clopidogrel + aspirin|
79809137|NCT00669149|Drug|enoxaparin + clopidogrel + aspirin|
79809138|NCT00669149|Drug|bivalirudin + clopidogrel + aspirin|
79809139|NCT00669227|Other|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
79809140|NCT00669227|Other|placebo suspension|intracoronary administration at the same day as cell aspiration
79809141|NCT04032275|Other|Chronic hepatitis B infection|Chronic hepatitis B infection patients
79645192|NCT04680559|Behavioral|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
79321204|NCT05990634|Device|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
79321205|NCT05990621|Biological|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
79479394|NCT04122703|Device|percutaneous tibial nerve stimulation (PTNS)|The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
79479395|NCT04122703|Device|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
79809142|NCT00663455|Drug|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
79479397|NCT04109924|Drug|Irinotecan|Given IV
79479398|NCT04109924|Biological|Bevacizumab|Given IV
79479399|NCT04109924|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79479400|NCT04100564|Device|Supraglottic airway device|Initial advanced airway management with a supraglottic device
79479401|NCT04100564|Other|Standard airway management|Initial advanced airway management with standard care method
79479402|NCT04093596|Genetic|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
79645193|NCT04680559|Behavioral|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
79809143|NCT00663533|Device|Vas-X|mechanical vasectomy device
79809144|NCT00669695|Drug|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
79809145|NCT00669695|Other|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
79809146|NCT00669695|Other|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
79321206|NCT05990608|Other|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
79321207|NCT05990582|Diagnostic Test|CBCL|A questionnaire on behaviour
79302175|NCT03322319|Procedure|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
79321208|NCT05990582|Diagnostic Test|SDQ|A questionnaire on behaviour
79975487|NCT01572714|Behavioral|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
79645194|NCT00179166|Drug|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
79321209|NCT05990582|Diagnostic Test|CCC-2-NL|A questionnaire on communcational skills
79321210|NCT05990582|Diagnostic Test|MCH Feeding scale|A questionnaire on feeding problems
79321211|NCT05990582|Diagnostic Test|TRF|A questionnaire on behaviour
79645195|NCT02895334|Behavioral|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
79645196|NCT00170222|Drug|doxycycline|
79809147|NCT00663689|Drug|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
79975488|NCT01572714|Behavioral|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
79975489|NCT01572714|Behavioral|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
79302176|NCT05012319|Drug|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
79302177|NCT03221803|Other|OT Vertical attachment|new extra coronal castable attachment
79321212|NCT05990582|Diagnostic Test|WISC-5-NL|An IQ test for children
79809148|NCT00669773|Drug|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
79809149|NCT00669773|Drug|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
79321213|NCT05990582|Diagnostic Test|Movement ABC|A test to assess motor function
79321214|NCT05990582|Diagnostic Test|CELF-5-NL|A test to assess language development
79321215|NCT05990582|Diagnostic Test|Emma Toolbox|Test of executive functions
79321216|NCT05990556|Procedure|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
79479403|NCT04093596|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
79809150|NCT00669851|Drug|AI-700|
79809151|NCT00824616|Drug|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
79809152|NCT00824616|Drug|Placebo|Placebo tablets, taken 3 times daily.
79809153|NCT00824616|Drug|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
79809154|NCT04155671|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
79975490|NCT03779945|Biological|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
79809155|NCT04155671|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
79809156|NCT05443620|Device|Weight vest|A vest weighing up to a maximum of 15 kg.
79809157|NCT05443620|Device|Wheelchair|Wheelchair in which participants will be sitting to reduce loading on lower extremities.
79809158|NCT00663845|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
79809159|NCT00663845|Drug|Placebo|Matching placebo
79809160|NCT00708240|Drug|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
79809161|NCT04155515|Drug|TG-2349|TG-2349 400mg
79809162|NCT04155515|Drug|DAG181|DAG181 200mg
79302178|NCT03221803|Other|OT cap attachment|standard extra coronal attachment
79302179|NCT03322241|Other|overall wellness|Wellness lab testing
79302180|NCT05011773|Device|Deep brain stimulation|Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
79302181|NCT03221725|Procedure|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
79302182|NCT03319043|Drug|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
79479404|NCT04093596|Drug|Fludarabine|Chemotherapy for lymphodepletion
79479405|NCT04093596|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
79479406|NCT04093596|Drug|Nirogacestat|a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
79479407|NCT04092530|Behavioral|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
79809163|NCT04155515|Drug|Ribavirin|Ribavirin 1000mg/1200mg
79809164|NCT00664001|Dietary Supplement|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
79809165|NCT00664001|Dietary Supplement|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
79809166|NCT00670163|Behavioral|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
79975491|NCT03779945|Procedure|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
79302183|NCT05019183|Other|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
79302184|NCT05019183|Other|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
79302185|NCT05019183|Device|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
79302186|NCT05019183|Biological|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
79302187|NCT02451475|Drug|Amitriptyline|Amitriptyline 25 mg/day
79302188|NCT02451475|Drug|Venlafaxine|Venlafaxine 75 mg/day
79302189|NCT02451475|Drug|Paroxetine|Paroxetine 25 mg/day
79302190|NCT03322163|Other|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
79975492|NCT01561235|Other|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
79975493|NCT02485990|Drug|Tremelimumab|
79479408|NCT04091750|Drug|Nivolumab|"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"
79479409|NCT04091750|Drug|Ipilimumab|Induction: 1mg/kg IV every 3 weeks x 4 cycles
79479410|NCT04091750|Drug|Cabozantinib|Induction and Maintenance: 40mg PO daily
79975494|NCT02485990|Drug|Olaparib|
79975495|NCT01313819|Drug|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
79975496|NCT03315442|Other|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
79645197|NCT02894983|Other|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
79645198|NCT02894983|Other|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
79975497|NCT03464383|Drug|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
79975498|NCT03464383|Other|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
79975499|NCT03464383|Other|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
79975500|NCT03780335|Diagnostic Test|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
79975501|NCT03779633|Drug|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
79975502|NCT03779633|Other|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
79479411|NCT04074720|Procedure|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
79975503|NCT03720067|Drug|Propranolol|40mg to 320mg / day
79975504|NCT03720067|Drug|Carvedilol|6.25mg to 25mg / day
79975505|NCT03720067|Drug|Rosuvastatin|20mg / day
79479412|NCT04074720|Other|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
79645199|NCT02895022|Drug|Lidocaine 2% adrénalinée|
79645200|NCT02895022|Device|Epidural catheter|
79645201|NCT02895022|Procedure|Caesarean section|
79645202|NCT02895256|Drug|Any treatment for cluster headache|
79645203|NCT00409851|Drug|valsartan+amlodipine|
79645204|NCT00170261|Device|Use of an Implantable Loop Recorder|
79645205|NCT00409890|Drug|Hyoscine Butyl Bromide|
79645206|NCT05424094|Behavioral|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
79645207|NCT00170300|Device|Implantable Cardiac Resynchronisation (pacing) device|
79645208|NCT05423977|Drug|ZV0203|Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
79975506|NCT03720067|Drug|Placebo|Placebo of rosuvastatin
79975507|NCT03779555|Other|Medication Event Monitoring System|-Microchipped bottle cap
79975508|NCT03718663|Other|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
79975509|NCT03718663|Other|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
79975510|NCT03779399|Other|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
79645209|NCT05423938|Dietary Supplement|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA&DHA
79975511|NCT01444092|Drug|Entocort|Entocort capsules, oral
79645210|NCT05423938|Dietary Supplement|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
79645211|NCT00179205|Drug|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
79645212|NCT00179205|Drug|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
79975512|NCT03719989|Drug|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
79975513|NCT02480296|Drug|MYK-461|
79975514|NCT02480296|Drug|Placebo|Placebo comparator
79975515|NCT03716323|Device|immediate premolar implant with xenograft and allograft|"A peritome will be used for atraumatic extraction of remaining roots.~The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~Copious normal saline irrigation and curettage will be performed.~In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
79302191|NCT03226327|Dietary Supplement|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
79302192|NCT05019417|Drug|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
79302193|NCT03225937|Drug|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
79302194|NCT03225937|Drug|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
79302195|NCT03318887|Drug|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
79302196|NCT05011695|Other|physiotherapy|The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
79302197|NCT02487875|Other|rehabilitation|
79302198|NCT03119077|Drug|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
79302199|NCT03119077|Drug|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
79302200|NCT03119077|Drug|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
79302201|NCT03090945|Other|This is an obsevational cohort study|no intervention
79321217|NCT05990543|Drug|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
79321218|NCT05990530|Biological|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
79321219|NCT05990517|Biological|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
79321220|NCT05990374|Drug|Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc|The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
79645213|NCT05423899|Behavioral|Grace Robot|The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
79479413|NCT04074720|Other|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
79321221|NCT05990322|Behavioral|Project EMPOWER|Experimental Condition
79645214|NCT05423899|Behavioral|Treatment as Usual|The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
79645215|NCT05423821|Other|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
79645216|NCT05423704|Other|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
79645217|NCT05423626|Device|technologies of robotic mechanotherapy with FES|"Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~exoskeletal robotic device for moving the patient and forming a walking pattern~a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb."
79321222|NCT05990309|Diagnostic Test|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
79479414|NCT04073498|Drug|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
79479415|NCT04073498|Drug|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
79479416|NCT04066894|Procedure|Explantation|Undergo lead removal
79479417|NCT04066894|Other|Quality-of-Life Assessment|Ancillary studies
79479418|NCT04066894|Other|Questionnaire Administration|Ancillary studies
79479419|NCT04066894|Device|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
79479420|NCT04066894|Device|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
79479421|NCT04066894|Procedure|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
79479422|NCT04049695|Behavioral|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
79321223|NCT05990296|Behavioral|Multiprong CDS with referral to pharmacist co-management|Accepting the clinician-facing BPA default recommendation will have eligible patients within this arm referred to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
79645218|NCT05423626|Device|biofeedback virtual reality technologies|"Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~hardware and software complex, including a monitor and a personal computer;~virtual reality helmet;~sandals with air chambers."
79975516|NCT05460442|Procedure|Caudal Block group|Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
79975517|NCT05460442|Procedure|Pericapsular nerve group block|Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
79975518|NCT05460442|Procedure|Fascia iliaca group|Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
79479423|NCT04049695|Behavioral|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
79479424|NCT04046536|Device|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
79645219|NCT00170378|Drug|Enoxaparin|
79645220|NCT00179244|Drug|Rispridone (drug) and Bupropion ER (drug)|
79975519|NCT03779477|Behavioral|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
79321224|NCT05990296|Behavioral|Multiprong CDS with GDMT order set|Accepting the clinician-facing BPA default recommendation will open an order set for GDMT that lists common recommended options in such a way that facilitates optimal prescribing. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
79321225|NCT05990296|Behavioral|Focused education|A series of focused, interactive education sessions will train clinicians in why, when, and how to prescribe GDMT to patients, with incentives such as continuing medical education (CME) credits, and with virtual and recorded options available to those who are unable to attend in-person meetings.
79321226|NCT05990270|Behavioral|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
79975520|NCT05460208|Dietary Supplement|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
79975521|NCT05460208|Dietary Supplement|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
79975522|NCT05263115|Other|Resistance Exercise intervention|12-week progressive resistance exercise intervention
79975523|NCT05263115|Other|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
79975524|NCT05463328|Procedure|laparoscopic assisted pancreaticoduodenectomy|laparoscopic assisted pancreaticoduodenectomy.
79975525|NCT05463328|Procedure|Open pancreaticduodenctomy|Open pancreaticduodenctomy
79975526|NCT05462470|Procedure|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
79479425|NCT04046536|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
79479426|NCT04043195|Drug|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
79479427|NCT04043195|Drug|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
79479428|NCT04043195|Drug|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
79479429|NCT04038255|Drug|Nicoderm C-Q Transdermal Product|6 weeks of nicotine replacement therapy patches
79975527|NCT05462470|Procedure|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
79975528|NCT03774797|Other|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
79975529|NCT02480218|Other|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
79975530|NCT02479984|Procedure|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
79479430|NCT04038255|Behavioral|Orientation session|This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide written informed consent, and complete the baseline assessment.
79809167|NCT00670163|Behavioral|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
79809168|NCT00670163|Behavioral|Standard Care|Standard care will consist of usual care for STIs.
79809169|NCT00664079|Other|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
79975531|NCT02479984|Device|Laparoscopic ultrasound|
79479431|NCT04038255|Behavioral|Craving-to-Quit app|The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
79321227|NCT05990218|Device|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
79321228|NCT05990218|Device|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
79321229|NCT05990205|Drug|Life Style Intervention + Metformin|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
79321230|NCT05990205|Behavioral|Life Style Intervention|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week)
79321231|NCT05990179|Other|Genome sequencing-based newborn screening|Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
79321232|NCT05990153|Other|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
79321233|NCT05990153|Drug|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
79479432|NCT04038255|Behavioral|Two brief follow-up phone calls|The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.
79645221|NCT05423002|Other|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
79975532|NCT01265784|Drug|TP-434|
79975533|NCT01265784|Drug|Ertapenem|
79975534|NCT01265784|Drug|Placebo|Administered IV to maintain the blind.
79645222|NCT05423002|Other|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
79975535|NCT02485756|Other|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
79645223|NCT05423002|Other|Dim light|This light condition is the baseline (≤10 lux).
79645224|NCT00170417|Behavioral|Cognitive Behaviour Therapy|
79975536|NCT01315223|Other|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
79975537|NCT02479906|Device|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
79975538|NCT02479906|Device|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
79975539|NCT03778853|Drug|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
79975540|NCT02479750|Device|ColdZyme® mouth spray|
79645225|NCT00196872|Drug|Epirubicine|Epirbubicne is given
79809170|NCT00824382|Drug|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
79809171|NCT00824382|Drug|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
79809172|NCT00824382|Drug|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
79809173|NCT00824382|Drug|Placebo|2 puffs delivered by the RespimatÂ® inhaler
79809174|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
79645226|NCT00196872|Drug|Cyclophosphamide|Cyclophosphamide is given
79645227|NCT00196872|Drug|Taxol|Taxol is given
79645228|NCT00196872|Drug|Xeloda|Xeloda is given
79645229|NCT00196872|Drug|Ibandronat|Ibandronat is given
79645230|NCT04680325|Dietary Supplement|Juice daily consumption|Single-service bottles of juice were provided for 15 days of daily consumption in each arm
79645231|NCT00170456|Biological|rPA vaccine containing alhydrogel|
79645232|NCT00179283|Drug|sertraline|
79645233|NCT00179283|Drug|venlafaxine XR|
79809175|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
79809176|NCT00670319|Drug|Placebo|Placebo one tab orally per day
79809177|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
79809178|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
79809179|NCT00670397|Drug|HPPH|IV
79809180|NCT00708318|Drug|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
79809181|NCT00670475|Drug|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
79975541|NCT02479750|Device|Placebo|
79975542|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
79479433|NCT04038255|Behavioral|Group MT sessions|Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.
79645234|NCT05422807|Behavioral|BFST for Teens with Type 2 Diabetes|12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
79975543|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
79975544|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
79479434|NCT04038255|Behavioral|Brief advice on quitting smoking|Standard advice on how to quit smoking.
79479435|NCT04038255|Behavioral|Self-help smoking cessation materials|Written materials on how to quit smoking including contact info for state tobacco quitline.
79479436|NCT04031729|Drug|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
79645235|NCT04679974|Behavioral|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
79645236|NCT05420506|Device|NROT1|Dental anchored intestinal placement of obesity treatment device with endoscopic intervention
79479437|NCT04031729|Drug|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
79479438|NCT04024163|Drug|Benznidazole|Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
79975545|NCT03635814|Drug|YD312 50mg|YD312 50mg * 1 + placebo 6 tablets
79975546|NCT03635814|Drug|YD312 150mg|YD312 50mg * 3 + placebo 6 tablets
79975547|NCT03635814|Drug|YD312 350mg|YD312 50mg * 7 tablets
79479439|NCT04023019|Biological|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
79645237|NCT05420389|Other|breast massage|Mothers who were included in the breast massage group who met the research criteria were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale was filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
79645238|NCT05420389|Other|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
79975548|NCT03635814|Drug|Placebo|YD312 0mg * 7 tabets
79975549|NCT02485522|Other|No Intervention|No intervention
79975550|NCT04492852|Procedure|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
79975551|NCT04492852|Procedure|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
79645239|NCT05420389|Other|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the condition anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
79645240|NCT05420350|Drug|Lamotrigine and Bupropion|Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
79321234|NCT05990153|Other|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
79321235|NCT05990153|Other|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
79321236|NCT05990140|Other|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
79321237|NCT05990127|Drug|AK104|AK104 IV, q3w
79321238|NCT05990127|Drug|Tislelizumab|Tislelizumab IV, q3w
79321239|NCT05990127|Drug|carboplatin|carboplatin IV, q3w
79321240|NCT05990127|Drug|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
79321241|NCT05990127|Drug|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
79321242|NCT05990114|Other|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
79321243|NCT05990101|Behavioral|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
79321244|NCT05990088|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on the software algorithms|The patients will receive complete removable dentures designed based on the software algorithms and digitally manufactured using a milling machine.
79321245|NCT05990088|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
79645241|NCT05420350|Drug|Placebo|Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
79645242|NCT00170534|Behavioral|Behavior|
79645243|NCT03014635|Biological|Botulinum Toxins, Type A|Intramuscular injection
79321246|NCT05990062|Device|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
79479440|NCT04023019|Biological|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
79645244|NCT03014635|Biological|Placebos|Intramuscular injection
79645245|NCT00170573|Drug|Caelyx|Caelyx 40 mg/ m2biweekly
79645246|NCT00196911|Procedure|Implantation of stimulation electrodes in the STN|
79645247|NCT02885272|Procedure|Computed Tomography|Undergo PET/CT scans
79321247|NCT05990023|Other|Traditional vestibule rehabilitation training|"Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
79479441|NCT04023019|Biological|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
79479442|NCT04023019|Biological|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
79645248|NCT02885272|Radiation|Fludeoxyglucose F-18|Given IV
79302202|NCT03226093|Procedure|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
79479443|NCT04023019|Biological|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
79479444|NCT04023019|Biological|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
79645249|NCT02885272|Procedure|Magnetic Resonance Imaging|Undergo standard of care MRI
79645250|NCT02885272|Procedure|Positron Emission Tomography|Undergo PET/CT scans
79645251|NCT02793583|Biological|Ublituximab|
79479445|NCT04016402|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
79645252|NCT02793583|Drug|Umbralisib|
79809182|NCT00670475|Dietary Supplement|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
79809183|NCT00704886|Other|video|video of dementia
79809184|NCT04154033|Drug|Naltrexone|Topical naltrexone cream (1%)
79479446|NCT04014387|Drug|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
79645253|NCT02793583|Biological|Bendamustine|
79645254|NCT00170612|Biological|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
79645255|NCT00170612|Biological|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
79645256|NCT00196950|Biological|Meningococcal (vaccine)|
79645257|NCT02773966|Radiation|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
79645258|NCT02773966|Radiation|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
79645259|NCT00170690|Drug|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
79645260|NCT00170690|Drug|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
79645261|NCT02675569|Procedure|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
79645262|NCT02675569|Procedure|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
79645263|NCT00196989|Drug|Pioglitazone|
79645264|NCT00196989|Drug|GW677954|
79645265|NCT00170729|Drug|Prednisolone acetate|
79645266|NCT00170768|Drug|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
79645267|NCT00170768|Drug|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
79645268|NCT00170768|Drug|Placebo|Placebo once daily tablet (sham titration)
79645269|NCT00197067|Biological|RTS,S/AS02D and RTS,S/AS02A|
79645270|NCT02655562|Drug|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
79645271|NCT00170885|Drug|Everolimus|
79645272|NCT02607748|Other|18F-NaF PET and coronary CTA imaging|
79645273|NCT02502253|Drug|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract [GSE], and resveratrol) that contain abundant concentrations of polyphenols.
79809185|NCT04154033|Other|Placebo Cream|Topical placebo cream
79809186|NCT05530356|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
79809187|NCT05530356|Drug|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
79809188|NCT05530356|Drug|Dextran 40|Diagnostic aid/agent used to measure glomerular size selectivity
79809189|NCT05530356|Procedure|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
79809190|NCT05530356|Radiation|Positron Emission Tomography|Imaging study performed to study renal oxidative metabolism
79302203|NCT05011227|Drug|Camrelizumab|2 cycles before endoscopic surgery and one year after
79302204|NCT05011227|Drug|Chemotherapy|2 cycles before endoscopic surgery, with or without after surgery
79302205|NCT05011227|Procedure|endoscopic surgery|standard endoscopic surgery for recurrent nasopharyngeal carcinoma
79302206|NCT02487329|Other|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
79302207|NCT02487329|Other|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
79321248|NCT05990023|Other|Dual-task vestibule rehabilitation training|"Adding a dual task of digit countdown and recitation to clinical balance training exercises.~Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
79645274|NCT00179439|Procedure|nasal potential difference testing|
79321249|NCT05989984|Dietary Supplement|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
79321250|NCT05989984|Dietary Supplement|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
79321251|NCT05989971|Other|continuous renal replacement therapy|continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
79321252|NCT05989893|Behavioral|Language-based tasks|In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
79321253|NCT05989880|Device|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
79479447|NCT04014387|Drug|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
79645275|NCT05412667|Dietary Supplement|TWK10|"4 days without training: drink 2 hours before bedtime.~3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~To analyze the amino acid concentration in blood, drink it immediately before blood collection."
79809191|NCT00664313|Drug|Linezolid|600 mg po daily for 112 doses (16 weeks)
79645276|NCT05412667|Other|Placebo|"4 days without training: drink 2 hours before bedtime.~3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~To analyze the amino acid concentration in blood, drink it immediately before blood collection."
79479448|NCT04014387|Drug|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
79479449|NCT04005053|Drug|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
79645277|NCT00170924|Drug|Valsartan|
79645278|NCT01356940|Drug|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
79809192|NCT00664313|Drug|Placebo|Placebo given daily for 112 doses (16 weeks)
79645279|NCT01356940|Drug|placebo|identical placebo tablet administered bid for four weeks
79645280|NCT00197223|Biological|Influenza vaccine|
79645281|NCT00170963|Drug|valsartan/amlodipine|
79645282|NCT05405959|Device|Kinesio tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
79645283|NCT05405959|Device|Sham Kinesio Tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
79645284|NCT02492776|Drug|Omeprazole|20 mg oral capsules administered once daily for 8 days
79809193|NCT00670553|Drug|panobinostat|
79809194|NCT00664391|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
79645285|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
79645286|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
79645287|NCT02447614|Procedure|Adenotonsillectomy|Adenotonsillectomy
79479450|NCT04005053|Drug|Placebo oral tablet|Placebo
79645288|NCT02447614|Other|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
79645289|NCT02447614|Other|no treatment|just regular follow-up
79645290|NCT02963883|Other|SVO2 group / control group|
79645291|NCT05399563|Other||
79645292|NCT00171041|Drug|valsartan|
79645293|NCT05392699|Biological|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
79645294|NCT05392699|Biological|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
79321254|NCT05989880|Device|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
79975552|NCT03774953|Dietary Supplement|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
79975553|NCT05185752|Procedure|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
79975554|NCT05185752|Procedure|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
79321255|NCT05989880|Device|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
79479451|NCT04001179|Other|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
79479452|NCT03983512|Device|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
79479453|NCT03982225|Drug|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
79645295|NCT05392426|Device|Left Ventricular Global Longitudinal Strain|Left Ventricular Global Longitudinal Strain is collected from Speckle tracking imaging (STI) technique of echocardiography. This index is tested before and after the surgery.
79645296|NCT05392426|Device|EF CO SV EDV ESV|Ejection fraction、cardiac output、stroke volume、end diastolic volume、end systolic volume. These indexes are collected before and after the surgery, using traditional echocardiography.
79645297|NCT00179556|Drug|Isoflavone supplement|
79645298|NCT00171080|Drug|valsartan|
79645299|NCT00171080|Drug|irbesartan|
79645300|NCT05391568|Other|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
79645301|NCT05391568|Other|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
79645302|NCT02229877|Drug|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
79302208|NCT02487329|Other|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
79302209|NCT02487329|Other|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
79302210|NCT03226171|Drug|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
79302211|NCT03322085|Procedure|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
79302212|NCT05018715|Diagnostic Test|Machine learning model diagnosis|Machine learning model diagnosis
79302213|NCT03206515|Device|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
79302214|NCT03206515|Device|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
79302215|NCT03318731|Other|Sugar Pill|Taken orally in capsule form
79302216|NCT03318731|Dietary Supplement|Fenugreek Extract, Low Dose|Taken orally in capsule form
79302217|NCT03318731|Dietary Supplement|Fenugreek Extract, High Dose|Taken orally in capsule form
79302218|NCT03080103|Procedure|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
79302219|NCT03080103|Drug|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
79302220|NCT02487173|Device|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
79302221|NCT02487173|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
79302222|NCT02487173|Device|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
79302223|NCT03221413|Device|transcranial alternating current stimulation (tACS)|
79302224|NCT03221491|Device|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
79321256|NCT05989880|Device|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
79975555|NCT05185752|Procedure|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
79479454|NCT03982225|Drug|Placebo|Phosphate buffered saline placebo for injection
79479455|NCT03981796|Biological|Dostarlimab|Participants will be administered dostarlimab
79479456|NCT03981796|Drug|Placebo matching dostarlimab|Participants will be administered placebo matching dostarlimab
79645303|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
79975556|NCT02483026|Dietary Supplement|Multi vitamin|Multi vitamin
79645304|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
79809195|NCT00833040|Drug|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
79975557|NCT02483026|Dietary Supplement|vitamin D|Vitamin D
79479457|NCT03981796|Drug|Carboplatin|Participants will be administered carboplatin
79479458|NCT03981796|Drug|Paclitaxel|Participants will be administered paclitaxel
79479459|NCT03981796|Drug|Niraparib|Participants will be administered niraparib
79479460|NCT03981796|Drug|Placebo matching Niraparib|Participants will be administered placebo matching Niraparib
79645305|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
79645306|NCT00171119|Drug|valsartan|
79645307|NCT02122666|Procedure|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
79809196|NCT02629913|Device|mementor somnium|
79809197|NCT02629913|Other|wait list|delayed access to mementor somnium
79809198|NCT02629835|Other|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
79809199|NCT02629835|Other|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
79321257|NCT05989867|Diagnostic Test|blood test|"Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors"
79321258|NCT05989867|Device|Continuous Glucose Monitor|blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
79321259|NCT05989854|Behavioral|Exercise|8 week exercise intervention, 3x/wk
79321260|NCT05989815|Other|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
79321261|NCT05989815|Device|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
79321262|NCT05989789|Device|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
79479461|NCT03979040|Behavioral|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
79479462|NCT03979040|Behavioral|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
79645308|NCT02963961|Behavioral|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
79479463|NCT03971578|Other|No Intervention Provided|No Intervention Provided
79479464|NCT03961698|Drug|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
79645309|NCT00553228|Biological|Tdap|0.5 mL IM once at visit #2
79645310|NCT00553228|Biological|Td|0.5 mL IM once at visit #2
79645311|NCT02963688|Genetic|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
79645312|NCT00171236|Drug|Fluvastatin|
79645313|NCT01744171|Biological|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
79645314|NCT01744171|Other|Laboratory Biomarker Analysis|Correlative studies
79645315|NCT05357521|Other|stress test|TSST- psychosocial stress test
79645316|NCT00171275|Drug|Fluvastatin|
79479465|NCT03961698|Drug|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
79479466|NCT03961698|Drug|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
79975558|NCT02483104|Drug|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
79975559|NCT02483104|Drug|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
79975560|NCT02483104|Drug|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
79975561|NCT00116220|Drug|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
79645317|NCT05349448|Drug|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
79645318|NCT05349448|Drug|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
79645319|NCT00197262|Drug|GW685698X Aqueous Nasal Spray|
79645320|NCT00171353|Drug|valsartan|
79975562|NCT00116220|Radiation|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
79975563|NCT03785015|Other|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
79645321|NCT05347810|Other|Application of repetitive forces mimicking exoskeleton use|The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
79645322|NCT01656343|Drug|Calcineurin inhibitors (CNI)|No Intervention
79975564|NCT03785015|Other|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
79984684|NCT04939532|Behavioral|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
79984685|NCT03197740|Drug|Donepezil patch|Treatment
79302225|NCT03079479|Diagnostic Test|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
79645323|NCT01656343|Drug|Belatacept|No Intervention
79645324|NCT01550185|Drug|eltrombopag olamine|Given PO
79645325|NCT01550185|Procedure|standard follow-up care|Receive standard care
79645326|NCT01539811|Procedure|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
79645327|NCT01539811|Drug|Short course antibiotics|Short course (<2 weeks) of antibiotics will be prescribed
79645328|NCT01539811|Drug|Long course antibiotics|Long course (>2 weeks) of antibiotics will be prescribed
79645329|NCT01527136|Drug|entolimod|Given IM or SC
79321263|NCT05989659|Other|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
79321264|NCT05989646|Device|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
79645330|NCT01527136|Other|pharmacological study|Correlative studies
79645331|NCT01527136|Other|laboratory biomarker analysis|Correlative studies
79645332|NCT00171392|Drug|Enteric-coated mycophenolate sodium|
79984686|NCT03197740|Drug|aricept Tab|Comparator
79984687|NCT03197428|Other|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
79321265|NCT05989633|Other|Dermocosmetic product: Selenium Disluphide Shampoo (Dercos DS)|to assess the benefit of Dercos DS in subjects with dandruff
79321266|NCT05989607|Other|Lower sugar flavored water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
79321267|NCT05989607|Other|Plain Water|Commercially available bottled, spring water.
79321268|NCT05989594|Behavioral|Home-based mobile guided exercise-based cardiac rehabilitation|Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.
79321269|NCT05989594|Behavioral|Routine Care|Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
79321270|NCT05988879|Drug|Peginterferon alfa-2b Injection|The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
79321271|NCT05988593|Dietary Supplement|placebo|consume one bottle (30 mL) per day
79645333|NCT05331586|Behavioral|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
79645334|NCT00179595|Behavioral|relaxation response- meditation|
79645335|NCT05331430|Other|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
79645336|NCT00171431|Drug|Tegaserod|
79645337|NCT00197301|Biological|Vaccination|
79645338|NCT01330030|Drug|Selegiline|6mg/24 hrs for 8 weeks
79645339|NCT01330030|Other|matching placebo|placebo/24hrs for 8 weeks
79645340|NCT00171470|Drug|Tegaserod|
79645341|NCT00179634|Behavioral|Visualization relaxation|
79645342|NCT00179634|Behavioral|Visual Milieu Enhancement (Fine art photograph)|
79645343|NCT01280032|Radiation|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
79645344|NCT00171509|Drug|Cyclosporine microemulsion|
79645345|NCT00941356|Dietary Supplement|Bio-K+ CL1285|2 capsules per day before breakfast
79645346|NCT00941356|Dietary Supplement|Placebo|2 capsules per day before breakfast
79984688|NCT03197428|Other|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
79479467|NCT03961698|Drug|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
79479468|NCT03945643|Drug|Sildenafil|50mg administration of sildenafil, one time, one hour prior to measurements.
79975565|NCT02485678|Other|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
79302226|NCT03079479|Diagnostic Test|2D Kinematics Analysis|2D Kinematics Analysis of the gait
79302227|NCT04493021|Device|Dermal Cooling System|Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
79302228|NCT03077763|Drug|Sodium Nitrite|
79302229|NCT03120091|Device|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
79302230|NCT04955223|Drug|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
79302231|NCT03206281|Diagnostic Test|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
79302232|NCT04493099|Drug|Alvocidib Hydrochloride|Given IV
79302233|NCT04493099|Drug|Decitabine|Given IV
79302234|NCT04493099|Drug|Venetoclax|Given PO
79302235|NCT05004909|Drug|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
79302236|NCT03119545|Behavioral|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
79302237|NCT03077529|Dietary Supplement|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
79302238|NCT03077529|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
79975566|NCT02485678|Other|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
79975567|NCT02485678|Other|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
79975568|NCT05690555|Other|Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~Subjective assessment of bowel and bladder function~Visual and external palpation and assessment of external pelvic floor region~Intravaginal pelvic floor assessment~Pelvic floor muscle dynamics and coordination assessment~Instruction of pelvic floor coordination and lengthening~Discussion of dilator program and progression~Home program with instructions~6 weeks:~External scar assessment and treatment if tissue healing allows~Instruction to patient of scar mobilizations~Intravaginal pelvic floor assessment and treatment if indicated~Review of pelvic floor lengthening and coordination~Review and progression of dilator program if appropriate~Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
79321272|NCT05988593|Dietary Supplement|MelaGene+|consume one bottle (30 mL) per day
79645347|NCT05309512|Biological|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
79321273|NCT05987826|Drug|Furmonertinib|Furmonertinib 80mg QD oral 8 weeks.
79479469|NCT03945643|Other|Placebo|50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
79479470|NCT03938389|Drug|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
79645348|NCT00179712|Drug|CC-5013|
79645349|NCT00179712|Drug|topotecan|
79645350|NCT00611572|Drug|iomazenil|Given as IV infusion
79479471|NCT03938389|Drug|Valsartan 160mg|Participant will take Valsartan for 26 weeks
79645351|NCT00611572|Drug|iomazenil|saline IV infusion
79984689|NCT04050878|Device|Facial scanner (Bellus3D) to assess perioral alterations|Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
79302239|NCT03318575|Device|autoRIC|Automated Remote Ischemic Conditioning
79302240|NCT03318575|Device|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
79302241|NCT03119623|Drug|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
79302242|NCT03119623|Drug|Enalapril|enalapril 5mg, titrated up to 10mg po BID
79302243|NCT04463121|Device|Moderato IPG's CNT pacing signals|Assesment of cardiac function and sympatheric activity will be obtained simultaneously
79302244|NCT04463121|Device|CD Leycom Pressure/Volume Combination Catheters|Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
79302245|NCT03318419|Drug|Cladribine|5mg/㎡ d1-5
79302246|NCT03318419|Drug|G-CSF|300ug d0-14
79302247|NCT03318419|Drug|Cytarabine|10mg/㎡ q12h SC d1-14
79302248|NCT03318419|Drug|Pegaspargase|2500U/m2 im d1
79479472|NCT03938389|Drug|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
79645352|NCT00197340|Drug|Epidural ropivacaine|
79645353|NCT00171587|Drug|PTK787/ZK 222584 (vatalanib)|
79645354|NCT05261893|Other|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
79645355|NCT05261893|Other|Post Facilitation Stretching|Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
79645356|NCT00171626|Drug|Diclofenac Topical Sodium Gel 1%|
79645357|NCT05261854|Device|Pressure biofeedback|Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks
79645358|NCT05261854|Other|Conventional exercises for deep cervical muscle training|Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
79321274|NCT05985993|Device|low-intensity transcranial ultrasound stimulation (TUS)|The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
79321275|NCT05985824|Procedure|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
79321276|NCT05985421|Other|Fecal collection|approximate volume of 2 ml
79645359|NCT04723290|Diagnostic Test|Serological tests for SARS Cov-2|Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
79321277|NCT05985421|Other|Blood sampling|1 EDTA tube (7 ml) to test for chronic low-grade inflammation + 1 EDTA tube (7 ml) to test for intestinal inflammation, digestive permeability and microbial translocation
79321278|NCT05985421|Other|Polysomnography|Polysomnography
79479473|NCT03937973|Behavioral|Social rejection|Social rejection paradigm
79645360|NCT05261815|Other|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
79645361|NCT05261815|Other|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
79645362|NCT05259358|Other|exercise|exercises that increase muscular endurance
79645363|NCT00171665|Drug|Diclofenac topical sodium gel 1%|
79321279|NCT05985421|Other|Auto questionnaires|International RLS Study Group Severity Scale, Epworth Sleepiness Scale, Insomnia Severity Index, Beck Depression Inventory-II, Autonomic symtoms scale (SCOPA-AUT)
79321280|NCT05985356|Device|iTBS|iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
79321281|NCT05980286|Behavioral|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
79321282|NCT05980286|Behavioral|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
79321283|NCT05979701|Other|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
79645364|NCT00179751|Drug|CC-5013|
79645365|NCT00179751|Drug|gemcitabine|
79809200|NCT00664469|Drug|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
79809201|NCT00664469|Drug|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
79809202|NCT00664469|Drug|Comparator: Atorvastatin|Atorvastatin 20, 40 & 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
79645366|NCT05255419|Device|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
79645367|NCT05252806|Diagnostic Test|MRI examination of the prostate|Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement
79645368|NCT04710459|Procedure|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
79645369|NCT00171743|Drug|Cyclosporine microemulsion|
79645370|NCT00179790|Procedure|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
79984690|NCT02450266|Device|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
79302249|NCT03221647|Other|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
79302250|NCT03076827|Procedure|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
79302251|NCT03076827|Procedure|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
79302252|NCT03321851|Device|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
79645371|NCT00171782|Drug|VALSARTAN+HYDROCHLOROTHIAZIDE|
79645372|NCT02417701|Other|Laboratory Biomarker Analysis|Correlative studies
79645373|NCT02417701|Other|Pharmacological Study|Correlative studies
79645374|NCT02417701|Drug|Sapanisertib|Given PO
79645375|NCT00197379|Drug|roxithromycin|
79809203|NCT00664469|Drug|Comparator: Rosuvastatin|Rosuvastatin 10, 20 & 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
79809204|NCT00664547|Behavioral|Diet Weight Loss|
79809205|NCT00664547|Behavioral|Exercise Weight Loss|
79809206|NCT00664547|Behavioral|Exercise Without Weight Loss|
79809207|NCT02629757|Drug|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
79809208|NCT00843024|Drug|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
79984691|NCT02450266|Device|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
79809209|NCT00843024|Drug|Placebo|Placebo to match
79809210|NCT04154813|Drug|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
79809211|NCT04154813|Drug|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
79809212|NCT04154813|Behavioral|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
79809213|NCT04154813|Behavioral|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
79302253|NCT03221179|Biological|RO7049665|A single ascending dose (starting dose 1.5 micrograms [mcg])of RO7049665 will be administered SC.
79302254|NCT03221179|Biological|Placebo|Matching placebo will be administered SC once.
79302255|NCT05010447|Device|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
79302256|NCT03221101|Device|Home ventilator|
79302257|NCT03321773|Drug|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
79302258|NCT03321773|Drug|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
79302259|NCT03225703|Behavioral|Hopping|A unilateral, hopping based exercise programme lasting six months.
79302260|NCT03077217|Drug|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
79302261|NCT02487017|Procedure|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
79302262|NCT02487017|Biological|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
79302263|NCT05001243|Drug|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
79302264|NCT05001243|Drug|Pilocarpine Hydrochloride|Apply in the fellow eye
79302265|NCT05001243|Drug|Brimonidine Tartrate|Apply in the fellow eye
79302266|NCT03225781|Device|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
79321284|NCT05973838|Behavioral|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
79321285|NCT05968131|Other|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
79479474|NCT03929913|Device|Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)|The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
79809214|NCT00664703|Drug|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
79645376|NCT04723745|Behavioral|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
79809215|NCT00664703|Drug|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
79975569|NCT05690555|Other|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
79984692|NCT03197116|Other|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
79984693|NCT03197116|Other|No other|No additional reminder will be offered
79984694|NCT02444962|Device|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
79809216|NCT00664703|Drug|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
79809217|NCT00670787|Drug|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
79809218|NCT00664781|Drug|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
79984695|NCT04200989|Biological|Peanut allergen|Intralymphatic immunotherapy injections.
79984696|NCT02450110|Device|Spinal cord stimulation|
79479475|NCT03927820|Other|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
79479476|NCT03908736|Drug|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
79479477|NCT03905928|Other|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
79975570|NCT05690555|Other|Preoperative PFPT and Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
79321286|NCT05968131|Other|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
79479478|NCT03905928|Other|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
79645377|NCT04723745|Behavioral|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
79645378|NCT04723745|Behavioral|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
79479479|NCT03905928|Other|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
79809219|NCT00664781|Genetic|protein expression analysis|
79479480|NCT03905928|Other|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
79645379|NCT04723745|Behavioral|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
79479481|NCT03882203|Drug|CLAGE-FluBu|Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
79479482|NCT03880500|Other|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
79645380|NCT04723745|Behavioral|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
79645381|NCT04723745|Behavioral|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
79479483|NCT03872700|Drug|Intranasal fentanyl|Fentanyl Citrate
79645382|NCT00197418|Drug|rabeprazole, amoxicillin, clarithromycin, metronidazole|
79645383|NCT05101369|Drug|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
79645384|NCT00171821|Drug|Deferasirox|
79645385|NCT00179829|Procedure|WT 1 Testing|
79809220|NCT00664781|Genetic|western blotting|
79809221|NCT00664781|Other|immunohistochemistry staining method|
79809222|NCT00664781|Other|liquid chromatography|
79321287|NCT05967858|Other|observation|no intervention
79321288|NCT05965505|Drug|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
79321289|NCT05963230|Other|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
79321290|NCT05959018|Device|Arrow Three-Lumen Central Venous Catheter|Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
79321291|NCT05959018|Device|Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
79809223|NCT00664781|Other|mass spectrometry|
79809224|NCT00664781|Other|pharmacological study|
79809225|NCT04154969|Other|Physiotherapy including Vestibular rehabilitation|vestibular exercise (VOR TX1)
79809226|NCT04154969|Other|conventional Physiotherapy|conventional Physiotherapy
79809227|NCT00670865|Other|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
79321292|NCT05949190|Dietary Supplement|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
79321293|NCT05949190|Dietary Supplement|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
79321294|NCT05949190|Drug|Azithromycin|1g dose
79321295|NCT05949190|Drug|Albendazole|400mg dose
79321296|NCT05949190|Drug|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
79321297|NCT05949190|Behavioral|Cognitive behavioral therapy|Novel program developed for illiterate end-users
79321298|NCT05949190|Other|Insecticide-treated mosquito net|Bed net to prevent malaria
79321299|NCT05945017|Dietary Supplement|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
79321300|NCT05940077|Behavioral|Exercise|Community-based exercise involving non-contact boxing and individualized balance training
79321301|NCT05918601|Other|Health-risk behaviors|Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.
79321302|NCT05918601|Other|Theory of planned behavior, Self-determination theory|The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.
79321303|NCT05918601|Other|Assist them to adhere to their schedule of quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.
79321304|NCT05918601|Other|Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.
79321305|NCT05918601|Other|(AWARD) model|Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model
79321306|NCT05918601|Other|Receive four independent 1-minute videos|The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
79479484|NCT03872700|Drug|Placebo|Sterile Water Up to 5Cc
79479485|NCT03870386|Procedure|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
79479486|NCT03870386|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
79479487|NCT03858153|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
79479488|NCT03858153|Behavioral|Nutrition Education|12 weeks of implementing eating tips and tracking food.
79479489|NCT03852108|Other|Comfort Care|Face, Hand and body care for 15 to 45 minutes
79479490|NCT03846310|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
79479491|NCT03846310|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
79479492|NCT03846310|Drug|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
79479493|NCT03846310|Drug|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
79479494|NCT03846310|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
79479495|NCT03844347|Behavioral|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
79479496|NCT03832192|Behavioral|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
79479497|NCT03811964|Other|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
79479498|NCT03808870|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
79479499|NCT03776461|Device|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
79479500|NCT03766971|Behavioral|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
79479501|NCT03766971|Behavioral|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
79479502|NCT03766971|Drug|Cannabis|Participants will receive cannabis.
79479503|NCT03764696|Device|tight-fitting simple facemask|Oxygen will be administered by facemask at 10 L/min oxygen. The therapy will continue until after delivery
79479504|NCT03757832|Device|Liver Imaging|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality.
79321307|NCT05918159|Other|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
79321308|NCT05915949|Drug|Dapagliflozin 10mg Tab|Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
79479505|NCT03753347|Biological|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
79809228|NCT00670943|Other|Platelet function testing|
79975571|NCT05690555|Other|Cross-over Treatment|Any patients in the No PFPT arm who are determined to have pelvic floor dysfunction or symptoms that may benefit from PFPT referral, will be referred after the 12-week mark. Any patient in one of the PFPT arms who is determined to still need PFPT for persistent pelvic floor dysfunction or symptoms will be referred for continued care.
79975572|NCT01336452|Radiation|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
79321309|NCT05915949|Drug|Lobeglitazone 0.5 mg|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
79321310|NCT05915949|Drug|Dapagliflozin + Lobeglitazone|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
79321311|NCT05910437|Other|Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
79321312|NCT05902455|Procedure|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
79809229|NCT00832650|Drug|fesoterodine fumarate|8 mg OD for 14 days
79809230|NCT00832650|Drug|placebo|OD for 14 days
79809231|NCT00832650|Drug|solifenacin|10 mg OD for 14 days
79975573|NCT04492228|Other|Ketogenic diet|Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: <30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: <30g/day)
79975574|NCT01333176|Procedure|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If < 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result >6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~Did the clients who were counseled to do so get follow-up blood tests?~Were all the formal diagnostic tests performed?~Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~Did the family physicians find this useful?"
79975575|NCT01333176|Procedure|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
79975576|NCT01333176|Procedure|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
79975577|NCT01333176|Procedure|Blood test|HbA1c blood test
79975578|NCT01333176|Procedure|Blood test|HbA1c finger poke blood test
79975579|NCT03784859|Device|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
79975580|NCT05185596|Device|Transesophageal Echocardiography|transesophageal Echocardiography during advanced life support
79975581|NCT05185518|Device|Use of novel insulin injection port|use subcutaneous port into which glucose monitor is embedded
79975582|NCT03778775|Diagnostic Test|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
79975583|NCT03316690|Drug|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
79975584|NCT03316690|Drug|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
79975585|NCT03316690|Behavioral|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
79975586|NCT01333254|Procedure|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
79975587|NCT03315052|Drug|Budesonide|Oral steroid with high first-pass metabolism in liver
79975588|NCT03315052|Drug|Tacrolimus（FK506）|Calcineurin immunosuppressant
79975589|NCT03315052|Drug|Mycophenolate Mofetil|Immunosupressant
79321313|NCT05888441|Other|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast."
79321314|NCT05874037|Drug|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
79321315|NCT05864573|Biological|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
79321316|NCT05855941|Diagnostic Test|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
79645386|NCT05070442|Behavioral|Norm-based messaging and peer comparison features|"Participants are shown a version of NUSMart which includes Nutri-Score labels that are enabled and displayed besides all the products in the store. Additionally, they are shown a video that gives them background information about Nutri-Score labels and describes the following features enabled in this intervention:~Norm-based messaging will be displayed in the form of a happy or sad emoticon based on whether the participant's current basket average Nutri-Score (weighted by number of servings) is above or below other shoppers (Nutri-Score=3.98).~Peer comparison will be implemented as a vertical ruler display of the participant's current basket average Nutri-Score (weighted by number of servings) as well as that of their peers.~Nutri-Score=3.98 was chosen as it is 10% better than the mean Nutri-Score of baskets purchased by participants in the Nutri-Score labelled intervention arm of a prior study."
79645387|NCT05070442|Behavioral|Financial Incentives leveraging on loss aversion|"Participants are informed that they have received an additional $5 towards their participant reimbursement. However, this amount will be forfeited if they check-out with a basket average Nutri-Score (weighted by the number of servings) that falls below the average Nutri-Score of other shoppers i.e. 3.98. An indicator on the screen that informs the participants of this potential forfeiting will be included."
79975590|NCT03315052|Drug|Prednisone|Immunosuppresant
79975591|NCT05187468|Device|Extracorporeal Shockwave Therapy|1000 pulses at 60 mj, 10 Hz
79975592|NCT05187468|Device|Extracorporeal Shockwave Therapy|2000 pulses at 60 mj, 10 Hz
79479506|NCT03749967|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
79975593|NCT05187468|Device|Ultrasound therapy, Massage, Heat pack|Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
79975594|NCT03778697|Procedure|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
79975595|NCT05187390|Procedure|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
79479507|NCT03738800|Drug|CD5789 Cream 200 µg/g|A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
79975596|NCT02482948|Device|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
79321317|NCT05840198|Behavioral|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
79479508|NCT03738800|Drug|CD5789 Cream 100 µg/g|A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
79975597|NCT02482948|Drug|Collagenase|Study agent to be applied daily to the wound.
79975598|NCT03779321|Other|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
79975599|NCT05690477|Procedure|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
79975600|NCT02482792|Other|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
79321318|NCT05840198|Other|Treatment as usual|Youth in this condition receive treatment as usual from their health care providers
79321319|NCT05825365|Drug|Selumetinib|Selumetinib
79321320|NCT05825365|Drug|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
79321321|NCT05814939|Drug|VC005 tablets|VC005 groups repeat administration for 12 weeks
79321322|NCT05814939|Drug|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
79321323|NCT05814939|Drug|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
79975601|NCT02482792|Other|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
79321324|NCT05811234|Drug|CAL/BDP PAD Cream|As provided in real-world clinical practice.
79321325|NCT05795049|Other|Stool and saliva sample collection|Stool and saliva samples collection
79321326|NCT05795049|Other|Questionnaire completion|"Questionnaire on;~demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~IBS severity score for adults~Hospital Anxiety and Depression scores for adults~Somatization score for adults~Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~Quality of Life as measured by the PedsQL™ GI Symptoms Module~GI symptoms as measured by the PedsQL™ GI Symptoms Module~Anxiety, Depression as measured by the Pediatric PROMIS®"
79479509|NCT03738800|Drug|CD5789 Cream Vehicle|A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
79479510|NCT03738670|Procedure|Percutaneous RFA|Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
79975602|NCT03778619|Drug|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
79975603|NCT03778619|Drug|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
79975604|NCT03778619|Drug|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
79975605|NCT03778619|Biological|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
79975606|NCT03778619|Drug|Interleukin-2|1 x 10^6 IU/m2, together with MG4101
79975607|NCT05714176|Drug|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
79975608|NCT05714176|Drug|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
79975609|NCT05714176|Drug|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
79975610|NCT03156504|Drug|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
79975611|NCT03316612|Dietary Supplement|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
79975612|NCT03316612|Dietary Supplement|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
79975613|NCT05187312|Procedure|Endoscopic retrograde Cholangio- pancreatography|Endoscopic intervention in the biliary or pancreatic duct
79975614|NCT05187312|Procedure|Endoscopic ultrasound|Endoscopic investigation/intervention with ultrasound
79975615|NCT01333332|Drug|Capecitabine|Capecitabine
79975616|NCT01333332|Radiation|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
79975617|NCT01308827|Procedure|Blood culture|A baseline blood culture will be obtained in all participants
79975618|NCT01308827|Procedure|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
79975619|NCT03316534|Drug|Aspirin|Aspirin (100 mg once a day)
79975620|NCT01338948|Procedure|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
79975621|NCT05498051|Procedure|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
79975622|NCT04476420|Dietary Supplement|Nigella sativa oil|Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
79975623|NCT04476420|Drug|Betamethasone Valerate|it is a conventionally used drug for treating OSMF
79975624|NCT03778463|Other|Synovectomy|Removal of the synovium during total knee arthroplasty
79975625|NCT03314896|Procedure|Laparoscopic surgery|
79975626|NCT03778541|Drug|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
79975627|NCT03778541|Radiation|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
79975628|NCT03159468|Behavioral|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
79975629|NCT03159468|Behavioral|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
79809232|NCT00708396|Drug|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
79479511|NCT03734640|Other|Low-intensity monitoring strategy|Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment
79645388|NCT00179868|Behavioral|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~Acute GVHD > grade II defined according to the Seattle criteria~VOD- defined according to the modified Seattle criteria"
79809233|NCT00671021|Other|Platelet aggregation|Platelet aggregation TxA2 formation
79321327|NCT05786014|Behavioral|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
79479512|NCT03734640|Other|Guideline recommended standard monitoring|Post-tpa patients will be monitored in the usual care monitoring environment
79479513|NCT03734055|Behavioral|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
79645389|NCT05054023|Drug|Soulagel®|topic gel
79645390|NCT05054023|Drug|Arthrosyl®|topic gel
79645391|NCT00171860|Drug|imatinib mesylate|
79975630|NCT03159468|Other|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
79975631|NCT02479828|Drug|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
79975632|NCT02479828|Drug|Ropivacaine|
79321328|NCT05786014|Behavioral|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
79321329|NCT05783505|Other|Multicomponent intervention program|Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
79479514|NCT03734055|Behavioral|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
79479515|NCT03729752|Drug|[89]Zr-DFO-VRC-HIVMAB060-00-AB|Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
79479516|NCT03725345|Behavioral|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
79479517|NCT03720678|Drug|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
79321330|NCT05782686|Procedure|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
79479518|NCT03720678|Drug|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
79479519|NCT03719326|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist for oral use
79645392|NCT00553930|Drug|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
79479520|NCT03719326|Drug|IPI-549|IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
79479521|NCT03719326|Drug|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
79479522|NCT03719326|Drug|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor for intravenous (IV) use
79479523|NCT03717909|Drug|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
79645393|NCT00553930|Drug|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of >= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
79645394|NCT00179907|Procedure|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors < 20 mm, 21-25 mm and 26-40 mm respectively
79809234|NCT04153799|Biological|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10^6/kg CAR positive T cells; The second dose group: 1.58 × 10^6 / kg CAR positive T cells; The third dose group: 5 × 10^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
79479524|NCT03717909|Drug|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
79479525|NCT03715478|Drug|GSK2857916 with Pomalidomide and Dexamethasone|Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
79479526|NCT03711097|Drug|Vanish XT Dental Varnish|Varnish will be applied to the front surface of the intervention upper central and lateral incisors
79479527|NCT03709043|Drug|Standardized kudzu|Standardized kudzu
79479528|NCT03709043|Other|Placebo|Placebo
79479529|NCT03709043|Diagnostic Test|Sexually transmitted infection testing:|At baseline and month 3 visits, all participants will be tested for syphilis (serum RPR), Neisseria gonorrhea and Chlamydia trachomatis (urine, pharyngeal swab, and rectal swab nucleic acid amplification [NAAT]) through an established protocol that has been validated by our Public Health Laboratory (PHL) and others.145-149
79809235|NCT00671099|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
79479530|NCT03709043|Behavioral|Medical Management (MM) counseling for alcohol use:|MM has been used in a targeted pharmacotherapy trial98 and our team has successfully used MM in AUD trials. MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist.
79479531|NCT03709043|Diagnostic Test|Urinalysis for novel alcohol biochemical markers for recent alcohol use:|Urine samples will be collected at Enrollment, Month 1, Month 2 and Month 3 visits and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption in the past three days. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours.
79321331|NCT05732389|Drug|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
79479532|NCT03709043|Diagnostic Test|Dried Blood Spot (DBS) Testing for PEth:|DBS samples will be collected at enrollment, weeks 12, and post-treatment visits at month 3. Samples will be dried overnight using standardized methods. PEth testing of DBS samples will be conducted at the United States Drug Testing Laboratories in Des Plaines, IL using liquid chromatography-tandem mass spectrometry system following extraction into methanol.
79975633|NCT02479828|Device|ultrasound|
79479533|NCT03709043|Behavioral|Behavioral survey measurements:|Standardized and validated behavioral measures will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection.152,153 To minimize potential social desirability bias, staff will not have access to data during the trial. The draft of the ACASI survey instrument is included in the appendix.
79479534|NCT03709043|Behavioral|Ecological Momentary Assessment procedure:|Participants will receive daily SMS texts to collect data on alcohol consumption, number of drinks on drinking days, targeted medication administration prior to anticipated drinking sessions, and sexual risk behaviors
79479535|NCT03700138|Drug|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
79645395|NCT05038345|Procedure|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
79809236|NCT00671099|Dietary Supplement|Placebo|Placebo
79479536|NCT03700138|Drug|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
79479537|NCT03688464|Drug|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
79479538|NCT03688464|Drug|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
79479539|NCT03688464|Drug|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
79645396|NCT00171899|Drug|imatinib mesylate|
79645397|NCT00197457|Procedure|serum pepsinogen|
79645398|NCT00197457|Procedure|urea breath test|
79645399|NCT00171938|Drug|imatinib mesylate|
79809237|NCT00665093|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
79809238|NCT00665093|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
79975634|NCT02479828|Drug|Placebo|
79975635|NCT01320449|Drug|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
79975636|NCT01320449|Behavioral|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
79975637|NCT01320449|Other|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
79321332|NCT05732389|Drug|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
79479540|NCT03682055|Drug|VK-2019|EBNA1 inhibitor
79479541|NCT03677999|Diagnostic Test|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
79479542|NCT03677973|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
79479543|NCT03677973|Other|Placebo|Matching Placebo
79975638|NCT02482714|Behavioral|Physical activity.|Have subject do moderate physical activity.
79975639|NCT02479672|Device|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
79975640|NCT02479672|Procedure|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
79975641|NCT02479672|Device|VividTrac®|
79479544|NCT03668002|Procedure|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
79479545|NCT03668002|Procedure|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
79479546|NCT03666065|Drug|Aspart insulin|Standard insulin
79975642|NCT05187234|Other|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
79321333|NCT05716841|Other|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
79479547|NCT03664518|Drug|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50~150×109/L，the eltrombopag dose Maintain. platelet count between 150~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
79645400|NCT05003050|Other|Meditation|Holistic natural therapy
79645401|NCT05003050|Other|Pranic Healing|Energy therapy
79975643|NCT03774251|Biological|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
79479548|NCT03654716|Drug|ALRN-6924|ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
79975644|NCT03774251|Device|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
79975645|NCT03314818|Device|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
79975646|NCT03430063|Drug|SDREGN2810|Standard dose intravenous (IV) infusion
79809239|NCT00595517|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
79975647|NCT03430063|Drug|SDREGN2810/ipi|Combination therapy dose IV
79975648|NCT03430063|Drug|HDREGN2810|High dose IV
79975649|NCT02485366|Drug|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
79975650|NCT02485366|Procedure|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
79809240|NCT00671255|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
79975651|NCT01308905|Device|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
79975652|NCT03158220|Biological|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
79975653|NCT04492462|Other|Formal Physical Therapy|Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
79809241|NCT00671255|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
79809242|NCT00671255|Drug|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
79809243|NCT00911651|Drug|Salbutamol|400 µg inhalation once
79302267|NCT04492631|Dietary Supplement|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
79302268|NCT04492631|Other|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
79302269|NCT03225469|Behavioral|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
79302270|NCT05397899|Other|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
79302271|NCT05397899|Other|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
79809244|NCT00911651|Drug|ipratropium bromide|80 µg inhalation once
79809245|NCT00665249|Behavioral|Motivational Interviewing|See MotivationalInterviewing.org
79975654|NCT04492462|Other|Self-directed Physical Therapy|Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
79975655|NCT01308983|Drug|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
79975656|NCT03718585|Other|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
79975657|NCT03316456|Diagnostic Test|Observational: Stool Sample Collection|"Observational: Stool Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
79975658|NCT03316456|Diagnostic Test|Observational: Blood Sample Collection|"Observational: Blood Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
79975659|NCT03316456|Diagnostic Test|Observational: Urine Sample Collection|"Observational: Urine Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
79645402|NCT02351947|Other|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
79321334|NCT05712408|Behavioral|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
79321335|NCT05699538|Behavioral|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
79479549|NCT03654716|Drug|Cytarabine|Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
79479550|NCT03650101|Procedure|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
79479551|NCT03649958|Device|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
79479552|NCT03649958|Device|Cereset 2x|Cereset 2x for five 90 minute sessions
79479553|NCT03644342|Drug|Nirapaib|(see treatment regimen and method of treatment assignment)
79479554|NCT03629756|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
79479555|NCT03629756|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
79645403|NCT00179946|Procedure|HLA typing|
79645404|NCT00171977|Drug|Imatinib Mesylate|
79645405|NCT04679662|Device|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
79645406|NCT04679545|Drug|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
79645407|NCT04679545|Drug|Placebo|An inactive compound.
79479556|NCT03629743|Device|EEG|EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
79645408|NCT04679701|Device|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
79645409|NCT02240407|Genetic|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10^13 vg per TA muscle (range of 7.64 x 10^11 vg/gm to 4.6 x 10^11 vg/gm based on TA weight).
79645410|NCT02240407|Drug|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
79645411|NCT02240407|Other|saline|Same volume as rAAV9-DES-hGAA injection will be used.
79645412|NCT02240407|Drug|Rituxan|Patients will receive Rituxan (dose: 750 mg/m^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m^2.
79645413|NCT02240407|Drug|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
79645414|NCT02240407|Drug|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
79645415|NCT02240407|Drug|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
79645416|NCT02240407|Drug|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
79645417|NCT00172016|Drug|Zoledronic acid|
79645418|NCT04950673|Device|Cognivue|Computerized Cognitive Assessment Device
79645419|NCT00197613|Drug|(A) zidovudine, lamivudine and nevirapine|
79645420|NCT00197613|Drug|(B) zidovudine, lamivudine and efavirenz|
79645421|NCT00197613|Drug|(C) zidovudine, didanosine, and nevirapine|
79645422|NCT00197613|Drug|(D) zidovudine, didanosine, and efavirenz|
79645423|NCT00197613|Drug|(E) stavudine, lamivudine, and nevirapine|
79645424|NCT00197613|Drug|(F) stavudine, lamivudine and efavirenz|
79645425|NCT00197613|Procedure|Adherence Strategy Standard of Care (SOC)|
79645426|NCT00197613|Procedure|Adherence Strategy Community-Based DOT|
79645427|NCT00180024|Drug|irbesartan (drug)|
79645428|NCT00172055|Drug|Zoledronic acid|
79645429|NCT04941313|Drug|3D229|3D229 is an investigational drug.
79645430|NCT04941313|Other|Placebo|Matching placebo
79645431|NCT04934449|Device|Occlusal splint|Using occlusal splints during sleep for 2 months
79645432|NCT04682275|Other|Psychological measurements|A questionnaire test (Beck depression Inventory) for depression was performed.
79645433|NCT00172094|Drug|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
79645434|NCT00172094|Drug|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
79479557|NCT03629743|Device|ECOG|ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
79321336|NCT05698511|Drug|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
79321337|NCT05690672|Diagnostic Test|Delirium Screening|Either 3D-CAM or 4AT
79321338|NCT05675488|Diagnostic Test|Ultrasound|Thickness of flexor tendon and A1 pulley at MCP joint level
79645435|NCT00172094|Drug|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
79645436|NCT00197691|Procedure|blood draws, etc.|
79321339|NCT05671029|Drug|Pritelivir and moxifloxacin placebo|oral administration
79321340|NCT05671029|Drug|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
79321341|NCT05671029|Drug|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
79321342|NCT05669443|Device|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
79321343|NCT05669443|Device|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
79321344|NCT05653921|Other|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
79479558|NCT03629613|Dietary Supplement|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
79645437|NCT03455179|Other|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
79645438|NCT03455179|Other|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
79645439|NCT03455179|Other|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
79321345|NCT05643469|Other|Self-determination theory-based intervention plus instant messaging|subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.
79321346|NCT05643469|Other|AWARD model|Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
79321347|NCT05638581|Biological|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
79321348|NCT05638581|Biological|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
79321349|NCT05633615|Biological|Axicabtagene Ciloleucel|Given IV
79321350|NCT05633615|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79321351|NCT05633615|Procedure|Computed Tomography|Undergo PET-CT or CT
79321352|NCT05633615|Drug|Cyclophosphamide|Given IV
79321353|NCT05633615|Drug|Fludarabine|Given IV
79321354|NCT05633615|Biological|Lisocabtagene Maraleucel|Given IV
79321355|NCT05633615|Biological|Mosunetuzumab|Given IV
79645440|NCT04682002|Other|Osteopathic manipulative treatment|"OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken."
79645441|NCT04682002|Other|Usual care|Administration of routine care based on international guidelines
79321356|NCT05633615|Other|Patient Observation|Undergo observation
79321357|NCT05633615|Drug|Polatuzumab Vedotin|Given IV
79321358|NCT05633615|Procedure|Positron Emission Tomography|Undergo PET-CT
79321359|NCT05633615|Biological|Tisagenlecleucel|Given IV
79809246|NCT00665249|Behavioral|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
79975660|NCT03774017|Procedure|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
79479559|NCT03629613|Other|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
79479560|NCT03628677|Drug|Domvanalimab|Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
79479561|NCT03628677|Drug|Zimberelimab|Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
79479562|NCT03619083|Other|SAE battery|The SAE battery yields 12 variables.
79479563|NCT03619083|Behavioral|Assessments|Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
79975661|NCT03774017|Procedure|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
79321360|NCT05619510|Behavioral|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
79321361|NCT05608070|Drug|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
79975662|NCT02484976|Behavioral|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
79321362|NCT05608070|Drug|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
79321363|NCT05587543|Behavioral|PK Blood Collection|All subjects were subjected to PK blood sampling as prescribed by the protocol.
79321364|NCT05587543|Drug|CAR|Target A positive subjects will receive CAR-T cell therapy.
79645442|NCT04682002|Other|Mindfulness|Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.
79645443|NCT04682002|Other|Yoga|Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.
79645444|NCT04682002|Other|Clinical nutrition|Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.
79321365|NCT05587543|Drug|TCR|Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
79321366|NCT05587504|Other|E-cigarette with sweetness type 1 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1."
79321367|NCT05587504|Other|E-cigarette with sweetness type 1 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2."
79321368|NCT05587504|Other|E-cigarette with sweetness type 2 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1."
79321369|NCT05587504|Other|E-cigarette with sweetness type 2 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2."
79479564|NCT03617952|Behavioral|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
79479565|NCT03594448|Procedure|Specimen Collection|Undergo collection of blood samples
79479566|NCT03594448|Procedure|Serial Liquid Biopsy|Undergo serial liquid biopsy
79479567|NCT03586895|Behavioral|e-Connect|e-Connect
79321370|NCT05579470|Behavioral|NIATx|For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (<4 weeks).
79321371|NCT05564130|Drug|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
79479568|NCT03584217|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
79479569|NCT03584217|Drug|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
79645445|NCT04682002|Other|Coaching|There will be five personalized coaching sessions during the pregnancy.
79645446|NCT04895254|Device|Diagnostic colonoscopy|The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
79645447|NCT04895254|Procedure|Therapeutic colonoscopy|The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
79645448|NCT02909062|Device|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
79645449|NCT02909062|Behavioral|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
79975663|NCT01336842|Drug|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
79975664|NCT02485132|Other|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
79975665|NCT03785171|Procedure|surgical revascularization|Indirect revascularization procedure
79975666|NCT02485210|Procedure|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
79975667|NCT03156270|Device|Vivaer Stylus|Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
79321372|NCT05564130|Drug|Sodium chloride|Sodium chloride 9 mg/mL
79321373|NCT05553691|Drug|SPL026|Intravenous
79479570|NCT03584217|Procedure|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
79479571|NCT03583086|Drug|Vorolanib|Given by mouth
79479572|NCT03583086|Biological|Nivolumab|Given by IV
79479573|NCT03568292|Other|Best Practice|Receive standard of care
79479574|NCT03568292|Other|Laboratory Biomarker Analysis|Correlative studies
79479575|NCT03568292|Device|Oculus Rift Headset|Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure
79479576|NCT03568292|Other|Questionnaire Administration|Ancillary studies
79321374|NCT05528926|Other|Non-Violent Resistance|"The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
79479577|NCT03557710|Behavioral|Devaluing energy-dense foods for cancer-control|A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
79479578|NCT03549520|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
79479579|NCT03547518|Device|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
79645450|NCT00172133|Drug|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
79645451|NCT00202293|Drug|Olanzapine|
79975668|NCT02485054|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
79479580|NCT03547518|Device|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
79975669|NCT01339026|Drug|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
79975670|NCT01339026|Drug|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
79975671|NCT03429049|Drug|CNTX-4975-05|Receiving CNTX-4975-05 injection
79479581|NCT03543098|Procedure|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
79645452|NCT00202293|Drug|Lithium|
79645453|NCT00202293|Drug|Chlorpromazine|
79645454|NCT02908867|Other|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
79645455|NCT00197730|Drug|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
79645456|NCT00197730|Drug|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
79809247|NCT00665249|Other|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
79809248|NCT00665327|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
79975672|NCT03429049|Drug|Placebo|Receiving Placebo injection
79975673|NCT03314740|Drug|Paclitaxel|Comparator active compound
79975674|NCT03314740|Drug|Cediranib|Experimental compound
79975675|NCT03314740|Drug|Olaparib|Experimental compound
79975676|NCT02482558|Other|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
79645457|NCT02909023|Biological|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
79321375|NCT05528926|Other|Parent Management Training|"The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
79321376|NCT05528926|Drug|Treatment As Usual|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
79321377|NCT05526534|Device|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% ~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
79321378|NCT05526534|Device|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
79321379|NCT05515848|Other|No intervention|There is no intervention in this retrospective study.
79645458|NCT02908828|Dietary Supplement|Calanus oil|
79645459|NCT02908828|Dietary Supplement|placebo dietary oil|
79645460|NCT00172172|Drug|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
79645461|NCT00172172|Drug|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
79479582|NCT03543098|Procedure|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
79479583|NCT03543098|Procedure|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
79479584|NCT03543098|Procedure|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
79479585|NCT03542578|Device|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
79479586|NCT03534804|Drug|Cabozantinib|Cabozantinib is administered at 40 mg oral daily
79479587|NCT03534804|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
79479588|NCT03532477|Drug|Venlafaxine|Patients are tested for their normal prescription metaprolol medication
79645462|NCT00172172|Drug|placebo|Placebo injected subcutaneously and 700 mg calcium orally
79645463|NCT02908711|Drug|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
79645464|NCT00202332|Procedure|Coronary artery bypass|
79809249|NCT00665327|Drug|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
79302272|NCT05010135|Device|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
79302273|NCT03225391|Behavioral|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
79302274|NCT03225391|Behavioral|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
79302275|NCT05009745|Procedure|PGT-A Strategy|PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
79302276|NCT03205891|Drug|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
79302277|NCT03205891|Drug|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
79302278|NCT03205891|Device|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
79302279|NCT05010057|Dietary Supplement|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
79302280|NCT05010057|Dietary Supplement|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
79302281|NCT03221023|Drug|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
79302282|NCT03221023|Drug|Saline Solution|Individuals in the control arm will receive intrawound saline solution
79302283|NCT02490839|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
79321380|NCT05509972|Device|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
79321381|NCT05455606|Other|Best Practice|Receive usual care
79321382|NCT05455606|Other|Chart Abstraction|Ancillary studies
79479589|NCT03524742|Other|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
79479590|NCT03524742|Other|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
79655798|NCT04546048|Behavioral|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
79975677|NCT01339104|Drug|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
79975678|NCT03778151|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
79975679|NCT03428815|Device|Prosthesis suspension liner|Liners out of phase change material will be fitted
79479591|NCT03524430|Procedure|Core needle biopsy|"1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin."
79479592|NCT03519347|Other|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
79975680|NCT02482480|Other|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
79975681|NCT02482480|Other|Control|Dietary and general recommendations
79975682|NCT05187078|Procedure|Allis clamp|Physicians utilized an Allis clam for cervical stabilization during IUD placement.
79975683|NCT05187078|Procedure|Single-tooth tenaculum|Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
79975684|NCT05681507|Drug|Transversus thoracic muscle plane block|Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
79975685|NCT05681507|Procedure|Standard postoperative analgesia|Standard of postoperative ICU analgesic care, per institutional protocol
79975686|NCT02482636|Biological|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
79975687|NCT02482636|Biological|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
79975688|NCT02482636|Biological|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
79321383|NCT05455606|Other|Educational Intervention|Physicians access genomic testing education materials
79321384|NCT05455606|Procedure|Genomic Profile|Patients undergo genomic testing
79321385|NCT05455606|Other|Interview|Ancillary studies
79321386|NCT05455606|Other|Questionnaire Administration|Ancillary studies
79321387|NCT05455606|Other|Tumor Board Review|Patients undergo genomic tumor board review
79321388|NCT05453188|Device|Experimental|Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
79321389|NCT05453188|Genetic|Control|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
79321390|NCT05448573|Diagnostic Test|Fatigue Screening and assessment|(Newly) diagnosed cancer-patients from any cancer entity. No intervention.
79321391|NCT05439668|Other|Classic abdominal strengthening exercises|Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
79321392|NCT05439668|Other|Hypopressive abdominal exercises program|Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
79321393|NCT05425030|Dietary Supplement|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
79975689|NCT02482636|Biological|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
79975690|NCT02482636|Biological|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
79321394|NCT05425030|Behavioral|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
79321395|NCT05421949|Other|Exercise group|Incremental Shuttle Walking Test
79321396|NCT05384171|Behavioral|Measurement-Based Transition Assistance|Measurement-Based Transition Assistance (MBTA) provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
79321397|NCT05384171|Behavioral|Assessment Only|Veterans randomized to this condition will complete a well-being assessment only
79321398|NCT05374564|Drug|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
79321399|NCT05370599|Drug|Anti-hypertensive agent: amlodipine|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
79321400|NCT05370599|Drug|Anti-hypertensive agent: Chlorthalidone|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
79321401|NCT05370599|Drug|Anti-hypertensive agent: Losartan|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
79321402|NCT05370599|Device|Home BP monitoring with cuffed device|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
79321403|NCT05370599|Device|Home BP monitoring with cuffed device + BP patch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
79321404|NCT05370599|Device|Home BP monitoring with cuffed device + BP watch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
79321405|NCT05365529|Behavioral|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
79479593|NCT03519347|Other|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
79479594|NCT03519347|Other|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
79975691|NCT02482636|Biological|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
79975692|NCT03155724|Device|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
79975693|NCT03784469|Other|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
79975694|NCT02482402|Drug|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
79975695|NCT02482402|Drug|Placebo|inhalation solution placebo
79321406|NCT05365529|Behavioral|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
79321407|NCT05331482|Other|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
79321408|NCT05331482|Other|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
79479595|NCT03519347|Other|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
79321409|NCT05301712|Drug|Naloxone hydrochloride 5.0mg/5ml|"Initial dose: 4mg, Intravenous injection~Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~Total dose: 4mg+8mg/day*7=60mg"
79975696|NCT03777839|Diagnostic Test|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
79975697|NCT03426787|Behavioral|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
79321410|NCT05301712|Drug|Sodium Chloride 45mg/5ml|"Initial dose: 4ml, Intravenous injection~Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~Total dose: 4ml+8ml/day*7=60ml"
79321411|NCT05288712|Other|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
79479596|NCT03519347|Diagnostic Test|Point of Care Testing|POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
79479597|NCT03519347|Device|Cardiac Monitor|Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
79479598|NCT03493412|Drug|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
79479599|NCT03493412|Drug|Placebo|Placebo
79655749|NCT04548115|Behavioral|ARTISAN Condition|Youth and senior participants will be randomly paired and engage in the 5-weekly, 3-hour ARTISAN intervention as dyads (totaling 15 hours of intervention). In the first four weeks of the ARTISAN, dyads will engage in themed museum tours facilitated by a docent (45min), guided storytelling (45 min) and professionally-led art-making (45 min). The remaining time (45 min) is allocated for session breaks, session introduction/closing, and buffer time for movement around the gallery. The final week involves an exhibition where participants share their artworks with the public and reflect on their experiences and artworks. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
79975698|NCT03774173|Drug|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
79975699|NCT01336998|Dietary Supplement|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
79975700|NCT05713864|Device|BTL-899|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
79975701|NCT05713864|Device|HPM-6000UF|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
79975702|NCT03774095|Dietary Supplement|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
79975703|NCT03774095|Dietary Supplement|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
79975704|NCT01333410|Drug|tacrolimus ointment|2 applications per days for 6 months
79321412|NCT05288712|Other|Conventional training protocol|Conventional training protocol
79321413|NCT05268939|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
79321414|NCT05268939|Diagnostic Test|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
79321415|NCT05266612|Drug|VG2025|"1.0×108PFU Day 1 and 15~2.0×108PFU Day 1 and 15~3.0×108PFU Day 1 and 15~4.0×108PFU Day 1 and 15"
79321416|NCT05266612|Drug|Nivolumab Injection [Opdivo]|Flat dose of 240 mg every two weeks.
79321417|NCT05222191|Drug|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
79479600|NCT03484364|Behavioral|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
79479601|NCT03474198|Drug|Rifampicin|10mg/kg
79479602|NCT03474198|Drug|Isoniazid|5mg/kg
79479603|NCT03474198|Drug|Pyrazinamide|25mg/kg
79479604|NCT03474198|Drug|Ethambutol|15mg/kg
79479605|NCT03474198|Drug|Linezolid|600mg
79975705|NCT01333410|Drug|Mometasone furoate|2 applications per day for 6 months
79321418|NCT05222191|Drug|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
79321419|NCT05222191|Drug|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
79479606|NCT03474198|Drug|Clofazimine|200mg
79479607|NCT03474198|Drug|Rifapentine|1200mg
79975706|NCT03426631|Drug|Placebo oral capsule|Placebo capsule 30 minutes before sleep
79655750|NCT04548115|Behavioral|Intergenerational Participatory Arts Condition|Youths and senior participants in this condition will be randomly paired and engage in a 5-weekly 45-minute group-based art activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). A professional artist or art therapist will facilitate art-making sessions with the participants in a community space, utilizing the same mediums that were used in ARTISAN. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
79321420|NCT05189015|Drug|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
79975707|NCT03426631|Drug|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
79321421|NCT05161845|Biological|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
79321422|NCT05161169|Genetic|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
79321423|NCT05153070|Drug|Cyclosporin|• Ciclosporin: 3.5mg/kg, twice a day, oral, between Day 1 and Day 60
79321424|NCT05153070|Drug|ILT101|• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
79479608|NCT03474198|Drug|Levofloxacin|1000mg
79975708|NCT02482012|Other|Survey|This was a survey
79321425|NCT05153070|Drug|Placebo|• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
79975709|NCT04604951|Device|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
79975710|NCT01315470|Drug|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
79975711|NCT02482090|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
79975712|NCT02482090|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
79975713|NCT02482090|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
79321426|NCT05138705|Biological|Quadrivalent Influenza Virus Split Vaccine|0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
79321427|NCT05129631|Behavioral|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
79321428|NCT05107661|Behavioral|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
79321429|NCT05065671|Drug|Tolcapone 100 MG|Tolcapone 100 mg by mouth once
79321430|NCT05065671|Drug|Duloxetine 20 MG|Duloxetine 20 mg by mouth once
79479609|NCT03474198|Drug|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
79479610|NCT03474198|Drug|Rifampicin|35mg/kg
79479611|NCT03457129|Drug|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
79321431|NCT05057741|Behavioral|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
79321432|NCT05045638|Drug|Rosuvastatin|Oral dose
79479612|NCT03449511|Other|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
79479613|NCT03449511|Other|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
79321433|NCT05045638|Drug|Sotorasib|Oral dose
79321434|NCT05040360|Drug|Capecitabine|Given PO
79321435|NCT05040360|Drug|Temozolomide|Given PO
79321436|NCT05017948|Other|Risk score based intervention|Targeted interventions based off of risk score software
79479614|NCT03449511|Other|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
79479615|NCT03449511|Other|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
79479616|NCT03421288|Drug|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
79479617|NCT03421288|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
79479618|NCT03421288|Drug|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
79479619|NCT03421288|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
79479620|NCT03421288|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
79479621|NCT03418922|Drug|Lenvatinib|Specified doses will be administered orally on specified days.
79479622|NCT03418922|Drug|Nivolumab|Specified doses will be administered intravenously on specified days.
79479623|NCT03385993|Device|Technology based guided meditation and relaxation|Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
79479624|NCT03376971|Procedure|Biopsy|Undergo lung biopsy
79479625|NCT03376971|Other|Laboratory Biomarker Analysis|Correlative studies
79479626|NCT03368092|Drug|Dornase Alfa Inhalant Solution [Pulmozyme]|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
79479627|NCT03368092|Drug|Placebos|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
79479628|NCT03360513|Other|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
79479629|NCT03342027|Drug|Bupropion|medication for smoking cessation
79479630|NCT03342027|Behavioral|Positively smoke free|an 8 session, tailored behavioral intervention for treating tobacco dependence
79975714|NCT02482090|Drug|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
79302284|NCT02490839|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
79302285|NCT03077373|Behavioral|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
79302286|NCT03205969|Device|Functional mobile game|Functional mobile game for chemotherapy side effect education
79302287|NCT02486861|Other|optical coherence tomography|
79302288|NCT03205735|Diagnostic Test|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
79302289|NCT04492865|Device|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
79302290|NCT03077295|Other|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
79302291|NCT03077295|Other|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
79302292|NCT02490527|Dietary Supplement|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
79302293|NCT02490527|Drug|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
79302294|NCT02490527|Other|Placebo|A substance that has no therapeutic effect and will act as a control.
79302295|NCT05000775|Dietary Supplement|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
79302296|NCT05000775|Dietary Supplement|Placebo|Placebo
79302297|NCT02490449|Drug|Dexlansoprazole MR|Administration of drug after or before diet
79321437|NCT05011734|Other|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
79479631|NCT03342027|Other|Brief advice to quit smoking|Standardized brief advice to quit smoking (standard of care)
79479632|NCT03336606|Drug|MEDI0562|Surgical resection of tumor
79655751|NCT04548115|Behavioral|Intergenerational Art-space Condition|Youths and senior participants in this condition will engage in a 5-weekly 45-minute group-based curated museum tour that follow the ARTISAN themes with 15 minutes of preparation/break time, and conducted by a trained docent at the National Museum Singapore (totaling 5 hours of intervention).The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
79479633|NCT03329716|Other|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
79479634|NCT03314922|Drug|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
79321438|NCT05011513|Drug|PF-07321332|PF-07321332 (tablet)
79321439|NCT05011513|Drug|Ritonavir|Ritonavir (capsule)
79321440|NCT05011513|Drug|Placebo|Placebo (tablet)
79321441|NCT05011513|Drug|Placebo|Placebo (capsule)
79321442|NCT05010317|Behavioral|Mindfulness and acceptance based therapy|This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.
79321443|NCT05010317|Behavioral|Standard of care|Usual clinic based counselling offered as routine care to adolescents
79321444|NCT04983771|Device|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
79321445|NCT04960787|Other|Educational Intervention|Watch online educational videos
79321446|NCT04960787|Behavioral|Patient Navigation|Meet with CENTS counselor and PAF case manager
79655752|NCT04548115|Behavioral|Intergenerational Storytelling Condition|Youths and senior participants in this condition will be paired to engage in a 5-weekly 45 minute group-based storytelling activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). Storytelling sessions will be conducted by a trained facilitator, and conversation starters from ARTISAN intervention will be used. The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
79809250|NCT00671333|Procedure|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
79975715|NCT05643313|Device|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
79321447|NCT04960787|Other|Quality-of-Life Assessment|Ancillary studies
79321448|NCT04960787|Other|Questionnaire Administration|Complete questionnaires
79975716|NCT03773861|Other|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
79321449|NCT04958759|Other|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
79321450|NCT04958759|Other|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
79479635|NCT03309098|Diagnostic Test|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
79975717|NCT01337154|Drug|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
79975718|NCT01337154|Drug|Placebo|Tablets, orally, daily
79975719|NCT03719911|Behavioral|Live diabetes coaching program|Live diabetes coaching program
79975720|NCT03777683|Dietary Supplement|Dietary Supplement (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
79321451|NCT04958759|Other|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
79975721|NCT03777683|Other|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
79321452|NCT04956978|Other|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
79321453|NCT04944862|Biological|CDX-0159|administered intravenously
79321454|NCT04944862|Drug|Normal saline|administered intravenously
79479636|NCT03302910|Other|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
79479637|NCT03302910|Other|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
79975722|NCT02482324|Drug|ALZT-OP1a|Mast cell stabilizer
79975723|NCT02482324|Drug|ALZT-OP1b|anti-inflammatory
79975724|NCT02482324|Device|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
79479638|NCT03297203|Behavioral|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
79975725|NCT05676437|Diagnostic Test|Stress radiography|Radiographic examination during clinical stress test of knee laxity
79975726|NCT05185284|Drug|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
79975727|NCT05185284|Drug|Favipiravir|200 mg coated tablets
79975728|NCT05185284|Drug|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
79975729|NCT03484429|Device|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
79975730|NCT03484429|Other|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
79479639|NCT03286010|Behavioral|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
79975731|NCT03784703|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
79975732|NCT03784703|Drug|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
79975733|NCT05525260|Drug|Limonene capsule|Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
79975734|NCT05525260|Drug|Limonene capsules(Placebo)|Limonene capsules(Placebo)
79975735|NCT01339182|Drug|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
79975736|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
79975737|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
79975738|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
79975739|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
79321455|NCT04920552|Device|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
79321456|NCT04920552|Device|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
79321457|NCT04832022|Other|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
79321458|NCT04818034|Drug|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
79321459|NCT04812028|Drug|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
79321460|NCT04807972|Drug|ABBV-927|Intravenous (IV) Infusion
79321461|NCT04807972|Drug|Budiglimab|Intravenous (IV) Infusion
79321462|NCT04807972|Drug|modified FOLFIRINOX|Intravenous (IV) Infusion
79321463|NCT04792190|Drug|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
79645465|NCT04804774|Behavioral|WW program modified for people with Type 2 diabetes|This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
79645466|NCT04799938|Behavioral|Exercise|180 minutes of moderate-intensity exercise per week
79645467|NCT00172211|Drug|Physioneal|
79645468|NCT04798846|Procedure|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
79645469|NCT04681846|Procedure|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
79645470|NCT02908594|Device|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
79645471|NCT04791280|Procedure|Faeces collection|"faeces collection at inclusion~follow-up visit 6 months after inclusion"
79975740|NCT01337232|Behavioral|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
79321464|NCT04792190|Drug|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
79645472|NCT04723901|Biological|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
79975741|NCT01337310|Drug|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
79975742|NCT03484273|Device|LifeWrap Compression Garment|Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
79975743|NCT02724592|Device|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
79975744|NCT02724592|Device|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
79975745|NCT05186844|Behavioral|survey application|Scales and questionnaires were applied to children and their parents according to age groups.
79975746|NCT03773783|Device|Button and Bead appliance|Button and Bead appliance
79975747|NCT03773783|Device|Twin Block appliance|Twin Block appliance
79975748|NCT01333566|Behavioral|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
79975749|NCT01333566|Behavioral|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
79645473|NCT00197769|Biological|9 valent pneumococcal con jugate vaccine|
79302298|NCT03205501|Drug|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
79479640|NCT03282656|Biological|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
79645474|NCT04791241|Other|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
79645475|NCT04768855|Drug|LY3540378|Administered IV or SC.
79645476|NCT04768855|Drug|Placebo|Administered IV or SC.
79302299|NCT03205501|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
79302300|NCT03077139|Device|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
79302301|NCT03225235|Radiation|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
79302302|NCT04993521|Procedure|Block type|Regular block type
79302303|NCT02452177|Drug|Vitamin D|
79302304|NCT05000697|Drug|Oxaliplatin|Patients will receive 5FU + Oxaliplatin during the consolidation chemotherapy after long course chemoradiation
79302305|NCT05000697|Drug|5FU|Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
79645477|NCT04768855|Drug|LY3540378|Administered SC.
79645478|NCT02908633|Procedure|canaloplasty and phacoemulsification|
79479641|NCT03245541|Drug|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
79479642|NCT03245541|Radiation|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
79479643|NCT03244644|Drug|RBX2660|RBX2660 is a rectally administered microbiota suspension
79645479|NCT02908438|Drug|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
79645480|NCT00202410|Biological|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
79975750|NCT02476864|Drug|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
79302306|NCT03205189|Other|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
79302307|NCT02486705|Behavioral|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
79302308|NCT02486705|Behavioral|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
79302309|NCT03220633|Drug|ATB-346|
79302310|NCT03220633|Drug|Placebo|
79302311|NCT04992819|Procedure|Chronobiological Approach Nutrition Model|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
79302312|NCT03224923|Drug|Ticagrelor 60mg|twice daily
79975751|NCT02476864|Drug|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
79302313|NCT03224923|Drug|Clopidogrel 75mg|once daily
79302314|NCT03224923|Drug|Aspirin 81 mg|once daily
79302315|NCT03321461|Drug|TMTP1|Fluorescent sites will be removed
79302316|NCT03321461|Drug|ICG|Fluorescent sites will be removed
79302317|NCT05004753|Dietary Supplement|Artemisinin|a herbal supplement
79302318|NCT05004753|Drug|Dexamethasone|corticosteroids
79479644|NCT03244644|Drug|Placebo|Placebo is normal saline solution administered rectally
79479645|NCT03244644|Drug|Open label RBX2660 (only for confirmed CDI recurrence)|RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
79645481|NCT00202410|Other|placebo|subcutaneous administration of physiologic solution
79645482|NCT04756999|Behavioral|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
79645483|NCT02908555|Other|No intervention|This is a descriptive study with no intervention
79645484|NCT02908321|Behavioral|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
79302319|NCT02486471|Procedure|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
79302320|NCT02486471|Other|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
79302321|NCT03224689|Device|PEEK-Optima Femoral Component|TKA Surgery
79302322|NCT02486549|Procedure|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
79479646|NCT03240809|Biological|Brodalumab|140 mg SC dose
79479647|NCT03240809|Biological|Brodalumab|70 mg SC dose
79479648|NCT03207854|Procedure|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
79479649|NCT03207854|Other|Laboratory Biomarker Analysis|Correlative studies
79479650|NCT03207854|Other|Questionnaire Administration|Ancillary studies
79645485|NCT04743895|Device|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
79645486|NCT04742296|Device|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
79645487|NCT00197808|Biological|menjugate|men C conjugate vaccine
79645488|NCT00197808|Biological|Men C conjugate vaccine|men C conjugate vaccine
79645489|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
79645490|NCT00197808|Biological|Men C Conjugate|men C conjugate vaccine
79645491|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
79479651|NCT03201549|Dietary Supplement|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
79479652|NCT03200301|Procedure|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
79479653|NCT03199638|Drug|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
79479654|NCT03199638|Behavioral|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
79479655|NCT03192995|Drug|lorcaserin|lorcaserin 20 mg tablet
79479656|NCT03192995|Drug|Placebo Oral Tablet|placebo 20 mg. tablet
79479657|NCT03192995|Behavioral|Substance use counseling|Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
79479658|NCT03192995|Behavioral|ACASI|Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
79479659|NCT03192995|Diagnostic Test|Cocaine metabolites|Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
79975752|NCT02761122|Procedure|Human biological samples|"Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
79975753|NCT01320527|Dietary Supplement|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
79302323|NCT02486549|Procedure|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
79302324|NCT02486549|Drug|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
79302325|NCT02486549|Device|Ultrasound|The Ultrasound will be used for brachial plexus visualization
79479660|NCT03192995|Behavioral|Ecological Momentary Assessment (EMA)|EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
79479661|NCT03192995|Behavioral|Balloon Analogue Risk Task (BART)|BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
79479662|NCT03192995|Behavioral|Qualitative Exit Interview|The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
79479663|NCT03174977|Drug|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
79479664|NCT03150511|Drug|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
79479665|NCT03150511|Drug|Placebo|Daily self-administered placebo
79645492|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
79479666|NCT03121677|Biological|Personalized tumor vaccine|"Cycle 12 vaccine administration is optional~The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
79321465|NCT04789044|Drug|NTX-001|• PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
79321466|NCT04775199|Behavioral|Language Intervention|The examiners will target vocabulary and grammar in the context of preschool science instructions.
79321467|NCT04770012|Drug|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
79321468|NCT04770012|Drug|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
79321469|NCT04770012|Drug|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
79321470|NCT04755244|Drug|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
79321471|NCT04755244|Drug|venetoclax|BCL-2 inhibitor
79479667|NCT03121677|Drug|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
79321472|NCT04755244|Drug|azacitidine|Hypomethylating agent (HMA)
79479668|NCT03121677|Biological|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
79479669|NCT03121677|Procedure|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
79479670|NCT03121677|Procedure|Leukapheresis|"Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
79321473|NCT04750239|Drug|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
79321474|NCT04718740|Drug|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
79321475|NCT04717544|Behavioral|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
79321476|NCT04699305|Device|ActiGraft|Whole blood clot (WBC) gel
79479671|NCT03121677|Biological|Rituximab|-Other anti-CD20 mAb treatment can be used
79645493|NCT00172328|Biological|Hepatitis B vaccine|
79321477|NCT04663828|Other|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
79321478|NCT04663828|Device|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
79321479|NCT04663828|Other|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
79321480|NCT04663828|Other|Sound therapy|Several sounds and music are used for tinnitus disorder
79975754|NCT01320527|Other|Placebo|A mixture of 6 vitamins and nutriceuticals
79321481|NCT04659122|Biological|AT-100|reconstituted AT-100 for intratracheal administration
79321482|NCT04652063|Other|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
79321483|NCT04647916|Biological|Sacituzumab Govitecan|Given IV
79479672|NCT03121677|Procedure|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
79321484|NCT04615546|Behavioral|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
79321485|NCT04615546|Other|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
79975755|NCT01339338|Procedure|warming the contrast media|warm the contrast media with 37℃ water-bathing
79321486|NCT04590248|Drug|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
79321487|NCT04586231|Drug|Belzutifan|Immediate-release 40 mg tablet
79479673|NCT03110926|Drug|mFOLFOX6|Induction Chemotherapy
79975756|NCT01309061|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
79975757|NCT03314428|Behavioral|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
79975758|NCT03773549|Other|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
79321488|NCT04586231|Drug|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
79321489|NCT04586231|Drug|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
79321490|NCT04572139|Diagnostic Test|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
79321491|NCT04565457|Device|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
79321492|NCT04560816|Drug|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
79321493|NCT04560816|Drug|Placebo|Placebo will be administered orally.
79479674|NCT03110926|Combination Product|Chemoradiation|Chemoradiation
79479675|NCT03110861|Device|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
79479676|NCT03104595|Drug|EC-18|oral administration
79479677|NCT03098277|Device|Accelerometer|Wear Microsoft Band 2
79479678|NCT03098277|Other|Laboratory Biomarker Analysis|Correlative studies
79479679|NCT03098277|Other|Physical Activity Measurement|Perform physical activities recorded by Microsoft Kinect 2
79479680|NCT03098277|Behavioral|Telephone-Based Intervention|Complete PRO questionnaires
79479681|NCT03092856|Biological|Anti-OX40 Antibody PF-04518600|Given IV
79479682|NCT03092856|Drug|Axitinib|Given PO
79479683|NCT03092856|Other|Laboratory Biomarker Analysis|Correlative studies
79479684|NCT03092856|Other|Placebo|Given IV
79302326|NCT03224611|Device|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
79302327|NCT03318185|Procedure|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
79302328|NCT03318185|Procedure|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
79302329|NCT03224533|Diagnostic Test|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
79302330|NCT03076125|Behavioral|SCORRE|3 components based on the Health Belief Model
79479685|NCT03091816|Device|Computed Tomography Perfusion Imaging|Undergo DPCT
79479686|NCT03091816|Other|Laboratory Biomarker Analysis|Correlative studies
79479687|NCT03091816|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79809251|NCT00671333|Procedure|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
79479688|NCT03043950|Drug|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
79479689|NCT03035331|Procedure|Cryosurgery|Undergo cryosurgery
79479690|NCT03035331|Biological|Dendritic Cell Therapy|Given IT
79302331|NCT03076125|Behavioral|Attention-Control Activity|sexual health education
79302332|NCT02490605|Procedure|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
79302333|NCT02490605|Procedure|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
79302334|NCT03318107|Device|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
79302335|NCT04485403|Drug|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight <70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
79479691|NCT03035331|Other|Laboratory Biomarker Analysis|Correlative studies
79479692|NCT03035331|Biological|Pembrolizumab|Given IV
79479693|NCT03035331|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
79479694|NCT03035331|Other|Quality-of-Life Assessment|Ancillary studies
79479695|NCT03015194|Device|Edwards SAPIEN 3 transcatheter heart valve|"Used to relieve aortic stenosis in patients with symptomatic heart disease~In this study it is not used for aortic stenosis-----the device is used in the mitral valve position."
79809252|NCT00823836|Drug|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
79809253|NCT00823836|Drug|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
79975759|NCT03635736|Other|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
79302336|NCT02490059|Other|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
79302337|NCT03073239|Genetic|ALS patients genetic characterization|Genetic findings in ALS patients
79302338|NCT03073239|Other|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
79302339|NCT03220867|Drug|Risperidone: Xian Risperdal (test)|Participants will receive 1*1 mg tablet of Xian Risperdal under fasting or fed condition.
79302340|NCT03220867|Drug|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
79302341|NCT02490137|Behavioral|Race Car Video Game|Repeatedly playing a race car video game
79302342|NCT03073473|Diagnostic Test|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
79302343|NCT03205345|Drug|Emricasan (25 mg)|25 mg emricasan
79302344|NCT03205345|Drug|Emricasan (5 mg)|5 mg emricasan
79302345|NCT03205345|Drug|Placebo|Matching Placebo
79302346|NCT03318029|Dietary Supplement|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
79302347|NCT03318029|Dietary Supplement|Placebo|rice flour with no vitamin D
79302348|NCT03076281|Drug|Metformin Hydrochloride|Given orally
79302349|NCT03076281|Drug|Doxycycline|Given orally
79302350|NCT03076281|Drug|Metformin +Doxycycline|Given orally
79302351|NCT03317951|Other|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
79479696|NCT03015194|Device|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
79975760|NCT05451550|Procedure|Brachial plexus block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
79321494|NCT04560816|Drug|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
79321495|NCT04530682|Biological|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
79645494|NCT04710394|Behavioral|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
79645495|NCT00172367|Drug|Lycopene|
79645496|NCT00202488|Drug|H. pylori treatment|
79645497|NCT04668664|Device|EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).
79975761|NCT05451550|Procedure|General anesthesia|General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.
79975762|NCT05451550|Procedure|Suprascapular nerve block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
79975763|NCT01339494|Dietary Supplement|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
79321496|NCT04520425|Procedure|Osteopathic manipulative therapy|"Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
79645498|NCT04632316|Drug|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
79645499|NCT04632316|Drug|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
79645500|NCT04630327|Other|Beck Depression Inventory-21 (diagnostic survey)|Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients
79321497|NCT04511013|Drug|Binimetinib|Given PO
79321498|NCT04511013|Drug|Encorafenib|Given PO
79321499|NCT04511013|Biological|Ipilimumab|Given IV
79321500|NCT04511013|Biological|Nivolumab|Given IV
79321501|NCT04510597|Procedure|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
79321502|NCT04510597|Drug|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
79321503|NCT04477603|Device|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
79321504|NCT04468061|Drug|Sacituzumab Govitecan|Intravenous Infusion
79321505|NCT04468061|Drug|Pembrolizumab|Intravenous Infusion
79975764|NCT02476708|Dietary Supplement|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
79975765|NCT02476708|Dietary Supplement|Placebo|oral placebo capsule
79975766|NCT01341522|Procedure|MRI exam|MRI exam
79975767|NCT01341522|Procedure|control|waiting room
79975768|NCT03769571|Behavioral|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
79321506|NCT04465591|Diagnostic Test|troponin T fragmentation test|laboratory test from blood sample
79321507|NCT04417517|Drug|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
79321508|NCT04417517|Drug|azacitidine|Hypomethylating agent (HMA)
79321509|NCT04381806|Drug|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
79975769|NCT02479204|Drug|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
79975770|NCT02479204|Drug|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
79321510|NCT04374760|Behavioral|SMS-intervention|SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
79321511|NCT04337177|Drug|VAL-413|a flavored preparation of orally administered irinotecan
79321512|NCT04337177|Drug|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
79321513|NCT04327609|Device|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
79645501|NCT04630327|Other|Beck Anxiety Inventory|Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients
79975771|NCT02479204|Drug|Placebo|ACT-33441-matching placebo
79975772|NCT02479204|Drug|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
79321514|NCT04327609|Device|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
79321515|NCT04310202|Other|Abbreviated Profile of Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.
79321516|NCT04310202|Other|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.
79975773|NCT02479204|Drug|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
79975774|NCT03784547|Drug|Ocrelizumab|already described
79975775|NCT01339572|Drug|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~Pre-apheresis peripheral blood CD34+ count <20 cells/μL on day 5.~Estimated CD34+ cell collection is < 25% of target cell dose after 1 day of apheresis.~Estimated CD34+ cell collection is < 50% of target cell dose after 2 days of apheresis."
79479697|NCT03003338|Drug|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
79645502|NCT04630327|Other|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety
79645503|NCT00197886|Drug|Changing dose of norepinephrine and blood pressure|
79645504|NCT04626427|Device|WavelinQ™ EndoAVF System|AVF endovascular creations using the WavelinQ™ EndoAVF System
79645505|NCT00172445|Procedure|blood sampling, neck lymph node biopsy|
79645506|NCT04612114|Diagnostic Test|Belun Ring|Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
79645507|NCT00202527|Device|Nasal continuos positive airway pressure|
79645508|NCT00172484|Procedure|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
79645509|NCT00172484|Procedure|nursing program|To establish a systemic stroke prevention, education protocol
79645510|NCT00172484|Procedure|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
79645511|NCT02908360|Genetic|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
79645512|NCT02908399|Device|FLIR ONE|
79645513|NCT02908243|Other|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
79975776|NCT01339572|Drug|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~Standard risk: 5 μg/kg SQ BID.~High risk: 10 μg/kg SQ BID."
79975777|NCT03773705|Procedure|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
79975778|NCT04382118|Other|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
79645514|NCT00197925|Biological|Onco-peptide loaded autologous dendritic cells|
79655753|NCT04548115|Behavioral|Control Condition|Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
79655754|NCT00414089|Drug|90Y-ibritumomab tiuxetan (Zevalin)|
79655755|NCT00261612|Drug|bortezomib|
79479698|NCT03003338|Drug|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
79479699|NCT02965638|Other|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
79479700|NCT02960308|Radiation|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
79479701|NCT02953977|Behavioral|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
79479702|NCT02946879|Biological|AAV OPTIRPE65|comparison of different doses of AAV RPE65
79479703|NCT02944500|Drug|liraglutide|
79975779|NCT01320605|Biological|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
79479704|NCT02944500|Other|Placebo|
79302352|NCT03317951|Other|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
79302353|NCT03317873|Dietary Supplement|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
79302354|NCT03317873|Dietary Supplement|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
79302355|NCT04992897|Device|Remote Electrical Neuromodulation (REN)|Acute migraine treament
79302356|NCT02452255|Drug|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
79302357|NCT02452255|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
79302358|NCT02452255|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
79302359|NCT04492787|Drug|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
79302360|NCT04492787|Drug|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
79302361|NCT04992741|Other|education and motivational interview|The control group will remain subject to the routine process without any intervention.
79479705|NCT02944058|Procedure|Multiloc nail|Intervention is surgery with Multiloc nail
79655756|NCT00261612|Drug|rituximab|
79975780|NCT01341678|Drug|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
79975781|NCT01341678|Dietary Supplement|NeutraPhos|Diet will be supplemented with NeutraPhos
79975782|NCT01341678|Other|Diet Only|Diet containing 1500mg of phosphorus
79302362|NCT03205033|Drug|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
79302363|NCT03205033|Drug|Placebo oral capsule|1 capsule/day 1 hour before go to bed
79302364|NCT03205267|Drug|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to <G2.
79302365|NCT03076905|Drug|F901318|Evaluation of AUC0-t
79302366|NCT02452099|Procedure|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
79302367|NCT02452099|Procedure|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
79302368|NCT02452099|Procedure|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
79479706|NCT02944058|Procedure|Philos plate|Intervention is surgery with Philos plate
79321517|NCT04310202|Other|Additional follow-up visits after surgery|There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
79321518|NCT04205968|Drug|Fluorouracil|Given IV bolus or IV
79321519|NCT04205968|Drug|Irinotecan|Given IV
79321520|NCT04205968|Drug|Irinotecan Hydrochloride|Given IV
79321521|NCT04205968|Drug|Leucovorin|Given IV
79321522|NCT04205968|Drug|Leucovorin Calcium|Given IV
79321523|NCT04205968|Drug|Paclitaxel|Given IV
79321524|NCT04205968|Biological|Ramucirumab|Given IV
79321525|NCT04146922|Other|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
79479707|NCT02923934|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
79655757|NCT00261612|Drug|dexamethasone|
79655758|NCT00261612|Procedure|treatment protocol|
79655759|NCT04547764|Drug|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
79479708|NCT02923934|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
79479709|NCT02913313|Drug|BMS-986207|Specified dose on specified days
79479710|NCT02913313|Biological|Nivolumab|Specified dose on specified days
79479711|NCT02913313|Biological|Ipilimumab|Specified dose on specified days
79479712|NCT02908477|Radiation|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
79479713|NCT02908477|Drug|Docetaxel|15 mg/m2. Experimental arm only.
79479714|NCT02908477|Drug|Cisplatin|40 mg/m2. Standard arm only.
79479715|NCT02904967|Biological|Extra Blood Draw|
79479716|NCT02900014|Procedure|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
79479717|NCT02888626|Device|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
79479718|NCT02884791|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
79479719|NCT02873715|Behavioral|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
79645515|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
79655760|NCT04547764|Drug|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
79975783|NCT02481856|Drug|SQ tree SLIT-tablet|
79975784|NCT02481856|Drug|Placebo|
79975785|NCT02481778|Other|Blood sampling|
79302369|NCT03076671|Behavioral|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
79302370|NCT03317717|Drug|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
79302371|NCT03317717|Drug|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
79302372|NCT03076593|Other|Exposure: Fall|Participants will be asked about prior falls
79302373|NCT03220789|Procedure|Drilling at low speed|
79302374|NCT03220789|Procedure|Drilling at conventional or high speed|
79302375|NCT03076749|Other|Creating models for the diagnosis of BL allergy|
79479720|NCT02873715|Behavioral|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
79479721|NCT02860013|Device|Telemedicine|
79479722|NCT02837627|Other|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
79479723|NCT02809716|Other|Biomarker Analysis|Correlative studies
79479724|NCT02809716|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
79479725|NCT02772770|Other|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
79655761|NCT04547647|Radiation|X- Ray|X-Ray with A-P and lateral view of the whole spine.
79975786|NCT05185206|Device|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (> 70 mm)."
79321526|NCT04146922|Other|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
79655762|NCT04547608|Other|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
79321527|NCT04141020|Procedure|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
79321528|NCT04141020|Procedure|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
79321529|NCT04141020|Drug|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
79321530|NCT04097743|Behavioral|Coping Statement|Daily practice of coping statement
79321531|NCT04092582|Drug|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
79321532|NCT04092582|Drug|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
79321533|NCT04071457|Drug|Lenalidomide|Commercially available intervention
79321534|NCT04071457|Drug|Daratumumab/rHuPH20|SWOG-Held IND
79321535|NCT04060719|Drug|BI 894416|tablet
79321536|NCT04060719|Drug|Rifampicin|tablet
79655763|NCT00236249|Drug|Lidocaine|
79655764|NCT00269061|Drug|pioglitazone|
79655765|NCT02214472|Behavioral|Biofeedback|
79655766|NCT02214472|Drug|Placebo|
79655767|NCT04547452|Radiation|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
79645516|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
79645517|NCT04556500|Other|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
79645518|NCT00202566|Drug|Ivabradine|
79645519|NCT04534270|Drug|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight>30kg), for 12 weeks
79645520|NCT02908282|Device|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
79645521|NCT02908282|Device|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
79645522|NCT00172601|Procedure|mobilization|
79645523|NCT00197964|Behavioral|Enhance asthma knowledge, self-efficacy, social support|
79645524|NCT02908126|Drug|Oxytocin|Oxytocin drug
79645525|NCT02907931|Other|Point of Care Ultrasound|
79984697|NCT03748355|Genetic|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
79984698|NCT02444884|Drug|MLN8237|
79984699|NCT02450032|Biological|G17DT|
79321537|NCT04024488|Behavioral|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
79479726|NCT02772770|Procedure|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
79321538|NCT04024488|Behavioral|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
79321539|NCT04011384|Behavioral|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
79321540|NCT03910413|Diagnostic Test|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
79321541|NCT03877406|Drug|Empagliflozin 10 MG|addition of empagliflozin 10 MG
79321542|NCT03877406|Drug|Hypoglycemics Oral|dose escalation of hypoglycemics oral
79479727|NCT02772770|Procedure|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
79645526|NCT00202605|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
79645527|NCT04455334|Other|Error-augmented treadmill training|walk on split-belt treadmill
79479728|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
79975787|NCT05185206|Device|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (> 70 mm)."
79645528|NCT04455334|Other|active control group|walk on tie-belt treadmill
79645529|NCT04455334|Other|Error-augmented concept combined physical therapy group|Error-augmented concept combined physical therapy
79645530|NCT04455334|Other|conventional physical therapy group|conventional physical therapy
79645531|NCT04455334|Other|NO INTERVENTION|NO INTERVENTION
79321543|NCT03808675|Behavioral|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
79321544|NCT03808675|Behavioral|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
79321545|NCT03746106|Drug|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
79321546|NCT03746106|Drug|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
79321547|NCT03746106|Dietary Supplement|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
79813758|NCT02610452|Other|Clown therapy|"The clowns intervene by twos: a game takes place.~The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~The original game proposal is adjusted according to mutual empathy with those present.~The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
79975788|NCT02481700|Procedure|Third molar removal|The surgical removal of third molars
79975789|NCT02479282|Procedure|natural cesarean section|
79975790|NCT02479282|Procedure|traditional cesarean section|
79975791|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
79321548|NCT03737461|Drug|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
79321549|NCT03737461|Other|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
79321550|NCT03723460|Other|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
79321551|NCT03722173|Drug|Itraconazole|Oral solution
79321552|NCT03722173|Drug|BI 894416|Tablet
79321553|NCT03717194|Drug|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
79321554|NCT03717194|Drug|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
79975792|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
79975793|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
79975794|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
79975795|NCT03154476|Drug|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
79975796|NCT03154476|Drug|Placebo|Placebo capsules matching study drug
79645532|NCT02907853|Behavioral|Contingency Management|as described above
79975797|NCT02479594|Behavioral|competence-feedback|competence-feedback
79975798|NCT02479594|Other|control|control group without competence-feedback
79975799|NCT03769337|Diagnostic Test|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
79813759|NCT02609360|Other|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
79321555|NCT03695380|Drug|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
79321556|NCT03695380|Drug|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
79321557|NCT03695380|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
79321558|NCT03678025|Drug|Abiraterone|Given PO
79655768|NCT04547452|Drug|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
79655769|NCT04547335|Drug|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
79321559|NCT03678025|Drug|Bicalutamide|Given PO
79321560|NCT03678025|Drug|Degarelix|Given via injection
79321561|NCT03678025|Drug|Docetaxel|intravenous
79321562|NCT03678025|Drug|Flutamide|Given PO
79321563|NCT03678025|Drug|Goserelin Acetate|Given SC
79321564|NCT03678025|Drug|Histrelin Acetate|Receive SC
79321565|NCT03678025|Drug|Leuprolide Acetate|Receive SC or IM
79321566|NCT03678025|Drug|Nilutamide|Given PO
79321567|NCT03678025|Procedure|Orchiectomy|Undergo bilateral orchiectomy
79321568|NCT03678025|Drug|Prednisone|Given PO
79321569|NCT03678025|Other|Quality-of-Life Assessment|Ancillary studies
79813760|NCT02609360|Other|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
79813761|NCT02609360|Other|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
79813762|NCT00444535|Drug|lapatinib|1500 mg oral lapatinib (once daily)
79813763|NCT00444535|Drug|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
79813764|NCT04110288|Drug|Paclitaxel|Paclitaxel to treat peripheral arterial disease
79813765|NCT04110288|Device|Non-drug coated Device Treatment|
79655770|NCT00236288|Drug|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
79813766|NCT03863158|Other|No intervention|No intervention / medical records only
79813767|NCT00826306|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
79479729|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
79645533|NCT02907658|Behavioral|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
79645534|NCT02907775|Device|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
79479730|NCT02754726|Drug|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
79645535|NCT02907775|Device|Electrodes|electrodes placed over the radial nerve in radial grove
79321570|NCT03678025|Radiation|Radiation Therapy|Standard radiation
79321571|NCT03678025|Procedure|Radical Prostatectomy|Standard surgery
79321572|NCT03678025|Drug|Triptorelin|injection
79645536|NCT00198003|Behavioral|Educational program to address patients' expectations|
79645537|NCT02907580|Behavioral|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
79813768|NCT04832360|Behavioral|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
79321573|NCT03636256|Drug|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
79321574|NCT03636256|Drug|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
79321575|NCT03636256|Other|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
79479731|NCT02754726|Drug|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
79479732|NCT02754726|Drug|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
79479733|NCT02754726|Drug|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
79479734|NCT02754726|Drug|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
79479735|NCT02733185|Drug|disodium EDTA|
79479736|NCT02733185|Dietary Supplement|Oral Multi Vitamins/Minerals (OMVM)|
79479737|NCT02733185|Drug|Placebo disodium EDTA|
79479738|NCT02733185|Dietary Supplement|Placebo Oral Multi Vitamins/Minerals (OMVM)|
79479739|NCT02713997|Drug|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
79479740|NCT02713997|Drug|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
79813769|NCT04025502|Device|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
79813770|NCT00826384|Procedure|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
79302376|NCT03317639|Behavioral|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
79302377|NCT03220555|Device|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
79479741|NCT02692300|Procedure|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
79479742|NCT02684227|Drug|Carboplatin|Given IV
79479743|NCT02684227|Drug|Enzalutamide|Given PO
79479744|NCT02684227|Other|Laboratory Biomarker Analysis|Correlative studies
79479745|NCT02684227|Drug|Paclitaxel|Given IV
79479746|NCT02684227|Other|Pharmacological Study|Correlative studies
79302378|NCT03220555|Drug|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
79302379|NCT05004597|Other|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
79975800|NCT02476630|Device|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
79975801|NCT02476630|Other|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
79975802|NCT01339650|Drug|ABT-767|ABT-767 once or twice daily for a 28 day cycle
79975803|NCT03784391|Drug|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
79975804|NCT01339728|Procedure|far-infrared ray|The duration of far-infrared ray is 20 minutes.
79975805|NCT05338918|Other|Mental Imagery with Virtual Reality Training|Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
79975806|NCT05338918|Other|Virtual Reality Training|Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
79302380|NCT02489669|Device|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
79302381|NCT03204877|Drug|Melatonin|Oral capsules
79302382|NCT03204877|Other|Placebo|Oral capsules
79302383|NCT03220399|Drug|NVP-1603-1 (P)|1capsule, single oral dosing
79302384|NCT03220399|Drug|NVP-1603-2 (T)|1tablet, single oral dosing
79302385|NCT03220399|Drug|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
79302386|NCT02489747|Dietary Supplement|WBE|wheat bran extract (3 g/day)
79302387|NCT02489747|Dietary Supplement|Placebo|Placebo
79302388|NCT03076437|Combination Product|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
79302389|NCT03224845|Behavioral|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
79302390|NCT02486393|Procedure|Parotid surgery|Surgery of the parotid gland tumours
79302391|NCT05003973|Behavioral|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
79302392|NCT05003973|Behavioral|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
79302393|NCT03204799|Other|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
79302394|NCT03204799|Drug|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
79302395|NCT03204799|Drug|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
79302396|NCT03317327|Drug|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
79302397|NCT03317327|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
79645538|NCT02907580|Behavioral|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
79655771|NCT04547296|Drug|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH <7.2, 5% sodium bicarbonate injection was given to correct it.
79975807|NCT03635580|Other|Negative control|Untreated-control group
79975808|NCT02479516|Behavioral|Community Health Assessment Program Philippines (CHAP-P)|
79975809|NCT01320761|Drug|ATX-101-BA-free|ATX-101-BA-free
79975810|NCT01320761|Drug|ATX-101-BA|ATX-101-BA
79975811|NCT01341756|Radiation|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
79302398|NCT03220243|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
79302399|NCT03204331|Drug|Relugolix|Relugolix 40-mg tablet administered orally once daily.
79302400|NCT03204331|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
79302401|NCT03204331|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
79302402|NCT03204331|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
79302403|NCT03317249|Diagnostic Test|ECG|12-lead electrocardiogram
79302404|NCT03317249|Diagnostic Test|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
79975812|NCT02476552|Drug|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
79302405|NCT03317249|Diagnostic Test|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
79302406|NCT03317249|Diagnostic Test|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
79302407|NCT03317249|Other|Echocardiogram|optional (for non-IST participants only)
79302408|NCT03072849|Procedure|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
79975813|NCT02476552|Drug|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of [14C]-niraparib)
79975814|NCT02476552|Drug|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
79975815|NCT03773315|Dietary Supplement|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
79809254|NCT00671411|Drug|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings & Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 & 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings & energy w/i FDA guidelines. This will only be performed while imaging the kidney."
79975816|NCT03773315|Dietary Supplement|Placebo|Starch placebo 500 mg/day for 12 weeks
79975817|NCT01316718|Drug|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
79975818|NCT01316718|Drug|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
79975819|NCT01339806|Behavioral|Cognitive Rehab|APT-III, Other standard individual and group interventions.
79809255|NCT04154735|Drug|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
79809256|NCT04154735|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
79809257|NCT04154735|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
79321576|NCT03636256|Drug|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
79321577|NCT03633201|Device|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
79809258|NCT04154735|Drug|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
79975820|NCT01339806|Behavioral|Brainworks|POSIT
79975821|NCT01339806|Behavioral|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
79975822|NCT01316952|Drug|Carvedilol immediate release only|All dosages of carvedilol immediate release
79975823|NCT01316952|Drug|Carvedilol extended release only|All dosages of carvedilol extended release
79975824|NCT01316952|Drug|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
79975825|NCT01316952|Drug|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
79809259|NCT04154735|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
79645539|NCT04682080|Behavioral|Needle-free injection|"This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version"
79645540|NCT00407732|Behavioral|psychosocial intervention|motivational enhancing case management intervention
79645541|NCT04682119|Drug|LY3526318|Administered orally.
79809260|NCT04154735|Drug|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
79809261|NCT04154735|Drug|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
79809262|NCT00665405|Radiation|CT scan|Thoracic CT scan
79809263|NCT00665483|Other|Skin Prick Test|Skin Prick Test
79302409|NCT03072849|Drug|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC <0.8.
79645542|NCT04682119|Drug|Placebo|Administered orally.
79645543|NCT02907385|Device|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
79809264|NCT00705042|Drug|Etanercept|
79479747|NCT02637024|Radiation|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
79479748|NCT02637024|Radiation|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
79479749|NCT02623972|Drug|Eribulin|administered IV for 4 cycles
79813771|NCT04107714|Behavioral|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~Lesson 4: Telling your story: Participants learn how to tell their own story.~In a booster session, participants discuss their experiences with disclosure or non-disclosure."
79479750|NCT02623972|Drug|Adriamycin|administered IV with cyclophosphamide for 4 cycles
79479751|NCT02623972|Drug|Cyclophosphamide|administered IV with adriamycin for 4 cycles
79479752|NCT02601495|Behavioral|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
79479753|NCT02601339|Procedure|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
79479754|NCT02568618|Genetic|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
79479755|NCT02536300|Drug|Idelalisib|Idelalisib tablet administered orally
79645544|NCT00198120|Drug|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
79302410|NCT05463497|Drug|Treatment A|JW0201: single administration, Tablet, Oral, BID for 5 days
79302411|NCT05463497|Drug|Treatment B|C2103: single administration, Tablet, Oral, BID for 5 days
79302412|NCT05463497|Drug|Treatment C|JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
79302413|NCT05463497|Drug|Treatment D|C2104 : single administration, Tablet, Oral, QD for 5 days
79302414|NCT05463497|Drug|Treatment E|JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
79645545|NCT00198120|Drug|Placebo|Placebo: same dosing schedule and capsule strength
79645546|NCT02907541|Other|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
79302415|NCT03073083|Procedure|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
79302416|NCT03073083|Procedure|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
79302417|NCT03073083|Procedure|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
79302418|NCT03317171|Dietary Supplement|Flavonoids, DHA, EPA|oral administration
79302419|NCT03317171|Dietary Supplement|placebo compound|oral administration
79809265|NCT04030806|Other|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
79809266|NCT00879437|Drug|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
79809267|NCT00879437|Drug|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
79813772|NCT05753852|Drug|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
79813773|NCT00821782|Drug|Levofloxacin; Azithromycin|
79321578|NCT03633201|Device|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
79321579|NCT03614676|Procedure|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
79975826|NCT01316952|Drug|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
79975827|NCT01316952|Other|No β-blocker|No β-blocker within the month prior to the index date
79321580|NCT03614676|Procedure|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
79321581|NCT03614676|Other|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
79321582|NCT03614676|Procedure|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
79321583|NCT03614676|Other|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
79645547|NCT02907541|Other|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
79645548|NCT02907541|Other|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
79645549|NCT02907424|Dietary Supplement|2 months of treatment|standard 2 months of treatment
79645550|NCT02964065|Biological|Live-Attenuated influenza Vaccine(LAIV)|
79645551|NCT02964065|Biological|Placebo|
79645552|NCT02907346|Behavioral|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
79645553|NCT00198159|Drug|ZD1839 Iressa|
79975828|NCT02726074|Drug|Perampanel|
79975829|NCT02479438|Other|Diagnosed with GERD|Recording of patient outcomes
79975830|NCT02481388|Other|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
79975831|NCT02476318|Device|ArterX Vascular Sealant|
79302420|NCT03220321|Other|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
79302421|NCT03220321|Other|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
79302422|NCT03075657|Drug|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
79302423|NCT03075657|Drug|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
79302424|NCT03075657|Drug|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
79302425|NCT03075657|Drug|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
79302426|NCT02451865|Drug|Binimetinib|Given PO
79302427|NCT02451865|Drug|Docetaxel|Given IV
79302428|NCT02451865|Other|Laboratory Biomarker Analysis|Correlative studies
79302429|NCT05004207|Diagnostic Test|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
79302430|NCT03317093|Drug|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
79302431|NCT03317093|Other|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
79975832|NCT02476240|Behavioral|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
79975833|NCT02478814|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
79321584|NCT03559946|Device|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
79975834|NCT05449444|Drug|Masitinib 4.5 mg/kg/day|Masitinib 4.5 mg/kg/day
79975835|NCT05449444|Drug|Placebo|Matching placebo
79479756|NCT02534948|Behavioral|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
79479757|NCT02525692|Drug|ONC201|
79479758|NCT02514382|Drug|Bortezomib|Given SC or IV
79975836|NCT05449444|Other|Best supportive care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
79975837|NCT05449444|Drug|Masitinib 6.0 mg/kg/day|Masitinib 6.0 mg/kg/day
79975838|NCT02481544|Behavioral|Gratitude Journaling Plus SOC|
79975839|NCT02481544|Behavioral|Memorable Events Journaling Plus SOC|
79479759|NCT02514382|Drug|Dexamethasone|Given PO, IV, or IM
79809268|NCT00879437|Radiation|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
79809269|NCT04043832|Diagnostic Test|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
79809270|NCT00665639|Drug|micafungin|IV
79975840|NCT02478970|Device|Konan SP4000|current standard of care at Kellogg Eye Center
79809271|NCT00665639|Drug|caspofungin|IV
79975841|NCT02478970|Device|NIDEK CEM-350|newly marketed device
79975842|NCT03482635|Drug|Spesolimab|Solution for infusion
79975843|NCT03482635|Drug|Placebo|Solution for infusion
79975844|NCT05428852|Other|Laboratory Biomarker Analysis|Correlative Studies
79975845|NCT05428852|Other|Neurocognitive Assessment|NRG-CC
79975846|NCT05428852|Other|Questionnaire Administration|Ancillary studies
79479760|NCT02514382|Other|Laboratory Biomarker Analysis|Correlative studies
79479761|NCT02514382|Other|Pharmacological Study|Correlative studies
79809272|NCT00671489|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
79809273|NCT00671567|Drug|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
79975847|NCT05428852|Device|Fitbit|Fitbit Activity Tracking
79975848|NCT05428852|Dietary Supplement|Dietary Intervention|Undergo ketogenic diet
79975849|NCT01309217|Behavioral|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
79975850|NCT01309217|Other|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
79975851|NCT02476162|Device|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
79479762|NCT02514382|Biological|Wild-type Reovirus|Given IV
79479763|NCT02511067|Drug|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
79975852|NCT03768869|Drug|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
79479764|NCT02511067|Drug|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
79645554|NCT02907112|Behavioral|Meat reduction|Advice, Motivational material and food products provided to participants
79645555|NCT02907190|Other|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
79809274|NCT00671567|Drug|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
79809275|NCT00671567|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
79975853|NCT03768869|Drug|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
79975854|NCT03768869|Drug|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
79975855|NCT03768791|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
79645556|NCT02907190|Other|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
79321585|NCT03559946|Device|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
79809276|NCT04153253|Drug|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
79321586|NCT03480581|Behavioral|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
79321587|NCT03480581|Behavioral|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
79321588|NCT03451331|Drug|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting ~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
79321589|NCT03451331|Drug|Gemcitabine|1000 mg/m^2
79321590|NCT03451331|Drug|Carboplatin|AUC 4.5 (based on the Calvert formula)
79321591|NCT03451331|Drug|Oxaliplatin|130 mg/m^2
79321592|NCT03418961|Drug|Carvedilol|Given PO
79321593|NCT03418961|Other|Laboratory Biomarker Analysis|Correlative studies
79321594|NCT03418961|Other|Patient Observation|Undergo observation
79813774|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
79813775|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
79975856|NCT03768791|Other|SCS is switched on|Spinal cord stimulator is on
79645557|NCT02964026|Device|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
79321595|NCT03406884|Biological|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
79321596|NCT03386357|Combination Product|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
79321597|NCT03386357|Drug|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
79809277|NCT04153253|Procedure|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
79809278|NCT00671645|Drug|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
79809279|NCT00675857|Drug|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
79809280|NCT00675857|Other|placebo|Dosage: 4 capsules BID for 26 weeks
79321598|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
79809281|NCT02629601|Behavioral|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
79321599|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
79321600|NCT03279029|Biological|blood samples|blood samples
79809282|NCT02629601|Behavioral|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
79321601|NCT03279029|Biological|biopsy|biopsy of aortic valve
79321602|NCT03263091|Drug|Roxadustat|Oral tablets
79321603|NCT03263091|Drug|Placebo|Oral tablets
79321604|NCT03230890|Device|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
79321605|NCT03043716|Other|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
79321606|NCT03041220|Procedure|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
79809283|NCT02629601|Behavioral|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
79809284|NCT02629601|Behavioral|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
79809285|NCT02629601|Behavioral|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
79813776|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
79975857|NCT02479048|Dietary Supplement|Test meal 1|High fat meal (HF) with ½ avocado (~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
79321607|NCT03013218|Drug|Evorpacept (ALX148)|Evorpacept (ALX148)
79321608|NCT03013218|Drug|Pembrolizumab|Keytruda
79321609|NCT03013218|Drug|Trastuzumab|Herceptin
79321610|NCT03013218|Drug|Rituximab|Rituxan
79321611|NCT03013218|Drug|Ramucirumab + Paclitaxel|Standard of care chemotherapy
79321612|NCT03013218|Drug|5-FU + Cisplatin|Standard of care chemotherapy
79321613|NCT02996487|Drug|Vancomycin|
79321614|NCT02996487|Other|Placebo|
79645558|NCT02907307|Device|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
79645559|NCT02907307|Device|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
79645560|NCT02907307|Drug|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
79645561|NCT00553345|Drug|selenium|
79645562|NCT00553345|Drug|vitamin E|
79645563|NCT00553345|Procedure|chemoprevention|
79813777|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
79813778|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
79813779|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
79809286|NCT00675935|Other|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
79975858|NCT02479048|Dietary Supplement|Test meal 2|High fat meal (HF) with 1 avocado (~136g) matched for energy but not macronutrient content or type.
79975859|NCT02479048|Dietary Supplement|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
79975860|NCT02475928|Dietary Supplement|zinc gluconate|Zinc supplementation plus nutritional education
79975861|NCT02475928|Dietary Supplement|Placebo|
79975862|NCT02475928|Behavioral|Nutritional education|
79645564|NCT02907229|Device|NCVC-CS1|Intervention Description
79975863|NCT01320917|Device|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
79975864|NCT01320917|Device|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
79975865|NCT02478658|Other|exercise training|high-intensity resistance training
79975866|NCT02475616|Drug|PCO371|
79975867|NCT02475616|Drug|Placebo|
79321615|NCT02980276|Drug|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
79321616|NCT02980276|Other|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
79321617|NCT02920671|Other|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
79321618|NCT02920671|Other|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
79321619|NCT02920671|Other|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
79321620|NCT02920671|Other|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
79645565|NCT02907151|Other|Survey|Complete a survey prior to the consultation and a questionnaire after
79645566|NCT00407771|Drug|Tirofiban|
79321621|NCT02914600|Drug|Filgotinib|Tablet(s) administered orally once daily
79321622|NCT02914600|Drug|Placebo|Tablet(s) administered orally once daily
79321623|NCT02727478|Other|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
79321624|NCT02614794|Drug|tucatinib|300 mg orally twice daily
79321625|NCT02614794|Drug|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
79645567|NCT00198198|Drug|Aripiprazole|
79645568|NCT02206087|Drug|PER977|Reversal of heparin-induced anticoagulation
79645569|NCT02206087|Drug|Placebo|Reversal of heparin-induced anticoagulation
79321626|NCT02614794|Drug|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
79321627|NCT02614794|Drug|placebo|Oral dose twice daily
79321628|NCT02495896|Drug|Cisplatin|Given IV
79321629|NCT02495896|Drug|Docetaxel|Given IV
79645570|NCT02206087|Drug|Heparin Sodium|
79645571|NCT02193139|Drug|WL8713, 6 mg|
79645572|NCT02193139|Drug|WL8713, 12 mg|
79645573|NCT02193139|Drug|WL8713, 18 mg|
79645574|NCT02193139|Drug|WL8713, 24 mg|
79645575|NCT02193139|Drug|Placebo|
79645576|NCT00198237|Drug|docetaxel & capecitabine|
79321630|NCT02495896|Drug|Gemcitabine Hydrochloride|Given IV
79321631|NCT02495896|Other|Laboratory Biomarker Analysis|Correlative studies
79321632|NCT02495896|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
79321633|NCT02495896|Other|Pharmacological Study|Correlative studies
79321634|NCT02495896|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
79645577|NCT02191774|Procedure|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
79645578|NCT04723550|Device|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
79645579|NCT04723550|Other|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
79645580|NCT02161627|Device|Saluda Medical External Trial System|
79645581|NCT02161627|Device|Saluda Medical External Trial System|
79645582|NCT00198354|Drug|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
79645583|NCT00198354|Drug|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
79645584|NCT02160262|Drug|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
79321635|NCT02442297|Biological|HER2-specific T cells|"Dosing Schedule 1:~Cycle 1 A: 1x10^7 cells~Cycle 2 A: 1x10^7 cells~Cycle 3 A: 1x10^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10^7 cells~Cycle 2 B: 3x10^7 cells~Cycle 3 B: 3x10^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10^7 cells~Cycle 2 B: 3x10^7 cells~Cycle 3 C: 1x10^8 cells~Subsequent cycles*~*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."
79321636|NCT02411253|Drug|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
79655772|NCT02214511|Behavioral|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
79975868|NCT01320995|Procedure|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
79321637|NCT02411253|Drug|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
79321638|NCT02266745|Drug|PT-112 Injection|
79321639|NCT02125968|Other|interactive video game|short- and medium-term therapeutic effects
79321640|NCT02125968|Other|therapeutic exercise|short- and medium-term therapeutic effects
79655773|NCT02214511|Behavioral|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
79655774|NCT00236327|Drug|fentanyl|
79975869|NCT02481232|Biological|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
79321641|NCT02100904|Procedure|Radiofrequency ablation of fibroids|
79321642|NCT02100904|Procedure|Myomectomy of fibroids|
79321643|NCT02015325|Behavioral|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health & Hygiene education program.
79321644|NCT01997502|Device|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
79321645|NCT01997502|Other|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
79479765|NCT02501733|Device|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
79975870|NCT03768713|Drug|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
79975871|NCT03768713|Drug|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
79321646|NCT01886391|Behavioral|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
79645585|NCT02158585|Drug|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
79321647|NCT01803165|Procedure|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
79321648|NCT01782443|Drug|Ziv-aflibercept|
79645586|NCT02158585|Drug|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
79645587|NCT00202917|Drug|Fludarabine|
79321649|NCT01736072|Procedure|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
79321650|NCT01736072|Procedure|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
79321651|NCT01712815|Other|laboratory biomarker analysis|Correlative studies
79321652|NCT01712815|Other|pharmacological study|Correlative studies
79321653|NCT01712815|Other|questionnaire administration|Ancillary studies
79645588|NCT00202917|Drug|Thiotepa|
79321654|NCT01712815|Radiation|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
79321655|NCT01712815|Procedure|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
79321656|NCT01649232|Device|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
79321657|NCT01555632|Drug|atorvastatin calcium|Given PO
79321658|NCT01555632|Drug|placebo|Given PO
79321659|NCT01337921|Dietary Supplement|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
79321660|NCT01274026|Drug|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
79321661|NCT01225757|Device|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
79321662|NCT01186029|Drug|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
79479766|NCT02491840|Procedure|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
79479767|NCT02462239|Other|Whole-body FDG PET-CT|
79479768|NCT02458274|Other|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
79645589|NCT00202917|Drug|Melphalan|
79645590|NCT00202917|Drug|OKT-3|
79645591|NCT00202917|Procedure|CD3/CD19 depletion on CliniMACS|
79645592|NCT02145364|Device|Ultherapy® treatment|Microfocused ultrasound treatment
79645593|NCT02135536|Biological|NGM282|NGM282
79645594|NCT00202956|Drug|Bugusan|
79645595|NCT02109406|Drug|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
79645596|NCT02109406|Drug|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
79645597|NCT02109406|Drug|Placebo MDI|Placebo MDI administered as two inhalations BID
79645598|NCT02109016|Drug|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
79645599|NCT00202995|Drug|Glatiramer Acetate|20 mg s.c. daily
79645600|NCT00202995|Drug|Betaseron|250 mg every other day
79479769|NCT02409147|Procedure|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
79479770|NCT02402439|Drug|Islet cells|Transplantation of islets into the gastrointestinal submucosa
79479771|NCT02402439|Procedure|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
79645601|NCT00202995|Drug|Rebif|44 ug 3 times a week
79321663|NCT00955968|Drug|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
79321664|NCT00955136|Device|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
79321665|NCT00896012|Procedure|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
79321666|NCT00896012|Drug|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
79479772|NCT02392026|Drug|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
79645602|NCT04678219|Other|Dietary Intervention|Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
79645603|NCT04677868|Drug|Methotrexate|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
79645604|NCT00198393|Drug|Gefitinib|250 mg/day, until progression
79645605|NCT00198393|Drug|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
79645606|NCT00198393|Drug|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
79645607|NCT02104336|Drug|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
79479773|NCT02389036|Drug|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
79479774|NCT02389036|Drug|SDD Gastric Suspension|2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 ^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
79479775|NCT02389036|Drug|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
79479776|NCT02375854|Other|Observation|
79479777|NCT02369523|Drug|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
79479778|NCT02369523|Drug|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
79479779|NCT02369523|Drug|Bupivacaine|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
79479780|NCT02355340|Other|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
79479781|NCT02355340|Other|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
79479782|NCT02339064|Drug|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
79645608|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
79655775|NCT00269139|Behavioral|Crisis resolution|
79655776|NCT02214589|Other|Oral glucose, facilitated tucking, NNS|
79655777|NCT02214589|Other|Oral glucose and NNS|
79975872|NCT02481076|Device|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
79975873|NCT02481076|Other|Braun frame|The leg is elevated on a Braun frame
79975874|NCT02481076|Device|compression bandage|application of flowtron hydroven boot and compression bandage
79975875|NCT03768635|Other|necrotizing external otitis|description of necrotizing external otitis
79975876|NCT02478736|Other|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
79479783|NCT02311192|Device|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
79479784|NCT02298777|Procedure|- Skin biopsy - Urine sample - Blood sample|
79479785|NCT02277717|Drug|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
79809287|NCT02629523|Drug|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
79479786|NCT02273219|Drug|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
79975877|NCT02475694|Other|No intervention|No treatment
79975878|NCT05713474|Diagnostic Test|Diagnostic EMG exam with microEMG|Diagnostic EMG exam with microEMG
79975879|NCT05713474|Diagnostic Test|Conventional EMG|Diagnostic EMG exam with conventional EMG
79975880|NCT02480842|Other|Alloplastic free ROM|
79975881|NCT02480842|Other|Alloplastic limited ROM|
79975882|NCT02480842|Other|Oncoplastic free ROM|
79975883|NCT02480842|Other|Oncoplastic limited ROM|
79975884|NCT05713396|Drug|Quinapril|Per os
79479787|NCT02273219|Drug|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
79479788|NCT02246140|Other|Cerebral MRI and MRA|
79479789|NCT02207712|Device|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
79479790|NCT02207712|Drug|Ranibizumab|Standard ranibizumab treatment only
79479791|NCT02207127|Procedure|MRI, DISE, and Surgery|MRI, DISE, and Surgery
79479792|NCT02187991|Drug|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
79479793|NCT02187991|Drug|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
79645609|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
79479794|NCT02152046|Procedure|ROP exam with spring loaded retractor|
79479795|NCT02152046|Procedure|ROP exam with screw retractor|
79479796|NCT02118922|Procedure|Brillouin imaging|
79655778|NCT02214589|Other|Facilitated tucking and NNS|
79809288|NCT02629679|Behavioral|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
79809289|NCT02629679|Behavioral|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
79809290|NCT04152005|Other|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
79809291|NCT00671801|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
79975885|NCT05713396|Drug|Losartan|Per os
79975886|NCT05713396|Drug|Quinapril + Losartan|Per os
79975887|NCT02480530|Behavioral|Individual Feedback|Patient gets feedback reports on adherence weekly.
79975888|NCT02480530|Behavioral|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
79975889|NCT02480608|Drug|Imatinib|
79975890|NCT02480608|Drug|Hydroxyurea|
79975891|NCT02480686|Drug|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
79984700|NCT03201796|Drug|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
79984701|NCT03201796|Drug|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
79975892|NCT02475538|Device|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
79984702|NCT03107260|Other|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
79321667|NCT00896012|Drug|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
79321668|NCT00876226|Drug|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
79321669|NCT00816413|Drug|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
79321670|NCT00816413|Drug|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
79321671|NCT00816413|Drug|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
79479797|NCT02111382|Other|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
79645610|NCT02100436|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
79655779|NCT04546984|Drug|HEC96719|Part 2：Mulltiple doses up to 10 days
79655780|NCT00236366|Drug|fentanyl|
79321672|NCT00816413|Genetic|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
79321673|NCT00816413|Genetic|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
79975893|NCT02475538|Device|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
79975894|NCT02475382|Drug|Nivolumab|Specified dose on specified days
79321674|NCT00816413|Genetic|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
79321675|NCT00816413|Other|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
79321676|NCT00816413|Other|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
79321677|NCT00816413|Other|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
79321678|NCT00816413|Other|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
79321679|NCT00816413|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
79321680|NCT00816413|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
79975895|NCT02475460|Procedure|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
79321681|NCT00816413|Radiation|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
79321682|NCT00734838|Device|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
79645611|NCT00554827|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
79975896|NCT02475460|Device|HeartMate 3™|HM 3 LIS
79975897|NCT02475304|Drug|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
79975898|NCT02475304|Drug|Placebo|
79975899|NCT02478346|Drug|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
79984703|NCT02727998|Drug|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
79984704|NCT02727998|Drug|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
79321683|NCT00579241|Procedure|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
79321684|NCT00488943|Device|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
79321685|NCT05917080|Other|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia & applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
79321686|NCT05917054|Other|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
79321687|NCT05917041|Device|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
79321688|NCT05917015|Dietary Supplement|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
79321689|NCT05917015|Other|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
79321690|NCT05917002|Device|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
79321691|NCT05917002|Device|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
79321692|NCT05916976|Diagnostic Test|cardiac MRI|Multiparametric MRI of the heart
79321693|NCT05916924|Other|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
79321694|NCT05916898|Device|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
79321695|NCT02342977|Drug|Placebo|Patients will randomly receive placebo
79321696|NCT02342977|Drug|Lacosamide|Patients will randomly receive lacosamide
79321697|NCT05916859|Other|Group 2 PDT (10 s)|- Conventional endodontic treatment associated with PDT (10 s)
79321698|NCT05916859|Other|Group 3 PDT 20 s|Conventional endodontic treatment associated with PDAT (20 s)
79645612|NCT00554827|Dietary Supplement|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
79321699|NCT05916859|Other|Group 1. Placebo|Conventional endodontic treatment
79321700|NCT05916846|Procedure|EUS-guided radiofrequency ablation of pancreatic cyst|EUS-RFA is performed with an 19 Gauge RFA needle (STARMed/TaeWoong Medical USA) applying up to 30 Watt (W) current with Continuance Mode setting. RFA confirmation is confirmed endoscopically via EUS (white bubbles on EUS imaging) and impedance monitoring on the VIVA™ Combo System. Impedance has a maximum value up 800 Ohms. Sequential doses of electrical energy at 10W-30W are applied to ablate the PCN.
79321701|NCT05916846|Device|FDA-cleared device (EUS-RFA probe)|FDA-cleared device (EUS-RFA probe).
79321702|NCT05916833|Other|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
79321703|NCT05916833|Other|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
79321704|NCT05916781|Drug|Mycophenolate Mofetil|During the first 18 months, participants will take MMF+TAC. After 18 months, participants without lupus flare will randomly stop MMF or TAC.
79984705|NCT02444806|Other|Full polysomnography|Full sleep and respiratory monitoring with EEG
79984706|NCT02444806|Other|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
79809292|NCT00671801|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
79321705|NCT05916781|Drug|Tacrolimus|During the first 18 months, participants will take MMF+TAC. After 18 months, participants without lupus flare will randomly stop MMF or TAC.
79321706|NCT05916781|Drug|Glucocorticoid|Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months. Participants in steroid maintenance group will consistently take glucocorticoid.
79645613|NCT00554827|Drug|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
79975900|NCT02478424|Drug|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
79975901|NCT02478424|Drug|cyclosporine|
79975902|NCT02478424|Drug|Methotrexate|
79975903|NCT02475148|Drug|JNJ 54175446|
79975904|NCT02475148|Drug|Placebo|
79975905|NCT02475148|Other|High fat/high Calorie Breakfast|
79321707|NCT05916768|Other|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
79321708|NCT05916768|Other|usual care|symptomatic treatments
79321709|NCT05916755|Diagnostic Test|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
79321710|NCT05916755|Diagnostic Test|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
79321711|NCT05916755|Diagnostic Test|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
79321712|NCT05916755|Diagnostic Test|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
79321713|NCT05916755|Diagnostic Test|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
79321714|NCT05916755|Diagnostic Test|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
79321715|NCT05916755|Drug|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
79645614|NCT00203034|Drug|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
79645615|NCT00203034|Drug|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
79809293|NCT04153331|Other|Nasal swab|Patient included in emergency with a nasal swab
79813780|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
79975906|NCT03712787|Drug|Tilavonemab|solution for IV infusion
79975907|NCT04492150|Drug|Dextrose 5%/Nacl 0.3% Inj_#3|250 mL/hour of dextrose 5% intravenous drip
79975908|NCT04492150|Drug|Saline|250 mL/hour of normal saline intravenous drip
79975909|NCT02475226|Other|type of the brain injury|epidural hematoma
79809294|NCT00676325|Procedure|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
79809295|NCT00676325|Device|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
79321716|NCT05916755|Drug|Chemotherapy|Standard NACT will be given.
79321717|NCT05916742|Procedure|CAF|Periodontal surgical technique to treat gingival recessions
79809296|NCT00676325|Procedure|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
79975910|NCT02475226|Other|type of the brain injury|subdural hematoma
79321718|NCT05916742|Procedure|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
79809297|NCT00676481|Behavioral|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
79809298|NCT00672035|Biological|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
79809299|NCT00676559|Drug|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
79975911|NCT02475226|Other|type of the brain injury|subarachnoid hematoma
79975912|NCT02475226|Other|type of the brain injury|intraparenchymal hematoma
79975913|NCT02475226|Other|type of the brain injury|scull fracture
79321719|NCT05916742|Device|VCMX|Porcine derived collagen matrix.
79321720|NCT05916742|Drug|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
79321721|NCT05916742|Drug|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
79321722|NCT05916742|Drug|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
79321723|NCT05916729|Drug|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
79321724|NCT05916729|Dietary Supplement|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
79975914|NCT02475226|Other|type of the brain injury|brain contusion
79984707|NCT02636270|Drug|Increlex|Treat PAPP-A2 deficient patients with Increlex
79645616|NCT00203034|Other|Placebo|oral placebo once daily
79645617|NCT04677673|Drug|Chemotherapy|Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
79645618|NCT04677673|Procedure|Curative gastrectomy|Radical gastrectomy with D2 lymph node dissection
79321725|NCT05916716|Procedure|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
79321726|NCT05916716|Procedure|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
79321727|NCT05916716|Device|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
79321728|NCT05916716|Drug|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
79645619|NCT00203073|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
79321729|NCT05916716|Drug|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
79809300|NCT00676559|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
79809301|NCT00672113|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
79809302|NCT00672113|Drug|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
79645620|NCT00203073|Drug|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
79809303|NCT00676637|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
79809304|NCT00676637|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
79645621|NCT04677634|Dietary Supplement|ISOThrive Prebiotic Nectar|The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
79809305|NCT00877799|Drug|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
79645622|NCT00554866|Other|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
79645623|NCT02078674|Biological|Monovalent Avian Influenza VLP (H7N9)|
79645624|NCT02078674|Biological|Matrix-M1™ adjuvant|
79645625|NCT02078674|Biological|Placebo|
79809306|NCT00877799|Drug|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
79809307|NCT00877799|Drug|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
79809308|NCT00877799|Drug|Placebo|Matched placebo administered the day after surgery (Day 1)
79809309|NCT00877799|Drug|Placebo|Matched placebo administered immediately after surgery (Day 0)
79809310|NCT00672347|Drug|Clonidine|1 mcg/kg
79809311|NCT00672347|Drug|Morphine|20 mcg/kg
79809312|NCT00672347|Drug|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
79809313|NCT00672347|Drug|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
79809314|NCT00676871|Drug|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
79809315|NCT00676871|Drug|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
79809316|NCT00676871|Drug|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
79809317|NCT00676871|Drug|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
79321730|NCT05916703|Diagnostic Test|SOLUS examination|"The examination of each subject will include: i) B-mode US, ii), color Doppler US, iii) shear wave elastography, and iv) SOLUS multimodal imaging.~For each subject various ultrasound images (modalities i-iii) will be taken and these images will determine the location for the SOLUS measurements (iv).~All measurements (i-iv) will be taken at the lesion location, in the normal breast tissue around the lesion, and in the mirror location of the contralateral breast.~Optically derived data (blood volume, blood oxygen saturation, water, lipid and collagen concentrations, tissue scattering parameters) will be obtained. Every subject included in the study will be evaluated separately by 3 radiologists, with different level of experience in breast imaging."
79321731|NCT05916638|Other|blood sample|blood sample collection
79809318|NCT00676871|Drug|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
79321732|NCT05916599|Device|ultrasound|a device which is used in intensive care units,
79645626|NCT00198432|Drug|Paclitaxel, vinorelbine, cisplatin|
79645627|NCT02075281|Biological|HM11260C|Glucagon-like peptide-1 analogue
79645628|NCT02075281|Biological|Placebo|
79809319|NCT00676871|Drug|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
79809320|NCT00676871|Drug|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
79809321|NCT00676949|Biological|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
79809322|NCT02629445|Device|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
79809323|NCT00677027|Other|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
79809324|NCT00677027|Other|placebo|Placebo
79809325|NCT00672581|Drug|ZD4054|10mg, Oral tablet, single dose
79321733|NCT05916573|Drug|HSK16149|single oral adminiatration, 20mg
79321734|NCT05916521|Drug|0.454% stannous fluoride|Brush two times daily
79321735|NCT05916521|Drug|0.76% sodium monofluorophosphate|Brush two times daily
79321736|NCT05916521|Drug|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
79321737|NCT05916508|Drug|0.454% stannous fluoride|Brush two times daily
79479798|NCT02111382|Other|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
79645629|NCT02074579|Drug|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
79645630|NCT02074579|Drug|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
79645631|NCT02072863|Drug|Oprozomib|Study subjects will receive oprozomib administered orally.
79645632|NCT02072863|Drug|Melphalan|Study subjects will receive melphalan 9 mg/m2.
79645633|NCT02072863|Drug|Prednisone|Study subjects will receive prednisone 60 mg/m2.
79645634|NCT02072161|Drug|ETC-1002|ETC-1002 capsules, taken once daily oral
79645635|NCT02072161|Drug|Placebo|Placebo capsules, taken once daily oral
79655781|NCT04546789|Drug|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
79655782|NCT00261690|Behavioral|Virtual Reality Distraction|Using virtual reality distraction during a procedure
79655783|NCT04547179|Drug|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
79655784|NCT04547179|Device|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
79655785|NCT04547179|Other|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
79655786|NCT04547101|Drug|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
79809326|NCT00595127|Drug|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
79809327|NCT00595127|Drug|Fludarabine|Fludarabine (30mg/m^2/day x 5 days)
79809328|NCT00595127|Radiation|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
79809329|NCT00672659|Drug|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
79809330|NCT00672659|Drug|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
79321738|NCT05916508|Drug|0.76% sodium monofluorophosphate|Brush two times daily
79321739|NCT05916508|Drug|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
79321740|NCT05916469|Drug|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
79321741|NCT05916469|Drug|Norethindrone Acetate|norethindrone acetate 5 mg daily
79321742|NCT05916456|Diagnostic Test|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
79321743|NCT05916456|Diagnostic Test|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
79321744|NCT05916456|Diagnostic Test|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
79321745|NCT05916430|Diagnostic Test|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
79479799|NCT02108860|Drug|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
79479800|NCT02108860|Drug|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
79321746|NCT05916391|Genetic|FT-003|Administration via intraocular injection
79321747|NCT05916365|Biological|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
79321748|NCT05916326|Biological|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
79321749|NCT05916326|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
79321750|NCT05916274|Biological|Blood and fecal samples|Blood and fecal samples will be performed
79321751|NCT05916274|Procedure|Coolonic biopsies|colonic biopsies will be analysed
79321752|NCT05916248|Biological|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
79479801|NCT02079181|Radiation|fluorine F 18 d-FMAU|Given IV
79479802|NCT02079181|Procedure|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
79645636|NCT02072161|Drug|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
79975915|NCT02478268|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
79321753|NCT05916209|Procedure|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
79479803|NCT02079181|Procedure|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
79479804|NCT02076906|Device|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
79479805|NCT02072642|Device|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
79321754|NCT05916105|Drug|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
79321755|NCT05916066|Dietary Supplement|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
79321756|NCT05916027|Behavioral|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
79975916|NCT02478268|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
79975917|NCT04053881|Drug|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
79975918|NCT05713162|Behavioral|Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).|The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
79321757|NCT05916014|Diagnostic Test|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
79321758|NCT05916001|Other|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
79321759|NCT05916001|Dietary Supplement|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
79321760|NCT05916001|Procedure|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
79321761|NCT05915962|Procedure|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
79321762|NCT05915936|Procedure|LVMR|laoparoscopic ventral mesh rectopexy
79479806|NCT02072642|Device|Placebo light therapy|4 weeks with Placebo light therapy
79479807|NCT02043457|Other|phenotyping|
79975919|NCT05713084|Other|mandibular setback using BSSRO|mandibular setback using BSSRO
79321763|NCT05915936|Procedure|PSR|perineal stapler resection
79479808|NCT02039934|Other|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
79479809|NCT01947218|Procedure|bronchial biopsies|
79479810|NCT01947218|Other|Determination of CO in exhaled air|
79479811|NCT01860937|Procedure|leukapheresis or collection of PBMCs|
79479812|NCT01860937|Drug|cyclophosphamide based chemotherapy regimens|
79479813|NCT01860937|Biological|modified T cells|
79479814|NCT01856686|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
79645637|NCT00198471|Drug|Vitrase|
79645638|NCT02067793|Drug|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
79479815|NCT01856686|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
79975920|NCT01567553|Other|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
79645639|NCT02067793|Drug|Placebo|Single intravenous injection into the arm on Day 0
79645640|NCT02067793|Drug|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
79645641|NCT02067793|Drug|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
79645642|NCT02066545|Drug|CLS001 Topical Gel|
79975921|NCT03768557|Drug|Minocycline|Minocycline (200mg)
79975922|NCT03768557|Other|placebo|Lactose (400mg)
79975923|NCT02478190|Other|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
79321764|NCT05915923|Procedure|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
79321765|NCT05915923|Procedure|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
79321766|NCT05915923|Procedure|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
79321767|NCT05915871|Drug|Tegoprazan|Tablet for oral administration
79321768|NCT05915871|Drug|Bismuth|Capsule for oral administration
79479816|NCT01852448|Genetic|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
79645643|NCT02066545|Drug|CLS001 Topical Gel Vehicle|
79645644|NCT04723121|Diagnostic Test|Urine ELISA for immunological markers (IL-2 and IL-10)|IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
79975924|NCT02478190|Other|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
79984708|NCT04366349|Biological|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
79984709|NCT04366349|Biological|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
79984710|NCT04366349|Other|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
79645645|NCT04723121|Diagnostic Test|Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis|blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
79645646|NCT00203112|Drug|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
79645647|NCT00203112|Drug|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
79645648|NCT00554905|Procedure|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
79645649|NCT00554905|Procedure|TACE|TACE first, then RFA within 2 weeks
79645650|NCT04677478|Other|Impact of respiratory isolation on quality of life|Semi-structured interviews
79975925|NCT05712928|Behavioral|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
79321769|NCT05915871|Drug|Amoxicilli|Capsule for oral administration
79321770|NCT05915871|Drug|Clarithromycin|Tablet for oral administration
79321771|NCT05915858|Other|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~The angle of hip flexion should not exceed 60 degree.~The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
79645651|NCT00173108|Behavioral|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
79645652|NCT02062060|Drug|Abametapir Lotion 0.74% w/w|
79645653|NCT02062060|Drug|Vehicle Lotion|
79645654|NCT00198510|Drug|Vitrase|7.5 IU of Vitrase
79645655|NCT00198510|Drug|Vitrase|55 IU of Vitrase
79645656|NCT00198510|Drug|Vitrase|75 IU of Vitrase
79645657|NCT02057380|Drug|linsitinib|oral
79645658|NCT02057380|Drug|erlotinib|oral
79975926|NCT01309373|Other|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
79645659|NCT02057380|Drug|paclitaxel|Intravenous (IV) infusion
79984711|NCT02108990|Drug|Acetaminophen|
79984712|NCT01766648|Device|Far Cortical locking screw fixation|Standard screw fixation
79321772|NCT05915858|Other|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~The process is repeated 3-5 times with a 30"
79321773|NCT05915845|Other|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
79479817|NCT01833689|Dietary Supplement|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
79645660|NCT02057380|Drug|Bortezomib|Subcutaneous or IV
79645661|NCT02057380|Drug|Dexamethasone|IV, Oral
79645662|NCT02057341|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
79645663|NCT00554944|Procedure|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
79645664|NCT02052778|Drug|Futibatinib|oral once daily dosing, 21-day cycle
79479818|NCT01796834|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
79645665|NCT00203151|Drug|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
79479819|NCT01770145|Drug|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
79645666|NCT02050828|Drug|AKB-9778|
79645667|NCT02050828|Drug|ranibizumab|
79645668|NCT02050828|Drug|Placebo|
79645669|NCT02050828|Drug|Sham|
79321774|NCT05915845|Other|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
79321777|NCT05915819|Other|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump & turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
79479820|NCT01770145|Drug|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
79645670|NCT02048059|Drug|ANG1005|
79645671|NCT00198549|Drug|Vitrase (ovine hyaluronidase) Lyophilized|
79984713|NCT01766648|Device|Standard screw fixation|
79984714|NCT03194074|Drug|Propofol|In propofol/remifentanil group, propofol at a rate 75~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
79984715|NCT03194074|Drug|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
79984716|NCT03748277|Procedure|Decompression|Bilateral decompression
79975927|NCT02480140|Other|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
79321778|NCT05915819|Other|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
79321779|NCT05915793|Other|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
79321780|NCT05915793|Other|Diaphragm strengthening|Diaphragm strengthening
79321781|NCT05915780|Device|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
79321782|NCT05915780|Device|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
79321783|NCT05915754|Other|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
79321784|NCT05915754|Other|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
79307037|NCT05502042|Behavioral|Case Manager and Peer Support Group|Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.
79645672|NCT02046694|Drug|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
79645673|NCT02044081|Drug|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
79645674|NCT02044081|Drug|Placebo|Placebo is the vehicle without C16G2
79645675|NCT02044081|Drug|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
79645676|NCT00203190|Drug|Topiramate|
79645677|NCT02019589|Drug|Progesterone|
79645678|NCT02019589|Drug|Placebo|
79975928|NCT02480140|Other|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
79975929|NCT02480140|Other|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
79975930|NCT04034381|Other|No intervention (descriptive survey only)|No intervention
79307038|NCT05496465|Drug|ARS-1|A single treatment of ARS-1.
79307039|NCT05496465|Drug|Placebo|A single treatment of placebo nasal spray
79307040|NCT05485194|Other|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
79307041|NCT05483556|Device|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
79645679|NCT02018926|Drug|Mocetinostat|Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
79645680|NCT02018926|Drug|Azacitidine|Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
79645681|NCT02017912|Biological|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
79645682|NCT02017912|Biological|Placebo|Excipient administration by combined intramuscular and intrathecal administration
79645683|NCT00203346|Procedure|Greater Occipital Nerve Block|
79645684|NCT02013310|Drug|HT-0712|
79645685|NCT02013310|Drug|Placebo|
79645686|NCT01993264|Other|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
79645687|NCT01989325|Drug|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
79645688|NCT01989325|Drug|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
79307042|NCT05483556|Device|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
79307043|NCT05479045|Biological|NY-ESO-1 Peptide vaccine|300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 4 weeks.
79307044|NCT05479045|Drug|Nivolumab|480 milligrams (mg), intravenously, every 4 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
79307045|NCT05466721|Device|Hydrustoma C3|The participant will use the device for 14 days.
79307046|NCT05466721|Device|Coloplast Alterna|The participant will use the device for 14 days.
79307047|NCT05463393|Biological|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
79975931|NCT03783845|Combination Product|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
79975932|NCT05349370|Other|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
79975933|NCT03768479|Device|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
79321785|NCT05915676|Diagnostic Test|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
79321786|NCT05915663|Other|nasogastric tube and orogastric tube|nasogastric tube in period 1 and orogastric tube in period 2
79321787|NCT05915663|Other|orogastric tube and nasogastric tube|orogastric tube in period 1 and nasogastric tube in period 2
79321788|NCT05915650|Behavioral|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
79321789|NCT05915650|Behavioral|Routine Education|Carry out routine education intervention for TKA patients
79321790|NCT05915624|Other|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
79321791|NCT05915611|Other|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
79321792|NCT05915611|Other|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
79479821|NCT01770145|Drug|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
79975934|NCT01560689|Drug|Budesonide/formoterol|800 µg/j twice a day, every day
79975935|NCT01560689|Drug|Placebo|Twice a day, every day
79975936|NCT02474914|Drug|Octreotide|Octreotide will be given after PD
79975937|NCT02474914|Drug|Placebo|Octreotide will NOT be given after PD
79975938|NCT03768401|Other|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
79984717|NCT03748277|Procedure|PLIF|Traditional open surgery
79975939|NCT03768401|Behavioral|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
79321793|NCT05915598|Other|Right/left discrimination training|"Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team"
79321794|NCT05915598|Other|usual care|"Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function."
79321795|NCT05915585|Device|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
79321796|NCT05915520|Behavioral|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
79321797|NCT05915520|Other|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
79479822|NCT01758081|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
79645689|NCT01989325|Drug|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
79975940|NCT03768323|Other|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
79479823|NCT01758081|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
79975941|NCT03768323|Other|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
79321798|NCT05915507|Other|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
79321799|NCT05915507|Other|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
79321800|NCT05915481|Drug|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
79321801|NCT05915481|Radiation|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
79321802|NCT05915416|Behavioral|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
79321803|NCT05915403|Diagnostic Test|Fibromyalgia Impact Questionnaire|diagnostic tests
79321804|NCT05915286|Drug|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
79321805|NCT05915286|Drug|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
79321806|NCT05915273|Other|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH & Co., Ispringen, Germany)- were used for the CAD/CAM group
79321807|NCT05915273|Other|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
79321808|NCT05915273|Other|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
79321809|NCT05915260|Diagnostic Test|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
79975942|NCT03768245|Behavioral|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
79479824|NCT01758081|Dietary Supplement|Vitamin D3 placebo|
79479825|NCT01758081|Dietary Supplement|fish oil placebo|
79479826|NCT01749137|Drug|Setmelanotide|Daily subcutaneous infusion
79479827|NCT01749137|Drug|Placebo|Daily subcutaneous infusion
79984718|NCT03748277|Procedure|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
79984719|NCT03748277|Procedure|Screw Fixation|Transpedicular Screw Fixation
79645690|NCT01989325|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
79645691|NCT00409929|Drug|AEB071|
79645692|NCT01978366|Drug|HT-100|May be administered in either fed or fasted state
79975943|NCT03768245|Dietary Supplement|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
79975944|NCT03769103|Drug|Osimertinib|Daily oral osimertinib
79645693|NCT03455023|Other|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
79645694|NCT02962986|Drug|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
79809331|NCT00877487|Drug|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
79321813|NCT05915221|Procedure|SMS|Receive SMS
79321814|NCT05915156|Other|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
79321815|NCT05915130|Behavioral|Gait training|They will negotiate (natural or virtual) obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
79321816|NCT05915117|Dietary Supplement|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
79321817|NCT05915117|Drug|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
79479828|NCT01726582|Drug|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
79645695|NCT02962986|Drug|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
79809332|NCT00877487|Drug|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
79809333|NCT02629211|Device|NaviAid™ AB|NaviAid™ AB Procedure
79809334|NCT00677261|Procedure|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
79975945|NCT03769103|Radiation|Stereotactic radiotherapy|1-5 fractions of stereotactic radiotherapy
79984720|NCT01163864|Behavioral|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
79321818|NCT05915091|Diagnostic Test|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
79321819|NCT05915091|Other|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
79479829|NCT01726582|Radiation|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
79321820|NCT05915065|Device|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
79479830|NCT01726582|Drug|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
79479831|NCT01726582|Radiation|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
79479832|NCT01726582|Drug|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
79479833|NCT01726582|Radiation|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
79479834|NCT01726582|Drug|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
79479835|NCT01726582|Radiation|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
79479836|NCT01726582|Drug|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
79479837|NCT01726582|Radiation|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
79479838|NCT01726582|Radiation|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
79479839|NCT01726582|Drug|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
79479840|NCT01726582|Drug|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
79645696|NCT04676893|Drug|D418 Tab.|1T
79479841|NCT01726582|Other|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
79479842|NCT01693965|Other|sputum samples|
79645697|NCT04676893|Drug|CKD-388 Tab.|1T
79645698|NCT04677361|Combination Product|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
79645699|NCT01972867|Device|NanoKnife Procedure|Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
79655787|NCT04546906|Biological|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
79655788|NCT00236405|Drug|epoetin alfa|
79655789|NCT00269178|Behavioral|Peer Health Education Programme|
79975946|NCT03768167|Procedure|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
79975947|NCT03773081|Device|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
79975948|NCT01561547|Behavioral|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
79321821|NCT05915052|Procedure|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
79479843|NCT01687127|Dietary Supplement|Folic acid|Supplement
79321822|NCT05915052|Procedure|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
79321823|NCT05915013|Drug|Ketamine|Intravenous ketamine
79321824|NCT05915013|Drug|Perampanel|Oral perampanel (6 mg)
79479844|NCT01687127|Dietary Supplement|5-methyltetrahydrofolate, calcium salt|Supplement
79479845|NCT01658787|Device|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
79479846|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
79479847|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
79479848|NCT01565200|Drug|T-DM1|3.6 mg/kg iv every 3 weeks
79321825|NCT05915013|Drug|Placebo|Oral placebo
79479849|NCT01565200|Procedure|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
79479850|NCT01476787|Drug|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
79479851|NCT01476787|Drug|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
79479852|NCT01476787|Drug|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
79479853|NCT01476787|Drug|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
79655790|NCT00236444|Drug|risperidone|
79975949|NCT01561547|Dietary Supplement|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
79975950|NCT04998214|Diagnostic Test|liver function , prothrombin time , INR , US .|analytic
79479854|NCT01476787|Drug|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
79479855|NCT01410825|Biological|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
79479856|NCT01398332|Device|Stent graft (EXCLUDER)|Endovascular repair
79479857|NCT01373489|Behavioral|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
79479858|NCT01289834|Device|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH & Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
79809335|NCT00677261|Procedure|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
79809336|NCT00677261|Procedure|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
79321826|NCT05915000|Diagnostic Test|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
79321827|NCT05914935|Drug|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
79479859|NCT01289834|Device|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
79479860|NCT01229059|Dietary Supplement|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
79479861|NCT01222351|Drug|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
79479862|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
79479863|NCT01059786|Drug|Pentostatin|28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.
79645700|NCT04677127|Behavioral|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
79645701|NCT00409968|Procedure|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
79645702|NCT04677088|Biological|TCR-T cells|Patients will receive 1 x 10^4 cells/kg to 5 x 10^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
79645703|NCT04676971|Drug|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
79645704|NCT04676971|Drug|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
79645705|NCT01968733|Drug|Solithromycin|
79645706|NCT01968733|Drug|Moxifloxacin|
79809337|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
79809338|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
79479864|NCT01059786|Drug|Rituximab|Rituximab 375 mg/m2 on day 1, 15 for 6 x 28-day cycles (all 72 patients)
79479865|NCT01059786|Drug|Bendamustine|28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each cycle
79479866|NCT01046123|Radiation|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
79975951|NCT03772769|Diagnostic Test|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
79479867|NCT00993408|Device|ACT-293987 (NS-304)|
79975952|NCT03772769|Diagnostic Test|Microbial culture|Standard diagnosis by microbial culture.
79975953|NCT05710354|Dietary Supplement|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
79975954|NCT02474680|Genetic|Pharmacogenetic testing|Psychotropic genotyping panel
79975955|NCT04636151|Behavioral|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
79975956|NCT01309607|Drug|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~Lapatinib 750mg daily continuously"
79975957|NCT01561625|Other|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
79975958|NCT05710276|Other|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
79321828|NCT05914922|Other|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
79975959|NCT04001933|Other|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
79975960|NCT03767855|Drug|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
79479868|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
79479869|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
79321829|NCT05914896|Drug|HighOsmo|This group received a priming solution with high osmolality
79321830|NCT05914753|Drug|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
79479870|NCT00968747|Behavioral|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
79645707|NCT00410553|Drug|Eribulin Mesylate|Given IV
79975961|NCT03767855|Drug|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
79975962|NCT03767855|Drug|CK-3773274 - Tablets|CK-3773274 formulated as tablets
79479871|NCT00968747|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
79479872|NCT00951366|Other|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
79479873|NCT00934999|Procedure|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
79479874|NCT00934999|Procedure|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
79479875|NCT00923819|Procedure|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
79645708|NCT00410553|Drug|Gemcitabine Hydrochloride|Given IV
79645709|NCT00410007|Behavioral|High Sodium Diet|250-350 mmol
79809339|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
79975963|NCT03783455|Procedure|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
79645710|NCT00410007|Behavioral|Low Sodium Diet|25-35 mmol
79645711|NCT00410007|Behavioral|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
79645712|NCT01968187|Drug|FE 992097|
79645713|NCT01968187|Drug|Placebo|
79645714|NCT01966549|Drug|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
79645715|NCT01966549|Drug|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
79645716|NCT01965613|Biological|Xilonix|IV
79645717|NCT00410592|Drug|Esomeprazole 40mg|
79321831|NCT05914753|Drug|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
79321832|NCT05914740|Procedure|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
79321833|NCT05914727|Diagnostic Test|eNose|Collection of breath profile with eNose
79321834|NCT05914727|Diagnostic Test|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
79321835|NCT05914727|Diagnostic Test|Condensate sample|Collection of exhaled breath condensate with EcoScreen
79321836|NCT05914714|Drug|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
79321837|NCT05914701|Drug|Letermovir for secondary prophylaxis|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
79321838|NCT05914675|Drug|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
79645718|NCT00410592|Drug|Pantoprazole 40mg|
79645719|NCT00410592|Drug|Lansoprazole 30mg|
79645720|NCT01965106|Drug|QPI-1007 Injection|1.5 mg QPI-1007 Injection
79321839|NCT05914662|Drug|Zanubrutinib, Bendamustine and Rituximab|Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
79479876|NCT00923819|Behavioral|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
79479877|NCT00903890|Other|Survey|Survey asking questions regarding the subjects cardiac and general health.
79479878|NCT00871065|Drug|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
79479879|NCT00794339|Drug|64Cu-ATSM|
79479880|NCT00794339|Drug|FDG|
79479881|NCT00792662|Drug|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
79479882|NCT00792662|Drug|Placebo|Standard inactive pill.
79479883|NCT00786682|Drug|docetaxel|
79479884|NCT00786682|Drug|hydroxychloroquine|
79479885|NCT00675844|Drug|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
79321840|NCT05914623|Procedure|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
79645721|NCT01965106|Drug|(including placebo)|Sham injection procedure
79645722|NCT00173537|Procedure|for BMPR II study|
79645723|NCT00173537|Genetic|BMPRII|
79321841|NCT05914623|Procedure|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
79321842|NCT05914610|Drug|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
79321843|NCT05914610|Drug|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
79321844|NCT05914610|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
79479886|NCT00672672|Biological|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
79479887|NCT00575081|Device|Stereotactic brain procedures|Stereotactic brain procedures
79479888|NCT00571714|Drug|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
79479889|NCT00571714|Drug|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
79479890|NCT00514254|Other|questionnaire administration|
79479891|NCT00514254|Other|study of socioeconomic and demographic variables|
79645724|NCT00410085|Drug|L-NMMA (N-mono.methyl-L-arginine)|
79645725|NCT01951690|Drug|defactinib (VS-6063)|
79645726|NCT01941043|Drug|CERC-301|
79645727|NCT01941043|Other|Placebo|
79645728|NCT00410631|Biological|filgrastim|
79645729|NCT00410631|Drug|carboplatin|
79645730|NCT00410631|Drug|cisplatin|
79645731|NCT00410631|Drug|cyclophosphamide|
79645732|NCT00410631|Drug|dacarbazine|
79645733|NCT00410631|Drug|doxorubicin hydrochloride|
79645734|NCT00410631|Drug|etoposide phosphate|
79645735|NCT00410631|Drug|ifosfamide|
79645736|NCT00410631|Drug|isotretinoin|
79645737|NCT00410631|Drug|melphalan|
79645738|NCT00410631|Drug|topotecan hydrochloride|
79645739|NCT00410631|Drug|vincristine sulfate|
79645740|NCT00410631|Drug|vindesine|
79645741|NCT00410631|Procedure|autologous hematopoietic stem cell transplantation|
79645742|NCT00410631|Procedure|conventional surgery|
79645743|NCT00410631|Procedure|peripheral blood stem cell transplantation|
79479892|NCT00514254|Procedure|evaluation of cancer risk factors|
79479893|NCT00506662|Drug|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
79975964|NCT03783455|Procedure|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
79321845|NCT05914610|Drug|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time Q3W 4-6cycles
79321846|NCT05914597|Other|Setting up home delivery of Colon capsule endoscopy|Feasibility study of home delivery of CCE
79479894|NCT00506662|Drug|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
79479895|NCT00494910|Behavioral|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
79479896|NCT00494910|Behavioral|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
79479897|NCT00476125|Behavioral|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
79479898|NCT00476125|Behavioral|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
79321847|NCT05914584|Drug|Baricitinib 4 MG|Reference drug
79321848|NCT05914558|Diagnostic Test|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
79321849|NCT05914545|Drug|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
79321850|NCT05914519|Procedure|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
79321851|NCT05914519|Procedure|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
79321852|NCT05914493|Other|The effect of posture on cognitive function in early adolescence athletes|"Posture evaluation:~The form of Corbin et al. will be applied.~Evaluation of cognitive functions:~Basically, the Stroop test will be used, which evaluates the concentration and maintenance of attention depending on time and the task given."
79321853|NCT05914454|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|anakinra 100 mg per day for 14 days
79479899|NCT00476125|Behavioral|16 Hour Fast|Subjects will fast for 16 hours.
79479900|NCT00455039|Drug|GW572016|Dose: 1500 mg daily
79479901|NCT00410956|Biological|bevacizumab|
79645744|NCT00410631|Radiation|iobenguane I 131|
79479902|NCT00410956|Drug|dexamethasone|
79479903|NCT00410956|Drug|floxuridine|
79479904|NCT00410956|Genetic|protein expression analysis|
79479905|NCT00410956|Other|flow cytometry|
79479906|NCT00410956|Other|immunoenzyme technique|
79479907|NCT00410956|Other|immunohistochemistry staining method|
79645745|NCT00410631|Radiation|radiation therapy|
79655791|NCT00269217|Drug|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
79655792|NCT00269217|Drug|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
79975965|NCT03783455|Procedure|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
79975966|NCT03783455|Procedure|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
79975967|NCT03783455|Procedure|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
79321854|NCT05914441|Other|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
79321855|NCT05914428|Other|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
79321856|NCT05914415|Other|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
79321857|NCT05914402|Procedure|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
79321858|NCT05914363|Other|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling, combined with support for behaviour change through 'floor clubs'.
79479908|NCT00410956|Other|immunologic technique|
79809340|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
79809341|NCT02629289|Drug|HSP-130|
79479909|NCT00410956|Other|laboratory biomarker analysis|
79975968|NCT03783611|Behavioral|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
79321859|NCT05914350|Procedure|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
79321860|NCT05914350|Drug|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
79479910|NCT00410956|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79321861|NCT05914350|Drug|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
79479911|NCT00380159|Drug|Elvucitabine|Elvucitabine 10 mg in combination with background ART
79645746|NCT01938742|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, & 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
79809342|NCT02629289|Drug|US-approved Neulasta|
79809343|NCT02629289|Drug|EU-approved Neulasta|
79975969|NCT05305066|Drug|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
79809344|NCT00677339|Drug|L-arginine|L-arginine 6g orally daily
79809345|NCT00677339|Drug|Vitamin D|Cholecalciferol 50000 IU once monthly orally
79809346|NCT00677339|Drug|Placebo L-arginine|placebo L-arginine once daily
79321862|NCT05914350|Drug|medical ozone|10 ml of medical ozone
79321863|NCT05914337|Behavioral|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
79321864|NCT05914337|Biological|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
79479912|NCT00380159|Drug|Lamivudine|
79479913|NCT00380159|Drug|Emtricitabine|
79479914|NCT00336986|Drug|recombinant interleukin-21|
79479915|NCT00325741|Drug|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
79479916|NCT00161213|Drug|gemcitabine hydrochloride|
79479917|NCT00161213|Drug|imatinib mesylate|
79479918|NCT00118131|Drug|cisplatin|
79479919|NCT00118131|Drug|docetaxel|
79479920|NCT00006436|Biological|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
79479921|NCT00006436|Biological|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
79479922|NCT00006436|Drug|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
79809347|NCT00677339|Drug|Placebo Vitamin D|placebo vitamin D orally once monthly
79809348|NCT00672893|Other|Vibration Response Imaging|12 seconds of recording lung sounds
79479923|NCT03636464|Other|Blood collection|Pharmacokinetics
79809349|NCT00672971|Other|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
79809350|NCT00672971|Other|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
79809351|NCT00673205|Drug|Bicalutamide|150mg p.o. daily
79809352|NCT00673205|Drug|Placebo|
79321865|NCT05914324|Device|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
79321866|NCT05914324|Device|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
79809353|NCT00673283|Device|bi-plane chest radiography|Bi-plane radiography of the thorax
79321867|NCT05914298|Diagnostic Test|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
79809354|NCT00677495|Dietary Supplement|Gluten-free diet|Gluten-free diet
79809355|NCT00677573|Drug|Fostimon|450 IU for 4 days then adjusted
79809356|NCT00677651|Procedure|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
79321868|NCT05914298|Diagnostic Test|PUL|measurement of ulnar length with anthropometer and patient's height
79321869|NCT05914298|Diagnostic Test|Range of motion|measurement of range of motion of elbow, forearm and wrist
79321870|NCT05914285|Drug|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
79321871|NCT05914285|Drug|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
79321872|NCT05914272|Drug|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
79321873|NCT05914220|Device|AI Insights Application|Predictive AI Model Risk score
79321874|NCT05914207|Behavioral|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
79321875|NCT05914207|Other|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
79645747|NCT01938742|Drug|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 & 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
79645748|NCT00173615|Procedure|Extracorporeal membrane oxygenation|
79809357|NCT00677651|Procedure|Blood sample|Blood will be sampled from an IV line
79809358|NCT00677651|Radiation|CT Scan|Single image at the level of the liver
79809359|NCT00677651|Radiation|DEXA|Whole body scan
79809360|NCT02628431|Device|Elfi tech monitor|
79809361|NCT00677105|Drug|JNJ-26481585|
79809362|NCT00677729|Drug|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
79809363|NCT00677729|Drug|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
79809364|NCT02629055|Other|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
79809365|NCT02628509|Device|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
79813781|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
79813782|NCT00821860|Other|talc|Talc pleurodesis
79813783|NCT00821860|Procedure|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
79813784|NCT00821860|Procedure|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
79321876|NCT05914168|Device|Breast Tomosynthesis|Three dimensional mammography
79321877|NCT05914129|Other|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
79321878|NCT05914129|Other|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
79321879|NCT05914129|Other|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
79321880|NCT05915494|Other|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
79479924|NCT03632798|Diagnostic Test|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
79479925|NCT03632798|Drug|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel."
79479926|NCT03208673|Device|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
79645749|NCT01930357|Biological|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
79645750|NCT01930357|Biological|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
79645751|NCT01913158|Drug|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
79645752|NCT01913158|Drug|Placebo suppository|Hydrogenated palm kernel oil suppositories
79645753|NCT01908595|Drug|M518101|
79645754|NCT00173654|Procedure|blood drawing|
79813785|NCT00794196|Behavioral|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
79321881|NCT05915494|Other|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
79321882|NCT05914103|Procedure|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
79813786|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
79321885|NCT05914051|Other|Colloid preload|250 cc of colloid preload solution will be infused in the intervention group
79321886|NCT05914025|Behavioral|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
79321887|NCT05914012|Other|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
79321888|NCT05913986|Dietary Supplement|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
79321889|NCT05913986|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
79479927|NCT02399917|Drug|Azacitidine|Given SC or IV
79479928|NCT02399917|Biological|Lirilumab|Given IV
79479929|NCT02400073|Device|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
79479930|NCT00356486|Drug|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
79479931|NCT00356486|Drug|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
79321890|NCT05913960|Device|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79321891|NCT05913960|Device|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
79321892|NCT05913960|Device|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
79321893|NCT05913947|Drug|Lithium|The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
79321894|NCT05913947|Drug|Cariprazine|The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
79479932|NCT02978846|Other|Clinical Observation|Undergo side effects evaluation using cards
79479933|NCT02400463|Drug|Ruxolitinib|
79479934|NCT03604718|Biological|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
79321895|NCT05913934|Behavioral|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
79479935|NCT03331835|Biological|Brodalumab|Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).> Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.
79479936|NCT03331835|Drug|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
79479937|NCT03523286|Other|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
79479938|NCT02401555|Device|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
79645755|NCT01903954|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
79645756|NCT01903954|Drug|placebo|Orally b.i.d.
79645757|NCT01903954|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
79645758|NCT01903954|Drug|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
79645759|NCT01893190|Drug|Nimodipine|Based upon Investigator Judgement
79321896|NCT05913856|Other|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
79321897|NCT05913856|Other|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
79321898|NCT05913843|Device|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
79479939|NCT05723042|Other|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
79479940|NCT05723042|Other|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
79479941|NCT02402881|Behavioral|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
79479942|NCT03435848|Drug|BST-236|1 to 4 courses
79479943|NCT03332459|Drug|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
79809366|NCT02635295|Behavioral|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
79809367|NCT02635139|Behavioral|Breakfast skipping|18h fasting period in the morning
79809368|NCT02635139|Behavioral|Dinner skipping|18h fasting period in the evening
79321899|NCT05913830|Other|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
79321900|NCT05913804|Biological|YTS104 Cells injection|YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
79479944|NCT03332459|Drug|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
79479945|NCT02403895|Drug|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
79479946|NCT02403895|Drug|paclitaxel|Taxane
79645760|NCT01893190|Drug|Nimodipine Microparticles|Based upon Investigator Judgement
79645761|NCT00198588|Drug|argatroban|beginning dose: 0.7microgram/kg/H
79645762|NCT00173693|Behavioral|exercise for strength, balance, health education|
79809369|NCT02628353|Dietary Supplement|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
79645763|NCT01887886|Drug|erlotinib|150 mg orally daily
79479947|NCT03987776|Behavioral|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
79645764|NCT01887886|Drug|onartuzumab|15 mg/kg IV every 3 weeks
79645765|NCT01887886|Drug|placebo|IV every 3 weeks
79645766|NCT01885156|Drug|Naftin 1% Cream|Topically applied once a day
79645767|NCT01885156|Drug|Placebo Cream|Topically applied once a day
79645768|NCT01882699|Device|Cereve Sleep System|cerebral hypothermia
79645769|NCT01877395|Biological|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
79645770|NCT01877395|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
79645771|NCT01874938|Biological|LY2875358|Administered IV
79645772|NCT01874626|Drug|Placebo|Placebo cream
79645773|NCT01874626|Drug|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
79645774|NCT00410709|Drug|NatrOVA Creme Rinse (1%)|
79645775|NCT01873534|Drug|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
79645776|NCT01871428|Drug|aleglitazar|150 mcg orally daily
79645777|NCT01871428|Drug|placebo|matching aleglitazar placebo orally daily
79645778|NCT01870609|Drug|defactinib (VS-6063)|
79645779|NCT01870609|Drug|Placebo|Sugar pill manufactured to mimic defactinib tablet
79645780|NCT00410748|Drug|OROS hydromorphone HCI CR|
79645781|NCT01867762|Drug|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
79645782|NCT01867762|Drug|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
79645783|NCT00198627|Drug|Co-Trimoxazole; TMP-SMZ|
79645784|NCT01862224|Drug|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
79645785|NCT01862224|Drug|Placebo|Matching placebo once daily (Week 0 to Week 12).
79645786|NCT01862224|Drug|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
79975970|NCT05305066|Drug|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight <100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
79975971|NCT05305066|Drug|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
79321901|NCT05913778|Device|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
79321903|NCT05913661|Drug|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
79321904|NCT05913661|Drug|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
79479948|NCT03987776|Behavioral|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
79645787|NCT01861249|Drug|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
79645788|NCT01859962|Drug|PPI-668|
79645789|NCT01859962|Drug|BI 207127 Dose 1|
79645790|NCT01859962|Drug|BI 207127 Dose 2|
79645791|NCT01859962|Drug|Faldaprevir|
79645792|NCT01859962|Drug|Ribavirin|
79645793|NCT01859962|Drug|BI 207127 Placebo|
79645794|NCT00198666|Drug|Zinc|Elemental Zinc
79645795|NCT01853995|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
79645796|NCT00173888|Drug|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
79645797|NCT00173888|Drug|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
79645798|NCT01853722|Drug|DCN01|Three serial applications per periocular region.
79321905|NCT05913635|Behavioral|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
79321906|NCT05913635|Behavioral|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
79645799|NCT01853722|Drug|Unisol|Three serial applications per periocular region.
79321907|NCT05913622|Device|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
79321908|NCT05913596|Drug|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
79321909|NCT05913583|Drug|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
79321910|NCT05913570|Drug|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
79321911|NCT05913557|Behavioral|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
79479949|NCT03905252|Other|sample analysis|blood, Random urine sample and 24-hour urine samples
79479950|NCT03333317|Drug|Lumicitabine|Participants will receive oral administration of lumicitabine.
79479951|NCT03333317|Drug|Placebo|Participants will receive oral administration of matching placebo.
79645800|NCT00554983|Biological|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
79645801|NCT00554983|Biological|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
79645802|NCT00555022|Drug|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
79645803|NCT00555022|Drug|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
79645804|NCT00555022|Drug|Placebo|Subjects will receive placebo.
79645805|NCT00203385|Drug|Divalproex|Depakote up to 2000mg/d
79645806|NCT00555100|Drug|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
79645807|NCT00555100|Drug|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
79645808|NCT00555139|Drug|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
79655793|NCT00269217|Drug|Comparator: simvastatin|Duration of Treatment 12 Weeks
79984721|NCT01163864|Behavioral|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
79984722|NCT03201952|Drug|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
79645809|NCT00555139|Drug|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
79479952|NCT02406859|Behavioral|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
79645810|NCT00555139|Drug|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
79984723|NCT03201952|Drug|Placebos|Ileostomy administration of 5cc saline placebo once
79479953|NCT02406859|Behavioral|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
79645811|NCT00555139|Drug|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
79645812|NCT00198705|Behavioral|Improved management of severe neonatal infections|
79645813|NCT01842451|Drug|VX-135|
79645814|NCT01842451|Drug|Daclatasvir|
79984724|NCT04179461|Drug|Cholecalciferol|Oral administration
79984725|NCT04179461|Drug|antihistamine|Oral administration
79321912|NCT05913505|Behavioral|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
79321913|NCT05913505|Behavioral|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
79479954|NCT05722730|Procedure|Pilates Exercises|The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
79479955|NCT02406937|Dietary Supplement|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
79645815|NCT01825954|Device|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
79645816|NCT04676620|Procedure|CK surgery|CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
79809370|NCT02628353|Dietary Supplement|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
79645817|NCT00203463|Drug|topiramate|
79645818|NCT04676581|Other|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
79321914|NCT05913492|Behavioral|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
79975972|NCT03767777|Device|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
79321915|NCT05913466|Drug|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
79321916|NCT05913466|Drug|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
79479956|NCT02406937|Dietary Supplement|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
79479957|NCT02406937|Dietary Supplement|Breast Feeding|Oral intake of breast milk
79645819|NCT00407849|Drug|triamcinolone acetonide|Intravitreal injection
79645820|NCT04676503|Dietary Supplement|BIOVAGINIL|Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.
79809371|NCT02628197|Dietary Supplement|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
79984726|NCT04179461|Drug|Azithromycin|Oral administration
79809372|NCT02628197|Procedure|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
79809373|NCT00673751|Drug|GLP-2|450 nmol subcutaneous
79809374|NCT00673751|Drug|Placebo|
79813787|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
79321917|NCT05913427|Drug|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
79321918|NCT05913427|Drug|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
79645821|NCT04676269|Biological|Amnion only|Patients endometrium will be transplanted with amnion only (without seeded cells)
79975973|NCT02474836|Biological|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
79975974|NCT02474836|Biological|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
79975975|NCT02474836|Biological|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
79975976|NCT05708326|Behavioral|5:2 Method (intermittent fasting regimen)|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
79975977|NCT05708326|Behavioral|16/8 Method (intermittent fast regimen)|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
79975978|NCT03772535|Diagnostic Test|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
79321919|NCT05913414|Drug|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
79321920|NCT05913414|Drug|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
79321921|NCT05913414|Radiation|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
79321922|NCT05913362|Behavioral|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
79645822|NCT04676269|Biological|Amnion - endometrium cells|Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
79645823|NCT04676269|Biological|Amnion - amnion epithelial cells|Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
79321923|NCT05913349|Behavioral|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
79321924|NCT05913336|Drug|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
79813788|NCT00807092|Drug|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
79975979|NCT02478112|Device|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
79975980|NCT02478034|Other|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
79321928|NCT05913310|Drug|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
79321929|NCT05913310|Drug|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
79321930|NCT05913297|Diagnostic Test|Magnetic Resonance|Magnetic Resonance
79321931|NCT05913297|Diagnostic Test|Polysomnographic evaluation|Polysomnographic evaluation
79321932|NCT05913258|Device|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
79645824|NCT04676269|Biological|Amnion-EnSC-AESC|Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
79645825|NCT01819909|Procedure|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
79975981|NCT02477956|Dietary Supplement|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
79975982|NCT02477956|Dietary Supplement|vitamin D|
79984727|NCT04179461|Drug|emollient cream|Topical
79321933|NCT05913258|Device|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
79321934|NCT05913245|Dietary Supplement|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
79321935|NCT05913245|Other|Water|Preoperative water
79645826|NCT01819909|Procedure|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
79645827|NCT00198744|Behavioral|Medifast FIT! for Kids|
79645828|NCT00198744|Behavioral|standard recommendations for dietary intake in children|
79645829|NCT00198744|Behavioral|both diet plans with and without a parent dieting|
79984728|NCT04179461|Drug|Fluticasone Propionate|Nasal spray
79645830|NCT00407927|Drug|Epinastine Nasal Spray|
79645831|NCT01818154|Other|LED phototherapy|
79645832|NCT01818154|Other|narrowband UVB phototherapy|
79645833|NCT01818076|Drug|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
79645834|NCT01809964|Biological|ANT-1401|
79321936|NCT05913206|Behavioral|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
79321937|NCT05913206|Behavioral|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
79321938|NCT05913206|Behavioral|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
79321939|NCT05913206|Behavioral|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
79321940|NCT05913180|Drug|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
79321941|NCT05913180|Drug|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
79321942|NCT05913167|Procedure|laparoscopic nephrectomy|laparoscopic nephrectomy
79321943|NCT05913141|Other|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
79975983|NCT02472574|Device|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
79975984|NCT02472574|Drug|rt-PA|Up to 4 doses of 0.3~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
79321944|NCT05913128|Procedure|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
79321945|NCT05913115|Drug|FPA144|FPA144 will be administered intravenously Q2W.
79321946|NCT05913102|Drug|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
79321947|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
79321948|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
79975985|NCT05708248|Drug|pentoxifylline|400 mg pentoxifylline tablets twice daily with meals for 6 months
79975986|NCT04600505|Drug|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
79975987|NCT04600505|Drug|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
79321949|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
79645835|NCT01809964|Biological|Vehicle|
79645836|NCT00203541|Device|TELFA™ A.M.D. Island dressing|
79975988|NCT04600505|Drug|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
79975989|NCT03772379|Device|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
79975990|NCT03772379|Procedure|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
79321950|NCT05913063|Device|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
79321953|NCT05912998|Procedure|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
79321954|NCT05912985|Other|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
79321955|NCT05912972|Other|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
79321956|NCT05912907|Other|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
79321957|NCT05912881|Other|Olfactory training|Participants perform olfactory training using sticks filled with scented essential oils.
79645837|NCT01807546|Drug|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
79975991|NCT02474992|Behavioral|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
79975992|NCT03772223|Drug|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
79975993|NCT03772223|Drug|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
79975994|NCT03772223|Drug|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
79321958|NCT05912881|Other|Placebo training|Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.
79655794|NCT04546204|Other|vaginal delivery|normal vaginal spontaneous delivery
79479958|NCT03210155|Device|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
79479959|NCT03210155|Device|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
79479960|NCT02408263|Procedure|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
79479961|NCT03210701|Other|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
79479962|NCT04345016|Device|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
79975995|NCT03783377|Drug|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
79975996|NCT03783377|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
79479963|NCT02354833|Drug|Phenylephrine|
79479964|NCT02354833|Drug|Norepinephrine|
79645838|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
79645839|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
79645840|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
79645841|NCT02963220|Behavioral|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
79645842|NCT01802866|Drug|ACU-4429|Take orally once daily for 24 months
79645843|NCT01802866|Drug|Placebo|Take orally once daily for 24 months
79645844|NCT03454984|Drug|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
79645845|NCT01785433|Drug|Tiotropium HFA BAI 4.5 mcg|
79645846|NCT01785433|Drug|Tiotropium HFA BAI 9.0 mcg|
79645847|NCT01785433|Drug|SPIRIVA® HandiHaler® 18 mcg/day|
79645848|NCT01785433|Drug|Spiriva® Respimat® 5 mcg/day|
79645849|NCT00203580|Drug|Tinzaparin sodium|
79975997|NCT02472340|Procedure|Muscle Biopsy|Muscle Biopsy
79975998|NCT02474602|Device|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
79813789|NCT00807092|Drug|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
79321959|NCT05912868|Device|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
79321960|NCT05912855|Device|qNOX|Non
79321961|NCT05912842|Behavioral|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
79645850|NCT01781104|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
79645851|NCT01781104|Drug|Placebo|Placebo delivered subcutaneously once daily for 14 days.
79321962|NCT05912842|Behavioral|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
79321963|NCT05912816|Drug|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
79321964|NCT05912751|Other|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
79321965|NCT05912751|Other|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
79321966|NCT05912725|Procedure|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
79479965|NCT03337724|Drug|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
79321967|NCT05912712|Other|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
79321968|NCT05912712|Other|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
79321969|NCT05912712|Drug|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
79321970|NCT05912712|Biological|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
79321971|NCT05912699|Other|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~Heat-inactivated L. fermentum K8 Postbiotic.~Microcrystalline cellulose."
79321972|NCT05912699|Other|Placebo|The placebo capsules contain microcrystalline cellulose only.
79479966|NCT03337724|Drug|Paclitaxel|Paclitaxel, 80 mg/square meter (m^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
79479967|NCT03337724|Drug|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
79479968|NCT04295447|Other|Standard of care|"Observation only or~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
79479969|NCT04295447|Drug|Apalutamide 60Mg Tab|(4 x 60 mg) once daily on days 1-28 of a 28-day cycle
79645852|NCT01777594|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
79645853|NCT01777555|Drug|CVT-301|
79645854|NCT01777555|Drug|Placebo|
79645855|NCT01777165|Drug|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
79645856|NCT01777165|Drug|Placebo|Placebo infusion
79645857|NCT00203619|Device|Wireless capsule endoscopy|wire less capsule endoscopy
79645858|NCT00203619|Other|standard care|standard diagnostic evaluation as decided by treating physician
79645859|NCT01773928|Biological|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
79645860|NCT01773928|Biological|VCIV manufactured with the current manufacturing process (VCIV current)|
79645861|NCT01773928|Biological|Fluzone®, licensed trivalent influenza vaccine (TIV)|
79645862|NCT00174161|Behavioral|self-care, health behavior|
79645863|NCT01768975|Drug|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
79645864|NCT01768975|Other|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
79645865|NCT01756924|Drug|CEM-102|
79645866|NCT01756924|Drug|IV or Oral standard of care antibiotics|
79645867|NCT01756924|Drug|Rifampin|
79975999|NCT03783299|Diagnostic Test|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
79976000|NCT03783299|Diagnostic Test|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
79645868|NCT00198861|Other|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
79976001|NCT03783299|Drug|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
79976002|NCT03783299|Drug|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
79321973|NCT05912686|Drug|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
79321974|NCT05912686|Drug|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
79321975|NCT05912660|Device|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
79321976|NCT05912621|Drug|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
79321977|NCT05912582|Radiation|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
79321978|NCT05912569|Procedure|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
79321979|NCT05912543|Procedure|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
79321980|NCT05912530|Other|no intervention|there is no intervention will done
79321981|NCT05912491|Diagnostic Test|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
79479970|NCT04190147|Other|Structural, functional and metabolic eye examinations|Structural, functional and metabolic eye examinations
79645869|NCT01756339|Drug|Solithromycin|
79645870|NCT01756339|Drug|Moxifloxacin|
79645871|NCT01756339|Other|Placebo to match solithromycin|
79645872|NCT00174200|Drug|Risperidone 2 mg|
79645873|NCT00203658|Drug|Tinzaparin sodium|
79984729|NCT04179461|Drug|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
79984730|NCT03193840|Procedure|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
79976003|NCT03771833|Device|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
79479971|NCT02355067|Behavioral|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
79479972|NCT02355067|Behavioral|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
79645874|NCT01754935|Drug|VX-509|50 mg oral tablet
79645875|NCT01754935|Drug|VX-509 matching placebo|0 mg oral tablet
79976004|NCT04491838|Drug|Pozelimab|Single subcutaneous (SC) injection
79976005|NCT03771911|Device|AED|Instructions provided by an AED
79976006|NCT03771911|Device|Telephone|Instructions provided by emergency Call Center (telephonically) with the help of an AED.
79645876|NCT00174239|Drug|cabergoline|
79976007|NCT03109054|Diagnostic Test|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
79976008|NCT03767387|Other|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
79307048|NCT05461885|Behavioral|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
79479973|NCT03340337|Device|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79479974|NCT03340337|Device|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79307049|NCT05442125|Other|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
79479975|NCT03340337|Device|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79479976|NCT05722106|Behavioral|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
79976009|NCT02474524|Behavioral|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
79976010|NCT02474524|Behavioral|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
79479977|NCT03340415|Other|Accelerated Rehabilitation plan|early weight bearing after surgery
79307050|NCT05442125|Other|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
79479978|NCT05722028|Procedure|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
79645877|NCT00174239|Drug|controlled-release levodopa / carbidopa|
79645878|NCT01751152|Drug|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
79645879|NCT01751152|Drug|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
79645880|NCT00203697|Drug|minocycline|
79645881|NCT00174278|Drug|Somatropin|
79645882|NCT01750957|Drug|Placebo|orally daily, 12 weeks
79976011|NCT03771755|Drug|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
79976012|NCT03771755|Drug|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
79307051|NCT05438563|Procedure|MRI-Guided Transurethral Ultrasound Ablation|Undergo MRI-Guided TULSA
79307052|NCT05438563|Other|Quality-of-Life Assessment|Ancillary studies
79307053|NCT05438563|Other|Questionnaire Administration|Ancillary studies
79307054|NCT05438563|Procedure|Digital Rectal Examination|Undergo DRE
79307055|NCT05438563|Procedure|Cystoscopy|Undergo cystoscopy
79307056|NCT05438563|Procedure|Biopsy|Undergo biopsy
79307057|NCT05438563|Procedure|Bone Scan|Undergo bone scan
79307058|NCT05438563|Procedure|PSMA PET Scan|Undergo PSMA PET
79307059|NCT05438563|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79307060|NCT05436392|Behavioral|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
79321982|NCT05912478|Other|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
79479979|NCT02356003|Device|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
79321983|NCT05912478|Other|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
79479980|NCT02356471|Device|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
79976013|NCT02472106|Device|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
79321984|NCT05912465|Other|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
79321985|NCT05912439|Behavioral|SidekickHealth|Usage of mobile application called SidekickHealth.
79321986|NCT05912387|Drug|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
79321987|NCT05912374|Behavioral|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
79321988|NCT05912374|Behavioral|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
79321989|NCT05912348|Behavioral|Obesogenic Lifestyle Group|Young men will transition into a sedentary lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups. One of the control groups will undergo a sedentary intervention.
79321990|NCT05912348|Behavioral|Sedentary Control|Young men will transition into a sedentary lifestyle for 10 days.
79479981|NCT02356471|Other|Questionnaire Administration|Ancillary studies
79479982|NCT02356471|Other|Quality-of-Life Assessment|Ancillary studies
79479983|NCT03340805|Drug|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
79976014|NCT02472184|Procedure|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
79976015|NCT02472184|Procedure|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
79321991|NCT05912335|Drug|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
79321992|NCT05912322|Dietary Supplement|Black chokeberry juice|100ml black chokeberry juice/day
79321993|NCT05912309|Behavioral|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
79321994|NCT05912309|Behavioral|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. Endurance training: 2 times/week, performed as high intensity interval training which is time-efficient, safe and effective reducing visceral adipose tissue in postmenopausal women. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
79321995|NCT05912309|Behavioral|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
79321996|NCT05912296|Drug|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
79321997|NCT05912296|Drug|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
79321998|NCT05912296|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
79321999|NCT05912296|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
79322000|NCT05912218|Biological|MEI6570|Saline Control
79322001|NCT05912205|Drug|Disitamab Vedotin|Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)
79322002|NCT05912205|Radiation|radiotherapy|radiotherapy
79322003|NCT05912192|Drug|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
79322004|NCT05912192|Drug|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
79809375|NCT00911885|Behavioral|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
79322005|NCT05912192|Drug|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
79322006|NCT05912179|Diagnostic Test|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
79322007|NCT05912179|Diagnostic Test|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
79322008|NCT05912179|Diagnostic Test|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
79976016|NCT03783221|Other|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
79976017|NCT03783221|Other|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
79976018|NCT03767309|Procedure|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
79479984|NCT03340805|Drug|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
79809376|NCT00677963|Drug|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
79813790|NCT00807092|Drug|metformin|Metformin dose must remain the same as that used prior to the trial.
79976019|NCT03767309|Procedure|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
79479985|NCT03838484|Drug|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
79645883|NCT01750957|Drug|RO4917523|Dose A orally daily, 12 weeks
79645884|NCT01750957|Drug|RO4917523|Dose B orally daily, 12 weeks
79645885|NCT01746082|Biological|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects >/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
79322009|NCT05912140|Other|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
79322010|NCT05912127|Device|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
79322011|NCT05912114|Drug|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
79322012|NCT05912114|Drug|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
79479986|NCT03838484|Drug|Placebo patch|Placebo skin patch will be applied to the skin.
79479987|NCT02357173|Other|electronic cigarette|
79479988|NCT02357173|Other|cigarette group|
79479989|NCT03336008|Other|no intervention|No intervention but clinical assessement for all recruited subjects
79479990|NCT02357485|Biological|ADSC|Single injection of ADSC
79645886|NCT00198900|Behavioral|survey of information|
79645887|NCT01745497|Drug|Ferrous sulfate|3mg/kg liquid
79645888|NCT01745497|Drug|Placebo|Equivalent volume of liquid with similar color and taste.
79645889|NCT00174317|Drug|Celecoxib|
79645890|NCT00174317|Drug|Diclofenac|
79645891|NCT01743625|Drug|COV155|COV155 tablets
79645892|NCT01743625|Drug|placebo|
79645893|NCT01737892|Drug|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
79645894|NCT01737892|Drug|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
79645895|NCT00203736|Drug|Sulfadoxine-pyrimethamine|
79645896|NCT00203736|Drug|Artesunate plus sulfadoxine-pyrimethamine|
79645897|NCT01731730|Drug|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
79645898|NCT01731730|Drug|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
79645899|NCT01731730|Drug|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
79479991|NCT05721872|Combination Product|D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)|"After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients."
79479992|NCT05721872|Drug|FOLFOX/FOLFIRI regimen|"FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks"
79479993|NCT02408965|Drug|Methergine|0.2 mg of methylergonovine maleate
79479994|NCT02408965|Other|placebo|saline placebo to maintain blinding
79479995|NCT03299426|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
79479996|NCT03299426|Biological|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
79479997|NCT05721794|Other|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
79322013|NCT05912036|Behavioral|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
79645901|NCT01718938|Drug|velusetrag dose 1|
79645902|NCT01718938|Drug|velusetrag dose 2|
79645903|NCT01718938|Drug|velusetrag dose 3|
79976020|NCT02477566|Drug|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
79976021|NCT02477566|Drug|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
79976022|NCT05432531|Drug|Anti JAK1,2|Induction of remission of active lupus nephritis
79322014|NCT05912010|Diagnostic Test|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
79322015|NCT05911984|Drug|9MW3811 Injection|Intravenous injection
79322016|NCT05911971|Other|Experimental|specific reeducation (not detailed to maintain blinding of participants)
79322017|NCT05911971|Other|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
79645904|NCT01718938|Drug|placebo|
79645905|NCT00174356|Drug|CI 1033|
79645906|NCT00174356|Drug|PACLITAXEL|
79645907|NCT00174356|Drug|CARBOPLATIN|
79645908|NCT00198939|Behavioral|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
79645909|NCT00198939|Other|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
79645910|NCT01718158|Biological|Peginterferon Lambda-1a|
79976023|NCT05432531|Drug|Cyclophosphamid|Induction of remission of active lupus nephritis
79976024|NCT01309685|Drug|Varenicline|
79645911|NCT01718158|Biological|Peginterferon Alfa-2a|
79645912|NCT01718158|Drug|Ribavirin|
79645913|NCT01718158|Drug|Daclatasvir|
79645914|NCT01718158|Drug|Telaprevir|
79645915|NCT00174395|Drug|eletriptan|
79645916|NCT00203775|Drug|risperidone|
79813791|NCT00794118|Other|As per clinical practice|As per clinical practice
79322018|NCT05911945|Procedure|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
79322019|NCT05911945|Procedure|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
79322020|NCT05911919|Device|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
79479998|NCT02409277|Other|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
79645917|NCT00555256|Drug|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
79645918|NCT01703923|Drug|FP01|
79976025|NCT03772067|Device|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
79976026|NCT03772067|Diagnostic Test|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
79479999|NCT02410291|Other|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
79480000|NCT03216356|Behavioral|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
79480001|NCT03216356|Behavioral|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
79645919|NCT01703923|Drug|placebo|
79645920|NCT01703533|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
79645921|NCT01703533|Drug|Placebo|Strawberry flavored solution and Water for Injection
79645922|NCT00174434|Drug|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
79322021|NCT05911893|Dietary Supplement|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
79322022|NCT05911893|Behavioral|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
79322023|NCT05911893|Behavioral|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
79322024|NCT05911867|Other|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
79322025|NCT05911867|Other|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
79480002|NCT03216356|Drug|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
79976027|NCT03772067|Diagnostic Test|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
79976028|NCT03772067|Diagnostic Test|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
79976029|NCT03772067|Diagnostic Test|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
79480003|NCT03216356|Drug|Placebo|polyethylene glycol 3350 powder
79480004|NCT03216356|Drug|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
79645923|NCT00174434|Drug|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
79480005|NCT03330275|Device|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
79480006|NCT03330275|Device|Commercial ACUVUE OASYS|senofilcon A
79480007|NCT03330275|Device|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
79809377|NCT00673829|Biological|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
79645924|NCT01702441|Drug|Subcutaneous AKB-9778|
79645925|NCT01691755|Drug|Placebo|oral doses once a day for 26 weeks
79645926|NCT01691755|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
79645927|NCT00203814|Drug|Sulfadoxine-pyrimethamine|
79645928|NCT00203814|Drug|Artesunate plus sulfadoxine-pyrimethamine|
79645929|NCT00174473|Drug|Voriconazole|
79645930|NCT01674361|Drug|Bitopertin|Bitopertin once daily orally.
79809378|NCT00673829|Biological|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
79813792|NCT02549872|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
79813793|NCT04112550|Drug|Methadone Hydrochloride|FDA approved medication to treat pain
79976030|NCT03772067|Diagnostic Test|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
79976031|NCT03772067|Diagnostic Test|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
79976032|NCT03772067|Diagnostic Test|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
79976033|NCT03772067|Diagnostic Test|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
79813794|NCT04112550|Drug|Oxycodone-Acetaminophen|FDA approved medication to treat pain
79322026|NCT05911867|Other|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
79976034|NCT03772067|Other|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
79976035|NCT03772067|Diagnostic Test|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
79322027|NCT05911854|Device|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
79322028|NCT05911854|Device|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
79976036|NCT03783065|Drug|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
79322029|NCT05911854|Other|complete decongestive therapy|"Complete decongestive therapy consists of:~Meticulous skin care with the use of emollients~Using short stretch bandages or continuous wearing of a pressure garment~Manual lymphatic drainage therapy~Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
79322030|NCT05911815|Radiation|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
79322031|NCT05911737|Behavioral|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
79322032|NCT05911711|Other|Prognostic factor|normal person (no sepsis group)
79322033|NCT05911685|Device|SeaLA™ left atrial appendage occluder|"Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
79322034|NCT05911672|Device|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
79322035|NCT05911659|Drug|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
79322036|NCT05911646|Other|OSA-18 Survey|"OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe >81."
79322037|NCT05911646|Other|Decisional Conflict (DCS)|The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
79322038|NCT05911633|Device|BioPearl™|TACE
79322039|NCT05911607|Procedure|Low power laser|Phototherapy for extraction sockets using two different lasers.
79976037|NCT03783065|Procedure|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
79322040|NCT05911581|Other|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
79322041|NCT05911581|Other|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
79322042|NCT05911542|Behavioral|Survey|Participants complete survey about pain management practices
79322043|NCT05911529|Behavioral|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
79322044|NCT05911529|Behavioral|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
79322045|NCT05911503|Drug|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
79322046|NCT05911490|Behavioral|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
79645931|NCT01674361|Drug|Placebo|Placebo matched to bitopertin once daily orally.
79645932|NCT01674361|Drug|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
79976038|NCT03783065|Procedure|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
79322047|NCT05911490|Behavioral|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
79322048|NCT05911477|Drug|RhBMP-2|1mg RhBMP-2 for one fusion-level
79322049|NCT05911464|Drug|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
79645933|NCT01667341|Biological|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
79645934|NCT01667341|Biological|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
79645935|NCT01667341|Biological|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
79976039|NCT01309763|Biological|AFFITOPE AD03|s.c. injection
79322050|NCT05911438|Drug|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
79322051|NCT05911438|Other|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
79322052|NCT05911425|Drug|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
79480008|NCT02411929|Drug|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
79645936|NCT00174512|Drug|GTN|
79645937|NCT00174512|Drug|Moxifloxacin|
79645938|NCT00199017|Drug|Dexamethasone/Prednisolone|
79645939|NCT00199017|Drug|Cyclophosphamide|
79645940|NCT00199017|Drug|Vincristine|
79645941|NCT00199017|Drug|Daunorubicin|
79645942|NCT00199017|Drug|Asparaginase|
79645943|NCT00199017|Drug|G-CSF|
79645944|NCT00199017|Drug|Mercaptopurine|
79645945|NCT00199017|Drug|Cytarabine|
79645946|NCT00199017|Drug|Methotrexate|
79645947|NCT00199017|Drug|VP16|
79645948|NCT00199017|Drug|Vindesine|
79645949|NCT00199017|Drug|Adriamycin|
79645950|NCT00199017|Drug|Thioguanine|
79645951|NCT00199017|Drug|HDARAC|
79645952|NCT00199017|Procedure|CNS irradiation|
79645953|NCT00199017|Procedure|Mediastinal irradiation|
79645954|NCT00199017|Drug|Cladribine|
79645955|NCT01665391|Drug|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
79976040|NCT01309763|Biological|AFFITOPE AD03 + Alum|s.c. injection
79322053|NCT05911412|Behavioral|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
79322054|NCT05911386|Other|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
79322055|NCT05911373|Other|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
79322056|NCT05911373|Other|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
79322057|NCT05911347|Dietary Supplement|Psyllium|15g psyllium added to inulin solution to form a gel
79322058|NCT05911347|Dietary Supplement|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
79322059|NCT05911347|Dietary Supplement|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
79645956|NCT01665391|Drug|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
79480009|NCT02411929|Drug|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
79480010|NCT02411929|Drug|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
79480011|NCT00356954|Drug|N-acetylcystein|
79480012|NCT00356954|Drug|ascorbic acid|
79645957|NCT01665391|Drug|Placebo|Placebo administered to match active treatment group
79645958|NCT01665352|Drug|TTP054|Administered orally once daily for 12 weeks.
79645959|NCT01665352|Drug|Placebo|Administered orally once daily for 12 weeks.
79813795|NCT00640042|Drug|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
79813796|NCT00807014|Drug|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
79322065|NCT05911282|Drug|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
79322066|NCT05911282|Other|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
79322067|NCT05911230|Diagnostic Test|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
79322068|NCT05911100|Diagnostic Test|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
79976041|NCT03771599|Other|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
79322069|NCT05911100|Diagnostic Test|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
79322070|NCT05911100|Diagnostic Test|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
79322071|NCT05911100|Diagnostic Test|Heart echocardiography|It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
79322072|NCT05911100|Other|SF-36 Quality of Life Questionnaire|https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
79322073|NCT05911100|Diagnostic Test|Demographic and antropometric measures|Age, sex, height. weight, body mass index (BMI)
79645960|NCT01660633|Drug|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
79645961|NCT01660633|Other|Autologous Transplantation|Patients who are myeloablative conditioning in multiple myeloma undergoing autologous transplantation( patients own blood-forming stem cells are collected to replace diseased bone marrow or bone marrow damaged by cancer treatment)
79645962|NCT00174551|Drug|prazosin|
79645963|NCT00203853|Device|pillbox, wristwatch|
79322074|NCT05911100|Other|Indicators characterizing the severity of the underlying disease|"Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~Medications taken."
79645964|NCT04676659|Drug|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
79645965|NCT01655680|Drug|ABT-126|ABT-126 Middle Dose
79645966|NCT01655680|Drug|ABT-126|ABT-126 Low Dose
79645967|NCT01655680|Drug|ABT-126|ABT-126 High Dose
79645968|NCT01655680|Drug|Placebo|Placebo
79645969|NCT00174590|Drug|risperidone|
79645970|NCT01653379|Drug|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
79645971|NCT01652482|Drug|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter [mg/m^2] administered as intravenous bolus and then 5-FU 2400 mg/m^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
79322075|NCT05911022|Drug|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
79976042|NCT03771599|Other|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
79976043|NCT04586933|Dietary Supplement|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
79322076|NCT05911022|Dietary Supplement|Probiotic Formula|oral sachets once daily for two weeks
79322077|NCT05911022|Other|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
79322078|NCT05910931|Drug|ICG angiography|"A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
79322079|NCT05910918|Behavioral|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
79322080|NCT05910905|Procedure|Prefabricated pediatric zirconia crown group|Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
79322081|NCT05910905|Procedure|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
79976044|NCT04586933|Dietary Supplement|Placebo (soya)|Placebo (soya)
79976045|NCT04586933|Behavioral|Dietary guidance|Dietary guidance
79976046|NCT03771443|Drug|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
79976047|NCT03766997|Drug|Compound Betamethasone Injection|local injection
79976048|NCT03766997|Drug|Hydrocortisone Butyrate 0.1% Cream|topical use
79322082|NCT05910892|Drug|Aromatherapy packet|5 deep breaths from packet prior to treatment
79322083|NCT05910892|Drug|Placebo packet|5 deep breaths from packet prior to treatment
79322084|NCT05910710|Genetic|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
79322085|NCT05910684|Diagnostic Test|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
79322086|NCT05910593|Diagnostic Test|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
79322087|NCT05910138|Diagnostic Test|Serum Interlukin-15|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
79322088|NCT05910138|Diagnostic Test|Serum Interlukin-21|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
79480013|NCT05715554|Other|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
79645972|NCT01652482|Drug|Cetuximab|Cetuximab 400 mg/m^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
79976049|NCT03766919|Device|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
79480014|NCT02358889|Biological|hI-con1|Intravitreal injection of hI-con1 0.3 mg
79813797|NCT00807014|Drug|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
79976050|NCT03782831|Procedure|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
79976051|NCT03782831|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
79645973|NCT01652482|Drug|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter [mg/m^2] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
79813798|NCT04830566|Other|Myofascial release technique|Myofascial technique on the thoracolumbar fascia and lumbar paraspinal muscles
79976052|NCT03782831|Drug|Placebos|intravenous injection every 2 weeks
79976053|NCT03782909|Behavioral|Behaviour change intervention|"The behaviour change intervention consists of;~Feedback via an app based food diary~Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
79976054|NCT03766841|Behavioral|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
79976055|NCT03771365|Procedure|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
79645974|NCT01652482|Drug|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m^2 [racemic form] or 200 mg/m^2 [L-isomer form] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
79480015|NCT02358889|Biological|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
79480016|NCT02358889|Other|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
79480017|NCT02978924|Device|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
79645975|NCT01652482|Drug|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
79645976|NCT00174629|Drug|Docetaxel/DDP|
79645977|NCT00174629|Drug|docetaxel/gemcitabine|
79645978|NCT02962947|Drug|Propranolol|80 mgR propranolol once daily
79645979|NCT02962947|Drug|Placebo|placebo once daily
79645980|NCT00555334|Procedure|RFA|radiofrequency ablation
79645981|NCT00555334|Drug|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
79645982|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
79813799|NCT04830566|Other|Simulated Myofascial Release technique|Superficial hands contact on the lumbar area
79645983|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
79645984|NCT01640080|Drug|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
79322089|NCT05909306|Other|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
79645985|NCT00174668|Drug|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
79322090|NCT05909241|Drug|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
79322091|NCT05909098|Combination Product|autologous NK cell|autologous NK cell
79645986|NCT00174668|Drug|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
79645987|NCT00174668|Drug|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
79645988|NCT01636843|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
79976056|NCT03771365|Procedure|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
79976057|NCT03771365|Procedure|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
79976058|NCT03771287|Device|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
79322092|NCT05908825|Drug|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
79645989|NCT01636843|Drug|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
79645990|NCT00174707|Drug|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
79645991|NCT00174707|Drug|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
79645992|NCT00174707|Drug|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
79645993|NCT01635907|Drug|Dovitinib|
79645994|NCT01633372|Drug|itacitinib|
79645995|NCT01235923|Drug|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
79645996|NCT01235923|Drug|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
79645997|NCT00204009|Behavioral|Disease Surveillance, Family Studies, Questionnaire Followup|
79976059|NCT03771287|Device|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
79984731|NCT03748199|Drug|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
79645998|NCT01144741|Other|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
79645999|NCT01144741|Other|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
79322093|NCT05908825|Drug|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
79322094|NCT05908578|Other|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
79322095|NCT05908578|Other|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
79322096|NCT05908136|Other|restorative materials|two types of composite with strip crown in primary molars
79322097|NCT05908123|Behavioral|The Blank Center CARE Model(TM) for Individuals who Stutter|The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
79322098|NCT05908071|Drug|SHEN26 capsule|Capsule administered orally after meals.
79646000|NCT01144741|Other|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
79646001|NCT01144741|Other|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
79646002|NCT01144741|Other|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
79646003|NCT01144741|Other|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
79976060|NCT01560767|Drug|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
79322099|NCT05908071|Drug|SHEN26 placebo|Capsule administered orally after meals.
79646004|NCT01144741|Other|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
79646005|NCT00174746|Drug|AVE2635A|
79646006|NCT01080196|Behavioral|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
79976061|NCT01560767|Drug|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
79976062|NCT03770897|Procedure|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
79646007|NCT00199134|Drug|Letrozole|Size of the tumor is followed
79646008|NCT00174824|Drug|Insulin glargine|
79646009|NCT00199173|Device|SIR Spheres intra-arterial hepatic|
79646010|NCT00174863|Drug|SR31747A|
79646011|NCT00712582|Drug|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
79646012|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
79646013|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
79646014|NCT00174902|Drug|inderal (drug), acetylsalicylic acid (drug)|
79646015|NCT00204087|Behavioral|Cognitive behavioral therapy (CBT)|
79646016|NCT00204087|Behavioral|Supportive Counselling (SC)|
79646017|NCT00174980|Drug|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
79646018|NCT00568282|Procedure|phlebotomy|Standard of care
79646019|NCT00373711|Drug|Iodine-124|2 mCi, oral
79646020|NCT00373711|Drug|Iodine-123|2 mCi, oral
79646021|NCT00373711|Drug|F-18 FDG|10-15 mCi, iv
79646022|NCT02894047|Biological|blood|measurement of CaSR expression levels on synovial fluid monocytes
79646023|NCT02894359|Device|cone beam imagery of cervical spine|
79646024|NCT00199212|Drug|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
79646025|NCT00175058|Device|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
79646026|NCT00555373|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
79646027|NCT00555412|Drug|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
79976063|NCT03770897|Procedure|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
79322100|NCT05907876|Other|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
79646028|NCT00555412|Drug|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
79976064|NCT03782675|Device|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
79976065|NCT03782675|Device|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
79976066|NCT03771131|Behavioral|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
79976067|NCT03766607|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
79480018|NCT03524365|Procedure|RYGB|Roux-&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
79646029|NCT00555412|Drug|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
79646030|NCT00555412|Drug|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
79646031|NCT00555451|Drug|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~HE3286 5 mg or placebo QD for 28 days;~HE3286 10 mg (5 mg BID) or placebo BID for 28 days~HE3286 20 mg (10 mg BID) or placebo BID for 28 days~HE3286 40 mg (20 mg BID) or placebo BID for 28 days~HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
79646032|NCT00199251|Drug|RUPATADINE|
79646033|NCT00555490|Dietary Supplement|Soy protein|35 % of protein from soy protein for 4-years
79976068|NCT03766607|Drug|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
79976069|NCT03766607|Drug|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
79984732|NCT03748199|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
79984733|NCT03201484|Other|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
79322101|NCT05907785|Behavioral|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
79322102|NCT05907655|Drug|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
79322103|NCT05907655|Diagnostic Test|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
79322104|NCT05907655|Diagnostic Test|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
79322105|NCT05907655|Device|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
79646034|NCT00175097|Other|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
79976070|NCT03766529|Procedure|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
79646035|NCT00175097|Other|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
79646036|NCT00175097|Other|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
79646037|NCT00175097|Other|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
79646038|NCT02894242|Device|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
79646039|NCT02894281|Device|pupillary light reflex|measure with infra-red cameras
79646040|NCT02894164|Other|No intervention|
79646041|NCT00204126|Device|Treadmill with partial body weight support|
79646042|NCT00204126|Device|Surface Functional Electrical Stimulation|
79646043|NCT02894086|Other|database.|database
79646044|NCT00175175|Behavioral|"Allied health professional-run osteoporosis service (case-management)"|
79646045|NCT02894125|Other|SPA Therapy|
79976071|NCT05515835|Device|body composition analysis|Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
79322106|NCT05907512|Drug|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
79322107|NCT05907512|Drug|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
79322108|NCT05907460|Device|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
79322109|NCT05907434|Diagnostic Test|Nephrocheck (AKI score)|Early biomarker of AKI
79322110|NCT05907421|Behavioral|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
79322111|NCT05907356|Other|sciatic nerve slider technique in supine lying position|The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
79322112|NCT05907356|Other|sciatic nerve slider technique in slump position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
79322113|NCT05907356|Other|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
79322114|NCT05907200|Other|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
79322115|NCT05907200|Other|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
79322116|NCT05906446|Other|Multicomponent (Exercise + Protein Supplementation)|"Exercises selected from a pre-specified list, reassessed weekly~Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~Participants will also be offered a protein supplement within 30 min of exercise.~Sessions will be supervised"
79322117|NCT05906407|Other|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
79646046|NCT02894320|Behavioral|Behavioral observation|
79322120|NCT05906056|Device|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
79322121|NCT05906056|Other|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
79322122|NCT05906056|Drug|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
79322123|NCT05906043|Behavioral|Exercise Intervention|Exercise intervention
79646047|NCT00199290|Drug|Trafermin (genetical recombination)|
79646048|NCT04676542|Other|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
79322124|NCT05906043|Behavioral|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
79322125|NCT05906043|Dietary Supplement|Probiotic|Use of a probiotic
79322126|NCT05905770|Drug|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
79646049|NCT04676776|Drug|Levonorgestrel|All participants receive 1.5 mg levonorgestrel on day 1
79646050|NCT04676776|Drug|Mifepristone|All participants receive 200 mg mifepristone on day 3
79646051|NCT00175214|Behavioral|Multifaceted intervention (patient education, physician guidelines, reminders)|
79646052|NCT04676464|Diagnostic Test|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
79322127|NCT05905627|Behavioral|exercise|intervention group
79322128|NCT05905510|Drug|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
79490411|NCT02367170|Procedure|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
79646053|NCT04676230|Procedure|Experimental group|Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
79976072|NCT03771209|Diagnostic Test|ultrasound examination|ultrasound assessment
79984734|NCT04017611|Device|INVSENSOR00038|Noninvasive regional oximeter
79322129|NCT05905510|Drug|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
79322130|NCT05905510|Drug|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
79322131|NCT05904964|Drug|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
79322132|NCT05904964|Other|Endocrine therapy|Doctors choose endocrine therapy independently
79322133|NCT05904483|Other|PFA|PFA
79322134|NCT05904418|Other|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
79322135|NCT05904418|Other|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
79322136|NCT05904418|Radiation|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
79322137|NCT05904353|Procedure|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
79322138|NCT05904353|Procedure|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
79322139|NCT05903469|Other|Implicit Attitude Test|The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
79322140|NCT05903274|Drug|JSP191|Subjects will receive intravenous JSP191
79322141|NCT05903014|Drug|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
79322142|NCT05903014|Behavioral|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
79322143|NCT05901818|Drug|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
79322144|NCT05896098|Other|Ultrasound|Measurement of the airway by ultrasound in obese patients.
79322145|NCT05895500|Drug|Injection for SC administration (120mg/syringe)|Injection
79322146|NCT05895500|Drug|Tablet (50mg/tablet), oral|Tablet
79646054|NCT04676230|Procedure|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
79646055|NCT00204165|Procedure|MRI of the small bowel|
79646056|NCT04676074|Device|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
79976073|NCT03782597|Behavioral|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
79976074|NCT03770819|Procedure|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
79322147|NCT05893680|Other|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
79322148|NCT05893680|Other|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
79322149|NCT05893680|Drug|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
79322150|NCT05893680|Other|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
79646057|NCT00175253|Drug|alemtuzumab|
79646058|NCT00175253|Procedure|islet transplant|
79646059|NCT00199329|Drug|ondansetron adding in PCA|
79976075|NCT03770975|Procedure|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
79646060|NCT04675918|Procedure|Cardiac arrest|Definition of characteristics of cardiac arrest and resuscitation as well as post-resuscitational care and follow up.
79976076|NCT03770975|Procedure|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
79976077|NCT04518683|Device|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
79322151|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
79322152|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
79322153|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
79322154|NCT05888753|Procedure|Adrenalectomy|Scheduled adrenal surgery
79322155|NCT05887739|Diagnostic Test|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
79976078|NCT04518683|Device|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
79322156|NCT05881603|Other|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
79322157|NCT05880771|Other|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
79480019|NCT03524365|Procedure|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
79646061|NCT04675645|Other|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
79976079|NCT01567709|Drug|Alisertib|Given PO
79976080|NCT01567709|Other|Laboratory Biomarker Analysis|Correlative studies
79976081|NCT01567709|Other|Pharmacological Study|Correlative studies
79646062|NCT00175292|Drug|Probiotic - VSL#3|
79976082|NCT01567709|Drug|Vorinostat|Given PO
79976083|NCT01321619|Drug|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
79976084|NCT01321619|Drug|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
79976085|NCT03766217|Combination Product|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
79976086|NCT03766217|Combination Product|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
79976087|NCT03766139|Biological|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
79976088|NCT03766139|Biological|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
79646063|NCT04675684|Behavioral|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
79646064|NCT00555529|Procedure|radial artery applanation tonometry (RAAP)|non-invasive tonometry
79646065|NCT00555607|Drug|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
79646066|NCT02963792|Other|Preventing Professionals burnout|
79976089|NCT03766061|Procedure|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
79976090|NCT03766061|Procedure|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
79976091|NCT03765905|Diagnostic Test|study|Scube-1 scube-2 scube-3
79976092|NCT03765827|Drug|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
79322158|NCT05879224|Combination Product|Revised case management package|"Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~Prescription of short course primaquine (7 mg/kg total)(Day 0):~PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~Participant counselling at the health facility (Day 0):~Supervision of first dose of primaquine~Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
79322159|NCT05877716|Device|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
79646067|NCT00555685|Drug|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
79646068|NCT00555685|Drug|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
79646069|NCT00555724|Drug|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
79646070|NCT00199368|Drug|Istradefylline ( KW-6002)|
79976093|NCT03765827|Drug|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
79646071|NCT00555763|Device|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
79646072|NCT00555802|Other|exercise|exercise
79646073|NCT04675528|Drug|DHP107(Oral paclitaxel)|DHP107 200 mg/m2 orally twice daily on Days 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m2 orally once daily on Days 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
79976094|NCT03765671|Drug|Elafibranor|120mg oral single dose
79976095|NCT03765593|Procedure|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
79646074|NCT04675177|Drug|Polidocanol foam sclerotherapy|"i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;"
79646075|NCT04675177|Procedure|Doppler-guided hemorrhoidal artery ligation|"i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid."
79646076|NCT00175370|Drug|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
79646077|NCT00204243|Drug|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
79976096|NCT03765515|Device|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
79976097|NCT03765515|Device|Q-Fix|Q-Fix
79976098|NCT03765203|Diagnostic Test|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
79646078|NCT00204243|Drug|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
79646079|NCT04675138|Other|No intervention will be provided to the subject|No intervention will be provided to the subject
79976099|NCT03765203|Other|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
79984735|NCT03119350|Other|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
79984736|NCT03117296|Other|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
79984737|NCT03117296|Other|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
79984738|NCT03117296|Other|OT post procedure|PT and OT Daily until goals met or patient discharge.
79984739|NCT03117296|Other|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
79976100|NCT03765047|Behavioral|Intervention Arm|"The physical activity intervention consists of:~School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
79976101|NCT03771053|Drug|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
79322160|NCT05877716|Behavioral|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
79976102|NCT03771053|Drug|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
79976103|NCT03770429|Drug|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
79322161|NCT05877716|Other|Early Psychosis Coordinated Specialty Care|Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
79322162|NCT05877625|Procedure|Expectoration care|"Endotracheal aspiration: from discarded samples after expectoration care~BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~Oropharyngeal swabs"
79322163|NCT05874492|Other|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
79322164|NCT05873361|Other|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
79322165|NCT05872321|Other|Complication|whether or not complications occur
79646080|NCT04675372|Drug|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
79646081|NCT04675372|Drug|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
79646082|NCT00175409|Procedure|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
79646083|NCT00175409|Procedure|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
79976104|NCT03770585|Procedure|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
79976105|NCT03770585|Procedure|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
79976106|NCT03770663|Drug|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
79976107|NCT03770663|Drug|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
79646084|NCT00204282|Behavioral|Educational presentation, group discussion, questionnaires|
79646085|NCT04424602|Drug|cyclo phosphamide|500mg vial
79646086|NCT04424602|Drug|mycophenolate|500mg film-coated tablets.
79646087|NCT00175448|Procedure|physiotherapy|See Detailed Description.
79646088|NCT00199407|Drug|Istradefylline (KW-6002)|
79976108|NCT03770507|Other|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
79976109|NCT03048422|Drug|Dolutegravir|One 50 mg DTG tablet was administered orally once daily
79322166|NCT05871840|Other|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
79322167|NCT05869149|Behavioral|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
79322168|NCT05868057|Drug|SHR7280 tablets|SHR7280 tablets 1 time
79322169|NCT05868057|Drug|SHR7280 dry suspension|SHR7280 dry suspension 1 time
79655795|NCT04546282|Other|Description of the molecular alterations detected in blood samples of patients treated by osimertinib|Description of the molecular alterations detected in blood samples of patients treated by osimertinib. This test is usualyy performed routinely to detect conventional mutations including EGFR T790M. We performed panel of genes screeining based on next generation sequencing. Thius, iIn some cases, new mutations can be detected by this assay.
79655796|NCT04546321|Other|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
79976110|NCT03048422|Drug|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
79976111|NCT03048422|Drug|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
79976112|NCT03048422|Drug|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
79976113|NCT03770195|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
79976114|NCT03770117|Procedure|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
79976115|NCT03770117|Procedure|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
79976116|NCT01561781|Drug|Digoxin|Oral tablets 0.25mg, single dose
79976117|NCT01561781|Drug|Vandetanib|Oral tablets, 300 mg, single dose
79976118|NCT03770039|Drug|Oral PF-06700841 containing 14C microtracer|Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
79976119|NCT03770039|Drug|Oral unlabeled PF-06700841|60 mg unlabeled PF-06700841 oral dose in 2nd period
79976120|NCT03770039|Drug|IV 14C-labeled PF-06700841|30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
79976121|NCT01321385|Other|laboratory biomarker analysis|
79976122|NCT01321385|Other|study of socioeconomic and demographic variables|
79976123|NCT03782363|Biological|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
79480020|NCT03524365|Other|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
79322170|NCT05862909|Other|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
79322171|NCT05862909|Other|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
79322172|NCT05860140|Other|Education video|Six minutes long education video focusing on protein and energy meals
79322173|NCT05858268|Genetic|Whole-genome sequencing|Whole-genome sequencing
79307061|NCT05436392|Behavioral|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
79322174|NCT05856656|Behavioral|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
79322175|NCT05856058|Drug|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
79322176|NCT05855421|Device|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
79976124|NCT03782363|Biological|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
79976125|NCT03782363|Biological|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
79976126|NCT03782363|Biological|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
79480021|NCT05715476|Procedure|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
79655797|NCT00236483|Drug|tramadol hydrochloride + acetaminophen|
79655799|NCT04546165|Procedure|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
79976127|NCT05693168|Device|ANNE Limb Sensor|Pulse Oximeter
79976128|NCT01321775|Drug|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
79984740|NCT03196882|Drug|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
79984741|NCT03196882|Drug|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
79322177|NCT05854069|Behavioral|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
79322178|NCT05854069|Behavioral|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
79322179|NCT05847608|Dietary Supplement|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
79322180|NCT05847608|Dietary Supplement|Placebo|Oleic Acid, Linoleic Acid
79322181|NCT05846776|Device|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
79322182|NCT05840666|Other|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
79322183|NCT05840666|Other|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
79322184|NCT05840666|Other|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
79322185|NCT05839184|Device|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
79322186|NCT05836792|Other|Cycle Ergometer|Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.
79322187|NCT05836792|Device|Transcutaneous electrical nerve stimulation|Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.
79480022|NCT03499327|Dietary Supplement|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
79480023|NCT03499327|Dietary Supplement|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
79480024|NCT05715398|Drug|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
79480025|NCT03134690|Procedure|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
79480026|NCT03134690|Procedure|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
79976129|NCT03764657|Procedure|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
79480027|NCT05721014|Other|OsteoStrong|"This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are chest press, leg press, pull-down and deadlift. The participants press and/or pull isometrically for around 10-15 seconds 1-3 times on every machine.~The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor."
79480028|NCT05721014|Other|Individually Adapted and Combined Physical Training|"This training method is based on the current recommendations on physical activity for people with osteoporosis.~The training is divided into two training sessions:~Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down.~Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down.~The training session takes around 60 minutes and is performed in a group with the help of a training instructor. The participants also have the option to do a home based exercise programme that they could do in a few cases when they were unable to attend the physical group training."
79480029|NCT05713682|Procedure|alveolar ridge preservation|bone grafting at extracted sites
79646089|NCT04389892|Diagnostic Test|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
79646090|NCT00175487|Procedure|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
79646091|NCT00199446|Drug|Istradefylline (KW-6002)|
79976130|NCT03764657|Procedure|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
79976131|NCT03764579|Behavioral|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
79976132|NCT03764423|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
79976133|NCT03764423|Dietary Supplement|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
79976134|NCT03764345|Drug|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
79976135|NCT03769961|Other|No intervention|No interventions - Observational study
79976136|NCT03769883|Behavioral|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
79322188|NCT05836792|Device|Ultrasound|Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes
79322189|NCT05836792|Other|Isometric exercises|The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
79322190|NCT05835895|Genetic|GNSC-001|intra-articular injection
79480030|NCT05720858|Other|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
79976137|NCT03769883|Behavioral|Diet|Dietary intervention
79480031|NCT03003572|Other|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
79480032|NCT00358124|Drug|insulin glargine|
79646092|NCT04314973|Device|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
79976138|NCT04223531|Drug|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
79976139|NCT03769805|Drug|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
79322191|NCT05835895|Drug|transient immune-modulation|oral
79322192|NCT05835895|Drug|Placebo|intra-articular injection
79322193|NCT05834426|Diagnostic Test|Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)|For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.
79322194|NCT05832411|Device|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
79976140|NCT03764267|Drug|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
79480033|NCT00358124|Drug|rosiglitazone|
79480034|NCT00358124|Drug|metformin|
79480035|NCT02839070|Other|Sleep/Wake Schedule|Timing of sleep and wake
79480036|NCT00358202|Drug|cefepime|cefepime hydrochloride 1gm IM q24h
79480037|NCT00358202|Drug|ceftriaxone|ceftriaxone 1 gm IM q24h
79480038|NCT02818400|Procedure|composite tissue allotransplantation|
79646093|NCT04314973|Other|Walking exercises|Walking exercises without wearing the robotic device.
79646094|NCT04306393|Drug|Nitric Oxide Gas|"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively."
79646095|NCT04304092|Other|Exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
79322195|NCT05831904|Device|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
79976141|NCT03764267|Drug|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
79976142|NCT03758885|Drug|Nolasiban|Nolasiban single oral administration
79322196|NCT05830669|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
79322197|NCT05830669|Procedure|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
79322198|NCT05825651|Other|no interventions|This is an observational study without any intervention.
79322199|NCT05824884|Behavioral|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
79322200|NCT05824884|Behavioral|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
79322201|NCT05824884|Behavioral|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
79322202|NCT05824884|Behavioral|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
79322203|NCT05824546|Procedure|Intervention Arm (uSINE-PAMS technique):|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
79480039|NCT05720234|Drug|avatrombopag|Patients with body weight ≥50kg were given 60mg/day and patients with body weight < 50kg were given 40mg/day for 12 weeks.
79480040|NCT02802566|Dietary Supplement|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
79480041|NCT02802566|Dietary Supplement|Standard prenatal vitamin|Standard prenatal vitamin
79976143|NCT03758885|Drug|Placebo|Placebo single oral administration
79976144|NCT01321931|Drug|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
79976145|NCT01321931|Drug|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
79480042|NCT03340883|Biological|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
79976146|NCT01321931|Drug|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
79976147|NCT03764189|Procedure|microosteoperforation|small holes made using large round bur
79322204|NCT05824546|Procedure|Control Arm (traditional landmark-based technique):|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be similarly identified by palpation of external landmarks of iliac crests and spinous process of lumbar vertebrae L3, L4 and L5. Markings on the patients' skin surface will be made with a washable marker or any other methods according to the operator's preference to enable relocation of the site of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted into marked entry site.
79322205|NCT05823896|Drug|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
79480043|NCT04142489|Other|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
79480044|NCT04736225|Other|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
79646096|NCT00175526|Behavioral|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
79646097|NCT00204321|Drug|sirolimus (drug), mmf (drug)|
79646098|NCT00175565|Drug|inhaled fluticasone 500 mcg b.i.d.|
79976148|NCT02400203|Other|Control|
79976149|NCT02400203|Other|Hemp foods|
79976150|NCT03764111|Device|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
79976151|NCT03764111|Device|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
79976152|NCT04305197|Drug|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
79322206|NCT05823896|Drug|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
79322207|NCT05822154|Other|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
79976153|NCT04305197|Drug|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
79976154|NCT04305197|Drug|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
79976155|NCT04305197|Drug|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
79976156|NCT03763409|Drug|Losartan Potassium|active drug
79976157|NCT03763409|Other|placebo|placebo
79976158|NCT01322477|Other|F18-FDG PET/CT|
79646099|NCT04257799|Other|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
79646100|NCT04251208|Other|Observational Study|No intervention will be administered.
79646101|NCT04251013|Device|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~Performing a dozen back and forth movements in the stenosis~Bile aspiration if possible, by the catheter of the brush for cytological analysis~The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
79976159|NCT03763097|Diagnostic Test|Pelvic floor ultrasound|Pelvic floor ultrasound will include transperineal and introital ultrasound
79976160|NCT01321853|Other|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
79976161|NCT01321853|Other|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
79976162|NCT03763955|Behavioral|MIRT|"4 week MIRT provide:~front to front treatment (1 hour/day for 5 days/week)~treatment with robotic devices (1 hour/day for 5 days/week)~occupational therapy (1 hour/day for 5 days/week)"
79976163|NCT03763019|Procedure|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
79976164|NCT03763019|Procedure|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
79976165|NCT03762863|Device|Tourniquet application skill retention|Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
79976166|NCT03758807|Other|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
79976167|NCT03758807|Other|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
79976168|NCT03762785|Drug|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
79322208|NCT05821413|Behavioral|Data to care|Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems. A score is assigned that reflects how much support is needed. A care plan is developed to address areas of need. The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs. Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down. All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management. Participants work with case managers for 6 months.
79322209|NCT05821413|Behavioral|Standard of Care|Participants can use standard case management and other services offered by the clinic.
79322210|NCT05821088|Procedure|Biopsy|Undergo tissue biopsy
79322211|NCT05821088|Procedure|Biospecimen Collection|Undergo blood sample collection
79322212|NCT05821088|Drug|Carboplatin|Given IV
79322213|NCT05821088|Procedure|Computed Tomography|Undergo CT
79322214|NCT05821088|Drug|Etoposide|Given IV
79322215|NCT05821088|Drug|Ifosfamide|Given IV
79322216|NCT05821088|Drug|Lenalidomide|Given PO
79480045|NCT04345172|Device|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
79976169|NCT03763487|Diagnostic Test|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
79976170|NCT03763487|Procedure|spleen volumetry|Ultrasound examination of spleen to scaled the size.
79322217|NCT05821088|Procedure|Positron Emission Tomography|Undergo PET
79322218|NCT05821088|Biological|Tafasitamab|Given IV
79322219|NCT05807750|Other|Post-discharge income supplement|$300 income supplement
79322220|NCT05807750|Other|Enhanced care planning|Enhanced care planning provided by a nurse care manager
79322221|NCT05807529|Drug|2ccPA|"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
79322222|NCT05807529|Drug|Placebo|"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
79322223|NCT05802966|Behavioral|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, & Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
79976171|NCT03756701|Behavioral|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~Introduction and Drawings~Autogenic Training and Biofeedback~Guided Imagery~Meditation~Mobilizing, Transforming, and Celebrating Emotion~Genograms part 1~Genograms part 2~Mindful Eating and Healthy Nutrition~Spirituality~Closing Drawings and Ritual"
79984742|NCT03196882|Drug|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
79322224|NCT05802654|Radiation|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
79322225|NCT05795699|Drug|Ripasudil|K-321 ophthalmic solution
79322226|NCT05795699|Drug|Placebo|Placebo ophthalmic solution
79322227|NCT05794581|Drug|CT-868|CT-868
79480046|NCT03341975|Behavioral|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
79480047|NCT02978378|Other|biomarker levels|The level of the biomarker hyaluronic acid will be measured
79480048|NCT04344704|Other|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset & Stability, and Morphmatch methods
79307062|NCT05433012|Device|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
79322228|NCT05794581|Drug|Placebo|Placebo as SC Injection
79322229|NCT05794581|Drug|Victoza|Victoza as active comparator as SC Injection
79480049|NCT03344861|Drug|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
79307063|NCT05432856|Behavioral|Time restricted eating, nutrition education, and sedentary time reduction strategies|"TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life."
79322230|NCT05794438|Behavioral|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
79322231|NCT05794438|Behavioral|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
79322232|NCT05791318|Drug|VYD222|Monoclonal antibody
79646102|NCT04251013|Device|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~Performing a dozen back and forth movements in the stenosis~Bile aspiration if possible, by the catheter of the brush for cytological analysis~The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
79646103|NCT00204399|Behavioral|Telephone counseling support|
79646104|NCT00175604|Drug|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
79322233|NCT05791318|Other|Placebo|Matching Placebo
79322234|NCT05790915|Combination Product|Standardized interventions|Standardized interventions according organ dysfunction
79322235|NCT05785949|Procedure|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5~7 mm.
79322236|NCT05785949|Device|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
79655800|NCT04546165|Procedure|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
79984743|NCT04172831|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
79322237|NCT05785390|Drug|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
79322238|NCT05785390|Other|Placebo|Identical placebo
79322239|NCT05776498|Procedure|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
79322240|NCT05776498|Procedure|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
79322241|NCT05770518|Behavioral|Biofeedback|Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.
79322242|NCT05770518|Behavioral|Laryngeal control therapy (LCT)|This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
79322243|NCT05769517|Diagnostic Test|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
79322244|NCT05767944|Other|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal & distal phalanges
79322245|NCT05767944|Other|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks & divisions
79322246|NCT05766787|Device|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
79322247|NCT05766787|Device|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
79322248|NCT05766787|Device|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
79322249|NCT05765253|Device|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
79322250|NCT05765253|Device|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
79322251|NCT05765253|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
79322252|NCT05764135|Behavioral|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
79322253|NCT05754190|Device|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
79322254|NCT05753839|Procedure|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
79655801|NCT04546165|Procedure|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
79655802|NCT04545970|Combination Product|Facial cleanser|Facial cleanser to be used by study participants
79655803|NCT04545970|Combination Product|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
79655804|NCT04545970|Combination Product|Sunscreen|Sunscreen to be applied after application of serum in the morning.
79646105|NCT04242043|Diagnostic Test|intel@med-feasibility|"Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care."
79322255|NCT05753839|Procedure|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
79322256|NCT05753839|Other|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
79480050|NCT03344861|Device|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
79480051|NCT05719922|Other|Resistance Training|Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
79976172|NCT03762629|Behavioral|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
79976173|NCT03762551|Other|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
79322257|NCT05753085|Device|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
79322258|NCT05751265|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
79480052|NCT02579954|Behavioral|Rehabilitation|
79480053|NCT02978768|Other|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
79480054|NCT02978768|Device|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
79322259|NCT05751265|Drug|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
79976174|NCT04664855|Other|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
79976175|NCT03758729|Drug|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
79976176|NCT03758729|Radiation|Radiation Therapy|Radiation Therapy
79976177|NCT03756623|Drug|Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
79322260|NCT05751265|Drug|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
79322261|NCT05746988|Other|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
79322262|NCT05744687|Drug|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
79480055|NCT02978768|Device|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
79480056|NCT03348683|Drug|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
79480057|NCT03348683|Drug|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
79480058|NCT04344782|Drug|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
79480059|NCT05693480|Device|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
79480060|NCT03835910|Behavioral|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
79480061|NCT03835910|Procedure|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
79480062|NCT03835910|Behavioral|No Social Incentive applied|No social incentive will be applied
79480063|NCT03835910|Procedure|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
79480064|NCT03351101|Device|Senofilcon C|Senofilcon C Contact Lens
79480065|NCT03351101|Device|Samfilcon A|Samfilcon A Contact Lens
79480066|NCT05692544|Procedure|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
79480067|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
79480068|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
79480069|NCT03223337|Drug|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
79646106|NCT04230187|Drug|mFOLFOXIRI plus Bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
79646107|NCT04230187|Drug|mFOLFOX6 Plus Bevacizumab|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
79322263|NCT05744687|Drug|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
79322264|NCT05743413|Procedure|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
79322265|NCT05743413|Procedure|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
79646108|NCT00199485|Drug|Angelica Sinensis|Angelica Sinensis / placebo
79646109|NCT00175643|Drug|imiquimod|
79646110|NCT00554008|Procedure|laparoscopic appendectomy|appendix removal via scope
79480070|NCT03834974|Behavioral|Sun Safety Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
79480071|NCT03834974|Behavioral|Digital Health Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
79322266|NCT05737823|Behavioral|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
79322267|NCT05737823|Behavioral|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
79322268|NCT05733845|Other|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
79322269|NCT05733520|Behavioral|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
79322270|NCT05733520|Behavioral|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
79322271|NCT05732896|Device|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
79480072|NCT03223649|Other|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
79480073|NCT03223649|Other|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
79480074|NCT02360215|Radiation|Whole brain radiation therapy with hippocampal avoidance|Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
79322272|NCT05727436|Dietary Supplement|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
79322273|NCT05727436|Dietary Supplement|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
79322274|NCT05723289|Device|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
79480075|NCT02360215|Drug|Memantine|Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.
79646111|NCT00554008|Procedure|open appendectomy|open operation for removal of appendix
79322275|NCT05716854|Drug|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
79322276|NCT05716854|Drug|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
79480076|NCT02360215|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
79480077|NCT05719688|Device|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
79646112|NCT00204438|Drug|0.15mg desogestrel /0.03mg ethinyl estradiol|
79976178|NCT03756623|Drug|Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
79976179|NCT03756623|Other|Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
79480078|NCT01349192|Drug|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: <40kg : 15mg/kg daily for 14 days divided every 12 hours.
79480079|NCT01349192|Drug|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: <40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
79322277|NCT05716854|Drug|Placebo (Part 1)|Subjects receive matching placebo for treatments.
79480080|NCT01349192|Drug|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: < 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
79480081|NCT01349192|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
79480082|NCT01349192|Drug|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
79976180|NCT04664153|Drug|PF-07038124 ointment|PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
79322278|NCT05716854|Drug|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
79976181|NCT04664153|Drug|Vehicle ointment|Vehicle ointment with QD dosing for 6 weeks
79976182|NCT03756467|Behavioral|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
79976183|NCT04663295|Device|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
79322279|NCT05716854|Drug|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
79322280|NCT05716854|Drug|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
79322281|NCT05716854|Drug|Placebo (Part 2)|Subjects receive matching placebo for treatments.
79976184|NCT03758495|Other|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
79322282|NCT05714553|Drug|Fosifloxuridine Nafalbenamide|Intravenous infusion
79322283|NCT05714553|Drug|Leucovorin|Intravenous infusion
79976185|NCT03762239|Other|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
79322284|NCT05714553|Drug|Pembrolizumab|Intravenous infusion
79480083|NCT01349192|Drug|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
79480084|NCT01349192|Behavioral|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks."
79480085|NCT02360371|Drug|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
79322285|NCT05714553|Drug|Docetaxel|Intravenous infusion
79322286|NCT05713760|Drug|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
79322287|NCT05701488|Drug|Durvalumab|Intravenous infusion
79322288|NCT05701488|Drug|Tremelimumab|Intravenous infusion
79322289|NCT05701488|Device|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
79322290|NCT05700461|Combination Product|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
79322291|NCT05700279|Procedure|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
79322292|NCT05700279|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
79322293|NCT05698433|Other|No intervention|No intervention
79322294|NCT05692973|Behavioral|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
79480086|NCT02362321|Drug|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
79480087|NCT02362321|Other|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
79480088|NCT05719376|Drug|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day~OP-1day
79480089|NCT05719376|Drug|control group|Ferritin<100, TSAT<20 : Monofer 200mg IV, twice/ Ferritin 100~200, TSAT<20 : Monofer 200mg IV, once / Ferritin 201~500, TSAT<20 : Monofer 100mg IV, once / Not administer in any other case
79646113|NCT00554047|Other|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
79646114|NCT00554047|Other|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
79646115|NCT00175682|Drug|Prazosin HCL|See Detailed Description
79646116|NCT00554086|Drug|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
79646117|NCT04173364|Drug|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
79646118|NCT04173364|Drug|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
79480090|NCT02413879|Device|CleanCision|Wound protection during colorectal surgery.
79646119|NCT04171453|Drug|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
79646120|NCT00199524|Device|Navigator Ureteral Access Sheath|ureteral access sheath
79976186|NCT03762239|Other|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
79976187|NCT03762083|Device|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of BV.
79322295|NCT05692973|Behavioral|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
79480091|NCT05718908|Dietary Supplement|Food supplement|FibrofixPlus® is an authorized food supplement.
79976188|NCT03762005|Other|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
79976189|NCT03762005|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
79976190|NCT03761927|Device|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
79322296|NCT05690334|Drug|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
79646121|NCT04138732|Behavioral|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
79646122|NCT00204516|Biological|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
79646123|NCT00204516|Drug|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
79646124|NCT00175721|Procedure|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
79646125|NCT04105582|Biological|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
79307064|NCT05429320|Procedure|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
79307065|NCT05429320|Other|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
79307066|NCT05423990|Diagnostic Test|Video-Electroencephalography|Three types of video EEG monitoring equipment produced by Nicolet, Bio-logic and Nihon Kohden were used to collect data in the multi-center. The 19-lead recording electrode was placed according to the international 10-20 system, and the average lead was used. The recording time was 24h. All patients underwent eyes open and closed test, intermittent photic stimulation and hyperventilation induction test.
79307067|NCT05423756|Other|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
79307068|NCT05423756|Other|Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
79307069|NCT05423743|Other|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
79307070|NCT05423743|Other|Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having an abdominal infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
79307071|NCT05423730|Other|White Wine|One serving (5 ounces) of white wine daily for 3 weeks
79307072|NCT05423730|Other|Grape Juice|One serving (6 ounces) of white grape juice daily for 3 weeks
79307073|NCT05419869|Drug|ALTO-100 PO Tablet|Two tablets daily
79322297|NCT05690334|Drug|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
79646126|NCT04093180|Procedure|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
79646127|NCT04093180|Procedure|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
79322298|NCT05690334|Drug|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
79480092|NCT00354991|Drug|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
79976191|NCT03761927|Device|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
79976192|NCT03761927|Device|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
79480093|NCT05718752|Diagnostic Test|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
79976193|NCT04228445|Drug|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
79976194|NCT04228445|Drug|Saline spray|Placebo
79984744|NCT04172831|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
79984745|NCT03196804|Drug|LC28-0126|LC28-0126
79984746|NCT03196804|Drug|Placebo|Placebo
79809379|NCT02628119|Procedure|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
79809380|NCT02628119|Procedure|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
79809381|NCT04152629|Drug|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
79809382|NCT04152629|Drug|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
79809383|NCT02628977|Behavioral|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
79809384|NCT02628977|Behavioral|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
79809385|NCT04152707|Device|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
79809386|NCT00673907|Other|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
79809387|NCT02535299|Drug|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
79307074|NCT05419479|Drug|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
79646128|NCT04679584|Other|Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
79646129|NCT00199563|Drug|Viagra|Sildenafil 100mg daily for 12 weeks
79809388|NCT02535299|Drug|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
79809389|NCT00673985|Other|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
79809390|NCT00673985|Device|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
79813800|NCT04809272|Behavioral|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
79646130|NCT00175760|Procedure|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
79646131|NCT04679506|Drug|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
79809391|NCT02628041|Radiation|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
79322299|NCT05689411|Device|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
79646132|NCT02962830|Drug|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
79809392|NCT02628041|Radiation|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
79809393|NCT00674063|Drug|alefacept|IV
79809394|NCT04151459|Drug|Metformin|Use Metformin for 3 months to treat PCOS
79809395|NCT00674141|Drug|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
79646133|NCT04065100|Diagnostic Test|Sebum test|Measuring sebum in newborn
79809396|NCT00678197|Other|Access Intervention|
79646134|NCT00199602|Drug|warfarine - low molecular heparin|
79809397|NCT00678197|Other|Bonus/Pay-for-Performance Intervention|
79809398|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
79809399|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
79322300|NCT05688592|Procedure|PET-CT|"This is a before-and-after study (not a clinical trial)~in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
79480094|NCT05718752|Diagnostic Test|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
79322301|NCT05685407|Drug|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
79322302|NCT05685407|Other|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
79480095|NCT00355069|Behavioral|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
79480096|NCT02986399|Other|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
79480097|NCT02959424|Other|Spanish Northwestern Esophageal Quality of Life questionnaire|
79809400|NCT00878501|Drug|AZD1386|oral, during 4 weeks
79809401|NCT00878501|Drug|AZD1386|oral, during 4 weeks
79322303|NCT05684276|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
79322304|NCT05684276|Drug|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
79480098|NCT02118818|Genetic|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
79480099|NCT02112578|Drug|Meclizine|25 mg, 3 times per day up to 30 days
79480100|NCT02112578|Drug|Dimenhydrinate|50 mg, 3 times per day up to 30 days
79480101|NCT01958762|Other|Invitation for oral cavity cancer screening|
79480102|NCT02415439|Drug|VBP15|
79480103|NCT02415439|Drug|Placebo|
79480104|NCT05717036|Device|Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP|The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement. This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma. The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement. It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
79976195|NCT03761771|Device|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU > 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
79480105|NCT00358280|Drug|Ropivacaine|
79480106|NCT00358280|Drug|Bupivacaine|
79480107|NCT02363803|Drug|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
79480108|NCT02363803|Drug|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
79480109|NCT02364271|Other|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
79480110|NCT02364271|Biological|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
79480111|NCT02364271|Other|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
79480112|NCT02366611|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
79480113|NCT03417193|Drug|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
79646135|NCT00554125|Drug|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
79646136|NCT00175838|Drug|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
79646137|NCT00175838|Drug|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
79646138|NCT03986671|Device|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
79646139|NCT00204555|Drug|Imiquimod|
79646140|NCT00408044|Procedure|cardiac surgery with sternotomy|
79646141|NCT03964441|Biological|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
79646142|NCT03964441|Biological|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
79646143|NCT03964441|Other|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
79646144|NCT03964441|Other|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
79646145|NCT03964441|Other|professional interviews (optional organizational study)|interview to understand how the decision is formed
79646146|NCT03964441|Other|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
79646147|NCT00199641|Device|enteral nutrition|
79646148|NCT00175955|Drug|Levetiracetam|
79646149|NCT03847909|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
79646150|NCT03847909|Drug|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
79646151|NCT00199680|Procedure|PET|
79307075|NCT05419479|Drug|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
79646152|NCT03758287|Drug|CT053PTSA|
79646153|NCT03758287|Drug|Gefitinib|
79646154|NCT03726346|Device|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
79646155|NCT00204594|Drug|rM28|
79646156|NCT00204594|Drug|autologous PBMCs|
79809402|NCT00878501|Drug|Placebo|Oral, during 4 weeks
79813801|NCT00592631|Device|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
79813802|NCT00592631|Device|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
79480114|NCT02366845|Biological|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
79646157|NCT04679779|Other|designed occupational therapy program|Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
79646158|NCT04679779|Other|Wii virtual reality games|"Bowling~Frisbee~Basketball~Boxing"
79646159|NCT04679077|Other|Cytocam-IDF imaging device|Observation of the microcirculation
79646160|NCT03722953|Other|Control|"Ultrasound~Blood Pressure~Heart Rate~Oxygen Saturation"
79646161|NCT03722953|Other|Aerobic Exercise|"Ultrasound~Blood Pressure~Heart Rate~Oxygen Saturation"
79813803|NCT05757674|Other|Sample examination|No intervention will be performed
79976196|NCT05460923|Other|Proprioceptive Neuromuscular Facilitation|including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
79976197|NCT05460923|Other|Swiss Ball Exercises|trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
79976198|NCT03756233|Drug|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
79976199|NCT04641299|Drug|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
79976200|NCT04641299|Drug|Placebo|Placebo solution
79480115|NCT02366845|Diagnostic Test|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
79480116|NCT02366845|Diagnostic Test|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
79646162|NCT00204633|Drug|Darbepoetin alfa|
79646163|NCT00176111|Procedure|peripheral nerve stimulation (procedure)|
79655805|NCT04545931|Device|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
79813804|NCT04116125|Procedure|Radiotherapy|Adjuvant radiotherapy on axillary region
79307076|NCT05419479|Drug|APX005M|Via IV on two days per cycle, dosage per protocol
79307077|NCT05419479|Drug|FOLFIRI|every two weeks through an infusion at a dose determined by physician
79307078|NCT05416437|Device|PneumoCool|Device to channel medical air to the patient to alleviate dyspnea
79307079|NCT05416437|Other|Current supportive measures that are used in the hospital for standard of care|a room fan, or any other currently used supportive measures can be used for patients in the control arm
79307080|NCT05415800|Behavioral|Quality Improvement Practice Facilitation Intervention|"The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care."
79307081|NCT05412212|Other|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
79322305|NCT05684276|Drug|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
79322306|NCT05679427|Radiation|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
79322307|NCT05676385|Dietary Supplement|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
79322308|NCT05676385|Dietary Supplement|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
79976201|NCT05280899|Other|Weight-bearing As Tolerated|The WBAT group will be instructed to bear weight as tolerated immediately following their surgical procedure. The rehabilitation protocols provided will be identical beyond the initial weightbearing recommendations. Following the initial protection phase (three weeks), whereby the two weightbearing interventions will be provided, patients will progress through standardized phases including mobility and neuromuscular retraining, muscle balance and strengthening, functional training, and finally, advanced training for return to work and sport.
79322309|NCT05676385|Dietary Supplement|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
79322310|NCT05669820|Dietary Supplement|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
79322311|NCT05669820|Dietary Supplement|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
79322312|NCT05665322|Procedure|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
79322313|NCT05665322|Procedure|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
79480117|NCT02367391|Behavioral|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
79480118|NCT02367391|Behavioral|Control|Usual Care. All participants receive the active medication, Varenicline.
79480119|NCT02368093|Drug|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
79976202|NCT05280899|Other|Partial Weight-bearing|"The PWB group will be instructed to bear weight to a maximum of 20 lbs of bodyweight on the operative limb for the initial three weeks (termed toe touch), with graduated return to full weightbearing thereafter."
79976203|NCT03761693|Other|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~blood glucose concentration drops < 3.6 mmol/L;~the child shows symptoms/signs of a low blood glucose concentration;~patients parent(s) or guardian(s) request end of fast."
79976204|NCT03758339|Drug|tucatinib|Single dose of 300 mg of [¹⁴C]-tucatinib containing approximately 150 μCi of [¹⁴C] radioactivity
79480120|NCT05719129|Behavioral|Date With Destiny (DWD) Seminar|6 days of immersive seminar
79976205|NCT03698591|Device|Transcranial magnetic stimulation task|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
79976206|NCT03698591|Device|Sham transcranial magnetic stimulation task|A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
79322314|NCT05664698|Behavioral|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri & Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
79322315|NCT05663203|Other|Internet-Based Intervention|Attend CRCWeb intervention
79322316|NCT05663203|Other|Interview|Complete interview
79322317|NCT05663203|Other|Survey Administration|Complete survey
79322318|NCT05663203|Other|Electronic Health Record Review|Medical records are reviewed
79976207|NCT03755921|Other|bried and intensive therapy|Speech Therapy Exercises
79322319|NCT05662540|Device|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
79480121|NCT04345081|Procedure|Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
79480122|NCT04345081|Procedure|Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery|Classic Skin- Sparing Mastectomy
79646164|NCT03635515|Device|Gentlewave|The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
79655806|NCT04545931|Drug|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
79480123|NCT05719051|Drug|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
79322320|NCT05661006|Dietary Supplement|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight & height Collecting data regarding the palatability of the product"
79322321|NCT05661006|Dietary Supplement|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
79322322|NCT05659797|Device|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of [18F]-Fluoroestradiol (FES).
79322323|NCT05659797|Drug|18F-FES|Radiolabelled fluoroestradiol for PET imaging
79322324|NCT05659173|Diagnostic Test|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
79322325|NCT05658952|Other|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
79322326|NCT05658952|Other|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
79322327|NCT05658952|Other|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
79322328|NCT05641051|Drug|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
79655807|NCT00236522|Drug|levofloxacin|
79322329|NCT05641051|Drug|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
79322330|NCT05638334|Drug|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
79322331|NCT05633329|Procedure|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
79322332|NCT05633329|Procedure|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
79655808|NCT00261729|Drug|Paroxetine|paroxetine 20 mg
79976208|NCT03761303|Device|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
79976209|NCT03761303|Device|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
79984747|NCT04839770|Device|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
79655809|NCT00261729|Drug|Prazosin|Prazosin
79655810|NCT00261729|Drug|placebo|placebo capsules
79655811|NCT04541836|Diagnostic Test|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
79322333|NCT05632926|Drug|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
79322334|NCT05632926|Drug|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
79322335|NCT05632926|Drug|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
79322336|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
79655812|NCT04541758|Procedure|surgical treatment|surgical treatment and Conservative treatment
79322337|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
79480124|NCT03342937|Drug|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~Safety validation part: all Cycles are 21 days in length.~Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
79480125|NCT05718739|Device|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
79655813|NCT04541758|Procedure|Conservative treatment|Conservative treatment
79655814|NCT04541641|Procedure|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
79655815|NCT04541641|Procedure|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
79655816|NCT00236561|Drug|topiramate, propranolol|
79322338|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
79322339|NCT05631626|Drug|Placebo|Placebo
79984748|NCT02444650|Device|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
79322340|NCT05630040|Device|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
79480126|NCT05718661|Behavioral|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
79322341|NCT05630040|Device|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
79322342|NCT05627128|Other|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
79480127|NCT05718661|Behavioral|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
79480128|NCT05718349|Other|Biospecimen sampling|From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.
79480129|NCT00354757|Drug|rabeprazole|
79655817|NCT02215330|Drug|Eplerenone|
79322343|NCT05626673|Behavioral|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
79322344|NCT05626218|Other|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
79322345|NCT05623488|Drug|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
79322346|NCT05623488|Device|Mesothelin Expression Testing|Laboratory Developed Test
79480130|NCT03328819|Other|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
79480131|NCT02376283|Drug|Prasugrel|
79655818|NCT02215330|Drug|Maltodextrin|
79655819|NCT00261768|Behavioral|Digital noise reduction|
79655820|NCT02214667|Behavioral|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
79984749|NCT02444650|Device|tonometer|
79976210|NCT05089799|Behavioral|Exposure and interaction with a socially assistive robot|"Description of scenarios involving robot and users~welcoming patients and family members l: the robot explains its own functionalities and answers persons 'questions.~providing a reminder about sanitary gestures (prevention of virus transmission). In addition, it could mediate a conversation between two or more people so that they keep the appropriate physical distance between them.~providing patients with an assistance to prepare the medical consultations : the robot helps patients to fill in paper forms for professionals. The robot also provides information on the course of consultations and the users 'rights in the hospital.~providing orientation and guidance to the consultation rooms and the available services : the robot helps people to find their way around the hospital.~Providing entertainment to patients and families during the waiting time: the robot offers activities to patients and caregivers"
79976211|NCT04606199|Behavioral|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
79322347|NCT05621967|Behavioral|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
79322348|NCT05621967|Behavioral|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
79322349|NCT05621967|Behavioral|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
79322350|NCT05618366|Drug|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
79976212|NCT05085665|Drug|Ivermectin|single dose, 150 ug/kg
79655821|NCT02214667|Behavioral|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
79976213|NCT05017493|Combination Product|Xagrotin|A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
79976214|NCT04599803|Device|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
79976215|NCT01322087|Dietary Supplement|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
79976216|NCT03755843|Diagnostic Test|PASSIVE LEG RISING|"Pasive Leg Rising: In the supine method, the legs are lifted passively from the horizontal position to a 30° to 45° elevation while the head of the bed is flat.~Fluid Challenge: Fluid responsiveness is generally defined as an increase in SV or CO of 10% to 15% in response to a 250 mL crystalloid fluid bolus"
79976217|NCT05002985|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
79976218|NCT03758183|Procedure|total knee arthroplasty|
79976219|NCT03760757|Dietary Supplement|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
79322351|NCT05618366|Drug|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
79322352|NCT05610683|Device|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
79655822|NCT02214667|Behavioral|Jail and community-based behavioral health services|Existing behavioral health service programs
79813805|NCT05757596|Drug|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
79322353|NCT05600985|Procedure|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
79480132|NCT02376283|Drug|Clopidogrel|
79646165|NCT03635515|Procedure|Standard Endodontic Protocol|The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
79646166|NCT00204672|Drug|Achipex|
79646167|NCT00199719|Drug|Ribavirine|
79646168|NCT00176189|Device|All ceramic FPDs|
79646169|NCT03523117|Drug|Ferric carboxymaltose|Intravenous iron
79646170|NCT03523117|Drug|Ferrous Sulfate|oral iron therapy
79646171|NCT00204711|Other|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
79480133|NCT02376283|Drug|ticagrelor|
79322354|NCT05599399|Dietary Supplement|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
79646172|NCT03514186|Behavioral|Speech and Language Therapy|"Includes:~one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~one hour in a conversation group that emphasizes multimodality communication"
79646173|NCT03430882|Drug|Carboplatin|Given IV
79646174|NCT03430882|Drug|Paclitaxel|Given IV
79322355|NCT05599373|Device|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
79646175|NCT03430882|Drug|Sapanisertib|Given PO
79646176|NCT00199758|Drug|cisplatin|
79976220|NCT03760757|Dietary Supplement|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
79646177|NCT00199758|Drug|Gemcitabine|
79646178|NCT00199758|Drug|Taxol|
79322356|NCT05599373|Device|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
79322357|NCT05599373|Device|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
79646179|NCT03291886|Drug|Entinostat|Given PO
79646180|NCT03291886|Drug|Entinostat(Placebo)|Given PO
79646181|NCT03291886|Drug|Exemestane|Given PO
79646182|NCT04679116|Procedure|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
79646183|NCT04679116|Procedure|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
79646184|NCT00204750|Procedure|Bougie Dilation|Bougie dilation will be performed as standard
79646185|NCT00204750|Procedure|Needle-knife incision|Needle-knife incision will be performed
79646186|NCT00176345|Behavioral|Exercise Training|
79646187|NCT00199953|Drug|Rabeprazole 20 mg twice a day for 90-day period treatment|
79646188|NCT03184090|Drug|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
79646189|NCT03184090|Drug|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
79976221|NCT03755609|Drug|Oxycodone|0.1 mg/kg intravenously
79976222|NCT03755609|Drug|fentanyl|1ug/kg intravenously
79976223|NCT04580303|Drug|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
79984750|NCT03118960|Device|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
79976224|NCT04577183|Device|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
79976225|NCT03760445|Drug|HDM201|2.5 mg and 10mg capsules, given orally
79976226|NCT03760445|Drug|cytarabine|20mg or 1000 mg or other strengths as locally available given intravenously
79480134|NCT02376361|Device|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~Recirculation, access flow will be performed according to HD03 Manual.~Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
79646190|NCT03160846|Drug|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
79976227|NCT03760445|Drug|anthracycline|20mg or other strength as locally available given intravenously
79976228|NCT03760445|Drug|midostaurin|25mg capsules given orally
79976229|NCT03760445|Drug|liposomal cytarabine/daunorubicin|100mg/44mg or other strength as locally available given intravenously
79976230|NCT03760445|Drug|posaconazole|100mg delayed release tablet or other strength as locally available given orally
79976231|NCT03760445|Drug|midazolam|2mg/mL oral solution or in other strength as locally available
79976232|NCT05460377|Biological|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
79480135|NCT00425347|Drug|HuLuc63|Not applicable for HuLuc63.
79480136|NCT02301793|Behavioral|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
79480137|NCT02301793|Behavioral|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
79480138|NCT02380183|Device|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
79646191|NCT00176384|Behavioral|Aerobic endurance exercise training (ergometer)|
79646192|NCT00204789|Drug|Difluoromethylornithine|
79646193|NCT00176540|Drug|dextromethorphan hydrobromide|
79646194|NCT02968381|Behavioral|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
79646195|NCT02968381|Behavioral|Control Condition|Telephone coaching using standard cognitive behavioral methods
79976233|NCT05460377|Biological|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
79976234|NCT05460377|Biological|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
79646196|NCT00199992|Procedure|application of autologous platelet gel|
79809403|NCT00674375|Other|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
79813806|NCT05757596|Drug|Placebo|0.9% Saline, volume matched
79976235|NCT05460377|Biological|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
79322358|NCT05591898|Behavioral|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
79813807|NCT00791388|Drug|Placebo|oral capsule, 2x/day for 14 days
79813808|NCT00791388|Drug|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
79813809|NCT00791388|Drug|PG-760564|oral capsule, 100mg, 2x/day for 14 days
79646202|NCT00176579|Procedure|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
79976236|NCT05693012|Diagnostic Test|cfDNA methylation assessment|An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
79480139|NCT02380261|Other|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
79646203|NCT00176618|Drug|sulindac|Sulindac 150 mg po BID
79646204|NCT00176618|Drug|curcumin|Curcumin 250 mg po BID
79646205|NCT02657005|Drug|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
79813810|NCT00791388|Drug|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
79984751|NCT03118960|Device|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
79984752|NCT01562717|Drug|Ibuprofen|3 times a day
79976237|NCT03626558|Other|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
79322359|NCT05589740|Behavioral|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
79480140|NCT02382913|Biological|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
79646206|NCT00410787|Drug|OROS hydromorphone HCI (slow release)|
79976238|NCT04345562|Procedure|Skin preparation patterns with ChloraPrep 2 x 26 mL single|2 different patterns of skin preparation
79976239|NCT03626324|Device|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
79976240|NCT04339634|Other|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
79976241|NCT05692856|Drug|Clenbuterol|Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
79984753|NCT01562717|Drug|Placebo|3 times a day
79322360|NCT05589740|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
79322361|NCT05588739|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
79322362|NCT05587998|Drug|AZD4041 and morphine|Participants will receive 2 doses of morphine (IV administration) and multiple doses of AZD4041 (Oral solution)
79322363|NCT05587998|Other|Placebo and morphine|Participants will receive 2 doses of morphine (IV administration) and multiple doses of Placebo (Oral solution)
79322364|NCT05585398|Drug|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
79322365|NCT05579860|Drug|Olezarsen|Olezarsen will be administered by SC injection.
79322366|NCT05573555|Drug|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
79322367|NCT05573555|Drug|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
79646207|NCT00554164|Drug|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
79646208|NCT00554164|Drug|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
79655823|NCT02278510|Drug|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
79322368|NCT05571735|Biological|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
79480141|NCT02382913|Biological|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
79480142|NCT02382913|Biological|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
79480143|NCT05718115|Diagnostic Test|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
79646209|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
79976242|NCT05692856|Drug|Placebo|Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
79976243|NCT04574999|Drug|Estriol|Gel for vaginal application
79646210|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
79646211|NCT00176657|Drug|HEMOBAG Assessment|
79813811|NCT00791388|Drug|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
79976244|NCT04574999|Other|Placebo|Gel for vaginal application
79976245|NCT03758027|Behavioral|CARESS|"The goals of each component are as follows:~Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~Release endorphins - a release for the internal stress created by the emotion; and~Self-soothe - a method of quelling and containing."
79322369|NCT05571735|Biological|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
79322370|NCT05571735|Biological|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
79322371|NCT05569005|Other|THS use|Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
79322372|NCT05569005|Other|Cigarette|Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
79976246|NCT03758027|Behavioral|Isometric Exercise|5-minute protocol for cravings management and affect regulation
79976247|NCT04565249|Drug|PLN-74809|PLN-74809
79976248|NCT04565249|Drug|Placebo|Placebo
79976249|NCT03760367|Other|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
79322373|NCT05569005|Other|Smoking Abstinence|Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
79480144|NCT05718037|Biological|Recombinant Zoster Vaccine|0.5mL, Intramuscular
79480145|NCT05718037|Biological|Placebo|0.5mL, Intramuscular
79480146|NCT05718037|Biological|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
79976250|NCT03760367|Other|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
79976251|NCT04942925|Device|Verofilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
79976252|NCT04942925|Device|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
79976253|NCT01322243|Other|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
79976254|NCT03755531|Drug|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
79655824|NCT02278510|Drug|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
79322374|NCT05561491|Biological|ONCOS-102|Oncolytic virus
79322375|NCT05561491|Biological|Balstilimab|Anti PD-1
79322376|NCT05558527|Behavioral|social support|social support is provided in the form of social touch (hand holding)
79322377|NCT05556252|Other|Hydrogenated water consumption|Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
79322378|NCT05556252|Other|Drinking water consumption|Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
79322379|NCT05554237|Drug|Placebo|Placebo
79322380|NCT05554237|Drug|PF-07612577|PF-07612577
79322381|NCT05554237|Drug|PF-06264006|PF-06264006
79322382|NCT05550870|Dietary Supplement|Raw fenugreek seed powder|It will be given to group 1
79322383|NCT05550870|Dietary Supplement|Roasted fenugreek seed powder|It will be given to group 2
79322384|NCT05546151|Drug|BMS-986322|Specified dose on specified days
79322385|NCT05546151|Other|Placebo for BMS-986322|Specified dose on specified days
79322386|NCT05544695|Device|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
79322387|NCT05538312|Drug|ARV-471|Participants will receive a single dose of ARV-471 by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of ARV-471
79322388|NCT05538312|Drug|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
79322389|NCT05537519|Biological|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
79322390|NCT05529862|Genetic|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
79809404|NCT04162145|Device|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
79322391|NCT05529862|Genetic|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
79322392|NCT05529862|Genetic|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
79322393|NCT05529862|Genetic|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
79322394|NCT05529277|Other|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
79322395|NCT05529043|Behavioral|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
79322396|NCT05529043|Behavioral|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
79322397|NCT05520593|Dietary Supplement|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
79322398|NCT05516316|Drug|EP395|Capsule for oral use
79322399|NCT05516316|Drug|Placebo|Capsule for oral use
79322400|NCT05515393|Drug|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
79322401|NCT05515393|Drug|XY03-EA Placebo|XY03-EA Placebo
79322402|NCT05507476|Drug|Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray|The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
79322403|NCT05507476|Drug|Epinephrine topical 1:100,000 Nasal Packs|The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
79322404|NCT05507450|Biological|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
79322405|NCT05507450|Biological|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
79322406|NCT05507450|Biological|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
79322407|NCT05507450|Biological|Placebo|0.5 mL SC dose of placebo
79322408|NCT05507138|Device|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
79976255|NCT03755531|Drug|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
79322409|NCT05507138|Behavioral|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
79322410|NCT05502757|Other|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
79322411|NCT05495282|Other|Microvideo|Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
79976256|NCT04917653|Device|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
79322412|NCT05494125|Other|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
79976257|NCT04917653|Other|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
79480147|NCT05717959|Behavioral|Oropharyngeal Exercises|Oropharyngeal Exercises
79646212|NCT02572141|Drug|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
79976258|NCT03755453|Device|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
79976259|NCT04913363|Other|Green space|Green space in which activities take place
79976260|NCT04902053|Diagnostic Test|Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.|Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.
79976261|NCT03760133|Drug|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
79976262|NCT03760055|Device|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
79976263|NCT03759977|Other|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
79976264|NCT04854707|Drug|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
79976265|NCT04854707|Drug|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
79322413|NCT05494125|Other|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
79322414|NCT05492422|Device|Central Executive Training (CET)|Central Executive Training (CET)
79322415|NCT05492422|Behavioral|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
79322416|NCT05492006|Behavioral|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
79322417|NCT05492006|Behavioral|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
79322418|NCT05484401|Drug|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
79322419|NCT05484401|Drug|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
79322420|NCT05484401|Other|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
79322421|NCT05484401|Other|Placebo Tablets|2 x Tablets once in 12 hours
79646213|NCT02572141|Drug|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
79646214|NCT00410865|Genetic|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
79813812|NCT00794040|Drug|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
79322422|NCT05474651|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
79646215|NCT02470039|Drug|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
79976266|NCT04854707|Drug|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
79646216|NCT02470039|Drug|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
79646217|NCT02470039|Drug|placebo|Administered once daily
79646218|NCT00176696|Device|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
79646219|NCT02459236|Drug|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
79646220|NCT02459236|Drug|Placebo|
79646221|NCT00200031|Device|Interstim therapy|
79322423|NCT05473117|Diagnostic Test|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
79322424|NCT05468814|Procedure|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
79646222|NCT00554203|Drug|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
79813813|NCT00794040|Drug|Add-on placebo following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
79322425|NCT05468814|Procedure|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
79322426|NCT05461547|Diagnostic Test|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
79322427|NCT05461547|Other|Usual Care|Usual care to decide diagnosis and treatment
79646223|NCT00554242|Dietary Supplement|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
79322428|NCT05457101|Other|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
79322429|NCT05456139|Behavioral|Treatment as Usual|"Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
79646224|NCT00176735|Drug|Capecitabine|
79646225|NCT00554281|Device|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
79322430|NCT05456139|Behavioral|Early Social Interaction Mobile Coaching (ESI-MC)|The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
79322431|NCT05454241|Drug|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
79646226|NCT00554320|Procedure|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
79646227|NCT00554320|Procedure|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
79646228|NCT00410943|Drug|OROS Hydromorphone HCI SR (slow release)|
79646229|NCT03455101|Other|There is no intervention.|There is no intervention.
79646230|NCT00176774|Drug|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
79646231|NCT00176774|Drug|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
79322432|NCT05448196|Other|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
79976267|NCT04854707|Drug|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
79976268|NCT04854707|Drug|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
79976269|NCT03215069|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
79976270|NCT03215069|Drug|Placebo oral capsule|Placebo PO daily
79322433|NCT05447676|Drug|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
79322434|NCT05447676|Other|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
79322435|NCT05447676|Other|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
79646232|NCT00176774|Drug|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
79322436|NCT05447676|Behavioral|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
79976271|NCT03759821|Behavioral|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
79976272|NCT03759821|Behavioral|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
79322437|NCT05442580|Drug|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
79646233|NCT00176774|Drug|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
79813814|NCT02603796|Other|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
79976273|NCT03759821|Behavioral|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
79976274|NCT03759821|Behavioral|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
79976275|NCT03759743|Dietary Supplement|LMT1-48|capsules containing Probiotics
79976276|NCT03759743|Dietary Supplement|Placebo|capsules that did not contain any probiotics
79976277|NCT01322321|Drug|ACZ885|
79976278|NCT01322321|Drug|Placebo|
79976279|NCT04557371|Other|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
79322438|NCT05442580|Drug|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
79322439|NCT05442580|Drug|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
79480148|NCT05717881|Dietary Supplement|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
79976280|NCT04557371|Other|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
79646234|NCT02429167|Device|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
79813815|NCT04109742|Drug|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
79976281|NCT04557371|Other|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
79976282|NCT03755141|Drug|Herzuma|Herzuma + Treatment of Physician's Choice
79976283|NCT04555655|Dietary Supplement|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
79976284|NCT04555655|Dietary Supplement|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
79976285|NCT04555655|Other|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
79976286|NCT03757871|Device|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
79976287|NCT04848233|Dietary Supplement|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
79976288|NCT05460065|Drug|single E4 30 mg|Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)
79976289|NCT05460065|Drug|single E4 100 mg|Administration of a single i.v. infusion of E4 100 mg (n=6)
79976290|NCT05460065|Drug|multiple E4 100 mg|Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
79976291|NCT05460065|Drug|Placebo|"Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)"
79976292|NCT03759509|Behavioral|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
79976293|NCT04834271|Other|Side-lying external rotation exercise with a dumbbell|Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.
79976294|NCT04834271|Other|Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
79976295|NCT04834271|Other|Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
79976296|NCT03759353|Diagnostic Test|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
79976297|NCT03759353|Drug|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
79976298|NCT03759353|Drug|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
79976299|NCT03759353|Diagnostic Test|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
79976300|NCT05393375|Other|No intervention|No intervention
79984754|NCT03196648|Other|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
79984755|NCT03196648|Other|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
79984756|NCT03196648|Other|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
79322440|NCT05442580|Drug|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
79322441|NCT05442580|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
79322442|NCT05442580|Drug|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
79322443|NCT05441462|Procedure|Silastic Joint Replacement|Participants who have had silastic joint replacement surgery for degenerative or inflammatory arthritis within the last three years
79322444|NCT05439603|Drug|ANC-501|Five 10 mg capsules per day
79976301|NCT03754985|Device|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
79976302|NCT04825379|Device|bioactive composite|Cention N
79976303|NCT04825379|Device|posterior composite|G-ænial Posterior
79976304|NCT05280977|Other|POST ISOMETRIC RELAXATION|Group A (Post Isometric Relaxation + Conventional Physiotherapy): This group will receive Muscle Energy Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session.
79976305|NCT05280977|Other|POST FACILITATION STRETCHING|"Group B (Post Facilitation Stretching + Conventional Physiotherapy):~This group will receive Post Facilitation Stretching Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session."
79480149|NCT05717881|Dietary Supplement|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
79322445|NCT05437640|Behavioral|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
79480150|NCT00355303|Drug|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
79976306|NCT03757559|Drug|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
79480151|NCT00355303|Drug|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
79480152|NCT05717569|Drug|Vitamin D|o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
79813816|NCT04109742|Drug|Placebo curcumin capsule|matching placebo to active curcumin capsules
79976307|NCT03757559|Drug|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
79322446|NCT05437640|Behavioral|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
79976308|NCT03757559|Drug|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
79976309|NCT03757559|Drug|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
79976310|NCT03757559|Drug|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
79976311|NCT03754907|Procedure|Endocutter stapler|Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson & Johnson K.K., Tokyo, Japan)
79322447|NCT05436028|Device|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
79646235|NCT02429167|Device|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
79646236|NCT02421679|Drug|TNX-102 SL|TNX-102 Sublingual tablets
79646237|NCT00200070|Device|Spinal Cord Stimulation|
79976312|NCT03754907|Procedure|suture material|absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
79646238|NCT02389777|Biological|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
79646239|NCT02389777|Biological|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
79480153|NCT05716633|Diagnostic Test|MRI|Serial MRI scans will be performed starting at day 15 from date of pain. Subsequent scans will be performed at 5 days interval till the clinically significant encapsulation (for all the collections in an individual patient) is seen.
79813817|NCT00813488|Drug|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
79976313|NCT03759119|Behavioral|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
79976314|NCT03759119|Behavioral|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~Complete educational session with primary investigator.~Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
79480154|NCT02385097|Drug|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
79480155|NCT02385097|Drug|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
79646240|NCT02387788|Drug|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
79646241|NCT02383810|Drug|Elsiglutide|
79646242|NCT02383810|Drug|Placebo|
79646243|NCT00410982|Drug|Busulfan|Day -10 = 32 mg/m^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m^2 Intravenous
79646244|NCT00410982|Drug|Gemcitabine|Day -8 = 75 mg/m^2 Intravenous bolus; Day -3 = 75 mg/m^2 Intravenous bolus.
79646245|NCT00410982|Drug|Melphalan|Day -3 and Day -2 = 60 mg/m^2 Intravenous.
79646246|NCT00410982|Other|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
79480156|NCT02387359|Drug|Plecanatide|
79976315|NCT01322399|Procedure|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
79976316|NCT01322399|Procedure|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
79976317|NCT02658929|Biological|bb2121|bb2121
79976318|NCT02652923|Drug|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
79322448|NCT05426863|Behavioral|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
79480157|NCT02387359|Drug|Placebo|
79646247|NCT00410982|Drug|Rituximab for Patients with B-Cell Malignancies|375 mg/m^2 Intravenous on Days 1 and 8.
79976319|NCT03754829|Behavioral|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
79976320|NCT03754751|Procedure|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~Low-pressure pneumoperitoneum (8-9 mmHg)~Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~PONV prophylaxis in patients of risk~Postoperative care~Early mobilization (2 h after surgery)~Early fluid intake (2 h after surgery)~Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
79480158|NCT02387749|Genetic|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
79480159|NCT00355381|Behavioral|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
79646248|NCT00410982|Drug|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
79646249|NCT02372578|Drug|ASP3662|oral
79646250|NCT02372578|Drug|pregabalin|oral
79322449|NCT05426629|Device|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
79322450|NCT05425901|Other|biopsy|endoscopy biopsies (6)
79976321|NCT03754751|Procedure|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~Standard CO2 pressure (12-14 mmHg)~No additional anesthesia~Postoperative care~Mobilization in 4-6 h after surgery~Fluid intake in 6 hours~Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
79480160|NCT05713825|Procedure|Endovascular embolization or surgery|"Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
79976322|NCT04539275|Drug|Convalescent Plasma|Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
79322451|NCT05423340|Other|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
79322452|NCT05423340|Other|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
79322453|NCT05418582|Drug|DZD9008 and intraconazole|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
79322454|NCT05418582|Drug|DZD9008 and carbamazepine|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
79322455|NCT05417425|Combination Product|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
79322456|NCT05414617|Device|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
79480161|NCT05712655|Other|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
79480162|NCT00355459|Drug|Tetracycline: Doxycycline analog|
79480163|NCT02390791|Other|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
79480164|NCT02390791|Other|treatment as usual standard portal|Standard version of myADHDportal.com web software
79480165|NCT02392351|Device|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
79480166|NCT02392351|Device|Renal Angiography|Percutaneous renal angiography
79480167|NCT02393677|Drug|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
79480168|NCT02393677|Drug|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
79480169|NCT02394457|Drug|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
79480170|NCT02394457|Procedure|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
79646251|NCT02372578|Drug|ASP3662 placebo|oral
79646252|NCT02372578|Drug|pregabalin placebo|oral
79809405|NCT04162145|Device|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
79322457|NCT05414617|Device|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
79480171|NCT05686213|Behavioral|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
79976323|NCT04539275|Other|Masked Saline Placebo|0.9% saline solution will be used as the Masked Saline Placebo
79976324|NCT04784897|Drug|Brilacidin|Brilacidin IV infusion
79480172|NCT05686213|Behavioral|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
79480173|NCT00355225|Procedure|ITN distribution channel|
79480174|NCT00355771|Drug|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
79480175|NCT00355771|Drug|Placebo|1 tablet OD in the morning for 8 weeks
79480176|NCT05502679|Other|Weight bearing as tolerated|Bearing weight on lower limb extremity
79646253|NCT02367313|Drug|Vapendavir|Vapendavir 264 mg twice daily
79976325|NCT04784897|Drug|Placebo|Placebo IV infusion
79976326|NCT04784897|Drug|Standard of Care (SoC)|SoC therapies for COVID-19
79976327|NCT02651597|Other|Oatmeal|
79976328|NCT03757325|Drug|DNL747|DNL747
79322458|NCT05414526|Other|InterCARE package|"The InterCARE package includes:~Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
79322459|NCT05412628|Diagnostic Test|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
79480177|NCT05502679|Other|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
79480178|NCT05664139|Drug|Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel|"Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death."
79480179|NCT05463211|Device|Trexo Plus Pediatric Exoskeleton|Wearable pediatric robotic walker for the lower extremities
79480180|NCT03224351|Drug|VX-659|Tablet for oral administration.
79480181|NCT03224351|Drug|TEZ/IVA|TEZ/IVA fixed-dose combination tablet for oral administration.
79480182|NCT03224351|Drug|IVA|Tablet for oral administration.
79976329|NCT03757325|Drug|Placebo|Placebo
79976330|NCT03758963|Device|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
79976331|NCT05692778|Other|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
79976332|NCT05692778|Other|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
79976333|NCT05692700|Other|aromatherapy|essential oil application by inhalation
79480183|NCT03224351|Drug|Placebo (matched to VX-659/TEZ/IVA)|Placebo matched to VX-659 and TEZ/IVA.
79480184|NCT03224351|Drug|TEZ|Tablet for oral administration.
79976334|NCT05692700|Other|Placebo|Placebo essential oil
79976335|NCT01322711|Drug|Atorvastatin|Atorvastatin 40 mg day
79976336|NCT01322711|Drug|Placebo|Diet
79322460|NCT05394103|Drug|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
79322461|NCT05394103|Drug|Pembrolizumab|Pembrolizumab will be administered Q6W
79322462|NCT05389618|Other|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
79322463|NCT05388474|Other|No ibalizumab or Pre-ibalizumab treatment|Patient registry
79646254|NCT02367313|Drug|Vapendavir|Vapendavir 528 mg twice daily
79646255|NCT02367313|Drug|Placebo|Placebo twice daily
79646256|NCT00410319|Behavioral|Fear-reducing Information|
79646257|NCT00410319|Behavioral|Symptom-based exercise|
79646258|NCT02363491|Drug|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
79646259|NCT00554359|Drug|I5NP (a small interfering RNA)|Single IV injection of experimental drug
79646260|NCT00554359|Drug|placebo|Single IV injection of saline
79322464|NCT05388474|Biological|On ibalizumab treatment|Patient registry
79322465|NCT05384769|Procedure|Liquid Biopsy|Undergo liquid biopsy
79322466|NCT05384769|Procedure|Low Dose Computed Tomography of the Chest|Undergo low dose CT
79976337|NCT04532099|Device|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
79646261|NCT00411021|Procedure|Pipelle (Endometrial Sampling)|
79480185|NCT03224351|Drug|VX-561|Tablet for oral administration.
79480186|NCT03224351|Drug|Placebo (matched to VX-659/TEZ/VX-561)|Placebo matched to VX-659, TEZ and VX-561.
79976338|NCT04532099|Device|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
79480187|NCT05663281|Diagnostic Test|thrombus imaging appearance|Imaging appearance of intracranial and/or extracranial arterial thrombus
79480188|NCT05658055|Drug|Vonoprazan|Potassium-competitive acid blocker
79646262|NCT00554398|Drug|MK-0518 400mg twice a day|Raltegravir, MK-0518
79976339|NCT04532099|Device|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
79646263|NCT00554476|Drug|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
79646264|NCT00204867|Other|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
79646265|NCT02349022|Radiation|[89Zr]Df-IAB2M|
79976340|NCT04532099|Device|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
79322467|NCT05384769|Other|Survey Administration|Ancillary studies
79322468|NCT05383976|Other|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
79322469|NCT05379699|Other|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
79322470|NCT05379699|Other|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
79480189|NCT05658055|Drug|Amoxicillin|Antibiotic for H. pylori eradication
79976341|NCT03041792|Drug|Liraglutide|Liraglutide
79976342|NCT03041792|Other|Placebo|Placebo
79976343|NCT05384093|Device|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
79480190|NCT05658055|Drug|probiotics|Medilac-S; Enterococcus faecium 4.5*10^8 and Bacillus subtilis 5.0*10^7, Hanmi,Beijing, China
79480191|NCT04745533|Diagnostic Test|Antigen detection test|To compare the results of the antigen detection test against the polymerase chain reaction in the study of contacts of COVID-19 patients during quarantine.
79646266|NCT02343445|Drug|P-1037|P-1037 is a novel ENaC inhibitor
79646267|NCT02343445|Drug|Hypertonic Saline|4.2% saline solution
79646268|NCT02343445|Drug|Saline|0.17% saline solution
79646269|NCT02338648|Drug|SUN-131 1.5% TDS|Active transdermal patch
79646270|NCT02338648|Drug|Placebo TDS|Placebo transdermal patch for blinding
79646271|NCT02336698|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
79646272|NCT02336698|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
79646273|NCT02336698|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
79646274|NCT00204906|Dietary Supplement|vitamin D supplementation|
79809406|NCT02627885|Behavioral|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
79322471|NCT05379439|Other|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
79322472|NCT05374044|Diagnostic Test|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
79322473|NCT05372744|Other|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
79976344|NCT03753581|Device|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
79976345|NCT03753581|Device|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
79976346|NCT04051424|Device|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
79322474|NCT05372159|Other|none, observational study|none, observational study
79480192|NCT03911375|Other|Mindfulness Based Stress Reduction (MBSR)|"Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention."
79976347|NCT04051424|Device|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
79976348|NCT04051424|Device|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
79976349|NCT03753503|Behavioral|exercise|exercised three times a week in the 8-week HIIT program
79976350|NCT03753503|Behavioral|conventional physical therapy|
79322475|NCT05363540|Procedure|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
79322476|NCT05363540|Procedure|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
79322477|NCT05360069|Device|Linear stapler|Linear stapler is adopted in esophagojejunostomy
79480193|NCT05462041|Other|DBD Donor Heart Transplantation|A technique of donor heart procurement.
79480194|NCT05462041|Device|DCD Donor Heart Transplantation|A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
79480195|NCT05459155|Other|Synapse medicine platform|Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics
79480196|NCT01721876|Drug|Placebo|Placebo matching Volasertib
79480197|NCT01721876|Drug|Volasertib|Volasertib
79976351|NCT03625856|Dietary Supplement|Chlorella Vulgaris|Chlorella capsules 1500 mg/day
79976352|NCT03625856|Dietary Supplement|Placebo|Starch 1500 mg
79976353|NCT05375123|Device|Ultrasound image acquisition|"Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation)."
79480198|NCT01721876|Drug|Cytarabine|Cytarabine
79480199|NCT05455411|Behavioral|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
79646275|NCT02335918|Drug|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
79976354|NCT03757169|Other|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
79322478|NCT05360069|Device|Circular stapler|Circular stapler is adopted in esophagojejunostomy
79976355|NCT03757169|Other|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
79976356|NCT05366270|Device|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
79322479|NCT05347771|Drug|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
79322480|NCT05347771|Drug|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
79322481|NCT05343611|Behavioral|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at ~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
79646276|NCT00200109|Device|Occipital Nerve Stimulation|Each group had a different plan
79976357|NCT05366270|Device|Sham|Sham (mild heating) using Heckel Hyperthermia Device
79322482|NCT05343611|Dietary Supplement|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
79322483|NCT05343611|Dietary Supplement|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
79322484|NCT05342844|Drug|Dexmedetomidine 0.5 mcg|0.5 mcg/kg
79322485|NCT05342844|Drug|Dexmedetomidine 1 mcg|1 mcg/kg
79322486|NCT05339087|Drug|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
79322487|NCT05339087|Other|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
79976358|NCT04507763|Drug|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
79976359|NCT03045302|Drug|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
79976360|NCT05365100|Drug|BN102|oral tablets: BN102, BID
79976361|NCT03754595|Procedure|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
79976362|NCT03754595|Procedure|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
79976363|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
79976364|NCT00705484|Drug|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
79976365|NCT03754517|Diagnostic Test|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
79322488|NCT05333133|Dietary Supplement|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
79322489|NCT05332509|Device|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
79322490|NCT05332509|Device|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
79322491|NCT05323617|Drug|Romiplostim|Administered as a subcutaneous injection.
79480200|NCT05455411|Behavioral|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
79480201|NCT03224585|Drug|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
79480202|NCT03224585|Drug|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
79480203|NCT05452681|Other|Educational Intervention|Receive Y-AMBIENT
79480204|NCT05452681|Other|Quality-of-Life Assessment|Ancillary studies
79480205|NCT05452681|Other|Questionnaire Administration|Ancillary studies
79480206|NCT05452681|Other|Control Intervention|Receive cookbook and socialization calls
79480207|NCT01457612|Dietary Supplement|Strawberry|20g twice per day (BID) in beverage
79480208|NCT01457612|Dietary Supplement|Placebo1|Placebo Beverage 1 without fiber
79480209|NCT01457612|Dietary Supplement|Placebo2|Placebo Beverage 2 with Fiber
79646277|NCT04679155|Behavioral|Eating Time Restriction|early vs late time of day restriction
79646278|NCT04678609|Other|Exercise|CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
79976366|NCT03754439|Behavioral|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
79976367|NCT03754361|Procedure|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
79976368|NCT03754361|Procedure|IHD|HD 4hour 2-3times per week
79976369|NCT02471872|Behavioral|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
79646279|NCT00176813|Drug|Gemcitabine|
79646280|NCT00176813|Drug|Cisplatin|
79976370|NCT02471872|Other|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
79646281|NCT00176813|Drug|Celecoxib|
79646282|NCT04678375|Diagnostic Test|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
79646283|NCT04678531|Drug|Swabs containing tea tree oil and chamomile oil|Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
79646284|NCT04678531|Drug|Baby shampoo|Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
79976371|NCT05459597|Drug|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
79480210|NCT03423641|Drug|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
79646285|NCT04678063|Other|Exposure to Placebo|Patients are exposed to placebo in the EEC
79646286|NCT04678063|Other|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
79976372|NCT05358626|Diagnostic Test|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
79976373|NCT03754283|Device|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
79976374|NCT03753425|Procedure|Low volume bowel preparation in inflammatory bowel diseases|Low volume bowel preparation in inflammatory bowel diseases
79976375|NCT05692310|Other|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
79976376|NCT05692310|Other|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
79976377|NCT03753269|Drug|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
79322492|NCT05323617|Drug|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
79322493|NCT05323617|Drug|Cyclosporine A|Administered orally.
79646287|NCT04678063|Other|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
79976378|NCT03753269|Drug|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
79976379|NCT03753191|Device|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
79976380|NCT05692076|Device|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
79976381|NCT01322789|Biological|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
79976382|NCT05691998|Other|Prosthetic foot questionnaire|Prosthetic foot related questions will be asked to the patients
79646288|NCT02332759|Device|Materna Medical|
79646289|NCT02320708|Drug|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
79976383|NCT03754205|Device|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
79984757|NCT03111914|Diagnostic Test|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
79322494|NCT05322161|Behavioral|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~Yoga postures (Asana) = low impact gentle postures meant to be done individually~Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~Meditation (Dhyana) = guided meditation"
79322495|NCT05316012|Device|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
79646290|NCT02320708|Drug|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
79646291|NCT02320708|Drug|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
79976384|NCT05459441|Biological|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
79646292|NCT02320708|Drug|Placebo|2 placebo caplets for acetaminophen taken orally one time
79646293|NCT02320708|Drug|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
79976385|NCT05459441|Drug|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
79976386|NCT05691842|Other|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
79976387|NCT05691842|Other|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
79976388|NCT04523831|Drug|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
79976389|NCT04523831|Drug|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
79976390|NCT05691764|Drug|Cyclosporin|Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
79976391|NCT05691764|Procedure|remote ischemic preconditioning|Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
79646294|NCT02320708|Drug|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
79809407|NCT02627885|Other|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
79809408|NCT00674453|Drug|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
79646295|NCT02310802|Drug|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
79646296|NCT02310802|Drug|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
79646297|NCT02310802|Drug|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
79646298|NCT02310802|Drug|Placebo|Placebo dispersible tablets for single oral administration
79646299|NCT02310412|Biological|INTERCEPT treated platelets|
79646300|NCT02309671|Drug|FE 999049|
79646301|NCT02309671|Drug|follitropin beta|
79809409|NCT00674453|Other|Placebo|Matching placebo tablet given once daily for 2 years
79809410|NCT02634671|Other|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
79976392|NCT05691764|Drug|Placebo|Intravenous placebo
79646302|NCT02296645|Drug|ZuraPrep|Apply topically.
79976393|NCT04707664|Drug|Sargramostim|All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
79976394|NCT04707664|Drug|Placebo|All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
79646303|NCT02296645|Drug|ChloraPrep|Apply topically.
79976395|NCT03752879|Procedure|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
79976396|NCT01316276|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
79322496|NCT05310877|Behavioral|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
79813818|NCT00813488|Drug|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."
79322497|NCT05302765|Other|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
79646304|NCT02295865|Drug|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
79646305|NCT02295865|Drug|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
79646306|NCT02295865|Drug|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
79646307|NCT02295865|Drug|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
79646308|NCT02288845|Drug|ITI-007|
79646309|NCT02282761|Drug|ITI-007|
79646310|NCT02282761|Drug|Placebo|
79646311|NCT02282215|Biological|CLT-008|Single intravenous infusion
79646312|NCT02282215|Biological|G-CSF|Daily subcutaneous injections
79646313|NCT00176969|Drug|Capsaicin|
79646314|NCT02266342|Device|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
79976397|NCT03756857|Procedure|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
79976398|NCT03756857|Procedure|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
79976399|NCT04700566|Biological|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
79976400|NCT02474290|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
79976401|NCT05691608|Biological|Solid tumor and CT DNA|Biopsy and blood sample
79976402|NCT03753971|Other|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
79322498|NCT05293431|Other|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
79976403|NCT02474212|Drug|Enoxaparin|
79322499|NCT05293431|Other|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
79976404|NCT04111601|Device|Blue light imaging|Advanced virtual chromoendoscopy
79976405|NCT05227118|Drug|MK-8189|MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
79976406|NCT05227118|Drug|Placebo|MK-8189 matching placebo administered orally QD
79976407|NCT03756779|Other|Dietary intervention|Dietary intervention with dietary modification of fat intake.
79976408|NCT05200286|Drug|Olorofim|Single oral dose
79976409|NCT03753815|Device|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
79976410|NCT03753815|Device|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
79976411|NCT02474446|Dietary Supplement|Vitamin D|150,000 IU of Vitamin D3 Oral solution
79976412|NCT05199818|Drug|Palonosetron HCl Buccal Film 0.5 mg|Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
79976413|NCT05199818|Drug|IV Palonosetron 0.25 mg|IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
79976414|NCT03753737|Other|Questionnaires and semi-structured interview|"Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder."
79976415|NCT03752645|Device|Transverse Many Channels Laser Instrument|The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
79976416|NCT02474134|Drug|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
79976417|NCT04668989|Device|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week.
79322500|NCT05292508|Diagnostic Test|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
79646315|NCT04678687|Procedure|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
79646316|NCT00204945|Drug|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
79646317|NCT00177008|Drug|Aripiprazole|
79976418|NCT04668989|Device|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week.
79976419|NCT03752489|Diagnostic Test|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
79976420|NCT03752489|Diagnostic Test|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
79976421|NCT02473900|Drug|HIP1403|Oseltamivir 75mg
79976422|NCT02473900|Drug|HGP0919|Oseltamivir phosphate 75mg
79976423|NCT04513691|Diagnostic Test|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
79976424|NCT02471638|Device|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
79976425|NCT04689178|Other|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
79322501|NCT05291169|Device|Omeza® Collagen Matrix|"Omeza® Collagen Matrix is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin protectant. When applied to a wound surface, the matrix is naturally incorporated into the wound over time. Omeza® Collagen Matrix is designed for intimate contact with both regular and irregular wound beds, to provide a conducive environment for the patient's natural wound healing process.~Contains: Fish collagen, cod liver oil, medium chain triglyceride oil, coconut oil, hemp seed oil, triethyl citrate, ethyl linoleate, caprylic acid, red palm concentrate, monolaurin, cetyl esters NF, beeswax, ascorbyl palmitate, sea salt Omeza® Collagen Matrix is supplied in a sterile single use vial."
79976426|NCT04689178|Other|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
79976427|NCT03700385|Device|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
79976428|NCT02471950|Procedure|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
79322502|NCT05290766|Procedure|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
79976429|NCT02471794|Behavioral|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
79976430|NCT01322867|Drug|alprazolam tablet|0,25 mg oral tablets given once
79976431|NCT01322867|Drug|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
79976432|NCT04624828|Procedure|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
79976433|NCT04624828|Drug|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
79976434|NCT04624828|Biological|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
79976435|NCT02473978|Device|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
79322503|NCT05290766|Procedure|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
79322504|NCT05290766|Device|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
79322505|NCT05290610|Other|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
79322506|NCT05278533|Dietary Supplement|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
79646318|NCT04677985|Combination Product|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
79646319|NCT00554632|Drug|Ethinyl estradiol and norgestimate|Oral contraceptive
79976436|NCT02477722|Other|EFP-NF|
79976437|NCT02477722|Other|Sham|
79976438|NCT05461079|Diagnostic Test|obtention of up to three semen samples|sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (<15 mill), up to three semen samples will be collected.
79322507|NCT05278533|Dietary Supplement|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
79322508|NCT05276674|Device|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
79646320|NCT00554632|Drug|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
79646321|NCT02963870|Other|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
79322509|NCT05275699|Drug|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
79322510|NCT05263674|Drug|Rapid sedation|High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
79976439|NCT04491760|Other|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
79976440|NCT03750929|Other|Combined acute physical exercises (strength and aerobic)|Patients will be submmitted to combined acute physical exercises (strength and aerobic)
79976441|NCT04585594|Behavioral|Mi Propio Camino (MPC)|The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.
79322511|NCT05259085|Drug|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
79322512|NCT05257668|Other|High Intensity Interval Exercise Training|High Intensity Interval Training Group
79976442|NCT04585594|Behavioral|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
79976443|NCT04498403|Drug|Crisaborole 2%|Crisaborole 2% ointment
79976444|NCT02471560|Drug|dimethyl fumarate|As per the prevailing local label.
79976445|NCT02471560|Drug|injectable MS DMT|As described above.
79322513|NCT05257668|Other|Moderate Intensity Exercise Training|Moderate Intensity Training Group
79646322|NCT00204984|Drug|oral hydralazine and intravenous nesiritide|vasodilators
79646323|NCT02254993|Drug|C16G2|antimicrobial peptide
79646324|NCT02253745|Drug|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
79646325|NCT02253745|Drug|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
79976446|NCT02477488|Drug|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
79646326|NCT02236195|Drug|Mocetinostat|
79646327|NCT00200148|Procedure|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
79809411|NCT02634671|Other|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
79322514|NCT05251181|Drug|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
79322515|NCT05251181|Drug|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
79322516|NCT05248009|Device|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
79322517|NCT05236348|Device|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
79322518|NCT05231837|Behavioral|Experimental: Fee Waiver|Fees are waived for youth sports programs at the park and recreation center
79322519|NCT05231837|Behavioral|Fee Waiver Plus Intensive Outreach|Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
79976447|NCT03750851|Other|Placebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
79322520|NCT05230030|Behavioral|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
79976448|NCT03750851|Other|CPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
79322521|NCT05229965|Drug|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
79322522|NCT05229965|Drug|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
79480211|NCT04832659|Behavioral|CEASE|The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
79809412|NCT02634671|Other|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
79809413|NCT02627807|Radiation|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
79322523|NCT05229965|Drug|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
79322524|NCT05229120|Behavioral|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
79322525|NCT05227391|Procedure|Oral Letrozole|Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.
79322526|NCT05227391|Procedure|Oral estradiol valerate|Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.
79322527|NCT05220631|Behavioral|Technology intervention|Older Adult Technology Services (OATS) 5-week technology intervention
79322528|NCT05220631|Behavioral|Digital Nutrition Intervention|15-week nutrition intervention delivered completely online
79322529|NCT05215600|Device|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
79322530|NCT05211986|Drug|IMM01-STEM|IMMUNA (IMM01-STEM) is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
79809414|NCT02627807|Radiation|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
79809415|NCT02627807|Drug|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
79976449|NCT03750851|Other|Laser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
79976450|NCT03750851|Other|LaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
79322531|NCT05209880|Behavioral|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
79480212|NCT04832659|Behavioral|CEASE + BIO|Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine. Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor. The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline. The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies. BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
79976451|NCT05163106|Drug|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
79976452|NCT05163106|Drug|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
79976453|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
79322532|NCT05207709|Drug|Ribociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
79322533|NCT05207709|Drug|Palbociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
79322534|NCT05207709|Drug|Paclitaxel +/- Tislelizumab|Patients in this arm could receive as the first line of therapy
79322535|NCT05203731|Behavioral|Exercise|Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
79322536|NCT05203731|Behavioral|Sitting|Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
79480213|NCT01112072|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
79976454|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
79976455|NCT02477410|Dietary Supplement|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
79322537|NCT05203315|Drug|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate [HP] and tazarotene [Taz] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
79322538|NCT05203315|Drug|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
79322539|NCT05203276|Drug|Envafolimab|300mg，SC，Q3W，d1
79322540|NCT05203276|Drug|Endostar|210mg，CIV，Q3W，d1-3
79976456|NCT05594524|Behavioral|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
79322541|NCT05201066|Drug|decitabine|Solution for intravenous infusion
79809416|NCT02627807|Drug|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
79976457|NCT02471248|Device|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
79976458|NCT02471248|Device|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
79976459|NCT02477254|Biological|Vaccination|A quadrivalent HPV vaccine
79976460|NCT04362137|Drug|Ruxolitinib|Ruxolitinib 5 mg tablets
79322542|NCT05201066|Drug|Spartalizumab|Solution for intravenous infusion
79322543|NCT05201066|Drug|Sabatolimab|Solution for intravenous infusion
79322544|NCT05201066|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
79322545|NCT05201066|Drug|Venetoclax|Tablet for oral administration
79322546|NCT05201066|Drug|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
79646328|NCT00200148|Procedure|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
79646329|NCT02236156|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
79646330|NCT02236156|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
79976461|NCT04362137|Drug|Placebo|Matching-image placebo
79976462|NCT04491916|Drug|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
79322547|NCT05186714|Behavioral|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
79322548|NCT05171348|Drug|CM326|a humanized monoclonal antibody
79976463|NCT02473588|Device|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
79976464|NCT02477098|Drug|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
79646331|NCT02236156|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
79976465|NCT02477098|Drug|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
79322549|NCT05171348|Drug|Placebo|Placebo
79322550|NCT05167487|Drug|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
79322551|NCT05167487|Drug|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
79322552|NCT05162638|Procedure|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel & advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN & OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter & advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath & pulled out. Catheter then threaded & advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
79322553|NCT05159778|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
79646332|NCT00177086|Other|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
79646333|NCT02235259|Drug|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
79646334|NCT02235259|Drug|Placebo|
79976466|NCT03752255|Other|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
79976467|NCT05099380|Device|senofilcon A C3|TEST Lens
79976468|NCT05099380|Device|senofilcon A|CONTROL Lens
79976469|NCT03108742|Device|INSORB|dermal stapler for skin closure
79976470|NCT03108742|Procedure|classic intradermal suture|intradermal suture for skin closure
79976471|NCT02473744|Other|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
79976472|NCT02476942|Drug|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
79976473|NCT02476942|Drug|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
79322554|NCT05159778|Biological|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
79646335|NCT00205023|Procedure|Sonohysterography|SHG during surgery for endometrial cancer.
79322555|NCT05159050|Drug|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1*: 50 mg/m^2; Dose Level 2: 100 mg/m^2; Dose Level 3: 135 mg/m^2; Dose Level 4: 175 mg/m^2; Dose Level 5: 200 mg/m^2~*Starting Dose"
79322556|NCT05152888|Drug|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
79322557|NCT05151484|Drug|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
79480214|NCT05437159|Behavioral|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
79480215|NCT05437159|Behavioral|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
79976474|NCT02473432|Procedure|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
79976475|NCT02473432|Procedure|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
79976476|NCT02473432|Procedure|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
79976477|NCT02473354|Drug|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air [21% Oxygen]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
79976478|NCT02473354|Drug|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
79976479|NCT02473354|Drug|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
79976480|NCT04382638|Combination Product|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
79322558|NCT05151484|Drug|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
79322559|NCT05151380|Device|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
79322560|NCT05147324|Behavioral|"MyPlan - Individualized Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating plan adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of eating plan at three months is based on weight status, adherence according to logs, and youth/guardian acceptability.
79322561|NCT05132322|Behavioral|Educational Outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
79646336|NCT03455062|Other|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
79646337|NCT00177125|Device|ErectAid|
79322562|NCT05132322|Behavioral|Audit & Feedback (unit level)|Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
79322563|NCT05132322|Behavioral|Audit & Feedback (real time, individual-level)|Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
79646338|NCT02207257|Drug|PER977|Reversal of edoxaban-induced anticoagulation
79646339|NCT02207257|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
79976481|NCT04382638|Device|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
79480216|NCT05437159|Behavioral|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
79480217|NCT05437159|Device|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
79646340|NCT02207257|Drug|Edoxaban|
79480218|NCT05437159|Device|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
79809417|NCT02627807|Drug|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
79976482|NCT02470936|Behavioral|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
79976483|NCT03628612|Biological|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
79976484|NCT02470858|Drug|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
79480219|NCT05437159|Behavioral|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
79646341|NCT00554710|Drug|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
79646342|NCT00554710|Drug|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
79646343|NCT00205062|Procedure|PET-CT|
79646344|NCT04659265|Other|Suspected diagnosis of a pre-treating physician|Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
79809418|NCT02627807|Drug|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
79976485|NCT02470858|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
79976486|NCT02470858|Drug|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
79976487|NCT02473198|Drug|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
79809419|NCT00674531|Procedure|Artery resection|Artery resection
79809420|NCT00678431|Dietary Supplement|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
79809421|NCT00678431|Dietary Supplement|Placebo|Liquid placebo
79976488|NCT02473198|Drug|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
79976489|NCT02473198|Drug|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
79322564|NCT05132322|Behavioral|Clinical Pathway Integrated into Electronic Health Record|Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
79322565|NCT05128227|Behavioral|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
79322566|NCT05128227|Behavioral|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
79322567|NCT05124574|Other|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~Sampling of amniotic fluid in case of cesarean section~Sampling of the placenta for histological and virological study."
79322568|NCT05124574|Other|Samples concern newborns of SARS-COV-2 + mothers at birth|"In the birth room:~Collection of gastric fluid (PCR SARS-COV-2),~Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~In the newborn at D3 of life:~- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~In symptomatic newborns:~1 yellow tube (SARS-COV-2 + RT-qPCR serology).~nasopharyngeal PCR,"
79322569|NCT05121831|Drug|DGX-001Dose 1|Dose level 1 of DGX-001
79322570|NCT05121831|Drug|DGX-001 Dose 2|Dose level 2 of DGX-001
79322571|NCT05121831|Drug|DGX-001 Dose 3|Dose level 3 of DGX-001
79480220|NCT05662514|Dietary Supplement|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units [CFU] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
79480221|NCT05662514|Other|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
79480222|NCT04825795|Drug|DPP4-inhibitor|Prescription of DPP4-inhibitor during the period between the two coronary CT scan
79480223|NCT04825795|Drug|No DPP4-inhibitor|No prescription of DPP4-inhibitor during the period between the two coronary CT scan
79480224|NCT03225599|Other|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
79809422|NCT00678509|Biological|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
79809423|NCT00674687|Drug|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
79809424|NCT00674687|Drug|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
79322572|NCT05121831|Drug|DGX-001 Dose 4|Dose level 4 of DGX-001
79480225|NCT05659238|Behavioral|the effect on language development & attention|Tv & other electronic devices effects onn children's language development & attention
79480226|NCT03226223|Drug|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
79809425|NCT02628821|Other|Preterm Infants treated with non-invasive ventilation.|
79322573|NCT05121831|Drug|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
79322574|NCT05118009|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
79322575|NCT05113537|Drug|Abemaciclib|Given Orally
79322576|NCT05113537|Drug|Lutetium Lu 177-PSMA-617|Given IV
79480227|NCT05620771|Drug|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
79809426|NCT02634749|Other|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
79809427|NCT02634749|Other|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
79976490|NCT02473198|Drug|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
79976491|NCT03614728|Drug|GSK3326595|GSK3326595 will be administered.
79322577|NCT05110300|Device|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
79322578|NCT05110300|Device|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
79646345|NCT00177203|Behavioral|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
79976492|NCT03614728|Drug|5-Azacitidine|5-Azacitidine will be administered.
79976493|NCT03154086|Drug|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
79646346|NCT00200187|Procedure|low venous pressure general anesthesia|
79646347|NCT00200187|Procedure|combined spinal-epidural anesthesia|
79646348|NCT04659109|Drug|glenzocimab|IV administration as a sterile product
79976494|NCT03154086|Drug|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
79976495|NCT02471482|Other|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
79322582|NCT05092542|Behavioral|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
79322583|NCT05088252|Drug|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.
79322584|NCT05088252|Drug|Propofol|After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
79480228|NCT05620771|Drug|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
79646349|NCT04659109|Drug|Placebo|IV administration
79646350|NCT00177242|Drug|Gefitinib|
79646351|NCT04659070|Drug|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
79646352|NCT04659070|Drug|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
79646353|NCT04659070|Drug|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
79646354|NCT04659148|Procedure|Total proctocolectomy|Total proctocolectomy: surgical removal of the colon, rectum, and anus
79646355|NCT04658875|Dietary Supplement|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
79646356|NCT04658875|Other|Wash-out|2 weeks washout period to each study subject to avoid any possible carryover effect.
79322587|NCT05069298|Dietary Supplement|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
79322588|NCT05068258|Procedure|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
79322589|NCT05065632|Diagnostic Test|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
79322590|NCT05062759|Drug|Tezepelumab|210 mg SC injection Q4W.
79809428|NCT02634749|Other|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
79809429|NCT00656747|Drug|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
79809430|NCT00656747|Drug|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
79646357|NCT04658875|Other|Placebo supplementation|Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.
79646358|NCT04658875|Other|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks
79655825|NCT02278510|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
79809431|NCT00678743|Drug|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
79809432|NCT04152317|Drug|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
79809433|NCT04152317|Drug|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
79322591|NCT05062759|Drug|Placebo|SC injection Q4W.
79322592|NCT05057715|Biological|VCN-01|Intravenous administration of VCN-01
79322593|NCT05057715|Biological|huCART-meso Cells|Intravenous administration of huCART-meso cells
79322594|NCT05056454|Behavioral|Online therapy with coaching|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or Rainfrog's ParentMood course. Lesson content is presented as illustrated stories about characters who are anxious and depressed then gain mastery over their problems using CBT techniques. The efficacy of each online course will be compared for equivalency.~Following each lesson, participants are provided a document that summarizes key lesson information and practical homework exercises that reinforce the content of the lesson. Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
79809434|NCT02628665|Drug|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
79809435|NCT02628665|Device|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
79322595|NCT05056454|Behavioral|Clinical care|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider and will be comparable to that provided in the TAU arm.
79480229|NCT05716880|Drug|Ketosteril|Daily dose = 1 tabl / 5 kg of ideal body weight
79646359|NCT04658875|Other|Systematic physical exercise program|Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (~ 10 min), a main physical conditioning phase (~ 25 min), and a cool-down or relaxation phase (~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
79646360|NCT00177281|Drug|S CKD602|
79646361|NCT04658524|Diagnostic Test|Thyroid function|laboratorial thyroid tests
79976496|NCT05691374|Procedure|Ultrasound (US) examination|"Shear-Wave Elastography (SWE) measurements of operated shoulder (quality, elasticity of repaired tendon) compared to healthy contralateral side. Parameters documented by regular US: Diameter of repaired tendon/ tendon thickness (mm), Rotator cuff muscle fatty infiltration (Grade 0-4), Signs of suture cut-through (yes | no), Signs of anchor displacement and location (lateral|medial row), Location of defect (at the foot print|medial cuff failure), Status of long biceps tendon (intact|in continuity|defect). Tissue elasticity measured by SWE in longitudinal orientation (in passive state and with active tension): Trapezius and Deltoid muscle: uninjured superficial muscle for individual patient muscle quality, SSP muscle and tendon: anterior and posterior part, SSC muscle and tendon: cranial and caudal part, ISP muscle and tendon, Biceps muscle and tendon: native (intraarticular) or subpectoral tenodesis (extraarticular)"
79976497|NCT05691374|Procedure|Clinical examination|Clinical examination for shoulder range of motion and strength measurement
79480230|NCT05716880|Other|Medium Protein Diet (MPD)|MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
79646362|NCT00200226|Drug|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
79646363|NCT00200226|Drug|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
79646364|NCT00408083|Drug|MultiHance|0.5 mmol/kg as a single dose administration
79646365|NCT00408083|Drug|Magnevist|0.5 mmol/kg as a single dose administration
79646366|NCT04658485|Device|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
79655826|NCT04546243|Procedure|resection group|patients received VATS
79655827|NCT04546243|Radiation|radiotherapy group|patients received radiotherapy
79655828|NCT02278627|Other|manual lymphatic drainage|
79809436|NCT00674843|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
79646367|NCT04658485|Device|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
79322596|NCT05050240|Other|Cooling Vest Procedure|"A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar_CoolFlow_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation."
79646368|NCT04658719|Device|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
79646369|NCT04658719|Device|Standard Care|Uncoated Foley Catheter
79646370|NCT00200265|Behavioral|diet|diet
79646371|NCT00408122|Procedure|PET/CT scan and EUS|
79809437|NCT00678977|Drug|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
79809438|NCT00678977|Drug|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
79976498|NCT02470780|Drug|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
79976499|NCT02470780|Drug|Placebo|Placebo matching Rifaximin treatment.
79976500|NCT05691296|Behavioral|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
79809439|NCT00678977|Drug|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
79976501|NCT05691296|Behavioral|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
79976502|NCT02473120|Biological|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
79976503|NCT02472808|Other|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
79976504|NCT02472808|Other|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
79646372|NCT04658563|Other|High Density Exercise Training Program - Yoga|A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
79646373|NCT04658329|Drug|Antiretroviral|Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
79646374|NCT04658602|Procedure|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
79646375|NCT00200304|Behavioral|Internet weight loss with SlimFast and human counseling|
79646376|NCT00200304|Behavioral|Internet weight loss with SlimFast and computer counseling|
79646377|NCT00200304|Behavioral|Internet weight loss program with SlimFast|
79976505|NCT02472808|Other|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
79976506|NCT02472808|Other|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
79976507|NCT05687942|Device|REBUILD|3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
79976508|NCT05180292|Drug|Carvedilol 12.5 MG|Carvedilol 12.5 mg
79976509|NCT01315938|Drug|Abatacept Active Treatment|Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
79976510|NCT01315938|Drug|Abatacept Delayed-Onset Treatment|Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
79976511|NCT03108430|Other|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
79976512|NCT04800354|Behavioral|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
79480231|NCT04735991|Behavioral|Kapok Initiative|"The detailed process is:~After randomization, the Kapok assistant will contact the patient's family~The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
79976513|NCT04800354|Behavioral|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
79976514|NCT05684432|Other|No intervention|No intervention
79976515|NCT02470624|Other|treatment following current guideline|
79976516|NCT01339884|Drug|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
79322597|NCT05050240|Other|Fasting overnight|Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
79322598|NCT05047640|Biological|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
79322599|NCT05047640|Biological|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
79976517|NCT05112614|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
79976518|NCT05112614|Other|Electronic Health Record Review|Review of medical records
79976519|NCT04260646|Device|Enuresis Alarm Rodger and Timer watch (Rodger)|Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
79322600|NCT05047224|Behavioral|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
79322601|NCT05047224|Behavioral|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
79976520|NCT04260646|Device|Timer watch (Rodger)|Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
79976521|NCT04736394|Drug|APL-1202|APL-1202 single-agent oral treatment
79646378|NCT00408161|Behavioral|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
79976522|NCT04736394|Drug|Epirubicin Hydrochloride|Epirubicin hydrochloride
79976523|NCT04257370|Device|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
79976524|NCT04257370|Other|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
79976525|NCT01339962|Other|Non-interventional|Non-interventional (retrospective chart reviews)
79976526|NCT01341834|Drug|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
79322602|NCT05043714|Biological|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
79322603|NCT05039073|Drug|Brentuximab Vedotin|Given IV
79322604|NCT05039073|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
79322605|NCT05039073|Biological|Nivolumab|Given IV
79322606|NCT05039073|Other|Quality-of-Life Assessment|Ancillary studies
79322607|NCT05039073|Other|Questionnaire Administration|Ancillary studies
79322608|NCT05037669|Biological|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
79976527|NCT01340040|Drug|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
79322609|NCT05033262|Other|Our Memory Care Wishes|Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
79322610|NCT05029999|Drug|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
79976528|NCT02723344|Dietary Supplement|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
79322611|NCT05029999|Drug|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
79322612|NCT05029999|Drug|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
79322613|NCT05025956|Drug|Fisetin|Oral Fisetin 20 mg/kg taken for 8 days total.
79322614|NCT05025956|Drug|Placebo|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
79480232|NCT05419297|Drug|Buprenorphine Buccal Film [Belbuca]|buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
79480233|NCT05419297|Other|Urine Drug Screening|Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
79480234|NCT05419297|Device|actigraph|Subjects will wear this device to monitor sleep and activity
79480235|NCT05419297|Behavioral|PROMIS 29|questionnaire will be administered once a week via e-dairy to monitor mood and sleep
79976529|NCT02723344|Other|Sunflower and medium chain triglyceride oils|Placebo
79976530|NCT01340118|Drug|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
79976531|NCT03401398|Drug|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
79322615|NCT05023967|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79976532|NCT03401398|Drug|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
79976533|NCT01340274|Behavioral|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
79322616|NCT05023967|Drug|Extended Release Metformin Hydrochloride|Given PO
79322617|NCT05023967|Other|Monitoring|Use continuous glucose monitoring system
79322618|NCT05023967|Other|Nutritional Assessment|Receive nutritional counseling
79322619|NCT05023967|Other|Short-Term Fasting|Perform intermittent fasting
79322620|NCT05022264|Diagnostic Test|RIA-VS|Measuring vital signs with a new contactless camera technique
79322621|NCT05012254|Drug|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
79480236|NCT05419297|Other|sit to stand test|Subjects will complete this daily with specific instructions through the e-diary
79322622|NCT05012254|Drug|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
79976534|NCT01340274|Behavioral|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
79322623|NCT05012254|Drug|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
79322624|NCT05012254|Drug|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
79480237|NCT05419297|Other|numerical rating scale pain score|subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
79976535|NCT02469766|Procedure|SWL|Patients in this arm will undergo SWL
79976536|NCT02469766|Procedure|Semirigid URS|Patients in this arm will undergo semirigid URS
79976537|NCT02469766|Procedure|Flexible URS|Patients in this arm will undergo Flexible URS
79809440|NCT00674921|Drug|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
79646379|NCT00408161|Behavioral|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
79809441|NCT00674921|Drug|Placebo|starch, magnesium stearate, sodium lauryl sulphate
79809442|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
79809443|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
79976538|NCT03635658|Procedure|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
79976539|NCT03635658|Procedure|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
79976540|NCT02723188|Device|Sham stimulation (1.5 milliampere,30 seconds)|
79976541|NCT02723188|Device|DC stimulation (1.5 milliampere, 20 minutes)|
79976542|NCT02723188|Device|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
79976543|NCT04422366|Biological|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
79976544|NCT04422366|Biological|GARDASIL®|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
79976545|NCT01375582|Drug|B & L Soothe Lubricant Eye Drops|Eye Drop
79976546|NCT01375582|Drug|Liposic EDO|Eye Drop
79976547|NCT01375582|Drug|OcuFresh Eye Wash|Saline drop
79976548|NCT04409964|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
79976549|NCT04409964|Drug|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
79976550|NCT04409964|Drug|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
79646380|NCT00557518|Drug|Alagebrium|200 mg bid
79646381|NCT00557518|Drug|Placebo|bid
79646382|NCT00557557|Drug|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
79646383|NCT00557557|Drug|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
79976551|NCT03220282|Other|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
79976552|NCT03220282|Other|Preterm infant formula|Preterm formula determined by clinical practice
79976553|NCT04328376|Diagnostic Test|ECG coupled to phonocardiography|"A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography."
79646384|NCT04657978|Procedure|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
79976554|NCT03310996|Other|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
79976555|NCT01342146|Drug|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
79976556|NCT01342146|Drug|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
79976557|NCT01342146|Drug|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
79976558|NCT02471092|Other|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
79480238|NCT05419297|Behavioral|patient global impression of function|subjects will be asked three questions once a day to assess their personal impression of functional status
79976559|NCT03212716|Drug|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
79976560|NCT03212716|Drug|Diltiazem|60 mgx3 per day during 10 days.
79976561|NCT03212716|Drug|Placebos|Placebo of diltiazem
79976562|NCT03310840|Other|others|others
79976563|NCT05184114|Diagnostic Test|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
79976564|NCT02469922|Device|Positron emission tomography|
79976565|NCT02469922|Radiation|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
79322625|NCT05012254|Drug|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
79480239|NCT05419297|Behavioral|PROMIS - sleep|Subjects will answer 5 questions about sleep every morning via e-diary
79480240|NCT05716802|Behavioral|dance/movement therapy|dance/movement therapy plus treat as usual
79480241|NCT05716802|Behavioral|treatment as usual|The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
79480242|NCT03226457|Drug|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
79976566|NCT04762836|Drug|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
79646385|NCT04658134|Dietary Supplement|Glycine|Oral glycine tablets (100 mg/kg/day) in divided doses
79646386|NCT04658212|Procedure|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
79646387|NCT04658212|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
79976567|NCT04762836|Behavioral|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
79976568|NCT04762836|Behavioral|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
79976569|NCT04762836|Other|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
79976570|NCT04762836|Drug|Placebo|Placebo control in oral form
79976571|NCT04755660|Behavioral|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
79976572|NCT00705406|Drug|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
79976573|NCT00705406|Drug|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
79322626|NCT05012254|Drug|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol [2,3 d]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
79322627|NCT05012241|Diagnostic Test|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
79976574|NCT04318314|Diagnostic Test|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
79322628|NCT05009121|Diagnostic Test|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
79322629|NCT05009108|Diagnostic Test|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
79322630|NCT05005052|Drug|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
79976575|NCT01342224|Biological|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
79976576|NCT01342302|Behavioral|Psychosocial Intervention for Couples|Intervention delivered on line
79646388|NCT00177359|Behavioral|gait intervention|
79646389|NCT04658017|Device|GARNET device|Use of new filter in conjunction with standard of care dialysis.
79646390|NCT00200382|Drug|PS-341 (Velcade-drug)|
79646391|NCT04657744|Drug|Sphingomod|1 capsule contains 0.5 mg Fingolimod
79646392|NCT04657744|Drug|Gilenya|1 capsule contains 0.5 mg Fingolimod
79646393|NCT00177398|Drug|Glargine insulin vs regular insulin|
79646394|NCT04657627|Behavioral|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
79809444|NCT00674999|Drug|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
79809445|NCT00882713|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
79322631|NCT05005052|Drug|Placebo|Placebo and no compression or venopharmaceutical regimen
79322632|NCT05001139|Device|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
79976577|NCT03155178|Drug|3M CHG/IPA Prep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
79322633|NCT04995978|Drug|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
79322634|NCT04995978|Drug|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
79322635|NCT04995952|Behavioral|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
79976578|NCT03155178|Drug|ChloraPrep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
79976579|NCT02470546|Drug|Metformin|Metformin 1000mg twice a day
79976580|NCT02470546|Drug|Placebo|Placebo 1000mg twice a day
79322636|NCT04995952|Behavioral|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
79322637|NCT04993781|Behavioral|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
79976581|NCT01315626|Other|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
79322638|NCT04993157|Drug|FIA586|FIA586 capsule
79322639|NCT04988867|Drug|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
79322640|NCT04987294|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
79322641|NCT04987294|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
79646395|NCT04657627|Behavioral|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
79655829|NCT04545892|Drug|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
79976582|NCT03310762|Other|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
79976583|NCT03310762|Other|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
79976584|NCT05158920|Behavioral|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
79976585|NCT03310606|Other|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
79976586|NCT01315704|Drug|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
79976587|NCT05184036|Diagnostic Test|Low Vision|"The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
79976588|NCT05158608|Drug|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
79976589|NCT05158608|Drug|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
79322642|NCT04987242|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
79322643|NCT04987242|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
79322644|NCT04984005|Behavioral|Low intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.
79322645|NCT04984005|Behavioral|Moderate intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.
79322646|NCT04984005|Behavioral|Intermittent high intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
79322647|NCT04977050|Diagnostic Test|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
79322648|NCT04976192|Combination Product|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
79322649|NCT04976192|Combination Product|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
79322650|NCT04973553|Other|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
79322651|NCT04970290|Device|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
79322652|NCT04967677|Diagnostic Test|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
79322653|NCT04963062|Device|Holmium laser with Moses lasers|The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.
79322654|NCT04963062|Device|Holmium laser with thulium lasers|The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
79976590|NCT01342536|Behavioral|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
79976591|NCT03310372|Radiation|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
79976592|NCT03310372|Drug|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
79322655|NCT04958551|Other|No intervention|No intervention
79976593|NCT01340508|Radiation|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
79976594|NCT05310604|Procedure|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
79322656|NCT04958486|Drug|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
79322657|NCT04952961|Behavioral|Training in Vulval Self-Examination|Face-to-face training in vulval self-examination Supplemented with use of aids ( hand mirror, mobile phone with selfie-stick), patient information leaflet, reminders to self-examine
79322658|NCT04949165|Dietary Supplement|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
79322659|NCT04944979|Biological|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
79322660|NCT04942210|Biological|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
79322661|NCT04942210|Biological|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
79646396|NCT04657471|Other|revised HOME-CoV score|"Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score <2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score > 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required."
79976595|NCT05183958|Radiation|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 >60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
79976596|NCT05183958|Drug|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
79976597|NCT05183958|Drug|Chemotherapy|4 cycles for combined therapy.
79976598|NCT03108664|Drug|SYL1001 ophthalmic solution|1 drop in the affected eye
79976599|NCT03108664|Drug|Vehicle opthalmic solution|1 drop in the affected eye
79322662|NCT04940767|Drug|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
79322663|NCT04940767|Drug|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
79322664|NCT04926623|Device|FreeStyle Libre|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
79322665|NCT04926623|Other|SMBG|Self-Monitoring of Blood Glucose
79646397|NCT00177437|Behavioral|home testing kit|
79646398|NCT04657510|Other|COVID-19|Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
79976600|NCT04848012|Device|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
79976601|NCT01342614|Drug|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
79976602|NCT01342614|Drug|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
79322666|NCT04923334|Behavioral|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
79809446|NCT04053101|Device|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
79809447|NCT02627729|Device|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
79976603|NCT03310294|Dietary Supplement|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
79809448|NCT02627729|Device|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
79976604|NCT03310294|Dietary Supplement|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
79976605|NCT03108508|Dietary Supplement|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
79976606|NCT03108508|Dietary Supplement|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
79976607|NCT03108508|Dietary Supplement|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
79976608|NCT01342692|Drug|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
79809449|NCT04162223|Biological|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
79976609|NCT01342692|Drug|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
79976610|NCT01342692|Drug|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
79976611|NCT01342692|Drug|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
79809450|NCT04162223|Biological|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
79976612|NCT04043208|Behavioral|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
79976613|NCT04043208|Dietary Supplement|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
79480243|NCT03226457|Drug|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
79480244|NCT03226457|Drug|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
79480245|NCT05610787|Device|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
79976614|NCT05155488|Other|No Intervention|This is a non-interventional study.
79480246|NCT04344548|Biological|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
79480247|NCT03721029|Device|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
79976615|NCT03310216|Procedure|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
79322667|NCT04923334|Behavioral|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
79322668|NCT04914117|Drug|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
79322669|NCT04913805|Drug|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
79480248|NCT03721029|Procedure|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
79480249|NCT00003159|Drug|carboplatin|
79480250|NCT00003159|Drug|cisplatin|
79480251|NCT00003159|Drug|docetaxel|
79480252|NCT00003159|Drug|gemcitabine hydrochloride|
79809451|NCT04151381|Drug|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
79809452|NCT04151537|Behavioral|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
79809453|NCT04151537|Behavioral|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
79480253|NCT00003159|Drug|ifosfamide|
79480254|NCT00003159|Drug|mitomycin C|
79480255|NCT00003159|Drug|paclitaxel|
79480256|NCT00003159|Drug|vinblastine sulfate|
79480257|NCT00003159|Drug|vinorelbine tartrate|
79480258|NCT00003159|Procedure|conventional surgery|
79480259|NCT00003159|Procedure|neoadjuvant therapy|
79480260|NCT03228017|Drug|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
79480261|NCT02978300|Device|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
79809454|NCT00675077|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
79976616|NCT03310216|Procedure|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
79322670|NCT04913805|Drug|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
79480262|NCT02978300|Device|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
79480263|NCT00355927|Procedure|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
79480264|NCT00357422|Procedure|Operation|No drug needed
79480265|NCT00357422|Procedure|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
79480266|NCT05647538|Procedure|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
79480267|NCT03358355|Drug|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
79480268|NCT05716568|Other|Contrast dose reduction, CT-angiography|Contrast dose reduction for CT-angiography in pre-operative aorta
79976617|NCT02469688|Drug|ASP4070|intramuscular or intradermal
79646399|NCT04657237|Procedure|Thoracic Paravertebral block|TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
79322671|NCT04913805|Other|Potassium Chloride|Active control
79322672|NCT04912713|Other|Stress group|This group will perform the MAST stress protocol
79322673|NCT04912713|Other|Control group|This group will perform the MAST control protocol
79480269|NCT02959268|Device|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
79322674|NCT04907968|Drug|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~XMT-1536~UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
79322675|NCT04907968|Drug|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~XMT-1536~UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
79480270|NCT00356005|Drug|azithromycin plus artesunate|
79480271|NCT00356005|Drug|Artesunate|
79480272|NCT00376337|Drug|Micafungin|IV
79646400|NCT00177476|Behavioral|behavioral weight loss|
79646401|NCT00205296|Behavioral|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
79322676|NCT04902794|Device|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
79322677|NCT04902794|Device|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
79480273|NCT00376337|Drug|Systemic antifungal therapy|IV
79480274|NCT02959346|Procedure|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
79646402|NCT04657042|Diagnostic Test|Magnetic Resonance Imaging|Four-dimensional MRI of torso
79646403|NCT04656886|Drug|Intravenous Infusion|
79646404|NCT04656808|Behavioral|Guilt Focused Intervention|Psychotherapy, group intervention
79646405|NCT04656808|Behavioral|Cognitive behavioral therapy|Psychotherapy, group intervention
79646406|NCT00177515|Behavioral|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
79646407|NCT04656457|Device|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
79646408|NCT04656457|Other|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
79809455|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
79976618|NCT02469688|Drug|Placebo|intramuscular or intradermal
79976619|NCT03310138|Device|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
79976620|NCT03310138|Device|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
79646409|NCT00200421|Drug|Nebivolol and Atenolol|
79646410|NCT04656613|Biological|Gam-COVID-Vac|the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
79646411|NCT04656613|Other|placebo|Placebo Comparator
79646412|NCT04656769|Procedure|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
79809456|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
79809457|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
79809458|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
79809459|NCT00809133|Drug|BIBW2992|MTD dose of part A
79809460|NCT00809133|Drug|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
79322678|NCT04900220|Drug|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
79322679|NCT04900220|Drug|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
79322680|NCT04896684|Biological|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
79322681|NCT04896320|Drug|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
79809461|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
79809462|NCT00809133|Drug|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
79809463|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
79809464|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
79480275|NCT02959346|Procedure|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
79480276|NCT00003165|Drug|doxorubicin-HPMA conjugate|
79976621|NCT03998046|Behavioral|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
79976622|NCT03998046|Behavioral|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
79480277|NCT04329273|Other|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
79646413|NCT04656574|Behavioral|Simulation-based training|The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
79322682|NCT04893564|Biological|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
79322683|NCT04893564|Biological|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
79322684|NCT04887259|Biological|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
79322685|NCT04887259|Biological|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
79322686|NCT04877613|Drug|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
79646414|NCT00177554|Drug|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
79646415|NCT00205335|Device|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
79646416|NCT00205335|Device|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
79646417|NCT04656340|Other|non-medication, non-interventional therapies|non-medication, non-interventional therapies
79322687|NCT04877613|Drug|Fludarabine|Lyphodepletion
79322688|NCT04877613|Drug|Cyclophosphamide|Lyphodepletion
79322689|NCT04871607|Biological|Basiliximab|Given IV
79322690|NCT04871607|Drug|Carmustine|Given IV
79646418|NCT04655989|Device|DBB-EXA ES Hemodialysis System|The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
79809465|NCT00679133|Drug|MGCD265|Oral daily administration; 7 days on / 7 days off
79322691|NCT04871607|Drug|Cytarabine|Given IV
79322692|NCT04871607|Drug|Etoposide|Given IV
79322693|NCT04871607|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
79322694|NCT04871607|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
79322695|NCT04871607|Biological|Yttrium Y 90 Basiliximab|Given IV
79322696|NCT04869917|Behavioral|Decision Aid intervention|"Displays information about the benefits and risks of ILI and metformin~Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~Prompts patients to commit to immediate next steps~Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
79646419|NCT04656106|Drug|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
79322697|NCT04869917|Behavioral|Text Messaging intervention|"Defines prediabetes and includes individualized A1c values~Present benefits and risks of intensive lifestyle intervention and metformin~States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~Encourages initiating intensive lifestyle intervention or discussing metformin with provider~Include selected behavioral content from diabetes prevention program~Initial message with automatic opt-in, allows opt-out for messages~Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
79480278|NCT04329273|Other|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
79646420|NCT04656262|Drug|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
79646421|NCT04656262|Drug|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
79322698|NCT04869917|Behavioral|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
79322699|NCT04869397|Biological|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|"The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes."
79322700|NCT04869397|Other|Placebo|Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
79322701|NCT04865042|Drug|Gabapentin 300mg|"The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~Day 1 (1st day of hospitalization): 1 capsule/day~Day 2: 2 capsules/day~Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
79646422|NCT00200460|Drug|Nebivolol|
79646423|NCT04655950|Other|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
79646424|NCT04655872|Drug|[14C]TPN171H|A single 10 mg oral dose of [14C]TPN171H containing approximately 100 microcurie of [14C]-TPN171H.
79646425|NCT00177632|Behavioral|behavioral weight loss|
79646426|NCT04655833|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
79646427|NCT00200499|Drug|Nebivolol|
79646428|NCT04655677|Biological|CD19/CD20-directed CAR-T cells|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
79646429|NCT04655560|Other|no intervention|qualitative study
79646430|NCT00557596|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
79646431|NCT02962635|Device|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
79322702|NCT04865042|Drug|PLACEBO|"The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~Day 1 (1st day of hospitalization): 1 capsule/day~Day 2: 2 capsules/day~Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
79322703|NCT04861441|Device|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
79322704|NCT04861441|Device|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
79646432|NCT04655794|Drug|3HP|all patients taking 3HP under directly observed preventive therapy (DOPT) program
79322705|NCT04853368|Drug|ABBV-576|Oral capsules
79322706|NCT04853368|Drug|Galicaftor|Oral capsules
79322707|NCT04853368|Drug|Placebo|Oral capsules
79322708|NCT04853368|Drug|Navocaftor|Oral capsules
79480279|NCT04329273|Other|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
79646433|NCT04655443|Other|Standard Care|Standard cardiovascular care
79322709|NCT04853368|Drug|ABBV-119|Oral capsules
79322710|NCT04838106|Other|Not applicable as observational study|Not applicable as observational study.
79322711|NCT04837365|Other|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
79480280|NCT02979145|Other|No intervention involved|
79480281|NCT03424187|Dietary Supplement|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
79809466|NCT04151771|Other|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
79646434|NCT04655209|Behavioral|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
79646435|NCT04655209|Behavioral|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
79646436|NCT04655209|Behavioral|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
79646437|NCT04655131|Dietary Supplement|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
79646438|NCT04654975|Procedure|Esophagectomy for esophageal cancer|Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)
79322712|NCT04833790|Behavioral|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
79322713|NCT04833790|Behavioral|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
79480282|NCT00003171|Drug|bryostatin 1|
79809467|NCT04151771|Other|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
79646439|NCT04655014|Other|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
79322714|NCT04833790|Behavioral|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
79646440|NCT00200538|Drug|memantine|
79322715|NCT04833790|Behavioral|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
79322716|NCT04833790|Behavioral|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
79322717|NCT04830592|Biological|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
79322718|NCT04830592|Biological|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
79480283|NCT05392777|Diagnostic Test|Residual syntax score|residual syntax score will be calculated as the conventional syntax score from the web based tool, but subtract the score of the culprit lesion(s) that are fixed (stented) in the index procedure.
79480284|NCT05641610|Genetic|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10^12vg/kg, 5.0×10^12vg/kg, 1.0×10^13vg/kg.
79480285|NCT00003183|Biological|filgrastim|
79480286|NCT00003183|Drug|mitoxantrone hydrochloride|
79646441|NCT04655599|Drug|Olorinab|Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
79646442|NCT04655599|Drug|Placebo|Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
79646443|NCT00177710|Drug|Amphotericin B|
79646444|NCT04654936|Behavioral|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
79322719|NCT04827849|Other|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
79646445|NCT04654936|Behavioral|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
79976623|NCT03998046|Behavioral|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
79322720|NCT04824131|Drug|Oral cabotegravir (CAB)|30 mg tablets
79646446|NCT00557635|Procedure|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
79646447|NCT04654624|Drug|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
79809468|NCT00675155|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
79322721|NCT04824131|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
79809469|NCT02634593|Behavioral|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
79322722|NCT04824131|Drug|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
79322723|NCT04815707|Procedure|Occcult hernia repair|The occult hernia will be repaired during the same inguinal hernia repair
79976624|NCT03310060|Drug|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
79646448|NCT04654624|Drug|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
79646449|NCT00177749|Drug|Posaconazole|
79646450|NCT00200577|Drug|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
79646451|NCT04654585|Other|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
79809470|NCT00912275|Drug|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
79976625|NCT03310060|Drug|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
79809471|NCT00675233|Drug|HPPH|Given IV
79809472|NCT00675233|Procedure|laser therapy|Escalating light doses with 665 nm light
79809473|NCT04151303|Procedure|Cervical cerclage|Cervical cerclage and cervical cerclage removal
79322724|NCT04810975|Device|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
79480287|NCT02979223|Drug|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
79480288|NCT03687723|Device|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
79480289|NCT01805271|Drug|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
79322725|NCT04803851|Drug|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
79322726|NCT04781296|Device|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
79480290|NCT01805271|Drug|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
79480291|NCT03427931|Other|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
79480292|NCT05385289|Behavioral|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
79480293|NCT01768767|Drug|Placebo|
79480294|NCT01768767|Drug|Ketamine|
79480295|NCT01768767|Drug|Ketamine/Lithium|
79976626|NCT02470000|Device|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
79480296|NCT00358046|Drug|ILY101|
79480297|NCT00376493|Drug|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
79480298|NCT05574530|Dietary Supplement|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
79480299|NCT05574530|Dietary Supplement|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
79480300|NCT00003195|Biological|recombinant interferon alfa|
79480301|NCT00003195|Drug|busulfan|
79480302|NCT00003195|Procedure|allogeneic bone marrow transplantation|
79480303|NCT00003195|Procedure|peripheral blood stem cell transplantation|
79480304|NCT00003195|Radiation|radiation therapy|
79809474|NCT04152395|Other|EVAR|Patients undergoing EVAR
79976627|NCT02470000|Device|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
79976628|NCT02470000|Other|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
79976629|NCT03740958|Drug|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
79322727|NCT04776447|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
79322728|NCT04776447|Drug|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
79976630|NCT03740958|Drug|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
79322729|NCT04776447|Drug|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
79322730|NCT04768556|Other|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
79322731|NCT04768556|Other|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
79322732|NCT04768504|Drug|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
79480305|NCT03231917|Procedure|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
79976631|NCT01340820|Drug|AERAS-422|rBCG
79976632|NCT01340820|Drug|BCG Tice|1-8 x 10^5 CFU
79322733|NCT04763967|Device|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
79976633|NCT05290246|Behavioral|Time restricted eating|Limiting daily eating time to an 8 hour window
79976634|NCT05290246|Behavioral|Caloric reduction|Cut caloric intake by 15%
79976635|NCT05251584|Drug|Mupirocin|Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
79646452|NCT04654585|Other|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
79976636|NCT05251584|Drug|Gentamicin|Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
79976637|NCT05251506|Device|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
79646453|NCT00205491|Drug|Venlafaxine|
79646454|NCT04654819|Device|Dental anesthesia simulator usage|Training on dental anesthesia simulator
79322734|NCT04763967|Device|Standard of Care|Current Standard of Care for pediatric patients
79322735|NCT04762342|Other|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~Bilateral leg-press~Bilateral plantar flexion~Bilateral knee extension~Unilateral banded dorsal flexion~Bilateral lying leg curl~Back extension~Shoulder press~Seated row~Chest press~Lat pull-down"
79322736|NCT04755452|Procedure|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
79322737|NCT04755452|Procedure|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
79322738|NCT04748172|Biological|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
79322739|NCT04748172|Diagnostic Test|AMH sampling|Blood sample for AMH on recruitment and after three months
79322740|NCT04748172|Diagnostic Test|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
79646455|NCT04654780|Behavioral|Taxes|"a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO."
79646456|NCT04654780|Behavioral|Subsidies|A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
79646457|NCT04654780|Behavioral|Control|Average or current food prices will apply. Based on the average of the values reported by three supermarkets
79646458|NCT04654390|Drug|DWP16001 Amg|Tablets, Orally, Once daily
79976638|NCT03309982|Dietary Supplement|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
79976639|NCT03309982|Other|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
79976640|NCT05183568|Behavioral|Mindful Self-Compassion|Self-guided bibliotherapy (specific chapters to read each week) and daily use of a meditation app for 45 minutes
79976641|NCT03309904|Other|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
79976642|NCT04406142|Device|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
79976643|NCT02470078|Device|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
79322741|NCT04747041|Combination Product|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
79322742|NCT04741646|Drug|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC and matching placebo will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
79646459|NCT00205530|Behavioral|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
79322743|NCT04741646|Drug|Placebo|Placebo to match Ferric Citrate tablets
79322744|NCT04736823|Drug|AK112|IV infusion
79322745|NCT04736823|Drug|Pemetrexed|IV infusion
79322746|NCT04736823|Drug|Paclitaxel|IV infusion
79322747|NCT04736823|Drug|Carboplatin|IV infusion
79322748|NCT04736823|Drug|Docetaxel|IV infusion
79646460|NCT04654741|Drug|Medroxyprogesterone Acetate|1 pill per day
79646461|NCT04654741|Drug|Ganirelix Acetate|1 injection per day
79322749|NCT04732676|Other|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
79322750|NCT04731571|Radiation|CBCT-guided Adaptive Radiotherapy|The aim is to deliver adaptive radiotherapy using a CBCT-based radiotherapy delivery system.
79322751|NCT04729946|Device|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
79322752|NCT04729621|Combination Product|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
79480306|NCT03231917|Procedure|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
79480307|NCT02979067|Procedure|Nasal oxygen flow|Nasal oxygen flow during apnoea
79480308|NCT05716256|Drug|Ulinastatin|The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
79646462|NCT04654195|Genetic|polymorphism analysis|DNA will be purified from whole blood samples by commercial DNA isolation kits. Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR.
79322753|NCT04729621|Combination Product|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
79976644|NCT02470078|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
79976645|NCT02470156|Behavioral|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
79976646|NCT02470156|Behavioral|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
79976647|NCT05251350|Procedure|surgery|our study is observational and we use secondary data
79322754|NCT04726514|Device|SleepFlex|SleepFlex Program
79322755|NCT04707885|Device|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at ~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
79480309|NCT05716256|Procedure|TOF monitoring|The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
79646463|NCT04654195|Drug|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
79646464|NCT00200616|Procedure|Antimicrobial prophylaxis|
79646465|NCT04654156|Diagnostic Test|Contrast Boost post processing technique|Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
79809475|NCT02608749|Behavioral|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
79322756|NCT04695028|Other|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
79322757|NCT04694534|Diagnostic Test|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
79809476|NCT02608749|Behavioral|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
79322758|NCT04694534|Diagnostic Test|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
79322759|NCT04684836|Other|Exposure to telemedicine, after the onset of the pandemic|Telemedicine exposure will be defined based on the proportion of all visits at a given clinic that are delivered via telemedicine in each month.
79322760|NCT04684121|Drug|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
79809477|NCT02608749|Behavioral|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
79809478|NCT00675311|Behavioral|DM-Standard|Device/t+ Medical Diabetes Management System
79322761|NCT04684121|Drug|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
79646466|NCT04654078|Drug|IN-C004 with water|One time dose of IN-C004 taken with water
79646467|NCT04654078|Drug|IN-C004 without water|One time dose of IN-C004 taken without water
79322762|NCT04672369|Biological|IBI939|IBI939 injection
79322763|NCT04672369|Biological|Sintilimab|Sintilimab injection
79646468|NCT04654078|Drug|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
79646469|NCT00177983|Behavioral|(relapse rate)|
79646470|NCT04654000|Procedure|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
79809479|NCT00675311|Behavioral|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
79809480|NCT00882557|Drug|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
79809481|NCT00882557|Drug|daptomycin|6 mg/kg administered after a hemodialysis session
79809482|NCT02627573|Procedure|Unrelated allogeneic stem cell transplantation|
79322764|NCT04672356|Biological|IBI939|IBI939 injection
79809483|NCT02627573|Drug|Busulfan|
79809484|NCT02627573|Drug|Fludarabine monophosphate|
79809485|NCT02627573|Drug|Tacrolimus|
79322765|NCT04672356|Biological|Sintilimab|Sintilimab injection
79322766|NCT04668170|Biological|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
79322767|NCT04668170|Biological|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
79809486|NCT02627573|Drug|Mycophenolate mofetil|
79322768|NCT04665869|Behavioral|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
79322769|NCT04665869|Behavioral|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
79646471|NCT04654000|Procedure|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
79646472|NCT00205569|Behavioral|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
79646473|NCT03454789|Drug|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
79646474|NCT03454789|Drug|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
79809487|NCT02627573|Drug|Cyclophosphamide|
79809488|NCT02627573|Drug|Thymoglobulin|
79809489|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 100 μg/mL
79809490|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 200 μg/mL
79809491|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 300 μg/mL
79809492|NCT00656825|Drug|Placebo|Placebo will be randomly given to 4 subjects in each panel
79809493|NCT00675389|Behavioral|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for ~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
79976648|NCT03309748|Procedure|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
79976649|NCT03309748|Device|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
79322770|NCT04664023|Procedure|Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
79480310|NCT03667365|Procedure|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
79976650|NCT03309670|Other|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
79976651|NCT01316016|Dietary Supplement|Rose hip|40 g of rose hip powder daily for 6 weeks.
79480311|NCT03667365|Other|strict clinical surveillance|strict clinical surveillance strategy
79646475|NCT03454789|Drug|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
79646476|NCT03454789|Drug|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
79976652|NCT03152682|Dietary Supplement|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
79976653|NCT03152682|Other|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
79322771|NCT04664023|Procedure|Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
79322772|NCT04642781|Diagnostic Test|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
79322773|NCT04635995|Biological|LVGN7409|IV infusion once every 3 weeks (Q3W).
79976654|NCT03169998|Device|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
79976655|NCT01341132|Procedure|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
79322774|NCT04633889|Drug|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
79322775|NCT04633889|Drug|Normal saline|Normal saline (240mL) intravenous infusion over 12 hours
79322776|NCT04630886|Drug|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
79976656|NCT00705250|Drug|bendamustine hcl|Patients will receive bendamustine 120mg/m^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is > 1000/ul and the platelet count is > 75,000/ul.
79976657|NCT03309592|Drug|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
79322777|NCT04630886|Drug|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
79322778|NCT04626349|Other|FOCUS+ (face-to-face nurse-led intervention)|"Home-based psycho-educational intervention consisting of two 90-minute home visits and one 30-minute video-conferencing session, conducted by a trained intervention nurse over a period of 12 weeks (4 weeks between each session).~The intervention is comprehensively manualized and there is a protocol to guide delivery of the intervention for each home visit and video call. The content of the sessions is always tailored to the needs of the dyads, so certain topics can be discussed more in-depth and specific information can be shared. The nurses who will deliver the FOCUS+ intervention will receive an extensive online training and additional continuous follow-up training to provide them with the knowledge and skills required to successfully implement the intervention. A FOCUS+ core booklet is provided as a supporting guide for the dyads that they can refer to at their own discretion and reinforces key intervention messages linked to the core components of the intervention."
79322779|NCT04626349|Other|iFOCUS (web-based intervention)|"Self-managed psycho-educational intervention that is completed autonomously by the patient-caregiver dyads together. It encompasses four sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and the family caregiver, sitting side by side at a computer. Patient-caregiver dyads have flexibility as to when they want to complete the intervention session. Based on the information patients and caregivers provided at enrollment and during the web-based sessions, they receive tailored individual and dyadic messages. An online personal workbook is provided containing the results of the interactive exercises that are provided to the dyads during the web-sessions. Any information brochures, leaflets and information sheets that the dyad indicated as 'of interest to them' during the web-sessions will be included as a hyperlink in their personal workbook."
79322780|NCT04619316|Drug|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
79480312|NCT03362957|Device|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
79976658|NCT03309592|Drug|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
79322781|NCT04619316|Drug|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
79480313|NCT03362957|Diagnostic Test|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
79480314|NCT00356083|Drug|Methadone|
79976659|NCT04641312|Drug|LY3457263|Administered SC
79976660|NCT04641312|Drug|Dulaglutide|Administered SC
79976661|NCT04641312|Drug|Placebo|Administered SC
79976662|NCT04640220|Procedure|Intra-articular steroid injection|Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
79976663|NCT06209762|Other|Exercise|The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
79322782|NCT04618484|Other|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
79480315|NCT02977832|Dietary Supplement|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
79480316|NCT02977832|Drug|Alfuzosin|10Mg Oral Tablet, Extended Release
79480317|NCT04344236|Drug|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
79480318|NCT04344236|Drug|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
79646477|NCT04653727|Other|Cross-sectional survey|No intervention.
79976664|NCT06209749|Other|Sensory-based intervention module|Consists of sensory-based activities (Set A-F) with six weeks of individual sessions and six weeks of group sessions
79976665|NCT06209736|Drug|OMS906 study drug|OMS906 study drug dose 5mg/kg IV administration at 4-week internals
79976666|NCT06209723|Other|Vegetarian diet|Participants will follow a vegetarian diet during a period of five weeks
79809494|NCT00675389|Behavioral|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
79809495|NCT00675467|Behavioral|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
79322783|NCT04618211|Drug|Deucrictibant|deucrictibant soft capsules for oral use
79322784|NCT04618211|Drug|Placebo|Matching placebo capsules for oral use
79646478|NCT00178022|Behavioral|Case management and problem solving therapy|
79322785|NCT04610528|Drug|U3 1402|6.4 mg/kg dose
79322786|NCT04610528|Drug|U3 1402|5.6 mg/kg dose
79322787|NCT04609111|Drug|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
79322788|NCT04609111|Drug|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
79322789|NCT04599062|Drug|Talimogene Laherparepvec|Talimogene Laherparepvec
79322790|NCT04599062|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
79322791|NCT04597359|Drug|Placebo Administration|Given PO
79322792|NCT04597359|Other|Quality-of-Life Assessment|Ancillary studies
79322793|NCT04597359|Other|Questionnaire Administration|Ancillary studies
79322794|NCT04597359|Drug|Sinecatechins|Given PO
79322795|NCT04590196|Drug|Longvida curcumin|longvida curcumin verdure sciences formulation
79322796|NCT04590196|Other|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
79322797|NCT04589208|Drug|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
79322798|NCT04582864|Drug|Flotetuzumab|Will be provided by MacroGenics Inc.
79322799|NCT04582864|Procedure|Donor lymphocyte infusion|DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
79322800|NCT04580524|Procedure|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
79646479|NCT04653532|Behavioral|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
79646480|NCT04653532|Device|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
79646481|NCT00200655|Drug|Pravastatin|
79646482|NCT00200655|Drug|Placebo|
79322801|NCT04580524|Procedure|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
79809496|NCT00675467|Behavioral|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
79809497|NCT00679445|Device|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
79480319|NCT04344236|Drug|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
79646483|NCT04653649|Biological|HSP-CAR30|Anti-CD30 CAR T-cells
79646484|NCT00178061|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
79976667|NCT06209710|Procedure|Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation|Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.
79322802|NCT04566328|Drug|Bortezomib|Given SC
79322803|NCT04566328|Biological|Daratumumab and Hyaluronidase-fihj|Given SC
79322804|NCT04566328|Drug|Dexamethasone|Given PO
79322805|NCT04566328|Drug|Lenalidomide|Given PO
79322806|NCT04566328|Other|Quality-of-Life Assessment|Ancillary studies
79322807|NCT04565795|Device|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
79322808|NCT04563013|Device|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
79809498|NCT00675545|Drug|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
79322809|NCT04559724|Device|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
79322810|NCT04559139|Drug|Cisplatin|Given IV
79322811|NCT04559139|Drug|Gemcitabine Hydrochloride|Given IV
79809499|NCT00679523|Drug|AN2690 Solution, 5.0%|Once daily application for 180 days
79809500|NCT00679523|Drug|AN2690 Solution, 7.5%|Once daily application for 180 days
79809501|NCT00675701|Drug|placebo|capsules
79809502|NCT00675701|Drug|lixivaptan|capsules
79809503|NCT00675701|Drug|moxifloxacin|tablets
79646485|NCT04653493|Biological|CD19 CAR engineered autologous T-cells|"Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities."
79322812|NCT04559139|Procedure|Lymphadenectomy|Undergo portal lymphadenectomy
79646486|NCT04653493|Drug|Cyclophosphamide|Given IV
79322813|NCT04559139|Procedure|Partial Hepatectomy|Undergo partial hepatectomy
79322814|NCT04551222|Drug|probenecid|1 gr. orally of probenecid twice daily for 180 days
79322815|NCT04551222|Drug|Placebo|identical tablets to probenecid
79646487|NCT04653493|Drug|Fludarabine|Given IV
79646488|NCT04653493|Drug|Mesna|Given IV
79646489|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day,|
79646490|NCT00200694|Drug|ramipril 10 mg + valsartan 160 mg/day,|
79646491|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
79646492|NCT00557713|Drug|bevacizumab|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
79809504|NCT00808899|Drug|Temsirolimus|Temsirolimus
79809505|NCT00808899|Drug|Irinotecan|Irinotecan
79976668|NCT06209710|Procedure|Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation|Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
79976669|NCT06209697|Dietary Supplement|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
79976670|NCT06209684|Procedure|Titanium|Spinal stabilization using titanium screws and rods
79322816|NCT04541056|Behavioral|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
79322817|NCT04541056|Behavioral|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
79322818|NCT04537208|Biological|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
79322819|NCT04537208|Biological|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
79646493|NCT00557752|Device|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
79322820|NCT04537208|Biological|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
79976671|NCT06209684|Procedure|Carbofix|Spinal stabilization using CarboFix screws and rods
79976672|NCT06209671|Biological|INS19 CAR-T Cells|INS19 CAR-T Cells, 1-2×10^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m^2/day (D-5~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m^2/day (D-5~D-3), determined by tumor burden at baseline.
79976673|NCT06209658|Diagnostic Test|breastfeeding education of Teach Back|breastfeeding education simple explanation is given and the woman is asked to explain and practice.
79976674|NCT06209658|Other|breastfeeding education simple explanation|breastfeeding education simple explanation
79322821|NCT04537208|Biological|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
79322822|NCT04537208|Biological|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
79322823|NCT04537208|Biological|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
79322824|NCT04527549|Drug|Dabrafenib Mesylate|Given PO
79322825|NCT04527549|Drug|Hydroxychloroquine Sulfate|Given PO
79322826|NCT04527549|Drug|Placebo Administration|Given PO
79322827|NCT04527549|Drug|Trametinib Dimethyl Sulfoxide|Given PO
79646494|NCT00178100|Behavioral|Interpersonal Psychotherapy|
79322828|NCT04522414|Other|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
79322829|NCT04514783|Device|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~Removal of old dressing~Woundworks® 3D imaging~Applying analgesic if necessary~Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~Debridement using Debritom+ micro water jet technology~Wound cleansing with NaCl 0.9% solution~Woundworks® 3D imaging~Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~Removal of old dressing~Woundworks® 3D imaging~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
79322830|NCT04514783|Other|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~Removal of old dressing~Woundworks® 3D imaging~Applying analgesic if necessary~Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~Debridement using scalpel and curette~Wound cleansing with NaCl 0.9% solution~Woundworks® 3D imaging~Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~Removal of old dressing~Woundworks® 3D imaging~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
79976675|NCT06209645|Device|tDCS (Transcranial Direct Current Stimulation)|The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
79976676|NCT06209645|Device|tACS (Transcranial Alternating Current Stimulation)|The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
79976677|NCT06209593|Dietary Supplement|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
79976678|NCT06209580|Drug|AMT-253 for injection|Administered intravenously
79646495|NCT00178100|Drug|paroxetine|
79322831|NCT04512950|Drug|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
79322832|NCT04512950|Drug|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
79976679|NCT06209567|Diagnostic Test|68Ga-PSMA-11 PET Scans|Participants will be injected intravenously with 68Ga-PSMA-11 via intravenous catheter. PET scans will first be interpreted without information on the results of other imaging modalities. Following the blinded read of the 68Ga-PSMA-11 PET scans, all recorded findings will be correlated with the results of CE CT and MR studies and 18F-FDG PET/CT or PET/MR performed as part of standard clinical care.
79976680|NCT06209489|Other|White cover|"A white cover will be covered over the incubator during phototherapy.~Baby massage will be applied during phototherapy."
79646496|NCT04653415|Drug|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
79646497|NCT04653415|Drug|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
79646498|NCT04653415|Drug|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
79646499|NCT04653415|Drug|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
79646500|NCT00205608|Device|Positron Emission Tomography|camera is new
79809506|NCT00808899|Procedure|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
79976681|NCT06209450|Procedure|Ventral hernia repair with mesh fixation|Sutured versus suturless mesh fixation
79976682|NCT06209424|Behavioral|Habitual Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).
79809507|NCT00808899|Drug|Cyclophosphamide|Cyclophosphamide
79809508|NCT00808899|Drug|Doxorubicin|Doxorubicin
79809509|NCT00808899|Drug|Etoposide|Etoposide
79809510|NCT00808899|Drug|Cisplatin|Cisplatin
79809511|NCT00808899|Drug|Topotecan|Topotecan
79809512|NCT00808899|Procedure|PBSC|Peripheral Blood Stem Cell Harvest
79809513|NCT00808899|Radiation|Radiation Therapy|Radiation Therapy
79976683|NCT06209424|Behavioral|Step-Reduction|Participants will be required to reduce their daily step-counts to <2,000 steps/day. Further, they will be required to refrain from structured physical activity.
79976684|NCT06209424|Behavioral|Resistance Exercise|Participants will undergo a 50-minute resistance exercise protocol, which includes multiple sets of different exercises using weights. Each set will consist of 10 repetitions at 75% of their 1 repetition maximum (1RM). The exercises include bench press superset with lat pulldowns, overhead press superset with seated cable rows, leg press, and leg extensions with 90s rest in between sets. Before the exercise protocol, there will be a standardized 10-minute warm-up that involves cycling, leg swings, arm circles, bodyweight squats, and bench push-ups
79976685|NCT06209411|Behavioral|Home Based Testing|Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
79976686|NCT06209411|Behavioral|Clinic Based Screening|Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
79322833|NCT04512430|Drug|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~No premedication administered for atezolizumab specifically is permitted~Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles > 2 at the discretion of the treating physician.~If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
79322834|NCT04512430|Drug|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
79809514|NCT00808899|Drug|13-cis-retinoic acid|13-cis-retinoic acid
79322835|NCT04512430|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
79322836|NCT04512430|Drug|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo[2,3 d]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
79322837|NCT04605458|Combination Product|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
79322838|NCT04605458|Combination Product|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and CO breath test monitoring.
79809515|NCT00808665|Drug|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
79322839|NCT04502433|Drug|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
79322840|NCT04499339|Drug|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
79322841|NCT04495348|Drug|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
79322842|NCT04485468|Other|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
79322843|NCT04484818|Drug|Darolutamide|Given PO
79322844|NCT04484818|Drug|Goserelin Acetate|Given via injection
79809516|NCT00808665|Drug|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
79809517|NCT04586517|Other|Heavy-load resistance training|Supervised heavy-load resistance training during chemotherapy treatment
79480320|NCT01543659|Drug|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
79809518|NCT04586517|Other|Control|Activity as usual during chemotherapy
79322845|NCT04484818|Drug|Leuprolide Acetate|Given IV
79322846|NCT04484818|Drug|Placebo Administration|Given PO
79322847|NCT04484818|Other|Quality-of-Life Assessment|Ancillary studies
79322848|NCT04484818|Drug|Triptorelin|Given via injection
79322849|NCT04484012|Drug|Acalabrutinib|Given PO
79322850|NCT04484012|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
79480321|NCT00383409|Drug|multivitamins|
79322851|NCT04478370|Biological|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
79322852|NCT04478227|Drug|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
79322853|NCT04477200|Drug|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
79322854|NCT04477200|Radiation|Radiation Therapy|40.5 Gy in 15 fractions
79322855|NCT04477200|Procedure|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
79809519|NCT04576533|Behavioral|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
79809520|NCT00808509|Biological|adalimumab|40 mg every other week via subcutaneous injection
79809521|NCT00808509|Drug|methotrexate|At least 10 mg/week administered orally or subcutaneously
79322856|NCT04477200|Drug|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
79322857|NCT04477200|Drug|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
79322858|NCT04477200|Drug|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
79322859|NCT04477200|Radiation|Radiation Therapy|60 Gy in 30 fractions
79322860|NCT04455802|Drug|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
79322861|NCT04455802|Drug|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
79322862|NCT04446052|Drug|GM-CSF priming|
79322863|NCT04446052|Drug|Placebo|Placebo
79322864|NCT04443088|Drug|INV-1120|INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
79322865|NCT04443088|Combination Product|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
79322866|NCT04428658|Behavioral|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
79322867|NCT04428658|Behavioral|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
79322868|NCT04428658|Behavioral|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
79322869|NCT04426890|Biological|CT-P39|Prefilled syringe (PFS) of 1 mL solution
79480322|NCT00383409|Drug|placebo|
79809522|NCT05754723|Behavioral|e-Psychotherapy/Psychoeducation|Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
79809523|NCT05754645|Other|Blood withdrawal|venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
79322870|NCT04426890|Biological|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
79322871|NCT04422132|Radiation|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
79322872|NCT04422132|Radiation|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
79322873|NCT04411914|Drug|Clavulanic Acid|Drug will be given in 250mg capsules.
79809524|NCT02608827|Device|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
79322874|NCT04411914|Other|Placebo|Placebo
79322875|NCT04411836|Drug|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
79322876|NCT04411836|Drug|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
79322877|NCT04392635|Device|Trocar Placement Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle and trocar during laparoscopic surgery.
79322878|NCT04389671|Drug|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
79322879|NCT04388748|Behavioral|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
79322880|NCT04383457|Device|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
79322881|NCT04381494|Device|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
79322882|NCT04364048|Drug|Induction Durvalumab|Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
79322883|NCT04364048|Drug|Chemotherapy|Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
79322884|NCT04364048|Radiation|Radiation|Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
79809525|NCT02608827|Other|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
79809526|NCT04440657|Behavioral|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
79809527|NCT02608593|Procedure|Strattice|Implant based reconstruction with strattice cover of part or all of implant
79322885|NCT04364048|Drug|Consolidation durvalumab|Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
79322886|NCT04355819|Behavioral|Disclosure timing|When patients are told that a hernia was present on the CT scan
79322887|NCT04350359|Device|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
79322888|NCT04350359|Device|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
79322889|NCT04350359|Device|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
79480323|NCT00355537|Drug|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
79322890|NCT04315064|Drug|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
79322891|NCT04311580|Combination Product|intravesical electromotive administration of mitomycin|
79322892|NCT04303182|Procedure|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
79322893|NCT04303182|Procedure|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
79322894|NCT04301492|Drug|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
79322895|NCT04300816|Behavioral|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
79480324|NCT00355537|Drug|0.9% saline|Saline injection intramuscular every 2 weeks
79480325|NCT00003207|Drug|pegylated liposomal doxorubicin hydrochloride|
79480326|NCT00003207|Drug|PSC 833|
79480327|NCT02978144|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
79480328|NCT02978144|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
79480329|NCT00003387|Drug|carboplatin|
79480330|NCT00003387|Drug|chemotherapy|
79646501|NCT04653259|Other|LYFE MD app|"LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives."
79646502|NCT00557791|Drug|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
79480331|NCT00003387|Drug|paclitaxel|
79480332|NCT00003387|Radiation|radiation therapy|
79646503|NCT00557791|Drug|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
79646504|NCT00178139|Behavioral|Music Therapy|Music Therapy
79646505|NCT04653298|Other|Evaluation of quality of life, comorbidities and return to work status|Quality of life will be evaluated thanks to several methods: Short Form 36, EQ 5D 5L and return to work status Questionnaires will be evaluated through postal and phone call at least 12 months after ECMO.
79646506|NCT04653376|Procedure|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
79646507|NCT00178217|Behavioral|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
79646508|NCT04653025|Device|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
79646509|NCT04653103|Procedure|Liver biopsy|Biopsy of the liver to assess for Non-alcoholic steatohepatitis
79322896|NCT04300816|Behavioral|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
79646510|NCT04652947|Diagnostic Test|MRI diagnostic|no intervention, patient only have MRI
79646511|NCT00205647|Drug|Oral N-acetycystein (NAC)|
79646512|NCT04652635|Procedure|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
79646513|NCT04652284|Drug|Rifabutin|150 mg
79646514|NCT04652284|Drug|Amoxicillin|1000 mg
79646515|NCT04652284|Drug|Esomeprazole|40 mg
79646516|NCT04652284|Drug|Clarithromycin|500 mg
79646517|NCT04652284|Drug|Tinidazole|500 mg
79976687|NCT06209398|Biological|Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )|Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
79976688|NCT06209398|Biological|Recombinant Hepatitis B Vaccine|Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
79646518|NCT04652323|Drug|Biocompatibility of calcium silicate cements|The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
79646519|NCT04652011|Procedure|Minimally Invasive Gynecologic Surgery|Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
79646520|NCT04652011|Procedure|osteopathic manipulative treatment|Osteopathic manipulative treatment
79646521|NCT04652011|Drug|Pain killer|Common pain killer (paracetamol, Ibuprofen, ketoprofen)
79646522|NCT00178295|Radiation|Radiation Therapy|standard of care for the cancer being treated
79646523|NCT00205686|Drug|DHEA|
79646524|NCT00205686|Behavioral|exercise|
79646525|NCT04651933|Genetic|Homologous recombination deficiency model|A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
79480333|NCT03430349|Biological|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
79646526|NCT04652128|Drug|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
79646527|NCT04652128|Drug|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
79646528|NCT04651894|Device|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
79646529|NCT00205725|Drug|Ziprasidone, Olanzapine|
79646530|NCT04651738|Diagnostic Test|DNA methylation testing|Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
79976689|NCT06209398|Biological|Group A meningococcal polysaccharide vaccine|This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
79809528|NCT02627651|Other|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
79322897|NCT04297787|Device|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
79322898|NCT04295473|Procedure|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
79322899|NCT04290039|Drug|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
79809529|NCT05326113|Other|Physiotherapy|After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
79322900|NCT04290039|Drug|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
79322901|NCT04282850|Procedure|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
79322902|NCT04278339|Other|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
79480334|NCT03430349|Biological|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
79480335|NCT02977988|Behavioral|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
79976690|NCT06209385|Drug|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally QD for 21 days
79976691|NCT06209372|Procedure|Group PENG|Pericapsular Nerve Group Block (PENG)
79322903|NCT04267211|Other|Illustrated handout at prenatal consult|Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
79809530|NCT05326113|Drug|Control group|All patients will be treated with standard course of PPIs after POEM without physiotherapy.
79322904|NCT04267211|Other|Standard Prenatal Consult|Standard prenatal consult
79813819|NCT02604030|Other|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
79976692|NCT06209372|Drug|Group C|Tramadol infusion
79976693|NCT06209359|Drug|Ammonium Chloride|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
79976694|NCT06209359|Drug|Placebo|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
79976695|NCT06209346|Other|TeleRehab Group|"The duration of treatment for the Experimental Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the ET program and respiratory control practices.All the sessions mentioned above will be in online format, through the TRAK platform."
79976696|NCT06209346|Other|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. Participants in the Control Group will have the same follow-up evaluations as the Experimental Group and will receive informative material. They will not have access to the audiovisual material generated for the Experimental Group.
79976697|NCT06209333|Other|Standard Patient Education|Standard Patient Education will take approximately 20 minutes. Within the scope of standard patient education, some recommendations will be made to the patient to lose weight, drink sufficient water, avoid consuming caffeinated foods and beverages, acidic/carbonated or alcoholic beverages, spicy/acidic foods, and quit smoking. Patients will be evaluated on the day they receive standard patient training (before receiving this training) and 10 weeks after the training.
79322905|NCT04266249|Drug|Docetaxel|Given IV
79322906|NCT04266249|Procedure|Lumpectomy|Undergo lumpectomy
79976698|NCT06209333|Other|bladder training|Interval urination in bladder training in bladder training will be determined according to the bladder diaries filled in by the patients. If the patient is able to do it, bladder education will be improved by increasing the interval urination in bladder training. A total of 5 sessions of bladder training will be applied to patients, the first session of which will be face-to-face. Within the scope of Bladder Training, the patient will be given information about bladder, pelvic floor, incontinence and relaxation techniques. The patient will be asked to fill out a 3-day bladder diary before starting bladder training, and an appropriate progressive timed voiding program will be drawn according to the bladder diaries, and the patient will be given a training brochure to implement this program.
79480336|NCT02977988|Behavioral|Brain and Recovery (B&R)|B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
79480337|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
79480338|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
79480339|NCT01542021|Drug|androgen deprivation therapy|
79480340|NCT04706897|Drug|Dexmedetomidine, ketamine and lidocaine|A loading infusion of syringe (B) containing the a mixture [dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
79480341|NCT04706897|Drug|Normal saline|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
79480342|NCT00003213|Drug|dexamethasone|4 mg Dexamethasone in the morning
79480343|NCT00003213|Drug|granisetron hydrochloride|1 mg Granisetron in the morning
79480344|NCT00003213|Drug|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
79480345|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
79480346|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
79480347|NCT05716022|Diagnostic Test|Blood Collection|Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.
79480348|NCT05716022|Diagnostic Test|Bronchoscopy|Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.
79646531|NCT04651426|Device|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
79646532|NCT00178373|Drug|Modafinil|
79646533|NCT00178373|Drug|sugar pill|
79646534|NCT00200928|Biological|BCG|
79322907|NCT04266249|Procedure|Mastectomy|Undergo mastectomy
79322908|NCT04266249|Drug|Nab-paclitaxel|Given IV
79322909|NCT04266249|Drug|Paclitaxel|Given IV
79322910|NCT04266249|Biological|Pertuzumab|Given IV
79480349|NCT03847675|Behavioral|Reach out and Read|"The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger."
79480350|NCT02978066|Other|Spinal anaesthesia|
79480351|NCT00003399|Drug|carmustine|
79646535|NCT04651777|Drug|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
79809531|NCT04305951|Procedure|Comprehensive acupuncture therapy (CAT) (Hwato®/ Dongbang®)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 15 body acupoints with only manual stimulation will be used: Shen-Men (HT7), He-Gu (LI4), Wai-Guan (TE5), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6) in two sides, and Zhong-Wan (CV12), Guan-Yuan (CV4), and Shui-Gou (GV26) in midline. Electrical stimulation will be conducted on six pairs of frontal acupoints located on the frontal, parietal, and temporal scalp areas.~Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 min."
79809532|NCT04305951|Procedure|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 min to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
79809533|NCT00807885|Drug|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
79809534|NCT00807573|Drug|Paclitaxel|Day 1: Paclitaxel (90 mg/m^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m^2 over 60 minutes)
79809535|NCT00807573|Drug|Pemetrexed|Day 1: Pemetrexed (500 mg/m^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
79809536|NCT00807573|Drug|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
79809537|NCT00842712|Drug|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
79809538|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
79809539|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) as intravenous infusion over 2 hours on Day 1.
79809540|NCT00842712|Drug|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m^2 as intravenous infusion on Day 1.
79480352|NCT00003399|Drug|cisplatin|
79480353|NCT00003399|Drug|cyclophosphamide|
79480354|NCT00003399|Drug|dexamethasone|
79480355|NCT00003399|Drug|etoposide|
79322911|NCT04266249|Radiation|Radiation Therapy|Undergo radiation therapy
79322912|NCT04266249|Biological|Trastuzumab|Given IV
79322913|NCT04266249|Biological|Trastuzumab Emtansine|Given IV
79322914|NCT04260126|Combination Product|Pembrolizumab and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
79322915|NCT04247997|Procedure|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
79480356|NCT00003399|Drug|melphalan|
79480357|NCT00003399|Drug|paclitaxel|
79480358|NCT00003399|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79480359|NCT03376061|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
79480360|NCT02978989|Procedure|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
79480361|NCT02978989|Procedure|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
79322916|NCT04246463|Device|Thoracic|Implant of a Relay stent graft system
79322917|NCT04246463|Device|Abdominal|Implant with an Anaconda or Treo Stent graft system
79322918|NCT04246463|Device|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
79322919|NCT04246463|Device|Illiac Artery|Implant with an Anaconda Iliac leg only
79480362|NCT02977910|Procedure|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
79646536|NCT04651231|Procedure|releasable sutures in punch trabeculectomy|punch trabeculectomy,scleral flap suturing
79646537|NCT04650958|Procedure|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
79976699|NCT06209333|Other|pelvic floor exercise|This training will take between 45 and 60 minutes.Within the scope of exercise training, patients will be taught 3 types of contractions: maximal (fast), slow and submaximal contractions. The patient will be asked to continue the maximum and submaximal contraction for 1-2 seconds, and to continue the Deceleration contraction for 3-10 seconds. These contractions will be performed in different positions such as supine, lying on the side, sitting, crawling, squatting and standing, specifically for the pelvic floor November muscle strength of the patient. These exercises will be performed every day and each type of contraction (maximal, slow and submaximal contraction) will be performed 8-12 repetitions, 3 sets per day. Progress will be achieved with follow-ups.
79976700|NCT06209320|Drug|Lower dose atropine sulfate eye drops|administer to eyes
79976701|NCT06209320|Drug|Low dose atropine sulfate eye drops|administer to eyes
79809541|NCT00842712|Drug|Cisplatin|Cis will be administered at a dose of 80 mg/m^2 as intravenous infusion on Day 1.
79322920|NCT04246333|Other|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
79322921|NCT04241757|Diagnostic Test|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
79322922|NCT04239573|Procedure|Computed Tomography|Undergo CT
79322923|NCT04239573|Procedure|Endoscopic Ultrasound|Undergo EUS
79809542|NCT00842712|Drug|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m^2 as intravenous infusion on Days 1 and 8.
79809543|NCT00842712|Drug|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m^2 as intravenous infusion on Days 1 and 8.
79809544|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
79809545|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
79976702|NCT06209320|Drug|placebo|administer to eyes
79976703|NCT06209294|Drug|AK104|AK104(10 mg/kg) d1,22
79976704|NCT06209294|Drug|Carboplatin|AUC=2 d1,8,15,22, 29, 36
79976705|NCT06209294|Drug|Nab paclitaxel|125mg／m2 d1,8,15,22,29,36
79322924|NCT04239573|Procedure|Magnetic Resonance Imaging|Undergo MRI
79322925|NCT04239573|Other|Quality-of-Life Assessment|Ancillary studies
79322926|NCT04239573|Other|Questionnaire Administration|Ancillary studies
79322927|NCT04233112|Drug|Melatonin 5 mg|Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
79322928|NCT04233112|Device|Osteogenic loading|Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
79322929|NCT04233112|Device|Mock for Osteogenic Loading|Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
79322930|NCT04233112|Drug|Placebo (plant fiber) for melatonin|Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
79480363|NCT04656223|Combination Product|MF/IND/GLY plus sensor system|"There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label."
79976706|NCT06209281|Drug|Lower dose atropine sulfate eye drops|Administer to eyes
79322931|NCT04226755|Dietary Supplement|Sodium chloride|1 gram tid (with every meal)
79809546|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
79813820|NCT02603874|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
79976707|NCT06209281|Drug|Low dose atropine sulfate eye drops|Administer to eyes
79322932|NCT04223596|Drug|Brigatinib|Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
79322933|NCT04222387|Device|OCT-B scan|OCT-B scan (Optical coherence tomography)
79322934|NCT04217954|Drug|OXA, 5-FU and bevacizumab plus Toripalimab|"concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~The concomitant treatment repeat every three week, up to 6 cycles.~Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
79322935|NCT04210427|Drug|Polyethylene Glycol 3350|All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
79976708|NCT06209281|Drug|placebo|Administer to eyes
79976709|NCT06209268|Drug|Paricalcitol injection|5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
79322936|NCT04210427|Device|SmartPill Motility System & PillCam Patency Capsule|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
79809547|NCT00842712|Drug|Chemotherapy|Cis 80 mg/m^2 intravenous infusion on Day 1 + Vin 25 mg/m^2 or Cis 75 mg/m^2 intravenous infusion on Day 1 + Gem 1250 mg/m^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
79809548|NCT00705120|Other|Bone Marrow Cell Transplantation|
79809549|NCT00705120|Radiation|Irradiation, Total Body|
79976710|NCT06209268|Drug|Placebo|0.9% NaCl 1 ml per day in five consecutive days
79322937|NCT04201574|Drug|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
79322938|NCT04201574|Drug|ALY688 0.4%|ALY688 0.4% Ophthalmic Solution
79322939|NCT04201574|Drug|Vehicle|Vehicle Ophthalmic Solution
79480364|NCT04656223|Drug|FDC therapy|There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
79480365|NCT05715944|Drug|AZD 1222|Vaccine
79480366|NCT03376295|Drug|LABA and the LAMA tiotropium (LABA-TIO)|combinational drug
79480367|NCT03376295|Drug|LABA and an ICS (LABA-ICS)|combinational drug
79809550|NCT00705120|Drug|Cyclophosphamide|
79976711|NCT06209255|Procedure|Pelvic Osteotomy - Ganz Procedure|Ischial osteotomy was performed on the pubic arch; this was followed by iliac osteotomy, performed using Schanz screws in the iliac wing. The osteotomized acetabulum was overturned, and inclination was reduced.
79322940|NCT04194034|Biological|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
79322941|NCT04194034|Drug|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
79809551|NCT00705120|Drug|Cyclosporin|
79976712|NCT06209242|Procedure|Percutaneous pinning|Using k- wire percutaneous pinning with local anesthesia with one-day surgery protocol
79976713|NCT06209242|Procedure|Cast immobilization|Using sugar tong slab and then replace to short arm casting within 1 week
79809552|NCT00705120|Procedure|Mesenchymal Stem Cell Transplantation|
79809553|NCT00705120|Drug|Busulfan|
79809554|NCT00708474|Device|OsseoFit™ Porous Tissue Matrix™|Bone void filler
79322942|NCT04356170|Drug|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
79809555|NCT00842244|Drug|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
79322943|NCT04356170|Drug|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
79322944|NCT04356170|Drug|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
79322945|NCT04176133|Drug|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
79322946|NCT04176133|Drug|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
79322947|NCT04176133|Drug|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
79322948|NCT04175418|Other|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
79322949|NCT04175418|Other|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
79322950|NCT04171908|Other|Conventional therapy|Conventional Physical therapy for the upper limb
79322951|NCT04171908|Other|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
79976714|NCT06209229|Biological|sodium nucleinate|"Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
79976715|NCT06209203|Drug|lowe-dose ZKY001 eye drops|eye drops
79976716|NCT06209203|Drug|Medium-dose ZKY001 eye drops|eye drops
79322952|NCT04166318|Drug|Capecitabine|Given PO
79322953|NCT04166318|Drug|Fluorouracil|Given IV
79322954|NCT04166318|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79322955|NCT04166318|Drug|Mitomycin|Given IV
79322956|NCT04166318|Other|Quality-of-Life Assessment|Ancillary studies
79322957|NCT04166318|Other|Questionnaire Administration|Ancillary studies
79322958|NCT04165213|Behavioral|COPE online training|"The intervention being tested is PACE staff training in COPE - accomplished with the creation of self-paced online learning modules.~The modules will include rich multimedia content and interactive assessments to keep the learner engaged and will allow for easy packaging of the content into the latest interoperability standards for such content including the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions and will be designed using a hyperlearning model with four dimensions. The self-paced modules will be highly interactive featuring integrated multimedia content, assessments, and learner evaluations to allow PACE staff to engage with the content at a high level and practice application in simulated scenarios. Each module will require approximately 45-60 minutes/module for the learner to complete.le for the learner to complete."
79322959|NCT04158921|Other|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. > 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
79646538|NCT00178412|Behavioral|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
79646539|NCT00178412|Behavioral|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
79976717|NCT06209203|Drug|placebo|eye drops
79809556|NCT00842244|Drug|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
79809557|NCT00842244|Drug|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m^2 on day 1.
79976718|NCT06209190|Radiation|total marrow and total lymphoid irradiation|doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system plus conditioning scheme of our institution
79976719|NCT06209177|Drug|ARO-CFB|ARO-CFB for sc injection
79976720|NCT06209177|Drug|Placebo|sterile normal saline (0.9% NaCl for sc injection)
79646540|NCT04651309|Other|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
79646541|NCT00205764|Drug|Melphalan|
79322960|NCT04152330|Other|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
79322961|NCT04150614|Drug|Granisetron Transdermal Patch|Antiemetic
79322962|NCT04150614|Drug|Intravenous Dexamethasone|Antiemetic
79322963|NCT04150614|Drug|Ondansetron|ondansetron
79480368|NCT03381989|Device|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
79480369|NCT05310019|Other|Physiotherapy and Electroacupuncture|TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
79809558|NCT00832416|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
79809559|NCT00832416|Drug|Placebo|One Placebo tablet daily.
79976721|NCT06209151|Other|monitor signs of infection|Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation & mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
79322964|NCT04138940|Behavioral|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
79976722|NCT06209138|Drug|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
79322965|NCT04131712|Other|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
79322966|NCT04126096|Diagnostic Test|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
79976723|NCT06209138|Other|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
79322967|NCT04125836|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
79322968|NCT04121455|Drug|Olaptesed pegol|Olaptesed pegol continuous administration for 26 weeks
79322969|NCT04121455|Radiation|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
79322970|NCT04121455|Drug|Bevacizumab|Bevacizumab every 2 weeks i.v. for 26 weeks
79322971|NCT04121455|Drug|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
79322972|NCT04117958|Drug|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
79322973|NCT04117672|Dietary Supplement|Salovum|Active egg yolk powder
79976724|NCT06209099|Procedure|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
79976725|NCT06209099|Procedure|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
79322974|NCT04117672|Dietary Supplement|Placebo egg yolk powder|Normal egg yolk powder
79322975|NCT04115631|Drug|Acalabrutinib|Given PO
79322976|NCT04115631|Drug|Bendamustine|Given IV
79322977|NCT04115631|Drug|Bendamustine Hydrochloride|Given IV
79322978|NCT04115631|Drug|Cytarabine|Given IV
79322979|NCT04115631|Biological|Rituximab|Given IV
79480370|NCT05310019|Other|Physiotherapy|The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
79646542|NCT00557908|Drug|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
79646543|NCT00557986|Procedure|Primary surgery|Primary breast surgery before systemic therapy
79809560|NCT00705198|Drug|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
79809561|NCT00705198|Drug|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
79809562|NCT00705198|Radiation|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
79809563|NCT00708630|Behavioral|Extended information on side effects|More detailed information on possible side effects of vaccine
79809564|NCT00702936|Drug|TELMISARTAN|80 mg daily
79809565|NCT00702936|Drug|RAMIPRIL|5 mg daily
79322980|NCT04112667|Other|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
79322981|NCT04112667|Other|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
79322982|NCT04112667|Other|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
79646544|NCT00558142|Drug|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
79646545|NCT00558142|Drug|Visipaque 320|100mls IV dose as single dose
79809566|NCT00705276|Drug|Lactic acid (Dermacyd Femina Delicata)|
79809567|NCT00841776|Drug|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
79809568|NCT00841776|Drug|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
79809569|NCT00708786|Device|ICD|Ventricular arrhythmia treatment
79809570|NCT00708786|Device|CRT-D|Ventricular arrhythmia treatment
79809571|NCT00683800|Drug|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
79322983|NCT04109482|Biological|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
79322984|NCT04109482|Drug|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
79322985|NCT04109482|Drug|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
79322986|NCT04109196|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
79322987|NCT04094584|Drug|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
79322988|NCT04091308|Other|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
79322989|NCT04091308|Other|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
79322990|NCT04091308|Other|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
79322991|NCT04082338|Behavioral|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
79322992|NCT04082338|Behavioral|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
79480371|NCT03244865|Device|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
79480372|NCT03832712|Procedure|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
79646546|NCT00558142|Drug|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
79646547|NCT00205842|Drug|alvimopan|
79322993|NCT04074616|Device|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
79322994|NCT04074616|Device|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
79322995|NCT04070560|Procedure|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
79322996|NCT04070560|Procedure|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
79322997|NCT04053283|Biological|NG-641|NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
79480373|NCT03832712|Drug|Best Medical Treatment|Unselective β-blockers such as Propanolol
79646548|NCT04650997|Behavioral|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
79809572|NCT00683800|Drug|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
79809573|NCT00683644|Drug|Zinc|Zinc taken once daily
79809574|NCT00683644|Drug|Placebo oral capsule|Placebo capsules taken once daily
79809575|NCT00745576|Drug|SAM-531|
79322998|NCT04023370|Device|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
79322999|NCT04020341|Drug|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
79323000|NCT04020341|Drug|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
79323001|NCT04020341|Drug|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
79323002|NCT04020341|Drug|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
79323003|NCT04015141|Drug|Perampanel Oral Suspension|Perampanel oral suspension.
79323004|NCT04015141|Drug|Perampanel Tablet|Perampanel tablet.
79323005|NCT04014166|Other|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
79323006|NCT04011280|Drug|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
79323007|NCT04002934|Drug|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
79323008|NCT03994367|Other|High animal protein isolate|Increased dietary protein content from animal protein isolates
79323009|NCT03994367|Other|High animal protein whole food|Increased dietary protein content from animal protein whole food
79323010|NCT03994367|Other|High plant protein isolate|Increased dietary protein content from plant protein isolates
79323011|NCT03994367|Other|High plant protein whole food|Increased dietary protein content from animal protein whole food
79480374|NCT05715866|Device|non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
79323012|NCT03990428|Behavioral|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
79323013|NCT03988621|Behavioral|ViCCY|Virtual Health Coaching for You
79480375|NCT05715866|Procedure|therapeutic exercise|patients receive adapted therapeutic exercise
79976726|NCT06209099|Procedure|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
79323014|NCT03987711|Drug|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
79323015|NCT03987711|Drug|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
79323016|NCT03987711|Other|No oral anticoagulation|No oral anticoagulation
79323017|NCT03983967|Biological|Immuncell-LC|Activated T lymphocyte
79323018|NCT03962348|Behavioral|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
79323019|NCT03961893|Device|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
79323020|NCT03961893|Device|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
79323021|NCT03945669|Procedure|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
79323022|NCT03945669|Procedure|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
79323023|NCT03940950|Biological|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
79323024|NCT03940950|Drug|Placebo|Saline control that contains no active ingredient
79323025|NCT03938688|Procedure|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
79480376|NCT05715866|Behavioral|sleep hygiene measures|caregivers receive a brochure with sleep hygiene measures
79480377|NCT00003219|Drug|perillyl alcohol|
79480378|NCT00356551|Behavioral|Family Spirit curriculum|
79480379|NCT03247985|Device|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
79646549|NCT04650724|Drug|T cell infusion agent targeting BCMA chimeric antigen receptor|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
79809576|NCT00753064|Drug|Antiscorpion venom serum(AScVS).|"AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 > 10-15 3 6 >15- 21 4 8"
79809577|NCT00753064|Drug|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
79323026|NCT03937635|Biological|Daratumumab|Given IV
79323027|NCT03937635|Drug|Dexamethasone|Given PO
79480380|NCT03247985|Device|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open & laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
79480381|NCT04329351|Procedure|Guided Bone regeneration|Guided bone regeneration to ridge preservation
79480382|NCT05715788|Drug|Nitric oxide|Nitric oxide inhalation at 20 ppm
79480383|NCT05715788|Behavioral|prone positioning|vatilation in prone position
79323028|NCT03937635|Drug|Lenalidomide|Given PO
79323029|NCT03937635|Other|Quality-of-Life Assessment|Ancillary studies
79323030|NCT03937635|Other|Questionnaire Administration|Ancillary studies
79323031|NCT03933176|Procedure|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
79323032|NCT03924778|Behavioral|DASH diet|brief description
79323033|NCT03924778|Behavioral|standard American diet|describe
79480384|NCT00003225|Drug|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
79480385|NCT00003225|Drug|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
79809578|NCT00753064|Drug|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
79809579|NCT00751738|Drug|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
79809580|NCT00751816|Drug|systemic chemotherapy|
79646550|NCT04650802|Device|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
79323034|NCT03922971|Other|Option 1: National comparison|Ability to view center's rate compared with all others.
79323035|NCT03922971|Other|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
79323036|NCT03921554|Drug|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
79323037|NCT03892044|Drug|Duvelisib|Given PO
79323038|NCT03892044|Biological|Nivolumab|Given IV
79323039|NCT03886038|Biological|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
79646551|NCT00205920|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
79809581|NCT00751816|Other|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
79809582|NCT00751816|Procedure|adjuvant therapy|
79976727|NCT06209073|Other|Virtual Reality exercise|after explaining the treatment method for patients, the patients will perform full body aerobic exercise by applying kick boxing to destroy walls of rock; the patient moves most of body muscles in this game. He or she flex and extend the shoulder and the elbow with flexion and extension in the knee. squatting exercise, endurance exercise, coordination for arm and shoulder exercise will also performed in virtual reality
79976728|NCT06209073|Other|conventional treatment|the patients will receive conventional treatment in the form of aerobic exercise, resistance exercise and endurance exercise.
79646552|NCT04651036|Drug|QL0605|a pegfilgrastim biosimilar to US Neulasta.
79323040|NCT03869749|Behavioral|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
79323041|NCT03869749|Behavioral|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
79646553|NCT04651036|Drug|US Neulasta|US Neulasta
79646554|NCT00178451|Drug|Abciximab|
79646555|NCT04650529|Device|stent, ballooning|DES, BMS, BRS, DEB, and POBA can be used for PCI
79646556|NCT04650685|Device|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
79646557|NCT04650685|Device|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
79809583|NCT00751816|Procedure|management of therapy complications|
79809584|NCT00751816|Procedure|musculoskeletal complications management/prevention|
79809585|NCT00751816|Procedure|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
79809586|NCT00751816|Radiation|radiation therapy|
79323042|NCT03868891|Device|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
79323043|NCT03867851|Drug|IBsolvMIR|Study drug IBsolvMIR
79323044|NCT03867851|Drug|Heparin|Clinical praxis
79646558|NCT04650685|Device|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
79323045|NCT03857490|Behavioral|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
79323046|NCT03851250|Drug|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
79323047|NCT03851250|Drug|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
79323048|NCT03850912|Other|eSyM App Usage|Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM
79646559|NCT04650334|Behavioral|Collaborative Care|Health services intervention to implement a team based model of care for perinatal depression.
79809587|NCT00685360|Drug|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
79976729|NCT06209047|Drug|bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone|bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
79323049|NCT03850912|Other|SASS Questionnaire|"A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received."
79323050|NCT03832920|Other|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
79323051|NCT03827655|Drug|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
79323052|NCT03827655|Drug|TAK-954|TAK-954 intravenous infusion.
79323053|NCT03810651|Other|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
79976730|NCT06209008|Drug|Intravesical injection of Platlet Rich Plasma (PRP)|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
79976731|NCT06208995|Other|36-Item Short Form Survey Instrument (SF-36)|Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html
79323054|NCT03809780|Drug|Lenalidomide|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
79646560|NCT00205959|Device|Locking proximal humerus plate|
79323055|NCT03809780|Drug|Dexamethasone|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
79809588|NCT00685360|Drug|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results."
79809589|NCT00685360|Drug|Placebo|Placebo tablets matching 50-mg tablets of delamanid
79323056|NCT03802604|Biological|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10^6 PFU/mL. On week 3 (i.e. 21 days [± 2] days), a second talimogene laherparepvec injection will be administered at a dose of 10^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 [± 2] days). The maximum volume for each injection will be 4.0 mL.
79646561|NCT00205959|Device|Proximal Humerus Internal Locking System|
79646562|NCT00205959|Device|Proximal Humerus Nail|
79323057|NCT03802604|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 [± 2] days), for a total of 4 treatment courses.
79976732|NCT06208982|Diagnostic Test|Colonoscopy images and videos|A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.
79809590|NCT04060264|Biological|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
79323058|NCT03801382|Device|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
79809591|NCT04060264|Biological|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
79323059|NCT03801382|Diagnostic Test|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
79809592|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
79809593|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
79809594|NCT00576472|Drug|Methylphenidate|Please see detailed description for dosing information and study design.
79809595|NCT00823212|Device|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
79323060|NCT03800680|Behavioral|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~Complete all 24 GlycoLeap lessons and quizzes~Weight Monitoring: Weigh at least once a week.~Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~Medication: Take medications as prescribed."
79480386|NCT03249779|Device|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
79480387|NCT00356161|Device|interventionally implanted hepatic arterial port catheter|
79480388|NCT03382847|Combination Product|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
79480389|NCT04735211|Procedure|Surgery|Pediatric Surgery with hospitalized
79323061|NCT03800680|Behavioral|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
79323062|NCT03793361|Drug|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
79480390|NCT00376415|Drug|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
79480391|NCT00376415|Drug|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
79480392|NCT05303779|Other|Exercise Interventions of Eye Muscles|Application of eye exercise for improving eye control post strabismus surgery
79480393|NCT05303779|Drug|Medication and eye glasses|medication and eye glasses used post strabismus surgery
79480394|NCT04734899|Other|Exercise program|Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg
79809596|NCT00823212|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).
79480395|NCT04734899|Other|Foot core training|Short foot exercises with passive modeling, active assisted modeling, active modeling, functional training
79809597|NCT00823212|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
79323063|NCT03793361|Drug|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
79323064|NCT03786406|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
79323065|NCT03785873|Drug|Nivolumab|Intravenous (IV) infusion
79323066|NCT03785873|Drug|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
79323067|NCT03785873|Drug|5-Fluorouracil|Intravenous (IV) infusion
79323068|NCT03785873|Drug|Leucovorin|Intravenous (IV) infusion
79323069|NCT03783507|Behavioral|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
79323070|NCT03783507|Behavioral|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
79323071|NCT03783507|Behavioral|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
79646563|NCT00178490|Drug|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
79323072|NCT03783507|Behavioral|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
79646564|NCT04650412|Other|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
79646565|NCT04650373|Procedure|Bariateric surgery|Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
79646566|NCT04650763|Biological|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
79646567|NCT04650763|Device|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
79323073|NCT03783195|Other|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
79323074|NCT03782064|Drug|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
79323075|NCT03782064|Biological|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
79323076|NCT03773471|Behavioral|Mobile Health App|ArthritisPower App
79646568|NCT00205998|Device|Locking Compression Plate 2,4mm|
79646569|NCT00205998|Device|Locking Compression Plate 3,5mm|
79646570|NCT00178529|Behavioral|Psychoeducation, Counseling and Skill Training|
79646571|NCT04650139|Procedure|PCI - percutaneous coronary intervention|percutaneous coronary intervention
79976733|NCT06208969|Behavioral|intensive nutrition counseling|individualized regular nutrition education
79323077|NCT03772522|Behavioral|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
79323078|NCT03764488|Drug|Tofersen|Administered as specified in the treatment arm.
79646572|NCT04649827|Other|Clinical Observation|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
79646573|NCT00206037|Device|COLLOSS E|
79323079|NCT03764488|Drug|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
79323080|NCT03763708|Device|Spinal Cord Stimulation|Programming
79976734|NCT06208956|Drug|Dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
79323081|NCT03761160|Other|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
79323082|NCT03761160|Other|Usual care|Usual care per hospital guidelines
79323083|NCT03755518|Drug|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
79323084|NCT03753490|Other|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
79976735|NCT06208956|Drug|Propofol|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
79323085|NCT03753490|Other|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
79480398|NCT03440723|Device|DilaCheck|Measuring device for the measurement of cervical dilation
79480399|NCT03440723|Diagnostic Test|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
79480400|NCT05614076|Procedure|conserved chalky white enamel margins of class V cavities|during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
79646574|NCT00206037|Device|TomoFix Plate|
79976736|NCT06208943|Other|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
79976737|NCT06208917|Drug|Ondansetron (Oral soluble film OR injections) ,Dexamethasone|Participants will randomly assigned 1:1 to receive treatment (Oral soluble film of Ondansetron plus dexamethasone OR Ondansetron injections plus dexamethasone).
79976738|NCT06208891|Procedure|Robotic myomectomy|Robotic assisted laparoscopic myomectomy
79323086|NCT03747042|Drug|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
79323087|NCT03739112|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
79323088|NCT03739112|Biological|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
79323089|NCT03738072|Diagnostic Test|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
79646575|NCT04650022|Device|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
79323090|NCT03724071|Biological|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
79976739|NCT06208865|Procedure|lumbar erector spinae plane block|All procedures were performed under ultrasound (US) guidance. The patient was monitored in the operating room and placed in the prone position under a sterile drape. A 2-6 MHz convex US probe was used during the procedure. The transverse processes of the lumbar vertebrae were visualized and then a 22 gauge spinal needle was advanced to the transverse process of the L3 vertebra. After contacting the transverse process, a total of 15 mL of drug consisting of 2 mL of methylprednisolone and 6 mL of 0.025% bupivacaine was injected into this area, and the spread of the drug in the craniocaudal area was visualized. The patients were followed up for possible complications after the procedure.
79323091|NCT03724071|Drug|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
79323092|NCT03709446|Drug|Leflunomide|Single agent leflunomide
79984758|NCT03744923|Procedure|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
79323093|NCT03708965|Drug|JR-141|IV infusion (lyophilized powder)
79809598|NCT00823212|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
79809599|NCT00807495|Drug|Alisertib|Alisertib capsules
79809600|NCT05753943|Drug|QUALI|Medication 1 pill at night
79809601|NCT02561494|Drug|Nefopam|
79809602|NCT02561494|Drug|Saline|
79646576|NCT00178568|Behavioral|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
79809603|NCT05748795|Procedure|bronchoscopy brochoalveolar lavage|"2%lidocaine gel will be used to anaesthesize nasal mucosa.6ml lidocaine 2%diluted in 5cc normal saline lidocaine spray solution will be used for anaesthesizing the vocal cords and mucosa of the bronchial tree(13).~Intravenous midazolam (0.01-0.1mg\kg) will be given to achieve conscious sedation in selected cases(13).~Flexible Bronchoscopy will be done under continuous monitoring for O2 saturation, heart rate, blood pressure and respiratory rate.~The bronchoscope will be introduced into the nasal cavity and advanced to the level of the vocal cords. Lidocaine will be instilled through the bronchoscope to the vocal cords and tracheobronchial tree.~Using sterile bronchoscope in the lobar bronchus of tumor location,100 mL of sterile normal saline in fractionated doses will be injected and then BAL will be removed by suction to be collected in sterile side-way bottles."
79809604|NCT00751894|Drug|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
79323094|NCT03708809|Device|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
79323095|NCT03708809|Other|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
79809605|NCT00745732|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
79480401|NCT05614076|Procedure|Total removal of demineralized enamel margins of class V cavities|during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
79480402|NCT03838094|Biological|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
79809606|NCT00745732|Radiation|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
79323096|NCT03705910|Other|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
79323097|NCT03705910|Other|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
79323098|NCT03701646|Device|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
79323099|NCT03689296|Other|Questionnaires (Phase 3)|"CardioVascular Risk (CVR) questionnaire representation~SF12~Getting Better My Way~My recovery plan~Psycom~Partner In Health scale"
79323100|NCT03689296|Other|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
79480403|NCT03838094|Biological|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
79480404|NCT03441269|Drug|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
79480405|NCT05367596|Behavioral|Continuous Energy Restriction (CER)|Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
79480406|NCT05367596|Behavioral|Alternate Day Modified Fasting (ADMF)|Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
79480407|NCT05367596|Behavioral|Group Health Education Sessions|Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
79480408|NCT05367596|Behavioral|Late Evening Snack|The participants will have a late evening snack with a protein supplement.
79480409|NCT05367596|Behavioral|Physical activity|All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
79646577|NCT04649944|Diagnostic Test|Serological test and phone interview|"Families are interviewed by telephone to gather information about the family cluster (i.e. age and number of cohabitants, their symptoms and swab results, if performed), the subject who tested positive (i.e.sex, age, course of the disease, symptoms suggestive of COVID-19) and children aged between 4 and 16 y.o. (i.e. sex, age, drug therapy and/or chronic diseases, symptoms suggestive of COVID-19).~Children, young adults and the cohabitant who previously tested positive to the swab undergo a serological test for the detection of IgG and IgM antibodies for Sars-Cov-2."
79809607|NCT05958693|Drug|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)"
79323101|NCT03689296|Other|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
79809608|NCT05958693|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
79809609|NCT05958680|Behavioral|ASDactive|An integrated theory-based intervention to promote habitual physical activity behaviours in autistic youth
79323102|NCT03679338|Device|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
79323103|NCT03671525|Drug|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
79323104|NCT03671525|Drug|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
79323105|NCT03653611|Other|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
79323106|NCT03653611|Other|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
79323107|NCT03653611|Other|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
79323108|NCT03653611|Other|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
79323109|NCT03653611|Other|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
79323110|NCT03648437|Drug|Paracetamol 10Mg/mL|Experimental drug
79646578|NCT04650061|Behavioral|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
79323111|NCT03648437|Drug|0.45% Sodium Chloride|Placebo comparator
79323112|NCT03648437|Drug|Ibuprofen|Standard therapy
79323113|NCT03648437|Drug|Indomethacin|Standard therapy
79323114|NCT03643042|Other|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
79323115|NCT03622593|Drug|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
79323116|NCT03622593|Drug|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
79323117|NCT03622593|Procedure|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
79323118|NCT03620058|Biological|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
79323119|NCT03620058|Biological|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
79646579|NCT04650061|Device|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
79323120|NCT03618186|Combination Product|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
79646580|NCT00206115|Drug|Seroquel Sustained Release (SR)|
79646581|NCT00206115|Drug|Seroquel Immediate Release (IR)|
79646582|NCT00206115|Drug|Placebo|
79976740|NCT06208852|Other|Virtual Navigator Program|For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
79646583|NCT04649554|Device|Exablate treatment|Ablation
79646584|NCT04649437|Diagnostic Test|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
79646585|NCT04649281|Device|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
79976741|NCT06208839|Device|SBIRT/eIntervention for those with moderate risk drug or alcohol use|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~Online view of the referrals made for them e.g. to healthcare provider~Secure messaging with the referring provider~Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
79323121|NCT03614260|Device|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
79323122|NCT03614260|Procedure|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
79323123|NCT03602066|Drug|Chlorine Dioxide Sterilization|Given via oral rinse
79323124|NCT03602066|Other|Laboratory Biomarker Analysis|Correlative studies
79323125|NCT03602066|Other|Placebo|Given via oral rinse
79646586|NCT04638556|Diagnostic Test|lncRNA detection|The lncRNAs in the plasma of three groups of patients will be tested.
79646587|NCT00206154|Drug|Budesonide/formoterol pMDI|
79646588|NCT00206154|Drug|Budesonide pMDI|
79323126|NCT03593655|Device|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
79323127|NCT03593655|Drug|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
79323128|NCT03591133|Drug|TS-143|
79323129|NCT03591133|Drug|Placebo|
79323130|NCT03577106|Device|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
79480410|NCT05367596|Behavioral|Self-monitoring|Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
79646589|NCT00206154|Drug|Formoterol Turbuhaler|
79646590|NCT04638868|Device|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
79646591|NCT04638868|Device|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
79646592|NCT00178724|Other|No Treatment Given|Intervention is not given.
79323131|NCT03572530|Drug|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
79323132|NCT03572530|Drug|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
79323133|NCT03572530|Drug|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
79323134|NCT03569280|Combination Product|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
79323135|NCT03558087|Drug|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
79323136|NCT03558087|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.
79976742|NCT06208839|Device|SBIRT/eIntervention those assessed with high risk.|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~Online view of the referrals made for them e.g. to healthcare provider~Secure messaging with the referring provider~Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
79323137|NCT03558087|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.
79323138|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
79976743|NCT06208839|Other|SBIRT/TAU for those with moderate risk drug or alcohol use|Treatment as usual
79976744|NCT06208839|Other|SBIRT/TAU for those assessed with high risk.|Treatment as usual for high risk group
79976745|NCT06208826|Drug|Toripalimab|Toripamab, IV, 240mg, every 3 weeks for 15 cycles
79976746|NCT06208826|Radiation|Radiation Therapy|Radiation Therapy
79976747|NCT06208826|Drug|Cisplatin|Chemotherapy agent
79976748|NCT06208813|Dietary Supplement|Creatine|Creatine supplementation
79323139|NCT03549442|Combination Product|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
79480411|NCT05367596|Behavioral|Remotely Supervised Exercise Sessions|Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
79480412|NCT03383627|Device|Continuous Glucose Monitoring|"The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
79646593|NCT04639063|Other|Microscopic examination using H&E stained slides|Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
79646594|NCT00559702|Drug|natalizumab|natalizumab
79646595|NCT00559702|Other|standard of care|standard of care as determined by the Investigator and Treating Neurologist
79646596|NCT00559741|Biological|cetuximab|
79323140|NCT03549442|Combination Product|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
79323141|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
79323142|NCT03542695|Procedure|Computed Tomography|Undergo PET/CT
79323143|NCT03542695|Drug|Copper Cu-64-DOTA-alendronate|Given IV
79323144|NCT03542695|Other|Pharmacokinetic Study|Correlative studies
79323145|NCT03542695|Procedure|Positron Emission Tomography|Undergo PET/CT
79323146|NCT03541876|Other|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
79323147|NCT03524183|Behavioral|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
79323148|NCT03512405|Biological|Blinatumomab|Given IV
79323149|NCT03512405|Other|Laboratory Biomarker Analysis|Correlative studies
79323150|NCT03512405|Biological|Pembrolizumab|Given IV
79809610|NCT05958667|Behavioral|Quitxt text messaging or Chat|Mobile intervention using proven social cognitive, motivational interviewing, and brief intervention methods for promoting behavior change - blends bilingual text and social media messaging for smoking cessation tailored to the language and culture of young adult smokers in our vulnerable region of South Texas.
79976749|NCT06208800|Other|Blend Aromatherapy|Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
79646597|NCT00559741|Drug|fluorouracil|
79323151|NCT03508934|Device|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
79323152|NCT03508934|Other|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
79480413|NCT05366426|Other|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
79480414|NCT05366426|Other|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
79646598|NCT00559741|Drug|irinotecan hydrochloride|
79646599|NCT00559741|Drug|leucovorin calcium|
79646600|NCT00559741|Other|pharmacological study|
79646601|NCT00559780|Behavioral|Resistance training|12 weeks of resistance training (3/week)
79646602|NCT00559780|Behavioral|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
79646603|NCT00559780|Behavioral|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
79809611|NCT05958667|Other|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit.
79646604|NCT00178763|Device|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
79646605|NCT00178763|Other|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
79323153|NCT03506594|Device|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the Capenergy® brand device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41graus radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
79323154|NCT03500107|Device|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
79323155|NCT03491215|Drug|Ruxolitinib|Ruxolitinib taken orally (5mg tablets) or oral pediatric formulation and dosage based on age group
79323156|NCT03490565|Behavioral|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
79323157|NCT03458416|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
79646606|NCT00178763|Other|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
79646607|NCT00559858|Dietary Supplement|pyridoxine hydrochloride|
79646608|NCT00559858|Other|placebo|
79323158|NCT03441308|Behavioral|Educational method of group treatment|
79323159|NCT03441113|Drug|MMB|Tablet(s) administered orally once daily
79323160|NCT03430219|Device|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
79323161|NCT03428009|Other|Magnetic Resonance Imaging|Study interventions are minimal risk.
79323162|NCT03419234|Drug|Abiraterone Acetate|Given PO
79323163|NCT03419234|Drug|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
79323164|NCT03419234|Drug|Cabazitaxel|Given IV
79646609|NCT00559858|Procedure|quality-of-life assessment|
79646610|NCT00559975|Biological|Subunit influenza vaccine|0.5 mL single dose vaccine
79646611|NCT00559975|Biological|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
79646612|NCT00559975|Biological|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
79646613|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
79646614|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
79646615|NCT00206193|Drug|mifepristone|
79646616|NCT00206193|Drug|misoprostol|
79646617|NCT00206193|Drug|sulprostone|
79323165|NCT03419234|Other|Laboratory Biomarker Analysis|Correlative studies
79323166|NCT03419234|Procedure|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
79323167|NCT03419234|Other|Pharmacological Study|Correlative studies
79323168|NCT03419234|Drug|Prednisone|Given PO
79323169|NCT03388242|Other|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
79323170|NCT03364231|Drug|Umbralisib|Oral Daily Dose
79646618|NCT04638439|Drug|P1101 + Nivolumab + Entecavir|"P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks) *, followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks) **, with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.~*: HBsAg will be checked at treatment week 12 (or 16, if applicable).~**: Only patients with > 0.5 log10 decline in HBsAg at treatment week 12 or 16 will be sequentially treated with Anti-PD1."
79323171|NCT03343093|Behavioral|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
79323172|NCT03343093|Behavioral|Control|usual care, surveys every 3 months
79323173|NCT03335228|Device|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
79323174|NCT03303625|Biological|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1*10^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
79323175|NCT03303625|Biological|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5*10^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
79323176|NCT03303625|Drug|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
79323177|NCT03299816|Behavioral|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
79323178|NCT03299816|Behavioral|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
79323179|NCT03297554|Behavioral|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
79480415|NCT05366426|Other|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
79480416|NCT03252353|Drug|octreotide capsules|octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
79480417|NCT03252353|Drug|Matching placebo|Matching placebo capsules
79480418|NCT00358358|Drug|Fluticasone Propionate/Salmeterol 500/50mcg combination|
79646619|NCT00178802|Other|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
79480419|NCT00358358|Drug|Fluticasone Propionate 500mcg|
79480420|NCT00358358|Drug|Salmeterol 50mcg|
79646620|NCT00560014|Dietary Supplement|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
79323180|NCT03288493|Biological|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
79480421|NCT05349734|Other|overbody blanket|applying overbody blanket with forced-air blower set to 43℃
79646621|NCT00560014|Dietary Supplement|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
79646622|NCT04638010|Behavioral|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
79480422|NCT05349734|Other|underbody blanket|applying underbody blanket with forced-air blower set to 43℃
79646623|NCT04638010|Behavioral|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
79646624|NCT00201045|Other|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
79646625|NCT04638166|Other|Mineral water|Drinking mineral water for 12 weeks
79646626|NCT04638166|Other|Plain water|Drinking plain water for 12 weeks
79646627|NCT04637737|Device|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
79646628|NCT04637737|Behavioral|Conventional therapy|The control group received the usual gait training.
79646629|NCT04637854|Procedure|Operating microscope|Third molar extraction using microscope
79646630|NCT04637854|Procedure|Surgical loupes|Third molar extraction using loupes with co-axial illumination
79646631|NCT04637854|Procedure|Naked eyes|Third molar extraction using naked eyes
79646632|NCT04637659|Procedure|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
79646633|NCT00201084|Behavioral|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
79646634|NCT04637503|Biological|GD2, PSMA and CD276 CAR-T cells|infusion, for 1x10^6~1x10^7 cells/kg via IV
79646635|NCT00408239|Drug|YM150|Oral
79646636|NCT00408239|Drug|enoxaparin|Sub cutaneous
79646637|NCT04637308|Drug|Succinylated gelatin|"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."
79646638|NCT04637542|Other|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
79646639|NCT00201162|Dietary Supplement|Soy|Dietary supplement of isolated soy protein containing isoflavones
79646640|NCT00201162|Dietary Supplement|Placebo|dietary supplement casein placebo
79480423|NCT03441581|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
79480424|NCT02265510|Drug|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
79480425|NCT02265510|Drug|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
79323181|NCT03288493|Drug|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
79646641|NCT04637464|Other|Early termination of empirical antibiotics|Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
79646642|NCT00408278|Drug|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
79809612|NCT05958654|Behavioral|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|DETECT-RPC is an elder mistreatment (EM) screening tool designed for medics who respond to older adults' homes and will be adapted for home-based primary care (HBPC). The DETECT-RPC tool is designed to (1) be brief, (2) be based on the clinician's direct observations of the older adult and the older adult's physical and social environment, (3) provide reporting guidance, and (4) be integrated into their existing procedures and medical charting software.
79809613|NCT05958641|Other|Questionnaires|Participants will be asked to complete the questionnaire including general demographic information, the cognition, resistance and use of NPS as well as the behavioral expression of addiction susceptibility genes and adverse childhood experience.
79323182|NCT03287349|Other|Blood draw|Two 12.5 mL blood draws
79646643|NCT00408278|Drug|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
79646644|NCT00408278|Drug|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
79646645|NCT00408278|Drug|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
79809614|NCT05958602|Behavioral|Technology|See previous response.
79809615|NCT05958602|Behavioral|Standard DSMES Only|See previous response.
79809616|NCT05958602|Behavioral|Traditional Recruitment Methods|See previous response.
79323183|NCT03287349|Other|Photograph|Photograph of severe reaction, will be anonymized
79323184|NCT03287349|Diagnostic Test|Autoimmune testing|Autoimmune testing in patients without prior testing
79323185|NCT03267433|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
79809617|NCT05958602|Behavioral|CHW-Led Recruitment Methods|See previous response.
79323186|NCT03267433|Other|Laboratory Biomarker Analysis|Correlative studies
79323187|NCT03267433|Biological|Rituximab|Given IV
79480426|NCT02265510|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
79480427|NCT02265510|Drug|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
79646646|NCT00560053|Drug|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
79809618|NCT05958589|Drug|Caudal block with levobupivacaine|After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
79323188|NCT03238690|Device|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
79809619|NCT05958589|Drug|General anesthesia|On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
79809620|NCT05958589|Procedure|Inguinal hernioplasty|Elective inguinal hernioplasty
79323189|NCT03238300|Drug|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
79480428|NCT02265510|Drug|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
79646647|NCT00560053|Procedure|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
79646648|NCT00560053|Drug|Maintenance|"At 3 months of transplantation or with >1.500 neutrophiles/ > 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
79646649|NCT00560053|Procedure|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
79646650|NCT00560053|Procedure|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
79646651|NCT00560092|Drug|intrathecal magnesium sulfate|intrathecal magnesium sulfate
79646652|NCT00560170|Drug|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
79809621|NCT05958563|Device|continuous positive airway pressure treatment|CPAP treatment for one year
79323190|NCT03238300|Drug|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
79646653|NCT00560170|Drug|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
79480429|NCT02265510|Drug|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
79646654|NCT04637152|Drug|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
79646655|NCT02963909|Biological|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
79646656|NCT02963909|Other|Placebo|0.9% Sodium Chloride 5 mcg
79646657|NCT02963909|Biological|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
79646658|NCT02963909|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
79646659|NCT04637191|Device|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
79646660|NCT04637347|Device|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
79646661|NCT04637269|Biological|anti-BCMA CAR-T|5×10^7 /KG 15×10^7 /KG 45×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.
79646662|NCT00408356|Drug|Zinc|
79646663|NCT04636918|Drug|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
79323191|NCT03233191|Procedure|Digital Mammography|Undergo DM
79323192|NCT03233191|Procedure|Digital Tomosynthesis Mammography|Undergo TM
79323193|NCT03233191|Other|Laboratory Biomarker Analysis|Correlative studies
79323194|NCT03215511|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
79323195|NCT03214003|Radiation|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
79646664|NCT00560209|Drug|ONO-1101|placebo for 1 minute IV
79809622|NCT05958550|Behavioral|The tympanic membrane temperature of patients was measured.|After the patient entered the anesthesia recovery room ( PACU ) at the end of the operation, the ear canal was cleaned with cotton swabs by nurses trained in the use of ear temperature guns to avoid the impact of earwax. The patient was in a supine position, the patient 's head was fixed, the patient 's auricle was gently pulled back and up, the ear canal was straight, the ear temperature gun was put into the ear canal, the temperature of the patient 's left and right ears was measured uniformly, and the average value was taken as the final body temperature value. Thereafter, the same measurement was performed every 20 minutes until the patient left the resuscitation room.
79480430|NCT02265510|Drug|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
79646665|NCT00560209|Drug|ONO-1101|0.06 mg/kg for 1 minute IV
79323196|NCT03214003|Radiation|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
79323197|NCT03186417|Biological|2 million hMSC/kg|2 million hMSCs/kg infusion
79323198|NCT03186417|Biological|4 million hMSC/kg|4 million hMSC/kg infusion
79323199|NCT03186417|Biological|6 million hMSC/kg|6 million hMSC/kg infusion
79646666|NCT00560209|Drug|ONO-1101|0.125 mg/kg for 1 minute IV
79323200|NCT03186417|Biological|placebo|placebo infusion
79323201|NCT03180996|Device|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
79480431|NCT02265510|Drug|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
79480432|NCT02265510|Drug|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
79480433|NCT02265510|Drug|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
79480434|NCT02265510|Drug|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
79480435|NCT02265510|Drug|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
79480436|NCT03254147|Drug|warfarin|warfarin
79646667|NCT04636957|Drug|Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution|0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
79646668|NCT04636957|Drug|Ciprofloxacin 0.3% solution|0.4mL/vial, each vial contains 1.2mg ciprofloxacin
79323202|NCT03178045|Other|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
79323203|NCT03178045|Other|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
79323204|NCT03175744|Device|Stellarex DCB|Intervention with the Stellarex DCB
79323205|NCT03175744|Device|PTA Catheter|Intervention with an uncoated Standard PTA
79323206|NCT03171311|Procedure|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
79323207|NCT03171311|Procedure|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
79809624|NCT05958498|Combination Product|injectable platelet rich fibrin and microosteoperforation|i-PRF which second product of blood versus mops which is surgical procedure
79323208|NCT03168750|Device|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
79323209|NCT03154307|Device|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
79323210|NCT03139825|Other|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
79323211|NCT03139370|Drug|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
79323212|NCT03139370|Drug|Cyclophosphamide|Administered intravenously
79323213|NCT03139370|Drug|Fludarabine|Administered intravenously
79323214|NCT03139370|Device|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
79323215|NCT03133221|Drug|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
79809625|NCT05958459|Other|Eye Exercise|The individuals in the study group will perform home-based eye exercises for at least 1 session (~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
79809626|NCT05958459|Other|no intervention|no intervention
79809627|NCT05958394|Behavioral|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
79809628|NCT05958329|Behavioral|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
79480437|NCT03254147|Drug|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
79809629|NCT05958277|Drug|Vitamin B3|Vitamin B3 upto 16 mg/day
79809630|NCT05958277|Drug|Vitamin B12|Vit B12 upto 250 mcg per day
79809631|NCT05958238|Device|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
79646669|NCT00178958|Device|Holter Monitor|
79323216|NCT03112928|Device|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~Pain evaluation~Placement of the electrodes and fiducial marker~Practice of motor execution in Augmented Reality (AR)~Gaming using phantom movements~Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
79323217|NCT03112928|Device|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
79323218|NCT03089203|Biological|CART-PSMA-TGFβRDN cells|autologous CAR T cells
79323219|NCT03089203|Drug|Cyclophosphamide|300 mg/m2/day given over 3 days
79323220|NCT03089203|Drug|Fludarabine|30 mg/m2/day given over 3 days
79323221|NCT03079037|Device|Stimulation|Traditional deep brain stimulation
79323222|NCT03072602|Dietary Supplement|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
79323223|NCT03072602|Other|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
79323224|NCT03070366|Drug|Chemotherapy|"cisplatin~5FU~carboplatin~cetuximab"
79323225|NCT03070366|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy
79323226|NCT03049540|Drug|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
79323227|NCT03049540|Drug|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
79323228|NCT03012880|Biological|Daratumumab|Given IV
79646670|NCT04636996|Other|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
79323229|NCT03012880|Drug|Dexamethasone|Given PO
79323230|NCT03012880|Drug|Ixazomib Citrate|Given PO
79646671|NCT04636567|Drug|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
79809632|NCT05958238|Other|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
79323231|NCT03012880|Other|Laboratory Biomarker Analysis|Correlative studies
79323232|NCT03012880|Drug|Lenalidomide|Given PO
79323233|NCT03012880|Other|Questionnaire Administration|Ancillary studies
79323234|NCT02999087|Drug|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
79323235|NCT02999087|Drug|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
79323236|NCT02999087|Drug|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
79323237|NCT02999087|Radiation|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
79323238|NCT02983461|Drug|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
79323239|NCT02983461|Drug|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
79323240|NCT02950987|Device|Whole Body MRI|
79646672|NCT04636606|Procedure|Home Exercise|Educational training program about oral dysphagia in patients with temporomandibular disorders.
79646673|NCT04636606|Procedure|Manual Therapy Combined with Home Exercise|Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
79480438|NCT03254147|Drug|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
79480439|NCT03254147|Drug|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
79480440|NCT03254147|Drug|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
79480441|NCT04735601|Procedure|Ahmed Valve|Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome
79480442|NCT04735757|Other|Contrast-enhanced MRI|Contrast-enhanced MRI
79480443|NCT04735757|Other|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
79480444|NCT03384329|Drug|Resveratrol Pill|Resveratrol 500 mg
79646674|NCT04636606|Procedure|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
79646675|NCT04636645|Other|Normal treadmill|Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
79646676|NCT04636645|Other|Anti-gravity treadmill with lower limb positive pressure|Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
79809633|NCT05958212|Behavioral|Gait training program|"Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill. It consists of forward walking at increased speed over the affected leg and retro walking (backward walking) at individual's own pace (5 minutes/set for three sets, with rest periods in each session). This program also consists of a standardized set of warm-up and cool-down exercises at each training session.~Participants will also receive conventional physiotherapy treatment in the outpatient physiotherapy clinic."
79323241|NCT02945085|Other|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
79323242|NCT02945085|Other|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
79323245|NCT02935543|Biological|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10^7 CART19 cells, Day 2, 30% fraction: 3x10^7-1.5x10^8 CART19 cells, Day 3, 60% fraction: 6x10^7-3x10^8 CART19 cells
79323246|NCT02925364|Radiation|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
79323247|NCT02924727|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
79480445|NCT03384329|Drug|Placebos|Placebo Pills
79480446|NCT03384953|Behavioral|Clinical Hypnosis - Group Treatment|group treatment
79480447|NCT03384953|Behavioral|Clinical Hypnosis - Individual Treatment|individual treatment
79480448|NCT00359060|Behavioral|Physical activity|
79480449|NCT03443063|Drug|Lemborexant|oral tablet
79480450|NCT03256253|Drug|Pregabalin|pregabalin up to 600 mg/day
79480451|NCT00358514|Device|Continuous Compartment Pressure Monitoring|See Detailed Description.
79323248|NCT02924727|Drug|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
79646677|NCT04636645|Other|Anti-gravity treadmill with without lower limb positive pressure|Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
79646678|NCT04636489|Dietary Supplement|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
79646679|NCT04636489|Other|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
79646680|NCT00560287|Device|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
79646681|NCT00560287|Device|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
79646682|NCT00560326|Drug|Tacrolimus Ointment 0.03%|Once or twice daily topical application
79646683|NCT00201279|Drug|13-cis Retino Acid|
79646684|NCT00560365|Other|laboratory biomarker analysis|
79809634|NCT05958212|Behavioral|Conventional training only|Conventional physiotherapy treatment in the outpatient physiotherapy clinic.
79323249|NCT02924727|Drug|Placebo of LCZ696|Matching placebo of LCZ696 tablets
79323250|NCT02924727|Drug|Placebo of ramipril|Matching placebo of ramipril capsule
79323251|NCT02924727|Drug|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
79323252|NCT02924727|Drug|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
79480452|NCT03256799|Drug|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
79646685|NCT00560365|Procedure|computed tomography|
79646686|NCT00560365|Procedure|magnetic resonance imaging|
79646687|NCT00560365|Procedure|quality-of-life assessment|
79646688|NCT00560443|Drug|ketorolac|0,5 mg/kg per os one time
79646689|NCT00560443|Drug|tramadol|2,5 mg/ kg per os in one dose
79323253|NCT02905110|Drug|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
79323254|NCT02905110|Drug|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
79323255|NCT02905110|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
79323256|NCT02901626|Device|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~Nulliparous 65 mm, 32 mm~Multiparous 70 mm, 32 mm~Alternative 70 mm, 35 mm"
79646690|NCT00560521|Behavioral|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
79646691|NCT00179114|Drug|Botulinum Toxin Type A|
79646692|NCT00179114|Drug|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
79646693|NCT04636450|Procedure|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
79646694|NCT04636450|Procedure|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
79646695|NCT04636372|Device|Intense pulsed light therapy|Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
79809635|NCT05958173|Dietary Supplement|Capsaicin|Oral stimulation with natural TRPV1 agonist
79809636|NCT05958173|Dietary Supplement|Piperine|Oral stimulation with natural TRPA1/V1 agonist
79323257|NCT02893163|Behavioral|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
79646696|NCT04636372|Other|Hot compress massage|Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
79809637|NCT05958173|Dietary Supplement|Placebo|Oral stimulation with placebo solution
79323258|NCT02893163|Other|Usual Care|Usual Care by Family Doctor
79323259|NCT02872337|Behavioral|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
79323260|NCT02872337|Behavioral|Group Preoperative Education Session (per the standard of care)|
79646697|NCT00201318|Drug|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
79646698|NCT00179153|Dietary Supplement|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
79646699|NCT04636099|Device|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
79809638|NCT05958160|Other|Modified Atkins diet|The modified Atkins diet is a less restrictive version of the ketogenic diet
79809639|NCT05958160|Drug|Topiramate|Topiramate is an anti-seizure medication
79809640|NCT05958108|Behavioral|SinergiAPS intervention|Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
79809641|NCT05958095|Device|MamaLift Plus|MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.
79323261|NCT02856815|Biological|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10^9 ~ 2 x 10^10 lymphocytes / 60kg adult) for 1 hour
79323267|NCT02819037|Procedure|gas chromatography|
79323268|NCT02819037|Procedure|Stool analysis for detection of malabsorption|
79646700|NCT04636294|Diagnostic Test|SARS-CoV-2 PCR|SARS-CoV-2 PCR of nasopharyngeal lysate.
79646701|NCT00201357|Drug|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
79646702|NCT04636021|Diagnostic Test|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
79646703|NCT00179192|Procedure|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
79646704|NCT00179192|Procedure|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
79646705|NCT04635982|Other|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
79646706|NCT00201396|Radiation|CCRT|Radiation with weekly Cisplatin
79646707|NCT00201396|Drug|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
79646708|NCT04635709|Device|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
79646709|NCT04635592|Diagnostic Test|SARS-CoV2 nasal swab|SARS-CoV2 nasal swab and venous blood for SARS-CoV2 antibodies
79646710|NCT04635475|Behavioral|RISE Bundle|Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
79323269|NCT02808507|Other|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
79480453|NCT03257189|Device|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
79646711|NCT04635514|Procedure|Lateral colporrhaphy|
79480454|NCT03257189|Device|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
79646712|NCT00201435|Drug|Paclitaxel weekly in combination with capecitabine|
79646713|NCT00201435|Drug|Docetaxel every 3 week in combination with capecitabine|
79646714|NCT00560599|Drug|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
79646715|NCT00560599|Behavioral|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
79646716|NCT00560599|Drug|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
79646717|NCT04635202|Behavioral|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
79646718|NCT04635202|Behavioral|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
79646719|NCT04635124|Behavioral|Dog visit|An visitor visits the participant with a dog
79646720|NCT04635124|Behavioral|Encourage to engage in activity|In each visit the visitor invites the participant to engage in an activitty
79480455|NCT03257189|Device|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
79646721|NCT04635553|Drug|Praziquantel 600 milligram|A single treatment with a dose of 40 milligram/kilogram (mg/kg)
79646722|NCT00201513|Behavioral|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
79646723|NCT00201513|Behavioral|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
79646724|NCT00201513|Behavioral|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
79646725|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|TID
79646726|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|QID
79646727|NCT00560638|Drug|vehicle of loteprednol etabonate|TID or BID according to the randomization
79646728|NCT04634656|Drug|Lidocaine|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
79646729|NCT04634656|Drug|Normal saline|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
79646730|NCT00201552|Drug|Statin|
79646731|NCT04634500|Drug|Dapagliflozin|Dapagliflozin Tablet
79809642|NCT05958095|Device|Digital Sham App|The digital sham app delivers content, tips, and suggestion for general wellbeing support.
79809643|NCT05958069|Drug|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
79809644|NCT05958004|Procedure|Radical prostatectomy (RP)|Radical prostatectomy will be done by experienced urologists using Da Vinci Xi robotic surgical system
79323270|NCT02798523|Drug|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
79323271|NCT02798523|Drug|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
79323272|NCT02797977|Drug|SRA737, gemcitabine, cisplatin|
79323273|NCT02797977|Drug|SRA737, gemcitabine|
79323274|NCT02786589|Biological|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
79323275|NCT02772588|Drug|ARN-509|
79809645|NCT05957991|Drug|Metformin Hydrochloride tablet|Treatment with metformin
79323276|NCT02772588|Drug|Abiraterone|
79809646|NCT05957991|Drug|Placebo|Treatment with placebo
79809647|NCT05957991|Behavioral|Lifestyle intervention|Changing behaviour on diet and excersise
79323277|NCT02772588|Drug|Leuprolide|
79323278|NCT02772588|Radiation|stereotactic, ultra-fractionated radiotherapy|
79809648|NCT05957991|Behavioral|No lifestyle intervention|No changes in behaviou on diet and excersise
79480456|NCT03257189|Other|Activity classification|Visual annotation of subject posture and other activities used for reference
79480457|NCT01238211|Drug|Cytarabine|Given IV
79480458|NCT01238211|Drug|Dasatinib|Given PO
79480459|NCT01238211|Drug|Daunorubicin Hydrochloride|Given IV
79480460|NCT01238211|Other|Laboratory Biomarker Analysis|Correlative studies
79480461|NCT00375947|Other|Hand Exercise|
79480462|NCT00375947|Other|sham hand cream|placebo intervention
79480463|NCT04735445|Diagnostic Test|Digital rectal exam and / or anal cytology (day 1 and after 36 months)|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
79480464|NCT04735445|Diagnostic Test|Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
79480465|NCT04735445|Diagnostic Test|Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)|For Cervix Screening in sexually active woman (day 1 and after 36 months)
79480466|NCT04735445|Diagnostic Test|Semestral cervical cytology and cervical sample for HPV detection|For Cervix Screening in sexually active woman (semestral)
79480467|NCT04735445|Diagnostic Test|Appointment for mammography (day 1 and after 36 months)|For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
79480468|NCT04735445|Diagnostic Test|Annual appointment for mammography|For Breast Screening in woman between 45-70 years old (annual)
79480469|NCT04735445|Diagnostic Test|Semestral appointment for liver ultrasound|"For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~Asian male> 40 years old~Asian woman> 50 years old~African man or woman~HCC family history"
79323279|NCT02767973|Other|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
79809649|NCT05957939|Drug|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
79480470|NCT04735445|Diagnostic Test|Semestral appointment for liver ultrasound|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
79480471|NCT04735445|Diagnostic Test|Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
79480472|NCT04735445|Diagnostic Test|Fecal occult blood test (day 1 and after 36 months)|"For Colon Screening:~Age between 50-70 years old"
79480473|NCT04735445|Diagnostic Test|Annual fecal occult blood test|"For Colon Screening:~Age older than 40 years"
79480474|NCT04735445|Diagnostic Test|Digital rectal exam and PSA determination (day 1 and after 36 months)|"For Prostate Screening:~Man older than 50 years"
79480475|NCT04735445|Diagnostic Test|Annual digital rectal exam and PSA determination|"For Prostate Screening:~Man older than 50 years"
79480476|NCT04735445|Diagnostic Test|Annual appointment for low dose computed tomography for lung screening|"For Lung Screening: should accomplish~ALL the following criteria:~Age > 40 years~Active smoker or former smoker<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~No contraindications for thoracic surgery~No lung infection in the last 2 months"
79323283|NCT02748668|Other|Blood specimen collection|
79323284|NCT02742025|Other|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
79323285|NCT02742025|Other|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
79480477|NCT04735445|Diagnostic Test|Annual general inspection for skin lesions suggestive of malignancy|"For Skin Screening:~Woman ≥18 years Man ≥40 years"
79480478|NCT04344314|Device|Peripheral Intravenous Catheter|Randomised controlled
79480479|NCT00003231|Drug|cisplatin|
79480480|NCT00003231|Drug|docetaxel|
79976750|NCT06208774|Procedure|Ultrasound-guided PENG or ISBP block|The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
79976751|NCT06208761|Other|Triphala capsule supplementation and high-intensity interval training|Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other
79976752|NCT06208748|Drug|Bezuclastinib in combination with sunitinib|Bezuclastinib in combination with sunitinib (sutent)
79976753|NCT06208735|Biological|CLIC-2201|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-2201 CAR-T cells. All treatments will be delivered intravenously.
79480481|NCT00003231|Procedure|surgical procedure|
79480482|NCT00003231|Radiation|radiation therapy|
79480483|NCT03259139|Behavioral|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
79480484|NCT05132036|Other|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
79480485|NCT00003405|Biological|recombinant interferon alfa|
79976754|NCT06208722|Behavioral|Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism|Information provided in arm descriptions.
79976755|NCT06208709|Device|carpal arch space augmentation (CASA)|A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
79976756|NCT06208709|Device|standard of care (SOC)|A BOA brace that can be adjusted to the arm of the participant.
79976757|NCT06208696|Other|"Tomando control de su salud (Spanish Chronic Disease Self-Management)"|"Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management."
79976758|NCT06208683|Biological|Mumps vaccine, Live (MV)|0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
79480486|NCT00003405|Drug|amifostine trihydrate|
79480487|NCT00003405|Drug|bromodeoxyuridine|
79480488|NCT00003405|Drug|cytarabine|
79480489|NCT00003405|Drug|idarubicin|
79480490|NCT00003405|Drug|idoxuridine|
79809650|NCT05957913|Drug|Truvada (tenofovir/emtricitabine)|Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
79976759|NCT06208683|Biological|Influenza Vaccine, inactivated, quadrivlent(QIV)|0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
79480491|NCT00003405|Drug|isotretinoin|
79480492|NCT00003405|Drug|mitoxantrone hydrochloride|
79480493|NCT05131646|Drug|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
79480494|NCT03260699|Device|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
79480495|NCT00003411|Drug|motexafin gadolinium|
79480496|NCT00003411|Radiation|radiation therapy|
79480497|NCT05128136|Device|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
79809651|NCT05957887|Drug|Dapagliflozin|Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
79809652|NCT05957861|Behavioral|web-based aerobic exercise|Our designed AE program involved core muscle training through movements including marching, step touches, lunges, v-steps, box steps, twists, knee-ups, scoops, and scissors.
79809653|NCT05957835|Dietary Supplement|BR-HIGH|4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)
79809654|NCT05957835|Dietary Supplement|BR-MOD|2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)
79323286|NCT02742025|Other|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
79323287|NCT02742025|Procedure|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
79646732|NCT04634422|Procedure|Plasma exchange and convalescent plasma|In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
79809655|NCT05957835|Dietary Supplement|BR-LOW|1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)
79976760|NCT06208657|Drug|Paxalisib, Irinotecan, Temozolomide|Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
79976761|NCT06208657|Drug|Pimasertib|Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
79976762|NCT06208631|Behavioral|Gait retraining|Changing muscle coordination while walking
79976763|NCT06208605|Behavioral|Transdiagnostic Network Informed Personalized Treatment|Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
79976764|NCT06208605|Behavioral|Enhanced Cognitive Behavioral Therapy for Eating Disorders|Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
79976765|NCT06208566|Behavioral|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
79976766|NCT06208566|Behavioral|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
79976767|NCT06208553|Other|QI toolkit implementation|Patients and clinicians will have access to online toolkits of resources (e.g., video, checklist, rehabilitation tracker, quick guides) reflecting quality indicators for rehabilitation care after total hip and knee replacement surgery.
79323288|NCT02720692|Drug|N1539|
79646733|NCT00201591|Behavioral|Exercise training for 10 weeks|
79323289|NCT02720692|Drug|Intravenous Placebo|
79323290|NCT02712151|Procedure|Abdominal Wall Block|bilateral TAP and RS blocks.
79809656|NCT05957835|Dietary Supplement|PL|4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)
79809657|NCT05957796|Device|"Novel Snaps Eye Shield"|"Using a novel eye shield, Snaps manufactured in Morgantown, WV by Intermed Labs after cataract surgery that has a different adhesive mechanism that utilizes adhesive and snap-on attachments to the shield."
79323291|NCT02712151|Procedure|Surgical infiltration|distributed between the 4 laparoscopic port sites.
79323292|NCT02712151|Drug|Sterile saline|Placebo injection
79323293|NCT02712151|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
79323294|NCT02712151|Device|Ultrasound|For nerve localization
79323295|NCT02712151|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
79323296|NCT02707484|Drug|Thalidomide (100mg)|Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
79809658|NCT05957796|Other|Standard Alcon Eye Shield|Use normal Alcon eye shield with tape to adhere to shield to eye postop.
79809659|NCT05957783|Other|Cerebral palsy Gait analysis technique|Visual gait analysis in cerebral palsy new technique
79809660|NCT05957744|Procedure|Colorectal surgery|Right hemicolectomy, left colectomy, total colectomy, anterior resection
79323297|NCT02707484|Drug|Thalidomide (50mg)|Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
79323298|NCT02707484|Drug|placebo|Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
79323299|NCT02692664|Device|Endovascular aorto-iliac repair|
79323300|NCT02687243|Device|Interactive Virtual Application|Online application via tablet
79323301|NCT02674971|Behavioral|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
79323302|NCT02659215|Device|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
79323303|NCT02659215|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
79646734|NCT04633954|Drug|Brimonidine Tartrate 0.15% Oph Soln|One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
79646735|NCT04634032|Genetic|mRNA expression and SNP analysis|mRNA expression and SNP analysis from samples
79976768|NCT06208540|Drug|Cerebrolysin|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 8 more weeks till a maximum of 24 weeks.
79976769|NCT06208540|Other|olfactory and gustatory trainings|olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
79976770|NCT06208527|Dietary Supplement|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
79323304|NCT02656303|Biological|Ublituximab|Ublituximab IV infusion
79323305|NCT02656303|Drug|Umbralisib|Umbralisib tablets
79323306|NCT02650622|Procedure|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
79323307|NCT02646683|Drug|vedolizumab|
79646736|NCT04634032|Diagnostic Test|Blood sampling|Peripheral blood sampling for SNP analysis
79646737|NCT00560872|Device|remote magnetic catheter navigation|use of the Stereotaxis system
79646738|NCT00560872|Procedure|cavotricuspid isthmus ablation|conventional (manual) approach
79646739|NCT00201630|Drug|Uroxatrol (drug)|
79809661|NCT05957705|Procedure|Maxilar Sinus augmentation|The patients will be submitted to bilateral sinus augmentation using two different techniques to provide enough bone tissue for dental implants placement.
79976771|NCT06208527|Other|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
79323308|NCT02640586|Device|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
79323309|NCT02640209|Biological|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
79323310|NCT02628626|Drug|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
79323311|NCT02628626|Drug|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
79976772|NCT06208475|Other|Resistance exercise|Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
79976773|NCT06208462|Drug|Adebrelimab|1200mg，i.v. , q3w
79323312|NCT02628626|Other|Placebo|Placebo will be identical in appearance to the active drug.
79323313|NCT02617797|Device|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
79323314|NCT02617797|Device|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
79976774|NCT06208462|Drug|Lenvatinib|8mg,qd
79323317|NCT02609542|Other|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
79323318|NCT02588456|Biological|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
79323319|NCT02559609|Behavioral|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
79323320|NCT02559609|Behavioral|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
79323321|NCT02559609|Behavioral|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
79323322|NCT02555384|Other|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
79323323|NCT02555384|Other|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
79323324|NCT02554812|Drug|Avelumab|Anti-PD-L1 antibody
79323325|NCT02554812|Drug|Utomilumab|Anti-4-1BB antibody
79323326|NCT02554812|Drug|PF-04518600|OX40 Agonist
79976775|NCT06208462|Drug|Gemcitabine|1000 mg/m2，q3w
79976776|NCT06208462|Drug|Cisplatin|25 mg/m2，q3w
79976777|NCT06208449|Procedure|Robotic repair for EA|The paitents with EA were repaired by Da Vinci robot
79976778|NCT06208449|Procedure|Thoracoscopic repair for EA|The patients with EA were repaired by thoracoscopy
79323327|NCT02554812|Drug|PD 0360324|Anti-M-CSF
79323328|NCT02554812|Drug|CMP-001|TLR9 agonist
79323329|NCT02546167|Biological|CART-BCMA|
79323330|NCT02527707|Drug|lonafarnib|antiviral farnesyltransferase inhibitor
79323331|NCT02527707|Drug|Ritonavir|Cytochromes P450 3A4 inhibitor used to boost lonafarnib
79976779|NCT06208449|Procedure|Thoracotomy repair for EA|The patients with EA were repaired by traditional open thoracotomy.
79323332|NCT02470754|Device|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
79646740|NCT04634188|Diagnostic Test|Procalcitonin|Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
79646741|NCT00179231|Drug|olanzapine vs. clozapine|
79976780|NCT06208436|Other|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
79323333|NCT02470754|Device|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
79323334|NCT02453191|Drug|Talimogene Laherparepvec|Talimogene Laherparepvec
79323335|NCT02453191|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
79646742|NCT04634305|Procedure|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
79646743|NCT04633876|Behavioral|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
79976781|NCT06208410|Drug|JS105|JS105 is administered once daily, orally
79323336|NCT02386371|Procedure|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
79323337|NCT02386371|Radiation|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
79646744|NCT04633876|Behavioral|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
79646745|NCT04633876|Other|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
79976782|NCT06208410|Drug|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
79976783|NCT06208410|Drug|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
79976784|NCT06208410|Drug|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
79976785|NCT06208410|Drug|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
79976786|NCT06208410|Drug|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
79976787|NCT06208410|Drug|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
79976788|NCT06208410|Drug|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
79323338|NCT02367924|Drug|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
79480498|NCT05440721|Device|Treatment A with device Clickotine® (Active intervention)|The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
79480499|NCT05440721|Device|Treatment B with smoking education (control)|The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
79480500|NCT00003243|Biological|aldesleukin|
79480501|NCT00003243|Biological|filgrastim|
79480502|NCT00003243|Biological|therapeutic allogeneic lymphocytes|
79646746|NCT04633720|Other|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
79976789|NCT06208397|Diagnostic Test|Magnetic Resonance Elastography and routine MRI|Assessed boundary conditions through MRE-base SII before surgery and recorded HGP of tumor after surgery.
79646747|NCT00201669|Drug|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
79976790|NCT06208384|Drug|Statin eye drop|Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
79976791|NCT06208384|Drug|Placebo|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
79976792|NCT06208358|Device|tACS|We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.
79323339|NCT02364726|Procedure|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
79480503|NCT00003243|Drug|cyclophosphamide|
79480504|NCT00003243|Drug|etoposide|
79480505|NCT00003243|Drug|pegylated liposomal doxorubicin hydrochloride|
79480506|NCT04344158|Drug|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
79480507|NCT04344158|Drug|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
79646748|NCT04633798|Procedure|IPL/Lipiflow|To treat patients with MGD using intense pulsed light combined with lipiflow
79976793|NCT06208332|Behavioral|Photo-Narrative|Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
79976794|NCT06208280|Drug|After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.|"Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m^2 (D-5~D-3) Drug: Cyclophosphamide: 250-300 mg/ m^2 (D-5~D-3)"
79976795|NCT06208267|Drug|Tranexamic acid|This is a 4 arm RCT using the four dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
79976796|NCT06208228|Device|Kinesiotaping|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
79323340|NCT02364726|Behavioral|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
79323341|NCT02364726|Behavioral|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
79323342|NCT02352090|Drug|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
79323343|NCT02352090|Drug|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
79323344|NCT02352090|Drug|Dienogest|One tablet orally for 9 weeks, continuous use
79323345|NCT02277522|Biological|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
79323346|NCT02226432|Procedure|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~Comparision of both groups will be statistified"
79323347|NCT02226432|Device|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
79323348|NCT02226432|Other|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
79323349|NCT02159742|Other|Data Collection|
79809662|NCT05957705|Procedure|Dental implant placement using guided surgery|After 4 months of sinus augmentation, patients will be prepared to receive dental implants for oral rehabilitation. Performed by guided surgery the implants will be placed at the best location for the rehabilitation and at the place were the sinus lighting were performed.
79323350|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
79323351|NCT02135107|Drug|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
79323352|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
79480508|NCT04344158|Drug|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
79480509|NCT00384345|Device|Bright Light Therapy|
79480510|NCT00384345|Behavioral|Exercise|
79480511|NCT00003249|Drug|carboxyamidotriazole|
79480512|NCT00003249|Drug|chemotherapy|
79480513|NCT00003249|Drug|ketoconazole|
79480514|NCT03268343|Drug|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
79480515|NCT04329663|Device|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
79480516|NCT03744637|Drug|MK-5475|Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization
79809663|NCT05957666|Drug|Misoprostol Oral Tablet|oral misoprostol 50 microgram repeated after 6 hours if required
79809664|NCT05957666|Drug|vaginal misoprostol|vaginal misoprostol 50 microgram repeated after 6 hours if required
79480517|NCT03744637|Drug|Placebo|Single inhaled dose of placebo to match MK-5475
79480518|NCT00003255|Drug|carboplatin|
79809665|NCT05957653|Drug|lidocaine and sufentanil|A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.
79809666|NCT05957653|Drug|Saline|A total of 20ml normal saline was injected into the bladder through the catheter.
79809667|NCT05957640|Combination Product|Yttrium-90 carbon microspheres SIRT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
79809668|NCT05957614|Procedure|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
79976797|NCT06208202|Behavioral|Behavioral Intervention|Receive and use flavored e-cigarettes (EC) as directed
79323353|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
79323354|NCT02097706|Drug|NMDA receptor antagonist (active drug)|
79480519|NCT00003255|Drug|topotecan hydrochloride|
79480520|NCT03269435|Procedure|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
79480521|NCT03269435|Drug|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
79480522|NCT00003261|Drug|methotrexate|
79976798|NCT06208202|Other|Biospecimen Collection|Undergo biosample sample collection
79976799|NCT06208202|Other|Survey Administration|Complete surveys
79323355|NCT02097706|Other|Lactose packed capsule (inert/inactive arm)|
79323356|NCT02030847|Biological|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10^8 transduced CAR T cells
79323357|NCT02030847|Biological|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10^7 CART-19 cells.
79480523|NCT00003261|Drug|zidovudine|
79480524|NCT00003261|Procedure|neoadjuvant therapy|
79480525|NCT00003261|Radiation|radiation therapy|
79480526|NCT05288582|Device|NovaTears|Over-the-counter eye drop
79480527|NCT03279731|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
79646749|NCT04633798|Procedure|IPL/MGX|To treat patients with MGD using intense pulsed light combined with meibomian gland massage
79323358|NCT02030847|Biological|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
79323359|NCT02030847|Biological|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10^7), 30% on Day 2 (3x10^7-1.5x10^8), 60% on Day 3 (6x10^7-3x10^8).
79480528|NCT03279731|Drug|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
79480529|NCT03390257|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
79480530|NCT04524403|Drug|Miricorlilant|Miricorilant 600mg for oral dosing
79480531|NCT04524403|Drug|Miricorlilant|Miricorilant 900mg for oral dosing
79480532|NCT04524403|Drug|Miricorlilant|Placebo for oral dosing
79323360|NCT02030834|Biological|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
79480533|NCT05107934|Biological|RPH-104|solution for subcutaneous injection, 40 mg/mL
79646750|NCT04633486|Diagnostic Test|zoom-endoscopy|Endoscopic monitoring of intestinal transplant recipients is done with zoom-endoscopes for exact diagnostic of intestinal mucosa.
79646751|NCT04633525|Procedure|Optimum Cup Orientation|Participants will have X-rays taken before surgery to determine the target optimal zone for orientation of the cup implant, using EBRA software. The surgeon may or may not implant in this target zone, depending on what they believe is in the patient's best interest. X-rays will be taken at 12 months after surgery to determine if they target cup orientation was achieved.
79323361|NCT01982448|Drug|Cisplatin|
79646752|NCT00201708|Drug|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
79323362|NCT01982448|Drug|Paclitaxel|
79323363|NCT01980264|Device|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
79480534|NCT05107934|Drug|Placebo|0.9% Sodium Chloride solution for Injection
79480535|NCT03391115|Behavioral|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
79323364|NCT01885299|Radiation|SRS/SBRT|Intervention varies by condition being treated.
79323365|NCT01839838|Radiation|Proton Therapy|
79323366|NCT01837602|Biological|cMet RNA CAR T cells|
79323367|NCT01809041|Drug|Sevoflurane|
79323368|NCT01809041|Drug|propofol|
79323369|NCT01809041|Drug|remifentanil|
79323370|NCT01805466|Device|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
79323371|NCT01805466|Device|Conventional CPB|conventional miniature cardiopulmonary bypass technique
79323372|NCT01773421|Drug|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
79323373|NCT01773421|Drug|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
79323374|NCT01747486|Biological|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
79480536|NCT03391115|Behavioral|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
79323375|NCT01733238|Drug|PNT2258|
79480537|NCT04343690|Behavioral|Crisis management coaching|Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
79480538|NCT04477837|Drug|Apixaban 5 MG|frequency of heavy menstrual bleeding
79480539|NCT04477837|Drug|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
79480540|NCT04477837|Drug|Edoxaban 60 MG|frequency of heavy menstrual bleeding
79646753|NCT00201708|Drug|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
79480541|NCT04477837|Drug|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
79480542|NCT05099588|Other|Other: observational study|Observational study
79480543|NCT03397121|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
79480544|NCT03397121|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
79480545|NCT05267821|Drug|Anakinra|See information in arm/group descriptions
79480546|NCT05267821|Drug|Placebo|See information in arm/group descriptions
79646754|NCT00201708|Drug|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
79646755|NCT04632901|Diagnostic Test|VA assessment|"The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test."
79323376|NCT01689727|Drug|Technetium Tc 99m EC20|
79323377|NCT01689714|Drug|Tc 99m EC20|
79323378|NCT01689662|Drug|Tc 99m EC20|
79323379|NCT01689636|Drug|Tc 99m EC20|
79323380|NCT01686256|Drug|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
79323381|NCT01684098|Drug|Tc 99m EC20|
79323382|NCT01593254|Drug|Imatinib|
79323383|NCT01593254|Drug|Dasatinib|
79480547|NCT02264574|Drug|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
79323384|NCT01581489|Procedure|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
79323385|NCT01570998|Radiation|Intraoperative Radiation Therapy|Undergo IORT
79323386|NCT01570998|Other|Laboratory Biomarker Analysis|Correlative studies
79323387|NCT01559818|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
79323388|NCT01537601|Procedure|Circumcision|Circumcision
79323389|NCT01537601|Other|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
79323390|NCT01525394|Drug|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
79323391|NCT01525394|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
79323392|NCT01525394|Drug|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
79480548|NCT02264574|Drug|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
79323393|NCT01510678|Behavioral|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F&Vs is perceived cost of these foods, information regarding lower-cost options for F&Vs will be included in the manual.
79323394|NCT01510678|Behavioral|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
79323395|NCT01510678|Behavioral|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
79323396|NCT01454934|Drug|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
79480549|NCT02264574|Drug|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
79480550|NCT03398213|Other|Acupuncture|Acupuncture
79480551|NCT03398213|Other|Sham procedure|Ear stimulation with plaster
79480552|NCT00356785|Behavioral|health education|
79323397|NCT01454934|Drug|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
79323398|NCT01442246|Drug|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
79323399|NCT01439282|Drug|eribulin mesylate|Cohort I & II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
79323400|NCT01439282|Drug|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
79323401|NCT01391026|Behavioral|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
79323402|NCT01326312|Drug|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
79480553|NCT00356785|Behavioral|food supplementation|
79480554|NCT00356785|Behavioral|food supplementation combined with physical activity program|
79646756|NCT04632901|Diagnostic Test|CVA assessment|"The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed."
79323403|NCT01326312|Drug|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
79480555|NCT03668821|Other|Questionnaire|Quality of life and frailty questionnaires
79323404|NCT01326312|Drug|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
79480556|NCT03624049|Other|Exercise|Community based exercise programs held 2-3 times per week
79480557|NCT03624049|Other|Health Class|Community based health class held 1 time per week
79480558|NCT03400163|Drug|BMS-986036|BMS-986036 20 mg QD
79646757|NCT00410358|Drug|Gimatecan|
79646758|NCT04632979|Procedure|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
79646759|NCT04632862|Drug|DWP16001|DWP16001 A mg
79323405|NCT01321554|Drug|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
79480559|NCT03400163|Drug|Placebo|Placebo QD
79480560|NCT04412863|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
79480561|NCT04412863|Drug|pegylated interferon-alfa 2a|pegylated interferon-alfa 2a given by subcutaneous injection
79480562|NCT05498298|Device|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
79323406|NCT01321554|Drug|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
79480563|NCT03400475|Drug|Simvastatin|One topical application in peri-implant gingival crevice
79480564|NCT03400475|Other|Placebo|One topical application in peri-implant gingival crevice
79646760|NCT04633174|Device|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
79646761|NCT04633135|Device|Philips stove|Philips Smokeless stove HD4012LS
79646762|NCT04633135|Device|Gyapa stove|Wood stove made in Ghana
79976800|NCT06208176|Procedure|High-definition transcranial direct current (HD-tDCS), active condition|Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.
79323407|NCT01321554|Drug|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
79323408|NCT01308437|Biological|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
79323409|NCT01308437|Biological|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
79480565|NCT01641900|Drug|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
79646763|NCT00410397|Procedure|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
79646764|NCT00410397|Procedure|Sham Manipulation|Neutral positional, gentle palpation
79646765|NCT04632745|Other|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
79646766|NCT04632823|Combination Product|Comprehensive Non-pharmacological Treatment Program|dietary supplement, specific type of exercise, self-management education
79646767|NCT04632277|Other|Water|Participants will receive a tab water
79323410|NCT01269346|Drug|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
79323411|NCT01268293|Drug|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
79323412|NCT01268150|Drug|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
79976801|NCT06208176|Procedure|High-definition transcranial direct current (HD-tDCS), sham condition|Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
79323413|NCT01267175|Device|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
79646768|NCT04632277|Dietary Supplement|Water with low Mg|Participants will receive Low Mg bottle water (50mg/l)
79976802|NCT06208163|Procedure|Chiropractic|Chiropractic spinal adjustments
79976803|NCT06208137|Behavioral|Health monitoring and regular return follow-up reminders|Health monitoring & reminders for blood tests and follow-up visits until 1 year post-transplant
79323414|NCT01259908|Procedure|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
79646769|NCT04632277|Dietary Supplement|Water with high Mg|Participants will receive High Mg bottle water (100mg/l)
79646770|NCT00179504|Behavioral|Relaxation Response|Relaxation training
79323415|NCT01231841|Drug|cyclosporine|Given orally
79976804|NCT06208111|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
79976805|NCT06208098|Diagnostic Test|Salivary cortisol dosage|saliva sample at 8 - 9h & at T30
79976806|NCT06208085|Dietary Supplement|Avocado|Intervention arm
79976807|NCT06208072|Drug|Irbesartan 150mg|Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.
79976808|NCT06208072|Drug|Eplerenone 25 mg|Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
79323416|NCT01231841|Biological|anti-thymocyte globulin|Given IV
79323417|NCT01133756|Drug|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
79323418|NCT01133756|Drug|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
79323419|NCT01133756|Drug|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
79480566|NCT01641900|Drug|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
79480567|NCT03834571|Drug|Carboplatin|Given IV
79480568|NCT03834571|Drug|Cisplatin|Given IV
79480569|NCT03834571|Drug|Paclitaxel|Given IV
79646771|NCT04632355|Other|Interview|This interview will be conducted to collecting all outcomes about musculoskeletal pain in COVID-19 survivors
79646772|NCT04632472|Device|Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy|Cardiac resynchronization therapy trial comparing types of leads.
79646773|NCT00410436|Behavioral|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
79646774|NCT04632394|Diagnostic Test|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
79323420|NCT01126736|Drug|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
79480570|NCT03834571|Procedure|Patient Monitoring|Undergo active monitoring
79480571|NCT03834571|Radiation|Radiation Therapy|Undergo radiation
79646775|NCT04632394|Procedure|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
79480572|NCT05647668|Procedure|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
79480573|NCT00359918|Drug|fibrinolysis|Primary PCI
79480574|NCT00359918|Procedure|Primary PCI|Primary PCI
79480575|NCT03402659|Drug|neflamapimod|40 mg neflamapimod capsule
79646776|NCT00179543|Behavioral|Relaxation response|
79646777|NCT04632550|Procedure|Circumferential pulmonary vein isolation(CPVI) group|"PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~Evaluation of procedure time, radiofrequency ablation time~Evaluation of the complication after the procedure.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
79809669|NCT05957614|Procedure|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
79976809|NCT06208059|Other|manual acupuncture|In manual acupuncture, the scalp motor area on the lesion side will be needled and left in place for 30 minutes after obtaining qi. During the needle retention, the needles will be twisted intermittently for 2 minutes twice, at a frequency of approximately 200 r/min.
79976810|NCT06208059|Other|electroacupuncture|In electroacupuncture, the scalp motor area will be needled, and after obtaining qi, the treatment will involve applying electroacupuncture stimulation using a continuous wave with a frequency of 2 Hz. The intensity of the stimulation will be adjusted based on the patient's tolerance, and each treatment session will last for 30 minutes.
79480576|NCT03402659|Other|placebo|matching placebo capsule
79809670|NCT05957601|Other|No intervention was made as it was a descriptive epidemiological study.|No intervention was made as it was a descriptive epidemiological study.
79809671|NCT05957588|Other|Proning group|"Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed."
79976811|NCT06208033|Drug|SMET12|"platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~Toripalimab, IV, 3mg/kg，Q2W；~SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
79480577|NCT05270096|Other|Advice|non-interventional study
79480578|NCT00376571|Procedure|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
79480579|NCT00376649|Behavioral|lifestyle changing workshop|
79480580|NCT00376727|Biological|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
79480581|NCT00376727|Genetic|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
79480582|NCT00376727|Other|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
79480583|NCT00376727|Other|laboratory biomarker analysis|Cetuximab Pharmacodynamics
79480584|NCT00358592|Device|Mobius™ retractor|
79480585|NCT00358592|Device|traditional metal retraction instruments|
79323421|NCT01126736|Drug|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
79323422|NCT01126736|Drug|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
79323423|NCT01117844|Radiation|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
79976812|NCT06208033|Drug|SMET12|"platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~Toripalimab, IV, 3mg/kg，Q2W；~SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
79323424|NCT01111461|Drug|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
79323425|NCT01104155|Drug|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
79323426|NCT01104155|Drug|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
79323427|NCT01067287|Drug|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
79323428|NCT01067287|Biological|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
79323429|NCT01065597|Device|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
79323430|NCT01051856|Device|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
79323431|NCT01051856|Procedure|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
79809672|NCT05957588|Other|Control group|A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
79323432|NCT01029366|Biological|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
79323433|NCT00897767|Other|biologic sample preservation procedure|
79323434|NCT00879086|Drug|Eribulin Mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
79323435|NCT00879086|Drug|Ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
79480586|NCT03282071|Behavioral|Joyful Parenting Intervention|"Two-session interactive talks for parents to promote praise & appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
79809673|NCT05957562|Procedure|EA/TOF primary repair with Azygos vein preservation|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
79809674|NCT05957562|Procedure|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
79323436|NCT00796263|Drug|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily"
79323437|NCT00715442|Drug|Sunitinib|50 mg by mouth daily for 28 consecutive days
79323438|NCT00715442|Procedure|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
79323439|NCT00675922|Drug|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
79323440|NCT00591812|Device|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
79323441|NCT00466531|Biological|therapeutic autologous lymphocytes|
79323442|NCT00466531|Drug|cyclophosphamide|
79323443|NCT00458653|Biological|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
79323444|NCT00244933|Dietary Supplement|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
79480587|NCT05239585|Device|Epilog device|Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
79480588|NCT00359996|Behavioral|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
79480589|NCT00359996|Other|No additional educational sessions|
79480590|NCT05236153|Diagnostic Test|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
79976813|NCT06208033|Drug|SMET12|"chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~Toripalimab, IV, 3mg/kg，Q2W；~SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
79809675|NCT05957549|Other|Speech discrimination|Two different speech sounds are played at the same sound intensity.
79976814|NCT06207994|Device|Narrow TR|The width of the PRICO SpO2 TR is set to 3% SpO2.
79809676|NCT05957523|Device|Remote ischaemic preconditioning|The participant rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training will be performed twice daily (once in the morning and once in the evening), and heart rate and blood pressure before and after each training will be recorded for 7 days.
79809677|NCT05957497|Biological|Biological samples transport and analysis|Biological samples transport and analysis
79809678|NCT05957471|Drug|Drug: BC3195 for Injection|BC3195 via intravenous(IV).
79976815|NCT06207994|Device|Shifted TR|The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
79976816|NCT06207968|Device|Knee surgery with FH Ortho devices|"This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons."
79976817|NCT06207955|Drug|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A|TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
79976818|NCT06207955|Drug|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin|TMJ Arthrocentesis I-PRF Intra-articular Injection
79976819|NCT06207955|Drug|TMJ Arthrocentesis|TMJ Arthrocentesis By Saline
79976820|NCT06207838|Device|MiniMed 780G system|The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
79976821|NCT06207825|Diagnostic Test|Test images and videos|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.
79323445|NCT00244933|Drug|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
79976822|NCT06207799|Drug|Elranatamab|Given by SC
79976823|NCT06207799|Drug|Lenalidomide|Given by PO
79976824|NCT06207799|Drug|Plerixafor|Given by SC
79976825|NCT06207799|Drug|Melphalan|Given by IV
79976826|NCT06207799|Drug|Busulfan|Given by PO
79323446|NCT00244933|Procedure|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
79323447|NCT00165425|Procedure|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
79323448|NCT00121719|Drug|Lenvatinib|Lenvatinib tablets taken orally, once daily.
79323449|NCT00053209|Drug|gemcitabine hydrochloride|
79323450|NCT00053209|Drug|pemetrexed disodium|
79323451|NCT00039429|Drug|atrasentan hydrochloride|
79323452|NCT00014508|Biological|sargramostim|
79323453|NCT00014508|Drug|cyclophosphamide|
79323454|NCT00014508|Drug|cyclosporine|
79323455|NCT00014508|Drug|fludarabine phosphate|
79323456|NCT00014508|Drug|melphalan|
79323457|NCT00014508|Procedure|peripheral blood stem cell transplantation|
79323458|NCT00006390|Biological|alemtuzumab|
79323459|NCT00006390|Biological|filgrastim|
79323460|NCT00006390|Drug|cyclophosphamide|
79323461|NCT00006390|Procedure|peripheral blood stem cell transplantation|
79323462|NCT00006390|Radiation|radiation therapy|
79323463|NCT00005962|Biological|sargramostim|
79323464|NCT00005962|Drug|cyclophosphamide|
79323465|NCT00005962|Drug|cytarabine|
79323466|NCT00005962|Drug|gemtuzumab ozogamicin|
79323467|NCT00005962|Drug|liposomal daunorubicin citrate|
79323468|NCT00005962|Drug|topotecan hydrochloride|
79480591|NCT05468606|Biological|GA2|GA2 sporozoites administered by 50 mosquito bites
79480592|NCT05468606|Biological|BCG|0.1 mL BCG vaccine intradermally
79480593|NCT05468606|Biological|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
79646778|NCT04632550|Procedure|Posterior box isolation(POBI) group|"PVI will be performed using a radiofrequency catheter~Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~Esophageal temperature will be monitored to prevent esophageal injury.~The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~Evaluation of procedure time, radiofrequency ablation time~Evaluation of the complication after the procedure.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
79976827|NCT06207799|Drug|G-CSF|Given by IV
79976828|NCT06207799|Procedure|Stem cell transplant|Given by IV
79323469|NCT00005847|Biological|recombinant interferon alfa|
79480594|NCT05468606|Drug|Imiquimod|250mg imiquimod 5% cream topical
79976829|NCT06207786|Other|Povidone-Iodine Swabs|Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.
79323470|NCT00005847|Drug|estramustine phosphate sodium|
79323471|NCT00005847|Drug|isotretinoin|
79480595|NCT05468606|Other|Mock immunization|50 bites by uninfected mosquitoes
79480596|NCT04293289|Other|CICS-1 (investigational device),SPM-011(investigational drug)|Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
79480597|NCT04290871|Drug|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
79480598|NCT04290871|Other|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
79480599|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
79646779|NCT04632550|Procedure|POBI+Anterior linear ablation(AL) group|"PVI, POBI will be performed using a radiofrequency catheter~Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~Esophageal temperature will be monitored to prevent esophageal injury.~The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~Evaluation of procedure time, radiofrequency ablation time~Evaluation of the complication after the procedure.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
79646780|NCT04632082|Behavioral|Telepsychoeducation with personalized videos|1 session with a psychologist plus 1 video a week for 4 weeks chosen based on symptom presentation
79976830|NCT06207786|Diagnostic Test|Staphylococcus nasal swab|Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization
79323472|NCT00005847|Drug|mitoxantrone hydrochloride|
79323473|NCT00005847|Drug|paclitaxel|
79323474|NCT00005847|Drug|vinorelbine ditartrate|
79323475|NCT00005644|Drug|gemcitabine hydrochloride|
79323476|NCT00005644|Drug|paclitaxel|
79323477|NCT00003871|Biological|fowlpox virus vaccine vector|
79323478|NCT00003871|Biological|recombinant vaccinia prostate-specific antigen vaccine|
79323479|NCT00003809|Biological|cetuximab|
79976831|NCT06207786|Drug|Antibiotic|Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
79323480|NCT00003809|Drug|cisplatin|
79323481|NCT00003808|Drug|theophylline|
79323482|NCT00003800|Other|immunohistochemistry staining method|
79323483|NCT00003800|Other|laboratory biomarker analysis|
79323484|NCT00003800|Procedure|radionuclide imaging|
79323485|NCT00003649|Biological|Ad5CMV-p53 gene|
79323486|NCT00003592|Drug|methotrexate|
79323487|NCT00003592|Drug|paclitaxel|
79323488|NCT00003518|Drug|gemcitabine hydrochloride|
79323489|NCT00003518|Drug|paclitaxel|
79323490|NCT00003444|Biological|recombinant interferon alfa|
79323491|NCT00003444|Radiation|radiation therapy|
79323492|NCT00003388|Biological|filgrastim|
79323493|NCT00003388|Drug|cyclophosphamide|
79809679|NCT05957458|Device|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
79323494|NCT00003388|Drug|cytarabine|
79323495|NCT00003388|Drug|methotrexate|
79323496|NCT00003388|Drug|pegylated liposomal doxorubicin hydrochloride|
79323497|NCT00003388|Drug|prednisone|
79323498|NCT00003388|Drug|vincristine sulfate|
79323499|NCT00003388|Radiation|radiation therapy|
79323500|NCT00003376|Drug|carboplatin|
79323501|NCT00003376|Drug|cisplatin|
79323502|NCT00003376|Drug|doxorubicin hydrochloride|
79323503|NCT00003376|Drug|methotrexate|
79323504|NCT00003376|Drug|paclitaxel|
79323505|NCT00003376|Drug|vinblastine|
79323506|NCT00003353|Biological|filgrastim|
79323507|NCT00003353|Drug|melphalan|
79323508|NCT00003353|Procedure|bone marrow ablation with stem cell support|
79323509|NCT00003353|Procedure|peripheral blood stem cell transplantation|
79323510|NCT00003309|Biological|filgrastim|
79323511|NCT00003309|Drug|cisplatin|
79323512|NCT00003309|Drug|cyclophosphamide|
79323513|NCT00003309|Drug|etoposide|
79323514|NCT00003309|Drug|vincristine sulfate|
79323515|NCT00003309|Procedure|adjuvant therapy|
79323516|NCT00003309|Radiation|radiation therapy|
79323517|NCT00003308|Radiation|stereotactic radiosurgery|
79323518|NCT00003237|Drug|cisplatin|
79323519|NCT00003237|Drug|paclitaxel|
79323520|NCT00003237|Procedure|surgical procedure|
79323521|NCT00003129|Drug|valrubicin|
79323522|NCT00003027|Biological|aldesleukin|
79323523|NCT00003027|Biological|filgrastim|
79323524|NCT00003027|Biological|recombinant interferon alfa|
79323525|NCT00003027|Drug|cisplatin|
79323526|NCT00003027|Drug|dacarbazine|
79323527|NCT00003027|Drug|vinblastine|
79323528|NCT00002934|Procedure|long-term screening|
79323529|NCT00002914|Drug|piritrexim|
79323530|NCT00002872|Biological|bleomycin sulfate|
79323531|NCT00002872|Drug|doxycycline|
79323532|NCT00002872|Other|talc|
79323533|NCT00002868|Biological|filgrastim|
79323534|NCT00002868|Biological|recombinant interferon alfa|
79323535|NCT00002868|Drug|busulfan|
79323536|NCT00002868|Drug|cytarabine|
79323537|NCT00002868|Drug|etoposide|
79323538|NCT00002868|Drug|hydroxyurea|
79323539|NCT00002868|Drug|idarubicin|
79323540|NCT00002868|Procedure|peripheral blood stem cell transplantation|
79323541|NCT00002695|Genetic|DNA stability analysis|
79323542|NCT00002695|Genetic|microsatellite instability analysis|
79323543|NCT00002695|Genetic|mutation analysis|
79323544|NCT00002695|Other|laboratory biomarker analysis|
79323545|NCT00002668|Behavioral|Observation|
79323546|NCT00002668|Behavioral|Educational Intervention and Behavioral Skills Training|
79323547|NCT00002667|Other|cytology specimen collection procedure|
79323548|NCT00002667|Other|immunoenzyme technique|
79323549|NCT00002667|Procedure|study of high risk factors|
79323550|NCT00002650|Dietary Supplement|folic acid|
79323551|NCT03145987|Dietary Supplement|Vitis vinifera extract|
79323552|NCT03145987|Other|Placebo|
79323553|NCT05007665|Biological|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
79323554|NCT04477915|Other|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
79323555|NCT04477915|Other|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
79323556|NCT05007353|Behavioral|Structured Lifestyle Intervention|Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
79480600|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
79480601|NCT03283787|Device|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
79323557|NCT05007353|Behavioral|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
79323558|NCT03146065|Biological|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
79323559|NCT03146065|Drug|Placebo|Comparison of Placebo to different doses of PF-06730512
79323560|NCT03088397|Behavioral|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
79323561|NCT03088397|Behavioral|Website|Patient directed to website with information on various contraceptive methods.
79480602|NCT03284411|Device|Spinal Cord Stimulation|Programming
79323562|NCT03088397|Behavioral|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
79480603|NCT03465787|Drug|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
79480604|NCT03465787|Drug|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
79480605|NCT05071352|Drug|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
79480606|NCT05071352|Drug|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
79480607|NCT00376025|Dietary Supplement|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
79480608|NCT00376103|Drug|temozolomide|75 mg/m2/day
79480609|NCT00376103|Procedure|Brachytherapy|60 Gy to 1 cm
79323563|NCT03146455|Other|no intervention|no intervention
79323564|NCT03078725|Drug|Glyburide|oral hypoglycemic agent
79323565|NCT03078725|Drug|Metformin|oral hypoglycemic agent
79323566|NCT02346409|Device|tACS of the cerebellum|tACS of the cerebellum
79323567|NCT05007119|Procedure|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
79323568|NCT05007119|Procedure|Cupping|Cupping with blood letting
79480610|NCT00376103|Procedure|External Beam Radiation Therapy|60 Gy
79480611|NCT05259878|Other|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
79480612|NCT03403517|Drug|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
79480613|NCT03403517|Drug|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
79480614|NCT04281979|Drug|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
79480615|NCT04281979|Drug|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
79480616|NCT03404219|Behavioral|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
79480617|NCT01640808|Drug|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
79480618|NCT01640808|Drug|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
79646781|NCT04632082|Behavioral|Telepsychoeducation without personalized videos|1 session with a psychologist focused on reassurance and aspects of the outbreak
79646782|NCT04632160|Device|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
79646783|NCT00179582|Drug|VSL#3|
79646784|NCT04632121|Drug|Nicorandil 20 MG|Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
79646785|NCT04631887|Behavioral|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
79646786|NCT00186732|Procedure|Subcuticular Suture|
79646787|NCT00186732|Procedure|Surgical Staples|
79646788|NCT00560911|Behavioral|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
79976832|NCT06207773|Other|Educator verbal feedback|the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
79976833|NCT06207760|Drug|Minocycline|Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
79976834|NCT06207747|Diagnostic Test|additional PET/CT at 4 weeks, analysing using quantative analysis|Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
79323569|NCT02346487|Drug|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day~Between 6 and 9.9kg: 3 capsules twice a day~Between 10 and 13.9kg: 4 capsules twice a day~Between 14 and 19.9kg: 5 capsules twice a day~Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~Between 3 and 5.9kg: 1 tablet twice a day~Between 6 and 9.9kg: 1.5 tablets twice a day~Between 10 and 13.9kg: 2 tablets twice a day~Between 14 and 19.9kg: 2.5 tablets twice a day~Between 20 and 24.9kg: 3 tablets twice a day"
79976835|NCT06207721|Drug|Polyethylene Glycols|Polyethylene Glycols syrup (0.7 g/kg daily)
79323570|NCT03086837|Behavioral|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
79976836|NCT06207721|Other|Physical therapy program|The physical therapy program includes exercises and massage
79976837|NCT06207708|Other|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
79323571|NCT02341963|Drug|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
79480619|NCT03404375|Device|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
79646789|NCT00560911|Behavioral|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
79323572|NCT05007197|Behavioral|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
79323573|NCT05006651|Device|McGrath MAC|Intubaion with McGrath MAC
79323574|NCT05006651|Device|Trachway|Intubaion with Trachway
79323575|NCT05014685|Drug|Rabeprazole|20mg bid
79323576|NCT05014685|Drug|Bismuth potassium citrate|0.6g bid
79323577|NCT05014685|Drug|Metronidazole|0.4g tid
79646790|NCT00179699|Drug|CC-5013|
79323578|NCT05014685|Drug|Amoxicillin|1g tid
79323579|NCT03111823|Behavioral|Exercise Intervention|Undergo aerobic exercise sessions
79323580|NCT03111823|Other|Quality-of-Life Assessment|Ancillary studies
79323581|NCT03111823|Other|Questionnaire Administration|Ancillary studies
79480620|NCT05227885|Other|questionnaire form|A questionnaire will be applied to all participants. A questionnaire form will be applied to collect data on demographic information, pain, disease activity, nutritional habits, physical activity status and physical functional status of the patients included in the study.
79976838|NCT06207708|Diagnostic Test|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
79323582|NCT02346097|Device|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
79323583|NCT05014763|Procedure|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
79323584|NCT05015309|Drug|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
79323585|NCT02345785|Other|urologic surgery and caudal block|
79323586|NCT05006495|Procedure|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
79323587|NCT05006495|Procedure|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
79323588|NCT03111901|Drug|Pembrolizumab|Pembrolizumab solution
79323589|NCT03111901|Drug|Interleukin-2|Interleukin-2 solution
79323590|NCT02345941|Other|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
79323591|NCT02345941|Other|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
79323592|NCT05014607|Biological|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 5-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
79323593|NCT04816357|Other|Questionaire|only questionaire
79323594|NCT02341729|Drug|ticagrelor|crushed tablets and non-crushed tablets
79323595|NCT05014373|Combination Product|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
79480621|NCT00421681|Behavioral|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
79646791|NCT00179699|Drug|pemetrexed|
79976839|NCT06207695|Behavioral|Brief Group Intervention|This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
79976840|NCT06207682|Drug|Avacopan|Orally via capsules
79976841|NCT06207682|Drug|Simvastatin|Orally via tablets
79323596|NCT05014373|Procedure|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
79323597|NCT02039245|Drug|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
79323598|NCT03083951|Procedure|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
79323599|NCT03083951|Procedure|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
79323600|NCT04762459|Drug|Almonertinib|Almonertinib 110mg PO once daily
79323601|NCT04762459|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
79323602|NCT04762459|Drug|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
79323603|NCT03078569|Drug|Testosterone gel|treatment with testosterone gel
79323604|NCT03078335|Other|Glove based care|Described in Experimental Arm: Glove based care
79480622|NCT05068310|Device|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
79323605|NCT03078335|Other|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
79323606|NCT02345863|Drug|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
79323607|NCT02345863|Drug|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
79646792|NCT04631614|Other|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
79646793|NCT04631614|Other|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
79976842|NCT06207669|Other|Music therapy|Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
79976843|NCT06207656|Drug|EBC|"Patients will receive the following per 28-day cycle:~Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
79976844|NCT06207643|Procedure|carotid endarterectomy|removing carotid artery atheromatous plaque surgically
79976845|NCT06207617|Procedure|Immediate implant placement + customized healing abutment|Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
79976846|NCT06207617|Procedure|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
79976847|NCT06207604|Procedure|Open sinus lifting without bone grafting and simultaneous implant placement|no bone graft will be used after open sinus lifting
79976848|NCT06207604|Procedure|Open sinus lifting with bone grafting and simultaneous implant placement|bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
79323608|NCT02345863|Drug|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
79323609|NCT03078257|Drug|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
79323610|NCT03078257|Drug|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
79323611|NCT03078257|Drug|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
79323612|NCT03078257|Drug|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
79323613|NCT03078257|Drug|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
79323614|NCT03078257|Drug|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
79323615|NCT03078257|Drug|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
79323616|NCT02341573|Drug|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
79323617|NCT02341573|Drug|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
79323618|NCT02346019|Procedure|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
79323619|NCT05005715|Drug|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
79480623|NCT05068310|Device|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
79646794|NCT04631614|Other|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
79976849|NCT06207591|Device|ECoG (electrocorticography) sensing|Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
79976850|NCT06207578|Procedure|implant placement using crestal sinus approach|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
79323620|NCT05005715|Drug|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
79646795|NCT04631614|Other|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
79323621|NCT02341651|Other|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
79323622|NCT03083795|Behavioral|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
79976851|NCT06207578|Procedure|Implant placement using osseodensification|The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
79976852|NCT06207565|Procedure|Vestibular Flap Group|Achieving the vestibular flap, a 1-cm long horizontal vestibular access incision using a 15c blade 3-4mm apical to the mucogingival junction of the hopeless tooth, exposing the alveolar bone. Flap dissection in a coronal direction to detach the periosteum is completed, forming a sub-periosteal tunnel.
79323623|NCT02345707|Drug|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
79323624|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
79323625|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
79323626|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
79323627|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
79323628|NCT02341339|Procedure|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
79323629|NCT05005481|Other|NIL intervention|NIL intervention will be performed on patients.
79323630|NCT02345473|Genetic|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
79976853|NCT06207565|Procedure|Single Flap Approach group|A modified envelope flap originally reported as an access flap for single implant insertion in areas of esthetic relevance will be performed. A sulcular incision on the labial aspect extending at least one tooth mesial and distal to the implant site (permitting enough accessibility for bone augmentation) is done. The flap is reflected by performing a split-thickness flap elevation starting from the interproximal incisions, leaving the anatomical papillae in situ. While the full-thickness flap elevation is performed on the labial aspect of the included surgical area, starting at the sulcus, and reaching at least 3 mm apical to the bone crest.
79323631|NCT05005637|Drug|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 4RH (4 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
79323632|NCT05005637|Drug|Prednisone tablet|Oral prednisone will be given at the dose of 1 mg/kgBW/day (max 60 mg/day) until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
79323633|NCT03078179|Dietary Supplement|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
79323634|NCT03078179|Dietary Supplement|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
79323635|NCT02341183|Device|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
79976854|NCT06207539|Drug|hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
79323636|NCT02341183|Device|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
79323637|NCT05013515|Drug|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
79323638|NCT02345551|Behavioral|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
79323639|NCT05013671|Other|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
79323640|NCT05013671|Other|balance|compare the balance of residents with BPPV with residents without BPPV
79646796|NCT04631614|Other|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
79976855|NCT06207539|Drug|misoprostol under the generic name of misotac tablets|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
79976856|NCT06207526|Behavioral|Blended face-to-face and smartphone intervention|The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
79976857|NCT06207513|Procedure|Suction Circuit Flushing with Chlorhexidine|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
79976858|NCT06207500|Procedure|Pharmacist-led Medication Reconciliation|The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
79976859|NCT06207474|Other|Video + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
79976860|NCT06207474|Other|Video + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
79976861|NCT06207474|Other|Paper + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
79323641|NCT02341261|Behavioral|Standard Care Counseling|
79323642|NCT02341261|Behavioral|Supervised Exercise and Counseling|
79323643|NCT02336893|Behavioral|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
79809680|NCT05957419|Procedure|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
79809681|NCT05957380|Drug|DA-2803|All participants are administered one tablet per day for 48 weeks
79809682|NCT05957380|Drug|DA-2803-R|All participants are administered one tablet per day for 48 weeks
79976862|NCT06207474|Other|Paper + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
79976863|NCT06207435|Behavioral|Transportation|Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
79976864|NCT06207422|Other|Moderate intensity training program|A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = [(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
79976865|NCT06207422|Other|High intensity training program|A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
79323644|NCT05013203|Diagnostic Test|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
79323645|NCT05013203|Diagnostic Test|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
79976866|NCT06207396|Diagnostic Test|serum and urine analysis|Spiking will be analyzed by immunoassay testing and high-resolution screening
79323646|NCT03082469|Device|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
79323647|NCT02336659|Drug|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
79323648|NCT02336659|Drug|sitagliptin|DPP-4 Inhibition
79323649|NCT02336659|Other|Placebo|Saline
79323650|NCT03082625|Drug|Transdermal Magnesium|Magnesium
79976867|NCT06207383|Device|Conduction system pacing|Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
79976868|NCT06207383|Procedure|Atrioventricular nodal ablation|Catheter ablation of the atrioventricular node
79976869|NCT06207383|Procedure|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
79976870|NCT06207370|Drug|Tafenoquine|Oral Tafenoquine
79976871|NCT06207370|Other|Placebo|Placebo
79323651|NCT03082625|Drug|Placebo|
79323652|NCT02336581|Behavioral|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
79323653|NCT02336581|Behavioral|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
79323654|NCT03081923|Drug|Durvalumab|anti-PD-L1 mono therapy
79323655|NCT03081923|Drug|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
79323656|NCT02345395|Procedure|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
79323657|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
79323658|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
79323659|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
79323660|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
79323661|NCT02341105|Procedure|Catheter ablation|Pulmonary vein isolation by catheter ablation
79323662|NCT02341105|Drug|Amiodarone|antiarrhythmic therapy using Amiodarone
79323663|NCT03078101|Drug|Empagliflozin 10 MG [Jardiance]|administered orally once daily
79323664|NCT03078101|Drug|Placebo Oral Tablet|administered orally once daily
79323665|NCT03082079|Procedure|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
79480624|NCT05068310|Device|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
79480625|NCT05068310|Device|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
79646797|NCT04631614|Other|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
79809683|NCT05957380|Drug|Placebo of DA-2803|All participants are administered one tablet per day for 48 weeks
79809684|NCT05957380|Drug|Placebo of DA-2803-R|All participants are administered one tablet per day for 48 weeks
79809685|NCT05957341|Device|active rTMS: 20min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 20 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
79323666|NCT02345239|Drug|Pantoprazole|proton pump inhibitor
79323667|NCT02340871|Genetic|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
79323668|NCT03081767|Diagnostic Test|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
79323669|NCT02340793|Dietary Supplement|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
79323670|NCT03081065|Dietary Supplement|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
79323671|NCT04688203|Drug|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
79480626|NCT03404609|Device|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
79480627|NCT02263326|Drug|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
79323672|NCT04688203|Drug|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
79480628|NCT02263326|Drug|lamivudine|300 mg tablet by mouth once daily for 48 weeks
79480629|NCT02263326|Drug|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
79480630|NCT02977520|Procedure|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
79480631|NCT04344925|Device|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
79480632|NCT04344925|Device|Standard Mask|Patient will be put on BIPAP using the standard mask
79480633|NCT00356317|Behavioral|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
79480634|NCT00356317|Behavioral|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
79480635|NCT00356395|Drug|ramipril, candesartan|
79323673|NCT03145753|Other|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
79480636|NCT05485038|Procedure|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
79480637|NCT05485038|Procedure|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
79480638|NCT00356473|Drug|Atorvastatin|
79480639|NCT04036903|Radiation|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
79480640|NCT05461742|Behavioral|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
79323674|NCT03145753|Other|HIV/HCV Education|Only education and support will be provided in this arm
79323675|NCT04679233|Other|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
79480641|NCT03407651|Biological|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
79976872|NCT06207357|Procedure|optical trocar to create the pneumoperitoneum for bariatric surgery|The technique involves the use of 4 12 mm trocars. Pneumoperitoneum is induced by a 0° optical trocar and maintained at 15 mmHg. The first trocar is usually inserted along the left mid-clavicular line approximately 2 fingers from the costal arch, another trocar along the left axillary line, a third trocar 1 cm to the right of the midline, and the fourth trocar along the right mid-clavicular line. A 10 mm, 30 ° laparoscope is used.
79323676|NCT03145597|Device|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
79976873|NCT06207344|Drug|Dexmedetomidine and propofol|Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
79323677|NCT03145597|Device|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
79323678|NCT02336035|Procedure|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
79480642|NCT00356941|Drug|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
79480643|NCT00356941|Drug|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
79480644|NCT00356941|Procedure|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
79809686|NCT05957341|Device|active rTMS: 50min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 50 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
79323679|NCT05254561|Biological|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
79809687|NCT05957341|Device|sham rTMS: 20min inter-session interval|The parameters in this group are the same as in the active rTMS: 20min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
79323680|NCT04536025|Other|Qualitative focus group interviews|Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
79323681|NCT04536025|Other|Qualitative semi-structured interviews|People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
79323682|NCT04509973|Drug|Dexamethasone|ATC code: H02AB02
79976874|NCT06207344|Drug|Dexmedetomidine and desflurane|Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
79323683|NCT02637557|Drug|IW-3718|
79976875|NCT06207331|Drug|Dexmedetomidine 0.5 μg/kg|Participants inhale the atomized 0.5 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
79976876|NCT06207331|Drug|Dexmedetomidine 1 μg/kg|Participants inhale the atomized 1 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
79976877|NCT06207331|Drug|Saline|Participants inhale atomized 2 ml 0.9% saline.
79323684|NCT02637557|Drug|Matching Placebo|
79480645|NCT05456672|Other|Test meals and food baskets|"Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)"
79480646|NCT03338881|Drug|[14C]-TAK-659|[14C]-TAK-659 solution.
79976878|NCT06207318|Behavioral|Acceptance and commitment therapy|The intervention will be based on Acceptance and Commitment Therapy (ACT). ACT is an empirically-based therapeutic approach that focuses on psychological flexibility, acceptance, and the reduction of experiential avoidance. It encourages individuals to change their relating to thoughts and experiences and act in accordance with their values.
79323685|NCT02637557|Drug|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
79480647|NCT03338881|Drug|TAK-659|TAK-659 tablets.
79480648|NCT03450083|Drug|Benralizumab|30mg Benralizumab will be delivered subcutaneously
79323686|NCT04491253|Behavioral|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
79480649|NCT03450083|Drug|Placebo|Subcutaneous placebo injection
79480650|NCT03289507|Dietary Supplement|Treatment1|Longvida Capsule formulation A
79480651|NCT03289507|Dietary Supplement|Treatment2|Longvida Capsule formulation B
79323687|NCT04480645|Device|CivaDerm|radioactive bandage
79480652|NCT03289507|Dietary Supplement|Treatment3|Curcuma longa extract of Rhizomes
79976879|NCT06207292|Radiation|Stereotactic Ablative Radiotherapy|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"
79323688|NCT05254249|Drug|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
79976880|NCT06207279|Diagnostic Test|rating|rating scales, test ANT
79323689|NCT05254249|Other|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
79323690|NCT03145909|Drug|ABBV-176|Intravenous infusion
79976881|NCT06207266|Behavioral|emotion intelligence program|The programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program.
79323691|NCT02344927|Other|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
79323692|NCT02344927|Other|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
79323693|NCT02344849|Drug|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
79480653|NCT03578549|Device|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
79323694|NCT02336113|Behavioral|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
79323695|NCT03145363|Behavioral|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
79323696|NCT03145363|Behavioral|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
79323697|NCT02336191|Procedure|living donor liver transplantation|living donor liver transplantation
79976882|NCT06207253|Drug|Diclofenac Sodium|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
79976883|NCT06207253|Drug|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
79976884|NCT06207240|Device|NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve|Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
79976885|NCT06207227|Device|VITA AV Clinical System|The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
79976886|NCT06207188|Other|Non-Interventional Study|Non-interventional study
79480654|NCT05042960|Other|Brightness|Changing the colors or brightness on the device (computer screen) for one month
79323698|NCT02336347|Drug|AVP-786|
79323699|NCT02336347|Drug|AVP-923|
79323700|NCT02341027|Device|Jadelle|within 5 days of delivery and before discharge from hospital
79323701|NCT02341027|Device|Jadelle|6-8 weeks (42-56 days) postpartum
79323702|NCT03112291|Procedure|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
79480655|NCT03580343|Drug|tofacitinib|tofacitinib extended release, 11mg, daily, oral
79480656|NCT05445440|Drug|Methotrexate|Specified dose on specified days
79323703|NCT02340637|Behavioral|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
79480657|NCT05445440|Drug|Leucovorin|Specified dose on specified days
79480658|NCT05445440|Drug|BMS-986371|Specified dose on specified days
79480659|NCT05445440|Drug|Sulfasalazine|Specified dose on specified days
79480660|NCT05041322|Drug|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
79976887|NCT06207136|Other|Mediterranean-style diet|Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
79976888|NCT06207123|Drug|LP-118|LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
79976889|NCT06207123|Drug|Ponatinib|Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
79976890|NCT06207123|Drug|Vincristine|Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
79976891|NCT06207123|Drug|Dexamethasone|Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
79976892|NCT06207123|Drug|Methotrexate|Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
79976893|NCT06207097|Other|physiotherapy techniques|Dry neeling: invasive physiotherapy technique where an acupuncture needle is used on painful points Elastic taping: physiotherapy technique where elastic bandage is used on the skin Exercise program: physical exercise prescription
79976894|NCT06207045|Procedure|limb elevation|limb elevation more than 45 degrees
79976895|NCT06207019|Device|Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold|rotary single files
79976896|NCT06207006|Behavioral|eConquerFear-HK|The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
79976897|NCT06207006|Behavioral|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
79976898|NCT06206993|Behavioral|Resistance training including the Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Experimental group will additionally train with Kieser A5 pelvic floor trainer.
79976899|NCT06206993|Behavioral|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Active Comparator trains without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts.
79323704|NCT02340637|Behavioral|TAU|Treatment as usual
79323705|NCT02335879|Biological|Gonal-F|
79480661|NCT05041322|Drug|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
79480662|NCT00422825|Drug|imatinib|
79976900|NCT06206980|Other|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
79323706|NCT05005325|Other|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
79323707|NCT05005325|Other|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
79323708|NCT03077945|Behavioral|heart rate variability biofeedback and cognitive reappraisal|
79323709|NCT03077945|Behavioral|control tasks|
79323710|NCT02039479|Drug|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
79323711|NCT02039479|Drug|Placebo|Placebo as ADD-on to every necessary treatment as usual
79976901|NCT06206980|Other|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
79976902|NCT06206967|Other|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
79976903|NCT06206967|Other|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
79976904|NCT06206954|Behavioral|MyHealthPath Tool|Tailored, brief online tool to help patients learn about weight treatment options
79480663|NCT03453515|Behavioral|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
79809688|NCT05957341|Device|sham rTMS: 50min inter-session interval|The parameters in this group are the same as in the active rTMS: 50min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
79323712|NCT05013281|Procedure|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
79480664|NCT03453515|Behavioral|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
79480665|NCT05036486|Genetic|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
79976905|NCT06206954|Behavioral|MyHealthPath Guide|Informational material to help patients learn about weight treatment options
79323713|NCT05013125|Diagnostic Test|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
79323714|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
79323715|NCT02340481|Drug|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
79323716|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
79323717|NCT02340481|Drug|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
79323718|NCT03077867|Procedure|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
79809689|NCT05957328|Drug|Ferric Pyrophosphate Liposomal|Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
79809690|NCT05957328|Drug|ferrous ascorbate|one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
79809691|NCT05957315|Device|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
79809692|NCT05957302|Drug|Ketamine|100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
79323719|NCT04426279|Other|questionnaire assesment|15-minute face-to-face questionnaire
79323720|NCT05012501|Diagnostic Test|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
79323721|NCT02344771|Procedure|Elective colon cancer surgery|
79809693|NCT05957302|Drug|Fentanyl|100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
79809694|NCT05957263|Other|Biofeedback training and Osteopathy procedure|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscle. muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, l
79809695|NCT05957263|Other|Biofeedback training|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.
79809696|NCT05957263|Other|Osteopathy procedure|specific techniques included muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. In addition, there was a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, low amplitude manipulation performed three times a week for 15 minutes each session for 10 weeks.
79809697|NCT05957250|Diagnostic Test|[68Ga]Ga-FAPI-46 PET/CT|one or two [68Ga]Ga-FAPI-46 PET/CT scan(s)
79323722|NCT03077633|Procedure|Cervical Cerclage placement|Cervical Cerclage placement
79323723|NCT03077633|Drug|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
79480666|NCT03456245|Device|Vision device validation|Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
79480667|NCT05229614|Radiation|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy[RBE], 8 Gy[RBE]/fraction, one fraction/day, for 3 days.
79480668|NCT05229614|Drug|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
79480669|NCT05433194|Biological|ABO1009-DP|Vaccine
79480670|NCT02977754|Other|This is an observational study|Imaging
79480671|NCT00360074|Drug|Thyroxin, Triiodothyronine|
79480672|NCT05219396|Device|Knee arthroplasty|Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
79480673|NCT02260986|Drug|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
79646798|NCT04631614|Other|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
79976906|NCT06206915|Drug|XZ120 injection|in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
79976907|NCT06206889|Other|NAS|NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
79976908|NCT06206863|Other|Exercise Intervention|Participate in virtual exercise classes
79323724|NCT05005169|Diagnostic Test|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
79480674|NCT02260986|Drug|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
79480675|NCT02260986|Other|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
79480676|NCT05421650|Radiation|CCRT|"Radiation: Extended field-external beam radiation therapy (EF-EBRT) + brachytherapy + lymph node boost.~Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~Radiation and chemotherapy are administered concurrently."
79480677|NCT05421650|Procedure|Surgical debulking of bulky or multiple lymph nodes|"Open/minimally invasive method.~Surgical debulking of bulky or multiple lymph nodes.~Postoperative imaging evaluation to determine whether the lymph node has been successfully removed."
79480678|NCT05421650|Radiation|CCRT|"Radiation: EBRT/EF-EBRT + brachytherapy + lymph node boost.~Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~Radiation and chemotherapy are administered concurrently."
79976909|NCT06206863|Other|Questionnaire Administration|Ancillary studies
79323725|NCT05005169|Diagnostic Test|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
79323726|NCT05253781|Drug|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
79323727|NCT05253781|Other|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
79323728|NCT05012423|Drug|Placebo|"Matching Placebo~Placebo will be administered as oral capsules."
79323729|NCT05012423|Drug|ECC0509|"ECC0509 1 mg and 10 mg capsules~ECC0509 will be administered as oral capsules."
79323730|NCT05012423|Drug|Placebo|"Matching Placebo~Placebo will be given orally during each dosing day."
79323731|NCT05012423|Drug|ECC0509|"ECC0509 1 mg and 10 mg capsules~Placebo will be given orally during each dosing day."
79480679|NCT05210582|Drug|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
79480680|NCT05009420|Other|Avocado|avocado served with crackers as breakfast
79480681|NCT05408156|Other|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
79323732|NCT03077477|Drug|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
79323733|NCT03077477|Drug|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
79323734|NCT02344615|Procedure|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
79323735|NCT02344615|Procedure|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
79323736|NCT03145519|Device|Vasofix Certo Catheter|Placement of IV-catheter
79323737|NCT03145519|Device|OptiVein Catheter|Placement of IV-catheter
79323738|NCT02340559|Behavioral|Meta-cognitive Training|
79323739|NCT02340559|Behavioral|Psychoeducational group|
79480682|NCT05647356|Drug|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
79480683|NCT05200676|Device|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
79480684|NCT05200676|Device|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
79809698|NCT05957224|Other|Shake 1 then Shake 2|Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake
79809699|NCT05957224|Other|Shake 2 then Shake 1|Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
79809700|NCT05957172|Device|ZOLL Arrhythmia Management System|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)
79976910|NCT06206811|Drug|OD-07656|innate immune modulator
79480685|NCT05647278|Drug|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
79480686|NCT05647278|Drug|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
79976911|NCT06206798|Behavioral|Resourcefulness Group|The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
79976912|NCT06206772|Diagnostic Test|Resting state HD-EEG recording|All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
79976913|NCT06206759|Drug|administration of vitamin C|administration of vitamin C to ICU patients
79976914|NCT06206733|Drug|ASKB589|ASKB589 will be administered as a minimum 3-hour IV infusion
79323740|NCT02340325|Drug|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
79323741|NCT02340325|Drug|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
79976915|NCT06206733|Drug|Oxaliplatin|Oxaliplatin will be administered as a minimum 2-hour IV infusion
79646799|NCT04631614|Other|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
79976916|NCT06206733|Drug|Capecitabine|Capecitabine will be administered orally twice daily (bid).
79976917|NCT06206733|Drug|Tislelizumab|Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
79976918|NCT06206733|Drug|Placebo|Placebo will be administered as a minimum 3-hour IV infusion
79976919|NCT06206720|Drug|Deuremidevir Hydrobromide for Suspension|"15 mg/kg group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, 10 times.~30 mg/kg group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, 10 times.~50 mg/kg group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, 10 times."
79976920|NCT06206720|Drug|Placebo|"15 mg/kg group: 5 subjects will receive placebo once every 12 hours, 10 times.~30 mg/kg group: 5 subjects will receive placebo once every 12 hours, 10 times.~50 mg/kg group: 5 subjects will receive placebo once every 12 hours, 10 times."
79976921|NCT06206681|Procedure|Ultra-pulsed Carbon Dioxide Laser|Excision of eyelid lesion
79323742|NCT05229367|Other|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
79976922|NCT06206668|Other|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
79976923|NCT06206642|Diagnostic Test|PET/CT|Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
79976924|NCT06206590|Other|Whole-proteomic assay|Whole-proteomic analysis was performed on all the blood samples
79976925|NCT06206577|Procedure|Horizontal ridge augmentation by symphyseal bone block placed and fixed buccally as onlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed buccally in deficient area with fixation screws
79976926|NCT06206577|Procedure|Horizontal ridge augmentation by symphyseal bone block interpositioned in space created between buccal and lingual cortex as inlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed in bone split created at deficient area with fixation screws
79976927|NCT06206564|Drug|Artesunate ointment|Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
79976928|NCT06206564|Drug|Placebo|Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
79976929|NCT06206551|Other|Spiritual Needs Questionnaire|This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
79323743|NCT05229367|Other|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
79323744|NCT02340247|Other|Water|
79323745|NCT02340247|Drug|Ursodeoxycholic Acid|
79323746|NCT02340247|Drug|Chenodeoxycholic Acid|
79323747|NCT02340013|Drug|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
79323748|NCT02339857|Procedure|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
79323749|NCT02638337|Drug|Ospemifene|60 mg tablet
79323750|NCT02638337|Drug|Placebo|Tablet identical to the ospemifene tablet without drug
79323751|NCT02339935|Behavioral|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
79323752|NCT02339935|Other|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
79323753|NCT02339623|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound~- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~- CL measurement using 2D ultrasound"
79323754|NCT05178823|Drug|Chlorhexidine mouthwash|Comparison of oral rinses
79323755|NCT02335567|Other|there is no intervention|
79323756|NCT03105583|Drug|Medication use during pregnancy|
79323757|NCT03105583|Dietary Supplement|Supplement use during pregnancy|
79323758|NCT03105583|Other|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
79323759|NCT03105115|Drug|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
79323760|NCT03105115|Drug|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
79323761|NCT03080831|Drug|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
79323762|NCT03080831|Drug|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
79323763|NCT03105349|Drug|elbasvir/grazoprevir|16 weeks treatment
79323764|NCT03105349|Drug|Sofosbuvir|16 weeks treatment
79323765|NCT03105349|Drug|Ribavirin|16 weeks treatment
79323766|NCT03077555|Drug|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
79323767|NCT03077555|Drug|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
79480687|NCT05407142|Biological|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
79480688|NCT05407142|Other|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
79976930|NCT06206512|Drug|Extended release torsemide|This is an extended-release formulation of torsemide
79323768|NCT02335723|Device|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
79323769|NCT02335723|Device|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
79323770|NCT05005091|Dietary Supplement|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
79323771|NCT02335645|Other|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
79323772|NCT03080285|Device|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
79323773|NCT03080285|Device|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
79323774|NCT02335333|Other|No treatment|
79480689|NCT04986800|Behavioral|PROACTIVE Parent|PROACTIVE Parent will educate parents about their child's mental health symptoms and treatment, how to talk to the child's therapist to support treatment goals at home and in the community. PROACTIVE Parent will teach parents the function of child behavior, the role of symptomatology in child behaviors, and strategies to promote effective behavior management and healthy coping. Parents will also learn skills to manage their own emotional dysregulation to promote calm parental responding and promote healthy parent-child interaction and communication.
79480690|NCT00360152|Procedure|Fine needle aspiration biopsy (FNAB)|
79480691|NCT00360152|Procedure|Sentinel Lymph Node Biopsy|
79480692|NCT05181800|Other|FIRMAGON Cohort|Non-interventional
79480693|NCT02977364|Drug|HS-10241|
79480694|NCT05181020|Behavioral|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
79976931|NCT06206512|Drug|Immediate release torsemide|This is the generic, immediate release formulation of torsemide
79976932|NCT06206512|Drug|Extended release torsemide placebo|Placebo of extended release torsemide
79480695|NCT00358748|Drug|Hydrocortisone|See detailed description above.
79480696|NCT05383664|Other|Ultra Violet Light Exposure|Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
79480697|NCT00359606|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
79323775|NCT03077321|Behavioral|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
79646800|NCT00201747|Drug|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
79480698|NCT00359606|Other|Laboratory Biomarker Analysis|Correlative Studies
79480699|NCT00359606|Other|Pharmacological Study|Correlative Studies
79480700|NCT00359606|Drug|Tetrahydrouridine (THU)|Given PO and IV
79480701|NCT00359840|Drug|darbepoetin alfa|
79480702|NCT02259582|Drug|Pemetrexed|
79480703|NCT02259582|Drug|Carboplatin|
79480704|NCT02259582|Drug|demcizumab|
79480705|NCT00360386|Drug|Clopidogrel|
79480706|NCT02977208|Procedure|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
79480707|NCT02977208|Procedure|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
79646801|NCT00201747|Drug|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
79646802|NCT04632004|Other|Invitation to participate|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
79480708|NCT02977208|Procedure|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms
79480709|NCT02977208|Drug|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
79480710|NCT03238651|Drug|TAK-659|TAK-659 Tablets.
79480711|NCT04866108|Drug|fruquintinib plus capecitabine|oral fruquintinib plus capecitabine
79480712|NCT04343768|Drug|Hydroxychloroquine|This Drug will be used in all arms.
79480713|NCT04343768|Drug|Lopinavir / Ritonavir|This Drug will be used in all arms.
79646803|NCT04631458|Other|standard of care.|Observational trial.
79646804|NCT00179738|Drug|CC5013|
79646805|NCT04631653|Device|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
79646806|NCT00186771|Device|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
79646807|NCT00186771|Device|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
79646808|NCT04631341|Dietary Supplement|Melatonin|Melatonin 5mg every night, for one year
79480714|NCT04343768|Drug|Interferon Beta-1A|This drug will be only used in Arm 1.
79480715|NCT04343768|Drug|Interferon Beta-1B|This drug will be only used in Arm 2.
79646809|NCT04723238|Drug|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
79323776|NCT03077321|Behavioral|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
79323777|NCT02335255|Drug|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
79323778|NCT02335255|Drug|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
79323779|NCT02335255|Drug|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
79323780|NCT02344459|Device|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
79323781|NCT05012345|Procedure|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
79323782|NCT02344381|Dietary Supplement|Sucrose|
79323783|NCT02344381|Dietary Supplement|Glucose|
79323784|NCT05012033|Other|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
79323785|NCT03145831|Drug|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
79323786|NCT05011877|Device|High-flow nasal cannula therapy|High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
79323787|NCT03080051|Drug|[18F]MNI-952|Subjects will undergo PET imaging using [18F]MNI-952, a PET radioligand for imaging tau.
79323788|NCT03080051|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-952.
79323789|NCT02344303|Drug|TRV130|
79323790|NCT02344303|Drug|Moxifloxacin|
79323791|NCT02344303|Drug|Placebo|
79323792|NCT05011955|Behavioral|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
79323793|NCT05011955|Behavioral|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
79323794|NCT05011955|Other|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
79323795|NCT02335177|Behavioral|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
79646810|NCT04723238|Drug|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
79646811|NCT04631575|Drug|SHR6390|SHR6390, PO,single-dose
79646812|NCT04631068|Procedure|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
79976933|NCT06206512|Drug|Immediate release torsemide placebo|Placebo of immediate release torsemide
79323796|NCT03076931|Procedure|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
79323797|NCT03076931|Procedure|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
79323798|NCT03076931|Procedure|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
79323799|NCT02339467|Other|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
79323800|NCT02339467|Other|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
79323801|NCT02343991|Device|Transcranial ExABlate|MR Guided Focused Ultrasound
79323802|NCT02334943|Biological|Blood test|Blood test
79323803|NCT02335021|Dietary Supplement|Sucralose|2 packets per 12 fl oz
79323804|NCT02335021|Dietary Supplement|Sucrose|equisweet to sucralose
79323805|NCT02335021|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
79809701|NCT05957146|Device|Routine hemodialysis|"Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~Anticoagulation: nadroparin."
79323806|NCT02335021|Dietary Supplement|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
79323807|NCT02344069|Drug|Fibrinogen|Human fibrinogen concentrate as a injection
79323808|NCT02344069|Drug|Placebo|Saline 0.9% as a injection
79480716|NCT03221335|Device|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
79646813|NCT00201786|Drug|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
79646814|NCT04631146|Drug|Camrelizumab|PD-1 inhibitors
79646815|NCT04723433|Other|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
79646816|NCT04723433|Other|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
79646817|NCT04630678|Other|Virtual Reality Therapy|Virtual reality games were applied to participants for 30 minutes.
79809702|NCT05957133|Procedure|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
79323809|NCT02343913|Device|PAC checklist|
79323810|NCT02334475|Biological|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
79323811|NCT02334475|Biological|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
79323812|NCT02343835|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
79976934|NCT06206499|Procedure|soft tissue augmentation|"Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans & Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants."
79480717|NCT05925946|Dietary Supplement|CURE-DM|"This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice."
79646818|NCT04630678|Other|Conventional Physiotherapy|Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
79976935|NCT06206486|Other|no intervention, observational|This study is observational. No intervention description available.
79323813|NCT02334553|Drug|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
79323814|NCT02334553|Drug|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
79646819|NCT04630678|Other|Activity Training|Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
79976936|NCT06206473|Other|mEEG assessment|mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
79976937|NCT06206447|Procedure|Tunnel-cuffed Catheter|Tunnel-cuffed Catheter in right internal jugular vein
79976938|NCT06206447|Procedure|Non-ccuffed Catheter|Non-ccuffed Catheter in right internal jugular vein
79976939|NCT06206434|Diagnostic Test|Point of care ultrasonography|Transthoracic echocardiogrpahy followed spinal anesthesia and 5 ml/kg Ringers lactate fluid co-loading
79323815|NCT02334709|Radiation|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
79323816|NCT02334631|Drug|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
79323817|NCT02334631|Drug|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
79323818|NCT02334397|Behavioral|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
79323819|NCT02334319|Drug|Ganetespib|Given IV
79480718|NCT05925933|Other|Intervention|high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
79480719|NCT05925829|Biological|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
79323820|NCT02334319|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79809703|NCT05957133|Procedure|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
79809704|NCT05957094|Drug|Pharmacological agent: Citalopram|Participants will be given 40 mg in capsule form, which is a normal clinical dose.
79976940|NCT06206395|Device|Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging|"2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment."
79976941|NCT06206382|Procedure|Whipple operation|Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
79323821|NCT02334319|Other|Laboratory Biomarker Analysis|Correlative studies
79323822|NCT02338765|Behavioral|mHealth Physical Activity|
79323823|NCT02338765|Behavioral|Buddy-partnered exercise|
79323824|NCT02338531|Drug|PF-03084014|
79809705|NCT05957094|Other|Placebo|Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.
79323825|NCT02338531|Procedure|Breast cancer surgery|
79480720|NCT05925816|Behavioral|Video|Video uses BA techniques for approximately 5 minutes
79976942|NCT06206369|Other|No intervention, retrospective study|No intervention, retrospective study
79976943|NCT06206330|Other|Platelet rich plasma|After application of platelet rich plasma after surgery, the patients have examined for infection, hematoma, pain, recurrence and the time of epithelialization of the wound.
79976944|NCT06206304|Other|Root canal therapy|Traditional root canal therapy was performed with rubber-dam isolation.
79480721|NCT05925816|Behavioral|Active game|Game provides positive feedback in response to decisions made by participants
79480722|NCT05925816|Behavioral|Neutral game|Game without feedback
79809706|NCT05957068|Behavioral|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
79323826|NCT02338453|Behavioral|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
79323827|NCT02338453|Behavioral|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
79809707|NCT05957068|Behavioral|Control|Usual care group.
79976945|NCT06206278|Drug|Infigratinib|Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
79323828|NCT02332213|Procedure|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
79323829|NCT02332213|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
79323830|NCT02332213|Procedure|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
79323831|NCT02332213|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
79976946|NCT06206252|Other|Medical Cannabis|Participants will be restricted to specific medical cannabis products from Ethos Dispensary. They will be randomized to one medical cannabis formulation (tincture or vaporization) for the duration of the study. Each month for three months, they will purchase a different composition (predominantly THC, predominantly CBD, or balanced products) of their designated formulation. The order of compositions will be randomized and double-blinded, so participants and the research team will not know which compositions of medical cannabis they are using each month.
79323832|NCT02332213|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
79323833|NCT02332213|Procedure|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
79809708|NCT05957029|Device|NuEra Tight RF system|monopolar radiofrequency device
79809709|NCT05956977|Device|resection with help of 3D ultrasound|see above
79976947|NCT06206226|Behavioral|OHDC-DC|90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
79976948|NCT06206213|Behavioral|Assessment of two different locomotion types.|Exposure to virtual environment by the HMD in two different locomotion styles.
79976949|NCT06206200|Other|Cognitive dual task training (intervention group)|Simultaneously performing cognitive tasks and motor rehabilitative exercises.
79323834|NCT02332135|Procedure|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
79976950|NCT06206200|Other|Standard of care physiotherapy (control group)|The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
79323835|NCT02332135|Drug|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
79480723|NCT05925790|Diagnostic Test|IL1RA Antibody Assay|-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described [Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527].
79646820|NCT00179816|Drug|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
79646821|NCT04630444|Drug|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
79976951|NCT06206187|Other|Automated detection of the intracardiac thrombus through deep learning|A deep learning model will identify the intracardiac thrombus. The AI model will produce an assessment of intracardiac thrombus using video based features.
79976952|NCT06206187|Other|Electrophysiologist judgment of the intracardiac thrombus|Cardiac electrophysiologists use their own experience to determine whether there is intracardiac thrombus
79976953|NCT06206174|Drug|TGRX-814|Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
79976954|NCT06206161|Behavioral|Indicated Prevention, Clinical Staff|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
79976955|NCT06206161|Behavioral|Selective Prevention|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use).
79976956|NCT06206161|Behavioral|Expanded Paraprofessional Workforce|Brief interventions delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
79480724|NCT05925790|Diagnostic Test|suPAR Testing|"-The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available CHORUS suPAR Extended kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method."
79646822|NCT04630405|Device|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
79646823|NCT04630405|Device|Aerogen Solo|Aerogen Ltd., Galway, Ireland
79646824|NCT00186810|Drug|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
79976957|NCT06206135|Drug|the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)|The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
79976958|NCT06206096|Drug|oxaliplatin+capecitabine+bevacizumab+PD-1 antibody|oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
79976959|NCT06206083|Genetic|Descriptive and analytical|Patients with EC endometroid
79646825|NCT00186810|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
79646826|NCT04630600|Other|No intervention|Normal waiting room without an aquarium
79480725|NCT05925764|Diagnostic Test|Whole Slide Image based Deep Learning Signature|Deep Learning Signature Based on Whole Slide Image for Predicting the Novel Grading System In Resected Lung Adenocarcinoma
79646827|NCT04630600|Other|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
79646828|NCT04630600|Other|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
79646829|NCT04630288|Drug|Clopidogrel|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
79646830|NCT04630288|Drug|Ticagrelor|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
79646831|NCT00179855|Procedure|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
79646832|NCT00561028|Other|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
79646833|NCT00201942|Procedure|PET scan|
79809710|NCT05956925|Behavioral|Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.|The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
79323836|NCT03518359|Behavioral|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
79480726|NCT05925751|Diagnostic Test|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
79480727|NCT05925738|Diagnostic Test|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting the Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
79646834|NCT00561067|Drug|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
79480728|NCT05925673|Other|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
79646835|NCT00561067|Drug|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
79323837|NCT03518359|Behavioral|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
79323838|NCT05134675|Dietary Supplement|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
79323839|NCT04987177|Other|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
79323840|NCT02334241|Device|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
79323841|NCT02334241|Device|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
79323842|NCT02334163|Drug|Nitazoxanide|500 mg nitazoxanide tablets twice daily
79323843|NCT02334163|Drug|Oral lactulose|Oral lactulose (65%)
79976960|NCT06206018|Procedure|PROM_R knee rehabilitation program|"The rehabilitation program consists of 5 weekly sessions for 4 weeks, supervised by a specialized physiotherapist at every session.~All patients follow the same order of treatment and exercises, starting with massage and mobilization, followed by the corresponding exercise program, and ending with Neuromuscular Electrical Stimulation (NMES) and cryotherapy."
79323844|NCT02334163|Drug|Metronidazole|250 mg metronidazole tablets every 8 hours
79323845|NCT02334163|Drug|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
79323846|NCT02039635|Dietary Supplement|Korean Red Ginseng|Given Orally
79323847|NCT02039635|Dietary Supplement|Placebo|Given Orally
79323848|NCT02332057|Drug|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
79480729|NCT05925673|Other|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
79323849|NCT02332057|Drug|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
79976961|NCT06205992|Device|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
79646836|NCT00561106|Drug|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
79323850|NCT02331745|Drug|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
79323851|NCT02331745|Drug|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
79323852|NCT02638259|Drug|GP2015|Enbrel comparator
79323853|NCT02333929|Device|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
79323854|NCT02333851|Drug|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
79813821|NCT04109664|Procedure|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
79323855|NCT02333851|Drug|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
79323856|NCT02334007|Drug|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
79323857|NCT02334007|Other|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
79323858|NCT02333695|Device|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
79323859|NCT02338375|Biological|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
79646837|NCT00561106|Drug|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
79646838|NCT00179894|Behavioral|Physician training|Physicians are trained in guidelines for medication management.
79646839|NCT04630639|Device|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
79323860|NCT02338063|Behavioral|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
79323861|NCT02338063|Behavioral|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
79323862|NCT02637323|Drug|FX006 32 mg|Single 5 mL IA injection
79323863|NCT02637323|Drug|TCA IR 40|Single 1 mL IA injection
79646840|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
79646841|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
79646842|NCT00186849|Drug|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
79323864|NCT02338141|Device|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
79480730|NCT05925673|Other|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
79323865|NCT02338141|Device|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
79323866|NCT02338297|Procedure|TACE|Transarterial chemoembolisation (TACE)
79323867|NCT02338297|Drug|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
79323868|NCT02338297|Drug|PVA|Occlude arterioportal shunts(APS) with PVA
79323869|NCT02338219|Other|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
79480731|NCT05925647|Drug|Messenchymal stem cell secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
79813822|NCT00797316|Drug|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
79323870|NCT02338219|Other|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
79323871|NCT05011643|Other|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
79323872|NCT03111979|Dietary Supplement|beta-alanine|
79323873|NCT03111979|Dietary Supplement|Placebo|
79323874|NCT05004623|Device|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
79480732|NCT05925647|Drug|Placebo|NaCl 0,9% infusion
79480733|NCT05925543|Procedure|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
79480734|NCT05925504|Drug|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
79480735|NCT05925491|Drug|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
79813823|NCT00797316|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
79976962|NCT06205992|Device|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
79976963|NCT06205992|Device|2D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
79323875|NCT05004779|Procedure|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
79646843|NCT00186849|Procedure|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
79646844|NCT00179933|Behavioral|Newborn Individualized Assessment Program|
79646845|NCT04629898|Behavioral|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
79323876|NCT05004779|Procedure|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
79323877|NCT05011019|Drug|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
79323878|NCT02331823|Drug|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
79323879|NCT02331823|Drug|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
79976964|NCT06205992|Device|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
79323880|NCT05011097|Drug|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
79646846|NCT00201981|Drug|Rebamipide|"OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
79976965|NCT06205979|Drug|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
79976966|NCT06205979|Drug|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
79976967|NCT06205966|Dietary Supplement|BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)|BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
79976968|NCT06205966|Other|Placebo|Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
79323881|NCT02890459|Other|Prize incentive - Low|Low expected prize value.
79323882|NCT02890459|Other|Prize incentive - High|High expected prize value.
79976969|NCT06205940|Behavioral|Nature walks|Audio guided nature walks versus non guided nature walks
79976970|NCT06205927|Radiation|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
79976971|NCT06205927|Radiation|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
79976972|NCT06205914|Procedure|fixation of patella fractures by craniofacial mesh plate osteosynthesis augmented by screws|patellar fracture fixation using MatrixNEURO Contourable Mesh plates (Synthes®). Made of titanium with an incredibly low profile
79323883|NCT02890459|Other|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
79323884|NCT02890459|Other|Travel Voucher|Travel voucher to assist with linkage to care.
79323885|NCT02890459|Other|Standard care|Includes HIV viral load and treatment adherence counseling.
79323886|NCT02890459|Behavioral|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
79976973|NCT06205888|Other|18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT|Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
79976974|NCT06205849|Drug|IRE + intratumoral mitazalimab (CD40 antibody) injection|Surgical IRE will be performed using the NanoKnife System with intraoperative ultrasound guidance via laparotomy under general anesthesia. Mitazalimab (CD40 antibody) will be administered 5 minutes after completion of IRE by slow injection into the center of the ablated zone using a small needle. Core needle biopsies of the tumor will be obtained immediately prior to IRE for identification of candidate tumor antigens. Peripheral blood will be obtained immediately prior to and 12 weeks after the study intervention for analysis of systemic immune effects.
79323887|NCT02890459|Behavioral|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
79809711|NCT05956886|Behavioral|sleep chatbot|Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
79976975|NCT06205849|Device|NanoKnife|Non-thermal tumor ablation using short pulses of high voltage electrical current delivered using 19-gauge needles placed via laparotomy using ultrasound guidance
79976976|NCT06205836|Drug|Cemiplimab|Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
79323888|NCT02890459|Behavioral|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
79323889|NCT02890459|Behavioral|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
79323890|NCT02890459|Behavioral|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
79809712|NCT05956873|Device|REVAR|Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
79323891|NCT03077009|Drug|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
79323892|NCT02333773|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
79323893|NCT05011175|Other|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
79323894|NCT02331979|Device|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
79323895|NCT03079817|Other|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
79323896|NCT03079817|Other|Proprioceptive Drills|Active balance and proprioception drills
79323897|NCT04477525|Procedure|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score >5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
79323898|NCT04477525|Drug|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
79323899|NCT03079973|Drug|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
79323900|NCT03079973|Drug|Vehicle of P-3073|Once daily for 24 weeks.
79809713|NCT05956834|Device|PAMSys|Wearable accelerometer and gyroscope for measuring movement
79976977|NCT06205836|Drug|Fianlimab|Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
79976978|NCT06205823|Drug|Immunotherapy|Immunotherapy
79323901|NCT03076853|Other|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
79323902|NCT05004545|Drug|Propofol|Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
79323903|NCT03079895|Behavioral|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
79323904|NCT02337595|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
79323905|NCT05003999|Device|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
79809714|NCT05956834|Device|LEGSys|Wearable accelerometer and gyroscope for measuring movement
79323906|NCT05003999|Device|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
79976979|NCT06205797|Drug|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA"
79480736|NCT05925413|Drug|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
79480737|NCT05925387|Other|CANAP Education|The volunteer group included in the research consists of Yeditepe University Nursing Students. All nursing students over the age of 18, at all levels of the nursing program, will be included in the study based on voluntary participation, in accordance with the sample size. The purpose and design of the research will be explained to the 1st, 2nd, 3rd, and 4th-year nursing students. The announcement of the study will be made through Yeditepe University Nursing's social media accounts, and a consent link provided. Participants who sign the document in the consent link and upload it to the shared Google Drive received the pre-test link. Participants who complete all the procedures are provided with a participant certificate prepared by the researchers as an incentive.
79480738|NCT05925374|Behavioral|Substance use stigma training|The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
79480739|NCT05925361|Procedure|Laparoscopic pedicled single flap peritoneum vaginoplasty|After the perineal part of the operation, in which the vaginal cavity will be dissected, a laparoscopy will be started. During laparoscopy, a single flap peritoneum will be harvested. The flap will be checked for adequate blood supply. The flap will be brought down to the (neo) vaginal cavity and sutured around a dilatator cylinder wise.
79480740|NCT05925335|Device|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
79480741|NCT05925283|Drug|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
79323907|NCT02337439|Behavioral|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
79480742|NCT05925283|Drug|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
79976980|NCT06205797|Drug|Xeomin®|"Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA"
79976981|NCT06205784|Other|Prehabilitative exercise|3-4 weeks of heavy resistance exercise
79323908|NCT02337439|Behavioral|Active Control Training|Commercially available educational software
79323909|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
79323910|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
79480743|NCT05925283|Drug|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
79480744|NCT05925257|Other|ePRO application and proactive clinical care with nurses.|The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
79480745|NCT05925205|Procedure|Muscle energy technique combined with the physical therapy program.|A manual therapy technique
79480746|NCT05925205|Procedure|Strain counterstrain technique combined with the physical therapy program|A manual therapy technique
79480747|NCT05925205|Procedure|The physical therapy program|Electrotherapy and exercise.
79480748|NCT05925153|Other|No intervention|No intervention
79646847|NCT00179972|Device|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
79809715|NCT05956691|Dietary Supplement|AllerPops|Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
79809716|NCT05955573|Diagnostic Test|xray|radiological description
79976982|NCT06205771|Other|H2S content|H2S content
79809717|NCT05954338|Drug|DWC202307|DWC202307
79809718|NCT05954338|Drug|DWJ1543|DWJ1543
79976983|NCT06205732|Other|Immunotherapy, targeted therapy.|Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
79976984|NCT06205719|Drug|ciprofol|sedation
79480749|NCT05925010|Dietary Supplement|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
79480750|NCT05924958|Drug|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
79480751|NCT05924945|Device|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
79480752|NCT05924945|Device|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
79480753|NCT05924893|Drug|Naltrexone Hydrochloride|naltrexone film
79480754|NCT05924893|Drug|Carboxy methyl cellulose|Carboxy methyl cellulose drops
79480755|NCT05924763|Device|Biphasic Cartilage Repair Implant (BiCRI)|The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
79809719|NCT05954338|Drug|DWC202216|DWC202216
79809720|NCT05954273|Procedure|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
79809721|NCT05954247|Drug|DWJ1543|DWJ1543
79976985|NCT06205719|Drug|Remazolam|sedation
79976986|NCT06205719|Drug|Flumazenil|antagonism
79976987|NCT06205719|Drug|Remifentanil|2ug/kg Remifentanil
79976988|NCT06205706|Drug|BI-1910|BI-1910 administered as a flat-dose IV infusion once every 3 weeks
79976989|NCT06205706|Drug|Pembrolizumab|Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
79976990|NCT06205693|Procedure|Fast Degradable, Biodegradable ARCHEMEDES stent|Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
79976991|NCT06205680|Device|NAA for topical anaesthesia of the nasal cavity|NAA for topical anaesthesia of the nasal cavity
79323911|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
79480756|NCT05924737|Other|Sleep deprivatin|40 hours of continuous awakening
79480757|NCT05924737|Other|Sleep recovery|sleep recovery after 40 hours of continuous awakening
79480758|NCT05924724|Device|Flash Glucose Monitoring|The FGM is a non-invasive device typically worn on the upper arm, designed to continuously measure blood glucose levels without the need for fingerstick capillary measurements.
79480759|NCT05924711|Other|Retrospective analysis of demographic and radiographic data previously obtained from the patient.|The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
79480760|NCT05924659|Other|Neurofeedback|Neurofeedback training
79480761|NCT05924633|Dietary Supplement|Supplement containing a protein hydrolysate + beta glucan (Wellmune®)|Supplement taken daily for 4 weeks.
79480762|NCT05924633|Dietary Supplement|Placebo supplement containing maltodextron|Placebo supplement taken daily for 4 weeks.
79480763|NCT05924607|Other|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
79323912|NCT05010863|Other|Blood collection|The subject will be drawn a 5ml blood sample
79480764|NCT05924607|Other|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
79480765|NCT05924581|Other|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
79480766|NCT05924555|Other|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
79480767|NCT05924555|Other|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
79480768|NCT05924555|Other|Echography of upper leg|Determine upper leg muscle size
79480769|NCT05924555|Other|Hand grip strength with hand dynamometer|Determine muscle strength
79480770|NCT05924555|Other|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
79480771|NCT05924542|Behavioral|Kelaa Mental Resilience App|"Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change."
79480772|NCT05924490|Behavioral|Real-time strategy-based videogame training|Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
79480773|NCT05924490|Behavioral|Semantic Knowledge training|Packages of various cross-word puzzles include word search, word ladder, and word wheel.
79480774|NCT05924451|Behavioral|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
79646848|NCT04629742|Other|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
79323913|NCT05003375|Behavioral|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT*-NBacktask**, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~*SDMT: Symbol Digit Modalities Test: see description in outcome measures~**N-Back Task: see description in outcome measures"
79323914|NCT05010239|Other|30-minute Mindfulness-Based Supportive Therapy|The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
79480775|NCT05924425|Drug|Daridorexant 50 mg|Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
79976992|NCT06205667|Procedure|Computer Guided Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.
79976993|NCT06205667|Procedure|Conventional Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
79976994|NCT06205641|Drug|Xuanfei Baidu Granule Placebo|Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
79646849|NCT04629742|Other|Standard pizza|A standard pizza administered to 12 healthy subjects
79646850|NCT04629391|Device|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
79646851|NCT04629235|Other|wonder around|wonder around after 8 hours of bedrest
79976995|NCT06205641|Drug|Xuanfei Baidu Granule|Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
79323915|NCT05010239|Other|30-minute supportive listening|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
79323916|NCT03111589|Biological|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
79646852|NCT04629235|Behavioral|bedrest|24 hours of bedrest
79646853|NCT00180011|Drug|Omalizumab|injectable medication
79976996|NCT06205641|Drug|Baloxavir Marboxil Tablet|Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
79480776|NCT05924425|Drug|Placebo|Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
79480777|NCT05924425|Procedure|Polysomnography|A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
79480778|NCT05924425|Behavioral|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, M1, M2
79480779|NCT05924425|Behavioral|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
79809722|NCT05954247|Drug|DWC202216|DWC202216
79323917|NCT03111589|Diagnostic Test|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
79809723|NCT05951712|Drug|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
79809724|NCT05951712|Drug|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
79323918|NCT05003297|Other|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
79323919|NCT02337283|Drug|BI 425809|Tablets
79323920|NCT02337283|Drug|Placebo|Tablets
79323921|NCT05010395|Behavioral|Letter intervention|Letter intervention
79323922|NCT02331433|Drug|APN1125|APN1125 orally at ascending doses
79809725|NCT05951712|Drug|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
79323923|NCT02331433|Drug|Placebo|Matching Placebo
79323924|NCT02327221|Drug|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
79323925|NCT02327221|Drug|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
79323926|NCT02327065|Device|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
79646854|NCT00186966|Drug|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
79646855|NCT00186966|Drug|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
79323927|NCT02327065|Device|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
79323928|NCT02333539|Behavioral|Adherence behaviors and recommendations for improvement.|
79302432|NCT03224143|Behavioral|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
79323929|NCT02333539|Behavioral|Adherence behavior that needs improvement is targeted|
79480780|NCT05924425|Procedure|Actimetrics|Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
79480781|NCT05924425|Procedure|24-hour Ambulatory Blood Pressure Monitoring (ABPM|Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
79646856|NCT00186966|Procedure|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
79646857|NCT00186966|Radiation|Total body irradiation|See Detailed Description section for details of treatment interventions.
79646858|NCT04629001|Diagnostic Test|Covid-19 PCR , IGM|test for Covid-19
79646859|NCT04629040|Other|Lateral wedge insole|Lateral wedge insole for knee osteoarthritis patient
79646860|NCT04629040|Other|Ordinary insole|Ordinary insole
79646861|NCT00180050|Drug|Budesonide|
79809726|NCT05951712|Other|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
79323930|NCT02333617|Other|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point [No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
79809727|NCT05951595|Drug|Artemether-Lumefantrine-Amodiaquine (ALAQ)|A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
79646862|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
79646863|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
79323931|NCT02333617|Other|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
79323932|NCT02333617|Other|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
79646864|NCT00575341|Drug|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
79646865|NCT00575341|Drug|placebo|placebo, oral, once daily
79646866|NCT04579471|Diagnostic Test|SARS-CoV-2 IgG|Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
79646867|NCT00180089|Drug|Budesonide|
79809728|NCT05951595|Drug|Artemether-Lumefantrine (AL)|A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
79646868|NCT00575419|Drug|N-acetylcysteine|"Dose Level 1: 150 mg/kg/day~Dose Level 2: 300 mg/kg/day~Dose Level 3: 600 mg/kg/day~Dose Level 4: 900 mg/kg/day~Dose Level 5: 1200 mg/kg/day"
79809729|NCT05951595|Drug|Artesunate-Amodiaquine (ASAQ)|ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
79323933|NCT02333617|Other|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
79323934|NCT02333305|Dietary Supplement|CoQ10|• 2 dosages according to patient weight: Weight < 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
79323935|NCT02333305|Other|Sanomit Placebo|• according to patient weight: Weight < 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
79809730|NCT05950438|Procedure|Esophagectomy|Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract.
79323936|NCT02326909|Device|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
79323937|NCT02326909|Device|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
79323938|NCT02326987|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
79323939|NCT02326987|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
79323940|NCT02039713|Device|DeSyne drug eluting stent group|
79323941|NCT02333461|Dietary Supplement|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
79323942|NCT02333461|Dietary Supplement|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
79323943|NCT02333461|Dietary Supplement|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
79646869|NCT00575497|Procedure|More frequent hemodialysis|Six Day per week short daily hemodialysis
79646870|NCT00575497|Procedure|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
79646871|NCT00575497|Procedure|More frequent hemodialysis|Every other day short daily hemodialysis
79976997|NCT06205589|Biological|ID93 + GLA-SE vaccine|At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
79976998|NCT06205589|Biological|Placebo vaccine|At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
79976999|NCT06205576|Device|DCB catheter|Trade name of DCB catheter：Acoart Orchid＆Dhalia
79646872|NCT00575497|Procedure|More frequent hemodialysis|Every other night hemodialysis
79977000|NCT06205563|Behavioral|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
79323944|NCT02333461|Dietary Supplement|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
79323945|NCT02333461|Dietary Supplement|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
79323946|NCT02332837|Behavioral|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
79323947|NCT02332837|Behavioral|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
79323948|NCT02332837|Behavioral|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
79323949|NCT02326753|Device|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
79323950|NCT02326753|Device|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
79323951|NCT02326753|Device|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
79323952|NCT02332993|Dietary Supplement|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
79323953|NCT03104881|Device|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
79646873|NCT00575497|Procedure|More frequent hemodialysis|5 days per week short daily hemodialysis
79646874|NCT00575497|Procedure|More frequent hemodialysis|5 nights per week hemodialysis
79646875|NCT00575497|Procedure|Conventional Hemodialysis|3 days per week short daily hemodialysis
79323954|NCT03104881|Device|2D end-effector type robot|2 dimension end-effector type upper extremity robot
79323955|NCT02326675|Other|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
79646876|NCT00180128|Drug|all-trans retinoid acid|
79646877|NCT00180128|Drug|idarubicin|
79646878|NCT00180128|Drug|mitoxantrone|
79646879|NCT00180128|Drug|daunorubicin|
79646880|NCT00180128|Drug|cytarabine|
79480782|NCT05924425|Other|Biomarker assay|Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
79480783|NCT05924399|Behavioral|Affect Labeling Training|(1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
79323956|NCT02326675|Other|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
79323957|NCT02331667|Other|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
79977001|NCT06205563|Behavioral|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
79977002|NCT06205550|Drug|Flecainide|Flecainide monotherapy
79977003|NCT06205550|Drug|Flecainide + beta-blocker|Flecainide + beta-blocker
79323958|NCT02331667|Other|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
79323959|NCT02331511|Drug|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
79323960|NCT02331511|Drug|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
79977004|NCT06205537|Other|Control Liquid Supplement|Ready to drink supplement.
79480784|NCT05924373|Drug|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
79480785|NCT05924347|Diagnostic Test|MRI|Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)
79977005|NCT06205537|Other|Experimental Liquid Supplement|Ready to drink supplement.
79480786|NCT05924347|Diagnostic Test|Scolioscan|3D ultrasound of the spine
79480787|NCT05924347|Diagnostic Test|Skeletal maturity assessment|At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
79480788|NCT05924308|Other|electroacupuncture|every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
79646881|NCT00575536|Procedure|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
79646882|NCT00575575|Behavioral|cognitive behavior therapy|cognitive behavior therapy once a week
79646883|NCT00575614|Drug|prucalopride|1 mg o.d.
79646884|NCT00575614|Drug|placebo|o.d.
79646885|NCT00575731|Behavioral|Weight management strategies|
79646886|NCT00180167|Drug|randomization between two established Chemotherapies|
79323961|NCT02331511|Drug|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
79323962|NCT02326441|Drug|KX2-361|
79977006|NCT06205511|Diagnostic Test|Oral HPV Sample|The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
79323963|NCT03144271|Drug|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
79323964|NCT03144271|Drug|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
79323965|NCT02332525|Device|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
79323966|NCT02039791|Biological|Nimotuzumab|200mg/w,weekly, 6 weeks
79809731|NCT05950425|Other|Aspiration training|"Pre-test application; All mothers whose children are hospitalized in the PICU will be filled in the questionnaires after verbally expressing and signing the informed consent before being admitted to the intensive care unit and starting the education.~In practice; The mother of the child who is planned to be discharged from the intensive care unit is given training a week before. Aspiration training will be given to the Experimental I group with the video method, and to the Experimental II group with the picture training booklet method. The materials of these trainings will be given to the mothers and they will be asked to look after them when they come to the next care.~Final test application; scales will be filled in the mother on the day of the child's discharge."
79323967|NCT02039791|Drug|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
79646887|NCT04579627|Behavioral|Questionnaire|A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
79809732|NCT05929157|Drug|artesunate-pyronaridine|Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
79977007|NCT06205498|Drug|acalabrutinib|patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125
79977008|NCT06205485|Drug|Leucovorin|400 mg/m2
79977009|NCT06205485|Drug|Oxaliplatin|85 mg/m2 or 130 mg/m2 on day 1
79323968|NCT02039791|Drug|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
79323969|NCT06276335|Other|Immediate implant placement and guided bone regeneration (Test)|In this group, immediately after tooth extraction, a tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. A prefabricated surgical template based on 3D pre-extraction planning will be used to place the implant. The jumping distance between the implant and the residual buccal bone will be measured and filled with slow resorption bone graft material (Bio-Oss®, Geistlich, Wolhusen, Switzerland) as per standard of practice.
79323970|NCT06276335|Other|Late implant placement and guided bone regeneration (Control)|A tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed after complete bone healing (4 - 6 months after tooth extraction) in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. Guided bone regeneration (GBR) will be performed simultaneously with the aim to re-establish the bone contour and treat any fenestration/dehiscence if needed. A bovine osteoconductive graft (Bio-Oss®, Geistlich, Wolhusen, Switzerland) will be loosely compacted on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
79323971|NCT06276322|Other|Low back pain group|The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine
79323972|NCT06276322|Other|Healthy group|Low back pain kinematics compare them with asymptomatic kontrols
79323973|NCT06276296|Diagnostic Test|Holter EKG - 1 day before ablation|24 hours Holter EKG - 1 day before ablation
79809733|NCT05905432|Drug|Vaccine AnAPN1|AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
79977010|NCT06205485|Drug|Fluoruracil|bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
79977011|NCT06205485|Drug|Capecitabine|1,000 mg/m2 twice daily for 14 days
79977012|NCT06205485|Radiation|Radiation|54 Gy (27-30 fractions)
79323974|NCT06276296|Procedure|Radiofrequency ablation|Pulmonary vein isolation using radiofrequency ablation
79323975|NCT06276296|Procedure|Pulsed field ablation|Pulmonary vein isolation using pulsed field ablation
79323976|NCT06276296|Diagnostic Test|Holter EKG - 1 month after ablation|24 hours Holter EKG 1 month after ablation
79323977|NCT06276283|Drug|DZD9008 plus Bevacizumab|DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
79323978|NCT06276270|Device|Mucopad HA|The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
79323979|NCT06276257|Procedure|Paravertebral block|An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.
79323980|NCT06276257|Procedure|Usual analgesia|The patient will receive analgesia as per the anesthesiologist's preferences.
79323981|NCT06276231|Drug|Salbutamol|Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
79323982|NCT06276231|Other|0.9% Normal Saline|Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
79323983|NCT06276231|Drug|Diclofenac Injection|75 mg of Diclofenac intramuscular Injection
79977013|NCT06205472|Radiation|Adjuvant SIB radiotherapy|Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
79323984|NCT06276218|Device|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
79977014|NCT06205459|Procedure|deep marginal acquisition using thermacut bur|thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
79977015|NCT06205446|Behavioral|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
79323985|NCT06276205|Drug|Vitamin D|"if Vitamin D level suboptimal, 50,000 IU/week for 8 weeks followed by 2000 IU/d~if optimal Vitamin D level, 2000 IU/d"
79809734|NCT05881616|Other|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
79480789|NCT05924308|Other|sham acupuncture|Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
79480790|NCT05924230|Other|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is >50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
79323986|NCT06276205|Drug|Levothyroxin|commenced at a dose of 1.6mcg/kg/day and will be titrated 8 weekly according to response
79323987|NCT06276192|Other|Digital Physiotherapy (diSAID)|"The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform."
79323988|NCT06276192|Other|Traditional Physiotherapy|Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
79480791|NCT05924230|Other|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is >50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
79480792|NCT05924178|Behavioral|exercise rehablitation|Preoperative exercise rehabilitation in experimental group was performed.
79480793|NCT05924178|Behavioral|routine treatment|The control group receives conventional treatment preoperative.
79480794|NCT05924165|Drug|5mg Oxycodone, Q6 PRN|Oxycodone is an opioid that is used to relieve moderate to severe pain.
79977016|NCT06205446|Behavioral|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
79977017|NCT06205446|Behavioral|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
79977018|NCT06205446|Behavioral|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
79480795|NCT05924165|Drug|10mg Ketorolac, Q6 PRN|Ketorolac is an NSAID used to relieve moderately severe pain.
79809735|NCT05881616|Other|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
79323991|NCT06276166|Other|No intervention|No intervention
79480796|NCT05924139|Dietary Supplement|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
79480797|NCT05924139|Dietary Supplement|Placebo|4 capsules per day of coconut oil
79480798|NCT05924113|Behavioral|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
79480799|NCT05924100|Drug|Luspatercept Injection [Reblozyl]|"Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit."
79480800|NCT05924074|Biological|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
79480801|NCT05924061|Other|Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women|The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
79480802|NCT05923983|Other|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
79480803|NCT05923983|Other|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
79480804|NCT05923957|Other|TENS and Exercise|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
79480805|NCT05923931|Device|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
79480806|NCT05923931|Device|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, etc.
79480807|NCT05923918|Drug|PBK_M2101 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
79480808|NCT05923918|Drug|PBK_M2101 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
79480809|NCT05923918|Drug|Oral Sulfate Tablet 2-Day|Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
79480810|NCT05923879|Drug|Selinexor combined with lenalidomide and rituximab|Selinexor combined with lenalidomide and rituximab
79646888|NCT04579354|Other|virtual reality tour|Patients will be guided via VR on their way through the hospital to the operating theater
79809736|NCT05881616|Other|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
79809737|NCT05880251|Behavioral|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
79646889|NCT04579705|Other|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
79977019|NCT06205420|Other|Injectable composite resin restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
79977020|NCT06205420|Other|Injectable giomer restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
79646890|NCT00575809|Other|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
79809738|NCT05880251|Behavioral|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
79809739|NCT05879471|Diagnostic Test|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
79809740|NCT05873894|Device|EEG|EEG recordings and analysis. Sensory evoked potentials analysis Motor evoked potentials studies
79809741|NCT05864651|Other|Tele-exercise program|The tele-exercise program focused on lunge movement with additional strengthening abdominal and lumbopelvic muscle training while maintaining neuromuscular control. The difficulty of training was adjusted every week according to the five-step mastery program
79809742|NCT05864651|Other|Conventional Fencing Exercise|The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite & Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.
79977021|NCT06205394|Other|Non-Interventional Study|Non-interventional study
79646891|NCT00180206|Device|Birmingham Hip Resurfacing|
79809743|NCT05861167|Biological|selective intensive induction therapy based on ustekinumab clinical decision-making tools|At week 0 and week 8, UST was induced intravenously twice (stratified according to body weight, see instructions for dosage), and at the third time, intravenous or standard subcutaneous injection regimen was used according to CRP standard
79809744|NCT05828459|Drug|OT-A201|OT-A201 IV infusion qw or q2w
79977022|NCT06205381|Drug|AV078|Oral solution containing active ingredient, AV078
79977023|NCT06205381|Drug|Placebo|Oral solution with no active ingredients
79809745|NCT05828459|Drug|IMids|Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
79809746|NCT05828459|Drug|Bevacizumab|Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
79977024|NCT06205381|Drug|Itraconazole|Once daily oral dose of 200 mg itraconazole administered for 9 days
79809747|NCT05828459|Drug|Paclitaxel|Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
79809748|NCT05828459|Drug|TBD Compound|Combination regimen for hematological malignancy
79809749|NCT05824845|Procedure|Hip/Knee Replacement|Hip/Knee Replacement
79323994|NCT06276127|Drug|Oral Bisoprolol|Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
79646892|NCT00575848|Dietary Supplement|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
79646893|NCT00575848|Dietary Supplement|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
79809750|NCT05817071|Procedure|Arthroscopic massive rotator cuff repair|Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.
79809751|NCT05817071|Procedure|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
79809752|NCT05809895|Drug|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
79977025|NCT06205381|Drug|Midazolam|2.5 mg midazolam administered orally on day 1 and day 18
79977026|NCT06205381|Drug|Fexofenadine|120 mg fexofenadine administered orally on day 1 and day 18
79977027|NCT06205355|Device|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
79977028|NCT06205355|Device|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
79977029|NCT06205342|Drug|Mesenchymal Stem Cells|Autologous bone marrow derived MSCs
79977030|NCT06205342|Other|Other: Placebo|Control
79977031|NCT06205329|Drug|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo on day 1
79977032|NCT06205329|Drug|WPV01 Dose 5-8 and Ritonavir|WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
79977033|NCT06205329|Drug|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo from day 1 to day 6
79977034|NCT06205329|Drug|WPV01 Dose 13-15 and Ritonavir|WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
79977035|NCT06205329|Drug|WPV01 Dose 16|Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
79323995|NCT06276127|Drug|Intravenous Diltiazem|Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
79323996|NCT06276114|Device|Stent Underexpansion|Stent underexpansion was diagnosed as stent expansion of <80% assessed with intravascular imaging.
79323997|NCT06276101|Biological|NWRD08 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
79977036|NCT06205303|Other|Patient Decision Aid (Video)|Patient decision aid on thyroxine replacement is a video designed to assist the hypothyroid adults with under-replacement. It provides clear and balanced information about hypothyroidism, the role of thyroxine, treatment benefits, potential risks, and factors interfering thyroxine absorption and bioavailability. The PDA aims to empower patients to engage in shared decision-making with their healthcare provider, ensuring they understand the options and can make choices aligned with their preferences and values.
79977037|NCT06205030|Drug|anti-diabetic herbal drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
79977038|NCT06204978|Dietary Supplement|short-chain fructo-oligosaccharides (dose 1)|10 g / day at breakfast during 7 days (Day 8 - Day 14)
79977039|NCT06204978|Dietary Supplement|short-chain fructo-oligosaccharides (dose 2)|20 g / day at breakfast during 7 days (Day 8 - Day 14)
79323998|NCT06276075|Procedure|Conventional rehabilitation, the Erigo®Pro table, motor imagery|66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
79324000|NCT06276049|Other|custom GPT supported self-directed learning|"The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience."
79324001|NCT06276036|Other|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
79324002|NCT06276023|Behavioral|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
79324003|NCT06276023|Behavioral|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
79646894|NCT00575926|Drug|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
79809753|NCT05809895|Drug|Tislelizumab|200 mg intravenously (IV) Q3W
79809754|NCT05809895|Drug|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
79646895|NCT00576004|Procedure|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
79646896|NCT00576043|Procedure|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
79646897|NCT00576160|Behavioral|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
79809755|NCT05809895|Drug|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
79809756|NCT05809895|Drug|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
79809757|NCT05809895|Drug|Placebo|normal saline intravenously (IV) Q3W
79977040|NCT06204978|Other|Baseline|0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
79480811|NCT05923840|Diagnostic Test|Chemoreflex Testing|The carotid body chemoreflex can be tested by holding carbon dioxide (CO2) constant (isocapnic) and applying hypoxia and hyperoxia. Measurements are then made of expiratory minute volume and of sympathetic activity. The central chemoreflex measures isocapnic and hypercapnic responses in the presence of hyperoxia to suppress the carotid body chemoreflex.
79646898|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
79977041|NCT06204965|Behavioral|Time-restricted eating|Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
79646899|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
79977042|NCT06204887|Procedure|Manual dynamic activation|The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.
79646900|NCT00576238|Drug|urea|Topical application twice daily for up to 6 months
79646901|NCT00576277|Drug|AV411|
79646902|NCT00576355|Behavioral|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
79977043|NCT06204887|Procedure|Passive ultrasonic activation|A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.
79646903|NCT00576355|Behavioral|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
79646904|NCT00576394|Drug|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
79646905|NCT00576394|Drug|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
79646906|NCT00576433|Drug|Methotrexate|As prescribed
79977044|NCT06204887|Procedure|Laser activation|A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
79977045|NCT06204250|Drug|GS1-144|Oral tablets.
79324005|NCT06275997|Device|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
79977046|NCT06204250|Drug|Placebo|Matching placebo tablets.
79977047|NCT06203821|Drug|NP137|NP137 for the Treatment of Resectable Pancreatic Cancer
79977048|NCT06203730|Behavioral|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
79977049|NCT06203522|Procedure|Data collection of successful completion of MRI|age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure
79324006|NCT06275984|Other|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
79324007|NCT06275971|Device|Dexcom G6|Glycemic control was monitored using CGM data for seven days following cardiac surgery
79324008|NCT06275971|Device|SMBG or venous/arterial blood glucose|Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
79324009|NCT06275958|Drug|Doublet Chemotherapy, Standard Dose (100%)|Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
79809758|NCT05809895|Drug|Pembrolizumab|200 mg intravenously (IV) Q3W
79809759|NCT05809895|Drug|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
79809760|NCT05804786|Device|3D electromagnetic navigation guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
79977050|NCT06203327|Other|Esophagogastroscopy (OLGA 0-Ⅰ)|Surveillance endoscopies at years 3-5.
79977051|NCT06203327|Other|Esophagogastroscopy (OLGA II)|Surveillance endoscopies at years 2-3.
79480812|NCT05923840|Diagnostic Test|Baroreflex testing|Baroreceptors are measured by the change of heart rate (HR) and sympathetic activity with changing blood pressure using the modified Oxford technique. Blood pressure is lowered an amount by a bolus of sodium nitroprusside and then raised by a bolus of phenylephrine. When standing baroreflexes are activated and the investigators will measure chemoreflex activity upright to see how baroreflex effects the chemoreflexes. Similarly chemoreflexes affect the baroreflexes best observed when the patients are supine.
79324010|NCT06275958|Drug|Doublet Chemotherapy, Dose-reduced (75%)|75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
79977052|NCT06203327|Other|Esophagogastroscopy (OLGA III-IV)|Surveillance endoscopies every year.
79480813|NCT05923840|Diagnostic Test|Orthostatic stress testing|Orthostatic Stress tests are administered in two forms: a standing test to evoke the initial orthostatic hypotensive response that sensitizes and triggers the carotid body chemoreflex by intermittent stagnant ischemia. And the 70 degree upright tilt test that best identifies causal changes in regional blood volumes and flows and in respiratory patterns of hyperpneic hypocapnia.
79480814|NCT05923814|Drug|CD25 prophylaxis|The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
79480815|NCT05923801|Device|switch to BT electrode position|use of different electrode positions of ECT device
79480816|NCT05923801|Device|continue with RUL electrode position|use of different electrode positions of ECT device
79480817|NCT05923762|Behavioral|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
79480818|NCT05923723|Other|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
79480819|NCT05923723|Other|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
79324011|NCT06275958|Drug|Monotherapy, Standard Dose (100%)|- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
79324012|NCT06275958|Drug|Monotherapy, Dose-reduced (75%)|"75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)"
79480820|NCT05923710|Procedure|Primary anterior cruciate ligament repair|Only arthroscopic primary anterior cruciate ligament repair was performed in patients with proximal anterior cruciate ligament tear.
79480821|NCT05923710|Procedure|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET) with iliotibial band|In addition to primary anterior cruciate ligament repair, lateral extraarticular tenodesis was performed using the iliotibial band.
79646907|NCT00576433|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
79646908|NCT00576511|Drug|prucalopride|4 mg o.d.
79646909|NCT00576511|Drug|placebo|Placebo o.d.
79646910|NCT00576550|Drug|Urea|Urea cream applied twice daily up to six months
79324013|NCT06275945|Combination Product|Voro Urologic Scaffold|radical prostatectomy
79324014|NCT06275932|Other|Interventional group|Newborns will be covered with a thermal blanket during skin-to-skin contact in delivery room.
79324015|NCT06275932|Other|Standard of care group|Newborns will be covered with a bed wetting mat and cotton sheet during skin-to-skin contact in delivery room.
79324016|NCT06275919|Drug|Regorafenib 40 MG Oral Tablet|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
79324017|NCT06275919|Drug|Local Standard of Care|In this setting there are not drugs with indication. Every site will treat patients as per their experience.
79324018|NCT06275906|Other|Mediterranean diet and moderate intensity physical exercise (outdoor walking).|Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
79324019|NCT06275893|Biological|IC14|recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen
79324020|NCT06275880|Other|Intra-articular infiltration of PVP Collagen|Intra-articular collagen injection plus physiotherapy program
79324021|NCT06275880|Other|Rehabilitation|Patients who received conservative treatment through rehabilitation with a home program for one month
79646911|NCT00576550|Drug|betamethasone valerate|Application once daily for two weeks
79480822|NCT05923697|Behavioral|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
79324022|NCT06275867|Other|Free high-quality care|Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
79480823|NCT05923684|Behavioral|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
79324023|NCT06275867|Other|Close distance|The network of contracted providers is located close to where participants live.
79324024|NCT06275867|Other|Far distance|The network of contracted providers is located far to where participants live.
79324025|NCT06275841|Drug|vepdegestrant|experimental
79324026|NCT06275841|Drug|esomeprazole|Experimental treatment to assess an endpoint
79324027|NCT06275828|Device|slow beat mesic listening by headphone|classic slow beat type from researcher
79324028|NCT06275815|Other|Sit Together and Read (STAR)|Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.
79480824|NCT05923671|Diagnostic Test|Histological analysis|Histological staining of gingival biopsies with haematoxylin-eosin.
79480825|NCT05923671|Diagnostic Test|Immunohistochemical analysis|Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
79324029|NCT06275815|Behavioral|Monetary Reward|Caregiver receives a monetary reward of $0.50 for each session logged (up to 60 sessions) and audio-recording completed (up to 15 audio recordings).
79324030|NCT06275815|Behavioral|Text Encouragement|Caregiver receives three tailored encouraging text messages specific to each week of the Sit Together and Read intervention.
79324031|NCT06275802|Behavioral|Nutrition Education|Nutrition interventions consisting of 8 modules (powerpoint supported classroom lesson, video demonstration, role-play, healthy plate model game, poster preparation, bookmarks, refrigerator magnets, etc. preparation of reminder messages, competitions such as slogan-painting contest, activities such as sports and nutrition festival).
79646912|NCT00576550|Drug|betamethasone valerate|Application twice daily for two weeks
79646913|NCT00576589|Drug|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
79646914|NCT00576589|Drug|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
79646915|NCT00576706|Drug|Rebamipide|Rebamipide 100㎎, 12 weeks
79646916|NCT00576706|Drug|Misoprostol|Misoprostol 200㎍ 12 weeks
79646917|NCT00576745|Procedure|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
79646918|NCT00576745|Device|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
79809761|NCT05794724|Procedure|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
79809762|NCT05794711|Procedure|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
79809763|NCT05794698|Procedure|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
79809764|NCT05791162|Other|Blood collection|Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
79809765|NCT05791162|Other|Urine sample|Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
79809766|NCT05791097|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous infusion. 900 mg of ociperlimab will be administered on Day 1 of each 21-day cycle
79646919|NCT00180284|Device|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
79646920|NCT00576784|Drug|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
79646921|NCT00576862|Drug|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
79809767|NCT05791097|Drug|Placebo|Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
79809768|NCT05791097|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle
79977053|NCT06203288|Behavioral|Mindfulness-based social and emotional learning (MBSEL) program for educators|MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, & Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
79977054|NCT06203288|Behavioral|Mindfulness-based social and emotional learning (MBSEL) program for students|MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
79324032|NCT06275802|Behavioral|nutritional status, eating habits|At the beginning of the study (June 2022), an introductory form (sociodemographic characteristics, body image (Stunkart scale), dietary habits, knowledge about weight status) was applied to all students. Adolescent Nutrition Literacy Scale (ANLS), Instrument of Nutrition Literacy, Mediterranean Diet Quality Index (KID-MED), Eating Attitudes Test 26 (EAT-26), International Physical Activity Questionnaire Short Form (IPAQ) were applied, anthropometric measurements and three-day food consumption records were taken
79324033|NCT06275789|Procedure|Alveolar ridge preservation|Premolar tooth will be extracted flapless and ridge preservation procedure with bone grafting material will be done.
79324039|NCT06275763|Drug|Phase C: Eplerenone|Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
79324040|NCT06275763|Drug|Phase C: Spironolactone|Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
79324041|NCT06275763|Drug|Phase C: Torasemide|Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
79324042|NCT06275763|Drug|Phase B: Triplixam / Elestar HCT|Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
79809769|NCT05791097|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of pembrolizumab will be administered on Day 1 of each 21-day cycle
79809770|NCT05791097|Drug|Carboplatin|Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL*min) on Day 1 of each 21-day cycle
79809771|NCT05791097|Drug|Cisplatin|Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m^2) on Day 1 of each 21-day cycle
79324043|NCT06275763|Diagnostic Test|Phase A: Confirmation of uncontrolled hypertension|Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
79977055|NCT06203171|Other|Observational|Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
79977056|NCT06203067|Behavioral|Standard of Care|Quarterly clinic visits with endocrinology provider.
79646922|NCT04578808|Other|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
79646923|NCT04723199|Device|Electrocautetery LAMS|Electrocautetery LAMS
79977057|NCT06203067|Behavioral|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
79324044|NCT06275750|Device|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
79324045|NCT06275737|Other|Prehabilitation program|"Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)~Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)"
79324046|NCT06275724|Other|inclisiran|Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
79646924|NCT00576940|Drug|Reconvan|isocaloric, immunomodulating entral diet
79324047|NCT06275711|Behavioral|Therapeutic communication methods|Drawing pictures, story completion, breathing and relaxation exercises
79324048|NCT06275698|Dietary Supplement|Manuka honey MGO 1000|Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
79324049|NCT06275698|Dietary Supplement|Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
79324050|NCT06275685|Device|SeizureWise algorithm|An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
79646925|NCT00576940|Drug|Peptisorb|isocaloric, isopeptic standard diet
79646926|NCT00202020|Drug|Cilostazol 200mg/day Oral|
79646927|NCT00202020|Drug|Aspirin 100mg/day Oral|
79646928|NCT00577018|Drug|Prucalopride|4 mg o.d.
79646929|NCT00577018|Drug|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
79646930|NCT00577018|Other|Placebo|o.d.
79646931|NCT04578847|Drug|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
79646932|NCT04578847|Drug|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
79646933|NCT04578847|Drug|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
79646934|NCT04578847|Drug|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
79646935|NCT00180362|Device|procedure|
79809772|NCT05791097|Drug|Pemetrexed|Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m^2) on Day 1 of each 21-day cycle
79809773|NCT05791097|Drug|Paclitaxel|Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m^2) on Day 1 of each 21-day cycle
79646936|NCT00577057|Procedure|Conventional Radiotherapy|
79646937|NCT00577057|Procedure|Accelerated Radiotherapy|
79646938|NCT00577057|Drug|Cisplatin|
79809774|NCT05791097|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m^2) on Day 1, 8 and 15 of each 21-day cycle
79646939|NCT00577057|Drug|5-fluorouracil|
79646940|NCT00577057|Drug|Capecitabine|
79646941|NCT00187005|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
79646942|NCT00187005|Drug|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
79809775|NCT05783349|Biological|Unique blod sample|sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
79324051|NCT06275685|Device|Multi-day Visualizations|Multi-day visualizations of sensor derived data
79324052|NCT06275672|Other|Adapted version of the mhGAP-IG|An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
79324053|NCT06275659|Device|CT-100-004-A|Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
79324054|NCT06275659|Device|CT-100-004-B|The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
79324055|NCT06275646|Other|PRP layer|platelet rich plasma layer was applied in addition to dartos flap
79324056|NCT06275646|Other|dartos flap|dartos flap alone was used
79324057|NCT06275633|Drug|Levodopa|Medicine response
79324058|NCT06275620|Biological|AGTC-501 (high dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
79324059|NCT06275620|Biological|AGTC-501 (low dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
79324060|NCT06275620|Biological|AGTC-501 (high dose and modified corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
79324061|NCT06275607|Behavioral|Cognitive Behavioral Affective Therapy|Active training in regulating anger.
79809776|NCT05778721|Other|respond to questionnaires by telephone|Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
79324062|NCT06275607|Behavioral|Emotional Discussion|General discussion of emotions; no therapy or training is offered.
79324063|NCT06275594|Drug|Byfavo|For induction and maintenance of sedation
79324064|NCT06275594|Drug|Midazolam|For induction and maintenance of sedation
79977058|NCT06202924|Behavioral|Static balance assessment|Biodex stabilometer device will be used to evaluate the static balance of the participants.
79809777|NCT05768906|Other|observational|Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
79324065|NCT06275581|Device|Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)|Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
79324066|NCT06275581|Device|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
79480826|NCT05923645|Device|Transcranial magnetic stimulation (Hf rTMS)|"TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
79977059|NCT06202924|Behavioral|Dynamic balance assessment:|Individuals' dynamic balance performances were evaluated with the Y balance test. Y balance test is a test method with proven validity and reliability in athletes and healthy subjects. (Intra-class correlation 0.99-1, Inter-class correlation 0.85-0.91).
79324067|NCT06275568|Behavioral|Usual Care Fresh Connect cardholder engagement|"Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~Texts for all cardholders per month (1-2 outbound texts)~Welcome call from About Fresh cardholder engagement team~1 text - notification that Fresh Connect funds have been reloaded~As-needed program updates (e.g. new retailers), inactivity outreach~Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc."
79324068|NCT06275568|Behavioral|Enhanced engagement communication|Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
79977060|NCT06202924|Behavioral|Isokinetic strength evaluation:|Quadriceps muscle strength of the participants will be evaluated with an isokinetic dynamometer. Isokinetic dynamometers are considered the gold standard in muscle strength measurements. These devices have the ability to objectively report the amount of force produced by individuals at predetermined angular speed and joint range of motion.
79324070|NCT06275542|Device|Train of four monitoring device intraoperative|Only group B will receive reversal strategy based on the presence of TOF monitoring device prior to extubation. If they meet the criteria, patients will then be extubated.
79324071|NCT06275542|Drug|Neostigmine|For subjects in Group A, the first researcher calculated the time of the last administration of the muscle relaxant and the subject's spontaneous breathing efforts. Neostigmine was administered based on the reversal protocol. For subjects in the TOF monitoring group (Group B), the first researcher attached the TOF monitoring device. After it was attached and turned on, TOF stimulation was provided without calibration, with a stimulation intensity of 50 mA. Measurements were taken in a 12-second cycle mode. Neostigmine was administered according to the measured TOF value at the start of skin/muscle closure as the protocol.
79480827|NCT05923632|Behavioral|Dijital Game and Health Education|After the children in the experimental group are informed about the digital game designed according to The Roy Adaptation Model (RAM) and The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
79480828|NCT05923619|Procedure|Total pulpotomy|Total pulpotomy procedures explained in arm descriptions.
79480829|NCT05923619|Procedure|Root canal treatment|Root canal treatment procedures explained in arm descriptions.
79480830|NCT05923580|Behavioral|Group- based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
79480831|NCT05923554|Other|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
79480832|NCT05923541|Drug|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
79480833|NCT05923515|Drug|JMKX000197|for injection
79480834|NCT05923463|Behavioral|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
79480835|NCT05923463|Behavioral|standard feedback email messages|Providers receive metrics in a common format.
79480836|NCT05923450|Procedure|Colorectal Resection|Radical resection of colorectal cancer
79480837|NCT05923320|Behavioral|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
79480838|NCT05923281|Drug|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
79480839|NCT05923281|Drug|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
79480840|NCT05923281|Drug|Placebo (once daily)|Placebo tablet
79480841|NCT05923216|Dietary Supplement|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
79977061|NCT06202794|Device|Experimental: Experimental group|TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
79480842|NCT05923216|Dietary Supplement|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
79809778|NCT05763680|Diagnostic Test|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
79977062|NCT06202794|Device|Sham Comparator: Control group|Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
79977063|NCT06202599|Drug|Fruquintinib|For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
79977064|NCT06202378|Drug|3 ampoules of SHPL-49 Injection|3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
79324072|NCT06275542|Procedure|Air chalenge prior to extubation|After surgery was completed and the TOF ratio was ≥ 0.90, the TOF device was removed, and extubation was performed in Group B. In Group A, after a minimum of 15 minutes following reversal, patients received only ambient air without supplemental O2. Extubation was performed if the patient could maintain an SpO2 > 95% for a minimum of 3 minutes. If within 15 minutes after reversal the patient did not meet the extubation criteria, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed. If there was suspicion of opioid-induced hypoventilation, naloxone was administered at 0.4-0.8 mcg intravenously.If the patient was unable to maintain oxygen saturation for the 3-minute duration, oxygen supplementation was reinstated, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed.
79324073|NCT06275542|Device|Train of Four monitoring device in recovery room|Upon arrival in the recovery room, all subjects were fitted with SpO2, EKG, NIBP monitors, and the TOF monitoring device. TOF values were measured by a second researcher who was unaware of the type of intervention. Measurements were taken twice sequential
79324074|NCT06275529|Procedure|Transforaminal Epidural Steroid Injection|"Epidural injections have been used since about 1900 for the treatment of low back and lower extremity pain, with steroids added to local anesthetics in about 1950. The epidural space can be entered by 3 approaches: caudal, interlaminar, and transforaminal. Transforaminal Epidural Steroid Injections:~After the patient is monitored in pron position and asepsis is ensured, the epidural space is entered with the appropriate needle through the transforaminal space by giving the necessary angles to the fluoroscopy. Then the location is confirmed with radiopaque agent and steroid injection is performed. The procedure takes 15-20 minutes."
79324075|NCT06275516|Device|multi-sensory stimulation immersive VR+ treadmill training|Treadmill training with multi-sensory stimulation immersive VR in VR+treadmill training group
79646943|NCT00180401|Behavioral|CRT-P and CRT-D devices|
79646944|NCT00577330|Dietary Supplement|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
79324076|NCT06275516|Device|treadmill training|Only treadmill training in treadmill training group
79646945|NCT04579003|Other|Mobilization|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
79480843|NCT05923151|Procedure|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
79324077|NCT06275503|Behavioral|Screening invitation mode|Cluster randomized study to compare mode of invitation
79646946|NCT04579003|Other|Mobilization with movement|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
79646947|NCT00202059|Drug|Zoledronic acid|
79324078|NCT06275490|Biological|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
79324079|NCT06275490|Biological|L-PRF block|The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
79324080|NCT06275477|Diagnostic Test|68Ga-FAPI46|Depending on the situation, it is planned that this evaluation will be transversal (performing [68Ga] Ga-FAPI PET/CT at baseline) or longitudinal (performing [68Ga] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
79977065|NCT06202378|Drug|6 ampoules of SHPL-49 Injection|6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
79324081|NCT06275464|Combination Product|BT-600|NaviCap device containing liquid formulation of Tofacitinib
79324082|NCT06275464|Combination Product|BT-600 Placebo|NaviCap device containing placebo formulation
79324084|NCT06275438|Other|The delivery being performed via cesarean section surgery rather than natural childbirth|At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
79977066|NCT06202378|Drug|0.9% Sodium Chloride Injection|100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
79324085|NCT06275425|Drug|Total intravenous anesthesia with Byfavo|General anesthesia is maintained with intravenous continuous administration of Byfavo.
79324086|NCT06275425|Drug|Inhalation anesthesia with Sevoflurane|General anesthesia is maintained with Sevoflurane.
79646948|NCT00202059|Behavioral|Physical activity intervention|
79646949|NCT04578418|Dietary Supplement|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
79646950|NCT04578418|Other|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
79646951|NCT04578418|Dietary Supplement|Placebo|Placebo supplementation twice daily
79646952|NCT00180440|Device|ICD|all models of Guidant/Bsc ICD's
79977067|NCT06202235|Diagnostic Test|Magnetic Resonance Imaging|Both CKD Patients and Healthy Volunteers will undergo Magnetic Resonance Elastography (MRE) to evaluate liver and renal viscoelasticity. For CKD patients, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, CKD patients will undergo a renal biopsy to assess the extent of fibrosis
79324087|NCT06275412|Behavioral|The 3Ms 2.0 Intervention|The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
79324088|NCT06275412|Behavioral|Educational Attention Control (EAC)|The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
79324089|NCT06275399|Diagnostic Test|OCT examination|OCT examination for precise evaluation of plaque morphology within the coronary stenosis.
79324090|NCT06275399|Diagnostic Test|Blood sampling|Blood sampling directly from coronary artery (proximal and distal segment) arteries
79324091|NCT06275399|Diagnostic Test|Assessment of vFFR and shear stress parameters|The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
79324092|NCT06275386|Device|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
79480844|NCT05923047|Drug|Mepolizumab|Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
79324093|NCT06275373|Drug|Teprotumumab Injection [Tepezza]|IGF1 monoclonal antibody
79324094|NCT06275360|Drug|Nivolumab|Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
79324095|NCT06275347|Other|Low-fat normoprotein Controlled Ketogenic Diet.|Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.
79480845|NCT05923047|Procedure|Polypeptomy|This group will undergone in-office nasal polypectomy.
79646953|NCT00577369|Other|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
79646954|NCT00577447|Dietary Supplement|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
79977068|NCT06202222|Other|rehabilitation|The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.
79977069|NCT06202144|Device|Noninvasive support|Noninvasive respiratory support delivered through a helmet
79977070|NCT06202027|Drug|FGF23-related hypophosphataemic rickets and osteomalacia|FGF23-related hypophosphataemic rickets and osteomalacia
79977071|NCT06201806|Other|Test food breakfast with NCS or witout NCS|"Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups."
79977072|NCT06201715|Drug|Tofacitinib 5 MG|5mg tofacitinib tablet twice daily
79977073|NCT06201598|Device|Group 1 - Intervention 1|Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
79977074|NCT06201416|Biological|SBT777101|Experimental treatment
79977075|NCT06201130|Diagnostic Test|Suctioning of artificial airway|Collection of tracheal aspirates in either the PICU or NICU will occur. We will instill 1 mL of normal saline, then perform bag ventilation, and then suction out aspirate. Suctioning is routinely performed for tracheostomy and endotracheal tube hygiene - for instance, it is performed on tracheostomies by caregivers at home. The aspirates that will be collected will be clinically indicated and otherwise would be discarded. If the patients weren't enrolled in this research, the aspirates would have been collected anyways.
79977076|NCT06200987|Device|Penile vibrator|In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
79324096|NCT06275347|Other|Hypocaloric Balanced Diet|Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
79324097|NCT06275321|Other|Synchronous-supervised online home-based group|An online exercise program combining endurance and strength training
79324098|NCT06275321|Other|Exercise recommendation group|General recommendation about physical exercise. No supervised
79324099|NCT06275308|Other|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
79324100|NCT06275282|Device|Intramuscular electrodes|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
79324101|NCT06275269|Procedure|Ultrasound-Guided|Ultrasound-Guided Triamcinolone Injection
79324102|NCT06275269|Procedure|Translaryngeal Endoscopic Mucosal Injection|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone
79324103|NCT06275256|Procedure|Rezum|The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
79324104|NCT06275256|Device|iTind|The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
79324105|NCT06275243|Diagnostic Test|Kit Buccal swab collection & stabilization de Canvax®|Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
79324106|NCT06275243|Other|Cholesterol levels according to ApoE Genotype|Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
79324107|NCT06275243|Other|Assessing cardiovascular risk factors in all participants|Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
79646955|NCT00577447|Dietary Supplement|Placebo|Placebo capsule containing corn and soybean oil
79324108|NCT06275217|Behavioral|Mindfulness-based yoga program|The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
79324109|NCT06275217|Other|Psychoeducation|Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
79324110|NCT06275204|Drug|Bismuth-based quadruple therapy|"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
79646956|NCT00180518|Device|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
79646957|NCT00187044|Biological|PolyEnv1 vaccine|administered subcutaneously as 10*7 pfu in 0.8 mL
79324111|NCT06275204|Drug|Levofloxacin-based quadruple therapy|"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
79324112|NCT06275204|Drug|Standard triple therapy|"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
79324113|NCT06275204|Drug|Levofloxacin-based triple|"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
79324116|NCT06275178|Procedure|Medical thoracoscopy|The included particpants are the patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy.
79646958|NCT00577603|Procedure|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
79646959|NCT00577603|Other|no intervention|
79646960|NCT00577681|Drug|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
79646961|NCT02963675|Other||external unexposed reference group
79646962|NCT00577759|Other|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
79646963|NCT00577759|Other|Passive Intervention|Provision of tools to help with referrals to community resources
79646964|NCT00577759|Other|No intervention|No intervention
79646965|NCT00577798|Procedure|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
79646966|NCT00187083|Drug|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
79646967|NCT00187083|Drug|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
79809779|NCT05754294|Diagnostic Test|Polarization of red blood cells|Pre and perioperative data blood sample were collected for each patient 5 minutes (min) before the CPB start and 5 minutes before the end of the CPB for Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR) and Plasma Free Hemoglobin (pFHb). At the end of CPB the residual blood from the extracorporeal circulation was treated with cell-saver and the treated and concentrated red blood cells were collected in a transfusion bag. Two milliliters (ml) was taken from the bag, one ml was subjected to a blood gas test for the evaluation of the Hemoglobin (Hb) content and one ml was subjected inside a cuvette to the release of positive ions (polarization) with a charge of 50 Millivolt (mV) for a time of 5 seconds through charge circuit, after the trend of the conserved charge was measured through a multimeter, instrument that can measure multiple electrical properties.
79809780|NCT05712850|Procedure|SiJoin® Transfixing Sacroiliac Fusion Device|Sacroiliac Fusion
79646968|NCT00187083|Drug|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
79646969|NCT00187083|Drug|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
79646970|NCT00187083|Drug|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
79977077|NCT06200701|Behavioral|Job Crafting program|The training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
79646971|NCT00187083|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
79646972|NCT00577837|Drug|risedronate|tablet, 5 mg risedronate daily for 6 months
79809781|NCT05709223|Device|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
79809782|NCT05709223|Device|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
79324120|NCT06275139|Other|Integrated Assessment of Cervicocerebral Vessels|Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment.
79324121|NCT06275126|Other|CONSYDER decision aid|Web-based breast cancer surgery decision aid
79324122|NCT06275100|Other|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
79324125|NCT06275074|Procedure|Dry Needling|Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
79324126|NCT06275074|Other|Therapeutic Exercise|Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
79646973|NCT00577837|Drug|risedronate|tablet, 100 mg risedronate monthly for 6 months
79646974|NCT00577837|Drug|risedronate|tablet, 150 mg risedronate monthly for 6 months
79646975|NCT00577837|Drug|experimental|tablet, 200 mg risedronate monthly for 6 months
79646976|NCT00180557|Device|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
79646977|NCT00577876|Procedure|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
79646978|NCT00577915|Other|Radiology/MRI scan|MRI spectroscopy
79646979|NCT00577954|Procedure|Multimodal MRI|Multimodal MRI
79646980|NCT00202098|Procedure|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
79809783|NCT05705908|Other|Hot Foot Bath 1|"Hot foot bath device has a built-in heater (max. 44°C),~Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
79324127|NCT06275061|Procedure|Metabolic and Bariatric Surgery|Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
79324128|NCT06275048|Other|Wrist/hand immobilization|Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.
79480846|NCT05923021|Other|cheek acupuncture|Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
79324129|NCT06275035|Drug|Memantine Oral Tablet|Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
79480847|NCT05922995|Drug|Tasimelteon|20 mg capsules taken on a nightly basis
79977078|NCT06200649|Other|massage|Massage application; It will be done on the back, which is the five basic massage areas. Massage application will be started with eflorage. The massage will be continued with petrissage by grasping the subcutaneous tissue and muscle layer with the help of thumb and other fingers, starting from the waist circumference. Petrissage will be applied for 5 minutes. After petrissage, the massage was continued with friction movements, which is the other stage. Friction will be applied for 5 minutes. Tapotment will be done after friction. Tapotman will take 5 minutes. After taping, the entire back area will be finished by efflorescence for 2 minutes, just like at the beginning.
79977079|NCT06200415|Drug|Glucosamine Sulfate|Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
79324130|NCT06275022|Procedure|Inflow occlusion with perforation of septation and sclerotherapy|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
79977080|NCT06200415|Drug|Ginger Oil|Ginger (Zingiber officinale Roscoe) has been found to have biological activities such as antioxidant, anti-inflammatory, antimicrobial, and anticancer activities.
79977081|NCT06200350|Other|Experimental group|Tailored training based on the profile of each participant.
79324131|NCT06275022|Procedure|Perforation of septation and sclerotherapy|Perforation of septation and sclerotherapy
79324132|NCT06275022|Procedure|Indocyanine green-guided partial resection and sclerotherapy|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
79480848|NCT05922839|Drug|Zanubrutinib|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
79977082|NCT06200350|Other|Control group|They will continue with the traditional training.
79324133|NCT06275022|Procedure|Partial resection and sclerotherapy|Partial resection and sclerotherapy
79324134|NCT06274996|Drug|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
79480849|NCT05922813|Biological|BMI2004|hyaluronidase, recombinant
79480850|NCT05922813|Other|0.9% NaCl|Normal Saline
79646981|NCT00578032|Behavioral|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
79646982|NCT00180596|Device|Contak heart failure devices|
79646983|NCT00578110|Device|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
79646984|NCT00578149|Drug|Bevacizumab|
79646985|NCT00578149|Drug|Carboplatin|
79646986|NCT00578149|Drug|Paclitaxel|
79480851|NCT05922800|Device|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
79977083|NCT06200155|Drug|Psilocybin|Given by PO
79977084|NCT06200155|Other|Niacin|Given by PO
79646987|NCT00187122|Drug|Vincristine|See Detailed Description section for description of treatment plan.
79646988|NCT00187122|Procedure|Radiation Therapy|See Detailed Description section for description of treatment plan.
79977085|NCT06199765|Other|Needlestick Injury Prevention|this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
79646989|NCT00187122|Drug|Daunomycin|See Detailed Description section for description of treatment plan.
79977086|NCT06198517|Other|Moxibustion|The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
79646990|NCT00187122|Drug|L-Asparaginase|See Detailed Description section for description of treatment plan.
79646991|NCT00187122|Drug|Cytarabine|See Detailed Description section for description of treatment plan.
79646992|NCT00187122|Drug|Methotrexate|See Detailed Description section for description of treatment plan.
79646993|NCT00187122|Drug|Mercaptopurine|See Detailed Description section for description of treatment plan.
79977087|NCT06198517|Other|Symptomatic treatment|The control group received conventional symptomatic treatment.
79646994|NCT00187122|Drug|Etoposide|See Detailed Description section for description of treatment plan.
79646995|NCT00187122|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
79646996|NCT00187122|Drug|Prednisone|See Detailed Description section for description of treatment plan.
79646997|NCT00187122|Drug|Dexamethasone|See Detailed Description section for description of treatment plan.
79646998|NCT00180635|Drug|Aminoguanidine|500mg
79646999|NCT00180635|Drug|Placebos|2ml
79977088|NCT06197815|Behavioral|The assistance type during ERCP|The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
79480852|NCT05922800|Drug|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
79977089|NCT06197087|Other|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
79480853|NCT05922748|Other|imaging|Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest
79480854|NCT05922748|Other|Evoked Potentials|EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz
79480855|NCT05922748|Other|MEG|MEG signals reflect changes in magnetic field evoked by changes in neuronal activity
79480856|NCT05922748|Behavioral|Behavioural tests|Behavioural tests will be evaluated.
79809784|NCT05705908|Other|Hot Foot Bath 2|"Hot foot bath device has a built-in heater (max. 44°C),~Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~3 drops of lavender essential oil were dripped in the water"
79809785|NCT05692128|Other|Hematological and chemistry tests|Laboratory tests
79809786|NCT05690425|Drug|BC3402 Injection|Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
79809787|NCT05683873|Procedure|Electrocardiogram|Inclusion visit, V1, V2 and V3
79809788|NCT05683873|Procedure|transthoracic echocardiography|V1, V2 and V3
79809789|NCT05683873|Biological|standard biology|Inclusion visit
79809790|NCT05683873|Biological|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
79809791|NCT05683873|Biological|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
79809792|NCT05683873|Other|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
79809793|NCT05683873|Other|72-hour continuous Holter-ECG recording|V1
79809794|NCT05677893|Drug|MBS-COV|MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
79809795|NCT05677893|Other|Placebo|Normal saline
79809796|NCT05664659|Drug|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
79809797|NCT05664659|Drug|Carbetocin|100 micrograms carbetocin
79809798|NCT05661370|Other|Dermloop Learn|Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
79809799|NCT05627479|Drug|GIK solution|Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.
79809800|NCT05627479|Drug|Isotonic Normal Saline Solution|Placebo injection - administered intravenously.
79809801|NCT05626478|Drug|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
79809802|NCT05626478|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
79809803|NCT05626478|Drug|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
79809804|NCT05625113|Device|neuroprosthesis|Use at least one time every day the gripping neuroprosthesis in daily life activities.
79809805|NCT05616884|Procedure|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
79809806|NCT05604001|Device|hysteroscopic ablation of submucous uterine fibroid using diode laser|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma
79809807|NCT05600309|Biological|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
79809808|NCT05600309|Drug|regorafenib|Oral
79809809|NCT05600309|Drug|TAS-102|Oral
79480857|NCT05922735|Behavioral|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
79480858|NCT05922696|Drug|Cholecalciferol|50.000IU weekly in Group A , or 200.000IU monthly in Group B
79480859|NCT05922670|Behavioral|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
79809810|NCT05578079|Other|Music|"Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach."
79809811|NCT05578079|Other|Music|Intervention-2 group will listen to lullaby.
79324136|NCT06274970|Other|Enhanced recovery protocols|Enhanced recovery Protocol with Recommendations Preoperative Consideration-Preadmission education, nutritional assessment, Peri operative Calcium and Vitamin D supplementation, Reduce preoperative fasting Preoperative fasting, Precarb drink (250ml= 1glass) administered to the patient at 6:00 AM, Nutrition interventions individualized, Antibiotic prophylaxis, Postoperative nausea and vomiting prophylaxis, Patients should receive short acting anxiolytics Operative Considerations-Hypothermia prevention, Goal-directed fluid management,Nerve monitoring can prevent nerve injuries, may be useful Dressings and drain use -individualized Postoperative Considerations- No post operative antibiotics in clean surgery, Pain management Opioid-sparing, multimodal analgesia, Postoperative Early mobilization, Urinary catheters should be removed less than 24 hours after completion of surgery Perioperative pulmonary physical therapy Steam Inhalation Incentive spirometry Chest Physiotherapy
79977090|NCT06196450|Dietary Supplement|Vivomixx|Vivomixx is a commercially available probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis.
79977091|NCT06196450|Dietary Supplement|Microcrystalline maltose|Microcrystalline maltose as placebo
79977092|NCT06196320|Drug|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
79977093|NCT06196320|Drug|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
79977094|NCT06195228|Drug|dabrafenib plus trametinib with or without PD-1 antibody|advanced thyroid cancer patients who harbor BRAF V600E mutation
79977095|NCT06195228|Drug|entrectinib or larotrectinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor NTRK mutation
79647000|NCT00578266|Drug|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT~6 5 CYTOXAN 50 mg/kg WITH MESNA~5 CYTOXAN 50 mg/kg WITH MESNA;~4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~2 TBI; CAMPATH; TACROLIMUS~1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
79647001|NCT00578422|Other|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
79647002|NCT00578422|Procedure|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
79647003|NCT04578496|Drug|Afamelanotide|
79647004|NCT00202137|Behavioral|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
79647005|NCT00202137|Behavioral|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
79977096|NCT06195228|Drug|pralsetinib or selpercatinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
79809812|NCT05574114|Radiation|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
79977097|NCT06195228|Drug|anlotinib or anlotinib plus anti-PD-1 antibody|For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
79977098|NCT06195228|Drug|lenvatinib plus anti-PD-1 antibody|Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
79977099|NCT06195228|Drug|Other Targets: precise treatment based on the target|Advanced thyroid cancer patients who had other treatment targets not included above
79977100|NCT06194162|Device|Weighted blanket|"The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment. Participants will be asked to choose one out of at least three different weighted blankets, each with different weight classes. The choice of weighted blanket is solely taken by the participant after having tried all five blankets.~Adherence to the weighted blanket intervention is defined as reported use 60 % of the intervention period.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
79324137|NCT06274970|Other|Conventional Protocols|Preoperative- Antibiotic prophylaxis, short or long-acting anxiolytics, no post operative nausea and vomiting, no Serum vitamin D correction Operative-Hypothermia prevention, Postoperative- Routine use of post operative prophylactic antibiotics, pain management multimodal analgesia, urinary catheters maybe be removed less than 24 hours after completion of surgery, Perioperative pulmonary physical therapy Steam Inhalation Incentive spirometry Chest Physiotherapy
79324138|NCT06274957|Other|CONTROL|Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education
79324139|NCT06274957|Device|PEP DEVICE|"Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device."
79647006|NCT00578500|Procedure|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
79977101|NCT06194162|Device|Non-weighted blanket|"The control comparator will receive a sham intervention in the form of a non-weighted blanket as an add on to usual care. Participants will be asked to choose one out of two different sham blankets.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
79977102|NCT06194019|Device|lung ultrasonography|N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.
79647007|NCT00578578|Dietary Supplement|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
79977103|NCT06192485|Other|proactive balance training|20 participants will receive a proactive balance training program
79977104|NCT06192485|Other|Reactive balance training|20 participants will receive a Reactive balance training program
79647008|NCT00578656|Dietary Supplement|Baked Milk|Extensively heated milk
79647009|NCT00578851|Device|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
79647010|NCT00578890|Procedure|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
79809813|NCT05574114|Drug|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
79977105|NCT06191848|Drug|Tirzepatide|Participants will receive tirzepatide subcutaneously
79977106|NCT06191848|Drug|Placebo|Participants will receive placebo subcutaneously
79977107|NCT06190795|Other|AMPLIFY Smartphone Application|AMPLIFY Smartphone Application enables prescription and progression of exercises/functional activities, while offering immediate feedback on upper limb movement performed, real-time logging and monitoring of adherence through virtual platform
79977108|NCT06190795|Other|Hardcopy Manual|Hardcopy Manual
79977109|NCT06190080|Other|Digestive endoscopy|Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
79809814|NCT05574114|Biological|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
79977110|NCT06190054|Device|MERAMIRT|"MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role"
79977111|NCT06190028|Device|Iridium A Gel|IRIDIUM® A gel is a sterile, preservative free ophthalmic gel, containing Carbopol, amino acids, Echinacea and Aloe extract. IRIDIUM® A gel is indicated for the protection of the eye surface particularly at night, even in the presence of changes in histological continuity and blepharitic conditions, including those of an iatrogenic nature, following the use of hypotonic eye drops and of the preservatives contained therein.
79324140|NCT06274957|Device|HFCWO DEVICE|"Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device"
79324141|NCT06274944|Device|nasogastric tube placement pH confirmation device|Each participation will get the contents tested by the novel device and the standard of care procedure.
79324142|NCT06274931|Procedure|Bronchoscopy|Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.
79480860|NCT05922631|Procedure|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
79647011|NCT00579007|Behavioral|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
79324143|NCT06274918|Device|Personalized Body-Worn Alcohol Dispenser|This is an alcohol dispenser that will be worn on the Anesthesia Providers scrub pants, near the hip. It will be worn by both the attending physician and the resident physician/CRNA/SRNA. The device is produced by Georgia-Pacific.
79324144|NCT06274905|Drug|EMLA|EMLA cream
79324145|NCT06274905|Drug|Ethyl chloride|Ethyl chloride
79324146|NCT06274905|Drug|Aqueous cream BP|Aqueous cream
79324147|NCT06274892|Other|Remote monitoring PROs|Attendance at RT review appointments triaged based on remotely monitored PROs
79324148|NCT06274879|Drug|Gemcitabin, Cisplatin and Durvalumab|CICI (Gemcitabin d1 & d8 Cisplatin d1 & d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.
79480861|NCT05922631|Procedure|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was <30cmH2O
79480862|NCT05922592|Procedure|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
79809815|NCT05569694|Other|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
79480863|NCT05922592|Procedure|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
79324149|NCT06274879|Procedure|Biliary Radiofrequency Ablation|Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks
79480864|NCT05922553|Behavioral|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
79480865|NCT05922553|Behavioral|Common Mukbang|Common Mukbang videos made and uploaded by the famous Mukbang makers.
79480866|NCT05922553|Behavioral|General short videos|Short videos that don't contain any food cues.
79480867|NCT05922540|Other|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
79480868|NCT05922488|Procedure|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
79480869|NCT05922488|Procedure|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
79480870|NCT05922475|Dietary Supplement|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
79647012|NCT00579046|Drug|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
79809816|NCT05560490|Device|FibroFix Cartilage P Knee Implantation|The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
79480871|NCT05922475|Other|Placebo|Resistance exercise training only group did not consume supplemental protein.
79480872|NCT05922436|Drug|QLG2071|intravenous injection
79480873|NCT05922436|Drug|Cleviprex®|intravenous injection
79977112|NCT06189625|Other|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~Application of local ice for a maximum of 10 minutes as required.~Elevation of the affected limb when resting.~Early mobilization and load according to tolerance, using crutches if required.~Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
79647013|NCT00579085|Drug|Ketamine|IV Ketamine .35mg/kg times ten days.
79647014|NCT00579085|Other|IV NSS|Placebo inactive ingredients
79647015|NCT00579085|Other|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
79647016|NCT00579202|Device|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
79809817|NCT05531214|Behavioral|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
79324150|NCT06274879|Procedure|Endoscopic Retrograde Cholangio-Pancreatography with stenting|ERCP with stenting are applied at baseline and as clinically indicated
79324151|NCT06274866|Other|exercise program|Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program
79324152|NCT06274866|Other|control group|Individuals in the control group were followed up with an exercise training brochure.
79480874|NCT05922410|Radiation|cone beam computed tomography|cone beam computed tomography
79480875|NCT05922384|Drug|KL-7SHRNA injection solution|Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
79480876|NCT05922371|Diagnostic Test|NuQ H3.1 Nucleosome Assay|Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
79324153|NCT06274853|Drug|GS-441524|Oral GS-441524 capsules
79977113|NCT06189625|Procedure|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended."
79324154|NCT06274853|Drug|Placebo|Placebo capsules
79809818|NCT05489627|Procedure|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
79324156|NCT06274814|Procedure|ultrasound guided Rhomboid intercostal block (RIB) and the RIB combined with the sub-serratus plane block (RISS)|"RIB group patient positioned in the lateral decubitus position with the breast on the operating side lying superiorly. The ipsilateral arm was abducted.~RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected."
79324157|NCT06274801|Drug|Seralutinib|Capsule containing seralutinib
79324158|NCT06274801|Device|Gereic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib delivery
79324159|NCT06274788|Drug|Omegaven® (fish oil triglycerides) Injectable Emulsion|"Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator"
79324160|NCT06274775|Other|Educational Video|Educational video about the nail biopsy procedure
79324161|NCT06274762|Other|Training and BSE application on a model|A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
79809819|NCT05488795|Behavioral|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
79809820|NCT05481645|Drug|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
79809821|NCT05481645|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
79324164|NCT06274736|Device|Motiva Sizer|No intervention will be made,
79977114|NCT06188286|Other|Transcutaneous electrical acupoint stimulation|The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.
79977115|NCT06188286|Other|sham Transcutaneous electrical acupoint stimulation|The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output
79324165|NCT06274723|Other|Expert|Participants will view a brief description of an expert source.
79977116|NCT06186726|Radiation|carbon ion radiotherapy|The patients received 72GyE/18 doses of carbon ion radiotherapy.
79324166|NCT06274723|Other|Peer|Participants will view a brief description of a peer source.
79977117|NCT06185452|Drug|Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
79977118|NCT06185452|Drug|Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
79324167|NCT06274723|Other|1 Sided|Participants will view e-cigarette education messages in one-sided.
79324168|NCT06274723|Other|2 Sided|Participants will view e-cigarette education messages in two-sided.
79324169|NCT06274710|Behavioral|ODYSSEE-KH|Automated digital counselling program
79324170|NCT06274697|Device|Evaluation by magnetic sensor|Evaluation by magnetic sensor on arm and leg
79809822|NCT05481645|Drug|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
79809823|NCT05481645|Drug|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
79324172|NCT06274671|Other|Magnetic Resonance Imaging|A Magnetic Resonance Imaging (duration: about 60 minutes) with research sequences for the visualization of alterations of the glymphatic system.
79977119|NCT06184945|Behavioral|Realtime audit and feedback|ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data
79324173|NCT06274658|Behavioral|High-intensity interval exercise|Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
79977120|NCT06184945|Behavioral|RN Implementation Facilitator|ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation
79977121|NCT06183983|Diagnostic Test|Extended MRI|The MRI-protocol before radiotherapy is extended with 20 minutes.
79324174|NCT06274645|Device|The OptiCross High Definition (60 MHz) and OptiCross (40MHz) Intravascular Ultrasound (IVUS) catheter from Boston Scientific|The IVUS-guided PCI procedure includes the use of IVUS before PCI (highly recommended) and after PCI (mandatory)
79480877|NCT05922358|Combination Product|Anti-allergic treatment|"For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h*1h, 45ml/h*1h, then 225ml/h*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h*0.5h, then 150ml/h*3 hours."
79480878|NCT05922345|Drug|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
79480879|NCT05922345|Drug|TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
79324175|NCT06274632|Behavioral|ADELANTE|A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
79324176|NCT06274619|Biological|RSV A Memphis 37|RSV A Memphis 37 challenge agent
79977122|NCT06183320|Procedure|Restoration with Incremental Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
79977123|NCT06183320|Procedure|Restoration with Bulk Fill Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
79977124|NCT06182332|Other|Electronic Health Record Review|Undergo medical record review
79977125|NCT06182332|Other|Internet-Based Intervention|Use AI algorithm
79324177|NCT06274606|Other|Exercise Group|Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
79324178|NCT06274593|Device|OCT|Peripapillary angiography (OCT) at baseline and each year during 3 year
79324179|NCT06274580|Device|embolization of the middle meningeal artery|Embolization of the MMA is occluded with PVA particles or liquid embolizing materials
79809824|NCT05481645|Drug|Doxorubicin Hydrochloride Injection|Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
79809825|NCT05481645|Drug|Gemcitabine Hydrochloride Injection|Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
79977126|NCT06180902|Diagnostic Test|Inferior vena cava's diameter ratio|"In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as [(IVCmax - IVCmin) / IVCmin] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is [(IVCmax - IVCmin) / IVCmax] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values < 18% denote 'non-responders'."
79977127|NCT06180902|Diagnostic Test|Central venous pressure|"In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~CVP > 12 mmHg (16.3 cm H2O) indicates a non-responder."
79324180|NCT06274567|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
79324181|NCT06274567|Device|Sham (placebo) TMS|Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
79324182|NCT06274554|Drug|Fluconazole|Oral fluconazole capsules.
79647017|NCT04578262|Procedure|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
79809826|NCT05481645|Drug|Docetaxel injection|Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
79809827|NCT05425498|Other|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
79324183|NCT06274554|Drug|Placebo|Oral placebo capsules will be used as a comparator.
79324184|NCT06274554|Biological|IL-23 Therapy|Risankizumab (IL-23) or Ustekinumab (IL-12/23) as standard of care treatment.
79324185|NCT06274541|Genetic|Somatic and Germline BRCA1/2 Testing|Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
79324186|NCT06274528|Drug|Lemborexant 10 mg|Within FDA approved dose 10 mg; capsule; QD, 6 month duration
79324187|NCT06274528|Drug|Lemborexant 20mg|20 mg; capsule; QD; 6 month duration
79324188|NCT06274528|Drug|Placebo|0 mg; capsule; QD; 6 month duration
79809828|NCT05410925|Drug|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
79324189|NCT06274515|Procedure|Tumor Tissue and Blood Draw|Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
79324190|NCT06274502|Other|YOLOv8|After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model.
79324193|NCT06274476|Other|implant placement|ridge splitting piezo surgery and implant placement
79324194|NCT06274463|Behavioral|Exercise therapy including a trunk stabilization exercise program|All patients will undergo 30 sessions of exercise therapy, including a trunk stability exercise program, for 30 minutes per day, 5 days a week for 6 weeks
79324195|NCT06274450|Combination Product|skin care product|Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream
79647018|NCT04578262|Procedure|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
79647019|NCT04577950|Procedure|Lymphatic drainage of endometrial cancer|Nanocoll® is injected a day before surgery in the cervix at four points. A lymphoscintigraphy is performed 2 or 3 hours afterward. At the beginning of the surgery, the operative field already in place and before the beginning of laparoscopic, 2ml (10mg) of ICG, distributed in four points around the tumor, is injected under the endometrium intra-myometrial under endoscopic control. As ICG spreads slower than blue dye, ICG is always injected first. Then, Bleu Patenté® is injected at two sites in the uterine isthmus, opposite of the uterine arteries. The risk of false negative results, because a tracer migrated too quickly, is reduced when the injection takes place when patients are already anesthetized.
79324196|NCT06274450|Other|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
79324197|NCT06274437|Drug|BND-35|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
79324198|NCT06274437|Drug|Nivolumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
79324199|NCT06274437|Drug|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
79324200|NCT06274424|Behavioral|The Friends Program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
79977128|NCT06180902|Diagnostic Test|Passive leg raising test|"In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~Over 10% Pulse Pressure (PP) increase in the second measurement;~The ratio of PP change to CVP change (∆PP / ∆CVP) > 1;~Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~Less than 10% PP increase in the second measurement;~The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~Second measurement CVP > 12 mmHg (16.3 cm H2O)."
79324201|NCT06274411|Procedure|Standby cannulated ECMO|Femoral cannulas are inserted and connected to the primed circuit. Clamps are kept on circuit, and ECMO is on standby during PCI. ECMO is initiated if needed.
79324202|NCT06274411|Procedure|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI.
79324203|NCT06274398|Drug|TAF/EVG rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
79324204|NCT06274398|Drug|Matching placebo rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
79324205|NCT06274385|Dietary Supplement|Betalain-rich concentrate (AltRed)|"A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
79480880|NCT05922306|Drug|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
79480881|NCT05922306|Drug|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
79480882|NCT05922228|Other|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
79480883|NCT05922228|Other|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
79324206|NCT06274385|Other|Placebo|"A single dose (2 x empty capsules) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
79324207|NCT06274372|Device|flow controlled ventilation|effects of flow controlled ventilation
79809829|NCT05410925|Drug|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
79647020|NCT04578067|Behavioral|Lifestyle intervention|on physical activity and healthier eating
79647021|NCT00187161|Drug|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
79809830|NCT05397652|Drug|Tranexamic Acid Injectable Product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
79324208|NCT06274372|Device|volume controlled ventilation|effects of volume controlled ventilation
79324209|NCT06274359|Behavioral|Digital storytelling|Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
79324210|NCT06274346|Other|Multiangular Isometric exercise|already were described in arm descriptions
79324211|NCT06274333|Drug|Dexmedetomidine 0.5 mic/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
79324212|NCT06274333|Drug|Tramadol 1mg/kg|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
79324213|NCT06274333|Drug|Paracetamol 10mg/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
79324216|NCT06274307|Procedure|Transversus abdominis plane block|A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
79324217|NCT06274294|Drug|CT-P13|Induction treatment.
79647022|NCT04578184|Diagnostic Test|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
79324218|NCT06274281|Device|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
79647023|NCT00579475|Drug|Mifegyne|tablets, 50 mg every other day
79324219|NCT06274281|Other|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
79647024|NCT00579475|Drug|placebo|
79647025|NCT00579592|Drug|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
79647026|NCT00579631|Behavioral|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
79647027|NCT00180791|Drug|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
79647028|NCT01054248|Drug|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
79324220|NCT06274268|Diagnostic Test|Sarcopenia diagnostic test|the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
79324221|NCT06274242|Dietary Supplement|Haruna|Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)
79977129|NCT06180902|Diagnostic Test|Fluid challenge|"In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~Pulse Pressure (PP) increase > 10% in second measurement;~Ratio of PP change to CVP change (∆PP / ∆CVP) > 1;~Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~PP increase < 10% in second measurement;~Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~Second CVP measurement > 12 mmHg (16.3 cm H2O)."
79324222|NCT06274242|Dietary Supplement|Placebo Powder|Isolate Soy Protein and Isomalt
79324223|NCT06274229|Other|Air pollution and noise reducing installations|A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.
79324224|NCT06274216|Drug|Vitamin D3|5000 IU of vitamin D3 orally every day for 12 weeks
79480885|NCT05922189|Other|SBS Decompression Technique|The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
79480886|NCT05922189|Other|Placebo Technique|The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
79480887|NCT05922163|Device|Evidence-based VR simulation|Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
79480888|NCT05922150|Radiation|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
79647029|NCT01054248|Drug|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
79647030|NCT01054248|Drug|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
79647031|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
79647032|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
79480889|NCT05922150|Drug|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
79480890|NCT05922137|Behavioral|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and limiting alcohol consumption
79324225|NCT06274216|Drug|Vitamin E 400|400mg of vitamin E orally every day for 12 weeks
79480891|NCT05922137|Behavioral|Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
79647033|NCT00579904|Dietary Supplement|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
79647034|NCT00579904|Dietary Supplement|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
79647035|NCT00180830|Drug|Glivec|
79647036|NCT00180830|Drug|Gleevec|
79324226|NCT06274203|Drug|Vitamin D3|Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (<20 ng/mL): 200,000 IU.
79809831|NCT05397652|Drug|Placebo|Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
79977130|NCT06180902|Procedure|Fluid infusion|After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: [(CO(after) - CO(before)) / CO(before)] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
79977131|NCT06179446|Biological|PF-07985819 pdmFlu Vaccine|Intramuscular injection
79324227|NCT06274190|Diagnostic Test|bowel e-diary|This bowel diary will be available on the smartphone in the form of an application.
79324228|NCT06274177|Device|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
79809832|NCT05397405|Drug|PCSK9 inhibitor|The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
79809833|NCT05385341|Other|Telerehabilitation (Tele RCV)|20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.
79809834|NCT05385341|Other|Rehabilitation (RCV)|20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
79324232|NCT06274151|Drug|Naproxen 500 Mg|Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
79324233|NCT06274151|Procedure|Rehabilitation|Rehabilitation after muscle strain injury
79324234|NCT06274151|Drug|Placebo|Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
79480892|NCT05922111|Device|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
79480893|NCT05922111|Device|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
79480894|NCT05922098|Other|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
79480895|NCT05922072|Procedure|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
79480896|NCT05922072|Procedure|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
79480897|NCT05922020|Other|Oxygen gas|Administration of Oxygen by inhalation
79480898|NCT05921929|Drug|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
79480899|NCT05921890|Drug|GS3-007 oral liquid|The dosage was calculated according to body weight, once a day or twice a day.
79480900|NCT05921877|Diagnostic Test|venous sampling|venous sampling
79480901|NCT05921851|Other|no intervention|no intervention
79480902|NCT05921838|Other||
79480903|NCT05921825|Diagnostic Test|Red cell distribution width|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
79480904|NCT05921825|Diagnostic Test|lactate albumin ratio measurement|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
79809835|NCT05368077|Procedure|Adenotonsillectomy|Adenotonsillectomy is a standard surgical procedure for pediatric OSA treatment, which involves removal of hypertrophied tonsils and adenoids.
79809836|NCT05345522|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
79809837|NCT05345522|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
79324236|NCT06274125|Procedure|Robotic-Assisted Laparoscopic Radical Prostatectomy|To evaluate kidney damage in patients undergoing robotic radical prostatectomy, NGAL measurement will be performed.
79324237|NCT06274112|Device|TMS|TMS will be administered in either an active format that induces neuromodulatory effects or a sham comparison format that does not induce neuromodulatory effects.
79480905|NCT05921799|Procedure|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
79480906|NCT05921773|Device|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
79480907|NCT05921773|Device|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
79480908|NCT05921734|Procedure|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
79977132|NCT06179446|Biological|Placebo|Intramuscular injection
79977133|NCT06179446|Biological|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
79977134|NCT06179368|Diagnostic Test|hypothroidism|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
79480909|NCT05921734|Procedure|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
79480910|NCT05921721|Device|EOS|This modality simultaneously captures biplanar radiographs (anteroposterior and lateral images) through the whole-body slot scanning with patients in standing position with ultralow irradiation
79480911|NCT05921708|Other|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
79480912|NCT05921708|Other|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
79977135|NCT06179368|Diagnostic Test|euothyroid|throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
79977136|NCT06179225|Behavioral|HMD AR|Older adults will wear head mounted display to engage in collaborative augmented reality activities: sharing a meal, playing board games, and decorating home.
79324238|NCT06274099|Other|nursing care|It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
79324239|NCT06274086|Procedure|Two-session catheter-directed sclerotherapy|"After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook)."
79324240|NCT06274073|Procedure|Dorsal digital block|Dorsal regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedure mentioned are compared)
79324241|NCT06274073|Procedure|Palmar digital block|Palmar regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedures mentioned are compared)
79480913|NCT05921708|Other|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
79480914|NCT05921708|Other|Assessment4|Body-Cathexis Scale (BCS)
79809838|NCT05345522|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
79809839|NCT05342584|Drug|Venetoclax Oral Tablet|Given PO
79809840|NCT05342584|Drug|Daunorubicin|Given IV
79977137|NCT06179225|Behavioral|2-D AV|Older adults will use 2-D AV to engage with family members at a distance.
79809841|NCT05342584|Drug|Cytarabine|Given IV
79809842|NCT05340504|Drug|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
79809843|NCT05340504|Drug|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
79977138|NCT06178341|Device|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
79977139|NCT06177665|Other|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
79480915|NCT05921708|Other|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
79480916|NCT05921695|Drug|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
79809844|NCT05338658|Drug|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
79480917|NCT05921682|Other|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
79480918|NCT05921669|Behavioral|Provide breastfeeding education|Providing breastfeeding education within the first 24 hours after birth
79809845|NCT05333549|Drug|Istradefylline|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
79809846|NCT05323084|Dietary Supplement|Dietary supplement|1 week of each intervention at bedtime with a 2-week washout period in between interventions
79809847|NCT05319652|Behavioral|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
79809848|NCT05309993|Device|PTNS|See arm description
79809849|NCT05309993|Device|TENS|See arm description
79809850|NCT05308693|Other|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
79480919|NCT05921656|Other|Construction and evaluation of airway leakage risk model of patients with endotracheal tube|"Conduct statistical analysis on general information, respiratory data, tracheal catheter data, and cross-sectional area of the patient's airway to clarify the current status of airway leakage and related influencing factors.~Based on multivariate logistic regression, a line chart prediction model for predicting the risk of airway leakage in patients with tracheal catheters is constructed. The clinical efficacy of the prediction model is evaluated by using the area under the ROC curve, the Calibration scatter plot, and the DCA decision line, respectively, to assess its discrimination, calibration, and clinical practicality."
79480920|NCT05921630|Other|Education|Patient education before pulmonary function test
79977140|NCT06177665|Other|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
79977141|NCT06177457|Drug|PF-07293893|PF-07293893 will be administered as tablets every day (QD) over 14 days
79977142|NCT06177457|Drug|Placebo|Placebo will be administered as tablets; QD over 14 days
79977143|NCT06177457|Drug|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
79977144|NCT06177301|Drug|Tislelizumab combined with GX|"Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
79977145|NCT06177301|Drug|Tislelizumab combined with GP|"Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 ~ 6 cycles."
79977146|NCT06176430|Drug|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
79977147|NCT06176131|Other|Telemedicine-based cross-sector collaboration for patient management|Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
79977148|NCT06175832|Drug|Elonva®|Single injection
79977149|NCT06175832|Drug|Puregon®|Multiple injections
79977150|NCT06175832|Drug|Orgalutran®|Multiple injections
79977151|NCT06175832|Drug|Gonapeptyl®|Double injection
79977152|NCT06175832|Drug|Cerazette®|Oral tablet
79977153|NCT06173505|Combination Product|Vudalimab + Carboplatin + Pemetrexed|Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous
79977154|NCT06173505|Combination Product|Pembrolizumab + Carboplatin + Pemetrexed|Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
79977155|NCT06173115|Device|Perclose Proglide system|"Preclosure technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site."
79977156|NCT06172855|Device|Electroacupuncture at ST36|Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
79977157|NCT06169852|Device|Neuromodulation eXperiment Testbed system (NEXT) stimulation|Initial studies in this aim will use NEXT to stimulate and record neural activity at clinically effective sites.
79977158|NCT06168604|Behavioral|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist
79977159|NCT06168604|Behavioral|Health Promotion Program|The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
79977160|NCT06167811|Other|whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
79977161|NCT06166888|Drug|AK131|AK131 is an anti-PD-1 and CD73 bispecific antibody
79977162|NCT06166381|Drug|Parenteral Antibacterial Agents|Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
79977163|NCT06166381|Drug|Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft|in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
79480921|NCT05921617|Other|No intervention|Routine care
79480922|NCT05921539|Drug|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
79480923|NCT05921539|Drug|axillary nerve injection|ultrasound-guided axillary nerve injection
79977164|NCT06164314|Drug|Dexmedetomidine|In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
79977165|NCT06163859|Behavioral|Intervention Group|FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
79977166|NCT06163482|Other|Mixed meal|Each individual will ingest 5 mL/kg of Boost energy drink.
79977167|NCT06161974|Drug|Olutasidenib + TMZ|Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
79977168|NCT06158568|Other|Percutaneous Electrical Nerve Stimulation|Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves
79480924|NCT05921526|Diagnostic Test|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
79977169|NCT06158568|Other|Placebo Percutaneous Electrical Nerve Stimulation|Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves
79809851|NCT05303363|Device|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
79480925|NCT05921526|Diagnostic Test|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
79480926|NCT05921513|Procedure|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
79480927|NCT05921500|Drug|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
79480928|NCT05921422|Other|Cognitive assessment|"All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD)."
79480929|NCT05921357|Other|Questionnaire|Questionnaire and examine
79647037|NCT00580021|Other|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
79324246|NCT06274047|Drug|Apalutamide|Given by PO
79480930|NCT05921344|Device|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
79480931|NCT05921331|Device|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
79480932|NCT05921331|Other|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
79647038|NCT00202176|Drug|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
79809852|NCT05296954|Procedure|high resolution cartography|High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.
79809853|NCT05295615|Device|ECHS AD Device|Pulsed electromagnetic therapy device
79809854|NCT05295615|Device|ECHS Sham AD Device|Non-functioning electromagnetic therapy device
79977170|NCT06158568|Other|Exercise|Application of three weeks of progressive exercises targeting the shoulder musculature
79977171|NCT06156982|Drug|Evusheld|Administration of Evusheld 600 mg
79324247|NCT06274047|Drug|Androgen Deprivation Therapy|Given by PO
79324248|NCT06274034|Other|Electronic Health Record Review|Ancillary studies
79324249|NCT06274034|Other|Medical Device Usage and Evaluation|Wear MUSE S headband
79324250|NCT06274034|Procedure|Meditation Therapy|Participate in meditation
79647039|NCT00580060|Biological|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
79647040|NCT00180869|Procedure|transfusion of allogeneic red blood cell concentrate|
79647041|NCT00180869|Procedure|transfusion of leuko-reduced red blood cell concentrate|
79977172|NCT06156410|Drug|Cabozantinib|Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
79977173|NCT06155123|Drug|Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)|Monthly or quarterly mAbs administration for a year
79977174|NCT06152588|Other|Time restricted eating|"3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions.~9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives."
79647042|NCT00580099|Other|assisted exercise|4 weeks of passive range of motion exercise
79809855|NCT05278715|Drug|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
79809856|NCT05278715|Drug|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
79809857|NCT05278715|Drug|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
79809858|NCT05262738|Drug|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
79324251|NCT06274034|Other|Survey Administration|Ancillary studies
79324252|NCT06274021|Device|Transcutaneous spinal stimulation at 100 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 100 Hz, performed at a sub-motor threshold for 30 minutes.
79647043|NCT00580099|Other|cuddle|cuddle infant for 20 minutes
79977175|NCT06151184|Procedure|Chiropractic adjustment|6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
79647044|NCT00580177|Procedure|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
79647045|NCT00580177|Procedure|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
79647046|NCT00580177|Procedure|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
79647047|NCT00187239|Device|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
79647048|NCT00180908|Drug|Etoposide, Ifosfamide, Methotrexate|
79647049|NCT00180908|Drug|Doxorubicin, Methotrexate|
79809859|NCT05262738|Drug|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
79809860|NCT05257681|Procedure|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
79809861|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
79647050|NCT04578145|Diagnostic Test|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
79809862|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
79324253|NCT06274021|Device|Transcutaneous spinal stimulation at 50 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
79324254|NCT06274021|Combination Product|Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg."
79809863|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
79324255|NCT06274021|Combination Product|Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial."
79324256|NCT06274021|Device|Sham transcutaneous spinal stimulation|Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
79324257|NCT06274008|Drug|Exparel|Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
79324258|NCT06273995|Other|Behavioral Activation|All participants will undergo behavioral activation treatment for 8-10 weeks
79324259|NCT06273982|Behavioral|STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)|STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.
79324260|NCT06273982|Behavioral|ARC (assisted referral to community care)|ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
79324261|NCT06273969|Other|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa"
79647051|NCT00202215|Behavioral|Chrysalis Day Program|
79647052|NCT00580450|Drug|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
79647053|NCT00180947|Drug|Vinorelbine, cyclofosfamide|
79977176|NCT06145581|Behavioral|Supportive Care (home-based physical activity)|Receive health coaching
79977177|NCT06145581|Other|Exercise Intervention|Participate in home-based physical activity
79977178|NCT06145581|Other|telephone interview|Participate in a telephone interview
79324262|NCT06273943|Drug|Cabotegravir Tablets, for oral use.|Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
79324263|NCT06273943|Drug|Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.|Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
79324264|NCT06273943|Drug|Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use|"Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient."
79324265|NCT06273943|Procedure|Rectal Biopsies|"This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm."
79324266|NCT06273930|Drug|5% CALCIUM SODIUM PHOSPHOSILICATE|Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity
79324267|NCT06273930|Drug|8% Arginine|Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
79324268|NCT06273917|Other|PRIDE|"Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically."
79324269|NCT06273904|Device|Active transcranial focused ultrasound (tFUS)|Active non-invasive low-intensity focused ultrasound will be delivered using a proprietary head-worn device and control software from Attune Neurosciences. On an active stimulation day, focused ultrasound will be delivered to the brain region of interest using parameters from published research that are demonstrated to safely cause temporary changes in the activity in that brain area.
79480933|NCT05921318|Combination Product|Beijing protocol|"For patients <55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
79647054|NCT00580528|Behavioral|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
79647055|NCT00580528|Behavioral|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
79647056|NCT00202254|Behavioral|Physiotherapy|
79647057|NCT00202254|Behavioral|Occupational therapy|
79647058|NCT00202254|Behavioral|Speech pathology|
79977179|NCT06145581|Other|Remote Monitoring|Undergo remote monitoring
79324270|NCT06273904|Device|Sham transcranial focused ultrasound (tFUS)|Non-active low-intensity ultrasound will also be conducted using a proprietary head-worn device and control software from Attune Neurosciences. On the sham stimulation day, the device will be activated in a manner that produces similar sensory effects (i.e., low-volume beeping-type noise from the device) but also prevents delivery of a focused ultrasound beam to the brain area of interest or any other brain area.
79809864|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
79809865|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
79324271|NCT06273891|Drug|Erythromycin|"Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
79324272|NCT06273891|Drug|Azithromycin|"Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
79809866|NCT05256719|Biological|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
79809867|NCT05256719|Biological|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
79809868|NCT05256719|Biological|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
79809869|NCT05256719|Biological|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
79809870|NCT05256719|Biological|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
79809871|NCT05242445|Drug|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
79809872|NCT05242445|Drug|Placebo|Placebo will be administered via SC injection or as an IV infusion.
79809873|NCT05229835|Other|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
79324273|NCT06273865|Diagnostic Test|Several assays|Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
79324274|NCT06273852|Drug|PBA-0405|Intratumoral microdose injection by the CIVO device.
79324275|NCT06273839|Drug|Tafamidis 61 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
79324276|NCT06273839|Drug|Tafamidis 70 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
79324277|NCT06273839|Drug|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
79324278|NCT06273826|Diagnostic Test|"Colorectal Leakage App"|"The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring."
79977180|NCT06145581|Procedure|Patient Monitoring|Monitor physical activity
79324279|NCT06273813|Drug|Ketorolac Tromethamine 15 MG/ML|Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
79324280|NCT06273813|Drug|Ketorolac Tromethamine|Three doses of topical ketorolac tromethamine over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods in cohort 1 Three doses of Ketorolac Tromethamine, 6 hours apart, over the course of 5 days in cohorts 2 and 3
79324281|NCT06273800|Procedure|Blood sample|Collection of serum sample at the day of start of neo adjuvant treatment
79324282|NCT06273787|Other|diaphragmatic release|diaphragmatic myofascial release for 1 months 3 sessions per week
79324283|NCT06273774|Drug|MK-8189|Oral Tablet
79977181|NCT06145581|Other|Questionnaire Administration|Ancillary studies
79647059|NCT04577872|Other|Pelvic floor muscle training|The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
79324284|NCT06273774|Drug|Placebo|Oral Tablet
79324285|NCT06273761|Behavioral|Medication Management Service (MMS)|Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
79480934|NCT05921292|Combination Product|Omeza Products Used in Combination|"Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza combination therapy which includes the use of the following products:~Omeza Lidocaine Lavage~Omeza Collagen Matrix~Omeza Skin Protectant At each treatment (on days 0, 7, 14, 21, and 28; +/- 3 days each), the patient's wound/ulcer will be cleaned with Omeza Lidocaine Lavage. Omeza Collagen Matrix will be applied as the primary dressing and Omeza Skin Protectant will be applied on periwound and surrounding intact skin. Treatments may be repeated during an optional 8 additional weeks (on days 35, 42, 49, 56, 63, 70, and 77; +/- 3 days each)."
79977182|NCT06145464|Behavioral|Adhesion to the use of collective shadow|Quantitative evaluation of the use of shadow provided by one or two collective fabric devices, with 6 per 3 metres of size, containing 100% UV blocking filters, that will be installed in the sand on Foz do Lizandro beach, according to the recommendations provided in all groups of the study.
79977183|NCT06145464|Behavioral|Adhesion to the use of sun protector|Quantitative evaluation of the use of sun protector according to the recommendations provided in all groups of the study.
79977184|NCT06145464|Behavioral|Adhesion to the use of the information disposed in the infographic|Quantitative evaluation of the use of the information disposed in the infographic and provided in all groups of the study.
79324286|NCT06272578|Diagnostic Test|Echocardiography|Echocardiography
79977185|NCT06145464|Behavioral|Adhesion to the health literacy sessions in the interventional groups|Provision of health literacy sessions about skin cancer prevention by two different types of providers in the two interventional groups, 15 days before the use of sun protective interventions implemented at the beach
79647060|NCT00580684|Biological|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
79324287|NCT06271993|Device|ColActivePlus Collagen Matrix Dressing|The test product, positive control and negative control will be applied directly to the volar forearm skin of the subject. The sites will be a minimum of 2cm from each other to minimize cross contamination.
79324288|NCT06271980|Other|ENCORE|A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
79324289|NCT06271850|Other|Ergonomics breastfeeding training|The ergonomics training includes the most ergonomically appropriate methods to breastfeed and ergonomic guidelines, including how to cuddle and breastfeed the baby correctly.
79324290|NCT06271850|Other|Pilates exercises|Pilates exercises, 3 times per week, for 8 weeks, in the form of neck extensor stretching, neck extensor and rotation stretching, pectoral muscle stretching, strengthening of deep neck flexors and scapular retractor, and core strengthening exercises ( pelvic bridging, plank, cat and camel, curl up, single leg abdominal press and double leg abdominal press).
79480935|NCT05921240|Other|observational study, no intervention|no intervention
79977186|NCT06144827|Device|Multiparametric MRI scans|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
79480936|NCT05921227|Behavioral|VAULT Phase 6|VAULT is an input-based word learning intervention based on principles of statistical learning.
79480937|NCT05921214|Behavioral|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
79647061|NCT00180986|Procedure|Platelet concentrates|
79647062|NCT00580762|Procedure|Roux-en-y gastric bypass (RYGB)|
79480938|NCT05921201|Behavioral|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
79480939|NCT05921188|Behavioral|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
79480940|NCT05921110|Procedure|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
79480941|NCT05921110|Procedure|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
79647063|NCT00209040|Behavioral|Acoustic Startle Testing|See protocol description for methodological details
79647064|NCT00580918|Other|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
79324291|NCT06271811|Procedure|Flossing band|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
79324292|NCT06271811|Other|Conventional physiotherapy|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
79324293|NCT06271291|Other|Non-Interventional Study|Non-interventional study
79324294|NCT06271096|Drug|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
79324295|NCT06271096|Drug|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
79324296|NCT06270810|Behavioral|Aerobic Exercise|Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
79977187|NCT06144827|Device|Multiparametric MRI scans + HepQuantShunt Test|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
79977188|NCT06142929|Procedure|Microfasciectomy|Using the microscope in Dupuytren's surgery
79324297|NCT06270810|Behavioral|Increasing non-Exercise Physical Activity|Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
79480942|NCT05921097|Diagnostic Test|Histamin-induced axon-reflex flare response|Histamin-induced axon-reflex flare response
79647065|NCT00581035|Biological|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
79647066|NCT00581035|Biological|Prevenar|1 dose at 2,3.5,6 and 12 months
79647067|NCT00581035|Biological|Meningitec|1 dose at 2,6 and 12 months
79647068|NCT04577521|Device|BioVisc Ortho Single|BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.
79647069|NCT00187317|Behavioral|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
79647070|NCT00187317|Other|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
79977189|NCT06141499|Behavioral|Provider educational materials|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
79977190|NCT06141499|Behavioral|Patient letters|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
79977191|NCT06139575|Drug|Lutetium Lu 177 JH020002 Injection|Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
79977192|NCT06139224|Dietary Supplement|10 day prebiotic consumption|20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
79977193|NCT06135662|Procedure|CAF + CTG|Surgical techniques for mandibular gingival recession: coronally advanced flap + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
79809874|NCT05213351|Other|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~Right-left discrimination training (lateralization training)~Imagination of hand movements (motor imagery):~Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
79977194|NCT06135662|Procedure|Tunnel Technique + CTG|Surgical techniques for mandibular gingival recession: tunnel technique + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
79324298|NCT06270745|Drug|indocyanine green|Whether to use ICG to assess anastomotic perfusion during digestive system surgery
79324300|NCT06270030|Drug|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
79480943|NCT05921097|Diagnostic Test|Local heating-induced axon-reflex flare response|Local heating-induced axon-reflex flare response
79324301|NCT06270030|Drug|LNZ100 (Aceclidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
79324302|NCT06270030|Drug|Placebo (Vehicle) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
79324303|NCT06269926|Behavioral|Cognitive Behavioral Therapy for Chronic Pain|Treatment for chronic pain that addresses the relationship between thoughts, feelings and behaviors.
79324304|NCT06269926|Other|Pain education|A booklet on chronic pain (in this study, an educational pamphlet from the Oregon state health department) that provides pain education in addition to usual medical care.
79324305|NCT06269874|Diagnostic Test|microvascular function assessment|mircovascular function parameters will be measured by administering adenosine in two different pathways
79647071|NCT04577560|Genetic|First polar body biopsy in MII oocytes|Since PBs are by-products of the meiotic division of the oocyte and are not required for fertilization and subsequent embryo development, they can be removed to assess exclusively maternal chromosomal information without harming the embryo integrity. As previously described, PB biopsy does not impact the morphokinetic parameters of the embryo development and can be safely applied without the risk of impairing the reproductive potential of the embryo.
79809875|NCT05213351|Other|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
79647072|NCT04577560|Genetic|PGT-A blastocyst|preimplantation genetic screening for aneuploidies
79647073|NCT00581074|Behavioral|diet (grapefruit or grapefruit juice)|weight loss diet
79647074|NCT00581191|Drug|SLV-351|SLV-351 capsules taken once
79647075|NCT00187356|Procedure|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
79647076|NCT00581269|Behavioral|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
79647077|NCT00581269|Dietary Supplement|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
79809876|NCT05206396|Diagnostic Test|TIL assessment in pre-existing histopathological specimens|TIL assessment in pre-existing histopathological specimens and their relation to complete pathological response and 1-year invasive disease-free interval
79324307|NCT06269380|Procedure|Esophagogastroduodenoscopy|During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.
79324308|NCT06269380|Procedure|Endoscopic biopsy sampling|The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.
79647078|NCT00581425|Biological|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
79809877|NCT05189249|Other|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
79324309|NCT06269107|Drug|IcoSema|IcoSema will be administered subcutaneously.
79977195|NCT06134505|Procedure|Use of Barrier cream group 1 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
79324310|NCT06269107|Drug|Insulin glargine|Insulin glargine will be administered subcutaneously.
79647079|NCT04577248|Device|edge-to-edge valve repair|edge-to-edge valve repair
79647080|NCT04577092|Other|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
79647081|NCT04577092|Other|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
79647082|NCT04577092|Other|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
79977196|NCT06134505|Procedure|Use of Barrier cream 2 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
79977197|NCT06134505|Procedure|Use of olive oil in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
79977198|NCT06133647|Procedure|managing Male Breast Cancer Patients at Methodist Health System|To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
79977199|NCT06133478|Drug|NUV001 active cohort 1|6 participants will be assigned to receive active treatment
79977200|NCT06133478|Drug|NUV001 active cohort 2|6 participants will be assigned to receive active treatment
79480944|NCT05921097|Diagnostic Test|2-point discrimination tasks|2-point discrimination tasks
79480945|NCT05921097|Diagnostic Test|NC-Stat DPNCheck|NC-Stat DPNCheck
79647083|NCT04577092|Other|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
79647084|NCT00187395|Procedure|Randomized to either a 'less tight' group or a 'tight' group|
79647085|NCT04577053|Device|Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device|Manufactured by QX World Ltd. in Budapest, Hungary
79647086|NCT00581464|Behavioral|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
79977201|NCT06133478|Drug|NUV001 active cohort 3|6 participants will be assigned to receive active treatment
79480946|NCT05921097|Diagnostic Test|QST|QST
79480947|NCT05921097|Diagnostic Test|Biothesiometry|Biothesiometry
79480948|NCT05921071|Drug|Tranexamic acid|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
79480949|NCT05921071|Drug|Placebo|patients will receive 10 ml of normal saline 0.9% intravenously.
79480950|NCT05921058|Drug|Secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
79480951|NCT05921058|Drug|Placebo|NaCl 0,9% infusion
79977202|NCT06133478|Drug|NUV001 active cohort 4|6 participants will be assigned to receive active treatment
79977203|NCT06133478|Drug|NUV001 placebo cohort 1|2 participants will be assigned to receive placebo
79977204|NCT06133478|Drug|NUV001 placebo cohort 2|2 participants will be assigned to receive placebo
79977205|NCT06133478|Drug|NUV001 placebo cohort 3|2 participants will be assigned to receive placebo
79977206|NCT06133478|Drug|NUV001 placebo cohort 4|2 participants will be assigned to receive placebo
79647087|NCT00581464|Behavioral|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
79977207|NCT06132893|Drug|BHV-7000|BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
79324311|NCT06269081|Behavioral|Supportive-Expressive Peer Social Support Group Intervention|The social support group intervention involves weekly virtual support group meetings for 8 consecutive weeks. The groups, facilitated by trained research staff, will last approximately 90 minutes each week and include 5-12 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Facilitators will encourage mutual support among group members, promote greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy.
79324312|NCT06269081|Behavioral|Individual Strengths-Based Case Management Intervention|The strengths-based case management (SBCM) intervention helps participants address the multiple structural barriers faced by rural older people living with HIV. This intervention, delivered by trained research staff, includes two 60-minute telephone- or video-based SBCM counseling sessions, with shorter follow-up sessions to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
79324313|NCT06268600|Radiation|Modified neck target volume delineation|Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
79809878|NCT05179044|Device|Guardian Sport Rehabilitator knee brace|The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
79324315|NCT06266546|Drug|Tranexamic acid|Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
79324316|NCT06266065|Device|Coronary Sinus Reducer|Implantation of Coronary Sinus Reducer
79324317|NCT06264999|Device|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
79324318|NCT06264999|Device|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
79324319|NCT06264934|Device|Breast scan using the Z-scanner|Four repeated scans of both breasts using the Z-scanner.
79324320|NCT06264934|Device|Breast scan using the Z-scanner|A scan of both breasts using the Z-scanner.
79977208|NCT06132893|Drug|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
79324322|NCT06262997|Other|Pilates|Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.
79480952|NCT05921032|Other|Exercise intervention|8 weeks of exercise with two session in a week
79480953|NCT05921019|Device|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
79977209|NCT06132893|Drug|Placebo|Matching placebo taken once daily
79480954|NCT05921019|Device|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
79480955|NCT05920980|Drug|lidocaine|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
79480956|NCT05920980|Drug|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
79647088|NCT04577131|Behavioral|Weekly check-in|Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
79480957|NCT05920954|Procedure|ERCP|Repeat ERCP
79977210|NCT06132087|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
79977211|NCT06132087|Procedure|Computed Tomography|Undergo CT
79977212|NCT06132087|Procedure|Distal Pancreatectomy|Undergo distal pancreatectomy
79977213|NCT06132087|Procedure|Laparoscopy|Undergo laparoscopy
79977214|NCT06132087|Procedure|Magnetic Resonance Imaging|Undergo MRI
79977215|NCT06132087|Procedure|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
79977216|NCT06132087|Other|Questionnaire Administration|Ancillary studies
79977217|NCT06132087|Procedure|Surgical Procedure|Undergo surgical resection
79977218|NCT06132087|Procedure|Total Pancreatectomy|Undergo total pancreatectomy
79324323|NCT06262997|Other|Pilates and Kinesiotape|Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
79324324|NCT06261645|Other|Early Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
79324325|NCT06261645|Other|Delayed Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
79324326|NCT06260566|Drug|N-Acetylcysteine|"This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation."
79647089|NCT00209079|Drug|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
79977219|NCT06131671|Other|Whole-body electrical stimulation|"The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles."
79977220|NCT06129864|Drug|volrustomig|volrustomig
79977221|NCT06129292|Behavioral|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
79977222|NCT06129279|Other|EFT group|"Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed."
79977223|NCT06129266|Other|oral care with breastmilk|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
79977224|NCT06124521|Behavioral|ComBaT Glaucoma|ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
79977225|NCT06123494|Drug|SHR-A1811|SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
79324327|NCT06258746|Drug|[14C]HSK31679|A single oral dose of 160 mg/100 μCi [14C]HSK31679 after fasting for at least 10 hours.
79647090|NCT04576975|Drug|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
79647091|NCT04576975|Drug|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
79647092|NCT04576975|Drug|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
79647093|NCT03453073|Behavioral|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
79647094|NCT03453073|Other|physician diagnosis of first occurrence of serious chronic disease|
79647095|NCT00187434|Device|Infant Flow System|
79647096|NCT00187434|Device|Bubble CPAP|
79647097|NCT00581620|Biological|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
79647098|NCT00209118|Drug|paroxetine|
79977226|NCT06123494|Drug|Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan|Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
79977227|NCT06121362|Dietary Supplement|Protocatechuic Acid or PCA|PCA 1000 mg capsule
79977228|NCT06121362|Dietary Supplement|Placebo|Placebo capsule
79977229|NCT06120231|Diagnostic Test|Pulse width modulation|Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
79977230|NCT06116110|Other|Long-term Follow-Up|No intervention
79977231|NCT06115707|Other|The lying flat (0°) head position for 72 hours|The lying flat (0°) head position for 72 hours after endovascular therapy.
79977232|NCT06115707|Other|The The head elevation (30°) position for 72 hours|The head elevoatin (30°) position for 72 hours after endovascular therapy.
79977233|NCT06114056|Biological|JWK007 Single intravenous infusion administration|"Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient."
79324328|NCT06256991|Drug|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
79324329|NCT06256991|Drug|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
79324331|NCT06256562|Drug|GZR18|Titrated to dose 1, dose 2, dose 3 or dose 4
79324332|NCT06256562|Other|Placebo|Administered the same volume as GZR18
79324333|NCT06256549|Drug|GZR18|Titrated to low dose or middle or high dose
79324334|NCT06256549|Drug|Semaglutide|Titrated to 1.0 mg once a week
79324335|NCT06256536|Drug|GZR18|0.6 mg-30 mg
79324336|NCT06256536|Other|Placebo|administered the same volume as GZR18
79324337|NCT06256523|Drug|GZR18|0.5mg-13mg
79977234|NCT06112561|Device|CO/CI/SVR|fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.
79977235|NCT06110962|Device|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
79647099|NCT00581815|Device|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
79977236|NCT06107543|Drug|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
79324338|NCT06256523|Other|Placebo|administered the same volume as GZR18
79809879|NCT05163626|Behavioral|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
79977237|NCT06107543|Drug|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
79480958|NCT05920928|Radiation|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
79480959|NCT05920928|Radiation|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
79480960|NCT05920902|Other|routine therapy of acute ischemia stroke|Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
79480961|NCT05920889|Drug|Semaglutide|0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
79647100|NCT00581815|Device|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
79977238|NCT06107153|Drug|Insulin Glargine 100 UNT/ML Pen Injector [Lantus]|Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
79977239|NCT06107153|Drug|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
79977240|NCT06107153|Drug|Pioglitazone 30mg|Pioglitazone 30mg
79977241|NCT06106893|Biological|CD19 Universal CAR-γδ T Cells|Intravenous infusion of CD19 Universal CAR-γδ T Cells
79324342|NCT06255912|Drug|LTC004 + MIL-97|Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
79324343|NCT06255912|Drug|LTC004 + MIL-97+chemotherapy|LTC004 + MIL-97+chemotherapy
79324344|NCT06254976|Behavioral|exercise|2 weeks of home exercise
79324345|NCT06254976|Biological|intraarticular knee PRP injections|2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
79324346|NCT06254859|Procedure|Traditional thyroid surgery.|The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
79480962|NCT05920876|Drug|QLS32015|Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
79480963|NCT05920837|Device|MyotonPRO|Muscles' viscoelastic properties assess with myotonPRO.
79480964|NCT05920837|Other|Box and Block Test|Upper extremity's functionality assess with Box and Block Test.
79647101|NCT00582088|Biological|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer <1:20.
79647102|NCT00582244|Behavioral|CBT and relaxation|Group A: CBT and relaxation.
79480965|NCT05920811|Other|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
79324347|NCT06254508|Behavioral|Online program that includes exercise guided by the FITT-VP principle and dietary advice|"Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4~6 peers.~Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance."
79809880|NCT05163210|Behavioral|AO+VR|The experimental treatment will consist of 15 hours (min. 15, max. 20), and will be carried out 4 days/week for a total duration of 5 weeks. During the rehabilitation sessions, the patient will be instructed to carefully watch videos lasting about 1.5 minutes, presented on Liquid Crystal Display (LCD) monitor, consisting in unimanual or bimanual actions performed by an actor, from a lateral perspective. Subsequently, the patient will be asked to imitate the actions presented for at least 3 consecutive times, within a time window of 3 min., using the same objects observed in the video, in a virtual scenario (VR), through the Khymeia Virtual Reality Rehabilitation System (VRRS).
79324348|NCT06254508|Behavioral|Conventional in-clinic nutrition and exercise advice and self-control|Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
79324349|NCT06254261|Drug|RAY1225|Administered SC
79480966|NCT05920811|Other|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
79324350|NCT06254261|Drug|Placebo|Placebo
79324351|NCT06254001|Drug|Bupropion|Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy
79324352|NCT06254001|Drug|Nicotine replacement therapy (Nicotine patches)|Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
79324353|NCT06253923|Drug|Amantadine Hydrochloride|MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
79480967|NCT05920785|Diagnostic Test|Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile|"comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~general blood test, general urine test,~biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~glycated hemoglobin,~- glucose tolerance test,~ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~blood pressure monitoring.~Special laboratory methods:~Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~analysis of feces for microbiota by MALDI-TOF mass spectrometry,~bioimpedance measurement."
79324354|NCT06253923|Drug|Placebo|The placebo for this study is 0.9% Sodium Chloride IV Solution.
79480968|NCT05920707|Drug|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
79480969|NCT05920707|Drug|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
79480970|NCT05920707|Drug|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
79480971|NCT05920694|Device|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
79480972|NCT05920694|Other|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
79809881|NCT05163210|Behavioral|CO+VR|Patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist. Thus, the general setting for carrying out the rehabilitation sessions will be identical to that of the experimental treatment, except for the fact that the control group will not be involved in action observation before preforming the exercises. Thus, the control treatment is not based on action imitation, but on purely motor execution.
79809888|NCT05152901|Drug|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
79809889|NCT05152901|Drug|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
79324361|NCT06251661|Other|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
79324362|NCT06251661|Other|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
79324363|NCT06249776|Device|Supernova revascularization device|Mechanical Thrombectomy
79324364|NCT06247683|Device|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
79809890|NCT05152901|Drug|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
79809891|NCT05152901|Drug|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
79809892|NCT05147935|Behavioral|Palliative Care Consultation|In person or telehealth clinic visit with palliative care physician or nurse practitioner
79809893|NCT05126303|Drug|RMC-035|Concentrate for Solution for Infusion
79809894|NCT05126303|Drug|Placebo|Concentrate for Solution for Infusion
79809895|NCT05089747|Biological|Blood sampling for biomarker analysis (microRNA, circulating DNA…)|From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
79809896|NCT05078580|Drug|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
79809897|NCT05078580|Drug|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
79809898|NCT05078580|Drug|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
79324366|NCT06241677|Drug|alteplase or tenecteplase|Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
79977242|NCT06106880|Drug|Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
79324367|NCT06238726|Behavioral|Reminder|Shingrix messages via SMS, patient portal, email, and/or another modality
79977243|NCT06106880|Drug|Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
79809899|NCT05078580|Drug|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
79324369|NCT06238115|Drug|Tirofiban|Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
79324370|NCT06238115|Drug|aspirin, clopidogrel|aspirin 100 mg/day, clopidogrel 75 mg/day
79324371|NCT06237179|Behavioral|Exercise Training Intervention|5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.
79324372|NCT06237179|Behavioral|Healthy Living Education|During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
79647103|NCT00582244|Behavioral|Physical activity|Group B: Physical exercise program.
79977244|NCT06106880|Dietary Supplement|Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
79324377|NCT06236451|Drug|Aripiprazole|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
79324378|NCT06236451|Drug|Risperidone|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
79324379|NCT06234969|Device|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
79324380|NCT06234969|Device|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
79480973|NCT05920668|Drug|Orelabrutinib|Orelabrutinib monotherapy for CLL/SLL 12 cycles
79977245|NCT06106880|Other|Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
79977246|NCT06106295|Drug|Metyrapone|250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
79977247|NCT06103734|Combination Product|Zavegepant 10 mg|4 doses of zavegpant 10 mg intranasal spray device
79809900|NCT05074550|Drug|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
79809901|NCT05074433|Drug|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
79977248|NCT06103734|Combination Product|Placebo - Control 1|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
79977249|NCT06103734|Combination Product|Placebo - Control 2|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
79977250|NCT06103474|Diagnostic Test|Lumbar Magnetic Resonance Imaging (MRI)|Lumbar Magnetic Resonance Imaging (MRI)
79977251|NCT06102005|Drug|SAR443765|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79977252|NCT06102005|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79977253|NCT06100705|Drug|Testosterone Cypionate|Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
79324381|NCT06234475|Behavioral|Mobile health support|"Brief smoking cessation advice~Health warning leaflet~Smoking cessation information booklet~Referral card~E-messages on SC-related information and details on community SC services for 3 months~Acceptance and Commitment Therapy based real-time Chat-based support for 3 months"
79324382|NCT06234475|Behavioral|Financial incentive|"Brief smoking cessation advice~Health warning leaflet~Smoking cessation information booklet~Referral card~An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
79324383|NCT06234475|Behavioral|Combine intervention|"Brief smoking cessation advice~Health warning leaflet~Smoking cessation information booklet~Referral card~E-messages on SC-related information and details on community SC services for 3 months~Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
79324384|NCT06234475|Behavioral|Control group|"Brief smoking cessation advice~Health warning leaflet~Smoking cessation information booklet~Referral card~E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending"
79809902|NCT05074433|Drug|Placebo|Administered SC
79809903|NCT05064319|Drug|Gabapentin|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
79324387|NCT06227338|Drug|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
79324388|NCT06224426|Other|Normobaric high-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.
79324389|NCT06224426|Other|Normobaric low-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
79809904|NCT05064319|Drug|Placebo|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
79809905|NCT05047406|Dietary Supplement|Bacillus clausii Probiotic liquid|mini bottles for oral administration containing 2 million spores of Bacillus clausii
79647104|NCT00582244|Behavioral|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
79647105|NCT00582244|Other|Control group|Waiting list control group
79647106|NCT00181025|Drug|Tasonermine (TNFa)|
79647107|NCT00181025|Drug|Melphalan|
79647108|NCT00582283|Drug|I124-NM404|I-124-NM404
79647109|NCT00209313|Drug|Acyclovir|Acyclovir 800 mg twice daily or placebo
79647110|NCT00582439|Device|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
79647111|NCT04576624|Behavioral|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
79647112|NCT04576624|Behavioral|social activity|24 social gathering events
79647113|NCT00582634|Drug|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
79647114|NCT04723407|Other|questionnaires|Questionnaire completion
79647115|NCT00181064|Behavioral|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
79647116|NCT00582673|Drug|AFQ056|
79647117|NCT00582673|Drug|Placebo|
79809906|NCT05045430|Device|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
79324395|NCT06223373|Device|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
79324396|NCT06223373|Device|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
79480974|NCT05920655|Diagnostic Test|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
79480975|NCT05920616|Other|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
79809907|NCT05026957|Device|SharedHeart|A smartphone application
79324397|NCT06220773|Drug|BR1019A|Subjects take the investigational products once a day for 12 weeks.
79480976|NCT05920616|Other|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
79480977|NCT05920564|Other|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
79480978|NCT05920564|Other|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
79480979|NCT05920551|Other|Gastrocnemius Stretching Exercises|The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.
79480980|NCT05920551|Other|Standard care|Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
79809908|NCT05021367|Drug|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
79809909|NCT05010564|Genetic|Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy|"Three dose levels will be evaluated with the opportunity to dose de-escalate (dose level -1) for toxicity.~DL-1: 3x10^6 cells/m2~DL1: 1×10^7 cells/m2~DL2: 3×10^7 cells/m2~DL3: 1×10^8 cells/m2~Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of fludarabine)must be completed greater than or equal to 48 hours prior to infusion of CAR-T cells.~The protocol will allow for up to three additional infusions of the CAR-T product for subjects who meet criteria for retreatment."
79809910|NCT05006482|Other|Best Practice|Receive usual follow-up survivorship care
79809911|NCT05006482|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
79809912|NCT05006482|Other|Educational Intervention|Participate in survivorship health education sessions
79324398|NCT06220773|Drug|BR1019B|Subjects take the investigational products once a day for 12 weeks.
79324399|NCT06220773|Drug|BR1019C|Subjects take the investigational products once a day for 12 weeks.
79324400|NCT06220773|Drug|BR1019A-1|Subjects take the investigational products once a day for 12 weeks.
79324401|NCT06220773|Drug|BR1019B-1|Subjects take the investigational products once a day for 12 weeks.
79480981|NCT05920538|Drug|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
79480982|NCT05920538|Other|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
79977254|NCT06100705|Drug|Sipuleucel-T|Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
79324402|NCT06220773|Drug|BR1019C-1|Subjects take the investigational products once a day for 12 weeks.
79480983|NCT05920525|Device|Electrical stimulation|A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
79647118|NCT04576780|Other|Integrated Large Complex Polyp Referral Pathway|"The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection."
79647119|NCT04576858|Diagnostic Test|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
79809913|NCT05006482|Other|Exercise Intervention|Participate in EXCAP program
79324404|NCT06214793|Drug|Taletrectinib|Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
79324405|NCT06211413|Other|no intervention|no intervention
79647120|NCT00209352|Drug|Acyclovir|
79324406|NCT06208371|Procedure|Surgical resection and/or ablation therapy and/or SBRT|Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy
79324407|NCT06208371|Drug|Palliative Chemotherapy|Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
79324408|NCT06208306|Drug|Itepekimab (SAR440340)|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
79324409|NCT06208306|Drug|Placebo|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
79480984|NCT05920525|Procedure|Traditional retraction of the front upper teeth|The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
79480985|NCT05920512|Drug|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
79480986|NCT05920499|Other|AUDIT and Feedback|"AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group."
79480987|NCT05920486|Device|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
79480988|NCT05920486|Device|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
79324410|NCT06206902|Drug|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m^2 (D-5~D-3) Drug: Cyclophosphamide: 300 mg/ m^2 (D-5~D-3)
79647121|NCT00181142|Drug|Zenapax|
79647122|NCT00582829|Other|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
79647123|NCT00582829|Other|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
79647124|NCT00582829|Other|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
79647125|NCT00582868|Device|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
79647126|NCT00582868|Other|CSF|analysis of CSF for cleaved tau protein
79647127|NCT00582868|Other|Whole blood|Analysis of whole blood for cleaved-tau protein
79809914|NCT05006482|Other|Questionnaire Administration|Ancillary studies
79809915|NCT05006482|Procedure|Tailored Intervention|Participate in GEM consultation
79324411|NCT06204029|Behavioral|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
79324412|NCT06201689|Dietary Supplement|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
79324413|NCT06201689|Dietary Supplement|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
79324414|NCT06201689|Dietary Supplement|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
79324415|NCT06198374|Dietary Supplement|Sodium propionate|The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
79324416|NCT06198374|Other|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
79324417|NCT06194929|Drug|Defactinib|Defactinib will be administered at 200 mg twice daily orally per arm description.
79324418|NCT06194929|Drug|Avutometinib|Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
79324419|NCT06194929|Drug|Encorafenib|Encorafinib administered orally per arm description.
79647128|NCT00582985|Drug|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
79977255|NCT06100172|Device|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Use of tAN for pain relief is an attractive alternative to pharmacologic and opioid-based approaches because it is safe and effective and presents no addiction liability.
79324420|NCT06194903|Device|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
79647129|NCT00187551|Other|Interruption of enfuvirtide|treatment interruption
79977256|NCT06100172|Device|Sham Control Device|This device looks like the active device, but no stimulation will be delivered.
79647130|NCT00187551|Other|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
79647131|NCT00181181|Drug|atorvastatin|Atorvastatin 80 mg daily for 3 months
79647132|NCT00181181|Other|placebo|placebo daily
79977257|NCT06099730|Device|Pulsed Field Ablation (PFA)|PFA using Irreversible Electroporation (IRE) Ablation System
79647133|NCT04576468|Procedure|Open flap debridement|Surgical intevention
79647134|NCT04576468|Procedure|perforated membrane|surgical intervention
79647135|NCT04576468|Procedure|leucocyte - platelet rich fibrin|surgical intervention
79647136|NCT04576351|Other|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
79647137|NCT00187590|Behavioral|Case manager phone call after an ER visit|
79647138|NCT00181220|Drug|valproic acid|
79647139|NCT00583063|Drug|sunitinib|25 mg daily (oral dosing)
79647140|NCT00583063|Drug|rapamycin|4 mg daily (oral dosing)
79647141|NCT04576312|Drug|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
79647142|NCT04576312|Drug|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
79977258|NCT06092099|Device|TENA SmartCare Change Indicator|The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
79324421|NCT06194903|Device|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
79647143|NCT04576234|Dietary Supplement|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
79647144|NCT00209391|Drug|Gadodiamide Injection|
79647145|NCT00181298|Drug|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
79480989|NCT05920473|Device|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
79480990|NCT05920473|Device|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
79647146|NCT00181298|Drug|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
79647147|NCT04576273|Diagnostic Test|Pathology examination|Gross and microscopic evaluation
79977259|NCT06091189|Behavioral|Relevant Trier Social Stressor Test (TSST)|The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.
79977260|NCT06091189|Drug|Ethanol|The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
79977261|NCT06091189|Behavioral|Placebo Trier Social Stressor Test (TSST)|The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
79977262|NCT06091189|Behavioral|Placebo Beverage|Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.
79647148|NCT00583180|Drug|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
79647149|NCT00583258|Drug|Alfuzosin (Xatral)|10 mg PO once a day
79647150|NCT00583258|Drug|Placebo Alfuzosin|10 mg PO once a day
79647151|NCT04576039|Diagnostic Test|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
79647152|NCT00187629|Behavioral|dietary phosphorus|varying amts dietary phosphorus
79977263|NCT06091189|Behavioral|Irrelevant Trier Social Stressor Test (TSST)|The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
79977264|NCT06091111|Device|THD, THN|New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
79977265|NCT06090162|Diagnostic Test|ctDNA detection|ctDNA detection on CSF and blood
79324423|NCT06186037|Drug|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
79324424|NCT06186037|Drug|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
79324425|NCT06185465|Device|Prontosan Wound Irrigation Solution|After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
79647153|NCT00583336|Device|ShuntCheck|Thermal dilution test for CSF flow
79647154|NCT00181532|Drug|Celecoxib|
79647155|NCT04576390|Drug|Ondansetron 4 mg|Antiemetic drug
79647156|NCT04576390|Drug|Palonosetron 75 mcg|Antiemetic drug
79647157|NCT00583570|Behavioral|dietary education|dietary education
79324426|NCT06185465|Device|Normal Saline|After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
79324427|NCT06184750|Procedure|Biopsy|Undergo biopsy
79324428|NCT06184750|Procedure|Biospecimen Collection|Undergo collection of blood samples
79324429|NCT06184750|Procedure|Mammography|Undergo mammography
79324430|NCT06184750|Other|Questionnaire Administration|Ancillary studies
79324431|NCT06184750|Drug|Tamoxifen|Given PO
79324432|NCT06183684|Device|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
79480991|NCT05920460|Behavioral|Cognitive Behavioral Therapy Program|"Brief description of the Cognitive Behavioral Therapy program is given below:~Session 1: Mutual understanding and rapprochement~Session 2: Sleep hygiene education~Session 3: Psychoeducation about stimulus control strategies; monitoring sleep environments, and identification of behavioral habits at bedtime, dysfunctional beliefs, and attitudes about sleep.~Session 4: Training on relaxation techniques~Session 5: Psycho education about depression~Session 6: Cognitive restructuring~Session 7: The terminating session"
79809916|NCT04999488|Drug|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
79324433|NCT06181760|Drug|Fenretinide|Ascending single doses of oral fenretinide
79324434|NCT06181760|Drug|Placebo|Single oral dose of matching placebo capsules
79324435|NCT06181214|Dietary Supplement|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
79324436|NCT06181214|Dietary Supplement|Placebo|Maltodextrin placebo
79324437|NCT06179407|Drug|MK-6552|Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
79480992|NCT05920447|Device|LMA|Monitor the ventilatory parameter and incidence of complications
79647158|NCT00583648|Other|Urinanlysis|sending a Urine sample to the laboratory for processing
79977266|NCT06089863|Other|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
79809917|NCT04999488|Other|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
79809918|NCT04987671|Drug|AMX0035|Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.
79809919|NCT04985630|Dietary Supplement|Mitopure|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
79480993|NCT05920434|Other|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
79480994|NCT05920421|Procedure|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
79647159|NCT00181571|Drug|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
79809920|NCT04985630|Dietary Supplement|Pomegranate Juice|100% Pomegranate juice
79809921|NCT04952571|Drug|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
79809922|NCT04946071|Behavioral|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
79809923|NCT04945733|Drug|Amivantamab|Amivantamab will be administered intravenously.
79809924|NCT04940390|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
79809925|NCT04940390|Drug|Placebo|Placebo for STS101
79809926|NCT04939142|Combination Product|SVd (Selinexor+Bortezomib+dexamethasone)|Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
79977267|NCT06089486|Diagnostic Test|ICA|Patients will undergo annual CAV surveillance with ICA
79647160|NCT00181571|Drug|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
79647161|NCT00187707|Drug|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
79977268|NCT06089486|Diagnostic Test|PET|Patients will undergo annual CAV surveillance with PET
79324438|NCT06179407|Drug|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
79977269|NCT06089434|Diagnostic Test|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of ~ 80-100 TEE clips per case).
79324439|NCT06179160|Drug|INCB161734|INCB161734 will be administered at protocol defined dose.
79647162|NCT00583687|Device|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
79647163|NCT00583687|Other|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
79977270|NCT06089434|Diagnostic Test|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
79977271|NCT06087627|Drug|Dupilumab SAR231893 (REGN668)|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
79977272|NCT06086626|Drug|Cefiderocol|Administered via intravenous (IV) infusion
79977273|NCT06086626|Drug|Standard of Care|Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
79977274|NCT06080178|Drug|Plasma-lyte|Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
79977275|NCT06080178|Drug|Norepinephrine|When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
79977276|NCT06080178|Drug|Plasma-lyte|"Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg."
79324440|NCT06179160|Drug|Cetuximab|Cetuximab will be administered at protocol defined dose.
79647164|NCT00583687|Other|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
79647165|NCT00583687|Device|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
79647166|NCT00583726|Behavioral|motivational interviewing|telephone counseling
79647167|NCT00583726|Behavioral|written materials only|dietary guidance materials and pedometers
79647168|NCT00583765|Drug|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
79324441|NCT06179160|Drug|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
79324443|NCT06171191|Behavioral|Move-ARound And Get Active|The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
79324444|NCT06170944|Device|Remote ischemic preconditioning|The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
79647169|NCT00187746|Drug|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
79647170|NCT00181649|Drug|Recombinant human prolactin|
79647171|NCT04575571|Other|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
79324445|NCT06170736|Procedure|Doppler-Guided Haemorrhoidal Artery Ligation|The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.
79480995|NCT05920395|Other|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
79647172|NCT00583843|Procedure|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
79647173|NCT00209430|Drug|Iodixanol 320 mgI/mL|
79647174|NCT00181688|Drug|Iressa (ZD1839)|
79647175|NCT00181688|Drug|Arimidex (Anastrozole)|
79809927|NCT04939142|Combination Product|Vd (Bortezomib+dexamethasone)|Vd Arm (~50): Bortezomib (Cycles 1-8 [BIW], Cycles ≥ 9 [QW]) + dexamethasone (Cycles 1-8 [Four times a week], Cycles ≥ 9 [BIW])
79809928|NCT04922021|Drug|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
79480996|NCT05920395|Other|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
79977277|NCT06080178|Drug|Norepinephrine|"When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg."
79324446|NCT06170736|Procedure|Radiofrequency ablation|The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.
79324447|NCT06170216|Drug|immunochemotherapies|Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
79809929|NCT04922021|Drug|LEO 138559 placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
79809930|NCT04901507|Device|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
79809931|NCT04876365|Other|Non-Interventional|This is a Non-Interventional Study.
79324450|NCT06167265|Drug|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
79324451|NCT06167265|Drug|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
79809932|NCT04848025|Device|Custom-designed tracheobronchial prostheses|Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
79809933|NCT04844463|Drug|JNJ-68179280|JNJ-68179280 will be administered as an oral capsule.
79809934|NCT04844463|Other|Placebo|Matching placebo will be administered as an oral capsule.
79809935|NCT04819542|Device|Bandage|Bandage
79324452|NCT06162221|Drug|RMC-6291|Oral tablet
79324453|NCT06162221|Drug|RMC-6236|Oral tablet
79324454|NCT06162221|Drug|Pembrolizumab|IV Infusion
79324455|NCT06162221|Drug|Cisplatin|IV Infusion
79324456|NCT06162221|Drug|Carboplatin|IV Infusion
79324457|NCT06162221|Drug|Pemetrexed|IV infusion
79324458|NCT06161610|Device|LITT|The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
79324459|NCT06161610|Other|Control|The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
79809936|NCT04819542|Device|No bandage|No bandage
79977278|NCT06079177|Device|Ultrasound|LUS using B-lines Caval-Aorta index using ultrasound
79977279|NCT06078033|Biological|Mobilization with movement|Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.
79977280|NCT06078033|Biological|Sham mobilization with movement|Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
79977281|NCT06076395|Device|LMA (Laryngeal Mask Airway)|Pressure controlled versus Volume controlled ventilation using LMA
79977282|NCT06075888|Diagnostic Test|Metagenomic diagnosis (mNGS, DISQVER)|Blood sample taken for metagenomic sequencing at inclusion visit.
79809937|NCT04804384|Device|Prehension neuroprosthesis|"The experimental condition corresponds to patients in the condition where the prehension neuroprosthesis is active, which means that the extensor muscles of the fingers and thumb will be stimulated by the prehension neuroprosthesis to ensure the opening of the hand. The prehension neuroprosthesis designates a functional electrical stimulation device controlled by the patient which will itself trigger the stimulation of the extensor muscles of the fingers (closed-loop control), according to stimuli which it controls voluntarily. The goal is to restore an opening of the fingers to capture objects.~The control condition corresponds to the patients in the condition where the prehension neuroprosthesis is inactive."
79480997|NCT05920382|Procedure|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
79480998|NCT05920369|Other|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
79480999|NCT05920369|Other|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.
79809938|NCT04801108|Procedure|Robotic or VATS lobar fissure completion|The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.
79809939|NCT04801108|Device|Endobronchial valves placement|Endobronchial valves will be placed in the target lobe after the fissure completion.
79809940|NCT04775147|Other|Intensive BP lowering|The aim is to achieve a systolic BP level of <120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
79977283|NCT06075758|Other|ribociclib|"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."
79977284|NCT06074120|Device|Low-level laser therapy|Low-level laser therapy would be introduced via a vaginal probe (gain medium: Gallium-Aluminum-Arsenide, wavelength 660nm) for 30 minutes per treatment, once a week, for 8 courses.
79977285|NCT06073379|Other|Korean manupuncture|Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands
79977286|NCT06073379|Other|Placebo session|Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
79324468|NCT06160466|Device|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
79324469|NCT06160466|Device|White light|White light endoscopy
79324470|NCT06158100|Drug|Venetoclax|Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
79324471|NCT06158100|Drug|Azacitidine|Azacitidine will be administered at a dose of 20mg/m^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.
79324472|NCT06158100|Biological|Donor Lymphocyte Infusion|"Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~DLI 1: 1x10^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~DLI 2: 5x10^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~DLI 3: 1x10^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD."
79324473|NCT06157866|Other|Electroacupuncture|During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. A low-amplitude, sub-sensory electrical current will be activated by the acupuncturist.
79324474|NCT06157866|Behavioral|Cognitive Training|Cognitive training with a pain specialist.
79481000|NCT05920369|Other|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
79647176|NCT04575454|Other|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~Starting PET continuous acquisition~Morphological MRI sequences~MRI in Resting state N°1~MRI DTI acquisition~IRM in 2D-Arterial Spin Labelling~IRM in Resting state 2~End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
79647177|NCT00583882|Other|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
79809941|NCT04770337|Device|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
79324475|NCT06157866|Behavioral|Education Training|Education training with a pain specialist.
79324476|NCT06153537|Drug|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
79324477|NCT06149494|Drug|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
79324478|NCT06149494|Drug|Placebo|Participants randomized to the placebo cohort will be administered placebo.
79809942|NCT04770337|Device|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
79324483|NCT06148311|Drug|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
79324484|NCT06148311|Drug|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
79324485|NCT06146257|Drug|GLB-001|Administered orally according to the assigned treatment schedule
79324486|NCT06141889|Drug|Azelaprag|oral, apelin receptor (APJ) agonist
79481001|NCT05920330|Other|Nasal Plug|Please see the arm description for details.
79647178|NCT03453034|Drug|TQ-B3233|QD or BID in different stage of this research
79647179|NCT00209469|Drug|alendronate sodium|
79647180|NCT00181727|Drug|divalproex sodium extended release|
79647181|NCT03452995|Procedure|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
79647182|NCT03452956|Other|None-Observation Only|No intervention-this is an observational study
79324487|NCT06134557|Procedure|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
79324488|NCT06127810|Device|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
79324489|NCT06127810|Drug|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
79324490|NCT06125522|Drug|vepdegestrant|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
79324491|NCT06125522|Drug|Samuraciclib|Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
79324492|NCT06125145|Behavioral|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
79324493|NCT06124040|Behavioral|psychological assessment evaluation|"A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months)."
79647183|NCT00187785|Behavioral|Spanish speaker level|
79647184|NCT00583999|Other|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
79647185|NCT00584038|Behavioral|educational instruction and phone follow-up|Educational instruction and phone follow-up.
79647186|NCT00584038|Behavioral|educational instruction in clinic|Educational instruction in clinic.
79647187|NCT00584155|Drug|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
79647188|NCT00584155|Drug|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
79647189|NCT00411372|Drug|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
79647190|NCT00181922|Drug|ziprasidone (Geodon)|
79647191|NCT00584311|Other|MRI and Ultrasound|MRI and US of the joint
79324494|NCT06123052|Other|Interview|"This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy."
79324495|NCT06121882|Device|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
79324496|NCT06121882|Drug|Saline Injection|Intra-articular knee injection of saline
79324497|NCT06119529|Drug|LY3872386|Administered either IV or SC.
79324498|NCT06119529|Drug|Prednisone|Administered orally.
79324499|NCT06119529|Drug|Placebo|Administered either IV or SC.
79977287|NCT06068530|Drug|DHA/piperaquine and a SLD-PQ|Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
79324500|NCT06118034|Drug|Colchicine 0.5 MG|Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
79324501|NCT06118034|Drug|Placebo|Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
79324502|NCT06114732|Behavioral|Walking exercise behaviour change intervention + TENS|"MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one & two) and two 20-minute follow-up telephone calls (weeks six & 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake."
79324503|NCT06111807|Diagnostic Test|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
79324504|NCT06111586|Drug|Frexalimab|Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
79324505|NCT06111586|Drug|Placebo|IV Infusion at Day 1 and SC Injection from W2 to W102
79324506|NCT06111586|Drug|Insulin|SC injection, dose and frequency will be established and/or adjusted by investigator
79324507|NCT06108674|Other|Pharmaceutical care via telepharmacy and usual care|Pharmacotherapeutic monitoring via telephone consultation
79324508|NCT06108674|Other|Pharmaceutical care in-person and usual care|Face-to-face pharmacotherapeutic monitoring
79481002|NCT05920304|Device|virtual Hospital at Home (vHaH)|"Participants randomized to vHaH will transferred home for home-based admission. Participants will be provided with equipment for self-monitoring (respiratory rate, oxygen saturation, blood pressure, heart rate and temperature). They will receive an app on their smartphone or tablet for transferring of self-measurements and communication with the hospital during their home-based admission.~Supporting the telemedicine concept, a mobile hospital-based care team will perform clinical tasks including intravenous administration, blood samples and on-site clinical assessment in the participant's home, when relevant.~Daily ward rounds will be conducted as video consultations. Before leaving the hospital, participants will receive thorough education on how to self-monitor and how to use the app."
79647192|NCT00584350|Other|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
79481003|NCT05920278|Device|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
79481004|NCT05920265|Procedure|Quadratus Lumborum plain Block|ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .
79977288|NCT06068530|Biological|Study vaccine R21/Matrix-M™|The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.
79324509|NCT06106100|Procedure|Antireflux mucosal ablation|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
79481005|NCT05920265|Procedure|fascia iliaca block|ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%
79481006|NCT05920265|Diagnostic Test|control group|no intervention
79481007|NCT05920239|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI imaging is a diagnostic technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures. It provides high-resolution images of soft tissues, organs, and bones, allowing for the detection and evaluation of various medical conditions.Two experienced radiologists specializing in musculoskeletal imaging will evaluate the images obtained through conventional MRI. Cases demonstrating involvement, characterized by findings such as thickening exceeding 4 mm in the inferior glenohumeral capsuloligamentous complex, signal increase indicating edema on fluid-sensitive sequences, and a reduction in axillary recess volume (greater than 0.53 ml), will be included in the study.
79481008|NCT05920239|Diagnostic Test|Sonoelastography|Sonoelastography is a medical imaging technique that combines ultrasound imaging with elastography. It is used to assess the mechanical properties and stiffness of tissues in the body.The probe will be carefully positioned perpendicular to the anterior part of the glenohumeral capsuloligamentous complex (IGHCC), ensuring no pressure is applied and preventing anisotropy. It will be specifically oriented in the coronal plane towards the axillary recess. The grayscale examination will reveal irregularly thickened and heterogeneous structures at the axillary recess level in the patient group. On the other hand, in the control group, measurements will be taken from the anterior band of the normal, thin, smooth, and homogeneous structure of the IGHCC.
79481009|NCT05920200|Procedure|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
79481010|NCT05920200|Procedure|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
79481011|NCT05920200|Procedure|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
79481012|NCT05920187|Other|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
79481013|NCT05920174|Device|NEO|Subjects will be implanted with the NEO device.
79481014|NCT05920161|Behavioral|Socially Evaluated Cold Pressor Test|The SECPT is a brief validated laboratory-based stress induction containing both physical and social elements
79647193|NCT00584350|Other|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
79647194|NCT00584350|Other|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
79647195|NCT00411489|Procedure|endolumenal surgery|
79977289|NCT06064929|Drug|Felzartamab|Specified dose on specified days
79977290|NCT06064877|Biological|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
79324510|NCT06106100|Procedure|Sham procedure|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
79324511|NCT06105021|Drug|AFNT-211|Engineered TCR T-Cell
79809943|NCT04757168|Device|NOGA TM probe|"Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure."
79977291|NCT06064877|Biological|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
79977292|NCT06064877|Other|Placebo|Placebo for this study will be normal saline
79481015|NCT05920161|Behavioral|Control|This is matched to the SECPT but with warm instead of cold water
79481016|NCT05920070|Procedure|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
79481017|NCT05920057|Behavioral|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
79481018|NCT05920044|Other|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
79977293|NCT06058039|Drug|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
79481019|NCT05920044|Other|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
79481020|NCT05920031|Other|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
79977294|NCT06058039|Drug|Placebo|Placebo will be administered orally
79977295|NCT06057766|Other|Physical activity tele coaching program|"The program includes~one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented."
79977296|NCT06057675|Drug|Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.
79977297|NCT06057675|Drug|Control (1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
79324514|NCT06101329|Drug|Lenacapavir Tablet|Tablets administered orally without regard of food
79324515|NCT06101329|Drug|Lenacapavir Injection|Injection administered subcutaneously
79324516|NCT06101329|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
79324517|NCT06098144|Drug|Nicoderm C-Q Gum|"Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition."
79324518|NCT06098144|Behavioral|Tobacco Quit-line|The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
79324519|NCT06098144|Behavioral|Brief Behavioral Counseling|"The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes."
79324520|NCT06098144|Behavioral|Intensive Behavioral Counseling|Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
79481021|NCT05920031|Other|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
79481022|NCT05920031|Other|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
79481023|NCT05920018|Dietary Supplement|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
79481024|NCT05920018|Dietary Supplement|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
79481025|NCT05920018|Other|Maltose placebo|Daily application of four sachets for 48 weeks
79481026|NCT05920018|Other|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
79809944|NCT04742998|Other|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
79481027|NCT05919992|Drug|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on empty stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
79481028|NCT05919992|Drug|Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
79481029|NCT05919992|Drug|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
79977298|NCT06056141|Drug|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
79481030|NCT05919992|Drug|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
79481031|NCT05919979|Behavioral|34-hour fasting in sedentary conditions|Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
79481032|NCT05919979|Behavioral|34-hour fasting with high-intensity exercise|Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
79809945|NCT04722354|Other|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
79977299|NCT06056141|Device|Foley Catheter|Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
79977300|NCT06056063|Device|Halcyon 4.0|This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
79977301|NCT06054750|Drug|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
79324525|NCT06094504|Other|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
79324526|NCT06093282|Behavioral|ARCH|"ARCH is a 4-month health outreach intervention that includes the following components:~Screening and referral to address social determinants of health~A 12-session adaptation of Behavioral Activation Treatment for Depression~Weekly contacts from an outreach worker~Optional resources aimed at promoting physical activity and weight management"
79324527|NCT06093282|Behavioral|Traditional Health Outreach|"The Traditional Health Outreach comparator is a 4-month health outreach intervention that includes the following components:~Screening and referral to address social determinants of health~Support calls from an outreach worker at least once every 3 weeks"
79809946|NCT04722354|Procedure|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
79324529|NCT06088979|Drug|TOUR006 - 20 MG|TOUR006 20 MG
79324530|NCT06088979|Other|Placebo|Placebo
79324531|NCT06088979|Drug|TOUR006 - 50 MG|TOUR006 - 50 MG
79324532|NCT06088901|Procedure|Autologous Blood Patch|2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
79324533|NCT06088680|Device|Glycar Pericardial Patch|Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
79324534|NCT06084533|Drug|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer [11C]-CS1P1. Participants will then undergo a [11C]-CS1P1 PET scan.
79324535|NCT06084117|Other|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
79324536|NCT06084117|Other|NIV|Respiratory support with Non-invasive ventilation, standard of care
79324537|NCT06080009|Genetic|exome sequencing (retrospective) and exome and methylome sequencing (prospective)|"Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed."
79324538|NCT06078280|Device|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
79481033|NCT05919966|Other|Chlorhexidine bathing|The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
79481034|NCT05919953|Device|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
79809947|NCT04722354|Dietary Supplement|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
79809948|NCT04722354|Other|Placebo|Those in this group will receive placebo (300 mg cornstarch)
79324539|NCT06078267|Device|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
79324540|NCT06076044|Device|toDCS 2mA 1Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.
79324541|NCT06076044|Device|toDCS 2mA 10Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.
79324542|NCT06076044|Device|tDCS 1mA|The subgroup treated by transcranial direct current stimulation of 1mA.
79324543|NCT06076044|Device|sham|The subgroup treated by sham stimulation.
79324544|NCT06075849|Drug|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
79324545|NCT06075147|Drug|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
79324546|NCT06073665|Drug|Levothyroxine Sodium|Levothyroxine dose will depend on dose at baseline and randomization group
79324547|NCT06071468|Device|Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically < 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
79324548|NCT06071286|Procedure|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
79324549|NCT06070376|Device|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
79324550|NCT06070376|Device|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
79809949|NCT04717141|Other|Selective nerve block|"D0 :~Information, collection of consent, inclusion,~Clinical and instrumental evaluation,~Realization of the selective nerve block,~Post-selective nerve block clinical and instrumental re-evaluation,~Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
79809950|NCT04709419|Device|Celliant Diabetic Medical Socks|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction."
79977302|NCT06054750|Drug|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
79647196|NCT00182039|Drug|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
79977303|NCT06054477|Drug|ALE.C04|Q3W
79977304|NCT06054477|Drug|Pembrolizumab|200mg Q3W
79977305|NCT06053801|Other|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
79324562|NCT06057779|Other|Slow and heavy exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
79324563|NCT06057779|Other|Slow and light exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into neutral ankle position at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
79324564|NCT06057779|Other|Fast and heavy exercise therapy|6 sets of 30 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 1 Hz, with 1-min rest period between each set.
79324565|NCT06057727|Behavioral|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
79324566|NCT06057727|Behavioral|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
79324567|NCT06057727|Behavioral|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
79324568|NCT06057727|Behavioral|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
79977306|NCT06053398|Drug|Phenylephrine|Intraoperative phenylephrine infusion Phenylephrine infusion to be titrated as needed to target a mean arterial pressure (MAP) > 65 mm Hg.
79977307|NCT06053398|Drug|Norepinephrine|Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP > 65 mm Hg.
79977308|NCT06051422|Device|three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.
79977309|NCT06051227|Drug|Fentanyl Citrate|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
79647197|NCT00182039|Drug|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
79324569|NCT06057064|Biological|Biological: AZD3152|300 mg single dose of AZD3152 IM
79647198|NCT00584389|Drug|rimonabant|20mg/d (oral) once daily for 12 weeks
79977310|NCT06051227|Drug|Esketamine|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
79324570|NCT06057064|Biological|Biological: Placebo|Single dose of Placebo IM (0.9% sodium chloride)
79324571|NCT06056791|Biological|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.
79647199|NCT00584389|Behavioral|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
79977311|NCT06048783|Behavioral|Program of systematic and periodic spiritual accompaniment and care|Systematic and periodic spiritual accompaniment and care
79977312|NCT06047496|Behavioral|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
79977313|NCT06045455|Diagnostic Test|Multimodal brain CT|Multimodal brain CT includes NCCT, CTP, and CTA
79977314|NCT06045455|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI examination will be performed between the 3rd and 7th day after the admission to the hospital
79977315|NCT06044168|Dietary Supplement|Dietary Supplement: Leucine|150mg/kg body mass/day
79977316|NCT06043713|Drug|Bendamustine|Receive IV
79977317|NCT06043713|Procedure|Biopsy|Undergo tissue biopsy
79977318|NCT06043713|Procedure|Biospecimen Collection|Undergo blood sample collection
79977319|NCT06043713|Procedure|Computed Tomography|Undergo CT
79977320|NCT06043713|Drug|Cyclophosphamide|Receive IV
79809951|NCT04709419|Device|Control (placebo) Medical Socks|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
79324572|NCT06055985|Other|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
79324573|NCT06055985|Drug|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
79809952|NCT04688554|Diagnostic Test|fMRI and DTI|Neurologic imaging correlates
79809953|NCT04688554|Behavioral|Behavioral questionnaires|RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
79809954|NCT04688554|Behavioral|Disease-Specific Patient-Reported Outcomes|Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
79324574|NCT06054269|Biological|FLUAD Quadrivalent|0.5 mL intramuscular dose of FLUAD Quadrivalent
79324575|NCT06054269|Biological|FluQuadri|0.5 mL intramuscular dose of FluQuadri
79324576|NCT06053424|Drug|AZD7798|Solution
79324577|NCT06053424|Drug|[11C]AZ14132516|Radioligand
79809955|NCT04688554|Behavioral|Behavioral tests|Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
79324579|NCT06052072|Device|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
79324580|NCT06051890|Drug|Extended-Release Buprenorphine (XRB)|XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
79324581|NCT06051890|Drug|Sublingual Buprenorphine (SLB)|Maintenance of existing SLB prescription (treatment as usual).
79324582|NCT06049849|Device|Biophoton Energizing Brain and Whole Body|The patient is to be energized within a strong biophoton field which is constantly generated by active biophoton generators.
79324583|NCT06049563|Diagnostic Test|Diagnostic MRI|MRI scan of the upper abdomen performed with the low-field 0.4T MRI system.
79324584|NCT06045117|Device|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
79809956|NCT04659421|Drug|combined therapy with rh-ES and CV|"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."
79809957|NCT04636684|Diagnostic Test|Proteomic analysis|Proteomic analysis based on mass spectrometry on the sample of valve tissues.
79647200|NCT00584428|Procedure|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
79647201|NCT00216372|Drug|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
79977321|NCT06043713|Procedure|Echocardiography|Undergo ECHO
79647202|NCT00216372|Other|Placebo|A single intra-muscular injection on day 0.
79647203|NCT00584584|Drug|QAX576|
79977322|NCT06043713|Drug|Fludarabine|Receive IV
79977323|NCT06043713|Procedure|Leukapheresis|Undergo leukapheresis
79977324|NCT06043713|Procedure|Magnetic Resonance Imaging|Undergo MRI
79977325|NCT06043713|Procedure|Multigated Acquisition Scan|Undergo MUGA
79977326|NCT06043713|Procedure|Positron Emission Tomography|Undergo PET
79977327|NCT06043713|Biological|T-cell Receptor-engineered T-cells|Receive FHA11KRASG12V-TCR IV
79977328|NCT06042517|Device|Ultrasound|The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.
79324588|NCT06040346|Drug|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
79324589|NCT06039514|Device|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
79324590|NCT06039514|Device|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
79324591|NCT06033391|Device|GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)|"GGOC was originally designed to challenge maladaptive beliefs that underline OCD symptoms in adult population. It was adapted to adolescent population. It consists of statements that are presented to the user, and that can portray either negative (I can't trust myself) or positive beliefs (I have a lot of good characteristics). Users have to respond by either pulling these towards Accept or Reject."
79324592|NCT06033391|Device|GGN-AD (GG Neutral - Adolescents)|"it was designed to have a comparison group. It consists of neutral statements such as Madrid is a Spanish city, that ought not to produce changes in the direction of our hypothesis. These have to be Accepted or Rejected based on their veracity."
79647204|NCT00584584|Drug|Placebo|
79977329|NCT06042517|Diagnostic Test|OGTT with unlabeled glucose and liver NMR|Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.
79647205|NCT00584662|Drug|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
79647206|NCT04575532|Device|Use of the pinpointIQ solution (physIQ, Inc.)|Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.
79977330|NCT06042517|Diagnostic Test|OGTT with carbon-13 labeled glucose and liver NMR|Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.
79977331|NCT06042517|Diagnostic Test|CGM glucose reading|A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
79324594|NCT06031025|Other|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
79324595|NCT06026891|Drug|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
79324596|NCT06024824|Radiation|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
79324597|NCT06024369|Device|CPM Device|Wearable monitor used for 5 minutes per day.
79481035|NCT05919953|Behavioral|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
79647207|NCT04575298|Dietary Supplement|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
79809958|NCT04614948|Biological|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
79324598|NCT06023615|Other|mHealth app/dashboard|In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
79324601|NCT06015880|Procedure|Biospecimen Collection|Undergo blood sample collection
79324602|NCT06015880|Procedure|Computed Tomography|Undergo PET/CT
79324603|NCT06015880|Drug|Lenalidomide|Given PO
79324604|NCT06015880|Biological|Mosunetuzumab|Given IV
79324605|NCT06015880|Drug|Polatuzumab Vedotin|Given IV
79324606|NCT06015880|Procedure|Positron Emission Tomography|Undergo PET/CT
79324607|NCT06014515|Drug|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
79481036|NCT05919706|Behavioral|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
79481037|NCT05919316|Device|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
79481038|NCT05919316|Drug|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
79647208|NCT00209508|Drug|GPI 1485|
79324608|NCT06014515|Drug|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
79977332|NCT06042517|Diagnostic Test|HEC - Hyperinsulinemic-Euglycemic-Clamp|A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
79977333|NCT06041217|Drug|Semaglutide|Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
79324609|NCT06013995|Drug|BMS-986326|Specified dose on specified days
79324610|NCT06013995|Other|Placebo for BMS-986326|Specified dose on specified days
79324611|NCT06013020|Drug|NOAC+DAPT|Century Clot-guided rivaroxaban plus DAPT.
79324612|NCT06013020|Drug|DAPT|Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
79809959|NCT04614948|Other|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
79977334|NCT06041217|Drug|Placebo|Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
79977335|NCT06040320|Drug|Polatuzumab vedotin|Given at 1.8 mg/kg
79977336|NCT06040320|Drug|Rituximab|Given at 375 mg/m^2
79977337|NCT06040320|Drug|CHP|Cyclophosphamide (750 mg/m^2) + doxorubicin (50 mg/m^2) + prednisone (100 mg days 2-6)
79324615|NCT06008626|Device|Cryosa Procedure|Cryotherapy
79324616|NCT06007131|Device|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
79324617|NCT06007079|Device|CPM Device|Wearable monitor
79324618|NCT06006520|Other|control|No exercises will be given.
79324619|NCT06006520|Other|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
79324620|NCT06006520|Other|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
79324621|NCT06005285|Behavioral|Early Start Denver Model (ESDM)|The Early Start Denver Model focuses on teaching inside children's play and care activities, carried out within a joint activity structure. Adults follow children's leads into activities, embed teaching objectives inside the play, use the play as the reward, and build targeted skills following developmental science and ABA principles.
79324622|NCT06005285|Behavioral|Early Intensive Behavioral Intervention (EIBI)|Treatment as usual provided by community-based autism agencies
79324623|NCT06004414|Behavioral|App-based Cognitive Behavioral Therapy (CBT)|SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.
79324624|NCT06004414|Behavioral|Psychotherapy|Psychotherapy with a licensed clinician in the school-based health center.
79324625|NCT06002763|Other|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
79647209|NCT00182195|Procedure|Control Ventilation Strategy|
79324626|NCT06002763|Other|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
79647210|NCT00584779|Drug|Gabapentin|CLcr:14-5 mL/min
79647211|NCT00584779|Drug|Gabapentin|CLcr: 29-15 mL/min
79647212|NCT00584779|Drug|Gabapentin|Hemodialysis
79977338|NCT06038578|Biological|TRK-950|5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
79977339|NCT06038578|Drug|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
79977340|NCT06038578|Drug|Paclitaxel|80 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
79977341|NCT06037252|Drug|Tirzepatide|Administered SC
79977342|NCT06037252|Drug|Placebo|Administered SC
79977343|NCT06036017|Other|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
79324627|NCT06002763|Other|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
79481039|NCT05919004|Diagnostic Test|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
79481040|NCT05918445|Drug|PM8002|IV infusion
79481041|NCT05918146|Drug|Dextrose|Dextrose injection plus physical therapy
79481042|NCT05918146|Drug|Normal saline|Normal saline injection plus physical therapy
79481043|NCT05918133|Drug|PM8002|IV infusion
79481044|NCT05918133|Drug|nab-paclitaxel|IV infusion
79481045|NCT05918107|Drug|PM8002|IV infusion
79977344|NCT06036017|Other|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
79481046|NCT05918107|Drug|Pemetrexed|IV infusion
79481047|NCT05918107|Drug|Cisplatin|IV infusion
79481048|NCT05918107|Drug|Carboplatin|IV infusion
79481049|NCT05917496|Other|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
79481050|NCT05917496|Behavioral|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
79324628|NCT06001541|Behavioral|Web-SUCCEED|web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
79977345|NCT06036017|Other|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
79647213|NCT00584779|Drug|Gabapentin|CLcr: 29-30 mL/min
79647214|NCT00584818|Drug|PB127 for Injectable Suspension|"Stages 1 & 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 & 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
79647215|NCT00216411|Biological|Botulinum toxin type A|
79647216|NCT00216411|Drug|Placebo|
79647217|NCT00584896|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
79324629|NCT06000475|Behavioral|Cognitive Processing Therapy|CPT as described in the treatment manual
79324630|NCT06000475|Behavioral|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
79324631|NCT05998408|Drug|Ruxolitinib|Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
79324632|NCT05995847|Behavioral|Harmonica playing program plus basic PR care with routine follow-up|The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.
79647218|NCT00182234|Behavioral|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
79647219|NCT00585091|Drug|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
79647220|NCT00585208|Drug|Ramelteon|Ramelteon 8mg daily
79647221|NCT00585208|Drug|Placebo|matching placebo for ramelteon 8mg daily
79647222|NCT00216450|Drug|rabeprazole sodium|
79481051|NCT05916950|Device|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
79647223|NCT00182273|Procedure|Canalith repositioning maneuver (CRM)|
79647224|NCT00585442|Drug|calcitriol|1.0 mcg daily
79647225|NCT00585442|Drug|Placebo|Placebo
79647226|NCT00585481|Procedure|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
79809960|NCT04614064|Other|Exposure to London Underground ambient particulate matter|Exposure to particulate matter on the London Underground
79809961|NCT04614064|Other|Exposure to London air ambient particulate matter|Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)
79977346|NCT06033404|Procedure|Normal Clinical practice|Normal Clinical practice
79324633|NCT05995847|Behavioral|Basic PR care with routine follow-up|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
79481052|NCT05916547|Procedure|pancreatic extracorporeal shock wave lithotripsy|Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.
79481053|NCT05913089|Drug|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
79481054|NCT05913089|Drug|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
79647227|NCT00585481|Procedure|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
79977347|NCT06031701|Behavioral|Neuro-psychosocial teleassistance program|The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
79481055|NCT05911152|Procedure|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
79481056|NCT05902000|Device|Carotid Stenting|Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.
79647228|NCT00585520|Drug|Progesterone|200mg BID for 5 days
79647229|NCT00585520|Drug|Placebo|Placebo
79647230|NCT00216489|Drug|rabeprazole sodium|
79647231|NCT00408395|Biological|Influenza vaccine|Seasonal Influenza Vaccine
79481057|NCT05902000|Procedure|Thrombectomy|Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.
79647232|NCT00585598|Other|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
79647233|NCT00585754|Drug|Guanfacine|1.5mg BID
79647234|NCT00585754|Drug|Placebo|placebo
79647235|NCT00209547|Drug|fospropofol disodium|
79647236|NCT00585793|Drug|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
79647237|NCT00585871|Drug|clonidine|0.1 mg tid
79647238|NCT00585871|Drug|metoprolol|25 mg tid
79647239|NCT00408512|Drug|thiazides|Up to 25 mg per day
79647240|NCT00408512|Procedure|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
79647241|NCT00585949|Procedure|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
79647242|NCT00585949|Procedure|Angiography|Angiography is an imaging technique to see coronary blood vessels.
79647243|NCT00585988|Device|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
79647244|NCT00585988|Device|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
79647245|NCT04722393|Other|Exercise|Exercise training
79647246|NCT03452761|Dietary Supplement|Ketone Salts|Subjects will take 2 servings of ketone salts daily for 6 weeks
79809962|NCT04608019|Other|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
79809963|NCT04608019|Other|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
79324634|NCT05993481|Diagnostic Test|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
79324635|NCT05989841|Behavioral|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
79324636|NCT05989841|Behavioral|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
79324637|NCT05987241|Procedure|Biospecimen Collection|Undergo collection of tissue and blood
79324638|NCT05987241|Other|cfDNA or ctDNA Measurement|Undergo ctDNA surveillance
79324639|NCT05987241|Procedure|Computed Tomography|Undergo CT
79481058|NCT05902000|Drug|Dual antiplatelet treatment|Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
79481059|NCT05902000|Drug|Intraoperative Drug Treatment|Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
79481060|NCT05897268|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
79481061|NCT05897268|Drug|Tislelizumab|a PD-1 immune check inhibitor
79324640|NCT05987241|Procedure|Magnetic Resonance Imaging|Undergo MRI
79324641|NCT05987241|Biological|Nivolumab|Given IV
79324642|NCT05987241|Other|Quality-of-Life Assessment|Ancillary studies
79324643|NCT05987241|Other|Questionnaire Administration|Ancillary studies
79324644|NCT05987241|Biological|Relatlimab|Given IV
79324647|NCT05980585|Device|CPM Device|Daily use of the CPM wearable device
79481062|NCT05897268|Drug|Lenvatinib|Lenvatinib capsules
79647247|NCT04722861|Other|GVFQ-40|GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
79647248|NCT03452722|Drug|intraventricual recombinant tissue plasminogen activator application|
79809964|NCT04607954|Biological|Durvalumab|Given IV
79324649|NCT05978518|Device|CPM Device + Monitoring|Daily device use & data monitoring leading to symptomology assessment and notification to provider.
79324650|NCT05978518|Drug|CPM Device|Daily device use
79324653|NCT05973851|Drug|Esketamine Nasal Product|See arm description
79324654|NCT05973851|Drug|Ketamine Hydrochloride|See arm description
79647249|NCT03452683|Behavioral|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
79324655|NCT05973851|Drug|Esketamine hydrochloride|See arm description
79324656|NCT05973851|Drug|Second-line Antidepressants|See arm description
79324657|NCT05973786|Drug|Escitalopram|ATC code: N06AB10
79324658|NCT05973786|Drug|Sertraline|See arm description
79324659|NCT05973786|Drug|Venlafaxine|See arm description
79324660|NCT05973786|Drug|Lithium|See arm description
79324661|NCT05973786|Drug|Valproate acid|See arm description
79647250|NCT00408551|Drug|floxuridine|Given IV
79647251|NCT00408551|Drug|fluorouracil|Given IV
79647252|NCT00408551|Drug|irinotecan hydrochloride|Given IV
79647253|NCT00408551|Drug|leucovorin calcium|Given IV
79324662|NCT05973786|Drug|Quetiapine|See arm description
79324663|NCT05972720|Drug|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
79324664|NCT05972720|Drug|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
79324665|NCT05972720|Drug|CRG-022 cells (Experimental drug)|Investigational agent
79647254|NCT00408551|Drug|oxaliplatin|Given IV
79647255|NCT00586183|Procedure|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
79647256|NCT04575415|Drug|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
79324669|NCT05960305|Other|P1213416|Tobacco Flavor
79324670|NCT05960305|Other|P1213422|Tobacco Flavor
79977348|NCT06029894|Dietary Supplement|Citicoline Supplement|Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A & B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
79977349|NCT06029894|Other|Placebo|Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A & B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
79977350|NCT06029673|Drug|Cabergoline 1 MG|Dopamine agonist
79977351|NCT06029673|Drug|Placebo|Placebo
79481063|NCT05897177|Behavioral|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
79809965|NCT04607954|Drug|Lurbinectedin|Given IV
79977352|NCT06029439|Drug|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
79977353|NCT06029426|Drug|NMRA 335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
79324671|NCT05960305|Other|P1213716|Tobacco Flavor
79324672|NCT05960305|Other|P1213722|Tobacco Flavor
79977354|NCT06029426|Drug|Placebo|Placebo will be administered orally
79977355|NCT06027918|Procedure|Infraclavicular brachial plexus block|In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
79324673|NCT05960305|Other|P1211216|Menthol Flavor
79324674|NCT05960305|Other|P1211222|Menthol Flavor
79324675|NCT05960305|Other|P1213616|Menthol Flavor
79324676|NCT05960305|Other|P1213622|Menthol Flavor
79324677|NCT05960305|Other|P1213816|NTNM Flavor
79647257|NCT04575415|Drug|Erlotinib|Erlotinib 150mg, orally once a day
79647258|NCT04575415|Drug|Gefitinib|Gefitinib 250mg, orally once a day
79647259|NCT04575415|Drug|Icotinib|Icotinib 125mg three times a day
79324678|NCT05960305|Other|P1213822|NTNM Flavor
79324679|NCT05960305|Other|P1211916|NTNM Flavor
79324680|NCT05960305|Other|P1211922|NTNM Flavor
79324681|NCT05960240|Drug|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
79324682|NCT05960240|Drug|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
79647260|NCT04575415|Drug|Afatinib|Afatinib 40 mg or clinical routine dose once daily
79647261|NCT04575415|Drug|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
79809966|NCT04594096|Behavioral|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
79809967|NCT04594096|Behavioral|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
79809968|NCT04585841|Drug|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
79809969|NCT04583007|Drug|Lanadelumab 150 mg|TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks [Q2W] or for every 4 weeks [Q4W]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
79809970|NCT04583007|Drug|Lanadelumab 300 mg|TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
79324683|NCT05960240|Drug|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
79324684|NCT05958875|Drug|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
79324685|NCT05958875|Drug|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
79324686|NCT05954325|Procedure|Immunoadsorption vs. sham immunoadsorption|5 treatments within 14 days
79324688|NCT05951881|Other|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~the Electronic Medical Record~the patient's medication history~the reference pharmacy"
79324689|NCT05949684|Biological|Luspatercept|Specified dose on specified days
79324690|NCT05949684|Biological|Epoetin Alfa|Specified dose on specified days
79324691|NCT05949333|Drug|Eflapegrastim|long-acting granulocyte-colony stimulating factor
79647262|NCT04575415|Drug|Osimertinib|Osimertinib 80 mg once daily
79977356|NCT06025942|Behavioral|Purrble intervention|"When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)"
79977357|NCT06025747|Drug|Abemaciclib|Given PO
79481064|NCT05895019|Drug|Propofol|Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.
79977358|NCT06025747|Procedure|Computed Tomography|Undergo CT
79977359|NCT06025747|Procedure|Magnetic Resonance Imaging|Undergo MRI
79977360|NCT06025747|Radiation|Radiation Therapy|Undergo radiation therapy
79809971|NCT04572022|Other|Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
79977361|NCT06025747|Procedure|Therapeutic Surgical Procedure|Undergo surgery
79977362|NCT06025396|Drug|TMP-301|Multiple ascending dose active
79324695|NCT05946447|Device|Ultrasound|The gastric antrum will be scanned using ultrasound.
79324696|NCT05943509|Behavioral|Alternative rehabilitation strategies|Counseling intervention.
79324697|NCT05943509|Behavioral|Usual Care|Usual care audiology pathway.
79324698|NCT05938426|Device|ET-101|Patients have training sessions twice a day. Each training session takes about 10~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
79324699|NCT05938426|Device|Sham Device|Sham device has only cognitive function test excluding training programs.
79481065|NCT05893056|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
79481066|NCT05893056|Drug|Tislelizumab|a PD-1 immune check inhibitor
79977363|NCT06025396|Drug|Placebo|Multiple ascending dose comparator
79977364|NCT06025370|Other|Prone Position|"All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups."
79977365|NCT06024070|Other|Rigid Tape|"The patient was rested in supine or long sitting position on a table Pre-wrap was applied to cover all the area before tapping Two strips used separately as anchors at the two ends of the pre-wrap. Two Longitudinal stirrup of tape were used from medial side of the superior anchor to lateral side of the same anchor.~Two horizontal stirrup of tape were used from medial side of the distal anchor to lateral side of the same anchor to support the medial side of the foot.~Figure-of-eight straps were utilized for the taping. Lateral heel lock was applied.The tape then proceeded from the lateral side of the foot, looping around the heel, and returning to the same starting point by crossing over the Achilles tendon from behind.~Medial heel lock was applied, the tape application was similar to the lateral heel lock but was at the opposite direction.~Superior and inferior anchors were applied to support all the previous strips"
79977366|NCT06022016|Genetic|For each person (index case or related) included in this study:|"an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~a saliva sample will be taken (if applicable) so that a genetic analysis can be performed."
79977367|NCT06020664|Drug|NOX-1416+SOC|NOX1416+SOC as provided in Arm/group description
79977368|NCT06020664|Other|Placebo+SOC|Placebo+SOC as provided in Arm/group description
79977369|NCT06017245|Device|whole-body vibration to Control|Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
79324700|NCT05938023|Drug|ATL1102 25mg|Dose and scheduled as specified in the Arm description
79324701|NCT05938023|Drug|ATL1102 50mg|Dose and scheduled as specified in the Arm description
79324702|NCT05938023|Drug|Placebo|Dose and scheduled as specified in the Arm description
79324703|NCT05936359|Drug|INCA033989|INCA033989 will be administered at protocol defined dose.
79324704|NCT05936359|Drug|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
79324705|NCT05930041|Procedure|Experimental CSP|Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
79324706|NCT05930041|Procedure|Active Comparator HS-EMR|Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
79324707|NCT05929222|Radiation|Radiotherapy|Involved-Site Radiation Therapy 24Gy
79647263|NCT00586222|Dietary Supplement|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
79647264|NCT00586222|Other|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
79324708|NCT05929222|Other|Radiotherapy plus Obinutuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
79324709|NCT05922124|Drug|Cefiderocol|Test drug regimen
79324710|NCT05922124|Drug|Ampicillin-sulbactam|Synergistic combination
79324711|NCT05922124|Drug|Colistin|Historical comparator
79324712|NCT05922124|Drug|Meropenem|Historical comparator synergistic combination
79324713|NCT05918211|Drug|Udenafil|Active drug
79324714|NCT05918211|Drug|Placebo|Matching Placebo
79481067|NCT05893056|Drug|Lenvatinib|Lenvatinib capsules
79481068|NCT05891379|Drug|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
79481069|NCT05891379|Drug|oral immunosuppressant|Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
79481070|NCT05889650|Procedure|External Lumbar drainage|ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage
79647265|NCT00408668|Biological|PEV3A|
79647266|NCT00408668|Biological|FP9 ME-TRAP|
79647267|NCT00408668|Biological|MVA ME-TRAP|
79977370|NCT06016725|Other|Exercise Intervention|Participate in online resistance training sessions
79977371|NCT06016725|Other|Informational Intervention|Given educational materials
79977372|NCT06016725|Other|Nutritional Assessment|Participate in online nutritional counseling
79977373|NCT06016725|Other|Physical Performance Testing|Ancillary studies
79481071|NCT05889546|Procedure|Biospecimen Collection|Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
79481072|NCT05888324|Other|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
79324715|NCT05916235|Device|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
79324716|NCT05910489|Other|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
79324717|NCT05910229|Other|Phone call|In the experimental arm the patient will be called 3 days before the CT scan
79809972|NCT04557020|Drug|PD-1 antibody|neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
79809973|NCT04557020|Drug|Gemcitabine|neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
79809974|NCT04557020|Drug|Cisplatin|neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
79481073|NCT05883852|Drug|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
79481074|NCT05883852|Drug|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
79481075|NCT05883852|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
79809975|NCT04557020|Radiation|IMRT|70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
79809976|NCT04555551|Biological|Infusion of MCARH109 T cells|Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
79809977|NCT04543786|Device|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
79809978|NCT04521140|Drug|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
79809979|NCT04521140|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
79324729|NCT05905783|Drug|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
79324730|NCT05905783|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
79481076|NCT05883852|Drug|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
79481077|NCT05883852|Drug|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
79481078|NCT05883852|Drug|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
79977374|NCT06016725|Other|Quality-of-Life Assessment|Ancillary studies
79977375|NCT06016725|Other|Questionnaire Administration|Ancillary studies
79809980|NCT04519658|Drug|CIN-107|CIN-107 tablets by mouth once daily
79809981|NCT04519658|Drug|Placebo|placebo tablets by mouth once daily
79977376|NCT06016387|Drug|Tucatinib 150 MG|Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
79977377|NCT06016387|Drug|Trastuzumab|"MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations."
79977378|NCT06016387|Drug|Capecitabine|Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
79324738|NCT05902533|Radiation|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
79324739|NCT05902533|Drug|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
79324740|NCT05902533|Drug|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
79647268|NCT00586300|Other|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
79647269|NCT00586300|Behavioral|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
79977379|NCT06016387|Radiation|Brain & Spinal Radiation|Brain & Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
79324741|NCT05900986|Drug|LS301-IT 0.025 mg/kg|The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
79324742|NCT05900986|Drug|LS301-IT 0.05 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
79324743|NCT05900986|Drug|LS301-IT 0.075 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
79647270|NCT00586300|Other|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
79481079|NCT05883371|Other|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
79481080|NCT05882760|Drug|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch & Rinse Tetric - N - Bond (Ivoclar)
79481081|NCT05882760|Drug|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
79481082|NCT05882760|Drug|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
79481083|NCT05882760|Drug|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
79481084|NCT05881200|Device|Magnetic mitohormesis|"The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments"
79481085|NCT05879458|Drug|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
79481086|NCT05879432|Drug|LSALT Peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
79647271|NCT00586378|Device|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
79977380|NCT06013878|Other|Transfer Training with clinician|Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
79977381|NCT06010004|Drug|Orforglipron|Administered orally
79647272|NCT00209625|Drug|irinotecan|
79977382|NCT06005688|Drug|Vepdegestrant|Participants will receive a single dose of Vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 20 days between two doses of Vepdegestrant.
79977383|NCT06005688|Drug|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for 19 days in Period 2.
79481087|NCT05879432|Drug|Placebo|0.9% saline solution
79481088|NCT05876650|Other|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
79481089|NCT05876650|Other|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
79647273|NCT00209625|Drug|leucovorin|
79647274|NCT00209625|Drug|fluorouracil|
79647275|NCT00586417|Other|punch biopsy|skin biopsies
79647276|NCT00408707|Procedure|local infiltration analgesia|
79647277|NCT00586534|Behavioral|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
79647278|NCT00586534|Behavioral|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
79647279|NCT00586807|Other|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
79647280|NCT00216528|Drug|risperidone|
79647281|NCT00586885|Drug|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
79647282|NCT00587002|Procedure|IVUS|Intravascular ultrasound with virtual histology
79977384|NCT06003621|Biological|Tiragolumab|600mg IV every 21 days from Cycle 1 Day 1
79977385|NCT06003621|Biological|Atezolizumab|1,200mg IV every 21 days from Cycle 2 Day 1
79977386|NCT06003361|Device|Digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for depression.
79977387|NCT06003361|Other|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
79647283|NCT00182312|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
79481090|NCT05875090|Diagnostic Test|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
79647284|NCT00209664|Drug|irinotecan|
79324744|NCT05900986|Drug|LS301-IT 0.1 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
79324745|NCT05899673|Drug|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
79809982|NCT04511572|Procedure|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed [31]. The procedure is performed under local anesthesia.
79809983|NCT04507178|Drug|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
79809984|NCT04497259|Other|Teleevaluation|Patients will answer to a questionnaire filled through a chatbot link
79809985|NCT04497259|Other|Teleconsultation|A teleconsultation (skype-like connection) at 6 and 9 months after surgery
79324750|NCT05893641|Behavioral|A regular training volume|Participate will maintain their training volume of 35 h/week
79324751|NCT05893641|Behavioral|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
79324752|NCT05893641|Behavioral|A longer rest group|Participate will maintain the 35 h/week of exercise training
79809986|NCT04497259|Other|Classical consultation|Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.
79809987|NCT04496674|Drug|CC-1 and Toczilizumab|Adminsitration of CC-1 and Toczilizumab
79647285|NCT00209664|Drug|S-1|
79647286|NCT04575493|Dietary Supplement|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
79809988|NCT04495699|Other|None - observational|If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
79324755|NCT05886036|Procedure|Biopsy|Undergo tissue biopsy
79324756|NCT05886036|Procedure|Biospecimen Collection|Undergo blood sample collection
79324757|NCT05886036|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79324758|NCT05886036|Procedure|Computed Tomography|Undergo PET/CT
79324759|NCT05886036|Other|Fludeoxyglucose F-18|Receive FDG
79324760|NCT05886036|Biological|Mosunetuzumab|Given SC
79324761|NCT05886036|Procedure|Positron Emission Tomography|Undergo PET/CT
79324762|NCT05886036|Biological|Rituximab|Given IV
79324763|NCT05886036|Biological|Rituximab and Hyaluronidase Human|Given SC
79324764|NCT05885828|Other|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
79481091|NCT05872360|Dietary Supplement|Bundle Group 1 with Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium & Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day. Practice according to Nutrilite Lifestyle Guideline per day.
79647287|NCT04575493|Drug|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
79647288|NCT00587119|Drug|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
79647289|NCT00216567|Drug|topamax|
79324765|NCT05885828|Other|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
79977388|NCT06001645|Diagnostic Test|Blood and bronchoalveolar fluid collection and analysis|Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
79647290|NCT00182351|Procedure|D-dimer|
79324766|NCT05885828|Behavioral|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
79977389|NCT06001645|Diagnostic Test|Chest CT scan|Computed Tomography Scan per normal clinical practice
79977390|NCT06000683|Behavioral|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
79977391|NCT06000683|Behavioral|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
79977392|NCT06000683|Behavioral|Patient Reminders|Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
79977393|NCT06000683|Behavioral|Provider Reminers|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
79977394|NCT05998889|Behavioral|Experimental group|Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain
79977395|NCT05998889|Behavioral|Control group|Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
79977396|NCT05997186|Procedure|Surgical reconstruction|Surgical reconstruction with a free reinnervated profunda artery perforator flap
79977397|NCT05996419|Other|DSB-I|Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they identified prior to start.
79324767|NCT05885828|Other|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
79809989|NCT04495660|Device|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
79324768|NCT05885828|Other|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
79324769|NCT05885347|Other|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
79481092|NCT05872360|Dietary Supplement|Bundle Group 2 without Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium & Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day.
79809990|NCT04495660|Behavioral|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
79324770|NCT05885347|Other|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
79324771|NCT05885347|Other|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
79324772|NCT05885347|Other|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
79809991|NCT04495660|Behavioral|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
79977398|NCT05988398|Behavioral|READY To Stand Curriculum|Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
79647291|NCT00182351|Procedure|Serial Compression Ultrasound|
79977399|NCT05987189|Diagnostic Test|miLungDx|At study enrollment a blood sample will be drawn prior to any invasive diagnostic study or treatment. On this blood sample a novel lung cancer test relying on small RNA signatures will be performed and evaluated.
79977400|NCT05987072|Drug|Sisunatovir|Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
79977401|NCT05985681|Procedure|Biospecimen Collection|Undergo blood sample and vaginal swab collection
79324773|NCT05885334|Other|control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
79324774|NCT05885334|Other|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
79324775|NCT05885334|Other|Augmented reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
79324776|NCT05885334|Other|360 videos|Caregivers will receive a educational solution of 360 degrees videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
79324777|NCT05884931|Device|Nexpowder|Hemostatic powder for endoscopy after colonoscopy polypectomy
79324778|NCT05884931|Procedure|Conventional Treatment|Standard hemostatic procedure
79324779|NCT05884762|Other|electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~Calibration phase at rest.~Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~In the Neurofeedback group, the patient will receive visual feedback of a virtual hand moving on a computer screen in front of him/her, depending on his/her brain activations. He will also receive haptic feedback (vibrations) in the flexor muscles of his wrist."
79977402|NCT05985681|Biological|HPV16 RG1 VLP Vaccine|Given IM
79977403|NCT05985681|Other|Questionnaire Administration|Ancillary studies
79324780|NCT05884762|Other|SHAM electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~Calibration phase at rest.~Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~In the SHAM group, the visual feedback and haptic feedback are randomly generated"
79324781|NCT05882058|Drug|BI 764532|BI 764532
79809992|NCT04495660|Behavioral|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
79977404|NCT05985681|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given via injection
79977405|NCT05985681|Other|Saline|Given IM
79977406|NCT05980403|Other|no intervention|no intervention
79977407|NCT05979207|Drug|MMV367|Single dose
79977408|NCT05979207|Other|P. falciparum IBSM infection|Induced Blood Stage Malaria
79481093|NCT05872360|Dietary Supplement|Control Group 1|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium & Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day.
79481094|NCT05872360|Dietary Supplement|Control Group 2 with Nutrilite Lifestyle|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium & Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day. Practice according to Nutrilite Lifestyle Guideline per day.
79809993|NCT04495660|Behavioral|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
79809994|NCT04495660|Behavioral|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
79977409|NCT05976555|Biological|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|This is dose level 0 (de-escalation).
79977410|NCT05976555|Biological|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|This is dose level 1, the starting dose.
79977411|NCT05976555|Biological|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|This is dose level 2.
79977412|NCT05976555|Biological|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|This is dose level 3.
79977413|NCT05976555|Biological|Maximum tolerated dose|The maximum tolerated dose is yet to be determined.
79977414|NCT05975983|Drug|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
79977415|NCT05975983|Drug|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
79977416|NCT05972681|Drug|Bupivacaine and epinephrine|Women in the bupivacaine and epinephrine arm will get 10 milliliters (ml) of bupivacaine with epinephrine injected to the vaginal laceration site.
79977417|NCT05972681|Other|Sham normal saline arm|Women in the sham normal saline arm will get 10 milliliter (ml) of normal saline injected to the vaginal laceration site.
79977418|NCT05969236|Drug|MDI-1228_mesylate Ophthalmic Solution|"MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~0.1% (0.4 mL [0.4 mg] free base)~0.3% (0.4 mL [1.2 mg] free base)"
79977419|NCT05969236|Drug|Placebo|The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
79809995|NCT04495660|Behavioral|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
79809996|NCT04485949|Combination Product|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
79324784|NCT05878184|Drug|SC291|SC291 is an allogeneic CAR-T cell therapy
79324785|NCT05875701|Biological|NVX-CoV2373|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
79324786|NCT05875701|Biological|SARS-CoV-2 rS antigen/Matrix-M Adjuvant|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
79324787|NCT05868083|Drug|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
79481095|NCT05859529|Drug|JS002|The drug was administered by a single subcutaneous injection
79481096|NCT05859360|Other|Physical performance and cardiovascular health measures|"Retinal vessel analysis~Muscle ultrasound~Knee extension~Voluntary activation~spiroergometry"
79481097|NCT05857553|Other|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
79481098|NCT05857553|Other|No Direct Cash Transfer|No intervention
79481099|NCT05857514|Drug|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
79481100|NCT05857514|Procedure|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
79809997|NCT04485949|Combination Product|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
79809998|NCT04485949|Procedure|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
79324788|NCT05864209|Other|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
79324789|NCT05864209|Other|Cloth Diapers|Subscription to cloth diaper service.
79324790|NCT05864209|Other|Conventional Disposable Diapers|3-month supply.
79324791|NCT05864209|Other|Conventional Baby Products|Products include wipes and diaper cream.
79324792|NCT05860569|Genetic|GC304|Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
79324793|NCT05856916|Dietary Supplement|Creatine monohydrate|Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
79324794|NCT05856916|Dietary Supplement|Placebo|Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
79324795|NCT05856760|Drug|Sparsentan|Target dose of 400 mg daily
79809999|NCT04485949|Drug|SOC: Temozolomide|Temozolomide administered orally.
79810000|NCT04474717|Diagnostic Test|Breath Condensate Collection|Breath Condensate Collection
79810001|NCT04474717|Diagnostic Test|clinical examination, spirometry|spirometry
79977420|NCT05968820|Behavioral|Sleep Health Enhancement Intervention|The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
79647292|NCT00587353|Other|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
79647293|NCT00587392|Device|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
79977421|NCT05968768|Drug|Naxitamab|Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
79977422|NCT05967689|Drug|TAS6417|Oral tablets/capsules
79977423|NCT05965700|Drug|NVG-291|A once daily injection
79977424|NCT05962450|Biological|iNKT Cells|the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108~109cells/m2.
79977425|NCT05962450|Drug|PD-1|Intravenous infusion, according to the drug instructions.
79647294|NCT00587470|Drug|Candesartan|Maximum vasodilation.
79647295|NCT00587470|Drug|atacand|maximum vasodilation
79647296|NCT00587470|Drug|Placebo|Placebo
79810002|NCT04474717|Diagnostic Test|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
79810003|NCT04456140|Procedure|Biospecimen Collection|Undergo collection of blood samples
79977426|NCT05962450|Drug|Regorafenib|Oral administration, according to the drug instructions.
79977427|NCT05962372|Behavioral|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
79977428|NCT05962372|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
79977429|NCT05960747|Other|Simulation group|Specific training for medical students by using an augmented virtual reality simulator for thoracentesis
79324800|NCT05843981|Device|Implant placement TS III|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
79647297|NCT00209703|Drug|Oxaliplatin|
79647298|NCT00209703|Drug|l-Leucovorin|
79647299|NCT00209703|Drug|5-Fluorouracil|
79647300|NCT04575103|Drug|Antipsychotic|Antipsychotic treatment >0.5 DDD
79647301|NCT00182390|Procedure|Red blood cell transfusion|
79647302|NCT00587548|Other|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
79647303|NCT00587626|Device|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
79647304|NCT00587626|Device|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
79647305|NCT00216606|Drug|topiramate|
79810004|NCT04456140|Other|Genetic Counseling|Watch pre-test genetic counseling video
79810005|NCT04456140|Other|Genetic Testing|Undergo genetic testing
79810006|NCT04456140|Other|Survey Administration|Ancillary studies
79324801|NCT05843981|Device|Implant placement ks|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
79324802|NCT05842876|Device|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
79324803|NCT05842876|Diagnostic Test|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
79324804|NCT05842876|Diagnostic Test|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
79481101|NCT05851170|Other|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
79810007|NCT04449861|Drug|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
79324805|NCT05842876|Other|Satisfaction Survey|Survey to assess which method of monitoring is preferred
79810008|NCT04426812|Other|No intervention; just data collection|No intervention; just data collection
79324806|NCT05832151|Drug|CIN-102 Dose 1|2 capsules twice daily for 12 weeks
79324807|NCT05832151|Drug|CIN-102 Dose 2|2 capsules twice daily for 12 weeks
79481102|NCT05851170|Other|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
79647306|NCT00587665|Drug|ketamine|Single IV dose of 0.1 mg/kg of ketamine
79810009|NCT04425967|Radiation|pre-operative radiotherapy|pre-operative radiotherapy
79810010|NCT04405765|Device|NPWT and lyopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
79810011|NCT04405765|Device|NPWT and cryopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
79977430|NCT05960097|Biological|CV0701 Bivalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
79977431|NCT05960097|Biological|CV0701 Bivalent Medium dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
79324808|NCT05832151|Drug|Placebo|2 capsules twice daily for 12 weeks
79324809|NCT05830864|Drug|Isoflurane|no other intervention
79324810|NCT05826041|Behavioral|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
79647307|NCT00587665|Drug|Placebo|Saline given of equal volume to drug
79647308|NCT00182429|Drug|Metronidazole and Rifampin|
79977432|NCT05960097|Biological|CV0701 Bivalent Low dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
79977433|NCT05960097|Biological|CV0601 Monovalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
79977434|NCT05960097|Biological|Control vaccine|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
79977435|NCT05960097|Biological|CV0801 Monovalent|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
79977436|NCT05956158|Behavioral|Behavioral Treatment|This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.
79977437|NCT05956158|Behavioral|Sleep Education Treatment|This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
79977438|NCT05954442|Drug|Everolimus|Everolimus is a kind of mTOR inhibitors which has been approved to use in several kinds of cancers, especially in metastatic breast cancer .
79977439|NCT05954442|Drug|Investigator's Choice of Chemotherapy|Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
79647309|NCT00587704|Procedure|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
79977440|NCT05951972|Other|nutritional|participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
79977441|NCT05951959|Drug|Acalabrutinib|Investigational Product
79977442|NCT05951959|Drug|Venetoclax|Investigator Product
79977443|NCT05951959|Drug|Rituximab|Investigator Product
79324811|NCT05826041|Behavioral|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
79324812|NCT05816395|Drug|RHH646|RHH646 capsule for oral use
79324813|NCT05816395|Drug|Placebo|RHH646 placebo capsule for oral use
79977444|NCT05950139|Biological|Peptide vaccine|Peptide vaccine
79977445|NCT05949866|Behavioral|Movement and Cognition Intervention Group|"Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching)."
79481103|NCT05842577|Device|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
79977446|NCT05949866|Behavioral|Health Tracker Group (Control Group)|Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
79977447|NCT05944458|Drug|N acetyl cysteine|Fluimucil 600 mg iv to be taken twice daily as infusion
79481104|NCT05842577|Other|At-home conventional rehabilitation|The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
79977448|NCT05943522|Other|Asciminib|There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
79977449|NCT05943106|Biological|Durvalumab|Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.
79977450|NCT05943106|Biological|BCG|Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
79977451|NCT05942690|Procedure|manual osteopathic intervention|The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
79977452|NCT05939791|Other|Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518|The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.
79977453|NCT05939791|Other|Physical exercise|The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
79647310|NCT00587704|Procedure|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
79647311|NCT00587821|Other|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
79647312|NCT00216645|Drug|doxorubicin hydrochloride|
79647313|NCT00587899|Procedure|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
79481105|NCT05842122|Behavioral|Pharmacy PrEP/PEP for a fee|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~Cost to client: 250 KES per pharmacy PrEP/PEP visit~Payment to pharmacy:* 0 KES per pharmacy PrEP/PEP visit *Pharmacies paid by the research team (i.e., the implementer in this trial)"
79481106|NCT05842122|Behavioral|Pharmacy PrEP/PEP for free|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~Cost to client: 0 KES per pharmacy PrEP/PEP visit~Payment to pharmacy:* 250 KES per pharmacy PrEP/PEP visit *Pharmacies paid by the research team (i.e., the implementer in this trial)"
79481107|NCT05842122|Behavioral|HTS counselor supported pharmacy PrEP/PEP for free|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery with support from a HTS counselor (to assist with screening and HIV testing)~Cost to client: 0 KES per pharmacy PrEP/PEP visit~Payment to pharmacy:* 100 KES per pharmacy PrEP/PEP visit *Pharmacies paid by the research team (i.e., the implementer in this trial)"
79977454|NCT05938127|Device|Inspiratory muscle strength training|High-resistance inspiratory muscle strength training (IMST) is a time-efficient (~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles
79977455|NCT05938127|Device|Sham Inspiratory muscle strength training|Low-resistance inspiratory muscle strength training
79481108|NCT05842122|Behavioral|Pharmacy referral to clinic-based PrEP/PEP|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) referral to clinic-based PrEP/PEP services~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~Cost to client: 0 KES per pharmacy PrEP/PEP referral~Payment to pharmacy:* 100 KES per pharmacy PrEP/PEP referral *Pharmacies paid by the research team (i.e., the implementer in this trial)"
79977456|NCT05936099|Behavioral|E-cigarette & Tobacco Use Treatment Intervention|The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
79977457|NCT05935826|Dietary Supplement|Purity formulation by Amino Co|2 months of twice daily consumption of Purity or Placebo
79977458|NCT05935826|Dietary Supplement|Placebo|Placebo powder
79977459|NCT05934851|Procedure|Frozen-Section Directed Excision|Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
79977460|NCT05934851|Procedure|Wide Local Excision|Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
79481109|NCT05839353|Other|SBAR training by serious game|SBAR training by serious game
79647314|NCT00182468|Other|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
79324814|NCT05815979|Behavioral|virtual reality|Presentation of the virtual reality glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
79481110|NCT05838456|Device|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
79977461|NCT05934526|Drug|Placebo|Matching capsule containing placebo
79481111|NCT05835752|Drug|RAY1225|Administered SC
79481112|NCT05835752|Drug|Placebo|Administered SC
79481113|NCT05835752|Drug|RAY1225|Administered SC
79481114|NCT05835752|Drug|Placebo|Administered SC
79481115|NCT05835752|Drug|RAY1225|Administered SC
79481116|NCT05835752|Drug|Placebo|Administered SC
79481117|NCT05832892|Drug|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
79481118|NCT05832892|Drug|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
79481119|NCT05832892|Drug|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
79481120|NCT05832892|Drug|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
79481121|NCT05832398|Drug|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
79481122|NCT05832398|Drug|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
79481123|NCT05824325|Drug|SHR-A1811|HER2 ADC
79481124|NCT05824325|Drug|TROP2 ADC|TROP2 ADC
79481125|NCT05823987|Drug|H101|a modified human recombinant type 5 adenovirus with genetic modifications
79481126|NCT05823987|Drug|Tislelizumab|a PD-1 immune check inhibitor
79481127|NCT05823987|Drug|Lenvatinib|Lenvatinib capsules
79481128|NCT05823467|Drug|TMP-SMX DS|Oral Antibiotic - used to treat post operative wound infections.
79481129|NCT05823467|Device|ciNPT dressing|Negative pressure wound VAC placed on incision post operatively.
79481130|NCT05823337|Dietary Supplement|selenium+ diet|Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.
79481131|NCT05823337|Dietary Supplement|only diet|diet suitable for pregnancy
79481132|NCT05821595|Drug|JYB1907|for injection
79481133|NCT05819957|Other|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
79481134|NCT05818696|Behavioral|Lethal Means Counseling (LMC)|The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
79647315|NCT00588016|Drug|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
79647316|NCT00216684|Drug|fentanyl|
79647317|NCT00588133|Drug|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = >6.6: reduce infusion to 1.5 mg/kg/hr"
79977462|NCT05934526|Drug|Seralutinib|Capsule containing seralutinib
79977463|NCT05934526|Device|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
79977464|NCT05932940|Procedure|Gonioscopy-Assisted Transluminal Trabeculotomy|Ab interno angle surgery one of MIGS to lower IOP
79977465|NCT05932810|Behavioral|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
79481135|NCT05818696|Behavioral|CBT for Uncertainty - Enhanced (CUE)|CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
79481136|NCT05815693|Behavioral|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
79647318|NCT00588133|Drug|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
79647319|NCT00588172|Drug|Metformin|1000mg bid for 1 week
79481137|NCT05798039|Behavioral|ENRICH|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
79324815|NCT05813587|Biological|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
79324816|NCT05813587|Other|Normal saline|Normal saline
79324817|NCT05810363|Drug|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min ~0.3 μg/kg/min for maintenance.
79324818|NCT05810363|Drug|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min ~0.3 μg/kg/min for maintenance.
79324819|NCT05810285|Device|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
79324820|NCT05809596|Device|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
79324821|NCT05807204|Dietary Supplement|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
79647320|NCT00182507|Drug|Olanzapine|
79977466|NCT05932810|Behavioral|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
79324822|NCT05807204|Dietary Supplement|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
79324823|NCT05804903|Device|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
79481138|NCT05796791|Drug|Ketamine Hydrochloride|IM ketamine given in weekly session for a total of 3 weeks
79481139|NCT05796791|Behavioral|Motivational enhancement therapy|Brief motivational based therapy
79481140|NCT05794152|Other|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
79481141|NCT05794152|Other|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
79481142|NCT05794152|Other|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
79977467|NCT05932199|Drug|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
79977468|NCT05932199|Drug|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
79977469|NCT05931835|Device|VERAFEYE System|The VERAFEYE System will be used during standard of care, catheter-based treatments for atrial flutter or atrial fibrillation; or left atrial appendage/atrial septal defect closure procedures.
79977470|NCT05930782|Drug|Piperaquine Phosphate|PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
79977471|NCT05930782|Drug|Piperaquine Phosphate|PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
79977472|NCT05929742|Behavioral|virtual reality training|The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.
79324824|NCT05804396|Device|Relivion®|Active stimulation device
79324825|NCT05800366|Drug|Glofitamab|human IgG1-bispecific antibody, via IV infusion
79481143|NCT05792566|Other|Atomic app|Using the Atomic app to improve physical activity
79481144|NCT05789745|Drug|Recombinant human plasma gelsolin|intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
79481145|NCT05789745|Other|placebo|intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
79481146|NCT05788406|Other|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
79481147|NCT05787899|Other|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
79481148|NCT05783960|Other|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
79307082|NCT05411939|Other|Shared Decision-Making Tool|The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
79481149|NCT05783726|Other|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
79977473|NCT05929742|Behavioral|early rehabilitation|Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
79324826|NCT05800366|Drug|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
79324827|NCT05800366|Drug|Rituximab|Per standard care, via IV infusion
79324828|NCT05800366|Drug|Doxorubicin Hydrochloride|Per standard care, via IV infusion
79324829|NCT05800366|Drug|Cyclophosphamide|Per standard care, via IV infusion
79324830|NCT05800366|Drug|Prednisone|Per standard care, orally
79481150|NCT05783726|Behavioral|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
79481151|NCT05783726|Behavioral|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
79481152|NCT05783726|Behavioral|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
79810012|NCT04405050|Device|Restrata|Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
79481153|NCT05780177|Behavioral|Brief Behavioral Treatment for Insomnia (BBTI)|Participants in this arm will receive 4 sessions (20-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.
79481154|NCT05780177|Behavioral|Progressive Muscle Relaxation Training (PMRT)|Participants in this arm will receive 4 sessions (20-60 minutes) of progressive muscle relaxation training called PMRT.
79977474|NCT05928351|Other|Pain Neuroscience Education|"The experimental group will follow a PNE protocol based on previous procedure for 6 weeks in addition to the standard physiotherapy program (SPP) in postoperative period.~Each PNE session will take 45-60 min. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience."
79307083|NCT05411939|Other|Video|Short video that describes knee osteoarthritis and possible treatment options.
79307084|NCT05411939|Other|Standard of Care|Standard of care counseling for a patient presenting with knee osteoarthritis.
79307085|NCT05410977|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
79307086|NCT05410977|Other|Electronic Health Record Review|Medical records reviewed
79307087|NCT05405296|Device|Truenat™ MTB Plus/COVID-19|Truenat™ MTB Plus/COVID-19is a disposable, room temperature stable, chip-based Real Time duplex PCR test, along with freeze dried PCR reagents provided in microtube for performing Real Time PCR for infectious disease and runs on the Truelab® Real Time micro-PCR Analyzer.
79307088|NCT05399641|Drug|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
79307089|NCT05390983|Procedure|Carotid endarterectomy with stent removal|Standard carotid endarterectomy will be extended with the stent removal
79307090|NCT05388929|Drug|Methocarbamol|Methocarbamol after surgery
79307091|NCT05388929|Drug|Standard Opioid|Standard opioid after surgery or at discharge
79307092|NCT05388929|Drug|Standard opioid plus methocarbamol|Standard opioid plus methocarbamol after surgery or at discharge
79307093|NCT05378529|Other|Lp(a) Screening|Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
79307094|NCT05371080|Biological|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
79307095|NCT05369403|Drug|Lebrikizumab|Administered SC
79307096|NCT05365841|Drug|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
79307097|NCT05363670|Drug|ARS-1|ARS-1
79307098|NCT05363670|Drug|Albuterol MDI|180 mcg
79307099|NCT05363670|Drug|Placebo|Placebo
79307100|NCT05361837|Procedure|Single level serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third rib
79307101|NCT05361837|Procedure|Single level serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
79307102|NCT05361837|Procedure|Bilevel serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third and fifth rib
79977475|NCT05928351|Other|Standard Physiotherapy Program (SPP)|The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.
79324831|NCT05800145|Behavioral|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
79324832|NCT05800145|Behavioral|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
79324833|NCT05800145|Behavioral|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
79324834|NCT05798117|Drug|YTB323|Single infusion of YTB323
79324835|NCT05797285|Device|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
79324836|NCT05793723|Diagnostic Test|Pulmonary function testing device|Patients will undergo pulmonary function tests with the Exhalyzer D (Ecomedics, Switzerland) device. This device consists of 1) an ultrasonic flow measuring system for measuring flow, volume and molecular mass, 2) a nitrogen washout system to measure functional residual capacity (FRC) and other indices, 3) a carbon dioxide infrared measurement device for monitoring the level of carbon dioxide in exhaled breath.
79324838|NCT05785741|Drug|DB-1310|Administered I.V.
79977476|NCT05924516|Behavioral|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
79647321|NCT04574752|Diagnostic Test|next generation sequencing|diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques on S. aureus detection in orthopaedic patients
79324843|NCT05777291|Device|Activity watch monitoring|Patients will be using activity devices during the study period
79324844|NCT05777291|Device|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
79324845|NCT05777291|Behavioral|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
79324846|NCT05775354|Diagnostic Test|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
79810013|NCT04405050|Device|Negative Pressure Wound Therapy (NPWT)|Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
79810014|NCT04392375|Drug|Nifedipine 30 MG|Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
79810015|NCT04392375|Drug|Placebos|At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
79324847|NCT05771688|Device|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
79324848|NCT05770882|Drug|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
79810016|NCT04375748|Diagnostic Test|Performing routine care (clinical and paraclinical tests)|ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
79324849|NCT05770882|Drug|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
79810017|NCT04375748|Diagnostic Test|Examinations for the research:|"Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)"
79324853|NCT05764161|Drug|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
79324854|NCT05764161|Drug|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
79324855|NCT05762471|Drug|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
79324856|NCT05762471|Drug|Placebo|Patients will receive GSBR-1290 or matching Placebo
79647322|NCT00209742|Drug|UFT|P.O. everyday
79647323|NCT00209742|Drug|USEL/Leucovorin|P.O. everyday
79647324|NCT00209742|Drug|Krestin|P.O. everyday
79647325|NCT00182546|Procedure|Two diagnostic management strategies|
79324857|NCT05760573|Behavioral|Family Wellness Program (FWP)|The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
79647326|NCT03452605|Dietary Supplement|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
79307103|NCT05361837|Procedure|Bilevel serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
79307104|NCT05343936|Other|Active surveillance|"The active surveillance protocol involves a TRUS prostate biopsy at eligibility, at 12 months and then every two years. MRI with or without biopsy at eligibility and then every two years. Clinical evaluation with digital rectal examination and PSA every 6 months. Every year a quality of life and anxiety evaluation are planned.~A new prostate biopsy is indicated if biochemical progression by PSA or changes in multiparametric MRI. Triggers for definitive intervention are biopsy pathological reclassification with Gleason score greater than 6, clinical progression or patient's request."
79307105|NCT05326750|Device|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
79307106|NCT05323253|Device|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
79307107|NCT05323123|Behavioral|PrEP Romania|Enrolled participants will receive PrEP education and adherence counseling from trained counselors, and have a medical evaluation from a physician, who will prescribe PrEP.
79307108|NCT05313009|Drug|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
79307109|NCT05313009|Drug|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
79307110|NCT05308004|Other|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
79307111|NCT05293626|Drug|NR082 Injection|"The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in > 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in > 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC."
79307112|NCT05293626|Device|Injection needle|"19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration."
79307113|NCT05293158|Drug|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
79307114|NCT05286814|Drug|Floxuridine|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL [pump volume] / Pump Flow Rate)
79647327|NCT00216723|Drug|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"
79810018|NCT04362540|Diagnostic Test|MRI scan|On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
79810019|NCT04318002|Biological|RH5.1/Matrix-M|3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
79810020|NCT04314570|Procedure|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
79810021|NCT04314570|Procedure|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
79810022|NCT04278573|Drug|Vitamin D3|Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
79810023|NCT04278573|Drug|Placebo|0.3 ml injection of sterilized propylene glycol: dehydrated alcohol (9:1 ratio) with no active study ingredient
79324858|NCT05760274|Diagnostic Test|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
79647328|NCT03452566|Drug|Ingenol mebutate gel|3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
79810024|NCT04267003|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
79810025|NCT04233580|Device|Amnio Excel + weekly|Amnio Excel + weekly
79810026|NCT04233580|Device|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
79324861|NCT05755438|Drug|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
79324862|NCT05755438|Drug|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
79810027|NCT04201197|Drug|Inje cocktail|Acute drug exposure
79324863|NCT05750758|Drug|rivaroxaban|rivaroxaban 2.5mg bid for 1m
79324864|NCT05739981|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV
79324865|NCT05739981|Drug|Carboplatin|Carboplatin AUC 5-6 IV
79324866|NCT05739981|Drug|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: [1] Cycle 1, [2] the last cycle of neoadjuvant therapy immediately preceding ICS, and [3] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
79324867|NCT05739981|Drug|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
79647329|NCT03452488|Drug|BIO101|"Oral capsules containing the BIO101 active principle is 20-hydroxyecdysone (20E) at 97%.~Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
79647330|NCT03452488|Drug|Placebo oral capsule|Oral capsules containing Microcrystalline cellulose, Colloidal anhydrous silica
79647331|NCT00182585|Procedure|computer-based HIV, STD & Hepatitis Education|
79647332|NCT00182585|Procedure|educator-delivered HIV, STD and Hepatitis education|
79647333|NCT03452449|Procedure|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
79810028|NCT04201197|Drug|THC Cannabis extract|Acute drug exposure
79810029|NCT04201197|Drug|THC/CBD Cannabis Extract|Acute drug exposure
79810030|NCT04193670|Other|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
79324868|NCT05739708|Other|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
79324869|NCT05738655|Dietary Supplement|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
79324870|NCT05738655|Dietary Supplement|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
79324871|NCT05738655|Dietary Supplement|Placebo|Placeo (300 mg/day)
79647334|NCT00209781|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
79324872|NCT05737524|Other|Telerehabilitation (VAST 2)|The telehealth platform will be available by a web secure link accessible on a home computer or loaded on user friendly tablets that are customized for the patient's impairments. Telerehabilitation services will include 2 out of 3 disciplines: Occupational Therapy, Speech Therapy, Physical Therapy. All therapy interventions will be delivered by licensed therapists and will be based on patients' specific impairments and goals. Therapy intervention will be provided 3x/wk. for each of 2 disciplines. The intervention will be going on for 4 weeks which will total to 24 sessions. Self-management support with trained health coach will be integrated into 1 therapy session each week. An additional individual 30 minute session will occur with the health coach each week.
79324873|NCT05733702|Other|All participants will be asked to provide data and samples for collection and analysis.|During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
79324874|NCT05732870|Procedure|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
79324875|NCT05731128|Drug|Dupilumab|injection solution subcutaneous
79324876|NCT05731128|Drug|Placebo|injection solution subcutaneous
79324877|NCT05728918|Dietary Supplement|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
79324878|NCT05728918|Dietary Supplement|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
79647335|NCT00209781|Device|ITNs|
79647336|NCT00588328|Device|PET/CT scan|PET/CT scans
79647337|NCT00588367|Device|Mayo Interactive Breath Hold Monitor|Biofeedback device
79647338|NCT00209820|Behavioral|Supervised Nordic Walking|
79647339|NCT00209820|Behavioral|Unsupervised Nordic Walking|
79647340|NCT00209820|Behavioral|Advice to stay active|
79647341|NCT00182663|Drug|clarithromycin|Given PO
79647342|NCT00182663|Drug|thalidomide|Given PO
79647343|NCT00182663|Drug|dexamethasone|Given PO
79647344|NCT00588679|Other|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
79647345|NCT00216762|Drug|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
79977477|NCT05920772|Behavioral|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
79977478|NCT05920148|Procedure|Knee arthroplasty|At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
79977479|NCT05920135|Drug|BBT-207|BBT-207 given orally alone
79977480|NCT05918549|Device|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
79977481|NCT05911841|Drug|LY3454738|Administered SC
79647346|NCT00588757|Device|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
79647347|NCT00588757|Device|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
79647348|NCT00182702|Drug|ixabepilone|Given IV
79647349|NCT00182702|Other|laboratory biomarker analysis|Correlative studies
79647350|NCT00588835|Drug|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
79647351|NCT00588835|Drug|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
79647352|NCT00209859|Drug|Methotrexate|
79647353|NCT00209859|Drug|Intraarticular betamethasone|
79977482|NCT05911841|Drug|Placebo|Administered SC
79977483|NCT05910346|Behavioral|education and counseling based on maternal role theory|Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
79307115|NCT05286814|Drug|5-Fluorouracil|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
79307116|NCT05286814|Drug|Irinotecan|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
79647354|NCT00209859|Drug|Cyclosporine/placebo-cyclosporine|
79647355|NCT00588913|Biological|aldesleukin|
79324879|NCT05728814|Drug|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
79324880|NCT05727904|Biological|Lifileucel plus Pembrolizumab|A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
79977484|NCT05907967|Device|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
79977485|NCT05907564|Device|Thrombectomy|Use of Aventus Thrombectomy System to treat pulmonary embolism
79977486|NCT05905367|Drug|Fentanyl|Symptom-inhibited IV fentanyl induction
79977487|NCT05905367|Drug|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
79977488|NCT05905367|Drug|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
79977489|NCT05905172|Drug|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
79977490|NCT05905172|Drug|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
79324881|NCT05727904|Biological|Pembrolizumab with Optional Crossover Period|"Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2."
79324882|NCT05725213|Drug|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
79647356|NCT00588913|Biological|therapeutic autologous lymphocytes|
79647357|NCT00588913|Drug|zoledronic acid|
79647358|NCT00182741|Dietary Supplement|calcitriol|
79647359|NCT00182741|Drug|mitoxantrone hydrochloride|
79647360|NCT00182741|Drug|prednisone|
79977491|NCT05903066|Procedure|Magnetic Resonance Enterography (MRE)|MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
79977492|NCT05902949|Procedure|Streching Group|The Streching group will perform a conventional stretching exercise.
79977493|NCT05902949|Procedure|Heel group|The heel pad group will be applied a plantar support during the months of the study.
79977494|NCT05902364|Other|Polyethylene glycol 400 and propylene glycol solution/drops|commercially available eye drops
79977495|NCT05901155|Device|MedAL-mentor|MedAL-mentor is a near real-time monitoring and benchmarking dashboard based on data collected through ePOCT+, providing direct feedback on several clinical indicators (antibiotic prescription, performance of key measurements, signs, and diagnostic tests).
79977496|NCT05898646|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79977497|NCT05898646|Biological|Daratumumab|Given SC
79977498|NCT05898646|Procedure|Echocardiography|Undergo echocardiography
79977499|NCT05898646|Other|Questionnaire Administration|Ancillary studies
79977500|NCT05898646|Procedure|X-Ray Imaging|Undergo x-ray imaging
79977501|NCT05898646|Procedure|Biospecimen Collection|Undergo blood sample collection
79977502|NCT05898126|Procedure|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
79977503|NCT05898126|Procedure|Usual care|Standard of care
79647361|NCT00589030|Radiation|brachytherapy|The target dose of TheraSphere® is 80-150Gy
79647362|NCT00589030|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
79647363|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
79647364|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
79977504|NCT05896397|Procedure|Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
79324883|NCT05724108|Procedure|Biospecimen Collection|Undergo collection of blood samples
79647365|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
79977505|NCT05895968|Procedure|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
79977506|NCT05895578|Dietary Supplement|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
79977507|NCT05895578|Dietary Supplement|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
79977508|NCT05895578|Dietary Supplement|Placebo|1 capsule of placebo every 12 hours for 6-months.
79977509|NCT05893498|Device|FFRangio|A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
79977510|NCT05893498|Device|FFR or NHPR|Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
79977511|NCT05892302|Behavioral|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
79647366|NCT00589186|Biological|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
79324884|NCT05724108|Procedure|Computed Tomography|Undergo CT
79324885|NCT05724108|Drug|Lutetium Lu 177 Dotatate|Given IV
79324886|NCT05724108|Procedure|Magnetic Resonance Imaging|Undergo MRI
79324887|NCT05724108|Drug|Triapine|Given PO
79324888|NCT05723835|Drug|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
79324889|NCT05719441|Biological|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
79647367|NCT00589186|Drug|celecoxib|
79647368|NCT00589186|Other|flow cytometry|
79647369|NCT00589186|Other|immunoenzyme technique|
79647370|NCT00589186|Other|laboratory biomarker analysis|
79647371|NCT00182780|Dietary Supplement|American ginseng|
79647372|NCT00182780|Other|Placebo|
79647373|NCT00589225|Genetic|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
79647374|NCT00589264|Dietary Supplement|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
79324890|NCT05719441|Biological|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
79324891|NCT05719441|Other|Placebo|Sodium Chloride for Injection USP, 0.9%
79481155|NCT05779605|Device|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
79324892|NCT05719441|Drug|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
79324893|NCT05718570|Drug|Somapacitan|Sogroya therapy in participants with AGHD.
79977512|NCT05892302|Behavioral|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
79977513|NCT05892250|Behavioral|Conventional physical therapy|Manual techniques and therapeutic exercise
79324897|NCT05713266|Device|MouthLabTM|Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
79324898|NCT05712356|Drug|LSTA1|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
79647375|NCT00589264|Dietary Supplement|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
79647376|NCT00589381|Drug|fenretinide lipid matrix|
79324899|NCT05712356|Drug|Paclitaxel|paclitaxel 175 mg/m^2 IV administered over 3 hours every 21 days
79647377|NCT00209898|Procedure|Fast initiation procedure|
79647378|NCT00182819|Drug|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
79324900|NCT05712356|Drug|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
79324901|NCT05712356|Drug|Cisplatin|cisplatin 25 mg/m^2 IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
79647379|NCT00182819|Radiation|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
79324902|NCT05712356|Drug|Gemcitabine|gemcitabine 1000 mg/m^2 IV administered over 30 minutes on day 1 and day 8 every 21 days up to 8 cycles
79324903|NCT05712356|Drug|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
79647380|NCT00589498|Dietary Supplement|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
79647381|NCT00589537|Other|questionnaire administration|
79647382|NCT00589537|Procedure|computed tomography|
79647383|NCT00589537|Procedure|magnetic resonance imaging|
79647384|NCT00589537|Procedure|quality-of-life assessment|
79324904|NCT05712278|Drug|SAR445419|Cell suspension, by intraveneous (IV) injection
79324905|NCT05712278|Drug|fludarabine|Solution for injection , by IV injection
79324906|NCT05712278|Drug|cytarabine|Solution for injection, by IV injection
79324907|NCT05709067|Dietary Supplement|Probiotic|6 Billion CFU per day
79324908|NCT05709067|Dietary Supplement|Placebo|0 CFU per day
79324909|NCT05707806|Device|MRI|Enables the use of custom pulse sequence
79324910|NCT05705349|Drug|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
79324911|NCT05705349|Drug|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
79324912|NCT05705349|Drug|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
79324913|NCT05705349|Drug|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
79647385|NCT00216840|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
79324914|NCT05704244|Drug|FE 999326|75 mL FE 999326 (3 x 10^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
79324915|NCT05701735|Behavioral|CECIL Patient Decision Aid|"The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration."
79481156|NCT05779605|Device|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
79481157|NCT05771090|Device|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
79481158|NCT05759364|Drug|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
79481159|NCT05759364|Drug|Placebo|Placebo
79481160|NCT05754931|Other|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
79481161|NCT05754931|Other|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
79481162|NCT05754632|Device|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
79307117|NCT05286814|Device|Intera 3000 Hepatic Artery Infusion Pump (HAIP)|Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
79481163|NCT05749926|Biological|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
79481164|NCT05749926|Biological|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
79481165|NCT05749146|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
79481166|NCT05740540|Device|IRS-8|Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
79977514|NCT05892250|Behavioral|Conventional physical therapy + Dynamic Humeral Centering exercises|Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
79977515|NCT05888103|Drug|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) in 1.5 mL
79977516|NCT05888103|Drug|Matching Placebo for Inclisiran|Matching s.c. placebo in 1.5 mL
79307118|NCT05286814|Drug|Oxaliplatin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. Arm 2: GemOx (gemcitabine [800 mg/m2 IV over 30 minutes] and oxaliplatin [85 mg/ m2 IV over 120 minutes])
79810031|NCT04193670|Procedure|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
79810032|NCT04193670|Other|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
79810033|NCT04174443|Procedure|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
79810034|NCT04174443|Procedure|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
79810035|NCT04156191|Drug|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
79810036|NCT04156191|Drug|ARQ-151 cream 0.05%|ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
79647386|NCT00589615|Behavioral|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
79647387|NCT00589732|Drug|Valsartan|Valsartan 160mg per day
79810037|NCT04128306|Behavioral|Behavioral task|In the task, participants will see an object approaching toward them. During its movement, the object disappears, and the participants have to press a button to indicate when they estimate the object to contact with them. The motion parameters of the ball will be varied. The pre and post-surgery phases will test the participants in a long duration version of the task, approximately 30 minutes. The per surgery phase will be made of a 5 minutes version of the task, and the participants will receive a direct cortical stimulation for 4 seconds, at an intensity of 1 to 10 milliampere (mA), in the premotor ventral area, or posterior parietal cortex or somesthetic associative areas.
79977517|NCT05887713|Device|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
79324923|NCT05688852|Drug|VTX958|Dose A VTX958
79324924|NCT05688852|Drug|VTX958|Dose B VTX958
79324925|NCT05688852|Drug|VTX958 Placebo|Placebo
79324926|NCT05688371|Drug|standard dose morphine|Receiving 0.05 mg morphine/kg as a bolus.
79324927|NCT05688371|Drug|low dose morphine plus dexmedetomidine|Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine
79324928|NCT05685303|Device|Alleviant ALV1 System|Creation of interatrial shunt
79324929|NCT05685303|Other|Sham-Control|Cardiac imaging
79977518|NCT05887713|Device|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
79977519|NCT05884437|Procedure|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
79977520|NCT05883449|Drug|AFM13|anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
79977521|NCT05883449|Drug|AB-101|NK cell therapy, intravenous infusion
79977522|NCT05883449|Drug|Cyclophosphamide|Lymphodepleting chemotherapy, intravenous infusion
79977523|NCT05883449|Drug|Fludarabine|Lymphodepleting chemotherapy, intravenous infusion
79977524|NCT05883449|Drug|Interleukin-2|Immune cytokine, subcutaneously
79977525|NCT05882981|Other|Sit and reach test|It will be used to measure the flexibility of the participants.
79977526|NCT05882981|Other|Hand grip strength measurement|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
79977527|NCT05882981|Other|Back-leg-chest muscle strength measurement|An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
79977528|NCT05882981|Other|Functional performance|Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
79977529|NCT05882981|Other|Functional capacity|Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
79977530|NCT05879718|Drug|Placebo|Placebo (intravenous infusion)
79977531|NCT05879718|Drug|PF-06823859|PF-06823859 (intravenous infusion)
79977532|NCT05878041|Diagnostic Test|Molecular and genetic screening|Molecular and genetic screening
79977533|NCT05875727|Biological|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
79977534|NCT05874297|Other|Best Practice|Receive standard of care
79977535|NCT05874297|Behavioral|Internet-Based Intervention|Access to enhanced Cook for your life website
79977536|NCT05874297|Other|Questionnaire Administration|Ancillary studies
79977537|NCT05873413|Behavioral|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
79977538|NCT05873413|Behavioral|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
79977539|NCT05873413|Behavioral|Attention-only Control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
79977540|NCT05872685|Drug|S1|S-1 orally intake as perioperative chemotherapy
79481167|NCT05740540|Device|IST 12 & IST 16|Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).
79481168|NCT05737732|Device|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, <50lux at eye light level between 6:00PM and bedtime.
79481169|NCT05737732|Device|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, <50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
79810038|NCT04128306|Procedure|Awake surgery|"The patient is first anesthetized for opening the scalp and skull, then awake. During this waking phase, the surgeon passes a few quick and simple tests to the patient, visual (for example, line bisection), language (for example, repeating a list of words) etc. While doing this task, the neurosurgeon disrupts the functioning of certain brain regions by direct electrical stimulation of the cortex in order to identify the regions whose dysfunction will have an impact on the current task.~During the operation, the areas involved in the construction of the peri-personal space will be stimulated by direct electrical stimulation, for a duration of 4 seconds at an intensity of 1 to 10 mA. These areas are:~Ventral premotor cortex (with the exception of the primary motor cortex controlling the dominant hand, so as not to interfere with the motor response of the patient)~Posterior parietal cortex~Associative somesthetic areas"
79324930|NCT05685238|Drug|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
79481170|NCT05737238|Behavioral|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
79481171|NCT05730205|Drug|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
79481172|NCT05720364|Drug|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
79324931|NCT05684588|Diagnostic Test|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
79481173|NCT05720364|Drug|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
79481174|NCT05720364|Drug|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
79647388|NCT00182897|Behavioral|Skills Building for Caregiver Health and Care-recipient|
79324932|NCT05679479|Biological|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
79324933|NCT05679479|Other|Normal saline|0.9% normal saline
79647389|NCT00589771|Drug|Saccharomyces boulardii|"Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~Ispaghula husk 1 Tsf daily after dinner for six weeks"
79647390|NCT00589771|Drug|Placebo|"Cap Placebo TDS for six weeks~Ispaghula husk 1 Tsf daily after dinner for six weeks"
79810039|NCT04128306|Other|Neurological assessment|The Mini Mental State Evaluation, which generally assesses the cognitive state of an individual through his 6 subtests testing both working memory, episodic and semantic praxies as well as spatio-temporal orientation capacity.
79324934|NCT05678257|Drug|Fosifloxuridine Nafalbenamide|Intravenous infusion
79324935|NCT05678257|Drug|Leucovorin|Intravenous infusion
79324936|NCT05678257|Drug|Irinotecan|Intravenous infusion
79481175|NCT05710861|Device|F-HIFU|A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
79481176|NCT05710861|Procedure|Radical Prostatectomy|A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
79481177|NCT05709899|Other|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
79647391|NCT00216879|Drug|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
79647392|NCT00589927|Drug|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
79647393|NCT00589927|Drug|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
79647394|NCT00182936|Behavioral|Delirium Abatement Program|
79647395|NCT00589966|Behavioral|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
79647396|NCT00589966|Behavioral|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
79324937|NCT05678257|Biological|Bevacizumab|Intravenous infusion
79324938|NCT05678257|Drug|5-FU|Intravenous infusion
79647397|NCT00590083|Biological|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
79647398|NCT00209937|Drug|Gaboxadol|
79647399|NCT00182975|Drug|DHEA replacement|
79647400|NCT00590278|Drug|Tomudex|
79324939|NCT05677971|Drug|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
79324940|NCT05677971|Other|Placebo|Participants will receive placebo (sterile normal saline [0.9% NaCl]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
79324941|NCT05676970|Behavioral|Telehealth: Wellness and Vaccination|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
79647401|NCT00590278|Procedure|Radiotherapy|
79647402|NCT00590278|Procedure|Haematology|
79647403|NCT00590278|Procedure|Biochemistry|
79647404|NCT00216918|Drug|Atomoxetine Hydrochloride|
79647405|NCT00590356|Device|StarClose®|Closure device for femoral artery suture site occlusion
79647406|NCT00590356|Device|AngioSeal®|Closure device for femoral artery suture site occlusion
79647407|NCT04574791|Drug|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
79647408|NCT00183014|Behavioral|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
79647409|NCT00183014|Behavioral|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
79647410|NCT04574674|Behavioral|Flexibility exercise programme|Static passive flexibility exercises.
79324942|NCT05676970|Behavioral|TeleHealth: Wellness Only|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
79647411|NCT04574674|Behavioral|Resistance exercise programme|Body weight and resistance bands exercises.
79647412|NCT00210015|Drug|INS37217 Nasal Spray|
79647413|NCT04574557|Diagnostic Test|micro RNA|"miRNA was isolated from serum using a miRNeasy Mini Kit (Qiagen, Cat; 217004)cDNA was isolated from obtained miRNA samples using a miScript Reverse Transcription Kit (Qiagen, Cat; 218060) Quantitative Real-Time PCR (qPCR) will be done using (miScript SYBR Green PCR Kit Qiagen Cat. No: 218073)The qPCR assays were performed in duplicate The relative expressions of Three miRNAs were selected for RT-PCR validation Two were selected from over-expressed miRNAs (miR-34a, miR-146b), one from under-expressed miRNAs (miR-122) were analyzed using the standard 2-ΔΔCT method. These miRNAs were selected due to their pathophysiological relation with NASH.~Predicted gene targets of all differentially expressed miRNAs will be identified. Genes with functions that are potentially relevant to the pathogenesis of NASH and gene targets that are commonly studied e.g. lipogenesis (e.g. FAS), inflammation (c-JUN kinase) will be included in the study"
79647414|NCT00590473|Device|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
79647415|NCT00590512|Dietary Supplement|High sodium|
79647416|NCT00590512|Dietary Supplement|Low sodium|
79324963|NCT05673187|Drug|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
79647417|NCT00216957|Procedure|Coronary bypass surgery without cardiopulmonary bypass|
79647418|NCT00183053|Device|BedEx Patient Occupancy Monitoring System|
79647419|NCT00590551|Other|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
79647420|NCT00183131|Behavioral|Brief Personalized Feedback|
79647421|NCT00590629|Drug|Niaspan|1500 mg Niaspan for 16 weeks
79647422|NCT00590668|Diagnostic Test|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
79647423|NCT00590785|Drug|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
79647424|NCT00590785|Drug|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
79647425|NCT00590785|Drug|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
79647426|NCT00590785|Drug|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
79647427|NCT00590785|Drug|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
79647428|NCT00210054|Drug|denufosol tetrasodium (INS37217)|
79977541|NCT05872685|Drug|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
79977542|NCT05872685|Drug|Serplulimab|Perioperative serplulimab, 300 mg IV infusion
79977543|NCT05872685|Drug|Placebo|Perioperative placebo, 300 mg IV infusion
79324964|NCT05670106|Drug|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
79324965|NCT05670106|Other|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
79324966|NCT05670106|Drug|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
79481178|NCT05708092|Behavioral|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
79481179|NCT05706233|Procedure|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
79481180|NCT05706233|Procedure|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS > 3, 20 mg if NRS > 5, 30 mg if NRS > 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
79481181|NCT05705050|Drug|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
79324970|NCT05668260|Device|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
79810040|NCT04128306|Other|Neurological assessment|The Wechsler Adult Intelligence Scale was selected for two of its subtests: The Subtest Codes checking the processing of information, visuo-constructive abilities but also attention. The subtest Cubes evaluates the capacities of visuospatial and constructive organizations as well as the referencing of the space in relation to the subject.
79810041|NCT04128306|Other|Neurological assessment|The State-Trait Anxiety Inventory, consisting of two self-administered questionnaires: Questionnaire A, measuring the state of anxiety of the person on the present moment and B measuring anxiety as a character trait of the person
79324973|NCT05664074|Drug|Rectal indomethacin|"Dosage based on subject's weight:~>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
79324974|NCT05664074|Drug|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
79481182|NCT05705050|Other|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
79481183|NCT05699772|Behavioral|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
79481184|NCT05699772|Behavioral|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott & White Institute for Rehabilitation.
79481185|NCT05693753|Device|Use of XCM for the treatment of MAGRs with mCAF technique|After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
79481186|NCT05693753|Procedure|Treatment of MAGRs with CTG|After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
79810042|NCT04128306|Other|Neurological assessment|The Verbal Fluences test, in its oral version. Categorial and lexical fluences make it possible to quickly realize a possible lack of the word of the person as well as disturbances of working memory or the capacity of inhibition.
79977544|NCT05869461|Behavioral|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
79481187|NCT05693454|Drug|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
79481188|NCT05693454|Drug|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
79810043|NCT04128306|Other|Neurological assessment|The board of the Corsi cubes that evaluates the non-verbal visual-spatial working memory of the participants with a reminder location that tests the visuo-spatial notebook and a reminder to who tests the central administrator of the working memory.
79810044|NCT04128306|Other|Neurological assessment|The neurocognitive naming test was chosen to verify correct access to both semantic memory and lexicon, as well as to test the early visual process of image processing necessary for our task.
79324976|NCT05659927|Drug|MG-ZG122 Humanized Monoclonal Antibody Injection|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
79324977|NCT05659927|Drug|Placebo|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
79324978|NCT05659784|Other|Telerehabilitation|Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
79324979|NCT05657639|Drug|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
79324980|NCT05657639|Drug|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
79647429|NCT00183209|Behavioral|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
79324982|NCT05652569|Other|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
79810045|NCT04128306|Other|Neurological assessment|Benton lines are commonly used to determine possible deficits in the localization of isolated objects or judgment of line direction.
79810046|NCT04128306|Other|Neurological assessment|The patient will finally pass a depression assessment test, answering Beck's questionnaire.
79481189|NCT05693454|Drug|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
79481190|NCT05691270|Behavioral|IN-Control (Birth Control Navigator Program)|Pilot Study of IN-Control Program within the state of Indiana
79481191|NCT05684952|Drug|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
79481192|NCT05672108|Procedure|Computed Tomography|Undergo CT
79481193|NCT05672108|Drug|Ethiodized Oil|Given IA
79481194|NCT05672108|Drug|Mitomycin|Given IA
79481195|NCT05672108|Procedure|Transarterial Chemoembolization|Undergo TACE
79481196|NCT05672108|Device|Tris-acryl Gelatin Microspheres|Given IA
79810047|NCT04107740|Drug|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
79481197|NCT05668429|Drug|Ibrexafungerp|carbon-14 ([14^C])-Ibrexafungerp
79647430|NCT00217035|Dietary Supplement|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
79647431|NCT00210093|Drug|denufosol tetrasodium (INS37217)|
79810048|NCT04107740|Drug|Placebo|BID, 10mg per day, for 24 weeks
79810049|NCT04085315|Drug|Osimertinib|Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
79810050|NCT04085315|Drug|Alisertib|Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
79810051|NCT04067960|Procedure|Biospecimen Collection|Undergo collection of saliva
79810052|NCT04067960|Other|Genetic Testing|Undergo pharmacogenomics testing
79810053|NCT04067960|Other|Quality-of-Life Assessment|Ancillary studies
79810054|NCT04067960|Other|Questionnaire Administration|Ancillary studies
79810055|NCT04038190|Behavioral|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
79810056|NCT04028050|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.
79647432|NCT00183326|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
79647433|NCT00183326|Behavioral|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
79647434|NCT00477295|Drug|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
79810057|NCT04028050|Drug|Carboplatin|Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.
79810058|NCT04028050|Drug|Etoposide|Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
79647435|NCT00477295|Drug|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
79647436|NCT00217074|Other|acupuncture|
79647437|NCT00183365|Behavioral|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
79324989|NCT05650541|Device|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
79810059|NCT04016805|Drug|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody~administered as an IV infusion"
79810060|NCT04016805|Drug|Umbralisib|"Phosphoinositide-3-kinase (PI3K) delta inhibitor~Tablet form, to taken orally on a daily basis"
79810061|NCT04016805|Drug|Ibrutinib|"Bruton Tyrosine Kinase (BTK) inhibitor~Tablet form, to taken orally on a daily basis"
79810062|NCT04016805|Drug|Venetoclax|"BCL-2 inhibitor~Tablet form, to be taken orally"
79810063|NCT04016805|Drug|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
79324994|NCT05640466|Device|Reduction and fixation of metatarsal neck fracture by metaizeau's technique|Reduction and fixation of metatarsal neck fracture by metaizeau's technique
79324995|NCT05634954|Drug|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
79324996|NCT05634954|Diagnostic Test|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
79481198|NCT05664490|Behavioral|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
79481199|NCT05648591|Drug|Iloperidone|oral tablet
79647438|NCT00183365|Behavioral|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
79810064|NCT04002986|Genetic|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
79810065|NCT03982199|Biological|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.
79810066|NCT03982199|Biological|Placebo|Participants will receive a single IM injection of placebo control on Day 1.
79810067|NCT03979508|Drug|Abemaciclib|Given PO
79810068|NCT03979508|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgical resection
79810069|NCT03978715|Other|No intervention-retrospective study|This is a retrospective study. No intervention
79810070|NCT03972527|Device|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
79810071|NCT03972527|Other|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
79810072|NCT03971955|Other|Mixed Meal Test|a standard liquid mixed meal will be administered to the participant. The test meal with 1 kcal/ml and with the following caloric distribution Protein: 25%, Carbohydrate: 53%, Fat: 22% is given at a dose of 6 mL per kilogram body weight. Maximum dose is 360 mL and it will be ingested over 5 minutes. Blood samples will be taken 10 min prior to ingestion (t=-10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 minutes.
79810073|NCT03971955|Other|Dual Energy X-Ray Absorptiometry (DEXA)|DEXA Scans will be performed to obtain body composition measures (body fat and estimated muscle mass) using a General Electric (GE) Lunar iDXA whole-body scanner.
79810074|NCT03971955|Procedure|Adipose Tissue Biopsy|The abdominal skin 6-10 cm lateral to the umbilicus will be cleansed with chlorhexidine. A sterile drape is placed, and the skin and adipose tissue will be anesthetized using Lidocaine. A 3-4 mm Mercedes Liposuction cannula will be inserted for aspiration of up to 2g of adipose tissue.
79810075|NCT03969199|Behavioral|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
79810076|NCT03969186|Behavioral|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
79324997|NCT05634954|Diagnostic Test|Static - PET/CT Scan|Group 2: Static whole-body scans
79324998|NCT05625932|Drug|Tinzaparin|Patients < 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients > 100 kg will receive a fixed dose of 8000 IU daily.
79324999|NCT05624684|Diagnostic Test|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
79810077|NCT03968393|Drug|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for 24 months: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
79325004|NCT05615844|Drug|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
79810078|NCT03959358|Drug|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
79810079|NCT03959358|Drug|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
79325005|NCT05615844|Device|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
79325006|NCT05615714|Other|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
79325007|NCT05615714|Other|Sham stimulation|Stimulation will be turned off.
79325008|NCT05615415|Drug|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
79325009|NCT05615415|Drug|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
79325010|NCT05615415|Device|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
79325011|NCT05611801|Drug|marstacimab|marstacimab
79481200|NCT05635409|Biological|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
79647439|NCT04571788|Procedure|Foldable Capsular Buckle|Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera >10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.
79810080|NCT03958240|Other|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~at Baseline.~at every surgical procedure or tumor biopsy.~every 6 months (± 2 months) (only blood sample).~at the time of the progression or recurrence, if applicable.~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks)."
79325013|NCT05608291|Drug|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
79325014|NCT05608291|Drug|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
79647440|NCT04571788|Procedure|Silicone scleral padding|Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
79325015|NCT05608291|Drug|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
79325016|NCT05608291|Drug|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
79810081|NCT03902431|Behavioral|ABCS training|Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
79810082|NCT03855787|Procedure|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
79810083|NCT03828448|Drug|Ublituximab|- anti-CD 20 monoclonal antibody administered via IV infusion
79977545|NCT05869461|Behavioral|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
79977546|NCT05867992|Other|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
79977547|NCT05867667|Other|Cardiac Rehab|Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
79977548|NCT05867654|Drug|Amoxicillin-clavulanate 875mg/125mg q12hrs|Oral antibiotic used based on indication
79325017|NCT05603754|Drug|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
79325018|NCT05603754|Drug|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
79810084|NCT03828448|Drug|Umbralisib|- PI3K Delta Inhibitor oral daily dose
79325020|NCT05599984|Drug|ABBV-706|Intravenous (IV) Infusion
79325021|NCT05599984|Drug|Cisplatin|Intravenous infusion
79325022|NCT05599984|Drug|Budigalimab|IV Infusion
79325023|NCT05599984|Drug|Carboplatin|Intravenous infusion
79325024|NCT05596955|Drug|Buprenorphine injection|Extended release once-a-month buprenorphine injection . Study arm undergoes 2 fMRI examinations and weekly monitoring visits
79325025|NCT05596955|Drug|Naltrexone Injection|Extended release once-a-month naltrexone injection. Study arm undergoes 2 fMRI examinations and weekly monitoring visits
79810085|NCT03793127|Other|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
79810086|NCT03793127|Other|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
79977549|NCT05867654|Drug|oral clindamycin 300mg q6hrs|Oral antibiotic used based on indication
79977550|NCT05867654|Drug|Levofloxacin 750mg QID|Oral antibiotic used based on indication
79810087|NCT03793127|Other|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
79810088|NCT03787511|Other|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
79325026|NCT05595447|Drug|Brentuximab Vedotin 50 MG [Adcetris]|Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
79977551|NCT05865249|Other|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
79325033|NCT05573867|Other|Physical activity on prescription|"All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
79481201|NCT05621941|Behavioral|Game-Supported Goal Management Training|The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.
79481202|NCT05621941|Behavioral|Information Group|In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
79481203|NCT05613426|Drug|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
79481204|NCT05613426|Drug|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
79481205|NCT05603065|Drug|Tislelizumab + cisplatin + paclitaxel|Tislelizumab 200mgD1 + cisplatin 75mg/m^2D1 + paclitaxel 150mg/m^2D1 Q3W 3 cycles
79481206|NCT05603065|Drug|Tislelizumab + radiotherapy|Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
79325034|NCT05571553|Other|Recommendations and reorientation towards healthcare resources|"Phase 1~After completing the CARE© questionnaire, participants will be given recommendations.~After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~After completing the CARE© questionnaire, participants will be given recommendations.~If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
79481207|NCT05601700|Drug|Letrozole tablets|ATC: L02BG04
79481208|NCT05601700|Drug|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
79810089|NCT03787511|Other|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
79977552|NCT05865197|Other|Data collection|Data collection of clinically relevant signals using home-based sensor system
79810090|NCT03787511|Other|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
79810091|NCT03783572|Other|Clinical evaluation|For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
79977553|NCT05861375|Diagnostic Test|Fibroscan|Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
79325035|NCT05571267|Drug|Zimura|Zimura 2 mg, administered by intravitreal injection
79325036|NCT05571267|Drug|Avastin|Avastin 1.25 mg, administered by intravitreal injection
79977554|NCT05858957|Drug|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
79977555|NCT05858957|Drug|Saline|100 ml saline infusion apply to the Group S
79325037|NCT05571267|Drug|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
79325038|NCT05571267|Drug|Eylea|Eylea 2 mg, administered by intravitreal injection
79325039|NCT05569174|Drug|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
79325040|NCT05569174|Other|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
79481209|NCT05601362|Device|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
79325041|NCT05568264|Other|Physical Therapy intervention|The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
79977556|NCT05853705|Behavioral|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
79977557|NCT05852938|Drug|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
79325042|NCT05567887|Drug|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
79325043|NCT05562674|Behavioral|Support group|"This is a group-based, peer specialist and clinician co-facilitated psychosocial intervention for Veterans with SMI, called Veteran Voices and Visions (VVV). VVV is an adaptation of a community-based support group model called the Hearing Voices (HV) approach. The approach facilitates group cohesion around and normalization of the common psychotic symptoms of SMI: hallucinations, delusions, and social isolation."
79325044|NCT05562674|Behavioral|Healthy Lifestyles|This will be a group matched with the experimental condition for location, format, degree of interaction, and duration, but with a distinct content, that focuses on nutrition and lifestyle.
79481210|NCT05601362|Device|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
79977558|NCT05852938|Drug|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
79481211|NCT05592938|Radiation|rPBI|External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
79481212|NCT05585138|Other|segmental breathing exercise|Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
79977559|NCT05852002|Drug|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
79325045|NCT05562570|Behavioral|Physical activity intervention coupled with standard post-cancer directed treatment care|AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of <15-min, three days per week at low intensity (e.g., activities expending >1.5 to 3 METs or intensity <5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.
79481213|NCT05585138|Other|deep breathing|conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
79481214|NCT05582629|Drug|JT001|JT001 administered orally in tablet form every 12 hours for 5 days
79647441|NCT00476593|Drug|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
79647442|NCT00476593|Drug|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
79481215|NCT05582629|Drug|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
79977560|NCT05849896|Device|Acquisition of HD sEMG signals using the WPM-SEMG device|The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
79977561|NCT05847114|Other|Stres ball|Stress ball compression for 15 minutes during surgery
79481216|NCT05579600|Behavioral|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
79647443|NCT00210132|Drug|Ropivacaine|
79647444|NCT00183404|Drug|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
79647445|NCT00217113|Behavioral|Geriatric home visit and Action Plan|
79977562|NCT05845099|Device|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
79481217|NCT05579600|Behavioral|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
79481218|NCT05576532|Drug|BCL2 Inhibitor plus IM2 regimen|oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
79481219|NCT05573074|Device|Transcranial Photobiomodulator|Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
79481220|NCT05573074|Device|Sham|Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
79481221|NCT05567289|Procedure|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
79647446|NCT00183521|Behavioral|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
79977563|NCT05845099|Device|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
79977564|NCT05842954|Drug|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients < 35kg will take a fraction of the dose according to weight group as defined in the protocol.
79977565|NCT05842954|Drug|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
79977566|NCT05841940|Drug|[14C]HLX208|Carbon-14 labeled HLX208
79977567|NCT05840770|Procedure|Biospecimen Collection|Undergo blood sample collection
79977568|NCT05840770|Biological|Cemiplimab|Given IV
79977569|NCT05840770|Procedure|Computed Tomography|Undergo CT scan
79977570|NCT05840770|Procedure|Magnetic Resonance Elastography|Undergo MRI
79977571|NCT05840770|Procedure|Positron Emission Tomography|Undergo PET scan
79977572|NCT05837221|Diagnostic Test|Metagenomic sequencing|Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
79977573|NCT05837221|Diagnostic Test|Metabolic analysis|Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
79325046|NCT05562570|Other|Standard post-cancer directed treatment care control|AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
79325047|NCT05562193|Behavioral|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of <15-min, three days per week at low intensity (e.g., activities expending >1.5 to 3 METs or intensity <5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
79325048|NCT05562193|Other|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
79481222|NCT05567289|Procedure|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
79481223|NCT05566730|Behavioral|CT-MICART App|App designed with the goal of treating CUD in African American adults
79481224|NCT05566730|Behavioral|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
79481225|NCT05562453|Device|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
79481226|NCT05562453|Device|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
79810092|NCT03783572|Other|Clinical evaluation and Instrumental evaluation|For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
79810093|NCT03762954|Other|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
79481227|NCT05558150|Drug|Ilaprazole|Ilaprazole 10mg
79325049|NCT05560646|Drug|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
79325050|NCT05560646|Drug|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
79481228|NCT05558150|Drug|Aceclofenac|Aceclofenac 100mg
79810094|NCT03744559|Behavioral|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
79977574|NCT05834023|Drug|Bupivacaine-Lidocaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
79977575|NCT05834023|Drug|Bupivacaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
79977576|NCT05832437|Behavioral|BREATHE-Peds Intervention|BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
79977577|NCT05832437|Behavioral|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
79977578|NCT05831189|Drug|RBX2660|RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
79325051|NCT05556473|Drug|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-[18F]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
79325059|NCT05553197|Behavioral|Cognitive Behavioural Therapy (CBT)|20 sessions of face-to-face, individual CBT
79325060|NCT05553197|Other|Ecological Momentary Assessment (EMA)|Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
79325061|NCT05549323|Drug|PF-07054894|Oral
79481229|NCT05535946|Drug|ABX464|Administered once daily in the morning with food
79481230|NCT05535946|Drug|Placebo|Administered once daily in the morning with food
79481231|NCT05526716|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
79481232|NCT05526716|Biological|QIV|Single 0.5 mL IM injection
79481233|NCT05526716|Biological|Matching Placebo for V116|Single 0.5 mL of sterile saline IM injection
79481234|NCT05507216|Drug|ABX464|Administered once daily in the morning with food
79481235|NCT05507216|Drug|Placebo|Administered once daily in the morning with food
79481236|NCT05507203|Drug|ABX464|Administered once daily in the morning with food
79481237|NCT05507203|Drug|Placebo|Administered once daily in the morning with food
79481238|NCT05502523|Procedure|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
79481239|NCT05502523|Procedure|Biospecimen Collection|Correlative studies
79325062|NCT05549323|Drug|Placebo|Placebo
79325063|NCT05542160|Dietary Supplement|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
79481240|NCT05502159|Drug|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
79481241|NCT05502159|Drug|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
79481242|NCT05496296|Device|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
79481243|NCT05484739|Other|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
79481244|NCT05484739|Other|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
79481245|NCT05484739|Other|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
79977579|NCT05829460|Drug|Semaglutide|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
79481246|NCT05484739|Other|Control|Participants will NOT receive either water spray or a fan exposure.
79481247|NCT05471180|Other|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
79977580|NCT05829460|Drug|Placebo|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
79481248|NCT05471180|Device|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
79481249|NCT05469425|Behavioral|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~Type: Walking~Frequency: 3 sessions per week~Duration: 30 minutes~Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~Frequency: 2 sessions per week~Duration: 2 sets x 15 repetitions~Rest in-between sets: 45 seconds~Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
79481250|NCT05467748|Drug|Tazemetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
79977581|NCT05829460|Drug|Progestin|Released via the levonorgestrel-releasing IUD.
79977582|NCT05829460|Behavioral|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (13 months total). Each telephone session will be 30 minutes long.
79977583|NCT05828082|Procedure|Biopsy|Undergo biopsy
79325064|NCT05540262|Drug|Edaravone|Edaravone injection 30mg three times a day
79325065|NCT05537688|Behavioral|Identification of Graphic Markers|"The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team."
79325066|NCT05521997|Drug|Telaglenastat|-800 mg twice per day by mouth
79977584|NCT05828082|Procedure|Biospecimen Collection|Correlative studies
79977585|NCT05828082|Procedure|Computed Tomography|Undergo CT
79977586|NCT05828082|Procedure|Magnetic Resonance Imaging|Undergo MRI
79977587|NCT05828082|Procedure|Positron Emission Tomography|Undergo PET/MRI or PET/CT
79977588|NCT05828082|Drug|Tuvusertib|Given PO
79977589|NCT05828082|Procedure|Ultrasound Imaging|Undergo U/S
79481251|NCT05460871|Drug|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
79481252|NCT05460390|Other|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
79481253|NCT05459181|Diagnostic Test|HeartCare|Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
79481254|NCT05457998|Diagnostic Test|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
79481255|NCT05457998|Diagnostic Test|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
79325067|NCT05521997|Radiation|Radiation treatment|"Standard of care~External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
79325068|NCT05521997|Drug|Cisplatin|"Standard of care~Weekly administration of cisplain"
79325069|NCT05521061|Dietary Supplement|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
79810095|NCT03744559|Behavioral|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
79977590|NCT05826015|Drug|Paclitaxel|IV over 3 hours
79977591|NCT05826015|Drug|Batiraxcept|IV over 60 minutes
79977592|NCT05821231|Combination Product|SBRT + MEDI5752|"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"
79977593|NCT05819892|Drug|Paclitaxel|Given by IV (vein)
79325070|NCT05520567|Drug|Gilteritinib|Oral
79325071|NCT05520567|Drug|Venetoclax|Oral
79325072|NCT05520567|Drug|Azacitidine|Subcutaneous injection or intravenous infusion
79325073|NCT05515536|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
79481256|NCT05457998|Diagnostic Test|[18F]-MK-6240 Injection|PET imaging of Tau aggregates
79481257|NCT05438316|Drug|Ramipril tablet 10 mg|Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
79481258|NCT05438316|Drug|Tritace® tablet 10 mg|Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
79481259|NCT05436548|Other|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
79977594|NCT05819892|Drug|Carboplatin|Given by IV (vein)
79977595|NCT05819892|Drug|Dostarlimab|Given by IV (vein)
79977596|NCT05819892|Drug|Cisplatin|Given by IV (vein)
79977597|NCT05812131|Behavioral|COPEWeb online training|COPE training delivered via online COPEWEb to providers
79977598|NCT05812131|Behavioral|COPE In Person|COPE training provided in person to providers
79977599|NCT05808153|Radiation|radiotracer injection|MRI with radiotracer injection
79977600|NCT05803564|Device|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
79977601|NCT05802719|Other|Blood sampling|"The procedure consists of collecting 4 additional tubes of blood (20mL) at each visit for research purposes, in order to perform the immunological assays.~Blood samples at the inclusion, 3 month and 6 month after initiation of anti-TNF therapy"
79977602|NCT05801978|Biological|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
79810096|NCT03744559|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) will identify patterns of brain activity associated with RET and potentially predictive of treatment outcomes. The fMRI is used during the baseline and 24-hour follow-up test sessions while participants complete a cue-reactivity task. The collection of fMRI data is based on findings from human fear conditioning fMRI studies, in which groups receiving RET in the reconsolidation window exhibited less fear that was associated with attenuated BOLD response in the amygdala, relative to the control. We propose that the R-E arm will evidence attenuated cue reactivity in medial prefrontal cortex, limbic regions and ventral striatum, and that greater reduction in BOLD response in regions of interest will predict decreased smoking.
79325075|NCT05501873|Device|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
79325076|NCT05500417|Drug|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
79325077|NCT05500417|Biological|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
79325078|NCT05497284|Drug|LTP001|LTP001 will be administered once daily in the morning
79481260|NCT05436548|Other|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
79325079|NCT05497284|Drug|Placebo|Placebo to LTP001 will be administered once daily in the morning
79325080|NCT05497284|Drug|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
79325081|NCT05494866|Drug|Cobicistat Oral Tablet|Cobicistat Oral Tablet
79325082|NCT05494866|Drug|Gemcitabin|Gemcitabin
79325083|NCT05494866|Drug|Nab paclitaxel|nab-Paclitaxel
79481261|NCT05436470|Device|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
79481262|NCT05432700|Other|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
79325084|NCT05492448|Dietary Supplement|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
79325085|NCT05492448|Dietary Supplement|L. salivarius AP-32 and L. reuteri GL-104|Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
79325086|NCT05492448|Dietary Supplement|L. reuteri GL-104|Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
79325087|NCT05487001|Procedure|dexamethasone group|"1) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
79810097|NCT03744559|Other|No functional magnetic resonance imaging (fMRI)|No functional magnetic resonance imaging (fMRI) serves as the control intervention to the fMRI intervention. Participants who are randomized to the no fMRI intervention or who have a contraindication to MRI will complete an identical cue-reactivity task in a cue-reactivity lab during the baseline and 24-hour follow-up test sessions.
79810098|NCT03742440|Biological|GrafixPL PRIME|GrafixPL PRIME
79810099|NCT03737929|Procedure|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
79325088|NCT05487001|Procedure|sham group|"2) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
79325089|NCT05485831|Drug|Epidiolex 100 mg/mL Oral Solution|As prescribed in routine clinical practice in Italy.
79325090|NCT05484661|Dietary Supplement|BCAA|Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
79810100|NCT03737929|Procedure|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
79810101|NCT03714308|Drug|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
79810102|NCT03713125|Behavioral|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
79325091|NCT05478252|Drug|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
79325092|NCT05478252|Drug|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
79481263|NCT05427734|Device|Jaspr2.0|Participants assigned to this condition will receive access to Jaspr2.0 and its companion mobile app, Jaspr-at-Home, for 12 weeks.
79481264|NCT05427734|Device|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
79481265|NCT05426525|Drug|Empagliflozin|Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
79810103|NCT03702270|Other|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
79481266|NCT05426525|Drug|Multivitamin-Placebo|Participants will take 1 multivitamin per day for 13 weeks.
79481267|NCT05417698|Other|Exercise Only (Ex only)|Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
79481268|NCT05417698|Other|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale."
79481269|NCT05415384|Device|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
79810104|NCT03580369|Biological|Ligelizumab|Liquid in vial
79977603|NCT05801978|Biological|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
79977604|NCT05801146|Drug|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
79307119|NCT05286814|Drug|Leucovorin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
79481270|NCT05415384|Procedure|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
79481271|NCT05414981|Drug|ABI-H3733|25 mg or 100 mg tablets for oral administration
79481272|NCT05414981|Drug|Placebo|25 mg or 100 mg tablets for oral administration
79481273|NCT05403138|Drug|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
79481274|NCT05403138|Drug|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
79810105|NCT03580369|Biological|Omalizumab|Lyophilized powder for solution in vial
79810106|NCT03580369|Other|Placebo|Liquid in vial
79810107|NCT03554083|Drug|Atezolizumab|Given IV
79810108|NCT03554083|Drug|Cobimetinib|Given PO
79810109|NCT03554083|Biological|Tiragolumab|Given IV
79810110|NCT03554083|Drug|Vemurafenib|Given PO
79810111|NCT03503773|Drug|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
79810112|NCT03503773|Other|Sham control|endovascular, renal angiography
79977605|NCT05801146|Drug|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
79977606|NCT05796765|Biological|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
79977607|NCT05796765|Biological|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
79481275|NCT05394220|Diagnostic Test|16S rRNA gene amplicon sequencing|molecular sequencing for the microbiome in parapneumonic effusion
79977608|NCT05796765|Drug|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
79977609|NCT05795166|Other|No treatment given|No treatment given
79977610|NCT05791981|Behavioral|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
79977611|NCT05791981|Behavioral|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
79810113|NCT03479476|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
79810114|NCT03479476|Drug|Metformin|Active medication.
79977612|NCT05791981|Device|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
79810115|NCT03399539|Drug|Dexamethasone|Given PO
79810116|NCT03399539|Drug|Ixazomib Citrate|Given PO
79810117|NCT03399539|Other|Laboratory Biomarker Analysis|Correlative studies
79810118|NCT03399539|Drug|Venetoclax|Given PO
79977613|NCT05791591|Dietary Supplement|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
79481276|NCT05392192|Drug|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
79481277|NCT05392192|Drug|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
79481278|NCT05363644|Biological|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
79481279|NCT05353972|Drug|IMG-007 or placebo|intravenously administered
79647447|NCT00183521|Behavioral|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
79977614|NCT05791591|Dietary Supplement|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
79977615|NCT05791591|Dietary Supplement|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
79977616|NCT05789355|Dietary Supplement|NUV001|Daily supplementation with NUV001 at 1000 mg (4 tablets of 250 mg each) for 90 days with a prolonged follow-up of 1 month (30 days) after stopping the supplementation
79977617|NCT05786417|Other|Clinician Discretion|Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
79977618|NCT05786417|Drug|Beta blocker|Selection of the specific BB and initial starting dose will be determined by the treating clinician.
79977619|NCT05786417|Drug|Calcium channel blocker|Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
79977620|NCT05782413|Other|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
79307120|NCT05286814|Drug|M9241|M9241 will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of M9241 will be reduced to 4 mcg/kg.
79307121|NCT05286814|Drug|Gemcitabine|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 2: GemOx (gemcitabine [800 mg/m2 IV over 30 minutes] and oxaliplatin [85 mg/ m2 IV over 120 minutes])
79307122|NCT05286814|Drug|Dexamethasone|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
79307123|NCT05266469|Other|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
79307124|NCT05266469|Other|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.
79810119|NCT03358706|Drug|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
79325094|NCT05473182|Other|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
79481280|NCT05353140|Device|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
79481281|NCT05353140|Drug|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
79481282|NCT05353140|Drug|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
79647448|NCT00183521|Behavioral|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
79647449|NCT00210171|Procedure|Toxicity : Time to progression, 1 and 2 years survival|
79647450|NCT00476476|Drug|Erlotinib|Orally every day for about 4-6 weeks
79810120|NCT03358706|Drug|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
79810121|NCT03358706|Drug|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
79810122|NCT03358706|Drug|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
79325095|NCT05468619|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
79481283|NCT05351944|Behavioral|Dialectical behavioral therapy skills for the intervention experimental group A|Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
79481284|NCT05351944|Drug|psychoeducation or Atomoxetine or stimulants according to ADHD severity|the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
79481285|NCT05346055|Behavioral|Engage Prism (2.0)|Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
79810123|NCT03358706|Drug|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
79810124|NCT03358706|Drug|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
79810125|NCT03358706|Drug|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
79810126|NCT03358706|Drug|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
79810127|NCT03338920|Drug|sumatriptan nasal powder|nasal powder administered via nosepiece
79325096|NCT05466877|Drug|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
79325097|NCT05466877|Drug|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
79325098|NCT05464082|Other|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
79481286|NCT05340465|Drug|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
79481287|NCT05340465|Drug|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
79810128|NCT03338920|Drug|Placebo|lactose monohydrate powder administered via nosepiece
79810129|NCT03331289|Drug|Placebo|Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
79810130|NCT03331289|Drug|Exenatide|Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
79810131|NCT03331289|Drug|Dapagliflozin|Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
79810132|NCT03331289|Drug|Exenatide and Dapagliflozin|Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
79810133|NCT03280303|Other|non-interventional|
79481288|NCT05340465|Drug|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
79977621|NCT05782413|Other|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
79977622|NCT05780801|Drug|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
79325101|NCT05457634|Other|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
79325102|NCT05457634|Other|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
79325103|NCT05457634|Other|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
79325104|NCT05457634|Other|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
79325105|NCT05457634|Other|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
79481289|NCT05340465|Drug|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
79977623|NCT05779969|Other|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
79481290|NCT05332522|Behavioral|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
79481291|NCT05332405|Drug|Indocyanine green|The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
79481292|NCT05314231|Drug|ALXN1720|All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
79810134|NCT03215810|Procedure|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
79977624|NCT05779202|Other|No intervention is planned.|No intervention is planned.
79810135|NCT03215810|Drug|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
79810136|NCT03215810|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
79325106|NCT05457634|Other|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
79325107|NCT05454137|Behavioral|Shared medical appointment|Shared medical appointment
79977625|NCT05775939|Other|Fludeoxyglucose F-18|Given FDG
79977626|NCT05775939|Procedure|Positron Emission Tomography|Undergo PET-CT
79977627|NCT05775939|Procedure|Computed Tomography|Undergo PET-CT
79977628|NCT05775939|Other|Questionnaire Administration|Ancillary studies
79977629|NCT05773105|Drug|Cadonilimab+regorafenib|cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
79977630|NCT05766657|Dietary Supplement|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
79977631|NCT05766657|Dietary Supplement|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
79481293|NCT05312697|Biological|Setrusumab|A fully human anti-sclerostin monoclonal antibody (mAb)
79481294|NCT05312411|Biological|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
79481295|NCT05312411|Drug|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
79977632|NCT05766020|Behavioral|Listen training|Auditory skills with the inclusion of cognitive control.
79977633|NCT05763342|Device|The Phoenix Research System|Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
79977634|NCT05757193|Dietary Supplement|DeltaG|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate
79325108|NCT05454124|Behavioral|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
79325109|NCT05454124|Behavioral|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
79325110|NCT05453578|Other|Placebo|0.9 percent sodium chloride
79481296|NCT05309265|Other|Multidisciplinary vocational rehabilitation intervention|"Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
79481297|NCT05303090|Drug|H101|H101 intratumorally injection starts at day 0.
79977635|NCT05757037|Device|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz].
79977636|NCT05756491|Other|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
79977637|NCT05756491|Other|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
79977638|NCT05756491|Other|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
79325111|NCT05453578|Biological|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
79325112|NCT05447403|Other|Chewing gum combined with WeChat enhanced instructions|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
79325113|NCT05446675|Procedure|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
79325114|NCT05446675|Procedure|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
79647451|NCT00183560|Behavioral|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
79647452|NCT00183560|Drug|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
79977639|NCT05756491|Other|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
79325115|NCT05446142|Drug|Encorafenib capsule formulation (CAP)|A single encorafenib dose of the CAP formulation
79481298|NCT05303090|Drug|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79481299|NCT05303090|Drug|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79647453|NCT00183560|Drug|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
79647454|NCT00217152|Drug|CellCept|
79810137|NCT03215810|Drug|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
79977640|NCT05750147|Other|Blood Sample Collection|Blood for DNA and biomarker analysis
79977641|NCT05748990|Drug|Intranasal insulin|160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
79325116|NCT05446142|Drug|Encorafenib first formulation|first formulation
79325117|NCT05446142|Drug|Encorafenib second formulation|second formulation
79325118|NCT05446142|Drug|Rabeprazole tablet|Proton-pump inhibitor
79647455|NCT00183599|Behavioral|5 Minutes of Simple Advice|
79647456|NCT00183599|Behavioral|Motivational Enhancement Therapy (MET)|
79647457|NCT00183599|Behavioral|Cognitive Behavioral Therapy (CBT)|
79647458|NCT00210210|Drug|Ketamine|
79647459|NCT00476086|Drug|Gemcitabine|
79647460|NCT00476086|Drug|Oxaliplatin|
79647461|NCT00476086|Radiation|Radiation|
79647462|NCT00183638|Behavioral|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
79647463|NCT00183638|Behavioral|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
79647464|NCT00476047|Combination Product|Tositumomab and Iodine I 131 Tositumomab|Give IV
79810138|NCT03215810|Other|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
79810139|NCT03215810|Drug|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
79810140|NCT03208478|Procedure|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
79481300|NCT05287347|Diagnostic Test|Blood Specimen|"Blood samples will be collected from study participants at one time-point in the study, for the following:~tumor markers CEA and CA 19-9: 2 ml blood will be collected.~glycomics: 0.5 cc blood will be collected~ctDNA: 20 cc blood will be collected"
79647465|NCT00217191|Drug|Ibuprofen|
79647466|NCT00183716|Behavioral|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
79810141|NCT03208478|Procedure|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
79977642|NCT05748990|Drug|Placebo|0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
79977643|NCT05746624|Behavioral|keypresses|benign behavioral intervention-- keypresses
79647467|NCT00183716|Behavioral|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
79647468|NCT00476008|Drug|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
79647469|NCT00476008|Drug|Placebo|One tablet placebo morning and evening (BID) for 12 months
79647470|NCT04722705|Device|fractional Er:YAG laser|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
79810142|NCT03208478|Device|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
79810143|NCT03183895|Device|Left ventricular restoration|The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.
79810144|NCT03177018|Diagnostic Test|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
79810145|NCT03169257|Behavioral|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
79977644|NCT05746091|Procedure|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
79325122|NCT05445453|Other|Museum visit|"The intervention is a visit of the MMFA. This visit can be done alone or accompanied.~The visit of the MMFA is free for the patient."
79647471|NCT04722705|Device|Intense pulse light|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
79977645|NCT05744479|Drug|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
79977646|NCT05744479|Drug|Placebo|Oral placebo for 24 weeks
79977647|NCT05744479|Behavioral|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
79647472|NCT00412035|Drug|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
79977648|NCT05743621|Drug|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
79325123|NCT05444907|Other|No Intervention / Exposure|No intervention / exposure since this is an observational study
79481301|NCT05254600|Behavioral|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
79647473|NCT00412035|Drug|saline injection|10 units per kilo to maximum of 400 units
79647474|NCT00183833|Drug|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
79647475|NCT00210288|Biological|SC599|
79647476|NCT00183911|Drug|floxuridine, 5-Fluorouracil, leucovorin|
79647477|NCT00183911|Procedure|External Beam Radiotherapy|
79647478|NCT00183911|Procedure|Surgery|
79647479|NCT00412152|Drug|Oxycodone nalaxone prolonged release tablets (OXN)|
79325124|NCT05443724|Drug|CVL-231 30 mg|Oral tablets
79325125|NCT05441969|Other|No intervention/expousure|No interventions/expousure since this is an observational study.
79481302|NCT05243329|Drug|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
79977649|NCT05743621|Drug|Enzalutamide|160 mg daily PO
79647480|NCT02963402|Drug|Tocilizumab|
79647481|NCT02963402|Drug|Adalimumab|
79647482|NCT00210327|Drug|Bortezomib (drug)|
79810146|NCT03167671|Device|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
79647483|NCT00425516|Drug|Taxotere|
79647484|NCT00425516|Drug|5-Fluorouracil|
79647485|NCT00425516|Drug|Epirubicin|
79647486|NCT00425516|Drug|Cyclophosphamide|
79647487|NCT00412191|Drug|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
79647488|NCT00183950|Drug|Noscapine|
79810147|NCT03167671|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
79977650|NCT05743036|Drug|ZN-c3|ZN-c3 tablet by mouth, in combination with encorafenib
79977651|NCT05743036|Drug|Encorafenib|Encorafenib capsule by mouth, in combination with ZN-c3
79977652|NCT05743036|Drug|Cetuximab|Infusion
79977653|NCT05740462|Behavioral|Recipes consumption|Participants will eat two recipes a day for 17 weeks
79977654|NCT05740462|Behavioral|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
79325126|NCT05439759|Behavioral|Condition 1: Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
79481303|NCT05242562|Drug|Plenvu|a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
79481304|NCT05242562|Drug|Moviprep|a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
79481305|NCT05238766|Behavioral|DEAL|The DEAL protocol is an Acceptance and Commitment Therapy and Behavioral Activation informed clinical protocol to undermine accommodation and help parents adhere with behavioral treatment plan components.
79481306|NCT05237297|Drug|Ilaprazole|Ilaprazole 10mg
79481307|NCT05237297|Drug|Naproxen|Naproxen 500mg
79481308|NCT05237297|Drug|Aceclofenac|Aceclofenac 100mg
79481309|NCT05237297|Drug|Celecoxib|Celecoxib 200mg
79481310|NCT05235945|Behavioral|Online exercise intervention|Described in arm descriptions
79481311|NCT05229172|Device|Volume Targeted Ventilation|There is no study specific intervention planned. Procedures will be conducted according to standard of care of each participating hospital and the instructions for use of the study device.
79481312|NCT05218434|Drug|AX-158|Oral administrations of AX-158
79481313|NCT05216952|Drug|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
79481314|NCT05216952|Drug|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
79481315|NCT05213676|Drug|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
79481316|NCT05213676|Other|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
79481317|NCT05211739|Device|Lehfilcon A toric contact lenses|FDA-cleared silicone hydrogel toric contact lenses used as indicated
79481318|NCT05211739|Device|Comfilcon A toric contact lenses|Commercially available silicone hydrogel toric contact lenses used as indicated
79810148|NCT03154255|Behavioral|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
79481319|NCT05211739|Device|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
79481320|NCT05206110|Drug|10 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
79481321|NCT05206110|Drug|30 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
79481322|NCT05194839|Drug|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
79481323|NCT05194839|Drug|Placebo|Matching placebo
79481324|NCT05178095|Device|Artificial intelligence|Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
79481325|NCT05178095|Device|No Artificial Intelligence|Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
79481326|NCT05169736|Behavioral|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
79647489|NCT00408746|Behavioral|palatal development|Impressions of preterm and term palates.
79647490|NCT00210366|Drug|Idarubicin|
79810149|NCT03102554|Genetic|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
79977655|NCT05739032|Other|Aerobic exercise and strength training|"Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed."
79977656|NCT05738850|Drug|ABBV-932|Oral Capsule
79977657|NCT05738850|Drug|Placebo|Oral Capsule
79977658|NCT05735483|Drug|Lebrikizumab|Administered SC
79325127|NCT05439759|Behavioral|Condition 2: Training spatial integration|Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
79325128|NCT05439759|Behavioral|Condition 3: Training spatial attention|The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
79481327|NCT05165810|Behavioral|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
79481328|NCT05165810|Behavioral|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
79481329|NCT05165810|Other|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
79481330|NCT05165810|Other|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
79481331|NCT05165810|Behavioral|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
79481332|NCT05165810|Behavioral|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
79481333|NCT05164250|Drug|REGN5458|
79481334|NCT05163392|Device|Silverlon|SIlver-plated biopatch
79481335|NCT05163392|Device|Control|Tegaderm without biopatch
79977659|NCT05735483|Drug|Placebo|Administered SC
79647491|NCT00408785|Drug|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
79647492|NCT00408785|Drug|sodium chloride|sodium chloride 0.9 mg
79977660|NCT05731882|Device|E-SeaLA, CardioPulse PFA system|First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
79977661|NCT05729568|Drug|Teropavimab|Administered intravenously
79977662|NCT05729568|Drug|Zinlirvimab|Administered intravenously
79977663|NCT05729568|Drug|Lenacapavir Tablet|Administered orally
79977664|NCT05729568|Drug|Lenacapavir Injection|Administered subcutaneously
79977665|NCT05729568|Drug|Antiretroviral Therapy|Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
79977666|NCT05727761|Drug|pioglitazone-metformin|Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
79977667|NCT05727176|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
79977668|NCT05724563|Drug|Zimberelimab|Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
79977669|NCT05724563|Drug|Domvanalimab|Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
79977670|NCT05721222|Drug|PRO1160|Intravenous infusion of PRO1160
79977671|NCT05715229|Drug|Nivolumab|Immunotherapy
79325129|NCT05439759|Behavioral|Condition 4: Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
79325130|NCT05436418|Drug|Melphalan|"Matched HCT: 100 mg/m^2 IV on day -2 over 30 minutes. Haplo HCT:~100 mg/m^2 IV on day -6 over approximately 20-30 minutes."
79481336|NCT05157113|Drug|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
79481337|NCT05157113|Drug|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
79481338|NCT05155618|Procedure|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
79481339|NCT05154240|Drug|INS018_055|INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.
79481340|NCT05154240|Drug|Placebo|Placebo
79481341|NCT05150054|Device|CardioFlux|Not an intervention
79647493|NCT00475735|Drug|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
79647494|NCT00475735|Drug|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
79810150|NCT03092531|Behavioral|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
79810151|NCT03036930|Procedure|Biospecimen Collection|Undergo collection of blood samples
79810152|NCT03036930|Procedure|HPV Self-Collection|Undergo self-collection of vaginal/cervical samples
79977672|NCT05715229|Drug|Ipilimumab|Immunotherapy
79977673|NCT05715229|Drug|Carboplatin|Chemotherapy
79977674|NCT05715229|Drug|Paclitaxel|Chemotherapy
79977675|NCT05715229|Drug|Pemetrexed|Chemotherapy
79977676|NCT05704049|Drug|Isatuximab|Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
79977677|NCT05704049|Drug|Carfilzomib|Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
79977678|NCT05704049|Drug|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
79977679|NCT05704049|Drug|Dexamethasone IV|Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
79977680|NCT05702814|Other|No Intervention|As this is an observational study, no intervention will be administered.
79325131|NCT05436418|Drug|Sirolimus|Sirolimus: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg)^d, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions and may be modified based on institutional practice.
79647495|NCT00475735|Drug|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
79977681|NCT05700929|Behavioral|Communication skills training for nurses|Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
79325132|NCT05436418|Radiation|Total Body Irradiation (TBI)|Haplo HCT only: A dose of 200 cGy will be administered on day -1.
79647496|NCT00475657|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
79977682|NCT05700006|Drug|Aromatase inhibitor|Standard of care anastrozole, exemestane, or letrozole
79647497|NCT00475657|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
79647498|NCT00210405|Dietary Supplement|"Sprinkles containing mulitple micronutrients"|
79647499|NCT00210405|Behavioral|Education/communication on use of micronutrient sprinkles|
79810153|NCT03036930|Other|Questionnaire Administration|Ancillary studies
79810154|NCT03036930|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
79977683|NCT05698537|Diagnostic Test|EEG|EEG registration performed in PwE to confirm epilepsy diagnosis
79325133|NCT05436418|Drug|Cyclophosphamide|based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
79481342|NCT05145192|Device|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
79481343|NCT05145192|Device|ParvoMedics CPET|ParvoMedics CPET
79647500|NCT00210405|Dietary Supplement|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
79647501|NCT00408941|Drug|Propofol|
79647502|NCT00408941|Drug|Prilocaine|
79647503|NCT00217230|Biological|CAIV-T|
79977684|NCT05698537|Diagnostic Test|Neuroimaging|Neuroimaging performed in PwE to diagnose epilepsy etiology
79325134|NCT05436418|Drug|Mycophenolate Mofeti|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
79647504|NCT02963480|Procedure|Cardiac Surgery|
79647505|NCT00217269|Device|Coronary Artery Stenting|Endeavor Drug eluting stent
79647506|NCT00217269|Device|Coronary Artery Stenting|Taxus Drug Eluting Stent
79647507|NCT00475423|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
79810155|NCT03032627|Procedure|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
79810156|NCT03032406|Drug|Hydroxychloroquine|Hydroxychloroquine
79810157|NCT03032406|Drug|Everolimus|Everolimus
79977685|NCT05698537|Diagnostic Test|Blood sample|Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
79481344|NCT05144243|Drug|Venetoclax|Tablet: Oral
79481345|NCT05144243|Drug|Azacitidine|Subcutaneous Injection (SC)
79481346|NCT05139238|Drug|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
79481347|NCT05139238|Drug|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
79481348|NCT05138614|Other|Medication for Opioid Use Disorder|medication management
79481349|NCT05138614|Behavioral|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
79647508|NCT02963519|Device|VistaCare®|
79647509|NCT02963519|Device|Dressings|
79647510|NCT00210444|Biological|Botulinum toxin type A|
79647511|NCT00475306|Drug|metoclopramide 10 mg|an anti-emetic medication
79810158|NCT02999269|Device|MECTA Spectrum 5000Q Amplitude|Current
79810159|NCT02977468|Drug|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
79810160|NCT02977468|Radiation|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
79810161|NCT02955355|Biological|HYQVIA|Participants will receive subcutaneous (SC) HYQVIA/HyQvia which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
79810162|NCT02910895|Other|tumor biopsy|biopsy
79481350|NCT05138614|Behavioral|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
79481351|NCT05138614|Behavioral|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
79647512|NCT00475306|Drug|Diphenhydramine 25 mg|used for prophylaxis against akathisia
79977686|NCT05698537|Other|Risk factor questionnaire|Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
79977687|NCT05697146|Other|ribociclib + ET|There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
79325135|NCT05436418|Drug|Fludarabine|Matched HCT: 25 mg/m^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m^2/day infused IV over approximately 30-60 minutes from day -5 to day -2
79325136|NCT05436418|Procedure|Allogeneic HSCT|Stem cell transplant
79977688|NCT05695716|Device|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
79977689|NCT05686668|Other|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
79325137|NCT05436418|Drug|Mesna|equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
79325138|NCT05436418|Drug|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is > 1000 cells/mm3 for three days or > 5000 for one day.
79325139|NCT05415072|Drug|DYP688|Single agent DYP688
79481352|NCT05127850|Behavioral|Consultation audio recording app|Smartphone or tablet mobile application which allows for voice recording
79481353|NCT05126173|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
79481354|NCT05120141|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
79481355|NCT05120141|Other|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
79481356|NCT05120141|Other|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
79325140|NCT05415007|Behavioral|GOLD Program|Participant will receive a 2-hour interventional session
79647513|NCT00475306|Drug|Placebo|placebo
79647514|NCT00475306|Drug|Metoclopramide 20 mg|Metoclopramide 20 mg
79647515|NCT00475228|Drug|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
79647516|NCT00183989|Drug|Fludarabine, Mitoxantrone and Rituximab|
79810163|NCT02891538|Drug|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).*
79325141|NCT05415007|Behavioral|Treatment as usual (TAU)|Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
79977690|NCT05684341|Combination Product|Connected Solution with H2S app which connects with blood glucose meter (BGM)|Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
79325142|NCT05413629|Other|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
79810164|NCT02728635|Other|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
79810165|NCT02728635|Procedure|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
79977691|NCT05683418|Drug|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
79325146|NCT05405114|Drug|NDec - oral decitabine-tetrahydrouridine|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
79325147|NCT05405114|Drug|HU - Hydroxyurea|Participants will get capsules daily (oral administration) according to local labelling
79481357|NCT05120141|Other|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
79481358|NCT05120141|Other|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
79977692|NCT05682937|Device|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention
79977693|NCT05680623|Diagnostic Test|PPAP diagnosis|"Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.~A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications."
79977694|NCT05679635|Device|Evone|The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.
79977695|NCT05679635|Device|Evita Infinity V500|Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
79977696|NCT05679232|Device|Hydrogel coating|hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
79977697|NCT05679232|Procedure|Control|standard cementless hip revision arthroplasty
79977698|NCT05677906|Other|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
79977699|NCT05677906|Other|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
79977700|NCT05675735|Behavioral|Clinic-Level Multidimensional Intervention|The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
79977701|NCT05674929|Drug|BPL-003|A single dose administered intranasally
79977702|NCT05671588|Procedure|Controlled combined exercise group|Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
79325148|NCT05405114|Drug|Placebo|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
79481359|NCT05120141|Other|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
79325149|NCT05404854|Other|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
79325150|NCT05404854|Other|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
79325151|NCT05404854|Other|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
79325152|NCT05404854|Other|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
79325153|NCT05394155|Dietary Supplement|Leucine|7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
79325154|NCT05385237|Diagnostic Test|4D-MRI|Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.
79325155|NCT05384496|Drug|Nivolumab and/or Ipilimumab|Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
79325156|NCT05384496|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.
79325157|NCT05384496|Drug|axitinib|5mg twice daily
79325158|NCT05379985|Drug|RMC-6236|Oral Tablets
79977703|NCT05671588|Procedure|Conventional rehabilitation|Patients will undergo conventional rehabilitation.
79325159|NCT05377996|Drug|XMT-1660|XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
79325160|NCT05371028|Other|Non-interventional Study|This is non-interventional study.
79325161|NCT05370274|Procedure|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
79325162|NCT05370274|Procedure|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
79325163|NCT05368558|Drug|Cariprazine|Oral Capsule
79325164|NCT05368558|Drug|Placebo|Oral Capsule
79325165|NCT05366790|Behavioral|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
79325166|NCT05364424|Drug|Glofitamab|Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
79647517|NCT00184067|Biological|Montanide ISA 51|
79647518|NCT00217308|Drug|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
79977704|NCT05669599|Biological|AMG 133|Participants will receive AMG 133 by subcutaneous (SC) injection.
79325167|NCT05364424|Drug|Obinutuzumab|Participants will receive IV obinutuzumab on Cycle 1 Day 1.
79325168|NCT05364424|Drug|Tocilizumab|Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
79325169|NCT05364424|Drug|Rituximab|Participants will receive up to 2 doses of IV rituximab.
79325170|NCT05364424|Drug|Ifosfamide|Participants will receive IV ifosfamide for up to 3 cycles.
79325171|NCT05364424|Drug|Carboplatin|Participants will receive IV carboplatin for up to 3 cycles.
79325172|NCT05364424|Drug|Etoposide|Participants will receive IV etoposide for up to 3 cycles.
79647519|NCT00184106|Drug|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
79647520|NCT00210483|Drug|almotriptan malate|
79481360|NCT05120141|Other|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
79481361|NCT05119231|Procedure|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
79481362|NCT05119231|Other|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
79647521|NCT00184145|Other|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
79977705|NCT05669599|Drug|Placebo|Participants will receive placebo by SC injection.
79810166|NCT02728635|Other|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
79810167|NCT02676206|Other|Classical music|Classical music will be played over the headphones
79810168|NCT02672332|Drug|SB204 4%|Once daily
79810169|NCT02672332|Drug|Vehicle Gel|Placebo comparator
79810170|NCT02667444|Drug|SB204 4%|Applied topically once daily
79307125|NCT05260957|Drug|Mosunetuzumab|"Induction Phase (Days -42 through -7):~1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77."
79307126|NCT05260957|Drug|Polatuzumab|"Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77."
79977706|NCT05667753|Behavioral|MINISTOP 3.0|MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.
79977707|NCT05666336|Biological|Telitacicept|It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
79307127|NCT05260957|Biological|CAR-T Cell Therapy|Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
79307128|NCT05243654|Drug|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
79307129|NCT05243654|Drug|Placebo|Placebo + standard-of-care MDT
79307130|NCT05238376|Behavioral|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
79481363|NCT05116735|Procedure|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
79481364|NCT05105152|Biological|SC-DARIC33|Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
79481365|NCT05103904|Other|Laboratory Biomarker Analysis|Correlative studies
79481366|NCT05103904|Drug|Lenvatinib|Given PO
79810171|NCT02667444|Drug|Vehicle Gel|Applied topically one daily
79810172|NCT02646384|Procedure|Ovarian tissue cryopreservation|Ovarian tissue will be removed
79977708|NCT05666336|Drug|Hydroxychloroquine|It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
79977709|NCT05666336|Drug|Prednisone|It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
79977710|NCT05666336|Drug|Methylprednisolone|It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
79977711|NCT05666336|Drug|Cyclophosphamide|It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
79977712|NCT05666336|Drug|Mycophenolate Mofetil|It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
79977713|NCT05666336|Drug|Tacrolimus|It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
79977714|NCT05665244|Procedure|Laryngeal cryotherapy|Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
79977715|NCT05665244|Device|Cryoprobe|Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
79977716|NCT05664178|Behavioral|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
79977717|NCT05660772|Device|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
79977718|NCT05660772|Drug|Corticosteroid|intra-articular knee injection of corticosteroid
79977719|NCT05660382|Drug|Miconazole (2%) oil and mineral oil|Twice daily application, for 14 days.
79977720|NCT05660382|Other|Placebo|Twice daily application, for 14 days
79647522|NCT00184145|Other|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
79647523|NCT00210561|Drug|tramadol hydrochloride , acetaminophen|
79810173|NCT02634710|Radiation|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
79977721|NCT05658263|Dietary Supplement|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
79977722|NCT05658263|Dietary Supplement|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
79977723|NCT05656235|Drug|Enfortumab vedotin|Enfortumab vedotin 1.25mg/kg on Days 1 and 8 every 3 weeks for up to 35 weeks (each cycle = 21 days)
79977724|NCT05656235|Drug|Pembrolizumab|Pembrolizumab 200mg on Day 1 every 3 weeks for up to 35 weeks (each cycle = 21 days)
79647524|NCT00217347|Device|Esophageal Capsule Endoscopy|
79647525|NCT00184223|Behavioral|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
79977725|NCT05654922|Drug|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
79977726|NCT05654922|Other|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
79325173|NCT05357898|Biological|SQZ-eAPC-HPV|Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.
79325174|NCT05357898|Biological|Pembrolizumab|programmed cell death 1 (PD-1) blocking antibody
79325175|NCT05350345|Other|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
79325176|NCT05346198|Drug|CART-BCMA|The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
79647526|NCT00184223|Other|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
79325177|NCT05345938|Drug|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
79325178|NCT05332925|Drug|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
79325179|NCT05330325|Drug|Somapacitan|Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
79647527|NCT00210600|Drug|PROCRIT (Epoetin alfa)|
79977727|NCT05653648|Dietary Supplement|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
79325180|NCT05330325|Drug|Norditropin®|Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
79325181|NCT05328180|Other|Sodium bicarbonate|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.
79325182|NCT05328180|Other|Control arm|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.
79325183|NCT05321095|Diagnostic Test|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
79325184|NCT05321095|Diagnostic Test|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
79325185|NCT05321095|Diagnostic Test|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
79325186|NCT05321082|Drug|BI 1015550|BI 1015550
79325187|NCT05321082|Drug|Placebo|Placebo
79647528|NCT00184262|Behavioral|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
79325188|NCT05318976|Drug|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
79325189|NCT05318976|Drug|Placebo|Placebo will be delivered by subcutaneous injection once a week
79325190|NCT05306418|Drug|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
79325191|NCT05305365|Drug|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
79325192|NCT05304936|Drug|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
79325193|NCT05293808|Drug|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
79647529|NCT00184262|Behavioral|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
79325194|NCT05293808|Drug|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
79325195|NCT05293808|Drug|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
79647530|NCT00217386|Biological|anti-thymocyte globulin|
79647531|NCT00217386|Biological|etanercept|
79647532|NCT00184301|Behavioral|inpatient treatment|inpatient treatment during 1 year
79647533|NCT00184301|Behavioral|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
79325196|NCT05292443|Other|Observation|observe the association of ctDNA with efficacy of treatment
79325197|NCT05290129|Drug|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
79325198|NCT05289167|Drug|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
79325199|NCT05289167|Drug|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
79325200|NCT05289167|Drug|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
79647534|NCT00184340|Device|eTherapy|secured e-mail system between patient and therapist
79647535|NCT00217503|Biological|bevacizumab|
79647536|NCT00217503|Biological|filgrastim|
79647537|NCT00217503|Biological|pegfilgrastim|
79647538|NCT00217503|Drug|bortezomib|
79647539|NCT00217503|Drug|cyclophosphamide|
79647540|NCT00217503|Drug|doxorubicin hydrochloride|
79647541|NCT00217503|Drug|etoposide|
79647542|NCT00217503|Drug|ganciclovir|
79647543|NCT00217503|Drug|valganciclovir|
79647544|NCT00217503|Drug|zidovudine|
79325201|NCT05287113|Drug|Retifanlimab|Retifanlimab 500mg will be administered intravenously every 4 weeks.
79325202|NCT05287113|Drug|INCAGN02385|INCAGN02385 350mg will be administered intravenously every 2 weeks.
79325203|NCT05287113|Drug|INCAGN02390|INCAGN02390 400 mg will be administered intravenously every 2 weeks.
79325204|NCT05287113|Drug|Placebo|Placebo will be administered intravenously.
79325205|NCT05287087|Behavioral|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~A questionnaire including the BDS checklist~A brief introductory animation about how to understand symptoms in general~Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
79325206|NCT05287087|Behavioral|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~A questionnaire including the BDS checklist~A brief introductory animation about how to understand symptoms in general~Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~A brief animation about the interaction of body and mind.~Thorough symptom explanations~Physical energy (focus on sleep, diet and activity)~Values and choices (focus on meaning and existential issues)~Emotional health (focus on emotion regulation)~Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
79325207|NCT05286047|Dietary Supplement|Bifidobacterium longum CCFM1029|Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.
79647545|NCT00184379|Behavioral|Psychoeducation|Structured disorder-related educational program for relatives
79325208|NCT05286047|Dietary Supplement|Placebo|Subjects take one capsule containing maltodextrin daily at bedtime.
79325209|NCT05285982|Drug|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
79325210|NCT05281640|Behavioral|Affect Dysregulation intervention|See relevant study arm for description
79325211|NCT05281640|Behavioral|Negative Self Concept intervention|See relevant study arm for description
79325212|NCT05281640|Behavioral|Disturbed Relationships intervention|See relevant study arm for description
79481367|NCT05093582|Drug|Levcromakalim|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
79647546|NCT00210678|Behavioral|No intervention|No treatment is given to the patients as this is an observational study.
79325213|NCT05263388|Drug|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.
79325214|NCT05263388|Other|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
79325215|NCT05248165|Device|PCI|Percutaneous coronary intervention
79325216|NCT05240638|Device|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
79325217|NCT05235555|Device|Transcatheter heart valve (THV) with CE approval|TAVI trough femoral access or alternative routes
79810174|NCT02632656|Other|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
79325218|NCT05232071|Drug|IVA337|800 mg
79325219|NCT05232071|Drug|Placebo|Placebo to match
79325220|NCT05232071|Drug|Empagliflozin|10 mg
79481368|NCT05093582|Drug|Saline|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
79647547|NCT00217542|Biological|recombinant interferon alfa-2b|Given SC
79647548|NCT00217542|Drug|amifostine/azacitidine|Given SC
79647549|NCT00184457|Behavioral|Strength training intervention|
79647550|NCT00210717|Drug|paliperidone palmitate|
79647551|NCT00184496|Drug|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
79647552|NCT00210756|Drug|epoetin alfa|
79647553|NCT00217659|Drug|anastrozole|
79647554|NCT00217659|Drug|goserelin acetate|
79647555|NCT00184574|Drug|biphasic insulin aspart|
79647556|NCT00184574|Drug|metformin|
79647557|NCT00210795|Drug|epoetin alfa|
79647558|NCT00408980|Behavioral|Fat and calorie controlled diet|
79647559|NCT00217698|Drug|cisplatin|
79810175|NCT02565628|Drug|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
79325221|NCT05230082|Other|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
79647560|NCT00217698|Drug|gefitinib|
79810176|NCT02565628|Drug|Placebo|Placebo
79647561|NCT00217698|Drug|gemcitabine hydrochloride|
79307131|NCT05237492|Drug|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
79307132|NCT05236764|Device|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
79647562|NCT00184613|Device|pump|
79647563|NCT00184613|Drug|insulin glargine|
79647564|NCT00184613|Drug|insulin aspart|
79647565|NCT00217776|Behavioral|Open Airways Educational Intervention|
79647566|NCT00217776|Behavioral|Peer Asthma Action Educational Intervention|
79647567|NCT00210834|Drug|epoetin alfa|
79307133|NCT05231954|Other|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
79307134|NCT05222906|Drug|Venglustat|tablet; oral
79810177|NCT02540993|Drug|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to < 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
79307135|NCT05222906|Drug|imiglucerase|sterile lyophilized product; intravenous
79307136|NCT05215314|Behavioral|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
79307137|NCT05212168|Biological|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
79810178|NCT02540993|Drug|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
79810179|NCT02519621|Device|NPWT PRO without irrigation|NPWT PRO without irrigation.
79810180|NCT02519621|Device|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
79810181|NCT02519621|Device|KCI Ulta|KCI Ulta NPWT without irrigation
79810182|NCT02501538|Device|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
79307138|NCT05212168|Other|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
79307139|NCT05212168|Biological|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
79325222|NCT05227703|Drug|CVL-231 15 mg|CVL-231 15 mg, oral (tablet), once per day for 6 weeks
79481369|NCT05090384|Drug|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
79325223|NCT05227703|Drug|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
79481370|NCT05090215|Behavioral|Aerobic and resistance training 12 week exercise programme|See arm/group description
79481371|NCT05090215|Diagnostic Test|Venous blood sampling|full blood count, urea & electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.
79647568|NCT00184652|Drug|somatropin|
79810183|NCT02486640|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
79810184|NCT02486640|Device|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
79810185|NCT02463500|Other|DFU|Standard care.
79810186|NCT02463487|Device|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
79810187|NCT02463487|Device|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
79810188|NCT02449239|Biological|Vicinium|Intravesical administration
79325224|NCT05227703|Drug|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
79325225|NCT05227690|Drug|CVL-231 10 mg|CVL-231 10 mg, oral (tablet), once per day for 6 weeks
79325226|NCT05227690|Drug|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
79325227|NCT05227690|Drug|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
79810189|NCT02330991|Drug|Temozolomide|
79810190|NCT02106858|Drug|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
79810191|NCT01582737|Drug|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
79810192|NCT01463891|Drug|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
79325228|NCT05222022|Device|Retitrack|Retitrack device measures and analyzes eye movement
79325229|NCT05213208|Drug|Propofol|Using > 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
79325230|NCT05193929|Device|OptiPulse™|TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait
79325231|NCT05193929|Device|Standard of Care offloading device|CAM boot
79325232|NCT05192889|Drug|Venetoclax|Given oral (PO).
79325233|NCT05192889|Drug|Navitoclax|Given oral (PO).
79325234|NCT05192889|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
79325235|NCT05192889|Drug|Vincristine|Given intravenously (IV).
79325236|NCT05192889|Drug|Calaspargase Pegol|Given intravenously (IV).
79481372|NCT05090215|Diagnostic Test|Muscle Ultrasound|Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)
79481373|NCT05090215|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET
79481374|NCT05090215|Behavioral|Quality of life questionnaire completion|The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
79647569|NCT00217815|Drug|Mycograb, Docetaxel|
79647570|NCT00184691|Drug|somatropin|
79977728|NCT05653258|Other|Lifestyle Intervention|"Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines."
79325237|NCT05192889|Drug|Dasatinib|Given oral (PO).
79325238|NCT05192889|Drug|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
79325239|NCT05192889|Biological|Blinatumomab|Given intravenously (IV).
79325240|NCT05192889|Drug|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
79325241|NCT05192889|Drug|Mercaptopurine|Given oral (PO).
79325242|NCT05192889|Drug|Cyclophosphamide|Given intravenously (IV).
79325243|NCT05192889|Drug|Etoposide|Given intravenously (IV).
79325244|NCT05192889|Drug|Leucovorin|Given oral (PO) or intravenously (IV).
79325245|NCT05192889|Drug|Intrathecal Triples|Given Intrathecal (IT).
79325246|NCT05192889|Drug|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
79325247|NCT05192889|Drug|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
79325248|NCT05192889|Radiation|Radiation|See detailed description section.
79325249|NCT05183035|Drug|Fludarabine|Intravenous (IV) infusion
79325250|NCT05183035|Drug|Cytarabine|Intravenous (IV) infusion
79325251|NCT05183035|Drug|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
79325252|NCT05183035|Drug|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
79325253|NCT05183035|Drug|Venetoclax|Orally via tablet or powder suspension
79325254|NCT05161481|Drug|Avenciguat (BI 685509)|Avenciguat (BI 685509)
79325255|NCT05161481|Drug|Placebo matching Avenciguat (BI 685509)|Placebo matching Avenciguat (BI 685509)
79810193|NCT01321567|Drug|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
79977729|NCT05653258|Drug|Dasatinib 100 MG|100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
79325257|NCT05156060|Drug|Gabapentin|Taken by mouth 3 times per day
79325258|NCT05156060|Drug|Ketamine|Administered intranasally 3 times per day
79325259|NCT05155189|Biological|TC-CAR031|Targeting GPC3 armored CART cell injection (C-CAR031)
79481375|NCT05085405|Behavioral|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
79481376|NCT05085405|Behavioral|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
79481377|NCT05085405|Behavioral|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
79810194|NCT01292928|Device|Stent implantation|Stent implantation during the index procedure.
79810195|NCT01290445|Drug|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
79810196|NCT01290445|Behavioral|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
79810197|NCT01290445|Other|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
79977730|NCT05653258|Drug|Quercetin 1000mg|Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
79977731|NCT05653258|Drug|Placebo|Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
79325260|NCT05155189|Drug|Lenvatinib|Tyrosine kinase inhibitors
79325261|NCT05155189|Drug|PD-1(L1) monoclonal antibody|Immune checkpoint inhibitors, ICIs
79307169|NCT05127161|Behavioral|Broad Implementation of Outpatient Stewardship (BIOS) intervention|The BIOS intervention consists of 3 components: (1) online educational modules covering topics related to appropriate antibiotic prescribing for ARTIs, (2) individualized audit and feedback reports displaying clinicians' rates of antibiotic prescription with peer comparison, (3) facilitation provided by the study team and by health system champions to support effective implementation of the intervention and to encourage clinicians to engage meaningfully in the intervention activities.
79307170|NCT05126966|Drug|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
79307171|NCT05126966|Drug|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
79307172|NCT05126966|Device|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
79977732|NCT05653258|Procedure|Abdominal adipose tissue biopsy|All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
79977733|NCT05653011|Other|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
79977734|NCT05652699|Other|High Flow Nasal Oxygen|Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
79977735|NCT05652699|Other|Conventional Oxygen Therapy|Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
79977736|NCT05650879|Drug|ELVN-002|capsule
79307173|NCT05123365|Drug|N-Acetylcysteine|Given PO
79307174|NCT05116085|Drug|Tislelizumab|Administered intravenously
79307175|NCT05113927|Device|Selene|SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
79307176|NCT05113745|Drug|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
79307177|NCT05113745|Drug|Placebo|Placebo tablets, taken twice daily
79307178|NCT05112484|Diagnostic Test|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
79307179|NCT05112484|Diagnostic Test|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
79307180|NCT05112484|Diagnostic Test|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
79307181|NCT05112484|Other|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
79307182|NCT05105971|Drug|BAT6026|Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
79307183|NCT05105308|Behavioral|Family Assisted Diet (FAD)|A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
79307184|NCT05105308|Behavioral|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
79307185|NCT05104697|Device|Transcranial Magnetic Stimulation|All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
79307186|NCT05091307|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
79307187|NCT05091307|Other|Placebo|Placebo will be administered as an IM injection.
79307188|NCT05091307|Biological|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
79307189|NCT05087992|Drug|BI 905711|BI 905711
79307190|NCT05087992|Drug|FOLFIRI|FOLFIRI
79307191|NCT05087992|Drug|Bevacizumab|Bevacizumab
79307192|NCT05084677|Combination Product|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
79647571|NCT04722471|Drug|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
79325262|NCT05153395|Other|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
79977737|NCT05650879|Drug|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
79977738|NCT05650879|Drug|Trastuzumab emtansine|intravenous
79325263|NCT05153395|Other|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
79325264|NCT05153395|Drug|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
79307193|NCT05082116|Drug|turoctocog alfa pegol (N8-GP)|N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
79647572|NCT00184730|Drug|somatropin|
79647573|NCT00210873|Drug|topiramate|
79977739|NCT05650255|Other|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
79977740|NCT05647122|Drug|AZD9592|Varying doses of AZD9592
79977741|NCT05647122|Drug|Osimertinib|tablets administered orally
79977742|NCT05647122|Drug|5-Fluorouracil (5-FU)|IV infusion
79977743|NCT05647122|Drug|Leucovorin|IV infusion
79977744|NCT05647122|Drug|Bevacizumab|IV infusion
79977745|NCT05645757|Drug|Ertapenem|A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
79977746|NCT05645757|Other|Placebo|Placebo
79307194|NCT05082025|Drug|Copanlisib|Given by IV
79307195|NCT05082025|Drug|fulvestrant|Given by IM
79307196|NCT05074537|Diagnostic Test|MRI exam|Participants who are receiving standard of care or investigational MRI exams at the Wright Center will be eligible for enrollment in this data bank.
79307197|NCT05074537|Diagnostic Test|PET/CT imaging exam|Participants who are receiving standard of care or investigational PET/CT exams at the Wright Center will be eligible for enrollment in this data bank.
79307198|NCT05074537|Diagnostic Test|CT imaging exam|Participants who are receiving standard of care or investigational CT exams at the Wright Center will be eligible for enrollment in this data bank.
79307199|NCT05063994|Drug|Chronocort|Over-encapsulated hydrocortisone modified-release capsules for oral administration - 5mg and 10mg
79307200|NCT05063994|Drug|Cortef|Over-encapsulated immediate-release hydrocortisone capsules for oral administration - 5mg and 20mg
79307201|NCT05058612|Drug|Midodrine|10 mg PO/NG q8h
79307202|NCT05058612|Drug|Placebo|Microcrystalline cellulose PO/NG 18h
79307203|NCT05037617|Drug|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be >= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
79307204|NCT05035732|Radiation|18F-fluciclovine|IV
79325265|NCT05152615|Dietary Supplement|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
79325266|NCT05144750|Behavioral|Fruit and Vegetable Prescription|"The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips."
79325267|NCT05143671|Procedure|Coronary artery bypass grafting|Coronary artery bypass grafting in coronary revascularization.
79325268|NCT05143671|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention in coronary revascularization.
79325269|NCT05143671|Procedure|Surgical valve replacement|Surgical mitral and / or aortic valve replacement.
79325270|NCT05143671|Procedure|Carotid artery stenting|Carotid artery stenting.
79977747|NCT05645757|Drug|WCK 6777|A combination of ertapenem (ERT) and zidebactam (ZID)
79481378|NCT05085405|Behavioral|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
79325271|NCT05139173|Device|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
79481379|NCT05082688|Biological|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
79481380|NCT05082688|Biological|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
79481381|NCT05082688|Biological|Placebo|0.9% NaCl
79325272|NCT05135559|Drug|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
79325273|NCT05131477|Drug|KY1005|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79325274|NCT05131477|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79481382|NCT05062915|Diagnostic Test|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
79481383|NCT05046158|Device|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
79481384|NCT05046158|Other|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
79647574|NCT00184769|Drug|somatropin|
79977748|NCT05645757|Drug|Zidebactam|A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
79977749|NCT05638867|Drug|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
79977750|NCT05638867|Drug|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
79977751|NCT05638087|Drug|Dexamethasone|Dexamethasone Oral Suspension
79481385|NCT05045703|Dietary Supplement|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
79481386|NCT05041478|Procedure|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
79481387|NCT05041478|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
79481388|NCT05033392|Drug|Toripalimab Injection|A domestic PD-1 antibody
79977752|NCT05638087|Drug|Placebo Control|Placebo Oral Mix
79977753|NCT05637476|Other|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~Pelvic drop.~Single leg -bridge.~Side-lying hip abduction with hip internal rotation.~Lateral step-up.~Standing hip abduction on stance or swing leg with extra resistance ."
79977754|NCT05637476|Other|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~Strength dorsiflexors of the ankle-using rubber band.~Eccentric calf exercise (calf raise) .~Balance and proprioceptive exercise using wobble boards.~Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
79481389|NCT05029414|Procedure|Endovascular Therapy|Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
79481390|NCT05018078|Biological|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
79977755|NCT05635084|Drug|YN001|Dose ranges from 2-90mg
79977756|NCT05635084|Drug|Placebo for YN001|5% dextrose injection to mimic the YN001
79977757|NCT05634343|Other|Laughter Therapy|"Laughter Therapy, also called therapeutic laughter; It is a kind of exercise that combines unconditional laughter and breathing techniques to reduce pain and stress and to give the individual a general sense of well-being. Laughter therapy is a method of simply laughing for no reason in which the person interacts in a group setting with improvisational or pantomime-like exercises and childlike play without humor, jokes or funny incidents. Thus, it is aimed to benefit from laughter."
79481391|NCT05008757|Other|no drug|no intervention
79647575|NCT00217854|Procedure|Bronchoscopic|Bronchoscopic procedure
79647576|NCT00210912|Drug|topiramate|
79325275|NCT05128513|Device|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
79325276|NCT05128500|Procedure|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
79325277|NCT05124873|Device|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
79325278|NCT05124249|Diagnostic Test|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
79481392|NCT05007730|Dietary Supplement|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
79481393|NCT05005728|Combination Product|vudalimab + carboplatin + cabazitaxel or docetaxel|Vudalimab IV, carboplatin IV, cabazitaxel or docetaxel IV
79481394|NCT05005728|Combination Product|vudalimab + olaparib|Vudalimab IV, olaparib oral
79481395|NCT05005728|Biological|vudalimab monotherapy|Vudalimab IV
79481396|NCT05005728|Combination Product|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
79810198|NCT01251718|Drug|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
79977758|NCT05634343|Other|Mindfulness|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
79481397|NCT05002660|Behavioral|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
79481398|NCT05002660|Behavioral|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
79481399|NCT04990037|Drug|CAN04|Administered intravenously
79481400|NCT04990037|Drug|FOLFIRINOX|Administered intravenously
79481401|NCT04985812|Drug|JNJ-67484703|Participants will receive JNJ-67484703.
79481402|NCT04985812|Drug|Placebo|Participants will receive placebo to JNJ-67484703.
79481403|NCT04980092|Other|one-year follow-up|patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health
79810199|NCT01194817|Device|High-Flexion Knee Replacement System using Cemented Fixation|
79810200|NCT01194817|Device|High-Flexion Knee Replacement System using Cementless Fixation|
79810201|NCT00925431|Behavioral|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
79647577|NCT00184847|Drug|acetylcholine|
79810202|NCT00925431|Behavioral|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
79810203|NCT00664456|Drug|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
79810204|NCT00664456|Drug|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
79977759|NCT05630144|Behavioral|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
79325279|NCT05124249|Procedure|PCI|Patients who undergoing PCI
79325280|NCT05116787|Drug|BCX9930 monotherapy|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
79481404|NCT04978116|Diagnostic Test|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
79977760|NCT05630001|Drug|Iptacopan|Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
79810205|NCT00664456|Radiation|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
79977761|NCT05629429|Drug|Olaparib|Olaparib 300mg BID PO
79481405|NCT04978116|Diagnostic Test|Low-dose CT scan (LDCT)|See above in CXR paragraph
79810206|NCT00581828|Drug|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
79977762|NCT05629429|Drug|Chemotherapy drug|Continue platinum based chemotherapy
79977763|NCT05629052|Procedure|Pulmonary endarterectomy|Surgical removal of a chronic clot from the pulmonary artery
79977764|NCT05629052|Procedure|Balloon pulmonary angioplasty|Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon
79977765|NCT05629052|Drug|Pulmonary hypertension (PH)-specific medication|Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
79977766|NCT05626777|Drug|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
79977767|NCT05626777|Drug|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
79325281|NCT05116787|Drug|Placebo|Administered orally twice daily
79325282|NCT05116774|Drug|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
79325283|NCT05116774|Drug|Eculizumab|Administered by intravenous infusion per current dose regimen
79325284|NCT05116774|Drug|Ravulizumab|Administered as intravenous infusion per current dose regimen
79810207|NCT00380861|Device|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
79810208|NCT00380861|Device|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
79810209|NCT00220337|Drug|Lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
79810210|NCT02608125|Drug|PRN1371|
79977768|NCT05613751|Behavioral|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
79977769|NCT05613452|Radiation|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
79325285|NCT05113303|Device|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
79481406|NCT04978116|Diagnostic Test|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
79810211|NCT00576316|Drug|Symbicort Turbuhaler 160/4.5|
79810212|NCT05421156|Procedure|Subtotal Laparoscopic Hysterectomy|Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
79810213|NCT05421156|Procedure|Total Laparoscopic Hysterectomy|Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
79810214|NCT00745810|Other|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
79810215|NCT00823134|Device|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
79810216|NCT00745888|Other|Chemiluminescence Analyzer|measure reactive oxygen species
79325286|NCT05113303|Device|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
79325287|NCT05101551|Drug|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~Dose Level 1: 400 µg/m2/dose once daily~Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
79481407|NCT04961944|Other|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
79810217|NCT00755872|Drug|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
79810218|NCT00755872|Drug|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
79810219|NCT00755872|Drug|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
79481408|NCT04959474|Other|Best Practice|Given standard dietary recommendations
79481409|NCT04959474|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
79810220|NCT00755872|Drug|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
79325288|NCT05101551|Drug|Topotecan|"Administered IV route on Days 1 to 5~Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
79325289|NCT05101551|Drug|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~Dose Level -2: 600 mg/m2/dose once daily by IV days 1~Dose Level -1: 600 mg/m2/dose once daily by IV days 1~Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
79325290|NCT05097989|Drug|ALXN2050|Oral tablets
79481410|NCT04959474|Procedure|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
79325291|NCT05097989|Drug|Placebo|Oral tablets
79977770|NCT05607992|Behavioral|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
79325292|NCT05096338|Other|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
79325293|NCT05092139|Device|endovascular treatment|all enrolled patients must receive endovascular treatment
79481411|NCT04959474|Other|Questionnaire Administration|Ancillary studies
79481412|NCT04959474|Other|Quality-of-Life Assessment|Ancillary studies
79481413|NCT04959474|Procedure|Resection|Undergo surgical resection
79481414|NCT04959474|Other|Dietary Intervention|Undergo a caloric restriction diet
79977771|NCT05606991|Other|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
79977772|NCT05605535|Biological|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
79325294|NCT05090085|Other|3M Adper Single Bond2|Two-step etch and rinse dental adhesive system
79325295|NCT05090085|Other|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
79325296|NCT05090085|Other|3m ESPE etch|32% phosphoric acid
79325297|NCT05090085|Other|OT Primer|Dimethyl Sulfoxide DMSO [(CH3)2SO] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
79325298|NCT05085067|Other|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
79325299|NCT05078593|Drug|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
79325300|NCT05078190|Other|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
79325301|NCT05070858|Drug|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
79325302|NCT05070858|Drug|Cemdisiran|SC administration as described in the protocol
79325303|NCT05070858|Other|Placebo|SC administration as described in the protocol
79325304|NCT05070858|Drug|Pozelimab|SC administration as described in the protocol
79325305|NCT05069766|Other|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
79325306|NCT05062590|Other|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
79481415|NCT04956354|Device|ANNE™ Monitoring System (2 sensors) - version B|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Chest and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - A chest unit (ANNE™ Chest) with embedded battery, sensors, and a three-axis accelerometer that captures the following signals: electrocardiography (ECG), temperature, seismocardiography (SCG) and the chest wall movements.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
79325307|NCT05059327|Drug|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
79325308|NCT05059327|Drug|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
79647578|NCT00184847|Procedure|twenty minutes of forearm ischemia|
79647579|NCT00184847|Procedure|three 5-minute periods of forearm ischemia|
79647580|NCT00184847|Drug|adenosine|
79647581|NCT00184847|Drug|caffeine|
79810221|NCT00755950|Dietary Supplement|Silymarin|280 mg three times daily for four weeks
79810222|NCT00755950|Dietary Supplement|Silymarin|420 mg three times daily for four weeks
79810223|NCT00755950|Other|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
79977773|NCT05605535|Drug|Paclitaxel|175 mg/m^2, every 3 weeks
79977774|NCT05605535|Drug|Carboplatin|AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
79325309|NCT05056077|Other|Counseling|Receive support person coaching
79325310|NCT05056077|Other|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with a history of cancer
79325311|NCT05056077|Behavioral|Health Education|Receive health coaching
79325312|NCT05056077|Other|Health Promotion and Education - Direct Text Messaging|Receive text messages
79325313|NCT05056077|Other|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
79647582|NCT00217893|Behavioral|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
79647583|NCT00217893|Behavioral|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
79977775|NCT05605535|Biological|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
79977776|NCT05605522|Drug|[225]-FPI-2059|"[225Ac]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, [225Ac]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation."
79325314|NCT05056077|Other|Questionnaires|Quality of Life and Behavioral Questionnaires
79325315|NCT05051124|Behavioral|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
79810224|NCT00756028|Drug|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
79810225|NCT00756028|Drug|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
79810226|NCT02560948|Biological|Placebo solution|4 x 2 injections over 21 days
79810227|NCT02560948|Biological|gpASIT+TM|4 x 2 injections over 21 days
79325316|NCT05051124|Behavioral|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
79325317|NCT05046275|Other|Data analysis|No intervention, data analysis only
79325318|NCT05043649|Drug|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
79325319|NCT05038150|Drug|SGN1|The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
79325320|NCT05030584|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
79325321|NCT05030584|Drug|Placebo|Matching placebo orally once daily.
79325322|NCT05014412|Drug|Elranatamab|BCMA-CD3 bispecific antibody
79325323|NCT05013879|Device|Kinesio(R)Tape for edema control|Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
79325324|NCT05013229|Drug|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
79481416|NCT04956354|Device|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
79325325|NCT05013229|Drug|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
79325326|NCT05013229|Drug|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
79325327|NCT05007782|Drug|GS-1811|Administered intravenously
79325328|NCT05007782|Drug|Zimberelimab|Administered intravenously
79325329|NCT04991935|Drug|CC-93538|CC-93538
79325330|NCT04982848|Drug|Talzenna|Talzenna treatment under Korea regulatory approval indication/dosage
79325331|NCT04976322|Drug|Dapirolizumab pegol|Subjects will receive dapirolizumab pegol at prespecified time-points.
79325332|NCT04974528|Biological|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
79647584|NCT00217893|Behavioral|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
79325333|NCT04974528|Biological|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
79325334|NCT04974528|Biological|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79325335|NCT04966715|Procedure|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
79325336|NCT04964934|Drug|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
79325337|NCT04964934|Drug|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
79325338|NCT04964934|Drug|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
79325339|NCT04964934|Drug|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
79325340|NCT04964934|Drug|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
79325341|NCT04964934|Drug|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
79325342|NCT04964934|Drug|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
79325343|NCT04964934|Drug|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
79325344|NCT04964934|Drug|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
79325345|NCT04964934|Drug|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
79325346|NCT04957719|Combination Product|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
79325347|NCT04957719|Combination Product|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
79325348|NCT04950712|Procedure|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
79325349|NCT04950712|Procedure|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
79325350|NCT04946032|Other|Epidural catheter|The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
79325351|NCT04939506|Behavioral|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
79325352|NCT04937751|Diagnostic Test|biomarkers|galactomannan, betaDglucan, resistance markers
79647585|NCT00217893|Behavioral|Usual education program|Participants will receive the usual education about ETS.
79647586|NCT00184886|Drug|Methotrexate 15 mg/week for 12 weeks|
79325353|NCT04935177|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
79325354|NCT04935177|Procedure|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
79325355|NCT04935177|Drug|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
79325356|NCT04935177|Drug|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
79325357|NCT04935177|Drug|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
79647587|NCT00210951|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
79647588|NCT00184925|Procedure|Tracheostomy|trachesotomy with subglottic drainage
79647589|NCT00184925|Device|cannula with subglottic drainage|
79647590|NCT00217932|Drug|Divalproex Sodium (Depakote)|
79647591|NCT00184964|Procedure|CT-scan, PET-scan|
79647592|NCT00210990|Drug|doripenem|
79647593|NCT00185003|Drug|endotoxin|
79647594|NCT00185003|Drug|Potassium channel blockers: TEA, Quinin, Tolbutamide|
79647595|NCT00185003|Drug|L-NMMA|
79647596|NCT00185042|Drug|Pactimibe, CS-505|
79647597|NCT00185081|Drug|Indium labeled IMP-205xm734|
79647598|NCT00185120|Drug|Olmesartan medoxomil|
79977777|NCT05605522|Drug|[111In]-FPI-2058|[111In]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive [111In]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
79325358|NCT04935177|Other|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
79810228|NCT02560090|Behavioral|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
79810229|NCT02560090|Behavioral|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
79810230|NCT02560090|Behavioral|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
79977778|NCT05604547|Diagnostic Test|Non-Invasive Infrared Spectroscopy|NIRS is a non-Invasive optical technique for characterizing microvascular hemodynamics.
79977779|NCT05603182|Drug|PRA052|PRA052
79810231|NCT00831792|Drug|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
79977780|NCT05603182|Other|Placebo|Placebo
79977781|NCT05603052|Biological|EuCorVac-19|COVID-19 vaccine
79977782|NCT05603052|Biological|ChAdOx1 nCoV-19|COVID-19 vaccine
79977783|NCT05602142|Drug|[11C]CPPC PET ligand|Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
79977784|NCT05599490|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
79977785|NCT05598515|Behavioral|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
79810232|NCT00705354|Drug|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
79325365|NCT04927481|Drug|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
79325366|NCT04925284|Drug|XB002|IV administration of XB002
79325367|NCT04925284|Drug|Nivolumab|IV administration of Nivolumab
79810233|NCT00705354|Procedure|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
79810234|NCT00575380|Drug|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
79325370|NCT04914286|Drug|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
79325371|NCT04914286|Drug|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
79647599|NCT00185120|Drug|Hydroclorothiazide|
79647600|NCT00185120|Drug|Benazepril|
79647601|NCT00185120|Drug|Amlodipine|
79647602|NCT00218049|Drug|GBR 12909|50mg GBR 12909 over 12 days
79977786|NCT05598385|Procedure|Open cannulation|A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.
79977787|NCT05598385|Procedure|Percutaneous cannulation|Cannulation is performed through a suture-mediated closure system.
79977788|NCT05595850|Behavioral|Mindfulness|Online non-meditation mindfulness program
79977789|NCT05595850|Behavioral|Mindful Learning|Online learning program
79977790|NCT05595200|Diagnostic Test|Level III portable sleep study|Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
79977791|NCT05593926|Dietary Supplement|Myota Metabolic Regulator|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
79977792|NCT05593328|Drug|Onvansertib|Oral capsule
79647603|NCT00218049|Drug|GBR 12909|GBR 12909 75 mg over 12 day period
79647604|NCT00218049|Drug|GBR 12909|GBR 12909 100 mg over 12 day period
79647605|NCT00211068|Drug|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
79977793|NCT05593328|Drug|FOLFIRI|FOLFIRI (irinotecan + fluorouracil [5-FU] + leucovorin) as intravenous (IV) infusion
79977794|NCT05593328|Drug|Bevacizumab|IV infusion
79977795|NCT05590208|Procedure|sleeve gastrectomy+ cruroplasty+ omental rap|sleeve gastrectomy+ cruroplasty+ omental rap
79977796|NCT05584540|Behavioral|UNTIRE App|Digital therapeutic application
79977797|NCT05582590|Drug|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
79977798|NCT05582590|Drug|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
79977799|NCT05582590|Biological|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
79977800|NCT05581745|Procedure|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
79977801|NCT05581043|Dietary Supplement|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
79977802|NCT05580718|Behavioral|MI-CBT|"Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
79977803|NCT05580614|Device|Sham|MRI (Magnetic Resonance Imaging) paired ERP/Sham YBOCs(Yale-Brown Obsessive Compulsive Scale) (4,8,12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
79977804|NCT05580614|Device|tVNS|MRI (Magnetic Resonance Imaging) paired ERP/tVNS YBOC's (Yale-Brown Obsessive Compulsive Scale) (4, 8, 12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
79481417|NCT04956354|Device|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
79977805|NCT05579366|Drug|PRO1184|Intravenous infusion of PRO1184
79977806|NCT05578885|Procedure|Bier block|patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
79325372|NCT04894435|Biological|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
79325373|NCT04894435|Biological|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
79325374|NCT04894435|Biological|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
79325375|NCT04894435|Other|0, 28 day schedule|Second injection administered 28 days post first injection
79977807|NCT05578417|Other|No Intervention|As this is an observational study, no intervention will be administered.
79325376|NCT04894435|Other|0, 112 day schedule|Second injection administered 112 days post first injection
79481418|NCT04953143|Behavioral|LiverPal Intervention|"Inpatient longitudinal palliative care intervention~- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~Therapeutic relationship~Symptom management~Coping with illness~Prognostic awareness and illness understanding~Treatment decision-making~End-of-life care"
79810235|NCT00575380|Drug|Vigamox Eye Drops|One drop three times a day for seven days
79325377|NCT04894435|Biological|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
79325378|NCT04892043|Biological|SQZ-AAC-HPV|Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16
79481419|NCT04949828|Drug|CREON|Oral Capsules
79481420|NCT04932941|Drug|MP1032|Hard gelatin capsules for oral administration.
79325379|NCT04892043|Drug|Ipilimumab|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
79325380|NCT04892043|Drug|Nivolumab|Programmed cell death 1 (PD-1) blocking antibody
79810236|NCT00840996|Drug|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
79810237|NCT00840996|Drug|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
79325384|NCT04888091|Procedure|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
79325385|NCT04888091|Procedure|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
79325386|NCT04876248|Biological|Belantamab Mafodotin|Given IV
79481421|NCT04932941|Drug|Placebo|Placebo capsules matched to MP1032 for oral administration.
79481422|NCT04927884|Biological|N-803|"Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)"
79325387|NCT04876248|Drug|Lenalidomide|Given PO
79325388|NCT04871893|Device|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
79325389|NCT04853602|Biological|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~Immunomodulatory Agent~Route of Administration:~Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance."
79325390|NCT04853017|Drug|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
79481423|NCT04927884|Biological|PD-L1 t-haNK|"Dose: ~2 × 10^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
79481424|NCT04927884|Drug|Sacituzumab Govitecan-Hziy|"Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
79481425|NCT04927884|Drug|Cyclophosphamide|"Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)"
79481426|NCT04925089|Other|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
79481427|NCT04923958|Diagnostic Test|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
79481428|NCT04923958|Diagnostic Test|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
79325391|NCT04852432|Device|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
79977808|NCT05576883|Behavioral|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology [PP], Mindfulness, Acceptance and Commitment Therapy [ACT], Breathing and relaxation, and Self-compassion [SC].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills [i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
79977809|NCT05575011|Drug|BIIB115|Administered as specified in the treatment arm
79325392|NCT04852432|Device|nasal prong|Oxygen is administered via nasal prong
79810238|NCT02559934|Drug|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
79810239|NCT00756184|Device|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
79810240|NCT00756184|Device|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
79810241|NCT00756340|Drug|Bevacizumab|"Bevacizumab IV every 2 weeks~Dose Level 0- 8 mg/kg~Dose Level 1 (starting dose)- 10 mg/kg~Dose Level 2- 10 mg/kg"
79977810|NCT05575011|Drug|BIIB115-Matching Placebo|Administered as specified in the treatment arm
79977811|NCT05574010|Drug|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
79977812|NCT05574010|Drug|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
79977813|NCT05574010|Other|Placebo: Group 1 in Part B|Placebo Intravenous (IV) infusion
79977814|NCT05574010|Drug|Group 2 in Part B|Dose 3 KAN-101 Intravenous (IV) infusion
79325401|NCT04837716|Biological|Bevacizumab|Given IV
79325402|NCT04837716|Drug|Carboplatin|Given IV
79325403|NCT04837716|Drug|Ensartinib|Given PO
79325404|NCT04837716|Drug|Pemetrexed|Given IV
79481429|NCT04923958|Diagnostic Test|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
79647606|NCT00185159|Drug|Olmesartan medoxomil|tablets
79647607|NCT00185159|Drug|Placebo Tablets|Tablets
79977815|NCT05574010|Drug|Group 3 in Part B|Dose 4 KAN-101 Intravenous (IV) infusion
79481430|NCT04923958|Diagnostic Test|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
79481431|NCT04923958|Diagnostic Test|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
79481432|NCT04923958|Diagnostic Test|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
79977816|NCT05574010|Drug|Group 4 in Part B|Dose 5 KAN-101 Intravenous (IV) infusion
79325405|NCT04833829|Behavioral|CHIMES Intervention|"There are six components to the intervention:~Posters and other print materials to prompt providers and patients to discuss MH care engagement.~Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~Expanded MH screening procedures, including at initial intake.~Case management, emphasizing MH care engagement.~Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~Regular case review meetings."
79481433|NCT04923958|Diagnostic Test|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
79481434|NCT04923958|Diagnostic Test|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
79481435|NCT04923958|Diagnostic Test|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
79325406|NCT04833829|Behavioral|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
79481436|NCT04923958|Diagnostic Test|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
79481437|NCT04923958|Diagnostic Test|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
79481438|NCT04901572|Diagnostic Test|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
79481439|NCT04894708|Procedure|colonoscopy|addition of polyp detection algorithm by Fujifilm
79810242|NCT00756340|Drug|Everolimus|"Everolimus~Dose Level 0- 4 mg/m2~Dose level 1 (starting dose)- 4 mg/m2~Dose Level 2- 5 mg/m2"
79977817|NCT05573724|Drug|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
79325407|NCT04826250|Procedure|Timing of medication|Either morning or nighttime medication
79325408|NCT04820257|Behavioral|Home based exercise|Exercise at home and behavioural change to increase daily exercise
79481440|NCT04881058|Device|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
79481441|NCT04875884|Device|Modified MRI|A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
79481442|NCT04870918|Behavioral|self-care intervention|Health education will be carried out by the nurse.
79481443|NCT04868773|Drug|Cabozantinib|Oral cabozantinib
79481444|NCT04868773|Drug|TAS-102|Oral TAS-102 (trifluridine and tipiracil)
79481445|NCT04865029|Other|Placebo injection and placebo pill|Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
79481446|NCT04865029|Drug|Estradiol Cypionate 5 mg/ml|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
79810243|NCT00705510|Drug|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
79810244|NCT05434780|Other|Kinesiology taping|Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
79810245|NCT00680914|Biological|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
79481447|NCT04865029|Drug|Progesterone 200 mg Oral Capsule|Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
79481448|NCT04859660|Drug|Tamsulosin|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
79481449|NCT04859660|Drug|Placebo|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
79810246|NCT00680914|Biological|Prevenar|3 doses administered intramuscularly.
79810247|NCT00680914|Biological|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
79810248|NCT00680836|Drug|Placebo|orally two times per day for 14 days
79810249|NCT00680836|Drug|Rifaximin|550 mg orally two times per day for 14 days
79325409|NCT04813055|Procedure|Therapeutic EUS|"EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~EUS-guided pancreatic duct drainage"
79325410|NCT04813055|Procedure|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
79325411|NCT04813055|Procedure|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
79325412|NCT04813055|Procedure|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
79977818|NCT05573724|Drug|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
79325413|NCT04809311|Other|Lifestyle|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
79977819|NCT05573490|Device|Cognitive Training|Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
79977820|NCT05573490|Behavioral|Tai Chi- Qi Gong|Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
79977821|NCT05573490|Device|Brain Games|Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
79977822|NCT05573490|Behavioral|Stretching|Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
79325414|NCT04809311|Drug|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
79325415|NCT04809311|Drug|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
79325416|NCT04809311|Drug|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
79977823|NCT05570149|Drug|Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution|migraine prophylaxis
79481450|NCT04855708|Other|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
79977824|NCT05567835|Drug|Fluorouracil|2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
79977825|NCT05567835|Drug|Leucovorin|200 mg mg/m2 IV over 2 hours Day 1,15
79977826|NCT05567835|Drug|Oxaliplatin|85 mg/m2 IV over 2 hours Day 1,15
79977827|NCT05567835|Drug|Docetaxel|60 mg/m2 IV over 60 minutes Day 1,15
79977828|NCT05567835|Biological|GSCF|Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
79977829|NCT05565144|Other|None, pure observational study|None, pure observational study
79977830|NCT05562141|Biological|Blood sample|Blood sample before induction, 1h after induction and 24h after the start of procedure
79977831|NCT05560399|Drug|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
79977832|NCT05560399|Drug|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
79481451|NCT04855708|Other|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
79647608|NCT02963636|Other|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
79647609|NCT00218127|Drug|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
79647610|NCT00218127|Drug|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
79647611|NCT00218127|Drug|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
79810250|NCT00753844|Biological|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
79977833|NCT05560399|Drug|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for > 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for > 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
79977834|NCT05559736|Device|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
79977835|NCT05558384|Behavioral|Aerobic Exercise|"A 15-week standardized aerobic exercise intervention.~Frequency: 5 days/wk (2 supervised)~Intensity: 50-59% heart rate reserve~Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)"
79977836|NCT05557331|Device|PIMPmyHospital (mobile app)|After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
79977837|NCT05556967|Dietary Supplement|Immulina|Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
79977838|NCT05555121|Drug|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
79810251|NCT02560168|Device|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
79977839|NCT05553600|Device|Tampon BR|Modified Regular Absorbency Tampons
79647612|NCT00185198|Drug|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
79647613|NCT00185198|Drug|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
79647614|NCT00211107|Drug|Dapoxetine|
79977840|NCT05553600|Device|Tampon CR|Reference Regular Absorbency Tampons
79977841|NCT05553600|Device|Tampon BS|Modified Super Absorbency Tampons
79977842|NCT05553600|Device|Tampon CS|Reference Super Absorbency Tampons
79325417|NCT04809311|Drug|Premixed insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
79810252|NCT02560168|Device|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
79810253|NCT02560168|Device|Transthoracic Echocardiography|
79810254|NCT00754000|Other|Observation|AE monitoring and EPIC QOL survey
79810255|NCT00754078|Radiation|Tomotherapy|30 fractions of tomotherapy treatment
79810256|NCT05428306|Drug|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
79810257|NCT05428306|Drug|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
79810258|NCT05428306|Drug|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
79810259|NCT05424796|Combination Product|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
79977843|NCT05553366|Drug|VX-548|Tablets for oral administration.
79977844|NCT05553366|Drug|HB/APAP|Capsules for oral administration.
79977845|NCT05553366|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
79977846|NCT05553366|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
79977847|NCT05550480|Device|Continuous glucose monitoring|Continuous glucose monitoring for 50 days
79647615|NCT04722198|Dietary Supplement|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (>10 billion CFU/capsule)
79647616|NCT00185237|Drug|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
79810260|NCT05424796|Combination Product|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
79810261|NCT05424796|Device|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
79977848|NCT05547386|Procedure|Computed Tomography|Undergo PET/CT scan
79977849|NCT05547386|Drug|Gallium Ga 68 Gozetotide|Given IV
79977850|NCT05547386|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79325418|NCT04803994|Drug|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
79325419|NCT04803994|Drug|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
79325420|NCT04803994|Procedure|TACE|Locoregional therapy will be performed as a standard-of-care procedure
79325421|NCT04781192|Drug|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks [q4w])
79977851|NCT05541016|Procedure|Biospecimen Collection|Undergo blood specimen collection for NavDx testing
79977852|NCT05541016|Drug|Cisplatin|Given IV
79977853|NCT05541016|Procedure|Computed Tomography|Undergo CT scan
79977854|NCT05541016|Radiation|Diffusing Alpha-emitter Radiation Therapy|Undergo DART
79977855|NCT05541016|Drug|Docetaxel|Given IV
79977856|NCT05541016|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
79977857|NCT05541016|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79977858|NCT05541016|Procedure|Magnetic Resonance Imaging|Undergo MRI
79977859|NCT05541016|Procedure|Modified Barium Swallow Study|Undergo MBSS
79977860|NCT05541016|Other|Observation|Undergo observation
79977861|NCT05541016|Procedure|Positron Emission Tomography|Undergo PET scan
79977862|NCT05541016|Other|Quality-of-Life Assessment|Ancillary studies
79481452|NCT04840303|Behavioral|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
79647617|NCT00185237|Drug|Placebo|Placebo patch
79481453|NCT04805957|Dietary Supplement|Sulforaphane|Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
79810262|NCT00757198|Drug|remifentanil|remifentanil infusion
79810263|NCT00757198|Drug|remifentanil|remifentanil infusion
79810264|NCT00757354|Procedure|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
79810265|NCT05421052|Other|Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors
79810266|NCT05418322|Behavioral|Oral Hygiene Intervention|The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
79325422|NCT04781192|Drug|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
79325423|NCT04779242|Drug|Omadacycline|IV for injection, oral tablets
79325424|NCT04779242|Drug|Moxifloxacin|IV solution, oral tablets
79481454|NCT04805892|Diagnostic Test|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
79647618|NCT00411567|Drug|inhaled corticosteroid therapy|
79647619|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
79647620|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
79647621|NCT00218166|Drug|GABA Agonists|GABA drugs administered acutely by mouth
79647622|NCT00185315|Drug|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
79810267|NCT00921778|Device|Lapcone|Use of Lapcone during LSH
79810268|NCT00921778|Procedure|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
79810269|NCT00757744|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
79810270|NCT00757744|Behavioral|Drug counseling|individual drug counseling
79977863|NCT05541016|Other|Questionnaire|Ancillary studies
79325425|NCT04774887|Biological|HPV vaccine, Merck|Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
79325427|NCT04748445|Diagnostic Test|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
79325428|NCT04742777|Drug|rapamycin|Taken orally 1mg daily for 8 weeks
79977864|NCT05540860|Drug|EDG-5506 Dose 1|EDG-5506 is administered orally once per day
79977865|NCT05540860|Drug|EDG-5506 Dose 2|EDG-5506 is administered orally once per day
79481455|NCT04804579|Behavioral|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
79481456|NCT04801758|Other|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
79481457|NCT04797884|Device|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
79977866|NCT05540860|Drug|EDG-5506 Dose 3|EDG-5506 is administered orally once per day
79325429|NCT04740541|Other|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
79325430|NCT04737720|Drug|Recombinant LCAT|iv infusion
79481458|NCT04797884|Device|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
79481459|NCT04797884|Device|Quality of Life Assessment|Ancillary services
79325431|NCT04731688|Behavioral|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
79481460|NCT04797585|Other|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy
79481461|NCT04797585|Other|Vaginal hysterectomy|Vaginal hysterectomy
79481462|NCT04796779|Device|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
79810271|NCT04052074|Other|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
79977867|NCT05540860|Drug|EDG-5506 Dose 4|EDG-5506 is administered orally once per day
79325432|NCT04721977|Drug|Tucatinib|Tucatinib 300 mg administered BID via oral tablet
79325433|NCT04721977|Biological|Trastuzumab|Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion
79977868|NCT05540860|Drug|EDG-5506 Dose 5|EDG-5506 is administered orally once per day
79977869|NCT05540860|Drug|Placebo|Placebo is administered orally once per day
79325434|NCT04721977|Drug|Capecitabine|Capecitabine 1000 mg/m^2 administered BID via oral tablet
79325435|NCT04720781|Drug|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
79325436|NCT04720781|Drug|Esomeprazole|esomeprazole (20mg/day)
79325437|NCT04718896|Drug|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
79325438|NCT04716881|Drug|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
79325439|NCT04709341|Device|TR Band 60MIN|TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
79325440|NCT04709341|Device|TR Band 120MIN|TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
79325441|NCT04707872|Diagnostic Test|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
79325442|NCT04707872|Diagnostic Test|Prospera|Donor derived cell-free DNA in patient blood
79325443|NCT04707872|Diagnostic Test|HLA antibody|Centralized measurement of HLA antibodies in patient blood
79481463|NCT04796779|Device|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
79481464|NCT04796779|Device|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
79977870|NCT05538572|Drug|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
79977871|NCT05531656|Drug|CT1812|Study Drug
79481465|NCT04793815|Procedure|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
79481466|NCT04793815|Drug|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
79481467|NCT04781816|Drug|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
79481468|NCT04781816|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
79481469|NCT04768920|Behavioral|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 ~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
79481470|NCT04762134|Drug|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
79481471|NCT04758195|Procedure|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
79481472|NCT04758195|Other|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
79481473|NCT04752358|Genetic|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
79481474|NCT04743934|Drug|Flibanserin 100 MG|Flibanserin 100mg tablets taken by mouth daily at bedtime
79481475|NCT04743934|Drug|Placebo|Visually identical placebo tablets taken by mouth daily at bedine
79481476|NCT04743934|Drug|Androgen deprivation therapy|Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
79481477|NCT04736329|Drug|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
79481478|NCT04735068|Drug|Binimetinib Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
79481479|NCT04735068|Drug|Hydroxychloroquine Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
79481480|NCT04721548|Drug|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
79977872|NCT05531656|Drug|Placebo|Non-active study drug
79977873|NCT05526651|Other|true electroacupuncture|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
79481481|NCT04721548|Drug|Placebo|1 mL of solution twice a day.
79481482|NCT04718493|Procedure|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
79481483|NCT04718493|Procedure|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
79647623|NCT00185354|Drug|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
79647624|NCT00185354|Drug|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
79977874|NCT05526651|Other|sham electroacupuncture|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
79977875|NCT05524246|Drug|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
79977876|NCT05523999|Other|Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA|Prospective study within the EMS 95, to evaluate if the maximum delay of 90 seconds between the call to the EMS and the recognition of the cardiac arrest is reached.
79481484|NCT04717089|Other|overnight intensive recovery / extended post anaesthetic care in PACU|From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
79481485|NCT04712799|Drug|Otrivin|oxymetazoline nasal spray
79481486|NCT04712734|Drug|Iloperidone|oral tablet, long-acting injection
79481487|NCT04712474|Behavioral|In-home decluttering practice|"The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments."
79481488|NCT04704648|Procedure|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
79481489|NCT04698343|Device|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
79481490|NCT04687098|Drug|Idarubicin|12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
79810272|NCT04052074|Other|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
79325444|NCT04706026|Other|Open Inguinal Hernia Repair - Local Anesthesia|Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
79810273|NCT04052308|Behavioral|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
79810274|NCT04052308|Behavioral|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
79647625|NCT00185393|Biological|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
79810275|NCT04052308|Behavioral|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
79810276|NCT04052308|Behavioral|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
79810277|NCT04052308|Behavioral|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
79810278|NCT04052308|Behavioral|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
79325445|NCT04706026|Other|Inguinal Hernia Repair - General Anesthesia|General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
79325446|NCT04704258|Procedure|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
79325447|NCT04704258|Device|FLOWer Embolic Protection System|FLOWer Embolic Protection System
79325448|NCT04702880|Biological|BMS-986012|Specified dose on specified days
79325449|NCT04702880|Drug|Carboplatin|Specified dose on specified days
79325450|NCT04702880|Drug|Etoposide|Specified dose on specified days
79325451|NCT04702880|Biological|Nivolumab|Specified dose on specified days
79810279|NCT00679432|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
79325452|NCT04698187|Drug|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
79977877|NCT05521906|Behavioral|Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)|The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
79977878|NCT05516199|Behavioral|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
79977879|NCT05516199|Behavioral|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
79977880|NCT05514574|Other|Music|"hussoni duseni  music"
79977881|NCT05514574|Other|Stress ball|Stress ball squeeze
79647626|NCT00185393|Other|no treatment|no treatment
79647627|NCT00409019|Drug|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
79810280|NCT00679432|Drug|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
79810281|NCT00679432|Drug|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
79810282|NCT00679432|Drug|Placebo|Placebo
79810283|NCT00679432|Drug|Asacol® 400 mg|2400 mg/day, 400 mg tablets
79977882|NCT05514327|Radiation|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
79325453|NCT04698187|Drug|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
79325454|NCT04695197|Drug|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to < 15 20 + 120 15 to < 25 40 + 240 25 to < 35 60 + 360 >=35 80 + 480; Twice daily for 3 days (total, six doses)
79325455|NCT04695197|Drug|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to < 8 60 + 20 8 to <15 120 + 40 15 to <20 180 + 60 20 to <24 kg 180 + 60 24 to <45 360 + 120 45 to <65 540 + 180 >=65 720 + 240; Once-daily for 3 days (total, three doses).
79325456|NCT04678986|Other|ER2|No intervention, data analysis only
79647628|NCT00409019|Drug|Adefovir|
79647629|NCT00409019|Drug|Tenofovir|
79810284|NCT02560870|Drug|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
79810285|NCT02560870|Drug|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
79810286|NCT00679354|Drug|cilengitide|Given IV
79810287|NCT00679354|Other|laboratory biomarker analysis|Correlative studies
79810288|NCT00679354|Other|pharmacological study|Correlative studies
79810289|NCT02559700|Behavioral|Brain training programme|An online package of brain training programmes
79810290|NCT02560714|Device|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
79810291|NCT02560792|Behavioral|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
79810292|NCT02560792|Behavioral|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
79810293|NCT02560792|Behavioral|Control Condition|Participants receive no information about affective response
79977883|NCT05513053|Biological|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
79977884|NCT05509049|Other|Precision nudging|Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
79977885|NCT05509049|Other|Standard of care|Standard of care communication (e.g., personalized letters and patient portal notices)
79977886|NCT05508750|Other|New Infant Formula|New infant formula fed daily ad libitum
79977887|NCT05508750|Other|Commercial Infant Formula|Commercially available infant formula fed daily ad libitum
79325457|NCT04666922|Drug|BI 765080|BI 765080
79325458|NCT04666922|Drug|Placebo|Placebo; 0.9% saline for injection
79325459|NCT04660214|Device|septotomy|endoscopic diverticulotomy
79647630|NCT00211146|Drug|epoetin alfa|
79810294|NCT04050826|Drug|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
79810295|NCT04050826|Drug|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
79810296|NCT04050826|Drug|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
79810297|NCT04050826|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
79810298|NCT04050826|Procedure|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
79810299|NCT00757900|Biological|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
79977888|NCT05505968|Other|Virtual Reality Headset|Virtual Reality Headset of the society Healthy Mind and is a CE Class 1 medical device. This virtual reality headset is a Pico G2 4K and corresponds to the model A7510 and is connected to a Bose Sound Link 2 AE headset.
79977889|NCT05503771|Behavioral|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
79977890|NCT05503771|Other|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
79977891|NCT05500040|Behavioral|Multimodal Rehabilitation|The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
79977892|NCT05499455|Device|Positional Sleep Belt|Rematee Positional Sleep Belt
79977893|NCT05499455|Device|Control|Control Device
79977894|NCT05499286|Other|Mindfulness Program|Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Curriculum
79977895|NCT05495243|Drug|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
79977896|NCT05495243|Drug|Placebo|Isotonic saline (0.9%)
79325460|NCT04658472|Drug|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
79325461|NCT04658472|Drug|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
79325462|NCT04634812|Drug|KBP-5074|a single oral dose of [14C]-KBP-5074
79325463|NCT04630665|Other|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
79325464|NCT04625257|Other|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
79810300|NCT00757978|Drug|memantine|memantine 10mg twice a day
79810301|NCT00757978|Drug|placebo|1 capsule of placebo twice a day
79810302|NCT00754702|Drug|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
79810303|NCT00754702|Drug|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
79810304|NCT00754780|Drug|Pirfenidone|Capsule 800 mg TID, oral
79325465|NCT04625257|Other|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
79325466|NCT04625257|Other|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
79325467|NCT04625257|Other|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
79481491|NCT04687098|Drug|Ara-C|"200mg/m2/day, intravenous at induction phase; days 1-7.~- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."
79325468|NCT04624698|Device|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
79325469|NCT04606537|Drug|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
79325470|NCT04606537|Drug|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
79810305|NCT00822900|Drug|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
79810306|NCT00822900|Drug|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
79325471|NCT04606537|Drug|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
79325472|NCT04601428|Biological|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
79977897|NCT05491213|Behavioral|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
79325473|NCT04595604|Procedure|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
79977898|NCT05487859|Drug|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
79325474|NCT04595604|Procedure|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
79325475|NCT04583293|Other|No intervention|This study does not involve any intervention or new treatment.
79325476|NCT04581785|Biological|hLB-001|hLB-001 via IV infusion
79810307|NCT00682786|Drug|5FU|
79481492|NCT04687098|Drug|G-CSF|"Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~Administration at consolidation phase day 7."
79810308|NCT00682786|Radiation|Radiation|
79810309|NCT00682786|Procedure|Surgery of resectable lesions|
79810310|NCT00682786|Drug|Irinotecan|
79481493|NCT04687098|Procedure|Allogeneic matched or unrelated donor transplant.|To be performed in patients in the intermediate or adverse risk groups.
79481494|NCT04687098|Procedure|Autologous peripheral blood stem cell transplant|To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
79481495|NCT04687098|Procedure|Measurable residual disease|To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
79481496|NCT04683406|Drug|ZSP1273 600 mg|3 X 200-mg tablet taken orally
79977899|NCT05487677|Device|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
79977900|NCT05487677|Procedure|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
79977901|NCT05486897|Other|None, pure observational study|None, pure observational study
79977902|NCT05486481|Drug|Venetoclax|Given orally (PO)
79325486|NCT04576156|Drug|Imetelstat|Imetelstat will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
79325487|NCT04576156|Drug|Best Available Therapy (BAT)|Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
79810311|NCT00840450|Drug|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
79481497|NCT04683406|Drug|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
79810312|NCT00754858|Drug|belotecan hydrochloride|
79325490|NCT04567433|Drug|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
79325491|NCT04567433|Drug|Hydrocortisone|Hydrocortisone compared to Placebo
79325492|NCT04567433|Procedure|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
79481498|NCT04683406|Drug|Oseltamivir(oral)|2 X 75-mg tablet taken orally
79481499|NCT04683406|Drug|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
79481500|NCT04677465|Device|RheOx Bronchial Rheoplasty|bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
79977903|NCT05486481|Drug|Dexamethasone|Given PO
79977904|NCT05486481|Drug|Daratumumab|Given Subcutaneously (SC)
79977905|NCT05486481|Device|Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay|Lab test
79977906|NCT05482945|Other|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
79325493|NCT04560699|Other|Physiotherapeutic treatment and medical care|Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26
79325494|NCT04560699|Other|medical care|medical care three times during the study period; baseline, week 13 and week 26
79325495|NCT04556890|Device|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
79325496|NCT04556890|Device|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
79325497|NCT04536012|Behavioral|Gamification and Social Incentives|Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
79325498|NCT04535882|Diagnostic Test|serum leucine-rich alpha-2 glycoprotein (LRG) levels|Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
79481501|NCT04677465|Device|Sham Procedure|staged sham procedure wherein bronchoscopy is performed, the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient)
79481502|NCT04676087|Procedure|Extracorporeal Photopheresis|Undergo ECP
79481503|NCT04676087|Biological|Mogamulizumab|Given IV
79481504|NCT04676087|Other|Quality-of-Life Assessment|Ancillary studies
79481505|NCT04672590|Other|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
79481506|NCT04671459|Combination Product|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
79481507|NCT04662086|Drug|Acebilustat|100 mg capsule administered orally once daily
79481508|NCT04662086|Drug|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
79481509|NCT04662073|Drug|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
79481510|NCT04662073|Drug|Placebo|Placebo to match camostat administered orally four times daily
79481511|NCT04656418|Biological|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
79481512|NCT04656418|Drug|Placebo|Buffer without active ingredient
79481513|NCT04647877|Drug|phenytoin cream|Phenytoin cream to be applied on the neuropathic pain area
79481514|NCT04647877|Other|Placebo cream|Placebo cream to be applied on the neuropathic pain area
79481515|NCT04629599|Behavioral|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
79810313|NCT00754858|Drug|cisplatin|
79977907|NCT05480709|Behavioral|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
79977908|NCT05478837|Drug|Cyclophosphamide|Given IV
79977909|NCT05478837|Drug|Fludarabine|Given IV
79977910|NCT05478837|Biological|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
79481516|NCT04629599|Behavioral|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
79481517|NCT04622306|Device|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
79810314|NCT05402748|Other|placenta-MSCs derived exosomes|Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
79647631|NCT00409058|Behavioral|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
79647632|NCT00211224|Drug|Riluzole|
79647633|NCT00409097|Drug|Rosiglitazone|
79810315|NCT00755014|Other|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
79810316|NCT00705588|Drug|Tadalafil|Orally, titrated to maximum 20mg od
79810317|NCT00705588|Drug|Vardenafil|Orally, titrated to 10 mg bid
79647634|NCT00218205|Drug|Epirubicin|
79647635|NCT00218205|Drug|Estramustine Phosphate|
79647636|NCT00218205|Drug|Celecoxib|
79810318|NCT00755092|Behavioral|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
79810319|NCT00755092|Behavioral|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
79810320|NCT00705744|Drug|Lactic acid (Dermacyd Femina)|
79810321|NCT00755170|Drug|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
79810322|NCT00755170|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
79810323|NCT00705822|Drug|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
79810324|NCT00705822|Drug|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
79810325|NCT00755248|Procedure|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
79325501|NCT04534699|Drug|KBP-5074|KBP-5074 tablet
79325502|NCT04533451|Drug|Pembrolizumab|Given IV
79325503|NCT04533451|Drug|Pemetrexed|Given IV
79325504|NCT04533451|Drug|Carboplatin|Given IV
79325505|NCT04533451|Other|Comprehensive Geriatric Assessment|Ancillary studies
79325506|NCT04533451|Other|Questionnaire Administration|Ancillary studies
79325507|NCT04533451|Other|Quality-of-Life Assessment|Ancillary studies
79325508|NCT04532957|Drug|KBP-7072|QD oral capsules
79325509|NCT04532957|Drug|Placebo|matching placebo capsules
79325510|NCT04530110|Drug|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing < threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
79810326|NCT00840294|Drug|Ciprofloxacin|
79810327|NCT02561026|Biological|Frozen plasma|patients randomized to receive frozen plasma transfusions
79810328|NCT04030884|Dietary Supplement|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
79325511|NCT04530006|Diagnostic Test|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
79325512|NCT04522947|Other|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
79325513|NCT04522791|Behavioral|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
79325514|NCT04522791|Behavioral|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
79810329|NCT00755404|Drug|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
79481520|NCT04608539|Drug|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
79810330|NCT00755404|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
79481521|NCT04608539|Drug|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
79977911|NCT05469321|Other|None, pure observationnal study|None, pure observational study following the usual management of the patients
79481522|NCT04608539|Drug|normal saline|Single-dose infusion (placebo), postoperative day 1
79481523|NCT04607044|Device|SALVATION™ EXTERNAL FIXATION|Wright Medical's lower extremity devices used to treat neuropathic patients
79810331|NCT00703170|Drug|Temsirolimus|
79810332|NCT00703170|Drug|Pegylated liposomal doxorubicin|
79810333|NCT02612142|Behavioral|physical exercise|endurance-training or stretching (sham exercise)
79810334|NCT00758056|Genetic|polymorphism analysis|
79810335|NCT00758056|Other|laboratory biomarker analysis|
79810336|NCT00758056|Other|questionnaire administration|
79810337|NCT00758134|Drug|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
79810338|NCT02560636|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
79810339|NCT02560636|Radiation|Radiotherapy|Radiotherapy
79810340|NCT00758212|Biological|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
79810341|NCT02560480|Device|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
79810342|NCT00680056|Drug|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
79977912|NCT05463731|Drug|Remternetug (IV)|Administered IV
79977913|NCT05463731|Drug|Remternetug (SC)|Administered SC
79977914|NCT05463731|Drug|Placebo|Administered IV or SC
79977915|NCT05462223|Combination Product|Alucent Vessel Restoration System for AVF|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~VRS Light Fiber~VRS Light Source"
79977916|NCT05462145|Device|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
79481524|NCT04601103|Drug|No SLS toothpaste|Toothpaste no Sodium Lauryl Sulfate
79481525|NCT04601103|Drug|Medium SLS toothpaste|Less than or equal to X ppm Sodium Lauryl Sulfate
79481526|NCT04601103|Drug|High SLS toothpaste|More than or equal to X ppm Sodium Lauryl Sulfate
79325515|NCT04522791|Behavioral|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
79325516|NCT04519320|Diagnostic Test|Pulmonary function testing|"D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~Blood test~Blood gases~Clinical examination~CT Scan~Pulmonary function testing (PFT)~6-minute walk test (6MWT)~MOS SF-36 Questionnaire~HADS scale~Ventilatory polygraphy~M6: D0 + 6 months~Clinical examination~PFT~6MWT~MOS SF-36 Questionnaire~HADS scale~M12: D0 + 12 months~Blood test~Blood gases~Clinical examination~CT Scan (If anomaly found at M3)~PFT~Pulmonary Exercise Stress Test~6MWT~MOS SF-36 Questionnaire~HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO <LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~Clinical examination~PFT~6MWT~MOS SF-36 Questionnaire~HADS scale"
79325517|NCT04507503|Drug|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
79325518|NCT04489732|Biological|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~Dose Level 0: 10 x 10^6 injected into one submandibular gland on Day 1"
79325519|NCT04482933|Drug|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
79325520|NCT04472117|Other|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
79481527|NCT04601103|Device|Anti-plaque|Rinse prevents bacterial adherence to teeth
79647637|NCT00409136|Behavioral|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
79647638|NCT00211263|Behavioral|Enhanced Clinical Intervention|
79810343|NCT00680056|Drug|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
79810344|NCT00758368|Drug|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
79810345|NCT00755482|Drug|Aquamin F|
79647639|NCT00211263|Drug|mood stabilizer|
79647640|NCT00185510|Drug|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
79647641|NCT00185510|Drug|Placebo|2 days a week Vehicle (Advabase)
79810346|NCT00755482|Drug|Placebo (maltodextran)|
79647642|NCT00218244|Other|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
79647643|NCT00218244|Other|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
79647644|NCT00185549|Behavioral|CF. DOC|
79647645|NCT00211302|Drug|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
79647646|NCT00185666|Procedure|Stereotactic radiosurgery|
79647647|NCT00218283|Drug|Nicotine Lozenge|Oral Nicotine replacement product
79647648|NCT00218283|Behavioral|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
79647649|NCT00185705|Drug|Telmisartan|
79325521|NCT04472117|Other|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
79977917|NCT05455021|Combination Product|Vessel Restoration System (VRS)|"The VRS includes the following components:~VRS 10-8-10 Dimer Coated Balloon Catheter~VRS Light Fiber~VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements."
79977918|NCT05454995|Other|Vessel Restoration System (VRS)|Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
79977919|NCT05451329|Drug|VVN539 Ophthalmic Solution 0.02%|Once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days
79325522|NCT04462276|Drug|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
79647650|NCT00211341|Dietary Supplement|Vitamin A|Weekly single oral dose 7000 micrograms
79325523|NCT04462276|Radiation|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
79325524|NCT04458207|Procedure|Oral prosthetic rehabilitation|Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
79647651|NCT00185783|Drug|Hydrocortisone Administration (Standard of Care Therapy)|
79647652|NCT00185861|Drug|Arsenic Trioxide|
79647653|NCT00185861|Procedure|Stereotactic radiosurgery|
79647654|NCT00211380|Drug|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
79647655|NCT00185939|Drug|Augmentin|
79647656|NCT00218322|Drug|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
79647657|NCT00218322|Drug|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
79977920|NCT05451329|Drug|VVN539 Ophthalmic Solution 0.04%|Once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days
79977921|NCT05451329|Drug|VVN539 Ophthalmic Solution Vehicle|Once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days
79325525|NCT04435366|Drug|Avacincaptad Pegol|Avacincaptad Pegol Intravitreal Injection
79325526|NCT04435366|Drug|Sham|Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
79325527|NCT04428944|Procedure|Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)|Standard PVI
79325528|NCT04428944|Procedure|Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)|Standard PVI + Ablation of drivers in LA and RA
79481528|NCT04586166|Device|RP Sling|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
79647658|NCT00185978|Behavioral|diet, physical activity, reduced sedentary behavior|
79647659|NCT00218361|Drug|Hydromorphone|
79647660|NCT00186134|Behavioral|physical activity|
79647661|NCT00218478|Behavioral|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
79647662|NCT00186173|Behavioral|After school sports program|After school team sports intervention designed specifically for overweight and obese children
79647663|NCT00186173|Behavioral|After school health education|After school health and nutrition education program
79647664|NCT00218517|Drug|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
79647665|NCT00218517|Drug|Placebo|Matching placebo capsules using blue 00 capsules
79647666|NCT00218556|Behavioral|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
79647667|NCT00186212|Behavioral|workbook/journal on coping with breast cancer|
79647668|NCT00186212|Behavioral|standard educational materials on breast cancer|
79977922|NCT05450978|Drug|Lamotrigine|Anti-seizure concentrations
79977923|NCT05450978|Drug|Levetiracetam|Anti-seizure concentrations
79325529|NCT04428944|Procedure|Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)|Standard PVI + Electrical isolation of the posterior wall of the left atrium
79481529|NCT04586166|Device|SIS|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
79647669|NCT00211419|Drug|Anecortave Acetate 15 mg|
79647670|NCT00211419|Drug|Triamcinolone Acetate 4 mg|
79977924|NCT05450562|Biological|SAR444200|Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion
79325530|NCT04428450|Device|Deprexis|CBT-based, integrative online self-help program
79325531|NCT04425148|Device|Transcranial Alternating Current Stimulation (tACS)|tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.
79325532|NCT04425148|Device|Sham Transcranial Alternating Current Stimulation (sham tACS)|Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
79325533|NCT04408313|Drug|XR-B|Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
79325534|NCT04408313|Drug|XR-NTX|Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
79481530|NCT04581499|Combination Product|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
79481531|NCT04581499|Other|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
79647671|NCT00211419|Procedure|Photodynamic Therapy with Verteporfin|
79647672|NCT00211419|Procedure|Thermal Laser|
79647673|NCT00186251|Procedure|high dose chemo then auto hematopoietic cell transplant|
79325538|NCT04401020|Drug|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
79810347|NCT00755638|Biological|ACE-031|single subcutaneous dose of ACE-031
79325539|NCT04393649|Other|ESOGER|Questionnaire
79325540|NCT04373265|Drug|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
79325541|NCT04373265|Drug|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
79810348|NCT04968886|Diagnostic Test|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
79810349|NCT05435794|Device|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
79810350|NCT05435794|Device|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
79977925|NCT05450562|Biological|Atezolizumab|concentrate for solution for infusion Route of administration: intravenous (IV) infusion
79977926|NCT05444192|Device|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
79325547|NCT04368663|Drug|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
79325548|NCT04366024|Other|other|clinical diagnosis
79325549|NCT04350138|Biological|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
79325550|NCT04350138|Other|Placebo|150mM sodium chloride (0.9% saline solution).
79325551|NCT04347369|Other|other|clinical diagnosis
79325552|NCT04344860|Drug|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
79325553|NCT04344860|Drug|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
79481532|NCT04575597|Drug|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
79481533|NCT04575597|Drug|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
79481534|NCT04571138|Biological|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
79481535|NCT04562792|Drug|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
79481536|NCT04551066|Drug|parsaclisib|parsaclisib will be administered QD orally
79481537|NCT04551066|Drug|ruxolitinib|ruxolitinib will be administered BID orally
79481538|NCT04551066|Drug|placebo|placebo will be administered QD orally
79481539|NCT04550377|Drug|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
79647674|NCT00211458|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
79647675|NCT00186290|Procedure|ablative allogeneic hematopoietic cell transplantation|
79647676|NCT00211497|Drug|MBI 226 Acne Solutions|
79647677|NCT00186329|Drug|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
79647678|NCT00218595|Behavioral|DBT|Dialectical behavior therapy plus opiate replacement medication.
79647679|NCT00218595|Behavioral|I/GDC|Individual and group drug counseling plus opiate replacement medication.
79647680|NCT00186407|Procedure|high dose chemo then auto hematopoietic cell transplant|
79325554|NCT04344717|Drug|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
79325555|NCT04344717|Drug|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
79810351|NCT05435560|Drug|Dexmedetomidine|During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
79810352|NCT05435560|Drug|Saline|During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
79810353|NCT00680992|Drug|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
79810354|NCT02559154|Drug|Bortezomib|
79810355|NCT02559154|Drug|Dexamethasone|
79810356|NCT02559154|Drug|Doxorubicin|
79810357|NCT02559154|Drug|Cyclophosphamide|
79810358|NCT02559154|Drug|Mitoxsnteone|
79977927|NCT05443594|Device|Phase 1: FARAPULSE Ablation System|PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
79325560|NCT04332744|Drug|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
79325561|NCT04332744|Drug|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
79325562|NCT04310397|Drug|Dabrafenib|Given PO
79325563|NCT04310397|Biological|Spartalizumab|Given IV
79325564|NCT04310397|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79325565|NCT04310397|Drug|Trametinib|Given PO
79325566|NCT04309110|Device|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
79810359|NCT02559154|Drug|Thalidomide|
79325568|NCT04298047|Other|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
79810360|NCT03798964|Other|Placental analysis|Analysis of placenta to determine expression of heparanase
79810361|NCT05435248|Drug|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
79810362|NCT02559076|Behavioral|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
79810363|NCT00805389|Biological|Engerix-B™|2 doses intramuscular injections
79810364|NCT00805389|Biological|Fendrix™|2 doses intramuscular injections
79810365|NCT00805389|Biological|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
79810366|NCT00805389|Biological|HBsAg (Booster injection)|Single dose intramuscular injection
79810367|NCT00678886|Biological|otelixizumab infusion plus physician determined standard of care|infusion
79810368|NCT00678886|Biological|placebo infusion plus physician determined standard of care|infusion
79810369|NCT04016103|Device|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
79977928|NCT05443594|Device|Phase 2: FARAPULSE Ablation System|PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
79810370|NCT05747235|Radiation|CT chest|All patients will undergo MSCT chest at both inspiratory and expiratory phases in supine position without any contrast media.
79810371|NCT00914199|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
79810372|NCT02607969|Other|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
79325569|NCT04294667|Drug|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
79325570|NCT04294667|Other|Placebo|Subjects will receive placebo at prespecified time-points.
79325571|NCT04294641|Drug|Ibrutinib|140 mg capsules for a dose of 420 mg daily for up to 12 months.
79325572|NCT04282915|Other|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
79325573|NCT04282915|Other|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
79325574|NCT04279522|Device|Relivion®DP- Active|Relivion®DP- Active stimulation device
79325575|NCT04279522|Device|Relivion®DP- Sham|Relivion®DP- Sham stimulation device
79810373|NCT03672279|Diagnostic Test|CogCheck|Novel self-administered cognitive assessment tool
79481540|NCT04550377|Drug|Placebo|non-active medication
79481541|NCT04546724|Biological|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
79810374|NCT00804843|Drug|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
79977929|NCT05441813|Drug|Virgin Coconut Oil|Standard of care with the addition of virgin coconut oil mouth rinse
79481542|NCT04546724|Biological|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
79810375|NCT00804843|Drug|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
79810376|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
79977930|NCT05440344|Drug|Imlunestrant|Administered orally.
79481543|NCT04546711|Other|Ketogenic Diet|The ketogenic diet (KD) is a high fat, very low carbohydrate diet
79481544|NCT04544813|Drug|JNJ-77474462|Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
79647681|NCT02962713|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
79647682|NCT02962713|Procedure|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
79647683|NCT00186524|Behavioral|Breast Cancer Support Group|
79325583|NCT04261309|Other|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
79325584|NCT04257032|Drug|Rosuvastatin|Tablet
79481545|NCT04544813|Drug|Anakinra|Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
79481546|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
79481547|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
79481548|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
79647684|NCT00218673|Behavioral|Peer mentor intervention|groups sessions, 8
79647685|NCT00186563|Procedure|Micro-plasmapheresis|
79647686|NCT00211575|Behavioral|Disease Management Assessment|
79647687|NCT00186602|Behavioral|Peer counseling|
79325585|NCT04257032|Drug|Rosuvastatin + BI 1323495|Tablets
79325586|NCT04257032|Drug|Dabigatran etexilate|Capsule
79325587|NCT04257032|Drug|Dabigatran etexilate + BI 1323495|Capsule and tablets
79325588|NCT04254133|Behavioral|Questionnaire|Complete questionnaire
79325589|NCT04254133|Procedure|Biospecimen Collection|Provide saliva samples
79325590|NCT04254133|Diagnostic Test|Genetic Testing|Undergo genetic testing
79325591|NCT04254133|Other|Genetic Counseling|Undergo counseling
79325592|NCT04254133|Other|Laboratory Biomarker Analysis|Correlative Studies
79481549|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
79481550|NCT04530513|Radiation|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
79481551|NCT04524364|Device|Pulsed Field Ablation (PFA) Therapy|Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
79481552|NCT04520113|Behavioral|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
79481553|NCT04504916|Drug|Zilovertamab vedotin|Intravenous infusion
79647688|NCT00218712|Behavioral|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
79647689|NCT00218712|Behavioral|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
79647690|NCT00186641|Procedure|high dose chemo and auto hematopoietic cell transplant|
79647691|NCT00218751|Behavioral|Home Visiting|
79647692|NCT00186680|Procedure|high dose chemo then auto hematopoietic cell transplant|
79647693|NCT00211614|Drug|Lansoprazole|
79325593|NCT04240028|Other|Data Collection|The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
79647694|NCT00218790|Procedure|Cool Dialysate|Decreased temperature of the dialysis bath
79647695|NCT00186758|Device|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
79810377|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
79810378|NCT00822120|Biological|bleomycin sulfate|
79481554|NCT04501679|Drug|Nemolizumab|Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.
79810379|NCT00822120|Biological|filgrastim|
79481555|NCT04501679|Drug|Placebo|Participants will receive matching placebo as SC injection.
79647696|NCT00186797|Procedure|Allogeneic stem cell transplant|
79647697|NCT00186797|Drug|Fludarabine, Cyclophosphamide|
79810380|NCT00822120|Drug|ABVD regimen|
79810381|NCT00822120|Drug|BEACOPP regimen|
79481556|NCT04501367|Drug|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
79647698|NCT00211653|Drug|N-Acetylcysteine|
79647699|NCT00186836|Biological|Engerix-B and Twinrix|
79810382|NCT00822120|Drug|cyclophosphamide|
79810383|NCT00822120|Drug|dacarbazine|
79810384|NCT00822120|Drug|doxorubicin hydrochloride|
79810385|NCT00822120|Drug|etoposide|
79810386|NCT00822120|Drug|prednisone|
79810387|NCT00822120|Drug|procarbazine hydrochloride|
79810388|NCT00822120|Drug|vinblastine sulfate|
79325598|NCT04210284|Dietary Supplement|Ensure|"Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~160 Calories, 20 from fat~2g Total fat~0.5g Saturated fat~20mg Cholesterol~135mg Sodium~170mg Potassium~19g Total carbohydrate~<1g Fiber~4g Sugar~16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables"
79810389|NCT00822120|Drug|vincristine sulfate|
79647700|NCT00186914|Biological|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
79810390|NCT00804687|Other|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
79810391|NCT00804687|Drug|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
79810392|NCT00804687|Drug|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
79325601|NCT04177810|Drug|Cemiplimab|Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
79325602|NCT04177810|Drug|Plerixafor|Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
79325603|NCT04175119|Device|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2, 3) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
79647701|NCT00211731|Behavioral|Chronic Disease Self Management Course|
79810393|NCT00678652|Biological|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
79647702|NCT00186953|Drug|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m^2 and escalated at 0.15 ml/m^2 increments, to 0.275 ml/m^2 and 0.425ml/m^2 and 0.500ml/m^2. We will now continue to escalate the dose of Optison at 0.300ml/m^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
79647703|NCT00218907|Procedure|Educational video|
79647704|NCT00187031|Drug|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
79810394|NCT00678652|Biological|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
79325604|NCT04168879|Drug|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
79325605|NCT04168879|Drug|normal saline|1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
79325606|NCT04135989|Device|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
79325607|NCT04135989|Device|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
79325608|NCT04135989|Drug|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
79647705|NCT00187070|Drug|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
79647706|NCT00187070|Procedure|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
79647707|NCT00187070|Radiation|Radiation Therapy|See Detailed Description section for details of treatment interventions.
79647708|NCT00211770|Behavioral|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
79647709|NCT00187109|Drug|Recombinant Human Thrombopoietin|
79647710|NCT00412308|Procedure|Tidal volume used in mechanical ventilation|
79647711|NCT00187148|Biological|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
79647712|NCT00211848|Drug|Polyenylphosphatidylcholine (PPC)|
79481557|NCT04501367|Drug|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
79481558|NCT04501367|Drug|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
79481559|NCT04500483|Diagnostic Test|indirect calorimetry|measurement of resting energy expenditure using indirect calorimetry
79481560|NCT04500288|Device|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
79647713|NCT00211848|Drug|Pegylated Interferon|
79647714|NCT00211848|Drug|Ribavirin|
79647715|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
79647716|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
79647717|NCT00412347|Drug|Insulin Drip Therapy|
79647718|NCT00187265|Device|Cardiac Resynchronization Therapy|
79647719|NCT00187304|Device|Aortic valve replacement|
79647720|NCT00211926|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
79647721|NCT00211926|Biological|placebo|single dose of placebo
79647722|NCT00187343|Device|Breast IMRT|
79647723|NCT00218946|Drug|Sucrose|30 % sucrose
79647724|NCT00218946|Device|Pacifier|
79977931|NCT05440097|Other|QIP intervention|"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
79307205|NCT05024929|Procedure|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
79307206|NCT05022004|Drug|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
79647725|NCT00218946|Other|sterile water|
79307207|NCT05022004|Drug|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
79307208|NCT05004259|Drug|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
79647726|NCT00187382|Drug|Multiple vs. single courses of antenatalcorticosteroids|
79647727|NCT00218985|Behavioral|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
79647728|NCT00187421|Procedure|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
79647729|NCT00211965|Biological|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
79647730|NCT00211965|Biological|placebo|single dose IM
79647731|NCT00219024|Drug|aliskiren|
79647732|NCT00187460|Behavioral|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
79647733|NCT00187499|Drug|Inhaled fluticasone 500 ug BID for 8 weeks|
79647734|NCT00212004|Drug|pioglitazone|
79307209|NCT04988555|Drug|DSP-5336|DSP-5336 orally
79307210|NCT04988503|Device|Coil embolization|coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
79307211|NCT04985760|Biological|Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
79307212|NCT04985760|Biological|Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 100mcg
79647735|NCT00212004|Other|control|
79647736|NCT00187538|Behavioral|Dietary|dietary
79647737|NCT00219063|Drug|aliskiren|
79647738|NCT00187577|Drug|Latanoprost (Xalatan)|
79647739|NCT00187577|Drug|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
79647740|NCT00187577|Drug|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
79647741|NCT00212043|Drug|carboplatin and gemcitabine|
79647742|NCT00219102|Drug|aliskiren|
79647743|NCT00212082|Drug|doxorubicin, docetaxel|
79647744|NCT00187733|Other|Fasting blood and urine collection|Not applicable no drugs dispensed
79647745|NCT00219180|Drug|aliskiren|
79977932|NCT05434949|Diagnostic Test|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
79325609|NCT04135989|Drug|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
79325610|NCT04129528|Drug|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
79325611|NCT04129528|Other|Placebo|Placebo for active drug
79481561|NCT04491617|Other|Standard opioid prescribing|Patients are routinely prescribed opioid medications in addition to non-opioids.
79647746|NCT00187772|Behavioral|Child-Parent Psychotherapy (CPP)|
79647747|NCT00187811|Procedure|Delta amino leavulinic acid photodynamic therapy|
79647748|NCT00212160|Procedure|omentectomy|RYGB with omentectomy
79647749|NCT00187850|Procedure|PP|Partial pulpotomy
79647750|NCT00187850|Procedure|DPC|Direct pulp capping
79647751|NCT00219219|Drug|Zoledronic acid|
79647752|NCT00187928|Drug|Topiramate|
79647753|NCT00212199|Drug|orlistat|
79647754|NCT00212199|Behavioral|Brief cognitive behavioral counseling|
79647755|NCT00187967|Device|pumps used for cardiopulmonary bypass|
79647756|NCT00219258|Drug|Zoledronic acid|
79647757|NCT00188006|Device|heparin-coated cardiopulmonary bypass|
79647758|NCT00212238|Behavioral|internet behavioral weight loss program|
79647759|NCT00188045|Drug|Propranolol - Spironolactone|
79647760|NCT00212277|Drug|Norethindrone,Ethinyl Estradiol|
79647761|NCT00188084|Procedure|DNA Index|
79647762|NCT00188084|Procedure|S-Phase%|
79647763|NCT00188084|Procedure|CD45 expression|
79647764|NCT00188084|Procedure|P16 metabolic way|
79647765|NCT00212316|Drug|sodium phenylbutyrate|
79810395|NCT00678652|Biological|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
79647766|NCT00219336|Behavioral|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
79481562|NCT04491617|Other|Restrictive opioid prescribing|Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
79810396|NCT00678652|Biological|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
79481563|NCT04487392|Drug|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
79481564|NCT04487392|Radiation|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
79307213|NCT04985760|Biological|Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
79307214|NCT04985760|Biological|Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 500mcg
79307215|NCT04984304|Behavioral|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
79481565|NCT04485546|Drug|cenegermin-bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
79481566|NCT04483479|Drug|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
79481567|NCT04478344|Other|Ultrasound guided hydrodissection of superior cluneal nerve|Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
79481568|NCT04475497|Other|Blood management|Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
79481569|NCT04475497|Other|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
79481570|NCT04442295|Drug|STK-001 - Single Ascending Doses|Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
79481571|NCT04442295|Drug|STK-001 - Multiple Ascending Doses|Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
79481572|NCT04427293|Drug|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
79481573|NCT04427293|Drug|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
79481574|NCT04391842|Combination Product|Sustained Acoustic Device with 1% Diclofenac patch|"Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~ZetrOZ ultrasound device~wearable ultrasound device~long duration ultrasound~LITUS device~long duration low intensity device"
79481575|NCT04383262|Drug|Lexiva|A repurposing approach, prospective, placebo-controlled clinical trial of Lexiva (used at the FDA approved, manufacturers recommended dose for HIV (1,400mg twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI ≥ 20, RFS ≥ 11 and MII-pH confirmed laryngeal reflux events).
79481576|NCT04373057|Dietary Supplement|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
79307216|NCT04984304|Diagnostic Test|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
79307217|NCT04963920|Device|Cytosorb® 300 ml|patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
79307218|NCT04954573|Radiation|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
79307219|NCT04953507|Procedure|Thermal Radiofrequency|Radiofrequency lesioning at level of T2, T3 using 80°c for 60-90 seconds
79481577|NCT04373057|Dietary Supplement|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
79481578|NCT04360681|Drug|Lofexidine|BID dosing, and a max daily dose of 1.6 mg/day
79481579|NCT04360681|Drug|Placebo oral tablet|Placebo
79481580|NCT04337255|Other|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
79481581|NCT04337255|Other|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
79977933|NCT05434949|Other|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
79977934|NCT05430412|Device|Adacolumn|The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
79647767|NCT00219336|Behavioral|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
79647768|NCT00188162|Device|CT|
79647769|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
79647770|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
79647771|NCT00188240|Drug|Pegasys; Copegus.|
79977935|NCT05428969|Drug|Bexmarilimab|Intravenous
79977936|NCT05428969|Drug|Azacitidine|As per label, subcutaneous
79647772|NCT00188279|Procedure|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
79647773|NCT00219414|Device|Adacolumn Apheresis System|
79647774|NCT00188318|Procedure|hyperfractionated accelerated radiotherapy|
79647775|NCT00219453|Device|Jet Injector with Protector Cap (HSI-500)|
79647776|NCT00188357|Behavioral|Education|
79647777|NCT00188396|Drug|Citalopram|
79647778|NCT00212433|Drug|Tagitol V, Lo So, Readi-Cat 2|
79307220|NCT04953507|Procedure|Chemical Neurolysis|injection of 2 to 3 ml of the chemical neurolytic agent (phenol in glycerin 6%)
79307221|NCT04953208|Device|active tDCS|Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
79307222|NCT04953208|Device|sham tDCS|sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
79307223|NCT04953208|Behavioral|cognitive and emotional control video game|a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
79307224|NCT04953208|Behavioral|sham video game|a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
79307225|NCT04952610|Drug|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
79307226|NCT04952610|Device|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
79307227|NCT04947553|Drug|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
79647779|NCT00188435|Procedure|Minimum Dose CT|
79647780|NCT00219531|Behavioral|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
79647781|NCT00188474|Behavioral|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
79647782|NCT00219570|Drug|clindamycin|
79647783|NCT00219570|Drug|nadifloxacin|
79647784|NCT00188513|Procedure|conformal intensity modulated radiotherapy (IMRT)|
79647785|NCT00212472|Drug|Factor VIII concentrates|To be determined at the discretion of the investigator.
79647786|NCT00212472|Other|Low-dose treatment|50 FVIII u/kg three times a week.
79977937|NCT05428969|Drug|Venetoclax|Oral
79977938|NCT05425420|Drug|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
79977939|NCT05422430|Behavioral|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
79977940|NCT05422430|Behavioral|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
79977941|NCT05417516|Radiation|Whole Breast Irradiation (WBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
79977942|NCT05417516|Radiation|Partial Breast Irradiation (PBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
79481582|NCT04337203|Behavioral|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
79481583|NCT04330248|Drug|Erdafitinib|Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
79647787|NCT00212472|Other|High-dose treatment|200 FVIII u/kg per day.
79325614|NCT04124341|Device|Prefrontal Cortical Stimulation (PCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
79481584|NCT04330248|Drug|Carbamazepine|Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
79481585|NCT04328844|Drug|IOA-244|IOA-244 will be administered orally once daily (QD)
79481586|NCT04328844|Drug|Avelumab Injection|Avelumab will be administered IV every 2 weeks
79481587|NCT04328844|Drug|Pemetrexed|Pemetrexed will be administered IV every 3 weeks
79481588|NCT04328844|Drug|Cisplatin|Cisplatin will be administered IV every 3 weeks
79481589|NCT04328844|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice a day (BD)
79481590|NCT04327024|Drug|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
79647788|NCT00188552|Drug|pentoxifylline|
79481591|NCT04327024|Drug|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
79481592|NCT04327024|Drug|Placebo for verinurad|Matching Capsule
79481593|NCT04327024|Drug|Placebo for allopurinol|Matching tablet
79481594|NCT04322149|Drug|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
79481595|NCT04315272|Drug|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
79481596|NCT04315272|Drug|Placebo|Placebo
79481597|NCT04309474|Drug|Elezanumab|Intravenous (IV) infusion
79481598|NCT04309474|Drug|Placebo|Intravenous (IV) infusion
79481599|NCT04304352|Drug|Vinorelbine|Metronomic Vinorelbine 40 mg orally thrice a week
79647789|NCT00188552|Drug|α-Tocopherol|
79647790|NCT00411606|Procedure|Thermography|Subjects will have a picture of their face taken with a thermal camera
79481600|NCT04304352|Drug|Capecitabine|Metronomic Capecitabine 500 mg, thrice daily
79481601|NCT04304352|Drug|Cyclophosphamide|Metronomic Cyclophosphamide 50 mg daily
79481602|NCT04297592|Drug|Cephalexin|500 mg oral tablet, 4 times daily for 7 days
79481603|NCT04297592|Drug|Doxycycline|100 mg oral tablet, 2 times daily for 7 days
79481604|NCT04297592|Drug|Cefadroxil|500 mg oral tablet, 2 times daily for 7 days
79481605|NCT04294459|Drug|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
79481606|NCT04294459|Drug|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
79647791|NCT00411723|Drug|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
79647792|NCT00411723|Drug|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
79647793|NCT00188630|Drug|N-acetylcysteine|
79647794|NCT00188630|Other|5% dextrose solution|
79647795|NCT00219609|Drug|UK-390,957|
79647796|NCT00188669|Drug|pentoxifylline|
79647797|NCT00188669|Drug|alpha-Tocopherol|
79647798|NCT00188747|Procedure|Thromboelastograph, Point of Care|
79647799|NCT00219648|Drug|PEP03|
79647800|NCT00409214|Drug|LS11 (talaporfin sodium)|
79647801|NCT00409214|Device|Light source (interstitial light emitting diodes)|
79647802|NCT00409214|Procedure|Intraoperative placement of device in glioma|
79647803|NCT00219687|Other|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
79325615|NCT04111510|Drug|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
79647804|NCT00219687|Other|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
79647805|NCT02963051|Drug|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
79977943|NCT05417217|Procedure|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
79977944|NCT05417217|Procedure|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
79977945|NCT05415124|Device|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
79977946|NCT05406115|Drug|AMG 786|Oral tablet
79977947|NCT05406115|Other|Placebo|Oral tablet
79977948|NCT05397639|Drug|Masupirdine 50 mg|Tablet, Once Daily
79977949|NCT05397639|Drug|Masupirdine 100 mg|Tablet, Once Daily
79977950|NCT05397639|Drug|Placebo|Matching Placebo Tablet, Once Daily
79325616|NCT04110262|Other|High dietary sodium intake|Fourteen day feeding period of high dietary sodium (3400 mg/day)
79325617|NCT04110262|Other|Low dietary sodium intake|Fourteen day feeding period of low dietary sodium (2300 mg/day)
79977951|NCT05396820|Other|Experimental pain|Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
79481607|NCT04294459|Drug|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
79481608|NCT04294459|Drug|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
79481609|NCT04294459|Drug|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
79481610|NCT04294459|Drug|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
79481611|NCT04268121|Drug|Neoadjuvant treatment|4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
79481612|NCT04268121|Drug|Adjuvant treatment|Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
79481613|NCT04266223|Device|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
79481614|NCT04256512|Device|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
79481615|NCT04256512|Other|Questionnaire Administration|Ancillary studies
79481616|NCT04254978|Drug|Bomedemstat|Oral administration
79481617|NCT04252612|Drug|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
79481618|NCT04251156|Drug|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
79481619|NCT04251156|Drug|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
79647806|NCT02963051|Drug|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
79647807|NCT02963051|Drug|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
79647808|NCT00219726|Drug|Imatinib mesylate|
79810397|NCT05740605|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
79810398|NCT05740605|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
79810399|NCT05740605|Behavioral|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
79810400|NCT05740605|Behavioral|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
79810401|NCT02607657|Drug|Eplerenone 25 mg|
79810402|NCT02607657|Drug|Eplerenone 50 mg|
79810403|NCT02607657|Drug|Eplerenone 100 mg|
79810404|NCT02607657|Drug|Eplerenone 50 mg twice a day|
79810405|NCT02607657|Drug|Eplerenone 25 mg twice a day|
79810406|NCT03658642|Behavioral|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
79810407|NCT04015947|Device|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
79481620|NCT04249986|Behavioral|The Borg Rating of Perceived Exertion|Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
79481621|NCT04243330|Behavioral|Audit and Feedback|The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
79810408|NCT04921228|Behavioral|Heart rate variability biofeedback|"5 days of 3-min HRV readings to establish baseline HRV~After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
79810409|NCT00840060|Behavioral|AMALS|Addressing multiple aspects of language simultaneously
79810410|NCT00840060|Behavioral|DTA|Discrete Trial Approach
79810411|NCT00574912|Drug|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
79325622|NCT04091451|Biological|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
79481622|NCT04243330|Behavioral|External Facilitation|Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
79647809|NCT00409253|Drug|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
79647810|NCT00409253|Drug|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD >105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
79647811|NCT00219765|Drug|Imatinib mesylate 600 mg|
79647812|NCT00219765|Drug|Cytarabine|
79647813|NCT00219765|Drug|Daunorubicine|
79325623|NCT04091451|Drug|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
79325624|NCT04085445|Device|AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter|To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
79325625|NCT04072458|Drug|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
79325626|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
79325627|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
79325628|NCT04069624|Other|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
79647814|NCT00409370|Device|SOMA safe enclosure|
79325629|NCT04064086|Other|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
79325630|NCT04064086|Other|Provision of the freely available resources for Kidney Disease Education|freely available resources
79325631|NCT04059016|Other|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
79647815|NCT00212550|Procedure|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
79647816|NCT00188786|Procedure|daily Cone Beam CT for imaging guidance for radiotherapy|
79647817|NCT00212589|Drug|Capecitabine|
79647818|NCT00212589|Drug|Fluorouracil + folinic acid|
79977952|NCT05395741|Drug|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
79325632|NCT04055207|Other|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
79325633|NCT04047303|Drug|CC-90010|CC-90010
79325634|NCT04036006|Behavioral|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
79647819|NCT00188825|Other|placebo|
79647820|NCT00188825|Drug|basiliximab|
79647821|NCT00212628|Drug|Minodronic acid hydrate|
79647822|NCT00219804|Drug|tetrabenazine or placebo|
79647823|NCT00188864|Drug|dexamethasone|
79647824|NCT00212667|Drug|ONO-5920|
79647825|NCT00188903|Procedure|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
79647826|NCT00219843|Drug|PV-10 (rose bengal disodium, 10%)|
79647827|NCT00188942|Drug|Fluoxetine+Olanzapine|
79647828|NCT00188942|Drug|Olanzapine|
79647829|NCT00188942|Procedure|Functional Magnetic Resonance Imaging|
79647830|NCT00212706|Drug|ONO-8025 (KRP-197)|
79647831|NCT00219882|Drug|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
79647832|NCT00189020|Biological|PCV7|PCV7 at age 2 and 4 months
79647833|NCT00189020|Biological|PCV7|PCV7 at age 2, 4 and 11 months
79647834|NCT00212745|Behavioral|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
79647835|NCT00219921|Drug|Intrathecal morphine at surgery, 0.1mg and placebo|
79647836|NCT00219921|Drug|Patient Controlled Analgesia with iv morphine and placebo|
79647837|NCT00219921|Drug|intrathecal morphine AND patient controlled analgesia with iv morphine|
79647838|NCT00212823|Drug|almotriptan malate|
79647839|NCT00189059|Drug|amitriptyline|
79647840|NCT00189176|Drug|Tetrathiomolybdate|
79647841|NCT00219960|Drug|North American Ginseng (Panax Quinquefolius)|
79325635|NCT04036006|Behavioral|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
79325636|NCT04032470|Device|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
79325637|NCT04029714|Procedure|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
79325638|NCT04026113|Drug|Linaclotide 72 μg (FC Participants)|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
79325639|NCT04026113|Drug|Placebo (FC Participants)|Matching placebo
79325640|NCT04026113|Drug|Linaclotide 145 μg (IBS-C Participants)|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
79325641|NCT04026113|Drug|Linaclotide 290 μg (IBS-C Participants)|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
79325642|NCT04024436|Drug|Futibatinib|Futibatinib 20mg once daily on a 28 day cycle
79325643|NCT04024436|Drug|Futibatinib plus Fulvestrant|Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
79481623|NCT04227444|Diagnostic Test|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
79481624|NCT04226742|Behavioral|ADAPT Platform (Treatment)|The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.
79481625|NCT04226742|Behavioral|ADAPT Comparison (Control)|The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
79647842|NCT00189215|Device|cardiac stabilizer instead of cardiopulmonary bypass|
79647843|NCT00212862|Other|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
79647844|NCT00189332|Drug|852A|
79647845|NCT00189371|Drug|paclitaxel, carboplatin, epoetin alpha|
79810412|NCT00574912|Drug|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
79810413|NCT00574912|Drug|Insulin Glargine 1.0 u/kg body wt SC|
79481626|NCT04223934|Other|optima4BP|"optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician."
79647846|NCT00212901|Drug|High dose ACE-I vs ARB|
79325644|NCT04018248|Drug|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
79325645|NCT04018248|Drug|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
79325646|NCT04009447|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
79325647|NCT04002063|Behavioral|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
79325648|NCT04002063|Behavioral|CBT alone|CBT therapy individual
79325649|NCT03991806|Other|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
79325650|NCT03987360|Other|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
79647847|NCT00189410|Drug|Pegylated Liposomal Doxorubicin and Carboplatin|
79810414|NCT00574912|Drug|Insulin Glargine 1.5 u/kg body wt SC|
79810415|NCT00574912|Drug|Insulin Glargine 2.0 u/kg body wt SC|
79481627|NCT04223882|Behavioral|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
79647848|NCT00220038|Behavioral|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
79977953|NCT05395481|Drug|LY3849891|Administered SC.
79977954|NCT05395481|Drug|Placebo|Administered SC.
79481628|NCT04223882|Other|Usual care|outpatient medical appointments
79977955|NCT05394675|Drug|DS-9606a|Intravenous infusion
79977956|NCT05392751|Drug|EA-2353|EA-2353 Ophthalmic Suspension
79325651|NCT03978650|Other|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
79647849|NCT00212940|Behavioral|Supportive Therapy for Adherence to ART (behavior)|
79977957|NCT05392452|Device|CamAPS HX|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
79977958|NCT05392452|Drug|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
79977959|NCT05389046|Drug|Escitalopram|Escitalopram
79977960|NCT05389046|Drug|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
79977961|NCT05389046|Drug|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
79977962|NCT05389046|Drug|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
79977963|NCT05388487|Drug|HF1K16 /Arm 45 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
79977964|NCT05388487|Drug|HF1K16 /Arm 90 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
79977965|NCT05388487|Drug|HF1K16 /Arm 120 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
79977966|NCT05388487|Drug|HF1K16 /Arm 160 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
79977967|NCT05388487|Drug|HF1K16 /Arm 120 mg or 180 mg|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
79325652|NCT03971669|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
79325653|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
79325654|NCT03962985|Other|Guided tour at the Montreal Museum of Fine Arts|"The duration of the participation -3 months~The duration of the guided tour-45 minutes, each week~All participants will be asked to fill out some specific online questionnaires during their participations in the study"
79647850|NCT00189527|Procedure|respiratory settings|
79647851|NCT00220077|Procedure|Endoscopy|
79647852|NCT00189566|Drug|Paclitaxel|
79647853|NCT00189566|Drug|Topotecan|
79647854|NCT00189566|Drug|Carboplatin|
79647855|NCT00212979|Other|non intervention study|
79647856|NCT00189605|Device|Perc-DLR/Perc-DLG|Device technique will be used per IFU
79647857|NCT00189605|Drug|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
79647858|NCT00220116|Drug|Capecitabine, Oxaliplatin|
79481629|NCT04210505|Drug|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
79481630|NCT04210505|Other|Standard Care|Control group will receive standard care as provided by the dialysis center
79647859|NCT02963129|Drug|Mupirocin|Mupirocin ointment in the nose for 5 days
79977968|NCT05386550|Drug|Xevinapant (Debio 1143)|Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
79977969|NCT05386550|Radiation|IMRT|Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.
79647860|NCT02963129|Other|Placebo|Placebo ointment in the nose for 5 days
79647861|NCT00220155|Drug|Gemcitabine|
79647862|NCT00189644|Procedure|6 FEC 100|
79647863|NCT00189644|Procedure|4 FEC 100 followed by 4 Taxol|
79647864|NCT00213018|Drug|Carraguard (PC-515)|
79647865|NCT00189683|Procedure|Monitoring|
79647866|NCT00189683|Procedure|Xeloda|
79647867|NCT00213057|Drug|Carraguard (PC-515)|
79647868|NCT00189722|Drug|Tacrolimus|
79647869|NCT00220194|Drug|leuprolide acetate|
79647870|NCT00189761|Drug|Tacrolimus|
79647871|NCT00213096|Drug|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
79647872|NCT00189800|Drug|Solifenacin succinate|
79647873|NCT00220233|Drug|olmesartan medoxomil|
79647874|NCT00220233|Drug|amlodipine|
79647875|NCT00220233|Drug|hydrochlorothiazide|
79647876|NCT00220272|Drug|SR57667B|
79647877|NCT00189839|Drug|tacrolimus|Immunosuppression
79647878|NCT00213174|Behavioral|school playgrounds|
79647879|NCT00189878|Drug|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
79307228|NCT04930965|Behavioral|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
79307229|NCT04928911|Biological|COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
79307230|NCT04920006|Behavioral|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
79307231|NCT04916990|Behavioral|CARES Intervention|Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
79307232|NCT04911270|Device|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
79307233|NCT04911270|Other|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
79647880|NCT00189878|Drug|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
79647881|NCT00220311|Drug|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
79647882|NCT00189917|Biological|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
79810416|NCT00922896|Drug|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"Erlotinib 100 mg po q d daily AND~Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
79810417|NCT00674128|Device|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
79307234|NCT04898894|Drug|Venetoclax|Given orally (PO)
79307235|NCT04898894|Drug|Selinexor|Given Orally (PO)
79307236|NCT04898894|Drug|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
79307237|NCT04898894|Drug|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
79307238|NCT04898894|Biological|Filgrastim|Given subcutaneous (SubQ, SC)
79307239|NCT04898894|Drug|Methotrexate|Given intrathecal (IT)
79307240|NCT04898894|Drug|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
79307241|NCT04895943|Procedure|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
79307242|NCT04895943|Procedure|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
79647883|NCT00213213|Drug|Sucrose|
79647884|NCT00189956|Biological|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
79481631|NCT04194528|Drug|Oxycodone/acetaminophen 5/325 mg|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
79481632|NCT04194528|Device|Proteus digital medicine program|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
79325655|NCT03962972|Other|Frailty evaluation|It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with the three validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index and Rockwood frailty index.
79325656|NCT03961750|Other|OTAGO|12 Week exercise class programme
79325657|NCT03945773|Drug|Cabozantinib|Oral tablets of 60mg, 40mg and 20 mg.
79325658|NCT03937765|Procedure|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
79325659|NCT03933202|Drug|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
79481633|NCT04192006|Device|Total Knee Arthroplasty|Surgical implantation of prosthetic knee using robotic-arm assist
79481634|NCT04189614|Drug|Cofetuzumab Pelidotin|Intravenous (IV) infusion
79647885|NCT00213252|Drug|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
79647886|NCT00213252|Drug|Prednisolone|Six daily doses of oral prednisolone
79647887|NCT00189995|Drug|clozapine|
79647888|NCT00189995|Drug|haloperidol|
79647889|NCT00213291|Drug|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
79481635|NCT04181632|Device|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
79481636|NCT04181632|Device|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
79481637|NCT04181632|Device|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
79481638|NCT04179396|Drug|Rucaparib|Oral rucaparib will be administered twice daily
79481639|NCT04179396|Drug|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
79481640|NCT04179396|Drug|Abiraterone|Abiraterone will be administered once daily with prednisone
79647890|NCT00190034|Drug|N-Acetylcysteine 600mg/tab|
79977970|NCT05386550|Drug|Placebo|Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
79481641|NCT04174144|Procedure|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
79481642|NCT04163094|Drug|W_ova1 Vaccine|Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
79481643|NCT04158440|Drug|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m^2 by IV infusion Q3W
79647891|NCT00412503|Drug|Topotecan, Temozolomide|
79647892|NCT00213330|Procedure|rectal distension|
79647893|NCT00190112|Procedure|ventral cardiac denervation|
79647894|NCT00412581|Drug|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
79647895|NCT00412581|Drug|Dacarbazine|600 mg/m^2 intravenously on Day 1 of every study cycle.
79647896|NCT00412620|Drug|ABT-925|
79647897|NCT00412620|Drug|Placebo|
79810418|NCT00674128|Device|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
79810419|NCT00760942|Dietary Supplement|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
79810420|NCT00760942|Dietary Supplement|Similac human milk fortifier|Powdered human milk fortifier.
79810421|NCT00761020|Drug|Mefloquine|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
79810422|NCT00761020|Other|Control|No Intervention
79810423|NCT00804141|Drug|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
79810424|NCT04049032|Behavioral|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
79810425|NCT04049032|Behavioral|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
79810426|NCT00761098|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
79810427|NCT00761098|Drug|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
79810428|NCT03556137|Drug|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of [18F]FTC-146 and undergo a PET/MRI scan.
79810429|NCT00677092|Drug|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
79481644|NCT04158440|Drug|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m^2 by IV infusion Q3W
79481645|NCT04154267|Procedure|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
79810430|NCT02607579|Drug|Exparel|
79481646|NCT04146012|Device|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
79481647|NCT04138030|Procedure|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
79481648|NCT04138030|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
79810431|NCT02607579|Drug|Ropivacaine|
79810432|NCT03539367|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79810433|NCT03539367|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79325662|NCT03912428|Diagnostic Test|11C-MC1|PET radioligand for COX-2
79325663|NCT03912428|Drug|Celecoxib|COX-2 inhibitor
79481649|NCT04131088|Other|Follow up of midlines|The follow-up data to be collected will be recorded on a monitoring logbook that will follow the patient (Appendix 4). The latter will be involved in the follow-up of his data insofar as he will be able to solicit the various professionals performing care on his midline in order to aim at the exhaustiveness of the filling of the book.
79481650|NCT04124185|Diagnostic Test|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
79481651|NCT04117035|Procedure|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
79481652|NCT04117035|Procedure|GKRS standard care|Standard GKRS treatment
79481653|NCT04111978|Drug|Letrozole 2.5mg|Aromatase inhibitor
79481654|NCT04111978|Other|Placebo|Placebo tablet of Femara
79481655|NCT04105543|Drug|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
79481656|NCT04096014|Dietary Supplement|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
79481657|NCT04096014|Other|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
79481658|NCT04095923|Behavioral|Social media game|Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
79481659|NCT04095923|Behavioral|Standard self-regulation|Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
79481660|NCT04091282|Other|No intervention|No intervention
79481661|NCT04085458|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
79481662|NCT04077580|Drug|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
79481663|NCT04076618|Device|Vest|Weighted Vest worn > or = 8 hours per day
79481664|NCT04076618|Behavioral|Resistance Exercise Training|Structured exercise training 3 days a week
79647898|NCT00190151|Drug|ciprofloxacin|
79481665|NCT04076618|Behavioral|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
79481666|NCT04069884|Radiation|regional nodal irradiation|external-beam radiotherapy (XRT)
79481667|NCT04069884|Radiation|WBI|Whole Breast Irradiation
79481668|NCT04069884|Radiation|chestwall XRT|chestwall irradiation
79481669|NCT04055792|Drug|Sintilimab|Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
79481670|NCT04048512|Procedure|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
79481671|NCT04048512|Procedure|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
79481672|NCT04038645|Other|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
79481673|NCT04038645|Other|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
79481674|NCT04037826|Dietary Supplement|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
79810434|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
79307243|NCT04886895|Other|Let's Move|Motor intervention
79307244|NCT04886622|Drug|DT2216|DT2216 will be administered by intravenous infusion
79307245|NCT04883957|Drug|BGB-11417|Film-coated tablets administered orally as specified in the treatment arm.
79307246|NCT04880109|Drug|APX-115|Oral administration of APX-115 100 mg capsule once daily for 14 days
79307247|NCT04880109|Drug|Placebo|Oral administration of placebo capsule once daily for 14 days
79307248|NCT04866017|Drug|Tislelizumab|administered by intravenous infusion
79307249|NCT04866017|Drug|Durvalumab|administered by intravenous infusion
79307250|NCT04866017|Drug|Ociperlimab|administered by intravenous infusion
79307251|NCT04860050|Dietary Supplement|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
79307252|NCT04860050|Dietary Supplement|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
79307253|NCT04830124|Drug|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
79307254|NCT04830124|Drug|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
79307255|NCT04830124|Drug|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes once every 21 days or twice every 21 days
79307256|NCT04828486|Drug|Futibatinib|Given PO
79307257|NCT04828486|Biological|Pembrolizumab|Given IV
79307258|NCT04828486|Other|Quality-of-Life Assessment|Ancillary studies
79977971|NCT05385042|Dietary Supplement|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
79977972|NCT05385042|Dietary Supplement|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
79977973|NCT05375539|Drug|AGN-CognI.Q|Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
79977974|NCT05374603|Drug|Savolitinib|Savolitinib combine with Durvalumab
79977975|NCT05374603|Drug|Durvalumab|savolitinib plus durvalumab
79325664|NCT03911141|Behavioral|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
79481675|NCT04037826|Dietary Supplement|Placebo|Placebo
79647899|NCT00190190|Procedure|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
79977976|NCT05373953|Drug|CHF6001|CHF6001 will be administered using the NEXThaler® DPI device
79647900|NCT00190190|Procedure|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
79977977|NCT05372640|Drug|Abemaciclib|Given PO
79977978|NCT05372640|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
79977979|NCT05372640|Procedure|Biopsy|Undergo biopsy
79977980|NCT05372640|Procedure|Biospecimen Collection|Undergo blood sample collection
79977981|NCT05372640|Procedure|Diagnostic Imaging|Undergo imaging evaluation
79977982|NCT05372419|Drug|Lebrikizumab|Administered SC
79481676|NCT04036539|Procedure|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
79481677|NCT04033159|Drug|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
79810435|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
79481678|NCT04032899|Dietary Supplement|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
79977983|NCT05371041|Device|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
79977984|NCT05365217|Drug|Nonacog beta pegol|Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.
79325665|NCT03911141|Behavioral|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
79325666|NCT03910478|Device|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
79325667|NCT03910478|Other|Standard Control Strategy|Standard of care with office-based testing.
79325668|NCT03910075|Behavioral|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
79325669|NCT03910075|Behavioral|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
79481679|NCT04032899|Dietary Supplement|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
79647901|NCT00412659|Procedure|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
79977985|NCT05365035|Drug|Cladribine|Given by Vein (IV)
79977986|NCT05365035|Drug|Cytarabine|Given under the skin; subcutaneous injection (SQ)
79977987|NCT05365035|Drug|Venetoclax|Given by PO
79977988|NCT05365035|Drug|Azacitidine|Given by IV or subcutaneous injection (SQ)
79977989|NCT05364775|Other|Focus group|Focus group
79647902|NCT00412659|Procedure|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
79810436|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
79977990|NCT05362773|Drug|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
79977991|NCT05361811|Behavioral|Waitlist|8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
79977992|NCT05361811|Behavioral|ACT Intervention|8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
79977993|NCT05360511|Drug|particulate xenograft + erythropoietin gel.|"Surgical sites will be anaesthetized using local anaesthesia.~Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect."
79977994|NCT05360511|Combination Product|particulate xenograft|"All surgeries will be performed by the same operator as follows:~Surgical sites will be anaesthetized using local anaesthesia.~Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~In Group B (control group):~Particulate xenograft will be applied to fill the whole defect."
79325670|NCT03910075|Behavioral|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
79977995|NCT05358613|Behavioral|My Choices|"The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller & Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion."
79977996|NCT05357846|Drug|Sintilimab|Sintilimab 200mg, IV (in the vein) on day 1 and day 22
79325671|NCT03903172|Device|Abdominal binder|Abdominal binder
79325672|NCT03900624|Drug|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
79325673|NCT03896568|Biological|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
79810437|NCT03591640|Diagnostic Test|Blood test|Standard blood test
79810438|NCT02607267|Other|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
79810439|NCT04048954|Device|Applitabac|Smartphone application in screening on tabagism complications
79810440|NCT04847986|Behavioral|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
79325674|NCT03896568|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79810441|NCT04847986|Behavioral|Control group|The control group will receive care as usual with psychoeducation materials provided.
79647903|NCT00190229|Drug|Cyclophosphamide|Cyclophosphamide
79647904|NCT00213408|Procedure|Radiofrequency catheter ablation of typical atrial flutter|
79810442|NCT03416361|Dietary Supplement|4000IU Vitamin D3|Chewable blackcurrant flavoured tablets (two per day)
79810443|NCT04049968|Device|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
79481680|NCT04008407|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
79977997|NCT05357846|Radiation|Preoperative radiotherapy|External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
79481681|NCT04008407|Procedure|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs => 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
79977998|NCT05357846|Drug|Paclitaxel|50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
79481682|NCT04001062|Procedure|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
79977999|NCT05357846|Drug|Cisplatin|25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
79647905|NCT00190268|Drug|3,4-diaminopyridine|3,4-diaminopyridine
79647906|NCT00220350|Drug|leuprolide acetate|
79647907|NCT00190307|Drug|aspirin 75 mg/day|aspirin 75 mg/day
79647908|NCT00220389|Drug|SPM 907|
79810444|NCT04049968|Other|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
79810445|NCT00761254|Drug|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
79978000|NCT05357846|Procedure|esophagectomy|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
79978001|NCT05357469|Device|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
79325678|NCT03895320|Behavioral|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
79325679|NCT03895320|Behavioral|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
79978002|NCT05357469|Device|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
79978003|NCT05354349|Drug|PRA023 IV Low Dose|Drug
79978004|NCT05354349|Drug|PRA023 SC|Drug
79978005|NCT05354349|Drug|Placebo IV|Placebo
79978006|NCT05354349|Drug|Placebo SC|Placebo
79978007|NCT05354349|Drug|PRA023 IV High Dose|Drug
79325680|NCT03895320|Behavioral|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
79481683|NCT04001062|Other|Non-Operative Management|"For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of <2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of <2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
79325681|NCT03895320|Behavioral|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
79481684|NCT04000360|Other|High-Intensity Aerobic Exercise|The home-based exercise group will receive a Peloton indoor cycle delivered to their home and a heart rate monitor strap. Participants will be asked to cycle 3x/week for 12 months on their bike with their heart rate monitor at an aerobic intensity between 60-80% of heart rate reserve with a target cadence between 80-90 revolutions per minute (RPMs). Additionally, participants (both groups) will receive activity monitors to monitor their daily activity levels.
79481685|NCT03996915|Device|Pdt Photodynamic Therapy|device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
79481686|NCT03996915|Other|tongue scrapper|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
79481687|NCT03995927|Other|Data collection and analysis|Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
79481688|NCT03995927|Other|Quality of Life Questionnaire|Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
79481689|NCT03977259|Other|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
79481690|NCT03974217|Drug|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate [ADP]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
79647909|NCT02963168|Drug|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
79810446|NCT00761332|Drug|teriparatide|treatment will be prescribed according to usual standard of care
79325682|NCT03895320|Behavioral|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
79810447|NCT00761332|Drug|antiresorptives|treatment will be prescribed according to usual standard of care
79810448|NCT03356925|Diagnostic Test|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
79978008|NCT05353244|Device|PrTMS|Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.
79325683|NCT03895320|Behavioral|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
79978009|NCT05353244|Device|Sham|Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
79978010|NCT05348915|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
79978011|NCT05344417|Procedure|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
79978012|NCT05344417|Procedure|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
79978013|NCT05344417|Device|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
79978014|NCT05344417|Drug|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
79647910|NCT00409448|Behavioral|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
79647911|NCT00409448|Behavioral|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
79647912|NCT00190346|Device|Humidification devices: HH vs HME|
79647913|NCT00190385|Procedure|Ultrasonographic screening|Ultrasonographic screening
79647914|NCT00190424|Drug|CpG-ODN|
79647915|NCT00122798|Procedure|Stroke treatment|
79647916|NCT00190463|Drug|Amphotericin B|
79647917|NCT00213486|Drug|irinotecan|
79647918|NCT00190502|Drug|Polyclonal anti-T-cell antibodies|
79647919|NCT00220428|Biological|T-Cell Vaccination|
79647920|NCT00190541|Procedure|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
79647921|NCT00190541|Procedure|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
79325684|NCT03895320|Behavioral|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
79325685|NCT03892746|Device|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
79325686|NCT03892746|Device|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
79481691|NCT03974217|Drug|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
79647922|NCT00213525|Other|Questionnary for environmental factors research|Questionnary for environmental factors research
79647923|NCT00122837|Drug|Duloxetine|
79810449|NCT03321201|Procedure|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
79810450|NCT03321201|Procedure|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
79810451|NCT00839436|Drug|CYT107|
79810452|NCT00761410|Device|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
79978015|NCT05336955|Other|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
79325687|NCT03892694|Device|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
79481692|NCT03973684|Device|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
79647924|NCT00122837|Drug|venlafaxine|
79647925|NCT00122837|Drug|placebo|
79647926|NCT00220467|Behavioral|Aerobic exercise|
79647927|NCT00190580|Drug|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
79647928|NCT00190580|Drug|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
79647929|NCT00220506|Drug|Provigil|
79647930|NCT00190619|Drug|Duloxetine|
79647931|NCT00190619|Drug|Placebo|
79647932|NCT00213564|Drug|response to infliximab associated with methotrexate|
79647933|NCT00122876|Procedure|Photodynamic therapy|
79647934|NCT00122876|Drug|Talaporfin Sodium|
79647935|NCT00220545|Procedure|Laparoscopic ovarian diathermy|
79481693|NCT03973684|Other|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
79481694|NCT03971045|Drug|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
79325688|NCT03892694|Other|Sham|Sham control procedure
79325689|NCT03871036|Drug|Tremelimumab|See experimental arm description for more details.
79325690|NCT03871036|Drug|Durvalumab|See experimental arm description for more details.
79325691|NCT03871036|Drug|Paclitaxel|See experimental arm description for more details.
79325692|NCT03870672|Device|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
79325693|NCT03870672|Device|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
79325694|NCT03870672|Device|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
79325695|NCT03870672|Device|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
79325696|NCT03830580|Other|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
79325697|NCT03818022|Procedure|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
79325698|NCT03796364|Drug|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
79481695|NCT03969888|Drug|ABBV-3067|Tablet taken orally.
79481696|NCT03969888|Drug|Placebo ABBV-3067|Tablet taken orally.
79481697|NCT03969888|Drug|ABBV-2222|Capsule taken orally.
79481698|NCT03969888|Drug|Placebo ABBV-2222|Capsule taken orally.
79481699|NCT03966716|Device|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
79481700|NCT03966716|Device|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
79810453|NCT04049188|Radiation|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
79481701|NCT03960983|Device|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
79647936|NCT00190658|Drug|Somatropin (rDNA origin) for injection|
79978016|NCT05336955|Other|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
79325699|NCT03796364|Drug|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
79481702|NCT03960983|Procedure|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
79647937|NCT00190697|Drug|arzoxifene|
79978017|NCT05336955|Other|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
79325700|NCT03793166|Procedure|Biospecimen Collection|Undergo blood sample collection
79325701|NCT03793166|Drug|Cabozantinib|Given PO
79481703|NCT03960983|Radiation|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
79481704|NCT03960983|Procedure|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
79647938|NCT00122915|Device|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
79481705|NCT03952559|Drug|Baricitinib|Administered orally
79481706|NCT03952559|Drug|Placebo|Administered orally
79810454|NCT02607345|Dietary Supplement|Zusto|25gr
79481707|NCT03952559|Drug|Topical corticosteroid|Administered as standard-of-care
79481708|NCT03952468|Device|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
79481709|NCT03952468|Other|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
79325702|NCT03793166|Procedure|Computed Tomography|Undergo CT scan
79325703|NCT03793166|Biological|Ipilimumab|Given IV
79325704|NCT03793166|Procedure|Magnetic Resonance Imaging|Undergo MRI
79325705|NCT03793166|Biological|Nivolumab|Given IV
79325706|NCT03793166|Other|Quality-of-Life Assessment|Ancillary studies
79325707|NCT03793166|Other|Questionnaire Administration|Ancillary studies
79325708|NCT03791944|Device|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
79325709|NCT03791944|Device|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
79325710|NCT03791944|Device|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
79325711|NCT03791944|Device|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
79810455|NCT02607345|Dietary Supplement|Glucomedics®|25gr
79481710|NCT03945175|Drug|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
79481711|NCT03945175|Drug|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
79481712|NCT03942406|Combination Product|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
79481713|NCT03940235|Drug|Androgen deprivation therapy (ADT)|SBRT + ADT
79481714|NCT03940235|Radiation|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
79647939|NCT00190736|Drug|Atomoxetine Hydrochloride|
79647940|NCT00190736|Drug|placebo|
79647941|NCT00220584|Drug|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
79647942|NCT00122993|Behavioral|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
79647943|NCT00122993|Behavioral|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
79810456|NCT00709020|Drug|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
79978018|NCT05336955|Other|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
79810457|NCT00709020|Other|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
79481715|NCT03939156|Other|Completion of questionnaires|Completion of questionnaires at the time of study entry
79481716|NCT03935893|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
79481717|NCT03935893|Drug|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
79810458|NCT00709020|Other|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
79810459|NCT00709020|Other|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
79810460|NCT00709020|Other|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
79810461|NCT00709020|Other|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
79810462|NCT00709020|Other|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
79481718|NCT03927612|Device|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
79325714|NCT03788499|Other|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
79325715|NCT03784924|Diagnostic Test|MRI prostate|MRI and laboratory biomarkers
79325716|NCT03753555|Drug|Atorvastatin Calcium|20mg Qd for 12 months
79481719|NCT03927612|Device|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
79481720|NCT03924908|Behavioral|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
79481721|NCT03924908|Behavioral|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
79481722|NCT03916510|Biological|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
79481723|NCT03916510|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
79325717|NCT03753555|Drug|Atorvastatin Calcium|40-80mg Qd for 6 months
79325718|NCT03753555|Drug|Probucol|0.5g Bid for 6 months
79325719|NCT03753555|Drug|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
79325720|NCT03749187|Drug|PARP Inhibitor BGB-290|Given PO
79325721|NCT03749187|Drug|Temozolomide|Given PO
79325722|NCT03734679|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
79325723|NCT03734588|Genetic|SPK-8016|adeno-associated viral vector
79325724|NCT03733041|Device|rTMS|This group will receive rTMS treatment
79325725|NCT03733041|Device|Sham|This group will receive sham treatment
79325726|NCT03733041|Other|No intervention|This group will receive no intervention
79325727|NCT03725202|Drug|Upadacitinib|It will be administered orally.
79325728|NCT03725202|Drug|Corticosteroid (CS)|It will be administered orally.
79647944|NCT00122993|Behavioral|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
79647945|NCT00213681|Device|Boussignac CPAP - bilevel ventilation support|
79325729|NCT03725202|Other|Placebo|It will be administered orally.
79325733|NCT03709706|Drug|Lete-cel|lete-cel will be administered to eligible participants.
79325734|NCT03709706|Drug|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
79325735|NCT03691987|Biological|Preprocessed thawed donor FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
79325736|NCT03691987|Biological|Preprocessed thawed autologous FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
79325737|NCT03679221|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
79325738|NCT03676907|Procedure|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
79325739|NCT03674723|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
79647946|NCT00190814|Drug|duloxetine|
79647947|NCT00190814|Drug|placebo|
79325740|NCT03674619|Procedure|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
79481724|NCT03916510|Radiation|Radiotherapy|50 Gy/25#
79647948|NCT00220623|Drug|antidepressant medications, flexible drug choice|
79647949|NCT00220623|Behavioral|CBT, Psychodynamic or Supportive Psychotherapy|
79647950|NCT00220662|Behavioral|Readiness and Motivation Therapy|
79647951|NCT00220818|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
79647952|NCT00220818|Drug|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
79810463|NCT03388762|Dietary Supplement|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
79325741|NCT03674619|Behavioral|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
79325742|NCT03671967|Drug|Piperacillin/tazobactam|4.5 grams QID
79481725|NCT03915652|Behavioral|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
79325743|NCT03671967|Drug|Meropenem|1 gram TID
79325744|NCT03668769|Other|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
79325745|NCT03668769|Other|Interview|Ancillary studies
79325746|NCT03668769|Other|Questionnaire Administration|Ancillary studies
79325747|NCT03668769|Behavioral|Smoking Cessation Intervention|Participate in individual smoking cessation program
79647953|NCT00213759|Drug|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
79647954|NCT00213759|Drug|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
79647955|NCT00190853|Drug|Duloxetine|
79647956|NCT00213798|Procedure|Biopsy samples|
79647957|NCT00190892|Drug|olanzapine|
79810464|NCT03388762|Other|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
79325748|NCT03654079|Other|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
79325749|NCT03633253|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
79647958|NCT00190892|Drug|carbamazepine|
79647959|NCT00220857|Drug|Rabeprazole|
79810465|NCT02612220|Procedure|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
79810466|NCT02612220|Other|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
79325750|NCT03633240|Other|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
79325751|NCT03628768|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
79325752|NCT03626103|Behavioral|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
79810467|NCT04627246|Biological|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab: intravenous, starting after the last chemotherapy cycle. Administered as a flat dose of 240mg every 2 weeks during the vaccination period until the last vaccine dose or at least for 8 weeks after the end of last chemotherapy cycle if vaccination stops earlier. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity for a maximum of 2 years."
79325753|NCT03626103|Behavioral|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
79325754|NCT03604835|Other|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
79325755|NCT03598608|Biological|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
79325756|NCT03598608|Biological|Favezelimab|Administered as an IV infusion Q3W
79325757|NCT03558867|Drug|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
79325758|NCT03558867|Drug|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
79325759|NCT03528694|Biological|Durvalumab (MEDI4736)|Investigational product
79325760|NCT03528694|Biological|Bacillus Calmette-Guerin (BCG)|Standard of care
79325761|NCT03523390|Drug|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
79325762|NCT03523390|Drug|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
79810468|NCT00761488|Device|AcrySof® Toric IOL|Implanted into the study eye
79325763|NCT03523390|Drug|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
79325764|NCT03523390|Drug|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
79647960|NCT00213837|Device|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
79810469|NCT00761566|Other|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
79978019|NCT05336240|Behavioral|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
79647961|NCT00190931|Drug|Atomoxetine Hydrochloride|
79647962|NCT00190931|Drug|placebo|
79325767|NCT03503344|Drug|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
79325768|NCT03503344|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79325769|NCT03501576|Biological|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
79647963|NCT00220896|Drug|Donepezil|
79978020|NCT05336240|Behavioral|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
79978021|NCT05335993|Biological|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
79978022|NCT05335993|Drug|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is <77 kg or platelet count is <150,000 μL, the daily dosing will be 200mg.
79325770|NCT03439046|Drug|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
79325771|NCT03439046|Drug|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
79325772|NCT03439046|Drug|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
79647964|NCT00123032|Behavioral|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
79647965|NCT00123032|Procedure|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
79647966|NCT00190970|Drug|Ruboxistaurin|
79647967|NCT00220935|Device|Orthotrac Pneumatic Vest|
79647968|NCT00191009|Drug|atomoxetine hydrochloride|
79647969|NCT00191009|Drug|placebo|
79647970|NCT00220974|Behavioral|Internet-based tailored advice on cardiovascular risk|
79647971|NCT00213915|Drug|12 g of L-arginine glutamate during 6 weeks twice a day|
79647972|NCT00191048|Drug|Atomoxetine|
79978023|NCT05335941|Drug|Pemetrexed|Given by vein (IV)
79978024|NCT05335941|Drug|Zimberelimab|Given by vein (IV)
79978025|NCT05335941|Drug|Etrumadenant|Given by PO
79978026|NCT05333393|Behavioral|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
79325773|NCT03439046|Drug|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
79325774|NCT03436745|Drug|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach <50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
79481726|NCT03915587|Device|CardioQ-EDM and CipherOx-CRI|A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
79647973|NCT00221013|Procedure|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
79647974|NCT00123149|Drug|Epoetin alfa|
79647975|NCT00411840|Procedure|intraarterial and intramuscular injection of BMCs|
79647976|NCT00191087|Drug|Duloxetine|
79647977|NCT00213954|Procedure|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
79647978|NCT00191126|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
79481727|NCT03909100|Device|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
79325775|NCT03429543|Drug|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
79325776|NCT03429543|Drug|Insulin|Basal or multiple dose injection.
79481728|NCT03901482|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
79481729|NCT03901482|Drug|Placebos|Placebo for STS101
79481730|NCT03896295|Drug|M281|M281 injection administered as intravenous infusion
79647979|NCT00191126|Drug|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
79647980|NCT00191126|Procedure|surgery|surgery
79647981|NCT00221052|Drug|Diclofenac|
79647982|NCT00123188|Procedure|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
79647983|NCT00213993|Drug|antiperspirant|antiperspirant topically once daily to one foot
79647984|NCT00191204|Drug|Duloxetine|
79647985|NCT00221091|Procedure|ventriculo-peritoneal shunt|
79325777|NCT03429543|Drug|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
79647986|NCT00123227|Drug|Rosiglitazone|
79647987|NCT00221130|Procedure|surgical operation of cell transplantation|
79647988|NCT00191243|Drug|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
79647989|NCT00191243|Drug|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
79647990|NCT00214032|Drug|Pycnogenol|pycnogenol 300 mg daily
79647991|NCT00214032|Drug|Placebo|placebo 3 capsules daily
79647992|NCT00123266|Drug|Microplasmin|2 mg/kg, IA over 75 mins
79647993|NCT00221169|Procedure|Surgical resection|pet ct prior to surgery
79647994|NCT06117241|Behavioral|IMAGINE HEALTHY|An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
79647995|NCT06117215|Other|Data collection|data collection
79481731|NCT03882723|Device|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
79325778|NCT03429543|Drug|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
79325779|NCT03429543|Drug|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
79481732|NCT03861143|Drug|BT-11 (440 mg)|Oral, once daily tablet
79481733|NCT03861143|Drug|BT-11 (880 mg)|Oral, once daily tablet
79647996|NCT06117189|Other|Questionnaire|Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
79647997|NCT06117150|Device|Drug-eluting Coronary Spur Stent System|All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
79647998|NCT06117137|Drug|SGLT2 inhibitor|"Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin"
79647999|NCT06117111|Device|PaMo monitoring device|Comparison of the device to standard monitoring
79648000|NCT06117098|Device|Mobile application|Individual lifestyle intervention via an mobile application
79648001|NCT06117098|Behavioral|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"
79978027|NCT05333185|Behavioral|DİABOT (mobile application robot )|"DİABOT (mobile application robot ) Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type~1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet."
79648002|NCT06117098|Behavioral|Group-based lifestyle intervention|Group-based life style intervention at a Healthy Lifestyle Centre (ususal care)
79978028|NCT05329493|Device|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
79648003|NCT06117085|Device|CellFX® Percutaneous Electrode (PE) System|Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
79648004|NCT06117072|Other|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
79648005|NCT06117059|Radiation|3 fractions of prostate SBRT|Radical radiotherapy using only 3 fractions of prostate SBRT over 3 consecutive days
79648006|NCT06117046|Drug|Cardiopeptides|Cardiopeptide was administered intravenously once a day with 60mg of cardiopeptide for 3 days
79648007|NCT06117033|Other|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
79325780|NCT03427463|Drug|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
79325781|NCT03427463|Drug|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
79325782|NCT03425526|Biological|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
79325783|NCT03413254|Other|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
79481734|NCT03861143|Drug|Placebo|Oral, once daily tablet
79481735|NCT03853317|Biological|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
79481736|NCT03853317|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79648008|NCT06117020|Drug|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
79648009|NCT06117007|Dietary Supplement|Betalains|"Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)"
79648010|NCT06117007|Other|Placebo|Placebo capsules containing rice hulls. (0 mg betalains per capsule)
79648011|NCT06116994|Other|The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)|In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.
79325784|NCT03413254|Procedure|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
79648012|NCT06116994|Other|The buccal infiltration anesthesia with a conventional dental syringe|In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.
79481737|NCT03853317|Biological|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
79648013|NCT06116968|Drug|Aficamten|5-20mg
79481738|NCT03845010|Drug|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
79325785|NCT03413254|Procedure|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
79325786|NCT03393884|Biological|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
79648016|NCT06116903|Genetic|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
79648017|NCT06116877|Procedure|implant supported overdenture|mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
79648018|NCT06116864|Device|Endocuff and GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
79648019|NCT06116864|Device|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
79648020|NCT06116851|Other|MRI scan and laboratory visit|Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.
79648021|NCT06116851|Procedure|Prostate biopsies|The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.
79325787|NCT03393884|Drug|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
79481739|NCT03845010|Drug|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
79648022|NCT06116851|Procedure|Radical prostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
79648023|NCT06116851|Procedure|TURP and blood, urine and tissue sampling|Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.
79810470|NCT00761566|Other|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
79810471|NCT00761644|Drug|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.
79481740|NCT03845010|Procedure|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
79325788|NCT03393884|Drug|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
79325789|NCT03388606|Behavioral|Growth Mindset|30 Minute interactive video
79481741|NCT03829371|Drug|Velcade|Subcutaneous use
79481742|NCT03829371|Drug|Melphalan|Oral use
79481743|NCT03829371|Drug|Prednisone|Oral use
79481744|NCT03829371|Drug|Lenalidomide|Oral use
79481745|NCT03829371|Drug|Dexamethasone|Oral use
79481746|NCT03829371|Drug|Daratumumab|Subcutaneous Injection
79481747|NCT03826264|Procedure|TAVR|transcatheter aortic valve replacement (TAVR)
79810472|NCT00761644|Drug|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
79325791|NCT03362190|Drug|Zimura|Zimura in combination with Lucentis
79325792|NCT03362190|Drug|Lucentis|Zimura in combination with Lucentis
79325793|NCT03356860|Drug|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
79325794|NCT03356860|Drug|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
79325795|NCT03356860|Drug|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
79325796|NCT03356860|Drug|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
79325797|NCT03333044|Behavioral|Community Health Worker (CHW)-led health|Patients contacted a maximum of 10 times over 2 weeks to attend diabetes management sessions led by community health workers. Enrolled patients attend 5 Monthly group sessions led by a CHW held at the clinic
79978029|NCT05326243|Biological|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9*10^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
79978030|NCT05325151|Other|Educational Intervention|Receive GCPP intervention videos
79978031|NCT05325151|Other|Genetic Counseling|Receive genetic counseling
79978032|NCT05325151|Other|Survey Administration|Ancillary studies
79978033|NCT05321979|Drug|MBA-P01|MBA-P01 will be injected into the Glabellar line.
79978034|NCT05319834|Drug|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
79978035|NCT05319834|Drug|Placebo|group 2: oral placebo once daily at the same time with progesterone
79810473|NCT00761644|Drug|Temsirolimus|Days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
79325798|NCT03333044|Behavioral|HIT-enabled|During one on one visit, CHWs will assess social needs of patients using mobile technology. CHWs will give referral sources to patients generated by mobile app, and they will track through mobile app.
79325799|NCT03333044|Behavioral|Physician enabled care coordination|Forms on patient goal setting and referrals made are uploaded into EHR to physician
79325800|NCT03319082|Combination Product|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
79325801|NCT03314584|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
79325802|NCT03314584|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
79325803|NCT03312400|Drug|Danazol|Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
79325807|NCT03287193|Biological|Blood sample|for patient and its parents
79325808|NCT03287193|Genetic|high-throughput sequencing|exome or whole genome sequencing
79810474|NCT04049812|Device|PEMF|
79810475|NCT04049812|Device|Hot pack|
79810476|NCT04049812|Device|TENS|
79810477|NCT04049812|Device|Sham PEMF|
79810478|NCT04049734|Drug|oral losatan|50 mg of oral losartan one hour before the ERCP once
79810479|NCT04617418|Behavioral|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
79810480|NCT02559388|Drug|Montelukast|
79810481|NCT02559388|Drug|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
79810482|NCT03168256|Drug|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
79810483|NCT03168256|Drug|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
79810484|NCT03168256|Drug|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
79810485|NCT03168256|Drug|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
79978036|NCT05319574|Radiation|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
79978037|NCT05319574|Drug|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
79978038|NCT05318183|Other|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
79978039|NCT05318183|Other|White Bread (control)|Standardized white bread (128 g daily)
79978040|NCT05317975|Behavioral|Add-on telerehabilitation and home-based rehabilitation|"12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~Add-on telerehabilitation for instruction and supervision of exercise training"
79325809|NCT03283826|Biological|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
79325810|NCT03283826|Drug|Placebo|Placebo matching to ATA188
79325811|NCT03269136|Drug|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
79325812|NCT03269136|Drug|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
79325813|NCT03269136|Drug|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
79325814|NCT03269136|Drug|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
79325815|NCT03269058|Drug|Dapagliflozin|Dapagliflozin 10 mg daily per os
79325816|NCT03269058|Drug|Placebos|Placebo of Dapagliflozin per day per os
79325817|NCT03255174|Biological|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
79325818|NCT03254667|Biological|Brodalumab|Brodalumab
79325819|NCT03254667|Drug|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
79325820|NCT03246061|Device|Intracept System|BVN ablation using radiofrequency energy
79648024|NCT06116851|Procedure|Radical cystoprostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
79648025|NCT06116825|Other|1450ppm Fluoride toothpaste|1450ppm Fluoride toothpaste
79325821|NCT03246061|Other|Standard Care|Non-surgical standard care
79325822|NCT03217357|Device|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
79325823|NCT03194971|Other|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
79325824|NCT03194971|Device|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
79325825|NCT03194893|Drug|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
79325826|NCT03194893|Drug|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
79325827|NCT03182244|Drug|gilteritinib|oral
79325828|NCT03182244|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
79325829|NCT03182244|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|intravenous
79325830|NCT03182244|Drug|FLAG (Granulocyte colony-stimulating factor (G-CSF), Fludarabine, Cytarabine)|intravenous
79648026|NCT06116825|Other|1000Pppm Fluoride toothpaste|1000Pppm Fluoride toothpaste
79978041|NCT05317975|Behavioral|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
79648027|NCT06116799|Device|Orthotic|Arch support orthotic
79810486|NCT00761722|Drug|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
79810487|NCT00761800|Drug|Lactic acid|
79810488|NCT04582708|Device|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
79810489|NCT00761878|Procedure|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
79810490|NCT02558998|Other|Survey|
79978042|NCT05316194|Other|Digital treatment for hip and knee osteoarthritis|"The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program."
79325831|NCT03158896|Biological|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
79325832|NCT03137160|Biological|Ixekizumab|Injection
79325833|NCT03136705|Drug|Nicotinamide|Nicotinamide tablet
79325834|NCT03136705|Drug|Lanthanum Carbonate|Lanthanum Carbonate tablet
79325835|NCT03136705|Drug|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
79325836|NCT03136705|Drug|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
79325837|NCT03134196|Drug|Masked Placebo|Oral Placebo
79810491|NCT04529434|Other|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight & durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
79481748|NCT03812874|Drug|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
79648028|NCT06116773|Other|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
79810492|NCT04529434|Other|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
79810493|NCT04507906|Drug|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
79481749|NCT03812874|Drug|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
79325838|NCT03134196|Drug|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
79481750|NCT03786198|Behavioral|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
79481751|NCT03786198|Behavioral|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
79325839|NCT03130127|Drug|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
79325840|NCT03127007|Drug|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
79810494|NCT02558920|Other|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
79810495|NCT04471636|Device|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
79810496|NCT00762112|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
79810497|NCT00762190|Drug|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
79810498|NCT00762190|Drug|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
79481752|NCT03785964|Drug|Nirogacestat oral tablet|Nirogacestat tablet
79810499|NCT00762346|Drug|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
79810500|NCT04375930|Other|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
79325841|NCT03127007|Drug|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
79325842|NCT03110432|Drug|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
79325843|NCT03110432|Drug|Standard lipid lowering therapy|drug use according to the respective product labelling
79325844|NCT03071913|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
79325845|NCT03071913|Other|Laboratory Biomarker Analysis|Correlative studies
79325846|NCT03046251|Drug|Natalizumab|
79325858|NCT02989662|Drug|Mifepristone|Participants receive 6 doses.
79325859|NCT02989662|Drug|Placebo - Cap|Participants receive 6 doses
79648029|NCT06116773|Other|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~Breathing exercises~Moderate intensity (RPE 4-6) walking (150 min/week).~Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
79648030|NCT06116760|Device|Anodal or sham tDCS|"Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training."
79978043|NCT05315011|Other|Whole-body cryotherapy|"The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C."
79978044|NCT05315011|Other|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
79978045|NCT05303701|Drug|GV1001 Placebo|0.9% normal saline
79978046|NCT05303701|Drug|GV1001 1.12mg|Lyophilized peptide from hTERT
79325860|NCT02979873|Drug|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
79325861|NCT02944617|Other|Laboratory Biomarker Analysis|Correlative studies
79648031|NCT06116760|Behavioral|Audio-visual training|"90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse."
79325862|NCT02944617|Dietary Supplement|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
79325863|NCT02944617|Drug|VEGF-TKI|Must be received as standard of care chemotherapy
79325864|NCT02940301|Drug|Ibrutinib|Given PO
79325865|NCT02940301|Other|Laboratory Biomarker Analysis|Correlative studies
79325866|NCT02940301|Biological|Nivolumab|Given IV
79648032|NCT06116734|Drug|Grastofil®|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days
79648033|NCT06116734|Drug|Lapelga|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection
79648034|NCT06116695|Drug|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
79648035|NCT06116695|Drug|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
79648036|NCT06116682|Biological|Amivantamab|Given IV
79648037|NCT06116682|Procedure|Biospecimen Collection|Undergo collection of blood samples
79648038|NCT06116682|Procedure|Computed Tomography|Undergo CT scan
79325867|NCT02890849|Other|Liquid biopsy|
79325868|NCT02889627|Drug|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
79325869|NCT02869685|Radiation|radiotherapy|radiotherapy
79325870|NCT02867124|Drug|XR-NTX|Vivitrol
79325871|NCT02867124|Other|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
79978047|NCT05301816|Device|Spinal Cord Stimulator (SCS)|Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
79481753|NCT03785964|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
79325872|NCT02867124|Other|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
79325873|NCT02837965|Drug|treatment with topical superpotent corticosteroid therapy|
79481754|NCT03783975|Genetic|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
79481755|NCT03779230|Drug|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
79481756|NCT03743428|Drug|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
79648039|NCT06116682|Procedure|Magnetic Resonance Imaging|Undergo MRI
79978048|NCT05300607|Other|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
79307319|NCT04664101|Behavioral|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
79307320|NCT04664101|Other|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
79307321|NCT04649905|Procedure|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
79307322|NCT04649905|Procedure|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
79307323|NCT04631718|Radiation|Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)|"MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves.~Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration."
79307324|NCT04609137|Procedure|Early drain removal|"Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management."
79307325|NCT04609137|Procedure|Standard drain removal|"Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection"
79307326|NCT04598477|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
79307327|NCT04598477|Drug|prednisone|Oral prednisone tablets
79307328|NCT04588428|Drug|INO-4700|INO-4700 was administered ID.
79307329|NCT04588428|Drug|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
79307330|NCT04588428|Device|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device was administered following ID drug administration
79325874|NCT02837965|Drug|treatment with systemic therapy (methotrexate)|
79648040|NCT06116643|Dietary Supplement|Soluble protein hydrolysate (SPHi)|Participants that are already on stable maintenance therapy for ulcerative colitis will continue with their therapy regimen and the addition of 10g of SPHi in 100ml of water every day for 12 weeks.
79648041|NCT06116630|Diagnostic Test|DCE-MRI|Both groups will undergo DCE-MRIs.
79810501|NCT04375930|Other|Control|It consists of only skills and discharge education
79810502|NCT00762658|Drug|AN2728 Ointment, 5%|
79978049|NCT05297760|Biological|Polvac Grass+Rye|Suspension of micro crystalline tyrosine with grass and rye pollen allergen
79978050|NCT05297760|Drug|Saline 0.9%|Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
79978051|NCT05295953|Device|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
79978052|NCT05295953|Device|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
79325875|NCT02837965|Drug|treatment systemic therapy (prednisone)|
79325876|NCT02837965|Drug|treatment with systemic therapy (prednisone)|
79325877|NCT02837965|Drug|treatment with systemic therapy (doxycycline)|
79325878|NCT02815696|Device|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
79648042|NCT06116565|Biological|CM310|CM310, subcutaneous injection
79648043|NCT06116552|Behavioral|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
79648044|NCT06116552|Behavioral|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
79648045|NCT06116539|Drug|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
79648046|NCT06116539|Procedure|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
79648047|NCT06116513|Device|S53P4 bioactive glass granules|During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.
79810503|NCT00762658|Drug|AN2728 Ointment, 2%|
79810504|NCT00762658|Drug|AN2728 Ointment, 0.5%|
79810505|NCT00762658|Drug|AN2728 Ointment Vehicle|
79810506|NCT00762658|Drug|Betnesol®-V Creme, 0.1%|
79810507|NCT00762658|Drug|Protopic® Ointment, 0.1 %|
79810508|NCT02558452|Drug|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
79810509|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
79810510|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
79810511|NCT00762736|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
79810512|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
79810513|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
79978053|NCT05291325|Drug|3L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
79978054|NCT05291325|Drug|3L PEG|Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
79978055|NCT05291325|Drug|2L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
79978056|NCT05289180|Other|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
79481757|NCT03743428|Drug|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
79810514|NCT00762736|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
79978057|NCT05285280|Diagnostic Test|Echocardiography|The echocardiography will be performed with a GE Vingmed Ultrasoundís Vivid9 (Horten, Norway). All subjects are examined with color TDI, 2-dimensional and M-mode echocardiography, conventional spectral Doppler, 2DSTE, and where possible 4D Echocardiography in the left lateral decubitus position.
79325879|NCT02813369|Drug|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
79978058|NCT05279976|Other|Visualized Education|The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.
79978059|NCT05279976|Other|Distraction|Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
79978060|NCT05277636|Drug|3,4-methylenedioxymethamphetamine|A dose of 125 mg racemic MDMA will be administered.
79325880|NCT02813369|Drug|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
79978061|NCT05277636|Drug|S-3,4-methylenedioxymethamphetamine|A dose of 125 mg enantiomeric S-MDMA will be administered.
79978062|NCT05277636|Drug|R-3,4-methylenedioxymethamphetamine (125 mg)|A dose of 125 mg enantiomeric R-MDMA will be administered.
79325881|NCT02806440|Drug|Low dose naltrexone|Active comparator
79325882|NCT02806440|Drug|Placebo|Placebo comparator
79325883|NCT02798276|Procedure|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
79307331|NCT04581564|Device|Rhythm-based speech therapy app (i.e., Speech Hero)|Patients with non-fluent aphasia will practice speech production during the intervention period.
79307332|NCT04564157|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center."
79307333|NCT04564157|Drug|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
79325884|NCT02798276|Other|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
79978063|NCT05277636|Drug|R-3,4-methylenedioxymethamphetamine (250 mg)|A dose of 250 mg enantiomeric R-MDMA will be administered.
79978064|NCT05277636|Other|Placebo|Placebo (Mannitol)
79978065|NCT05274906|Other|Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat|Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
79978066|NCT05274815|Biological|Tezepelumab|Tezepelumab subcutaneous injection
79978067|NCT05270668|Drug|Tulisokibart|Tulisokibart administered at timepoints as directed by the protocol
79810515|NCT00762814|Device|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
79325886|NCT02788006|Drug|Regorafenib 160 mg|
79810516|NCT02915224|Drug|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
79810517|NCT02915224|Drug|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
79325889|NCT02723773|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
79325890|NCT02686658|Drug|Zimura|Zimura 20 mg/mL solution for intravitreal (IVT) injection
79325891|NCT02686658|Other|Sham|The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
79810518|NCT02813824|Drug|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
79978068|NCT05270668|Diagnostic Test|Companion diagnostic ( CDx)|CDx+ or CDx-
79978069|NCT05270668|Drug|Placebo|Placebo
79978070|NCT05267600|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
79325892|NCT02686125|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
79325893|NCT02684669|Drug|Naloxone|active drug infusion
79325894|NCT02684669|Drug|Normal saline|placebo comparator
79325895|NCT02677272|Other|Appropriateness of NH resident's transfer to ED|
79325896|NCT02654626|Drug|KBP-7072|Drug Intervention
79325897|NCT02654626|Other|Placebo|
79325898|NCT02653014|Drug|KBP-5074|
79325899|NCT02650401|Drug|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
79325900|NCT02642744|Other|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
79810519|NCT02813824|Drug|Placebo (for Aspirin 300)|Daily dose during 4 years
79810520|NCT02813824|Drug|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
79325901|NCT02639026|Radiation|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
79810521|NCT02813824|Drug|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
79978071|NCT05267600|Other|placebo|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
79978072|NCT05267600|Drug|Prednisone|Oral Prednisone
79978073|NCT05262270|Drug|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
79978074|NCT05262270|Drug|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
79978075|NCT05262270|Drug|Placebo (PLB) Injectable|3 doses of intramuscular injections (Week 0, 3, 6)
79978076|NCT05262270|Drug|Placebo (PLB) Injectable|2 doses of subcutaneous injections (Week 0, 4)
79481758|NCT03741582|Other|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
79325902|NCT02639026|Drug|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
79481759|NCT03739710|Drug|Docetaxel|Docetaxel will be administered.
79325903|NCT02639026|Drug|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
79325904|NCT02616640|Drug|Durvalumab|
79325905|NCT02616640|Drug|Pomalidomide|
79325906|NCT02616640|Drug|Dexamethasone|
79325907|NCT02598349|Radiation|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
79325908|NCT02598349|Drug|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
79325909|NCT02598349|Procedure|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
79481760|NCT03739710|Drug|Feladilimab|Feladilimab will be administered.
79481761|NCT03739710|Drug|Ipilimumab|Ipilimumab will be administered.
79481762|NCT03739710|Drug|GSK4428859A|GSK4428859A/EOS884448 will be administered.
79481763|NCT03739710|Drug|Dostarlimab|Dostarlimab will be administered.
79481764|NCT03739710|Drug|GSK6097608|GSK6097608 will be administered.
79325910|NCT02594813|Procedure|Biopsy or cold snare polypectomy|
79325911|NCT02579967|Drug|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
79325912|NCT02579967|Drug|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
79481765|NCT03734666|Behavioral|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
79481766|NCT03734666|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
79481767|NCT03728608|Device|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
79481768|NCT03728608|Device|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
79481769|NCT03718325|Device|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
79481770|NCT03718325|Device|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
79481771|NCT03714984|Other|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
79481772|NCT03714984|Other|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
79481773|NCT03714373|Drug|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
79481774|NCT03714373|Drug|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
79481775|NCT03714373|Drug|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
79481776|NCT03695081|Procedure|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital~Medication review post surgery~Optimised list of drugs in the discharge summary, in accordance with hospital procedures~Medication reconciliation, six weeks after discharge~Medication review, six weeks after discharge"
79481777|NCT03691064|Drug|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie [mCi]) every 8 weeks for a total of 4 doses.
79481778|NCT03690921|Drug|Cisplatin|Given IV
79481779|NCT03690921|Drug|Fluorouracil|Given IV
79481780|NCT03690921|Radiation|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
79978077|NCT05261204|Device|Transcatheter Aortic Valve Implantation|Patients who are deemed receive TAVI first underwent evaluation of their peripheral arteries before the procedure, in order to separate those eligible for transfemoral placement (TFP) from those who would require transapical placement. Technological advances achieved in the new platforms for the treatment of SHD have allowed the use of reduced size catheters and sheaths in the new armamentarium, favoring the TFP technique. The transcatheter valve (TV) is positioned at the level of the native aortic valve during the final step of valve replacement, when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system i traverses the aorta retrograde over a guidewire from its point of insertion in the femoral artery during the use of TFP. Before balloon inflation, the valve and balloon are collapsed on the catheter and fit within the sheath. After balloon inflation, the calcified native valve is replaced by the expanded TV
79810522|NCT05306782|Device|transcranial Electrical Stimulation|transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
79481781|NCT03690921|Procedure|Quality-of-Life Assessment|Ancillary studies
79481782|NCT03690921|Other|Questionnaire Administration|Ancillary studies
79978078|NCT05261204|Procedure|Bioprothesis|The bioprosthesis is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
79978079|NCT05261204|Procedure|Sutureless|The sutureless is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
79978080|NCT05254171|Drug|SBP-101|small molecule polyamine metabolic inhibitor for subcutaneous injection
79978081|NCT05254171|Drug|Nab-paclitaxel|paclitaxel protein-bound particles for injectable suspension
79978082|NCT05254171|Drug|Gemcitabine|gemcitabine for injection
79978083|NCT05254171|Other|Placebo|Normal Saline
79978084|NCT05254080|Device|Active taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath).
79810523|NCT05306782|Behavioral|Speech Therapy|Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
79810524|NCT02669680|Drug|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
79810525|NCT02669680|Other|Standard therapy|
79325913|NCT02579967|Drug|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
79325914|NCT02579967|Drug|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
79325915|NCT02579967|Procedure|Allo BMT|Allogeneic blood or marrow transplantation
79325916|NCT02574728|Drug|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
79325917|NCT02574728|Drug|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
79325918|NCT02574728|Drug|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
79481783|NCT03684889|Biological|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
79810526|NCT00673894|Drug|Sitagliptin|Glutamine 30g +sitagliptin 100mg
79810527|NCT00673894|Drug|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
79810528|NCT00763126|Behavioral|stress level|Stress levels
79810529|NCT00763204|Drug|AN2728 Cream, 2%|
79810530|NCT00763204|Drug|AN2728 Cream, 1%|
79810531|NCT00763204|Drug|AN2728 Cream, 0.3%|
79481784|NCT03684889|Biological|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
79810532|NCT00763204|Drug|AN2728 Cream Vehicle|
79810533|NCT00763204|Drug|Betnesol®-V Creme, 0.1%|
79810534|NCT02558140|Biological|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
79810535|NCT02558140|Biological|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
79810536|NCT02558218|Drug|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
79810537|NCT02558218|Drug|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
79810538|NCT00763438|Drug|Sertindole|Flexible dose
79810539|NCT00763516|Radiation|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
79325919|NCT02574728|Drug|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
79325920|NCT02527746|Drug|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
79325921|NCT02527746|Drug|EC regimen|Epirubicin 100 mg/m^2 (in vein) and Cyclophosphamide 600 mg/m^2 (in vein) on Day 1 of each cycle for 4 cycles.
79325922|NCT02408861|Procedure|Biospecimen Collection|Undergo blood sample collection
79325923|NCT02408861|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79325924|NCT02408861|Procedure|Computed Tomography|Undergo CT scan
79325925|NCT02408861|Biological|Ipilimumab|Given IV
79810540|NCT02558842|Other|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
79810541|NCT02158000|Other|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
79810542|NCT00674986|Device|Accu-Chek 360° View Blood Glucose Analysis Tool|
79325926|NCT02408861|Biological|Nivolumab|Given IV
79325927|NCT02408861|Procedure|Positron Emission Tomography|Undergo PET scan
79481785|NCT03680677|Procedure|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
79481786|NCT03680677|Other|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
79325928|NCT02397954|Drug|Zimura|Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
79810543|NCT00674986|Device|Accu-Chek Aviva Glucose Meter|
79325931|NCT02387957|Drug|Fovista®|
79325932|NCT02387957|Drug|bevacizumab|
79810544|NCT02559232|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
79325933|NCT02387957|Drug|ranibizumab|
79325934|NCT02387957|Drug|aflibercept|
79810545|NCT00758446|Drug|BLX-028914|50 mg capsules, p.o, daily, 14 days
79325943|NCT02257853|Other|Stress reduction intervention|Gentle chair yoga and breath work
79325944|NCT02251704|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
79810546|NCT00758446|Drug|BLX-028914|15 mg capsules, p.o, daily, 14 days
79810547|NCT00758446|Drug|placebo|capsules, p.o, daily, 14 days
79810548|NCT00763594|Behavioral|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
79648048|NCT06116474|Behavioral|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
79648049|NCT06116461|Drug|Nivolumab|Participants receive three reduced doses of 240 mg every four weeks
79648050|NCT06116448|Other|high-fidelity simulation|The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
79481787|NCT03680677|Diagnostic Test|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
79481788|NCT03657147|Behavioral|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
79481789|NCT03647306|Behavioral|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
79481790|NCT03647306|Behavioral|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
79810549|NCT00763594|Behavioral|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
79810550|NCT00763672|Other|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
79302433|NCT03224143|Behavioral|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
79325945|NCT02251704|Diagnostic Test|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
79325946|NCT02233829|Drug|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of [11C]raclopride.
79325947|NCT02233829|Radiation|Brain Dopamine Receptor|The radiotracer [11C] raclopride is used for imaging dopamine receptors and dopamine release.
79325948|NCT02214628|Drug|Fovista® (anti-PDGF BB) plus anti-VEGF|
79810551|NCT00763672|Other|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
79325950|NCT02203526|Drug|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
79325951|NCT02203526|Drug|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
79648051|NCT06116448|Other|hybrid simulation|The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
79810552|NCT00764842|Device|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
79325952|NCT02203526|Biological|Rituximab|Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
79325953|NCT02203526|Drug|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
79325954|NCT02203526|Drug|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
79810553|NCT02558062|Other|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
79978085|NCT05254080|Device|Sham taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath). During sham (placebo) stimulation, ear electrodes will be attached to the participant's ear but they will not receive any stimulation.
79978086|NCT05253469|Procedure|Cryopreserved Aortic Homograft|CAH is used for aortic root reconstruction and for repair of mitro-aortic curtain (emicommando procedure) and it is inserted as miniroot . In cases of PVE the infected prosthesis is removed with aggressive debridement of all infected and necrotic tissue. (7)The coronary ostia are prepared for reconstruction of aortic root. In complex valve endocarditis involving aortic and mitral valve a double homograft may be used.Mitro-aortic endocarditis intervalvular fibrosa is largely involved.The abscess cavity is precisely bounded and debrided. and a double homograft is used for the reconstruction (commando procedure
79978087|NCT05253469|Procedure|Stented/Non stented xenograft|The insertion of stented/non stented xenograft may be performed using separate or continuos stich with or without teflon pledget. Biological valves may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic bioroot using bioprosthetic valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
79810554|NCT00673660|Behavioral|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
79810555|NCT00763906|Device|norepinephrine infused at the clinician's discretion|
79810556|NCT00763906|Device|norepinephrine infused under computerized fuzzy logic control|
79648052|NCT06116448|Other|telesimulation|The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
79648053|NCT06116435|Behavioral|Prevent T2|The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
79810557|NCT00763984|Behavioral|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
79810558|NCT00763984|Behavioral|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
79481791|NCT03647306|Behavioral|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
79325955|NCT02203526|Drug|Ibrutinib (Arms 2, 3 and 4)|Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)
79325956|NCT02203526|Drug|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
79325957|NCT02203526|Drug|Ibrutinib (Arm 1 - Closed with Amendment G)|Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
79325958|NCT02203526|Drug|Ibrutinib (Arm 4)|Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
79810559|NCT00764062|Drug|Amoxicillin|Amoxicillin :drug
79810560|NCT00758914|Dietary Supplement|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
79810561|NCT00759070|Drug|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
79810562|NCT00759070|Drug|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
79810563|NCT00764140|Biological|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
79810564|NCT00672958|Drug|Vortioxetine|Encapsulated immediate-release tablets.
79810565|NCT00672958|Drug|Placebo|Vortioxetine placebo-matching capsules.
79810566|NCT00764218|Device|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
79325975|NCT02192619|Other|observational|
79325976|NCT02163694|Drug|Veliparib Placebo|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
79325977|NCT02163694|Drug|Veliparib|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
79481792|NCT03635489|Drug|Paclitaxel|175 mg/m^2 IV infusion on Day 1 of each 21-day cycle.
79481793|NCT03635489|Drug|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
79325978|NCT02163694|Drug|Carboplatin|Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
79325979|NCT02163694|Drug|Paclitaxel|Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
79325980|NCT02153957|Behavioral|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
79325981|NCT02107989|Device|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
79325982|NCT02107989|Device|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
79325983|NCT02107976|Dietary Supplement|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks
79325984|NCT02064764|Device|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
79325985|NCT02064764|Device|Arctic Front Advance™ Cardiac Cryoablation System|
79325986|NCT02019706|Radiation|DOTATATE PET-CT|68Ga-DOTATATE PET/CT
79325987|NCT02019706|Radiation|F-DOPA PET CT|68Ga-DOTATATE PET/CT
79325988|NCT02019706|Radiation|CT scan|routine CT scan
79481794|NCT03635489|Drug|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
79481795|NCT03635489|Drug|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
79810567|NCT00764218|Other|No positive airway pressure treatment|No treatment
79978088|NCT05253469|Procedure|Mechanical prostheses|The insertion of conventional mechanical valves may be performed using separate or continuos stich with or without teflon pledget. Mechanical prostheses may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic valved conduit with a mechanical valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
79978089|NCT05252754|Drug|Tacrolimus capsule|Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
79810568|NCT00764296|Other|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
79325989|NCT02019706|Diagnostic Test|Routine MRI scan|routine 1.5 or 3T MRI scan
79325990|NCT02019706|Diagnostic Test|Gated MRI scan|Cardiac gated MRI scan
79325991|NCT02019706|Drug|68Ga-DOTATATE|68Ga-DOTATATE radioligand
79325992|NCT02019706|Drug|18F-DOPA|18F-DOPA radioligand
79481796|NCT03633617|Drug|Dupilumab|Solution for injection administered subcutaneously
79481797|NCT03633617|Drug|Placebo|Matching placebo
79481798|NCT03631784|Drug|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
79481799|NCT03631784|Drug|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
79481800|NCT03631784|Drug|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
79481801|NCT03631784|Drug|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
79481802|NCT03631784|Drug|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
79810569|NCT00764296|Other|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
79810570|NCT00764374|Drug|YM443|oral
79810571|NCT00759226|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
79978090|NCT05252754|Drug|Placebo|Placebo PO, 1-2 hours prior to endoscopy.
79978091|NCT05252754|Drug|Rectal Indomethacin|100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
79810572|NCT00759226|Drug|Cisplatin|Cisplatin 30 mg/m2 (90 min)
79810573|NCT00759226|Drug|5-FU|5-FU 750 mg/m2 (24h CI)
79325995|NCT02013648|Drug|Dasatinib|
79481803|NCT03631784|Radiation|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
79481804|NCT03631784|Drug|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
79481805|NCT03631784|Drug|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
79481806|NCT03617705|Device|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
79481807|NCT03617705|Device|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
79481808|NCT03617705|Device|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
79481809|NCT03610997|Procedure|Photorefractive keratectomy|
79481810|NCT03607422|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
79325996|NCT02013648|Drug|Cytarabine|
79325997|NCT02013648|Drug|Daunorubicin|
79325998|NCT02013648|Drug|Idarubicin|
79325999|NCT01958086|Device|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
79481811|NCT03607422|Drug|Upadacitinib|Tablets taken orally once a day
79810574|NCT00759226|Drug|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
79810575|NCT00672646|Drug|AZD1386|95mg, oral solution, single dose
79810576|NCT00672646|Drug|Naproxen|500mg, capsule, single dose
79810577|NCT00672646|Drug|Placebo|AZD1386 Placebo oral solution
79810578|NCT04048798|Other|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
79810579|NCT04048798|Other|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
79481812|NCT03591484|Radiation|Photodynamic therapy|Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
79326000|NCT01944839|Drug|E10030|
79810580|NCT00764530|Device|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
79326001|NCT01944839|Drug|ranibizumab|
79326002|NCT01944839|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
79326003|NCT01940900|Drug|E10030|
79326004|NCT01940900|Drug|ranibizumab|
79326005|NCT01940900|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
79326006|NCT01940887|Drug|E10030|
79481813|NCT03591484|Device|Treatment with tongue scraper|Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
79481814|NCT03591484|Procedure|Periodontal treatment|Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
79810581|NCT00764530|Device|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
79810582|NCT00764998|Biological|Fluviral|
79810583|NCT00759460|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
79810584|NCT00759460|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
79810585|NCT00765154|Drug|darunavir|two 400mg tablets (800mg) once daily
79810586|NCT00765154|Drug|ritonavir|one 100mg capsule once daily
79326007|NCT01940887|Drug|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
79326008|NCT01940887|Drug|E10030 sham injection|Pressure on the eye with a syringe with no needle
79810587|NCT00759616|Device|Oxford Partial Knee|Oxford Partial Knee
79978092|NCT05249101|Drug|Ivaltinostat|Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
79326009|NCT01905046|Drug|metformin hydrochloride|given PO
79481815|NCT03591484|Procedure|hygiene procedures for the mucosa and dentures|edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
79481816|NCT03576885|Drug|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
79481817|NCT03576885|Drug|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
79481818|NCT03576612|Biological|AdV-tk|Given IT
79481819|NCT03576612|Drug|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
79481820|NCT03576612|Radiation|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
79481821|NCT03576612|Drug|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
79481822|NCT03576612|Biological|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
79481823|NCT03576612|Other|Laboratory Biomarker Analysis|correlative studies
79481824|NCT03576105|Combination Product|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
79978093|NCT05249101|Drug|Capecitabine|Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
79481825|NCT03576105|Combination Product|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
79481826|NCT03576105|Combination Product|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
79810588|NCT00764686|Other|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
79810589|NCT00764686|Other|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
79810590|NCT00764764|Procedure|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
79810591|NCT00764764|Procedure|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
79810592|NCT00672490|Drug|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
79978094|NCT05248126|Other|Standard patient education|The comparator intervention is the usual therapeutic training for patients (ETP) cursus currently used in the General Pulmonology unit at the Arnaud De Villeneuve Hospital, Montpellier, France and approved by the French Regional Health Authority for the Occitanie Region [Agence Régional de Santé Occitanie].
79481827|NCT03576105|Combination Product|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
79481828|NCT03574038|Device|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
79481829|NCT03574038|Other|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
79978095|NCT05248126|Other|Chatbot patient education|"The experimental intervention consists in providing the patient with access to a specific version of the Vik-Asthme chat bot for the duration of the study. Should the patient be unable to use or refuse to use the chatbot, the reasons for refusal will be documented and the patient will proceed with the comparator intervention."
79481830|NCT03568318|Drug|Placebo|Tablets taken orally once a day
79481831|NCT03568318|Drug|Upadacitinib|Tablets taken orally once a day
79326010|NCT01905046|Other|placebo|given PO
79326011|NCT01900132|Device|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
79326012|NCT01900132|Device|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
79326013|NCT01900132|Device|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
79481832|NCT03568318|Drug|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
79978096|NCT05247047|Device|TENA SmartCare Change Indicator|The intervention is a medical device system that consists of a reusable electronic sensor and an application installed on one or more smart phones. The device estimates the saturation level of an absorbing incontinence product used by a study subject. The device is non-invasive and does not have any effect on the function of the absorbing incontinence product.
79978097|NCT05244239|Drug|Lurbinectedin|Given IV
79978098|NCT05244239|Radiation|Palliative Radiation Therapy|Undergo RT
79978099|NCT05242367|Device|Modius Spero active device|Battery powered non-invasive neurostimulation device
79978100|NCT05242367|Device|Sham device|Placebo comparator sham device (no active stimulation)
79978101|NCT05241873|Drug|BLU-451|BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
79978102|NCT05241873|Drug|Carboplatin|Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
79481833|NCT03550794|Drug|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
79481834|NCT03550794|Drug|Placebo|50ml of 0.9% NACL will serve as the placebo
79326014|NCT01900132|Device|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
79481835|NCT03536572|Behavioral|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
79978103|NCT05241873|Drug|Pemetrexed|Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
79978104|NCT05241275|Drug|Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
79978105|NCT05238116|Drug|PC945|Sterile aqueous liquid for Nebulization
79481836|NCT03533673|Biological|ACTUS-101|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
79481837|NCT03532282|Behavioral|ONLINE ONLY|Access to an online cognitive behavioral therapy for insomnia
79481838|NCT03532282|Behavioral|STEPPED CARE|A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm. Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
79810593|NCT00672490|Drug|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
79810594|NCT04048096|Dietary Supplement|Krill Oil|Aker Biomarine Superba Krill Oil
79810595|NCT04048096|Dietary Supplement|Placebo|Mixed vegetable oil
79810596|NCT00770302|Drug|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
79810597|NCT00922012|Device|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
79978106|NCT05238116|Drug|Placebo|Sterile aqueous liquid for Nebulization
79978107|NCT05232916|Biological|Placebo|0.9% Normal Saline
79978108|NCT05232916|Biological|GLSI-100|500 mcg/mL GP2 and 125 mcg/mL GM-CSF
79810598|NCT00759850|Device|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
79810599|NCT02557984|Drug|Placebo|Placebo Pill
79648054|NCT06116435|Behavioral|Move group-based classes|The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
79810600|NCT02557984|Drug|Amisulpride|400 mg Amisulpride
79978109|NCT05230667|Other|PRP injection (PRP group)|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.
79978110|NCT05230667|Other|Corticosteroid injection (CS group)|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.
79978111|NCT05230667|Other|Normal saline injection (NS group)|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
79978112|NCT05228067|Device|anodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
79978113|NCT05228067|Device|cathodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
79978114|NCT05228067|Device|sham transcranial direct current stimulation|Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
79978115|NCT05226364|Procedure|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
79978116|NCT05226364|Procedure|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
79978117|NCT05226364|Procedure|Without tourniquet|The blood sample is taken without tourniquet
79810601|NCT02557984|Drug|Naltrexone|50 mg Naltrexone
79810602|NCT00765466|Drug|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
79810603|NCT00759928|Drug|Erlotinib|150 mg once daily by mouth
79978118|NCT05222971|Drug|Durvalumab|"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
79978119|NCT05222971|Drug|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
79978120|NCT05219500|Drug|FPI-2265|Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
79978121|NCT05218993|Diagnostic Test|A new dual-task measurement method with images|Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
79326030|NCT01747213|Drug|BNC|
79326031|NCT01747213|Other|Placebo|Microcrystalline cellulose fiber
79481839|NCT03513302|Dietary Supplement|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
79481840|NCT03513302|Dietary Supplement|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
79810604|NCT00759928|Drug|Sorafenib|400 mg twice daily by mouth
79810605|NCT00670930|Drug|omalizumab at a dose of 0.016mg/kg/IU/mL|
79648055|NCT06116435|Behavioral|Fitness Membership|Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
79326032|NCT01697371|Radiation|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
79326033|NCT01697371|Radiation|Proton Radiation|
79326034|NCT01684904|Radiation|Proton radiation|
79648056|NCT06116435|Behavioral|Mental Imagery|Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
79648057|NCT06116435|Behavioral|Move 1:1 Support|Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
79648058|NCT06116357|Device|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
79648059|NCT06116331|Other|Data collection|Participants will answer questionnaires and submit stool samples.
79326035|NCT01621594|Device|The Toshiba Aquilion ONE CT system|To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
79648060|NCT06116305|Other|No intervention|No intervention
79810606|NCT00670930|Drug|Placebo|
79481841|NCT03506880|Behavioral|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
79481842|NCT03506880|Behavioral|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
79481843|NCT03506321|Diagnostic Test|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
79326036|NCT01621581|Genetic|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
79326037|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
79326038|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
79326039|NCT01326104|Biological|TTRNA-xALT|TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
79648061|NCT06116279|Device|Insertion of electrode during planned neurosurgery for epilepsy|A novel, 300 micrometer, ultraflexible, low-impedance electrode proposes to cause minimal parenchymal (brain tissue) damage, and provide multiple contacts at multiple depths to allow unit-level recordings for a period of 15 minutes.
79648062|NCT06116253|Device|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
79648063|NCT06116253|Drug|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
79810607|NCT00670540|Other|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
79810608|NCT00591786|Drug|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
79810609|NCT00770536|Drug|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
79810610|NCT00770536|Drug|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
79326040|NCT01326104|Biological|TTRNA-DCs|TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
79648064|NCT06116240|Drug|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
79810611|NCT00770536|Drug|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
79810612|NCT00770536|Drug|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
79810613|NCT00770614|Drug|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
79810614|NCT00770614|Drug|Isotonic saline|0.9% sodium chloride
79810615|NCT00770614|Drug|Placebo|Placebo
79810616|NCT00765544|Device|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
79810617|NCT00765544|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
79810618|NCT04048174|Other|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
79978122|NCT05218993|Diagnostic Test|A new dual-task measurement method with cards|Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
79810619|NCT04048174|Other|Saline irrigation|Nasal and sinus irrigation with saline solution
79481844|NCT03467516|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
79481845|NCT03456102|Drug|Pravastatin|"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."
79481846|NCT03451448|Diagnostic Test|PET/MRI|PET/MRI with USPIO contrast
79810620|NCT00770926|Behavioral|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
79810621|NCT00771004|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
79810622|NCT00771004|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
79810623|NCT00674362|Biological|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
79810624|NCT00674362|Biological|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
79978123|NCT05217446|Drug|Encorafenib|capsule
79326056|NCT01087346|Behavioral|Reading Information|Reading information about risk factors for obesity among children
79326057|NCT01081431|Drug|Lenalidomide|10 mg d1-d21 of a 28-day cycle
79326058|NCT01081262|Biological|Bevacizumab|Given IV
79326059|NCT01081262|Drug|Capecitabine|Given PO
79326060|NCT01081262|Drug|Carboplatin|Given IV
79326061|NCT01081262|Other|Laboratory Biomarker Analysis|Correlative studies
79326062|NCT01081262|Drug|Oxaliplatin|Given IV
79326063|NCT01081262|Drug|Paclitaxel|Given IV
79326064|NCT01081262|Other|Quality-of-Life Assessment|Ancillary studies
79326065|NCT01036581|Device|MagPro X100 Magnetic Stimulator|Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
79481847|NCT03451448|Diagnostic Test|MRI|MRI with USPIO contrast
79481848|NCT03448666|Combination Product|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
79481849|NCT03442738|Procedure|Endocuff group|Endocuff Vision cap on Standard colonoscope
79648065|NCT06116240|Drug|AL2846 capsule|AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
79648066|NCT06116240|Drug|Pemetrexed disodium for injection|Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
79648067|NCT06116240|Drug|Cisplatin injection|Cisplatin is a chemotherapy drug.
79978124|NCT05217446|Biological|Cetuximab|IV
79978125|NCT05217446|Biological|Pembrolizumab|IV
79326066|NCT01036581|Device|Transcranial Rotating Magnetic Stimulator|Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
79481850|NCT03440398|Procedure|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
79481851|NCT03440398|Procedure|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
79481852|NCT03439865|Drug|Ivacaftor|150 mg tablet PO BID x 14 days
79481853|NCT03439865|Drug|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
79810625|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
79978126|NCT05210790|Drug|Placebo|Placebo
79481854|NCT03436654|Drug|Apalutamide|240mg daily orally
79978127|NCT05210790|Drug|Rusfertide|Experimental drug
79978128|NCT05209815|Behavioral|Questionnaire|Questionnaire
79481855|NCT03436654|Drug|Abiraterone Acetate|1000mg daily orally
79481856|NCT03436654|Drug|Prednisone|5mg BID orally
79481857|NCT03436654|Procedure|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
79481858|NCT03436654|Procedure|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
79810626|NCT00820950|Drug|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
79810627|NCT00820950|Drug|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
79978129|NCT05209568|Dietary Supplement|Gluten Powder|Single oral dose of gluten powder
79978130|NCT05208463|Behavioral|Joint Academy|Digitally deliverd exercise and education first line treatment for hip and knee osteoarthritis
79978131|NCT05208294|Drug|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
79481859|NCT03436654|Drug|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
79481860|NCT03436654|Radiation|Stereotactic Body Radiation Therapy|Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
79978132|NCT05208294|Drug|Placebo|Participants receive an inactive placebo capsule.
79978133|NCT05208294|Behavioral|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
79978134|NCT05208294|Behavioral|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
79978135|NCT05201014|Diagnostic Test|NT-pro-BNP|Blood draw
79978136|NCT05201014|Diagnostic Test|Electrocardiogram|electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart
79978137|NCT05201014|Diagnostic Test|Echocardiogram|medical imaging of the heart
79978138|NCT05200936|Drug|MM-120|MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
79648068|NCT06116227|Device|Whole Body Vibration Training Plus Conventional Physical Therapy Exercise Program.|Patients in the study group will receive the traditional physical therapy program first, followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude will be from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program was three sessions a week for eight weeks. WBV duration starts with 10 min in the 1st week and up to 25 min in the 8th week, with a regular increase of five minutes after every two successive weeks.
79978139|NCT05200936|Other|Placebo|A treatment which is designed to have no therapeutic value.
79326067|NCT01036581|Device|Magnetom Prisma Fit 3T Scanner|Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
79648069|NCT06116227|Other|Conventional Physical Therapy Exercise Program.|The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.
79648070|NCT06116214|Other|Vachellia Nelotica|As a root canal irrigant (herbal)
79648071|NCT06116214|Other|sodium hypochlorite|As a root canal irrigant
79810628|NCT00820950|Drug|Placebo cream|Cream applied once or twice daily for 56 days
79810629|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
79810630|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
79810631|NCT00765934|Drug|Rapydan|lidocaine / tetracaine 70/70 mg patch
79978140|NCT05196035|Drug|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 180±7 days
79978141|NCT05196035|Drug|Placebo|Placebo to finerenone, treatment duration will be 180±7 days
79326068|NCT00924027|Radiation|HDR Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
79648072|NCT06116188|Diagnostic Test|FDG-PET study|"Hyperinsulinemic, euglycemic clamp technique will be used to promote tissue glucose uptake and measure insulin sensitivity. Two cannulas will be inserted, one in a radial or an antecubital vein for PET tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. In the clamp study subjects are administered intravenous insulin at a steady rate of 40 mU/m2/min and normoglycemia is maintained using a variable rate infusion of 20% glucose based on plasma glucose measurements, which are performed every 5min from arterialized venous blood. We will also collect samples to determine plasma insulin, serum free fatty acid and metabolic biomarkers during the study.~The clamp will be performed together with [18F]-FDG-PET/CT."
79648073|NCT06116162|Device|SVF-gel Filling and CO2 fractional laser|"SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage."
79810632|NCT04049344|Drug|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
79978142|NCT05193877|Procedure|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
79978143|NCT05191641|Other|Individualized nursing care|Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
79978144|NCT05191381|Biological|Application of exosomes in a whole blood assay|Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
79978145|NCT05189418|Device|Ambulatory blood pressure monitoring (ABPM)|Periodic (quarterly) 48h ABPM evaluation during follow-up
79810633|NCT00709176|Behavioral|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
79978146|NCT05189418|Device|Home blood pressure monitoring (HBPM)|Periodic (monthly) 7-day HBPM, both during awake and sleep spans, during follow-up
79978147|NCT05187897|Behavioral|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
79978148|NCT05180812|Device|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
79326070|NCT00804154|Drug|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
79326071|NCT00783510|Biological|adalimumab|As prescribed by treating physician
79326072|NCT00783510|Drug|Methotrexate|As prescribed by treating physician
79810634|NCT00709176|Behavioral|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
79810635|NCT00670306|Drug|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
79810636|NCT00703248|Procedure|Osteopathic Manipulative Treatments|"opening the thoracic inlet~pectoral traction for 1 minute bilaterally~rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine ]~thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
79810637|NCT00709254|Drug|i.v. fentanyl|single dose, 200 ug
79481861|NCT03427346|Procedure|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
79810638|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
79648074|NCT06116123|Device|Massage mattress with cube/block system|Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
79648075|NCT06116097|Behavioral|Nutrition education|Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
79978149|NCT05176639|Drug|VRDN-001 Phase 1/2 MAD (HV and TED)|2 Infusions of multiple ascending doses of VRDN-001, ranging from 3 mg/kg to 20 mg/kg
79978150|NCT05176639|Drug|VRDN-001 Phase 3 Cohort (THRIVE)|5 Infusions of VRDN-001 10mg/kg
79978151|NCT05176639|Drug|VRDN-001 Placebo|5 Infusions of VRDN-001 placebo
79978152|NCT05170503|Drug|Sintilimab|Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) [40mg/m2 if BSA <1.25m2, 50mg/m2 if BSA ≥1.25m2 & <1.5m2, 60mg/m2 if BSA ≥1.5m2] po. Bid D1-14 for three cycles
79326075|NCT00712881|Drug|Liposomal doxorubicin hydrochloride|Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
79326076|NCT00712881|Drug|Cyclophosphamide|Cyclophosphamide will be administered per dose and schedule specified in the arm description.
79481862|NCT03427346|Procedure|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
79326077|NCT00712881|Drug|Trastuzumab|Trastuzumab will be administered per dose and schedule specified in the arm description.
79326078|NCT00712881|Drug|Free doxorubicin hydrochloride|Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
79326079|NCT00712881|Drug|Docetaxel|Docetaxel will be administered per dose and schedule specified in the arm description.
79326080|NCT00588991|Drug|Carboplatin|Given IV
79326081|NCT00588991|Other|Laboratory Biomarker Analysis|Correlative study
79326082|NCT00588991|Drug|Topotecan Hydrochloride|Given IV
79481863|NCT03427125|Drug|Tenapanor|Active Drug
79326083|NCT00588991|Drug|Veliparib|Given orally
79326084|NCT00568997|Drug|Pimecrolimus|Pimecrolimus 1% cream
79326085|NCT00362843|Drug|[15-O]water|
79326087|NCT00336063|Drug|Azacitidine|Given SC
79326088|NCT00336063|Other|Laboratory Biomarker Analysis|Correlative studies
79326089|NCT00336063|Other|Pharmacological Study|Correlative studies
79326090|NCT00336063|Drug|Vorinostat|Given PO
79326091|NCT00302146|Drug|15-0 H20|
79326092|NCT00216294|Drug|RG1068 (Synthetic Human Secretin)|
79481864|NCT03427125|Drug|Placebo|Inactive Drug
79481865|NCT03427125|Drug|Sevelamer Carbonate|Active control
79481866|NCT03420274|Behavioral|NEST|This is a point-of-care shared decision-making instrument.
79481867|NCT03420274|Behavioral|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
79481868|NCT03419637|Other|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
79810639|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
79810640|NCT00766012|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
79978153|NCT05166304|Drug|Rebamipide|patients will receive the standard therapy plus 100 mg Rebamipide three times daily
79978154|NCT05166304|Drug|Placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
79978155|NCT05164172|Drug|Eptinezumab|Concentrate for solution for infusion
79810641|NCT00766012|Drug|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
79326097|NCT00001711|Procedure|MRI|scan of healthy volunteers.
79326098|NCT00001529|Drug|G-CSF|
79326099|NCT00001452|Drug|oCRH|
79326100|NCT00001337|Drug|EPOCH|Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
79326101|NCT00001337|Biological|Rituximab|Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
79810642|NCT04048018|Diagnostic Test|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
79326103|NCT00001168|Behavioral|Balanced diet|
79810643|NCT02558608|Procedure|DIPL|dissection of the inferior pulmonary ligament
79810644|NCT02558608|Procedure|WR|wedge resection of the lung bleb
79810645|NCT02558608|Procedure|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
79978156|NCT05153889|Other|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
79978157|NCT05153889|Other|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
79326104|NCT02330887|Other|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
79326105|NCT02330887|Other|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
79481869|NCT03409692|Diagnostic Test|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
79648076|NCT06116084|Other|Ericksonian Hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
79326106|NCT03573817|Drug|Revefenacin|Revefenacin is administered via a nebulizer.
79648077|NCT06116084|Other|Hypnosis|A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
79648078|NCT06116058|Other|Experimental: Group A: integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles
79648079|NCT06116058|Other|Experimental: Group B :Instrument assissted soft tissue mobilization|IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.
79326107|NCT03573817|Drug|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
79326108|NCT03573817|Drug|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
79481870|NCT03377296|Other|Plasmodium vivax infection|Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.
79810646|NCT00672256|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
79810647|NCT02558686|Other|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
79648080|NCT06116058|Other|control group C conventional physical therapy|. The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
79810648|NCT02558686|Other|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
79810649|NCT02558686|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
79810650|NCT00760318|Drug|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
79326109|NCT03112057|Diagnostic Test|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
79326110|NCT02331043|Dietary Supplement|Plant stanol ester|
79326111|NCT02331043|Dietary Supplement|Placebo|
79326112|NCT03111511|Drug|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
79648081|NCT06116045|Drug|BZ371A 7.5 mg (1.5 ml)|7.5 mg gel
79648082|NCT06116045|Drug|BZ371A 5.0 mg (1.0 ml)|5.0 mg gel
79810651|NCT00591630|Drug|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
79648083|NCT06116045|Drug|BZ371A 2.5 mg (0.5 ml)|2.5 mg gel
79648084|NCT06116045|Drug|Placebo (1.5 ml)|BZ371A-matched placebo
79810652|NCT00591630|Drug|Carmustine|300 mg/m^2 by vein.
79810653|NCT00591630|Drug|Etoposide|200 mg/m^2 by vein every 12 hours.
79810654|NCT00591630|Drug|Cytarabine|200 mg/m^2 by vein every 12 hours.
79810655|NCT00591630|Drug|Melphalan|140 mg/m^2 by vein.
79810656|NCT00591630|Drug|Rituximab|"Arm 1, Arm 2 = 250 mg/m^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
79810657|NCT00591630|Procedure|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
79810658|NCT00766168|Other|HDS HI 1.54; pahrifocon A|Contact Lens
79810659|NCT00766168|Device|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
79326113|NCT03111511|Drug|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
79810660|NCT02557828|Procedure|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
79810661|NCT00760396|Drug|VGX-1027|Subjects will
79810662|NCT00760630|Device|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
79810663|NCT00771394|Drug|Tamsulosin hydrochloride|oral
79326114|NCT03111511|Drug|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
79326115|NCT02330965|Procedure|Blood Draw|Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
79326116|NCT02330965|Procedure|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
79326117|NCT03144505|Behavioral|MCT combined with RT Group|
79326118|NCT03144505|Behavioral|HIIT combined with RT Group|
79326119|NCT03144115|Drug|Oxytocin|
79810664|NCT00771394|Drug|Solifenacin succinate|oral
79810665|NCT00670228|Drug|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
79978158|NCT05151991|Other|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
79326120|NCT03144115|Drug|Placebos|
79326121|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
79326122|NCT02326285|Drug|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
79326123|NCT02326285|Drug|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
79326124|NCT02326285|Drug|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
79326125|NCT02326285|Procedure|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
79326126|NCT02332603|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
79326127|NCT02332603|Drug|Isotonic Sodium Chloride|Placebo
79326128|NCT02332447|Drug|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
79481871|NCT03377296|Procedure|Collection of 250mL blood from each volunteer (N=2)|Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
79481872|NCT03371706|Behavioral|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
79810666|NCT00670228|Drug|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
79810667|NCT00670228|Drug|Standard Therapy|Standard insulin therapy titrated to blood sugar control
79481873|NCT03371706|Behavioral|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
79481874|NCT03360708|Other|Laboratory Biomarker Analysis|Correlative studies
79810668|NCT02557360|Dietary Supplement|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
79810669|NCT00771628|Device|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
79326129|NCT02332447|Drug|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
79326130|NCT02331199|Device|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
79326131|NCT02331199|Device|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
79648085|NCT06116045|Drug|Placebo (1.0 ml)|BZ371A-matched placebo
79810670|NCT00771628|Device|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
79978159|NCT05151991|Other|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
79978160|NCT05140317|Procedure|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
79978161|NCT05129709|Behavioral|"My Health Priorities Identification Program"|"The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities."
79481875|NCT03360708|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
79648086|NCT06116045|Drug|Placebo (0.5 ml)|BZ371A-matched placebo
79648087|NCT06116019|Radiation|Online adaptive radiation therapy|Daily cone-beam CT based online adaptive radiation therapy
79326132|NCT02331121|Behavioral|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
79326133|NCT02331121|Behavioral|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
79326134|NCT02330809|Other|Daily extra water intake|Amount of extra daily water intake to consume
79648088|NCT06115954|Other|Self-Management Supported Telerehabilitation|Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
79648089|NCT06115941|Device|Pre-Op Incentive Spirometer|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
79648090|NCT06115928|Device|Virtual reality|Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
79481876|NCT03359863|Drug|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
79481877|NCT03353688|Device|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
79810671|NCT00766246|Drug|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
79810672|NCT00766246|Drug|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
79810673|NCT00766246|Drug|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
79326135|NCT02330809|Other|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
79326136|NCT05077813|Combination Product|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79481878|NCT03341273|Drug|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
79481879|NCT03341273|Other|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
79481880|NCT03341273|Device|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
79481881|NCT03330691|Biological|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
79481882|NCT03325062|Behavioral|MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
79481883|NCT03325062|Behavioral|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
79810674|NCT00766402|Drug|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
79481884|NCT03319901|Drug|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
79810675|NCT00766402|Drug|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
79481885|NCT03319901|Drug|Standard Chemotherapy|Standard treatment of chemotherapy is administered
79481886|NCT03301766|Drug|lidocaine 5% patch|transdermal patch
79648092|NCT06115863|Other|Early Cognitive Stimulation Interventions|early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
79648093|NCT06115850|Procedure|Music|In the music intervention group, the patients received music intervention during RT for 10 consecutive days and listened to music for approximately 10-15 minutes in each session.
79648094|NCT06115837|Procedure|multivisceral resection|The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection
79648095|NCT06115824|Drug|Orelabrutinib|Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
79326137|NCT05077813|Combination Product|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79481887|NCT03301766|Drug|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
79648096|NCT06115772|Other|Non-Interventional Study|Non-interventional study
79481888|NCT03301766|Drug|Non-medicated patch|non-medicated patch
79810676|NCT00771706|Drug|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
79810677|NCT00771706|Drug|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
79810678|NCT00771862|Procedure|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
79810679|NCT00771940|Drug|Ghrelin|Solvent, cont. infusion
79810680|NCT00772096|Drug|n-3 fatty acids|
79810681|NCT00760786|Drug|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
79810682|NCT00760786|Drug|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
79978162|NCT05127330|Behavioral|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
79978163|NCT05127330|Behavioral|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
79810683|NCT00760786|Drug|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
79810684|NCT00760786|Drug|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
79810685|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
79481889|NCT03296085|Procedure|Exam for quantity of edema|There is no intervention
79648097|NCT06115746|Behavioral|iDECIDE|iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
79810686|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
79810687|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
79978164|NCT05127044|Device|Diffuse Reflectance Spectroscopy|DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
79481890|NCT03284710|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10^6 cell culture infectious dose (CCID)50 and < 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
79481891|NCT03284710|Biological|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
79810688|NCT00760864|Drug|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
79810689|NCT00766480|Drug|cisplatin|Given IV
79810690|NCT00766480|Drug|fluorouracil|Given IV
79810691|NCT00766480|Radiation|radiation therapy|Patients undergo radiotherapy
79810692|NCT00772174|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
79810693|NCT00772174|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
79810694|NCT00772252|Other|liver support treatment|plasma exchange for liver support treatment
79978165|NCT05127044|Diagnostic Test|BiliChek|BiliChek will be used as a control for determining bilirubin content.
79978166|NCT05126446|Device|the Aorta Arch Stent Graft System combined with the Endovascular Needle System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with device
79978167|NCT05126147|Drug|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
79481892|NCT03284710|Biological|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (~625 mcg aluminum content); delivered as a 0.5 mL IM injection
79481893|NCT03284710|Biological|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
79481894|NCT03265821|Procedure|Healing after treatment|
79481895|NCT03248167|Drug|Cannabidiol|600 mg daily
79810695|NCT00766714|Device|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
79810696|NCT00766714|Device|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
79978168|NCT05124795|Drug|IMU-935|IMU-935 capsules
79978169|NCT05121142|Drug|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
79978170|NCT05118399|Drug|Bupivacaine Injection [Marcaine]|Bupivacaine injection [Marcaine] is the standard treatment used in our hospital.
79648098|NCT06115733|Drug|Fruquintinib、Capecitabine Tablets|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
79326138|NCT05077813|Combination Product|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79648099|NCT06115694|Device|TCI Articulating Introducer|use
79648100|NCT06115694|Device|GlideRite® Rigid Stylet|use
79326139|NCT05077813|Combination Product|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79481896|NCT03248167|Drug|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
79481897|NCT03244306|Biological|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
79648101|NCT06115655|Diagnostic Test|cfDNA methylation detection|Extract cfDNA from bile and plasma, and perform methylation detection.
79648102|NCT06115629|Other|Surveillance protocol|Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.
79648103|NCT06115616|Behavioral|Morning exercise|Exercise before noon in the morning
79648104|NCT06115616|Behavioral|Afternoon exercise|Exercise in the late after noon
79648105|NCT06115603|Dietary Supplement|Cannabigerol|80mg (1 mL) of Cannabigerol daily for 14 days
79648106|NCT06115603|Dietary Supplement|Placebo|Placebo (1 mL) daily for 14 days
79648107|NCT06115590|Dietary Supplement|Nutritional supplement|Nutritional intervention hypothesized to have an acute anxiolytic effect
79648108|NCT06115551|Combination Product|Fasting Mimicking Diet|FMD is a 5-day low calorie fasting-mimicking diet.
79810697|NCT00772486|Biological|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
79810698|NCT00766792|Procedure|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
79810699|NCT00766792|Procedure|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
79810700|NCT00772564|Drug|Atorvastatin|Oral Atorvastatin
79648109|NCT06115512|Drug|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
79648110|NCT06115512|Drug|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
79810701|NCT00766870|Drug|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
79810702|NCT00766870|Drug|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
79810703|NCT00766870|Drug|Placebo|Per oral doses, twice daily as capsules during 10 weeks
79810704|NCT00772720|Drug|raltegravir|raltegravir 400 mg BID for 7 days
79810705|NCT00772720|Drug|Placebo|Placebo BID for 7 days
79978171|NCT05118399|Drug|Bupivacaine Liposome 13.3 MG/ML [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
79326140|NCT05077813|Combination Product|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79326141|NCT05077813|Other|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
79326142|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
79326143|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
79326144|NCT02325973|Device|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
79326145|NCT00914251|Drug|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
79326146|NCT00914251|Drug|Placebo|Administration of oral Placebo, 500 mg/daily
79326147|NCT02330731|Procedure|injection sclerotherapy for gastric varices|The intravariceal technique of injection
79326148|NCT05076955|Drug|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
79326149|NCT02330575|Behavioral|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
79481898|NCT03243552|Drug|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
79481899|NCT03243552|Behavioral|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
79481900|NCT03242278|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
79481901|NCT03220737|Biological|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
79481902|NCT03220737|Other|Placebo|Placebo control for this study is normal (0.9%) saline.
79481903|NCT03198728|Drug|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
79481904|NCT03198728|Drug|AndroGel|topical testosterone gel 1.62%
79978172|NCT05115903|Drug|Tapered doses of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified
79481905|NCT03198663|Behavioral|POSSE|Popular-opinion leader
79978173|NCT05115903|Drug|Standard dose of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
79978174|NCT05114421|Drug|Lenvatinib|Given PO
79978175|NCT05114421|Biological|Pembrolizumab|Given IV
79481906|NCT03192852|Other|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
79481907|NCT03192852|Procedure|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
79481908|NCT03190590|Device|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
79648117|NCT06115447|Procedure|lung suturing with polyglactin|lung suturing with polyglactin
79648118|NCT06115447|Procedure|ung suturing with polypropylene|ung suturing with polypropylene
79648119|NCT06115434|Procedure|cystectomy|cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
79648120|NCT06115421|Drug|Roxadustat|hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
79648121|NCT06115408|Drug|Dienogest 2 MG|Clinical trial
79648122|NCT06115408|Drug|N-acetyl cysteine|Clinical trial
79648123|NCT06115343|Behavioral|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
79648124|NCT06115317|Other|Prism|Prism
79648125|NCT06115317|Other|Sham|Sham
79481909|NCT03190590|Device|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability
79481910|NCT03190590|Device|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
79648126|NCT06115304|Other|Large liquid meal, spinal catheter and venous line|"Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour"
79648127|NCT06114745|Drug|SHR-1707 injection|Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion
79648128|NCT06114563|Other|Spirulina yogurt|32 high cardiometabolic risk volunteers will be asked to consume 2 cups of yogurt with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.
79648129|NCT06114563|Other|Conventional yogurt|32 high cardiometabolic risk volunteers will be asked to consume 2 cups of conventional yogurt (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
79648130|NCT06114394|Procedure|UPV/EHU technique (Aguirre-Zorzano et al 2017)|"The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured."
79648131|NCT06114394|Procedure|Single incision technique (Huerzeler & Weng 1999)|The CTG is harvested with the single incsion technique described by Huerzeler & Weng in 1999.
79810706|NCT00775216|Behavioral|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
79810707|NCT00766948|Other|There is no intervention, this is a biorepository.|There are no interventions in this study.
79307397|NCT04293042|Biological|BK-virus specific CTLs|"HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
79307398|NCT04283227|Genetic|OTL-200|All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
79307399|NCT04271449|Device|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
79307400|NCT04271449|Behavioral|Virtual reality device|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
79307401|NCT04271449|Device|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure."
79307402|NCT04266301|Drug|MBG453|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
79481911|NCT03186118|Biological|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
79481912|NCT03159624|Other|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
79481913|NCT03159624|Other|Doyle silastic sheet|Doyle silastic sheet
79648132|NCT06113822|Device|ultrasonography|We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
79648133|NCT06113770|Other|preparation of the tooth to receive ready made zirconia crown|"Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit ."
79810708|NCT00775294|Drug|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
79307403|NCT04266301|Drug|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
79307404|NCT04266301|Drug|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
79481914|NCT03156114|Drug|BI 754111|Day 1 of 3 week cycle
79481915|NCT03156114|Drug|BI 754091|Day 1 of 3 week cycle
79481916|NCT03144804|Drug|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
79481917|NCT03142334|Biological|Pembrolizumab|IV infusion
79481918|NCT03142334|Drug|Placebo|IV infusion
79481919|NCT03135847|Device|Tactor|The tactor is a small robot providing touch and vibration.
79481920|NCT03131024|Dietary Supplement|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
79810709|NCT00772798|Drug|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
79810710|NCT00772876|Drug|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
79978176|NCT05113381|Device|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
79307405|NCT04262206|Drug|Atorvastatin 40 Mg Oral Tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
79307406|NCT04262206|Drug|Placebo oral tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
79307407|NCT04219800|Behavioral|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
79307408|NCT04219800|Behavioral|mHealth|"Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~SMS text messages; reminds of activity breaks.~Mobile video instruction for standing pause gymnastics."
79307409|NCT04214249|Procedure|Biospecimen Collection|Undergo collection of blood
79307410|NCT04214249|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79307411|NCT04214249|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79307412|NCT04214249|Procedure|Computed Tomography|Undergo CT
79307413|NCT04214249|Drug|Cytarabine|Given via continuous IV infusion
79307414|NCT04214249|Drug|Daunorubicin Hydrochloride|Given IV
79307415|NCT04214249|Procedure|Echocardiography|Undergo ECHO
79307416|NCT04214249|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
79307417|NCT04214249|Drug|Idarubicin Hydrochloride|Given IV
79307418|NCT04214249|Procedure|Multigated Acquisition Scan|Undergo MUGA
79307419|NCT04214249|Biological|Pembrolizumab|Given IV
79307420|NCT04214249|Procedure|Punch Biopsy|Undergo a skin punch biopsy
79307421|NCT04212052|Radiation|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
79307422|NCT04212052|Drug|concurrent chemotherapy|Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
79481921|NCT03131024|Other|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
79481922|NCT03126539|Drug|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
79481923|NCT03126539|Radiation|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
79648134|NCT06113770|Other|preparation of the tooth to receive CAD CAM PMMA custom made crown|"Open the interproximal contacts .~The tooth should be reduced circumferentially by approximately 0.5-1mm .~The preparation margin should be carefully extended and refined to a feather- edge approximately 1-2mm subgingivally .~Rubber base impression will be taken by BMS additional silicone kit to the prepared tooth and will be sent to the laboratory to be scanned and to design the crown .~The final crown will be cemented using glass ionomer cement ."
79648135|NCT06112808|Drug|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
79648136|NCT06112808|Drug|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
79481924|NCT03126539|Procedure|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
79481925|NCT03123250|Device|Aquablation|The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
79481926|NCT03121404|Procedure|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
79481927|NCT03113435|Other|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
79481928|NCT03107923|Diagnostic Test|Dobutamine stress test|Test of myocardial reserve
79481929|NCT03100552|Diagnostic Test|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
79648137|NCT06111573|Dietary Supplement|Vitamin D|"Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
79481930|NCT03099096|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
79307423|NCT04211337|Drug|Selpercatinib|Administered orally
79307424|NCT04211337|Drug|Cabozantinib|Administered orally
79307425|NCT04211337|Drug|Vandetanib|Administered orally
79481931|NCT03092817|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
79481932|NCT03092817|Other|Placebo|"Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose"
79978177|NCT05107128|Drug|SAGE-718|Oral capsules.
79978178|NCT05107128|Drug|Placebo|SAGE-718-matching oral capsules.
79978179|NCT05106478|Device|AuraGain|Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.
79481933|NCT03043664|Drug|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
79326150|NCT02330575|Behavioral|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
79326151|NCT05076721|Other|Simulation training|The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
79326152|NCT05076721|Other|Case-based discussion training|The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
79326153|NCT03144193|Other|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
79326154|NCT05077111|Procedure|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
79326155|NCT05077111|Procedure|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
79326156|NCT02330497|Procedure|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
79326157|NCT05075863|Drug|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
79326158|NCT05072119|Device|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
79326159|NCT02330419|Drug|Placebo|
79481934|NCT03043664|Drug|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
79481935|NCT03041467|Device|IN.PACT AV DCB|IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
79648138|NCT06111573|Drug|Diclofenac Sodium|"Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
79813824|NCT00587964|Radiation|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
79813825|NCT02608580|Other|Survey|
79326160|NCT02330419|Drug|Naltrexone|
79326161|NCT03143803|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
79481936|NCT03041467|Device|Standard Balloon Angioplasty|Standard PTA Balloon
79481937|NCT03021031|Other|Observational|Observational study
79481938|NCT03019406|Drug|Avalglucosidase alfa (GZ402666)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
79481939|NCT03019406|Drug|Alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
79481940|NCT02992522|Drug|Lenalidomide|Given PO
79481941|NCT02992522|Biological|Obinutuzumab|Given IV
79481942|NCT02992522|Drug|Venetoclax|Given PO
79481943|NCT02972593|Biological|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb >7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
79326162|NCT03143803|Drug|Placebo|Similar looking inactive powder
79326163|NCT05076331|Diagnostic Test|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
79326164|NCT05070325|Other|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
79481944|NCT02969681|Drug|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
79481945|NCT02969681|Drug|Chemotherapy|"mFOLFOX6~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
79481946|NCT02967107|Procedure|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
79481947|NCT02967107|Procedure|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
79481948|NCT02956590|Drug|Pitavastatin|Statin
79481949|NCT02956590|Drug|Placebo|Placebo
79481950|NCT02949700|Drug|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
79810711|NCT00767026|Behavioral|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
79648139|NCT06111222|Device|HECATE|The device is CE-approved. The device is a posterior chamber multifocal intraocular lens (IOL) indicated for aphakia after surgical extraction of the cataractous natural lens. The device is also indicated for non-cataractous, presbyopic patients (PRELEX) who seek greater independence from glasses for intermediate and/or near distances. It is an aspheric (aberration-neutral) IOL made of hydrophobic acrylic material, coated with heparin with modified C-loop haptics.
79648140|NCT06110728|Behavioral|Habit Change|Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
79648141|NCT06108193|Drug|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
79648142|NCT06106386|Other|cryotherapy|Cooling of irrigation
79326165|NCT05070325|Other|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
79326166|NCT05070325|Other|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
79326167|NCT05068141|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
79481951|NCT02947087|Drug|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
79481952|NCT02947087|Drug|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
79481953|NCT02927821|Behavioral|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
79326168|NCT05068141|Drug|Nab-paclitaxel|Paclitaxel for Injection (Albumin Bound), 100 mg/m^2, i.v., D1, D8, D15 of every 4-week cycle
79481954|NCT02868216|Behavioral|anger management training|
79481955|NCT02864550|Drug|Doxycycline|doxycycline 100mg orally daily
79481956|NCT02864550|Other|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
79978180|NCT05090540|Device|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
79978181|NCT05090540|Procedure|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
79648143|NCT06100835|Other|Complex intervention involving physical activity and behaviour change techniques|"The intervention protocol derives from a previous, extensive, co-creation phase involving end-users as well as relatives, experts, professionals working working with older adults, university students and researchers.~It will be based on a structured group-based PA programme supervised by trained professionals, tailored to participants' needs to include joyful components combined with self-management strategies to encourage behaviour change also beyond the sessions. All participants (including end-users but not only) will also be encouraged to join virtual communities of practice (VCoP) for further support and knowledge exchange."
79978182|NCT05090540|Procedure|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
79648144|NCT06097611|Drug|Tranexamic Acid administration|Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury
79648145|NCT06090617|Procedure|Skin Biopsy|Skin biopsies were obtained in all recruited patients.
79648146|NCT06090617|Procedure|Video-laparoscopic adrenalectomy|Video-laparoscopic adrenalectomy in those with unilateral PA. (PA group 1)
79648147|NCT06089226|Other|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
79481957|NCT02845258|Procedure|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
79481958|NCT02841995|Drug|Belumosudil (KD025)|Pharmaceutical form: Capsules or Tablets Route of administration: Oral
79648148|NCT06087458|Biological|VOY-101|VOY-101
79481959|NCT02822768|Procedure|Packing|The patient will receive packing as part of their wound care
79481960|NCT02822768|Other|No packing|The patient will not receive packing as part of their wound care
79481961|NCT02799485|Other|Laboratory Biomarker Analysis|Correlative studies
79481962|NCT02799485|Other|Pharmacological Study|Correlative studies
79481963|NCT02799485|Behavioral|Quality-of-Life Assessment|Ancillary studies
79481964|NCT02799485|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
79481965|NCT02739295|Drug|recombinant granulocyte - colony stimulating factor|
79481966|NCT02739295|Drug|NaCl 0.9%|
79326169|NCT03142477|Other|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
79326170|NCT03142477|Other|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
79326171|NCT03142477|Other|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
79326172|NCT02330263|Dietary Supplement|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
79326173|NCT05050435|Procedure|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
79326174|NCT03142165|Drug|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
79326175|NCT03142165|Other|Placebo|Placebo
79648149|NCT06086028|Other|Wrist worn sensor|Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
79648150|NCT06085638|Drug|Azacitidine|Given by SC (under the skin) or IV (vein)
79648151|NCT06085638|Drug|Tamibarotene|Given by PO
79648152|NCT06085638|Drug|Venetoclax|"Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax"
79810712|NCT00767026|Behavioral|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
79326176|NCT03142165|Drug|Diphenhydramine|50 mg intravenous administration
79326177|NCT03142165|Drug|Famotidine|20 mg intravenous administration
79326178|NCT02330029|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
79326179|NCT02330029|Device|Atractylodes|Atractylodes (~10-15g)
79326180|NCT02330029|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
79326181|NCT02330029|Device|Tangerine Peel|Tangerine Peel (~10g)
79326182|NCT02330029|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
79326183|NCT02330029|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
79326184|NCT02330029|Drug|Radix curcumae|Radix curcumae (~10g)
79648153|NCT06077201|Other|HBCR hands-off|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
79648154|NCT06077201|Other|HBCR interactive|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
79648155|NCT06060873|Other|Non-Interventional Study|Non-interventional study
79648156|NCT06056661|Behavioral|WMR|Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
79648157|NCT06033911|Device|FoodFlip© App with no nutrition symbol|Intervention control: participants will have access to food information such as calories or the Nutrition Facts table through FoodFlip©
79648158|NCT06033911|Device|FoodFlip© App with 'high-in' nutrition symbol|Intervention: Participants will have access to food information through FoodFlip© with Canada's 'high-in' NS
79810713|NCT00570778|Drug|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
79810714|NCT00570778|Drug|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
79810715|NCT00570778|Drug|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
79810716|NCT00775372|Drug|Clarithromycin 250mg/5mL|
79326185|NCT02330029|Drug|Fingered citron|Fingered citron (~10g)
79326186|NCT02330029|Drug|Tuckahoe|Tuckahoe (15g)
79326187|NCT02330029|Drug|Placebo|Placebo is blindly given to patients.
79326188|NCT03142555|Behavioral|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
79326189|NCT03142555|Behavioral|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
79326190|NCT02638103|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
79326191|NCT02638103|Drug|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
79481967|NCT02684825|Device|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
79648159|NCT06030284|Device|BurstDR-SCS|Spinal Cord Stimulation with a BurstDR-SCS system.
79648160|NCT06030284|Device|BurstDR-SCS|BurstDR-SCS system turned off.
79481968|NCT02682342|Other|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
79481969|NCT02672449|Radiation|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
79481970|NCT02643966|Device|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
79978183|NCT05090540|Procedure|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
79810717|NCT00668746|Drug|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
79326192|NCT02330107|Other|MAT & LAT|"For MAT, the magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
79326193|NCT03713983|Other|Observational study|Observational study
79978184|NCT05088967|Drug|IBI110|R2PD d1 IV every 3 weeks
79326194|NCT02330185|Device|ultrasonography|spinal anesthesia guided with ultrasonography
79978185|NCT05088967|Drug|sintilimab|200mg d1 IV every 3 weeks
79978186|NCT05084430|Drug|M032|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
79810718|NCT00767182|Other|blood sample|biological markers evaluated : D-Dimer, sEPCR
79978187|NCT05084430|Drug|Pembrolizumab|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
79978188|NCT05078034|Device|Helmet Non-Invasive Ventilation (HNIV)|HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
79978189|NCT05078034|Device|High Flow Nasal Oxygen|HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
79810719|NCT04047940|Drug|LY900020|Administered orally
79810720|NCT04047940|Drug|Metformin XR|Administered orally
79810721|NCT04047940|Drug|Atorvastatin|Administered orally
79978190|NCT05075850|Device|Neuroblate System|"All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.~Visual field testing will be conducted in a subset of enrolled patients."
79978191|NCT05075538|Biological|Spikevax|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978192|NCT05075538|Biological|Comirnaty|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978193|NCT05075538|Biological|Spikevax bivalent Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978194|NCT05075538|Biological|Spikevax bivalent Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978195|NCT05075538|Biological|Comirnaty Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978196|NCT05075538|Biological|Comirnaty Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978197|NCT05075538|Biological|Comirnaty Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79978198|NCT05075538|Biological|Spikevax Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
79810722|NCT04047940|Drug|Valsartan|Administered orally
79810723|NCT00773110|Drug|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
79810724|NCT00773110|Drug|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
79810725|NCT00773188|Drug|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
79810726|NCT00773188|Drug|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
79810727|NCT00773188|Drug|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
79810728|NCT00767260|Drug|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
79326195|NCT03143725|Drug|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
79326196|NCT04988971|Drug|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
79326197|NCT04988971|Drug|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
79326198|NCT03076619|Other|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
79326199|NCT02329873|Behavioral|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
79326200|NCT03143881|Behavioral|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
79326201|NCT03076541|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
79326202|NCT04931875|Device|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
79326203|NCT03076463|Dietary Supplement|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
79326204|NCT02329795|Radiation|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
79648161|NCT06015945|Device|Transcutaneous Electrical Acustimulation (TEA)|"The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study."
79810729|NCT00767260|Drug|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
79810730|NCT00767260|Device|HOT|Hyperbaric Oxygen Therapy
79810731|NCT00767260|Drug|SMT|hypoglycemic drugs or exogenous insulin
79326205|NCT02329795|Drug|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
79326206|NCT05002907|Other|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
79481971|NCT02640534|Drug|Enzalutamide|Enzalutamide 160 mg od until disease progression
79481972|NCT02640534|Drug|Metformin|850 mg bid until disease progression
79648162|NCT06013930|Behavioral|External Qigong|External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression
79648163|NCT06013930|Behavioral|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
79810732|NCT02557126|Drug|URC102|
79810733|NCT02557126|Drug|Placebo|
79810734|NCT00767494|Drug|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
79810735|NCT00767494|Drug|Azopt|Eye Drop Suspension, 1 drop BID
79810736|NCT00767494|Drug|Travatan|Eye Drop Solution, 1 drop BID
79810737|NCT00773500|Other|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
79810738|NCT00773578|Device|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
79810739|NCT00773578|Device|Measurement of biomarkers of nasal inflammation|Nasal lavage
79810740|NCT02557204|Procedure|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
79810741|NCT02557204|Procedure|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
79810742|NCT02557204|Procedure|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
79810743|NCT02557204|Procedure|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
79810744|NCT03874468|Device|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
79810745|NCT00773656|Other|Whole blood sample|70 ml per patient for collection of biological sample
79978199|NCT05075486|Behavioral|Collaborative quality improvement|Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
79978200|NCT05075213|Behavioral|contingency management (deposit contract)|Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.
79978201|NCT05075213|Behavioral|leaderboard and social feed|Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.
79481973|NCT02628366|Other|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
79648164|NCT06013930|Other|Psychoeducation|In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
79810746|NCT00775762|Drug|aspirin|Aspirin (75-100 mg)die for three months
79810747|NCT00775762|Drug|clopidogrel|Clopidogrel (75mg) die for three months
79810748|NCT00775762|Drug|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
79978202|NCT05075213|Behavioral|smoking cessation resource list|Participants will have access to a list of smoking cessation resources
79978203|NCT05072236|Procedure|bronchoscopic insertion|After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
79810749|NCT00775840|Drug|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
79978204|NCT05070845|Biological|PF-06835375|CXCR5 inhibitor
79978205|NCT05068713|Other|Usual Care + High Target of Mean Arterial Pressure|Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
79978206|NCT05068713|Other|Usual Care|Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
79810750|NCT00775840|Drug|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
79810751|NCT00775918|Drug|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
79810752|NCT00878189|Drug|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
79810753|NCT00775996|Drug|Clorazepate Dipotassium 15mg Tablets|
79326207|NCT05002907|Other|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
79978207|NCT05065021|Drug|Niraparib|Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
79326208|NCT05002907|Other|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
79481974|NCT02616484|Drug|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
79481975|NCT02616484|Other|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
79810754|NCT00773812|Drug|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
79810755|NCT00773812|Drug|placebo|One pill is taken once daily.
79810756|NCT00773890|Drug|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
79810757|NCT00773890|Drug|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
79810758|NCT00767728|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
79810759|NCT00767728|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
79810760|NCT00774124|Other|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
79978208|NCT05065021|Drug|Dostarlimab|Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
79978209|NCT05065021|Drug|Bevacizumab|Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
79978210|NCT05065021|Drug|Paclitaxel|Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
79326209|NCT05002907|Other|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
79481976|NCT02616484|Genetic|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
79481977|NCT02586038|Drug|MLN9708|
79481978|NCT02586038|Drug|Dexamethasone|
79481979|NCT02586038|Drug|Cyclophosphamide|
79481980|NCT02586038|Drug|Thalidomide|
79481981|NCT02581254|Device|Thin Wire Snare|
79810761|NCT00774124|Other|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
79810762|NCT00776074|Drug|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
79810763|NCT00776074|Drug|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
79810764|NCT02628587|Drug|Generic clopidogrel|"Comparison of different brands of clopidogrel:~*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
79810765|NCT02628587|Drug|Patent clopidogrel|"Comparison of different brands of clopidogrel:~*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
79810766|NCT04162457|Dietary Supplement|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
79481982|NCT02581254|Device|Thick Wire Snare|
79810767|NCT04162457|Dietary Supplement|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
79481983|NCT02579811|Drug|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
79481984|NCT02577549|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
79481985|NCT02577549|Behavioral|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
79481986|NCT02554383|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
79481987|NCT02554383|Drug|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
79481988|NCT02533960|Other|not applicable (observational study)|Observational study without study related intervention.
79481989|NCT02522871|Device|OCS™ Liver System|
79481990|NCT02522871|Other|Control|
79481991|NCT02519439|Drug|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
79648165|NCT06006221|Behavioral|Qi-gong relaxation exercise|Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
79810768|NCT04162457|Dietary Supplement|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
79810769|NCT04162457|Dietary Supplement|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
79978211|NCT05064735|Drug|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
79648168|NCT05991661|Drug|XKH001 Injection|100mg/ml，1ml/vial
79648169|NCT05991661|Drug|XKH001 Placebo Injection|1ml/vial
79648170|NCT05979831|Drug|DS-2325a|Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses
79648171|NCT05979831|Other|Placebo|Main Phase: IV infusion followed by SC doses
79648172|NCT05978284|Biological|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
79648173|NCT05976633|Other|Whole white rice (control)|One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
79810770|NCT02634437|Drug|Ulipristal acetate|
79810771|NCT00668200|Drug|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
79307426|NCT04210986|Dietary Supplement|Fisetin|Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
79307427|NCT04210986|Drug|Placebo oral capsule|Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
79307428|NCT04208984|Device|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
79307429|NCT04208984|Other|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
79307430|NCT04204876|Diagnostic Test|Magnet Resonance Imaging (MRI)|MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)
79307431|NCT04204876|Diagnostic Test|PET/CT analysis|Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
79307432|NCT04171765|Drug|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
79307433|NCT04171765|Drug|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
79307434|NCT04163952|Biological|Panitumumab|Given IV
79481992|NCT02514226|Procedure|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
79481993|NCT02514226|Procedure|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
79481994|NCT02514226|Procedure|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
79481995|NCT02514226|Other|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
79648174|NCT05976633|Other|Whole brown rice|One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
79648175|NCT05976633|Other|Whole wild rice|One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
79810772|NCT00668200|Dietary Supplement|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
79307435|NCT04163952|Biological|Talimogene Laherparepvec|Given IM
79307436|NCT04150029|Drug|MBG453|Solution for intravenous infusion
79307437|NCT04150029|Drug|Venetoclax|Tablet for oral administration
79307438|NCT04150029|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
79307439|NCT04145037|Drug|AVR-RD-02|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
79307440|NCT04143061|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
79307441|NCT04143061|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
79307442|NCT04143061|Biological|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
79307443|NCT04143061|Biological|Hepatitis A vaccine|Pharmaceutical form: Suspension for injection in prefilled syringe Route of administration: Intramuscular, 0.5 mL
79307444|NCT04143061|Biological|Measles, Mumps, and Rubella Virus Vaccine (MMR)|Pharmaceutical form: Lyophilized powder for injection Route of administration: Subcutaneous or Intramuscular, 0.5 mL
79307445|NCT04143061|Biological|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
79307446|NCT04143061|Biological|DTwP-HepB-Hib-IPV vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
79307447|NCT04143061|Biological|Varicella vaccine|"Pharmaceutical form: Sterile powder and diluent for injection in prefilled syringe Subcutaneous, 0.5 mL~Route of administration: Pharmaceutical form:"
79307448|NCT04128670|Device|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
79481996|NCT02476682|Other|blood or stool samples will be collected|blood or stool samples will be collected
79481997|NCT02470416|Device|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
79481998|NCT02378038|Drug|PNT2258|
79481999|NCT02371382|Device|Arthroplasty hip|Hip replacement
79482000|NCT02364687|Radiation|Computed tomography late enhancement imaging|
79482001|NCT02359175|Drug|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
79482002|NCT02359175|Drug|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
79482003|NCT02359175|Drug|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
79648176|NCT05976633|Other|15% Wild rice and 85% Brown rice blend - Stovetop|One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
79482004|NCT02359175|Drug|Oral Paracetamol|Paracetamol to be given orally
79648177|NCT05976633|Other|15% Wild rice and 85% Brown rice blend - Microwaved|One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
79648178|NCT05965583|Drug|BI 1815368|BI 1815368
79810773|NCT00668200|Dietary Supplement|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
79810774|NCT00679601|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
79810775|NCT00675779|Drug|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
79648179|NCT05965583|Drug|Itraconazole|Itraconazole
79648180|NCT05965349|Behavioral|Healthy Mind, Healthy Living|A telephone, 8-week MBCT workshop series including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
79307449|NCT04098250|Drug|Erenumab|a CGRP receptor monoclonal antibody
79648181|NCT05956106|Dietary Supplement|Black Mulberry Fruit Powder|Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
79648182|NCT05943496|Drug|Acalabrutinib|Given PO
79307450|NCT04098250|Other|Placebo|Placebo
79648183|NCT05943496|Procedure|Biospecimen Collection|Undergo blood sample collection
79307451|NCT04097028|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79307452|NCT04097028|Drug|Oxaliplatin|Given IV
79307453|NCT04063410|Procedure|Angiography|Undergo standard of care CTA
79307454|NCT04063410|Procedure|MRI-Based Angiogram|Undergo pPCA
79307455|NCT04063410|Other|Quality-of-Life Assessment|Ancillary studies
79307456|NCT04039607|Drug|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
79648184|NCT05943496|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
79648185|NCT05943496|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
79648186|NCT05943496|Procedure|Computed Tomography|Undergo CT scan
79307457|NCT04039607|Drug|Ipilimumab|Participants will receive ipilimumab as IV infusion.
79307458|NCT04039607|Drug|Sorafenib|Participants will receive sorafenib as oral tablets.
79307459|NCT04039607|Drug|lenvatinib|Participants will receive lenvatinib as oral capsules.
79307460|NCT04026412|Biological|nivolumab|Specified dose on specified days
79307461|NCT04026412|Biological|ipilimumab|Specified dose on specified days
79307462|NCT04026412|Biological|durvalumab|Specified dose on specified days
79307463|NCT04019522|Other|Acute Intermittent Hypoxia (AIH)|An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
79307464|NCT04015804|Other|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
79307465|NCT03980561|Drug|Varenicline|Active medication
79307466|NCT03980561|Drug|Placebo|Inactive medication
79307467|NCT03972306|Drug|Ocrelizumab|Administered by subcutaneous Injection
79307468|NCT03972306|Drug|Ocrelizumab|Administered by Intravenous (IV) Injection
79307469|NCT03972306|Drug|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
79307470|NCT03970967|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79307471|NCT03966807|Behavioral|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
79648187|NCT05943496|Procedure|Echocardiography|Undergo ECHO
79978212|NCT05064735|Drug|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
79648188|NCT05943496|Biological|Obinutuzumab|Given IV
79810776|NCT00675779|Drug|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
79810777|NCT00774280|Drug|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
79978213|NCT05063721|Biological|autologous mesoangioblasts|intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
79978214|NCT05051982|Device|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
79978215|NCT05050929|Radiation|Targeting All Brain Metastases|Volumetric Modulated Arc Therapy
79978216|NCT05049460|Device|Theta Burst Stimulation|Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.
79978217|NCT05049460|Device|Sham TMS|Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
79978218|NCT05045612|Other|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
79978219|NCT05044793|Device|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
79326210|NCT05002907|Other|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
79482005|NCT02359175|Drug|Oral NSAID|NSAID to be given orally
79648189|NCT05943496|Other|Questionnaire Administration|Ancillary studies
79648190|NCT05943496|Biological|Tafasitamab|Given IV
79648191|NCT05938894|Other|online games with various food images|Participant will play a series of online games with various food images.
79648192|NCT05938894|Other|online games with images of flowers and songbirds|Participant will play a series of online games with images of flowers and songbirds.
79648193|NCT05932602|Device|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
79648194|NCT05932602|Device|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
79648195|NCT05925686|Drug|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
79648196|NCT05924932|Device|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6|type of hybrid close loop insulin delivery system
79648197|NCT05924932|Device|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4|type of hybrid close loop insulin delivery system
79648198|NCT05913232|Drug|H-1337 0.6%|ophthalmic solution
79648199|NCT05913232|Drug|H-1337 1.0%|ophthalmic solution
79648200|NCT05913232|Drug|H-1337 Placebo|ophthalmic solution
79978220|NCT05038332|Radiation|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, ~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
79978221|NCT05038332|Radiation|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
79326211|NCT05002907|Other|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
79978222|NCT05035342|Biological|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
79326212|NCT05002907|Other|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
79326213|NCT02329561|Drug|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
79326214|NCT02329561|Behavioral|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
79326215|NCT02329561|Drug|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
79326216|NCT05000879|Behavioral|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
79326217|NCT02329639|Genetic|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
79482006|NCT02359175|Drug|Oral opioids|Opioids to be given orally
79482007|NCT02359175|Drug|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
79978223|NCT05035342|Biological|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
79978224|NCT05035316|Drug|acetylsalicylic acid|Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
79978225|NCT05035316|Drug|Calcium|Oral tablet: calcium, 1 tablet/day
79978226|NCT05028816|Device|Side 1: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
79326218|NCT05003063|Drug|Donepzil|Test
79326219|NCT05003063|Drug|Placebo oral tablet|Test
79326220|NCT03143491|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
79326221|NCT05002673|Device|DENTAL LOCAL ANESTHESİA|doing local and topical anesthesia with two different device
79326222|NCT02329717|Drug|PBI 05204|PBI 05204 daily dosing
79326223|NCT05001035|Other|Time of assessment|Immediate and after one month and after two months
79326224|NCT03076151|Drug|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
79326225|NCT05032651|Device|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
79326226|NCT05002517|Drug|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
79326227|NCT05002517|Drug|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
79482008|NCT02310139|Procedure|Colonoscopy|
79482009|NCT02306707|Procedure|Endoscopic Mucosal Resection|
79482010|NCT02306603|Procedure|Endoscopic Mucosal Resection|
79482011|NCT02305290|Procedure|Endoscopic Mucosal Resection|
79482012|NCT02238938|Procedure|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
79482013|NCT02238938|Procedure|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
79482014|NCT02215980|Drug|Lenalidomide|
79482015|NCT02215980|Drug|Dexamethasone|
79482016|NCT02196649|Device|Endoscopic Clip|
79648201|NCT05913232|Drug|Timolol 0.5%|ophthalmic solution
79326228|NCT03473275|Diagnostic Test|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
79482017|NCT02101021|Drug|Momelotinib|Tablet (s) administered orally once or twice daily
79326229|NCT03473275|Diagnostic Test|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
79326230|NCT05002205|Other|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
79326231|NCT05002205|Other|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
79326232|NCT05002205|Other|ECG|During two study visits, the presence of arrhythmia will be explored.
79326233|NCT05002205|Other|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
79326234|NCT05002205|Other|Vital parameters|blood pressure, pulse, weight
79326235|NCT05002361|Drug|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
79326236|NCT05002361|Drug|Isotonic saline|6 ml of isotonic saline
79326237|NCT02329405|Drug|Rifampicin|
79326238|NCT02329405|Drug|Placebo|
79326239|NCT05002283|Other|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
79482018|NCT02101021|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
79326240|NCT02329171|Drug|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
79326241|NCT02329171|Procedure|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
79326242|NCT05001971|Drug|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
79482019|NCT02101021|Drug|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
79482020|NCT02101021|Drug|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
79482021|NCT02088632|Biological|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
79326243|NCT05000801|Biological|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
79326244|NCT02329093|Procedure|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
79326245|NCT02329249|Behavioral|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
79326246|NCT02329249|Other|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
79326247|NCT05001893|Device|S53P4 bioactive glass putty|Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
79482022|NCT02088632|Other|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
79482023|NCT02031536|Drug|everolimus|Given PO
79482024|NCT02031536|Other|placebo|Given PO
79482025|NCT02028455|Biological|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
79482026|NCT02023996|Radiation|89Zr-DFO-trastuzumab|
79482027|NCT02023996|Device|PET imaging|
79482028|NCT02020720|Procedure|Biopsy|Undergo image-guided biopsy
79482029|NCT02020720|Procedure|Computed Tomography|Undergo 18F-DOPA-PET/CT
79482030|NCT02020720|Procedure|Diffusion Weighted Imaging|Undergo DTI
79326248|NCT03143335|Procedure|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
79326249|NCT03143335|Procedure|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
79978227|NCT05028816|Other|Side 1: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
79978228|NCT05028816|Device|Side 2: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
79978229|NCT05028816|Other|Side 2: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
79978230|NCT05027438|Behavioral|Cognitive Behavioral Therapy for Insomnia|A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
79978231|NCT05027438|Behavioral|Deprescribing|The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
79978232|NCT05026866|Drug|Donanemab|Administered intravenously
79978233|NCT05026866|Drug|Placebo|Administered intravenously
79326250|NCT05001659|Other|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
79326251|NCT02328781|Device|Drug-eluting stent|
79326252|NCT05000099|Other|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
79326253|NCT05000255|Behavioral|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
79482031|NCT02020720|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
79482032|NCT02020720|Other|Laboratory Biomarker Analysis|Correlative studies
79482033|NCT02020720|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
79482034|NCT02020720|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
79482035|NCT02020720|Procedure|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
79978234|NCT05020860|Drug|Paclitaxel|80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle
79978235|NCT05020860|Drug|Carboplatin|Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle
79978236|NCT05020860|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle
79978237|NCT05020860|Drug|Pertuzumab|Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle
79978238|NCT05020860|Drug|Doxorubicin|60 mg/m2 IV administered on Day 1 of each 14-day cycle
79978239|NCT05020860|Drug|Cyclophosphamide|600 mg/m2 IV administered on Day 1 of each 14-day cycle
79978240|NCT05020860|Drug|Pembrolizumab|"Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen."
79978241|NCT05020860|Drug|Pertuzumab/Trastuzumab/Hyaluronidase-zzxf|Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
79978242|NCT05013905|Drug|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
79978243|NCT05013905|Device|Companion diagnostic (CDx)|CDx+ or CDx-
79978244|NCT05011487|Drug|Osimertinib|80mg/qd oral for 60 days
79978245|NCT05011487|Drug|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
79978246|NCT05011487|Drug|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
79482036|NCT02019641|Other|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
79482037|NCT02019641|Other|Education|Weekly education
79482038|NCT02000141|Procedure|Endoscopic Mucosal Resection|
79326254|NCT05000255|Behavioral|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
79326255|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
79326256|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
79326257|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
79326258|NCT04498741|Drug|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
79326259|NCT04498741|Drug|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
79326260|NCT04498741|Drug|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
79326261|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
79978247|NCT05007925|Device|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
79326262|NCT04498741|Drug|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
79326263|NCT04999943|Biological|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
79326264|NCT04999865|Other|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
79326265|NCT04938635|Drug|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
79326266|NCT04938635|Drug|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
79326267|NCT04938635|Drug|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
79326268|NCT04938635|Drug|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
79978248|NCT05005962|Device|Neurothrombectomy|Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
79326269|NCT03551743|Combination Product|PRT064445/Edoxaban|
79326270|NCT03551743|Combination Product|Placebo/Edoxaban|
79326271|NCT03551743|Drug|Placebo|
79326272|NCT04932395|Drug|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
79326273|NCT04932395|Drug|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
79648202|NCT05899218|Behavioral|Critical Narrative Development|"Participants are asked to answer two prompts (describe an experience where you have felt seen as an LGBTQ+ person of color and describe an experience where you have felt unseen as an LGBTQ+ person of color)."
79326274|NCT04932239|Other|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
79326275|NCT04714879|Other|Device: anodal tDCS|anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)
79326276|NCT04714879|Other|Device: no stimulation|sham stimulation
79648203|NCT05895513|Drug|Pimavanserin 34 mg|5HT-2a receptor antagonist
79648204|NCT05895513|Drug|Placebo|Inactive Comparator
79978249|NCT05003817|Device|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
79978250|NCT05003440|Drug|NNC0385-0434|Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
79978251|NCT05003440|Drug|Placebo|Participants will get 1 tablet (oral use) of placebo per day for 10 days
79978252|NCT05003388|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79482039|NCT01968200|Drug|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
79648205|NCT05894538|Drug|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
79648206|NCT05894538|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
79648207|NCT05892614|Drug|efzofitimod 450 mg|IV infusion over approximately 60 minutes every 4 weeks
79648208|NCT05892614|Drug|efzofitimod 270 mg|IV infusion over approximately 60 minutes every 4 weeks
79648209|NCT05892614|Drug|Placebo|IV infusion over approximately 60 minutes every 4 weeks
79648210|NCT05890599|Behavioral|Yoga Therapy|"The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume."
79810778|NCT04151147|Procedure|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
79810779|NCT04151147|Procedure|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
79482040|NCT01964430|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
79482041|NCT01964430|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
79648211|NCT05890599|Behavioral|Health Education|Health education courses are conducted on-site once a week for 90 minutes over 12 weeks by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
79648212|NCT05881590|Other|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
79648213|NCT05878119|Drug|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
79810780|NCT00774358|Drug|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
79978253|NCT04999709|Device|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
79482042|NCT01934868|Drug|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
79648214|NCT05878119|Drug|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
79810781|NCT02627417|Drug|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
79810782|NCT02627417|Drug|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
79978254|NCT04996797|Drug|PRA023 IV|PRA023 administered by IV infusion
79978255|NCT04996797|Device|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
79978256|NCT04996797|Other|Placebo|Placebo administered by IV infusion
79978257|NCT04987203|Drug|Tivozanib|Tivozanib will be administered orally.
79978258|NCT04987203|Drug|Nivolumab|Nivolumab will be administered via intravenous infusion.
79978259|NCT04987034|Device|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
79978260|NCT04984876|Drug|ligelizumab|Subcutaneous injection once every 4 weeks
79978261|NCT04984876|Drug|Placebo|Subcutaneous injection once every 4 weeks
79978262|NCT04975724|Drug|Liposom Forte|Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
79978263|NCT04975724|Drug|Citalopram|The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
79978264|NCT04975724|Other|Placebo|Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
79978265|NCT04967989|Procedure|Low Energy SLT|SLT performed at low energy
79978266|NCT04967989|Procedure|Standard Energy SLT|SLT performed at standard energy
79978267|NCT04963153|Procedure|Biospecimen Collection|Undergo blood sample collection
79978268|NCT04963153|Procedure|Computed Tomography|Undergo CT
79978269|NCT04963153|Drug|Enfortumab Vedotin|Given IV
79978270|NCT04963153|Drug|Erdafitinib|Given PO
79978271|NCT04958941|Behavioral|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
79978272|NCT04949191|Drug|Pemigatinib|Pemigatinib tablets taken by mouth once daily as per protocol
79978273|NCT04949191|Drug|Retifanlimab|Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
79307472|NCT03966807|Behavioral|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
79307473|NCT03953144|Device|Synapse 3D Lung Modelling|The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
79307474|NCT03953144|Drug|IC-Green (ICG)|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
79307475|NCT03936309|Other|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
79978274|NCT04949191|Drug|Pembrolizumab|Commercially labeled products
79648215|NCT05878119|Other|Standardized, progressive, high intensity, multidimensional exercise|Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.
79307476|NCT03936309|Other|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
79326277|NCT04698811|Behavioral|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
79482043|NCT01934868|Drug|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
79482044|NCT01913717|Radiation|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
79482045|NCT01898494|Procedure|Transoral surgery|Undergo transoral surgical resection
79482046|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
79482047|NCT01898494|Drug|cisplatin|Given IV
79482048|NCT01898494|Drug|carboplatin|Given IV
79482049|NCT01863043|Procedure|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
79482050|NCT01863043|Procedure|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
79482051|NCT01841359|Drug|Pramlintide|See description above (arm description).
79978275|NCT04947904|Other|Reduction of the patient's fluid intake during the first 7 days|The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
79978276|NCT04945772|Biological|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
79810783|NCT02627417|Drug|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
79978277|NCT04945772|Procedure|Sham Injection|Sham Injection
79482052|NCT01786486|Device|Amplatzer Cardiac Plug|
79482053|NCT01683279|Biological|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
79648216|NCT05878119|Other|Usual Physical Activity|Participants will be asked to perform usual physical activity per listed in the protocol
79648217|NCT05874622|Drug|VC005 tablets|VC005 groups repeat administration for 4 weeks
79326278|NCT03142399|Dietary Supplement|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
79648218|NCT05874622|Drug|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 4 weeks
79648219|NCT05855798|Drug|Bupivacain|Bupivacaine is a local anesthetic agent commonly used in ESP block.
79810784|NCT00774436|Procedure|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
79810785|NCT02556892|Drug|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
79810786|NCT00774514|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
79482054|NCT01660451|Drug|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
79482055|NCT01601678|Procedure|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
79978278|NCT04943224|Drug|Trametinib|< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
79978279|NCT04943211|Drug|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
79978280|NCT04943198|Drug|Vemurafenib|20 mg/kg/day
79326279|NCT03076307|Behavioral|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
79326280|NCT03076229|Behavioral|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
79978281|NCT04941651|Behavioral|OBE-COACH program|"OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program.~The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses.~To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals.~The intensity level of the program is selected by the user at any time."
79326281|NCT03076073|Other|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
79326282|NCT02328859|Other|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
79326283|NCT02328859|Other|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
79326284|NCT04993937|Other|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
79326285|NCT04993937|Other|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
79648220|NCT05855798|Drug|Magnesium sulfate|Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..
79648221|NCT05855798|Drug|Ketamine Hydrochloride|Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
79810787|NCT00679679|Drug|Metformin|Metformin 750 mg BID for 4 months
79810788|NCT00679679|Drug|Placebo|Diet counseling and exercise
79810789|NCT00774592|Behavioral|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
79810790|NCT00774592|Behavioral|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
79810791|NCT00774592|Behavioral|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
79648222|NCT05852808|Drug|Intra-articular steroid injections|"The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation."
79810792|NCT00774592|Behavioral|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
79810793|NCT00774592|Behavioral|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
79810794|NCT00774592|Behavioral|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
79810795|NCT00838578|Biological|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
79810796|NCT00838578|Drug|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
79978282|NCT04941651|Device|Connected devices|"Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program.~The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate.~The balance (Web coach premium, Terraillon) is a connected scale to collect body weight."
79978283|NCT04941651|Device|Connected Activity Tracer|The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.
79810797|NCT00774826|Drug|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
79810798|NCT00774826|Drug|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
79810799|NCT00774826|Drug|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
79810800|NCT00656981|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
79810801|NCT00656981|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
79810802|NCT02634515|Drug|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
79810803|NCT02634515|Drug|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
79810804|NCT00705900|Drug|LCD|2 applications / day for 12 weeks
79810805|NCT00705900|Drug|calcipotriol|2 applications / day for 12 weeks
79810806|NCT00679835|Drug|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
79978284|NCT04941651|Behavioral|e-learning program|e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)
79326286|NCT03143257|Device|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of BC of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
79326287|NCT04993547|Other|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
79326288|NCT04654429|Drug|IV Ondansetron 4mg|IV ondansetron 4mg
79326289|NCT04654429|Other|Higher OT temperature range|OT temperature set to 19-22 degree celsius
79326290|NCT04654429|Drug|Placebo|IV Normal Saline 2cc will be given
79326291|NCT04654429|Other|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
79326292|NCT03075683|Behavioral|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
79326293|NCT03075683|Behavioral|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
79326294|NCT03075995|Other|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
79326295|NCT04639999|Other|Echocardiography|LV vortex flow in Echocardiography
79810807|NCT00774904|Drug|Losartan|Angiotensin II Type 1 Receptor Blockers
79810808|NCT00829296|Drug|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
79810809|NCT00829296|Drug|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
79810810|NCT00774982|Drug|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
79810811|NCT00774982|Drug|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
79810812|NCT00881621|Drug|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
79810813|NCT02634281|Drug|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
79810814|NCT02634281|Drug|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
79978285|NCT04930562|Drug|BN101|BN101 is an orally ROCK2 selective inhibitor
79978286|NCT04929899|Behavioral|Bright Ideas - CIN Training|Bright IDEAS is a validated problem-solving skill training intervention.
79326296|NCT03111355|Dietary Supplement|Brazil nut|one nut a day for 2 months, no intervention for 2 months
79326297|NCT04999397|Other|standards clinical management|outcomes seen in cardiac injuries post clincal care
79326298|NCT02328703|Other|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
79326299|NCT04999007|Other|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
79326300|NCT03979339|Procedure|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
79326301|NCT04998929|Other|complementary therapy|traditional techniques of treatment including, (a)cupping therapy, (b)Backstroke for young people, (c)Sitting on all fours while the other person holds both knees firmly with the hands, the patient is asked to bend at the back so that the abdominal muscles are stretched, (d)taking a nerve that passes under the armpit with two index fingers and thumbs and applying intense pressure to the extent that the patient goes unconscious due to the severity of the pain, (e)Hanging the patient from the horizontal bar and stretching the abdominal muscles, (f)Tie an onion-sized object such as, a bag of wheat or salt, with a scarf on the navel for one hour, (g) taking the gum of mountain pistachio tree which is the same as turpentine and halve a walnut and fill it with raw turpentine and put it inside the navel for 72 hours, and then move it in the umbilical region by twisting hand movements, (h)cupping therapy.
79326302|NCT03073499|Procedure|Oncological Home Hospitalization|
79810815|NCT00818766|Drug|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
79482056|NCT01601678|Procedure|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
79482057|NCT01586065|Device|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
79482058|NCT01579734|Drug|Tamoxifen|1 tablet, 5 mg / day for 5 years
79810816|NCT00818766|Drug|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
79482059|NCT01579734|Drug|Placebo|1 tablet day for 5 years
79482060|NCT01566240|Drug|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 & 36.
79482061|NCT01566240|Drug|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, & 36.
79810817|NCT00779350|Drug|sertraline 100 mg tablets|
79810818|NCT00680537|Procedure|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
79810819|NCT00705978|Drug|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
79810820|NCT00705978|Drug|Placebo|placebo
79810821|NCT04150835|Drug|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
79810822|NCT04150835|Drug|Xingnaojing placebo injection|Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
79810823|NCT04150835|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
79810824|NCT00667888|Radiation|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
79810825|NCT00667888|Radiation|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
79810826|NCT00680615|Behavioral|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
79482062|NCT01566240|Radiation|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
79482063|NCT01566240|Drug|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
79810827|NCT00680615|Behavioral|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
79810828|NCT02556970|Procedure|Single port VATS|Performing video-assisted thorascopic surgery through a single port
79810829|NCT02556970|Drug|Paracetamol|1g intraoperatively
79978287|NCT04927741|Other|Sweet Marjoram Essential Oil|"Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
79482064|NCT01556399|Other|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
79482065|NCT01550198|Device|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
79482066|NCT01529047|Behavioral|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
79810830|NCT02556970|Drug|Diclofenac|75mg intraoperatively
79810831|NCT02556970|Device|Camera (5mm diameter 30 degree videothoracoscope)|
79810832|NCT02556970|Device|Forceps grasper|
79810833|NCT02556970|Drug|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
79810834|NCT00776464|Device|Noveon laser|Two wavelenghts of light
79810835|NCT00594815|Drug|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
79810836|NCT00776542|Drug|Minocycline 100mg Tablets|
79482067|NCT01390584|Drug|Doxorubicin|IV
79810837|NCT04150679|Procedure|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
79482068|NCT01390584|Drug|Bleomycin|IV
79978288|NCT04927741|Other|Grapeseed Oil|"Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
79978289|NCT04920175|Other|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
79978290|NCT04908787|Drug|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
79978291|NCT04908787|Drug|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
79482069|NCT01390584|Drug|Vinblastine|IV
79810838|NCT04150679|Procedure|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
79978292|NCT04908787|Drug|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
79978293|NCT04908787|Drug|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
79978294|NCT04908787|Drug|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
79978295|NCT04908735|Drug|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
79978296|NCT04902872|Drug|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
79978297|NCT04896580|Behavioral|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
79978298|NCT04895241|Drug|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
79810839|NCT00776620|Drug|Glimepiride 1mg Tablets|
79810840|NCT00680693|Behavioral|Mindfulness training|8 weekly 2-hour classes
79810841|NCT00680693|Behavioral|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
79810842|NCT00776698|Drug|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
79810843|NCT00776698|Drug|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
79810844|NCT00776698|Drug|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
79810845|NCT04161833|Dietary Supplement|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
79978299|NCT04895241|Drug|Placebo|Administered as specified in the treatment arm.
79326303|NCT03970993|Biological|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
79326304|NCT03970993|Biological|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
79326305|NCT03970993|Biological|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
79326306|NCT04998695|Other|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
79482070|NCT01390584|Diagnostic Test|PET|fludeoxyglucose F 18 Imaging exam
79482071|NCT01390584|Radiation|INRT|selective external radiation therapy
79482072|NCT01390584|Drug|Dacarbazine|IV
79482073|NCT01390584|Drug|Etoposide|IV
79482074|NCT01390584|Drug|Cyclophosphamide|May be given orally, IV push, or by IV infusion
79482075|NCT01390584|Drug|Vincristine|IV
79482076|NCT01390584|Drug|Procarbazine|PO
79482077|NCT01390584|Drug|Prednisone|PO
79482078|NCT01374841|Drug|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
79978300|NCT04891822|Procedure|ERAS protocol|E: ERAS protocol C: control
79326307|NCT04998695|Other|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
79326308|NCT04998461|Biological|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
79810846|NCT00680147|Behavioral|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
79810847|NCT02634047|Device|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
79326309|NCT03111121|Drug|Sugammadex|receive reversal with sugammadex 4mg/kg
79326310|NCT03111121|Drug|neostigmine|receive reversal with neostigmine 0.04 mg/kg
79326311|NCT03111121|Drug|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
79810848|NCT02634047|Device|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
79326312|NCT03073421|Other|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
79326313|NCT04532359|Device|Implant placement|Implant placement
79810849|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
79326314|NCT04998383|Device|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
79326315|NCT02328469|Drug|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
79482079|NCT01374841|Other|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
79810850|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
79810851|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
79810852|NCT04150757|Drug|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
79810853|NCT04150211|Dietary Supplement|Polyherbal Exten(d) vs Placebo|Supplementation during 4 weeks
79810854|NCT04150367|Drug|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
79810855|NCT04150367|Drug|Rifampicin|Participants will get the dosage according to the instruction for use.
79978301|NCT04891289|Drug|Gemcitabine|See arm for details.
79326316|NCT02328469|Drug|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
79326317|NCT02328469|Other|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
79978302|NCT04891289|Drug|Oxaliplatin|See arm for details.
79326318|NCT02328469|Drug|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
79326319|NCT03141853|Other|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
79978303|NCT04891289|Drug|Dexamethasone|See arm for details.
79978304|NCT04891289|Drug|Floxuridine (FUDR)|See arm for details.
79978305|NCT04891289|Device|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
79978306|NCT04887506|Drug|TAVT-45|250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
79978307|NCT04887506|Drug|Zytiga|500 mg tablet, two tablets administered once daily
79978308|NCT04887506|Drug|Prednisone|mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
79978309|NCT04884360|Drug|Olaparib|Olaparib tablets 300 mg oral twice daily
79978310|NCT04884360|Other|Matching placebo|Matching placebo tablets taken orally at a dose of 300 mg twice daily
79978311|NCT04884308|Biological|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
79978312|NCT04883775|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
79326320|NCT03141853|Other|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
79482080|NCT01368731|Procedure|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
79326321|NCT03075371|Other|Glucose|75 g of glucose dissolved in 300 ml of water
79326322|NCT03075371|Other|Placebo|300 ml of tap water
79326323|NCT04998071|Drug|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
79326324|NCT03734263|Drug|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
79978313|NCT04883775|Drug|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
79482081|NCT01242800|Procedure|palliative surgery|Undergo standard palliative surgery
79482082|NCT01242800|Procedure|therapeutic conventional surgery|Undergo early surgery
79482083|NCT01242800|Radiation|palliative radiation therapy|Undergo standard palliative radiotherapy
79978314|NCT04883450|Diagnostic Test|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
79978315|NCT04872595|Other|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
79978316|NCT04872595|Radiation|Hyper fractionated total body irradiation|"(1375 - 1500cGy*) Day -9 to -6~*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
79326325|NCT03075293|Other|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
79326326|NCT03145051|Other|Saline solution|a nasal irrigation care
79326327|NCT03145051|Other|Respimer Netiflow|a nasal irrigation care
79326328|NCT03075059|Behavioral|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
79482084|NCT01242800|Radiation|radiation therapy|Undergo radiotherapy
79482085|NCT01216683|Biological|rituximab|Given IV
79482086|NCT01216683|Drug|Bendamustin|Given IV
79482087|NCT01216683|Drug|bortezomib|Given IV
79482088|NCT01216683|Drug|lenalidomide|Given orally
79482089|NCT01166113|Drug|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
79978317|NCT04872595|Drug|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
79978318|NCT04872595|Drug|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
79978319|NCT04872595|Drug|GCSF|Day +7
79978320|NCT04872595|Drug|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L
79978321|NCT04872595|Drug|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
79978322|NCT04872595|Drug|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
79978323|NCT04872569|Behavioral|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
79326329|NCT03671473|Device|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
79326330|NCT03073343|Dietary Supplement|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
79326331|NCT03075137|Device|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
79326332|NCT03074981|Device|Combined TopClosure & Vcare Alpha|"Combined TopClosure & Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
79326333|NCT03340051|Behavioral|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
79326334|NCT03340051|Behavioral|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
79326335|NCT03073265|Device|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
79810856|NCT04150367|Drug|Ethambutol|Participants will get the dosage according to the instruction for use.
79978324|NCT04871776|Behavioral|Messaging informed by construal level theory|"Messages are informed by construal level theory, which suggests that emphasizing why elicits more abstract thinking, or high-level construals, and can induce an emotional mindset, which could challenge an individual's sense of identity, autonomy, or political preferences. Conversely, emphasizing how is more cognitive and evokes concrete thinking, or low-level construals, and encourages a planning or implementation mindset, which may be better for encouraging vaccine uptake."
79326336|NCT03145129|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
79326337|NCT04438915|Behavioral|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
79326338|NCT04997837|Drug|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
79810857|NCT04150367|Drug|Rifampicin|Participants will get the dosage according to the instruction for use.
79810858|NCT04150367|Drug|Isoniazid|. Participants will get the dosage according to the instruction for use.
79810859|NCT04150367|Drug|Ethambutol|Participants will get the dosage according to the instruction for use.
79810860|NCT00680927|Other|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
79810861|NCT02634203|Procedure|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
79810862|NCT02634203|Drug|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
79978325|NCT04871776|Behavioral|Usual Care|Usual messaging sent by Mass General Brigham
79810863|NCT00680381|Behavioral|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
79810864|NCT00680381|Behavioral|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
79978326|NCT04869527|Device|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
79978327|NCT04854811|Drug|Roflumilast Oral Tablet|Once daily for 12 weeks
79810865|NCT00680381|Behavioral|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
79813826|NCT05640336|Procedure|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
79978328|NCT04854642|Drug|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
79482090|NCT01160107|Drug|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%; 2. The study stop (if PR <40% and grade 3-4 adverse events >25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are < 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are > 50% and PR rate > 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
79978329|NCT04852523|Drug|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
79978330|NCT04848337|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
79482091|NCT01145495|Other|Laboratory Biomarker Analysis|Correlative studies
79482092|NCT01145495|Drug|Lenalidomide|Given PO
79482093|NCT01145495|Biological|Rituximab|Given IV
79482094|NCT01124695|Drug|tamoxifen|PO
79482095|NCT01105169|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
79482096|NCT01105169|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
79482097|NCT01084083|Biological|cetuximab|Given IV
79482098|NCT01084083|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
79482099|NCT01084083|Drug|Paclitaxel|Given IV, 90 mg/m^2 on days 1, 8 and 15
79482100|NCT01084083|Drug|Cisplatin|Given IV, 75 mg/m^2 on day 1
79482101|NCT01079780|Biological|cetuximab|Given IV
79482102|NCT01079780|Biological|ramucirumab|Given IV
79978331|NCT04848337|Drug|Lenvatinib|Lenvatinib 20 mg orally daily.
79978332|NCT04844606|Drug|Mirikizumab|Administered SC
79978333|NCT04844606|Drug|Mirikizumab|Administered IV
79482103|NCT01079780|Drug|irinotecan hydrochloride|Given IV
79482104|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
79482105|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
79482106|NCT01013961|Biological|alemtuzumab|Given IV
79482107|NCT01013961|Biological|rituximab|Given IV
79482108|NCT00980590|Device|Airway Scope|Tracheal intubation by Airway Scope
79482109|NCT00980590|Device|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
79482110|NCT00979680|Radiation|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
79482111|NCT00979680|Radiation|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
79482112|NCT00959712|Behavioral|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
79482113|NCT00834093|Biological|Epstein-Barr Virus Specific Immunotherapy|
79482114|NCT00779194|Drug|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
79482115|NCT00665600|Drug|Levalbuterol HCl|Levalbuterol 0.63 TID
79482116|NCT00665600|Drug|Levalbuterol HCl|Levabuterol 1.25 mg TID
79482117|NCT00665600|Drug|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
79482118|NCT00665600|Drug|Placebo|Placebo TID
79482119|NCT00606294|Radiation|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
79482120|NCT00606294|Device|18F-FMISO PET scan|
79978334|NCT04839328|Drug|60mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
79482121|NCT00606294|Device|MRI|
79482122|NCT00606294|Device|FDG PET/CT scan|
79482123|NCT00583596|Device|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
79482124|NCT00583596|Other|Objective Performance Criteria|Compare results of device closure to objective performance criteria
79482125|NCT00551928|Drug|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
79482126|NCT00551928|Drug|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
79482127|NCT00551928|Drug|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
79978335|NCT04839328|Drug|Placebo|Placebos are the same as drugs, but contain no Hemay005.
79978336|NCT04833894|Biological|Efgartigimod IV|Intravenous infusion of Efgartigimod
79326339|NCT04997837|Drug|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
79326340|NCT04997837|Drug|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
79326341|NCT04997837|Drug|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
79326342|NCT04997837|Drug|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
79482128|NCT00551928|Drug|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
79482129|NCT00369499|Device|PFO Closure|
79482130|NCT00330564|Drug|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
79482131|NCT00316888|Biological|cetuximab|Given IV
79482132|NCT00316888|Drug|cisplatin|Given IV
79482133|NCT00316888|Drug|fluorouracil|Given IV
79482134|NCT00316888|Radiation|radiotherapy|Given once daily 5 days a week for 5 weeks
79482135|NCT00309478|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2
79482136|NCT00309478|Drug|Methotrexate|Methotrexate 40mg/m2
79482137|NCT00309478|Drug|Fluorouracil implant|Fluorouracil 600mg/m2
79482138|NCT00309478|Drug|Goserelin|Zoladex 3.6mg/28 days for 3 years
79482139|NCT00309478|Drug|Tamoxifen|Nolvadex 20mg/day for 5 years
79482140|NCT00295646|Drug|tamoxifen|20 mg/d
79978337|NCT04832971|Drug|ARO-ANG3|ARO-ANG3 Injection
79978338|NCT04832971|Drug|Placebo|Sterile Normal Saline (0.9% NaCl)
79978339|NCT04828733|Procedure|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
79978340|NCT04828733|Procedure|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
79978341|NCT04828733|Procedure|Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.|Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
79978342|NCT04824521|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a mindfulness-based intervention.
79978343|NCT04822337|Drug|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin|Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
79482141|NCT00295646|Drug|anastrozole|1 mg/d
79326343|NCT04997837|Radiation|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
79326344|NCT04997837|Drug|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
79326345|NCT04299295|Device|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
79482142|NCT00295646|Drug|zoledronic acid|4 mg q6m
79482143|NCT00295646|Other|goserelin|3.6 mg goserelin subcutaneously every 28 days
79482144|NCT00274924|Biological|filgrastim|Given subcutaneously or intravenous bolus.
79482145|NCT00274924|Biological|rituximab|Given IV
79482146|NCT00274924|Drug|carboplatin|Given IV
79482147|NCT00274924|Drug|cyclophosphamide|Given IV
79482148|NCT00274924|Drug|doxorubicin hydrochloride|Given IV
79482149|NCT00274924|Drug|etoposide|Given IV
79482150|NCT00274924|Drug|ifosfamide|Given IV
79482151|NCT00274924|Drug|prednisone|Taken orally
79482152|NCT00274924|Drug|vincristine|Given IV
79482153|NCT00104884|Drug|Depsipeptide|Given IV
79482154|NCT00096174|Biological|cetuximab C225|400 mg/m^2 IV over 120 minutes on Day 1, 250 mg/m^2 IV over 60 minutes on Day 8, then weekly
79482155|NCT00096174|Drug|cisplatin|75 mg/m^2 IV over 30-60 minutes starting day 15 every 3 weeks * 3 (Days 1, 22, and 43 of radiation therapy (RT))
79482156|NCT00096174|Radiation|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d * 7 weeks (35 fractions)
79482157|NCT00080938|Drug|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
79326346|NCT04299295|Device|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
79326347|NCT04997603|Other|Accelerometer|Fitbit brand
79326348|NCT02328157|Device|Vitrectomy with cataract surgery and toric IOL|
79326349|NCT02328157|Device|Vitrectomy with cataract surgery and common IOL|
79326350|NCT02328313|Behavioral|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
79326351|NCT04202263|Drug|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
79326352|NCT04202263|Drug|Placebos|Placement of minocycline cream 0%
79326353|NCT04996979|Drug|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
79326354|NCT04996979|Drug|Placebo|Standard care
79326355|NCT03145285|Drug|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
79326356|NCT04997291|Drug|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
79326357|NCT02328079|Drug|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
79482158|NCT00080938|Radiation|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
79482159|NCT00074282|Biological|rituximab|
79482160|NCT00074282|Drug|cyclophosphamide|
79482161|NCT00074282|Drug|pentostatin|
79482162|NCT00074282|Drug|Alemtuzumab|
79326358|NCT04190641|Device|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
79326359|NCT04992455|Other|Older Patients Receiving Chemotherapy|No Intervention
79326360|NCT03074903|Device|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
79482163|NCT00071981|Biological|incomplete Freund's adjuvant|Given by injection
79482164|NCT00071981|Biological|melanoma helper peptide vaccine|Given by injection
79978344|NCT04818684|Other|questionnaire|a questionnaire consisting of a list of support practices
79978345|NCT04818112|Behavioral|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
79482165|NCT00071981|Biological|multi-epitope melanoma peptide vaccine|Given by injection
79482166|NCT00071981|Biological|sargramostim|Given by injection
79482167|NCT00071981|Biological|tetanus peptide melanoma vaccine|Given by injection
79482168|NCT00070291|Drug|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
79482169|NCT00064350|Drug|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
79482170|NCT00064350|Drug|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
79482171|NCT00063986|Procedure|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
79482172|NCT00060346|Biological|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
79482173|NCT00060346|Drug|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
79482174|NCT00060346|Drug|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
79326361|NCT04992377|Drug|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
79326362|NCT02747329|Device|BuMA Supreme™ stent|
79326363|NCT02747329|Device|Xience V/Prime stent|
79326364|NCT04992533|Procedure|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
79326365|NCT04992533|Procedure|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
79326366|NCT04997213|Other|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
79326367|NCT04997213|Other|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
79326368|NCT02328001|Behavioral|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
79326369|NCT04996745|Behavioral|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
79978346|NCT04818112|Behavioral|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
79326370|NCT02578069|Device|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
79326371|NCT02578069|Device|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
79326372|NCT03141775|Other|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
79326373|NCT03142087|Other|exercises|exercise
79326374|NCT03074825|Drug|Chiauranib|Take 50mg orally once daily
79482175|NCT00060346|Drug|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
79482176|NCT00060346|Drug|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
79482177|NCT00057954|Procedure|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
79482178|NCT00057954|Drug|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
79326375|NCT02327767|Device|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
79326376|NCT03074747|Diagnostic Test|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
79326377|NCT03072485|Drug|Sirolimus|Topical sirolimus applied to the skin
79326378|NCT03072485|Drug|Metformin|Topical metformin applied to the skin
79326379|NCT03072485|Drug|Diclofenac|Topical diclofenac applied to the skin
79482179|NCT00057954|Radiation|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
79482180|NCT00057954|Procedure|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10^6 CD34/kg
79482181|NCT00057954|Drug|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
79482182|NCT00057954|Drug|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
79978347|NCT04817943|Other|Non applicable|When the patient enters the operating room, oxygen saturation, blood pressure, and electrocardiogram are monitored, and general anesthesia is induced using 1-2 mg/kg of 1% propofol. 0.8 mg/kg of rocuronium, a neuromuscular blocker, is injected intravenously, and a human endotracheal tube is intubated. A thermometer is attached to the inside of the double-layered endotracheal tube cuff, which measures the temperature in the trachea. After the endotracheal intubation is performed, the esophageal thermometer is inserted, and from this point, the temperature measured by the esophageal thermometer and the thermometer of the endotracheal tube are recorded. The temperature immediately after insertion of the esophageal thermometer is set as Tbaseline, and the temperature of the esophagus and trachea, the temperature of the operating room, and the temperature of breathing circuit with heated wire humidifier are recorded every 5 minutes from thereafter until the end of the operation.
79978348|NCT04817618|Drug|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
79978349|NCT04817618|Drug|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
79978350|NCT04812483|Drug|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
79978351|NCT04812483|Drug|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
79482183|NCT00057954|Drug|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with > 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
79482184|NCT00049530|Biological|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
79482185|NCT00045305|Drug|Cyclosporine|Immunosuppressant
79978352|NCT04809077|Other|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
79978353|NCT04806386|Dietary Supplement|Psyllium|Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.
79978354|NCT04804137|Other|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
79978355|NCT04804137|Other|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
79978356|NCT04804137|Other|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
79978357|NCT04804137|Other|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
79978358|NCT04800497|Procedure|Hepatic resection|Hepatic resection for HCC
79326380|NCT05080543|Drug|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
79326381|NCT03144973|Diagnostic Test|periosafe|mouth rinsing quick-test
79326382|NCT03074591|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
79326383|NCT03074591|Drug|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
79978359|NCT04800133|Biological|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
79978360|NCT04800133|Biological|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
79978361|NCT04800133|Biological|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
79978362|NCT04799249|Drug|Trilaciclib|Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
79978363|NCT04799249|Drug|Placebo|Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
79978364|NCT04799249|Drug|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
79482186|NCT00045305|Drug|Methotrexate|Antimetabolite
79482187|NCT00045305|Drug|Photopheresis|Psoralens
79326384|NCT03143413|Other|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
79326385|NCT03074669|Behavioral|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
79326386|NCT05080309|Dietary Supplement|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
79326387|NCT05080309|Other|free water only|Women will have free access to water only
79326388|NCT04991675|Behavioral|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
79482188|NCT00045305|Drug|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
79978365|NCT04799249|Drug|Carboplatin|Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
79978366|NCT04797429|Other|Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)|Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control
79978367|NCT04797429|Other|antidiabetic therapy according to the current guidelines|In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
79326389|NCT04991675|Behavioral|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
79482189|NCT00045305|Drug|Pentostatin|Purine analogue
79482190|NCT00045305|Procedure|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
79482191|NCT00045305|Procedure|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
79482192|NCT00045305|Radiation|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
79978368|NCT04795856|Drug|[11C] acetate|PET Tracer
79482193|NCT00033657|Drug|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
79482194|NCT00033657|Drug|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
79482195|NCT00033657|Drug|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
79482196|NCT00033657|Procedure|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
79482197|NCT00033657|Radiation|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
79482198|NCT00003389|Drug|Doxorubicin|given IV
79482199|NCT00003389|Drug|Bleomycin|given IV
79482200|NCT00003389|Drug|Vinblastine|given IV
79482201|NCT00003389|Drug|Dacarbazine|given IV
79482202|NCT00003389|Drug|Vincristine|given IV
79482203|NCT00003389|Drug|Mechlorethamine|given IV
79482204|NCT00003389|Drug|Etoposide|given IV
79482205|NCT00003389|Drug|Prednisone|taken orally
79482206|NCT00003389|Drug|Cyclophosphamide|given IV
79482207|NCT00003389|Radiation|Radiotherapy|
79482208|NCT00003138|Biological|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
79978369|NCT04795765|Procedure|SpineJack system|For use in the reduction of painful osteoporotic vertebral compression fractures.
79978370|NCT04795765|Procedure|Balloon kyphoplasty|Treatment of osteoporotic vertebral compression fractures.
79978371|NCT04795765|Procedure|Vertebroplasty|Treatment of osteoporotic vertebral compression fractures.
79978372|NCT04792489|Biological|MB-CART2019.1|Chimeric antigen receptor (CAR) T cell therapy
79978373|NCT04791761|Drug|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
79326390|NCT05080153|Dietary Supplement|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
79326391|NCT04991909|Drug|HRS4800|HRS4800
79326392|NCT04991909|Drug|Placebo|Placebo
79482209|NCT00003138|Biological|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
79482210|NCT00003138|Procedure|Transfusion|Red cell and platelet transfusions
79482211|NCT00002525|Drug|fluorouracil|"Perioperative 5-FU: 600 mg/m^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m^2 IV push on days 1-5"
79482212|NCT00002525|Drug|leucovorin calcium|given after surgery at dose of 20mg/m^2 IV push on days 1-5
79482213|NCT04031911|Device|Hydroposturotherapy|"Hydroposturotherapy combines:~posturotherapy (patient placed upside down with water jets sent to the kidneys)~lumbar percussion~hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
79482214|NCT04031911|Device|Standard support in urology|Dispensing of AFU plugs Dietary advice
79813827|NCT05640336|Procedure|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
79326393|NCT05079997|Device|MAGNETIC RESONANCE IMAGING|s a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from CT and PET scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.
79482215|NCT05475522|Device|Ultrasound guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection using ultrasound
79482216|NCT05475522|Device|5-aminolevulinic acid fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
79482217|NCT05470374|Procedure|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
79482218|NCT05646966|Other|one time testing|
79482219|NCT02259348|Drug|Cyclophosphamide|Given intravenously (IV)
79482220|NCT02259348|Drug|Fludarabine|Given IV
79482221|NCT02259348|Biological|G-CSF|Given IV or subcutaneously (SQ)
79482222|NCT02259348|Biological|Interleukin-2|Given SQ
79482223|NCT02259348|Drug|Melphalan|Given IV
79482224|NCT02259348|Drug|Thiotepa|Given IV
79482225|NCT02259348|Drug|Rituximab|Given IV
79482226|NCT02259348|Biological|Natural killer cell therapy|Given IV
79482227|NCT02259348|Biological|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
79482228|NCT02259348|Biological|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
79482229|NCT04864626|Other|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
79810866|NCT04161521|Procedure|Novel Technique of Placenta Accreta in Menoufia University Hospital|"Classical CS to decrease haemorrhage from placental bed.~Delievery of the fetus.~At the delivery 10 UI of oxytocin IV will be injected.~The placenta is not attempted to be delievered.~Opening of the broad ligament via round ligament division and ligation.~Gentle dissection of the urinary bladder from lateral to medial.~Bilateral uterine artery clamping at low level below the placental bed .~Gentle attempt to deliver The placenta.~If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~Intraperitoneal drain insertion."
79810867|NCT00681005|Drug|rabeprazole|20 mg bid for 14 days
79810868|NCT00681005|Drug|pantoprazole|pantoprazole 40 mg bid
79810869|NCT02626325|Other|High-carbohydrate or High-monounsaturated fat diets|
79810870|NCT04150055|Behavioral|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
79326394|NCT04082377|Procedure|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905*((height in cm)-152.4) for men, and = 45.5+0.905*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
79482230|NCT04864626|Other|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
79978374|NCT04791761|Drug|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
79482231|NCT00357019|Drug|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
79482232|NCT03162211|Other|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
79482233|NCT03994705|Biological|Descartes-11|CAR T-Cells
79482234|NCT03994705|Drug|Fludarabine|Pre-conditioning chemotherapy
79482235|NCT03994705|Drug|Cyclophosphamide|Pre-conditioning therapy
79326395|NCT04082377|Procedure|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
79326396|NCT04073875|Diagnostic Test|18F-GP1|18F-GP1 PET-CT scan
79978375|NCT04791761|Drug|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
79978376|NCT04791761|Other|Opioid disposal pouch|Half of the opioid group will be randomized assigned to an opioid disposal pouch arm. This pouch is a drug deactivation system that can be disposed in the trash in a household.
79978377|NCT04791761|Other|Opioid disposal education|An opioid disposal education document will be provided to all families in the opioid group. This education document has information on unused or expired prescription medication disposal and specific information about permanent collection sites within our health system, drug take-back locations, drug take back day, and disposing at home.
79326397|NCT03144739|Other|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
79978378|NCT04787991|Drug|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
79978379|NCT04787991|Drug|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
79978380|NCT04787991|Drug|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
79978381|NCT04787991|Drug|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
79978382|NCT04787991|Drug|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
79978383|NCT04787991|Drug|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
79978384|NCT04785547|Drug|Blinatumomab|15 mcg/m2/day for 28 days
79978385|NCT04785508|Device|neuromuscolar tape|neuromuscalar tape application in decompression technique (hand and arm)
79978386|NCT04785508|Behavioral|antigravity arm position|antigravity arm position
79326398|NCT03144739|Other|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
79326399|NCT03072407|Biological|PB-119 injection|
79326400|NCT03072407|Biological|PB-119 injection placebo|
79978387|NCT04783883|Device|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
79326401|NCT03144895|Procedure|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
79326402|NCT03144661|Drug|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
79326403|NCT04991441|Dietary Supplement|Controlled Dietary Sodium Restriction|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
79326404|NCT04991441|Dietary Supplement|Control Diet & Controlled Dietary Sodium Restriction|Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
79326405|NCT03111433|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
79326406|NCT03111433|Drug|Insulin|multiple dose insulin injection therapy
79978388|NCT04781322|Drug|Alirocumab|Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
79978389|NCT04781322|Other|Placebo|Heavy drinking healthy volunteers
79978390|NCT04780893|Device|Modius Sleep|The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
79978391|NCT04774523|Procedure|Echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.|"Patients in the AutoAdapt group undergo the echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.~Three steps must be followed:~Standard AV programming: perform echo for AoVTI assessment.~Echo-optimized AV programming: perform standard echo-based AV-optimization (Ritter method or iterative method, according to routine at investigational site); measure AoVTI at optimized setting.~AutoAdapt optimized programming: The system allows different programming options for the parameter 'Adaptive AV reduction'. The nominal value is 0.7, but it can be modified to different values ranging from 0.5 to 0.9. The AoVTI shall be measured at standard setting of the Adaptive Av reduction parameter, 0.7."
79326407|NCT04915313|Device|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 200mmHg and 5-min deflation.
79326408|NCT04915313|Device|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
79326409|NCT03143023|Drug|arginine toothpaste|acid neutralizer toothpaste
79978392|NCT04774523|Procedure|Echocardiography AV optimization|Patient in the control group undergo the routine echo-based AV-optimization that is usually performed at the investigational site (Ritter method or iterative method). Performance of an additional VV-delay optimization is left to the investigator discretion
79326410|NCT03143023|Drug|fluoride toothpaste|bactericidal toothpaste
79326411|NCT04914455|Diagnostic Test|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
79978393|NCT04774523|Procedure|Echocardiography|Echocardiography must be performed at baseline and 12 month Follow Up to collect the LVEF/LVESD(V)/LVEDD(V)
79978394|NCT04774523|Other|Self Assessment Score|Patient must complete the self assessment score at 6 and 12 month Follow Up, that will be use for the Packer Clinical Composite Score
79978395|NCT04773184|Procedure|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
79326412|NCT05079529|Drug|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
79326413|NCT05079529|Drug|Placebo Group|Takes placebo capsule 3 times daily for 90 days
79326414|NCT03074435|Device|Insecticidal paint|Houses will be painted with insecticidal paint
79326415|NCT03074435|Device|Larvicide|Larval breeding sites will be treated with larvicide
79648223|NCT05852808|Radiation|Low-dose radiation therapy|The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
79326416|NCT03074435|Biological|Ivermectin|Doses of Ivermectin will be injected to peri-domestic animals
79326417|NCT03074435|Behavioral|IEC|A reinforced information, education and communication strategy will be implemented.
79978396|NCT04773184|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing. This is like a moving x-ray of the swallow.
79326418|NCT03142945|Other|Traditional Physical Therapy|Physical therapy-based interventions
79326419|NCT03142945|Other|MDT based physical therapy|MDT based physical therapy
79978397|NCT04773184|Procedure|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
79978398|NCT04773184|Procedure|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
79978399|NCT04773184|Procedure|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
79978400|NCT04773184|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
79326420|NCT04996277|Procedure|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
79810871|NCT00681161|Other|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
79326421|NCT04996277|Procedure|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
79326422|NCT04996277|Procedure|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
79326423|NCT04996277|Behavioral|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
79978401|NCT04773184|Other|Voicing Tasks|Voicing tasks will be completed to assess vocal ability.
79978402|NCT04771338|Behavioral|VR-JIT/KF-STRIDE|Treatment group will receive 12 sessions of job interview training protocol.
79978403|NCT04764942|Drug|Carfilzomib|Given IV
79978404|NCT04764942|Drug|Dexamethasone|Given PO
79978405|NCT04764942|Drug|Pomalidomide|Given PO
79978406|NCT04764942|Other|Quality-of-Life Assessment|Ancillary studies
79978407|NCT04764942|Other|Questionnaire Administration|Ancillary studies
79978408|NCT04764942|Drug|Selinexor|Given PO
79978409|NCT04764942|Procedure|X-Ray Imaging|Undergo x-ray imaging
79978410|NCT04764942|Procedure|Computed Tomography|Undergo PET/CT
79978411|NCT04764942|Procedure|Positron Emission Tomography|Undergo PET/CT
79326424|NCT03111199|Other|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
79978412|NCT04764942|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
79810872|NCT00912353|Drug|AZD7268|Single Oral
79810873|NCT00912353|Drug|Placebo|Single Oral
79978413|NCT04764942|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
79978414|NCT04764942|Procedure|Biospecimen Collection|Undergo blood sample collection
79978415|NCT04755283|Biological|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
79978416|NCT04755283|Drug|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
79978417|NCT04754984|Behavioral|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
79810874|NCT04149665|Device|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
79810875|NCT02633969|Drug|Indomethacin Capsules low dose|
79810876|NCT02633969|Drug|Indomethacin Capsules high dose|
79813828|NCT05753696|Drug|Azilsartan|Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
79978418|NCT04754165|Other|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
79978419|NCT04754061|Drug|Psilocybin|"Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday)."
79978420|NCT04751383|Procedure|Biospecimen Collection|Undergo collection of blood samples
79978421|NCT04751383|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79978422|NCT04751383|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79978423|NCT04751383|Procedure|Computed Tomography|Undergo CT
79978424|NCT04751383|Biological|Dinutuximab|Given IV
79978425|NCT04751383|Procedure|Magnetic Resonance Imaging|Undergo MRI
79978426|NCT04751383|Biological|Magrolimab|Given IV
79978427|NCT04751383|Procedure|Resection|Undergo surgical resection
79978428|NCT04748549|Other|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
79978429|NCT04748549|Other|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
79810877|NCT00684827|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~Arm #A~Xopenex HFA MDI, Pirbuterol HFA MDI"
79810878|NCT00684827|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~Arm #B~Pirbuterol HFA MDI, Xopenex HFA MDI"
79978430|NCT04748549|Other|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
79978431|NCT04739436|Device|Hearing amplification|Bilateral vs. unilateral hearing aids for hearing loss
79978432|NCT04729322|Procedure|Biopsy|Undergo biopsy
79978433|NCT04729322|Procedure|Fecal Microbiota Transplantation|Undergo colonoscopic FMT
79978434|NCT04729322|Drug|Fecal Microbiota Transplantation Capsule|Given PO
79978435|NCT04729322|Drug|Metronidazole|Given PO
79978436|NCT04729322|Drug|Neomycin|Given PO
79978437|NCT04729322|Biological|Nivolumab|Given IV
79978438|NCT04729322|Biological|Pembrolizumab|Given IV
79978439|NCT04729322|Other|Questionnaire Administration|Ancillary studies
79978440|NCT04729322|Drug|Vancomycin|Given PO
79978441|NCT04727866|Device|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
79978442|NCT04727866|Device|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over ~T1-T4 posteriorly, anode over ~C5-T1 anteriorly
79978443|NCT04727866|Device|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over ~C3-C5 posteriorly, anode over ~C5-T1 anteriorly
79326425|NCT03111199|Other|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
79978444|NCT04727866|Device|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
79326426|NCT03111199|Other|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
79326427|NCT03111199|Other|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
79810879|NCT04149119|Device|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
79978445|NCT04724616|Other|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
79978446|NCT04722887|Biological|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
79978447|NCT04722887|Biological|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
79978448|NCT04713475|Biological|PBGM01|AAVhu68 viral vector
79978449|NCT04706091|Drug|Suvorexant|10-mg or 20-mg suvorexant capsules
79326428|NCT03833089|Combination Product|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
79813829|NCT05753696|Drug|Losartan|losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
79813830|NCT04109898|Device|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
79813831|NCT04788992|Other|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
79978450|NCT04706091|Other|Placebo|Matching placebo capsules
79978451|NCT04704219|Biological|Pembrolizumab|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
79978452|NCT04704219|Drug|Lenvatinib|Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
79978453|NCT04703920|Drug|Talazoparib|Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
79978454|NCT04703920|Drug|Belinostat|Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
79978455|NCT04702607|Procedure|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
79978456|NCT04699942|Device|Conventional (low flow) oxygen delivery via nasal cannula|Conventional (low flow) oxygen delivery via nasal cannula or face mask for 20 minutes
79978457|NCT04699942|Device|Revoxa Oxygen Rebrearther|Oxygen delivery via Revoxa Oxygen Rebreather device for 20 minutes
79978458|NCT04690192|Biological|CNCT19|2×10^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
79978459|NCT04690192|Drug|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
79978460|NCT04690192|Drug|busulfan|105mg/m2, day -7 until -5,
79978461|NCT04690192|Drug|Melphalan Injection|60mg/m2, day -3, -2
79978462|NCT04689594|Combination Product|CLS2702C/CLS2702D|"CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month [4 weeks]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months [24 weeks]); follow-up period, 6 months [24 weeks]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device"
79978463|NCT04687774|Device|ExaltTM Model D Single-Use Duodenoscope|The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
79978464|NCT04685473|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
79978465|NCT04685356|Other|IBAIP : Infant Behaviour Assessment and Intervention Program|The IBAIP intervention program consists of providing an intervention with the child and their family, at home, upon discharge from hospital and up to a corrected age of 6 months. Interventions therefore take place at the early stage of the child's brain development. The intervention is performed by a IBAIP-trained and certified physiotherapist or psychomotor therapist trained , at the rate of one session per month over a period of approximately 6 to 8 months (6 months of corrected age). The session takes place in the child's usual living environment, at home, in the presence of at least one of the parents. It focuses on the child's behaviors and consists of assisting the family in its interactions with the child so that these are adapted and responsive to the child's development needs over time through repeated interventions.
79978466|NCT04685356|Other|Standard Support|One medical consultation per month and, if indicated by the physician providing follow-up, medical specialist and / or paramedical (physiotherapy, speech therapy, psychomotricity, etc.) consultations including interventions in the case of developmental delays
79978467|NCT04685356|Other|Ages and Stages Questionnaire (ASQ)|Global development screening tool
79978468|NCT04685356|Other|Parenting Stress Index (PSI)|Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
79326429|NCT03071939|Other|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
79326430|NCT03142789|Drug|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
79326431|NCT03142789|Drug|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
79326432|NCT03142789|Drug|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
79326433|NCT03142789|Drug|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
79326434|NCT04996355|Other|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~5-FU~Oxaliplatin~Irinotecan~5-FU+ Oxaliplatin~5-FU+ Irinotecan~5-FU+ Oxaliplatin+ Irinotecan~5-FU+Cetuximab~Cetuximab~Regorafenib"
79326435|NCT03072329|Procedure|Pudendal nerve block|
79326436|NCT03072329|Drug|Bupivacaine|
79813832|NCT04788992|Other|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
79978469|NCT04685356|Other|Bayley Scales of Infant and Toddler Development (BSID-III)|This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
79326437|NCT02327689|Drug|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
79326438|NCT03141697|Device|Carbon Dioxide|Insufflation of Carbon Dioxide
79978470|NCT04676477|Drug|HER3-DXd|Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
79978471|NCT04676477|Drug|HER3-DXd|Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
79978472|NCT04676477|Drug|Osimertinib|Oral administration at 40 mg or 80 mg once daily
79978473|NCT04676477|Drug|Osimertinib|Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
79326439|NCT03141697|Device|Room air|Insufflation of room air
79326440|NCT03072017|Behavioral|MBAT|Breathing-based intervention
79326441|NCT02327923|Drug|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
79326442|NCT02327923|Drug|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
79978474|NCT04676477|Drug|HER3-DXd|Intravenous infusion 5.6 mg/kg Q3W
79326443|NCT02327923|Drug|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
79482236|NCT03984487|Behavioral|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
79482237|NCT03984487|Behavioral|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
79482238|NCT03960541|Drug|Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
79482239|NCT03960541|Drug|Saline Solution|Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
79482240|NCT03587207|Biological|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
79648224|NCT05845476|Other|Patient SOGI Self-Report|"EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record."
79978475|NCT04676477|Drug|HER3-DXd|Intravenous infusion 4.8 mg/kg Q3W
79978476|NCT04676477|Drug|Osimertinib|Oral administration at 80 mg once daily
79978477|NCT04676178|Drug|PRA023|PRA023
79978478|NCT04676178|Other|Placebo|Placebo
79978479|NCT04672434|Drug|Sym021|Sym021 is a humanized anti-PD-1 antibody.
79978480|NCT04672434|Drug|Sym024|Sym024 is an anti-CD73 antibody.
79978481|NCT04669691|Biological|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
79978482|NCT04664361|Dietary Supplement|Nicotinamide mononucleotide|Daily supplementation with NMN at 250 and 500 mg for 38 days in total
79978483|NCT04664361|Other|Placebo|Daily supplementation with placebo for 38 days in total
79978484|NCT04656652|Drug|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
79978485|NCT04656652|Drug|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
79326444|NCT02327923|Drug|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
79326445|NCT02327923|Drug|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
79326446|NCT02327923|Drug|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
79326447|NCT02327923|Drug|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
79326448|NCT02327923|Drug|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR < 50/min)
79326449|NCT02327923|Drug|Ephedrine|
79326450|NCT02327923|Drug|Morphine|
79326451|NCT02327923|Drug|Ketorolac|
79326452|NCT02327923|Drug|Ondansetron|
79326453|NCT02327923|Drug|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
79326454|NCT02327923|Drug|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
79326455|NCT02327923|Drug|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
79326456|NCT02327923|Drug|Glycopyrrolate|10 mcg/kg with neostigmine
79326457|NCT04991207|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
79326458|NCT04991207|Drug|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
79326459|NCT03072173|Drug|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
79326460|NCT03072173|Drug|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
79978486|NCT04655248|Device|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
79978487|NCT04650568|Device|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
79482241|NCT03587207|Biological|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group
79326461|NCT03141463|Biological|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
79326462|NCT03072095|Behavioral|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
79482242|NCT03587207|Biological|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
79482243|NCT03901261|Procedure|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
79482244|NCT03866785|Diagnostic Test|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
79648225|NCT05845476|Other|SOGI Resource for Clinical Care Education (SORCE)|SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.
79978488|NCT04650568|Other|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
79978489|NCT04649151|Biological|mRNA-1273|Sterile liquid for injection
79978490|NCT04649151|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79482245|NCT03866785|Diagnostic Test|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
79978491|NCT04649151|Biological|mRNA-1273.222|Sterile solution for injection
79482246|NCT03866785|Device|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
79326463|NCT03072095|Behavioral|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
79482247|NCT03866785|Other|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~Skills in physical activity advice~Knowledge of functional signs (symptoms)~Knowledge to examine heart rate and perceived effort rate"
79978492|NCT04638894|Procedure|Surgical treatment of patients with adult spinal deformity|Including all surgical interventions for patients with adult spinal deformity.
79978493|NCT04631744|Drug|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
79978494|NCT04611529|Drug|Ibuprofen 400 mg|Ibuprofen 400mg
79978495|NCT04611529|Drug|Topical diclofenac|Diclofenac 1% gel 4gm
79326464|NCT02327611|Drug|Custodiol|
79326465|NCT02327611|Drug|Enriched Ringer's lactate solution|
79482248|NCT03866785|Other|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
79978496|NCT04610580|Drug|ALXN1840|ALXN1840 will be administered orally.
79978497|NCT04609592|Drug|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
79326466|NCT03826849|Behavioral|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
79326467|NCT03072641|Dietary Supplement|ProBion Clinica|
79326468|NCT03074279|Other|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
79326469|NCT04991363|Procedure|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
79326470|NCT03764371|Diagnostic Test|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
79978498|NCT04609592|Drug|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
79978499|NCT04609592|Procedure|Computed Tomography (CT)|Medical Imaging
79978500|NCT04609592|Procedure|Magnetic Resonance Imaging (MRI)|Medical Imaging
79978501|NCT04609592|Procedure|PET/CT|Medical Imaging
79648226|NCT05845476|Other|Cancer Center Care Environment|At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
79648227|NCT05841550|Biological|TG01|All participants will receive the same treatment as described under arm
79648228|NCT05837039|Behavioral|Healthcare Provider|Questionnaires
79648229|NCT05837039|Behavioral|Caregiver Perception|Questionnaires
79648230|NCT05829239|Biological|ADI-PEG20|Intramuscular injection weekly for 8 weeks
79648231|NCT05829239|Other|Placebo|Intramuscular injection weekly for 8 weeks
79648232|NCT05823948|Drug|Insulin Icodec|Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.
79978502|NCT04608604|Other|Physiotherapy|Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
79978503|NCT04605783|Dietary Supplement|Travelan®|Travelan® (600mg) taken as 1 sachet twice daily with meals. Product will be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
79978504|NCT04605783|Other|Placebo|Maltodextrin - To be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
79978505|NCT04604210|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
79810880|NCT00820170|Drug|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
79326471|NCT03074123|Diagnostic Test|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
79810881|NCT00681239|Dietary Supplement|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
79326472|NCT05078749|Other|Exercise training group|A regular advanced exercise program will be given and followed.
79326473|NCT05078749|Other|Control training group|Basic exercises will be given at the beginning and will do the same exercises
79326474|NCT04433663|Other|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
79326475|NCT02327299|Dietary Supplement|Bouillon fortified with FePP|
79326476|NCT02327299|Dietary Supplement|Bouillon fortified with FePP + Stabilizer|
79326477|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4|
79326478|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4 + Stabilizer|
79648233|NCT05822570|Diagnostic Test|Assessment of Oxygen Dissociation Curve (ODC)|ODC will be assessed at 5 timepoints: T0 after installation of arterial catheter, T1 before clamping of the liver, T2 5-10 min before reperfusion of the liver graft, T3 45 min after reperfusion, T4 1 h after T3 or at end of surgery
79810882|NCT02627027|Drug|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
79810883|NCT02627027|Drug|CKD-395 0.25/750mg|oral administration
79326479|NCT03071627|Other|New items with spin|Interpretation of news items with spin
79326480|NCT03071627|Other|New items without spin|Interpretation of news items without spin
79326481|NCT03071783|Device|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
79326482|NCT02327377|Behavioral|Online Cognitive Behavior Therapy|
79326483|NCT02327377|Behavioral|Online Education|
79326484|NCT03071549|Drug|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
79326485|NCT03071549|Drug|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
79810884|NCT00681317|Drug|AZD6280|oral
79810885|NCT00709332|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
79810886|NCT00913536|Other|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
79810887|NCT00684905|Drug|bicalutamide|
79810888|NCT00684905|Drug|leuprolide acetate|
79810889|NCT00684905|Procedure|adjuvant therapy|
79810890|NCT00684905|Procedure|neoadjuvant therapy|
79810891|NCT00684905|Procedure|quality-of-life assessment|
79810892|NCT00684905|Radiation|brachytherapy|
79810893|NCT00685061|Drug|Thymoglobulin|Induction
79326486|NCT03144817|Other|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
79326487|NCT03074201|Procedure|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
79326488|NCT03074201|Device|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
79326489|NCT03734965|Device|AWAKEN INTUBATION|Intubation
79810894|NCT00685061|Drug|Campath-1H|Induction
79326490|NCT04994951|Drug|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
79326491|NCT04994951|Drug|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
79326492|NCT03717181|Drug|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
79810895|NCT00685061|Drug|Daclizumab|Induction
79810896|NCT02633813|Drug|Naftifine hydrochloride 2%|Topical application for two weeks
79810897|NCT02633813|Drug|Placebo|Topical application for two weeks
79810898|NCT02633813|Drug|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
79810899|NCT00818454|Drug|Combivent CFC MDI|
79326493|NCT03073889|Procedure|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
79326494|NCT03073889|Procedure|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
79326495|NCT03073889|Drug|Ropivacaine|
79326496|NCT03071471|Device|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~Only two screws are used~Incision size is much smaller~Simpler operation with shorter operative time~Less complication thanks to the three points above.~Minimal spinal mobility loss"
79326497|NCT03645967|Device|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
79648234|NCT05809856|Device|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
79648235|NCT05800990|Behavioral|dietary intervention|Research participants will be assigned to two dietary conditions.
79326498|NCT03570931|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
79326499|NCT05078515|Diagnostic Test|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
79326500|NCT04477369|Drug|DWJ1439|300mg single dose
79326501|NCT04477369|Drug|DWJ1464|300mg single dose
79326502|NCT04477369|Drug|DWC202003|300mg single dose
79326503|NCT04477369|Drug|DWC202004|300mg single dose
79326504|NCT02636699|Biological|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
79326505|NCT02636699|Biological|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
79648236|NCT05793619|Device|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79810900|NCT00818454|Drug|Albuterol HFA MDI|
79810901|NCT00818454|Drug|Respimat Combivent|
79810902|NCT02626247|Dietary Supplement|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
79326506|NCT05080855|Procedure|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
79326507|NCT03140839|Behavioral|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
79326508|NCT03140839|Behavioral|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
79326509|NCT03140839|Other|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
79326510|NCT03071705|Drug|Metformin|500 mg PO BID
79326511|NCT03071705|Drug|TKI|standard dose
79326512|NCT04995185|Radiation|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
79326513|NCT03351439|Drug|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
79482249|NCT04345159|Other|Questionnaire by phone call|"2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake."
79482250|NCT05723263|Behavioral|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).
79482251|NCT05723263|Behavioral|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)
79978506|NCT04603183|Drug|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
79482252|NCT05723263|Other|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 USD per test) and no community engagement component
79482253|NCT00357487|Device|peroperative scintillating probe|
79482254|NCT00357487|Device|operative gamma camera|
79482255|NCT03416621|Behavioral|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
79482256|NCT03416621|Behavioral|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
79978507|NCT04603183|Drug|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
79978508|NCT04603183|Drug|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
79326514|NCT03351439|Drug|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
79810903|NCT02626247|Other|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
79978509|NCT04603183|Drug|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
79978510|NCT04601350|Drug|remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia|remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
79978511|NCT04601350|Drug|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
79326515|NCT03351439|Drug|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
79978512|NCT04597125|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
79978513|NCT04597125|Drug|NAH therapy|Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone [AAP] or enzalutamide) by mouth (per os) daily
79978514|NCT04595968|Device|Vestal DM Active device|Battery powered non-invasive neurostimulation device
79326516|NCT03351439|Drug|Percocet|Standard of Care
79326517|NCT03351439|Drug|Naprosyn|Standard of Care
79326518|NCT04990661|Behavioral|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
79810904|NCT02627105|Behavioral|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
79810905|NCT02627105|Behavioral|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
79810906|NCT02626403|Device|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
79482257|NCT03416621|Drug|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
79326519|NCT03141385|Other|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
79482258|NCT03417557|Device|Comfilcon A lens (test)|contact lens
79482259|NCT03417557|Device|Omafilcon B lens (control)|contact lens
79482260|NCT03459131|Device|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
79482261|NCT03459131|Device|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
79482262|NCT03417713|Device|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
79482263|NCT03592121|Drug|AB-101|Apply approximately 1 hour prior to sexual activity
79648237|NCT05793619|Device|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79648238|NCT05792722|Procedure|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
79326520|NCT03141385|Other|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
79326521|NCT03139747|Drug|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
79326522|NCT03139747|Drug|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
79482264|NCT03592121|Drug|Placebo|Apply approximately 1 hour prior to sexual activity
79326523|NCT04433429|Dietary Supplement|Liposcudil Plus|
79326524|NCT04990583|Behavioral|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
79326525|NCT04990583|Behavioral|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
79326526|NCT04990271|Drug|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0~5 months
79326527|NCT04911049|Diagnostic Test|Blood Pressure measurement|Blood Pressure measurement
79326528|NCT04990193|Other|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
79326529|NCT04990193|Other|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
79326530|NCT03141541|Behavioral|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
79482265|NCT04332809|Procedure|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
79482266|NCT04332809|Procedure|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
79482267|NCT03596723|Drug|KPI-121 1%|eye drops
79482268|NCT03596723|Drug|Prednisolone acetate|eye drops
79482269|NCT04355117|Drug|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
79482270|NCT04357379|Behavioral|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
79326531|NCT03071315|Other|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
79482271|NCT03463889|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
79810907|NCT02626403|Device|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
79482272|NCT03463889|Procedure|Magnetic Resonance Imaging|Undergo MRI in combination with PET
79326532|NCT03071315|Other|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
79482273|NCT03463889|Procedure|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
79482274|NCT04484207|Other|A short video intervention|Three minutes video of a veteran that shares his personal story
79482275|NCT04484207|Other|A vignette intervention|A written description of the content of the video
79482276|NCT04485455|Device|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
79482277|NCT04485455|Device|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
79482278|NCT04525079|Drug|CT-P59|CT-P59 will be administered
79482279|NCT04525079|Drug|Placebo|Placebo-matching CT-P59
79326533|NCT02888821|Behavioral|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
79326534|NCT03073655|Other|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
79326535|NCT03073655|Other|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
79326536|NCT03073655|Other|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
79326537|NCT04770805|Procedure|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
79482280|NCT03599687|Other|Training in SALAD technique|The training session will be delivered, and will take around 45 minutes to complete, including time for participant practice. The training intervention will adopt the Advanced Life Support Group/Resuscitation Council 4-stage approach of skills teaching, and is comprised of: A real-time demonstration of the SALAD technique by the researcher; A repeated demonstration with an explanation of the rationale of the steps taken when performing SALAD (not real-time); Another demonstration of the SALAD technique conducted by the researcher, but guided by one of the participants; An attempt by the same participant who guided the researcher in the previous step, followed by a practice attempt by the other participants.
79978515|NCT04595968|Behavioral|Lifestyle modification|Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
79978516|NCT04595968|Device|Vestal DM Sham device|Placebo comparator sham device (no active stimulation)
79326538|NCT03139591|Drug|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
79326539|NCT03071237|Procedure|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
79326540|NCT02553967|Device|Functional MRI|Functional MRI
79326541|NCT04990115|Other|root canal shaping|root canal treatment
79326542|NCT04756375|Device|Virtual Reality|Use of virtual reality in the management of sickle cell patients with VOS
79326543|NCT04756375|Other|Usual Care|Usual management of sickle cell patients with VOS
79326544|NCT04987619|Dietary Supplement|Beetroot juice|Subjects will drink juice 120 minutes before each visit
79326545|NCT04987619|Other|Capri-Sun|70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
79326546|NCT03139357|Other|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
79326547|NCT03140917|Diagnostic Test|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
79326548|NCT04469101|Procedure|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
79326549|NCT04987853|Diagnostic Test|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~EchoCG + strain~CT scan of the lungs~Holter~SMAD~Kidney ultrasound~Ultrasound~Doppler ultrasonography of veins and arteries~Chalder Scale, EQ Questionnaire"
79482281|NCT04734509|Device|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
79482282|NCT03467477|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
79482283|NCT03467477|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
79482284|NCT04555031|Device|kalifilcon A lenses|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
79482285|NCT04555031|Device|Dalies Total 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
79326550|NCT04987853|Diagnostic Test|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4. Laboratory research methods:~The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
79326551|NCT04987853|Diagnostic Test|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
79326552|NCT04987853|Diagnostic Test|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
79326553|NCT05154565|Behavioral|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
79648239|NCT05792722|Procedure|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
79648240|NCT05787314|Behavioral|Low Glycemic Index Diet|"Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI > 55) were excluded from the diet and only low GI (GI < 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
79648241|NCT05729204|Other|Hypertonic seawater solution|Nasal irrigations with hypertonic seawater solution
79978517|NCT04595435|Procedure|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
79978518|NCT04595435|Radiation|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
79978519|NCT04594369|Drug|Brensocatib 10 mg|Oral tablet.
79326554|NCT02634983|Drug|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
79326555|NCT02634983|Drug|Placebo|Matching placebo
79326556|NCT05115799|Other|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
79326557|NCT05115799|Other|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
79326558|NCT02405845|Radiation|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
79326559|NCT04037215|Other|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~children controls not achieved with normal BMI;~children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
79326560|NCT04987151|Other|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups
79648242|NCT05725928|Behavioral|Mobility technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
79978520|NCT04594369|Drug|Brensocatib 25 mg|Oral tablet.
79978521|NCT04594369|Drug|Placebo|Brensocatib-matching oral tablet.
79978522|NCT04592250|Other|Survey Administration|Complete survey
79978523|NCT04584853|Drug|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
79326561|NCT04987151|Other|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
79326562|NCT04987151|Other|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
79326563|NCT03141229|Behavioral|Mindfulness based stress reduction|
79978524|NCT04584853|Drug|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
79326564|NCT04412291|Drug|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
79326565|NCT04412291|Drug|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
79326566|NCT04412291|Drug|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
79326567|NCT03141073|Drug|HMS5552|BID oral administration
79326568|NCT03141073|Drug|Placebo|BID oral administration
79326569|NCT04456361|Biological|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
79326570|NCT03139513|Drug|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
79326571|NCT03139513|Drug|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
79326572|NCT03071081|Drug|TOP1288|Oral TOP1288
79326573|NCT03071081|Drug|Placebo to TOP1288|Oral placebo to TOP1288
79482286|NCT04555031|Device|Precision 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
79648243|NCT05720884|Device|acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm * 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.
79978525|NCT04582227|Device|Ambu aura-i LMA|The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
79978526|NCT04577651|Device|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with 16-contact Directional Lead
79978527|NCT04574856|Radiation|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
79978528|NCT04574856|Drug|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
79978529|NCT04574856|Drug|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
79978530|NCT04574219|Other|Use of Facetime with child and parents during induction|Families will be able to use Facetime with their child when the child is taken to the operating room
79978531|NCT04573881|Device|HistoSonics System|The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
79978532|NCT04573478|Drug|Atrasentan|Film-coated tablet
79482287|NCT04555031|Device|Biotrue ONEday|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
79482288|NCT04574297|Behavioral|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
79648244|NCT05720884|Device|placebo acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm * 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
79648245|NCT05720130|Drug|[212Pb]Pb-ADVC001|[212Pb]Pb-ADVC001 administered intravenously under the dose escalation schedule
79648246|NCT05717439|Diagnostic Test|CAPS-5-R|A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
79978533|NCT04573478|Drug|Placebo|Film-coated tablet
79978534|NCT04570423|Drug|Eflapegrastim|Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
79978535|NCT04570423|Drug|Chemotherapy|Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
79978536|NCT04569461|Drug|pembrolizumab|200 mg of Pembrolizumab (KEYTRUDA) will be given by IV every 3 weeks for 5 cycles, a total of 15 weeks of treatment.
79978537|NCT04569461|Radiation|Stereotactic body radiation therapy|SBRT will begin on week 7 of the study. The radiation will be given every other day in 5 fractions of 6 Gy for a total of 30 Gy of radiation exposure.
79326574|NCT04986995|Drug|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
79326575|NCT04987073|Procedure|skin biopsy|A skin biopsy to cultivate fibroblasts.
79326576|NCT03139435|Procedure|Biopsy|Undergo skin biopsy
79326577|NCT03139435|Other|Questionnaire Administration|Ancillary studies
79326578|NCT03139435|Diagnostic Test|Ultrasound Tomography|Undergo peripheral nerve ultrasound
79326579|NCT03070067|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
79648247|NCT05717439|Diagnostic Test|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
79648248|NCT05712941|Drug|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique [FIGO] Stage III versus FIGO Stage IV versus recurrent)~EC tumor grade (Grade 1 versus Grade 2)~Geographic location (US versus Europe versus Rest of World)"
79978538|NCT04569461|Drug|Short-term androgen deprivation therapy|Short-term ADT will last for five months. It will consist of treatment with a 1 month dose beginning on Day 0 of the study. Then it will continue with either a single 4 month dose on week 5, or 4 additional 1 month doses, depending on patient and physician preference.
79978539|NCT04569461|Procedure|Radical Prostatectomy|Radical prostatectomy surgery will be performed between week 17 and week 20 of the study, as scheduling permits.
79978540|NCT04566263|Device|Neuroform EZ Stent System|The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
79978541|NCT04565236|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
79978542|NCT04565236|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
79978543|NCT04565236|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
79978544|NCT04564833|Drug|Low Dose RBT-1|intravenous administration
79978545|NCT04564833|Drug|High Dose RBT-1|intravenous administration
79978546|NCT04564833|Drug|Placebo|intravenous administration
79326580|NCT03971929|Drug|SHR0532|once daily(QD) for 4weeks
79326581|NCT03971929|Drug|SHR placebo|once daily(QD) for 4weeks
79326582|NCT03971929|Drug|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
79326583|NCT03071159|Device|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
79326584|NCT03626389|Other|Physiotherapy|
79326585|NCT03071003|Drug|SENS-401|Oral Administration
79326586|NCT03071003|Drug|Placebo|Oral Administration
79326587|NCT03139201|Device|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
79326588|NCT03139201|Device|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
79326589|NCT04986761|Procedure|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
79326590|NCT03139123|Other|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
79810908|NCT02611440|Behavioral|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
79810909|NCT00828984|Drug|macrogol 3350-based oral osmotic laxative|Given PO
79482289|NCT04574297|Diagnostic Test|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
79482290|NCT03468179|Dietary Supplement|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
79482291|NCT03472469|Drug|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
79482292|NCT03472469|Drug|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
79482293|NCT03472469|Drug|Ketorolac|Ketorolac 30mg IV once
79482294|NCT03472469|Drug|Celebrex|Celebrex 200mg PO every 12 hours
79482295|NCT03472469|Drug|Naproxen|Naproxen 500mg PO every 12 hours
79482296|NCT03472469|Drug|Tramadol|Tramadol 100mg PO every 6 hours
79482297|NCT03472469|Drug|Pregabalin|Pregabalin 100mg PO every 8 hours
79978547|NCT04561232|Behavioral|Prone and Upright Locomotor Training|"During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve."
79978548|NCT04559464|Device|AeriSeal|The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
79978549|NCT04559464|Device|Zephyr Valves|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
79482298|NCT03472469|Drug|Gabapentin|Gabapentin 300mg PO every 8 hours
79326591|NCT03070925|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
79326592|NCT05067829|Device|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
79326593|NCT04986371|Drug|Niraparib|Usage following drug insert is recommended
79326594|NCT05066971|Combination Product|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
79326595|NCT05021965|Procedure|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
79326596|NCT03069833|Diagnostic Test|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
79326597|NCT04986007|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
79326598|NCT03070847|Drug|Tranexamic Acid|Dose: 5mg/kg
79326599|NCT03070847|Drug|Tranexamic Acid|Dose: 10mg/kg
79978550|NCT04557540|Behavioral|Lifestyle Therapy|Receive The WORD lifestyle CER weight loss intervention
79978551|NCT04557540|Other|Quality-of-Life Assessment|Ancillary studies
79978552|NCT04557540|Other|Questionnaire Administration|Ancillary studies
79978553|NCT04557540|Other|Short-Term Fasting|Receive Fasting WORD intermittent fasting weight loss intervention
79326600|NCT03070847|Drug|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
79326601|NCT03140995|Behavioral|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
79326602|NCT03069911|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
79326603|NCT03069911|Biological|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
79810910|NCT00828984|Other|Placebo|Given PO
79810911|NCT00828984|Other|Laboratory Biomarker Analysis|Correlative studies
79810912|NCT05758584|Other|Intervention|Vibrating tourniquet
79810913|NCT05758584|Other|Distraction card|Distraction card
79326604|NCT03069755|Other|No intervention|No intervention
79482299|NCT03472469|Drug|Lidocaine|Lidocaine patch every 12 hours
79482300|NCT03472469|Drug|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
79482301|NCT03472469|Drug|Regional anesthesia|Regional anesthesia
79810914|NCT00828750|Drug|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
79978554|NCT04556305|Behavioral|Mind|See arm description.
79978555|NCT04556305|Behavioral|Move|See arm description.
79482302|NCT04926233|Drug|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
79978556|NCT04554459|Drug|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
79978557|NCT04553692|Drug|Aplitibart (IGM-8444)|DR5 Agonist Investigational Drug
79482303|NCT04926233|Device|Sp(t)iolto® Respimat®|Sp(t)iolto® Respimat®
79482304|NCT04943159|Drug|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
79482305|NCT04734665|Drug|Niraparib-Bevacizumab|"Niraparib 200mg or 300mg (once daily[QD]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
79482306|NCT02259114|Drug|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
79978558|NCT04553692|Drug|FOLFIRI|Chemotherapy Regimen
79978559|NCT04553692|Drug|Bevacizumab (and approved biosimilars)|Targeted Therapy
79978560|NCT04553692|Drug|Birinapant|SMAC-mimetic Investigational Drug
79978561|NCT04553692|Drug|Venetoclax|Targeted Therapy
79978562|NCT04553692|Drug|Gemcitabine|Chemotherapy
79978563|NCT04553692|Drug|Docetaxel|Chemotherapy
79978564|NCT04553692|Drug|Azacitidine|Chemotherapy
79978565|NCT04552613|Drug|EGFR-TKI|(A) Standard programme group, EGFR-TKI targeted therapy;
79482307|NCT03611777|Drug|Inhaled corticosteroid|Drug
79482308|NCT04864470|Behavioral|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
79978566|NCT04552613|Drug|EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)|(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
79978567|NCT04531839|Behavioral|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
79978568|NCT04528199|Drug|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of [18F]FLOR (FC303) injection followed by the PET/CT scan.
79978569|NCT04527380|Drug|Ixekizumab|Administered SC
79978570|NCT04527380|Drug|Adalimumab|Administered SC
79978571|NCT04524195|Drug|[18F]F-AraG Injection|Single dose of 5 mCi+/- [18F]F-AraG IV injection followed by the PET/CT scan. A baseline [18F]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second [18F]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
79978572|NCT04520048|Other|Determination of the UEMP levels|Quantification of UEMP by flow cytometry in urine (10 ml) collected at 26 ± 2 week and 34th ± 2 week of amenorrhea.
79978573|NCT04520048|Procedure|Aortic central pressure and the carotid-femoral pulse wave velocity|Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical)
79482309|NCT05458362|Behavioral|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
79326605|NCT04109521|Other|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
79326606|NCT04989257|Drug|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
79326607|NCT04989257|Drug|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
79326608|NCT03140527|Drug|PTI-801|Active
79326609|NCT03140527|Drug|Placebo|Placebo
79326610|NCT03140527|Drug|PTI-808|Active
79326611|NCT03140527|Drug|Placebo|Placebo
79326612|NCT03070769|Procedure|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
79326613|NCT03069443|Other|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
79326614|NCT04025983|Dietary Supplement|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
79326615|NCT04025983|Other|Placebo|The placebo contains neither IgY nor L. johnsonii.
79326616|NCT04892069|Drug|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
79326617|NCT04986059|Other|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
79978574|NCT04520048|Other|Vascular biomarker assay|Plasma angiogenic biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), other biomarkers assessment, including anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17), Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), as well as CEMP and CEC quantification using flow cytometry.
79326618|NCT03140449|Drug|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
79326619|NCT03140449|Drug|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
79326620|NCT03140449|Drug|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
79326621|NCT03138811|Drug|CSJ117|inhaled once daily dose
79326622|NCT03138811|Drug|Placebo Comparator|inhaled once daily dose
79326623|NCT02895451|Behavioral|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
79326624|NCT02659813|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
79326625|NCT04095143|Diagnostic Test|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
79326626|NCT04095143|Diagnostic Test|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
79326627|NCT04095143|Diagnostic Test|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
79326628|NCT04095143|Diagnostic Test|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
79326629|NCT04095143|Diagnostic Test|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
79326630|NCT04095143|Diagnostic Test|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
79482310|NCT05458362|Behavioral|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
79326631|NCT04095143|Diagnostic Test|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
79326632|NCT04917445|Behavioral|Spikes-focused bad news protocol|Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
79326633|NCT04904653|Device|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~HEMOPATCH 27 x 27 mm~HEMOPATCH 45 x 45 mm~HEMOPATCH 45 x 90 mm"
79326634|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
79326635|NCT03070691|Drug|LDE225B|Cream, 2x daily
79326636|NCT03070691|Drug|Vehicle|cream, 2x daily
79326637|NCT03137953|Procedure|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
79326638|NCT03137953|Diagnostic Test|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
79326639|NCT04985591|Procedure|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
79978575|NCT04520048|Procedure|Measurement of the uterine artery diameter|This measurement is added to the routine examination of the uterine artery. Bi-dimensional ultrasound imaging with angio-Doppler allows the study of the artery as the blood flow velocity and vessel diameter. Uterine artery Doppler pulsatility index (UtA-PI), mean flow velocity and diameter measurement could be calculated with Doppler instrument with software could determine instantaneous true mean blood flow velocity. Measurement is made by placing the cursor from outer edge to outer edge of the artery adventitia, on a cross-section and taking the largest diameter
79978576|NCT04518072|Other|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
79326640|NCT04985591|Procedure|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
79326641|NCT04985435|Drug|Filgotinib|200 mg tablet once daily or 100 mg once daily
79326642|NCT04985435|Drug|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
79482311|NCT03473171|Device|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
79978577|NCT04517656|Other|Blood samples|"A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~Samples before the allograft,~Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment."
79978578|NCT04517552|Drug|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer [11C] CS1P1. Participants will then undergo a [11C] CS1P1 PET/CT scan.
79482312|NCT05441514|Drug|Cobimetinib|Given PO
79482313|NCT05441514|Drug|Enasidenib Mesylate|Given PO
79482314|NCT03613493|Diagnostic Test|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
79978579|NCT04505813|Biological|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
79978580|NCT04502030|Biological|Panzyga|Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
79482315|NCT03613493|Behavioral|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
79482316|NCT03613493|Behavioral|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
79482317|NCT03613493|Behavioral|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
79482318|NCT04492397|Device|Test Contact Lens|Subjects will be randomized to wear test lenses.
79326643|NCT04985435|Behavioral|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
79326644|NCT03070457|Other|Early discharge|Patients randomised to early discharge or not
79326645|NCT03070457|Other|Conventional protocol|Discharge as usually done 48-72 hours after surgery
79326646|NCT03140683|Device|non-stress test|antepartum fetal monitoring
79482319|NCT04492397|Device|Control Contact Lens|Subjects will be randomized to wear control lenses.
79482320|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
79482321|NCT02258334|Biological|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
79482322|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
79326647|NCT03070613|Drug|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
79482323|NCT02258334|Biological|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
79326648|NCT03441139|Other|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
79326649|NCT03441139|Drug|Medical Analgesics|Best analgesic therapy at investigator's discretion
79978581|NCT04502030|Other|Placebo|Placebo
79326650|NCT04988789|Drug|Paclitaxel Drug Coated Balloon|Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
79326651|NCT04985279|Device|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
79482324|NCT03478163|Drug|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
79978582|NCT04501614|Drug|Ponatinib|Ponatinib tablets.
79978583|NCT04501614|Drug|Ponatinib AAF|Ponatinib age appropriate formulation i.e., capsules with ponatinib minitablets.
79978584|NCT04501614|Drug|Chemotherapy Agents|Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
79482325|NCT03478163|Drug|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
79482326|NCT05646810|Diagnostic Test|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
79482327|NCT05646810|Diagnostic Test|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
79482328|NCT04449263|Device|Lens A|Subjects will be randomized to wear Lens A (test) for 2 weeks.
79482329|NCT04449263|Device|Lens B|Subjects will be randomized to wear Lens B (control) for 2 weeks.
79482330|NCT04449263|Device|Habitual Lenses|All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
79326652|NCT04985279|Device|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
79326653|NCT04985669|Drug|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
79326654|NCT05083897|Other|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
79326655|NCT04988711|Diagnostic Test|Hb Oxymeter|Measurement of Hb Oximeter
79810915|NCT05758740|Behavioral|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
79326656|NCT04753957|Drug|micronized Progesterone|200mg micronized progesterone placed vaginally
79810916|NCT05758740|Behavioral|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
79326657|NCT03070379|Procedure|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
79326658|NCT03227263|Drug|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
79326659|NCT03227263|Drug|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
79326660|NCT04985201|Drug|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m^2 on Day 1,8 of each 21-day cycle.
79326661|NCT04985201|Drug|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
79326662|NCT03156595|Behavioral|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
79326663|NCT03156595|Behavioral|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
79326664|NCT04985123|Device|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
79326665|NCT03092713|Behavioral|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
79326666|NCT03092713|Behavioral|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
79326667|NCT04985045|Other|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
79326668|NCT04988243|Other|All aortic valve products on the market|"Subjects with severe aortic valve stenosis~Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~Be able to contact the subjects or their legal guardians / relatives;~The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
79326669|NCT02031601|Drug|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
79326670|NCT02031601|Drug|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
79482331|NCT05646732|Device|TMS-fMRI|Participants will undergo simultaneous TMS and fMRI
79482332|NCT04413929|Drug|Ergoferon|Oral administration
79482333|NCT04960202|Drug|PF-07321332|PF-07321332 (tablet)
79482334|NCT04960202|Drug|Ritonavir|Ritonavir (capsule)
79648249|NCT05712941|Drug|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique [FIGO] Stage III versus FIGO Stage IV versus recurrent)~EC tumor grade (Grade 1 versus Grade 2)~Geographic location (US versus Europe versus Rest of World)"
79648250|NCT05712941|Drug|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique [FIGO] Stage III versus FIGO Stage IV versus recurrent)~EC tumor grade (Grade 1 versus Grade 2)~Geographic location (US versus Europe versus Rest of World)"
79978585|NCT04497220|Behavioral|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
79978586|NCT04497220|Behavioral|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
79326671|NCT02031601|Drug|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
79326672|NCT02031601|Drug|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
79326673|NCT02031601|Drug|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
79326674|NCT02031601|Drug|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
79326675|NCT02031601|Drug|Erlotinib|150mg po once a day daily until disease progression
79482335|NCT04960202|Drug|Placebo|Placebo (tablet or capsule)
79482336|NCT03615911|Biological|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
79482337|NCT03618017|Behavioral|CCC website|ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
79482338|NCT03618017|Behavioral|Static care plan|"The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
79648251|NCT05709457|Behavioral|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
79648252|NCT05701007|Drug|abiraterone|mCRPC
79648253|NCT05701007|Drug|enzalutamide|mCRPC
79648254|NCT05701007|Drug|docetaxel|mCRPC
79648255|NCT05701007|Drug|apalutamide|mCRPC
79648256|NCT05701007|Drug|cabazitaxel|mCRPC
79978587|NCT04497168|Drug|Citalopram 20mg|20mg daily
79978588|NCT04497168|Drug|Placebo|matching placebo pills
79978589|NCT04490057|Drug|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
79326676|NCT02031601|Drug|Gefitinib|250mg po once a day daily until disease progression
79326677|NCT02031601|Drug|Icotinib|125mg po three times a day daily until disease progression
79648257|NCT05701007|Drug|Radium-223|mCRPC
79326678|NCT04988165|Drug|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
79648258|NCT05701007|Drug|Lutetium-177|mCRPC
79978590|NCT04490057|Drug|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
79648259|NCT05701007|Drug|degarelix|mCSPC
79648260|NCT05701007|Drug|goserelin|mCSPC
79978591|NCT04490057|Behavioral|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
79978592|NCT04483947|Drug|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
79978593|NCT04483947|Other|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
79978594|NCT04482478|Dietary Supplement|Extract of Dolichos lablab Linne (EDL)|Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
79326679|NCT02772679|Biological|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10^6 cells. The second cohort will receive 20x10^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
79326680|NCT04456127|Procedure|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
79326681|NCT04984187|Other|high intensity laser plus exercise|high intensity laser plus exercise
79326682|NCT04984187|Device|high intensity laser only|high intensity laser only
79326683|NCT04984187|Other|exercise|exercise only
79648261|NCT05701007|Drug|leuprorelin|mCSPC
79648262|NCT05701007|Drug|triptorelin|mCSPC
79648263|NCT05694936|Drug|Sodium Valproate|Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
79648264|NCT05694936|Drug|Panitumumab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
79648265|NCT05694936|Drug|Cetuximab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
79648266|NCT05687721|Drug|copanlisib|intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles
79326684|NCT05088343|Drug|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
79326685|NCT05088343|Drug|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
79326686|NCT04984265|Radiation|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
79326687|NCT03070145|Other|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
79326688|NCT03137485|Procedure|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
79326689|NCT03137485|Procedure|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
79326690|NCT03137485|Device|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
79648267|NCT05687721|Drug|Avelumab|800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
79648268|NCT05687188|Other|Blood Sample Collection|Participants will have 40 mL of blood drawn at baseline/pre-treatment. The study team will aim to have this blood collected at the time of standard of care blood draw if possible.
79648269|NCT05687188|Other|Tissue Sample Collection|At the time of tissue biopsy or surgical resection (if applicable) pancreatic tumor tissue, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
79648270|NCT05687188|Other|Data Collection|Participants will complete a study questionnaire at baseline that includes medical history, lifestyle, and family history information.
79978595|NCT04482478|Other|Placebo oral tablet|Placebo: consumed in the same way as the investigational product
79978596|NCT04482062|Device|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
79978597|NCT04482062|Drug|Optimal Medical Therapy|Optimal Medical Therapy
79326691|NCT03068507|Behavioral|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
79326692|NCT03137641|Other|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
79326693|NCT04983641|Other|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
79326694|NCT03068429|Drug|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
79482339|NCT03619811|Diagnostic Test|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
79326695|NCT03068351|Drug|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram [mg/kg] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
79978598|NCT04480008|Behavioral|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
79978599|NCT04479475|Behavioral|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
79326696|NCT03068351|Biological|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
79326697|NCT03137563|Other|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
79326698|NCT03140293|Drug|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
79326699|NCT03140293|Drug|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
79326700|NCT04983563|Device|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
79326701|NCT03137329|Behavioral|Exercise program|Physical therapy for aerobic and resistance training exercises
79326702|NCT03137329|Dietary Supplement|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
79326703|NCT03137329|Procedure|WLS|Weight loss surgery as planned
79326704|NCT04452695|Device|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
79482340|NCT03619889|Other|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
79482341|NCT03619889|Other|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
79482342|NCT02959112|Drug|Epinephrine|
79482343|NCT02959112|Other|Sterile water|
79482344|NCT02959112|Drug|Indomethacin Rectal Suppository|
79326705|NCT04584541|Biological|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
79326706|NCT04584541|Biological|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
79326707|NCT04584541|Biological|Stools|SarS-Cov-2 viral load assessment
79326708|NCT04982861|Drug|Cefixime Trihydrate 100 mg/5 mL Dry Syrup|Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
79326709|NCT04982861|Drug|Suprax 100 MG in 5 mL Oral Suspension|Participants received a single dose of 5 mL of Suprax with 240 mL of water
79326710|NCT04456049|Drug|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
79326711|NCT04572217|Drug|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
79326712|NCT04572217|Drug|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
79326713|NCT04553809|Procedure|ENB|ENB for biopsy sampling of peripheral lung lesion
79326714|NCT04553809|Procedure|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
79326715|NCT05083195|Other|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
79326716|NCT05083195|Other|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
79978600|NCT04474600|Drug|Propofol|The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.
79482345|NCT05377034|Combination Product|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
79482346|NCT05377034|Combination Product|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
79326717|NCT03137251|Device|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
79326718|NCT03137251|Device|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
79482347|NCT03481595|Device|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
79978601|NCT04474600|Drug|Desflurane|The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
79978602|NCT04469218|Device|SafeBreak Vascular|SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
79648271|NCT05687188|Other|Medical Image Collection|Medical images that are obtained during routine care such as computed tomography (CT) scans, magnetic resonance imaging (MRIs) and ultrasounds will be reviewed by the study team throughout the participant's medical care.
79978603|NCT04468321|Device|Apple Watch|Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.
79978604|NCT04468321|Device|Withings Move|Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
79978605|NCT04467515|Drug|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
79326719|NCT03137251|Device|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
79326720|NCT05635955|Drug|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores > 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
79326721|NCT05635955|Drug|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores > 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
79326722|NCT05635955|Drug|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
79326723|NCT03137017|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
79326724|NCT03137017|Drug|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
79326725|NCT04412681|Diagnostic Test|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
79326726|NCT05635565|Other|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
79482348|NCT04957550|Drug|SHR0302 tablets、Placebo|SHR0302 tablets dose 1 for 48 weeks
79482349|NCT04957550|Drug|SHR0302 tablets、Placebo|SHR0302 tablets dose 2 for 48 weeks
79648272|NCT05673928|Drug|Trastuzumab emtansine|Given by IV (vein)
79326727|NCT05635565|Other|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
79326728|NCT05635253|Other|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
79326729|NCT05635253|Other|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
79326730|NCT03069599|Procedure|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
79482350|NCT04957550|Drug|Placebo|SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
79326731|NCT05634941|Device|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
79326732|NCT05634941|Device|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
79326733|NCT05074069|Procedure|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
79482351|NCT03622619|Other|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
79482352|NCT03622619|Other|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
79482353|NCT04885244|Procedure|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
79482354|NCT04428359|Drug|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
79648273|NCT05673928|Drug|Tucatinib|Given by PO
79482355|NCT04428359|Drug|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
79482356|NCT02257632|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
79482357|NCT02257632|Drug|Aflibercept 2 mg|Administered as an intravitreal injection
79482358|NCT04943120|Procedure|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
79648274|NCT05668923|Behavioral|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
79326734|NCT04262479|Drug|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
79326735|NCT04262479|Drug|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
79648275|NCT05647772|Behavioral|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
79326736|NCT04275323|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
79326737|NCT04275323|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
79978606|NCT04464603|Device|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
79326738|NCT04133311|Drug|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, eye drops emulsion in single-dose containers
79326739|NCT04133311|Drug|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers
79482359|NCT04943120|Procedure|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
79482360|NCT04415489|Device|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
79326740|NCT04237025|Other|Nordic walking exercise|Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
79326741|NCT03217825|Drug|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
79326742|NCT03217825|Drug|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole- 5-methanol monopotassium salt.
79326743|NCT05183009|Device|eXciteOSA|eXciteOSA
79326744|NCT00157963|Drug|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
79482361|NCT04937036|Diagnostic Test|Polysomnography|Each of the patients will undergo polysomnography
79482362|NCT05436054|Drug|Picoprep|200 patients will be randomised to this arm
79482363|NCT05436054|Drug|Plenvu|200 patients will be randomised to this arm
79482364|NCT04864106|Device|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
79482365|NCT04383665|Device|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
79482366|NCT04383665|Device|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
79482367|NCT04383665|Device|STN DBS off|Existing DBS device turned off
79482368|NCT02977130|Behavioral|Map group|diabetes shared care plus conversation map intervention
79482369|NCT02977130|Behavioral|Control group|diabetes shared care
79482370|NCT01642914|Drug|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
79482371|NCT01642914|Drug|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
79482372|NCT01642914|Drug|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
79482373|NCT04381481|Behavioral|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
79482374|NCT04381481|Behavioral|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
79326745|NCT04014829|Diagnostic Test|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
79326746|NCT04014829|Diagnostic Test|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
79978607|NCT04464603|Other|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
79326747|NCT04014829|Diagnostic Test|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
79978608|NCT04458051|Drug|Tolebrutinib|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
79326748|NCT04014829|Diagnostic Test|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
79326749|NCT04014829|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
79978609|NCT04458051|Drug|Placebo|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
79978610|NCT04454515|Drug|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
79326750|NCT04014829|Diagnostic Test|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
79326751|NCT04014829|Diagnostic Test|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
79326752|NCT04014829|Diagnostic Test|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
79326753|NCT04014829|Diagnostic Test|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
79326754|NCT04014829|Diagnostic Test|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
79326755|NCT04014829|Diagnostic Test|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
79326756|NCT05634629|Procedure|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
79326757|NCT05634629|Procedure|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
79326758|NCT05088031|Device|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
79326759|NCT05087953|Diagnostic Test|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
79326760|NCT05087953|Diagnostic Test|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
79978611|NCT04454515|Drug|placebo|normal saline infusion
79326761|NCT05087797|Drug|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
79482375|NCT04381481|Behavioral|Experimental snack: Text warning|The snack contains a text warning (task 2)
79482376|NCT04381481|Behavioral|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
79978612|NCT04452981|Device|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
79978613|NCT04450771|Behavioral|Family-based Treatment for ARFID|This treatment includes 14 1-hour sessions that will be conducted approximately weekly over a 4 month period. It is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior.
79978614|NCT04450771|Behavioral|Manualized Non-Specific Usual Care for ARFID|This treatment is a manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model. It consists of sessions with the child alone and 5 parent-only meetings, all of which are 1-hour over a 4 month period.
79978615|NCT04444102|Procedure|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip & plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
79978616|NCT04442373|Diagnostic Test|Rotational thromboelastometry|1.8 ml blood sample
79978617|NCT04411849|Other|Best Practice|Receive usual care
79978618|NCT04411849|Procedure|HPV Self-Collection|Receive HPV self-testing intervention
79978619|NCT04411849|Other|Informational Intervention|Receive information about cervical cancer
79978620|NCT04411849|Behavioral|Patient Navigation Program|Receive telephone-based patient navigation
79978621|NCT04409782|Other|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
79978622|NCT04409782|Other|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
79978623|NCT04408625|Biological|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
79978624|NCT04408625|Drug|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
79978625|NCT04408625|Drug|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
79978626|NCT04408625|Drug|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
79978627|NCT04408105|Behavioral|Primary Care Provider Survey|To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.
79326762|NCT05087719|Combination Product|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
79326763|NCT05087719|Combination Product|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
79326764|NCT05087017|Other|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
79482377|NCT04381481|Behavioral|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
79482378|NCT01642602|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
79482379|NCT03488849|Device|SureCRIC|SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
79482380|NCT03488849|Other|Freehand|Freehand palpation approach to identification of the cricothyroid membrane
79326765|NCT05086861|Device|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
79326766|NCT05086783|Other|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
79326767|NCT05086783|Other|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
79326768|NCT05070949|Behavioral|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
79326769|NCT04011787|Dietary Supplement|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
79326770|NCT04011787|Dietary Supplement|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
79326771|NCT04011787|Diagnostic Test|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
79326772|NCT04011787|Diagnostic Test|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
79326773|NCT04011787|Radiation|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
79326774|NCT03867799|Drug|Nivolumab|Immunotherapy
79326775|NCT05085925|Behavioral|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
79326776|NCT05085925|Behavioral|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
79326777|NCT05085769|Procedure|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
79326778|NCT05085457|Diagnostic Test|ExPreS Protocol|Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
79326779|NCT03726073|Device|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
79326780|NCT03726073|Other|Usual care|Patients in this group only receive usual care developed by the study hospital
79326781|NCT04873297|Drug|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
79326782|NCT04873297|Drug|Placebo|Placebo 10 ml of plain water Via NG
79326783|NCT02633501|Drug|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
79326784|NCT02633501|Drug|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
79326785|NCT02633501|Device|MRI|
79326786|NCT05634473|Drug|Methacholine Chloride|Cholinergic agonists
79326787|NCT05634317|Behavioral|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
79648276|NCT05647772|Behavioral|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
79648277|NCT05647772|Behavioral|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
79648278|NCT05646303|Drug|Psilocybin|Psilocybin and psychotherapy
79648279|NCT05646303|Drug|Placebo|Placebo and psychotherapy
79648280|NCT05635838|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79648281|NCT05635838|Drug|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
79648282|NCT05630209|Device|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
79648283|NCT05630209|Drug|Doxorubicin|Doxorubicin infusion
79648284|NCT05615623|Device|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
79648285|NCT05615623|Drug|Doxorubicin|Doxorubicin infusion
79648286|NCT05601765|Other|Standard communication pathways after discharge|Standard communication pathways after discharge
79648287|NCT05601765|Other|Digital team-based communication after discharge|Standard communication pathways plus digital team-based communication after discharge
79482381|NCT04371419|Behavioral|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~Some individuals in a control group will see messages later."
79482382|NCT04848194|Procedure|skin biopsy and blood sampling|"4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~A blood sample"
79482383|NCT02256540|Drug|Climara|
79648288|NCT05593432|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79648289|NCT05593432|Drug|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
79482384|NCT02256540|Drug|Placebo patch|Placebo patch designed to match active Climara patches.
79482385|NCT02256540|Dietary Supplement|Resveratrol|
79326788|NCT05634317|Behavioral|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
79326789|NCT05085145|Biological|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
79482386|NCT02256540|Dietary Supplement|Placebo|Placebo tablets designed to match active resveratrol tablets.
79482387|NCT04366583|Device|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
79482388|NCT04366583|Device|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
79482389|NCT05646342|Other|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
79482390|NCT03627299|Drug|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
79648290|NCT05587946|Other|Experimental group|In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
79648291|NCT05574361|Device|Hypothermic Machine Perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
79326790|NCT05634239|Behavioral|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
79482391|NCT05646264|Drug|Agomelatine|Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
79648294|NCT05561530|Drug|ALG-125755|single or multiple doses of ALG-125755
79648295|NCT05561530|Drug|Placebo|single or multiple doses of placebo
79648296|NCT05553925|Other|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~Digital scale and Fitbit~Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~Weight, diet, and physical activity tracking~Regular, personalized feedback and support from a health coach~Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
79326791|NCT04858711|Drug|ketamine-lidocaine-dexmedetomidine|In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
79482392|NCT04841954|Diagnostic Test|hemp prick-test|hemp seed and flower prick-test
79482393|NCT04734431|Biological|Eosinophil count|Evaluation of the eosinophil count from admission to day 7
79482394|NCT01640184|Procedure|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
79482395|NCT01640184|Drug|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
79326792|NCT04858711|Drug|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
79326793|NCT03138187|Behavioral|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
79326794|NCT03138187|Behavioral|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
79326795|NCT03069209|Biological|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
79326796|NCT04771819|Device|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
79648297|NCT05545748|Behavioral|Zero (0) Tolerance Program (SToP)|"Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~Informative materials (information notes and brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~Informative telephone text messages: Reminder phone messages related to SHS and THS"
79326797|NCT03068975|Drug|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
79648298|NCT05545748|Behavioral|Exposure Feedback Group|1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
79326798|NCT03068975|Drug|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
79326799|NCT02034331|Drug|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
79326800|NCT02034331|Drug|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
79326801|NCT02034331|Drug|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
79326802|NCT02034331|Other|Heat application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
79326803|NCT03592225|Behavioral|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
79482396|NCT01640184|Procedure|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
79482397|NCT04904978|Other|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
79648299|NCT05540626|Device|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
79326804|NCT04166981|Procedure|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
79326805|NCT04166981|Procedure|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
79482398|NCT04904978|Other|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
79326806|NCT03068117|Other|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
79326807|NCT03538873|Behavioral|Physical activity|
79326808|NCT05077189|Other|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~Demographics Survey~DC/TMD Symptom Questionnaire (SQ)~Graded Chronic Pain Scale (GCPS)~Jaw Functional Limitation Scale-20 (JFLS-20)"
79326809|NCT04766957|Device|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
79326810|NCT03068039|Other|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
79326811|NCT03068039|Other|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
79326812|NCT05632991|Other|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
79326813|NCT05632991|Other|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
79326814|NCT05073601|Diagnostic Test|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested [Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
79326815|NCT03068195|Procedure|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
79326816|NCT03068195|Procedure|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
79326817|NCT03140059|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
79326818|NCT03140059|Procedure|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
79326819|NCT03067883|Drug|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
79482399|NCT04903574|Behavioral|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
79482400|NCT04903574|Other|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
79482401|NCT03630185|Device|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
79482402|NCT03630185|Device|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
79482403|NCT05421702|Procedure|laparoscopic conventional colectomy|Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
79326820|NCT05631821|Procedure|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
79326821|NCT03404245|Behavioral|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
79326822|NCT03404245|Behavioral|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
79326823|NCT05393167|Device|Echo_CT_MRI_US_x ray|Examination: General and systemic examinations of the studied neonates. Investigation will be done to the neonates according to the clinical examination including imaging studies as X-rays, U/S, echocardiography, CT and MRI studies
79326824|NCT03285763|Drug|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
79326825|NCT03231631|Behavioral|Education plan and adherence to exercise|"Send text messages with motivational sense at any time of the day, every 3 or 4 days.~They will be given the option of performing directed exercise at the cardiac rehabilitation center.~It will be recorded in an Excel table every time that text is sent to the patient.~At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
79482404|NCT05421702|Procedure|laparoscopic complete mesocolic excision|Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
79482405|NCT02256384|Device|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
79482406|NCT03631433|Drug|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
79482407|NCT03631433|Drug|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
79978628|NCT04408105|Behavioral|Gastroenterologist Survey|To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.
79482408|NCT04343612|Device|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
79326826|NCT03067805|Behavioral|Sexual Infidelity Condition|
79326827|NCT03067805|Behavioral|Emotional Infidelity Condition|
79326828|NCT03067805|Behavioral|Neutral Condition|
79326829|NCT03067805|Behavioral|Player in Jealousy Condition|
79326830|NCT03067805|Behavioral|Player in Non-Jealousy Condition|
79326831|NCT05393011|Drug|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
79326832|NCT05034835|Device|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
79326833|NCT05034835|Other|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
79482409|NCT03489941|Drug|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
79482410|NCT03489941|Drug|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
79482411|NCT03489941|Drug|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
79482412|NCT03585114|Drug|[F-18] DCFPyL|[18F]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of [18F]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
79326834|NCT03138421|Drug|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
79326835|NCT03138421|Drug|Placebo|Matching placebo
79978629|NCT04408105|Behavioral|Patient Survey|To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
79326836|NCT03110497|Radiation|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
79326837|NCT03110731|Behavioral|Physical training|Physical training (2x / week) was performed for 12 weeks
79326838|NCT03085771|Drug|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
79326839|NCT03085771|Drug|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
79326840|NCT05619965|Drug|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
79326841|NCT05619965|Device|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
79326842|NCT05619965|Device|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
79326843|NCT04659629|Drug|NL-201|NL-201 is a de novo protein therapeutic.
79978630|NCT04398524|Drug|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
79978631|NCT04398316|Drug|Lidocaine Iv|2 mg/kg over 5 minutes
79978632|NCT04398316|Drug|HYDROmorphone Injection|1 mg over 5 minutes
79326844|NCT04659629|Drug|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
79326845|NCT02985619|Drug|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
79326846|NCT02985619|Drug|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
79326847|NCT02985619|Drug|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
79326848|NCT05587205|Biological|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
79326849|NCT05587205|Other|Sham injection|Sham injection
79326850|NCT04958005|Diagnostic Test|ELISA|Enzim linked immunoabsorbant assay
79482413|NCT03585114|Procedure|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
79482414|NCT05646186|Dietary Supplement|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
79482415|NCT05646186|Dietary Supplement|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
79482416|NCT02973659|Drug|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
79482417|NCT02973659|Drug|Placebos|
79326851|NCT05583929|Other|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
79482418|NCT00377663|Behavioral|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
79648300|NCT05507008|Dietary Supplement|Kenetik Ketone Drink|BHB supplementation
79648301|NCT05501821|Drug|KBA1412|Part A, B, C
79648302|NCT05501821|Drug|Pembrolizumab|Part C only
79978633|NCT04396808|Device|Decipher|The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
79978634|NCT04396808|Device|Prolaris|The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
79978635|NCT04396808|Device|Oncotype Dx Genomic Prostate Score (GPS)|The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
79978636|NCT04396808|Other|Standard of care (askMUSIC score)|AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
79978637|NCT04396574|Drug|Lasmiditan|Administered orally
79978638|NCT04396236|Drug|Lasmiditan|Administered orally
79978639|NCT04396236|Drug|Placebo|Administered orally
79482419|NCT04439396|Drug|Ketorolac Tromethamine|nonsteroidal anti-inflammatory drug
79648303|NCT05500443|Dietary Supplement|Vitamin K2 (Menaquinone-7)|Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
79810917|NCT05306808|Other|physiotherapy class|The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
79326852|NCT03110419|Other|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
79326853|NCT04123613|Drug|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
79810918|NCT04030494|Diagnostic Test|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
79326854|NCT03110653|Drug|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
79326855|NCT03110653|Drug|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
79326856|NCT04116593|Behavioral|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
79326857|NCT05392387|Other|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
79326858|NCT04583579|Device|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
79326859|NCT04583579|Device|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
79648304|NCT05487586|Drug|ceftazidime avibactam group|Non-Interventional Study
79648305|NCT05482477|Other|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
79648306|NCT05481242|Other|retrospective observational study|retrospective observational study
79326860|NCT04583579|Device|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
79326861|NCT04583579|Device|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
79326862|NCT04583579|Device|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
79482420|NCT04439396|Other|Saline|saline fluid injection
79482421|NCT03493607|Drug|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
79482422|NCT02976974|Other|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
79648307|NCT05470010|Behavioral|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
79648308|NCT05461170|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
79978640|NCT04359758|Behavioral|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
79978641|NCT04359758|Behavioral|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
79326863|NCT04450199|Drug|Vitamin D2|Vitamin D tablets
79326864|NCT04450199|Other|Placebo|Over encapsulated sugar pills
79326865|NCT03067649|Behavioral|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
79326866|NCT03067649|Behavioral|Information only control|Participants are provided with a pamphlet containing referral information
79326867|NCT01884259|Drug|Docetaxel|75 mg/m² on day 1 of 21-days cycle
79482423|NCT02976974|Other|Therapeutic exercise|"Shoulder extension: Elastic bands.~Shoulder flexion: Elastic bands~Shoulder external rotation: Elastic bands.~Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
79482424|NCT00377039|Drug|AD 337|
79326868|NCT01884259|Drug|Cisplatin|75 mg/m² on day 1 of 21-days cycle
79326869|NCT01884259|Drug|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
79978642|NCT04353973|Other|Pre-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
79326870|NCT01884259|Biological|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
79326871|NCT01884259|Biological|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
79326872|NCT01884259|Radiation|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
79326873|NCT04930549|Drug|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
79326874|NCT04930549|Drug|Placebo|Patients receive placebo tablets once a day during 12 weeks
79326875|NCT04930549|Procedure|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
79326876|NCT04930549|Procedure|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
79482425|NCT02255760|Drug|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
79978643|NCT04353973|Other|Standard of Care|Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)
79326877|NCT04930549|Procedure|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
79326878|NCT04930549|Procedure|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
79326879|NCT05392153|Other|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
79326880|NCT03067727|Drug|Dinoprostone|The DVI contains 10 mg Dinoprostone
79326881|NCT03067727|Drug|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
79326882|NCT01794793|Drug|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
79326883|NCT01794793|Drug|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
79326884|NCT01794793|Drug|Pasireotide|Long Acting Release is administered by monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
79326885|NCT03067103|Drug|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
79326886|NCT03067103|Drug|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
79326887|NCT03067103|Drug|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
79326888|NCT01398319|Behavioral|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
79326889|NCT01398319|Behavioral|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
79482426|NCT02255760|Drug|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
79482427|NCT02255760|Drug|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
79810919|NCT04030494|Diagnostic Test|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
79810920|NCT04030494|Diagnostic Test|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
79810921|NCT00667810|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
79978644|NCT04353973|Other|Post-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
79978645|NCT04350021|Drug|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
79978646|NCT04347291|Behavioral|FAMS 2.0|FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
79978647|NCT04347291|Behavioral|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
79978648|NCT04336293|Device|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
79482428|NCT02255760|Drug|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
79482429|NCT02255760|Other|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
79648309|NCT05461170|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
79648310|NCT05461170|Drug|NRTI|NRTI given orally.
79326890|NCT01398319|Behavioral|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
79978649|NCT04336293|Device|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
79326891|NCT03068585|Drug|Neovasculgen (Cambiogeneplasmid)|treatment
79326892|NCT01305889|Behavioral|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
79326893|NCT01305889|Drug|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
79326894|NCT03138265|Behavioral|HIIT Device: ergometer|Supervised exercise training.
79326895|NCT05391997|Other|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
79326896|NCT05391997|Other|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
79326897|NCT03136939|Other|No intervention|No intervention
79326898|NCT03591107|Other|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
79326899|NCT03591107|Other|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
79326900|NCT00223171|Drug|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
79326901|NCT04563481|Other|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
79326902|NCT04563481|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
79326903|NCT04497493|Device|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
79326904|NCT04497493|Device|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
79326905|NCT05391685|Other|Scar release techniques + therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
79482430|NCT03497585|Behavioral|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
79482431|NCT05646108|Device|Endovascular treatment|Endovascular treatment
79482432|NCT00360464|Drug|Azithromycin SR|
79482433|NCT05369754|Biological|YBSW015 injection|Prepared YBSW015 injection is intravenously injected by an infusion pump or gravity infusion with intravenous infusion of 250 mL for 60 min±10 min.
79326906|NCT03138031|Procedure|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
79482434|NCT03637517|Drug|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
79482435|NCT03637517|Drug|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
79810922|NCT00667810|Drug|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
79482436|NCT03637517|Drug|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
79978650|NCT04331353|Behavioral|Comparator 1 (tailored approach)|Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
79978651|NCT04331353|Behavioral|Comparator 2 (insecticidal bait)|Cockroach bait
79978652|NCT04331275|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
79978653|NCT04328584|Procedure|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
79978654|NCT04325152|Device|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
79482437|NCT05645952|Other|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
79482438|NCT00377117|Procedure|Management|
79810923|NCT00667810|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
79978655|NCT04325152|Device|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
79482439|NCT00377117|Procedure|Screening|
79482440|NCT05651256|Drug|Botulinum toxin type A injection|The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
79482441|NCT00377195|Radiation|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
79810924|NCT00819390|Drug|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
79810925|NCT00819390|Drug|Placebo|Taken orally, once daily for 12 weeks.
79810926|NCT00876395|Drug|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
79978656|NCT04311086|Device|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
79978657|NCT04308174|Drug|Durvalumab + Gem/Cis|Neoadjuvant Durvalumab + Gemcitabine/Cisplatin
79326907|NCT04854265|Other|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
79326908|NCT04433507|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
79482442|NCT04297631|Drug|Tobramycin Powder|Everyone gets tobramycin powder.
79326909|NCT04433507|Procedure|Hiatal Hernia repair|Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
79326910|NCT04363385|Biological|Biological test|Blood sample
79326911|NCT04800991|Device|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
79326912|NCT04790851|Biological|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
79326913|NCT04790851|Biological|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
79326914|NCT04790851|Biological|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
79326915|NCT05431283|Drug|Tofacitinib|This study aims to assess the effectiveness of TOFA
79326916|NCT05391529|Behavioral|Interview|Semi structured patient interview via telephone
79326917|NCT03208985|Drug|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
79482443|NCT04297631|Device|Vancomyscin|Everyone gets the vancomyscin powder.
79648311|NCT05408429|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
79326918|NCT03644953|Drug|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
79648312|NCT05408429|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
79326919|NCT03630835|Other|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
79326920|NCT03067337|Device|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
79326921|NCT03067337|Device|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
79326922|NCT04764097|Drug|Dapagliflozin|SGTL2 Inhibitor
79326923|NCT04764097|Drug|Placebo|Placebo
79326924|NCT02922023|Device|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
79326925|NCT02922023|Other|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
79326926|NCT04761211|Device|smart bra|This is a patented infrared breast examination bra
79326927|NCT03605017|Behavioral|Virtual Reality Executive Function Training (VREFT)|
79648313|NCT05405439|Drug|TQB3823 tablets|TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
79648314|NCT05405439|Drug|Abiraterone acetate tablets|Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
79648315|NCT05405439|Drug|prednisone acetate tablets|Prednisone acetate tablet is a kind of glucocorticoids
79648316|NCT05399771|Device|Laser Doppler|Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.
79648317|NCT05399771|Device|Radiofrequency Heating System|The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
79648318|NCT05399771|Device|Thermal Imaging|Study team will take thermal imaging photographs of the treatment area following each treatment.
79978658|NCT04308174|Drug|Gem/Cis|Neoadjuvant Gemcitabine/Cisplatin
79810927|NCT00876395|Drug|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
79810928|NCT00876395|Drug|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
79978659|NCT04290546|Drug|Interleukin-15 Superagonist (N-803)|"-- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight."
79326928|NCT05391451|Procedure|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
79326929|NCT05391451|Procedure|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
79326930|NCT03140137|Drug|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
79326931|NCT03520309|Procedure|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
79326932|NCT03110341|Drug|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
79326933|NCT03110341|Drug|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
79326934|NCT03140215|Device|laryngeal mask insertion (Baska)|
79326935|NCT03140215|Device|laryngeal mask insertion (I-gel )|
79326936|NCT04720729|Biological|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 & L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
79326937|NCT03511417|Device|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
79326938|NCT03273751|Procedure|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
79326939|NCT03273751|Procedure|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
79326940|NCT03136315|Other|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
79326941|NCT03152539|Radiation|MRI|
79482444|NCT05645874|Diagnostic Test|Skin biopsy|Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n<80). Skin punch biopsies from children with acquired (n<80) or genetic NDD (n<80) or unknown etiology (N<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
79482445|NCT04296227|Device|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
79648319|NCT05399771|Other|Healthcare Questionnaire & Measurement|"A survey tool created to collect info from participants including:~Name~Age~Weight/ height~Pregnant or nursing?~History of blood clots?~Any wound healing problems?~Any active open wounds on the legs?~Any autoimmune disorders?~Phone number~Email address~A measurement of the participants calf will be taken as well using a measuring tape."
79978660|NCT04290546|Biological|CIML NK cell Infusion|(Dose 0 or -1) infused on Day 0
79978661|NCT04290546|Drug|Ipilimumab|single dose of lead-in ipilimumab via iv per protocol determined dose
79978662|NCT04290546|Drug|Cetuximab|Starting day +15, every 14 days for 8 total doses via IV per protocol
79326942|NCT03152539|Device|EEG|
79326943|NCT03152539|Device|NIRS|
79326944|NCT03136549|Other|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
79326945|NCT03136549|Other|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
79482446|NCT04430582|Other|Cognitive Assessment (not diagnostic)|Cognitive testing will assess working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
79482447|NCT04430582|Diagnostic Test|ECG|ECG will take place during screening visit.
79648320|NCT05376553|Drug|Cemiplimab|350mg intravenous infusion over 30 minutes
79648321|NCT05376553|Drug|Cisplatin|"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"
79326946|NCT05377801|Behavioral|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
79326947|NCT04537897|Drug|BI 474121|BI474121
79326948|NCT04537897|Drug|Midazolam|Midazolam
79326949|NCT04537897|Drug|Placebo|Placebo
79326950|NCT04543513|Other|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
79326951|NCT04421053|Behavioral|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
79482448|NCT04292639|Device|The Vital Detect Pulse Oximeter|The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
79482449|NCT04812470|Drug|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion
79482450|NCT04812470|Drug|Melphalan|Melphalan will be administered once as an intravenous infusion.
79482451|NCT04812470|Drug|Interleukin-2|After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
79482452|NCT03502265|Other|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
79482453|NCT05651178|Drug|Human CD19-CD22 Targeted T Cells Injection|Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
79482454|NCT02976194|Drug|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
79978663|NCT04284228|Biological|Infusion of NEXI-001 T Cells|"Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan"
79978664|NCT04276142|Behavioral|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
79978665|NCT04276142|Behavioral|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
79326952|NCT04405063|Device|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
79326953|NCT04400305|Behavioral|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
79326954|NCT04381039|Device|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
79326955|NCT01672853|Biological|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
79326956|NCT01672853|Biological|Placebo|Subcutaneous injections weekly for a total of 96 injections
79326957|NCT05090449|Drug|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
79326958|NCT05090449|Drug|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
79326959|NCT05090449|Drug|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
79326960|NCT05090449|Drug|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
79326961|NCT05090137|Other|Diuretics|As per group descriptions
79326962|NCT03067025|Device|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
79482455|NCT00360776|Drug|tipifarnib|Given orally
79482456|NCT00360776|Other|laboratory biomarker analysis|Correlative studies
79810929|NCT00876395|Drug|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
79482457|NCT04800458|Biological|Blood samples|"Thrombopoietin : 7 ml whole blood.~Anti-platelet antibodies free : 14 ml whole blood.~Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is < 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is < 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is < 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation."
79482458|NCT04343300|Other|Pilates|Intervention of12 weeks of Pilates
79810930|NCT05758662|Diagnostic Test|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
79810931|NCT00776854|Device|Noveon laser|870 and 930nm wavelengths
79326963|NCT05090059|Device|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
79326964|NCT03067415|Drug|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
79810932|NCT02633657|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
79326965|NCT03067415|Drug|D565(Latanoprost 50㎍/㎖)|D565 once daily
79326966|NCT05089981|Drug|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
79326967|NCT05089981|Drug|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
79326968|NCT03349801|Other|No intervention|According to clinical practice.
79326969|NCT03066401|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
79326970|NCT05089591|Device|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
79326971|NCT05089591|Device|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
79482459|NCT04343300|Other|exercise without Pilates|exercise without Pilates
79482460|NCT04274075|Drug|GDC-9545 Tablet, Fasted: Treatment A|One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
79482461|NCT04274075|Drug|GDC-9545 Capsule, Fasted: Treatment B|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
79482462|NCT04274075|Drug|GDC-9545 Capsule, Fed: Treatment C|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
79482463|NCT02976740|Radiation|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
79482464|NCT02976740|Drug|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
79482465|NCT02976740|Drug|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
79482466|NCT03639857|Device|532nm laser|532nm laser will be used to treat the lesion in this study arm.
79482467|NCT03639857|Device|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
79482468|NCT03639857|Drug|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
79482469|NCT04342910|Drug|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
79482470|NCT04342910|Drug|Apatinib Mesylate|250 mg qd
79810933|NCT02626169|Drug|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
79810934|NCT02626169|Drug|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
79810935|NCT00685217|Procedure|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
79810936|NCT00685217|Procedure|TVT (Gynecare)|Sling procedure for stress urinary incontinence
79810937|NCT04139915|Drug|Dactolisib|TORC1 inhibitor
79810938|NCT04139915|Drug|Placebo|Placebo capsule
79810939|NCT00685451|Behavioral|Cognitive Behavioral Therapy (CBT)|
79326972|NCT04206059|Radiation|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
79326973|NCT04206059|Diagnostic Test|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
79326974|NCT04206059|Diagnostic Test|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
79326975|NCT04206059|Other|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
79326976|NCT04206059|Other|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
79326977|NCT04206059|Other|0 db with QST|sham stimulation (0 dB volume)
79326978|NCT04206059|Drug|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
79326979|NCT04206059|Other|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
79326980|NCT05377645|Other|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
79326981|NCT05430737|Radiation|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
79326982|NCT05431049|Procedure|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
79326983|NCT04148573|Drug|NFX88 - 1|3 times a day
79326984|NCT04148573|Drug|NFX88 - 2|3 times a day
79326985|NCT04148573|Drug|NFX88 - 3|3 times a day
79326986|NCT04148573|Drug|PLACEBO - 4|3 times a day
79326987|NCT03136783|Other|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
79326988|NCT05430503|Diagnostic Test|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
79648322|NCT05376553|Drug|Docetaxel|"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"
79326989|NCT03110263|Other|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
79482471|NCT04342910|Drug|Paclitaxel|80 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
79482472|NCT04342910|Drug|Irinotecan|180 mg/m^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
79810940|NCT04148183|Drug|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
79326990|NCT03110263|Other|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
79482473|NCT03504839|Device|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
79482474|NCT04714073|Drug|BI 706321|BI 706321
79810941|NCT04148183|Drug|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
79810942|NCT04148183|Drug|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
79810943|NCT00681395|Drug|ABT-143|once daily for 6 days
79326991|NCT05730023|Device|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
79326992|NCT05730023|Behavioral|individualized language training|individualized language training
79326993|NCT05730023|Device|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
79326994|NCT05089045|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79326995|NCT04132817|Biological|Nivolumab|specified dose on specified days
79326996|NCT04132817|Biological|Ipilimumab|specified dose on specified days
79326997|NCT04132817|Drug|Nab-paclitaxel|specified dose on specified days
79978666|NCT04275167|Device|Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope|Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
79978667|NCT04274426|Drug|Carboplatin|Carboplatin will administered by intravenous route
79978668|NCT04274426|Drug|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
79326998|NCT05088811|Diagnostic Test|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
79326999|NCT03066635|Drug|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
79327000|NCT03066635|Drug|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
79327001|NCT05077267|Biological|ABNCoV2 100ug|IM injection 100ug dose
79327002|NCT05077267|Biological|ABNCoV2 50ug|IM injection 50ug dose
79327003|NCT05075083|Biological|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
79327004|NCT04073771|Device|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
79327005|NCT03136237|Drug|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
79648323|NCT05374759|Diagnostic Test|neutrophil gelatinase-associated lipocalin|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, blood samples will be taken and NGAL levels will measured.
79648324|NCT05374759|Diagnostic Test|renal resistive index|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, renal resistive index will measure and record.
79978669|NCT04274426|Drug|Gemcitabine|Gemcitabine will be administered by intravenous route
79978670|NCT04274426|Drug|Paclitaxel|Paclitaxel will be administered by intravenous route
79978671|NCT04274426|Drug|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
79327006|NCT03136237|Drug|Digoxin|Day 1 of Cohort 1
79327007|NCT03136237|Drug|BCX7353 + digoxin|Day 19 of Cohort 1
79327008|NCT03136237|Drug|Rosuvastatin|Day 1 of Cohort 2
79327009|NCT03136237|Drug|rosuvastatin + BCX7353|Day 15 of Cohort 1
79327010|NCT03136237|Drug|Cyclosporine + BCX7353|Day 14 of Cohort 3
79327011|NCT05430425|Other|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
79327012|NCT04001309|Other|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
79327013|NCT03136081|Diagnostic Test|Candidiasis infection occurence|Candidiasis infection occurence
79327014|NCT03135925|Other|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
79327015|NCT05729789|Behavioral|Group Written Exposure Therapy|Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
79978672|NCT04272801|Drug|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
79978673|NCT04272801|Behavioral|Patient reported outcomes|"Questionnaire inquiries include the following:~how cancer affects daily living~beliefs about medicines and sensitivity to medicine~symptoms~adherence to endocrine therapy~general health and well being~depression and anxiety~preference regarding radiation therapy"
79978674|NCT04265261|Drug|Placebo|Participants will receive oral placebo matched to RG7774
79978675|NCT04265261|Drug|RG7774|Participants will receive oral RG7774
79810944|NCT00681395|Drug|ABT-335|once daily for six days
79327016|NCT04021381|Dietary Supplement|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
79327017|NCT04021381|Dietary Supplement|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
79327018|NCT04020523|Other|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
79327019|NCT04158401|Device|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
79327020|NCT03066479|Device|Fitbit|Wearable activity & sleep tracker.
79327021|NCT03066479|Other|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
79810945|NCT00681395|Drug|Rosuvastatin|Once daily for 6 days
79482475|NCT04714073|Drug|Itraconazole|Itraconazole
79810946|NCT02633579|Drug|erythromycin lactobionate|intravenous administration of erythromycin
79810947|NCT02633579|Drug|Atropine|intravenous administration of atropine
79978676|NCT04262180|Other|Base intervention-Fitbit with EHR integration|Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal
79978677|NCT04262180|Other|Coaching Calls|Non-responders to base intervention will be randomized to coaching calls.
79978678|NCT04262180|Other|Online Gym|Non-responders to base intervention will be randomized to online gym.
79648325|NCT05371652|Drug|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
79810948|NCT02633579|Drug|Erythromycin with atropine|intravenous administration of erythromycin with saline
79810949|NCT02633579|Drug|Saline|intravenous administration of saline
79810950|NCT00685529|Drug|Racemic formoterol|12 µg of racemic formoterol fumarate BID
79810951|NCT00685529|Drug|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
79810952|NCT00685529|Drug|Racemic formoterol|24 µg of racemic formoterol fumarate BID
79327022|NCT03066479|Diagnostic Test|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
79327023|NCT03066791|Dietary Supplement|Turmeric tablets|
79327024|NCT03066791|Dietary Supplement|Curcumin and Bioperine tablets|
79327025|NCT03066791|Dietary Supplement|Placebo tablets|
79327026|NCT03066869|Drug|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
79482476|NCT04342676|Device|k ras|K ras
79482477|NCT04342676|Drug|Panitumumab|vectibex in stage iv
79482478|NCT04269629|Drug|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
79648326|NCT05367661|Drug|CHK336|Tablet
79648327|NCT05367661|Drug|Placebo|Tablet
79810953|NCT02633345|Dietary Supplement|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
79810954|NCT02633345|Dietary Supplement|Placebo|Placebo tablets
79810955|NCT00594659|Behavioral|Psychotherapy|Nine session treatment
79810956|NCT00594659|Behavioral|Computerized Psychotherapy|Nine session computer delivered treatment
79810957|NCT00594659|Behavioral|Motivational enhancement therapy|Two session treatment
79327027|NCT04200131|Diagnostic Test|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
79327028|NCT05729633|Other|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~Diagonal movement~Shoulder abduction~Shoulder adduction~Shoulder flexion~Shoulder extension~Elbow flexion~Elbow extension~Task-specific training will focus on the following activities:~Picking up a cup/glass by the side and drink~Brushing hair~Cleaning unaffected upper limb (hand to arm)~Wiping table~Wiping wall~Sliding card on table to a designated location~Clipping a clothe peg"
79482479|NCT01641822|Drug|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
79482480|NCT01641822|Drug|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
79482481|NCT01641822|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
79482482|NCT04250987|Device|SpeediCath(R)|IC SpeediCath ® connected to pressure sensor
79978679|NCT04261439|Drug|NIZ985|NIZ985 injection
79978680|NCT04261439|Drug|Spartalizumab|Spartalizumab infusion
79978681|NCT04261439|Drug|Tislelizumab|Tislelizumab infusion
79327029|NCT05729555|Drug|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
79482483|NCT05651100|Biological|CD19 and CD22 targeted CAR-T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
79482484|NCT04393844|Other|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
79482485|NCT05645094|Drug|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
79482486|NCT04393532|Device|Su2ura Approximation Device|the use of the study device during a laparoscopic surgery
79978682|NCT04257318|Other|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
79978683|NCT04256993|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
79978684|NCT04256993|Drug|Other standard care|Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
79978685|NCT04254289|Behavioral|Usual Care|Usual care
79978686|NCT04254289|Behavioral|Home-based exercise program|Home-based program determined by exercise physiologist
79482487|NCT04393532|Procedure|Laparoscopic hernia repair surgery|repairing primary umbilical hernia in a laparoscopic procedure using the study device.
79482488|NCT03507569|Drug|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
79810958|NCT00685607|Drug|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
79482489|NCT03507569|Other|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer [11C]Ro15-4513.
79327030|NCT05729555|Drug|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON & JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON & JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
79327031|NCT01603459|Drug|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
79327032|NCT03066245|Biological|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
79327033|NCT03066323|Other|Rice with tea extract|Rice with tea extract
79327034|NCT03066323|Other|Rice without tea extract|Rice without tea extract
79482490|NCT03508661|Other|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 &7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
79482491|NCT05358990|Other|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
79482492|NCT05358990|Other|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
79978687|NCT04251624|Behavioral|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
79978688|NCT04251624|Behavioral|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
79327035|NCT05424185|Behavioral|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
79327036|NCT02926027|Drug|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
79327037|NCT02926027|Drug|placebo|placebo
79327038|NCT05037305|Other|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
79327039|NCT03136003|Drug|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
79482493|NCT04871958|Device|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
79482494|NCT04342598|Other|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
79648328|NCT05355909|Procedure|Individualized high intensity preoperative fitness training|The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
79327040|NCT03136003|Behavioral|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
79327041|NCT03798353|Combination Product|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
79327042|NCT03798353|Procedure|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
79327043|NCT04962685|Other|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
79327044|NCT05410847|Drug|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
79327045|NCT04540939|Behavioral|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
79482495|NCT03645785|Dietary Supplement|Normal fluid intake without true lemon|16.9oz water with True Lemon
79482496|NCT03645785|Dietary Supplement|Double fluid intake plus 3 bottles of water with True Lemon|No intervention
79482497|NCT00360854|Drug|erlotinib hydrochloride|
79978689|NCT04251052|Procedure|Bilateral Salpingectomy|Undergo bilateral salpingectomy
79978690|NCT04251052|Procedure|Bilateral Salpingectomy with Oophorectomy|Undergo bilateral salpingo-oophorectomy
79978691|NCT04251052|Procedure|Biospecimen Collection|Undergo blood sample collection
79327046|NCT04540939|Behavioral|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
79482498|NCT00360854|Genetic|mutation analysis|
79482499|NCT00360854|Genetic|polymorphism analysis|
79482500|NCT00360854|Other|laboratory biomarker analysis|
79482501|NCT00360854|Other|pharmacological study|
79482502|NCT00360854|Radiation|radiation therapy|
79648329|NCT05342896|Behavioral|MIND diet|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines.
79810959|NCT00685607|Drug|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
79810960|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
79810961|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
79810962|NCT00912431|Drug|ABT-126|ABT-126 administered on Day 1 of Period 1
79327047|NCT04750291|Drug|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
79327048|NCT04750291|Other|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
79327049|NCT04708951|Device|ENDOCUFF VISION® device|ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
79482503|NCT05650944|Diagnostic Test|Hemogram|Sysmex XN-1000 hematological analyzer
79482504|NCT04783220|Behavioral|Comprehensive structured parent intervention|"Educational sessions and coaching on infants' behavior cues~Skills on motor stimulation~Written instructions for play and stimulation activities at discharge~Multidisciplinary follow-up~Developmental tracking and advice via a mobile app"
79482505|NCT03511001|Other|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
79482506|NCT04035356|Device|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
79482507|NCT03647033|Device|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
79482508|NCT04778930|Other|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
79810963|NCT00912431|Drug|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
79978692|NCT04251052|Other|Quality-of-Life Assessment|Ancillary studies
79978693|NCT04251052|Other|Questionnaire Administration|Ancillary studies
79978694|NCT04251052|Procedure|Transvaginal Ultrasound|Undergo transvaginal ultrasound
79978695|NCT04232553|Drug|Mirikizumab|Administered IV
79978696|NCT04232553|Drug|Mirikizumab|Administered SC
79978697|NCT04230668|Behavioral|Cognitive Processing Therapy with Suicide Risk Management|CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
79978698|NCT04230668|Behavioral|Treatment as Usual with Suicide Rick Management|In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
79978699|NCT04226547|Device|Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)|Implantation of an Amplatzer Amulet left atrial appendage occluder
79978700|NCT04226547|Drug|Non-Vitamin K Oral Antagonists|Initiation or continuation of a NOAC drug
79978701|NCT04225715|Drug|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
79327050|NCT04708951|Device|G-EYE® colonoscope|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
79327051|NCT03726749|Drug|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
79978702|NCT04225715|Drug|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
79978703|NCT04225715|Drug|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
79978704|NCT04225715|Drug|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
79978705|NCT04225715|Drug|PEG-IFN|PEG-IFN will be administered subcutaneously
79327052|NCT03726749|Drug|Prednisone|Prednisone is an anti-inflammatory medication
79327053|NCT04593745|Device|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
79327054|NCT03821077|Biological|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
79327055|NCT03756337|Device|Neuro 1 & Neuro 2|participant common fitting map used for tests
79327056|NCT03756337|Device|Neuro 2 & Neuro 1|participant common fitting map used for tests
79327057|NCT03066713|Other|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
79327058|NCT03066713|Other|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
79978706|NCT04225715|Drug|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
79978707|NCT04221490|Device|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
79978708|NCT04219969|Drug|Fludeoxyglucose F-18|Given IV
79327059|NCT03066713|Other|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
79978709|NCT04219969|Device|Magnetic Resonance Imaging|Undergo PET-MRI
79327060|NCT03066713|Other|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
79482509|NCT04778930|Other|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
79810964|NCT04161365|Procedure|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
79810965|NCT04161365|Procedure|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
79978710|NCT04219969|Procedure|Positron Emission Tomography|Undergo PET-MRI
79978711|NCT04213209|Drug|Brentuximab Vedotin (Genetical Recombination)|Brentuximab Vedotin Intravenous Infusion
79978712|NCT04211610|Diagnostic Test|Blood and urine sampling|"Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
79327061|NCT03066557|Procedure|TACE and Apatinib|TACE and Apatinib 250mg po qd
79327062|NCT03066557|Procedure|TACE|TACE
79327063|NCT04574401|Drug|IS-002|Intravenous injection of IS-002 Investigational Drug
79810966|NCT00657059|Drug|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( < 5 g NaCl/day), and then given a stable dose (150mg ~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
79978713|NCT04203303|Other|Observational|Observational
79327064|NCT05729087|Behavioral|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
79482510|NCT04871022|Procedure|Double layer closure of the hysterotomy|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
79482511|NCT04871022|Procedure|Purse closure of the hysterotomy|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
79978714|NCT04189679|Other|Immune signature in serum associated to the metabolic signature|Immune signature in serum associated to the metabolic signature
79978715|NCT04189679|Genetic|Meta-genomic signature of intestinal flora|Meta-genomic signature of intestinal flora
79327065|NCT05308667|Other|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
79482512|NCT05314205|Procedure|ligation of inter-sphincteric fistula tract|"The surgical treatment was achieved through identification of the fistula by injecting hydrogen peroxide (H2O2) through the external opening. Probing of the fistulous tract by a metallic probe for proper identification of the fistula in the inter-sphincteric plane.~Perpendicular skin incision (about 1 cm) was done at inter-sphinctric zone, perpendicular to the fistulous tract. Dissection between the internal and external sphincters and identification of the fistula.~Finally, Ligation and transection of the tract in inter-sphinctric space followed by excision of a segment and transferred for histopathology examination. Trans-fixation suture was applied near to the internal mucosal opening of the divided tract to confirm closure using polyglactin suture 2/0. Insertion of a probe to check the closure of the tract segments.~The remaining part of the tract was curetted till external opening and left for spontaneous healing."
79482513|NCT04362254|Drug|Spesolimab|Spesolimab
79482514|NCT03511937|Behavioral|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
79482515|NCT03511937|Other|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
79482516|NCT05641818|Other|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
79327066|NCT05308667|Other|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
79648330|NCT05342896|Behavioral|Mind diet plus Forest Bathing|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines. Forest Bathing will be another session per week, 2 hours forest bathing sessions on 4-consecutive weekends in a country park at daytime with sunny, cloudy or drizzling conditions. The walking distance for each forest bathing is one to two kilometres. The coach-to-participant ratio is approximately 1:16. Participants will then be required to self-practice 2h FB in the country park at daytime at the weekends of 8th week and 12th week of the intervention.
79648331|NCT05332483|Drug|Megestrol Acetate|Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
79648332|NCT05330507|Other|Wellinks|"30-day post-discharge period: virtual respiratory therapist sessions twice per week with synchronous virtual pulmonary rehabilitation and educational materials; at-home use of connected spirometer and pulse oximeter; at-home use of mobile app.~12-week intensive period: virtual health coaching sessions once every two weeks; asynchronous virtual pulmonary rehabilitation program; ongoing access to connected devices (spirometer and pulse oximeter) and mobile app."
79327067|NCT05728931|Biological|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
79327068|NCT05737927|Drug|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
79327069|NCT05737927|Drug|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
79327070|NCT05737927|Drug|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
79978716|NCT04187898|Biological|Eflapegrastim|"Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
79327071|NCT05737927|Drug|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
79648333|NCT05326165|Device|Juzo Compression Sleeve and Glove|Elasticized garment sized for arm and hand to create pressure to reduce swelling
79648334|NCT05326165|Device|Compression Sleeve Sensor|Small device embedded within compression sleeve garment collecting usage information
79648335|NCT05301192|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
79648336|NCT05301192|Drug|Saline|Saline will be used as the placebo comparator.
79648337|NCT05296512|Drug|Lenvatinib|Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
79648338|NCT05296512|Drug|Pembrolizumab|"Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib."
79327072|NCT05737927|Drug|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
79327073|NCT05737927|Drug|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
79327074|NCT04152967|Device|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
79327075|NCT04152967|Device|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
79327076|NCT05737771|Drug|DWC202213|DWC202213
79327077|NCT05737771|Drug|DWJ1563|DWJ1563
79327078|NCT05737771|Drug|DWP16001|DWP16001
79327079|NCT05728697|Device|Endoscopic ultrasound shear wave elastography|To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
79327080|NCT04477135|Other|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
79327081|NCT04477135|Procedure|ultrasonography|ultrasonography
79327082|NCT05737537|Diagnostic Test|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
79978717|NCT04187898|Biological|Eflapegrastim|"Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
79978718|NCT04187898|Biological|Eflapegrastim|"Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
79978719|NCT04187898|Biological|Eflapegrastim|Administered in Cycles 1-4, 30 mins after TC chemotherapy.
79978720|NCT04187898|Drug|Docetaxel|"75 mg/m^2 IV infusion.~Administered on Day 1 of each cycle."
79978721|NCT04187898|Drug|Cyclophosphamide|"600 mg/m^2 IV infusion.~Administered on Day 1 of each cycle."
79978722|NCT04186871|Drug|branebrutinib|Specified dose on specified days
79978723|NCT04186871|Drug|abatacept|Specified dose on specified days
79978724|NCT04186871|Drug|branebrutinib placebo|Specified dose on specified days
79327083|NCT05737303|Drug|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
79327084|NCT03066089|Drug|Fenfuro|
79327085|NCT04648501|Other|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
79327086|NCT04647565|Other|interviews|interviews (human and social sciences)
79327087|NCT03066167|Other|Validation of different dysphagia scores|
79327088|NCT04599049|Other|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
79327089|NCT03065699|Device|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
79327090|NCT03065855|Procedure|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
79978725|NCT04186546|Device|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
79978726|NCT04182087|Behavioral|Cognitive tasks|Attention, language, memory, decision-making or executive functions
79978727|NCT04180176|Other|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
79978728|NCT04163081|Behavioral|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
79978729|NCT04158154|Other|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
79978730|NCT04150783|Procedure|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
79978731|NCT04149951|Device|Vestal Device|Vestibular nerve stimulator
79978732|NCT04149951|Device|Placebo device|Sham nerve stimulator
79327091|NCT03065855|Procedure|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
79327092|NCT01678807|Biological|MK-8237 6 DU|
79327093|NCT01678807|Biological|MK-8237 12 DU|
79327094|NCT01678807|Biological|Placebo|
79327095|NCT05188313|Drug|Trastuzumab|Intravenous administration of study drug
79327096|NCT05188313|Drug|Pertuzumab|Intravenous administration of study drug
79327097|NCT05188313|Drug|Paclitaxel|Intravenous administration of study drug
79327098|NCT05188313|Drug|Carboplatin|Intravenous administration of study drug
79327099|NCT04540315|Behavioral|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
79327100|NCT03065777|Device|ONE ENDO|single file rotary system
79327101|NCT03065777|Device|F6 SKYTaper|single file rotary system
79327102|NCT03065777|Device|ProTaper Universal|multi-file rotary system
79327103|NCT04310137|Behavioral|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
79978733|NCT04145622|Drug|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
79978734|NCT04145349|Drug|Ramucirumab|Administered IV
79978735|NCT04145349|Drug|Cyclophosphamide|Administered orally
79978736|NCT04145349|Drug|Vinorelbine|Administered IV
79327104|NCT02514655|Device|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
79327105|NCT02514655|Other|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
79327106|NCT03066011|Drug|Isavuconazonium sulfate|Oral and Intravenous
79327107|NCT03066011|Drug|Voriconazole|Oral and Intravenous
79327108|NCT03066011|Drug|Posaconazole|Oral and intravenous
79327109|NCT03135769|Drug|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
79327110|NCT03781297|Other|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
79327111|NCT03781297|Other|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
79327112|NCT05539313|Device|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
79327113|NCT05728463|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
79327114|NCT03123211|Drug|Veliparib|Veliparib will be administered orally.
79327115|NCT05736991|Diagnostic Test|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
79482517|NCT05641584|Other|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
79978737|NCT04140526|Drug|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
79978738|NCT04140526|Drug|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
79327116|NCT05527457|Drug|BAY2586116|160 μg BAY2586116 nasal spray application
79327117|NCT05527457|Drug|Placebo|Placebo (saline) nasal spray application
79327118|NCT04096807|Other|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
79482518|NCT05640258|Diagnostic Test|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
79482519|NCT00361478|Behavioral|Exercise and education|Weekly exercise and education program for 8 weeks
79482520|NCT00361478|Behavioral|Education|Written educational material
79978739|NCT04134923|Drug|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer [11C] PIB. Participants will then undergo a [11C] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
79482521|NCT04018118|Biological|Biological sample|Additional blood samples for biobanking
79482522|NCT01641198|Device|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
79810967|NCT00657059|Drug|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
79978740|NCT04130997|Biological|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
79327119|NCT05520749|Drug|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
79327120|NCT05092243|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
79327121|NCT03609697|Behavioral|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
79327122|NCT03609697|Behavioral|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
79482523|NCT01641198|Device|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
79482524|NCT01641198|Device|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
79482525|NCT02975414|Procedure|rTARUP technique|obot-assisted rTARUP technique
79482526|NCT04214951|Drug|Eltrombopag|Patients will be given eltrombopag 50mg once daily for 6 weeks.
79482527|NCT04214951|Drug|Recombinant human thrombopoietin (rh-TPO)|Patients will be given rh-TPO 300 U/kg once daily for 21 days.
79978741|NCT04128839|Dietary Supplement|Aronia berry juice|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.
79327123|NCT03073525|Biological|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
79327124|NCT03073525|Drug|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
79327125|NCT05728307|Device|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
79327126|NCT02563015|Dietary Supplement|cholecalciferol|liquid drops
79327127|NCT02563015|Dietary Supplement|Reference 400|liquid drops
79327128|NCT02382445|Device|Anesthesia depth monitor|
79327129|NCT02382445|Device|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
79327130|NCT02382445|Drug|propofol and sevoflurane|
79327131|NCT05094973|Device|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
79327132|NCT02875535|Behavioral|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
79327133|NCT05736757|Drug|Tissue Plasminogen Activator|Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
79327134|NCT04483817|Device|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
79327135|NCT04483817|Device|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
79482528|NCT04012814|Device|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
79327136|NCT05733481|Device|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
79648339|NCT05290857|Other|Restart DOAC within 7 days of clinical hemostasis after GI bleeding|"In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator"
79978742|NCT04128839|Other|Sham comparator|The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
79978743|NCT04128761|Behavioral|Scarcity Narrative|Participants are presented with a hypothetical scarcity narrative and asked to listen and consider the scenario.
79327137|NCT05732233|Device|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
79327138|NCT05092087|Behavioral|nutrition counseling|nutrition counseling
79327139|NCT04413643|Device|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 >45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
79978744|NCT04128761|Behavioral|Neutral Narrative|Participants are presented with a hypothetical neutral narrative and asked to listen and consider the scenario.
79978745|NCT04122742|Procedure|skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
79327140|NCT05094583|Behavioral|Use of SmokeFree app|Intervention Arm
79327141|NCT05091775|Drug|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
79327142|NCT05091541|Drug|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection|CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
79978746|NCT04122742|Other|Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
79327143|NCT05376085|Drug|DA-5215 Tab|"single oral administration of 1 tablet of DA-5215 Tab with 150mL water"
79327144|NCT05376085|Drug|DA-5215-R Tab|"single oral administration of 1 tablet of DA-5215-R Tab with 150mL water"
79327145|NCT04821869|Drug|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
79327146|NCT04821869|Device|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
79327147|NCT05091463|Device|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
79327148|NCT05091385|Biological|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
79327149|NCT02631551|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
79327150|NCT02631551|Drug|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
79327151|NCT02631551|Drug|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
79327152|NCT02631551|Drug|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
79327153|NCT05094193|Procedure|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
79327154|NCT05094193|Procedure|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
79327155|NCT05094193|Procedure|Trocar site infiltration placebo|20 mL of normal saline
79327156|NCT05094193|Procedure|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
79327157|NCT03037255|Other|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
79327158|NCT05093725|Device|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
79327159|NCT05721911|Genetic|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
79327160|NCT04165811|Other|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
79327161|NCT04165811|Other|Counselling|Only physical activity counseling will be given to the subjects in this group.
79327162|NCT05091151|Drug|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
79327163|NCT04752917|Device|Noise Cancelling headphones|Use of headphones playing patients choice of music
79327164|NCT05377021|Behavioral|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
79327165|NCT05093257|Diagnostic Test|Laboratory investigations for control|"Complete blood picture .~Erythrocyte sedimentation rate(ESR).~Liver function tests .~Kidney function tests.~CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
79810968|NCT00657059|Drug|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
79810969|NCT00667732|Drug|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
79482529|NCT04770506|Other|Data extraction from medical files|Data extraction from medical files
79327166|NCT05093257|Diagnostic Test|Laboratory investigations for patients|"Complete blood picture .~Erythrocyte sedimentation rate(ESR).~Liver function tests .~Kidney function tests.~Anti-nuclear antibodies test by immunoflourescence for ITP patients.~Bone marrow aspiration (for diagnosis of ITP).~CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
79327167|NCT05093179|Procedure|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
79327168|NCT05093179|Procedure|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
79327169|NCT04626167|Procedure|Concomitant Renal and Urinary Bladder Allograft Transplantation|This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
79327170|NCT04538989|Drug|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
79327171|NCT04538989|Drug|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
79327172|NCT04538989|Drug|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
79327173|NCT04538989|Drug|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
79327174|NCT05704907|Other|gallbladder ultrasound|gallbladder ultrasound
79327175|NCT05093023|Genetic|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G>A and 3435 G>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
79327176|NCT04413175|Other|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
79482530|NCT05637918|Other|Group 1 (Patients who recorded as Grade 0)|When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
79482531|NCT05637918|Other|Group 2 ( Patients who recorded as Grade 1)|When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
79327177|NCT05092867|Other|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
79482532|NCT04762082|Drug|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
79482533|NCT03514277|Drug|Exparel|1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
79482534|NCT03514277|Drug|Bupivacaine|30 mL bupivacaine 0.5% w/v solution
79482535|NCT04861740|Other|Autism ALERT|Autism Access Link for Early Referral and Treatment [ALERT], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
79482536|NCT04861740|Other|Screening Intervention|Autism screening intervention only.
79810970|NCT00667732|Drug|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
79810971|NCT04161209|Drug|Citalopram|Single dose administration of citalopram (20mg)
79810972|NCT04161209|Other|Placebo|Lactose placebo tablet
79810973|NCT00767962|Other|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
79482537|NCT04227119|Device|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
79810974|NCT00767962|Other|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
79327178|NCT05421689|Biological|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 62 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
79327179|NCT05421689|Other|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
79810975|NCT04161053|Drug|Rifaximin|Rifaximin 550 mg twice daily for 6 months
79810976|NCT04161053|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily for 6 months
79327182|NCT05663333|Other|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
79327183|NCT04447469|Drug|mavrilimumab|anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
79327184|NCT04447469|Other|Placebo|matching placebo
79327185|NCT04447235|Drug|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
79327186|NCT04447235|Drug|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
79327187|NCT04447235|Drug|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
79978747|NCT04122742|Other|Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
79978748|NCT04122742|Other|Functional involvement of identified epigenetic alterations|Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
79978749|NCT04122742|Biological|Culture of lymphoblastoid line from blood sample|Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
79978750|NCT04121312|Behavioral|Facilitation Intervention|"See arm description"
79327188|NCT01680991|Drug|Obinutuzumab|Multiple doses of obinutuzumab.
79327189|NCT01700569|Drug|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
79978751|NCT04116853|Behavioral|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
79327190|NCT01700569|Drug|folinic acid at pharmacological dose is the escalated drug|
79327191|NCT01700569|Radiation|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
79327192|NCT05095675|Behavioral|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
79327193|NCT04442867|Other|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
79327194|NCT04442867|Other|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
79327195|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
79327196|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
79810977|NCT00777010|Other|Ketogenic diet|carbohydrate restricted diet
79327197|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
79327198|NCT05084443|Dietary Supplement|Drink|Roselle and placebo drink for 6 months
79327199|NCT03064529|Device|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
79327200|NCT05608109|Behavioral|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
79978752|NCT04116853|Behavioral|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
79978753|NCT04113811|Device|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
79327201|NCT05608109|Behavioral|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
79327202|NCT04139057|Drug|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
79327203|NCT04127903|Other|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
79810978|NCT00777010|Other|Healthy high carbohydrate diet|higher carbohydrate diet
79978754|NCT04111939|Other|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
79978755|NCT04111939|Other|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
79327204|NCT03065309|Drug|Remifentanil|bolus dose
79327205|NCT02819479|Drug|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
79810979|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
79810980|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
79810981|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
79810982|NCT00685841|Drug|Salmeterol MDI|Salmeterol MDI 42 mcg BID
79810983|NCT00685841|Drug|Placebo|Placebo BID MDI
79810984|NCT04145609|Behavioral|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
79810985|NCT00681785|Drug|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
79810986|NCT04139759|Other|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
79327206|NCT02819479|Drug|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery."
79327207|NCT05095285|Other|Swaddling|"Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~Common procedure steps:~Legal representatives of the infants will sign an informed consent form.~İncubator cover and nesting~Endotracheal suction(ES) was performed in the supine position.~ES was done at the time of care the baby needed.~No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~Aspiration was performed sterile at 80 mmHg pressure.~A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
79327208|NCT05095285|Other|Oropharyngeal colostrum|"Common procedure steps~In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
79327209|NCT04081025|Other|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
79327210|NCT05376943|Drug|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
79482538|NCT04227119|Device|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
79482539|NCT04861428|Other|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
79482540|NCT04861428|Other|Smoking as Usual|Cigarette smoking
79482541|NCT03651479|Other|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
79482542|NCT03651479|Other|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
79482543|NCT05334108|Drug|Ecopipam|ecopipam HCl ~2mg/kg/day
79482544|NCT05334108|Combination Product|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
79482545|NCT05334108|Drug|Cohort 2 Probe Substrate|bupropion
79482546|NCT05334108|Combination Product|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
79810987|NCT04139759|Other|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
79327211|NCT04074785|Drug|Abemaciclib|Abemaciclib 150 mg po bid
79482547|NCT04342832|Procedure|Cryoballoon ablation|If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
79810988|NCT00671788|Drug|Dasatinib|Given orally
79810989|NCT00671788|Other|Laboratory Biomarker Analysis|Correlative studies
79810990|NCT02626481|Drug|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
79810991|NCT02626481|Drug|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
79810992|NCT00779818|Device|Electrical acupuncture|Treatment by electrical acupuncture
79810993|NCT00779818|Device|Laser|Treatment by laser
79810994|NCT00777166|Drug|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
79327212|NCT04074785|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
79327213|NCT04533841|Drug|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
79327214|NCT04533841|Drug|Placebo|placebo
79327215|NCT04533841|Drug|Propranolol|Propranolol
79327216|NCT04537663|Drug|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
79327217|NCT04537663|Drug|Placebo|Intradermal injection of sterile 0.9% NaCl.
79648340|NCT05290857|Other|Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding|"In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team."
79648341|NCT05287269|Diagnostic Test|Ocular Coherence Tomography|OCT images were recorded as a fast macular radial line scan with captured on either Heidelberg Spectralis (Heidelberg Engineering GmbH, Germany) or Topcon DRI Triton (Topcon Medical Systems inc. USA).
79327218|NCT04536805|Drug|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
79327219|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
79327220|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
79327221|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
79327222|NCT05376865|Dietary Supplement|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
79327223|NCT04064411|Combination Product|abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
79327224|NCT04064411|Combination Product|abaloparatide solid microstructured transdermal system|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
79327225|NCT05086159|Behavioral|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
79482548|NCT04419792|Other|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
79648342|NCT05246839|Behavioral|Brief Video|Videos about colorectal cancer screening.
79648343|NCT05246839|Behavioral|Brief Video Plus|Videos about colorectal cancer screening and modalities.
79810995|NCT00777166|Drug|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
79810996|NCT00681941|Drug|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
79327226|NCT05086159|Behavioral|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
79327227|NCT05086159|Behavioral|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
79810997|NCT02557906|Procedure|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
79327228|NCT05085223|Other|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
79327229|NCT05085223|Other|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
79327230|NCT03064997|Dietary Supplement|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
79327231|NCT03064997|Dietary Supplement|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
79327232|NCT05083663|Drug|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
79327233|NCT05082415|Drug|Brolucizumab|Participants received brolucizumab injection during the index period
79327234|NCT05050825|Other|Patient clinical management based on the CDSA strategy|The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
79327235|NCT04012931|Drug|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
79327236|NCT04012931|Drug|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine [AZT], abacavir [ABC], tenofovir alafenamide [TAF], or tenofovir disoproxil fumarate [TDF] in combination with emtricitabine [FTC] or lamivudine [3TC]), whichever are approved and marketed or considered local standard of care for children aged between 2 and < 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir [DTG] or raltegravir) can also be administered in combination with RPV, as appropriate.
79810998|NCT02557906|Procedure|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
79810999|NCT02557906|Procedure|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
79327237|NCT05331287|Other|Head position|Influence of different head position on nasal endotracheal intubation
79327238|NCT03063359|Drug|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
79811000|NCT00657137|Drug|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
79327239|NCT03063359|Drug|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
79327240|NCT02629133|Behavioral|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
79811001|NCT00657137|Drug|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
79648344|NCT05244525|Drug|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
79648345|NCT05244525|Drug|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
79327241|NCT02660359|Biological|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
79811002|NCT00777244|Drug|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
79811003|NCT04160819|Other|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
79327242|NCT02660359|Biological|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79327243|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79648346|NCT05220358|Drug|Fostemsavir 600 MG [Rukobia]|FTR 600 mg PO BID added to daily suppressive HIV regimen
79811004|NCT04160897|Drug|Entecavir|entecavir naive for chronic hepatitis B patients
79482549|NCT03984656|Drug|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
79482550|NCT03984656|Drug|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~anterior serratus large muscle (serratus anterior)~intercostal muscle~4th and 5th ribs~pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
79482551|NCT03653351|Device|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
79648347|NCT05206955|Drug|Tadalafil|10 mg once daily orally week 1, 20 mg once daily orally during week 2, and 40 mg once daily orally during weeks 3 through 52
79648348|NCT05206955|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient
79648349|NCT05197829|Device|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
79648350|NCT05197829|Other|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
79648351|NCT05186311|Device|Capillary Blood Collection System|Test Blood Sample Collection
79811005|NCT04160897|Drug|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
79978756|NCT04104659|Drug|MK 6240|"PET tracer, [18F]MK-6240 (an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for [18F]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
79978757|NCT04100694|Drug|MCLA-128|
79327244|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79327245|NCT03063281|Other|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
79327246|NCT05287373|Device|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
79978758|NCT04100018|Biological|Nivolumab|Specified dose on specified days
79327247|NCT05287373|Other|conventional medical management|Conventional medical management
79978759|NCT04100018|Drug|Prednisone|Specified dose on specified days
79978760|NCT04100018|Drug|Docetaxel|Specified dose on specified days
79978761|NCT04100018|Other|Placebo|Specified dose on specified days
79978762|NCT04097561|Biological|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
79327250|NCT04626505|Drug|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
79327251|NCT04626505|Drug|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
79327252|NCT05276609|Drug|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
79327253|NCT05276609|Drug|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
79327254|NCT04909099|Other|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
79327255|NCT05068297|Other|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
79978763|NCT04094844|Other|Wearable activity sensor|Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.
79482552|NCT03653351|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
79482553|NCT03966248|Other|Chinese Tuina therapy|"The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~Massage the spleen and stomach meridians of the affected lower extremes;~Roll the soft tissues around the affected knee;~Relax the gastrocnalis muscle~The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~Push the patella and do the passive movement of the affected knee;~Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
79482554|NCT03966248|Other|Physical Manual therapy|"Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~Activity training: Mainly about the knee joint flexion and extension movement training.~Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
79482555|NCT03515681|Behavioral|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
79482556|NCT03655301|Drug|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
79482557|NCT03655301|Drug|Metformin|Single dose of 1000 mg is administered orally.
79482558|NCT04318106|Device|Precision tinted spectacle lenses|Precision tinted spectacles lenses (Cerium Technologies TM)
79482559|NCT04342988|Drug|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
79648352|NCT05182112|Radiation|Whole liver irradiation (WLI)|Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.
79648353|NCT05182112|Drug|Gemcitabine and Cisplatin|Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
79978764|NCT04094844|Behavioral|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets
79327256|NCT05068297|Other|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
79327257|NCT05067985|Procedure|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
79327258|NCT02672761|Behavioral|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
79327259|NCT02672761|Behavioral|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
79482560|NCT05279430|Behavioral|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
79482561|NCT04304846|Other|Questionnaires and interviews|List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
79978765|NCT04094844|Other|Survey administration|Caregivers and patients will be asked to respond to survey questions at 3 timepoints.
79327260|NCT02672761|Behavioral|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
79482562|NCT04291898|Device|AMPLATZER™ Septal Occluder.|Implantation of the AMPLATZER™ Septal Occluder in the ASD.
79482563|NCT04291898|Device|Occlutech Figulla Flex II®|Implantation of the Occlutech Figulla Flex II® in the ASD.
79482564|NCT04291898|Device|GORE® CARDIOFORM ASD Occluder|Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
79482565|NCT05634018|Diagnostic Test|aneurysmectomy with sampling of a segment of the aneurysm wall|"Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively.~In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample.~The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used."
79482566|NCT04740476|Drug|STK-001|STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
79482567|NCT05630586|Drug|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
79482568|NCT05630586|Other|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
79482569|NCT04870866|Drug|Nicotinamide ribonucleoside|Two year intervention
79482570|NCT04262102|Behavioral|SD_SF|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
79482571|NCT04262102|Behavioral|SD_BLW|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
79482572|NCT04262102|Behavioral|HFV_SF|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
79482573|NCT04262102|Behavioral|HFV_BLW|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
79648354|NCT05175248|Behavioral|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
79648355|NCT05173012|Drug|SAGE-324|SAGE-324 oral tablets.
79648356|NCT05173012|Drug|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
79648357|NCT05166213|Other|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
79327261|NCT02672761|Behavioral|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
79327262|NCT04449913|Behavioral|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
79327263|NCT04449913|Behavioral|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
79327264|NCT04262869|Drug|Carboplatin|Given IV
79327265|NCT04262869|Biological|Durvalumab|Given IV
79327266|NCT04262869|Drug|Paclitaxel|Given IV
79327267|NCT04262869|Drug|Pemetrexed|Given IV
79327268|NCT02628743|Drug|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
79327269|NCT05254613|Drug|ALXN1830|ALXN1830 will be administered as SC infusion(s).
79327270|NCT05254613|Drug|Placebo|Placebo will be administered as SC infusion(s).
79648358|NCT05162053|Drug|vicagrel Capsules|Oral administration for 7 days under fasting
79648359|NCT05162053|Drug|Clopidogrel Tablets|Oral administration for 7 days under fasting
79648360|NCT05154201|Drug|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
79327273|NCT04682821|Other|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
79327274|NCT03062813|Drug|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
79482574|NCT05620758|Other|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
79482575|NCT05620758|Other|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
79327275|NCT03062813|Drug|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
79327276|NCT05088577|Dietary Supplement|Whole egg|Daily consumption of two whole eggs during 8 weeks
79482576|NCT05620758|Other|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
79482577|NCT05620758|Other|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
79482578|NCT05620758|Other|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
79327277|NCT05088577|Dietary Supplement|Annatto-enriched egg|Daily consumption of two whole eggs enriched with annatto during 8 weeks
79327278|NCT05088577|Dietary Supplement|Egg whites - Control|Daily consumption of two eggs whites during 8 weeks
79327279|NCT04942327|Behavioral|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
79327280|NCT04601311|Behavioral|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
79327281|NCT04601311|Behavioral|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
79327282|NCT04582981|Drug|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
79327283|NCT04582981|Drug|Fruquintinib|Fruquintinib 5mg qd monotherapy
79327284|NCT03760627|Behavioral|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
79327285|NCT03760627|Behavioral|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
79978766|NCT04094844|Behavioral|Roadmap 2.0 information system with Positive Activities|Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.
79648361|NCT05149898|Drug|ZYN002|"CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~Patients who weigh > 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD."
79327286|NCT03579667|Behavioral|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
79327287|NCT03278821|Behavioral|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
79327288|NCT03278821|Behavioral|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
79648362|NCT05138341|Device|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
79327289|NCT04873427|Genetic|clonal heterogeneity evaluation|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
79978767|NCT04084574|Behavioral|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
79978768|NCT04069026|Drug|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
79978769|NCT04069026|Drug|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
79978770|NCT04058366|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
79978771|NCT04058366|Drug|IVA|Tablet for oral administration.
79978772|NCT04050007|Other|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
79327290|NCT04862741|Drug|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
79327291|NCT04862741|Drug|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
79327292|NCT04862741|Drug|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
79327293|NCT04862741|Drug|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
79327294|NCT04683055|Procedure|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
79327295|NCT04683055|Procedure|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
79327296|NCT02508493|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST)~Choice Reaction Time (CRT)~One-back working memory tool~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
79327297|NCT02508493|Other|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~Digit Symbol Substitution Test (DSST)~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~Variant of Choice Reaction Time (CRT)~Variant of the One-back working memory tool"
79327298|NCT04613089|Other|Natural History|Natural History and Clinical Follow Up.
79327299|NCT05098639|Behavioral|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
79327300|NCT05098639|Behavioral|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
79327301|NCT04469179|Biological|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
79327302|NCT04469179|Other|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
79327303|NCT04437121|Other|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
79978773|NCT04050007|Other|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
79978774|NCT04049760|Drug|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
79648363|NCT05125380|Diagnostic Test|VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)|A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.
79978775|NCT04046913|Behavioral|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
79327304|NCT04531579|Drug|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
79327305|NCT04531579|Drug|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
79978776|NCT04044937|Drug|F-18 Fluoroethyltyrosine (FET)|Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
79978777|NCT04044937|Procedure|Positron Emission Tomography (PET)|All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
79327306|NCT04362085|Drug|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
79482579|NCT02976506|Behavioral|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
79482580|NCT02976506|Behavioral|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
79482581|NCT04852614|Diagnostic Test|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
79482582|NCT02976662|Procedure|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
79648364|NCT05125380|Diagnostic Test|VIA (Visual Inspection with Acetic acid)|A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
79648365|NCT05110443|Other|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
79978778|NCT04036058|Other|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
79327307|NCT04354597|Drug|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
79327308|NCT04413409|Procedure|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
79327309|NCT05375461|Drug|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
79327310|NCT05375461|Drug|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
79327311|NCT05375461|Drug|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
79327312|NCT05097781|Drug|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
79327313|NCT05374213|Behavioral|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
79327314|NCT03062969|Procedure|Cleavage stage biopsy group|"intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~Time lapse embryo culture~Cleavage stage biopsy~aCGH analysis~Fresh euploid embryo transfer"
79327315|NCT03062969|Procedure|Trophectoderm biopsy group|"ICSI-IVF~Time lapse embryo culture~Day 3 zona pellucida opening~Trophectoderm biopsy~aCGH analysis~Frozen-thawed euploid embryo transfer"
79978779|NCT04031716|Behavioral|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
79978780|NCT04030455|Drug|Carboplatin|Given IV
79327316|NCT04245475|Behavioral|Virtual Reality psychological pain reduction|attention distraction
79327317|NCT05097547|Behavioral|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
79648366|NCT05109494|Radiation|Conventional Fractionated|50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive > 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.
79811006|NCT00777322|Procedure|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
79978781|NCT04030455|Drug|Cisplatin|Given IV
79978782|NCT04030455|Drug|Docetaxel|Given IV
79978783|NCT04030455|Biological|Pembrolizumab|Given IV
79327318|NCT03987139|Other|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
79482583|NCT03657407|Drug|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
79482584|NCT03657407|Drug|Glycerin Suppository|Glycerine rectal suppository
79648367|NCT05109494|Radiation|Hypofractionated|27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive > 97% of the prescribed dose
79648368|NCT05087680|Behavioral|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
79648369|NCT05087680|Behavioral|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
79978784|NCT04022980|Drug|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
79811007|NCT03874624|Diagnostic Test|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
79327319|NCT03987139|Other|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
79327320|NCT03987139|Other|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
79327321|NCT01117441|Drug|PEG-L-asparaginase|see detailed protocol description
79327322|NCT01117441|Drug|cyclophosphamide|see detailed protocol description
79327323|NCT01117441|Drug|cytarabine|see detailed protocol description
79327324|NCT01117441|Drug|daunorubicin hydrochloride|see detailed protocol description
79482585|NCT04243772|Other|Data extraction|Data extraction from medical files
79811008|NCT00682019|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
79978785|NCT04021108|Drug|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
79978786|NCT04008706|Drug|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
79978787|NCT03999983|Other|Observational Prospective Registry|This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
79327325|NCT01117441|Drug|dexamethasone|see detailed protocol description
79327326|NCT01117441|Drug|doxorubicin hydrochloride|see detailed protocol description
79327327|NCT01117441|Drug|etoposide|see detailed protocol description
79327328|NCT01117441|Drug|ifosfamide|see detailed protocol description
79327329|NCT01117441|Drug|mercaptopurine|see detailed protocol description
79327330|NCT01117441|Drug|methotrexate|see detailed protocol description
79327331|NCT01117441|Drug|prednisone|see detailed protocol description
79327332|NCT01117441|Drug|thioguanine|see detailed protocol description
79327333|NCT01117441|Drug|vincristine sulfate|see detailed protocol description
79327334|NCT01117441|Drug|vindesine|see detailed protocol description
79327335|NCT01117441|Drug|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
79327336|NCT01117441|Drug|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
79327337|NCT01117441|Radiation|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
79482586|NCT01639560|Drug|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
79482587|NCT01639560|Drug|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
79482588|NCT04243616|Drug|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
79482589|NCT04243616|Drug|Paclitaxel|80 mg/m^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
79482590|NCT04243616|Drug|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
79648370|NCT05073458|Drug|parsaclisinib|parsaclisib will be administered QD orally
79648371|NCT05073458|Drug|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
79648372|NCT05068102|Drug|BI 765063|BI 765063
79648373|NCT05068102|Drug|Ezabenlimab|Ezabenlimab
79648374|NCT05068102|Drug|[89Zr]Zr- BI 765063|[89Zr]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
79648375|NCT05068102|Drug|BI 770371|BI 770371
79648376|NCT05068102|Drug|[89Zr]Zr- BI 770371|[89Zr]Zr- BI 770371, specifically radiolabelled for immune-PET
79978788|NCT03997123|Drug|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
79327338|NCT04829123|Drug|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
79327339|NCT04829123|Drug|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
79327340|NCT05177159|Other|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
79327341|NCT05177159|Other|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
79327342|NCT05177159|Other|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
79978789|NCT03997123|Drug|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
79482591|NCT04243616|Drug|Doxorubicin|60 g/m^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
79482592|NCT04243616|Drug|Cyclophosphamide|600 g/m^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
79482593|NCT04209335|Other|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
79482594|NCT00361556|Behavioral|The Back Book|A book on how to prevent back pain
79482595|NCT00361556|Behavioral|The Back Guide|A guide for the prevention of back pain.
79482596|NCT00361556|Behavioral|General health book|A book on general health
79482597|NCT04205669|Drug|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
79482598|NCT01601652|Drug|Omegaven|1 g/kg/d iv infusion over 24h
79327343|NCT03939949|Behavioral|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
79327344|NCT03939949|Behavioral|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
79327345|NCT03939949|Behavioral|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
79327346|NCT04434599|Device|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
79327347|NCT04434599|Device|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
79327348|NCT04434599|Device|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
79327349|NCT01101451|Drug|Cisplatin|Given IV
79327350|NCT01101451|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
79327351|NCT01101451|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
79327352|NCT01101451|Other|Laboratory Biomarker Analysis|Correlative studies
79327353|NCT01101451|Other|Quality-of-Life Assessment|Ancillary studies
79327354|NCT01101451|Other|Questionnaire Administration|Ancillary studies
79327355|NCT03064919|Behavioral|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
79327356|NCT03656627|Drug|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
79327357|NCT04773665|Biological|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
79327358|NCT04773665|Biological|Placebo|0.9% sodium chloride
79327359|NCT04773665|Biological|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
79327360|NCT03064607|Other|Fluid collection|Fluids tested for biomarker S100beta
79327361|NCT04759703|Drug|Pramipexole|0.25 mg pramipexole tablets
79482599|NCT03516227|Behavioral|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
79482600|NCT03520283|Other|Interview|Ancillary studies
79482601|NCT03520283|Other|Questionnaire Administration|Ancillary studies
79482602|NCT03520283|Behavioral|System Support Mapping|Complete MAP
79811009|NCT00682019|Drug|Placebo|matching placebo
79978790|NCT03997123|Drug|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
79978791|NCT03995953|Behavioral|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for family members to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
79327362|NCT04759703|Drug|Placebo|Matching placebo tablets
79327363|NCT03595787|Procedure|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
79327364|NCT05087407|Procedure|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
79327365|NCT05087407|Procedure|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
79327366|NCT05086003|Combination Product|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
79327367|NCT05084131|Other|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
79978792|NCT03995953|Other|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
79327368|NCT05026801|Drug|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
79648377|NCT05056831|Behavioral|Behavioral Intervention|Attend face-to-face mind-body sessions
79327369|NCT03063047|Other|PD21871AA|A 100s size menthol cigarette.
79327370|NCT03063047|Other|PD21872AA|A 100s size menthol cigarette.
79327371|NCT05020795|Procedure|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
79327372|NCT03062735|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
79648378|NCT05056831|Other|Best Practice|Receive usual care
79811010|NCT00779896|Drug|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
79978793|NCT03992131|Drug|Rucaparib|Rucaparib will be administered per schedule specified in the arm description.
79978794|NCT03992131|Drug|Lucitanib|Lucitanib will be administered per schedule specified in the arm description.
79978795|NCT03992131|Drug|Sacituzumab govitecan|Sacituzumab govitecan will be administered per schedule specified in the arm description.
79978796|NCT03969004|Drug|Cemiplimab|Intravenous (IV) infusion over 30 minutes
79648379|NCT05056831|Other|Informational Intervention|Receive targeted text messages
79648380|NCT05056831|Other|Quality-of-Life Assessment|Ancillary studies
79811011|NCT00682097|Drug|RO4998452|Escalating oral doses
79978797|NCT03969004|Drug|Placebo|Intravenous (IV) infusion over 30 minutes
79978798|NCT03955445|Drug|LNP023|LNP023 capsules
79648381|NCT05056831|Other|Questionnaire Administration|Ancillary studies
79811012|NCT00682097|Drug|placebo|Oral doses
79648382|NCT04992637|Behavioral|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity & Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
79648383|NCT04992637|Other|Usual Care|Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
79978799|NCT03955029|Other|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if <6, increase by 5 watt the value of each peak at the next session).
79327373|NCT03062735|Other|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
79327374|NCT03818659|Other|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
79482603|NCT05107440|Other|BREATHE|A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
79482604|NCT05590494|Procedure|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
79482605|NCT04186481|Device|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
79482606|NCT03952130|Drug|LY900014|Administered SC
79482607|NCT03952130|Drug|Insulin Lispro|Administered SC
79482608|NCT03952130|Drug|Insulin Glargine|Administered SC
79482609|NCT03952130|Drug|Insulin Degludec|Administered SC
79482610|NCT03661541|Drug|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
79482611|NCT03661697|Device|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
79482612|NCT03661697|Other|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
79482613|NCT03661697|Other|Lytera|cosmeceutical serum applied to face daily for 12 weeks
79482614|NCT02975648|Behavioral|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
79482615|NCT02975648|Behavioral|usual care|Hospital health professionals offered orientation on care after discharge
79482616|NCT05575362|Other|Group A|Group A will receive Epleys maneuver and Cawthorne Cooksey exercise for two weeks.
79482617|NCT05575362|Other|Group B|Group B will receive Half Somersault maneuver along with Cawthorne Cooksey exercise for two weeks.
79482618|NCT04735133|Device|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
79482619|NCT03925532|Biological|Denosumab|Given SC
79482620|NCT04851912|Other|Winterlight Apps|Longitudinal speech recordings
79648384|NCT04979546|Other|Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|"Baseline, 6 months, and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group."
79811013|NCT02556268|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
79482621|NCT03922490|Device|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
79648385|NCT04979546|Other|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist|"Baseline and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."
79648386|NCT04979052|Drug|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
79648387|NCT04978350|Behavioral|Educational Workbook|"Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?"
79811014|NCT02556268|Drug|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
79978800|NCT03955029|Other|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if <6, increase by 5 watt the value of each peak at the next session)
79978801|NCT03953612|Drug|PREG 300/500 mg|2 doses of PREG (300/500 mg/day)
79978802|NCT03953612|Drug|Placebos|placebo
79978803|NCT03946878|Drug|Acalabrutinib|Given PO
79327375|NCT03818659|Other|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
79811015|NCT02556268|Drug|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
79811016|NCT02556268|Drug|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
79811017|NCT02556268|Drug|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
79978804|NCT03946878|Drug|Venetoclax|Given PO
79978805|NCT03946202|Drug|Hydrogen Peroxide|Hydrogen Peroxide
79978806|NCT03943004|Drug|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
79978807|NCT03921905|Diagnostic Test|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
79978808|NCT03914664|Diagnostic Test|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
79978809|NCT03914664|Diagnostic Test|Autonomic function testing procedure|Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
79978810|NCT03907397|Biological|Peanut Protein|up to 9043 mg
79978811|NCT03903835|Drug|Enzalutamide Oral Capsule|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
79978812|NCT03903835|Drug|Abiraterone Oral Tablet|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
79327376|NCT03789877|Other|Physical Activity|Participate in home-based walking program
79327377|NCT03789877|Other|Questionnaire Administration|Ancillary studies
79327378|NCT03789877|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
79327379|NCT03789877|Procedure|Sham Intervention|Undergo sham rTMS
79327380|NCT03786991|Other|No intervention|No intervention
79482622|NCT03922490|Procedure|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
79482623|NCT04242680|Device|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
79482624|NCT04242680|Device|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
79327381|NCT03943693|Device|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
79327382|NCT03943693|Device|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
79327383|NCT03493061|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
79327384|NCT03493061|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
79482625|NCT04242680|Device|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
79482626|NCT04242680|Behavioral|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
79482627|NCT04680260|Other|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
79482628|NCT04680260|Other|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
79648388|NCT04947475|Behavioral|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
79327385|NCT03493061|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
79327386|NCT03410017|Other|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
79327387|NCT04110613|Dietary Supplement|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
79327388|NCT03516877|Behavioral|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
79327389|NCT04800523|Device|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
79482629|NCT01640964|Drug|Terlipressin acetate|IV bolus injection
79482630|NCT01640964|Drug|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
79648389|NCT04934683|Procedure|Routine blood pressure control|Routine blood pressure control.
79648390|NCT04934683|Procedure|Tight blood pressure control|Tight blood pressure control.
79648391|NCT04934683|Drug|Etomidate|Anesthetic induction with etomidate.
79648392|NCT04934683|Drug|Propofol|Anesthetic induction with propofol.
79648393|NCT04928482|Behavioral|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
79327390|NCT04654897|Drug|[14C]-NT-814|120 mg radioactive labeled elinzanetant ([14C]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) [14C].
79327391|NCT03236077|Behavioral|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
79327392|NCT04554043|Drug|SHR7280|treatment
79327393|NCT04554043|Drug|Placebo oral tablet|blank control
79327394|NCT04523935|Other|Placebo|Fructose powder identical with the drugs was used
79482631|NCT04343066|Device|Implant insertion|"In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking < 10 cigarettes, previous horizontal bone augmentation, FMBS <20% and FMPS < 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis."
79482632|NCT03663101|Drug|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
79482633|NCT03663101|Biological|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
79978813|NCT03903835|Drug|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x [GFR ml/min + 25].
79978814|NCT03903835|Drug|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
79327395|NCT04523935|Drug|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
79978815|NCT03903835|Drug|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
79327396|NCT05059301|Biological|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
79327397|NCT03450473|Device|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
79327398|NCT01938430|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
79327399|NCT01938430|Drug|RBV|RBV tablets administered orally in a divided daily dose
79327400|NCT01937884|Drug|Parenteral Nutrition|
79482634|NCT03663101|Drug|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
79978816|NCT03903835|Drug|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
79978817|NCT03903835|Drug|Niraparib plus Abiraterone acetate plus Prednisone|Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
79978818|NCT03903835|Drug|Capivasertib plus Docetaxel|Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
79327401|NCT04625530|Drug|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
79327402|NCT04625530|Drug|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
79327403|NCT04625530|Drug|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
79482635|NCT03663101|Drug|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
79482636|NCT05430048|Drug|nasal Desmopressin|compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
79482637|NCT02975570|Drug|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
79482638|NCT02975570|Drug|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
79327404|NCT01916824|Drug|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
79327405|NCT01915732|Drug|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
79327406|NCT01915732|Drug|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
79327407|NCT04635436|Other|Pathologic group|"Participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without hanging to any support. The test sequence will be the following:~Baseline phase. 3 minutes walking at increasing speed from 0.2 m s-1 to 0.6 m s-1, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~Habituation phase. 30 seconds walking at 0.2 m s-1.~Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
79327408|NCT04634968|Behavioral|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
79327409|NCT04634968|Behavioral|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
79327410|NCT04634266|Device|Transcatheter tricuspid valve treatment (TTVT)|Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
79327411|NCT01936948|Procedure|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
79327412|NCT01936870|Drug|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
79327413|NCT01618864|Device|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
79327414|NCT01618708|Device|Synvisc-One (hylan G-F 20)|6-mL IA injection
79327415|NCT01618708|Device|Placebo|6 mL injection of phosphate buffered saline
79327416|NCT04434521|Behavioral|Questionnaire|Questionnaire about habits in terms of near vision activities
79327417|NCT04434521|Other|Eye examination|"The eye examination involves the following measurements:~Distant vision phoria with Thorington method~Close vision with Thorington method~Objective eye-to-eye refraction with self-refractometer~Binocular objective refraction with autorefractometer~Monocular/biocular/binocular refraction with Nidek TS610~SiView automatic refraction~Humphriss binocular refraction~MOU Binocular refraction"
79327418|NCT04615234|Device|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
79648394|NCT04928482|Behavioral|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
79648395|NCT04920344|Procedure|Transoral Surgery|Patients will undergo transoral surgery
79648396|NCT04920344|Radiation|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
79648397|NCT04920344|Drug|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
79648398|NCT04920344|Procedure|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
79648399|NCT04920344|Other|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
79811018|NCT02556268|Drug|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
79648400|NCT04920344|Other|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
79811019|NCT00682175|Other|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
79978819|NCT03903835|Drug|Apalutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
79978820|NCT03903835|Drug|Darolutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
79327419|NCT03315455|Drug|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
79327420|NCT03064139|Behavioral|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
79327421|NCT03064139|Behavioral|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
79327422|NCT02229149|Drug|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
79327423|NCT02229149|Drug|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
79327424|NCT02229149|Drug|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
79327425|NCT03259295|Device|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
79327426|NCT04871399|Procedure|Conventional Right hemicolectomy (Non-CME)|Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
79482639|NCT02975570|Drug|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
79482640|NCT02975570|Drug|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
79648401|NCT04920344|Other|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
79648402|NCT04920344|Other|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
79811020|NCT00780052|Drug|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
79978821|NCT03884543|Procedure|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
79978822|NCT03881098|Procedure|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
79648403|NCT04920344|Diagnostic Test|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
79327427|NCT04871399|Procedure|Right hemicolectomy with CME+CVL|"Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance."
79327428|NCT04432025|Procedure|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
79327429|NCT04432025|Procedure|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
79327430|NCT04867889|Device|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
79482641|NCT02975570|Drug|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
79978823|NCT03881098|Procedure|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
79482642|NCT05230602|Dietary Supplement|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
79482643|NCT05428644|Behavioral|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
79482644|NCT05220384|Behavioral|In-person Motivational Interview combined with Self-Management techniques|"This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date."
79648404|NCT04888000|Other|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
79648405|NCT04887688|Device|exciflex|untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
79648406|NCT04885634|Drug|Semaglutide Injectable Product|Subcutaneous injection of Semaglutide 2.4 mg once weekly
79648407|NCT04885634|Drug|Placebo|Subcutaneous injection of volume-matched placebo once weekly
79811021|NCT00780130|Other|No Intervention|male & female college students ages 20 to 50, asymptomatic normals
79978824|NCT03881098|Procedure|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
79978825|NCT03875144|Procedure|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
79978826|NCT03875144|Drug|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
79978827|NCT03875144|Drug|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
79978828|NCT03873870|Diagnostic Test|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
79978829|NCT03858530|Diagnostic Test|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
79978830|NCT03857256|Drug|CP105F|Natural Health Product
79978831|NCT03857256|Drug|Placebo|tablet manufactured to mimic the CP105F beta-glucan
79978832|NCT03856528|Other|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
79327431|NCT04867889|Device|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
79327432|NCT04440371|Combination Product|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
79327433|NCT04440371|Combination Product|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
79327434|NCT04430543|Behavioral|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
79327435|NCT04430543|Behavioral|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
79327436|NCT02087267|Procedure|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
79327437|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
79327438|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
79327439|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
79327440|NCT04432649|Biological|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
79648408|NCT04882579|Diagnostic Test|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~Deep venous ultrasound assessing presence of a deep venous thrombus~Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
79978833|NCT03850691|Drug|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
79978834|NCT03850691|Drug|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
79978835|NCT03850691|Drug|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
79978836|NCT03850691|Drug|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
79978837|NCT03847857|Biological|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
79327441|NCT03125447|Other|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
79327442|NCT04602923|Diagnostic Test|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
79327443|NCT04602923|Diagnostic Test|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
79327444|NCT04432805|Device|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
79327445|NCT04982939|Drug|Sintilimab|Sintilimab, 200mg IV d1 Q3W
79978838|NCT03847857|Procedure|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
79978839|NCT03840902|Drug|M7824|Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
79978840|NCT03840902|Drug|Placebo|Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
79327446|NCT04982939|Drug|S-1|S-1, 40-60mg BID d1-14 Q3W
79327447|NCT04982939|Drug|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
79327448|NCT04982549|Drug|Durvalumab|Durvalumab (intravenous infusion)
79327449|NCT04982549|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
79327450|NCT04982549|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
79327451|NCT04982549|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
79327452|NCT04982549|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
79327453|NCT04982627|Behavioral|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
79327454|NCT04982627|Behavioral|OUD Education & Treatment Resources|The OUD Education & Treatment Resources intervention is a web application that provides OUD education and treatment resources.
79327455|NCT03064061|Device|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
79327456|NCT04981691|Biological|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
79327457|NCT03062423|Drug|Sofodelevier|1 tablet contains 400 mg sofosbuvir
79648409|NCT04876846|Device|GEN 3 Monitoring of Fetus|"Measurement of tissue light scatter in the body in body during late term pregnancy and evaluation of signal integrity"
79327458|NCT03062423|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
79327459|NCT03062423|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
79327460|NCT00790933|Drug|Vedolizumab|Vedolizumab intravenous infusion
79327461|NCT04981457|Drug|Misoprostol and iso sorbide mononitrates|drug
79648410|NCT04874285|Dietary Supplement|HA|hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
79327462|NCT02161211|Behavioral|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
79327463|NCT02161211|Behavioral|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
79978841|NCT03840902|Drug|Durvalumab|Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
79978842|NCT03840902|Drug|Etoposide|Participants received etoposide 50 mg/m^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
79327464|NCT02161211|Behavioral|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
79327465|NCT01676701|Drug|Tabalumab Auto-Injector|Administered SC by auto-injector
79327466|NCT01676701|Drug|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
79327467|NCT04981379|Drug|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
79327468|NCT04981379|Drug|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo [Hydroxychloroquine (200 mg)], as two tablets per day for 5-day interval.
79327469|NCT04981379|Drug|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
79327470|NCT04981379|Drug|Placebo|Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
79811022|NCT02626637|Other|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
79327471|NCT04389775|Drug|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
79811023|NCT00780286|Device|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
79811024|NCT00780286|Device|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
79811025|NCT00875615|Drug|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
79811026|NCT00875615|Drug|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
79811027|NCT00875615|Drug|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
79327472|NCT04389775|Drug|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
79327473|NCT04389775|Drug|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~Subject to change following SRC review of each cohort.~Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
79327474|NCT04389775|Drug|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~Subject to change following SRC review of each cohort.~Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
79482645|NCT05220384|Behavioral|Video-based Motivational Interview combined with Self-Management techniques|"This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date."
79482646|NCT03907748|Other|Music Intervention|After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).
79811028|NCT00768352|Other|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
79811029|NCT02626559|Drug|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
79811030|NCT00780520|Dietary Supplement|alanine-glutamine infusion|
79978843|NCT03840902|Drug|Pemetrexed|Participants received pemetrexed at a dose of 500 mg/m^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
79978844|NCT03840902|Drug|Carboplatin|Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
79978845|NCT03840902|Drug|Paclitaxel|Participants received paclitaxel intravenously at a dose of 45 mg/m^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
79978846|NCT03840902|Drug|Cisplatin|In combination with etoposide, participants received cisplatin 50 mg/m^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
79327475|NCT05375383|Dietary Supplement|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79327476|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79327477|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79327478|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79327479|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
79811031|NCT00682409|Other|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
79811032|NCT00777400|Drug|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
79327480|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
79327481|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
79482647|NCT03907748|Other|Reading Intervention|After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
79482648|NCT05369520|Device|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
79327482|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
79482649|NCT05369520|Device|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
79327483|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79327484|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79327485|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79811033|NCT04143737|Behavioral|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
79811034|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
79811035|NCT00768508|Drug|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
79811036|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
79978847|NCT03840902|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray [Gy]).
79978848|NCT03839446|Drug|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
79978849|NCT03837821|Drug|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
79327486|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79327487|NCT03062501|Drug|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
79327488|NCT02987803|Other|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
79327489|NCT02102789|Drug|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
79327490|NCT02102789|Drug|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
79327491|NCT02998879|Drug|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
79327492|NCT02926651|Drug|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
79327493|NCT02926651|Drug|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
79327494|NCT04305145|Drug|Infliximab|Infusion
79327495|NCT04305145|Drug|Methylprednisolone|Infusion
79327496|NCT04305145|Drug|Prednisone|Orally
79327497|NCT04248673|Other|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
79327498|NCT04248673|Other|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
79327499|NCT01670279|Drug|Brexpiprazole|up to 3mg oral dose once daily
79327500|NCT01670279|Drug|Placebo|
79327501|NCT04226677|Other|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
79327502|NCT04226677|Other|Video based exercise|Exergame training include virtual reality games by xbox kinect.
79327503|NCT04226677|Other|Control group|first and last evaluations will be made
79327504|NCT03062579|Drug|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
79327505|NCT04188145|Drug|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
79327506|NCT04188145|Drug|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
79327507|NCT04981769|Diagnostic Test|Covid-19 test|PCR Covid-19 test
79327508|NCT04532125|Biological|ARGX-117|Subjects treated with ARGX-117
79811037|NCT00768508|Other|Placebo + Cognitive Behavioral Therapy|Placebo comparator
79811038|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
79811039|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
79811040|NCT00777478|Drug|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
79327509|NCT04532125|Other|Placebo|Subjects treated with placebo
79327510|NCT04532125|Biological|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
79327511|NCT04532125|Other|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
79327512|NCT04532125|Biological|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
79327513|NCT04532125|Other|Placebo PH20 SC|Subjects treated with placebo PH20 SC
79327514|NCT04980989|Device|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
79327515|NCT04102813|Behavioral|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
79327516|NCT03063983|Drug|Cyclophosphamide|Continuous oral cyclophosphamide
79811041|NCT04143425|Diagnostic Test|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
79327517|NCT03063983|Drug|Methotrexate|Continuous oral methotrexate
79327518|NCT03945721|Drug|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
79327519|NCT03945721|Radiation|Radiation Therapy|radiation therapy
79327520|NCT01876355|Drug|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
79327521|NCT01876355|Drug|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
79327522|NCT03943303|Radiation|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
79327523|NCT03943303|Radiation|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
79327524|NCT03062345|Other|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
79327525|NCT03062345|Other|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
79327526|NCT02747407|Biological|Hepatitis A Vaccine|
79327527|NCT02747407|Other|Laboratory Biomarker Analysis|Correlative studies
79327528|NCT02747407|Biological|Tetanus Toxoid Vaccine|
79978850|NCT03832595|Other|EHR-based PHM|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every ~6 months,~Medication therapy management: PharmD led telephonic medication therapy management with the patient every ~6 months,~and Nurse led CKD patient education, every ~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
79327529|NCT02747407|Biological|Trivalent Influenza Vaccine|
79327530|NCT01870193|Dietary Supplement|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
79327531|NCT04531501|Diagnostic Test|Saliva and NPS test|N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
79327532|NCT03063905|Drug|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
79811042|NCT04143425|Diagnostic Test|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
79327533|NCT04432415|Device|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
79978851|NCT03832595|Other|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
79978852|NCT03820986|Biological|Pembrolizumab|IV infusion
79327534|NCT04432415|Device|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
79327535|NCT04432415|Device|Placebo|biannual application of artificial saliva
79327536|NCT05331937|Combination Product|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
79327537|NCT02627495|Device|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
79327538|NCT05095753|Device|Earbud|In ear headphone with embedded infrasonic hemodynography technology
79327539|NCT04980755|Other|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
79327540|NCT03485053|Drug|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
79327541|NCT02356939|Device|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
79327542|NCT02356939|Procedure|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
79327543|NCT01670045|Drug|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
79482650|NCT03524339|Drug|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
79482651|NCT03524339|Drug|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
79482652|NCT03895112|Drug|AVID200|dose cohorts of 21-day cycles
79978853|NCT03820986|Drug|Lenvatinib|Oral capsule
79978854|NCT03820986|Drug|Placebo for lenvatinib|Oral capsule
79978855|NCT03819088|Dietary Supplement|Zinc|Given PO
79978856|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
79978857|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
79482653|NCT05440370|Device|MegaCarti®|MegaCarti® application after microfracture through athroscopic or incision surgery
79482654|NCT05440370|Procedure|Microfracture|Microfracture through athroscopic or incision surgery
79327544|NCT05102461|Dietary Supplement|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
79327545|NCT05102461|Dietary Supplement|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
79327546|NCT05375227|Other|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
79327547|NCT04980131|Device|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
79327548|NCT04980131|Device|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
79648411|NCT04870619|Other|High Intensity Gait Training|The intervention provided in this project is routinely delivered as a standard of care at the participating sites for patients after stroke that have a goal of walking improvement. The intervention consists of 45-60 minute, physical therapy sessions that occur five days per week (not weekends), focusing on prioritizing stepping practice at higher aerobic intensities during scheduled treatments (target training zone of 70-85% heart rate max (HRmax). Stepping is performed on treadmills and over ground, with safety harness systems and body weight support only as needed to ensure successful stepping. Tasks are progressed by increasing task difficulty as determined by the therapist. Accordingly, practice of non-walking tasks performed during physiotherapy, including bed mobility, transfers, and standing balance/ pre-gait activities, is limited.
79648412|NCT04862221|Drug|High-dose methylprednisolone|Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
79978858|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
79327549|NCT04974203|Device|AptameX|DNA aptamer-based test using patient's saliva
79327550|NCT05102227|Device|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
79327551|NCT03063671|Drug|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
79327552|NCT03063827|Drug|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
79327553|NCT03063827|Diagnostic Test|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
79327554|NCT05101837|Device|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
79327555|NCT04980209|Device|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
79327556|NCT03334201|Other|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
79327557|NCT03334201|Other|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
79327558|NCT01669421|Drug|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
79648413|NCT04862221|Drug|Equine anti-thymocyte globulin|Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
79978859|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
79327559|NCT03210571|Device|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
79327560|NCT05104021|Device|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
79327561|NCT05103865|Behavioral|Animal-assisted therapy (AAT)|
79327562|NCT05103865|Other|usual treatment|
79327563|NCT05103787|Procedure|deep parasternal intercostal plane block|Twenty milliliters of 0.25% bupivacaine will be placed bilaterally in the fascial plane between internal intercostal muscle and transversus thoracis muscle at intercostal space 4 or 5, lateral from sternum, with ultrasound guidance using high-frequency linear transducer.
79648414|NCT04862221|Drug|Prednisolone|"Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
79648415|NCT04862221|Drug|Placebo for prednisolone|"Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
79811043|NCT04143425|Diagnostic Test|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
79327564|NCT05103787|Procedure|control|Skin puncture with needle will be performed on the same location as the treatment group without administration of local anesthetics.
79327565|NCT03115021|Device|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
79327566|NCT03115021|Device|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
79327567|NCT03115021|Device|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
79327568|NCT03115021|Device|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
79327569|NCT04980053|Other|massage|Intervention group Control group
79327570|NCT04973969|Other|Decapeptyl|diagnosis of predictio value
79327571|NCT02961205|Dietary Supplement|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
79327572|NCT04979975|Other|Placebo|PBO- placebo matching to UB-621
79327573|NCT04979975|Biological|UB-621 low-dose|fully human anti-HSV mAb
79327574|NCT04979975|Biological|UB-621 high-dose|fully human anti-HSV mAb
79327575|NCT02958709|Drug|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
79327576|NCT02958709|Drug|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
79327577|NCT02958709|Drug|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
79327578|NCT04979663|Combination Product|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
79327579|NCT05307367|Behavioral|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
79327580|NCT04979819|Other|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
79327581|NCT04979585|Drug|Camrelizumab|200mg ,IV,d1,Q3W.
79327582|NCT04979585|Drug|Anlotinib|8mg,oral, d1-14,Q3W.
79327583|NCT04979585|Drug|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
79327584|NCT05101603|Device|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
79327585|NCT05101603|Device|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
79327586|NCT05101603|Procedure|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
79327587|NCT04400513|Device|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
79648416|NCT04862221|Drug|Placebo for infusions|Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
79648417|NCT04862221|Drug|Diphenhydramine|Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
79648418|NCT04862221|Drug|Methylprednisolone|Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
79648419|NCT04859699|Behavioral|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
79648420|NCT04855760|Drug|REL-1017|REL-1017 tablet
79648421|NCT04854434|Drug|Selinexor|Participants will receive selinexor oral tablets.
79978860|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
79648422|NCT04854434|Drug|Pembrolizumab|Participants will receive pembrolizumab intravenously.
79978861|NCT03807804|Biological|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
79327588|NCT02481817|Procedure|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
79327589|NCT02481817|Procedure|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
79648423|NCT04854434|Drug|Trifluridine|Participants will receive trifluridine oral tablets as SOC.
79648424|NCT04854434|Drug|Tipiracil|Participants will receive tipiracil oral tablets as SOC.
79978862|NCT03805269|Drug|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
79978863|NCT03805269|Drug|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
79327590|NCT02481817|Procedure|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
79327591|NCT04979741|Other|No interventions|Observational study, no intervention is required
79327592|NCT05103709|Other|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
79327593|NCT05103709|Other|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
79327594|NCT04979897|Other|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open [close] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
79327595|NCT05103553|Other|Outpatient Clinic|Follow-up in outpatient clinic
79327596|NCT04979195|Other|Patients with stable normal kidney function|Covid-19 patients with stable kidney function will represent group 1.
79327597|NCT04979195|Other|Patients with unstable kidney function|Covid-19 patients with unstable kidney function will represent group 2.
79811044|NCT00780598|Drug|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~120 mg for 6 months once daily, OR~240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
79648425|NCT04851535|Drug|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
79811045|NCT00780754|Drug|dutasteride|0.5mg
79811046|NCT00780754|Procedure|prostate biopsy|prostate biopsy
79811047|NCT02633423|Procedure|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
79811048|NCT02633423|Procedure|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
79811049|NCT02633423|Procedure|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
79978864|NCT03801902|Radiation|Accelerated Hypofractionated Radiation Therapy|160 Gy given as one 4 Gy fraction per day, 5 days per week for 15 fractions.
79978865|NCT03801902|Procedure|Biospecimen Collection|Undergo collection of blood samples
79978866|NCT03801902|Procedure|Computed Tomography|Undergo brain CT and chest CT
79978867|NCT03801902|Biological|Durvalumab|Administered intravenously (IV) as a 1500 mg fixed dose over 60 minutes for 13 cycles (1 cycle = 4 weeks), until disease progression or toxicity or death, whichever comes first.
79327598|NCT05101525|Procedure|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
79327599|NCT05103397|Drug|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
79327600|NCT05103397|Drug|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
79327601|NCT05103397|Drug|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
79327602|NCT05101447|Drug|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care [MMFBSA: 600 mg/m2/dose; max: 3 gram/day] or pharmacokinetically-driven precision dosing [MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg*h/L].
79327603|NCT05101291|Drug|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
79811050|NCT02633423|Procedure|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
79482655|NCT04201106|Behavioral|Open Label Placebo with Rationale|In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.
79482656|NCT04201106|Behavioral|Open Label Placebo without Rationale|In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
79811051|NCT00780832|Behavioral|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
79327604|NCT04342169|Drug|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
79482657|NCT04174313|Diagnostic Test|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 <100 despite the optimization of mechanical ventilation and prone positioning."
79482658|NCT00362024|Drug|MK0952|
79482659|NCT00362024|Drug|Comparator: Placebo|
79327605|NCT04342169|Drug|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
79811052|NCT00780832|Drug|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
79811053|NCT00597701|Drug|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
79811054|NCT00597701|Drug|Placebo|Placebo
79811055|NCT00597701|Drug|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
79327606|NCT05103163|Other|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
79978868|NCT03801902|Procedure|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
79327607|NCT04979273|Drug|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
79327608|NCT04979273|Drug|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
79811056|NCT02556658|Device|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
79811057|NCT02556658|Device|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
79978869|NCT03801902|Biological|Monalizumab|Administered IV as a 1500 mg fixed dose over 60 minutes (+/- 10 minutes)
79978870|NCT03801902|Biological|Oleclumab|Administered IV 3000 mg over 60 minutes (+/- 10 minutes)
79978871|NCT03801902|Radiation|Radiation Therapy|60 gy given as one 2 Gy fraction per day, 5 days per week for 30 fractions
79327609|NCT04979273|Procedure|argon plasma coagulation|Thermocoagulation
79482660|NCT03664193|Radiation|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
79648426|NCT04848090|Diagnostic Test|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
79811058|NCT02632955|Drug|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
79648427|NCT04829201|Procedure|functional septorhinoplasty or oropharyngeal/orthognathic surgery|obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
79811059|NCT02632955|Procedure|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
79648428|NCT04819464|Drug|Cenerimod|A single oral dose of 0.5 mg.
79648429|NCT04790253|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
79811060|NCT04048486|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
79811061|NCT04048486|Other|Physical development and General Health|Physical development and General health examination
79811062|NCT04048486|Other|Developmental Red flags|Developmental Red flags Questionnaires
79811063|NCT04160273|Diagnostic Test|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
79811064|NCT04048720|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
79811065|NCT00657293|Behavioral|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
79811066|NCT00657293|Behavioral|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
79327610|NCT04979273|Procedure|Hemoclip|Hemoclip
79327611|NCT05092555|Diagnostic Test|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
79327612|NCT05093881|Biological|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
79327613|NCT04973423|Radiation|MRI|2 additional MRI will be done for the CALM + MRI group
79327614|NCT05073991|Procedure|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
79648430|NCT04785989|Other|[U-13C]glucose|[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
79811067|NCT00780988|Biological|Autologous tumor cell + CpG vaccine|
79811068|NCT00780988|Procedure|Autologous hematopoietic and immune cell rescue (transplantation)|
79978872|NCT03779334|Drug|Risdiplam|Risdiplam will be administered orally.
79978873|NCT03778957|Drug|Durvalumab|Durvalumab IV (intravenous)
79978874|NCT03778957|Drug|Bevacizumab|Bevacizumab IV (intravenous)
79327615|NCT05073991|Procedure|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
79327616|NCT05073991|Procedure|TEVAR|Patients underwent TEVAR.
79327617|NCT05073991|Procedure|EVAR|Patients underwent EVAR.
79327618|NCT05099887|Biological|Procenta conformable barrier|Wound care dressing biologic allograft
79327619|NCT03061799|Dietary Supplement|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
79327620|NCT03061799|Dietary Supplement|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
79978875|NCT03778957|Other|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
79327621|NCT05036473|Drug|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
79327622|NCT05036473|Drug|Placebo|placebo tablets-matching the active groups.
79327623|NCT04979351|Other|Abdominal Massage|Abdominal massage will be applied twice a day.
79482661|NCT04668248|Other|Simulation|"The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns."
79648431|NCT04785989|Other|[13C5]glutamine|6mg/kg of body weight of [13C5]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
79978876|NCT03778957|Procedure|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
79978877|NCT03775486|Drug|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
79978878|NCT03775486|Drug|Placebo for Olaparib|Matching tablet
79327624|NCT04985851|Drug|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
79327625|NCT04985851|Drug|Durvalumab|durvalumab
79327626|NCT04929769|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
79482662|NCT04668248|Other|Online educational training|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.
79648432|NCT04784663|Behavioral|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
79648433|NCT04784663|Other|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
79648434|NCT04739826|Drug|Flumatinib Mesylate|Flumatinib mesylate tablets 600mg qd
79978879|NCT03775486|Drug|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
79978880|NCT03775486|Drug|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
79327627|NCT04929769|Other|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
79327628|NCT04930861|Drug|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
79327629|NCT04930861|Diagnostic Test|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
79327630|NCT04930861|Diagnostic Test|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
79978881|NCT03775486|Drug|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
79978882|NCT03775486|Drug|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
79978883|NCT03775486|Drug|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
79978884|NCT03775486|Drug|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
79978885|NCT03773965|Drug|Baricitinib|Administered orally.
79978886|NCT03763136|Biological|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
79327631|NCT04930861|Diagnostic Test|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
79327632|NCT04930861|Diagnostic Test|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
79327633|NCT04930861|Diagnostic Test|ECG|12-lead electrocardiogram with report.
79327634|NCT04930861|Diagnostic Test|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
79327635|NCT04930861|Diagnostic Test|NEWS-2 score|assessment of the participant by the NEWS-2 score.
79482663|NCT03526055|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
79482664|NCT00360932|Device|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
79482665|NCT05380050|Behavioral|Goal Management Training plus Attention Training|GMT is a Power Point directed interactive group training to use a five point strategy to plan and execute complex tasks. Attention Training utilizes Brain HQ attention modules and individualized attention goals.
79482666|NCT05380050|Behavioral|Brain Health Workshop and National Geographic Movies|BHW is a Power Point directed interactive training to learn about the brain and cognitive components. National Geographic Movies, participants select movies to watch with the therapists and answers questions regarding the content.
79482667|NCT03667547|Drug|Raltegravir|Raltegravir 600 mg tablet
79327636|NCT04930861|Diagnostic Test|WHO score|assessment of the participant by the score of the World Health Organization.
79327637|NCT04979507|Other|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
79327638|NCT05099575|Drug|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
79327639|NCT03061955|Biological|influenza vaccination|administration of influenza vaccination
79648435|NCT04739826|Drug|Nilotinib Pill|Nilotinib Capsules 300mg bid
79327640|NCT04979039|Other|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
79327641|NCT04919551|Drug|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
79327642|NCT03063515|Drug|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
79327643|NCT04907773|Other|Capillary blood sampling|Each subject will have one to two capillary blood collections.
79327644|NCT04907773|Other|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
79482668|NCT00361010|Drug|Levetiracetam|
79482669|NCT05060640|Procedure|Detection of anal HSIL in a routine colonoscopy.|Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.
79482670|NCT00361088|Drug|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
79648436|NCT04730583|Drug|Kybella|Injection into the cutaneous Neurofibromas lesion
79648437|NCT04730583|Device|1064nm laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
79811069|NCT02535455|Behavioral|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
79648438|NCT04730583|Device|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
79978887|NCT03762655|Device|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
79482671|NCT00361088|Drug|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
79648439|NCT04728451|Behavioral|Spectacle wear support|Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
79648440|NCT04728451|Device|Spectacles|Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
79327645|NCT04907773|Other|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
79327646|NCT04973813|Behavioral|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
79327647|NCT04973813|Behavioral|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
79327648|NCT04973813|Behavioral|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
79327649|NCT04973813|Behavioral|Guideline (G)|Web-based information about the national physical activity guideline.
79978888|NCT03742102|Drug|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
79978889|NCT03742102|Drug|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
79327650|NCT04894981|Device|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
79327651|NCT04894981|Device|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
79327652|NCT04894981|Device|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
79482672|NCT02975726|Device|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
79978890|NCT03742102|Drug|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
79978891|NCT03742102|Drug|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
79327653|NCT04894981|Device|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
79482673|NCT02975726|Procedure|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
79482674|NCT02975726|Biological|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
79482675|NCT02975726|Procedure|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
79648441|NCT04713046|Biological|CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10^6 CD4+ cells/kg; 2) 5 x 10^6 CD4+ cells/kg; or 3) 10^7 CD4+ cells/kg of recipient ideal body weight.
79327654|NCT04973501|Behavioral|Manual physiotherapeutic correction (MFK) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
79327655|NCT04973501|Behavioral|Dynamic Neuromuscular Stabilization (DNS) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
79327656|NCT04858945|Behavioral|Teach-back method|During the trial, women from teach-back group and controlled group will receive three education sessions The topics discussed at the first session included delivery mode, labor process and pain relief, newborn health and care (common health issues and care skills), perinatal die and excises, and perinatal psychological health. The topics discussed at the second session includ postpartum recovery, postpartum maternal health, perineum care (diet, oral care, perineal care, and hygiene), breastfeeding, postpartum blue and depression, neonatal care, neonatal screening tests, newborn vaccination and early child development. At two-week postpartum, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
79327657|NCT04973735|Drug|LY-CovMab|single IV infusion
79327658|NCT04973579|Procedure|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
79327659|NCT04834063|Diagnostic Test|Serum Zinc a level|Diagnostic test
79327660|NCT04834063|Diagnostic Test|serum selenium level|Diagnostic test
79327661|NCT04834063|Diagnostic Test|Fibroscan measurement|Diagnostic test
79482676|NCT04160975|Behavioral|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
79811070|NCT02556034|Other|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
79978892|NCT03742102|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
79978893|NCT03742102|Drug|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
79978894|NCT03729609|Drug|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
79327662|NCT04978961|Behavioral|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
79327663|NCT04978961|Behavioral|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
79327664|NCT04794205|Drug|Low Dose Beta-Caryophyllene|5 mg BCP
79327665|NCT04794205|Drug|Medium Dose Beta-Caryophyllene|30 mg BCP
79327666|NCT04794205|Drug|High Dose Beta-Caryophyllene|150 mg BCP
79327667|NCT04794205|Drug|Placebo|Placebo drug.
79327668|NCT04973033|Drug|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
79327669|NCT04436653|Device|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
79482677|NCT04172402|Drug|TS-1|Intervention is administered to patients in this Arm.
79482678|NCT04172402|Drug|Gemcitabine|Intervention is administered to patients in this Arm.
79482679|NCT04172402|Drug|Nivolumab|Intervention is administered to patients in this Arm.
79811071|NCT04031573|Drug|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
79978895|NCT03729401|Drug|Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily|DAPT with aspirin and ticagrelor
79978896|NCT03729401|Drug|Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily|Ticagrelor monotherapy
79978897|NCT03729401|Drug|Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily|Personalized therapy based on risk score and genotyping
79482680|NCT04153409|Drug|LAT8881|Two 30 mg capsules of LAT8881
79648442|NCT04713046|Biological|Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16|Standard dosing for bone marrow graft (target dose of 4 x 10^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
79648443|NCT04692831|Combination Product|89Zr-ss-pertuzumab PET/CT|Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
79327670|NCT02660281|Radiation|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
79327671|NCT02660281|Drug|Fludarabine|Fludarabine
79648444|NCT04677387|Behavioral|Nalox-comm Training Module|The online communication module will be 30-60 minutes. Content will include: 1) using non-judgmental language, 2) how to raise the topic of overdose (OD) and naloxone with patients in a non-threatening manner; 3) videos modeling how to initiate the conversation with patients and caregivers; 4) considerations in how to communicate differently with patients versus caregivers; and 5) addressing pharmacists' perceived barriers to naloxone counseling. Pharmacists can receive continuing education credit (0.1 CEU) for completing the course.
79648445|NCT04677387|Behavioral|Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists|A 55 minute long online module with videos, didactic content, and quizzes that covers the following topics: risk factors for overdose (OD), how to respond to OD, how naloxone works, types of naloxone, how to administer naloxone, medico-legal issues, how to bill for naloxone, and strategies to address overdose. Pharmacists can receive continuing education credit (0.125 CEUs) for completing the course.
79648446|NCT04677114|Drug|Buprenorphine and Outpatient Parenteral Antibiotic Therapy|Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.
79648447|NCT04677114|Drug|Buprenorphine and standard of care antibiotic treatment|All participants will receive treatment of OUD and the infection per usual clinical care.
79327672|NCT02660281|Drug|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
79327673|NCT02660281|Drug|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
79327674|NCT02660281|Drug|Busulfan|Busulfan
79648448|NCT04657575|Procedure|Narcotrend|ECT stimulation within an anaesthesia depth range of 41-64
79327675|NCT02660281|Drug|Melphalan|Melphalan
79327676|NCT02660281|Procedure|Stem Cell Infusion|Stem cell infusion
79327677|NCT02660281|Drug|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
79648449|NCT04643769|Drug|ORIN1001|Oral tablet - ORIN1001
79648450|NCT04643769|Drug|Placebo|Oral tablet - placebo
79648451|NCT04619225|Device|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
79327678|NCT02660281|Drug|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
79327679|NCT02660281|Drug|Thiotepa|Thiotepa
79811072|NCT04031573|Drug|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
79327680|NCT03061487|Procedure|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
79327681|NCT02438995|Drug|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
79327682|NCT03061409|Dietary Supplement|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
79327683|NCT03061409|Dietary Supplement|Placebo|served as placebo
79327684|NCT04978883|Other|No intervention|No intervention
79327685|NCT04662307|Device|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%~80% HRR determined in the pretest of cardiopulmonary exercise test.
79327686|NCT04526041|Other|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
79327687|NCT04526041|Other|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
79327688|NCT04526041|Other|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
79482681|NCT04153409|Drug|Placebo|Two capsules of placebo
79482682|NCT01638390|Device|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
79482683|NCT04662242|Drug|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
79482684|NCT04662242|Drug|normal saline|normal saline 100ml iv infusion for 7 days
79482685|NCT03535571|Dietary Supplement|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
79648452|NCT04614337|Drug|LUM-201|Administered orally once daily
79327689|NCT04526041|Other|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
79648453|NCT04614337|Drug|rhGH Norditropin® pen (34 µg/kg)|Administered subcutaneously (s.c., under the skin) once daily.
79811073|NCT04031573|Drug|Placebo|Placebo will be administered via the enteral route, every 12 hours.
79811074|NCT00682721|Drug|Placebo|Matching placebo two pills once daily
79978898|NCT03729011|Drug|Volatile agent|Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
79978899|NCT03729011|Drug|Propofol|Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
79978900|NCT03721497|Drug|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
79327690|NCT01669811|Drug|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
79327691|NCT01669811|Drug|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
79327692|NCT05173285|Diagnostic Test|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
79327693|NCT05173285|Behavioral|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
79327694|NCT05173285|Diagnostic Test|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
79327695|NCT05173285|Diagnostic Test|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
79482686|NCT04658966|Other|administration of a self-questionnaire|Women will have to fill in an online self questionnaire on pre-eclampsia
79482687|NCT04332185|Procedure|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
79482688|NCT03675581|Drug|Microgynon|fixed sequence trial
79482689|NCT03675581|Drug|Nintedanib|fixed sequence trial
79482690|NCT02975960|Biological|injection of autologous stromal vascular fraction|"Acquiring autologous stromal vascular fraction (SVF) from liposuction~purifying SVF from lipoaspirates and making syringe filled with SVF~SVF injection - Inject SVF on fingers subcutaneously."
79648454|NCT04613635|Device|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
79648455|NCT04613635|Device|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
79648456|NCT04601155|Device|AlloSure|AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
79648457|NCT04593121|Drug|BIIB107|Administered as specified in the treatment arm.
79648458|NCT04593121|Drug|Placebo|Administered as specified in the treatment arm.
79648459|NCT04589689|Behavioral|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
79648460|NCT04585737|Drug|Dolutegravir / Lamivudine Pill|Experimental
79648461|NCT04585737|Drug|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
79648462|NCT04543253|Other|MUSE biofeedback|biofeedback through a headband
79811075|NCT00682721|Drug|Valacyclovir|1 gram daily x number of days active in the study
79811076|NCT00671554|Biological|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
79978901|NCT03718364|Procedure|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
79648463|NCT04537299|Drug|Fisetin|~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 & 1 and Days 8 & 9)
79978902|NCT03717896|Drug|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
79978903|NCT03717896|Drug|Placebo|50mL 0.9% saline
79978904|NCT03715790|Behavioral|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
79482691|NCT05142228|Drug|Erenumab-Aooe|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
79482692|NCT05142228|Other|Placebo|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
79482693|NCT04154540|Other|Motion analysis|Gait and posture recording
79648464|NCT04537299|Drug|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
79978905|NCT03715790|Behavioral|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
79978906|NCT03697577|Diagnostic Test|CT scans|Patients will undergo CT or PETCT as part of their standard of care
79978907|NCT03697577|Diagnostic Test|DEXA scan|Patients will undergo DEXA scan to measure body fat mass. This is part of proposed study.
79648465|NCT04530799|Other|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
79811077|NCT00686465|Other|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
79978908|NCT03691610|Biological|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
79978909|NCT03691610|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
79978910|NCT03691610|Biological|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
79978911|NCT03691610|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
79978912|NCT03691610|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
79482694|NCT03678311|Device|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index >5 pauses per hour then given CPAP to wear for approximately 3 months.
79811078|NCT00768742|Device|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
79978913|NCT03691610|Biological|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
79482695|NCT03821636|Procedure|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
79482696|NCT03821636|Procedure|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
79482697|NCT00362102|Drug|Cetuximab|
79482698|NCT05122026|Drug|Rifapentine|As included in arm/group description
79482699|NCT05122026|Drug|Isoniazid|As included in arm/group description
79648466|NCT04503499|Other|Manuel Therapy|"The manual therapy protocol will consist of 45-60 minutes and the following techniques;~suboccipital decompression~cervical mobilization (in the posterior-anterior direction)~sternocleidomastoid release~scalene release~trapezoidal release~scalene release~pectoralis tractus~sternoclavicular joint mobilization~sternum mobilization~parasternal circumference intercostal and paravertebral release~diaphragm release~rib reasing~scapulothoracic joint mobilization~thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times."
79648467|NCT04494542|Procedure|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
79648468|NCT04494542|Procedure|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
79327696|NCT04972877|Other|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25*40/50 mm) will be inserted into a depth of 15~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
79482700|NCT04658498|Other|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
79482701|NCT04658498|Other|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
79648469|NCT04494451|Drug|Vit C|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
79482702|NCT04658498|Other|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
79327697|NCT04972877|Other|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18*25 mm) will be inserted superficially to a depth of < 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
79327698|NCT03061877|Other|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
79327699|NCT04601935|Biological|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10^6 cells/kg, 0.5 × 10^6 cells/kg, 1.0 × 10^6 cells/kg, 2.0 × 10^6 cells/kg, and 4.0 × 10^6 cells/kg, with 0.25 × 10^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
79327700|NCT04220723|Other|Frailty Assessment|"Liver Frailty Index measurements:~Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
79327701|NCT04220723|Other|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
79482703|NCT04655430|Other|3-second SDF application|Dosage: 3-second 38% SDF solution application
79482704|NCT04655430|Other|5-second SDF application|Dosage: 5-second 38% SDF solution application
79482705|NCT04655430|Other|10-second SDF application|Dosage: 10-second 38% SDF solution application
79482706|NCT04655430|Other|15-second SDF application|Dosage: 15-second 38% SDF solution application
79482707|NCT04655430|Other|30-second SDF application|Dosage: 30-second 38% SDF solution application
79482708|NCT04655430|Other|45-second SDF application|Dosage: 45-second 38% SDF solution application
79482709|NCT04655430|Other|60-second SDF application|Dosage: 60-second 38% SDF solution application
79482710|NCT04655430|Other|120-second SDF application|Dosage: 120-second 38% SDF solution application
79482711|NCT04655430|Other|180-second SDF application|Dosage: 180-second 38% SDF solution application
79482712|NCT02958878|Drug|Tamsulosin|
79482713|NCT02958878|Drug|Placebo Oral Capsule|
79648470|NCT04494451|Drug|Standard medical Treatment|iv antibiotics alone
79648471|NCT04491292|Other|Questionnaire Administration|Complete questionnaires
79648472|NCT04468126|Other|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
79648473|NCT04468126|Other|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
79648474|NCT04421170|Behavioral|smartphone app for smoking cessation|Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks.
79648475|NCT04419558|Drug|Pamrevlumab|Sterile solution for injection
79648476|NCT04419558|Drug|Placebo|Sterile solution for injection
79648477|NCT04397458|Drug|Saline|0.9% saline on each side
79648478|NCT04397458|Drug|Bupivacaine|0.25% bupivacaine (50mg) on each side
79648479|NCT04397458|Drug|Dexamethasone|3mg preservative-free dexamethasone on each side
79327702|NCT04978181|Drug|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
79327703|NCT04978025|Drug|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
79482714|NCT03813524|Device|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
79327704|NCT04978025|Drug|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
79327705|NCT05127811|Drug|ZN-d5|BION design
79327706|NCT04978103|Drug|Gum Arabic|A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
79327707|NCT04437173|Device|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
79327708|NCT04154579|Behavioral|HeRe We Arts|Art Therapy interventions to promote health, resilience & well-being will discussed; & experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, & music-assisted relaxation techniques will be utilized; & discussion of use of music to elicit positive physical & emotional responses will be held. Drums Alive (drumming & movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, & Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
79482715|NCT03812276|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
79482716|NCT04154384|Behavioral|Pain Management Strategies|The Life Care Specialist (LCS) teaches evidence-informed behavioral interventions and will work with the patient to develop personalized pain management strategies focused on behavioral education, including progressive muscle relaxation (PMR), the Community Resiliency Model (CRM®), motivational interviewing, and reflective listening.
79482717|NCT04154384|Behavioral|Life Care Specialist (LCS) Intervention|The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
79482718|NCT04154384|Other|Clinical Coordination with Referrals|The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
79648480|NCT04390425|Device|Experimental - Limb Occlusion pressure|This intervention involves lower tourniquet pressure than the standard of care. There is no change to tourniquet time or how the surgery is performed.
79648481|NCT04387162|Behavioral|Prism Adaptation Treatment|Spatial retraining treatment
79648482|NCT04383743|Drug|Cisplatin|Given IV
79648483|NCT04383743|Drug|Doxorubicin|Given IV
79648484|NCT04383743|Drug|Methotrexate|Given IV
79648485|NCT04383743|Biological|Pegfilgrastim|Given SC
79648486|NCT04383743|Biological|Pembrolizumab|Given IV
79648487|NCT04383743|Procedure|Radical Cystectomy|Undergo standard of care radical cystectomy
79648488|NCT04383743|Drug|Vinblastine Sulfate|Given IV
79648489|NCT04366531|Behavioral|START-VET|prison reentry program
79648490|NCT04366531|Other|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
79648491|NCT04360434|Drug|NI006|NI006 will be administered intravenously
79648492|NCT04360434|Drug|Placebo|Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
79648493|NCT04337853|Device|Intraoral stent|Radiotherapy with intraoral stent
79811079|NCT00781066|Procedure|Controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~Gently hold the cord and wait until the uterus is well contracted again;~With the next contraction, repeat CCT with counter-pressure."
79327709|NCT04154579|Behavioral|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
79327710|NCT04508179|Drug|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
79327711|NCT04508179|Drug|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
79811080|NCT00781066|Procedure|No controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
79811081|NCT02626091|Procedure|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation."
79811082|NCT02556814|Drug|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
79811083|NCT02556814|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
79811084|NCT02556814|Drug|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
79327712|NCT04508179|Drug|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
79327713|NCT04508179|Drug|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
79811085|NCT00682955|Drug|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
79811086|NCT00682955|Drug|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
79811087|NCT00686621|Drug|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
79327714|NCT04508179|Drug|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
79327715|NCT04400149|Diagnostic Test|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
79327716|NCT04437017|Drug|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
79327717|NCT04437017|Drug|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
79327718|NCT03061253|Other|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
79327719|NCT03061253|Other|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
79482719|NCT02976116|Drug|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
79811088|NCT00683033|Behavioral|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
79327720|NCT03061253|Other|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
79327721|NCT04972643|Dietary Supplement|EPA|EPA 2000mg Soft capsules
79327722|NCT04972643|Dietary Supplement|DHA|DHA 2000mg Soft capsules
79327723|NCT04972643|Dietary Supplement|Placebo|Placebo Soft capsules
79327724|NCT05107141|Procedure|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
79327725|NCT05107141|Device|bone graft plus a collagen membrane|
79327726|NCT05107063|Drug|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
79327727|NCT04977713|Other|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
79811089|NCT00683033|Behavioral|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
79811090|NCT04142879|Device|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
79327728|NCT04977713|Other|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
79327729|NCT05106907|Biological|ThisCART19 cells|0.2-60 x 10^6 CAR T cells per kg body weight
79327730|NCT05106829|Other|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
79327731|NCT05106829|Other|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
79327732|NCT04432181|Other|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
79482720|NCT02976116|Drug|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
79482721|NCT01600716|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
79482722|NCT01600716|Drug|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
79482723|NCT02975258|Procedure|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
79482724|NCT02975258|Other|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
79482725|NCT02975258|Procedure|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
79327733|NCT04422613|Diagnostic Test|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
79327734|NCT04971317|Behavioral|Sugar-Sweetened Beverage (SSB) Video|Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
79327735|NCT04971317|Behavioral|Water Video|Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
79327736|NCT04971317|Behavioral|Control|Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
79327737|NCT05106751|Device|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
79482726|NCT02975258|Procedure|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
79648494|NCT04337853|Other|No intraoral stent|Radiotherapy without intraoral stent
79978914|NCT03691610|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
79978915|NCT03691610|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
79978916|NCT03691610|Biological|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
79327738|NCT04383379|Behavioral|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
79327739|NCT05106673|Behavioral|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
79811091|NCT00683111|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
79811092|NCT00683111|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
79978917|NCT03691610|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
79978918|NCT03691610|Biological|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
79978919|NCT03677076|Other|Ancillary/Correlative|Collection of research blood and urine
79978920|NCT03675737|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
79978921|NCT03675737|Drug|Cisplatin|Administered as an IV infusion on Day 1 Q3W
79978922|NCT03675737|Drug|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
79978923|NCT03675737|Drug|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
79978924|NCT03675737|Drug|capecitabine|Administered orally BID on Days 1 to 14 Q3W
79327740|NCT05106673|Behavioral|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
79327741|NCT05106673|Behavioral|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
79482727|NCT02975258|Radiation|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
79648495|NCT04332874|Procedure|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
79648496|NCT04332874|Drug|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
79648497|NCT04332874|Drug|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
79648498|NCT04331522|Diagnostic Test|Oral provocation test|Titrated provocation with allergen
79648499|NCT04262856|Drug|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
79648500|NCT04262856|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
79648501|NCT04262856|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
79978925|NCT03675737|Drug|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
79978926|NCT03666273|Drug|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
79978927|NCT03666273|Drug|Bapotulimab (BAY1905254) + Pembrolizumab|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
79648502|NCT04262141|Drug|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
79648503|NCT04232085|Drug|Alemtuzumab|Preparative regimen
79648504|NCT04232085|Drug|Fludarabine|Preparative regimen
79648505|NCT04232085|Drug|Melphalan|Preparative regimen
79648506|NCT04232085|Radiation|Low Dose Total Body Irradiation|Preparative regimen
79648507|NCT04232085|Drug|Cyclophosphamide|GVHD prophylaxis
79648508|NCT04232085|Drug|Tacrolimus|GVHD prophylaxis
79648509|NCT04232085|Drug|Mycophenolate Mofetil|GVHD prophylaxis
79648510|NCT04195568|Device|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
79978928|NCT03662386|Procedure|OCT-A|Optical coherence tomography angiography (OCT-A)
79978929|NCT03662386|Procedure|Visual acuity (ETDRS)|Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
79978930|NCT03656562|Drug|VAY736|Powder for solution for injection
79978931|NCT03656562|Drug|VAY736 Placebo|Solution for injection
79978932|NCT03656562|Drug|CFZ533|Concentrate for solution for infusion
79978933|NCT03656562|Drug|CFZ533 Placebo|Solution for infusion
79978934|NCT03654053|Drug|Placebo Oral Tablet|Placebo taken once nightly at bed time.
79978935|NCT03654053|Drug|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
79978936|NCT03651973|Other|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
79978937|NCT03651973|Other|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
79978938|NCT03646045|Other|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
79978939|NCT03643562|Drug|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
79978940|NCT03635567|Biological|Pembrolizumab|IV infusion
79978941|NCT03635567|Drug|Paclitaxel|IV infusion
79327742|NCT05106673|Other|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
79327743|NCT04977557|Dietary Supplement|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
79327744|NCT04316143|Drug|Zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
79327745|NCT04977323|Other|TICK-B group|These interventions will use as distraction techniques.
79327746|NCT04977089|Diagnostic Test|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
79648511|NCT04158895|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
79648512|NCT04158882|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
79978942|NCT03635567|Drug|Cisplatin|IV infusion
79327747|NCT05104801|Drug|sitravatinib|sitravatinib 100mg QD PO
79327748|NCT05104801|Drug|tislelizumab|tislelizumab 200mg Q3W IV
79648513|NCT04137757|Other|Lower Body Negative Pressure|Lower body negative pressure will be applied.
79978943|NCT03635567|Drug|Carboplatin|IV infusion
79978944|NCT03635567|Biological|Bevacizumab|IV infusion
79978945|NCT03635567|Drug|Placebo to pembrolizumab|IV infusion
79327749|NCT04977011|Other|relaxing music|30 minutes relaxing music for continuity 3 days since admission
79327750|NCT04530877|Biological|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
79327751|NCT04530877|Dietary Supplement|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
79327752|NCT04971083|Behavioral|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
79482728|NCT02975258|Procedure|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
79648514|NCT04137757|Other|Sham Pressure|Noise will be turned on but no pressure will be applied.
79327753|NCT04971239|Drug|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
79648515|NCT04131647|Other|Weight Maintenance|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
79811093|NCT04138901|Procedure|Ultrasound guided subcostal transversus abdominis plane block (TAPB)|At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
79978946|NCT03620669|Drug|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
79978947|NCT03610711|Drug|Nivolumab|240mg administered IV over 30 minutes every 2 weeks for one year
79978948|NCT03610711|Drug|Relatlimab|every 2 weeks for one year
79978949|NCT03606967|Procedure|Biopsy|Undergo tumor biopsy
79978950|NCT03606967|Procedure|Biospecimen Collection|Undergo blood sample collection
79978951|NCT03606967|Drug|Carboplatin|Given IV
79978952|NCT03606967|Procedure|Computed Tomography|Undergo CT scan
79327754|NCT04971239|Device|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
79327755|NCT04971239|Device|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
79327756|NCT03062111|Procedure|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
79327757|NCT03062111|Procedure|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
79327758|NCT04903093|Drug|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
79327759|NCT04903093|Drug|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
79327760|NCT04903093|Drug|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
79327761|NCT04903093|Drug|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
79327762|NCT04903093|Drug|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
79327763|NCT04903093|Drug|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
79327764|NCT04903093|Drug|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
79327765|NCT04903093|Drug|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
79327766|NCT04970849|Other|observation|IBD doctors who perform the endoscopy perform the questionnaire
79327767|NCT04529785|Procedure|SVC only|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
79327768|NCT04529785|Procedure|SVC isolation with substrate modification and vein of Marshal ethanol infusion|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
79648516|NCT04131647|Other|Weight Maintenance + Intermittent Fasting|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
79327769|NCT04970615|Device|Three-dimensional printed model|Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
79327770|NCT04271293|Drug|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
79327771|NCT04208659|Procedure|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
79648517|NCT04119648|Behavioral|CAMS-4Kids|The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
79327772|NCT04208659|Procedure|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
79327773|NCT03060239|Other|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
79327774|NCT03059927|Procedure|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith & Nephew, Cruciate Retaining design
79327775|NCT03059927|Procedure|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Anterior Stabilized design
79327776|NCT03059927|Procedure|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Posterior Stabilized design
79327777|NCT03059849|Drug|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
79327778|NCT04822441|Other|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
79327779|NCT04976075|Other|no interventions|no interventions
79327780|NCT04796701|Other|Follow-Home-intervention|x
79327781|NCT04156165|Dietary Supplement|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
79327782|NCT04156165|Other|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
79327783|NCT04156165|Dietary Supplement|VLCD-Control|Lighter life VLCD products
79327784|NCT04156165|Other|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
79327785|NCT04970693|Drug|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
79327786|NCT04131751|Diagnostic Test|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
79327787|NCT04918537|Dietary Supplement|Walnuts|30g of plain walnuts in addition to habitual food intakes
79327788|NCT04970303|Drug|Methylphenidate|Retina or Concerta
79327789|NCT03942835|Other|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
79811094|NCT04138901|Drug|Ropivacaine 0.75% Injectable Solution|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
79327790|NCT03942835|Other|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
79327791|NCT03942835|Other|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
79327792|NCT04975529|Behavioral|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
79327793|NCT04902547|Behavioral|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
79327794|NCT04902547|Procedure|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
79327795|NCT04969679|Drug|E. coli Nissle 1917 (Mutaflor®)|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
79327796|NCT04969679|Drug|Placebo|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
79482729|NCT02975258|Procedure|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin & into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
79482730|NCT02975258|Procedure|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
79811095|NCT04138901|Device|21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
79978953|NCT03606967|Biological|Durvalumab|Given IV
79811096|NCT00690209|Procedure|Autologous bone marrow derived stem cells myocardial transplantation|
79811097|NCT04138745|Other|Transverse Thoracic Plane Block|A bilateral plane block in the transverse thoracic space
79811098|NCT00690287|Drug|AZD6370|Oral single doses a+b+c, o.d., suspension
79978954|NCT03606967|Drug|Gemcitabine Hydrochloride|Given IV
79327797|NCT04969757|Device|Predigraft group|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
79327798|NCT04432259|Drug|Dexamethasone|4 mg bid for 4 days
79978955|NCT03606967|Procedure|Magnetic Resonance Imaging|Undergo MRI
79327799|NCT04432259|Drug|Placebo|oral placebo
79811099|NCT00690287|Drug|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
79811100|NCT00690287|Drug|Placebo|Placebo
79978956|NCT03606967|Drug|Nab-paclitaxel|Given IV
79978957|NCT03606967|Biological|Personalized Synthetic Long Peptide Vaccine|Given SC
79327800|NCT03933085|Behavioral|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
79327801|NCT04969523|Procedure|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
79327802|NCT03578107|Behavioral|improvement of quality of stroke care|"hospital tool kits for quality improvement of reperfusion therapy ;~organizational stakeholder and opinion leader meetings;~data monitoring and feedback reports；~webinar for hospital teams"
79327803|NCT03059771|Behavioral|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
79327804|NCT03059771|Behavioral|Control|The control group will only engage in a goal-setting session.
79327805|NCT03918031|Behavioral|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
79327806|NCT03918031|Behavioral|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
79648518|NCT04109209|Behavioral|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
79648519|NCT04109209|Behavioral|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
79648520|NCT04086368|Device|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
79811101|NCT00922649|Device|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
79978958|NCT03606967|Drug|Poly ICLC|Given SC
79978959|NCT03606967|Biological|Tremelimumab|Given IV
79811102|NCT04142411|Drug|Insulin|Ultrasound guided perineural injection therapy (PIT)
79811103|NCT04142411|Drug|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
79327807|NCT03059693|Drug|HAT1 topical cream|
79327808|NCT03059693|Drug|Vehicle cream|
79327809|NCT05090683|Behavioral|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
79327810|NCT04964219|Drug|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
79482731|NCT03680105|Drug|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
79811104|NCT04142411|Device|Ultrasound|Philips Neuromuscular Ultrasound
79811105|NCT00683189|Drug|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
79978960|NCT03606486|Other|Biospecimen Collection|Undergo collection of tumor sample and blood draw
79978961|NCT03606486|Other|Laboratory Biomarker Analysis|Correlative studies
79978962|NCT03606486|Device|Lavage|Undergo uterine lavage
79978963|NCT03606486|Other|Pap Smear|Undergo pap smear
79978964|NCT03578536|Device|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
79978965|NCT03576547|Drug|Dexamethasone|Given PO or IV
79978966|NCT03576547|Drug|Ponatinib Hydrochloride|Given PO
79978967|NCT03576547|Biological|Rituximab|Given IV
79978968|NCT03576547|Drug|Venetoclax|Given PO
79327811|NCT04964219|Drug|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
79327812|NCT04975451|Drug|Anlotinib|Anlotinib plus DCb
79327813|NCT04975373|Drug|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
79327814|NCT04974983|Other|Observation of neurological deficits|Observation of neurological deficits
79648521|NCT04086368|Device|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
79811106|NCT00667576|Drug|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
79811107|NCT00667576|Drug|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
79327815|NCT04975061|Drug|YY-20394|YY-20394 is a small molecule inhibitor.
79327816|NCT04968977|Procedure|PCI vs. CABG|PCI vs. CABG
79327817|NCT04968665|Diagnostic Test|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
79327818|NCT04963829|Biological|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
79327819|NCT04963829|Biological|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
79327820|NCT04963829|Biological|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
79327821|NCT04963985|Drug|Tafamidis Pill|Oral
79327822|NCT04974905|Procedure|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
79648522|NCT04076657|Behavioral|Brock String Therapy|Oculomotor exercise to improve binocular vision function
79327823|NCT01669577|Procedure|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
79327824|NCT04974827|Drug|Camrelizumab|200mg/3weeks
79648523|NCT04076657|Behavioral|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
79648524|NCT04061135|Procedure|Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
79648525|NCT04057300|Drug|Ticagrelor 90mg|Ticagrelor tablet
79327825|NCT04974827|Drug|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
79327826|NCT04963595|Drug|Pyrotinib|400 mg once daily
79327827|NCT04963595|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
79327828|NCT04963595|Drug|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
79327829|NCT04963907|Device|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
79327830|NCT04963907|Device|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
79327831|NCT04963361|Other|patients were exposed to fear of movement|Patients completed the questionnaires independently
79327832|NCT04963361|Other|patients were not exposed to fear of movement|Patients completed the questionnaires independently
79327833|NCT04968431|Other|2D Echocardiography|Mitral valve area will be determined by 2 D echo-Doppler methods
79327834|NCT04968431|Other|3D Echocardiography|Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
79327835|NCT03061019|Procedure|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
79327836|NCT03061019|Procedure|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
79327837|NCT04955015|Procedure|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
79327838|NCT04963049|Other|Protocol with Mask|Look at differences in group with facemask and no mask
79327839|NCT04968041|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
79327840|NCT03060941|Behavioral|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
79482732|NCT03680105|Drug|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
79482733|NCT04844814|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|Anakinra 100 mg/d subcutaneous injection
79482734|NCT04844814|Drug|Prednisone|Prednisone 30 mg/d
79482735|NCT04844814|Drug|Placebo of Prednisone|Placebo of Prednisone
79482736|NCT04844814|Drug|Placebo of Anakinra|Placebo of Anakinra
79482737|NCT04833270|Other|KM non-pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
79482738|NCT04833270|Other|Pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
79811108|NCT04141787|Drug|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
79327841|NCT03060941|Behavioral|Facility access|Participants will receive at 6 month membership to a local fitness facility.
79327842|NCT03060941|Behavioral|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
79327843|NCT03060941|Behavioral|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
79482739|NCT02975102|Device|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
79482740|NCT02975102|Device|Vismed® Multi|Vismed® Multi 3 to 6 times per day for 3 months.
79648526|NCT04057300|Drug|Clopidogrel 75mg|Clopidogrel tablet
79648527|NCT04057300|Drug|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
79648528|NCT04056468|Drug|Mobocertinib|Mobocertinib capsule.
79648529|NCT04055376|Device|GENUS device (Active Settings)|"Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
79327844|NCT03060941|Behavioral|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
79327845|NCT04962425|Drug|Trastuzumab|Trastuzumab [Herceptin] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
79327846|NCT04962269|Diagnostic Test|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
79327847|NCT03060707|Drug|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
79327848|NCT03060863|Behavioral|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
79327849|NCT03060863|Behavioral|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
79327850|NCT03060863|Behavioral|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
79482741|NCT05011656|Device|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
79482742|NCT05011656|Device|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
79811109|NCT04141787|Drug|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
79811110|NCT02557594|Drug|Viread 300mg|single dose administration after 10hr fasting
79327851|NCT03060863|Behavioral|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
79327852|NCT04953533|Other|no intervention|
79327853|NCT04966949|Procedure|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
79327854|NCT04432103|Biological|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
79327855|NCT04432103|Biological|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
79327856|NCT02658175|Drug|Volanesorsen|300 mg volanesorsen administered via SC injection.
79327857|NCT03060005|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
79482743|NCT03536819|Device|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
79327858|NCT03060005|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
79811111|NCT02557594|Drug|DA-2802 319mg|single dose administration after 10hr fasting
79327859|NCT02774785|Device|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
79482744|NCT00376883|Drug|pamidronate|
79482745|NCT04651868|Other|GLP-2|A 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
79482746|NCT04651868|Other|Placebo|A 210 mins intravenous infusion with isotonic NaCl
79482747|NCT04651868|Other|CCK|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1)
79482748|NCT04651868|Other|Placebo|A 180 mins intravenous infusion with isotonic NaCl
79482749|NCT05356416|Other|Ischemic compression|"Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds."
79482750|NCT05356416|Other|Dry needling|"Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses."
79482751|NCT04734587|Diagnostic Test|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
79482752|NCT04651010|Other|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
79482753|NCT04195308|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
79482754|NCT04195308|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79482755|NCT04195308|Device|Open label TBS-DLPFC|"Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
79811112|NCT00687011|Drug|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
79811113|NCT00777868|Drug|Low Strength IDP-108|Topical application once a day for 9 months
79978969|NCT03574493|Procedure|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
79978970|NCT03564938|Drug|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
79978971|NCT03564496|Device|tDCS Administration during MRI|All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with ~30s ramp-up and ramp-down periods.
79327860|NCT04953455|Other|no intervention|no intervention
79327861|NCT03234361|Dietary Supplement|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
79327862|NCT03234361|Dietary Supplement|Low Phosphate Phase|2 capsules of sodium chloride.
79327863|NCT04953299|Behavioral|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
79811114|NCT00777868|Drug|High Strength IDP-108|Topical application once a day for 9 months
79811115|NCT00777868|Drug|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
79811116|NCT00777868|Drug|Vehicle|Topical application once a day for 9 months
79811117|NCT00687089|Other|Sexual, cognitive functional tests and measurement weight|
79811118|NCT00683267|Drug|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
79811119|NCT00683267|Drug|Placebo|One dose administered by direct instillation into the surgical site
79811120|NCT00683345|Drug|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
79811121|NCT00683345|Drug|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
79811122|NCT04138667|Other|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
79327864|NCT04953299|Behavioral|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
79648530|NCT04055376|Device|GENUS device (Sham Settings)|"Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
79327865|NCT04210141|Biological|lyophilized BPI viper antivenom|Antivenom
79327866|NCT04962191|Diagnostic Test|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
79648531|NCT04042922|Device|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
79648532|NCT04042922|Device|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
79648533|NCT03984682|Procedure|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
79648534|NCT03975400|Behavioral|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
79648535|NCT03950570|Drug|Abraxane|"The doses of ORIN1001 in both dose escalation and dose expansion will be 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600mg, 800 mg, 1,000 mg, 1,200 mg Weekly paclitaxel will be 80 mg/m2 given intravenously for the dose escalation and dose expansion phases.~cohorts as follows: 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,300 mg and 1,500 mg administered for 21 days (one cycle)."
79811123|NCT00687245|Drug|esomeprazole magnesium|capsules, oral, qd, one day
79811124|NCT00690521|Drug|metolazone or hydrochlorothiazide|The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
79811125|NCT00683501|Drug|DNB-001|four dosages of DNB-001, one placebo dosage
79811126|NCT02625701|Procedure|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
79811127|NCT02625701|Procedure|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
79811128|NCT00683579|Drug|Early Treatment with HAART|HAART with possibility of de-intensification
79327867|NCT04186117|Other|Blood sample|Blood sample before any treatment
79327868|NCT04953221|Drug|YJ001|Skin spray
79327869|NCT04006951|Other|Biological collection|"Blood samples are collected at different times :~Before any treatment~After pre-operative radiochemotherapy and before surgery (if applicable)"
79327870|NCT02926417|Procedure|High Density-Electroencephalogram|
79327871|NCT04952987|Drug|Diquafosol|Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion
79327872|NCT04418609|Other|further processing of health data|further processing of biological materials and health related personal data for research
79327873|NCT05106439|Behavioral|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
79327874|NCT05106439|Behavioral|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
79327875|NCT05106439|Behavioral|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
79327876|NCT04418531|Biological|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
79327877|NCT05037019|Procedure|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
79327878|NCT02555293|Drug|XIFAXAN® (Rifaximin)|
79327879|NCT05087251|Behavioral|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
79327880|NCT05087251|Behavioral|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
79327881|NCT04436575|Device|Point-of-care ultrasound|Point-of-care ultrasound prognostic performance : echocardiography mainly
79327882|NCT03293017|Drug|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
79327883|NCT03293017|Drug|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
79327884|NCT03293017|Drug|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
79327885|NCT04436809|Procedure|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
79327886|NCT04436809|Procedure|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
79482756|NCT05314673|Drug|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
79482757|NCT05314673|Procedure|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
79648536|NCT03932903|Behavioral|AYA ADAPTS (ADherence Assessments and Personalized Timely Support).|AYA ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in adolescents and young adults with acute lymphoblastic leukemia. Each participant will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days.
79811129|NCT00683579|Other|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
79327887|NCT04658251|Genetic|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
79327888|NCT04859491|Dietary Supplement|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
79648537|NCT03929250|Drug|2g Centella asiatica water extract product|2g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
79648538|NCT03929250|Drug|4g Centella asiatica water extract product|4g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
79648539|NCT03905941|Drug|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
79811130|NCT00683579|Drug|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA >100,000 copies/ml
79811131|NCT00666718|Drug|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
79811132|NCT00666718|Drug|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
79811133|NCT00666718|Drug|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
79811134|NCT00683735|Drug|Sitagliptin|100 mg once daily in the morning
79811135|NCT00683735|Drug|Metformin|up to 2000 mg/day
79811136|NCT00683735|Drug|Placebo|500mg 1-0-0-0
79811137|NCT00683735|Drug|Placebo|100mg 1-0-0-0
79811138|NCT02625467|Procedure|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
79978972|NCT03564496|Device|Remotely-supervised Daily tDCS Administration|"While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session."
79811139|NCT02625467|Procedure|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
79978973|NCT03564496|Device|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA|Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
79978974|NCT03564340|Drug|REGN4018|REGN4018 will be administered in a series of dose escalation and dose expansion cohorts by intravenous (IV) infusion and/or subcutaneous (SC) as described in the protocol.
79648540|NCT03905941|Drug|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
79648541|NCT03905603|Drug|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
79811140|NCT02625467|Drug|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
79811141|NCT04139681|Drug|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
79648542|NCT03905603|Drug|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
79648543|NCT03904524|Behavioral|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
79648544|NCT03799653|Other|No intervention|This is a prospective observational study, and there is no intervention.
79811142|NCT04047394|Drug|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
79327889|NCT04859491|Dietary Supplement|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
79327890|NCT04859491|Dietary Supplement|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
79327891|NCT05106049|Diagnostic Test|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
79327892|NCT04523545|Device|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
79327893|NCT05105815|Biological|IPM001|IPM001 will be used against tumor cells
79327894|NCT02625623|Drug|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
79327895|NCT02625623|Drug|Irinotecan|Irinotecan was administered at a dose of 150 mg/m ^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
79648545|NCT03797014|Drug|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
79482758|NCT04634318|Other|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
79978975|NCT03564340|Drug|cemiplimab|Cemiplimab will be administered by IV infusion after REGN4018 monotherapy lead-in phase.
79978976|NCT03564340|Drug|Sarilumab|Sarilumab will be administered by IV, one-time-only, prior to IV/SC REGN4018.
79978977|NCT03562247|Other|Usual Care of IPF|standard of care given to patients with IPF
79978978|NCT03562247|Other|Telenursing|scheduled phone calls with the patient and care giver
79978979|NCT03562247|Other|Telenursing and Remote Monitoring|scheduled phone calls and home monitoring of physiologic parameters
79978980|NCT03554720|Device|ATTUNE PS Knee|The ATTUNE PS Knee is the standard implants.
79327896|NCT02625623|Drug|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
79327897|NCT02625623|Other|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
79327898|NCT05105893|Other|Dates group|Seven dates to be provided to patients
79327899|NCT02749513|Drug|Itraconazole|
79648546|NCT03796273|Other|Best Practice|Undergo standard surgery
79648547|NCT03796273|Drug|Ketoconazole|Given PO
79978981|NCT03554720|Device|ATTUNE S+ PS Knee|The ATTUNE S+ PS Knee is the enhanced fixation.
79978982|NCT03539094|Other|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
79978983|NCT03535129|Behavioral|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
79978984|NCT03532581|Other|Indocyanine Green Solution|Given Subcutaneous injection
79327900|NCT05110339|Drug|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
79327901|NCT05110339|Drug|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
79327902|NCT05111665|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|
79648548|NCT03782207|Drug|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
79978985|NCT03532581|Procedure|Lymphangiography|Undergo lymphangiography
79978986|NCT03515837|Biological|pembrolizumab|IV infusion
79978987|NCT03515837|Drug|pemetrexed|IV infusion
79978988|NCT03515837|Drug|carboplatin|IV infusion
79978989|NCT03515837|Drug|cisplatin|IV infusion
79978990|NCT03515837|Drug|saline solution|IV infusion
79327903|NCT05111665|Behavioral|Relaxation Group Therapy (RGT)|
79327904|NCT05111665|Behavioral|Treatment as usual (TAU)|
79327905|NCT04966403|Other|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
79327906|NCT04966403|Other|trampoline-based stretch-shortening cycle exercises|muscle strength
79327907|NCT04830631|Device|Cathodal transcranial direct current stimulation (tDCS) over the contralesional motor cortex|Cathodal tDCS will be applied to the contralesional motor cortex with 2mA intesntisy for 30 mins/day. Total 10 sessions will be applied.
79327908|NCT04952831|Other|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
79327909|NCT04965545|Dietary Supplement|low copper diet|All patients with wilson disease should receive low copper diet
79327910|NCT04965467|Diagnostic Test|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
79482759|NCT04634318|Other|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
79648549|NCT03777215|Drug|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
79327911|NCT04813939|Device|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
79327912|NCT04795375|Behavioral|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
79648550|NCT03777215|Drug|Saline|Saline will be used as the placebo comparator.
79811143|NCT00683813|Behavioral|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
79978991|NCT03495713|Drug|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
79978992|NCT03485469|Behavioral|Hypnosis|"There ar 10 hypnosis sessions :~1st session of hypnosis : relaxation and orientation towards emotional cleansing.~2nd session of hypnosis: oriented towards digestion, physical and psychological~3rd session of hypnosis: oriented towards the feeling of security.~4th session of hypnosis: self-esteem oriented.~5th hypnosis session: oriented towards emotional management.~6th hypnosis session: oriented towards self-confidence.~7th hypnosis session: oriented towards the completion of the projects.~8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
79978993|NCT03485469|Behavioral|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
79327913|NCT04961411|Procedure|operation or non-operative treatment|type of operation or if possible non-operative treatment
79327914|NCT04425785|Other|Physical Exercise Program|A structured exercise program
79327915|NCT04425785|Behavioral|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
79327916|NCT05105659|Diagnostic Test|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
79327917|NCT05105659|Diagnostic Test|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
79327918|NCT05105659|Diagnostic Test|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
79327919|NCT05105659|Diagnostic Test|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
79811144|NCT02625779|Drug|Valproate and Placebo|
79327920|NCT05105659|Diagnostic Test|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
79327921|NCT05105581|Behavioral|Quality of life scale|"To assess the quality of life of patient~To assess the degree of OCD"
79327922|NCT05111275|Other|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
79811145|NCT02625779|Drug|Valproate and Cytidine-containing Drug|
79811146|NCT02625779|Drug|Valproate and Creatine-containing Drug|
79811147|NCT00667420|Drug|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
79811148|NCT04141319|Drug|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
79811149|NCT04141319|Drug|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
79327923|NCT05105347|Drug|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
79327924|NCT05110963|Behavioral|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
79327925|NCT05110963|Behavioral|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
79327926|NCT05110963|Behavioral|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
79482760|NCT05314595|Procedure|bilateral uterine artery ligation|"Spinal anaethesia with intrathecal morphia~Transverse skin incision~Adequate dissection of the bladder.~Incision of the uterus above placental edge.~Delivery of the fetus.~Delayed cord clamping (60 seconds) if the baby appears well.~Exteriorization of the uterus.~Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~At this point, a gentile trial to deliver the placenta is performed~A catheter is placed in the cervix from above to secure the cervical opening~Compression is applied to the site of bleeding from placenta site~Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
79482761|NCT03796442|Device|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
79482762|NCT03796442|Device|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
79482763|NCT03688685|Drug|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
79327927|NCT04424537|Dietary Supplement|Control diet|Meal replacement beverages made with whey protein
79327928|NCT04424537|Dietary Supplement|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
79327929|NCT04424537|Dietary Supplement|Low protein diet|meal replacement beverages(MRBs) containing low protein
79327930|NCT04965623|Device|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
79482764|NCT04633304|Device|EndoAVF System for endovascular AV fistula creation|AV fistula creation
79482765|NCT04823208|Drug|LY3437943|Administered SC
79482766|NCT04823208|Drug|Placebo|Administered SC
79327931|NCT05105191|Diagnostic Test|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
79327932|NCT04952441|Behavioral|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
79327933|NCT05110651|Drug|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels > 2000ng/ml
79482767|NCT04419636|Drug|Lu AG06466|capsules, orally
79811150|NCT04141319|Drug|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
79811151|NCT00683891|Drug|FazaClo (clozapine, USP) ODT|
79327934|NCT03060785|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|
79327935|NCT05104879|Other|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
79327936|NCT04952363|Device|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
79327937|NCT04952363|Device|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
79327938|NCT04961333|Behavioral|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
79327939|NCT05110573|Procedure|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
79327940|NCT04952207|Drug|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
79327941|NCT04632589|Drug|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
79327942|NCT04632589|Drug|Placebo|subjects ingest placebo tablet daily for 6 weeks
79327943|NCT05002699|Diagnostic Test|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
79327944|NCT04961099|Drug|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
79327945|NCT04965233|Behavioral|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
79327946|NCT04965233|Behavioral|Information reports|Reports containing general information on eczema
79482768|NCT05440292|Device|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
79327947|NCT04975009|Behavioral|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
79648551|NCT03775954|Diagnostic Test|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
79648552|NCT03738579|Device|Next Science Group|TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
79327948|NCT04964999|Other|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
79327949|NCT05108701|Behavioral|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
79327950|NCT05108545|Drug|Amphotericin B liposomes|Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
79327951|NCT04951973|Diagnostic Test|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
79327952|NCT05102695|Diagnostic Test|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
79327953|NCT03060395|Dietary Supplement|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
79327954|NCT03060395|Dietary Supplement|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
79327955|NCT03060395|Dietary Supplement|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
79327956|NCT03060395|Dietary Supplement|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
79648553|NCT03738579|Device|Control Group|Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
79648554|NCT03738579|Device|Antibacterial Control Group|Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
79648555|NCT03728699|Diagnostic Test|Sample Collection Blood|Collected from each patient twice weekly.
79327957|NCT03060395|Dietary Supplement|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
79327958|NCT03060395|Dietary Supplement|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
79327959|NCT03060395|Dietary Supplement|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
79327960|NCT03060395|Dietary Supplement|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
79327961|NCT05081323|Behavioral|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
79327962|NCT04431791|Drug|Regorafenib|oral regorafenib
79327963|NCT04431791|Drug|Fruquintinib|oral fruquintinib
79327964|NCT05007769|Drug|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
79327965|NCT05007769|Drug|Atezolizumab|Atezolizumab will be commercially available.
79327966|NCT05007769|Drug|N-803|Will be supplied free of charge to the participants by ImmunityBio
79327967|NCT04952051|Drug|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
79327968|NCT04952051|Drug|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
79327969|NCT04979143|Procedure|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
79327970|NCT04960943|Drug|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
79327971|NCT03058367|Dietary Supplement|IQP-AE-103 (330mg)|High dose capsules
79327972|NCT03058367|Dietary Supplement|IQP-AE-103 (165mg)|Low dose capsules
79327973|NCT03058367|Dietary Supplement|Placebo|Placebo identical to verum capsules
79327974|NCT03060317|Behavioral|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
79327975|NCT04964531|Other|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
79327976|NCT04964687|Procedure|Liver transplantation|Liver transplantation
79327977|NCT05081167|Drug|REL-1017|REL-1017 tablet
79327978|NCT05081167|Drug|Placebo|Placebo tablet
79327979|NCT03058445|Device|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
79327980|NCT03058445|Device|CVC|Injection of 5 ml of saline
79327981|NCT04431713|Drug|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
79327982|NCT04773925|Behavioral|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
79327983|NCT05104333|Biological|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
79327984|NCT05104333|Biological|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
79327985|NCT03058055|Behavioral|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
79327986|NCT03058055|Behavioral|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
79327987|NCT03058055|Behavioral|Reading|Book club that includes weekly one hour meetings and daily reading assignments
79327988|NCT04951895|Diagnostic Test|MRI|MRI of TMJ
79327989|NCT05094895|Procedure|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
79327990|NCT05094895|Procedure|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
79327991|NCT04819763|Other|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~The lower jaw moves to the left and back to the center with little contact to the spatula~The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~The left palm is placed on the left temple region~Right hand forms a fist and is placed on the tip of the right chin~Both arms are aligned parallel to the surface of the floor~The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
79327992|NCT04819763|Other|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
79327993|NCT04960631|Diagnostic Test|Double site CT guided needle biopsy|Double site CT guided needle biopsy
79978994|NCT03482245|Other|Blue Light|"Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single On/Off switch. It will be attached to a rolling stand.~This light is fitted with a blue spectrum filter (peak 441 nm) such that it produces 1000 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject."
79327994|NCT03059615|Drug|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
79327995|NCT03059615|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
79482769|NCT04113785|Device|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
79482770|NCT04112069|Device|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
79327996|NCT04951505|Drug|cefepime-taniborbactam|IV infusion
79327997|NCT04951349|Drug|GX-03|Same dosage used in Bactroban Nasal studies.
79482771|NCT04112069|Other|Usual Care|Usual care
79978995|NCT03481933|Device|Transcranial stimulation|"10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~left-excitatory tDCS (N=20)~right-inhibitory tDCS (N=20)~sham tDCS (N=20)~4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
79327998|NCT04951349|Drug|Petrolatum ointment|Viscous ointment similar in form to study drug.
79327999|NCT02658019|Drug|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
79328000|NCT03059303|Drug|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
79482772|NCT03544307|Behavioral|Taekwondo training|Exercise group
79482773|NCT04086407|Device|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
79482774|NCT04411290|Procedure|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
79482775|NCT04098575|Drug|Empagliflozin|drug
79328001|NCT03059303|Drug|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
79648556|NCT03728699|Diagnostic Test|Stool Sample|Collected from each patient twice weekly.
79648557|NCT03726554|Device|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
79648558|NCT03726554|Device|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
79328002|NCT03059303|Drug|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
79328003|NCT03059303|Drug|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
79328004|NCT03059303|Drug|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
79328005|NCT03059303|Drug|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
79648559|NCT03713294|Drug|Dexamethasone|Given IV and PO
79648560|NCT03713294|Biological|Elotuzumab|Given IV
79648561|NCT03713294|Drug|Pomalidomide|Given PO
79648562|NCT03691220|Behavioral|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
79648563|NCT03605342|Drug|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
79648564|NCT03605342|Behavioral|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
79648565|NCT03605342|Behavioral|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
79648566|NCT03604289|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
79648567|NCT03604289|Drug|Saline|Saline will be used as the placebo comparator
79648568|NCT03596450|Drug|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
79648569|NCT03596450|Drug|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
79648570|NCT03581604|Diagnostic Test|Allergy work-up|Allergy work-up
79328006|NCT03059303|Drug|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
79328007|NCT04593199|Behavioral|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
79328008|NCT04593199|Behavioral|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
79648571|NCT03581604|Other|Blood samples|Blood samples
79648572|NCT03579875|Drug|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
79328009|NCT03059225|Device|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
79328010|NCT03059225|Device|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
79978996|NCT03474991|Drug|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
79978997|NCT03443973|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
79978998|NCT03443973|Drug|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
79648573|NCT03579875|Drug|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
79648574|NCT03579875|Drug|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
79648575|NCT03579875|Drug|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
79648576|NCT03579875|Device|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
79648577|NCT03579875|Drug|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC >2.5 x 10^9/L for 3 consecutive days)
79648578|NCT03579875|Drug|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
79648579|NCT03579875|Drug|Rituximab|200 mg/m2 IV once on day -1
79978999|NCT03426306|Diagnostic Test|4DCT-Ventilation|4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
79648580|NCT03579875|Drug|Busulfan|Busulfan 0.6 mg/kg if > 4 years old and/or >12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
79979000|NCT03422679|Drug|CB-103|Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
79979001|NCT03409809|Behavioral|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
79979002|NCT03409809|Behavioral|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
79648581|NCT03570606|Device|bone graft substitute|orthopaedic or spine bony defects
79648582|NCT03451799|Other|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
79979003|NCT03409809|Behavioral|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
79328011|NCT03059537|Drug|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
79328012|NCT04416685|Procedure|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
79648583|NCT03451799|Radiation|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
79648584|NCT03451799|Drug|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
79648585|NCT03451149|Device|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
79648586|NCT03405753|Dietary Supplement|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
79979004|NCT03406611|Drug|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
79979005|NCT03406611|Drug|Placebo|Normal saline for subcutaneous injection
79979006|NCT03400826|Drug|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
79979007|NCT03400826|Drug|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
79979008|NCT03384238|Procedure|Fluorescence Imaging|Undergo fluorescence imaging
79979009|NCT03384238|Biological|Panitumumab|Given IV
79979010|NCT03384238|Drug|Panitumumab-IRDye800|Given IV
79328013|NCT04416685|Procedure|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
79328014|NCT04416685|Procedure|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
79482776|NCT05350410|Other|HALT-AD|Prior studies have shown that programs that focus on promoting brain health and managing lifestyle risks (such as poor diet, obesity, physical inactivity, sleep issues, loneliness) may help in preventing or lowering the risk of dementia. To address this, we have developed the HALT-AD program. HALT-AD is an educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk
79482777|NCT03776240|Drug|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
79482778|NCT03776240|Drug|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
79482779|NCT03776240|Drug|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
79979011|NCT03379532|Device|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
79979012|NCT03379532|Device|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
79979013|NCT03375242|Drug|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
79979014|NCT03368963|Drug|Nanoliposomal Irinotecan|Given IV
79328015|NCT04944407|Procedure|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
79482780|NCT04832100|Drug|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
79979015|NCT03368963|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79979016|NCT03365622|Drug|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
79482781|NCT04106492|Drug|SQ3370|SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
79482782|NCT04100720|Device|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
79482783|NCT02976272|Other|bortezomib|
79482784|NCT01600326|Procedure|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
79811152|NCT00683969|Drug|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
79811153|NCT00683969|Drug|placebo|po bid for 36 weeks
79811154|NCT00778024|Drug|fluoxetine HCL 40 mg capsules|
79979017|NCT03365622|Drug|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
79979018|NCT03365622|Drug|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
79979019|NCT03365622|Drug|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
79328016|NCT04944407|Procedure|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
79979020|NCT03361306|Drug|Elotuzumab|Experimental
79979021|NCT03355781|Device|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
79328017|NCT04428775|Drug|ALZT-OP1a (cromolyn)|"Mast cell stabilizer~Neuroinflammatory microglial modulator~anti-inflammatory"
79979022|NCT03355781|Procedure|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
79979023|NCT03355781|Other|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
79328018|NCT04944329|Procedure|Hip fracture surgery|Hip fracture surgery
79328019|NCT04436263|Behavioral|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
79328020|NCT04436263|Behavioral|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
79328021|NCT04951271|Behavioral|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
79328022|NCT04950569|Drug|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
79328023|NCT04944251|Behavioral|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
79328024|NCT04411043|Behavioral|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
79328025|NCT04944641|Behavioral|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
79328026|NCT04944641|Drug|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
79328027|NCT04436419|Dietary Supplement|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1*04-03/06 polymorphisms; recent hospitalization (<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
79328028|NCT04436419|Dietary Supplement|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
79811155|NCT00853658|Drug|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
79811156|NCT00853658|Drug|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
79482785|NCT01600326|Drug|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
79328029|NCT02624687|Behavioral|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
79328030|NCT02624687|Other|No intervention|No contact control
79482786|NCT04082819|Device|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
79328031|NCT04943705|Device|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
79328032|NCT04950491|Other|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, &Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
79328033|NCT04950491|Other|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
79482787|NCT04082819|Device|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
79328034|NCT04950491|Other|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, & Chaushu, 2004). Patients answered using a 5-category Likert scale.
79482788|NCT00361790|Drug|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
79328035|NCT04950335|Procedure|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
79328036|NCT04950335|Procedure|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
79328037|NCT04950179|Other|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
79482789|NCT04081961|Device|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
79482790|NCT04821102|Biological|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection under ultrasonic guided
79482791|NCT04821102|Drug|Saline|saline, 1 time injection under ultrasonic guided
79979024|NCT03325439|Drug|Brivaracetam (BRV) intravenous (iv)|"Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment."
79979025|NCT03325439|Drug|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
79979026|NCT03324425|Drug|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
79979027|NCT03301532|Drug|Triheptanoin|Dietary supplementation with triheptanoin
79979028|NCT03291899|Combination Product|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
79979029|NCT03260465|Device|seleXys PC|Total hip arthroplasty using the seleXys PC cup
79979030|NCT03260465|Device|RM|Total hip arthroplasty using the RM cup
79979031|NCT03247634|Behavioral|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
79979032|NCT03246347|Drug|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
79979033|NCT03221426|Biological|Pembrolizumab|IV infusion
79979034|NCT03221426|Drug|Placebo|IV infusion
79979035|NCT03221426|Drug|Cisplatin|IV infusion
79979036|NCT03221426|Drug|Capecitabine|Oral tablets
79979037|NCT03221426|Drug|5-fluorouracil|IV infusion
79328038|NCT04960319|Device|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
79328039|NCT04950647|Drug|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
79328040|NCT04950647|Drug|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
79979038|NCT03221426|Drug|Docetaxel|IV infusion
79979039|NCT03221426|Drug|Oxaliplatin|IV infusion
79979040|NCT03221426|Drug|Leucovorin|IV infusion
79979041|NCT03209713|Behavioral|HPV Vaccine Education|A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
79979042|NCT03209713|Behavioral|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session (in-person or over the phone). All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
79482792|NCT04143438|Procedure|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
79482793|NCT00361868|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
79482794|NCT00361868|Drug|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
79648587|NCT03405753|Dietary Supplement|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
79979043|NCT03207594|Other|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
79979044|NCT03207594|Other|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
79979045|NCT03207594|Other|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
79328041|NCT04950647|Drug|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
79328042|NCT01675765|Biological|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
79328043|NCT01675765|Biological|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
79328044|NCT04960163|Other|No intervention|No intervention
79328045|NCT04960085|Device|echocardiography|philips IE33
79328046|NCT04522453|Other|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
79328047|NCT04522453|Other|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
79328048|NCT04943237|Drug|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
79648588|NCT03405480|Other|Rehabilitation|Rehabilitation
79648589|NCT03401320|Drug|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
79648590|NCT03396874|Drug|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
79328049|NCT04943237|Drug|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
79328050|NCT05011435|Device|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
79328051|NCT04950413|Other|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
79482795|NCT04990362|Dietary Supplement|Pomegranate oil, Mediterranean Diet|Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol
79482796|NCT04990362|Dietary Supplement|Mediterranean Diet|Dietary Supplement: Mediterranean dietary protocol
79482797|NCT04564872|Drug|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
79482798|NCT04564872|Drug|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
79482799|NCT04564872|Drug|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
79648591|NCT03389620|Drug|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
79648592|NCT03364582|Other|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
79648593|NCT03303846|Procedure|Magnetic Resonance Imaging|Undergo high risk breast cancer screening MRI
79648594|NCT03303846|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
79648595|NCT03303846|Other|Laboratory Biomarker Analysis|Correlative studies
79648596|NCT03300817|Other|Laboratory Biomarker Analysis|Correlative studies
79648597|NCT03300817|Biological|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
79979046|NCT03207555|Drug|Ibrutinib|420 mg by mouth once daily.
79979047|NCT03203330|Biological|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
79979048|NCT03203330|Biological|Placebo Control|2 mL normal saline injection
79328052|NCT04950413|Other|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
79482800|NCT04079348|Device|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
79328053|NCT04950413|Device|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
79328054|NCT04285255|Drug|Fentanyl|opioids anaesthesia
79328055|NCT04285255|Drug|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
79328056|NCT04285255|Drug|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
79328057|NCT04285255|Procedure|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
79328058|NCT04285255|Drug|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
79328059|NCT04943003|Device|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
79328060|NCT04963543|Other|FID123238|Lubricant applied to the ocular surface
79328061|NCT04943081|Procedure|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
79328062|NCT04942691|Other|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
79328063|NCT04942847|Device|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
79328064|NCT04942847|Device|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
79482801|NCT04079348|Other|standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
79648598|NCT03264664|Drug|E7386|Oral immediate release tablets.
79648599|NCT03260712|Drug|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
79648600|NCT03260712|Drug|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
79328065|NCT04121299|Drug|Carvedilol|Carvedilol 40mg Extended Release Once Daily
79328066|NCT04121299|Drug|Amlodipine|Amlodipine 10mg Once Daily
79328067|NCT04942769|Drug|Selenium|selenium 100ug ，take it orally twice daily
79482802|NCT04074668|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
79482803|NCT04074668|Drug|Iohexol Inj 300 milligrams/milliliter (mg/ml)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
79482804|NCT04074668|Radiation|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
79482805|NCT04074668|Procedure|Renal Biopsy|Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.
79482806|NCT04343144|Drug|Nivolumab Injection|Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
79648601|NCT03260712|Drug|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
79648602|NCT03260257|Other|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
79482807|NCT04075409|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
79482808|NCT03743246|Drug|JCAR017|JCAR017
79482809|NCT03743246|Drug|Lymphodepleting|Lymphodepleting
79482810|NCT03743246|Drug|Fludarabine|Fludarabine
79979049|NCT03187288|Drug|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
79328068|NCT04253665|Behavioral|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
79328069|NCT04942301|Drug|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
79328070|NCT04942301|Device|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
79328071|NCT04942301|Combination Product|combination therapy|Combination therapy with chemotherapy drugs was used
79328072|NCT04959539|Procedure|endoscopic transcanal tympanoplasty with attico-antrostomy|Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac
79328073|NCT04959539|Procedure|endoscopic assisted canal wall up mastoidectomy|traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
79328074|NCT04184479|Behavioral|LEVAmethod by Bertz et al|Ordinary treatment
79482811|NCT03743246|Drug|Cyclophosphamide|Cyclophosphamide
79482812|NCT04074941|Other|Dietary intervention|Intervention include low sodium or usual sodium diet
79482813|NCT05346666|Drug|Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam|Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
79482814|NCT00361166|Drug|ACP-103|
79482815|NCT03694613|Other|Placental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
79482816|NCT03674294|Drug|Aprepitant|Aprepitant is manufactured by Merck & Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
79482817|NCT03674294|Drug|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
79482818|NCT03674294|Drug|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
79482819|NCT03674294|Drug|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
79482820|NCT03669146|Device|Glasses|Partial refractive correction in a pair of glasses.
79328075|NCT04959227|Other|Sema activity|sema activity 3 days a week for at least a year
79328076|NCT04725175|Drug|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
79328077|NCT04725175|Drug|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
79328078|NCT02625233|Device|senofilcon C|
79328079|NCT02625233|Device|comfilcon A|
79482821|NCT00377273|Drug|fluorouracil cream 0.5%|
79979050|NCT03147612|Biological|Blinatumomab|Given via central catheter
79979051|NCT03147612|Drug|Cyclophosphamide|Given IV
79979052|NCT03147612|Drug|Cytarabine|Given intrathecally or IV
79979053|NCT03147612|Biological|Filgrastim|Given SC
79648603|NCT03255915|Drug|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
79648604|NCT03255915|Other|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
79648605|NCT03235245|Drug|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
79979054|NCT03147612|Drug|Methotrexate|Given intrathecally or IV
79328080|NCT04704349|Radiation|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
79328081|NCT03059069|Drug|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
79328082|NCT03059069|Drug|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
79328083|NCT04942223|Device|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
79328084|NCT03710785|Behavioral|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
79328085|NCT04949945|Behavioral|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
79328086|NCT04563715|Diagnostic Test|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
79648606|NCT03235245|Drug|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
79648607|NCT03222492|Biological|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
79648608|NCT03222492|Biological|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
79979055|NCT03147612|Biological|Pegfilgrastim|Given SC
79979056|NCT03147612|Drug|Ponatinib|Given PO
79979057|NCT03147612|Biological|Rituximab|Given IV
79979058|NCT03147612|Drug|Vincristine|Given IV
79979059|NCT03141177|Biological|Nivolumab|Specified dose on specified day
79979060|NCT03141177|Drug|Cabozantinib|Specified dose on specified days
79979061|NCT03141177|Drug|Sunitinib|Specified dose on specified days.
79328087|NCT04563715|Behavioral|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
79328088|NCT04941677|Other|no intervention|no intervention in this study
79328089|NCT03057899|Drug|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
79328090|NCT03057899|Drug|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
79328091|NCT03284827|Drug|NOAC|edoxaban (60 mg once daily [OD]) for at least 6 months
79482822|NCT04842864|Behavioral|Fasting|23 hours fasting
79648609|NCT03156790|Drug|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
79648610|NCT03097783|Device|Restylane Perlane Lidocaine|Intradermal injection
79979062|NCT03141177|Biological|Ipilimumab|Specified dose on specified days
79979063|NCT03118986|Drug|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
79979064|NCT03118986|Drug|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
79979065|NCT03109288|Drug|Pioglitazone|15-45 mg po qd
79328092|NCT03284827|Drug|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
79328093|NCT04959071|Procedure|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
79979066|NCT03109288|Drug|clemastine fumarate|8 mg/day (divided into 3 doses of 2, 2, and 4 mg)
79648611|NCT03088059|Drug|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
79648612|NCT03088059|Drug|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
79648613|NCT03088059|Drug|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
79648614|NCT03088059|Drug|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
79979067|NCT03109288|Drug|Dantrolene|Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)
79979068|NCT03109288|Drug|Pirfenidone|"Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x >= 7d 534 mg po tid x >= 7d 801 mg po tid"
79979069|NCT03099499|Drug|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
79979070|NCT03098836|Drug|ARN-509|240 mg orally daily
79979071|NCT03098836|Drug|Abiraterone Acetate|1000 mg orally daily
79979072|NCT03098836|Drug|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
79979073|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
79979074|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
79328094|NCT04949321|Other|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
79482823|NCT03706313|Drug|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
79979075|NCT03071536|Drug|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
79979076|NCT03069937|Drug|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
79979077|NCT03069937|Drug|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
79979078|NCT03065387|Drug|Everolimus|Given PO
79979079|NCT03065387|Drug|Neratinib|Given PO
79979080|NCT03065387|Drug|Palbociclib|Given PO
79979081|NCT03065387|Drug|Trametinib|Given PO
79979082|NCT03058328|Other|Cognitive testing, testing of heart rate variability and blood samples|No intervention. Registration of ECG, cognitive testing and blood sampling is performed in the perioperative period and during follow up.
79328095|NCT04434001|Drug|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
79328096|NCT04434001|Drug|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
79328097|NCT04434001|Biological|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
79328098|NCT04958993|Drug|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
79328099|NCT04683913|Behavioral|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
79328100|NCT04683913|Other|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
79328101|NCT03603925|Diagnostic Test|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
79328102|NCT03603925|Diagnostic Test|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
79328103|NCT04958603|Procedure|"L type release surgery"|Lateral release of the lateral support belt
79328104|NCT03540901|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
79328105|NCT03540901|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
79482824|NCT03706313|Procedure|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
79979083|NCT03055325|Other|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
79979084|NCT03044613|Drug|Nivolumab|240mg or 1 mg/kg administered IV
79979085|NCT03044613|Drug|Relatlimab|80mg administered IV
79979086|NCT03044613|Drug|Carboplatin|standard care dose
79979087|NCT03044613|Drug|Paclitaxel|standard care dose
79979088|NCT03044613|Radiation|Radiation|standard care dose
79979089|NCT03035864|Drug|rhNGF|Eye Drop 20 μg/mL
79979090|NCT03035864|Other|Vehicle|Vehicle Eye Drop
79328106|NCT03517735|Device|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
79328107|NCT03517735|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
79328108|NCT03517735|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
79482825|NCT03706313|Drug|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
79482826|NCT05369364|Drug|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
79482827|NCT05369364|Drug|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
79328109|NCT04958915|Diagnostic Test|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
79328110|NCT03489811|Other|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
79482828|NCT03421106|Behavioral|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
79482829|NCT03421106|Other|Control Food Pantries|Normal food pantry use
79811157|NCT00690677|Drug|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
79811158|NCT02625857|Biological|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU]) and at a higher dose in Cohort 1B (1x10^9 CFU).
79328111|NCT03489811|Other|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
79328112|NCT03489811|Other|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
79328113|NCT04941131|Drug|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
79482830|NCT04542642|Device|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
79482831|NCT04542642|Device|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
79482832|NCT03706469|Drug|TAK-831 T2|TAK-831 T2 Tablets.
79482833|NCT03706469|Drug|TAK-831 T3|TAK-831 T3 Tablets.
79482834|NCT00361244|Drug|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
79482835|NCT00361244|Drug|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
79811159|NCT02625857|Biological|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
79328114|NCT03400501|Drug|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
79482836|NCT00361244|Drug|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
79328115|NCT03400501|Drug|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
79328116|NCT04940975|Behavioral|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
79328117|NCT04940975|Behavioral|Insomnia Education Program at Integrated Mental Health Clinic (IMHC)|A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
79328118|NCT04383847|Behavioral|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
79328119|NCT03231475|Drug|SPH1188-11|qd.po
79328120|NCT04415957|Other|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
79328121|NCT04958681|Other|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
79328122|NCT04949009|Drug|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
79328123|NCT04948541|Combination Product|osa treatment|different treatments can be included
79482837|NCT04532034|Behavioral|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
79482838|NCT04067232|Diagnostic Test|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
79328124|NCT04948541|Other|no treatment|no treatment was undergone
79482839|NCT03381482|Diagnostic Test|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
79328125|NCT04948229|Other|Blood serum samples|Blood serum samples will be taken.
79328126|NCT04940819|Behavioral|Mobile Application for Dietary Management|A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
79328127|NCT03058211|Diagnostic Test|Echocardiography|Standard protocols
79328128|NCT03058211|Diagnostic Test|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
79482840|NCT03381482|Diagnostic Test|Fasting blood sample|6x5 mL of fasting blood sample
79482841|NCT03381482|Diagnostic Test|Lumbar puncture|10 mL of CSF by lumbar puncture
79482842|NCT03545165|Drug|177Lu-PSMA-617|[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)]
79482843|NCT03545165|Drug|177Lu-J591|[1.35 GBq/m2 or 36.5 mCi/m2]
79482844|NCT03545165|Drug|68Ga-PSMA-HBED-CC|[185 ±74MBq or 5 ±2 mCi]
79482845|NCT02974946|Device|RenalGuard|
79482846|NCT04968522|Drug|Methylphenidate Hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
79482847|NCT04968522|Drug|Placebo|The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
79648615|NCT03088059|Drug|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
79328129|NCT04940429|Device|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
79328130|NCT04940429|Diagnostic Test|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
79482848|NCT04968522|Drug|Methylphenidate hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
79648616|NCT03088059|Drug|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
79648617|NCT03088059|Drug|INCAGN01876|INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
79328131|NCT02656693|Behavioral|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
79328132|NCT02656693|Behavioral|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
79328133|NCT04940273|Drug|Remifentanil Injection [Ultiva]|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
79482849|NCT04968522|Drug|Methylphenidate Hydrochloride 18 MG|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
79648618|NCT03048279|Behavioral|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
79648619|NCT03003130|Device|Restylane Defyne|Intradermal injection
79648620|NCT03003130|Device|Restylane|Intradermal injection
79648621|NCT03001388|Procedure|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
79648622|NCT02994069|Drug|Cisplatin|Cisplatin
79648623|NCT02994069|Radiation|XRT|Radiation Therapy
79648624|NCT02989844|Drug|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
79648625|NCT02979340|Procedure|MRI|non-invasive assessment of hepatic fibrosis and steatosis
79648626|NCT02948842|Drug|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
79648627|NCT02948842|Other|Saline|0.08ml of injectable normal saline
79328134|NCT04958525|Procedure|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
79328135|NCT04958525|Procedure|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
79482850|NCT04968522|Drug|Dexamphetamine sulfate|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
79482851|NCT00421850|Behavioral|UNITED Planned Care|
79482852|NCT03546491|Drug|Preventive Gel|0.4% Stannous Fluoride
79482853|NCT03546491|Drug|Marketed Control|0.243% Sodium Fluoride
79482854|NCT00361322|Drug|clindamycin phosphate|
79979091|NCT03021525|Procedure|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in <15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
79328136|NCT02642107|Radiation|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
79482855|NCT00361322|Drug|salicylic acid|
79482856|NCT03714659|Device|Lipogems|Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
79482857|NCT01637142|Drug|LY2140023|Administered orally.
79482858|NCT01637142|Drug|14C-LY2140023|Administered IV.
79482859|NCT01637142|Drug|14C-LY404039|Administered IV.
79482860|NCT04055519|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
79648628|NCT02834884|Genetic|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
79648629|NCT02834884|Genetic|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
79328137|NCT02642107|Radiation|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
79328138|NCT04948385|Drug|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
79328139|NCT04948385|Procedure|No sedation|No sedation
79328140|NCT03057821|Other|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
79328141|NCT04947761|Drug|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
79328142|NCT04947761|Other|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
79482861|NCT04055519|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
79482862|NCT04055519|Device|Multi-purpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
79482863|NCT01636986|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
79482864|NCT01636986|Device|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
79482865|NCT04055675|Diagnostic Test|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
79482866|NCT04831944|Drug|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
79648630|NCT02834884|Genetic|RP-1843 Arcagen|NGS panel
79648631|NCT02834884|Genetic|RP-1920 BioRadon|NGS panel
79648632|NCT02782468|Drug|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m^2 intravenous infusion.
79648633|NCT02782468|Drug|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m^2 intravenous infusion.
79482867|NCT02974712|Drug|Fentanyl|
79482868|NCT02974712|Drug|Saline|
79648634|NCT02782468|Drug|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m^2 intravenous infusion.
79648635|NCT02782468|Drug|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m^2 intravenous infusion.
79648636|NCT02782468|Drug|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2 intravenous or subcutaneous formulation.
79328143|NCT04958213|Drug|Dextrose prolotherapy injection|15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
79328144|NCT04958213|Combination Product|conventional physical therapy|4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
79328145|NCT04958135|Drug|Acoramidis|Film-coated immediate release oral tablet.
79328146|NCT04948151|Drug|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
79328147|NCT04948151|Drug|Placebo|Patients will apply 2-gram applications up to 9 times per month
79328148|NCT04939493|Other|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
79328149|NCT04939493|Other|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
79328150|NCT04939493|Other|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
79328151|NCT04947995|Device|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
79328152|NCT04939337|Drug|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
79328153|NCT04939025|Procedure|Multi-interventional program|"Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~Routine and tailored lengthening measures of the mesentery~Intraoperative control of pouch vascularization using ICG~Early diagnosis and active assessment of the integrity of the anastomosis.~Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
79328154|NCT04947371|Drug|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
79328155|NCT04957121|Other|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
79328156|NCT04957121|Other|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
79328157|NCT02633293|Drug|Inhaled Treprostinil|Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
79328158|NCT04938713|Drug|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
79328159|NCT04938713|Drug|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
79328160|NCT04938401|Other||
79648637|NCT02779244|Procedure|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
79648638|NCT02779244|Procedure|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
79328161|NCT04938011|Drug|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
79648639|NCT02664181|Drug|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
79648640|NCT02664181|Drug|oral decitabine|oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
79648641|NCT02664181|Drug|Tetrahydrouridine|Oral THU ~10 mg/kg twice weekly on consecutive days
79648642|NCT02651480|Dietary Supplement|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
79328162|NCT04938011|Drug|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
79328163|NCT04296019|Drug|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
79648643|NCT02651480|Dietary Supplement|Control Group|Unrestricted diet with no instruction.
79328164|NCT04947215|Diagnostic Test|stress biomarkers|used to estimate the reference values of putative biomarkers of birth stress such asCTnT, CTnI, copeptin, NT-proBNP and hs-CRP in the cord blood of full term neonates
79648644|NCT02605785|Drug|F-18 AV 1451|Tau PET scan
79328165|NCT05115565|Device|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
79328166|NCT03057665|Device|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
79328167|NCT04677907|Device|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
79328168|NCT04677907|Device|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
79328169|NCT03057509|Drug|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
79328170|NCT03057509|Device|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
79328171|NCT03057509|Other|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
79328172|NCT03057509|Drug|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
79328173|NCT05115487|Diagnostic Test|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
79328174|NCT04957199|Other||
79328175|NCT04436887|Procedure|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies >20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
79979092|NCT03021525|Procedure|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate <100 bpm, mean arterial pressure >65 mmHg, SpO2>94%, and core temperature >36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
79328176|NCT05115175|Behavioral|Mindfulness-Based Stress Reduction|Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
79328177|NCT03800329|Device|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
79328178|NCT03800329|Other|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
79328179|NCT04946513|Other|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
79328180|NCT03058133|Other|fMRI study|Functional brain activations of face-voice processing during a gender task
79979093|NCT02993068|Other|Educational Intervention|Watch genetic testing online educational video
79979094|NCT02993068|Other|Genetic Counseling|Receive post-telephone genetic counseling
79979095|NCT02993068|Other|Genetic Counseling|Receive pre-telephone genetic counseling
79979096|NCT02993068|Other|Laboratory Biomarker Analysis|Correlative studies
79979097|NCT02993068|Other|Questionnaire Administration|Ancillary studies
79328181|NCT04798495|Other|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
79328182|NCT05114707|Drug|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
79328183|NCT04937621|Diagnostic Test|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
79328184|NCT04937621|Drug|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
79328185|NCT04937621|Biological|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
79328186|NCT04937621|Other|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
79328187|NCT04937855|Other|no intervention|no intervention
79328188|NCT03572413|Procedure|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
79328189|NCT03572413|Drug|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
79328190|NCT04946747|Device|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
79328191|NCT04946747|Other|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
79328192|NCT04946747|Other|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
79328193|NCT04937933|Drug|Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
79482869|NCT04526340|Diagnostic Test|Blood sample|2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).
79482870|NCT04526340|Diagnostic Test|Bio-impedance measurement (BIA)|for every 30 minutes for 4 hours
79482871|NCT04526340|Dietary Supplement|Ingestion of testing nutrient/food capsules|The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.
79482872|NCT04526340|Diagnostic Test|Urine sample|3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
79482873|NCT02974556|Procedure|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
79482874|NCT02974556|Procedure|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
79648645|NCT02600884|Behavioral|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
79979098|NCT02961504|Biological|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
79648646|NCT02600884|Behavioral|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
79979099|NCT02961504|Biological|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
79648647|NCT02595866|Drug|Antiretroviral Therapy|Given PO
79979100|NCT02944071|Device|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
79328194|NCT04937933|Drug|Saline solution|saline solution
79328195|NCT04956419|Drug|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
79328196|NCT04956419|Drug|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
79328197|NCT04956653|Other|Without additional intervention|Only patients' information was collected
79328198|NCT04615429|Biological|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
79328199|NCT04615429|Other|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
79328200|NCT04956965|Radiation|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
79482875|NCT02974556|Drug|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
79482876|NCT04523142|Drug|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
79979101|NCT02942355|Drug|anastrozole|Anastrozole by mouth daily
79979102|NCT02942355|Drug|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
79979103|NCT02922751|Other|Liver Stiffness Measurement (LSM)|LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
79979104|NCT02902055|Drug|Neuromuscular Blocking Agents|Neuromuscular blockae
79328201|NCT05114395|Other|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
79328202|NCT05114395|Other|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
79328203|NCT04946669|Drug|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
79328204|NCT04956497|Device|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
79328205|NCT03219775|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)*~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
79328206|NCT04409015|Device|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
79648648|NCT02595866|Procedure|Biopsy|Undergo biopsy
79648649|NCT02595866|Procedure|Biospecimen Collection|Undergo blood sample collection
79648650|NCT02595866|Procedure|Computed Tomography|Undergo CT or PET/CT
79648651|NCT02595866|Biological|Pembrolizumab|Given IV
79979105|NCT02902055|Drug|Isotonic saline|Placebo
79979106|NCT02900651|Drug|MAK683|Drug: MAK683
79979107|NCT02889809|Drug|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
79979108|NCT02889809|Drug|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
79979109|NCT02889809|Drug|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (>=6 year old subjects)
79328207|NCT04946045|Other|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
79328208|NCT03057587|Device|NIRS Monitoring|NIRS data will be collected throughout the surgery
79979110|NCT02889809|Drug|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
79979111|NCT02884648|Drug|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
79328209|NCT03100045|Drug|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
79328210|NCT04946123|Dietary Supplement|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
79328211|NCT04945889|Diagnostic Test|Quick Sequential Organ Failure Assessment (qSOFA)|Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score <15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
79328212|NCT04945889|Diagnostic Test|Modified Early Warning Score (MEWS)|Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
79328213|NCT04945889|Diagnostic Test|National Early Warning Score (NEWS)|Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
79328214|NCT04945811|Diagnostic Test|Interlukein 6 and procalcitonin serum levels|Blood tests
79328215|NCT04955561|Other|Oxygen therapy|Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
79328216|NCT04955561|Other|Medical Air|Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
79482877|NCT04538456|Other|questionnaire and optional interview|Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
79979112|NCT02862353|Biological|blood sample|15 ml of blood
79979113|NCT02860741|Behavioral|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
79328217|NCT04955561|Other|10L/min O2|Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
79648652|NCT02595866|Procedure|Positron Emission Tomography|Undergo PET/CT
79979114|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
79979115|NCT02860364|Procedure|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
79979116|NCT02830204|Device|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
79328218|NCT04945577|Diagnostic Test|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
79328219|NCT04945577|Other|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
79648653|NCT02563769|Drug|Clavulanic acid|Clavulanic acid will be administered orally in 250mg capsules
79648654|NCT02563769|Drug|Intravenous cocaine|20/40mg Cocaine will be administered by IV
79648655|NCT02563769|Drug|Placebo|Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
79979117|NCT02815592|Drug|BMS-986012|
79979118|NCT02815592|Drug|Cisplatin|
79979119|NCT02815592|Drug|Etoposide|
79328220|NCT04945343|Procedure|Growing Rods|Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
79328221|NCT02623829|Drug|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
79648656|NCT02513407|Behavioral|Behavioral Dietary Intervention|Attend healthy nutritional education session
79648657|NCT02513407|Other|Educational Intervention|Attend EML educational session
79648658|NCT02513407|Behavioral|Exercise Intervention|Attend exercise educational session
79979120|NCT02815592|Drug|Platinum|
79979121|NCT02815592|Drug|Carboplatin|
79979122|NCT02807766|Behavioral|Behavior modification|Each group has 30 subjects and experiences six months' training.
79979123|NCT02807766|Behavioral|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
79328222|NCT02623829|Drug|Saline|1ml of normal saline will be administered
79328223|NCT04945499|Drug|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
79328224|NCT04944875|Procedure|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
79328225|NCT04944875|Procedure|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
79648659|NCT02513407|Behavioral|Exercise Intervention|Receive fitness tracker
79979124|NCT02807766|Behavioral|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
79979125|NCT02807766|Behavioral|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
79979126|NCT02792465|Drug|CFI-402257|
79979127|NCT02792465|Drug|Fulvestrant|
79979128|NCT02785224|Drug|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
79979129|NCT02784171|Drug|Cisplatin|
79979130|NCT02784171|Drug|Pemetrexed|
79328226|NCT04944875|Procedure|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
79979131|NCT02784171|Drug|Pembrolizumab|
79979132|NCT02759107|Drug|Tirzepatide|Administered SC
79979133|NCT02759107|Drug|Placebo|Administered SC
79979134|NCT02759107|Drug|Dulaglutide|Administered SC
79979135|NCT02733133|Drug|Testagen® TDS Testosterone 5% HypoSpray®|Topically applied Testosterone Hormone Replacement Lotion
79979136|NCT02729519|Procedure|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
79328227|NCT02655679|Drug|VTP-38543|VTP-38543 topical cream
79328228|NCT02655679|Other|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
79648660|NCT02513407|Other|Laboratory Biomarker Analysis|Correlative studies
79979137|NCT02712086|Other|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
79979138|NCT02697227|Behavioral|Behavioral Intervention|Receive BATS counseling
79979139|NCT02697227|Other|Laboratory Biomarker Analysis|Correlative studies
79979140|NCT02697227|Drug|Nicotine Patch|Receive nicotine patch
79328229|NCT02655679|Other|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
79328230|NCT04936295|Drug|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
79328231|NCT04955873|Device|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
79648661|NCT02513407|Other|Questionnaire Administration|Ancillary studies
79648662|NCT02454140|Radiation|SBRT|Fixed five-fraction stereotactic radiotherapy
79648663|NCT02420717|Drug|Cyclophosphamide|Given IV
79979141|NCT02697227|Other|Questionnaire Administration|Ancillary studies
79979142|NCT02697227|Behavioral|Smoking Cessation Intervention|Receive standard smoking cessation counseling
79979143|NCT02694094|Dietary Supplement|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for > 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
79979144|NCT02658968|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
79328232|NCT04955873|Device|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
79648664|NCT02420717|Drug|Cytarabine|Given IV
79648665|NCT02420717|Drug|Dasatinib|Given PO
79648666|NCT02420717|Drug|Dexamethasone|Given PO or IV
79648667|NCT02420717|Drug|Doxorubicin|Given IV
79648668|NCT02420717|Other|Laboratory Biomarker Analysis|Correlative studies
79648669|NCT02420717|Drug|Leucovorin|Given IV or PO
79648670|NCT02420717|Drug|Mercaptopurine|Given PO
79979145|NCT02651831|Other|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
79979146|NCT02651831|Other|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
79979147|NCT02622035|Behavioral|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
79979148|NCT02622035|Behavioral|Emotion induction|Film clip designed to induce anger or fear
79328233|NCT05114239|Drug|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
79648671|NCT02420717|Drug|Methotrexate|Given IV and PO
79648672|NCT02420717|Drug|Prednisone|Given PO
79648673|NCT02420717|Biological|Rituximab|Given IV
79648674|NCT02420717|Drug|Ruxolitinib Phosphate|Given PO
79648675|NCT02420717|Drug|Vincristine|Given IV
79648676|NCT02267330|Procedure|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
79648677|NCT02259621|Drug|Nivolumab|Anti-PD-1 Therapy
79648678|NCT02259621|Drug|Carboplatin|Anti-PD-1 Therapy
79648679|NCT02259621|Drug|Paclitaxel|Anti-PD-1 Therapy
79648680|NCT02257138|Drug|Decitabine|Given IV
79648681|NCT02257138|Other|Laboratory Biomarker Analysis|Correlative studies
79648682|NCT02257138|Drug|Ruxolitinib Phosphate|Given PO
79648683|NCT02228889|Procedure|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
79979149|NCT02622035|Behavioral|visual perceptual load|visual and interactivity-based load of virtual reality buffet environment
79979150|NCT02604940|Drug|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
79979151|NCT02604940|Drug|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
79979152|NCT02581137|Other|Laboratory Biomarker Analysis|Correlative studies
79979153|NCT02581137|Drug|Metformin Hydrochloride|Given PO
79979154|NCT02530697|Drug|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
79979155|NCT02530697|Drug|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
79979156|NCT02530697|Drug|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
79979157|NCT02523066|Device|Magna Ease|This study is non-intervention
79328234|NCT05114239|Other|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
79648684|NCT02228889|Other|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
79979158|NCT02489006|Drug|Olaparib|
79648685|NCT02228889|Other|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
79648686|NCT02228889|Other|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
79648687|NCT02228889|Other|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
79648688|NCT02228889|Other|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
79648689|NCT02228889|Other|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
79648690|NCT02228889|Other|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
79648691|NCT02228889|Other|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
79648692|NCT02228889|Other|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
79979159|NCT02489006|Drug|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
79979160|NCT02482467|Other|Hormonal analysis, pelvic US|
79979161|NCT02467582|Drug|Aspirin|Aspirin 100 mg daily
79979162|NCT02467582|Drug|Placebo|Placebo
79979163|NCT02465736|Drug|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
79979164|NCT02465736|Drug|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
79979165|NCT02465736|Radiation|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
79979166|NCT02465736|Procedure|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
79979167|NCT02465736|Drug|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
79328235|NCT05114083|Other|symptom assessment|symptom assessment
79328236|NCT04945031|Other|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
79328237|NCT05113849|Biological|IN-B009 (Low-dose)|Two doses, intramuscular injection
79328238|NCT05113849|Biological|IN-B009 (High-dose)|Two doses, intramuscular injection
79328239|NCT04935827|Other|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~Winter: December, January, February~Spring: March, April, May~Summer: June, July, August~Fall: September, October, November"
79328240|NCT04935827|Other|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~Group 1: No hospitalization prior to dialysis~Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
79328241|NCT04944719|Diagnostic Test|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
79328242|NCT04469725|Drug|KN046|KN046 5 milligram per kilogram, every 2 weeks
79979168|NCT02465736|Drug|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
79328243|NCT04418999|Drug|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
79328244|NCT04418999|Drug|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
79328245|NCT04427527|Behavioral|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
79328246|NCT02623361|Drug|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
79328247|NCT02623361|Drug|Sham Block|Sham Block by saline injection
79328248|NCT05113459|Drug|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
79328249|NCT04944485|Other|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
79328250|NCT04944485|Other|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
79328251|NCT04935983|Other|High CHO|Diet with high carbohydrate content
79328252|NCT04935983|Other|Low CHO|Diet with low carbohydrate content
79328253|NCT04935749|Device|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
79328254|NCT05113147|Other|In-depth individual interviews|In-depth individual interviews were based on a semistructured script designed to investigate the perceptions of the participants about the activity they performed, the ideal working conditions, the presence of disruptive behaviors, and their management.
79328255|NCT04955483|Diagnostic Test|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
79328256|NCT04447963|Device|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
79328257|NCT04933019|Genetic|Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
79328258|NCT04955093|Device|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
79328259|NCT04935281|Other|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
79328260|NCT04935281|Other|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
79328261|NCT04935515|Drug|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
79979169|NCT02453594|Biological|pembrolizumab|IV infusion
79979170|NCT02449421|Behavioral|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
79979171|NCT02449421|Behavioral|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
79979172|NCT02418026|Other|hypnosis|Conversational hypnotic induction and therapeutic suggestions
79979173|NCT02414178|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
79328262|NCT04935515|Drug|Oral low dose steroid|Low dose oral methyl prednisolone was added.
79328263|NCT04935515|Drug|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
79328264|NCT04935515|Drug|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
79328265|NCT04447729|Drug|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
79328266|NCT04090645|Device|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
79482878|NCT04819152|Behavioral|Tobacco cessation intervention|Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
79328267|NCT04932551|Other|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
79328268|NCT05110885|Other|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
79328269|NCT05104177|Procedure|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
79328270|NCT03951883|Other|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
79328271|NCT03951883|Other|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
79328272|NCT04376281|Drug|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
79328273|NCT04932629|Biological|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
79482879|NCT03557333|Combination Product|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
79482880|NCT04537520|Device|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
79482881|NCT04050605|Device|somofilcon A toric contact lens|Contact Lens
79328274|NCT04332445|Other|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
79482882|NCT04050605|Device|fanfilcon A toric contact lens|Contact Lens
79482883|NCT04818450|Drug|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
79482884|NCT02974790|Procedure|Echocardiography|Two-dimensional imaging echocardiography
79482885|NCT04035161|Combination Product|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
79482886|NCT04035161|Other|Reference Standard|60% (v/v) 1-propanol skin preparation
79482887|NCT04035161|Combination Product|Active Comparator|ChloraPrep® SEPP® skin preparation
79482888|NCT04035161|Other|Negative Control|0.9% Normal Saline skin preparation
79482889|NCT05369286|Drug|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
79482890|NCT04037969|Device|Nesofilcon A|Hydrogel contact lens for daily wear
79482891|NCT04037969|Device|Delefilcon A|Silicone hydrogel contact lens for daily wear
79648693|NCT02228889|Other|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
79648694|NCT02228889|Other|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
79648695|NCT02228889|Other|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
79328275|NCT04954703|Other|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
79328276|NCT04954703|Other|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
79328277|NCT04932863|Biological|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
79328278|NCT04278313|Procedure|PRP - Platelet Rich Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
79328279|NCT04278313|Procedure|PPP - Platelet Poor Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
79328280|NCT04934735|Procedure|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~Intake by a case manager~Referral to an occupational physician was within one week of the intake.~Charting an occupational rehabilitation program and timing the RTW date~Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~Provision of a guidance booklet for employers on the RTW of cardiac patients.~The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
79328281|NCT04232839|Drug|BI 894416 - Formulation A2|Tablet
79328282|NCT04232839|Drug|BI 894416 - Formulation C2|Tablet
79328283|NCT04232839|Drug|BI 894416 - Formulation D2|Capsule
79328284|NCT04232839|Drug|BI 894416 - Formulation F2|Capsule
79328285|NCT04232839|Drug|BI 894416 - Reference Formulation 1|Tablet
79328286|NCT04934813|Other|Alveolar ridge preservation|application of different bone graft and sealing means after tooth extraction
79328287|NCT04934423|Device|Direct Current Transcranial Stimulation - tDCS|Active intervention
79328288|NCT04934423|Device|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
79648696|NCT02228889|Other|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
79328289|NCT03890887|Drug|BI 1291583|Tablet
79328290|NCT03890887|Drug|Itraconazole|Oral solution
79328291|NCT05098951|Device|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
79648697|NCT02228889|Other|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
79648698|NCT02228889|Other|Assess overall complications at 30 days postoperatively|
79648699|NCT02228889|Other|Assess overall complications at 1 year postoperatively|
79648700|NCT02228889|Procedure|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
79328292|NCT04934501|Diagnostic Test|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
79328293|NCT04934501|Diagnostic Test|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
79328294|NCT04111861|Other|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
79328295|NCT04932161|Procedure|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
79328296|NCT04932161|Procedure|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
79328297|NCT05073523|Other|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
79328298|NCT04934345|Diagnostic Test|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
79328299|NCT04922177|Procedure|Indirect ceramic restoration|Indirect ceramic restoration using an optical impression.
79328300|NCT04922177|Procedure|Direct restoration|Restoration using a Glass Ionomer Cement
79328301|NCT03817957|Drug|Polyglucoferron|intravenous administration
79328302|NCT03817957|Drug|Ferric carboxymaltose|intravenous administration
79979174|NCT02413970|Device|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
79979175|NCT02408939|Drug|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
79979176|NCT02385110|Drug|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
79328303|NCT03817957|Drug|Ferrous Sulfate|oral administration
79328304|NCT04922489|Procedure|Dental implant placement|Dental implant placemente on edentulous jaw.
79328305|NCT04955171|Drug|BEOVU intravitreal injection|BEOVU intravitreal injection
79328306|NCT05015335|Drug|Adalimumab|ADA 40mg q2w
79328307|NCT05015335|Drug|Methotrexate|MTX 10mg qw
79328308|NCT03805243|Device|test of sensors for somnonaute device|test of sensors
79328309|NCT03805243|Device|test of sensors for uronaute device|test of sensors
79482892|NCT03583814|Behavioral|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
79482893|NCT03583814|Behavioral|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
79328310|NCT03805243|Device|test of sensors for toconaute device|test of sensors
79328311|NCT03805243|Device|test of sensors for neuronaute device|test of sensors
79482894|NCT04508192|Other|Exercise|Both interventions are simple strength exercises without technical equipment
79648701|NCT02228889|Device|Strattice|Strattice mesh
79648702|NCT02228889|Device|XenMatrix|Xenmatrix mesh
79328312|NCT03805243|Device|test of sensors for cardioskin device|test of sensors
79328313|NCT03056261|Procedure|Combined general and epidural|Combined general and epidural anaesthesia
79328314|NCT03056261|Procedure|General anaesthesia|General anaesthesia
79979177|NCT02385110|Drug|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
79328315|NCT04922099|Device|glycemic gap|"Measurements of HbA1c-based adjusted glycemic gap:~The estimated chronic average glucose levels (eAG) over the past 3 months will calculate from the equation AG = 28.7 × HbA1c - 46.7 Glycemic gap was calculated as the ADAG level subtracted from the admission glucose level."
79328316|NCT03534817|Behavioral|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
79328317|NCT04933799|Drug|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
79328318|NCT04933799|Drug|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
79328319|NCT03921619|Device|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
79328320|NCT04985383|Device|AKST1210 S-15 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min
79482895|NCT03718871|Behavioral|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
79482896|NCT05448872|Drug|Sacubitril/Valsartan|HF patients treated with Sac/Val
79482897|NCT00362258|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
79979178|NCT02385110|Drug|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
79979179|NCT02385110|Drug|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
79328321|NCT04985383|Device|AKST1210 S-15 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min
79328322|NCT04985383|Device|AKST1210 S-25 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min
79482898|NCT00362726|Drug|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
79482899|NCT00362726|Drug|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
79482900|NCT00362726|Drug|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
79648703|NCT02188368|Drug|POM|
79979180|NCT02385110|Behavioral|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
79328323|NCT04985383|Device|AKST1210 S-25 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min
79648704|NCT02188368|Drug|Steroids|
79979181|NCT02385110|Drug|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
79979182|NCT02379416|Drug|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
79979183|NCT02363296|Device|TMS|Paired associative stimulation and single pulse TMS
79328324|NCT04985383|Device|AKST1210 S-35 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min
79482901|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
79482902|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
79482903|NCT04011774|Other|PLANI-REV|Cognitive remediation program.
79482904|NCT04011774|Other|RELAXATION|Stimulation with no cognitive remediation.
79648705|NCT02188368|Drug|PLD|
79648706|NCT02188368|Drug|CFZ|
79648707|NCT02188368|Drug|BTZ|
79979184|NCT02302885|Other|Blood collection|Blood Collection
79979185|NCT02157493|Behavioral|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
79328325|NCT04985383|Device|AKST1210 S-35 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min
79328326|NCT03533257|Drug|AMX0035|Combination Therapy of TUDCA and Sodium Phenylbutyrate
79328327|NCT03533257|Drug|Placebo|Placebo
79979186|NCT02157493|Behavioral|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
79328328|NCT04933409|Procedure|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
79328329|NCT04933409|Procedure|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
79328330|NCT04574479|Procedure|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
79328331|NCT04574479|Drug|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
79328332|NCT04933487|Device|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
79328333|NCT03338257|Behavioral|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
79328334|NCT04933955|Procedure|vital pulp therapy|pulpotomy
79328335|NCT02925013|Procedure|Blood sampling|Blood sampling for lipid profile
79328336|NCT02925013|Other|Dietary- Normal western diet|Normal western diet
79328337|NCT04933175|Drug|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
79328338|NCT04933175|Drug|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
79328339|NCT02370901|Device|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
79328340|NCT02370901|Behavioral|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
79328341|NCT04431167|Behavioral|Living well with Lupus|The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
79328342|NCT04921709|Other|Medical tests|Blood tests
79328343|NCT04930835|Procedure|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
79328344|NCT04976725|Other|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
79648708|NCT02188368|Drug|CLA|
79979187|NCT02143830|Drug|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
79979188|NCT02143830|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
79482905|NCT03530072|Diagnostic Test|Karius Test|Next Generation Sequencing
79648709|NCT02188368|Drug|CY|
79328345|NCT04921553|Other|Data collection and quality of life questionnaire|"Data collection from the medical file~Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
79328346|NCT02195947|Drug|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
79328347|NCT04913207|Procedure|method of device size selection|device size selection based on 3D-CTA
79328348|NCT01698307|Other|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
79482906|NCT04471194|Diagnostic Test|Self-sampling HPV test|Tests for human papillomavirus from cervical cell sample
79979189|NCT02143830|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
79979190|NCT02143830|Drug|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
79979191|NCT02143830|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
79979192|NCT02143830|Biological|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
79979193|NCT02138110|Device|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
79328349|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
79328350|NCT03054545|Drug|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
79328351|NCT04111757|Device|Technolas® TENEO 317 Model 2|LASIK eye surgery
79482907|NCT04471194|Diagnostic Test|Fecal occult blood test|Tests for human hemoglobin from blood in fecal samples
79979194|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
79328352|NCT05119153|Dietary Supplement|Placebo Comparator|Placebo designed to mimic coffee color.
79328353|NCT05119153|Dietary Supplement|Light Roasted Coffee|12 oz light roast coffee
79328354|NCT05119153|Dietary Supplement|Medium Roasted Coffee|12 oz medium roast coffee
79328355|NCT05119153|Dietary Supplement|Dark Roasted Coffee|12 oz dark roast coffee
79328356|NCT04930913|Diagnostic Test|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
79328357|NCT04954339|Drug|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
79482908|NCT04467996|Device|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
79482909|NCT03261206|Other|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
79482910|NCT05330754|Dietary Supplement|Caffeine intake in mg|"Preanesthetic check-up was done. Average daily caffeine consumption in mg was calculated according to caffeine content in consumed drinks as estimated by Food Data Central."
79482911|NCT02374112|Dietary Supplement|Creatine|Creatine supplementation
79482912|NCT02374112|Other|Placebo|Placebo supplementation
79482913|NCT03506672|Other|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
79482914|NCT03506672|Other|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
79482915|NCT03251378|Drug|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
79482916|NCT03752177|Drug|LY3415244|Administered IV
79979195|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
79979196|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
79328358|NCT04930523|Other|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
79328359|NCT04930523|Other|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
79328360|NCT04304833|Other|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
79328361|NCT04304833|Behavioral|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, & pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
79811160|NCT00781300|Drug|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
79811161|NCT00781300|Drug|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
79328362|NCT04912661|Dietary Supplement|Ferinject|intravenous iron carboxymaltose
79328363|NCT04391959|Drug|AZR-MD-001 Active|AZR-MD-001 is an active ophthalmic ointment
79328364|NCT04391959|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
79811162|NCT04140851|Dietary Supplement|Dietary fiber intervention|Dietary intervention
79811163|NCT04140851|Dietary Supplement|Normal diet|Normal diet
79811164|NCT00781378|Drug|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
79811165|NCT00781378|Drug|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
79811166|NCT00687791|Device|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
79811167|NCT00687869|Behavioral|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
79328365|NCT03429985|Behavioral|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
79328366|NCT04921319|Diagnostic Test|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~VExUS 0: The patient will likely tolerate more fluid if clinically needed.~VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
79328367|NCT04939831|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
79328368|NCT04939831|Other|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
79328369|NCT04921085|Other|Cross-sectional obeservational survey|Cross-sectional obeservational survey
79328370|NCT03357523|Device|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
79328371|NCT03357523|Device|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
79328372|NCT03357523|Device|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
79328373|NCT03357523|Device|Heating bag|Applying a standard 10X13 [cm] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
79328374|NCT04912349|Procedure|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
79482917|NCT02271932|Other|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
79482918|NCT01601496|Device|FUSION Vascular Graft|All subjects who received the FUSION Vascular Graft at the baseline implant procedure.
79482919|NCT03224858|Other|SUMMIT intervention|See description in experimental arm.
79811168|NCT00687869|Behavioral|Case management|Usual stroke aftercare plus patient-information-notes
79482920|NCT03224858|Other|Enhanced usual care|See description in active comparator arm.
79979197|NCT02089217|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy
79328375|NCT04912349|Procedure|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
79328376|NCT04406207|Other|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
79328377|NCT04509739|Behavioral|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
79328378|NCT01966263|Procedure|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
79328379|NCT01966263|Procedure|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
79328380|NCT01966263|Procedure|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
79328381|NCT01966263|Procedure|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
79328382|NCT04930679|Drug|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
79328383|NCT04436185|Behavioral|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
79328384|NCT04400201|Drug|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
79328385|NCT04400201|Drug|Propofol|Intravenous injection at a dose of 1.5~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0~12 mg/kg/h for sedation maintenance
79328386|NCT05434845|Other|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
79979198|NCT02089217|Device|Carotid Stenting (CAS)|Carotid stenting
79979199|NCT02089217|Other|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
79328387|NCT04920773|Other|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
79482921|NCT03211832|Other|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
79979200|NCT02089217|Other|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
79979201|NCT02088775|Procedure|PET scan|Undergo PET-CT scan
79979202|NCT02088775|Procedure|CT Scan|Undergo PET-CT scan
79979203|NCT02088775|Procedure|hepatic artery embolization|Undergo standard radioembolization
79979204|NCT01973179|Radiation|Radiation therapy|Radiation therapy with protons
79979205|NCT01954316|Drug|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
79979206|NCT01949129|Drug|VP16|60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
79979207|NCT01949129|Radiation|TBI|2 x 2Gy/day , 3 days (total 12Gy)
79979208|NCT01949129|Drug|Thiotepa|2x5 mg/kg BW, 1 day
79979209|NCT01949129|Drug|Treosulfan|14g/m² BS, 3 days
79979210|NCT01949129|Drug|Fludarabine|30 mg/m² BS, 5 days
79979211|NCT01949129|Drug|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
79979212|NCT01949129|Drug|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
79979213|NCT01949129|Drug|Cyclophosphamide|as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
79979214|NCT01949129|Drug|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
79648714|NCT02074839|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
79328388|NCT04920773|Other|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
79328389|NCT04423107|Drug|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
79328390|NCT04423107|Drug|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
79328391|NCT01675531|Drug|Targin|Single arm for Targin
79328392|NCT04920851|Device|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
79482922|NCT04444128|Diagnostic Test|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
79482923|NCT04887948|Biological|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
79482924|NCT04887948|Biological|BNT162b2|RNA-based SARS-CoV-2 vaccine (BNT162b2)
79482925|NCT04887948|Other|Saline|Normal saline for injection
79648715|NCT01970306|Device|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
79648716|NCT01962636|Drug|Fludarabine|25 mg/m^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
79979215|NCT01918683|Radiation|TACE transarterial chemoembolization|
79328393|NCT05406999|Drug|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
79979216|NCT01918683|Radiation|stereotatic body radiotherapy (SBRT)|
79979217|NCT01917929|Device|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
79979218|NCT01898793|Drug|Fludarabine|
79328394|NCT05406999|Drug|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
79328395|NCT05406999|Drug|Prednisolone tablets|5 mg once daily, orally.
79328396|NCT05406999|Drug|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
79328397|NCT05406999|Drug|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
79328398|NCT05406999|Drug|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
79328399|NCT05406999|Drug|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
79328400|NCT05406999|Drug|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
79328401|NCT05406999|Procedure|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
79482926|NCT04882800|Device|Lyric extended wear hearing aid device A|Current commercially available extended wear hearing aid
79648717|NCT01962636|Drug|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
79648718|NCT01962636|Radiation|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
79648719|NCT01962636|Drug|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
79648720|NCT01962636|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
79811169|NCT00684125|Device|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
79979219|NCT01898793|Drug|Cyclophosphamide|
79979220|NCT01898793|Procedure|Leukapheresis|
79979221|NCT01898793|Biological|Cytokine-induced killer cells|
79979222|NCT01898793|Biological|IL-2|
79979223|NCT01898793|Drug|ALT-803|
79328402|NCT05118607|Device|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
79648721|NCT01962636|Biological|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
79979224|NCT01898793|Procedure|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
79979225|NCT01898793|Procedure|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
79328403|NCT04930211|Drug|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
79328404|NCT03177265|Behavioral|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
79328405|NCT03177265|Behavioral|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
79328406|NCT03177265|Behavioral|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
79328407|NCT03177265|Behavioral|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
79979226|NCT01898637|Other|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
79979227|NCT01898637|Device|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
79648722|NCT01795313|Biological|HLA-A2 restricted synthetic tumor antigen|
79328408|NCT03054311|Behavioral|Lifestyle Matters|
79648723|NCT01795313|Drug|Imiquimod|
79979228|NCT01858285|Genetic|Exome and/or whole genome sequencing|
79979229|NCT01858012|Behavioral|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
79979230|NCT01857934|Drug|cyclophosphamide|Given intravenously (IV)
79979231|NCT01857934|Drug|topotecan|Given IV
79328409|NCT04912271|Drug|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
79328410|NCT04912271|Drug|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
79648724|NCT01795313|Other|enzyme-linked immunosorbent assay|
79648725|NCT01795313|Other|flow cytometry|
79648726|NCT01795313|Other|immunohistochemistry staining method|
79979232|NCT01857934|Biological|hu14.18K322A|Given IV
79979233|NCT01857934|Procedure|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
79979234|NCT01857934|Procedure|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
79979235|NCT01857934|Drug|cisplatin|Given IV
79648727|NCT01795313|Other|laboratory biomarker analysis|
79648728|NCT01709292|Drug|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
79811170|NCT00684125|Device|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
79979236|NCT01857934|Drug|etoposide|Given IV
79648729|NCT01709292|Drug|Vemurafenib (Post Surgery) - Group A + C|"Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.~Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B."
79328411|NCT04912271|Drug|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
79648730|NCT01709292|Other|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
79648731|NCT01574274|Drug|SC-PEG|11 doses Intravenously over one hour
79648732|NCT01574274|Drug|Oncaspar|16 doses Intravenously over one hour
79811171|NCT02625389|Drug|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
79811172|NCT00687947|Drug|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
79648735|NCT01375140|Drug|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
79648736|NCT01375140|Drug|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
79811173|NCT00666562|Dietary Supplement|Defined Green Tea Catechin Extract|Given orally
79648737|NCT01375140|Drug|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
79811174|NCT00666562|Other|Laboratory Biomarker Analysis|Correlative studies
79811175|NCT00666562|Other|Pharmacological Study|Correlative studies
79811176|NCT00666562|Drug|Placebo|Given orally
79979237|NCT01857934|Drug|doxorubicin|Given IV
79979238|NCT01857934|Drug|vincristine|Given IV
79979239|NCT01857934|Drug|busulfan|Given IV
79979240|NCT01857934|Drug|melphalan|Given IV
79811177|NCT00666562|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79979241|NCT01857934|Biological|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
79979242|NCT01857934|Biological|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
79979243|NCT01857934|Radiation|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
79979244|NCT01857934|Biological|GM-CSF|Given subcutaneously (SQ)
79979245|NCT01857934|Biological|G-CSF|Given subcutaneously (SQ)
79328412|NCT04912271|Drug|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
79482927|NCT04882800|Device|Lyric extended wear hearing aid with fitting modification device B|Extended wear hearing aid with fitting modifications
79979246|NCT01857934|Drug|mesna|Given IV
79979247|NCT01857934|Drug|levetiracetam|Given IV
79979248|NCT01857934|Biological|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
79328413|NCT04912271|Drug|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
79328414|NCT02807779|Drug|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
79328415|NCT02807779|Device|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
79328416|NCT02807779|Device|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
79328417|NCT03057197|Procedure|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
79328418|NCT02769091|Drug|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
79328419|NCT02769091|Drug|Placebo|
79328420|NCT04912193|Drug|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
79328421|NCT02680561|Drug|Fluticasone Propionate MDPI|
79328422|NCT02680561|Drug|Fluticasone Propionate/Salmeterol MDPI|
79328423|NCT02680561|Drug|Fluticasone propionate/salmeterol|
79328424|NCT02532543|Biological|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
79328425|NCT02532543|Biological|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
79328426|NCT02532543|Biological|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
79328427|NCT02532543|Biological|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
79328428|NCT03057353|Device|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
79328429|NCT03054389|Other|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
79328430|NCT03054389|Other|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
79328431|NCT05118373|Behavioral|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
79328432|NCT03057275|Device|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
79328433|NCT05116111|Drug|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
79328434|NCT05116111|Drug|Placebo|Placebo, oral, twice daily
79328435|NCT04929977|Device|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
79328436|NCT05095051|Device|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
79328437|NCT05095051|Device|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
79328438|NCT05597631|Device|G-IVF PLUS|Experimental
79328439|NCT04912037|Device|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
79979249|NCT01857934|Drug|Isotretinoin|Given orally (PO)
79328440|NCT05406297|Procedure|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
79328441|NCT04824469|Other|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
79328442|NCT04258059|Device|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
79328443|NCT04258059|Device|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
79328444|NCT05406063|Radiation|SBRT|Stereotactic multiple fraction radiotherapy
79328445|NCT05037097|Biological|ARCT-165|Dose 3
79328446|NCT05037097|Biological|ARCT-154|Dose 2
79648738|NCT01144507|Procedure|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
79328447|NCT05037097|Biological|ARCT-021|Dose 1
79979250|NCT01857934|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79979251|NCT01849575|Behavioral|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
79979252|NCT01842282|Drug|Amlexanox|
79328448|NCT05025163|Drug|1.23% fluoride foam application|topical application of fluoride foam every 6 months
79979253|NCT01836497|Device|SD01 ICD lead|
79979254|NCT01757665|Device|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
79979255|NCT01748149|Drug|Vemurafenib|"Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery."
79328449|NCT05025163|Drug|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
79328450|NCT02674321|Drug|SD-809|
79979256|NCT01727284|Procedure|MR-guided cryoablation|
79979257|NCT01689584|Genetic|salivary kit|The saliva samples will be made of selected related (DNA).
79979258|NCT01653535|Behavioral|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
79648739|NCT01144507|Other|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
79648740|NCT01130077|Biological|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
79328451|NCT05070637|Procedure|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
79328452|NCT05070637|Procedure|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
79328453|NCT05070637|Procedure|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
79648741|NCT01130077|Biological|Poly-ICLC|Vaccine given every 3 weeks
79811178|NCT04048499|Device|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
79328454|NCT02532465|Device|Air-Q|
79328455|NCT02532465|Device|i-gel|
79811179|NCT00684281|Other|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
79811180|NCT00684281|Other|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
79328456|NCT02665507|Device|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
79328457|NCT02665507|Device|Sham|Hand held laser that emits no LLLI
79328458|NCT02528331|Device|Transcranial magnetic stimulation|
79811181|NCT00769054|Drug|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
79328459|NCT02528331|Behavioral|Cognitive behavioral therapy|
79328460|NCT02919241|Behavioral|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
79328461|NCT02919241|Behavioral|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
79328462|NCT02592031|Drug|XM17|300 IU corresponds to an injection volume of 0.5 mL.
79328463|NCT02592031|Drug|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
79328464|NCT02592031|Drug|Zoladex®|3.6 mg
79328465|NCT05002231|Drug|Losmapimod 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
79328466|NCT05002231|Drug|Losmapimod two 7.5 mg oral tablets|Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
79328467|NCT05002231|Drug|Losmapimod one 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
79328468|NCT04423263|Procedure|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
79328469|NCT04423263|Procedure|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
79979259|NCT01589081|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
79328470|NCT02857543|Other|Plant-Based Diet|
79328471|NCT02857543|Other|American Heart Association Diet|
79328472|NCT02857543|Other|Mediterranean Diet|
79328473|NCT05377671|Diagnostic Test|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
79328474|NCT04784299|Device|YVOIRE volume plus|Hyaluronic acid dermal filler
79328475|NCT04784299|Device|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
79328476|NCT02765659|Behavioral|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
79328477|NCT02765659|Behavioral|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
79328478|NCT02765659|Behavioral|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
79811182|NCT00769054|Drug|Isotonic NaCl|Local Infiltration with NaCl
79811183|NCT04138979|Drug|cyclophosphamide|First use of chemotherapy after breast cancer
79811184|NCT00694265|Procedure|Decompression|Surgical decompression of the median nerve
79811185|NCT00694265|Procedure|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
79811186|NCT04016129|Biological|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
79482928|NCT04854564|Behavioral|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
79482929|NCT04854564|Behavioral|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
79328479|NCT02333149|Dietary Supplement|Melatonin|"Children <40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
79328480|NCT02333149|Drug|Placebo|Placebo frequency and volume are identical to the experimental arm
79328481|NCT02315131|Drug|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
79328482|NCT02315131|Drug|Placebo|Placebo Comparator
79648742|NCT01104220|Other|Weight loss|Bariatric surgery-induced weight loss to achieve ~20%-30% reduction in initial body weight
79648743|NCT01063647|Drug|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
79648744|NCT01063647|Drug|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
79648745|NCT01063647|Drug|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
79648746|NCT00779974|Other|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
79648747|NCT00625586|Biological|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
79979260|NCT01589081|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
79328483|NCT02029963|Device|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
79648748|NCT00625586|Drug|Gemcitabine|1000 mg/m2 weekly, intravenously
79648749|NCT00400946|Drug|asparaginase|
79648750|NCT00400946|Drug|cyclophosphamide|
79328484|NCT02029963|Behavioral|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
79328485|NCT04514965|Other|Blood sampling|Blood sampling
79328486|NCT04514965|Device|Fibroscan|Measurement of liver stiffness
79328487|NCT04514965|Other|Question|Question about pruritus
79328488|NCT05122429|Behavioral|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
79328489|NCT05122273|Device|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
79328490|NCT01794715|Procedure|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
79482930|NCT03799289|Behavioral|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
79482931|NCT03799289|Behavioral|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
79482932|NCT04851444|Drug|SI-F019|Single dose is administered IV.
79482933|NCT03810053|Behavioral|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
79482934|NCT03829488|Drug|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water & electrolytes or as an alkalinising agent.
79648751|NCT00400946|Drug|cytarabine|
79648752|NCT00400946|Drug|dexamethasone|
79648753|NCT00400946|Drug|dexrazoxane hydrochloride|
79648754|NCT00400946|Drug|doxorubicin hydrochloride|
79648755|NCT00400946|Drug|etoposide|Given IV
79648756|NCT00400946|Drug|leucovorin calcium|
79648757|NCT00400946|Drug|mercaptopurine|Given orally
79648758|NCT00400946|Drug|methotrexate|
79648759|NCT00400946|Drug|methylprednisolone|
79328491|NCT05118217|Other|This is a non-interventional study|This is a non-interventional study
79328492|NCT02654977|Drug|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
79979261|NCT01589068|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
79328493|NCT05117983|Device|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
79328495|NCT05117437|Other|Physiological test|This test was conducted to determine the endurance levels of the participants.
79328496|NCT05117437|Other|Physical test|Height, weight, and BMI were determined
79328497|NCT05117437|Other|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
79328498|NCT05117359|Device|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
79328502|NCT03508297|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
79648760|NCT00400946|Drug|pegaspargase|Given IV
79328503|NCT02871115|Other|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
79328504|NCT02871115|Other|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
79648761|NCT00400946|Drug|prednisolone|
79648762|NCT00400946|Drug|therapeutic hydrocortisone|
79648763|NCT00400946|Drug|vincristine sulfate|
79648764|NCT00400946|Radiation|radiation therapy|
79979262|NCT01589068|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
79328505|NCT02078947|Behavioral|High Intensity Exercise|
79328506|NCT02078947|Behavioral|Moderate Continuous Exercise|
79648765|NCT00191321|Drug|Teriparatide|
79328507|NCT02078947|Behavioral|Usual Care|
79328508|NCT05122117|Device|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
79482935|NCT03829488|Drug|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
79648766|NCT00214071|Biological|Influenza vaccine|
79648767|NCT00191360|Drug|Somatropin|
79648768|NCT00221208|Behavioral|Resistance Training|
79648769|NCT00123305|Drug|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
79648770|NCT00123305|Drug|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
79648771|NCT00214110|Drug|Tamoxifen|
79648772|NCT00191399|Drug|Olanzapine|
79648773|NCT00191399|Drug|Fluoxetine|
79648774|NCT00221247|Procedure|Acupuncture|acupuncture
79979263|NCT01589055|Drug|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
79979264|NCT01572337|Procedure|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
79811187|NCT00666328|Drug|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
79328509|NCT05122117|Procedure|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
79328510|NCT05117047|Procedure|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
79648775|NCT00123344|Device|AT501 pacemaker|
79979265|NCT01572337|Other|Standard care|
79328511|NCT05116969|Drug|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
79328512|NCT00232999|Drug|Nebulized IVX-0142|
79328513|NCT05116657|Diagnostic Test|Nasal Lavage and Oral Wash|"Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
79328514|NCT05116501|Diagnostic Test|Whole-exome sequencing|Whole Exome Sequencing (WES), as a comprehensive genetic test, will be used to identify changes in a patient's DNA that are causative or related to patient's low VWF levels.
79328515|NCT05116345|Drug|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
79328516|NCT05116345|Drug|Topical Dexamethasone|topical dexamethasone drops
79328517|NCT05120401|Device|presbyopia glasses|fogging for glasses for far and intermediate
79328518|NCT05121181|Other|delphi project|delphy study
79648776|NCT00191438|Drug|gemcitabine|
79648777|NCT00191438|Drug|capecitabine|
79328519|NCT05096689|Other|MRI|Magnetic Resonance Imaging
79482936|NCT03883607|Drug|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
79482937|NCT03883607|Drug|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
79648778|NCT00191438|Drug|docetaxel|
79648779|NCT00221286|Drug|pegylated interferon alfa-2a|
79648780|NCT00221286|Drug|tenofovir DF / emtricitabine combination therapy|
79648781|NCT00221286|Drug|pegIFN / TDF / FTC combination therapy|
79811188|NCT00694343|Drug|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
79811189|NCT00694343|Drug|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
79811190|NCT00781534|Drug|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
79648782|NCT00123383|Drug|Modafinil|
79648783|NCT00214266|Drug|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
79648784|NCT04722965|Procedure|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
79811191|NCT00781534|Drug|Ginseng|
79979266|NCT01543763|Drug|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
79648785|NCT04722965|Procedure|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
79482938|NCT04846296|Other|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
79648786|NCT00221325|Drug|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
79648787|NCT00123461|Drug|Hectorol (doxercalciferol capsules), 0.5mcg|
79648788|NCT00191516|Drug|Atomoxetine|
79811192|NCT00781534|Drug|ginsenoside RE|active metabolite of ginseng
79979267|NCT01515527|Drug|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
79328520|NCT05076097|Drug|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
79328521|NCT04413019|Other|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~Penicillin may be used in patients who can't tolerate erythromycin~In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
79482939|NCT03805308|Procedure|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
79482940|NCT04826796|Behavioral|WhatsApp peer support|Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
79482941|NCT03926039|Behavioral|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
79648789|NCT00191555|Drug|olanzapine|
79648790|NCT00191555|Drug|haloperidol|
79648791|NCT00123500|Behavioral|Diet|Diet
79648792|NCT00123500|Behavioral|Physical Activity|Physical Activity
79648793|NCT00123500|Behavioral|Environment|Environment
79648794|NCT00123500|Other|Control Group|Control Group
79648795|NCT00221364|Drug|Mass treatment with oral azithromycin to an entire village|
79648796|NCT00123539|Drug|Estrogen Replacement Therapy|
79648797|NCT00123539|Procedure|Surgery|
79648798|NCT00214305|Behavioral|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
79648799|NCT00214305|Behavioral|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
79811193|NCT00781534|Dietary Supplement|Placebo (sugar pill)|placebo group
79811194|NCT00778180|Drug|furosemide 80 mg tablets|
79979268|NCT01515527|Drug|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
79648800|NCT00191594|Drug|Duloxetine Hydrochloride|
79648801|NCT00221442|Drug|Zonegran|zonegran (zonisamide)
79648802|NCT00221442|Drug|sugar pill|fake pill
79648803|NCT00123578|Drug|Lorazepam|Lorazepam
79648804|NCT00123578|Drug|Pentobarbital|Pentobarbital
79811195|NCT00688415|Drug|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
79811196|NCT00781690|Device|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
79811197|NCT00769210|Drug|Simvastatin|Simvastatin 40 mg tablet
79979269|NCT01515527|Drug|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
79979270|NCT01501513|Drug|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
79979271|NCT01501513|Drug|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
79979272|NCT01501513|Drug|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
79979273|NCT01500551|Drug|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet [mg BID] or solution [ml BID]) 5 - < 7 kg (2 mg or 2 ml) 7 - < 10 kg (2.5 mg or 2.5 ml) 10 - <15 kg (3 mg or 3 ml) 15 - <25 kg (3.5 mg or 3.5 ml) 25 - <40 kg (4 mg or 4 ml) >=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing <40 kg. Oral tablets (5 mg) will be used for subjects weighing >=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
79979274|NCT01500551|Drug|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
79979275|NCT01481532|Drug|Crotoxin|Intra patient dose escalation
79328522|NCT05119933|Drug|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
79328523|NCT05085847|Other|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (> 5 years each) experiences.
79328524|NCT05085847|Other|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
79328525|NCT04932577|Biological|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
79328526|NCT04932577|Biological|Placebo|Placebo
79811198|NCT00690911|Drug|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
79648805|NCT00214344|Behavioral|family preparation for withdrawing life support|
79648806|NCT00221481|Drug|divalproex or olanzapine|
79811199|NCT00781846|Drug|ridaforolimus|oral tablets, daily for 5 days/week
79979276|NCT01459497|Radiation|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
79979277|NCT01459497|Radiation|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
79979278|NCT01410942|Other|Placebo|Capsules by mouth twice daily.
79979279|NCT01410942|Drug|Methylphenidate|Starting dose 5 mg by mouth twice daily.
79979280|NCT01410942|Behavioral|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
79648807|NCT02962752|Dietary Supplement|Blackadder Juice|
79648808|NCT02962752|Other|Placebo|
79811200|NCT00781846|Drug|bevacizumab|IV infusion
79811201|NCT00853580|Drug|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
79328527|NCT04882111|Behavioral|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
79482942|NCT04393662|Diagnostic Test|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
79648809|NCT00191633|Drug|Atomoxetine|
79811202|NCT00853580|Device|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
79811203|NCT00781924|Procedure|biopsy|ultrasound guided biopsy of tumors.
79811204|NCT00782002|Biological|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
79328528|NCT05230069|Other|Interview|Patients will be interviewed post an emergency call and evaluation.
79328529|NCT04513639|Drug|Early treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at MRD reapperance
79328530|NCT04513639|Drug|Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at progressive disease
79811205|NCT00688493|Drug|Dapagliflozin|3 x 50 mg tablets, single oral dose
79811206|NCT00688493|Drug|Dapagliflozin|2 x 10 mg capsules, single oral dose
79811207|NCT00688493|Drug|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
79811208|NCT00688493|Drug|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
79979281|NCT01410942|Other|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
79811209|NCT00778414|Drug|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
79811210|NCT00688571|Device|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
79979282|NCT01410942|Other|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
79979283|NCT01410942|Other|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
79328532|NCT04746001|Diagnostic Test|Genomic sequencing|Sequencing data
79328533|NCT04746001|Diagnostic Test|Histological examination|Images for deep learning
79328534|NCT04696549|Behavioral|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
79328535|NCT05119543|Other|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
79328536|NCT05229913|Drug|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
79328537|NCT05229913|Drug|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
79328538|NCT05229913|Drug|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
79482943|NCT04393662|Diagnostic Test|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
79648810|NCT00221520|Drug|midazolam with 2 different levels of sedation scores|
79648811|NCT00191672|Drug|Gemcitabine|
79328539|NCT05229913|Drug|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
79648812|NCT00191672|Drug|Paclitaxel|
79648813|NCT00191672|Drug|Docetaxel|
79648814|NCT00214578|Drug|Seroquel (quetiapine)|
79648815|NCT00123617|Procedure|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
79979284|NCT01280994|Drug|Hyperpolarized 129Xenon Gas|Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
79648816|NCT00221559|Procedure|Blood sampling for determination of serum Zn|
79648817|NCT00191711|Drug|Gemcitabine|
79648818|NCT00221637|Drug|Sodium Valproate|
79648819|NCT00123656|Drug|esomeprazole|esomeprazole dosed qam for 8 weeks
79648820|NCT00123656|Drug|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
79648821|NCT00214617|Drug|Rosuvastatin at 5 mg/day and 40 mg/day|
79648822|NCT00221676|Biological|Alfarix|
79648823|NCT00123773|Procedure|Positron Emission Tomography|
79648824|NCT00214656|Drug|Recombinant Activated Factor VII|
79648825|NCT00191750|Drug|Pemetrexed|
79648826|NCT00221715|Device|femoropopliteal artery bypass|Bypass by autologous saphenous vein
79648827|NCT00221715|Device|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
79328540|NCT05229913|Drug|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
79328541|NCT04667923|Diagnostic Test|Respiratory monitoring|Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation
79328542|NCT04667923|Diagnostic Test|Respiratory muscles ultrasound|Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles
79328543|NCT04667923|Diagnostic Test|Electro impedance tomography|Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants
79328544|NCT04667923|Diagnostic Test|Capnography|Measurement of end-tidal carbon dioxide tension
79328545|NCT04667923|Diagnostic Test|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
79648828|NCT00214695|Drug|Experimental Peritoneal Dialysis Solution|
79648829|NCT00221754|Drug|Pravastatin (drug)|
79648830|NCT02963207|Other|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
79648831|NCT02963207|Other|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
79648832|NCT00191828|Drug|olanzapine|
79648833|NCT00214734|Drug|rAHF-PFM|
79648834|NCT00191867|Drug|Teriparatide|
79648835|NCT00221793|Procedure|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
79648836|NCT00123851|Drug|Tarceva (OSI-774)|
79648837|NCT00123851|Drug|Capecitabine|
79648838|NCT00123851|Drug|Oxaliplatin|
79648839|NCT02962440|Drug|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing [3H]-somapacitan
79648840|NCT00123890|Drug|GW873140|
79648841|NCT00409487|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
79648842|NCT00409487|Drug|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
79648843|NCT00412698|Drug|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
79648844|NCT00412698|Drug|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
79648845|NCT00123929|Drug|docetaxel|100 mg/m2 every 3 weeks times 4
79648846|NCT00123929|Drug|doxorubicin|75 mg/m2 every 3 weeks times 4
79648847|NCT00214812|Drug|HEC placebo gel|
79648848|NCT00124007|Biological|VRC-HIVADV014-00-VP|
79648849|NCT00124007|Biological|VRC-HIVDNA016-00-VP|
79648850|NCT00214929|Behavioral|treatment at home|
79328546|NCT04667923|Diagnostic Test|Quasistatic pressure-volume curve|Quasistatic pressure-volume curve
79328547|NCT05229757|Other|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
79328548|NCT05229757|Other|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
79328549|NCT05229289|Other|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
79328550|NCT05229289|Other|Fecal Microbiota Transplant|Fecal Microbiota Transplant
79328551|NCT01362517|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
79482944|NCT04393662|Diagnostic Test|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
79482945|NCT04000373|Device|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
79482946|NCT04049123|Drug|LY900014|Administered SC
79328552|NCT05229133|Device|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
79328553|NCT04330261|Other|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
79328554|NCT05108155|Procedure|Cemented THA|THA with cement fixation
79328555|NCT05108155|Procedure|Unemented THA|THA with uncemented / pressfit fixation
79482947|NCT04049123|Drug|Insulin Lispro|Administered SC
79482948|NCT04382196|Other|Online survey|An online survey will be administered
79482949|NCT04051463|Drug|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
79482950|NCT04051463|Drug|Placebo|Placebo eye drops instilled once daily
79482951|NCT04826328|Drug|FX301|FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
79482952|NCT04826328|Drug|Normal Saline|Single peripheral nerve injection
79482953|NCT04054661|Diagnostic Test|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
79648851|NCT00475033|Biological|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
79482954|NCT04054661|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
79482955|NCT04054661|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
79482956|NCT04128527|Device|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
79482957|NCT04132973|Behavioral|Compassion for Skin Conditions|Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
79328556|NCT04375735|Drug|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
79328557|NCT01362439|Drug|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
79328558|NCT05228743|Procedure|Comparing Hyperthermic Intraperitoneal Chemotherapy|After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
79328559|NCT05228743|Drug|Paclitaxel|A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
79328560|NCT05228743|Drug|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
79328561|NCT05228665|Behavioral|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
79328562|NCT05228587|Drug|Indocyanine green|Indocyanine green will be injected in all donor
79482958|NCT04184297|Drug|Tiotropium and Olodaterol (Tio+Olo)|drug
79482959|NCT04184297|Drug|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
79328563|NCT03307915|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5*10^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
79328564|NCT03307915|Biological|MVA-Mosaic|Participants will receive MVA-Mosaic 10^8 pfu as IM injection at Weeks 24 and 36.
79328565|NCT03307915|Biological|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
79482960|NCT04713839|Other|no intervention|We didn't have an intervention program, we used two questionnaires to evaluate participants.
79482961|NCT04031885|Drug|Abemaciclib|Administered orally
79482962|NCT04031885|Drug|Fulvestrant|Administered IM
79328566|NCT03307915|Drug|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
79328567|NCT04154059|Other|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
79328568|NCT05227963|Other|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
79328569|NCT05227963|Other|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
79328570|NCT05010343|Radiation|carbon ion irradation|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
79328571|NCT05010343|Radiation|Carbon Ion Irradiation With SIB|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
79328572|NCT04990921|Combination Product|Palliative Radiation and Pembrolizumab|Stereotactic radiation therapy will be administered as clinically indicated.
79328573|NCT02824237|Device|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
79328574|NCT02673385|Other|Brazelton scale|
79328575|NCT02628535|Biological|MGD009|B7-H3 x CD3 DART protein
79328576|NCT04984603|Procedure|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
79328577|NCT04853407|Drug|LY03005 extended-release tablet|orally once a day
79328578|NCT04853407|Drug|Placebo|orally once a day
79328579|NCT02653495|Biological|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
79648852|NCT00475033|Biological|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
79328580|NCT04218487|Drug|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
79328581|NCT04218487|Drug|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
79328582|NCT04218487|Other|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
79328583|NCT04507477|Biological|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
79328584|NCT02472925|Behavioral|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
79482963|NCT04031885|Drug|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
79482964|NCT04029545|Device|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
79648853|NCT00192062|Drug|gemcitabine|
79648854|NCT00192062|Drug|vinorelbine|
79648855|NCT00412776|Drug|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
79648856|NCT00192101|Drug|gemcitabine|
79648857|NCT00192101|Drug|cisplatin|
79648858|NCT00215007|Drug|Levofloxacin|
79648859|NCT00474994|Drug|sunitinib malate|
79648860|NCT00192140|Biological|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
79648861|NCT00474955|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
79648862|NCT00412815|Behavioral|Exercise training|
79979285|NCT01269593|Drug|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
79979286|NCT01217931|Drug|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
79979287|NCT01217931|Drug|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
79328585|NCT01391143|Biological|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
79328586|NCT01675141|Drug|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
79648863|NCT00124046|Procedure|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
79648864|NCT00124046|Procedure|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
79328587|NCT04505293|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
79328588|NCT03915223|Procedure|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
79979288|NCT01217931|Drug|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
79979289|NCT01192568|Drug|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
79328589|NCT05102149|Drug|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
79979290|NCT01063751|Device|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
79979291|NCT00898235|Genetic|clonality analysis|analyze clonality
79979292|NCT00898235|Genetic|polymerase chain reaction|analyze polymerase chain reaction
79979293|NCT00898235|Genetic|protein analysis|analyze protein
79979294|NCT00898235|Other|biologic sample preservation procedure|preserve biologic samples
79979295|NCT00898235|Other|laboratory biomarker analysis|analyze laboratory biomarkers
79979296|NCT00898235|Procedure|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
79979297|NCT00898235|Procedure|quality-of-life assessment|assess quality of life at each follow-up for life
79979298|NCT00809588|Biological|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
79979299|NCT00680901|Drug|Lapatinib|5 pills at 250mg each once daily
79328590|NCT05102149|Drug|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
79328591|NCT05102149|Drug|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
79328592|NCT05102149|Drug|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
79328593|NCT04019431|Dietary Supplement|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
79979300|NCT00680901|Drug|Placebo|5 pills once daily
79979301|NCT00680901|Drug|Capecitabine|1700mg/m2/day in two daily doses
79979302|NCT00680901|Drug|Oxaliplatin|130mg/m2 on day 1
79979303|NCT00557193|Drug|Asparaginase|Given IV, IM, or PO
79979304|NCT00557193|Procedure|Biospecimen Collection|Undergo blood sample collection
79979305|NCT00557193|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79979306|NCT00557193|Drug|Cyclophosphamide|Given IV
79328594|NCT04922749|Behavioral|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
79328595|NCT04412395|Dietary Supplement|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
79328596|NCT04412395|Drug|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
79328597|NCT04016935|Other|Observational|Observational
79482965|NCT04029311|Device|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
79482966|NCT04029311|Device|autoPAP|autoPAP
79482967|NCT04029311|Device|TAP PAP|TAP PAP
79648865|NCT00215046|Drug|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
79979307|NCT00557193|Drug|Cytarabine|Given IV or IT
79979308|NCT00557193|Drug|Daunorubicin Hydrochloride|Given IV
79979309|NCT00557193|Drug|Dexamethasone|Given IV or PO
79979310|NCT00557193|Procedure|Echocardiography|Undergo ECHO
79979311|NCT00557193|Drug|Etoposide|Given IV
79979312|NCT00557193|Biological|Filgrastim|Given IV or SC
79979313|NCT00557193|Other|Laboratory Biomarker Analysis|Correlative studies
79979314|NCT00557193|Drug|Lestaurtinib|Given PO
79979315|NCT00557193|Drug|Leucovorin Calcium|Given IV
79979316|NCT00557193|Drug|Mercaptopurine|Given PO
79979317|NCT00557193|Drug|Methotrexate|Given IV, IT, or PO
79979318|NCT00557193|Drug|Methylprednisolone|Given IV
79979319|NCT00557193|Procedure|Multigated Acquisition Scan|Undergo MUGA
79979320|NCT00557193|Drug|Pegaspargase|Given IM
79979321|NCT00557193|Other|Pharmacological Study|Correlative studies
79979322|NCT00557193|Drug|Prednisone|Given PO
79979323|NCT00557193|Drug|Therapeutic Hydrocortisone|Given IT
79979324|NCT00557193|Drug|Vincristine Sulfate|Given IV
79979325|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
79979326|NCT00516724|Drug|Carboplatin|intravenous injection
79979327|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
79979328|NCT00516724|Drug|Paclitaxel|Intravenous injection
79979329|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
79979330|NCT00516724|Drug|Paclitaxel + Carboplatin|Intravenous injection
79979331|NCT00408590|Biological|carcinoembryonic antigen-expressing measles virus|
79979332|NCT00408590|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|
79979333|NCT00408590|Genetic|reverse transcriptase-polymerase chain reaction|
79648866|NCT00215046|Drug|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
79979334|NCT00408590|Other|laboratory biomarker analysis|
79979335|NCT00408291|Procedure|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
79482968|NCT01638000|Drug|Mirabegron|oral tablet
79648867|NCT00192179|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
79648868|NCT00192179|Biological|Placebo|The placebo consisted of physiologic normal saline.
79648869|NCT00124085|Behavioral|Disease Management|
79648870|NCT00124085|Behavioral|Disease Management + Educational Home Visits|
79648871|NCT00474487|Biological|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
79648872|NCT00474487|Biological|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
79648873|NCT00474487|Biological|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
79979336|NCT00364637|Drug|Sevoflurane (Volatile Anesthetic)|
79979337|NCT00364637|Drug|Total intravenous anesthesia|
79979338|NCT00349830|Procedure|blood draw|
79979339|NCT00186888|Procedure|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
79328598|NCT04754269|Behavioral|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
79328599|NCT04754269|Behavioral|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
79328600|NCT04987099|Dietary Supplement|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
79328601|NCT04987099|Dietary Supplement|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
79328602|NCT03906721|Drug|Placebo|Sugar pill used to condition patients.
79328603|NCT03906721|Drug|Oxycodone|An opioid used for analgesia.
79328604|NCT03906721|Other|Essential Oil|An aromatic oil used for conditioning.
79328605|NCT03994081|Device|tACS|XCSITE100
79328606|NCT03994081|Device|Sham tACS|XCSITE100
79482969|NCT01638000|Drug|Solifenacin succinate|oral tablet
79482970|NCT04023695|Drug|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
79482971|NCT04023695|Drug|Corticosteroid with normal saline|Trigger finger injection
79482972|NCT04013789|Device|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
79482973|NCT04013789|Device|DACP contact lenses|Nelfilcon A soft contact lenses
79482974|NCT04211909|Drug|SOF/VEL|400/100 mg FDC tablet orally once daily.
79482975|NCT04211909|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
79979340|NCT00186888|Drug|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
79482976|NCT03559205|Other|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~Pre-clinic preparation.~Clinic dashboard.~Summary action plan.~Personal goal setting.~Follow-up and monitoring."
79328607|NCT04663711|Behavioral|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
79482977|NCT04223843|Drug|Tiotropium + olodaterol|Oral Inhalation
79482978|NCT04223843|Drug|Placebo|Oral Inhalation
79482979|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
79482980|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
79328608|NCT04096573|Drug|LC51-0255|LC51-0255
79482981|NCT05722951|Drug|Levetiracetam|levetiracetam will be given to 30 patients and monitored for 6 months
79482982|NCT05722951|Drug|Metformin|metformin + levetiracetam will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
79648874|NCT00474487|Biological|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
79328609|NCT04096573|Drug|Placebo|Placebo
79482983|NCT04838652|Drug|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
79482984|NCT05722795|Drug|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
79482985|NCT05119699|Device|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
79482986|NCT05722717|Genetic|Saliva collection at home|Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
79482987|NCT04810494|Drug|2% Lidocaine HCl topical solution|0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
79482988|NCT04810494|Drug|0.9% Sodium chloride|0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
79482989|NCT05722639|Device|X-Trodes acquisition system|No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
79482990|NCT05270928|Drug|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
79482991|NCT02832271|Drug|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
79482992|NCT02832271|Drug|Placebo|Placebo
79482993|NCT05109169|Combination Product|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~Metformin (Glucophage® XR)"
79482994|NCT05109169|Other|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
79482995|NCT04291014|Device|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
79482996|NCT05722405|Drug|Ixazomib plus low-dose lenalidomide|Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
79482997|NCT05722405|Drug|Ixazomib|Ixazomib alone
79482998|NCT04780074|Dietary Supplement|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
79328610|NCT04919083|Other|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
79328611|NCT04919083|Other|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
79328612|NCT04529863|Drug|Tocilizumab|Tocilizumab claim is used as the reference group.
79482999|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
79483000|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
79483001|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
79483002|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
79483003|NCT02826733|Device|Electroencephalogram (EEG)|
79483004|NCT02826733|Device|Near Infra Red Spectroscopy (NIRS)|
79328613|NCT04529863|Drug|Abatacept|Abatacept claim is used as the exposure group.
79483005|NCT02826733|Device|magnetic resonance imaging (MRI)|
79483006|NCT05098873|Other|psychodynamic|intervention with adolescents through the presentation of questions to be completed
79483007|NCT04770090|Other|Blood samples|Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.
79979341|NCT00186888|Procedure|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
79483008|NCT02767531|Drug|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
79483009|NCT05722249|Behavioral|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
79979342|NCT00186888|Radiation|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
79328614|NCT04456933|Procedure|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
79328615|NCT04456933|Procedure|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
79328616|NCT04441957|Device|Endovenous Mechano- Chemical Ablation|The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
79328617|NCT04432441|Other|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
79979343|NCT00186888|Drug|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml*hr, daily for 5 consecutive days, infused over 30 minutes.
79979344|NCT00186888|Drug|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
79979345|NCT00186888|Drug|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: < 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin < 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
79979346|NCT00186888|Drug|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
79979347|NCT00186888|Procedure|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
79648875|NCT00124124|Drug|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
79979348|NCT00186888|Other|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is > 2,000/mL in one occasion after the expected nadir.
79483010|NCT05722249|Behavioral|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
79483011|NCT04419324|Device|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
79979349|NCT00183482|Behavioral|Family Group Cognitive Behavioral|Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
79328618|NCT04432441|Other|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
79328619|NCT03883945|Drug|AIV001|intradermal injection
79328620|NCT03883945|Drug|Vehicle|intradermal injection
79328621|NCT04582591|Drug|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
79328622|NCT04217239|Procedure|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
79483012|NCT05722171|Biological|gdT cell injection targeting B7-H3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.
79483013|NCT04419246|Other|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
79979350|NCT00183482|Behavioral|Written Information|Families are mailed written materials that describe depression and stress in families with a depressed parent.
79979351|NCT00030771|Drug|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
79979352|NCT00030771|Radiation|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
79979353|NCT00030771|Procedure|Surgery|3-4 weeks after termination of radiotherapy
79328623|NCT04217239|Procedure|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
79328624|NCT04212481|Procedure|uniport video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
79328625|NCT04212481|Procedure|two ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using two ports
79483014|NCT04419246|Drug|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
79483015|NCT04419246|Other|general anesthesia|general anesthesia will be applied in accordance with standard procedures
79483016|NCT05722093|Drug|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
79483017|NCT04825626|Biological|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells.
79483018|NCT04758312|Behavioral|MY-Skills Mobile|Yoga and Self-Management Education
79328626|NCT04212481|Procedure|three ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using three ports
79328627|NCT04007575|Diagnostic Test|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
79648876|NCT00124124|Drug|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
79328628|NCT03997669|Other|Collection of pleural effusion|Detection of pleural effusion
79483019|NCT05721625|Other|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
79483020|NCT05721625|Other|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
79483021|NCT02649907|Dietary Supplement|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
79483022|NCT02649907|Other|Nutritional counseling|nutritional counseling for healthy eating behaviour
79648877|NCT00474253|Drug|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
79811211|NCT00865514|Drug|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
79979354|NCT03078192|Drug|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
79979355|NCT03078192|Device|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
79648878|NCT00474253|Drug|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
79648879|NCT00474253|Drug|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
79328629|NCT04497883|Drug|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
79328630|NCT04497883|Drug|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
79483023|NCT02649907|Dietary Supplement|formula diet|formula diet to help weight loss
79648880|NCT00124163|Procedure|Imaging procedure of CT colonography|
79648881|NCT00221871|Drug|Different dosages of Ketamine|
79648882|NCT00474058|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
79811212|NCT00865514|Genetic|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
79328631|NCT04497883|Drug|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
79328632|NCT03756103|Drug|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
79648883|NCT00474058|Other|Placebo|Placebo transdermal patches
79648884|NCT00192218|Biological|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
79328633|NCT03756103|Drug|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
79483024|NCT04411134|Biological|E7 TCR|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
79483025|NCT04229303|Drug|Voriconazole inhaled|"Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily [BID]) or 4 [20mg BID]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily [QD]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 [20mg BID] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler)."
79483026|NCT04229303|Drug|oral voriconazole|Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
79979356|NCT00703846|Drug|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
79979357|NCT03309514|Biological|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
79979358|NCT01341288|Device|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
79979359|NCT03309436|Drug|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
79328634|NCT03756103|Drug|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
79483027|NCT04419012|Other|observation|observation
79483028|NCT05721547|Other|Assessment|Assessment
79648885|NCT02277574|Biological|AMP-110|2, 5, or 10 mg/kg
79648886|NCT02277574|Other|Placebo|Placebo
79648887|NCT02962596|Other|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
79648888|NCT02277613|Biological|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
79979360|NCT03309436|Procedure|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
79328635|NCT03756103|Drug|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
79328636|NCT04347655|Procedure|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
79648889|NCT02277613|Other|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
79483029|NCT05266092|Other|Observational study|Observational study
79648890|NCT02277652|Device|The Miller Laryngoscope|Direct laryngoscopy
79648891|NCT02277652|Device|The Bonfils intubation fibrescope|Optical laryngoscopy
79648892|NCT02277652|Device|The GlideScope Ranger|Videolaryngoscopy
79648893|NCT02277652|Device|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
79979361|NCT05183334|Drug|Sildenafil 50 mg|PD5I
79979362|NCT05183334|Drug|Placebo|placebo
79979363|NCT05183334|Drug|Tramadol Hydrochloride 100 MG|opiod
79979364|NCT05232526|Other|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
79483030|NCT05263986|Drug|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
79648894|NCT02277730|Device|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
79811213|NCT00865514|Other|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
79979365|NCT05232526|Device|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
79328637|NCT03688633|Drug|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
79328638|NCT03688633|Other|Usual care|patients will be followed as usual
79648895|NCT02277730|Drug|phenylephrine|
79328639|NCT04436029|Biological|Descartes 11|Car T-cells
79328640|NCT03743935|Other|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
79648896|NCT02277730|Drug|ephedrine|
79328644|NCT03736759|Behavioral|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
79328645|NCT03662815|Biological|iNeo-Vac-P01|Neoantigen peptides
79328646|NCT03662815|Other|GM-CSF|immune adjuvant
79648897|NCT02277730|Device|manual vasopressor delivery|
79328647|NCT03490903|Device|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
79648898|NCT00124202|Behavioral|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
79483031|NCT00357643|Drug|Calcium 500 mg/day and vitamin D 700 IU/day|
79483032|NCT05069389|Other|Data collection|"Some data will be collected for all patients included :~specific treatment administered in COVID unit~dosages of treatment~inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
79648899|NCT00221910|Procedure|Ultrasound|
79648900|NCT04571437|Drug|Capecitabine|Capecitabine metronomic combined with Letrozole
79648901|NCT04571437|Drug|Letrozole 2.5mg|Letrozole daily alone
79648902|NCT00192257|Biological|CAIV-T and TIV|
79648903|NCT00215124|Drug|Filgrastim|
79483033|NCT00377507|Dietary Supplement|catechin extracts|catechin extracts solution
79483034|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
79483035|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
79648904|NCT00473824|Biological|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, [Civacir]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
79648905|NCT00215163|Drug|Cognitive-behavioral therapy and paroxetine-CR|
79328648|NCT03490903|Drug|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
79328649|NCT03490903|Drug|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
79483036|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
79483037|NCT00377585|Biological|Fluarix|
79483038|NCT00377585|Biological|adjuvanted influenza vaccine|
79483039|NCT04227600|Drug|JR-171 (lepunafusp alfa)|IV infusion
79648906|NCT00192335|Biological|CAIV-T|
79648907|NCT00192335|Biological|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
79483040|NCT03504410|Drug|CPI-613 + High Dose Cytarabine and Mitoxantrone|CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
79648908|NCT00192335|Biological|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
79648909|NCT00192374|Biological|CAIV-T, Liquid|
79648910|NCT00215202|Drug|Iressa (ZD1839)|
79648911|NCT00215241|Drug|sertraline and risperidone|
79648912|NCT00124241|Drug|telbivudine|
79483041|NCT03504410|Drug|High Dose Cytarabine and Mitoxantrone|Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
79483042|NCT03504410|Drug|Mitoxantrone, Etoposide and Cytarabine|"Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6"
79648913|NCT00124241|Drug|lamivudine|
79648914|NCT00221949|Device|Ultrasound|
79648915|NCT00124280|Drug|RAD001|
79648916|NCT00215280|Drug|ivermectin and albendazole|
79648917|NCT04727294|Behavioral|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
79648918|NCT00215319|Device|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
79979366|NCT05250882|Other|Enhanced perioperative care protocol|See arm/group description
79328650|NCT03438721|Behavioral|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
79328651|NCT03438721|Behavioral|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
79328652|NCT04435951|Other|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
79648919|NCT00192413|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
79328653|NCT04253509|Diagnostic Test|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
79328654|NCT03712579|Dietary Supplement|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
79483043|NCT03504410|Drug|Fludarabine, Cytarabine, Filgrastim|"Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
79483044|NCT03579186|Device|OKS|Optokinetic stimulation
79648920|NCT00192413|Biological|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
79648921|NCT00222027|Procedure|Collection of treatment-stratefying prognostic factors|
79648922|NCT00192452|Drug|MEDI-507|
79328655|NCT03712579|Dietary Supplement|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
79328656|NCT04248985|Other|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
79648923|NCT00215358|Drug|Formoterol Fumarate|
79648924|NCT00192491|Biological|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
79648925|NCT00192491|Biological|FluMist|Nasal sprayer of FluMist
79648926|NCT00192491|Other|Placebo|Nasal Sprayer of Placebo
79648927|NCT00222066|Procedure|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
79648928|NCT00192569|Drug|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
79648929|NCT00192569|Drug|Ribavirin (HIV conifected patients only)|"genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg)~Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
79328657|NCT03954613|Combination Product|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
79483045|NCT04243421|Device|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
79483046|NCT02464969|Drug|Apixaban|Tablet or Solution
79483047|NCT02464969|Drug|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
79648930|NCT00215397|Drug|Formoterol Fumarate|
79648931|NCT00192608|Drug|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
79648932|NCT00192608|Drug|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
79648933|NCT00215436|Drug|Formoterol Fumarate|
79483048|NCT04739982|Device|GuessWhat Mobile App|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
79648934|NCT00192686|Procedure|culture a.m. Kamme-Lindberg|
79648935|NCT00215514|Drug|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
79979367|NCT03304990|Other|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
79648936|NCT00215514|Drug|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
79483049|NCT05392530|Drug|Macitentan|Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
79648937|NCT00215514|Drug|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
79648938|NCT00215514|Procedure|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
79979368|NCT05129592|Behavioral|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
79648939|NCT00192725|Other|rapid tryptophan depletion|Amino-acid mixture without tryptophan
79648940|NCT00215592|Drug|Zonegran|
79648941|NCT00222144|Drug|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
79648942|NCT00222183|Drug|Elidel (pimecrolimus)|
79979369|NCT05119530|Diagnostic Test|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
79648943|NCT00192764|Drug|high-dose cyclophosphamide|
79648944|NCT00411957|Drug|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
79648945|NCT00192803|Drug|candesartan|
79979370|NCT03304834|Device|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
79979371|NCT01341366|Other|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
79979372|NCT01341366|Other|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
79979373|NCT03304756|Drug|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
79328658|NCT04504201|Other|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
79328659|NCT04052893|Procedure|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
79328660|NCT04052893|Procedure|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
79328661|NCT03367819|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79328662|NCT03367819|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79328663|NCT04051333|Device|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
79328664|NCT03044509|Diagnostic Test|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
79328665|NCT03044509|Diagnostic Test|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
79328666|NCT04875871|Radiation|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
79328667|NCT04875871|Diagnostic Test|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
79328668|NCT04875871|Diagnostic Test|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
79328669|NCT04875871|Diagnostic Test|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
79483050|NCT03559829|Device|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
79483051|NCT03498014|Other|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
79483052|NCT03498014|Other|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
79483053|NCT02460133|Drug|Paritaprevir|
79328670|NCT04875871|Diagnostic Test|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
79328671|NCT04875871|Diagnostic Test|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
79328672|NCT03598387|Other|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~The minimal target weekly Kt/V is 2.1-3.5/W."
79328673|NCT03598387|Other|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
79483054|NCT02460133|Drug|Ritonavir|
79483055|NCT02460133|Drug|Dasabuvir|
79483056|NCT02460133|Drug|Ombitasvir|
79483057|NCT02460133|Drug|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
79811214|NCT00865514|Other|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
79811215|NCT02556580|Drug|Albumin 20%|Intervention: intravenious infusion Drug: albumin
79811216|NCT00688649|Dietary Supplement|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
79328674|NCT04781725|Drug|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
79811217|NCT00688649|Dietary Supplement|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
79811218|NCT04136717|Other|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
79811219|NCT04136717|Device|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
79328675|NCT04781725|Other|Saline injection|Standard 0.9 % NaCl Normal Saline
79328676|NCT04761835|Biological|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
79483058|NCT02220452|Other|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
79483059|NCT02220452|Other|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
79483060|NCT04735614|Device|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
79483061|NCT04256603|Drug|Gabapentin|Timing of gabapentin initiation
79648946|NCT00222222|Procedure|vein puncture|comparison of different inflammatory markers in the blood of septic patients
79328677|NCT02550769|Procedure|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
79328678|NCT02550769|Procedure|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
79328679|NCT02320279|Device|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
79648947|NCT00192842|Drug|curcumin (+ gemcitabine)|
79648948|NCT00411996|Drug|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
79648949|NCT00192881|Device|Bx Sonic & Cypher stent from Cordis|
79648950|NCT00192920|Behavioral|Transfusion practice|
79648951|NCT00222261|Drug|aspirin|Aspirin 160 mg once daily for two years
79648952|NCT00222261|Drug|clopidogrel|clopidogrel 75 mg once daily for two years
79648953|NCT00192959|Drug|Xenon vs propofol|
79648954|NCT00215631|Drug|tadalafil|
79811220|NCT04136717|Device|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
79328680|NCT03554707|Genetic|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
79328681|NCT03554707|Radiation|Radiation|Standard radiation plan
79328682|NCT03554707|Drug|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
79328683|NCT03554707|Drug|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
79328684|NCT03554707|Drug|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
79328685|NCT02179333|Other|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
79328686|NCT03502759|Behavioral|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
79483062|NCT04256603|Other|No gabapentin|No gabapentin
79648955|NCT00222300|Behavioral|Strength training program|
79648956|NCT00193076|Drug|Gemcitabine|Gemcitabine
79648957|NCT00193076|Drug|Carboplatin|Carboplatin
79648958|NCT00193076|Drug|Trastuzumab|Trastuzumab
79648959|NCT00222339|Behavioral|task-specific training|
79648960|NCT00193115|Drug|Docetaxel|
79648961|NCT00193115|Drug|Doxorubicin|
79648962|NCT00193115|Drug|Cyclophosphamide|
79648963|NCT00193154|Drug|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
79648964|NCT00193154|Drug|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
79648965|NCT00222417|Procedure|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
79648966|NCT00222417|Procedure|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
79648967|NCT00193193|Drug|Paclitaxel|
79648968|NCT00193193|Drug|Estramustine|
79648969|NCT00193193|Drug|Carboplatin|
79648970|NCT00222456|Behavioral|Sensitizing parents|
79648971|NCT00193232|Drug|Docetaxel|
79648972|NCT00193232|Drug|Bortezomib|
79648973|NCT00222495|Drug|quetiapine|
79648974|NCT00222495|Drug|olanzapine|
79648975|NCT00222495|Drug|risperidone|
79648976|NCT00193271|Drug|Docetaxel|
79648977|NCT00193271|Drug|Estramustine|
79648978|NCT00222534|Drug|Acetazolamide|
79648979|NCT00222534|Drug|Placebo|
79648980|NCT00193310|Drug|Paclitaxel|
79648981|NCT00193310|Drug|Carboplatin|
79648982|NCT00193349|Drug|Imatinib|
79648983|NCT00193349|Drug|Irinotecan|
79648984|NCT00193349|Drug|Carboplatin|
79648985|NCT00215670|Drug|pegaptanib sodium (Macugen)|
79648986|NCT00193388|Drug|Topotecan|
79648987|NCT00215709|Drug|docetaxel|
79648988|NCT00193466|Drug|Rituximab|
79648989|NCT00193466|Drug|Fludarabine|
79648990|NCT00193466|Drug|CAMPTH-1H|
79648991|NCT00215748|Drug|Dexamethasone|
79979374|NCT06065423|Other|Manuel Lymphatic Drainage(MLD), Exercises|"MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients."
79979375|NCT06065410|Other|Baseline|Walking without any instruction or sound
79979376|NCT06065410|Other|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
79979377|NCT06065410|Other|White noise|Intrinsic focus accompanied by white noise
79979378|NCT06065410|Other|environmental sound|Intrinsic focus accompanied by environmental sound
79979379|NCT06065397|Procedure|Goal setting improvement program|A improvement program how to optimalize patient-centered goal setting in rehab care is being implemented.
79979380|NCT06065384|Other|experimental group: intensive motor training|Intervention group: receive an extra 12 hours of motor training each week (distributed over the week) for 10 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
79328687|NCT04349605|Behavioral|Meditation|Meditation involves guided breathing and mindfulness training.
79328688|NCT04349605|Behavioral|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
79328689|NCT04299451|Other|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
79328690|NCT04264663|Drug|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
79328691|NCT04264663|Drug|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
79648992|NCT00215826|Drug|Alferon LDO|
79648993|NCT00193544|Drug|Arsenic Trioxide|
79648994|NCT00193544|Drug|Thalidomide|
79648995|NCT00215865|Drug|PEGIntron plus ribavirin|
79648996|NCT00124358|Drug|Buprenorphine|
79648997|NCT00124358|Behavioral|Integrated HIV care and office-based opioid dependence treatment|
79648998|NCT00215904|Drug|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (~2g/day). Second arm : adjuvant treatment with placebo (~2g/day).
79648999|NCT00193583|Drug|Topotecan|
79649000|NCT00193583|Drug|Carboplatin|
79649001|NCT00215982|Drug|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
79649002|NCT00215982|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
79649003|NCT00215982|Drug|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
79649004|NCT00124397|Drug|Atorvastatin|
79649005|NCT00216021|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
79649006|NCT00216021|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
79649007|NCT00409526|Drug|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
79649008|NCT00216138|Drug|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
79649009|NCT00216138|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
79649010|NCT00216138|Drug|Premedication|Dexamethasone and antiemetic premedication
79979381|NCT06065384|Other|usual care|usual rehabilitation
79979382|NCT06065371|Drug|Capecitabine|Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
79979383|NCT06065371|Drug|Sacituzumab govetican|"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5."
79483063|NCT02975180|Device|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
79979384|NCT06065358|Procedure|Tumor biopsy|Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
79328692|NCT04264585|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend ~15 mins. per week/per client.
79328693|NCT04264585|Behavioral|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
79483064|NCT02975180|Behavioral|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
79483065|NCT03545334|Diagnostic Test|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
79483066|NCT00362492|Procedure|Bilateral ultrasound examination 7+/- 2 after surgery|
79483067|NCT03560141|Device|LID011121 contact lens|Investigational silicone hydrogel contact lens
79483068|NCT03560141|Device|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
79483069|NCT02199002|Device|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
79483070|NCT04418700|Device|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
79483071|NCT05721079|Device|ECP (Extracorporeal Photopheresis System)|After the cells have been inoculated with UVADE, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and the infused back into the patient.
79483072|NCT00362570|Drug|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
79483073|NCT03562559|Other|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
79649011|NCT00409604|Device|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
79649012|NCT00216177|Drug|Infliximab|Remicade
79649013|NCT00216177|Drug|Adalimumab|Humira
79649014|NCT00216216|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
79811221|NCT04136717|Other|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
79979385|NCT06065345|Device|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
79979386|NCT06065332|Other|Velez Intense Hydration Mask® (biotech cellulose face mask)|Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
79979387|NCT06065319|Device|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
79979388|NCT06065267|Drug|sequential|amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
79979389|NCT06065267|Drug|Levofloxacin 500Mg Oral Tablet|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
79979390|NCT06065254|Other|Efficacy of free gingival grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Two vertical incisions will be made in the previously elevated flap against the placed implant , where these two incisions will be 10 mm apart from each other, and the free graft to will be placed in this distance (10 x 10 mm). The graft will be obtained from the donor site (the hard palate), and will be thinned to obtain a regular graft with the required thickness. After that, the graft will be moved to its correct place accurately, while avoiding leaving a distance between the graft and the tissue underneath, and the graft will be sutured well to ensure its stability and correct placement.
79811222|NCT04136717|Other|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
79811223|NCT00782080|Drug|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
79811224|NCT00782080|Drug|Placebo|Placebo
79811225|NCT00769288|Drug|2'-F-ara-deoxyuridine|Given IV
79811226|NCT00769288|Other|positron emission tomography|Correlative studies
79811227|NCT00769288|Other|laboratory biomarker analysis|Correlative studies
79979391|NCT06065254|Other|Efficacy of connective tissue grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Vertical incisions will not be made in the previously elevated flap against the placed implant, where there is no need to suture the flap apically of the grafting place because the graft will be covered with it after fixing it in place. The area will be washed with the serum to remove the clot before fixing the graft.The graft will be obtained from the donor site according to the previously mentioned method. Then the epithelium will be removed to leave the connective tissue underneath, and then the graft will be moved to its place (buccally dental implant site) and the flap will be sutured over it.
79649015|NCT00473746|Drug|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
79811228|NCT00769288|Other|pharmacological study|Correlative studies
79979392|NCT06065254|Other|No types of grafts will be made to improve the quality of the peri-implant mucosa|The simple suturing of the two surgical incisions will be done after the completion of the dental implant process, with no procedure will be made to improve the quality of the peri-implant mucosa.
79649016|NCT00473746|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
79979393|NCT06065150|Procedure|Standard support|See arm/group descriptions
79649017|NCT00473746|Drug|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
79483074|NCT00357799|Device|VeinViewer|Using the VeinViewer, IV attempts will be made
79649018|NCT00409643|Drug|valsartan+amlodipine combination|
79649019|NCT00409643|Drug|valsartan|
79649020|NCT00409643|Drug|amlodipine|
79649021|NCT00473668|Biological|Zilbrix-Hib|Intramuscular injection, 1 dose
79649022|NCT00473668|Biological|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
79811229|NCT00769288|Other|pharmacogenomic studies|Correlative studies
79811230|NCT00688727|Behavioral|CBT|CBT, up to 12 sessions.
79328694|NCT04264585|Behavioral|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
79483075|NCT04727970|Drug|Tricaprilin|Tricaprilin will be emulsified in infant formula/milk
79483076|NCT03459638|Other|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
79483077|NCT00357253|Drug|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
79649023|NCT04722497|Other|Sound Education|All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
79483078|NCT00357253|Radiation|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
79483079|NCT03563027|Behavioral|Social Incentive Gamification|Game-based intervention with points and levels
79649024|NCT00216333|Drug|combined fixed dose combination|
79649025|NCT00124553|Behavioral|Intensive dietary advice|
79649026|NCT00223119|Device|Absorbable Sutures|
79649027|NCT00409721|Drug|Memantine|
79649028|NCT00223158|Drug|Liothyronine|
79483080|NCT03563027|Behavioral|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
79483081|NCT03563027|Behavioral|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
79649029|NCT00193622|Drug|Bevacizumab|
79483082|NCT05053945|Diagnostic Test|Esophagogastroduodenoscopy|"To set up a prospective study and registry (HAR-P) for patients with H. pylori infection, atrophic gastritis or intestinal metaplasia to evaluate their clinical features and outcomes. The objectives include:~Assess the short- and long-term patient outcomes of H. pylori patients~Characterize factors involved in the progression or regression of pre-neoplastic lesions, namely atrophic gastritis and intestinal metaplasia~Gather information for a better understanding on the efficacy and role of surveillance~Potential for the development of new screening/surveillance strategies and tools for better risk stratification of patients~Establish a biobank for H. pylori, atrophic gastritis and intestinal metaplasia patients"
79649030|NCT00193622|Drug|Erlotinib|
79649031|NCT00223197|Drug|Pregnenolone|
79483083|NCT04711590|Other|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
79483084|NCT02975024|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
79483085|NCT02975024|Device|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
79649032|NCT00473590|Drug|Bevacizumab|15 mg/kg administered by intravenous infusion
79649033|NCT00473590|Drug|Bortezomib|1.3 mg/m^2 administered by intravenous bolus injection
79649034|NCT00473590|Drug|placebo|Intravenous repeating dose
79328695|NCT02827045|Device|Vestibular test|
79483086|NCT02975024|Device|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
79649035|NCT00223275|Drug|Naltrexone|
79649036|NCT00124787|Drug|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
79649037|NCT00124787|Drug|Placebo|Placebo PO q 6 hours x 4 doses
79811231|NCT00688727|Behavioral|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
79811232|NCT04136561|Device|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
79811233|NCT00912938|Drug|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
79483087|NCT02068430|Drug|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
79483088|NCT02068430|Other|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
79483089|NCT02440334|Drug|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
79811234|NCT00912665|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
79979394|NCT06065150|Procedure|Early surgery proposed according to the radiological score|"If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~If score < 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management."
79483090|NCT02065700|Drug|Filgotinib|Tablets administered orally
79979395|NCT06065137|Diagnostic Test|Full dose DPT with propofol|Incremental administration of propofol up to a cummulative full therapeutic dose (2mg/kg) in POH patients investigated for propofol. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.02mg/kg-0.2 mg/kg -0.6 mg/kg -1.2mg/kg).
79979396|NCT06065137|Diagnostic Test|Full dose DPT with ketamine|Incremental administration of ketamine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for ketamine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mg/kg -0.1 mg/kg -0.3 mg/kg -0.6mg/kg).
79979397|NCT06065137|Diagnostic Test|Full dose DPT with etomidate|Incremental administration of etomidate up to a cummulative full therapeutic dose (0.2mg/kg) in POH patients investigated for etomidate. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.002 mg/kg -0.02 mg/kg -0.06 mg/kg -1.2mg/kg).
79483091|NCT03127592|Drug|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
79649038|NCT00223314|Behavioral|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
79979398|NCT06065137|Diagnostic Test|Full dose DPT with midazolam|Incremental administration of midazolam up to a cummulative full therapeutic dose (0.05mg/kg) in POH patients investigated for midazolam. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.0005 mg/kg -0.005 mg/kg -0.015 mg/kg -0.03mg/kg).
79979399|NCT06065137|Diagnostic Test|Full dose DPT with fentanyl|Incremental administration of fentanyl up to a cummulative full therapeutic dose (1mcg/kg) in POH patients investigated for fentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mcg/kg -0.1 mcg/kg -0.3 mcg/kg -0.6mcg/kg).
79483092|NCT03127592|Drug|Etodolac|Individual drug
79483093|NCT03127592|Drug|Cyclobenzaprine|Individual drug
79483094|NCT02974400|Behavioral|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
79483095|NCT02444234|Drug|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
79811235|NCT00912665|Device|Goldmann applanation tonometer|intraocular pressure measurements
79811236|NCT00912665|Other|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
79483096|NCT02444234|Drug|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
79483097|NCT02444936|Drug|ZOSTAVAX|Shingles vaccine
79483098|NCT02445014|Device|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
79649039|NCT00193661|Drug|Testosterone Gel (1%)|
79483099|NCT02445326|Drug|Dexamethasone|
79483100|NCT02445326|Other|Placebo Vehicle|
79979400|NCT06065137|Diagnostic Test|Full dose DPT with sufentanyl|Incremental administration of sufentanyl up to a cummulative full therapeutic dose (0.1mcg/kg) in POH patients investigated for sufentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.001 mcg/kg -0.01 mcg/kg -0.03 mcg/kg -0.06µg/kg).
79979401|NCT06065137|Diagnostic Test|Full dose DPT with alfentanil|Incremental administration of alfentanil up to a cummulative full therapeutic dose (10mcg/kg) in POH patients investigated for alfentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.1 mcg/kg -1 mcg/kg -3 mcg/kg -6µg/kg).
79483101|NCT02287831|Biological|umbilical cord mesenchymal stem cells|
79649040|NCT00206232|Drug|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
79483102|NCT04344457|Drug|Hydroxychloroquine|200 mg PO BID 7 days
79649041|NCT00193700|Drug|Testosterone Gel (1%)|
79649042|NCT00206271|Behavioral|neck collar; advice to act-as-usual; active mobilisation|
79649043|NCT00124826|Drug|Insulin|
79649044|NCT00223353|Other|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
79649045|NCT00193739|Drug|NACT|3 cycles of neoadjuvant chemotherapy
79649046|NCT00193739|Procedure|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
79649047|NCT00193739|Drug|Inj.Cisplatin|Concurrent chemo radiotherapy
79483103|NCT04344457|Drug|Indomethacin|50 mg PO TID 14 Days
79483104|NCT04344457|Drug|Zithromax Oral Product|500 mg PO QD 3 Days
79483105|NCT05720923|Device|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
79483106|NCT05052853|Drug|NMDAE|Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
79483107|NCT05052853|Drug|Placebo Cap|Use of placebo as a comparator
79483108|NCT05720845|Procedure|VESPA|Using Ventilatory strategy of prevent atelectasis for General Anesthesia.
79483109|NCT05720845|Procedure|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia.
79483110|NCT02978599|Drug|AVL-3288|daily for 5 days
79483111|NCT02978599|Drug|Placebo|daily for 5 days
79483112|NCT05720533|Drug|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
79483113|NCT04744766|Procedure|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
79483114|NCT01897688|Biological|Islet Cell Transplant|
79483115|NCT02446496|Drug|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
79483116|NCT02446496|Drug|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
79649048|NCT00193739|Radiation|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
79649049|NCT00124865|Biological|rFla-MBP|
79649050|NCT00206310|Drug|CRESTOR|
79649051|NCT00193778|Procedure|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
79649052|NCT00193778|Other|No Loco-regional treatment|This group will not receive any loco-regional treatment
79649053|NCT00223431|Device|all-ceramic fixed partial denture|
79649054|NCT00193817|Procedure|Two field vs Three field lymphadenectomy|
79649055|NCT00124904|Behavioral|Biofeedback|
79979402|NCT06065137|Diagnostic Test|Full dose DPT with remifentanil|Incremental administration of remifentanil up to a cummulative full therapeutic dose (0.5mcg/kg) in POH patients investigated for remifentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.005 mcg/kg -0.05 mcg/kg -0.15 mcg/kg -0.3µg/kg).
79979403|NCT06065137|Diagnostic Test|Full dose DPT with rocuronium|Incremental administration of rocuronium up to a cummulative full therapeutic dose (0.6mg/kg) in POH patients investigated for rocuronium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.006 mg/kg -0.06 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.18 mg/kg -0.42mg/kg) are administerd under general anesthesia.
79979404|NCT06065137|Diagnostic Test|Full dose DPT with atracurium|Incremental administration of atracurium up to a cummulative full therapeutic dose (0.5mg/kg) in POH patients investigated for atracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.005 mg/kg -0.05 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.15 mg/kg -0.35mg/kg) are administered under general anesthesia .
79483117|NCT04344691|Procedure|Rectus femoris stretching|Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
79649056|NCT00124904|Behavioral|Kegel exercises|
79483118|NCT00355693|Device|Pump for propofol delivery|
79483119|NCT02448368|Drug|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
79649057|NCT00206388|Drug|Zolendric acid|IV, 2mg/m2/dose on day 0
79649058|NCT00206388|Drug|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
79649059|NCT00125021|Drug|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
79649060|NCT00125021|Drug|OSI-774|Given once daily
79649061|NCT00193856|Drug|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
79649062|NCT00193856|Drug|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
79649063|NCT00193856|Radiation|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
79649064|NCT00223509|Drug|Lamotrigine|
79649065|NCT00193895|Drug|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
79649066|NCT00193895|Radiation|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
79649067|NCT00223548|Drug|sodium 2-mercaptoethane sulfonate|
79649068|NCT00125060|Drug|Simvastatin (20mg versus 80mg/day)|
79811237|NCT00912665|Device|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
79328696|NCT02765737|Other|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
79483120|NCT02448368|Drug|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
79483121|NCT02448368|Drug|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
79483122|NCT02448368|Drug|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
79483123|NCT02448368|Drug|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
79649069|NCT00223587|Other|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
79649070|NCT00223626|Drug|Topiramate|the maximum topiramate test dose is 200 mg/d.
79649071|NCT00223743|Drug|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
79649072|NCT00411177|Procedure|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
79649073|NCT00411177|Procedure|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
79649074|NCT00411255|Procedure|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
79649075|NCT00125099|Biological|VRC-HIVDNA009-00-VP|
79979405|NCT06065137|Diagnostic Test|Full dose DPT with cisatracurium|Incremental administration of cisatracurium up to a cummulative full therapeutic dose (0.15mg/kg) in POH patients investigated for cisatracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.0015 mg/kg -0.015 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.045 mg/kg -0.105mg/kg) are administered under general anesthesia .
79979406|NCT06065137|Diagnostic Test|Full dose DPT with succinylcholine|Incremental administration of succinylcholine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for succinylcholine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.01 mg/kg -0.1 mg/kg). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.3 mg/kg -0.7mg/kg) are administered under general anesthesia.
79328697|NCT02765737|Device|Mepilex Ag|
79328698|NCT04599751|Device|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
79328699|NCT04563559|Drug|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
79328700|NCT04563559|Drug|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
79328701|NCT02124187|Device|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
79483124|NCT02978365|Other|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
79483125|NCT02978365|Device|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
79483126|NCT05013307|Other|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
79483127|NCT02448914|Drug|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
79483128|NCT02448914|Drug|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
79649076|NCT00193973|Drug|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
79649077|NCT00193973|Radiation|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
79649078|NCT00223782|Behavioral|Gait Training with Feedback|
79328702|NCT02124187|Device|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
79328703|NCT02124187|Device|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
79811238|NCT00782236|Device|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
79649079|NCT00223782|Behavioral|Gait Training with no feedback|
79649080|NCT00411879|Drug|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin [20 IU IV maximum dose = 100 IU] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
79979407|NCT06065124|Procedure|Bariatric surgery strategy|Bariatric surgery including an intensive pre- and postoperative treatment scheme
79649081|NCT00411879|Drug|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
79979408|NCT06065111|Other|study tendon damage in osteogenesis imperfecta patients|"To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease.~To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease."
79979409|NCT06065085|Other|mobile education|"The study was conducted as a randomized controlled trial with 134 individuals with hypertension (68 experimental, 66 controlled) who applied a university hospital. The data were collected by Patient Information Form, Healthy Lifestyle Behaviour Scale II, EQ-5D General Quality of Life Scale, Mindful Attention Awareness Scale and Percieved Stress Scale were used. An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application."
79979410|NCT06065072|Device|Optical measurement|Optical measurements by optical biometers and an OCT
79328704|NCT05403073|Procedure|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
79649082|NCT00193505|Drug|Ifosfamide|
79811239|NCT00688805|Drug|Propranolol|40 mg given as a single oral administration in an opaque capsule
79979411|NCT06065046|Drug|Baricitinib 4 MG|Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
79979412|NCT06065046|Other|Standard treatment|Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
79979413|NCT06064994|Behavioral|Mindfulness meditation|"The experimental group received the Smith's version of the mindfulness meditation (Smith, 2005), which is a standardized theory-based intervention found to be effective in improving the different dimensions of health. The Smith's version of the mindfulness meditation (Smith, 2005), includes the following components:~Being mindful of breathing (5 minutes).~Being mindful of the body (5 minutes).~Being mindful of thought (5 minutes).~Being mindful of sounds (5 minutes).~Being mindful of taste (5 minutes)~Full meditation"
79328705|NCT02002819|Drug|levetiracetam|
79328706|NCT05399017|Device|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
79649083|NCT00193505|Drug|Carboplatin|
79649084|NCT00193505|Drug|Etoposide|
79328707|NCT05123833|Procedure|Hypospadias repair|surgical repair of hypospadias
79649085|NCT00193505|Drug|Rituximab|
79649086|NCT00193505|Drug|90Y Zevalin|
79649087|NCT00125177|Behavioral|Knack therapy|
79649088|NCT00125216|Behavioral|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
79649089|NCT00223860|Drug|Human chorionic gonadotropin (hCG)|
79649090|NCT00223860|Drug|Luteinizing hormone releasing hormone (LHRH)|
79811240|NCT00688805|Drug|Placebo|matching capsule containing no active medication
79811241|NCT00701480|Other|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
79811242|NCT00701480|Other|marketed skin cleanser|face washing 2-3 times/day
79811243|NCT04136639|Other|Miswak|sticks
79811244|NCT04136639|Other|Grape Seed Extract Mouthwash|Mouthwash
79811245|NCT04136639|Other|fluoride|mouthwash
79811246|NCT02613026|Drug|Pirarubicin|
79811247|NCT02613026|Drug|Docetaxel|
79811248|NCT02613026|Drug|Cyclophosphamide|
79649091|NCT00125255|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
79649092|NCT00125255|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
79811249|NCT04136483|Behavioral|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
79811250|NCT00769366|Behavioral|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
79811251|NCT00769366|Drug|Medical therapy|Optimal medical therapy after Acute myocardial infarction
79811252|NCT02614742|Drug|SFX-01|An intervention releasing sulforaphane.
79811253|NCT02614742|Drug|Placebo|Placebo otherwise identical to Active product
79811254|NCT00778726|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
79328708|NCT05123677|Diagnostic Test|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
79811255|NCT00688883|Drug|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
79649093|NCT00223899|Genetic|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
79811256|NCT00769522|Biological|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
79328709|NCT05123677|Diagnostic Test|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
79649094|NCT00223938|Drug|Oral Iron|Oral Iron
79649095|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 1
79328710|NCT05123521|Diagnostic Test|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
79811257|NCT00769522|Drug|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
79649096|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 2
79649097|NCT00125294|Drug|Methadone|
79811258|NCT00769522|Drug|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
79811259|NCT00769522|Drug|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
79811260|NCT04138511|Device|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
79811261|NCT00688961|Drug|Aspirin|generic aspirin
79811262|NCT00688961|Drug|omega-3 acid ethyl esters|4, 1 g capsules q.d.
79811263|NCT04138355|Other|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
79811264|NCT00778804|Behavioral|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
79811265|NCT00689039|Drug|AZD1305|ER tablet, administered as single and repeated doses.
79649098|NCT00206466|Drug|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
79979414|NCT06064942|Behavioral|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
79649099|NCT00206466|Drug|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
79811266|NCT00689039|Drug|Placebo|Tablet, administered as single and repeated doses.
79811267|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
79979415|NCT06064942|Behavioral|School services for families of children with ADHD|Selected school social personnel will deliver services as usual for the control group.
79979416|NCT06064838|Dietary Supplement|Flavonoids|1 capsule every 12h for 90 days
79979417|NCT06064799|Diagnostic Test|miRNA-223 & -214 detection|miRNA-223 & -214 detection in GCF samples by PCR kits
79979418|NCT06064786|Diagnostic Test|GCF levels of fetuin A and hsCRP evaluation|ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
79979419|NCT06064773|Diagnostic Test|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
79979420|NCT06064760|Behavioral|Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren|"The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~Session 1: Defining my role as grandparent.~Session 2: Deepening my relationships.~Session 3: Growing as grandparent.~Session 4: Discovering my emotional world.~Session 5: Caring for others and caring for myself."
79979421|NCT06064747|Device|LF-rTMS|"LF-rTMS group: using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);"
79979422|NCT06064747|Device|Sham stimulation|Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
79649100|NCT00125333|Drug|NF-kappaB Decoy|
79649101|NCT00224094|Drug|Premarin® (oral) vs. Alora® (transdermal)|
79811268|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
79649102|NCT00125411|Drug|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
79649103|NCT00206505|Drug|Taxotere|
79979423|NCT06064734|Device|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
79328711|NCT05123443|Biological|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
79328712|NCT05123443|Diagnostic Test|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
79328713|NCT01597193|Drug|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
79649104|NCT00206544|Drug|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
79328714|NCT01597193|Drug|anastrozole|1 mg/day
79328715|NCT01597193|Drug|exemestane|The exemestane dose is 25mg daily.
79328716|NCT01597193|Drug|fulvestrant|500 mg every 28 days
79649105|NCT00206544|Drug|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
79649106|NCT00206544|Other|placebo|adjunctive placebo daily in oral capsule
79649107|NCT00125450|Procedure|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
79649108|NCT00125450|Procedure|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
79328717|NCT01597193|Drug|enzalutamide|160 mg (4 capsules) taken orally daily.
79328718|NCT01597193|Drug|exemestane|The exemestane dose is 50 mg daily.
79328719|NCT04920461|Device|Additional MRI sequences|Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
79328720|NCT04920461|Other|Neuropsychological assessment|Neurovisual function assessed with neuropsychological tests
79328721|NCT04920305|Dietary Supplement|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
79328722|NCT04920305|Dietary Supplement|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
79328723|NCT04930133|Drug|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
79328724|NCT02649439|Biological|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
79649109|NCT00206583|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
79649110|NCT00194324|Drug|Miconazole nitrate|
79649111|NCT00194324|Procedure|Magnetic resonance imaging|
79649112|NCT00194324|Behavioral|Moderate levels of exercise|
79649113|NCT00224211|Behavioral|Music|
79649114|NCT00194363|Behavioral|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
79649115|NCT00206622|Drug|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
79649116|NCT00206622|Drug|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
79649117|NCT00206622|Drug|Placebo transdermal|Placebo
79328725|NCT02649439|Biological|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
79328726|NCT04911647|Device|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
79328727|NCT04911647|Device|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
79649118|NCT00194402|Drug|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
79649119|NCT00224250|Procedure|One- versus two-layer hysterotomy closure|
79649120|NCT00473512|Drug|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
79649121|NCT00473512|Drug|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
79649122|NCT00473512|Drug|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
79811269|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
79811270|NCT00865280|Drug|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
79811271|NCT00865280|Drug|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
79811272|NCT00865280|Drug|moxifloxacin|moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
79811273|NCT04136327|Drug|GLPG1972 film-coated tablets|single oral dose of GLPG1972
79649123|NCT00125489|Drug|chloroquine sulfate|
79649124|NCT00125489|Drug|sulfadoxine/pyrimethamine|
79649125|NCT00206661|Drug|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
79649126|NCT00206661|Drug|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
79649127|NCT00194441|Other|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
79649128|NCT00473434|Drug|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
79328728|NCT03057041|Drug|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
79328729|NCT03057041|Drug|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
79328730|NCT05123287|Drug|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
79328731|NCT04911569|Device|Cryoneurolysis|Cryoneurolysis
79328732|NCT05123209|Biological|IM83 CAR-T cells|3×10^9 CAR-T cells
79328733|NCT05123209|Combination Product|The second-line treatment of liver cancer|approved by NMPA
79649129|NCT00224328|Device|ODISsey Tissue Oximeter|
79649130|NCT00125567|Drug|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
79811274|NCT04136327|Drug|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion [14C]-GLPG1972
79811275|NCT04136327|Drug|[14C]-GLPG1972 oral solution|single oral dose of [14C]-GLPG1972
79979424|NCT06064708|Behavioral|Mindfulness-based intervention|"The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~Being mindful of the breath (5 minutes).~Being mindful of the body (5 minutes).~Being mindful of the thought (5 minutes)~Being mindful of the sound (5 minutes)~Being mindful during walking (5 minutes)~Full meditation (5 minutes)."
79811276|NCT00782548|Drug|KADIAN (morphine sulfate sustained-release) capsules|Capsules, 30 mg
79811277|NCT00782548|Drug|Avinza (morphine sulfate sustained-release) capsules|Capsules, 30 mg
79979425|NCT06064669|Drug|Metformin pretreatment before ovarian stimulation|The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
79979426|NCT06064669|Drug|Placebo pretreatment before ovarian stimulation|The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
79979427|NCT06064669|Drug|Metformin pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
79979428|NCT06064669|Drug|Placebo pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
79979429|NCT06064630|Device|Automatic continuous positive airway pressure|Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea
79979430|NCT06064552|Diagnostic Test|blood sugar|"High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS>95mg/dl, 1hr postprandial>126mg/dl, 2hrs postprandial >140mg/dl) should do HA1C if >5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation"
79979431|NCT06064539|Drug|Tolebrutinib|Tablet, taken orally
79979432|NCT06064539|Drug|gemfibrozil|Tablet, taken orally
79979433|NCT06064539|Drug|rifampicin|Tablet, taken orally
79979434|NCT06064513|Other|verbal empathy training|Empathy training will be given to nurses in the control group using face-to-face interview technique. In this training, the researcher will explain verbally what empathy is and how to make an empathetic approach to sick individuals. The training will be given to nurses twice, one week apart, at their own time.
79811278|NCT00689195|Dietary Supplement|Curcumin powder|oral capsules containing the investigational agent
79811279|NCT00689195|Dietary Supplement|Ashwagandha extract|4.5% extract of ashwagandha
79811280|NCT00769678|Device|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
79811281|NCT00694811|Behavioral|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
79811282|NCT00778882|Drug|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
79811283|NCT00865124|Drug|Spironolactone|25 mg capsule daily for 6 months
79811284|NCT00865124|Drug|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
79328734|NCT03056807|Other|25° head-up position|Angle person is positioned for procedure.
79328735|NCT03056807|Other|55° head-up position|Angle person is positioned for procedure.
79328736|NCT04377685|Other|CT-Scan|Chest CT scan on admission to the hospital
79328737|NCT03056885|Other|Conventional One-Lung Ventilation|Vt 10 ml/kg
79328738|NCT03056885|Other|Protective One-lung ventilation|Vt 5 ml/kg
79649131|NCT00125567|Drug|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
79649132|NCT00473083|Drug|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
79649133|NCT00473083|Drug|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
79649134|NCT00473083|Drug|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
79811285|NCT00865124|Other|Placebo|Placebo capsule daily
79811286|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
79649135|NCT00473083|Drug|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
79649136|NCT00194480|Drug|Pegylated Interferon|Weekly injections of pegIntereferon
79811287|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
79811288|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
79328739|NCT03056105|Other|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
79649137|NCT00125606|Procedure|conditioning for allogeneic HSCT|
79649138|NCT00472420|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
79649139|NCT00472420|Drug|First line chemotherapy|As prescribed
79328740|NCT03949777|Device|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
79649140|NCT00194519|Drug|Generic acyclovir|400 mg twice-daily oral
79649141|NCT00194519|Drug|Placebo|twice-daily oral
79649142|NCT00206700|Drug|Sargramostim (Leukine)|Open Label, 8 week cycle
79649143|NCT00125645|Drug|Irbesartan Oral Tablet|
79649144|NCT00194558|Behavioral|Internet co-management module|
79649145|NCT00224367|Behavioral|time to first ambulation|
79649146|NCT00125684|Drug|morphine|
79649147|NCT00194597|Drug|Viagra (sildenafil citrate)|
79811289|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
79649148|NCT00206739|Drug|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
79328741|NCT03056963|Behavioral|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
79979435|NCT06064513|Other|video based empathy training|Nurses in the video group will be shown a video recording about empathy. Nurses will be allowed to watch the training video twice, with an interval of one week. After the empathy training is completed, the evaluation phase will begin. For this purpose, 2 weeks and 4 weeks after the end of the last training, nurses in both study groups will be asked to fill out the Integrative Nursing Competency Scale and Empathy Level Determination Scale. In the study, a comparison of nurses' pre-test and post-test answers will be made to evaluate the effectiveness of video-based education.
79649149|NCT00125723|Other|PI Discretion|PI Discretion
79649150|NCT00224406|Drug|repertaxin|
79649151|NCT00194636|Procedure|nerve block|
79649152|NCT00206778|Drug|Lamotrigine|
79328742|NCT03056963|Behavioral|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
79328743|NCT04184323|Drug|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
79328744|NCT04184323|Drug|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
79328745|NCT03056027|Diagnostic Test|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
79649153|NCT00206778|Drug|Sodium Valproate|
79649154|NCT00125801|Drug|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
79649155|NCT00206817|Device|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
79649156|NCT00125840|Drug|clofarabine (IV formulation)|
79979436|NCT06064487|Diagnostic Test|renal cell arrest and damage biomarkers assessment|measurement of TIMP2 and IGFBP7, KIM-1
79979437|NCT06064383|Device|suicide attacks|select the most common causes, risk factors, methods and circumstances surrounding suicidal attempts in children and adolescents at aaiut university children hospital
79328746|NCT03055949|Behavioral|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
79649157|NCT00224445|Drug|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
79649158|NCT00224445|Drug|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
79649159|NCT00224445|Drug|Ritonavir|Ritonavir 100 mg capsule administered orally QD
79649160|NCT00194753|Drug|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
79649161|NCT00194753|Drug|Doxorubicin|24 mg/m2 IV weekly x 12
79649162|NCT00194753|Drug|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
79649163|NCT00194753|Drug|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
79649164|NCT00206856|Device|Triage® B-Type Natriuretic Peptide (BNP) Test|
79649165|NCT00125879|Biological|Myozyme|20 mg/kg qow or 40 mg/kg qow
79649166|NCT00206895|Procedure|Photodynamic therapy|
79649167|NCT00125918|Drug|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
79649168|NCT00125918|Drug|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
79649169|NCT00125918|Drug|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
79649170|NCT00125918|Drug|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
79328747|NCT04202107|Other|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
79328748|NCT04202107|Other|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
79328749|NCT04911413|Drug|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
79328750|NCT04911725|Device|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
79328751|NCT04929665|Procedure|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
79328752|NCT04911179|Other|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
79649171|NCT00125918|Drug|placebo|placebo tablet taken by mouth once a day for 16 weeks
79811290|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
79328753|NCT04095559|Diagnostic Test|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
79649172|NCT00224523|Drug|GW685698X|
79328754|NCT04095559|Diagnostic Test|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
79649173|NCT00224523|Drug|mometasone furoate|
79811291|NCT00871715|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
79649174|NCT00472303|Drug|Tapentadol Extended Release|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
79649175|NCT00472303|Drug|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
79328755|NCT04095559|Diagnostic Test|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
79328756|NCT04919915|Device|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
79483129|NCT05002309|Behavioral|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
79649176|NCT00472303|Drug|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
79649177|NCT00224562|Drug|TNF-alpha antagonists|
79328757|NCT03830203|Drug|BAT1806|8 mg/kg
79328758|NCT03830203|Drug|Actemra(EU-licensed)|8 mg/kg
79649178|NCT00125996|Drug|Venofer (intravenous iron sucrose)|
79649179|NCT00224601|Procedure|Colonoscopy with chromoscopy|
79649180|NCT00471718|Drug|ABT-751|"Phase I:~Cohort | Number of Patients |Dose (mg) ABT-751 (BID)~-1 | 3-6 |100 mg BID~1 | 3-6 |125 mg BID~2 | 3-6 |150 mg BID~3 | 3-6 |175 mg BID~4 | 3-6 |200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
79649181|NCT00194870|Procedure|EEG|computer-assisted analysis of the digitally-recorded EEG signals
79649182|NCT00206934|Drug|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
79649183|NCT00206934|Drug|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
79649184|NCT00194909|Drug|sildenafil (Viagra)|
79649185|NCT00224640|Drug|Iron chelating intervention|Iron chelating intervention
79649186|NCT00194948|Drug|escitalopram|
79649187|NCT00194948|Behavioral|interpersonal psychotherapy|
79649188|NCT00206973|Procedure|mannitol test|
79328759|NCT03668587|Other|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
79328760|NCT02622113|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
79328761|NCT02622113|Drug|Insulin|
79328762|NCT04920227|Procedure|phacoemulsification;|Group A: class combined with phacoemulsification
79328763|NCT03860155|Biological|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
79483130|NCT05002309|Drug|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
79483131|NCT00363272|Drug|ispinesib|Given IV
79483132|NCT00363272|Other|laboratory biomarker analysis|Correlative studies
79483133|NCT00363272|Other|pharmacological study|Correlative studies
79483134|NCT04341974|Diagnostic Test|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
79483135|NCT02978287|Drug|BAVU Solution|Tissue preservation solution for transplantation
79483136|NCT05719753|Device|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
79328764|NCT04430777|Drug|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
79328765|NCT04929587|Other|This is a observational research, there is no intervention|This is a observational research, there is no intervention
79328766|NCT04910789|Procedure|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
79328767|NCT04910789|Procedure|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
79328768|NCT02651467|Other|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
79328769|NCT02651467|Other|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
79328770|NCT02651467|Other|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
79328771|NCT04910477|Drug|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
79328772|NCT04910477|Drug|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
79328773|NCT04910477|Other|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
79328774|NCT03487705|Other|electromyographic essential tremor|"Making a recording electromyographic recording of the essential tremors in each child included at prospective.~Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
79483137|NCT05719753|Device|Standard Care|Bard Catheter
79483138|NCT01152541|Drug|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
79483139|NCT01152541|Drug|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
79483140|NCT01638546|Other|Laboratory Biomarker Analysis|Correlative studies
79483141|NCT01638546|Other|Placebo|Given PO
79483142|NCT01638546|Drug|Temozolomide|Given PO
79483143|NCT01638546|Drug|Veliparib|Given PO
79649189|NCT00126035|Device|Migraid|
79483145|NCT04948489|Drug|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
79649190|NCT00471445|Drug|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
79979438|NCT06064357|Other|Transverese friction massage and tissue floss technique|"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks."
79328775|NCT04431089|Drug|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
79328776|NCT02468245|Behavioral|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
79328777|NCT02468245|Behavioral|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
79328778|NCT04910555|Other|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
79483146|NCT04948489|Drug|Placebo|Placebo capsule everyday for 12 months
79483147|NCT03839953|Behavioral|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
79649191|NCT00471445|Other|placebo|Applied topically
79649192|NCT00207051|Drug|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
79649193|NCT00402467|Drug|Rivaroxaban (BAY59-7939)|2.5mg bid
79649194|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|5mg bid
79649195|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|10 mg bid
79649196|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|20mg bid
79649197|NCT00402467|Drug|Enoxaparine|30mg bid
79649198|NCT00402467|Drug|Enoxaparine|30mg bid
79649199|NCT00224679|Drug|Aspirin|
79328779|NCT04910633|Other|COCA is an observational study based on retrospective data issued from patient medial file.|"The following parameters will be collected from the medical files of the patients involved in this study:~Age~Gender~Cancer type~Cancer Stage~Cancer Treatment~COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~Living Status~Attribution of Mortality to COVID status~Comorbidities"
79328780|NCT05099419|Device|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
79328781|NCT04919603|Behavioral|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
79328782|NCT04919603|Behavioral|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
79328783|NCT05092633|Device|Miniscrew|Application of laser on miniscrew
79328784|NCT04929353|Other|Systematic symptom assessment|"Systematic symptom assessment~Conventional symptom assessment"
79483148|NCT03839953|Other|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
79483149|NCT05719597|Other|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
79483150|NCT05719597|Other|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
79483151|NCT05723497|Other|Elderberry juice|Participants will consume elderberry juice 1-week.
79483152|NCT05723497|Other|Placebo beverage|Participants will consume placebo for 1-week.
79328785|NCT03843151|Drug|BI 1358894|tablet
79328786|NCT03843151|Drug|Itraconazole|oral solution
79328787|NCT04919759|Behavioral|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
79328788|NCT04919759|Behavioral|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
79483153|NCT03833713|Behavioral|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
79483154|NCT03833713|Behavioral|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
79483155|NCT05723341|Drug|Bupivacain|%0,25
79483156|NCT05723341|Drug|Morphine|In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
79483157|NCT00363350|Drug|rituximab (anti-CD20)|2 infusions of 1000 mg
79979439|NCT06064344|Drug|Rituximab|Intralesional Rituximab Injection
79979440|NCT06064344|Radiation|Involved Site Radiation Therapy|Involved Site Radiation Therapy
79979441|NCT06064331|Drug|Lignocaine|IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe
79483158|NCT05717335|Drug|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
79483159|NCT00363428|Behavioral|exercise intervention|life style
79483160|NCT00363428|Behavioral|smoking cessation intervention|Life style
79483161|NCT00363428|Other|counseling intervention|life style
79483162|NCT00363428|Other|educational intervention|life style
79483163|NCT00363428|Procedure|conventional surgery|life style
79483164|NCT00363428|Procedure|pulmonary complications management/prevention|life style
79483165|NCT05717257|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
79979442|NCT06064331|Drug|Placebo|IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
79649200|NCT00224718|Procedure|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
79649201|NCT00224718|Procedure|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
79979443|NCT06064318|Procedure|Revision|Any type of knee revision, excluding knee arthrodesis and femur amputation
79979444|NCT06064305|Other|No study-specific interventions|Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
79979445|NCT06064292|Device|INSPIRATORY MUSCLE TRAINING|After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
79979446|NCT06064240|Other|We do not have any intervention type|We do not have any intervention type
79649202|NCT00402506|Drug|(MC-1) Pyridoxal 5'-phosphate|
79649203|NCT00195026|Device|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
79979447|NCT06064227|Other|training intervention|"In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization."
79979448|NCT06064201|Other|Short-chain fatty acids (SCFAs)|The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.
79483166|NCT04341818|Other|Strength Training and Vitamin D monthly|For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
79483167|NCT04341818|Other|Strength Training and Vitamin D daily|For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
79483168|NCT04341818|Other|Strength Training and no Vitamin D|For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
79483169|NCT00362804|Drug|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
79483170|NCT05715541|Other|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
79649204|NCT00207129|Drug|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
79649205|NCT00207129|Drug|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
79649206|NCT00402545|Drug|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
79649207|NCT00402545|Drug|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
79649208|NCT00402545|Drug|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
79649209|NCT00402545|Drug|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
79649210|NCT00224757|Procedure|Transoesophageal echocardiography|TEE
79649211|NCT00195065|Behavioral|Semi-structured, open-ended interviews|
79649212|NCT04722159|Device|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
79649213|NCT00126074|Drug|Tedisamil sesquifumarate|
79328789|NCT03711019|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
79328790|NCT03711019|Device|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
79483171|NCT02451488|Drug|GM-CSF|14 days in a dose of 125 µg/m^2
79979449|NCT06064201|Other|Placebo|To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
79483172|NCT02451488|Other|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
79483173|NCT05576701|Behavioral|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
79483174|NCT05576701|Other|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
79483175|NCT04341506|Device|Non-contact ECG|A non-contact ECG will be used to detect a patient cardiac electrical activity.
79483176|NCT05717101|Other|Electronic Health Record Review|Review of medical records
79649214|NCT00224835|Behavioral|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
79979450|NCT06064175|Drug|Ibuprofen 400 mg|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
79979451|NCT06064175|Drug|Ibuprofen 800 mg|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
79979452|NCT06064162|Drug|ketamine|60mg (.5mg/kg over 40 minutes intravenously)
79979453|NCT06064149|Behavioral|CARE-PC Web-Based Application|The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
79328791|NCT03711019|Device|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
79979454|NCT06064123|Diagnostic Test|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
79979455|NCT06064084|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test 50g
79979456|NCT06064084|Other|Intravenous isoglycaemic glucose clamp|Intravenous isoglycaemic glucose clamp
79979457|NCT06064084|Other|Liquid Mixed meal test|Liquid Mixed meal test 520 kcal
79328792|NCT04919837|Other|Low vision aids|the assisting devices fitting for low-vision patients
79328793|NCT02918305|Device|PRDS-001 Renal Denervation Ultrasound System|
79328794|NCT02918305|Procedure|Sham Procedure|
79649215|NCT00224835|Behavioral|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
79649216|NCT00195104|Drug|Arsenic Trioxide (Tricenox)|
79649217|NCT00195104|Drug|Cytarabine|
79649218|NCT00207207|Procedure|Alternate site blood glucose testing|
79649219|NCT00224913|Procedure|Neuromuscular electrical stimulation|
79649220|NCT00224913|Procedure|Voluntary exercise|
79649221|NCT00195143|Genetic|Surgical infusion of AAV-GAD into the subthalamic nucleus|
79483177|NCT03172494|Drug|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
79483178|NCT03172494|Drug|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
79483179|NCT03172494|Drug|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
79483180|NCT02452346|Drug|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
79483181|NCT02959255|Drug|Esomeprazole|dosage difference
79483182|NCT05716945|Drug|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
79483183|NCT05716945|Drug|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
79483184|NCT05716945|Other|Stop steroids|Half the patients in each study arm will discontinue steroids.
79328795|NCT04929509|Other|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
79328796|NCT04929509|Other|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
79328797|NCT04929509|Other|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
79328798|NCT02798107|Drug|idarucizumab|drug
79328799|NCT04403867|Procedure|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
79328800|NCT01865539|Device|Custom Foot Orthotic|Custom foot orthotic with custom design pads
79328801|NCT01865539|Device|Sham Orthotic|Leather insert without the custom design pads
79328802|NCT03054467|Drug|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
79328803|NCT03054467|Drug|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
79328804|NCT05009485|Device|Current Health platform|A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.
79328805|NCT04910165|Drug|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
79483186|NCT05716867|Biological|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
79483187|NCT04341584|Drug|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
79483188|NCT05716711|Other|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
79328806|NCT04910165|Drug|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
79328807|NCT02730325|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
79328808|NCT02730325|Other|Placebo|
79328809|NCT03054233|Procedure|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
79328810|NCT04928495|Drug|Vitamin C|Vitamin C 500 mg / day for ten days
79328811|NCT04928495|Drug|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
79328812|NCT04928495|Drug|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
79328813|NCT03053921|Procedure|recession coverage|recession coverage done using Zuchellis technique
79328814|NCT03053921|Procedure|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
79328815|NCT05015413|Device|Shockwave|Shock wave master 500 Germany
79483189|NCT05716555|Device|Deep brain stimulation|Electrical stimulation of lateral habenula
79483190|NCT04341428|Drug|DWP14012 20 mg|DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
79483191|NCT04341428|Drug|DWP14012 20 mg placebo|DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
79483192|NCT04341428|Drug|Lansoprazole 15 mg|Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
79328816|NCT01573429|Other|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
79979458|NCT06064045|Behavioral|Simulation-based team training intervention|"Participants in the intervention group will aim to participate in simulation at a higher quantity and frequency.~Moreover, the intervention group:~Enrolled 15 healthcare professionals in a 3-day training program to become simulator facilitators, enabling an increase in the utilization of simulation within the group (October 2022).~Organized a 2-day workshop for all pediatric simulation facilitators with the objective of establishing a more robust and standardized foundation for implementing simulation within their respective departments (March 2023).~Procured essential equipment, including mannequins, SimPads, and monitors (before the intervention period).~Provide simulator facilitators with access to an online repository where they can access scenarios for conducting simulations (during the intervention period)."
79483193|NCT04341428|Drug|Lansoprazole 15 mg Placebo|Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
79483194|NCT03171168|Device|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
79483195|NCT03171168|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
79483196|NCT02977975|Other|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
79483197|NCT02977975|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
79483198|NCT02978053|Behavioral|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
79483199|NCT02978053|Behavioral|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
79328817|NCT03055559|Dietary Supplement|Globifer Forte|
79328818|NCT04910009|Other|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
79979459|NCT06064019|Device|Nevisense|The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
79328819|NCT01518673|Procedure|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
79328820|NCT04909931|Drug|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
79328821|NCT04909931|Drug|Placebo|Second arm : add on placebo for 12 weeks
79483200|NCT02453360|Procedure|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
79649222|NCT00207285|Behavioral|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
79328822|NCT02360839|Device|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
79328823|NCT04919291|Device|Topoguided LASIK|Topoguided ablation profile on dominant eye
79328824|NCT04919291|Device|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
79328825|NCT04918589|Drug|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
79328826|NCT04918589|Drug|Normal Saline|40 mL topical of 0.9% normal saline
79328827|NCT05128981|Behavioral|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
79328828|NCT04101643|Drug|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
79328829|NCT02620787|Drug|Tedizolid|
79328830|NCT02620787|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
79328831|NCT04082455|Radiation|carbon ion radiotherapy|carbon ion radiotherapy
79328832|NCT04062799|Other|no intervention|It is an observationa study. There is no intervention.
79483201|NCT02453360|Drug|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
79483202|NCT05568901|Behavioral|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
79649223|NCT00207285|Procedure|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
79649224|NCT00195182|Behavioral|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
79649225|NCT00413088|Drug|bemiparin|
79328833|NCT04909619|Procedure|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
79649226|NCT00207324|Device|Silver Leaf Dressing|
79649227|NCT00409760|Drug|valsartan+amlodipine combination, valsartan, amlodipine|
79649228|NCT00413127|Drug|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
79649229|NCT00413127|Drug|NaCl 0,9%|Administration of placebo i.v.
79649230|NCT00126152|Behavioral|Exercise, education and medical management|
79649231|NCT00224991|Procedure|Intensive systematic information (osteoporosis school)|
79328834|NCT04909619|Procedure|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
79649232|NCT00126230|Drug|docetaxel and samarium|
79979460|NCT06063980|Procedure|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
79979461|NCT06063980|Procedure|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
79979462|NCT06063928|Procedure|Archive Sample Retrieval|Undergo collection of archival tumor tissue
79979463|NCT06063928|Procedure|Biospecimen Collection|Undergo blood sample collection
79328835|NCT05128747|Other|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
79328836|NCT03056729|Drug|BIIB076|Administered as single intravenous (IV) infusion
79979464|NCT06063928|Other|Electronic Health Record Review|Medical records reviewed
79328837|NCT03056729|Drug|Placebo|Administered as single IV infusion
79649233|NCT00207363|Drug|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
79649234|NCT00207363|Drug|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
79649235|NCT00126269|Drug|cisplatin|
79979465|NCT06063928|Other|Genetic Testing|Undergo genetic testing
79979466|NCT06063928|Other|Questionnaire Administration|Complete questionnaires
79979467|NCT06063915|Device|Isoinertial training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
79979468|NCT06063915|Other|Strength Training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
79649236|NCT00126269|Drug|gemcitabine|
79328838|NCT03053999|Other|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
79328839|NCT03053999|Other|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
79979469|NCT06063889|Diagnostic Test|Maximal Rate of Force Development Test for Ankle Muscles|This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.
79328840|NCT03843073|Device|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
79328841|NCT03053843|Dietary Supplement|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
79328842|NCT05128435|Diagnostic Test|Blood sample|Blood sample taken 3 to 5 months after the infection
79649237|NCT00207402|Drug|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
79649238|NCT00195299|Drug|Temsirolimus|
79649239|NCT00471328|Drug|Nilotinib|Nilotinib 400 mg twice daily (bid)
79649240|NCT00471328|Other|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
79649241|NCT00225030|Drug|antihypertensive drugs according to current guidelines|
79328843|NCT03055637|Procedure|Furlow double opposing z-plasty|* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
79649242|NCT00126308|Device|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
79328844|NCT03055637|Procedure|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
79649243|NCT00126308|Device|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
79649244|NCT00225069|Procedure|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
79649245|NCT00195377|Drug|Etanercept|
79649246|NCT00225108|Drug|Tinzaparin|
79649247|NCT00195416|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
79649248|NCT00207441|Behavioral|Arthritis Self management program|
79649249|NCT00207441|Behavioral|Chronic Disease Self Management Program|
79649250|NCT00225186|Drug|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
79979470|NCT06063863|Diagnostic Test|Nurse led screening with Optos ultra-widefield retinal-imaging device|The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
79979471|NCT06063837|Behavioral|Live Instruction and Fitness Tracking (LIFT-up)|A 12-week combined aerobic and resistance training exercise protocol
79328845|NCT03559855|Behavioral|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
79328846|NCT04918901|Combination Product|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
79328847|NCT03520231|Drug|Denosumab|RANK Ligand Inhibitor
79328848|NCT03520231|Other|Denosumab Placebo|Placebo
79328849|NCT03520231|Drug|Gemcitabine|Antineoplastic Agent
79328850|NCT03520231|Drug|Carboplatin|Antineoplastic Agent
79649251|NCT00195455|Drug|Trimegestone|
79649252|NCT00195455|Drug|17b Estradiol|
79649253|NCT00207480|Behavioral|Brief, motivational interviewing intervention|
79979472|NCT06063824|Other|Single-Session Method of Levels Intervention|This is a single session of method of levels psychotherapy delivered to patients of GP surgeries in primary care.
79979473|NCT06063811|Other|Ablation|VT ablation
79328851|NCT03520231|Drug|Cisplatin|Antineoplastic Agent
79328852|NCT03520231|Dietary Supplement|Calcium|Calcium Supplement
79328853|NCT03520231|Dietary Supplement|Vitamin D|Vitamin D Supplement
79328854|NCT05128357|Other|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
79328855|NCT05117749|Drug|Saffron 100|to Mild and Moderate UC patients
79328856|NCT05117749|Drug|Saffron 50|to Mild and Moderate UC patients
79328857|NCT05117749|Drug|Placebo|to Mild and Moderate UC patients
79649254|NCT00126347|Procedure|supplementation with betaine, serine, and folic acid|
79649255|NCT00225225|Drug|Rosiglitazone|
79649256|NCT00225225|Behavioral|dietary recommendation for weight maintenance|
79649257|NCT00126386|Drug|Zoledronic acid (Zometa)|
79649258|NCT00225264|Drug|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
79649259|NCT00225264|Drug|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
79649260|NCT00126464|Drug|fulvestrant|
79649261|NCT00126464|Drug|tamoxifen citrate|
79649262|NCT00126464|Procedure|conventional surgery|
79649263|NCT00126464|Procedure|neoadjuvant therapy|
79649264|NCT00207519|Behavioral|weekly behavioral modification group|
79649265|NCT00207519|Behavioral|liquid meal replacements|
79649266|NCT00195533|Drug|piperacillin-tazobactam|
79649267|NCT00195533|Drug|glycopeptide|
79649268|NCT00207558|Drug|folic acid|
79649269|NCT00195572|Drug|Isovorin|
79649270|NCT00195572|Drug|TS-1|
79649271|NCT00202280|Drug|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
79649272|NCT00225303|Drug|TMC125|
79649273|NCT00225342|Drug|Rosiglitazone|
79649274|NCT00225342|Drug|Gliclazide (Comparison drug)|
79649275|NCT00195611|Drug|Prevenar|
79649276|NCT00470470|Drug|imatinib mesylate|Given orally
79649277|NCT00470470|Other|laboratory biomarker analysis|Correlative studies
79649278|NCT00207636|Behavioral|Computer-based prostate cancer screening decision aid|
79649279|NCT00195689|Biological|Human anti-TNF monoclonal antibody/adalimumab|
79483203|NCT05568901|Behavioral|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
79483204|NCT05714137|Behavioral|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
79649280|NCT00470275|Drug|cytarabine|Given IV
79649281|NCT00225381|Device|connection of measuring device to anesthesia circuit|same as name
79979474|NCT06063798|Other|General anesthesia for laryngotracheal surgery|Patients undergoing general anesthesia and mechanical ventilation.
79979475|NCT06063798|Other|Mechanical ventilation by FCV|Mechanical ventilation is assured by Flow-controlled ventilation mode.
79328858|NCT04918667|Combination Product|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
79328859|NCT04918667|Dietary Supplement|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
79328860|NCT03456193|Procedure|LA transplant|"The proposed study treatment will include three central components:~Harvest of the left atrium and pulmonary veins from a suitable donor~Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
79328861|NCT03056495|Drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
79483205|NCT05716399|Device|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
79483206|NCT05716399|Device|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
79649282|NCT00225381|Procedure|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
79649283|NCT00225381|Procedure|changing operating room bed position (head down and up position)|same
79649284|NCT00225381|Procedure|adding PEEP during anesthesia|same
79979476|NCT06063798|Other|Mechanical ventilation by HFJV|Mechanical ventilation is assured by High frequency jet ventilation mode.
79979477|NCT06063772|Drug|Clevidipine|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
79483207|NCT05716399|Device|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
79979478|NCT06063772|Drug|Lactated Ringers, Intravenous|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
79328862|NCT03171805|Drug|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
79979479|NCT06063759|Device|VitalDetect|measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
79649285|NCT00225381|Procedure|placement of esophageal Doppler for cardiac output measurements|same
79649286|NCT00225381|Device|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
79328863|NCT03098329|Other|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
79483208|NCT02453672|Biological|SB8|SB8, proposed bevacizumab biosimilar
79979480|NCT06063746|Drug|Vidutolimod|
79979481|NCT06063707|Other|Taking peripheral blood|Taking peripheral blood of no more than 3ml
79979482|NCT06062134|Procedure|Pericapsular nerve group block|Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
79979483|NCT06062134|Drug|18 mL ropivacaine 0.5% + 2 mL radiopaque contrast|20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
79979484|NCT06061458|Diagnostic Test|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
79328864|NCT03053531|Device|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
79328865|NCT05117593|Drug|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
79483209|NCT02453672|Biological|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
79483210|NCT02453672|Biological|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
79649287|NCT00225381|Device|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
79979485|NCT06061237|Other|Aerobic Thai dance exercise|Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks. Aerobic exercise of modulate intensity (12-13 Borg's RPE)
79649288|NCT00225381|Device|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
79649289|NCT00225381|Device|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
79649290|NCT00195728|Drug|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
79649291|NCT00470158|Dietary Supplement|iron and zinc combined|Children >= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
79649292|NCT00470158|Dietary Supplement|iron and zinc on separate days|Children >= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
79649293|NCT00470158|Dietary Supplement|iron|Children >= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
79328866|NCT05117593|Drug|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
79328867|NCT02787187|Procedure|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
79328868|NCT02787187|Procedure|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
79483211|NCT03119064|Drug|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
79483212|NCT03119064|Drug|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
79483213|NCT00358033|Behavioral|Counseling|
79483214|NCT00358033|Behavioral|Interactive Education|
79649294|NCT00470158|Dietary Supplement|Zinc|Children >= 12 months received an average of 5mg zinc/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
79649295|NCT00470158|Dietary Supplement|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
79649296|NCT00475540|Device|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
79649297|NCT00472186|Drug|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
79649298|NCT00472186|Drug|Placebo|Placebo will also be administered based on weight.
79649299|NCT00195767|Drug|divalproex sodium|
79649300|NCT00225537|Drug|4-Methylumbelliferone (Heparvit®)|
79649301|NCT00202319|Procedure|Sedation management protocol|
79328869|NCT03053375|Device|MDCure|Battery powered portable pulsed electromagnetic therapy device
79328870|NCT05405023|Other|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
79328871|NCT05405023|Other|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
79328872|NCT04918277|Device|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
79328873|NCT04918433|Procedure|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
79328874|NCT05093803|Behavioral|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
79328875|NCT05093803|Behavioral|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
79483215|NCT00358033|Behavioral|Group Support|
79483216|NCT00358033|Procedure|Pharmacologic case management|Provided by clinical pharmacists
79483217|NCT02453750|Drug|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls <10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls >10%, the previous step will be repeated.
79483218|NCT02453750|Drug|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
79483219|NCT03107286|Drug|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
79483220|NCT03107286|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
79483221|NCT02454296|Drug|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
79649302|NCT00207675|Drug|infliximab|
79649303|NCT00202358|Drug|atenolol|
79649304|NCT00202358|Drug|placebo|
79649305|NCT00479713|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
79649306|NCT00479713|Drug|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
79483222|NCT02454296|Drug|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
79649307|NCT00479713|Drug|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
79649308|NCT00479713|Drug|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
79649309|NCT00207753|Drug|albendazole vs. combined albendazole/ivermectin treatment|
79649310|NCT00202397|Drug|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
79649311|NCT00202397|Other|placebo|capsule-shaped tablet bid for 8 weeks
79649312|NCT00479635|Drug|TPI 287|160 mg/m2 every three weeks for six cycles
79649313|NCT00479635|Drug|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
79649314|NCT00478972|Drug|Rimonabant|Tablet, oral administration
79328876|NCT04926467|Drug|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
79649315|NCT00478972|Drug|placebo (for Rimonabant)|Tablet, oral administration
79328877|NCT02302105|Radiation|IGRT|Image Guided RT to the prostate
79649316|NCT00478972|Other|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
79649317|NCT00207792|Drug|filgrastim|
79649318|NCT00195806|Drug|divalproex sodium|
79649319|NCT00477529|Drug|ABI-008|nab-docetaxel
79649320|NCT00472693|Drug|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
79649321|NCT00195845|Drug|Galantamine|
79649322|NCT00195845|Drug|Placebos|
79649323|NCT00202436|Procedure|Phlebotomy|Removal of 500 ml whole blood
79649324|NCT00202436|Procedure|Erythrocytapheresis|machinal removal of erythrocytes
79979486|NCT06060288|Diagnostic Test|Diagnosis by mobile phone imaging|"The photographs will be taken with a smartphone iPhone 14 Pro in a one-year period. Imaging will follow the recommendations regarding intraoral photography in oral mucosal screening set by (Lin et al., 2021).~Personal data and a brief description of the present illness concerning the main complaint will be informed by the patients and recorded in a diagnosis chart of the Oral medicine department Cairo University. Complete intraoral physical examination will be performed by the main investigator under supervision of the main supervisor and the co-supervisor using dental equipment with artificial light."
79483223|NCT03836833|Drug|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
79649325|NCT00195884|Behavioral|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
79649326|NCT00202475|Procedure|eythrocytapheresis|machinal collection of erythrocytes
79979487|NCT06059911|Dietary Supplement|Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)|Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids
79979488|NCT06059911|Dietary Supplement|Placebo dietary supplement (97% maltodextrin)|Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin
79328878|NCT05128045|Behavioral|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
79328879|NCT03053297|Other|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
79328880|NCT05127889|Drug|curodont|"To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~The varnish will be mixed with the brush to avoid separation of the material during storage~However, to guarantee the best results suction will be used during application of the varnish.~A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
79328881|NCT05127655|Procedure|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
79328882|NCT04926935|Diagnostic Test|Microbiological analysis of blood samples.|Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
79328883|NCT03053219|Drug|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
79328884|NCT04764019|Diagnostic Test|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
79483224|NCT03836833|Drug|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
79483225|NCT04744142|Drug|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
79979489|NCT06059664|Drug|Finerenone Oral Tablet|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
79979490|NCT06059664|Drug|Placebo|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
79979491|NCT06059339|Other|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
79979492|NCT06059313|Other|Submission of the NEO-PI-3 questionnaire|The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).
79979493|NCT06059313|Other|Submission of the Interpersonal Reactivity Index questionnaire (IRI)|The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
79979494|NCT06056232|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
79328885|NCT03055793|Other|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
79328886|NCT04583761|Behavioral|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
79328887|NCT04531891|Other|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
79328888|NCT04926389|Other|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
79328889|NCT04926389|Other|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
79328890|NCT04926155|Drug|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
79649327|NCT00202475|Procedure|whole blood collection|collection of whole blood
79483226|NCT04744142|Dietary Supplement|Increased protein intake|Subjects receive either normal or increased protein intake
79483227|NCT05716243|Device|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
79328891|NCT05133583|Other|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
79483228|NCT05716243|Device|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
79483229|NCT03098238|Biological|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
79483230|NCT03398694|Procedure|Radiosurgery|"Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure."
79328892|NCT04917965|Other|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
79328893|NCT04909775|Drug|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
79483231|NCT03362502|Genetic|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
79328894|NCT04909775|Drug|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
79979495|NCT06056232|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)-increase distress tolerance|Increase the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including more emotion exposure tasks, materials from Facing Your Feelings.
79328895|NCT04909775|Drug|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
79649328|NCT00225576|Other|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
79979496|NCT06056232|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)-decrease distress tolerance|Decrease the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including less emotion exposure tasks and interoceptive exposure tasks.
79649329|NCT00202514|Drug|divalproex sodium extended release|
79328896|NCT05133349|Drug|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
79328897|NCT04925141|Drug|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
79328898|NCT04209517|Other|Filming|Behavioural markers selection from video-recordings of the interview
79483232|NCT02457260|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
79483233|NCT05233410|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79483234|NCT05233410|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
79483235|NCT04602390|Drug|ANK-700|Intravenous (IV) infusion
79483236|NCT04602390|Drug|Placebo|Intravenous (IV) infusion
79483237|NCT05710471|Drug|Brolucizumab|Intravitreal injection
79483238|NCT05710471|Drug|Aflibercept|Intravitreal injection
79483239|NCT02457728|Device|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
79483240|NCT00358111|Device|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
79483241|NCT02458352|Device|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
79483242|NCT02458352|Device|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
79649330|NCT00207831|Drug|Tegafur and Uracil|
79649331|NCT00195923|Drug|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
79649332|NCT00225615|Drug|sapropterin dihydrochloride|
79483243|NCT05652894|Drug|HX008|Drug: HX008 200 mg ,Q3W
79649333|NCT00225654|Device|coronary stent|
79649334|NCT00202553|Drug|Perindopril|
79649335|NCT00202592|Drug|Perindopril|
79649336|NCT00196040|Device|PFX Closure System|
79649337|NCT00202631|Device|Surface Functional Electrical Stimulation|
79649338|NCT00196079|Device|Coronary stent|
79649339|NCT00225693|Device|drug eluting coronary stent|
79649340|NCT00196118|Device|Günther Tulip Vena Cava Filter|
79649341|NCT00225810|Drug|Crohn's Disease|
79979497|NCT06055894|Dietary Supplement|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily
79328899|NCT04908917|Device|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
79328900|NCT04908917|Device|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
79328901|NCT02651155|Drug|Lubiprostone|Lubiprostone capsules
79328902|NCT02651155|Drug|Placebo|Lubiprostone placebo-matching capsules
79979498|NCT06055894|Dietary Supplement|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily
79649342|NCT00411333|Drug|triamcinolone acetonide (Kenalog)|
79649343|NCT00202709|Behavioral|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
79328903|NCT04925063|Drug|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
79979499|NCT06055894|Dietary Supplement|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
79328904|NCT04909151|Device|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
79328905|NCT04909151|Device|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
79328906|NCT04909151|Device|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
79328907|NCT05127343|Procedure|Sealing deep pits and fissures|Application of the pit and fissure sealant
79979500|NCT06055894|Other|Whole food, plant-based diet (WFPBD)|Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
79979501|NCT06055205|Other|PAC-plan|The participants will be asked to complete electronic questionnaires at baseline, and at 6 weeks and 52 weeks after discharge from the hospital. The completion of these questionnaires will take place during the 6-week follow-up appointment at the hospital (a standard follow-up for all patients undergoing surgery at the Division of Orthopedic Surgery, Oslo University Hospital, Norway). Additionally, participants will be invited for a phone-based follow-up appointment with the study coordinator 52 weeks after discharge. The participants will receive the questionnaires electronically via SMS or email. If electronic options are not feasible, data can be collected through paper questionnaires sent by mail. Data will not be directly obtained from general practitioners.
79979502|NCT06051149|Procedure|caudal adhesolysis using RACZ Catheter|caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy
79328908|NCT05132959|Diagnostic Test|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
79328909|NCT04925297|Other|No intervention|No intervention will be given
79649344|NCT00225849|Drug|Aspirin|
79649345|NCT00196157|Procedure|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
79649346|NCT00196157|Procedure|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
79979503|NCT06051149|Procedure|caudal adhesiolysis using NAVI Catheter|caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy
79649347|NCT00202748|Behavioral|Increase in activity to control weight|
79483244|NCT05652894|Drug|Investigator's Choice Chemotherapy|"Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46~48 h.Component of mFOLFOX6 or FOLFORI."
79483245|NCT00358189|Device|Deep Brain Stimulation|
79649348|NCT00202748|Behavioral|Increase in activity to control weight.|
79649349|NCT00202787|Drug|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
79328910|NCT04495777|Other|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
79328911|NCT03055169|Genetic|genetic analysis|
79328912|NCT03055169|Biological|blood and stools samples|
79328913|NCT05132725|Behavioral|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
79483246|NCT04591080|Device|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
79483247|NCT04591080|Device|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
79483248|NCT05715853|Other|QSant|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
79483249|NCT05652816|Procedure|Split-thickness skin graft|Transplantation of autologous skin to burn area
79483250|NCT05652816|Biological|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
79483251|NCT05652816|Biological|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
79483252|NCT05702593|Procedure|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides [Bretischwerdt]. The technique was repeated three times, with a 15-second rest interval between each repetition.
79483253|NCT05702593|Procedure|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
79649350|NCT00202787|Drug|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
79649351|NCT00225888|Behavioral|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
79979504|NCT06044454|Other|qXR|a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
79979505|NCT06044298|Other|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
79979506|NCT06041932|Drug|Carvedilol|Carvedilol
79328914|NCT04908527|Behavioral|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
79979507|NCT06041932|Drug|Pentoxifylline|Pentoxiphylline
79328915|NCT04924829|Drug|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
79328916|NCT05132413|Drug|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
79328917|NCT05132413|Drug|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
79328918|NCT05132413|Drug|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
79483254|NCT00358969|Drug|guanfacine (Tenex)|
79483255|NCT01636362|Device|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
79483256|NCT00359047|Behavioral|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
79483257|NCT00359047|Behavioral|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
79649352|NCT00424437|Drug|Inhaled human insulin|
79649353|NCT00202865|Biological|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
79979508|NCT06040424|Combination Product|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
79979509|NCT06040424|Drug|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
79979510|NCT06038825|Device|topical vibration|topical vibration (Aprilla brand, giving 6000 vibrations per minute) is a device for pain relief during injection of local anesthetic.
79979511|NCT06037187|Diagnostic Test|Blood Draw|Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
79979512|NCT06036823|Drug|Insulin regular|Intravenous insulin
79979513|NCT06036823|Drug|Dextrose 50|to be given to both arms
79979514|NCT06036823|Drug|salbutamol|to be given to all patients
79328919|NCT04924751|Diagnostic Test|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
79328920|NCT05126953|Device|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
79328921|NCT05126953|Device|B+L Ultra Lenses|Commercially available Biotrue ONEday lenses
79328922|NCT03052829|Behavioral|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
79328923|NCT03052829|Behavioral|Usual care|Subjects will undergo their usual care without intervention
79328924|NCT04924595|Behavioral|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
79328925|NCT03052907|Behavioral|BSPAN|"Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach & Health Promotion and Delivery & Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach & Health Promotion component (Medium Capacity).~Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
79328926|NCT04133935|Procedure|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
79328927|NCT04133935|Procedure|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
79328928|NCT04924049|Other|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
79483258|NCT05544175|Procedure|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
79483259|NCT00358423|Drug|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
79483260|NCT00358423|Drug|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
79649354|NCT00202865|Biological|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
79649355|NCT00225927|Procedure|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
79979515|NCT06023836|Device|ESWT|Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
79328929|NCT04435717|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous (one dose)
79979516|NCT06023836|Procedure|Dry needling|Dry needling with Seirin branded 0.6*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
79979517|NCT06023823|Other|Toe spread out|toe-spread-out exercise.
79979518|NCT06023823|Other|Dry needling+Toe spread out|The group will be given 3 sessions of dry needling with Seirin branded 0.6*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
79328930|NCT04435717|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)|Tocilizumab 20 MG/ML Intravenous ( two doses)
79328931|NCT04907981|Diagnostic Test|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
79328932|NCT05124223|Diagnostic Test|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
79328933|NCT04075981|Drug|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
79649356|NCT00225966|Device|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
79979519|NCT06023264|Procedure|Dry needling|It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
79483261|NCT02896712|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
79483262|NCT02896712|Behavioral|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
79483263|NCT02896712|Behavioral|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
79979520|NCT06021990|Drug|Clopidogrel Bisulfate 75Mg Tab|Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
79979521|NCT06007378|Other|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
79649357|NCT00202943|Procedure|TCRFVR and LAUP|
79979522|NCT06007378|Other|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
79483264|NCT02896712|Drug|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
79979523|NCT06007378|Other|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
79979524|NCT05999279|Behavioral|Survey|Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
79979525|NCT05996302|Behavioral|Relocation to sea level|Relocation to sea level by bus and stay for 2 days
79979526|NCT05983679|Diagnostic Test|Blood sample|Blood sample
79979527|NCT05967819|Behavioral|Exercise Stress|Increased exercise volume
79483265|NCT02896712|Drug|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
79483266|NCT04744064|Dietary Supplement|Protein and carbohydrate|Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
79483267|NCT05346601|Drug|Chiauranib|50mg po only once
79649358|NCT00226005|Drug|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
79649359|NCT00196352|Drug|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
79649360|NCT00226044|Drug|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
79979528|NCT05967819|Behavioral|Psychosocial Stress|cognitive tasks
79979529|NCT05946018|Other|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
79979530|NCT05946018|Other|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
79979531|NCT05937776|Other|Fludeoxyglucose F-18|Given IV
79649361|NCT00202982|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
79649362|NCT00202982|Drug|glatiramer acetate 40 mg|glatiramer acetate 40 mg
79649363|NCT00207948|Drug|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
79649364|NCT00196391|Drug|DR-2021a|1 capsule daily for 10 days
79649365|NCT00196391|Drug|DR-2021b|1 capsule daily for 10 days
79979532|NCT05937776|Other|Gadoterate Meglumine|Given IV
79979533|NCT05937776|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo PET/contrast-enhanced MRI
79979534|NCT05937776|Procedure|Positron Emission Tomography|Undergo PET/contrast-enhanced MRI
79979535|NCT05910294|Other|questionnaires|Vaginal Assessment Scale (VAS) & Vulvar Assessment Scale (VuAS) Breast survivorship Tool (MSK Engage Symptom Assessment) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
79483268|NCT05336695|Diagnostic Test|PET/MR Imaging|PET/MRI Scan with [64Cu]FBP8 as directed by protocol
79483269|NCT05336695|Drug|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
79979536|NCT05910294|Other|moisturizers|Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
79483272|NCT02766686|Radiation|Radiotherapy with protons|
79483273|NCT02766686|Radiation|Radiotherapy with photons|
79649366|NCT00196391|Drug|DR-2021c|1 capsule daily for 10 days
79649367|NCT00196391|Drug|DR-2021d|1 capsule daily for 10 days
79649368|NCT00196391|Drug|DR-2021e|1 capsule daily for 10 days
79649369|NCT00196391|Other|Placebo|1 matching placebo capsule for 10 days
79649370|NCT00203060|Drug|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
79328934|NCT04075981|Other|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
79328935|NCT05122195|Other|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
79328936|NCT04917497|Drug|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
79649371|NCT00203060|Drug|placebo|tablet, once daily, 58 weeks
79649372|NCT00196430|Device|silver-contained textiles|
79649373|NCT00196430|Drug|corticosteroid|
79979537|NCT05910294|Other|moisturizers|potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
79979538|NCT05909020|Other|No intervention.|No intervention.
79979539|NCT05907993|Drug|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
79979540|NCT05902754|Dietary Supplement|Generally Recognized as Safe - Sulforaphane|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
79649374|NCT00226122|Drug|Indomethacin|Indomethacin capsules 50 mg
79979541|NCT05902754|Dietary Supplement|Placebo|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
79649375|NCT00196469|Drug|heparin|
79649376|NCT00226161|Procedure|Inguinal herniorrhaphy|
79649377|NCT00208065|Drug|almotriptan or pseudoephedrine|
79649378|NCT00203099|Drug|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
79649379|NCT00196508|Device|High Viscosity DERMABOND|
79649380|NCT00226200|Drug|Omalizumab|
79649381|NCT00208104|Behavioral|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
79649382|NCT00203138|Drug|rasagiline mesylate|
79649383|NCT00226278|Drug|ORG 34517|
79649384|NCT00196547|Drug|Montelukast (drug)|
79811292|NCT00871715|Behavioral|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
79328937|NCT03933007|Drug|Colchicine,|"the day of phenotyping assay~Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
79328938|NCT03933007|Drug|midazolam,|Midazolam 1 mg
79328939|NCT03933007|Drug|fexofenadine|Fexofenadine 120 mg
79328940|NCT04924439|Other|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
79328941|NCT05126875|Radiation|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
79328942|NCT03056651|Other|treatment in day-care heart failure unit|
79483274|NCT00708890|Behavioral|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
79483275|NCT05524285|Device|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
79979542|NCT05897619|Behavioral|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
79483276|NCT05524285|Device|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
79649385|NCT02962869|Drug|BAY987517|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
79649386|NCT02962869|Other|Untreated skin|One site is patched without treatment as control
79328943|NCT04917263|Diagnostic Test|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
79328944|NCT04907435|Procedure|simultaneous operations|simultaneous operations
79483277|NCT05693155|Behavioral|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
79483278|NCT04344379|Drug|hydroxychloroquine|200 mg BID per day
79649387|NCT00203177|Drug|rasagiline mesylate|0.5 rasagiline mesylate
79979543|NCT05890898|Behavioral|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
79979544|NCT05890898|Drug|Nitrous Oxide|Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.
79979545|NCT05875948|Drug|R2R01|Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
79328945|NCT05404399|Behavioral|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
79328946|NCT05404399|Behavioral|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
79328947|NCT04923503|Behavioral|diurnal fasting|subject conduct fasting in Ramadan for 30 days
79328948|NCT03862729|Procedure|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
79328949|NCT03862729|Procedure|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
79328950|NCT04907747|Drug|Vonoprazan|Potassium-competitive acid blocker
79328951|NCT04907747|Drug|Esomeprazole|Proton pump inhibitor
79328952|NCT04907747|Drug|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
79328953|NCT04907747|Drug|Amoxicillin|Antibiotic for H. pylori eradication
79328954|NCT04907747|Drug|Furazolidone|Antibiotic for H. pylori eradication
79328955|NCT03812263|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
79328956|NCT03052673|Drug|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
79328957|NCT03052673|Drug|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
79483279|NCT04344379|Drug|azithromycin|250 mg per day
79483280|NCT04344379|Drug|hydroxychloroquine placebo|200 mg BID per day
79483281|NCT02465216|Other|Placebo|Placebo
79483282|NCT02465216|Biological|ID93 + GLA-SE|ID93 + GLA-SE
79483283|NCT05448703|Other|Blood Samples for Biomarkers|blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
79483284|NCT02465372|Behavioral|CSPAP|Comprehensive School Physical Activity Program.
79483285|NCT00359125|Drug|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
79483286|NCT00359125|Other|Placebo|Placebo, 600 mg/day for 1 week.
79649388|NCT00203177|Drug|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
79649389|NCT00208143|Drug|Quetiapine|
79649390|NCT00208143|Drug|Risperidone|
79649391|NCT00196586|Drug|Interleukin 2|
79328958|NCT04907123|Other|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
79483287|NCT05688709|Behavioral|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
79483288|NCT05686603|Device|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece|Picosecond laser is a novel technology characterized by ultra-short, picosecond pulse duration which can be effective for many skin conditions, such as pigmentation, photoaging and wrinkles reduction. When combined with micro-lens array (MLA) optics, high-intensity, micro-injury zones can be generated in the epidermis and dermis, causing optical breakdown of surrounding tissue and stimulating of dermal remodeling with mild side-effects. Previous studies had showed the picosecond lasers with MLA afforded better or similar clinical outcomes as well as fewer side-effects in treating acne scar than non-ablative lasers.
79483289|NCT05686603|Device|a ablative fractional 2940-nm Er:YAG laser|2940-nm erbium yttrium aluminum garnet (Er:YAG) laser is one of the most commonly used treatments for atrophic acne scars, which can remove the damage tissue of the scars and allow collagen remodeling and re-epithelialization.
79649392|NCT00196586|Drug|pegylated interferon alpha 2a|
79649393|NCT00196586|Drug|ribavirin|
79649394|NCT00226317|Drug|Aripiprazole|
79649395|NCT00226356|Drug|Supplements of L-methionine, betaine and folate|
79649396|NCT00208182|Drug|Risperidone|
79649397|NCT00203255|Drug|Soy Isoflavones|
79649398|NCT00203333|Device|Medtronic REVEAL|
79328959|NCT04907123|Other|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
79328960|NCT05030857|Drug|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
79649399|NCT00208221|Drug|ramipril|
79649400|NCT00208221|Drug|ramipril-telmisartan|
79649401|NCT00196625|Drug|Amprenavir (drug)|
79649402|NCT00196625|Drug|ABT-378/r (drug)|
79649403|NCT00196625|Drug|Ritonavir (drug)|
79649404|NCT00226434|Procedure|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
79649405|NCT00226434|Procedure|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
79979546|NCT05875948|Drug|Terlipressin|"In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin."
79649406|NCT00410579|Other|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
79649407|NCT00208260|Drug|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
79979547|NCT05871268|Other|Physician Awareness|The patients' pre-visit Control Preference Scale response are shared with their physician.
79979548|NCT05871268|Other|Usual Care|The patients' pre-visit Control Preference Scale response are not shared with their physician.
79979549|NCT05864521|Dietary Supplement|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
79328961|NCT05030857|Drug|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
79328962|NCT04917341|Diagnostic Test|re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital|The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
79328963|NCT03810859|Biological|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
79649408|NCT00208260|Drug|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
79649409|NCT00208260|Drug|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
79649410|NCT00208260|Drug|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
79649411|NCT00208260|Drug|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
79649412|NCT00226473|Drug|Cisplatin, Vindesine, Dacarbazine (drugs)|
79649413|NCT00208299|Drug|Regadenoson|0.4 mg, bolus intravenous injection
79649414|NCT00208299|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
79649415|NCT00196664|Drug|Paroxetine|
79649416|NCT00196703|Drug|memantine|
79649417|NCT00196703|Procedure|constraint-induced language therapy|
79328964|NCT04917185|Other|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
79649418|NCT00208338|Device|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
79328965|NCT03319459|Drug|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
79328966|NCT03319459|Drug|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
79328967|NCT03319459|Drug|Trastuzumab|HER2/neu receptor inhibitor
79328968|NCT04998799|Behavioral|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
79328969|NCT04430933|Drug|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
79328970|NCT04430933|Drug|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
79649419|NCT00208338|Procedure|Rotator cuff repair|Standard surgical repair of torn rotator cuff
79649420|NCT00410618|Procedure|cognitive assessment|
79328971|NCT04430933|Drug|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
79328972|NCT04430933|Drug|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
79328973|NCT04839133|Device|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
79328974|NCT03056417|Behavioral|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
79328975|NCT04815343|Device|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
79328976|NCT04906733|Procedure|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
79328977|NCT03176095|Dietary Supplement|Probiotic|
79328978|NCT03176095|Dietary Supplement|Placebo|
79328979|NCT04906655|Drug|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
79328980|NCT03130699|Behavioral|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
79328981|NCT03130699|Behavioral|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
79649421|NCT00410618|Procedure|magnetic resonance imaging|
79649422|NCT00410618|Procedure|management of therapy complications|
79649423|NCT00413322|Drug|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
79649424|NCT00413322|Drug|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
79649425|NCT00196781|Behavioral|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
79649426|NCT00196781|Behavioral|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
79649427|NCT00413361|Drug|versus hydroxychloroquine|versus hydroxychloroquine
79649428|NCT00410657|Biological|alemtuzumab|
79649429|NCT00410657|Drug|methylprednisolone|
79649430|NCT00410657|Drug|prednisone|
79649431|NCT00410657|Other|flow cytometry|
79649432|NCT00410657|Other|immunologic technique|
79649433|NCT00410657|Other|pharmacological study|
79649434|NCT00196820|Drug|Capecitabine|
79649435|NCT00208377|Device|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
79649436|NCT00410696|Drug|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
79649437|NCT00410696|Drug|Pegfilgrastim|6 mg/day sc at day +1
79328982|NCT03130699|Behavioral|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
79649438|NCT00226512|Drug|Campath-1H /ATG|
79979550|NCT05864521|Dietary Supplement|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
79649439|NCT00409799|Drug|I-0401 (a new bone graft substitute)|1 time application
79649440|NCT00208416|Procedure|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
79649441|NCT00208416|Procedure|Conventional surgical technique|A conventional surgical technique used in total hip replacement
79649442|NCT00410735|Drug|Placebo|0 mg BID for 12 weeks
79979551|NCT05856786|Diagnostic Test|Optical coherence tomography|Posterior segment OCT (a non-contact procedure performed over one minute) is additionally performed for patients participating in this study. Proportion of change in measurements in microns will be analyzed.
79328983|NCT03056183|Behavioral|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
79328984|NCT03055091|Other|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
79328985|NCT03055091|Other|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
79328986|NCT02648581|Drug|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
79328987|NCT04916717|Other|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
79328988|NCT02609815|Drug|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
79328989|NCT02609815|Drug|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
79649443|NCT00410735|Drug|Pranlukast hydrate|225 mg BID for 12 weeks
79979552|NCT05855967|Drug|Ixekizumab|Administered SC
79979553|NCT05852041|Procedure|Biopsy of Prostate|Undergo MRI/PET prostate biopsy
79328990|NCT01315639|Biological|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
79328991|NCT04662463|Behavioral|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
79483290|NCT03042468|Drug|177Lu-PSMA-617|177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
79649444|NCT00208455|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
79649445|NCT00203372|Drug|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
79649446|NCT00203372|Drug|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
79649447|NCT00203372|Drug|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
79649448|NCT00203372|Drug|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
79979554|NCT05852041|Genetic|Decipher Prostate Cancer Test|Undergo decipher
79979555|NCT05852041|Other|Flotufolastat F-18 Gallium|Given IV
79979556|NCT05852041|Procedure|Magnetic Resonance Imaging|Undergo PET-MRI
79979557|NCT05852041|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79979558|NCT05852041|Procedure|Positron Emission Tomography|Undergo PET-MRI
79979559|NCT05852041|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
79649449|NCT00226551|Drug|Isoproterenol|
79649450|NCT00196859|Drug|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
79328992|NCT04662463|Behavioral|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
79328993|NCT04916561|Diagnostic Test|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
79649451|NCT00196859|Drug|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
79649452|NCT00208533|Drug|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
79328994|NCT04906967|Procedure|flaps|coverage of soft tissue defect around ankle
79483291|NCT03042468|Drug|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging
79649453|NCT00226629|Procedure|Endovascular vs Open Repair|
79649454|NCT00203450|Drug|Zonegran|zonisamide
79649455|NCT00203450|Drug|Placebo|Placebo pill
79649456|NCT00226668|Drug|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
79649457|NCT00226668|Drug|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
79649458|NCT00208572|Drug|Citalopram|
79979560|NCT05802602|Device|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
79979561|NCT05802602|Device|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
79979562|NCT05796453|Device|Clareon Vivity IOL - Non Toric|Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
79979563|NCT05796453|Device|Clareon Vivity IOL - Toric|Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
79649459|NCT00203489|Device|KERLIX A.M.D. Gauze|
79649460|NCT00226707|Drug|Pimecrolimus Cream 1%|
79649461|NCT00203528|Drug|divalproex sodium ER|
79649462|NCT00203528|Drug|risperidone|
79979564|NCT05796453|Device|Clareon PanOptix Trifocal IOL - Non Toric|Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
79979565|NCT05796453|Device|Clareon PanOptix Trifocal IOL - Toric|Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
79979566|NCT05788367|Procedure|The pericapsular nerve group|patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%
79979567|NCT05788367|Procedure|Interscalene brachial plexus block|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia
79979568|NCT05777187|Other|Clinical Decision Support|The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
79979569|NCT05758181|Other|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
79483292|NCT05158452|Procedure|Discussion|Attend a focus group
79649463|NCT00208611|Dietary Supplement|Vitamin B12 Supplementation|1000 micrograms daily
79649464|NCT00413517|Procedure|Epi-Lasik|A vision correcting surgery
79649465|NCT00203567|Drug|carbamazepine ER|Active study drug, no comparator
79649466|NCT00226746|Drug|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
79649467|NCT00203606|Drug|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
79649468|NCT00203645|Behavioral|Self-help treatment|"Workbook Becoming a Winner,"
79649469|NCT02962791|Procedure|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
79649470|NCT02962791|Device|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
79649471|NCT02962791|Device|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
79649472|NCT02962791|Device|Echocardiography|Standard Echocardiography will de bone for patient
79649473|NCT00203684|Drug|Flunisolide-HFA|
79649474|NCT00197093|Drug|SB773812|
79649475|NCT00226785|Drug|Dexmedetomidine|
79649476|NCT00197132|Drug|Avandia|
79649477|NCT00208728|Device|PC/SMART cardiopulmonary bypass circuit|
79483293|NCT04486326|Drug|Crofelemer|Crofelemer
79483294|NCT04486326|Drug|Placebo|placebo
79483295|NCT05297773|Behavioral|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to a maximum of 64% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
79483296|NCT05297773|Behavioral|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
79649478|NCT00208728|Device|PMEA modified cardiopulmonary bypass circuit|
79649479|NCT00208728|Device|Standard of care uncoated cardiopulmonary bypass circuit|
79649480|NCT00197171|Biological|Combined Hepatitis A and B vaccine|
79649481|NCT00226824|Drug|galantamine|
79649482|NCT00197210|Biological|Rotavirus|
79649483|NCT00197249|Biological|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
79649484|NCT00226863|Behavioral|meditation plus education|
79649485|NCT00226863|Behavioral|group psychotherapy with hypnosis plus education|
79649486|NCT00226863|Behavioral|education|
79649487|NCT00203723|Drug|Risperidone|
79649488|NCT00226902|Procedure|Changing hemoglobin concentration|
79649489|NCT00203762|Behavioral|Public sector antiretroviral treatment programmes|
79649490|NCT00226980|Drug|Thalidomide|
79649491|NCT00226980|Drug|Capecitabine|
79649492|NCT00203801|Drug|Sulfadoxine-pyrimethamine|
79649493|NCT00203801|Drug|Artesunate plus sulfadoxine-pyrimethamine|
79649494|NCT00203801|Drug|Artemether-lumefantrine|
79649495|NCT00208806|Other|congestive heart failure patients|observational echo data on congestive heart failure patients
79328995|NCT01118767|Other|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
79328996|NCT04922879|Behavioral|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
79328997|NCT04906343|Procedure|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
79328998|NCT05132023|Drug|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
79649496|NCT00227058|Drug|Orotic acid and Glutathione-(Nutritional Supplements)|
79328999|NCT05132023|Drug|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
79329000|NCT04916405|Other|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
79329001|NCT05404087|Device|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
79329002|NCT04904159|Procedure|Thyroidectomy|total thyroidectomy
79649497|NCT00197288|Biological|Influenza|
79649498|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
79649499|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
79649500|NCT00197327|Drug|Epidural bupivacaine (0.25% versus 0.0625%)|
79649501|NCT00227097|Behavioral|Education Notebook for anticoagulant treatment|
79649502|NCT00208923|Drug|Busulfan, Cyclophosphamide and Fludarabine|"Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
79329003|NCT04904159|Procedure|Lobectomy|Lobectomy
79329004|NCT04498663|Behavioral|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
79329005|NCT04916483|Other|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
79329006|NCT04916483|Other|usual care|The control group maintains the unit routine treatment.
79649503|NCT02963012|Other|ultrasound examination|
79649504|NCT00227136|Drug|5-Hydroxy-Tryptamine|
79329007|NCT05131711|Combination Product|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
79329008|NCT02619617|Drug|SOM230|The study evaluated SOM230 vs Placebo
79329009|NCT02619617|Drug|Placebo|The study evaluated SOM230 vs Placebo
79329010|NCT04012957|Drug|Desidustat Oral Tablet|Desidustat tablet
79329011|NCT04012957|Drug|Darbepoetin Alfa|Darbepoetin injection
79329012|NCT05125705|Biological|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
79329013|NCT05125705|Other|Saline injection|Saline injection
79329014|NCT04906031|Drug|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
79329015|NCT05131243|Procedure|Chemotherapy time|6 months of chemotherapy
79329016|NCT05131243|Procedure|Chemotherapy time|3 months of chemotherapy
79329017|NCT05125627|Drug|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
79329018|NCT05125627|Drug|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
79329019|NCT04399265|Dietary Supplement|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
79483297|NCT05297773|Other|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
79649505|NCT00203918|Behavioral|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
79649506|NCT00203918|Behavioral|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
79649507|NCT00208962|Procedure|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
79649508|NCT00227175|Behavioral|Semi-structured, open ended interview|
79329020|NCT04399265|Dietary Supplement|Maltose|Maltose power
79483298|NCT05295901|Device|mKOAH application|mobile app installed group
79329021|NCT05125549|Drug|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
79979570|NCT05749952|Device|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
79483299|NCT04450836|Drug|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
79649509|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
79483300|NCT04450836|Drug|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
79483301|NCT04436406|Diagnostic Test|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
79483302|NCT05679193|Drug|Propranolol|"Propranolol capsules 20mg taken orally~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
79649510|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
79649511|NCT00209001|Procedure|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
79329022|NCT05125549|Drug|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
79329023|NCT04903847|Drug|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
79979571|NCT05749952|Device|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
79329024|NCT04903847|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
79483303|NCT04795752|Device|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
79649512|NCT00209001|Procedure|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
79649513|NCT00197444|Drug|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
79483304|NCT04795752|Drug|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
79329025|NCT05130697|Other|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
79329026|NCT04905953|Drug|Neostigmine|Intrathecal injection of two doses of neostigmine (10 & 20 mic) during spinal anesthesia for cesarean section.
79329027|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
79649514|NCT00197444|Radiation|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
79649515|NCT00204074|Drug|17-beta-estradiol (drug)|
79649516|NCT00227292|Drug|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
79649517|NCT00227292|Drug|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
79649518|NCT00197483|Drug|Pergolide (drug)|
79649519|NCT00230529|Drug|infliximab|
79649520|NCT00204113|Device|Multi-purpose rehabilitation frame|
79649521|NCT00204113|Device|Surface Functional Electrical Stimulation|
79649522|NCT00230568|Drug|Aricept|
79649523|NCT00197522|Biological|CD34+ derived DCs|
79649524|NCT00204152|Behavioral|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
79649525|NCT00227331|Drug|Oral amoxicillin|
79649526|NCT00197561|Dietary Supplement|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
79979572|NCT05735717|Drug|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
79979573|NCT05735717|Drug|Busulfan|Busulfan 82.1 mg*hr/L IV on days -5 to -2 or days -8 to -5
79329028|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
79329029|NCT04905875|Procedure|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
79329030|NCT03637309|Behavioral|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
79329031|NCT04905719|Diagnostic Test|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
79329032|NCT03619681|Drug|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
79329033|NCT04905641|Procedure|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
79329034|NCT03609073|Device|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
79483305|NCT05501353|Other|no intervention|This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
79483306|NCT04795128|Biological|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
79483307|NCT02977741|Drug|Olanzapine|
79483308|NCT05292001|Drug|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
79329035|NCT04916093|Drug|Vildagliptin 50 MG|Galvus 50 mg oral tablets
79329036|NCT04916093|Drug|Sitagliptin 100mg|Januvia 100mg oral tablets
79329037|NCT04916093|Drug|MetFORMIN 1000 Mg Oral Tablet|Glucophage 1000 mg oral tablets
79329038|NCT03052205|Drug|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
79329039|NCT03512119|Drug|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
79483309|NCT05292001|Other|Saline Placebo|Normal saline
79483310|NCT01634178|Drug|Apremilast|Tablet for oral administration
79483311|NCT00358267|Procedure|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
79483312|NCT00358267|Procedure|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
79483313|NCT03832075|Diagnostic Test|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
79483314|NCT03832075|Diagnostic Test|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
79483315|NCT03832075|Diagnostic Test|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady & balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
79979574|NCT05735717|Drug|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
79979575|NCT05735717|Drug|Rituximab|200 mg/m2 intravenous given once on day-1
79979576|NCT05735717|Drug|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
79979577|NCT05734937|Other|gastric assessment of gastric volume|ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
79979578|NCT05723276|Drug|Psilocybin|Psilocybin 25mg PO
79979579|NCT05711524|Biological|Traditional Cryoprecipitate|This is the cryoprecipitate already currently being given to patients with a cryo order.
79329040|NCT04903769|Behavioral|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
79329041|NCT05130541|Behavioral|Proning|Rotating on long axis 90 degrees every 30 minutes
79329042|NCT05130541|Other|Supportive Care|Usual Care
79329043|NCT04903613|Drug|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
79329044|NCT04905485|Behavioral|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
79329045|NCT03052439|Other|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
79483316|NCT04418934|Device|Hemanext One|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
79483317|NCT05652192|Radiation|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
79483318|NCT00359359|Drug|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
79483319|NCT00359359|Drug|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
79483320|NCT04782804|Drug|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
79483321|NCT04782804|Drug|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
79649527|NCT00197561|Dietary Supplement|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
79483322|NCT04418388|Drug|PBK-1801|Administered orally
79483323|NCT04418388|Drug|PBK-1801|Administered orally
79483324|NCT04418388|Drug|PBK-1801|Administered orally
79649528|NCT00227409|Drug|calcium disodium EDTA (edetate calcium disodium)|
79649529|NCT00197639|Drug|Ritonavir-boosted indinavir|
79329046|NCT04905329|Drug|Empegfilgrastim|Extimia®
79329047|NCT02767921|Other|Cytology Specimen Collection Procedure|Correlative studies
79329048|NCT02767921|Other|Laboratory Biomarker Analysis|Correlative studies
79329049|NCT02767921|Procedure|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
79329050|NCT02767921|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
79329051|NCT02767921|Procedure|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
79329052|NCT04903379|Other|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
79329053|NCT02642809|Drug|Pembrolizumab|
79329054|NCT02642809|Radiation|Brachytherapy|
79329055|NCT02642809|Procedure|Endoscopic biopsy|
79329056|NCT02642809|Procedure|Computed tomography-guided biopsy|
79329057|NCT02642809|Procedure|Peripheral blood collection|
79329058|NCT03052361|Drug|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
79329059|NCT03052361|Drug|Placebos|similar looking and tasting liquid placebo
79483325|NCT04781400|Behavioral|Mobile phone support|Mobile phone support (SMS)
79483326|NCT04781400|Behavioral|Remote service delivery model|ART treatment delivery via a courier service
79483327|NCT05651880|Drug|Baricitinib 4 MG|4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)
79483328|NCT05668195|Procedure|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
79649530|NCT00230646|Behavioral|Exercise counseling|
79649531|NCT00197678|Dietary Supplement|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
79649532|NCT00197678|Dietary Supplement|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
79649533|NCT00227448|Drug|intravenous saline|
79649534|NCT00227448|Drug|intravenous phenylephrine|
79649535|NCT00227448|Drug|intravenous levophed|
79649536|NCT00227448|Drug|oral midodrine|
79649537|NCT00204191|Drug|tacrolimus|
79649538|NCT00227487|Other|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
79979580|NCT05711524|Biological|Pathogen-Reduced Cryoprecipitate|This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.
79329060|NCT05125393|Procedure|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
79329061|NCT04905095|Diagnostic Test|EWS|Early Warning Score will be implemented in the computer system of the nursing station. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
79649539|NCT00227487|Other|Administration of carbohydrate solution during clinically indicated endoscopy|"A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~Clinically indicated pinch biopsies will then be obtained.~The endoscopy procedures will take at least 1 - 1 ½ hours.~Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
79649540|NCT00227487|Other|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
79649541|NCT00204230|Drug|mycophenolate mofetil (drug)|
79649542|NCT00204269|Drug|Testosterone Gel Wolff|
79329062|NCT05125159|Procedure|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
79329063|NCT02532127|Other|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
79649543|NCT00227526|Behavioral|Prehabilitation|
79979581|NCT05709912|Behavioral|CARE Application|Self-administered, psychosocial mobile application comprised of 5 learning modules.
79979582|NCT05709912|Behavioral|Usual Care|Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
79979583|NCT05706857|Behavioral|Ultra Fast-track|Patients are extubated in the operating room
79979584|NCT05697705|Other|ChAdOx1 nCOV-19 vaccine (Vaxzeria)|Used as 2nd booster, 1st booster, or primary series
79329064|NCT04915547|Other|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
79329065|NCT05079607|Other|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
79329066|NCT05079607|Other|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
79329067|NCT02370589|Biological|Base Dose EBOV GP Vaccine|
79329068|NCT02370589|Biological|2x Base Dose EBOV GP Vaccine|
79483329|NCT05668195|Procedure|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
79979585|NCT05697705|Other|BNT162b2 (Pfizer)|Used as 2nd booster, 1st booster, or primary series.
79979586|NCT05697705|Other|Ad26.COV2.S (Janssen)|Used as 2nd booster, 1st booster, or primary series.
79979587|NCT05697705|Other|CoronaVac (Sinovac)|Used as 2nd booster, 1st booster, or primary series.
79979588|NCT05690971|Behavioral|App|"HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules"
79979589|NCT05690971|Behavioral|Usual Care|Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
79979590|NCT05681195|Drug|Pemetrexed|Participants will receive 900 mg/m^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
79979591|NCT05681195|Drug|Zanubrutinib|"Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression."
79329069|NCT02370589|Biological|4x Base Dose EBOV GP Vaccine|
79329070|NCT02370589|Biological|8x Base Dose EBOV GP Vaccine|
79329071|NCT02370589|Biological|Placebo|
79329072|NCT02370589|Biological|Matrix-M Adjuvant|
79329073|NCT04903145|Diagnostic Test|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
79329074|NCT04904939|Procedure|Bronchoscopic mucosal biopsy|Endobronchial forceps biopsy using flexible bronchoscope
79329075|NCT05067673|Other|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
79483330|NCT05245825|Other|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
79483331|NCT05245825|Other|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
79329076|NCT05067673|Other|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
79329077|NCT05049265|Biological|JS007|JS007 only
79329078|NCT04902989|Other|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
79649544|NCT00197756|Dietary Supplement|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
79329079|NCT05013619|Other|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
79329080|NCT05013619|Other|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
79649545|NCT00197756|Dietary Supplement|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
79979592|NCT05681195|Procedure|Autologous Stem Cell Transplant (ASCT)|ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
79979593|NCT05681195|Radiation|Whole Brain Radiation Therapy (WBRT)|WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
79649546|NCT00197756|Dietary Supplement|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
79649547|NCT00197756|Other|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
79649548|NCT00227565|Drug|carboplatin|
79329081|NCT05013619|Other|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
79329082|NCT05013619|Other|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
79649549|NCT00227565|Drug|pemetrexed disodium|
79649550|NCT00227565|Radiation|radiation|
79649551|NCT00204308|Drug|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
79649552|NCT02963246|Behavioral|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
79811293|NCT00871715|Behavioral|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
79649553|NCT00230724|Behavioral|Exercise Counseling|
79649554|NCT00204347|Drug|risperidone|
79649555|NCT00227682|Dietary Supplement|ascorbic acid|
79649556|NCT00227682|Drug|arsenic trioxide|
79649557|NCT00227682|Drug|dexamethasone|
79649558|NCT00227682|Drug|thalidomide|
79649559|NCT00197795|Biological|"Meningococcal outer membrane vesicle vaccine MenBVac"|
79649560|NCT00230763|Procedure|GSS questionnaire|D0, D30 and D84
79649561|NCT00230763|Procedure|IOP|D0, D30 and D84
79649562|NCT00230763|Drug|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
79649563|NCT00230763|Procedure|Visual acuity|D0 and D84
79811294|NCT00694889|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
79811295|NCT00694889|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
79811296|NCT00691067|Drug|mifepristone|200 mg po per day x 6 weeks
79329083|NCT04904783|Radiation|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
79329084|NCT05136079|Procedure|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
79483332|NCT05651646|Other|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
79483333|NCT05651490|Behavioral|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~Clarifying and defining the problem~Setting a realistic goal~Brainstorming multiple solutions~Generating pros and cons for each solution~Evaluating and choosing a preferred solution~Developing a specific action plan to implement the solution~Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
79483334|NCT05651490|Behavioral|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
79483335|NCT05469607|Device|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
79483336|NCT02978443|Drug|Nivolumab|nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
79649564|NCT00204386|Drug|Topiramate|
79649565|NCT04721964|Dietary Supplement|Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)|Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
79649566|NCT00197834|Drug|Depakote|
79649567|NCT00230841|Device|nebulized humidity|
79649568|NCT00197912|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
79649569|NCT02962323|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
79649570|NCT02962323|Drug|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
79649571|NCT00227838|Behavioral|Behavior Therapy|
79329085|NCT04915469|Other|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
79329086|NCT04959877|Behavioral|health education|data collect / Telemedicine
79483337|NCT02978443|Drug|Ipilimumab|ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
79649572|NCT00227916|Behavioral|Behavior Therapy|
79649573|NCT00204425|Dietary Supplement|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
79649574|NCT00204464|Procedure|Exercise|
79649575|NCT00230880|Behavioral|follow-up phone counseling|9 calls over 12 months
79649576|NCT00197951|Drug|Treatment of psychiatric symptoms associated to alcoholism|
79649577|NCT00230919|Behavioral|Diet counseling|
79329087|NCT04915235|Behavioral|Algorithm|Algorithm
79649578|NCT00204503|Drug|Depakote ER|
79329088|NCT05124145|Other|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
79329089|NCT04902755|Other|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
79329090|NCT05136625|Drug|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
79649579|NCT04721847|Other|Pain Neuroscience Education|In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
79329091|NCT05136625|Drug|Standard Preparation|Troncular scalp blockade. Local site infiltration
79329092|NCT04402697|Other|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
79329093|NCT04402619|Behavioral|Cognitive behavior therapy|"The ten modules cover:~Psychoeducation about sleep, sleep problems, and associations with alcohol~How to keep and use a sleep diary~Sleep hygiene~Sleep compression~Cognitive restructuring~Emotional regulation~Preparing for the future"
79329094|NCT04902001|Behavioral|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
79483338|NCT04343911|Device|Pink Pad ® (Xodus Medical Inc., New Kensington, PA)|a non-sliding foam mattress
79649580|NCT04721847|Other|Conventional Physical therapy|Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
79483339|NCT05651412|Other|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
79649581|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
79649582|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
79649583|NCT00230958|Drug|Viramidine|
79649584|NCT00230958|Drug|Ribavirin|
79649585|NCT00230958|Drug|pegylated interferon alfa-2b|
79649586|NCT02962856|Drug|BAY987517|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
79649587|NCT02962856|Other|Untreated Skin|This site is patched without treatment as irradiated control
79649588|NCT00227955|Drug|Imipramine|
79649589|NCT00227955|Behavioral|Interpersonal Psychotherapy|
79649590|NCT00228033|Drug|Elemental calcium (as carbonate)|
79649591|NCT00230997|Drug|Galantamine|
79649592|NCT00204581|Drug|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
79649593|NCT00231075|Drug|Paraplatin|
79649594|NCT00231075|Drug|Paclitaxel|
79649595|NCT00198146|Drug|Zenapax|
79649596|NCT00228072|Procedure|Suction-curettage|
79811297|NCT00691067|Drug|Placebos|placebo
79483340|NCT02465450|Drug|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
79483341|NCT02465450|Other|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
79329095|NCT04904315|Other|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
79483342|NCT04000152|Diagnostic Test|niPGT-A|"Two scenarios should be considered according to the results in the SBM analysis:~The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours."
79483343|NCT04000152|Other|Morphology criteria|Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
79483344|NCT04192500|Biological|OVX836|One single administration intramuscularly at Day 1.
79483345|NCT04192500|Biological|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|One single administration intramuscularly at Day 1.
79483346|NCT00608972|Drug|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
79483347|NCT00608972|Drug|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
79329096|NCT05124613|Other|Survey|"Information collected and stored in Survey:~Type of knee surgery the patient is waitlisted for~Demographics: age, sex, recent weight gain~Validated and bespoke questions:~EQ-5D survey (a validated questionnaire on health)~Bespoke questions on knee pain today~Bespoke questions on knee function today~Bespoke questions on change in knee pain since being waitlisted for surgery~Bespoke questions on change in knee function since being waitlisted for surgery~Bespoke questions on coping mechanisms patients use to manage symptoms~Bespoke questions on what support they would find beneficial whilst they wait for their surgery~Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
79329097|NCT04904393|Device|Implant of the device for Cardiac Contractility Modulation (CCM) Therapy|The intervention is an implant of CCM therapy devices and it is similar to conventional dual chamber cardiac devices with only difference of to insert n 2 leads fixed in right ventricular septum
79483348|NCT00608972|Drug|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
79483349|NCT02729714|Drug|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
79483350|NCT02729714|Drug|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
79483351|NCT02555982|Drug|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
79483352|NCT02555982|Drug|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
79483353|NCT04802382|Drug|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
79483354|NCT04802382|Diagnostic Test|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
79483355|NCT04802382|Procedure|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
79483356|NCT04802382|Procedure|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
79483357|NCT04802382|Diagnostic Test|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
79329098|NCT04904237|Drug|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
79811298|NCT04139291|Other|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
79979594|NCT05673408|Device|Philips IntelliVue X3 Patient Monitor|All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
79979595|NCT05664256|Other|Build capacity of canteen|"The investigators will conduct 1 day orientation training to the school nurse, principal and canteen managers of the facilities.~Different sessions on basic nutrition concept, healthy eating, healthy cooking practices including purchasing and serving will be conducted.~The investigators will develop training manuals: training curriculum, facilitators guide, and participants guide, aligning with policy contents."
79979596|NCT05664256|Other|Information, Education and Communication materials|Posters showing healthy plate model will be displayed on the canteen walls. The fact sheet on healthy eating will be distributed to all the public facilities and make it available at the entrance/ gate of the canteen.
79979597|NCT05664256|Other|Monitoring visit|A monitoring team from each municipality will be formed. The monitoring plan will be prepared with the team. At least one monitoring visit from the municipality government with onsite feedback will be done.
79979598|NCT05658107|Drug|BI 765423|BI 765423
79979599|NCT05658107|Drug|Placebo|Placebo
79979600|NCT05641623|Drug|OSU6162|OSU6162
79979601|NCT05641623|Drug|Placebo|Placebo
79329099|NCT05136469|Other|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
79979602|NCT05635201|Drug|Anesthesia induction with propofol|After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.
79329100|NCT05136469|Other|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
79329101|NCT04894487|Behavioral|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
79329102|NCT05136235|Diagnostic Test|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
79329103|NCT05136235|Diagnostic Test|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
79329104|NCT04902209|Procedure|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
79329105|NCT04894409|Device|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
79329106|NCT04894409|Device|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
79329107|NCT04949113|Drug|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
79329108|NCT04949113|Drug|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
79811299|NCT00691145|Drug|tacrolimus ointment|transdermal
79329109|NCT04901897|Device|kalifilcon A|kalifilcon A daily disposable contact lens
79329110|NCT04901897|Device|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
79329111|NCT04901897|Device|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
79483358|NCT04802382|Diagnostic Test|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
79483359|NCT04802382|Other|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
79483360|NCT04802382|Diagnostic Test|PK test|PK test will be performed on day 1 only (only in Brazil sites)
79979603|NCT05635201|Drug|Anesthesia induction with remimazolam|After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
79483361|NCT04802382|Diagnostic Test|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
79811300|NCT00694967|Procedure|McDonald cerclage placement|Transcervical McDonald cerclage placement
79811301|NCT00694967|Drug|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
79979604|NCT05613777|Drug|Microgynon®|ethinylestradiol (EE) and levonorgestrel (LNG)
79979605|NCT05613777|Drug|BI 425809|BI 425809
79979606|NCT05603338|Procedure|LSG with omental band|LSG with omental band
79811302|NCT04136249|Dietary Supplement|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
79483362|NCT04802382|Diagnostic Test|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
79483363|NCT04802382|Other|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
79811303|NCT00695045|Drug|intra thecal morphine|100 mcg intrathecal morphine given once .
79979607|NCT05603338|Procedure|LSG|just to do sleeve gastrectomy
79979608|NCT05602896|Other|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
79979609|NCT05574569|Behavioral|Group 1: Play Therapy|Play therapy will be given to children having emotional and behavioral problems.
79979610|NCT05574569|Behavioral|Group 2: Mindful Parenting|Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
79979611|NCT05574569|Behavioral|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
79979612|NCT05569252|Drug|DS-1211b|DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
79329112|NCT04895371|Other|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
79649597|NCT00198185|Procedure|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
79811304|NCT00695045|Drug|intra thecal morphine|200 mcg intrathecal morphine given once
79811305|NCT00695045|Drug|intra thecal morphine|300 mcg intrathecal morphine given once
79979613|NCT05569252|Other|Placebo|Placebo tablet administered once daily in the morning either in the fasted state or with a meal
79483364|NCT04802382|Diagnostic Test|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
79979614|NCT05567120|Other|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
79649598|NCT00204620|Drug|Bendamustin|
79811306|NCT02624453|Drug|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
79811307|NCT02624453|Drug|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
79811308|NCT00819234|Drug|Placebo|placebo pramlintide and placebo metreleptin twice daily
79811309|NCT00819234|Drug|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
79811310|NCT00689507|Biological|LY2127399|monoclonal antibody
79979615|NCT05562778|Other|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
79979616|NCT05562180|Behavioral|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
79329113|NCT04895371|Other|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
79979617|NCT05561725|Drug|Dexamethasone postoperative|"Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
79329114|NCT05135221|Biological|dual biological therapy|Simultaneous use of two biologicals.
79329115|NCT05135065|Other|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
79329116|NCT04894331|Other|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris & Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
79329117|NCT04894331|Other|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
79329118|NCT05134909|Device|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
79329119|NCT04893941|Drug|CM310|IL-4Rα monoclonal antibody
79329120|NCT04893941|Drug|Placebo|Placebo
79329121|NCT05057845|Drug|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
79329122|NCT05057845|Drug|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79329123|NCT05057845|Combination Product|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
79329124|NCT04901585|Procedure|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
79329125|NCT05109949|Drug|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
79329126|NCT05109949|Drug|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
79329127|NCT05109949|Other|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
79329128|NCT04893473|Device|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
79329129|NCT04901429|Procedure|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
79329130|NCT04926259|Drug|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
79329131|NCT04901663|Drug|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
79329132|NCT04901663|Drug|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
79483365|NCT04802382|Procedure|ECG|patients will undergo an ECG examination on days 1, and day 28
79483366|NCT04802382|Other|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
79483367|NCT04802382|Drug|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
79483368|NCT04802382|Drug|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
79649599|NCT02962518|Device|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
79649600|NCT02962518|Procedure|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
79649601|NCT02962518|Drug|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
79649602|NCT00198224|Procedure|phlebotomy|
79649603|NCT00228150|Drug|SR57667B|
79329133|NCT05134597|Genetic|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
79329134|NCT05134519|Drug|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
79329135|NCT04394663|Drug|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
79329136|NCT04394663|Drug|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
79329137|NCT05133193|Drug|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
79649604|NCT00204659|Drug|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
79329138|NCT04901117|Drug|Amoxicillin|Use according to the drug combination options selected by each center.
79329139|NCT04901117|Drug|Clarithromycin|Use according to the drug combination options selected by each center.
79329140|NCT04901117|Drug|Tetracycline|Use according to the drug combination options selected by each center.
79329141|NCT04901117|Drug|Metronidazole|Use according to the drug combination options selected by each center.
79329142|NCT04901117|Drug|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
79483369|NCT05648916|Other|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
79483370|NCT05462587|Drug|AVTX-803 (L-Fucose)|L-fucose crystalline powder
79483371|NCT02508012|Other|Immuno monitoring|treatment optimization
79483374|NCT05648058|Drug|Nefopam ampule|nefopam ampule 50 mg
79483375|NCT05648058|Drug|diphenhydramine ampule|diphenhydramine ampule 10 mg
79483376|NCT05653609|Device|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
79483377|NCT05218135|Other|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
79483378|NCT02978131|Other|Histopathological study|
79649605|NCT00231192|Drug|Repaglinide and Insulin|
79649606|NCT00409916|Device|BioZ Dx|
79329143|NCT04901117|Drug|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
79979618|NCT05561725|Drug|Standard of Care|"Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
79979619|NCT05559255|Other|Counterstrain manual manipulative treatment|"The steps required to perform counterstrain in any region of the body are as follows:~Find the tender point.~Assess the tenderness using a pain scale.~Passively and gently place the patient in a position-of-comfort that results in the greatest reduction of tenderness at the tender point. Approximate the position first, then fine-tune through small arcs of movement. Aim to achieve at least 70% tenderness reduction, with the goal of 100%.~Maintain the position for 90 seconds while continuing to monitor the patient's tender point.~Passively return the patient to a neutral position.~Re-test for tenderness at the tender point."
79649607|NCT00413556|Biological|ALK Grass tablet|
79649608|NCT00204698|Drug|Aciphex|20 mg of aciphex taken twice daily
79649609|NCT00228189|Biological|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
79649610|NCT00204737|Drug|prednisone|20mg x 2 weeks
79979620|NCT05556772|Procedure|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
79979621|NCT05556772|Other|Interview|Attend interview
79329144|NCT04901117|Drug|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
79329145|NCT05121571|Procedure|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
79329146|NCT05121571|Drug|Sorafenib|sorafenib 400mg bid
79649611|NCT00204737|Drug|placebo|placebo
79649612|NCT00231231|Device|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
79649613|NCT00231231|Device|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
79329147|NCT03051269|Drug|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
79329148|NCT03051269|Device|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
79649614|NCT00231270|Device|Cordis Nitinol Stent|
79979622|NCT05554991|Dietary Supplement|HMO|Composition comprising of HMO
79649615|NCT00231270|Device|PRECISE tapered stent|
79649616|NCT00231270|Device|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
79649617|NCT00198302|Drug|Aurexis®|
79979623|NCT05554991|Dietary Supplement|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
79979624|NCT05554991|Behavioral|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
79979625|NCT05548738|Drug|medthylprednisolone|a type of steroids injected in epidural space
79979626|NCT05548738|Drug|prolotherapy|a type of hypertonic glucose
79329149|NCT05088733|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
79329150|NCT05088733|Other|Routine medical care|Routine medical care
79329151|NCT04924777|Other|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
79329152|NCT04924777|Other|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
79329153|NCT04924777|Other|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
79649618|NCT00228228|Biological|T cell vaccination|
79649619|NCT00198380|Drug|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
79649620|NCT00228267|Drug|Propofol|
79649621|NCT00198419|Drug|Vitrase|
79649622|NCT00228306|Behavioral|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
79649623|NCT00198458|Drug|Vitrase|
79649624|NCT00231348|Drug|Nefazodone|
79649625|NCT00198497|Drug|Placebo|
79649626|NCT00198497|Drug|Vitrase|Hyaluronidase 55 IU in saline solution
79649627|NCT00198497|Drug|Vitrase|Hyaluronidase 75 IU in saline solution
79649628|NCT00231387|Drug|rosiglitazone|
79649629|NCT00198536|Drug|Ecabet 2.83%|
79649630|NCT00198536|Drug|Ecabet 3.70%|
79649631|NCT00198536|Drug|Vehicle|
79649632|NCT00231426|Device|ICD|
79649633|NCT00409955|Procedure|Lamellar transplant with lyophilized corneas|
79649634|NCT00228345|Procedure|Optical coherence tomography,Fluorescein angiography|
79649635|NCT00409994|Drug|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
79649636|NCT00410033|Drug|soluble human insulin|
79649637|NCT00410033|Drug|isophane human insulin|
79649638|NCT00410033|Drug|insulin aspart|
79649639|NCT00228462|Drug|Seroquel (quetiapine)|
79649640|NCT00231504|Procedure|Blood samples|Blood samples
79979627|NCT05537545|Procedure|Soft tissue grafting|A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
79979628|NCT05512143|Device|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
79979629|NCT05506969|Biological|rF1V vaccine and CpG 1018® adjuvant|rF1V vaccine and CpG 1018® adjuvant
79329154|NCT04861285|Device|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
79329155|NCT04861285|Device|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
79329156|NCT04861285|Device|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
79979630|NCT05506969|Biological|rF1V vaccine|rF1V vaccine
79979631|NCT05504343|Device|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
79329157|NCT04725955|Other|Enriched wheat bread|Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
79329158|NCT04674007|Other|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
79329159|NCT05005585|Procedure|immediate implant|immediate implant placement with VST technique versus early implant placement with contour augmentation technique
79329160|NCT04646239|Diagnostic Test|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
79329161|NCT04646239|Diagnostic Test|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
79329162|NCT04934527|Drug|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
79483379|NCT02978131|Other|Molecular study (Polymerase chain reaction)|
79979632|NCT05501483|Drug|Pioglitazone 45 mg|Starts with 45 mg
79979633|NCT05501483|Drug|Empagliflozin 25 MG|Starts with 25 mg
79979634|NCT05501483|Drug|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
79979635|NCT05500599|Drug|Fentanyl Citrate|Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
79329163|NCT05288647|Procedure|TMJ injection|four sodium hyaluronate injections in superior TMJ space
79329164|NCT05287009|Procedure|ILM nonpeeling|ILM is not peeled after ERM removal
79329165|NCT05287009|Procedure|ILM peeling|ILM is peeled after ERM removal
79329166|NCT04584619|Device|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
79329167|NCT04576663|Drug|Normal saline|Normal saline infusion simultaneous with subarachnoid block
79329168|NCT04576663|Drug|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
79329169|NCT04789369|Behavioral|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
79329170|NCT04905199|Procedure|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
79329171|NCT04763005|Behavioral|HIIT exercise intervention|The exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
79329172|NCT04763005|Behavioral|Physical activity recommendations|The control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.
79649641|NCT00198614|Drug|Carvedilol versus Metoprolol|
79329173|NCT05281549|Drug|Alteplase|Alteplase 0.9mg/kg are being used.
79329174|NCT05281549|Drug|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
79329175|NCT05281549|Drug|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
79329176|NCT05276479|Other|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
79329177|NCT04284475|Diagnostic Test|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
79329178|NCT04284475|Diagnostic Test|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
79329179|NCT04284475|Diagnostic Test|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
79329180|NCT05255809|Other|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
79329181|NCT05255809|Other|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
79329182|NCT05239351|Device|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
79329183|NCT05230147|Procedure|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
79329184|NCT05230147|Procedure|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
79329185|NCT04227301|Other|blood sampling|blood sampling for measurement of bone markers after a fasting period of at least 6 hours
79329186|NCT05214547|Device|Radial Extracorporeal Shock-wave Therapy|Radial Extracorporeal Shock Wave Therapy, also called radial pulse therapy. In contrast to regular focused shock wave therapy,Radial Extracorporeal Shock Wave Therapy creates a diverging pressure field, which reaches a maximal pressure already at the source, and therefore has a more superficial, but broader, effect than focused shock wave therapy. This treatment is increasingly used for calcific and non-calcific tendinopathy, probably because it is easier to apply and more affordable than focused shock wave therapy. The proposed mechanisms for the effect of Radial Extracorporeal Shock Wave Therapy include pain relief, tissue regeneration and destruction of calcification.
79649642|NCT00231543|Procedure|Laparoscopic fundoplication|
79649643|NCT00231543|Procedure|open Nissen fundoplication|
79649644|NCT00198653|Behavioral|Newborn Thermal Care Practice|
79649645|NCT00231582|Drug|epirubicin|epirubicin
79979636|NCT05498870|Drug|Adductor Canal Block (ACB) Only|Patients will receive an ACB with lidocaine skin wheal
79329187|NCT03965611|Procedure|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
79329188|NCT03965611|Procedure|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
79329189|NCT03965611|Procedure|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
79329190|NCT05191225|Drug|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
79329191|NCT05191225|Drug|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
79329192|NCT05187325|Other|no intervention|there is no intervention
79329193|NCT05185921|Behavioral|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
79329194|NCT03914833|Other|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
79329195|NCT03914833|Other|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
79979637|NCT05498870|Drug|Adductor Canal Block (ACB) + iPACK Block|Patients will receive an ACB with iPACK block
79483380|NCT05210101|Drug|Sotrovimab|Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
79979638|NCT05495698|Drug|single-inhaler triple therapy (Trimbow)|Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
79979639|NCT05495698|Device|E-health application: Curavista app & FindAir e-device|Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
79979640|NCT05495698|Drug|multi-inhaler triple therapy (Qvar + Bevespi)|Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
79979641|NCT05482971|Drug|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft (P1101)
79329196|NCT03909217|Procedure|TECAS Procedure|"Location:~Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
79329197|NCT03909217|Drug|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
79329198|NCT03909217|Drug|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
79649646|NCT00231582|Procedure|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
79649647|NCT00231582|Drug|paclitaxel|paclitaxel
79979642|NCT05482737|Other|no intervention|This is an observational retrospective study (meta-analysis)
79483381|NCT04344067|Device|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
79483382|NCT02959333|Biological|hAEC|hAEC: human amniotic epithelial cells
79483383|NCT02959411|Drug|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
79483384|NCT02959411|Drug|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
79483385|NCT05449873|Procedure|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
79979643|NCT05481541|Other|written education|"Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group."
79979644|NCT05475431|Drug|The sequential therapy|Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
79979645|NCT05475431|Drug|The triple therapy|Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
79483386|NCT02977819|Other|Meditation practice|18 months
79483387|NCT02977819|Other|Learning English as a foreign language|18 months
79483388|NCT00359593|Behavioral|Knowledge translation intervention package|
79483389|NCT05190991|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
79649648|NCT00231582|Drug|etoposide|etoposide
79329199|NCT04914533|Device|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
79329200|NCT04914065|Other|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~Inspiratory muscles: diaphragm~Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
79329201|NCT02650921|Device|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
79329202|NCT04914143|Other|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
79649649|NCT00231582|Drug|ifosfamide|ifosfamide
79649650|NCT00231582|Drug|carboplatin|carboplatin
79649651|NCT04721574|Device|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
79979646|NCT05475431|Drug|The hybrid therapy|Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
79329203|NCT04914143|Other|placebo|the control group was treated with placebo after chemotherapy
79329204|NCT04913987|Device|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
79329205|NCT04913987|Device|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
79979647|NCT05475431|Drug|The concomitant therapy|Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
79329206|NCT03054935|Other|Indirect Calorimetry|Measurement of resting energy expenditure
79329207|NCT04914299|Behavioral|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
79329208|NCT04914299|Behavioral|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
79329209|NCT03801109|Other|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
79483390|NCT05183503|Diagnostic Test|DC/TMD examination|Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
79979648|NCT05475431|Drug|Bismuth-based quadruple therapy|Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
79979649|NCT05469477|Behavioral|Persuasive education|The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
79329210|NCT03801109|Other|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
79329211|NCT03801109|Other|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
79329212|NCT03801109|Other|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
79979650|NCT05469477|Behavioral|WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
79329213|NCT04914221|Drug|JLP-2002|administration of JLP-2002
79329214|NCT04914221|Drug|Comparator|administration of comparator
79329215|NCT04739449|Behavioral|Coaching, Cleaning, Communication, Collaboration|"Coaching staff~Cleaning protocols, standardized~Communication with staff and leadership~Collaboration with local expertise"
79483391|NCT05434585|Biological|ABO1009-DP|Vaccine
79483392|NCT05434585|Biological|ABO-CoV.617.2|Vaccine
79483393|NCT05434585|Other|Placebo|Placebo
79483394|NCT05427955|Procedure|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
79649652|NCT04721574|Device|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
79649653|NCT02963324|Drug|Ivermectin|
79649654|NCT00228540|Drug|Modafinil|
79329216|NCT03711877|Device|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
79329217|NCT03711877|Device|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
79329218|NCT03054701|Other|Hip specific resistance exercise|Hip specific resistance exercise
79329219|NCT03054701|Other|Knee specific resistance exercise|Knee specific resistance exercise
79329220|NCT05124379|Device|Hemoclin Gel|Non sterile gel for intra-rectal use
79329221|NCT03344263|Diagnostic Test|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
79329222|NCT04892615|Device|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
79329223|NCT04892615|Device|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
79329224|NCT04892381|Diagnostic Test|Skin Biopsy|"Skin biopsy will be taken under local anesthesia :~From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~The level of PD1 and PD-L1 will be detected using ELISA technique.~The lesional biopsy will be assessed by routine hematoxylin and eosin (H&E) to confirm the diagnosis of LP"
79329225|NCT05100121|Device|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
79329226|NCT05100121|Other|Survivor-ship care|At coaching session with the district nurse, patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in a survivorship care plan which contain e.g., risk of symptoms, late effects, healthy lifestyle information, prevention tips and support of psychosocial concerns. The intervention incorporates coaching encounters using motivational interviewing techniques to engage patients in the patient-owned survivor-ship care plan that include health goals and strategies related to cancer follow-up, surveillance, symptom management, and health behavior.
79329227|NCT04900961|Other|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
79329228|NCT03054623|Procedure|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
79329229|NCT04892225|Behavioral|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
79329230|NCT04900649|Other|chest resistance exercise|lung function.
79329231|NCT04900649|Other|chest expansion exercises|thoracic excursion
79329232|NCT04913909|Dietary Supplement|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
79329233|NCT04891601|Procedure|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
79329234|NCT01596335|Drug|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
79329235|NCT01596335|Drug|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
79483395|NCT05427955|Procedure|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
79649655|NCT00198692|Behavioral|self-management|
79649656|NCT00231621|Drug|topiramate|
79811311|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
79979651|NCT05469477|Behavioral|Customized Habit Tips|Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
79329236|NCT04891679|Drug|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~hour= 20ml~hour= 30ml~hour= 30ml~hour= 30ml~hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
79979652|NCT05469477|Behavioral|Raffle Financial Incentive|Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
79329237|NCT04913831|Drug|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
79329238|NCT04913831|Drug|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
79329239|NCT04900415|Drug|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
79329240|NCT04900415|Device|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
79329241|NCT03051035|Drug|KO-947|Intravenous administration
79329242|NCT04900571|Drug|Nitrofurantoin 100 MG|Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
79329245|NCT04900727|Other|No intervention|No intervention
79329246|NCT04900181|Procedure|the same-day discharge surgery|the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
79329247|NCT04891211|Dietary Supplement|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
79979653|NCT05469477|Behavioral|Shared Pot Financial Incentive|This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
79329248|NCT03050957|Dietary Supplement|menthol|Alimentary bolus supplemented with menthol
79329249|NCT04885049|Drug|Racecadotril|Anti secretary
79329250|NCT04885049|Drug|DiaResQ Children's Powder for Suspension|oral immunoglobulins
79329251|NCT04884581|Device|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
79329252|NCT04056533|Biological|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
79483396|NCT05426161|Drug|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
79483397|NCT05426005|Drug|Cadonilimab|Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
79483398|NCT05630833|Drug|Gepotidacin|Gepotidacin will be administered.
79979654|NCT05469477|Behavioral|Weekly SMS Support text|Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
79979655|NCT05469477|Behavioral|Weekly SMS Encouragement|Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
79483399|NCT05630833|Drug|Nitrofurantoin|Nitrofurantoin will be administered.
79483400|NCT05630833|Drug|Placebo|Placebo will be administered.
79483401|NCT00359671|Drug|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
79483402|NCT00359671|Drug|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
79483403|NCT02978209|Device|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
79483404|NCT04744909|Device|SafeTrach for tracheotomy|The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
79811312|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
79329253|NCT04890899|Procedure|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
79329254|NCT04890587|Drug|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
79329255|NCT04890665|Behavioral|Online psychological intervention for healthcare workers|"The intervention is based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, Acceptance and Commitment Therapy and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of anxiety, depression, burnout, fatigue compassion, posttraumatic stress disorder, and affectations in sleep quality and perception of life quality in healthcare workers.~And 3 complementary modules that according to the scientific literature could affect the mental health of healthcare workers related to how to deliver bad health news, Psychological first aid and how beliefs could influence physical and emotional self-care in the face of the COVID-19 pandemic."
79329256|NCT04899713|Other|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
79483405|NCT03830905|Drug|XC221|Participants will receive 200 mg XC221 once a day during 3 days
79483406|NCT03830905|Drug|Placebo|Participants will receive Placebo once a day during 3 days
79483407|NCT05404321|Other|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
79811313|NCT02625311|Procedure|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
79811314|NCT00689585|Drug|Placebo|250mg matching placebo capsules
79811315|NCT00689585|Drug|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
79329257|NCT04430621|Drug|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
79329258|NCT04900259|Behavioral|COVID-19 pandemic|Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
79329259|NCT04884503|Drug|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
79329260|NCT04884503|Device|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
79329261|NCT04884425|Device|Pulsed Electromagnetic Frequency Device (Energy5)|A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
79329262|NCT03051893|Drug|Chronocort|Modified formulation of hydrocortisone
79329263|NCT04890197|Dietary Supplement|tahini|48 grams tahini
79329264|NCT04890197|Other|control|no intervention
79329265|NCT04889963|Biological|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
79329266|NCT04412213|Other|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
79329267|NCT04889885|Device|High-intensity laser therapy (HILT)|"HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise."
79329268|NCT04889885|Device|Sham laser|The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
79329269|NCT04899401|Dietary Supplement|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
79329270|NCT04899401|Other|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
79329271|NCT04889651|Drug|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
79329272|NCT04889651|Drug|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
79329273|NCT04898933|Procedure|eyelid lesion excision|eyelid lesion excision was done under local anesthesia
79329274|NCT04898777|Procedure|Biliary drainage|Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
79329275|NCT04889339|Device|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
79329276|NCT04889339|Device|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
79329277|NCT04884347|Dietary Supplement|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
79329278|NCT04884347|Dietary Supplement|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
79329279|NCT04883723|Device|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
79483408|NCT04343833|Procedure|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
79811316|NCT04136093|Other|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
79649657|NCT00198731|Behavioral|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
79649658|NCT00474526|Biological|Meningococcal ACWY Conjugate Vaccine|
79649659|NCT00474526|Biological|DTaP-IPV-HBV|
79649660|NCT00474526|Biological|Hib|
79649661|NCT00474526|Biological|Rotavirus|
79649662|NCT00474526|Biological|Pneumococcal 7-valent Conjugate Vaccine|
79649663|NCT00474526|Biological|HAV|
79649664|NCT00474526|Biological|MMR-V|
79649665|NCT00474526|Biological|DTaP|
79649666|NCT00231660|Drug|topiramate|
79649667|NCT00198770|Dietary Supplement|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
79649668|NCT00231699|Procedure|Plastic wrap (study group) and cotton (control group) wrap.|
79649669|NCT00198809|Drug|Biolean + Diet education|
79483409|NCT05141539|Device|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
79483410|NCT05141539|Device|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
79483411|NCT05133115|Behavioral|Fostering Resilience in Adolescents at Risk|"The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual & Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support."
79483412|NCT02977897|Drug|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
79483413|NCT05129059|Other|Logotherapy|Logotherapy is a method of finding meaning with three basic principles. The first principle is that life is meaningful in every situation , even in the most desperate moments. The second principle is that the main source of motivation is the desire to find meaning in life. The third is that an individual is free to choose his own attitude even in the worst conditions.
79483414|NCT05128201|Radiation|consolidative radiotherapy|local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)
79483415|NCT05115019|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
79483416|NCT05115019|Biological|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
79483417|NCT00359905|Drug|Silodosin|8 mg daily for 12 weeks
79483418|NCT00359905|Drug|Tamsulosin|0.4 mg daily for 12 weeks
79483419|NCT00359905|Drug|Placebo|once daily for 12 weeks
79649670|NCT00198809|Drug|Biolean Free + Diet education|
79649671|NCT00198809|Drug|Placebo + Diet education|
79649672|NCT00231738|Drug|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
79483420|NCT05086939|Drug|Autologous MSCs|Intra-articular injection 40 million/4 ml.
79483421|NCT05086939|Drug|Allogenic MSCs|Intra-articular injection 40 million/4 ml.
79649673|NCT00198848|Drug|Iron-folic acid supplement|
79483422|NCT05086939|Drug|Hyaluronic Acid|Intra-articular injection 60mg / 3 ml .
79483423|NCT00358813|Drug|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
79483424|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|"Chest MRI during the MRI cerebral~2 tubes of blood taken during the medical visit"
79483425|NCT04344223|Device|Balance Shoe|Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
79483426|NCT04344223|Device|Personal Shoe|Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
79649674|NCT00228657|Drug|4% Albumin / 0.9% Sodium Chloride|
79649675|NCT00198887|Procedure|Operations research|
79649676|NCT04722081|Other|physical therapy|physical therapy-specific exercises
79649677|NCT00198926|Behavioral|covert v overt nutrition labeling|
79649678|NCT00198926|Behavioral|varying meal nutrition manipulation|
79649679|NCT00478738|Drug|GSK961081|
79649680|NCT00198965|Behavioral|dietary education|
79649681|NCT00198965|Behavioral|dietary education and provided full fat snack foods|
79649682|NCT00198965|Behavioral|dietary education and provided fat free snack foods|
79649683|NCT00228696|Other|none, screening only|Screening protocol with no intervention
79649684|NCT00478426|Drug|Sunitinib Malate|Given PO
79649685|NCT00231855|Drug|Topotecan and Taxotere|
79649686|NCT00199004|Drug|Cyclophosphamide|
79649687|NCT00199004|Drug|Dexamethasone / Prednisolone|
79649688|NCT00199004|Drug|Vincristine|
79649689|NCT00199004|Drug|Daunorubicin|
79649690|NCT00199004|Drug|Asparaginase|
79649691|NCT00199004|Drug|Methotrexate|
79649692|NCT00199004|Drug|Cytarabine|
79649693|NCT00199004|Drug|Mercaptopurine|
79649694|NCT00199004|Drug|G-CSF|
79483427|NCT04344613|Device|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
79483428|NCT05603455|Dietary Supplement|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
79811317|NCT04136093|Other|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
79329280|NCT04883723|Other|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
79329281|NCT04898699|Device|UrSure Rapid Urine Tenofovir Test|A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
79483429|NCT05603455|Dietary Supplement|Placebo|Placebo
79811318|NCT04136093|Other|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
79811319|NCT00769912|Drug|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
79811320|NCT00769912|Drug|Placebo (air)|Placebo administration during the intervention
79811321|NCT00783016|Drug|Morphine|
79483430|NCT00360061|Behavioral|Cognitive Behaviour Therapy|
79483431|NCT04343599|Other|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
79483432|NCT04884061|Other|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
79649695|NCT00199004|Drug|Vindesine|
79811322|NCT02556502|Device|18F-Florbetaben PET|
79811323|NCT00778960|Behavioral|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
79811324|NCT00778960|Behavioral|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
79649696|NCT00199004|Drug|VP16|
79329282|NCT04898699|Device|OraQuick Rapid HIV Self-test kit|Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.
79329283|NCT04898699|Drug|Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]|Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
79483433|NCT04871191|Drug|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
79649697|NCT00199004|Drug|Adriamycin|
79979656|NCT05465551|Combination Product|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
79979657|NCT05464095|Device|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
79483434|NCT04871191|Drug|Tocilizumab|Subcutaneous injection of 162 mg per week
79483435|NCT04871191|Drug|Abatacept|Subcutaneous injection of 125 mg per week
79483436|NCT05016505|Behavioral|Reduction (relocation and reduction of personal smoking) and cessation|Individual-level. Peer educator to provide reduction/cessation and/or relocation support.
79483437|NCT05016505|Behavioral|Resident Endorsement|Building-level. Peer educator to conduct building-level sessions.
79483438|NCT05015023|Behavioral|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
79649698|NCT00199004|Drug|Thioguanine|
79483439|NCT00360139|Device|Sculptra Injection|
79483440|NCT02977429|Other|standardized fluid therapy|The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.
79483441|NCT02977429|Other|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
79483442|NCT02976805|Drug|4L PegLyte + 15 mg bisacodyl|Randomized
79649699|NCT00199004|Drug|VM26|
79649700|NCT00199004|Drug|Rituximab|
79649701|NCT00199004|Procedure|CNS irradiation|
79649702|NCT00199004|Procedure|Mediastinal irradiation (if residual TU)|
79483443|NCT02976805|Drug|6L PegLyte + 15 mg bisacodyl|Randomized
79649703|NCT00199004|Procedure|Stem cell transplantation|
79649704|NCT00228852|Drug|Busulfan, Fludarabine and ATG|
79649705|NCT00204776|Drug|Capecitabine and Oxaliplatin|
79649706|NCT00228891|Procedure|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
79649707|NCT00228891|Procedure|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
79649708|NCT00477412|Drug|Bortezomib|Given IV
79649709|NCT00477412|Drug|Cyclophosphamide|Given IV
79649710|NCT00477412|Drug|Cytarabine|Given IV
79649711|NCT00477412|Drug|Dexamethasone|Given PO or IV
79649712|NCT00477412|Drug|Doxorubicin|Given IV
79649713|NCT00477412|Drug|Methotrexate|Given IV
79329284|NCT04898699|Behavioral|2-way text message reminders|"All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff."
79329285|NCT04898699|Behavioral|HIV risk-reduction counseling|All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
79329286|NCT04883801|Diagnostic Test|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
79329287|NCT02618759|Drug|DSXS|active treatment
79329288|NCT02618759|Drug|Placebo|placebo treatment
79329289|NCT04899011|Other|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
79649714|NCT00477412|Biological|Rituximab|Given IV
79649715|NCT00477412|Drug|Vincristine|Given IV
79649716|NCT00410774|Biological|bevacizumab|
79811325|NCT00778960|Behavioral|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
79811326|NCT00778960|Behavioral|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
79329290|NCT04888715|Drug|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
79329291|NCT04888715|Drug|Pirfenidone|Pirfenidone
79329292|NCT04888715|Drug|Nintedanib|Nintedanib
79329293|NCT04888559|Other|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
79329294|NCT04888559|Other|Breakfast product: Reference|This intervention is a rice-based breakfast product.
79649717|NCT00410774|Drug|gemcitabine hydrochloride|
79649718|NCT00410774|Procedure|adjuvant therapy|
79649719|NCT00228930|Drug|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
79649720|NCT00410852|Procedure|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
79649721|NCT00410852|Procedure|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
79649722|NCT00410852|Procedure|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
79649723|NCT00231933|Behavioral|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
79811327|NCT00769990|Dietary Supplement|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
79811328|NCT00769990|Radiation|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
79811329|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
79811330|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
79811331|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
79649724|NCT00231933|Behavioral|Community integration (CI)|CI includes recovery group sessions and community integration activities.
79811332|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
79979658|NCT05464095|Device|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
79979659|NCT05456269|Drug|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
79979660|NCT05456269|Drug|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
79329295|NCT04897997|Procedure|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
79329296|NCT04888325|Other|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
79483444|NCT04835623|Drug|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
79329297|NCT04888325|Other|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
79979661|NCT05456269|Drug|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
79979662|NCT05456269|Drug|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
79979663|NCT05454813|Device|Wetness Sensing System Validation|Participants will use the Wetness Sensing System in a simulated setting in the sitting, supine and side position (participants are randomized to either the left or right side position).
79979664|NCT05454670|Procedure|Two-flap palatoplasty|Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
79483445|NCT04500613|Procedure|Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
79483446|NCT04500613|Other|No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)|Patients who are randomized to this group will not receive a bilateral erector spinae plane block
79979665|NCT05452941|Diagnostic Test|Diagnostic test on urine samples|Testing by BinaxNOW® S. pneumoniae and serotype-specific urine antigen detection (UAD) assays (UAD-1 and UAD-2).
79979666|NCT05451173|Radiation|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
79979667|NCT05451173|Radiation|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
79979668|NCT05451173|Drug|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
79811333|NCT02555800|Drug|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
79483447|NCT04498585|Other|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
79483448|NCT02976259|Drug|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
79483449|NCT00360217|Drug|docosahexanoic acid (DHA)|
79483450|NCT00360295|Drug|Azithromycin SR|
79811334|NCT02555800|Drug|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
79979669|NCT05449392|Drug|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
79979670|NCT05449392|Other|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
79979671|NCT05449327|Drug|Rivaroxaban 10 MG|Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
79979672|NCT05448846|Procedure|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
79329298|NCT03050723|Device|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
79329299|NCT04888403|Drug|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
79329300|NCT04883567|Diagnostic Test|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
79329301|NCT03050177|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
79329302|NCT03050177|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
79329303|NCT04882787|Device|BTE hearing aid|Amplification
79811335|NCT02555800|Other|Placebo|Saline solution
79811336|NCT00783172|Drug|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
79979673|NCT05448846|Behavioral|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~Chair sit to stand exercise | 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~Seated curl to press exercise | 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~Monopodal balance | 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
79979674|NCT05443685|Drug|ADX-629|Subjects will be administered ADX-629 250 mg tablets twice daily
79811337|NCT00783172|Biological|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
79329304|NCT03051581|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
79329305|NCT04882865|Device|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
79329306|NCT04883021|Device|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
79329307|NCT04897685|Behavioral|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
79329308|NCT03050411|Drug|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
79329309|NCT03050411|Drug|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
79811338|NCT00783250|Drug|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
79329310|NCT03050567|Diagnostic Test|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
79329311|NCT04882943|Other|questionnaires|Quality of life questionnaires
79649725|NCT00231933|Behavioral|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
79649726|NCT01086982|Drug|Octreotide acetate LAR|30 mg, single dose
79649727|NCT01086982|Drug|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
79649728|NCT00410930|Biological|Subcutaneous immunotherapy - Recombinant birch pollen|
79483451|NCT04984681|Behavioral|Mindfulness|The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
79483452|NCT04984681|Other|Usual Care|The control condition will continue receiving usual care or standard of care.
79483453|NCT02977351|Procedure|Non-surgical periodontal treatment|
79483454|NCT04482751|Drug|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
79483455|NCT04474015|Device|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
79483456|NCT04975243|Device|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
79483457|NCT04814095|Behavioral|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
79483458|NCT04814095|Diagnostic Test|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
79483459|NCT04813783|Other|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
79483460|NCT02976727|Drug|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
79483461|NCT02976727|Drug|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
79483462|NCT02976727|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
79483463|NCT02976727|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
79649729|NCT00228969|Drug|RWJ-333369|
79649730|NCT00410969|Device|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
79649731|NCT00231972|Behavioral|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
79649732|NCT00231972|Behavioral|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
79649733|NCT00204854|Behavioral|telephone counseling|
79649734|NCT00204893|Drug|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
79649735|NCT00232011|Drug|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
79649736|NCT00204971|Dietary Supplement|Enteral glutamine powder|nutritional supplement
79649737|NCT00204971|Other|placebo|placebo control
79649738|NCT00232050|Drug|Omalizumab|
79329312|NCT04887545|Diagnostic Test|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
79329313|NCT03049943|Device|low level laser|
79329314|NCT04896905|Other|Rehabilitation|Rehabilitative procedures in isolation ward
79329315|NCT04887233|Other|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
79329316|NCT04887233|Other|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
79329317|NCT04887311|Drug|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
79329318|NCT03050255|Other|Medical air|
79329319|NCT03050255|Other|Oxygen (2Liter/min)|
79329320|NCT03050255|Other|Oxygen (4Liter/min)|
79329321|NCT04886921|Behavioral|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
79329322|NCT04886843|Other|Cold pack|Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
79329323|NCT04886843|Device|NMES|NMES was applied to the nonaffected side ankle dorsiflexors
79329324|NCT03049631|Dietary Supplement|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
79329325|NCT03049631|Dietary Supplement|Raspberry|Red raspberries (1 cup equivalent)
79329326|NCT04886765|Drug|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
79329327|NCT04896671|Behavioral|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
79329328|NCT04396847|Drug|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
79329329|NCT04396847|Drug|Placebo oral tablet|Placebo Oral Tablet (BID)
79483464|NCT02976727|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
79649739|NCT00205010|Procedure|Lymphoscintigraphy|
79649740|NCT00232089|Drug|Tegaserod|
79649741|NCT00229086|Device|Gatekeeper Reflux Repari System (Device)|
79329330|NCT03051503|Drug|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
79329331|NCT03051503|Device|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
79329332|NCT04896437|Procedure|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
79329333|NCT04886687|Procedure|mechanical thrombectomy|mechanical thrombectomy
79649742|NCT00205127|Procedure|Cardiac PET imaging- rest and pharmacological stress|
79329334|NCT04886375|Procedure|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
79649743|NCT00232128|Procedure|Radiofrequency Ablation of pulmonary neoplasms|
79649744|NCT00205166|Procedure|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
79649745|NCT00205166|Drug|Caffeine|Caffeine 400 mg po
79649746|NCT00205166|Drug|Caffeine|Caffeine 200 mg po
79649747|NCT00205205|Behavioral|peer mentoring|
79649748|NCT00229125|Drug|Gabapentin|
79649749|NCT00229125|Drug|Lorazepam|
79649750|NCT00205244|Behavioral|Healing images, relaxation and distraction materials|
79329335|NCT04886375|Procedure|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
79649751|NCT00229164|Device|Transcutaneous Electric Nerve Stimulation (TENS)|
79649752|NCT00205283|Drug|Nelfinavir|
79649753|NCT00232167|Drug|Indiplon|
79649754|NCT00232167|Drug|Sertraline|
79649755|NCT00205322|Drug|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
79483465|NCT02976727|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
79649756|NCT00232206|Drug|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
79329336|NCT04882709|Device|Receiver-in-canal hearing aid 1 default|A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.
79329337|NCT04882709|Device|Receiver-in-canal hearing aid 2|A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.
79649757|NCT00229242|Drug|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
79329338|NCT04882709|Device|Receiver-in-canal hearing aid 1 strategy 1|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
79307477|NCT03936309|Other|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
79329339|NCT04882709|Device|Receiver-in-canal hearing aid 1 strategy 2|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
79649758|NCT00232245|Drug|Fish oil|
79649759|NCT00205400|Procedure|medical care delivery model|
79649760|NCT00232284|Drug|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
79649761|NCT00232284|Behavioral|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
79649762|NCT00229281|Behavioral|Group therapy|
79649763|NCT00232323|Behavioral|simulation training|
79649764|NCT00205478|Drug|VX-702|
79649765|NCT00205517|Procedure|Daily interruption of sedation versus sedation algorithm|
79649766|NCT00229320|Behavioral|Group therapy|
79649767|NCT00205556|Procedure|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
79649768|NCT00205556|Procedure|low flux hemodialysis|standard treatment
79649769|NCT02962206|Device|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
79649770|NCT02962206|Procedure|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
79649771|NCT00205595|Device|Positron Emission Tomography|
79329340|NCT04896359|Dietary Supplement|Vitamin C|12.5 grams of ascorbic acid
79329341|NCT04896359|Other|Placebo|vehicle
79329342|NCT04886609|Device|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
79329343|NCT04896203|Procedure|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
79483466|NCT02976727|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
79483467|NCT04945447|Other|Systematic pharmacist intervention|Already described in the arm group intervention group for patient level
79483468|NCT02977117|Other|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
79483469|NCT02977117|Other|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
79483470|NCT04793269|Other|No intervention|no intervention
79649772|NCT00205634|Drug|Biaxin ( clarithromycin)|
79649773|NCT00232362|Drug|Pioglitazone (Actos)|
79649774|NCT00232362|Drug|Anti-diabetic agent other than pioglitazone or rosiglitazone|
79649775|NCT00205751|Drug|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
79649776|NCT00229437|Drug|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
79649777|NCT00229437|Drug|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
79649778|NCT00229437|Drug|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
79649779|NCT00229437|Drug|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
79329344|NCT04895891|Device|EOS hand imaging|For each patient, EOS images are compared with CT images
79329345|NCT04896125|Drug|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
79329346|NCT03049319|Device|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
79329347|NCT03049319|Device|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
79483471|NCT00361465|Other|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
79483472|NCT00360841|Procedure|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
79483473|NCT00360841|Procedure|Sham auricular acupuncture|
79649780|NCT00205790|Device|Vascular graft|
79329348|NCT03049319|Device|Psoriashield|The psoriashield will be applied to patient's back.
79329349|NCT03049319|Device|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
79329350|NCT03049319|Device|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
79329351|NCT03049319|Device|Xtrac laser|The Xtrac laser will be applied to patient's back.
79329352|NCT04895657|Drug|Piperacillin/Tazobactam Continuous infusion|Continuous infusion
79329353|NCT04895657|Drug|Piperacillin/Tazobactam Intermittent infusion|Intermittent infusion
79329354|NCT04885673|Device|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
79329355|NCT04885673|Device|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
79329356|NCT04895423|Drug|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
79649781|NCT00205829|Device|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
79649782|NCT00229476|Drug|sertraline (Zoloft)|
79649783|NCT00205907|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
79649784|NCT00232440|Device|BodyFIX|
79649785|NCT00205946|Drug|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
79649786|NCT00205946|Drug|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
79649787|NCT00229515|Other|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
79649788|NCT00229515|Other|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
79649789|NCT00229515|Other|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
79329357|NCT04895423|Drug|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
79329358|NCT04895423|Drug|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
79329359|NCT04895423|Drug|Dupilumab therapy|Patients weighing <30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to <60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
79329360|NCT03051425|Dietary Supplement|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
79329361|NCT03051425|Dietary Supplement|Placebo|120 mL of low-fat milk
79329362|NCT03050099|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
79329363|NCT04882163|Drug|CC-220|CC-220
79483474|NCT00360451|Behavioral|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
79649790|NCT00229515|Other|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
79649791|NCT00205985|Device|Scaphoid screw|Conservative treatment versus application of scaphoid screw
79649792|NCT00206024|Drug|Esomeprazole magnesium (Nexium)|
79649793|NCT00206063|Drug|EXANTA|
79329364|NCT04882163|Drug|Polatuzumab vedotin|Polatuzumab vedotin
79329365|NCT04882163|Drug|Rituximab|Rituximab
79649794|NCT00232518|Procedure|Infection with hookworm larvae|
79329366|NCT04882163|Drug|Tafasitamab|Tafasitamab
79329367|NCT04882163|Drug|Gemcitabine|Gemcitabine
79329368|NCT04882163|Drug|Cisplatin|Cisplatin
79483475|NCT00360451|Behavioral|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
79483476|NCT04343131|Behavioral|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
79649795|NCT00206141|Drug|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
79811339|NCT00783250|Drug|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
79811340|NCT00783328|Drug|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
79329369|NCT04882163|Drug|Dexamethasone|Dexamethasone
79329370|NCT04882163|Drug|Bendamustine|Bendamustine
79483477|NCT02977273|Other|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
79483478|NCT02977273|Other|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
79329371|NCT04882163|Drug|Lenalidomide|Lenalidomide
79329372|NCT04882007|Drug|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
79329373|NCT04882007|Drug|Placebo|Normal saline
79329374|NCT04885751|Drug|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
79329375|NCT04885751|Drug|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
79329376|NCT03051347|Other|Itch Questionnaire and Interview|
79329377|NCT03051347|Other|Stigma Questionnaire and Interview|
79329378|NCT03051347|Other|Cognitive Interview and PROMIS Itch Questionnaire|
79329379|NCT04885517|Device|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
79329380|NCT03051191|Diagnostic Test|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
79483479|NCT02977273|Other|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
79483480|NCT02977273|Other|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
79483481|NCT04898647|Other|fundoscopic picture|A central review of numerised fundoscopic picture will be performed.
79649796|NCT00229593|Drug|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
79649797|NCT00229593|Drug|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
79649798|NCT00229632|Drug|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
79811341|NCT04047082|Diagnostic Test|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
79811342|NCT02555644|Drug|Prexasertib|Administered IV
79811343|NCT02555644|Drug|Cisplatin|Administered IV
79811344|NCT02555644|Drug|Cetuximab|Administered IV
79811345|NCT02555644|Radiation|Intensity Modulated Radiation Therapy|
79329381|NCT04895345|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79329382|NCT04895345|Radiation|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
79329383|NCT04885361|Biological|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
79329384|NCT03049163|Drug|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
79329385|NCT04894955|Device|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
79483482|NCT04898647|Biological|blood sample|"Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling"
79483483|NCT04898647|Procedure|bone marrow sample|Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
79483484|NCT00421759|Device|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
79649799|NCT00206180|Drug|esomeprazole magnesium (oral medication)|
79649800|NCT00206219|Drug|Gefitinib|
79649801|NCT00206219|Drug|methotrexate|
79329386|NCT04881695|Other|Questionary patients|"The patients will answer 1 questionnaire consisting of 5 parts :~General (demographic information)~Desire for a child~Hospital Anxiety and Depression scale~Sexual life~Additional questions regarding medical care"
79649802|NCT00206258|Drug|Pramlintide and glucagon|
79649803|NCT00206297|Drug|Pramlintide|
79649804|NCT00411047|Drug|gefitinib|oral drug taken daily around the same time
79649805|NCT00229671|Other|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
79649806|NCT00229671|Other|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
79649807|NCT00411125|Drug|Oral salmon calcitonin|
79329387|NCT04881695|Other|Questionary controls|"Witnesses will complete 1 survey containing 4 parts:~General (demographic information)~Desire to have a child~Hospital Anxiety and Depression scale~Sexual life"
79329388|NCT04885439|Behavioral|NextSteps|Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
79329389|NCT04410809|Biological|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
79329390|NCT04410809|Other|Placebo|The same composition as the active medication but without the active substance TA-46
79649808|NCT00229710|Drug|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
79329391|NCT04894565|Procedure|rehabilitation|physical therapy 24 hrs after surgery
79329392|NCT04881851|Dietary Supplement|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
79329393|NCT04881851|Dietary Supplement|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
79483485|NCT04895839|Behavioral|Patient Empowerment Program|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
79483486|NCT00360607|Drug|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
79649809|NCT00411164|Drug|OROS hydromorphone HCI (slow release)|
79649810|NCT00411203|Drug|Tamoxifen Citrate|
79483487|NCT00360607|Drug|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
79483488|NCT00360607|Drug|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
79483489|NCT00360607|Drug|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
79483490|NCT00360763|Drug|candesartan cilexetil|
79649811|NCT00411203|Drug|Placebo|
79649812|NCT00232635|Drug|A-60444|
79649813|NCT00229749|Drug|AVI-4065 Injection|
79649814|NCT00411281|Drug|cytarabine|Given subcutaneously
79649815|NCT00411281|Procedure|observation|No intervention
79649816|NCT00206414|Drug|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
79649817|NCT00206414|Drug|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
79329394|NCT04881851|Dietary Supplement|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
79329395|NCT04872335|Other|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
79483491|NCT02977039|Other|NDPR diet|nutrient rich plant based diert
79483492|NCT02977039|Other|USDA healthy eating diet|DASH diet
79483493|NCT04886245|Other|Video sequences|"videos will be made of each participant, during the realization of 5 movements that are the simple closure of the eyelids, the forced closure of the eyelids, the labial protrusion on the sound [o], the labial protrusion on the sound [pu] and the wide smile uncovering the teeth.~Then, a video sequence will be realized thanks to the dedicated software Tobii Pro Lab®."
79649818|NCT00232674|Drug|Pulmicort (budesonide) Turbuhaler|
79649819|NCT00206453|Drug|Taxotere|Chemotherapy IV
79649820|NCT00206492|Drug|Iressa|Iressa
79649821|NCT00206492|Drug|Tamoxifen|Tamoxifen
79649822|NCT00413595|Other|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
79649823|NCT00206570|Drug|Estradiol|
79649824|NCT00206609|Procedure|Oxygen and air administration|
79649825|NCT00424671|Drug|Licarbazepine|
79649826|NCT00206648|Drug|Betaferon/Betaseron|Betaseron 250 µg SC every other day
79649827|NCT00206648|Drug|Betaferon/Betaseron|Avonex 30 µg IM once per week
79649828|NCT01056159|Drug|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
79649829|NCT01056159|Drug|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
79649830|NCT00232791|Device|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
79649831|NCT00232791|Device|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
79649832|NCT00206765|Drug|Risperidone|
79649833|NCT00206765|Drug|Paroxetine|
79649834|NCT00424710|Drug|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
79649835|NCT00206843|Device|Triage BNP Test|
79649836|NCT00206882|Drug|corticosteroids|
79649837|NCT00232830|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
79329396|NCT04872335|Other|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
79329397|NCT03048929|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
79329398|NCT03048929|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
79329399|NCT04871789|Diagnostic Test|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
79329400|NCT04881305|Diagnostic Test|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
79329401|NCT04871633|Drug|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
79329402|NCT04871633|Drug|Conventional|IV Steroids Antibiotics
79329403|NCT04881071|Device|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
79329404|NCT04880915|Other|surgical smoke affects|The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
79329405|NCT04880993|Drug|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
79329406|NCT04880993|Drug|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
79329407|NCT05183243|Drug|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
79329408|NCT04871555|Other|MRI|structural imaging
79329409|NCT04430231|Other|Wait list time|
79329410|NCT04936997|Biological|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
79329411|NCT04880525|Other|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
79329412|NCT04880369|Dietary Supplement|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
79329413|NCT04880369|Dietary Supplement|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
79329414|NCT04880369|Dietary Supplement|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
79329415|NCT04870931|Procedure|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
79329416|NCT04879901|Diagnostic Test|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
79329417|NCT04738175|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
79329418|NCT04738175|Drug|Placebo|Diluent solution
79329419|NCT03046979|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
79483494|NCT04061083|Device|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
79649838|NCT00232830|Device|bare-metal stent|any bare-metal stent brand
79329420|NCT04711187|Drug|AT-527 Formulation 1|AT-527 Formulation 1 (R07496998)
79329421|NCT04711187|Other|Placebo Comparator|Placebo Comparator
79329422|NCT04711187|Drug|AT-527 Formulation 2|AT-527 Formulation 2 (R07496998)
79329423|NCT04676399|Drug|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
79329424|NCT04676399|Drug|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
79329425|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
79329426|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
79329427|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
79329428|NCT03047057|Drug|Lidocaine|IV Lidocaine infusion
79329429|NCT03047057|Drug|IV normal saline|IV normal saline infusion
79329430|NCT04630847|Biological|Fecal Microbiota Transplant|FMT utilizing stool from first degree relatives
79329431|NCT04430309|Behavioral|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
79329432|NCT04430309|Behavioral|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
79649839|NCT00206921|Device|Pulsed dye laser|
79649840|NCT00206921|Device|Intense pulsed light|
79649841|NCT00206960|Drug|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
79649842|NCT00206960|Drug|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
79649843|NCT00232869|Device|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
79329433|NCT04880135|Other|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
79329434|NCT04880135|Other|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
79649844|NCT00232869|Device|bare-metal stent|SMART™ bare-metal stent
79329435|NCT04879667|Procedure|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
79329436|NCT04550195|Drug|BMS-986337|Specified Dose on Specified Days
79329437|NCT04550195|Other|BMS-986337 Placebo|Specified Dose on Specified Days
79329438|NCT04550195|Biological|Famotidine|Specified Dose on Specified Days
79329439|NCT04525391|Drug|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
79483495|NCT04061083|Device|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
79483496|NCT02976025|Other|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
79649845|NCT00206999|Drug|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
79649846|NCT00229944|Drug|Azithromycin|
79649847|NCT00207077|Drug|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
79649848|NCT00229983|Behavioral|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
79649849|NCT00207116|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
79811346|NCT00871403|Drug|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m^2 once every 3 weeks, then pazopanib 800 mg once daily
79649850|NCT00232908|Drug|ARV regimen|As prescribed
79649851|NCT00232908|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
79811347|NCT00871403|Drug|pemetrexed and cisplatin|pemetrexed IV 500 mg/m^2 and cisplatin IV 75 mg/m^2 once every 3 weeks
79811348|NCT00689663|Procedure|Laparoscopic cholecystectomy|Randomized to three arm.
79483497|NCT02976025|Other|Collaborative Care|Standard collaborative care implementation training and support.
79483498|NCT04034329|Procedure|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
79483499|NCT04034329|Procedure|EVLA|Endovenous Laser Ablation
79649852|NCT00207155|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
79811349|NCT00695513|Dietary Supplement|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
79979675|NCT05431296|Device|Dexcom ONE Continuous Glucose Monitoring System|The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
79979676|NCT05411237|Drug|Pegylated liposomal doxorubicin|PLD 20 mg/m2 on Day 1 of every 21-day cycle
79979677|NCT05411237|Drug|Paclitaxel|PTX 100 mg/m2 on Day 1 of every 21-day cycle
79979678|NCT05402150|Behavioral|Behavioral Activation|"instruction to create a list of individual positive activities.~instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
79483500|NCT04010305|Drug|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
79483501|NCT04010305|Drug|Placebo film|Placebo film for BXCL501
79483502|NCT02975401|Procedure|rTAPP technique|robot-assisted rTAPP technique
79483503|NCT00361933|Drug|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
79483504|NCT03987763|Drug|IDP-122 Lotion|Topical
79979679|NCT05402150|Behavioral|Mindulness and Gratitude|"instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
79483505|NCT02975635|Other|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
79483506|NCT04785859|Diagnostic Test|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
79483507|NCT02976883|Other|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of [18F]HX4 and PET/CT scan
79483508|NCT02976571|Drug|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
79483509|NCT04733989|Other|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
79649853|NCT00230061|Biological|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
79649854|NCT00232947|Biological|Influenza virus vaccine (Fluviral)|
79649855|NCT00232947|Biological|Influenza virus vaccine (Fluzone)|
79649856|NCT00413673|Procedure|PRK|PRK
79811350|NCT00691379|Drug|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
79811351|NCT00691379|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
79811352|NCT00691379|Drug|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
79811353|NCT00689741|Biological|Cervarix|3 doses of IM injection
79329440|NCT04870697|Behavioral|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
79483510|NCT04731025|Drug|Gentamicin, Cefazolin and Vancomycin|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
79483511|NCT04731025|Other|Placebo|500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
79483512|NCT04730635|Drug|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
79483513|NCT04730635|Drug|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
79649857|NCT00207194|Behavioral|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
79979680|NCT05402150|Behavioral|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
79979681|NCT05387447|Behavioral|Conversational Voice Assistant-Enhanced|Interactive routine is based on tailoring to the participants type of pain and personality.
79329441|NCT04870697|Other|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
79329442|NCT04505423|Procedure|Blind CSF Drain Placement|CSF Drain placement without fluoroscopic image guidance.
79329443|NCT04505423|Procedure|Fluoroscopy-guided Drain Placement|CSF Drain placement utilizing fluoroscopic image guidance.
79329444|NCT04879511|Drug|metformin|Oral hypoglycemic drug metformin
79329445|NCT04879511|Drug|Basal/bolus insulin|Basal/bolus insulin
79811354|NCT00689741|Biological|placebo|3 doses of IM injection of Al(OH)3 placebo
79811355|NCT00695591|Other|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
79979682|NCT05387447|Behavioral|Conversational Voice Assistant-Standard|Interactive routine is a basic interaction with the voice assistant.
79329446|NCT03048695|Behavioral|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
79329447|NCT03046901|Drug|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
79329448|NCT03048539|Procedure|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
79483514|NCT04726189|Other|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
79483515|NCT04726189|Other|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
79329449|NCT04181801|Procedure|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
79329450|NCT04879277|Biological|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
79329451|NCT03046667|Dietary Supplement|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
79329452|NCT03046667|Dietary Supplement|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
79329453|NCT03046589|Drug|DP13|dose escalation
79329454|NCT03046589|Drug|placebo|control to dose-escalation
79329455|NCT04037813|Procedure|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
79329456|NCT02614079|Device|DSSEP|Collision testing after the placement of SCS leads
79329457|NCT03871049|Drug|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
79329458|NCT03871049|Drug|Bupivacaine|bupivacaine
79329459|NCT04878809|Other|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
79329460|NCT04878809|Other|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
79811356|NCT02624531|Drug|Taxane|NACT and Fertility-sparing Treatment Strategy
79329461|NCT04430465|Dietary Supplement|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
79329462|NCT04430465|Dietary Supplement|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
79329463|NCT04878653|Device|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
79329464|NCT04870541|Drug|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
79329465|NCT04870541|Drug|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
79329466|NCT04870385|Behavioral|5-week prevention program|Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
79811357|NCT02624531|Procedure|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
79329467|NCT04870385|Behavioral|Control|Control group waitlisted to receive prevention program after completion of final data collection.
79329468|NCT04870073|Procedure|Retrograde autologous priming|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
79483516|NCT04723225|Other|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
79811358|NCT00689897|Procedure|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
79811359|NCT00689897|Procedure|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
79811360|NCT00691457|Device|Opti-Free contact lens solution|Solution
79811361|NCT00691457|Device|ReNu Multiplus contact lens solution|Solution
79811362|NCT00691457|Device|Clear Care contact lens solution|Solution
79811363|NCT00689975|Behavioral|behavioral dietary intervention|
79811364|NCT00689975|Behavioral|exercise intervention|
79811365|NCT00689975|Other|counseling intervention|
79811366|NCT00689975|Other|flow cytometry|
79811367|NCT00689975|Other|immunoenzyme technique|
79811368|NCT00689975|Other|laboratory biomarker analysis|
79329469|NCT04870073|Drug|Mannitol|Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
79329470|NCT04870073|Procedure|Conventional Priming|The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
79329471|NCT04869839|Other|oral examination|examination done by dentist
79329472|NCT02616029|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
79329473|NCT04878341|Other|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
79329474|NCT04878497|Drug|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
79329475|NCT04878497|Drug|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
79329476|NCT04878497|Drug|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
79329477|NCT04878497|Drug|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
79329478|NCT04878497|Drug|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
79329479|NCT03277703|Biological|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
79649858|NCT00207194|Behavioral|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
79649859|NCT00230139|Device|SPECT/CT|
79649860|NCT00207233|Behavioral|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
79811369|NCT00689975|Procedure|complementary or alternative medicine procedure|
79329480|NCT03257033|Drug|Gemcitabine|Chemotherapy
79329481|NCT03257033|Drug|nab-paclitaxel|Chemotherapy
79329482|NCT03257033|Device|RenovoCath|Intra-arterial catheter
79329483|NCT03250169|Drug|Alemtuzumab|Licensed dose
79329484|NCT04429841|Procedure|Radical gastrectomy with D1 lymphadenectomy|
79329485|NCT04429841|Procedure|Radical gastrectomy with D2 lymphadenectomy|
79329486|NCT02614859|Drug|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
79329487|NCT02614859|Drug|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
79329488|NCT04384445|Biological|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
79329489|NCT04384445|Other|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
79329490|NCT04877795|Diagnostic Test|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
79329491|NCT03046355|Procedure|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
79811370|NCT00689975|Procedure|standard follow-up care|
79329492|NCT03046355|Procedure|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
79329493|NCT04877717|Drug|SHR-A1904|SHR-A1904
79329494|NCT04877951|Behavioral|LSVT BIG|LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
79329495|NCT04877171|Other|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
79329496|NCT04877171|Other|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
79329497|NCT03046277|Other|No intervention|No intervention
79329498|NCT04876859|Procedure|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
79329499|NCT04876859|Procedure|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
79329500|NCT03049241|Other|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
79329501|NCT03046043|Procedure|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
79329502|NCT03046043|Procedure|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
79329503|NCT05257889|Diagnostic Test|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
79329504|NCT03047915|Other|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
79329505|NCT04876313|Drug|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m^2 nab-paclitaxel IV on days 1 and 8
79329506|NCT04876313|Drug|Nivolumab|360 mg IV Q3W x 13 cycles
79329507|NCT04876469|Procedure|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
79329508|NCT02615249|Biological|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
79329509|NCT02615171|Behavioral|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
79329510|NCT02615171|Behavioral|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
79329511|NCT03049085|Drug|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
79329512|NCT03049085|Drug|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
79329513|NCT04876547|Procedure|appendectomy|appendectomy performance
79329514|NCT04876001|Behavioral|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
79329515|NCT04875845|Behavioral|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
79329516|NCT04869293|Device|Hypnosis 3D virtual reality headset|3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
79329517|NCT04875611|Drug|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
79329518|NCT04875689|Other|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~TENS for 15 minutes~Hot pack for 15 minutes~Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~Joint mobilizations"
79811371|NCT00695747|Procedure|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
79811372|NCT00690053|Procedure|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
79811373|NCT00695825|Dietary Supplement|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
79811374|NCT00695825|Dietary Supplement|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
79329519|NCT04875689|Diagnostic Test|Group B (Control)|"1. Participants of this group will receive only conventional therapy which will include;~TENS for 15 minutes~Hot pack for 15 minutes~Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
79329520|NCT04369625|Behavioral|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
79329521|NCT04369625|Behavioral|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
79979683|NCT05376449|Behavioral|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
79329522|NCT04369625|Behavioral|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
79329523|NCT04369625|Behavioral|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
79329524|NCT04366895|Other|conventional single implant overdenture|conventional manufactured implant overdenture
79329525|NCT04366895|Other|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
79329526|NCT04429763|Biological|Umbilical cord derived mesenchymal stem cells|One dosis of 1*10^6 cells/Kg
79483517|NCT00360919|Behavioral|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
79649861|NCT00207233|Behavioral|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
79329527|NCT04429763|Biological|Placebo|Placebo
79483518|NCT04676035|Drug|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
79649862|NCT00207233|Procedure|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
79649863|NCT00413712|Drug|Calcium Channel Blocker & Adenosine|
79649864|NCT00207272|Behavioral|1170-1870 kcal/day liquid diet|
79649865|NCT00207272|Procedure|Gastric bypass surgery|
79649866|NCT00207272|Procedure|Biopsy.visceral adipose tissue|
79483519|NCT03917797|Biological|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
79483520|NCT03917797|Drug|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
79483521|NCT03917797|Drug|Placebo|MSC infusion vehicle
79329528|NCT05256953|Procedure|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score >3, (max doses 300 mg/day)."
79329529|NCT05256953|Procedure|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score >3, (max doses 300 mg/day)."
79329530|NCT04875299|Other|The study is observational|The study is observational
79483522|NCT04342507|Other|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
79483523|NCT04342507|Dietary Supplement|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
79483524|NCT04359199|Radiation|Radiation Therapy|Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer
79483525|NCT04359199|Drug|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer
79483526|NCT04359199|Drug|Chemotherapy|Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
79649867|NCT00207272|Procedure|Biopsy.omental adipose tissue|
79649868|NCT00207272|Procedure|Biopsy. subcutaneous abdominal adipose tissue|
79649869|NCT00207272|Procedure|Blood sample|
79649870|NCT00230217|Drug|Rasburicase (SR29142)|
79329531|NCT04875143|Dietary Supplement|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
79979684|NCT05374408|Behavioral|BBN for Trauma Informed Care|"Brief explanation of BBN will be provided. Patient will be directed to areas of the app that are congruent with treatment focus identified during their standard of care appointment.~Patient will complete by going online or being contacted by a member of the research team member. The research assistant will contact all the patients in 2-3 days to help the patient navigate the BBN and complete the baseline survey if needed.~The patient will continue to meet with their BHP as determined by the standard of care interactions. BHP will highlight features contained in BBN for patient to use in between appointments.~Follow-up phone calls will be scheduled for 2 week and 6 weeks after the initial visit. During these phone- calls the participant will be contacted by a member of the research team to complete follow-up surveys."
79329532|NCT04874753|Other|change in kidney function and proteinuria|change in eGFR nad proteinuria in patients with chronic kidney disease
79979685|NCT05374291|Drug|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
79329533|NCT05256485|Behavioral|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
79329534|NCT04874987|Other|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
79329535|NCT04874675|Drug|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
79979686|NCT05374291|Drug|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
79979687|NCT05372575|Biological|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
79979688|NCT05365659|Drug|IKS03|IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
79979689|NCT05360732|Drug|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
79329536|NCT04874675|Drug|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
79329537|NCT04874363|Other|no intervention|no intervention
79483527|NCT04359199|Drug|Immunotherapy|"Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody."
79483528|NCT00362011|Behavioral|Salba diet|
79483529|NCT00360997|Behavioral|Conventional UK physical therapy|
79979690|NCT05353998|Other|CDS with Sleep Navigation|The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.
79329538|NCT04868669|Behavioral|In-home, intensive nutrition counseling|"Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~The messages to be provided through the counseling will be contextualized~Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~Counseling sessions will be conducted at the participant's place~Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~Sessions will be tailored according to each participant's need and progress"
79329539|NCT03048851|Device|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
79483530|NCT00360997|Procedure|Con UK PT + Mobilisation & tactile stimulation (MTS)|Con UK PT + Mobilisation & Tactile Stimulation (MTS) which is further randomised to 30, 60 or 120 mins/day
79979691|NCT05353998|Other|CDS-only|Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
79979692|NCT05349487|Device|SpeakFree HME Hands Free Valve|A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
79483531|NCT00361075|Drug|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
79649871|NCT00207311|Drug|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
79979693|NCT05349487|Other|Digital Occlusion|Using participant's own fingers, they will be putting their fingers over the stoma.
79979694|NCT05349487|Device|Digital Depression HME|A digital handheld press-down HME will be placed over stoma.
79979695|NCT05343949|Other|HIIT exercise program ABC|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
79979696|NCT05343949|Other|HIIT exercise program CAB|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
79979697|NCT05343949|Other|HIIT exercise program BCA|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
79979698|NCT05335967|Behavioral|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
79979699|NCT05335967|Other|Information package|The patients in this group will receive an information package on a healthy diet.
79979700|NCT05331261|Procedure|Total knee replacanent surgery|Breath exercises
79979701|NCT05329103|Drug|PEEL-224|Lyophilized powder reconstituted with D5W
79979702|NCT05328349|Behavioral|Education Program|After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
79483532|NCT04328857|Device|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
79979703|NCT05320757|Drug|Olaparib|a PARP inhibitor
79979704|NCT05318612|Procedure|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
79483533|NCT03844633|Drug|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
79483534|NCT03844633|Drug|Placebos|Placebos -- Shot administered within 48 hours of childbirth
79979705|NCT05318612|Procedure|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
79979706|NCT05305534|Device|QIAstat-Dx® BCID GN and GPF Plus AMR Panels|The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested
79979707|NCT05296356|Drug|OSU6162|OSU6162
79979708|NCT05293067|Diagnostic Test|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
79979709|NCT05267470|Drug|Bemarituzumab|Intravenous (IV) infusion
79329540|NCT03048851|Device|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
79329541|NCT03048851|Device|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
79483535|NCT00362089|Dietary Supplement|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
79483536|NCT04342741|Device|Foley catheter cervical ripening|Participants were assessed when labour was established or the following morning.
79483537|NCT04328701|Behavioral|Mindfulness-based Cognitive Behavioral Therapy|Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
79483538|NCT04660669|Other|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
79483539|NCT04660669|Other|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
79483540|NCT03822637|Drug|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
79483541|NCT03822637|Drug|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
79649872|NCT00207311|Behavioral|Xenicare Program|Xenicare program for 36 weeks.
79979710|NCT05267470|Drug|Docetaxel|IV infusion
79979711|NCT05267470|Drug|Pembrolizumab|IV infusion
79979712|NCT05267470|Drug|Carboplatin|IV infusion
79649873|NCT04721496|Behavioral|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
79483542|NCT05444101|Behavioral|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
79483543|NCT05444101|Behavioral|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
79483544|NCT05444101|Behavioral|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
79483545|NCT02975089|Dietary Supplement|"multi-nutrient supplement"|"1.3g/d multivitamins & minerals powder~Leaflet content (same as control)"
79483546|NCT02975089|Dietary Supplement|"multi-nutrient & soy protein supplement"|"1.3g/d multivitamins & minerals powder~16g/d isolated soy protein powder~Leaflet content (same as control)"
79483547|NCT02975089|Dietary Supplement|Nutrition education on balanced diet & food supplement|"Nutrition education with a designed plate~10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~25g/d milk powder (skimmed and calcium added)~Leaflet content (same as control)"
79483548|NCT02976493|Other|No Intervention|No Intervention
79483549|NCT02412306|Drug|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
79483550|NCT05616468|Biological|BGT007 Cell Injection|BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10^5cells/kg，1.0 × 10^6cells/kg，3.0 × 10^6cells/kg，6.0 × 10^6cells/kg，1.0 × 10^7cells/kg。
79811375|NCT00690131|Behavioral|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
79811376|NCT04136015|Drug|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
79811377|NCT02624063|Drug|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
79483551|NCT05616468|Drug|Fludarabine|Fludarabine 25~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
79483552|NCT05616468|Drug|cyclophosphamide|250~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
79483553|NCT02274168|Procedure|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
79811378|NCT02624063|Drug|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
79979713|NCT05267470|Drug|Paclitaxel|IV infusion
79979714|NCT05267470|Drug|Nab-paclitaxel|IV infusion
79979715|NCT05263999|Biological|Itolizumab|Itolizumab [Bmab600]
79979716|NCT05263999|Drug|EQ001 Placebo|EQ001 Placebo
79979717|NCT05257655|Procedure|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
79649874|NCT00207350|Device|Interstitial Laser Therapy|Device
79649875|NCT00233025|Drug|Duloxetine|
79329542|NCT03048851|Device|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
79329543|NCT03048851|Procedure|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
79329544|NCT04868513|Drug|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
79483554|NCT02274168|Procedure|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
79483555|NCT04285723|Other|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
79483556|NCT02976415|Other|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
79483557|NCT02975011|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
79483558|NCT02975011|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
79649876|NCT00233025|Drug|Placebo|
79811379|NCT05298683|Drug|Isatuximab|Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
79811380|NCT05298683|Drug|Pomalidomide|Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
79811381|NCT05298683|Drug|Dexamethasone|Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
79329545|NCT04868513|Drug|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
79329546|NCT05256407|Other|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
79649877|NCT00207428|Drug|Carbamazepine|
79649878|NCT00207467|Behavioral|Patient-delivered partner treatment|
79649879|NCT00207467|Behavioral|Booklet-enhanced partner referral|
79811382|NCT05298683|Drug|Acetaminophen (paracetamol)|Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
79329547|NCT04873973|Other|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
79329548|NCT04874129|Drug|YYC506-T and YYC506-A (phase 1)|Comparator
79329549|NCT04874129|Drug|YYC506 (phase 1)|Test
79329550|NCT04874129|Drug|YYC506-T and YYC506-A (phase 2)|Comparator
79329551|NCT04874129|Drug|YYC506 (phase 2)|Test
79329552|NCT05256173|Other|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
79329553|NCT05256173|Other|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
79979718|NCT05250609|Other|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
79329554|NCT05256173|Device|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
79329555|NCT05256173|Device|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
79329556|NCT03048071|Other|Data collection within medical files|Data collection within medical files
79329557|NCT04868825|Device|Ivory Dentin Graft|Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)
79329558|NCT04868825|Device|OsteoBiol Gen-Os|Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
79329559|NCT03048773|Device|shockwave therapy|Intervention with shockwave therapy
79329560|NCT03048773|Other|PT|Physical therapy 3 times per week for 3 weeks
79329561|NCT03048773|Other|placebo|sham shockwave therapy
79329562|NCT04868201|Device|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
79329563|NCT04429997|Procedure|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
79329564|NCT04429997|Procedure|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
79329565|NCT05255939|Procedure|distal TRA group|dTRA for PCI procedure to ACS patients.
79329566|NCT05255939|Procedure|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
79329567|NCT02648347|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79329568|NCT02648347|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
79329569|NCT05255783|Device|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
79329570|NCT02614703|Drug|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
79329571|NCT02614703|Other|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
79329572|NCT03047525|Biological|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
79329573|NCT04867967|Behavioral|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
79979719|NCT05247164|Procedure|EUS-guided Portal Vein sampling|"Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired."
79329574|NCT04867967|Behavioral|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
79329575|NCT05218265|Diagnostic Test|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
79979720|NCT05238181|Diagnostic Test|Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains|"The pathologists assess pyloric or pseudopyloric metaplasia. Pyloric or pseudopyloric metaplasia of corpus is defined as the presence of torturous deep glands in a pseudo-pylori pattern with focal or complete loss of parietal cells. The score of pyloric or pseudopyloric metaplasia of the corpus mucosa is ranging from 0 to 3. Score 0 is no loss of parietal cells with normal fundus gland patterns. Score 1 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia with few forming pylorus-like glands. Score 2 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia mixed with >= 4 pylorus-like glands. Score 3 was clusters of pylorus-like glands; the metaplasia involves > 60% of mucosa and extends to the lower third of mucosa."
79329576|NCT01669343|Drug|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
79329577|NCT04867811|Other|conventional therapy|conventional therapy
79329578|NCT04867811|Other|cupping therapy|cupping therapy
79329579|NCT04867811|Device|TENS|transcutaneous electrical nerve stimulation
79329580|NCT04867811|Other|TENS and cupping therapy|TENS and cupping therapy
79329581|NCT05403619|Diagnostic Test|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
79483559|NCT02975011|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
79483560|NCT02975011|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
79329582|NCT04678765|Procedure|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
79483561|NCT02975011|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79483562|NCT02975011|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79483563|NCT02975011|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
79483564|NCT02975011|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
79483565|NCT01352221|Drug|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
79483566|NCT01352221|Drug|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
79483567|NCT03681769|Device|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
79483568|NCT03681769|Device|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
79483569|NCT03681769|Device|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
79483570|NCT03681769|Device|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
79979721|NCT05238181|Diagnostic Test|Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains|"Mouse anti-human TFF2 monoclonal antibody (R&D Systems) is used to stain gastric corpus tissues to assess the presence and degree of SPEM. The score of TFF2 staining of the corpus mucosa is ranging from 0 to 3. Score 0 is not stained. Score 1 is a scattered pattern of TFF staining between parietal cells; the staining is limited in the middle third of the mucosa. Score 2 is TFF2-expressing cells distributed over both the middle and lower third of the glands. Score 3 is torturous gastric oxyntic glands with a diffuse expression of TFF2 into the whole glands over both the middle and lower third of the glands of the mucosa."
79979722|NCT05238181|Diagnostic Test|The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)|"We take five gastric mucosal biopsies in each patient under gastroscopy, including two from the antrum (at the lesser and greater curvature, 2 cm within the pylorus, respectively), two from the corpus (at the lesser curvature of the lower corpus and the greater curvature of the middle corpus, respectively), and one from the lesser curvature of the high corpus.~The pathologists assess the gastric pathology according to the updated Sydney system. Accordingly, the histological findings are translated into CGI, the Operative Link for Gastritis Assessment (OLGA), and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages."
79979723|NCT05237401|Procedure|Non-Surgical Periodontal treatment (NSPT)|participants will receive local anaesthesia, then thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes.
79979724|NCT05237401|Procedure|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|Patients will receive local anaesthesia and intrasulcular incisions will be made on the buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using diamond coated inserts, sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Osteoplasty (removal of non-supporting bone) may be carried out, as judged by the operator. The surgical site will be closed with resorbable or non-resorbable sutures.
79979725|NCT05231707|Behavioral|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
79979726|NCT05226052|Dietary Supplement|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
79979727|NCT05226052|Dietary Supplement|3 capsules of placebo|PGIC and PGIS assessment
79649880|NCT00233142|Behavioral|Expressive writing|Writing as therapeutic intervention
79649881|NCT00233142|Behavioral|Neutral writing|Non-expressive writing
79649882|NCT00207506|Behavioral|HoMBReS: A lay health advisor approach to STD prevention|
79649883|NCT00230295|Procedure|IMR LAG|
79483571|NCT03678805|Procedure|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
79649884|NCT02962700|Device|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
79649885|NCT00230334|Drug|Gleevec|
79649886|NCT00207584|Drug|Doxycycline treatment|
79649887|NCT00207623|Behavioral|Arthritis Basics for Change Education program|
79649888|NCT00207662|Drug|infliximab or placebo|
79649889|NCT00233181|Behavioral|Home-based adherence monitoring|
79649890|NCT00207701|Drug|infliximab|
79811383|NCT05298683|Drug|Ranitidine (or equivalent)|Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
79811384|NCT05298683|Drug|Diphenhydramine (or equivalent)|Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
79979728|NCT05218733|Procedure|Ultrasound Guided Erector Spinae Plane Block|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%
79329583|NCT04678765|Procedure|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
79329584|NCT03126643|Biological|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
79811385|NCT02624297|Other|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
79811386|NCT02624219|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
79329585|NCT02675179|Device|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
79329586|NCT02675179|Device|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
79329587|NCT04617067|Drug|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
79329588|NCT04617067|Drug|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
79483572|NCT03678805|Procedure|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
79483573|NCT03671005|Behavioral|Mindfulness-based group therapy|see above
79483574|NCT03671005|Other|Treatment as usual|see above
79811387|NCT02624219|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
79811388|NCT02624219|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
79811389|NCT00853112|Drug|PF-00489791|tablet form, 1 mg, single dose (Day 1)
79811390|NCT00853112|Drug|PF-00489791|tablet form, 2 mg, single dose (Day 1)
79811391|NCT00853112|Drug|PF-00489791|tablet form, 4 mg, single dose (Day 1)
79811392|NCT00853112|Drug|PF-00489791|tablet form, 10 mg, single dose (Day 1)
79811393|NCT00853112|Drug|PF-00489791|tablet form, 20 mg, single dose (Day 1)
79811394|NCT00853112|Drug|placebo|tablet form, single dose (Day 1)
79811395|NCT00853112|Drug|sildenafil|tablet form, 20 mg, single dose (Day 1)
79979729|NCT05218733|Drug|Intra thecal morphine.|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine
79979730|NCT05218733|Drug|General anesthesia using intravenous fentanyl (1µgm/kg)|Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
79979731|NCT05197192|Drug|Obinutuzumab|"Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v."
79329589|NCT04600531|Device|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
79329590|NCT04600531|Device|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
79329591|NCT05023057|Behavioral|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
79329592|NCT04669015|Biological|Novaferon|a novel recombinant antiviral protein drug
79329593|NCT04669015|Biological|Placebo|Formulation vehicle
79329594|NCT02590783|Procedure|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
79329595|NCT02590783|Procedure|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
79483575|NCT05195034|Drug|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
79483576|NCT05195034|Drug|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
79649891|NCT00233220|Behavioral|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
79649892|NCT00233220|Behavioral|Usual Care|Patients will receive usual care.
79649893|NCT00207779|Device|heparin impregnated central venous catheters|
79649894|NCT00233259|Behavioral|Mediterranean Diet|Mediterranean dietary program
79649895|NCT00233259|Behavioral|Physical Activity|Physical activity program
79649896|NCT00233259|Behavioral|Stress Management|Stress management program
79649897|NCT00233259|Behavioral|Social Support|Social support
79811396|NCT02624141|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
79329596|NCT01594931|Drug|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
79329597|NCT04981171|Procedure|Electro-thumbtack Needle Therapy|Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
79329598|NCT04981171|Procedure|Sham electro-thumbtack needle therapy|Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
79483577|NCT04790058|Other|Knowledge translation of the CSRS practice recommendations|The intervention is knowledge translation of the CSRS practice recommendations; the application of the practice recommendations will occur during the patient's ED visit and patients who are eligible for 15-day cardiac rhythm monitoring will have Holter monitor applied at the time of ED discharge. For the secondary objective to validate the accuracy of the ultra-low risk criteria of CSRS and assess for potential improvements in the practice recommendations and the prediction models we will request verbal consent during the index ED visit for addition of cardiac biomarker measurements [troponin and NT-proBNP] for patients who did not have such measurements performed as part of routine clinical care, and a 30-day telephone follow-up for serious outcome assessment. Patients who do not consent will be excluded from these portions of the study but included in the health resource utilization and generic patient safety outcome assessment objectives.
79483578|NCT05496894|Drug|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
79483579|NCT04418544|Device|Device used to record voice for screening|voice recording
79483580|NCT03567954|Diagnostic Test|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
79979732|NCT05197192|Drug|Venetoclax|"Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)"
79979733|NCT05197192|Drug|Acalabrutinib|"Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg)."
79979734|NCT05190094|Drug|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
79979735|NCT05173389|Other|TechnoBody|"1. Group-TechnoBody balance training (15 min / 5 days a week, 4 weeks) In the study, the first group will be included in the balance program with the TechnoBody device Patients will be applied 5 days of week~Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~Bobath Method- 30 minutes"
79979736|NCT05173389|Other|Thera-Trainer|"2. Group-Thera-Trainer balance training (15 min / 5 days a week, 4 weeks) the second group will be taken into the balance program with the Thera-Trainer device and the results of both groups will be compared after 4 weeks.~Patients will be applied 5 days of week~Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~Bobath Method- 30 minutes"
79979737|NCT05167058|Device|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
79979738|NCT05161065|Device|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
79329599|NCT04978831|Device|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
79329600|NCT04978831|Other|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
79329601|NCT04872725|Behavioral|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
79329602|NCT03045185|Procedure|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
79329603|NCT03045497|Drug|Perflutren Lipid Microspheres|Given IV
79329604|NCT03045497|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
79649898|NCT00233259|Behavioral|Smoking Cessation|Smoking cessation program
79649899|NCT00233259|Other|Control group|Usual Diabetes Care Control group
79649900|NCT00207818|Device|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
79811397|NCT00691613|Drug|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
79811398|NCT00691613|Drug|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
79649901|NCT00230373|Drug|imiquimod 5% cream (Aldara)|
79649902|NCT00230451|Procedure|Radiation|
79649903|NCT00230451|Drug|Paclitaxel|
79329605|NCT03045497|Device|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
79329606|NCT03047759|Device|water flosser|Powered
79329607|NCT03047759|Device|air floss|Powered
79329608|NCT04435639|Other|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
79329609|NCT04435639|Procedure|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
79329610|NCT04435639|Device|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
79329611|NCT04969237|Diagnostic Test|Vitamine D in blood samples|vitamine D values
79329612|NCT05138185|Device|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
79329613|NCT03045419|Procedure|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
79329614|NCT05048251|Device|cTBS|continuous theta burst stimulation
79329615|NCT05048251|Device|iTBS|intermittent theta burst stimulation
79811399|NCT00691691|Radiation|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
79329616|NCT05048251|Device|sham|sham stimulation
79649904|NCT00230451|Drug|Cisplatin|
79649905|NCT00230451|Drug|5-Fluorouracil|
79649906|NCT00207935|Behavioral|Swallow instruction|
79329617|NCT01594853|Behavioral|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
79329618|NCT03047681|Diagnostic Test|venous blood withdrawl|patients will be asked for a venous blood sample
79649907|NCT00411320|Drug|oral steroid-dexamethasone|2 week steroid trial
79649908|NCT00233337|Drug|Co-artemether|
79649909|NCT00230490|Drug|pradefovir mesylate|
79649910|NCT00230490|Drug|adefovir dipivoxyl|
79649911|NCT01089556|Drug|Duloxetine|Administered orally
79329619|NCT05137561|Procedure|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
79649912|NCT01089556|Drug|Pregabalin|Administered orally
79979739|NCT05148364|Behavioral|interview|"A spiritual consultant and a psychologist will interview the participants about their experiences of chronic low back pain, how they interpret their pain experience and how they cope with the persistent pain. Each participant will be interviewed individually.~Questions related to the following three aspects will be asked:~Attributes: describe the changes in your personality, mood, and general happiness you have observed after you starting having chronic low back pain.~Pain resilience: How would you describe this persisting pain experience? How do you arrange your daily activity? What do you do to deal with this persistent pain?~Spirituality: As a person with chronic low back pain, how do you interpret this pain experience? Do you seek connections with higher powers (such as powers from religion) when you are desperate because of pain? Since the pain is chronic and persistent, it might not go away, how would you define your life?"
79979740|NCT05147220|Drug|Remibrutinib|tablet taken orally
79979741|NCT05147220|Drug|Teriflunomide|capsule taken orally
79979742|NCT05136144|Drug|SM-020|Topical Akt Inhibitor SM-020 Gel
79979743|NCT05132127|Drug|sutimlimab|Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
79329620|NCT05137561|Procedure|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
79329621|NCT04341467|Drug|Amisulpride|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
79329622|NCT04341467|Drug|Olanzapine|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
79979744|NCT05129436|Drug|Vaxigrip Tetra 2020/2021|vaccine against seasonal influenza
79979745|NCT05123573|Behavioral|Clinical Skills|evaluate the students' ability to demonstrate essential clinical skills, clinical reasoning and problem-solving skills, management of life-threatening medical conditions, management of common medical problems, and placing the patients' needs and safety at the center of the care process.
79329623|NCT04933591|Drug|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
79979746|NCT05118529|Other|Routine care|Mobilization to chair
79329624|NCT04872881|Procedure|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
79329625|NCT04872881|Procedure|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
79329626|NCT04872881|Procedure|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
79329627|NCT04872881|Procedure|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
79329628|NCT04872881|Diagnostic Test|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
79979747|NCT05109741|Behavioral|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
79979748|NCT05109741|Behavioral|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
79329629|NCT04872881|Diagnostic Test|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
79329630|NCT04872881|Drug|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
79329631|NCT04872881|Drug|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
79329632|NCT04872881|Drug|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
79329633|NCT05137483|Other|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
79329634|NCT04872647|Behavioral|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
79483581|NCT05474508|Other|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
79649913|NCT01089556|Drug|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
79483582|NCT05474508|Other|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
79649914|NCT00411359|Behavioral|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
79329635|NCT04591249|Behavioral|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is <8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
79329636|NCT04591249|Other|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
79329637|NCT03044873|Drug|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
79329638|NCT03044873|Drug|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
79329639|NCT03044951|Procedure|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
79329640|NCT03044951|Procedure|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
79329641|NCT05137405|Procedure|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
79329642|NCT03044795|Drug|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
79329643|NCT04587583|Behavioral|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
79329644|NCT04581811|Other|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
79649915|NCT00233376|Procedure|Access to an antibiotic decision support system|
79649916|NCT00233376|Behavioral|Distribution of local antibiotic guidelines|
79649917|NCT00424424|Drug|MK0719|
79649918|NCT00233415|Device|Stereotactic Radiosurgery (Cyberknife)|
79649919|NCT00237159|Drug|Zoledronic acid|
79649920|NCT00424541|Drug|SPP100 (aliskiren)|
79649921|NCT01089127|Drug|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
79649922|NCT01089127|Drug|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
79979749|NCT05078853|Device|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
79979750|NCT05068479|Device|Bilateral Laser Scleral Microporation procedure|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
79979751|NCT05066087|Behavioral|DAHLIA treatment|6 weeks; CBT/ ACT/ process-based treatment; micro-learning format with 4 digital micro-sessions per week; exposure as the core process; guidance to be OPEN, AWARE, ACTIVE; weekly contact with therapist; booster sessions after 2- and 4 months;
79979752|NCT05066087|Other|Treatment as usual|Usual pain treatment; defined post-hoc based on what patients receive
79979753|NCT05064449|Drug|Soticlestat|Soticlestat tablets.
79979754|NCT05064449|Drug|Itraconazole|Itraconazole oral solution.
79483583|NCT02021604|Drug|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
79483584|NCT02016378|Behavioral|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
79329645|NCT04581811|Other|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
79329646|NCT04430153|Other|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
79329647|NCT03047291|Drug|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
79329648|NCT03047291|Device|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
79329649|NCT04487899|Device|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
79329650|NCT04865705|Drug|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
79329651|NCT04375111|Procedure|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
79483585|NCT02016378|Behavioral|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
79483586|NCT04192968|Other|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
79483587|NCT04192968|Other|Additional exams|"Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~Recording of cortical auditory evoked potentials in response to a click~Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
79483588|NCT03518034|Drug|Testosterone|It will be administered topically.
79483589|NCT03518034|Drug|Placebo|A matching placebo to testosterone will be administered topically.
79329652|NCT04375111|Procedure|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
79329653|NCT03044717|Other|Nutrition survey|Survey will be done prior to the initiation of the education
79329654|NCT03044717|Other|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
79329655|NCT03044717|Other|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
79329656|NCT04898179|Other|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
79329657|NCT04898179|Other|Control group|Usual care
79329658|NCT04867577|Diagnostic Test|CT scan of lung and spine|Dual energy CT scan of thorax and spine
79329659|NCT05137171|Drug|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
79329660|NCT04384679|Device|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
79483590|NCT04776798|Other|Taping|Tape applications will repeat twice per week, for 4 weeks.
79483591|NCT05180058|Other|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
79649923|NCT01089127|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
79979755|NCT05064449|Drug|Mefenamic acid|Mefenamic acid capsule.
79329661|NCT04866875|Behavioral|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
79329662|NCT04858997|Drug|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
79329663|NCT04858997|Drug|AI|AI, orally once daily (continuously)
79329664|NCT05135143|Combination Product|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
79329665|NCT04865549|Procedure|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
79329666|NCT04867265|Procedure|Mout-to-mouth ventilation|we will record the visibility of chest rising
79329667|NCT04867265|Procedure|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
79329668|NCT04858763|Other|No Intervention|There will be no intervention during this study.
79649924|NCT01089127|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
79649925|NCT00424580|Drug|Montelukast (10mg) and Desloratadine (5mg)|
79979756|NCT05059470|Drug|Pembrolizumab|Given by IV
79979757|NCT05054413|Other|Questionnaire Administration|Complete questionnaires
79483592|NCT04789278|Other|Notification|Notification of coronary calcium to the patient and their clinician
79649926|NCT01087957|Device|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
79649927|NCT01087957|Other|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
79649928|NCT00424658|Procedure|SAHS diagnosis|
79649929|NCT00233532|Drug|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
79649930|NCT00207974|Drug|Marine active|
79649931|NCT00233571|Biological|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
79649932|NCT00237198|Drug|Letrozole|
79649933|NCT00233610|Drug|Bicalutamide|
79649934|NCT00233610|Drug|Tamoxifen|
79649935|NCT00208130|Drug|Topiramate|
79649936|NCT00237237|Drug|vildagliptin|
79649937|NCT00208169|Drug|Aripiprazole|
79649938|NCT01087723|Drug|Bivalirudin|
79649939|NCT01087723|Drug|Heparin|
79649940|NCT00208208|Drug|Ziprasidone|
79649941|NCT01087528|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
79649942|NCT00208247|Behavioral|Cognitive behavioral psychotherapy|
79979758|NCT05033314|Drug|Rivaroxaban 10 MG|Rivaroxaban 10mg PO daily as thromboprophylaxis
79979759|NCT05033314|Drug|Placebo|matching placebo daily
79649943|NCT00237276|Procedure|colonoscopy|
79329669|NCT04863469|Behavioral|B-POC high load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
79329670|NCT04863469|Behavioral|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
79329671|NCT04867109|Other|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
79329672|NCT04867109|Diagnostic Test|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
79329673|NCT05306119|Other|Rehabilitation method|Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
79329674|NCT05305729|Other|No intervention|No intervention
79329675|NCT04488679|Other|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
79649944|NCT00233688|Device|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
79649945|NCT00233688|Procedure|Open surgical repair|Open surgical repair
79329676|NCT05305417|Procedure|Autologous Regenerative Endodontic Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
79329677|NCT05305417|Procedure|Conventional Root Canal Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
79329678|NCT05305339|Other|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
79329679|NCT04794283|Other|Breast milk|Milk substitute given during the first 24h
79329680|NCT05305183|Drug|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
79329681|NCT04782271|Drug|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
79329682|NCT04782271|Drug|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
79329683|NCT04782271|Drug|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
79329684|NCT04782271|Drug|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
79329685|NCT04781179|Behavioral|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
79649946|NCT01085812|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
79649947|NCT01085812|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily.
79649948|NCT00208286|Device|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
79649949|NCT00208286|Device|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
79649950|NCT00208364|Device|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
79649951|NCT01085734|Drug|Avastin|1.25mg intravitreally
79649952|NCT01085734|Drug|Osurdex|0.7mg intravitreally
79649953|NCT01085734|Drug|Avastin|1.25mg intravitreally
79649954|NCT00208403|Device|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
79649955|NCT00208403|Device|Palacos R|A high viscosity bone cement for use in total hip replacement
79329686|NCT04781179|Behavioral|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
79329687|NCT01668797|Drug|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
79329688|NCT01668797|Drug|Placebo|Placebo comparator for 52 weeks
79329689|NCT05305027|Behavioral|Prompt diagnois pregnancy outcome|
79483593|NCT05178966|Behavioral|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~Representation of BD~Definition, diagnosis and awareness of the disorder~Depressive, hypo / manic symptoms~Vulnerability to BD causes of BD, risk factors for relapses~Drug treatments, drug compliance and non-drug treatments~Early detection of prodromal signs~Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
79649956|NCT00233727|Procedure|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
79483594|NCT04801524|Behavioral|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
79483595|NCT04801524|Behavioral|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
79649957|NCT00233727|Procedure|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
79649958|NCT01084603|Drug|Oral Nicotine|A new l mg oral nicotine product
79649959|NCT01084603|Drug|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
79649960|NCT01084603|Drug|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
79649961|NCT00208442|Device|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
79811400|NCT05298527|Behavioral|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
79649962|NCT00208442|Device|Enduron|Standard polyethylene liner in a modular acetabular component
79649963|NCT01084174|Drug|Peanut powder|Delivered orally
79649964|NCT01084174|Drug|Peanut extract|Delivered sublingually
79649965|NCT01084174|Drug|Placebo extract|Delivered sublingually
79649966|NCT01084174|Drug|Placebo powder|Delivered orally
79649967|NCT00237354|Drug|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
79649968|NCT00233766|Device|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
79329690|NCT04759027|Other|subacromial distance measurement|distance between acromion and humerus
79329691|NCT05304637|Device|iTEAR100 treatment|Vibratory energy to the external nasal nerve
79329692|NCT04511767|Other|Do not take any interventions|Do not take any interventions
79329693|NCT05304559|Drug|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
79329694|NCT05304559|Device|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
79329695|NCT05304559|Drug|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
79329696|NCT03045263|Behavioral|Pivotal Response Treatment|Behavioral intervention for autism
79649969|NCT00208520|Drug|Carbamazepine|
79649970|NCT00208520|Drug|Lamotrigine|
79649971|NCT00208520|Drug|Levetiracetam|
79811401|NCT04135625|Behavioral|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
79811402|NCT04135625|Behavioral|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
79811403|NCT04135235|Drug|TAF|Propofol tenofovir fumarate
79811404|NCT04135235|Drug|TDF|Dipirofurate fumarate tenofovir
79329697|NCT04478851|Behavioral|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
79329698|NCT04866797|Other|cyclic merocyanine|long-UVA absorber
79329699|NCT04866797|Other|Placebo|Placebo
79329700|NCT04476355|Other|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
79329701|NCT04865471|Procedure|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
79329702|NCT04117711|Drug|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
79329703|NCT04117711|Drug|placebo|Matching placebo will be administered once in the morning before breakfast
79329704|NCT02613221|Drug|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
79329705|NCT05304325|Procedure|Bariatric surgery|Sleeve gastrectomy
79329706|NCT05304325|Other|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
79329707|NCT05304325|Other|Blood pressure|Systolic and diastolic blood pressure will be measured.
79329708|NCT05304325|Other|Anthropometric measurements|Body weight, height and waist circumference will be measured.
79329709|NCT05304325|Other|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
79329710|NCT05304325|Other|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
79329711|NCT05304325|Other|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
79329712|NCT05304325|Procedure|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
79329713|NCT05304169|Drug|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
79649972|NCT00237393|Drug|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
79329714|NCT04867031|Dietary Supplement|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing ~140µg of iodine.
79329715|NCT04867031|Dietary Supplement|Fish|One portion of cod (approx. 130g), providing ~140µg of iodine.
79649973|NCT00237393|Drug|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
79811405|NCT00460603|Drug|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
79329716|NCT04867031|Dietary Supplement|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing ~140µg of iodine.
79483596|NCT04801524|Behavioral|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
79483597|NCT04801524|Behavioral|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
79483598|NCT05172882|Procedure|Wound site infiltration|Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
79649974|NCT00208559|Drug|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
79649975|NCT00233805|Device|Sirolimus coated Bx Velocity™|drug-eluting stent
79649976|NCT00233805|Device|Bare metal Bx Velocity™|bare-metal stent
79811406|NCT00460603|Drug|AG-013726|AG-013726 5 mg bid every 2 weeks
79811407|NCT00460603|Drug|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
79811408|NCT00696059|Drug|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
79811409|NCT04131218|Drug|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
79811410|NCT00700388|Device|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
79811411|NCT00700388|Procedure|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
79811412|NCT02625155|Other|Urine diagnostic testing as SOC, drug regimen changes per SOC|
79811413|NCT02625155|Other|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
79329717|NCT03045107|Procedure|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
79979760|NCT05020522|Diagnostic Test|Luminal Index MRI (LI-MRI)|Multiecho T2 sequence; eventual biopsy of lesion(s) detected with LI-MRI only.
79329718|NCT03045107|Procedure|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
79329719|NCT05304091|Other|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
79329720|NCT04865081|Device|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
79483599|NCT05172882|Procedure|Transversalis fascia plane block|External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
79979761|NCT05020522|Diagnostic Test|LI-MRI targeted prostate biopsy|Biopsy targeted to suspicious lesions detected with LI-MRI only
79811414|NCT00700466|Drug|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
79811415|NCT00698282|Drug|AZD1981|Oral tablet, 250 mg single dose
79811416|NCT00698282|Drug|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
79811417|NCT00698282|Drug|Placebo|
79979762|NCT05020522|Diagnostic Test|Plasma methylation signature (ctMethSig)|Blood sample.
79329721|NCT04865003|Other|treatment of infection|
79811418|NCT02621645|Procedure|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
79811419|NCT02621645|Procedure|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
79811420|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
79979763|NCT05015257|Dietary Supplement|Standard F100|100 kcal and 3 g protein per 100 ml
79979764|NCT05015257|Dietary Supplement|Standard F75 + Plumpynut|Standard F75 with ready to-use therapeutic food (Plumpynut)
79979765|NCT05015257|Dietary Supplement|Alternative F75 with CMV + Plumpynut|Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
79979766|NCT05015257|Dietary Supplement|Alternative F75 without CMV + Plumpynut|Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
79979767|NCT05008432|Diagnostic Test|Home sleep apnea testing|Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
79329722|NCT04864769|Dietary Supplement|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
79329723|NCT04864769|Dietary Supplement|Soy protein isolate|Ingestion of 35 g Soy protein isolate
79329724|NCT04864769|Dietary Supplement|Whey protein isolate|Ingestion of 35 g Whey protein isolate
79329725|NCT04864769|Dietary Supplement|Water|Ingestion of water (control)
79649977|NCT01084135|Drug|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
79649978|NCT01084135|Other|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
79649979|NCT01083316|Drug|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
79329726|NCT03042455|Device|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
79329727|NCT03042455|Device|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
79979768|NCT04999592|Drug|Standard of care without prophylaxis|Administer antibiotics in response to infection
79979769|NCT04999592|Drug|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
79649980|NCT01083316|Drug|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
79329728|NCT03042455|Other|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
79329729|NCT04451785|Biological|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
79649981|NCT01083316|Drug|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
79649982|NCT00208637|Behavioral|moderate carbohydrate, high protein diet (MCHP)|
79649983|NCT00208637|Behavioral|high carbohydrate-high fibre (HCHF) diet|
79979770|NCT04997811|Drug|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
79979771|NCT04997811|Drug|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
79979772|NCT04997642|Behavioral|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~Geriatric Depression Scale Quality of Life Questionnaire~PDQ-39, SF-12"
79329730|NCT04451785|Diagnostic Test|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
79649984|NCT00208715|Drug|Provigil|
79979773|NCT04992676|Diagnostic Test|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
79649985|NCT01082614|Device|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV > 12%.
79649986|NCT00233844|Procedure|"Venipuncture with cough-trick"|
79649987|NCT00208793|Dietary Supplement|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
79649988|NCT00208793|Drug|Placebo|Placebo
79649989|NCT00208793|Dietary Supplement|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
79649990|NCT00208793|Dietary Supplement|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
79649991|NCT00233883|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
79649992|NCT00233883|Drug|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
79649993|NCT00208832|Procedure|Graphic medication schedule (Pill card)|
79649994|NCT00208832|Procedure|Refill reminder postcard|
79811421|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
79811422|NCT02621645|Device|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
79329731|NCT03042065|Device|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
79329732|NCT03042065|Device|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
79649995|NCT01081873|Drug|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
79649996|NCT00237471|Drug|Insulin (tight blood glucose control)|
79649997|NCT00208871|Procedure|Stereoscopic Digital Mammography|screening digital 3D mammogram
79649998|NCT00208910|Behavioral|Odorant Cue|
79649999|NCT00233922|Device|Osteosheet(r)|
79650000|NCT00208988|Procedure|Educational handout about prostate cancer screening|
79650001|NCT00208988|Procedure|Simple cue for patient to talk to doctor|
79650002|NCT00237510|Drug|terazosin|
79650003|NCT01081795|Drug|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
79650004|NCT01081795|Drug|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
79650005|NCT00233961|Biological|filgrastim|
79329733|NCT04858685|Other|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
79329734|NCT04709107|Other|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
79329735|NCT04709107|Other|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
79329736|NCT04858919|Diagnostic Test|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
79329737|NCT04858919|Diagnostic Test|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
79329738|NCT04858919|Diagnostic Test|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
79329739|NCT05303389|Procedure|Fixation of 2,3 or 4 column pilon fracture of the tibia|anterior to posterior screws in classic arm and posterolateral approach in new arm group
79329740|NCT04858841|Drug|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
79329741|NCT04858841|Drug|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
79329742|NCT04858841|Drug|Placebo|Administer placebo powder once a day in eligible patients
79329743|NCT03997747|Other|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
79329744|NCT03970915|Device|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
79979774|NCT04992676|Diagnostic Test|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
79329745|NCT03970915|Device|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
79329746|NCT05303155|Diagnostic Test|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
79329747|NCT04379089|Other|Observational study only|No Intervention
79329748|NCT04363177|Behavioral|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
79811423|NCT04117022|Dietary Supplement|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
79329749|NCT05302843|Drug|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
79329750|NCT05302219|Other|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
79329751|NCT05302219|Other|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
79329752|NCT05302219|Other|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
79329753|NCT04690465|Behavioral|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
79329754|NCT04690465|Behavioral|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
79329755|NCT04682743|Drug|paracetamol|received intravenous one gram of paracetamol over a 15-minute period,
79329756|NCT04682743|Drug|ondansetron|received intravenous 8 mg of ondansetron over a 15-minute period.
79329757|NCT04682743|Drug|normal saline|received intravenous 0.9% normal saline over a 15-minute period.
79329758|NCT03472573|Drug|Palbociclib|Given PO
79329759|NCT03472573|Drug|Dexamethasone|Given PO
79329760|NCT04357717|Diagnostic Test|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
79650006|NCT04710186|Procedure|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
79811424|NCT00700544|Drug|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight < 60 kgs 20 mg in patients with a weight > 60 kgs frequency: every day Duration: 2 years"
79329761|NCT05301985|Dietary Supplement|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
79329762|NCT04331509|Other|No Intervention|No Intervention
79329763|NCT04672915|Diagnostic Test|test of HBV DNA|Real time PCR or nested PCR to check
79329764|NCT04649593|Dietary Supplement|Samarin|Half of the group with a high AFL value will have a glass of Samarin to drink
79329765|NCT04636333|Biological|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
79650007|NCT00234000|Drug|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
79650008|NCT00234000|Drug|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
79650009|NCT00209105|Drug|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
79650010|NCT00209105|Behavioral|Psychosocial stress induction|Laboratory stress induction, no drug administration
79650011|NCT00209105|Procedure|Brain imaging of sad mood , self-reference, reward|Brain imaging
79811425|NCT00700544|Drug|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
79811426|NCT02612792|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
79811427|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
79811428|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
79811429|NCT04138121|Device|Ultrasound|Ultrasound scan of the cricothyroid membrane
79811430|NCT00662038|Drug|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
79811431|NCT00701792|Procedure|liver transplantation|liver transplantation
79329766|NCT04636333|Biological|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
79329767|NCT04636333|Biological|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
79329768|NCT04636333|Biological|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
79329769|NCT04636333|Biological|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
79329770|NCT04636333|Biological|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
79329771|NCT04636333|Biological|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
79329772|NCT04636333|Biological|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
79329773|NCT01362049|Other|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
79650012|NCT00209105|Behavioral|Acoustic startle|No drugs involved
79650013|NCT00234117|Drug|Rabeprazole|
79650014|NCT00209144|Drug|Intensive insulin therapy|
79650015|NCT00234156|Procedure|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
79650016|NCT00209222|Drug|Rituximab|antibody
79650017|NCT00209222|Drug|Cyclophosphamide|chemotherapy
79650018|NCT00209222|Drug|Doxorubicin|chemotherapy
79650019|NCT00209222|Drug|Vincristine|chemotherapy
79650020|NCT00209222|Drug|Prednisone|corticosteroide
79650021|NCT00209222|Drug|Cisplatinum|chemotherapy
79650022|NCT00209222|Drug|Ara-C|chemotherapy
79811432|NCT00701792|Other|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
79979775|NCT04972578|Device|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
79329774|NCT01362049|Other|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
79329775|NCT04435561|Other|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
79329776|NCT04435561|Other|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
79329777|NCT04481737|Behavioral|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
79329778|NCT04481737|Behavioral|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
79483600|NCT02666118|Procedure|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
79483601|NCT02666118|Procedure|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
79483602|NCT02666118|Procedure|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
79483603|NCT02666118|Procedure|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
79650023|NCT00209222|Drug|Dexamethasone|corticosteroide
79650024|NCT00209222|Drug|BCNU|chemotherapy
79979776|NCT04970069|Other|Video on analgesic education|A four minute video informing the patient about opioids.
79979777|NCT04970069|Other|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
79979778|NCT04969276|Biological|Quadrivalent Inactivated Influenza High Dose|Sterile suspension for injection in a pre-filled syringe Intramuscular injection
79979779|NCT04969276|Biological|COVID-19 mRNA Vaccine (nucleoside modified)|Sterile suspension (white to off-white) in multidose vial Intramuscular injection
79979780|NCT04969224|Drug|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
79329779|NCT03103009|Drug|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
79329780|NCT02839291|Other|quality of life questionaries|
79329781|NCT02839291|Drug|intravenous or oral bone antiresorptive treatments|
79329782|NCT04485481|Drug|ADX-914|Single dose from 0.1mg/kg to TBD
79329783|NCT04485481|Drug|Placebo|Matching single dose placebo
79329784|NCT04485481|Drug|ADX-914|Multiple dose from TBD to TBD
79979781|NCT04969224|Drug|IVA|Tablet for oral administration.
79979782|NCT04967560|Device|deep brain stimulation|Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.
79979783|NCT04966117|Behavioral|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
79650025|NCT00209222|Drug|Melphalan|chemotherapy
79329785|NCT04485481|Drug|Placebo|Matching multiple dose placebo
79329786|NCT03852511|Biological|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
79329787|NCT03787381|Device|Ultrasound|Vaginal ultrasound examination
79329788|NCT03153787|Other|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
79329789|NCT04196335|Device|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
79329790|NCT03357367|Device|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
79329791|NCT04183699|Diagnostic Test|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
79329792|NCT04173013|Biological|Uromune|2 sprays of solution once daily for a total of 3 months.
79329793|NCT03020875|Drug|Ofirmev|Intravenously administered acetaminophen.
79329794|NCT03020875|Drug|Per Os Acetaminophen|Orally administered acetaminophen.
79329795|NCT03102931|Other|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
79329796|NCT03102931|Other|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
79329797|NCT02996305|Drug|OV101 Regimen 1|
79329798|NCT02996305|Drug|OV101 regimen 2|
79329799|NCT02996305|Other|Placebo|
79329800|NCT02612909|Biological|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
79329801|NCT02612909|Biological|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
79329802|NCT02975479|Drug|ALK Diluent|
79329803|NCT02975479|Drug|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
79329804|NCT03102853|Other|Nordic diet|
79329805|NCT03102853|Other|Control diet|
79329806|NCT04866485|Drug|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
79650026|NCT00209222|Drug|Etoposide|chemotherapy
79650027|NCT00209222|Drug|G-CSF|growth factor
79650028|NCT00209222|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
79650029|NCT00209222|Procedure|chemotherapy: R-DHAP|immuno-chemotherapy
79650030|NCT00209222|Procedure|chemotherapy: Dexa-BEAM|chemotherapy
79650031|NCT00209222|Procedure|stem cell harvest|procedure
79650032|NCT00209222|Procedure|total body irradiation|radiation
79811433|NCT02621567|Device|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
79811434|NCT02621567|Device|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
79811435|NCT00784498|Drug|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
79979784|NCT04966117|Behavioral|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
79979785|NCT04954313|Drug|Subgingival chlorhexidine irrigation|The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).
79979786|NCT04954313|Other|Dental Supplies|Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.
79811436|NCT00784498|Drug|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
79979787|NCT04954313|Other|Periodonal Treatment|Initial periodontal treatment consisting of a pre-procedural rinse and scaling & root planing (SRP).
79979788|NCT04922307|Procedure|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
79979789|NCT04922307|Procedure|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
79979790|NCT04908228|Drug|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
79979791|NCT04908163|Behavioral|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
79650033|NCT00209222|Procedure|high-dose chemotherapy: Cyclophosphamide|chemotherapy
79650034|NCT00209222|Procedure|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
79650035|NCT00234195|Drug|bupropion extended release (Wellbutrin XL)|
79650036|NCT00209261|Drug|MINIRIN Oral Lyophilisate|
79650037|NCT00209261|Drug|Minirin tablet|
79979792|NCT04908163|Behavioral|Mediterranean diet-based culinary intervention|The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
79329807|NCT04858373|Other|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79650038|NCT00237549|Procedure|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
79329808|NCT04858373|Other|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79329809|NCT04858373|Other|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79811437|NCT01022983|Drug|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
79329810|NCT04858373|Other|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79329811|NCT02888041|Drug|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
79329812|NCT02888041|Drug|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
79329813|NCT04858139|Drug|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
79329814|NCT04858139|Drug|Placebo|Intravenous injection (20 min)
79329815|NCT01688167|Behavioral|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
79329816|NCT04864691|Biological|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
79329817|NCT02838745|Drug|Pemetrexed|
79650039|NCT00209300|Drug|Pentasa|
79811438|NCT01022983|Drug|Placebo|ml/kg/hours - same infusion rate as active comparator
79650040|NCT00234234|Drug|Adalimumab|
79650041|NCT00209378|Other|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
79650042|NCT00209378|Other|HfCitPre|regional anticoagulation with citrate containing replacement solution
79650043|NCT00234273|Procedure|Rehabilitation programme in Adapted Physical Activity (APA)|
79329818|NCT02838745|Drug|Cisplatin|
79329819|NCT03102541|Other|None intervention|
79329820|NCT04143919|Diagnostic Test|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
79329821|NCT04143919|Procedure|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
79329822|NCT04143919|Diagnostic Test|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
79329823|NCT00136435|Drug|prednisone|Induction Phase: Given orally on days 1-28
79979793|NCT04904679|Device|Pars plana Vitrectomy with internal limiting membrane peeling|The vitrectomy technique using pars plana 23-gauge will be performed with removal of the ILM (when present adhered to the macula) and placement of an amniotic membrane plug or a internal limiting membrane flap in the macular hole, with a fluid-air exchange and a buffering gas infusion (C3F8 12, 5%). The amniotic membrane plug will be made with a dermatological punch with a diameter of 1.0 to 2mm depending on the size of the macular hole measured by the OCT, and will be positioned inside de macular hole with the chorionic side facing the RPE ( retinal pigmented epithelium) with a 23 gauge forceps. The chorionic side of the membrane is the sticky one. The internal limiting membrane flap will be created at the same time of peeling and will bem positioned in as inverted flap over and inside the macular hole with a 23 gauge ILM forceps. These technics will be helped with de use of a extra lighting sclerotomy.
79329824|NCT00136435|Drug|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
79329825|NCT00136435|Drug|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
79979794|NCT04898790|Behavioral|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
79650044|NCT00234273|Behavioral|Therapeutic education primarily focused on dietary|
79811439|NCT00912860|Drug|Interferon beta-1a|serum free Avonex given IM once a week
79979795|NCT04881799|Drug|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
79979796|NCT04881799|Drug|Placebo|Daily injection
79979797|NCT04869631|Other|The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.|We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
79329826|NCT00136435|Drug|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
79329827|NCT00136435|Drug|asparaginase|Induction: Given into the muscle on day 5
79329828|NCT00136435|Drug|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
79329829|NCT00136435|Radiation|cranial radiation|Given in 10 daily treatments during CNS therapy phase
79329830|NCT00136435|Drug|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
79329831|NCT00136435|Drug|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
79650045|NCT00209456|Drug|DatSCAN|
79650046|NCT00237588|Drug|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
79650047|NCT00411437|Drug|Tolterodine ER|
79650048|NCT00411437|Drug|Oxybutynin ER|
79650049|NCT00234312|Drug|escitalopram and sertraline|
79329832|NCT00136435|Drug|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
79329833|NCT00136435|Drug|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
79483604|NCT02635932|Device|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
79979798|NCT04856215|Drug|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
79979799|NCT04826770|Drug|BNT162b2|vaccination against COVID-19
79483605|NCT02635932|Device|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
79483606|NCT05337774|Drug|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) [18F]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
79483607|NCT05291988|Other|Educational Intervention|Receive S2S education
79811440|NCT02621333|Biological|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
79979800|NCT04826770|Drug|AZD 1222|vaccination against COVID-19
79979801|NCT04826770|Drug|mRNA-1273|vaccination against COVID-19
79979802|NCT04821284|Drug|Gemcitabine Hydrochloride|Given IV
79979803|NCT04821284|Drug|Nab-paclitaxel|Given IV
79979804|NCT04821284|Drug|Fluorouracil|Given IV
79329834|NCT00136435|Drug|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
79329835|NCT04857749|Other|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
79483608|NCT05291988|Other|Fecal Immunochemical Test|Receive FIT kit
79483609|NCT05291988|Other|Questionnaire Administration|Ancillary Studies
79483610|NCT02389218|Device|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
79483611|NCT02389218|Drug|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
79483612|NCT01953120|Drug|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
79483613|NCT05343858|Dietary Supplement|Experimental: Group 1: Spirulina platensis|16 g/day (two doses of 8g)
79650050|NCT00411515|Drug|Mycophenolate Mofetil 2x 1g|
79979805|NCT04821284|Drug|Irinotecan Hydrochloride|Given IV
79979806|NCT04821284|Drug|Leucovorin Calcium|Given IV
79979807|NCT04821284|Drug|Oxaliplatin|Given IV
79979808|NCT04821284|Other|Perflubutane Microbubble|Oxaliplatin
79979809|NCT04821284|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
79979810|NCT04821284|Other|Quality-of-Life Assessment|Ancillary studies
79979811|NCT04818632|Drug|AZD9833|Part A: AZD9833 monotherapy dose escalation.
79979812|NCT04818632|Drug|AZD9833|Part B: AZD9833 monotherapy dose expansion
79979813|NCT04818632|Drug|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
79329836|NCT04857749|Other|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
79329837|NCT05045209|Other|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
79329838|NCT02612285|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
79329839|NCT02642185|Procedure|Microwave ablation|CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
79483614|NCT05343858|Dietary Supplement|Experimental: Group 2: Chlorella vulgaris|16 g/day (two doses of 8g)
79483615|NCT05343858|Dietary Supplement|Placebo Comparator: Group 3: Control|16 g/day (two doses of 8g)
79483616|NCT01634100|Drug|Probenecid|Probenecid
79483617|NCT01634100|Drug|Rifampicin|Rifampicin
79483618|NCT01634100|Drug|Empagliflozin|BI Drug
79483619|NCT01634100|Drug|Empagliflozin|BI Drug
79650051|NCT00237627|Drug|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
79650052|NCT00237627|Drug|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
79650053|NCT00237627|Drug|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
79650054|NCT00209495|Drug|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
79650055|NCT00234390|Drug|Pulmicort (budesonide) pMDI|
79650056|NCT00209534|Drug|fospropofol disodium|
79811441|NCT02621333|Drug|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
79811442|NCT04116086|Diagnostic Test|Prostate Biopsy Test|see earlier information
79811443|NCT02623673|Drug|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
79329840|NCT02642185|Procedure|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
79329841|NCT02609633|Device|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
79329842|NCT02609633|Device|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
79329843|NCT04053907|Other|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
79329844|NCT04053907|Other|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
79329845|NCT04053907|Other|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
79483620|NCT01634100|Drug|Rifampicin|Rifampicin
79483621|NCT01634100|Drug|Probenecid|Probenecid
79483622|NCT01634100|Drug|Empagliflozin (BI 10773)|BI Drug
79650057|NCT00209573|Drug|fospropofol disodium|
79650058|NCT00414141|Biological|Grass MATA MPL|4 subcutaneous injections
79650059|NCT00414141|Biological|Placebo|4 subcutaneous injections
79329846|NCT04053907|Other|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
79650060|NCT01081678|Drug|Placebo|Administered by subcutaneous (under the skin) injection
79650061|NCT01081678|Drug|Romosozumab|Administered by subcutaneous injection
79650062|NCT00209612|Drug|Taxol|Day1,15 X mg/m2, IV (in the vein)
79650063|NCT00209612|Drug|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
79650064|NCT01081249|Drug|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
79811444|NCT05021536|Other|Placebo|Matching Placebo Comparator
79811445|NCT05021536|Drug|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
79650065|NCT01081249|Drug|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
79650066|NCT00234429|Drug|Gefitinib, raltitrexed|
79650067|NCT00209651|Drug|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
79811446|NCT00701870|Drug|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
79979814|NCT04818632|Drug|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
79329847|NCT04857125|Other|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
79329848|NCT04857125|Other|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
79483623|NCT05226156|Behavioral|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with LBP consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three month.
79329849|NCT04864379|Biological|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
79483624|NCT01633944|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
79483625|NCT01633944|Drug|Placebo|Matching Placebo Buccal Film twice daily
79979815|NCT04807283|Device|Left Atrial Appendage Closure|Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
79979816|NCT04803565|Device|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
79483626|NCT04592419|Drug|KSI-301|Intravitreal Injection
79979817|NCT04803565|Device|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
79979818|NCT04791787|Other|Standard weight maintaining diet|Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
79979819|NCT04791787|Other|Weight maintaining isocaloric ketogenic diet|Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
79483627|NCT04592419|Drug|Aflibercept|Intravitreal Injection
79979820|NCT04791787|Dietary Supplement|Beta-hydroxy butyrate|A supplement of ketone ester of beta-hydroxy butyrate
79979821|NCT04790045|Drug|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
79483628|NCT04592419|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
79483629|NCT00589316|Procedure|Allogeneic Bone Marrow Transplantation|Given via central line
79979822|NCT04789733|Other|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
79979823|NCT04789733|Other|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
79979824|NCT04779216|Drug|Romosozumab Prefilled Syringe|Romosozumab 210mg Injection monthly for 12 months
79329850|NCT04864379|Other|GM-CSF|GM-CSF: 40 mcg
79329851|NCT04864379|Drug|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
79329852|NCT04864379|Procedure|RFA|Radiofrequency ablation surgery
79329853|NCT04849559|Drug|Tradipitant|Tradipitant Capsule
79329854|NCT04849559|Drug|Placebo|Placebo Capsule
79483630|NCT00589316|Drug|Cyclophosphamide|Given IV
79483631|NCT00589316|Drug|Fludarabine Phosphate|Given IV
79483632|NCT00589316|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
79483633|NCT00589316|Other|Laboratory Biomarker Analysis|Correlative studies
79483634|NCT00589316|Drug|Mycophenolate Mofetil|Given IV or PO
79483635|NCT00589316|Drug|Tacrolimus|Given IV or PO
79483636|NCT00589316|Radiation|Total-Body Irradiation|Undergo TBI
79483637|NCT01633788|Drug|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
79483638|NCT01633788|Drug|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
79483639|NCT01633788|Drug|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
79483640|NCT01633788|Drug|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
79650068|NCT00209651|Drug|TS-1|80 mg/m2, PO (oral) on day 1~14 of each 28 day cycle.
79979825|NCT04779216|Drug|Placebo|Placebo Injection monthly for 12 months
79979826|NCT04779216|Drug|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at 12 months through 24 months.
79979827|NCT04778761|Behavioral|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
79979828|NCT04778449|Other|Medical Chart Review|Medical charts are reviewed
79329855|NCT03044561|Drug|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
79329856|NCT03044561|Drug|matching placebo|orally, 4 times per day for 21 days
79329857|NCT03044405|Diagnostic Test|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
79329858|NCT03044405|Diagnostic Test|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
79329859|NCT02455141|Drug|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
79329860|NCT02455141|Drug|Taxanes|Paclitaxel: 80mg/m2, d1, qw*12 or Docetaxel: 80-100mg/m2,d1,q3w*4
79329861|NCT02455141|Drug|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4 or Docetaxel: 75mg/m2,d1,q3w*4 plus Carboplatin AUC=5-6, d1, q3w*4
79329862|NCT03044639|Drug|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
79329863|NCT04864301|Procedure|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
79329864|NCT02439385|Drug|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
79650069|NCT02961855|Drug|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
79650070|NCT02961855|Drug|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
79650071|NCT00209690|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79650072|NCT00209690|Drug|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79650073|NCT00209690|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79650074|NCT01081132|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
79650075|NCT01081132|Other|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
79329865|NCT02439385|Dietary Supplement|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
79329866|NCT04429529|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
79329867|NCT04429529|Other|0.9% Saline|Placebo
79329868|NCT03104959|Dietary Supplement|N-acetyl cysteine|
79329869|NCT03104959|Other|placebo|
79329870|NCT04006015|Other|No intervention being delivered.|No interventions are being delivered.
79329871|NCT03044171|Device|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
79329872|NCT03044171|Drug|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
79329873|NCT03044171|Drug|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
79650076|NCT00234468|Drug|Iressa (Gefitinib)|
79650077|NCT01080625|Drug|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
79329874|NCT03102463|Dietary Supplement|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
79329875|NCT03102463|Dietary Supplement|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
79329876|NCT03102463|Dietary Supplement|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
79329877|NCT03102463|Other|Lipid Load|100mL oral lipid load
79329878|NCT04863989|Procedure|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
79650078|NCT01080625|Drug|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
79329879|NCT03102385|Behavioral|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
79329880|NCT03102385|Behavioral|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
79650079|NCT01080625|Drug|placebo control|10ml of normal saline is administered at the time of reperfusion
79650080|NCT00209729|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
79329881|NCT04863755|Behavioral|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
79979829|NCT04778449|Other|Questionnaire Administration|Complete questionnaires
79979830|NCT04767282|Other|Fruit and Vegetable Prescription|$15 voucher for fruit and vegetables
79979831|NCT04760392|Behavioral|Goal-directed mobilization|"A short educational intervention with handout of a leaflet on GDM.~Definition of personal mobility goal level.~Communication of the mobility goal level to involved stakeholders.~Regular reassessment of the mobility goal level and booster sessions by physiotherapists."
79329882|NCT04863755|Behavioral|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
79329883|NCT03102229|Other|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
79483641|NCT04263493|Other|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
79483642|NCT04786860|Procedure|CPR|Cardiopulmonary resuscitation performed on patients with in-hospital cardiac arrest
79483643|NCT02032524|Drug|GZ402666|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
79483644|NCT00362245|Drug|Systemic and Intra-Thecal Amikacin Therapy|
79483645|NCT04786080|Behavioral|Parent Positive|"Parent Positive is a smartphone app delivering information and parenting support aiming to improve wellbeing within the family and reduce pressures on services given the ongoing pandemic-related challenges. It will consist of three zones, providing:~structured advice, support and tips for parents~facilitated parent-to-parent communication platform where parents can post questions of one another and parenting experts~access to carefully selected high-quality, evidence-based online parenting resources."
79483646|NCT00361543|Drug|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
79650081|NCT00209729|Drug|TS-1|Day 1-14, P.O. everyday
79650082|NCT00414180|Drug|Bupropion SR|
79483647|NCT00361543|Other|Lactose Capsules|1 tablet daily for 12 weeks
79483648|NCT00003417|Drug|carmustine|
79483649|NCT00003417|Radiation|radiation therapy|
79483650|NCT00003267|Procedure|infection prophylaxis and management|
79650083|NCT01089790|Drug|Dutogliptin|400 mg tablet, once daily
79650084|NCT01089790|Drug|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
79979832|NCT04754035|Drug|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
79979833|NCT04754035|Drug|Imbruvica Oral Product|Imbruvica 140 mg
79979834|NCT04748419|Radiation|consolidative hypofractionated radiation therapy (hfRT)|Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design
79979835|NCT04748419|Drug|Durvalumab 50 MG/ML|Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
79979836|NCT04744350|Procedure|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
79483651|NCT00003267|Procedure|management of therapy complications|
79483652|NCT00003267|Procedure|surgical procedure|
79483653|NCT00003423|Drug|asparaginase|
79483654|NCT00003423|Drug|cyclophosphamide|
79483655|NCT00003423|Drug|cytarabine|
79483656|NCT00003423|Drug|daunorubicin hydrochloride|
79483657|NCT00003423|Drug|dexamethasone|
79483658|NCT00003423|Drug|etoposide|
79483659|NCT00003423|Drug|mercaptopurine|
79483660|NCT00003423|Drug|methotrexate|
79650085|NCT00209768|Device|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
79650086|NCT01089010|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
79650087|NCT01089010|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
79650088|NCT01089010|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
79650089|NCT00234507|Biological|Botulinum toxin type A|
79979837|NCT04738279|Device|Non-Invasive Continuous Remote Patient Monitoring|Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
79979838|NCT04738279|Other|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Survey and qualitative interviewing of participants
79979839|NCT04731506|Behavioral|Family Connections|The program starts with 2 small group support sessions spaced one week apart that guides participants through developing an action plan; followed by 10 IVR calls (5-10 minutes) beginning with weekly (4), biweekly (4), and monthly (2) calls. During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
79329884|NCT03102229|Other|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
79329885|NCT04108429|Behavioral|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
79329886|NCT04857515|Device|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
79329887|NCT04857047|Drug|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
79329888|NCT04857047|Drug|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
79329889|NCT04856969|Drug|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
79329890|NCT04856969|Drug|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
79329891|NCT04856735|Other|Intraperİtoneal local anaesthesİc İn cesarean sectİon|After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
79650090|NCT01085266|Drug|Dimebon (latrepirdine)|
79650091|NCT01084330|Drug|AUY922|70mg/m2
79650092|NCT01084330|Drug|Docetaxel|Docetaxel 75mg/m2
79329892|NCT04856735|Other|Local wound infiltrasyon|A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
79329893|NCT04856735|Other|Control group|One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
79329894|NCT04856501|Behavioral|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
79329895|NCT04856501|Behavioral|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
79329896|NCT04856579|Procedure|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
79483661|NCT00003423|Drug|prednisolone|
79483662|NCT00003423|Drug|thioguanine|
79650093|NCT01084330|Drug|Irinotecan|Iriniotecan 350mg/m2
79650094|NCT00209807|Drug|escitalopram|escitalopram 10 mg/d for 6 weeks
79650095|NCT00209807|Drug|Reboxetine|Reboxetine 8 mg/d for 6 weeks
79650096|NCT00209807|Other|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
79650097|NCT04571671|Other|Collect retrospectively data|Analyse the incidence of Mullerian anomalies in these populations
79650098|NCT00414219|Behavioral|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
79650099|NCT04571476|Procedure|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
79329897|NCT03104803|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
79329898|NCT03041519|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
79329899|NCT03041519|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
79979840|NCT04728633|Drug|Carmustine|Given via infusion
79979841|NCT04728633|Drug|Ethiodized Oil|Given via infusion
79329900|NCT03938311|Other|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
79329901|NCT03041597|Procedure|placement of implants|surgical procedure and placement of implants
79483663|NCT00003423|Drug|vincristine sulfate|
79329902|NCT03041597|Procedure|immediate loading|cone-anchored implant supported removable dental prostheses placement
79483664|NCT00003273|Biological|filgrastim|
79483665|NCT00003273|Drug|carboplatin|
79483666|NCT00003273|Drug|cisplatin|
79650100|NCT04571476|Procedure|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
79650101|NCT04571476|Procedure|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
79650102|NCT04571476|Procedure|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
79979842|NCT04728633|Procedure|Transarterial Chemoembolization|Undergo TACE
79979843|NCT04728633|Other|Medical Device Usage and Evaluation|Given gelatin sponge via injection
79979844|NCT04721418|Radiation|11C-UCB-J|11C-UCB-J PET scan
79979845|NCT04717674|Drug|[18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)|[18F]FPIA radiotracer administration
79979846|NCT04717674|Procedure|PET/CT|PET/CT scan
79979847|NCT04716452|Drug|Ceramide NanoLiposome (Ceraxa)|Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.
79979848|NCT04712864|Biological|LB1901|LB1901 - an autologous CD4-targeted CAR-T immunotherapy
79979849|NCT04690205|Other|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
79650103|NCT00209846|Drug|Gaboxadol|
79979850|NCT04680923|Procedure|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
79979851|NCT04680923|Other|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
79979852|NCT04680923|Drug|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
79979853|NCT04669535|Biological|AXO-AAV-GM2 Starting Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
79979854|NCT04669535|Biological|AXO-AAV-GM2 Low Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
79329903|NCT03041597|Procedure|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
79329904|NCT03041597|Device|Ankylos implant|
79329905|NCT04435171|Procedure|Renal transplantation|Open or robot assisted renal transplantation
79329906|NCT04856345|Other|Walking with music with synchronisation|Walking with music than one can synch to
79329907|NCT04856345|Other|Walking with music without synchronisation|Walking with music than one cannot synch to
79329908|NCT04856345|Other|walking without music|Walking without music
79483667|NCT00003273|Drug|cyclophosphamide|
79483668|NCT00003273|Drug|etoposide|
79483669|NCT00003273|Drug|leucovorin calcium|
79483670|NCT00003273|Drug|methotrexate|
79483671|NCT00003273|Drug|temozolomide|
79483672|NCT00003273|Drug|thiotepa|
79483673|NCT00003273|Drug|vincristine sulfate|
79483674|NCT00003273|Procedure|autologous bone marrow transplantation|
79483675|NCT00003273|Procedure|peripheral blood stem cell transplantation|
79483676|NCT00003273|Radiation|radiation therapy|
79483677|NCT04329585|Drug|flumazenil|EEG is observed in both groups to compare the difference between two groups.
79979855|NCT04669535|Biological|AXO-AAV-GM2 Middle Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
79329909|NCT04856267|Device|"LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)"|Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
79979856|NCT04669535|Biological|AXO-AAV-GM2 High Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
79650104|NCT04571593|Behavioral|Yoga Nidra|The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
79979857|NCT04667949|Drug|Fingolimod 0.5mg|Subjects will receive fingolimod 0.5mg capsule QD up to month 24
79979858|NCT04646005|Drug|Cemiplimab|Administered intravenously (IV) every three weeks (Q3W)
79979859|NCT04646005|Biological|ISA101b|Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
79979860|NCT04636801|Drug|Experimental: CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
79979861|NCT04636801|Drug|Experimental: CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
79979862|NCT04636801|Drug|Placebo|CHF6001 matching placebo, 2 inhalations bid.
79979863|NCT04626245|Behavioral|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
79329910|NCT03919045|Drug|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
79329911|NCT03919045|Procedure|Placebo|Half of the group will be treated with needle stings without injections
79329912|NCT04856111|Drug|Pirfenidone|Same as arm description
79329913|NCT04856111|Drug|Nintedanib|Same as arm description
79329914|NCT02053051|Device|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
79650105|NCT01082068|Drug|XL147 (SAR245408)|given orally once daily as tablets
79650106|NCT01082068|Drug|XL765 (SAR245409)|given orally twice daily as capsules
79650107|NCT01082068|Drug|letrozole (Femara)|given orally once daily as tablets
79650108|NCT01086748|Drug|Risperidone|Administered orally.
79650109|NCT01086748|Drug|Placebo|Administered orally.
79650110|NCT01086748|Drug|LY2140023|Administered orally.
79979864|NCT04622722|Other|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
79979865|NCT04622722|Other|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
79979866|NCT04617535|Drug|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
79979867|NCT04614753|Other|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
79979868|NCT04614753|Other|Control Beverage|300ml of Sugar Water and Acid Content
79979869|NCT04610294|Device|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
79979870|NCT04610294|Device|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
79329915|NCT02053051|Drug|Novorapid|Multiple daily injections(MDI) of insulin
79329916|NCT04856423|Diagnostic Test|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
79329917|NCT03881683|Diagnostic Test|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
79329918|NCT04856033|Behavioral|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
79483678|NCT04329585|Drug|Placebos|Placebo is the normal saline, which is given in the controlled group.
79650111|NCT00237705|Drug|metoclopramide|
79650112|NCT00209885|Drug|Gabapentin|
79650113|NCT00209885|Drug|S-ketamine|
79650114|NCT00209885|Drug|Lidocaine|
79979871|NCT04607408|Biological|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
79979872|NCT04607408|Biological|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
79979873|NCT04607408|Biological|Placebo|Sodium Chloride for Injection, 0.9% USP
79979874|NCT04606602|Drug|SLN360|SLN360 for subcutaneous (s.c.) injection
79979875|NCT04606602|Drug|Placebo|Sodium chloride for subcutaneous (s.c.) injection
79979876|NCT04591431|Drug|Erlotinib|TT arm
79329919|NCT04856033|Behavioral|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
79329920|NCT04077541|Behavioral|internet platform|The trauma care bundles combined with the internet platform.
79329921|NCT04855565|Drug|ALY688-SR|single dose subcutaneous injection
79329922|NCT03864289|Behavioral|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
79329923|NCT04863911|Radiation|combined CT and MRI|"1 mL of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) will be diluted with 100 mL of saline; 8 mL of this will be mixed with 7 mL of iodine solution (340 mg/cc) and 3 mL of lidocaine 2% and injected under ultrasonographic guidance.~The fixed US-guided technique, the needle will be inserted into the needle guide hole and directed toward the hip joint, targeting the femoral head-neck junction. The volume injected varies from 10 to 20 mL, with a mean of 15 mL.~Ideally CT should be performed immediately after the injection and MR should be performed within 90 minutes after the initial injection."
79483679|NCT00003279|Biological|BCG vaccine|
79650115|NCT00209885|Drug|Droperidol|
79650116|NCT04999735|Behavioral|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
79650117|NCT04999735|Behavioral|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
79979877|NCT04591431|Drug|Trastuzumab|TT arm
79483680|NCT00003279|Biological|monoclonal antibody BEC2|
79483681|NCT00383487|Drug|Calcitriol|0.5 micrograms/kilogram q weekly
79483682|NCT00383487|Drug|Naproxen-n-butyl nitrate|400 mg BID, oral
79979878|NCT04591431|Drug|Trastuzumab emtansine|TT arm
79979879|NCT04591431|Drug|Pertuzumab|TT arm
79979880|NCT04591431|Drug|Lapatinib|TT arm
79979881|NCT04591431|Drug|Everolimus|TT arm
79483683|NCT00003429|Procedure|biopsy|
79483684|NCT00003429|Procedure|computed tomography|
79483685|NCT00003429|Procedure|positron emission tomography|
79483686|NCT00003429|Radiation|fludeoxyglucose F 18|
79483687|NCT00003435|Biological|anti-thymocyte globulin|
79483688|NCT00003435|Drug|melphalan|
79483689|NCT00003435|Procedure|antiviral therapy|
79483690|NCT00003435|Procedure|bone marrow ablation with stem cell support|
79979882|NCT04591431|Drug|Vemurafenib|TT arm
79979883|NCT04591431|Drug|Cobimetinib|TT arm
79979884|NCT04591431|Drug|Alectinib|TT arm
79979885|NCT04591431|Drug|Brigatinib|TT arm
79979886|NCT04591431|Drug|Palbociclib|TT arm
79979887|NCT04591431|Drug|Ponatinib|TT arm
79979888|NCT04591431|Drug|Vismogedib|TT arm
79979889|NCT04591431|Drug|Itacitinib|TT arm
79329924|NCT04855877|Drug|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
79329925|NCT04855877|Drug|Placebo|Oral administration of lactose tablet (placebo)
79329926|NCT03102073|Diagnostic Test|Radner test|"The A5 reading booklet is held by the subject~The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~Stop criterion: reading time longer than 20 seconds or severe errors."
79329927|NCT03041675|Device|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
79329928|NCT03041675|Device|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
79329929|NCT04849247|Drug|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
79483691|NCT00003435|Procedure|peripheral blood stem cell transplantation|
79483692|NCT00003435|Procedure|umbilical cord blood transplantation|
79483693|NCT00003435|Radiation|radiation therapy|
79483694|NCT00003291|Genetic|cytogenetic analysis|
79483695|NCT00003291|Genetic|mutation analysis|
79483696|NCT00003291|Other|laboratory biomarker analysis|
79483697|NCT00003441|Drug|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
79483698|NCT00002805|Biological|filgrastim|
79329930|NCT02845453|Drug|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
79483699|NCT00002805|Drug|cladribine|
79483700|NCT00002805|Drug|cytarabine|
79483701|NCT00002805|Drug|etoposide|
79329931|NCT02845453|Other|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
79329932|NCT01799629|Drug|Glycerin suppositories|
79329933|NCT04849403|Procedure|CTSP|In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
79483702|NCT00002805|Drug|methotrexate|
79483703|NCT00002805|Drug|mitoxantrone hydrochloride|
79483704|NCT00002805|Drug|therapeutic hydrocortisone|
79483705|NCT00002805|Procedure|allogeneic bone marrow transplantation|
79483706|NCT00002805|Procedure|autologous bone marrow transplantation|
79483707|NCT00002805|Procedure|peripheral blood stem cell transplantation|
79483708|NCT00002805|Radiation|low-LET cobalt-60 gamma ray therapy|
79979890|NCT04591431|Drug|Ipatasertib|TT arm
79483709|NCT00002805|Radiation|low-LET electron therapy|
79483710|NCT00002805|Radiation|low-LET photon therapy|
79483711|NCT00003297|Drug|mitoxantrone hydrochloride|
79483712|NCT00003297|Drug|thiotepa|
79483713|NCT00003297|Drug|topotecan hydrochloride|
79483714|NCT00003297|Procedure|peripheral blood stem cell transplantation|
79483715|NCT00002811|Drug|liposomal T4N5 lotion|
79483716|NCT00003447|Drug|gemcitabine hydrochloride|
79483717|NCT00003447|Drug|vinorelbine tartrate|
79483718|NCT00003315|Biological|sargramostim|
79483719|NCT00003315|Drug|liposomal amphotericin B|
79483720|NCT00002817|Biological|sargramostim|
79483721|NCT00002817|Biological|vaccinia-GM-CSF vaccine|
79483722|NCT00003321|Procedure|psychosocial assessment and care|
79483723|NCT00003321|Procedure|quality-of-life assessment|
79483724|NCT00003465|Drug|temozolomide|
79483725|NCT00002823|Drug|cisplatin|
79483726|NCT00002823|Drug|etoposide|
79483727|NCT00002823|Drug|vinblastine sulfate|
79483728|NCT00002823|Drug|vindesine|
79483729|NCT00002823|Drug|vinorelbine tartrate|
79483730|NCT00002823|Radiation|radiation therapy|
79483731|NCT00361621|Drug|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
79483732|NCT00361621|Drug|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
79483733|NCT00361621|Drug|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
79483734|NCT00361621|Drug|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
79483735|NCT00361621|Drug|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
79979891|NCT04591431|Drug|Entrectinib|TT arm
79979892|NCT04591431|Drug|Atezolizumab|TT arm
79329934|NCT04848701|Other|latent phase duration|latent phase duration in post term pregnancies
79329935|NCT04848701|Other|uterocervical angle (UCA)|uterocervical angle is the angle between lower segment of uterus and cervix
79329936|NCT04428827|Procedure|Unilateral adrenalectomy in patients with unilateral disease|Unilateral adrenalectomy in patients with unilateral disease
79329937|NCT03041129|Diagnostic Test|oral glucose tolerance test|6 hours OGTT
79329938|NCT03041129|Diagnostic Test|MRI of liver|MRI of the liver and use of DIXON method
79329939|NCT01597375|Drug|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
79329940|NCT01597375|Drug|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
79329941|NCT03044093|Drug|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
79329942|NCT03044093|Drug|Placebo|The group that will only get Misoprostol
79329943|NCT03044093|Drug|Misoprostol|Both groups will get think drug
79329944|NCT04848545|Other|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
79979893|NCT04591431|Drug|Nivolumab|TT arm
79329945|NCT01553071|Drug|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
79329946|NCT03044327|Procedure|LPS challenge|LPS inhalation and bronchial instillation
79979894|NCT04591431|Drug|Ipilimumab|TT arm
79979895|NCT04591431|Drug|Pemigatinib|TT arm
79979896|NCT04591431|Drug|Oncology Drugs|Standard of Care Arm
79979897|NCT04591431|Drug|Pralsetinib|TT arm
79329947|NCT01506973|Drug|Hydroxychloroquine (HCQ)|
79329948|NCT01506973|Drug|Gemcitabine|
79329949|NCT01506973|Drug|Abraxane|
79329950|NCT03041207|Behavioral|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
79329951|NCT04848467|Biological|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
79329952|NCT04848467|Biological|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
79329953|NCT04848467|Other|Placebo|One intramuscular injection as normal saline [0.9% NaCl].
79329954|NCT03102307|Other|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
79329955|NCT03102307|Procedure|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
79483736|NCT00361621|Drug|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
79483737|NCT00361621|Radiation|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
79483738|NCT00003327|Drug|paclitaxel|
79483739|NCT00003339|Biological|gp100 antigen|
79483740|NCT00003339|Biological|incomplete Freund's adjuvant|
79483741|NCT00003339|Biological|recombinant interleukin-12|
79483742|NCT00003339|Biological|tyrosinase peptide|
79979898|NCT04591431|Drug|Selpercatinib|TT arm
79979899|NCT04591431|Drug|Talazoparib|TT arm
79979900|NCT04591431|Drug|Tepotinib|TT arm
79979901|NCT04591431|Drug|Alpelisib|TT arm
79979902|NCT04588311|Drug|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
79979903|NCT04588311|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
79979904|NCT04563143|Other|Novel DBS Stimulation|Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
79329956|NCT02527161|Device|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
79979905|NCT04551677|Biological|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)"
79329957|NCT04848311|Procedure|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
79329958|NCT05431231|Diagnostic Test|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
79329959|NCT05431231|Diagnostic Test|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
79483743|NCT03620773|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
79483744|NCT03620773|Drug|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
79483745|NCT03620773|Procedure|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
79979906|NCT04551677|Biological|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM"
79483746|NCT03620773|Procedure|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
79979907|NCT04551378|Other|Quality-of-Life Assessment|Ancillary studies
79483747|NCT00002829|Biological|Recombinant Interferon Alfa|Daily
79483748|NCT00002829|Drug|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
79483749|NCT00002829|Drug|Etoposide|Administered intravenously on Day -8
79650118|NCT04999735|Behavioral|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
79483750|NCT00002829|Drug|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
79483751|NCT00002829|Procedure|Bone Marrow Transplantation|Infusion on Day 0.
79483752|NCT00002829|Radiation|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
79483753|NCT03614221|Drug|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
79979908|NCT04551378|Other|Survey Administration|Complete survey
79979909|NCT04546074|Drug|Pembrolizumab and Imatinib mesylate|"In Phase Ib study:~Level 1: Imatinib mesylate 200mg QD + Pembrolizumab 200mg Q3W, Level 2: Imatinib mesylate 400mg QD + Pembrolizumab 200mg Q3W"
79979910|NCT04546074|Drug|Pembrolizumab and Imatinib mesylate|In Phase II study, eligible patients receive the dose determined in phase Ib cohort.
79979911|NCT04537312|Procedure|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
79979912|NCT04537312|Other|Survey Administration|ancillary correlative
79979913|NCT04537312|Device|RNSM|Robot-assisted Nipple Sparing Mastectomy
79979914|NCT04515238|Drug|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
79979915|NCT04515238|Biological|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
79979916|NCT04515238|Biological|Zanubrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o"
79329960|NCT05431231|Diagnostic Test|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
79650119|NCT04999735|Behavioral|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
79329961|NCT05431231|Diagnostic Test|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
79650120|NCT00234546|Biological|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
79650121|NCT00234546|Drug|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
79329962|NCT05431231|Diagnostic Test|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
79483754|NCT03614221|Drug|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
79650122|NCT04994002|Drug|CERC-006|Oral solution
79650123|NCT00209924|Drug|Gaboxadol|
79650124|NCT00234585|Device|Renal Artery Stent with Protective Device/Drug|
79650125|NCT00209963|Drug|Gaboxadol|
79650126|NCT04990336|Combination Product|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
79650127|NCT04990336|Drug|Rhubarb single medicine|Rhubarb single medicine
79650128|NCT04990336|Combination Product|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
79650129|NCT00210002|Drug|Darbepoetin alfa (Aranesp®)|
79650130|NCT00210002|Drug|Ferric saccharose(Venofer®)|
79811447|NCT00696839|Behavioral|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
79811448|NCT02625077|Procedure|Laparoscopic gastroesophageal valvuloplasty|
79811449|NCT02625077|Procedure|Laparoscopic Toupet fundoplication|
79811450|NCT00784732|Drug|QAV680|
79811451|NCT00784732|Drug|QAV680|
79979917|NCT04515238|Biological|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
79329963|NCT05431231|Diagnostic Test|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
79329964|NCT05431231|Other|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
79329965|NCT05431231|Diagnostic Test|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, & Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
79329966|NCT05431231|Diagnostic Test|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, & Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
79329967|NCT05431231|Diagnostic Test|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, & Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
79329968|NCT03040583|Other|No intervention|Patients data will be collected during their disease follow-up
79329969|NCT03104335|Drug|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
79329970|NCT04863365|Drug|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
79483755|NCT00003489|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79483756|NCT00003345|Drug|cisplatin|
79811452|NCT00784732|Drug|Mometasone Furoate|
79811453|NCT00459979|Drug|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
79811454|NCT00459979|Procedure|conventional surgery|nephrectomy
79811455|NCT04117256|Device|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
79811456|NCT04117256|Device|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
79811457|NCT02621411|Drug|Substance use|Patients are found use of substances by preoperative screen
79811458|NCT00783484|Drug|PF-03716539|PF-03716539 10 mg oral solution, single dose
79979918|NCT04510740|Other|Physician's choice according to patient's needs.|Routine care as per site standard.
79979919|NCT04507126|Biological|Bacillus Calmette-Guerin (BCG)|Vaccine
79979920|NCT04500600|Other|Quality-of-Life Assessment|Ancillary studies
79979921|NCT04500600|Other|Questionnaire Administration|Complete questionnaire
79979922|NCT04498832|Biological|High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
79329971|NCT04863365|Drug|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
79329972|NCT04847765|Device|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
79329973|NCT03104179|Device|Cytosorb Adsorber|Cytokine adsorption during CPB
79329974|NCT04855175|Device|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
79329975|NCT04855175|Other|Autograft|Patients in this arm will use patient's own bone
79329976|NCT05430997|Device|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
79329977|NCT05430997|Device|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
79329978|NCT05376423|Biological|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
79329979|NCT00484471|Drug|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
79329980|NCT00484471|Drug|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
79329981|NCT00484471|Drug|placebo|placebo to aripiprazole, 22 weeks
79329982|NCT03041051|Biological|PCV13|
79329983|NCT03041051|Biological|PPV23|
79329984|NCT03835273|Other|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
79811459|NCT00783484|Drug|PF-03716539|PF-03716539 25 mg oral solution, single dose
79329985|NCT03835273|Other|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
79329986|NCT03835273|Other|Questionnaires|Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system [7,8]
79329987|NCT03103945|Device|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
79329988|NCT05591547|Radiation|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
79811460|NCT00783484|Drug|PF-03716539|PF-03716539 3 mg oral solution, single dose
79650131|NCT04991272|Other|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
79650132|NCT02277886|Drug|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
79811461|NCT00783484|Other|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
79650133|NCT02277886|Drug|esomeprazole|40mg/tablet, one tablet once before breakfast
79811462|NCT00783484|Drug|PF-03716539|PF-03716539 100 mg oral solution, single dose
79811463|NCT00783484|Drug|PF-03716539|PF-03716539 200 mg oral solution, single dose
79650134|NCT00413751|Drug|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
79650135|NCT00210041|Drug|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
79811464|NCT00783484|Drug|PF-03716539|PF-03716539 50 mg oral solution, single dose
79811465|NCT00783484|Other|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
79650136|NCT00210041|Drug|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
79650137|NCT02278042|Other|Beverage Consumption|
79650138|NCT00237783|Drug|dialysate sodium (140 mmol/L)|
79811466|NCT00783484|Drug|Midazolam|Midazolam 1 mg IV, single dose
79811467|NCT00783484|Drug|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
79979923|NCT04498832|Biological|Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
79811468|NCT00783484|Drug|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
79979924|NCT04493424|Drug|Spesolimab|Spesolimab
79979925|NCT04491539|Behavioral|Finding Respect and Ending Stigma around HIV (FRESH)|The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
79979926|NCT04490018|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
79979927|NCT04490018|Biological|Meningococcal group A, C, W-135, and Y conjugate vaccine|Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
79811469|NCT00783484|Drug|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
79811470|NCT00783484|Drug|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
79811471|NCT00783484|Drug|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
79811472|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
79811473|NCT00783484|Drug|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
79811474|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
79979928|NCT04490018|Biological|Human Papillomavirus 9-valent Vaccine (9vHPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79979929|NCT04490018|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79483757|NCT00003345|Drug|irinotecan hydrochloride|
79483758|NCT03596905|Drug|Plecanatide|Taken orally daily for 4 weeks
79483759|NCT03596905|Drug|Matching placebo|Taken orally daily for 4 weeks
79811475|NCT00706290|Behavioral|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
79483760|NCT00003495|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79483761|NCT00003501|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79329989|NCT04847999|Dietary Supplement|Dark chocolate|Dark chocolate
79329990|NCT05430841|Diagnostic Test|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
79329991|NCT05375721|Procedure|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
79329992|NCT04863053|Other|Blood samples will be taken to assess platelet function. There is no change in treatment.|
79329993|NCT03104101|Combination Product|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
79329994|NCT03104101|Device|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
79329995|NCT05400525|Dietary Supplement|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
79329996|NCT05400525|Other|Placebo control|3g Maltodextrin (i.e. DE 10) daily
79329997|NCT03104023|Procedure|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
79329998|NCT03104023|Combination Product|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
79329999|NCT04847687|Drug|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
79330000|NCT05430685|Dietary Supplement|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
79330001|NCT05430685|Other|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
79483762|NCT04563403|Behavioral|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
79483763|NCT00002835|Biological|Bleomycin Sulfate (BLM)|
79483764|NCT00002835|Biological|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
79483765|NCT00002835|Biological|Recombinant Interferon Alfa|
79483766|NCT00002835|Drug|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
79483767|NCT00002835|Drug|Cisplatin (CDDP)|
79979930|NCT04488536|Diagnostic Test|Clinical Frailty Scale|Frailty assessment
79483768|NCT00002835|Drug|Cyclophosphamide|
79483769|NCT00002835|Drug|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
79979931|NCT04484909|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
79330002|NCT01729455|Biological|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
79483770|NCT00002835|Drug|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
79483771|NCT00002835|Drug|Idarubicin|
79483772|NCT00002835|Drug|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
79483773|NCT00002835|Drug|Leucovorin Calcium|
79483774|NCT00002835|Drug|Melphalan|
79483775|NCT00002835|Drug|Methotrexate|
79330003|NCT01729455|Other|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
79483776|NCT00002835|Drug|Methylprednisolone|
79330004|NCT04854473|Device|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~Smart drain - a surgical drain with added sensing electrodes~Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
79330005|NCT03101839|Drug|AZD4785|KRAS Antisense Oligonucleotide
79330006|NCT04428983|Dietary Supplement|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
79330007|NCT03103867|Device|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
79483777|NCT00002835|Drug|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
79650139|NCT00237783|Drug|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
79650140|NCT00210080|Drug|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
79330008|NCT03103867|Device|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
79650141|NCT04991662|Drug|metaraminol|Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
79650142|NCT04991662|Drug|Phenylephrine|Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
79330009|NCT04847375|Drug|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
79330010|NCT03103711|Behavioral|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
79650143|NCT04991662|Drug|Norepinephrine|Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
79650144|NCT04997941|Drug|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
79330011|NCT03044015|Behavioral|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
79330012|NCT03044015|Behavioral|as usual|
79330013|NCT05430607|Behavioral|Running therapy|A 9-week running program.
79650145|NCT04997941|Diagnostic Test|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
79650146|NCT04997941|Procedure|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
79650147|NCT00210158|Procedure|Nitrous oxyde|
79811476|NCT00700700|Device|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~Insync Sentry 7298 & 7299~Concerto C174 ASK (Most frequently implanted)~Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~Contak Renewal 4 H190 & H199~Contak Renewal 3 H127~Devices by ELA/Sorin:~1. Ovatio CRT 6750"
79979932|NCT04484909|Radiation|Radiation Therapy|Undergo radiation therapy
79483778|NCT00002835|Drug|Vincristine Sulfate|
79483779|NCT00002835|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
79330014|NCT04847219|Device|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
79330015|NCT04847219|Device|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
79483780|NCT00002835|Radiation|Radiation Therapy|
79483781|NCT00003351|Drug|irinotecan hydrochloride|
79483782|NCT00361153|Drug|Colesevelam hydrochloride|Welchol tablet 625mg
79483783|NCT00361153|Drug|placebo|placebo
79483784|NCT00002847|Biological|aldesleukin|
79483785|NCT00002847|Biological|recombinant interferon alfa|
79483786|NCT00002847|Procedure|conventional surgery|
79483787|NCT04342117|Drug|duvelisib|25 mg BID, 15 mg BID
79650148|NCT00413790|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
79650149|NCT00413790|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
79650150|NCT00413790|Drug|Placebo|Placebo tablet once daily
79650151|NCT04571710|Drug|SHR1258|Drug: SHR1258 400mg
79650152|NCT04993612|Diagnostic Test|Blood gas analysis|"Two blood samples will be drawn from the wedge position, behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later."
79330016|NCT03799861|Other|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
79979933|NCT04481204|Drug|Cisplatin|Given IV
79330017|NCT03799861|Other|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
79330018|NCT04847297|Procedure|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
79330019|NCT04847297|Procedure|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
79330020|NCT04737343|Drug|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
79330021|NCT04737343|Drug|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
79330022|NCT04480723|Other|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
79330023|NCT04480723|Diagnostic Test|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
79330024|NCT04862819|Drug|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
79330025|NCT04862819|Procedure|scaling root planing|In the second group, on one side of the dental arch srp will be performed
79330026|NCT03776149|Dietary Supplement|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
79330027|NCT03776149|Dietary Supplement|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
79330028|NCT04854239|Procedure|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
79330029|NCT05578911|Other|"medical students group"|medical student in general practice or in specialty medicine
79650153|NCT04995211|Device|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
79650154|NCT00210197|Procedure|Blood collection (pre and postoperative): plasma coagulation parameters|
79650155|NCT04999774|Diagnostic Test|Different diagnostic tests|Each SAC will be tested with all tests
79650156|NCT02962245|Drug|berberine|
79979934|NCT04481204|Drug|Fluorouracil|Given IV
79979935|NCT04481204|Drug|Gemcitabine|Given IV
79330030|NCT02724631|Device|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
79330031|NCT03760783|Other|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
79330032|NCT03754231|Other|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
79330033|NCT03754231|Other|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
79330034|NCT05400213|Device|Vallos|Demineralized freeze-dried bone allograft (DFBA) in a small particle form
79330035|NCT05400213|Device|Vallomix|A combination of cow-derived xenograft and human-derived DFDBA particulate
79330036|NCT05400213|Device|Vallos-F|Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
79330037|NCT05400213|Device|Vallomix-F|A combination of cow-derived xenograft and human-derived DFDBA fibers
79330038|NCT02609399|Drug|Oseltamivir|Oral
79650157|NCT02962245|Drug|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
79650158|NCT04992754|Behavioral|psychotherapy, lifestyle counseling|psychotherapy, lifestyle counseling
79979936|NCT04481204|Drug|Irinotecan|Given IV
79979937|NCT04481204|Drug|Leucovorin|Given IV
79979938|NCT04481204|Drug|Nab-paclitaxel|Given IV
79979939|NCT04481204|Drug|Oxaliplatin|Given IV
79979940|NCT04481204|Radiation|Radiation Therapy|Undergo RT
79979941|NCT04473690|Biological|Low Dose of KBP-COVID-19|Low Dose of KBP-COVID-19 and adjuvant
79330039|NCT02609399|Drug|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
79979942|NCT04473690|Biological|High Dose of KBP-COVID-19|High Dose of KBP-COVID-19 and adjuvant
79979943|NCT04473690|Biological|Placebo|Buffered saline solution
79979944|NCT04466007|Drug|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
79979945|NCT04466007|Drug|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
79979946|NCT04466007|Drug|Placebos|0,9% physiological saline
79979947|NCT04455139|Drug|Topotecan|intravitreal or intra-arterial administration of topotecan
79330040|NCT05430217|Drug|Buspirone|1 tablet (15 mg) once per day for 28 days
79979948|NCT04455139|Drug|Melphalan|intravitreal or intra-arterial administration of topotecan
79979949|NCT04439994|Other|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
79979950|NCT04439994|Other|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
79979951|NCT04439994|Procedure|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
79979952|NCT04420416|Other|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
79979953|NCT04404569|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
79330041|NCT05430217|Drug|Placebo|1 placebo tablet once per day for 28 days
79330042|NCT05430061|Dietary Supplement|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
79330043|NCT04853927|Drug|Proxalutamide|Proxalutamide 300mg q.d suspension
79330044|NCT04853927|Drug|Placebo|Proxalutamide 300mg q.d placebo
79330045|NCT03103555|Drug|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
79330046|NCT03103555|Drug|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
79330047|NCT04846751|Behavioral|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
79330048|NCT05417685|Device|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
79330049|NCT05417685|Device|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
79330050|NCT05417685|Device|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
79979954|NCT04387422|Other|Experimental hyperglycemia|Experimental hyperglycemia with MRI
79979955|NCT04338815|Other|Exoskeleton optimization|Participants will walk 10 times of 1 minute duration while an optimization algorithm changes the assistance profile of an exoskeleton.
79979956|NCT04338815|Other|Endurance evaluation|Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.
79979957|NCT04330833|Other|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
79979958|NCT04330833|Other|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
79979959|NCT04312113|Drug|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
79979960|NCT04311099|Drug|Active drug|Injection of Ropivacaine
79979961|NCT04311099|Drug|Placebo|Injection of Saline solution
79979962|NCT04311099|Procedure|Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
79330051|NCT04853771|Behavioral|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
79330052|NCT02720185|Drug|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
79330053|NCT02720185|Procedure|Conventional Surgery|Undergo surgery
79330054|NCT02720185|Other|Laboratory Biomarker Analysis|Correlative studies
79330055|NCT04846673|Drug|Pregabalin 150mg + Alpha-lipoic acid 480mg|Pregabalin qd + alpha-lipoic acid qd
79330056|NCT04846673|Drug|Pregabalin 150mg|pregabalin qd
79330057|NCT04846673|Drug|Alpha-Lipoic Acid 480mg|alpha-lipoic acid qd
79330058|NCT04846283|Procedure|Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure|We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
79330059|NCT05398497|Device|Cryoablation|Cryoablation will be performed under ultrasound guidance.
79330060|NCT03040739|Other|use of O'ARM imaging system|use of O'ARM imaging system
79330061|NCT04498273|Drug|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
79979963|NCT04311099|Procedure|Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
79979964|NCT04311099|Procedure|Injection of placebo - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block with saline solution
79330062|NCT04498273|Drug|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
79330063|NCT04498273|Drug|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
79483788|NCT04342117|Drug|PI3K inhibitor|FDA approved PI3K inhibitors
79811477|NCT04130750|Combination Product|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
79979965|NCT04311099|Procedure|Injection of placebo - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
79979966|NCT04296396|Drug|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
79979967|NCT04296396|Drug|Fixed opioid prescription|20 tablets of oxycodone 5mg
79979968|NCT04291352|Dietary Supplement|Taurine|675mg taurine four times daily
79979969|NCT04291352|Other|Placebo|placebo four times daily
79979970|NCT04261335|Biological|CL2020 cells|1.5 million or 15 million cells, IV on day 5 to 14 of birth
79979971|NCT04259658|Combination Product|Calcium electroporation|Patients with cutaneous metastases will be treated with calcium electroporation.
79650159|NCT04990180|Behavioral|Shared Decision Making Intervention|Decision coaching will be provided to the Pulmonary Rehabilitation Specialists to provide the skills needed to facilitate shared decision making between themselves and patients (and carers). The patient decision aid will be an informational booklet which describes the available Pulmonary Rehabilitation options at the University Hospitals of Leicester. It will detail the risks and benefits of each option and provide interactive sections to engage patients with the content, guide them through it, encourage them to attribute personal meaning and preference to each one so they can make an informed and values-based decision about PR.
79650160|NCT00210236|Procedure|Conventional surgery|
79650161|NCT04571398|Other|ApricityRx mobile application|AE detection and monitoring software
79650162|NCT00237822|Behavioral|Adherence Feedback (AF)|
79650163|NCT00237822|Behavioral|AF + Contingency Management (AF + CM)|
79650164|NCT00237822|Behavioral|AF + Motivational Enhancement Therapy (AF + MET)|
79979972|NCT04257526|Behavioral|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
79979973|NCT04251715|Drug|Dexamethasone|Given intraarterially via HAI pump
79979974|NCT04251715|Drug|Floxuridine|Given intraarterially via HAI pump
79979975|NCT04251715|Device|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
79811478|NCT00783562|Other|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
79811479|NCT00783562|Other|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
79811480|NCT00783640|Drug|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
79483789|NCT00003357|Biological|GM2-KLH vaccine|
79483790|NCT00003357|Biological|QS21|
79650165|NCT04571203|Biological|Combined Deceased Donor Kidney and Hematopoietic Cell Transplants|This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
79650166|NCT00210275|Behavioral|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
79650167|NCT01059903|Drug|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
79811481|NCT00851786|Biological|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
79811482|NCT00851786|Biological|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
79811483|NCT00665626|Drug|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
79811484|NCT00665626|Drug|Placebo|Placebo, orally, twice-a-day
79979976|NCT04251715|Drug|Irinotecan|Given IV
79979977|NCT04251715|Drug|Leucovorin|Given IV
79979978|NCT04251715|Drug|Oxaliplatin|Given IV
79979979|NCT04251715|Other|Quality-of-Life Assessment|Ancillary studies
79330064|NCT04498273|Drug|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
79330065|NCT04853615|Drug|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
79330066|NCT04853537|Dietary Supplement|intermittent fasting diet|intermittent fasting diet to obese pregnant women >30 BMI and incidence of gestational diabetes
79330067|NCT02526693|Diagnostic Test|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
79979980|NCT04246515|Device|Blood Flow Restriction Training|Vascular occlusion of the injured limb.
79330068|NCT04440475|Procedure|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
79330069|NCT05573607|Dietary Supplement|Placebo|Maltodextrin tablet
79811485|NCT04116944|Behavioral|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
79979981|NCT04246515|Device|Sham Blood Flow Restriction Training|Blood Flow Restriction material will be attached to the limb without vascular occlusion.
79979982|NCT04246515|Other|Classic rehabilitation|Classic rehabilitation protocol after a hamstring injury consisiting out of stretching, strength, core stability,...
79979983|NCT04235764|Device|modified resectoscope|The modified resectoscope will be used post cystectomy (En-bloc TURBT) to resect areas of the tumor from the cystectomy specimen. These resected tumors will be sent for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation and compared to the remainder of the cystectomy specimens to see if the modified resectoscope can provide improved pathologic standards for the TURBT procedure.
79979984|NCT04235764|Procedure|TURBT|All patients will receive routine surgical transurethral resection of bladder tumors (TURBT).
79979985|NCT04220021|Drug|Metformin|Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
79979986|NCT04214873|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
79979987|NCT04202393|Behavioral|Integrated Treatment Adherence Program (ITAP)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
79979988|NCT04202393|Behavioral|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced assessment and evaluation with clinician feedback.
79979989|NCT04193306|Drug|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
79330070|NCT05573607|Dietary Supplement|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
79483791|NCT04208139|Diagnostic Test|IVUS|IVUS
79979990|NCT04193306|Other|Placebo|Placebo s.c. every 2 weeks
79979991|NCT04180241|Procedure|POEM|Peroral endoscopic myotomy
79979992|NCT04155099|Biological|RBX7455|RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
79650168|NCT04996771|Drug|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
79330071|NCT04435483|Drug|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
79330072|NCT04435483|Drug|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
79330073|NCT04435483|Drug|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
79330074|NCT05372445|Behavioral|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
79483792|NCT00003513|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79650169|NCT04996771|Drug|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
79650170|NCT04996615|Other|no intervention|no intervention
79650171|NCT00210314|Drug|high dose methotrexate|
79650172|NCT00210314|Drug|high dose cytarabine|
79650173|NCT00210314|Radiation|radiotherapy|
79650174|NCT04990024|Other|Dietary Intervention Med Diet|The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and group educational sessions on Med diet. During the group sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.
79650175|NCT04990024|Other|Dietary Intervention HP/LC Diet|This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to <130 g/d. The intervention consists of group educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
79650176|NCT04990024|Other|Dietary Intervention LF Diet|In this arm, participants will be advised to follow a calorie restricted LF diet with 500 Kcal/d energy restriction. Group and individual educational sessions will be held at the same frequency as the Med and HP/LC diets, and will have a similar content but targeting LF diet.
79650177|NCT04999501|Other|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
79650178|NCT00210392|Drug|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
79650179|NCT04990882|Other|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
79650180|NCT00413829|Drug|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
79650181|NCT04999267|Other|INVEST|The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.
79979993|NCT04155099|Biological|Placebo|Capsule with cellulose filler
79330075|NCT05372445|Behavioral|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
79330076|NCT05425849|Other|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
79330077|NCT04846205|Diagnostic Test|systematic etiological|"Theses following tests are made as usual practice :~Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~Transoesophageal ultrasound"
79330078|NCT03103633|Procedure|mean artery pressure|mean artery pressure declined with less than 20% of baseline
79979994|NCT04151550|Device|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
79330079|NCT03103633|Procedure|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
79330080|NCT03103633|Procedure|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
79330081|NCT03103633|Other|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
79330082|NCT04862039|Device|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
79330083|NCT04862117|Device|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
79330084|NCT03691909|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
79330085|NCT04861649|Biological|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
79330086|NCT03040817|Procedure|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
79330087|NCT03040817|Drug|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
79650182|NCT04993534|Behavioral|Stepped-care DWM/PM+|"The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support."
79811486|NCT04116944|Other|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
79811487|NCT00828672|Drug|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
79811488|NCT00828672|Drug|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
79979995|NCT04148352|Drug|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
79811489|NCT00828672|Drug|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
79307554|NCT03567018|Device|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
79979996|NCT04148352|Other|Placebo|Placebo injected every 2 weeks for 18 weeks
79979997|NCT04141995|Drug|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
79979998|NCT04141995|Drug|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
79979999|NCT04141995|Drug|Calcium Leucovorin|IV injection over 90 minutes
79980000|NCT04141995|Drug|Irinotecan|IV administration over 90 minutes
79980001|NCT04141995|Drug|Oxaliplatin|IV administration
79330088|NCT05416749|Drug|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
79330089|NCT05423431|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
79330090|NCT04853303|Device|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
79330091|NCT05412355|Procedure|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
79330092|NCT04853069|Drug|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
79330093|NCT04259853|Procedure|PCI|Revascularization on non culprit vessel
79330094|NCT05245279|Diagnostic Test|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
79330095|NCT05245279|Diagnostic Test|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
79330096|NCT04852913|Other|Bowen's Technique|The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
79330097|NCT04852913|Other|Convention Physical Therapy|"Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week"
79330098|NCT05397561|Other|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
79330099|NCT04846049|Other|Comprehensive Care|"Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~Care Planning with Interdisciplinary Team~Care coordination~Co-management with Primary care~Social work needs assessment~Patient-centered telehealth using phone, home telehealth, patient portal, Video~Transportation provided for all visits~Referral to Geriatric primary care clinic and mental health per Veteran need~Goals of Care and Veteran preferences conversation~Educate primary care providers about HNHR population, home and community based services, collaboration"
79330100|NCT04846049|Other|Standard Care|No intervention or treatment will be provided.
79330101|NCT03685045|Procedure|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
79330102|NCT04845971|Dietary Supplement|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
79330103|NCT05245045|Procedure|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
79330104|NCT05245045|Procedure|Red light|Red light
79307555|NCT03556891|Device|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
79483793|NCT03576001|Drug|Testosterone Undecanoate|administered through injections by study staff
79811490|NCT00828672|Radiation|radiotherapy|Total dose 45Gy
79980002|NCT04136054|Behavioral|Adjusted group CBT-i for Anxiety and Affective disorders|Adjusted group CBT-i for Anxiety and Affective disorders. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
79980003|NCT04136054|Other|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
79330105|NCT03663595|Other|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
79330106|NCT03663595|Other|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
79980004|NCT04134559|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
79330107|NCT04846361|Other|Vaginal hygiene wash|vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
79483794|NCT03576001|Behavioral|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
79483795|NCT03568201|Diagnostic Test|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
79483796|NCT04220827|Drug|Paclitaxel|Given IP
79980005|NCT04130529|Behavioral|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
79483797|NCT03567109|Other|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
79650183|NCT04993534|Other|Psychological First Aid + usual care (CAU)|All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
79650184|NCT02210104|Drug|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
79650185|NCT02210104|Drug|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
79811491|NCT04130984|Device|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
79811492|NCT02612870|Device|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
79811493|NCT02612870|Device|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
79307556|NCT03535506|Drug|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
79307557|NCT03533283|Drug|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
79307558|NCT03533283|Drug|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
79307559|NCT03533283|Drug|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
79307560|NCT03533283|Drug|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
79307561|NCT03533283|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
79307562|NCT03533283|Drug|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
79307563|NCT03519659|Diagnostic Test|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
79307564|NCT03519659|Diagnostic Test|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
79307565|NCT03519659|Diagnostic Test|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
79307566|NCT03519659|Diagnostic Test|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
79307567|NCT03519659|Diagnostic Test|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
79307568|NCT03516994|Behavioral|Respecting Choices First Steps|Advance Care Planning Approach
79307569|NCT03516994|Behavioral|Five Wishes Form|Advance Care Planning Approach
79307570|NCT03505762|Drug|Cyclophosphamide|Given IV
79307571|NCT03505762|Drug|Doxorubicin Hydrochloride|Given IV
79307572|NCT03505762|Other|Laboratory Biomarker Analysis|Correlative studies
79307573|NCT03505762|Drug|Prednisone|Given PO
79307574|NCT03505762|Other|Quality-of-Life Assessment|Ancillary correlative
79307575|NCT03505762|Other|Questionnaire Administration|Ancillary studies
79307576|NCT03505762|Biological|Rituximab|Given IV
79307577|NCT03505762|Drug|Vincristine Sulfate|Given IV
79307578|NCT03494335|Other|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
79307579|NCT03491059|Drug|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
79307580|NCT03491059|Radiation|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
79307581|NCT03491046|Device|PET scan|low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence
79307582|NCT03491046|Device|MRI scan|standard of care MRI
79307583|NCT03490812|Diagnostic Test|PET scan|Investigational PET scan as add-on to standard-of-care scan
79307584|NCT03490812|Other|Retrospective data analysis|Review of pre-existing data from January 1, 2001 through December 5, 2017
79307585|NCT03490656|Diagnostic Test|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
79307586|NCT03490656|Diagnostic Test|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
79307587|NCT03486444|Diagnostic Test|Phillips Lumify Diagnostic Ultrasound System|portable ultrasound device
79307588|NCT03486444|Other|Surveys|surveys assessing perception of ultrasound
79307589|NCT03484923|Drug|PDR001|400 mg of PDR001 administered every 4 weeks intravenously
79307590|NCT03484923|Drug|LAG525|600 mg of LAG525 administered every 4 weeks intravenously
79330108|NCT04846361|Other|placebo wash|placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
79330109|NCT04429373|Procedure|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
79330110|NCT04429373|Procedure|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
79330111|NCT05371977|Procedure|Trabeculectomy|trabeculectomy glaucoma surgery
79330112|NCT05371977|Procedure|Deep Sclerectomy|deep sclerectomy glaucoma surgery
79330113|NCT05244811|Drug|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
79483798|NCT04159857|Procedure|Fetal head extraction technique during the cesarean section|see above for the description about one-hand and two-hand fetal head extraction technique
79650186|NCT02210104|Biological|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10^10 cells/m^2 on Day 0.
79650187|NCT00234663|Drug|PTC124|
79483799|NCT00002865|Biological|filgrastim|
79650188|NCT02210182|Drug|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
79811494|NCT02612870|Device|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
79483800|NCT00002865|Drug|cyclophosphamide|
79650189|NCT02210182|Other|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
79650190|NCT00210509|Drug|almotriptan malate|
79650191|NCT02210260|Procedure|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
79811495|NCT02612870|Device|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
79811496|NCT02612870|Device|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
79330114|NCT05244811|Drug|Progestin|effect of progestin in treatment of ovarian cystn
79330115|NCT04845659|Drug|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
79330116|NCT03614611|Device|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
79483801|NCT00002865|Drug|cytarabine|
79483802|NCT00002865|Drug|dexamethasone|
79483803|NCT00002865|Drug|doxorubicin hydrochloride|
79483804|NCT00002865|Drug|etoposide|
79483805|NCT00002865|Drug|ifosfamide|
79483806|NCT00002865|Drug|leucovorin calcium|
79483807|NCT00002865|Drug|mesna|
79483808|NCT00002865|Drug|methotrexate|
79483809|NCT00002865|Drug|therapeutic hydrocortisone|
79483810|NCT00002865|Drug|vincristine sulfate|
79483811|NCT00002865|Radiation|low-LET cobalt-60 gamma ray therapy|
79330117|NCT04845581|Procedure|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT &gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT &gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
79650192|NCT02210260|Procedure|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
79650193|NCT02210260|Drug|Bupivacaine|
79650194|NCT02210260|Drug|Diamorphine|500mcg
79650195|NCT02210260|Device|A Painbuster® catheter|
79330118|NCT05404555|Other|two-dimensional speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients
79330119|NCT03043859|Behavioral|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
79330120|NCT02710669|Drug|(R)-propafenone|
79330121|NCT02710669|Drug|(S)-Propafenone|
79650196|NCT02210260|Device|25G Whitacre needle|
79330122|NCT02710669|Drug|Placebo|
79330123|NCT01649661|Behavioral|questionnaire|
79330124|NCT04844645|Other|mini program|To design, construct, and test the mini program in patients managing cancer pain
79330125|NCT04844645|Other|conventional pharmaceutical care|conventional pharmaceutical care
79330126|NCT02693041|Drug|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
79330127|NCT02693041|Drug|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
79650197|NCT02210299|Other|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
79330128|NCT04851743|Other|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
79330129|NCT05392959|Drug|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
79330130|NCT05392959|Drug|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
79330131|NCT04851977|Biological|Respiratory Syncytial Vaccine|BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo [saline/mannitol] by IM injection to the deltoid region of the other arm, given sequentially).
79330132|NCT04851977|Biological|Respiratory Syncytial Vaccine|BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm [one injection of 10 μg rRSV-G protein/10 μg CsA per arm], given sequentially). The high dose is twice the strength of the low dose.
79330133|NCT04851977|Biological|Placebo|Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm [one injection per arm], given sequentially).
79650198|NCT02210338|Device|Karl Storz C-MAC|
79650199|NCT02210338|Device|Bonfils Intubation Fibrescope|
79650200|NCT00234702|Drug|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
79650201|NCT00234702|Drug|Placebo|Placebo
79650202|NCT00210548|Drug|paliperidone palmitate|
79650203|NCT04571359|Other|Oxalate to creatinine ratio|Comparsion between 24 hours urine oxalate and spot urine oxalate to creatinine ratio
79650204|NCT04570735|Diagnostic Test|MRI|MRI
79650205|NCT04570813|Other|Artistic activies|12 workshops of artictic activities during 12 weeks
79811497|NCT00784888|Other|Aromatase inhibitors|non-interventional study
79980006|NCT04130529|Other|Sleep lectures|Lectures on the topic of sleep.
79330134|NCT04851431|Behavioral|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
79330135|NCT04851665|Other|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
79330136|NCT05370417|Other|Use of fluoride toothpaste|All participants will receive brushing instruction and will be provided with toothpaste with a concentration equal to or greater than 1000ppm of fluoride, indicating three daily brushings. With this generalized measure, all of them receive basic treatment for hypersensitivity.
79483812|NCT00002865|Radiation|low-LET photon therapy|
79650206|NCT00234741|Drug|STA-5326 mesylate|
79650207|NCT00210587|Drug|epoetin alfa|
79650208|NCT04570696|Other|NON INTERVENTIONAL|NON INTERVENTIONAL
79650209|NCT04570540|Diagnostic Test|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
79330137|NCT05370417|Radiation|Laser Therapy|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Applied in three perpendicular points and in contact with the surface. One in the vestibular, mesial and distal cervical third and the third in the center of the lesion. (6) Applied 10 seconds per point with an energy of 1 J."
79330138|NCT05370417|Procedure|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
79330139|NCT05370417|Procedure|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
79330140|NCT03043781|Other|Continuous epidural infusion|Continuous infusion, 5 ml/h
79330141|NCT03043781|Other|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
79650210|NCT04570540|Diagnostic Test|Pulmonary Function Test|Bodyplethysmographic assessment
79650211|NCT04570540|Diagnostic Test|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
79650212|NCT04570540|Diagnostic Test|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
79650213|NCT04570462|Other|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
79650214|NCT00234780|Procedure|pediatric nursing used in home to avoid hospitalization|
79330142|NCT03043937|Other|registry|
79330143|NCT05369949|Drug|DEX group|Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
79330144|NCT05369949|Other|Control group|Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
79330145|NCT03043703|Device|AirSense 10 AutoSet for Her|Positive airway pressure
79330146|NCT03043625|Other|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
79330147|NCT03043625|Other|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
79330148|NCT04423185|Drug|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
79330149|NCT04423185|Drug|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
79330150|NCT04423185|Drug|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
79330151|NCT04423185|Drug|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
79650215|NCT00210665|Drug|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
79811498|NCT00706368|Device|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
79811499|NCT00873119|Drug|belinostat, carboplatin, paclitaxel|
79330152|NCT04423185|Drug|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
79811500|NCT00873119|Drug|carboplatin, paclitaxel|
79811501|NCT00661726|Drug|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
79811502|NCT00865046|Other|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
79307591|NCT03484923|Drug|INC280|400 mg of INC280 administered twice daily orally
79307592|NCT03484923|Drug|ACZ885|200 mg of ACZ885 administered every 4 weeks subcutaneosuly
79307593|NCT03484923|Drug|LEE011|600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
79980007|NCT04107675|Drug|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
79650216|NCT04570189|Device|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
79650217|NCT04570345|Drug|ticagrelor monotherapy|• Drug: ticagrelor monothearpy after first 3 months dual therapy
79650218|NCT04570345|Drug|Aspirin with P2Y12 receptor inhibitor|• Drug: aspirin plus ticagrelor dual therapy during 12 months
79650219|NCT04570228|Device|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
79811503|NCT00865046|Other|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
79811504|NCT00706680|Drug|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
79980008|NCT04107675|Drug|Liposomal Placebo|Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
79650220|NCT04570228|Device|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
79650221|NCT04570072|Dietary Supplement|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
79650222|NCT04570072|Dietary Supplement|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
79650223|NCT00234819|Drug|Bazedoxifene/Conjugated Estrogen|
79650224|NCT00210704|Drug|Dapoxetine|
79811505|NCT02624999|Biological|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
79980009|NCT04095234|Procedure|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
79980010|NCT04095234|Procedure|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
79980011|NCT04058028|Drug|Rozibafusp Alfa|Rozibafusp Alfa will be presented in 5 mL glass vial
79650225|NCT04570306|Drug|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
79650226|NCT04570033|Diagnostic Test|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
79811506|NCT02624999|Drug|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
79811507|NCT02612480|Drug|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
79811508|NCT02612480|Drug|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
79811509|NCT02612480|Drug|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
79811510|NCT02612480|Drug|Placebo|7 day treatment with placebo
79811511|NCT00784966|Drug|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
79980012|NCT04058028|Drug|Placebo for Rozibafusp Alfa|Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
79330153|NCT04423185|Drug|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
79330154|NCT04423185|Drug|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
79330155|NCT04423185|Drug|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
79330156|NCT04423185|Drug|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
79330157|NCT04423185|Drug|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
79330158|NCT04423185|Drug|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
79330159|NCT04851275|Behavioral|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
79330160|NCT04851275|Behavioral|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
79330161|NCT04851041|Other|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
79330162|NCT04851041|Other|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
79330163|NCT04851197|Other|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
79330164|NCT03040271|Other|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
79330165|NCT04423419|Procedure|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
79980013|NCT04031209|Device|G7 Acetabular System|All patients will receive G7 Acetabular System
79980014|NCT04021459|Procedure|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~One on the arm vein (peripheral)~One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
79980015|NCT04003038|Procedure|Negative Pressure Wound Therapy|Receive wound care with NPWT
79980016|NCT04003038|Procedure|Wound Care Management|Receive wound care with a standard dressing (bandage)
79980017|NCT03999320|Other|Sophrology sessions|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
79980018|NCT03999320|Other|usual care|usual care
79980019|NCT03982082|Procedure|Physical Therapy|Undergo physical therapy
79980020|NCT03982082|Other|Questionnaire Administration|Ancillary studies
79980021|NCT03982082|Procedure|Ultrasound|Undergo ultrasound via MuscleSound technology
79330166|NCT04423419|Procedure|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
79330167|NCT04423419|Other|IV analgesia|IV analgesia
79330168|NCT04850885|Drug|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
79330169|NCT04851353|Behavioral|GT+VC|Gentle touch and verbal comfort,
79330170|NCT04851353|Behavioral|Smell|Smell breast milk
79330171|NCT04851353|Behavioral|Taste|Taste breast milk
79811512|NCT00784966|Drug|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
79483813|NCT04192357|Behavioral|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
79483814|NCT04192357|Behavioral|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
79980022|NCT03959215|Behavioral|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
79330172|NCT03043391|Biological|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
79330173|NCT04844177|Other|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~Cyclophosphamide 120 mg/kg (days -5, -4, -3)~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~Melphalan 180 mg/m2 (day -2)~Rituximab 100 mg/m2 (day -1)~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
79330174|NCT04844255|Dietary Supplement|dietary salt|2 grams of dietary salt
79330175|NCT04843865|Dietary Supplement|Chinese Herbs|Chinese Herbs
79330176|NCT02610725|Other|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
79330177|NCT04850417|Drug|Beta blocker, aspirin, clopidogrel|Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
79330178|NCT04843943|Drug|Sintilimab|Sintilimab: 200mg IV Q3W D1
79811513|NCT00828516|Other|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
79811514|NCT02623595|Radiation|Stereotactic body radiotherapy|A type of radiation therapy
79980023|NCT03959215|Other|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
79980024|NCT03915405|Drug|KHK2455|orally, once daily.
79330179|NCT04843943|Drug|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
79307594|NCT03479502|Drug|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
79307595|NCT03479502|Drug|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
79307596|NCT03471364|Drug|Ketoconazole|Applied topically
79330180|NCT04850261|Drug|hCG Injection|Ovulation will be induced by subcutaneous hCG injection
79330181|NCT04850261|Drug|Nafarelin nasal spray|Ovulation will be induced by nasal application of Nafarelin
79330182|NCT04850027|Procedure|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
79811515|NCT02623595|Drug|rhGM-CSF|Immune modulating agents
79980025|NCT03915405|Drug|Avelumab|IV Administration
79980026|NCT03883048|Other|Observation of bronchiectasis with pulmonary hypertension|
79330183|NCT04850183|Behavioral|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
79330184|NCT04849949|Other|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
79980027|NCT03851003|Procedure|Endometrial suturing|Suturing will include endometrium during cesarean incision repair
79330185|NCT04849949|Other|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
79330186|NCT04849949|Other|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
79330187|NCT04843553|Drug|Oral Nicotinamide|
79330188|NCT02684461|Drug|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
79330189|NCT04843475|Diagnostic Test|Echocardiography|Trans-thoracic Echocardiography
79330190|NCT03040193|Drug|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
79330191|NCT03040193|Drug|Saline Nebulization|Normal Saline Delivered via Nebulization
79330192|NCT03039101|Procedure|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
79980028|NCT03851003|Procedure|Non- endometrial suturing|Suturing will not include endometrium during cesarean incision repair
79330193|NCT03039101|Procedure|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
79330194|NCT03039101|Procedure|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
79330195|NCT03039101|Procedure|Peripheral blood|Peripheral blood draw
79330196|NCT03039101|Drug|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
79330197|NCT03039101|Drug|Placebo Oral Tablet|one pill orally, daily, for 1 week
79330198|NCT03604393|Behavioral|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
79330199|NCT03043469|Other|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
79330200|NCT03043469|Other|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
79330201|NCT03043469|Other|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
79330202|NCT03043469|Other|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
79330203|NCT03043469|Other|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
79330204|NCT03043469|Other|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
79330205|NCT03043469|Other|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
79330206|NCT03043469|Other|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
79483815|NCT00361309|Drug|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
79980029|NCT03851003|Device|Vaginal ultrasonography|All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar
79980030|NCT03851003|Other|Questionnaire|All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
79980031|NCT03829254|Drug|NUC-7738|NUC-7738
79980032|NCT03829254|Drug|Pembrolizumab|Pembrolizumab
79980033|NCT03826589|Drug|Avelumab|an anti-programmed cell death ligand 1
79980034|NCT03826589|Drug|Axitinib|a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
79980035|NCT03823573|Behavioral|Walk within 24 hours|Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
79330207|NCT03043469|Other|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
79650227|NCT04569721|Device|CT Guided Splanchnic Cryoablation|The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
79980036|NCT03803696|Behavioral|Enhanced Standard Care|"Baseline data collection, registration and randomization~Inform primary transplant clinician of sexual dysfunction causing distress~Receive American Cancer Society sexual educational material"
79307597|NCT03471364|Other|Laboratory Biomarker Analysis|Correlative studies
79307598|NCT03471364|Other|Placebo Administration|Applied topically
79307599|NCT03471364|Other|Quality-of-Life Assessment|Ancillary studies
79307600|NCT03471364|Other|Questionnaire Administration|Ancillary studies
79330208|NCT03043469|Other|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
79330209|NCT03043469|Diagnostic Test|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
79330210|NCT03043469|Other|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
79330211|NCT03043469|Other|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
79330212|NCT03043469|Other|Breath-hold test|Holding the breath a few times for as long as possible.
79330213|NCT03043469|Other|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
79330214|NCT03043469|Other|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
79330215|NCT03103399|Drug|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
79330216|NCT03103399|Drug|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
79330217|NCT03103399|Drug|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
79330218|NCT03103399|Drug|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
79483816|NCT04154943|Drug|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
79650228|NCT00234858|Drug|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
79650229|NCT00234858|Drug|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
79650230|NCT04569955|Behavioral|Knowledge and perception of clinical trial participation|This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries
79980037|NCT03803696|Behavioral|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~- 3 Monthly visits with trained study nurse practitioners~Referral to specialist if~Psychological etiology~Sexual Trauma~Relationship Discord~Concern for Malignancy or anatomic scarring requiring surgery"
79980038|NCT03788980|Procedure|Carotid endarterectomy|Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)
79330219|NCT03038945|Other|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
79330220|NCT03038945|Other|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
79330221|NCT03043157|Drug|rocuronium|intravenous rocuronium infusion
79330222|NCT05339113|Diagnostic Test|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
79330223|NCT04843163|Behavioral|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
79330224|NCT03103477|Other|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
79330225|NCT04840433|Device|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
79330226|NCT05332795|Drug|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
79330227|NCT05332795|Drug|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
79330228|NCT03040349|Behavioral|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
79330229|NCT03040349|Behavioral|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
79330230|NCT03040349|Behavioral|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
79330231|NCT05224453|Other|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d)
79330232|NCT05224453|Other|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (<1 g/kg aBW/d)
79330233|NCT05218837|Other|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
79650231|NCT04569838|Drug|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
79980039|NCT03788980|Diagnostic Test|Mini Mental Status Examination|Short questionnaire used to diagnose cognitive dysfunction
79980040|NCT03781414|Biological|CFZ533|Comparison with standard of care immunosuppression
79307601|NCT03461159|Other|Operant conditioning of H-reflexes|Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
79980041|NCT03781414|Drug|Tacrolimus - MMF - corticosteroids|Standard of care immunosupprevive regimen
79980042|NCT03757481|Other|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
79330234|NCT05211193|Device|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
79330235|NCT03042923|Drug|lactulose:mannitol (L:M) oral challenge|
79330236|NCT05178355|Drug|KVD824|Active
79330237|NCT05178355|Drug|Placebo to KVD824|Placebo
79811516|NCT04135001|Behavioral|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore & Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
79811517|NCT04135001|Other|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
79811518|NCT00665392|Drug|cisplatin|75 mg/m², day 1. 3 cycles
79330238|NCT04429295|Biological|DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
79330239|NCT04429295|Biological|DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
79330240|NCT04429295|Biological|Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
79330241|NCT04429295|Biological|Poliomyelitis Vaccine bivalent types 1 and 3|Pharmaceutical form:Oral suspension Route of administration: Oral
79330242|NCT04429295|Biological|Human Rotavirus, live attenuated|Pharmaceutical form:Oral suspension Route of administration: Oral
79330243|NCT04429295|Biological|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
79330244|NCT05258851|Drug|Ceftazidime-avibactam|Experimental
79330245|NCT05258851|Drug|Colistin|Control
79650232|NCT00210743|Drug|epoetin alfa|
79811519|NCT00665392|Drug|docetaxel|75 mg/m² Day 1. 3 cycles
79811520|NCT00665392|Drug|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
79811521|NCT00665392|Drug|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
79330246|NCT04843085|Other|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
79483817|NCT00361387|Drug|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
79483818|NCT00003369|Drug|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
79330247|NCT03103243|Behavioral|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
79330248|NCT03043001|Drug|Memantine|All the subjects will receive add-on memantine for 12 week
79330249|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
79330250|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
79330251|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
79330252|NCT04843007|Drug|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m2
79330253|NCT04840745|Drug|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
79330254|NCT04840745|Drug|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
79330255|NCT04840745|Drug|CKD-841 D 2.92mg|Single injection, subcutaneous injection
79330256|NCT04840745|Drug|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
79330257|NCT04842851|Device|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
79330258|NCT05073757|Device|Personalized guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with personalized guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
79330259|NCT04840355|Drug|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
79483819|NCT00003369|Drug|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
79811522|NCT00851630|Drug|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
79330260|NCT04435405|Other|Observational|video footage analysis of group and individual behavioral processes.
79330261|NCT04842695|Device|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
79330262|NCT05073289|Behavioral|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
79330263|NCT05073289|Other|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
79330264|NCT04840043|Other|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
79330265|NCT04840043|Other|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
79330266|NCT04534933|Device|Evone|Airway ventilation device
79483820|NCT04342351|Drug|sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
79483821|NCT04342351|Drug|perindopril|Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
79483822|NCT04342351|Other|Cardiopulmonary Exercise Test|All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
79483823|NCT04342351|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
79483824|NCT04342273|Drug|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
79483825|NCT04342273|Drug|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
79483826|NCT04342273|Drug|Placebo|Placebo will be administered once daily at Day 1 through Day 7
79330267|NCT04534933|Device|Primus|Airway ventilation device
79330268|NCT04842617|Drug|SHR6390|SHR6390 combined with endocrine therapy
79330269|NCT04842617|Drug|placebo|placebo combined with endocrine therapy
79330270|NCT04860557|Other|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A & B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
79980043|NCT03724331|Behavioral|Light Physical Activity 1|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital."
79330271|NCT05073211|Procedure|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
79650233|NCT04569916|Radiation|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
79330272|NCT04842539|Other|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
79330273|NCT04842539|Other|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
79330274|NCT05072899|Procedure|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
79330275|NCT05072899|Procedure|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
79330276|NCT02647645|Device|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
79811523|NCT04130594|Biological|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
79980044|NCT03724331|Behavioral|Light Physical Activity 2|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital."
79980045|NCT03724331|Behavioral|Support Education Activity|"Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day."
79980046|NCT03717753|Other|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
79980047|NCT03704363|Drug|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
79980048|NCT03704363|Other|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
79330277|NCT02647645|Procedure|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
79330278|NCT02647645|Device|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
79330279|NCT04842305|Diagnostic Test|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
79330280|NCT04839653|Drug|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
79330281|NCT04839653|Drug|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
79330282|NCT04839653|Drug|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
79483827|NCT04342273|Drug|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
79650234|NCT04569916|Drug|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
79650235|NCT04569916|Drug|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
79650236|NCT04569916|Drug|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
79650237|NCT04569643|Diagnostic Test|Actigraphy|Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
79650238|NCT04569643|Diagnostic Test|Cardiorespiratory monitoring|All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
79811524|NCT04130594|Other|placebo|placebo
79811525|NCT04135157|Procedure|Pectoralis nerve block II|PECS II block will be performed 30 min. before general anesthesia.
79330283|NCT05072587|Behavioral|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
79330284|NCT05072587|Behavioral|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
79330285|NCT04842149|Dietary Supplement|Bif195 capsules|1 capsule daily for 8 weeks
79330286|NCT04842149|Dietary Supplement|Placebo capsules|1 capsule daily for 8 weeks
79330287|NCT04919941|Other|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
79330288|NCT04839263|Procedure|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~Hospitalization on surgery day~No prolonged fasting~Perioperative strategy:~Pain control based on limited systemic opioid therapy use~Anti-nausea prophylaxis~Anaesthesia via IV propofol / remifentanyl~Bladder catheter removal postoperative~Postoperative strategy:~Pain control using balanced analgesia~Gum chewing~Early oral refeeding and rapid mobilization~Venflon removal 6 hours post-op"
79330289|NCT04353895|Device|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
79330290|NCT04353895|Device|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
79330291|NCT04842383|Drug|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
79980049|NCT03701334|Drug|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
79980050|NCT03701334|Other|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
79980051|NCT03689179|Behavioral|Time for Living and Caring (TLC)|"Time for Living & Caring (TLC) is an online, self-administered intervention. It includes three types of modules: a virtual coaching module (defined as a series or prompts, reminders, and suggestions delivered electronically through an interactive calendar website) that guides caregivers through assessment, goal setting, and goal review activities using an interactive calendar for each planned respite period they have. Supplementary modules provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?. Optional modules include interactive online forum, peer-to-peer chat functions, and videos or messages to provide daily affirmation, inspiration, and humor for caregivers."
79330292|NCT05072353|Device|SEFFICARE|"The SEFFI is a 5-step technique:~Preparation: the lower/lateral abdomen is chosen as the donor site.~Anesthesia: the donor site is injected with a local anesthetic.~Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
79811526|NCT04135157|Procedure|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
79811527|NCT04135157|Other|Control|Only general anesthesia will be performed.
79811528|NCT00784108|Device|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
79980052|NCT03681483|Drug|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
79980053|NCT03672461|Other|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
79980054|NCT03672461|Other|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants."
79980055|NCT03620617|Dietary Supplement|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
79330293|NCT04884139|Drug|Dolutegravir/Lamivudine as a single pill|- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
79330294|NCT04884139|Drug|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~Route of adminstration: oral~Schedule of administration: once a day for 96 weeks."
79330295|NCT04860167|Drug|Propofol|Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
79330296|NCT04860167|Drug|Diclofenac Sodium and Lignocaine 10 % spray|Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
79330297|NCT04841993|Drug|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
79330298|NCT04841993|Drug|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
79330299|NCT04841993|Drug|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
79330300|NCT05072431|Other|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
79330301|NCT04839341|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
79330302|NCT05071885|Other|games based exercise|Range of motion and strengthening exercises
79330303|NCT04841915|Dietary Supplement|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
79330304|NCT04841915|Behavioral|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
79650239|NCT04569643|Diagnostic Test|Neuroimaging|All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
79811529|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
79330305|NCT04841915|Behavioral|Weight loss|4 weeks eucaloric diet ~13 MJ/day followed by, 20 weeks hypocaloric diet ~9 MJ/day until 5% weight loss is achieved.
79330306|NCT02514031|Drug|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
79330307|NCT02514031|Drug|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
79330308|NCT02514031|Drug|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
79330309|NCT04841603|Device|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
79330310|NCT04841603|Device|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
79330311|NCT04823533|Dietary Supplement|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
79330312|NCT03042845|Device|Tiger cardiac catheter|Tiger cardiac catheter
79330313|NCT03042845|Device|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
79330314|NCT02473549|Device|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
79330315|NCT02473549|Device|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
79330316|NCT02473549|Device|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
79650240|NCT04569643|Other|Assessment of cognitive function|Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
79650241|NCT04569643|Other|Sleep quality and mood questionnaires|Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
79980056|NCT03617003|Drug|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
79330317|NCT02473549|Device|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
79330318|NCT04841681|Behavioral|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
79650242|NCT04569760|Drug|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
79650243|NCT04569760|Drug|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
79650244|NCT00210782|Drug|topiramate, phenytoin|
79811530|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
79980057|NCT03617003|Procedure|Endoscopy|Endoscopy of the bladder
79980058|NCT03612531|Procedure|Manual Therapy|Receive manual therapy
79650245|NCT00237861|Drug|risperidone|
79980059|NCT03611556|Drug|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
79650246|NCT00237861|Drug|olanzapine|
79811531|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
79811532|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
79980060|NCT03611556|Drug|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
79980061|NCT03611556|Drug|Gemcitabine|Participants will receive IV infusion of gemcitabine as stated in arm description.
79330319|NCT03042533|Device|Conventional Compression|Method of Nail fitting
79650247|NCT00237861|Drug|quetiapine|
79650248|NCT00237900|Drug|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
79650249|NCT04569565|Device|PleurX catheter|Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
79650250|NCT04569292|Other|No intervention on patients|No intervention on patients
79650251|NCT04569526|Device|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
79650252|NCT00210821|Drug|topiramate|
79650253|NCT00237939|Drug|Aripiprazole|
79650254|NCT04569370|Procedure|Laparoscopic Cholecystectomy|Surgical removal of Gall bladder using laparoscopy
79980062|NCT03611556|Drug|Nab-paclitaxel|Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
79650255|NCT04569019|Other|Vacciantion status in health care workers|Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
79980063|NCT03611556|Drug|Oxaliplatin|Participants will receive IV infusion of oxaliplatin as stated in arm description.
79980064|NCT03611556|Drug|Folinic acid|Participants will receive IV infusion of folinic acid as stated in arm description.
79980065|NCT03611556|Drug|5-FU|Participants will receive IV infusion of 5-FU as stated in arm description.
79980066|NCT03608657|Drug|Apremilast|Apremilast
79980067|NCT03600857|Other|Home administration of misoprostol|First dose of misoprostol administration at home
79980068|NCT03593070|Behavioral|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
79330320|NCT03042533|Device|Standard Backslapping|Method of Nail fitting
79330321|NCT03042533|Device|Dynamic Locking with Backslapping|Method of Nail fitting
79330322|NCT04751461|Other|Product A|P0213420, a 1.8% nicotine ENDS product
79650256|NCT04569214|Drug|PAZ320|Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
79650257|NCT04569214|Other|Placebo|Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
79980069|NCT03586518|Diagnostic Test|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
79980070|NCT03586518|Diagnostic Test|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
79483828|NCT00003525|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79483829|NCT00003375|Drug|lomustine|
79483830|NCT00003375|Drug|procarbazine hydrochloride|
79650258|NCT00210860|Drug|topiramate|
79650259|NCT00237978|Drug|Adapalen|
79650260|NCT00237978|Radiation|VIS and wIRA|
79980071|NCT03586518|Procedure|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
79980072|NCT03586518|Diagnostic Test|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
79330323|NCT04751461|Other|Product B|P0213520, a 1.8% nicotine ENDS product
79330324|NCT04751461|Other|Product C|P0211220, a 1.8% nicotine ENDS product
79330325|NCT04751461|Other|Product D|P0211820, a 1.8% nicotine ENDS product
79330326|NCT04751461|Other|Product E|P0213417, a 2.4% nicotine ENDS product
79330327|NCT03038711|Drug|BMS-986166|Specified dose on specified days
79330328|NCT03038711|Other|Placebo matching BMS-986166|Specified dose on specified days
79330329|NCT03038633|Other|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
79330330|NCT04622917|Drug|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
79330331|NCT04622917|Drug|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
79330332|NCT03039803|Procedure|uterine closure during cesarean section|
79330333|NCT03038477|Drug|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
79483831|NCT00003375|Drug|vincristine sulfate|
79483832|NCT00003375|Radiation|radiation therapy|
79483833|NCT04329195|Drug|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
79483834|NCT04329195|Drug|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
79483835|NCT03498391|Drug|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
79483836|NCT03498391|Drug|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
79483837|NCT00003939|Drug|trabectedin|
79483838|NCT00003543|Biological|monoclonal antibody A33|
79483839|NCT00003543|Drug|carmustine|
79483840|NCT00003543|Drug|fluorouracil|
79483841|NCT00003543|Drug|streptozocin|
79483842|NCT00003543|Drug|vincristine sulfate|
79483843|NCT00003549|Drug|CMF regimen|
79483844|NCT00003549|Drug|cyclophosphamide|
79650261|NCT04568941|Behavioral|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
79650262|NCT04568941|Behavioral|Core Needle Biopsy|Core Needle Biopsy
79650263|NCT04568941|Behavioral|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
79650264|NCT04568668|Device|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized adverse drug event information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display the adverse drug event information in their systems, and generate patient-specific medication-level alerts when pharmacists attempt to re-dispense a culprit medication."
79330334|NCT04004533|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
79330335|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
79330336|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10^11 Sf2WC cells administered orally on Days 0, 28, and 56
79330337|NCT03038243|Other|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
79330338|NCT03101449|Other|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
79330339|NCT03101449|Other|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
79650265|NCT04568746|Procedure|emergency vital room|At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room
79650266|NCT04568746|Procedure|box|patient with score < 2 will be supported in box
79650267|NCT00210899|Drug|ceftobiprole medocaril|
79483845|NCT00003549|Drug|fluorouracil|
79483846|NCT00003549|Drug|methotrexate|
79650268|NCT00210899|Drug|Vancomycin plus Ceftazidime|
79650269|NCT04568785|Behavioral|Brief Intervention for Influenza vaccine|Previous to the intervention, patients were asked about the reasons to reject the influenza vaccine. Brief Intervention was performed by the healthcare professional during the consultation. It was given verbally, with written support.
79330340|NCT03038321|Drug|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
79330341|NCT03038321|Drug|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
79980073|NCT03586518|Diagnostic Test|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
79330342|NCT03038321|Drug|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
79330343|NCT02531373|Biological|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
79330344|NCT02531373|Biological|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
79330345|NCT02531373|Biological|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
79330346|NCT02531373|Biological|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
79330347|NCT02531373|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
79330348|NCT03101683|Radiation|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
79483847|NCT00002883|Drug|cisplatin|
79483848|NCT00002883|Drug|fluorouracil|
79483849|NCT00002883|Procedure|adjuvant therapy|
79483850|NCT00002883|Procedure|conventional surgery|
79483851|NCT00002883|Procedure|neoadjuvant therapy|
79483852|NCT03492463|Drug|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
79483853|NCT03492463|Other|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
79483854|NCT03492463|Other|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
79650270|NCT04568785|Behavioral|Normal advice|In the CG the influenza vaccine advice was the normal advice that professionals used to give their patients and was not asked for the reasons for the rejection of the vaccine to prevent them from influencing the advice.
79650271|NCT04568863|Drug|Melatonin intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
79650272|NCT04568863|Drug|Placebo intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
79483855|NCT03492463|Other|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
79650273|NCT02210377|Other|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
79330349|NCT03042377|Other|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
79483856|NCT00003945|Drug|cisplatin|
79980074|NCT03580525|Drug|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
79980075|NCT03580525|Drug|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
79650274|NCT02210377|Other|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
79650275|NCT02210416|Procedure|inguinal hernia surgery|
79650276|NCT00210938|Drug|Doripenem|
79980076|NCT03580525|Drug|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
79980077|NCT03580525|Drug|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
79980078|NCT03580525|Drug|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
79980079|NCT03573583|Behavioral|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
79980080|NCT03573583|Behavioral|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
79980081|NCT03560700|Dietary Supplement|lactobacillus probiotic strain|Approved Dietary supplement
79980082|NCT03560700|Other|placebo|placebo comparator
79330350|NCT03042377|Drug|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
79483857|NCT00003945|Drug|topotecan hydrochloride|
79483858|NCT00003951|Drug|exatecan mesylate|
79483859|NCT00003957|Biological|filgrastim|
79483860|NCT00003957|Biological|recombinant human stem cell factor|
79483861|NCT00003957|Drug|cyclophosphamide|
79483862|NCT00003957|Drug|cytarabine|
79483863|NCT00003957|Drug|etoposide|
79483864|NCT00003957|Drug|melphalan|
79483865|NCT00003957|Drug|mitoxantrone hydrochloride|
79483866|NCT00003957|Drug|paclitaxel|
79483867|NCT00003957|Procedure|peripheral blood stem cell transplantation|
79483868|NCT00004833|Drug|Immune globulin|
79483869|NCT00003555|Drug|amifostine trihydrate|
79483870|NCT00003555|Drug|paclitaxel|
79650277|NCT02278081|Drug|lansoprazole|the lansoprazole will be taken orally.
79650278|NCT02278081|Drug|placebo|the lansoprazole placebo will be taken orally.
79330351|NCT03042377|Drug|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid & antibiotic paste and the cavity was filled with temporary restorative material.
79330352|NCT03042377|Drug|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
79650279|NCT02278159|Procedure|Peritoneal dialysis|
79330353|NCT05071573|Other|Optimised electronic patient records|Viral load champions trained in the monitoring of patient on antiretroviral therapy to aid prompt identification of virological failure and institution of appropriate clinical management
79483871|NCT00003963|Biological|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
79483872|NCT00003963|Drug|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
79650280|NCT02278159|Procedure|Home hemodialysis|
79650281|NCT02278276|Drug|sodium polysulthionate|Bioavailable composition of α-sulfur
79811533|NCT05603000|Behavioral|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
79811534|NCT02621255|Drug|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
79811535|NCT02621255|Drug|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
79980083|NCT03549780|Device|Stomal Occlusion Device|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
79980084|NCT03515720|Procedure|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
79980085|NCT03501992|Behavioral|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
79980086|NCT03501992|Behavioral|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
79330354|NCT05071417|Drug|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
79330355|NCT03039881|Device|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
79483873|NCT00384423|Drug|PRX-03140|
79483874|NCT00003969|Drug|tanespimycin|
79483875|NCT00384501|Device|Intacs|
79483876|NCT00004845|Drug|Rofecoxib|
79483877|NCT00004845|Drug|Naproxen|
79483878|NCT00003981|Drug|indisulam|
79650282|NCT02278276|Drug|Placebo|400 mg capsules containing placebo
79650283|NCT02210455|Behavioral|Strongest Families FASD intervention|
79650284|NCT02210455|Other|Psychoeducation|
79650285|NCT00210977|Drug|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
79650286|NCT02210494|Drug|Secretrol|
79650287|NCT02210611|Procedure|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
79330356|NCT04859777|Drug|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
79330357|NCT04859777|Drug|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
79330358|NCT03039725|Other|Observational|Retrospective chart review on vaccine compliance
79330359|NCT05071261|Diagnostic Test|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
79330360|NCT05562609|Drug|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
79330361|NCT05562609|Other|Placebo|Ampoules and packaging for all arms will be identical in appearance.
79650288|NCT02210611|Procedure|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
79650289|NCT00211016|Drug|doripenem|
79330362|NCT04370873|Drug|MK-5475|MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization
79980087|NCT03501992|Behavioral|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
79330363|NCT04370873|Drug|Placebo|Placebo administered as dry powder inhalation according to randomization
79330364|NCT05388201|Other|N95|3M N95 Respirator
79330365|NCT05388201|Other|KN95|KN95 Mask (with and without clip)
79330366|NCT05388201|Other|KF94|KF94 Mask (with and without clip)
79330367|NCT05388201|Other|Surgical|Surgical Mask (with and without clip)
79330368|NCT03632707|Radiation|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
79330369|NCT03632707|Procedure|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
79330370|NCT04429451|Biological|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
79650290|NCT04568512|Diagnostic Test|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
79650291|NCT04568512|Diagnostic Test|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
79650292|NCT04568473|Other|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
79330371|NCT03101527|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
79330372|NCT05367219|Device|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
79330373|NCT04838873|Procedure|Open radical cystectomy|Standard open radical cystectomy and urinary diversion
79330374|NCT04838873|Procedure|Laparoscopic-assisted radical cystectomy|Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
79330375|NCT03039959|Diagnostic Test|No intervention|No intervention
79330376|NCT04544839|Device|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
79330377|NCT05071339|Drug|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
79330378|NCT04838483|Device|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
79483879|NCT00385281|Biological|FluMist|
79483880|NCT00003993|Biological|aldesleukin|
79483881|NCT00003993|Drug|bryostatin 1|
79330379|NCT04521829|Other|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
79330380|NCT05386485|Other|None intervation|Observational Study
79330381|NCT02606279|Drug|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
79330382|NCT02606279|Other|Placebo|
79330383|NCT03037697|Other|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
79330384|NCT03037697|Other|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
79330385|NCT04859855|Procedure|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
79330386|NCT04859855|Procedure|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
79811536|NCT04047238|Other|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~Welcome to the patient and reality orientation therapy (7 minutes)~Conducting the main activity of reminiscence (40 minutes)~Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
79330387|NCT04859387|Other|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
79330388|NCT04859387|Other|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
79330389|NCT03039491|Biological|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
79330390|NCT03039491|Biological|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
79330391|NCT03037853|Other|Healthy volunteers|MRI scanner
79330392|NCT03037775|Other|Baseline|measurement of baseline hemodynamic parameters
79330393|NCT03037775|Device|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
79330394|NCT03037775|Device|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
79330395|NCT03037775|Device|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
79811537|NCT00828204|Device|single-use autoinjector with a prefilled liquid Avonex syringe|
79330396|NCT03039257|Dietary Supplement|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
79330397|NCT04838093|Diagnostic Test|PCR|"Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials."
79650293|NCT04568473|Other|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
79811538|NCT00828204|Device|Avonex prefilled syringe via manual IM injection|
79811539|NCT00828204|Drug|BG9418 (interferon beta-1a)|
79330398|NCT04859309|Behavioral|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
79330399|NCT04859309|Procedure|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
79330400|NCT04859543|Device|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
79330401|NCT04789967|Behavioral|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
79330402|NCT04789967|Behavioral|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
79330403|NCT04789967|Other|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
79330404|NCT04833569|Biological|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
79330405|NCT04833569|Device|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
79330406|NCT04837781|Procedure|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
79330407|NCT03038009|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
79330408|NCT03466801|Drug|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
79811540|NCT00696215|Drug|placebo|Placebo 1 mg once a day
79811541|NCT00696215|Drug|rasagiline|1mg
79330409|NCT03466801|Drug|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight >60kg ,500mg/d<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
79330410|NCT04833725|Device|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
79330411|NCT03101605|Other|e-learning teaching module|As described
79330412|NCT03101605|Other|Standard teaching method|As described
79330413|NCT05069779|Drug|Diazepam|Oral administration of 10 mg of diazepam
79650294|NCT04568278|Other|ePRO-CTCAE application|The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
79330414|NCT04837469|Procedure|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
79330415|NCT03251911|Drug|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
79330416|NCT04824755|Procedure|Yune Zhao|Yune Zhao did congenital cataract surgeries
79330417|NCT04837391|Device|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
79330418|NCT04837391|Diagnostic Test|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
79650295|NCT04568317|Behavioral|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
79811542|NCT00784186|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
79811543|NCT00784186|Drug|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
79330419|NCT04837391|Diagnostic Test|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
79811544|NCT00784186|Drug|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
79811545|NCT02621099|Device|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
79811546|NCT00851552|Biological|rituximab|Given IV
79811547|NCT00851552|Drug|bortezomib|Given IV
79330420|NCT04837391|Diagnostic Test|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
79330421|NCT02643355|Drug|Olanzapine|
79330422|NCT02643355|Drug|Clonidine|
79330423|NCT03036527|Procedure|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
79483882|NCT00004857|Biological|alemtuzumab|30 mg subQ injection tiw for 6 weeks
79483883|NCT00004857|Drug|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
79811548|NCT00851552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
79811549|NCT00851552|Genetic|gene expression analysis|Correlative Study
79811550|NCT00851552|Genetic|polymerase chain reaction|Correlative Study
79811551|NCT00851552|Genetic|polymorphism analysis|Correlative Study
79811552|NCT00851552|Genetic|proteomic profiling|Correlative Study
79811553|NCT00851552|Other|flow cytometry|Correlative Study
79811554|NCT00851552|Other|laboratory biomarker analysis|Correlative Study
79811555|NCT02611986|Device|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
79811556|NCT02611986|Device|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
79811557|NCT02621177|Biological|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
79811558|NCT02621177|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
79811559|NCT00785122|Drug|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
79330424|NCT03036527|Procedure|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
79330425|NCT03036527|Procedure|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
79330426|NCT02604017|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
79330427|NCT03036605|Drug|Bupivacaine|%0.5 bupivacaine
79650296|NCT04568317|Device|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
79650297|NCT00238017|Drug|amodiaquine-artesunate versus amodiaquine|
79650298|NCT04567966|Procedure|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
79650299|NCT04567966|Procedure|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
79650300|NCT04567927|Other|Ultrasonography|Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
79330428|NCT03036605|Drug|Dexamethasone|8 mg Dexamethasone
79330429|NCT04837079|Other|Clinical observational study|Clinical observational study
79330430|NCT03099967|Device|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
79330431|NCT03098875|Drug|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
79330432|NCT03098875|Drug|Propofol|General anesthesia using propofol as a hypnotic agent
79330433|NCT03098875|Drug|Remifentanil|General anesthesia using remifentanil as an analgesic.
79330434|NCT04837157|Device|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
79330435|NCT03099031|Drug|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
79330436|NCT03037151|Drug|Grazaoprevir/Elbasavir|treatment naive
79330437|NCT03037151|Drug|Grazaoprevir/Elbasavir/RBV|treatment experienced
79330438|NCT03101059|Procedure|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
79330439|NCT03037229|Device|Smartphone ECG|
79330440|NCT03037229|Device|Standard 12-lead ECG|
79483884|NCT03476239|Drug|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
79650301|NCT02962011|Device|Knotless barbed suture|uterine incision closure
79650302|NCT02962011|Device|polyglactin 910|uterine incision closure
79650303|NCT04568356|Diagnostic Test|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
79650304|NCT04567576|Drug|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
79650305|NCT00211094|Drug|Dapoxetine|
79650306|NCT04567459|Dietary Supplement|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
79330441|NCT03100981|Behavioral|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
79330442|NCT03100981|Behavioral|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
79330443|NCT03036371|Behavioral|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
79330444|NCT03101215|Dietary Supplement|phosphorus|adding of phosphorus to high carbohydrate meal
79330445|NCT04824287|Other|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
79330446|NCT03101137|Drug|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
79330447|NCT03101137|Drug|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
79330448|NCT03101137|Drug|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
79330449|NCT01881451|Drug|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
79330450|NCT01881451|Procedure|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
79330451|NCT04429139|Drug|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
79330452|NCT04428125|Diagnostic Test|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
79330453|NCT04428125|Diagnostic Test|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
79330454|NCT05069077|Other|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
79330455|NCT05069077|Other|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
79307602|NCT03461159|Other|Operant conditioning of motor evoked potentials|Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
79483885|NCT03476239|Drug|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
79330456|NCT04833257|Drug|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
79330457|NCT03098953|Drug|Loteprednol Etabonate|one drop per eye for each eye
79330458|NCT03099889|Behavioral|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
79330459|NCT04823507|Device|BIOFLEX DUO+|"Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
79330460|NCT03099577|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330461|NCT03099577|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330462|NCT03099577|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330463|NCT03099577|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330464|NCT03099577|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330465|NCT03099577|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330466|NCT03099577|Radiation|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
79330467|NCT04833179|Biological|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
79811560|NCT00785122|Drug|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
79330468|NCT04833179|Other|placebo|placebo
79483886|NCT00004863|Drug|GEM 231|
79483887|NCT00004863|Drug|paclitaxel|
79483888|NCT04073043|Behavioral|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
79483889|NCT00004875|Drug|enoxaparin|
79307603|NCT03456895|Other|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
79483890|NCT00004875|Drug|heparin|
79483891|NCT04071171|Drug|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
79650307|NCT04567147|Dietary Supplement|Probiotic|Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).
79650308|NCT04567147|Dietary Supplement|Placebo|Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
79650309|NCT00238056|Drug|domperidone Drug|
79811561|NCT04116554|Drug|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
79650310|NCT04722380|Procedure|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
79650311|NCT04566952|Drug|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
79650312|NCT04566952|Drug|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
79650313|NCT04567069|Biological|DC vaccine|"Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes."
79650314|NCT04567069|Biological|CTL|Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
79650315|NCT04567069|Drug|Sintilimab Injection|The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
79650316|NCT04566874|Device|ALIF|Anterior Lumbar Interbody Fusion
79650317|NCT04566796|Drug|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
79650318|NCT04566796|Drug|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
79650319|NCT00238173|Biological|filgrastim|
79650320|NCT00238173|Drug|acetylcysteine|administered i.v. over 30 to 60 minutes
79650321|NCT00238173|Drug|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
79650322|NCT00238173|Drug|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
79811562|NCT04116554|Device|0.9%saline|20 ml of 0.9%saline will be injected on each side
79811563|NCT00459355|Behavioral|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
79650323|NCT00238173|Drug|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
79650324|NCT00238173|Drug|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
79650325|NCT00238173|Drug|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
79650326|NCT00211133|Drug|epoetin alfa|
79650327|NCT04566913|Procedure|Pontic Shield Technique|• Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
79650328|NCT04566835|Other|Standart Care given during normal examination|This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.
79650329|NCT04566835|Behavioral|Health Promotion Program with cartoon education for Children with Asthma|First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
79811564|NCT00700856|Drug|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
79811565|NCT00700856|Drug|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
79811566|NCT00790114|Drug|AZD7325|Oral, day 1-12
79811567|NCT00790114|Drug|Midazolam|single dose, twice during treatment
79811568|NCT00790114|Drug|Caffeine|single dose, twice during treatment
79980088|NCT03501992|Behavioral|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
79330469|NCT03036137|Device|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
79330470|NCT03036137|Device|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
79330471|NCT05069233|Other|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
79330472|NCT04833101|Biological|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
79980089|NCT03477162|Drug|Metformin|Metformin will be given to patients prior to surgery.
79980090|NCT03449069|Drug|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
79330473|NCT04833101|Biological|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
79330474|NCT04833101|Biological|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
79330475|NCT03100903|Drug|BI 655130|single dose
79330476|NCT04837313|Procedure|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
79980091|NCT03426761|Drug|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
79980092|NCT03426761|Drug|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
79650330|NCT04567030|Device|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
79330477|NCT05068765|Other|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
79330478|NCT05068765|Other|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
79330479|NCT00794599|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
79330480|NCT00794599|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
79330481|NCT04836611|Procedure|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
79330482|NCT00783133|Drug|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
79330483|NCT00783133|Drug|fexofenadine|Allegra 180 mg daily x 7 days
79330484|NCT04823819|Device|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
79811569|NCT01023139|Behavioral|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
79811570|NCT02555176|Dietary Supplement|Dietary intervention|Follow a low-carbohydrate diet
79330485|NCT04823819|Device|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
79330486|NCT03098719|Behavioral|Active Mobility|see detailed discription
79330487|NCT04823429|Behavioral|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
79330488|NCT04823429|Behavioral|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
79330489|NCT03098407|Drug|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
79330490|NCT03098407|Drug|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
79330491|NCT04836143|Drug|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
79330492|NCT01595555|Behavioral|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
79330493|NCT05068453|Drug|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
79330494|NCT05068453|Drug|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
79330495|NCT05068453|Radiation|RT|3 times radiation，totally 24-30 Gy for each lession.
79330496|NCT00751075|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
79330497|NCT00751075|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
79330498|NCT00751075|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
79330499|NCT00751075|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
79330500|NCT00731185|Drug|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
79330501|NCT00731185|Drug|Placebo|
79330502|NCT04836299|Drug|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
79330503|NCT04836299|Drug|Placebo|Participants will be randomly assigned to receive a single of placebo.
79650331|NCT00211211|Device|Balloon Kyphoplasty|
79650332|NCT00238212|Drug|sorafenib tosylate|Given orally
79980093|NCT03397667|Other|ABC ANSWERS|Primary Care plus ABC ANSWERS
79330504|NCT00651391|Drug|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
79980094|NCT03397667|Other|Control|Primary Care as usual
79330505|NCT00651391|Drug|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
79330506|NCT00651391|Drug|Placebo|oral placebo once daily in the evening for 12 weeks
79330507|NCT05067751|Device|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
79330508|NCT04823351|Behavioral|Surgical Mask|The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
79330509|NCT04434859|Other|No intervention|No intervention
79330510|NCT04823117|Other|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
79330511|NCT00650689|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
79330512|NCT00650689|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
79330513|NCT05067517|Drug|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
79330514|NCT05067517|Drug|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
79650333|NCT00238212|Other|laboratory biomarker analysis|Correlative studies
79330515|NCT05067361|Procedure|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
79330516|NCT05067361|Procedure|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
79330517|NCT03100669|Procedure|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
79330518|NCT03100513|Drug|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
79330519|NCT03100513|Drug|Polyethylene Glycol|PEG as single dose of (3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
79650334|NCT04566757|Biological|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
79650335|NCT04566679|Dietary Supplement|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
79650336|NCT04566679|Dietary Supplement|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
79650337|NCT00211250|Drug|Valproic Acid and Depakote ER|
79650338|NCT00238251|Drug|gefitinib|Once daily during days 1-28
79650339|NCT00238251|Drug|temozolomide|Once daily on days 1-21
79650340|NCT00238251|Radiation|radiation therapy|Whole brain radiotherapy
79650341|NCT04566718|Drug|Metformin|metformin cessation
79650342|NCT02210845|Behavioral|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
79811571|NCT00459043|Drug|ZD6474|Taken orally once every morning
79980095|NCT03392974|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
79980096|NCT03364283|Procedure|Surgical position|
79980097|NCT03332667|Radiation|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
79330520|NCT05059561|Radiation|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
79980098|NCT03332667|Drug|Dinutuximab|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
79330521|NCT02530905|Drug|SRP-4045|SRP-4045 solution for IV infusion.
79330522|NCT02530905|Drug|Placebo|SRP-4045 placebo-matching solution for IV infusion.
79330523|NCT00552097|Drug|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
79980099|NCT03332667|Drug|Vorinostat|Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
79330524|NCT00552097|Drug|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
79330525|NCT05067049|Device|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
79330526|NCT05067049|Device|Unconnected arm|Follow-up visits with the pysicians as usual
79330527|NCT00396175|Drug|MK0906, finasteride / Duration of Treatment : 48 Weeks|
79330528|NCT00396175|Drug|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
79330529|NCT02530671|Device|Toothbrushing with manual toothbrush|
79330530|NCT02530671|Device|Toothbrushing with power toothbrush|
79330531|NCT02603393|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
79330532|NCT02603393|Drug|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
79330533|NCT02603393|Drug|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
79330534|NCT04832945|Drug|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
79330535|NCT02642653|Drug|Lovastatin|Once per day dosing
79330536|NCT02642653|Other|Placebo|Once per day dosing
79330537|NCT01659567|Drug|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
79330538|NCT01659567|Drug|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
79330539|NCT04832633|Diagnostic Test|Different contrast media injection methods|Different contrast media injection methods
79980100|NCT03332667|Drug|Sargramostim|Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m^2
79330540|NCT04835909|Behavioral|Modern board and card games group|Modern board and card games group
79330541|NCT04835909|Behavioral|Paper and pencil tasks group|Paper and pencil tasks group
79330542|NCT05032729|Other|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
79330543|NCT05032729|Other|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
79330544|NCT04835753|Device|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
79330545|NCT04835753|Other|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
79330546|NCT05059171|Device|OneSahpe single file|The rotary motion of OneShape single file
79330547|NCT05059171|Device|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
79330548|NCT04822805|Drug|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
79330549|NCT05059249|Procedure|Hot Pack|Superficial Heating
79330550|NCT05059249|Procedure|Manual Traction|Manual Traction for 10 minutes
79330551|NCT05059249|Procedure|Mechanical Traction|Mechanical Traction for 10 minutes
79330552|NCT05059249|Procedure|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
79330553|NCT05059249|Procedure|TENS|TENS for 10 minutes with hot pack
79330554|NCT04835285|Diagnostic Test|Npf.|3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload
79330555|NCT04095637|Device|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
79650343|NCT02210845|Behavioral|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
79330556|NCT04835207|Other|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
79330557|NCT05058937|Diagnostic Test|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
79330558|NCT04832555|Radiation|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
79330559|NCT04832789|Device|Venovenous ECMO|Venovenous ECMO
79980101|NCT03332667|Drug|Potassium Iodide|Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
79330560|NCT05066893|Other|telehealth visits|intensive visits with doctor
79330561|NCT04435093|Other|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
79980102|NCT03309813|Device|Transcranial ExAblate|ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
79980103|NCT03309813|Device|Sham Transcranial ExAblate|Sham ExAblate Thalamotomy procedure
79483892|NCT04071171|Drug|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
79650344|NCT02210845|Other|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
79650345|NCT00211289|Behavioral|Education by community pharmacist|
79980104|NCT03309813|Device|Crossover Transcranial Exablate|Subjects randomized to the Sham Exablate could opt for the Crossovover Transcranial Exablate Arm (Exablate Thalamotomy) after completing the Month 3 visit in the Sham Arm.
79980105|NCT03304847|Other|ablation|radio-frequency applications on arrhythmogenic substrate
79980106|NCT03299205|Behavioral|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
79980107|NCT03287492|Other|Informational Intervention|Receive QPS
79330562|NCT03100435|Device|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
79330563|NCT03100435|Other|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
79330564|NCT03036995|Drug|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
79650346|NCT02210884|Dietary Supplement|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
79650347|NCT00238290|Drug|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
79650348|NCT02895217|Other|ergocycle|
79650349|NCT02895178|Behavioral|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
79650350|NCT00211328|Drug|anecortave acetate|
79980108|NCT03287492|Other|Informational Intervention|Receive GIS
79980109|NCT03287492|Other|Questionnaire Administration|Ancillary studies
79980110|NCT03274830|Device|aneXys|150 patients with the aneXys cup
79980111|NCT03272906|Device|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
79980112|NCT03272906|Device|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
79980113|NCT03272906|Behavioral|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
79980114|NCT03271580|Diagnostic Test|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
79980115|NCT03271580|Procedure|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
79980116|NCT03271580|Other|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
79980117|NCT03271580|Other|Ankle Brachial Index|Blood pressure test
79330565|NCT03036995|Other|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
79330566|NCT03100279|Behavioral|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, & Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
79483893|NCT04071171|Drug|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
79483894|NCT04071171|Drug|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
79650351|NCT02894944|Biological|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
79980118|NCT03268837|Device|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
79980119|NCT03268837|Device|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
79980120|NCT03266055|Dietary Supplement|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
79650352|NCT00238329|Biological|PEG-interferon alfa-2b|
79650353|NCT00238329|Drug|thalidomide|
79811572|NCT00459043|Drug|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
79980121|NCT03266055|Dietary Supplement|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
79330567|NCT03100279|Behavioral|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
79330568|NCT04835051|Behavioral|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child <6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
79330569|NCT04001101|Combination Product|RT and Anti-PD-1|limited metastatic site radiation
79330570|NCT04001101|Drug|Anti-PD-1|anti-PD-1 therapy alone
79330571|NCT04299893|Drug|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
79330572|NCT04299893|Drug|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
79330573|NCT04834895|Other|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
79330574|NCT04834895|Other|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
79811573|NCT00795262|Drug|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
79330575|NCT05066425|Dietary Supplement|Soluble Corn Fiber|Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks
79330576|NCT05066425|Dietary Supplement|Maltodextrin|Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks
79330577|NCT04832243|Other|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
79330578|NCT04831931|Other|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
79330579|NCT05066035|Drug|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
79330580|NCT05066035|Drug|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to >0.9 in the recovery room before discharge to the ward.
79330581|NCT04428593|Drug|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
79811574|NCT00795262|Drug|accupril, placebo|accupril 40 mg
79811575|NCT00795262|Drug|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
79811576|NCT00785200|Other|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
79811577|NCT00785200|Other|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
79811578|NCT01023373|Drug|Medical treatment|hypotensive drugs, statins and anti-platelets
79811579|NCT01023373|Procedure|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
79811580|NCT01023373|Device|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
79811581|NCT01023373|Device|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
79330582|NCT04428593|Drug|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
79330583|NCT04428593|Drug|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
79650354|NCT02894866|Device|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
79650355|NCT02894905|Drug|AL-335|Participants with various degrees of impaired renal function (mild [Cohort 1], moderate [Cohort 2], severe [Cohort 3]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
79650356|NCT02894827|Biological|Blood sample|
79650357|NCT02894827|Other|Flow cytometry|
79650358|NCT02894827|Other|western blot|
79650359|NCT00211367|Drug|Anecortave Acetate|
79650360|NCT02894788|Other|ICU admission|
79811582|NCT00817206|Drug|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
79811583|NCT00817206|Drug|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
79811584|NCT01023529|Radiation|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
79811585|NCT02611518|Drug|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
79330584|NCT04428593|Drug|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
79483895|NCT00004881|Biological|MVA-MUC1-IL2 vaccine|
79483896|NCT00003561|Biological|recombinant interferon alfa|
79650361|NCT00238368|Biological|filgrastim|
79650362|NCT00238368|Biological|rituximab|
79650363|NCT00238368|Drug|busulfan|
79483897|NCT00003561|Biological|sargramostim|
79483898|NCT00003567|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
79483899|NCT00003567|Biological|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
79650364|NCT00238368|Drug|cisplatin|
79650365|NCT00238368|Drug|cyclophosphamide|
79650366|NCT00238368|Drug|cytarabine|
79650367|NCT00238368|Drug|doxorubicin hydrochloride|
79650368|NCT00238368|Drug|etoposide|
79650369|NCT00238368|Drug|methylprednisolone|
79650370|NCT00238368|Drug|prednisone|
79650371|NCT00238368|Drug|vincristine sulfate|
79650372|NCT00238368|Procedure|autologous bone marrow transplantation|
79650373|NCT00238368|Procedure|peripheral blood stem cell transplantation|
79650374|NCT00238368|Procedure|positron emission tomography|
79650375|NCT00238368|Radiation|fludeoxyglucose F 18|
79650376|NCT00238368|Radiation|radiation therapy|
79811586|NCT02611518|Drug|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
79811587|NCT02611518|Drug|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
79811588|NCT01023607|Drug|Atorvastatin|Atorvastatin 20mg/day
79811589|NCT01023607|Drug|Atorvastatin|Atorvastatin, 60mg/day
79811590|NCT01023607|Drug|Rosuvastatin|Rosuvastatin,10mg/day
79811591|NCT00706758|Behavioral|IBS school|Structured patient group education
79811592|NCT00706758|Behavioral|IBS-guidebook|Written information - IBS-guidebook
79330585|NCT03852667|Behavioral|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
79330586|NCT03852667|Other|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
79650377|NCT02894749|Radiation|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
79330587|NCT03753373|Other|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
79483900|NCT00003567|Biological|therapeutic autologous lymphocytes|
79483901|NCT00003567|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
79483902|NCT00003567|Drug|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
79483903|NCT00003567|Drug|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
79483904|NCT00003567|Procedure|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
79483905|NCT00003573|Biological|filgrastim|
79650378|NCT02894593|Other|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
79650379|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
79811593|NCT02609412|Other|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
79811594|NCT02609412|Other|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
79811595|NCT02609412|Device|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
79483906|NCT00003573|Drug|cisplatin|
79483907|NCT00003573|Drug|cyclophosphamide|
79483908|NCT00003573|Drug|etoposide|
79483909|NCT00003573|Drug|vincristine sulfate|
79483910|NCT00003573|Radiation|radiation therapy|
79483911|NCT00003585|Biological|aldesleukin|
79483912|NCT00003585|Biological|recombinant interferon alfa|
79483913|NCT00003585|Drug|fluorouracil|
79330588|NCT03753373|Other|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
79330589|NCT04831853|Other|nasopharyngeal swabbing procedure (self swabbing first)|Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
79330590|NCT04831853|Other|nasopharyngeal swabbing procedure (conventionnal swabbing first)|patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
79330591|NCT05058625|Device|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
79330592|NCT05058625|Other|Control Group|Normal volleyball training
79330593|NCT04831463|Behavioral|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
79330594|NCT03099811|Behavioral|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
79330595|NCT03099811|Behavioral|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
79483914|NCT00003585|Drug|isotretinoin|
79483915|NCT00003585|Procedure|surgical procedure|
79483916|NCT00003591|Drug|paclitaxel|
79483917|NCT00003591|Radiation|radiation therapy|
79483918|NCT02975323|Drug|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
79483919|NCT00003597|Biological|recombinant human thrombopoietin|
79483920|NCT00003597|Drug|carboplatin|
79483921|NCT00003597|Drug|etoposide|
79483922|NCT00003597|Drug|ifosfamide|
79483923|NCT00003597|Biological|G-CSF|
79483924|NCT04188379|Biological|efgartigimod|Intravenous infusion of efgartigimod
79483925|NCT04188379|Other|Placebo|Intravenous infusion of placebo
79483926|NCT00004005|Drug|fluorouracil|
79483927|NCT00004005|Drug|irinotecan hydrochloride|
79483928|NCT00004005|Drug|leucovorin calcium|
79483929|NCT00004005|Procedure|conventional surgery|
79483930|NCT00004005|Radiation|radiation therapy|
79483931|NCT00003603|Drug|cyclophosphamide|
79483932|NCT00003603|Drug|dexamethasone|
79483933|NCT00003603|Drug|idarubicin|
79483934|NCT00003603|Drug|lomustine|
79483935|NCT00003603|Drug|melphalan|
79483936|NCT00003603|Drug|prednisolone|
79483937|NCT00004887|Drug|carboplatin|
79483938|NCT00004887|Drug|cisplatin|
79483939|NCT00004887|Drug|ifosfamide|
79483940|NCT00004887|Drug|mitomycin C|
79483941|NCT00004887|Drug|paclitaxel|
79483942|NCT00004887|Drug|vinblastine sulfate|
79483943|NCT00004893|Biological|recombinant interleukin-12|
79483944|NCT00004011|Drug|carboplatin|
79483945|NCT00004011|Drug|paclitaxel|
79483946|NCT00004011|Procedure|conventional surgery|
79483947|NCT00004017|Procedure|conventional surgery|
79483948|NCT00004017|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
79483949|NCT00004905|Biological|filgrastim|
79483950|NCT00004905|Biological|recombinant interferon alfa|
79483951|NCT00004905|Drug|cyclophosphamide|
79483952|NCT00004905|Drug|cytarabine|
79483953|NCT00004905|Drug|etoposide|
79483954|NCT00004905|Drug|idarubicin|
79483955|NCT00004905|Procedure|peripheral blood stem cell transplantation|
79483956|NCT00004905|Radiation|radiation therapy|
79483957|NCT00004029|Biological|recombinant viral vaccine therapy|
79483958|NCT00004029|Biological|sargramostim|
79483959|NCT00004041|Biological|Ad5CMV-p53 gene|
79483960|NCT00004041|Procedure|conventional surgery|
79483961|NCT00362323|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
79483962|NCT00362323|Drug|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
79483963|NCT00004917|Biological|epoetin alfa|
79483964|NCT00004917|Drug|cisplatin|
79483965|NCT00004917|Radiation|radiation therapy|
79483966|NCT00421915|Drug|Enbrel (etanercept)|
79483967|NCT00362713|Drug|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
79330596|NCT03722095|Device|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
79330597|NCT03722095|Device|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
79330598|NCT03722095|Device|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
79330599|NCT04822415|Drug|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
79330600|NCT04822415|Drug|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
79330601|NCT03661333|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
79980122|NCT03260491|Drug|U3-1402 (FL-DP)|U3-1402 (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
79980123|NCT03260491|Drug|U3-1402 (CTM-1 Lyo-DP)|U3-1402 (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
79330602|NCT05065177|Biological|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
79483968|NCT02382601|Radiation|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
79980124|NCT03260491|Drug|U3-1402 (CTM-3 Lyo-DP)|U3-1402 (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
79980125|NCT03259685|Other|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
79980126|NCT03259685|Other|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
79330603|NCT05065177|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
79330604|NCT04821947|Other|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
79483969|NCT02382601|Radiation|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
79330605|NCT03037073|Drug|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
79330606|NCT03037073|Drug|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
79330607|NCT03099421|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
79330608|NCT04834739|Other|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
79330609|NCT04834739|Other|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
79330610|NCT04834739|Other|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
79330611|NCT04834739|Other|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
79330612|NCT04834739|Other|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
79330613|NCT04834739|Other|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
79483970|NCT02382601|Procedure|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
79650380|NCT02894593|Other|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
79483971|NCT02382601|Behavioral|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
79650381|NCT02894593|Other|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
79980127|NCT03259685|Other|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
79980128|NCT03251027|Radiation|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
79650382|NCT02894632|Device|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
79650383|NCT00211406|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
79650384|NCT02894554|Drug|Telbivudine|
79483972|NCT02382601|Procedure|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
79980129|NCT03251027|Other|Quality-of-Life|Ancillary studies
79980130|NCT03248479|Drug|Magrolimab|Administered intravenously
79980131|NCT03248479|Drug|Azacitidine|Administered according to region-specific drug labeling either subcutaneously or intravenously
79483973|NCT02382601|Procedure|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
79650385|NCT02894554|Drug|Lamivudine|
79650386|NCT00238407|Drug|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
79650387|NCT00238407|Radiation|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
79980132|NCT03243955|Device|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
79980133|NCT03243955|Device|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
79980134|NCT03194126|Procedure|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
79980135|NCT03194126|Procedure|Mifepristone + Misoprostol OR oxytocine|standart support
79980136|NCT03193970|Behavioral|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
79330614|NCT04834739|Other|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
79330615|NCT04834739|Other|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
79330616|NCT04834739|Other|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
79330617|NCT03100357|Other|Thyroidectomy|Thyroid surgery for benign nodular goiter
79330618|NCT05058235|Other|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
79330619|NCT05058235|Other|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
79330620|NCT03100201|Other|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
79330621|NCT03100201|Other|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
79330622|NCT03099343|Behavioral|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
79330623|NCT05058079|Behavioral|Intraoperative Hand Held|Intraoperative hand holding
79330624|NCT03423589|Dietary Supplement|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
79330625|NCT05064475|Diagnostic Test|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
79330626|NCT05057299|Other|retrospective data analysis|chart review, analysis and reporting outcomes
79330627|NCT05057455|Procedure|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
79330628|NCT05057533|Other|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~Related to defecation (may be increased or unchanged by defecation)~Associated with a change in stool frequency~Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. [2] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
79330629|NCT05063773|Device|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
79483974|NCT02382601|Radiation|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
79483975|NCT00004047|Drug|exatecan mesylate|
79483976|NCT00003627|Drug|cisplatin|
79483977|NCT00003627|Drug|fluorouracil|
79483978|NCT00003627|Radiation|radiation therapy|
79483979|NCT00004059|Drug|7-hydroxystaurosporine|
79483980|NCT00004059|Drug|fluorouracil|
79330630|NCT02897479|Drug|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
79330631|NCT05046925|Procedure|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
79330632|NCT05046925|Procedure|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
79650388|NCT02894515|Drug|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
79650389|NCT02894515|Drug|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
79330633|NCT04470973|Drug|Cefuroxime|Patients receive cefuroxime as part of standard care.
79650390|NCT02894671|Other|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
79650391|NCT00211445|Procedure|Photodynamic Therapy with Verteporfin|
79650392|NCT00211445|Drug|verteporfin|
79811596|NCT00665002|Biological|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
79811597|NCT00665002|Drug|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
79650393|NCT02894710|Drug|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
79811598|NCT00665002|Drug|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
79811599|NCT05757024|Device|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
79650394|NCT02894710|Drug|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
79650395|NCT00238446|Drug|EC-MPS|
79811600|NCT02554240|Drug|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
79650396|NCT05428189|Diagnostic Test|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
79811601|NCT02554240|Drug|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
79811602|NCT02554240|Drug|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
79330634|NCT04470973|Drug|Amikacin|Patients receive amikacin as part of standard care.
79330635|NCT05046457|Dietary Supplement|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
79330636|NCT05063071|Drug|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
79330637|NCT05045911|Procedure|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
79330638|NCT05045989|Behavioral|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
79330639|NCT05045599|Behavioral|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
79483981|NCT00003633|Drug|docetaxel|
79650397|NCT05428189|Device|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
79650398|NCT00211484|Drug|Anecortave Acetate|
79650399|NCT05428111|Diagnostic Test|flow cytometric immunophynotyping|Expression of programmed death-1 (PD-1) & programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
79650400|NCT00238485|Drug|Licarbazepine|
79650401|NCT05428072|Other|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol & lactulose) subjects within 2-3 days of the initial sugar test.
79811604|NCT05756868|Behavioral|Time restricted feeding|In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
79650402|NCT05428072|Drug|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 & 1 hour before the sugar drink.
79330640|NCT05062681|Drug|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
79330641|NCT05062681|Drug|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
79330642|NCT05045521|Other|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 * 8 squat jumps, 2 * 8 scissor jumps, and 2 * 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
79330643|NCT05045521|Other|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
79330644|NCT05045521|Other|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
79330645|NCT05056519|Biological|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
79650403|NCT00211523|Drug|MBI 226 Acne Solutions|
79330646|NCT05056519|Biological|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
79330647|NCT05045287|Radiation|hypofractionated radiotherapy|Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
79330648|NCT05045131|Procedure|Left atrial combined pulmonary vein isolation and posterior wall isolation|
79330649|NCT05045053|Drug|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
79330650|NCT05044741|Procedure|Emergency surgical enterostomy|Emergency surgical enterostomy
79330651|NCT03097627|Drug|ICG Intervention|The intervention to be administered is the drug indocyanine green.
79330652|NCT03097627|Device|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
79330653|NCT05055739|Device|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
79330654|NCT05055895|Drug|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
79483982|NCT00003633|Drug|estramustine phosphate sodium|
79483983|NCT00003633|Drug|mitoxantrone hydrochloride|
79483984|NCT00003633|Drug|prednisone|
79483985|NCT00003639|Biological|recombinant interferon alfa|
79483986|NCT00003639|Drug|chlorambucil|
79483987|NCT00003639|Drug|dexamethasone|
79483988|NCT00003639|Drug|idarubicin|
79483989|NCT00004923|Drug|docetaxel|
79650404|NCT05427916|Device|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
79650405|NCT05427916|Other|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
79650406|NCT00238524|Drug|SPM 927|
79811605|NCT02611050|Behavioral|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
79811606|NCT02611050|Behavioral|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
79811607|NCT03847987|Drug|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
79811608|NCT03847987|Drug|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
79330655|NCT05055583|Drug|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
79330656|NCT05055583|Procedure|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
79330657|NCT05055583|Drug|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
79330658|NCT05061589|Procedure|permanent colostomy|An operation that creates an opening for the colon through the abdomen
79330659|NCT03097705|Diagnostic Test|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
79330660|NCT05060809|Drug|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
79330661|NCT03097549|Device|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
79330662|NCT03097549|Device|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
79330663|NCT03097471|Device|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
79330664|NCT05055349|Other|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
79330665|NCT03098095|Behavioral|Physical Activity|Moderate physical activity
79330666|NCT05061043|Other|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
79330667|NCT05061043|Other|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
79330668|NCT05054959|Other|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
79330669|NCT05054959|Other|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
79330670|NCT03097393|Diagnostic Test|measure Serum procalcitonin level|measuring procalcitonin level
79330671|NCT03097237|Other|Wholegrain rye|Cereal products based on wholegrain rye
79330672|NCT03097237|Other|Refined wheat|Cereal products based on refined wheat
79330673|NCT05060419|Drug|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
79330674|NCT05060419|Drug|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
79330675|NCT05060419|Drug|Saline|180min
79330676|NCT05060419|Drug|Saline|30min
79483990|NCT00004923|Drug|irinotecan hydrochloride|
79483991|NCT00004929|Biological|MUC-2-KLH vaccine|
79650407|NCT05427877|Device|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
79483992|NCT00004929|Biological|QS21|
79650408|NCT00211562|Drug|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
79330677|NCT05055193|Drug|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
79330678|NCT05060185|Device|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
79330679|NCT05060107|Biological|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
79330680|NCT05060263|Drug|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
79330681|NCT05036551|Diagnostic Test|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
79330682|NCT03096925|Behavioral|Guided self-help|Web-based guided self-help intervention
79330683|NCT03097159|Procedure|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
79330684|NCT03097003|Drug|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
79330685|NCT03098251|Procedure|3D typing|typing the patient with 3D typing system and give specific treatment
79330686|NCT03098251|Procedure|routine typing|typing the patient with routine typing system and give specific treatment
79330687|NCT05055037|Other|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
79330688|NCT05043727|Combination Product|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
79330689|NCT05043727|Combination Product|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
79330690|NCT02605967|Drug|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
79330691|NCT02605967|Drug|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
79330692|NCT05043571|Biological|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
79330693|NCT04473079|Dietary Supplement|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
79330694|NCT04473079|Dietary Supplement|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
79330695|NCT05036161|Other|Nasal high flow|Newborns with respiratory distress treated with NHF.
79330696|NCT05036161|Other|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
79330697|NCT03036059|Drug|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
79330698|NCT03096769|Other|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
79330699|NCT04834427|Drug|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1~0.25 mg/kg; Bolus intravenous injection (dose 0.1~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h.~Intramuscular injection：The dose is 2~4 mg/kg."
79483993|NCT00004065|Drug|tanespimycin|
79483994|NCT00004071|Drug|leflunomide|
79483995|NCT00004071|Drug|mitoxantrone hydrochloride|
79483996|NCT00004071|Drug|prednisone|
79483997|NCT00004077|Drug|cisplatin|
79330700|NCT04834427|Drug|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
79330701|NCT05035849|Drug|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
79330702|NCT03095443|Other|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
79483998|NCT00004077|Drug|ifosfamide|
79330703|NCT03095443|Other|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
79330704|NCT03095443|Other|Attention Control|Participant receives an audio-book.
79330705|NCT04821479|Biological|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
79330706|NCT05043493|Procedure|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
79483999|NCT00004077|Drug|paclitaxel|
79484000|NCT00004083|Drug|cisplatin liposomal|
79484001|NCT00004941|Drug|monoclonal antibody cA2|
79484002|NCT00004983|Behavioral|diabetes self-management education|
79484003|NCT00003657|Biological|filgrastim|
79484004|NCT00003657|Drug|Amifostine|
79484005|NCT00003657|Drug|Carboplatin|
79484006|NCT00003657|Drug|Etoposide|
79811609|NCT03847987|Drug|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
79811610|NCT00660010|Drug|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
79484007|NCT00003657|Drug|Ifosfamide|
79484008|NCT00003657|Procedure|peripheral blood stem cell transplantation|
79484009|NCT00004089|Biological|filgrastim|
79484010|NCT00004089|Drug|fluorouracil|
79484011|NCT00004089|Drug|hydroxyurea|
79484012|NCT00004089|Drug|paclitaxel|
79811611|NCT04015908|Drug|Celecoxib|Celecoxib 100mg
79330707|NCT05043181|Biological|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
79330708|NCT03035981|Other|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330709|NCT03035981|Other|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330710|NCT03035981|Other|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330711|NCT03035981|Other|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330712|NCT03035981|Other|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330713|NCT03035981|Other|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330714|NCT03035981|Other|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
79330715|NCT05035381|Drug|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
79330716|NCT03035903|Device|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
79330717|NCT03035903|Device|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
79330718|NCT05043025|Other|Identification of the cricothyroid membrane|The cricothyroid membrane is identified using a laryngeal handshake technique in different patient positions.
79484013|NCT00004089|Procedure|conventional surgery|
79330719|NCT04152187|Other|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
79484014|NCT00004089|Radiation|radiation therapy|
79484015|NCT00004095|Drug|gemcitabine hydrochloride|
79484016|NCT00004095|Drug|irinotecan hydrochloride|
79484017|NCT00004101|Biological|apolizumab|
79484018|NCT00003663|Biological|rituximab|
79484019|NCT00003663|Drug|dexamethasone|
79484020|NCT00004107|Biological|filgrastim|as prescribed by physician
79484021|NCT00004107|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
79811612|NCT04015908|Drug|Acetaminophen|Acetaminophen 325mg
79330720|NCT04821323|Drug|Indomethacin|Indomethacin capsules will be administered orally.
79330721|NCT04821323|Diagnostic Test|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
79330722|NCT04821557|Dietary Supplement|Protease + Protein|Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
79330723|NCT04821557|Dietary Supplement|Placebo + Protein|Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
79330724|NCT04434703|Procedure|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
79330725|NCT04434703|Procedure|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
79484022|NCT00004107|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
79484023|NCT00004107|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
79484024|NCT00004107|Radiation|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
79484025|NCT00003669|Drug|arzoxifene hydrochloride|
79484026|NCT00004113|Drug|temozolomide|
79484027|NCT00003675|Drug|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
79484028|NCT00004137|Biological|filgrastim|
79484029|NCT00004137|Drug|carboplatin|
79484030|NCT00004137|Drug|paclitaxel|
79484031|NCT00004137|Drug|topotecan hydrochloride|
79484032|NCT00003681|Biological|epoetin alfa|
79484033|NCT00003681|Drug|amifostine trihydrate|
79484034|NCT00005001|Biological|HIV-1 Immunogen|
79484035|NCT00005007|Drug|Etanercept|
79650409|NCT05427721|Drug|Thymol|200 mg each 8 hours for 90 days
79811613|NCT04015908|Drug|Pregabalin|Pregabalin 50 mg
79811614|NCT04015908|Drug|Oxycodone|oxycodone 5-10 mg
79811615|NCT04015908|Drug|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
79330726|NCT04434703|Procedure|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
79330727|NCT03035825|Dietary Supplement|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
79330728|NCT03035825|Other|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
79330729|NCT04834037|Behavioral|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
79330730|NCT05035069|Drug|Ciprofol|Ciprofol infusion, starting with 0.8 ~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 ~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
79330731|NCT05035069|Drug|Propofol|Propofol infusion, starting with 4 ~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 ~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
79330732|NCT05035147|Drug|albumin-bound paclitaxel|Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
79330733|NCT01668173|Drug|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
79330734|NCT05042713|Other|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
79330735|NCT03036761|Procedure|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
79330736|NCT04821167|Procedure|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
79330737|NCT05054101|Other|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
79330738|NCT03036449|Behavioral|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
79330739|NCT05034757|Other|HA only|HA injection only
79330740|NCT05034757|Other|ESWT once|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
79330741|NCT05034757|Other|ESWT twice|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
79330742|NCT05034523|Radiation|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
79330743|NCT04427813|Behavioral|questionaire to husband and wife|a form of questions will be asked to every partner
79330744|NCT04834115|Drug|Ivermectin Tablets|Oral ivermectin at a one time dose
79330745|NCT04834115|Other|Placebo|Oral placebo at a one time dose
79330746|NCT04820777|Other|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
79330747|NCT04820777|Other|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
79330748|NCT04821011|Device|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
79330749|NCT04821011|Device|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
79330750|NCT04821011|Device|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
79330751|NCT01505465|Drug|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
79650410|NCT00211601|Behavioral|Disease Management Assessment|
79811616|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
79811617|NCT00790816|Drug|Lapatinib|Lapatinib monotherapy
79650411|NCT05427682|Drug|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
79811618|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
79811619|NCT00873041|Drug|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
79811620|NCT00873041|Drug|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
79330752|NCT01505465|Drug|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
79811621|NCT05758506|Device|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
79811622|NCT00795496|Procedure|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
79980137|NCT03180151|Procedure|piezotome assisted orthodontic tooth movement|"Surgical procedure~After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~The incisions will be kept minimal.~The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~As we will not use bone graft so we don't need use suturing after cortication.~We give patient antibiotic and analgesic cover."
79980138|NCT03116139|Diagnostic Test|V/Q imaging|Standard of care
79980139|NCT03116139|Diagnostic Test|Computed tomography scan|Standard of care
79330753|NCT05618015|Procedure|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
79484036|NCT04712487|Diagnostic Test|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
79484037|NCT00384579|Drug|Botulinum toxin B|Botulinum Toxin B
79484038|NCT00384579|Drug|Placebo|Placebo
79980140|NCT03108677|Other|Blood samples|15 ml peripheral blood
79980141|NCT03061565|Drug|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
79980142|NCT03061565|Drug|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
79980143|NCT03055481|Other|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
79980144|NCT03055481|Other|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
79980145|NCT02994459|Other|Weight Loss|Diet-induced weight loss (obese only)
79330754|NCT05618015|Procedure|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
79330755|NCT04833881|Other||
79484039|NCT00004149|Drug|arsenic trioxide|
79484040|NCT00384657|Drug|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
79811623|NCT00795496|Procedure|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
79811624|NCT00795496|Procedure|Serum IgE blood testing|One blood test to measure total serum IgE
79330756|NCT04833803|Behavioral|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
79330757|NCT04833647|Diagnostic Test|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
79330758|NCT05617937|Other|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
79330759|NCT04820543|Drug|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
79330760|NCT04816487|Drug|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
79330761|NCT04360577|Procedure|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
79330762|NCT04831229|Other|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
79484041|NCT00005013|Drug|Sertraline|
79484042|NCT00005013|Drug|Hypericum perforatum (St. John's wort)|
79484043|NCT00004161|Drug|fenretinide|
79650412|NCT00238602|Procedure|Stereotactic radiosurgery|
79650413|NCT05427604|Other|Olive oil|ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
79330763|NCT04831229|Other|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
79330764|NCT04830371|Biological|EuTCV (Vi-CRM Typhoid conjugate vaccine)|Single dose, Intramuscular administration
79330765|NCT04830371|Biological|Typbar-TCV|Single dose, Intramuscular administration
79650414|NCT05427604|Other|Olive Oil|ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
79650415|NCT05427604|Other|DHA oil|ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
79650416|NCT05427604|Other|DHA oil|ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
79650417|NCT05427409|Dietary Supplement|Beta-alanine supplementation|In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
79650418|NCT05427331|Drug|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
79484044|NCT00004161|Drug|Placebo|
79484045|NCT00004173|Drug|oxaliplatin|
79484046|NCT00004173|Drug|paclitaxel|
79484047|NCT00005025|Biological|herpes simplex thymidine kinase|
79484048|NCT00005025|Drug|ganciclovir|
79484049|NCT00004179|Biological|rituximab|
79484050|NCT00004179|Drug|CHOP regimen|
79484051|NCT00004179|Drug|cyclophosphamide|
79484052|NCT00004179|Drug|doxorubicin hydrochloride|
79484053|NCT00004179|Drug|prednisone|
79484054|NCT00004179|Drug|vincristine sulfate|
79484055|NCT00003687|Drug|dextromethorphan hydrobromide|
79484056|NCT00003687|Drug|morphine sulfate|
79484057|NCT00003693|Drug|Dolastatin 10|IV bolus once every 3 weeks.
79484058|NCT00005031|Drug|irofulven|
79650419|NCT00238641|Drug|Botulinum Toxin type B|
79650420|NCT05427175|Radiation|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
79650421|NCT05427175|Drug|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
79811625|NCT00795496|Procedure|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
79811626|NCT00795574|Drug|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
79811627|NCT00795574|Drug|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
79330766|NCT04820699|Other|post isometric relaxation and muligan bent leg raise|6 week intervention
79330767|NCT04820699|Other|muligan bent leg raise|muligan bent leg raise
79330768|NCT04830293|Procedure|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
79330769|NCT04816409|Other|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
79330770|NCT04816409|Other|Neurodevelopmental therapy|"Starting Posture~Start and evaluate the supreme effective posture to move from(usually straight)~Reassemble to mid plane (head/trunk)~Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
79330771|NCT04820465|Other|Non available due to cross-sectional study design|Non available since this study (survey) has a cross-sectional design
79330772|NCT04816331|Other|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
79330773|NCT04830059|Behavioral|Exercise|Two types of exercise intervention and control group
79330774|NCT04830059|Behavioral|Air purification|Air purification in order to reduce the PM2.5 and PM10
79330775|NCT04820621|Drug|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release [MR] tablet
79330776|NCT04816253|Drug|Normal saline|Normal saline irrigation and No other drug placed after extraction
79330777|NCT04816253|Drug|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
79330778|NCT04816253|Drug|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
79330779|NCT04816253|Drug|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
79330780|NCT04820231|Other|intra-articular PRP injection|
79330781|NCT04816097|Drug|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
79330782|NCT04815941|Other|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
79330783|NCT04363619|Diagnostic Test|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
79650422|NCT05427136|Diagnostic Test|Lung function measurements|"All lung function tests are non-invasive and last about 60 minutes per child:~Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged.~Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits."
79811628|NCT05206864|Other|Medical Food: SBD111|One capsule administered twice daily with morning and evening meals for 28 days
79811629|NCT05206864|Other|Placebo|One capsule administered twice daily with morning and evening meals for 28 days
79330784|NCT04363073|Device|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
79330785|NCT04363073|Device|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
79650423|NCT05427136|Diagnostic Test|Breath Analysis|Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
79650424|NCT05427136|Diagnostic Test|Magnetic resonance imaging (MRI)|Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
79650425|NCT05427136|Other|Standardized interview to assess respiratory symptoms|Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
79980146|NCT02968992|Drug|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
79980147|NCT02968992|Other|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
79980148|NCT02950493|Other|perflutren lipid microsphere|Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
79330786|NCT04820153|Device|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
79330787|NCT04820153|Behavioral|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
79484059|NCT00005037|Drug|temozolomide|
79484060|NCT00005037|Drug|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
79484061|NCT00385047|Biological|Group A FMP2.1/AS01B|
79484062|NCT00385047|Biological|Group B FMP2.1/AS02A|
79484063|NCT00004203|Drug|oxaliplatin|
79484064|NCT00003705|Drug|BMS-184476|
79484065|NCT00004209|Drug|cisplatin|
79484066|NCT00004209|Drug|mitomycin C|
79484067|NCT00004209|Drug|vinblastine sulfate|
79484068|NCT00005049|Drug|carboplatin|
79811630|NCT02609256|Procedure|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
79980149|NCT02928185|Behavioral|semi-structured interviews|
79980150|NCT02910414|Drug|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
79980151|NCT02910414|Device|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
79980152|NCT02909036|Device|Melphalan|
79980153|NCT02909036|Drug|Pegfilgrastim|
79980154|NCT02909036|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|
79980155|NCT02899221|Radiation|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
79980156|NCT02899221|Procedure|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
79980157|NCT02899221|Other|Laboratory Biomarker Analysis|Correlative studies
79484069|NCT00005049|Drug|cisplatin|
79980158|NCT02893397|Device|Activity Monitor|Wear a fitbit
79484070|NCT00005049|Drug|floxuridine|
79980159|NCT02893397|Behavioral|Exercise Intervention|Undergo supervised exercise sessions
79980160|NCT02879604|Other|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
79484071|NCT00004215|Biological|filgrastim|
79484072|NCT00004215|Biological|leridistim|
79484073|NCT00004215|Drug|cytarabine|
79484074|NCT00004215|Drug|daunorubicin hydrochloride|
79484075|NCT00004221|Drug|Carboplatin|Given IV
79484076|NCT00004221|Drug|Cyclophosphamide|Given IV
79484077|NCT00004221|Biological|Filgrastim|Given SQ
79330788|NCT04819529|Behavioral|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS <2, 6> environmental orientation will be considered~Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~Education: daily visits by trained family members and health staff about the intervention process"
79330789|NCT04829825|Diagnostic Test|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
79330790|NCT04815863|Diagnostic Test|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
79330791|NCT04815863|Diagnostic Test|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
79484078|NCT00004221|Drug|Paclitaxel|Given IV
79650426|NCT05427136|Other|Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT|Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
79650427|NCT05427136|Other|Collection of genetic samples|Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
79650428|NCT00211679|Drug|Botulinum Toxin Type A|
79650429|NCT05427058|Procedure|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
79980161|NCT02879604|Other|Usual|Usual care
79980162|NCT02863926|Biological|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
79650430|NCT05427058|Procedure|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
79330792|NCT04815863|Diagnostic Test|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
79330793|NCT04815629|Radiation|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
79330794|NCT03035591|Drug|ODM-207|
79330795|NCT04819685|Drug|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
79330796|NCT04819607|Other|model of care|Multidisciplinary model of care for BMFS patients.
79330797|NCT02600351|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79330798|NCT02600351|Drug|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79484079|NCT00004221|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
79484080|NCT00004221|Drug|Topotecan Hydrochloride|Given IV
79484081|NCT00005055|Drug|glufosfamide|
79484082|NCT00003711|Drug|irinotecan hydrochloride|
79484083|NCT00003711|Drug|pemetrexed disodium|
79484084|NCT00004227|Biological|cetuximab|
79650431|NCT00238680|Behavioral|Bladder rehabilitation|
79650432|NCT00238680|Behavioral|Bladder rehabilitation with programmable timer|
79650433|NCT04680091|Drug|Pyrotinib Maleate|single oral dose, 400 mg, fed.
79980163|NCT02843425|Other|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
79980164|NCT02843425|Other|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
79980165|NCT02756793|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
79650434|NCT04680091|Drug|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
79330799|NCT02640235|Device|CELSTAT|
79330800|NCT02640235|Device|Surgicel Original|
79330801|NCT05053789|Device|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
79330802|NCT05053789|Device|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
79330803|NCT04829435|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
79330804|NCT04829435|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
79330805|NCT05042635|Drug|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
79330806|NCT05042635|Drug|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
79330807|NCT04815395|Drug|Oxytocin|Administration of oxytocin (24IU) orally
79330808|NCT04815395|Drug|Oxytocin|Administration of oxytocin (24IU) intranasally
79650435|NCT04680364|Other|partnered dance|Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
79811631|NCT02609256|Other|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
79330809|NCT04815395|Drug|Placebo|Administration of placebo orally
79330810|NCT04819139|Other|Active Excersises|Active thumb exercises
79330811|NCT04819139|Other|Reeducation ADL|Reeducation in the activities daily life
79330812|NCT04819139|Other|Joint protection|Used of a thumb orthosis
79330813|NCT04819139|Other|Proprioception exercises|Specific proprioception exercises
79330814|NCT05034679|Biological|Vcinated|Patients who were vacinated.
79330815|NCT03096691|Device|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
79330816|NCT03096535|Procedure|Cooling|Individualized cooling protocol.
79330817|NCT03096535|Procedure|Thermoneutral|Thermoneutral control day.
79330818|NCT05034445|Diagnostic Test|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
79330819|NCT05034211|Procedure|Programmed intermittent bolus epidural|one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
79330820|NCT05034211|Procedure|Provider administered analgesia on patient request|one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
79330821|NCT02599961|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
79330822|NCT03096301|Device|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
79330823|NCT03096301|Device|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
79330824|NCT03096301|Device|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
79484085|NCT00004227|Procedure|conventional surgery|
79484086|NCT00004227|Radiation|radiation therapy|
79484087|NCT00003621|Drug|carmustine|
79484088|NCT00003621|Drug|cisplatin|
79484089|NCT00003621|Drug|etoposide|
79811632|NCT00785434|Drug|escitalopram|Dose ranging up to 50mg
79330825|NCT04829513|Other|kinesio taping|In kinesiology taping with the inhibition method, an I-shaped tape of 15-20 cm in length will be applied on the sacroiliac joint on both sides without stretching the ends with 50% stretching in the middle. In addition, a 25-30 cm long I band will be applied over the right spina iliaca posterior superior, towards the left spina iliaca posterior superior. In the facia correction technique, 2 bands with no cut ends, a 10-15 cm web-shaped band divided into 4 or 5 parts with a width of 1-15 cm will be applied cross over the sacroiliac joint, without stretching the ends with 50% stretching in the middle.
79330826|NCT05033977|Other|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
79330827|NCT05033977|Other|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
79330828|NCT05034055|Drug|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
79330829|NCT05617703|Drug|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
79980166|NCT02756793|Other|Standard of Care Treatment|"May include:~Continue with current systemic agent(s)~Observation~Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
79980167|NCT02744092|Drug|Rivaroxaban|Anticoagulation therapy.
79330830|NCT03095365|Other|Dry needling|Insertion of solid filament needles in the muscle
79484090|NCT00003621|Radiation|radiation therapy|
79484091|NCT00385359|Procedure|aerosol drug deposition strategies|
79484092|NCT00385359|Drug|Albuterol|
79484093|NCT02972619|Other|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
79484094|NCT00004233|Drug|fluorouracil|
79980168|NCT02744092|Drug|Apixaban|Anticoagulation therapy.
79980169|NCT02744092|Drug|Edoxaban|Anticoagulation therapy.
79484095|NCT00004233|Drug|leucovorin calcium|
79484096|NCT00004233|Drug|triacetyluridine|
79484097|NCT00003717|Drug|estramustine phosphate sodium|
79484098|NCT00003717|Drug|paclitaxel|
79484099|NCT00004239|Drug|Compound 506U78|
79484100|NCT00003723|Drug|gemcitabine hydrochloride|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days)
79484101|NCT00005061|Biological|bevacizumab|
79484102|NCT00004245|Drug|sodium salicylate|
79484103|NCT00004251|Drug|letrozole|2.5 mg of letrozole per day
79484104|NCT00005067|Drug|motexafin lutetium|Given IV
79484105|NCT00005067|Drug|photodynamic therapy|Undergo photodynamic therapy
79484106|NCT00003729|Drug|cytarabine|
79484107|NCT00003729|Drug|fludarabine phosphate|
79484108|NCT00003729|Drug|idarubicin|
79484109|NCT00004263|Drug|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
79484110|NCT00004263|Drug|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
79980170|NCT02744092|Drug|Dabigatran|Anticoagulation therapy.
79980171|NCT02744092|Drug|Warfarin|Anticoagulation therapy.
79980172|NCT02744092|Drug|Dalteparin|Anticoagulation therapy.
79980173|NCT02744092|Drug|Enoxaparin|Anticoagulation therapy.
79980174|NCT02744092|Drug|Fondaparinux|Anticoagulation therapy.
79980175|NCT02729402|Other|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
79980176|NCT02704117|Device|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
79980177|NCT02700386|Combination Product|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
79980178|NCT02685098|Biological|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.
79980179|NCT02649959|Drug|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
79980180|NCT02647827|Other|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
79330831|NCT03095365|Other|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
79330832|NCT03095365|Other|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
79330833|NCT03096613|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
79330834|NCT05042245|Drug|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
79484111|NCT00003735|Drug|topotecan hydrochloride|given by mouth
79330835|NCT05042245|Drug|Silymarin capsule|Silymarin capsules in the active comparator arm.
79980181|NCT02647827|Device|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
79980182|NCT02647827|Drug|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
79980183|NCT02605421|Drug|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
79980184|NCT02605421|Drug|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
79980185|NCT02605421|Drug|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
79330836|NCT05042245|Drug|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
79330837|NCT05042245|Drug|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
79330838|NCT04427657|Procedure|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
79330839|NCT04427657|Procedure|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
79330840|NCT03035669|Behavioral|Mindfulness group|8 week program
79330841|NCT03035669|Behavioral|Reading group|8 week program
79330842|NCT03095209|Drug|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
79330843|NCT03095209|Drug|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
79484112|NCT00005073|Drug|zoledronic acid|
79484113|NCT00004275|Drug|growth hormone|
79484114|NCT00004275|Drug|oxandrolone|
79484115|NCT00003741|Biological|monoclonal antibody HeFi-1|
79484116|NCT00005079|Procedure|conventional surgery|
79484117|NCT00004287|Genetic|H5.001CBCFTR|
79484118|NCT00005085|Drug|becatecarin|
79980186|NCT02605421|Drug|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
79980187|NCT02605421|Drug|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
79980188|NCT02605421|Biological|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
79980189|NCT02605421|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC > 2000/μL for 3 consecutive days.
79980190|NCT02582905|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
79980191|NCT02582905|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
79650436|NCT00211718|Drug|intra-articular botulinum toxin type a|
79980192|NCT02582905|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
79650437|NCT04680247|Procedure|VA-LCP|Surgery using the VA-LCP implant
79980193|NCT02548364|Drug|Calcifediol|calcifediol treatment
79330844|NCT03095209|Radiation|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
79650438|NCT04680247|Procedure|NCB-PT|Surgery using the NCB-PT implant
79330845|NCT05617547|Diagnostic Test|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
79330846|NCT05034133|Drug|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
79330847|NCT03096379|Diagnostic Test|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
79330848|NCT03096457|Drug|Paromomycin Sulfate|topical application 2 times a day during 20 days
79330849|NCT03096457|Drug|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
79330850|NCT03096457|Other|Placebo|topical application 2 times a day during 20 days
79330851|NCT03096223|Drug|KHK4083|IV administration
79650439|NCT00238719|Drug|Venlafaxine ER|
79650440|NCT04680169|Device|Bronchoscopic intubation through AuraGain LMA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
79650441|NCT04680169|Device|Bronchoscopic intubation through I-gel SGA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
79650442|NCT04680208|Procedure|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
79650443|NCT00211796|Drug|Divalproex Sodium ER|
79650444|NCT00238758|Drug|Omega-3 Polyunsaturated Fatty Acids|
79330852|NCT05617469|Other|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
79330853|NCT03096145|Behavioral|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
79330854|NCT03096145|Behavioral|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
79330855|NCT03096145|Behavioral|Health incentive|Smokers receive a $25 gift card if they call the quitline
79330856|NCT04814303|Procedure|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
79330857|NCT04814303|Procedure|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
79330858|NCT04814303|Procedure|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
79330859|NCT05053477|Drug|mehylprednisolone injection|(40 mg)
79484119|NCT00004293|Drug|glucocerebrosidase|
79484120|NCT00003747|Drug|carboplatin|
79330860|NCT05053477|Device|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
79330861|NCT05053477|Biological|platelet-rich plasma|2 ml of PRP
79330862|NCT04814459|Other|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
79330863|NCT05033587|Drug|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
79330864|NCT05033587|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
79330865|NCT05033587|Radiation|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
79980194|NCT02548364|Drug|Placebo|placebo control group
79650445|NCT05426824|Drug|Pegaspargase（P-GOD）|stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
79330866|NCT05053009|Drug|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
79484121|NCT00003747|Drug|temozolomide|
79484122|NCT00004311|Drug|leuprolide acetate|
79484123|NCT00004311|Drug|spironolactone|
79484124|NCT00004317|Drug|Leucovorin calcium|See arm descriptions
79980195|NCT02546375|Drug|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
79980196|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
79980197|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
79980198|NCT02504333|Drug|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
79484125|NCT00004317|Drug|Pyrimethamine|See arm descriptions
79484126|NCT00004317|Drug|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
79484127|NCT00004317|Drug|Sulfadiazine|See arm descriptions
79330867|NCT03095131|Device|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
79330868|NCT05617235|Device|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~In order to stimulate the facilitation of the diaphragmatic function~Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
79330869|NCT03095911|Other|News items with spin|Interpretation of news items with spin
79484128|NCT02973243|Device|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
79330870|NCT03095911|Other|News items without spin|Interpretation of news items without spin
79484129|NCT00005091|Drug|exatecan mesylate|
79484130|NCT00004323|Drug|anti-thymocyte globulin|
79484131|NCT00004323|Drug|cyclophosphamide|
79484132|NCT00004323|Drug|cyclosporine|
79484133|NCT00004323|Drug|mesna|
79484134|NCT00004323|Drug|methotrexate|
79484135|NCT00004323|Drug|methylprednisolone|
79484136|NCT00003753|Drug|dexamethasone|
79650446|NCT05426824|Drug|Pegaspargase（PEMD）|stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
79650447|NCT05426668|Other|No Intervention|No Intervention
79980199|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
79980200|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
79980201|NCT02498964|Other|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
79980202|NCT02491931|Dietary Supplement|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
79980203|NCT02473042|Procedure|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
79980204|NCT02473042|Drug|Zofran|4 mg by vein for 1 dose.
79980205|NCT02473042|Drug|Dexamethasone|10 mg by vein for 1 dose.
79484137|NCT00003753|Drug|floxuridine|
79484138|NCT00003753|Drug|irinotecan hydrochloride|
79484139|NCT00003753|Procedure|adjuvant therapy|
79484140|NCT00003753|Procedure|conventional surgery|
79484141|NCT00005097|Drug|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
79484142|NCT00003759|Biological|BCG vaccine|
79484143|NCT00003759|Drug|valrubicin|
79484144|NCT00003759|Procedure|conventional surgery|
79484145|NCT00003765|Drug|O6-benzylguanine|
79484146|NCT00003765|Drug|carmustine|
79484147|NCT00004347|Behavioral|diet|
79484148|NCT00003771|Biological|therapeutic estradiol|
79484149|NCT00003771|Drug|norethindrone acetate|
79484150|NCT00004359|Drug|methoxsalen|
79484151|NCT00004401|Drug|botulism immune globulin|
79484152|NCT00003783|Biological|filgrastim|
79484153|NCT00003783|Drug|asparaginase|
79484154|NCT00003783|Drug|cyclophosphamide|
79484155|NCT00003783|Drug|cytarabine|
79484156|NCT00003783|Drug|daunorubicin hydrochloride|
79484157|NCT00003783|Drug|dexamethasone|
79484158|NCT00003783|Drug|etoposide|
79484159|NCT00003783|Drug|idarubicin|
79484160|NCT00003783|Drug|leucovorin calcium|
79811633|NCT02620709|Behavioral|Hula intervention|Hula and heart health education
79811634|NCT00785590|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
79650448|NCT00211835|Behavioral|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
79484161|NCT00003783|Drug|mercaptopurine|
79330871|NCT03095989|Behavioral|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
79484162|NCT00003783|Drug|methotrexate|
79811635|NCT00458341|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
79980206|NCT02473042|Drug|Phenergan|6.25 mg by vein for 1 dose.
79484163|NCT00003783|Drug|prednisone|
79484164|NCT00003783|Drug|vincristine sulfate|
79484165|NCT00003783|Radiation|radiation therapy|
79484166|NCT00003789|Drug|isolated limb perfusion|Undergo isolated limb perfusion
79484167|NCT00003789|Drug|melphalan|Given via limb perfusion
79484168|NCT00003789|Biological|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
79484169|NCT00003789|Other|pharmacological study|Correlative studies
79650449|NCT00211835|Behavioral|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
79650450|NCT05426590|Device|Specular biomicroscopy|Specular microscopy will be done before and 3 weeks after cataract surgery
79811636|NCT00692081|Behavioral|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
79811637|NCT00692081|Behavioral|Special vocational training|as provided in German special centres for vocational training
79980207|NCT02473042|Drug|Pepcid|10 mg by vein for 1 dose.
79330872|NCT04813913|Drug|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
79330873|NCT03095755|Other|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
79330874|NCT03095755|Other|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
79330875|NCT04828889|Device|Anal dilators|Anal sphincter training for relaxation
79650451|NCT00238797|Drug|Gefitinib|
79811638|NCT02610894|Other|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
79811639|NCT02610894|Other|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
79811640|NCT00790894|Drug|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
79980208|NCT02473042|Behavioral|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
79980209|NCT02328235|Other|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
79330876|NCT04828889|Procedure|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
79330877|NCT05033509|Other|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
79330878|NCT04828655|Behavioral|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
79330879|NCT05033197|Behavioral|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
79330880|NCT05041933|Drug|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
79330881|NCT04828499|Procedure|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
79484170|NCT00003789|Other|laboratory biomarker analysis|Correlative studies
79484171|NCT00004407|Drug|immune globulin|
79484172|NCT00003795|Procedure|quality-of-life assessment|
79980210|NCT02305173|Drug|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
79980211|NCT02305173|Drug|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
79980212|NCT02285439|Drug|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
79980213|NCT02273388|Drug|BI 6727|BI 6727
79980214|NCT02272790|Drug|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
79484173|NCT00004419|Drug|insulin-like growth factor I|
79484174|NCT00004431|Drug|L-baclofen|
79484175|NCT00384891|Device|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
79980215|NCT02272790|Drug|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
79330882|NCT04828499|Procedure|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
79330883|NCT05042089|Other|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
79330884|NCT04819061|Other|tDCS Active|This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
79484176|NCT00384891|Drug|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
79484177|NCT00004437|Device|Multichannel Auditory Brain Stem Implant|
79484178|NCT00384969|Drug|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
79484179|NCT00385437|Behavioral|Driving Simulator Testing|
79484180|NCT00385437|Drug|Mirtazapine Treatment|
79484181|NCT00004443|Drug|NTBC|
79484182|NCT00004449|Behavioral|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
79484183|NCT00004449|Behavioral|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
79484184|NCT00004467|Drug|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
79330885|NCT04819061|Other|tDCS sham|"This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies."
79484185|NCT00004467|Drug|Placebo|Infusion of 5% dextrose
79484186|NCT00003801|Procedure|management of therapy complications|
79484187|NCT00003801|Procedure|quality-of-life assessment|
79484188|NCT00004479|Drug|midodrine|
79484189|NCT00004485|Drug|cyclosporine|
79484190|NCT00004485|Drug|fludarabine|
79484191|NCT00004485|Drug|mycophenolate mofetil|
79484192|NCT00004485|Procedure|Bone Marrow Transplantation|
79484193|NCT00385125|Drug|Bendamustine|
79484194|NCT00385125|Drug|Rituximab|
79484195|NCT00004497|Drug|UT-15|
79330886|NCT04814381|Drug|Ketamine + Magnesium sulfate (drug combination)|A single infusion will be performed over 2 hours with 90 days follow-up.
79484196|NCT00003819|Biological|QS21|
79484197|NCT00003819|Biological|TF(c)-KLH conjugate vaccine|
79484198|NCT00003819|Biological|Thomsen-Friedenreich antigen|
79484199|NCT00003819|Biological|keyhole limpet hemocyanin|
79484200|NCT00003825|Drug|pentosan polysulfate sodium|
79484201|NCT00003825|Procedure|quality-of-life assessment|
79484202|NCT00003831|Procedure|conventional surgery|
79484203|NCT00004533|Drug|Adeno-associated virus-CFTR vector|
79484204|NCT00004551|Drug|nicotine replacement patch|
79484205|NCT00004551|Behavioral|mood management|
79484206|NCT00004569|Procedure|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
79484207|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
79484208|NCT02678312|Drug|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
79484209|NCT02678312|Drug|Placebo of LCZ696|
79484210|NCT02678312|Drug|Placebo of Enalapril|
79484211|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
79484212|NCT00003837|Drug|nelarabine|
79484213|NCT00003843|Drug|irinotecan hydrochloride|
79484214|NCT00003843|Genetic|mutation analysis|
79484215|NCT00003843|Genetic|polymorphism analysis|
79484216|NCT00003849|Biological|rituximab|
79484217|NCT00004575|Drug|Miconazole, L-NMMA, Bradykinin|
79484218|NCT02972775|Other|no interventions. observational study|
79484219|NCT00422006|Procedure|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
79484220|NCT00422006|Procedure|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
79484221|NCT00422006|Behavioral|diet|diet
79484222|NCT00422006|Other|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
79484223|NCT00004581|Drug|Lopinavir/Ritonavir|
79484224|NCT00004581|Drug|Nevirapine|
79330887|NCT05041777|Device|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. [2] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
79330888|NCT04819217|Dietary Supplement|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 < eGFR < 45 ml/min/1.73m2 and UACR > 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
79330889|NCT04819217|Dietary Supplement|Probiotics|Probiotics
79330890|NCT05041465|Other|Clay mask|Clay mask powders- French green, Rhassul and bentonite
79484225|NCT02466230|Device|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
79484226|NCT02467166|Device|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
79484227|NCT00003855|Procedure|axillary lymph node dissection|
79484228|NCT00003855|Radiation|whole breast irradiation|
79484229|NCT02468570|Other|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
79484230|NCT02468804|Device|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
79484231|NCT02468804|Device|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
79484232|NCT00004257|Drug|fluorouracil|
79484233|NCT00004257|Drug|oxaliplatin|
79484234|NCT00004257|Procedure|conventional surgery|
79484235|NCT00004257|Radiation|radiation therapy|
79650452|NCT05426551|Other|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
79484236|NCT00004647|Drug|mexiletine|
79484237|NCT02469116|Drug|Docetaxel|
79484238|NCT02469116|Drug|Carboplatin|
79484239|NCT02469116|Drug|Pegylated G-CSF|
79484240|NCT00003861|Other|laboratory biomarker analysis|
79484241|NCT00362960|Drug|Olmesartan medoxomil|
79484242|NCT00362960|Drug|Losartan|
79484243|NCT00004659|Procedure|irradiation|
79484244|NCT00004659|Procedure|radiosurgery|
79484245|NCT00003867|Drug|capecitabine|
79484246|NCT00003867|Drug|irinotecan hydrochloride|
79330891|NCT04818905|Dietary Supplement|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
79484247|NCT00363506|Behavioral|Serotona Plus and dietary behavior management|
79484248|NCT00004665|Drug|dehydroepiandrosterone|
79484249|NCT00363584|Drug|capecitabine|
79330892|NCT04818905|Other|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
79330893|NCT05052619|Drug|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
79330894|NCT05052619|Other|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
79330895|NCT04813679|Diagnostic Test|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
79330896|NCT05052775|Other|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
79330897|NCT05052775|Other|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
79330898|NCT05052775|Other|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
79330899|NCT04427423|Other|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
79330900|NCT05052463|Other|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
79330901|NCT04813367|Procedure|Surgery of twisted fallopian tubes|Patients diagnosed with twisted fallopian tube go through surgery.
79330902|NCT03094741|Other|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
79330903|NCT04818437|Other|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
79330904|NCT04818437|Other|CORE STABILITY EXERCISES|"Abdominal bracing while lying in supine position.~Abdominal bracing with heel slide while lying in supine position.~Abdominal bracing with Leg lifts while lying in supine position.~Abdominal bracing with bridging while lying in supine position.~Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
79330905|NCT03095677|Other|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
79484250|NCT00363584|Other|clinical observation|
79484251|NCT00363584|Procedure|adjuvant therapy|
79484252|NCT00003873|Drug|fluorouracil|Given IV or orally
79484253|NCT00003873|Drug|eniluracil|Given orally
79484254|NCT00363116|Drug|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
79484255|NCT00004689|Drug|amithiozone|
79484256|NCT00004689|Drug|clarithromycin|
79484257|NCT00004689|Drug|ethambutol|
79484258|NCT00004689|Drug|rifampin|
79484259|NCT00004689|Drug|streptomycin|
79484260|NCT02470910|Device|Magnetic Resonance Imaging|
79484261|NCT00004695|Drug|PEG-interleukin-2|
79484262|NCT00004731|Drug|Coenzyme Q10|
79484263|NCT00003885|Drug|arsenic trioxide|
79484264|NCT00003891|Drug|lurtotecan liposome|
79484265|NCT00004755|Drug|allopurinol|
79484266|NCT00004755|Drug|glucantime|
79484267|NCT02473718|Other|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
79484268|NCT02473718|Device|Ultrasound|
79484269|NCT00003897|Biological|gp100 antigen|
79484270|NCT00003897|Biological|sargramostim|
79484271|NCT00003903|Procedure|management of therapy complications|
79650453|NCT05426317|Other|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
79330906|NCT03095677|Other|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
79650454|NCT00211874|Behavioral|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
79980216|NCT02272790|Drug|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
79980217|NCT02272790|Drug|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
79980218|NCT02272790|Drug|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
79980219|NCT02172885|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
79980220|NCT02115191|Device|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
79811641|NCT00790894|Drug|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
79811642|NCT02623283|Other|No intervention given|Participants will have a full dental examination but no operative intervention
79980221|NCT02115191|Procedure|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
79980222|NCT02100956|Drug|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
79811643|NCT00785668|Drug|AER 001|10 mg dry powder administered using a handheld device
79330907|NCT04813757|Other|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
79330908|NCT04813757|Other|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
79811644|NCT02623127|Drug|Sunitinib|
79980223|NCT02100956|Drug|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
79980224|NCT02081885|Procedure|Tricalcium Phosphate / Chitosan|
79980225|NCT02081885|Procedure|Autologous Graft|
79330909|NCT03094897|Drug|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
79980226|NCT02068586|Drug|Sunitinib|Given PO
79980227|NCT02068586|Drug|Valproic Acid|Given PO
79980228|NCT02068586|Drug|Sunitinib Malate|Given PO
79980229|NCT02068586|Drug|Sunitinib Malate + Valproic Acid|Given PO
79980230|NCT02009644|Device|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
79980231|NCT01757418|Drug|Immune Globulin Intravenous|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
79980232|NCT01757418|Other|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
79980233|NCT01535430|Diagnostic Test|Brain mapping|Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
79980234|NCT01438411|Drug|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
79650455|NCT05426278|Device|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ & 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
79650456|NCT00238836|Behavioral|Self-management of chronic illness|
79650457|NCT05426044|Drug|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
79650458|NCT05426044|Device|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
79330910|NCT03094897|Device|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
79330911|NCT04813523|Drug|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
79330912|NCT05032261|Drug|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
79330913|NCT04812977|Drug|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
79330914|NCT05040997|Diagnostic Test|Small airways assessment|Small airways assessment
79330915|NCT05052073|Diagnostic Test|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
79330916|NCT05052073|Diagnostic Test|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
79330917|NCT04813133|Other|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
79330918|NCT04813133|Other|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
79330919|NCT04813133|Other|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
79484272|NCT00003909|Drug|motexafin gadolinium|Given IV
79650459|NCT05425966|Behavioral|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
79650460|NCT05425693|Other|Hybrid Warm-up|Dynamic + stretching exercises
79650461|NCT05425693|Other|Dynamic Warm-up|Dynamic exercises
79650462|NCT05425693|Other|Stretching Warm-up|Stretching exercises
79330920|NCT05032027|Other|probiotics|recieving probiotics at the first day of chemoradiotherapy daily
79330921|NCT04813211|Procedure|mobile artificial cervical vertebrae replacement|"Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~Anesthesia: General anesthesia via oral tracheal intubation.~Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
79330922|NCT04813211|Procedure|anterior cervical corpectomy and fusion|"Position: The patient is in a supine position with the neck hyperextended.~Anesthesia: General anesthesia via oral tracheal intubation.~Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
79330923|NCT03098017|Other|Short pasta (dry)|50g available carbohydrate portion of penne (~71g uncooked) will be cooked according to package instructions and served with 500mL water
79484273|NCT00003909|Radiation|radiation therapy|Undergo radiation therapy
79330924|NCT03098017|Other|Long pasta (dry)|50g available carbohydrate portion of spaghetti (~71g uncooked) will be cooked according to package instructions and served with 500mL water
79484274|NCT00003909|Other|pharmacological study|Correlatives studies
79980235|NCT01393483|Other|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
79330925|NCT03098017|Other|Couscous|50g available carbohydrate portion of couscous (~70g uncooked) will be cooked according to package instructions and served with 500mL water
79330926|NCT03098017|Other|Glucose|50g available carbohydrate portion of glucose monohydrate (~55g) will be dissolved in 500mL water
79330927|NCT05619341|Dietary Supplement|psyllium|psyllium 20g
79650463|NCT00238875|Procedure|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
79650464|NCT05425654|Drug|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
79980236|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
79980237|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
79980238|NCT01343342|Dietary Supplement|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
79980239|NCT01302834|Biological|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
79484275|NCT02474498|Drug|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
79484276|NCT02474498|Device|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
79484277|NCT02474498|Procedure|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
79650465|NCT05425576|Drug|OT-101|OT-101 in combination of pembrolizumab
79811645|NCT05263492|Drug|Lenvatinib|Lenvatinib once a day by mouth every day
79811646|NCT05263492|Drug|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
79811647|NCT04134611|Device|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
79330928|NCT05619341|Dietary Supplement|inulin|long chain fructan
79330929|NCT05040919|Other|collection of medical and socio-demographic data|collection of medical and socio-demographic data
79330930|NCT05040607|Other|Data Collection|"The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~Retrospective data of pulmonary function, respiratory muscle strength, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength (Intervention Group).~Retrospective data of pulmonary function, respiratory muscle strength, and functional capacity before and after airway clearance techniques performed for 6 weeks as home-based therapy in PCD with decreased respiratory muscle strength (Control group)."
79484278|NCT00004767|Drug|Sodium Benzoate|
79484279|NCT00004767|Drug|Sodium Phenylacetate|
79484280|NCT00004767|Drug|Sodium Phenylbutyrate|
79484281|NCT00004767|Behavioral|Dietary Intervention|
79484282|NCT00004779|Genetic|Ad5-CB-CFTR|
79484283|NCT00004785|Drug|dexamethasone|
79484284|NCT00004785|Drug|methylprednisolone|
79330931|NCT05040607|Other|Data Collection|-Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL)
79330932|NCT05040529|Procedure|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
79330933|NCT05040529|Procedure|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
79330934|NCT05040139|Procedure|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
79330935|NCT05040139|Procedure|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
79330936|NCT05031793|Other|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
79330937|NCT05031793|Other|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
79330938|NCT05039905|Drug|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
79330939|NCT05039983|Other|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
79484285|NCT02476448|Drug|Normal saline|Used to distend the bladder for cystoscopic evaluation
79330940|NCT05031403|Other|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
79484286|NCT02476448|Drug|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
79484287|NCT02476448|Drug|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
79484288|NCT02476448|Drug|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
79484289|NCT00004797|Drug|fructose|
79484290|NCT00004797|Drug|placebo|
79484291|NCT00385749|Device|RV apical vs RV septal defibrillation threshold testing|
79484292|NCT00004809|Procedure|gene therapy|
79811648|NCT04134611|Device|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
79811649|NCT02620631|Drug|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
79484293|NCT00003933|Other|laboratory biomarker analysis|
79484294|NCT02496104|Behavioral|Package n°1 of the APIB|
79484295|NCT00004815|Drug|growth hormone|
79484296|NCT00004827|Drug|docosahexaenoic acid|
79980240|NCT01302834|Drug|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
79330941|NCT05031403|Other|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
79811650|NCT02620631|Drug|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
79811651|NCT00816036|Behavioral|Smoking Cessation Guideline Implementation|"1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
79811652|NCT00795652|Behavioral|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
79980241|NCT01302834|Radiation|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
79980242|NCT01203839|Radiation|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
79980243|NCT01153698|Drug|dabigatran|anticoagulation
79980244|NCT01142427|Other|Cytology Specimen Collection Procedure|Correlative studies
79980245|NCT01142427|Other|Laboratory Biomarker Analysis|Correlative studies
79330942|NCT05039827|Other|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
79330943|NCT05039827|Other|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
79330944|NCT05040061|Behavioral|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
79330945|NCT05040061|Behavioral|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
79811653|NCT02622971|Other|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
79811654|NCT02622971|Other|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
79811655|NCT00795730|Drug|NSA-789|
79330946|NCT05051371|Device|Train of four monitoring|Train of four monitoring in postoperative care unit
79811656|NCT00795730|Other|placebo|
79811657|NCT04027920|Drug|Shenghua Decoction|Three days' shenghua decoction treatment
79811658|NCT04030572|Drug|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
79811659|NCT00795808|Drug|Metformin|500mg tds for 6 months
79811660|NCT00795808|Drug|Placebo|One tablet tds for 6 months
79330947|NCT05051839|Procedure|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
79330948|NCT05031559|Behavioral|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
79330949|NCT05031559|Behavioral|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
79330950|NCT05031559|Behavioral|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
79650466|NCT05425381|Behavioral|Enhanced version of Interconnected Systems Framework|"District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~Detailed memoranda of understanding between schools and collaborating mental health centers~Community mental health clinicians meaningfully participate in MTSS teams~Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~Universal screening of students' social, emotional, behavioral, and academic functioning~Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~A Community of Practice (Wenger, 2010) among the ISFE schools"
79811661|NCT00795808|Drug|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
79811662|NCT00795808|Drug|Metformin|500mg tds for 6 months
79330951|NCT05039749|Device|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
79330952|NCT05039437|Dietary Supplement|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
79811663|NCT00795808|Drug|Clomiphene|Ovulatory dose for 6 months
79811664|NCT04135781|Drug|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
79811665|NCT04135781|Drug|Tegafur|S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
79811666|NCT04135781|Drug|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
79330953|NCT05039437|Dietary Supplement|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
79330954|NCT05030779|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
79330955|NCT05031091|Other|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
79330956|NCT05051683|Procedure|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
79650467|NCT05425381|Behavioral|Positive Behavioral Interventions and Supports with Co-located School Mental Health|"PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai & Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010)."
79650468|NCT00238914|Drug|Naltrexone|50mg of oral naltrexone daily
79650469|NCT00238914|Behavioral|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
79650470|NCT00238914|Behavioral|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
79650471|NCT05425342|Device|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
79650472|NCT04668976|Device|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
79650473|NCT04668976|Drug|Floxuridine (FUDR)|Please see Detailed Description.
79650474|NCT04668976|Drug|Gemcitabine|Please see Detailed Description.
79650475|NCT04668976|Drug|Oxaliplatin|Please see Detailed Description.
79484297|NCT04744610|Diagnostic Test|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
79484298|NCT02483468|Behavioral|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
79650476|NCT04668976|Drug|Irinotecan (CPT-11)|Please see Detailed Description.
79650477|NCT04668976|Drug|Fluorouracil|Please see Detailed Description.
79330957|NCT04814069|Drug|Tislelizumab|Tislelizumab 200mg q3w
79330958|NCT05031169|Procedure|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
79330959|NCT05051137|Biological|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
79811667|NCT04135781|Drug|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
79330960|NCT05051137|Drug|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
79484299|NCT02483468|Device|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
79484300|NCT02483468|Device|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
79484301|NCT02279823|Drug|CB-03-01 solution|Investigational drug solution
79484302|NCT02279823|Drug|Minoxidil Solution 5%|FDA approved marketed product
79484303|NCT02279823|Drug|Placebo solution|Vehicle solution
79484304|NCT02480582|Other|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\kg
79330961|NCT05039125|Radiation|ultrasonic cavitation|"From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~Part III: 3cm above the umbilicus to 2cm below the umbilicus~After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
79650478|NCT04668976|Drug|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
79650479|NCT00238953|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79650480|NCT04669366|Drug|sunitinib|As provided in real world
79650481|NCT04669366|Drug|axitinib|As provided in real world
79650482|NCT04668703|Procedure|Conbercept intravitreal injection|intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery
79650483|NCT04669327|Other|gait analysis|Vicon nexus with MTI force plate form
79650484|NCT04721301|Combination Product|Nivolumab plus Ipilimumab plus Maraviroc|In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
79650485|NCT04668625|Behavioral|Participate in a massive musical event|Participate in a massive musical event
79650486|NCT04668508|Drug|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
79811668|NCT04046692|Other|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
79811669|NCT04046692|Other|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
79330962|NCT05038969|Drug|Stomopral|1 capsule contains 40 mg Esomeprazole
79330963|NCT05038969|Drug|Nexium|1 capsule contains 40 mg Esomeprazole
79811670|NCT04046692|Other|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
79811671|NCT04046692|Other|Hospital School Experience, point of view of parents|Operators interview parents
79811672|NCT05758350|Behavioral|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
79811673|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
79811674|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
79330964|NCT04434547|Biological|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
79330965|NCT04434391|Other|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
79650487|NCT04668430|Other|imaging and motion analysis|performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
79650488|NCT00238992|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
79650489|NCT00556465|Drug|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
79650490|NCT04668469|Drug|Ivermectin|"evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection"
79650491|NCT04668469|Drug|Hydroxychloroquine|evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
79650492|NCT04668469|Behavioral|personal protective Measures|evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
79650493|NCT04668547|Device|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
79811675|NCT04135313|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14
79811676|NCT04135313|Drug|Oxaliplatin|130 mg/m2 iv day 1
79811677|NCT04135313|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
79811678|NCT04135313|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
79811679|NCT04135313|Procedure|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
79330966|NCT05030389|Behavioral|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
79330967|NCT05030389|Behavioral|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
79330968|NCT05030389|Behavioral|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
79811680|NCT00785746|Other|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
79330969|NCT05030389|Behavioral|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
79330970|NCT05038579|Procedure|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
79330971|NCT05038657|Drug|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
79330972|NCT03094585|Other|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
79330973|NCT03094585|Other|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
79330974|NCT05038501|Other|To study comorbidities in patients undergoing Oncosurgeries|In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
79330975|NCT03095833|Other|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
79330976|NCT03095833|Other|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
79330977|NCT03095833|Other|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
79330978|NCT03095833|Other|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
79484305|NCT02480582|Other|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
79811681|NCT05262972|Other|Conservatory treatment|Personalized plantar orthosis
79811682|NCT05262972|Other|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
79811683|NCT00692159|Drug|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
79811684|NCT00692315|Drug|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
79330979|NCT03095833|Other|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
79330980|NCT03095833|Other|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
79330981|NCT03095833|Other|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
79330982|NCT03095833|Other|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
79650494|NCT00211913|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
79650495|NCT00211913|Biological|placebo|single IM dose
79650496|NCT00239031|Drug|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
79650497|NCT00239070|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79650498|NCT00211952|Drug|celecoxib|
79650499|NCT00239109|Drug|Ziprasidone|
79650500|NCT00239109|Drug|Olanzapine|
79650501|NCT00239109|Procedure|Scales|
79811685|NCT02609022|Biological|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
79330983|NCT03095833|Other|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
79650502|NCT00239109|Procedure|measures of the body (Weight...)|
79650503|NCT00239109|Procedure|Serum analysis|
79650504|NCT00211991|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
79650505|NCT00239148|Drug|E1 and G1|
79650506|NCT00212030|Drug|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
79650507|NCT00212030|Drug|placebo|Control
79650508|NCT00239187|Drug|E1 and G1|
79650509|NCT00212069|Drug|gemcitabine, carboplatin|
79650510|NCT02961777|Other|implementation of care pathway|implementation of a care pathway
79650511|NCT00212108|Drug|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
79330984|NCT03095833|Other|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
79330985|NCT03095833|Other|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
79330986|NCT05038423|Behavioral|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., & Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., & Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
79330987|NCT05038423|Behavioral|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
79330988|NCT05038189|Diagnostic Test|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
79330989|NCT05038189|Diagnostic Test|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
79650512|NCT00239265|Drug|Tamuslosin|
79650513|NCT00212186|Drug|Selenium Supplements (essential nutrient)|
79650514|NCT00414258|Procedure|breastfeeding|See detailed description.
79330990|NCT05038189|Diagnostic Test|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
79330991|NCT05051215|Other||
79980246|NCT01115582|Drug|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
79980247|NCT01048853|Procedure|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
79330992|NCT04973059|Device|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
79330993|NCT04973059|Device|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
79330994|NCT05038111|Drug|Dexmedetomidine|perioperative dexmedetomidine infusion
79330995|NCT05030077|Drug|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
79330996|NCT05030077|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
79330997|NCT05030077|Drug|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
79330998|NCT05030077|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
79811686|NCT02609022|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
79330999|NCT05038033|Behavioral|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
79331000|NCT05038033|Behavioral|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
79331001|NCT05029531|Combination Product|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
79331002|NCT05037643|Procedure|TIPS|Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
79331003|NCT05029453|Drug|Apatinib|In experimental group, the drug used with apatinib and chemotherapy.
79331004|NCT04434625|Drug|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group and those in the control group underwent colonoscopy directly
79811687|NCT02623049|Other|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
79811688|NCT02608944|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
79811689|NCT02608944|Drug|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
79811690|NCT02608944|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
79980248|NCT01048853|Other|Quality-of-Life Assessment|Ancillary studies
79980249|NCT01048853|Procedure|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
79980250|NCT01048853|Procedure|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
79980251|NCT01048853|Procedure|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
79980252|NCT01040624|Radiation|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
79980253|NCT01040624|Radiation|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
79980254|NCT01000753|Other|Cytology Specimen Collection Procedure|Correlative studies
79811691|NCT02608944|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
79811692|NCT02608944|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
79980255|NCT00959283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79811693|NCT00696917|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
79811694|NCT00696917|Biological|Engerix™-B|3-dose intramuscular injection
79331005|NCT05029765|Dietary Supplement|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
79331006|NCT05029765|Dietary Supplement|Healthy diet (WHO recommendations)|Recommendations according to WHO
79811695|NCT00913614|Drug|Eplivanserin (SR46349)|Oral administration
79331007|NCT05029765|Dietary Supplement|Placebo|Placebo
79331008|NCT05029765|Dietary Supplement|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
79331009|NCT02640157|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
79811696|NCT05755230|Other|No intervention|No intervention
79811697|NCT05756478|Other|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
79811698|NCT00664534|Drug|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
79980256|NCT00959283|Other|Pharmacological Study|Correlative studies
79980257|NCT00919269|Other|Cytology Specimen Collection Procedure|Correlative studies
79980258|NCT00919269|Other|Laboratory Biomarker Analysis|Correlative studies
79980259|NCT00899990|Other|Laboratory Biomarker Analysis|Correlative studies
79980260|NCT00899275|Other|Cytology Specimen Collection Procedure|Correlative studies
79811699|NCT00664534|Drug|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
79811700|NCT00594035|Device|Spinal Sealant System|
79331010|NCT02640157|Drug|Sofosbuvir|Tablet
79811701|NCT00594035|Device|Standard of care|Standard of care: devices intended to provide a watertight closure
79811702|NCT02620475|Device|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
79331011|NCT02640157|Drug|Daclatasvir|Tablet
79331012|NCT04471519|Biological|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
79331013|NCT04471519|Biological|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
79650515|NCT00414297|Device|ECP Therapy|application of ECP Therapy to CAD Patients
79811703|NCT00913848|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
79811704|NCT00913848|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
79811705|NCT00790972|Drug|Sinofresh|two sprays in each nostril three times daily for one week
79811706|NCT00790972|Drug|Placebo|two sprays in each nostril three times daily for one week
79980261|NCT00804856|Drug|Volasertib|Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
79331014|NCT04471519|Biological|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
79331015|NCT04471519|Biological|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
79331016|NCT04471519|Biological|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
79331017|NCT04471519|Biological|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
79331018|NCT05037565|Dietary Supplement|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
79331019|NCT05037721|Other|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
79331020|NCT05037721|Other|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
79650516|NCT00212303|Behavioral|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
79650517|NCT00414336|Drug|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
79650518|NCT00212342|Drug|Norethisterone,Ethinylestradiol|
79980262|NCT00804856|Drug|Cytarabine|Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
79980263|NCT00769652|Behavioral|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
79331021|NCT05037253|Drug|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
79331022|NCT05029297|Drug|Capsaicin|
79331023|NCT05028907|Drug|5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
79484306|NCT02415842|Other|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
79650519|NCT00212342|Drug|Sugar pill|
79650520|NCT00414375|Procedure|Operation on Admission|Laparoscopic appendectomy on admission
79980264|NCT00769652|Behavioral|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during & after treatment."
79650521|NCT00414375|Procedure|Drainage and Interval Appendectomy|drainage with interval appendectomy
79331024|NCT05028907|Drug|sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
79331025|NCT03094117|Other|News items with spin|Interpretation of news items with spin
79331026|NCT03094117|Other|News items without spin|Interpretation of news items without spin
79331027|NCT05050201|Device|Sleepio|Digital CBT application for insomnia
79331028|NCT05026411|Diagnostic Test|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
79650522|NCT00212381|Drug|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
79650523|NCT00212381|Dietary Supplement|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
79331029|NCT05026411|Diagnostic Test|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
79484307|NCT04040361|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W
79484308|NCT04040361|Drug|Ramucirumab|Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W
79650524|NCT00414414|Drug|Prednisone|
79650525|NCT00414414|Drug|placebo|placebo
79650526|NCT00212420|Procedure|parenteral nutrition; enteral nutrition|
79650527|NCT00239304|Drug|Gefitinib|
79650528|NCT00239304|Drug|Cisplatin|
79650529|NCT00239304|Procedure|Radiotherapy|
79650530|NCT00212459|Behavioral|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
79650531|NCT00212459|Behavioral|Control|No more contacts are made with control patients after the initial counseling session.
79650532|NCT00239343|Drug|gefitinib|
79331030|NCT05026411|Diagnostic Test|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
79331031|NCT03094351|Procedure|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
79331032|NCT03094351|Procedure|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
79331033|NCT03094273|Procedure|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
79331034|NCT05025319|Radiation|X-ray image|Bedside x-ray at intensive unit.
79331035|NCT05025553|Dietary Supplement|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
79331036|NCT05028127|Drug|Bimekizumab|Subjects will be receiving bimekizumab at pre-specified time-points.
79331037|NCT05024695|Device|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
79331038|NCT05049811|Behavioral|mini program|To design, construct, and test the mini program in patients managing cancer pain
79980265|NCT00294580|Drug|Maloprim|
79980266|NCT01315860|Other|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
79980267|NCT03309358|Drug|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
79484309|NCT04040361|Procedure|Surgery|Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
79650533|NCT00411593|Drug|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
79650534|NCT00411593|Drug|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
79484310|NCT00385905|Device|Excel Drug-eluting stent|
79484311|NCT00385983|Device|Harmonic Scalpel|
79484312|NCT02481206|Device|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
79484313|NCT00386061|Drug|rimonabant (SR141716)|
79650535|NCT00239382|Drug|Meloxicam ampoule|
79980268|NCT03309358|Drug|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
79980269|NCT03309280|Other|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
79980270|NCT03309280|Diagnostic Test|Evolution of the renal function|Evolution of the renal function in the next two days
79980271|NCT04391556|Drug|Firmagon|120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
79980272|NCT03314194|Other|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
79980273|NCT05066490|Other|Endurance exercise|Treadmill training at moderate intensity.
79331039|NCT05049811|Behavioral|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
79331040|NCT05028049|Drug|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
79331041|NCT05028049|Drug|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
79331042|NCT05028049|Other|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
79484314|NCT02415998|Procedure|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
79484315|NCT02481440|Biological|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
79650536|NCT00239382|Drug|Meloxicam tablet|
79650537|NCT00411827|Procedure|PRK with conjunctival impression cytology before and after surgery|
79650538|NCT00411827|Procedure|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
79650539|NCT00239421|Drug|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
79650540|NCT00239421|Drug|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
79980274|NCT05066490|Other|Resistance exersises.|Resistance exercises using the 10 repetition maximum.
79331043|NCT05028049|Other|plateau areas|Patients should be long staying residents in plateau areas (altitude level>3000 meters above sea level)
79331044|NCT05024461|Diagnostic Test|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~Pre-analytical particularities and analytical particularities~Cycle threeshold~Demographic variables~Clinical variables~Clinical criteria~Questionnaire on the perception of the 2 sampling methods"
79331045|NCT03093649|Other|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
79331046|NCT03093649|Other|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
79331047|NCT05024617|Other|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
79484316|NCT02481596|Behavioral|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
79484317|NCT02481596|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
79484318|NCT02481596|Behavioral|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
79484319|NCT00386139|Drug|Aliskiren/HCTZ|
79811707|NCT00796042|Other|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
79980275|NCT03304444|Drug|Bupivacaine|bupivacaine hydrochloride used in TAP block
79980276|NCT03304444|Drug|liposomal bupivacaine|liposomal bupivacaine used in TAP block
79980277|NCT03314116|Other|Guidance on auditory protection|by video or medic
79980278|NCT03304366|Diagnostic Test|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
79980279|NCT03304288|Drug|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
79980280|NCT03304288|Drug|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
79980281|NCT03309124|Other|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
79484320|NCT00005553|Procedure|Catheter Ablation|
79484321|NCT00005571|Drug|h5G1.1-mAb|
79484322|NCT00005577|Drug|gemcitabine hydrochloride|
79484323|NCT00386217|Behavioral|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
79484324|NCT00005583|Drug|cisplatin|
79484325|NCT00005583|Drug|doxorubicin hydrochloride|
79980282|NCT03309124|Other|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
79980283|NCT03309124|Other|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
79980284|NCT03309124|Other|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
79980285|NCT03309124|Other|Meal skipping|No food given
79980286|NCT02469454|Drug|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
79484326|NCT00005583|Drug|epirubicin hydrochloride|
79484327|NCT00005583|Procedure|adjuvant therapy|
79484328|NCT00005583|Procedure|conventional surgery|
79484329|NCT00005583|Radiation|radiation therapy|
79484330|NCT00005589|Biological|filgrastim|
79980287|NCT02469454|Drug|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
79811708|NCT00796042|Other|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
79331048|NCT05049109|Behavioral|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
79980288|NCT03313960|Drug|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop | Premium (i.e., One Drop | Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
79650541|NCT00212498|Procedure|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
79811709|NCT04135469|Other|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
79980289|NCT03313960|Other|"One Drop | Premium"|"Participants in this group will receive One Drop | Premium (i.e., One Drop | Experts in-app CDE coaching with the One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
79980290|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
79980291|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
79980292|NCT03313726|Drug|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
79980293|NCT03313726|Drug|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
79331049|NCT05049109|Behavioral|Usual post-stroke follow-up care|"1-2 weeks follow up visit with primary care.~4-6 week and 12 week follow up visit with stroke practitioner~At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
79484331|NCT00005589|Biological|rituximab|
79484332|NCT00005589|Drug|carmustine|
79484333|NCT00005589|Drug|cyclophosphamide|
79484334|NCT00005589|Drug|cytarabine|
79484335|NCT00005589|Drug|etoposide|
79484336|NCT00005589|Drug|melphalan|
79484337|NCT00005589|Procedure|bone marrow ablation with stem cell support|
79484338|NCT00005589|Procedure|peripheral blood stem cell transplantation|
79484339|NCT00005601|Biological|rituximab|
79484340|NCT00005601|Drug|cisplatin|
79484341|NCT00005601|Drug|cytarabine|
79484342|NCT00005601|Drug|dexamethasone|
79484343|NCT00005601|Drug|sargramostim|
79484344|NCT00005607|Drug|FOLFIRI regimen|
79484345|NCT00005607|Drug|fluorouracil|
79484346|NCT00005607|Drug|irinotecan hydrochloride|
79484347|NCT00005607|Drug|leucovorin calcium|
79484348|NCT00005613|Drug|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
79484349|NCT00005613|Drug|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
79484350|NCT00005613|Drug|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
79484351|NCT00005619|Genetic|polymerase chain reaction|
79650542|NCT00239460|Drug|Tiotropium|
79811710|NCT04135469|Other|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
79980294|NCT03308812|Behavioral|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
79331050|NCT05027659|Other|virtual reality glasses|Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
79331051|NCT03093571|Device|Auricular stimulation|Auricular stimulation with indwelling fixed needles
79331052|NCT03093571|Behavioral|Relaxation|Progressive muscle relaxation
79331053|NCT05023915|Drug|dexamethasone|40 mg qd for 4 days
79331054|NCT05023915|Drug|diammonium glycyrrhizinate enteric-coated capsule|150mg tid for 3 months
79331055|NCT05024071|Device|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~Static action under steady state.~No load movement in steady state.~Static action under unstable state.~Movement to overcome its own resistance in an unstable state.~Free strength exercise in unstable state.~Core explosive power exercise under unstable conditions."
79980295|NCT03308812|Behavioral|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
79331056|NCT05024071|Device|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~Static action under steady state.~No load movement in steady state.~Static action under unstable state.~Movement to overcome its own resistance in an unstable state.~Free strength exercise in unstable state.~Core explosive power exercise under unstable conditions."
79331057|NCT01673347|Biological|Meniscal Allograft|Meniscal allograft
79331058|NCT05027191|Diagnostic Test|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
79331059|NCT05027191|Drug|Desflurane|Desflurane
79331060|NCT05027191|Drug|Sevoflurane|Sevoflurane
79331061|NCT03094507|Drug|Tivicay|50 mg once daily
79331062|NCT03094507|Drug|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
79331063|NCT02528253|Biological|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
79331064|NCT02528253|Biological|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
79331065|NCT02528253|Biological|Tanezumab 5 mg SC|Tanezumab 5 mg SC
79331066|NCT02528253|Biological|Tanezumab 10 mg SC|Tanezumab 10 mg SC
79331067|NCT02528253|Biological|Tramadol PR oral|Tramadol PR oral
79331068|NCT03093103|Drug|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
79331069|NCT03093103|Drug|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
79331070|NCT03092947|Other|No intervention|
79331071|NCT03092869|Other|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
79331072|NCT03092869|Other|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
79331073|NCT03094039|Procedure|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
79331074|NCT03094039|Procedure|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
79331075|NCT03093805|Dietary Supplement|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
79331076|NCT05026879|Biological|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
79331077|NCT03093883|Drug|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
79331078|NCT03093883|Drug|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
79331079|NCT05047861|Procedure|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
79331080|NCT05047861|Procedure|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
79331081|NCT03094429|Drug|NaBen®|2000 mg/day or 1000 mg/day, twice daily
79331082|NCT03094429|Other|Placebo|0 mg total, twice daily
79331083|NCT05023759|Dietary Supplement|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
79331084|NCT05023447|Behavioral|BRIDGE Intervention|Intensive clinical assessment; >16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation
79331085|NCT05023447|Behavioral|Service as Usual|Likely to range from social services, mental-health services, forensic services to no intervention
79331086|NCT05026255|Procedure|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
79331087|NCT03090607|Device|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
79331088|NCT03090607|Drug|Saline|Endoscopic injection of saline
79484352|NCT00005619|Other|flow cytometry|
79484353|NCT00005619|Other|immunohistochemistry staining method|
79484354|NCT00005625|Drug|trabectedin|
79484355|NCT00005631|Biological|filgrastim|
79484356|NCT00005631|Biological|rituximab|
79484357|NCT00005631|Drug|carboplatin|
79484358|NCT00005631|Drug|etoposide|
79484359|NCT00005631|Drug|ifosfamide|
79650543|NCT00212576|Behavioral|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
79331089|NCT04964635|Device|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
79331090|NCT03092557|Other|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
79331091|NCT03090529|Other|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
79331092|NCT03092167|Other|Physical exercises|Physical exercises
79331093|NCT01672957|Drug|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
79331094|NCT01672957|Drug|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
79331095|NCT05018065|Behavioral|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
79811711|NCT04135391|Behavioral|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
79811712|NCT02620163|Drug|telmisartan/amlodipine 40/5mg|
79331096|NCT05022979|Other|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
79331097|NCT05023213|Behavioral|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
79331098|NCT05047393|Other|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels < 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
79331099|NCT05047081|Behavioral|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
79331100|NCT05047081|Other|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
79331101|NCT05022745|Other|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
79331102|NCT04465435|Other|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
79331103|NCT04465435|Other|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
79331104|NCT03090217|Behavioral|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
79331105|NCT03090217|Behavioral|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
79331106|NCT05022277|Behavioral|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
79331107|NCT05022277|Behavioral|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
79331108|NCT05022043|Diagnostic Test|Serum Presepsin|Estimation of Serum Presepsin at time of admission
79484360|NCT00005637|Drug|carmustine|
79811713|NCT02620163|Drug|YH22162 40/5/12.5 mg|
79811714|NCT02620163|Drug|telmisartan/amlodipine 80/5mg|
79811715|NCT02620163|Drug|YH22162 80/5/25 mg|
79484361|NCT00005637|Drug|temozolomide|
79331109|NCT05021887|Drug|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
79650544|NCT00212576|Behavioral|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
79650545|NCT00239499|Drug|Tiotropium|
79650546|NCT00239499|Drug|Salmeterol plus Fluticasone|
79650547|NCT00212615|Drug|Oxaliplatin (Eloxatin)|
79650548|NCT00212615|Drug|Capecitabine (Xeloda)|
79650549|NCT00222573|Drug|clopidogrel and metoprolol|
79331110|NCT05021887|Drug|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
79484362|NCT00005643|Drug|pegylated liposomal doxorubicin hydrochloride|
79650550|NCT00212654|Drug|ONO-1101|
79650551|NCT00222612|Other|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
79650552|NCT00222612|Drug|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
79650553|NCT00222612|Drug|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
79650554|NCT00212693|Drug|ONO-2506PO|
79650555|NCT00212732|Drug|ONO-8025 (KRP-197)|
79650556|NCT00239538|Drug|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
79484363|NCT00005649|Drug|capecitabine|
79650557|NCT00239538|Drug|valsartan combined with hydrochlorothiazide (160/12.5mg)|
79484364|NCT00005649|Drug|paclitaxel|
79484365|NCT02256631|Biological|VRC01|Administered by subcutaneous injection in the thigh
79331111|NCT05022199|Device|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
79331112|NCT05021575|Other|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~data were collected from CVD prevention program~data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
79650558|NCT00212810|Drug|Topiramate|
79331113|NCT05021575|Other|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
79484366|NCT02256631|Biological|VRC01LS|Administered by subcutaneous injection in the thigh
79484367|NCT02256631|Biological|VRC07-523LS|Administered by subcutaneous injection in the thigh
79484368|NCT00005655|Biological|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
79331114|NCT05021575|Other|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
79484369|NCT00005655|Biological|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
79484370|NCT02972697|Radiation|11C-acetate ligand|
79484371|NCT02972697|Radiation|FDG ligand|
79650559|NCT00222651|Drug|tenecteplase|
79650560|NCT00239616|Drug|iron sucrose injection USP|
79650561|NCT00213005|Drug|Carraguard (PC-515)|
79650562|NCT00239655|Drug|MK0812|
79484372|NCT00005673|Drug|Capravirine|
79484373|NCT02247349|Biological|BMS-986012 (anti-fucosyl-GM1)|
79484374|NCT02247349|Biological|Nivolumab|
79484375|NCT03407443|Other|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
79484376|NCT03407443|Other|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
79650563|NCT00213044|Drug|Carraguard (PC-515)|
79484377|NCT03390673|Drug|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
79484378|NCT03390673|Drug|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
79484379|NCT02975791|Other|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
79484380|NCT02975791|Procedure|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
79484381|NCT04155775|Other|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count >50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
79484382|NCT00005727|Behavioral|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
79650564|NCT00213083|Drug|Carraguard (PC-515)|
79650565|NCT04709406|Drug|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
79650566|NCT00213122|Drug|miglitol|
79650567|NCT00213161|Drug|iron supplement, iron drops|
79650568|NCT00213200|Drug|morphine, amethocaine|
79650569|NCT00239811|Drug|FTY720|
79650570|NCT00213278|Drug|vinblastine sulphate injection|Vinblastine dose: 6 mg/m^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
79650571|NCT00222846|Behavioral|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
79650572|NCT00222846|Behavioral|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
79650573|NCT00213317|Procedure|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
79650574|NCT00239850|Behavioral|lifestyle changes|
79650575|NCT00239889|Drug|Salmon calcitonin|
79331115|NCT05021575|Other|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
79331116|NCT05021419|Other|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
79331117|NCT05021419|Other|Standard Protocol|Current standard optimization protocol as per NICE and ESC
79811716|NCT02620163|Drug|telmisartan/amlodipine 40/5mg placebo|
79811717|NCT02620163|Drug|YH22162 40/5/12.5 mg placebo|
79331118|NCT05021731|Drug|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
79331119|NCT05021731|Drug|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
79331120|NCT05021731|Drug|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
79484383|NCT00005739|Behavioral|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
79484384|NCT00005739|Behavioral|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
79484385|NCT02974933|Drug|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
79331121|NCT05009953|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
79331122|NCT05009953|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
79484386|NCT00005769|Drug|Hormone Replacement Therapy|
79484387|NCT00005775|Drug|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
79484388|NCT00005775|Drug|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
79484389|NCT02519036|Drug|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
79650576|NCT00222924|Behavioral|weight loss/ exercise|
79811718|NCT02620163|Drug|telmisartan/amlodipine 80/5mg placebo|
79811719|NCT02620163|Drug|YH22162 80/5/25 mg placebo|
79331123|NCT05009953|Drug|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
79331124|NCT05009953|Drug|Leucovorin|Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
79331125|NCT05009407|Biological|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
79331126|NCT05009641|Dietary Supplement|L-carnitine|
79331127|NCT03079453|Drug|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
79331128|NCT03090373|Device|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
79331129|NCT03090451|Behavioral|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
79331130|NCT03090139|Drug|Anti-TNF Therapy|Anti-TNF therapy.
79484390|NCT02519036|Drug|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
79484391|NCT02519036|Drug|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
79484392|NCT02519036|Drug|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
79484393|NCT02519036|Drug|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
79484394|NCT02519036|Other|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
79484395|NCT00005787|Biological|epoetin alfa|
79484396|NCT00005787|Biological|filgrastim|
79484397|NCT00005787|Biological|recombinant flt3 ligand|
79484398|NCT00005787|Biological|recombinant interleukin-3|
79650577|NCT00239967|Drug|Rimonabant (SR141716)|
79650578|NCT00239967|Drug|Placebo|
79650579|NCT00213395|Device|Interface for noninvasive ventilation|
79650580|NCT00213434|Device|Herbst oral appliance|
79650581|NCT00223002|Drug|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
79650582|NCT00213512|Drug|Mabthera|
79650583|NCT00223041|Drug|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
79650584|NCT00213551|Drug|Glutamine|
79811720|NCT02620241|Other|sitting position|
79811721|NCT02622893|Drug|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
79331131|NCT05610813|Drug|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
79331132|NCT05610813|Drug|Opiod therapy|"The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made before randomization (at visit 1) to ensure that the outcome of the randomization does not influence the opioid selection.~Preferably oral administration~Preferably retarded release preparations~Titration and dosage according to SmPC (maximum titration phase 3 weeks)~The dosage and the chosen opioid (opioid rotation) can be adapted to the patient's specific needs in the course of the study."
79331133|NCT03090061|Diagnostic Test|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
79331134|NCT03090061|Diagnostic Test|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
79331135|NCT05009563|Radiation|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
79650585|NCT00213551|Drug|Glucose|
79650586|NCT00213551|Drug|glutamine-antioxidants containing solution|
79650587|NCT00240006|Procedure|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
79980296|NCT03308734|Behavioral|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
79980297|NCT03308656|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
79980298|NCT03304132|Other|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
79980299|NCT03304132|Other|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
79980300|NCT03303976|Biological|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
79484399|NCT00005787|Biological|sargramostim|
79980301|NCT03303976|Biological|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
79484400|NCT00005787|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79484401|NCT00005793|Drug|Cytarabine|
79980302|NCT03313648|Procedure|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
79980303|NCT03313648|Procedure|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
79484402|NCT00005793|Drug|Daunorubicin|
79484403|NCT00005793|Drug|Etoposide|
79484404|NCT00005793|Drug|Topotecan|
79484405|NCT00005799|Drug|fludarabine phosphate|Given IV
79484406|NCT00005799|Radiation|total-body irradiation|Undergo low-dose TBI
79484407|NCT00005799|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
79484408|NCT00005799|Procedure|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
79484409|NCT00005799|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
79484410|NCT00005799|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
79484411|NCT00005799|Drug|cyclosporine|Given PO
79484412|NCT00005799|Drug|mycophenolate mofetil|Given PO
79484413|NCT00005799|Other|pharmacological study|Correlative studies
79331136|NCT05021341|Dietary Supplement|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
79331137|NCT05021341|Dietary Supplement|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
79331138|NCT05021341|Dietary Supplement|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
79331139|NCT05021341|Dietary Supplement|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
79484414|NCT00005799|Other|laboratory biomarker analysis|Correlative studies
79811722|NCT02622893|Drug|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
79811723|NCT05758116|Drug|Tislelizumab|Tislelizumab: 200mg d1,q21d*17
79811724|NCT00912821|Drug|6 L dialysate|6 L peritoneal dialysis solution
79811725|NCT00912821|Drug|8 L dialysate|8 L peritoneal dialysis solution
79980304|NCT04490668|Biological|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
79980305|NCT03313414|Drug|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
79980306|NCT04441684|Diagnostic Test|Blood sample for serological test|"Serology tests:~By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."
79980307|NCT02468518|Drug|Vitamin E capsule|Capsules will be distributed to each participant free of cost
79980308|NCT03308500|Behavioral|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
79980309|NCT03308500|Behavioral|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
79980310|NCT03308422|Behavioral|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
79331140|NCT05020561|Behavioral|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
79331141|NCT05020561|Behavioral|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
79811726|NCT00692393|Procedure|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
79811727|NCT00692393|Procedure|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
79980311|NCT03308344|Behavioral|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
79980312|NCT03313336|Drug|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
79980313|NCT03313336|Drug|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
79331142|NCT05017909|Behavioral|Face to face education|Face to face education techniques on the acquisition of the mothering Role
79331143|NCT05017909|Behavioral|Web based education|web based education techniques on the acquisition of the mothering Role
79331144|NCT05017909|Behavioral|No education|Control group will not be educated
79331145|NCT05020639|Drug|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
79331146|NCT05009017|Drug|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
79331147|NCT05008939|Drug|Sevoflurane|Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
79980314|NCT03313336|Drug|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
79980315|NCT03308266|Diagnostic Test|electromyography|
79980316|NCT05285332|Procedure|surgical treatment 1|Mastectomy OR Breast conserving surgery
79980317|NCT05285332|Procedure|surgical treatment 2|Resection of metastasis
79980318|NCT05285332|Drug|Systemic therapy|Endocrine therapy or chemotherapy or targeted therapy
79980319|NCT05262322|Drug|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
79980320|NCT05262322|Drug|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
79980321|NCT05262322|Drug|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
79331148|NCT05008939|Drug|Placebo|Patients received 30% oxygen for 1 hour.
79331149|NCT05361525|Procedure|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
79484415|NCT00386373|Drug|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
79484416|NCT00005805|Dietary Supplement|St. John's wort|
79484417|NCT00005811|Drug|topotecan hydrochloride|Given IT
79484418|NCT00005811|Other|laboratory biomarker analysis|Correlative studies
79484419|NCT01689831|Biological|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
79484420|NCT01689831|Biological|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
79484421|NCT02520518|Drug|Dapagliflozin|
79484422|NCT02520518|Drug|Placebo|
79484423|NCT02520518|Behavioral|Weight maintenance|
79484424|NCT02520518|Behavioral|Ad libitum dietary intake|
79484425|NCT02520518|Behavioral|Dietary restriction|
79484426|NCT01689987|Drug|Cyclophosphamide|Given IV
79484427|NCT01689987|Drug|Dexamethasone|Given PO
79484428|NCT01689987|Drug|Hydroxychloroquine|Given PO
79484429|NCT01689987|Other|Laboratory Biomarker Analysis|Correlative studies
79484430|NCT01689987|Other|Pharmacological Study|Correlative studies
79484431|NCT01689987|Drug|Sirolimus|Given PO
79484432|NCT01680939|Drug|Morphine|0.2-0.5 mg/kg PO q4h
79484433|NCT01680939|Drug|Ibuprofen|10mg/kg PO q6hrs
79484434|NCT01689597|Drug|Morphine|Comparison of different dosages of drug
79484435|NCT01689597|Drug|Placebo|
79484436|NCT01686477|Other|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
79484437|NCT01686477|Other|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
79484438|NCT01686477|Other|Preterm Formula used when there is a shortfall in mother's own milk|
79331150|NCT05361525|Procedure|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
79331151|NCT05361369|Drug|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
79331152|NCT05020093|Procedure|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
79331153|NCT05020093|Procedure|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
79331154|NCT05360823|Other|Birth ball|Exercises for childbirth
79331155|NCT05360823|Other|Squatting|Exercises for childbirth
79331156|NCT05017285|Procedure|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
79331157|NCT05017285|Procedure|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
79331158|NCT05610501|Procedure|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
79331159|NCT05008861|Procedure|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
79811728|NCT02624921|Other|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
79811729|NCT05758038|Procedure|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
79980322|NCT03313258|Device|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
79980323|NCT03313258|Device|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
79980324|NCT03308110|Drug|PF-06650833|Two formulations of PF-006650833
79980325|NCT03308032|Behavioral|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
79980326|NCT03308032|Behavioral|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
79980327|NCT03303586|Other|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
79980328|NCT03303586|Other|Control|Participants will not wearing compression stockings for two weeks.
79980329|NCT03303508|Diagnostic Test|anti-ds DNA|venous blood samples
79980330|NCT02469376|Drug|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
79331160|NCT05008861|Drug|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
79331161|NCT05008861|Drug|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
79331162|NCT05016739|Device|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
79331163|NCT04434235|Other|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
79484439|NCT05140161|Device|collagen|use of hemostatic device in order to reduce bleeding in nail surgery
79484440|NCT02521766|Device|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
79331164|NCT05383053|Device|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
79331165|NCT04433923|Device|Phototherapy with aluminum foil|
79331166|NCT04433923|Device|Phototherapy without aluminum foil|
79331167|NCT03091933|Biological|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
79331168|NCT05016973|Drug|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
79331169|NCT05016973|Drug|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
79331170|NCT03091855|Other|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
79331171|NCT03091855|Diagnostic Test|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
79331172|NCT05359575|Behavioral|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
79650588|NCT00213590|Drug|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
79650589|NCT00243633|Procedure|Real-time contrast-enhanced ultrasound sonography|
79650590|NCT00213629|Other|transcriptome analysis|transcriptome analysis from muscle biopsy
79650591|NCT00213629|Other|T cell repertoire analysis|blood T cell repertoire analysis
79650592|NCT00240045|Drug|Midodrine, albumin, octreotide LAR|
79650593|NCT00240045|Drug|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
79650594|NCT00213668|Dietary Supplement|glutamine (dipeptiven)|
79980331|NCT02469532|Device|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
79980332|NCT02469532|Device|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
79331173|NCT05359575|Behavioral|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
79331174|NCT05359575|Behavioral|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
79331175|NCT05359575|Behavioral|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
79331176|NCT03091699|Drug|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
79331177|NCT03091699|Behavioral|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
79331178|NCT05016115|Behavioral|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
79331179|NCT03091543|Drug|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
79331180|NCT03091543|Drug|Placebo|2 capsules of placebo
79650595|NCT00243672|Drug|Atorvastatin|
79650596|NCT00243672|Drug|Gemfibrozil|
79650597|NCT00240084|Drug|nesiritide (Natrecor(TM))|administration of IV nesiritide
79331181|NCT03091543|Drug|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
79650598|NCT00243711|Drug|Carboxymethylcellulose sodium and Glycerin|
79650599|NCT00240123|Drug|Benadryl versus Placebo|
79650600|NCT00240279|Drug|Rosuvastatin|
79650601|NCT00240279|Procedure|aortic pulse wave velocity measurements|
79650602|NCT00243750|Drug|Methotrexate|
79980333|NCT03303430|Diagnostic Test|MRI|Diffusion weighted imaging 24 hours after revascularisation
79331182|NCT03091543|Drug|BIA 6-512 50 mg dose|2 capsules of 25 mg
79331183|NCT03091543|Drug|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
79331184|NCT03091543|Drug|BIA 6-512 200 mg dose|2 capsules of 100 mg
79650603|NCT00213863|Device|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
79650604|NCT00243789|Drug|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, <30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
79650605|NCT00213941|Device|Echocardiography|
79650606|NCT00243828|Device|Total Face Mask|
79650607|NCT00214058|Drug|Carboplatin|
79650608|NCT00214058|Drug|Docetaxel|
79650609|NCT00240318|Drug|Rosuvastatin calcium|
79650610|NCT00243945|Drug|Rotigotine|
79980334|NCT02469142|Procedure|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
79980335|NCT03303352|Procedure|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
79331185|NCT04253457|Drug|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
79331186|NCT05380947|Drug|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
79331187|NCT05380947|Drug|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
79980336|NCT04490980|Drug|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
79331188|NCT05380947|Drug|Rabeprazole sodium|Rabeprazole sodium
79331189|NCT05008471|Dietary Supplement|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
79331190|NCT05342727|Device|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
79331191|NCT05342727|Device|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
79331192|NCT03088969|Other|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
79331193|NCT02525133|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
79331194|NCT02525133|Other|Placebo|Plain collagen implant (vehicle)
79484441|NCT02521766|Device|Commercially Available Intraocular Lens|IOL per investigator's standard of care
79650611|NCT00214214|Drug|Campath 1H® (Alemtuzumab)|
79650612|NCT00240357|Procedure|Lifestyle Regulation|
79650613|NCT00214253|Drug|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
79650614|NCT00240396|Drug|Narcotics alone|
79650615|NCT00240396|Drug|Narcotics and NSAIDS|
79650616|NCT00214292|Procedure|fluorescence spectroscopy and diffuse spectroscopy|
79650617|NCT00214331|Drug|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
79331195|NCT05356299|Other|Magnetictape bandage application|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
79331196|NCT05016427|Biological|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
79331197|NCT05602311|Drug|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
79331198|NCT05016349|Drug|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
79331199|NCT05016349|Drug|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
79331200|NCT05016349|Drug|Mifepristone|Mifepristone 200mg capsules daily for 28 days
79331201|NCT05016349|Drug|Cannabidiol|Liquid taken orally for daily for 28 days
79331202|NCT05016349|Drug|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
79331203|NCT05016349|Drug|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
79980337|NCT03303274|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
79980338|NCT03307954|Device|Ekso Therapy (Exoskeleton Suit)|
79980339|NCT03307954|Other|Usual Physiotherapy|
79980340|NCT03307876|Other|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
79331204|NCT05016349|Drug|Standard therapy|Patients will receive the approved standard therapy tamoxifen
79980341|NCT02468284|Drug|degarelix|
79980342|NCT03313102|Biological|blood samples|sample of 16 blood tubes
79980343|NCT03307720|Drug|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
79331205|NCT05355675|Other|blood sample|collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
79331206|NCT05355675|Other|stool sample|collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
79484442|NCT02521766|Procedure|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
79650618|NCT00214331|Drug|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
79980344|NCT03307720|Drug|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
79331207|NCT05016193|Device|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
79331208|NCT05016193|Behavioral|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
79331209|NCT05380635|Drug|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
79331210|NCT03091309|Other|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
79484443|NCT01689675|Behavioral|Computer based pain management|
79484444|NCT02482610|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
79484445|NCT02482610|Other|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
79484446|NCT02482610|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
79650619|NCT00214331|Drug|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
79650620|NCT00243984|Drug|topiramate|
79980345|NCT03303118|Other|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
79980346|NCT03312946|Device|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
79980347|NCT03302962|Behavioral|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
79980348|NCT03312790|Device|Tasks|Augmented reality device Real condition
79980349|NCT03302884|Other|biological sampling|Tumor and blood samples
79980350|NCT03307642|Other|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
79331211|NCT03091309|Behavioral|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
79331212|NCT03091309|Behavioral|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
79331213|NCT03091309|Behavioral|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
79331214|NCT03091309|Other|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence [self-reported using the 5 item Medication Adherence Report Scale (MARS-5)] and IBD related disease activated [self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity].
79331215|NCT03091309|Other|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence [self-reported using the Medication Adherence Report Scale (MARS-5)], patient trust in physician [self-reported using the Trust in Physician Scale (TIPS)], IBD related disease activated [self-reported using the PRO-2 or 6-Point Mayo Score], IBD-specific health related quality of life [self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)], patient satisfaction [self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire]and IBD specific knowledge [self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire].
79331216|NCT05015959|Other|observation|quality
79331217|NCT03091387|Diagnostic Test|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
79484447|NCT02483000|Biological|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
79484448|NCT02483000|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
79484449|NCT02483000|Drug|Carmustine|Given IV
79650621|NCT00214370|Drug|Propofol-Fentanyl|
79650622|NCT00214370|Drug|Propofol alone|
79650623|NCT00240435|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
79650624|NCT00240435|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
79650625|NCT00244023|Drug|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
79980351|NCT03312712|Radiation|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
79980352|NCT03312712|Other|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
79980353|NCT03312712|Other|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
79484450|NCT02483000|Drug|Clearing Agent|Given IV
79484451|NCT02483000|Drug|Cytarabine|Given IV
79484452|NCT02483000|Drug|Etoposide|Given IV
79484453|NCT02483000|Radiation|Indium In 111-DOTA-Biotin|Given IV
79650626|NCT00244023|Drug|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
79650627|NCT00244023|Other|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
79484454|NCT02483000|Other|Laboratory Biomarker Analysis|Correlative studies
79484455|NCT02483000|Drug|Melphalan|Given IV
79484456|NCT02483000|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
79484457|NCT02483000|Other|Pharmacological Study|Correlative studies
79484458|NCT02483000|Radiation|Yttrium Y 90-DOTA-Biotin|Given IV
79484459|NCT02088151|Device|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
79484460|NCT02279745|Drug|Ralinepag|Active
79650628|NCT02962622|Other|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
79650629|NCT00244062|Behavioral|counseling|
79650630|NCT00214565|Drug|Galida|
79331218|NCT04254393|Behavioral|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
79331219|NCT04254393|Other|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
79331220|NCT03079609|Procedure|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
79331221|NCT03079609|Procedure|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
79331222|NCT05538819|Drug|Glimepiride|Glimepiride 1-4 mg/day
79331223|NCT05015647|Dietary Supplement|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
79484461|NCT02484092|Biological|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
79484462|NCT02420210|Drug|Bendamustine Hydrochloride|Given IV
79484463|NCT02420210|Biological|Obinutuzumab|Given IV
79484464|NCT02420210|Drug|Dexamethasone|Given PO
79484465|NCT02420210|Other|Quality-of-Life Assessment|Ancillary studies
79484466|NCT02420210|Other|Laboratory Biomarker Analysis|Correlative studies
79650631|NCT00240474|Drug|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
79650632|NCT00240474|Drug|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
79650633|NCT00214604|Drug|Rosuvastatin|10mg
79650634|NCT00214604|Drug|rosuvastatin|20mg
79980354|NCT03312712|Diagnostic Test|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
79980355|NCT03302806|Other|Non interventional Study|
79484467|NCT02974777|Drug|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
79484468|NCT02974777|Drug|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
79484469|NCT02974777|Drug|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
79650635|NCT00214604|Drug|pravastatin|40mg
79650636|NCT04720950|Other|Exercise|1 hour of exercise on a motorised treadmill at 70% maximal heart rate
79650637|NCT00214643|Drug|Fosmidomycin|30 mg/kg
79650638|NCT00214643|Drug|clindamycin|10 mg/kg
79650639|NCT00414531|Drug|Atorvastatin|20 to 80 mg per day
79650640|NCT00214682|Drug|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
79980356|NCT04608786|Drug|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
79484470|NCT02485964|Other|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
79980357|NCT04608786|Drug|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
79980358|NCT01314872|Drug|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
79331224|NCT05015647|Other|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
79980359|NCT01314872|Drug|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
79331225|NCT05354583|Drug|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
79331226|NCT03079219|Drug|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
79331227|NCT03079219|Drug|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
79331228|NCT03079219|Drug|Experimental drug: Dexamethasone|Day 1: 12mg QD
79331229|NCT03079219|Drug|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
79331230|NCT03079219|Drug|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
79484471|NCT04821609|Behavioral|Resistance Training|The resistance training will be for arms and legs, self-loading type, and external weights.
79331231|NCT03079219|Drug|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
79331232|NCT03079219|Drug|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
79331233|NCT03078985|Procedure|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
79331234|NCT03078985|Device|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
79331235|NCT03078829|Drug|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
79331236|NCT05019469|Device|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
79331237|NCT03091153|Other|Medication Review|In depth medication review with a focus on deprescribing
79331238|NCT05015179|Procedure|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
79484472|NCT00361699|Drug|Statin|
79484473|NCT04829799|Drug|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
79484474|NCT04829799|Drug|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
79484475|NCT02975947|Device|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher & Paykel's HUMIGARD system (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
79484476|NCT02975947|Device|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
79484477|NCT01789333|Device|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
79980360|NCT01314872|Drug|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
79331239|NCT05019781|Other|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, & Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
79331240|NCT05019781|Other|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
79331241|NCT05019391|Device|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
79331242|NCT05019157|Other|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
79331243|NCT05019157|Other|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
79484478|NCT01789333|Drug|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
79484479|NCT02524106|Drug|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
79980361|NCT01314872|Drug|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
79331244|NCT05008237|Drug|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
79331245|NCT05014711|Drug|Remifentanil|Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT < 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
79331246|NCT05014711|Drug|Fentanyl|Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT < 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
79484480|NCT02524106|Drug|Placebo|placebo
79484481|NCT04827459|Behavioral|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
79484482|NCT04117477|Drug|Xylitol|Xylitol dental wipes
79484483|NCT04117477|Other|Placebo|Placebo dental wipes
79980362|NCT04602312|Other|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
79331247|NCT03087721|Behavioral|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
79980363|NCT01343628|Drug|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
79650641|NCT00214682|Behavioral|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
79811730|NCT00922727|Biological|L. reuteri|The oil drops contains 10^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10^8 CFU/ 5 drops and less than 8 x 10^8 CFU/ 5 drops.
79980364|NCT01343628|Drug|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
79331248|NCT03087721|Behavioral|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
79331249|NCT05007457|Other|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
79331250|NCT05018923|Drug|Rabeprazole|20mg bid
79331251|NCT05018923|Drug|Bismuth potassium citrate|0.6g bid
79331252|NCT05018923|Drug|Metronidazole|0.4g qid
79331253|NCT05018923|Drug|Doxycycline|0.1g bid
79331254|NCT05018923|Drug|Tetracycline|0.5g qid
79484484|NCT04824027|Procedure|Harmonic motion imaging|Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
79484485|NCT02524418|Procedure|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
79484486|NCT04820049|Drug|F573|F573 for injection
79484487|NCT04820049|Other|Placebo|Water for injection
79484488|NCT01761877|Drug|Sulindac|
79484489|NCT02421146|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
79484490|NCT02421146|Device|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
79331255|NCT03090919|Biological|Platelet transfusion|
79331256|NCT03090919|Other|Saline|
79331257|NCT05019079|Other|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
79331258|NCT03086863|Device|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
79331259|NCT03086863|Device|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
79331260|NCT05019001|Procedure|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
79331261|NCT05019001|Procedure|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
79331262|NCT05019313|Device|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
79331263|NCT03086473|Drug|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
79331264|NCT03086473|Drug|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
79331265|NCT03086005|Drug|Metformin|
79331266|NCT03079141|Drug|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
79331267|NCT03079141|Other|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
79331268|NCT03085615|Other|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
79331269|NCT03090763|Genetic|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
79331270|NCT03085849|Drug|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
79331271|NCT03085849|Drug|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
79811731|NCT00922727|Biological|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops.
79811732|NCT00570310|Drug|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
79980365|NCT00703924|Drug|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
79980366|NCT00703924|Drug|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
79811733|NCT00570310|Drug|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
79980367|NCT03152526|Device|Interventions|CliniMACS® CD3 and CD19 Reagent System
79331272|NCT03085849|Drug|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
79331273|NCT03090685|Procedure|True auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
79331274|NCT03090685|Procedure|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
79331275|NCT03079063|Biological|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
79331276|NCT03079063|Biological|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
79331277|NCT03085303|Device|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
79331278|NCT04434079|Other|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
79331279|NCT05015101|Other|Cohort observation|Cohort observation
79331280|NCT01659255|Drug|Tirabrutinib|Capsules administered orally
79331281|NCT05014633|Other|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
79331282|NCT05308485|Other|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
79331283|NCT05341089|Drug|LY3502970|Administered orally.
79331284|NCT05001529|Biological|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
79980368|NCT03302650|Drug|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
79980369|NCT03302650|Drug|Normal saline|Patients will receive normal saline.
79980370|NCT03302650|Drug|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
79980371|NCT01343706|Drug|Placebo|Solution for oral administration
79331285|NCT05307159|Dietary Supplement|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
79811734|NCT00696995|Drug|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
79980372|NCT01343706|Drug|Placebo .|Immediate release solid oral dosage
79980373|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage medium
79980374|NCT03312478|Drug|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
79980375|NCT03619694|Device|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
79980376|NCT03307408|Other|blood collection|Standard routine practice clinico-biological data will be collected
79980377|NCT05058222|Other|Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise|• The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
79980378|NCT05058222|Other|Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise|• The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
79980379|NCT03302572|Other|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
79980380|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
79980381|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
79331286|NCT05001061|Drug|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
79980382|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
79980383|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
79980384|NCT03312322|Other|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
79980385|NCT03312322|Other|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
79331287|NCT05531955|Drug|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
79650642|NCT00214682|Behavioral|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
79484491|NCT04744519|Other|Collect data|- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
79811735|NCT00664066|Drug|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
79331288|NCT05531955|Other|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
79331289|NCT05006911|Drug|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
79811736|NCT02620085|Procedure|blood sampling|blood sampling
79980386|NCT03312322|Other|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
79980387|NCT04543344|Drug|Recifercept|recifercept powder for solution for injection
79331290|NCT05339295|Drug|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
79650643|NCT00214682|Drug|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
79811737|NCT02610738|Behavioral|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
79331291|NCT05353491|Behavioral|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
79331292|NCT05353491|Behavioral|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
79650644|NCT00214682|Behavioral|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
79650645|NCT00214682|Behavioral|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
79650646|NCT00214721|Drug|Experimental Peritoneal Dialysis Solution|
79650647|NCT00214760|Device|PGET|resolbable liner
79331293|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
79331294|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
79650648|NCT00214760|Device|PMMA|cement liner
79650649|NCT00240513|Drug|Minocycline|100 mg capsules OD for 3 months
79650650|NCT00240513|Drug|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
79650651|NCT00214838|Drug|Atiprimod|
79811738|NCT02555020|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
79811739|NCT02555020|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
79811740|NCT02555020|Dietary Supplement|Allocated to MN NPO group,|Patients received NPO from MN.
79811741|NCT02619929|Drug|Vinorelbine oral|
79811742|NCT00785902|Device|AtriCure Bipolar System|
79811743|NCT00796198|Drug|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
79811744|NCT00796198|Drug|Xalatan|Xalatan ophthalmic solution one drop at 10pm
79331295|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
79331296|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
79331297|NCT05307081|Drug|Artificial Tears|Artificial Tears are an FDA approved intervention
79331298|NCT05306535|Procedure|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
79331299|NCT05350995|Other|No intervention|No intervention
79331300|NCT04462705|Procedure|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
79484492|NCT00362791|Behavioral|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
79484493|NCT00362791|Behavioral|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
79980388|NCT04543344|Other|Placebo|solution for injection
79980389|NCT03302338|Drug|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
79331301|NCT02637895|Drug|Placebo|Placebo pill matching Vortioxetine.
79331302|NCT02637895|Drug|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
79331303|NCT05013697|Drug|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
79331304|NCT05013697|Drug|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
79980390|NCT03302338|Drug|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
79650652|NCT00240552|Drug|fosamprenavir|
79650653|NCT00240552|Drug|Telzir®|
79650654|NCT00214877|Drug|Methylene Blue|
79980391|NCT01343784|Other|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
79980392|NCT03307096|Procedure|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
79331305|NCT05305911|Drug|Dapagliflozin|Dapagliflozin once daily for six months
79331306|NCT05305911|Drug|Placebo|Placebo once daily for six months
79484494|NCT00362791|Behavioral|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
79484495|NCT02488070|Procedure|Computed Tomography|Part of PET/CT scan
79484496|NCT02488070|Drug|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
79484497|NCT02488070|Procedure|Magnetic Resonance Imaging|Part of PET/MRI scan
79484498|NCT02488070|Procedure|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
79650655|NCT00214955|Drug|ORAVESCENT Fentanyl Citrate|
79484499|NCT02974699|Dietary Supplement|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
79484500|NCT02974699|Dietary Supplement|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
79650656|NCT00244179|Drug|interferon-gamma|
79650657|NCT00244179|Drug|infliximab|
79650658|NCT00244179|Drug|dmard|
79650659|NCT00214994|Drug|Gabitril|
79650660|NCT00240630|Drug|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
79650661|NCT00240630|Drug|placebo|placebo to match
79650662|NCT00239772|Behavioral|Cognitive Processing Therapy|
79980393|NCT03307096|Procedure|FURS|Parents are treated by FURS
79980394|NCT05250492|Procedure|Prosthetic hip surgery|"Total hip prosthesis performed by an anterior approach with intra-articular infiltration of an anesthetic product intraoperatively.~OR~- Total hip prosthesis performed by an anterior approach with infiltration of the same anesthetic product by ultrasound-guided PENG block intraoperatively."
79980395|NCT04355364|Drug|Dornase Alfa Inhalation Solution [Pulmozyme]|Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
79650663|NCT00239772|Behavioral|Prolonged Exposure Therapy|
79811745|NCT00692549|Device|ultrasound|
79980396|NCT04355364|Procedure|standard procedure|Patients will receive the usual care in accordance with good practice.
79980397|NCT03312244|Drug|Pyridostigmine Bromide|Pyridostigmine 180mg/day p.o.
79331307|NCT05013775|Diagnostic Test|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
79331308|NCT05013775|Diagnostic Test|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
79331309|NCT05007067|Device|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
79331310|NCT05349435|Drug|Fezagepras|Investigational drug
79331311|NCT05349435|Drug|Sodium phenylbutyrate|Investigational drug
79331312|NCT05007223|Drug|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
79650664|NCT00244218|Drug|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
79650665|NCT04721028|Device|Human body component analyzer|The body composition analyzer is a kind of instrument that can measure the body composition health index. It is composed of professional tester, professional consulting management software, color printer A/B machine and so on.
79331313|NCT05305599|Drug|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
79331314|NCT05305599|Drug|Placebo|Placebo
79331315|NCT03083587|Behavioral|Normal lifestyle|Normal lifestyle
79331316|NCT03083587|Behavioral|Exercise|Mild exercise 3 min every half hour
79331317|NCT03083587|Procedure|muscle and fat biopsy|Biopsy under local anesthesia
79331318|NCT03083587|Device|Continuous glucose monitoring|Glucose concentrations during the study period
79650666|NCT00215111|Behavioral|Low carbohydrate, reduced glycemic load, and a control diet|
79650667|NCT00244257|Biological|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
79811746|NCT00791050|Device|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
79811747|NCT02622503|Drug|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
79331319|NCT03083587|Device|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
79650668|NCT00244257|Biological|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
79650669|NCT00244257|Biological|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
79650670|NCT00244257|Biological|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
79650671|NCT00244257|Biological|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
79650672|NCT00215189|Behavioral|In SHAPE (Pilot Health Promotion Intervention)|
79650673|NCT00244296|Drug|Duloxetine hydrochloride|
79980398|NCT03312244|Drug|Placebo|Placebo
79980399|NCT05250336|Other|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
79980400|NCT03306940|Drug|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
79980401|NCT03302260|Behavioral|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
79980402|NCT03149328|Other|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
79650674|NCT00244296|Drug|placebo|
79650675|NCT00215228|Drug|duloxetine vs. escitalopram|
79650676|NCT00215267|Drug|praziquantel|
79980403|NCT03312166|Device|Compression device|"interventions on patient are :~surgical excision of ear lobe keloid~application of compression device on sutured skin"
79980404|NCT03312088|Device|Freedom Knee PCK Components|Total Knee Revision
79980405|NCT00739050|Drug|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
79980406|NCT00739050|Drug|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
79331320|NCT05000281|Drug|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
79331321|NCT05348889|Drug|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
79650677|NCT00240669|Device|Resorbable device PLLA/PGA|
79650678|NCT00240669|Device|Titanium device|
79650679|NCT00215306|Device|CHARITÉ Artificial Disc|
79650680|NCT00215306|Device|Anterior Interbody Fusion with BAK Cage|
79650681|NCT00240708|Drug|risperidone|
79650682|NCT00215345|Drug|Taxotere|
79331322|NCT03081949|Drug|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
79331323|NCT04999579|Device|T scan|Occlusal load analysis
79331324|NCT04999813|Combination Product|Comprehensive intensive intervention|"Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~Weight loss guidance."
79331325|NCT05347797|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
79331326|NCT05347563|Procedure|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment…)
79331327|NCT03076255|Procedure|Computed Tomography|Undergo CT simulation
79331328|NCT03076255|Device|Medical Device|Given thermoplastic mask
79331329|NCT03076255|Device|Medical Device|Given MID
79650683|NCT00215345|Drug|Celecoxib|
79650684|NCT00240747|Drug|Synercid|
79650685|NCT00215384|Drug|Formoterol Fumarate|
79650686|NCT04709523|Procedure|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
79980407|NCT03302182|Drug|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
79331330|NCT03076255|Procedure|Cone-Beam Computed Tomography|Undergo CBCT imaging
79331331|NCT03076177|Other|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
79331332|NCT03076411|Drug|Pepsin|
79331333|NCT05006755|Combination Product|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
79650687|NCT04709523|Procedure|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
79650688|NCT00215423|Drug|Formoterol Fumarate|
79650689|NCT04668352|Drug|Dactolisib|TORC1 inhibitor
79650690|NCT04668352|Other|Placebo|Placebo
79650691|NCT00215462|Drug|Vinorelbine|
79650692|NCT04668196|Device|High-flow nasal cannula treatment|Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
79650693|NCT04668196|Device|Continuous positive airway pressure (CPAP) treatment|Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
79650694|NCT04668196|Device|Noninvasive ventilation treatment|Standard operating procedures represented by noninvasive ventilation treatment
79331334|NCT05006755|Combination Product|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
79484501|NCT04824651|Biological|COVID-19 vaccine|Vaccination done as part of France's COVID-19 Vaccination Campaign
79484502|NCT05138913|Drug|TXA|After the arthroscopic operation was completed, a local TXA injection was performed
79484503|NCT05138913|Drug|Saline|After the arthroscopic operation was completed, a local saline injection was performed
79980408|NCT03302182|Drug|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
79980409|NCT03306784|Other|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
79331335|NCT05347173|Drug|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
79331336|NCT05347173|Drug|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
79484504|NCT02421224|Behavioral|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
79484505|NCT02421224|Behavioral|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
79484506|NCT02421224|Behavioral|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
79484507|NCT02421224|Behavioral|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
79484508|NCT02421224|Behavioral|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
79484509|NCT02421224|Behavioral|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
79980410|NCT01343862|Drug|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
79980411|NCT01343862|Drug|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
79980412|NCT03311932|Drug|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
79980413|NCT03311932|Drug|Cortef®|Immediate release hydrocortisone tablets
79980414|NCT03311698|Behavioral|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
79980415|NCT00604812|Drug|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
79980416|NCT00604812|Drug|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
79980417|NCT00604812|Drug|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
79484510|NCT04821219|Other|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
79484511|NCT04825353|Procedure|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
79980418|NCT00604812|Drug|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
79980419|NCT03302026|Behavioral|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
79980420|NCT03301948|Other|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
79980421|NCT03301948|Other|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
79484512|NCT04825353|Procedure|Standard PCNL|patient undergo SPCNL
79980422|NCT04347408|Diagnostic Test|Covid-19 Antibody testing (IgG and IgM)|Antibody testing for previous exposure to Covid-19
79811748|NCT00791206|Procedure|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
79980423|NCT04347408|Other|Blood Storage|Storage of blood for multi-omics analysis
79980424|NCT03301870|Drug|ATx201 Gel 2%|2% active gel
79980425|NCT03301870|Drug|ATx201 Gel 4%|4% active gel
79980426|NCT03301870|Drug|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
79331337|NCT05006287|Drug|Non-vitamin K oral anticoagulants (NOACs)|"NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated."
79484513|NCT04106089|Behavioral|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
79980427|NCT03301870|Drug|Negative Control|Water for Injection, USP
79980428|NCT03301870|Drug|ATx201 Placebo|matching placebo gel
79980429|NCT03306628|Other|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
79980430|NCT01343940|Behavioral|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
79980431|NCT01343940|Behavioral|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
79331338|NCT05006287|Drug|Warfarin|"Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above."
79331339|NCT05303415|Other|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
79331340|NCT05013151|Dietary Supplement|Dates|Consumption of 6 dates a days until 41 weeks of gestation
79331341|NCT05013151|Dietary Supplement|Castor oil|One time consumption of 60 CC Castor oil
79331342|NCT05303337|Other|Stool sampling|Stool samples will be collected from participants at baseline and W52
79331343|NCT05303337|Other|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
79331344|NCT05006365|Device|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
79331345|NCT05006209|Other|One visit root canal treatment|
79331346|NCT05006209|Other|Two visit root canal treatment|
79331347|NCT05346003|Procedure|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
79331348|NCT03081013|Behavioral|Social information|Social comparison information will be provided to the study participants weekly via SMS
79331349|NCT03081013|Device|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
79331350|NCT03078673|Other|training intervention, motor skill training|cross country specific motor skill strength training
79650695|NCT04668079|Other|Modified cross body stretch|"Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given"
79650696|NCT04668079|Other|Modified sleeper stretch|"Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given"
79650697|NCT00215501|Drug|Capecitabine|Orally twice a day for 14 days (dosage will vary)
79650698|NCT00215501|Drug|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
79331351|NCT03078673|Other|training intervention, maximal strength training|general maximal strength training
79331352|NCT03078673|Other|control group|regular training
79331353|NCT03075787|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
79331354|NCT03076099|Drug|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
79331355|NCT03076099|Other|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
79484514|NCT03320317|Other|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
79484515|NCT03320317|Other|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
79484516|NCT03320317|Other|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
79650699|NCT00215501|Drug|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
79650700|NCT00215501|Drug|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
79650701|NCT04667728|Device|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
79331356|NCT05301621|Other|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
79331357|NCT03075709|Other|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
79331358|NCT03075631|Other|Questionnaire|Questionnaires
79331359|NCT03075865|Device|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
79484517|NCT03320317|Other|Learning session 4|Feedback report, Best practice symposium
79484518|NCT03319849|Combination Product|NT-501|Surgery to receive one NT-501 device implant.
79650702|NCT04667650|Other|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
79980432|NCT03306550|Drug|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
79331360|NCT05554965|Drug|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
79331361|NCT05554965|Drug|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
79331362|NCT03078517|Device|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
79331363|NCT03078517|Device|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
79331364|NCT05300217|Other|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
79484519|NCT03319849|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
79484520|NCT01501201|Procedure|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
79484521|NCT01501201|Drug|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
79484522|NCT04097275|Other|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
79811749|NCT00791206|Procedure|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
79650703|NCT04667845|Device|Home Ovulation Test|Digital read home ovulation test
79331365|NCT05300217|Other|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
79331366|NCT05335161|Device|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to ~37ºC.
79331367|NCT05268471|Device|Positional device (PD)|OSA treatment with PD for 6 months
79331368|NCT05268471|Device|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
79331369|NCT05299749|Other|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
79331370|NCT05299749|Other|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
79650704|NCT04668040|Other|Muscle energy technique|Muscle energy technique for illiopsoas, rectus femoris, erector spinae & hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3
79650705|NCT04668040|Other|Stretching|Stretching exercises for illiopsoas, rectus femoris, erector spinae & hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
79650706|NCT00240786|Drug|acetaminophen extended release|
79650707|NCT00215579|Drug|Depot Risperidone Microsphere (Consta)|
79650708|NCT04667611|Behavioral|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
79650709|NCT04667806|Behavioral|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
79650710|NCT00556621|Drug|cisplatin|
79650711|NCT00556621|Drug|gemcitabine hydrochloride|
79650712|NCT00556621|Procedure|biopsy|
79650713|NCT00556621|Procedure|cystoscopy|
79650714|NCT00556621|Procedure|therapeutic conventional surgery|
79650715|NCT00556621|Radiation|radiation therapy|
79650716|NCT00244452|Drug|Cetrorelix|
79650717|NCT02962583|Other|Weight loss|
79980433|NCT03306550|Drug|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
79650718|NCT02962583|Drug|Probiotic Formula|
79650719|NCT02962583|Drug|Placebos|
79650720|NCT00556660|Drug|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
79650721|NCT00556699|Drug|rituximab|Escalating intravenous repeating dose
79650722|NCT00556699|Drug|SGN-40|Escalating intravenous repeating dose
79650723|NCT00556738|Procedure|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
79650724|NCT00556738|Procedure|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
79484523|NCT04097275|Other|Withdraw of blood|"Blood will be collected in:~1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
79331371|NCT05299047|Other|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
79331372|NCT05299047|Other|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
79650725|NCT00411866|Drug|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
79484524|NCT04096729|Other|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
79650726|NCT00411866|Drug|Ketoconazole|Ketoconazole will be available as 200mg tablets.
79650727|NCT00244491|Behavioral|Care Transitions Intervention|
79650728|NCT04667182|Other|Meal-Tagging App and Web-based Portal:|Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.
79650729|NCT04667182|Device|Fitness Tracker|Fitness tracker will be worn around the clock for 18 weeks.
79650730|NCT04667299|Drug|Rabeprazole|20mg bid
79650731|NCT04667299|Drug|Bismuth potassium citrate|0.6g bid
79650732|NCT04667299|Drug|Metronidazole|0.4g qid
79331373|NCT05267769|Drug|AP707|Preparation of Cannabis flowers (Cannabis flos)
79331374|NCT05267223|Other|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
79650733|NCT04667299|Drug|Amoxicillin|1g bid
79650734|NCT04720794|Device|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
79650735|NCT04667143|Drug|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
79484525|NCT03299959|Device|Agili-C implant|Agili-C implant
79484526|NCT03299959|Procedure|SSOC|microfracture and/or debridement
79484527|NCT00362869|Drug|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
79484528|NCT00362869|Drug|Placebo|Sodium bicarbonate solution
79484529|NCT00362869|Biological|Enteroaggregative E. coli (EAEC)|Dosages: 1X10^9, 5X10^9, 1X10^10, and 5X10^10 cfu; given in a sodium bicarbonate solution
79650736|NCT04666870|Other|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
79650737|NCT04666753|Dietary Supplement|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at <10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
79650738|NCT00240825|Drug|Ibuprofen|
79650739|NCT00240825|Drug|Placebo|
79650740|NCT00240825|Drug|Acetaminophen|
79980434|NCT03311620|Procedure|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
79980435|NCT03311542|Biological|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
79331375|NCT04422483|Other|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
79331376|NCT05297097|Dietary Supplement|Trulacta breastmilk supplement|one supplement daily
79331377|NCT05266053|Device|PICO 7 dressing|The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
79484530|NCT04087213|Device|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
79650741|NCT04666597|Procedure|Modified CariesCare International management|"Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~D-DETECT & ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~D-DO: Appropriate Tooth-preserving & Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
79650742|NCT04666675|Drug|Upadacitinib|Oral; Tablet
79650743|NCT04666675|Drug|Placebo for Upadacitinib|Oral; Tablet
79650744|NCT00244530|Drug|Nifedipine|
79650745|NCT04666480|Device|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
79650746|NCT00411905|Drug|Bortezomib|
79650747|NCT04666363|Other|Lavender oil|the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
79650748|NCT00240864|Drug|placebo|
79650749|NCT00240864|Drug|acetaminophen|
79331378|NCT05266053|Other|Standard wound dressing|Standard abdominal dressing at the time of cesarean
79331379|NCT05501379|Other|No intervention - observational study only|No intervention - observational study only
79331380|NCT05331573|Device|apomorphine pump|observationnal
79484531|NCT03292237|Dietary Supplement|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
79484532|NCT03257215|Drug|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
79650750|NCT00240864|Drug|ibuprofen|
79650751|NCT00556777|Procedure|axillary lymph node dissection|
79650752|NCT00556777|Procedure|conventional surgery|
79650753|NCT00556777|Procedure|sentinel lymph node biopsy|
79650754|NCT00556777|Radiation|intraoperative radiation therapy|
79650755|NCT00556816|Behavioral|on demand clinic|Outpatient on demand clinic
79650756|NCT00556816|Behavioral|Control|conventional outpatient clinic
79650757|NCT00556855|Other|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
79650758|NCT00556855|Other|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
79650759|NCT00244569|Drug|13C-Methacetin|
79650760|NCT00244569|Device|Breath ID Machine|
79650761|NCT00557011|Drug|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
79650762|NCT00557011|Drug|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
79650763|NCT00557011|Drug|Placebo|Placebo capsule taken once daily in the morning
79650764|NCT00557050|Other|Training|10-week eccentric hamstring muscle training
79331381|NCT05262075|Other|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
79980436|NCT02468362|Procedure|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
79650765|NCT00557089|Drug|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
79650766|NCT00557089|Other|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
79650767|NCT04666324|Drug|Simethicone Solution|Oral daily treatment for four weeks
79650768|NCT04666324|Dietary Supplement|Multilac Baby|Oral daily treatment for four weeks
79980437|NCT02468362|Procedure|open intersphincteric resection|
79980438|NCT04507152|Other|Blood flow restriction resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.
79484533|NCT03257215|Drug|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
79980439|NCT04507152|Other|Resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
79980440|NCT02467660|Behavioral|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
79331382|NCT05261451|Other|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
79650769|NCT04720833|Dietary Supplement|dried plum|Dried plum
79650770|NCT04720833|Dietary Supplement|Calcium and vitamin D|Calcium and vitamin D supplement
79650771|NCT04666519|Diagnostic Test|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
79650772|NCT00215618|Device|Uterine Balloon Therapy|UBT with post procedure curettage
79331383|NCT05260359|Drug|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
79331384|NCT05260359|Drug|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
79331385|NCT05260359|Other|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
79650773|NCT00215618|Device|Uterine Balloon Therapy|UBT without post procedure curettage
79650774|NCT04666285|Other|Experience of pandemic|Experience of the pandemic will be studied through online questionnaire responses
79650775|NCT00215696|Genetic|BioBypass®|
79650776|NCT00244608|Drug|Budesonide/Formoterol Turbuhaler|
79331386|NCT05260359|Other|Petrolatum vehicle|SU-E-101413-83
79650777|NCT00244608|Drug|Budesonide Turbuhaler (Pulmicort)|
79650778|NCT00244608|Drug|Terbutaline Turbuhaler|
79650779|NCT04666168|Biological|Auto CAR-T|Biological: Auto CAR-T
79650780|NCT04666168|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
79650781|NCT04666168|Procedure|Leukapheresis|Leukapheresis
79980441|NCT02467660|Behavioral|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
79980442|NCT03311464|Drug|adalimumab|Study drug will be administered subcutaneously.
79307604|NCT03456895|Other|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
79331387|NCT05260359|Other|0.9% Saline|low irritancy control
79331388|NCT05260359|Other|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
79331389|NCT05260359|Other|Undosed patch|negative control
79331390|NCT05330091|Dietary Supplement|Once Daily Women's Probiotic|Active product
79331391|NCT05330091|Other|Placebo|Placebo product
79484534|NCT03257215|Drug|Stoss placebo|A single 1.5 mL dose administered on Day 1
79650782|NCT00215735|Device|debridement, dressing, and APC|ebridement, dressing, and APC
79650783|NCT04666207|Diagnostic Test|PCR|RT-PCR for SARS-CoV-2
79650784|NCT00240903|Biological|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
79980443|NCT05013840|Behavioral|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
79980444|NCT02468440|Other|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
79980445|NCT03306238|Procedure|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
79650785|NCT04665661|Behavioral|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
79650786|NCT04665661|Behavioral|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
79650787|NCT00244647|Drug|RESTEN-MP|
79650788|NCT00215774|Drug|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
79980446|NCT03306238|Procedure|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
79980447|NCT05217030|Other|Animal assisted therapy|Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
79980448|NCT03306160|Other|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
79980449|NCT05214066|Drug|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
79980450|NCT03306004|Other|Questionare|
79650789|NCT04665778|Other|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
79331392|NCT05295849|Behavioral|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
79331393|NCT05328063|Other|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
79484535|NCT03257215|Drug|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
79484536|NCT02422940|Drug|dalfampridine-ER 7.5 mg|
79484537|NCT02422940|Drug|dalfampridine-ER 10 mg|
79484538|NCT00361855|Drug|NX-CP105|
79650790|NCT00240942|Drug|Letrozole|
79650791|NCT04665466|Device|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
79980451|NCT02468206|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
79980452|NCT02468206|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
79980453|NCT02468206|Drug|N-butyl-2-cyanoacrylate|
79980454|NCT02468206|Drug|Lauromacrogol|
79650792|NCT00215891|Drug|PEG-Interferon a-2b + Ribavirin|
79650793|NCT04665544|Procedure|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
79980455|NCT04502472|Biological|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
79980456|NCT03301402|Device|Air purifier|Air purifier with filter at automatic mode on all time
79650794|NCT02961816|Drug|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
79650795|NCT02961816|Drug|Panobinostat|20 mg by mouth daily from Day -9 to -2.
79650796|NCT02961816|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
79331394|NCT05328063|Other|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
79331395|NCT05257707|Diagnostic Test|Molecular biology|"Samples will be taken as part of routine care consultations. These include~Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~Blood samples taken to isolate plasma, cells or serum.~CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~Urine samples collected in sterile ECBU jars.~Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~Surgical parts.~Eyebrows.~Saliva samples or gargle samples."
79331396|NCT05294835|Drug|Ketamine|ketamine infusion
79331397|NCT04422405|Procedure|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
79331398|NCT02522481|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
79650797|NCT02961816|Drug|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
79650798|NCT02961816|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
79650799|NCT02961816|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
79980457|NCT04969068|Drug|Remimazolam|Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS>75 and MOAA/S > 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
79980458|NCT03301324|Device|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
79980459|NCT01344174|Drug|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
79980460|NCT03301246|Device|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
79980461|NCT05162274|Drug|Lazertinib(G001)|Current formulation
79980462|NCT05162274|Drug|Lazertinib(G002)|New formulation
79980463|NCT03023566|Drug|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
79980464|NCT04345302|Behavioral|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
79307605|NCT03456895|Other|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
79331399|NCT02522403|Procedure|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
79331400|NCT02522403|Device|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
79331401|NCT05326581|Device|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
79980465|NCT04345302|Behavioral|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
79980466|NCT03301090|Other|Placebo|Placebo
79331402|NCT02522325|Drug|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
79331403|NCT02522325|Drug|Cocaine|Intranasal cocaine will be administered during experimental sessions.
79331404|NCT02522325|Drug|Placebo|Placebo capsules will contain only cornstarch.
79650800|NCT02961816|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
79650801|NCT02961816|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
79980467|NCT03301090|Biological|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
79650802|NCT02961816|Drug|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
79980468|NCT03301090|Biological|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
79980469|NCT04342962|Drug|tagraxofusp|Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
79331405|NCT04243395|Other|Pork|1 oz lean pork
79331406|NCT04243395|Other|Egg|1 large whole egg
79331407|NCT04243395|Other|Black beans|0.5 cups cooked black beans
79331408|NCT04243395|Other|Almonds|0.5 oz almonds
79331409|NCT01672879|Biological|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
79331410|NCT01672879|Biological|SIM|Intravenous infusion over 30 minutes every 2 weeks
79650803|NCT02961816|Other|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
79650804|NCT02961816|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
79980470|NCT03300934|Device|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
79980471|NCT04321044|Genetic|Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation|We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
79331411|NCT02601209|Drug|Pazopanib|Given PO
79331412|NCT02601209|Drug|Pazopanib Hydrochloride|Given PO
79331413|NCT02601209|Drug|Sapanisertib|Given PO
79331414|NCT05012839|Other|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
79650805|NCT02961816|Biological|Stem Cell Infusion|Stem cells administered by vein on Day 0.
79650806|NCT02961816|Drug|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
79331415|NCT01659021|Drug|Idelalisib|150 mg tablets administered orally twice daily
79331416|NCT01659021|Drug|Ofatumumab|Administered intravenously
79331417|NCT05012449|Procedure|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
79331418|NCT05012215|Procedure|Paravertebral|Ultrasound-guided paravertebral block
79980472|NCT03300778|Behavioral|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
79331419|NCT05012215|Procedure|Caudal block|Caudal block
79331420|NCT05012137|Procedure|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
79331421|NCT05012137|Drug|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
79331422|NCT05291559|Dietary Supplement|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
79331423|NCT05291559|Dietary Supplement|Placebo|The placebo is an identical product to Enterade except without added amino acids.
79331424|NCT03075319|Procedure|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
79331425|NCT03075319|Procedure|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
79331426|NCT04999033|Other|no intervention|This is a cross-sectional study, and no intervention will be included
79331427|NCT04818203|Biological|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10^7 cells/1 mL/vial
79331428|NCT04818203|Other|Placebo|The injection solution without clusters of autologous dermal fibroblasts
79331429|NCT05252793|Behavioral|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
79484539|NCT04072549|Behavioral|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
79484540|NCT02526680|Device|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
79980473|NCT03300778|Behavioral|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
79331430|NCT04827797|Device|balls|Birth balls to exercise
79331431|NCT04999189|Other|Mobile app forDiabetes (Tessera Multimedia, 2020)|Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
79331432|NCT05290779|Procedure|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
79484541|NCT00588523|Drug|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
79484542|NCT02527694|Device|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
79331433|NCT05252481|Device|Active tDCS|Eight sessions of transcranial current direct stimulation
79484543|NCT02527694|Device|mechanical CPR|
79484544|NCT02974387|Drug|Fluorometholone(FML)|
79980474|NCT05117190|Procedure|Facial Allotransplantation|
79980475|NCT04490746|Other|with no intervention, Collect samples|only with observation,there is no need to intervene
79331434|NCT05252481|Device|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
79331435|NCT04998955|Behavioral|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
79484545|NCT02974387|Drug|Loteprednol (Lotemax)|
79484546|NCT02440633|Drug|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
79484547|NCT03211975|Other|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
79484548|NCT00534703|Genetic|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10^13 DRP (DNase resistant particles)
79331436|NCT04827641|Other|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
79331437|NCT05324631|Drug|SHR0302|SHR0302, oral, once daily
79331438|NCT05324631|Drug|SHR0302 placebo|SHR0302 placebo, oral, once daily
79484549|NCT00534703|Drug|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
79484550|NCT00430183|Drug|docetaxel|75 mg/m^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
79484551|NCT00430183|Drug|LHRH agonist|Given intramuscularly
79484552|NCT00430183|Procedure|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
79650807|NCT04665427|Other|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
79650808|NCT03454867|Device|Hemofiltration|
79980476|NCT03635268|Other|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
79650809|NCT03454867|Procedure|Standard acute ischemic stroke treatment|
79650810|NCT04665349|Dietary Supplement|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
79980477|NCT03311386|Drug|Actilyse|thrombolytic therapy
79980478|NCT03620448|Device|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
79980479|NCT03620448|Other|Oxygen Arm|Oxygen therapy from oxygen cylinders
79980480|NCT01343238|Behavioral|Diet|12 week diet behavior modification
79980481|NCT01343238|Behavioral|Exercise|12 week exercise behavioral intervention
79980482|NCT01343238|Behavioral|Diet and Exercise|12 week diet and exercise behavioral modification intervention
79980483|NCT04343040|Dietary Supplement|carbohydrate supplement (Preload™)|carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.
79980484|NCT04343040|Procedure|6 hours of preoperative fasting|Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.
79980485|NCT03305692|Diagnostic Test|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
79650811|NCT00244686|Drug|Mepolizumab|open label investigational product
79650812|NCT04665232|Drug|aqueous subcutaneous progesterone|25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
79650813|NCT00216008|Drug|docetaxel|
79650814|NCT00216008|Drug|cisplatin|
79650815|NCT00216008|Procedure|radiation|
79650816|NCT00216008|Procedure|surgery|
79650817|NCT04665076|Biological|Auto CAR-T|Biological: Auto CAR-T
79650818|NCT04665076|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
79650819|NCT04665076|Procedure|Leukapheresis|Leukapheresis
79650820|NCT04665193|Diagnostic Test|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
79650821|NCT00241020|Drug|Octreotide|
79650822|NCT00216047|Drug|PTK787|PTK787 daily
79650823|NCT00216047|Drug|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*
79650824|NCT04665310|Drug|Envarsus XR|tacrolimus, extended-release tablets, a calcineurin inhibitor
79980486|NCT01343316|Device|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
79650825|NCT04664920|Device|exergame|motor-cognitive training device
79650826|NCT00241059|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79650827|NCT00216164|Drug|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
79650828|NCT00216164|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
79650829|NCT04664803|Drug|Cefecin Tab.|
79650830|NCT04664803|Drug|Omnicef Cap.|
79650831|NCT04664725|Drug|Repaglinide, Bupropion and SHR3680|Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
79650832|NCT04664764|Drug|Degludec|Basal insulin comparison
79650833|NCT04664764|Drug|Glargine|Basal insulin comparison
79650834|NCT04664764|Drug|NPH insulin|Basal insulin comparison
79650835|NCT00216242|Biological|Influenza virus vaccine (Fluviral)|
79650836|NCT00216242|Biological|Saline placebo|
79650837|NCT04664686|Procedure|AF catheter ablation|Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
79650838|NCT04664686|Procedure|AV node ablation|AV node ablation
79331439|NCT05011747|Procedure|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
79331440|NCT05011747|Procedure|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
79331441|NCT04422327|Dietary Supplement|Probiotic capsule|"Each probiotic capsule contains 5 x 10^8 CFU B. longum 35624® and 5 x 10^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd."
79331442|NCT03075475|Behavioral|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
79331443|NCT06163456|Other|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
79331444|NCT06163430|Drug|TERN-701|TERN-701 orally QD
79331445|NCT06163417|Procedure|laparoscopic|laparoscopic
79331446|NCT06163378|Device|Rubato Life App|An algorithmically enhanced personalized music-based intervention
79331447|NCT06163339|Other|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
79331448|NCT06163313|Other|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
79331449|NCT06163248|Other|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
79331450|NCT06163248|Other|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
79331451|NCT06163235|Other|Obemar platform|Online platform for education and follow-up
79980487|NCT02468908|Drug|Molgramostim|
79980488|NCT02468908|Drug|Placebo|
79980489|NCT01344408|Procedure|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
79980490|NCT02468128|Drug|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
79980491|NCT02468128|Drug|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
79980492|NCT01343394|Biological|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
79980493|NCT03305536|Dietary Supplement|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
79331452|NCT06163196|Other|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
79484553|NCT04341415|Procedure|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
79980494|NCT01344486|Procedure|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
79980495|NCT01344486|Procedure|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
79980496|NCT01343472|Behavioral|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
79980497|NCT01343472|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
79980498|NCT02467816|Behavioral|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
79980499|NCT02467816|Behavioral|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
79980500|NCT02467816|Behavioral|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
79980501|NCT01316406|Drug|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
79331453|NCT06163183|Device|Edi catheter|
79331454|NCT06163170|Drug|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
79331455|NCT06163170|Drug|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
79331456|NCT06163157|Other|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
79331457|NCT06163144|Other|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~*Automated cell counters~Advia 2120 8 difference~PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
79484554|NCT04341415|Procedure|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
79484555|NCT02443519|Behavioral|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
79650839|NCT04664374|Other|MyMood|Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
79650840|NCT00216281|Drug|Clozapine augmented with atomoxetine up to 40 mg or placebo|
79650841|NCT04664296|Other|Review of medical patient file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
79650842|NCT04664296|Other|Phone call interview|less than 15 minutes phone call
79650843|NCT04664452|Other|Questionnaire|Participants will be asked to fill the questionnaire
79811750|NCT05326685|Other|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
79980502|NCT02467426|Drug|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
79980503|NCT03300388|Dietary Supplement|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
79980504|NCT03300388|Dietary Supplement|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
79484556|NCT00362947|Drug|LMWH parnaparin subcutaneously|
79484557|NCT00362479|Drug|DR-1021|1 tablet daily
79980505|NCT03300388|Other|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
79484558|NCT00363025|Procedure|Two post-remission strategies|
79484559|NCT00363025|Drug|Idarubicin versus daunorubicin|
79484560|NCT02444143|Drug|tacrolimus extended release|
79484561|NCT00362557|Device|MRI|Magnetic resonance imaging
79484562|NCT02445625|Device|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
79484563|NCT02445859|Drug|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
79484564|NCT02446483|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
79484565|NCT02446483|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
79484566|NCT02447575|Other|Education on Use of MDI|After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
79484567|NCT00362635|Drug|Clevudine|
79484568|NCT02449291|Drug|APD421|
79484569|NCT02449291|Drug|Placebo|
79650844|NCT00241137|Drug|valsartan|
79650845|NCT00216359|Drug|Fuzeon (Enfuvirtide)|
79650846|NCT00216359|Procedure|Laboratory diagnostic (CD4-cells)|
79650847|NCT00216359|Procedure|Laboratory diagnostics (HIV-1 viral load)|
79650848|NCT00216359|Drug|antiretroviral co-medication beside Fuzeon|
79811751|NCT00814710|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
79811752|NCT00814710|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
79811753|NCT00814710|Biological|Hiberix|Intramuscular injection, 3 doses
79331459|NCT06163066|Other|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
79331460|NCT06163053|Drug|Immunotherapy|Immune checkpoint inhibitors in approved indications
79331461|NCT06163040|Drug|Elotuzumab in combination with pomalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
79331462|NCT06163040|Drug|Elotuzumab in combination with lenalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
79331463|NCT06163027|Device|Shotblocker|Shotblocher will be administered during spinal needle injection
79331464|NCT06163027|Other|Shotblocker(Plasebo)|The back side of the shotblocher will be applied during spinal needle injection
79331465|NCT06163001|Behavioral|Supervised aerobic and resistance exercises|4 weeks of preoperative supervised aerobic and resistance exercises
79331466|NCT06163001|Dietary Supplement|Dietary supplementation|4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
79331467|NCT06162988|Drug|68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.|68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
79331468|NCT06162962|Other|Retrospective analysis|Retrospective analysis
79331469|NCT06162936|Diagnostic Test|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
79650849|NCT04664491|Behavioral|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~Regular pulmonary function testing for lung function monitoring~Strengthened COPD education~Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
79650850|NCT04664491|Other|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
79650851|NCT04664530|Drug|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
79811754|NCT00814710|Biological|Tritanrix-HepB|Intramuscular injection, 3 doses
79980506|NCT02467348|Drug|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
79980507|NCT02467348|Drug|Ascitic fluid|
79980508|NCT04296942|Biological|Brachyury-TRICOM|Every three weeks, until cycle 9, then every 12 weeks: *Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10^8 infectious units (Inf.U). *Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10^9 Inf.U.
79980509|NCT04296942|Drug|Entinostat|5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
79980510|NCT04296942|Biological|M7824|1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
79980511|NCT04296942|Biological|Ado-trastuzumab emtansine|3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
79980512|NCT02468050|Behavioral|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
79331470|NCT06162936|Diagnostic Test|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
79331471|NCT06162936|Diagnostic Test|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
79331472|NCT06162923|Behavioral|On-site video group|Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
79331473|NCT06162923|Behavioral|Remote video group|After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
79331474|NCT06162910|Diagnostic Test|Daniels Water Swallow Test|Clinical water swallow dysphagia screening
79484570|NCT04744753|Drug|Calcium Ionophore A23187|"Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF."
79484571|NCT02420041|Procedure|Active comparator: Fluoroscopic Guided SIJ injection|"Needle entry point is in the lower one-third of the SIJ~Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~Patient observed in recovery bay for 20 minutes and then discharged home"
79650852|NCT04664530|Drug|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
79650853|NCT04663984|Behavioral|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
79650854|NCT04664218|Device|HIPEC device|To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
79650855|NCT00216398|Drug|Lanreotide (Autogel formulation)|
79650856|NCT00241215|Drug|Botulinum toxin serotype A|
79331475|NCT06162910|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopic evaluation of swallowing function
79331476|NCT06162897|Behavioral|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
79331477|NCT06162858|Other|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
79331478|NCT06162845|Behavioral|A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions|Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
79331479|NCT06162845|Behavioral|Paper-based home exercise program for pelvic floor muscle exercise|Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
79331480|NCT06162832|Combination Product|Allograft and rHPDGF-BB|At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
79331481|NCT06162832|Combination Product|Allograft and Saline solution|This will be used as the control group
79331482|NCT06162793|Behavioral|RehaPlus+|24-week eHealth intervention
79331483|NCT06162780|Diagnostic Test|ultrasonic cardiography|Trans-thoracic echocardiography is performed in the resting position. Trans-esophageal echocardiography is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to ASE guideline.
79331484|NCT06162780|Procedure|Transcatheter mitral valve Edge-to-Edge Repair|There are two commercial systems including Mitraclip and Dragonfly for clinical use. The patient who receives general anaesthesia undergoes operation guided by X-ray and trans-esophageal echocardiography, according to the recommended surgical procedure. MR success is defined as DMR ≤ grade 2+ after TEER. After crossing the atrial septum during the operation, full dose heparin was given for anticoagulation. Post-intervention antithrombotic therapy was used as indicated. Anticoagulation was chosen if the patient has an indication for anticoagulation, otherwise aspirin was prescribed.
79650857|NCT04663789|Procedure|reinforcement of the staple line|The operator will perform reinforcement of the staple line with a continuous lock stitch.
79650858|NCT04663789|Procedure|staple only|The operator transect the pancreas with stapler only, without staple line reinforcement.
79811755|NCT00796276|Drug|IR OROS paliperidone and ER OROS paliperidone|
79331485|NCT06162767|Procedure|Esophagectomy by Ivor-Lewis Procedure|Esophagectomy was conducted by Ivor-Lewis Procedure.
79331486|NCT06162767|Procedure|Esophagectomy by Optimized Sweet Procedure|Esophagectomy was conducted by Optimized Sweet Procedure.
79331487|NCT06162754|Other|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
79331488|NCT06162741|Behavioral|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
79484572|NCT02420041|Procedure|Ultrasound Guided Sacroiliac Joint Injection|"Sterile preparation (with chlorhexidine) and drape~Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~Patient observed in recovery bay for 20 minutes and then discharged home"
79484573|NCT02420041|Device|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
79484574|NCT02420041|Device|SonoSite S-nerve|
79484575|NCT02420041|Device|iohexol|
79484576|NCT02420041|Drug|triamcinolone/lidocaine|
79484577|NCT02421055|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
79484578|NCT02421055|Procedure|Laparoscopic Sleeve Gastrectomy|
79980513|NCT02468050|Behavioral|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
79484579|NCT02450383|Drug|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
79484580|NCT02450383|Procedure|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
79484581|NCT02421211|Drug|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
79980514|NCT04442620|Other|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
79980515|NCT04442620|Other|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
79980516|NCT04442620|Other|Control diet (CD)|Control Diet
79980517|NCT01343550|Other|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
79811756|NCT00796354|Drug|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
79980518|NCT03305380|Other|No interventions|As this is a patient registry, there are no interventions.
79980519|NCT01344564|Drug|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
79980520|NCT04894812|Other|Neurodevelopmental technique|"st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~nd month: balance and corrective reactions; using CP ball and tilt board.~rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
79307606|NCT03456895|Other|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
79484582|NCT02421211|Drug|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
79484583|NCT02421211|Drug|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
79484584|NCT00363259|Drug|Peginterferon alfa-2b|
79484585|NCT00363259|Drug|Ribavirin|
79811757|NCT00796354|Drug|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
79811758|NCT00796432|Drug|OROS paliperidone|
79980521|NCT01344720|Drug|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
79331489|NCT06162741|Behavioral|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
79331490|NCT06162715|Drug|Tirzepatide|Tirzepatide will be initiated 3 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 4 weeks until the maximum 15 mg dose or the maximum tolerated dose is achieved. Patients will then complete a final 4 weeks of the study drug.
79331491|NCT06162702|Procedure|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
79331492|NCT06162676|Behavioral|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
79331493|NCT06162663|Drug|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
79331494|NCT06162663|Other|Placebo Control|Matched Placebo Control for 28 days
79331495|NCT06162650|Radiation|Short-course radiotherapy|Short-course radiotherapy, 5×5 Gy.
79331496|NCT06162650|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
79331497|NCT06162624|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
79331498|NCT06162624|Behavioral|Cognitive Behavioral Therapy (CBT)|"As control condition, CBT book Feeling Good Self-Help Book will be used"
79331499|NCT06162598|Other|Ventriloquist Puppet|one day preparation intervention applied by researcher for children under the inhaler treatment. Preparation will be 30 minutes long
79331500|NCT06162546|Other|Registry|Registry Participation, providing data and clinical specimen
79331501|NCT06162533|Biological|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
79331502|NCT06162520|Other|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
79331503|NCT06162507|Biological|CM310|CM310 injection
79331504|NCT06162468|Procedure|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
79331505|NCT06162442|Drug|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
79331506|NCT06162403|Other|Peripheral Nerve Stimulation|The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
79331507|NCT06162390|Drug|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
79331508|NCT06162338|Biological|LY-M001 Injection|With 5.0 × 10^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity [DLT] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
79331509|NCT06162299|Biological|YS-HBV-002|YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
79331510|NCT06162286|Drug|Omadacycline|Omadacycline IV/PO
79331511|NCT06162286|Drug|Moxifloxacin|Moxifloxacin IV/PO
79331512|NCT06162273|Device|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
79331513|NCT06162260|Procedure|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
79484586|NCT02421757|Device|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
79484587|NCT02421757|Device|Placebo|The placebo Transcutaneous device
79484588|NCT02423317|Device|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
79484589|NCT02423317|Device|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
79484590|NCT02424175|Biological|Fecal Microbiota Transplantation|
79484591|NCT03093259|Drug|ABX464|ABX464 is a new Anti-inflammatory drug
79484592|NCT03093259|Drug|Placebo oral capsule|Placebo matching with ABX464
79484593|NCT02528318|Combination Product|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
79484594|NCT02528318|Device|nCPAP alone|nCPAP therapy
79484595|NCT02423408|Drug|TNX-201|TNX-201 capsule
79484596|NCT02423408|Drug|Placebo|Placebo capsule
79811759|NCT02555566|Procedure|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
79811760|NCT02555566|Procedure|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
79331514|NCT06162208|Other|Standard exercise program based on telerehabilitation|Exercises included in a standard exercise program based on telerehabilitation; Week 0-3 Patellar mobilization Isometric quadriceps femoris exercise Terminal extension exercise Active assisted knee flexion Straight leg lift Active hip abduction Active assisted knee flexion in sitting SAFTE Cold pack application Week 3-6 Straight leg raises with weights Hip abduction in weighted side lying Knee flexion in the prone position Knee extension in weight-bearing sitting Sliding forward in the chair to increase the knee flexion angle Standing weighted hip abduction Standing knee flexion with weight Squat Walking Climbing stairs Action observation therapy will be practiced by watching videos of all exercises with a focus on close-up action.
79331515|NCT06162195|Device|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
79331516|NCT06162195|Device|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
79331517|NCT06162182|Diagnostic Test|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager & Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
79811761|NCT05757960|Procedure|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
79980522|NCT01344720|Drug|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
79331518|NCT06162182|Diagnostic Test|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
79331519|NCT06162169|Drug|JAB-21822|JAB-21822 was administered orally
79331520|NCT06162169|Drug|Itraconazole|Itraconazole was administered orally
79331521|NCT06162169|Drug|Omeprazole|Omeprazole was administered orally
79331522|NCT06162169|Drug|Midazolam , Rosuvastatin calcium and digoxin|Midazolam , Rosuvastatin calcium and digoxin was administered orally
79484597|NCT02528786|Other|No Intervention|No study drug will be administered in this study.
79484598|NCT02424968|Biological|Anti-Thymocyte Globulin|Given per standard institutional practice
79650859|NCT04663360|Other|Adverse Drug Reaction (ADRe) Profile|ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
79980523|NCT04442230|Biological|NasoVAX|NasoVAX consists of replication-deficient adenovirus vectors in suspension
79980524|NCT04442230|Other|Placebo|Normal saline
79331523|NCT06162169|Drug|Rifampicin|Rifampicin was administered orally
79331524|NCT06162156|Other|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
79980525|NCT04921098|Procedure|Diode Laser Cyclophotocoagulation|A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
79484599|NCT02424968|Drug|Cyclosporine|Given PO
79484600|NCT02424968|Drug|Mycophenolate Mofetil|Given PO
79484601|NCT02424968|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
79484602|NCT02424968|Biological|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
79484603|NCT02424968|Radiation|Total Nodal Irradiation|Undergo TLI
79484604|NCT02424799|Drug|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
79484605|NCT02424799|Drug|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
79650860|NCT00216437|Drug|Capecitabine (Xeloda)|
79650861|NCT00244920|Drug|bicalutamide|
79650862|NCT00244920|Drug|leuprolide acetate|
79650863|NCT00244920|Drug|squalamine lactate|
79650864|NCT00244920|Procedure|adjuvant therapy|
79331525|NCT06162065|Drug|Oxybutynin Pill|pharmacological antimuscarinic treatment
79331526|NCT06162065|Dietary Supplement|Boldo supplement|treatment supplemented with boldo
79331527|NCT06161961|Device|WRL TTP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
79331528|NCT06161909|Drug|sintilimab|200mg fixed dose Q3W,1 year
79331530|NCT06161883|Other|Soffritto|The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
79331531|NCT06161870|Drug|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
79331532|NCT06161870|Drug|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
79331533|NCT06161818|Drug|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
79331534|NCT06161792|Drug|0.8 mg RCN3028|Oral
79331535|NCT06161792|Drug|Placebo|Oral
79331536|NCT06161779|Other|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
79331537|NCT06161766|Drug|terlipressin or noradrenalin plus albumin|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
79331538|NCT06161740|Procedure|muscle strengthening|The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
79331539|NCT06161727|Other|HPV exposure|According to group descriptions
79331540|NCT06161714|Drug|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|4% articaine with 1:100,000 epinephrine buccal infiltration
79331541|NCT06161714|Drug|Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml|2% Lidocaine with 1:100,000 epinephrine buccal infiltration
79331542|NCT06161701|Other|no intervention|no intervention
79331543|NCT06161688|Drug|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
79331544|NCT06161688|Other|Placebo|Matching placebo for Ensitrelvir
79331545|NCT06161662|Other|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will be given
79331546|NCT06161662|Other|Control|Electrodes will be attached on the surface of acupoints but no stimulation will be given
79331547|NCT06161623|Behavioral|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions.
79331548|NCT06161597|Behavioral|Family Check-Up Online|Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
79331549|NCT06161480|Device|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
79650865|NCT00244920|Procedure|antiandrogen therapy|
79650866|NCT00244920|Procedure|antiangiogenesis therapy|
79650867|NCT00244920|Procedure|conventional surgery|
79650868|NCT00244920|Procedure|neoadjuvant therapy|
79650869|NCT00244920|Procedure|releasing hormone agonist therapy|
79331550|NCT06161467|Device|Ultrasound devices|Safe , no radiation
79331551|NCT06160492|Drug|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
79331552|NCT06159361|Behavioral|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
79650870|NCT04663477|Diagnostic Test|patient-completed Caprini Risk Score|The participants will be asked to complete patient-completed Caprini Risk Score
79650871|NCT04663438|Drug|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
79650872|NCT00216515|Drug|galantamine hydrobromide|
79650873|NCT04663516|Other|Exergaming|games provided by the console requiring the movement of upper body, lower body and trunk.
79650874|NCT00244959|Drug|anastrozole|1 mg orally daily for 12 months
79650875|NCT00244959|Procedure|adjuvant therapy|treatment received after breast cancer surgery
79650876|NCT04663672|Other|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
79650877|NCT04663672|Other|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
79650878|NCT04663672|Other|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
79811762|NCT00786058|Drug|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
79484606|NCT02424799|Drug|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
79484607|NCT02492750|Biological|Anakinra|Given SC
79484608|NCT02492750|Drug|Dexamethasone|Given PO
79484609|NCT02492750|Other|Laboratory Biomarker Analysis|Correlative studies
79484610|NCT02492750|Drug|Lenalidomide|Given PO
79484611|NCT02492750|Other|Placebo|Given SC
79484612|NCT00363337|Drug|aripiprazole|open label treatment with aripiprazole
79650879|NCT04663672|Behavioral|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
79650880|NCT04663048|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
79650881|NCT04663009|Device|AutoPulse|A band circumflex of the chest that provide chest cage compressions.
79650882|NCT00244998|Drug|fulvestrant|IM
79650883|NCT04663165|Procedure|Periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
79650884|NCT04663165|Procedure|Regenerative periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
79811763|NCT00871169|Drug|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
79331553|NCT06155786|Device|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
79331554|NCT06155786|Device|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
79331555|NCT06155786|Device|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
79331556|NCT06155773|Procedure|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
79331557|NCT06155773|Procedure|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
79331558|NCT06155773|Procedure|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
79331559|NCT06155773|Procedure|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
79331560|NCT06155591|Other|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
79331561|NCT06154720|Drug|Antibiotics|After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
79331562|NCT06154434|Drug|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
79331563|NCT06154213|Behavioral|Building Habits Together|"Private, hidden Facebook group Building Habits Together includes 24 weeks on content based on the Diabetes Prevention Program and the Habit app."
79331564|NCT06154213|Behavioral|Getting Healthy Together|"Private, hidden Facebook group Getting Healthy Together includes 24 weeks on content based on the Diabetes Prevention Program and the MyFitnessPal app."
79484613|NCT02453347|Device|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
79484614|NCT02493452|Drug|Plecanatide|
79484615|NCT02493452|Drug|Placebo|
79484616|NCT02428309|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
79484617|NCT02429869|Drug|everolimus|
79650885|NCT04663243|Behavioral|Thinking healthy Program sessions designed for antenatal period|Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
79650886|NCT00216554|Drug|risperidone|
79484618|NCT02430337|Behavioral|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
79484619|NCT02430337|Behavioral|SafeCare|SafeCare, an evidence-based home visiting program
79484620|NCT02493608|Device|scalpel|used to cut the abdominal wall.
79484621|NCT02493608|Device|Diathermy|Diathermy used to cut , coagulate the tissue
79484622|NCT02494076|Drug|EzPAP|
79484623|NCT02494076|Other|Standard Care|
79484624|NCT02431273|Drug|TDF IVR|
79484625|NCT02431273|Drug|TDF-FTC IVR|
79484626|NCT02431273|Drug|TDF-FTC-MVC IVR|
79484627|NCT02428478|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
79484628|NCT02428478|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
79484629|NCT04341493|Drug|Nitazoxanide 500 MG|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
79484630|NCT04341493|Drug|Hydroxychloroquine|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
79484631|NCT02431741|Device|Mepilex Transfer Ag|
79331565|NCT06154057|Procedure|Dental Implants installed in an grafted area (sinus lifting)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
79331566|NCT06154057|Procedure|Dental Implants installed in an grafted area (ridge augmentation)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
79331567|NCT06154057|Procedure|Dental Implants installed in an grafted area (extraction sites)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
79331568|NCT06153836|Procedure|Neurotization Procedure|Undergo placement of nerve graft
79331569|NCT06153836|Other|Questionnaire Administration|Ancillary studies
79331570|NCT06153836|Procedure|Subcutaneous Mastectomy|Undergo standard of care NSM
79331571|NCT06153719|Other|12-weeks combined exercise intervention|This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
79331572|NCT06153303|Behavioral|Acceptance and commitment therapy|The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
79331573|NCT06153004|Behavioral|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
79331574|NCT06153004|Drug|Antidepressant medication (ADM)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
79331575|NCT06150612|Behavioral|Unwinding Anxiety|In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.
79331576|NCT06150534|Other|No Intervention|This is a non-interventional study.
79331577|NCT06150456|Procedure|extraction|extraction: in all groups, extraction will be performed
79331578|NCT06150456|Radiation|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
79650887|NCT04662892|Drug|Pegfilgrastim-Cbqv|Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
79331579|NCT06150456|Biological|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
79331580|NCT06147518|Drug|Metformin|Metformin: 1.5g/d CTPA,1g/d CTPB
79331581|NCT06147518|Drug|Sitagliptin|Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c>7%
79650888|NCT00241254|Drug|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
79650889|NCT00241254|Drug|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
79650890|NCT00216632|Drug|risperidone|
79331582|NCT06147518|Drug|Dapagliflozin|Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c>7%
79331583|NCT06145698|Device|Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device|Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.
79331584|NCT06145048|Drug|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
79331585|NCT06144593|Other|Dietary macronutrient composition|Intermittent carbohydrate restriction
79484632|NCT02432287|Drug|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
79484633|NCT02432287|Drug|Placebo|there is no other name we used for the placebo
79484634|NCT02532998|Drug|AZD9977 oral suspension|AZD9977 oral suspension, single dose
79980526|NCT03305302|Procedure|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
79331586|NCT06143683|Procedure|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
79331587|NCT06143683|Procedure|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
79331588|NCT06140108|Drug|Empagliflozin 10 MG|Each participant will receive empagliflozin 10mg daily for 3 months.
79331589|NCT06140108|Drug|MetFORMIN 500 Mg Oral Tablet|Each participant will receive metformin 1000mg daily for 3 months.
79331590|NCT06134440|Dietary Supplement|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
79331591|NCT06134258|Other|mixed meal test|mixed meal test after fasting
79331592|NCT06132139|Device|VisAR|The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
79331593|NCT06128889|Behavioral|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
79484635|NCT02532998|Drug|AZD9977 placebo oral suspension|oral suspension, single dose
79484636|NCT02532998|Drug|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
79650891|NCT04662775|Behavioral|HERizon Project|"1. Participants were asked to complete 3x30-minute physical activity sessions each week & record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
79331594|NCT06114199|Behavioral|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
79331595|NCT06114199|Behavioral|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
79331596|NCT06112015|Other|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
79331597|NCT06108154|Behavioral|Educational breastfeeding traning session|Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
79331598|NCT06106009|Drug|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
79650892|NCT04662814|Other|shock wave therapy|Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
79331599|NCT06106009|Drug|Placebo|Oral solution, oral suspension or solid oral formulation(s)
79650893|NCT04662814|Other|dietary modification|Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
79980527|NCT04442542|Other|Respiratory muscle training 1 (Experimental Group)|"The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity"
79331600|NCT06106009|Drug|Midazolam|Midazolam oral solution
79331601|NCT06098729|Behavioral|Digital Exercise|A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
79331602|NCT06097312|Other|Data collection|The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
79331603|NCT06096935|Other|bood sample|Exome measurements
79331604|NCT06095401|Other|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
79331605|NCT06095401|Other|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent [TED] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
79331606|NCT06087237|Drug|Pentoxifylline|400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.
79331607|NCT06087237|Drug|Placebo|placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
79650894|NCT04662736|Other|patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
79650895|NCT04662853|Diagnostic Test|Gut microbiota determination from feces samples.|Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
79331608|NCT06084247|Device|Curved KARL STORZ fetoscope|The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
79331609|NCT06084247|Device|Conventional Scopes|The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
79484637|NCT02532998|Drug|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
79484638|NCT00363194|Drug|Pazopanib (GW786034)|Pazopanib (GW786034)
79650896|NCT00216710|Behavioral|Home Visiting|
79331610|NCT06074315|Device|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
79331611|NCT06074315|Device|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
79331612|NCT06072664|Behavioral|Caloric Compensation Index (COMPX)|Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
79331613|NCT06072651|Behavioral|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
79331614|NCT06072638|Behavioral|Eating in Absence of Hunger|Researcher gives child free access to palatable foods following a satiating meal.
79331615|NCT06070090|Procedure|Acupuncture|The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
79331616|NCT06067958|Drug|Dexmedetomidine|Intranasal administration of dexmedetomidine will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
79331617|NCT06067958|Drug|Saline|Intranasal administration of saline 0.9% will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
79331618|NCT06062511|Dietary Supplement|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
79331619|NCT06062511|Dietary Supplement|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
79331620|NCT06062511|Dietary Supplement|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
79811764|NCT02610114|Other|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
79811765|NCT02610114|Other|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
79331621|NCT06048094|Drug|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
79331622|NCT06034236|Other|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~Sitting at a table and reaching in different directions for objects located beyond arm's length.~Sit to stand from various chair heights~Stepping forward, backward and sideways onto blocks of various heights.~Heel lifts in standing~Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~Reciprocal leg flexion and extension.~Sit ups~Standing up from chair, walking a short distance and returning to the chair.~Walking races between participants~Walking over various surfaces and obstacles"
79484639|NCT02453581|Drug|OZ439|OZ439 Powder for Oral Suspension
79331623|NCT06034236|Other|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
79331624|NCT06034223|Other|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
79331625|NCT06034223|Other|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
79650897|NCT00245076|Behavioral|smoking cessation intervention|
79980528|NCT04442542|Other|Respiratory muscle training 2 (Control Group)|Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
79331626|NCT06033872|Combination Product|Focused education, medication adjustment and telemonitoring|"Focused diabetes education session for Ramadan fasting~Participants will be taught to record~Meal plans~Physical activities~Blood glucose monitoring, and~Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
79331627|NCT06033157|Behavioral|Physiotherapist supervised training|"A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder."
79980529|NCT04246788|Other|Intensive robotic rehabilitation|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
79484640|NCT02533466|Other|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
79484641|NCT02533466|Other|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
79484642|NCT02454127|Behavioral|Atkins Diet|Dietary counseling for 1 year
79650898|NCT00245076|Other|internet-based intervention|
79650899|NCT04662502|Dietary Supplement|Bifidobacterium longum 35624|Bifidobacterium longum 35624, 1 x 10^9 CFU/capsule, 1 capsule/day over 1 month
79650900|NCT04662658|Drug|Hyperpolarized Xenon -129 MRI|e-cigarette sub-study
79650901|NCT04662424|Other|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
79650902|NCT00216788|Drug|Esomeprazole (Nexium) 40 mg/day|
79650903|NCT04662346|Other|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
79650904|NCT00245115|Biological|filgrastim|
79650905|NCT00245115|Drug|busulfan|
79980530|NCT04246788|Other|classical physiotherapy|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
79331638|NCT06004752|Drug|Ciclosporin|Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
79331639|NCT06004752|Drug|Avatrombopag|Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
79331640|NCT06003764|Other|Pulsed electromagnetic field|low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
79650906|NCT00245115|Drug|cyclophosphamide|
79331641|NCT06003764|Other|traditional skin care|traditional skin care( the patients will receive the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing will be used. Additionally, the patient will be advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
79331642|NCT06002581|Device|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
79650907|NCT00245115|Procedure|in vitro-treated bone marrow transplantation|
79650908|NCT00245115|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79980531|NCT05727982|Diagnostic Test|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
79331643|NCT06002581|Device|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
79650909|NCT04662385|Drug|aloe vera toothpaste|aloe vera toothpaste have antimicrobial and other multipotential effects.
79980532|NCT03220854|Radiation|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
79980533|NCT03220854|Other|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
79331644|NCT06002581|Device|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
79331645|NCT05998239|Other|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
79484643|NCT02454127|Behavioral|Zone Diet|Dietary counseling for 1 year
79484644|NCT02454127|Behavioral|Weight Watchers Diet|Dietary counseling for 1 year
79650910|NCT04662385|Drug|Colgate Total|Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities & gingivitis
79650911|NCT00216827|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
79811766|NCT00791284|Drug|Intermediate release (IR) Paliperidone|
79980534|NCT03220854|Other|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
79980535|NCT02467894|Other|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
79980536|NCT03305224|Drug|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
79980537|NCT03305068|Drug|Celecoxib|
79331646|NCT05998239|Other|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
79331647|NCT05996341|Device|blood flow restriction|12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
79331648|NCT05987124|Drug|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
79331649|NCT05986682|Drug|Blenrep|Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.
79331650|NCT05971602|Drug|Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
79331651|NCT05971602|Drug|Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
79331652|NCT05971602|Drug|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care [SOC]). All the doses administered will be weight-based.
79331653|NCT05971602|Drug|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)|X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
79331654|NCT05971485|Drug|Melatonin 10 mg|Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
79331655|NCT05955183|Drug|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
79331656|NCT05955183|Drug|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
79331657|NCT05946603|Drug|Administration of IS-002|Intravenous administration of IS-002 approximately 24 hours prior to surgery
79331658|NCT05946603|Device|Firefly fluorescent imaging|Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002
79331659|NCT05946603|Procedure|robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection|Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
79331660|NCT05939401|Other|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
79331661|NCT05935514|Behavioral|WW Intervention|The core of the WW food program is the Points® system which assigns each food and beverage a Points® value. Participants will be assigned a personalized daily and weekly Points® Budget, based on reported goals, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System, which is intended to monitor interstitial fluid glucose levels to aid users in the management of diabetes. The System consists of the following primary components: 1) A disposable sensor that incorporates a subcutaneously implanted electrochemical glucose sensor and associated on-body electronics, and 2) A disposable, sensor application device, which is used to adhere the sensor to the skin of the user and to insert the sensor tail just below the surface of the skin.
79650912|NCT04662229|Device|Eco-guided Percutaneous Electrical Stimulation|Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.
79650913|NCT04662229|Device|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
79980538|NCT04242810|Device|rTMS|TMS will be applied over task-based target at an intensity up of 130% rMT. The optimal coil placement during stimulation will be guided using the BrainSight neuronavigation system.
79650914|NCT00241332|Drug|fentanyl|
79484645|NCT02454127|Behavioral|Ornish Diet|Dietary counseling for 1 year
79484646|NCT02974244|Drug|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
79650915|NCT00216866|Drug|Dalteparin|
79650916|NCT00216866|Drug|Warfarin|
79650917|NCT00557206|Drug|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
79980539|NCT04242810|Device|Sham rTMS|An electrical sham coil that produces the same auditory and somatosensory stimulations, without a significant magnetic field, will be used as an active control.
79980540|NCT04242810|Procedure|MRI scan|Participants will undergo an MRI scan directly after rTMS stimulation that will last less than 120 minutes. During the scan, subjects will encode and retrieve object pictures.
79980541|NCT01317420|Drug|BI 836845|Intravenous infusion once every three weeks
79980542|NCT04490590|Drug|Chidamide+ Etoposide|Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
79980543|NCT01344798|Biological|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
79331662|NCT05935514|Behavioral|Usual Care|The Usual Care arm will continue to receive routine medical care by their provider, in addition to a 50-minute virtual, on-line session with a Registered Dietician, with additional materials at the time of their 6- and 12-month follow-up assessments.
79331663|NCT05928039|Biological|TNFa Antagonist - Infliximab|• Infliximab 5 mg/kg intravenously [IV] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
79331664|NCT05928039|Biological|TNFa Antagonist - Adalimumab|• Adalimumab subcutaneously [SC] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
79331665|NCT05928039|Biological|Anti-IL12/23 or anti-IL23 - Ustekinumab|• Ustekinumab ~6 mg/kg IV x1, then 90 mg SC every 8 weeks
79331666|NCT05928039|Biological|Anti-IL12/23 or anti-IL23 - Risankizumab|• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
79331667|NCT05928039|Biological|Anti-integrin - Vedolizumab IV|• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
79484647|NCT02974244|Drug|basal insulin|basal insulin treatment in the customary clinical care in USA
79331668|NCT05928039|Biological|Anti-integrin - Vedolizumab IV and SC|• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
79331671|NCT05909566|Other|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
79484648|NCT04743986|Biological|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
79484649|NCT04743986|Drug|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
79484650|NCT03016897|Other|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
79484651|NCT02974322|Drug|GED-0301|GED-0301
79484652|NCT02974322|Drug|Placebo|Placebo
79484653|NCT02436031|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
79484654|NCT02436031|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
79484655|NCT02454283|Drug|Vanoxerine HCl|
79484656|NCT02454283|Drug|Placebo|
79484657|NCT02437669|Drug|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
79484658|NCT02430818|Drug|ketamine|
79484659|NCT02430818|Drug|morphine|
79331672|NCT05909566|Device|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
79331673|NCT05904210|Drug|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
79331674|NCT05903781|Diagnostic Test|Prostate MRI|MRI of the prostate
79331675|NCT05903040|Drug|Lasmiditan|Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
79331676|NCT05903027|Drug|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
79331677|NCT05901831|Drug|Finerenone|Dose A, Dose B, oral
79331678|NCT05901831|Other|Placebo|Oral
79331679|NCT05896670|Drug|licaminlimab|ophthalmic suspension 60 mg/mL Subjects will receive licaminlimab eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
79331680|NCT05896670|Other|vehicle of OCS-02|inert ophthalmic suspension vehicle of OCS-02 Subjects will receive vehicle eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
79331681|NCT05896514|Device|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
79331682|NCT05893160|Drug|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
79331683|NCT05893160|Other|Placebo|Inert placebo formulation
79331684|NCT05889689|Behavioral|Relationship Smarts Plus & Mind Matters|18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum
79331685|NCT05889689|Behavioral|Relationship Smarts Plus alone|14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.
79484660|NCT02455453|Drug|18F-FFNP|
79484661|NCT02455453|Device|CTI/Siemens Biograph 40 PET/CT Scanner|"Will include (1) 18-FDG-PET/CT scan~Will include (2) 18F-FFNP-PET/CT scans"
79484662|NCT02455453|Drug|Estradiol|
79484663|NCT02455453|Drug|18F-FDG|
79484664|NCT02997865|Behavioral|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
79331686|NCT05889689|Behavioral|Preparing Adolescents for Young Adulthood (PAYA).|A financial literacy curriculum
79331687|NCT05878249|Procedure|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
79331688|NCT05878249|Procedure|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
79331689|NCT05878249|Procedure|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
79331690|NCT05878249|Procedure|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
79331691|NCT05869851|Other|Pavlik Harness|The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
79331692|NCT05862870|Behavioral|painTRAINER|patient self-administered pain management web application
79331693|NCT05862493|Diagnostic Test|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
79331694|NCT05842343|Other|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
79331695|NCT05842343|Other|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
79331696|NCT05822492|Procedure|Group QLB3|"Patients who applied the QLB3 block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
79331697|NCT05822492|Procedure|Group ESPB|"Patients who applied ESP block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
79331698|NCT05822492|Other|Group Control|"Patients who did not use block before PCNL surgery were included in this group.~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
79484665|NCT02457403|Device|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
79307607|NCT03456895|Other|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
79307608|NCT03433469|Drug|Osimertinib|Given PO (orally)
79307609|NCT03433469|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79307610|NCT03427736|Drug|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
79307611|NCT03427736|Drug|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
79307612|NCT03427736|Drug|Ketamine|IV Ketamine will be given per standard of care, not prescribed for this study
79307613|NCT03427736|Drug|Oxycodone|PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study
79307614|NCT03427736|Drug|Morphine|IV Morphine will be given per standard of care, not prescribed for this study
79307615|NCT03397342|Device|CPAP machine|Use of CPAP machine during MRI
79307616|NCT03387618|Diagnostic Test|Digital PET/CT imaging|Next generation PET/CT imaging
79331699|NCT05820659|Behavioral|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
79331700|NCT05820256|Dietary Supplement|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
79331701|NCT05820256|Dietary Supplement|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
79331702|NCT05820139|Procedure|Control Group|Patients will be randomized to a 200mL (control group)
79331703|NCT05820139|Procedure|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
79331704|NCT05800405|Procedure|Biospecimen Collection|Undergo blood sample collection
79331705|NCT05800405|Biological|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR-T per standard of care
79331706|NCT05800405|Procedure|Computed Tomography|Undergo PET/CT
79331707|NCT05800405|Radiation|External Beam Radiation Therapy|Undergo radiation therapy
79331708|NCT05800405|Procedure|Leukapheresis|Receive leukapheresis
79331709|NCT05800405|Procedure|Magnetic Resonance Imaging|Undergo MRI
79331710|NCT05800405|Procedure|Positron Emission Tomography|Undergo PET/CT
79331711|NCT05776251|Device|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
79331712|NCT05774977|Other|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
79331713|NCT05774977|Other|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
79331714|NCT05774977|Other|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
79331715|NCT05774977|Other|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
79650918|NCT04661917|Drug|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
79331716|NCT05774977|Other|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
79331717|NCT05774977|Other|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
79331718|NCT05773261|Device|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
79331719|NCT05773261|Device|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
79331720|NCT05755620|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
79331721|NCT05755620|Other|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
79331722|NCT05755620|Biological|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 [PEG lipid]).
79331723|NCT05750459|Drug|Artesunate|Artesunate is a succinic ester of artemether.
79331724|NCT05743166|Procedure|Bariatric surgery|JDF11 JDF41 JDF97
79331725|NCT05742646|Behavioral|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
79650919|NCT04661917|Drug|Placebo|Matching placebo orally once daily for 28 days.
79331726|NCT05742646|Behavioral|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
79331727|NCT05724030|Device|integrated pulmonary index|integarted pumobary index monitoring
79331728|NCT05724030|Device|saturation|saturation monitorization
79331729|NCT05722938|Drug|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
79331730|NCT05722938|Drug|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
79331731|NCT05702281|Device|ReLARC|ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
79331732|NCT05698121|Device|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
79331733|NCT05695417|Drug|OTX-TKI|Injection of OTX-TKI
79331734|NCT05695417|Drug|Sham|Sham Injection of OTX-TKI
79331735|NCT05694676|Other|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
79331736|NCT05694676|Other|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
79331737|NCT05694676|Other|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
79331738|NCT05688748|Other|Dengue self-monitoring system|The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
79331739|NCT05679570|Drug|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period[1]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period[2]:~Subjects completed continuation dosing period[1], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
79331740|NCT05677581|Other|iodine nutrition status|iodine nutrition status
79331741|NCT05675007|Dietary Supplement|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
79331742|NCT05675007|Dietary Supplement|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
79331743|NCT05655507|Drug|Zuranolone|Administered as capsules
79307617|NCT03382548|Drug|Reducing Antibiotics treatment duration|Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
79331746|NCT05622591|Drug|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
79331747|NCT05622110|Procedure|Adhesive glue closure|Incision closure with adhesive glue
79331748|NCT05622110|Procedure|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
79331749|NCT05622097|Other|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
79484666|NCT02457403|Other|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
79484667|NCT02533934|Drug|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
79484668|NCT02983513|Behavioral|Early Intervention|
79484669|NCT02459119|Drug|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
79484670|NCT02956525|Drug|Dexibuprofen|Dexibuprofen 200 mg
79484671|NCT02519023|Drug|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
79331750|NCT05622097|Other|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
79331751|NCT05610072|Drug|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
79331752|NCT05610072|Drug|Hydromorphone|Subjects will receive up to 144 mg oral hydromorphone daily.
79331753|NCT05610072|Drug|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
79331754|NCT05610072|Drug|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
79331755|NCT05609123|Diagnostic Test|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
79331756|NCT05608044|Drug|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
79331757|NCT05608044|Drug|Balstilimab|An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody.
79331758|NCT05608044|Drug|Standard of Care|Regorafenib or trifluridine and tipiracil.
79980544|NCT03300154|Behavioral|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
79331759|NCT05604300|Dietary Supplement|Vitamin E incorporated oat supplement|A twice daily supplementation of Vitamin E incorporated oat for 12 weeks
79331760|NCT05604300|Dietary Supplement|Oat supplement|A twice daily supplementation of oat for 12 weeks
79331761|NCT05603884|Drug|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC > 20×109/L"
79331762|NCT05599386|Diagnostic Test|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
79331763|NCT05597150|Dietary Supplement|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
79331764|NCT05596214|Combination Product|Curcumin-Berberine (coptis)|dietary supplement
79331765|NCT05596214|Combination Product|Placebo|Placebo
79331766|NCT05594199|Behavioral|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
79331767|NCT05589233|Biological|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
79331768|NCT05575076|Drug|Simufilam|simufilam 100 mg oral tablet, twice daily
79331769|NCT05568797|Biological|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine administered intramuscularly.
79331770|NCT05568797|Biological|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
79331771|NCT05565105|Radiation|Total Body Irradiation (TBI)|Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of < 15 cGy/minute.
79331772|NCT05565105|Drug|Thiotepa|Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
79331773|NCT05565105|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m^2 x 5 if cyclophosphamide is contraindicated
79331774|NCT05565105|Drug|Busulfan|Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
79331775|NCT05565105|Drug|Melphalan|Melphalan: 70 mg/m^2/day x 2
79331776|NCT05565105|Drug|Fludarabine|Fludarabine: 25 mg/m^2/day x 5
79331777|NCT05539807|Behavioral|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
79331778|NCT05536154|Drug|Etoposide|Day 1~Day 2: 75mg/m^2
79331779|NCT05536154|Drug|Cytarabine|Day 1~Day 2: 200mg/m^2, q12h
79331780|NCT05536154|Drug|PEG-rhG-CSF|Day 6: 6mg
79331781|NCT05534971|Procedure|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
79331782|NCT05530135|Other|Exercise program|Exercise program
79331783|NCT05530135|Other|Cognitive behavioural therapy|Cognitive behavioural therapy
79331784|NCT05530135|Other|Standard clinical care|Standard clinical care
79331785|NCT05523674|Other|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
79331786|NCT05523674|Other|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
79811767|NCT00791362|Other|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
79331788|NCT05500001|Behavioral|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
79331789|NCT05499676|Device|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
79811768|NCT00814632|Drug|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
79331790|NCT05499676|Device|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
79331791|NCT05477979|Other|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
79331792|NCT05444335|Device|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
79331793|NCT05443737|Behavioral|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
79331794|NCT05430334|Combination Product|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
79331795|NCT05430334|Combination Product|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
79331796|NCT05430334|Combination Product|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
79811769|NCT00786136|Drug|rosuvastatin|rosuvastatin
79811770|NCT02622737|Other|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
79307618|NCT03382548|Drug|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
79331797|NCT05430334|Combination Product|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
79331798|NCT05430334|Combination Product|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
79331799|NCT05426213|Device|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
79331800|NCT05418907|Radiation|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
79331801|NCT05395026|Other|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
79331802|NCT05387434|Behavioral|Diabetes Prevention Program-Remote (DPP-R)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
79331803|NCT05387434|Behavioral|Diabetes Prevention Program-Facebook (DPP-FB)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
79331804|NCT05363280|Drug|AL8326 low dose group|Taken AL3826 at low dose orally
79331805|NCT05363280|Drug|AL8326 middle dose group|Taken AL3826 at middle dose orally
79331806|NCT05363280|Drug|AL8326 high dose group|Taken AL3826 at high dose orally
79331807|NCT05345132|Drug|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
79811771|NCT02622737|Device|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
79331808|NCT05345132|Drug|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
79484672|NCT02519023|Drug|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
79331809|NCT05343806|Drug|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
79331810|NCT05343806|Drug|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
79331811|NCT05343312|Drug|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
79331812|NCT05343312|Drug|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
79331813|NCT05343312|Drug|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
79484673|NCT02519023|Device|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
79484674|NCT02519023|Drug|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
79811772|NCT02622737|Device|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
79484675|NCT02519023|Drug|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
79484676|NCT02519023|Drug|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
79484677|NCT02519023|Drug|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
79484678|NCT02535572|Device|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
79484679|NCT02535572|Device|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
79484680|NCT02497040|Drug|Levobupivacaine|local injection
79484681|NCT02497040|Drug|Bupivacaine|local injection
79484682|NCT02497040|Drug|placebo|local injection
79331814|NCT05343312|Drug|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
79331815|NCT05328960|Other|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
79331816|NCT05326308|Drug|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
79650920|NCT04661800|Other|Sniffin's stick test|The sniffin's stick test is a three-part test consisting of smelling odor pens: 1) determining a detection threshold, 2) discriminating ability, 3) ability to identify odors. It lasts about 30 minutes, is achievable in the room.
79650921|NCT04661527|Drug|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
79331817|NCT05326308|Drug|Obinutuzumab|according to the Summary of Product Characteristics (SmPC).
79331818|NCT05324254|Device|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
79331819|NCT05319808|Other|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
79331820|NCT05319808|Device|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
79331821|NCT05319808|Other|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
79484683|NCT02523235|Drug|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
79307619|NCT03371225|Device|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
79331822|NCT05318300|Dietary Supplement|tested formula with fiber|formula containing fibers
79331823|NCT05318300|Dietary Supplement|Control|formula without fiber
79331824|NCT05315700|Drug|ORIC-114|ORIC-114 oral daily
79484684|NCT02498522|Drug|Metformin|83 patients will continue metformin until end of 1st trimester
79650922|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
79650923|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
79650924|NCT00245193|Behavioral|Motivationally-Enhanced Interpersonal Psychotherapy|
79650925|NCT04661488|Device|AI driven triage-system|AI driven triage-system
79650926|NCT04661605|Diagnostic Test|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
79650927|NCT04661722|Other|No intervention|No intervention
79811773|NCT00796588|Other|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
79811774|NCT04031352|Other|implementation of CATCH scale|subject completed the CATCH scale
79811775|NCT02554942|Drug|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
79331825|NCT05315700|Drug|Chemotherapy drug|21 days for up to 4 cycles
79331826|NCT05313256|Drug|Lidocaine epinephrine buffered with sodium bicarbonate|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
79331827|NCT05313256|Drug|Lidocaine epinephrine|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
79331828|NCT05305859|Drug|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
79331829|NCT05302271|Biological|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
79331830|NCT05302271|Drug|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
79331831|NCT05281731|Device|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
79331832|NCT05281731|Procedure|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
79650928|NCT04661449|Other|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
79980545|NCT03300154|Behavioral|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
79980546|NCT01317498|Other|Standard Care|CD4, liver function and CBC every 6 months
79980547|NCT01317498|Other|Virological Monitoring|Viral Load test every 6 months
79980548|NCT04242654|Procedure|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
79980549|NCT03299998|Procedure|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
79980550|NCT03299998|Procedure|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
79331833|NCT05281731|Genetic|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
79331834|NCT05281731|Device|Definity®|Being used off-label in this trial
79331835|NCT05279300|Drug|CS5001|CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
79331836|NCT05277571|Biological|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
79331837|NCT05277571|Drug|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
79331838|NCT05275959|Other|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
79331839|NCT05269381|Drug|Cyclophosphamide|Given IV
79331840|NCT05269381|Biological|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
79331841|NCT05269381|Biological|Pembrolizumab|Given IV
79650929|NCT00241371|Drug|Clofarabine|
79307620|NCT03371225|Procedure|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
79331842|NCT05269381|Biological|Sargramostim|Given SC
79484685|NCT02459197|Behavioral|Heat Pain Stimuli A|
79650930|NCT04661098|Procedure|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
79650931|NCT00217061|Device|Decision Aid Statin Choice|
79811776|NCT00786214|Other|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
79811777|NCT00786214|Other|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
79980551|NCT04240470|Procedure|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
79331843|NCT05247827|Other|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
79331844|NCT05227209|Drug|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
79980552|NCT02467114|Device|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
79331845|NCT05225415|Drug|CT1812|Orally administered CT1812
79331846|NCT05223582|Drug|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
79331847|NCT05223582|Drug|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
79331848|NCT05223582|Drug|Prednisone|Patients would be treated with 5mg prednisone bid.
79331849|NCT05223582|Drug|Androgen deprivation therapy|Patients would get medical castration.
79331850|NCT05223582|Procedure|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
79331851|NCT05206448|Drug|Letrozole|Letrozole tablet
79331852|NCT05206448|Drug|Clomiphene Citrate|Clomiphene Citrate tablet
79331853|NCT05193604|Drug|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
79980553|NCT02467114|Device|Sham coil stimulation|Stimulation with a sham coil as a comparison
79980554|NCT02467114|Other|Control without stimulation|
79331854|NCT05193604|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
79331855|NCT05193604|Drug|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
79331856|NCT05193604|Drug|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
79331857|NCT05188261|Drug|IW-3300|A single dose of IW-3300 administered rectally (as a low-volume [20 mL] enema) following a fast of at least 6 hours.
79331858|NCT05188261|Drug|Placebo|A single dose of placebo administered rectally (as a low-volume [20 mL] enema) following a fast of at least 6 hours.
79484686|NCT02459197|Behavioral|Heat Pain Stimuli B|
79484687|NCT02459197|Behavioral|Positive Video|
79484688|NCT02459197|Behavioral|Neutral Video|
79484689|NCT02459197|Drug|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
79484690|NCT02459197|Drug|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
79484691|NCT02431052|Drug|Olumacostat Glasaretil|
79484692|NCT02431052|Other|Vehicle|
79484693|NCT02919787|Drug|5-FU|Neoadjuvant treatment
79484694|NCT02919787|Drug|Oxaliplatine|Neoadjuvant treatment
79980555|NCT02467036|Behavioral|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
79331859|NCT05186090|Behavioral|24-week resistance exercise program|This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
79331860|NCT05181553|Other|Canada's Food Guide principles (CFG diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
79331861|NCT05181553|Other|Standard North American diet (NAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
79331862|NCT05159999|Other|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
79980556|NCT05468632|Drug|Semaglutide|Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
79980557|NCT03299920|Other|Standardized instructions|Specific instructions related to peripheral nerve block.
79980558|NCT03299920|Other|Conventional instructions|Usual post-operative instructions.
79331863|NCT05159999|Drug|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
79331864|NCT05153876|Other|Questionnaires|Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
79331865|NCT05146245|Other|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
79331866|NCT05146245|Other|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
79484695|NCT02919787|Drug|Irinotecan|Neoadjuvant treatment
79484696|NCT02919787|Procedure|Pancreatic surgery|All patients
79484697|NCT02919787|Drug|5-FU|Adjuvant treatment
79484698|NCT02919787|Drug|Oxaliplatine|Adjuvant treatment
79484699|NCT02919787|Drug|Irinotecan|Adjuvant treatment
79811778|NCT02619773|Procedure|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
79811779|NCT00791440|Behavioral|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
79980559|NCT02466880|Device|Telemedicine|A diabetes self-management and education program delivered via telemedicine
79980560|NCT02466880|Other|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
79980561|NCT05727826|Device|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
79980562|NCT04763044|Drug|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
79980563|NCT04763044|Drug|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
79980564|NCT04763044|Drug|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
79980565|NCT04763044|Drug|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
79980566|NCT04763044|Drug|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
79484700|NCT02459275|Other|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
79980567|NCT03299764|Device|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
79980568|NCT03299764|Device|Standard non-invasive ventilation|Standard non-invasive ventilation
79650932|NCT04661371|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
79811780|NCT00791440|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
79811781|NCT02622659|Drug|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
79811782|NCT02622659|Drug|Xiaoer Jiebiao Oral Liquid|"1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day"
79484701|NCT02459275|Drug|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
79650933|NCT00245232|Behavioral|Cognitive Therapy|
79811783|NCT02555488|Device|diode laser|MB and diode
79811784|NCT02555488|Device|diode laser|diode laser
79650934|NCT00245232|Behavioral|Cognitive Processing Therapy|
79650935|NCT00245232|Behavioral|Written Exposure|
79811785|NCT02555488|Drug|Methylene blue|Methylene blue and diode laser was used
79811786|NCT02554864|Drug|lidocaine|Local anesthetic
79811787|NCT02554864|Drug|ropivacaine|Local anesthetic
79980569|NCT01315028|Other|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
79980570|NCT01315028|Other|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
79331867|NCT05145387|Behavioral|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
79331868|NCT05143853|Procedure|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
79331869|NCT05143853|Procedure|no fixation around AC joint|there will be no additional fixation around AC joint in this group
79331870|NCT05143853|Procedure|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
79331871|NCT05129605|Diagnostic Test|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
79331872|NCT05110924|Other|Standard of care|Patients in the treatment arm will receive standard care.
79331873|NCT05110924|Other|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
79331874|NCT05096754|Device|OCS Liver|Transplant with an OCS preserved liver.
79484702|NCT02498834|Behavioral|Educational Video and Question Prompt List|Educational Video and Question Prompt List
79980571|NCT02720536|Drug|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
79980572|NCT05453032|Device|NeuroConn|A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
79980573|NCT05727748|Other|Multimodal exercise with augmented reality|The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
79331875|NCT05094037|Device|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
79331876|NCT05094037|Other|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
79331877|NCT05090345|Other|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
79331878|NCT05072808|Other|View PACCI-ED and referral recommendations|Results of parent completed PACCI-ED and referral recommendations
79331879|NCT05059652|Device|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
79331880|NCT05058469|Device|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
79331881|NCT05040217|Genetic|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
79331882|NCT05040217|Biological|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
79331883|NCT05034042|Drug|Fezolinetant|oral
79331884|NCT05034042|Drug|Placebo|oral
79484703|NCT02524561|Drug|CEE pill|Conjugated equine estrogens 0.45 mg/day
79331885|NCT05025865|Drug|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
79650936|NCT04660630|Diagnostic Test|Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases|According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
79650937|NCT04660630|Behavioral|Regular follow-up and patient education|The subjects received regular follow-up and patient education.
79980574|NCT05727748|Other|Multimodal exercise|"The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed)."
79980575|NCT05727748|Other|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
79980576|NCT03299608|Diagnostic Test|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
79980577|NCT03299452|Drug|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
79331886|NCT05025865|Drug|Placebo|A placebo will be given in capsule form to study participants.
79484704|NCT02524561|Drug|Estradiol patch|Climara 50 mcg/day
79484705|NCT02524561|Drug|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
79484706|NCT02524561|Other|Placebo tablet|Placebo tablet
79484707|NCT02524561|Other|Placebo patch|placebo patch
79331887|NCT05012618|Drug|LUNA18|LUNA18 Capsule
79650938|NCT04660786|Drug|triamcinolone acetonide|local immunosuprresent
79650939|NCT04660786|Drug|vitamin D|local immunomodulator
79650940|NCT00217100|Dietary Supplement|Multivitamin|1 tablet a day
79331888|NCT05012618|Drug|Cetuximab|Cetuximab as a IV infusion
79331889|NCT04996680|Device|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
79331890|NCT04996680|Other|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
79484708|NCT02524561|Other|Placebo progesterone|placebo progesterone
79484709|NCT02431598|Drug|gadoxetate disodium|
79484710|NCT02431598|Drug|gadoterate dimeglumine|
79484711|NCT02431598|Drug|Saline|
79484712|NCT00363974|Drug|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
79650941|NCT00217100|Dietary Supplement|Placebo|1 tablet a day
79650942|NCT04660981|Behavioral|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
79650943|NCT00241410|Biological|OralvacB2MPL|Comparison of different dosages of drug
79650944|NCT04660825|Other|A resistance band exercise programme|A resistance band based exercise programme lasting six months
79980578|NCT03299452|Drug|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
79650945|NCT04660825|Other|Control|Maintained usual physical activity
79650946|NCT04660513|Procedure|Bariatric surgery|Subjects with morbid obesity underwent bariatric surgery
79650947|NCT00217139|Drug|Celgosivir|
79650948|NCT04660591|Device|femoral stem in hip arthroplasty|using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
79650949|NCT00245310|Procedure|Indocyangreen (ICG) clearance|
79980579|NCT03299452|Drug|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
79331891|NCT04996680|Device|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
79331892|NCT04993482|Other|No intervention|This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
79331893|NCT04978675|Drug|Fluorine F 18 rhPSMA-7.3|Given IV
79331894|NCT04978675|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79331895|NCT04978675|Procedure|Positron Emission Tomography|Undergo PET/MRI
79331896|NCT04976855|Drug|INDV-2000|Capsule for oral administration
79331897|NCT04976855|Drug|Placebo|Capsule for oral administration
79331898|NCT04976855|Drug|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
79331899|NCT04919226|Drug|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
79331900|NCT04919226|Drug|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
79980580|NCT03168438|Drug|Letetresgene autoleucel|Letetresgene autoleucel (GSK3377794) as an IV infusion
79980581|NCT03168438|Drug|Letetresgene autoleucel with pembrolizumab|Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
79980582|NCT03168438|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
79980583|NCT03168438|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
79980584|NCT03168438|Drug|Pembrolizumab|Pembrolizumab is available as an IV infusion
79980585|NCT03299374|Other|Pilates Intervention|Intervention based on Pilates principles
79331901|NCT04919226|Other|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
79331902|NCT04919226|Drug|Everolimus|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
79331903|NCT04919226|Drug|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
79331904|NCT04904692|Procedure|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
79331905|NCT04904692|Procedure|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
79331906|NCT04904692|Procedure|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
79331907|NCT04865978|Drug|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
79331908|NCT04865978|Drug|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
79331909|NCT04865978|Device|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
79331910|NCT04861558|Drug|5Fluorouracil|Injection of 250-850 mg/m2.
79331911|NCT04861558|Drug|Irinotecan|Injection of 360 mg/m2
79331912|NCT04861558|Drug|Oxaliplatin|Injection of 460 mg/m2
79331913|NCT04858061|Behavioral|Virtual Reality Cue Exposure Therapy|Exposure to alcohol-related cues within virtual environments
79980586|NCT03299374|Other|Fall prevention intervention|Intervention based on principles to prevent falls
79980587|NCT03299296|Drug|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
79331914|NCT04858061|Behavioral|Treatment-as-usual|Pharmacotherapy and psychotherapy
79331915|NCT04851964|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
79331916|NCT04851964|Other|Placebo|Placebo subcutaneous injection
79980588|NCT03299296|Drug|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
79980589|NCT02466724|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
79980590|NCT03137784|Drug|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
79331917|NCT04851587|Behavioral|In-Person (or Remote) Intervention|Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
79331918|NCT04851366|Behavioral|PROCARE+ (with add-on modules)|The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
79331919|NCT04851366|Behavioral|PROCARE (UP-A for selective purposes)|This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
79331920|NCT04851366|Behavioral|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
79331921|NCT04848896|Device|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
79331922|NCT04848896|Procedure|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
79331923|NCT04837638|Behavioral|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
79331924|NCT04803214|Device|ReActiv8|Market-approved ReActiv8 device implanted
79331925|NCT04800484|Device|Tall Soft|Tall heel wedge made of soft foam
79331926|NCT04800484|Device|Tall Firm|Tall heel wedge made of firm foam
79331927|NCT04800484|Device|Short Soft|Short heel wedge made of soft foam
79331928|NCT04800484|Device|Short Firm|Short heel wedge made of firm foam
79331929|NCT04792892|Other|Questionnaires|Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
79331930|NCT04792008|Biological|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
79331931|NCT04792008|Biological|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
79484713|NCT04743739|Drug|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
79650950|NCT04660552|Device|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for approximately 15 minutes at a time, twice a week, for a period of 8 weeks.
79980591|NCT03137784|Drug|Placebo|In each treatment arm, patient will receive placebo
79331932|NCT04786379|Procedure|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
79650951|NCT04660318|Device|Remote photoplethysmography for physiological parameters|physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
79980592|NCT02466256|Procedure|Intraocular lens implantation|Intraocular lens implantation
79331933|NCT04786379|Procedure|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
79484714|NCT04743739|Drug|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
79484715|NCT02499380|Device|PneumRx Coil System|
79484716|NCT02461693|Drug|Caffeine|200mg delivered as pill; one-time dose
79484717|NCT02461693|Drug|Placebo|Lactose-based pill; one-time dose
79484718|NCT02525263|Biological|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
79650952|NCT04660318|Device|standard acquisition system for physiological parameters|physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
79980593|NCT02466256|Device|Autosert Injector|Motorised injection device for intraocular lens implantation
79980594|NCT02466256|Device|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
79650953|NCT00217178|Drug|Vitamins: Folic acid, B6, B12|
79980595|NCT02466256|Device|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
79331934|NCT04778410|Drug|Magrolimab|Administered intravenously
79331935|NCT04778410|Drug|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
79331936|NCT04778410|Drug|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
79331937|NCT04778410|Drug|Mitoxantrone|Administered intravenously, 8 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
79331938|NCT04778410|Drug|Etoposide|Administered intravenously, 100 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
79331939|NCT04778410|Drug|Cytarabine|Administered intravenously, 1000 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
79331940|NCT04778410|Drug|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
79331941|NCT04776083|Drug|first line systemic therapy|first line systemic therapy according to the genetic mutation 0f the patient
79331942|NCT04776083|Radiation|3D radiotherapy or IMRT|Hypo-fractionated radiotherapy to the primary lesion
79331943|NCT04772521|Behavioral|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
79980596|NCT01314716|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
79331944|NCT04772521|Behavioral|Personalized chat-based interactions|Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
79331945|NCT04772521|Behavioral|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
79331946|NCT04772521|Behavioral|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
79331947|NCT04772521|Drug|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
79331948|NCT04768257|Behavioral|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
79331949|NCT04764357|Device|Paxman Scalp Cooling System|Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
79331950|NCT04764357|Other|Alopecia Assessments|Photographs of the hair will be taken before initiation of chemotherapy (baseline) and at a visit 4 weeks (3-6 week window) after the last dose of chemotherapy for those being treated for a non-cancerous condition. Patient with solid tumors will have photographic documentation at baseline, 2-5 weeks after every 2 cycles of chemotherapy, and at end of study (approximately 4 weeks following the last chemotherapy treatment with a range of 3-6 weeks).
79331951|NCT04764357|Other|Patient Reported Outcomes Questionnaires|"Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, end of chemotherapy administration, and 4 week follow up.~Tolerability Questionnaire each time the cooling cap is used and at the end of study"
79331952|NCT04763174|Behavioral|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
79331953|NCT04755322|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
79331954|NCT04755322|Drug|Folic acid|5 mg
79980597|NCT01314716|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
79980598|NCT05727358|Behavioral|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
79980599|NCT03144180|Device|Q-cup|This technology is a different way of collecting umbilical cord blood.
79980600|NCT03299218|Dietary Supplement|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
79331955|NCT04755322|Drug|Low-dose aspirin|75 mg
79331956|NCT04738409|Other|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA&T), in terms of improvement in androgens level and immune-metabolic risk parameters
79331957|NCT04738409|Other|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
79331958|NCT04721795|Drug|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
79331959|NCT04721795|Drug|Standard anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
79650954|NCT04660357|Other|survey study|survey study
79980601|NCT03299218|Behavioral|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
79650955|NCT00241449|Drug|Fulvestrant|intramuscular injection 250 mg
79650956|NCT00241449|Drug|Tamoxifen|20 mg oral tablet
79650957|NCT00412100|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
79980602|NCT03299218|Other|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
79980603|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
79980604|NCT01344954|Drug|Rivaroxaban|Administered orally as a capsule once a day for 35 days
79980605|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
79484719|NCT02525575|Behavioral|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
79331960|NCT04717336|Other|SODIUM CHLORIDE|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
79331961|NCT04717336|Other|placebo|placebo capsules, salt treatment
79331962|NCT04707066|Behavioral|Treatment As Usual (TAU)|Treatment As Usual
79331963|NCT04707066|Behavioral|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1|Collaborative Assessment and Management of Suicidality
79331964|NCT04707066|Behavioral|Dialectical Behavior Therapy (DBT) - Phase 2|Dialectical Behavior Therapy
79484720|NCT02525653|Drug|albumin-bound paclitaxel|
79331965|NCT04707066|Behavioral|Maintenance/Monitoring - Phase 2|Maintenance/Monitoring
79331966|NCT04707066|Behavioral|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
79331967|NCT04705415|Drug|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
79331968|NCT04705415|Drug|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
79980606|NCT05727280|Behavioral|Progressive Relaxation Exercise Practices|The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
79980607|NCT05414786|Biological|eOD-GT8 60mer mRNA Vaccine (100µg)|"2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~No control group. There is no blinding and no randomization in this open label study"
79980608|NCT05329402|Device|Lung cancer surgery|Only the brand of electric cutting stapler used by different groups was different, and the rest were treated according to routine treatment
79980609|NCT01352832|Other|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
79980610|NCT01352832|Other|Usual Care|Usual Care
79484721|NCT02525653|Drug|gemcitabine|
79980611|NCT01347918|Device|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
79980612|NCT01347918|Dietary Supplement|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
79650958|NCT04659889|Diagnostic Test|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
79980613|NCT05727124|Device|Poul Gjessing|maxillary canine retraction
79811788|NCT04134377|Other|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
79980614|NCT05727124|Device|T loops|T loops
79980615|NCT01347996|Drug|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg [16,400 IU/kg] body weight twice daily for 10, 21 day cycles
79980616|NCT01345032|Other|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
79980617|NCT01345032|Other|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
79980618|NCT01348074|Drug|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
79980619|NCT01352910|Device|rTMS|120 pulses 0.2 Hz
79980620|NCT01352910|Device|Sham rTMS|120 pulses 0.2 Hz
79980621|NCT01352988|Drug|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
79811789|NCT02622425|Dietary Supplement|Placebo|maltodextrin
79811790|NCT02622425|Dietary Supplement|PD01|Carotenoid-producing Bacillus strain PD01
79980622|NCT02466802|Drug|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
79484722|NCT02431754|Drug|Tadalafil|Administered orally
79484723|NCT02431754|Drug|Placebo|Administered orally
79650959|NCT04659733|Drug|Anlotinib hydrochloride|Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
79484724|NCT02431754|Drug|Alpha1 Blocker|Administered orally
79484725|NCT02499692|Device|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
79484726|NCT02526277|Device|MMF07 Foot Massager|
79484727|NCT02526277|Device|Heat Therapy|
79331969|NCT04693494|Other|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
79484728|NCT02500628|Drug|Metformin|500 mg orally after baseline testing of heart rate
79484729|NCT02526667|Drug|Chlorhexidine gluconate|2% CHG solution on cloth
79980623|NCT02466802|Drug|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
79980624|NCT01353066|Drug|Intensive Medical Treatment|
79980625|NCT01353066|Other|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
79650960|NCT04660006|Procedure|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
79980626|NCT01348230|Other|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
79980627|NCT01348308|Drug|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
79980628|NCT01348308|Drug|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
79980629|NCT04078386|Biological|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
79331970|NCT04662164|Drug|hepalatide|3 different dosage will be given sequentially to T2D patients
79484730|NCT02526667|Drug|DynaHex-2|2% CHG solution
79484731|NCT02526667|Other|Vehicle|Excipients of CHG product only
79650961|NCT04659850|Other|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
79650962|NCT04659850|Other|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
79650963|NCT04659850|Other|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
79980630|NCT04078386|Biological|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
79484732|NCT02535806|Drug|Velcade|4 doses of study drug will be given.
79484733|NCT02535806|Drug|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
79484734|NCT02535806|Drug|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
79484735|NCT02535806|Drug|Dexamethasone|Days 1-5 and 15-19
79484736|NCT02535806|Drug|Mitoxantrone|Days 1 and 2
79484737|NCT02535806|Drug|Vincristine|Days 1, 8, 15, 22
79484738|NCT02535806|Drug|Pegaspargase|Days 3 and 17
79650964|NCT04659850|Other|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
79650965|NCT00241488|Drug|Rosuvastatin|
79650966|NCT04659460|Device|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
79650967|NCT04659694|Other|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
79811791|NCT00786292|Other|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
79331971|NCT04654468|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
79331972|NCT04647162|Procedure|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
79331973|NCT04647162|Procedure|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
79331974|NCT04647162|Procedure|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
79331975|NCT04647162|Other|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
79331976|NCT04644016|Drug|Clofarabine|Clofarabine 30 mg/m2
79331977|NCT04644016|Drug|Fludarabine|Fludarabine 10 mg/m2
79331978|NCT04644016|Drug|Busulfan|Busulfan per PK
79331979|NCT04644016|Drug|Cyclosporine-A|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
79331980|NCT04644016|Drug|Mycophenolate Mofetil|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
79331981|NCT04644016|Biological|Cord Blood Graft|The CB graft will be infused on day 0 per standard practice
79331982|NCT04626921|Drug|CNM-Au8|30 mg of CNM-Au8
79331983|NCT04622176|Diagnostic Test|MMUS|MMUS will be used to perform diagnostics, we will compare with MRI and histology
79650968|NCT00412178|Device|telecommunication based glucose monitoring system|
79650969|NCT04659499|Drug|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
79650970|NCT00245349|Procedure|F-18 Fluorothymidine|
79650971|NCT04659304|Drug|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
79650972|NCT04659655|Procedure|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
79650973|NCT00412256|Drug|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
79331984|NCT04615910|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
79331985|NCT04603924|Drug|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
79331986|NCT04603924|Drug|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
79331987|NCT04596657|Dietary Supplement|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
79650974|NCT04649320|Other|questionnaire|"13-item questionnaire about cancer patient's distress and everyday life,~EORTC-QLQ-C30"
79650975|NCT00241527|Drug|Esomeprazole|
79811792|NCT00851318|Drug|Certolizumab pegol|Subcutaneous (SC) injection
79811793|NCT00851318|Drug|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
79811794|NCT00791596|Other|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
79331988|NCT04569058|Device|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
79331989|NCT04562766|Drug|Rilzabrutinib|400mg Caplet
79331990|NCT04562766|Drug|Placebo|400mg Caplet
79331991|NCT04553757|Other|Survey Administration|Complete survey
79331992|NCT04528082|Drug|Apremilast|Participants will receive apremilast orally.
79331993|NCT04528082|Drug|Placebo|Participants will receive the matching placebo orally.
79331994|NCT04527731|Device|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
79331995|NCT04519827|Other|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
79331996|NCT04519827|Other|Amino Acid-based infant formula|An amino acid-based infant formula
79331997|NCT04518085|Behavioral|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
79331998|NCT04518085|Behavioral|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
79980631|NCT04078386|Biological|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
79331999|NCT04518085|Behavioral|Mindfulness session|Single session mindfulness session delivered by audio file
79332000|NCT04518085|Behavioral|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
79332001|NCT04513067|Biological|YQ23|YQ23 as a single agent will be given in Stage 1.
79332002|NCT04513067|Combination Product|Pembrolizumab|Pembrolizumab will be given in combination with YQ23 in Stage 2
79811795|NCT00791752|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
79980632|NCT04074174|Drug|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
79332003|NCT04513054|Genetic|Blood collection for genetic analysis|Blood collection for genetic analysis
79332004|NCT04505410|Drug|Tofacitinib|10mg tofacitinib tablets taken twice daily for eight weeks
79332005|NCT04505410|Other|Fast Mimicking Diet|FMD is a five day meal plan that includes foods such as soups, snacks, bards, teas and supplements (omega-3 fatty acids) for a total of 66 items per box. The diet is plant-based, gluten free and dairy free without any artificial preservatives, chemicals or biologically active ingredients.
79332006|NCT04505410|Drug|Ustekinumab induction|Participant will be initiated with ustekinumab induction therapy as second line biologic therapy
79332007|NCT04505410|Drug|Infliximab induction|Participant will be initiated with infliximab induction therapy as second line biologic therapy
79332008|NCT04488289|Other|Lifestyle|Cardiovascular risk and lifestyle
79332009|NCT04479696|Other|Educational Intervention|Receive standard of care verbal and written education materials
79811796|NCT00791752|Drug|Placebo|Placebo
79332010|NCT04479696|Other|Questionnaire Administration|Ancillary studies
79980633|NCT04074174|Drug|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
79980634|NCT04074174|Drug|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
79484739|NCT02865343|Device|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
79484740|NCT02865343|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
79980635|NCT01348386|Drug|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
79332011|NCT04479696|Other|Survey Administration|Complete optional survey
79332012|NCT04479696|Other|Video|Watch NIRS video
79332013|NCT04478266|Drug|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
79332014|NCT04478266|Drug|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
79332015|NCT04478266|Drug|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
79484741|NCT02536040|Drug|38% diammine silver fluoride|treatment of cavity with study agent
79811797|NCT00786370|Drug|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
79332016|NCT04478266|Drug|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
79332017|NCT04478266|Drug|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
79332018|NCT04478266|Drug|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
79811798|NCT00786370|Drug|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
79811799|NCT00786370|Drug|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
79980636|NCT01348386|Drug|Placebo|
79980637|NCT03620292|Drug|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
79980638|NCT03620292|Device|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
79980639|NCT01353300|Genetic|DNA analysis|
79980640|NCT01353300|Genetic|cytogenetic analysis|
79332019|NCT04457778|Drug|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
79332020|NCT04457778|Drug|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
79484742|NCT02536040|Other|Water|Fluoride free, distilled water
79484743|NCT02536196|Device|Embolic Protection Device|Embolic protection
79484744|NCT02536196|Procedure|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
79484745|NCT02461771|Drug|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
79484746|NCT02815345|Device|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
79980641|NCT01353300|Genetic|gene expression analysis|
79980642|NCT01353300|Genetic|gene rearrangement analysis|
79980643|NCT01353300|Genetic|mutation analysis|
79980644|NCT01353300|Genetic|polymerase chain reaction|
79980645|NCT01353300|Genetic|polymorphism analysis|
79980646|NCT01353300|Other|laboratory biomarker analysis|
79332021|NCT04457778|Drug|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
79332022|NCT04456504|Biological|Recombinant hepatitis B vaccine with CpG adjuvant|Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
79332023|NCT04450693|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
79332024|NCT04450693|Other|Standard care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
79332025|NCT04435288|Drug|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
79980647|NCT01353300|Other|medical chart review|
79332026|NCT04435288|Drug|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
79484747|NCT04341649|Other|Manual Head Massage|Duration 10 minutes.
79980648|NCT01345266|Procedure|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
79811800|NCT02624609|Other|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
79980649|NCT05252026|Behavioral|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
79980650|NCT05252026|Behavioral|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
79980651|NCT01353378|Drug|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
79980652|NCT01465334|Drug|Ofatumumab|
79980653|NCT01465334|Drug|High-Dose Methylprednisolone|
79980654|NCT01465334|Drug|Alemtuzumab|
79980655|NCT01348464|Procedure|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
79980656|NCT04019262|Radiation|Radiation Therapy|Radiation
79980657|NCT04019262|Drug|Temozolomide Oral Product|Oral Temozolomide (150mg/m^2 or 75 mg/m^2)
79980658|NCT03626246|Other|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~Bone density (DXA)~Thoracic and lumbar spine plain films.~HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~Measure levels of Advanced Glycation End products (AGEs) in the skin."
79980659|NCT00702208|Device|Delphi Screener|Self-sampling device for cervical vaginal lavage
79980660|NCT02464618|Behavioral|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
79980661|NCT05322746|Device|Focal muscle vibration|Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
79980662|NCT02464774|Procedure|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
79332027|NCT04435288|Drug|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
79332028|NCT04435288|Drug|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
79650976|NCT04648735|Other|driving evaluation and practice|"The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc."
79980663|NCT02464774|Procedure|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
79980664|NCT02464774|Drug|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
79980665|NCT02464774|Radiation|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
79980666|NCT05583578|Device|Home-based mobility testing and active tDCS|"A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was"
79980667|NCT05583578|Device|Sham tDCS|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
79332029|NCT04426968|Drug|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
79332030|NCT04426968|Drug|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
79332031|NCT04426968|Drug|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
79332032|NCT04426968|Drug|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
79332033|NCT04426968|Drug|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
79332034|NCT04426968|Drug|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
79332035|NCT04426968|Drug|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
79332036|NCT04406974|Procedure|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
79332037|NCT04406974|Procedure|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
79332038|NCT04379505|Device|Ring gantry kV-CBCT combined with linear accelerator (Halcyon)|-Varian Medical Systems is the manufacturer
79980668|NCT05549726|Drug|Cabotegravir Injectable Suspension|CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.
79332039|NCT04379505|Radiation|Quad shot radiation|Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
79332040|NCT04356352|Drug|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
79332041|NCT04356352|Drug|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
79650977|NCT04648657|Device|Lung Ultrasound|Echography of Lungs based on artifacts study
79650978|NCT04648657|Device|Electric impedance tomography|Low alternating electrical currents (usually <5 milliampere at 50-80 kHz) applied through different pair of electrodes on thorax
79332042|NCT04356352|Other|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
79484748|NCT04341649|Device|BREO Helmet Massager|Duration 10 minutes.
79332043|NCT04286295|Drug|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
79332044|NCT04286295|Drug|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
79332045|NCT04286295|Drug|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
79332046|NCT04286269|Other|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
79332047|NCT04286269|Other|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
79332048|NCT04286087|Procedure|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
79332049|NCT04286087|Procedure|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
79484749|NCT04341649|Device|Low Laser Therapy (LLT)|Duration 7 minutes.
79980669|NCT05549726|Other|Dynamic Choice Delivery Model|The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.
79484750|NCT04341649|Device|Sham LLT|Duration 7 minutes.
79650979|NCT00217217|Device|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
79650980|NCT04648813|Drug|tiotropium bromide monohydrate (Spiriva Respimat)|administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
79650981|NCT04648813|Drug|matching placebo|administered daily, 2 inhalations per dose for a total of 8 doses
79484751|NCT04341649|Device|TENS ear stimulation|Duration 7 minutes.
79484752|NCT04341649|Behavioral|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
79484753|NCT04341649|Behavioral|Relaxed Reading time|Duration 10 minutes.
79484754|NCT02463799|Drug|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
79484755|NCT02463799|Biological|Sipuleucel-T|3 infusions of sipuleucel-T alone
79484756|NCT02537444|Drug|Acalabrutinib|
79484757|NCT02537444|Drug|acalabrutinib and pembrolizumab combination|
79484758|NCT02464033|Drug|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
79484759|NCT02464033|Drug|Vitamin D|
79484760|NCT02464033|Drug|Etanercept|
79650982|NCT00245388|Drug|Muraglitazar|
79650983|NCT04648384|Dietary Supplement|Blend Protein Supplementation|Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
79650984|NCT04648384|Dietary Supplement|Placebo Supplementation|Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
79484761|NCT02432300|Behavioral|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
79332055|NCT04275726|Device|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
79484762|NCT02432456|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
79484763|NCT02432456|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
79484764|NCT02432456|Procedure|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
79484765|NCT02432456|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
79484766|NCT02432456|Drug|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
79484767|NCT02432456|Drug|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
79811801|NCT02624609|Other|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
79980670|NCT05549726|Other|Standard of Care|The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
79980671|NCT05536232|Behavioral|Low carbohydrate diet|Low carbohydrate diet under 75 g per day
79484768|NCT02432456|Drug|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
79484769|NCT02432456|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
79650985|NCT04648384|Other|Resistance Exercise|10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
79811802|NCT00796900|Drug|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
79980672|NCT00973856|Other|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
79980673|NCT00973856|Other|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
79980674|NCT01348620|Device|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
79980675|NCT01348620|Procedure|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
79980676|NCT01353456|Drug|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
79980677|NCT01353456|Drug|Normal Saline|Same volume as dexmedetomidine given
79980678|NCT00920972|Drug|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
79484770|NCT02531971|Drug|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
79484771|NCT02531971|Drug|Duragesic®|TDDS dosage is 25 micrograms/hour (worn for 72 h)
79484772|NCT02531971|Drug|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour (worn for 72 h)
79484773|NCT02464657|Drug|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
79484774|NCT02464657|Drug|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
79484775|NCT02464657|Drug|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
79484776|NCT02464657|Drug|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
79650986|NCT04648423|Drug|Sodium Oxybate|solution for oral administration
79332056|NCT04275726|Device|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
79332057|NCT04267744|Other|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
79332058|NCT04241068|Drug|Aducanumab|Administered as specified in the treatment arm.
79332059|NCT04233216|Drug|ISL|ISL 0.75 mg capsule taken by mouth.
79332060|NCT04233216|Drug|DOR|DOR 100 mg tablet taken by mouth.
79332061|NCT04233216|Drug|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
79332062|NCT04233216|Drug|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
79332063|NCT04233216|Drug|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
79332064|NCT04218409|Drug|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
79332065|NCT04218409|Drug|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
79332066|NCT04218409|Other|Placebo Oxycodone|Oxycodone 0 mg orally
79332067|NCT04218409|Other|Placebo oxytocin|Intranasal placebo administration
79332068|NCT04218409|Drug|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
79332069|NCT04217408|Device|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
79332070|NCT04198857|Behavioral|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
79332071|NCT04173507|Drug|Avelumab|Given IV
79332072|NCT04173507|Drug|Talazoparib|Given PO
79332073|NCT04173507|Drug|Talazoparib Tosylate|Given PO
79332074|NCT04165798|Diagnostic Test|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
79980679|NCT00920972|Drug|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
79332075|NCT04165798|Procedure|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
79332076|NCT04165798|Procedure|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~genetics~ribonucleic acid (RNA)~serum biomarker~plasma biomarker~circulating tumor DNA (ctDNA)"
79332077|NCT04157348|Biological|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
79332078|NCT04157348|Biological|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
79332079|NCT04157348|Biological|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
79980680|NCT00920972|Drug|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
79484777|NCT02464657|Drug|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
79650987|NCT04648423|Drug|Placebo|solution for oral administration
79650988|NCT00558181|Drug|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
79650989|NCT00217256|Device|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
79980681|NCT00920972|Drug|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
79980682|NCT01353534|Biological|A/H5N1 Antigen|A/H5N1 Antigen
79980683|NCT01353534|Drug|Vaccine Enhancement Patch|Vaccine Enhancement Patch
79980684|NCT01345422|Other|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
79980685|NCT05472116|Device|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
79332080|NCT04157348|Biological|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
79332081|NCT04124393|Procedure|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
79332082|NCT04121260|Drug|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
79332083|NCT04118660|Other|Tissue Banking|Blood, tissue, and fluid collection
79650990|NCT00217256|Device|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
79332084|NCT04084249|Diagnostic Test|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
79332085|NCT04084249|Other|Intensified Follow-up Schedule|PET/CT-scans every 3. month
79332086|NCT04082689|Behavioral|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
79332087|NCT04077411|Other|Observational|This is an observational study with no interventions.
79332088|NCT04075864|Behavioral|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
79332089|NCT04074330|Drug|TAK-981|TAK-981 intravenous infusion.
79332090|NCT04074330|Drug|Rituximab|Rituximab intravenous infusion.
79332091|NCT04035226|Other|No intervention|No intervention will be administered as a part of this study.
79332092|NCT04011852|Device|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
79332093|NCT04007874|Drug|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
79332094|NCT04007874|Drug|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
79332095|NCT04001946|Device|Button Huggie|low profile, external securement device for G-buttons
79332096|NCT03978624|Drug|Pembrolizumab|200 mg IV on day 1 and day 22
79332097|NCT03978624|Drug|Entinostat|5 mg given orally on day 1, day 8 and day 15
79332098|NCT03971474|Drug|Docetaxel|Given IV
79332099|NCT03971474|Drug|Gemcitabine|Given IV
79332100|NCT03971474|Drug|Gemcitabine Hydrochloride|Given IV
79332101|NCT03971474|Biological|Pembrolizumab|Given IV
79650991|NCT00241566|Device|implantation of stimulator|
79332102|NCT03971474|Drug|Pemetrexed|Given IV
79332103|NCT03971474|Drug|Pemetrexed Disodium|Given IV
79332104|NCT03971474|Biological|Ramucirumab|Given IV
79332105|NCT03954314|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
79332106|NCT03931460|Drug|Medical Abortion|Medical Abortion
79332107|NCT03930992|Drug|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
79332108|NCT03930992|Drug|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
79332109|NCT03930992|Drug|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
79332110|NCT03930992|Drug|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
79332111|NCT03927027|Drug|Isosulfan Blue|Given SC
79332112|NCT03927027|Procedure|Axillary Lymph Node Dissection|Undergo ALND
79332113|NCT03927027|Procedure|Mapping|Undergo ARM
79332114|NCT03927027|Other|Quality-of-Life Assessment|Ancillary studies
79332115|NCT03927027|Other|Questionnaire Administration|Ancillary studies
79332116|NCT03926130|Drug|Mirikizumab|Administered IV
79332117|NCT03926130|Drug|Mirikizumab|Administered SC
79332118|NCT03926130|Drug|Ustekinumab|Administered IV
79332119|NCT03926130|Drug|Ustekinumab|Administered SC
79332120|NCT03926130|Drug|Placebo|Administered IV
79332121|NCT03926130|Drug|Placebo|Administered SC
79650992|NCT00558220|Procedure|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
79650993|NCT00558220|Procedure|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
79332122|NCT03919526|Biological|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
79332123|NCT03919526|Drug|Fludarabine|30mg/m2/d
79332124|NCT03919526|Drug|Cyclophosphamide|300mg/m2/d
79332125|NCT03905798|Drug|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
79650994|NCT00558220|Procedure|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are >20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
79650995|NCT00558220|Procedure|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
79650996|NCT00558220|Procedure|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
79650997|NCT00558220|Radiation|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
79980686|NCT01345500|Other|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
79332126|NCT03901079|Other|single-arm study|single-arm study
79332127|NCT03881696|Drug|Omalizumab|Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
79332128|NCT03881696|Drug|Placebo for Omalizumab|Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
79332129|NCT03881696|Drug|Multi-Allergen Oral Immunotherapy|"Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol."
79332130|NCT03881696|Drug|Placebo for Multi-Allergen Oral Immunotherapy|Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.
79484778|NCT02533063|Device|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
79332131|NCT03881696|Other|Double-Blind Placebo-Controlled Food Challenge Based Treatment|"Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food; or~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time."
79332132|NCT03845296|Drug|Rucaparib|Given PO
79332133|NCT03841448|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
79332134|NCT03841448|Drug|Cemdisiran|Cemdisiran was administered by SC injection.
79332135|NCT03819296|Other|Best Practice|Receive standard of care
79332136|NCT03819296|Other|Biospecimen Collection|Undergo collection of stool, blood, and tissue samples
79332137|NCT03819296|Procedure|Endoscopic Procedure|Undergo endoscopy
79332138|NCT03819296|Procedure|Fecal Microbiota Transplantation|Undergo FMT
79332139|NCT03819296|Biological|Infliximab|Given intravenously (IV)
79332140|NCT03819296|Other|Laboratory Biomarker Analysis|Ancillary studies
79332141|NCT03819296|Drug|Prednisone|Given orally
79332142|NCT03819296|Biological|Vedolizumab|Given IV
79332143|NCT03814850|Device|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
79332144|NCT03809520|Radiation|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
79332145|NCT03805581|Drug|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
79332146|NCT03790943|Diagnostic Test|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
79332147|NCT03769766|Drug|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
79332148|NCT03769766|Drug|Placebo|Take medication one 500mg pill twice daily
79332149|NCT03755167|Drug|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
79332150|NCT03746873|Behavioral|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
79332151|NCT03737318|Behavioral|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
79332152|NCT03737318|Behavioral|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
79307621|NCT03371225|Device|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
79332153|NCT03737318|Behavioral|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
79332154|NCT03735238|Other|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
79332155|NCT03728088|Other|Rating scales concerning non-technical attributes|
79332156|NCT03725956|Procedure|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
79332157|NCT03713580|Drug|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
79332158|NCT03712657|Combination Product|ERAS|"preoperative pain control;~avoiding application of ureter;~avoiding application of gastric tube;~avoiding application of irrigation;~avoiding application of drainage;~early exercising postoperatively;~early oral feeding postoperatively;~early discharging."
79332159|NCT03703856|Drug|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
79332160|NCT03703856|Drug|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
79332161|NCT03699540|Drug|Marijuana|Experimental, non-therapeutic administration of active marijuana dose(s)
79332162|NCT03699540|Drug|Alcohol|Experimental, non-therapeutic administration of active alcohol dose(s)
79332163|NCT03699540|Drug|placebo alcohol|Experimental, non-therapeutic administration of inactive alcohol dose(s)
79332164|NCT03699540|Drug|Inactive marijuana|Experimental, non-therapeutic administration of inactive marijuana dose(s)
79332165|NCT03691714|Drug|Durvalumab|Two hour infusion
79332166|NCT03691714|Drug|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
79332167|NCT03673657|Dietary Supplement|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
79332168|NCT03673657|Radiation|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
79332169|NCT03673657|Drug|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
79332170|NCT03656718|Biological|nivolumab|(Subcutaneous) Specified dose on specified days
79332171|NCT03656718|Drug|rHuPH20|Specified dose on specified days Permeation enhancer
79332172|NCT03656718|Biological|nivolumab|(IV) Specified Dose on Specified Days
79332173|NCT03652805|Drug|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
79332174|NCT03645928|Biological|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.
79332175|NCT03645928|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
79332176|NCT03645928|Drug|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
79332177|NCT03645928|Biological|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
79332178|NCT03645928|Drug|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
79332179|NCT03645928|Drug|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
79332180|NCT03577431|Biological|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. If a minimum arTreg-CSB dose of 1 to < 2.5 x 10^6 cells, the product will be infused. If the dose obtained after product manufacture is < 1 x 10^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 125 x 10^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10^6 cells, and ≥ 2.5 to 125 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
79332181|NCT03577431|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
79332182|NCT03577431|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
79332183|NCT03577431|Drug|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
79332184|NCT03577431|Drug|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
79332185|NCT03528642|Other|Questionnaire Administration|Ancillary studies
79332186|NCT03528642|Radiation|Radiation Therapy|Undergo RT
79332187|NCT03528642|Drug|Telaglenastat Hydrochloride|Given PO
79332188|NCT03528642|Drug|Temozolomide|Given PO
79332189|NCT03486067|Drug|CC-93269|Specified dose on specified days
79332190|NCT03481881|Drug|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
79484779|NCT02467075|Drug|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
79484780|NCT02467075|Drug|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
79980687|NCT01345500|Other|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
79484781|NCT02533921|Other|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
79484782|NCT02533921|Other|Standard of Care|Usual care defined as including both a PCP and neurologist
79484783|NCT02535481|Device|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
79484784|NCT02535481|Procedure|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
79484785|NCT00363961|Behavioral|Resistance exercise|resistance exercise vs sham comparison
79332191|NCT03474731|Behavioral|Diabetes Self Management Program|"Diabetes Self Management Program (DSMP) in a group setting: The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Groups randomized to one of two arms (DSMP only and CCN) will receive the DSMP. The DSMP has demonstrated significant improvements in communication with physicians, healthy eating, and hypoglycemia at six and twelve months. The DSMP and other self-management programs have been shown to increase self-efficacy, knowledge, and skill building; ensure accountability/monitoring; improve patient-provider interaction; leverage local assets; address sustainability, and be cost effective."
79332192|NCT03474731|Behavioral|Tailored Patient Navigation (PN) only|Tailored Patient Navigation (PN) only: The goal of this arm of the project is to try to get participants to attend their recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs. We will have to add an additional eligibility criterion for this group-they have to be out of compliance with medical appointments. Most participants will need PN services, owing to missed, rescheduled, or infrequent appointments. This means not attending their office visits, as recommended, which typically is every 3 months. We will interact with them to verify attendance and, at times, to access patient medical records if needed.
79332193|NCT03474731|Behavioral|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : Both group education classes and patient navigation
79332194|NCT03409185|Device|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
79332195|NCT03409185|Device|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
79332196|NCT03407144|Biological|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
79332197|NCT03407144|Drug|doxorubicin|"25 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
79332198|NCT03407144|Drug|vinblastine|"6 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
79484786|NCT02535949|Drug|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
79484787|NCT02535949|Other|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
79484788|NCT02536105|Drug|Methylphenidate HCl ER tablets 1|
79484789|NCT02536105|Drug|Placebo|
79484790|NCT02536105|Drug|Methylphenidate HCl ER tablets 2|
79484791|NCT02536105|Drug|Methylphenidate HCl ER for suspension|
79332199|NCT03407144|Drug|dacarbazine|"375 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
79332200|NCT03407144|Drug|cyclophosphamide|500 mg/m^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
79332201|NCT03407144|Drug|vincristine|"1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
79332202|NCT03407144|Drug|prednisone/prednisolone|"60 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
79332203|NCT03407144|Drug|bleomycin|10 units/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
79332204|NCT03407144|Drug|etoposide|125 mg/m^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
79332205|NCT03407144|Radiation|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
79332206|NCT03396276|Drug|Suboxone|8mg of buprenorphine/2mg of naloxone
79484792|NCT02758951|Other|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
79980688|NCT01345500|Other|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
79484793|NCT02758951|Combination Product|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
79484794|NCT02758951|Combination Product|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
79332207|NCT03396276|Behavioral|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
79332208|NCT03396276|Behavioral|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
79332209|NCT03396276|Behavioral|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
79980689|NCT04948814|Biological|Fecal microbiota transplantation|FMT utilizing stool from healthy children
79980690|NCT04948814|Drug|Vancomycin|40mg/kg/day
79980691|NCT02718898|Drug|Ixekizumab|Administered SC
79980692|NCT02718898|Drug|Placebo|Administered SC
79980693|NCT01353690|Biological|AMDC|Cell Treatment
79332210|NCT03382782|Behavioral|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
79332211|NCT03382782|Behavioral|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI & Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
79332212|NCT03382782|Behavioral|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
79332213|NCT03377062|Diagnostic Test|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
79332214|NCT03362970|Device|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in ~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
79332215|NCT03362970|Other|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
79332216|NCT03360916|Drug|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
79332217|NCT03360916|Drug|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
79332218|NCT03360916|Drug|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
79332219|NCT03360916|Behavioral|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
79332220|NCT03351998|Drug|Lipitor 20Mg Tablet|20 mg/day pills.
79332221|NCT03351998|Drug|Lipitor 80Mg Tablet|80 mg/day pills.
79332222|NCT03351998|Drug|Placebo Oral Tablet|Matching placebo pill.
79484795|NCT02758951|Combination Product|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area [BSA] of irinotecan, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
79484796|NCT02758951|Procedure|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
79980694|NCT03619616|Drug|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
79980695|NCT03619616|Drug|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
79980696|NCT03619616|Drug|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
79980697|NCT03619616|Drug|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
79980698|NCT03619616|Drug|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
79980699|NCT03619616|Drug|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
79980700|NCT03619616|Drug|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
79980701|NCT01317264|Other|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
79811803|NCT00796900|Drug|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
79811804|NCT02619461|Other|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
79811805|NCT00791830|Drug|Irbesartan|Tablets, 300 mg * 1 daily, 1 year
79811806|NCT00791830|Drug|Placebo matching irbesartan 150 mg|Tablets, 300 mg * 1 daily, 1 year
79332227|NCT03276676|Drug|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
79332228|NCT03255200|Device|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
79650998|NCT04648345|Procedure|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
79650999|NCT00217295|Drug|Avonex and Topamax|
79332229|NCT03211741|Drug|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
79980702|NCT01317264|Other|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
79980703|NCT01317264|Other|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
79980704|NCT01317264|Other|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
79332230|NCT03203525|Biological|Bevacizumab|Given IV
79332231|NCT03203525|Drug|Fluorouracil|Given via pump
79651000|NCT04648267|Other|Cast and bolster placement duration|The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.
79651001|NCT04648267|Other|Standard of care|This will be standard of care - the patient will have his cast and bolster on for 5-7 days
79651002|NCT00245427|Drug|all macrolide antibiotics|Varies based on antibiotic
79980705|NCT03986580|Device|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
79980706|NCT03682614|Drug|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
79980707|NCT03682614|Other|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
79651003|NCT00245427|Drug|all beta-lactam antibiotics|Varies based on antibiotic
79811807|NCT04137809|Device|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
79811808|NCT00786448|Drug|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
79980708|NCT04489654|Biological|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
79980709|NCT03660228|Other|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
79332232|NCT03203525|Drug|Leucovorin|Given via pump
79332233|NCT03203525|Drug|Oxaliplatin|Given via pump
79332234|NCT03203525|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79332235|NCT03203525|Drug|Temsirolimus|Given IV
79332236|NCT03203525|Procedure|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
79484797|NCT02758951|Procedure|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after randomisation.
79484798|NCT02436668|Drug|Ibrutinib|
79332237|NCT03195140|Device|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
79332238|NCT03184454|Device|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
79332239|NCT03182192|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
79332240|NCT03173924|Drug|18F-NaF|Baseline IV followed by PET/CT IMAGING
79332241|NCT03173924|Drug|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
79332242|NCT03173924|Drug|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
79332243|NCT03137771|Radiation|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
79332244|NCT03137771|Drug|Docetaxel|Given IV
79980710|NCT01317888|Drug|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
79332245|NCT03137771|Drug|Gemcitabine|Given IV
79332246|NCT03137771|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
79332247|NCT03137771|Drug|Pemetrexed Disodium|Given IV
79980711|NCT05726734|Drug|Vonoprazan|potassium-competitive acid blocker
79307622|NCT03371225|Procedure|Sham Exercise|Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
79307623|NCT03370718|Drug|Cabozantinib|Given PO
79332248|NCT03137771|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
79332249|NCT03137771|Drug|Erlotinib Hydrochloride|Given PO
79332250|NCT03137771|Drug|Pembrolizumab|Given IV
79332251|NCT03134755|Drug|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
79332252|NCT03096262|Behavioral|Output-Focus Condition|Users are asked to tag more, and force feedback is exerted the more points the user has
79332253|NCT03096262|Behavioral|Input-Focus Condition|Users are asked to tag more and force feedback is exerted based on the number of images the user has analyzed.
79332254|NCT03083184|Drug|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
79332255|NCT03083184|Drug|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
79332256|NCT03023631|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
79332258|NCT02983292|Device|PyroTITAN™ HRA|Humeral Resurfacing
79332259|NCT02965716|Biological|Pembrolizumab|Given IV
79332260|NCT02965716|Biological|Talimogene Laherparepvec|Given IL
79484799|NCT02436668|Drug|Gemcitabine|
79484800|NCT02436668|Drug|Nab-paclitaxel|
79484801|NCT02503982|Drug|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
79484802|NCT02438540|Drug|metformin|metformin tablet 500 mg
79332261|NCT02946528|Device|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
79332262|NCT02946528|Device|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
79332263|NCT02916108|Other|Reading EEG|EEG recording for 5 minutes (not an intervention)
79332264|NCT02877693|Radiation|Thoracic MRI Scan|The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
79332265|NCT02876328|Biological|Ad26.ZEBOV|0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
79332266|NCT02876328|Biological|MVA-BN-Filo|0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
79332267|NCT02876328|Biological|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
79332268|NCT02876328|Biological|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
79332269|NCT02876328|Biological|rVSV boost|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
79332270|NCT02875223|Drug|CC-90011|Specified dose on specified days
79332271|NCT02875223|Drug|Rifampicin|Specified dose on specified days
79332272|NCT02875223|Drug|Itraconazole|Specified dose on specified days
79332273|NCT02870920|Drug|Tremelimumab|
79307624|NCT03370718|Other|Pharmacogenomic Study|Correlative studies
79332274|NCT02870920|Drug|Durvalumab|
79332275|NCT02870920|Other|Best Supportive Care|
79332276|NCT02869217|Drug|Cyclophosphamide|
79332277|NCT02869217|Biological|TBI-1301|
79332278|NCT02869217|Drug|Fludarabine|
79332279|NCT02863523|Behavioral|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
79332280|NCT02804061|Behavioral|NELIP|
79332281|NCT02697630|Drug|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
79332282|NCT02697630|Drug|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
79332283|NCT02691338|Other|EEG|EEG analysis
79332284|NCT02691338|Other|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
79980712|NCT05726734|Drug|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
79332285|NCT02676180|Other|Group|
79332286|NCT02639806|Drug|Sevoflurane|
79332287|NCT02639806|Drug|Lidocaine|
79332288|NCT02633553|Radiation|adjuvant radiotherapy|50Gy/25Fx
79332289|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
79332290|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
79332291|NCT02542059|Radiation|68Ga-exendin PET/CT|68Ga-exendin PET/CT
79332292|NCT02468232|Drug|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
79484803|NCT02438540|Other|acupuncture|Electro body acupuncture and auricular acupuncture
79651004|NCT00558298|Drug|risperidone|
79332293|NCT02468232|Drug|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
79332294|NCT02468232|Drug|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
79332295|NCT02468232|Drug|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
79332296|NCT02262780|Drug|Low dose of telmisartan|
79332297|NCT02262780|Drug|High dose of telmisartan|
79332298|NCT02262780|Drug|HCTZ|
79332299|NCT02221778|Radiation|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days"
79332300|NCT02210117|Biological|Bevacizumab|Given IV
79332301|NCT02210117|Procedure|Biopsy|Undergo biopsy
79332302|NCT02210117|Biological|Ipilimumab|Given IV
79332303|NCT02210117|Other|Laboratory Biomarker Analysis|Correlative studies
79332304|NCT02210117|Procedure|Metastasectomy|Undergo metastasectomy
79332305|NCT02210117|Biological|Nivolumab|Given IV
79332306|NCT02210117|Procedure|Therapeutic Conventional Surgery|Undergo nephrectomy
79332307|NCT02199600|Device|GMK Sphere Knee Replacement|
79484804|NCT02506634|Drug|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
79484805|NCT02506868|Drug|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
79484806|NCT02541422|Dietary Supplement|N Acetyl Cysteine|
79980713|NCT05726734|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
79307625|NCT03370718|Other|Pharmacokinetic Study|Correlative studies
79307626|NCT03369821|Diagnostic Test|Beta Cell Loss and Immune Function|Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
79332308|NCT02185443|Radiation|SBRT|"60Gy in 3 fractions (20Gy/fraction) over 14 days~60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
79332309|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
79332310|NCT02161380|Drug|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
79332311|NCT02161380|Drug|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
79332312|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
79332313|NCT01994239|Drug|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
79484807|NCT02541422|Other|placebo|
79484808|NCT02541812|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
79484809|NCT02542046|Drug|Barium|Administration of barium oral contrast agent prior to CT scan
79484810|NCT02542046|Drug|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
79484811|NCT02542046|Drug|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
79484812|NCT02439164|Drug|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
79980714|NCT05726734|Drug|Esomeprazole|Proton pump inhibitor
79332314|NCT01994239|Radiation|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
79332315|NCT01985230|Device|ReActiv8 Implantable Stimulation System implanted and activated.|
79332316|NCT01895933|Device|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
79332317|NCT01804816|Procedure|Acupuncture|Standardized acupuncture administration for 10 sessions.
79484813|NCT02542280|Procedure|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
79484814|NCT02542280|Procedure|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
79484815|NCT02542280|Drug|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
79484816|NCT02439710|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
79332318|NCT01804816|Other|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
79332319|NCT01803555|Drug|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
79332320|NCT01803555|Drug|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
79332321|NCT01803555|Drug|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
79332322|NCT01803555|Drug|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
79332323|NCT01499628|Behavioral|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
79332324|NCT01499628|Behavioral|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
79332325|NCT01499628|Behavioral|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
79332326|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization"
79332327|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
79484817|NCT04341272|Device|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
79484818|NCT02440022|Combination Product|Lutonix DCB|
79484819|NCT02440022|Device|Standard Balloon Angioplasty Catheter|
79484820|NCT02440022|Procedure|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
79332328|NCT01297764|Drug|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~15 15 300 40~20 15 300 40~20 25 300 40~20/27* 25 300 40~20/27* 25 400 40"
79484821|NCT02440178|Drug|Micafungin|
79811809|NCT00692705|Drug|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
79980715|NCT01317966|Drug|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
79332329|NCT01245179|Drug|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~15 mg MWF 3 weeks on, 1 week off (if needed)~15 mg MWF every week (starting dose)~20 mg MWF 3 weeks on, 1 week off~20 mg MWF every week"
79332330|NCT01112306|Drug|ACT-293987|Tablets, twice daily
79332331|NCT00967863|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
79332332|NCT00967863|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
79332333|NCT00633633|Other|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
79332334|NCT00633633|Behavioral|Exercise Training|Exercise training 3 times a week.
79332335|NCT00633633|Behavioral|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
79332336|NCT00607828|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
79332337|NCT00574886|Biological|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
79980716|NCT01345734|Drug|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
79980717|NCT01318044|Drug|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
79980718|NCT01353768|Other|retrospective chart review|retrospective chart review
79980719|NCT01353846|Other|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
79980720|NCT01353846|Drug|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
79332338|NCT00542438|Behavioral|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
79332339|NCT00542438|Behavioral|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
79332340|NCT00242814|Drug|Micardis|
79332341|NCT00242814|Drug|Amlodipine|
79332342|NCT00242814|Procedure|Abdominal biopsy|
79332343|NCT00168857|Drug|telmisartan|
79332344|NCT00168857|Drug|losartan|
79332345|NCT04827329|Other|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
79332346|NCT05251467|Other|Focus group|Focus group to confirm PROM conceptual framework
79332347|NCT05251467|Other|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
79332348|NCT05251467|Other|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
79484822|NCT02543840|Other|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
79980721|NCT01349010|Drug|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
79484823|NCT02543840|Other|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
79980722|NCT01349010|Drug|Placebo|1 tablet bid. p.o for 8 weeks
79980723|NCT01345812|Drug|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
79980724|NCT01345812|Drug|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
79980725|NCT05232370|Drug|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
79980726|NCT05232370|Drug|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
79980727|NCT01349088|Drug|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
79980728|NCT01349088|Drug|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
79307627|NCT03369821|Other|Immune Function with RNAseq|Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
79307628|NCT03367572|Drug|Dexamethasone|Given PO
79307629|NCT03367572|Other|Laboratory Biomarker Analysis|Correlative studies
79307630|NCT03367572|Drug|Netupitant/Palonosetron Hydrochloride|Given PO
79332349|NCT05251467|Device|Testing of the pilot PROM in a smartphone app (n = 100)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
79332350|NCT04925167|Drug|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
79332351|NCT04925167|Drug|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
79332352|NCT04812587|Behavioral|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
79332353|NCT04998565|Other|Routine care|Reverse pressure applied to the areola
79332354|NCT04998565|Procedure|Electrical Acupuncture|Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
79332355|NCT04998565|Procedure|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation over bil breasts
79332356|NCT04427267|Other|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
79332357|NCT04817657|Biological|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1*10^11 virus particles per milliliter (vp/ml) as intramuscular injection.
79332358|NCT04812431|Biological|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
79332359|NCT05011669|Drug|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
79332360|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
79980729|NCT01349088|Drug|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
79980730|NCT01349166|Behavioral|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
79332361|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
79332362|NCT02524665|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
79332363|NCT02524665|Other|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
79332364|NCT02524665|Other|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
79332365|NCT02524665|Other|Skin Perfecting Lotion|Available over the counter.
79332366|NCT04812353|Other|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
79332367|NCT03079843|Other|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
79484824|NCT05078606|Device|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
79980731|NCT04490434|Drug|DWP14012|DWP14012 40mg, bid
79980732|NCT04490434|Drug|Celecoxib|Celecoxib 200mg, bid
79980733|NCT04490434|Drug|Naproxen|Naproxen 500mg, bid
79332368|NCT03079843|Other|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
79332369|NCT04433689|Device|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
79332370|NCT04817423|Other|No intervention|No intervention
79332371|NCT03079765|Behavioral|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
79332372|NCT03079765|Behavioral|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
79332373|NCT04998175|Procedure|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
79332374|NCT04427969|Behavioral|prone position|to lay in prone position at least 12 hour in a day at ICU
79484825|NCT05078606|Device|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
79811810|NCT00692705|Drug|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
79980734|NCT04490434|Drug|Meloxicam|Meloxicam 15mg, qd
79980735|NCT01353924|Biological|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
79980736|NCT01353924|Biological|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
79307631|NCT03367572|Drug|Olanzapine|Given PO
79307632|NCT03367572|Other|Placebo|Given PO
79307633|NCT03367572|Drug|Prochlorperazine|Given PO
79332375|NCT04998253|Drug|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
79332376|NCT05289999|Device|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
79332377|NCT05289999|Device|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
79332378|NCT04827017|Other|follow up|follow up population
79332379|NCT03078439|Other|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
79332380|NCT05324475|Dietary Supplement|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
79332381|NCT05324475|Dietary Supplement|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
79332382|NCT05324475|Dietary Supplement|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
79332383|NCT03078283|Other|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
79332384|NCT03075007|Radiation|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
79332385|NCT03075007|Procedure|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
79332386|NCT03078205|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
79980737|NCT04643782|Device|ANNE Sleep|ANNE sleep system
79332387|NCT03078205|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
79332388|NCT02638129|Drug|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
79980738|NCT03143166|Drug|Dabigatran Etexilate|Tablet, film coated
79332389|NCT02638129|Drug|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
79484826|NCT05078606|Procedure|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
79484827|NCT02546570|Drug|Oxytocin|See arm/group descriptions for dosage amount and procedure.
79484828|NCT02546570|Drug|Placebo|See arm/group descriptions for dosage amount and procedure.
79484829|NCT02743351|Biological|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
79651005|NCT04647955|Drug|Itopride|Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.
79651006|NCT04647955|Drug|Placebo|Patients were treated for 8 weeks.
79980739|NCT03143166|Drug|Rabeprazol sodium|Tablet
79980740|NCT02466568|Drug|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
79980741|NCT02466568|Biological|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
79484830|NCT02743351|Biological|Control Arm|Untreated mobilized peripheral blood (mPB) cells
79651007|NCT04647799|Device|smartphone|Samsung A 71
79651008|NCT00217334|Behavioral|Volunteer-led pharmacy sessions with feedback to physicians|
79651009|NCT00245505|Drug|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
79332390|NCT03079687|Drug|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
79980742|NCT02466100|Behavioral|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
79332391|NCT04997551|Drug|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~Day 1: 1 single dose of 1 mg orally, in a single dose.~Days 2 to 6: 0.5 mg every 12 hours v.o.~Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
79332392|NCT04997707|Drug|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
79811811|NCT00791986|Device|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
79811812|NCT04137653|Drug|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
79980743|NCT02843646|Device|Walk Aide training|
79332393|NCT04997707|Drug|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
79332394|NCT04997707|Diagnostic Test|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
79484831|NCT02548910|Procedure|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
79980744|NCT02466178|Device|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
79980745|NCT05264818|Procedure|Glycocheck|Assessment of the sublingual microvascularization
79980746|NCT05264818|Procedure|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
79980747|NCT02879994|Other|Laboratory Biomarker Analysis|Correlative studies
79980748|NCT02879994|Biological|Pembrolizumab|Given IV
79651010|NCT04647838|Drug|Tepotinib|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
79651011|NCT00245544|Drug|MK0759|
79651012|NCT00217373|Biological|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
79651013|NCT00217373|Biological|Recombinant Interferon Alfa-2b|Given SC
79651014|NCT00217373|Biological|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
79651015|NCT00217373|Biological|Sargramostim|Given SC
79651016|NCT04647370|Procedure|remote ischemic preconditioning|3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
79651017|NCT04647370|Procedure|Sham remote ischemic preconditioning|3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
79811813|NCT04137653|Drug|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
79980749|NCT02466022|Drug|Dexmedetomidine|Bolus dose prior to spinal anesthetic
79980750|NCT02466022|Drug|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
79307634|NCT03367572|Other|Quality-of-Life Assessment|Ancillary studies
79980751|NCT02466022|Drug|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
79332395|NCT04997863|Device|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
79332396|NCT04997863|Device|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
79332397|NCT05010889|Procedure|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
79332398|NCT05010499|Drug|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
79332399|NCT05010499|Drug|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
79332400|NCT05010187|Behavioral|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
79332401|NCT05010187|Behavioral|Behavioral: Health Coaching (HC)|Single-session health coaching.
79332402|NCT03075241|Drug|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
79332403|NCT03075241|Drug|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
79332404|NCT03075241|Drug|Placebo|Inactive or inert pill which will be used as a comparator
79332405|NCT03074929|Behavioral|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
79980752|NCT02466022|Drug|Fentanyl|Intrathecal Fentanyl 10ug
79332406|NCT04997083|Device|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
79332407|NCT04997083|Device|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
79332408|NCT04994119|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
79332409|NCT04994119|Drug|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
79332410|NCT03074851|Dietary Supplement|low sodium salt|To give free low sodium salt intervention for 2 months
79332411|NCT03074851|Other|informational intervention|to give reporter informational intervention.
79332412|NCT01658943|Drug|Akt Inhibitor MK2206|Given PO
79651018|NCT04646980|Dietary Supplement|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
79651019|NCT04646980|Other|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
79980753|NCT02466022|Drug|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
79332413|NCT01658943|Drug|Fluorouracil|Given IV
79332414|NCT01658943|Drug|Oxaliplatin|Given IV
79332415|NCT01658943|Drug|Selumetinib|Given PO
79332416|NCT02600819|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
79980754|NCT03943758|Dietary Supplement|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
79980755|NCT03943758|Dietary Supplement|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
79980756|NCT03937596|Drug|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
79332417|NCT02600819|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
79332418|NCT03077971|Behavioral|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
79332419|NCT03077971|Behavioral|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
79332420|NCT04433533|Drug|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
79332421|NCT04433533|Drug|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
79332422|NCT04996459|Drug|Tislelizumab|Tislelizumab 200mg iv q3w
79332423|NCT04811963|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
79484832|NCT02548910|Device|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
79332424|NCT04993105|Other|Exercise + Graston.|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
79980757|NCT03937596|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
79980758|NCT03937596|Drug|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
79484833|NCT02538523|Device|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
79484834|NCT02538523|Device|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
79484835|NCT02510144|Drug|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
79980759|NCT03578172|Drug|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)<100pg/ml，progesterone (P)<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
79484836|NCT02510144|Drug|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
79332425|NCT04993105|Other|exercise only|gastrocnemius and plantarstretching
79332426|NCT03074773|Drug|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
79332427|NCT03074773|Device|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
79332428|NCT03074773|Procedure|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
79332429|NCT03074773|Drug|Bupivacaine|it is an amino amide local anesthetic drug
79332430|NCT03074773|Other|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
79484837|NCT02538679|Other|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
79484838|NCT02538679|Drug|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
79484839|NCT02538679|Drug|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
79484840|NCT02511236|Behavioral|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
79651020|NCT04646863|Radiation|laser therapy|performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).
79651021|NCT04646863|Other|exercise|"The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~Modified Hundred~Modified Single Leg Stretch~One Leg Circle~Modified Scissors"
79811814|NCT04137497|Diagnostic Test|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
79811815|NCT00797056|Drug|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
79980760|NCT03578172|Drug|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration >60 days.
79980761|NCT05726500|Diagnostic Test|Arterial blood gas analysis|The researches will collect 2 ml of arterial blood using an arterial line already in place for clinical purposes to perform and arterial gas analysis.
79980762|NCT05726500|Diagnostic Test|Venous blood gas analysis|The researches will collect 2 ml of arterial blood using a central venous line already in place for clinical purposes to perform a gas analysis.
79980763|NCT05726500|Diagnostic Test|Esophageal pressure monitoring|The researchers will position an esophageal balloon to evaluate esophageal pressure
79980764|NCT05726500|Diagnostic Test|Intrabdominal pressure|The researches will assess intrabdominal pressure using the urinary catheter system already in place for clinical purposes .
79980765|NCT05726500|Diagnostic Test|Electrical impedance tomopgraphy|The researches will evaluate regional ventilation distribution using Electrical impedance tomography at different levels of positive end-expiratory pressure
79980766|NCT01345890|Procedure|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
79651022|NCT04646863|Other|combination|laser therapy + Pilates exercises
79811816|NCT00797056|Drug|Placebo|Saline SQ daily for 10 days
79811817|NCT00797056|Drug|Aspirin|Aspirin 75 mg/day for 14 days
79651023|NCT04647292|Drug|anti-hypertensive|"The recommended target SBP will be 115-125 mmHg in the intervention arm. A medication algorithm based on the SPRINT trial protocol will be provided. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~At scheduled face-to-face or remote follow-up, patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate (up or down) antihypertensive medication will be given to the patient."
79651024|NCT00241605|Drug|rosiglitazone/metformin|
79651025|NCT00217412|Drug|vorinostat|Given orally
79811818|NCT00797056|Drug|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
79651026|NCT00217412|Drug|isotretinoin|Given orally
79811819|NCT02622269|Device|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
79811820|NCT02622269|Device|Standard compression device|Compression of the abdomen with the standard compression device
79811821|NCT02554162|Other|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
79332431|NCT03077581|Drug|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
79332432|NCT03077581|Drug|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
79332433|NCT03077581|Drug|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
79811822|NCT00593957|Drug|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
79980767|NCT01354080|Other|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
79980768|NCT01354080|Other|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
79980769|NCT03928158|Drug|LCZ 696|50-100-200 mg tablet
79332434|NCT04993573|Other|Questionnaire|Questions about the impact of COVID-19 in their works
79332435|NCT04993573|Other|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
79332436|NCT03073447|Other|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
79651027|NCT04646824|Drug|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
79651028|NCT00217451|Drug|Fosmidomycin-clindamycin|
79332437|NCT03074461|Procedure|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
79811823|NCT00593957|Drug|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
79980770|NCT03928158|Drug|Valsartan|40-80-160 mg tablet
79980771|NCT01354158|Drug|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
79651029|NCT04646629|Device|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
79651030|NCT04646629|Device|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
79651031|NCT00217529|Biological|pegfilgrastim|
79651032|NCT00217529|Drug|carboplatin|
79651033|NCT00217529|Drug|docetaxel|
79651034|NCT00217529|Drug|erlotinib hydrochloride|
79651035|NCT00245661|Drug|Temazepam|
79651036|NCT04646512|Dietary Supplement|Taurine group and exercise and placebo group and exercise|Both groups supplemented with taurine and / or placebo will perform physical training.
79651037|NCT04646512|Other|Physical training with Deep Water Running|There will be a physical training for eight weeks.
79980772|NCT02466490|Drug|Fimasartan|Fimasartan tablets
79980773|NCT02466490|Drug|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
79980774|NCT01345968|Drug|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
79980775|NCT01345968|Drug|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
79332438|NCT03074461|Procedure|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
79332439|NCT04996537|Other|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
79332440|NCT04996303|Drug|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
79332441|NCT04996303|Device|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg ~ 1g) pulse 3 days -> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
79332442|NCT03077503|Drug|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
79332443|NCT03077503|Drug|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
79332444|NCT03077503|Drug|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
79332445|NCT03077503|Device|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
79332446|NCT04993417|Other|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
79332447|NCT04993417|Other|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
79332448|NCT03074383|Behavioral|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
79332449|NCT03074383|Behavioral|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
79332450|NCT05518695|Drug|BAT2022|Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
79332451|NCT05285475|Other|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
79332452|NCT05285319|Radiation|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
79332453|NCT05285319|Radiation|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
79332454|NCT04136067|Drug|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
79332455|NCT04136067|Drug|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
79332456|NCT03073291|Behavioral|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
79651038|NCT04646317|Drug|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
79651039|NCT04646317|Drug|Normal Saline|0.9% as placebo
79651040|NCT00217568|Biological|pegfilgrastim|
79651041|NCT00217568|Drug|carboplatin|
79651042|NCT00217568|Drug|docetaxel|
79811824|NCT00697151|Drug|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
79332457|NCT05244291|Other|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
79332458|NCT03073135|Behavioral|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
79332459|NCT03073135|Behavioral|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
79332460|NCT03072979|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy
79332461|NCT05284383|Behavioral|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
79332462|NCT05284383|Behavioral|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
79651043|NCT04646161|Drug|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
79651044|NCT04646122|Device|Optical Coherence Tomography|Optical Coherence Tomography parameters
79651045|NCT04645888|Procedure|Impacted tooth surgery|Surgical extraction of İmpacted tooth
79651046|NCT00241722|Drug|Alvimopan|
79980776|NCT04547842|Drug|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
79980777|NCT04547842|Drug|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
79651047|NCT00241722|Drug|Placebo|
79651048|NCT00558337|Drug|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
79651049|NCT04646278|Drug|Hyperemic stimuli|Hyperemic simuli of coronary flow by adenosine or nicorandil injection
79980778|NCT03928080|Diagnostic Test|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
79980779|NCT03142932|Device|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
79980780|NCT03142932|Other|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
79811825|NCT00697151|Drug|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
79980781|NCT03142932|Behavioral|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
79980782|NCT03536676|Other|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
79980783|NCT03536676|Other|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
79980784|NCT00702052|Drug|Everolimus|Everolimus tablets
79332463|NCT05284383|Behavioral|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
79332464|NCT05284383|Behavioral|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
79980785|NCT04499326|Other|Validated quality of life questionnaire (EQ-5D & C-CAP)|Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months
79980786|NCT03140280|Drug|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
79980787|NCT01354392|Drug|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
79980788|NCT01318200|Procedure|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
79980789|NCT01318200|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
79651050|NCT04645849|Biological|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
79651051|NCT00558376|Drug|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
79651052|NCT00558376|Drug|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
79811826|NCT04046770|Device|Drug administration and Flushing procedure using Double-Chamber Syringe|The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
79811827|NCT04046770|Device|Drug administration and Flushing procedure using Classic Syringe|To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
79980790|NCT01346124|Radiation|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
79811828|NCT00697229|Biological|Engerix™-B|Intramuscular injection, 1 or 3 doses
79811829|NCT00697229|Biological|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
79980791|NCT01354470|Drug|Modafinil|600 mg Modafinil capsule
79980792|NCT01354548|Device|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
79332465|NCT04995991|Behavioral|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
79332466|NCT04995991|Behavioral|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
79332467|NCT03077113|Diagnostic Test|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
79332468|NCT03077113|Diagnostic Test|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
79332469|NCT03072901|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
79332470|NCT03073057|Drug|Budesonide/formoterol|2 inhalations as a single dose
79332471|NCT03073057|Other|Charcoal|
79332472|NCT03073057|Drug|Symbicort Turbuhaler|2 inhalations as a single dose
79332473|NCT03073369|Drug|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
79484841|NCT02511236|Behavioral|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
79651053|NCT00217646|Drug|Sorafenib Tosylate|Given orally
79811830|NCT00792220|Procedure|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
79980793|NCT04911608|Other|cervical spinal manipulation|High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
79651054|NCT00558454|Drug|Iron|Ferrous succinate mixture
79651055|NCT00558493|Drug|Clevudine|clevudine 30 mg qd for 24 seeks
79980794|NCT04911608|Other|cervical spinal mobilization|Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
79980795|NCT01349478|Device|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
79980796|NCT01349556|Drug|Tretinoin|tretinoin 0.025% cream
79980797|NCT03480126|Other|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
79980798|NCT01349634|Other|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
79980799|NCT01346358|Biological|IMC-CS4|
79332474|NCT03073369|Drug|Placebo|Oral Placebo - one capsule once daily for 6 weeks
79332475|NCT04995757|Device|Stent Retriever|Stent Retriever for acute ischemic stroke
79332476|NCT03072823|Dietary Supplement|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
79332477|NCT03072823|Dietary Supplement|placebo|olive oil ethyl esters
79332478|NCT04995679|Procedure|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
79332479|NCT04995289|Other|Prone position on ECMO patient|blood gas analysis before and after PP
79651056|NCT04645615|Device|Cardioblate surgical ablation system|This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
79332480|NCT03076957|Drug|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
79332481|NCT03077035|Other|glass ionomer sealants|
79332482|NCT03077035|Other|resin-based sealant|
79332483|NCT04992325|Diagnostic Test|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
79332484|NCT03074071|Behavioral|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
79332485|NCT01652911|Device|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
79484842|NCT02511236|Drug|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
79651057|NCT04645615|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
79651058|NCT00217763|Drug|3APS|
79811831|NCT00792220|Procedure|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
79484843|NCT02467387|Drug|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
79811832|NCT00797368|Other|Manual Therapy and Exercise|Manual Therapy and Exercise
79811833|NCT00797368|Other|Home exercises|Home exercises
79811834|NCT02619539|Procedure|plasma fibrinogen measurement|plasma fibrinogen measurement
79811835|NCT02621957|Drug|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
79811836|NCT02621957|Drug|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
79332486|NCT03073993|Procedure|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
79332487|NCT04433611|Drug|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
79332488|NCT04433611|Drug|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
79332489|NCT04992559|Drug|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
79332490|NCT04992481|Procedure|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
79332491|NCT04992481|Procedure|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
79332492|NCT04992481|Procedure|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
79332493|NCT04992481|Procedure|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
79332494|NCT04992091|Other|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
79332495|NCT02597933|Drug|Nintedanib|
79332496|NCT02597933|Drug|Placebo|
79332497|NCT03072667|Drug|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
79332498|NCT04995367|Device|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
79332499|NCT05004415|Drug|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
79332500|NCT04912843|Drug|NR082 injection|Intravitreal injection（IVT）
79332501|NCT04912843|Device|Sham Injection|Sham Intravitreal Injection
79484844|NCT02467387|Drug|Lactated Ringer's Solution|One time infusion 1.5mL/kg
79332502|NCT04995133|Drug|Colistin|intravenous administration
79332503|NCT04827173|Procedure|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
79484845|NCT05073068|Behavioral|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
79484846|NCT05073068|Behavioral|Control|No exercise
79484847|NCT02974478|Dietary Supplement|Orange juice with meals|orange juice (20% of energy requirement/day)
79484848|NCT02974478|Dietary Supplement|Orange juice between meals|orange juice (20% of energy requirement/day)
79484849|NCT02974478|Dietary Supplement|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
79484850|NCT02512874|Other|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
79484851|NCT02512874|Device|Dynamometer|Grip Test
79484852|NCT02512874|Radiation|DEXA|Body Composition Testing
79484853|NCT02512874|Other|Gait Speed Test|15 foot walk test
79484854|NCT02512874|Device|Activity Monitor|Measures energy expenditure and activity
79484855|NCT02512874|Other|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
79484856|NCT02721979|Drug|Apalutamide|Given PO
79484857|NCT02721979|Other|Laboratory Biomarker Analysis|Correlative studies
79484858|NCT02721979|Other|Quality-of-Life Assessment|Ancillary studies
79484859|NCT02721979|Other|Questionnaire Administration|Ancillary studies
79484860|NCT02551094|Drug|colchicine|0.5 mg tablet taken once a day
79651059|NCT04645459|Other|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
79980800|NCT03462498|Drug|1-months DAPT|1-month DAPT followed by 59-month monotherapy
79332504|NCT04994821|Device|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
79332505|NCT04994821|Behavioral|Cognitive Reappraisal|Emotion regulation therapy
79332506|NCT04361669|Other|Medication safety review|Implementation of a medication safety review using a clinical decision support system
79811837|NCT00870233|Behavioral|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
79811838|NCT00696683|Other|None, this is an observational study|
79332507|NCT04361591|Other|Observational only|Observational Study
79332508|NCT04991623|Device|Kinesiology taping|We used kinesiology taping in abdominal muscles
79332509|NCT04991623|Other|Conventional physiotherapy|We used conventional physiotherapy to comparate
79980801|NCT03462498|Drug|12-month DAPT|12-month DAPT followed by 48-month monotherapy
79332510|NCT04360889|Drug|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
79332511|NCT04360889|Drug|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
79332512|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
79484861|NCT02551094|Drug|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
79484862|NCT02513498|Drug|Ixazomib Citrate|Given PO
79484863|NCT02513498|Other|Laboratory Biomarker Analysis|Correlative studies
79484864|NCT02513498|Other|Quality-of-Life Assessment|Ancillary studies
79980802|NCT04282590|Drug|TRK-750/Placebo|Powder for oral solution
79332513|NCT03072589|Drug|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
79811839|NCT00851084|Drug|aflibercept|administration: IV infusion
79980803|NCT04282590|Drug|Placebo/TRK-750|Powder for oral solution
79980804|NCT01354626|Other|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
79980805|NCT01354626|Other|low-protein|The control group will get a diet which is according to healthy eating guidelines.
79980806|NCT03136380|Drug|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
79332514|NCT04994743|Drug|CORT113176|CORT113176 lipid capsule formulation for oral administration
79332515|NCT04994743|Drug|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
79332516|NCT04812041|Other|CAM-ICU 7 score|A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
79332517|NCT04812041|Other|4C Mortality Score|4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
79484865|NCT02513498|Other|Questionnaire Administration|Ancillary studies
79484866|NCT00363740|Drug|GW685698X Aqueous Nasal Spray|
79484867|NCT04787354|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
79484868|NCT04787354|Drug|Capecitabine|Capecitabine: 2,000 mg/m2/day
79484869|NCT02514044|Drug|Dexedrine|10 mg immediate release of Dexedrine
79332518|NCT03076879|Behavioral|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
79332519|NCT04811885|Other|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
79980807|NCT03136380|Drug|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
79332520|NCT03072355|Other|Elastic Band|Localized muscle resistance test for shoulder
79332521|NCT03072355|Other|Isokinetic dynamometer|Localized muscle resistance test for shoulder
79332522|NCT04426877|Behavioral|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
79332523|NCT04426877|Behavioral|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
79332524|NCT03076801|Behavioral|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
79332525|NCT04426799|Other|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
79332526|NCT04994353|Dietary Supplement|No supplementation|1st Week: No supplementation
79332527|NCT04994353|Dietary Supplement|High Performance (HP) Inulin|2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
79332528|NCT04994353|Dietary Supplement|Isomalto-oligosaccharide (IMO)|3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
79980808|NCT01346436|Procedure|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
79332529|NCT04994353|Dietary Supplement|Combination HP-Inulin and IMO|"4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water."
79332530|NCT04994353|Dietary Supplement|Dextrose solution|5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
79332531|NCT04994353|Dietary Supplement|Glucose solution|6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
79332532|NCT04826783|Device|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
79332533|NCT03072745|Diagnostic Test|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
79332534|NCT04807829|Drug|Nabilone|Nabilone is a synthetic endocannabinoid and CB1 agonist.
79332535|NCT04807829|Drug|Placebo|Inactive placebo comparator
79484870|NCT02514044|Device|Active tDCS|1.5 mA tDCS anodal tDCS
79484871|NCT02514044|Behavioral|Speech Therapy|60 min of speech therapy
79811840|NCT00851084|Drug|oxaliplatin|administration: IV infusion
79811841|NCT00851084|Drug|5-FU|administration: IV infusion
79811842|NCT00851084|Drug|Folinic Acid|administration: IV infusion
79980809|NCT01354704|Drug|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
79307635|NCT03332238|Device|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
79307636|NCT03332238|Device|Ringer's solution|Ringer's solution
79811843|NCT04137419|Dietary Supplement|Probiotic lozenges|Probiotic strains
79811844|NCT04137419|Other|Placebo|Similar to ProlacSan lozenges in taste in colour
79980810|NCT01346670|Drug|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
79332536|NCT04994275|Other|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or <300 µg/L And TSAT<20%) or no iron deficiency
79332537|NCT05619029|Radiation|X-ray|Chest radiographs
79332538|NCT03076645|Behavioral|Facilitator support and education|Group engaged with facilitator support and education
79332539|NCT03072511|Behavioral|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
79332540|NCT03072511|Drug|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
79811845|NCT02619695|Drug|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
79332541|NCT05616611|Radiation|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
79332542|NCT05616611|Other|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
79332543|NCT05616611|Radiation|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
79332544|NCT04991545|Device|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~Group A: control group~Group B: Intervention group using Infrared"
79332545|NCT04811807|Device|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
79332546|NCT03073681|Device|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
79811846|NCT02621879|Procedure|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
79332547|NCT04807751|Drug|Delgocitinib cream|Cream for topical application
79332548|NCT04807751|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
79332549|NCT03072277|Dietary Supplement|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
79332550|NCT03072277|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
79332551|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16 virus
79332552|NCT03072121|Drug|Shexiang Baoxin pill|Conventional western medicine & shexiang baoxin pill
79332553|NCT03072121|Drug|SBP placebo|Conventional western medicine & placebo (for shexiang baoxin pill)
79332554|NCT03072121|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
79332555|NCT03072121|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
79332556|NCT03072121|Drug|Atorvastatin Calcium|10 mg tablet, two tablets each night.
79332557|NCT03072121|Drug|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
79332558|NCT03072121|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
79484872|NCT02514044|Drug|Placebo|
79811847|NCT02619383|Device|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
79811848|NCT02621801|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
79332559|NCT03072121|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
79332560|NCT05618873|Device|Flutter device|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
79484873|NCT02514044|Device|Sham tDCS|
79484874|NCT02515058|Device|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
79651060|NCT04645459|Other|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
79651061|NCT00558532|Procedure|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
79651062|NCT00558649|Biological|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
79980811|NCT01354782|Drug|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
79980812|NCT03136068|Drug|Digoxin|Trans-abdominal injection
79484875|NCT02515058|Device|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
79484876|NCT02552810|Device|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
79484877|NCT02552810|Device|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
79651063|NCT00558727|Drug|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
79980813|NCT03136068|Drug|Placebo|Trans-abdominal injection
79484878|NCT02553512|Other|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
79484879|NCT02553746|Device|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
79651064|NCT00217802|Behavioral|six-session telephone counseling program|
79651065|NCT04645225|Device|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
79980814|NCT01350024|Procedure|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
79980815|NCT01350024|Procedure|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
79980816|NCT01346748|Drug|statin|Sinvastatin 80 mg per day - 21 days versus placebo
79980817|NCT01318590|Drug|EUS procedure with drug injection|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
79980818|NCT01318590|Other|EUS procedure|EUS procedure without any drug injection
79980819|NCT01346826|Drug|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
79651066|NCT00558805|Behavioral|FISP + Usual Care|
79332561|NCT05618873|Device|positive expiratory pressure mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
79332562|NCT04993963|Other|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
79332563|NCT04993963|Other|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
79332564|NCT05618795|Other|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
79332565|NCT04994041|Other|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
79332566|NCT04994041|Other|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
79332567|NCT02597855|Drug|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
79332568|NCT02597855|Drug|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
79651067|NCT00558805|Behavioral|Usual Care|
79811849|NCT02617199|Drug|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
79811850|NCT02617199|Drug|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
79980820|NCT01346826|Drug|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
79980821|NCT01346826|Drug|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
79332569|NCT04987567|Dietary Supplement|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
79332570|NCT04987567|Dietary Supplement|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
79332571|NCT04811495|Other|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
79332572|NCT05004103|Other|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
79332573|NCT04807049|Other|Observational|Observational
79332574|NCT05003869|Procedure|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
79332575|NCT04806815|Other|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~Menstrual Symptom Questionnaire~Fatigue Severity Scale~Short Form Of Coronavirus Anxiety Scale"
79651068|NCT04645303|Drug|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
79651069|NCT04645303|Drug|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
79651070|NCT00217841|Drug|Aurograb|
79811851|NCT02617433|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
79332576|NCT03072199|Drug|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
79332577|NCT04811105|Procedure|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
79332578|NCT04990999|Procedure|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
79332579|NCT04990999|Procedure|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
79332580|NCT04811183|Behavioral|Pharmaceutical consultation|"Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected."
79332581|NCT04901533|Procedure|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
79332582|NCT04901533|Procedure|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
79332583|NCT04825925|Device|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
79332584|NCT05003479|Biological|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
79332585|NCT05003479|Biological|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
79332586|NCT04806659|Drug|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
79332587|NCT03070093|Drug|gilteritinib|oral
79332588|NCT04806581|Drug|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
79332589|NCT04806737|Drug|Teriflunomide Oral Tablet|The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.
79332590|NCT03070249|Behavioral|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
79332591|NCT04825691|Diagnostic Test|Immunohistochemistry of prostate biopsy|Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
79332592|NCT04991233|Procedure|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
79332593|NCT04991233|Procedure|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
79332594|NCT04810637|Drug|GX-I7|Recombinant human interleukin-7 hybrid Fc
79332595|NCT04353167|Other|observational evaluation|Patients will be evaluated only observationally without intervention
79332596|NCT04987411|Diagnostic Test|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
79332597|NCT04987411|Diagnostic Test|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
79332598|NCT04987411|Diagnostic Test|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
79484880|NCT02553746|Procedure|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
79332599|NCT04987411|Diagnostic Test|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
79332600|NCT04991155|Drug|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
79332601|NCT04825457|Procedure|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
79332602|NCT03070015|Behavioral|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI > 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables & no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch & 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (~50% kcal from carbohydrate,~25% from protein,~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
79332603|NCT03070015|Behavioral|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts & sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day & men ate 1500 kcal/day. Subjects with BMI >40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
79332604|NCT03071653|Procedure|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
79332605|NCT03071653|Other|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
79332606|NCT02604407|Drug|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
79332607|NCT02604407|Other|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
79332608|NCT02604407|Drug|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
79332609|NCT04462315|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
79332610|NCT04462315|Device|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
79332611|NCT04825535|Behavioral|Standard psychiatry and cognitive behavioral online intervention|The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
79484881|NCT02554760|Device|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
79484882|NCT02555228|Drug|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
79484883|NCT02555228|Other|Water|5mls of water is given at least 30 minutes before the gastroscopy.
79484884|NCT04654130|Other|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
79484885|NCT02555306|Drug|0.5 mg of DE-122|DE-122 Injectable Solution
79332612|NCT04825535|Behavioral|Standard psychiatry and cognitive behavioural in-person intervention|The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% [3,18 ]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) [41]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
79332613|NCT04461067|Diagnostic Test|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
79332614|NCT04806425|Drug|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
79980822|NCT01354860|Other|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
79980823|NCT01354860|Other|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
79332615|NCT04806425|Drug|Placebo|normal saline is given in same volume to normal saline group over the same duration
79811852|NCT02619227|Other|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
79980824|NCT03422562|Dietary Supplement|Florababy|Probiotic supplement
79980825|NCT03422016|Diagnostic Test|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
79980826|NCT01355016|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
79332616|NCT04460677|Behavioral|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
79332617|NCT04460677|Behavioral|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
79332618|NCT03071731|Drug|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
79811853|NCT00845858|Drug|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
79980827|NCT01346982|Drug|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
79980828|NCT02719002|Device|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
79980829|NCT01355172|Biological|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
79332619|NCT03071731|Drug|Placebos|Administration of a nebulized placebo before the administration of a functional test
79332620|NCT04809779|Drug|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
79332621|NCT04809935|Drug|98% dehydrated alcohol|"coeliac plexus is identified and punctured~Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
79484886|NCT02555306|Drug|1.0 mg of DE-122|DE-122 Injectable Solution
79811854|NCT00845858|Drug|Placebo|30 minutes before meals and at bedtime
79980830|NCT02585232|Behavioral|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
79332622|NCT04809935|Device|19G EUSRA needle, Taewoong Medical, Korea|"10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
79332623|NCT04255927|Drug|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
79332624|NCT04255927|Drug|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
79332625|NCT04809857|Other|Exercise|
79332626|NCT03069781|Drug|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
79332627|NCT03069781|Drug|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
79332628|NCT04427111|Device|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
79332629|NCT03069625|Behavioral|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
79332630|NCT03069625|Behavioral|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
79332631|NCT04809389|Biological|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
79332632|NCT04809389|Biological|Matching placebo|0.9% NaCl solution
79811855|NCT02617043|Radiation|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
79811856|NCT02616809|Other|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
79332633|NCT03069391|Behavioral|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
79332634|NCT03069391|Device|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
79332635|NCT03069391|Device|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
79332636|NCT04805723|Procedure|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
79332637|NCT04805723|Procedure|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
79332638|NCT03071575|Biological|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
79332639|NCT03071575|Biological|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
79332640|NCT04798391|Drug|Dexamethasone|Steroids and analgesics
79332641|NCT03071497|Diagnostic Test|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
79332642|NCT05616455|Drug|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
79332643|NCT05616455|Drug|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
79332644|NCT04986319|Diagnostic Test|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
79332645|NCT02593097|Drug|Metformin|Metformin 500mg twice daily
79651071|NCT04644835|Device|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
79651072|NCT04644835|Device|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
79332646|NCT02593097|Drug|Matching Placebo|Matching Placebo twice daily
79332647|NCT05003011|Device|Cardiospire|Non-invasive hemodynamic monitoring
79332648|NCT05002855|Other|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
79332649|NCT04805801|Drug|Emicizumab subcutaneous injection|Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
79484887|NCT02555306|Drug|2.0 mg of DE-122|DE-122 Injectable Solution
79484888|NCT02555306|Drug|4.0 mg of DE-122|DE-122 Injectable Solution
79484889|NCT02555930|Other|No Intervention|No intervention - observational only
79651073|NCT04644913|Behavioral|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
79651074|NCT04644757|Other|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
79651075|NCT00217880|Procedure|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
79651076|NCT04644523|Other|Dermoscopy|"dermoscopy is currently used in daily practice in dermatology, for melanoma screening. Dermoscopy will be used in this study on peri-ungueal area.~This is a non-invasive and painless exam."
79651077|NCT04644718|Device|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
79651078|NCT04644562|Other|Erector Spinae plane block|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
79332650|NCT04990765|Behavioral|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
79484890|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
79651079|NCT00217607|Drug|paclitaxel|
79811857|NCT02616809|Other|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
79484891|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
79332651|NCT04990765|Behavioral|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
79332652|NCT04797923|Drug|1. Treatment: IP chemotherapy + Systemic chemotherapy|1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
79332653|NCT04797923|Procedure|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2. Response evaluation after 4 cycles of IP + systemic chemotherapy~Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~IP chemotherapy should not exceed total of 8 cycles."
79332654|NCT04798157|Radiation|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
79484892|NCT02556788|Drug|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
79332655|NCT04990453|Other|RPD frameworks fabricated from PEEK material|extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
79484893|NCT02556788|Drug|Placebo Cream|Placebo cream applied once daily during 12 weeks.
79484894|NCT02516150|Drug|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
79332656|NCT03071419|Behavioral|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
79332657|NCT04805567|Device|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
79332658|NCT04985617|Other|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
79332659|NCT03071029|Behavioral|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
79484895|NCT02516150|Drug|Glucagon|injection of 50 micrograms of glucagon
79484896|NCT04025060|Behavioral|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
79484897|NCT04025060|Behavioral|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
79484898|NCT04025060|Behavioral|Regular soda|Subjects are asked to consume regular soda daily for two weeks
79484899|NCT04542434|Drug|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
79484900|NCT04542434|Drug|Placebo|Matching placebo tablets 3 times daily for 14 days
79484901|NCT02557178|Behavioral|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
79484902|NCT04415528|Other|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
79484903|NCT03943628|Behavioral|Familias Unidas|
79484904|NCT04186286|Drug|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
79484905|NCT04186286|Drug|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
79484906|NCT04186286|Drug|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
79811858|NCT02616809|Other|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
79484907|NCT02560922|Behavioral|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
79332660|NCT03071107|Behavioral|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
79332661|NCT04990063|Drug|Chemotherapy|Standard chemotherapy drug
79332662|NCT04990063|Biological|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
79332663|NCT04985461|Device|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
79332664|NCT04985149|Other|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be < 3.8 ms, amplitude > 10 Mv, and conduction velocity > 36 m/sec in sensory response of the sural nerve."
79332665|NCT04985149|Other|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
79332666|NCT05001997|Dietary Supplement|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
79484908|NCT04341038|Drug|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
79980831|NCT02585232|Behavioral|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
79980832|NCT01355328|Procedure|laser and radiofrequency|different laser and radiofrequency with different fluences
79980833|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
79332667|NCT01657461|Drug|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
79332668|NCT01657461|Device|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
79332669|NCT05001919|Procedure|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
79332670|NCT05001919|Procedure|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
79332671|NCT05001763|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
79980834|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
79980835|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
79980836|NCT02556606|Drug|Midazolam|single 40 min infusion of MID 0.03mg/Kg
79980837|NCT01355562|Drug|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
79332672|NCT05001763|Drug|Placebo|Glucose, 2mg, tablet.
79332673|NCT04989985|Drug|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40~60mg Bid，d1~14, q3w"
79332674|NCT04989985|Drug|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40~60mg Bid，d1~14, q3w"
79980838|NCT01355640|Other|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
79980839|NCT01355640|Other|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
79980840|NCT01350570|Other|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
79980841|NCT01350570|Other|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
79980842|NCT01350570|Other|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
79332675|NCT05242653|Procedure|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
79484909|NCT04341038|Drug|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
79980843|NCT01350570|Drug|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
79332676|NCT05242653|Procedure|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
79332677|NCT05239845|Dietary Supplement|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
79332678|NCT05239845|Other|Control|Maltodextrin
79332679|NCT05001841|Procedure|Lung Transplantation|Double lung transplant
79332680|NCT05001607|Device|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
79332681|NCT05321355|Device|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
79332682|NCT04989673|Other|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
79332683|NCT04989673|Other|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
79332684|NCT04989673|Other|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
79332685|NCT04989673|Other|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
79332686|NCT02592551|Drug|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
79332687|NCT02592551|Drug|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume [w/v]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
79332688|NCT02592551|Other|no other name|Neither MEDI4736 nor Tremelimumab will be used.
79332689|NCT04989127|Diagnostic Test|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
79332690|NCT04989127|Procedure|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
79332691|NCT04989127|Biological|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
79332692|NCT04989127|Drug|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
79332693|NCT04989127|Drug|Analgesic|Analgesics are prescribed for the patients.
79332694|NCT04989127|Drug|Antibiotic|Patients with penicillin allergy
79332695|NCT05320653|Dietary Supplement|Medical nutrition|Nutrition therapy of the critically ill patients
79332696|NCT04984213|Device|Karma Posterior Fixation Device|Posterior Fixation
79980844|NCT01355718|Drug|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
79980845|NCT01347138|Other|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
79980846|NCT03377790|Combination Product|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
79332697|NCT03070873|Device|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
79811859|NCT02616809|Other|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
79980847|NCT03377790|Combination Product|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
79332698|NCT03070873|Device|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
79332699|NCT03070873|Procedure|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
79332700|NCT05320185|Device|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
79332701|NCT05238753|Device|Non-invasive electromagnetic stimulation|Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
79332702|NCT04984135|Procedure|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
79332703|NCT04797377|Biological|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
79332704|NCT04989205|Behavioral|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising ~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
79484910|NCT04743050|Drug|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
79484911|NCT04743050|Diagnostic Test|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
79484912|NCT02561702|Other|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
79332705|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
79332706|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
79332707|NCT04982809|Drug|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
79332708|NCT04797533|Device|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~Micro-changes in weight distribution~Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~Movement and sleep~Heart rate"
79332709|NCT04808765|Procedure|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
79332710|NCT05518071|Drug|CRGD-ZW800-1|Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
79332711|NCT05518071|Device|Intraoperative near-infrared fluorescence imaging|Intraoperative imaging will be performed with at least one of the following CE-marked near-infrared (NIR) fluorescence imaging systems: Quest Spectrum imaging platform (v2/3.0) for open-procedures, the Olympus or Karl-Storz system for the diagnostic laparoscopy or the Intuitive Surgical Da Vinci Xi (Firefly-mode) for minimally invasive robot-assisted procedures. With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
79332712|NCT03068533|Other|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
79332713|NCT03068533|Other|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
79332714|NCT04804865|Other|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
79332715|NCT05281341|Drug|Growth Hormone|In GH groups (Group 4A & 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B & 3B) will receive only standard COS without GH supplementation
79332716|NCT03068377|Dietary Supplement|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
79332717|NCT03068377|Dietary Supplement|Placebo|soft gel capsules without test material
79332718|NCT04809155|Behavioral|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
79332719|NCT04988659|Other|Exposures|Exposures
79332720|NCT05280249|Other|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
79980848|NCT02717494|Biological|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
79980849|NCT02717494|Biological|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
79980850|NCT02717494|Other|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
79980851|NCT03306342|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
79980852|NCT01355874|Drug|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
79980853|NCT01355874|Drug|Placebo|Placebo ointment BID for 14 days during double blind.
79980854|NCT01355874|Drug|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
79332721|NCT05635981|Other|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
79332722|NCT04797689|Behavioral|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
79332723|NCT04797689|Behavioral|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
79332724|NCT04988581|Other|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
79332725|NCT05516511|Diagnostic Test|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
79332726|NCT04796987|Diagnostic Test|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
79332727|NCT05237895|Diagnostic Test|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
79332728|NCT04796753|Other|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
79332729|NCT05237271|Other|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
79484913|NCT02561702|Drug|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
79484914|NCT02563496|Drug|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
79484915|NCT02563496|Drug|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
79484916|NCT02563808|Other|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
79484917|NCT02563808|Other|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
79484918|NCT02540161|Drug|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
79484919|NCT02540161|Drug|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
79484920|NCT02467465|Other|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
79484921|NCT02467465|Device|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
79484922|NCT02564354|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
79980855|NCT02422368|Drug|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
79980856|NCT02422368|Drug|Methylprednisolone +Placebo|"Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
79980857|NCT01355952|Dietary Supplement|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
79484923|NCT02467777|Device|Bair Hugger|
79484924|NCT02467777|Device|VitaHeat|
79332730|NCT05237271|Other|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
79332731|NCT03068299|Other|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
79332732|NCT03068299|Other|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
79332733|NCT05280015|Dietary Supplement|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
79332734|NCT05280015|Other|placebo|placebo add-on venlafaxine
79332735|NCT03070795|Procedure|early feeding|start oral sips four hours after cesarean section
79332736|NCT03070795|Procedure|delayed feeding|start oral feeding on post operation day 1 (>12hours) after surgery
79332737|NCT04805099|Drug|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
79332738|NCT04808687|Drug|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area < 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 < 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
79332739|NCT05635825|Other|Observational Survey|Collection of a 4-day food record
79332740|NCT04804397|Dietary Supplement|Sucrose|Sucrose sweetened soft drinks
79332741|NCT05279703|Drug|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
79332742|NCT05279703|Drug|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
79332743|NCT05279703|Drug|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
79332744|NCT05635747|Device|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
79332745|NCT04796519|Procedure|Total knee arthroplasty|Surgical procedure
79332746|NCT03070639|Behavioral|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
79332747|NCT03070639|Behavioral|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
79332748|NCT05279001|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
79332749|NCT04804475|Other|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
79332750|NCT04808375|Other||
79332751|NCT04808063|Procedure|Prophylactic mesh implantation|Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
79332752|NCT03070561|Biological|sublingual film with peanut extract|
79980858|NCT01347372|Behavioral|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
79980859|NCT02292108|Behavioral|dietetic counselling|
79980860|NCT02292108|Behavioral|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
79332753|NCT05514951|Diagnostic Test|Blood sampling|Blood sampling
79332754|NCT04796441|Biological|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
79980861|NCT01347450|Dietary Supplement|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
79980862|NCT01347450|Dietary Supplement|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
79332755|NCT04988737|Other|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
79332756|NCT05278845|Drug|SLC-391|SLC-391 is an AXL inhibitor
79332757|NCT05392933|Diagnostic Test|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
79332758|NCT04796675|Drug|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
79332759|NCT04954677|Other|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
79332760|NCT05233839|Other|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
79332761|NCT05233839|Other|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
79332762|NCT05233761|Drug|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
79332763|NCT05233761|Drug|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
79332764|NCT04803929|Biological|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
79332765|NCT04796207|Dietary Supplement|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
79332766|NCT04796207|Dietary Supplement|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season."
79332767|NCT05317923|Other|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
79332768|NCT04786925|Other|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
79484925|NCT02540629|Procedure|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
79484926|NCT02568644|Dietary Supplement|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
79651080|NCT04644484|Biological|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
79651081|NCT04644484|Biological|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
79651082|NCT04644484|Biological|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
79332769|NCT04786925|Other|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
79651083|NCT04644250|Drug|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
79980863|NCT05720572|Drug|Antazoline|Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
79332770|NCT05230875|Behavioral|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
79332771|NCT05276037|Other|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
79332772|NCT04803617|Other|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
79332773|NCT05229939|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
79332774|NCT05275413|Behavioral|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
79332775|NCT05275413|Behavioral|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
79332776|NCT05275413|Other|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
79332777|NCT04795349|Procedure|Vacuum-assisted breast biopsy|In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
79332778|NCT04786535|Procedure|Expanded Hemodialysis|"Single-use Theranova 400 Dialyzer~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 500 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
79332779|NCT04786535|Procedure|High-flux Conventional Hemodialysis|"Single-use high-flux hemodialyzer~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 500 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
79651084|NCT04644250|Drug|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
79651085|NCT04644250|Radiation|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
79980864|NCT05720572|Drug|Propafenone|Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
79651086|NCT00245739|Drug|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
79651087|NCT04644211|Drug|Ruxolitinib|Pill taken by mouth.
79811860|NCT02616653|Procedure|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
79332780|NCT04786535|Procedure|Hemodiafiltration|"Single-use high-flux hemodialyzer~Post-dilution mode~Minimum convective volume of 23 L~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 700 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
79980865|NCT01356030|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
79332781|NCT05272917|Other|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
79332782|NCT05272917|Behavioral|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
79332783|NCT04803695|Diagnostic Test|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
79332784|NCT05316987|Radiation|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
79332785|NCT04925895|Other|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
79332786|NCT04925895|Other|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
79332787|NCT04925895|Other|Cryotherapy|application of cold pack on knee joint for 10 minutes
79332788|NCT04925895|Other|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
79332789|NCT04795115|Other|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
79332790|NCT05616377|Other|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
79811861|NCT00850538|Radiation|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
79980866|NCT01356030|Procedure|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
79980867|NCT01347528|Behavioral|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
79980868|NCT02465944|Drug|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
79980869|NCT02465944|Drug|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
79332791|NCT05616377|Other|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
79332792|NCT04785755|Drug|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
79484927|NCT02568644|Other|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
79332793|NCT04785755|Drug|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
79484928|NCT02568644|Drug|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
79484929|NCT02541409|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
79484930|NCT02541409|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
79484931|NCT02541409|Drug|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
79484932|NCT02569112|Device|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
79484933|NCT02569112|Device|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
79332794|NCT04785755|Drug|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
79332795|NCT04244253|Drug|OPC-64005 20 mg , Once-daily|Active, High Dose
79332796|NCT04244253|Drug|OPC-64005 10 mg , Once-daily|Active, Low Dose
79332797|NCT04244253|Drug|Placebo, Once-daily|Placebo
79332798|NCT04785833|Drug|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
79484934|NCT02569658|Drug|Tranexamic Acid|
79484935|NCT02569658|Drug|Placebo|
79484936|NCT02541565|Drug|Cyclophosphamide|Given IV
79484937|NCT02541565|Drug|Doxorubicin Hydrochloride|Given IV
79484938|NCT02541565|Other|Laboratory Biomarker Analysis|Correlative studies
79484939|NCT02541565|Biological|Pembrolizumab|Given IV
79484940|NCT02541565|Drug|Prednisone|Given PO
79484941|NCT02541565|Biological|Rituximab|Given IV
79484942|NCT02541565|Drug|Vincristine Sulfate|Given IV
79484943|NCT04708184|Drug|GLPG3970 oral solution|GLPG3970 for oral administration
79484944|NCT04708184|Drug|GLPG3970 tablet|GLPG3970 for oral administration
79484945|NCT04707950|Drug|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~Bleeding continues after 30 minutes~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
79484946|NCT04707950|Drug|Oxytocin|both groups will be given oxytocin as a standard management
79980870|NCT01356108|Device|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
79332799|NCT04240899|Other|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
79332800|NCT04785911|Drug|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
79332801|NCT04795193|Procedure|Minimal invasive coronary surgery|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
79332802|NCT04795193|Procedure|Off-pump coronary artery bypass surgery|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
79332803|NCT05615441|Device|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
79484947|NCT03681236|Procedure|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
79484948|NCT03593564|Behavioral|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
79484949|NCT04044560|Biological|blinatumomab|Continuous intravenous infusion
79484950|NCT02569892|Device|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
79484951|NCT02571218|Device|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
79980871|NCT04471792|Drug|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
79980872|NCT04471792|Dietary Supplement|Cellulose|Cellulose will be used in combination with muscle stretching.
79332804|NCT05615441|Device|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
79332805|NCT04794959|Diagnostic Test|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
79332806|NCT05218941|Procedure|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
79332807|NCT05218941|Procedure|Conventional implant surgery|Flap implant surgery
79332808|NCT04785599|Behavioral|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
79332809|NCT04785599|Behavioral|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
79332810|NCT04785599|Device|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
79332811|NCT05314101|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
79332812|NCT05314101|Drug|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
79484952|NCT02571218|Device|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
79811862|NCT00850538|Procedure|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
79811863|NCT02619149|Drug|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
79811864|NCT02619149|Drug|Saline solution|Saline iv as placebo control
79980873|NCT01356186|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
79980874|NCT01347684|Behavioral|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
79980875|NCT01347684|Drug|Standard care using current drugs|Standard Drug therapy
79332813|NCT05314101|Drug|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
79484953|NCT02573402|Device|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
79484954|NCT02573402|Device|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
79484955|NCT03791060|Drug|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
79484956|NCT00364364|Drug|Radiolabeled humanized PAM4 IgG|
79980876|NCT05716750|Dietary Supplement|Vitamin D|50,000 IU vit D treatment for 8 weeks
79980877|NCT05709886|Device|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
79484957|NCT03256916|Drug|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
79484958|NCT03256916|Drug|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
79811865|NCT04134065|Drug|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
79980878|NCT01350882|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
79980879|NCT01350882|Drug|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
79980880|NCT01357200|Other|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
79980881|NCT01357278|Procedure|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
79332814|NCT02595749|Drug|Oxytocin|
79332815|NCT02595749|Drug|Placebo|
79811866|NCT04134065|Drug|Placebo oral capsule|the capsule contain nothing
79811867|NCT05602298|Other|Quality of Recovery 15 survey|QOR 15 is a patient reported outcomes measure (PROM) tool used as a global measure of patient recovery after surgery and anesthesia. It uses fifteen questions to assess various domains of patient health: pain, physical comfort, physical independence, psychological support, and emotional state.
79811868|NCT02616731|Drug|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
79332816|NCT05218707|Other|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
79332817|NCT01657305|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
79811869|NCT02616731|Drug|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
79332818|NCT01657305|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
79811870|NCT00850460|Drug|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
79332819|NCT04785209|Other|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
79332820|NCT04803461|Diagnostic Test|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
79332821|NCT04794881|Other|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
79332822|NCT04794881|Other|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
79332823|NCT04426721|Drug|Ozone|10 cc of oxygen-ozone
79332824|NCT04426721|Drug|Hyaluronic Acid|Sinovial forte 32 mg\2ml
79811871|NCT00850460|Drug|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
79811872|NCT04137263|Other|DOSE formulation|over-the-counter topical
79332825|NCT05221359|Device|ExOlin®|"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."
79332826|NCT05221359|Drug|Insulin aspart|Use of NovoRapid insulin during all periods of the clinical investigations
79332827|NCT04803071|Dietary Supplement|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
79332828|NCT04803071|Dietary Supplement|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
79332829|NCT04803071|Dietary Supplement|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
79332830|NCT04794413|Drug|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
79332831|NCT04802993|Other|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
79980882|NCT04489966|Behavioral|Aerobic training|The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
79332832|NCT02634307|Drug|ALKS 8700|Administered as specified in the treatment arm.
79332833|NCT01365273|Device|Mepitel One|Dressing
79332834|NCT04793945|Combination Product|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
79811873|NCT00661492|Drug|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
79811874|NCT00661492|Drug|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
79811875|NCT04116632|Drug|BMS-963272|Single dose with varying frequency among groups
79332835|NCT05312775|Procedure|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
79332836|NCT05312775|Procedure|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
79332837|NCT04794257|Device|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
79332838|NCT04794179|Device|Naida Link CROS|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
79332839|NCT05311449|Other|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
79332840|NCT05311449|Other|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
79332841|NCT04784741|Other|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
79332842|NCT04784741|Device|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
79332843|NCT04784741|Device|Biodex Balance System|Pre and post balance assessment by Biodex balance system
79332844|NCT04784741|Procedure|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
79332845|NCT05635279|Other||
79332846|NCT04802915|Procedure|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
79332847|NCT05616143|Device|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
79332848|NCT04988191|Drug|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
79332849|NCT04988191|Drug|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
79484959|NCT03256916|Radiation|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
79332850|NCT04988191|Drug|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
79332851|NCT05310201|Behavioral|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
79332852|NCT02595437|Drug|Triferic|
79484960|NCT02579876|Drug|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
79484961|NCT02579876|Drug|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
79484962|NCT00364052|Drug|oral Valganciclovir vs oral Ganciclovir|
79811876|NCT04116632|Drug|Placebo|Specified dose on specified days
79332853|NCT04784975|Other|No intervention|No intervention
79332854|NCT03069001|Drug|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
79332855|NCT03069001|Drug|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
79651088|NCT00217919|Behavioral|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
79651089|NCT04644445|Dietary Supplement|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
79332856|NCT04784195|Behavioral|Observation|Verification of morfology and functionality of neck muscles
79332857|NCT03070717|Procedure|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
79651090|NCT00558883|Drug|acarbose|oral application
79811877|NCT02619071|Procedure|Tumor sampling|Bone marrow aspirate, blood sampling
79332858|NCT04239651|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
79332859|NCT04239651|Other|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
79332860|NCT04784273|Procedure|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
79332861|NCT04784273|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
79332862|NCT04793789|Other|monofocal toric lens|not applicable as patients are already implanted with the monofocal toric lens
79332863|NCT05163171|Other|questionnaire|questionnaire for conjugal violence prevalence
79332864|NCT05353621|Behavioral|VAS reported Stress|VAS reported Stress measurement during simulation
79811878|NCT02619071|Biological|Constiutional DNA sampling|Buccal swab or Hair follicles
79332865|NCT04426643|Biological|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
79332866|NCT04426643|Other|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
79332867|NCT03070405|Drug|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
79332868|NCT03070405|Drug|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
79332869|NCT03068065|Drug|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
79811879|NCT00693095|Biological|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
79811880|NCT00693095|Biological|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
79332870|NCT03068065|Drug|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
79980883|NCT02476084|Other|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
79332871|NCT03068065|Drug|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
79980884|NCT02476084|Other|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
79980885|NCT02476084|Other|Biological samples collection|Draw of research blood samples.
79332872|NCT05109117|Drug|ChapStick Active Performance Unscented|Sunscreen lip balm.
79332873|NCT04988347|Combination Product|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
79332874|NCT04988347|Other|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
79332875|NCT05473169|Device|Videofluoroscopy|Swallowing assessment
79980886|NCT02476084|Other|Questionnaires|Administration of validated patients' questionnaires.
79332876|NCT04452097|Biological|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
79332877|NCT04452097|Other|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
79484963|NCT02787668|Other|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO <10%; fat >65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
79980887|NCT01844856|Drug|Eravacycline|
79332878|NCT05213091|Other|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
79332879|NCT04802369|Diagnostic Test|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
79811881|NCT02619305|Other|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
79332880|NCT04988269|Diagnostic Test|Blood sampling|Assessment of circulating levels of plasma ACTH, plasma aldosterone and serum interleukin -6 levels at day 1
79332881|NCT04988269|Diagnostic Test|Saliva sampling|Assessment of diurnal variation of cortisol and DHEA levels in the saliva at 4 different time points during the day (0.800, 12.00, 18.00, 22.00) at day 2.
79332882|NCT05109039|Dietary Supplement|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
79811882|NCT00850070|Drug|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
79980888|NCT01844856|Drug|Ertapenem|
79980889|NCT01844856|Drug|Placebo|Administered IV to maintain the blind.
79980890|NCT02465788|Device|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
79980891|NCT00618098|Biological|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was < 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
79332883|NCT05109039|Dietary Supplement|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
79811883|NCT00850070|Drug|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
79811884|NCT04134143|Biological|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
79332884|NCT05211921|Device|Multi-Gyn ActiGel Plus|vaginal gel
79332885|NCT04987801|Other|Drug Toxicity|Patients who took over dose of Drugs
79332886|NCT05161611|Drug|Zinc sulfate|10 mg of oral zinc sulfate will be given to neonates per day
79484964|NCT02787668|Other|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
79651091|NCT04644094|Other|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
79651092|NCT04644406|Other|Efficacy of the Pertuzumab-Trastuzumab combination|The efficacy of the pertuzumab in combination with one of the biosimilars of Trastuzumab will be estimated by measuring the PFS at 6 months after the beginning of the treatment.
79651093|NCT00217958|Behavioral|SHS reduction intervention based on social cognitive learning theory|
79980892|NCT00618098|Biological|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of < 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was < 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
79980893|NCT02464228|Drug|Tipifarnib|oral
79980894|NCT04051736|Biological|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
79980895|NCT05687968|Behavioral|"3D/AR MetaFood  nutrition education, and receive instant feedback from the nutritionists or AI after recording their dietary food image."|"The participants record diet images by using Taiwan FoodAPP and receive instant feedback from the nutritionists or AI after recording their dietary food image. The dietitian will use 3D/AR MetaFood food nutrition education platform to do nutrition education for patients."
79980896|NCT05687968|Behavioral|conventional nutrition education by dietitian|The participants receive conventional health and nutrition education from state registered dietitian.
79980897|NCT01350960|Drug|SPC5001|3 weekly SC injections
79980898|NCT01350960|Drug|Saline 0.9%|3 weekly SC injections
79980899|NCT01350960|Drug|SPC5001|3 weekly SC injections
79332887|NCT05161611|Other|Placebo|10 mg of normal saline will be given to neonates per day
79332888|NCT05161611|Other|Phototherapy|Neonates will be put under phototherapy
79332889|NCT05634655|Other|no interventions between two groups|no interventions between two groups
79332890|NCT04802525|Other|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
79332891|NCT03660475|Drug|Naltrexone|naltrexone formulated as ophthalmic solution
79332892|NCT03660475|Drug|Placebos|Placebo ophthalmic solution
79332893|NCT04802213|Other|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
79332894|NCT04802213|Device|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
79332895|NCT04802213|Device|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
79332896|NCT05211609|Diagnostic Test|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
79332897|NCT05615987|Drug|Onabotulinumtoxina for Injection|200iu/2ml in both groups
79332898|NCT05478135|Device|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
79332899|NCT03069157|Procedure|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
79332900|NCT05107557|Biological|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
79332901|NCT02594735|Drug|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight < 50 KG).
79332902|NCT03645499|Drug|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
79332903|NCT03645499|Drug|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
79332904|NCT03645499|Drug|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
79332905|NCT03645499|Drug|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
79332906|NCT03645499|Drug|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
79484965|NCT02582216|Device|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
79651094|NCT04643977|Device|mARG-01-17 (mesohyal AGRIBENONE)|Dermal Filler
79651095|NCT04643821|Drug|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
79651096|NCT04643509|Device|Niccomo|Niccomo monitoring added to pulmonary arterial catheter monitoring
79651097|NCT04643665|Procedure|Double-lung transplantation|
79651098|NCT00558922|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
79651099|NCT04643392|Procedure|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
79811885|NCT00693251|Procedure|Crush technique|Crush technique
79332907|NCT04793243|Dietary Supplement|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
79332908|NCT05158569|Other|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
79332909|NCT05158569|Other|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
79332910|NCT05472467|Drug|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
79332911|NCT05472467|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
79332912|NCT05472467|Drug|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
79332913|NCT04760639|Diagnostic Test|Breath test|Participants provide a breath sample
79332914|NCT04793165|Device|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
79332915|NCT04793399|Drug|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
79332916|NCT04793399|Drug|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
79332917|NCT05634265|Behavioral|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
79484966|NCT02582840|Drug|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
79484967|NCT02582840|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
79651100|NCT04643236|Behavioral|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
79651101|NCT04643236|Behavioral|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
79651102|NCT00218075|Drug|Levodopa|
79651103|NCT00218075|Drug|Carbidopa|
79980900|NCT01350960|Drug|SPC5001|3 weekly SC injections
79980901|NCT01350960|Drug|SPC5001|3 weekly SC injections
79980902|NCT01350960|Drug|SPC5001|3 weekly SC injections
79980903|NCT01351038|Drug|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
79980904|NCT02465710|Procedure|Pelvic organ prolapse surgery without mesh|retrospective study
79332918|NCT05157711|Drug|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
79332919|NCT05157711|Drug|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
79332920|NCT05157711|Drug|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
79484968|NCT02582840|Drug|Placebo tablet|Placebo tablet. Oral dose
79651104|NCT00218075|Behavioral|Clinical Management|
79651105|NCT00218075|Behavioral|Relapse Prevention Therapy|
79651106|NCT00218075|Behavioral|Contingency Management|
79651107|NCT00559000|Behavioral|KIDNET|Narrative Exposure Therapy for Children
79651108|NCT00414570|Drug|[18]F-FLT PET scan|Injection of [18]F-FLT radiopharmaceutical followed by PET imaging.
79651109|NCT00559039|Other|questionnaire administration|
79651110|NCT00559039|Procedure|evaluation of cancer risk factors|
79651111|NCT00218114|Drug|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
79651112|NCT00218114|Drug|Placebo|Participants will be on matching placebo.
79651113|NCT00559078|Other|Interview|Hour-long, qualitative, phone interview
79980905|NCT02465710|Procedure|Pelvic organ prolapse surgery with mesh|
79980906|NCT01351116|Radiation|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
79980907|NCT01351116|Radiation|EBR|EBR of 20 Gy in 5 daily fractions over one week
79332921|NCT04793321|Device|Baby carrier|"It is made in china.~It is made of Cotton-Polyester.~It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~It is suitable for newborn to 12-months baby~It is available online at babyshopstores https://www.babyshopstores.com/"
79332922|NCT04793321|Device|Biodex Balance System|"The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
79332923|NCT04793321|Other|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
79332924|NCT04793321|Device|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~Heart Rate Monitoring~Handrail~Open Platform"
79332925|NCT05105997|Drug|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
79332926|NCT05105997|Drug|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
79332927|NCT04801433|Other|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
79332928|NCT04801433|Drug|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
79332929|NCT04801433|Other|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
79332930|NCT05105607|Drug|D-4517.2|Subcutaneous (SC) injection
79332931|NCT04793087|Diagnostic Test|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
79332932|NCT05206383|Behavioral|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
79332933|NCT05206383|Behavioral|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
79332934|NCT05206383|Behavioral|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
79332935|NCT04450459|Diagnostic Test|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
79332936|NCT04421781|Other|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
79332937|NCT04801511|Drug|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
79332938|NCT04159675|Biological|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
79332939|NCT05471765|Device|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of < 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
79332940|NCT05471765|Device|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of < 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
79332941|NCT05156229|Biological|CDK-003|CDK-003 administered subcutaneously
79332942|NCT03069235|Behavioral|Family member / peer support|supplemental individualized counselling
79332943|NCT03069235|Behavioral|Enhanced intervention with counselor support|"hands on EBF demonstrations"
79332944|NCT03069235|Behavioral|standard of care|one on one and in-group counselling
79332945|NCT04793009|Device|funnel-shaped, intraperitoneal mesh placement|Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
79332946|NCT05615909|Radiation|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
79332947|NCT05615909|Radiation|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
79332948|NCT04453891|Device|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
79980908|NCT05046340|Other|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
79980909|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
79980910|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
79332949|NCT05471687|Device|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
79332950|NCT05471687|Drug|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
79332951|NCT04230369|Behavioral|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
79307637|NCT03328091|Other|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
79332952|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
79651114|NCT00559117|Drug|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
79980911|NCT01356342|Biological|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months~<3 years;0.25 mL per injection2 injections at 4 weeks apart~3~<9 years;0.5 mL per injection2 injections at 4 weeks apart~9~<18 years;0.5 mL per injection1 injections"
79484969|NCT02583230|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
79651115|NCT04643275|Device|BTL-899|Treatment with study device.
79651116|NCT00424788|Procedure|Plasma exchange|
79651117|NCT00424788|Drug|natalizumab treatment|
79651118|NCT00218153|Drug|Naltrexone|
79651119|NCT04642924|Drug|SGM-101|Fluorescence-guided surgery
79811886|NCT00693251|Procedure|provisional T stenting|Provisional T stenting
79811887|NCT00797680|Other|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
79811888|NCT00797680|Other|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
79332953|NCT03068845|Device|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
79332954|NCT03068845|Device|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
79332955|NCT05370729|Drug|N-acetyl cysteine|Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
79332956|NCT05471531|Biological|Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
79332957|NCT05471531|Biological|Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
79484970|NCT00364988|Drug|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
79484971|NCT00364988|Drug|losartan|losartan (100 mg daily)
79484972|NCT00365222|Drug|Temozolomide|temozolomide 75 mg/m2 /d
79484973|NCT04340804|Behavioral|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
79484974|NCT04340804|Behavioral|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
79484975|NCT02580188|Drug|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
79484976|NCT04741958|Diagnostic Test|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
79484977|NCT02584790|Device|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
79484978|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
79484979|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
79484980|NCT02586896|Behavioral|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
79980912|NCT01788306|Drug|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
79332958|NCT04426331|Behavioral|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
79980913|NCT02464462|Dietary Supplement|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
79980914|NCT02464462|Other|Placebo|Rice powder pills
79980915|NCT03135210|Other|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
79332959|NCT04426331|Behavioral|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
79332960|NCT05104671|Other|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~towel slide~Scapular Clock:~Scapular Proprioceptive Neuromuscular facilitation:~Inferior Glide.~Scapular Orientation Exercise (SOE):~Protraction and retraction in front of a mirror:"
79332961|NCT05104671|Other|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
79651120|NCT04643119|Device|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
79651121|NCT04643119|Device|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
79980916|NCT03135210|Device|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
79980917|NCT02464150|Dietary Supplement|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
79980918|NCT02464384|Procedure|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
79980919|NCT01351194|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
79332962|NCT05104671|Other|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
79332963|NCT04792619|Other|Bobath Approach|The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
79332964|NCT04792619|Other|Isometric scapular exercises|Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
79980920|NCT01351194|Procedure|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
79332965|NCT04801199|Drug|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
79332966|NCT04801199|Drug|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
79332967|NCT05104359|Other|Observational|HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.
79484981|NCT02586896|Behavioral|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
79484982|NCT02586974|Device|Humigard|warmed and humidified CO2 insufflation
79484983|NCT05249504|Other|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
79484984|NCT05249504|Other|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
79980921|NCT04270864|Drug|Ipilimumab|20mg (4mL) IT
79980922|NCT04270864|Drug|Nivolumab|360mg IV then 480mg IV
79980923|NCT04270864|Drug|Tilsotolimod|8 mg (2mL) IT
79332968|NCT05102877|Device|Neuromuscular electrical stimulation|Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
79332969|NCT05154357|Other|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
79332970|NCT05154357|Other|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
79332971|NCT05153421|Device|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
79332972|NCT05203575|Behavioral|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
79332973|NCT05203575|Behavioral|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
79332974|NCT05203575|Behavioral|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
79484985|NCT05249504|Behavioral|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
79484986|NCT05249504|Behavioral|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
79484987|NCT05249504|Other|Community resources|Learn about community resources
79484988|NCT05249504|Other|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
79484989|NCT02791568|Procedure|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
79484990|NCT02791568|Procedure|MRI Scan|MR imaging will take approximately 30 minutes.
79484991|NCT02791568|Drug|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
79980924|NCT01318668|Biological|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
79980925|NCT01318746|Procedure|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
79980926|NCT01357434|Behavioral|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
79332975|NCT05203575|Behavioral|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
79332976|NCT05445791|Drug|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
79332977|NCT05445791|Other|Placebo|Placebo 500 mg twice daily until disease progression
79484992|NCT05372432|Other|Handgrip strengths measurements with Jamar-type hand dynamometer and, tip pinch strengths measurements with pinchmeter|The handgrip strength and tip pinch strength of the participants were measured using the Jamar-type hand dynamometer and pinch meter available in our clinic. The handgrip strengths were measured with shoulders in adduction and neutral rotation, elbows in 90 degrees flexion, and forearms and wrists in a neutral position, while the tip pinch strengths were measured by squeezing a pinch meter between the thumb and index finger. Participants took a deep breath and then applied gripping force with maximal force while exhaling. In the analysis, the average of the three measurements made with an interval of five minutes was taken as the basis for the analysis.
79332978|NCT05152875|Other|biological|fungal colonization by weekly cultures
79484993|NCT05372432|Other|The Nine Hole Peg Test|This test was used to evaluate the hand dexterity of the participants. This test consists of a square area and nine holes in this area, nine cylinders suitable for these holes, and a storage box. Participants quickly took the nine cylinders from the storage box and placed them in the holes, and after placing all the cylinders, they put the cylinders back in the storage box one by one. In the evaluation of the test, the time elapsed during these operations was measured in seconds with a chronometer, and shorter times were considered to indicate better hand dexterity.
79484994|NCT05371730|Drug|NCR300|Intravenous infusion of NK cells（NCR300）
79651122|NCT00241878|Behavioral|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
79980927|NCT01351272|Drug|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
79980928|NCT01351428|Drug|Nifedipine|30-60 mg, twice daily
79980929|NCT02193048|Other|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
79332979|NCT04801277|Procedure|Electroacupuncture on acupoints vs sham points|Randomized double blinded clinical trial
79332980|NCT05150457|Drug|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
79332981|NCT04792229|Other|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
79332982|NCT05102175|Other|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
79332983|NCT04800653|Procedure|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
79332984|NCT05203263|Device|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
79332985|NCT05203263|Device|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
79332986|NCT05203263|Device|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
79332987|NCT04792307|Other|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
79332988|NCT05101473|Other|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
79332989|NCT04800419|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a third generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting cancer survivors in aligning behavior with their personal values. The objectives of the therapy are for client to learn to focus on behaviors and actions that are in line with their individual values - the things they care about most. ACT facilitates development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors. ACT is useful in cancer patients, because it can help them to deal with the negative emotions caused by cancer instead of avoiding these.
79332990|NCT04800419|Behavioral|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
79332991|NCT05100537|Behavioral|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
79332992|NCT05100537|Other|continuing a routine life|No intervention will be made in the control group.
79332993|NCT04800575|Device|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
79332994|NCT04800575|Device|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
79332995|NCT05203029|Other|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
79332996|NCT04349111|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
79332997|NCT02634151|Drug|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
79484995|NCT05247944|Procedure|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
79484996|NCT05247944|Procedure|Open repair|Open surgery for complex abdominal aortic aneurysm
79332998|NCT02634151|Drug|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
79332999|NCT04799951|Other|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
79333000|NCT05202639|Other|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
79333001|NCT05147337|Drug|E2511|E2511 tablets.
79333002|NCT05147337|Drug|Placebo|E2511 matched placebo tablets.
79333003|NCT04791605|Other|Gait analysis|Kinematic and kinetic analysis
79333004|NCT04791683|Other|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
79333005|NCT04799873|Drug|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
79333006|NCT05145699|Device|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
79333007|NCT04799561|Behavioral|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
79333008|NCT05199519|Drug|IBI345|IBI345 CAR-T cell injection by intravenous infusion
79333009|NCT04799639|Drug|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
79651123|NCT00241878|Behavioral|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
79333010|NCT05614973|Procedure|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
79333011|NCT05614973|Procedure|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
79333012|NCT04799093|Diagnostic Test|EyeBOX|Eye-Tracking based diagnostic
79484997|NCT05247554|Drug|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
79307638|NCT03328091|Other|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
79333013|NCT04790981|Other|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
79333014|NCT04790981|Other|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
79333015|NCT05142501|Other|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
79333016|NCT03068689|Procedure|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
79333017|NCT03068689|Other|Placebo|Placebo
79333018|NCT04798937|Other|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
79333019|NCT05629897|Other|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
79333020|NCT05154539|Diagnostic Test|Remote digital assessment|Remote digital assessment of test group participants
79980930|NCT05006326|Drug|68Ga-PSMA|Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
79333021|NCT05154539|Diagnostic Test|Conventional physical assessment|Conventional physical assessment of control group participants
79333022|NCT04798703|Drug|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
79333023|NCT04798313|Drug|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
79333024|NCT04798313|Drug|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
79333025|NCT01655823|Drug|Placebo|Sham treatment acting as control arm
79333026|NCT01655823|Drug|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
79333027|NCT01360645|Drug|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
79333028|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
79980931|NCT05006326|Device|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
79333029|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
79333030|NCT05132855|Biological|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
79484998|NCT05247554|Drug|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
79651124|NCT04643197|Device|Barbed PDS suture (STRATAFIX Symmetric PDS Plus)|STRATAFIX Symmetric PDS Plus is a barbed suture.
79333031|NCT05132855|Biological|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
79333032|NCT05132855|Biological|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
79333033|NCT05141799|Device|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
79651125|NCT04643197|Device|Non-barbed PDS suture (PDS Plus)|Non-barbed suture
79651126|NCT00218192|Behavioral|Behavior Therapy|
79980932|NCT05006326|Device|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
79980933|NCT05003830|Device|PET/MR|18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
79980934|NCT00701662|Biological|Vivaglobin|
79484999|NCT05217368|Other|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
79485000|NCT05217368|Other|antenatal education|Routine antenatal education will be given.
79485001|NCT02596022|Drug|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
79333034|NCT05105711|Behavioral|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
79333035|NCT04345289|Biological|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
79333036|NCT04345289|Other|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
79333037|NCT05195463|Other|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
79485002|NCT02596022|Drug|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
79485003|NCT05208320|Behavioral|Adherence|"Patients received interventions as follow:~The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~Home health education by Community Health Workers every month for 6 months"
79485004|NCT00364442|Drug|fluticasone propionate/salmeterol|investigational drug
79651127|NCT04643314|Other|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
79651128|NCT04643080|Other|Yogurt|6 oz. of a commercially available yogurt were provided daily for 12 weeks
79651129|NCT00245817|Behavioral|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
79651130|NCT00559156|Dietary Supplement|arginine/omega-3 fatty acids/nucleotides oral supplement|
79485005|NCT00364520|Other|Shanghai workers|
79485006|NCT02597582|Procedure|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
79485007|NCT00364598|Drug|Anginera, a human tissue replacement therapy|
79651131|NCT00559156|Drug|cisplatin|
79651132|NCT00559156|Procedure|adjuvant therapy|
79651133|NCT00559156|Radiation|radiation therapy|
79651134|NCT04642846|Other|Silver Diamine Fluoride (SDF)|Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment
79651135|NCT04642612|Device|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~Patient awake and supine in the holding area~After sedation~After interscalene nerve block"
79651136|NCT04642768|Dietary Supplement|KetoneAid Ketone Ester|Commercially available ketone supplement
79333038|NCT05195463|Other|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
79333039|NCT05195463|Other|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
79333040|NCT04343105|Procedure|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
79333041|NCT04342793|Drug|Placebo oral tablet|Placebo
79333042|NCT04342793|Drug|ALS-L1023 1,200mg|ALS-L1023
79333043|NCT04342793|Drug|ALS-L1023 1,800mg|ALS-L1023
79980935|NCT01356420|Dietary Supplement|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
79980936|NCT01357590|Device|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
79333044|NCT05095389|Device|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
79980937|NCT04489576|Procedure|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 & 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
79980938|NCT02464306|Drug|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
79980939|NCT01575990|Behavioral|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~Educational component~Values clarification exercise~Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
79980940|NCT01575990|Behavioral|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
79333045|NCT05095389|Other|standard care|standard care
79333046|NCT05095389|Other|Placebo|placebo
79980941|NCT04489810|Dietary Supplement|Placebo|Maltodextrin capsule manufactured to mimic the Glutalytic® and DE111® capsules
79980942|NCT04489810|Dietary Supplement|Glutalytic®|1 capsule containing 350 mg of Glutalyltic®
79980943|NCT04489810|Dietary Supplement|DE111®|1 capsule containing Bacillus subtilis DE111
79980944|NCT04489810|Other|Meal A|Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
79980945|NCT04489810|Other|Meal B|Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
79333047|NCT04790747|Drug|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
79333048|NCT03068221|Other|anaerobic exercise|assessing anaerobic exercise status
79333049|NCT05181085|Drug|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
79333050|NCT05181085|Drug|Placebo|inactive analogue
79333051|NCT05195385|Procedure|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
79333052|NCT05056103|Device|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
79333053|NCT04336163|Device|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
79333054|NCT05139381|Drug|Mepolizumab|Treatment with Mepoluzimab
79485008|NCT05371574|Drug|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
79333055|NCT05614505|Dietary Supplement|Ready to use therapeutic foods|locally produced therapeutic foods
79333056|NCT04790591|Procedure|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
79333057|NCT02633527|Drug|Placebo|Placebo was administered once daily
79333058|NCT02633527|Drug|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
79333059|NCT02633527|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
79485009|NCT02599766|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
79485010|NCT02599766|Other|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
79485011|NCT05371418|Procedure|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
79811889|NCT02618837|Procedure|Downstream strategy|"At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel* daily for at least 12 months~If subject is >75 years old or <60 kg, daily dose of prasugrel should be 5mg"
79485012|NCT05371418|Device|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
79651137|NCT04642768|Dietary Supplement|Maltodextrin|Commercially available maltodextrin supplement
79651138|NCT00241917|Behavioral|Hepatitis C educational video|
79651139|NCT00241917|Other|Video|Prevention education video about hepatitis C
79651140|NCT04642495|Diagnostic Test|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
79651141|NCT04642456|Diagnostic Test|Balance Assessment Scale|The newly developed balance, based on the Balance Evaluation Systems Test (BESTest) and Trunk Control Measurement Scale (TCMS), will be administered by two raters (normative and clinical database + interrater reliability)
79651142|NCT04642456|Diagnostic Test|Trunk strength measurement with EMG|A trunk strength protocol in sitting position, using a hand-held dynamometer is developed. During the trunk strength measurements muscle activity of certain muscles of the trunk will be measured using surface electromyography (EMG)
79651143|NCT04642456|Diagnostic Test|MRI spine/pelvis|We will be capturing 3D Magnetic Resonance (MR) images of the subject lying supine with extended knees, using a T1 weighted spine-echo (SE) sequence with interslice distance 3 mm in the area of the hip) extended with full spine MRI images (sagittal full spine T1- and T2- weighted images as part of the standard sagittal view of full spine to check for significant stenosis or spinal cord pathology) and additional T1-weighted axial slices at level L4, T12 and T8 with interslice distance 4 mm.The field of view covers the full spine, pelvis and hip smaller trochanter.
79651144|NCT04642456|Diagnostic Test|EOS stereoradiographic full body exam|Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
79811890|NCT02618837|Procedure|Upstream strategy|"At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
79811891|NCT00792376|Drug|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
79485013|NCT05371340|Dietary Supplement|Quercetin (500 mg)|Once-daily 500 mg Quercetin
79485014|NCT05371340|Other|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
79485015|NCT02601170|Biological|Platelet-Rich Plasma Intra-Articular Injection|
79485016|NCT02601170|Drug|Hyaluronic Acid Viscosupplementation|
79333060|NCT02633527|Drug|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
79333061|NCT02633527|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
79333062|NCT04790669|Procedure|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale & sphygmomanometer.
79333063|NCT04790669|Procedure|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline & post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale & sphygmomanometer.
79333064|NCT05092971|Behavioral|Multi-arm bandit tasks|Part 1 to be completed in the clinic. Subject participation is for one part and is pseudo-randomly.
79333065|NCT05092971|Device|Multi-arm bandit tasks|Part 2 to be completed in the scanner. Subject participation is for one part and is pseudo-randomly.
79333066|NCT05092893|Other|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
79333067|NCT01667549|Other|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
79333068|NCT05092581|Drug|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
79485017|NCT05371262|Drug|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
79485018|NCT02602496|Other|Fruits and Vegetables|5 servings of fruits or vegetables
79485019|NCT02602496|Other|Whole Grain|3 servings of whole grain
79485020|NCT02602496|Other|Control|3 servings of refined grain
79485021|NCT02603666|Device|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
79980946|NCT01351662|Behavioral|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
79651145|NCT04642456|Diagnostic Test|Balance Assessment Scale 2|Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
79651146|NCT04642456|Diagnostic Test|Trunk strength measurement with EMG 2|Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
79651147|NCT04642339|Biological|Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
79651148|NCT04642339|Biological|Placebo|Placebo
79811892|NCT00792376|Drug|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
79811893|NCT00592358|Drug|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
79980947|NCT01357746|Procedure|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
79980948|NCT01351818|Drug|Growth Hormone|
79980949|NCT02463916|Other|Exercise|8 week structured exercise programme
79980950|NCT02463994|Drug|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
79980951|NCT02463994|Radiation|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
79333069|NCT04790357|Other|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
79333070|NCT04790357|Other|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
79333071|NCT05614427|Diagnostic Test|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
79333072|NCT04089371|Device|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
79333073|NCT04089371|Device|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
79333074|NCT04010981|Other|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
79980952|NCT01356654|Device|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
79333075|NCT04010981|Other|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
79333076|NCT05191017|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
79333077|NCT05191017|Drug|Enzalutamide|Enzalutamide
79333078|NCT05190159|Device|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
79333079|NCT03973385|Device|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
79333080|NCT05137431|Other|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~Respiratory parameters (respiratory rate)~SpO2~Ventilator settings~Patient's tolerance (VAS; between 0-100)~Arterial blood gas (HFNO and NIV at 1 hour)~Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~Loss of consciousness~Agitation~Persistent hypotension~Need for fluid resuscitation~Need for vasopressor~Respiration rate ≥40/min~SpO2 <92~pH<7.30"
79333081|NCT05135871|Drug|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
79333082|NCT04338659|Biological|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
79333083|NCT05190003|Other|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
79333084|NCT03744611|Dietary Supplement|CE|550mg capsule (Eucommia ulmoides Oliver extract)
79333085|NCT03744611|Dietary Supplement|Placebo|550mg capsule (Placebo)
79333086|NCT04755179|Procedure|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~Conventional laparoscopy (three-trocar technique)~In case of purulent fluid: Suction and no peritoneal lavage procedure~Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~Closure of wounds as appropriate"
79333087|NCT04755179|Procedure|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~Gridiron incision at the right lower quadrant. (McBurney's point)~After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~The appendiceal stump will be closed by ligation, not a purse string suture.~Closure of wounds as appropriate"
79485022|NCT00366002|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
79485023|NCT00422240|Drug|Adapalene/Benzoyl Peroxide|
79485024|NCT05366972|Device|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
79485025|NCT00365534|Procedure|MEI|
79333088|NCT04755179|Procedure|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~Combination A:~Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children <40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children > 40 kg~Gentamicin 7mg/kg once daily~Combination B:~Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
79333089|NCT04755179|Procedure|Direct appendectomy|laparoscopic or open appendectomy as described
79333090|NCT05133999|Biological|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
79333091|NCT05133999|Other|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
79333092|NCT05133219|Other|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
79333093|NCT05131503|Other|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
79333094|NCT05090553|Procedure|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
79333095|NCT05090553|Biological|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
79333096|NCT05090553|Genetic|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
79333097|NCT05090553|Genetic|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
79333098|NCT04789811|Other|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
79333099|NCT04789811|Other|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
79333100|NCT05089461|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
79333101|NCT04789343|Other|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
79333102|NCT05730439|Procedure|Biospecimen Collection|Undergo collection of blood
79333103|NCT05730439|Drug|Nicotine Oral Pouch|Receive ZYN brand NP
79333104|NCT05730439|Drug|Nicotine Oral Pouch|Receive Rogue brand NP
79485026|NCT02605304|Drug|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
79980953|NCT01356654|Device|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
79333105|NCT05730439|Other|Questionnaire Administration|Ancillary studies
79333106|NCT05730439|Drug|Smokeless Tobacco|Receive usual SLT
79333107|NCT03683147|Other|Laboratory Biomarker Analysis|Correlative studies
79333108|NCT03683147|Behavioral|Meditation-Based Stress Reduction Program|Participate in 6-week online program
79333109|NCT03683147|Other|Quality-of-Life Assessment|Ancillary studies
79333110|NCT03683147|Other|Questionnaire Administration|Ancillary studies
79333111|NCT05730361|Biological|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
79333112|NCT05730361|Biological|ScTIL injection and B lymphocytes adjuvant|B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is > 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
79980954|NCT04235686|Drug|Mydayis Extended-Release Capsule|Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®
79333113|NCT04789187|Procedure|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
79333114|NCT04789187|Procedure|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
79333115|NCT05550493|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.
79333116|NCT05550493|Behavioral|Counseling|Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.
79485027|NCT02605304|Drug|Ribavirin|"Based on weight at entry:~For weight <75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
79980955|NCT04235686|Drug|Placebo|Matching placebo
79980956|NCT02079948|Drug|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~Blood draw at each monthly visit~Cognitive performance testing to assess memory performance~Physical function testing to assess walking speed and measure muscle endurance~Pain assessment testing to assess the presence and location of daily pain~Self-reported function and quality of life to measure disability and mobility limitations, and~Depression assessment testing to assess participants' level of depression."
79485028|NCT05365880|Drug|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
79485029|NCT05365880|Drug|Placebo|The active placebo comparator will be provided to participant.
79980957|NCT02079948|Drug|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~Blood draw at each monthly visit~Cognitive performance testing to assess memory performance~Physical function testing to assess walking speed and measure muscle endurance~Pain assessment testing to assess the presence and location of daily pain~Self-reported function and quality of life to measure disability and mobility limitations, and~Depression assessment testing to assess participants' level of depression"
79485030|NCT04741490|Drug|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
79485031|NCT04741490|Radiation|radiotherapy|45-55Gy/1.8～2.0Gy
79485032|NCT05603468|Drug|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
79485033|NCT05603468|Drug|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
79980958|NCT02079948|Procedure|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
79980959|NCT02079948|Procedure|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
79980960|NCT02463838|Other|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
79980961|NCT01357824|Procedure|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
79980962|NCT04178824|Behavioral|Discount Intervention|15% or 30% discount on fruits and vegetables
79485034|NCT05603468|Drug|Normal saline|Normal saline
79485035|NCT02606708|Radiation|Accelerated intensity modulated radiation therapy (AIMRT)|
79485036|NCT05365256|Behavioral|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
79485037|NCT05365256|Behavioral|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
79333117|NCT05550493|Behavioral|Approach Bias Modification|In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).
79485038|NCT05584904|Other|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
79333118|NCT05550493|Behavioral|Cognitive Training|The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
79485039|NCT02607254|Drug|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
79485040|NCT02607254|Drug|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
79485041|NCT02609204|Diagnostic Test|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
79485042|NCT02611154|Drug|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
79980963|NCT01357902|Drug|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
79980964|NCT03247764|Other||observational study
79980965|NCT05313776|Other|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
79485043|NCT05140538|Other|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
79485044|NCT05140538|Other|SRP + toothpaste|Use of domiciliary products twice a day
79485045|NCT05548244|Behavioral|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
79980966|NCT01318824|Procedure|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
79333119|NCT03671291|Behavioral|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
79333120|NCT05730283|Drug|ORC-13661|High-dose intervention (30mg daily)
79333121|NCT05730283|Drug|ORC-13661|Low-dose intervention (12mg daily)
79333122|NCT05730283|Drug|Placebo|Placebo intervention
79333123|NCT05087667|Device|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
79333124|NCT05087667|Device|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
79333125|NCT05613959|Device|Veress +|The Veress+ safety mechanism was used
79333126|NCT05613959|Device|Conventional Veress|The Conventional Veress Needle was used
79485046|NCT05548244|Behavioral|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Intelligence Scale for Children-Short Form to assess IQ.
79485047|NCT02613338|Device|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
79485048|NCT02614274|Dietary Supplement|Nutraceutical joint health formulation|A Proprietary Blend
79485049|NCT05104502|Behavioral|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
79485050|NCT05083988|Device|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
79485051|NCT05083988|Device|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
79485052|NCT02617784|Drug|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
79485053|NCT05537168|Procedure|Pediatric cardiac surgery under cardiopulmonary bypass|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
79485054|NCT00366158|Device|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
79485055|NCT00366158|Device|Ventricular Intrinsic Preference|Programming of pacemaker
79485056|NCT04955756|Diagnostic Test|mNGS|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
79485057|NCT04955756|Diagnostic Test|Multiplex PCR|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
79485058|NCT05732012|Behavioral|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
79485059|NCT00365612|Drug|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
79485060|NCT02974166|Other|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
79980967|NCT01318824|Procedure|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
79980968|NCT02465476|Procedure|telemedicine|treatment pathway organized by telemedicine
79333127|NCT05730049|Device|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
79333128|NCT04226937|Other|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
79333129|NCT04517279|Behavioral|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
79333130|NCT04517279|Behavioral|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
79333131|NCT04789031|Dietary Supplement|Oral nutritional supplementation (ONS)|Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
79333132|NCT05126745|Device|color flow Doppler ultrasonography|Doppler ultrasonography
79333133|NCT04789421|Device|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
79333134|NCT04789421|Device|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
79333135|NCT05126199|Other|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
79980969|NCT02878590|Device|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
79980970|NCT05634382|Drug|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
79333136|NCT05126199|Other|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
79485061|NCT02974166|Other|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
79485062|NCT02974166|Drug|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
79333137|NCT04789265|Other|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
79333138|NCT05493787|Behavioral|Reminder|Patient portal, SMS, email, and/or another modality
79333139|NCT05613569|Drug|KLS-2031|KLS-2031 administered by transforaminal epidural injection
79333140|NCT04830163|Combination Product|Brain state-dependent paired corticomotoneuronal stimulation (PCMS)|Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
79980971|NCT05634382|Procedure|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
79333141|NCT04788719|Other|Gait analysis|Gait analysis
79333142|NCT05125263|Other|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps* 3 sets, 1 min interval)"
79485063|NCT02974166|Drug|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
79485064|NCT05493098|Other|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
79980972|NCT01317732|Device|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
79485065|NCT05493098|Other|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
79485066|NCT05731778|Drug|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
79811894|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous [SC] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
79485067|NCT05731778|Drug|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
79811895|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
79485068|NCT05477264|Drug|Tislelizumab|"Induction therapy: Tislelizumab combined with radiation~Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."
79980973|NCT05625958|Device|Cilioscleral Interposition Device|Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
79651149|NCT04642300|Procedure|Holmich Protocol|"Module 1 (1st two weeks):~i)Isometric adduction ii)Abdominal sit-ups iii)Isometric adduction iv)Compound abdominal sit-ups and hip flexion v)Balance exercise on wobble board vi)One-foot exercise on sliding board~Module 2 (from 3rd week):~i)Leg abduction and adduction exercise carried out in side lying ii)Low back extension exercise prone on the end of bench iii)One leg weight pulling abduction/adduction standing iv)Abdominal sit ups v)One leg coordination exercise vi)Training in sideways motion vii)Balance exercise on wobble board"
79651150|NCT04642300|Procedure|Myofascial Release Technique|"Transverse friction massage: 10 mins on painful area of adductor-tendon insertion into pubic bone~Stretching of adductor muscles, hamstrings muscles and hip flexors:3 times and each stretch is 30s with Contract relax technique"
79651151|NCT04642573|Other|non interventional|non interventional
79651152|NCT00245895|Drug|Aranesp|Aranesp
79651153|NCT00559195|Biological|epoetin beta|
79651154|NCT00559195|Procedure|quality-of-life assessment|
79811896|NCT00787072|Drug|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
79811897|NCT00787072|Drug|Placebo|Oral suspension
79980974|NCT04634409|Drug|Bamlanivimab|Administered IV.
79980975|NCT04634409|Drug|Etesevimab|Administered IV.
79980976|NCT04634409|Drug|Placebo|Administered IV.
79980977|NCT04634409|Drug|VIR-7831|Administered IV.
79980978|NCT04634409|Drug|Bebtelovimab|Administered IV.
79980979|NCT01352052|Other|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
79651155|NCT00245934|Drug|Enbrel|
79651156|NCT04642144|Other|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
79651157|NCT04642144|Other|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
79651158|NCT00218231|Drug|300 mg/day bupropion-sr|300 mg/day for 1 week
79980980|NCT04896034|Device|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
79811898|NCT00869999|Drug|Everolimus|Taken orally once daily in the morning
79651159|NCT00218231|Drug|0 mg/day bupropion-sr|0 mg/day bupropion-sr
79651160|NCT04641910|Other|No intervention|No intervention
79651161|NCT04641754|Drug|WX-0593 Tablets|tablets, 60 mg→180mg, quaque die（QD）
79811899|NCT00869999|Drug|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
79980981|NCT04896034|Device|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
79980982|NCT01352130|Drug|Ondansetron|Intravenous Ondansetron 8 mgs
79333143|NCT05125263|Other|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps* 3 sets, 1 min interval)"
79333144|NCT04805515|Behavioral|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
79333145|NCT05729971|Procedure|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
79485069|NCT00422318|Drug|Benzbromarone (drug)|
79485070|NCT00364676|Drug|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
79651162|NCT04641676|Diagnostic Test|NGS testing|NGS test will be performed
79651163|NCT00241995|Drug|Anticonvulsants|
79811900|NCT04030988|Drug|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
79811901|NCT04030988|Drug|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
79980983|NCT01352130|Drug|Granisetron|Intravenous Granisetron 1 mgs
79980984|NCT02463604|Procedure|Coronary Angiography|Coronary angiography is performed following usual site standards
79980985|NCT05605834|Other|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
79980986|NCT05605834|Other|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
79980987|NCT00005780|Drug|EPOCH-R|EPOCH-R for 6 cycles
79980988|NCT00005780|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
79333146|NCT05170919|Drug|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
79333147|NCT05170919|Drug|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if > 65 yrs. and 5 mg/per day if <65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
79333148|NCT05729893|Other|root canal sealers|different sealer used in obturating root canals (resin and bio ceramic)
79333149|NCT05602285|Device|Dislodgement device|Breakaway device that prevents IV dislodgement
79333150|NCT05729737|Diagnostic Test|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in pancreatic tumors, it is safe and widely used in liver and pancreatic disease.
79333151|NCT05179629|Drug|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
79333152|NCT05613491|Drug|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
79485071|NCT00364676|Drug|VLI|Patients are dosed on Day 1 of a 21-day cycle.
79485072|NCT00364754|Drug|Tesmilifene (YMB 1002)|
79485073|NCT05731700|Device|Drug Eluting Balloon|PCI of in-stent restenosis
79485074|NCT00366236|Drug|Nitazoxanide|
79651164|NCT00218270|Drug|Tobacco free snuff|Tobacco free snuff
79651165|NCT04641520|Other|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
79333153|NCT05613491|Drug|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
79333154|NCT05082207|Other|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
79333155|NCT05082207|Other|sham group|a deflated cuff placed on the upper arm for 30 min
79333156|NCT05157425|Dietary Supplement|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
79333157|NCT05157425|Dietary Supplement|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
79333158|NCT05179317|Drug|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
79333159|NCT03276065|Device|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
79333160|NCT03276065|Other|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
79333161|NCT05177757|Other|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
79485075|NCT05731466|Device|CardioMems HF System|"Implantation CardioMems device.~Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
79485076|NCT04622540|Procedure|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
79333162|NCT04410679|Biological|injectable PRF|blood sample and centrifuged to obtain i-PRF
79333163|NCT04788407|Drug|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
79333164|NCT04788407|Drug|Placebo|Subjects will receive placebo TID for 7 days
79333165|NCT03066427|Drug|Sunitinib|Sunitinib 50 mg/d
79485077|NCT04741880|Drug|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
79980989|NCT00005780|Biological|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
79980990|NCT01356732|Drug|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
79980991|NCT02463682|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
79485078|NCT04741880|Drug|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
79485079|NCT05447234|Biological|Tcrx T cell|Sequential IV infusion
79485080|NCT05433818|Behavioral|Group A|Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
79651166|NCT04641793|Device|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
79651167|NCT00245973|Drug|Bifeprunox|
79651168|NCT04641715|Procedure|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
79980992|NCT02463682|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
79980993|NCT01356810|Other|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
79980994|NCT01356810|Other|Standard Care|Delirium management by the attending physician's preferences.
79980995|NCT05602246|Procedure|Transobturator cystocele repair|Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.
79980996|NCT05602246|Procedure|Anterior colporrhaphy|The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
79980997|NCT01978938|Drug|Eravacycline|
79485081|NCT05433818|Other|Group B|education with a structured and expert opinion-based breastfeeding brochure
79980998|NCT01978938|Drug|Levofloxacin|
79651169|NCT00218309|Drug|Hydromorphone|
79651170|NCT04641598|Procedure|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
79651171|NCT04641598|Procedure|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
79651172|NCT04641364|Drug|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
79651173|NCT04641364|Drug|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
79651174|NCT04641364|Drug|human albumin injection|multiple doses of intravenous infusion
79651175|NCT04641481|Biological|BBV152|BBV152 (6µg-Algel - Imidazoquinoline)
79651176|NCT04641481|Biological|Placebo|Placebo (PBS+Alum, without antigen)
79980999|NCT02465554|Procedure|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
79981000|NCT02465320|Drug|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
79981001|NCT02465320|Drug|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
79981002|NCT02465008|Drug|Levobupivacaine|
79981003|NCT02465008|Drug|Placebo|
79981004|NCT01356888|Device|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
79981005|NCT01356888|Device|Percutaneous Coronary Intervention (Orsiro DES)|stenting
79981006|NCT01352208|Drug|ASP9521|oral
79981007|NCT01358058|Radiation|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
79651177|NCT04720638|Other|Short fiber reinforced flowable resin composite restorations|reinforced flowable resin composite
79811902|NCT00792454|Behavioral|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
79811903|NCT00703352|Drug|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
79981008|NCT01330485|Behavioral|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
79981009|NCT01330485|Behavioral|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
79333166|NCT04788485|Drug|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
79333167|NCT05118087|Procedure|Webril Padded Plaster Splint|Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
79651178|NCT04720638|Other|Conventional resin composite restoration|Microhybrid resin composite
79651179|NCT00218348|Drug|Dextro-Amphetamine Sulfate|
79651180|NCT04641130|Other|Exposure to birch pollen in EEC|Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
79333168|NCT05118087|Procedure|Pre-Fabricated Fracture Brace|Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
79333169|NCT03067909|Other|CIED surgery|
79333170|NCT05177133|Drug|Capecitabine|PO Capecitabine
79333171|NCT05177133|Drug|Oxaliplatin|IV Oxaliplatin
79333172|NCT05177133|Drug|Retifanlimab|IV retifanlimab
79651181|NCT00246051|Behavioral|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
79333173|NCT03065803|Procedure|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
79333174|NCT03065803|Procedure|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
79333175|NCT02994563|Device|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
79333176|NCT03066505|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
79811904|NCT05326607|Device|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
79811905|NCT05326607|Device|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
79811906|NCT00797758|Other|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
79811907|NCT02618525|Other|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
79811908|NCT02618525|Other|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
79981010|NCT03041090|Device|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
79811909|NCT00703430|Drug|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
79333177|NCT03066505|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
79333178|NCT02866643|Drug|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
79333179|NCT02866643|Drug|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
79811910|NCT00797836|Procedure|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/*epidemiology/*statistics & numerical data Occupational Exposure/*statistics & numerical data~Tuberculosis/*diagnosis/*epidemiology/prevention & control Immunologic Tests/methods/*standards Disease Transmission, Horizontal/*statistics & numerical data Patient Isolation~Tuberculin Test/standards/*methods Immunoassay/methods/*standards T-Lymphocytes/immunology Interferon Type II/*blood/*analysis~*Reagent Kits, Diagnostic~Mass Screening/*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/*methods"
79981011|NCT04105114|Drug|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
79981012|NCT04105114|Device|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
79333180|NCT05729581|Behavioral|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
79333181|NCT05176821|Drug|esomeprazole plus amoxicillin|amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
79333182|NCT05176821|Drug|amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole|amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
79333183|NCT05555641|Drug|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
79485082|NCT04621838|Other|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
79485083|NCT04615130|Other|Rehabilitation|Rehabilitation, exercise training
79981013|NCT04105114|Device|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
79485084|NCT04551326|Other|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
79981014|NCT04105114|Device|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
79981015|NCT04105114|Device|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
79981016|NCT04105114|Device|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
79981017|NCT03222882|Procedure|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
79981018|NCT01352364|Other|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
79485085|NCT04490486|Biological|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
79485086|NCT04490486|Other|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
79485087|NCT05421728|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
79981019|NCT02071875|Device|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
79981020|NCT05309330|Other|No Intervention|This is a non-interventional study.
79981021|NCT05573230|Drug|Midazolam|Administered orally.
79485088|NCT05421728|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
79485089|NCT00365924|Drug|Forteo|Open label single arm study with Forteo as an intervention
79485090|NCT05731310|Drug|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
79485091|NCT05360030|Drug|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
79333184|NCT05555641|Drug|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
79333185|NCT05116527|Drug|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
79333186|NCT05116527|Drug|Placebo|Placebo THC - marijuana flower with no THC content
79333187|NCT03067831|Biological|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
79333188|NCT05175729|Diagnostic Test|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
79333189|NCT01672801|Drug|Placebo|oral administration
79333190|NCT01672801|Drug|Nimodipine|oral administration
79651182|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~Positive on the Berlin Questionnaire~Clinic visit, exam with a physician, given a home diagnostic device (HDD)~High risk on HDD, seen by physician, given a CPAP machine~Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~Contacted by a sleep health clinic at 3, 6, 12 months~After 12 months subject will be referred to their primary care physician"
79333191|NCT04939259|Device|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
79333192|NCT04939259|Device|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
79811911|NCT04046380|Diagnostic Test|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
79811912|NCT02618447|Device|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
79811913|NCT02618447|Procedure|Portal vein embolization|
79981022|NCT05573230|Drug|LY3502970|Administered orally.
79333193|NCT05080257|Device|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
79333194|NCT05729269|Diagnostic Test|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
79333195|NCT04787861|Other|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
79333196|NCT05612087|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
79333197|NCT05729113|Behavioral|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
79333198|NCT05613335|Procedure|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
79333199|NCT05613335|Procedure|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
79333200|NCT05508997|Device|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd & 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~Secondary outcome.~Ventilation by PaCO2 value from ABGs.~Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
79333201|NCT05612009|Combination Product|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
79333202|NCT01655901|Behavioral|Active video gaming|
79333203|NCT01655901|Behavioral|Passive video gaming|
79333204|NCT01655901|Behavioral|Resting|
79333205|NCT05504551|Procedure|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
79485092|NCT05360030|Drug|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
79485093|NCT05360030|Drug|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
79485094|NCT05360030|Device|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
79981023|NCT05573230|Drug|Cyclosporine|Administered orally.
79333206|NCT05173779|Procedure|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
79333207|NCT05475353|Behavioral|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
79333208|NCT05475353|Procedure|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
79333209|NCT05113797|Diagnostic Test|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
79485095|NCT05360030|Device|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
79981024|NCT03635034|Device|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
79981025|NCT03635034|Device|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
79981026|NCT01357044|Dietary Supplement|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
79981027|NCT01357044|Dietary Supplement|Placebo|Tablets, two in the morning and two in the evening
79981028|NCT04856722|Procedure|mini-PNL|PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
79981029|NCT04856722|Procedure|RIRS|RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
79981030|NCT04856722|Procedure|SWL|SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
79333210|NCT05113797|Behavioral|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
79811914|NCT00693407|Procedure|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS >30 is reported.
79811915|NCT02616341|Behavioral|Team ERP (T-ERP) Intervention|
79333211|NCT04787081|Other|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
79333212|NCT04787081|Other|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
79333213|NCT05729035|Radiation|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
79333214|NCT05172375|Behavioral|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
79485096|NCT05360030|Device|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
79333215|NCT04911803|Behavioral|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
79811916|NCT02616341|Behavioral|Treatment as Usual (TAU)|
79811917|NCT00787306|Behavioral|Active risk factor surveillance|Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
79651183|NCT00246051|Other|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
79651184|NCT04641208|Device|mobile phone|The root mean square (RMS) of the signal will be calculated by using electromyography, and were normalized to the EMG data maximum voluntary isometric contraction (MVIC)
79811918|NCT02618681|Other||
79811919|NCT00792532|Procedure|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
79811920|NCT00792532|Device|DBS electrodes|Deep brain stimulation (DBS) electrodes
79811921|NCT02618603|Drug|Botulinum toxin A|
79333216|NCT04911803|Behavioral|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
79333217|NCT04838405|Drug|CT-388|Synthetic Peptide
79333218|NCT04838405|Drug|Placebo|Placebo
79651185|NCT00559312|Drug|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
79651186|NCT00559312|Drug|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
79811922|NCT02618603|Drug|Triamcinolone Acetonide|
79811923|NCT02616497|Drug|Aspirin|COX-1 inhibitor
79811924|NCT02616497|Drug|Triflusal|COX-1 inhibitor
79811925|NCT00570232|Drug|Erlotinib|150 mg per day by mouth for 12 months
79811926|NCT05755854|Biological|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10^7cells/kg) ,dose 2 (1 × 10^8 cells/kg) ,dose 3 (2 × 10^8cells/kg)
79333219|NCT05111301|Device|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
79333220|NCT05475275|Procedure|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was <0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
79333221|NCT05078463|Device|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
79333222|NCT05078463|Drug|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
79333223|NCT05078463|Drug|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
79333224|NCT05078463|Drug|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
79333225|NCT05078463|Device|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
79333226|NCT05077137|Biological|Tetanus Diptheria Vaccine|tetanus and diphtheria toxoids
79333227|NCT05077137|Biological|Polio Boost Immunization|trivalent inactivated polio vaccine
79485097|NCT05731232|Dietary Supplement|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
79485098|NCT05731154|Other|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
79485099|NCT05731076|Behavioral|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
79485100|NCT00364910|Behavioral|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
79651187|NCT00559351|Procedure|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
79981031|NCT05559190|Other|Pulsed electromagnetic field|Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.
79981032|NCT05559190|Other|Graduated abdominal strengthening exercises|Four specific muscle core exercises were performed
79981033|NCT05550142|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
79981034|NCT05550142|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
79981035|NCT05550142|Drug|Placebo|Saline solution
79981036|NCT04045834|Device|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
79333228|NCT04786769|Drug|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
79333229|NCT05611541|Behavioral|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
79333230|NCT05611541|Behavioral|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
79333231|NCT05170113|Dietary Supplement|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
79333232|NCT05170113|Dietary Supplement|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
79333233|NCT05170113|Dietary Supplement|Caffeine formulation|Caffeine formulation capsule- I capsule daily
79333234|NCT05170113|Dietary Supplement|Placebo|Placebo capsule- 1 capsule daily
79333235|NCT05475119|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
79333236|NCT05475119|Device|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
79333237|NCT05110521|Behavioral|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
79333238|NCT05110521|Behavioral|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
79485101|NCT00364910|Behavioral|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
79485102|NCT05730998|Dietary Supplement|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
79485103|NCT05730998|Dietary Supplement|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
79485104|NCT05341778|Other|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
79485105|NCT05341778|Other|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
79485106|NCT05341778|Other|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
79485107|NCT05341778|Other|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
79485108|NCT05341778|Other|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
79981037|NCT00116142|Drug|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
79333239|NCT01295723|Radiation|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~Single reference dose per fraction: 2.7 Gy (ICRU)~Number of fractions: 15~Number of fractions per week: 5~Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
79333240|NCT01295723|Radiation|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
79333241|NCT05611463|Drug|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
79485109|NCT05341778|Other|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
79485110|NCT05341778|Other|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
79981038|NCT00116142|Drug|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
79485111|NCT05341778|Other|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
79333242|NCT05110365|Other|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
79333243|NCT05110131|Device|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
79333244|NCT05611385|Other|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
79333245|NCT05475041|Procedure|Major liver resection|Major liver resection (3 or more contiguous segments)
79333246|NCT05475041|Procedure|Technically major liver resection|Minor liver resection (<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
79333247|NCT01656759|Drug|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
79333248|NCT04234737|Behavioral|Hypnotherapy|Hypnotherapy
79333249|NCT05053815|Other|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
79333250|NCT04998747|Drug|AMG 701|AMG 701 will be administered as SC or intravenous injection.
79333251|NCT04998747|Drug|AMG 701|AMG 701 will be administered as SC injection.
79333252|NCT02631577|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
79333253|NCT02631577|Drug|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
79333254|NCT02631577|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
79333255|NCT01667081|Drug|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
79485112|NCT05341778|Device|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
79485113|NCT04742426|Other|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
79485114|NCT04742426|Other|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
79811927|NCT05755854|Drug|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
79811928|NCT05755854|Drug|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
79651188|NCT00559351|Drug|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
79651189|NCT00559351|Radiation|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
79651190|NCT00218504|Drug|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
79811929|NCT05755854|Drug|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
79981039|NCT00116142|Drug|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
79981040|NCT01357122|Device|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
79981041|NCT01357122|Procedure|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
79981042|NCT02463214|Other|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
79981043|NCT05547256|Biological|COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|50μg/dose
79981044|NCT05547256|Biological|COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|100μg/dose
79981045|NCT05547256|Drug|Placebo|Saline solution
79981046|NCT03135522|Drug|Zinc Acetate 50 Mg Oral Capsule|"Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
79981047|NCT03135522|Drug|Placebo oral capsule|"Day 0 (randomization) to day 3 Placebo (one capsule per day)~Day 4 to day 7 If well tolerated: placebo (two capsules per day)~Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
79981048|NCT02463292|Other|no intervention|no intervention
79981049|NCT01361334|Drug|Pazopanib|800 mg QD p.o.
79981050|NCT02463370|Other|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
79651191|NCT00242034|Procedure|CT and MRI with contrast|
79651192|NCT00559429|Drug|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
79651193|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
79651194|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
79651195|NCT00559429|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
79333256|NCT04998045|Behavioral|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
79485115|NCT04740944|Behavioral|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
79485116|NCT05730686|Procedure|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
79811930|NCT04133129|Behavioral|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
79811931|NCT04133129|Behavioral|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
79811932|NCT00787384|Drug|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
79811933|NCT02616419|Device|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
79811934|NCT02616419|Drug|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
79981051|NCT02463370|Other|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
79333257|NCT05052411|Other|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
79333258|NCT04545619|Device|QDOT MICRO System|QDOT Micro Catheter with nGEN Generator
79485117|NCT05272202|Drug|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
79333259|NCT05474885|Biological|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
79333260|NCT05728879|Combination Product|APR-TD011 (RLF-TD011)|APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
79333261|NCT04421469|Drug|Triprilimab(JS001)|"JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~JS001 maintenance treatment."
79333262|NCT03067753|Drug|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
79333263|NCT03067753|Drug|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
79333264|NCT03067753|Drug|Prednisolone|
79485118|NCT05272202|Device|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
79485119|NCT05272202|Device|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
79811935|NCT00797992|Drug|Injection|Intravitreal injection of 1.25 mg bevacizumab
79485121|NCT04741100|Other|Ex-vivo analysis|Ex-vivo analysis
79811936|NCT02618369|Device|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
79811937|NCT04137341|Drug|GLPG1972 - A|Film-coated tablet, formulation A
79811938|NCT04137341|Drug|GLPG1972 - B|Film-coated tablet, formulation B
79811939|NCT04137341|Drug|GLPG1972 - C|Film-coated tablet, formulation C
79981052|NCT02463370|Other|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
79485122|NCT05726474|Behavioral|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
79811940|NCT00798070|Drug|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
79981053|NCT02463370|Other|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
79485123|NCT05726474|Behavioral|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
79333265|NCT05073861|Behavioral|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
79485124|NCT04668638|Other|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
79485125|NCT05707442|Procedure|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
79485126|NCT05707442|Drug|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
79485127|NCT05707442|Behavioral|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
79485128|NCT04604132|Drug|Derazantinib|Derazantinib will be administered orally at a dose of 300 mg once a day and at a dose of 200 mg twice daily as monotherapy in the Substudy 1.
79811941|NCT00798070|Drug|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
79811942|NCT02618291|Other|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
79811943|NCT02618291|Other|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
79307639|NCT03323151|Drug|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
79307640|NCT03323151|Drug|Ixazomib|Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
79307641|NCT03323151|Drug|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
79981054|NCT01757782|Drug|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be <10% of previous value and SpO2 was not increasing >5 of previous value) and blood pressure remained stable
79981055|NCT01757782|Drug|Placebo (distilled water)|Distill water oral
79485129|NCT04604132|Drug|Derazantinib-paclitaxel-ramucirumab|"Derazantinib will be administered at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 in combination with paclitaxel and ramucirumab.~Paclitaxel will be administered intravenously at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 on days 1, 8, and 15 of a 28-day cycle in combination with derazantinib and ramucirumab.~Ramucirumab will be administered intravenously at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 every 2 weeks in combination with derazantinib and paclitaxel."
79485130|NCT04604132|Drug|Derazantinib-atezolizumab|"Derazantinib will be administered orally at a dose of 300 mg once a day in combination with atezolizumab.~Atezolizumab will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with derazantinib."
79811944|NCT00693563|Behavioral|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
79811945|NCT00809328|Drug|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
79485131|NCT04604132|Drug|Paclitaxel-ramucirumab|"Paclitaxel will be administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab will be administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
79485132|NCT05193188|Drug|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
79981056|NCT02023905|Drug|Everolimus|everolimus at 10 mg daily continuously
79307642|NCT03323151|Drug|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
79811946|NCT00868517|Other|True group auricular acupuncture|Received true group auricular acupuncture
79811947|NCT00868517|Other|Sham group auricular acupuncture|Received sham auricular acupuncture.
79981057|NCT02023905|Drug|Temozolomide|Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
79981058|NCT01318980|Drug|GSK2190915 100mg milled tablet|Taken orally
79981059|NCT01318980|Drug|[14C] radiolabelled GSK2190915 solution|Microtracer solution
79981060|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
79981061|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
79811948|NCT00868517|Other|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
79811949|NCT00798148|Drug|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
79485133|NCT05193188|Drug|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
79981062|NCT01318980|Drug|GSK2190915 100mg enteric-coated tablet.|Taken orally
79981063|NCT02465086|Other|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
79981064|NCT01361412|Biological|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
79981065|NCT01361412|Biological|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
79333266|NCT05613179|Procedure|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
79333267|NCT05613179|Procedure|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
79485134|NCT04799262|Drug|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if<10 the daily GC dosage was decreased by 2.5mg; if>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
79333268|NCT04331639|Dietary Supplement|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
79333269|NCT05073393|Behavioral|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
79333270|NCT04212351|Genetic|Frameshift Array blood sample test|Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
79333271|NCT05050149|Drug|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
79333272|NCT05557799|Radiation|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
79485135|NCT01196130|Behavioral|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
79485136|NCT01196130|Other|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
79485137|NCT01041534|Other|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
79811950|NCT00787462|Drug|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
79811951|NCT00787462|Drug|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
79333273|NCT05557799|Radiation|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
79485138|NCT00851136|Drug|bevacizumab|Intravenous repeating dose
79485139|NCT00851136|Drug|FOLFOX|Intravenous repeating dose
79485140|NCT00851136|Drug|PRO95780|Intravenous repeating dose
79811952|NCT02618135|Other|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
79981066|NCT01330563|Drug|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
79981067|NCT05099952|Procedure|Biospecimen Collection|Undergo collection of cheek cell and blood samples
79333274|NCT05613101|Procedure|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
79333275|NCT05613101|Procedure|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
79333276|NCT05613023|Radiation|SBRT|Stereotactic Body Radiotherapy
79981068|NCT05099952|Other|Counseling|Meet with therapist
79333277|NCT03067597|Drug|Dinoprostone|The DVI contains 10 mg dinoprostone
79333278|NCT02518971|Drug|Tamsulosin|0.4 mg daily
79333279|NCT02518971|Drug|Placebo|one capsule daily
79333280|NCT03067519|Other|Fast track surgery|early feeding and mobilization after surgery
79333281|NCT03067519|Other|Conventional management|Management per the primary surgeon
79981069|NCT05099952|Other|Educational Intervention|Participate in BBT-CI sessions
79333282|NCT04733963|Drug|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
79333283|NCT04733963|Drug|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
79485141|NCT02618642|Radiation|Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.|"Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded."
79485142|NCT04774848|Device|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
79485143|NCT04774848|Device|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
79485144|NCT00366392|Device|Optical Aids|
79333284|NCT03066115|Drug|L-NMMA|See arm description.
79981070|NCT05099952|Other|Electronic Health Record Review|Medical records are reviewed
79333285|NCT03066115|Drug|Ketorolac|See arm description.
79333286|NCT03066115|Drug|Ascorbic Acid|See arm description.
79333287|NCT03066115|Procedure|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
79485145|NCT04774458|Procedure|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
79981071|NCT05099952|Other|Medical Device Usage and Evaluation|Wear actigraphy watch
79981072|NCT05099952|Other|Questionnaire Administration|Ancillary studies
79981073|NCT03636009|Other|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
79981074|NCT03636009|Other|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
79981075|NCT03636009|Other|active exercise program|Participants will have 4-5 exercises to perform at each session
79981076|NCT03636009|Other|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
79981077|NCT02464852|Behavioral|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
79981078|NCT02464852|Behavioral|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
79981079|NCT02464852|Device|Sheffield Support Snood|
79981080|NCT02464852|Device|sEMG|
79981081|NCT05191602|Diagnostic Test|drainge fluid|including bilirubin
79981082|NCT01330641|Procedure|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
79333288|NCT03066115|Procedure|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
79333289|NCT04212039|Drug|Saline Solution|0.5 ml/kg saline
79333290|NCT04212039|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
79333291|NCT03066037|Procedure|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
79333292|NCT04433377|Procedure|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
79333293|NCT04433377|Procedure|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
79485146|NCT00366470|Drug|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
79307643|NCT03308578|Drug|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
79333294|NCT05048589|Drug|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
79333295|NCT05048589|Drug|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
79333296|NCT05728567|Other|whether the participants had T2DM|whether the participants had T2DM
79333297|NCT03067285|Drug|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
79333298|NCT03067285|Drug|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
79333299|NCT01365039|Device|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
79333300|NCT01365039|Device|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
79333301|NCT03067207|Behavioral|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
79485147|NCT00366470|Other|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
79485148|NCT04773210|Device|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
79485149|NCT04773210|Device|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
79485150|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^6 TCID50
79485151|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^5 TCID50
79485152|NCT00366782|Biological|Placebo|Placebo for rB/HPIV3 vaccine
79485153|NCT01116804|Procedure|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
79485154|NCT01116804|Procedure|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
79981083|NCT01333761|Device|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
79485155|NCT01116804|Procedure|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
79811953|NCT02618135|Other|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
79811954|NCT00792766|Drug|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
79981084|NCT01333839|Other|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
79981085|NCT02875080|Drug|OPC-34712|
79981086|NCT01315041|Drug|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
79981087|NCT01315041|Drug|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
79981088|NCT01358214|Behavioral|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
79981089|NCT04897503|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
79981090|NCT01333917|Drug|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
79981091|NCT02463526|Other|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
79981092|NCT02463526|Other|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
79981093|NCT03129360|Drug|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
79981094|NCT03129360|Drug|Placebo|Prepared in capsules to appear identical to levetiracetam.
79485156|NCT01116804|Procedure|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
79811955|NCT02617979|Other|SAFECARE at Home customized lessons|
79485158|NCT02620904|Drug|Mifepristone|
79485159|NCT02620904|Drug|placebo|
79981095|NCT01330875|Other|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
79307644|NCT03308578|Drug|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
79333302|NCT03065881|Device|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV [1] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
79485160|NCT00300768|Drug|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
79485161|NCT00300768|Drug|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
79485162|NCT00300768|Drug|4 mg moxidectin|Single dose, tablets encapsulated for blinding
79485163|NCT00300768|Drug|8 mg moxidectin|single dose, tablets encapsulated for blinding
79485164|NCT02621060|Drug|Placebo|Placebo: 1200 mg per day for three months
79485165|NCT02621060|Drug|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
79485166|NCT04740788|Device|Monofocal IOL|Patients are already implanted with a monofocal lens
79485167|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
79485168|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
79485169|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
79485170|NCT04740554|Behavioral|Control Group Typically Developing|Control group with tipical development.
79485171|NCT02624180|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
79485172|NCT02624180|Drug|Placebo|A substance containing no medication
79485173|NCT04339946|Diagnostic Test|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
79485174|NCT04339946|Diagnostic Test|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
79485175|NCT05068232|Radiation|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
79307645|NCT03276832|Drug|Imiquimod|Applied cutaneously
79307646|NCT03276832|Procedure|Biopsy|Undergo biopsy
79307647|NCT03276832|Biological|Pembrolizumab|Given IV
79333303|NCT05047575|Other|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
79333304|NCT03065959|Drug|reldesemtiv|oral
79333305|NCT03065959|Drug|Placebo|oral
79333306|NCT05463939|Drug|Teclistamab|Teclistamab will be administered subcutaneously (SC).
79485176|NCT05068232|Drug|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
79333307|NCT04993365|Biological|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
79333308|NCT04993365|Biological|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
79333309|NCT03067363|Drug|MOR107|MOR107 solution for injection
79651196|NCT04641403|Procedure|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
79333310|NCT03067363|Drug|Placebo|Solution for injection manufactured to match MOR107 solution for injection
79333311|NCT03067363|Other|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
79333312|NCT05428813|Behavioral|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
79333313|NCT05046561|Drug|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
79333314|NCT05046561|Drug|Placebo|Placebo oral capsule
79333315|NCT05419219|Device|the multi-domain Tai Chi Digital therapy Software Application|regular Tai Chi exercise, 40 Hz gamma sound stimulation and 18 BPM breath control exercise
79333316|NCT04447651|Other|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
79333317|NCT05370703|Behavioral|My A:care|Mobile application with Motivational messages
79333318|NCT05370703|Behavioral|Smart Coach|Mobile application with Motivational messages
79333319|NCT01364727|Drug|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
79333320|NCT02633215|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
79333321|NCT04990869|Dietary Supplement|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
79333322|NCT04990869|Dietary Supplement|Placebo|Placebo
79485177|NCT05068232|Drug|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
79307648|NCT03276832|Procedure|Computed Tomography|Undergo CT or PET/CT
79307649|NCT03276832|Procedure|Positron Emission Tomography|Undergo PET/CT
79485178|NCT05068232|Drug|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
79485179|NCT02625428|Drug|Optison|
79333323|NCT05728177|Combination Product|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
79307650|NCT03276832|Procedure|Magnetic Resonance Imaging|Undergo MRI
79333324|NCT01364649|Drug|Vortioxetine|Vortioxetine tablets
79333325|NCT01364649|Drug|Escitalopram|Escitalopram tablets
79333326|NCT01364649|Drug|Placebo|Vortioxetine Placebo-matching capsules
79333327|NCT03065569|Drug|Bupivacaine|16 mL of 0.125% bupivacaine
79333328|NCT05723419|Procedure|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
79333329|NCT03065491|Dietary Supplement|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
79333330|NCT03065491|Other|Placebo|Oral administration: 1 tablet per day
79485180|NCT02625428|Diagnostic Test|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
79485181|NCT02625428|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
79333331|NCT02588261|Drug|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
79333332|NCT02588261|Drug|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
79485182|NCT05055596|Behavioral|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
79651197|NCT00218582|Behavioral|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
79333333|NCT02588261|Drug|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
79333334|NCT03065257|Procedure|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
79485183|NCT05055596|Behavioral|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
79651198|NCT00218582|Behavioral|Standard psychiatric day treatment|Individual counseling, groups, medication
79651199|NCT04641169|Procedure|echocardiography|Four measurements in echocardiography performed in addition to standard care
79651200|NCT00242073|Procedure|MRI Prostate|
79651201|NCT04640740|Procedure|hip arthroplasty|two different approaches of total hip arthroplasty
79333335|NCT05040633|Device|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
79333336|NCT05040633|Other|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
79333337|NCT05711407|Genetic|Gene Polymorphisms of MMP-8|Saliva Samples
79333338|NCT05286229|Drug|ABBV-383|Intravenous (IV) Infusion
79333339|NCT04426487|Drug|Progesterone|Intramusculer progesterone
79333340|NCT03797937|Other|Magnetic resonance imaging (MRI)|MRI scanner
79333341|NCT04989465|Biological|Investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
79333342|NCT04989465|Biological|Control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
79333343|NCT05557565|Drug|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
79333344|NCT03066895|Device|BabyGentleStick|Experimental device.
79333345|NCT03066895|Device|Standard Lancing Device|HMC standard of care.
79333346|NCT05040243|Other|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
79485184|NCT04326764|Drug|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
79333347|NCT05040243|Other|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
79333348|NCT05697133|Other|SEMSTOP|This program has been developed based on Story Theory and will be implemented individually online. The session content, units and topics in the program are arranged according to the conceptual content and flow of the theory. The program has been created in a certain flow, based on the concepts of purposeful dialogue, connecting with itself and facilitating the theory.
79485185|NCT05187546|Drug|[18F]-PI2620|[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
79333349|NCT05697133|Other|control|control grup
79333350|NCT04988217|Drug|Interferon-Alpha2B|Nebulized interferon alpha 2B
79485186|NCT02628236|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
79485187|NCT02628236|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
79651202|NCT00218621|Procedure|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
79651203|NCT00246168|Drug|tramadol hydrochloride + acetaminophen|
79651204|NCT00218660|Drug|Naltrexone|150mg/day Naltrexone
79333351|NCT04988217|Drug|Placebo|Nebulized placebo
79333352|NCT01359449|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
79333353|NCT01359449|Biological|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
79651205|NCT00218660|Behavioral|BRENDA|Psychosocial Treatment
79651206|NCT00218660|Behavioral|CBT|Cognitive Behavioral Therapy
79651207|NCT00218660|Drug|Placebo|
79333354|NCT01672723|Drug|Naltrexone|
79333355|NCT04443673|Dietary Supplement|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
79651208|NCT04640389|Other|Cross-sectional study/no intervention|Cross-sectional study/no intervention.
79333356|NCT05037903|Behavioral|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
79333357|NCT05033145|Drug|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
79333358|NCT05033145|Drug|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
79333359|NCT05031975|Drug|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
79981096|NCT05074524|Device|Repetitive Transcranial Magnetic Stimulation|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
79485188|NCT02629094|Drug|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
79333360|NCT05031975|Drug|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
79333361|NCT05029947|Procedure|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
79333362|NCT02632747|Drug|Empagliflozin|Empagliflozin will be taken once daily
79485189|NCT02630030|Drug|Ixazomib|Given PO
79651209|NCT04640467|Diagnostic Test|Biophsical profile|There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.
79981097|NCT05074524|Device|Sham Repetitive Transcranial Magnetic Stimulation|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
79981098|NCT01315275|Drug|Ranibizumab|
79811956|NCT02616107|Other|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~Becoming a Cancer Caregiver [role, changes, challenges, adjusting, self-care]~Basics of Cancer Caregiving [physical, functional, emotional, social, & spiritual support; treatment timeline worksheet]~Caregiver's Role in Managing Patient Care [who/what is involved; health care professionals worksheet]~Managing Cancer Symptoms and Side Effects [common symptoms/side effects; maintaining health; nutrition & exercise; medication management worksheet]~Care Options: [information on curative, palliative and hospice care]~Talking About Goals of Care [information on goals of care conversations]~Managing Transitions [defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet]"
79981099|NCT01358292|Procedure|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
79981100|NCT01358292|Procedure|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
79485190|NCT04289792|Drug|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
79485191|NCT04289792|Radiation|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
79307651|NCT03274258|Biological|Ipilimumab|Given IV
79307652|NCT03274258|Biological|Nivolumab|Given IV
79333363|NCT02632747|Drug|Placebo (matching empagliflozin)|Placebo will be taken once daily
79333364|NCT02632747|Drug|ramipril|Ramipril will be taken once or twice daily
79333365|NCT04217811|Other|No intervention|No intervention
79333366|NCT04217343|Diagnostic Test|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
79333367|NCT04216797|Drug|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
79333368|NCT05029401|Drug|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
79333369|NCT05029401|Drug|Placebo|Matching placebo to the IMP (DMX-1002)
79333370|NCT05029011|Device|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
79333371|NCT05028855|Diagnostic Test|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
79333372|NCT05025813|Drug|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
79333373|NCT05064501|Diagnostic Test|spirometry|Lung function test: pre and post bronchodilator spirometry
79651210|NCT04640467|Diagnostic Test|Cerebroplacental ratio|CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
79811957|NCT02616107|Other|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
79981101|NCT02463136|Behavioral|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
79333374|NCT05064501|Other|Asthma control test|Asthma control test
79333375|NCT05064345|Drug|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
79333376|NCT05064345|Drug|Placebo|Palcebo
79485192|NCT02631590|Drug|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
79485193|NCT02631590|Drug|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
79485194|NCT02631590|Drug|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
79485195|NCT02253654|Drug|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
79485196|NCT02252406|Drug|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
79485197|NCT02252406|Other|Placebo|Matching placebo tablets daily for 24 weeks.
79651211|NCT04640233|Biological|Gam-COVID-Vac|Vaccine for intramuscular injection
79651212|NCT04640233|Other|Placebo|Placebo comparator
79651213|NCT02961621|Behavioral|Stress Reduction Training for 9-1-1 Telecommunicators|
79651214|NCT00218699|Behavioral|Cognitive-Behavioral Intervention|
79811958|NCT00787696|Behavioral|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
79811959|NCT00798382|Other|soy protein formula|ad lib for 0-35 days of age
79333377|NCT05623735|Other|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
79333378|NCT05623735|Other|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
79981102|NCT02463136|Device|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
79485198|NCT05178186|Procedure|Thyroidectomy|Surgery for thyroid carcinoma
79811960|NCT00798382|Other|Commercially available soy formula|ad lib for 0-35 days of age
79811961|NCT00798382|Other|Soy formula experimental #2|ad lib for 0-35 days of age
79811962|NCT00868439|Drug|patiromer|Active investigational drug
79981103|NCT01361646|Drug|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
79981104|NCT02462902|Drug|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
79811963|NCT00868439|Drug|placebo|placebo
79811964|NCT00798460|Drug|adefovir|adefovir 10mg
79811965|NCT00798460|Drug|clevudine|clevudine 30mg
79811966|NCT00798460|Drug|lamivudine|lamivudine 100mg
79811967|NCT00798538|Other|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
79811968|NCT00798538|Other|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
79811969|NCT02615873|Drug|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
79811970|NCT00814164|Drug|clofarabine|IV
79811971|NCT00814164|Drug|daunorubicin hydrochloride|IV
79811972|NCT00814164|Genetic|cytogenetic analysis|Correlative study
79981105|NCT02462902|Drug|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
79811973|NCT00814164|Genetic|protein expression analysis|Correlative Study
79811974|NCT00814164|Other|immunologic technique|Correlative Study
79981106|NCT03165045|Drug|Spiolto® Respimat®|6 weeks
79811975|NCT00814164|Other|pharmacological study|Correlative Study
79811976|NCT02609334|Drug|CRD007|One single dose given 3 hours prior to Mannitol challenge
79811977|NCT02609334|Other|Placebo|One single dose given 3 hours prior to Mannitol challenge
79811978|NCT00693641|Other|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
79981107|NCT02462746|Dietary Supplement|L-Cysteine|The trade name is New Root Herbal Inc.
79333379|NCT04421547|Drug|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
79333380|NCT04421547|Drug|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
79333381|NCT05061069|Diagnostic Test|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
79333382|NCT03885583|Procedure|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
79333383|NCT03885583|Procedure|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
79333384|NCT03066817|Drug|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
79333385|NCT03066817|Drug|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
79333386|NCT05060913|Drug|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
79333387|NCT05060913|Drug|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
79333388|NCT05060367|Dietary Supplement|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
79485199|NCT05101200|Other|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
79333389|NCT05060367|Dietary Supplement|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
79333390|NCT05059821|Biological|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
79333391|NCT05165251|Drug|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
79333392|NCT05165251|Drug|Amlodipine 5mg|amlodipine 5mg QD
79333393|NCT05165251|Other|Lifestyle intervention|Lifestyle intervention
79333394|NCT04209075|Dietary Supplement|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
79333395|NCT04209075|Drug|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
79333396|NCT04209075|Dietary Supplement|Placebo|Placebo Comparator
79333397|NCT05151601|Dietary Supplement|Experimental|2 x sachets per day
79651215|NCT04640116|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
79811979|NCT00693641|Other|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
79333398|NCT05151601|Other|Placebo|2 x sachets per day
79333399|NCT04433221|Biological|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10^6~1x10^7 cells/kg via IV and vaccines 1-5x10^6 irradiated cells via subcutaneous injection
79333400|NCT05125939|Other|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
79333401|NCT03065101|Device|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
79485200|NCT05101200|Other|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
79651216|NCT04640116|Procedure|microwave ablation (MWA)|MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
79333402|NCT03065101|Other|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
79333403|NCT03065101|Device|Sliding Hip Screw|Sliding Hip Screw
79333404|NCT05023473|Procedure|Pericapsular nerve group block|patients will receive pericapsular nerve group block
79333405|NCT05023473|Drug|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
79333406|NCT03066661|Drug|Entrectinib|Open-label expanded access, capsules
79651217|NCT00242112|Procedure|MRI Prostate|
79333407|NCT05105503|Device|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
79333408|NCT05020977|Other|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
79333409|NCT03775629|Drug|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
79811980|NCT00659230|Drug|Nepicastat|100-800mg
79811981|NCT00659230|Drug|Placebo|100-800mg placebo
79333410|NCT03775629|Drug|Polmacoxib|Polmacoxib
79333411|NCT03775629|Drug|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
79651218|NCT00559546|Drug|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
79651219|NCT00218777|Behavioral|Comprehensive Behavioral Intervention for Tics|
79651220|NCT00559624|Drug|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
79651221|NCT04639921|Diagnostic Test|positive test followed by gluten-free diet|DBPCFC with gluten
79811982|NCT04133831|Other|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: [(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)] / [number of patients alive on waitlist at start of year]."
79333412|NCT04976205|Radiation|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
79333413|NCT01671319|Drug|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
79333414|NCT05055609|Drug|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
79485201|NCT02246478|Drug|TAS-205|"Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
79333415|NCT05019105|Drug|Placebo|Oral matching placebo
79333416|NCT05019105|Drug|ALKS 1140|Active oral dose of ALKS 1140
79485202|NCT02246478|Drug|Placebo|"Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
79485203|NCT02252016|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
79333417|NCT04933747|Drug|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
79485204|NCT02252016|Drug|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
79981108|NCT02463058|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
79981109|NCT01361724|Behavioral|Physical therapy|Physical therapy program for people with PD--one on one with a PT
79981110|NCT01361724|Behavioral|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
79333418|NCT04933747|Drug|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
79333419|NCT05018325|Procedure|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
79333420|NCT05018325|Procedure|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
79333421|NCT05018325|Procedure|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
79333422|NCT03064711|Diagnostic Test|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
79333423|NCT03064945|Device|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
79485205|NCT05066100|Other|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
79333424|NCT05016141|Behavioral|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
79333425|NCT03763305|Drug|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
79333426|NCT03763305|Drug|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
79333427|NCT03763305|Drug|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
79333428|NCT03763305|Drug|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
79811983|NCT04133831|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
79811984|NCT00792844|Dietary Supplement|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
79981111|NCT01361724|Behavioral|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
79981112|NCT01358448|Behavioral|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
79333429|NCT03763305|Drug|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
79333430|NCT03763305|Drug|Fentanyl|Fentanyl intravenous injection for anesthetic induction
79485206|NCT04784442|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
79981113|NCT01358448|Behavioral|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
79981114|NCT02462668|Procedure|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
79333431|NCT05054361|Diagnostic Test|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
79333432|NCT05054361|Diagnostic Test|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
79333433|NCT05054361|Diagnostic Test|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
79333434|NCT05054361|Procedure|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
79811985|NCT00792844|Dietary Supplement|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
79811986|NCT02615795|Device|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
79811987|NCT00809094|Drug|N-acetylcysteine (NAC)|
79811988|NCT00809094|Drug|Placebo|
79485207|NCT04784442|Drug|120mg of ETC-1002(bempedoic acid)|120mg, tablet, once daily, for 12 weeks
79811989|NCT00658996|Device|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
79811990|NCT00658996|Device|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
79981115|NCT02462668|Procedure|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
79981116|NCT02462668|Procedure|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
79485208|NCT04784442|Drug|60mg of ETC-1002(bempedoic acid)|60mg, tablet, once daily, for 12 weeks
79981117|NCT01333995|Behavioral|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
79485209|NCT04784442|Drug|Placebo|placebo, tablet, once daily, for 12 weeks
79651222|NCT04639921|Dietary Supplement|Placebo|Placebo
79651223|NCT00246207|Drug|CONCERTA (OROS methylphenidate hydrochloride)|
79651224|NCT04639882|Behavioral|Personalized normative feedback|Information presenting perceived and actual drinking norms.
79651225|NCT00218816|Behavioral|Nebulizer Education Intervention|Asthma Education
79651226|NCT00218816|Behavioral|Standard Asthma Education Groups|Asthma Education
79981118|NCT03620136|Drug|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
79485210|NCT02249832|Device|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
79485211|NCT02248974|Other|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
79651227|NCT04639804|Drug|Tegoprazan|Tegoprazan 50 mg tablet
79651228|NCT04639804|Drug|Naproxen|Naproxen 500 mg tablet
79651229|NCT04639804|Drug|Aceclofenac|Aceclofenac 100 mg tablet
79651230|NCT04639804|Drug|Celecoxib|Celecoxib 200 mg capsule
79651231|NCT00559663|Dietary Supplement|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
79485212|NCT02246166|Drug|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
79651232|NCT00559663|Dietary Supplement|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
79333435|NCT05054361|Diagnostic Test|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
79333436|NCT05054361|Diagnostic Test|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
79333437|NCT03066973|Behavioral|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
79333438|NCT05015283|Procedure|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter < 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
79651233|NCT04639570|Other|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
79333439|NCT05015283|Procedure|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size < 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter < 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
79333440|NCT03066583|Biological|trephination with placebo|trephination under US guidance and placebo injection
79333441|NCT03066583|Biological|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
79333442|NCT04972305|Other|Exercise and ergonomics|12 week exercise and fit bike
79333443|NCT04972305|Other|Ergonomics|Fit bike
79333444|NCT03064477|Behavioral|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
79333445|NCT03064477|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
79333448|NCT01670539|Device|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
79333449|NCT04431895|Drug|Tofacitinib 5 MG|tofacitinib 5 mg tablet administered twice a day for 6 months
79333450|NCT02516163|Device|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
79333451|NCT03064633|Drug|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
79485213|NCT02246166|Other|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
79485214|NCT02706847|Drug|Placebo|Tablet; Oral
79485215|NCT02706847|Drug|Upadacitinib|Tablet; Oral
79485216|NCT02245620|Drug|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
79485217|NCT02245620|Drug|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
79485218|NCT02244996|Dietary Supplement|Lycium Barbarum|Traditional Chinese Herbs
79485219|NCT02244996|Dietary Supplement|Placebo|Placebo
79333452|NCT03064633|Drug|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
79333453|NCT03064633|Drug|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
79485220|NCT02470741|Drug|Letrozole|
79485221|NCT02470741|Other|Placebo|
79485222|NCT02543437|Device|Trident Acetabular X3 Insert|
79485223|NCT02544607|Drug|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
79811991|NCT02615639|Biological|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells & Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
79981119|NCT03620136|Drug|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
79333454|NCT02589665|Drug|Mirikizumab|
79333455|NCT02589665|Drug|Placebo|
79333456|NCT01905397|Device|Conventional wound therapy|Sterile bandages and wound coverings
79485224|NCT02544607|Other|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
79485225|NCT02243280|Drug|ABT-493|Tablet
79485226|NCT02243280|Drug|ABT-530|Tablet
79485227|NCT02549365|Drug|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
79485228|NCT02549365|Procedure|Surveillance (nasal swabbing) during influenza season|
79485229|NCT00363571|Drug|GTN, Diamox|
79485230|NCT04744675|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
79485231|NCT04744675|Drug|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
79485232|NCT02471521|Other|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
79485233|NCT02471521|Drug|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
79485234|NCT02624479|Drug|Sodium thiosulfate|oral administration of thiosulfate
79485235|NCT02623075|Biological|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
79485236|NCT04341337|Other|interview|questionnaire about ethics in surgery
79485237|NCT02554435|Device|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
79811992|NCT02615639|Drug|Entecavir|0.5mg tablet every night by mouth
79333457|NCT01905397|Device|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
79333458|NCT05010603|Genetic|Blood Draw|Collection of blood samples for genetic testing
79333459|NCT05010603|Other|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
79651234|NCT04639687|Behavioral|Food as Medicine Delivery|12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
79333460|NCT04613843|Other|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
79333461|NCT04613843|Other|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
79333462|NCT04457453|Other|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
79333463|NCT04457453|Other|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
79333464|NCT04457453|Other|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
79333465|NCT04426409|Drug|tarivid ointment|Vaseline ointment is applied to both noses.
79333466|NCT04966923|Other|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
79651235|NCT00218855|Drug|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
79811993|NCT02615639|Drug|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells & IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
79811994|NCT02615639|Drug|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
79811995|NCT02615639|Drug|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells & Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
79811996|NCT02615639|Drug|Telbivudine|Telbivudine 600mg tablet every day by mouth
79333467|NCT04421157|Other|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
79811997|NCT00798616|Drug|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
79811998|NCT00798616|Drug|placebo|oral or IV placebo
79811999|NCT02618057|Drug|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
79812000|NCT02618057|Drug|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
79812001|NCT02617823|Procedure|lateral position|patients placed on their left side after epidural catheter insertion
79485238|NCT02554435|Behavioral|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
79651236|NCT00218855|Drug|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
79812002|NCT00867815|Drug|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
79812003|NCT04137029|Drug|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
79651237|NCT04639609|Other|Characterization of Neuromuscular Function and Fatigue|at inclusion
79333468|NCT04421157|Other|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
79485239|NCT02554435|Device|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
79651238|NCT04639726|Dietary Supplement|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
79651239|NCT04639726|Other|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
79333469|NCT04432753|Behavioral|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
79485240|NCT02555449|Drug|[¹⁴C]-LY3202626|Administered as solution by mouth
79485241|NCT02248818|Drug|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
79651240|NCT04639765|Other|CBT without Personalization|Intervention involves a video describing CBT without a message about personalization.
79651241|NCT04639765|Other|CBT with Personalization|Intervention involves a video describing CBT with a message about personalization.
79651242|NCT04639765|Other|ADM without Personalization|Intervention involves a video describing antidepressant medication without a message about personalization.
79651243|NCT04639765|Other|ADM with Personalization|Intervention involves a video describing antidepressant medication with a message about personalization.
79651244|NCT04639765|Other|Combined Treatment without Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
79651245|NCT04639765|Other|Combined Treatment with Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
79485242|NCT02248818|Drug|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
79485243|NCT02472223|Drug|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
79485244|NCT02472223|Drug|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
79812004|NCT04137029|Drug|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
79651246|NCT00218894|Procedure|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
79651247|NCT00246246|Drug|risperidone|
79651248|NCT04639375|Biological|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
79651249|NCT04639492|Dietary Supplement|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
79651250|NCT04639453|Diagnostic Test|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
79812005|NCT04137029|Diagnostic Test|metacholine test|The participants will receive inhalation of metacholine once
79812006|NCT00787774|Drug|resume raltegravir|resume raltegravir after 16 weeks of stopping
79812007|NCT00452413|Drug|enzastaurin|Administered orally
79812008|NCT00452413|Drug|erlotinib|Administered orally
79812009|NCT00793000|Drug|PF-04287881|75 mg oral dose (prepared solution) given once
79812010|NCT00793000|Drug|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
79812011|NCT00793000|Drug|PF-04287881|150 mg oral dose (prepared solution) given once
79812012|NCT00793000|Drug|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
79485245|NCT02596087|Other|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
79485246|NCT02247960|Drug|Ciprofloxacin|
79485247|NCT02472457|Other|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
79485248|NCT02472457|Other|Free Diet|This diet contains no restrictions.
79485249|NCT02473783|Drug|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
79485250|NCT02473783|Other|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
79485251|NCT02557555|Other|educational information|patients will receive pamphlet on labor analgesia options.
79485252|NCT02543749|Biological|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
79812013|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
79812014|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
79333470|NCT04432753|Behavioral|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
79333471|NCT05473793|Dietary Supplement|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (~3mm).
79333472|NCT05473793|Other|Placebo|The control arm receives a placebo consisting of rice puff particles.
79333473|NCT01362595|Drug|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
79485253|NCT02632526|Drug|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
79485254|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
79485255|NCT02632526|Drug|AZD5718 placebo oral suspension|Single and multiple doses
79485256|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
79812015|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
79812016|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
79812017|NCT00793000|Drug|PF-04287881|1000 mg oral dose (prepared solution) given once
79812018|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
79812019|NCT00793000|Drug|PF-04287881|1250 mg oral dose (prepared solution) given once
79812020|NCT00793000|Drug|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
79812021|NCT00793000|Drug|PF-04287881|1500 mg oral dose (prepared solution) given once
79812022|NCT00793000|Drug|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
79812023|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
79333474|NCT04421391|Dietary Supplement|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
79333475|NCT05556941|Behavioral|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
79333476|NCT05556941|Behavioral|Occupational therapy standard care|Occupational therapy standard care
79333477|NCT03064399|Procedure|without lateral ligament repairment|microfracture without repairment of the lateral ligament
79333478|NCT03064399|Procedure|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
79333479|NCT04948983|Other|Decision aid (DA) for breast cancer screening|The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
79333480|NCT04948983|Other|Standarised information for breast cancer screening|Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
79333481|NCT04426097|Procedure|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
79333482|NCT04426097|Procedure|Without Blockade|Without Blockade
79333483|NCT05556551|Other|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
79333484|NCT05556551|Other|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
79485257|NCT04740866|Radiation|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. ([50Gy in 25 fractions conventional fractionation including tumor bed & pelvic lymph nodes]
79485258|NCT04340414|Device|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
79485259|NCT02247804|Drug|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
79485260|NCT02247804|Drug|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
79333485|NCT04411173|Dietary Supplement|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
79333486|NCT05556317|Behavioral|Resistive exercise|advices and resistive exercise
79333487|NCT04411407|Device|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
79333488|NCT05556083|Drug|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
79333489|NCT05556083|Drug|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
79333490|NCT05556005|Drug|Trimetazidine Dihydrochloride|Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
79485261|NCT02247804|Other|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
79485262|NCT02247804|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
79333491|NCT05556005|Drug|Placebo|Starch tablets used twice daily
79333492|NCT04373603|Drug|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
79333493|NCT04373603|Other|Saline|sodium chloride and water for use as control
79333494|NCT04373603|Drug|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
79333495|NCT02519595|Drug|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
79333496|NCT02519595|Drug|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
79485263|NCT00366860|Behavioral|Soy bread|
79485264|NCT02635880|Device|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
79981120|NCT02462824|Behavioral|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
79333497|NCT02519595|Drug|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
79333498|NCT05610917|Combination Product|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
79333499|NCT05610917|Combination Product|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
79333500|NCT04278755|Drug|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
79333501|NCT04277975|Other|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
79333502|NCT04277975|Other|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
79981121|NCT01319448|Drug|Proguanil|Proguanil tablets, 1.5mg/kg/day
79333503|NCT04093349|Genetic|SPK-3006|adeno-associated viral (AAV) vector
79333504|NCT04062695|Drug|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
79333505|NCT04062695|Drug|Placebo oral tablet|tablets containing placebo
79333506|NCT05555927|Device|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
79333507|NCT04330235|Other|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
79485265|NCT04943822|Other|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
79485266|NCT00366938|Drug|Lumiracoxib|
79485267|NCT05026320|Drug|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
79485268|NCT05026320|Drug|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
79333508|NCT04330079|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
79333509|NCT04330079|Other|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
79333510|NCT05555693|Other|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
79485269|NCT05026320|Drug|Placebo gel|bid for 5 days (final application on morning of Day 6)
79485270|NCT00367328|Device|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
79812024|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
79812025|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
79981122|NCT01319448|Drug|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
79981123|NCT01319448|Drug|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
79981124|NCT01319526|Genetic|DNA analysis|
79333511|NCT00660673|Drug|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
79333512|NCT00660673|Device|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
79333513|NCT00660673|Device|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
79981125|NCT01319526|Genetic|RNA analysis|
79981126|NCT01319526|Other|laboratory biomarker analysis|
79981127|NCT03296878|Other|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
79981128|NCT03296878|Other|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
79981129|NCT04385121|Other|Questionnary|Family member's will answer the questionnaires by phone
79981130|NCT01365780|Procedure|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
79333514|NCT05612867|Dietary Supplement|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
79981131|NCT01319604|Device|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
79981132|NCT01319604|Device|Tonometer|Tonometric assessment of IOP
79981133|NCT02462434|Behavioral|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
79333515|NCT05473559|Procedure|Adductor canal block with Ipack block or selective tibial nerve block|Ultrasound guided
79333516|NCT05555459|Procedure|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
79812026|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
79981134|NCT01334073|Drug|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
79333517|NCT03816137|Biological|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
79333518|NCT03816137|Biological|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC-ConM SOSIP. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
79333519|NCT03816137|Biological|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
79333520|NCT03816137|Biological|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
79333521|NCT03816137|Biological|Mosaic SOSIPs|"Mosaic gp140 Env trimers designed to overcome the immunodominance of hypervariable regions of Env~The immunogen will be used at the dosage of 100 ug (3x33ug) and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle."
79333522|NCT03644381|Other|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
79333523|NCT05612711|Drug|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
79333524|NCT04807309|Drug|Danazol Pill|Danazol 200 mg orally twice a day
79333525|NCT04807309|Drug|Placebo|Placebo twice a day
79333526|NCT04744649|Drug|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40~60mg Bid，d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40~60mg Bid,d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
79333527|NCT04744649|Drug|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40~60mg Bid,d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
79981135|NCT05189574|Procedure|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
79981136|NCT03296722|Behavioral|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
79981137|NCT01358604|Genetic|polymerase chain reaction|
79981138|NCT01358604|Genetic|protein expression analysis|
79981139|NCT01358604|Genetic|western blotting|
79981140|NCT01358604|Other|flow cytometry|
79981141|NCT01358604|Other|immunohistochemistry staining method|
79981142|NCT01358604|Other|laboratory biomarker analysis|
79812027|NCT00793000|Drug|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
79981143|NCT02462590|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
79981144|NCT02462590|Drug|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
79333528|NCT04801225|Device|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
79333529|NCT05612633|Drug|zelavespib|Oral zelavespib 100 mg will be administered once daily
79333530|NCT04002661|Drug|Flibanserin|Flibanserin tablet
79333531|NCT04002661|Drug|Placebo|Oral Tablet
79333532|NCT05458583|Procedure|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
79812028|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
79812029|NCT05091450|Behavioral|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
79812030|NCT04134533|Other|Gross Motor Function Measurement|These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
79981145|NCT01361880|Behavioral|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
79333533|NCT05458583|Procedure|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
79333534|NCT05458583|Procedure|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
79333535|NCT05458583|Procedure|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
79333536|NCT03998605|Behavioral|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
79333537|NCT03998605|Behavioral|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
79333538|NCT04983277|Other|no intervention|no intervention
79333539|NCT03201575|Device|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
79333540|NCT03201575|Device|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
79333541|NCT04426955|Drug|Camrelizumab|IV infusion
79333542|NCT04426955|Drug|Paclitaxel|IV infusion
79981146|NCT01928199|Drug|Sitagliptin|
79333543|NCT04426955|Drug|Cisplatin|IV infusion
79333544|NCT04426955|Drug|Placebo|IV infusion
79333545|NCT04426955|Radiation|Radiation|Concurrent Radiation
79485271|NCT04840784|Drug|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
79485272|NCT02640716|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
79485273|NCT02640716|Behavioral|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
79333546|NCT02630563|Drug|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
79333547|NCT02630563|Drug|Cyclosporine|Cyclosporine will be administered as per center practice.
79333548|NCT02630563|Drug|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
79333549|NCT04982341|Procedure|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
79333550|NCT04432987|Drug|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
79333551|NCT05412329|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
79333552|NCT05555381|Behavioral|young-D program|"needs detection by means of survey and interviews (mixed-methods)~6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
79485274|NCT04068272|Drug|Bosentan|Eyedrop
79812031|NCT00798772|Dietary Supplement|Micronutrients and antioxidants|8 capsules twice daily for two years
79981147|NCT01928199|Drug|Placebo|
79333553|NCT05397743|Other|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
79333554|NCT05555225|Other|Methylome|Epigenetic study : analysis of DNA methylation
79333555|NCT05555147|Drug|nerve block with 0.5% ropivacaine|After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
79333556|NCT05555147|Other|without any nerve block|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
79333557|NCT02587247|Drug|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
79333558|NCT02555111|Drug|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
79333559|NCT02521415|Drug|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
79333560|NCT02521415|Drug|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
79333561|NCT02521415|Drug|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
79333562|NCT02461511|Other|Therapeutic Education|participation in a therapeutic education program on diabetes
79485275|NCT04068272|Drug|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
79485276|NCT02243202|Drug|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
79333563|NCT02078141|Drug|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
79333564|NCT02588339|Drug|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
79333565|NCT02588339|Drug|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
79333566|NCT02588339|Drug|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
79485277|NCT02243202|Drug|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
79485278|NCT02243202|Drug|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
79981148|NCT03713866|Diagnostic Test|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
79333567|NCT05554913|Drug|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
79333568|NCT05554913|Drug|Placebo|Placebo comparator
79333569|NCT05554757|Device|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
79333570|NCT05554757|Device|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
79333571|NCT05612321|Device|Vacuum application|vacuum-assisted delivery
79333572|NCT05317247|Diagnostic Test|Cough sounds|The investigators will discover a cough audio signature and then validate it.
79485279|NCT02243202|Drug|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
79485280|NCT02243046|Drug|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
79485281|NCT02243046|Drug|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
79812032|NCT00798772|Dietary Supplement|Multivitamins and minerals|8 capsules twice daily for two years
79981149|NCT03128892|Device|Oxygen Reserve Index - RD Lite Sensors|
79485282|NCT02243046|Drug|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
79485283|NCT04034810|Device|Intracranial aneurysm treated with Silk vista and silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
79333573|NCT05242601|Other||no intervention
79333574|NCT05554523|Device|Photoacoustic imaging|Photoacoustic imaging
79981150|NCT03296644|Device|Class II correction using PowerScope2|
79981151|NCT03296644|Device|Class II correction using Forsus|
79485284|NCT04016636|Other|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
79485285|NCT02207946|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79485286|NCT02207946|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79981152|NCT01845441|Drug|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
79485287|NCT03976076|Drug|JBPOS0101|JBPOS0101 (investigational product)
79485288|NCT04933500|Device|Whitacre spinal needle|25G Whitacre spinal needle
79485289|NCT05588726|Behavioral|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
79981153|NCT01845441|Drug|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
79981154|NCT01845441|Drug|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
79333575|NCT04426565|Behavioral|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
79333576|NCT04426565|Behavioral|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
79333577|NCT04426565|Behavioral|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
79485290|NCT05588726|Behavioral|Mindfulness|Once weekly coaching calls with advice on mindfulness
79485291|NCT04235036|Drug|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
79485292|NCT04235036|Drug|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
79485293|NCT03875300|Behavioral|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
79485294|NCT02560051|Drug|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
79485295|NCT02560051|Drug|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
79485296|NCT02560051|Drug|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
79485297|NCT02560051|Drug|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
79485298|NCT02560051|Drug|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
79485299|NCT03786770|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
79485300|NCT00367718|Drug|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
79485301|NCT02474407|Drug|diazepam nasal spray|
79981155|NCT03296488|Drug|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
79485302|NCT02474407|Drug|diazepam rectal gel|
79485303|NCT05588492|Drug|Rifamycin-containing regimen|Rifamycin-containing regimen
79485304|NCT05588492|Drug|Rifamycin-free regimen|Rifamycin-free regimen
79981156|NCT03296488|Drug|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
79981157|NCT01365858|Other|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
79333578|NCT04426565|Behavioral|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
79333579|NCT04328831|Biological|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
79333580|NCT05700851|Dietary Supplement|Immuno-nutrition supplement|Oral Impact® is a powdered oral nutritional supplement that contains a unique combination of ingredients with immuno-modulating properties, namely omega-3 fatty acids, arginine and nucleotides, as well as soluble fibre.
79333581|NCT05612165|Device|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(1000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
79333582|NCT05612165|Device|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
79333583|NCT05554055|Biological|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
79333584|NCT05558345|Behavioral|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
79333585|NCT05543291|Behavioral|renal function|levels of eGFR
79333586|NCT05553899|Radiation|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
79333587|NCT05553821|Other|Cold sand bag|A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
79333588|NCT05553821|Other|A sand bag|A sand bag
79333589|NCT05543135|Diagnostic Test|basic audiological evaluation|pure tone audiometry&immitancemetry
79333590|NCT05543057|Radiation|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
79333591|NCT05549375|Device|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
79333592|NCT05700617|Drug|1:1 Randomization to receive milrinone or dobutamine|Randomized to receive either inotropic agent: milrinone or dobutamine
79333593|NCT05700617|Drug|1:1 Randomization to receive dobutamine or milrinone|Randomized to receive either inotropic agent: milrinone or dobutamine
79333594|NCT05542979|Drug|HH-003 injection|HH-003 injection is administrated via I.V. infusion
79333595|NCT05542979|Drug|Placebo|Placebo is administrated via I.V. infusion
79333596|NCT05542745|Device|palatal and buccal retraction|comparison
79333597|NCT05553587|Drug|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: … Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
79333598|NCT04322747|Diagnostic Test|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
79333599|NCT02629159|Drug|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
79333600|NCT02629159|Drug|Adalimumab|Administered by subcutaneous injection once every other week
79333601|NCT02629159|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
79333602|NCT02629159|Drug|Upadacitinib|Tablets taken orally once a day
79333603|NCT05548829|Biological|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
79333604|NCT05553431|Device|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
79485305|NCT02475031|Device|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
79981158|NCT01365936|Drug|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
79981159|NCT01365936|Drug|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
79981160|NCT02462356|Procedure|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
79981161|NCT02462356|Procedure|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
79981162|NCT01331343|Device|Guardian RT Telemetered Glucose Monitoring System|
79981163|NCT01358838|Device|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
79333605|NCT05552885|Other|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
79333606|NCT04982263|Diagnostic Test|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
79333607|NCT05548673|Behavioral|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
79333608|NCT05548595|Dietary Supplement|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
79333609|NCT05548595|Other|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
79333610|NCT02628769|Drug|Solithromycin|
79485306|NCT02475031|Drug|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
79333611|NCT02628769|Drug|Placebo|
79333612|NCT05552807|Drug|SCT-I10A|Administered intravenously
79485307|NCT03777956|Drug|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
79485308|NCT03777956|Drug|Placebo|Identical placebo are given as capsules and taken orally twice a day.
79981164|NCT01334151|Drug|Insulin LISPRO|Single doses of: 0.15 U/kg
79981165|NCT01334151|Drug|recombinant human insulin|Single doses of: 0.15 U/kg
79981166|NCT01361958|Drug|NOMAC|
79981167|NCT03039686|Drug|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
79981168|NCT03039686|Drug|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
79981169|NCT03296410|Biological|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
79333613|NCT05552807|Drug|SCT200|Administered intravenously
79333614|NCT05552807|Drug|paclitaxel|Administered intravenously
79333615|NCT05552807|Drug|docetaxel|Administered intravenously
79485309|NCT02476357|Device|Harmonic scalpel|
79651251|NCT04639453|Diagnostic Test|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
79333616|NCT04432909|Diagnostic Test|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
79333617|NCT05552729|Drug|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
79333618|NCT05548049|Device|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
79333619|NCT05548049|Device|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
79333620|NCT05547971|Radiation|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
79333621|NCT03062527|Other|Dietary Intervention: Low vs. moderate glycemic index|
79333622|NCT05547893|Other|simulation|participating a simulated clinical ethical situation with simulation patients
79333623|NCT04981561|Drug|GATE-251|Single dose of GATE-251
79333624|NCT04981561|Drug|Placebo|Placebo
79333625|NCT02626819|Behavioral|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
79333626|NCT02626819|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
79485310|NCT02519491|Other|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
79485311|NCT02519491|Other|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
79485312|NCT02560753|Drug|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
79485313|NCT02481505|Drug|Chloroprocaine HCl 1%|Intrathecal Route
79485314|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
79333627|NCT05552651|Drug|Envafolimab|300mg,sc,d1,Q3W;
79333628|NCT05552651|Drug|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
79333629|NCT05552651|Drug|Carboplatin|AUC=5, iv,D1,Q3W
79485315|NCT02563093|Biological|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
79485316|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
79485317|NCT02563093|Biological|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
79485318|NCT02564029|Drug|PF-06372865|Single dose
79485319|NCT02564029|Drug|Placebo|Placebo for PF-06372865 and placebo for lorazepam
79485320|NCT02564029|Drug|Lorazepam|2 mg single oral dose
79485321|NCT05588336|Drug|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
79485322|NCT05588258|Other|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
79485323|NCT02564497|Biological|Process E Belatacept|
79485324|NCT02564497|Biological|Process C Belatacept|
79485325|NCT03957278|Device|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
79485326|NCT02565901|Drug|Carboplatin|Given IV
79485327|NCT02565901|Drug|Docetaxel|Given IV
79485328|NCT02565901|Other|Laboratory Biomarker Analysis|Correlative studies
79485329|NCT02565901|Drug|Sirolimus|Given PO
79333630|NCT05542199|Other|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
79333631|NCT05542199|Behavioral|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
79333632|NCT04981327|Drug|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
79333633|NCT05699837|Device|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
79333634|NCT05547815|Biological|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
79333635|NCT05541965|Other|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
79333636|NCT05547737|Drug|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
79485330|NCT03926624|Drug|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
79485331|NCT03926624|Drug|Cytarabine|cytosine arabinoside (ara-C)
79485332|NCT03926624|Drug|Azacitidine|Azacitidine
79981170|NCT03296410|Biological|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
79981171|NCT03296410|Biological|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
79981172|NCT03296410|Biological|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
79485333|NCT03926624|Drug|Decitabine|Decitabine
79333637|NCT05547659|Drug|Pregabalin 150mg|Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
79333638|NCT05547659|Drug|Acetaminophen 1 G Oral Tablet|Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
79333639|NCT05547659|Drug|Celecoxib 400Mg Oral Capsule|Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
79333640|NCT05552417|Other|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
79485334|NCT03926624|Drug|Mitoxantrone|Mitoxantrone
79485335|NCT03926624|Drug|Etoposide|Etoposide
79485336|NCT03926624|Drug|Fludarabine|Fludarabine
79485337|NCT03926624|Drug|Idarubicin|Idarubicin
79485338|NCT03926624|Drug|Venetoclax|Venetoclax
79485339|NCT03926624|Drug|Cladribine|Cladribine
79651252|NCT04639453|Diagnostic Test|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
79651253|NCT04639453|Diagnostic Test|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
79981173|NCT03296410|Biological|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
79981174|NCT05189184|Drug|Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin|Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
79651254|NCT04639453|Diagnostic Test|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
79981175|NCT04639089|Drug|platlet rich plasma on sternal healing post median sternotomy|"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery"
79981176|NCT03290872|Device|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
79333641|NCT04426175|Device|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
79333642|NCT05552105|Other|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
79333643|NCT05541575|Other|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
79333644|NCT05541419|Drug|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
79333645|NCT05541419|Drug|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
79333646|NCT05551637|Dietary Supplement|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
79333647|NCT05547035|Behavioral|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~assess the depression severity by using MADRS scale~assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
79333648|NCT02630251|Drug|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
79333649|NCT04321109|Other|Allograft|Corticocancellous mineralized allograft
79333650|NCT04321109|Other|Collagen cone|Collagen matrix
79333651|NCT05551559|Procedure|bariatric surgery|bariatric surgery
79485340|NCT02566135|Device|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
79981177|NCT03290872|Device|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
79981178|NCT01362036|Drug|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
79981179|NCT03589300|Device|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
79981180|NCT01366170|Genetic|microarray analysis|
79981181|NCT01366170|Genetic|protein expression analysis|
79981182|NCT01366170|Genetic|western blotting|
79981183|NCT01366170|Other|flow cytometry|
79981184|NCT01366170|Other|immunohistochemistry staining method|
79981185|NCT01366170|Other|laboratory biomarker analysis|
79981186|NCT01366170|Other|mass spectrometry|
79651255|NCT04639453|Diagnostic Test|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
79651256|NCT00242190|Drug|oxaliplatin|
79651257|NCT00242190|Drug|gemcitabine|
79651258|NCT00242190|Procedure|radiation therapy|
79651259|NCT00218933|Behavioral|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
79981187|NCT04613661|Other|Australian Spasticity Assessment Scale|Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity
79981188|NCT01358916|Other|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
79981189|NCT05288504|Drug|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
79981190|NCT05288504|Drug|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
79981191|NCT01362114|Drug|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
79485341|NCT02566135|Device|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
79485342|NCT03565640|Device|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
79485343|NCT03565640|Device|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
79651260|NCT00218933|Behavioral|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
79333652|NCT05541263|Behavioral|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
79333653|NCT04980937|Procedure|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
79333654|NCT03063229|Device|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
79333655|NCT03063229|Other|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
79333656|NCT03063229|Procedure|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
79333657|NCT03063229|Device|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
79333658|NCT03063229|Procedure|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
79333659|NCT03063229|Other|Food Diary|Participants will keep a 7 day weighed food diary.
79333660|NCT03063229|Device|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
79333661|NCT03063229|Other|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
79333662|NCT03063229|Procedure|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
79333663|NCT03063229|Procedure|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
79333664|NCT03063229|Drug|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
79333665|NCT03063229|Drug|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
79485344|NCT05588024|Device|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
79485345|NCT04744441|Procedure|CHOLECYSTECTOMY|Surgical treatment
79485346|NCT04744441|Procedure|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
79485347|NCT04744441|Procedure|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
79651261|NCT04638985|Biological|sIPV+DTaP+MMR|sIPV+DTaP+MMR at the age of 18 month old
79333666|NCT05541185|Biological|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
79333667|NCT05541185|Biological|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
79333668|NCT05541185|Biological|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
79333669|NCT02518113|Drug|LY3039478|Administered orally
79333670|NCT02518113|Drug|Dexamethasone|Administered orally
79333671|NCT02518113|Drug|Placebo|Administered orally
79333672|NCT05541107|Drug|MAT2203|oral lipid nanocrystal amphotericin B
79333673|NCT05541107|Drug|Amphotericin B|Intravenous Amphotericin B
79333674|NCT03062839|Drug|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
79333675|NCT05540951|Drug|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
79333676|NCT05540951|Drug|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
79333677|NCT03062293|Device|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
79333678|NCT05540639|Behavioral|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
79333679|NCT04981093|Drug|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
79485348|NCT04744597|Behavioral|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
79485349|NCT04744597|Behavioral|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
79651262|NCT04638985|Biological|sIPV|sIPV at the age of 18 month old
79651263|NCT04638985|Biological|DTaP|DTaP at the age of 18 month old
79651264|NCT04638985|Biological|MMR|MMR at the age of 18 month old
79485350|NCT04744597|Behavioral|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
79485351|NCT03551210|Drug|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
79485352|NCT03551210|Drug|Nemonoxacin|Capsules, 250 mg
79485353|NCT03551210|Drug|Tavanic|Solution for infusion, 500 mg (100 ml)
79485354|NCT03551210|Drug|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
79651265|NCT04638907|Procedure|Assessment of NM block|Observation of resulting course of NM block under teratment and monitoring as described.
79812033|NCT00867503|Drug|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
79485355|NCT03551210|Drug|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
79485356|NCT03551210|Drug|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
79485357|NCT02482675|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
79485358|NCT02482675|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
79485359|NCT02482675|Other|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
79485360|NCT02482675|Other|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
79485361|NCT04339088|Other|Questionnaires|Questionnaires to assess quality of life
79485362|NCT00364195|Drug|Tesmilifene (YMB1002)|
79485363|NCT03466424|Radiation|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
79485364|NCT02566369|Drug|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
79485365|NCT02566369|Drug|Placebo cream|Placebo cream applied once daily for 12 weeks
79485366|NCT05587790|Behavioral|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
79651266|NCT04709718|Procedure|hepatectomy|liver resection taking over the liver hemangioma
79651267|NCT00412295|Device|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
79651268|NCT04628884|Drug|Conventional dose|Conventional dose used to calculated the protamine dose
79812034|NCT05055648|Radiation|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
79812035|NCT05055648|Radiation|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
79651269|NCT04628884|Drug|Dosing according residual heparin|In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
79651270|NCT04629157|Device|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
79333680|NCT04981093|Drug|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
79333681|NCT05699681|Diagnostic Test|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~Apical four chamber (A4C) view~Apical two chamber view (A2C) view~Right ventricle (RV) focused A4C view~Right ventricular systolic pressure (RVSP)~Pulmonary arterial acceleration time (PAAT),~Tricuspid annular plane systolic excursion (TAPSE),~Tricuspid annular plane systolic velocity (s'),~Right ventricular fractional area change (RV FAC)~RV free wall strain,~RV myocardial performance index (MPI),~RV isovolumic relaxation time (IVRT),~RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
79333682|NCT05004831|Drug|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
79333683|NCT05546489|Behavioral|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
79333684|NCT04981015|Diagnostic Test|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
79651271|NCT00561262|Other|questionnaire administration|
79812036|NCT04134299|Dietary Supplement|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
79812037|NCT00793156|Drug|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
79981192|NCT01362114|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
79981193|NCT03296254|Behavioral|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
79333685|NCT05551247|Drug|Envafolimab|300mg,sc,d3,Q3W;
79333686|NCT05551247|Drug|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
79333687|NCT05540561|Other|blood collection|Biological analyses in the framework of care with conservation of blood samples
79333688|NCT05540483|Drug|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
79812038|NCT00793156|Drug|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
79812039|NCT00793156|Other|Placebo|Placebo daily dose
79981194|NCT03296254|Behavioral|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
79333689|NCT05002257|Other|music therapy|Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
79333690|NCT05002257|Other|No music therapy|Usual care
79333691|NCT05546255|Drug|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
79485367|NCT02569411|Other|Financial Incentive|money
79651272|NCT00561262|Procedure|high-intensity focused ultrasound ablation|
79651273|NCT00561262|Procedure|quality-of-life assessment|
79651274|NCT00561301|Drug|GemDOx|gemcitabine oxliplatin
79651275|NCT00412334|Drug|Copegus|1200-1600mg/day po
79651276|NCT00412334|Drug|Copegus|1000-1200mg/day po
79981195|NCT03735290|Biological|ilixadencel|Intra-tumoral injection
79981196|NCT03735290|Drug|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
79981197|NCT01359072|Other|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
79981198|NCT03290716|Other|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
79812040|NCT04132739|Behavioral|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
79333692|NCT05546255|Drug|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
79333693|NCT05001477|Device|TULSA Procedure|Transurethral ultrasound ablation procedure
79333694|NCT05546177|Other|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
79333695|NCT05546177|Other|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
79333696|NCT05551091|Dietary Supplement|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
79333697|NCT02629861|Drug|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
79333698|NCT02629861|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
79333699|NCT05540249|Dietary Supplement|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
79333700|NCT05461287|Drug|QLS31904|QLS31904 ONLY
79485368|NCT04743427|Other|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
79485369|NCT04743427|Device|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
79485370|NCT02569723|Drug|Carbon C 14 Oxaliplatin|Intravenous infusion
79485371|NCT02569723|Drug|Oxaliplatin|Intravenous infusion
79651277|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
79812041|NCT04132739|Behavioral|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
79651278|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
79651279|NCT00561379|Drug|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
79651280|NCT00561379|Drug|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
79651281|NCT04629118|Device|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
79812042|NCT04132739|Behavioral|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
79812043|NCT00798850|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull & East Yorshire Yospitals NHS Trust.
79981199|NCT03290716|Other|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
79981200|NCT04702152|Behavioral|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
79651282|NCT00242229|Drug|DVS-233 SR|
79651283|NCT00561496|Drug|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
79651284|NCT00218972|Behavioral|Aerobic interval training|
79651285|NCT00218972|Behavioral|moderate intensity training|
79651286|NCT00218972|Behavioral|Recommendation of regular exercise|
79651287|NCT00561535|Dietary Supplement|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
79651288|NCT00561535|Dietary Supplement|placebo (starch)|Once daily
79651289|NCT03454672|Device|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
79333701|NCT05546021|Procedure|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
79485372|NCT02570425|Device|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
79333702|NCT04958733|Procedure|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
79981201|NCT04669704|Other|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
79981202|NCT04669704|Other|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
79981203|NCT03296176|Biological|blood sample|blood sample for metabolome analyse
79981204|NCT03619538|Drug|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
79981205|NCT03619538|Other|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
79981206|NCT03290638|Procedure|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
79981207|NCT05188950|Device|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
79981208|NCT03296098|Drug|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
79981209|NCT01366326|Drug|Methylnaltrexone bromide|Subcutaneous MNTX
79333703|NCT04958733|Procedure|Absence of autologous bone grafting|Donor sites will be left unfilled
79333704|NCT05540015|Procedure|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
79485373|NCT02570425|Device|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
79981210|NCT01822275|Drug|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
79485374|NCT02571439|Procedure|Surgical TAP block|surgeon administered TAP block
79485375|NCT02571439|Procedure|Conventional TAP block|Anesthesiologist administered TAP block
79485376|NCT02571439|Drug|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
79981211|NCT01822275|Radiation|Radiation therapy|
79981212|NCT03296020|Other|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
79981213|NCT03295942|Drug|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
79981214|NCT04631796|Device|Lehfilcon A contact lenses|Silicone hydrogel contact lenses with investigational coating
79981215|NCT04631796|Device|Multipurpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
79981216|NCT05655026|Device|NIV, HFNO|Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
79333705|NCT05540015|Procedure|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
79485377|NCT02573857|Drug|DSM265|Oral suspension from bulk powder
79485378|NCT02573857|Drug|OZ439|Oral suspension from powder in a bottle
79485379|NCT02576041|Drug|Bilastine|Bilastine tablets once a day for 7+3 days
79485380|NCT02576041|Drug|Placebo|Placebo tablets once a day during 7+3 days run in period
79485381|NCT02576899|Behavioral|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
79485382|NCT02576899|Behavioral|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
79485383|NCT03678428|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
79485384|NCT03678428|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
79485385|NCT03678428|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
79651290|NCT03454672|Device|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
79981217|NCT03290482|Diagnostic Test|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
79981218|NCT03290482|Device|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
79485386|NCT03678428|Drug|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
79485387|NCT03678428|Drug|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
79485388|NCT03678428|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
79485389|NCT02577601|Drug|Ulipristal Acetate|
79485390|NCT02577601|Drug|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
79485391|NCT02577991|Drug|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
79485392|NCT02577991|Drug|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
79485393|NCT05024227|Behavioral|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
79651291|NCT00246285|Drug|risperidone|
79651292|NCT00219011|Drug|aliskiren|
79651293|NCT03454633|Procedure|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
79651294|NCT04628923|Other|QUADRATUS LUMBORUM BLOCK|QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
79651295|NCT04628611|Device|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
79651296|NCT04628611|Device|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
79651297|NCT00242268|Drug|Simvastatin|
79485394|NCT04956133|Behavioral|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
79485395|NCT04847167|Procedure|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
79333706|NCT05545709|Procedure|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
79485396|NCT02207634|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
79485397|NCT02207634|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
79485398|NCT02207634|Drug|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
79485399|NCT04712383|Combination Product|Fitbit Care intervention arm|Entire suite of Fitbit Care.
79333707|NCT05545631|Other|no intervention|no intervention in this study
79485400|NCT02485561|Behavioral|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
79485401|NCT02485561|Behavioral|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
79485402|NCT00364039|Drug|AV650|
79485403|NCT02486263|Other|Study Arm - acid suppression plus feeding bundle|"Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~Total fluid volume restriction (120-140 milliliters/kilogram/day)~Feeding duration over 30 minutes~Infant feeds with right side down~Infant is placed on back following feeds"
79485404|NCT02486263|Other|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
79485405|NCT00422149|Drug|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
79485406|NCT00422149|Drug|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
79485407|NCT00422149|Drug|Placebo treatment|Placebo treatment
79981219|NCT03290482|Diagnostic Test|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
79981220|NCT01331421|Drug|exemestane|25 mg tablet
79981221|NCT04625478|Other|Patients having had an osteo-articular infection with Stahylococcus|Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
79333708|NCT02482935|Drug|Abemaciclib|Administered orally
79981222|NCT01656434|Drug|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
79981223|NCT01656434|Drug|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
79333709|NCT05551013|Drug|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~Progression post TMZ (will receive APG-157 only)~Ongoing Optune (will receive concurrent Optune + APG-157)~Progression post Optune (will receive APG-157 only)"
79333710|NCT02513823|Dietary Supplement|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
79485408|NCT03452228|Drug|evinacumab|Administered by Intravenous (IV)
79485409|NCT03452228|Drug|Placebo|Administered by Intravenous (IV)
79485410|NCT02974231|Radiation|Intensity-modulated radiation therapy|
79485411|NCT04341727|Drug|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
79485412|NCT04341727|Drug|Azithromycin|Antibiotic
79485413|NCT04341727|Drug|Chloroquine Sulfate|Antimalarial
79485414|NCT04320901|Device|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
79485415|NCT04320901|Device|Harmonic|Harmonic ACE 7+
79485416|NCT04272385|Other|Observational|Observational
79981224|NCT01656434|Other|Placebo|tablet
79981225|NCT01656434|Drug|ethinylestradiol (EE)|EE 10 μg tablet
79981226|NCT01656434|Drug|ferrous fumarate|ferrous fumarate 75 mg tablet
79333711|NCT04980859|Drug|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
79485417|NCT04247737|Other|gluten free diet|Participants keep a gluten free diet for six weeks
79485418|NCT03437018|Other|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
79333712|NCT04432519|Procedure|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
79485419|NCT04244227|Device|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
79485420|NCT04340102|Behavioral|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
79485421|NCT00367094|Drug|Benazepril plus hydrochlorothiazide|
79981227|NCT01319214|Drug|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
79981228|NCT01331499|Device|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
79333713|NCT05545475|Drug|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
79981229|NCT01331499|Procedure|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
79981230|NCT01359228|Drug|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
79981231|NCT01359228|Drug|Placebo|Placebo 1 tablet three times a day for 14 days.
79333714|NCT05539703|Other|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
79333715|NCT02513745|Device|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
79333716|NCT02513745|Device|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
79485422|NCT02581111|Drug|Naloxone|Naloxone 8-mg IV bolus
79485423|NCT02581111|Drug|Normal saline|
79981232|NCT01334307|Device|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
79981233|NCT01334307|Device|Control|Standard of Care
79981234|NCT02931396|Device|FES|
79333717|NCT05545397|Drug|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
79333718|NCT05545397|Device|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
79981235|NCT03607058|Other|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
79981236|NCT03607058|Other|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
79981237|NCT01366482|Device|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
79981238|NCT01366482|Device|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
79485424|NCT05587400|Behavioral|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
79485425|NCT05587400|Drug|dobutamine test|infusion dobutamine
79485426|NCT05587400|Drug|inhaled nitric oxide|nitric oxide inhalation
79485427|NCT04339868|Drug|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
79485428|NCT04339868|Drug|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
79485429|NCT00367172|Behavioral|Directly Administered Antiretroviral Therapy|
79485430|NCT05585216|Drug|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
79981239|NCT01366482|Device|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
79485431|NCT03334526|Other|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
79485432|NCT03334526|Other|mental training|The task to imagine for the training group will be an abduction of the thumb
79485433|NCT03334526|Other|electrical stimulation|electrical stimulation of the muscles
79981240|NCT01366560|Drug|Active|GSK962040 125mg
79333719|NCT04952727|Biological|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
79333720|NCT04952727|Biological|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
79333721|NCT05539625|Dietary Supplement|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
79333722|NCT05539625|Other|Placebo|Placebo
79485434|NCT00367250|Drug|Cetuximab|weekly i.v.
79485435|NCT00367250|Drug|Trastuzumab|weekly i.v.
79485436|NCT02489227|Drug|CHS-1420|
79485437|NCT02489227|Drug|Adalimumab|
79485438|NCT02490631|Drug|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
79485439|NCT02207556|Drug|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~Patient has completed 1 year of doxycycline therapy~Patient develops any grade 3-4 toxicity related to doxycycline use."
79485440|NCT03732638|Drug|Rimegepant|Rimegepant 75 mg tablet EOD
79485441|NCT03732638|Drug|Placebo|Placebo tablet to match rimegepant tablet EOD
79485442|NCT02572609|Drug|Ambroxol hydrochloride soft pastille|
79981241|NCT01366560|Drug|Placebo|Matching Placebo
79981242|NCT05172128|Dietary Supplement|lyophilized blueberry supplement|lyophilized blueberry supplement bid
79485443|NCT02572609|Drug|Mucosolvan ® adult syrup|
79485444|NCT02587117|Drug|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
79485445|NCT02587117|Drug|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
79485446|NCT03266588|Drug|Rimegepant|75 mg oral tablet
79485447|NCT02587351|Drug|Metoprolol succinate|Extended release Metoprolol succinate
79485448|NCT02587351|Other|Placebo|Matching placebo
79485449|NCT00364117|Behavioral|Timely Discharge (Remote Presence Technology)|
79485450|NCT05249491|Diagnostic Test|Microbiological evaluation of dental plaques with children with or without black tooth stain|Evaluation of the etiological factors of black tooth stain according to the questionnaire
79485451|NCT05538338|Other|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
79981243|NCT02461030|Drug|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
79981244|NCT02461030|Drug|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
79333723|NCT05539547|Device|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: >50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
79981245|NCT02461030|Procedure|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
79485452|NCT05538338|Other|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
79485453|NCT05249413|Procedure|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
79485454|NCT05249335|Drug|OST|The subject will receive Orafang for colonoscopy
79651298|NCT04628845|Device|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
79485455|NCT05249335|Drug|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
79651299|NCT04628845|Device|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
79651300|NCT04628806|Diagnostic Test|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
79651301|NCT04628689|Other|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
79981246|NCT03295864|Diagnostic Test|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
79485456|NCT00422396|Drug|Fenofibrate (drug)|
79651302|NCT04628455|Device|Inversion and snaring|"Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B [midway between umbilicus and symphysis pubis] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's [Point C] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port."
79981247|NCT03295864|Diagnostic Test|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
79651303|NCT00246363|Drug|Silymarin|Silymarin (milk thistle)
79651304|NCT00246363|Drug|Placebo|Placebo
79651305|NCT00219050|Drug|aliskiren|
79651306|NCT04628533|Behavioral|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
79981248|NCT01599494|Drug|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
79333724|NCT05539547|Other|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
79485457|NCT04034797|Other|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
79485458|NCT04034797|Other|No photo|Usual management without photography teletransmission
79485459|NCT03992209|Other|Standard care|Usual operating room practice
79333725|NCT05545241|Behavioral|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
79485460|NCT03992209|Other|Protocolized care|Hand washing per protocol
79485461|NCT03704701|Diagnostic Test|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
79485462|NCT00364273|Drug|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
79485463|NCT00364273|Drug|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
79333726|NCT05545241|Behavioral|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
79485464|NCT00364273|Drug|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
79485465|NCT02495467|Drug|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
79485466|NCT02495467|Drug|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
79485467|NCT03432247|Behavioral|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
79485468|NCT03432247|Behavioral|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
79981249|NCT01599494|Drug|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
79485469|NCT05249179|Other|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
79485470|NCT05249179|Other|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
79485471|NCT05249023|Other|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
79981250|NCT01599494|Drug|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
79981251|NCT01599494|Drug|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
79333727|NCT05539235|Drug|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
79333728|NCT04940403|Device|Burt|18 one-hour sessions of unimanual upper-limb tasks during robot-assisted training with the Burt.
79333729|NCT04940403|Device|Burt + BurtVision|18 one-hour sessions of combination of unimanual and bimanual upper-limb tasks during robot-assisted training with the BurtVision.
79333730|NCT05545163|Device|I-gel with standard insertion technique|"Standard I-gel insertion technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down the manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate. Then I-gel slided downwards and backwards along hard palate with a continuous but gentle push until a definitive resistance is felt)~Modified jaw thrust technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate with gently advancing into oropharynx. Then after, I-gel left in oral cavity and both hands used to thrust jaw by lifting angle of mandible with little fingers and other fingers to stabilise jaw. And, at this point, both hand's thumbs used to apply balance force from I-gel stem head towards final placement position by looking at integral bite block mark at incisor teeth level)"
79333731|NCT04433143|Drug|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
79333732|NCT02477553|Behavioral|DA - Quantitative|
79333733|NCT02477553|Behavioral|DA - Verbal|
79333734|NCT01665911|Drug|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
79485472|NCT04743037|Behavioral|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
79812044|NCT00798850|Procedure|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~Station 2-Exercise bicycles~Station 3-Knee extensions with weights(2kg beanbag)~Station 4-Heel raises~Station 5-Knee bends(Alternating legs after 10 bends)~Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
79333735|NCT01665911|Drug|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
79333736|NCT01665911|Drug|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
79333737|NCT01665911|Drug|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
79333738|NCT01665911|Other|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
79333739|NCT03063073|Drug|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection [Precedex]
79333740|NCT03063073|Drug|Bupivacaine|
79485473|NCT02495623|Drug|SYN-010 21 mg|
79485474|NCT02495623|Drug|SYN-010 42 mg|
79485475|NCT02495623|Drug|Placebo|
79651307|NCT04628533|Behavioral|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
79651308|NCT04628299|Other|Sham Laser|Sham Laser in plantar fascia
79651309|NCT04628299|Other|Myofascial Induction|Myofascial Induction in plantar fascia
79485476|NCT05248087|Device|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
79485477|NCT05248087|Device|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
79485478|NCT02495779|Drug|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
79485479|NCT02495779|Behavioral|CBT-based counseling|Brief CBT-based counseling to promote adherence
79333741|NCT02452359|Device|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
79333742|NCT04620733|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
79333743|NCT04620733|Drug|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
79485480|NCT02502019|Device|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
79485481|NCT05247931|Diagnostic Test|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
79651310|NCT04628221|Device|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
79651311|NCT00219089|Drug|aliskiren|
79651312|NCT00246402|Drug|Acipimox|
79812045|NCT00798850|Procedure|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
79812046|NCT05757726|Device|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
79651313|NCT00561613|Other|SILCS and lubricant|
79651314|NCT00561613|Other|SILCS and spermicide|
79981252|NCT01599494|Drug|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
79981253|NCT03295786|Drug|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
79981254|NCT03295786|Device|Renishaw Drug Delivery System|Stereotactically implanted device
79981255|NCT05268302|Biological|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
79651315|NCT00561691|Drug|nimotuzumab|monoclonal antibody
79981256|NCT05268302|Biological|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose|Medium dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
79981257|NCT05268302|Biological|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose|High dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
79333744|NCT04620733|Drug|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
79333745|NCT05538923|Other|No intervention was given to the patients|This study was an observational epidemiological study.
79485482|NCT05247775|Procedure|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
79651316|NCT00561769|Drug|Norditropin pen|12 IU per day
79651317|NCT00242307|Drug|Roflumilast|
79651318|NCT00219128|Drug|aliskiren|
79981258|NCT02462278|Device|TempuRing|
79485483|NCT02828839|Procedure|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
79485484|NCT05217277|Diagnostic Test|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
79485485|NCT05216497|Drug|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
79485486|NCT05216497|Drug|Placebo|1-2 capsules for 7 days on top of standard therapy
79981259|NCT03198052|Biological|CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR|CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
79981260|NCT03194932|Drug|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
79981261|NCT03194932|Drug|Cytarabine|Given intravenously (IV) or intrathecally (IT).
79981262|NCT03194932|Drug|Idarubicin|Given IV.
79485487|NCT02502487|Procedure|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
79651319|NCT04628143|Drug|Nafamostat Mesilate|Administered intravenously as a continuous infusion
79651320|NCT04627792|Behavioral|IUSECAMH Parent Intervention (Waitlist)|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
79651321|NCT04627987|Diagnostic Test|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
79651322|NCT04627987|Diagnostic Test|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
79651323|NCT04627987|Procedure|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
79651324|NCT04627987|Diagnostic Test|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
79651325|NCT04627987|Diagnostic Test|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
79651326|NCT00219167|Drug|aliskiren|
79333746|NCT05544851|Other|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
79333747|NCT05550155|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment|a 4-month maintenance procedure of active rTMS
79651327|NCT04627909|Other|Robot|The patient interacts with a robot
79333748|NCT05550155|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|a 4-month maintenance procedure of sham rTMS
79333749|NCT04429009|Device|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
79333750|NCT04429009|Device|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
79485488|NCT02502487|Drug|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
79485489|NCT02502487|Drug|Tetracaine|1% Tetracaine gel instilled into urethra
79812047|NCT02613104|Other|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
79812048|NCT02613104|Other|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
79812049|NCT02613104|Other|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
79981263|NCT03194932|Drug|Intrathecal Triple Therapy|Given IT.
79485490|NCT05473832|Other|Day Cream cosmetic product compared to untreated side|Applied once daily in the morning
79981264|NCT03194932|Drug|Azacitidine|Given IV.
79981265|NCT03144388|Procedure|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
79981266|NCT03144388|Procedure|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
79333751|NCT02476617|Drug|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
79333752|NCT02476617|Drug|dasabuvir|dasabuvir tablets
79333753|NCT02476617|Drug|ribavirin|ribavirin tablets
79333754|NCT05550077|Diagnostic Test|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
79485491|NCT05473832|Other|Night cream cosmetic product compared to untreated side|Applied once daily in the evening
79485492|NCT05473832|Other|Eye cream cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening around the eye area
79651328|NCT04627909|Other|Medical Personnel|The patient interacts with medical personnel
79651329|NCT04627909|Other|Caregiver|The patient interacts with the caregiver
79333755|NCT05550077|Procedure|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
79333756|NCT05538845|Device|Screw fixation|Screw fixation to patients
79485493|NCT05473832|Other|Serum cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening
79651330|NCT04627519|Dietary Supplement|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
79651331|NCT04627636|Other|Myofascial trigger points pressure (MTrP) release|Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
79333757|NCT05538845|Device|Suture button|Suture button for patients
79333758|NCT05699213|Diagnostic Test|Lung MRI|MRI of the lung
79333759|NCT05699213|Diagnostic Test|Blood Draw|Blood Draw
79333760|NCT05535725|Drug|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
79333761|NCT03062137|Diagnostic Test|blood gas sampling|
79333762|NCT05698355|Other|Telerehabilitation Treatment|Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
79333763|NCT04980235|Diagnostic Test|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
79333764|NCT05535647|Drug|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
79333765|NCT05535647|Drug|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
79333766|NCT03064321|Behavioral|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
79333767|NCT03064321|Other|Information Control|Information on websites that are general health promoting
79333768|NCT05535569|Drug|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
79333769|NCT04980079|Procedure|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
79333770|NCT04980079|Procedure|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
79333771|NCT05538455|Device|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
79333772|NCT04980313|Device|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
79333773|NCT04980313|Device|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
79333774|NCT05544539|Drug|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
79333775|NCT05544539|Drug|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
79485494|NCT02632045|Drug|LEE-011|600 mg capsule (3x 200 mg capsules)
79485495|NCT02632045|Drug|Fulvestrant|500 mg injection
79485496|NCT02632045|Drug|Placebo|600 mg capsule (3x 200 mg capsules)
79485497|NCT02503735|Drug|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
79485498|NCT04001881|Other|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
79485499|NCT04001881|Drug|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
79333776|NCT04979689|Other|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
79333777|NCT04979689|Other|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
79333778|NCT05538377|Other|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
79333779|NCT05538377|Other|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
79485500|NCT03019640|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
79812050|NCT02613104|Other|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
79981267|NCT03290170|Procedure|Measured Resection|Bony landmarks are used to set femoral component rotation.
79981268|NCT03290170|Procedure|Gap Balancing|Relies on ligament releases prior to bone cuts.
79981269|NCT03037580|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
79981270|NCT03037580|Drug|Placebo|Placebo (sugar pill) for TID oral administration
79333780|NCT03822871|Drug|CTT1403|Escalating doses of 0.75 GBq - 13.5 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
79485501|NCT03019640|Drug|Carmustine|Given IV
79485502|NCT03019640|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
79485503|NCT03019640|Drug|Cytarabine|Given IV
79485504|NCT03019640|Drug|Etoposide|Given IV
79485505|NCT03019640|Biological|Filgrastim|Given SC
79485506|NCT03019640|Drug|Lenalidomide|Given PO
79485507|NCT03019640|Drug|Melphalan|Given IV
79981271|NCT03290092|Drug|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
79485508|NCT03019640|Biological|Rituximab|Given IV
79485509|NCT02456389|Other|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
79485510|NCT02456389|Other|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
79981272|NCT03290092|Drug|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
79981273|NCT03290014|Diagnostic Test|polysomnography|Monitoring of brain activity and respiratory variables during sleep
79485511|NCT02456389|Other|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
79485512|NCT02456389|Other|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
79485513|NCT02456389|Other|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
79812051|NCT02615561|Device|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
79981274|NCT03290014|Diagnostic Test|Actigraphy|monitoring daily physical activity for 7 days
79981275|NCT03290014|Diagnostic Test|Osler test|Evaluation of subjects´ ability to remain awake
79651332|NCT04627636|Other|Shockwave therapy application|The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
79981276|NCT03295708|Dietary Supplement|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
79333781|NCT03822871|Drug|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
79485514|NCT02456389|Other|Standard postoperative care|Routine postoperative care, as medically indicated
79485515|NCT02339779|Procedure|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
79485516|NCT02339779|Procedure|breast implant|"Implant-based reconstruction typically will occur as follows:~During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
79651333|NCT04627636|Other|conventional therapy|Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
79651334|NCT00242346|Drug|candesartan cilexetil|
79651335|NCT00219245|Drug|Rivastigmine|
79651336|NCT04627480|Device|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
79812052|NCT02615561|Other|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
79812053|NCT02615561|Other|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
79812054|NCT00799006|Drug|Placebo|Subjects will be given placebo or PF-04620110
79812055|NCT00799006|Drug|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
79981277|NCT03295708|Dietary Supplement|soybean oil capsule|placebo capsule
79812056|NCT00793234|Drug|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
79812057|NCT00793234|Drug|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
79333782|NCT03822871|Drug|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
79651337|NCT04627363|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
79651338|NCT04627363|Drug|Bevacizumab|15mg/kg intravenously every 3 weeks
79651339|NCT04627363|Drug|Toripalimab|240mg intravenously every 3 weeks
79651340|NCT04627207|Drug|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
79651341|NCT04627207|Drug|CKD-333 1 Tab|Other names: Test
79651342|NCT00219323|Drug|Omalizumab|
79981278|NCT05155826|Device|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
79981279|NCT05154734|Drug|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
79333783|NCT05544383|Behavioral|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
79333784|NCT05544383|Other|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
79485517|NCT02136901|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
79485518|NCT02136901|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
79485519|NCT02136901|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
79485520|NCT02136901|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
79485521|NCT00585338|Device|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
79485522|NCT00581204|Device|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
79812058|NCT04571112|Device|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
79485523|NCT02506309|Device|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
79485524|NCT02506309|Device|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
79485525|NCT00580892|Device|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
79485526|NCT00580736|Device|Optical Clearing|Optical Clearing
79333785|NCT04425551|Procedure|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
79812059|NCT04133597|Device|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
79333786|NCT05538299|Behavioral|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
79333787|NCT03064165|Drug|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
79333788|NCT03064165|Procedure|Sham block|Injection as for obturator nerve block, but with placebo
79333789|NCT03064165|Procedure|Obturator nerve block|Postoperative obturator nerve block
79333790|NCT03064165|Drug|Sodium Chloride 9mg/mL|Placebo
79485527|NCT02507011|Drug|Carvedilol|Beta-adrenergic receptor blocker
79485528|NCT02507011|Drug|Placebo|Placebo
79812060|NCT00697775|Biological|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
79812061|NCT00697775|Biological|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
79333791|NCT05544149|Radiation|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
79333792|NCT05535491|Other|Educational and Research Hospital|breathing exercise
79333793|NCT05535413|Drug|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
79333794|NCT03813199|Drug|ABX464 50mg|ABX464 is a new anti-inflammatory drug
79333795|NCT03813199|Drug|Matching Placebo|placebo matching with ABX464
79333796|NCT03813199|Drug|ABX464 100mg|ABX464 is a new anti-inflammatory drug
79333797|NCT03813199|Drug|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
79333798|NCT05537909|Other|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
79333799|NCT03064009|Other|Infection|This is an observational trial
79333800|NCT05699135|Drug|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
79333801|NCT03791593|Drug|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
79333802|NCT04732715|Behavioral|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
79651343|NCT00242424|Biological|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
79981280|NCT03289624|Behavioral|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG & PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, & ending with a review of material, addressing questions, & previewing the next session. Sessions titles are: Communication & Health Education; Care Values; Care Preferences; Family, Friends, & Community Resources; Taking care of yourself-taking care of each other; & Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values & preferences are supported when decisions have to be in the future."
79333803|NCT03064243|Drug|apatinib|apatinib 500mg po. qd.
79333804|NCT05537831|Device|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
79981281|NCT01183520|Dietary Supplement|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
79981282|NCT02978404|Drug|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
79333805|NCT05543993|Drug|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
79651344|NCT04627324|Device|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
79333806|NCT05698043|Drug|CKD-386(5)|Test
79333807|NCT05698043|Drug|D013, D326, D337|Reference
79333808|NCT04979845|Other|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
79333809|NCT04979845|Other|Video exercise|Patients will receive video instructions for home based exercises
79333810|NCT05699057|Behavioral|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
79333811|NCT03062215|Behavioral|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
79333812|NCT05543603|Drug|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
79981283|NCT02978404|Radiation|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
79981284|NCT04489186|Device|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
79333813|NCT05543603|Drug|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
79333814|NCT05543603|Drug|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
79333815|NCT05543603|Drug|Distilled water|15 ml distilled water, one minute rinse
79485529|NCT05379218|Device|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
79485530|NCT02977286|Drug|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
79485531|NCT02977286|Drug|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
79485532|NCT02977286|Drug|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
79651345|NCT04627324|Device|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
79651346|NCT04627402|Drug|Conbercept and TA|Intravitreous injection of Conbercept and TA
79981285|NCT04441918|Combination Product|JS016 (anti-SARS-CoV-2 monoclonal antibody)|JS016 (anti-SARS-CoV-2 monoclonal antibody)
79981286|NCT03289546|Behavioral|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
79981287|NCT03289546|Behavioral|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
79981288|NCT01331577|Behavioral|Cognitive Behavioural Training|Two day seminar
79981289|NCT01331577|Behavioral|Integrative Kinesiology Intervention|Two day seminar
79333816|NCT04979923|Drug|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
79333817|NCT05543525|Other|Echocardiography|Transthoracic echocardiography
79333818|NCT05543525|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
79333819|NCT04519411|Diagnostic Test|Transpulmonary pressure measurements|Transpulmonary pressure measurements
79651347|NCT04627402|Drug|Conbercept|Intravitreous injection of Conbercept
79651348|NCT04627051|Device|Atherectomy and balloon angioplasty|Atherectomy and balloon angioplasty of arterial-venous graft stenosis
79651349|NCT00219362|Biological|one injection of vCP1452 at W0, W4, W8 and W20|
79651350|NCT00219362|Biological|one injection of vCP1452 at W4, W8 and W20|
79651351|NCT00219362|Biological|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
79651352|NCT04626895|Device|Paxman Scalp Cooling Device|Paxman scalp cooling device
79651353|NCT04626817|Device|Isokinetic device (Biodex System 4)|The measurement of muscle strength with isokinetic device
79651354|NCT00246597|Drug|epoetin alfa|
79333820|NCT03714997|Procedure|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
79333821|NCT03706885|Drug|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
79333822|NCT01665599|Drug|Testosterone gel (FE 999303)|
79333823|NCT04979221|Drug|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
79333824|NCT04503109|Device|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
79981290|NCT04735718|Device|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
79333825|NCT05697887|Dietary Supplement|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
79333826|NCT01671085|Drug|LY3015014|Administered SQ
79485533|NCT02977286|Drug|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
79333827|NCT01671085|Drug|Placebo|Administered SQ
79333828|NCT05537363|Other|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
79333829|NCT05537363|Other|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
79333830|NCT05537363|Other|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
79333831|NCT03063931|Drug|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
79333832|NCT03063931|Drug|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
79333833|NCT03621631|Behavioral|Optimized Tai Chi intervention|Optimized Tai Chi intervention
79333834|NCT03621631|Behavioral|Traditional Tai Chi intervention|Traditional Tai Chi intervention
79333835|NCT03063775|Device|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
79651355|NCT04626739|Drug|CD19 CAR-T|CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
79651356|NCT04626739|Drug|CD22 CAR-T|CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
79651357|NCT04626739|Drug|CD19+CD22 CAR-T|CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
79981291|NCT03289468|Diagnostic Test|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
79333836|NCT03063775|Other|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
79333837|NCT03063775|Other|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
79651358|NCT04626739|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
79651359|NCT04626739|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
79333838|NCT03063775|Device|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
79333839|NCT03063541|Drug|Acetylsalicylic acid|100 mg daily as one tablet
79333840|NCT03063541|Other|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
79333841|NCT04978753|Drug|Anlotinib|"Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week;~Almonertinib: 110mg, orally once a day;"
79333842|NCT03545737|Other|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
79333843|NCT03545737|Other|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
79333844|NCT03063853|Other|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
79333845|NCT03063853|Procedure|Elective cesarean delivery|non emergent elective cesarean delivery
79333846|NCT03062761|Other|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
79333847|NCT03062761|Other|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
79333848|NCT03063151|Diagnostic Test|Surface Electromyography (EMG)|
79333849|NCT04978597|Drug|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
79333850|NCT04978597|Drug|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
79333851|NCT03490513|Drug|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
79333852|NCT03490513|Drug|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
79485534|NCT02977286|Drug|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
79333853|NCT03457675|Device|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
79333854|NCT03457675|Other|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
79485535|NCT02977286|Drug|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
79485536|NCT02977286|Drug|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
79485537|NCT02977286|Drug|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
79485538|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
79651360|NCT00219401|Biological|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
79651361|NCT04627129|Drug|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
79333855|NCT04977973|Behavioral|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
79333856|NCT04977973|Behavioral|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
79333857|NCT04977661|Drug|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
79651362|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
79651363|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
79651364|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
79333858|NCT04977661|Drug|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
79333859|NCT04977661|Drug|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
79333860|NCT04977895|Diagnostic Test|Minimal residual disease (MRD) monitoring|Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM
79333861|NCT04977427|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
79333862|NCT04977427|Drug|Prednisolone Acetate 1% Oph Susp|Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
79333863|NCT04977505|Device|pushlock|The surgery procedure was performed with pushlock for fixation
79333864|NCT04977505|Device|gryphon|The surgery procedure was performed with Gryphon for fixation
79333865|NCT03295123|Other|phone interview with the mother|it's a telephone survey about children's health
79333866|NCT03267043|Behavioral|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
79333867|NCT03267043|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
79333868|NCT04235257|Biological|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
79333869|NCT04977193|Biological|LY011|CAR-T
79333870|NCT04977115|Procedure|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
79333871|NCT04977115|Procedure|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
79333872|NCT04224415|Drug|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
79333873|NCT03217045|Other|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
79333874|NCT03061981|Drug|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
79333875|NCT03061981|Drug|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
79333876|NCT03061981|Drug|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
79333877|NCT02510001|Drug|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
79333878|NCT02510001|Drug|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
79333879|NCT02510001|Drug|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
79333880|NCT02452047|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
79333881|NCT02452047|Drug|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours
79333882|NCT02452047|Drug|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
79333883|NCT02452047|Drug|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
79333884|NCT02475369|Drug|pancrelipase|
79333885|NCT02474589|Drug|tecovirimat|Study is based on Animal Regulatory Rule
79333886|NCT02474589|Other|Placebo|Does not apply
79333887|NCT02586233|Drug|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
79333888|NCT02586233|Drug|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
79333889|NCT03936101|Diagnostic Test|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
79333890|NCT05592431|Device|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
79651365|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
79333891|NCT05592431|Device|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
79333892|NCT05537207|Device|low level laser therapy|low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2
79333893|NCT05537207|Other|non-steroidal drugs|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
79333894|NCT05537129|Procedure|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
79333895|NCT02474355|Procedure|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
79333896|NCT02474355|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
79333897|NCT02474355|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
79333898|NCT02474355|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
79333899|NCT02474355|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
79333900|NCT02474199|Biological|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
79333901|NCT02474199|Drug|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
79333902|NCT02474199|Drug|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
79333903|NCT02474199|Drug|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
79333904|NCT02474199|Procedure|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
79333905|NCT02450487|Drug|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
79333906|NCT02473965|Drug|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
79333907|NCT02473965|Drug|Placebo|
79333908|NCT04939311|Drug|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
79333909|NCT04939311|Drug|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
79485539|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
79333910|NCT02472795|Drug|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
79333911|NCT02472795|Drug|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
79333912|NCT02507349|Behavioral|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
79651366|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
79651367|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
79651368|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
79333913|NCT02507349|Behavioral|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
79333914|NCT02506881|Drug|Darbepoetin alfa|
79333915|NCT02506257|Drug|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
79333916|NCT02506257|Drug|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
79333917|NCT02506257|Drug|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
79333918|NCT02506257|Drug|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
79333919|NCT02506101|Device|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
79333920|NCT02505945|Drug|Omeprazole|
79333921|NCT02505945|Device|LINX Reflux Management System|
79333922|NCT02505867|Device|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
79333923|NCT02472639|Device|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
79333924|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not use device
79333925|NCT02472405|Device|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
79333926|NCT02472405|Device|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
79333927|NCT02448771|Drug|Palbociclib|
79333928|NCT02448771|Drug|Bazedoxifene|
79333929|NCT02504541|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
79333930|NCT04924257|Drug|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS <10).
79333931|NCT04924257|Procedure|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS <10).
79333932|NCT04924179|Drug|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
79333933|NCT04975945|Drug|Ceftriaxone Sodium|Intravenous vs local action
79651369|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
79651370|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
79333934|NCT03053479|Procedure|Laparoscopic sacrocolpopexy|see arm/group descriptions
79333935|NCT03053479|Procedure|Transvaginal mesh procedure|see arm/group descriptions
79333936|NCT03053479|Procedure|Amreich-Richter procedure|see arm/group descriptions
79333937|NCT03034603|Dietary Supplement|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
79333938|NCT03034603|Dietary Supplement|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
79333939|NCT03061747|Device|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
79333940|NCT03063307|Procedure|Atraumatic Restorative Treatment|
79333941|NCT03063307|Other|Silver Diamine Fluoride|
79333942|NCT03061825|Device|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
79981292|NCT04441606|Radiation|68Ga-FAPI-04 PET/CT|"Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
79485540|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
79651371|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
79651372|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
79651373|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
79333943|NCT02970565|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
79981293|NCT03532191|Other|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
79981294|NCT01331655|Drug|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
79981295|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
79981296|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
79651374|NCT04626856|Biological|Low dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
79651375|NCT04626856|Biological|Medium dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
79981297|NCT03295474|Other|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
79333944|NCT02970565|Behavioral|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
79651376|NCT04626856|Biological|High dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
79651377|NCT04626856|Biological|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
79651378|NCT04626856|Biological|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
79651379|NCT00246636|Drug|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
79651380|NCT00246636|Drug|Antara (fenofibrate)|Antara (fenofibrate) + placebo
79981298|NCT01331733|Drug|hMG-HP|
79981299|NCT01331733|Drug|hMG + GnRH antagonist|
79981300|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
79651381|NCT00219440|Other|Actos plus standard diet|Actos plus standard diet
79651382|NCT00219440|Other|Actos plus structured diet|Actos plus structured diet
79651383|NCT00219440|Other|Metformin plus standard diet|Metformin plus standard diet
79333945|NCT04434313|Device|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
79333946|NCT04874935|Drug|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
79485541|NCT05345210|Drug|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
79485542|NCT05345210|Drug|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
79485543|NCT00540566|Device|Optical Biopsy imaging|Optical Biopsy imaging
79981301|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
79981302|NCT01085578|Drug|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
79981303|NCT03289390|Drug|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
79981304|NCT04488796|Behavioral|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
79485544|NCT02976896|Drug|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
79485545|NCT01810705|Drug|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
79485546|NCT01712191|Device|NUsurface Meniscus Implant|
79981305|NCT04488796|Behavioral|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
79981306|NCT04488796|Behavioral|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
79981307|NCT04488796|Behavioral|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
79981308|NCT04488796|Behavioral|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
79333947|NCT04874935|Drug|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
79333948|NCT04975477|Procedure|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
79333949|NCT04975477|Procedure|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
79333950|NCT03061591|Dietary Supplement|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
79333951|NCT03061591|Other|Placebo|Placebo capsules
79485547|NCT02508103|Drug|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
79485548|NCT02508103|Drug|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
79981309|NCT04488796|Behavioral|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
79981310|NCT00897104|Drug|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
79485549|NCT02508259|Drug|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
79333952|NCT02961361|Drug|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
79333953|NCT02961361|Drug|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
79333954|NCT04974229|Other|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
79333955|NCT04974931|Device|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
79485550|NCT02508259|Drug|Saline|50 ml IV over 30 minutes
79485551|NCT04707859|Diagnostic Test|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
79651384|NCT04626700|Device|iNAP|iNAP for the treatment of OSA
79651385|NCT04626700|Device|CPAP|CPAP for the treatment of OSA
79981311|NCT00897104|Drug|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
79981312|NCT00897104|Drug|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
79981313|NCT03289156|Behavioral|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
79981314|NCT03289156|Behavioral|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
79981315|NCT03289078|Other|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
79485552|NCT04708093|Device|whole body vibration training|Oscillating platform
79485553|NCT05237180|Other|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
79651386|NCT00246675|Drug|Frusemide|
79651387|NCT00219479|Drug|Phenytoin (Dilantin) levels during change in enteral feeding|
79651388|NCT04626778|Drug|Peroxyl Mouthwash|Mouthwash
79333956|NCT04975165|Procedure|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
79333957|NCT04974073|Drug|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
79333958|NCT04975087|Other|Patients group|Patients will complete the mentioned questionnaires.
79333959|NCT04973995|Behavioral|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
79333960|NCT04974853|Combination Product|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
79333961|NCT04973839|Behavioral|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
79333962|NCT04973839|Behavioral|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
79651389|NCT04626778|Drug|Placebo Mouthwash|Mouthwash
79333963|NCT04973839|Behavioral|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
79333964|NCT04973839|Behavioral|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
79333965|NCT02426281|Drug|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
79651390|NCT04626973|Drug|Ezetimibe/Statin Combination therapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
79651391|NCT04626973|Drug|Statin monotherapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
79651392|NCT04626973|Drug|Ezetimibe/Statin Combination therapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
79651393|NCT04626973|Drug|Statin monotherapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
79651394|NCT00242463|Drug|Nandrolone (anabolic steroid)|
79651395|NCT00242463|Drug|Placebo|
79651396|NCT00561808|Other|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
79333966|NCT02426281|Drug|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
79333967|NCT02448537|Drug|PM01183|
79333968|NCT02448537|Drug|Doxorubicin|
79333969|NCT02448537|Drug|Gemcitabine|
79333970|NCT03062371|Behavioral|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
79333971|NCT03062683|Other|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
79333972|NCT03060265|Drug|Paracetamol|Administrating Paracetamol IV pre-cesarean section
79333973|NCT03060265|Drug|PLACEBO|Administrating SALINE IV pre-cesarean section
79333974|NCT02504151|Drug|Cannabidiol|
79333975|NCT02504151|Drug|Placebo|
79333976|NCT03060109|Other|Blood draw within 12 hours of injury|
79651397|NCT00219518|Procedure|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
79651398|NCT00561886|Drug|Formoterol|One inhalation of 24µg Formoterol
79812062|NCT00697775|Biological|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
79812063|NCT00799084|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
79812064|NCT00799084|Behavioral|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
79333977|NCT02448381|Drug|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
79333978|NCT02448381|Drug|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
79333979|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
79485554|NCT02509585|Drug|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
79485555|NCT02240706|Procedure|Best Supportive Care|At Discretion of the Investigator (Transfusions)
79485556|NCT02240706|Drug|BI 836858|Monotherapy with BI 836858
79812065|NCT02609958|Drug|Varlitinib|"varlitinib tablets with:~starting dose: 300mg BID~target dose: 400mg BID~dose modification by investigator allowed between 200mg BID to 500mg BID"
79812066|NCT04133051|Drug|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
79333980|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FSPG PET/CT
79333981|NCT02448225|Radiation|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
79485557|NCT00534469|Biological|aldesleukin|
79812067|NCT04133051|Drug|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
79812068|NCT00788242|Drug|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
79812069|NCT00788242|Drug|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
79812070|NCT05039970|Other|WellQuest™|WellQuest™ is a mobile device-based serious health game.
79812071|NCT04031027|Drug|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
79812072|NCT00694031|Procedure|Hemodialysis|3 times per week
79333982|NCT02448225|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
79333983|NCT02448225|Other|Laboratory Biomarker Analysis|Correlative studies
79485558|NCT00534469|Biological|filgrastim|
79485559|NCT00534469|Drug|busulfan|
79485560|NCT00534469|Drug|cytarabine|
79485561|NCT00534469|Drug|etoposide|
79485562|NCT00534469|Drug|idarubicin|
79485563|NCT00534469|Procedure|autologous hematopoietic stem cell transplantation|
79485564|NCT00534469|Procedure|bone marrow transplantation|
79485565|NCT00534469|Procedure|peripheral blood stem cell transplantation|
79485566|NCT00534469|Radiation|total-body irradiation|
79485567|NCT03757351|Drug|DNL747|Repeating oral dose
79651399|NCT04626622|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
79651400|NCT04626622|Drug|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
79651401|NCT00561964|Drug|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
79651402|NCT00561964|Drug|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
79485568|NCT03757351|Drug|Placebo|Repeating oral dose
79485569|NCT04341805|Procedure|PrevOmega|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
79333984|NCT02448225|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
79485570|NCT04341805|Procedure|Physiological saline|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
79485571|NCT03654859|Other|cardiopulmonary resuscitation|no pre-specified
79485572|NCT01600092|Biological|RotaTeq™ experimental formulation|
79485573|NCT01600092|Biological|RotaTeq™ existing formulation|
79485574|NCT00364975|Behavioral|gourmet cooking workshop|
79485575|NCT02588599|Device|Erchonia LUNULA|Active low level laser light therapy
79485576|NCT02240628|Device|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
79485577|NCT02240628|Drug|Saline|Patients in arm 2 will receive Saline with the Propofol.
79485578|NCT02240628|Drug|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
79485579|NCT02589067|Drug|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
79485580|NCT02589067|Drug|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
79485581|NCT02511379|Other|Propylene Glycol 0.6% eye drops|
79485582|NCT02207400|Drug|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
79485583|NCT02207400|Drug|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
79485584|NCT02511535|Biological|TBE booster vaccination|
79485585|NCT04341961|Other|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
79485586|NCT03545035|Drug|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
79485587|NCT03539341|Behavioral|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
79333985|NCT02448225|Procedure|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
79333986|NCT02503215|Device|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
79333987|NCT02447991|Drug|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
79333988|NCT02447991|Drug|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
79333989|NCT02586155|Drug|Apabetalone|100 mg capsule
79333990|NCT02586155|Drug|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
79485588|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
79485589|NCT02589847|Biological|RBX2660|suspension of intestinal microbes
79333991|NCT02586155|Drug|Atorvastatin|High-Intensity Statin
79333992|NCT02586155|Drug|Rosuvastatin|High-Intensity Statin
79333993|NCT05697731|Diagnostic Test|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
79333994|NCT02446743|Biological|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
79981316|NCT00792506|Drug|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
79981317|NCT03288922|Procedure|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
79981318|NCT03288922|Procedure|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
79981319|NCT02462200|Procedure|Breast-conserving surgery (BCS)|
79981320|NCT02462200|Procedure|Cavity shave margins (CSM)|
79981321|NCT02462200|Behavioral|BREAST-Q Questionnaire|
79981322|NCT02462200|Device|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
79333995|NCT02586077|Drug|Exparel|
79333996|NCT05536661|Other|Preservative free hyaluronic acid artificial tear|Ocular lubricant
79333997|NCT03241121|Behavioral|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
79333998|NCT03241121|Behavioral|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
79333999|NCT03241121|Device|Eating patterns|Data collection on eating patterns via the smartphone app
79334000|NCT05591807|Other|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
79334001|NCT05536583|Procedure|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
79334002|NCT05536505|Genetic|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
79334003|NCT05536271|Drug|Bisoprolol Fumarate|antihypertensive medicine prescribed for acute coronary syndrome patients
79334004|NCT05536193|Drug|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
79334005|NCT05536193|Diagnostic Test|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
79334006|NCT05535881|Behavioral|Strengths to Grow Program|In an online, self-directed format, the Strengths to Grow program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
79334007|NCT04425707|Drug|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
79334008|NCT05697185|Drug|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
79334009|NCT02583425|Drug|DFN-11 Injection|
79981323|NCT02462200|Other|Indocyanine green|
79485590|NCT02589847|Drug|Standard of Care Antibiotics|Standard of Care Antibiotics
79981324|NCT02462200|Device|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
79981325|NCT02462200|Procedure|Peripheral blood draw|-Time of surgery if coordinator is available
79981326|NCT04488718|Other|EnergieShake® Junior Powder Complete|Oral Nutritional Supplement
79334010|NCT05535803|Biological|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
79981327|NCT03295162|Drug|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
79981328|NCT03295162|Combination Product|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
79981329|NCT05230238|Device|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
79334011|NCT05535803|Other|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
79981330|NCT04586842|Behavioral|Community-based Occupational Therapy|Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
79981331|NCT04586842|Behavioral|Standard community-based intervention|Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
79981332|NCT05226026|Behavioral|NiteCAPP HELPS|4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
79981333|NCT05226026|Other|Tapered Withdrawal|Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
79334012|NCT05511233|Dietary Supplement|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
79334013|NCT02581163|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
79334014|NCT02581163|Drug|Dasabuvir|Tablet
79334015|NCT02581163|Drug|Ribavirin|Tablet
79334016|NCT05591495|Procedure|laparoscopy in upper abdominal surgical emergencies in adults|evaluation the role of laparoscopy in upper GIT emergencies in adults
79334017|NCT05535179|Drug|honeysuckle and semen oroxyli solution|The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
79334018|NCT05462405|Procedure|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
79334019|NCT05679089|Device|early detection test|Blood collection and early detection testing
79334020|NCT05591261|Behavioral|ePREP|6-session online psychoeducational program with supporting coach calls
79334021|NCT05589545|Device|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
79334022|NCT01938547|Drug|clevidipine|
79334023|NCT05685485|Procedure|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
79485591|NCT02512393|Device|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
79981334|NCT03295084|Drug|Irinotecan|Dose Escalation
79981335|NCT03295084|Drug|Capecitabine|Dose Escalation
79981336|NCT01339689|Drug|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
79981337|NCT01339689|Drug|Placebo|capsules, bid, up to 12 weeks
79981338|NCT03038126|Other|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
79981339|NCT03038126|Other|Usual care|Standard clinical care
79334024|NCT05685485|Procedure|Tied off Tube|Ahmed implantation with vicryl ligature
79812073|NCT00694031|Procedure|On-line hemodiafiltration|3 times per week
79981340|NCT00702806|Drug|Org 36286|Intra-abdominal injection of Org 36286
79981341|NCT00702806|Drug|Puregon®|Subcutaneous Puregon® 150 IU
79981342|NCT00702806|Drug|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
79981343|NCT00702806|Drug|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
79812074|NCT02609802|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
79812075|NCT02609802|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
79334025|NCT05695625|Other|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered."
79334026|NCT05695625|Other|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered."
79334027|NCT05695547|Other|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
79334028|NCT05697107|Drug|Ripretinib Oral Tablet|Oral kinase inhibitor
79334029|NCT05586737|Drug|Rituximab|1 gram rituximab twice with two weeks interval
79334030|NCT05678933|Drug|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
79334031|NCT05678933|Drug|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
79485592|NCT02512393|Device|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
79981344|NCT01331811|Other|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~interview on anamnesis~clinical examination~evaluation of HIV infection stage~hematology and biochemistry tests~CD4 count~HIV viral load~IGRA~chest radiograph~Abdominal ultrasonograph to detect abdominal lymphadenopathy~Tuberculin skin test~gastric aspirates, sputum and string tests according to the age of children~nasopharyngeal aspirate~stool sample~lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
79334032|NCT05678933|Drug|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79334033|NCT05678933|Drug|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79334034|NCT05678933|Drug|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
79334035|NCT05678933|Drug|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
79334036|NCT05678855|Behavioral|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
79334037|NCT05357495|Behavioral|Affective Posner fMRI frustration induction task|During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
79334038|NCT05678777|Device|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
79334039|NCT05678621|Drug|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
79334040|NCT05678621|Drug|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
79334041|NCT05678621|Drug|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
79334042|NCT05338073|Diagnostic Test|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
79334043|NCT05334953|Device|ESWT|"Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
79485593|NCT04743115|Drug|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
79485594|NCT02592421|Drug|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
79485595|NCT02592421|Drug|Placebo|Placebo Comparator
79485596|NCT02512783|Drug|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
79485597|NCT02512783|Drug|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
79651403|NCT00562003|Procedure|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
79485598|NCT02512783|Drug|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
79485599|NCT02513095|Drug|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
79485600|NCT02592655|Device|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
79485601|NCT02592655|Device|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
79651404|NCT00562003|Drug|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
79651405|NCT00219596|Drug|Xalacom|
79651406|NCT00219596|Drug|unfixed Latanoprost and Timolol|
79485602|NCT02592655|Device|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
79485603|NCT02592655|Device|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
79812076|NCT02617745|Other|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
79334044|NCT05334953|Device|Phonophoresis|"Group 2 ( n=17) will be given five times a week total 10 sessions of diclofenac phonophoresis + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
79981345|NCT04441281|Procedure|Traction of the cervix for IUD insertion|Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
79981346|NCT03635931|Procedure|Concentrated Growth Factor|surgical treatment with CGF for papilla regeneration
79334045|NCT05334953|Device|Ultrasound|"Group 3 (n=17) will be given five times a week total 10 sessions of ultrasound therapy+ home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
79981347|NCT01331967|Drug|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
79485604|NCT02592655|Device|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
79334046|NCT05334953|Other|Control group|Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises
79334047|NCT05240729|Procedure|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
79812077|NCT02609646|Drug|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
79485605|NCT00365131|Drug|Cerezyme (imiglucerase for injection)|
79981348|NCT00696878|Drug|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
79981349|NCT00696878|Biological|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
79812078|NCT02609646|Drug|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
79812079|NCT02609646|Drug|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
79334048|NCT05530577|Drug|Semaglutide|Semaglutide (subcutaneous)
79334049|NCT05530577|Drug|Sham/placebo|Sham subcutaneous injection
79334050|NCT04718909|Drug|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
79334051|NCT04718909|Drug|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
79981350|NCT00696878|Biological|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
79981351|NCT00696878|Biological|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
79981352|NCT00696878|Drug|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
79981353|NCT01231971|Drug|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
79981354|NCT01231971|Drug|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
79981355|NCT01150929|Device|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
79334052|NCT05216549|Other|Water-based exercise|8 weeks x 2 times per week for 45 min
79334053|NCT05216549|Other|Land-based exercise|8 weeks x 2 times per week for 45 min
79334054|NCT05183399|Device|GORE® VIABAHN® Endoprosthesis|
79334055|NCT05379881|Behavioral|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
79485606|NCT02513641|Device|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of ~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
79485607|NCT02513719|Device|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
79334056|NCT04315337|Behavioral|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
79334057|NCT05160155|Procedure|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
79334058|NCT05160155|Procedure|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
79334059|NCT02627677|Drug|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
79334060|NCT02627677|Drug|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
79334061|NCT02627677|Drug|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
79334062|NCT05660603|Other|control|patients will receive standard general anesthesia
79485608|NCT00363727|Drug|ropinirole controlled-release (REQUIP CR) for RLS|
79485609|NCT02514889|Behavioral|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
79485610|NCT02514889|Behavioral|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits & vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
79485611|NCT03230773|Device|Defibrillator model|Comparison of the performance of different public access defibrillators
79485612|NCT02515825|Device|CADence|
79485613|NCT04340869|Other|Theobromine|Natural extract from Cocoa
79485614|NCT04340869|Other|Remin Pro|Remin Pro
79812080|NCT02609646|Drug|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
79485615|NCT00366067|Drug|Phenytoin|
79485616|NCT02343757|Device|PET/MRI|
79485617|NCT00364429|Drug|[123]I-CNS 1261|Study Drug
79485618|NCT00364429|Drug|Lorazepam|Study Drug
79485619|NCT00364429|Drug|Risperidone|Study Drug
79485620|NCT00364585|Device|GreenLight Model 120 Laser System|
79485621|NCT02593903|Drug|Septra|
79485622|NCT02596321|Drug|Mitizax|Allergen extract
79485623|NCT02596321|Drug|Placebo|Placebo tablet
79485624|NCT02596867|Drug|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
79485625|NCT02597101|Drug|Metformin|background drug
79485626|NCT02597101|Drug|saxagliptin|background drug
79485627|NCT02597101|Drug|AZD9668|study drug
79485628|NCT02597101|Drug|placebo|placebo for AZD9668 to be added to background drugs
79485629|NCT05578261|Device|intermittent theta burst stimulation|stimulatory protocol
79485630|NCT02600611|Drug|iclaprim|Experimental treatment
79485631|NCT02600611|Drug|vancomycin|Active comparator
79812081|NCT02610504|Device|Durolane|single injection of 3ml
79812082|NCT04136873|Drug|CVL-231|CVL-231
79812083|NCT04136873|Drug|Matching Placebo|Placebo matching CVL-231
79812084|NCT04132583|Drug|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
79812085|NCT04132583|Drug|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
79812086|NCT05754762|Drug|Remifentanil|Advanced intravenous injection of remifentanil before the etomidate injection
79485632|NCT02600767|Drug|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
79485633|NCT00365287|Drug|anti-thymocyte globulin|
79485634|NCT00365287|Drug|cyclophosphamide|
79485635|NCT00365287|Drug|cyclosporine|
79485636|NCT00365287|Drug|fludarabine phosphate|
79485637|NCT00365287|Drug|mycophenolate mofetil|
79485638|NCT00365287|Procedure|radiation therapy|
79485639|NCT00365287|Procedure|umbilical cord blood transplantation|
79485640|NCT00365443|Biological|V502|
79485641|NCT00365521|Procedure|Photodynamic Therapy|
79485642|NCT04743193|Other|2.5 %sevoflurane|for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
79485643|NCT04743193|Other|8% sevoflurane low flow anesthesia|For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
79485644|NCT05371171|Procedure|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation
79651407|NCT04626193|Drug|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
79485645|NCT05371171|Procedure|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation
79485646|NCT05366491|Diagnostic Test|Il-38 serum level|measurement of serum levels of IL-38
79812087|NCT02608866|Radiation|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
79485649|NCT05362591|Procedure|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
79485650|NCT05362591|Procedure|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
79485651|NCT02608177|Drug|Linagliptin|Receives 4 weeks of study drug linagliptin
79485652|NCT02608177|Drug|Glipizide|Receives 4 weeks of study drug glipizide
79485653|NCT04742335|Other|Survey|Survey will be applied to the participants.
79485654|NCT05555095|Behavioral|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
79651408|NCT04626193|Drug|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
79651409|NCT00246714|Drug|repeated injections of endotoxin during 5 days|
79485655|NCT02608489|Drug|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
79485656|NCT02608489|Drug|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
79485657|NCT02609113|Device|Strong Magnetic Wristband|
79485658|NCT02609113|Device|Weaker Magnetic Wristband|
79485659|NCT02611765|Drug|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
79485660|NCT02611765|Drug|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
79485661|NCT02612857|Drug|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
79485662|NCT02612857|Drug|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
79485663|NCT02612857|Drug|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
79651410|NCT04626232|Procedure|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
79651411|NCT04626232|Procedure|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
79651412|NCT00242541|Drug|Octreotide acetate|
79651413|NCT00219635|Drug|UK-390,957|
79651414|NCT04625998|Behavioral|Enhanced CATCH Elementary School Program|Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.
79485664|NCT05553769|Other|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
79485665|NCT05550571|Device|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
79485668|NCT02615743|Behavioral|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
79334063|NCT05660603|Procedure|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
79334064|NCT05660603|Procedure|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
79651415|NCT04625998|Behavioral|CATCH Early Childhood (CEC)|Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
79651416|NCT04625842|Other|Focus group interview|Group interview with patients who received radiation treatment
79651417|NCT04720599|Diagnostic Test|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
79651418|NCT04625686|Behavioral|Mental Health Treatment|Treatment of suicidal ideation
79651419|NCT04625920|Device|SootheVR: AppliedVR, Los Angeles, California|a head-mounted display
79651420|NCT00219674|Behavioral|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
79651421|NCT00219674|Behavioral|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
79651422|NCT00219674|Behavioral|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
79651423|NCT00219674|Behavioral|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
79651424|NCT00246792|Behavioral|Group treatment|
79651425|NCT04625881|Dietary Supplement|Apple derived fiber|This is a combination of soluble and insoluble fiber
79651426|NCT04625608|Drug|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
79651427|NCT04625608|Other|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
79651428|NCT00219713|Drug|nitrous oxide and oxygen|
79651429|NCT04625491|Other|Observational|Observational
79334065|NCT05660603|Device|Ultrasound|ultrasound
79334066|NCT03059875|Behavioral|Medical consultation for a Standardized Geriatric Evaluation|
79334067|NCT05677685|Device|VISUPRIME|twice daily
79334068|NCT05677685|Device|Placebo|twice daily
79334069|NCT04964479|Drug|TQB2450 injection|1200mg injection once every 3 week
79334070|NCT04964479|Drug|Anlotinib Hydrochloride Capsules|12mg capsule once daily
79334071|NCT04964479|Drug|Pembrolizumab injection|200mg injection once every 3 week
79334072|NCT04964479|Drug|Placebo|Placebo capsule once daily
79334073|NCT04964401|Procedure|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
79334074|NCT04964245|Device|accelometer|the respiration parameters are measured using an accelometer.
79334075|NCT04964245|Device|thermographic camera|the respiration parameters are measured using an thermographic camera.
79334076|NCT04964245|Device|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
79334077|NCT04964245|Device|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
79334078|NCT03059797|Drug|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
79334079|NCT03059797|Drug|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
79334080|NCT02501811|Biological|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
79651430|NCT04625335|Other|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
79981356|NCT03288688|Other|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
79981357|NCT03295006|Device|TheraSphere|Patients who had received TheraSphere
79981358|NCT00731757|Drug|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
79981359|NCT03625622|Drug|AR1001|AR1001 Active Oral Tablet
79334081|NCT02501811|Biological|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
79334082|NCT02501811|Biological|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
79334083|NCT04964011|Other|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
79334084|NCT02585999|Device|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
79981360|NCT03625622|Drug|Placebo|Placebo Oral Tablet
79981361|NCT03108274|Drug|Danicopan|Oral tablet.
79981362|NCT03108274|Drug|Midazolam|Oral syrup.
79981363|NCT03108274|Drug|Fexofenadine|Oral tablet.
79981364|NCT03108274|Drug|Mycophenolate Mofetil|Oral tablet.
79334085|NCT04963621|Behavioral|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
79334086|NCT05696951|Other|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
79334087|NCT01444495|Radiation|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
79334088|NCT01444495|Procedure|Surgery|Total mesorectal excision of rectal cancer
79334089|NCT01439269|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
79334090|NCT02582255|Biological|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
79334091|NCT04973761|Other|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
79334092|NCT04973761|Other|Strip composite crowns|Strip composite crowns
79334093|NCT04973371|Diagnostic Test|Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test|Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® [Cepheid, Sunnyvale, CA] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
79334094|NCT03061435|Procedure|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
79812088|NCT02608866|Radiation|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
79812089|NCT05326152|Biological|hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)|Randomized placebo-controlled comparative effectiveness clinical trial
79812090|NCT05326152|Biological|Intralesional saline|Intralesional saline
79485669|NCT02615743|Device|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
79485670|NCT02616523|Drug|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
79334095|NCT03061435|Procedure|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
79981365|NCT01334541|Behavioral|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~Risk Assessment~Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~Clinical Follow-Up Protocol"
79485671|NCT02616523|Drug|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
79485672|NCT02616523|Other|placebo|The participants will be given infusion of normal saline intravenously.
79485673|NCT02616523|Drug|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
79485674|NCT05732155|Drug|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
79485675|NCT05528419|Drug|Sacubitril-valsartan|sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up
79981366|NCT04296357|Diagnostic Test|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
79485676|NCT05528419|Drug|Valsartan|valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up
79981367|NCT04296357|Other|Physical development and General Health|Physical development and General health examination
79334096|NCT04432363|Device|Transcranial direct current stimulation|Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
79651431|NCT04625335|Other|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
79334097|NCT02500719|Device|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
79651432|NCT00219752|Drug|Imatinib mesylate 400 mg|
79981368|NCT04296357|Diagnostic Test|Developmental Red flags|Developmental Red flags Questionnaires
79334098|NCT04963855|Drug|GT300|SIngle oral dose
79334099|NCT04963855|Drug|Microcrystalline cellulose|placebo
79334100|NCT03061357|Behavioral|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
79812091|NCT00914004|Drug|Desipramine HCl 50 mg Tablets Cord Laboratories|
79334101|NCT05695235|Device|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
79334102|NCT05695235|Device|Oura ring|Wearable sleep tracking device
79334103|NCT05695235|Behavioral|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
79334104|NCT04973215|Other|no intervention|this is not an intervention study
79334105|NCT04963309|Other|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
79485677|NCT04340713|Other|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
79812092|NCT00914004|Drug|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
79485678|NCT04741867|Other|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
79485679|NCT04340791|Behavioral|Increased proportion of lower energy density items|The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
79485680|NCT04340791|Behavioral|Labelling|"When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
79334106|NCT05019209|Drug|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
79334107|NCT05019209|Other|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
79334108|NCT04963387|Other|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
79334109|NCT04963387|Other|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
79334110|NCT05694299|Device|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
79334111|NCT05694299|Other|Nasal patch|Regular adhesive tape for medical use.
79334112|NCT05674253|Drug|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
79485681|NCT02974465|Procedure|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
79812093|NCT00867113|Drug|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
79812094|NCT02610270|Dietary Supplement|2 Gums|760 mg DHA
79812095|NCT02610270|Dietary Supplement|3 Gums|1140 mg DHA
79812096|NCT02608710|Drug|RDEA3170 4.5 mg|
79812097|NCT02608710|Drug|RDEA3170 6 mg|
79812098|NCT02608710|Drug|RDEA3170 12 mg|
79812099|NCT02615483|Other|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
79651433|NCT04625452|Behavioral|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
79651434|NCT00242697|Procedure|spinal analgesia and anesthesia for coronary artery surgery|
79981369|NCT02332564|Other|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
79981370|NCT01332045|Procedure|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
79981371|NCT01332045|Procedure|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
79334113|NCT04954417|Diagnostic Test|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
79334114|NCT04954417|Other|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
79485682|NCT02974465|Procedure|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
79485683|NCT02974465|Procedure|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
79485684|NCT05483413|Behavioral|progressive relaxation exercises|Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
79485685|NCT05480293|Drug|Ranibizumab|ranibizumab，0.5mg,IVT
79651435|NCT04625179|Other|Melatonin and hyaluronic acid and sinus membrane elevation|3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
79651436|NCT04625179|Procedure|sinus membrane elevation without any materials|No materials will be placed at the sinus space.
79485686|NCT05480293|Drug|SCT510A|SCT510A，1.25mg,IVT
79485687|NCT05731609|Other|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
79485688|NCT05461417|Device|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
79651437|NCT00219791|Drug|glucarpidase (50 Units/kg)|
79651438|NCT04624867|Drug|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
79651439|NCT04624516|Other|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
79651440|NCT02962232|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
79651441|NCT02962232|Device|PTA catheter|control group
79981372|NCT03294928|Other|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
79334115|NCT04954417|Procedure|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
79334116|NCT02500641|Drug|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
79334117|NCT02500641|Drug|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
79334118|NCT02500641|Drug|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
79981373|NCT02278588|Drug|Rasagiline|
79981374|NCT03288610|Diagnostic Test|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
79334119|NCT02500641|Drug|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
79334120|NCT02500641|Drug|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
79334121|NCT05662553|Procedure|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
79485689|NCT05731531|Device|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
79485690|NCT04901143|Device|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
79485691|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
79485692|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
79485693|NCT05731375|Diagnostic Test|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
79485694|NCT00365755|Drug|carboplatin|
79485695|NCT00365755|Drug|cisplatin|
79485696|NCT00365755|Drug|cyclophosphamide|
79485697|NCT00365755|Drug|etoposide|
79981375|NCT00696800|Drug|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
79981376|NCT00696800|Biological|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79981377|NCT00696800|Drug|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
79981378|NCT00696800|Drug|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79485698|NCT00365755|Drug|melphalan|
79485699|NCT00365755|Drug|vincristine sulfate|
79485700|NCT00365755|Procedure|autologous bone marrow transplantation|
79981379|NCT00696800|Biological|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
79485701|NCT00365755|Procedure|conventional surgery|
79981380|NCT00696800|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
79981381|NCT00696800|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
79485702|NCT00365911|Procedure|Taking blood sample|A blood sample will be taken.
79485703|NCT00364741|Drug|Oxygen|During and 2 hours after surgery
79485704|NCT04743817|Device|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
79485705|NCT05731219|Biological|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
79485706|NCT05730985|Dietary Supplement|Miotrof® formula|1 sachet per day for 4 months
79485707|NCT05730985|Dietary Supplement|Placebo formula|1 sachet per day for 4 months
79334122|NCT05662553|Procedure|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
79651442|NCT04624711|Drug|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
79485708|NCT05730907|Drug|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
79651443|NCT04624711|Drug|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
79485709|NCT04541875|Other|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
79485710|NCT05729191|Biological|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
79485711|NCT04340401|Drug|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
79651444|NCT00246909|Drug|Pantoprazole|
79651445|NCT04624594|Other|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
79651446|NCT04624594|Other|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
79651447|NCT04624282|Diagnostic Test|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
79651448|NCT00219869|Drug|Galantamine|
79651449|NCT00246948|Procedure|Active conservative treatment of sciatica|
79981382|NCT00696800|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
79981383|NCT03294772|Other|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
79334123|NCT04973293|Drug|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
79334124|NCT04973293|Drug|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
79334125|NCT05657249|Diagnostic Test|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
79981384|NCT03294772|Other|liquid soap|DCCs received liquid soap and a program educational.
79981385|NCT03288532|Drug|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
79485712|NCT04340401|Drug|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
79485713|NCT04340401|Drug|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
79651450|NCT04624360|Drug|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
79651451|NCT04624360|Other|Placebo|2cc 0.9% Saline
79981386|NCT03288532|Drug|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
79485714|NCT04340401|Radiation|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
79485715|NCT04340401|Procedure|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
79651452|NCT04624438|Other|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
79651453|NCT04624438|Other|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
79812100|NCT04030260|Drug|Regorafenib and PD-1 antibody in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
79651454|NCT04624438|Other|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
79651455|NCT00219908|Drug|Mitoxantrone|
79651456|NCT00242736|Drug|Esomeprazole|
79651457|NCT04624048|Diagnostic Test|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
79812101|NCT04030260|Radiation|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
79812102|NCT00697385|Drug|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
79812103|NCT04133753|Behavioral|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
79485716|NCT05726149|Device|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
79651458|NCT01580605|Drug|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
79651459|NCT04623970|Procedure|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
79485717|NCT05726149|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
79651460|NCT00219947|Other|blood draw|"T cell subset enumeration~Serologic reactivity with HIV antigens~Viral load assays by bDNA, PCR, or RT-PCR~Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~HIV-1 Resistance Testing"
79651461|NCT04623892|Drug|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline [0.9% (w/v) sodium chloride solution], and the infusion time is 60 ± 10 min.
79651462|NCT00242775|Drug|Budesonide/formoterol Turbuhaler|
79812104|NCT00451555|Drug|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
79812105|NCT00451555|Drug|placebo|oral, daily
79651463|NCT00242775|Drug|Salmeterol/fluticasone Diskus|
79812106|NCT00451555|Drug|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
79651464|NCT00562081|Behavioral|Education|24/7 access to a Certified Asthma Educator
79651465|NCT00562081|Behavioral|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
79651466|NCT00219986|Drug|Potent HAART during acute or early HIV-1 infection|
79651467|NCT04623619|Dietary Supplement|Acetyl L-Carnitine|Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
79651468|NCT00562198|Drug|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
79651469|NCT00562198|Drug|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
79651470|NCT00220025|Device|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
79812107|NCT00808236|Device|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
79812108|NCT00808236|Other|Control|Advanced cardiac life support according to American Heart Association & European Resuscitation Council 2005 Guidelines
79334126|NCT04972669|Device|Electrical Acupuncture Stimulation|Participants received acupuncture at bilateral Baliao. After skin disinfection, sterile adhesive pads were placed on bilateral Baliao, and acupuncture needles were inserted through the adhesive pads. Following needle insertion, small, equal manipulations of twirling, lifting, and thrusting were performed on all needles to reach de qi. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
79334127|NCT04972669|Device|sham Acupuncture|Participants received sham acupuncture at locations one inch besides bilateral Baliao without needle insertion. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
79334128|NCT05061173|Other|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
79334129|NCT05061173|Other|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
79485718|NCT05726149|Device|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
79485719|NCT04340635|Other||Without intervention
79485720|NCT04143607|Drug|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
79485721|NCT04143607|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
79485722|NCT04143607|Drug|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
79485723|NCT04143607|Drug|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
79651471|NCT03454594|Device|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
79651472|NCT00246987|Drug|Muraglitazar|
79651473|NCT04623463|Behavioral|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
79651474|NCT04623814|Other|Food|HEC113995 20mg will be taken orally fasted or with food
79651475|NCT04623814|Drug|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
79651476|NCT04623814|Drug|placebo|The placebo will be administered fasted or with food for 10 days.
79651477|NCT00220064|Drug|Irinotecan, 5-Fluorouracil, Leucovorin|
79651478|NCT01580644|Drug|GLPG0187 prodrug|
79651479|NCT04623151|Behavioral|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
79812109|NCT00867035|Drug|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
79812110|NCT00867035|Drug|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
79812111|NCT05012748|Other|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
79812112|NCT05754684|Biological|Natural killer cell|Natural killer cells isolated from HLA-haploidentical relative donor
79651480|NCT04623073|Procedure|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
79651481|NCT00220103|Drug|epirubicin, capecitabine, cisplatin|
79651482|NCT00220103|Procedure|Surgical resection|
79334130|NCT05061173|Other|Combined Exercise Training Group|"Combined Exercise training includes [Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
79334131|NCT04962451|Drug|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
79334132|NCT04962451|Drug|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
79485724|NCT04126291|Behavioral|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
79651483|NCT04623307|Diagnostic Test|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
79651484|NCT00247026|Drug|curcumin; coenzyme q10|
79651485|NCT00562237|Biological|S205 placebo|2 i.m. injections per subject (0.5 mL each)
79651486|NCT00562237|Biological|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
79651487|NCT00562237|Biological|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
79651488|NCT00562237|Biological|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
79334133|NCT05059925|Other|Structured gym activities|"Planned and structured activities such as Strength training~Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~Sit-ups (2 sets of 10 repetitions)~Stair climbing, (2 sets of 10 stairs up and down)~Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
79812113|NCT05754684|Drug|Dinutuximab beta|Dinutuximab beta iv for 5 days
79334134|NCT05059925|Other|Traditional aerobic activities|"Activities performed such as~Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
79334135|NCT04962295|Other|No intervention|No intervention
79334136|NCT05010083|Behavioral|diet and lifestyle program|See description of main arm.
79812114|NCT05754684|Drug|Interleukin-2|Interleukin-2 sc alternate day for 6 doses
79334137|NCT04953793|Behavioral|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
79334138|NCT04953793|Other|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
79485725|NCT04110067|Other|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
79485726|NCT04802863|Drug|XNW4107, Imipenem/Cilastatin|Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
79485727|NCT04756843|Device|Quad-helix|Fixed orthodontic appliance
79485728|NCT04677751|Device|Acupuncture intervention|Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
79651489|NCT00562237|Biological|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
79651490|NCT00562237|Biological|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
79651491|NCT00562237|Biological|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
79812115|NCT05754684|Drug|Granulocyte-Macrophage Colony-Stimulating Factor|Granulocyte-macrophage colony-stimulating factor sc daily till ANC >2,000/mm3
79981387|NCT00598208|Drug|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
79981388|NCT00598208|Drug|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
79334139|NCT04953871|Drug|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
79334140|NCT03059719|Biological|Exenatide injection(Byetta)|
79334141|NCT03059719|Biological|PB-119 injection|
79334142|NCT04980599|Dietary Supplement|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10^11CFU) 350ml/d for 60days
79334143|NCT04980599|Dietary Supplement|maltodextrin|maltodextrin ,for 60days
79334144|NCT04980599|Dietary Supplement|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10^10cfu) 60days;
79334145|NCT04980599|Dietary Supplement|Probiotic powder E5|probiotic powder 8g/day for 60days
79485729|NCT04652869|Device|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
79651492|NCT00562276|Procedure|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
79981389|NCT00537914|Drug|Somatropin|Infant, Small for Gestational Age, Omnitrope®/Somatropin, rhGH,
79334146|NCT04980599|Dietary Supplement|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10^7cfu) for 60days
79334147|NCT04980599|Dietary Supplement|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10^9cfu) for 60days
79334148|NCT04980599|Dietary Supplement|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10^10cfu) for 60days
79334149|NCT04980599|Dietary Supplement|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10^11cfu) for 60days
79485730|NCT04652869|Behavioral|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
79651493|NCT01580683|Drug|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
79651494|NCT01580683|Other|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
79651495|NCT04623229|Procedure|MCS|Manual Cataract Surgery
79651496|NCT04623229|Procedure|ReLACS Early|ReLACS with early administration of anesthesia
79812116|NCT05754684|Drug|Spironolactone|Spironolactone po three time daily
79334150|NCT04972435|Diagnostic Test|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
79334151|NCT03060031|Drug|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
79334152|NCT03060031|Drug|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
79334153|NCT02499783|Biological|adalimumab|subcutaneous injections of adalimumab
79334154|NCT02499783|Other|placebo|subcutaneous injections of placebo
79334155|NCT04972045|Drug|CuminUP60®|4 capsules, 400 mg / capsule
79334156|NCT04972045|Drug|Curcumin capsules|4 capsules, 400 mg / capsule
79485731|NCT04622839|Other|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~Agents used in nerve block (lidocaine vs ropivacaine)~Location of injection for analgesic~Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~Number of pills in the initial opioid prescription~Instructions for sling wear (duration of use or type of sling)~Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
79485732|NCT00366379|Drug|GK Activator (2)|25-200mg po bid for 20 weeks
79651497|NCT04623229|Procedure|ReLACS Standard|ReLACS with standard time administration of anesthesia
79651498|NCT04623112|Device|Hearing aid feature: Frequency Compression|FC Deactivated/Activated & set to default/Activated & set to hearing loss
79651499|NCT04623385|Combination Product|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
79651500|NCT04623385|Drug|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
79651501|NCT04623346|Procedure|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
79651502|NCT04623034|Drug|Ademetionine|
79334157|NCT04953481|Other|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
79334158|NCT03059017|Drug|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
79334159|NCT03059017|Drug|Niosomes|Niosomes
79334160|NCT04971421|Diagnostic Test|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
79334161|NCT04971421|Diagnostic Test|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
79334162|NCT05691335|Procedure|Standard CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
79651503|NCT00220220|Drug|olmesartan medoxomil|
79651504|NCT00220220|Drug|amlodipine|
79651505|NCT04622800|Other|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
79651506|NCT00242853|Procedure|Power doppler ultrasonography|
79651507|NCT00242853|Procedure|High frequency ultrasonography|
79334163|NCT05691335|Procedure|Accelerated CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
79334164|NCT05691335|Procedure|Transepithelial CXL|Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
79651508|NCT00242853|Procedure|Exhaled nitric oxide assessment|
79651509|NCT04622878|Procedure|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
79981390|NCT00480662|Drug|alendronate|Duration of Treatment : 6 Months
79334165|NCT04772885|Drug|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
79485733|NCT02619799|Drug|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
79485734|NCT02619799|Drug|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
79485735|NCT02621983|Behavioral|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
79485736|NCT02621983|Behavioral|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
79485737|NCT04741165|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
79334166|NCT04772885|Drug|KT-474|KT-474 oral tablet(s)
79334167|NCT04755413|Other|Medical/Behavioral therapy|"Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~Overweight/Obese: Advise calorie reduction, dietician consultation.~Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of <55mg/dl in diabetes~Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~Diabetes management: HbA1c goal 6.5%"
79485738|NCT04741165|Drug|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
79485739|NCT04741165|Drug|Lenvatinib|Administered orally once a day during each 21-day cycle
79651510|NCT00220259|Drug|Fluticasone or placebo|
79981391|NCT00398606|Drug|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
79981392|NCT00398606|Drug|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
79334168|NCT04755413|Other|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
79334169|NCT04755413|Other|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
79334170|NCT04961983|Behavioral|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~The potential roles of tour guides in tourists' health,~The importance of travel health information for tourists,~Assessment of tourist's health risks,~Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~Weekly travel health Information sharing through WhatsApp group for 2 months."
79334171|NCT04961749|Other|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
79334172|NCT04953013|Drug|sodium bicarbonate|Drug exposure
79334173|NCT04953169|Other|Biobank Video|The video describes the process of biobanking with visuals
79485740|NCT04741243|Device|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
79485741|NCT05138497|Other|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
79485742|NCT02623855|Behavioral|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
79981393|NCT00395408|Drug|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
79981394|NCT00395408|Drug|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
79485743|NCT02623855|Behavioral|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
79485744|NCT02623855|Device|Pedometry|Participants will record their daily pedometry.
79485745|NCT02623855|Behavioral|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
79485746|NCT04340011|Other|Colposcopy|prospective resident education for colposcopy
79485747|NCT02625181|Procedure|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
79334174|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
79485748|NCT02625181|Procedure|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
79334175|NCT04425655|Drug|Fludarabine|30mg/m2 days 1 through 5
79334176|NCT04425655|Drug|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
79651511|NCT04622956|Drug|Methotrexate Injectable Solution|"Phase 1:~Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~Level 0 [Starting Dose]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
79651512|NCT00242892|Procedure|Intra coronary measures of pressure|Intra coronary measures of pressure
79981395|NCT02462044|Drug|240 mg Iodine|
79981396|NCT02462044|Drug|300 mg Iodine|
79981397|NCT02462044|Drug|370 mg Iodine|
79334177|NCT04970719|Drug|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
79334178|NCT04970719|Drug|Dexamethasone|and 6 mg* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
79334179|NCT04970719|Drug|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
79334180|NCT02468193|Drug|Osilodrostat|Osirodrostat 1mg, 5mg & 10mg in the form of film-coated tablets was used for oral administration.
79334181|NCT04970797|Drug|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
79334182|NCT04431817|Device|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
79334183|NCT02466555|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
79334184|NCT04960969|Other|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
79334185|NCT04972201|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
79334186|NCT02466399|Drug|POLAT-001|Subconjunctival injection
79334187|NCT02466399|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
79485749|NCT02625181|Procedure|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
79485750|NCT02625181|Procedure|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
79485751|NCT02625181|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
79485752|NCT02625181|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
79485753|NCT02625181|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
79485754|NCT02625181|Procedure|Elective surgery|Surgical procedures that are scheduled and not an emergency.
79485755|NCT02625181|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
79485756|NCT02625181|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
79485757|NCT02625181|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
79485758|NCT02625181|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
79485759|NCT02625181|Drug|Scopolamine|Prophylactic antiemetic
79485760|NCT02625181|Drug|Droperidol|Prophylactic antiemetic & rescue antiemetic
79651513|NCT04622566|Drug|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
79651514|NCT04622488|Drug|Diclofenac Potassium|- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
79981398|NCT03294616|Device|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
79334188|NCT03059251|Biological|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
79485761|NCT02625181|Drug|Haloperidol|Prophylactic antiemetic & rescue antiemetic
79485762|NCT02625181|Drug|Dexamethasone|Prophylactic antiemetic & rescue antiemetic
79485763|NCT02625181|Drug|Promethazine|Prophylactic antiemetic & rescue antiemetic
79485764|NCT02625181|Drug|Meclizine|Prophylactic antiemetic & rescue antiemetic
79485765|NCT02625181|Drug|Aprepitant|Prophylactic antiemetic & rescue antiemetic
79651515|NCT00220298|Drug|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
79651516|NCT04622761|Drug|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 * intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~*Cabazitaxel dose should be capped at 50mg (BSA=2)"
79651517|NCT00247104|Drug|Cranberries - Vaccinium macrocarpon|
79981399|NCT00289874|Drug|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
79485766|NCT02625181|Drug|Metoclopramide|Rescue antiemetic
79485767|NCT02625181|Drug|Fentanyl|Analgesic drug / Opioid
79485768|NCT02625181|Drug|Sufentanil|Analgesic drug / Opioid
79485769|NCT02625181|Drug|Alfentanil|Analgesic drug / Opioid
79485770|NCT02625181|Drug|Remifentanil|Analgesic drug / Opioid
79981400|NCT00289874|Drug|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
79485771|NCT02625181|Drug|Morphine|Analgesic drug / Opioid
79485772|NCT02625181|Drug|Meperidine|Analgesic drug / Opioid
79485773|NCT02625181|Drug|Hydromorphone|Analgesic drug / Opioid
79485774|NCT02625181|Drug|Methadone|Analgesic drug / Opioid
79485775|NCT02625181|Drug|Oxycodone|Analgesic drug / Opioid
79485776|NCT02625181|Drug|Oxymorphone|Analgesic drug / Opioid
79485777|NCT02625181|Drug|Hydrocodone|Analgesic drug / Opioid
79485778|NCT02625181|Drug|Ketamine|Analgetic / Analgesic drug
79485779|NCT02625181|Drug|Ondansetron|Prophylactic antiemetic & rescue antiemetic
79485780|NCT02625181|Drug|Granisetron|Prophylactic antiemetic & rescue antiemetic
79485781|NCT02625181|Drug|Dolasetron mesylate|Prophylactic antiemetic & rescue antiemetic
79485782|NCT02625181|Drug|Palonosetron|Prophylactic antiemetic & rescue antiemetic
79485783|NCT02625181|Drug|Tropisetron|Prophylactic antiemetic & rescue antiemetic
79651518|NCT04622371|Other|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
79812117|NCT05298839|Diagnostic Test|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
79334189|NCT04936191|Device|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
79812118|NCT00694187|Drug|Zaleplon|
79812119|NCT02617121|Drug|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
79334190|NCT04970251|Drug|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
79334191|NCT04970017|Radiation|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
79334192|NCT02465931|Other|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
79485784|NCT02625181|Drug|Ramosetron|Prophylactic antiemetic & rescue antiemetic
79812120|NCT02617121|Drug|Ramosetron|ramosetron 0.3 mg iv at end of surgery
79651519|NCT00247143|Drug|Kaletra (drug)|
79651520|NCT04622215|Diagnostic Test|ICIQ questionnaire|questionnaire
79651521|NCT04622137|Procedure|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
79812121|NCT02617121|Drug|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
79334193|NCT02465931|Other|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
79485785|NCT05442229|Other|establish a new Chinese children's speech and language norm|1063 normally developing children and 96 abnormally developing children will be retrospectively enrolled from the medical records of stratified, randomly selected centers. A total of 4137 children with normal development and 448 children with abnormal development aged from 2 to 6 years old will be selected from 11 hospitals in China by multi-center, stratified, unequal proportion random sampling and face-to-face survey. Children's speech and language development was assessed by the Speech and Language Development Scale for children aged 2 to 6, compiled by the Linguistics and Language Research Centre of the Education University of Hong Kong.
79485786|NCT02625571|Behavioral|Phase-based treatment of sexual behavior problems of children|
79485787|NCT05046223|Procedure|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
79485788|NCT05046223|Procedure|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
79485789|NCT04741321|Other|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
79485790|NCT04740853|Behavioral|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
79651522|NCT00412412|Drug|CNF2024|Oral doses of CNF2024 as specified in the protocol.
79651523|NCT00412412|Drug|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
79651524|NCT00242931|Other|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
79651525|NCT04622098|Procedure|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~the tumor location,~layer of origin,~maximal diameter,~regularity of extraluminal border,~echopattern,~presence of cystic spaces or echogenic foci."
79651526|NCT00412490|Behavioral|Questionnaire|Written survey at 1 Month & 6 Months post surgery.
79651527|NCT00412490|Behavioral|Interview|One-on-One meeting lasting about one hour, at 1 Month & 6 Months post surgery.
79651528|NCT00247182|Behavioral|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
79981401|NCT02461732|Behavioral|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
79334194|NCT04961125|Genetic|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
79334195|NCT04970329|Drug|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
79651529|NCT00247182|Behavioral|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
79981402|NCT02461732|Behavioral|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
79485791|NCT02628223|Procedure|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
79485792|NCT02628223|Device|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
79485793|NCT02630017|Drug|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
79485794|NCT02630017|Drug|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
79485795|NCT02630017|Drug|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
79334196|NCT02465463|Procedure|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
79334197|NCT02465463|Device|flexible sigmoidoscopy|
79334198|NCT04970095|Device|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
79334199|NCT04970095|Device|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
79485796|NCT02630017|Drug|Non-ADHD placebo first, methylphenidate second|
79485797|NCT00366925|Device|Adacolumn®|
79485798|NCT02630719|Drug|Timolol eye drops|eye drops
79485799|NCT02630719|Drug|Artificial tears|Placebo drop
79485800|NCT02630953|Behavioral|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
79485801|NCT02630953|Behavioral|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
79485802|NCT02633371|Drug|Oxybutynin 3% gel|
79485803|NCT04159519|Drug|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation and Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
79334200|NCT04960657|Drug|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
79485804|NCT04159519|Drug|Fasenra®|Participants received Benralizumab 30 mg/mL, 1 mL fill volume via Subcutaneous every 4 weeks for first 3 doses.
79981403|NCT02039830|Behavioral|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
79485805|NCT04159519|Drug|Ventolin®|Participants received Salbutamol sulfate 100 μg per inhalation as needed.
79485806|NCT04079491|Other|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
79485807|NCT04871659|Other|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
79485808|NCT02634073|Drug|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
79981404|NCT02039830|Behavioral|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
79334201|NCT04960657|Drug|PACAP38|PACAP38 infusion
79334202|NCT02464059|Drug|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
79334203|NCT04969159|Other|no intervention|standard treatment in the clinical routine
79334204|NCT04960501|Procedure|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
79334205|NCT04960423|Procedure|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
79334206|NCT02463357|Dietary Supplement|Quercetin|
79485809|NCT02634073|Drug|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
79485810|NCT00366613|Procedure|Cataract surgery with Perfect Capsule and Sodium Chloride|
79485811|NCT00366691|Drug|Acular LS|
79651530|NCT00247182|Behavioral|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
79651531|NCT04622059|Behavioral|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
79334207|NCT02463357|Drug|Nifedipine extended release|
79334208|NCT02463357|Drug|Methazolamide|
79334209|NCT02463357|Drug|Metformin|
79334210|NCT02463357|Drug|Placebo|
79334211|NCT02463357|Drug|Nitrite|
79334212|NCT04960345|Device|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
79334213|NCT02579759|Drug|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
79651532|NCT04621903|Other|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
79651533|NCT04621942|Other|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
79334214|NCT02579759|Drug|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
79334215|NCT02579759|Drug|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
79334216|NCT04960189|Procedure|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
79334217|NCT04935255|Other|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
79334218|NCT04960267|Device|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
79334219|NCT04960033|Behavioral|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
79334220|NCT04952935|Procedure|True Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
79334221|NCT04952935|Procedure|Sham Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
79485812|NCT00366691|Drug|Lotemax|
79485813|NCT00366769|Device|Wavefront-guided LASIK using CustomVue platform|
79485814|NCT02637427|Biological|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
79485815|NCT04400071|Behavioral|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
79651534|NCT04621942|Other|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
79651535|NCT04621591|Device|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
79334222|NCT05600465|Behavioral|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
79981405|NCT00245570|Drug|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
79981406|NCT00245570|Drug|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
79981407|NCT00245570|Drug|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
79981408|NCT00245570|Drug|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
79981409|NCT02461888|Drug|Ixazomib|Chemotherapy
79334223|NCT05600465|Behavioral|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
79485816|NCT04400071|Behavioral|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
79651536|NCT04621474|Diagnostic Test|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
79981410|NCT02461888|Drug|Cyclophosphamide|Chemotherapy
79981411|NCT02461888|Drug|Dexamethasone|Chemotherapy
79981412|NCT00229970|Drug|montelukast sodium|7 mg or 14 mg single injection
79981413|NCT00229970|Drug|Comparator: Placebo|Placebo single injection
79981414|NCT02460796|Other|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
79981415|NCT00111722|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
79981416|NCT00111722|Drug|Comparator: placebo / Duration of Treatment - 1 day|
79981417|NCT03288064|Dietary Supplement|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
79981418|NCT03288064|Dietary Supplement|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
79981419|NCT03288064|Dietary Supplement|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
79981420|NCT04626596|Drug|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
79981421|NCT02461810|Device|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
79981422|NCT02461810|Procedure|Balloon Kyphoplasty|
79485817|NCT02638051|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
79485818|NCT02638051|Dietary Supplement|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
79485819|NCT02638051|Drug|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
79485820|NCT00367393|Drug|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
79485821|NCT00367471|Drug|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
79485822|NCT00367471|Drug|carboplatin|An alkylating agent used in the treatment of some cancers
79485823|NCT00367471|Drug|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
79485824|NCT00367471|Drug|paclitaxel|A mitotic inhibitor used in cancer treatment
79485825|NCT04380883|Device|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
79485826|NCT04380883|Device|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
79485827|NCT03643003|Behavioral|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
79485828|NCT03643003|Behavioral|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
79651537|NCT04621552|Device|WEB embolization|Treatment of intracranial aneurysms with WEB with the use of the virtual simulation before implantation of the device
79651538|NCT00412568|Procedure|Photorefractive Keratectomy (PRK)|vision correction with PRK
79651539|NCT00242970|Device|3-Dimensional Color Scanning|Color imaging of the face and neck.
79651540|NCT04621669|Drug|SHR3680|240 mg
79651541|NCT04621669|Drug|digoxin|0.25 mg
79651542|NCT04621669|Drug|Rosuvastatin calcium|10 mg
79485829|NCT02207244|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
79485830|NCT02207244|Drug|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
79485831|NCT02207244|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
79485832|NCT02207244|Drug|Placebo for adalimumab|Placebo for adalimumab [two 0.8 milliliter (mL) injections] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
79485833|NCT02638207|Drug|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
79485834|NCT04363879|Procedure|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
79485835|NCT04363879|Procedure|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
79485836|NCT02207088|Drug|ombitasvir/paritaprevir/ritonavir|tablet
79485837|NCT02207088|Drug|dasabuvir|tablet
79485838|NCT02207088|Drug|Ribavirin|tablet
79485839|NCT02638597|Drug|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
79485840|NCT02638597|Behavioral|smoking cessation counseling|smoking cessation counseling
79485841|NCT03585595|Other|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
79334224|NCT04969393|Device|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
79485842|NCT04333615|Behavioral|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
79485843|NCT04339309|Procedure|Non-surgical periodontal treatment with interdental hygiene devices|
79485844|NCT04339309|Procedure|Non-surgical periodontal treatment without interdental hygiene devices|
79485845|NCT02206620|Drug|Donepezil|
79485846|NCT02239926|Drug|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
79485847|NCT02239926|Drug|Placebo|
79485848|NCT02239692|Drug|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
79485849|NCT00367705|Dietary Supplement|VSL#3®|1-2 sachets/day per os, 6 months
79485850|NCT00367705|Dietary Supplement|Placebo|1-2 sachets/day per os, 6 months
79485851|NCT04340089|Behavioral|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
79485852|NCT02641249|Device|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
79485853|NCT04860414|Biological|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
79485854|NCT04860414|Other|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
79651543|NCT04621669|Drug|metformin hydrochloride|500 mg
79651544|NCT00412646|Drug|TMC125|
79981423|NCT01882036|Procedure|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
79812122|NCT05005572|Other|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
79334225|NCT04969393|Other|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
79334226|NCT04960111|Device|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
79334227|NCT04968691|Other|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
79485855|NCT04860414|Other|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
79485856|NCT04860414|Other|Objective taste tests|Recording of gustatory evoked potentials
79812123|NCT00663208|Drug|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
79812124|NCT00663208|Drug|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
79812125|NCT02609490|Drug|Azilsartan tablets|20mg/tablet
79812126|NCT02609490|Drug|Azilsartan placebo tablets|placebo tablet
79812127|NCT02609490|Drug|Olmesartan medoxomil tablets|20mg/tablet
79981424|NCT01882036|Other|Hypocaloric diet|Hypocaloric liquid diet for 10 days
79981425|NCT03619460|Procedure|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
79981426|NCT03619460|Procedure|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
79334228|NCT04968691|Other|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
79334229|NCT04959955|Diagnostic Test||
79334230|NCT04951843|Dietary Supplement|Black soybean koji product|Black soybean koji product
79334231|NCT04968769|Other|ischemic compression|manual therapy
79334232|NCT04968769|Other|kinesio taping|elastic therapeutic taping
79334233|NCT04968769|Other|exercise|posture exercises
79334234|NCT04952155|Drug|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
79485857|NCT00367783|Drug|CP-741,952|
79981427|NCT05235100|Drug|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
79981428|NCT03287986|Other|MRI|Structural and functional sequences
79651545|NCT00247221|Behavioral|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
79651546|NCT00247221|Behavioral|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
79651547|NCT00562393|Other|Nutritional|Overfeeding high fat diet for 28 days
79651548|NCT00562432|Device|Plexisyl-AF|Plexisyl-AF implants
79651549|NCT00562432|Other|No Treatment|CABG without the experimental treatment
79651550|NCT00562471|Other|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
79651551|NCT00562471|Other|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
79334235|NCT04959721|Combination Product|Injection with triamcinolone acetonide, bupivacaine, and normal saline|"Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast."
79334236|NCT04717739|Device|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
79334237|NCT04968613|Drug|Madopar monotherapy|In addition to basic treatment, the patient also received Madopar treatment
79334238|NCT04968613|Drug|senfrol monotherapy|In addition to the basic treatment, the patient also received the rofosson treatment
79651552|NCT00220376|Drug|SPM 907|
79485858|NCT02641561|Drug|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
79651553|NCT00243009|Drug|cyclosporine|
79651554|NCT00243009|Drug|fludarabine phosphate|
79651555|NCT00243009|Drug|mycophenolate mofetil|
79651556|NCT00243009|Procedure|allogeneic bone marrow transplantation|
79651557|NCT00243009|Procedure|peripheral blood stem cell transplantation|
79651558|NCT00243009|Radiation|radiation therapy|
79651559|NCT00562510|Drug|Raltegravir|Raltegravir 400 mg BID added to stable HAART
79651560|NCT00562510|Drug|Placebo|Placebo BID added to stable HAART
79651561|NCT00562666|Other|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
79651562|NCT00220415|Drug|SPM 927|
79651563|NCT00243048|Dietary Supplement|soy protein isolate|
79651564|NCT00243048|Radiation|radiation therapy|
79651565|NCT04621396|Other|Observational screening study|
79651566|NCT04621513|Device|laser acupuncture (RJ laser S/N 1813458)|use a low-level-laser acupuncture on acupoint
79651567|NCT04621513|Drug|western medicine|Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
79651568|NCT00220454|Drug|Climara|
79651569|NCT00220454|Drug|Hydrocortone|
79651570|NCT00562705|Behavioral|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
79651571|NCT00562705|Behavioral|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
79651572|NCT00247260|Device|32P BioSilicon|
79651573|NCT04621084|Behavioral|Eating habits|Questionnary online
79485859|NCT02641561|Drug|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
79485860|NCT02641561|Drug|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
79485861|NCT02641561|Drug|Placebo|Placebo would be a suppository 50 mg x 2
79485862|NCT02206152|Drug|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
79485863|NCT02206152|Drug|Placebo|
79485864|NCT00367081|Drug|TMX-SMX (Bactrim(R))|
79485865|NCT00367081|Drug|Pyrimethamine plus Sulfadiazine plus leucoverin|
79485866|NCT00367159|Procedure|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
79485867|NCT04146571|Drug|Ensartinib|Oral, ALK inhibitor
79334239|NCT04968613|Drug|placebo monotherapy|In addition to basic treatment, the patient also received selegiline treatment
79334240|NCT04968535|Device|StimaWELL|mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
79485868|NCT05342376|Drug|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
79485869|NCT05342376|Drug|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
79485870|NCT02239536|Procedure|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
79334241|NCT03058549|Behavioral|Family Expectations|Relationship education and referral services for expectant couples.
79334242|NCT04676555|Drug|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
79334243|NCT04676555|Drug|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
79485871|NCT02239536|Procedure|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
79485872|NCT02239224|Biological|Placebo|Concentrate for solution for infusion
79485873|NCT02239224|Biological|ATYR1940|Concentrate for solution for infusion
79651574|NCT04621162|Behavioral|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
79334244|NCT02445963|Biological|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
79334245|NCT04314167|Drug|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
79485874|NCT01600014|Drug|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
79485875|NCT01600014|Drug|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
79485876|NCT02237196|Biological|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
79485877|NCT02237196|Biological|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
79485878|NCT02237196|Biological|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
79485879|NCT02237196|Biological|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
79485880|NCT03953755|Procedure|Tricuspid valve repair|Tricuspid valve repair
79485881|NCT04740619|Procedure|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
79485882|NCT04418310|Procedure|Lay open and curettage|Lay open and curettage
79812128|NCT02609490|Drug|olmesartan medoxomil placebo tablets|placebo tablet
79651575|NCT04621162|Behavioral|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
79651576|NCT04621162|Behavioral|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
79485883|NCT04418310|Procedure|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
79485884|NCT04776096|Drug|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
79334246|NCT04968301|Device|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
79334247|NCT05575427|Drug|Minocycline|The patients will receive minocycline oral between 7-28 days
79981429|NCT04612010|Device|WAVES (Wobble-oscillator Auditory/Visual Excitatory Stimulation)|An app-based stimulation program administered that provides desynchronizing visual and auditory stimulation. The frequency of the stimulation oscillates around the baseline frequency determined by EEG.
79981430|NCT03294382|Drug|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
79334248|NCT05575427|Drug|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
79334249|NCT05575427|Drug|Placebo|Capsule without active compound
79334250|NCT03059095|Behavioral|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
79334251|NCT04959253|Combination Product|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
79334252|NCT04959253|Combination Product|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
79334253|NCT02499159|Drug|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
79334254|NCT02499159|Drug|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
79334255|NCT01664039|Drug|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
79334256|NCT01664039|Drug|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
79334257|NCT04968145|Other|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
79485885|NCT04776096|Drug|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
79485886|NCT02237118|Device|Mepitel One|
79485887|NCT02237118|Device|UrgoTul|
79485888|NCT02234622|Behavioral|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
79651577|NCT04621162|Behavioral|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
79651578|NCT04621162|Behavioral|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
79981431|NCT03294382|Drug|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
79981432|NCT05206370|Drug|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
79981433|NCT05206370|Drug|Placebo|film-coated oral tablets containing matched placebo
79981434|NCT05206370|Behavioral|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
79981435|NCT05205434|Other|Synchronous telerehabilitation programme|Exercise program and educational program
79981436|NCT05205434|Other|Asynchronous telerehabilitation programme|Exercise program educational program
79981437|NCT00092066|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
79981438|NCT03294226|Device|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
79981439|NCT03294226|Device|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
79485889|NCT02234622|Behavioral|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
79485890|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
79651579|NCT04621162|Behavioral|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
79981440|NCT01239082|Procedure|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
79981441|NCT01239082|Procedure|FIT|Annual FIT testing
79981442|NCT05225636|Procedure|thrombectomy|Extraction of intracranial thrombus in an acute large vessel occlusion
79981443|NCT03287518|Dietary Supplement|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
79334258|NCT02445573|Other|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
79334259|NCT02445573|Other|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
79334260|NCT05645705|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
79334261|NCT05645705|Other|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
79334262|NCT05645705|Other|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
79334263|NCT05645705|Other|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
79334264|NCT05645705|Other|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
79334265|NCT04968067|Device|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
79485891|NCT05588947|Other|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
79485892|NCT05588947|Other|Active Control|Life After Stroke educational video
79485893|NCT02203032|Drug|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
79485894|NCT02203032|Drug|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
79485895|NCT02203032|Drug|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
79485896|NCT02203032|Drug|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
79485897|NCT02169414|Drug|BIA 9-1067 5 mg|OPC, Opicapone
79485898|NCT02169414|Drug|BIA 9-1067 25 mg|OPC, Opicapone
79485899|NCT02169414|Drug|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
79485900|NCT02169414|Drug|Placebo|PLC, Placebo
79485901|NCT02169414|Drug|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
79651580|NCT00243087|Drug|BI 2536|
79651581|NCT04621357|Radiation|Brain MRI|Brain MRI will include differents sequences.
79651582|NCT04621357|Biological|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
79981444|NCT03287518|Dietary Supplement|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
79651583|NCT04621123|Biological|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
79651584|NCT04621123|Other|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
79812129|NCT00810810|Biological|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
79981445|NCT05225246|Other|Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital|Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
79981446|NCT03287440|Behavioral|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
79651585|NCT04621240|Behavioral|Online SMART & Stress Solutions|1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
79812130|NCT00810810|Biological|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
79812131|NCT00810810|Biological|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
79812132|NCT00661258|Behavioral|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
79812133|NCT05754606|Diagnostic Test|Audio recordings|Automatica analysis of audio recordings
79334266|NCT04968067|Device|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
79334267|NCT05644613|Other|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
79334268|NCT05644613|Other|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
79334269|NCT02445339|Drug|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
79334270|NCT04951375|Procedure|arthroscopic repair|arthroscopic repair
79334271|NCT04951531|Procedure|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
79334272|NCT04951531|Procedure|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
79812134|NCT05757414|Device|Tailored Lighting Intervention (LIT)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
79981447|NCT03287440|Behavioral|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
79981448|NCT05654792|Device|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation in cases of severe aortic stenosis
79334273|NCT04951531|Procedure|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
79334274|NCT04934787|Device|ENMS-BSF assisted gait training|"ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
79334275|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
79334276|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
79485902|NCT02201940|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79485903|NCT02201940|Drug|Placebo|Tablet administered orally once daily
79812135|NCT05757414|Device|Actigraph|An actigraph is a wrist worn device that measures rest and activity patterns
79981449|NCT03287362|Behavioral|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
79812136|NCT02610348|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
79812137|NCT02610348|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
79812138|NCT05757336|Drug|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
79981450|NCT03287362|Behavioral|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
79981451|NCT03287362|Behavioral|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
79334277|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
79334278|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
79334279|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
79334280|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
79981452|NCT05224934|Radiation|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
79981453|NCT04051034|Dietary Supplement|Omega 3|"Active: 1.25 g capsules/420 35-count bottles [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles [1.25-gram high oleic safflower oil capsule]"
79981454|NCT04051034|Other|Placebo|Active: 1.25 g capsules [1.25-gram high oleic safflower oil capsule] and heat therapy, increase internal body temperature 1.2 C above baseline.
79981455|NCT03287284|Device|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
79651586|NCT00243126|Behavioral|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
79334281|NCT03674931|Behavioral|musical practice|Intensive weekly musical keyboard training over 12 months
79651587|NCT04620967|Drug|Insulin aspart|Insulin aspart (Iasp) in insulin pump
79651588|NCT04620967|Drug|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
79651589|NCT00220493|Drug|Ritalin|
79651590|NCT04620655|Drug|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
79651591|NCT00247299|Device|IPL Quantum Product manufactured by Luminis Ltd.|
79651592|NCT04620616|Other|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
79651593|NCT04620616|Other|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
79981456|NCT03287284|Behavioral|Resistance Training|Resistance Training
79981457|NCT03287284|Device|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
79981458|NCT01334619|Procedure|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
79981459|NCT03287206|Biological|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
79981460|NCT03287206|Biological|blood samples from parents|secondary controls for children's analyses
79981461|NCT05223764|Other|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
79981462|NCT03223623|Device|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
79981463|NCT03223623|Device|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
79981464|NCT03223623|Device|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
79981465|NCT03287128|Drug|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
79981466|NCT05223686|Drug|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
79981467|NCT00457275|Drug|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
79981468|NCT04496804|Behavioral|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
79485904|NCT05588869|Other|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
79485905|NCT03568435|Other|Non-Interventional|Non-Interventional
79485906|NCT05588791|Diagnostic Test|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
79485907|NCT03085069|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
79485908|NCT03485365|Drug|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
79981469|NCT04496804|Behavioral|Wellness for MS (WellMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing wellness in people with MS.
79334282|NCT03674931|Behavioral|music education|Recreative weekly musical courses without practice over 12 months
79485909|NCT03485365|Drug|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
79981470|NCT03294070|Combination Product|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
79485910|NCT03485365|Drug|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
79485911|NCT03485365|Drug|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
79981471|NCT04075370|Other|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A&B and COWA over time.
79981472|NCT03953703|Drug|Levocarnitine|Levocarnitine 1000 mg twice per day for 6 weeks
79485912|NCT02169336|Drug|Intranasal Dexmedetomidine|
79485913|NCT02169336|Other|Intranasal Placebo|
79981473|NCT03953703|Drug|Placebo|Placebo 1000 mg twice per day for 6 weeks
79981474|NCT03299140|Behavioral|Family Focused Therapy|
79485914|NCT03043807|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
79981475|NCT04479566|Drug|Lithium Carbonate 250 MG|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
79981476|NCT04479566|Drug|Calcium Carbonate 500 MG|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
79981477|NCT06030297|Procedure|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fib"
79334283|NCT04959409|Drug|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
79334284|NCT03058939|Drug|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
79334285|NCT03058939|Drug|Perjeta|Only administered to patients with HER2-positive disease.
79334286|NCT03058939|Drug|Herceptin SC|Only administered to patients with HER2-positive disease.
79334287|NCT03058939|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
79485915|NCT03043807|Drug|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
79485916|NCT03043807|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
79485917|NCT03043807|Radiation|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
79485918|NCT03043807|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
79485919|NCT02609828|Drug|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
79485920|NCT05588635|Other|Identification of predictive factors|Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
79651594|NCT04620616|Other|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
79651595|NCT00247338|Drug|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
79651596|NCT00220532|Drug|Folic acid with riboflavin|
79334288|NCT03058939|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
79981478|NCT06030297|Drug|ZTlido 1.8 % Topical System|ZTLI(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4. Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base and also contains the following inactive ingredients: butylated hydroxytoluene, dipropylene glycol, isostearic acid, mineral oil, polyisobutylene, silicone dioxide, styrene/isoprene/styrene block copolymer, and terpene resin. DO (lidocaine topical system) 1.8% is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of ZTLIDO is 10 cm × 14 cm × 0.08 cm. Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-
79334289|NCT03058939|Drug|LHRH agonist|Administered to all premenopausal patients.
79334290|NCT03058939|Drug|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
79334291|NCT03058939|Drug|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
79334292|NCT03061045|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
79485921|NCT05588557|Drug|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
79651597|NCT04620694|Device|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
79651598|NCT04620499|Device|EEG|PEER EEG
79334293|NCT04951297|Other|None, just observation|None ,just observation test
79334294|NCT03058471|Drug|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
79334295|NCT03058471|Drug|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
79334296|NCT03058471|Drug|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
79334297|NCT03060967|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
79334298|NCT02579603|Drug|Nintedanib|Nintedanib 150mg bid
79334299|NCT02579603|Drug|Pirfenidone|
79334300|NCT04958629|Other|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
79334301|NCT04958863|Other|Surgical mask|Use of a surgical mask during test
79334302|NCT04958863|Other|Polyester reusable mask|Use of a polyester reusable mask during test
79334303|NCT04416841|Behavioral|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
79651599|NCT00243165|Behavioral|Lifemel honey intake every day|
79651600|NCT04620772|Drug|Cyclophosphamide injection|Cyclophosphamide vs placebo
79651601|NCT00220571|Device|Coronary Angioplasty (PTCA)|
79651602|NCT04620421|Other|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
79651603|NCT00243204|Drug|talabostat mesylate|
79651604|NCT00243204|Drug|docetaxel|
79485922|NCT05588557|Drug|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
79651605|NCT04620577|Other|antibiotic|normal saline
79651606|NCT04620850|Device|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
79981479|NCT06030297|Diagnostic Test|PeriCam PSI NR|It is a method that visualizes tissue blood perfusion in real time. LASCA provides new means to study the microcirculation in ways that were not possible in the past. PeriCam PSI System combines dynamic response and high spatial resolution in one instrument, providing both real-time graphs and video recordings of the tissue being studied. To further enhance its usability, dedicated application software, PIMSoft, has been developed.
79812139|NCT00871871|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
79812140|NCT00871871|Drug|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
79334304|NCT04416841|Behavioral|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
79334305|NCT04416841|Behavioral|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
79334306|NCT05696639|Procedure|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
79334307|NCT04967911|Other|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
79334308|NCT04967911|Other|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
79334309|NCT04951141|Biological|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
79334310|NCT03060889|Drug|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
79485923|NCT01632306|Drug|LY2090314|LY2090314 administered IV
79485924|NCT01632306|Drug|FOLFOX|FOLFOX administered IV
79485925|NCT01632306|Drug|Gemcitabine|Gemcitabine administered IV
79485926|NCT01632306|Drug|Nab-paclitaxel|Nab-paclitaxel administered IV
79485927|NCT02346565|Procedure|Exercise ECG|
79651607|NCT00562744|Other|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
79651608|NCT00220610|Device|Transcranial magnetic stimulation|
79651609|NCT04620460|Device|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
79651610|NCT04620031|Drug|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
79812141|NCT00871871|Drug|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
79485928|NCT02346565|Procedure|Stress Echocardiography|
79812142|NCT00871871|Drug|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
79812143|NCT02608788|Drug|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
79334311|NCT04950829|Device|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
79485929|NCT02600065|Other|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
79485930|NCT02201784|Drug|Levobupivacaine|Comparison of Equipotent doses
79981480|NCT06030297|Diagnostic Test|Medoc Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds)."
79485931|NCT02201784|Drug|Ropivacaine|Comparison of equipotent doses
79485932|NCT04340479|Diagnostic Test|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~Anterior midclavicular right and left (apical, medial, basal)~Posterior paraspinal right and left* (apical, medial, basal)~*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
79485933|NCT02201472|Device|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
79981481|NCT06030297|Other|Inactive Topical System|Inactive, non-medicated topical system comprised of an adhesive material containing, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of the system is 10 cm × 14 cm × 0.08 cm.
79981482|NCT06030271|Device|Microcatheter|Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
79981483|NCT06030232|Device|Therasphere|Transarterial radioembolization
79981484|NCT06030219|Drug|Omadacycline|10-day course
79334312|NCT04950829|Device|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
79334313|NCT04950829|Procedure|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
79334314|NCT05564195|Diagnostic Test|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
79485934|NCT02162329|Behavioral|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
79485935|NCT02162329|Procedure|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
79485936|NCT02162329|Procedure|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
79485937|NCT02162329|Behavioral|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
79981485|NCT06030219|Drug|Vancomycin Pill|10-day course
79981486|NCT06030219|Drug|Moxifloxacin|10-day course
79981487|NCT06030180|Device|EsoGuard|EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
79981488|NCT06030167|Behavioral|Insecure attachment and psychosocial functioning in autistic adults|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
79334315|NCT04967755|Drug|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
79651611|NCT04620031|Drug|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
79651612|NCT00243282|Behavioral|Relaxation Response (instruction, pocket practice card prov)|
79651613|NCT00243282|Behavioral|Mindfulness training using model developed from UMass|
79812144|NCT02608788|Drug|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
79812145|NCT02608788|Drug|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
79812146|NCT02608788|Drug|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
79812147|NCT05754372|Diagnostic Test|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
79334316|NCT04950907|Diagnostic Test|vats|Use uniportal tubeless VATS to obtain the biopsy
79334317|NCT04950907|Diagnostic Test|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
79334318|NCT04950595|Other|Plant-based mince|Spaghetti bolognaise meal made with plant-based mince
79334319|NCT04950595|Other|Beef mince|Spaghetti bolognaise meal made with beef mince
79334320|NCT04421365|Device|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
79334321|NCT04411589|Device|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
79334322|NCT04411589|Device|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
79334323|NCT04958395|Diagnostic Test|FFR and d-FFR|Measure FFR and d-FFR
79334324|NCT03060733|Other|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
79334325|NCT04311827|Other|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
79334326|NCT04958317|Other|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
79334327|NCT04958317|Other|Late exercise|Participants will exercise for 30 minutes after an evening meal.
79334328|NCT04950751|Biological|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
79334329|NCT04950361|Other|talocalcaneal coalition|patients with talocalcaneal coalition
79334330|NCT04967131|Other|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
79651614|NCT04620109|Drug|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
79651615|NCT04620109|Drug|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
79651616|NCT00220649|Drug|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
79651617|NCT04620265|Other|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
79651618|NCT04620265|Other|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
79812148|NCT04132349|Drug|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
79812149|NCT00913926|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
79812150|NCT02617355|Device|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
79812151|NCT02617355|Device|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
79812152|NCT02617355|Device|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
79651619|NCT04620265|Other|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
79812153|NCT02617355|Device|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
79981489|NCT06030128|Behavioral|core stabilization exercise|All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
79981490|NCT06030115|Other|Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)|Data collected on participants who completed the intensity recovery progression protocol program
79334331|NCT05546957|Drug|Aspirin|Administered orally once per day (QD)
79334332|NCT05546957|Drug|rivaroxaban low dose|Administered orally twice per day (BID)
79334333|NCT05546957|Drug|rivaroxaban high dose|Administered orally QD
79334334|NCT04950205|Drug|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
79334335|NCT05544461|Behavioral|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
79334336|NCT04415047|Device|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
79485938|NCT02647346|Device|Daily use of podimetrics smart-foot mat|
79485939|NCT05441995|Other|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
79485940|NCT02554838|Other|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
79485941|NCT02554838|Other|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
79485942|NCT02554838|Behavioral|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
79485943|NCT05588089|Other|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
79651620|NCT04620265|Other|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
79651621|NCT04620265|Other|The conventional exercise program|This group received the conventional exercise program only.
79651622|NCT00243321|Procedure|high dose-rate brachytherapy|High dose-rate brachytherapy
79812154|NCT02617355|Device|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
79981491|NCT06030089|Other|Pharmacokinetic sampling|4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2
79485946|NCT05587933|Procedure|cholecystectomy|cholecystectomy
79485947|NCT05587933|Drug|Antispasmodic|Antispasmodic
79485948|NCT02018263|Drug|Cocaine hydrochloride|
79485949|NCT02018263|Behavioral|Exercise|
79485950|NCT02018263|Drug|Nicotine|
79485951|NCT05442073|Other|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
79485952|NCT02649608|Drug|0.04 mg Lu AE04621|0.04 mg dose group
79485953|NCT02649608|Drug|0.08 mg Lu AE04621|0.08mg dose group
79485954|NCT02649608|Drug|0.2 mg Lu AE04621|0.2 mg dose group
79485955|NCT02649608|Drug|0.4 mg Lu AE04621|0.4 mg dose group
79485956|NCT02649608|Drug|0.6 mg Lu AE04621|0.6 mg dose group
79981492|NCT06030089|Other|Vital status determination|Survival situation 12 months after start of treament
79485957|NCT02649608|Drug|0.8 mg Lu AE04621|0.8 mg dose group
79485958|NCT02649608|Drug|1.0 mg Lu AE04621|1.0 mg dose group
79334337|NCT05540093|Other|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
79334338|NCT05540093|Other|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
79485959|NCT02649608|Drug|1.2 mg Lu AE04621|1.2 mg dose group
79485960|NCT02168946|Drug|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
79485961|NCT02168946|Drug|Best Available Therapy|Antibiotic(s) chosen by Investigator
79334339|NCT03924479|Device|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
79485962|NCT02649842|Device|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
79651623|NCT00243321|Procedure|intensity-modulated radiation therapy|intensity-modulated radiation therapy
79651624|NCT04620148|Drug|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
79651625|NCT04620148|Drug|Placebo|Matching placebo concentrate solution
79651626|NCT00220688|Device|Acupressure Wristbands|
79812155|NCT02615405|Dietary Supplement|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 & 2.
79334340|NCT05696405|Procedure|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
79334341|NCT03838601|Drug|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
79812156|NCT02615405|Dietary Supplement|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 & 2.
79981493|NCT06030089|Other|Toxicity assessments|Toxicity events
79981494|NCT06030089|Drug|Venetoclax and azacitidine combination|Response to treatment
79334342|NCT05592041|Drug|Banaba Leaf Extract|a herbal extract in the form of Bigel
79334343|NCT02625259|Drug|TAK-117|TAK-117 capsules
79334344|NCT02625259|Drug|Lansoprazole|Lansoprazole capsules
79334345|NCT02625259|Drug|TAK-117|TAK-117 tablets
79485963|NCT02650856|Drug|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
79485964|NCT02650856|Biological|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
79485965|NCT02168478|Drug|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
79485966|NCT02168478|Other|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
79485967|NCT02168478|Other|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
79485968|NCT00367874|Drug|Buprenorphine|
79485969|NCT00367874|Drug|Valproate|
79485970|NCT00367562|Drug|ENALAPRIL VALSARTAN METHYLPREDNISONE|
79485971|NCT02302976|Drug|cocaine hydrochloride|
79485972|NCT02302976|Drug|exenatide|
79485973|NCT02302976|Drug|placebo|
79485974|NCT05075564|Drug|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79485975|NCT05075564|Drug|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79485976|NCT02244164|Drug|Incretinomimetics|
79485977|NCT02244164|Drug|DPP-4 inhibitors|
79485978|NCT02152670|Drug|Methylphenidate|
79485979|NCT02152670|Drug|Alpha Methyl Para Tyrosine (AMPT)|
79485980|NCT02152670|Other|[11C]PHNO|
79485981|NCT02152670|Other|[11C]raclopride|
79485982|NCT02652416|Drug|BI 1026706|oral administration
79485983|NCT02652416|Drug|Placebo|placebo
79485984|NCT02028806|Drug|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
79651627|NCT04619641|Device|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
79651628|NCT04619641|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
79981495|NCT06030011|Behavioral|NYU Electronic Patient Visit Assessment (ePVA)|The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
79981496|NCT06030011|Behavioral|Usual Care|Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
79981497|NCT06029946|Diagnostic Test|elastography, ultrasound|First local anesthesia with lidocaine 2%, then 3 smears will be obtained for each nodule using a 20-22 gauge needle, multiple passes within the lesion will be made to obtain sufficient cells, the aspirate will be spread over a glass, fixed with ethanol 95% and submitted to the pathology department to be reported.
79334346|NCT04958083|Diagnostic Test|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
79981498|NCT06029933|Biological|Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)|Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
79334347|NCT02577107|Drug|ranibizumab|
79334348|NCT02577107|Drug|Conbercept|
79334349|NCT04958473|Drug|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
79334350|NCT04958473|Drug|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
79334351|NCT04957927|Drug|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
79651629|NCT04619758|Other|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
79651630|NCT00247455|Drug|Low fibre breakfast cereal (puffed rice/cornflakes)|
79334352|NCT01161953|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
79334353|NCT04957849|Procedure|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
79334354|NCT04957849|Procedure|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
79334355|NCT04688801|Drug|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
79334356|NCT04688801|Drug|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
79334357|NCT04957771|Other|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
79334358|NCT04966975|Other|neoadjuvant chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
79334359|NCT04957459|Other|No intervention|No intervention
79334360|NCT04950049|Drug|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
79651631|NCT00247455|Drug|High fibre cereal (All Bran/Bran Flakes)|
79651632|NCT04619914|Drug|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1)
79651633|NCT04619914|Drug|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
79651634|NCT00220766|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
79651635|NCT00220766|Drug|Dextrose, 5% in Water|
79651636|NCT04619875|Other|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
79651637|NCT04619875|Other|SG1|SG1 is a novel glycan
79651638|NCT04619875|Other|Lactulose|Lactulose is a synthetic dissacharide
79651639|NCT00243360|Behavioral|diagnostic and treatment clinical algorithms|
79651640|NCT04619290|Drug|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
79651641|NCT04619290|Other|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
79651642|NCT04619563|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
79981499|NCT06029933|Biological|High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)|Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
79981500|NCT06029881|Device|Movesense MD|This device can be attached to the skin (on the chest and center of mass) during sleep using a belt and adhesive electrodes.
79334361|NCT04950049|Other|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
79651643|NCT04619329|Device|GSMs-TACE|TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
79651644|NCT04619329|Procedure|Surgical Resection|Surgical Resection of HCC
79334362|NCT04950049|Other|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
79651645|NCT00220844|Drug|Desipramine|
79651646|NCT00220844|Drug|Amitriptyline|
79981501|NCT06029868|Dietary Supplement|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
79334363|NCT04950049|Other|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
79334364|NCT04966897|Dietary Supplement|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
79981502|NCT06029868|Dietary Supplement|Placebo Black seed oil capsule|Placebo Black seed oil capsule
79981503|NCT06029855|Other|Kabat Therapy|The participants of group A will receive Kabat Rehabilitation with routine physical therapy. The protocol will be given to the participants for three sessions/week for six weeks. Each session will be of 30 minutes.
79485985|NCT01756118|Drug|BEZ235|A minimum of 3 dose levels
79651647|NCT04619212|Device|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
79651648|NCT00247494|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
79651649|NCT04619407|Diagnostic Test|Nasopharyngeal swab|SARS-CoV-2 PCR
79651650|NCT04619407|Diagnostic Test|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
79651651|NCT00562783|Drug|Vitaliver|
79651652|NCT00562783|Drug|Placebo|
79651653|NCT00243399|Drug|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
79651654|NCT00562822|Procedure|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
79651655|NCT00562822|Other|Physical and medical therapy|Treatment with physical and medical therapy alone
79651656|NCT00220922|Procedure|Alcohol Wipes vs. No Alcohol Wipes|
79651657|NCT00243438|Device|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
79651658|NCT04618939|Biological|BR-TD-1001|0.5 mL, IM
79651659|NCT04618939|Biological|Td-pur inj|0.5 mL, IM
79981504|NCT06029855|Other|Mime Therapy|The participants of group B will receive Mime Therapy in addition to routine physical therapy. The protocol will be given to the participants once a week for six weeks, while physical therapy will be given on alternate days. Each session will be of 30 minutes.
79981505|NCT06029829|Drug|Sintilimab|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
79981506|NCT06029816|Drug|Neratinib tablets|Neratinib tablets
79651660|NCT00562900|Procedure|robotic assisted cholecystectomy|robotic assisted cholecystectomy
79334365|NCT04966897|Dietary Supplement|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
79651661|NCT00562900|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
79981507|NCT06029803|Procedure|Adrenal Venous Sampling via Antecubital Approach|Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
79651662|NCT04618900|Procedure|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
79651663|NCT00221000|Drug|Methoxsalen|
79981508|NCT06029803|Procedure|Adrenal Venous Sampling via Femoral Approach|Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
79651664|NCT00221000|Procedure|Extracorporeal Photopheresis|
79651665|NCT04619134|Other|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
79334366|NCT03737045|Other|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
79334367|NCT05587673|Drug|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
79334368|NCT02444793|Drug|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
79334369|NCT02444793|Drug|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
79334370|NCT04957381|Behavioral|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
79334371|NCT04957069|Procedure|fixation|double row fixation with 3-4 wire anchors
79334372|NCT04957069|Procedure|primary repair|end-to-end repair
79334373|NCT04966429|Drug|Maraviroc|Tablets
79334374|NCT04956913|Device|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
79651666|NCT04619134|Other|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
79651667|NCT00243477|Drug|Escitalopram|Escitalopram 10mg or placebo once a day
79334375|NCT04956913|Device|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
79334376|NCT04949659|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
79334377|NCT04949581|Other|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
79651668|NCT04619173|Other|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
79651669|NCT04619173|Other|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
79651670|NCT04618783|Biological|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
79651671|NCT04618783|Biological|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
79651672|NCT04618783|Biological|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
79812157|NCT02615405|Dietary Supplement|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
79334378|NCT04949581|Other|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
79651673|NCT04618783|Biological|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
79981509|NCT06029790|Other|gum chewing|For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence.
79651674|NCT04618783|Biological|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
79812158|NCT04130789|Other|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
79812159|NCT04130789|Other|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
79812160|NCT00849680|Other|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
79334379|NCT04949971|Behavioral|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
79334380|NCT04966195|Radiation|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
79334381|NCT04965883|Procedure|Excision and Grafting|reconstruction of deep burn by grafting
79485986|NCT04339712|Drug|Anakinra|In case of diagnosis of MAS treatment with anakinra
79651675|NCT00221039|Drug|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
79651676|NCT00243516|Device|PREtest Consult|
79334382|NCT04965883|Procedure|dressing then delayed grafting|multiple dressing and delayed grafting
79334383|NCT04949347|Biological|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
79485987|NCT04339712|Drug|Tocilizumab|In case of diagnosis of immune dysregulation treatment with tocilizumab
79485988|NCT02656160|Drug|Placebo|Placebo 3 hrs before sleep
79485989|NCT02656160|Drug|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
79485990|NCT02684396|Drug|TAK-648|TAK-648 Solution
79485991|NCT02684396|Drug|TAK-648 Placebo|TAK-648 placebo-matching solution
79485992|NCT02657252|Drug|Glucose|Sclerotherapy of telangiectasis in one lower limb.
79485993|NCT02657252|Drug|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
79485994|NCT02657564|Drug|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
79651677|NCT00562939|Biological|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
79651678|NCT00562939|Biological|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
79651679|NCT04618510|Device|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
79812161|NCT00849680|Biological|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
79812162|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
79812163|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
79812164|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
79812165|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
79812166|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
79812167|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
79981510|NCT06029764|Procedure|extended one-level interbody fusion|For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
79981511|NCT06029751|Other|No intervention|No intervention
79981512|NCT06029738|Behavioral|Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)|MCT-OCD is a group education for OCD patients.
79334384|NCT04956367|Procedure|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
79334385|NCT04956367|Device|CO2 laser with PRP|CO2 laser with PRP
79334386|NCT04956367|Device|CO2 laser with placebo|CO2 laser with placebo
79334387|NCT04956601|Radiation|vaginal brachytherapy/pelvic external beam radiotherapy|high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
79334388|NCT04966039|Other|No intervention.|There was no intervention.
79334389|NCT04956055|Other|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
79334390|NCT04955977|Other|Physical exercise program|"Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m.~Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s."
79334391|NCT04955977|Other|Health education in COPD|Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.
79651680|NCT04618510|Device|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
79981513|NCT06029699|Device|high flow nasal cannula|device are used for weaning patients after mechanical ventilation extubation
79981514|NCT06029699|Device|non invasive positive pressure ventilation|device are used for weaning patients after mechanical ventilation extubation
79981515|NCT06029686|Device|Stanford Glove|The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
79981516|NCT06029660|Device|IMPEDE-FX RapidFill Implants|Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
79981517|NCT06029660|Procedure|EndoVascular Aneurysm Repair|Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
79981518|NCT06029634|Diagnostic Test|T-bet B cell|The frequency, function, and phenotype of T-bet B cells was tested
79981519|NCT06029621|Procedure|RATS for Thymectomy|a minimally invasive surgical type for Thymoma: RATS
79981520|NCT06029621|Procedure|VATS for Thymectomy|a minimally invasive surgical type for Thymoma: VATS
79981521|NCT06029595|Drug|Experimental: CHF6001 3200 μg|800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
79981522|NCT06029595|Drug|Placebo Comparator: CHF6001 Placebo|2 inhalations of CHF6001 matching placebo BID
79981523|NCT06029582|Device|VR headset|Virtual Reality Headset
79981524|NCT06029569|Procedure|Rapamycin drug balloon angioplasty|Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.
79334392|NCT04956211|Procedure|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
79651681|NCT04618627|Other|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
79981525|NCT06029569|Procedure|Paclitaxel drug balloon angioplasty|Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
79334393|NCT04949035|Diagnostic Test|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
79981526|NCT06029491|Device|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulse TM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
79334394|NCT04948879|Procedure|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
79334395|NCT04948957|Drug|Esmolol|
79334396|NCT04948957|Drug|Nitroglycerin|
79334397|NCT04948801|Drug|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
79334398|NCT04948255|Other|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
79334399|NCT04965415|Behavioral|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
79334400|NCT04965415|Behavioral|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
79334401|NCT04948567|Other|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
79334402|NCT04948567|Other|split-dose of PEG|purgative for bowel preparation
79334403|NCT04955665|Procedure|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
79334404|NCT04955665|Procedure|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
79334405|NCT04965571|Genetic|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
79334406|NCT04955509|Other|MRI|conventional MRI and diffusion MRI
79334407|NCT03060655|Biological|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
79334408|NCT03060655|Biological|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
79334409|NCT03060187|Other|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
79334410|NCT04955353|Dietary Supplement|AVC-H2|A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
79334411|NCT04955353|Dietary Supplement|Placebo|A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
79485995|NCT04740086|Procedure|Calcium alginate hydrogel|"The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~The IFO was closed with a 3/0 braided resorbable suture.~The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
79485996|NCT04857008|Device|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
79485997|NCT04339400|Drug|TQ05105|TQ05105 is a JAK2 inhibitor.
79485998|NCT04693832|Device|5inD|Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
79981527|NCT06029374|Procedure|Functional Treatment|Patients receiving buddy taping for fingers IV and V and an elastic bandage in terms of a functional treatment. Duration of bandage treatment is determined with 4 weeks.
79485999|NCT02684630|Device|Trima Accel System|Platelet Apheresis Procedure
79486000|NCT04670042|Device|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
79651682|NCT04618549|Procedure|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
79334412|NCT03060343|Biological|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10^5 cells/kg, Dose Level Two: 1.0×10^6 cells/kg, Dose Level Three: 1.0×10^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
79334413|NCT04955119|Diagnostic Test|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
79334414|NCT04965103|Procedure|SCR|Superior Capsule reconstruction
79486001|NCT04739618|Drug|Keytruda Injectable Product|PD-1 inhibitor antibody
79486002|NCT04739618|Drug|Yervoy Injectable Product|Anti-CTLA-4 antibody
79486003|NCT04739618|Drug|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
79651683|NCT04618549|Procedure|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
79651684|NCT04618549|Procedure|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
79651685|NCT00221078|Device|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
79651686|NCT04618588|Procedure|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
79651687|NCT00247533|Procedure|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
79651688|NCT04618159|Other|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
79651689|NCT04618120|Other|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
79981528|NCT06029374|Procedure|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
79981529|NCT06029361|Device|Selfit Device group|During 21 days, intervention group will receive physical therapy of 45 minutes which 15 minutes out of the 45 minutes will be with the SELFIT system
79981530|NCT06029361|Other|Control Group|Conventional physical therapy of 45 minute
79334415|NCT04965103|Procedure|Bridging|Tendon repair with graft interposition
79334416|NCT04954963|Diagnostic Test|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
79334417|NCT03060421|Device|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
79334418|NCT04955041|Other|MRI|T2* MRI
79334419|NCT04954885|Procedure|Biospecimen Collection|Undergo stool sample
79334420|NCT04954885|Other|Physical Performance Testing|Undergo short physical performance battery
79334421|NCT04954885|Other|Physical Performance Testing|Perform 6-minute walk test
79334422|NCT04954885|Other|Questionnaire Administration|Complete questionnaires
79334423|NCT04965805|Device|cold plasmaJet kINPen Med|experimental, non-inferiority
79334424|NCT04965805|Device|Best practice wound dressings|comparative,
79486004|NCT04739618|Procedure|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
79651690|NCT04618120|Other|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
79651691|NCT00221156|Drug|Acarbose|
79651692|NCT04618276|Other|Photodynamic Therapy|PDT with two different photosensitizers
79981531|NCT06029205|Behavioral|Conscious Awareness-Based Educatıon|The effect of Conscious Awareness-Based Education on nurses
79981532|NCT06029205|Behavioral|Stress coping training|The effect of stress coping training on nurses
79334425|NCT02624713|Behavioral|obesity treatment|"Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
79334426|NCT03058081|Device|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher&Paykel)
79486005|NCT02684942|Drug|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
79651693|NCT04618042|Drug|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
79981533|NCT06029166|Device|Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)|Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
79981534|NCT06029101|Procedure|posterior fossa craniectomy with or without duraplasty|craniectomy of occipital bone and duroplasty with graft to expand the shallow posterior fossa and reposition the cerebellar tonsils.
79981535|NCT06028958|Other|Neck Isometrics Exercises|Isometric exercises are tightening (contractions) of a specific muscle or group of muscles. During isometric exercises, the muscle doesn't noticeably change length. The affected joint also doesn't move. Isometric exercises help maintain strength.
79486006|NCT02684942|Drug|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
79486007|NCT04339010|Other|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
79486008|NCT04339010|Other|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
79486009|NCT04739774|Drug|CHF6001 DPI|Single dose of CHF6001
79486010|NCT04739774|Drug|Itraconazole|Repeated doses of oral Itraconazole
79486011|NCT02685956|Device|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
79486012|NCT02660918|Drug|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
79486013|NCT02660918|Other|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
79486014|NCT02687126|Device|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
79812168|NCT00849680|Biological|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
79981536|NCT06028958|Other|Global Posture Re-Education|Global postural rehabilitation (GPR) is an approach that considers the body in its overall aspect. This technique aims to relax the envelope of the muscles (fascia) while relaxing the muscle chains to reduce the strain on the joints. The end result is a more suitable posture and less pain.
79334427|NCT04430179|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300 mg every other week for 24 weeks
79334428|NCT04430179|Other|Placebo|No active drug
79486015|NCT04564196|Procedure|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
79486016|NCT02688218|Behavioral|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
79486017|NCT02688218|Behavioral|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
79486018|NCT00367315|Drug|Lumiracoxib|
79486019|NCT02662244|Device|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
79486020|NCT01328587|Drug|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
79651694|NCT04618042|Drug|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
79651695|NCT04618003|Behavioral|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
79812169|NCT04045691|Drug|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
79812170|NCT04045691|Drug|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
79812171|NCT00810342|Behavioral|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
79812172|NCT00810342|Behavioral|physical activity standard|standard print and website information on how to become more active
79981537|NCT06028919|Device|Temperature controlled DiamondTemp (DT) ablation catheter|The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
79981538|NCT06028919|Device|Tacticath/Tactiflex (TF) ablation catheter|The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
79981539|NCT06028906|Diagnostic Test|Multimodal physiological monitoring and cerebral autoregulation monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) and ECG.~Non-invasive cerebral autoregulation index Mx will by calculated as a Pearson correlation coefficient between slow ABP and slow CBFV waves.~Invasive cerebral autoregulation index (Pressure reactivity index PRx) will by calculated as a Pearson correlation coefficient between slow ABP and slow ICP waves.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
79981540|NCT06028867|Procedure|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
79981541|NCT06028841|Biological|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
79981542|NCT06028828|Drug|Fludarabine|Given Day-5, Day-4, Day-3, Day-2
79981543|NCT06028828|Drug|Melphalan|Given Day-5
79981544|NCT06028828|Radiation|Total Body Irradiation|Given Day-1
79981545|NCT06028815|Behavioral|Group music therapy|Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
79651696|NCT00243555|Procedure|allergy skin testing|
79651697|NCT00243555|Procedure|venepuncture|
79651698|NCT00221234|Behavioral|Print materials, pedometers/logbooks|
79651699|NCT00221234|Behavioral|Print materials, pedometers/logbooks, telephone counselling|
79334429|NCT04946929|Drug|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
79981546|NCT06028789|Diagnostic Test|Blood sample test|"The following groups of biomarkers will be examined:~standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~microbiology cultures according to the clinical status~serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~cell function assay: IL-18 and IFN-γ~hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)"
79651700|NCT04617691|Drug|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
79651701|NCT04617613|Drug|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
79651702|NCT04617613|Drug|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
79651703|NCT04617652|Drug|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
79981547|NCT06028789|Procedure|Thoracic Aortic Surgery|Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
79981548|NCT06028763|Procedure|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
79334430|NCT04946929|Drug|Low molecular weight heparin|half amount low molecular weight heparin
79334431|NCT04933045|Device|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
79334432|NCT03058159|Other|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
79651704|NCT04617652|Drug|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
79651705|NCT02961738|Behavioral|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
79651706|NCT00221273|Procedure|ACL surgery|
79651707|NCT04617730|Device|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
79651708|NCT04617730|Other|Flamigel®|The control arm will be treated according to the standard of care.
79651709|NCT04617223|Procedure|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
79334433|NCT02624791|Device|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
79334434|NCT02624791|Device|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
79334435|NCT02624791|Other|No contact lenses|simulated driving tests
79334436|NCT03058237|Drug|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
79334437|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
79334438|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
79486021|NCT02087449|Device|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
79486022|NCT05441761|Drug|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
79334439|NCT03058237|Drug|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
79486023|NCT02685007|Other|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
79334440|NCT04947241|Drug|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
79334441|NCT04946539|Diagnostic Test|Ultrasonography|Enthesitis assessment via ultrasonography
79486024|NCT00581503|Device|diagnostic|oct imaging
79812173|NCT04130945|Other|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
79334442|NCT03058393|Other|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
79334443|NCT04944511|Drug|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
79486025|NCT05587621|Drug|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
79486026|NCT04739215|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
79334444|NCT03057925|Device|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
79334445|NCT04933279|Dietary Supplement|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
79486027|NCT04739215|Drug|Placebo|One Placebo capsule daily oral
79486028|NCT02665364|Biological|IFNα-Kinoid|
79486029|NCT02665364|Other|Placebo|
79486030|NCT02665364|Other|ISA 51 VG|
79651710|NCT04617184|Other|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
79651711|NCT00247572|Drug|NRP104|
79651712|NCT00221312|Drug|Fosamax|
79651713|NCT04616989|Behavioral|Psycho-education|Provide psycho-education to members of the community
79651714|NCT04616989|Behavioral|Comparator|Distribution of COVID-19 leaflets to members of the community
79651715|NCT04617106|Procedure|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
79812174|NCT00849524|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
79486031|NCT02688829|Device|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
79486032|NCT00556309|Device|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
79486033|NCT02689063|Drug|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
79486034|NCT02689063|Drug|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
79812175|NCT00808080|Biological|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
79486035|NCT02689063|Drug|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
79334446|NCT04933279|Dietary Supplement|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
79334447|NCT03057301|Device|iCare home tonometer|All subjects will be taught to use the home care tonometer.
79334448|NCT04943809|Device|POD 26P AY FT|Routine cataract surgery
79334449|NCT04943809|Device|POD 26P AY F|Routine cataract surgery
79486036|NCT02689063|Drug|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
79486037|NCT02690935|Drug|2LALERG|Homeopathic drug
79651716|NCT04617145|Other|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
79651717|NCT00221351|Procedure|CRP point of care testing|
79651718|NCT00243594|Biological|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
79651719|NCT04616911|Procedure|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
79651720|NCT04616911|Procedure|LIFT|Ligation of the intersphincteric fistula tract
79812176|NCT04036266|Procedure|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
79812177|NCT00866723|Drug|bevacizumab|
79334450|NCT04946695|Other|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
79334451|NCT03058003|Diagnostic Test|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
79334452|NCT03058003|Other|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
79334453|NCT02577029|Drug|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
79334454|NCT02577029|Drug|entecavir|0.5 mg once daily; oral
79334455|NCT02577029|Biological|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
79486038|NCT02690935|Drug|Placebo|Placebo
79486039|NCT00367861|Drug|interruption of Glivec®|interruption of Glivec®
79486040|NCT02666846|Drug|Ibuprofen|
79486041|NCT02666846|Drug|Diclofenac|
79486042|NCT02666846|Drug|Methyl-salicylate / Menthol|
79486043|NCT02666846|Drug|Placebo|
79486044|NCT02643979|Drug|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
79486045|NCT02643979|Drug|Propofol|100mg of Propofol
79486046|NCT02643979|Drug|Saline|1mL of saline
79486047|NCT02667392|Procedure|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
79486048|NCT02667392|Procedure|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
79651721|NCT04616638|Behavioral|Resistance Training for Empowerment (RT-POWER)|The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
79651722|NCT04616638|Behavioral|A traditional RT intervention|The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
79651723|NCT04616872|Drug|Methotrexate-LDE|MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
79651724|NCT04616872|Drug|Placebo-LDE|Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
79651725|NCT00221390|Drug|Ropinirole (+ physical therapy)|
79651726|NCT00221390|Drug|(vs.) Placebo + physical therapy|
79651727|NCT00247650|Drug|Zoledronic Acid; Letrozole|
79651728|NCT04616755|Other|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
79651729|NCT04616716|Drug|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
79981549|NCT06028763|Procedure|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
79981550|NCT06028737|Drug|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
79981551|NCT06028737|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
79334456|NCT02577029|Drug|tenofovir disoproxil|300 mg once daily; oral
79334457|NCT02577029|Drug|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
79651730|NCT04616521|Procedure|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
79486049|NCT05587231|Drug|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
79981552|NCT06028737|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
79981553|NCT06028737|Drug|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
79981554|NCT06028711|Other|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
79334458|NCT04932889|Other|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
79334459|NCT04932889|Other|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
79486050|NCT05587231|Drug|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
79486051|NCT02667704|Drug|Bosentan|
79486052|NCT02667704|Drug|Nintedanib|
79812178|NCT00697853|Biological|Engerix™-B|3-dose intramuscular injection
79334460|NCT04932889|Other|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
79334461|NCT04946617|Drug|undefined|Rinsing with mouthwashes
79334462|NCT04946383|Drug|Dasatinib plus Quercetin|Dasatinib plus Quercetin
79486053|NCT02645617|Drug|Varnish|Topical application to the teeth
79486054|NCT02668952|Drug|0.9% Normal Saline (0.9% Sodium Chloride) injection|
79486055|NCT02668952|Drug|Isolyte S injection|
79486056|NCT02648971|Procedure|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
79486057|NCT02648971|Procedure|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
79651731|NCT00251043|Behavioral|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
79812179|NCT00697853|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
79812180|NCT02615327|Dietary Supplement|8 g Polydextrose|8g of Polydextrose
79812181|NCT02615327|Dietary Supplement|12 g Polydextrose|12 g of Polydextrose
79334463|NCT04943653|Drug|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
79334464|NCT04942951|Diagnostic Test|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
79334465|NCT04942951|Other|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
79334466|NCT04942951|Other|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
79334467|NCT04942951|Other|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
79334468|NCT02577887|Device|Patients implanted with a St. Jude Medical pacemakers|
79334469|NCT04943029|Drug|Carrelizumab|Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
79334470|NCT04943029|Drug|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.
79651732|NCT00251043|Behavioral|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
79651733|NCT00563017|Drug|Long-acting Risperidone microspheres injection|
79651734|NCT00563056|Drug|Flutiform|
79651735|NCT00563056|Drug|Flixotide plus Foradil|
79651736|NCT00563095|Procedure|Transcatheter Arterial Chemoembolization (TACE)|
79651737|NCT00563095|Procedure|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
79334471|NCT04943029|Drug|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
79334472|NCT04943029|Procedure|Surgery|Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
79334473|NCT05236283|Diagnostic Test|Blood Culture|Blood Culture
79334474|NCT04932499|Other|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
79651738|NCT00563134|Drug|GR270774|
79651739|NCT00563173|Drug|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
79651740|NCT00221468|Drug|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
79651741|NCT00563212|Drug|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
79651742|NCT00563251|Drug|Azithromycin|
79486058|NCT02689154|Device|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
79486059|NCT02694445|Other|observation|The study is non-interventional.
79334475|NCT04932499|Other|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
79334476|NCT05535101|Device|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
79334477|NCT05535101|Device|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
79334478|NCT04943107|Other|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
79334479|NCT03660059|Drug|Peficitinib|Oral
79334480|NCT03660059|Drug|Plaebo|Oral
79334481|NCT03660059|Drug|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
79334482|NCT04943263|Other|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
79334483|NCT04932343|Diagnostic Test|cohort study|no intervention
79486060|NCT02690168|Behavioral|Fasting|72 hour fasting
79486061|NCT02694601|Dietary Supplement|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
79334484|NCT04943185|Device|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
79486062|NCT02694601|Dietary Supplement|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
79486063|NCT02694601|Dietary Supplement|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
79486064|NCT02694835|Device|Delefilcon A contact lenses with UV Absorber|
79486065|NCT02694835|Device|Delefilcon A contact lenses|
79486066|NCT02696083|Device|Provant Therapy System|
79651743|NCT00563251|Drug|Placebo tablet|
79981555|NCT06028711|Other|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
79651744|NCT03454516|Other|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
79334485|NCT04942873|Other|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
79334486|NCT03634319|Device|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
79334487|NCT04946227|Drug|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
79486067|NCT05585203|Behavioral|Contingency management|"The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total."
79812182|NCT02615327|Dietary Supplement|16 g Polydextrose|16 g of Polydextrose
79812183|NCT02615327|Dietary Supplement|Placebo|0 g of Polydextrose
79981556|NCT06028685|Device|Acupoint stimulation|The experimental group will receive low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3). The stimulation will be administered three times per week for a duration of six weeks.
79334488|NCT04945525|Other|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
79334489|NCT04932187|Drug|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
79334490|NCT04931719|Combination Product|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
79334491|NCT04931719|Combination Product|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
79334492|NCT04945681|Biological|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 15 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
79981557|NCT06028685|Device|Acupoint stimulation(placebo)|The control group will receive sham low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3), without emitting laser beams.The stimulation will be administered three times per week for a duration of six weeks.
79981558|NCT06028659|Other|Coffee|Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
79981559|NCT06028659|Other|Water|150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
79981560|NCT06028633|Drug|pembrolizumab|pembrolizumab 200mg IV on day 1 for every 3 weeks
79981561|NCT06028633|Drug|lenvatinib|lenvatinib 8mg taken orally every day
79981562|NCT06028633|Drug|albumin-bound paclitaxel|albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
79981563|NCT06028594|Drug|Pozelimab|Subcutaneous (SC) administration
79981564|NCT06028594|Drug|Cemdisiran|Subcutaneous (SC) administration
79981565|NCT06028581|Other|breastfeeding support system|Using the breastfeeding support system
79981566|NCT06028425|Drug|LOXO-783|Administered orally.
79981567|NCT06028412|Procedure|Segmentectomy|Patients in the lung segment group underwent anatomical segmental resection surgery, including subsegmental resection of the lung Patients in the lung segment group underwent anatomical segmental resection surgery, including subsegmental resection of the lung It is recommended to perform intraoperative lymph node sampling and rapid pathological examination (not mandatory). If lymph node metastasis is found during the surgery, the surgery must be switched to lobectomy. Lymph node sampling, selective lymph node dissection, or systematic lymph node dissection can also be used.
79334493|NCT04945291|Behavioral|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
79334494|NCT04945291|Behavioral|Mobile applications|the participant will use a mobile application to log their calories
79334495|NCT04942795|Device|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
79334496|NCT04942561|Device|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
79486068|NCT05585203|Behavioral|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
79486069|NCT02650219|Genetic|genetic analyses|
79981568|NCT06028412|Procedure|Lobectomy|lobectomy
79981569|NCT06028399|Other|Concurrent Training|The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise & toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
79981570|NCT06028399|Other|Aerobic Training|The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
79981571|NCT06028373|Drug|ATG-031|ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.
79981572|NCT06028308|Device|Smartphone playing a sound|A sound will be played from a portable device (smartphone mounted with earphones) during movement
79981573|NCT06028269|Device|Smartphone playing a sound|A sound will be played from a portable device (smartphone) during movement
79981574|NCT06028256|Drug|Norepinephrine Hydrochloride|"Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform.~Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision."
79981575|NCT06028256|Drug|Placebo|Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
79334497|NCT04942561|Device|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
79334498|NCT04942171|Procedure|Atrial fibrillation catheter ablation group|"Pulmonary vein isolation~Additional treatment for lesions caused by non-pulmonary veins~Esophageal temperature monitoring to prevent damage to the esophagus~Evaluation of procedure time and radiofrequency ablation time~Evaluation of complications after the procedure~Rhythm follow-up after the procedure is conducted in accordance with the above study design.~Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
79334499|NCT04942171|Drug|Medical therapy group|"Use of beta-blockers or calcium channel blockers for pulse rate control~Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
79334500|NCT04944823|Other|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
79334501|NCT04930939|Other|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
79334502|NCT03597347|Drug|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
79334503|NCT03597347|Device|PARI eFlow nebulizer system|PARI eFlow nebulizer system
79334504|NCT04944355|Other|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
79334505|NCT04942015|Drug|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
79486070|NCT05574439|Behavioral|TCOC treatment|The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
79334506|NCT04942015|Drug|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
79486071|NCT05574439|Drug|Semaglutide 3 mg|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
79334507|NCT04941859|Behavioral|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
79334508|NCT04942249|Other|No intervention|No intervention
79334509|NCT04431427|Device|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
79486072|NCT02698033|Drug|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
79486073|NCT02698033|Other|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
79486074|NCT02690948|Biological|Pembrolizumab|Given IV
79651745|NCT02961543|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
79334510|NCT04431427|Device|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
79334511|NCT04930627|Drug|Empagliflozin|dosis depending on body weight: <20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; >40 kg 2 x 10 mg
79651746|NCT02961543|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
79334512|NCT03057769|Drug|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
79334513|NCT03057769|Drug|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
79334514|NCT03057769|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
79334515|NCT05508269|Genetic|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
79486075|NCT02690948|Drug|Vismodegib|Given PO
79486076|NCT02698735|Drug|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
79486077|NCT02698735|Drug|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
79981576|NCT06028243|Other|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Information stage|The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis (400 minutes and two days). They held the training at all participants' convenience outside the class hours. The training consisted of four sections: (1) osteoporosis and diagnosis-treatment methods, (2) current approaches to the prevention of osteoporosis, (3) osteoporosis and nutrition, and (4) osteoporosis and physical exercise. The researchers employed interactive teaching methods and consulted three experts to prepare PowerPoint presentations. At the end of the training, the researchers taught the intervention group participants how to fill out the healthy life diary, such as calculating daily calcium intake. The researchers texted the intervention group participants all training videos on WhatsApp to allow them to watch them again.
79981577|NCT06028243|Other|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Motivation stage|The researchers regularly texted (WhatsApp) spot and reminder notifications concerning the prevention of osteoporosis. They asked them to assess the health behaviors they recorded in their diaries every week (daily calcium intake, weekly exercise duration, etc.) and the problems they experienced during the process. The researchers provided individual counseling to the participants by telephone (combating smoking, exercise barriers, food exchange for calcium sources, etc.)
79981578|NCT06028243|Behavioral|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Behavior skills stage|The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity.
79334516|NCT05508269|Procedure|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
79334517|NCT05531045|Diagnostic Test|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
79334518|NCT04633577|Drug|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
79334519|NCT04633577|Drug|0.9% normal saline|0.9% normal saline
79334520|NCT04941625|Diagnostic Test|serum cystatin C|blood sampling
79651747|NCT00221507|Behavioral|Reminder-Recall-Outreach|
79651748|NCT00221507|Behavioral|Case Management|
79981579|NCT06028217|Other|prognosis status|observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
79334521|NCT04941625|Diagnostic Test|serum beta-microglubulin|blood sampling
79334522|NCT04941625|Diagnostic Test|urine|neutrophil gelatinase-associated lipocalin
79334523|NCT04944589|Procedure|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
79334524|NCT04922125|Combination Product|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
79334525|NCT04922125|Combination Product|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
79334526|NCT04922203|Other|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
79651749|NCT00221507|Behavioral|Patient Navigator|
79651750|NCT03454477|Procedure|conventional open surgery|conventional open surgery
79651751|NCT03454477|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy
79651752|NCT03454477|Device|robotic thyroidectomy|robotic thyroidectomy
79651753|NCT03454399|Procedure|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
79651754|NCT03454360|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
79651755|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
79486078|NCT02691260|Behavioral|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
79486079|NCT02691260|Behavioral|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
79486080|NCT02691260|Behavioral|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
79486081|NCT02691416|Drug|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
79334527|NCT04922047|Drug|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
79486082|NCT02691416|Drug|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
79486083|NCT02650999|Drug|Pembrolizumab|200mg intravenously (IV)
79486084|NCT02691962|Device|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
79486085|NCT02701387|Device|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
79486086|NCT02701387|Device|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
79486087|NCT02693132|Behavioral|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
79334528|NCT03057535|Drug|Sodium Bicarbonate|
79486088|NCT02693132|Behavioral|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
79486089|NCT02693132|Behavioral|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
79486090|NCT05502211|Drug|Fentanyl|induction of anaesthesia using fentanyl
79486091|NCT05502211|Drug|Lidocaine IV|induction of anesthesia using lidocaine
79486092|NCT04339244|Other|RALRP under lower mean BP|RALRP under regulation of lower mean BP
79486093|NCT04339244|Other|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
79486094|NCT02673944|Device|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
79486095|NCT02674412|Drug|Buspirone|
79334529|NCT03057535|Drug|Sodium Chloride|
79486096|NCT02674412|Drug|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
79486097|NCT00367952|Drug|apricitabine|800mg apricitabine twice daily orally for 96 weeks
79486098|NCT04708106|Other|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
79486099|NCT04708106|Other|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
79486100|NCT04708106|Other|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
79334530|NCT04407013|Other|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
79334531|NCT04407013|Other|Control group with usual care|Control group will receive usual care (symptom monitoring only)
79334532|NCT04941235|Device|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
79334533|NCT04921891|Procedure|Infraclavicular nerve block|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
79486101|NCT02697188|Drug|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
79486102|NCT02697188|Drug|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
79486103|NCT04707560|Procedure|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
79486104|NCT05421104|Other|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
79651756|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
79651757|NCT00251082|Drug|Placebo|Placebo
79651758|NCT00221546|Drug|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
79651759|NCT04616092|Drug|FEFINJECT|FEFINJECT injection
79981580|NCT06028204|Drug|Biologic Agent|Biologic group will have biological agent commenced if considered necessary as part of routine care.
79486105|NCT02652481|Device|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~* May only be used internationally outside the US"
79334534|NCT04921891|Procedure|Without nerve block|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
79334535|NCT04941079|Other|no intervention|no intervention
79334536|NCT03057457|Device|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
79334537|NCT04921579|Procedure|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
79334538|NCT04921579|Procedure|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
79334539|NCT04921657|Drug|Rosuvastatin 10mg|
79486106|NCT05420714|Device|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
79812184|NCT02613455|Procedure|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
79981581|NCT06028191|Other|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
79981582|NCT06028191|Device|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
79486107|NCT02697890|Device|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
79486108|NCT02697890|Device|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
79486109|NCT05419154|Procedure|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
79812185|NCT02613455|Drug|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
79981583|NCT06028178|Diagnostic Test|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
79334540|NCT04930471|Drug|Metformin|Treatment with Metformin as prescribed by the treating physician.
79334541|NCT04921813|Other|3 dimensional scoliosis exercise|Schroth exercises
79334542|NCT04921813|Other|Balance Exercise|Balance-coordination exercises
79486110|NCT02653183|Device|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
79486111|NCT02653183|Device|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
79486112|NCT05418920|Procedure|left-opening single-flap technique|left-opening single-flap technique
79486113|NCT05418920|Procedure|double-flap group technique|double-flap group technique
79486114|NCT02701400|Biological|Durvalumab|Given IV
79812186|NCT02613455|Drug|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
79334543|NCT04921813|Other|Brace treatment|Brace usage
79334544|NCT04930393|Procedure|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
79334545|NCT03057223|Device|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
79334546|NCT04940923|Diagnostic Test|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
79334547|NCT02576951|Drug|Galcanezumab|Administered SC
79334548|NCT02576951|Drug|Placebo|Administered SC
79334549|NCT04921501|Device|HD ECG|This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
79334550|NCT04921501|Device|Conventional 12-lead ECG|This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
79334551|NCT04921267|Behavioral|training|training with filtered speech
79486115|NCT02701400|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79486116|NCT02701400|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79486117|NCT02701400|Biological|Tremelimumab|Given IV
79486118|NCT00368173|Drug|rhIGF-I/rhIGFBP-3|
79812187|NCT00849212|Drug|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
79981584|NCT06027242|Dietary Supplement|oral glutamine|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
79981585|NCT06027242|Dietary Supplement|Maltodextrin|Maltodextrin
79981586|NCT06026449|Dietary Supplement|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
79981587|NCT06025929|Other|Maitland's mobilization technique|Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
79651760|NCT04616482|Behavioral|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
79981588|NCT06025929|Other|Mulligan's mobilization techniques|Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
79651761|NCT00221585|Behavioral|Psychosocial treatment/Psychodynamic treatment|
79981589|NCT06025929|Other|Interferential Therapy (IFT)|Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
79981590|NCT06025695|Combination Product|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
79981591|NCT06025695|Combination Product|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
79334552|NCT05530811|Drug|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
79334553|NCT05530811|Drug|Bupivacaine|0.5% bupivacaine
79334554|NCT04940845|Drug|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
79334555|NCT04940845|Drug|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
79334556|NCT05507567|Drug|Neumifil|Liquid for intranasal spray administration
79334557|NCT05507567|Drug|Placebo|Liquid for intranasal spray administration
79334558|NCT04921111|Drug|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
79334559|NCT04921111|Drug|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
79334560|NCT04921111|Drug|placebo|aluminium phosphate
79334561|NCT04921111|Drug|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
79334562|NCT05530733|Procedure|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
79651762|NCT04616404|Dietary Supplement|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
79651763|NCT04616404|Other|Placebo|Tablets with no active ingredient
79981592|NCT06025500|Diagnostic Test|31P-Magnetic Resonance Spectroscopy (31P-MRS)|31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
79981593|NCT06024863|Diagnostic Test|Screening stress test on a bicycle ergometer (usual practise)|
79334563|NCT05530733|Procedure|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
79334564|NCT03057145|Drug|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
79334565|NCT03057145|Drug|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
79334566|NCT04921423|Behavioral|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
79334567|NCT04425005|Other|Home-based exercise|Home-based exercise training, supervised by videoconference.
79981594|NCT06024330|Diagnostic Test|VAN assessment|An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
79981595|NCT06024330|Diagnostic Test|VES assessment|An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
79981596|NCT06024330|Diagnostic Test|LARIO assessment|An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
79334568|NCT03056989|Drug|SPX-101|Inhalation solution twice daily for 7 days.
79486119|NCT05403710|Drug|Botulinum toxin|Standard-of-care administration of botulinum toxin (50 units/axilla injected intradermally) will be performed for routine treatment of Hidradenitis Suppurativa
79651764|NCT04720482|Diagnostic Test|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
79651765|NCT04720482|Diagnostic Test|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
79651766|NCT00221624|Drug|Peginterferon alfa-2a|
79651767|NCT00221624|Drug|ribavirin|
79651768|NCT00221624|Drug|amantadine|
79812188|NCT04119011|Biological|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
79486120|NCT05400824|Diagnostic Test|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
79486121|NCT04738994|Dietary Supplement|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
79334569|NCT04940455|Other|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
79486122|NCT04738994|Other|Control group|Standard hospital diet
79486123|NCT02653417|Drug|RAD1901|RAD1901
79486124|NCT02653417|Other|Placebo|Placebo
79334570|NCT04920877|Other|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
79486125|NCT02677766|Other|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
79981597|NCT06023446|Diagnostic Test|Optical Coherence Tomography|The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
79981598|NCT06022497|Other|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
79486126|NCT02677766|Other|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
79486127|NCT04338997|Drug|IZD174|Small molecule inhibitor of NLRP3
79486128|NCT02705365|Other|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
79486129|NCT02705365|Other|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
79486130|NCT02703350|Drug|LY900014|Administered subcutaneously (SC)
79486131|NCT02703350|Drug|Insulin Lispro|Administered SC
79486132|NCT02682056|Device|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
79486133|NCT02682056|Device|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
79486134|NCT02682056|Device|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
79486135|NCT02706925|Drug|BI 443651|
79486136|NCT02706925|Drug|Placebo|
79812189|NCT04119011|Other|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
79334571|NCT04929925|Diagnostic Test|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
79486137|NCT05378438|Other|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
79486138|NCT04739228|Behavioral|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
79486139|NCT04739228|Behavioral|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
79486140|NCT05470465|Drug|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
79651769|NCT04616053|Behavioral|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
79651770|NCT04615975|Dietary Supplement|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
79334572|NCT04940143|Drug|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
79486141|NCT05470465|Drug|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
79486142|NCT05470465|Drug|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
79486143|NCT00368030|Drug|Eszopiclone|Eszopiclone 3 mg QD
79651771|NCT04615897|Procedure|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
79334573|NCT04940143|Other|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
79334574|NCT03057067|Procedure|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
79334575|NCT03056911|Drug|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
79334576|NCT04929613|Behavioral|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
79651772|NCT00221663|Device|surgery techniques (sternotomy for aortic valve replacement)|
79334577|NCT04920409|Other|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which < 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
79486144|NCT00368030|Other|Placebo|Placebo tablet
79981599|NCT06015009|Other|Symptom management mobile health application with personalised support|"Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
79486145|NCT02656069|Drug|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
79486146|NCT02656069|Drug|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
79486147|NCT00368186|Biological|Pneumo 23|
79486148|NCT02707172|Behavioral|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
79981600|NCT06011785|Drug|Silica 12CH|Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
79334578|NCT04920409|Other|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
79334579|NCT04920721|Other|no intervention|no intervention descriptiv study
79486149|NCT02707172|Behavioral|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
79486150|NCT05351762|Drug|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
79486151|NCT05346536|Other|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~CellSearch®, FDA-USA approved technology~EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
79486152|NCT02683772|Device|Astral|Astral ventilator
79486153|NCT02708641|Drug|pembrolizumab|200 mg IV given every three weeks
79486154|NCT02657629|Other|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
79334580|NCT04939675|Drug|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
79334581|NCT04939675|Drug|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
79486155|NCT02657629|Other|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
79486156|NCT02683928|Biological|GBR 830|
79486157|NCT02683928|Biological|Placebo|
79486158|NCT02708186|Drug|Nelotanserin|once daily, oral, 20-mg tablets
79486159|NCT02708186|Drug|Placebo|once daily, oral, matching tablets
79486160|NCT02710591|Drug|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline"
79651773|NCT04615741|Behavioral|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
79334582|NCT04939675|Drug|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
79334583|NCT04939285|Procedure|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
79334584|NCT04929691|Device|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
79813833|NCT04107480|Procedure|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
79981601|NCT06009939|Other|Occlusion of the circulation in the arm and foot|A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
79334585|NCT04929691|Other|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
79334586|NCT04939129|Diagnostic Test|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
79334587|NCT04938739|Other|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
79486161|NCT04339322|Other|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
79486162|NCT02710981|Drug|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
79486163|NCT02710981|Drug|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
79486164|NCT04189796|Dietary Supplement|Cheese|Daily oral intake of cheese
79981602|NCT06009003|Drug|REL-1017|REL-1017 tablet
79981603|NCT06005090|Procedure|Far Cortical Locking Technique|Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
79981604|NCT06002464|Procedure|Acupuncture|Patient will have session of 30 minutes of acupuncture every day during 3 days
79486165|NCT02711839|Dietary Supplement|Commercial diabetic formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
79981605|NCT06002464|Procedure|Bilateral ESP catheter|Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
79981606|NCT06002425|Other|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
79334588|NCT04938739|Other|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
79486166|NCT02711839|Dietary Supplement|White sweet potato formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
79486167|NCT04738916|Device|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
79486168|NCT05362123|Other|non interventional|Online google form questioner
79981607|NCT06002425|Other|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
79981608|NCT06002412|Other|Image quality control|The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
79651774|NCT04615741|Behavioral|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
79651775|NCT04615663|Behavioral|Score SMI|the investigator will complete the SMI score
79981609|NCT05998278|Procedure|Personalized Optimization of Systematic Prostate Biopsy|Login the model based on our previous study (https://daringsky.shinyapps.io/prediction_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
79981610|NCT05988320|Procedure|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
79651776|NCT04615780|Other|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
79981611|NCT05987319|Device|RadioFrequency Microneedling Device|RadioFrequency device will be used for the treatment of dermatologic conditions.
79334589|NCT03055975|Diagnostic Test|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
79334590|NCT04929301|Other|Antenatal milk expression|Hand-expression of breast milk in pregnancy
79334591|NCT04929301|Other|Education handouts|Educational breastfeeding handouts
79334592|NCT03055663|Other|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
79334593|NCT03055663|Procedure|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
79486169|NCT05331404|Radiation|PET examination|PET examinations with auditory stimuli such as human voice and environmental sounds.
79486170|NCT05331404|Other|Quality of life assessment|"quality of life assessment by :~Speech, Spatial and Qualities of Hearing~Hearing Handicap Inventory For The Elderly Screening~Short Form Health Survey"
79486171|NCT04739917|Biological|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
79981612|NCT05981183|Device|Transcutaneous electrical nerve stimulation unit (TENS)|The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
79334594|NCT03055663|Drug|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
79334595|NCT04928443|Other|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
79334596|NCT04928443|Other|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
79334597|NCT02621047|Drug|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
79334598|NCT03057691|Other|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
79334599|NCT03057379|Other|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
79334600|NCT04928365|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
79334601|NCT04938037|Procedure|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
79334602|NCT04431271|Procedure|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
79486172|NCT04739917|Other|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
79486173|NCT02713711|Radiation|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
79486174|NCT02713711|Procedure|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
79486175|NCT02713711|Procedure|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
79486176|NCT02659501|Drug|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
79486177|NCT02659501|Drug|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
79486178|NCT02659501|Drug|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
79486179|NCT02659501|Drug|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
79486180|NCT02659501|Drug|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
79651777|NCT04615780|Other|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
79651778|NCT06178250|Other|3D sonography|Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
79981613|NCT05976308|Drug|Bushen Huatan Decoction|The treatment group used Bushen Huatan Decoction, including Tusizi (the seed of Chinese dodder), Fupenzi (Raspberry), Bajitian (Morinda officinalis), Duzhong (Eucommia ulmoides), Shudi (prepared Rehmanniaroot), Fuling (Tuckahoe), Zelan (Aconitum gymnandrum), Zexie (Rhizoma alismatis), Guizhi (Cassia twig), Zhebeimu (Thunberg Fritillary Bulb), Taoren (Peach kernel) and Chuanxiong (Ligusticum wallichii). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
79334603|NCT04919785|Device|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
79334604|NCT04928833|Other|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
79334605|NCT04928833|Other|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
79334606|NCT04919473|Biological|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
79334607|NCT04937569|Drug|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
79334608|NCT04937257|Other|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
79334609|NCT04937257|Other|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
79334610|NCT04937335|Other|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
79334611|NCT04919005|Other|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
79334612|NCT04927507|Behavioral|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
79651779|NCT06178237|Device|Purabond|Application of Purabond to surgical field
79651780|NCT06178211|Drug|Immunotherapy: Adebrelimab|Adebrelimab 1200mg Q3W
79651781|NCT06178211|Drug|chemotherapy: carboplatin plus nab-paclitaxel|carboplatin plus nab-paclitaxel
79334613|NCT04937101|Drug|Chlorpheniramine-Codeine|When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
79486181|NCT02718157|Device|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
79486182|NCT00367939|Drug|valsartan + amlodipine|
79486183|NCT02720107|Drug|fingolimod|
79486184|NCT02662387|Device|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
79334614|NCT04431505|Other|apoptosis|study of apoptotic changes due to anaesthesia
79486185|NCT02662387|Other|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
79486186|NCT02722837|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79486187|NCT02710526|Drug|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
79486188|NCT04339231|Procedure|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
79486189|NCT02724787|Behavioral|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
79812190|NCT00703586|Drug|Maraviroc|"ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
79981614|NCT05976308|Drug|Placebo|The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
79334615|NCT04937023|Drug|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
79334616|NCT04937179|Procedure|Ischemic Conditioning Low - Sham Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
79334617|NCT04937179|Procedure|Ischemic Conditioning High - Active Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
79334618|NCT04936711|Device|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
79334619|NCT04936711|Drug|Marcaine|Marcaine spray at incision site after closure
79486190|NCT02725645|Other|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
79486191|NCT02664961|Drug|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
79486192|NCT02664961|Drug|Bevacizumab|Bevacizumab will be dosed every two weeks.
79334620|NCT04936945|Procedure|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
79334621|NCT04936789|Device|IMES|Surgical implantation of IMES
79486193|NCT02725801|Device|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
79486194|NCT02725801|Device|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
79486195|NCT02665273|Procedure|Greater occipital nerve block|Bilateral greater occipital nerve block
79486196|NCT02665273|Drug|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
79651783|NCT06178172|Other|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
79651784|NCT06178159|Drug|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
79651785|NCT06178159|Drug|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
79651786|NCT06178159|Drug|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
79812191|NCT04130399|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
79812192|NCT04130399|Drug|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
79334622|NCT04936555|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
79334623|NCT04927273|Other|Survey|Surveyed neurological and orthopedic surgeons
79334624|NCT03056521|Other|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
79334625|NCT04431349|Drug|Ticagrelor 180mg|Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
79334626|NCT04431349|Drug|Clopidogrel 75mg|Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
79307712|NCT02722616|Device|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
79334627|NCT03056677|Dietary Supplement|Control|200mls water will be given prior to a mixed carbohydrate meal
79334628|NCT03056677|Dietary Supplement|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
79486197|NCT02713178|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
79486198|NCT02713178|Drug|Placebo|Normal saline.
79486199|NCT02665741|Device|Olympus transparent cap|distal colonoscope attachment
79486200|NCT02665741|Device|Medivators Endocuff|distal colonoscope attachment
79486201|NCT02665741|Device|Control|No distal colonoscope attachments
79486202|NCT05267756|Device|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
79812193|NCT00810264|Device|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
79334629|NCT03056677|Dietary Supplement|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
79981615|NCT05976295|Drug|Jianpi Qushi Huatan Decoction|The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.
79981616|NCT05976295|Drug|Placebo|The control group will receive a placebo treatment.
79334630|NCT04431583|Procedure|Bariatric surgery- single surgeon service|
79334631|NCT04431583|Procedure|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
79334632|NCT04431583|Procedure|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
79334633|NCT04431115|Other|Interviews|Interviews for stakeholders
79651787|NCT06178146|Drug|Thymosin Alpha1|Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.
79334634|NCT03055741|Drug|Donepezil|5mg or 10mg, once a day, 24 weeks
79334635|NCT03055741|Drug|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
79334636|NCT03055741|Drug|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
79334637|NCT04926883|Other|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
79334638|NCT04414657|Other|blood sampling for biobank|blood sampling for biobank
79334639|NCT04936087|Other|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
79334640|NCT04936165|Procedure|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
79334641|NCT04926727|Other|Survey|Observational study
79334642|NCT04927039|Drug|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
79651788|NCT06178146|Drug|Immunosuppressant|Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
79651789|NCT06178107|Dietary Supplement|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
79651790|NCT06178107|Dietary Supplement|Placebo Comparator|Placebo comparator Maltodextrin
79651791|NCT06178081|Other|Periodontal Healthy|Non surgical periodontal therapy
79651792|NCT06178068|Device|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
79812194|NCT00849056|Biological|albiglutide|albiglutide weekly subcutaneous injection
79486203|NCT02726971|Drug|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
79981617|NCT05972057|Procedure|cardiac surgery|All cardiac surgery patients who met the inclusion criteria were included in the cardiac surgery department of Renji Hospital.
79334643|NCT04927039|Drug|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
79486204|NCT04121936|Other|There will be no intervention|There will be no intervention
79486205|NCT04048850|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
79486206|NCT02727751|Drug|Tenapanor|
79334644|NCT04926493|Biological|microbiological characterization|microbiological characterization of endotracheal tube biofilm
79334645|NCT04918303|Device|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
79334646|NCT03055585|Biological|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
79334647|NCT03055585|Other|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
79334648|NCT04926649|Procedure|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
79334649|NCT03055351|Behavioral|Stop&Go Intervention|Stop&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
79334650|NCT02443155|Drug|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
79334651|NCT02443155|Drug|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
79486207|NCT02713256|Drug|CFZ533|CFZ533 intravenously over approximately one hour
79486208|NCT05153551|Other|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
79486209|NCT05152849|Drug|AXA1125|AXA1125 administered BID with or without food
79486210|NCT05152849|Drug|Placebo|Matching Placebo administered BID with or without food
79812195|NCT00849056|Drug|placebo|placebo weekly subcutaneous injection
79334652|NCT02443155|Drug|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
79334653|NCT03055117|Behavioral|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
79334654|NCT03055117|Behavioral|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
79334655|NCT03055117|Behavioral|Home exercise|Supervised home exercise
79486211|NCT02714504|Drug|Voriconazole or posaconazole|Azole with activity against molds
79486212|NCT02665975|Behavioral|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
79486213|NCT02665975|Behavioral|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
79486214|NCT02718248|Device|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
79486215|NCT02718248|Behavioral|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
79486216|NCT02668003|Behavioral|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
79486217|NCT00368576|Drug|SB 480848, tablets|
79486218|NCT02724800|Behavioral|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
79812196|NCT02612948|Drug|Quetiapine|escalating dose to prevent delerium.
79812197|NCT00706862|Drug|Talactoferrin|Oral, 1.5 grams twice per day
79812198|NCT00706862|Drug|Placebo|Oral, twice per day
79486219|NCT02724800|Behavioral|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
79486220|NCT02730247|Drug|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
79486221|NCT02730247|Drug|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
79486222|NCT03889106|Drug|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
79486223|NCT04738604|Other|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
79981618|NCT05968625|Device|Thermoformed retainers|conventional thermoformed retainers fabricated on stone models.
79486224|NCT04738604|Other|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
79486225|NCT00369200|Drug|AFP464|Given IV
79486226|NCT00369200|Other|laboratory biomarker analysis|Correlative study
79981619|NCT05968625|Device|3D-printed retainers|3D-printed retainers fabricated directly by DLP printer.
79486227|NCT00369200|Other|pharmacological study|Correlative study
79486228|NCT02730403|Other|Treatment As Usual|
79486229|NCT05207618|Dietary Supplement|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
79486230|NCT02669329|Device|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
79486231|NCT02727842|Device|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
79486232|NCT02727842|Device|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
79812199|NCT00707018|Device|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
79981620|NCT05967260|Device|DailyDose Smart Snack app|A decision support tool that predicts the likelihood of overnight low blood sugar based on current CGM and inputted exercise. App will recommend a snack at bedtime based on the minimum low glucose predicted and the time of the low glucose.
79981621|NCT05967260|Device|Dexcom G6 CGM|A commercially available Continuous Glucose Monitoring system that utilizes a transmitter and sensor to measure sensor glucose levels that transmit to a smart phone app.
79981622|NCT05966311|Device|Percutaneous Ultrasound Gastrostomy|Ultrasound guided placement of gastrostomy tube using the PUMA-G Pediatric System
79981623|NCT05964465|Drug|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
79981624|NCT05963152|Behavioral|Habitual Physical Activity|Participants will be asked to maintain their normal activity levels
79981625|NCT05963152|Behavioral|Morning Exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
79486233|NCT00368329|Drug|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg & 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
79486234|NCT00368329|Drug|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
79486235|NCT00368329|Drug|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
79486236|NCT00368329|Drug|Carboplatin|AUC 2, based onCalvert formula IV infusion
79981626|NCT05963152|Behavioral|Afternoon Exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
79981627|NCT05959720|Drug|Prednisone|60 mg/m2 D1 to D21
79981628|NCT05959720|Drug|Vincristin|1.5 mg/m2 D1, D8, D15 and D22
79981629|NCT05959720|Drug|Daunorubicin|40 mg/m2 D1, D8, D15 and D22
79981630|NCT05959720|Drug|Peg-asparaginase|2000 UI/m2 D12 and D26
79486237|NCT02670343|Drug|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
79334656|NCT04935541|Drug|Dexmedetomidine infusion|After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
79334657|NCT04935541|Drug|Remifentanil infusion|After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
79334658|NCT04935151|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
79486238|NCT02730260|Behavioral|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
79486239|NCT02730260|Behavioral|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
79486240|NCT00368407|Device|308-nm excimer laser|
79486241|NCT00367549|Dietary Supplement|Energy-containing soft drink|Commercial energy/sports drink
79486242|NCT05128370|Other|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
79486243|NCT02730884|Drug|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
79486244|NCT02730884|Behavioral|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
79486245|NCT02732587|Drug|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
79486246|NCT02731820|Dietary Supplement|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
79486247|NCT02731820|Dietary Supplement|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
79981631|NCT05959720|Drug|Intrathecal Suspension|MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
79981632|NCT05959720|Drug|Cyclophosphamide|1000 mg/m2 D36 and D64
79334659|NCT04935151|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
79486248|NCT02731820|Dietary Supplement|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
79486249|NCT02731820|Dietary Supplement|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
79486250|NCT02732899|Drug|Sirolimus|
79486251|NCT02732899|Drug|EYLEA|
79651793|NCT06178042|Combination Product|MI Paste Plus|Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
79651794|NCT06178042|Combination Product|Remin Pro|The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
79981633|NCT05959720|Drug|Cytarabine|75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60
79981634|NCT05959720|Drug|Mercaptopurine|30 mg/m2 D36 to D63 and D1 to D56 of consolidation
79981635|NCT05959720|Drug|Methotrexate|3.000 mg/m2 D8, D22, D36 and D50
79486252|NCT04339153|Behavioral|Parent Training for Disruptive Behaviours|Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
79981636|NCT05959720|Drug|Doxorubicin|30 mg/m2 D1 and D22
79981637|NCT05950633|Other|Standard of Care|Participants will receive standard of care postoperative instructions
79981638|NCT05950633|Other|Active Recovery|Participants will receive instructions to increase their fitness to walking at least 30 minutes a day for 5 days a week following surgery and abdominal and pelvic floor exercises will focus on abdominal wall strengthening and abdominal pressure management, urinary urgency and retention, bowel and constipation management
79981639|NCT05950321|Procedure|Paramedian cervical epidural steroid injection|For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
79981640|NCT05950321|Procedure|Selective nerve root pulsed radiofrequency|For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
79981641|NCT05948020|Biological|CBT102-A capsule|"Orally CBT102-A will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with 1.25×10^11 live cell. The shelf life is 6 months.~Subjects receive oral dose of 1 capsule CBT102-A (1.25 x 10^11 live cell) before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule CBT102-A (2.5 x 10^11 live cell) before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule CBT102-A (5 x 10^11 live cell) before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule CBT102-A (1 x 10^12 live cell) before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
79981642|NCT05948020|Other|Placebo capsule|"Orally placebo will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with Lactose powder filler. The shelf life is 6 months. The color, condition, smell and other appearances are exactly the same as CBT102-A.~Subjects receive oral dose of 1 capsule placebo before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule placebo before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule placebo before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule placebo before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
79981643|NCT05935735|Behavioral|Brief Behavioral Therapy for Insomnia (BBTI)|4 in-person sessions; 1 individual and 3 group sessions
79981644|NCT05928117|Other|Education|Pregnant women will be given training to cope with the fear of childbirth.
79981645|NCT05927701|Other|Group comparaison|Questionnaires
79334660|NCT04935073|Drug|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
79334661|NCT04935073|Drug|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
79486253|NCT03647462|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
79486254|NCT02733757|Drug|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
79486255|NCT00368264|Drug|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
79486256|NCT00368264|Drug|placebo|azathioprine (2 mg/kg) plus four placebo infusions
79486257|NCT05086406|Other|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
79486258|NCT02734147|Drug|Ascorbic Acid|
79486259|NCT02734147|Other|Normal Saline|
79651795|NCT06178042|Combination Product|Control|Patients instructed to follow a routine home care.
79812200|NCT00707018|Device|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
79812201|NCT00913406|Other|Lutein fortification|
79812202|NCT00913406|Other|Standard formula|
79334662|NCT04934761|Procedure|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV <10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
79334663|NCT04934761|Procedure|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
79334664|NCT04934605|Procedure|Cochlear implantation|Cochlear implantation
79334665|NCT04934059|Drug|Yuxuebi tablet|0.5g/ tablet
79486260|NCT00368342|Drug|Erythromycin, Azithromycin , Clarithromycin|
79981646|NCT05926180|Drug|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
79981647|NCT05921864|Other|Passive heat exposure|Participants will be exposed to heat in a chamber.
79981648|NCT05921864|Other|Active heat exposure|Participants will participate to a 6-hour run.
79981649|NCT05921175|Device|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
79981650|NCT05921175|Device|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
79334666|NCT04934059|Drug|Placebo tablet|0.5g/ tablet
79334667|NCT04917835|Device|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
79334668|NCT04917991|Dietary Supplement|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
79486261|NCT02673541|Device|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
79486262|NCT02673541|Device|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
79486263|NCT02732366|Behavioral|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
79812203|NCT02612714|Drug|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
79812204|NCT02612636|Other|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
79981651|NCT05917067|Diagnostic Test|Fluorescence imaging of the parathyroid glands of children|Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
79334669|NCT04917991|Dietary Supplement|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
79486264|NCT02732366|Other|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
79486265|NCT03609320|Behavioral|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
79486266|NCT03609008|Drug|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
79486267|NCT03609008|Drug|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
79486268|NCT02732600|Other|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
79486269|NCT02734238|Drug|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
79486270|NCT02734238|Drug|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
79486271|NCT02734849|Drug|AK001 low dose|25 mg AK001 will be administered as multiple doses
79486272|NCT02734849|Drug|AK001 high dose|250 mg AK001 will be administered as multiple doses
79334670|NCT04917757|Diagnostic Test|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
79334671|NCT04917289|Drug|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
79486273|NCT02734849|Drug|Placebo|Placebo will be administered as multiple doses
79334672|NCT04917913|Dietary Supplement|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
79334673|NCT04917913|Dietary Supplement|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
79334674|NCT04925869|Other|Observational study|Observational study
79334675|NCT04925635|Behavioral|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
79334676|NCT04925635|Behavioral|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
79334677|NCT03055273|Behavioral|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
79334678|NCT04916899|Drug|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
79334679|NCT04933981|Diagnostic Test|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
79334680|NCT04925245|Other|Clinical Reminder|Clinical reminder in the electronic medical record
79334681|NCT04933357|Radiation|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
79486274|NCT04707547|Biological|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
79486275|NCT04707547|Procedure|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
79486276|NCT02735551|Drug|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
79812205|NCT02612636|Other|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
79981652|NCT05905926|Drug|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
79981653|NCT05892666|Other|On-site recruitment (information and consent) following a random sampling recruitment schedule|A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
79812206|NCT02612558|Drug|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
79812207|NCT00702026|Dietary Supplement|multispecies probiotic (Ecologic 801)|once daily, 5 gram [10e9 cfu/gram]
79812208|NCT00702026|Dietary Supplement|Placebo|once daily, 5 gram [10e9 cfu/gram]
79981654|NCT05892666|Other|First phone call 1-3 days after the initial visit|Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
79981655|NCT05892666|Other|Second phone call 8-14 days after the initial visit|A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
79334682|NCT04933357|Radiation|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
79334683|NCT04916821|Dietary Supplement|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
79334684|NCT04916665|Drug|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
79334685|NCT04933201|Other|Music|Perioperative musical intervention
79334686|NCT04933201|Other|Routine perioperative treatment|Routine perioperative treatment
79334687|NCT04925323|Biological|BLOOD SAMPLES|BLOOD SAMPLES
79812209|NCT02612402|Device|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
79334688|NCT04925323|Biological|surgical tissue samples|unused surgical tissue removed during plastic surgeries
79334689|NCT02460159|Drug|EZ 10 mg/Atorva 20 mg FDC|
79486277|NCT02735551|Other|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
79334690|NCT02460159|Drug|EZ 10 mg/Atorva 10 mg FDC|
79486278|NCT02735551|Other|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
79486279|NCT02736175|Drug|Dexamethasone|
79486280|NCT02736175|Other|Placebo Vehicle|
79486281|NCT02735174|Device|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
79651796|NCT06178016|Other|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
79651797|NCT06177990|Other|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
79651798|NCT06177990|Other|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
79651799|NCT06177951|Other|NICU Discharge Passport|"The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns."
79812210|NCT02612402|Device|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
79812211|NCT00837434|Drug|Etanercept|50 mg dose of etanercept by subcutaneous injection
79334691|NCT04925011|Drug|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
79334692|NCT04924855|Other|Blood sampling (4 per year)|Blood sampling (4 per year)
79334693|NCT04913155|Radiation|Low-dose CT screening|Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
79334694|NCT02498067|Behavioral|rPlan dual protection waiting room app intervention|
79334695|NCT04916353|Drug|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
79334696|NCT04916353|Drug|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
79486282|NCT02735174|Other|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
79486283|NCT02735174|Behavioral|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
79486284|NCT02735174|Other|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
79486285|NCT02735642|Behavioral|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
79812212|NCT00837434|Drug|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
79812213|NCT00703742|Drug|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
79812214|NCT00702104|Other|survey administration|
79812215|NCT00702182|Drug|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
79334697|NCT02497755|Behavioral|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
79334698|NCT02497755|Device|smartphone|
79334699|NCT03056599|Drug|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
79334700|NCT03056599|Device|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
79334701|NCT04924465|Other|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
79651800|NCT06177951|Other|NICU Infant Care Class|The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
79334702|NCT04916275|Other|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
79651801|NCT06177938|Dietary Supplement|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
79334703|NCT02619175|Device|Stroke Subjects Perturbation-Based Balance Training|
79334704|NCT02619175|Device|Stroke Subjects Weight Shifting and Gait training|
79334705|NCT04924231|Behavioral|astigmatism|astigamatism at least 1 month after the cataract surgery
79486286|NCT02735642|Behavioral|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
79486287|NCT02735642|Behavioral|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
79651802|NCT06177925|Drug|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
79334706|NCT03056443|Device|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
79651803|NCT06177925|Drug|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
79334707|NCT04915885|Other|Routine care|Routine contraceptive counseling and routine method availability
79334708|NCT04915885|Other|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
79651804|NCT06177925|Drug|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
79651805|NCT06177925|Radiation|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
79334709|NCT04915885|Other|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
79334710|NCT04915963|Dietary Supplement|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
79334711|NCT04915807|Drug|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
79334712|NCT04915807|Drug|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
79334713|NCT04915651|Device|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
79334714|NCT01360021|Drug|Symbicort|Breath actuated metered dose inhaler
79334715|NCT01360021|Drug|Symbicort|Actuation counter pressured metered dose inhaler
79334716|NCT01360021|Drug|Budesonide|Actuation counter pressured metered dose inhaler
79334717|NCT04924309|Other|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
79334718|NCT04915573|Diagnostic Test|Specimen|Sputum will be collected in clean disposable containers
79486288|NCT02735642|Behavioral|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
79651806|NCT06177899|Procedure|Splitting of bone and fixation of bone laminae differ between the 3 groups.|In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
79812216|NCT00702182|Drug|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
79812217|NCT00702182|Drug|Erlotinib|Daily Oral Erlotinib 100 mg
79812218|NCT00702260|Drug|Ramipril|10 mg capsule
79812219|NCT00702416|Procedure|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
79981656|NCT05890677|Procedure|Surgical Intervention|LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
79334719|NCT04912219|Device|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
79334720|NCT04915339|Behavioral|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
79334721|NCT04915339|Behavioral|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
79486289|NCT02735642|Behavioral|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
79334722|NCT04915339|Behavioral|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
79486290|NCT02735642|Other|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
79812220|NCT00702416|Procedure|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current <0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
79981657|NCT05890677|Procedure|Conservative Complex Physical Decongestion Therapy|Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.
79334723|NCT04923373|Other|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~initial training in hospital~physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
79334724|NCT04923373|Procedure|standard physiotherapy|standard physiotherapy
79334725|NCT04915417|Radiation|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
79334726|NCT04912297|Biological|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
79334727|NCT02497287|Drug|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
79334728|NCT02497287|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
79334729|NCT02497287|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
79334730|NCT02497287|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
79486291|NCT03449576|Other|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
79812221|NCT00702416|Drug|Ropivacaine|"Block induction [1% (wt/vol) solution]:~20 ml (200 mg)~Postoperative analgesia [0.2% (wt/vol) solution]:~Background infusion: 4 ml/h (8 mg/h)~Incremental on-demand dose: 2 ml (4 mg)~Lockout time: 15 min"
79812222|NCT00702416|Drug|Paracetamol|1 g iv q8h
79812223|NCT00702416|Drug|Morphine|5 mg im prn q1h (in the postoperative period)
79812224|NCT00702416|Drug|Fentanyl|50 µg iv prn (in the intraoperative period)
79486292|NCT03449576|Other|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
79486293|NCT05446610|Other|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
79486294|NCT02736955|Drug|Valbenazine|
79486295|NCT00369356|Drug|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
79334731|NCT02497287|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants < 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
79486296|NCT00369356|Device|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
79486297|NCT00369356|Device|Bare metal coronary stent|Stenting with BMS only
79486298|NCT03409562|Behavioral|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
79486299|NCT03409562|Behavioral|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
79486300|NCT05446441|Procedure|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
79651807|NCT06177873|Other|foot bath|On the morning of surgery, the purpose of the study will be explained to the patients and their written consent will be obtained. Then, Introductory Information Form, STAI and VASS were applied. The pain level of the patients will be evaluated with VAS-Pain 4 hours after the surgery. SAI and VAS-Comfort will be applied to patients with pain level 4 and above. Then, patients in the experimental group will receive a hot water foot bath for 20 minutes. Before the hot water foot bath, patients will be lifted from their beds and placed on the chair in the room. Hot water will be poured into the foot bath tub and the patient will be asked to put his feet in the water. The water level will be adjusted to include the patients ankles. The temperature of the water will be constantly checked with a water thermometer and kept at 41-42 °C. A hot water foot bath will be applied for 20 minutes and then the patients feet will be dried with a towel.
79334732|NCT04923607|Drug|TQC2731|TQC2731 injection
79334733|NCT04923607|Drug|Placebo|Matching placebo with no active ingredients
79334734|NCT04911985|Device|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
79334735|NCT04912141|Drug|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
79651808|NCT06177847|Device|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
79651809|NCT06177821|Device|Rezum®|Rezum® Water vaporization device
79651810|NCT06177808|Device|Wolverine cutting balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.
79334736|NCT04915105|Diagnostic Test|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
79334737|NCT04923451|Device|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
79334738|NCT04923451|Device|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
79334739|NCT04922385|Other|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
79486301|NCT02677753|Radiation|Fluoroscopy|
79486302|NCT04958798|Behavioral|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
79334740|NCT04923061|Other|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
79334741|NCT04923061|Other|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
79334742|NCT03056287|Behavioral|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
79334743|NCT03056287|Other|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
79334744|NCT04911829|Behavioral|Psychotherapy|
79334745|NCT04911595|Diagnostic Test|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
79334746|NCT04911595|Diagnostic Test|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
79334747|NCT02458287|Biological|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
79486303|NCT02679469|Drug|nalmefene hydrochloride 10 mg|
79651811|NCT06177808|Device|Non-compliant balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
79651812|NCT06177782|Device|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
79651813|NCT06177782|Device|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
79334748|NCT02458287|Biological|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
79486304|NCT05445973|Procedure|Percutaneous Radiofrequency Ablation|In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
79486305|NCT05445986|Procedure|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
79486306|NCT05445986|Procedure|gap filling|to use biomaterials to fill the jumping gap
79486307|NCT05445986|Procedure|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
79486308|NCT02681809|Drug|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
79486309|NCT02681809|Drug|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
79486310|NCT02681809|Drug|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
79486311|NCT05445661|Device|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
79651814|NCT06177769|Device|LMA classic|Airway is secured with LMA clasic
79334749|NCT02458287|Biological|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
79334750|NCT02458287|Biological|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
79334751|NCT04914715|Device|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
79334752|NCT04914715|Device|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
79486312|NCT05445661|Other|Normal Saline|Sham Comparator
79486313|NCT05445271|Diagnostic Test|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
79486314|NCT04805125|Biological|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
79486315|NCT04805125|Biological|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
79486316|NCT04339075|Other|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
79486317|NCT05445115|Device|Mollie device|medical device
79486318|NCT05444959|Dietary Supplement|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
79486319|NCT05444959|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
79486320|NCT00368017|Drug|pioglitazone|30 mg once a day for 12 weeks
79486321|NCT00368017|Drug|placebo|1 pill once a day for 12 weeks
79486322|NCT04672447|Dietary Supplement|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
79486323|NCT04672447|Dietary Supplement|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
79486324|NCT04672447|Dietary Supplement|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
79486325|NCT04672447|Dietary Supplement|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
79486326|NCT00367627|Drug|Albendazole|
79651815|NCT06177769|Device|LMA Proseal|Airway is secured with LMA proseal
79486327|NCT05444647|Procedure|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
79651816|NCT06177769|Device|I-gel|Airway is secured with I-gel
79651817|NCT06177756|Behavioral|Nutritional and lifestyle counseling|"At risk children Intervention Arm: schedule at least four visits/year with anthropometric monitoring, educate parents on the appropriate diet, active lifestyle from the first year of life, regular self-monitoring of their child's anthropometry and appropriate dietary composition and portion control, provide tailor-made nutritional suggestions.~Not-at-risk children Intervention Arm: educational website with interactive tools for growth self-monitoring and diverse lifestyle suggestions."
79651818|NCT06177743|Device|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
79651819|NCT06177730|Other|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
79486328|NCT04739137|Diagnostic Test|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
79486329|NCT04739137|Diagnostic Test|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
79486330|NCT00368485|Device|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
79486331|NCT00368563|Drug|Helioblock SX|
79651820|NCT06177678|Drug|TFC-003|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
79651821|NCT06177678|Drug|COSOPT ophthalmic solution|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
79486332|NCT04633759|Other|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
79651822|NCT06177626|Behavioral|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
79334753|NCT04914871|Behavioral|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
79651823|NCT06177626|Behavioral|Balance Training|Training 5x a week for 30 minutes. Standard of care.
79651824|NCT06177587|Other|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
79651825|NCT06177574|Drug|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
79651826|NCT06177561|Procedure|Lymphoplasma exchange|The LPE treatment regimen is: LPE*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2*2 times, gamma globulin 0.4g/kg/d*5d.
79334754|NCT04914871|Behavioral|Educational session accident prevention and wound management|It will be provided to the control group
79334755|NCT02441517|Drug|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
79334756|NCT03688347|Procedure|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
79486333|NCT05436223|Drug|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
79486334|NCT04536103|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
79651827|NCT06177548|Procedure|Minimally invasive Bentall procedure|The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
79651828|NCT06177535|Dietary Supplement|Kavalactones|Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
79651829|NCT06177535|Drug|Placebo|Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
79651830|NCT06177522|Drug|Adbelimumab|1200mg，i.v. , q3w
79651831|NCT06177522|Drug|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
79651832|NCT06177522|Drug|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
79651833|NCT06177509|Other|Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
79651834|NCT06177496|Procedure|local ablation|treatment of HCC
79651835|NCT06177496|Procedure|TACE|treatment of HCC
79486335|NCT05444179|Behavioral|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
79486336|NCT04738903|Procedure|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
79486337|NCT05434897|Drug|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
79486338|NCT05434897|Drug|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
79486339|NCT05443789|Behavioral|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
79486340|NCT05443789|Behavioral|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
79486341|NCT04738747|Behavioral|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
79486342|NCT05443477|Dietary Supplement|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
79334757|NCT03688347|Procedure|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
79334758|NCT03688347|Other|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
79334759|NCT03688347|Genetic|Microbiome analysis|Study of microbial communities found in and on the human body.
79334760|NCT03688347|Genetic|DNA Banking|Secure, long term storage of an individual's genetic material.
79334761|NCT03688347|Procedure|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
79651836|NCT06177496|Drug|Sorafenib|treatment of HCC
79651837|NCT06177470|Device|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
79334762|NCT03056131|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
79334763|NCT03056209|Drug|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
79334764|NCT03056209|Drug|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
79334765|NCT03056209|Drug|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
79334766|NCT03056209|Drug|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
79334767|NCT03056209|Drug|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
79334768|NCT03056209|Drug|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
79334769|NCT03056209|Drug|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
79334770|NCT03056209|Drug|Placebo|oral administration, placebo
79334771|NCT02457819|Drug|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
79334772|NCT03056053|Drug|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
79334773|NCT04922905|Other|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~the Peri traumatic distress inventory (Jehel et al., 2005)~and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
79486343|NCT05443477|Dietary Supplement|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
79486344|NCT05443477|Dietary Supplement|control|participants received two oral capsules containing control powder every day for the 3 months.
79486345|NCT05424523|Drug|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
79486346|NCT05443243|Procedure|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
79486347|NCT05413759|Other|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 & 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 & 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
79486348|NCT04147039|Behavioral|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
79486349|NCT04338607|Procedure|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
79486350|NCT04338607|Device|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
79334774|NCT04922905|Other|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~the Peri traumatic distress inventory (Jehel et al., 2005)~and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
79486351|NCT05442931|Drug|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
79651838|NCT06177470|Device|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
79651839|NCT06177444|Drug|Antibiotic|Postoperative antibiotic treatment
79334775|NCT04914559|Other|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
79334776|NCT04914559|Other|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
79334777|NCT02496039|Drug|NUEDEXTA®|NUEDEXTA® only
79334778|NCT04911205|Other|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
79334779|NCT04911283|Other|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
79334780|NCT04911283|Other|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
79334781|NCT02441283|Drug|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
79651840|NCT06177431|Drug|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
79651841|NCT06177405|Drug|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
79651842|NCT06177379|Other|healthy volunteer|Volunteers age between 50 and 75 years
79651843|NCT06177366|Diagnostic Test|Blood sampling|Blood samples will be collected at diagnosis, in the same time as BOM is performed
79334782|NCT02441283|Drug|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
79334783|NCT04922359|Drug|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
79334784|NCT04922359|Drug|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
79334785|NCT03054493|Behavioral|no intervention|no intervention
79486352|NCT05442931|Drug|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
79651845|NCT06177340|Device|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
79651846|NCT06177327|Other|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
79651847|NCT06177314|Other|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
79486353|NCT05442931|Drug|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
79486354|NCT05442931|Other|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
79486355|NCT05442541|Behavioral|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
79651848|NCT06177288|Combination Product|DEBIRI Combined With Chemotherapy and Bevacizumab|After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
79334786|NCT04910737|Procedure|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
79334787|NCT02495883|Other|Ethanol|50ml of 40% Ethanol
79334788|NCT02495883|Drug|Propranolol|Beta blocker
79334789|NCT04910893|Device|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
79651849|NCT06177275|Procedure|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
79334790|NCT04910893|Other|Standard of Care|Standard intensive care of patients suffering septic shock
79334791|NCT02495025|Behavioral|Telephone-based developmental screening and care coordination|
79651850|NCT06177275|Procedure|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
79651851|NCT06177262|Behavioral|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
79651852|NCT06177249|Biological|Control vaccine|A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
79651853|NCT06177249|Biological|Experimental vaccine|A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
79334792|NCT04910659|Other|acupuncture|P6, LI4 and LI 11 stimulation
79334793|NCT04910347|Drug|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
79334794|NCT04914169|Device|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
79334795|NCT02439957|Drug|Brincidofovir|
79334796|NCT02439957|Drug|Valganciclovir|
79334797|NCT04914013|Other|no intervention|no intervention
79651854|NCT06177236|Diagnostic Test|cervical cancer screening|The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
79651855|NCT06177223|Behavioral|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
79812225|NCT00702416|Procedure|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
79334798|NCT02494401|Other|Internet-based self-management program|
79334799|NCT02494401|Other|Scleroderma book|
79334800|NCT03054415|Procedure|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
79334801|NCT04922515|Other|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
79334802|NCT04922437|Procedure|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
79651856|NCT06177197|Device|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~Infant < 6 months: half a dose to a single dose administered per nostril 8 times a day.~Infant > 6 months: one single dose administered per nostril 6 times a day."
79334803|NCT04922437|Procedure|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
79334804|NCT04913545|Diagnostic Test|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
79334805|NCT04913935|Diagnostic Test|Muscle-Skeleton Ultrasonography|postero-anterior radiography
79334806|NCT04910191|Diagnostic Test|Electronic stethoscope|Electronic stethoscope
79334807|NCT02457195|Drug|granisetron|Application granisetron transdermal patch preoperatively
79651857|NCT06177197|Device|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~Infant < 6 months: half a dose to a single dose administered per nostril 8 times a day.~Infant > 6 months: one single dose administered per nostril 6 times a day."
79651858|NCT06177171|Drug|Olaparib|Given orally
79651859|NCT06177171|Drug|ASTX727|Given Orally
79651860|NCT06177158|Behavioral|oral hygiene instructions|"Standardized motivation and oral hygiene instructions regarding the tooth brushing will be demonstrated to all three groups using modified bass technique and a standardized brush, medium bristled brush with toothpaste, the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily. For interdental cleaning aids each patient will be instructed to use the suitable methods regarding the space between teeth.~clinically for each patient to ensure that the patients understood the instruction sessions. Before receiving oral hygiene instructions and motivation, the salivary sample will be collected and clinical periodontal parameters will be measured at a base line visit then, after 3 weeks, saliva will be collected and the same clinical measurements will be taken."
79651861|NCT06177145|Other|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
79651862|NCT06177119|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
79651863|NCT06177119|Drug|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
79651864|NCT06177119|Drug|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
79651865|NCT06177119|Drug|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
79651866|NCT06177119|Drug|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
79651867|NCT06177119|Drug|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
79981658|NCT05889234|Device|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
79981659|NCT05889234|Drug|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
79981660|NCT05859594|Other|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
79334808|NCT04913779|Drug|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
79334809|NCT04913779|Drug|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
79334810|NCT04904497|Behavioral|Early Occupational Therapy|"Occupational therapists will implement the following activities:~Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS <2, 6> environmental orientation will be considered~Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~Education: trained family members and health staff about the intervention process"
79334811|NCT04913623|Procedure|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
79651868|NCT06177119|Drug|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
79651869|NCT06177093|Radiation|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
79651870|NCT06177080|Other|transperineal ultrasound|descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
79651871|NCT06177067|Drug|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
79651872|NCT06177067|Drug|Venetoclax|Given by mouth (tablet)
79651873|NCT06177067|Drug|Azacitidine|Given intravenously (IV) infusion
79981661|NCT05849064|Behavioral|Behavioral Control|Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
79334812|NCT03054259|Drug|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
79334813|NCT03054259|Drug|Methylprednisolone|100mg infusion on days 1 and 15
79981662|NCT05849064|Behavioral|Targeted Intervention|Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
79651874|NCT06177067|Drug|intrathecal (IT) chemotherapy|Given intrathecal (IT)
79334814|NCT03054259|Drug|Normal Saline|250ml infusion on days 1 and 15
79651875|NCT06177067|Drug|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
79651876|NCT06177067|Drug|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
79651877|NCT06177054|Behavioral|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
79334815|NCT02456727|Procedure|Group/Community Acupuncture|Acupuncture treatment in a group setting.
79334816|NCT02456727|Procedure|Individual Acupuncture|Acupuncture treatment in an individual setting.
79334817|NCT03054025|Device|Smart Phone Monitoring Device|Use activity tracker application
79651882|NCT06177028|Drug|Lenalidomide 10 mg|Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
79651883|NCT06177002|Diagnostic Test|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
79651884|NCT06176976|Dietary Supplement|Lugol's iodine solution 5%|4 drops of LS every 8 hours for 10 days preoperatively will be given
79651885|NCT06176950|Other|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
79651886|NCT06176937|Drug|Hyaluronic acid|Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
79651887|NCT06176937|Other|empty socket|Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
79651888|NCT06176924|Device|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
79651889|NCT06176924|Other|Relaxation technique|Relaxation technique
79651890|NCT06176911|Drug|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
79651891|NCT06176911|Drug|Danazol|200 mg twice daily.
79334818|NCT04910035|Other|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
79651892|NCT06176898|Device|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~Six minute walking test (6MWT)~Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
79651893|NCT06176872|Diagnostic Test|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
79334819|NCT03052387|Other|assigned intervention|"* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~Using fissure bur to harvest the graft for the defect.~Closure using vicryl 3-O sutures."
79334820|NCT04909879|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
79334821|NCT04909879|Drug|Placebo|Excipient solution
79334822|NCT04894513|Other|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
79334823|NCT04894513|Other|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
79334824|NCT04921137|Other|No endocrine therapy|No endocrine therapy given
79334825|NCT04921137|Other|Endocrine therapy|Endocrine therapy given for at least 5 years
79334826|NCT04894201|Radiation|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
79334827|NCT03052465|Other|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
79334828|NCT04893889|Diagnostic Test|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
79334829|NCT02456103|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
79651894|NCT06176859|Other|HIV PrEP Delivery|To test an end-to-end decentralized delivery service for pre-exposure prophylaxis (PrEP) to safely increase PrEP access and use among priority populations in South Africa.
79812226|NCT00827918|Drug|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
79651895|NCT06176846|Behavioral|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
79334830|NCT04894357|Other|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
79334831|NCT04399603|Other|no intervention-mechanistic study|no intervention-mechanistic study
79334832|NCT01653327|Drug|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
79334833|NCT01653327|Drug|Placebo|
79334834|NCT03053869|Drug|Benzodiazepine - limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
79334835|NCT03053869|Drug|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
79334836|NCT03053947|Drug|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
79981663|NCT05845086|Behavioral|Preoperative patient education|In this study, preoperative patient education will be given, reinforced with multimedia supported written and verbal teach-back method, created according to the literature. Videos of exercises used to increase postoperative mobilization (deep breathing exercise, coughing exercise, intensive spirometer use, etc.) will be taken by the researcher in a professional studio. The captured videos will be embedded in the PowerPoint presentation and presented to the patient with a tablet computer. The powerpoit presentation should be a maximum of 30 slides and the patient education should take a maximum of 30 minutes. Patients will be evaluated face-to-face on the 1st, 2nd, 3rd days after surgery and by phone on the 15th day. The prepared powerpoint presentation will be left with the patient as a printout. The prepared video will be given to the patient after the training with a program (via WhatsApp, e-mail, bluetooh) on their phones in accordance with the preferences of the patients.
79981664|NCT05833360|Device|Exai oncRNA blood test|A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.
79812227|NCT00827918|Drug|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
79981665|NCT05830851|Other|real tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
79334837|NCT04893733|Drug|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
79334838|NCT04903483|Other|bispectral index monitoring|intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
79334839|NCT04903405|Other|No intervention|No intervention is involved in this study
79334840|NCT04903639|Diagnostic Test|sleep study|The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
79334841|NCT03051139|Behavioral|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
79334842|NCT03053323|Behavioral|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
79334843|NCT03053557|Behavioral|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
79334844|NCT04903171|Other|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
79334845|NCT03053635|Drug|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
79334846|NCT03053011|Other|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
79334847|NCT04909489|Other|cross-sectional study without intervention|cross-sectional study without intervention
79334848|NCT04893031|Drug|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
79334849|NCT02493855|Drug|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
79334850|NCT02493855|Drug|Dasabuvir|Dasabuvir tablets
79334851|NCT02493855|Drug|Ribavirin (RBV)|Ribavirin tablets
79334852|NCT04902157|Diagnostic Test|Cycle threshold|cycle threshold number
79334853|NCT04892563|Procedure|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
79334854|NCT04892563|Drug|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
79334855|NCT04909255|Drug|mirabegron|use beta-3 agonist for sjogren syndrome patient
79334856|NCT04909255|Drug|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
79334857|NCT03052231|Device|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
79334858|NCT04891939|Other|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So & Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
79334859|NCT04891939|Other|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
79334860|NCT04892095|Other|No intervention|This is an observational cross-sectional study. No intervention is considered.
79812228|NCT00827918|Drug|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
79334861|NCT04891861|Drug|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
79812229|NCT00813150|Drug|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
79812230|NCT00813150|Drug|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
79981666|NCT05830851|Other|sham tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
79486356|NCT05393479|Behavioral|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
79486357|NCT05442385|Other|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
79486358|NCT05442307|Behavioral|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
79486359|NCT05442307|Behavioral|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
79651896|NCT06176846|Behavioral|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
79981667|NCT05830448|Behavioral|Cognitive Behavioral Therapy|The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.
79981668|NCT05830448|Behavioral|T.R. Mobile Mental Health Support System produced by the Ministry of Health|No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
79981669|NCT05828472|Drug|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
79981670|NCT05828472|Drug|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
79981671|NCT05827601|Diagnostic Test|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
79981672|NCT05827601|Diagnostic Test|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
79981673|NCT05827198|Other|Low-sugar candies compared to regular sugar candies|Acute intake
79334862|NCT04902313|Behavioral|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
79334863|NCT04891783|Device|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus[26]. Plaque is defined as a focal protrusion in the lumen at least cIMT>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching >0.5 mm [26]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
79334864|NCT03053167|Drug|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
79334865|NCT03053167|Drug|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
79486360|NCT05440513|Device|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
79334866|NCT03052543|Device|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
79334867|NCT04902079|Device|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
79334868|NCT04901923|Drug|ACP-196|Participants will receive ACP-196 oral capsule(s) in all parts.
79334869|NCT04901923|Drug|Itraconazole|Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
79334870|NCT04901845|Other|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
79334871|NCT04908007|Other|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
79334872|NCT04908007|Other|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
79651897|NCT06176833|Procedure|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
79812231|NCT00813150|Drug|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
79812232|NCT00807846|Drug|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
79812233|NCT00807846|Drug|Naproxen|Naproxen 7.5 mg/kg PO BID [maximum of 500 mg BID] for 6 weeks
79812234|NCT05754138|Device|Sport SICD|Follow up
79981674|NCT05825898|Procedure|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
79981675|NCT05821517|Device|Helmet virtual reality.|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
79981676|NCT05821517|Drug|Administration of METHOXYFLURANE|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
79486361|NCT05439967|Other|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
79334873|NCT04908007|Other|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
79486362|NCT05439967|Other|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
79486363|NCT05439811|Procedure|Swan-Ganz Catheter|Swan-Ganz Catheter
79486364|NCT05439499|Drug|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
79486365|NCT05439499|Drug|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
79981677|NCT05821517|Drug|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
79486366|NCT04003987|Drug|Liposomal bupivacaine|20ml
79334874|NCT04908007|Other|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
79486367|NCT04003987|Drug|bupivacaine, 0.125%|60ml
79334875|NCT03050905|Drug|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
79334876|NCT03050905|Drug|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
79334877|NCT03050827|Drug|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
79334878|NCT03050827|Drug|Placebo|Non-active placebo for 3% oxybutynin
79334879|NCT04891159|Other|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
79334880|NCT04900909|Device|Aortic Valve Replacement|Surgical replacement of aortic valves
79334881|NCT04891003|Diagnostic Test|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
79812235|NCT00810108|Drug|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
79812236|NCT05297370|Behavioral|Mixed and match Intervention|Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
79812237|NCT05297370|Other|Control|Participants in the control group will receive a self-help quitting leaflet issued by the TACO
79981678|NCT05819762|Diagnostic Test|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab LS screening panel on a specified Flow Cytometry
79334882|NCT04907617|Other|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of <36.5°C.
79486368|NCT03984331|Device|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
79486369|NCT03984331|Device|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
79334883|NCT04907617|Other|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
79812238|NCT00827606|Drug|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
79334884|NCT04907617|Other|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of <36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
79334885|NCT04907617|Other|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
79334886|NCT02438787|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
79334887|NCT02438787|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
79334888|NCT02438787|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
79334889|NCT02438787|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
79486370|NCT05448001|Drug|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
79486371|NCT05448001|Drug|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
79486372|NCT05366257|Other|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
79486373|NCT05366257|Other|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
79486374|NCT05447845|Diagnostic Test|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
79486375|NCT05447767|Device|KIT BMAC AND at-SVF FIDIA|intra-articular infiltration or intra-articular and intra-osseous infiltration
79981679|NCT05807919|Other|Diet low in all FODMAP groups|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
79334890|NCT04901065|Drug|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
79334891|NCT04901065|Drug|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
79334892|NCT04430803|Dietary Supplement|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
79334893|NCT04430803|Other|Control Water|A glass of tap water
79334894|NCT04412005|Other|No intervention|No intervention
79334895|NCT02493777|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
79334896|NCT02493777|Drug|Placebo|
79486376|NCT05447455|Procedure|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
79486377|NCT05447455|Procedure|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
79486378|NCT00369109|Other|biologic sample preservation procedure|
79486379|NCT00369109|Other|immunohistochemistry staining method|
79486380|NCT00369109|Other|laboratory biomarker analysis|
79812239|NCT04892082|Behavioral|Mindful Moment|The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
79812240|NCT04892082|Other|Waiting-List Control (WLC)|The control group only receive the intervention at the end of the intervention group.
79307713|NCT02722616|Drug|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
79334897|NCT04890691|Device|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
79334898|NCT04890457|Device|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
79334899|NCT04890457|Device|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
79334900|NCT03052699|Procedure|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
79334901|NCT04907149|Drug|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
79334902|NCT04907149|Drug|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
79334903|NCT04907149|Drug|[14]GLPG3970 oral solution|Participants will receive a single oral dose [14C]GLPG3970.
79334904|NCT04431037|Dietary Supplement|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
79486381|NCT00369109|Procedure|biopsy|
79486382|NCT00369187|Drug|large protein molecule|
79486383|NCT03831139|Behavioral|TIM&SARA|
79486384|NCT05446987|Other|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
79651898|NCT06176807|Radiation|Venous Excess Ultrasound Score|"-- The IVC diameter : Grade 0: <5 mm with respiratory variation Grade I: 5-9 mm with respiratory variation Grade II: 10-19 mm with respiratory variation Grade III: >20 mm with respiratory variation Grade IV: >20 mm with minimal or no respiratory variation~- Hepatic vein (HV) interrogation by pulsed wave Doppler identification and analysis of A, S, and D waves.~Grade 0: normal S > D Grade I: S < D with antegrade S Grade III: S flat or inverted or biphasic trace - Portal vein Doppler (PD)as follow: Grade 0: <0.3 pulsatility index Grade I: 0.3-0.49 pulsatility index Grade III: 0.5-1.0 pulsatility index Pulsatility index is calculated as (Vmax - Vmin)/Vmax~- VEXUS staging of venous congestion. (VEXUS ) Grade 0: IVC grade <III, HD grade 0, PV grade 0 Grade I: IVC grade IV, but normal HV/PV pattern Grade II: IVC grade IV with mild flow pattern abnormalities in HV/PV Grade III: IVC grade IV with severe flow pattern abnormalities in HV/PV"
79812241|NCT04016220|Drug|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
79812242|NCT04016220|Drug|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
79812243|NCT00663052|Drug|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
79334905|NCT03052621|Procedure|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
79651899|NCT06176794|Drug|immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 2omg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
79334906|NCT04906681|Device|i-ACT|i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
79334907|NCT04906915|Drug|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
79651900|NCT06176781|Drug|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
79334908|NCT04900285|Device|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
79981680|NCT05807919|Other|Diet - Mediterranean|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
79334909|NCT03052777|Behavioral|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
79334910|NCT04906837|Diagnostic Test|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
79334911|NCT04906291|Other|Toothpaste use|Brushing three times a day
79651901|NCT06176781|Drug|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
79981681|NCT05803811|Dietary Supplement|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
79334912|NCT04900129|Combination Product|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
79334913|NCT02616601|Drug|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
79334914|NCT02616601|Drug|Carac® (Fluorouracil) Cream|Topical cream, brand product.
79334915|NCT02616601|Drug|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
79486385|NCT05446987|Other|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
79651902|NCT06176742|Other|Active Cycle Breathing Technique|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
79812244|NCT00663052|Drug|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
79981682|NCT05801120|Dietary Supplement|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
79981683|NCT05798273|Procedure|intra-arterial injection|"All patients will receive an intravenous injection of [68Ga]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive [68Ga]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection."
79486386|NCT05446753|Dietary Supplement|Animal-based meats|Animal-based meats from beef, pork and chicken
79981684|NCT05798273|Device|synchronous PET/MRI scan|Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
79981685|NCT05798273|Other|Radiopharmacon Contrast agent|Type: [68Ga]Ga-PSMA-11 dosage: 1.5 MBq/kg
79334916|NCT04927845|Behavioral|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
79307714|NCT02658487|Drug|Cytarabine|Given IV
79334917|NCT02492997|Device|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
79334918|NCT02492997|Other|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
79334919|NCT03052075|Other|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
79334920|NCT04906603|Device|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
79334921|NCT02437305|Behavioral|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
79334922|NCT02437305|Behavioral|ABCDEs of Melanoma|Conventional melanoma educational intervention.
79334923|NCT03051919|Other|observation|
79334924|NCT04393207|Drug|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
79334925|NCT04393207|Drug|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
79334926|NCT04393207|Drug|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
79334927|NCT02492841|Drug|Mineral trioxide aggregate|Mineral trioxide aggregate
79334928|NCT02492841|Drug|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
79334929|NCT02492841|Drug|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
79334930|NCT04817917|Biological|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
79307715|NCT02658487|Drug|Vosaroxin|Given IV
79334931|NCT04817917|Other|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
79334932|NCT04412161|Procedure|Liver transplantation|Living donor liver transplantation
79334933|NCT02436915|Other|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
79486387|NCT05446753|Dietary Supplement|Plant-based meat alternatives|Plant-based meat alternatives of beef, pork and chicken
79981686|NCT05780606|Other|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
79307716|NCT02607046|Other|Exercise training|The exercise program includes supervised and home-based walking and strength exercise.
79307717|NCT02607046|Other|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
79981687|NCT05764057|Drug|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines* for 6 months (experimental group)~*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
79334934|NCT02436915|Other|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
79334935|NCT04815499|Dietary Supplement|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
79334936|NCT04815499|Dietary Supplement|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
79334937|NCT04398901|Other|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
79334938|NCT02492763|Drug|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen [60 μg, 120 μg] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen [60 μg, 120 μg, 180 μg] over the first 3 weeks is used to achieve the final dose up to 300 μg.
79334939|NCT02492763|Drug|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
79334940|NCT02492763|Drug|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
79334941|NCT02492763|Drug|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
79334942|NCT04899817|Drug|Granisetron|The drug is given after induction of general anesthesia
79334943|NCT04905667|Drug|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
79334944|NCT04905667|Drug|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
79334945|NCT03050749|Device|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
79334946|NCT02491671|Device|Hemopatch|
79334947|NCT02491671|Procedure|standard preventive measures|
79334948|NCT04889677|Drug|Danicopan|
79334949|NCT04889677|Drug|Placebo|
79334950|NCT04397107|Drug|IL-2|Patients were received low dose recombinant human Interleukin-2
79334951|NCT02453841|Drug|Oxymetazoline|
79334952|NCT04430647|Procedure|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
79334953|NCT04430647|Procedure|Phacoemulsification alone|standard phacoemulsification for catarct extraction
79334954|NCT04889365|Diagnostic Test|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
79334955|NCT04889365|Diagnostic Test|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
79334956|NCT04889131|Behavioral|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
79334957|NCT04889131|Behavioral|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
79334958|NCT04889131|Other|Activity Monitor|Garmin VivoSmart activity monitor throughout study
79334959|NCT04888663|Drug|Trastuzumab + Ramucirumab + Paclitaxel|For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
79334960|NCT04899427|Drug|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
79334961|NCT04899427|Drug|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
79334962|NCT04899427|Drug|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
79812245|NCT05599880|Drug|Bortezomib|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
79307718|NCT02604914|Drug|ND0612|Subcutaneous solution
79486388|NCT00369733|Drug|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
79651903|NCT06176742|Other|Bubble Positive Expiratory Pressure Device|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
79334963|NCT02453685|Drug|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
79334964|NCT02453685|Drug|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
79334965|NCT02453685|Drug|insulin aspart|Injected s.c./subcutaneously once daily.
79334966|NCT04888975|Device|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
79334967|NCT04918797|Biological|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
79334968|NCT05530187|Device|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
79334969|NCT04905355|Device|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
79334970|NCT03051841|Drug|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
79334971|NCT04905043|Drug|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
79334972|NCT04905043|Drug|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
79812246|NCT00707252|Drug|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
79334973|NCT03050983|Device|IPI|Enable the IPI algorithm and IPI alarm algorithm
79334974|NCT02436759|Drug|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
79334975|NCT02436759|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
79334976|NCT04888819|Drug|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
79334977|NCT04888819|Drug|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
79334978|NCT02436681|Device|MIROMESH|
79334979|NCT03052153|Other|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
79334980|NCT03051685|Drug|DFN-15 Dose 1|
79651904|NCT06176729|Drug|Polatuzumab Vedotin, Rituximab, Lenalidomide|polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
79651905|NCT06176716|Drug|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
79651906|NCT06176690|Biological|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
79651907|NCT06176664|Device|Low flow oxygen|Standard nasal cannula oxygen up to 2 liters/minute
79651908|NCT06176664|Device|High-flow nasal cannula oxygen|High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
79334981|NCT03051685|Drug|DFN-15 Dose 2|
79334982|NCT03051685|Drug|DFN-15 Dose 3|
79812247|NCT00707252|Drug|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
79486389|NCT05234281|Other|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~Concentrated group intervention (2-5 days): (further described below)~Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~Initiate treatment when the patient is ready for change~Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~Assist the patient when breaking the patterns.~Use long sessions to ensure that they face a broad range of potential micro-choices~Work side-by side with others going through an analogous pattern of change~Prepare them for taking responsibility for integrating the change into every-day living"
79334983|NCT03051685|Drug|Active Comparator|
79334984|NCT04888351|Other|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
79486390|NCT05222737|Device|medency diode laser|intra pocket application of diode laser
79486391|NCT05222737|Drug|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
79486392|NCT00368719|Drug|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
79486393|NCT05445193|Behavioral|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
79486394|NCT00369811|Drug|Oxycodone, fentanyl|
79486395|NCT03647761|Device|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
79486396|NCT03615547|Drug|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
79981688|NCT05764057|Drug|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines* for 6 months (control group)~*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
79334985|NCT04888351|Other|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
79334986|NCT04904731|Other|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
79334987|NCT04904887|Procedure|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
79334988|NCT04078243|Device|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
79334989|NCT04898881|Other|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
79486397|NCT03615547|Other|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
79486398|NCT00422539|Drug|70% trichloroacetic acid|
79486399|NCT05166655|Behavioral|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
79486400|NCT05120791|Dietary Supplement|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
79486401|NCT05120791|Dietary Supplement|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
79334990|NCT04898881|Other|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
79334991|NCT04904185|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
79334992|NCT04904185|Drug|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
79334993|NCT04904185|Biological|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
79334994|NCT04904185|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
79651909|NCT06176638|Behavioral|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
79981689|NCT05758597|Drug|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
79334995|NCT04887961|Drug|PLD and Trabectedin rechallenge|Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
79334996|NCT04887883|Behavioral|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
79486402|NCT05120791|Dietary Supplement|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
79486403|NCT05120791|Dietary Supplement|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
79486404|NCT03562897|Dietary Supplement|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
79486405|NCT05431309|Diagnostic Test|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
79486406|NCT05431309|Other|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
79486407|NCT05429047|Biological|Tozinameran|Tozinameran during pregnancy
79486408|NCT05429047|Other|COVID-19|SARS-CoV-2 infection during pregnancy
79981690|NCT05758597|Drug|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
79334997|NCT04887649|Drug|Morphine|morphine 3 mg
79334998|NCT04887649|Drug|saline solution|4 cc of saline solution in epidural cateter in postpartum
79334999|NCT04887649|Drug|Morphine|morphine 2 mg for epidural cateter in postpartum
79335000|NCT03050437|Drug|Cisplatin|cisplatin is added to Pem/cis arm
79335001|NCT03050437|Drug|Pemetrexed|Pem is applied to both arms
79335002|NCT03050593|Diagnostic Test|MRI scan, Echo scan|
79335003|NCT02436135|Drug|Idelalisib|Idelalisib tablets administered orally for 24 weeks
79335004|NCT02436135|Drug|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
79335005|NCT04898569|Drug|Ferinject|Ferric carboxymaltose injection
79335006|NCT04898569|Drug|Normal Saline Flush|placebo
79335007|NCT03050515|Biological|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
79486409|NCT05429047|Other|No SARS-CoV-2 exposure|No SARS-CoV-2 exposure during pregnancy
79486410|NCT05119387|Other|Observation|Observation of genetic characteristics
79486411|NCT03475147|Device|eyeFusion|Smartphone app based flicker fusion test.
79651910|NCT06173284|Drug|611|subcutaneous injection
79651911|NCT06173284|Drug|Matching placebo|subcutaneous injection
79651912|NCT06171802|Drug|Empagliflozin|10 mg empagliflozin daily for six months
79651913|NCT06171802|Drug|Placebo|Placebo capsule once daily for six months
79981691|NCT05745038|Behavioral|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
79981692|NCT05732337|Device|Poxclin Coolmousse|cooling mousse for application in the skin
79981693|NCT05730465|Behavioral|Use of Omron Home Blood Pressure Cuff|Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge
79981694|NCT05725187|Device|MobiCare|It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
79335008|NCT02489799|Behavioral|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
79335009|NCT02489799|Behavioral|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
79335010|NCT04391257|Device|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
79335011|NCT04884841|Other|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
79335012|NCT04884841|Other|Patients without postoperative complications|Patients without postoperative complications
79335013|NCT04884529|Behavioral|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
79335014|NCT04884217|Drug|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
79335015|NCT04884217|Drug|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
79335016|NCT03050281|Other|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
79335017|NCT03050281|Other|Lectures|Standard Anatomy lectures were offered.
79335018|NCT02435277|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
79335019|NCT02435277|Drug|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
79335020|NCT02435277|Drug|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
79335021|NCT02435277|Drug|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
79335022|NCT04898335|Device|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
79335023|NCT02420223|Drug|Propranolol|
79651914|NCT06171763|Other|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
79651915|NCT06171698|Device|Research Prototype Monitor|Continuous vital sign is collected via a research prototype monitor
79812248|NCT00826748|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
79981695|NCT05722366|Other|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
79981696|NCT05722366|Other|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
79335024|NCT02433483|Drug|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
79335025|NCT02433483|Drug|Intrathecal Triples|given IT.
79335026|NCT02433483|Biological|HPC-A|Given IV.
79335027|NCT02419755|Drug|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
79335028|NCT02419755|Drug|Vorinostat|Vorinostat should be taken orally (PO) with food.
79335029|NCT02419755|Drug|Mitoxantrone|Given by intravenous (IV) injection.
79335030|NCT02419755|Drug|Cytarabine|Given by intravenous (IV) injection.
79335031|NCT02419755|Drug|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
79812249|NCT00922844|Drug|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
79307719|NCT02604914|Drug|LCIG|Intrajejunal Gel
79307720|NCT02593175|Drug|Carboplatin|Given IV
79307721|NCT02593175|Drug|Paclitaxel|Given IV
79335032|NCT02419755|Drug|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
79335033|NCT02419755|Drug|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
79335034|NCT02419755|Drug|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
79335035|NCT02419755|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
79335036|NCT02419755|Drug|Mercaptopurine|Given orally (PO).
79335037|NCT02419755|Drug|Doxorubicin|Given intravenously (IV).
79335038|NCT04913025|Drug|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
79335039|NCT04913025|Drug|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
79486412|NCT03443167|Behavioral|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
79651916|NCT06171503|Behavioral|letter of invitation on MI in PMTCT service|A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
79486413|NCT03443167|Behavioral|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
79651917|NCT06171269|Radiation|Radiation|Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
79651918|NCT06171269|Radiation|MRI|The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
79651919|NCT06171269|Other|Androgen Deprivation Therapy|Treatment of treating physician choice will be given for 6-24 months.
79812250|NCT00707330|Drug|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
79981697|NCT05717777|Other|There is no intervention, only observational study|There is no intervention, only observational study
79981698|NCT05716100|Drug|XEN1101|XEN1101 Capsules
79486414|NCT05066737|Procedure|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
79981699|NCT05716100|Drug|Placebo|Placebo Capsules
79486415|NCT05367583|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
79486416|NCT03105128|Drug|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
79486417|NCT03105128|Drug|risankizumab IV|Risankizumab administered by intravenous infusion
79981700|NCT05714072|Drug|Ruxolitinib|10mg BID or 15mg BID
79486418|NCT03105128|Drug|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
79486419|NCT03331393|Other|Non-interventional|Non-interventional
79812251|NCT00707408|Drug|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
79981701|NCT05714072|Drug|Abemaciclib|50, 100 and 150 mg
79981702|NCT05705154|Behavioral|Psychology interventions|"Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~Identifying the connections between body and mind to address anxiety and breathlessness~Coping skills for managing anxiety using principles from narrative therapy and mindfulness~Online materials to improve self-efficacy with home practice~Social connection with other CYP for peer support, and resource sharing~Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
79307722|NCT02593175|Biological|Panitumumab|Given IV
79307723|NCT02579889|Device|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
79486420|NCT03122509|Drug|durvalumab|1500 mg durvalumab via IV infusion
79486421|NCT03122509|Drug|tremelimumab|75 mg tremelimumab via IV infusion
79651920|NCT06170697|Drug|Camrelizumab|200mg, iv, d1, q3w
79651921|NCT06170697|Drug|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
79651922|NCT06170697|Drug|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
79651923|NCT06170697|Drug|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
79651924|NCT06170697|Drug|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
79335040|NCT02488551|Device|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
79335041|NCT02488551|Other|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
79335042|NCT02488239|Device|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
79335043|NCT02488005|Device|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
79335044|NCT02487771|Drug|DHA|600 mg DHA capsule
79335045|NCT02487771|Drug|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
79335046|NCT01359943|Biological|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
79335047|NCT01359943|Drug|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
79335048|NCT04898101|Drug|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
79335049|NCT04898101|Drug|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (<10 μg; ≤1 μCi) IV solution dose of [14C]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (<10 μg; ≤1 μCi) of [14C]ACP-196 on Day 1.
79981703|NCT05702658|Behavioral|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
79335050|NCT04884451|Behavioral|Lifestyle modification|Diet and physical activity modification and behavioral approach
79335051|NCT02432703|Drug|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
79335052|NCT02432703|Drug|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
79335053|NCT04887727|Dietary Supplement|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
79335054|NCT04887727|Dietary Supplement|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
79335055|NCT04887493|Drug|Misoprostol|Misoprostol 25µg will be used for both the study arms
79335056|NCT04898257|Dietary Supplement|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
79335057|NCT02486757|Drug|micronized progesterone|
79486422|NCT03122509|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
79981704|NCT05686317|Device|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
79307724|NCT02579889|Device|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
79335058|NCT02486757|Drug|transdermal estradiol|
79335059|NCT04887103|Other|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
79335060|NCT04887181|Other|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
79335061|NCT04887181|Other|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
79335062|NCT04887181|Other|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
79335063|NCT04883515|Dietary Supplement|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
79335064|NCT04883515|Dietary Supplement|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
79335065|NCT04883515|Procedure|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
79981705|NCT05686317|Diagnostic Test|Sham procedure|CS angiography
79981706|NCT05680298|Drug|Dupilumab|solution for injection, Subcutaneous injection
79981707|NCT05680233|Drug|OA-235i (4 mg)|3 participants will receive 4 mg as a single subcutaneous dose
79486423|NCT03122509|Procedure|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
79486424|NCT03113695|Drug|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
79981708|NCT05680233|Drug|OA-235i (8 mg)|3 participants will receive 8 mg as a single subcutaneous dose
79981709|NCT05680233|Drug|OA-235i Dose 3|3 participants will receive a single escalating subcutaneous dose
79981710|NCT05680233|Drug|OA-235i Escalating Dose 4|3 participants will receive a single escalating subcutaneous dose
79981711|NCT05680233|Drug|OA-235i Escalating Dose 5|3 participants will receive a single escalating subcutaneous dose
79981712|NCT05680233|Drug|OA-235i Multiple Dose|8 participants will receive a daily subcutaneous dose for 7 consecutive days
79981713|NCT05677113|Drug|QBECO|QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
79981714|NCT05677113|Drug|Placebo|Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
79981715|NCT05674630|Device|Magic Touch drug eluting balloon based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
79981716|NCT05674630|Device|Drug-eluting stent-based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
79981717|NCT05652673|Drug|nivolumab|Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
79486425|NCT03113695|Drug|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
79812252|NCT04041596|Device|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
79981718|NCT05643534|Drug|Tenapanor 50 MG|Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
79335066|NCT04883515|Procedure|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
79981719|NCT05643534|Drug|Tenapanor 25 mg bid|Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
79981720|NCT05643534|Drug|Placebo|Participants will be randomized to receive matching placebo
79335067|NCT04883593|Drug|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
79335068|NCT04883593|Drug|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
79486426|NCT03113695|Drug|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
79486427|NCT04892329|Other|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
79486428|NCT00369434|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|
79651925|NCT06170697|Radiation|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
79651926|NCT06170476|Drug|HSK21542-60μg|HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
79651927|NCT06170476|Drug|HSK21542-120μg|HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
79651928|NCT06170476|Drug|HSK21542-180μg|HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
79335069|NCT04883203|Drug|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
79335070|NCT04883203|Drug|Physiological Irrigating Solution|ARM 2 : placebo
79335071|NCT04883047|Other|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
79486429|NCT05286385|Device|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
79486430|NCT05286385|Device|CP1150 (modified firmware)|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware.
79335072|NCT04897555|Device|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
79335073|NCT04882969|Device|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
79651929|NCT06170476|Drug|Placebo|A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
79651930|NCT06170463|Drug|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
79651931|NCT06170463|Drug|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
79651932|NCT06170463|Drug|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
79651933|NCT06170398|Diagnostic Test|Wideband tympanometry|Wideband tympanometry
79651934|NCT06170398|Diagnostic Test|Electrocochleography|Electrocochleography
79486431|NCT05286385|Device|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
79486432|NCT05286385|Device|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
79651935|NCT06170398|Diagnostic Test|Vestibular Evoked Myogenic potentials|Vestibular Evoked Myogenic potentials
79651936|NCT06169748|Device|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
79651937|NCT06169748|Device|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
79335074|NCT03051529|Other|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
79335075|NCT02418819|Drug|PF-06412562 3mg BID|PF-06412562
79335076|NCT02418819|Drug|PF-06412562 9mg BID|PF-06412562
79335077|NCT02418819|Drug|PF-06412562 45mg BID|PF-06412562
79335078|NCT02418819|Other|Placebo|Placebo
79335079|NCT04886869|Dietary Supplement|caffeine|oral consumption
79335080|NCT04886947|Procedure|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
79651938|NCT06169748|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
79651939|NCT06169254|Device|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
79651940|NCT06169020|Device|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
79981721|NCT05643404|Diagnostic Test|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
79335081|NCT04897477|Drug|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
79335082|NCT04886713|Diagnostic Test|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
79335083|NCT04886713|Diagnostic Test|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~Biventricular mass, wall thickness~T1 mapping; native and > 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~Late enhancement for detection of regional fibrosis and scar~Myocardial feature tracking for analysis of deformation/motion~Epicardial fat volume"
79335084|NCT04886713|Diagnostic Test|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
79335085|NCT04886557|Procedure|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
79486433|NCT04828928|Procedure|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
79486434|NCT00368797|Drug|XRP0038 (NV1FGF)|
79486435|NCT04847323|Device|V-bend Bonded Retainer|Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
79335086|NCT04897087|Other|patient safety event|This study will explore the perceptions of patients, carers and relatives who have experienced a patient safety event. Telephone interviews will be undertaken lasting up to 60 minutes This study involves NHS patients, their carers or relatives. We will ask participants about their experience of being involved a patient safety event and the barriers and enablers to participation in the review. We will ask what 'good' patient involvement in patient safety reviews should look like from those with lived experience. This is because we wish to understand from their perspective what matters to them when things go wrong and how best to involve them.
79335087|NCT03049891|Other|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
79335088|NCT03049891|Other|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
79335089|NCT03049891|Other|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
79335090|NCT02576639|Drug|CNP520|
79335091|NCT02576639|Drug|Placebo|Matching placebo to CNP520 was supplied in capsules.
79335092|NCT03049579|Dietary Supplement|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
79335093|NCT03049579|Dietary Supplement|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
79335094|NCT02418585|Drug|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
79335095|NCT02418585|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
79335096|NCT02418585|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
79335097|NCT02418585|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
79335098|NCT02418585|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
79651941|NCT06169020|Device|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
79981722|NCT05643404|Diagnostic Test|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
79335099|NCT02418585|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
79335100|NCT04896853|Biological|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
79335101|NCT05530031|Procedure|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
79651942|NCT06168565|Device|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
79651943|NCT06168045|Diagnostic Test|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
79981723|NCT05642585|Drug|MY008211A tablets|Single oral
79981724|NCT05642585|Drug|Placebo|Single oral
79981725|NCT05638932|Drug|Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)|Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
79981726|NCT05624125|Other|Beetroot juice|Two 70 ml beetroot juice drinks daily for 4 months.
79981727|NCT05624125|Other|Placebo|Two 70 ml placebo drinks daily for 4 months.
79981728|NCT05621395|Other|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
79981729|NCT05621395|Other|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
79981730|NCT05620953|Diagnostic Test|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
79486436|NCT04847323|Device|Vacuum-formed Retainer|Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
79486437|NCT04796558|Other|AVAS Classification|Validation of AVAS classification
79486438|NCT04784234|Dietary Supplement|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
79981731|NCT05618652|Behavioral|Equity Focused and Trauma-Informed Communication Intervention|Clinician communication intervention that includes didactic training and real-time feedback on communication behaviors during clinical encounters.
79335102|NCT04897165|Other|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
79335103|NCT04897165|Other|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
79335104|NCT05529875|Drug|Propofol|intravenous propofol using target-controlled infusion (TCI) devices.
79335105|NCT05529875|Drug|sevoflurane|inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
79335106|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
79335107|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
79335108|NCT03051451|Drug|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
79335109|NCT02417961|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
79335110|NCT03049657|Device|Angiolite|Percutaneous coronary intervention
79335111|NCT03049657|Device|Xience|Percutaneous coronary intervention
79335112|NCT05529719|Other|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
79335113|NCT03050047|Biological|BCD-100|Anti-PD1 monoclonal antibody
79486439|NCT04784234|Other|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
79981732|NCT05614063|Drug|XEN1101|XEN1101 Capsules
79981733|NCT05614063|Drug|Placebo|Placebo Capsules
79335114|NCT04886089|Device|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
79335115|NCT04896463|Radiation|Abdominal ultrasound (US)|abdominal examination with US device
79335116|NCT04885933|Diagnostic Test|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
79486440|NCT04774796|Other|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
79486441|NCT05444738|Drug|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
79335117|NCT04883125|Drug|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
79335118|NCT04882423|Other|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
79486442|NCT05444738|Drug|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
79486443|NCT05253859|Other|No intervention|Registry study: No intervention
79486444|NCT04734158|Other|corneal imaging|corneal imaging using AS-OCT
79486445|NCT05243953|Drug|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
79335119|NCT04882423|Other|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
79335120|NCT04882423|Other|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
79335121|NCT04882423|Other|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
79335122|NCT05529563|Procedure|LSG|LSG
79335123|NCT04882267|Behavioral|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
79335124|NCT04430413|Biological|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
79335125|NCT04882345|Drug|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
79335126|NCT05529485|Procedure|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
79335127|NCT04882033|Drug|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
79335128|NCT05474183|Drug|Ketamine|drug
79335129|NCT04885777|Drug|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
79335130|NCT04885777|Other|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
79335131|NCT05529407|Device|Simple Vaginal Tampon|Use of single use vaginal tampons
79335132|NCT05529407|Device|Glass Vaginal Trainer|Use of glass vaginal trainers
79335133|NCT04885855|Drug|Sofosbuvir 400 MG|Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
79335134|NCT04885855|Drug|Ravidasvir 200mg|Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
79335135|NCT05196659|Behavioral|Integrated comprehensive cardiovascular disease management|"Electronic Health Record-Decision Support Software (EHR-DSS):~Electronic patient health record storage~Management prompts to the clinical team (following algorithms)~Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~Non-physician health worker-led continuity of care:~- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~Text-message based reminders for a healthy lifestyle~Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~Quarterly audit and feedback to the clinical team"
79335136|NCT04895683|Behavioral|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
79335137|NCT05534555|Diagnostic Test|FebriDx|Testing of finger-prick blood sample using FebriDx
79335138|NCT05534399|Procedure|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
79335139|NCT03051295|Other|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
79335140|NCT02632721|Drug|Decitabine|
79335141|NCT02632721|Drug|BI 836858|
79335142|NCT05529095|Drug|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
79335143|NCT05529095|Drug|Placebo|Placebo (sugar pill)
79335144|NCT01596127|Drug|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
79335145|NCT03051373|Drug|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
79335146|NCT03051373|Drug|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
79335147|NCT04881331|Other|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
79335148|NCT04895059|Drug|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
79335149|NCT04895059|Drug|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
79651944|NCT06167525|Device|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
79335150|NCT04895059|Drug|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
79486446|NCT05243953|Drug|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
79486447|NCT02741258|Device|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
79651945|NCT06167395|Dietary Supplement|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
79486448|NCT02741258|Drug|skin cream|cream to treat skin erythema due to radiotherapy
79486449|NCT02757313|Drug|Low dose THC marijuana|
79486450|NCT02757313|Drug|High dose THC marijuana|
79981734|NCT05605574|Behavioral|Advance Care Planning conversations|In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
79335151|NCT04391413|Device|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
79486451|NCT02757313|Drug|Placebo marijuana|
79486452|NCT02672293|Drug|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
79486453|NCT04738591|Device|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
79981735|NCT05600127|Drug|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
79486454|NCT02379806|Drug|Enoxaparin|
79981736|NCT05596357|Other|questionnaires|The patient must answer questionnaires before and after reconstructive surgery
79981737|NCT05595616|Device|Insertion of tracheal thermometer and pulmonary artery catheter|Endotracheal intubation of endotracheal tube with thermometer (Human Endotracheal Tube, Insung Medical Co., Korea) and insertion of Swan-Ganz catheter
79981738|NCT05568160|Drug|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
79981739|NCT05568160|Drug|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
79981740|NCT05568160|Other|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
79981741|NCT05568160|Other|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
79335152|NCT05467475|Drug|BI 1819479|BI 1819479
79335153|NCT05467475|Drug|Esomeprazole|Esomeprazole
79335154|NCT05528705|Biological|LAENNEC|Subacromial spatial administration
79486455|NCT02379806|Drug|Placebo|
79486456|NCT02636647|Biological|Fecal transplant|
79486457|NCT02358356|Drug|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
79486458|NCT02358356|Drug|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
79981742|NCT05565261|Device|complete denture|Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
79981743|NCT05552287|Drug|Infliximab|IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
79335155|NCT05528705|Other|0.9% normal saline|Subacromial spatial administration
79335156|NCT04430491|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
79335157|NCT05534165|Drug|Tecovirimat|600 mg po BID
79335158|NCT05534165|Drug|Placebo|identical placebo 600 mg po BID
79335159|NCT04885387|Device|chest CT|chest CT pectus deformities diagnostic
79335160|NCT04885387|Device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
79335161|NCT04885309|Procedure|Nerve Stimulator-guided Obturator Nerve Block|Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
79486459|NCT02358356|Drug|Temozolomide|temozolomide 75mg/m2 b.i.d.
79486460|NCT04700761|Procedure|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
79335162|NCT04880941|Behavioral|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
79335163|NCT04880551|Radiation|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
79981744|NCT05550948|Device|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
79486461|NCT04700761|Procedure|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
79981745|NCT05550363|Drug|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
79812253|NCT00806988|Procedure|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~The heart will be arrested with cardioplegia.~A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
79981746|NCT05550363|Other|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
79486462|NCT05206201|Drug|ZY19489 Capsule|Two part study with single and multiple dose
79651946|NCT06167395|Dietary Supplement|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
79335164|NCT05528627|Other|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
79981747|NCT05542407|Drug|Atezolizumab|10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
79335165|NCT04880005|Behavioral|Clinical decision support|"Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments.~The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice."
79486463|NCT05206201|Drug|Placebo Capsule|Two part study with single and multiple dose
79651947|NCT06167395|Dietary Supplement|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
79651948|NCT06167057|Drug|Mitomycin/Gemcitabine|UTUC treatment
79651949|NCT06167057|Drug|Saline|UTUC treatment
79651950|NCT06166394|Drug|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
79981748|NCT05542407|Drug|ONC201|375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
79651951|NCT06166394|Drug|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
79651952|NCT06166368|Other|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
79981749|NCT05535062|Device|repetitive Transcranial Magnetic Stimulation|the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
79981750|NCT05530759|Procedure|Biopsy Specimen|Undergo collection of tissue samples
79981751|NCT05530759|Procedure|Biospecimen Collection|Undergo collection of blood and buccal swab samples
79981752|NCT05530759|Procedure|Biospecimen Collection|Undergo collection of archived tissue and blood samples
79981753|NCT05530759|Other|Medical Chart Review|Review of medical record
79981754|NCT05517642|Biological|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
79981755|NCT05517642|Biological|mRNA vaccine BNT162b2 (Pfizer)|Subjects will be randomized to receive a second booster dose of BNT162b2.
79335166|NCT04880005|Behavioral|Digital Lifestyle Coaching|As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
79335167|NCT04880005|Behavioral|Integration to Standard Electronic Health Record|Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
79486464|NCT04689776|Behavioral|Dual-Task Training|The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
79486465|NCT05194033|Dietary Supplement|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
79486466|NCT05194033|Dietary Supplement|Placebo daily|Placebo 1 time/day for 7 consecutive days
79486467|NCT04668391|Procedure|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
79486468|NCT04668391|Procedure|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
79486469|NCT04658888|Device|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
79486470|NCT05192551|Other|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
79812254|NCT00806988|Procedure|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
79981756|NCT05497219|Diagnostic Test|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
79981757|NCT05493982|Behavioral|Stanford Vaping Prevention curriculum|Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
79981758|NCT05490420|Other|manual lymphatic drainage (MLD)|MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions.
79486471|NCT05192395|Drug|DWJ1525|DWJ1525
79486472|NCT05192395|Drug|DWP16001|DWP16001
79651953|NCT06166316|Device|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
79651954|NCT06164522|Other|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
79651955|NCT06164470|Behavioral|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
79812255|NCT05749770|Other|blood testing|blood testing for basal hormones and markers of inflammation
79812256|NCT00788320|Drug|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
79812257|NCT00788320|Drug|Placebo|Placebo three times a week for 8 weeks
79981759|NCT05488873|Drug|WST-057 Active|WST-057 Topical Solution
79981760|NCT05488873|Drug|Placebo|Matching Placebo Topical Solution
79335168|NCT05377697|Other|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
79335169|NCT05528393|Diagnostic Test|Blood sampling|blood sampling
79335170|NCT01595581|Drug|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
79335171|NCT01595581|Drug|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
79335172|NCT05534009|Other|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
79335173|NCT03050125|Device|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
79335174|NCT03050125|Device|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
79335175|NCT03050125|Device|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
79335176|NCT05373563|Procedure|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
79335177|NCT03048955|Device|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
79335178|NCT03048955|Procedure|Direct decompression Surgery|A surgical procedure - the control
79335179|NCT04885153|Drug|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
79335180|NCT04885153|Drug|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
79486473|NCT05192395|Drug|DWC202101|DWC202101
79486474|NCT02350699|Device|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
79486475|NCT00368498|Drug|teicoplanin|
79486476|NCT02108899|Behavioral|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
79486477|NCT05172817|Drug|Advixa (Adalimumab)|Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
79486478|NCT04600622|Behavioral|Rural Diabetes One-Day Education and Care program (R-D1D)|One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
79486479|NCT04600622|Behavioral|Diabetes Education Materials|Diabetes Education Materials
79486480|NCT05142163|Other|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV <11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
79486481|NCT05142163|Other|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI <10%, for values >10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
79335183|NCT03048643|Behavioral|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
79335184|NCT04884997|Drug|toripalimab|toripalimab 3mg/kg, Q2w;
79335185|NCT04884997|Drug|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
79335186|NCT03048721|Procedure|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
79486482|NCT04559737|Other|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
79486483|NCT05443958|Other||
79486484|NCT00961142|Drug|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
79812258|NCT00799162|Other|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
79812259|NCT00807144|Drug|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
79812260|NCT00807144|Drug|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
79812261|NCT00799240|Drug|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
79981761|NCT05486663|Other|Tactile/kinesthetic Group|Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
79981762|NCT05470686|Biological|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
79335187|NCT03048721|Procedure|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
79335188|NCT04879771|Procedure|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
79335189|NCT03048565|Behavioral|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
79335190|NCT04879693|Device|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
79335191|NCT04885075|Drug|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
79335192|NCT04885075|Drug|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
79335193|NCT01610687|Drug|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
79812262|NCT00799240|Drug|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
79812263|NCT02555410|Device|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
79812264|NCT02555332|Other|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
79335194|NCT04884919|Device|Regular Gauze|Regular gauze
79335195|NCT04884919|Device|Chitosan Dressing|Dressing made of chitosan material
79335196|NCT04879303|Behavioral|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
79812265|NCT00591006|Drug|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
79335197|NCT04879303|Behavioral|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
79335198|NCT05533931|Other|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
79335199|NCT05533931|Other|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
79335200|NCT04879381|Other|Sputum samples|During consultation, one expectoration will be performed.
79486485|NCT04338373|Combination Product|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
79651956|NCT06164457|Other|ePROM Survey|The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,[4] the EuroQol EQ5D-5L,[5] the Medical Outcomes Study Social Support Scale (8 item version),[6] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools[7], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).[8]
79981763|NCT05470439|Behavioral|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
79981764|NCT05447897|Other|Qualitative Group Interviews|One time interview, 60-90 minutes
79981765|NCT05447897|Other|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
79981766|NCT05438498|Drug|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
79335201|NCT05528237|Device|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
79335202|NCT05533853|Other|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
79335203|NCT05533853|Other|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
79335204|NCT03048409|Other|Enteral Formula|Enteral feeding with a peptide-based formula.
79335205|NCT05528081|Other|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
79335206|NCT04879147|Diagnostic Test|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
79335207|NCT04878835|Biological|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
79486486|NCT00368953|Device|Yukon Choice stent system|coronary stent implantation
79486487|NCT00368953|Device|Taxus Liberté stent system|coronary stent implantation
79651957|NCT06163846|Diagnostic Test|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
79335208|NCT05528003|Procedure|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
79651958|NCT06161987|Behavioral|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
79651959|NCT06160713|Drug|Itraconazole 65 MG|Two capsules of suba-itraconazole 65 mg twice daily for 6 months
79486488|NCT00900055|Genetic|microarray analysis|
79486489|NCT00900055|Genetic|polyacrylamide gel electrophoresis|
79486490|NCT00900055|Genetic|polymerase chain reaction|
79486491|NCT00900055|Genetic|protein expression analysis|
79486492|NCT00900055|Genetic|reverse transcriptase-polymerase chain reaction|
79486493|NCT00900055|Genetic|western blotting|
79486494|NCT00900055|Other|chromatography|
79486495|NCT00900055|Other|high performance liquid chromatography|
79486496|NCT00900055|Other|immunoenzyme technique|
79486497|NCT02200614|Drug|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
79486498|NCT02200614|Drug|Placebo|Matching placebo 2 tablets twice daily with food.
79651960|NCT06160713|Other|Standard care|Standard care for bronchiectasis
79335209|NCT03049423|Device|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
79981767|NCT05436964|Other|saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
79486499|NCT00369031|Biological|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
79335210|NCT03049423|Diagnostic Test|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
79335211|NCT04878523|Dietary Supplement|multi berries juice|Testing product
79486500|NCT00369031|Biological|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
79486501|NCT00369031|Biological|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
79981768|NCT05436964|Drug|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
79981769|NCT05417477|Device|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
79981770|NCT05413655|Drug|EX039|The dosage form of EX039 is the capsule for oral use
79335212|NCT04878523|Dietary Supplement|Placebo drink|Blank
79335213|NCT05527925|Device|MRI|Brain testing of patients using MRI
79335214|NCT04872283|Procedure|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
79335215|NCT04872283|Drug|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
79335216|NCT04872283|Drug|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
79486502|NCT05452382|Procedure|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
79486503|NCT05452382|Procedure|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
79486504|NCT05061901|Drug|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
79651961|NCT06160687|Procedure|PSV mode during NIV|NIV will be delivered using PSV mode of ventilation
79651962|NCT06160687|Procedure|ASV intellisync|ASV intellisync mode will be used to deliver NIV
79651963|NCT06159699|Other|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
79335217|NCT04872283|Drug|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
79335218|NCT04872283|Drug|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
79335219|NCT05182385|Drug|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
79486505|NCT05061901|Drug|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
79486506|NCT04398056|Drug|Chemotherapy plus radiotherapy and Toripalimab|"Chemotherapy:~The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
79486507|NCT00368888|Device|Urine collection bag for infants|
79981771|NCT05413655|Drug|Placebo|The dosage form of Placebo is the capsule for oral use
79486508|NCT05452603|Device|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
79335220|NCT05182385|Drug|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
79335221|NCT04871581|Device|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
79981772|NCT05412706|Drug|Niraparib|"Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles."
79335222|NCT04871581|Device|Placebo|Similar to Device, but having no influence on clenching intensity
79335223|NCT04871347|Drug|TWP-101|IV infusion
79335224|NCT04589533|Other|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
79335225|NCT05524805|Device|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
79981773|NCT05408494|Behavioral|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
79981774|NCT05408494|Behavioral|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
79335226|NCT04466761|Dietary Supplement|Monosaccharide Powder|Monosaccharide powder dissolved in water.
79335227|NCT04466761|Other|Placebo Comparator|Placebo (cellulose powder).
79335228|NCT04425083|Other|no intervention|no intervention
79335229|NCT05527613|Other|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
79335230|NCT04878133|Diagnostic Test|OCT - optical coherence tomography|"The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console."
79335231|NCT05527535|Diagnostic Test|Diabetic retinopathy screening by artificial intelligence|Screening diabetic patients' eyes with AI through digital health platform
79486509|NCT05451992|Dietary Supplement|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
79651964|NCT06155318|Diagnostic Test|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
79981775|NCT05407571|Behavioral|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
79981776|NCT05388071|Other|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
79981777|NCT05376150|Drug|XEN1101 10 mg|XEN1101 oral capsule
79981778|NCT05376150|Drug|XEN1101 20 mg|XEN1101 oral capsule
79651965|NCT06154174|Dietary Supplement|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
79981779|NCT05376150|Drug|Placebo|Placebo capsule
79981780|NCT05362786|Drug|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10^6 cells at day 0 and day 84
79981781|NCT05362786|Drug|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10^6 cells at day 0
79335232|NCT05527535|Diagnostic Test|Diabetic retinopathy screening by healthcare personnel|Screening diabetic patients' eyes by conventional method (healthcare personnel)
79335233|NCT04877899|Device|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
79335234|NCT05533385|Other|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
79335235|NCT04389073|Drug|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
79335236|NCT04389073|Biological|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
79335237|NCT04389073|Biological|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
79335238|NCT04389073|Drug|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
79335239|NCT04389073|Drug|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
79335240|NCT04389073|Drug|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
79335241|NCT05175443|Other|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
79651966|NCT06154174|Dietary Supplement|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
79651967|NCT06154174|Drug|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
79651968|NCT06151418|Drug|Novel hormonal therapy|As provided in real-world setting
79651969|NCT06151236|Drug|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
79651970|NCT06150716|Drug|ION356|Administered as intrathecal (IT) injection.
79651971|NCT06146530|Device|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
79651972|NCT06145555|Behavioral|Acute psychological sleep stabilization|See above (arm description)
79651973|NCT06145555|Behavioral|Sleep hygiene education|See above (arm description)
79651974|NCT06144671|Drug|GT201|Autologous tumor infiltrating lymphocyte injection
79486510|NCT05451992|Dietary Supplement|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
79486511|NCT05443022|Radiation|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
79486512|NCT05443022|Radiation|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
79486513|NCT04338919|Procedure|Percutaneous coronary intervention|PCI with stent implantation
79812266|NCT00591006|Drug|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
79981782|NCT05358392|Other|emotional freedom technique (EFT)|EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
79981783|NCT05349084|Diagnostic Test|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
79981784|NCT05339243|Other|ES 1|Two capsules orally once daily after breakfast for 84 days
79335242|NCT04371445|Drug|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
79335243|NCT04371445|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
79335244|NCT05524337|Behavioral|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
79486514|NCT04338919|Drug|Ticagrelor plus aspirin|Ticagrelor plus aspirin
79486515|NCT05442944|Procedure|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
79651975|NCT06140186|Drug|Topical Timolol|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
79651976|NCT06140186|Drug|Betamethasone Valerate|Betamethasone valerate 0.1% cream application twice daily
79486516|NCT05451758|Other|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
79486517|NCT04351009|Procedure|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
79486518|NCT02231892|Device|TMS|HAC coil (real rTMS or sham rTMS)
79486519|NCT05442476|Other|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
79335245|NCT05524337|Behavioral|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
79486520|NCT05442476|Other|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
79486521|NCT05442476|Other|conventional physiotherapy|conventional physiotherapy
79486522|NCT05451290|Drug|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
79981785|NCT05339243|Other|HT ES1|Two capsules orally once daily after breakfast for 84 days
79981786|NCT05339243|Other|Placebo|Two capsules orally once daily after breakfast for 84 days
79981787|NCT05338398|Device|Bocaliner|Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.
79981788|NCT05338398|Drug|Benzydamine|Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
79335246|NCT05524337|Behavioral|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
79335247|NCT04230577|Device|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
79335248|NCT04230577|Device|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
79335249|NCT05533307|Diagnostic Test|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
79335250|NCT03049267|Drug|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
79335251|NCT03049267|Drug|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
79335252|NCT02615509|Radiation|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
79335253|NCT05524259|Dietary Supplement|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
79335254|NCT05524259|Dietary Supplement|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
79335255|NCT03047317|Biological|MABp1|Single dose of intravenous MABp1
79335256|NCT05533151|Device|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
79335257|NCT04112095|Drug|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
79335258|NCT05257993|Drug|JPI-547|"Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~Capsules should be swallowed whole and should not be chewed, crushed or split."
79335259|NCT05257993|Drug|modified FOLFIRINOX|"After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~Repeated administration every 2 weeks on a 14-day cycle"
79335260|NCT05257993|Drug|Gemcitabine-nab-paclitaxel|"After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~Administration on Days 1, 8, and 15 on a 28-day cycle"
79335261|NCT05533073|Drug|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
79335262|NCT05533073|Drug|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
79335263|NCT05533073|Drug|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
79335264|NCT04050553|Drug|Tirzepatide|Administered SC
79335265|NCT04050553|Drug|Placebo|Administered SC
79335266|NCT03946891|Drug|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
79335267|NCT03946891|Drug|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
79335268|NCT05524103|Drug|ALMB-0166|A single dose of ALMB-0166 injection.
79335269|NCT05257915|Drug|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients <12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
79335270|NCT05257837|Behavioral|Gun handling behavior|Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
79812267|NCT00591006|Drug|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
79812268|NCT00788398|Procedure|Saline Solution|Irrigation with Saline
79335271|NCT05257837|Other|Debriefing|Children and their parents will be debriefed on the actual purpose of the study, including the role of the safety video and how the movie clips were edited.
79335272|NCT04870723|Behavioral|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
79335273|NCT04870879|Procedure|Liver Transplant|Liver Transplant from cadaveric donors
79335274|NCT04870879|Drug|Chemotherapy|Chemotherapy
79335275|NCT03849625|Drug|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
79812269|NCT00788398|Procedure|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
79812270|NCT00788398|Procedure|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
79335276|NCT03046849|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation.
79335277|NCT03046693|Drug|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
79335278|NCT03046693|Drug|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
79335279|NCT05257369|Device|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
79335280|NCT04632329|Device|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
79981789|NCT05331248|Behavioral|Leaders in Action: Household Training|Leaders in Action (LIA) is a norms-centered intervention that aims to reduce the acceptance and prevent the incidence of gender-based violence (GBV) in Peru by shifting social norms around GBV. LIA has two main phases: first, the recruitment of CHVs and second, delivering content against GBV to population at risk in rural villages. There are two types of CHV, first CEM's Promotors (MIMP's professionals working at local Women Centers - CEM) recruit leaders of local social organizations and trained them to be Facilitators of LIA. These Facilitators are to be located in each district center and will conduct LIA activities across all treated villages in the district. The second type are leaders at the village level who will be trained by Facilitators to become Community Agents. Both Community Agents and Facilitators are to be known as CHVs and will work together to conduct the second phase of LIA: training sessions at households level to women at risk of IPV.
79981790|NCT05331248|Behavioral|Leaders in Action: Group Training|Leaders in Action (LIA) is a norms-centered intervention that aims to reduce the acceptance and prevent the incidence of gender-based violence (GBV) in Peru by shifting social norms around GBV. LIA has two main phases: first, the recruitment of CHVs and second, delivering content against GBV to population at risk in rural villages. First CEM's Promotors (MIMP's professionals working at local Women Centers - CEM) recruit leaders of local social organizations and trained them to be Facilitators of LIA. These Facilitators are to be located in each district center and will conduct LIA activities across all treated villages in the district. Then, Facilitators train additional volunteers at the village level who will become Community Agents. Both Community Agents and Facilitators are to be known as CHVs and will work together to conduct the second phase of LIA: gender-segregated and village-level group sessions using edutainment and workshop-style sessions to men and women at risk of IPV.
79981791|NCT05331248|Behavioral|Leaders in Action: Village Leaders Targeting|Leaders in Action (LIA) would target one village leader (e.g. president, mayor, etc.) to receive either LIA's household or group treatment. The treatment will be based on the original village treatment assignment.
79981792|NCT05314179|Behavioral|DOULA-AC 1|"Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2)practical assistance, 3) family support, and/or 4)legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula."
79335281|NCT03327493|Diagnostic Test|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~Lymphocytes Th1/Th2 pattern by flow cytometry~Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~Hemodynamic parameters~Cumulated doses of catecholamines~Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
79335282|NCT05523791|Dietary Supplement|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
79335283|NCT05523791|Dietary Supplement|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
79335284|NCT03049345|Procedure|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
79335285|NCT03049345|Drug|Radioactive Tracers|see above
79335286|NCT03049345|Drug|Methylene Blue 20 MG/ML|see above
79335287|NCT02575079|Device|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
79335288|NCT05526911|Drug|TBAJ-876|"Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
79335289|NCT05526911|Drug|TBAJ-876|"Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~Day 20: 200 mg TBAJ-876 oral suspension, fasting~Day 21 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
79812271|NCT00788398|Procedure|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
79335290|NCT05526911|Drug|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
79335291|NCT05526911|Drug|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
79335292|NCT05526911|Drug|TLD|Day 1 and Day 20: fixed dose combination of dolutegravir 50 mg + tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg, fasted
79486523|NCT05452135|Other|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
79335293|NCT03046771|Behavioral|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
79981793|NCT05307276|Other|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
79335294|NCT03048175|Procedure|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
79486524|NCT04284865|Other|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
79812272|NCT00788398|Procedure|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
79981794|NCT05307276|Other|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
79981795|NCT05306548|Procedure|Surgical carpal tunnel release|Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
79335295|NCT04870489|Combination Product|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
79486525|NCT00369889|Drug|bevacizumab|iv every 21 days
79486526|NCT00369889|Drug|Erlotinib|oral daily
79812273|NCT02606916|Radiation|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
79486527|NCT00369044|Drug|prednisone|
79486528|NCT00370045|Drug|Bivalirudin with and without eptifibatide|
79812274|NCT02606916|Drug|DDP|DDP(25 mg/m2.qw) for six weeks.
79812275|NCT02606916|Drug|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
79486529|NCT05442320|Device|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
79486530|NCT05451056|Drug|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
79981796|NCT05306548|Drug|Injection, Triamcinolone Hexacetonide, Per 5 Mg|Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
79981797|NCT05303662|Diagnostic Test|Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs|Pooled throat/nose sample and a rectal sample is taken prior to the ERCP
79981798|NCT05303662|Diagnostic Test|MDRO-testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's
79981799|NCT05303662|Diagnostic Test|Microbiome through rectal swab|An rectal swab is collected for microbiome purposes
79981800|NCT05303662|Diagnostic Test|Microbiome testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis
79981801|NCT05296941|Procedure|Brush sampling|Brush sampling instead of surgical biopsy for control of reaccurance
79981802|NCT05293886|Other|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
79335296|NCT04870489|Device|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
79335297|NCT05526677|Device|x-guide dynamic navigation system|One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
79486531|NCT04304690|Other|blood sample|2 blood samples at T0 and 3 months
79486532|NCT02231580|Drug|BN82451B|BN82451B capsule
79486533|NCT02231580|Drug|Placebo|Placebo capsule
79486534|NCT05442242|Procedure|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
79486535|NCT05442242|Procedure|High tibial osteotomy|Medial open wedge high tibial osteotomy
79486536|NCT05441150|Drug|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
79335298|NCT05532761|Other|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
79335299|NCT04301453|Other|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
79335300|NCT02614183|Drug|Galcanezumab|Administered SC
79335301|NCT02614183|Drug|Placebo|Administered SC
79335302|NCT05523011|Drug|Exosome ointment|100 µg MSC exosomes/g ointment
79335303|NCT05522933|Other|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health & work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
79335304|NCT05526209|Procedure|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
79335305|NCT04870567|Radiation|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
79335306|NCT04870567|Radiation|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
79335307|NCT05526131|Other|Questionare|"Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders."
79335308|NCT05256433|Other|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
79335309|NCT05256433|Other|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
79335310|NCT05522621|Drug|TJAOA102|Once enrolled, participants will be administrated TJAOA102
79335311|NCT05256043|Diagnostic Test|Diabetes Diagnosis|HbA1c > 6.5%
79335312|NCT05532527|Drug|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
79335313|NCT05231941|Drug|Lidocaine IV|Bolus and infusion of lidocaine will be administered
79335314|NCT05231941|Drug|Ropivacaine|Bilateral TAP block will be given to these patients
79335315|NCT05217745|Dietary Supplement|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
79335316|NCT05217745|Dietary Supplement|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
79335317|NCT05216575|Drug|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
79486537|NCT05441150|Drug|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
79486538|NCT04270214|Drug|Dysport Injectable Product|Dysport injections optimized using kinematics
79812276|NCT00788476|Other|Survey|"Survey packets to adult (>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
79486539|NCT05018689|Other|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
79335318|NCT05522543|Other|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
79335319|NCT05522543|Other|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
79486540|NCT05018689|Other|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
79486541|NCT04217707|Behavioral|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
79486542|NCT05144022|Behavioral|Bungee jump|Bungee jump from a cran
79486543|NCT05450510|Other|Accelerated (ACCEL) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.
79486544|NCT05450510|Other|Slow (SLOW) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
79812277|NCT02554084|Other|Optical Coherence Tomography|Digital images of tear film
79812278|NCT05715918|Biological|Vaccine for intramuscular injection|Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
79812279|NCT05715918|Other|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
79812280|NCT00799630|Dietary Supplement|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
79486545|NCT04746703|Radiation|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
79812281|NCT02554552|Drug|YY1201 2ml|YY1201 2ml
79812282|NCT02554552|Drug|Placebo 2ml|phosphate buffered saline 2ml
79812283|NCT02554552|Drug|YY1201 3ml|YY1201 2ml
79812284|NCT02554552|Drug|Placebo 3ml|phosphate buffered saline 3ml
79812285|NCT03764124|Diagnostic Test|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
79812286|NCT00788554|Procedure|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
79812287|NCT00788554|Procedure|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
79812288|NCT00799786|Behavioral|Building Better Caregivers Online Workshop|
79486546|NCT05438810|Drug|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
79486547|NCT05438810|Drug|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
79981803|NCT05293886|Other|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
79981804|NCT05291286|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion
79981805|NCT05291286|Other|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
79981806|NCT05283109|Biological|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
79486548|NCT04738513|Procedure|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
79486549|NCT04738513|Procedure|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
79981807|NCT05283109|Drug|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
79981808|NCT05270031|Device|Balloon dilation of the eustachian tube|Balloon dilation of the eustachian tube
79486550|NCT04338854|Procedure|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
79486551|NCT02166606|Device|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
79981809|NCT05242289|Device|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
79981810|NCT05239104|Other|No intervention|This is an observational study with no intervention
79335320|NCT05522387|Drug|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
79486552|NCT04730401|Biological|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
79486553|NCT04730401|Biological|Placebo|200mL saline
79981811|NCT05237687|Drug|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
79486554|NCT05451121|Drug|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
79486555|NCT05451121|Drug|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
79486556|NCT05451121|Drug|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
79335321|NCT05532449|Drug|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
79335322|NCT05532371|Other|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
79486557|NCT04967443|Drug|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
79486558|NCT04967443|Drug|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
79486559|NCT04967443|Drug|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
79335323|NCT05532371|Other|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
79486560|NCT04724317|Procedure|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
79486561|NCT04724317|Procedure|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
79486562|NCT04724317|Procedure|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
79651977|NCT06138119|Behavioral|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
79651978|NCT06138002|Device|LumbaCure®|LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
79981812|NCT05235113|Device|Tele-Exergame Platform|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
79981813|NCT05235113|Device|No Tele-Exergame Platform|Subjects will perform exercises in the home exercise twice a week without tele-exergaming platform.
79486563|NCT04697017|Other|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
79486564|NCT04943419|Diagnostic Test|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
79486565|NCT02230956|Biological|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
79486566|NCT02230956|Drug|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
79486567|NCT02230410|Device|CryoBalloon Focal Ablation|
79981814|NCT05225012|Other|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
79335324|NCT05532371|Other|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
79335325|NCT05532371|Other|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
79335326|NCT02352103|Procedure|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
79486568|NCT05447936|Dietary Supplement|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
79486569|NCT04739384|Drug|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
79486570|NCT04739384|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
79486571|NCT05450575|Drug|Amosartan Q tablet|Amlodipine, Losartan, Rosuvastatin
79486572|NCT04704596|Device|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
79486573|NCT04704596|Device|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
79486574|NCT05450497|Drug|Propofol|comparing sedative agents
79486575|NCT05450497|Drug|Dexmedetomidine|comparing sedative agents
79486576|NCT05450497|Drug|Dexmedetomidine and propofol|comparing sedative agents
79335327|NCT02352103|Procedure|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
79486577|NCT02230332|Drug|Alendronate|
79486578|NCT02230332|Drug|Placebo|
79486579|NCT04928989|Other|convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
79486580|NCT02230254|Device|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
79486581|NCT04927819|Device|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
79486582|NCT05447468|Other|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
79486583|NCT05447468|Other|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
79486584|NCT05447468|Other|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
79486585|NCT05447468|Other|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
79486586|NCT05447468|Other|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
79486587|NCT05447468|Other|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
79486588|NCT04587739|Combination Product|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
79486589|NCT05449652|Other|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
79486590|NCT05449574|Diagnostic Test|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
79486591|NCT04579159|Device|Preventicus heartbeat app in combination with wearables|CE certified devices
79981815|NCT05219760|Device|LIVIA|"The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance."
79981816|NCT05219526|Diagnostic Test|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
79981817|NCT05219526|Diagnostic Test|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
79981818|NCT05210569|Device|Vivity|Vivity intraocular lens (IOL)
79335328|NCT02352103|Device|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
79335329|NCT05146037|Other|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
79335330|NCT05146037|Other|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
79486592|NCT05447390|Diagnostic Test|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
79486593|NCT04577287|Device|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
79486594|NCT05449184|Procedure|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
79651979|NCT06138002|Procedure|Physical Exercises supervised by the physiotherapist|A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
79335331|NCT04870021|Biological|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
79486595|NCT05449184|Procedure|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
79486596|NCT04569175|Other|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
79335332|NCT04870021|Behavioral|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
79335333|NCT04144387|Procedure|Myelogram|Two additional myelograms will be performed comparing to standard of care.
79335334|NCT05525897|Other|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
79335335|NCT04877509|Biological|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
79335336|NCT05525819|Drug|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
79335337|NCT05525819|Drug|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
79335338|NCT05525819|Drug|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
79335339|NCT03044743|Drug|Fludarabine|To modify immune micro-environment
79335340|NCT03044743|Drug|Cyclophosphamide|To modify immune micro-environment
79335341|NCT03044743|Drug|Interleukin-2|To sustain the survival of infused T cells
79335342|NCT05532293|Drug|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro & in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
79335343|NCT05532293|Other|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
79335344|NCT03044665|Drug|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
79335345|NCT03044665|Drug|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
79335346|NCT03046537|Diagnostic Test|Breath test|Collecting breath test from participants
79486597|NCT04338542|Genetic|Tumor biobsies analysis|Analysis on archived tumor biopsies
79486598|NCT05449951|Other|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
79486599|NCT05449951|Other|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
79486600|NCT02198664|Biological|AR101 - Peanut protein capsule|Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
79486601|NCT05449028|Drug|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
79486602|NCT05449028|Drug|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
79486603|NCT05449028|Drug|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
79651980|NCT06137066|Dietary Supplement|200mg GCE +200mg ALA|200mg green coffee extract + 200mg alpha-lipoic acid
79335347|NCT03046615|Device|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
79335348|NCT03046615|Device|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
79335349|NCT04877353|Device|NIV|NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
79486604|NCT05449028|Drug|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
79486605|NCT05449028|Drug|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
79651981|NCT06137066|Dietary Supplement|200mg GCE +400mg ALA|200mg green coffee extract + 400mg alpha-lipoic acid
79651982|NCT06137066|Dietary Supplement|200mg GCE + 200mg DHB|200mg green coffee extract + 200mg dihydroberberine
79335350|NCT05521841|Procedure|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
79335351|NCT05521841|Procedure|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
79486606|NCT04543825|Device|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath.
79651983|NCT06137066|Dietary Supplement|Placebo|microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
79651984|NCT06136000|Other|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
79335352|NCT05525351|Device|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
79335353|NCT05525351|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
79335354|NCT05525351|Drug|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
79335355|NCT05525351|Drug|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
79335356|NCT04869865|Dietary Supplement|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
79335357|NCT04869475|Drug|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
79335358|NCT05521763|Behavioral|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
79335359|NCT03044821|Procedure|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
79812289|NCT00844844|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
79812290|NCT05748054|Drug|Silver Diamine Fluoride|A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
79812291|NCT00660790|Other|Intensified Treatment of risk factors|Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
79335360|NCT02612155|Biological|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
79812292|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which <2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
79335361|NCT02612155|Biological|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
79335362|NCT05100251|Drug|WBC100|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage enroll 12 pancreatic patients with positive c-myc expression."
79335363|NCT04876885|Other|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
79335364|NCT04865185|Diagnostic Test|Xylocaine spray 100mg/ml|Topical application
79335365|NCT04865185|Diagnostic Test|Ethanol|Topical application
79651985|NCT06136000|Other|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
79335366|NCT05518565|Other|No intervention|No intervention
79335367|NCT04865107|Biological|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
79335368|NCT04865107|Biological|Placebo|PlasmaLyte A and 5% Human Albumin
79812293|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
79335369|NCT05531903|Device|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
79335370|NCT03046459|Biological|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
79335371|NCT03046381|Drug|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
79335372|NCT05521373|Device|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
79335373|NCT05521373|Device|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
79335374|NCT05521295|Other|no intervention|no intervention in this study
79335375|NCT04876807|Drug|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
79335376|NCT04876807|Drug|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
79335377|NCT05518409|Biological|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
79335378|NCT05518409|Drug|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
79335379|NCT02614729|Other|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
79335380|NCT02614729|Other|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
79335381|NCT02614729|Other|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
79335382|NCT02614729|Other|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
79335383|NCT05531825|Device|A device for detecting arteriovenous fistula vascular function|An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
79335384|NCT05518331|Drug|avatrombopag|Avatrombopag, 40-60 mg (body weight < 80 kg, 40 mg per day; body weight > 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
79651986|NCT06134323|Device|medication-combined transcutaneous vagus nerve stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation
79812294|NCT00799942|Drug|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
79486607|NCT04338841|Other|HOME-CoV rule implementation|"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments."
79486608|NCT04538287|Device|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
79486609|NCT04338464|Behavioral|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~Relational theory (Belgrave, 2002) & South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek & Ehrenriech-May, 2012; Ritschel, Noriel & Lindsay, 2015).~Psychoeducation on mental health, sexual health, and substance use.~Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
79335385|NCT04876573|Drug|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
79335386|NCT05521139|Diagnostic Test|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
79335387|NCT03046147|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
79335388|NCT03046069|Other|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
79486610|NCT05448794|Other|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
79486611|NCT05446922|Other|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
79486612|NCT04845139|Drug|Nivolumab|Nivolumab given intraventricularly
79486613|NCT05446844|Other|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~Caring behaviors during psychological care included offering religious sound meditation.~Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~Caring behaviors during health teaching included providing health teaching for patients.~Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
79486614|NCT05446844|Other|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
79651987|NCT06134323|Device|medication-combined sham stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
79812295|NCT00913172|Other|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
79335389|NCT03046069|Other|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
79335390|NCT03046069|Other|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
79335391|NCT03046069|Other|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
79486615|NCT04738669|Other|mHealth|The mHealth intervention includes telephonic call and SMS.
79486616|NCT04738669|Behavioral|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
79335392|NCT03046069|Other|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
79486617|NCT05446688|Drug|6MW3211|6MW3211 injection, 45mg/kg, Q2W
79981819|NCT05200143|Drug|Ipilimumab|Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
79486618|NCT04563806|Device|Magnetic Resonance Imaging|Undergo MRI-guided surgery
79651988|NCT06129552|Procedure|Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation|Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
79651989|NCT06123598|Behavioral|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
79651990|NCT06123598|Behavioral|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
79335393|NCT04864873|Diagnostic Test|Metagenomic next generation sequencing using Oxford Nanopore|See previous.
79335394|NCT04864873|Diagnostic Test|Standard microbiological diagnostic pathway|See previous.
79335395|NCT04864717|Drug|Doxycycline 100mg po once daily x 6 months|active intervention
79335396|NCT04864717|Drug|Isotretinoin 40 mg po once daily x 6 months|active intervention
79335397|NCT04876495|Dietary Supplement|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~Tropicana Trop50 Orange Juice 207mL~Water 43 mL~Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
79335398|NCT04876495|Dietary Supplement|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~Tropicana Trop50 Orange Juice 250mL~Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
79651991|NCT06119048|Dietary Supplement|L-Phenylalanine|100 mg/kg
79486619|NCT04563806|Procedure|Therapeutic Conventional Surgery|Undergo spinal surgery
79981820|NCT05200143|Drug|Nivolumab|Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
79981821|NCT05200143|Drug|Cabozantinib|Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
79486620|NCT04738526|Other|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
79486621|NCT04738526|Other|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
79486622|NCT04738526|Other|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
79486623|NCT05449483|Drug|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
79486624|NCT05448482|Procedure|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
79486625|NCT05448404|Drug|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
79486626|NCT05448404|Drug|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
79335399|NCT04876495|Dietary Supplement|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~Tropicana Trop50 Orange Juice 183mL~Water 67mL~Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
79335400|NCT04876261|Dietary Supplement|Oliphenolia® bitter|"ingredients: concentrated watery extract of olives 94%, lemon juice 6%~35 mg hydroxytyrosol, 0,24 mg Oleuropein"
79335401|NCT04876261|Dietary Supplement|Oliphenolia®|"ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~38 mg hydroxytyrosol, 0,28 mg Oleuropein"
79335402|NCT04876261|Dietary Supplement|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"extra virgin olive oil~5 mg hydroxytyrosol"
79651992|NCT06113185|Other|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
79651993|NCT06112613|Other|Electronic Health Record Review|Ancillary studies
79335403|NCT05518097|Other|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
79335404|NCT05518019|Dietary Supplement|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
79335405|NCT02613871|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79335406|NCT05531747|Other|Skin biopsy|A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
79335407|NCT05531747|Other|Blood sample|42mL of blood (6 tubes of 7mL) sampled at initiation visit
79335408|NCT04425161|Other|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
79335409|NCT04875949|Procedure|Immunoabsorption/plasmapheresis procedure|
79335410|NCT05520671|Other|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
79486627|NCT05449093|Other|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
79486628|NCT04338308|Device|new-DES|with ot without embolic protection device
79486629|NCT04338308|Device|BMS|with ot without embolic protection device
79651994|NCT06112613|Other|Health Promotion and Education|Receive access to educational materials
79651995|NCT06112613|Procedure|Health Telemonitoring|Utilize the WiseBag medication dispenser
79651996|NCT06112613|Other|Interview|Complete an interview
79651997|NCT06112613|Behavioral|Patient Navigation|Receive healthcare provider follow ups as part of the CONCURxP program
79651998|NCT06112613|Other|Survey Administration|Ancillary studies
79651999|NCT06112613|Other|Text Message-Based Navigation Intervention|Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
79652000|NCT06111235|Drug|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
79652001|NCT06111235|Other|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
79652002|NCT06105801|Procedure|Endobronchial ultrasound with transbronchial needle aspiration|Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
79486630|NCT04438759|Device|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
79486631|NCT04793659|Drug|Oral Fasudil 90 mg/day|Oral tablet
79486632|NCT04793659|Drug|Oral Fasudil 180 mg/day|Oral tablet
79486633|NCT04793659|Drug|Oral Placebo|Oral tablet
79652003|NCT06105801|Procedure|Bronchoscopy|Participants will undergo Bronchoscopy
79335411|NCT05520671|Other|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
79335412|NCT04869709|Drug|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
79335413|NCT05021081|Device|TRP-200|JJVC Investigational Contact Lens
79335414|NCT05021081|Device|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
79335415|NCT04864327|Behavioral|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
79335416|NCT05520437|Dietary Supplement|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
79335417|NCT05520437|Dietary Supplement|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
79335418|NCT02612077|Other|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
79335419|NCT02612077|Drug|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
79486634|NCT05448937|Procedure|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
79486635|NCT05448937|Procedure|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
79486636|NCT00370201|Drug|colchicine|
79486637|NCT00422552|Drug|Indacaterol (QAB149)|
79652004|NCT06105801|Procedure|Cryobiopsy|Participants will undergo Cryobiopsy
79652005|NCT06102876|Other|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
79486638|NCT00370279|Procedure|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
79486639|NCT05448859|Procedure|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
79335420|NCT04622735|Combination Product|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
79335421|NCT04622735|Drug|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
79486640|NCT03203954|Behavioral|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
79486641|NCT03203954|Behavioral|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
79486642|NCT03203954|Behavioral|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
79486643|NCT05448781|Drug|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
79486644|NCT03187652|Diagnostic Test|CT Perfusion Study|Brain and cardiac CT perfusion scan
79335422|NCT04622735|Drug|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
79486645|NCT03187652|Diagnostic Test|Echocardiogram|Speckle tracking Echocardiography
79486646|NCT03187652|Diagnostic Test|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
79486647|NCT03187652|Diagnostic Test|MRI|MRI to assess white matter changes
79486648|NCT05448625|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79486649|NCT05448079|Other|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
79335423|NCT03045991|Behavioral|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
79335424|NCT03045991|Behavioral|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
79486650|NCT03219697|Behavioral|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
79486651|NCT05442788|Biological|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
79486652|NCT05442788|Biological|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
79335425|NCT03045991|Behavioral|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
79486653|NCT05442788|Biological|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
79486654|NCT03182101|Behavioral|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
79486655|NCT05442164|Behavioral|DANAKIR support network|"The DANAKIR intervention will consist of:~Structured written discharge information~Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
79486656|NCT03123835|Procedure|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
79335426|NCT04615559|Diagnostic Test|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
79335427|NCT05517629|Other|It is an observational cross-sectional study|It is an observational cross-sectional study
79335428|NCT03046303|Procedure|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
79486657|NCT02958943|Behavioral|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
79486658|NCT04475822|Behavioral|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
79335429|NCT04875637|Diagnostic Test|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
79335430|NCT05531669|Behavioral|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
79335431|NCT05531669|Behavioral|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
79335432|NCT02613481|Drug|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
79652006|NCT06100146|Dietary Supplement|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
79335433|NCT04864015|Device|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
79335434|NCT05298917|Device|silicone hydrogel contact lens|silicone hydrogel contact lens
79335435|NCT04385251|Other|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 & 28:~Vital and hospitalization status; Symptoms and health status"
79335436|NCT04864093|Diagnostic Test|muscular ultrasound|respiratroy and muscular ultrasound
79335437|NCT04384705|Other|research specific blood sample|"one blood sample before the epidemic phase~one blood sample during epidemic phase~one blood sample after epidemic phase"
79335438|NCT05517551|Procedure|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
79335439|NCT05520125|Biological|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
79335440|NCT05520125|Other|Standard treatment of bone defects|Standard surgical treatment of bone defects
79335441|NCT04297319|Procedure|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
79335442|NCT04297319|Procedure|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
79335443|NCT05517395|Behavioral|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
79335444|NCT05517395|Behavioral|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
79335445|NCT05048615|Drug|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
79335446|NCT05048615|Drug|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
79486659|NCT04475822|Behavioral|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
79486660|NCT04475822|Behavioral|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
79486661|NCT04338451|Other|Music during the first part of ESWL|Music listening during first part of ESWL
79486662|NCT04338451|Other|Music during the second part of ESWL|Music listening during second part of ESWL
79486663|NCT02992574|Radiation|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
79652007|NCT06100146|Other|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
79652008|NCT06097273|Biological|mRNA-1083|Suspension for injection
79335447|NCT05048615|Drug|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
79335448|NCT05531435|Drug|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
79335449|NCT05517317|Combination Product|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
79486664|NCT02848027|Biological|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
79486665|NCT02829229|Behavioral|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials & 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
79486666|NCT05439044|Other|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
79486667|NCT04256083|Biological|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
79486668|NCT00370825|Drug|Combination therapy with AmBisome and miltefosine|
79335450|NCT05517239|Drug|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
79335451|NCT05519813|Drug|Metformin|Use Metformin for 3 months to treat PCOS
79486669|NCT05428046|Behavioral|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
79486670|NCT05428046|Behavioral|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
79486671|NCT04445870|Other|data record|Data record on registers without medical files
79486672|NCT04040101|Device|smartphone-based balance training system|use smartphone application to training balance
79486673|NCT00370136|Drug|ultrasound contrast|
79652009|NCT06097273|Biological|Placebo|0.9% sodium chloride suspension for injection
79652010|NCT06097273|Biological|Influenza Vaccine|Commercially available formulation (Suspension for injection [pre-filled syringe])
79652011|NCT06097273|Biological|COVID-19 Vaccine|Commercially available formulation (Suspension for injection)
79652012|NCT06095661|Other|REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.|The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
79486674|NCT02602093|Procedure|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
79486675|NCT02602093|Procedure|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
79486676|NCT05419778|Device|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
79335452|NCT05519813|Drug|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
79335453|NCT05517005|Dietary Supplement|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
79335454|NCT05519657|Other||
79335455|NCT05082311|Other|Observational study|This is an observational study
79486677|NCT05419778|Device|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
79652013|NCT06095531|Device|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
79335456|NCT05519501|Device|SyntrFuge System|Microsized Adipose Tissue
79486678|NCT00370357|Drug|3% w/w SPL7013 Gel (VivaGel™)|
79335457|NCT05519501|Procedure|Standard of Care|Offloading
79335458|NCT02613403|Drug|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
79335459|NCT02613403|Drug|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
79335460|NCT05531279|Drug|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
79335461|NCT04875403|Other|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
79335462|NCT04875403|Other|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
79335463|NCT05519267|Behavioral|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
79335464|NCT05519267|Behavioral|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
79335465|NCT03044119|Biological|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
79486679|NCT02808962|Procedure|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
79335466|NCT03044119|Biological|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
79335467|NCT04863937|Device|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
79335468|NCT03044275|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
79335469|NCT03044275|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
79335470|NCT04640597|Device|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
79486680|NCT02165826|Drug|Roflumilast|Roflumilast tablets
79486681|NCT02165826|Drug|Roflumilast Placebo|Roflumilast placebo-matching tablets
79486682|NCT02165826|Drug|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
79486683|NCT02535247|Drug|MK-3475|
79486684|NCT02535247|Drug|Copanlisib|
79486685|NCT00370916|Behavioral|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
79486686|NCT00370916|Behavioral|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
79486687|NCT02509897|Other|Hypoxic training|Hypoxic training 3 times per week four four weeks
79486688|NCT02509897|Other|Normoxic training|Normoxic training 3 times per week four four weeks
79486689|NCT04337996|Diagnostic Test|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
79652014|NCT06095323|Device|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
79652015|NCT06091215|Device|Sciton Joule System|Sciton Joule System
79652016|NCT06088277|Behavioral|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
79486690|NCT04417920|Procedure|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
79486691|NCT02626130|Procedure|Cryosurgery|Undergo cryoablation
79335471|NCT04874701|Drug|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
79335472|NCT04874701|Other|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
79335473|NCT03045835|Device|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
79335474|NCT03045835|Device|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
79486692|NCT02626130|Other|Laboratory Biomarker Analysis|Correlative studies
79486693|NCT02626130|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79981822|NCT05198271|Other|Management of risk factors|"For all patients:~Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6~Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling~Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report.~Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)"
79335475|NCT05516693|Other|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
79335476|NCT04874779|Other|non|follow up investigations
79981823|NCT05198271|Behavioral|Smoking cessation|"- For active smoking patients:~Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist~Nicotine substitutes +/- varenicline according to tobacco consumption~Online notebook to record tobacco consumption and triggers"
79652017|NCT06088277|Behavioral|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
79652018|NCT06087354|Other|The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
79335477|NCT05002127|Drug|Evorpacept (ALX148)|IV Q2W
79486694|NCT02626130|Biological|Tremelimumab|Given IV
79652019|NCT06086951|Behavioral|Pai.ACT Group|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
79652020|NCT06086951|Other|Control Group|Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
79652021|NCT06084013|Other|Non-Interventional Study|Non-interventional study
79981824|NCT05198271|Behavioral|weightloss|-For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve
79981825|NCT05198271|Other|periodontal disease treatment|- For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6
79981826|NCT05198271|Behavioral|increased physical activity|- For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months
79335478|NCT05002127|Drug|Trastuzumab|IV Q2W
79335479|NCT05002127|Drug|Ramucirumab|IV Q2W
79335480|NCT05002127|Drug|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
79335481|NCT04863547|Other|Data collection|Data collection
79335482|NCT04874389|Diagnostic Test|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
79335483|NCT04873921|Other|sterile kinesio taping|Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
79335484|NCT04869241|Diagnostic Test|surface EMG|Carrying backpacks forward or backward
79652022|NCT06083948|Drug|Noradrenalin|Infusion of noradrenaline during anesthesia and surgery
79981827|NCT05198271|Behavioral|Decreased anxiety|"- For anxious patients:~Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence~Delivery of connected equipment for the practice of cardiac coherence"
79981828|NCT05148442|Drug|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
79981829|NCT05148325|Drug|BAT4706|The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
79981830|NCT05144373|Behavioral|Gross motor intervention, gross and fine motor intervention|"For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months."
79335485|NCT04429867|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
79335486|NCT04429867|Drug|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
79981831|NCT05144360|Drug|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
79335487|NCT03044041|Drug|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
79335488|NCT03047941|Diagnostic Test|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
79335489|NCT04863391|Diagnostic Test|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
79335490|NCT04869007|Device|hysterosonography|Isthmocele mesured by hysterosonography before ART procedure
79981832|NCT05144360|Drug|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
79981833|NCT05142254|Drug|Tadalafil|2.5-5 mg/day
79981834|NCT05142254|Drug|Hydroxyurea|20 mg/kg/day
79981835|NCT05142254|Drug|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
79981836|NCT05141019|Diagnostic Test|Panel-based pharmacogenetic genotyping|After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
79981837|NCT05127187|Diagnostic Test|Rapid diagnosis test against HIV and hepatitis C and B|combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample
79981838|NCT05125978|Drug|Canadá|Canadá association 1 tablet twice a day
79981839|NCT05125978|Other|Canadá placebo|Placebo of Canadá association 1 tablet twice a day
79335491|NCT05029427|Other|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
79335492|NCT05029427|Other|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
79335493|NCT04429789|Behavioral|Active-Alert Hypnosis|Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
79335494|NCT04429789|Behavioral|Traditional Hypnosis|Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
79335495|NCT05518955|Behavioral|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
79335496|NCT04863235|Behavioral|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
79335497|NCT04863235|Behavioral|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
79335498|NCT03048097|Drug|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
79335499|NCT03048097|Drug|Rubidium|used in PET scans
79652023|NCT06083948|Drug|Phenylephrine|Infusion of phenylephrine during anesthesia and surgery
79652024|NCT06083870|Drug|Oba01|Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
79652025|NCT06082492|Diagnostic Test|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
79981840|NCT05125978|Drug|Dipyrone|Dipyrone 1 tablet twice a day
79981841|NCT05125978|Other|Dipyrone placebo|Placebo of dipyrone 1 tablet twice a day
79981842|NCT05125978|Drug|Tramadol hydrochloride|Tramadol 1 coated tablet twice a day
79981843|NCT05125978|Other|Tramadol hydrochloride placebo|Placebo of tramadol 1 coated tablet twice a day
79652026|NCT06082492|Diagnostic Test|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
79652027|NCT06081998|Other|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
79335500|NCT03048097|Diagnostic Test|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
79652028|NCT06081998|Other|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
79335501|NCT03048253|Biological|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
79652029|NCT06078540|Other|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~Provide patients with simple tools to organize and track their health information;~Provide easy access to information related to patients' health conditions or treatments;~Help patients document, show, or communicate potential medical conditions to health care providers;"
79652030|NCT06077591|Other|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
79335502|NCT05516303|Genetic|Genetic polymorphism|One blood tube will be taken for genetic testing
79335503|NCT05516303|Diagnostic Test|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
79652031|NCT06069544|Biological|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
79652032|NCT06069544|Other|Placebo|Isotonic NaCl solution (0.9%)
79652033|NCT06064474|Behavioral|High ventilation breathwork with retention (HVBR)|Intervention
79335504|NCT04863079|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
79652034|NCT06064474|Behavioral|Placebo HVBR|Placebo
79652035|NCT06063031|Dietary Supplement|Active|Active nutritional supplement plus telerehabilitation
79652036|NCT06063031|Other|Placebo|Placebo nutritional supplement plus telerehabilitation
79335505|NCT05512325|Drug|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) * 150mg/m2/day BSA(Body Surface Area)=[weight (kg)* height (cm)/3600]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
79335506|NCT04868383|Behavioral|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
79335507|NCT05518643|Procedure|ERAS protocol|ERAS protocol as described above
79335508|NCT03047863|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
79335509|NCT03047863|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
79335510|NCT04868227|Dietary Supplement|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
79652037|NCT06062810|Drug|Crizotinib - Usual|"XALKORI - crizotinib capsule (high dose)~XALKORI 250 mg taken orally twice daily"
79652038|NCT06062810|Drug|Crizotinib - Study|"XALKORI - crizotinib capsule (low dose)~XALKORI 200 mg taken orally twice daily"
79652039|NCT06057922|Drug|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
79652040|NCT06056050|Biological|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
79652041|NCT06056050|Biological|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
79652042|NCT06056050|Biological|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
79652043|NCT06054425|Drug|Risankizumab|Infusion; intravenous
79652044|NCT06050187|Procedure|implant casts fabrication|four implant casts fabricated
79652045|NCT06046495|Drug|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
79652046|NCT06044857|Drug|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
79652047|NCT06040723|Device|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
79335511|NCT04863001|Drug|Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
79335512|NCT04873531|Drug|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
79335513|NCT04873531|Drug|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
79335514|NCT03045601|Diagnostic Test|CT-FFR|Invasive FFR and CCTA With CT-FFR
79335515|NCT03045601|Diagnostic Test|Stress echocardiography|Stress echocardiography and invasive FFR
79335516|NCT02572817|Biological|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
79335517|NCT02572817|Biological|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
79335518|NCT04862845|Drug|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
79335519|NCT04862845|Drug|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
79335520|NCT04862845|Drug|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
79335521|NCT04873609|Behavioral|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
79335522|NCT04873141|Drug|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
79335523|NCT04862377|Drug|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
79335524|NCT04862377|Drug|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
79335525|NCT05516225|Drug|PBCLN-003|Human Milk Oligosaccharide Concentrate
79335526|NCT04867993|Drug|Amikacin|15 mg/kg/36h
79652048|NCT06036225|Behavioral|Prehabilitation|Remote prehabilitation multi-component.
79335527|NCT04873219|Device|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
79335528|NCT04988009|Other|Electronic Health Record Review|Review of medical chart
79335529|NCT04988009|Other|Survey Administration|Complete survey
79335530|NCT04872985|Drug|Pyrotinib|400 mg orally once per day
79335531|NCT04872985|Drug|Epirubicin|100 mg/m2,q3W*4
79335532|NCT04872985|Drug|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w*4
79335533|NCT04872985|Drug|Cyclophosphamide|600 mg/m2, q3w*4
79335534|NCT04872985|Drug|Docetaxel|100 mg/m2, q3w*4
79335535|NCT04872985|Drug|Nab paclitaxel|120mg/m2 qw*12
79335536|NCT04872985|Drug|Placebo|400 mg orally once per day
79335537|NCT04872907|Device|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
79652049|NCT06035744|Drug|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
79652050|NCT06035744|Drug|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
79652051|NCT06035536|Device|Symphony™ plus Off-loading|Application of Symphony™
79335538|NCT04872907|Device|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
79335539|NCT04872907|Drug|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
79335540|NCT02566109|Diagnostic Test|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
79335541|NCT04868071|Behavioral|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
79335542|NCT04861909|Device|AT LISA tri 839MP|Non interventional study
79335543|NCT03047707|Diagnostic Test|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
79335544|NCT02566031|Drug|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
79335545|NCT02566031|Drug|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
79486695|NCT02198040|Other|Manual Therapy|"5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~15 minutes. Passive muscle stretching (within the limits of mobility).~15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
79652052|NCT06035536|Device|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
79652053|NCT06032286|Device|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
79652054|NCT06028334|Behavioral|GetUp&Go|A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
79652055|NCT06028334|Behavioral|GetUp&Go with 10-Week Delay|No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
79652056|NCT06017817|Device|Lumoral Treatment|Anti-infective photodynamic therapy for plaque-induced oral conditions
79652057|NCT06017817|Procedure|Standard oral hygiene instructions|Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
79652058|NCT06017817|Procedure|Scaling and root planing (SRP|non-surgical anti-infective treatment by scaling and root planing
79652059|NCT06017817|Procedure|surgical anti-infective peri-implantitis treatment|surgical anti-infective peri-implantitis treatment
79652060|NCT06015750|Drug|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
79335546|NCT04861753|Other|Reiki and back massage|In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
79335547|NCT04861675|Procedure|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
79335548|NCT04901039|Other|Lung ultrasound|Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
79335549|NCT04901039|Other|Echocardiography|Comprehensive echocardiography with evaluation of filling pressures
79335550|NCT04901039|Other|Peripheral venous pressure|Assessment of peripheral venous pressure
79335551|NCT04901039|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging
79335552|NCT04901039|Other|Pulmonary scintigraphy|Assessment of pulmonary perfusion with scintigraphy
79335553|NCT04861519|Other|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
79335554|NCT04769765|Other|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
79335555|NCT03045523|Drug|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
79335556|NCT03045523|Drug|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
79335557|NCT03045523|Drug|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
79335558|NCT04984967|Device|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
79335559|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
79335560|NCT04872829|Device|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
79335561|NCT03045211|Device|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
79335562|NCT04872361|Procedure|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
79335563|NCT04872361|Procedure|High PEEP|PEEP of 10 cm H2O will be applied
79652061|NCT06015750|Drug|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
79652062|NCT06015750|Drug|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
79652063|NCT06015750|Drug|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
79652064|NCT06015750|Drug|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
79652065|NCT06015659|Drug|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
79652066|NCT06015659|Drug|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
79335564|NCT04872361|Procedure|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
79981844|NCT05116878|Dietary Supplement|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
79981845|NCT05116878|Dietary Supplement|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
79981846|NCT05098574|Drug|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
79981847|NCT05098574|Drug|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
79335565|NCT04872361|Device|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~three or more B lines~coalescent B lines~consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
79335566|NCT03045367|Procedure|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
79335567|NCT04763681|Behavioral|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson & Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
79981848|NCT05097430|Behavioral|Alcohol-focused brief intervention|The primary intervention component is the Check Your Drinking (CYD) intervention - an electronically-delivered brief intervention designed to assess and provide personalized feedback regarding the quantity, frequency, and severity of one's alcohol consumption. Additionally, intervention condition participants who are identified as having a concurrent substance use concern or who may be experiencing depression will receive information about local resources that can assist with such concerns.
79335568|NCT04861129|Procedure|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
79335569|NCT04861129|Procedure|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
79335570|NCT05507489|Drug|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
79335571|NCT04761341|Drug|NUTROF TOTAL|1 per day over a course of 3 months
79335572|NCT05507411|Radiation|Neoadjuvant Radiotherapy|41.4Gy/23F
79335573|NCT05507411|Drug|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m^2 QW Carboplatin: AUC=2 QW
79335574|NCT05507411|Drug|Immunotherapy|Camrelizumab 200mg Q3W
79335575|NCT05515913|Other|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
79335576|NCT05515913|Behavioral|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
79335577|NCT05515913|Other|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
79981849|NCT05093192|Other|Exercise trial|Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
79981850|NCT05070728|Drug|Sham Injector|Sham injection
79981851|NCT05070728|Drug|FAI Insert|FAI insert
79981852|NCT05065229|Device|Oxygen saturation probe Mindray 520 N and Mindray 521 N|"Two oxygen saturation probes will be used in this study:~Mindray 520 N is a disposable oxygen saturation sensor for neonates and adults. It is a disposable, single-use sensor that is wrapped around the infant's arm or foot. Its ends stick together giving a firm, close contact with the skin.~Mindray 521 N is another disposable oxygen saturation sensor for neonates and adults that is used on the neonatal unit in routine practice. As Mindray 520 N and 521 N are CE marked and used within their intended purposes we do not require a letter of no objection from the MHRA for that usage. The Mindray probes will be used without modification and there are no safety issues to the patient. Therefore, a letter of no objection from the MHRA is not required and this is not a medical device study under the Medical Devices Directive."
79981853|NCT05017597|Other|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during & after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms & any identified barriers or supports. Weeks 1, 3, 5, & 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, & 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal & action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
79981854|NCT04997278|Device|Coordinated Reset spinal cord stimulation|"Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass & Majtanik, 2006)."
79981855|NCT04994600|Other|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA_2nd_phase group.
79981856|NCT04992390|Behavioral|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
79652067|NCT06012981|Behavioral|ACT|"The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree."
79652068|NCT06008704|Diagnostic Test|Clinical assessment|The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
79981857|NCT04988386|Drug|Acoramidis (AG10)|Acoramidis (AG10) twice daily
79652069|NCT06008704|Diagnostic Test|Pain characteristics assessment|The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
79486696|NCT02198040|Other|Educational group|"Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
79486697|NCT02618720|Drug|ornidazole|
79486698|NCT02618720|Drug|Placebo|
79486699|NCT04338139|Procedure|bone regeneration|bone regeneration using bio-oss collagen
79486700|NCT05359328|Device|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
79335578|NCT05515913|Other|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
79486701|NCT02197806|Drug|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
79486702|NCT02197806|Drug|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
79981858|NCT04976881|Behavioral|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
79981859|NCT04976881|Behavioral|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
79486703|NCT02197806|Drug|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
79486704|NCT03660085|Behavioral|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
79486705|NCT02323165|Other|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
79486706|NCT02171845|Other|surgical biopsies|
79486707|NCT04109599|Behavioral|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
79486708|NCT04109599|Behavioral|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
79486709|NCT04109599|Behavioral|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
79486710|NCT02229864|Device|Coronary artery stenting: Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm"
79486711|NCT04273802|Drug|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
79486712|NCT04273802|Drug|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
79981860|NCT04976881|Behavioral|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
79335579|NCT05515913|Other|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
79335580|NCT05515913|Other|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
79335581|NCT02569853|Drug|DFN-11|
79652070|NCT06008704|Diagnostic Test|MRI|The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
79652071|NCT06008704|Diagnostic Test|Thermotest|The thermotest is performed to assess the pain perception threshold
79335582|NCT02569853|Other|Placebo|
79335583|NCT04894643|Radiation|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
79335584|NCT04894643|Drug|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
79335585|NCT04894643|Drug|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
79652072|NCT06008704|Diagnostic Test|UPDRS-III Scale|The UPDRS-III scale allows to asses motor functionality of PD patients
79981861|NCT04976881|Behavioral|Text Messaging|Within ~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
79652073|NCT06008704|Diagnostic Test|[18F]-MPPF PET scan|The PET scan after injection of [18F]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
79981862|NCT04970108|Drug|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
79652074|NCT06007352|Drug|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
79652075|NCT06007352|Other|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
79981863|NCT04970108|Drug|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
79981864|NCT04968015|Drug|Cytarabine-Venetoclax Association|Consolidation treatment with cytarabine + venetoclax
79981865|NCT04968015|Drug|Cytarabine-Idarubicin Association|Consolidation treatment with cytarabine + idarubicin
79981866|NCT04955366|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
79981867|NCT04955366|Drug|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
79335586|NCT04894643|Drug|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
79335587|NCT04894643|Procedure|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
79335588|NCT05511857|Behavioral|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
79335589|NCT05511857|Behavioral|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
79335590|NCT05511857|Behavioral|Distraction|The participants will engage in a distraction task.
79486713|NCT02229552|Other|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
79652076|NCT06004479|Other|Carotenoid Intake|Carotenoid intake assess by 24 hour dietary recalls
79652077|NCT06004479|Other|Serum carotenoid concentration|Serum total carotenoid concentration
79981868|NCT04934371|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
79981869|NCT04934371|Device|Sham TDCS|Sham control will be administered to the same area as active TDCS
79981870|NCT04922476|Dietary Supplement|Alflorex®|Each probiotic capsule contains 1 x 10^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.
79981871|NCT04900636|Device|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
79486714|NCT02042989|Drug|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
79335591|NCT05511545|Other|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
79486715|NCT02042989|Drug|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
79335592|NCT05506865|Drug|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
79812296|NCT00788632|Behavioral|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
79335593|NCT05506865|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
79335594|NCT05506709|Device|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
79335595|NCT05506553|Device|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
79335596|NCT05506553|Device|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
79335597|NCT05506397|Other|Acupressure|Acupressure is a technique based on stimulating certain points on the body with stimulation methods such as hands and fingers.
79812297|NCT00788632|Behavioral|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
79486716|NCT02214134|Genetic|Tumour markers testing|
79486717|NCT04248686|Behavioral|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
79486718|NCT04093531|Drug|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
79486719|NCT05272670|Behavioral|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
79812298|NCT00788632|Behavioral|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
79812299|NCT00793468|Drug|GSK598809|GSK598809 once daily for 12 weeks
79812300|NCT00793468|Drug|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
79335598|NCT04140773|Dietary Supplement|D-serine|Capsule D-serine
79335599|NCT04140773|Other|Placebo|Capsule D-serine
79812301|NCT00793468|Drug|Placebo|Placebo once daily for 12 weeks
79335600|NCT05506319|Other|Norepinephrine|"The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours."
79335601|NCT05506319|Other|Vasopressin|"The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours."
79812302|NCT00836810|Drug|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
79486720|NCT04186520|Biological|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
79486721|NCT04186520|Biological|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
79486722|NCT04186520|Biological|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
79652078|NCT05996185|Drug|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
79652079|NCT05996185|Drug|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
79652080|NCT05979584|Device|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
79652081|NCT05979584|Device|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
79335602|NCT05506007|Drug|DA-5216|"During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
79486723|NCT04172948|Device|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
79486724|NCT04172948|Behavioral|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
79652082|NCT05975047|Drug|LIV001|Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
79652083|NCT05975047|Drug|Placebo|Participants will receive matching placebo across Part A and B of the study
79486725|NCT04059757|Biological|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
79486726|NCT04164680|Diagnostic Test|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
79486727|NCT05224076|Other|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
79486728|NCT05208944|Drug|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
79652084|NCT05966766|Other|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
79652085|NCT05966766|Other|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
79812303|NCT00836810|Drug|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
79812304|NCT00788788|Drug|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
79812305|NCT00658684|Drug|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
79486729|NCT05208944|Drug|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
79486730|NCT01809379|Drug|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
79335603|NCT05506007|Drug|DA-5216-R|"During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
79486731|NCT01802840|Dietary Supplement|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
79486732|NCT01723969|Genetic|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
79486733|NCT02229396|Drug|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
79335604|NCT05506007|Drug|DA-5216|"During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
79335605|NCT05506007|Drug|DA-5216|"During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
79486734|NCT02229396|Drug|Exentide|2 mg
79486735|NCT02229396|Drug|Dapagliflozin|10 mg once daily Dapagliflozin
79486736|NCT05202158|Procedure|Addition of gentamicin to irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.
79486737|NCT05202158|Procedure|Only irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
79486738|NCT00370370|Drug|bevacizumab|Injection of intravitreal bevacizumab
79486739|NCT00370370|Drug|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
79486740|NCT01457833|Device|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
79486741|NCT01457833|Device|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
79486742|NCT00370435|Drug|GW274150|
79652086|NCT05955482|Other|NuvoAir Clinical Service|The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
79486743|NCT01107613|Behavioral|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
79486744|NCT01269164|Procedure|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
79486745|NCT00370513|Drug|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
79486746|NCT05179382|Other|Control protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position.
79486747|NCT05179382|Other|Hydration protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position. V. Water ingestion distributed in 10 equal portions, administered at regular intervals of 15 minutes from the 15th minute of exercise until the end of the recovery period.
79486748|NCT02197416|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
79486749|NCT00370591|Drug|Salmeterol/fluticasone propionate and fluticasone propionate|
79486750|NCT05166044|Biological|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
79981872|NCT04889209|Biological|Ad26.COV2.S|Formulated to contain 5x10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.
79981873|NCT04889209|Biological|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
79981874|NCT04889209|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
79981875|NCT04889209|Biological|mRNA-1273.211|Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).
79981876|NCT04889209|Biological|mRNA-1273.222|Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.
79335606|NCT05515757|Behavioral|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
79486751|NCT00598988|Procedure|traditional Chinese acupuncture|10 treatments over 6 weeks
79335607|NCT04591067|Other|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~Gait function~Muscle activity during walking~Endurance during walking~Hip muscle strength~Hip range of motion~Hip and muscle-tendon-related groin pain~Hip and groin related patient-reported outcome measures (PROMs)"
79486752|NCT00598988|Other|standard medical care|standard care as provided by primary physician
79486753|NCT03956173|Other|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
79486754|NCT03080311|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
79335608|NCT05515133|Other|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
79486755|NCT00371527|Drug|ipratropium|
79486756|NCT00392756|Drug|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
79335609|NCT05505851|Other|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
79652087|NCT05955352|Procedure|Perineal warm compression Technique|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
79486757|NCT05143658|Procedure|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
79486758|NCT04027322|Drug|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
79812306|NCT04046146|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
79486759|NCT04027322|Drug|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
79486760|NCT04027322|Drug|Normal saline|Placebo for the control group.
79486761|NCT00371215|Biological|rThrombin|1000 U/mL applied topically
79486762|NCT03845257|Diagnostic Test|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as >300/µl (or >150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
79486763|NCT05454475|Other|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
79335610|NCT05505851|Other|Sequential Core Stability Corrective Exercise Approach|"Corrective Exercises~Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~Core Stability exercises~Beginning~Progressing~Advanced"
79652088|NCT05953870|Other|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
79652089|NCT05950841|Drug|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
79335611|NCT04969445|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
79335612|NCT05505695|Other|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
79652090|NCT05950841|Drug|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
79812307|NCT04046146|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
79812308|NCT00800098|Drug|herbal topical cream|
79812309|NCT00788866|Dietary Supplement|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
79812310|NCT00788866|Dietary Supplement|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
79812311|NCT00800332|Drug|CYT003-QbG10|subcutaneous injection
79335613|NCT05505695|Other|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
79486764|NCT00371072|Procedure|trabeculectomy with mitomycin-C|
79652091|NCT05950841|Drug|Carob flour|Twice daily dose of 1 capsule (carob flour)
79652092|NCT05949294|Drug|ARO-SOD1 Injection|single doses of ARO-SOD1 Injection by IT infusion
79812312|NCT00800332|Drug|Placebo|subcutaneous injection
79335614|NCT04945187|Other|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
79335615|NCT05505539|Drug|5-fluorouracil|Given intralesionally by injection
79335616|NCT04588103|Other|Heat therapy|Lower limb warm water immersion (42 degrees C)
79335617|NCT04588103|Other|Exercise training|Moderate-intensity cycling exercise (~40-59% VO2 reserve)
79335618|NCT04943315|Procedure|Monolithic zirconia|posterior crowns
79335619|NCT04943315|Procedure|Metal-ceramic|posterior crowns
79335620|NCT05514977|Procedure|Erector spine plane block|Thoracic ESPB
79335621|NCT04140539|Biological|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
79335622|NCT05505461|Drug|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
79335623|NCT05505383|Other|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
79335624|NCT05514743|Procedure|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day &in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
79652093|NCT05938283|Device|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
79335625|NCT05511311|Procedure|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
79335626|NCT05511311|Procedure|Standard Therapy|Standard therapy for 12 weeks
79812313|NCT00660400|Drug|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
79335627|NCT05514665|Device|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
79335628|NCT05514275|Drug|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
79335629|NCT04877249|Behavioral|Split-belt treadmill training|1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
79335630|NCT05510999|Other|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
79335631|NCT05510999|Dietary Supplement|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
79335632|NCT05510999|Dietary Supplement|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
79335633|NCT05510999|Dietary Supplement|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
79335634|NCT05510999|Dietary Supplement|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
79652094|NCT05931861|Device|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
79652095|NCT05930067|Device|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
79652096|NCT05930067|Device|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
79335635|NCT05505149|Other|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
79652097|NCT05926765|Genetic|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
79981877|NCT04889209|Biological|SARS-CoV-2 rS/M1|SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume [w/v]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)
79486765|NCT03056365|Procedure|Advanced Nurse (AN)|Protocoled AN-based management of detox
79335636|NCT05505071|Device|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
79486766|NCT03056365|Procedure|General Practitioner (GP)|'As usual' medical management of detox
79486767|NCT00370448|Behavioral|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
79486768|NCT00371228|Procedure|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
79486769|NCT05454644|Other|Person-Centred Prescription Model|"Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~Correct and practical directions: Medication Regimen Complexity Index (MRCI).~Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~Drug-disease interactions: Beers Criteria.~Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan"
79486770|NCT05118698|Drug|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
79486771|NCT05118698|Other|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
79486772|NCT00370526|Procedure|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
79981878|NCT04889092|Other|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
79652098|NCT05926765|Genetic|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
79486773|NCT05454397|Other|Observational study, no intervention|Observational study, no intervention
79486774|NCT05454332|Drug|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
79652099|NCT05926765|Other|Placebo|Administration of diluent via Stensen's duct to each parotid gland
79652100|NCT05922943|Behavioral|Harmony & Health program|Harmony & Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
79981879|NCT04889092|Other|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
79335637|NCT05504993|Other|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
79335638|NCT05514041|Drug|Varenicline solution|OC-01 nasal spray 0.03 mg
79981880|NCT04884568|Device|Exufiber|Wound dressed with Exufiber for up to 21 days.
79981881|NCT04875286|Other|Electronic Health Record Review|Medical records reviewed
79981882|NCT04875286|Other|Questionnaire Administration|Complete questionnaires
79981883|NCT04864743|Drug|ADVATE|a single dose.
79981884|NCT04864743|Drug|FRSW117|a single dose.
79335639|NCT05514041|Drug|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Placebo nasal spray (OC-01 Vehicle Nasal Spray)
79335640|NCT04691531|Device|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
79335641|NCT04691531|Device|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
79652105|NCT05913648|Other|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
79981885|NCT04828096|Other|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
79335642|NCT05513963|Behavioral|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
79335643|NCT05510765|Behavioral|Transportation service|Improved transportation assets applied to all aspects of subjects life
79981886|NCT04771806|Procedure|Magnetic Resonance Imaging|Undergo MRI
79335644|NCT05504759|Other|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
79335645|NCT05504759|Other|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
79335646|NCT05504759|Other|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
79335647|NCT02570711|Drug|ACP-196|ACP-196 capsule
79335648|NCT02570711|Drug|Nab-paclitaxel|Nab-paclitaxel infusion
79335649|NCT02570711|Drug|Gemcitabine|Gemcitabine infusion
79335650|NCT05513729|Drug|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
79652106|NCT05911958|Drug|SHR-A1811 for injection|SHR-A1811 for injection
79652107|NCT05907135|Dietary Supplement|Beet|Beet-based powder with other ingredients
79335651|NCT05513729|Drug|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
79652108|NCT05907135|Dietary Supplement|Placebo|Placebo powder.
79652109|NCT05906784|Other|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
79652110|NCT05906784|Other|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
79652111|NCT05895045|Behavioral|Yoga|Restorative Vinyasa Yoga
79981887|NCT04771806|Other|Neurocognitive Assessment|Undergo neurocognitive testing
79981888|NCT04771806|Other|Quality-of-Life Assessment|Ancillary studies
79981889|NCT04771806|Other|Questionnaire Administration|Ancillary studies
79981890|NCT04767061|Drug|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On [A] vs Off [B]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
79981891|NCT04753294|Device|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
79981892|NCT04753294|Device|Avance Solo Adapt NPWT System|Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
79335652|NCT05504603|Drug|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
79335653|NCT05504603|Drug|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
79335654|NCT05504603|Drug|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
79335655|NCT05504603|Drug|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
79486775|NCT05454332|Other|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
79486776|NCT03977714|Device|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
79652112|NCT05887609|Drug|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 [FOLR1] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
79981893|NCT04750967|Drug|Lidocaine 1% Injectable Solution|Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
79981894|NCT04750967|Drug|Amitriptyline|Amitriptyline 25 mg daily
79335656|NCT05510609|Device|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
79335657|NCT04863131|Biological|EXG-5003|COVID-19 self-replicating mRNA vaccine
79335658|NCT04863131|Biological|Placebo|placebo solution
79335659|NCT05504369|Other|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
79335660|NCT05504369|Other|Placebo tape|Tape without nano particles applied to the skin
79335661|NCT05513495|Other|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
79335662|NCT05513417|Device|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
79335663|NCT05504213|Drug|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
79335664|NCT05504213|Drug|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
79335665|NCT04424771|Behavioral|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
79335666|NCT02570165|Drug|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
79335667|NCT02570165|Drug|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
79335668|NCT02570165|Drug|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
79335669|NCT04661813|Other|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
79335670|NCT05513339|Device|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
79486777|NCT03977714|Device|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
79335671|NCT05510453|Other|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
79652113|NCT05887609|Drug|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
79652114|NCT05886894|Device|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
79652115|NCT05886894|Device|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
79652116|NCT05886881|Device|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
79981895|NCT04742075|Drug|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
79981896|NCT04729517|Drug|AI201901|Twice daily inhaled AI201901 for 4 weeks
79981897|NCT04729517|Drug|Azelastine Hydrochloride|Twice daily inhaled Azelastine Hydrochloride for 4 weeks
79981898|NCT04720963|Drug|Remimazolam|intranasal remimazolam
79981899|NCT04720963|Other|Distilled water for injection|intranasal distilled water for injection
79981900|NCT04720963|Drug|Dexmedetomidine|Intranasal dexmedetomidine
79981901|NCT04703556|Device|Devices for deep brain stimulation|Effect of DBS parameters (amplitude, frequency) on gait and balance deficits, and their dynamical evolution over a pre-defined time
79335672|NCT05513105|Diagnostic Test|Iron study of neonates|Blood sambles
79335673|NCT05510375|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
79335674|NCT05510375|Dietary Supplement|Multivitamin|Multivitamin
79335675|NCT05510375|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
79335676|NCT05510375|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
79981902|NCT04696315|Diagnostic Test|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
79981903|NCT04688034|Drug|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
79486778|NCT03977714|Device|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
79652117|NCT05886881|Device|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
79981904|NCT04681638|Drug|Pathogen-Reduced Plasma|The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL*kg*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
79981905|NCT04681638|Drug|Crystalloid Solutions|The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL*kg*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
79981906|NCT04669275|Behavioral|Telephone Counselıng|Telephone counseling
79981907|NCT04666701|Drug|Escócia association|Escócia association tablet
79981908|NCT04666701|Other|Placebo Ketorolac|Placebo Ketorolac tablet
79981909|NCT04666701|Other|Placebo Scopolamine|Placebo Scopolamine dragee
79981910|NCT04666701|Drug|Ketorolac Tromethamine|Ketorolac tablet
79981911|NCT04666701|Drug|Scopolamine|Scopolamine dragee
79981912|NCT04666701|Other|Placebo Escócia association|Placebo Escócia association tablet
79335677|NCT05512715|Procedure|radioactive iodine|radioactive iodine 15mci
79335678|NCT05510219|Drug|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
79652118|NCT05886881|Device|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
79652119|NCT05886881|Device|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
79652120|NCT05886881|Device|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
79486779|NCT03977714|Device|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
79335679|NCT05503745|Other|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
79486780|NCT03977714|Device|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
79486781|NCT03924518|Drug|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
79486782|NCT03924518|Drug|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
79486783|NCT05454163|Other|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
79652121|NCT05869799|Dietary Supplement|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
79981913|NCT04649866|Diagnostic Test|plethysmography|"Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~SNP 0.8, 1.6 and 3.2 mcg/min~ACh 7.5, 15 and 30 mcg/min~Normal saline"
79652122|NCT05869799|Dietary Supplement|Placebo Capsules|Maltodextrin was used as a placebo
79981914|NCT04643405|Drug|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
79981915|NCT04643405|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
79981916|NCT04643405|Drug|Nab paclitaxel|Nab-Paclitaxel 125mg/m^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
79981917|NCT04638660|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
79981918|NCT04638660|Drug|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
79335680|NCT05503745|Other|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
79335681|NCT02564471|Drug|Chloroquine|FDA approve dosing schedule
79981919|NCT04629963|Other|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
79335682|NCT02564471|Drug|Atovaquone and Proguanil|FDA approve dosing schedule
79486784|NCT05037344|Behavioral|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
79335683|NCT02564471|Drug|Doxycycline|FDA approve dosing schedule
79652123|NCT05860543|Diagnostic Test|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
79981920|NCT04629963|Other|Surveys, a fingerstick blood sample, EMAs, and a digital wearable device|The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
79981921|NCT04614220|Behavioral|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
79335684|NCT02564471|Biological|Rabies Vaccine|FDA approve dosing schedule
79335685|NCT05503667|Drug|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
79335686|NCT05503667|Drug|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
79335687|NCT04411979|Other|treatment-as-usual plus aerobic walking|aerobic walking
79652124|NCT05856266|Procedure|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
79652125|NCT05856266|Other|Haemophilia Joint Health Score (HJHS)|Functional joint examination
79981922|NCT04604236|Behavioral|Mapping Enhanced Counseling|Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.
79335688|NCT05512637|Diagnostic Test|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
79812314|NCT00660400|Procedure|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
79335689|NCT02563067|Drug|QAW039|QAW039 150 mg once daily
79812315|NCT00800410|Behavioral|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
79335690|NCT02563067|Drug|QAW039|QAW039 450 mg once daily
79335691|NCT02563067|Drug|Placebo|Placebo once daily
79335692|NCT02568683|Drug|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
79812316|NCT00788944|Procedure|blood draw|Test Article was not provided to subjects for this study.
79335693|NCT02568683|Drug|Vincristine|VCR administered intravenously
79335694|NCT05502731|Drug|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
79335695|NCT05502731|Drug|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
79812317|NCT00793702|Biological|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
79335696|NCT05502497|Other|Observational|No application will be made to the control group.
79335697|NCT05502497|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
79335698|NCT05503277|Device|LTSD|measuring seal pressure
79335699|NCT05503277|Device|i-gel|measuring seal pressure
79486785|NCT05454085|Dietary Supplement|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
79486786|NCT05453786|Drug|SID1903|Single oral administration of SID1903 after an overnight fast
79981923|NCT04604236|Behavioral|Active Linkage|Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
79981924|NCT04601051|Biological|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
79335700|NCT05502419|Procedure|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
79335701|NCT05502419|Procedure|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
79652126|NCT05848557|Behavioral|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
79335702|NCT05503121|Diagnostic Test|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
79335703|NCT05503043|Drug|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
79335704|NCT05503043|Drug|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
79335705|NCT04579211|Diagnostic Test|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
79812318|NCT00826514|Drug|Tanezumab|Intravenous, 20 mg, single dose.
79812319|NCT00826514|Drug|Placebo|Intravenous placebo, single dose
79335706|NCT02563925|Radiation|Brain radiotherapy or Stereotactic Radiosurgery|
79335707|NCT02563925|Drug|Tremelimumab|
79812320|NCT00800566|Drug|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
79981925|NCT04598438|Behavioral|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
79981926|NCT04598438|Behavioral|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
79981927|NCT04593329|Drug|TIRADENTES ASSOCIATION|Tiradentes association tablet
79981928|NCT04593329|Drug|DIPYRONE|Dipyrone 500 mg
79981929|NCT04593329|Drug|TRAMADOL|Tramadol 50 mg
79335708|NCT02563925|Drug|HER2 directed therapy|
79335709|NCT02563925|Drug|Durvalumab|
79335710|NCT01663727|Drug|Bevacizumab [Avastin]|Intravenous repeating dose
79335711|NCT01663727|Drug|Paclitaxel|Intravenous repeating dose
79335712|NCT01663727|Drug|Placebo|Intravenous repeating dose
79486787|NCT05453786|Drug|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
79486788|NCT03893396|Device|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
79486789|NCT00369902|Procedure|acupuncture|
79486790|NCT03886922|Drug|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
79812321|NCT00793858|Drug|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
79335713|NCT02614261|Drug|Galcanezumab|Administered SC
79335714|NCT02614261|Drug|Placebo|Administered SC
79335715|NCT04859023|Diagnostic Test|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
79335716|NCT04859023|Diagnostic Test|saliva sample (Self-sample)|Tested by RT-PCR.
79335717|NCT04859023|Other|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
79335718|NCT04859023|Other|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
79335719|NCT03043261|Behavioral|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
79335720|NCT03043417|Behavioral|CHC's given the intervention|CHC's NOT given the intervention
79335721|NCT03042325|Drug|Alogliptin|Alogliptin tablets
79335722|NCT03045445|Diagnostic Test|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
79335723|NCT03045445|Diagnostic Test|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
79335724|NCT01594411|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
79335725|NCT01594333|Drug|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
79335726|NCT01594333|Drug|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
79335727|NCT04860895|Diagnostic Test|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
79335728|NCT04860583|Other|Renal ultrasound|
79335729|NCT03042247|Diagnostic Test|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
79335730|NCT03042403|Other|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
79335731|NCT04858633|Drug|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
79335732|NCT04858633|Other|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
79335733|NCT04858633|Other|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
79335734|NCT04867291|Dietary Supplement|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with ~450mL of water.
79335735|NCT04867291|Dietary Supplement|Seaweed Sheets|Portion equivalent to 200 µg of iodine (~10g), consumed with two slices of white bread and ~450mL of water.
79335736|NCT04867291|Dietary Supplement|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and ~450mL of water.
79335737|NCT04867291|Dietary Supplement|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and ~450mL of water.
79652127|NCT05842434|Device|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
79335738|NCT03043495|Procedure|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
79335739|NCT03043495|Drug|Dexamethasone|Various doses of Dexamethasone (2, 4 & 8 mg) to be used as an Adjuvant to Local anesthetic drugs
79652128|NCT05837845|Drug|MDMA|Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
79981930|NCT04593329|Other|TIRADENTES ASSOCIATION PLACEBO|Tiradentes association placebo tablet
79335740|NCT03043183|Procedure|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
79335741|NCT03042949|Device|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
79335742|NCT03042949|Device|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
79335743|NCT03043027|Drug|liposomal bupivicaine|local anesthetic
79335744|NCT03043027|Drug|Bupivacaine|local anesthetic
79335745|NCT03043027|Drug|Saline Solution|saline injection
79335746|NCT04861207|Drug|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
79335747|NCT04858165|Procedure|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
79335748|NCT04858321|Procedure|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
79335749|NCT04858087|Other|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
79335750|NCT03041935|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
79652129|NCT05837845|Behavioral|Cognitive Processing Therapy|Participants will receive 12-16 sessions of Cognitive Processing Therapy
79652130|NCT05837845|Behavioral|MDMA-assisted Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
79981931|NCT04593329|Other|DIPYRONE PLACEBO|Dipyrone placebo tablet
79335751|NCT03041935|Procedure|Caudal-epidural nerve block|See arm description
79981932|NCT04593329|Other|TRAMADOL PLACEBO|Tramadol placebo capsule
79652131|NCT05835544|Other|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
79981933|NCT04579588|Biological|Flu shot|All participants will receive a single shot of the flu vaccine
79981934|NCT04563546|Other|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
79652132|NCT05835544|Other|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
79652133|NCT05835544|Other|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
79981935|NCT04520373|Other|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
79981936|NCT04520373|Biological|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
79981937|NCT04515251|Diagnostic Test|Ultrasound measurements|ultrasound measurement at the level of the left renal vein on a sagittal plane according to age
79981938|NCT04502290|Device|Combined Non-invasive brain stimulation and functional electrical hand stimulation|Participants will receive synchronously combined non-invasive brain stimulation (delivered via electrical/magnetic stimulation) with functional electrical stimulation (delivered via DS7A or Neuromove) of the weak hand
79981939|NCT04499521|Device|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
79981940|NCT04498988|Other|Observational study without interventions|
79981941|NCT04492384|Other|non-interventional|Interview on health conditions
79335752|NCT03041935|Drug|Acetaminophen|See arm description
79335753|NCT03041935|Drug|Sevoflurane|See arm description
79335754|NCT03041935|Drug|Remifentanil|See arm description
79335755|NCT03041935|Drug|Propofol|See arm description
79981942|NCT04453657|Device|FamilyChildCare (provisional name of app)|Parents will provide their child(ren) access to a smartphone, tablet, or computer for approximately 30 minutes, three times per week for 15 weeks with a total dosage of instruction of about 22.5 hours. Parents and providers will receive self-care, parenting, and parent engagement tips and resources through push notifications twice a day. Additionally, daily reminders will be sent to parents through push notification to give their child(ren) access to the learning games. After 15 weeks of app engagement, the providers and parents will be contacted by the PI to notify them of the 15 week time mark and provide the information for post-surveys via Qualtrics.
79981943|NCT04448392|Drug|Valacyclovir|Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days
79335756|NCT03041935|Drug|Morphine|See arm description
79335757|NCT03041935|Drug|Ondansetron|See arm description
79335758|NCT03041935|Drug|Dexamethasone|See arm description
79335759|NCT03041935|Drug|Ketorolac|See arm description
79335760|NCT03041935|Drug|Ropivacaine|See arm description
79335761|NCT03042013|Drug|ASP8273|Oral
79335762|NCT04857853|Other|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
79335763|NCT04857853|Other|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
79335764|NCT04857853|Other|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
79981944|NCT04423796|Device|Robotic-assisted early mobilization|The early mobilization is done by robotic assistance devices.
79335765|NCT03042793|Biological|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
79335766|NCT03042871|Drug|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
79335767|NCT03042637|Drug|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
79335768|NCT03045133|Drug|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
79335769|NCT03045133|Drug|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
79335770|NCT04866745|Device|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
79486791|NCT03886922|Drug|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
79486792|NCT00370058|Procedure|ECT treatment|
79812322|NCT00800644|Procedure|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
79812323|NCT00800722|Drug|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
79981945|NCT04423796|Other|Early mobilization|Early mobilization by health care professionals without robotic assistance.
79486793|NCT03864224|Behavioral|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
79812324|NCT04046458|Behavioral|Nighttime Vital Sign EHR Alert|A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
79812325|NCT04046458|Other|No EHR alert|No change to EHR function; no alert visible to providers
79981946|NCT04388904|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
79486794|NCT04738370|Other|Sample collection|Bloods +/- urine +/- vaginal swabs taken
79486795|NCT05453552|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
79486796|NCT05453552|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
79486797|NCT05453552|Drug|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
79486798|NCT05453552|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
79486799|NCT05453552|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
79981947|NCT04373941|Drug|Filgrastim|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
79335771|NCT04866745|Device|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
79486800|NCT05453552|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
79486801|NCT05453318|Procedure|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
79486802|NCT05018624|Behavioral|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
79981948|NCT04367480|Device|Placebo Administration|Wear placebo TENS device
79981949|NCT04367480|Other|Questionnaire Administration|Ancillary studies
79981950|NCT04367480|Device|Transcutaneous Electrical Nerve Stimulation|Wear active TENS device
79812326|NCT04046068|Procedure|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
79486803|NCT05018624|Behavioral|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
79486804|NCT05018624|Behavioral|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
79812327|NCT00826280|Drug|regadenoson|IV
79812328|NCT00826280|Drug|overencapsulated caffeine|oral
79812329|NCT00826280|Radiation|technetium|IV
79812330|NCT00826280|Drug|placebo|oral
79981951|NCT04348604|Behavioral|Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)|"Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers & Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience."
79652134|NCT05835544|Other|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
79652135|NCT05833828|Procedure|on-pump surgery|"the surgery will be performed on-pump"
79981952|NCT04348604|Behavioral|Enhanced Treatment as Usual (ETAU)|Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
79335772|NCT04866745|Device|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
79981953|NCT04309942|Other|Guided Clinical Pharmacy Consultation|These patients will have the benefit of a Guided Clinical Pharmacy Consultation
79981954|NCT04281706|Drug|Etomidate vs Propofol as induction agent|Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
79981955|NCT04279834|Behavioral|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
79981956|NCT04279834|Behavioral|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
79981957|NCT04263415|Drug|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
79652136|NCT05833828|Procedure|off-pump surgery|"the surgery will be performed off-pump"
79981958|NCT04263415|Other|Placebo|once-weekly injection with placebo pen for 16 weeks
79981959|NCT04249219|Other|Viewing e-cigarette ads|All participants will see the same e-cigarette ads presented in a random order.
79652137|NCT05830318|Other|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
79652138|NCT05820893|Drug|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
79652139|NCT05814835|Drug|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
79981960|NCT04246437|Drug|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of [18F]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
79981961|NCT04246437|Drug|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral [18F]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
79981962|NCT04246437|Drug|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral [18F]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
79335773|NCT04860115|Procedure|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
79486805|NCT05018624|Behavioral|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
79486806|NCT05018624|Behavioral|General health through IM Apps|After baseline, they will receive regular e-message through IM Apps with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
79335774|NCT02609659|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
79335775|NCT02609659|Drug|ribavirin|Tablet
79652140|NCT05814835|Drug|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
79652141|NCT05814835|Drug|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
79812331|NCT00794014|Procedure|Conservative strategy|"Main vessel stenting was performed.~Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow <3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.~Side branch stenting was performed if TIMI flow <3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup."
79812332|NCT00794014|Procedure|Aggressive strategy|"Main vessel was performed.~Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.~Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup."
79981963|NCT04223193|Drug|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
79335776|NCT04856995|Other|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
79335777|NCT04859881|Other|No intervention|No intervention
79335778|NCT04429711|Drug|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
79335779|NCT04429633|Drug|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
79335780|NCT04856839|Diagnostic Test|high throughput sequencing and electromyography|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
79486807|NCT05018624|Behavioral|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
79335781|NCT03042091|Drug|Polyethylene Glycol|Given orally
79335782|NCT03042091|Drug|Neomycin|Given orally
79335783|NCT03042091|Drug|Metronidazole Hydrochloride|Given orally
79812333|NCT00800800|Drug|Rosuvastatin|40 mg, oral, single dose
79335784|NCT03042091|Procedure|Therapeutic Conventional Surgery|Undergo colorectal resection
79812334|NCT00800800|Drug|Placebo|oral, single dose
79812335|NCT00864851|Biological|Replagal|Intravenous (IV) infusion for 12 months
79335785|NCT04859569|Drug|LY01011|subcutaneously (SC) once every 4 weeks (Q4W)
79812336|NCT00703898|Drug|nevirapine|200 mg/day twice a day
79812337|NCT00794092|Drug|Sinerem administration|Single dose
79812338|NCT04030754|Combination Product|amniotic membrane|amniotic membrane is a biological dressing
79981964|NCT04223193|Drug|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
79335786|NCT04859569|Drug|Xgeva®|subcutaneously (SC) once every 4 weeks (Q4W)
79335787|NCT04859959|Diagnostic Test|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
79812339|NCT04030754|Combination Product|duoderm dressing|duoderm dressing is a synthetic dressing
79486808|NCT03851120|Dietary Supplement|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
79335788|NCT04856605|Procedure|surgery|regular surgery
79981965|NCT04222660|Dietary Supplement|Blackmores Omega Daily (4 1g capsules per day)|Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.
79981966|NCT04206371|Diagnostic Test|Defibrillator threshold testing|Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
79981967|NCT04184700|Dietary Supplement|EHCF+LGG|Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
79335789|NCT04856371|Drug|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
79335790|NCT04856371|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
79335791|NCT04856371|Drug|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
79335792|NCT04856371|Drug|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
79335793|NCT04866277|Other|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
79335794|NCT03041779|Drug|Diclofenac Sodium 50Mg Suppository|
79335795|NCT03041779|Drug|Paracetamol 500Mg Suppository|
79335796|NCT02612779|Drug|Elotuzumab|
79335797|NCT02612779|Drug|Pomalidomide|
79335798|NCT02612779|Drug|Dexamethasone|
79486809|NCT03851120|Dietary Supplement|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
79486810|NCT03851120|Behavioral|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
79486811|NCT05011838|Other|1. Health Services Redesign|"1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs."
79812340|NCT00800956|Drug|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi [14C]-esreboxetine
79812341|NCT00857207|Behavioral|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
79812342|NCT00801034|Drug|Calcium|tablets, 1 tablet 2 times per day in 28 days
79981968|NCT04184700|Dietary Supplement|RHF|Rice hydrolysed formula
79981969|NCT04184700|Dietary Supplement|SF|Soy formula
79981970|NCT04184700|Dietary Supplement|EHWF|extensively hydrolysed whey formula
79335799|NCT02612779|Drug|Nivolumab|
79335800|NCT02612623|Drug|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
79335801|NCT02612623|Drug|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
79335802|NCT03041857|Radiation|Observational use of fluoroscopy|
79335803|NCT04809961|Other|I-care app|A smart phone app to enable healthcare worker peer support for improved workplace wellbeing.
79335804|NCT04808011|Device|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
79812343|NCT00801034|Drug|Potassium|Tablets, 5 tablets 2 times per day for 28 days
79981971|NCT04184700|Dietary Supplement|AAF|amino acid based formula
79335805|NCT04866355|Other|Lumbar spine manipulation|Lumbar spine manipulation
79335806|NCT04866355|Drug|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
79335807|NCT04866121|Procedure|Acupuncture|A standardized acupuncture protocol will be administered
79335808|NCT04849819|Drug|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
79335809|NCT02607865|Drug|semaglutide|Oral administration once-daily
79335810|NCT02607865|Drug|sitagliptin|Oral administration once-daily
79981972|NCT04178941|Behavioral|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
79981973|NCT04178941|Behavioral|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
79486812|NCT05011838|Other|2. Clinical Staff Training|"2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care."
79812344|NCT04130477|Device|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
79812345|NCT04130477|Device|Clear Aligner therapy|Clear Aligner therapy
79335811|NCT02607865|Drug|placebo|Oral administration once-daily
79335812|NCT04856137|Drug|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
79335813|NCT03041545|Device|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
79486813|NCT05011838|Other|3. Patient and Community Engagement|"3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged."
79812346|NCT00794326|Drug|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
79812347|NCT00836498|Biological|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
79812348|NCT00836498|Biological|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
79812349|NCT00836498|Biological|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
79812350|NCT04132037|Other|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
79812351|NCT02615015|Other|Blood draw|
79812352|NCT00801190|Other|HES (130/0.4)|33 ml/kg i.v. during surgery
79812353|NCT00801190|Other|Ringer's Lactate|33 ml/kg i.v.
79335814|NCT04849195|Other|No intervention|No intervention
79335815|NCT04849351|Drug|HMPL-689|All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
79335816|NCT03044899|Procedure|All surgeries in adult patients|All surgeries in adult patients
79335817|NCT03045055|Device|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
79812354|NCT00702728|Drug|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
79335818|NCT03045055|Procedure|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
79981974|NCT04167527|Device|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
79486814|NCT04976972|Device|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
79335819|NCT03045055|Device|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
79486815|NCT04976972|Procedure|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
79812355|NCT00702728|Drug|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
79812356|NCT04132115|Drug|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79652142|NCT05814588|Other|Anodal TDCS|"RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads)."
79652143|NCT05814588|Other|Sham Anodal TDCS|rehacom cognitive therapy will be provided to this group participants
79652144|NCT05804526|Drug|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
79981975|NCT04167527|Combination Product|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
79652145|NCT05804526|Drug|JS001|JS001 240mg by intravenous (IV) infusion
79812357|NCT04132115|Drug|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79812358|NCT04132115|Drug|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79486816|NCT04976738|Drug|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
79652146|NCT05796505|Behavioral|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
79981976|NCT04137731|Device|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
79652147|NCT05793827|Behavioral|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
79812359|NCT04132115|Drug|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79812360|NCT04132115|Drug|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79812361|NCT04132115|Drug|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
79812362|NCT04132115|Drug|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
79981977|NCT04114071|Behavioral|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
79981978|NCT04095663|Procedure|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
79981979|NCT04095663|Other|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
79812363|NCT04132115|Drug|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
79812364|NCT04132115|Drug|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79812365|NCT04132115|Drug|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
79812366|NCT04132115|Drug|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
79812367|NCT00801268|Drug|tripterygium wilfordii|TW，60mg/d
79812368|NCT00801268|Drug|Emodin|100mg/d
79335820|NCT04849117|Procedure|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
79486817|NCT04951934|Device|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
79486818|NCT04951934|Procedure|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
79981980|NCT04088760|Drug|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
79981981|NCT04054310|Diagnostic Test|Liver Multi Scan|MRI to create cT1, T2* and PDFF images of patients liver.
79981982|NCT04051294|Dietary Supplement|Commercial kombucha tea|Commercially-available kombucha tea.
79981983|NCT04051294|Dietary Supplement|Brewed kombucha tea|Kombucha tea brewed
79335821|NCT04848493|Biological|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
79486819|NCT04950296|Other|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
79652148|NCT05793827|Behavioral|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
79652149|NCT05774041|Device|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
79812369|NCT02611622|Behavioral|LUMA ENT™|
79335822|NCT04855591|Drug|SHR-1703|SHR-1703 will be administered subcutaneously
79335823|NCT04855591|Drug|Placebo|Placebo of SHR-1703 will be administered subcutaneously
79335824|NCT04848649|Other|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
79335825|NCT04855279|Other|neutral sodium fluoride|Topically applied
79812370|NCT02611622|Other|Survey|Demographic and Patient Satisfaction Survey
79981984|NCT04051294|Other|Control: Tea|Tea brewed in our lab.
79981985|NCT04051294|Other|Control: Water|Tap water
79981986|NCT04049539|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79981987|NCT03989752|Device|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
79981988|NCT03976323|Biological|Pembrolizumab|IV infusion
79335826|NCT04855279|Other|ACP-CCP gel|Topically applied
79335827|NCT04855279|Other|nano-hydroxyapatite solution|Topically applied
79981989|NCT03976323|Drug|Pemetrexed|IV infusion
79981990|NCT03976323|Drug|Carboplatin|IV infusion
79981991|NCT03976323|Drug|Cisplatin|IV infusion
79981992|NCT03976323|Drug|Olaparib|Tablets
79981993|NCT03969511|Procedure|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
79981994|NCT03969511|Procedure|standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
79486820|NCT04950296|Other|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
79652150|NCT05769582|Biological|Anti-BK polyomavirus (AntiBKV)|Participants in the study arm will each receive 4 doses (1,000 mg) administered at 4 weekly intervals administered on Days 1, 29, 57 and 85.
79652151|NCT05761964|Behavioral|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
79812371|NCT02614937|Drug|ranibizumab|0.5 mg IVT ranibizumab
79981995|NCT03960307|Other|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
79335828|NCT04855279|Other|glycerine|Topically applied
79335829|NCT04848259|Drug|Normal saline|Saline will be applied after surgery
79335830|NCT04848259|Drug|Dexamethasone|Dexamethason will be given IV before surgery
79335831|NCT04848259|Drug|Honey|Honey will be applied locally after surgery
79335832|NCT04848259|Drug|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
79486821|NCT04950296|Other|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
79486822|NCT03787082|Drug|Nitrates|1,000 mg/11.18 mmol, oral
79486823|NCT03787082|Drug|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
79486824|NCT03787082|Drug|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
79812372|NCT02614937|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
79981996|NCT03911700|Device|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
79335833|NCT03040609|Behavioral|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
79335834|NCT03040609|Behavioral|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
79335835|NCT03040609|Behavioral|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
79335836|NCT04848571|Combination Product|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly radix polygoni multiflori, Rehmannia glutinosa.
79335837|NCT04840537|Procedure|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
79335838|NCT03038971|Biological|Dose Level 1|Short and Tall Ragweed Mix
79335839|NCT03038971|Biological|Dose Level 2|Short and Tall Ragweed Mix
79335840|NCT03038971|Biological|Placebo|Saline with 0.4% Phenol
79335841|NCT03039127|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
79486825|NCT05451134|Other|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
79486826|NCT05449886|Procedure|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
79486827|NCT04945304|Procedure|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
79486828|NCT04945304|Procedure|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
79812373|NCT00707564|Device|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
79812374|NCT00707564|Device|Gauze with pressure|Gauze with pressure
79812375|NCT00789490|Dietary Supplement|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
79981997|NCT03908879|Procedure|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
79335842|NCT03039049|Drug|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
79335843|NCT03038893|Diagnostic Test|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
79486829|NCT02165202|Drug|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
79486830|NCT02165202|Drug|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
79486831|NCT01628874|Device|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
79486832|NCT01628874|Drug|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
79486833|NCT01628874|Drug|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
79486834|NCT04891718|Biological|MVC-101|Intratumoural microdose injection by the CIVO device.
79486835|NCT04891718|Biological|Nivolumab|Intratumoural microdose injection by the CIVO device.
79486836|NCT04891718|Combination Product|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
79486837|NCT03770689|Drug|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
79486838|NCT03770689|Drug|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
79486839|NCT03770689|Drug|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
79486840|NCT03770689|Drug|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
79486841|NCT03770689|Drug|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m^2) twice daily 5 days per week up to 5.5 weeks.
79486842|NCT03770689|Radiation|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
79486843|NCT00371306|Drug|Insulin versus glucovance (glyburide/metformin)|
79486844|NCT00371384|Procedure|massage|UP to 10 massages over 10 weeks
79652152|NCT05761964|Behavioral|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
79335844|NCT03038893|Diagnostic Test|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
79335845|NCT03040453|Device|Microwave ablation|
79335846|NCT03040453|Device|Irreversible electroporation|
79486845|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
79486846|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
79486847|NCT02196714|Drug|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
79486848|NCT02196714|Drug|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
79486849|NCT03620474|Drug|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
79652153|NCT05758701|Combination Product|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
79652154|NCT05758701|Device|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
79812376|NCT00789490|Dietary Supplement|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
79812377|NCT00697931|Biological|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
79812378|NCT00697931|Biological|Engerix™-B|Intramuscular injection, 3 doses
79335847|NCT04848181|Drug|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
79335848|NCT04848181|Drug|finasteride|two weeks finasteride administration before TURP
79335849|NCT04848181|Drug|no treatment received|no treatment received before TURP
79486850|NCT04337905|Device|ADHD-VR diagnosis tool|"Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments."
79335850|NCT04848415|Other|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
79486851|NCT03566264|Other|Non-Interventional|Non-Interventional
79486852|NCT00370760|Drug|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
79486853|NCT00370760|Drug|placebo|
79335851|NCT04847791|Dietary Supplement|Bovine lactoferrin|Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
79335852|NCT04847791|Dietary Supplement|Placebo administration|capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
79335853|NCT04848103|Behavioral|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation [TENS], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
79335854|NCT04847869|Device|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
79335855|NCT03041389|Behavioral|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
79335856|NCT03041389|Behavioral|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
79335857|NCT04847713|Other|extraction of blood samples|Two blood samples (3.5 ml each) will be collected directly into purple K2-EDTA tubes and stored at 4°C for up to 24 hours for analysis
79486854|NCT05227508|Dietary Supplement|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
79335858|NCT03041155|Behavioral|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
79335859|NCT03041233|Other|Observation / Data Collection|"The following data will be reviewed / collected:~BASELINE VISIT: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~ABLATION PROCEDURE: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6 and 12 MONTH FOLLOW-UP (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
79335860|NCT04375813|Drug|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
79335861|NCT04375813|Drug|Placebos|placebo capsules visually identical to eRapa oral capsules
79335862|NCT03041077|Dietary Supplement|Instaflex Advanced|Joint function
79335863|NCT03041077|Dietary Supplement|Placebo|Placebo
79335864|NCT04847245|Drug|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
79335865|NCT04847245|Drug|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
79486855|NCT05227508|Other|placebo|Comprecel microcrystalline cellulose
79486856|NCT05203562|Procedure|Suction evacuation|both groups underwent complete mole evacuation using suction curettage.
79486857|NCT05203562|Drug|Letrozole tablets|Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
79652155|NCT05747196|Device|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
79652156|NCT05745636|Dietary Supplement|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
79652157|NCT05745636|Dietary Supplement|Placebo|2 capsules per day for 4 weeks.
79652158|NCT05742971|Device|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
79652159|NCT05739292|Biological|EuNmCV-5|0.5mL single intramuscular dose on Day 0
79335866|NCT04847245|Drug|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
79335867|NCT04847245|Drug|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
79652160|NCT05739292|Biological|Menveo|0.5mL single intramuscular dose on Day 0
79335868|NCT04840225|Other|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
79335869|NCT04839913|Diagnostic Test|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
79335870|NCT04839835|Other|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
79652161|NCT05737225|Device|Near Infrared Spectroscopy (NIRS)|We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
79652162|NCT05698524|Drug|PCI 24781|Patients will take the PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.
79652163|NCT05698524|Drug|Temozolomide|Patients will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
79652164|NCT05695560|Other|No Intervention|As this is an observational study, no intervention will be administered.
79652165|NCT05692401|Behavioral|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
79652166|NCT05688657|Device|Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
79486858|NCT04844138|Behavioral|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
79486859|NCT05453383|Drug|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
79335871|NCT04847401|Diagnostic Test|H. pylori stool antigen|using H. pylori antigen kits in stool
79335872|NCT04846699|Procedure|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
79335873|NCT04847089|Device|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
79335874|NCT04846621|Drug|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
79335875|NCT04846621|Drug|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
79652167|NCT05688657|Device|Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
79652168|NCT05679024|Drug|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
79981998|NCT03908879|Procedure|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
79981999|NCT03908879|Procedure|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
79652169|NCT05677282|Drug|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
79652170|NCT05677282|Drug|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
79652171|NCT05677282|Drug|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
79335876|NCT04846777|Device|Mindfulness ecological momentary intervention|Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
79335877|NCT04846777|Device|Self-monitoring placebo|Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
79652172|NCT05675345|Device|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
79652173|NCT05675345|Device|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
79652174|NCT05675345|Device|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
79652175|NCT05675345|Device|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
79652176|NCT05672303|Behavioral|Palmar grasp reflex|The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
79335878|NCT04846543|Other|MRI Scan|MRI scan
79335879|NCT04854655|Other|Conventional resin composite|nanofilled resin composite
79335880|NCT04854655|Other|Activa Presto|calcium and phosphate hybrid material
79335881|NCT04854655|Other|Giomer|fluoride releasing hybrid material
79812379|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)] given one month apart
79812380|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)] given one month apart
79812381|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)] given one month apart
79812382|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg)] given one month apart
79652177|NCT05665335|Device|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
79652178|NCT05657119|Behavioral|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~Receive 4 weeks of tailored text message reminders and encouragement"
79652179|NCT05657119|Behavioral|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~Receive 4 weeks of tailored text message reminders and encouragement"
79652180|NCT05657119|Behavioral|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~Participate in a 10-minute scripted conversation about safe gun storage practice~Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~Receive 4 weeks of tailored text message reminders and encouragement"
79652181|NCT05657119|Behavioral|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
79812383|NCT00789568|Drug|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
79812384|NCT00789568|Drug|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
79652182|NCT05654662|Drug|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million [ppm] Fluoride ion [F])
79652183|NCT05654662|Drug|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
79652184|NCT05650567|Drug|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
79652185|NCT05650567|Drug|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
79652186|NCT05640323|Device|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
79812385|NCT00789568|Drug|Moxifloxacin placebo|Moxifloxacin placebo tablet
79812386|NCT00789646|Procedure|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
79812387|NCT00789646|Procedure|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
79982000|NCT03826628|Drug|rapamycin|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
79982001|NCT03826628|Drug|placebo|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
79812388|NCT02554006|Behavioral|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
79812389|NCT02554006|Behavioral|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
79335882|NCT03038737|Other|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
79335883|NCT03038737|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
79652187|NCT05633459|Drug|QRL-201 - Dose 1|"Drug: Dose 1 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79812390|NCT00801346|Other|laboratory biomarker analysis|
79812391|NCT00801346|Other|metabolic assessment|
79652188|NCT05633459|Drug|QRL-201 - Dose 2|"Drug: Dose 2 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)~Diluent: artificial cerebrospinal fluid (aCSF)"
79335884|NCT04854421|Device|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
79486860|NCT05453305|Procedure|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
79486861|NCT05453305|Procedure|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
79982002|NCT03813238|Drug|TEV-50717|Dosage ranging from 6 mg to 48 mg.
79982003|NCT03813238|Drug|Placebo|Dosage ranging from 6 mg to 48 mg.
79982004|NCT03810482|Device|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
79335885|NCT04846153|Other|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
79335886|NCT04846153|Device|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
79335887|NCT04854577|Procedure|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
79335888|NCT04854577|Procedure|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
79335889|NCT04846465|Other|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
79982005|NCT03810482|Other|6 minute walking test|Performed according to current recommendations during routine visits (baseline and ~90 days for the purposes of this study).
79982006|NCT03782493|Behavioral|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
79335890|NCT04846075|Behavioral|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
79335891|NCT04860427|Device|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
79335892|NCT04860427|Device|two miniplates|two miniplates open reduction and fixation
79335893|NCT04839445|Procedure|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
79335894|NCT04839445|Procedure|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
79335895|NCT04845607|Drug|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
79982007|NCT03772028|Drug|cisplatin|HIPEC with cisplatin after cytoreductive surgery
79335896|NCT04142515|Other|no intervention|no intervention
79982008|NCT03770390|Procedure|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
79982009|NCT03769506|Combination Product|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
79982010|NCT03769506|Drug|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
79982011|NCT03740165|Biological|Pembrolizumab|IV infusion
79982012|NCT03740165|Drug|Placebo for pembrolizumab|IV infusion
79982013|NCT03740165|Drug|Carboplatin|IV infusion
79982014|NCT03740165|Drug|Paclitaxel|IV infusion
79982015|NCT03740165|Drug|Olaparib|Oral tablet
79982016|NCT03740165|Drug|Placebo for olaparib|Oral tablet
79982017|NCT03740165|Biological|Bevacizumab|IV infusion
79982018|NCT03740165|Drug|Docetaxel|IV infusion
79486862|NCT04766762|Procedure|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
79486863|NCT04766762|Procedure|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
79486864|NCT04750304|Behavioral|Application ARTHe|Patient will use ARTHe Application for 3 months
79486865|NCT04330040|Drug|Olaparib|Tablet
79486866|NCT02737891|Drug|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
79486867|NCT02737891|Drug|Placebo|
79486868|NCT04994834|Dietary Supplement|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
79812392|NCT00801346|Other|questionnaire administration|
79812393|NCT00801346|Procedure|assessment of therapy complications|
79486869|NCT02196558|Drug|E6011|
79486870|NCT04941092|Other|no intervention|no intervention, retrospective comparison
79486871|NCT05453149|Behavioral|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
79486872|NCT04902404|Other|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
79486873|NCT04338217|Device|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
79486874|NCT04338217|Device|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
79486875|NCT05452993|Device|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
79486876|NCT02740153|Other|No Intervention Given|
79486877|NCT04809662|Drug|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for ~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
79812394|NCT00801346|Procedure|fatigue assessment and management|
79812395|NCT00801346|Procedure|quality-of-life assessment|
79812396|NCT00801424|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
79335897|NCT04845763|Other|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
79335898|NCT04853797|Drug|Ivabradine|To investigate the role of ivabradine on levcromakalim-induced migraine in patients with migraine without aura.
79335899|NCT04853797|Drug|Calcium|To investigate the role of calcium on levcromakalim-induced migraine in patients with migraine without aura.
79486878|NCT02196324|Drug|serlopitant|NK1 receptor antagonist
79486879|NCT02196324|Drug|Placebo|Placebo
79812397|NCT00856973|Drug|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
79812398|NCT00856973|Drug|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
79812399|NCT00856973|Drug|Placebo|1 tablet per day for 12 weeks
79812400|NCT00794482|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
79812401|NCT00801502|Dietary Supplement|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
79812402|NCT00801502|Other|Control|No change to habitual diet from week 20 of pregnancy until giving birth
79486880|NCT03618979|Biological|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
79307725|NCT02570815|Drug|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
79982019|NCT03737240|Drug|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
79982020|NCT03737240|Drug|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
79982021|NCT03737240|Drug|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
79982022|NCT03733717|Drug|Isatuximab SAR650984|"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"
79982023|NCT03720587|Other|Semi-structured interviews|Semi-struuctured telephone interviews
79982024|NCT03692312|Drug|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
79982025|NCT03692312|Drug|Placebo|Matching placebo formulation
79982026|NCT03639051|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
79982027|NCT03639051|Other|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
79335900|NCT04845529|Device|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
79335901|NCT04845295|Other|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
79335902|NCT04845373|Other|Mediterranean diet|Diet intervention:Mediterranean diet
79335903|NCT04845373|Other|Control diet: Low fat diet|Low fat diet
79486881|NCT03618979|Biological|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
79486882|NCT03618979|Biological|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
79486883|NCT03448016|Radiation|[C-11]|Radiolabel
79335904|NCT03040531|Dietary Supplement|Genistein aglycone|27mg bid in tablets
79335905|NCT03040531|Drug|Alendronate Oral Tablet|70 mg/week in tablets
79335906|NCT03040531|Dietary Supplement|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
79335907|NCT03040375|Behavioral|Peer counselling|
79335908|NCT04839055|Drug|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
79335909|NCT04839055|Drug|Abiraterone|Abiraterone
79335910|NCT04838821|Biological|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
79335911|NCT04838821|Biological|placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
79486884|NCT03448016|Drug|NOP-1A|Tracer
79486885|NCT03390530|Drug|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
79982028|NCT03632044|Drug|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
79486886|NCT03390530|Drug|Placebo|Placebo
79812403|NCT00794638|Drug|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
79812404|NCT00794638|Drug|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
79812405|NCT00801580|Drug|doxorubicin liposomal|"Cyclophosphamide~Mesna~Methotrexate~Doxorubicin liposomal~Vincristine~Dexamethasone~Rituximab~Cytarabine"
79812406|NCT00699569|Dietary Supplement|hyperimmune colostrum|hyperimmune colostrum
79982029|NCT03632044|Other|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
79982030|NCT03617198|Biological|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
79982031|NCT03601728|Behavioral|personalized prehabilitation|The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.
79982032|NCT03582722|Drug|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
79982033|NCT03582722|Drug|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
79307726|NCT02568189|Device|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
79335912|NCT04838665|Drug|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
79335913|NCT04838665|Drug|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
79982034|NCT03582722|Dietary Supplement|Multivitamin|A multivitamin will be provided to be taken once daily, at bedtime.
79982035|NCT03553875|Drug|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
79335914|NCT04838665|Drug|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
79335915|NCT03038659|Device|Penile Duplex|Measuring intima media thickness
79335916|NCT04845061|Drug|Nebivolol Tablets|cardio selective beta-1 blocker
79812407|NCT00699569|Dietary Supplement|Placebo|
79812408|NCT00794716|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
79982036|NCT03553875|Drug|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
79982037|NCT03535324|Behavioral|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
79982038|NCT03535324|Other|Control|There will be no intervention
79982039|NCT03532178|Drug|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
79812409|NCT04132271|Other|Personalized diet|Modified texture and volumen diet according to the OD specifications
79812410|NCT04132271|Other|Control|Nutritional Recommendations according to the OD specifications
79812411|NCT00794872|Other|blood sampling|
79812412|NCT00801658|Device|selective Laser Trabeculoplasty (SLT)|
79307727|NCT02556099|Drug|Hydroxyurea|drug to be administered
79307728|NCT02553460|Drug|ITMHA|Given intrathecally (IT).
79307729|NCT02553460|Drug|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
79652189|NCT05633459|Drug|QRL-201 - Dose 3|"Drug: Dose 3 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79812413|NCT02553382|Dietary Supplement|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
79982040|NCT03532178|Drug|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
79982041|NCT03526549|Biological|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
79812414|NCT02553382|Dietary Supplement|Positive Control|Oat bran blend and wheat bran capsules
79307730|NCT02553460|Drug|Mitoxantrone|Given IV.
79307731|NCT02553460|Drug|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
79812415|NCT00844532|Device|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
79335917|NCT03040765|Drug|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
79335918|NCT03040765|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
79335919|NCT04853953|Other|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
79335920|NCT01668667|Drug|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
79652190|NCT05633459|Drug|QRL-201 - Dose 4|"Drug: Dose 4 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79652191|NCT05633459|Drug|QRL-201 - Dose 5|"Drug: Dose 5 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79812416|NCT00805194|Drug|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
79812417|NCT00805194|Drug|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
79982042|NCT03526549|Other|Observation|No treatment administered during 180 days of observation.
79652192|NCT05633459|Drug|QRL-201 - Dose 6|"Drug: Dose 6 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79982043|NCT03519997|Drug|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
79982044|NCT03519997|Drug|Bavituximab|Bavituximab 3mg/kg IV weekly
79982045|NCT03511976|Behavioral|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
79982046|NCT03511976|Behavioral|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
79812418|NCT00836186|Radiation|Radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
79812419|NCT00657046|Drug|Droxidopa|Capsules containing 200 mg droxidopa
79812420|NCT00657046|Drug|Placebo|Capsules with mannitol substituted for droxidopa
79812421|NCT00707720|Device|TERIS procedure|The implantation of the restrictive implant
79486887|NCT03534739|Other|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
79812422|NCT00707798|Biological|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
79812423|NCT00707798|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
79812424|NCT00704054|Drug|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
79812425|NCT00801736|Drug|Cisplatin, Paclitaxel|"Cisplatin 75mg/m2, Day 1~Paclitaxel 175mg/m2, Day 1"
79982047|NCT03511976|Behavioral|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
79982048|NCT03511976|Drug|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
79335921|NCT01668667|Drug|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
79335922|NCT01668667|Drug|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
79335923|NCT01668667|Drug|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
79652193|NCT05633459|Drug|QRL-201 - Dose 7|"Drug: Dose 7 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79652194|NCT05633459|Drug|QRL-201- Dose 8|"Drug: Dose 8 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
79652195|NCT05626634|Drug|LP352|LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
79652196|NCT05625412|Drug|BMS-986360|Specified dose on specified days
79812426|NCT04950244|Diagnostic Test|High-sensitivity cardiac troponin I (hs-cTnI)|"Capillary and veinous whole blood sampling for hs-cTnI was collected. The sample was tested at the bedside with a point-of-care device (Atellica VTLi, Siemens Healthineers).~The result of both hs-c TnI values obtained was blinded to the treating physician"
79812427|NCT00856661|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
79812428|NCT00856661|Drug|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
79486888|NCT03534739|Other|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
79486889|NCT03534739|Other|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
79486890|NCT05450419|Dietary Supplement|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 & week 4.
79652197|NCT05625412|Drug|Docetaxel|Specified dose on specified days
79812429|NCT02606994|Drug|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
79812430|NCT02606994|Drug|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
79812431|NCT02606994|Drug|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
79486891|NCT05450419|Dietary Supplement|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 & week 4.
79812432|NCT00844376|Drug|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
79812433|NCT00844376|Drug|Lipitor|A single dose of 80 mg Lipitor tablet
79982049|NCT03461900|Other|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
79982050|NCT03461900|Other|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
79486892|NCT03507049|Procedure|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
79652198|NCT05625412|Drug|Nivolumab|Specified dose on specified days
79486893|NCT03507049|Procedure|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
79652199|NCT05625412|Drug|Capecitabine|Specified dose on specified days
79486894|NCT03507049|Radiation|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
79982051|NCT03452111|Drug|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
79652201|NCT05601284|Behavioral|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
79812434|NCT04046302|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
79486895|NCT03345446|Diagnostic Test|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
79486896|NCT02195700|Drug|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
79652202|NCT05601284|Behavioral|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
79812435|NCT04046302|Drug|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
79812436|NCT00914394|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
79812437|NCT00914394|Drug|Phenylephrine|1µg/kg/min, infusion period 20 minutes
79812438|NCT00914394|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
79812439|NCT00914394|Device|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
79812440|NCT00914394|Device|Goldmann applanation tonometer|intraocular pressure measurements
79812441|NCT00914394|Device|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
79982052|NCT03449901|Drug|pegylated arginine deiminase|-Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
79982053|NCT03449901|Drug|Gemcitabine|-Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
79486897|NCT02195700|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
79486898|NCT00370669|Drug|bevacizumab|
79486899|NCT00370669|Drug|triamcinolone acetonide|
79486900|NCT04738214|Other|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
79652203|NCT05599048|Drug|Hyperpolarized 13C-Pyruvate|Given IV
79486901|NCT05349344|Other|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday & Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
79652204|NCT05599048|Procedure|Magnetic Resonance Imaging (MRI)|Imaging procedure
79652205|NCT05598333|Drug|AB-1002|Intracoronary Infusion of AB-1002 or placebo
79486902|NCT05349344|Other|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
79652206|NCT05571410|Behavioral|HTN Chat bot|Remote monitoring via automated messaging program
79652207|NCT05564273|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.
79486903|NCT02740543|Drug|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
79486904|NCT02228460|Drug|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
79652208|NCT05564273|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
79486905|NCT05349266|Biological|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
79652209|NCT05563857|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
79652210|NCT05563857|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
79812442|NCT04045678|Drug|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
79982054|NCT03449901|Drug|Docetaxel|-Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
79652211|NCT05562011|Device|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
79652212|NCT05554640|Device|Acuvue® Oasys MAX 1-Day|TEST Lens
79652213|NCT05554640|Device|Dailies Total 1|CONTROL Lens
79652214|NCT05550727|Other|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
79652215|NCT05548712|Device|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
79652216|NCT05548712|Device|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
79652217|NCT05540665|Drug|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
79652218|NCT05540665|Drug|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
79812443|NCT04045678|Drug|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
79982055|NCT03449901|Procedure|Tumor biopsy|"Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort"
79486906|NCT00370747|Drug|Ecabet|ophthalmic solution 2.83%
79486907|NCT00370747|Drug|Ecabet|ophthalmic solution 3.70%
79486908|NCT00370747|Drug|Placebo|
79486909|NCT02752256|Drug|Tissue Plasminogen Activator|
79486910|NCT05368909|Dietary Supplement|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
79486911|NCT05368909|Dietary Supplement|Placebo|Placebo product
79652219|NCT05540665|Drug|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
79652220|NCT05540327|Drug|M5049 low dose|Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 48 weeks.
79652221|NCT05540327|Drug|M5049 medium dose|Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 48 weeks.
79652222|NCT05540327|Drug|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 48 weeks.
79652223|NCT05540327|Drug|Placebo|Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.
79652224|NCT05540327|Drug|M5049 very high dose|Participants will receive film-coated tablets of M5049 at a very high dose orally, BID for up to 48 weeks.
79982056|NCT03449901|Procedure|Research blood draw|-Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
79486912|NCT03454555|Behavioral|Shared Decision Making|The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality (AHRQ) SHARE Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient (Agency for Healthcare Research and Quality, 2017). Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice.
79812444|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
79486913|NCT03454555|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention (Monticone et al., 2015), including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
79486914|NCT04104542|Behavioral|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
79486915|NCT04104542|Behavioral|Healthy Lifestyle|Diet and Exercise
79652225|NCT05534464|Other|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
79652226|NCT05534464|Other|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
79652227|NCT05534464|Other|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
79652228|NCT05534126|Procedure|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
79812445|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
79812446|NCT00801814|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
79812447|NCT00801814|Dietary Supplement|PolyGlycopleX (PG)|5.0 grams of PGX
79812448|NCT00801814|Dietary Supplement|PolyGlycopleX|7.5 grams of PGX
79812449|NCT00801814|Dietary Supplement|Control|0g of PGX
79812450|NCT00801814|Dietary Supplement|Second Control|0g of PGX
79486916|NCT02227446|Drug|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
79652229|NCT05534126|Procedure|Placebo|Sham
79652230|NCT05518721|Procedure|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
79652231|NCT05517785|Other|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
79812451|NCT00658606|Drug|alefacept|IM
79812452|NCT00658606|Procedure|Narrow Band UVB Phototherapy|UVB Phototherapy
79812453|NCT00795106|Drug|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
79982057|NCT03435380|Behavioral|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
79486917|NCT00371371|Procedure|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
79486918|NCT00371371|Procedure|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
79486919|NCT00371371|Procedure|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
79652232|NCT05510908|Other|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
79652233|NCT05510908|Other|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
79652234|NCT05510674|Diagnostic Test|OWL-EVO1|EVOC probe
79335924|NCT04852939|Other|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
79335925|NCT04852939|Other|Conventional physical therapy|"Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~Pendulum stretch, 10 revolutions.~Cross body stretch, 4 repetitions.~Towel stretch/hand behind the back, 4 repetitions.~Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
79652235|NCT05503992|Other|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
79652236|NCT05497453|Drug|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
79652237|NCT05497453|Drug|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
79335926|NCT03040219|Drug|Folic Acid|Tablets
79652238|NCT05497453|Drug|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
79652239|NCT05497453|Drug|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
79982058|NCT03435380|Behavioral|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
79982059|NCT03435380|Behavioral|Control|Mailed educational materials.
79335927|NCT03038503|Drug|Methylene Blue|after defined refractory shock (need NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
79486920|NCT04738058|Drug|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
79486921|NCT04738058|Drug|placebo|placebo
79812454|NCT00795106|Drug|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
79812455|NCT00809302|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
79812456|NCT00589290|Drug|Belinostat (PDX101)|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
79812457|NCT00801970|Behavioral|Psychological Treatment|15 weekly therapy sessions.
79812458|NCT00801970|Behavioral|Group Therapy|3 months of weekly group therapy sessions.
79812459|NCT00802048|Drug|Local anesthetic (Ropivacaine)|Local anesthetic infusion
79812460|NCT00802048|Drug|Saline|Saline serum infusion
79812461|NCT00802126|Drug|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
79812462|NCT02552680|Other|Exercise|Physical Exercise
79652240|NCT05481190|Behavioral|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
79652241|NCT05481190|Behavioral|Just observation|Standard care was given to the children in the control group.
79335928|NCT03038503|Drug|Terlipressin|after defined refractory shock (need NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
79486922|NCT02227368|Drug|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
79652242|NCT05472168|Other|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
79486923|NCT02227368|Drug|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
79812463|NCT02552680|Other|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
79812464|NCT02552680|Other|Brochure|Manual/brochure containing information about general health
79812465|NCT00809380|Behavioral|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
79812466|NCT00809380|Behavioral|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
79812467|NCT04820374|Procedure|pupil's light and pupil diameter|It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
79982060|NCT03428711|Drug|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
79982061|NCT03428711|Drug|Placebo Oral Tablet|Indistinguible placebo tablet
79982062|NCT03382457|Device|Transcatheter Tricuspid Valve Reconstruction|Reconstruction of the tricuspid valve through a transcatheter approach
79486924|NCT02162862|Behavioral|Behavioral Counseling|
79486925|NCT02162862|Drug|bupropion-SR|
79652243|NCT05465629|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
79652244|NCT05465629|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
79812468|NCT00843518|Drug|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
79982063|NCT03363659|Drug|Disulfiram|Disulfiram is taken orally, twice daily.
79982064|NCT03363659|Dietary Supplement|Copper gluconate|Copper gluconate is taken orally, twice daily
79652245|NCT05465616|Dietary Supplement|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
79486926|NCT02752490|Drug|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
79486927|NCT02752490|Drug|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
79812469|NCT00843518|Drug|Placebo|Placebo orally twice daily for 12 weeks
79812470|NCT02552524|Device|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
79982065|NCT03363659|Drug|Temozolomide|Temozolomide is taken once daily
79982066|NCT03328078|Drug|Emavusertib|Emavusertib (formulated for oral administration for BID dosing)
79982067|NCT03328078|Drug|ibrutinib|560 mg QD of oral ibrutinib
79982068|NCT03308877|Behavioral|BMI|Four 45-minute, brief motivational sessions for substance use
79982069|NCT03308877|Behavioral|Stadard Care (SC)|Standard procedures at pretrial program + assessement
79486928|NCT03402607|Procedure|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
79486929|NCT03402607|Radiation|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
79335929|NCT02608879|Procedure|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
79486930|NCT02752880|Drug|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
79486931|NCT02752880|Drug|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
79486932|NCT05277727|Dietary Supplement|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
79486933|NCT05277727|Dietary Supplement|Placebo|1 capsule to be taken twice daily with food (morning and evening).
79486934|NCT04054232|Other|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~What peripheral artery disease is and why diagnosis may be important~Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
79486935|NCT02226198|Drug|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
79486936|NCT02226198|Drug|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
79486937|NCT02754518|Drug|Entresto|
79486938|NCT05177029|Drug|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
79486939|NCT05177029|Drug|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
79486940|NCT05169307|Drug|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
79486941|NCT02751385|Drug|Microgynon|
79486942|NCT02751385|Drug|Nintedanib|
79982070|NCT03299166|Drug|Troriluzole|Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
79486943|NCT05349032|Dietary Supplement|Curcumin|Oral supplement
79982071|NCT03299166|Drug|Placebo|Matching capsule once daily (QD)
79335930|NCT02608879|Procedure|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
79486944|NCT05057689|Drug|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
79335931|NCT02608879|Procedure|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
79652246|NCT05463770|Drug|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
79812471|NCT02552524|Device|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
79982072|NCT03295227|Biological|Pembrolizumab|Given IV
79486945|NCT05057689|Drug|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
79486946|NCT05057689|Drug|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
79486947|NCT02754674|Procedure|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
79652247|NCT05457608|Device|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
79652248|NCT05457608|Device|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
79812472|NCT00809536|Drug|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
79812473|NCT00809536|Drug|Metformin|Single, oral, 500 mg of metformin immediate release
79335932|NCT02608879|Other|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
79335933|NCT04852549|Other|Oculomotor exercise|"While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
79335934|NCT04852705|Biological|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
79335935|NCT04852705|Biological|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
79335936|NCT03040297|Device|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
79335937|NCT03040297|Device|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
79812474|NCT00809536|Drug|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
79812475|NCT00809536|Drug|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
79812476|NCT00809692|Procedure|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
79812477|NCT00809692|Procedure|new technique for histamine response|laser Dopper technique and genotyping
79982073|NCT03284138|Device|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
79982074|NCT03284138|Device|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
79335938|NCT03040297|Device|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
79335939|NCT04852315|Dietary Supplement|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
79335940|NCT04852315|Dietary Supplement|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
79486948|NCT04737980|Drug|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
79812478|NCT00843284|Drug|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
79982075|NCT03245593|Other|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
79982076|NCT03245593|Other|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
79486949|NCT04737980|Drug|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
79652249|NCT05452772|Drug|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
79652250|NCT05452772|Drug|Niacin|Participants will received two niacin sessions, 1 week apart
79652251|NCT05452447|Device|Transfluthrin|Passive emanator with formulated transfluthrin
79652252|NCT05452447|Device|Placebo|Passive emanator with formulated inert ingredients
79982077|NCT03217747|Drug|Avelumab|Given IV
79982078|NCT03217747|Biological|Ivuxolimab|Given IV
79982079|NCT03217747|Radiation|Radiation Therapy|Undergo radiation therapy
79982080|NCT03217747|Biological|Utomilumab|Given IV
79982081|NCT03204812|Biological|Durvalumab|Given IV
79486950|NCT04737980|Drug|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
79486951|NCT04737980|Drug|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
79652253|NCT05447884|Other|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
79812479|NCT02972892|Device|Et Control Feature|Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
79812480|NCT02972892|Device|Conventional Fresh Gas|"Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case."
79335941|NCT03038425|Drug|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
79812481|NCT00802282|Drug|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
79335942|NCT03038425|Drug|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
79335943|NCT03038191|Device|Neuroelectrics Enobio 8(R)|Monitoring
79486952|NCT00371696|Drug|diclofenac|
79812482|NCT00802282|Behavioral|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
79652254|NCT05447884|Other|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
79652255|NCT05447884|Other|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
79812483|NCT00802282|Behavioral|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
79812484|NCT00802516|Dietary Supplement|stanol ester|enriched margarine
79486953|NCT00371696|Drug|paracetamol|
79486954|NCT00371696|Device|heat retaining knee support|
79812485|NCT00802516|Dietary Supplement|sterol ester|enriched margarine
79812486|NCT00802516|Dietary Supplement|No intervention|placebo margarine
79812487|NCT02606760|Drug|P-3073|
79812488|NCT02606760|Drug|Vehicle of P-3073|
79812489|NCT00652834|Procedure|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
79812490|NCT00652834|Drug|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
79982082|NCT03204812|Biological|Tremelimumab|Given IV
79335944|NCT04844047|Other|Exercise|refer to arm descriptors
79335945|NCT04844047|Other|Exercise|refer to arm descriptors
79335946|NCT04843969|Behavioral|Stress induction|Exposure to a psychosocial stressor
79335947|NCT04843969|Behavioral|Control stress exposure|Exposure to a control task (no stress)
79335948|NCT04843969|Behavioral|Cue induction|Exposure to a smoking-related task
79335949|NCT04843969|Behavioral|Neutral cue exposure|Exposure to neutral cues
79335950|NCT04851769|Drug|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
79486955|NCT00371696|Device|standard knee support|
79812491|NCT02553148|Other|Need for children's palliative care|Need for children's palliative care
79486956|NCT03459170|Biological|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
79486957|NCT03459170|Drug|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
79486958|NCT05348798|Other|Web based survey|Web-based survey on exercise addiction and personality traits
79486959|NCT02756624|Drug|AC-170 0.24%|
79486960|NCT02756624|Drug|AC-170 Vehicle|
79652256|NCT05445583|Behavioral|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
79982083|NCT03201250|Drug|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
79982084|NCT03194750|Other|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of < 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
79335951|NCT04851769|Drug|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
79335952|NCT04851769|Procedure|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
79335953|NCT04843813|Dietary Supplement|Lutein|Participants will consume daily soft gels containing the lutein supplement.
79335954|NCT04843813|Dietary Supplement|Placebo|Participants will consume daily soft gels containing the safflower oil.
79335955|NCT04843189|Procedure|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
79486961|NCT02753413|Biological|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
79486962|NCT02753413|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
79652257|NCT05445583|Behavioral|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
79652258|NCT05445583|Behavioral|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
79812492|NCT00825812|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
79335956|NCT04843267|Drug|Tislelizumab|Tislelizumab in first-line treatment of Hodgkin's lymphoma
79335957|NCT04843657|Behavioral|Observation for symptom distress|Observation for symptom distress
79335958|NCT04838899|Radiation|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
79335959|NCT03037957|Device|ARIES Group A Strep Assay|
79335960|NCT04852081|Drug|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
79335961|NCT04852081|Drug|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
79335962|NCT04852081|Drug|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
79486963|NCT02958800|Other|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
79486964|NCT04937491|Device|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
79486965|NCT00372086|Drug|Rosiglitazone|
79486966|NCT04850521|Other|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
79486967|NCT03380000|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
79486968|NCT03380000|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
79486969|NCT02754427|Behavioral|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
79486970|NCT02754427|Behavioral|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
79335963|NCT04852081|Drug|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
79486971|NCT02973932|Behavioral|Cognitive-bahavioral psychotherapy|
79486972|NCT04777669|Other|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
79486973|NCT04759885|Drug|Phase II: NTC015 low dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
79486974|NCT04759885|Drug|Phase II: NTC015 medium dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
79486975|NCT04759885|Drug|Phase II: NTC015 high dose|Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
79486976|NCT04759885|Drug|Phase III: NTC015 selected dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
79486977|NCT04759885|Drug|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)|"The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure."
79486978|NCT02754661|Device|COLON Capsule endoscopy|
79335964|NCT04852081|Drug|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
79335965|NCT04852081|Drug|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
79335966|NCT04852081|Drug|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
79335967|NCT04852081|Drug|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
79335968|NCT04852081|Drug|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
79486979|NCT02754661|Device|Computed Tomographic Colonography|
79486980|NCT02757092|Other|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
79486981|NCT04728295|Device|Exablate 4000|Exablate Pallidothalamic Tractotomy
79486982|NCT04738045|Drug|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
79652259|NCT05445583|Behavioral|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
79652260|NCT05439772|Drug|Ondansetron|Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
79812493|NCT00825812|Drug|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
79812494|NCT00802594|Drug|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
79982085|NCT03194750|Other|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
79812495|NCT02606682|Drug|NPT200-11|Single doses of NPT200-11capsules, orally administered
79812496|NCT02606682|Drug|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
79486983|NCT04738045|Drug|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
79486984|NCT02755129|Other|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
79652261|NCT05433181|Drug|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
79652262|NCT05433181|Other|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
79652263|NCT05432271|Behavioral|Exposure to calorie information|Calories for all beverages and foods
79652264|NCT05432271|Behavioral|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
79652265|NCT05432271|Behavioral|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
79652266|NCT05432271|Behavioral|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
79812497|NCT00707876|Drug|ferumoxytol|Dose 1 versus non-contrast MRA
79812498|NCT00707876|Drug|ferumoxytol|Dose 2 versus non-contrast MRA
79812499|NCT00707876|Drug|ferumoxytol|Dose 3 versus non-contrast MRA
79812500|NCT00809770|Behavioral|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
79812501|NCT00809770|Behavioral|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
79812502|NCT00810004|Drug|Ferinject|Intravenous infusion of iron
79812503|NCT05746962|Device|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
79812504|NCT05746962|Device|Navigation screen|ScopeGuide's 3D visualisation screen
79652267|NCT05432271|Behavioral|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
79982086|NCT03181204|Procedure|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
79335969|NCT04851067|Other|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
79982087|NCT03181204|Procedure|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
79982088|NCT03181204|Procedure|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
79335970|NCT04851067|Other|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
79335971|NCT04838509|Other|no intervention|retrospective descriptive without intervention
79335972|NCT04843033|Drug|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
79335973|NCT02608099|Drug|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
79335974|NCT02608099|Drug|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
79486985|NCT02755129|Other|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
79652268|NCT05423691|Drug|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
79652269|NCT05418673|Drug|BIIB122|Administered as specified in the treatment arm.
79652270|NCT05418673|Drug|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
79812505|NCT00802750|Device|LoFric POBE|"LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
79307732|NCT02553460|Drug|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
79307733|NCT02553460|Drug|Bortezomib|Given IV.
79307734|NCT02553460|Drug|Vorinostat|Taken PO or NG.
79307735|NCT02553460|Drug|Cyclophosphamide|Given IV.
79335975|NCT04842877|Drug|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
79335976|NCT04842565|Drug|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
79335977|NCT04842565|Device|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
79335978|NCT04850755|Drug|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
79335979|NCT03038035|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
79335980|NCT03038035|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
79812506|NCT00802750|Device|LoFric POBE|"Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
79307736|NCT02553460|Drug|Mercaptopurine|Given PO or NG.
79307737|NCT02553460|Drug|Methotrexate|Given IV, IM or PO.
79307738|NCT02553460|Drug|Leucovorin Calcium|Leucovorin rescue PO or IV.
79982089|NCT03166384|Device|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
79982090|NCT03166384|Procedure|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
79486986|NCT02755129|Other|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
79652271|NCT05417763|Device|Randomized physiological measurements by the two systems|To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
79652272|NCT05417022|Device|Diamondback 360TM orbital atherectomy system|Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
79982091|NCT03149029|Drug|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
79982092|NCT03149029|Drug|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
79982093|NCT03149029|Drug|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
79982094|NCT03025763|Other|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
79335981|NCT03037801|Device|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
79335982|NCT04850131|Procedure|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
79652273|NCT05414175|Drug|Mavacamten|Specified dose on specified days
79652274|NCT05407064|Drug|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
79652275|NCT05407064|Other|Placebo|A substance that is designed to have no therapeutic value.
79652276|NCT05402111|Drug|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
79982095|NCT03025763|Other|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
79982096|NCT03025763|Procedure|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
79982097|NCT03025763|Procedure|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
79335983|NCT04842487|Drug|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
79486987|NCT02755129|Other|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
79486988|NCT02755129|Other|Reveal LINQ accelerometer|Walking exercises test
79486989|NCT02755129|Other|3D accelerometer|Walking exercises test
79486990|NCT04670263|Device|Tear Film Imager|Tear Film Imager recording
79486991|NCT02755285|Device|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
79486992|NCT02226120|Drug|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
79652277|NCT05402111|Drug|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
79652278|NCT05378620|Behavioral|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
79652279|NCT05362292|Drug|Tolterodine Tartrate ER|Anticholinergic
79652280|NCT05362292|Drug|Mirabegron|Beta-3-adrenergic agonist
79652281|NCT05362292|Drug|Placebo|matching placebo pill
79652282|NCT05360238|Biological|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
79652283|NCT05351268|Radiation|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
79652284|NCT05348005|Device|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
79335984|NCT03040063|Procedure|Combined endovascular approach (EVAR)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Heparin 70-80 IU/kg i.a.~implantation of peripheral stent graft VIABAHN~implantation of peripheral stent SUPERA into stent graft~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~control angiography in 12 hrs or earlier according to clinical status and symptoms~repeated angiography in 24 hrs"
79486993|NCT02973919|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, & Renssen, 1999; de Jongh, Holmshaw, Carswell, & van Wijk, 2011; Lapsekili & Yelboga, 2014; Muris, Merckelbach, van Haaften, & Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
79652285|NCT05347407|Procedure|Colonoscopy|Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
79652286|NCT05345444|Device|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
79812507|NCT00802828|Drug|Famotidine Tablets, 40 mg|
79812508|NCT00824720|Drug|High Dose Device|inserted for 14 days
79812509|NCT00824720|Drug|Low Dose Device|inserted for 14 days
79812510|NCT00824720|Device|Placebo Device|inserted for 14 days
79812511|NCT00802906|Device|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
79307739|NCT02553460|Drug|Cytarabine|Given IV.
79335985|NCT03040063|Procedure|Standard optimal therapy (OPT)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Unfractionated heparin 70-80 IU/kg i.a.~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~control angiography in 12 hrs or according to clinical status and symptoms~repeated angiography in24 hrs~Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
79486994|NCT02973919|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).
79486995|NCT04587973|Procedure|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
79335986|NCT04841941|Device|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
79335987|NCT04841863|Device|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
79335988|NCT04841863|Other|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
79335989|NCT04833673|Behavioral|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
79335990|NCT04833673|Behavioral|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
79335991|NCT04837885|Procedure|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
79335992|NCT04837885|Procedure|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
79335993|NCT04837885|Drug|LUTATHERA® by intra-arterial hepatic (IAH) injection|"One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations"
79982098|NCT03025763|Procedure|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
79982099|NCT03025763|Procedure|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
79486996|NCT04587973|Procedure|Group Ropivacaine|Plain ropivacaine group
79982100|NCT03025763|Procedure|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
79982101|NCT02976701|Drug|DLBS1033|
79486997|NCT04587973|Procedure|Group Control|Control group
79486998|NCT02756689|Other|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
79486999|NCT02756689|Other|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
79982102|NCT02976701|Drug|Placebo|
79307740|NCT02553460|Drug|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
79307741|NCT02553460|Drug|Vincristine|Given IV.
79487000|NCT04766580|Behavioral|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
79487001|NCT04558177|Device|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
79487002|NCT02757326|Drug|Opaganib|Opaganib, [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt] is an orally available inhibitor of the enzyme SK2.
79812512|NCT00802906|Drug|bevacizumab|1.5 mg initial intravitreal injection
79982103|NCT02976701|Drug|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
79982104|NCT02853305|Biological|Pembrolizumab|IV infusion
79982105|NCT02853305|Drug|Cisplatin|IV infusion
79982106|NCT02853305|Drug|Carboplatin|IV infusion
79982107|NCT02853305|Drug|Gemcitabine|IV infusion
79982108|NCT02838927|Other|No intervention|No intervention
79487003|NCT02757950|Biological|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
79982109|NCT02815995|Drug|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
79652287|NCT05343000|Behavioral|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
79652288|NCT05337982|Other|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
79652289|NCT05331625|Behavioral|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
79982110|NCT02815995|Drug|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
79982111|NCT02778529|Device|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
79812513|NCT00802984|Device|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
79982112|NCT02735902|Drug|Vitamin K antagonist or direct oral anticoagulant treatment|"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"
79982113|NCT02735902|Drug|Aspirin|"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
79487004|NCT05348408|Drug|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
79307742|NCT02525757|Drug|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
79982114|NCT02664701|Other|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
79982115|NCT02664701|Other|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
79335994|NCT04837885|Procedure|Scan|Scans after completion of LUTATHERA® treatment injection
79335995|NCT03039829|Dietary Supplement|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
79335996|NCT03039829|Dietary Supplement|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
79335997|NCT03039829|Dietary Supplement|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
79335998|NCT04833595|Behavioral|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
79335999|NCT03039907|Procedure|Total Knee Arthroplasty|Total knee arthroplasty
79487005|NCT02753881|Drug|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
79982116|NCT02664701|Other|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
79982117|NCT02664701|Other|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
79982118|NCT02609464|Device|Interrupted Knotted Sutures|
79982119|NCT02609464|Device|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
79982120|NCT02524275|Drug|Capecitabine|Given PO
79982121|NCT02524275|Drug|Docetaxel|Given IV
79982122|NCT02524275|Other|Quality-of-Life Assessment|Ancillary studies
79982123|NCT02524275|Other|Questionnaire Administration|Ancillary studies
79982124|NCT02516709|Radiation|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
79982125|NCT02509039|Drug|CC-122|5 continuous days out of 7 days per week intermittent dosing
79487006|NCT02753881|Drug|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
79487007|NCT00425360|Biological|sargramostim|
79487008|NCT00425360|Biological|telomerase peptide vaccine GV1001|
79487009|NCT00425360|Drug|capecitabine|
79487010|NCT00425360|Drug|gemcitabine hydrochloride|
79487011|NCT05349253|Dietary Supplement|Garlic extracts|One intake in total
79487012|NCT05349253|Dietary Supplement|Placebo|One intake in total
79487013|NCT04337437|Drug|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
79487014|NCT04337437|Drug|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
79487015|NCT05348096|Drug|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
79336000|NCT04833205|Drug|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
79336001|NCT03036475|Device|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
79336002|NCT03037645|Drug|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
79336003|NCT04371913|Radiation|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
79336004|NCT04370665|Device|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
79336005|NCT04312243|Drug|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
79336006|NCT04841551|Drug|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
79336007|NCT03037567|Behavioral|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
79336008|NCT04833049|Drug|TAK-994 Oral Tablet|TAK-994 tablet.
79336009|NCT04833049|Drug|[14C]TAK-994 Intravenous Infusion|[14C]TAK-994 intravenous infusion.
79652290|NCT05322044|Behavioral|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
79652291|NCT05317546|Drug|Cannabidiol|In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
79336010|NCT04833049|Drug|[14C]TAK-994 Oral Suspension|[14C]TAK-994 oral suspension.
79336011|NCT04841161|Behavioral|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
79336012|NCT04841161|Behavioral|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
79336013|NCT04841239|Other|Herbal topical formulation|
79487016|NCT04337359|Drug|Ruxolitinib|5 mg. Tablet
79652292|NCT05313243|Drug|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
79652293|NCT05313243|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
79652294|NCT05311670|Behavioral|Patient-reported outcomes monitoring|o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
79652295|NCT05310565|Procedure|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
79652296|NCT05295290|Diagnostic Test|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
79652297|NCT05292365|Behavioral|RE-PACT Intervention|"Create respiratory illness action plan~Weekly mHealth text messages~Monthly study assessments~Action planning and JIT coaching"
79336014|NCT04841395|Diagnostic Test|Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)|Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
79336015|NCT03036241|Device|Conventional angioplasty|Angioplasty with conventional balloon
79336016|NCT03036241|Device|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
79336017|NCT03037333|Procedure|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
79652298|NCT05289661|Drug|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
79652299|NCT05289661|Drug|Topical Placebo|topical Placebo
79652300|NCT05286853|Biological|Renal Autologous Cell Therapy (REACT)|Participants will receive either 2 REACT injections or 2 Sham REACT injections into biopsied and non-biopsied contralateral kidneys 3 months apart.
79336018|NCT03037333|Procedure|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
79336019|NCT03039517|Device|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
79652301|NCT05286541|Procedure|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
79652302|NCT05286541|Procedure|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
79652303|NCT05275972|Drug|Ripasudil|Topical Ripasudil 0.4%
79652304|NCT05275972|Drug|Placebo|Topical Placebo
79652305|NCT05264207|Behavioral|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~Self-care of chronic conditions and medication management~Healthy habits: physical activity and healthy eating~Access to social support resources~Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
79982126|NCT02499120|Drug|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
79487017|NCT04337606|Drug|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
79487018|NCT04337606|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
79487019|NCT04337606|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
79487020|NCT02759354|Other|Blood Sample|Blood sample at approx. 4 years of age
79982127|NCT02499120|Drug|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
79487021|NCT01190306|Device|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
79982128|NCT02499120|Drug|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
79982129|NCT02444754|Other|Medical Chart Review|Obtain medical data
79982130|NCT02444754|Other|Questionnaire Administration|Complete demographics questionnaires
79982131|NCT02444754|Other|Survey Administration|Complete surveys
79982132|NCT02310451|Biological|blood test|blood test to J0-M3-M6-M12
79982133|NCT02227992|Biological|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
79982134|NCT02227992|Device|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
79982135|NCT02210078|Biological|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given IV
79982136|NCT02175251|Procedure|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
79982137|NCT02175251|Procedure|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
79982138|NCT02175251|Procedure|Sham Comparator|10 session in 5 days with sham-controlled
79982139|NCT02106598|Drug|fluorescent cRGDY-PEG-Cy5.5-C dots|
79982140|NCT01871766|Drug|Vincristine|"Dosage and route of administration:~< 1 year of age=0.025 mg/kg intravenously (IV)~> 1 year and < 3 years= 0.05 mg/kg IV~≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants."
79982141|NCT01871766|Drug|Dactinomycin|"Dosage and route of administration:~< 1 year=0.025 mg/kg IV push~≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
79982142|NCT01871766|Drug|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~< 3 years of age = 40 mg/kg IV~≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)"
79982143|NCT01871766|Procedure|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
79982144|NCT01871766|Procedure|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
79982145|NCT01871766|Drug|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
79982146|NCT01871766|Drug|Sorafenib|Dosage and route of administration: 90 mg/m^2/dose twice daily.
79982147|NCT01871766|Drug|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
79982148|NCT01871766|Procedure|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
79982149|NCT01871766|Drug|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
79982150|NCT01871766|Drug|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
79487022|NCT01190306|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
79487023|NCT02759575|Drug|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
79487024|NCT02759575|Radiation|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
79982151|NCT01871766|Drug|Etoposide|"Dosage and Route of Administration:~Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis"
79982152|NCT01871766|Drug|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
79336020|NCT03039517|Device|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
79982153|NCT01871766|Drug|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
79982154|NCT01871766|Drug|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
79336021|NCT03039361|Behavioral|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
79652306|NCT05264207|Behavioral|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
79982155|NCT01871766|Drug|^1^1C-methionine|Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
79336022|NCT04840771|Procedure|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
79336023|NCT04837651|Device|Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
79487025|NCT02759575|Drug|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
79487026|NCT02760056|Drug|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
79336024|NCT04837651|Device|T-Detect COVID T-cell blood test|A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
79336025|NCT04832581|Behavioral|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
79336026|NCT04832191|Device|CE-SM|contrast enhanced spectral mammography &contrast enhanced magnetic resonance imaging
79336027|NCT03039205|Drug|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
79336028|NCT03039205|Drug|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
79336029|NCT04837261|Drug|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
79487027|NCT02760056|Drug|Placebo|Patient will receive a matching placebo to take twice daily for one week.
79487028|NCT02764970|Drug|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
79982156|NCT01728155|Drug|chemotherapy|
79982157|NCT01628029|Other|Counseling|Undergo CBT
79982158|NCT01628029|Drug|Methylphenidate Hydrochloride|Given PO
79982159|NCT01628029|Procedure|Phototherapy|Undergo light therapy
79982160|NCT01628029|Other|Placebo Administration|Given PO
79982161|NCT01628029|Other|Quality-of-Life Assessment|Ancillary studies
79982162|NCT01628029|Procedure|Sham Intervention|Undergo sham light therapy
79982163|NCT01628029|Drug|Therapeutic Melatonin|Given PO
79982164|NCT01538342|Other|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
79982165|NCT01538342|Other|2 biopsies|
79982166|NCT01538342|Other|biopsy|1 biopsy ok healthy skin
79652307|NCT05263245|Other|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
79982167|NCT01346787|Drug|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
79982168|NCT01097928|Procedure|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
79982169|NCT01033565|Drug|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
79982170|NCT01027143|Dietary Supplement|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
79336030|NCT04837261|Drug|Flecainide|80 mg/m2/d
79336031|NCT04837261|Drug|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
79336032|NCT04832035|Other|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
79336033|NCT04832035|Behavioral|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
79336034|NCT04792177|Behavioral|Emotion regulation skills training|The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
79336035|NCT04832347|Other|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
79336036|NCT04832347|Other|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
79336037|NCT04428697|Procedure|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
79336038|NCT04831489|Radiation|Imaging|pre and postoperative CT scan of lung
79336039|NCT04831879|Device|GONDOLA AMPS|The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
79336040|NCT04831645|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
79652308|NCT05263037|Device|EaseVRx|VR software with interactive content
79652309|NCT05263037|Device|Sham VR|VR with neutral non-interactive content
79652310|NCT05250856|Drug|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of ~5 μg of PPE per mg of PLGA.
79982171|NCT01027143|Drug|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
79336041|NCT04831645|Procedure|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
79336042|NCT04824937|Drug|Telaglenastat|Capsule, taken by mouth
79982172|NCT01023984|Procedure|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
79487029|NCT05336006|Other|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
79487030|NCT05336006|Other|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
79487031|NCT05320718|Drug|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
79982173|NCT01023984|Procedure|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
79336043|NCT04824937|Drug|Talazoparib|Capsule, taken by mouth
79652311|NCT05250856|Drug|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
79982174|NCT00981656|Drug|cisplatin|60-minute intravenous (IV) infusion of 15 mg/m^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
79982175|NCT00981656|Drug|5-fluorouracil|Continuous IV infusion of 500 mg/m^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
79982176|NCT00981656|Drug|Mitomycin|IV bolus dose of 12 mg/m^2 on day 1 of radiation treatment.
79982177|NCT00981656|Radiation|Three-Dimensional Conformal Radiation Therapy|Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
79982178|NCT00895622|Radiation|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
79982179|NCT00895622|Radiation|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
79982180|NCT00847535|Biological|autologous muscle cell injection|Injection of autologous muscle cells
79982181|NCT00742157|Drug|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
79336044|NCT03037099|Behavioral|Enhanced GI Concept Education|
79336045|NCT04836949|Device|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
79982182|NCT00539591|Drug|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
79982183|NCT00539591|Drug|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
79336046|NCT04836949|Device|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
79652312|NCT05244278|Device|Medtronic-GI genius (CADe system for detecting colorectal polyps)|Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
79652313|NCT05226689|Device|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
79982184|NCT00539591|Drug|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
79982185|NCT02460718|Behavioral|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
79982186|NCT03635853|Drug|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
79982187|NCT03293992|Drug|0.01% RO7058584|Once daily morning administration for 7 days
79982188|NCT03293992|Drug|0.1% RO7058584|Once daily morning administration for 7 days
79982189|NCT03293992|Drug|1% RO7058584|Once daily morning administration for 7 days
79982190|NCT03293992|Drug|Matching Placebo|Once daily morning administration for 7 days
79982191|NCT03293992|Drug|Latanoprost 0.005%|Once daily morning or evening dosing
79982192|NCT01332201|Drug|Advagraf|oral
79982193|NCT01332201|Drug|Prograf|oral
79982194|NCT05223452|Device|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
79336047|NCT04836793|Other|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
79336048|NCT04428073|Biological|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
79336049|NCT04824313|Diagnostic Test|Chest CT|Chest CT without intravenous contrast material
79336050|NCT04824313|Diagnostic Test|Chest CTA|Chest CT with intravenous contrast material
79336051|NCT04824235|Other|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
79336052|NCT04824235|Other|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
79982195|NCT03293914|Behavioral|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
79336053|NCT04824157|Other|Non|Follow up
79982196|NCT01332279|Drug|everolimus|Given PO
79982197|NCT01332279|Drug|erlotinib hydrochloride|Given PO
79982198|NCT01332279|Procedure|biopsy|Correlative studies
79982199|NCT01332279|Other|laboratory biomarker analysis|Correlative studies
79982200|NCT01332279|Other|immunohistochemistry staining method|Correlative studies
79982201|NCT01332279|Genetic|polyacrylamide gel electrophoresis|Correlative studies
79982202|NCT01332279|Other|pharmacological study|Correlative studies
79982203|NCT01332279|Radiation|external beam radiation therapy|Undergo EBRT
79307743|NCT02525757|Drug|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
79336054|NCT04824001|Other|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
79336055|NCT03036085|Drug|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
79336056|NCT03036085|Drug|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
79336057|NCT03036085|Drug|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
79336058|NCT03036085|Drug|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
79982204|NCT01332279|Genetic|microarray analysis|Correlative studies
79982205|NCT03298906|Drug|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
79982206|NCT03298906|Drug|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
79982207|NCT03298828|Biological|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
79982208|NCT03298828|Biological|CD19 CAR T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
79336059|NCT04823767|Other|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
79336060|NCT04836481|Other|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
79336061|NCT04831333|Other||
79336062|NCT04831255|Drug|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
79336063|NCT04831177|Procedure|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
79336064|NCT02432235|Drug|Camidanlumab tesirine|Intravenous (IV) infusion.
79336065|NCT02431533|Dietary Supplement|PX0612|PX0612 is a probiotic contained in a veggie capsule.
79336066|NCT02431533|Dietary Supplement|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
79487032|NCT05314166|Other|meditation practice|Description: meditation practice
79336067|NCT02416791|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
79336068|NCT02416791|Device|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
79336069|NCT02416791|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
79336070|NCT02416791|Other|Physical Therapy|Physical therapy will be administered for 40 minutes.
79487033|NCT05302544|Other|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
79336071|NCT02416791|Other|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
79336072|NCT02414841|Drug|Vonapanitase|
79336073|NCT02414841|Drug|Placebo|
79336074|NCT02413593|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79336075|NCT02413593|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79336076|NCT04942275|Drug|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
79487034|NCT05302544|Other|motor activities|motor activities usually performed
79336077|NCT01652703|Biological|Evolocumab|Administered by subcutaneous injection
79982209|NCT02461576|Device|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
79336078|NCT01652703|Other|Placebo|Administered by subcutaneous injection
79487035|NCT02739698|Drug|Paclitaxel|
79487036|NCT02739698|Procedure|Radical surgery-peritonectomy|
79487037|NCT00371618|Procedure|Fluoroscopy|
79982210|NCT02461342|Other|not intervention|This is a cross-sectional study, no intervention was performed.
79336079|NCT01652469|Drug|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
79336080|NCT01652469|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
79487038|NCT02766374|Behavioral|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
79336081|NCT02429427|Drug|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
79982211|NCT03878277|Drug|Starbucks® Cold brew - 325ml bottle|Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
79652314|NCT05221645|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
79982212|NCT03286972|Device|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
79652315|NCT05221645|Drug|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
79336082|NCT02429427|Other|Placebo|Two capsules once daily with food
79336083|NCT05370573|Other|No intervention|Observational - no interventions
79336084|NCT02412735|Drug|Rexlemestrocel-L|Rexlemestrocel-L injection
79652316|NCT05221645|Drug|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
79652317|NCT05221645|Drug|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
79652318|NCT05221645|Drug|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
79652319|NCT05217693|Drug|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
79652320|NCT05191823|Drug|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
79336085|NCT02412735|Drug|Rexlemestrocel-L + HA Mixture|Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
79336086|NCT02412735|Drug|Placebo|Saline control solution
79336087|NCT02412657|Drug|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
79652321|NCT05191823|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
79652322|NCT05183477|Other|fast track|short cut for the request of xrays directly at triage
79652323|NCT05183477|Other|normal pathway|x-ray would be required according to doctor's clinical evaluation.
79982213|NCT03697629|Drug|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
79982214|NCT03286816|Drug|SodiumChloride|
79982215|NCT03286816|Drug|Sodium Lactate|
79982216|NCT01334697|Drug|recombinant human cardiotrophin-1|Single dose intravenous administration
79982217|NCT01334697|Other|Placebo|Single dose intravenous administration
79336088|NCT02412657|Drug|Normal Saline|
79336089|NCT02428413|Device|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
79336090|NCT02428413|Device|Standard oxygen mask|Provide supplemental oxygen
79336091|NCT02412111|Drug|Ivacaftor|
79336092|NCT02412111|Drug|Tezacaftor/Ivacaftor|
79336093|NCT02427477|Device|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
79336094|NCT02427477|Device|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
79336095|NCT02427399|Other|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
79336096|NCT02427399|Other|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
79336097|NCT02427399|Other|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
79336098|NCT02427399|Other|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
79487039|NCT02766374|Behavioral|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
79487043|NCT04336904|Drug|Favipiravir|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
79487044|NCT04336904|Other|Placebo|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
79487045|NCT02767934|Other|Laboratory Biomarker Analysis|Correlative studies
79487046|NCT02767934|Biological|Pembrolizumab|Given IV
79652324|NCT05183230|Behavioral|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
79652325|NCT05183230|Behavioral|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
79652326|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
79487047|NCT02194998|Drug|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
79652327|NCT05166837|Drug|Placebo|Intravenous injection
79652328|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
79652329|NCT05166837|Drug|Placebo|Intravenous injection
79336099|NCT02426541|Drug|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
79336100|NCT02426541|Drug|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
79336101|NCT02484651|Drug|Sugammadex|Reversal of deep neuromuscular block
79487048|NCT02194998|Drug|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
79336102|NCT02484651|Drug|Rocuronium|Maintenance of deep neuromuscular block
79982218|NCT02460094|Drug|BIIB092|See Arm Descriptions for dosing information.
79652330|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
79652331|NCT05166837|Drug|Placebo|Intravenous injection
79652332|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
79652333|NCT05166837|Drug|Placebo|Intravenous injection
79652334|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
79336103|NCT02410551|Drug|Pacritinib|200 mg by mouth twice a day for 60 days.
79982219|NCT02460094|Drug|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
79336104|NCT02410551|Drug|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
79982220|NCT01315119|Procedure|SPY Intra-Operative Angiography|Calculated per patient
79982221|NCT03642951|Device|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
79982222|NCT03642951|Device|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
79982223|NCT04485663|Drug|ALG-010133|Single or multiple doses of ALG-010133
79982224|NCT04485663|Drug|Placebo|Single or multiple doses of Placebo
79982225|NCT03286738|Drug|FOLFIRI, target agent|"Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
79982226|NCT01332513|Drug|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
79982227|NCT01332513|Drug|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
79982228|NCT01332513|Drug|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
79336105|NCT02410551|Behavioral|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
79336106|NCT02410551|Behavioral|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
79982229|NCT01332513|Drug|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
79336107|NCT02410551|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
79652335|NCT05166837|Drug|Placebo|Intravenous injection
79652336|NCT05146765|Device|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
79652337|NCT05146765|Other|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
79652338|NCT05144763|Device|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
79652339|NCT05140252|Behavioral|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
79336108|NCT02410551|Drug|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
79652340|NCT05136846|Drug|Carboplatin|Given IV
79336109|NCT02424591|Drug|Ketamine|Infusion at a rate of 10 mcg/kg/min
79336110|NCT02424591|Other|Placebo|Placebo IV
79336111|NCT02408523|Drug|Lacosamide Tablet|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
79336112|NCT02408523|Drug|Lasosamide Oral Solution|"Active Substance: Lacosamide~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
79336113|NCT02408523|Other|Placebo Tablet|"Active Substance: Placebo~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
79336114|NCT02408523|Other|Placebo Oral Solution|"Active Substance: Placebo~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
79336115|NCT04830319|Other|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
79336116|NCT04830319|Other|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
79982230|NCT01332513|Drug|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
79982231|NCT01332513|Drug|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
79336117|NCT04836403|Other|Sinus and nasal quality of life survey questionnaire (SN-5)|"The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)"
79487049|NCT02194998|Drug|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
79487050|NCT05257850|Device|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
79487051|NCT05257850|Device|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
79487052|NCT02194062|Drug|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
79487053|NCT02194062|Drug|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
79652341|NCT05136846|Biological|Durvalumab|Given IV
79652342|NCT05136846|Drug|Paclitaxel|Given IV
79652343|NCT05136846|Drug|Papaverine|Given IV or SC
79652344|NCT05136846|Radiation|Radiation Therapy|Undergo RT
79652345|NCT05136846|Drug|Pemetrexed|Given IV
79652346|NCT05130463|Drug|empagliflozin/linagliptin|tablet
79982232|NCT03293836|Procedure|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
79982233|NCT03293836|Procedure|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
79336118|NCT04836091|Behavioral|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
79487054|NCT02194062|Drug|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
79487055|NCT02768558|Radiation|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
79487056|NCT02768558|Drug|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
79487057|NCT02768558|Drug|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
79487058|NCT02768558|Drug|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
79487059|NCT02768558|Other|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
79487060|NCT00372164|Procedure|American Society of Interventional Pain Physician Guidelines|
79487061|NCT00372242|Behavioral|Prospective Longitudinal Interventional Stury|
79487062|NCT02193828|Biological|Collagenase clostridium histolyticum|Single injection into nodule
79487063|NCT02193828|Biological|Placebo|Single injection into nodule
79487064|NCT04738136|Drug|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
79487065|NCT02772302|Device|mindBEAGLE EEG-based brain-computer interface|
79487066|NCT02192970|Drug|Bevacizumab|
79652347|NCT05129358|Drug|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
79652348|NCT05129358|Dietary Supplement|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
79652349|NCT05126693|Other|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
79487067|NCT05173532|Other|Balance Training|static and dynamic balance and gait stability exercises
79487068|NCT05173532|Other|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
79487069|NCT05162144|Procedure|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
79487070|NCT05149352|Behavioral|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
79652350|NCT05110261|Drug|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight < 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
79652351|NCT05110261|Drug|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight <5 kg) or 1.0 mL (if weight >=5 kg)
79652352|NCT05108831|Device|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
79652353|NCT05106894|Behavioral|smartphone application to promote nurturing care|see arm description
79307744|NCT02525757|Drug|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
79307745|NCT02525757|Radiation|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
79307746|NCT02502266|Drug|Cediranib|Given PO
79307747|NCT02502266|Drug|Cediranib Maleate|Given PO
79307748|NCT02502266|Procedure|Computed Tomography|Undergo CT
79652354|NCT05106894|Behavioral|printed caregiving materials|see arm description
79652355|NCT05101759|Procedure|Comprehensive Geriatric Assessment|A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
79652356|NCT05096169|Drug|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
79652357|NCT05096169|Drug|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
79652358|NCT05089708|Drug|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
79652359|NCT05089708|Drug|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
79336119|NCT04836091|Behavioral|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
79652360|NCT05088980|Device|VOLBELLA with Lidocaine|Facial Injection
79982234|NCT03286660|Diagnostic Test|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~Saturation at rest, and at the end of the exercise~the number of total a chair rise"
79336120|NCT04836169|Device|InCaveo's EOA system with integrated mobile CBT|integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
79336121|NCT04836013|Dietary Supplement|combined Lactobacilli|1 oral stick per day for 30 days starting the day of antibiotic treatment
79652361|NCT05088460|Drug|REGN4461|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
79652362|NCT05088460|Drug|Matching Placebo|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
79652363|NCT05075590|Diagnostic Test|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
79652364|NCT05071768|Behavioral|Focused ACT|Brief acceptance and commitment therapy
79652365|NCT05071014|Drug|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
79652366|NCT05071014|Procedure|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
79652367|NCT05066178|Behavioral|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
79652368|NCT05063565|Device|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
79652369|NCT05063565|Drug|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~Absence of clinical symptoms or signs indicating clinically significant disease progression~No decline in performance status~Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~No other treatment discontinuation criteria are met"
79652370|NCT05063565|Drug|Tremelimumab immunotherapy|300 mg, single administration
79307749|NCT02502266|Procedure|Magnetic Resonance Imaging|Undergo MRI
79652371|NCT05061017|Drug|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
79652372|NCT05061017|Drug|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
79336122|NCT04836013|Other|Placebo|1 oral stick per day for 30 days starting the day of antibiotic treatment
79336123|NCT04822909|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
79487071|NCT05149352|Behavioral|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
79652373|NCT05061017|Drug|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
79652374|NCT05058898|Other|blood samples|5 mL
79652375|NCT05058898|Other|Scabs and pus samples|if available
79336124|NCT04831099|Drug|Testosterone gel|The route of administration is transdermal.
79336125|NCT04831099|Drug|Placebo|The route of administration is transdermal
79336126|NCT04830085|Procedure|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
79336127|NCT04822831|Behavioral|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
79652376|NCT05057546|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
79336128|NCT04822831|Behavioral|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
79336129|NCT04830241|Drug|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
79336130|NCT04302337|Procedure|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
79336131|NCT04302337|Procedure|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
79336132|NCT03036943|Radiation|Fluciclovine|Fluciclovine (18F) PET/CT scan completed >= 48 hours prior to surgical resection for breast cancer
79336133|NCT03036865|Drug|BOS161721|Single dose administered IV or SC
79336134|NCT03036865|Drug|Placebo|Single dose administered IV or SC
79652377|NCT05053646|Procedure|Meniscal repair|The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
79652378|NCT05053646|Procedure|Marrow venting procedure|After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
79336135|NCT04835389|Biological|AlloGen Liquid|Amniotic fluid
79336136|NCT04835389|Drug|Placebo|0.9% normal saline
79336137|NCT04832893|Diagnostic Test|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
79336138|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
79336139|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
79336140|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
79336141|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
79487072|NCT05457296|Drug|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
79487073|NCT04336514|Device|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
79652379|NCT05046717|Device|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
79652380|NCT05032066|Drug|HZN-825|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
79652381|NCT05032066|Drug|Placebo|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
79982235|NCT03549585|Other|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
79982236|NCT03625778|Drug|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
79982237|NCT03625778|Drug|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
79982238|NCT04269538|Drug|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
79336142|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
79336143|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
79336144|NCT04367935|Drug|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
79336145|NCT04829773|Drug|Palovarotene|oral capsules
79336146|NCT04829773|Drug|midazolam|oral syrup
79336147|NCT04822285|Behavioral|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
79336148|NCT04822285|Behavioral|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
79307750|NCT02502266|Drug|Olaparib|Given PO
79307751|NCT02502266|Drug|Paclitaxel|Given IV
79487074|NCT04336592|Behavioral|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
79487075|NCT04338230|Other|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
79487076|NCT04336436|Behavioral|Mindfulness training|Mindfulness training
79652382|NCT05029284|Behavioral|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
79652383|NCT05028374|Drug|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
79982239|NCT04269538|Drug|Placebo|Placebo SC dosing
79336149|NCT04829695|Drug|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
79982240|NCT03298750|Procedure|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
79982241|NCT03619382|Radiation|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
79307752|NCT02502266|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79307753|NCT02502266|Other|Questionnaire Administration|Ancillary studies
79982242|NCT03619382|Radiation|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
79982243|NCT00398541|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
79982244|NCT03625700|Drug|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
79982245|NCT03293602|Device|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
79982246|NCT03650036|Drug|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
79307754|NCT02502266|Drug|Topotecan|Given IV
79307755|NCT02502266|Drug|Topotecan Hydrochloride|Given IV
79307756|NCT02470728|Other|New Clinical Pathway|
79307757|NCT02453282|Biological|MEDI4736 (Durvalumab)|
79336150|NCT04829695|Drug|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
79336151|NCT03035539|Other|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
79336152|NCT03035539|Other|Standard treatment|Standard treatment
79336153|NCT04821973|Device|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
79336154|NCT04821973|Device|usual monitoring|usual nurse respiratory monitoring
79336155|NCT04822207|Procedure|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
79336156|NCT03035695|Device|Axiostat®|
79336157|NCT03035695|Device|Cotton Gauze|
79652384|NCT05023369|Drug|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
79652385|NCT05022251|Procedure|Lumbar discectomy|surgically removing a hernia
79652386|NCT05020990|Device|Lens A (delefilcon A)|Daily disposable for one week
79652387|NCT05020990|Device|Lens B (stenfilcon A)|Daily disposable for one week
79982247|NCT03650036|Drug|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
79982248|NCT03298672|Drug|NDX-1017|Solution of NDX-1017 for subcutaneous injection
79982249|NCT03298672|Drug|Placebo|Placebo solution for subcutaneous injection
79982250|NCT04049162|Dietary Supplement|Blueberry Plus Exercise (BB-EX)|Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
79336158|NCT04822051|Other|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
79982251|NCT04049162|Dietary Supplement|Blueberry Placebo Plus Exercise (P-EX)|Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
79982252|NCT04489264|Drug|Transplant, Autologous|high dose chemotherapy followed by autologous stem cell transplantation
79982253|NCT03298594|Diagnostic Test|specific cervicograph|
79982254|NCT03286582|Drug|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
79982255|NCT03286582|Drug|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
79336159|NCT04821427|Behavioral|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
79652388|NCT05008055|Drug|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
79982256|NCT05202002|Behavioral|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
79336160|NCT04821583|Drug|Hydrocortisone|Hydrocortisone is orally administered.
79336161|NCT04821583|Drug|Placebo|Placebo is orally administered.
79982257|NCT05202002|Behavioral|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
79336162|NCT04834921|Device|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
79982258|NCT02460640|Procedure|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
79982259|NCT02460640|Procedure|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
79982260|NCT02460640|Drug|Morphine|
79982261|NCT02460640|Drug|Ropivacaine|
79982262|NCT03568760|Behavioral|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
79336163|NCT04829149|Other|Observational|Statin therapy group and Rosuzet tablet group
79487077|NCT04336436|Behavioral|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
79487078|NCT05456906|Other|No intervention|No interventions
79487079|NCT04336358|Other|Telemedicine|Telemedicine consultation online
79652389|NCT05001776|Procedure|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
79652390|NCT05001776|Drug|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
79982263|NCT03568760|Behavioral|Comprehension training|Reading and hearing comprehension
79336164|NCT01668355|Other|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
79336165|NCT01667731|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79336166|NCT01667731|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79336167|NCT05618119|Drug|[18F]MC225|[18F]MC225 PET scan
79336168|NCT04828759|Behavioral|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
79982264|NCT03298516|Drug|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
79487080|NCT04335266|Drug|SHR2554|SHR2554
79652391|NCT04981678|Drug|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
79487081|NCT05456438|Other|İntervention 1|Group 1 applied coconut oil to the nipple
79982265|NCT03298516|Drug|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
79982266|NCT03293446|Diagnostic Test|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
79982267|NCT04973228|Drug|ARQ-154 - Active|ARQ-154 Foam 0.3% - Active
79982268|NCT04973228|Drug|ARQ-154 Vehicle|ARQ-154 Foam - Vehicle
79982269|NCT03288298|Drug|luteolin|flavonoid natural extract
79982270|NCT03288298|Drug|nano-luteolin|nanoparticles of luteolin
79982271|NCT03298360|Other|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
79487082|NCT05456438|Other|İntervention 2|Group 2 applied tea tree oil to the nipple
79982272|NCT03298282|Other|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
79652392|NCT04981678|Drug|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
79652393|NCT04974710|Diagnostic Test|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
79652394|NCT04970901|Drug|Loncastuximab Tesirine|Intravenous (IV) infusion
79652395|NCT04970901|Drug|Polatuzumab Vedotin|IV infusion
79652396|NCT04970901|Drug|Glofitamab|IV infusion
79652397|NCT04970901|Drug|Mosunetuzumab|Subcutaneous (SC) injection
79652398|NCT04970901|Drug|Obinutuzumab|IV infusion
79652399|NCT04959526|Diagnostic Test|Shear-wave elastography|Ultrasound based imaging of diaphragm muscle activity
79487083|NCT04737824|Procedure|"An adaptation of the balloon-blowing exercise"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
79336169|NCT04828759|Behavioral|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
79487084|NCT04737824|Procedure|"An adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
79487085|NCT02743442|Device|da Vinci® Si™|
79487086|NCT02760277|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
79487087|NCT02760277|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
79487088|NCT02760277|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
79487089|NCT02760277|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
79487090|NCT02776904|Other|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
79336170|NCT04828525|Drug|Dexamethasone|adjuvant dexamethasone treatment
79487091|NCT02776904|Other|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
79652400|NCT04947397|Diagnostic Test|Pupillometry|Pupillometry prior to extubation
79336171|NCT04828525|Drug|normal saline|placebo
79336172|NCT04821505|Behavioral|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
79336173|NCT04821505|Behavioral|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
79652401|NCT04940013|Drug|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
79652402|NCT04929249|Drug|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
79652403|NCT04926779|Diagnostic Test|Biozek Covid-19 Antigen Rapid Test (Saliva)|Self-collection of nasopharyngeal and saliva samples and self test performance - Biozek Covid-19 Antigen Rapid Test (Saliva) and Biozek Covid-19 Antigen Rapid Test (Nasopharyngeal Swab). Both procedures are supervised by trained study personnel.
79982273|NCT03298282|Other|Coronary CTA|Coronary images by OCT and Coronary CTA and FFR values will be registered.
79982274|NCT03298282|Other|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
79307758|NCT02453282|Biological|MEDI4736 (Durvalumab)+Tremelimumab|
79487092|NCT02776904|Other|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
79487093|NCT02776904|Other|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
79487094|NCT02744534|Drug|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
79487095|NCT02744534|Procedure|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
79982275|NCT05170802|Other|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
79982276|NCT03298126|Procedure|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
79982277|NCT05160740|Drug|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
79982278|NCT03286192|Behavioral|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
79652404|NCT04924270|Biological|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
79652405|NCT04924270|Other|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
79982279|NCT05073614|Genetic|immunohistochemical detection of Heparanase in chronic gastritis|immunohistochemical detection of Heparanase in chronic gastritis specimens.
79982280|NCT03286036|Other|biomarkers|This is an observational study, there is no intervention
79982281|NCT03285802|Drug|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
79982282|NCT03285802|Drug|Everolimus|Everolimus 10mg daily q 28 days
79982283|NCT03293290|Drug|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
79982284|NCT03929822|Diagnostic Test|Contrast-Enhanced Spectral Mammography|A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
79982285|NCT04969796|Other|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
79982286|NCT02461264|Drug|Single red blood packed cells Transfusion|
79982287|NCT02461264|Drug|Two packed red blood cells Transfusion|
79982288|NCT03770780|Drug|SAGE-718|SAGE-718 in combination with Ketamine
79982289|NCT03770780|Drug|Placebo|Placebo in combination with Ketamine
79982290|NCT05130086|Drug|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
79982291|NCT05111210|Other|Blood sample|Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
79982292|NCT05111210|Other|Data collection|collection of socio-demographic, clinical and biological data.
79982293|NCT05111210|Other|skin biopsies|skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
79982294|NCT03285334|Device|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
79487096|NCT02744534|Procedure|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
79336174|NCT04835155|Procedure|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
79487097|NCT04335565|Other|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
79487098|NCT04335409|Diagnostic Test|Questionnaire|The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
79487099|NCT04335409|Other|Mobile Application|In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
79652406|NCT04916197|Drug|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
79982295|NCT03285334|Device|iRace files|rotary mechanical preparation
79982296|NCT03285256|Behavioral|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
79982297|NCT03285256|Behavioral|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
79982298|NCT03285256|Behavioral|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
79982299|NCT03297814|Biological|Platelet lysate|Intramuscular injection of platelet lysate
79652407|NCT04916197|Drug|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
79336175|NCT04828915|Other|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
79336176|NCT04828915|Other|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
79336177|NCT04427683|Behavioral|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
79487100|NCT00371852|Drug|lactoserum|
79652408|NCT04910269|Biological|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
79652409|NCT04910269|Other|Placebo|Infusion of 35 milliliters standard isotonic saline
79982300|NCT03297814|Biological|Placebo|intramuscular injection of normal saline
79982301|NCT03297736|Device|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
79982302|NCT03297736|Device|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
79982303|NCT05110274|Procedure|Overnight Metabolic Flexibility|Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
79652412|NCT04883008|Device|CorPath GRX with technIQ automated movements enabled (technIQ ON)|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist."
79982304|NCT05110274|Procedure|Clamp Metabolic Flexibility|Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m^2/min and two hours at an insulin dose of 80 mU/m^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
79982305|NCT02461186|Drug|Arterolane maleate-piperaquine phosphate (Synriam)|
79812514|NCT00803140|Procedure|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized."
79982306|NCT02461186|Drug|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
79812515|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
79982307|NCT04921670|Diagnostic Test|Infliximab Assay|Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
79982308|NCT03297658|Device|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
79982309|NCT03297658|Device|sham|Micro electrodes will be placed but there will be no stimulation
79982310|NCT03285100|Diagnostic Test|Venipuncture|"Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
79982311|NCT03285022|Procedure|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
79982312|NCT03292978|Dietary Supplement|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
79982313|NCT03292978|Dietary Supplement|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
79982314|NCT04488640|Procedure|Thyroid biopsy with ultrasound|Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
79982315|NCT03512210|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
79982316|NCT03512210|Other|Minimal Monitoring (MINMON) Strategy|"MINMON Strategy:~No pre-treatment HCV genotyping~Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~No scheduled on-treatment laboratory monitoring or clinic visits~Remote contact with participants at week 4 and week 22"
79336178|NCT04828213|Device|Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)|The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
79812516|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
79982317|NCT03284944|Device|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
79982318|NCT03284944|Device|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
79307759|NCT02453282|Drug|Paclitaxel + Carboplatin|Chemotherapy Agents
79812517|NCT00803296|Other|Oral glucose tolerance test (OGTT)|
79812518|NCT00803296|Other|Isoglycemic intravenous glucose infusion|
79336179|NCT04828213|Device|Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance|The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
79982319|NCT03422276|Other|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
79982320|NCT03422276|Other|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
79336180|NCT04821193|Drug|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
79336181|NCT04821193|Drug|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
79336182|NCT04821037|Behavioral|ACT|Acceptance and Commitment Therapy
79652413|NCT04883008|Device|CorPath GRX with technIQ automated movements disabled (technIQ OFF).|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled."
79336183|NCT04820725|Diagnostic Test|Plantar pressure and gait|Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
79336184|NCT04828291|Behavioral|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
79336185|NCT04820803|Other|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
79982321|NCT02461108|Behavioral|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
79982322|NCT02461108|Behavioral|Tax|Frame the price difference as a 10% tax on less nutritious food items.
79982323|NCT02461108|Behavioral|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
79982324|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
79982325|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
79982326|NCT00383721|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
79336186|NCT04820803|Other|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
79652414|NCT04879732|Device|ACTIS|ACTIS Hip stem
79652415|NCT04854278|Other|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
79652416|NCT04822571|Other|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
79652417|NCT04822298|Drug|AMG 160|AMG 160 administered as an intravenous (IV) infusion
79982327|NCT00383721|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
79982328|NCT00383721|Drug|Placebo|Placebo MDI twice a day for 26 weeks
79652418|NCT04786184|Behavioral|CALM Breathing|CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.
79652419|NCT04786184|Behavioral|Traditional outpatient PR|"After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information."
79652420|NCT04781543|Drug|HZN-825 BID|300 mg oral tablets BID
79652421|NCT04781543|Drug|Placebo|Placebo BID
79982329|NCT03292822|Dietary Supplement|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
79982330|NCT03292822|Drug|Paclitaxel|chemotherapeutic drug
79652422|NCT04781543|Drug|HZN-825 QD|300 mg oral tablets QD
79652423|NCT04773158|Behavioral|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
79652424|NCT04756037|Drug|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
79652425|NCT04729907|Drug|Nusinersen|Administered as specified in the treatment arm
79652426|NCT04722250|Device|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
79652427|NCT04722250|Device|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
79336187|NCT03036787|Behavioral|family based intervention|behavioural advises to family for normal motor development
79652428|NCT04707248|Drug|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
79652429|NCT04707248|Drug|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
79982331|NCT03395288|Drug|D-Mannose|A total of 2 g D-mannose daily
79982332|NCT03297502|Drug|pimecrolimus cream 1%|
79982333|NCT03297502|Drug|Elidel (pimecrolimus) cream 1%|
79982334|NCT03297502|Drug|placebo|
79982335|NCT05067452|Other|Food support|Diabetes-tailored food support. Project Open Hand will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
79982336|NCT05067452|Other|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
79336188|NCT04834843|Other|Observational study, no intervention|Observational study, no intervention
79336189|NCT04827511|Other|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
79982337|NCT01334775|Procedure|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
79982338|NCT03292744|Drug|Alfacalcidol|alfacalcidol 0,5 mcg
79652430|NCT04703595|Genetic|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
79652431|NCT04690010|Procedure|Ambulatory tubeless PCNL|Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.
79336190|NCT04827667|Diagnostic Test|bronchoalveolar lavage|Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
79652432|NCT04690010|Procedure|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
79982339|NCT01329861|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
79652433|NCT04681105|Drug|Acetaminophen|Given PO
79652434|NCT04681105|Drug|Dexamethasone|Given IV
79336191|NCT04834609|Procedure|Injection of autologous adipose tissue in anal fistula|
79336192|NCT04834531|Drug|Zhuli capsule|This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
79336193|NCT04834531|Drug|Placebo|The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
79336194|NCT04834531|Other|Standard medical treatment|"Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks."
79652435|NCT04681105|Drug|Diphenhydramine|Given IV or PO
79982340|NCT04189978|Diagnostic Test|Clinical evaluation|The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.
79982341|NCT03035942|Drug|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
79982342|NCT03035942|Drug|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
79982343|NCT03035942|Drug|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
79982344|NCT04189354|Device|Transcranial direct current stimulation (t-DCS) device|t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
79336195|NCT04360135|Drug|Acetaminophen|Preemptive acetaminophen the day before surgery
79982345|NCT01334853|Other|No drug will be used|Biomarker
79982346|NCT01334853|Other|No drug will be used|Biomarker
79982347|NCT03386708|Procedure|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
79982348|NCT03386708|Biological|human umbilical cord mesenchymal stem cell|2 * 10^7 cells (2ml)
79336196|NCT04360135|Drug|Placebo|Preemptive placebo the day before surgery
79652436|NCT04681105|Biological|Flotetuzumab|Given IV
79652437|NCT04681105|Drug|Ibuprofen|Given PO
79652438|NCT04681105|Drug|Ranitidine|Given IV
79652439|NCT04668924|Procedure|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for < 45 Diopters (D) 7.2J/cm^2 will be used; for 45-50D 10J/cm^2 will be used; for > 50D 15 J/cm^2 will be used.
79652440|NCT04666467|Device|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
79982349|NCT02820519|Drug|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
79307760|NCT02453282|Drug|Gemcitabine + Cisplatin|Chemotherapy Agents
79652441|NCT04648709|Diagnostic Test|ELISPOT|measure of immune response by ELISPOT
79652442|NCT04648709|Diagnostic Test|QUANTIFERON|measure of immune response by QUANTIFERON
79652443|NCT04647890|Drug|FT011|Two x 100mg capsules once daily for 12 weeks
79652444|NCT04647890|Drug|FT011|Two x 200mg capsules once daily for 12 weeks
79652445|NCT04647890|Drug|Placebo|Two placebo capsules once daily for 12 weeks
79652446|NCT04642638|Drug|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
79652447|NCT04642638|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
79652448|NCT04642638|Drug|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
79652449|NCT04642638|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
79652450|NCT04634825|Biological|Enoblituzumab|Anti-B7-H3 antibody
79652451|NCT04634825|Biological|Retifanlimab|Anti-PD-1 antibody
79652452|NCT04634825|Biological|Tebotelimab|PD-1 X LAG-3 bispecific DART molecule
79336197|NCT04827823|Other|Retrospective evaluation of amalgam and composite restorations|Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
79652453|NCT04614974|Drug|Famotidine|Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
79336198|NCT04827589|Drug|Tirabrutinib|Tablets administered orally
79336199|NCT04827589|Drug|Placebo|Tablets administered orally
79336200|NCT04834687|Behavioral|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
79336201|NCT04834687|Behavioral|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
79336202|NCT04827277|Procedure|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
79982350|NCT01334931|Radiation|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
79336203|NCT04827277|Procedure|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
79652454|NCT04614974|Other|Speech Language Therapy|Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
79652455|NCT04609020|Device|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
79652456|NCT04609020|Drug|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
79652457|NCT04609020|Device|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
79652458|NCT04603482|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
79652459|NCT04603482|Behavioral|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
79652460|NCT04603482|Behavioral|Diversional Activites|An audiovisual format presenting 12 activities for adults including but not limited; crossword puzzles, reading, gardening, exercise, cooking/baking, board games, learning a new language, social activities, online games, etc.
79652461|NCT04590001|Device|MobiusHD|The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
79652462|NCT04585425|Behavioral|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
79982351|NCT01334931|Radiation|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
79307761|NCT02453282|Drug|Gemcitabine + Carboplatin|Chemotherapy Agents
79307762|NCT02453282|Drug|Pemetrexed + Cisplatin|Chemotherapy Agents
79307763|NCT02453282|Drug|Pemetrexed + Carboplatin|Chemotherapy Agents
79652463|NCT04585425|Behavioral|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
79652464|NCT04583514|Behavioral|Control|Weight-stable Control group
79652465|NCT04583514|Behavioral|Overfeeding|30% Overfeeding group
79652466|NCT04540432|Other|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
79336204|NCT02605837|Drug|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
79336205|NCT02605837|Drug|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
79336206|NCT04820569|Procedure|Resection and chemotherapy|
79982352|NCT02460250|Procedure|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
79982353|NCT01332591|Procedure|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
79982354|NCT02616146|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
79982355|NCT02616146|Drug|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
79982356|NCT01332669|Procedure|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
79982357|NCT03297268|Other|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
79652467|NCT04540432|Diagnostic Test|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
79982358|NCT03107806|Device|OptiScanner®|"Glucose monitoring by OptiScanner® for 48 h~Glucose lowering intervention (insulin) guided by OptiScanner®"
79652468|NCT04522271|Other|Resistant Starch|7.5 g resistant starch/m2 oral consumption
79652469|NCT04522271|Other|Placebo|Placebo oral consumption of food-grade cornstarch
79982359|NCT04050800|Drug|Carbon 11 Butanol|Two sequential administrations of a PET tracer
79307764|NCT02453282|Biological|Tremelimumab|
79336207|NCT05619133|Device|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~a presence sensor~ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
79336208|NCT04819789|Other|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
79652470|NCT04520607|Drug|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
79982360|NCT01332747|Drug|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
79982361|NCT01332747|Drug|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
79652471|NCT04520607|Drug|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
79982362|NCT01332747|Drug|Atorvastatin|atorvastatin 10 mgs once daily
79982363|NCT05098652|Behavioral|CuRB-IT|9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
79982364|NCT03472833|Drug|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
79336209|NCT04819789|Other|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
79336210|NCT04819789|Other|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
79336211|NCT04819789|Other|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
79336212|NCT04833985|Procedure|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
79982365|NCT03472833|Drug|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
79336213|NCT04827121|Procedure|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
79336214|NCT04827121|Procedure|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
79652472|NCT04520594|Other|Resistant Starch|7.5 g resistant starch/m2 oral consumption
79652473|NCT04520594|Other|Placebo|Placebo oral consumption of food-grade cornstarch
79652474|NCT04517435|Drug|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
79652475|NCT04517435|Drug|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
79652476|NCT04517435|Drug|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
79652477|NCT04517435|Drug|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
79982366|NCT03284554|Dietary Supplement|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
79982367|NCT03284554|Dietary Supplement|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
79982368|NCT03284554|Dietary Supplement|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
79652478|NCT04517435|Drug|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
79336215|NCT04820101|Drug|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
79336216|NCT04826887|Other|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
79336217|NCT04826887|Other|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
79336218|NCT04328311|Other|Watermelon Juice|500 mL watermelon juice (What a Melon), containing ~1 g of L-citrulline.
79336219|NCT04328311|Other|Water|500 mL low nitrate water
79336220|NCT04428463|Procedure|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
79336221|NCT04428463|Procedure|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
79336222|NCT04819633|Other|Determination of serum sestrin levels|Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
79336223|NCT04819867|Drug|Propolis|propolis is an extract derived from bee hives
79336224|NCT04819867|Drug|Gluma Desensitizer|Gluma is a desensitizer agent
79336225|NCT04827043|Combination Product|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
79336226|NCT04827043|Combination Product|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
79336227|NCT02423343|Drug|Galunisertib|Administered orally
79336228|NCT02423343|Drug|Nivolumab|Administered IV
79336229|NCT04909515|Drug|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
79652479|NCT04517435|Drug|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
79336230|NCT04909515|Drug|GM-CSF|250 - 500 microgram/m2/day
79336231|NCT04909515|Drug|Isotretinoin|160 mg/m2/day
79652480|NCT04488133|Drug|Nusinersen|Administered as specified in the treatment arm.
79652481|NCT04473365|Other|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
79336232|NCT02605447|Drug|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
79336233|NCT02605447|Device|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
79336234|NCT05617729|Other|Saline applied via swab|sterile saline applied via swab
79336235|NCT05617729|Other|Povidone-iodine based gel|gel applied via swab
79336236|NCT02485899|Biological|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
79336237|NCT02485899|Device|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
79336238|NCT04362553|Device|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
79336239|NCT05619055|Other|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
79336240|NCT04818931|Drug|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
79652482|NCT04470011|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
79652483|NCT04470011|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
79982369|NCT03785288|Radiation|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
79336241|NCT02423109|Device|fanfilcon A|contact lens
79336242|NCT02423109|Device|enfilcon A|contact lens
79336243|NCT02420691|Other|Laboratory Biomarker Analysis|Correlative studies
79336244|NCT02420691|Other|Pharmacological Study|Correlative studies
79336245|NCT02420691|Drug|Ribociclib|Given PO
79336246|NCT02406651|Drug|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
79336247|NCT02406651|Drug|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
79336248|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
79336249|NCT02406261|Drug|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
79336250|NCT02406261|Drug|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
79336251|NCT02406261|Drug|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
79336252|NCT02406261|Drug|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
79336253|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
79652484|NCT04468399|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
79652485|NCT04468399|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
79652486|NCT04459299|Device|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
79982370|NCT03292354|Other|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
79812519|NCT03704064|Behavioral|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
79812520|NCT03704064|Behavioral|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants < 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are >10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
79982371|NCT01332825|Other|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
79336254|NCT04421001|Device|I-port use|patient will use I-port device fo 2 months
79652487|NCT04448054|Other|MRI|"Case 1: Routine care protocol not requiring injection~Realization of the non-injected MRI protocol adapted to the indication~+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~Realization of the injected MRI protocol adapted to the indication~Before gadolinium injection:~Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~After gadolinium injection:~Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~FABIR 0.9 3D sequence (+ 4 min)~3D sequence T1 TSE 0.7 (+ 2 min 30)~FLAIR HR coronal sequence (+ 3 min 30)~Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
79652488|NCT04443530|Drug|Ultimaster™ Tansei™ stents|Patients receiving Ultimaster™ Tansei™ stents
79336255|NCT04420767|Device|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
79487101|NCT04337125|Other|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
79487102|NCT02744846|Drug|Antibiotics exposure|
79487103|NCT02762071|Drug|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
79487104|NCT02762071|Drug|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
79487105|NCT05456282|Device|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
79487106|NCT05456282|Device|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
79487107|NCT04336891|Drug|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
79487108|NCT04336891|Drug|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
79487109|NCT04336891|Drug|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
79487110|NCT04336891|Drug|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
79487111|NCT05456048|Drug|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
79487112|NCT05456048|Drug|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
79487113|NCT05348707|Other|epidemiology|To review medical records to describe diagnosis and severity of the disease.
79487114|NCT05348707|Other|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
79487115|NCT02745626|Device|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
79487116|NCT02763865|Device|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
79982372|NCT03625232|Device|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
79982373|NCT03284476|Other|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
79982374|NCT01332903|Drug|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
79307765|NCT02435212|Drug|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use.
79307766|NCT02435212|Drug|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use
79487117|NCT02763865|Device|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
79487118|NCT04337528|Other|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
79487119|NCT04337528|Other|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
79336256|NCT04420767|Device|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
79487120|NCT04337528|Other|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
79982375|NCT03292276|Device|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
79336257|NCT04420767|Behavioral|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
79336258|NCT02405091|Drug|NBI-98854|
79336259|NCT02485353|Drug|Vosaroxin and Cytarabine|
79982376|NCT01335087|Other|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
79336260|NCT02603107|Drug|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
79336261|NCT02603107|Drug|ATV|300 mg capsule administered orally once daily with food
79336262|NCT02603107|Drug|DRV|800 mg tablet administered orally once daily with food
79336263|NCT02603107|Drug|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
79487121|NCT02746406|Device|Peritron+|Peritron+ device to measure intravesical pressure
79812521|NCT00824564|Drug|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
79336264|NCT02603107|Drug|ATV/co|300/150 mg FDC tablet administered orally once daily with food
79336265|NCT02603107|Drug|DRV/co|800/150 mg FDC tablet administered orally once daily with food
79336266|NCT02603107|Drug|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
79336267|NCT02603107|Drug|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
79336268|NCT02603107|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
79336269|NCT04826263|Other|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
79336270|NCT04826263|Other|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
79487122|NCT04337918|Drug|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
79652489|NCT04421950|Dietary Supplement|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
79652490|NCT04421950|Dietary Supplement|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
79652491|NCT04418596|Radiation|bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)|low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
79812522|NCT00824564|Procedure|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
79336271|NCT04826263|Other|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
79336272|NCT02484729|Drug|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
79336273|NCT02484729|Drug|Placebo, oral suspension|Matching placebo
79336274|NCT02484729|Drug|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
79336275|NCT02601625|Drug|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
79336276|NCT02601625|Drug|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
79336277|NCT02601625|Drug|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
79336278|NCT02601625|Drug|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
79336279|NCT02601625|Drug|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
79336280|NCT02601625|Drug|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
79336281|NCT04819087|Behavioral|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
79336282|NCT04819165|Other|COVID-19|Impact of covid-19 on infections associated with health care devices.
79336283|NCT04819321|Device|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
79336284|NCT03036553|Other|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
79336285|NCT04834141|Other|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
79336286|NCT04826497|Drug|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
79336287|NCT04826497|Drug|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
79336288|NCT04834219|Procedure|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
79336289|NCT04834219|Procedure|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
79336290|NCT04819243|Drug|Pabociclib, Endocrine, Talazoparib, Atezolizumab|"Palbociclib 125mg~AI~GnRH agonist~Talazoparib~Atezolizumab"
79487123|NCT04337918|Drug|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
79487124|NCT02765269|Device|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
79812523|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
79336291|NCT04819243|Drug|Pabociclib, Endocrine, Talazoparib,|"Palbociclib 125mg~AI~GnRH agonist~Talazoparib"
79336292|NCT05618821|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
79982377|NCT01335087|Device|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
79982378|NCT03292120|Other|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
79336293|NCT04818619|Diagnostic Test|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
79336294|NCT02601469|Drug|DSXS|twice daily for 28 days
79336295|NCT05618743|Procedure|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
79487125|NCT02747186|Drug|Lidocaine|Intraoral maxillary field block
79812524|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
79982379|NCT01337427|Drug|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
79336296|NCT04826107|Drug|DP303c treatment|DP303c injection, every 3 weeks.
79336297|NCT04826107|Drug|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
79336298|NCT04826107|Drug|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
79336299|NCT04826107|Drug|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
79487126|NCT02766517|Drug|Capsaicin|Administered topically
79982380|NCT03283228|Diagnostic Test|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
79487127|NCT04335344|Other|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
79982381|NCT01335165|Drug|ALXN1102|Single Ascending Dose IV
79982382|NCT01335165|Drug|ALXN1103|Single Ascending Dose IV or SC
79982383|NCT02459938|Drug|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
79982384|NCT02459938|Drug|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
79982385|NCT04850313|Device|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
79982386|NCT03284164|Drug|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
79336300|NCT04826107|Drug|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
79336301|NCT04816435|Diagnostic Test|Ultrasound test|Ultrasound evaluation of airway
79336302|NCT05617417|Other|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
79336303|NCT02604589|Drug|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
79336304|NCT02604589|Procedure|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
79336305|NCT02604589|Drug|bupivicaine 0.25%|Low Dose analgesia
79336306|NCT02604589|Drug|bupivicaine 0.5%|High dose analgesia
79336307|NCT04825249|Procedure|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
79336308|NCT04825249|Procedure|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
79487128|NCT05348239|Drug|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
79812525|NCT00803374|Drug|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
79812526|NCT00803374|Drug|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
79336309|NCT04818307|Other|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
79487129|NCT02766673|Drug|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
79487130|NCT02766673|Drug|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
79487131|NCT05455736|Other|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
79487132|NCT05455580|Behavioral|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
79487133|NCT02766907|Device|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
79487134|NCT00372320|Genetic|Gene Transfer|
79652493|NCT04398537|Device|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
79487135|NCT00372320|Drug|AdhAQP1|
79487136|NCT00371930|Procedure|application of a dye suspension followed by a laser intervention|
79652494|NCT04398537|Device|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
79652495|NCT04392011|Drug|Midazolam HCl|Oral syrup, 2 mg/mL
79652496|NCT04392011|Drug|Dextromethorphan HBr|Oral liquid capsules, 15 mg
79652497|NCT04392011|Dietary Supplement|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
79812527|NCT00803374|Drug|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
79812528|NCT00803374|Drug|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
79487137|NCT02767609|Device|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
79487138|NCT00372008|Drug|Testosterone|
79336310|NCT04818307|Other|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
79336311|NCT02601001|Drug|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
79487139|NCT05348161|Procedure|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
79812529|NCT00803530|Drug|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
79982387|NCT01335243|Procedure|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
79982388|NCT03107728|Device|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
79982389|NCT03107728|Device|Conventional orthotic brace|Participants will use the standard of care orthosis
79982390|NCT01337583|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
79982391|NCT01337583|Other|Placebo|Vaginal Ring containing no drug substance
79652498|NCT04365569|Behavioral|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
79652499|NCT04329429|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
79652500|NCT04324294|Drug|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
79812530|NCT00803608|Device|TrueContour® Insole|Novel designed insole
79812531|NCT00803608|Device|Current standard of care insole|Current Medicare approved A5513 insole
79982392|NCT01337583|Drug|Dapivirine|
79982393|NCT03107962|Drug|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
79982394|NCT05094050|Drug|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
79982395|NCT03200457|Device|1,5 Tesla abdominal MRI|Measurement of the fat and iron
79336312|NCT02601001|Drug|Placebo|Matching placebo tablets
79652501|NCT04323046|Biological|Nivolumab|Given IV
79652502|NCT04323046|Other|Quality-of-Life Assessment|Ancillary studies, given in person or online
79336313|NCT04825405|Procedure|hand motor coordination in a sitting position after use TipStim Glove|The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
79487140|NCT05348161|Procedure|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
79487141|NCT05348161|Procedure|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
79487142|NCT05348161|Procedure|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
79487143|NCT05348161|Procedure|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
79652503|NCT04323046|Other|Questionnaire Administration|Ancillary studies, given in person or online
79812532|NCT00708188|Device|Multidetector raw CT|Multidetector raw CT
79812533|NCT00803764|Drug|Naproxen Tablets, 500 mg|
79982396|NCT03200457|Device|3 Tesla abdominal MRI|Measurement of the fat and iron
79982397|NCT02460406|Other|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching & walking so on).
79336314|NCT05618665|Other|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
79336315|NCT05618665|Other|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
79336316|NCT04818151|Drug|Warfarin|Warfarin treatment for VTE
79336317|NCT04818151|Drug|Apixaban|Apixaban treatment for VTE
79336318|NCT04817527|Drug|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
79336319|NCT05617339|Behavioral|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
79336320|NCT02604199|Drug|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
79336321|NCT02604199|Other|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
79336322|NCT02604199|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
79336323|NCT02604199|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
79336324|NCT02604199|Drug|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
79336325|NCT04807699|Other|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
79336326|NCT04817215|Drug|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
79336327|NCT04817059|Device|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
79652504|NCT04303260|Behavioral|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
79652505|NCT04298593|Device|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
79336328|NCT04816903|Diagnostic Test|Gyni|Vaginal discharge collection
79336329|NCT04816045|Procedure|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
79336330|NCT04816045|Procedure|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
79336331|NCT04816123|Drug|[14C]Donafenib|Each volunteers received a single 300 mg dose of [14C]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
79336332|NCT04807465|Device|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
79336333|NCT04807465|Device|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
79652506|NCT04288414|Diagnostic Test|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
79812534|NCT02611310|Other|No intervention|No intervention administered in this study.
79812535|NCT02553694|Other|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
79336334|NCT04807465|Device|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
79336335|NCT04807621|Biological|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
79336336|NCT04807621|Biological|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
79336337|NCT04807543|Drug|17-hydroxyprogesterone caproate|intramuscular injection weekly
79487144|NCT05348161|Procedure|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
79487145|NCT05349578|Diagnostic Test|swab RUT|rapid urease test using swab instead of biopsied tissue
79487146|NCT02973763|Drug|Alflutinib|
79487147|NCT04335734|Procedure|Nissen Fundoplication with wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures. Wrap was fixated to both diaphragmatic crura or to the body of stomach using two non-absorbable stitches on each side.
79487148|NCT04335734|Procedure|Nissen Fundoplication without wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures.
79652507|NCT04283604|Drug|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
79336338|NCT04807543|Drug|Castor Oil|intramuscular injection weekly
79336339|NCT05616559|Combination Product|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
79487149|NCT02767843|Device|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
79487150|NCT04337593|Drug|Basiliximab|20mg d1,8, repeated every 3 weeks
79487151|NCT04337593|Drug|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
79652508|NCT04273048|Other|Diet Intervention - Group 1|They will be provided with a Mediterranean diet plan.
79652509|NCT04273048|Other|Exercise Intervention - Group 1|They will be provided with an exercise plan to follow.
79336340|NCT04815811|Other|Blood collection|Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
79652510|NCT04271072|Other|No intervention|No intervention
79982398|NCT02460406|Other|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
79652511|NCT04250753|Other|Walking task|30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
79652512|NCT04242264|Other|Placebo|0.9% Sterile Normal Saline, USP
79652513|NCT04242264|Biological|Shigella sonnei strain 53G|1.5 x 10^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
79652514|NCT04242264|Biological|WRSs2|10^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
79652515|NCT04206852|Procedure|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
79652516|NCT04185038|Biological|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
79982399|NCT04891172|Biological|Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)|"Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant"
79982400|NCT03284086|Diagnostic Test|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
79982401|NCT03284086|Diagnostic Test|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
79982402|NCT03189303|Device|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
79982403|NCT03284008|Other|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
79982404|NCT03284008|Other|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
79652517|NCT04176939|Biological|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
79652518|NCT04170374|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
79652519|NCT04170374|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
79652520|NCT04168242|Device|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
79652521|NCT04168242|Other|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
79336341|NCT04815811|Other|Stool collection|Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
79336342|NCT04815655|Procedure|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
79336343|NCT02600845|Device|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
79336344|NCT04427995|Device|OMNI surgical system|GATT + viscodilation
79652522|NCT04148911|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
79812536|NCT02553694|Other|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
79812537|NCT02553694|Other|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
79982405|NCT03135249|Drug|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
79652523|NCT04148911|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
79652524|NCT04144933|Drug|Acetaminophen, Gabapentin|975 mg, 300 mg
79652525|NCT04144933|Drug|Acetaminophen, Gabapentin|975 mg, 300 mg
79652526|NCT04144933|Drug|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
79652527|NCT04144933|Drug|Dexamethasone, Ondansetron|6 mg, 4 mg
79336345|NCT04806997|Diagnostic Test|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
79652528|NCT04144933|Drug|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
79652529|NCT04144933|Drug|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
79652530|NCT04144933|Drug|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
79652531|NCT04130854|Drug|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~Short course radiation therapy 5 Gy x 5 days~Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~Leucovorin 400mg/m2 IV Day 1 of each cycle~5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
79652532|NCT04130854|Drug|mFOLFOX and Radiation Therapy 5Gy x 5 days|"Short course radiation therapy 5 Gy x 5 days~Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~Leucovorin 400mg/m2 IV Day 1 of each cycle~5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
79652533|NCT04124120|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
79812538|NCT02553694|Other|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
79982406|NCT03292042|Behavioral|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~Second part: 1 hour of physical activity (walk)"
79652534|NCT04124120|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
79652535|NCT04106258|Drug|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
79812539|NCT00704366|Drug|AZD0530|oral, tablet, once daily, dose will be variable
79812540|NCT00708266|Device|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
79812541|NCT00708266|Dietary Supplement|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
79812542|NCT00708266|Other|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
79812543|NCT00803842|Drug|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
79812544|NCT03700554|Device|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
79812545|NCT03700554|Procedure|Chest tube|Chest tube insertion
79982407|NCT01335321|Drug|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
79336346|NCT04798105|Behavioral|Effects of tDCS of dlPFC on Probabilistic Selection Task|Predictors of Probabilistic Selection Task Performance including anodal tDCS of dlPFC, eye blink rate, extraversion and impulsiveness
79652536|NCT04092673|Drug|eFT226|eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
79652537|NCT04092673|Drug|Sotorasib|Recommended dosage: 960 mg orally once daily
79336347|NCT04798183|Diagnostic Test|3-dimensional scan|Facial 3-dimensional scan according to posture
79336348|NCT04806763|Device|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
79336349|NCT04806763|Device|Control|Distance, single-vision glasses were used as control
79336350|NCT05617261|Other|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
79982408|NCT01335321|Drug|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
79982409|NCT03291964|Diagnostic Test|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
79982410|NCT03635697|Behavioral|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
79336351|NCT04797949|Drug|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
79982411|NCT03283774|Other|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
79982412|NCT03041805|Procedure|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
79982413|NCT03041805|Procedure|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
79336352|NCT04797793|Drug|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
79982414|NCT03041805|Procedure|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
79982415|NCT03041805|Procedure|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
79336353|NCT04797793|Drug|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
79336354|NCT04797793|Drug|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
79652538|NCT04092673|Drug|Fulvestrant|500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
79982416|NCT03041805|Procedure|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
79982417|NCT03041805|Procedure|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
79336355|NCT04806529|Drug|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
79652539|NCT04092673|Drug|Abemaciclib|Dose in combination with fulvestrant: 150 mg twice daily
79982418|NCT03041805|Device|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
79652540|NCT04092673|Drug|Trastuzumab|600 mg every 3 weeks
79982419|NCT03041805|Drug|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
79982420|NCT03291730|Behavioral|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
79982421|NCT03291730|Other|Art-therapy|May help reduce anxiety of receiving chemotherapy
79982422|NCT01333137|Drug|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
79982423|NCT01333137|Drug|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
79982424|NCT03283618|Behavioral|Video Conferencing Group|
79982425|NCT02459704|Procedure|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
79982426|NCT02459704|Device|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
79982427|NCT03041727|Other|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
79982428|NCT03041727|Other|Standard exercises protocol|Stretching and strengthening exercises
79982429|NCT02459626|Other|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
79982430|NCT01337817|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
79982431|NCT01337817|Other|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
79982432|NCT03282838|Drug|DFN-15 (fasted)|DFN-15 administered to fasted subjects
79982433|NCT03282838|Drug|DFN-15 (fed)|DFN-15 administered to fed subjects
79982434|NCT03282838|Drug|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
79982435|NCT01333293|Drug|injections|subcutaneous injections
79336356|NCT04806529|Drug|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
79336357|NCT04796857|Drug|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
79336358|NCT04796857|Drug|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
79336359|NCT04796623|Drug|TQB3616 capsules|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
79336360|NCT04796623|Drug|Fulvestrant injection|Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
79652541|NCT04082572|Biological|Pembrolizumab|Given IV
79652542|NCT04079751|Procedure|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
79652543|NCT04079751|Procedure|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
79812546|NCT00922246|Device|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
79487152|NCT04790864|Behavioral|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
79487153|NCT04790864|Behavioral|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
79652544|NCT04075266|Drug|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
79982436|NCT03291574|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
79336361|NCT04815421|Other|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
79982437|NCT03291574|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
79982438|NCT03282760|Biological|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
79982439|NCT04535440|Other|No intervention|No intervention
79982440|NCT04431466|Drug|Ivermectin|SOC plus different dosing regimens of Ivermectin
79982441|NCT04431466|Other|Standard of Care|Standard treatment for COVID-19
79982442|NCT03291418|Drug|ATB-346 OR Placebo|Comparison of gastrointestinal effects
79982443|NCT03291418|Drug|Naproxen sodium|Comparison of gastrointestinal effects
79982444|NCT03291262|Other|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
79982445|NCT03282526|Diagnostic Test|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
79982446|NCT02885181|Drug|GS-9876|One tablet administered orally once daily
79982447|NCT02885181|Drug|Filgotinib|Two tablets administered orally once daily
79336362|NCT04815421|Other|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
79336363|NCT04815265|Drug|Remimazolam|Remimazolam is used for sedation
79336364|NCT04815265|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation
79336365|NCT04796389|Other|Music|Preferred music of the participant administered using headphones.
79336366|NCT04806841|Behavioral|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
79812547|NCT00658528|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
79336367|NCT04806841|Other|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
79812548|NCT00658528|Drug|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
79812549|NCT02872974|Other|GDM|Exposure to GDM during fetal life
79812550|NCT03871426|Procedure|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
79812551|NCT00806104|Dietary Supplement|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
79812552|NCT00806104|Dietary Supplement|Maltodextrins|Dietary supplementation for 4 weeks
79812553|NCT00806338|Drug|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
79812554|NCT00806338|Drug|Placebo|
79982448|NCT02885181|Drug|GS-9876 placebo|One tablet administered orally once daily
79982449|NCT02885181|Drug|Filgotinib placebo|Two tablets administered orally once daily
79982450|NCT02885181|Drug|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
79982451|NCT03291184|Device|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
79812555|NCT04017052|Drug|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
79812556|NCT00806572|Drug|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
79812557|NCT00856583|Drug|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
79982452|NCT03291106|Diagnostic Test|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
79982453|NCT03291106|Diagnostic Test|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
79982454|NCT03291106|Diagnostic Test|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
79982455|NCT03291106|Diagnostic Test|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
79982456|NCT02459782|Procedure|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
79812558|NCT00856583|Drug|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
79812559|NCT00856349|Behavioral|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
79812560|NCT00803244|Drug|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
79982457|NCT02884089|Drug|Abemaciclib|Administered orally
79982458|NCT02884089|Drug|Metformin|Administered orally
79982459|NCT02884089|Drug|Iohexol|Administered intravenously (IV)
79982460|NCT02884089|Drug|Placebo|Administered orally
79982461|NCT04150354|Behavioral|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
79336370|NCT05616481|Procedure|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
79487154|NCT04737902|Procedure|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
79336371|NCT05616481|Procedure|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
79336372|NCT02599129|Drug|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
79336373|NCT02599129|Drug|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
79487155|NCT04336813|Other|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
79487156|NCT04707638|Other|No intervention used|No intervention used
79487157|NCT04337671|Other|Moderate intensity aerobic training|"The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks."
79487158|NCT04337047|Other|questionnaire assesment|questionnaire assesment
79487159|NCT05339581|Radiation|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
79812561|NCT00803244|Drug|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
79812562|NCT02608632|Device|Renal denervation guided by HFS|
79812563|NCT02608632|Device|Renal denervation as standard procedure|
79812564|NCT02614313|Procedure|Open breath test with fructose|Open randomised fructose 35g during breath test
79812565|NCT02614313|Procedure|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
79812566|NCT02614313|Procedure|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
79336374|NCT04796077|Other|Pop-Up Book|Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
79336375|NCT04806061|Drug|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH >7.5
79336376|NCT04806061|Drug|standard care|standard care
79812567|NCT02614313|Procedure|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
79812568|NCT02614391|Other|Active distraction using a tablet|Playing a videogame using a computer tablet
79812569|NCT02614391|Other|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
79812570|NCT05706558|Procedure|Esophagectomy|Esophagectomy
79812571|NCT04131803|Drug|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
79812572|NCT04131803|Drug|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
79812573|NCT02608008|Device|Data analysis|data parameters Analysis
79812574|NCT02608086|Behavioral|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
79336377|NCT04805749|Other|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~Cranial osteopathy techniques to address the vagus parasympathetic nerves."
79336378|NCT04814797|Other|Capnography data included in Lung Clearance Index measurement|Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
79652545|NCT04073225|Device|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
79652546|NCT04073225|Device|Hand Bike|The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
79336379|NCT04814641|Biological|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level < 1.55 mmol/L at any time between admission and the 5th day.
79652547|NCT04064112|Procedure|S-BLR|Surgery of slanted bilateral LR recession for CI-IXT patients
79812575|NCT02608086|Behavioral|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
79982462|NCT01315431|Drug|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
79812576|NCT02607852|Device|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
79982463|NCT03265054|Biological|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
79336380|NCT04814719|Drug|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
79336381|NCT04814719|Drug|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
79336382|NCT04795609|Other|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~Trunk control.~Orthostatism.~Walk training.~Aerobic exercises.~Muscle strengthening."
79336383|NCT04805905|Other|FACE-Q patient reported outcome|"As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment."
79336384|NCT04805827|Drug|Gabapentin|1 tablet contains 600 mg Gabapentin
79336385|NCT04805827|Drug|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
79336386|NCT04805359|Behavioral|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
79652548|NCT04064112|Procedure|C-BLR|Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
79652549|NCT04015765|Procedure|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
79652550|NCT04008797|Drug|E7386|E7386, tablets, orally.
79812577|NCT05753358|Other|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
79812578|NCT04014114|Other|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
79812579|NCT05753280|Drug|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
79812580|NCT02606370|Other|Unstable shoe|Wearing Unstable shoes during 1 month
79812581|NCT02606214|Drug|TBA-354|
79336387|NCT04805359|Behavioral|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
79812582|NCT02606214|Drug|TBA-354 Placebo|
79336388|NCT02596711|Drug|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
79336389|NCT02596711|Behavioral|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
79336390|NCT02596711|Other|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
79652551|NCT04008797|Drug|Lenvatinib|Lenvatinib, capsules, orally.
79652552|NCT03999229|Drug|SNO|S-nitrosylating agent (SNO) Inhalation
79652553|NCT03999229|Drug|Normal Saline|Normal Saline transfusion
79652554|NCT03999229|Drug|Red Blood Cell|Blood transfusion (RBCs)
79652555|NCT03994601|Drug|BMS-986288|Specified dose on specified days
79652556|NCT03994601|Drug|Nivolumab|Specified dose on specified days
79652557|NCT03994601|Drug|Regorafenib|Specified dose on specified days
79652558|NCT03978598|Drug|Etonogestrel|Immediate v. Standard insertion.
79652559|NCT03978598|Device|Nexplanon|Implant.
79336391|NCT02596711|Behavioral|Health Education and Handouts|Participants receive general health education and handouts.
79487160|NCT05339581|Combination Product|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
79487161|NCT05339581|Drug|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
79487162|NCT05339581|Drug|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
79487163|NCT05339581|Drug|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
79487164|NCT05339581|Drug|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
79812583|NCT04022148|Biological|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
79336392|NCT02596711|Behavioral|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
79487165|NCT04336579|Behavioral|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
79336393|NCT02596711|Behavioral|Counseling Sessions|Participants attend 3 counseling sessions during the study.
79336394|NCT04805281|Other|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
79336395|NCT04805281|Other|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
79336396|NCT05616403|Other|No intervention|This is an observational study without any intervention
79487166|NCT05335525|Device|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
79812584|NCT00804570|Drug|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
79336397|NCT04814251|Other|Observationnal cohort|data collection
79487167|NCT04064684|Drug|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
79487168|NCT04064684|Drug|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
79652560|NCT03969056|Behavioral|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
79652561|NCT03969056|Behavioral|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
79812585|NCT00804570|Drug|placebo|once daily, orally, 16 weeks
79812586|NCT05753124|Other|Observational|This is an observational study
79652563|NCT03951649|Drug|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
79652564|NCT03949855|Drug|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
79812587|NCT02606292|Procedure|Photoacoustic endoscopy|
79812588|NCT02606292|Procedure|Endoscopic ultrasound (standard of care)|
79812589|NCT02606292|Procedure|Endoscopic surgery (standard of care)|
79812590|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
79812591|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
79812592|NCT00824408|Drug|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
79336398|NCT04814485|Drug|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
79336399|NCT04288141|Other|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
79336400|NCT04280887|Device|MyPad|Ultrasound bed wetting alarm
79336401|NCT04280029|Device|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus). The drug coating is formulated with Sirolimus microspheres suspended in a phospholipid blend. The balloon catheter component of the SELUTION SLR™ DEB is a conventional single use, sterile, rapid exchange catheter to dilate vascular lesions. The semi-compliant balloon is inflated for 60 seconds (minimum of 30 seconds) to transfer the Sirolimus loaded microspheres to the target vessel wall. The balloon is then deflated and removed from the body.
79487169|NCT04064684|Device|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
79336402|NCT04280029|Device|Control|The treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices
79336403|NCT04262401|Behavioral|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
79652565|NCT03949855|Drug|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
79336404|NCT04262401|Behavioral|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
79336405|NCT04795063|Procedure|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
79487170|NCT05334199|Device|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
79487171|NCT05325385|Other|There are no interventions - this is a database study only|There are no interventions - this is a database study only
79487172|NCT04715906|Behavioral|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
79487173|NCT02192190|Drug|LY2951742|Administered subcutaneously (SC)
79652566|NCT03949855|Drug|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
79652567|NCT03920267|Drug|BMS-986165|Specified dose on specified days
79652568|NCT03918915|Drug|SYD-101 Dose 1|Sterile topical ophthalmic solution
79487174|NCT02192190|Other|Placebo- oral|Administered orally
79487175|NCT02192190|Other|Placebo - SC|Administered SC
79652569|NCT03918915|Drug|SYD-101 Dose 2|Sterile topical ophthalmic solution
79487176|NCT02192190|Drug|Celecoxib|Administered orally
79487177|NCT02748889|Drug|Carboplatin|Standard chemotherapy
79487178|NCT02748889|Drug|Etoposide|Standard chemotherapy
79487179|NCT02748889|Biological|MPDL3280A|Experimental biologic
79487180|NCT02749201|Device|Gastrisail|Light Intensity and gastric wall thickness assessment
79487181|NCT05402228|Diagnostic Test|temporomandbular joint disorders|no intervention
79487182|NCT04334720|Other|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
79487183|NCT02224638|Device|TheraHoney HD|Honey
79487184|NCT02224638|Device|SkinTegrity|Hydrogel
79487185|NCT04334642|Other|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
79487186|NCT04690868|Drug|AD-213-A|1 tablet administered before the breakfast during 5 days
79487187|NCT04690868|Drug|AD-2131|1 tablet administered before the breakfast during 5 days
79652570|NCT03918915|Drug|Vehicle|Sterile topical ophthalmic solution without active ingredient
79652571|NCT03913455|Drug|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
79652572|NCT03913455|Drug|Carboplatin|Carboplatin AUC 4 IV Day 5
79652573|NCT03896945|Drug|Placebo|oral capsules
79652574|NCT03896945|Drug|AVP-786|oral capsules
79652575|NCT03894891|Drug|Nivolumab|Nivolumab is a type of immunotherapy.
79487188|NCT04654988|Drug|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
79487189|NCT04654988|Drug|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
79487190|NCT04654988|Drug|Placebo Prednisone|Placebo Prednisone
79487191|NCT04654988|Drug|Placebo Azathioprine|Placebo Azathioprine
79487192|NCT02749903|Drug|enzalutamide|oral
79652576|NCT03894891|Drug|Cisplatin|Cisplatin is a chemotherapy drug.
79487193|NCT04631432|Diagnostic Test|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
79652577|NCT03894891|Drug|Docetaxel|Docetaxel is a chemotherapy drug.
79652578|NCT03894891|Radiation|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
79652579|NCT03883490|Diagnostic Test|ECG|A 12-lead ECG will be taken for each participant.
79652580|NCT03883490|Diagnostic Test|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
79652581|NCT03883490|Diagnostic Test|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
79652582|NCT03883490|Diagnostic Test|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
79652583|NCT03883490|Diagnostic Test|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
79652584|NCT03883412|Other|Exercise|16 weeks of treatment
79652585|NCT03883412|Drug|Liraglutide|16 weeks of Liraglutide
79812593|NCT02611700|Drug|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
79336406|NCT04795063|Procedure|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
79652586|NCT03866707|Other|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
79812594|NCT02611700|Drug|Paclitaxel|175mg/m^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
79336407|NCT04804501|Device|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
79336408|NCT04804501|Other|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
79336409|NCT04814017|Procedure|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
79336410|NCT04814017|Procedure|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
79336411|NCT04804657|Dietary Supplement|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
79336412|NCT04804657|Dietary Supplement|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
79336413|NCT04804423|Drug|38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
79336414|NCT04804423|Drug|Sodium fluoride varnish (generic name; Duraphat®)|22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
79336415|NCT04804111|Drug|arm 0|placebo group
79336416|NCT04804111|Drug|arm 1|3 mg of the URC102 group
79336417|NCT04804111|Drug|arm 2|6 mg of the URC102 group
79336418|NCT04804111|Drug|arm 3|9 mg of the URC102 group
79336419|NCT04804111|Drug|arm 4|Febuxostat 80 mg
79336420|NCT04794673|Other|brain damage|Have or not have the brain damage and the location of the damage
79652587|NCT03866707|Other|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
79652588|NCT03866707|Other|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
79652589|NCT03864614|Drug|SAGE-217|SAGE-217
79652590|NCT03863080|Drug|RVT-1401|Subcutaneous administration of RVT-1401
79652591|NCT03863080|Drug|Placebo|Subcutaneous administration of Placebo
79812595|NCT02611700|Drug|Cisplatin|60mg/m^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
79812596|NCT02611700|Drug|Placebo|400mg,day1,weekly,until disease progression or toxicity
79812597|NCT05429840|Drug|MT1980|single dose
79812598|NCT05429840|Drug|Placebo|single dose
79652592|NCT03843723|Other|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
79652593|NCT03840837|Drug|Rivastigmine transdermal patch|Titration of transdermal rivastigmine, as per arm description.
79652594|NCT03834493|Biological|Pembrolizumab|IV infusion
79336421|NCT04794049|Drug|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
79652595|NCT03834493|Drug|Enzalutamide|Capsules/Tablets
79652596|NCT03834493|Drug|Placebo|IV infusion
79652597|NCT03827057|Behavioral|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
79652598|NCT03827057|Behavioral|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
79652599|NCT03820687|Other|Clinical Trial Educational Video|Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.
79652600|NCT03820687|Other|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
79652601|NCT03820687|Other|Low literacy booklet|A bilingual low-literacy booklet with educational content about clinical trials.
79336422|NCT04794049|Drug|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
79652602|NCT03820687|Other|Navigator|Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
79652603|NCT03818854|Biological|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
79812599|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
79812600|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
79812601|NCT00866333|Drug|Entinostat|Entinostat tablets
79336423|NCT04794127|Drug|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
79812602|NCT00834080|Drug|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
79336424|NCT04794127|Drug|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
79812603|NCT00823472|Drug|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
79812604|NCT04131569|Diagnostic Test|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
79812605|NCT04118699|Drug|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
79336425|NCT04804267|Drug|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
79336426|NCT04804267|Drug|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
79336427|NCT04804267|Drug|Placebo|Drug: Placebo orally once daily
79652604|NCT03818854|Biological|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
79336428|NCT04427059|Procedure|Transversus Abdominis Plane (TAP) block|"The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side."
79336429|NCT04427059|Procedure|Port-Site Infiltration (PSI)|The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
79336430|NCT04793971|Procedure|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
79336431|NCT04794439|Drug|Dentifrices|Dentifrice on plaque
79336432|NCT02596009|Device|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
79336433|NCT02596009|Device|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
79652605|NCT03808558|Drug|TVB-2640|TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
79652606|NCT03770416|Drug|Ibrutinib|Given PO
79652607|NCT03770416|Biological|Nivolumab|Given IV
79652608|NCT03762590|Other|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
79652609|NCT03762590|Other|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
79652610|NCT03729518|Radiation|Radiation Therapy (IMRT or IMPT)|"Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
79812606|NCT04118699|Drug|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
79812607|NCT00856193|Drug|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
79812608|NCT00856193|Drug|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
79812609|NCT00698087|Biological|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
79812610|NCT00698087|Biological|Engerix™-B|Intramuscular injection, 2 or 3 doses
79812611|NCT04130087|Drug|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
79812612|NCT04130087|Drug|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
79812613|NCT00652366|Drug|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
79812614|NCT00652366|Drug|Erlotinib, standard dose|100mg, PO, once daily
79812615|NCT00652366|Drug|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
79336434|NCT02596009|Device|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
79336435|NCT02590939|Device|CEFALY Active|Active external trigeminal nerve stimulation
79336436|NCT02590939|Device|CEFALY Placebo|Placebo external trigeminal nerve stimulation
79336437|NCT04793503|Other|conventional complete denture|the complete denture constructed by packing technique
79336438|NCT04793503|Other|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
79336439|NCT04793503|Other|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
79336440|NCT04793113|Other|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
79336441|NCT04813471|Drug|Endothelial Protocol|Endothelial Protocol
79336442|NCT04813393|Other|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
79336443|NCT04803175|Drug|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
79487194|NCT04631432|Behavioral|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino & Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
79487195|NCT02224560|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
79652613|NCT03681223|Device|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
79652614|NCT03681223|Device|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
79812616|NCT00841568|Drug|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
79812617|NCT00855959|Drug|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
79336444|NCT04803175|Drug|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
79336445|NCT04793347|Device|shock master (shock waves device)|device produces shock waves
79652615|NCT03681223|Procedure|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
79652616|NCT03681223|Procedure|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
79812618|NCT00855959|Drug|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
79812619|NCT00704600|Drug|nelfinavir|"Phase I:~take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~day 0: PET-CT~Phase II:~take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~day 7 biopsy~day 7, 21 and week 15 :PET-CT + perfusion CT"
79812620|NCT00699881|Drug|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
79812621|NCT00708578|Drug|Glimepiride|Once a day before breakfast
79812622|NCT00708578|Drug|Metformin|After breakfast and supper
79812623|NCT00708578|Drug|Insulin Glargine|Injection in the morning
79812624|NCT04130009|Procedure|Tourniquet use|Use of Tourniquet in The TKA
79812625|NCT00806650|Genetic|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
79812626|NCT00806650|Genetic|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
79652617|NCT03675282|Drug|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
79652618|NCT03675282|Drug|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
79652619|NCT03643861|Radiation|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
79652620|NCT03631043|Procedure|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
79652621|NCT03631043|Drug|Lenalidomide|Given PO
79652622|NCT03631043|Biological|Vaccine Therapy|Given personalized vaccine SC
79812627|NCT00806650|Diagnostic Test|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
79652623|NCT03613103|Device|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
79812628|NCT00806650|Other|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
79812629|NCT00806650|Other|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
79812630|NCT00841100|Drug|Kuvan|20mg/kg by mouth once daily
79487196|NCT02224560|Drug|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
79652624|NCT03613103|Device|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
79652625|NCT03609580|Drug|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
79652626|NCT03609580|Drug|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
79812631|NCT00841100|Other|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
79487197|NCT00372710|Drug|Zoledronic acid|
79487198|NCT02973776|Drug|LEO 90100 aerosol foam|
79487199|NCT02973776|Drug|Dermoval®/Dermovate®|
79487200|NCT02973776|Drug|Diprosone|
79487201|NCT02973776|Drug|Elocon|
79487202|NCT02973776|Drug|Locoid|
79487203|NCT02973776|Other|LEO 90100 foam vehicle|
79812632|NCT02614157|Procedure|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
79812633|NCT02614157|Device|labeled line|
79812634|NCT02552992|Behavioral|Yoga|
79812635|NCT02552992|Behavioral|Self-Directed Mind-Body Program|
79812636|NCT00704678|Drug|SBR759|1g tid
79487204|NCT02161458|Drug|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
79487205|NCT02161458|Drug|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
79487206|NCT02161458|Drug|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
79652627|NCT03602521|Other|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
79652628|NCT03584932|Behavioral|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
79487207|NCT02161458|Drug|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
79652629|NCT03583710|Drug|Cisplatin|Given IV
79652630|NCT03583710|Drug|Etoposide|Given IV
79652631|NCT03583710|Drug|Mitotane|Given PO
79652632|NCT03583710|Other|Quality-of-Life Assessment|Ancillary studies
79652633|NCT03564093|Drug|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
79336446|NCT04793425|Behavioral|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
79336447|NCT04351087|Device|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
79487208|NCT04336657|Other|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
79487209|NCT04336657|Diagnostic Test|IgG|Measure the past immunity of the disease (if possible)
79487210|NCT05144828|Device|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
79652634|NCT03564093|Drug|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
79652635|NCT03520101|Procedure|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is >18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
79652636|NCT03520101|Procedure|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
79652637|NCT03500991|Biological|HER2-specific chimeric antigen receptor (CAR) T cell|Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
79652638|NCT03483103|Biological|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
79336448|NCT04803253|Device|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
79982464|NCT03874546|Other|Questionnaire|"Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
79652639|NCT03482479|Drug|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
79652640|NCT03482479|Other|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
79652641|NCT03449108|Biological|Aldesleukin|Given IV
79652642|NCT03449108|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
79652643|NCT03449108|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Given IV
79652644|NCT03449108|Drug|Cyclophosphamide|Given IV
79652645|NCT03449108|Drug|Fludarabine|Given IV
79652646|NCT03449108|Biological|Ipilimumab|Given IV
79812637|NCT00704678|Drug|Sevelamer HCl|1.6 g tid
79982465|NCT03282448|Behavioral|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus & Miller, 2014).
79982466|NCT01335711|Drug|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)"
79982467|NCT01335711|Drug|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
79982468|NCT00092625|Drug|MK0653, ezetimibe|
79812638|NCT00704678|Drug|Sevelamer HCl|1.5 g tid
79812639|NCT00704678|Drug|Sevelamer HCl|0.8 g tid
79812640|NCT00804076|Biological|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
79652647|NCT03449108|Biological|Nivolumab|Given IV
79652648|NCT03449108|Other|Quality-of-Life Assessment|Ancillary studies
79652649|NCT03449108|Other|Questionnaire Administration|Ancillary studies
79812641|NCT00810160|Dietary Supplement|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
79982469|NCT00092625|Drug|Comparator: ezetimibe, placebo|
79982470|NCT04477863|Other|Follow-up Interview|Non Applicable
79982471|NCT01333371|Procedure|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
79652650|NCT03415685|Device|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
79652651|NCT03414242|Other|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
79652652|NCT03412747|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
79652653|NCT03412747|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
79652654|NCT03412747|Other|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
79652655|NCT03410992|Drug|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
79652656|NCT03410992|Other|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
79652657|NCT03394079|Procedure|PCI|Percutaneous Coronary Intervention
79652658|NCT03386396|Dietary Supplement|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
79652659|NCT03386396|Dietary Supplement|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
79652660|NCT03383445|Procedure|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).
79652661|NCT03383445|Procedure|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
79812642|NCT00810160|Dietary Supplement|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
79812643|NCT00810160|Dietary Supplement|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
79982472|NCT01333449|Drug|Decitabine|20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
79336449|NCT04803253|Device|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
79652662|NCT03383445|Procedure|Acurate neo|The TAVR procedure will be performed with the ACURATE neo aortic valve.
79982473|NCT02809677|Other|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
79336450|NCT04803253|Device|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
79336451|NCT04803253|Device|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
79336452|NCT04792723|Drug|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
79652663|NCT03383445|Procedure|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
79652664|NCT03370913|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
79652665|NCT03364660|Device|Epidural Stimulation|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord.
79652666|NCT03364660|Biological|Stand Training|Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame.
79336453|NCT04792723|Drug|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
79652667|NCT03348150|Procedure|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
79652668|NCT03348150|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
79652669|NCT03342404|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
79652670|NCT03342404|Other|Placebo|Placebo, Subcutaneous, every 21 days
79487211|NCT05144828|Drug|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
79652671|NCT03342404|Other|Best Supportive Care (BSC)|Best Supportive Care (BSC)
79652672|NCT03329599|Drug|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
79652673|NCT03277196|Drug|Ivacaftor|Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 96 Visit.
79652674|NCT03272698|Drug|Ketamine|IV Ketamine 0.50 mg/kg
79652675|NCT03272698|Procedure|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
79652676|NCT03235492|Device|SmartAlbu|"Plan:~Consent an individual~Measure and record temperature, blood pressure, heart rate, height and weight~Obtain two samples of saliva for the SmartAlbu portable salivary sensor~Take a venous blood sample for HbA1c and~Glycated albumin~Obtain blood sample from a finger stick for point of care HbA1c device"
79982474|NCT02789007|Other|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
79982475|NCT01333605|Drug|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
79982476|NCT05186103|Other|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
79812644|NCT00810160|Dietary Supplement|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
79982477|NCT05182515|Drug|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
79652677|NCT03231657|Diagnostic Test|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
79336454|NCT04813081|Procedure|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
79336455|NCT04427215|Other|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
79336456|NCT04813237|Other|n a|the participants are not subjected to any type of intervention
79652678|NCT03225482|Behavioral|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
79812645|NCT00708656|Drug|mesalazine (Asacol®)|800 mg tablets
79812646|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
79812647|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
79812648|NCT04118543|Other|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
79336457|NCT04427449|Biological|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10^6 cells/kg body weight
79336458|NCT04803487|Other|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
79487212|NCT05455255|Other|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
79487213|NCT02223858|Behavioral|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
79487214|NCT02223858|Behavioral|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
79982478|NCT05182437|Radiation|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12<= 10 cc reducing the risk on radionecrosis.
79336459|NCT04803487|Other|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
79487215|NCT04336501|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
79487216|NCT05041400|Other|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
79982479|NCT02881047|Device|CO2 Laser|Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
79982480|NCT02881047|Radiation|Ultrasound|Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
79982481|NCT02881047|Diagnostic Test|Skin Biopsy|standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
79982482|NCT05182281|Device|Whole Body Vibration and Infrared Therapy|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
79982483|NCT05182281|Device|Infrared Therapy|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
79982484|NCT05182281|Other|Classical Treatment|1000 mg Ca and 880 IU vitamin D treatment were given
79982485|NCT01337895|Other|Low dairy|No more than 1 serving per day
79982486|NCT01337895|Other|High dairy|4 or more servings per day
79982487|NCT01341717|Drug|Sitagliptin|100 mg once daily for 6 months
79982488|NCT01341717|Drug|Glimepiride|1 mg/2 mg/3 mg once daily
79982489|NCT01341717|Drug|Metformin|>=1000 mg twice daily
79336460|NCT04803097|Diagnostic Test||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
79982490|NCT01341717|Drug|Insulin|TDD > 10 IU once/twice daily
79982491|NCT03157089|Drug|Afatinib|Film-coated tablet
79982492|NCT03157089|Drug|pembrolizumab|Solution for infusion
79336461|NCT05616169|Device|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
79336462|NCT04812769|Device|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
79336463|NCT04812769|Other|Standard of Care|Standard of care will be delivered to the control home.
79336464|NCT04792333|Drug|firibastat|Single oral dose of 500 mg administration on Day 1
79487217|NCT02223390|Behavioral|Improving AIDS Care after Trauma (ImpACT)|
79487218|NCT05454865|Dietary Supplement|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
79487219|NCT05454865|Dietary Supplement|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
79487220|NCT04507646|Other|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
79487221|NCT04507646|Other|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
79487222|NCT02973841|Device|Sono-ease device|insertion of US guided IJV using sono-ease device
79487223|NCT04507022|Drug|Estradiol Valerate|2mg three times daily
79487224|NCT04507022|Drug|Progesterone|100 mg daily intramuscular
79487225|NCT04507022|Drug|Aromatase inhibitor|2.5 mg twice daily for 5 days
79487226|NCT00372788|Drug|AZD6244|oral vial
79487227|NCT00372788|Drug|Pemetrexed|oral
79487228|NCT04957316|Device|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
79487229|NCT02774941|Device|Jet Nebulizer|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
79487230|NCT02774941|Device|Vibrating Mesh Nebulizer|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
79487231|NCT04334018|Device|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
79982493|NCT03635541|Other|observational group of NAFLD|there's no intervention for patients for it is a observational study
79982494|NCT03158727|Biological|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
79982495|NCT03158727|Other|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
79982496|NCT01338051|Biological|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
79982497|NCT01338129|Dietary Supplement|vitamin c|1000 mg of vitamin c for 45 days
79982498|NCT01338129|Drug|placebo|placebo pills
79487232|NCT04334018|Device|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
79487233|NCT05253001|Device|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
79487234|NCT05441293|Procedure|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
79487235|NCT04759794|Diagnostic Test|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
79487236|NCT04336423|Diagnostic Test|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
79487237|NCT05211505|Device|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
79487238|NCT00372151|Dietary Supplement|L-Theanine|400 mg/day, caps.
79487239|NCT00372151|Other|Placebo|caps.
79487240|NCT04336267|Device|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
79487241|NCT04336267|Device|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
79487242|NCT00372476|Drug|Imatinib and Vinorelbine|
79487243|NCT04457492|Other|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
79487244|NCT04334096|Behavioral|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
79487245|NCT04737967|Drug|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
79487246|NCT04737967|Drug|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
79487247|NCT05350111|Behavioral|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
79487248|NCT03464630|Behavioral|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
79336465|NCT04803019|Combination Product|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
79336466|NCT04803019|Device|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
79336467|NCT04802785|Drug|Citicoline|Citicoline 500 mg (Vitaae®) per os
79982499|NCT05181969|Device|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
79982500|NCT05181969|Device|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
79336468|NCT04802785|Drug|Cytochrome C6|Cytochrome10 mg per os
79336469|NCT04802785|Drug|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
79336470|NCT04802785|Drug|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
79336471|NCT04802785|Drug|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
79336472|NCT04802785|Drug|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
79336473|NCT04802785|Drug|Domperidone Oral Product|Domperidone 1 tablet per os
79487249|NCT03464630|Behavioral|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
79487250|NCT04766918|Procedure|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
79487251|NCT04766918|Procedure|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
79487252|NCT04334564|Drug|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
79487253|NCT04334564|Drug|Placebos|Placebos were controls.
79487254|NCT04334551|Drug|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
79982501|NCT05181969|Device|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
79336474|NCT04802785|Drug|Simethicone|3-4 capsules per os
79487255|NCT04334785|Device|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
79487256|NCT03365414|Biological|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
79487257|NCT03365414|Drug|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
79487258|NCT00373022|Behavioral|exercise intervention|
79652679|NCT03225482|Behavioral|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
79812649|NCT04118543|Other|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
79982502|NCT05181969|Device|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
79982503|NCT05174481|Other|Early warning system for emergency department overcrowding|In this study, no interventions are performed.
79982504|NCT01315977|Dietary Supplement|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
79336475|NCT04802785|Drug|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
79336476|NCT04802785|Drug|Magnesium hydroxide|magnesium hydroxide 30 mg per os
79652680|NCT03213457|Drug|Estradiol/Norethindrone Acetate|Tablets
79652681|NCT03213457|Drug|Placebo for Elagolix|Tablet
79812650|NCT00913328|Drug|Montelukast (Singulair)|10 mg tablet once daily
79812651|NCT00913328|Drug|Placebo|Oral placebo once daily
79982505|NCT00092157|Drug|MK0733, simvastatin|
79982506|NCT00092157|Drug|Comparator: simvastatin|
79982507|NCT00089895|Drug|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG [coronary artery bypass graft]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
79336477|NCT04802785|Drug|Probiotic Formula|1 capsule per os.
79336478|NCT04802785|Drug|Melatonin 5 mg|Melatonin 5 mg per os.
79336479|NCT04802941|Device|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
79336480|NCT04802941|Drug|General practice|General practice
79336481|NCT02598193|Drug|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
79487259|NCT00373022|Other|flow cytometry|
79487260|NCT00373022|Other|laboratory biomarker analysis|
79487261|NCT00373022|Procedure|management of therapy complications|
79487262|NCT00373022|Procedure|psychosocial assessment and care|
79487263|NCT00373022|Procedure|quality-of-life assessment|
79487264|NCT05131399|Device|Phase A1|Plastic standard ankle foot orthosis
79487265|NCT05131399|Device|Phase B1|carbon medical device ankle foot orthosis
79487266|NCT05131399|Device|Phase A2|Plastic standard ankle foot orthosis
79487267|NCT05131399|Device|Phase B2|carbon medical device ankle foot orthosis
79652682|NCT03213457|Drug|Elagolix|Tablet
79652683|NCT03213457|Drug|Placebo for E2/NETA|Tablets
79652684|NCT03207503|Procedure|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
79652685|NCT03198078|Drug|Brexpiprazole (OPC-34712)|Once-daily, tablets
79812652|NCT00651820|Drug|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel."
79982508|NCT00089895|Drug|Placebo|intravenous; delivery to match eptifibatide to maintain blind
79982509|NCT01335945|Procedure|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
79336482|NCT02598193|Drug|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
79336483|NCT04791631|Procedure|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
79336484|NCT04791397|Procedure|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
79336485|NCT04791397|Procedure|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
79336486|NCT04802239|Other|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~State of calm at rest of 3 minutes.~Hypnotic induction by catalepsy of the eyes guided by breathing.~The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
79336487|NCT04802239|Other|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
79336488|NCT04802551|Other|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
79336489|NCT02595073|Drug|DSXS|Active treatment
79336490|NCT02595073|Drug|Placebo|Placebo treatment
79336491|NCT04791007|Drug|OB-002|vaginal or rectal administration
79336492|NCT04791007|Drug|Placebo|vaginal or rectal administration
79336493|NCT04802083|Biological|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
79336494|NCT02593825|Behavioral|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
79336495|NCT02593825|Behavioral|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
79336496|NCT04790929|Device|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
79652686|NCT03198078|Drug|Aripiprazole|Once-daily, tablets
79652687|NCT03198078|Drug|Placebo|Once-daily, tablets
79652688|NCT03190057|Device|BIOFREEDOM™ FAMILY stent|Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
79982510|NCT05166681|Procedure|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
79652689|NCT03181984|Drug|Hemoporfin|Hemoporfin mediated photodynamic therapy
79812653|NCT00651820|Drug|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
79812654|NCT02612168|Device|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
79982511|NCT05166291|Device|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
79812655|NCT04017208|Drug|ASP2713|Administered intravenously
79812656|NCT04017208|Drug|placebo|Administered intravenously
79336497|NCT04790929|Behavioral|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
79336498|NCT04802005|Other|Aerobic Interval Training|The aerobic interval training group
79982512|NCT05166291|Other|traditional anesthesia|local anesthesia applyed with dental syringe
79982513|NCT01341873|Other|educational intervention|Undergo APN FCI
79982514|NCT01341873|Other|psychosocial support for caregiver|Undergo APN FCI
79982515|NCT01341873|Procedure|quality-of-life assessment|Ancillary studies
79982516|NCT01341873|Other|questionnaire administration|Ancillary studies
79336499|NCT04790383|Other|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
79336500|NCT04790383|Other|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
79336501|NCT04790539|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
79336502|NCT04790149|Other|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
79336503|NCT04790149|Other|NEUROM + tDCS|NEUROM combined to tDCS
79336504|NCT04790149|Other|NEUROM|protocol to induce motor recovery
79336505|NCT04789993|Other|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
79336506|NCT04812301|Radiation|Egg-white sandwich|1 mCi of Tc-99m sodium phytate is added into the egg-white sandwich
79336507|NCT04812301|Radiation|Abbott Vital®|1 mCi of Tc-99m sodium phytate is added into the Abbott Vital®
79336508|NCT04427371|Other|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
79336509|NCT04812145|Radiation|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
79336510|NCT04801069|Device|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
79336511|NCT04426903|Other|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
79652690|NCT03165994|Drug|APX005M|APX005M intravenous (IV) infusion
79652691|NCT03165994|Radiation|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
79652692|NCT03165994|Drug|Paclitaxel|Paclitaxel IV infusion
79812657|NCT00804232|Behavioral|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
79982517|NCT01338441|Drug|Erythromycin|4mg/Kg, IV during 20 min once
79982518|NCT01338441|Drug|Placebo|4mg/Kg, IV during 20 min once
79982519|NCT01341951|Drug|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
79982520|NCT01336101|Device|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
79982521|NCT01338597|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
79982522|NCT01336179|Procedure|Salvadora persica|twice daily use, two minutes interval
79982523|NCT01336179|Procedure|Toothbrush|Twice daily use two minutes interval
79652693|NCT03165994|Drug|Carboplatin|Carboplatin IV infusion
79652694|NCT03165994|Procedure|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 10-16
79652695|NCT03145545|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
79652696|NCT03131817|Device|Activa PC+S Prefrontal|
79982524|NCT01342185|Device|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
79982525|NCT01342185|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
79982526|NCT01342185|Drug|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
79982527|NCT02714218|Biological|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
79982528|NCT02714218|Biological|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
79336512|NCT04426903|Other|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
79812658|NCT00866177|Other|Laboratory Biomarker Analysis|Correlative studies
79812659|NCT00866177|Drug|Selumetinib|Given orally
79336513|NCT04812223|Procedure|Delayed umbilical cord clamping|The umbilical cord will be clamped 60 seconds after the baby is born.
79336514|NCT04812223|Procedure|Early umbilical cord clamping|The umbilical cord will be clamped 15 seconds after the baby is born.
79336515|NCT04812223|Procedure|Milking of the umbilical cord|The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
79812660|NCT00804310|Drug|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
79336516|NCT04789759|Device|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
79336517|NCT04789759|Procedure|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
79336518|NCT04789525|Other|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
79336519|NCT04801147|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
79812661|NCT00804310|Drug|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
79982529|NCT02714218|Biological|Nivolumab 1 mg/kg IV|
79982530|NCT02714218|Biological|Ipilimumab 3 mg/kg IV|
79982531|NCT02714218|Biological|Nivolumab 6 mg/kg IV|A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to ~ 480mg.
79336520|NCT02388165|Biological|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
79336521|NCT02388165|Other|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
79336522|NCT04811755|Behavioral|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
79336523|NCT04800679|Drug|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
79487268|NCT03305588|Device|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
79487269|NCT03233594|Other|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
79812662|NCT04131101|Behavioral|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
79336524|NCT04800679|Drug|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
79336525|NCT04800679|Drug|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
79336526|NCT04811911|Radiation|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
79487270|NCT03233594|Other|Healthy Control Group|Participants will not receive any interventions.
79487271|NCT05107609|Behavioral|Acute Self-Compassion Intervention|Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
79487272|NCT04328558|Other|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
79336527|NCT04811911|Drug|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
79336528|NCT04789603|Other|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
79336529|NCT04789603|Other|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
79336530|NCT04789603|Other|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
79487273|NCT05350033|Device|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
79487274|NCT05350033|Device|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
79487275|NCT05350033|Device|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
79487276|NCT05350033|Device|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
79487277|NCT04247672|Device|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
79487278|NCT05456971|Device|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
79652697|NCT03105713|Other|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
79652698|NCT03069638|Drug|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
79812663|NCT00833924|Device|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
79812664|NCT04131257|Behavioral|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
79812665|NCT02614235|Device|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
79812666|NCT00840086|Drug|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
79812667|NCT04118777|Drug|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
79812668|NCT04129385|Procedure|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
79487279|NCT05456971|Device|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
79487280|NCT04737590|Device|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
79487281|NCT04737434|Device|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
79336531|NCT04789135|Drug|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
79336532|NCT04348669|Other|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
79336533|NCT04800445|Diagnostic Test|Salivary CRP|Salivary C reactive protein in neonatal sepsis
79336534|NCT02404545|Device|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
79487282|NCT04737434|Device|electromagnetic field with no wave|electromagnetic field with no wave
79487283|NCT05349877|Behavioral|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
79487284|NCT05349877|Behavioral|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
79487285|NCT05349877|Behavioral|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
79652699|NCT03069638|Drug|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
79652700|NCT03054584|Other|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
79652701|NCT02978118|Device|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
79652702|NCT02973594|Drug|Ivabradine|
79652703|NCT02973594|Drug|Placebo|
79652704|NCT02938442|Biological|P10s-PADRE with MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Paclitaxel|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions over a three-week period in combination with standard neoadjuvant chemotherapy.
79982532|NCT01342263|Behavioral|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
79982533|NCT05185869|Drug|SHR6390|SHR6390, Oral Administration
79982534|NCT05185869|Drug|Nab-paclitaxel|Paclitaxel-albumin, Intravenous Injection
79982535|NCT05185869|Drug|Gemcitabine|Gemcitabine, Intravenous Injection
79982536|NCT03154047|Drug|NEOD001|humanized monoclonal antibody
79336535|NCT04788979|Drug|Melatonin 5Mg Oral Tablet|"control without treatment~obese periodontitis patients treated only by scaling and root planning~obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
79336536|NCT04811209|Other|1.Baseline Measurements Before Surgery|"Baseline demographic data~Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~Preoperative pain state using NRS (0-10)~Preoperative functional state using the QoR-15 questionnaire~Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~Pain castastrophizing scale"
79336537|NCT04811209|Other|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
79336538|NCT04811209|Other|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
79487286|NCT02590640|Device|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
79487287|NCT02590640|Device|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
79652705|NCT02938442|Drug|Doxorubicin + Cyclophosphamide + Paclitaxel|Eligible subjects will be enrolled and receive standard neoadjuvant chemotherapy alone
79336539|NCT04811209|Other|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
79487288|NCT04233476|Drug|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg
79652706|NCT02924402|Biological|XmAb13676|Biological
79812669|NCT00708812|Drug|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
79336540|NCT04811209|Other|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
79336541|NCT04811209|Other|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
79336542|NCT04811209|Other|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
79336543|NCT04811209|Other|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
79336544|NCT04800211|Other|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
79336545|NCT04800211|Other|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
79336546|NCT04811443|Drug|Empegfilgrastim|Extimia®
79336547|NCT04810897|Other|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
79336548|NCT04788355|Drug|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
79812670|NCT00708812|Drug|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
79336549|NCT04788355|Drug|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
79336550|NCT04788355|Drug|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
79336551|NCT04788355|Drug|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
79336552|NCT04800289|Other|questionnaires|questionnaires about disease and satisfaction of patient
79336553|NCT02420379|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
79487289|NCT00371995|Drug|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
79812671|NCT04127747|Drug|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
79812672|NCT04127747|Drug|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
79812673|NCT00822926|Drug|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
79652707|NCT02923193|Device|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
79652708|NCT02923193|Drug|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
79652709|NCT02910531|Dietary Supplement|Alpha lipoic acid|Already mentioned in arm/group descriptions.
79652710|NCT02910531|Drug|Placebo|Already mentioned in arm/group descriptions.
79652711|NCT02883062|Drug|Atezolizumab|Given IV
79652712|NCT02883062|Procedure|Biospecimen Collection|Undergo collection of blood samples
79652713|NCT02883062|Drug|Carboplatin|Given IV
79652714|NCT02883062|Procedure|Lumpectomy|Undergo lumpectomy
79812674|NCT00822926|Drug|Saline|Subcutaneous injection of saline into scar tissue
79336554|NCT04799743|Drug|Resveratrol|Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
79336555|NCT04799743|Drug|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
79336556|NCT04788199|Other|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
79336557|NCT04788121|Drug|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
79336558|NCT04788121|Other|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
79336559|NCT04811053|Drug|HR021618|Treatment group A: HR021618 injection
79652715|NCT02883062|Procedure|Mastectomy|Undergo mastectomy
79652716|NCT02883062|Drug|Paclitaxel|Given IV
79652717|NCT02821286|Other|Observational study|Blood sampling
79652718|NCT02808650|Other|Laboratory Biomarker Analysis|Correlative studies
79652719|NCT02808650|Other|Pharmacokinetic (PK) study|Correlative studies
79812675|NCT00698555|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
79336560|NCT04811053|Drug|Placebo|Treatment group B: Saline injection
79336561|NCT04810819|Drug|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
79652720|NCT02808650|Drug|Prexasertib|Given IV
79652721|NCT02797548|Drug|Aspirin only|Aspirin only during surgery
79652722|NCT02797548|Drug|No antiplatelet therapy|No antiplatelet therapy will be during surgery
79652723|NCT02778997|Procedure|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
79652724|NCT02727803|Biological|Allogeneic Natural Killer Cell Line NK-92|Given IV
79652725|NCT02727803|Biological|Anti-Thymocyte Globulin|Given IV
79652726|NCT02727803|Drug|Busulfan|Given IV
79336562|NCT04810819|Drug|Placebo|Placebo
79336563|NCT04799509|Procedure|VATS lobectomy|VATS lobectomy
79652727|NCT02727803|Drug|Clofarabine|Given IV
79652728|NCT02727803|Drug|Cyclophosphamide|Given IV
79652729|NCT02727803|Drug|Fludarabine Phosphate|Given IV
79652730|NCT02727803|Other|Laboratory Biomarker Analysis|Correlative studies
79652731|NCT02727803|Drug|Melphalan|Given IV
79652732|NCT02727803|Biological|Rituximab|Given IV
79652733|NCT02727803|Radiation|Total-Body Irradiation|Undergo total body irradiation
79812676|NCT00698555|Biological|Engerix™-B|3-dose intramuscular injection
79812677|NCT00822770|Drug|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
79812678|NCT00822770|Drug|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
79982537|NCT02457676|Behavioral|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
79982538|NCT01338675|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
79982539|NCT03852862|Drug|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
79336564|NCT04810663|Radiation|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
79336565|NCT04810507|Drug|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
79336566|NCT04810585|Drug|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~Folinic acid: 400 mg/m2 IV infusion for over 2 hours~Irinotecan: 150 mg/m2 IV infusion for over 1 hours~5-FU: 400 mg/m2 IV bolus injection for over 5 minute~5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
79336567|NCT04787887|Drug|Abcertin|60IU/kg Single Intravenous Administration
79336568|NCT04787887|Drug|EU-sourced Cerezyme|60IU/kg Single Intravenous Administration
79336569|NCT04799041|Drug|GTX 2/3|There were 15 patients in this group. Each one received only one treatment.
79336570|NCT04799041|Drug|Placebo|There were 15 patients in this group. Each one received only one treatment.
79336571|NCT02347761|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
79336572|NCT02347761|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
79336573|NCT02347761|Drug|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
79336574|NCT04798807|Diagnostic Test|Nutritional screening|
79336575|NCT04798963|Procedure|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
79336576|NCT04798963|Procedure|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
79982540|NCT03852862|Drug|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
79336577|NCT04798729|Device|Digital Occlusal Recording with T-Scan|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the T-Scan (T-Scan III, version 9.1, Tekscan Inc., South Boston, USA).
79336578|NCT04798729|Device|Digital Occlusal Recording with Cerec Omnicam|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the CEREC Omnicam™ (version 4.2, Sirona Dental Systems, New York, USA).
79336579|NCT04787263|Biological|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10^6 CAR+ cells/kg.
79336580|NCT04810039|Other|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
79336581|NCT04809727|Procedure|Cervical biopsy|4 quadrant biopsy
79336582|NCT04798417|Dietary Supplement|Probiotic supplement|Use of a probiotic sachet
79336583|NCT04798417|Dietary Supplement|Prebiotic supplement|Prebiotic sachets
79336584|NCT04798417|Dietary Supplement|Maltodextrin|Placebo comparator
79336585|NCT04426747|Other|No intervention|No intervention
79336586|NCT04809649|Drug|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
79336587|NCT04354831|Biological|anti-SARS-CoV-2 convalescent plasma|"SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~Study drug will be administered as a single intravenous infusion"
79336588|NCT04787185|Radiation|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
79652734|NCT02727803|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplantation
79652735|NCT02676960|Other|MRI without sedation|
79652736|NCT02630693|Drug|Palbociclib 100mg|100mg PO daily
79652737|NCT02630693|Drug|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
79652738|NCT02630693|Drug|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
79652739|NCT02626338|Drug|Crenolanib|
79652740|NCT02626338|Drug|Mitoxantrone|
79652741|NCT02626338|Drug|Cytarabine|
79652742|NCT02626338|Drug|Etoposide|
79652743|NCT02626338|Drug|Fludarabine|
79652744|NCT02626338|Drug|G-CSF|
79652745|NCT02626338|Drug|Idarubicin|
79652746|NCT02622100|Device|Bioresorbable Vascular Scaffold|
79812679|NCT00822770|Drug|Fludarabine|Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
79336589|NCT04786795|Drug|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
79336590|NCT04786795|Drug|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
79336591|NCT04375189|Other|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
79336592|NCT04809337|Other|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
79336593|NCT04808635|Other|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
79652747|NCT02603146|Drug|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
79812680|NCT00822770|Drug|Busulfan|Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
79336594|NCT05614219|Other|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C > 4 mmol/L in persons under the age of 40, or LDL-C > 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
79982541|NCT01338753|Other|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.~The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.~The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
79336595|NCT04241575|Diagnostic Test|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
79336596|NCT02596945|Drug|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
79336597|NCT04761523|Behavioral|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
79336598|NCT04761523|Behavioral|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
79487290|NCT05456737|Other|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
79652748|NCT02603146|Drug|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
79652749|NCT02532621|Device|Venous InterGraft Connector|The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
79652750|NCT02532621|Procedure|sutured arterial anastomosis of an implanted vascular graft for hemodialysis|The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
79652751|NCT02532621|Procedure|hemodialysis|The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
79812681|NCT00822770|Procedure|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
79812682|NCT00822770|Drug|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
79812683|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
79487291|NCT04333940|Procedure|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
79336599|NCT04786483|Other|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
79336600|NCT04786327|Procedure|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
79336601|NCT04786327|Procedure|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
79336602|NCT04786327|Combination Product|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
79336603|NCT05614141|Device|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
79487292|NCT04335877|Other|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
79487293|NCT00372307|Drug|Application of pimecrolimus|
79336604|NCT05614141|Other|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
79487294|NCT04137133|Diagnostic Test|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
79336605|NCT04153435|Drug|Calcium Chloride|Calcium chloride 5 mmol
79487295|NCT04647110|Drug|crizotinib|as provided in real world practice
79487296|NCT04647110|Drug|alectinib|as provided in real world practice
79336606|NCT04153435|Drug|Sodium chloride 0.9%|Placebo
79336607|NCT04121845|Device|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
79336608|NCT04121845|Other|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
79336609|NCT02404389|Drug|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
79336610|NCT02404389|Drug|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
79336611|NCT01667419|Drug|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
79336612|NCT01667419|Drug|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
79336613|NCT04786015|Other|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
79487297|NCT04647110|Drug|brigatinib|as provided in real world practice
79487298|NCT04647110|Drug|ceritinib|as provided in real world practice
79487299|NCT04647110|Drug|lorlatinib|as provided in real world practice
79487300|NCT05455957|Other|exercise|neuromuscular and vestibulo-ocular training
79487301|NCT04061785|Other|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
79487302|NCT05455801|Device|negative preassure wound therapy|wound treated with negative pressure therapy dressing
79487303|NCT04061330|Drug|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
79487304|NCT04061330|Drug|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
79487305|NCT00372632|Drug|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
79487306|NCT00372632|Drug|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
79487307|NCT05455723|Procedure|Tracheal Intubation|Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
79487308|NCT05455645|Other|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
79812684|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
79336614|NCT04089709|Behavioral|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
79336615|NCT04808791|Drug|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
79336616|NCT04808791|Drug|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
79812685|NCT02611388|Device|fake stimulation|Patients were only attached electrodes without electric current
79336617|NCT04808791|Drug|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
79336618|NCT04808557|Other|Biorepair Total Protection|Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
79336619|NCT04808557|Other|Sensodyne Repair & Protect|Volunteers will use Sensodyne Repair & Protect for home oral hygiene for the following 30 days from the bonding procedure.
79487309|NCT04525352|Biological|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
79812686|NCT00822692|Drug|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
79812687|NCT00822692|Drug|placebo|matched placebo 2 pills PO BID x 7 days
79812688|NCT02612012|Radiation|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
79487310|NCT03991195|Dietary Supplement|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
79487311|NCT03991195|Dietary Supplement|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
79487312|NCT04821115|Device|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
79812689|NCT03260127|Behavioral|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
79812690|NCT03260127|Behavioral|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
79812691|NCT02607111|Drug|Dalteparin|
79812692|NCT00703196|Dietary Supplement|folic acid|Given orally once daily
79336620|NCT04808089|Other|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
79336621|NCT04808089|Other|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
79336622|NCT04785937|Diagnostic Test|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
79336623|NCT04785313|Biological|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
79336624|NCT04785313|Other|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
79336625|NCT04785235|Procedure|Non-Surgical Periodontal Therapy|
79336626|NCT04807855|Device|The cMLP device|There is only one medical device we are testing, so only one intervention.
79336627|NCT03843853|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
79336628|NCT03843853|Drug|S-1|S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14
79336629|NCT03843853|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg d1
79336630|NCT04784767|Biological|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
79336631|NCT04784767|Drug|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
79336632|NCT04784767|Biological|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
79487313|NCT04821115|Device|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
79487314|NCT04333693|Procedure|Vascular surgery|Open vascular, endovascular or hybrid procedures
79487315|NCT04809883|Diagnostic Test|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
79487316|NCT04792021|Drug|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
79487317|NCT05093413|Behavioral|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
79652752|NCT02484859|Drug|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
79652753|NCT02484859|Drug|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
79652754|NCT02484859|Drug|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
79812693|NCT00703196|Other|placebo|Given orally once daily
79652755|NCT02482870|Device|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
79652756|NCT02482870|Device|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
79652757|NCT02482168|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
79652758|NCT02452918|Drug|Oritavancin|Administered intravenously
79652759|NCT02452918|Drug|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
79336633|NCT04784611|Behavioral|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
79336634|NCT04337749|Drug|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
79336635|NCT04337749|Device|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
79336636|NCT04337749|Combination Product|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
79336637|NCT04337749|Device|Placebo socks|Placebo socks were given to patients for 2 weeks
79336638|NCT05054179|Drug|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
79336639|NCT05054179|Other|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
79336640|NCT05054179|Drug|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
79336641|NCT03688945|Procedure|Art Therapy|Attend art viewing sessions
79336642|NCT03688945|Other|Best Practice|Receive standard of care
79336643|NCT03688945|Other|Questionnaire Administration|Ancillary studies
79336644|NCT05612113|Behavioral|Live Supervision + Session Goal Formulation|"Read under Arms"
79336645|NCT05612113|Other|Session Goal Formulation|"Read under Arms"
79336646|NCT05014477|Procedure|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
79336647|NCT03679585|Other|Internet-Based Intervention|Undergo Talking Pictures social media intervention
79336648|NCT03679585|Other|Quality-of-Life Assessment|Ancillary studies
79336649|NCT03679585|Other|Questionnaire Administration|Ancillary studies
79336650|NCT04972825|Behavioral|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
79336651|NCT03588637|Other|No intervention|No intervention
79336652|NCT05472727|Other|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
79336653|NCT05472727|Other|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
79336654|NCT05472571|Other|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
79336655|NCT03529669|Device|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
79336656|NCT05472493|Biological|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, ~3 mm). CETO (~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from ~0-90 minutes.
79336657|NCT02588833|Drug|Pegcetacoplan|Complement (C3) Inhibitor
79336658|NCT05472415|Other|cognicise|"a combination of cognition and exercise training"
79336659|NCT05472415|Device|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
79652760|NCT02431507|Device|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
79652761|NCT02412787|Drug|Idursulfase-IT|Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (>8 months to 30 months of age) and 10 mg (>30 months to 3 years of age).
79336660|NCT04884373|Diagnostic Test|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
79487318|NCT03905629|Other|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay >15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
79487319|NCT04334161|Combination Product|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
79487320|NCT04978285|Other|Anemia|Depends on Day 3 Hb result
79652762|NCT02412787|Drug|Elaprase|Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
79652763|NCT02379520|Genetic|HPV Specific T Cells|"Dose escalation study with 5 dose levels: DL1-1×10^7 cells/m2, DL2-3×10^7 cells/m2, and DL3-1×10^8 cells/m2, DL4- 2 to 3×10^8 cells/m2, DL5- 0.8 to 1×10^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion & nivolumab & HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) & no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level."
79652764|NCT02379520|Drug|Cytoxan|500mg/m^2/day x 3 days (on days -4, -3 and -2)
79336661|NCT05613673|Other|No intervention - observational study only|No intervention - observational study only
79336662|NCT05472103|Behavioral|ergonomics surgical workshop|ergonomics surgical workshop
79487321|NCT04957303|Device|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
79487322|NCT00372463|Behavioral|6-week Online Diabetes Self-Management Educational Program|
79487323|NCT04926961|Device|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
79487324|NCT04926961|Device|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
79652765|NCT02379520|Drug|Fludarabine|30mg/m^2/day x 3 days (on days -4, -3, and -2)
79652766|NCT02379520|Biological|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
79652767|NCT02356653|Device|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
79812694|NCT00913250|Drug|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
79487325|NCT04737811|Other|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
79487326|NCT04540003|Other|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
79487327|NCT04333927|Drug|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
79487328|NCT04333927|Other|Observation|Patients in observation group will not receive any anti-cancer therapy.
79652768|NCT02342691|Drug|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
79982542|NCT01336257|Other|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
79336663|NCT05613595|Behavioral|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
79487329|NCT04333927|Procedure|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
79487330|NCT04333927|Radiation|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
79652769|NCT02342691|Drug|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
79652770|NCT02332902|Drug|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
79652771|NCT02324608|Biological|cetuximab|Given IV
79336664|NCT05613595|Behavioral|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
79982543|NCT03107650|Procedure|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
79336665|NCT05471869|Diagnostic Test|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
79487331|NCT04334005|Dietary Supplement|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
79487332|NCT04445233|Device|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
79487333|NCT00373009|Behavioral|Traditional Army training|As usual training for Soldiers
79487334|NCT00373009|Behavioral|Core stabilization exercise only|Core stabilization exercise
79487335|NCT00373009|Behavioral|Psychosocial education class only|Psychosocial education class
79652772|NCT02324608|Other|laboratory biomarker analysis|Correlative studies
79982544|NCT05185791|Other|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
79982545|NCT05185791|Other|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
79982546|NCT02457286|Drug|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
79982547|NCT02457286|Behavioral|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
79982548|NCT02457286|Device|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
79336666|NCT05613439|Procedure|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
79487336|NCT00373009|Behavioral|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
79487337|NCT00966914|Drug|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
79652773|NCT02323867|Device|Alpha Beta T cell depletion|
79652774|NCT02305654|Procedure|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
79652775|NCT02305654|Drug|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
79336667|NCT05613439|Procedure|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
79336668|NCT05613439|Procedure|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
79336669|NCT05471713|Other|Autonomic dysfunction|Autonomic dysfunction
79336670|NCT04789057|Drug|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
79336671|NCT04789057|Drug|Placebo|p.o., once daily
79336672|NCT05611723|Other|Exposure to disability|Disability status assessed by functional measures
79336673|NCT05611645|Radiation|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
79336674|NCT05611645|Drug|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
79336675|NCT05611567|Procedure|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
79336676|NCT05611567|Behavioral|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
79336677|NCT05611489|Procedure|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
79336678|NCT05611489|Procedure|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
79336679|NCT04426513|Other|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
79336680|NCT02977195|Drug|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
79487338|NCT00966914|Drug|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
79652776|NCT02305654|Drug|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
79652777|NCT02305654|Drug|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
79652778|NCT02305654|Radiation|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
79982549|NCT01342497|Drug|isoniazide|Tablets, dosing 3 times daily, 12 weeks
79982550|NCT01342497|Drug|placebo|tablets, dosing 3 times daily, 12 weeks
79336681|NCT04340167|Biological|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
79652779|NCT02305654|Procedure|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
79652780|NCT02229084|Biological|Chemovax - P10s-PADRE/ MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Docetaxel (or Paclitaxel)|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions over a three-week period.
79652781|NCT02213497|Radiation|18F-FDG (Fluorodeoxyglucose) PET|
79652782|NCT02213497|Drug|Carboplatin|
79652783|NCT02213497|Drug|Paclitaxel|
79982551|NCT03264976|Diagnostic Test|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
79336682|NCT02907697|Behavioral|Life Steps-Drug Use|
79982552|NCT03282370|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
79982553|NCT03282370|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
79336683|NCT02907697|Behavioral|General Health Education|
79336684|NCT02906215|Behavioral|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
79336685|NCT02835079|Drug|Tamoxifen|
79336686|NCT02474095|Other|Quality-of-Life Assessment|Ancillary studies
79336687|NCT02474095|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
79652784|NCT02153307|Device|Implantable loop recorders system Reveal ICM LINQ®,|
79336688|NCT05455567|Diagnostic Test|OCTA|Choriocapillary vessel density calculated with OCTA
79336689|NCT05446285|Other|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
79336690|NCT05436145|Behavioral|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
79336691|NCT01667107|Drug|Posaconazole|
79336692|NCT01667107|Drug|Calogen®|
79487339|NCT00505544|Behavioral|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
79652785|NCT02138721|Procedure|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
79652786|NCT02038660|Device|Balloon angioplasty|
79652787|NCT01897168|Device|No intervention|
79652788|NCT01800760|Dietary Supplement|Probiotics|Probiotics once a day for three weeks.
79336693|NCT04412239|Behavioral|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
79652789|NCT01750073|Drug|Cyclophosphamide|Given IV
79652790|NCT01750073|Drug|Doxorubicin Hydrochloride|Given IV
79652791|NCT01750073|Other|Laboratory Biomarker Analysis|Correlative studies
79652792|NCT01750073|Drug|Paclitaxel|Given IV
79652793|NCT01750073|Radiation|Radiation Therapy|Undergo RT
79336694|NCT02410213|Drug|Ferric Carboxymaltose (FCM)|
79336695|NCT04411615|Drug|Omega 3|rTG form Omega-3
79336696|NCT01802203|Device|truFreeze Spray Cryotherapy|spray cryotherapy
79336697|NCT04685551|Behavioral|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
79336698|NCT04638673|Device|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
79336699|NCT04638673|Device|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1&2 and active stimulation for weeks 3&4 of the stimulation portion of this study.
79336700|NCT05240131|Drug|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
79336701|NCT05240131|Drug|Placebo|Placebo is administered orally twice a day.
79336702|NCT05240131|Drug|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
79487340|NCT00505544|Device|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
79487341|NCT04430959|Drug|Candesartan|Candesartan 4 mg, tablets, orally, once daily for 4 weeks
79487342|NCT04430959|Drug|Placebo|Candesartan placebo-matching tablets, orally, once daily for 4 weeks
79652794|NCT01750073|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
79652795|NCT01750073|Biological|Trastuzumab|Given IV
79652796|NCT01723774|Drug|PD0332991|
79336703|NCT05220943|Behavioral|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
79652797|NCT01723774|Drug|Anastrozole|
79652798|NCT01723774|Drug|Goserelin|
79652799|NCT01723774|Procedure|Surgery (standard of care)|-Breast and axillary lymph node surgery
79336704|NCT05475145|Procedure|Resin based sealing [RBS]|
79336705|NCT05614999|Other|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
79487343|NCT03821870|Diagnostic Test|Inditreat|Tumoroid formation and drug sensitivity analysis
79652800|NCT01723774|Procedure|Tumor biopsy|
79652801|NCT01674140|Drug|anastrozole|Given orally
79652802|NCT01674140|Drug|everolimus|Given PO
79652803|NCT01674140|Drug|exemestane|Given orally
79336706|NCT05188339|Drug|4% sodium citrate|"Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months."
79336707|NCT05188339|Drug|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
79487344|NCT03821870|Drug|Experimental drug|Second line treatment based on drug sensitivity analysis
79487345|NCT04430101|Procedure|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
79487346|NCT04430101|Procedure|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
79652804|NCT01674140|Drug|goserelin acetate|Given subcutaneously or intramuscularly
79652805|NCT01674140|Drug|letrozole|Given orally
79652806|NCT01674140|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
79652807|NCT01674140|Drug|tamoxifen citrate|Given PO
79652808|NCT01674140|Other|placebo|Given PO
79652809|NCT01433198|Other|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
79652810|NCT01356628|Drug|PD-0332991|PD-0332991, 125mg, 3 cycles
79652811|NCT01294072|Dietary Supplement|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
79652812|NCT01294072|Dietary Supplement|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
79487347|NCT04820413|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
79336708|NCT04393909|Behavioral|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
79336709|NCT04393909|Behavioral|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
79487348|NCT03045289|Behavioral|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
79336710|NCT04393909|Behavioral|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
79336711|NCT04393909|Behavioral|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
79487349|NCT04737655|Drug|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
79487350|NCT05063396|Procedure|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
79652813|NCT01294072|Other|No intervention|no treatment
79652814|NCT01087554|Drug|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
79982554|NCT01342575|Procedure|Intra-operative exposure maneuvers|"Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
79487351|NCT05063396|Procedure|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
79487352|NCT04737499|Behavioral|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
79487353|NCT05055752|Drug|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
79652815|NCT01087554|Drug|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
79652816|NCT01087554|Drug|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
79982555|NCT01338831|Drug|LFA102|
79336712|NCT05474911|Device|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
79336713|NCT05474911|Other|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
79336714|NCT05614765|Drug|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
79336715|NCT05613127|Biological|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
79336716|NCT05613127|Biological|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
79336717|NCT05610865|Other|Control; Standard-of-care management|Patients will undergo conventional wound care management.
79487354|NCT05042492|Device|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
79652817|NCT01087554|Drug|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
79487355|NCT05441059|Drug|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
79336718|NCT05610865|Biological|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone & inside of wound surface bed.
79336719|NCT05610865|Biological|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
79336720|NCT05610865|Biological|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
79487356|NCT00373100|Drug|Zinc acetate|
79487357|NCT00373100|Drug|Placebo|Placebo
79487358|NCT04223323|Dietary Supplement|Almonds|Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
79487359|NCT04223323|Dietary Supplement|Pretzels|Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
79652818|NCT01012817|Other|Laboratory Biomarker Analysis|Correlative studies
79652819|NCT01012817|Other|Pharmacogenomic Study|Correlative studies
79336721|NCT05134051|Device|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
79336722|NCT02590003|Drug|Carboplatin|
79336723|NCT02590003|Drug|Nab-paclitaxel|
79336724|NCT05474521|Device|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
79336725|NCT05614531|Genetic|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
79336726|NCT04131439|Diagnostic Test|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
79336727|NCT05474443|Other|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
79336728|NCT05474443|Other|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
79336729|NCT04116697|Other|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
79336730|NCT04116697|Other|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
79336731|NCT05474365|Other|Stepwise training|The protocol of stepwise training is mentioned in Detailed description in Study Description.
79336732|NCT05474209|Other|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
79336733|NCT05474053|Drug|Ticagrelor 90mg (Brilique)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
79336734|NCT05474053|Drug|Ticagrelor 90mg (Ticaloguard)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
79336735|NCT04027465|Dietary Supplement|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
79652820|NCT01012817|Other|Pharmacological Study|Correlative studies
79652821|NCT01012817|Drug|Topotecan Hydrochloride|Given IV
79652822|NCT01012817|Drug|Veliparib|Given PO
79652823|NCT00920582|Biological|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
79652824|NCT00920582|Drug|Placebo|IV dosing daily for 14 days repeated at Week 26
79652825|NCT00920582|Biological|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
79652826|NCT00920582|Biological|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
79652827|NCT00898638|Other|biologic sample preservation procedure|
79652828|NCT00898638|Other|medical chart review|
79812695|NCT00913250|Drug|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
79652829|NCT00867048|Drug|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
79336736|NCT05473819|Drug|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe [Tyco Healthcare, tyco.com] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
79336737|NCT05473819|Drug|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
79336738|NCT04842721|Drug|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
79336739|NCT04842721|Other|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
79336740|NCT05614375|Procedure|endoscopic surgery|transnasal endoscopic surgery
79652830|NCT00735423|Device|No intervention|IDE used for outcome measurement not intervention
79652831|NCT00616395|Device|No intervention|
79336741|NCT05612893|Other|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
79336742|NCT03882307|Drug|sofosbuvir and daclatasvir|oral tablets
79336743|NCT03858517|Device|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
79336744|NCT04803799|Other|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
79982556|NCT03282214|Behavioral|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
79487360|NCT04960748|Behavioral|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
79652832|NCT00568490|Procedure|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
79652833|NCT00568490|Procedure|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
79652834|NCT00439049|Drug|modafinil|400 mg daily
79652835|NCT00439049|Drug|d-amphetamine|60mg daily
79652836|NCT00439049|Drug|L-Dopa|800/200mg daily
79652837|NCT00439049|Drug|Naltrexone|50mg daily
79652838|NCT00254423|Drug|Dasatinib|Given PO
79487361|NCT04943510|Other|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
79652839|NCT00254423|Other|Laboratory Biomarker Analysis|Correlative studies
79982557|NCT05185635|Diagnostic Test|Neuropsychological testing|potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
79982558|NCT01336335|Device|CPAP|CPAP
79982559|NCT03590002|Device|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
79982560|NCT01338909|Drug|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
79982561|NCT01338909|Drug|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
79982562|NCT03264742|Other|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
79982563|NCT01342653|Other|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
79982564|NCT02458456|Other|Isometric resistance training|Isometric exercise using a hand dynamometer.
79982565|NCT03264820|Device|Laser Doppler|- Laser measurements at the level of each finger at 47 °C and at ambient temperature
79982566|NCT03264820|Device|Laser speckle|- Laser measurements at the forearm
79982567|NCT03264820|Behavioral|pain evaluation|Visual scale assesment pain
79336745|NCT04800601|Other|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
79336746|NCT04800601|Other|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
79982568|NCT03264820|Other|Blood pressure and heart rate|Measurement of blood pressure and heart rate
79982569|NCT03282136|Drug|Incretin Effect|The patients will receive incretins therapy.
79982570|NCT03282136|Device|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
79982571|NCT03156621|Drug|Alirocumab|Alirocumab SC Q2W
79336747|NCT04762771|Drug|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase > 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
79982572|NCT03156621|Drug|Placebo|Matching placebo SC Q2W
79982573|NCT03282058|Device|Silastic Stent|The silastic stent is a splint made of silicone.
79487362|NCT02973698|Other|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
79487363|NCT02973698|Other|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
79652840|NCT00254423|Other|Pharmacological Study|Correlative studies
79652841|NCT00254423|Other|Quality-of-Life Assessment|Ancillary studies
79652842|NCT00254423|Other|Questionnaire Administration|Ancillary studies
79652843|NCT04720092|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
79336748|NCT04339465|Behavioral|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
79336749|NCT04339465|Behavioral|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
79336750|NCT05466409|Other|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
79336751|NCT05466409|Other|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
79336752|NCT05466409|Other|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
79487364|NCT02973698|Other|Control|No intervention will do
79487365|NCT04209140|Drug|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
79487366|NCT00372541|Drug|ceftriaxone|
79487367|NCT04334486|Other|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
79487368|NCT04334473|Procedure|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
79487369|NCT04334473|Diagnostic Test|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
79652844|NCT04720092|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
79652845|NCT00221702|Drug|PegIntron|100 mcg SC/week for 36 months
79652846|NCT00221702|Drug|intron A|3mui TIWW SC for 18 months
79982574|NCT03264898|Device|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
79336753|NCT05466409|Other|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
79336754|NCT05466409|Other|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
79336755|NCT05466409|Other|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
79336756|NCT05466409|Other|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
79336757|NCT05466409|Other|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
79336758|NCT05466409|Other|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
79336759|NCT05466409|Other|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
79336760|NCT05614297|Diagnostic Test|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
79336761|NCT04754737|Other|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
79336762|NCT04754737|Other|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
79336763|NCT04754737|Procedure|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
79336764|NCT04705363|Behavioral|Dialectal Features Varied|Participants will randomized to interact with a VHA that speaks either Standardized American English, a low level of African American English, or a high level of African American English
79336765|NCT04705363|Behavioral|Video Intervention|Participants will randomized to either receive a video introduction from the voice actor or receive no introduction
79336766|NCT04705363|Behavioral|VHA with no voice|virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
79336767|NCT05612737|Procedure|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
79336768|NCT04608721|Other|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
79336769|NCT04426357|Drug|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
79336770|NCT04603417|Diagnostic Test|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
79487370|NCT03522740|Other|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
79487371|NCT04762381|Drug|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
79487372|NCT04762381|Other|Placebo|Saline
79487373|NCT01547468|Procedure|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
79487374|NCT01547468|Procedure|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
79487375|NCT04717687|Procedure|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
79487376|NCT04333628|Drug|chloroquine|oral treatment of chloroquine
79487377|NCT04333628|Other|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
79487378|NCT00373412|Biological|VCL CT02 pDNA vaccine|
79336771|NCT05421481|Other|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
79336772|NCT04580563|Drug|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
79487379|NCT00373412|Biological|Towne CMV vaccine|
79336773|NCT04580563|Drug|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
79487380|NCT03409328|Behavioral|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
79652847|NCT04615702|Diagnostic Test|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~Clinically (abdominal pain consistent with acute pancreatitis),~Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~Imaging criteria of acute pancreatitis"
79652848|NCT04615702|Device|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
79336774|NCT04481035|Drug|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
79487381|NCT02241967|Device|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
79487382|NCT02241967|Device|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
79652849|NCT04615702|Device|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
79652850|NCT04615702|Diagnostic Test|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
79652851|NCT04615702|Device|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
79487383|NCT02241967|Device|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
79812696|NCT02608554|Behavioral|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
79487384|NCT02241967|Device|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
79652852|NCT04615702|Drug|Ringer lactate|"The initial infusion rate for mild cases :~For patients without dehydration is (130-150mL/h).~In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~For patients without dehydration is (130-150mL/h).~In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~A mean arterial pressure of 65mmHg or more,~Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
79982575|NCT03281980|Other|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
79982576|NCT03281980|Other|Government Intervention (UCT+HE)|fgbfgjhgykghilk
79652853|NCT04615702|Combination Product|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
79982577|NCT03156543|Device|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
79982578|NCT03156543|Other|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
79652854|NCT04615702|Combination Product|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"Mild attack: no antibiotic prophylaxis administered.~Severe attack:~Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~Duration: Not more than 2 weeks~Antibiotics given:~Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~In case of pancreatic infection, Carbapenems ± metronidazole were given."
79812697|NCT02608554|Behavioral|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
79982579|NCT03264586|Drug|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~- EMLA cream was applied, 1 hour before the expected time of birth."
79982580|NCT03264586|Drug|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
79487385|NCT03315728|Other|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
79652855|NCT04615702|Dietary Supplement|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~The nutrition started with small amount and increased gradually over 16hrs~Infusion rate ꞊ Total caloric requirements / 16hrs"
79652856|NCT04615702|Device|nasogastric tube|in case of ileus or vomiting
79812698|NCT02612246|Drug|GLPG1972 single ascending doses|single dose, oral solution
79812699|NCT02612246|Drug|Placebo single dose|single dose, oral solution, matching placebo
79982581|NCT03264586|Procedure|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
79982582|NCT01342731|Drug|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
79982583|NCT03271996|Procedure|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
79982584|NCT03271996|Procedure|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
79336775|NCT04481035|Other|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
79336776|NCT02404311|Biological|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
79336777|NCT02404311|Biological|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
79336778|NCT02404311|Biological|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
79336779|NCT02404311|Biological|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
79336780|NCT03032107|Drug|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
79336781|NCT03032107|Drug|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
79336782|NCT02841163|Drug|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
79812700|NCT02612246|Drug|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
79812701|NCT02612246|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
79812702|NCT00914277|Drug|SAR407899|Oral administration
79812703|NCT00914277|Drug|Placebo|Oral administration
79812704|NCT00914277|Drug|Sildenafil|Oral administration
79812705|NCT00708968|Behavioral|FOCUS Program|Supportive, educative sessions with patients and spouses.
79982585|NCT01342809|Behavioral|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
79982586|NCT02459860|Behavioral|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
79336783|NCT02841163|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
79336784|NCT02841163|Procedure|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
79336785|NCT02841163|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
79336786|NCT02841163|Procedure|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
79336787|NCT05388175|Device|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
79336788|NCT05388175|Device|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
79336789|NCT05700955|Drug|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
79336790|NCT01650519|Drug|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
79336791|NCT01650519|Drug|IV ketorolac|30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) administered intravenously over no less than 15 seconds
79336792|NCT01650285|Drug|Cabazitaxel|"Dose Level Day 1, 22, 43~5.0 mg/m2~10.0 mg/m2~15.0 mg/m2~20.0 mg/m2"
79336793|NCT05612503|Other|Traditional physical therapy program|resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
79812706|NCT00704756|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
79812707|NCT00704756|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg : 800 mg, 65 - 85 kg : 1000 mg, >85 kg : 1200 mg) orally for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
79812708|NCT00806442|Drug|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
79812709|NCT00806442|Dietary Supplement|Corn Oil|9 g/day of corn oil
79982587|NCT02459860|Behavioral|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
79812710|NCT02606955|Device|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
79336794|NCT05612503|Other|Virtual reality-based exercises|Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
79336795|NCT02347527|Behavioral|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
79336796|NCT02347527|Behavioral|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
79982588|NCT01339065|Drug|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
79982589|NCT02460016|Drug|AK0529|AK0529 pellets for oral administration
79982590|NCT03281746|Procedure|Dental Procedure|Undergo dental examination
79336797|NCT02197039|Drug|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
79336798|NCT02197039|Procedure|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
79336799|NCT05557903|Biological|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
79336800|NCT04335097|Device|Biosensors|Sensor that detect vital signs
79336801|NCT02386839|Drug|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
79336802|NCT01718041|Drug|Experimental: VRS-317|Active treatment arm
79336803|NCT05557669|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
79336804|NCT05347459|Drug|Dapagliflozin|usual and customary doses for type 2 diabetes management
79336805|NCT05347459|Drug|Empagliflozin|usual and customary doses for type 2 diabetes management
79336806|NCT05347459|Drug|Canagliflozin|usual and customary doses for type 2 diabetes management
79336807|NCT05347459|Drug|Sitagliptin|usual and customary doses for type 2 diabetes management
79336808|NCT05347459|Drug|Saxagliptin|usual and customary doses for type 2 diabetes management
79336809|NCT05347459|Drug|Linagliptin|usual and customary doses for type 2 diabetes management
79336810|NCT05347459|Drug|Vildagliptin|usual and customary doses for type 2 diabetes management
79336811|NCT05346445|Drug|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
79336812|NCT05346445|Drug|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
79982591|NCT03281746|Other|Educational Intervention (prevention education)|Receive prevention education
79982592|NCT03281746|Other|Interview|Ancillary studies
79982593|NCT03281746|Other|Survey Administration|Ancillary studies
79982594|NCT03281746|Other|Educational Intervention (one-on one education)|Receive one-on-one education
79982595|NCT05187507|Other|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
79982596|NCT05187507|Other|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
79982597|NCT05187507|Other|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
79982598|NCT05187507|Other|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
79982599|NCT01339143|Drug|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
79982600|NCT01339143|Drug|pioglitazone|15mg, QD, PO, 16 weeks
79487386|NCT02088931|Biological|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease <50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
79487387|NCT00373178|Drug|rosiglitazone|
79487388|NCT00373178|Drug|metformin|
79487389|NCT00373178|Drug|Anti-diabetic medications|
79487390|NCT03254732|Drug|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
79336813|NCT05334121|Dietary Supplement|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
79487391|NCT03254732|Drug|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
79487392|NCT04611451|Other|classic lumbar home exercise|classic lumbar home exercise
79652857|NCT04615702|Procedure|retroperitoneal necrosectomy|"General anesthesia , Supine position with 30 degree tilt towards the right side~A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~Then, aspiration is done from the possible collection.~After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
79812711|NCT00821678|Other|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
79336814|NCT05334121|Other|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
79336815|NCT05612269|Diagnostic Test|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
79336816|NCT05557201|Biological|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
79336817|NCT05557123|Device|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
79487393|NCT04611451|Device|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
79487394|NCT04611451|Other|Whole body vibration exercise|Whole body vibration exercise
79812712|NCT04112121|Behavioral|Meeting with a Chaplain coupled with Biblical Readings|
79812713|NCT02608242|Drug|YH22189|
79812714|NCT02608242|Drug|Twynsta 80/10mg|
79812715|NCT02608242|Drug|Crestor 20mg|
79487395|NCT02923466|Biological|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
79487396|NCT02923466|Biological|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
79487397|NCT01052168|Other|skills training|participants will train using different performance goals (based on different metrics)
79812716|NCT04111653|Other|Mud therapy|Application of sludge poultice
79812717|NCT02607696|Drug|Zolpidem Hemitartarate|
79982601|NCT03281434|Dietary Supplement|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
79487398|NCT00813566|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
79336818|NCT05557123|Device|conventional treatment|conventional treatment with rivoxaban
79487399|NCT00813566|Drug|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
79487400|NCT00813566|Drug|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
79487401|NCT00813566|Drug|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
79336819|NCT01649271|Drug|Herceptin|3-weekly
79982602|NCT03281434|Dietary Supplement|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
79487402|NCT03908359|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
79487403|NCT03908359|Procedure|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
79487404|NCT03879733|Behavioral|Thrive by Three|"The intervention consists of the following components:~Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~Feedback to group staff on 8 CLASS-quality dimensions~Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~Written material to parents, supervisors, and staff~Web page for staff and parents: tf3.no"
79487405|NCT03879733|Behavioral|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
79487406|NCT02885012|Drug|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
79487407|NCT04555915|Other|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
79487408|NCT02885246|Other|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
79487409|NCT03802435|Procedure|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
79487410|NCT03802435|Procedure|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
79487411|NCT03802435|Procedure|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
79487412|NCT05005663|Other|surgical management of incisional hernia|surgical repair of the incisional hernia
79487413|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
79487414|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
79487415|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
79812718|NCT00915057|Drug|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
79812719|NCT03556722|Device|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
79812720|NCT03556722|Device|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
79812721|NCT00839852|Drug|Cariprazine|Cariprazine was supplied in capsules.
79982603|NCT05185245|Procedure|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
79982604|NCT03271684|Other|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
79336820|NCT01649271|Drug|afatinib|at MTD level
79336821|NCT01649271|Drug|trastuzumab|3-weekly
79487416|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
79487417|NCT02885636|Drug|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
79982605|NCT03271684|Other|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
79982606|NCT05130411|Dietary Supplement|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
79336822|NCT01649271|Drug|Herceptin|weekly
79336823|NCT01649271|Drug|afatinib|at MTD level
79336824|NCT01649271|Drug|afatinib|escalating dose
79487418|NCT02885636|Other|Saline placebo|Saline inhaled through a nebulizer as a single dose
79336825|NCT05700877|Other|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
79336826|NCT05700877|Other|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
79336827|NCT05558917|Procedure|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
79336828|NCT05558917|Procedure|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
79652858|NCT04615702|Procedure|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
79652859|NCT04615702|Procedure|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
79812722|NCT02604849|Drug|Neomycin|
79336829|NCT05558839|Behavioral|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
79487419|NCT03691129|Behavioral|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
79487420|NCT03625921|Behavioral|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
79812723|NCT02604849|Drug|Streptomycin|
79812724|NCT02604849|Drug|Gentamicins|
79812725|NCT05632107|Device|TOF-Watch®；DELSYS® Wireless surface EMG|TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.
79982607|NCT03264430|Drug|Ketamine|an antagonist of the NMDA receptor
79487421|NCT03625921|Behavioral|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
79487422|NCT00373087|Drug|entacapone|entacapone
79487423|NCT00373087|Drug|l dopa versus placebo|l dopa versus placebo
79487424|NCT02892110|Drug|Varenicline|2 mg daily
79812726|NCT00704834|Other|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
79982608|NCT03264430|Drug|bupivacaine|local anaesthetic
79336830|NCT04334239|Other|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
79812727|NCT00709046|Drug|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
79812728|NCT00709046|Drug|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
79812729|NCT00833690|Drug|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
79982609|NCT01339221|Procedure|Stool samples|Stool samples collected and checked for the presence of rotavirus
79982610|NCT03269890|Procedure|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
79982611|NCT03269890|Procedure|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
79336831|NCT02385669|Drug|Ipilimumab|Checkpoint blockade inhibitor
79336832|NCT02385669|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
79336833|NCT05558683|Other|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
79336834|NCT02402907|Device|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
79336835|NCT02402907|Device|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
79336836|NCT05254093|Other|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
79487425|NCT02892110|Drug|Placebo|2 mg daily
79487426|NCT02778152|Device|Laser depilation|Laser depilation of natal cleft (pilonidal region)
79487427|NCT02779166|Drug|Celecoxib|Received 400mg celecoxib prior to surgery
79487428|NCT02779166|Drug|placebo|
79487429|NCT03597607|Behavioral|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
79812730|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
79812731|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
79812732|NCT00820898|Drug|Gemcitabine Hydrochloride|Given IV
79982612|NCT03269812|Procedure|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
79982613|NCT01336725|Behavioral|Teaching life style changes|Single group: Teaching, group sessions, physical activity
79982614|NCT01336725|Other|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
79982615|NCT01336725|Other|Teaching|Morbid obesity group attend 40 hours of group sessions
79982616|NCT03270124|Behavioral|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
79982617|NCT03270124|Behavioral|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
79982618|NCT03270124|Behavioral|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
79982619|NCT01339377|Device|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
79336837|NCT05254093|Other|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
79336838|NCT02345889|Device|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
79652860|NCT04615702|Procedure|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
79652861|NCT04615702|Procedure|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
79652862|NCT04615702|Procedure|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
79336839|NCT02345889|Device|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
79336840|NCT02345889|Device|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
79336841|NCT02345889|Device|Standard Colonoscopy|Current standard of care colonoscopy
79336842|NCT05556421|Diagnostic Test|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
79336843|NCT04328623|Procedure|Hypnosis|"conversational hypnosis technique call the magic glove"
79336844|NCT04328623|Procedure|Infiltration|Ultrasound-guided hand infiltration
79336845|NCT02345811|Device|Sapphire|silicone-hydrogel contact lens
79336846|NCT02345811|Device|senofilcon A|contact lens
79336847|NCT05549869|Diagnostic Test|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
79336848|NCT05556109|Diagnostic Test|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
79487430|NCT03597607|Behavioral|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
79487431|NCT02898740|Behavioral|Structural exercise|Exercise instruction and encouragement
79487432|NCT02898740|Behavioral|Health education|Provision of general information about a variety of health topics
79487433|NCT00373165|Drug|Ganciclovir|
79487434|NCT02898974|Behavioral|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
79487435|NCT04400227|Other|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
79487436|NCT00372931|Drug|AL-37807|
79652863|NCT04615585|Other|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
79652864|NCT04615585|Procedure|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
79336849|NCT02586493|Drug|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
79487437|NCT02901080|Device|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
79487438|NCT02901080|Behavioral|Pregnancy test|- Pregnancy test x 1 (day 1)
79487439|NCT02901080|Other|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
79487440|NCT02901080|Other|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
79487441|NCT02901080|Other|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
79487442|NCT02901080|Other|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
79652865|NCT04615468|Drug|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
79982620|NCT03281356|Behavioral|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
79982621|NCT05250999|Other|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
79982622|NCT05250999|Other|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
79982623|NCT05250999|Other|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
79982624|NCT03281278|Other|standard treatment|standard medical treatment
79982625|NCT05250921|Procedure|Corticision|Corticision will be performed to enhance teeth alignment.
79487443|NCT02901080|Other|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
79487444|NCT02901080|Other|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
79487445|NCT04866589|Behavioral|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
79487446|NCT04333550|Drug|Deferoxamine|Intravenous infusion of Deferoxamine
79487447|NCT04737733|Other|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
79652866|NCT00221741|Drug|Fresh Frozen Plasma (blood product)|
79652867|NCT04615858|Dietary Supplement|Genepro Generation 3 Protein|Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
79652868|NCT04615858|Dietary Supplement|Whey Protein|Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
79336850|NCT02586493|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
79336851|NCT05543395|Behavioral|Domestic Violence Questionnaire|Domestic Violence Questionnaire
79336852|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
79336853|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
79336854|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
79336855|NCT02400333|Drug|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
79652869|NCT04615351|Drug|Metformin|Medication
79652870|NCT04615156|Drug|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
79652871|NCT00221780|Device|left ventricular pacing|
79652872|NCT04615312|Drug|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
79652873|NCT04614961|Other|Lifestyle therapy - individual|Individual therapy
79652874|NCT04614961|Other|Lifestyle therapy - group|Group therapy
79652875|NCT04614961|Other|Medical therapy|Medical therapy
79336856|NCT02399475|Drug|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
79336857|NCT02399475|Drug|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
79336858|NCT02399475|Drug|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
79336859|NCT04420377|Dietary Supplement|Carnipure|Supplement contains L-carnitine tartrate.
79336860|NCT04420377|Other|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
79336861|NCT02399163|Drug|Fluoride free toothpaste|Brushing with fluoride free toothpaste
79336862|NCT02399163|Drug|Fluoride toothpaste|Brushing with fluoride containing toothpaste
79652876|NCT04614961|Procedure|Bariatric surgery|Surgical and endoscopic therapy
79652877|NCT04618666|Procedure|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
79652878|NCT00251121|Other|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
79652879|NCT00251121|Other|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
79336863|NCT02399163|Drug|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
79336864|NCT02398227|Behavioral|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
79336865|NCT02398227|Behavioral|PCT|Present Centered Therapy for PTSD
79336866|NCT02397915|Drug|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
79336867|NCT02397915|Drug|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
79336868|NCT02397837|Drug|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
79336869|NCT02397837|Drug|Placebo|placebo match study drug
79336870|NCT02586415|Procedure|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
79336871|NCT02586415|Device|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
79652880|NCT04614883|Device|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
79652881|NCT04614883|Other|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
79652882|NCT00221819|Device|heated humidifier (device)|
79652883|NCT00221819|Device|Heat and moisture exchanger (device)|
79652884|NCT04614727|Combination Product|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks & seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
79336872|NCT02586415|Device|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
79982626|NCT05250921|Device|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
79487448|NCT04863625|Behavioral|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
79487449|NCT02827838|Biological|Durvalumab|Given IV
79487450|NCT02827838|Other|Laboratory Biomarker Analysis|Correlative studies
79487451|NCT02827838|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79487452|NCT00373243|Drug|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
79487453|NCT02758184|Device|ROTEM-based coagulation monitoring|
79336873|NCT02586415|Device|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System [026, 032, 041] Penumbra System Separator Flex [026, 032, 041, 054] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 & ACE68"
79487454|NCT02758184|Procedure|Spine surgery|
79487455|NCT03099733|Other|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
79487456|NCT02915185|Procedure|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
79652885|NCT04614415|Device|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
79652886|NCT04614415|Other|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
79652887|NCT04614688|Behavioral|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
79336874|NCT02586415|Device|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
79336875|NCT02383017|Dietary Supplement|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
79652888|NCT00247923|Procedure|Hysteroscopic resection of endometrial polyps. (TCRP)|
79652889|NCT04614298|Drug|KHK4827-Active|Single SC administration
79652890|NCT04614298|Drug|KHK4827-Placebo|Single SC administration
79652891|NCT04613986|Device|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
79982627|NCT03281122|Drug|Placebo|Specified dose on specified days
79336876|NCT02383017|Dietary Supplement|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
79336877|NCT05556031|Other|Standard care|Standard clinical care
79982628|NCT03281122|Drug|BMS-986224|Specified dose on specified days
79336878|NCT05549791|Drug|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
79336879|NCT02382939|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
79652892|NCT04614259|Drug|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). [104] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
79336880|NCT02382939|Drug|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
79336881|NCT05549557|Drug|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
79336882|NCT05543005|Other|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
79336883|NCT05542927|Diagnostic Test|urine chloride|Serum chloride, urinary chloride & serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride & urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI & mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
79336884|NCT04425889|Diagnostic Test|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
79336885|NCT05555563|Other|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
79336886|NCT04426435|Drug|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
79336887|NCT05549245|Device|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
79336888|NCT05549245|Device|CPAP|Patients were treated with CPAP for three nights
79336889|NCT05699005|Drug|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature >38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia >4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level <7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
79336890|NCT05549167|Drug|Sirolimus|Sirolimus 0,8 mg/m2, but <2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
79336891|NCT05542693|Biological|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
79336892|NCT05542693|Biological|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
79336893|NCT05542693|Biological|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
79652893|NCT04614259|Combination Product|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
79336894|NCT05542693|Biological|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
79336895|NCT05549089|Device|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
79336896|NCT05549089|Device|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
79336897|NCT05549089|Device|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
79336898|NCT04323553|Diagnostic Test|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
79487457|NCT02915185|Device|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
79487458|NCT00373477|Procedure|Generalist Care Manager vs Usual Care|
79982629|NCT03635463|Device|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
79982630|NCT03635463|Device|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
79982631|NCT02713594|Behavioral|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
79336899|NCT04323553|Other|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
79336900|NCT05542537|Behavioral|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
79336901|NCT05542537|Behavioral|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
79336902|NCT05542537|Behavioral|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
79487459|NCT02909647|Procedure|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
79487460|NCT02909647|Procedure|Osteosynthesis|osteosynthesis using volar locking plate
79487461|NCT02887885|Drug|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
79487462|NCT02902172|Drug|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
79487463|NCT02902172|Drug|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
79487464|NCT02663102|Other|Data collection|Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
79982632|NCT02713594|Other|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
79652894|NCT00251160|Procedure|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
79336903|NCT05542537|Behavioral|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
79336904|NCT04320667|Diagnostic Test|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
79336905|NCT05548933|Procedure|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
79812733|NCT05370092|Other|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
79336906|NCT05542459|Drug|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
79336907|NCT05698849|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
79336908|NCT05700175|Diagnostic Test|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA_MFS_signature).~The obtained TAA_MFS_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
79336909|NCT05554783|Diagnostic Test|Trendelenburg position|Positioning the patient with head 15 degrees down
79487465|NCT02784548|Other|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
79487466|NCT02402894|Other|no intervention|
79812734|NCT05370092|Other|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
79812735|NCT05370092|Other|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
79812736|NCT00865709|Drug|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
79812737|NCT00865709|Drug|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
79812738|NCT00839306|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
79812739|NCT00839306|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
79812740|NCT02612090|Dietary Supplement|Active Treatment Beverage|Strawberry
79812741|NCT02612090|Dietary Supplement|Placebo Treatment Beverage|Placebo
79336910|NCT05698615|Behavioral|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
79982633|NCT01339455|Procedure|AHSCT|"AHSCT Procedure:~Mobilization and Harvesting:~Cyclophosphamide~Rituximab~GSCF~Dexamethasone~Apheresis~Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~Cyclophosphamide~MESNA~Rabbit ATG~Rituximab~Methylprednisolone~Stem Cell infusion~GSCF"
79336911|NCT05542225|Procedure|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
79982634|NCT01339533|Device|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
79336912|NCT05542225|Procedure|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
79336913|NCT05542225|Procedure|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
79336914|NCT02587819|Drug|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
79336915|NCT04426045|Procedure|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
79487467|NCT02777749|Drug|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
79487468|NCT02785172|Drug|IDP-118 Vehicle Lotion|Vehicle
79487469|NCT02785172|Drug|IDP-118 Vehicle Cream|Vehicle
79487470|NCT02785172|Drug|IDP-118 Lotion|Lotion
79487471|NCT02785172|Drug|Ultravate Cream|Cream
79487472|NCT02582125|Drug|ONO-4538|
79487473|NCT02906696|Drug|Bosutinib|Given PO
79487474|NCT02906696|Other|Laboratory Biomarker Analysis|Correlative studies
79487475|NCT02503657|Drug|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
79487476|NCT02503657|Drug|Placebo|Excipients of MN-001/tipelukast
79812742|NCT00698243|Drug|OSI-027|Administered orally
79812743|NCT04131335|Drug|AEONTM Repair|Lubricating eye drops
79982635|NCT03281044|Drug|Fecal microbiota capsules|Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
79812744|NCT04131335|Other|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
79812745|NCT04131023|Behavioral|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
79812746|NCT00839072|Drug|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
79812747|NCT00839072|Drug|Trazodone HCl|300 mg extended-release caplet, single dose
79812748|NCT02613845|Other|no intervention|
79812749|NCT04118465|Procedure|external cephalic version|external cephalic version
79336916|NCT04426045|Procedure|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
79336917|NCT05548465|Drug|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
79982636|NCT03281044|Drug|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
79982637|NCT01336881|Genetic|RNA analysis|
79336918|NCT05548465|Drug|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
79336919|NCT04882735|Drug|Acoramidis|TTR stabilizer administered orally twice daily (BID)
79487477|NCT02779543|Device|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
79487478|NCT02779543|Device|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
79487479|NCT02779543|Device|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
79812750|NCT00704990|Dietary Supplement|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
79982638|NCT01336881|Genetic|gene expression analysis|
79982639|NCT01336881|Genetic|microarray analysis|
79336920|NCT05548309|Device|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher & Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
79336921|NCT05548309|Device|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
79982640|NCT01336881|Genetic|nucleic acid sequencing|
79982641|NCT01336881|Other|diagnostic laboratory biomarker analysis|
79982642|NCT02458612|Other|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
79336922|NCT05554471|Device|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
79982643|NCT02458612|Other|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
79982644|NCT03264274|Drug|Aflibercept|Antiangiogenic
79982645|NCT03264274|Procedure|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
79652895|NCT00251160|Procedure|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
79336923|NCT05542069|Device|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
79812751|NCT00855803|Radiation|radiation|Given in 1 or 5 fractions
79336924|NCT05541991|Dietary Supplement|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
79336925|NCT05541991|Dietary Supplement|placebo coated tablet|coated tablet without active principle
79336926|NCT05541991|Dietary Supplement|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
79336927|NCT05700097|Drug|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
79336928|NCT05700097|Drug|Placebo injection|placebo control arm for the standard protocol
79336929|NCT05541835|Diagnostic Test|sampling|venous sampling of patient
79336930|NCT05554081|Device|Peezy urine collection device|use peezy collection to obtain urine sample
79336931|NCT05554003|Drug|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
79652896|NCT00563329|Procedure|Reduction Intervention + Adherence Intervention|
79652897|NCT00563329|Behavioral|Reduction Intervention|
79652898|NCT00563329|Procedure|control|
79336932|NCT05541757|Drug|In vitro heparin|In vitro heparin and in vitro LMWH
79336933|NCT05541601|Other|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
79487480|NCT02785406|Drug|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
79812752|NCT02613923|Behavioral|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
79336934|NCT05547997|Other|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
79336935|NCT05547997|Other|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
79336936|NCT05700565|Other|Extracorporeal photopheresis|ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.
79336937|NCT05700565|Other|Other immunosuppressive or immunomodulatory drugs|Other immunosuppressive or immunomodulatory drugs
79336938|NCT05541523|Behavioral|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
79982646|NCT01339611|Behavioral|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
79982647|NCT02457208|Drug|Isoniazid (H)|
79982648|NCT02457208|Drug|Rifampicin (R)|
79982649|NCT02457208|Drug|Pyrazinamide (Z)|
79336939|NCT05541523|Behavioral|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
79336940|NCT05541445|Drug|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
79336941|NCT05541289|Biological|BBV152|Single Arm; BBV152 (COVAXIN™)
79336942|NCT05699785|Other|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
79336943|NCT05699785|Other|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
79336944|NCT05547763|Procedure|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
79336945|NCT05540977|Drug|Donepezil|Donepezil 5mg QN
79336946|NCT05540977|Other|Usual care|Usual care
79336947|NCT05553535|Diagnostic Test|MRI|retrospective review of shoulder MRI
79336948|NCT05547685|Diagnostic Test|Methylene blue intradermal injection|Methylene blue intradermal injection
79336949|NCT05553379|Diagnostic Test|FeNO measurement|FeNO measurement at each visit
79487481|NCT02785406|Drug|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
79487482|NCT02062489|Drug|Tamoxifen|20 mg(2#)/day, PO, daily
79487483|NCT02062489|Drug|Placebo|2#/day, PO, daily
79487484|NCT02786810|Drug|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
79487485|NCT02908178|Procedure|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
79487486|NCT02780869|Device|HEMOBLAST Bellows|
79487487|NCT02780869|Device|Absorbable gelatin sponge, USP with thrombin|
79487488|NCT02908490|Drug|Sildenafil|Sildenafil 50 mg once daily
79487489|NCT02908490|Other|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
79982650|NCT02457208|Drug|Ethambutol (E)|
79982651|NCT01337037|Device|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
79982652|NCT01337037|Procedure|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
79336950|NCT05540821|Diagnostic Test|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
79336951|NCT05540587|Drug|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~CrCl 15-50mL/min~Body weight ≤ 60kg~Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
79336952|NCT05540587|Drug|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
79336953|NCT05540509|Behavioral|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
79336954|NCT05540509|Behavioral|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
79336955|NCT05540431|Drug|Activated Charcoal|RCT
79336956|NCT05540431|Dietary Supplement|Probiotic|RCT
79336957|NCT05540431|Other|No intervention|RCT
79336958|NCT05700409|Behavioral|Intensive lifestyle consultations|detailed above
79336959|NCT05553067|Genetic|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
79336960|NCT04319809|Device|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
79336961|NCT05547139|Other|Protocolized weaning of respiratory support|The protocolized weaning aims to keep babies on CPAP for a longer period of time and will measure how long it takes babies to wean to 2L nasal cannula support or come off all support (room air, RA).
79336962|NCT04318249|Behavioral|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
79336963|NCT04318249|Behavioral|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
79336964|NCT05540119|Procedure|Surgery|Patients who undergo surgery are separately assessed
79336965|NCT05552677|Other|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
79336966|NCT05539885|Procedure|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
79336967|NCT05539885|Procedure|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
79487490|NCT00374036|Drug|ECC|capecitabine
79812753|NCT02613923|Behavioral|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
79487491|NCT00374036|Drug|FOLFIRI|Irinotecan
79487492|NCT02345018|Procedure|Mechano-chemical ablation|Treatment with mechano-chemical ablation
79812754|NCT02613923|Procedure|Blood Draw|blood sample measured for stress and sleep markers
79336968|NCT05552599|Procedure|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
79982653|NCT01337037|Procedure|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
79982654|NCT01337037|Procedure|Open lobectomy|standard lobectomy procedure by thoracotomy approach
79982655|NCT01339845|Biological|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
79336969|NCT05552521|Diagnostic Test|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
79336970|NCT04426123|Drug|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
79336971|NCT04426123|Other|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
79336972|NCT05539651|Drug|RBD5044|Subcutaneously Administered RBD5044 in Healthy Subjects
79336973|NCT05539651|Drug|Placebo|Subcutaneously Administered Placebo in Healthy Subjects
79336974|NCT04425811|Other|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
79336975|NCT01666951|Drug|LCP-Tacro tablets|Tacrolimus
79336976|NCT01666951|Drug|Prograf|Tacrolimus
79336977|NCT05699395|Diagnostic Test|Non interventional|No intervention
79487493|NCT02910362|Device|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
79652899|NCT04613908|Device|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
79812755|NCT02613923|Other|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
79336978|NCT05539339|Other|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
79336979|NCT05539261|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
79336980|NCT05539261|Diagnostic Test|Neuropsychological scale|Multi dimensional neuropsychological test
79336981|NCT05539183|Procedure|Blood withdrawal|Blood withdrawal
79812756|NCT02613923|Other|Insomnia Severity Index (ISI)|
79812757|NCT02613923|Other|SF-12 quality of life survey|
79652900|NCT04613908|Other|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~Level 1: MRC (shoulder) <3 + MRC <3 (hip).~Level 2: MRC (shoulder) ≥ 3 + MRC (hip) <3.~Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~Level 4: Standing without assistance and walking with or without assistance."
79652901|NCT04613908|Other|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
79652902|NCT00412763|Drug|Silymarin (Silybum marianum)|
79336982|NCT05539105|Procedure|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
79652903|NCT00251199|Drug|VX-950|
79652904|NCT00251199|Drug|peginterferon|
79652905|NCT04614181|Dietary Supplement|Nestle Resource drink|Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
79336983|NCT05539105|Procedure|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
79336984|NCT05539105|Procedure|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
79336985|NCT05546203|Other|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
79652906|NCT04614181|Other|Usual care|Usual fracture care as determined by clinical team
79652907|NCT00563446|Drug|Darbepoetin alfa|
79652908|NCT00563485|Drug|Doxazosin GITS (Cardura XL)|
79652909|NCT00563485|Drug|Terazosin (Hytrin)|
79652910|NCT00251277|Drug|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
79812758|NCT02614001|Device|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
79982656|NCT01339845|Behavioral|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
79982657|NCT02457130|Drug|Ticagrelor|
79982658|NCT02457130|Drug|Clopidogrel|
79982659|NCT01337193|Other|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
79336986|NCT05546203|Device|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
79336987|NCT05546203|Behavioral|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
79336988|NCT05551507|Drug|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
79982660|NCT01337193|Other|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
79982661|NCT03280810|Other|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
79336989|NCT05538559|Other|Chemomechanical caries removal by Carie-Care|caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
79336990|NCT05538559|Other|Mechanical caries removal by Atraumatic Restorative Technique|caries in primary teeth will be removed using the mechanical caries removal by ART method.
79336991|NCT05698303|Drug|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
79812759|NCT02614001|Other|post-stroke rehabilitation program|
79812760|NCT02607774|Drug|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
79812761|NCT02607774|Drug|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
79812762|NCT00838916|Biological|albiglutide|albiglutide weekly injection
79982662|NCT02457052|Device|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
79982663|NCT05250531|Behavioral|multicomponent therapy|patient education,Exercise training,Private Psychotherapy,relaxation
79812763|NCT00838916|Drug|insulin glargine|insulin glargine
79982664|NCT01340001|Procedure|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
79982665|NCT03269266|Diagnostic Test|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
79982666|NCT03263884|Device|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
79487494|NCT02910362|Device|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
79652911|NCT00412802|Drug|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
79812764|NCT00703274|Behavioral|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
79812765|NCT00838682|Drug|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
79812766|NCT00838682|Drug|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
79812767|NCT02612324|Behavioral|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
79812768|NCT02612324|Behavioral|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
79812769|NCT00913484|Drug|Disulfiram|Disulfiram 250 mg per day
79982667|NCT03263884|Device|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
79336992|NCT05551351|Diagnostic Test|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
79336993|NCT02586805|Drug|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
79487495|NCT02910674|Device|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
79487496|NCT02911844|Drug|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
79652912|NCT00412802|Drug|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
79652913|NCT00563524|Drug|ILV-094|SC and IV administration on days 1, 14, 28, and 42
79652914|NCT04613869|Drug|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
79652915|NCT04613869|Drug|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
79652916|NCT04613869|Drug|Hydromorphone|No esketamine added
79812770|NCT00913484|Drug|Placebo|Placebo daily
79812771|NCT00709280|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
79982668|NCT01337271|Procedure|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
79982669|NCT01337271|Procedure|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
79336994|NCT02586805|Drug|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
79336995|NCT02586805|Drug|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
79487497|NCT02911922|Device|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
79487498|NCT02911922|Device|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
79652917|NCT00251355|Drug|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
79652918|NCT00251355|Drug|5-Fluorouracil|5-FU via continuous IV infusion.
79652919|NCT00251355|Procedure|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
79336996|NCT02586805|Drug|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
79336997|NCT05545423|Other|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
79336998|NCT05545423|Other|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
79487499|NCT02911922|Radiation|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
79652920|NCT02962388|Drug|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
79812772|NCT00709280|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
79812773|NCT00820040|Device|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
79812774|NCT00709358|Other|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
79336999|NCT05545345|Procedure|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
79337000|NCT05545345|Procedure|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
79337001|NCT05545267|Procedure|Angioplasties|Transluminal angioplastie
79652921|NCT02962388|Drug|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
79652922|NCT02962388|Drug|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
79652923|NCT04613167|Drug|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
79652924|NCT04613167|Drug|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
79487500|NCT02790788|Drug|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
79487501|NCT02790788|Drug|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
79487502|NCT02793674|Device|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
79487503|NCT02793674|Device|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
79652925|NCT04613167|Drug|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
79812775|NCT00709358|Other|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
79337002|NCT05550883|Other|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
79337003|NCT05550883|Drug|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
79337004|NCT05545189|Diagnostic Test|colonoscopy,polypectomy|polyp removal during colonoscopy
79337005|NCT05537779|Device|CT examination|Administration of contrast medium using the power injector
79337006|NCT05698225|Other|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
79487504|NCT03001778|Other|Usability Testing|"Usability testing of ready made workouts in a group format."
79487505|NCT02888665|Drug|Doxorubicin Hydrochloride|Given IV
79652926|NCT04613284|Drug|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
79812776|NCT00705302|Behavioral|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
79487506|NCT02888665|Other|Laboratory Biomarker Analysis|Correlative studies
79487507|NCT02888665|Biological|Pembrolizumab|Given IV
79652927|NCT04613284|Radiation|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
79652928|NCT00248079|Device|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
79652929|NCT00221858|Procedure|Ultrasound guided blocks|
79337007|NCT04736017|Device|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
79652930|NCT04613401|Other|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
79337008|NCT05545033|Device|Virtual reality|5 to 15 minutes of virtual reality exposure
79337009|NCT05550649|Procedure|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
79337010|NCT05544955|Dietary Supplement|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
79337011|NCT05544955|Dietary Supplement|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
79652931|NCT00563602|Other|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
79337012|NCT05544877|Behavioral|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
79337013|NCT05550415|Drug|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
79337014|NCT05550415|Drug|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
79337015|NCT05699161|Genetic|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
79487508|NCT02918396|Device|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as <0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
79652932|NCT00563641|Other|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
79652933|NCT00563641|Other|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
79652934|NCT00248118|Drug|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
79652935|NCT04613011|Device|Ultrasound|Checking vein width snd copression using US
79652936|NCT04612894|Drug|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
79487509|NCT02918396|Device|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
79487510|NCT02918396|Device|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
79487511|NCT02781571|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
79337016|NCT05537155|Procedure|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
79487512|NCT02918630|Drug|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
79487513|NCT02918630|Drug|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
79487514|NCT02781649|Drug|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
79337017|NCT05537155|Other|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
79337018|NCT05550259|Procedure|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
79337019|NCT05537077|Other|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
79337020|NCT05537077|Other|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
79337021|NCT05537077|Other|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
79812777|NCT00705302|Behavioral|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
79487515|NCT02781649|Drug|Ribavirin|Ribavirin 1200 mg/d (> 75 kg) or 1000 mg/d (< 75 kg) by mouth daily in two divided doses
79337022|NCT05544643|Device|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
79337023|NCT05550025|Drug|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
79337024|NCT05544409|Device|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
79337025|NCT05700253|Device|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF* CRFA; Avanos Medical).
79487516|NCT02781649|Drug|Sofosbuvir|Sofosbuvir 400 mg daily
79487517|NCT02794766|Drug|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
79487518|NCT02794766|Drug|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
79487519|NCT02794766|Drug|Placebo|Placebo 1 gum each 12 hours for 10 days
79487520|NCT02794844|Drug|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
79652937|NCT04612894|Procedure|surgery|Perform surgery if operable after neoadjuvant therapy
79652938|NCT04612894|Procedure|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
79652939|NCT00251394|Drug|Rituxan|Given intravenously once weekly for four weeks.
79652940|NCT00251394|Drug|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
79652941|NCT00221936|Behavioral|Self-administration or nurse administered medication|
79812778|NCT05320952|Device|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
79337026|NCT05700253|Device|Hyaluronic Acid Injection|Synvisc-One ([Hylan G-F 20]; Sanofi) will be administered as a single intra-articular dose (6 mL).
79487521|NCT01709539|Procedure|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
79487522|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
79487523|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
79487524|NCT02795780|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
79337027|NCT05536765|Procedure|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
79337028|NCT05536687|Device|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
79337029|NCT05544331|Behavioral|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
79337030|NCT05544331|Behavioral|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
79337031|NCT05535673|Drug|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
79487525|NCT02795780|Procedure|PET Scan|positron emission tomography (PET) scan
79487526|NCT02783443|Other|General anesthesia|General anesthesia
79487527|NCT02783443|Other|Regional anesthesia|Regional anesthesia
79487528|NCT02796092|Device|Fibered platinum coils|
79487529|NCT02796092|Device|Vascular plugs|
79652942|NCT04612777|Behavioral|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
79812779|NCT00803712|Drug|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
79812780|NCT00803712|Drug|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
79812781|NCT00591344|Behavioral|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
79652943|NCT04612777|Behavioral|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
79337032|NCT05544253|Procedure|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
79487530|NCT02889289|Other|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
79487531|NCT02784613|Drug|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
79487532|NCT00373568|Drug|miltefosine: 2.5 mg/kg/day for 42 days|
79812782|NCT00591344|Behavioral|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
79812783|NCT05758610|Drug|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
79812784|NCT05757050|Dietary Supplement|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
79487533|NCT02890303|Device|Zepto System|Anterior Capsulotomy using the Zepto System.
79487534|NCT03002012|Drug|Sertraline|sertraline 400mg/day
79487535|NCT03002012|Drug|Placebo Oral Tablet|matched placebo tablet
79487536|NCT03002012|Drug|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
79337033|NCT05535517|Other|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
79337034|NCT05535517|Other|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
79337035|NCT05535517|Other|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
79337036|NCT05535517|Other|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
79337037|NCT05535517|Other|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
79337038|NCT05535517|Other|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
79337039|NCT05698069|Diagnostic Test|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
79337040|NCT05698069|Other|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
79337041|NCT05698069|Other|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
79337042|NCT05536531|Device|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
79337043|NCT05536063|Procedure|bilateral erector spinae plane block in pediatric cardiac surgeries|The ESPB will be performed after induction of anesthesia, endotracheal tube insertion and before the start of operation, with the child in a right lateral decubitus position under aseptic precautions. A high frequency linear ultrasound transducer will be placed over the T4 transverse process lateral to the spinous process. After identifying the muscles above the hyperechoic transverse process image, a 5-cm 22 gauge needle will be inserted in-plane in a cephalo-caudad direction. The endpoint is defined as the needle pointing to the tip of transverse process piercing the erector spinae muscle. The local anesthetic will be deposited at this position, After careful negative aspiration, local anesthetic, according to study groups , The process will be repeated on thecontralateral side
79337044|NCT05535985|Device|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
79337045|NCT05535985|Device|placebo acupuncture|placebo acupuncture
79337046|NCT05544097|Other|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
79337047|NCT05592535|Procedure|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
79337048|NCT05699083|Other|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
79337049|NCT05697913|Other|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
79337050|NCT05543941|Device|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
79337051|NCT05543941|Device|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
79337052|NCT04425733|Drug|MK-5475|MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
79337053|NCT04425733|Drug|Placebo|MK-5475-matching placebo administered QD via inhalation
79337054|NCT05543863|Diagnostic Test|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
79812785|NCT05757050|Dietary Supplement|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
79652944|NCT04612777|Behavioral|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
79812786|NCT00803634|Drug|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
79812787|NCT00803634|Drug|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
79337055|NCT05543473|Other|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
79337056|NCT05696041|Other|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
79337057|NCT05498701|Drug|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
79337058|NCT05498701|Drug|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
79337059|NCT05695807|Device|Carboxytherapy|Device generating CO2 gas
79337060|NCT02580877|Drug|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
79812788|NCT00838526|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
79812789|NCT00838526|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
79982670|NCT03268798|Device|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
79487537|NCT02798354|Behavioral|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
79487538|NCT02890381|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
79337061|NCT02580877|Drug|500mg oral insulin crystals every other week|human insulin crystals in capsules
79487539|NCT02890381|Biological|Placebo|Isotonic diluent, administered as nose drops
79487540|NCT00373646|Drug|Thalidomide, Pharmion|200 mg p.o. daily
79487541|NCT03005054|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
79487542|NCT03005054|Procedure|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
79487543|NCT02891629|Device|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
79337062|NCT05688163|Other|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
79487544|NCT02891863|Device|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
79982671|NCT01340079|Behavioral|virtual world|health education using virtual world Second Life
79487545|NCT03001453|Drug|Liposomal Bupivacaine|266mg liposomal bupivacaine
79487546|NCT03001453|Drug|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
79487547|NCT03001453|Drug|Saline|Normal saline
79487548|NCT03001843|Drug|Ketamine|Anesthesia of only Ketamine
79487549|NCT03001843|Drug|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
79337063|NCT05688163|Other|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
79337064|NCT04316923|Diagnostic Test|ECG|ECG will be performed during each visit in the study group.
79337065|NCT04316923|Diagnostic Test|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
79337066|NCT04316923|Diagnostic Test|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
79337067|NCT04316923|Diagnostic Test|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
79337068|NCT05697523|Other|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
79487550|NCT03001843|Behavioral|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
79487551|NCT03003793|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
79487552|NCT02784925|Device|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
79487553|NCT02785159|Drug|IDP-118 Lotion|Lotion
79487554|NCT02785159|Drug|Tazorac Cream|Cream
79487555|NCT02785159|Drug|IDP-118 Vehicle Lotion|Lotion
79487556|NCT02785159|Drug|IDP-118 Vehicle Cream|Cream
79487557|NCT02786719|Drug|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
79982672|NCT01340079|Behavioral|face to face|health education delivered in face to face groups
79982673|NCT03268720|Other|FODMAP low diet|2 week FODMAP low diet
79982674|NCT03268720|Other|gluten-free diet|2 week gluten-free diet
79487558|NCT02786719|Drug|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
79487559|NCT02786719|Drug|Cisplatin|Cycle 3+5 (given daily x 4 days)
79487560|NCT02786719|Drug|Etoposide|Cycle 3+5 (given daily for 3 days)
79337069|NCT04425499|Other|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
79337070|NCT01905631|Drug|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
79487561|NCT02786719|Drug|Vincristine|Cycle 4+6 (given daily for 3 days)
79812790|NCT02611934|Procedure|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
79337071|NCT05679115|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
79337072|NCT01808989|Other|Exercise oxymetry|
79487562|NCT02786719|Drug|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
79487563|NCT02786719|Drug|Doxorubicin|Cycle 4+6 (given daily for 3 days)
79487564|NCT02786719|Drug|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
79487565|NCT03003949|Drug|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
79487566|NCT03003949|Drug|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
79487567|NCT03003949|Drug|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
79487568|NCT03003949|Drug|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
79487569|NCT02896075|Other|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
79487570|NCT02896075|Other|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
79812791|NCT00914472|Biological|heparin sodium - APP|Heparin 5000 IU / mL
79487571|NCT02787655|Behavioral|Aerobic exercise + Cognitive Training Group|stationary bicycling
79487572|NCT02787655|Behavioral|Cognitive training Only|20 minutes of cognitive training using Mindfit program
79487573|NCT02798978|Drug|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
79812792|NCT00914472|Biological|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
79812793|NCT02611466|Drug|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
79812794|NCT02611466|Drug|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
79812795|NCT02611466|Drug|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
79812796|NCT02688270|Drug|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
79337073|NCT05591521|Other|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
79337074|NCT05591287|Procedure|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
79337075|NCT05535205|Other|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
79812797|NCT02688270|Drug|Vehicle Cream (placebo)|Vehicle administered topically
79812798|NCT02610920|Procedure|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
79337076|NCT05535205|Other|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
79337077|NCT05679037|Other|Placebo|Inactive capsules
79337078|NCT05679037|Drug|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
79337079|NCT05587465|Device|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
79337080|NCT05695651|Diagnostic Test|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
79337081|NCT05678881|Drug|High dose RLS103|8 mg CBD inhaled powder
79337082|NCT05678881|Drug|placebo inhaled powder|placebo inhaled powder
79337083|NCT05678881|Drug|Low dose RLS103|4 mg CBD inhaled powder (open label)
79337084|NCT05678725|Device|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
79812799|NCT02610920|Drug|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
79812800|NCT00913562|Drug|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
79337085|NCT05678725|Device|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
79337086|NCT05678725|Device|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 0mA for 20 minutes with the ramp up and down time of 40 seconds.
79337087|NCT05678569|Diagnostic Test|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
79337088|NCT02582983|Drug|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
79337089|NCT02582749|Drug|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
79337090|NCT02582749|Drug|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
79487574|NCT02798978|Drug|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
79652945|NCT04612543|Device|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
79337091|NCT02582749|Radiation|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
79337092|NCT05461261|Drug|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
79337093|NCT05461261|Drug|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
79487575|NCT02898103|Device|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
79487576|NCT02898103|Device|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
79487577|NCT02898103|Device|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
79487578|NCT03005041|Other|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
79487579|NCT03005041|Other|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
79812801|NCT00913562|Drug|Placebo|one tablet a day for 12 weeks
79812802|NCT02661204|Device|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
79812803|NCT04010136|Other|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
79812804|NCT00818246|Device|Sham light|
79812805|NCT00818246|Device|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
79337094|NCT05461261|Drug|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
79337095|NCT05383729|Other|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
79337096|NCT05383729|Other|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.[1]
79337097|NCT05339815|Device|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
79652946|NCT04612543|Device|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
79652947|NCT04612816|Other|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
79982675|NCT05250297|Other|no intervention|standard prenatal care
79982676|NCT03280654|Other|overactive bladder|Association between groups and over active bladder symptoms
79337098|NCT05285761|Behavioral|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
79337099|NCT05285761|Behavioral|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
79812806|NCT00705380|Behavioral|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
79982677|NCT03280498|Procedure|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
79982678|NCT01340157|Drug|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
79652948|NCT02961387|Device|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
79652949|NCT02961387|Device|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
79652950|NCT00221975|Drug|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
79652951|NCT00221975|Drug|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
79812807|NCT00705380|Behavioral|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
79812808|NCT00818168|Biological|Infliximab|"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"
79982679|NCT02459470|Procedure|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
79982680|NCT01340235|Drug|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
79982681|NCT02459548|Other|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
79982682|NCT02459548|Other|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
79982683|NCT05243979|Radiation|DEXA scan|bone study
79487580|NCT03007225|Drug|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
79487581|NCT03007225|Drug|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
79812809|NCT02607540|Other|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
79812810|NCT02607540|Other|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
79812811|NCT02607540|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
79812812|NCT02608398|Other|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
79812813|NCT00817778|Drug|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
79337100|NCT05204875|Radiation|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
79337101|NCT05678413|Procedure|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
79337102|NCT05678413|Procedure|DVIU|DVIU
79337103|NCT05678335|Drug|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
79337104|NCT05678335|Drug|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
79337105|NCT02582671|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
79337106|NCT02582671|Drug|Dasabuvir|Tablet
79337107|NCT02582671|Drug|Ribavirin|Tablet
79337108|NCT05696899|Other|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
79337109|NCT05154721|Device|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
79337110|NCT05154721|Device|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
79337111|NCT02585713|Drug|Apixaban|Given PO
79487582|NCT02799290|Biological|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
79487583|NCT02799290|Biological|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
79487584|NCT02800148|Drug|Azelaic acid foam|
79487585|NCT02800148|Drug|Azelaic acid foam|
79487586|NCT02800148|Drug|Azelaic acid foam - Placebo|
79812814|NCT00817778|Drug|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
79337112|NCT02585713|Drug|Dalteparin|Given SC
79337113|NCT02585713|Other|Questionnaire Administration|Ancillary studies
79337114|NCT05032495|Other|Surveys|Surveys to evaluate prior experience, opinions and intervention acceptability.
79337115|NCT05032495|Other|Focus group|To answer any questions and discuss topics covered in the standard presentation.
79337116|NCT05078671|Drug|Olaparib|olaparib treatment
79337117|NCT05078671|Drug|Cobicistat|Pharmacokinetic booster
79337118|NCT02579863|Biological|Pembrolizumab|IV infusion
79337119|NCT02579863|Drug|Lenalidomide|oral capsules
79337120|NCT02579863|Drug|Dexamethasone|oral tablets
79487587|NCT03008707|Procedure|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
79487588|NCT02801006|Device|stenfilcon A|contact lens
79487589|NCT02801006|Device|etafilcon A|contact lens
79812815|NCT05758532|Biological|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
79812816|NCT00705458|Procedure|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
79812817|NCT00705458|Procedure|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
79982684|NCT03263962|Drug|Canrenone|Evaluation of canrenone therapy in patients with CHF
79982685|NCT02459314|Dietary Supplement|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
79982686|NCT02459314|Dietary Supplement|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
79982687|NCT03280420|Procedure|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
79337121|NCT05677945|Drug|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"Drying the mucosa with gauze,topical anesthesia will be applied.~Administration of local anesthesia with vasoconstrictor.~Rubber dam isolation.~Caries removal & access cavity using a round bur mounted on a high-speed contra with coolant.~Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~Radicular section will be kept untouched,no instrumentation.~Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~Drying the access cavity with sterile cotton pellets.~Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier & condensed over orifices using a moist cotton pellet.~Cavity sealing with RMGI capsules.~Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
79337122|NCT05677945|Drug|3Mix: Modified triple antibiotic mix in propylene glycol|"Drying the mucosa with gauze,topical anesthesia will be applied.~Administration of local anesthesia with vasoconstrictor.~Rubber dam isolation.~Caries removal & access cavity using a round bur mounted on a high-speed contra with coolant.~Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~Radicular section will be kept untouched,no instrumentation.~Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~Drying the access cavity with sterile cotton pellets.~Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier & condensed over orifices using a moist cotton pellet.~Cavity sealing with RMGI capsules.~Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
79487590|NCT02790463|Behavioral|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
79812818|NCT00813098|Drug|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
79812819|NCT00813098|Drug|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
79812820|NCT00813098|Drug|Placebo|Matching placebo dosing with daily oral intake
79812821|NCT00705692|Drug|Levamisole|
79812822|NCT00705692|Drug|Placebo|
79812823|NCT05758454|Behavioral|Caries and Obesity Prevention|A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
79812824|NCT00705770|Drug|Anecortave Acetate|"Low dose~Sustained release depot suspension"
79812825|NCT00705770|Drug|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
79812826|NCT00705770|Drug|Anecortave Acetate|"High dose~Sustained release depot suspension"
79812827|NCT00705770|Drug|Placebo|Placebo treatment with vehicle
79652952|NCT00221975|Drug|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (<2 months versus ≥2 months).
79337123|NCT05650177|Behavioral|blended Mindfulness-Based Intervention (bMBI)|The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
79652953|NCT04612582|Drug|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
79652954|NCT04612582|Drug|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
79812828|NCT02609906|Device|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
79337124|NCT05677789|Diagnostic Test|Medical observation|Likely suitable for home treatment
79337125|NCT05677789|Diagnostic Test|Supportive treatment (BSC)|Consider hospital supervised treatment
79337126|NCT05677789|Diagnostic Test|Intensive care management|Manage in hospital as severe pneumonia
79337127|NCT02582515|Drug|D-cycloserine|
79652955|NCT00248157|Drug|Octreotide acetate in microspheres|
79652956|NCT04612855|Other|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
79652957|NCT00222014|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
79812829|NCT02609906|Device|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
79652958|NCT00222014|Procedure|Paracenthese|Paracenthese
79337128|NCT02582515|Drug|Placebo|
79337129|NCT02579629|Drug|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
79337130|NCT02579629|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
79487591|NCT02791399|Behavioral|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
79652959|NCT04612426|Device|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
79652960|NCT04612426|Device|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
79652961|NCT04612504|Biological|SynOV1.1|SynOV1.1 will be administered intratumorally.
79982688|NCT03280420|Procedure|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
79982689|NCT05186649|Other|WARFARIN|5 mg of daily dosage
79337131|NCT02579629|Drug|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
79337132|NCT02579629|Device|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
79487592|NCT02902081|Drug|Cannabidiol|
79812830|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
79487593|NCT02902081|Drug|Placebo|
79487594|NCT02801942|Procedure|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
79652962|NCT03454321|Other|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
79652963|NCT00251472|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
79812831|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
79812832|NCT00796653|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
79812833|NCT00796653|Drug|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
79982690|NCT02458534|Other|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
79487595|NCT02801942|Procedure|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
79812834|NCT00806286|Drug|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
79812835|NCT00806286|Drug|Paclitaxel|Intravenous (IV), 200 mg/m^2, once every three weeks for up to 18 weeks
79487596|NCT02801942|Procedure|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
79337133|NCT05677555|Drug|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
79337134|NCT05677555|Drug|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
79337136|NCT04874857|Other|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
79337137|NCT04874857|Other|Baby oil|Massage application
79487597|NCT02801942|Other|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
79487598|NCT02791945|Behavioral|Medical Management Counseling|Brief alcohol counseling
79487599|NCT02791945|Drug|N-acetylcysteine|Experimental supplement
79337138|NCT05677477|Other|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
79337139|NCT05677399|Other|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
79337140|NCT02343939|Drug|Entospletinib|Tablet(s) administered orally every 12 hours
79337141|NCT02343939|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
79487600|NCT02791945|Drug|Placebo|Placebo comparator
79487601|NCT02793817|Drug|KPI-121 1% Ophthalmic Suspension dosed BID|
79487602|NCT02793817|Drug|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
79487603|NCT00374114|Procedure|cervical conization|
79812836|NCT00806286|Drug|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
79812837|NCT00806286|Drug|Placebo Tablets|Placebo tablets matching CS-7017 tablets
79812838|NCT03537924|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79812839|NCT03537924|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79812840|NCT02607384|Behavioral|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
79812841|NCT02607384|Behavioral|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
79982691|NCT02458534|Other|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
79982692|NCT02458534|Other|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
79982693|NCT05184465|Procedure|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
79982694|NCT03263728|Diagnostic Test|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
79982695|NCT03263338|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
79982696|NCT03152019|Drug|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
79982697|NCT03152019|Drug|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
79982698|NCT05007639|Other|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
79337142|NCT02343939|Drug|Cytarabine|100 mg/m^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
79337143|NCT02343939|Drug|Decitabine|20 mg/m^2 administered intravenously
79337144|NCT02343939|Drug|Azacitidine|75 mg/m^2 administered intravenously or subcutaneously
79337145|NCT02397447|Drug|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
79812842|NCT02607384|Other|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
79337146|NCT02397447|Drug|Placebo|Placebo: 2000 mg per day for three months
79337147|NCT02397057|Drug|Injectafer|
79812843|NCT02605980|Behavioral|Sedentary time|
79982699|NCT05007639|Other|No public Health intervention programme|
79982700|NCT05198115|Behavioral|aerobic exercise|aerobic training for 8 weeks, 3 times a week, and 60 min each time
79982701|NCT04813107|Drug|APL-1202 in combination with tislelizumab|For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
79982702|NCT04813107|Drug|Tislelizumab alone|For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
79982703|NCT01340391|Device|Omnicast|dorsal splint 2-5 weeks
79982704|NCT02714062|Drug|Placebo|po once daily
79982705|NCT02714062|Drug|VI-0521 Mid Dose|po once daily
79982706|NCT02714062|Drug|VI-0521 Top Dose|po once daily
79982707|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"3 pulses at 50Hz repeated each 200 ms for 2 seconds~80% MT~20 days treatment"
79982708|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
79982709|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
79337148|NCT02397057|Other|Placebo|
79337149|NCT02343549|Device|NovoTTF100A|
79337150|NCT02343549|Drug|Bevacizumab|
79337151|NCT02343549|Drug|Temozolomide|
79337152|NCT02343159|Drug|dimethyl fumarate|120 mg and 240 mg delayed release capsules
79487604|NCT00374114|Procedure|ultrasonic surgical aspiration of the cervix|
79487605|NCT03007394|Drug|Lorcaserin|Lorcaserin Capsule
79812844|NCT00590538|Drug|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
79812845|NCT00590538|Drug|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
79812846|NCT00590538|Drug|Placebo|The placebo is given to match the active comparator for four days.
79652964|NCT04612270|Other|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
79982710|NCT04782063|Other|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
79982711|NCT03268564|Behavioral|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
79982712|NCT03280342|Drug|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
79982713|NCT03280342|Drug|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
79982714|NCT04966689|Behavioral|combined speech and music therapy|he telerehabilitation intervention that include both speech therapy and music therapy at the same time
79812847|NCT02608320|Drug|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
79652965|NCT00222053|Drug|Thalidomide|Per os thalidomide
79652966|NCT00222053|Drug|Biphosphonates|Biphosphonates
79652967|NCT04612153|Other|Epidemiologic|Epidemiologic study. Observational, transverse study
79652968|NCT00251511|Drug|Arsenic Trioxide|
79812848|NCT02608320|Drug|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
79982715|NCT04966689|Behavioral|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
79982716|NCT04966689|Behavioral|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
79812849|NCT02608320|Drug|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
79812850|NCT02608320|Drug|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
79812851|NCT02608320|Drug|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
79812852|NCT02608320|Drug|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
79982717|NCT03280186|Procedure|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
79982718|NCT01315743|Behavioral|Team COOL|1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
79982719|NCT05155839|Drug|MRG001|Administrated intravenously
79487606|NCT03007394|Drug|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
79487607|NCT00374192|Drug|Eszopiclone|3 mg per day
79487608|NCT00374192|Drug|Placebo|Placebo
79487609|NCT00374270|Behavioral|Lifestyle Counselling; Opinion Leader Influence Statements|
79982720|NCT03279796|Biological|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
79982721|NCT03279796|Drug|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
79982722|NCT03263494|Device|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
79487610|NCT02806544|Drug|Tamoxifen|Tamoxifen 20mg by mouth daily
79487611|NCT03008174|Other|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
79982723|NCT03151395|Other|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
79982724|NCT03279172|Procedure|direct laryngoscope|procedure entubatıon
79982725|NCT03279172|Procedure|videolaryngoscope|
79982726|NCT03278392|Behavioral|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
79487612|NCT02809430|Device|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
79487613|NCT00374348|Drug|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
79982727|NCT03278392|Behavioral|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
79487614|NCT03014492|Device|Q Collar|Collar designed to mitigate slosh in the brain
79487615|NCT02928380|Device|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
79982728|NCT01340469|Biological|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
79982729|NCT02713828|Drug|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
79487616|NCT02928380|Device|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
79487617|NCT02928536|Other|no intervention|This is an observational study. No intervention is considered
79487618|NCT02930174|Device|noninvasive positive pressure ventilation|Application of various levels of positive pressure
79487619|NCT02933372|Drug|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
79982730|NCT02713828|Drug|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response [PR] or Complete Response [CR]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
79487620|NCT02933450|Drug|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
79487621|NCT02902237|Biological|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
79487622|NCT02903407|Drug|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
79487623|NCT02903407|Drug|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
79487624|NCT02903407|Drug|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
79487625|NCT02811302|Device|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
79982731|NCT05183997|Diagnostic Test|complete blood count|laboratory test
79982732|NCT05183997|Diagnostic Test|prothrombin time|laboratory test
79982733|NCT05183997|Diagnostic Test|prothrombin concentration|laboratory test
79982734|NCT05183997|Drug|Verapamil|drug will be add to prolong the effect of regional block
79812853|NCT04111887|Behavioral|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
79982735|NCT05119101|Drug|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
79487626|NCT02905981|Drug|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
79812854|NCT04111575|Behavioral|Music Therapy|Music Therapy
79982736|NCT05119101|Drug|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
79812855|NCT05728788|Drug|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
79487627|NCT02905981|Drug|Shohl's solution|Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
79487628|NCT02905981|Drug|Triferic|Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
79982737|NCT01340547|Drug|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
79982738|NCT01340547|Drug|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
79487629|NCT02907073|Drug|BF4|Single IV dose of 9-11 millicurie (mCi) sodium [Fluorine-18] radiolabeled B4^F
79982739|NCT03268408|Behavioral|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
79982740|NCT01340703|Procedure|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
79982741|NCT03263182|Behavioral|Introduction of the Safe Childbirth Checklist|"Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
79982742|NCT05002881|Other|Moringa oleifera (E-HS-01)|One capsule to be taken stat
79982743|NCT05002881|Other|Placebo|One capsule to be taken stat
79982744|NCT02458300|Other|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
79487630|NCT02812160|Device|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
79487631|NCT00374023|Drug|Zinc, or Vitamin A or both|
79487632|NCT02812238|Dietary Supplement|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
79487633|NCT02812238|Drug|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
79812856|NCT02604927|Dietary Supplement|Beta-alanine|
79812857|NCT02604927|Dietary Supplement|Dextrose|
79812858|NCT00914082|Behavioral|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
79812859|NCT04111341|Drug|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
79812860|NCT04111341|Drug|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
79487634|NCT03015649|Device|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
79487635|NCT03015961|Drug|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
79487636|NCT03015961|Drug|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
79982745|NCT02458300|Other|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
79487637|NCT02814656|Drug|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
79812861|NCT00914238|Behavioral|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
79812862|NCT00914238|Behavioral|OPUS 5 years|
79812863|NCT05681832|Behavioral|Intervention group|"The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch."
79982746|NCT02458300|Other|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
79487638|NCT02814656|Drug|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
79812864|NCT04110951|Behavioral|Pranayama Breathing Technique|Yogic Breathing Technique
79812865|NCT04110951|Behavioral|Relaxation technique|Progressive relaxation technique
79982747|NCT02458300|Other|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
79982748|NCT02458300|Other|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
79982749|NCT01316601|Drug|QAX567|
79982750|NCT03268174|Other|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
79812866|NCT00914550|Other|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
79812867|NCT02608164|Dietary Supplement|3000IU(75μg) vitamin D3|
79812868|NCT02606058|Procedure|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
79812869|NCT02604693|Other|Nothing|No interventions will be administered.
79337153|NCT02343159|Device|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
79337154|NCT02343159|Behavioral|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
79337155|NCT02395653|Drug|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
79337156|NCT01664923|Drug|Enzalutamide|160 mg, daily, by mouth.
79337157|NCT01664923|Drug|Bicalutamide|50 mg, daily, by mouth
79337158|NCT04743583|Device|Endosonography B-mode examination|Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
79337159|NCT05696665|Other|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
79337160|NCT05696665|Drug|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
79337161|NCT05696665|Drug|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
79487639|NCT03018223|Drug|Fludarabine|Myeloablative conditioning: 40 mg/m^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
79652969|NCT04611958|Drug|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
79652970|NCT00412919|Drug|Azacitidine|
79652971|NCT04611646|Behavioral|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
79487640|NCT03018223|Drug|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
79487641|NCT03018223|Drug|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
79487642|NCT03018223|Radiation|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
79487643|NCT03018223|Procedure|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
79487644|NCT03018223|Drug|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
79982751|NCT03268174|Other|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
79982752|NCT01340781|Procedure|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
79982753|NCT03277222|Biological|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
79982754|NCT03277222|Biological|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
79982755|NCT03277144|Device|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
79982756|NCT03277144|Other|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
79982757|NCT05387902|Device|Extracorporeal Membrane Oxygenation|Patients with high-risk PCI receive mechanical circulatory support with ECMO.
79337162|NCT04465201|Device|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
79337163|NCT04403347|Dietary Supplement|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
79337164|NCT04403347|Drug|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
79337165|NCT05677009|Device|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
79982758|NCT04931667|Drug|Lorecivivint|Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
79982759|NCT03262948|Drug|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
79982760|NCT03262948|Drug|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
79982761|NCT03262948|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
79337166|NCT05677009|Other|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
79652972|NCT04611646|Behavioral|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
79982762|NCT03635619|Other|No intervention|No intervention
79982763|NCT03276598|Drug|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
79982764|NCT03276598|Drug|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
79982765|NCT03276598|Drug|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
79487645|NCT03018223|Drug|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
79487646|NCT03018223|Drug|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is > 1,000/mm^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
79487647|NCT03018925|Drug|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
79487648|NCT02814890|Procedure|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
79487649|NCT02814890|Procedure|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
79652973|NCT04611490|Procedure|Spine Fusion|Each patient will undergo a spine fusion for a evolutive idiopathic scoliosis with the help of the surgivisio system.
79982766|NCT03276598|Drug|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
79982767|NCT03276598|Drug|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
79982768|NCT03263104|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
79487650|NCT03019783|Drug|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
79487651|NCT03019783|Other|Placebo|The control group will stay on their baseline regimen
79652974|NCT00222170|Drug|Rabeprazole|
79812870|NCT00915135|Drug|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
79812871|NCT02607462|Biological|PRP|
79812872|NCT02607462|Other|Placebo|
79982769|NCT03263104|Dietary Supplement|Maltodextrin|
79982770|NCT03275896|Other|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
79982771|NCT03275272|Diagnostic Test|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
79982772|NCT02875860|Device|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
79982773|NCT02875860|Device|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
79982774|NCT02875860|Other|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
79337167|NCT05675761|Drug|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
79337168|NCT01664533|Drug|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
79337169|NCT05673655|Drug|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
79337170|NCT05673655|Drug|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
79487652|NCT02815982|Behavioral|NOURISH-T|Overweight/obesity family intervention
79812873|NCT00796419|Drug|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
79982775|NCT03267706|Other|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
79982776|NCT03262792|Dietary Supplement|Placebo|Microcrystalline cellulose
79982777|NCT03262792|Dietary Supplement|Andrographis Paniculata|Andrographis Paniculata 150 mg
79982778|NCT03262792|Dietary Supplement|Andrographis Paniculata|Andrographis Paniculata 300 mg
79982779|NCT01359462|Drug|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
79982780|NCT02457988|Device|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
79982781|NCT02875392|Other|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
79812874|NCT00796419|Drug|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
79982782|NCT02875392|Other|placebo pills|taking placebo pills as if patients are under treatment.
79982783|NCT03262636|Drug|Indocyanine Green|Indocyanine Green
79982784|NCT03267862|Other|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
79982785|NCT03267784|Biological|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
79982786|NCT01366794|Other|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
79982787|NCT01359540|Device|OMNI Apex Modular™ Hip Device|
79982788|NCT01359540|Device|OMNI Apex ARC™ Hip Device|
79337171|NCT05692297|Drug|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
79337172|NCT05692297|Drug|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
79337173|NCT05696587|Other|Multimodal rehabilitation|"The multimodal rehabilitation program included comprehensive therapy 5 times a week during the 4 weeks between assessments. The therapy consists of:~Individual physical therapy focused on improving range of motion and alleviating pain in the affected limb;~Mechanical desensitization;~Transcutaneous electric nerve stimulation (TENS) electrotherapy;~Aquatherapy (arm or leg whirlpool bath of the affected extremity);~Graded Motor Imagery, including the Recognise™ app and mirror therapy;~Psychoeducation on relaxation and coping with chronic pain."
79337174|NCT05696509|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
79337175|NCT05696509|Drug|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
79337176|NCT05696509|Drug|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
79337177|NCT02584855|Drug|Ixekizumab|Administered SC
79337178|NCT02584855|Drug|Placebo|Administered SC
79337179|NCT05654935|Radiation|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
79337180|NCT05654935|Radiation|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
79812875|NCT04110873|Drug|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
79812876|NCT04110873|Drug|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
79812877|NCT04110873|Drug|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
79982789|NCT03262480|Other|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
79982790|NCT01359618|Drug|TC-5214|Single dose, oral tablets
79982791|NCT01359618|Other|Placebo comparator|Single dose, oral tablets
79337181|NCT04523857|Drug|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
79337182|NCT04523857|Drug|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
79337183|NCT02581345|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
79337184|NCT02581345|Biological|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
79337185|NCT05579509|Drug|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
79337186|NCT05579509|Behavioral|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
79337187|NCT04314661|Biological|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
79487653|NCT02815982|Behavioral|Enhanced Usual Care|Publicly available overweight/obesity materials
79982792|NCT01359618|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
79487654|NCT03019939|Drug|Isavuconazole|Given PO or IV
79812878|NCT04110717|Device|Vestal Device|Vestibular nerve stimulator
79812879|NCT04110717|Device|Control Device|Control Device
79812880|NCT04110717|Behavioral|Hypocaloric Diet|Hypocaloric diet
79982793|NCT01359618|Other|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
79812881|NCT02604615|Drug|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
79982794|NCT03267550|Device|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
79982795|NCT03267628|Procedure|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
79982796|NCT03267628|Procedure|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
79812882|NCT02604615|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
79982797|NCT03267628|Procedure|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
79337188|NCT04314661|Biological|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
79487655|NCT03017924|Device|Q collar|q-collar concussion prevention device
79982798|NCT03267628|Procedure|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
79487656|NCT03020095|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
79487657|NCT03020095|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
79487658|NCT03020095|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
79487659|NCT03020095|Drug|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)administered orally
79487660|NCT02818244|Device|Fit Bit Blaze Heart Rate Monitoring Device|
79487661|NCT02818244|Device|Garmin Forerunner 235 Heart Rate Monitoring Device|
79487662|NCT02818244|Device|Tom Tom Spark Cardio Heart Rate Monitoring Device|
79487663|NCT02818244|Device|Apple Watch Heart Rate Monitoring Device|
79487664|NCT02818244|Device|Scosche Rhythm + Heart Rate Monitor|
79812883|NCT02604615|Radiation|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
79982799|NCT05189886|Procedure|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
79652975|NCT04611724|Drug|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
79982800|NCT01359696|Drug|GDC-0425|Oral escalating dose
79982801|NCT01359696|Drug|gemcitabine|Intravenous repeating dose
79982802|NCT03268018|Device|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
79982803|NCT04323904|Other|Retrospective data collection|Retrospective data collection from patients with hantavirus infection and matching control group patients.
79337189|NCT04314661|Biological|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
79337190|NCT04314661|Biological|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
79337191|NCT05696431|Other|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
79337192|NCT05696431|Other|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
79337193|NCT05696431|Other|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
79337194|NCT05696275|Behavioral|exercise|20-30 minutes of walking and elastic band exercise per day
79652976|NCT00563758|Drug|tegaserod|
79652977|NCT00563836|Drug|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
79652978|NCT00222209|Behavioral|Experimental heat pain model|
79652979|NCT00563875|Drug|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
79652980|NCT00248196|Device|Reprieve Endovascular Temperature Therapy System|
79337195|NCT05575453|Other|Kvatchii Portal|Online education portal
79337196|NCT05629351|Other|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
79337197|NCT05575219|Drug|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
79652981|NCT04611685|Drug|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
79652982|NCT04611685|Drug|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
79652983|NCT04611412|Other|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
79337198|NCT05575219|Drug|Clonidine (protocolized initiation)|"Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-167 hours. Decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours).~Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of >/= 168 hours or with infusion time of 120-167 hours at doses >/= 1.1 mcg/kg/min. Decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
79337199|NCT05568745|Device|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
79982804|NCT03262714|Other|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
79982805|NCT03262714|Other|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
79487665|NCT02934698|Drug|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
79487666|NCT03019796|Drug|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
79337200|NCT05568745|Drug|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
79337201|NCT05568745|Drug|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
79487667|NCT03020719|Drug|Oral Glutathione|Oral Glutathione oral powder
79652984|NCT00222248|Behavioral|Pelvic floor muscle training and bladder training|
79652985|NCT00248235|Behavioral|Exercise|
79982806|NCT03262714|Other|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
79487668|NCT03020719|Drug|Placebo|Placebo oral powder
79982807|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
79487669|NCT02935088|Device|Fractional Flow Reserve|Measurement of physiologic parameters
79487670|NCT03021343|Drug|Colchicine|colchicine given as per trial protocol
79487671|NCT03022435|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
79487672|NCT03022435|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
79487673|NCT03022435|Biological|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
79487674|NCT02936648|Other|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
79652986|NCT00563914|Drug|ferroquine (SSR97193)|associated with artesunate
79652987|NCT00563914|Drug|amodiaquine|associated with artesunate
79487675|NCT03023683|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
79982808|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
79982809|NCT03127644|Drug|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
79487676|NCT03020498|Biological|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
79487677|NCT03020498|Biological|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
79487678|NCT03025945|Drug|Nepafenac 0.3%|
79982810|NCT01366950|Behavioral|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
79487679|NCT03025945|Drug|Saline Solution|
79812884|NCT04110639|Device|Intracranial pressure (ICP) monitor|The investigators' hypothesis is that by utilizing an intracranial pressure (ICP) monitor to detect the presence or absence of waveforms in the femoral head, investigators could reliably assess the perfusion levels within the femoral head and possibly reduce the incidence of osteonecrosis.
79337202|NCT04302493|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
79337203|NCT04302493|Behavioral|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
79487680|NCT02937194|Behavioral|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
79487681|NCT02937194|Behavioral|Pamphlets distribution|Oral health pamphlets distribution
79982811|NCT01362426|Drug|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
79982812|NCT01367028|Drug|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
79337204|NCT02581189|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
79337205|NCT02581189|Drug|Dasabuvir|Tablet
79337206|NCT02581189|Drug|Ribavirin|Tablet
79487682|NCT02937506|Drug|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
79487683|NCT02937506|Drug|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
79487684|NCT03026803|Drug|Oxaliplatin|Given IV
79487685|NCT03026803|Drug|Capecitabine|Given PO
79487686|NCT02938052|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
79982813|NCT01367028|Drug|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
79982814|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
79982815|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
79487687|NCT03027661|Drug|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
79487688|NCT03027661|Drug|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
79487689|NCT03022526|Procedure|CSE|
79487690|NCT03022526|Procedure|Epidural|
79487691|NCT03022526|Drug|Bupivacaine / fentaNYL|
79812885|NCT04110639|Other|Standard of Care|10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
79812886|NCT00796107|Drug|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
79812887|NCT00796107|Drug|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
79812888|NCT00795951|Biological|T.R.U.E. Test|48 hour application of 28 allergens and negative control
79982816|NCT03965962|Biological|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
79812889|NCT04110483|Procedure|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
79652988|NCT00563953|Drug|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
79982817|NCT03965962|Biological|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
79982818|NCT03965962|Biological|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
79652989|NCT00563992|Drug|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
79982819|NCT03965962|Biological|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
79337207|NCT05535127|Diagnostic Test|"Palpation with  laryngeal handshake technique"|Information alredy included
79982820|NCT03262402|Procedure|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
79337208|NCT05535127|Diagnostic Test|Palpation strategy plus sequential ultrasound|Information alredy included
79982821|NCT05188794|Procedure|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
79982822|NCT05188794|Procedure|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
79337209|NCT05535127|Diagnostic Test|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
79982823|NCT03273088|Drug|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
79337210|NCT05595655|Behavioral|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
79982824|NCT04235634|Drug|Prostavasin|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
79982825|NCT03262090|Drug|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
79337211|NCT04425265|Procedure|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
79337212|NCT04425265|Procedure|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
79982826|NCT03262090|Drug|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
79982827|NCT03262090|Drug|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
79982828|NCT03262090|Drug|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
79982829|NCT03262090|Drug|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
79982830|NCT01359774|Other|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
79982831|NCT01359774|Other|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
79337213|NCT05594641|Other|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
79337214|NCT05594641|Other|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
79337215|NCT04686253|Other|not appliable|not appliable
79487692|NCT02794441|Drug|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
79652990|NCT00563992|Drug|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
79652991|NCT00251550|Drug|Pemetrexed|
79982832|NCT03272854|Other|No intervention performed, the study is observational|
79982833|NCT03151551|Drug|Ixekizumab|Administered SC
79652992|NCT00251550|Drug|Cisplatin|
79652993|NCT04611373|Drug|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
79652994|NCT00222287|Behavioral|Feldenkrais Movement class|
79982834|NCT03151551|Drug|Adalimumab|Administered SC
79337216|NCT05551039|Other|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
79652995|NCT04611256|Biological|MSC|Two intravenous infusion of 1*10E6 adipose tissue derived-MSCs /kg body weight reach
79652996|NCT04611256|Drug|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
79337217|NCT04685941|Drug|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
79652997|NCT04611061|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
79982835|NCT01362582|Drug|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
79652998|NCT04611061|Drug|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
79337218|NCT04685941|Other|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
79337219|NCT02576977|Biological|Pembrolizumab|pembrolizumab 200 mg IV infusion
79337220|NCT02576977|Drug|Pomalidomide|pomalidomide 4 mg capsules
79652999|NCT04610983|Dietary Supplement|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
79653000|NCT04610983|Dietary Supplement|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
79653001|NCT04610983|Dietary Supplement|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
79653002|NCT04611178|Device|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
79337221|NCT02576977|Drug|Dexamethasone|dexamethasone 40 mg tablets
79337222|NCT04421755|Other|Produce delivery|weekly home delivery of fresh fruits and vegetables
79337223|NCT04421755|Other|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is ~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
79337224|NCT05213845|Procedure|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
79337225|NCT05867290|Behavioral|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
79337226|NCT05867277|Other|music|The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
79487693|NCT02794441|Other|Placebo|Matched oral solution
79487694|NCT02941640|Procedure|E group|The securing the base of appendix by endoloop.
79487695|NCT02941640|Procedure|S group|The securing the base of appendix by Stapler.
79653003|NCT00222326|Behavioral|Pelvic floor muscle training and lifestyle modification|
79653004|NCT00564031|Drug|Femanest|2mg/day
79653005|NCT00564031|Drug|gestapuran|5mg/day
79653006|NCT00564031|Drug|placebo|daily
79653007|NCT00564031|Drug|Femanest plus Gestapuran|combined daily
79653008|NCT04610632|Diagnostic Test|home pregnancy test|use of home pregnancy test
79653009|NCT00564109|Procedure|retrospective Observation|retrospective Observation
79653010|NCT00222365|Drug|Arnica montana, 5 CH|
79653011|NCT00222365|Drug|Bryonia alba, 5 CH|
79653012|NCT00222365|Drug|Hypericum perforatum, 5 CH|
79653013|NCT00222365|Drug|Ruta graveolens, 3 DH|
79653014|NCT04610437|Procedure|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
79653015|NCT02961426|Drug|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
79982836|NCT03272776|Device|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
79653016|NCT04610359|Drug|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL * 5 sites)
79653017|NCT04610281|Device|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
79982837|NCT05186376|Procedure|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
79487696|NCT02941640|Procedure|H group|The securing the base of appendix by Hem-o-lok clip.
79487697|NCT02941640|Procedure|DS group|The securing the base of appendix by DS clip.
79487698|NCT02941640|Device|Endoloop|
79487699|NCT02941640|Device|Stapler|
79487700|NCT02941640|Device|Hem-o-lok clip|
79487701|NCT02941640|Device|DS clip|
79653018|NCT04610008|Other|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
79653019|NCT04610164|Drug|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
79337227|NCT05867264|Other|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~Steward's awakening score is ≥ 6 points.~Level of sobriety ≥ 3.~There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
79337228|NCT05867264|Combination Product|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~Steward's awakening score is 6 points.~Level of sobriety ≥ 3.~There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
79337229|NCT05867264|Other|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
79337230|NCT05867212|Drug|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
79337231|NCT05867199|Behavioral|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
79337232|NCT05867160|Other|ASM as adjunctive therapy|ASM approved as adjunctive therapy
79337233|NCT05867134|Behavioral|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
79337234|NCT05867095|Procedure|Surgical navigation|Patients will be operated with assistance of a navigation system
79487702|NCT02794597|Behavioral|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
79487703|NCT00373555|Procedure|Bronchoscopy|
79487704|NCT02822612|Device|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
79487705|NCT03028363|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
79653020|NCT00222443|Drug|Irinotecan|
79653021|NCT04610203|Dietary Supplement|25 g Nutralys Pea Protein|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
79653022|NCT04610203|Dietary Supplement|50 g Nutralys S85 Plus.|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
79982838|NCT01367106|Procedure|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
79337235|NCT05867095|Procedure|Conventional|Patients will be operated using the conventional technique
79337236|NCT05867082|Other|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
79337237|NCT05866978|Behavioral|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
79337238|NCT05866965|Other|PRF|centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
79487706|NCT03028363|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
79487707|NCT02823080|Drug|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
79487708|NCT03028987|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
79487709|NCT03028987|Biological|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
79487710|NCT03022916|Drug|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
79653023|NCT04610203|Dietary Supplement|50 g Glucose|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
79487711|NCT03022916|Other|Nail polish|Application of nail polish only to both big toe nails
79337239|NCT05866965|Other|standard third molar surgical removal|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
79337240|NCT05866900|Device|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
79487712|NCT03022916|Drug|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
79337241|NCT05866861|Drug|CUG252|CUG252 will be administered by subcutaneous injection.
79337242|NCT05866861|Drug|Placebo|Placebo will be administered by subcutaneous injection.
79487713|NCT03022916|Drug|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
79487714|NCT03031795|Drug|Ketorolac|Oral Tablet
79487715|NCT03031795|Drug|Placebo|Oral Tablet
79487716|NCT02942654|Drug|LY900014|Administered subcutaneously (SC)
79487717|NCT02942654|Drug|Insulin Lispro|Administered SC
79487718|NCT02825966|Device|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
79653024|NCT04609969|Diagnostic Test|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
79487719|NCT03028220|Device|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
79982839|NCT05169216|Behavioral|Cognitive-Behavioral Therapy|"Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~Week 0. Familiarization: Information gathering~1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~2nd week: To integrate daily mental training.~3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~5th and 6th weeks: To integrate the content already provided.~7th week. Link with the team: To strengthen the bond between team members.~8th week. Daily routines: To improve the daily routine prior to the competition.~9th and 10th weeks: To integrate the content already provided."
79982840|NCT01359852|Drug|[11C] JNJ-42491293|Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
79982841|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
79982842|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|"Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
79982843|NCT01359852|Drug|[11C] JNJ-42491293|Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
79337243|NCT05866848|Other|Placebo|Flour capsules as a placebo.
79337244|NCT05866848|Other|Anhydrous caffeine (45mg)|Capsules dosed with 45mg of anhydrous caffeine.
79337245|NCT05866848|Other|Anhydrous caffeine (120mg)|Capsules dosed with 120mg of anhydrous caffeine.
79337246|NCT05866822|Other|APA|24 APA sessions
79337247|NCT05866822|Other|PAE|8 individuals sessions of PAE
79487720|NCT03028220|Device|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
79487721|NCT02909959|Drug|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
79487722|NCT02909959|Drug|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
79487723|NCT00373724|Procedure|radiofrequency denervation|
79487724|NCT00373802|Drug|Phenylephrine|
79487725|NCT04333394|Dietary Supplement|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
79487726|NCT04333394|Other|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
79487727|NCT00373633|Procedure|Thoracic Epidural|Gold standard for post thoracotomy pain
79487728|NCT00373633|Procedure|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
79337248|NCT05866796|Diagnostic Test|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
79982844|NCT05075434|Other|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
79337249|NCT05866783|Diagnostic Test|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
79982845|NCT05075434|Other|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
79337250|NCT05866783|Diagnostic Test|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
79337251|NCT05866744|Other|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
79337252|NCT05866744|Other|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
79337253|NCT05866744|Other|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
79487729|NCT02945150|Drug|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
79487730|NCT02911753|Other|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
79487731|NCT02911753|Other|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
79653025|NCT04609969|Diagnostic Test|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
79653026|NCT00222482|Drug|Depakote ER|
79982846|NCT03262168|Other|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
79982847|NCT01359930|Other|placebo|matching placebo
79653027|NCT04610125|Biological|Auto CAR-T|Biological: Auto CAR-T
79982848|NCT01359930|Drug|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
79337254|NCT05866614|Drug|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
79337255|NCT05866614|Drug|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
79337256|NCT05866588|Behavioral|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~Follow-up: Providing education and counseling for childbirth.~Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~Follow-up: To provide counseling on the issues needed with the approaching of the birth.~Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~Follow-up: To evaluate the transition to motherhood.~Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
79337257|NCT05866575|Other|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
79812890|NCT04110483|Procedure|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
79812891|NCT04110561|Device|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
79812892|NCT00795717|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
79812893|NCT00795717|Drug|Placebo|2 capsules given twice daily
79812894|NCT00805740|Drug|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
79653028|NCT04610125|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
79653029|NCT04610125|Procedure|Leukapheresis|Leukapheresis
79337258|NCT05866575|Other|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
79653030|NCT04610242|Diagnostic Test|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
79982849|NCT05075512|Drug|anlotinib, fulvestrant|anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
79982850|NCT01316757|Biological|cetuximab|Given IV
79982851|NCT01316757|Drug|paclitaxel|Given IV
79337259|NCT05866562|Drug|Dupilumab|every other week 200 mg or 300 mg (weight-based) SC injections
79487732|NCT02911753|Other|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
79487733|NCT02829320|Drug|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
79653031|NCT00564148|Drug|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
79653032|NCT00222521|Drug|Glargine insulin|
79812895|NCT00805740|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
79982852|NCT01316757|Drug|carboplatin|Given IV
79812896|NCT05613075|Procedure|tooth extraction and socket preservation with demineralized tooth graft|tooth extraction and socket preservation with demineralized tooth graft
79812897|NCT05613075|Procedure|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid
79812898|NCT04110015|Device|virtual visual field|Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
79812899|NCT02605902|Behavioral|(i)Comprehensive Behavioral Intervention for Tics|
79982853|NCT01316757|Drug|erlotinib hydrochloride|Given PO
79982854|NCT01316757|Other|laboratory biomarker analysis|Correlative studies
79982855|NCT01367340|Behavioral|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
79487734|NCT02829320|Drug|Iron|Subjects will receive supplemental iron therapy if ferritin is <=100 ng/mL and TSAT is <=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
79487735|NCT03032263|Device|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
79487736|NCT03032263|Device|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
79487737|NCT03032965|Drug|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
79487738|NCT03032965|Drug|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
79653033|NCT04609774|Other|Severe Acute Respiratory Syndrome CoronaVirus 2 detection|Severe Acute Respiratory Syndrome CoronaVirus 2 Detection by Real-Time Polymerase Chain Reaction and cell culture
79812900|NCT02605902|Behavioral|internet-delivered psychoeducation and relaxation training|
79337260|NCT05866562|Drug|Placebo|Placebo comparator
79337261|NCT05866510|Drug|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
79337262|NCT05866497|Diagnostic Test|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
79337263|NCT05866497|Diagnostic Test|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
79337264|NCT05866393|Behavioral|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
79337265|NCT05866380|Other|heart failure risk factors|observational study with diabetes patient with heart failure risk factors
79337266|NCT05866289|Other|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
79337267|NCT05866263|Other|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
79337268|NCT05866224|Other|Telerehabilitation program|The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
79487739|NCT03030638|Drug|Olodaterol|Drug
79487740|NCT03030638|Drug|Indacaterol|Drug
79487741|NCT02949518|Other|Enhanced Recovery Pathway (ERP) for Spine|The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
79653034|NCT04609540|Drug|Trastuzumab|Dual anti-HER2 therapy
79653035|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
79812901|NCT01227876|Drug|Ster|prednisolone 1% ophthalmic suspension
79812902|NCT01227876|Drug|Pred Fort|prednisolone 1% ophthalmic suspension
79812903|NCT00795639|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
79812904|NCT00795639|Drug|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
79812905|NCT05297292|Drug|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
79337269|NCT05866211|Other|Previous exposure to SARS-CoV-2|This is an observational study in which no intervention will be applied.
79337270|NCT05866172|Procedure|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
79337271|NCT05866172|Drug|Zoledronic acid|Zoledronic acid 4mg iv.drip
79337272|NCT05866146|Other|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
79337273|NCT05866146|Other|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
79337274|NCT05866120|Other|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
79337275|NCT05866120|Other|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
79337276|NCT05866120|Other|Power training|The individuals will be submitted to the same exercises as the therapy protocol on the ground, but with a focus on power training, with fewer repetitions of the exercises and greater speed of movement in the concentric phase of the movement. As with other therapies, participants will be accompanied by therapists in small activity groups.
79337277|NCT05866068|Drug|Clomiphene|Clomiphene citrate 100mg daily during IVF stimulation
79487742|NCT02949674|Drug|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
79487743|NCT02949674|Drug|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
79487744|NCT03033511|Drug|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
79487745|NCT03033511|Drug|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
79487746|NCT03033511|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
79487747|NCT03033511|Drug|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
79487748|NCT03033134|Device|BSJ003W|BSJ003W implant
79487749|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
79487750|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
79487751|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
79487752|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
79487753|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
79487754|NCT02951312|Drug|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
79812906|NCT05297292|Drug|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
79487755|NCT02951312|Drug|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
79487756|NCT02796625|Other|Painful Stimuli|warm or painful heat administration
79487757|NCT03035929|Drug|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
79487758|NCT02951702|Drug|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
79337278|NCT05866042|Device|tDCS|TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
79487759|NCT02911909|Device|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
79487760|NCT02911909|Other|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
79487761|NCT02952872|Behavioral|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
79487762|NCT02799667|Device|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
79487763|NCT02799667|Device|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
79487764|NCT02914795|Other|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
79337279|NCT05865951|Other|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
79337280|NCT05865951|Other|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
79487765|NCT02953418|Device|Radiofrequency ablation|RFA
79487766|NCT02915029|Other|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
79337281|NCT05865938|Device|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
79487767|NCT02831660|Drug|idarucizumab|
79487768|NCT02831816|Drug|ZuraPrep|Apply topically.
79487769|NCT02831816|Drug|ChloraPrep|Apply topically.
79487770|NCT02831816|Drug|ZP Vehicle|Apply topically.
79487771|NCT02832284|Device|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
79487772|NCT03036163|Drug|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
79487773|NCT03036163|Drug|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
79487774|NCT03036163|Drug|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
79487775|NCT03036163|Drug|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
79487776|NCT03036163|Drug|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
79487777|NCT03036163|Drug|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
79487778|NCT03036163|Drug|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
79487779|NCT02832674|Device|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
79487780|NCT02973607|Procedure|Nephrectomy|This is observational in design.
79487781|NCT03034928|Device|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
79487782|NCT03034928|Device|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
79337282|NCT05865925|Drug|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
79487783|NCT03034928|Device|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
79487784|NCT03034928|Device|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
79487785|NCT03038815|Device|VACOped|restriction of ankle joint motion
79487786|NCT03038815|Device|Ortho Tri|restriction of ankle joint motion
79653036|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
79653037|NCT00222560|Behavioral|Intensive physical activity counselling by an integrated physical activity counsellor|
79812907|NCT05674734|Behavioral|4FM Acceptance Training|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
79812908|NCT05612373|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
79337283|NCT05865912|Combination Product|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
79337284|NCT05865912|Combination Product|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
79487787|NCT02800213|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
79487788|NCT02800213|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
79487789|NCT02953886|Device|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
79653038|NCT04609462|Procedure|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
79653039|NCT04609462|Procedure|High flow nasal cannula|Breathing support with High-flow nasal cannula
79487790|NCT03035318|Device|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
79487791|NCT03035318|Device|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
79812909|NCT04012398|Diagnostic Test|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
79812910|NCT02604225|Drug|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
79812911|NCT02604225|Drug|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
79487792|NCT03035318|Device|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
79487793|NCT03035318|Device|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
79487794|NCT03035318|Device|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
79487795|NCT03035708|Drug|Varenicline|1 mg BID
79487796|NCT03035708|Drug|Placebo oral capsule|1 mg BID
79487797|NCT00374426|Drug|sertraline|
79487798|NCT03040154|Other|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
79487799|NCT03040154|Other|Usual Care Video that is publicly available|
79337285|NCT05865899|Procedure|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
79487800|NCT02916745|Drug|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
79487801|NCT02916745|Device|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
79487802|NCT02954198|Drug|Tacrolimus|goal trough level 5-12ng/mL
79487803|NCT02954198|Drug|Prednisone|goal dose 5mg QD
79487804|NCT02954198|Drug|Mycophenolate mofetil|goal dose 1g BID
79487805|NCT02954198|Drug|Everolimus|goal trough level 3-8ng/mL
79337286|NCT05865873|Behavioral|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
79337287|NCT05865847|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
79653040|NCT04609267|Diagnostic Test|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
79653041|NCT00222638|Drug|Influenza vaccination|
79487806|NCT02956070|Drug|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
79487807|NCT02956070|Drug|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch [50%], lactose monohydrate [35%], dibasic calcium phosphate [14%], and magnesium stearate [1%]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
79653042|NCT04609384|Device|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
79812912|NCT00537108|Behavioral|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support & skills-building for school continuation, higher education, and job readiness.
79653043|NCT04609150|Other|Bone marrow fat quantification by MRI|Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
79653044|NCT00222677|Drug|aspirin|100 mg daily
79812913|NCT02604303|Other|No Intervention|No intervention; prospective observational study
79653045|NCT00564343|Other|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
79982856|NCT01367340|Behavioral|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
79337288|NCT05865834|Other|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
79337289|NCT05865834|Other|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
79337290|NCT05865821|Procedure|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
79337291|NCT05865821|Other|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
79487808|NCT02956616|Drug|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
79487809|NCT02956616|Other|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
79487810|NCT02956616|Procedure|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
79487811|NCT02809183|Drug|Placebo|oral suspension
79982857|NCT01362660|Other|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
79487812|NCT02809183|Drug|TRC101|oral suspension
79487813|NCT02958956|Drug|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
79487814|NCT02833922|Behavioral|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
79487815|NCT02917447|Behavioral|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
79487816|NCT02917447|Behavioral|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
79487817|NCT05829616|Drug|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
79487818|NCT05829590|Diagnostic Test|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
79487819|NCT05829551|Drug|RAY1216 dose 1|RAY1216 dose 1 or Placebo
79653046|NCT00564382|Procedure|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
79653047|NCT00564460|Drug|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
79653048|NCT00564460|Drug|Placebo|Placebo once daily for 8 weeks
79653049|NCT04609033|Drug|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
79653050|NCT04609033|Drug|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
79337292|NCT05865782|Behavioral|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
79337293|NCT05865769|Other|Balance|measuring pulmonary and vestibular functions in all subjects
79982858|NCT05074966|Drug|Experimental: mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
79337294|NCT05865730|Other|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
79487820|NCT05829551|Drug|RAY1216 dose 2|RAY1216 dose 2 or Placebo
79487821|NCT05829551|Drug|RAY1216 dose 3|RAY1216 dose 3 or Placebo
79487822|NCT05829551|Drug|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 &ritonavir or Placebo
79982859|NCT05074966|Drug|Active Comparator: FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
79337295|NCT05865717|Behavioral|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) & desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
79487823|NCT05829551|Drug|RAY1216 dose 5|RAY1216 dose 5 or Placebo
79653051|NCT04609033|Drug|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
79653052|NCT04609033|Drug|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
79653053|NCT00222716|Behavioral|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
79487824|NCT05829551|Drug|RAY1216 dose 6|RAY1216 dose 6 or Placebo
79487825|NCT05829551|Drug|RAY1216 dose 7|RAY1216 dose 7 or Placebo
79487826|NCT05829551|Drug|RAY1216 dose 8|RAY1216 dose 8 or Placebo
79487827|NCT05829551|Drug|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
79487828|NCT05829551|Drug|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
79487829|NCT05829538|Behavioral|SuJok|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.
79487830|NCT05829538|Behavioral|Massage|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
79487831|NCT05829473|Other|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
79653054|NCT04608799|Drug|Perampanel|Efficacy of epilepsy drugs
79812914|NCT00589602|Procedure|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be >0.5 x 105 but <1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be >2 x 106 cells/kg.
79812915|NCT00589602|Procedure|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
79982860|NCT01340859|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
79982861|NCT01362738|Procedure|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
79982862|NCT01362738|Procedure|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
79337296|NCT05865717|Other|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
79337297|NCT05865691|Other|biomarker assay|blood sample on the day of inclusion
79653055|NCT04608565|Device|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
79653056|NCT00248313|Drug|Rapamune®|
79812916|NCT00589602|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
79812917|NCT00589602|Radiation|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
79982863|NCT01341015|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
79337298|NCT05865639|Behavioral|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
79337299|NCT05865639|Behavioral|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
79337300|NCT05865626|Other|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
79812918|NCT00794157|Drug|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
79812919|NCT00794157|Drug|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
79487832|NCT05829473|Other|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
79487833|NCT05829447|Device|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
79487834|NCT05829382|Dietary Supplement|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
79487835|NCT05829382|Dietary Supplement|Placebo|Capsule containing placebo administered daily by the participant during the trial period
79487836|NCT05829369|Other|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
79337301|NCT05865613|Device|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
79487837|NCT05829369|Other|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
79653057|NCT00222755|Behavioral|Disease Management|Self-management, care management, guidelines
79653058|NCT04608760|Drug|Meksibel|2 ml solution
79653059|NCT04608370|Behavioral|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
79812920|NCT00794157|Drug|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
79487838|NCT05829369|Other|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
79487839|NCT05829304|Other|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A&B will be at the same patient.
79487840|NCT05829304|Other|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A&B will be at the same patient.
79487841|NCT05829278|Procedure|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
79653060|NCT04608370|Behavioral|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
79653061|NCT04608526|Diagnostic Test|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
79653062|NCT00248352|Behavioral|Consultation with Endocrinologist|
79653063|NCT00248352|Behavioral|Counseling from Dietician|
79653064|NCT00248352|Behavioral|Counseling from Diabetes Educator|
79653065|NCT00222794|Drug|Atomoxetine (Strattera)|
79653066|NCT04608253|Diagnostic Test|11C-choline PET/CT|11C-choline PET/CT
79653067|NCT04608643|Diagnostic Test|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
79653068|NCT04608175|Other|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
79653069|NCT00222833|Drug|Aripiprazole|
79653070|NCT04608097|Behavioral|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
79812921|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
79337302|NCT05865600|Other|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure > 100 mmHg.
79487842|NCT05829265|Behavioral|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
79487843|NCT05829213|Procedure|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~Creating the seromuscular flap (arch-bridge)~The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
79982864|NCT03267004|Device|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich [whole wheat bread 52g(female & male), Turkey 70g(female) & 133g(male), Provolone cheese 23g(female & male), tomato 50g(female & male), lettuce 45g(female & male)]; Chicken and wild rice [chicken 98g(female & male), wild rice 71g(female) & 107g(male)]; chocolate chips cookies [44g(female) & 60.5g(male)]; potato chips [39g(female) & 52g(male)]."
79982865|NCT03267004|Device|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham & Cheddar cheese wrap [Tortilla 45g(female & male), Ham deli 76g(female) & 103g(male), cheddar cheese 21g(female) & 32g(male), Spring Mix 36g(female & male), Fat Free ranch dressing 29g(female & male)]; Pasta with broccoli and Alfredo sauce [Pasta 91g(female) & 121g(male), Broccoli 66g(female & male), Alfredo sauce 38g(female) & 50g(male)]; Chocolate Ice-cream [107g(female), 138g(male)]; Red seedless grapes [365g (female), 471g(male)]."
79982866|NCT01341093|Behavioral|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
79982867|NCT01341093|Behavioral|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
79337303|NCT05865600|Diagnostic Test|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
79337304|NCT05865600|Diagnostic Test|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
79337305|NCT05865600|Other|Standard of care|Standard of care
79653071|NCT04608097|Behavioral|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
79653072|NCT04607902|Behavioral|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
79812922|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
79812923|NCT02607072|Drug|Placebo|
79982868|NCT03267082|Other|Laparoscopic management of perforated appendicitis|"Insertion of Ports~Exposure of the Appendix~peritoneal toilet and aspiration of pus after abdominal exposure~Isolation of Mesoappendicular Artery~Clipping and Dividing of the Artery~Application of 3 x Endoloops~Division of the Appendix~Retrieval of the Appendix in an Endobag"
79982869|NCT05188482|Device|vibroacoustic therapy|Vibroacoustic respiratory therapy
79982870|NCT03266926|Drug|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
79982871|NCT03266926|Drug|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
79982872|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
79982873|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
79337306|NCT05865574|Drug|BAT1706 Injection|1 vial/carton, 400 mg/16 mL/vial
79337307|NCT05865548|Drug|Aspirin 150 mg|Aspirin 150 mg PO daily
79337308|NCT05865548|Procedure|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
79337309|NCT05865509|Other|Escape room|Students were given training on stress response using the escape room method.
79337310|NCT05865509|Other|Storytelling|Students were given training on stress response using the storytelling method.
79337311|NCT05864079|Diagnostic Test|Platelet count|Platelet count in study groups
79337312|NCT05864079|Diagnostic Test|Developmental endothelial locus-1 (DEL-1)|Serum DEL-1 in study groups
79337313|NCT05864079|Diagnostic Test|soluble P-selectin (sP-sel)|Serum sP-sel in study groups
79337314|NCT05863247|Other|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
79337315|NCT05862363|Dietary Supplement|Microbiota-directed complementary food (MDCF)-2|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
79487844|NCT05829200|Device|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
79487845|NCT05829161|Behavioral|no intervention|no intervention
79337316|NCT05862363|Dietary Supplement|Ready-to-use supplementary food (RUSF)|RUSF is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MDCF-2 is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth6. RUSF will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
79487846|NCT05829148|Drug|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
79487847|NCT05829148|Drug|Melatonin|Melatonin
79487848|NCT05829148|Drug|Pregabalin|Pregabalin
79487849|NCT05829148|Drug|Placebo|Placebo
79487850|NCT05829122|Procedure|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
79487851|NCT05829096|Other|The COMBINED approach|"Patient-level intervention:~Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~Clinician-level implementation toolkit:~Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
79982874|NCT01343745|Drug|Placebo|pressurised metered dose inhaler
79982875|NCT03267160|Diagnostic Test|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
79982876|NCT01367418|Drug|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
79982877|NCT01367418|Drug|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
79982878|NCT03266692|Biological|ACTR087|Autologous T cell product
79982879|NCT03266692|Biological|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
79487852|NCT05829057|Biological|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
79487853|NCT05829057|Biological|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
79487854|NCT05829018|Diagnostic Test|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
79487855|NCT05828862|Procedure|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
79982880|NCT03147495|Diagnostic Test|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
79982881|NCT01360086|Biological|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
79982882|NCT01360086|Drug|cisplatin|Cisplatine (50mg/m²)
79337317|NCT05862363|Procedure|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (<18.5kg/m2; 18-30 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
79337318|NCT05862363|Behavioral|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care
79337319|NCT05862012|Drug|ISB 2001|Participants will receive escalating doses of ISB 2001
79982883|NCT01360086|Drug|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
79982884|NCT01360086|Drug|leucovorin calcium|
79982885|NCT01360086|Procedure|adjuvant therapy|
79982886|NCT01360086|Procedure|neoadjuvant therapy|
79982887|NCT01360086|Procedure|quality-of-life assessment|
79982888|NCT01360086|Procedure|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
79982889|NCT03262246|Other|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
79982890|NCT04454346|Device|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
79982891|NCT05183451|Procedure|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
79982892|NCT05183451|Procedure|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
79982893|NCT02458924|Biological|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
79982894|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 1
79982895|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 2
79982896|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 3
79982897|NCT01367496|Drug|IV Methylnaltrexone (MNTX)|
79982898|NCT02458846|Other|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
79337320|NCT05862012|Drug|ISB 2001|Participants will receive injection of ISB 2001 at 2 putative recommended Phase 2 doses as determined in Part 1.
79487856|NCT05828862|Procedure|no hypotension prediction index guidance|silencing hypotension prediction index guidance during surgery
79487857|NCT05828784|Device|Intersomatic arthrodesis|"Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain."
79487858|NCT05828771|Procedure|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
79487859|NCT05828745|Drug|CB06-036|CB06-036 capsule
79487860|NCT05828745|Drug|Placebo|Placebo capsule
79487861|NCT05828732|Other|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
79653073|NCT04607902|Behavioral|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
79487862|NCT05828680|Other|Observation|No intervention
79487863|NCT05828576|Diagnostic Test|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
79337321|NCT05861440|Drug|Prednisolone|adjunct steroid per study protocol
79653074|NCT04607902|Behavioral|Growth Mindset SSI|Online, 30-minute self-administered program for youth
79337322|NCT05861440|Drug|standard anti-tuberculosis agents|standard anti-tuberculosis agents
79337323|NCT05858814|Biological|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
79337324|NCT05858125|Other|Social Media Navigation Aid Kit|"The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to >65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference."
79337325|NCT05854654|Diagnostic Test|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
79337326|NCT05853094|Procedure|Ileostomy|Protective loop ileostomy after low anterior resection
79337327|NCT05853094|Procedure|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
79487864|NCT05828563|Diagnostic Test|Blood sample test|Blood sample will be taken to determine immunological indices
79487865|NCT05828550|Diagnostic Test|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
79653075|NCT00251628|Other|Standard Care|standard care
79653076|NCT00251628|Other|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
79653077|NCT00251628|Other|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
79653078|NCT00251628|Other|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
79337328|NCT05834491|Device|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
79653079|NCT04608058|Behavioral|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
79982899|NCT02458846|Other|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
79653080|NCT04608058|Behavioral|Routine training|The control group received the clinics' routine training include face to face class education.
79653081|NCT00564538|Drug|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
79653082|NCT00564538|Drug|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
79337329|NCT05834491|Device|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
79653083|NCT00251706|Drug|amiodarone|
79653084|NCT00199121|Drug|Zidovudine (drug)|
79812924|NCT04110093|Drug|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
79337330|NCT05828992|Other|No intervention administered|Survey only to gather people's experiences, opinions and needs.
79337331|NCT05820295|Behavioral|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
79337332|NCT05820295|Behavioral|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
79337333|NCT05819502|Drug|Restylane line of injectable|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
79653085|NCT04607824|Behavioral|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
79653086|NCT04607824|Behavioral|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
79653087|NCT04607863|Diagnostic Test|Case control|Is a case-control research
79653088|NCT04607785|Drug|Miswak mouthwash group|Twice daily for seven days for two months
79653089|NCT04607785|Device|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
79653090|NCT00248391|Behavioral|upright feeding|
79653091|NCT00199160|Drug|BAY 43-9006|
79653092|NCT04607629|Biological|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
79812925|NCT02607150|Other|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
79487866|NCT05828498|Dietary Supplement|THE Mediterranean diet|The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
79487867|NCT05828485|Drug|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
79337334|NCT05816304|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
79653093|NCT04607629|Biological|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
79337335|NCT05805345|Device|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
79337336|NCT05805345|Device|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
79337337|NCT05805345|Device|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
79337338|NCT05805345|Device|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
79337339|NCT05782062|Device|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
79337340|NCT05782062|Device|Balloon|Use of balloon for disrupting thrombus.
79337341|NCT05771025|Procedure|Hepatectomy|Patients in the hepatectomy group receive liver resection.
79487868|NCT05828446|Device|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
79487869|NCT05828433|Other|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
79653094|NCT00251784|Drug|Sildenafil|
79653095|NCT04607473|Device|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
79653096|NCT05558852|Procedure|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
79653097|NCT04607512|Drug|telaglenastat|glutaminase inhibitor
79653098|NCT04607512|Other|telaglenastat placebo|matching placebo for telaglenastat
79653099|NCT04607512|Other|moxifloxicin|positive control
79653100|NCT04607239|Procedure|Telemonitoring|"A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~A monthly call by the attending physician for treatment titration and side effects check."
79653101|NCT04607239|Procedure|Usual Care without Telemonitoring|"Attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician.~Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
79337342|NCT05866029|Drug|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
79812926|NCT03180918|Procedure|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
79337343|NCT05866029|Drug|Teriparatide|Teriparatide was sequentially treated with Denosumab
79337344|NCT05764278|Other|exercise|exercise group: first bed exercise after 0~24hr onset ; sit at bed after 24~48hr onset control group: first bed exercise after 24~48hr onset ; sit at bed after 48~72hr onset
79337345|NCT05762705|Behavioral|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
79337346|NCT05762705|Behavioral|Treatment as Usual +|non-PrEP related mobile gaming application
79337347|NCT05751473|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
79487870|NCT05828433|Other|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
79487871|NCT05828420|Other|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
79487872|NCT05828420|Other|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
79487873|NCT05828420|Other|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
79487874|NCT05828394|Procedure|DFGG|Depithelised free gingival graft harvesting technique
79487875|NCT05828394|Procedure|SCTG|Subepithelial connective tissue graft harvesting technique
79487876|NCT05828381|Drug|Envafolimab|300mg,sc,d1,q3w; for a total of 2 cycles.
79487877|NCT05828381|Drug|Abraxane|100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
79487878|NCT05828381|Drug|Cisplatin|75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
79337348|NCT05751473|Behavioral|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
79487879|NCT05828316|Behavioral|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
79487880|NCT05828264|Behavioral|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
79487881|NCT05828251|Procedure|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
79487882|NCT05828251|Procedure|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
79487883|NCT05828251|Procedure|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
79487884|NCT05828238|Drug|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
79487885|NCT05828238|Drug|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
79487886|NCT05828225|Drug|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
79487887|NCT05828212|Drug|CD19 CAR-T cells injection|CD19 CAR-T cells in the treatment of R/R neuromyelitis optica
79487888|NCT05828199|Drug|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
79487889|NCT05828199|Drug|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
79653102|NCT04607395|Radiation|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
79653103|NCT00248430|Biological|aldesleukin|
79653104|NCT00248430|Biological|therapeutic allogeneic lymphocytes|
79487890|NCT05828121|Behavioral|POINT1|Receiving treatment
79653105|NCT00248430|Drug|melphalan|
79653106|NCT00248430|Procedure|bone marrow ablation with stem cell support|
79653107|NCT00248430|Procedure|peripheral blood stem cell transplantation|
79653109|NCT04607161|Other|no intervention|no intervention
79653110|NCT04607278|Dietary Supplement|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
79653111|NCT04607278|Dietary Supplement|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
79653112|NCT04607278|Dietary Supplement|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
79653113|NCT00564577|Biological|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
79337349|NCT05747105|Behavioral|Sleep Extension|The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, ~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
79337350|NCT05740618|Drug|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
79653114|NCT04719975|Other|Mental Fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
79653115|NCT04719975|Other|Control (Documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
79653116|NCT00564616|Device|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
79337351|NCT05736718|Behavioral|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
79487891|NCT05828056|Device|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
79337352|NCT05736718|Behavioral|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
79337353|NCT05698290|Other|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
79337354|NCT05691387|Behavioral|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
79337355|NCT05691387|Behavioral|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
79337356|NCT05684198|Device|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
79337357|NCT05684146|Device|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
79337358|NCT05684146|Device|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
79337359|NCT05682846|Drug|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
79337360|NCT05682222|Drug|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
79337361|NCT05682222|Drug|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
79487892|NCT05827991|Device|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
79487893|NCT05827991|Drug|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
79487894|NCT05827991|Device|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
79487895|NCT05827939|Other|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
79337362|NCT05682222|Drug|Placebo oral capsule|Placebo.
79337363|NCT05677295|Drug|duloxetine|Duloxetine 30 mg per day
79487896|NCT05827913|Device|Polylevolactic Acid Injection|The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
79487897|NCT05827913|Device|1565nm Non-ablative Fractional Laser|M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
79487898|NCT05827913|Device|Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser|combination of the two treatments described above
79487899|NCT05827848|Device|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
79487900|NCT05827835|Drug|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
79337364|NCT05677295|Drug|Imipramine|Imipramine 25 mg per day
79337365|NCT05664750|Drug|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
79487901|NCT05827835|Other|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
79487902|NCT05827796|Drug|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
79487903|NCT05827796|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
79337366|NCT05664750|Drug|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
79487904|NCT05827796|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
79487905|NCT05827796|Drug|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
79487906|NCT05827783|Procedure|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
79337367|NCT05623514|Combination Product|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
79337368|NCT05608304|Behavioral|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
79337369|NCT05608304|Behavioral|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
79653117|NCT00564655|Procedure|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
79337370|NCT05608304|Behavioral|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley & Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
79337371|NCT05580640|Procedure|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
79982900|NCT02458846|Device|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
79337372|NCT05569122|Diagnostic Test|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
79337373|NCT05569122|Device|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
79337374|NCT05569122|Device|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
79337375|NCT05569122|Device|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
79337376|NCT05569122|Drug|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
79337377|NCT05499741|Device|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
79337378|NCT05476991|Drug|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
79337379|NCT05476991|Drug|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
79337380|NCT05476991|Drug|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
79337381|NCT05471323|Biological|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
79337382|NCT05465226|Drug|Oliceridine|see arm description
79337383|NCT05465226|Drug|Historical opioid use|Historical matched, control group in 2:1 ratio
79337384|NCT05464134|Radiation|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
79982901|NCT02458846|Other|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near & far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
79337385|NCT05461599|Device|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
79337386|NCT05455710|Device|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
79337387|NCT05451693|Behavioral|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
79337388|NCT05450003|Device|Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation|irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
79337389|NCT05443321|Other|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
79337390|NCT05437380|Diagnostic Test|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
79337391|NCT05402436|Other|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
79337392|NCT05382806|Drug|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
79337393|NCT05379972|Drug|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
79337394|NCT05379972|Drug|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
79337395|NCT05379972|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
79337396|NCT05369494|Other|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
79337397|NCT05366400|Diagnostic Test|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
79337398|NCT05362435|Behavioral|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
79337399|NCT05358366|Behavioral|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
79337400|NCT05336188|Device|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
79337401|NCT05335187|Device|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
79337402|NCT05334420|Behavioral|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
79337403|NCT05334420|Other|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
79982902|NCT05183373|Other|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
79337404|NCT05312008|Drug|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
79337405|NCT05312008|Drug|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
79337406|NCT05307900|Other|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
79337407|NCT05296252|Behavioral|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
79337408|NCT05296252|Behavioral|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
79337409|NCT05281874|Behavioral|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
79337410|NCT05281874|Behavioral|A healthy lifestyles attention control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
79337411|NCT05281874|Behavioral|Positive Change (+Change) Plus Booster|Positive Change (+Change) Plus Booster
79337412|NCT05280639|Device|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
79337413|NCT05280639|Other|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
79337414|NCT05268276|Other|1-perineal ice-gel pad application|For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
79653118|NCT00564655|Procedure|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
79653119|NCT00564694|Procedure|psychosocial assessment and care|
79653120|NCT00564694|Procedure|quality-of-life assessment|
79487907|NCT05827783|Procedure|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
79487908|NCT05827770|Drug|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
79487909|NCT05827731|Behavioral|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
79653121|NCT04719546|Other|Observation of related perinatal factors|Data described in Primary outcome measures will be collected in both groups
79653122|NCT04607083|Diagnostic Test|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
79653123|NCT04606849|Other|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
79653124|NCT04606849|Device|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
79653125|NCT01580722|Procedure|early reconstruction|patients underwent < 8 weeks reconstruction after injury
79337415|NCT05268276|Other|2-performance of pelvic floor exercises (Kegel exercises)|women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
79487910|NCT05827692|Behavioral|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
79487911|NCT05827666|Dietary Supplement|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
79487912|NCT05827666|Dietary Supplement|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
79487913|NCT05827666|Dietary Supplement|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
79653126|NCT01580722|Procedure|delay reconstruction|patients underwent > 8 weeks reconstruction after injury
79653127|NCT04606810|Other|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
79653128|NCT04606888|Device|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
79653129|NCT00248469|Behavioral|In-school Sexual Health Education|
79812927|NCT00588237|Drug|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
79653130|NCT00248469|Behavioral|Youth-friendly health services|
79653131|NCT00248469|Behavioral|Youth condom promotion & distribution|
79812928|NCT02605746|Drug|ceritinib 750mg|
79653132|NCT00248469|Behavioral|Community activities related to adolescent sexual health|
79653133|NCT04606654|Other|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
79812929|NCT02604381|Dietary Supplement|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
79812930|NCT02604381|Other|Placebo|
79982903|NCT05074576|Other|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
79812931|NCT04109781|Procedure|Microscope assisted discectomy|Microdiscectomy
79812932|NCT04109859|Drug|Saline|When using saline, if found mean arterial pressure <65mmHg, Cardic Output>4L/min, Sequential Vascular Response<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
79812933|NCT04109859|Drug|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
79812934|NCT04010058|Device|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
79812935|NCT00790023|Drug|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
79812936|NCT00790023|Drug|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
79812937|NCT00790023|Drug|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
79337416|NCT05268276|Other|3- perineal warm compresses application|women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
79337417|NCT05242432|Biological|Ad26/protein preF RSV Vaccine|Ad26/protein preF RSV vaccine will be administered as an IM injection.
79337418|NCT05242432|Other|Placebo|Matching Placebo will be administered as an IM injection
79487914|NCT05827666|Dietary Supplement|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
79812938|NCT00588822|Biological|Rituximab|Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
79337419|NCT05220982|Behavioral|Conversation Training Therapy|Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
79337420|NCT05220982|Behavioral|Global Voice Prevention and Therapy Model|Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
79337421|NCT05220982|Behavioral|Modified Conversation Training Therapy|Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
79487915|NCT05827640|Other|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
79487916|NCT05827588|Device|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
79487917|NCT05827575|Device|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
79487918|NCT05827562|Diagnostic Test|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~CD3+CD4-CD8αα+~CD3+CD4-CD8α+CD8βlow~CD3+CD4-CD8α+CD8βhigh~CD3+CD4+CD8αβhigh~CD3+CD4+CD8αα+"
79812939|NCT04115202|Procedure|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
79812940|NCT05563467|Drug|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
79487919|NCT05827497|Drug|Baricitinib 2 MG|baricitinib 2 mg once daily
79487920|NCT05827497|Drug|Methotrexate 25mg|25mg daily
79487921|NCT05827471|Diagnostic Test|Diagnosis of colon cancer|Clinical diagnosis results
79487922|NCT05827393|Procedure|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
79487923|NCT05827380|Behavioral|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
79487924|NCT05827315|Diagnostic Test|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
79487925|NCT05827315|Diagnostic Test|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
79487926|NCT05827315|Diagnostic Test|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
79487927|NCT05827263|Diagnostic Test|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
79653134|NCT04606654|Other|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
79487928|NCT05827263|Device|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
79653135|NCT04606147|Procedure|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position &arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
79653136|NCT04606147|Procedure|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
79653137|NCT00251823|Drug|Eptifibatide facilitated PCI|
79653138|NCT04606225|Drug|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
79982904|NCT05074576|Other|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
79982905|NCT01341249|Drug|Experimental DW224aa|DW224aa tablet, single dose
79982906|NCT01341249|Drug|Experimental DW224a|DW224a capsule, single dose
79653139|NCT04606225|Drug|Placebo Oral Tablet|administration of placebo (oral)
79653140|NCT05528549|Other|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
79982907|NCT01360164|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
79653141|NCT04606108|Drug|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with Liposome doxorubicin and Ifosfamide
79812941|NCT00914706|Other|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
79982908|NCT02459158|Drug|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
79982909|NCT02459158|Drug|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
79982910|NCT03634956|Drug|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
79982911|NCT01344135|Dietary Supplement|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
79982912|NCT01344135|Dietary Supplement|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
79487929|NCT05827263|Diagnostic Test|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
79487930|NCT05827250|Device|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
79337422|NCT05220982|Behavioral|Modified Global Voice Prevention and Therapy Model|Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
79337423|NCT05213923|Procedure|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
79982913|NCT01344135|Behavioral|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~Optimising dietary intake to physical activity pattern and energy expenditure.~Minimize deterioration of dietary intake during acute exacerbations.~Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
79337424|NCT05209243|Radiation|SBRT|SBRT (all metastatic lesions)
79337425|NCT05209243|Radiation|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
79337426|NCT05203237|Biological|VK2735|Administered SC
79337427|NCT05203237|Biological|Placebo|Administered SC
79337428|NCT05203237|Drug|VK2735 Placebo|Administered orally
79337429|NCT05203237|Drug|VK2735 Drug|Administered orally
79337430|NCT05195931|Diagnostic Test|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
79812942|NCT00589914|Drug|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
79812943|NCT00589914|Drug|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
79487931|NCT05827120|Device|Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis|"Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;"
79337431|NCT05195931|Diagnostic Test|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
79653142|NCT04719507|Procedure|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
79982914|NCT01344135|Behavioral|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~Integration of exercise behaviour into daily routine~Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
79337432|NCT05195931|Diagnostic Test|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
79337433|NCT05163496|Drug|Psilocybin (Usona Institute)|PAP + psilocybin 25 mg
79487932|NCT05827120|Device|Local catheter directed thrombolysis alone|- Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
79337434|NCT05163496|Drug|Active placebo|PAP + niacin 250mg
79337435|NCT05162443|Drug|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
79337436|NCT05150964|Device|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
79337437|NCT05135533|Device|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting.
79487933|NCT05825846|Device|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (~2 min) involves the participant physically walking down a ~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
79487934|NCT05825495|Drug|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
79487935|NCT05825495|Other|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
79982915|NCT03261934|Other|No intervention|No intervention
79982916|NCT01367574|Drug|SC MNTX|Dose 1
79337438|NCT05135533|Device|Sham|The Sham group will not receive electrical stimulation.
79337439|NCT05135533|Other|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting
79487936|NCT05825443|Drug|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
79487937|NCT05824169|Genetic|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
79337440|NCT05114668|Drug|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
79487938|NCT05824104|Other|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
79653143|NCT04719507|Procedure|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
79653144|NCT04719507|Drug|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
79653145|NCT04605757|Other|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
79982917|NCT01367574|Drug|SC MNTX|Dose 2
79982918|NCT01367574|Drug|SC MNTX|Dose 3
79982919|NCT05074108|Behavioral|Pilot study|Aiming for an interaction 6 week course that will discuss many aspects of health and wellness.
79982920|NCT04693689|Other|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
79337441|NCT05112432|Device|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
79337442|NCT05112432|Behavioral|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
79982921|NCT04693689|Other|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
79337443|NCT05112432|Other|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
79337444|NCT05107960|Drug|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
79337445|NCT05091255|Procedure|Cryotherapy|The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
79337446|NCT05085756|Behavioral|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
79337447|NCT05013190|Other|No intervention|This is a non-interventional study.
79337448|NCT04952402|Biological|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
79337449|NCT04952402|Biological|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
79653146|NCT04605835|Diagnostic Test|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
79487939|NCT05824052|Other|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
79487940|NCT05824039|Dietary Supplement|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
79653147|NCT04605952|Diagnostic Test|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
79982922|NCT04693689|Other|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
79982923|NCT04693689|Other|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
79982924|NCT04693689|Other|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
79337450|NCT04952402|Biological|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
79337451|NCT04941144|Biological|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
79982925|NCT04693689|Other|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
79982926|NCT04693689|Other|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
79982927|NCT03266848|Diagnostic Test|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
79337452|NCT04938895|Behavioral|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
79487941|NCT05823090|Device|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
79337453|NCT04930055|Biological|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
79337454|NCT04890535|Drug|TBAJ-587|oral suspension
79337455|NCT04890535|Drug|Placebo|matching placebo oral suspension for TBAJ-587
79337456|NCT04849000|Drug|SHR-1209|SHR-1209
79337457|NCT04849000|Drug|SHR-1209 Placebo|SHR-1209 Placebo
79487942|NCT05822934|Drug|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
79337458|NCT04843319|Drug|VERU-100|GnRH antagonist
79337459|NCT04842045|Drug|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
79487943|NCT05821972|Drug|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
79487944|NCT05821972|Drug|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
79982928|NCT03266614|Behavioral|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
79982929|NCT03126786|Drug|IVT aflibercept|IVT aflibercept [2 mg/0.05 mL]
79982930|NCT03126786|Drug|Sham SC|sham SC
79337460|NCT04839302|Drug|Indocyanine green solution|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
79487945|NCT05821764|Other|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~The cord blood sample (10 mL) immediately after delivery.~Data collection :~A data collection sheet for the attention of the investigator (doctor or midwife) ;~Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
79653148|NCT04605640|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
79982931|NCT03126786|Drug|SC CLS-TA|CLS-TA [4 mg/100 μL] SC injection
79337461|NCT04810650|Other|Mobility Dynamic Treatment Intervention|"1) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
79337462|NCT04810650|Other|Health Living Intervention for Heavy Alcohol Users|1) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
79337463|NCT04810650|Other|Hypertension Linkage|1) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
79337464|NCT04810650|Other|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
79337465|NCT04810650|Other|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
79337466|NCT04810650|Other|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
79337467|NCT04810650|Other|Standard of Care|Local country standard of care protocols
79337468|NCT04810650|Other|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
79487946|NCT05816525|Procedure|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
79487947|NCT05816525|Procedure|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
79487948|NCT05815446|Device|CT|NON CONTASR COMPUTED TOMOGRAPHY
79487949|NCT05812976|Other|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
79487950|NCT05812976|Other|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
79653149|NCT04605562|Drug|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
79653150|NCT04605562|Drug|Palbociclib|Administered orally
79487951|NCT05811598|Device|repeated ultra low lever red light|Myopia indoor lighting therapy
79653151|NCT04605562|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
79653152|NCT04605562|Drug|PD-1 blocking antibody|Administered every 3 weeks
79653153|NCT04605562|Drug|Galunisertib|Administered orally
79653154|NCT00248586|Behavioral|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
79487952|NCT05807516|Other|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
79487953|NCT05803616|Diagnostic Test|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
79487954|NCT05794178|Behavioral|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
79487955|NCT05794178|Behavioral|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
79487956|NCT05794178|Behavioral|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more [40%], sit less [40%], inspirational quotes [20%])
79982932|NCT04593771|Drug|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
79653155|NCT00248586|Behavioral|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
79653156|NCT00402857|Behavioral|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
79653157|NCT04605523|Procedure|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
79653158|NCT04605601|Other|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
79812944|NCT00789555|Drug|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
79812945|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
79982933|NCT05183061|Drug|Ehedrine Norepineprine|No interventions required considering that this was a retrospective study.
79982934|NCT03266458|Procedure|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
79812946|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
79812947|NCT04009902|Behavioral|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
79982935|NCT01360242|Procedure|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
79982936|NCT01360242|Procedure|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
79487957|NCT05794178|Behavioral|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
79487958|NCT05787392|Behavioral|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
79812948|NCT03905460|Diagnostic Test|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
79337469|NCT04795895|Diagnostic Test|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
79337470|NCT04795895|Diagnostic Test|Standard routine (SR)|Standard routine (SR)
79337471|NCT04780815|Other|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
79337472|NCT04780815|Other|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
79337473|NCT04754945|Drug|Bortezomib|Given SC
79337474|NCT04754945|Drug|Cyclophosphamide|Given IV or PO
79337475|NCT04754945|Drug|Dexamethasone|Given IV or PO
79337476|NCT04754945|Biological|Isatuximab|Given IV
79337477|NCT04754776|Biological|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
79337478|NCT04728841|Genetic|Injection of GS001|"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is < 5 IU/dL.The dose levels are as follows:~2×10^12 vg/kg~6×10^12vg/kg or other recommended doses~2×10^13 vg/kg or other recommended doses"
79653159|NCT04605601|Other|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
79812949|NCT04112472|Device|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
79982937|NCT04581057|Biological|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~Search for CHIP-associated mutations in circulating leukocytes~Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
79337479|NCT04723667|Behavioral|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
79337480|NCT04723667|Behavioral|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
79337481|NCT04702178|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
79337482|NCT04702178|Biological|Saline Placebo|Intramuscular injection of saline placebo
79337483|NCT04698967|Behavioral|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
79337484|NCT04698967|Behavioral|Transitional Work Experience|Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
79337485|NCT04588740|Drug|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
79487959|NCT05774236|Device|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
79487960|NCT05774236|Drug|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
79982938|NCT02456506|Radiation|Hyperfractionated IMRT|
79487961|NCT05764473|Other|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
79487962|NCT05764473|Other|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
79337486|NCT04588740|Drug|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
79337487|NCT04580498|Drug|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
79337488|NCT04580498|Drug|SHR-1701|Drug: SHR-1701 30mg/kg
79337489|NCT04574843|Procedure|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
79653160|NCT04605367|Device|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
79653161|NCT04605289|Drug|lemongrass essential oil gel|"The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
79982939|NCT02456506|Radiation|Conventional Fraction IMRT|
79982940|NCT01367652|Drug|Letrozole|2.5 mg tablet
79982941|NCT01367652|Drug|Letrozole|2.5 mg Tablet
79982942|NCT02456584|Drug|DMPA 150|injectable contraceptive
79982943|NCT02456584|Drug|DMPA 300|injectable contraceptive
79982944|NCT02456584|Drug|DMPA 104|injectable contraceptive
79982945|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~150mg EGCG two times daily (p.o.) over the course of three years.~Colonoscopy after 3 years"
79982946|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~Placebo two times daily (p.o.) over the course of three years~Colonoscopy after 3 years"
79982947|NCT03146403|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
79982948|NCT03146403|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79982949|NCT03146403|Other|0.9% normal saline|Placebo
79982950|NCT03261778|Device|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
79337490|NCT04560075|Behavioral|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
79337491|NCT04560075|Behavioral|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
79337492|NCT04544462|Other|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
79337493|NCT04528498|Other|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
79337494|NCT04523337|Behavioral|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
79337495|NCT04523337|Behavioral|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
79337496|NCT04483414|Drug|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
79337497|NCT04483414|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
79337498|NCT04469569|Behavioral|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
79487964|NCT05759468|Drug|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, >75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
79487965|NCT05759468|Drug|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
79487966|NCT05755698|Behavioral|Emotional Awareness and Expression Therapy|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
79487967|NCT05755269|Procedure|Biospecimen Collection|Undergo collection of blood samples
79653162|NCT04605289|Drug|Placebo|"The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
79812950|NCT04115046|Device|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
79337499|NCT04428385|Other|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
79487968|NCT05755269|Procedure|Genotyping|Undergo genotyping
79487969|NCT05755269|Other|Survey Administration|Complete surveys
79653163|NCT04605289|Procedure|Scaling and root planing|Conventional mechanical treatment by ultra-sonic scalers
79812951|NCT04115046|Device|FibroScan|manufactured by Echosens
79812952|NCT04115046|Device|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
79812953|NCT00451321|Drug|Otelixizumab|Infusion
79812954|NCT03770455|Drug|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
79812955|NCT03770455|Drug|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
79812956|NCT01025869|Device|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
79337500|NCT04428385|Other|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
79812957|NCT01026025|Device|Duet TRS|This is a single arm study.
79812958|NCT01026259|Other|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
79487970|NCT05748587|Diagnostic Test|Serum Iron|Serum iron levels in study groups
79337501|NCT04378010|Drug|EDP-305 1.5 mg|Tablet
79487971|NCT05748587|Diagnostic Test|RBCs Alpha-synuclein|α-syn levels in RBCs
79337502|NCT04378010|Drug|EDP-305 2 mg|Tablet
79337503|NCT04378010|Drug|Placebo|Tablet
79487972|NCT05748587|Diagnostic Test|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
79487973|NCT05748587|Radiation|Brain computed tomography|Brain CT of patients after admission
79487974|NCT05748587|Diagnostic Test|Brain Iron|Iron in brain homogenate of rats
79653164|NCT04605328|Other|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
79653165|NCT00251901|Drug|Esomeprazole|
79653166|NCT04605133|Device|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
79653167|NCT04605250|Other|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
79812959|NCT01026259|Other|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
79812960|NCT03753997|Behavioral|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
79487975|NCT05748587|Diagnostic Test|Brain Alpha-synuclein|α-syn expression in rat's brain
79487976|NCT05748587|Diagnostic Test|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
79487977|NCT05748587|Drug|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
79487978|NCT05739019|Other|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
79487979|NCT05727241|Diagnostic Test|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
79487980|NCT05710315|Drug|Relizorb|Relizorb cartridges will be used with routine enteral feedings for 5 days
79812961|NCT01026337|Genetic|mutation analysis|Correlative study
79812962|NCT01026337|Other|pharmacological study|Correlative study
79812963|NCT01026337|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
79812964|NCT01026337|Drug|sunitinib malate|Given orally
79812965|NCT01026337|Other|immunohistochemistry staining method|Correlative study
79337504|NCT04365114|Diagnostic Test|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
79337505|NCT04365114|Diagnostic Test|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
79337506|NCT04365114|Diagnostic Test|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
79337507|NCT04361006|Device|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
79337508|NCT04361006|Device|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
79337509|NCT04349072|Drug|Mavacamten|Mavacamten Capsules Other names: MYK-461
79337510|NCT04349072|Drug|Placebo|Placebo
79337511|NCT04319354|Diagnostic Test|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
79337512|NCT04313868|Drug|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
79337513|NCT04312191|Other|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
79487981|NCT05710315|Other|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days
79487982|NCT05706389|Dietary Supplement|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
79487983|NCT05706324|Biological|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
79487984|NCT05703412|Behavioral|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
79487985|NCT05703412|Behavioral|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
79487986|NCT05694611|Diagnostic Test|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
79337514|NCT04277559|Other|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
79337515|NCT04277559|Other|Classical music|Patients will listen to classical music through headphones before surgery.
79812966|NCT01026337|Other|laboratory biomarker analysis|Correlative study
79487987|NCT05694611|Drug|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
79487988|NCT05689385|Other|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~Individualized exercise prescription according to the results of cardiopulmonary exercise test.~At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~Weekly follow-up call from a case manager via phone call or communication app."
79487989|NCT05686954|Other|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
79487990|NCT05686954|Other|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
79812967|NCT03746275|Drug|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
79487991|NCT05686954|Other|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
79812968|NCT03746275|Drug|Acetylsalicylic acid|75 - 100 mg once daily according to local label
79812969|NCT01026415|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
79337516|NCT04277559|Other|No music|Patients will not listen to music.
79812970|NCT01026415|Drug|rifampin|600 mg/day PO
79337517|NCT04275700|Procedure|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
79337518|NCT04242277|Device|Investigational WF-OCT device|Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
79337519|NCT04240886|Drug|fosmanogepix|IV and oral fosmanogepix
79337520|NCT04240665|Behavioral|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
79337521|NCT04223154|Device|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
79337522|NCT04223154|Device|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
79812971|NCT01026415|Drug|midazolam|1 mg IV
79812972|NCT01026415|Drug|ketoconazole|400 mg/day PO
79812973|NCT01026415|Drug|brentuximab vedotin|1.2 mg/kg IV every 21 days
79812974|NCT03731611|Procedure|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
79487992|NCT05686954|Other|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
79487993|NCT05683535|Drug|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
79487994|NCT05678244|Drug|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
79337523|NCT04173065|Drug|VK2809|Capsule
79337524|NCT04173065|Drug|Placebos|Capsule
79337525|NCT04173026|Other|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
79653168|NCT00564772|Drug|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
79487995|NCT05678244|Drug|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
79487996|NCT05677074|Dietary Supplement|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
79487997|NCT05677074|Dietary Supplement|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
79812975|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
79812976|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
79812977|NCT01026727|Drug|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
79812978|NCT01026727|Drug|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
79812979|NCT00802464|Biological|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
79812980|NCT00802464|Biological|Placebo|2 vaccinations at Months 0 and 2 with placebo
79812981|NCT04112082|Behavioral|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
79337526|NCT04173026|Other|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
79487998|NCT05677074|Dietary Supplement|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
79487999|NCT05675800|Drug|Psilocybin|Psilocybin administered with psychological support
79488000|NCT05675319|Drug|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
79488001|NCT05675319|Drug|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
79488002|NCT05675319|Drug|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
79653169|NCT00564811|Dietary Supplement|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
79653170|NCT00564967|Behavioral|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
79653171|NCT00564967|Behavioral|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
79653172|NCT03454243|Drug|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
79488003|NCT05675319|Drug|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
79488004|NCT05675319|Drug|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
79488005|NCT05675319|Drug|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
79982951|NCT02458144|Procedure|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
79337527|NCT04099511|Behavioral|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
79337528|NCT04099511|Behavioral|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
79488006|NCT05675319|Drug|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
79488007|NCT05675319|Drug|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
79982952|NCT01316991|Dietary Supplement|Chewing Gum|chewing gum will be provided
79488008|NCT05675319|Drug|Autologous Stem Cells|Autologous Stem Cell Transplantation
79488009|NCT05650580|Drug|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
79488010|NCT05649345|Drug|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
79653173|NCT00251940|Drug|Tesaglitazar 0.5 or 1 mg|
79653174|NCT00251940|Drug|Glibenclamide 2.5, 5, 10 or 15 mg|
79653175|NCT04604977|Behavioral|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
79488011|NCT05649332|Device|Argogen|Spray in short intervals, lightly pressing the dispenser button and pointing the spray on the area to be treated.
79488012|NCT05648812|Diagnostic Test|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
79982953|NCT01316991|Dietary Supplement|No Gum|no chewing gum will be provided
79653176|NCT04604938|Drug|Losartan|administration of losartan (50 mg) (oral)
79982954|NCT03634878|Other|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
79653177|NCT04604938|Drug|Placebo oral tablet|administration of placebo (oral)
79653178|NCT00248742|Behavioral|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
79488013|NCT05648812|Drug|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
79653179|NCT00565006|Drug|MK0859|
79812982|NCT04112082|Other|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
79337529|NCT04092660|Behavioral|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~Health Pamphlet at the initial screening~Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~Booster phone calls in between the follow-up visits"
79337530|NCT04092660|Device|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances [MAA] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
79337531|NCT04074161|Drug|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
79812983|NCT05752656|Other|Clinical examinations|Clinical examinations and administration of clinical scales
79812984|NCT02604966|Drug|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
79812985|NCT02604966|Drug|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
79337532|NCT04074161|Drug|Placebo (semaglutide)|Administered once weekly for 68 weeks
79337533|NCT04074161|Drug|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
79337534|NCT04074161|Drug|Placebo (liraglutide)|Administered once daily for 68 weeks
79337535|NCT04066075|Behavioral|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
79337536|NCT04062981|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
79488014|NCT05648695|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
79653180|NCT04604587|Drug|1. amyloid PET；2. T807 PET|"Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
79653181|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
79653182|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
79653183|NCT00252018|Behavioral|Daily intake of broccoli sprouts|
79653184|NCT05467943|Drug|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
79812986|NCT02605668|Behavioral|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
79488015|NCT05648695|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
79488016|NCT05644080|Radiation|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
79653185|NCT04604392|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
79653186|NCT00252096|Device|Nucleic acid amplification test|
79653187|NCT04604470|Other|Decision tool|no intervention.
79653188|NCT00565162|Drug|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
79337537|NCT04044456|Behavioral|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
79337538|NCT04044456|Behavioral|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
79337539|NCT04044456|Behavioral|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
79337540|NCT04044456|Behavioral|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
79337541|NCT04006652|Drug|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
79337542|NCT03997903|Drug|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
79337543|NCT03982212|Drug|Copaxone|"Agent: Glatiramer acetate (Copaxone®)~Dose: 40 mg~Route: Intratumoral injection~Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
79337544|NCT03966157|Device|Nasal Bridle|Feeding tube secured with nasal bridle
79653189|NCT05439707|Device|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
79812987|NCT02605668|Behavioral|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
79653190|NCT05439707|Device|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
79337545|NCT03888898|Other|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
79337546|NCT03888898|Other|Control fit test evaluation|control comparator for fit testing time threshold
79337547|NCT03843528|Drug|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
79982955|NCT03266380|Diagnostic Test|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
79982956|NCT01317381|Procedure|Observational|Blood draw
79982957|NCT01360476|Dietary Supplement|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
79982958|NCT01360476|Dietary Supplement|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
79337548|NCT03843528|Drug|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
79337549|NCT03837691|Device|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
79653191|NCT00248820|Procedure|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
79812988|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
79812989|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
79982959|NCT01317069|Drug|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
79982960|NCT01367808|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
79982961|NCT01367808|Drug|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
79982962|NCT01367808|Drug|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
79337550|NCT03837691|Behavioral|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
79337551|NCT03827824|Device|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
79337552|NCT03827824|Device|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
79337553|NCT03827460|Behavioral|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
79982963|NCT01317225|Drug|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
79982964|NCT01317225|Drug|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
79337554|NCT03827460|Behavioral|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
79337555|NCT03779789|Drug|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index [ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
79337556|NCT03779789|Drug|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
79337557|NCT03779789|Drug|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
79337558|NCT03779789|Drug|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
79653192|NCT04603885|Behavioral|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
79488017|NCT05641376|Drug|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
79653193|NCT04603885|Behavioral|Stretching exercise|stretching exercise
79812990|NCT00914160|Drug|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
79812991|NCT02605590|Drug|AIR DNase|
79812992|NCT02605590|Drug|Placebo|
79812993|NCT00450619|Radiation|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
79488018|NCT05641376|Drug|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
79982965|NCT01363206|Biological|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
79337559|NCT03779789|Drug|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
79653194|NCT04603768|Other|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise & Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
79653195|NCT04603768|Other|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright & contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets & 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
79653196|NCT04603768|Other|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation & isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
79653197|NCT04603963|Device|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
79812994|NCT00450619|Biological|Sargramostim|100 mcg/injection x 4 days given subcutaneously
79812995|NCT00450619|Biological|Recombinant vaccinia-TRICOM vaccine|2 x 10^8 PFU given subcutaneously on day 1.
79812996|NCT00450619|Biological|Recombinant fowlpox-TRICOM vaccine|1 x 10^9 PFU given subcutaneously on days 15 and 29
79982966|NCT01363206|Biological|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
79488019|NCT05634356|Behavioral|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
79488020|NCT05628766|Other|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
79488021|NCT05622734|Behavioral|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
79337560|NCT03779789|Drug|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
79488022|NCT05615805|Other|OSDI questionnaire|Ocular Surface Disease Index
79488023|NCT05615805|Other|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
79337561|NCT03779789|Drug|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
79488024|NCT05615311|Dietary Supplement|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
79488025|NCT05615311|Other|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
79488026|NCT05607615|Drug|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
79488027|NCT05607615|Drug|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
79488028|NCT05597683|Procedure|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
79488029|NCT05593939|Behavioral|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
79488030|NCT05593939|Behavioral|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
79488031|NCT05593939|Dietary Supplement|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
79488032|NCT05577845|Drug|Ramosetron|Ramosetron, 4 weeks
79488033|NCT05540847|Procedure|Interfascial Injection|Interfascial Injection on Ultrasound-guided Obturator Nerve Block
79488034|NCT05540847|Procedure|Subpectineal Injection|Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
79337562|NCT03737539|Diagnostic Test|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
79337563|NCT03733210|Drug|Panitumumab-IRDye800|30 mg administered intravenously (IV)
79337564|NCT03733210|Drug|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
79488035|NCT05527912|Drug|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
79982967|NCT01344213|Drug|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
79982968|NCT01344213|Drug|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
79488036|NCT05502588|Behavioral|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
79982969|NCT01344213|Drug|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
79982970|NCT01344213|Drug|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
79337565|NCT03733210|Device|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
79337566|NCT03733210|Device|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
79337567|NCT03733210|Device|Explorer Air camera|Fluorescence camera manufactured by SurgVision
79337568|NCT03733210|Device|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
79337569|NCT03733210|Device|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
79337570|NCT03733210|Device|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
79337571|NCT03733210|Device|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
79337572|NCT03733210|Device|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
79337573|NCT03733210|Device|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
79337574|NCT03733210|Device|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
79488037|NCT05502588|Behavioral|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
79488038|NCT05496920|Diagnostic Test|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
79488039|NCT05496920|Diagnostic Test|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
79488040|NCT05492786|Behavioral|Alert|Non-interruptive best practice alert in the electronic health record
79653201|NCT04603729|Drug|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
79982971|NCT04416048|Drug|Rivaroxaban|Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and <50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
79337575|NCT03733210|Device|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
79982972|NCT04416048|Other|Standard Of Care (SOC)|Standard of care treatment
79982973|NCT04766385|Drug|KHK7791|oral administration
79337576|NCT03733132|Drug|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
79337577|NCT03733132|Drug|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
79337578|NCT03667820|Drug|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
79337579|NCT03667820|Radiation|SABR|Stereotactic Ablative Radiation (SABR)
79337580|NCT03627468|Drug|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
79337581|NCT03627468|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
79337582|NCT03613116|Dietary Supplement|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
79488041|NCT05492786|Behavioral|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
79488042|NCT05492786|Behavioral|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
79488043|NCT05492786|Behavioral|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
79337583|NCT03595176|Device|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
79337584|NCT03588039|Drug|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
79488044|NCT05492045|Drug|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
79488045|NCT05492045|Drug|Other|Standard treatment of NSCLC.
79488046|NCT05491187|Drug|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
79488047|NCT05491187|Drug|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
79488048|NCT05480878|Drug|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
79488049|NCT05480878|Drug|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
79488050|NCT05480878|Drug|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
79653202|NCT04603729|Drug|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
79653203|NCT04604080|Other|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
79337585|NCT03588039|Biological|Pembrolizumab|Intravenously administered
79488051|NCT05463289|Diagnostic Test|Point of Care Autonomous AI diabetic retinopathy exam|Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
79488055|NCT05461222|Device|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
79488056|NCT05448963|Device|da Vinci SPⓇ Single-port System|Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
79488057|NCT05430906|Drug|AK104 - Chemotherapy|AK104 10mg/kg then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)] of each 21-day cycle
79488058|NCT05429242|Other|Ultrasonographic examination|Measurement of placental volume at the first trimester of pregnancy by using ultrasound.
79488059|NCT05419986|Genetic|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
79488060|NCT05414331|Other|Discontinuing all beta-blocker|All beta-blockers will be stopped 2 months after CABG
79488061|NCT05404256|Other|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
79488062|NCT05404256|Other|Radical gastrectomy +D2 lymphadenectomy|Radical gastrectomy +D2 lymphadenectomy
79488063|NCT05403567|Other|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
79488064|NCT05398367|Dietary Supplement|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
79488065|NCT05396378|Dietary Supplement|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
79488066|NCT05383716|Drug|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
79488067|NCT05380570|Radiation|Occupational radiation exposure|Ionizing radiation in workplaces
79488068|NCT05378945|Drug|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
79488069|NCT05378945|Drug|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
79488070|NCT05376644|Drug|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
79488071|NCT05376644|Drug|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
79488072|NCT05357638|Behavioral|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
79488073|NCT05357638|Behavioral|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
79488074|NCT05357638|Behavioral|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
79488075|NCT05352724|Dietary Supplement|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
79488076|NCT05347966|Other|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
79488077|NCT05345314|Procedure|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
79488078|NCT05334732|Behavioral|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
79488079|NCT05333835|Drug|HR17031 injection|HR17031 injection
79488080|NCT05333835|Drug|INS068 injection|INS068 injection
79488081|NCT05333835|Drug|SHR20004 injection|SHR20004 injection
79488082|NCT05330377|Drug|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
79812997|NCT03704857|Other|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
79488083|NCT05330377|Drug|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
79488084|NCT05330377|Drug|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
79488085|NCT05330377|Drug|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
79488086|NCT05330377|Drug|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
79488087|NCT05326087|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
79488088|NCT05326087|Drug|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
79488089|NCT05323435|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
79488090|NCT05323435|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
79488091|NCT05322252|Drug|Mifepristone|200mg orally
79488092|NCT05322252|Drug|Misoprostol|Per clinician
79488093|NCT05318820|Drug|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test [T]/Reference[R]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product [i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
79488094|NCT05311917|Other|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
79488095|NCT05311917|Other|base in prism prescription|base in prism prescription according to sheards criterion
79488096|NCT05311917|Other|conventional placebo|using near glasses with aimless eye training
79337586|NCT03570021|Procedure|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection [Hartl DM, Ann Surg 2012], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons [Hartl DM, World J Surg 2012]."
79653204|NCT04603534|Other|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
79653205|NCT00248898|Procedure|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
79653206|NCT04603378|Other|KB195|KB195 is a novel glycan
79812998|NCT03704857|Other|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
79982974|NCT04226664|Procedure|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
79982975|NCT01317459|Behavioral|Guided self-determination|Group counselling
79982976|NCT04488406|Other|No Intervention|Not applicable to these subjects. There is no study-related intervention
79337587|NCT03570021|Procedure|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
79337588|NCT03553004|Drug|Niraparib Treatment|Niraparib treatment by mouth (oral)
79653207|NCT04603378|Other|Polydextrose|Polydextrose is an oligosaccharide
79337589|NCT03488667|Drug|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
79653208|NCT04603378|Other|Pullulan|Pullulan is an oligosaccharide
79337590|NCT03488667|Drug|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
79337591|NCT03416959|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
79653209|NCT04603378|Other|Maltodextrin|Maltodextrin is a digestible carbohydrate
79653210|NCT04603573|Device|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
79982977|NCT01363284|Drug|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
79982978|NCT04334889|Other|Visual cues|Participants will be asked to move following cues displayed on a screen in front of them.
79982979|NCT04327557|Behavioral|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
79337592|NCT03406247|Drug|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months"
79982980|NCT04327557|Behavioral|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
79982981|NCT01363362|Procedure|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
79982982|NCT03265834|Other|< 10 days of antibiotics|Antibiotic duration
79812999|NCT03704857|Other|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
79982983|NCT03265834|Other|28 days of antibiotics|Antibiotic duration
79982984|NCT01344291|Drug|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
79982985|NCT03733353|Drug|EDP1815|EDP1815 is an orally administered monoclonal microbial
79982986|NCT03733353|Drug|Placebo oral capsule|Placebo
79982987|NCT03733353|Drug|Placebo oral tablet|Placebo
79982988|NCT01367964|Drug|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
79982989|NCT02458222|Other|language game therapy|participants will take part in game therapy
79337593|NCT03406247|Drug|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
79337594|NCT03399175|Drug|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
79337595|NCT03317535|Procedure|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
79337596|NCT03317535|Procedure|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
79337597|NCT03317535|Procedure|Spontaneous breath|Patients will be kept spontaneous breath.
79982990|NCT02458222|Other|standard therapy|usual clinical care
79337598|NCT03317535|Procedure|Controlled ventilation|Patient will be kept with controlled ventilation.
79488098|NCT05259423|Other|Enriched Education Program|Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
79982991|NCT04386837|Other|Turkish Aphasia Rapid Test|Same
79982992|NCT04326933|Drug|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day & Nilotinib in adose of 600mg/day)
79982993|NCT01347723|Other|scrambler therapy|Undergo scrambler therapy
79982994|NCT01347723|Other|questionnaire administration|Ancillary studies
79982995|NCT01347723|Procedure|management of therapy complications|Undergo scrambler therapy
79982996|NCT03265756|Device|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
79982997|NCT01317537|Other|Electronic personal health record|
79982998|NCT05234788|Procedure|Renal Denervation surgery|Renal Denervation surgery using TransRadial Access
79982999|NCT01347801|Drug|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
79983000|NCT01347801|Drug|Placebo (Saline)|Normal saline (NaCl 0,9%)
79983001|NCT01347801|Drug|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
79983002|NCT01347801|Other|OGTT|Oral glucose tolerance test with 75 g glucose
79653211|NCT04603573|Device|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
79653212|NCT00252213|Drug|Human BNP|
79813000|NCT03704857|Other|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
79813001|NCT03704857|Other|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
79813002|NCT03704857|Other|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
79983003|NCT01347801|Other|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
79983004|NCT04733560|Procedure|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
79983005|NCT04733560|Procedure|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
79813003|NCT03704857|Other|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
79983006|NCT04733560|Drug|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
79983007|NCT01347957|Other|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
79983008|NCT01347957|Other|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
79983009|NCT04735965|Drug|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
79653213|NCT00565201|Drug|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
79813004|NCT03704857|Other|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
79337599|NCT03313206|Drug|Pembrolizumab|"Neo-adjuvant therapy :~Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
79337600|NCT03313206|Procedure|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
79813005|NCT03704857|Other|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
79813006|NCT00802074|Drug|Raltegravir|400mg BID
79813007|NCT00802074|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
79983010|NCT04735965|Drug|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
79983011|NCT04735965|Drug|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
79813008|NCT00802074|Drug|Ritonavir|100 mg BID or QD
79813009|NCT03995719|Other|Preoperative education|65 patients were instructed to a preoperative stoma-education program
79813010|NCT03995719|Other|Postoperative education|73 patients, receiving the same information in postoperative period.
79813011|NCT04112004|Other|Collecting sodium reports and outcome measures|
79983012|NCT03265990|Procedure|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
79983013|NCT03265990|Procedure|Conventional haemorrhoidectomy|"According to the Ferguson technique~Manual anal sphincter stretching up to 4 fingers~Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
79983014|NCT01344525|Procedure|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
79983015|NCT01344525|Procedure|Gastric Banding|Gastric Banding
79983016|NCT01344525|Procedure|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
79337601|NCT03313206|Radiation|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
79337602|NCT03313206|Drug|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
79337603|NCT03250377|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablet~Concentration: 25 mg and 50 mg~Route of administration: Oral use"
79337604|NCT03107520|Diagnostic Test|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
79337605|NCT03107520|Drug|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
79488099|NCT05259423|Other|Typical Education Program|Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
79488100|NCT05251272|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
79983017|NCT01344525|Procedure|Roux-en-Y Bypass|Roux-en-Y Bypass
79983018|NCT03265444|Biological|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
79983019|NCT02456428|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79983020|NCT02456428|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79983021|NCT02456428|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
79337606|NCT03052816|Drug|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
79337607|NCT03052816|Drug|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
79337608|NCT03029156|Device|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
79337609|NCT03029156|Device|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
79337610|NCT02955940|Drug|Ruxolitinib|5 mg BID
79337611|NCT02955940|Drug|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
79337612|NCT02955940|Drug|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
79488101|NCT05246943|Diagnostic Test|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
79488102|NCT05246904|Other|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
79813012|NCT04112394|Other|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
79983022|NCT02456428|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79488103|NCT05241600|Behavioral|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
79983023|NCT02456428|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79983024|NCT02456428|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79653214|NCT00565201|Drug|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
79653215|NCT05361824|Drug|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
79653216|NCT05361824|Drug|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
79983025|NCT02456428|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79983026|NCT02456428|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
79983027|NCT03265522|Behavioral|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
79337613|NCT02742922|Behavioral|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
79337614|NCT02702596|Other|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
79653217|NCT04603612|Procedure|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
79983028|NCT03265522|Behavioral|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
79983029|NCT03265522|Behavioral|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
79983030|NCT01348113|Other|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
79983031|NCT03259516|Drug|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
79983032|NCT03259516|Drug|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
79983033|NCT03259516|Drug|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
79983034|NCT03259516|Drug|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
79983035|NCT03259516|Drug|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
79983036|NCT03259516|Drug|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
79983037|NCT03259516|Drug|Sildenafil|20 mg per os three times a day during the whole course of treatment
79983038|NCT03259516|Drug|Melphalan|2 mg per os daily during the whole course of treatment
79337615|NCT02702596|Behavioral|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
79983039|NCT01344681|Drug|Micafungin sodium|"Treatment period (active treatment): an average 14 days~Dosage:~- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~Administration Method:~Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
79337616|NCT02702596|Behavioral|Standard Education|The the use of a pamphlet to educate people about depression.
79337617|NCT02682238|Drug|BBI-4000, 15%|
79337618|NCT02682238|Other|Vehicle gel|
79653218|NCT00248937|Behavioral|Positive affect and self-affect induction|
79983040|NCT01344681|Drug|Itraconazole|"Treatment period (active treatment): an average 14 days~Dosage:~- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~Administration Method:~Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
79983041|NCT01348191|Procedure|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
79983042|NCT03259360|Behavioral|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
79983043|NCT03259360|Behavioral|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
79983044|NCT01348269|Drug|Aclasta|1 x intravenous non-current drip (infusion)
79653219|NCT04603222|Device|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
79653220|NCT04603222|Other|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
79653221|NCT04603339|Other|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
79653222|NCT05314829|Other|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
79337619|NCT02674711|Behavioral|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
79653223|NCT00252252|Device|VPAP non-invasive ventilator|
79653224|NCT00252252|Device|AutoVPAP non-invasive ventilator|
79653225|NCT04603456|Drug|Lacteol fort|Lacteol fort is a drug containing lactobacilli
79653226|NCT04603456|Drug|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
79983045|NCT01348269|Drug|Placebo|NaCl Solution
79653227|NCT04603456|Drug|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
79653228|NCT00252291|Drug|Aridol|
79653229|NCT00252291|Drug|Methacholine|
79653230|NCT00252291|Procedure|Exercise challenge|
79653231|NCT04602793|Diagnostic Test|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
79983046|NCT03259594|Procedure|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
79653232|NCT04602676|Diagnostic Test|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
79653233|NCT04602676|Diagnostic Test|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
79337620|NCT02606201|Other|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
79337621|NCT02577978|Device|Medacta GMK posterior stabilized prosthesis|
79337622|NCT02577978|Device|Medacta GMK Sphere prosthesis|
79653234|NCT04602832|Other|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
79983047|NCT03259594|Drug|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
79337623|NCT02564705|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|
79337624|NCT02564705|Procedure|Posterior Fusion|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
79653235|NCT05285501|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
79653236|NCT05285501|Behavioral|Group relaxation and psychoeduaction|A single session of relaxation (10 minutes) psychoeducation (10 minutes) will contain minilectures about mental well-being and psychohygiene. In summary 20 minutes.
79337625|NCT02539771|Other|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
79337626|NCT02393625|Drug|Ceritinib (LDK378)|
79337627|NCT02393625|Drug|Nivolumab|
79983048|NCT03259672|Drug|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
79983049|NCT03259672|Drug|Desflurane|Desflurane was used as a maintenance anesthetic agent.
79983050|NCT03547960|Dietary Supplement|Guar gum|Fibre supplement to be taken with each meal
79983051|NCT03547960|Dietary Supplement|Cellulose|Placebo. Fibre supplement to be taken with each meal
79983052|NCT03259438|Behavioral|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
79983053|NCT03259438|Behavioral|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
79983054|NCT03261388|Behavioral|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
79983055|NCT03258970|Other|Observational cohort study|taking vitamin supplements
79983056|NCT03259282|Biological|Analysis of gamma globulin|Electrophoresis of proteins
79983057|NCT03265288|Drug|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
79983058|NCT03265288|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
79337628|NCT02294032|Drug|Immunosuppressive Agents|standard of care for patients post-transplant
79488104|NCT05241600|Behavioral|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
79488105|NCT05235334|Device|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
79488106|NCT05229016|Behavioral|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
79337629|NCT02168829|Drug|Rivaroxaban|
79488107|NCT05212454|Drug|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
79488108|NCT05207189|Biological|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
79488109|NCT05204901|Device|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
79653237|NCT05285501|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
79813013|NCT04112394|Other|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
79813014|NCT00450385|Drug|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
79813015|NCT00450385|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
79813016|NCT00450385|Drug|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
79813017|NCT00450385|Drug|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
79813018|NCT00450385|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
79337630|NCT02168829|Drug|Acetylsalicylic acid|
79983059|NCT03261466|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
79983060|NCT03261466|Drug|Placebos|
79488110|NCT05201820|Device|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
79983061|NCT02458066|Other|IRS: bendiocarb|carbamate insecticide
79983062|NCT02458066|Other|IRS: deltamethrin|Pyrethroid insecticide
79983063|NCT03261310|Drug|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
79983064|NCT03259126|Device|SCUT|Two different home made curtains were attached to the angiographic table
79983065|NCT03259048|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
79337631|NCT01732120|Procedure|Off-clamp partial nephrectomy|
79337632|NCT01719562|Procedure|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
79337633|NCT01719562|Other|Physical Activity|Tailored aerobic exercise program onsite and at home.
79337634|NCT01719562|Other|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
79337635|NCT01719562|Device|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
79337636|NCT01719562|Other|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
79337637|NCT01700439|Device|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
79337638|NCT01647698|Behavioral|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
79337639|NCT01647698|Behavioral|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
79983066|NCT02456272|Device|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
79337640|NCT01647698|Behavioral|No training|No training during the experiment.
79337641|NCT01433289|Drug|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
79653238|NCT04602910|Device|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
79653239|NCT00248976|Behavioral|Net-present value of individual health behaviors in years|
79653240|NCT04602715|Drug|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
79653241|NCT04602715|Drug|Placebo|Placebo Control
79653242|NCT04602403|Procedure|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
79653243|NCT00565240|Drug|Marvelon|oral contraceptive
79653244|NCT00565240|Drug|Nuvaring|contraceptive vaginal ring
79653245|NCT00565240|Drug|Letrozole|Aromatase Inhibitors
79653246|NCT00565279|Drug|ASF1057|Twice daily, topical
79653247|NCT00565279|Drug|ASF1057|Twice daily, Topical
79653248|NCT04602637|Other|Training load|Monitoring training load during covid
79983067|NCT02456272|Procedure|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
79983068|NCT02456350|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
79983069|NCT02456350|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
79983070|NCT02456350|Biological|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
79983071|NCT02456038|Drug|Asfotase Alfa (ALXN1215)|
79983072|NCT03258736|Procedure|inguinal hernia surgery|repair of inguinal hernia
79983073|NCT01368120|Device|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
79983074|NCT01368120|Device|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
79983075|NCT01368120|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
79983076|NCT04971486|Behavioral|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
79983077|NCT04226274|Drug|REN001|Once daily for 12 weeks
79983078|NCT01363674|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
79337642|NCT01433289|Drug|Placebo|
79983079|NCT01319370|Drug|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
79983080|NCT01319370|Drug|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
79983081|NCT01363752|Drug|Advagraf|oral
79653249|NCT04602442|Drug|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.
79653250|NCT04602442|Drug|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.
79337643|NCT01345552|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
79653251|NCT04602442|Drug|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
79653252|NCT00249015|Behavioral|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
79337644|NCT00995475|Drug|Fluticasone propionate|
79653253|NCT04602247|Dietary Supplement|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
79653254|NCT04602247|Dietary Supplement|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
79653255|NCT04602247|Dietary Supplement|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
79653256|NCT04602247|Dietary Supplement|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
79653257|NCT04602247|Other|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
79653258|NCT04602247|Other|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
79653259|NCT04601896|Other|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
79653260|NCT04602130|Other|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
79653261|NCT04602130|Other|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
79653262|NCT04602130|Other|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
79653263|NCT04602130|Other|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
79653264|NCT00252330|Drug|SR58611A|
79653265|NCT04602052|Procedure|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
79983082|NCT01363752|Drug|Mycophenolate Mofetil|oral
79983083|NCT01363752|Drug|Sirolimus|oral
79983084|NCT01363752|Drug|Corticosteroids|i.v. and oral
79337645|NCT00995475|Drug|Placebo|
79337646|NCT00945529|Drug|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
79337647|NCT00921115|Drug|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
79337648|NCT00921115|Drug|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
79337649|NCT00130351|Device|formoterol|
79653266|NCT04602208|Procedure|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device [EDAP TMS S.A., Vaulx-en-Velin, France] until July 2013 and then with the Focal-One device [EDAP TMS S.A.]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
79653267|NCT04602013|Drug|Sintilimab|Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
79653268|NCT04602013|Drug|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
79653269|NCT04602013|Radiation|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
79653270|NCT04601701|Drug|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
79653271|NCT04601701|Drug|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
79653272|NCT05233748|Device|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
79337650|NCT04130893|Behavioral|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
79653273|NCT00252369|Drug|Infliximab|
79653274|NCT00252369|Procedure|Instillation of fibrin glue|
79653275|NCT04601662|Procedure|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
79337651|NCT04130893|Behavioral|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
79983085|NCT01368198|Other|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
79653276|NCT04601662|Other|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
79983086|NCT01368198|Other|OPTIVE™|One instillation of the eye drop in each eye
79983087|NCT01360710|Drug|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
79983088|NCT01360710|Drug|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
79983089|NCT01368354|Behavioral|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
79983090|NCT01363830|Behavioral|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
79337652|NCT03906565|Drug|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
79337653|NCT05534659|Device|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
79337654|NCT05534659|Device|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
79337655|NCT05530681|Diagnostic Test|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
79653277|NCT04601545|Behavioral|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
79653278|NCT04601545|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
79653279|NCT00565318|Drug|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
79653280|NCT00565318|Drug|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
79653281|NCT00249054|Device|ASR hip prosthesis|Implantation of resurfacing prosthesis
79653282|NCT00249054|Device|ReCap hip prosthesis|Implantation of resurfacing prosthesis
79337656|NCT05530681|Diagnostic Test|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
79337657|NCT05530525|Diagnostic Test|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
79337658|NCT05530525|Diagnostic Test|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
79983091|NCT01363830|Behavioral|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
79983092|NCT01360788|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
79983093|NCT01368510|Behavioral|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
79983094|NCT01368510|Behavioral|Waitlist|Minimal contact waitlist weekly for 4 weeks
79337659|NCT05530525|Diagnostic Test|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
79337660|NCT04425187|Drug|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
79337661|NCT04425187|Drug|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
79337662|NCT03756649|Procedure|Blood Draw|50 ml will be collected
79337663|NCT03756649|Procedure|Urine Collection|50 ml will be collected
79337664|NCT03756649|Procedure|Stool Collection|Three 25 ml tubes will be collected
79337665|NCT04425109|Behavioral|meal test response|soy fermented versus non fermented meal test
79337666|NCT05530447|Drug|Samelisant|Tablet
79983095|NCT01360944|Drug|LAS41004|once daily, topical, 100 microgram
79337667|NCT03730207|Device|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
79337668|NCT03730207|Device|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
79337669|NCT03693547|Drug|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
79488111|NCT05168969|Other|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
79488112|NCT05145920|Behavioral|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
79488113|NCT05140837|Diagnostic Test|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
79653283|NCT00565357|Device|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
79337670|NCT05534113|Drug|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
79488114|NCT05140837|Drug|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
79337671|NCT05534035|Biological|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
79488115|NCT05135598|Other|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
79653284|NCT00565357|Other|Control|Standard care in the neonatal intensive care unit
79653285|NCT05201144|Drug|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
79653286|NCT05201144|Other|Placebo|Equal volume of placebo
79653287|NCT00252408|Drug|Hormone replacement therapy|
79337672|NCT05534035|Biological|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
79653288|NCT04601389|Biological|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
79653289|NCT04601389|Biological|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
79653290|NCT04600843|Other|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
79653291|NCT04600843|Other|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
79653292|NCT00565396|Drug|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
79653293|NCT00252447|Procedure|Pre-Operative Conformal Radiotherapy|
79653294|NCT04600765|Diagnostic Test|hsCRP serum measurement of inflammation|hsCRP inflammation change as result of non-contaminated diet
79653295|NCT04601116|Drug|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
79653296|NCT04601116|Drug|Placebo oral tablet|Placebo 1 tablet per day for 2 years
79983096|NCT01360944|Drug|reference|once daily, 100 microgram
79983097|NCT01364064|Drug|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
79983098|NCT01361022|Drug|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
79983099|NCT01361022|Drug|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
79983100|NCT01364142|Procedure|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
79337673|NCT05530057|Drug|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~Dose reductions for eribulin, but not for SB3, is permitted.~Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
79653297|NCT04600687|Other|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
79653298|NCT00249093|Drug|oxygen|
79653299|NCT04600726|Other|no intervention|no interventioni
79653300|NCT04600453|Other|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
79983101|NCT01364220|Drug|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
79983102|NCT01364220|Other|Placebo tablet|Placebo tablet, once daily, for 14 days
79337674|NCT05530057|Drug|Eribulin Mesylate|"Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
79337675|NCT05533957|Other|Application of different dosages of oxygen therapy|To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
79983103|NCT01368744|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Groups: OSNA Breast Cancer System"
79337676|NCT04310917|Other|blood lipoprotein (a) test|research specific blood sample
79337677|NCT02576587|Other|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI >=15) will be place on CPAP therapy.
79337678|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
79337679|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 75 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
79337680|NCT05519839|Drug|qNIV Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV and 75 μg Matrix-M1 Adjuvant (Influenza Vaccine) on Day 0.
79653301|NCT04600297|Device|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
79653302|NCT04600024|Diagnostic Test|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
79983104|NCT01361100|Device|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
79653303|NCT00249132|Drug|risperidone|
79983105|NCT01368978|Device|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
79653304|NCT05154461|Other|Alginate|BHB covered in alginate will be realised in stomach-duodenum
79653305|NCT05154461|Other|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
79653306|NCT00565474|Drug|Fluvastatin|Graft vasculopathy
79488116|NCT05113030|Other|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
79488117|NCT05113030|Other|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
79488118|NCT05109598|Biological|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
79488119|NCT05100485|Diagnostic Test|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
79488120|NCT05100485|Diagnostic Test|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
79653307|NCT00252486|Drug|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
79653308|NCT04600492|Drug|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
79337681|NCT05519839|Drug|SARS-CoV-2 rS Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS, Diluent, and 50 μg Matrix-M1 Adjuvant (SARS-CoV-2 rS Vaccine) on Day 0.
79337682|NCT05519839|Drug|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza on Day 0.
79337683|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of co-formulated mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
79337684|NCT03648073|Drug|[68Ga]DOTATATE-PET/MRI|[68Ga]DOTATATE-PET/MRI
79337685|NCT03622411|Device|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
79337686|NCT03622411|Device|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
79337687|NCT03622411|Behavioral|aphasia therapy|language exercises provided by the speech therapist in hospital
79337688|NCT05533879|Other|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
79337689|NCT05369845|Other|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
79337690|NCT05529745|Other|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
79337691|NCT05533723|Procedure|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
79488121|NCT05096845|Biological|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2~8°C protected from light Expiry date: 24 months after production date"
79488122|NCT05096845|Other|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
79488123|NCT05091866|Other|Quality-of-Life Assessment|Ancillary studies
79653309|NCT00402935|Other|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
79488124|NCT05091866|Other|Questionnaire Administration|Ancillary studies
79488125|NCT05091866|Biological|Therapeutic Progesterone|Given SC
79488126|NCT05084989|Biological|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
79488127|NCT05084989|Biological|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
79337692|NCT05533723|Procedure|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
79488128|NCT05084989|Biological|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
79488129|NCT05084989|Biological|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
79653310|NCT00402935|Procedure|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
79653311|NCT00402935|Procedure|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
79653312|NCT00402935|Procedure|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
79983106|NCT03719040|Device|Physiologic pacing device implant|An alternative and potentially more effective pacing strategy for patients with electrical conduction abnormalities is physiologic pacing. Physiologic pacing is achieved by delivering a pacing stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch (LBB) of the His-Purkinje system, with a permanent lead. Physiologic pacing activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony. Physiologic pacing has emerged as a feasible and safe alternative to pacemaker therapy and CRT with clinical and electrophysiological advantages.
79337693|NCT05529667|Drug|INCB054828, Paclitaxel|"phase 1>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
79337694|NCT05533645|Other|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
79983107|NCT01361256|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
79983108|NCT01361256|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
79983109|NCT02713204|Drug|REGN910-3|
79983110|NCT02713204|Drug|Intravitreal Aflibercept Injection (IAI)|
79337695|NCT03571633|Drug|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
79337696|NCT03571633|Drug|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
79337697|NCT03535597|Device|Quikclot Radial Pad|The QuikClot® Radial® pad will be applied over the radial artery access site covered with either a Coban™ bandage or a Tegaderm™ dressing after TRA.
79488130|NCT05080881|Diagnostic Test|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
79983111|NCT03695172|Drug|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
79983112|NCT03695172|Procedure|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
79983113|NCT03695172|Biological|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
79653313|NCT04600063|Procedure|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
79337698|NCT03473353|Other|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
79983114|NCT03695172|Procedure|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
79337699|NCT05533489|Other|No intervention|No intervention This study is a retrospective descriptive study.
79337700|NCT05529433|Procedure|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
79337701|NCT05529433|Procedure|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
79337702|NCT05529433|Procedure|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
79983115|NCT03721107|Biological|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
79337703|NCT05533255|Other|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
79983116|NCT03721107|Other|Placebo|Placebo control
79983117|NCT01364376|Drug|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
79983118|NCT01344837|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79983119|NCT01344837|Other|Immunohistochemistry Staining Method|Correlative studies
79983120|NCT01344837|Other|Medical Chart Review|Correlative studies
79337704|NCT05533255|Other|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
79337705|NCT05529355|Drug|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
79337706|NCT05529355|Drug|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
79337707|NCT05529355|Drug|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
79337708|NCT05533021|Other|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
79337709|NCT03244033|Other|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
79983121|NCT01344837|Genetic|Microarray Analysis|Correlative studies
79983122|NCT01344837|Other|Study of Socioeconomic and Demographic Variables|Correlative studies
79983123|NCT01344837|Genetic|Western Blotting|Correlative studies
79983124|NCT01369056|Behavioral|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
79653314|NCT04600063|Procedure|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
79653315|NCT04599985|Other|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
79653316|NCT04599985|Other|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
79653317|NCT04599712|Drug|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram [mg] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
79653318|NCT04599673|Drug|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
79813019|NCT01026883|Other|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
79813020|NCT01566019|Procedure|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
79983125|NCT01348503|Drug|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
79983126|NCT01348503|Drug|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
79337710|NCT03244033|Behavioral|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
79653319|NCT04599673|Other|normal saline|10 ml normal saline
79813021|NCT00588354|Drug|Clonidine|200 or 400 micrograms clonidine
79813022|NCT00588354|Drug|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
79813023|NCT00588354|Drug|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
79813024|NCT01566097|Device|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~Information on the risk of continued smoking and benefits of cessation~Messages that address common misbeliefs regarding smoking cessation services and medications~Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~Behavioral only~Nicotine replacement therapy~Bupropion~Varenicline"
79813025|NCT04114968|Other|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
79813026|NCT00449761|Drug|LBH589|
79813027|NCT00800982|Procedure|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
79983127|NCT03260998|Diagnostic Test|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
79337711|NCT05528887|Biological|Autologous CAR-T cells|D0: CAR-T cells will be infused intravenously.
79337712|NCT05528887|Drug|Fludarabine|D-5 to D-3: Fludarabine (30 mg/m^2/day) will be administered intravenously for 3 days.
79337713|NCT05528887|Drug|Cyclophosphamide|D-5 to D-3: Cyclophosphamide (500 mg/m^2/day) will be administered intravenously for 3 days.
79813028|NCT00800982|Drug|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
79813029|NCT01019395|Drug|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
79813030|NCT04115124|Behavioral|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
79337714|NCT05532787|Other|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
79337715|NCT03009019|Drug|DFN-15 Active|
79337716|NCT03009019|Other|DFN-15 Placebo|
79337717|NCT04425343|Genetic|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
79337718|NCT05340751|Diagnostic Test|Blood drawn|Hemoglobin and Hematocrit Levels
79337719|NCT02575807|Biological|CRS-207|via IV infusion
79337720|NCT02575807|Drug|Epacadostat|PO BID
79337721|NCT02575807|Biological|Pembrolizumab|via IV infusion
79488131|NCT05080881|Diagnostic Test|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
79488132|NCT05080881|Diagnostic Test|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
79488133|NCT05080881|Diagnostic Test|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
79488134|NCT05080881|Diagnostic Test|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
79813031|NCT00830960|Drug|Prasugrel|Oral, daily, 90 days
79813032|NCT00830960|Drug|Clopidogrel|Oral, daily, 90 days
79983128|NCT01369134|Device|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
79337722|NCT05334589|Device|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
79337723|NCT05532553|Device|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
79337724|NCT02813785|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
79337725|NCT02813785|Drug|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 21-day cycle.
79983129|NCT01344915|Procedure|Locked knee brace|
79983130|NCT01344915|Procedure|Locked knee brace|
79983131|NCT01369290|Drug|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
79983132|NCT01369290|Drug|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
79653320|NCT04599595|Device|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
79653321|NCT00565513|Procedure|blood test|cord blood and maternal milk test
79488135|NCT05080881|Diagnostic Test|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
79488136|NCT05079828|Diagnostic Test|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
79488137|NCT05079828|Diagnostic Test|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
79653322|NCT00565552|Drug|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
79337726|NCT04302181|Drug|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
79337727|NCT05528185|Other|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
79337728|NCT05532475|Diagnostic Test|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
79488138|NCT05068492|Diagnostic Test|CT|enhanced CT with standard procedure
79488139|NCT05068492|Diagnostic Test|MRI|enhanced MRI with standard procedure
79488140|NCT05068492|Diagnostic Test|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
79488141|NCT05068492|Diagnostic Test|Ultrasound|Digestive ultrasound with standard procedure
79488142|NCT05052892|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
79488143|NCT05050474|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
79653323|NCT00414687|Drug|Ventavis (Iloprost, BAYQ6256)|
79337729|NCT05527951|Other|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
79488144|NCT05042700|Drug|Melatonin|Enema with 25 mg melatonin
79653324|NCT04599244|Other|emergency pulpotomy|removal of coronal pulp
79653325|NCT04599283|Device|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
79653326|NCT04599322|Other|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
79488145|NCT05042700|Drug|Placebo|Enema without melatonin
79488146|NCT05042401|Drug|SHR-1703|SHR-1703 low dose
79488147|NCT05042401|Drug|placebo|placebo low dose
79488148|NCT05042401|Drug|SHR-1703|SHR-1703 high dose
79337730|NCT05527951|Other|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
79488149|NCT05042401|Drug|placebo|placebo high dose
79488150|NCT05039450|Drug|EFX|Investigational drug, Efruxifermin
79488151|NCT05039450|Drug|Placebo|Placebo
79488152|NCT05028582|Drug|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
79488153|NCT05028582|Drug|ARQ-154 Vehicle|Vehicle
79488154|NCT05010954|Drug|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
79488155|NCT05010954|Drug|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
79488156|NCT05001724|Biological|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
79983133|NCT01369290|Drug|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
79488157|NCT05001724|Drug|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
79488158|NCT05001724|Drug|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
79488159|NCT05001022|Drug|ALG-020572|Single or multiple doses of ALG-020572
79488160|NCT05001022|Drug|Placebo|Single or multiple doses of Placebo
79488161|NCT04996368|Drug|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
79653327|NCT04599205|Drug|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
79983134|NCT01369290|Other|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
79983135|NCT01369290|Drug|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
79488162|NCT04994444|Drug|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
79488163|NCT04987892|Device|UroLift System|Prostatic lift
79488164|NCT04987892|Drug|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
79983136|NCT04173975|Device|With knee exoskeleton|BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
79983137|NCT03533452|Drug|Ropivacaine|Local anesthetic injection
79488165|NCT04986280|Diagnostic Test|[18F]PSMA-1007|PSMA PET/CT using the intervention.
79488166|NCT05019222|Drug|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
79488167|NCT05019222|Drug|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
79488168|NCT04985318|Drug|Cablivi®|Intervention with Cablivi® take place outside of the study
79653328|NCT04599127|Other|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
79653329|NCT04599127|Other|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
79653330|NCT04599400|Other|There is no intervention in our study|There is no intervention in our study
79653331|NCT04598737|Procedure|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
79653332|NCT04598737|Procedure|Lithium disilicate|Lithium disilicate laminate veneer treatment
79488169|NCT04966663|Drug|Nivolumab|Antineoplastic agent
79488170|NCT04966663|Drug|Pemetrexed|Antineoplastic agent
79488171|NCT04966663|Drug|Gemcitabine|Antineoplastic agent
79488172|NCT04966663|Drug|Cisplatin|Antineoplastic agent
79488173|NCT04966663|Drug|Carboplatin|Antineoplastic agent
79488174|NCT04966663|Procedure|ctDNA blood test|Blood will be collected for ctDNA testing
79983138|NCT03533452|Drug|Normal saline|Sham injection
79488175|NCT04960917|Behavioral|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
79653333|NCT00565591|Drug|Albuterol sulfate|Single dose dry powder by inhalation
79653334|NCT00252603|Drug|Galantamine|
79653335|NCT00565630|Device|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
79653336|NCT05011526|Biological|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
79337731|NCT05527795|Other|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"Frequency of relapse to adjuvant immunotherapy according to clinical features~Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
79337732|NCT05527795|Other|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
79653337|NCT05011526|Biological|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
79653338|NCT00565786|Device|ArCom® Polyethylene|Argon packaged compression molded polyethylene
79653339|NCT00565786|Device|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
79653340|NCT00252642|Drug|Peginterferon Alpha-2a|
79337733|NCT05527795|Other|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
79653341|NCT00565942|Procedure|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
79653342|NCT00565942|Procedure|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
79337734|NCT05527795|Other|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
79653343|NCT04598542|Drug|Lorecivivint (LOR)|0.07 mg
79653344|NCT04598542|Drug|Triamcinolone acetonide (TA)|40 mg
79813033|NCT04114578|Other|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
79813034|NCT01026961|Drug|Phenylephrine HCL|Phenylephrine HCL 10mg
79813035|NCT01026961|Drug|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
79337735|NCT05527795|Other|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
79337736|NCT05527795|Other|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
79488176|NCT04957875|Device|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
79488177|NCT04927988|Other|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
79488178|NCT04922593|Drug|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
79488179|NCT04922593|Drug|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
79488180|NCT04914000|Behavioral|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
79813037|NCT01566253|Drug|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
79813038|NCT01566253|Drug|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
79653345|NCT04995263|Behavioral|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
79653346|NCT04995263|Behavioral|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
79813039|NCT01023763|Other|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
79813040|NCT02604888|Other|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
79983139|NCT03258346|Other|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
79983140|NCT03258346|Dietary Supplement|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
79983141|NCT03258346|Dietary Supplement|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
79337737|NCT04128553|Behavioral|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
79983142|NCT03488082|Behavioral|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
79337738|NCT05527561|Behavioral|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
79337739|NCT05527561|Behavioral|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
79337740|NCT05527249|Dietary Supplement|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
79653347|NCT04995263|Behavioral|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
79983143|NCT04138797|Procedure|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
79983144|NCT04138797|Device|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
79983145|NCT04359147|Drug|"Yohimbine"|Effects on neural correlates of decision-making under risk and selective attention to threat
79337741|NCT05527249|Other|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
79653348|NCT04995263|Behavioral|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
79653349|NCT04995263|Other|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
79983146|NCT04359147|Drug|"Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
79983147|NCT04359147|Drug|"Yohimbine + Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
79983148|NCT04359147|Drug|"Placebo"|Effects on neural correlates of decision-making under risk and selective attention to threat
79983149|NCT03260764|Device|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
79983150|NCT03260764|Device|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
79337742|NCT05532085|Other|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
79337743|NCT05532085|Other|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
79337744|NCT05532085|Other|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
79337745|NCT05532085|Other|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
79337746|NCT02303119|Drug|Rituximab IV|intra-venous, 375 mg/m²
79337747|NCT02303119|Drug|Rituximab SC|sub-cutaneous, 1400 mg
79983151|NCT03260764|Device|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
79983152|NCT03260764|Device|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
79653350|NCT04995263|Device|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
79653351|NCT04598581|Radiation|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
79653352|NCT04598581|Other|Sham irradiation|Sham irradiation
79653353|NCT00252681|Procedure|laparotomy|
79983153|NCT01364454|Other|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
79983154|NCT03260374|Device|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
79337748|NCT02006251|Device|Real-time Instrumentation|To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
79337749|NCT02006251|Procedure|Standard Total Hip Arthroplasty|Total hip arthroplasty performed according to standard of care
79337750|NCT02575339|Drug|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
79983155|NCT03260374|Device|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
79983156|NCT03260374|Device|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
79337751|NCT02575339|Drug|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
79337752|NCT02575339|Drug|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
79983157|NCT04188093|Other|PACU discharge criteria and continuous monitoring on the ward|"PACU discharge criteria (modified aldrete score).~Continous monitoring of vital signs 96 postoperative hours"
79983158|NCT01369368|Drug|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
79337753|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
79337754|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
79337755|NCT01712659|Drug|Ruxolitinib|Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
79337756|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
79337757|NCT01640587|Drug|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
79337758|NCT01640587|Drug|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
79337759|NCT05531851|Other|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
79337760|NCT01610713|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
79653354|NCT00252681|Procedure|primary peritoneal drainage|
79983159|NCT03258424|Drug|PTI-428|PTI-428 or placebo will be given QD for 14 days.
79983160|NCT03258424|Drug|Placebo|PTI-428 or placebo will be given QD for 14 days.
79983161|NCT01348581|Device|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
79983162|NCT04103619|Device|AccuTite|Subjects will undergo treatment with AccuTite
79983163|NCT04103619|Device|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
79983164|NCT01369446|Device|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
79653355|NCT04598503|Other|full history and clinical examination|For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) [10]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
79813041|NCT03849313|Drug|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
79813042|NCT04111614|Drug|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
79813043|NCT04111614|Drug|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
79653356|NCT04598191|Drug|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
79337761|NCT01606189|Drug|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
79337762|NCT01606189|Drug|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
79813044|NCT01019473|Drug|AFQ056|
79813045|NCT01019473|Drug|Placebo|
79813046|NCT01023919|Device|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
79813047|NCT04028622|Other|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
79813048|NCT03844087|Device|Multiplanar neuromuscular training|See arm description
79813049|NCT00830804|Drug|Raltegravir|400 mg tablet taken orally twice daily
79337763|NCT01606189|Drug|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
79337764|NCT05526859|Other|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
79337765|NCT05526859|Other|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
79337766|NCT05524987|Behavioral|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits and a text messaging program for 12 consecutive months
79337767|NCT01663987|Drug|tiotropium bromide|18 mcg once a day (QD)
79337768|NCT01663987|Drug|Placebo|once a day (QD)
79653357|NCT04598191|Drug|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
79813050|NCT00830804|Drug|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
79813051|NCT00789477|Procedure|Laser Photocoagulation|laser every 16 weeks as needed
79813052|NCT00789477|Drug|Intravitreal Aflibercept Injection|
79813053|NCT01024075|Drug|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
79813054|NCT01024075|Drug|Saline|8cc of Saline mixed with Sinufoam
79813055|NCT00913874|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
79813056|NCT00913874|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
79813057|NCT04106661|Other|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
79813058|NCT00796614|Drug|tamsulosin hydrochloride|Oral
79813059|NCT00796614|Drug|Placebo|Oral
79337769|NCT05531773|Other|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
79488181|NCT04902950|Drug|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
79983165|NCT03258268|Device|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
79983166|NCT03258268|Other|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
79983167|NCT03257956|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
79983168|NCT03257956|Device|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
79653358|NCT04598113|Device|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
79653359|NCT04956848|Device|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
79813060|NCT02603445|Drug|BCL201|
79813061|NCT02603445|Drug|Idelalisib|
79813062|NCT04106505|Behavioral|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
79983169|NCT01348659|Drug|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
79488182|NCT04902950|Drug|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
79488183|NCT04889118|Biological|Pembrolizumab|IV infusion
79488184|NCT04889118|Drug|Lenvatinib|Oral capsule
79488185|NCT04889118|Drug|Placebo for lenvatinib|Oral capsule
79337770|NCT05305651|Drug|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
79488186|NCT04844125|Drug|SHR-1209|SHR-1209
79488187|NCT04844125|Drug|SHR-1209 Placebo|SHR-1209 Placebo
79488188|NCT04831138|Procedure|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
79488189|NCT04820296|Other|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
79488190|NCT04819971|Drug|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
79488191|NCT04819971|Drug|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
79488192|NCT04819971|Drug|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
79488193|NCT04819971|Drug|S1|S1 (orally, 400mg/m2 BID on day 1~14 of every cycle for 3 preoperative and 3 postoperative cycles )
79337771|NCT05526625|Other|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC & IJV.
79813063|NCT04106505|Behavioral|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
79983170|NCT01348659|Drug|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
79983171|NCT01370070|Drug|MK-2206|200mg weekly repeated q 28 days
79983172|NCT03252574|Other|A|AIR+ Smart Mask Only
79983173|NCT03252574|Other|B|AIR+ Smart Mask with micro-ventilator
79337772|NCT05524831|Other|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
79337773|NCT05524831|Other|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
79337774|NCT05531695|Behavioral|Exercise (either aerobic or flexibility)|
79337775|NCT05531617|Procedure|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
79488194|NCT04819971|Drug|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
79813064|NCT00448747|Drug|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
79653360|NCT04598308|Diagnostic Test|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
79983174|NCT04847310|Other|Group brief transdiagnostic cognitive-behavioral therapy|An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).
79983175|NCT04847310|Other|Individual brief transdiagnostic cognitive-behavioral therapy|An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
79337776|NCT05524519|Drug|Basic treatment|"Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
79337777|NCT05524519|Procedure|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
79488195|NCT04800874|Drug|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
79653361|NCT04598230|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
79653362|NCT04598230|Drug|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
79653363|NCT00249171|Drug|risperidone|
79653364|NCT04598464|Other|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
79653365|NCT00565981|Drug|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
79653366|NCT00565981|Drug|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
79653367|NCT04952519|Drug|Amantadine|Patients are treated with high doses of amantadine.
79337778|NCT05524519|Procedure|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
79337779|NCT05524519|Procedure|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
79337780|NCT05524441|Other|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
79337781|NCT02380677|Drug|CRLX301|
79983176|NCT04847310|Other|Treatment as usual|Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
79983177|NCT01348737|Drug|AZD3839|Single Oral Dose
79983178|NCT01348737|Drug|AZD3839 Placebo|Single Oral Dose
79337782|NCT02380287|Drug|humanized monoclonal antibody against human IL-17|
79337783|NCT02343003|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
79337784|NCT02343003|Drug|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
79653368|NCT04598035|Diagnostic Test|Diagnostic Tests|"Blood and Urine laboratory tests~ECG and blood pressure for cardiovascular measurements~Self-report questionnaires about pain"
79653369|NCT00414921|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
79983179|NCT02455570|Other|No intervention|No intervention
79983180|NCT01369602|Drug|PF-04991532|single dose 300-mg
79983181|NCT01369602|Drug|PF-04991532|single dose 300-mg
79983182|NCT01369602|Drug|PF-04991532|single dose 300-mg
79337785|NCT04900701|Other|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
79337786|NCT02394561|Biological|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
79337787|NCT04904913|Drug|IBI362|IBI362 administered subcutaneously (SC) once a week.
79337788|NCT04904913|Other|placebo|placebo administered subcutaneously (SC) once a week.
79337789|NCT02342223|Device|Voluma|
79337790|NCT02393547|Drug|Varenicline|All subjects receive Varenicline
79337791|NCT02393547|Drug|Lorcaserin|All subjects receive Lorcaserin
79337792|NCT02574637|Drug|Brazikumab IV Infusion|Brazikumab IV infusion as per protocol specified dosing schedule.
79337793|NCT02574637|Drug|Brazikumab SC Injection|Brazikumab IV infusion as per protocol specified dosing schedule.
79653370|NCT00414921|Drug|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
79653371|NCT00414921|Other|placebo|inactive substance
79653372|NCT04597762|Drug|Cyclosporin|Cyclosporin eyedrops
79653373|NCT04597762|Drug|Hydrocortisone|Hydrocortisone eyedrops
79813065|NCT00448747|Drug|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
79983183|NCT01369602|Drug|PF-04991532|single dose 300-mg
79983184|NCT02455492|Other|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
79983185|NCT01364532|Procedure|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
79983186|NCT01364532|Procedure|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
79983187|NCT03260608|Behavioral|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
79983188|NCT01345149|Behavioral|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
79983189|NCT03252496|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
79983190|NCT03252496|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
79983191|NCT03252496|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
79337794|NCT02574637|Drug|Placebo|Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
79337795|NCT05531539|Device|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
79488196|NCT04790890|Device|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
79488197|NCT04785573|Dietary Supplement|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
79488198|NCT04782050|Device|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
79337796|NCT05526235|Behavioral|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
79983192|NCT03252496|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
79983193|NCT03252496|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
79488199|NCT04772820|Behavioral|Telephone-based coaching|A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
79488200|NCT04727632|Drug|[18F]Fluoroestradiol (FES) PET/CT|[18F]Fluoroestradiol (FES) PET/CT
79653374|NCT04597645|Other|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
79983194|NCT03252496|Drug|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
79653375|NCT00249210|Drug|levofloxacin|
79813066|NCT00830180|Biological|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
79813067|NCT02603679|Drug|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
79813068|NCT02603679|Drug|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
79983195|NCT03252496|Drug|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
79983196|NCT03252496|Drug|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
79813069|NCT02603679|Drug|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
79813070|NCT02603679|Drug|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
79813071|NCT03995485|Drug|KW-136 capsule|KW-136 60 mg was provided in a single capsule of 60 mg.
79983197|NCT03252496|Drug|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
79983198|NCT03252496|Drug|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
79488201|NCT04724148|Drug|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1~2 mg/kg fentanyl.
79488202|NCT04716244|Other|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
79653376|NCT04597957|Dietary Supplement|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
79653377|NCT04597723|Drug|oxygen|Patients will be given different concentrations of oxygen.
79653378|NCT00252798|Drug|Gefitinib|
79653379|NCT00252798|Drug|Carboplatin|
79813072|NCT03995485|Drug|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
79813073|NCT02605434|Drug|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
79813074|NCT02605434|Drug|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
79813075|NCT02605434|Drug|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
79813076|NCT02605434|Drug|Placebo- Sinemet|Placebo for Sinemet tables
79813077|NCT05758298|Other|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
79813078|NCT05758298|Drug|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
79813079|NCT05758298|Drug|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
79653380|NCT00252798|Drug|Paclitaxel|
79653381|NCT00252798|Procedure|Radiation|
79653382|NCT04597567|Procedure|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
79653383|NCT04597216|Device|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
79653384|NCT04597255|Device|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
79653385|NCT04597489|Procedure|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
79653386|NCT04597489|Procedure|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
79653387|NCT02961660|Drug|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
79653388|NCT04870151|Procedure|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
79653389|NCT04870151|Procedure|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
79653390|NCT04597177|Radiation|ST-IMRT SW-IMRT|
79813080|NCT00789321|Drug|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
79813081|NCT00789321|Drug|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
79813082|NCT02603367|Other|Communication Intervention|Undergo communication coaching
79813083|NCT02603367|Other|Educational Intervention|Receive COMFORT communication curriculum
79813084|NCT02603367|Other|Psychosocial Support for Caregiver|Undergo communication coaching
79813085|NCT02603367|Other|Questionnaire Administration|Complete questionnaires
79813086|NCT03998553|Procedure|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
79813087|NCT04105959|Drug|RIST4721|RIST4721 oral solution
79653391|NCT04596904|Other|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
79653392|NCT04596904|Other|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
79653393|NCT04596787|Procedure|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
79653394|NCT00252837|Drug|Tesaglitazar|
79653395|NCT00252837|Behavioral|Dietary and Lifestyle counseling|
79653396|NCT04596748|Dietary Supplement|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
79813088|NCT04105959|Drug|Placebo|Placebo oral solution
79813089|NCT04126421|Device|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
79813090|NCT04126421|Device|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
79813091|NCT00811928|Drug|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~3 chemotherapy cycles or~Total treatment duration up to 12 weeks (84 days)"
79488203|NCT04712214|Device|Intra-operative multispectral / hyperspectral analysis|During surgery, the operating surgeon will be using standard NHS neurosurgical equipment such as an endoscope and/or a microscope. This equipment is operated in exactly the same way as with any other procedure, but either the microscope or the endoscope in use will be connected to the system of camera and filters for multispectral/hyperspectral analysis. During each surgical intervention, tissue-specific spectral data will be collected at specific stages - mostly once the brain surface is exposed and at the end of the resection on the surgical cavity. The operation will be visually recorded in order to sync visual data with the spectral data obtained at the same moment in time. The video recording will not be patient identifiable and will be viewed only by members of the research team working on this project (see below). The use of video recording equipment will be included in the patient information sheet given to all patients prior to gaining consent
79337797|NCT05526235|Behavioral|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
79488204|NCT04703803|Combination Product|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
79488205|NCT04693221|Other|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
79488206|NCT04693221|Other|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
79488207|NCT04686383|Drug|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
79488208|NCT04670978|Drug|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
79488209|NCT04668768|Drug|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
79488210|NCT04664075|Biological|Respiratory infections|With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.
79653397|NCT04596748|Dietary Supplement|Placebo|Placebo caps
79813092|NCT00811928|Drug|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~3 chemotherapy cycles or~Total treatment duration up to 12 weeks (84 days)"
79337798|NCT05526235|Behavioral|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
79337799|NCT05531383|Drug|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) & serum NSE levels in patients with moderate to severe TBI as well as their outcome.
79337800|NCT05524207|Procedure|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
79337801|NCT02392611|Drug|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
79653398|NCT00403013|Procedure|Positioning and anesthesia|Positioning during axillary plexus block
79653399|NCT04597060|Device|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
79653400|NCT04597060|Other|corticosteroid injection|corticosteroid injection using TA 10mg/ml
79653401|NCT00566176|Device|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
79337802|NCT02392611|Drug|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
79337803|NCT02392611|Drug|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
79337804|NCT02378961|Drug|VOX|100 mg tablet(s) administered orally once daily with food
79653402|NCT00566215|Procedure|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
79337805|NCT02378961|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
79337806|NCT02378883|Device|Apollo™ Onyx™ Delivery Micro Catheter|
79337807|NCT05145829|Diagnostic Test|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
79337808|NCT05531071|Device|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
79337809|NCT05531071|Procedure|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
79337810|NCT05531071|Combination Product|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
79337811|NCT05518591|Behavioral|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
79337812|NCT05518513|Drug|Bupivacain|adductor canal block with 0.25% bupivacaine
79337813|NCT05518279|Drug|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
79337814|NCT05518279|Drug|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
79337815|NCT04424953|Device|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
79337816|NCT04424953|Device|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
79488211|NCT04657835|Device|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
79488212|NCT04657835|Biological|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
79488213|NCT04657835|Procedure|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
79488214|NCT04657835|Device|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
79488215|NCT04657835|Other|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
79653403|NCT00566215|Procedure|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
79653404|NCT00566332|Drug|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
79337817|NCT05523193|Other|Formal treatment model|Formal treatment model , no further surgery or minimally invasive treatment was performed
79337818|NCT05523037|Drug|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
79337819|NCT05523037|Drug|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
79337820|NCT04625647|Drug|Sotorasib|Given PO
79653405|NCT00566332|Drug|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
79653406|NCT00403052|Drug|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
79488216|NCT04639323|Diagnostic Test|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
79653407|NCT04596943|Diagnostic Test|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), [68Ga]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
79653408|NCT00252876|Drug|tesaglitazar|
79653409|NCT04597021|Device|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
79653410|NCT04596709|Dietary Supplement|Vitalose|dissolved in water
79337821|NCT05122741|Drug|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
79337822|NCT05122741|Drug|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
79983199|NCT03252496|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
79337823|NCT05525767|Drug|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
79983200|NCT03252496|Drug|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
79983201|NCT01345227|Procedure|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
79337824|NCT05522725|Other|Single-use wipes installed at the bedside|
79337825|NCT05025085|Drug|AGEN1777|An immunoglobulin gamma (IgG1) antibody
79337826|NCT05025085|Drug|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
79337827|NCT05522491|Drug|Olaparib|All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
79337828|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
79653411|NCT04596709|Dietary Supplement|isomaltulose|dissolved in water
79653412|NCT04596709|Dietary Supplement|sucrose|dissolved in water
79653413|NCT04596709|Dietary Supplement|glucose|dissolved in water
79653414|NCT04596358|Other|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
79653415|NCT00566371|Drug|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
79337829|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
79653416|NCT00566371|Drug|placebo|placebo
79653417|NCT04825769|Device|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
79653418|NCT04596397|Other|Inpatient setting|These women stay at the hospital.
79653419|NCT04596397|Other|Outpatient setting|These women can leave the hospital.
79653420|NCT00252915|Biological|GM-CSF (verum)|sagramostim
79653421|NCT04596280|Procedure|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
79337830|NCT02340975|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
79337831|NCT02340975|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
79653422|NCT04595929|Procedure|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
79813093|NCT00698321|Behavioral|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
79983202|NCT03237234|Other|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
79983203|NCT03237234|Device|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
79983204|NCT03688425|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
79983205|NCT03688425|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
79337832|NCT02340975|Biological|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
79337833|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
79337834|NCT02392377|Drug|Paclitaxel|Given IV or IVPB
79653423|NCT04595929|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
79813094|NCT00698321|Behavioral|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
79337835|NCT02392377|Drug|Carboplatin|Given IV or IVPB
79337836|NCT02392377|Drug|Oxaliplatin|Given IV
79337837|NCT02392377|Drug|Leucovorin Calcium|Given IV
79813095|NCT02611544|Behavioral|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
79813096|NCT02611544|Behavioral|Survivorship Education|6-week survivorship education group (SE; n=32)
79337838|NCT02392377|Drug|Fluorouracil|Given IV
79337839|NCT02392377|Radiation|Radiation Therapy|Undergo radiation therapy
79337840|NCT02392377|Procedure|Therapeutic Conventional Surgery|Undergo esophagectomy
79337841|NCT02392377|Other|Laboratory Biomarker Analysis|Correlative studies
79337842|NCT02340819|Drug|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
79653424|NCT04595929|Drug|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
79653425|NCT04595929|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
79653426|NCT04595929|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
79653427|NCT04595929|Procedure|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
79653428|NCT04595929|Procedure|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
79653429|NCT04595929|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
79653430|NCT00249327|Behavioral|education|
79653431|NCT04596085|Dietary Supplement|Investigational Product - ViraCide|Viracide
79653432|NCT04596085|Other|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
79653433|NCT00566410|Drug|Dichloroacetate|Continuous daily oral dosage (bid).
79813097|NCT02611544|Behavioral|Enhanced Usual Care|enhanced usual care (EUC; n=26)
79337843|NCT04904289|Other|All intervention of real world|We analyzed all data we can obtain from our databases
79488217|NCT04639206|Behavioral|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
79983206|NCT03252418|Drug|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
79337844|NCT02340663|Device|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
79983207|NCT03252418|Device|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
79983208|NCT01348893|Behavioral|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
79337845|NCT02340663|Device|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
79488218|NCT04639180|Drug|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
79488219|NCT04639180|Drug|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
79983209|NCT03260452|Procedure|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
79983210|NCT01364610|Device|Bravo|Bravo pH Monitoring System sited manometrically.
79983211|NCT01364610|Device|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
79983212|NCT03687567|Procedure|Preimplantation genetic diagnosis|
79337846|NCT02573467|Drug|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
79337847|NCT02573467|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
79488220|NCT04611698|Device|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
79488221|NCT04607486|Diagnostic Test|3DfUS and IPSA of leg muscles|"3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
79653434|NCT04596007|Drug|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
79653435|NCT04596007|Drug|Placebo|placebo
79813098|NCT00788775|Drug|Nilotinib|
79813099|NCT05756036|Other|None Observational study|Non interventional study
79983213|NCT01364688|Drug|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
79983214|NCT01364688|Drug|no drug|no drug
79337848|NCT04903899|Combination Product|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
79653436|NCT00252954|Drug|Levetiracetam|Tablets 2000-3000 mg per day
79653437|NCT04595812|Drug|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
79983215|NCT03260686|Other|experimental|video guide for upper limb exercise
79983216|NCT03252106|Procedure|Contour augmentation with implant placement|Contour augmentation with implant placement
79983217|NCT01370148|Drug|conivaptan hydrochloride|Intravenous
79653438|NCT04595812|Drug|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
79983218|NCT03260296|Other|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
79653439|NCT04595812|Drug|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
79488222|NCT04570722|Other|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
79488223|NCT04546360|Procedure|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
79488224|NCT04531943|Drug|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
79488225|NCT04531943|Drug|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
79488226|NCT04530825|Other|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
79488227|NCT04530825|Other|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
79488228|NCT04517565|Diagnostic Test|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
79488229|NCT04517565|Behavioral|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
79337849|NCT05517733|Biological|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
79337850|NCT05517733|Device|Diode laser|"A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
79337851|NCT02337387|Biological|Blosozumab|Administered SC
79337852|NCT02337387|Other|Placebo|Administered SC
79337853|NCT04903665|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
79337854|NCT02574247|Procedure|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
79337855|NCT02391363|Behavioral|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
79488230|NCT04516850|Genetic|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
79488231|NCT04516850|Genetic|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
79488232|NCT04504383|Drug|PN-943|Administered by the oral route BID for the duration of the study.
79488233|NCT04504383|Drug|Placebo|Administered by the oral route BID for 12 weeks.
79488234|NCT04503460|Drug|Salmeterol Xinafoate|All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
79488235|NCT04503460|Drug|Salmeterol Fluticasone|Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
79983219|NCT01370226|Behavioral|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
79983220|NCT01370226|Behavioral|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
79983221|NCT01348971|Dietary Supplement|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
79983222|NCT01348971|Other|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
79983223|NCT03260062|Behavioral|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
79337856|NCT02391363|Behavioral|Information and referral|Resource counseling and follow-up for mental health and basic needs
79488236|NCT04500977|Behavioral|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
79488237|NCT04486573|Diagnostic Test|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
79653440|NCT04595812|Procedure|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
79653441|NCT04596046|Procedure|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
79653442|NCT00252993|Drug|DDP225|
79653443|NCT04595539|Behavioral|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
79337857|NCT05522335|Biological|BBV154(Intranasal) & covaxin|Intervention Covaxin
79337858|NCT05512429|Other|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
79337859|NCT05522257|Diagnostic Test|[18F]-JK-PSMA-7 PET/CT scan|A [18F]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a [18F]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
79337860|NCT04903509|Drug|BI 1820237|BI 1820237
79337861|NCT04903509|Drug|Placebo|Placebo
79337862|NCT04903509|Drug|Saxenda®|Saxenda®
79337863|NCT04903509|Drug|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
79337864|NCT05517499|Drug|Dexamethasone|Randomized clinical trial
79337865|NCT05450211|Device|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
79337866|NCT05450211|Device|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
79337867|NCT05512351|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
79653444|NCT00566566|Other|sample without DNA|family history, anthropometric measurements and blood sampling
79337868|NCT04898985|Diagnostic Test|ImmunoSEQ|experiment assay
79653445|NCT04595695|Behavioral|Transparent mask|A transparent mask worn by the surgeons in customary fashion will be used.
79983224|NCT03260062|Other|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
79983225|NCT04684953|Procedure|Throid autotransplantation|Operative
79983226|NCT04684953|Drug|Hormone|thyroid hormone replacement therapy
79983227|NCT01345383|Procedure|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
79337869|NCT05517343|Other|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
79337870|NCT05517187|Other|no intervention|Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors
79337871|NCT05517187|Biological|Platelet rich fibrin|Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
79337872|NCT05512273|Procedure|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
79337873|NCT05512273|Procedure|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
79337874|NCT05521711|Other|Food|Commercially available powders or liquids
79337875|NCT05517109|Other|Hemodynamic goal including lower goal of systolic blood pressure|Different hemodynamic goals in different study arms
79813100|NCT00448669|Drug|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
79653446|NCT04595695|Behavioral|Typical surgical covered mask|A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
79653447|NCT04595578|Device|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
79653448|NCT00249366|Drug|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
79813101|NCT00448669|Drug|Placebo Oral Tablet|
79983228|NCT03252184|Device|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
79813102|NCT00591734|Drug|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
79983229|NCT03252184|Device|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
79337876|NCT05516875|Drug|JM-010|JM-010
79337877|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
79337878|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
79488238|NCT04436198|Device|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length > 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length < 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
79488239|NCT04436198|Device|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
79337879|NCT02569957|Drug|Acetylcysteine|Given IV and PO
79337880|NCT01649427|Drug|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
79488240|NCT04414748|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
79488241|NCT04414748|Drug|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
79337881|NCT01649427|Drug|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
79488242|NCT04397419|Dietary Supplement|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~2-3 hours after surgery: 250 ml~Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
79488243|NCT04397419|Other|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~2-3 hours after surgery: 250 ml~Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
79488244|NCT04395196|Dietary Supplement|Choline bitartrate|Provided in beverage form
79813103|NCT00591734|Drug|Everolimus|10 mg by mouth daily
79813104|NCT00788697|Drug|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
79813105|NCT00788697|Other|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
79813106|NCT05755880|Procedure|Intrathecal dexamethason|After general anesthesia intrathecal dexamthasone will be added
79983230|NCT03252184|Device|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
79337882|NCT05521633|Drug|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
79337883|NCT05512195|Radiation|New delineation approach|New delineation approach
79337884|NCT05512117|Device|Midline insertion|Midline catheter insertion
79337885|NCT02375373|Other|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
79337886|NCT05521555|Procedure|Total knee arthroplasty|First intention total knee arthroplasty
79337887|NCT02336607|Drug|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
79488245|NCT04395196|Dietary Supplement|Placebo|Provided in beverage form
79653449|NCT00249366|Drug|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
79653450|NCT04595461|Other|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
79653451|NCT04595461|Other|Control|Standard patient education with verbal and written education
79653452|NCT04595227|Device|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
79653453|NCT04635683|Drug|Lenalidomide|Given PO
79488246|NCT04371900|Behavioral|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
79488247|NCT04371900|Behavioral|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
79488248|NCT04371783|Procedure|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
79488249|NCT04371783|Procedure|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
79488250|NCT04368104|Diagnostic Test|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
79488251|NCT04702568|Drug|BCX9930|BCX9930 for oral administration
79488252|NCT04307264|Procedure|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
79983231|NCT03052920|Device|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
79983232|NCT01345461|Device|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
79488253|NCT04297189|Behavioral|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
79488254|NCT04294381|Behavioral|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
79488255|NCT04287283|Other|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
79488256|NCT04283786|Other|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
79983233|NCT03252262|Other|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
79983234|NCT01349127|Dietary Supplement|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
79983235|NCT01349127|Dietary Supplement|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
79337888|NCT02336607|Drug|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
79488257|NCT04259710|Behavioral|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
79488258|NCT04259710|Behavioral|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
79488259|NCT04259710|Behavioral|Pedometer only|the participant will be given a pedometer and instructed how to use it.
79488260|NCT04233515|Drug|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
79653454|NCT04635683|Biological|Ublituximab|Given IV
79337889|NCT02336607|Drug|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
79488261|NCT04228549|Device|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
79488262|NCT04228549|Device|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
79488263|NCT04169373|Drug|Upadacitinib|Upadacitinib tablet administered orally
79488264|NCT04169373|Drug|Placebo|Placebo for upadacitinib tablet administered orally
79488265|NCT04154930|Device|Restylane-L®|Intradermal injection.
79488266|NCT04150042|Drug|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
79488267|NCT04150042|Drug|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
79337890|NCT02336607|Drug|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
79337891|NCT02374671|Device|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
79488268|NCT04150042|Drug|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
79488269|NCT04150042|Drug|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
79488270|NCT04150042|Drug|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
79653455|NCT04635683|Drug|Umbralisib|Given PO
79983236|NCT01349127|Dietary Supplement|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
79488271|NCT04150042|Device|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
79488272|NCT04137705|Other|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
79488273|NCT04124471|Behavioral|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
79488274|NCT04121520|Other|Questionnaire|"Comprehensive perioperative assessment~Questionnaire administration"
79488277|NCT04093024|Drug|Nintedanib|Capsule
79488278|NCT04093024|Drug|Placebo|Capsule
79653456|NCT04595383|Device|ti.care|Electronic platform for doctor-patient communication
79653457|NCT04595110|Other|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
79653458|NCT00253032|Device|PRIMA|
79983237|NCT03486964|Drug|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
79983238|NCT01364844|Drug|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
79653459|NCT04595344|Other|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
79653460|NCT04595344|Other|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
79983239|NCT04005027|Other|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
79983240|NCT03259906|Other|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
79337892|NCT02569801|Drug|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
79337893|NCT02569801|Drug|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
79337894|NCT05521477|Dietary Supplement|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
79337895|NCT05516641|Dietary Supplement|Soluble Corn Fiber|once daily additive to diet
79337896|NCT05516641|Dietary Supplement|Maltodextrin|once daily additive to diet
79337897|NCT05521165|Other|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
79337898|NCT05511727|Device|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter [FC]) and Cook cervical ripening balloon have been the most commonly used mechanical method
79337899|NCT05516407|Drug|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
79337900|NCT05511571|Device|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
79653461|NCT04595344|Other|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
79653462|NCT00403091|Behavioral|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
79983241|NCT03259906|Procedure|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
79983242|NCT03259906|Procedure|posterior osteosynthesis|Osteosynthesis using a posterior plate
79983243|NCT03259906|Procedure|Anterior osteosynthesis|Osteosynthesis using an anterior plate
79983244|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 20 mg capsule
79983245|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 40 mg capsule.
79983246|NCT01369836|Drug|Placebo|A single oral dose of matched placebo.
79983247|NCT01317303|Procedure|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
79983248|NCT01317303|Procedure|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
79983249|NCT01317303|Procedure|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
79983250|NCT01317303|Procedure|iTBS|190 seconds of intermittent theta-burst stimulation
79488279|NCT04091503|Drug|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
79983251|NCT03251950|Behavioral|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
79337901|NCT05511571|Other|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
79488280|NCT04085406|Device|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
79488281|NCT04067752|Other|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
79983252|NCT01349205|Drug|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
79983253|NCT01349205|Drug|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
79983254|NCT01349205|Drug|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
79983255|NCT03251794|Diagnostic Test|three dimensional ultrasound|evaluation of the suprarenal glands
79983256|NCT03251794|Diagnostic Test|color Doppler|Doppler evaluation of the suprarenal artery
79337902|NCT05511571|Other|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
79337903|NCT02573311|Drug|tamsulosin hydrochloride|
79337904|NCT05520853|Radiation|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
79337905|NCT05511493|Device|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
79337906|NCT05511493|Device|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
79488282|NCT04067752|Other|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
79488283|NCT04067388|Other|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
79653463|NCT00403091|Behavioral|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
79653464|NCT00566605|Procedure|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty [IEK])
79337907|NCT05516251|Device|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
79653465|NCT00566605|Procedure|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
79813107|NCT00848549|Drug|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
79983257|NCT01370304|Other|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
79983258|NCT01370304|Other|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
79983259|NCT01370304|Other|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
79983260|NCT01349283|Biological|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
79983261|NCT01349283|Biological|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
79983262|NCT03259828|Radiation|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
79983263|NCT03982485|Drug|Apatinib|Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
79653466|NCT04594954|Dietary Supplement|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
79488284|NCT04052841|Procedure|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
79337908|NCT05516251|Drug|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
79337909|NCT05520697|Behavioral|Nutritional intervention|Nutritional treatment with caloric restriction.
79337910|NCT05520697|Behavioral|Mental exercise.|Mental exercise.
79488285|NCT04052841|Procedure|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
79337911|NCT05520697|Behavioral|Physical training.|Exercise.
79337912|NCT04886791|Procedure|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
79488286|NCT04052841|Procedure|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
79337913|NCT04886791|Procedure|Vaginal hysterectomy|Vaginal hysterectomy
79337914|NCT05516173|Diagnostic Test|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
79337915|NCT02571049|Drug|DFN-11|Sumatriptan 3 mg versus 6 mg
79337916|NCT04597801|Drug|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
79337917|NCT05520385|Diagnostic Test|blood group and Rh|check of blood group , Rh for patient and control
79337918|NCT05516095|Device|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
79337919|NCT05516095|Device|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
79337920|NCT04296955|Other|Motivational interview as a new health communication intervention|Same as intervention name
79337921|NCT04979533|Device|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
79337922|NCT05511259|Other|exercise|Square stepping exercise
79337923|NCT05520151|Dietary Supplement|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
79337924|NCT05520151|Other|control|no intervention
79337925|NCT04297423|Drug|Plenvu|randomization 1:1
79337926|NCT05515861|Procedure|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
79337927|NCT04295941|Drug|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
79337928|NCT05510869|Procedure|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
79337929|NCT05510869|Procedure|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
79337930|NCT05510869|Procedure|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
79488287|NCT04048941|Procedure|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
79488288|NCT04048941|Procedure|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
79488289|NCT04048941|Procedure|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
79488290|NCT04014790|Drug|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
79337931|NCT05515549|Other|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
79488291|NCT04014790|Drug|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
79488292|NCT04009031|Device|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
79983264|NCT03982485|Drug|Paclitaxel|Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
79983265|NCT03982485|Drug|Cisplatin|Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
79337932|NCT02573155|Drug|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79337933|NCT02573155|Drug|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79653467|NCT04594954|Other|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum [(2 to 3 minutes per 50 ml).]~The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~100 mL freshly thawed sample will be given once in 15 days for 3 doses~Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~The patient will be allowed to consume liquid diet two hours after the procedure."
79337934|NCT02573155|Drug|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79337935|NCT02573155|Drug|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79488293|NCT03978130|Other|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
79337936|NCT02573155|Drug|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79488294|NCT03973606|Other|Heath literacy assessment in Arab women in East Jerusalem|A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
79488295|NCT03969628|Diagnostic Test|ICCMS|Risk caries assessment will consider ICCMS criteria
79983266|NCT03982485|Procedure|Surgery|Surgery
79983267|NCT03259750|Other|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
79337937|NCT02573155|Drug|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79337938|NCT02573155|Drug|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79337939|NCT02573155|Drug|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
79337940|NCT02573155|Drug|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
79488296|NCT03965234|Drug|Cisplatin|Given via infusion
79488297|NCT03965234|Procedure|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
79983268|NCT03246490|Other|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
79488298|NCT03965234|Procedure|Metastasectomy|Undergo metastasectomy
79337941|NCT02573155|Drug|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
79488299|NCT03947723|Device|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
79488300|NCT03921060|Drug|Denosumab|treatment with denosumab every 6 months for up to 5 years
79488301|NCT03907891|Behavioral|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
79488302|NCT03907891|Behavioral|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
79337942|NCT02573155|Drug|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
79337943|NCT05045755|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
79337944|NCT05519761|Device|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
79337945|NCT05510791|Dietary Supplement|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
79488303|NCT03907891|Behavioral|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
79488304|NCT03862924|Device|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
79488305|NCT03861156|Drug|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
79488306|NCT03827070|Drug|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (<5 μm) - only 19%
79488307|NCT03827070|Drug|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (<5 μm) - only 11%
79488308|NCT03812718|Device|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
79488309|NCT03812718|Device|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
79488310|NCT03752073|Device|Trans-cervical cervical balloon|Insertion of Foley Catheter
79488311|NCT03752073|Device|Hygroscopic cervical dilator|Insertion of Dilapan-s
79488312|NCT03748303|Drug|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
79488313|NCT03735004|Device|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
79488314|NCT03723473|Device|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
79488315|NCT03710538|Dietary Supplement|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
79488316|NCT03710538|Behavioral|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
79653468|NCT04594954|Other|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
79337946|NCT05510791|Dietary Supplement|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
79337947|NCT05515471|Drug|SHR8058 eye drops|SHR8058 eye drops
79813108|NCT00848549|Drug|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
79653469|NCT00253071|Behavioral|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
79337948|NCT05515471|Drug|saline eye drops.|saline eye drops.
79337949|NCT05510713|Device|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
79337950|NCT05519371|Drug|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
79653470|NCT00249405|Drug|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
79653471|NCT00249405|Behavioral|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
79983269|NCT03966339|Drug|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
79983270|NCT03251716|Drug|berberine|berberine 300mg TID add-on for berberine adjunctive group
79337951|NCT05519371|Drug|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
79337952|NCT04948645|Drug|ABBV-CLS-7262|Oral
79337953|NCT04948645|Drug|Placebo|Oral
79337954|NCT05515003|Other|Individualized patient education|Patients in the intervention group will be applied one-session individualized patient education by the researcher. Educational session will last between 30 and 60 minutes. Problem-focused education will be applied related to the issues that the patient had difficulty in coping with. The subjects that the patient lacks knowledge about will be determined and the patient will be trained on these subjects and a discussion session will be arranged in the form of questions and answers. The education topics will include; fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise and sleep.
79337955|NCT04847947|Drug|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
79337956|NCT04847947|Drug|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
79337957|NCT05519137|Device|Active lighting intervention|Lighting intervention designed to impact the circadian system
79337958|NCT05519137|Device|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
79337959|NCT05510479|Other|Software as medical device|At home measurements of visual acuity through a mobile app
79337960|NCT05518981|Device|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
79337961|NCT05514925|Drug|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
79337962|NCT05514925|Procedure|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
79337963|NCT05514847|Drug|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
79337964|NCT05514847|Drug|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
79337965|NCT05510401|Other|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
79653472|NCT00566644|Device|levonorgestrel-releasing intrauterine system|
79653473|NCT00566644|Other|questionnaire administration|
79653474|NCT00566644|Procedure|observation|
79337966|NCT05510323|Drug|Prednisolone|RAS blockade as much as tolerated or allowed
79337967|NCT05510323|Drug|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
79337968|NCT05514691|Diagnostic Test|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
79337969|NCT05514691|Diagnostic Test|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
79813109|NCT00788151|Biological|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
79983271|NCT03251872|Drug|Olaparib|Olaparib tablets
79337970|NCT05514613|Other|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
79488317|NCT03681314|Other|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
79488318|NCT03680053|Drug|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
79337971|NCT05510167|Behavioral|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
79488319|NCT03680053|Drug|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
79488320|NCT03673007|Behavioral|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
79488321|NCT03673007|Behavioral|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
79488322|NCT03671902|Device|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
79813110|NCT00788151|Biological|Pneumococcal polysaccharide vaccine|0.5 mL, SC
79337972|NCT05514379|Behavioral|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
79337973|NCT04128397|Device|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
79337974|NCT04128397|Device|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
79488323|NCT03657602|Drug|Kyleena Intrauterine System|Participant will be randomly allocated to this intervention
79337975|NCT02568475|Behavioral|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
79983272|NCT02455258|Other|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
79337976|NCT05507671|Biological|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
79337977|NCT05507671|Other|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
79337978|NCT02568397|Drug|Lanabecestat|Administered orally
79337979|NCT02568397|Drug|Dabigatran etexilate|Administered orally
79337980|NCT02566525|Device|CytoSorb|Cytosorb device use during cardiopulmonary bypass
79488324|NCT03657602|Drug|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
79488326|NCT03633929|Other|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
79813111|NCT04116359|Drug|Cisplatin|Given IV
79813112|NCT04116359|Drug|Etoposide|Given IV
79813113|NCT04116359|Drug|Etoposide Phosphate|Given IV
79813114|NCT04116359|Drug|Molibresib|Given PO
79813115|NCT04116359|Drug|Molibresib Besylate|Given PO
79813116|NCT00788073|Drug|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
79337981|NCT05514145|Device|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
79813117|NCT00788073|Drug|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
79813118|NCT04118153|Drug|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL) per dose.
79337982|NCT05514145|Device|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
79337983|NCT05513989|Device|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
79337984|NCT05513989|Device|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
79488327|NCT03632369|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
79488328|NCT03629626|Procedure|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
79488329|NCT03625687|Drug|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
79488330|NCT03584399|Other|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
79488331|NCT03574194|Dietary Supplement|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
79488332|NCT03523468|Procedure|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
79653475|NCT04625660|Device|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
79813119|NCT00848393|Drug|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
79488333|NCT03523468|Procedure|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
79653476|NCT04594447|Device|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
79983273|NCT02455258|Other|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
79653477|NCT04594447|Device|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
79653478|NCT04594720|Other|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
79653479|NCT04594720|Other|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
79813120|NCT00848393|Drug|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
79813121|NCT00848393|Drug|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
79653480|NCT04594330|Drug|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
79813122|NCT00815516|Drug|micafungin|Administered by intravenous infusion
79813123|NCT00815516|Drug|amphotericin B deoxycholate|Administered by intravenous infusion
79813124|NCT04118309|Behavioral|Exercise|
79813125|NCT04118309|Other|Placebo|
79813126|NCT00705926|Drug|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
79337985|NCT05513911|Other|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
79337986|NCT05513755|Procedure|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
79337987|NCT05513677|Device|M4D|Coated catheter
79337988|NCT05513677|Device|Standard of Care|Standard of Care
79337989|NCT05507593|Biological|DLL3-CAR-NK cells|Patients of Group A will be received 1x10^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10^9 DLL3-CAR-NK cells infusion treatment.
79337990|NCT05507281|Procedure|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
79337991|NCT05507281|Procedure|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
79337992|NCT05507281|Procedure|Control|General anesthesia
79983274|NCT03251404|Other|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
79337993|NCT05507047|Drug|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
79337994|NCT04757857|Drug|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
79653481|NCT04594330|Other|placebo|15 mL of placebo twice a day for 14 days
79653482|NCT04618133|Behavioral|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
79337995|NCT04754191|Drug|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
79653483|NCT04618133|Behavioral|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
79813127|NCT00705926|Other|No treatment|Participants in this group will not receive treatment at this stage of their infection.
79813128|NCT05755724|Other|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
79813129|NCT05755724|Other|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
79337996|NCT05513287|Other|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
79813130|NCT05087576|Behavioral|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
79813131|NCT05087576|Behavioral|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
79983275|NCT02930226|Biological|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
79337997|NCT05513131|Drug|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3~d14； Azacitidine 75mg/m2/d，d1~d7 Homoharringtonine 2mg/d d1~d7
79337998|NCT05509465|Device|Ergonomic chinrest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
79337999|NCT05509465|Device|Ergonomic chinrest used with a low Super Kun shoulder rest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
79488334|NCT03504683|Behavioral|Early Time-Restricted Feeding|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
79653484|NCT04618133|Behavioral|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
79653485|NCT04594057|Behavioral|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
79983276|NCT02930226|Biological|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
79983277|NCT03251560|Drug|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
79653486|NCT04594135|Drug|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
79653487|NCT00253110|Drug|risperidone|
79488335|NCT03504683|Behavioral|Mid-day Time-Restricted Feeding|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
79488336|NCT03504683|Behavioral|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
79488337|NCT03469284|Other|Best Practice|Given standard of care therapy
79488338|NCT03469284|Drug|Methylene Blue|Given lower dose PO
79488339|NCT03469284|Drug|Methylene Blue|Given medium dose PO
79488340|NCT03469284|Drug|Methylene Blue|Given higher dose PO
79653488|NCT00253110|Drug|haloperidol|
79653489|NCT04594252|Drug|ALXN1840|Administered orally as tablets.
79653490|NCT04594174|Procedure|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP <65 mm Hg or a Systolic Blood Pressure <90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
79653491|NCT04598672|Behavioral|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
79983278|NCT03251560|Drug|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
79983279|NCT03160521|Drug|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
79983280|NCT03160521|Drug|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
79983281|NCT03160521|Drug|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
79338000|NCT05506657|Other|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
79338001|NCT05506657|Other|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
79338002|NCT05512975|Dietary Supplement|Dairy protein porridge arm|Regular porridge ingredients with additional delical whey protein fortification
79653492|NCT00566683|Drug|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
79338003|NCT05512975|Dietary Supplement|Plant protein porridge arm|Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
79338004|NCT05512975|Dietary Supplement|Control Porridge arm|Regular porridge ingredients with no additional protein fortification
79338005|NCT05512897|Procedure|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
79338006|NCT05509387|Device|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
79653493|NCT00566683|Drug|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
79488341|NCT03465072|Other|Exercise training|8 weeks, 3 times per week, 30-40 minutes
79653494|NCT00566761|Drug|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
79653495|NCT00566800|Drug|erlotinib hydrochloride|
79653496|NCT00566800|Other|laboratory biomarker analysis|
79653497|NCT00566800|Procedure|biopsy|
79653498|NCT04593589|Other|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
79653499|NCT04593706|Drug|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
79983282|NCT02722434|Other|Laboratory Biomarker Analysis|Correlative studies
79983283|NCT02722434|Other|MC5-A Scrambler Therapy|Undergo Scrambler therapy
79338007|NCT05506501|Procedure|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
79488342|NCT03452150|Drug|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
79983284|NCT02722434|Other|Questionnaire Administration|Ancillary studies
79983285|NCT02722434|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
79983286|NCT03251248|Drug|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
79983287|NCT03251248|Drug|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
79983288|NCT03246256|Other|Group 1|
79983289|NCT04438590|Dietary Supplement|Kelulut Honey|The Substance being tested to be used as an alternative
79983290|NCT04438590|Dietary Supplement|Carborie|The commercially available substance
79488343|NCT03447340|Behavioral|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
79813132|NCT00787917|Drug|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
79338008|NCT05506501|Procedure|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
79338009|NCT05506267|Device|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
79813133|NCT00787917|Drug|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
79338010|NCT05512663|Device|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
79813134|NCT00787917|Drug|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
79338011|NCT05512507|Behavioral|Physical Therapy Program|Physical Therapy Program
79338012|NCT05509153|Drug|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
79338013|NCT05509153|Drug|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
79338014|NCT05506189|Other|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
79338015|NCT05506033|Procedure|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
79488344|NCT03447340|Other|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
79488345|NCT03425331|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
79488346|NCT03425331|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
79488347|NCT03358797|Behavioral|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
79813135|NCT04106271|Other|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q & A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
79813136|NCT05758064|Drug|Duphaston|10 mg tablet will be given twice
79813137|NCT05758064|Drug|prolutex|subcutaneous injection daily
79813138|NCT00814892|Biological|allogeneic tumor cell vaccine|Given intradermally
79813139|NCT00814892|Biological|therapeutic autologous dendritic cells|Given intradermally
79813140|NCT00787839|Other|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
79813141|NCT00787839|Other|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
79813142|NCT02610764|Procedure|Blood Test for CTC evaluation|
79813143|NCT04105647|Behavioral|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
79338016|NCT04594837|Device|PTR Physical Therapy while wearing Robot group (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
79338017|NCT04594837|Other|Physical Therapy Only (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
79653500|NCT04593706|Drug|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
79338018|NCT04594837|Device|Cross over group for Physical Therapy n Sub-Acute group. (Phase II)|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
79338019|NCT04594837|Device|Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
79338020|NCT05509075|Dietary Supplement|nutraceuticals|antioxidants
79653501|NCT04593706|Drug|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
79653502|NCT04593706|Drug|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
79653503|NCT04593667|Device|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
79653504|NCT04593238|Drug|Double Antibiotic paste|Metronidazole and Ciprofloxacin
79653505|NCT04593238|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
79338021|NCT05508919|Device|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
79338022|NCT05508919|Other|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
79338023|NCT04735393|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
79653506|NCT04593316|Other|Saliva collection|A saliva sample will be collected before physical exercise.
79653507|NCT04593316|Behavioral|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
79653508|NCT04593316|Other|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
79653509|NCT04593316|Other|Physical exercise|The participant will perform a walk/run test.
79653510|NCT04593316|Other|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
79653511|NCT04593316|Other|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
79653512|NCT04593433|Other|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
79653513|NCT04593511|Drug|LY03009 F1|a single dose of LY03009 F1
79653514|NCT04593511|Drug|LY03009 F2|a single dose of LY03009 F2
79653515|NCT04593511|Drug|LY03009 F3|a single dose of LY03009 F3
79653516|NCT04593511|Drug|LY03009 F4|a single dose of LY03009 F4
79338024|NCT04735393|Drug|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
79338025|NCT04735393|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
79338026|NCT04735393|Drug|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
79983291|NCT03246178|Other|MSD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed."
79338027|NCT05508841|Other|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
79338028|NCT05502445|Other|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
79338029|NCT05505877|Drug|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
79338030|NCT05508685|Other|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
79338031|NCT05508685|Other|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
79338032|NCT05508685|Other|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
79338033|NCT05508685|Other|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
79338036|NCT02336451|Drug|Ceritinib|LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
79338037|NCT02374593|Drug|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
79338038|NCT02374593|Device|Ultrasound|
79338039|NCT01648101|Drug|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
79338040|NCT01648101|Drug|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
79338041|NCT01648101|Other|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
79653517|NCT00566839|Procedure|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
79653518|NCT00566839|Procedure|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
79653519|NCT04593160|Drug|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
79653520|NCT04593160|Drug|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
79653521|NCT04593160|Drug|Placebo|Preoperative single dose of placebo
79653522|NCT04592965|Behavioral|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
79338042|NCT02336373|Drug|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
79338043|NCT02372799|Drug|Vilazodone|
79338044|NCT02372799|Drug|Placebo|
79338045|NCT02372799|Drug|Fluoxetine|
79338046|NCT02566993|Drug|Lurbinectedin (PM01183)|
79338047|NCT02566993|Drug|Doxorubicin (DOX)|
79338048|NCT02566993|Drug|Cyclophosphamide (CTX)|
79338049|NCT02566993|Drug|Vincristine (VCR)|
79338050|NCT02566993|Drug|Topotecan|
79653523|NCT04592965|Behavioral|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
79338051|NCT05508607|Other|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
79338052|NCT05508529|Dietary Supplement|Chaga Mushroom|Effect of chaga on immune/mood support
79488348|NCT03358797|Behavioral|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
79488349|NCT03358797|Behavioral|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
79338053|NCT05508529|Dietary Supplement|Algae Extract|Effect of algae extract on immune/mood support
79338054|NCT05508529|Dietary Supplement|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
79653524|NCT04592965|Other|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
79653525|NCT04592965|Other|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
79653526|NCT00253149|Drug|risperidone|
79653527|NCT04592926|Device|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
79653528|NCT04592926|Other|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
79653529|NCT00566917|Procedure|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
79338055|NCT05508529|Dietary Supplement|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
79338056|NCT05508529|Dietary Supplement|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
79338057|NCT05508529|Dietary Supplement|Placebo|Placebo control
79338058|NCT05505487|Other|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
79338059|NCT05508451|Procedure|Double jaw surgery|A type of orthognathic surgery
79338060|NCT05508373|Biological|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
79338061|NCT02311881|Drug|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
79488350|NCT03358797|Behavioral|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
79488351|NCT03348280|Diagnostic Test|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
79488352|NCT03344770|Device|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
79488353|NCT03344770|Device|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
79488354|NCT03313115|Behavioral|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
79488355|NCT03295136|Behavioral|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
79653530|NCT00566917|Procedure|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
79653531|NCT00249483|Drug|Venlafaxine|Venlafaxiine 300mg/day
79653532|NCT00249483|Drug|Placebo|Placebo
79653533|NCT00566956|Procedure|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
79338062|NCT02311881|Drug|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
79338063|NCT02311881|Drug|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
79338064|NCT02565511|Biological|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
79338065|NCT02565511|Other|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
79338066|NCT02565511|Drug|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
79338067|NCT02565511|Other|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
79338068|NCT02565511|Other|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
79338069|NCT05505331|Radiation|three-Dimensional ultrasonography|transadominal and transvaginal examination
79653534|NCT00567034|Drug|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
79653535|NCT00567034|Drug|placebo|lactose placebo, 1 capsule every day for 12 weeks
79338070|NCT05505331|Radiation|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
79653536|NCT03454126|Drug|BIIB095|Administered as specified in the treatment arm.
79653537|NCT03454126|Drug|Placebo|Administered as specified in the treatment arm.
79653538|NCT04592263|Other|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
79338071|NCT05505331|Procedure|myomectomy|myoma excision
79338072|NCT02561455|Drug|Gilteritinib|oral tablet
79338073|NCT02561299|Device|Peripheral Orbital Atherectomy System|Orbital Atherectomy
79338074|NCT02561299|Device|014 Drug Coated Balloon|Drug Coated Balloon
79338075|NCT04549051|Device|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
79338076|NCT04549051|Drug|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
79338077|NCT04547413|Behavioral|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
79338078|NCT05505253|Drug|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
79338079|NCT05505253|Drug|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
79338080|NCT05501977|Procedure|thoracotomy|thoracic surgery for pulmonary diseases
79653539|NCT02961309|Drug|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
79653540|NCT04484363|Drug|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
79338081|NCT04784377|Other|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
79338082|NCT04784377|Other|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
79338083|NCT04784377|Other|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
79338084|NCT04541095|Other|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
79338085|NCT04541095|Other|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
79338086|NCT02566759|Drug|TAK-831 Oral Suspension|TAK-831 oral suspension.
79338087|NCT02566759|Drug|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
79338088|NCT02566759|Drug|TAK-831 Tablet|TAK-831 tablet.
79338089|NCT04782349|Other|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
79338090|NCT04782349|Other|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
79338091|NCT04782349|Other|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
79338092|NCT05507983|Drug|Tranexamic acid|Tranexamic acid 1500 mg
79338093|NCT05507983|Drug|Placebo|Placebo, sodium chloride 0.9%
79338094|NCT05501509|Procedure|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
79338095|NCT05501509|Procedure|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
79338096|NCT05501431|Device|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
79653541|NCT04484363|Drug|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
79653542|NCT04592302|Diagnostic Test|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
79653543|NCT04592146|Device|Frailty multicomponent intervention supported by POSITIVE|This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
79653544|NCT04592146|Other|Frailty multicomponent intervention|This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
79338097|NCT05504785|Device|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
79338098|NCT05504629|Behavioral|Concurrent training order 1|atag
79488356|NCT03270163|Diagnostic Test|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~three simple electrical stimulations,~three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
79488357|NCT03270163|Diagnostic Test|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~three simple magnetic stimulations,~three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
79488358|NCT03270163|Diagnostic Test|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
79488359|NCT03260647|Other|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
79488360|NCT03214029|Diagnostic Test|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
79338099|NCT05504629|Behavioral|RT+ET|aetaer
79338100|NCT05501197|Other|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
79653545|NCT04592380|Drug|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
79338101|NCT05501197|Other|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
79338102|NCT05504473|Device|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
79813144|NCT04105647|Behavioral|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
79338103|NCT05504317|Drug|AK111|Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
79338104|NCT05504317|Drug|Placebo|Subjects will receive corresponding dose of placebo injection subcutaneously.
79338105|NCT05504239|Drug|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
79338106|NCT05504239|Drug|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
79488361|NCT03205293|Behavioral|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
79338107|NCT04587661|Behavioral|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
79488362|NCT03201523|Other|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
79488363|NCT03167489|Behavioral|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
79488364|NCT03149211|Drug|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
79488365|NCT03149211|Drug|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
79488366|NCT03141671|Drug|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
79488367|NCT03141671|Drug|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
79488368|NCT03141671|Radiation|Salvage radiation|Radiation
79488369|NCT03141671|Drug|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
79338108|NCT04587661|Behavioral|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
79338109|NCT04651699|Device|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
79488370|NCT03141671|Drug|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
79488371|NCT03141671|Drug|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
79488372|NCT03108820|Behavioral|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
79653546|NCT04592380|Drug|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
79653547|NCT04592380|Drug|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
79338110|NCT04651699|Device|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
79338111|NCT02335983|Drug|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
79338112|NCT02335983|Drug|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
79338113|NCT02335983|Drug|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
79338114|NCT04640311|Drug|Daprodustat|Daprodustat will be available as oral tablets.
79338115|NCT05274529|Behavioral|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
79338116|NCT05274529|Behavioral|Work ability|A remote coaching programme concentrating on work ability
79338117|NCT05274529|Behavioral|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
79338118|NCT05274529|Behavioral|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
79338119|NCT05274529|Other|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
79338120|NCT04578691|Device|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
79338121|NCT04578691|Device|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
79338122|NCT02334423|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
79338123|NCT02334423|Other|0.9% sterile, unpreserved saline|Placebo
79338124|NCT02310789|Drug|Ivacaftor|150mg administered orally twice daily.
79338125|NCT02310789|Drug|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
79338126|NCT02310789|Drug|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
79338127|NCT02310789|Device|Macroduct sweat stimulator|
79338128|NCT02372253|Drug|Verapamil|
79338129|NCT02372253|Drug|Placebo|
79338130|NCT02559895|Drug|ALD403|
79338131|NCT02559895|Drug|Placebo|
79338132|NCT02371629|Drug|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
79488373|NCT03108820|Other|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
79653548|NCT04592380|Drug|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
79653549|NCT00253188|Drug|galantamine hydrobromide|
79653550|NCT04471220|Device|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
79653551|NCT04592497|Procedure|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
79653552|NCT00249522|Behavioral|Contingency management|
79338133|NCT02371629|Drug|Placebo|Placebo to NVA237
79338134|NCT02371629|Drug|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
79338135|NCT02559817|Drug|Linaclotide Dose A|
79338136|NCT02559817|Drug|Linaclotide Dose B|
79338137|NCT02559817|Drug|Linaclotide Dose C|
79338138|NCT02559817|Drug|Linaclotide Approved Adult Dose|
79338139|NCT02559817|Drug|Matching Placebo|
79338140|NCT05504005|Device|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
79338141|NCT02564887|Device|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
79338142|NCT04517929|Other|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
79338143|NCT04577443|Drug|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
79653553|NCT04438265|Drug|levobupivacaine|local anesthetic
79653554|NCT04438265|Device|ultrasound device|scream
79653555|NCT04592068|Device|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
79653556|NCT04592068|Other|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
79653557|NCT04595071|Device|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
79653558|NCT04592107|Diagnostic Test|eGFR|estimated glomerular filtration rate
79338144|NCT04577443|Drug|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
79338145|NCT02333487|Drug|Lu AF35700|5 mg tablets for oral administration
79338146|NCT05500729|Other|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
79338147|NCT05500729|Other|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
79338148|NCT04411537|Drug|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
79488374|NCT03043430|Drug|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
79488375|NCT03043430|Drug|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
79338149|NCT04411537|Drug|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
79338150|NCT04411537|Drug|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1*28 6/6) or 65mg/m2 qw (UGT1A1*28 6/7)
79488376|NCT03035890|Radiation|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
79338151|NCT04411537|Radiation|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
79488377|NCT03035890|Drug|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
79653559|NCT00249561|Behavioral|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
79653560|NCT00249561|Behavioral|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg & Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
79653561|NCT04591756|Other|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
79653562|NCT04591795|Drug|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
79813145|NCT02602977|Other|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
79338152|NCT05500495|Other|no intervention|no intervention
79813146|NCT02602977|Other|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
79338153|NCT05503615|Other|Observational|No application will be made to the control group.
79338154|NCT05503615|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
79338155|NCT05503537|Procedure|post-isometric relaxation technique|Post-isometric relaxation technique will be performed by asking the patient to contract his calf muscles using 20% of his strength. Maintain the contraction for 10 second with 15 second of rest time between each contractions. A total of 4 contractions will be performed.
79338156|NCT05503537|Procedure|Static stretching|Static stretching will be performed by asking patient to perform dorsiflexion till the point of discomfort. The patient will hold the stretch for 15 second and 5 repetitions will be performed.
79338157|NCT05503537|Procedure|Basic Cardiac Rehabilitation Protocol|Ankle pumps, leg slides, walking
79338158|NCT05503459|Other|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
79488378|NCT03004261|Biological|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
79488379|NCT03004261|Drug|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
79488380|NCT03004261|Drug|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
79488381|NCT02908061|Procedure|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
79338159|NCT05503459|Other|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
79488382|NCT02908061|Procedure|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
79488383|NCT02883972|Other|Intervention letter|Behavioural-insight informed letter template
79813147|NCT02602977|Biological|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group [n=10], single-dose RIPC group [n=10] and control group [n=10]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
79813148|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
79983292|NCT03246178|Other|HFD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed."
79983293|NCT03954015|Diagnostic Test|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
79338160|NCT05500027|Diagnostic Test|serum test|serum test of sCD58 and TGFbeta1
79338161|NCT04630171|Device|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
79338162|NCT04630171|Device|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
79338163|NCT04630171|Other|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
79488384|NCT02883972|Other|Control letter|Invitation letter used by local area last year (updated as required)
79488385|NCT02883972|Other|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
79488386|NCT02856425|Drug|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
79488387|NCT02856425|Drug|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
79653563|NCT04591795|Drug|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
79338164|NCT04630171|Device|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
79488388|NCT02785952|Biological|Ipilimumab|Given IV
79488389|NCT02785952|Other|Laboratory Biomarker Analysis|Correlative studies
79488390|NCT02785952|Biological|Nivolumab|Given IV
79488391|NCT02785952|Other|Quality-of-Life Assessment|Ancillary studies
79653564|NCT04591639|Drug|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
79653565|NCT04591639|Drug|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
79488392|NCT02785952|Other|Questionnaire Administration|Ancillary studies
79488393|NCT02769117|Procedure|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
79813149|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
79813150|NCT00787605|Drug|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
79653566|NCT04719585|Drug|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
79983294|NCT03954015|Drug|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
79813151|NCT00787605|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
79813152|NCT00787605|Drug|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
79813153|NCT00448591|Drug|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
79813154|NCT00448591|Drug|Taxane-based chemotherapy|As prescribed
79338165|NCT04630171|Device|Group #5: Ultrasound (US) utilized for identification of site for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
79338166|NCT04630171|Other|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
79488394|NCT02769117|Procedure|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
79488395|NCT02763085|Device|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
79813155|NCT00651664|Drug|alisertib|Alisertib (MLN8237) capsules
79813156|NCT00787527|Drug|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
79488396|NCT02757573|Procedure|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
79813157|NCT00787527|Drug|Cyclophosphamide|750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
79983295|NCT03251092|Drug|PTI-808|Active
79983296|NCT03251092|Drug|Placebo|Placebo
79983297|NCT03251092|Drug|PTI-428|Active
79983298|NCT03251092|Drug|PTI-801|Active
79983299|NCT01365000|Drug|NKTR118 Formulation 1|Oral dose, 25 mg
79983300|NCT01365000|Drug|NKTR118 Formulation 2|Oral dose, 25 mg
79983301|NCT01365000|Drug|NKTR118 Formulation 3|Oral dose, 25 mg
79813158|NCT00787527|Drug|Doxorubicin|50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
79813159|NCT00787527|Drug|Vincristine|1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
79813160|NCT00787527|Drug|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
79813161|NCT04105881|Dietary Supplement|Investigation|Cross sectional intervention
79813162|NCT00804388|Procedure|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
79813163|NCT04025151|Behavioral|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
79813164|NCT04025151|Behavioral|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
79983302|NCT01365000|Drug|NKTR118 Formulation 1a|Oral dose, 25 mg
79983303|NCT01365000|Drug|NKTR118 Formulation 3a|Oral dose, 25 mg
79983304|NCT01349361|Procedure|Daylight mediated photodynamic therapy|
79338167|NCT05503381|Procedure|Laparoscopic radical resection of low rectal cancer with transanal specimens|According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
79338168|NCT04696081|Other|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
79338169|NCT05503147|Drug|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
79338170|NCT04619095|Dietary Supplement|Psyllium|See the information already included in the arm descriptions.
79653567|NCT04592029|Drug|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
79653568|NCT00253227|Drug|galantamine hydrobromide|
79338171|NCT04619095|Dietary Supplement|Placebo|See the information already included in the arm descriptions.
79653569|NCT04591678|Drug|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
79653570|NCT04591444|Drug|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
79813165|NCT04025151|Behavioral|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
79813166|NCT04025151|Behavioral|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
79983305|NCT01345773|Procedure|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
79983306|NCT03246100|Behavioral|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
79338172|NCT05499949|Diagnostic Test|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
79338173|NCT05499949|Diagnostic Test|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
79338174|NCT05499949|Diagnostic Test|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
79813167|NCT04025151|Behavioral|General health through SMS|After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
79813168|NCT04025151|Behavioral|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
79813169|NCT00804466|Device|OncoE6|HPV oncoprotein assay
79983307|NCT03147040|Drug|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
79983308|NCT03147040|Drug|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
79338175|NCT04490005|Other|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
79653571|NCT04591444|Drug|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
79653572|NCT04591444|Other|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
79653573|NCT04404335|Diagnostic Test|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
79983309|NCT03245944|Procedure|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
79338178|NCT05499793|Dietary Supplement|Zingiber Officinale powder|Ginger powder
79338179|NCT05499793|Dietary Supplement|Placebo|Starch powder
79338180|NCT05499715|Biological|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
79338181|NCT04557553|Dietary Supplement|Lagenbone|Traditional Chinese medicine herbal formula
79338182|NCT05502991|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
79338183|NCT02333331|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
79338184|NCT02333331|Other|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
79338185|NCT02563561|Drug|Apaziquone|One dose of apaziquone administered by intravesical administration
79338186|NCT02563561|Other|Placebo|Matching placebo (containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
79338187|NCT05499481|Drug|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
79338188|NCT05564533|Behavioral|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
79813170|NCT00804466|Device|EVA System|low-cost colposcope
79338189|NCT04413955|Device|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
79488397|NCT02748798|Drug|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
79488398|NCT02748798|Drug|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
79653574|NCT04591522|Other|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
79653575|NCT00249600|Behavioral|Contingency management|
79813171|NCT00806884|Other|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
79813172|NCT00806884|Other|Control group measurements|None other than control group measurements
79813173|NCT04025073|Other|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
79813174|NCT04025073|Other|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
79338190|NCT05498077|Procedure|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
79338191|NCT04140955|Procedure|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
79488399|NCT02748798|Drug|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
79488400|NCT02748798|Drug|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
79488401|NCT02748798|Device|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
79488402|NCT02748798|Device|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
79813175|NCT00810238|Biological|C-Cure|Intraventricular injection
79813176|NCT03998007|Device|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
79338195|NCT05564143|Procedure|EUS-guided gastroenterostomy (EUS-GE)|Treatment
79338196|NCT05564143|Procedure|Laparoscopic gastroenterostomy (LGE)|Treatment
79813177|NCT00806962|Drug|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
79983310|NCT03245944|Procedure|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
79983311|NCT03251170|Drug|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
79983312|NCT03251170|Drug|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
79338197|NCT05564065|Procedure|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
79338198|NCT05564065|Procedure|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
79338199|NCT05497609|Other|no intervention. Care as ususal|No intervention
79983313|NCT03251170|Drug|Midazolam|Patients will receive 0.05 mg/Kg midazolam
79983314|NCT03539601|Drug|Crisaborole ointment, 2%|Applied twice a day (BID)
79488403|NCT02748798|Device|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
79488404|NCT02654236|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
79488405|NCT02654236|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
79488406|NCT02604563|Other|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
79813178|NCT00806962|Device|placebo|intranasal, puff of air, 2 doses, 21 days apart
79813179|NCT00806962|Biological|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
79813180|NCT00806962|Biological|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
79813181|NCT04105569|Procedure|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
79813182|NCT00804544|Device|SPECT/CT|SPECT/Low-Dose MultiSclice CT
79983315|NCT03539601|Drug|Hydrocortisone butyrate cream, 0.1%|Applied BID
79983316|NCT03539601|Drug|Pimecrolimus cream, 1%|Applied BID
79983317|NCT03539601|Drug|Crisaborole Vehicle|Applied BID
79983318|NCT03245788|Other|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
79983319|NCT03245710|Other|Placebos|starch
79983320|NCT03245710|Dietary Supplement|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
79983321|NCT03250858|Behavioral|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
79983322|NCT03250858|Behavioral|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
79983323|NCT04652583|Device|Earstim - Active Stimulation|Intramuscular stimulation
79983324|NCT04652583|Device|Earstim - Sham Stimulation|Sham stimulation
79983325|NCT02455180|Drug|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
79488407|NCT02604563|Other|Activities of Daily Living Questionnaire|"10 items about daily functional status~Baseline and no more frequently than every 6 months until death"
79488408|NCT02604563|Other|Instrumental Activities of Daily Living, subscale of the OARS|"7 items about daily functional status~Baseline and no more frequently than every 6 months until death"
79488409|NCT02604563|Other|Karnofsky Self-reported Performance Rating Scale|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
79338200|NCT04047511|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
79338201|NCT04047511|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
79488410|NCT02604563|Other|Number of Falls|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
79488411|NCT02604563|Other|Physical Health Section, subscale of the OARS|"13 items about comorbidity~Baseline and no more frequently than every 6 months until death"
79488412|NCT02604563|Other|MOS Social Activity Survey|"4 items about social activity~Baseline and no more frequently than every 6 months until death"
79488413|NCT02604563|Other|Unintentional Weight Loss|"2 items about nutrition~Baseline and no more frequently than every 6 months until death"
79488414|NCT02604563|Genetic|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
79983326|NCT03514719|Diagnostic Test|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
79338202|NCT04047511|Behavioral|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
79338203|NCT03983707|Device|Purastat®|Use of Purastat®
79338204|NCT04424875|Drug|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
79338205|NCT04424875|Drug|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
79338206|NCT05563363|Other|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
79338207|NCT05563363|Other|standard inpatient treatment|Inpatient treatment on addiction ward
79338208|NCT03961555|Biological|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
79338209|NCT03961555|Biological|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
79338210|NCT03961555|Biological|Rabies vaccine|it should be administered in deltoid muscle
79488415|NCT02604563|Genetic|Buccal Swab|"Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~Baseline and no more frequently than every 6 months until death"
79338211|NCT04277845|Drug|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
79488416|NCT02604563|Other|Heart Health and Smoking History from BRFSS questionnaire|"7 items about heart health and smoking history~Baseline and no more frequently than every 6 months until death"
79488417|NCT02604563|Other|Gait Speed|"Research coordinator will test gait speed~Baseline and no more frequently than every 6 months until death"
79488418|NCT02604563|Other|Grip Strength|"Research coordinator will test grip strength~Baseline and no more frequently than every 6 months until death"
79488419|NCT02604563|Other|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
79983327|NCT03514719|Drug|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
79983328|NCT03251014|Other|YSS|Intervention providing steamed whole YSS (~265 g/day, 3 days/week) for eight weeks
79983329|NCT03251014|Other|Salmon|Intervention providing steamed salmon fillet (~246 g/day, 3 days/week) for eight weeks
79983330|NCT01349439|Drug|Propranolol|1mg per Kg (participant weight)
79338212|NCT03874117|Other|Twice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
79338213|NCT03874117|Other|Thrice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
79488420|NCT02604563|Other|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
79653576|NCT03453970|Behavioral|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
79338214|NCT05497141|Device|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
79338215|NCT02559505|Biological|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
79488421|NCT02604563|Procedure|Optional bone marrow biopsy|-1 optional bone marrow biopsy
79488422|NCT02604563|Procedure|Blood draw for trauma measurements|-For Arm E only
79488423|NCT02597491|Behavioral|TLC monthly|Tobacco longitudinal care monthly
79813183|NCT01019551|Drug|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
79813184|NCT01019551|Biological|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
79813185|NCT00787137|Drug|PG102|A single intravenous infusion
79813186|NCT00787137|Drug|Placebo comparator|Phosphate-buffered saline
79813187|NCT02553226|Drug|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
79813188|NCT02553226|Drug|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
79813189|NCT00810316|Drug|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
79813190|NCT00810316|Drug|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
79813191|NCT00810316|Drug|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
79488424|NCT02597491|Behavioral|TLC quarterly|Tobacco longitudinal care quarterly
79488425|NCT02597491|Behavioral|MTM|Medication management therapy
79488426|NCT02597491|Behavioral|4 week assessment|4 week assessment
79488427|NCT02597491|Behavioral|8 week assessment|8 week assessment
79488428|NCT02584270|Device|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis improves speech and swallowing function through reshaping the palatal contours in order to obtain contact of the tongue to the hard palate during function. It is intended to be fabricated after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
79488429|NCT02584270|Other|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
79488430|NCT02565537|Procedure|LASIK|WFG vs. WFO LASIK
79488431|NCT02443727|Drug|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
79488432|NCT02443727|Other|Placebo|Dosage and details described in arm.
79813192|NCT00448435|Drug|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
79983331|NCT01349439|Drug|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
79338216|NCT02559505|Other|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
79983332|NCT03620331|Procedure|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
79983333|NCT03620331|Procedure|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
79983334|NCT03245554|Drug|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
79338217|NCT02559505|Biological|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
79338218|NCT04470349|Device|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
79338219|NCT04470349|Device|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
79338220|NCT05563207|Other|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
79338221|NCT05563207|Other|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
79338222|NCT05563207|Other|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
79338223|NCT05563207|Other|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
79338224|NCT05563207|Other|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
79488433|NCT02429700|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
79653577|NCT04591327|Procedure|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
79653578|NCT04591132|Device|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
79653579|NCT00253266|Drug|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
79653580|NCT00253266|Drug|Quetiapine|Quetiapine up to 200 mg/d for four weeks
79813193|NCT00448435|Drug|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
79813194|NCT00804622|Drug|telbivudine|daily oral administration,600mg,over 12 weeks
79813195|NCT00804622|Drug|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
79813196|NCT00804622|Drug|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
79813197|NCT02603055|Biological|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
79813198|NCT02603055|Biological|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
79983335|NCT01346007|Biological|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
79983336|NCT02455102|Other|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
79983337|NCT01349517|Procedure|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
79983338|NCT01349517|Procedure|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
79338225|NCT05563207|Other|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
79488434|NCT02429700|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
79653581|NCT04591288|Other|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
79653582|NCT04591288|Other|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
79653583|NCT00253305|Drug|Organogel of naftifine, 2%|
79983339|NCT01349517|Procedure|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
79338226|NCT05497063|Drug|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
79338227|NCT05497063|Drug|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
79488435|NCT02429700|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
79488436|NCT02429700|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
79488437|NCT02429700|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
79488438|NCT02429687|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
79488439|NCT02429687|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
79653584|NCT00253305|Drug|Organogel of terbinafine, 2%|
79653585|NCT00253305|Drug|Organogel of naftifine, 6%|
79653586|NCT00253305|Drug|Organogel of terbinafine, 6%|
79983340|NCT01349517|Procedure|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
79488440|NCT02429687|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
79488441|NCT02429687|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
79338228|NCT05496985|Diagnostic Test|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
79338229|NCT04277611|Procedure|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
79338230|NCT05561413|Behavioral|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
79813199|NCT00810472|Other|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
79983341|NCT03245476|Other|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
79338231|NCT05561413|Behavioral|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
79338232|NCT05560945|Drug|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
79338233|NCT05560945|Drug|1.5% Arginine Dentifrice|Toothpaste
79338234|NCT05560945|Drug|8.0% Arginine Dentifrice|Toothpaste
79653587|NCT04591600|Drug|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
79338235|NCT05559463|Dietary Supplement|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
79338236|NCT05559385|Device|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
79338237|NCT05559385|Procedure|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
79338238|NCT04047277|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
79338239|NCT04224961|Device|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
79338240|NCT04424563|Device|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
79338241|NCT04424563|Drug|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
79653588|NCT04591600|Drug|Standard of care|"Standard care~Acetaminophen 500mg on need~Vitamin C 1000mg twice/ day~Zinc 75-125 mg/day~Vitamin D3 5000IU/day~Azithromycin 250mg/day for 5 days~Oxygen therapy/ C-Pap if needed~dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~Mechanical ventilation, if needed"
79653589|NCT04590742|Drug|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
79653590|NCT04590742|Drug|Placebo|Patient given 6 weeks of placebo tablet
79653591|NCT00253344|Drug|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
79653592|NCT00253344|Drug|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
79653593|NCT04590859|Procedure|Block performed|Comparing block performed with penile blood flow
79653594|NCT04590859|Device|LMA placement|Placement of LMA for airway securement
79813200|NCT00810472|Procedure|Penetrating keratoplasty|Corneal transplantation.
79983342|NCT03245476|Other|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
79983343|NCT03250780|Procedure|indigo-carmine 0.2% using a spray catheter|
79983344|NCT03250780|Procedure|0.03% using a foot pump|
79983345|NCT01349751|Drug|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
79983346|NCT01349751|Drug|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
79338242|NCT04424563|Drug|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received
79488442|NCT02429687|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
79488443|NCT02372136|Dietary Supplement|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
79488444|NCT02372136|Dietary Supplement|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
79338243|NCT04038151|Device|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
79338244|NCT04038151|Device|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
79488445|NCT02268552|Drug|branaplam|
79983347|NCT03245632|Other|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
79813201|NCT02603289|Device|Invisalign|
79983348|NCT01346163|Drug|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
79983349|NCT01346163|Other|Placebo|Placebo will be used as a comparator to the active arm.
79653595|NCT00567346|Drug|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
79983350|NCT01346241|Behavioral|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
79983351|NCT03245164|Other|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
79983352|NCT03245164|Other|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
79488446|NCT02207777|Procedure|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
79488447|NCT02207777|Behavioral|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
79488448|NCT02194829|Drug|AZD1775|Given PO
79488449|NCT02194829|Drug|Gemcitabine|Given IV
79488450|NCT02194829|Drug|Nab-paclitaxel|Given IV
79488451|NCT02168400|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
79488452|NCT02087046|Device|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
79653596|NCT00567346|Drug|grass pollen extract|Patients will receive matching placebo sublingually
79653597|NCT00567385|Drug|somatropin|
79983353|NCT03004131|Drug|Azelastine hydrochloride + fluticasone propionate nasal spray|
79488453|NCT01891994|Drug|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
79653598|NCT00253383|Other|counseling intervention|
79653599|NCT00253383|Other|educational intervention|
79653600|NCT00253383|Procedure|psychosocial assessment and care|
79653601|NCT00253383|Procedure|quality-of-life assessment|
79653602|NCT00567424|Drug|GW273225|
79653603|NCT00567463|Device|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
79653604|NCT00253422|Drug|anastrozole|
79653605|NCT00253422|Drug|exemestane|
79653606|NCT00253422|Drug|fulvestrant|
79653607|NCT04590625|Drug|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
79653608|NCT04590625|Drug|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
79983354|NCT03004131|Drug|Placebos|
79983355|NCT03004131|Drug|fluticasone propionate nasal spray + loratadine|
79488454|NCT01751490|Other|physiotherapy|physiotherapy
79488455|NCT01751490|Procedure|shoulder stabilisation surgery|arthroscopic stabilisation surgery
79488456|NCT01390038|Device|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
79488457|NCT01370460|Drug|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
79488458|NCT01370460|Drug|Placebo|100mL 0.9% sterile saline
79488459|NCT01008241|Behavioral|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
79488460|NCT00965302|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
79488461|NCT00965302|Behavioral|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
79488462|NCT00621192|Drug|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
79488463|NCT00278200|Biological|Inactivated EBV-infected vaccine|
79488464|NCT00255346|Drug|Dasatinib (BMS-354825)|70 mg orally twice daily
79488465|NCT00114894|Other|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
79653609|NCT04590625|Drug|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
79653610|NCT04590625|Drug|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
79653611|NCT04590469|Other|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
79653612|NCT00253461|Procedure|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
79653613|NCT00253461|Procedure|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
79653614|NCT00253461|Radiation|11C topotecan|Phase I and II: IV over 10 minutes
79653615|NCT00253461|Radiation|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
79653616|NCT04590352|Procedure|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
79338245|NCT05496361|Device|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
79653617|NCT04590352|Procedure|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
79813202|NCT00804700|Behavioral|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
79338246|NCT05496361|Device|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
79338247|NCT05496127|Other|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
79338248|NCT05496049|Device|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
79338249|NCT05496049|Device|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
79983356|NCT03245086|Device|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
79338250|NCT05495893|Drug|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
79338251|NCT05495893|Drug|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
79488466|NCT00114894|Other|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
79338252|NCT03542461|Drug|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
79488467|NCT02834624|Drug|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
79488468|NCT02834624|Drug|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
79653618|NCT04590352|Procedure|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
79653619|NCT04590391|Device|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
79653620|NCT04590157|Device|Low Level Laser Therapy|Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
79653621|NCT04590157|Other|Pelvic floor muscle training|exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
79653622|NCT00567658|Drug|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
79338253|NCT03542461|Other|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
79488469|NCT02917603|Behavioral|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
79488470|NCT02837744|Device|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
79488471|NCT02918617|Drug|Control toothpaste containing Novamin® technology|
79488472|NCT02918617|Drug|Control toothpaste containing 1500 ppm fluoride as MFP|
79488473|NCT02918617|Drug|Test toothpaste with nano-HAP (high concentration)|
79813203|NCT02602899|Procedure|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
79653623|NCT04589806|Procedure|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
79983357|NCT03245086|Procedure|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
79338254|NCT04201639|Device|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
79338255|NCT04201015|Device|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
79338256|NCT04191967|Device|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
79338257|NCT05491291|Other|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
79338258|NCT02556307|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
79338259|NCT02556307|Drug|Ribavirin|Ribavirin according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
79338260|NCT02861521|Device|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
79983358|NCT01349985|Other|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
79338261|NCT02861521|Device|Sham|Sham shoe modification
79488474|NCT02918617|Drug|Test toothpaste with nano-HAP (low concentration)|
79488475|NCT02918617|Drug|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
79488476|NCT02918617|Drug|Control toothpaste without nano-HAP|
79338262|NCT05495347|Other|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
79488477|NCT02918617|Drug|Test toothpaste with nano-HAP (medium concentration)|
79653624|NCT00567697|Drug|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
79338263|NCT05491135|Biological|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
79338264|NCT02232997|Other|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF < 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
79338265|NCT02232997|Other|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF <35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
79338266|NCT05491057|Drug|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
79488478|NCT02918617|Drug|Test cream with nano-HAP (higher concentration)|
79488479|NCT02918617|Drug|Control cream without nano-HAP|
79488480|NCT02839772|Other|Current skin care regimen plus 2% glycerine added to soaking water|
79488481|NCT02839772|Other|Current skin care regimen|
79488482|NCT02918773|Device|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
79488483|NCT02918773|Device|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
79488484|NCT03040466|Device|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
79488485|NCT03040466|Device|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
79488486|NCT02918851|Biological|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
79983359|NCT01349985|Other|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
79338267|NCT05490901|Diagnostic Test|Exercise hemodynamic test|Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
79488487|NCT02918851|Biological|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
79488488|NCT02918851|Biological|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
79488489|NCT03041636|Drug|Ruxolitinib|Given PO
79983360|NCT03250546|Procedure|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
79983361|NCT03250546|Procedure|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
79983362|NCT01350063|Drug|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
79338268|NCT05495191|Diagnostic Test|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
79338269|NCT05495113|Device|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79338270|NCT05495113|Device|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79338271|NCT04364737|Biological|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; ~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
79338272|NCT04364737|Other|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
79338273|NCT02559115|Radiation|68Ga-RM2 (RM2)|
79983363|NCT01350063|Device|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
79488490|NCT03041636|Drug|Ruxolitinib Phosphate|Given PO
79813204|NCT02553070|Other|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
79813205|NCT02602743|Drug|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
79983364|NCT01350063|Other|No intervention|
79338274|NCT02559115|Device|PET/CT Scan|
79338275|NCT05494957|Drug|New regimen(BdqCfzLzd+XY)|The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
79338276|NCT05494879|Behavioral|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
79338277|NCT05490823|Device|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
79338278|NCT04424485|Procedure|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
79338279|NCT04424485|Procedure|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
79488491|NCT03042715|Behavioral|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
79488492|NCT02844998|Behavioral|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
79488493|NCT02844998|Drug|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
79813206|NCT02602743|Drug|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
79813207|NCT02602743|Drug|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
79813208|NCT00810550|Other|Carotid ultrasound|Measurement of intima-media thickness
79813209|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
79983365|NCT00700804|Behavioral|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
79983366|NCT00700804|Behavioral|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
79983367|NCT03635307|Other|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
79983368|NCT02928094|Biological|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
79983369|NCT02928094|Biological|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
79488494|NCT03043105|Drug|Thalidomide, cyclophosphamide and prednisone|"Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
79338280|NCT04424485|Diagnostic Test|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
79488495|NCT02845700|Behavioral|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
79488496|NCT02845700|Behavioral|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
79488497|NCT03043885|Device|FDBA|Graft material used to graft extraction socket
79338281|NCT04424485|Diagnostic Test|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
79488498|NCT03043885|Device|PRF|Autologous blood product used to graft extraction socket
79488499|NCT03043885|Procedure|Blood Clot|Surgical treatment of extraction socket without addition of graft material
79488500|NCT00374647|Drug|mycophenolate mofetil|
79338282|NCT05490745|Behavioral|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
79488501|NCT00374647|Drug|sirolimus|
79488502|NCT02961062|Drug|SAF312|
79813210|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
79813211|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
79983370|NCT03421041|Drug|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
79338283|NCT05490745|Other|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
79338284|NCT05494645|Drug|Exparel|Liposomal bupivicaine
79338285|NCT05494645|Drug|Peripheral Nerve Block|Peripheral nerve block without Exparel
79488503|NCT02961062|Drug|Placebo|
79488504|NCT00374725|Behavioral|Administration of probiotic (L. rhamnosus and L. acidophilus)|
79488505|NCT02962934|Other|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
79488506|NCT02962934|Other|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
79488507|NCT02919007|Device|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
79488508|NCT02964416|Drug|Injection Tramadol|
79488509|NCT02964416|Other|placebo|0.9% Normal saline in 10 ml syringe
79488510|NCT02812771|Drug|Efinaconazole|Solution
79813212|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
79488511|NCT02967458|Drug|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
79488512|NCT03046225|Device|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
79488513|NCT03046225|Device|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
79338286|NCT05494567|Drug|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
79338287|NCT05494567|Drug|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
79338288|NCT05494567|Drug|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
79338289|NCT04331587|Device|BF-P190 4 mm thin bronchoscope|"EVIS EXERA III Bronchofiberviedoscopes~Olympus"
79338290|NCT04331587|Device|BF-MP190F 3 mm ultrathin bronchoscope|"EVIS EXERA III Bronchofiberviedoscopes~Olympus"
79338291|NCT04331587|Device|Radial ultrasound probe (UM S20-17S)|-Olympus
79488514|NCT03046225|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
79488515|NCT02813473|Radiation|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
79488516|NCT02813473|Radiation|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
79488517|NCT02969876|Drug|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
79488518|NCT02970032|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
79488519|NCT02970032|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
79488520|NCT02813551|Drug|Torsemide|
79488521|NCT02813551|Drug|Placebo|
79983371|NCT03244774|Drug|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
79983372|NCT03244774|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
79338292|NCT04331587|Device|PeriView FLEX 21G Single Use Aspiration Needle|"NA-403D-2021~Gyrus ACMI, Inc."
79338293|NCT00609115|Device|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
79983373|NCT01346553|Device|ESVV device|wearing the ESVV device for 6 hours
79488522|NCT02970422|Other|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
79488523|NCT02817763|Procedure|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
79488524|NCT02817763|Procedure|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
79488525|NCT02817763|Drug|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
79813213|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
79983374|NCT01350219|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
79488526|NCT03049501|Behavioral|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
79488527|NCT03049501|Behavioral|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
79488528|NCT03050203|Other|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
79338294|NCT00609115|Device|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
79338295|NCT00609115|Device|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
79338296|NCT05494411|Drug|Mitomycin for pyelocalyceal solution|
79338297|NCT05494333|Other|no intervention|NO intervention
79983375|NCT03250468|Behavioral|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
79983376|NCT01346631|Other|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
79488529|NCT03050203|Other|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
79338298|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
79338299|NCT04080895|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
79338300|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
79338301|NCT04080895|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
79338302|NCT04265209|Drug|SPECT|[123I]-FP-CIT SPECT imaging procedure
79488530|NCT02970812|Device|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
79653625|NCT00567697|Drug|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
79653626|NCT04589416|Other|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
79653627|NCT04589455|Dietary Supplement|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
79653628|NCT04589494|Drug|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
79653629|NCT04589299|Biological|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
79653630|NCT00253500|Biological|pegfilgrastim|6 mg in a syringe
79653631|NCT00253500|Drug|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
79653632|NCT00253500|Procedure|conventional surgery|to remove small piece of cancer
79488531|NCT02970812|Device|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
79338303|NCT04265209|Drug|PET|[18F] LBT-999 PET imaging procedure
79653633|NCT04588909|Procedure|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
79983377|NCT02903823|Drug|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
79338304|NCT04077619|Behavioral|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
79338305|NCT04077619|Behavioral|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
79338306|NCT04251169|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1
79338307|NCT04251169|Drug|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
79488532|NCT02846714|Behavioral|FLARE|
79488533|NCT02921737|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
79488534|NCT02819011|Device|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
79983378|NCT03244930|Drug|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
79488535|NCT02819011|Other|Control|Subjects will be provided with a pair of New Balance 813 shoes
79488536|NCT02846792|Biological|Nivolumab|Given IV
79488537|NCT02846792|Drug|Plinabulin|Given IV
79653634|NCT04589026|Drug|Cosentyx|Cosentyx injection will be administered subcutaneously.
79813214|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
79653635|NCT04589026|Drug|Candin|Candin will be administered interadermally along with NaCl solution.
79653636|NCT04589182|Device|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
79653637|NCT04589182|Device|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
79653638|NCT00249639|Behavioral|Contingency management|Rewards valued $1-$100
79653639|NCT04588987|Biological|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
79813215|NCT00810628|Behavioral|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
79813216|NCT00448279|Drug|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
79813217|NCT00448279|Drug|Chemotherapy|Schedule and dose at the investigator's discretion
79338308|NCT04073329|Other|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with > 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as < 1 mm step and < 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
79338309|NCT04279951|Other|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
79338310|NCT04279951|Dietary Supplement|Omega-3|1 gram of omega-3 per day for 20 weeks
79338311|NCT04279951|Dietary Supplement|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
79338312|NCT05494099|Procedure|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
79338313|NCT05494099|Procedure|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
79338314|NCT05494099|Procedure|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
79338315|NCT04165837|Drug|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
79338316|NCT04165837|Drug|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
79338317|NCT04163341|Behavioral|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
79338318|NCT04279561|Procedure|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
79338319|NCT04279561|Drug|Gallium Ga 68 Gozetotide|Given IV
79338320|NCT04279561|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
79338321|NCT01662895|Drug|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
79338322|NCT01662895|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
79338323|NCT05494021|Other|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
79338324|NCT05494021|Device|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
79338325|NCT05493943|Device|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
79338326|NCT05493943|Other|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
79338327|NCT05493865|Behavioral|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a two-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents and their parents by comparing to a no-intervention waitlist control group.
79338328|NCT04318171|Device|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~Plaque volume where detectable.~Max area stenosis.~Volumetric stenosis.~Measured length.~3D GSM. The entire assessment should not take more than 45 minutes."
79338329|NCT05499091|Procedure|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
79338330|NCT05489809|Procedure|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
79338331|NCT05489809|Procedure|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
79338332|NCT05493631|Biological|MG1113|MG1113 subcutaneous (SC) injection
79813218|NCT01024153|Behavioral|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
79813219|NCT00810706|Drug|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
79813220|NCT00807196|Drug|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
79338333|NCT05498857|Drug|Intramuscular ephedrine|Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
79653640|NCT04589104|Behavioral|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to release & integrate difficult emotions~Week 3: Writing to nurture gratitude~Week 4: Writing to enhance strengths & resources~Week 5: Writing to cultivate positive meaning & savor goodness~Week 6: Writing to invite insight, perspective, & growth"
79653641|NCT04588558|Device|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
79653642|NCT04588558|Other|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
79813221|NCT00807196|Drug|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
79813222|NCT00807196|Drug|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
79813223|NCT00807196|Drug|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
79338334|NCT05498857|Drug|Placebo|Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
79338335|NCT04424329|Dietary Supplement|Fibers and probiotics|A blend of fibers and seven probiotics
79338336|NCT05498545|Biological|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
79338337|NCT05489497|Procedure|Primary closure with or without omental grafting|Primary closure with or without omental grafting
79338338|NCT05489419|Behavioral|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
79338339|NCT05493319|Other|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
79338340|NCT05498467|Drug|Anakinra|100 mg Anakinra injections s.c.
79338341|NCT05498467|Drug|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
79338342|NCT05498311|Radiation|Intraoperative Radiotherapy (IORT)|The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
79338343|NCT05498311|Procedure|Breast conservative surgery|Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
79338344|NCT05498311|Radiation|External Beam Hypofractionated Radiotherapy (EBRT)|A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
79338345|NCT05489263|Other|No intervention|No intervention
79338346|NCT05486221|Other|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
79338347|NCT05489107|Other|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
79813224|NCT00807196|Other|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
79813225|NCT00448123|Drug|Tamsulosin|Study Drug
79813226|NCT00448123|Drug|Placebo|Placebo
79338348|NCT05492929|Other|The deep breathing group|The deep breathing group
79338349|NCT05492929|Other|4-7-8 breathing technique|4-7-8 breathing technique Group
79338350|NCT02557399|Drug|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
79338351|NCT02557399|Drug|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
79338352|NCT02557399|Drug|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
79338353|NCT05485909|Other|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
79338354|NCT05485909|Drug|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
79338355|NCT04139395|Drug|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
79338356|NCT04139395|Drug|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
79338357|NCT04139395|Device|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
79338358|NCT04139395|Device|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
79488538|NCT02850068|Device|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
79488539|NCT02819323|Drug|PEG-ELS|polyethylene glycol based bowel preparation
79488540|NCT02819323|Drug|BLI800|BLI800 bowel preparation
79488541|NCT03053401|Procedure|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
79488542|NCT03053401|Procedure|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
79488543|NCT03053401|Device|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
79338359|NCT04139395|Device|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
79488544|NCT03053401|Device|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
79338360|NCT02555371|Biological|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
79338361|NCT02555371|Drug|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
79488545|NCT03053401|Drug|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
79488546|NCT03053401|Drug|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
79338362|NCT05489029|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
79338363|NCT04122235|Other|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
79338364|NCT02555215|Drug|dimethyl fumarate|administered orally
79338365|NCT05485597|Device|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
79338366|NCT05492305|Drug|GLP-1 receptor agonist|Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
79338367|NCT02555683|Drug|QAW039|QAW039 150 mg once daily
79338368|NCT02555683|Drug|QAW039|QAW039 450 mg once daily
79488547|NCT02819557|Drug|Ataluren|White to off-white powder for oral suspension.
79488548|NCT02820181|Device|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
79488549|NCT02820181|Device|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
79338369|NCT02555683|Drug|Placebo|Placebo once daily
79338370|NCT04424095|Diagnostic Test|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
79338371|NCT04424095|Diagnostic Test|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
79338372|NCT02554981|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
79338373|NCT02556775|Biological|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
79338374|NCT02556775|Biological|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
79338375|NCT01662505|Drug|Volasertib|Patient to receive volasertib
79338376|NCT05485363|Diagnostic Test|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
79338377|NCT05491993|Diagnostic Test|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
79338378|NCT03986749|Procedure|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
79653643|NCT04588558|Device|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
79653644|NCT04588831|Device|Mouthguard|Protective device for orofacial complex for patients playing contact sports
79653645|NCT00567736|Drug|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
79653646|NCT00567736|Drug|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
79653647|NCT00253539|Drug|arzoxifene hydrochloride|Given orally
79653648|NCT00253539|Drug|tamoxifen citrate|Given orally
79338379|NCT04074733|Diagnostic Test|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
79653649|NCT00253539|Other|placebo|Given orally
79653650|NCT04180163|Drug|Lanadelumab|Lanadelumab solution, SC
79338380|NCT04074733|Diagnostic Test|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
79338381|NCT04074733|Diagnostic Test|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
79653651|NCT04588636|Behavioral|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
79338382|NCT05488717|Other|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
79338383|NCT05485207|Drug|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
79338384|NCT03897907|Other|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
79338385|NCT03897907|Other|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
79653652|NCT04588636|Device|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
79653653|NCT04588636|Device|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
79983379|NCT03250312|Other|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
79338386|NCT05488639|Other|Registration of football exposure and occurrence of injuries and illnesses only|"Injury & illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
79338387|NCT05488561|Diagnostic Test|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
79983380|NCT01350297|Procedure|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
79338388|NCT03879109|Drug|Chemotherapy FOLFIRINOX, 6 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
79338389|NCT03879109|Radiation|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
79338390|NCT03879109|Procedure|Surgery|"Surgery will be performed at:~Arm A: 8 weeks (±1) after the end of treatment~Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~Total mesorectal excision (TME)~Extended-TEM (e-TME)~Pelvic exenteration (PE)"
79983381|NCT01350375|Drug|Botox|
79338391|NCT05485129|Device|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
79338392|NCT04032535|Drug|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
79653654|NCT04588636|Device|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
79653655|NCT04588675|Diagnostic Test|MRI|the patients will underwent dobutamine stress cardiac MRI
79653656|NCT04720365|Device|play-based rehabilitaion|usual re-education treatment by their physiotherapist
79983382|NCT01350375|Drug|Saline|
79983383|NCT02855697|Drug|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
79653657|NCT00567775|Drug|human insulin|
79653658|NCT00567775|Drug|inhaled human insulin|
79653659|NCT00567814|Drug|Metyrapone|Twice daily
79983384|NCT02855697|Drug|Cediranib|20mg dose of cediranib was selected for this study
79983385|NCT02855697|Drug|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
79338393|NCT05488327|Drug|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
79338394|NCT05488171|Drug|Methylone|Single oral dose of 200 mg of methylone.
79338395|NCT05488171|Drug|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
79338396|NCT05488171|Drug|Placebo|Single oral dose of placebo.
79338397|NCT05480137|Procedure|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
79338398|NCT05480059|Other|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
79338399|NCT05479903|Procedure|acupuncture|Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
79338400|NCT05479903|Behavioral|computerized cognitive training system|One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
79338401|NCT05479903|Behavioral|aerobic exercise|Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
79338402|NCT05479903|Behavioral|tranditional cognitive training|One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
79338403|NCT05479903|Other|Conventional treatment|Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
79338404|NCT05484817|Diagnostic Test|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
79338405|NCT05479825|Procedure|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
79488550|NCT02860286|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
79488551|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
79338406|NCT05484583|Drug|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
79338407|NCT05484583|Radiation|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
79338408|NCT05484583|Drug|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
79488552|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
79488553|NCT03054103|Drug|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
79488554|NCT02860988|Behavioral|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
79338409|NCT05479747|Drug|post operative analgesics|post-operative pain killer
79338410|NCT05487937|Other|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
79338411|NCT05487781|Combination Product|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
79338412|NCT05487469|Drug|Thymosin Alpha1|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
79338413|NCT05487469|Other|Blank Control|the Control group did not receive Thymosin alpha 1 or any placebo.
79488555|NCT02822287|Drug|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
79488556|NCT03043274|Drug|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
79488557|NCT03054649|Device|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
79653660|NCT00567814|Drug|Oxazepam|Twice Daily
79653661|NCT00567814|Drug|Placebo|Twice daily
79338414|NCT05479669|Diagnostic Test|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
79338415|NCT05479669|Diagnostic Test|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
79338416|NCT05479669|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
79813227|NCT00810784|Behavioral|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
79813228|NCT00804934|Drug|Lucentis|0.5mg Lucentis every four months
79488558|NCT03054649|Procedure|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
79983386|NCT03250156|Behavioral|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
79983387|NCT03250156|Behavioral|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
79813229|NCT00805012|Drug|docetaxel+CDDP|docetaxel+CDDP
79813230|NCT00805012|Drug|docetaxel+S-1|docetaxel+S-1
79983388|NCT03249766|Other|Observational|Observational study
79983389|NCT03894501|Behavioral|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
79813231|NCT00922324|Drug|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
79813232|NCT00447499|Drug|Somatuline Autogel (lanreotide acetate)|Injections
79813233|NCT00447499|Behavioral|Home administration|Questionnaire
79813234|NCT00805090|Drug|Sporanox|200 mg
79813235|NCT00805090|Drug|Diclofenac Sodium|37.5 mg
79813236|NCT02552758|Biological|omega-3 fatty acid|omega-3 fatty acid
79813237|NCT02552758|Biological|placebo|placebo
79813238|NCT02552758|Device|positron emission tomography (PET)|
79813239|NCT00810862|Drug|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
79813240|NCT00810862|Other|placebo base cream|apply to affected study area twice daily for 21 days
79338417|NCT05479669|Diagnostic Test|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
79338418|NCT05479669|Diagnostic Test|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
79338419|NCT05484427|Other|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
79338420|NCT05484271|Procedure|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
79338421|NCT05479435|Behavioral|Blue Prescription Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
79338422|NCT05479435|Behavioral|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
79488559|NCT04333316|Procedure|large head|implantation of large head total hip
79653662|NCT04588753|Other|active isolated stretch|"Active Isolated Stretch (AIS);~The shortened hamstring muscle will be isolated.~The hamstring will be stretched.~This Stretches will be Repeated eight to 10 times.~Stretch will be hold for no more than two seconds.~Exhale on the stretch; inhale on the release. Other amputees training exercises;~weight-shifting~Dynamic balancing activities~Stool stepping~Braiding~Gait exercises~Climbing/descending the stairs"
79653663|NCT04588753|Other|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~2. Other amputees training exercises;~weight-shifting~Dynamic balancing activities~Stool stepping~Braiding~Gait exercises~Climbing/descending the stairs"
79653664|NCT04588090|Procedure|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m^2, DDP: 70mg/m^2 (35mg/m^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
79653665|NCT04588090|Procedure|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m^2, DDP: 25mg/m^2) 6 cycles of chemotherapy
79813241|NCT00800436|Drug|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
79813242|NCT00810940|Drug|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP < 20 mmHg, then IV 100 ml same schedule for 24 hours
79983390|NCT03894501|Behavioral|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
79983391|NCT03249922|Device|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
79983392|NCT03244228|Drug|HTL0016878|Oral solution
79813243|NCT00810940|Drug|mannitol|mannitol plus standard treatment
79813244|NCT04109508|Drug|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
79983393|NCT03244228|Drug|Placebo - Concentrate|Matching placebo
79983394|NCT01350531|Behavioral|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
79983395|NCT01350531|Behavioral|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
79488560|NCT04333316|Procedure|dual mobility cup|implantation of dual mobility total hip
79488561|NCT02975804|Device|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
79488562|NCT03054805|Drug|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
79983396|NCT02454010|Biological|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
79983397|NCT03249688|Other|Regular health advice|Routine healthy lifestyle counseling
79983398|NCT03249688|Behavioral|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
79338423|NCT05479435|Behavioral|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
79488563|NCT03054805|Drug|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
79338424|NCT05479357|Drug|Oxytocin|10 iu will be given intravenously.
79338425|NCT05479357|Drug|Carbetocin|100 micrograms will be given intravenously.
79653666|NCT04588090|Radiation|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
79653667|NCT00253578|Drug|sorafenib tosylate|Given PO
79338426|NCT05487391|Drug|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
79653668|NCT00253578|Other|laboratory biomarker analysis|Correlative studies
79983399|NCT03249688|Dietary Supplement|Medical food|Medical food product (Fortasyn Connect)
79983400|NCT01346865|Drug|Cilostazol|Cilostazol 100mg bid
79983401|NCT01346865|Drug|Placebo|Placebo 1tablet bid
79983402|NCT03244462|Drug|BAY1834845|Single oral dose (IR [immediate release] tablets)
79983403|NCT03244462|Drug|BAY1834845|I.v. infusion of [13C6]-labeled BAY1834845
79338427|NCT05487391|Drug|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
79338428|NCT05487391|Drug|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
79338429|NCT05487391|Drug|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
79338430|NCT05487391|Drug|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
79488564|NCT00374101|Drug|omeprazole|
79488565|NCT00374101|Drug|pantoprazole|
79488566|NCT00374738|Behavioral|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
79488567|NCT00374179|Drug|CT-322|IV solution, weekly or bi-weekly
79983404|NCT03244462|Drug|Methotrexate|Single dose of commercially available MTX
79983405|NCT01346943|Device|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
79983406|NCT01347021|Procedure|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
79653669|NCT04153565|Drug|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
79983407|NCT03244540|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
79338431|NCT05487391|Drug|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
79488568|NCT00374257|Procedure|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
79653670|NCT04153565|Drug|Pemetrexed|Participants will receive Pemetrexed 500 mg/m^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
79488569|NCT02979626|Procedure|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
79488570|NCT02822599|Drug|RiaStAP|To decrease post-operative bleeding volume.
79488571|NCT02822599|Drug|Saline|Placebo consisting of normal saline 0.9%
79488572|NCT04737421|Device|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
79653671|NCT04153565|Drug|Cisplatin|Participants will receive Cisplatin 75 mg/m^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
79983408|NCT03244540|Procedure|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
79338432|NCT05487391|Drug|Placebo|Placebo
79338433|NCT05484193|Drug|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
79338434|NCT05484193|Drug|Progesterone|vaginal progesterone for luteal phase support
79653672|NCT04588324|Drug|SHR2150|Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
79653673|NCT04588324|Drug|Anti-Cancer Agent|The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
79653674|NCT04588324|Drug|SHR2150|Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
79983409|NCT03244540|Device|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
79983410|NCT03244540|Drug|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
79983411|NCT03244540|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
79338435|NCT05479279|Other|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
79488573|NCT04737421|Device|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
79983412|NCT03244540|Procedure|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
79338436|NCT05479279|Other|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
79338437|NCT03796195|Drug|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
79983413|NCT03244540|Procedure|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
79983414|NCT03244540|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
79338438|NCT05484037|Other|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
79338439|NCT05478967|Procedure|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
79338440|NCT05483959|Other|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
79338441|NCT04268407|Drug|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
79983415|NCT03244540|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
79983416|NCT03244540|Drug|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
79983417|NCT01347099|Behavioral|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
79983418|NCT01347099|Behavioral|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
79983419|NCT03243916|Radiation|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
79488574|NCT04737421|Device|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
79488575|NCT04737421|Device|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
79983420|NCT03893799|Drug|RBT-1|intravenous administration
79983421|NCT03249610|Behavioral|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
79983422|NCT02389803|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
79983423|NCT02389803|Dietary Supplement|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
79983424|NCT03341715|Drug|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
79338442|NCT04014751|Other|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
79338443|NCT05489653|Behavioral|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
79338444|NCT05483725|Biological|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
79338445|NCT05486845|Other|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
79983425|NCT03341715|Other|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
79488576|NCT00373789|Drug|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
79338446|NCT05478889|Procedure|Minimally invasive pancreatoduodenectomy|Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
79338447|NCT05478811|Device|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
79338448|NCT05478811|Device|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
79338449|NCT03781141|Procedure|Wound closure|Comparison of two wound closures
79983426|NCT03249298|Drug|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
79488577|NCT00373789|Drug|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
79983427|NCT03249298|Drug|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
79488578|NCT03045926|Drug|Diosmectite (Smecta®)|
79488579|NCT02928055|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
79338450|NCT05486767|Diagnostic Test|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
79488580|NCT02983058|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner
79488581|NCT02983058|Device|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
79488582|NCT00373867|Behavioral|Standard physical therapy|Treatment-based classification physical therapy
79338451|NCT05478655|Other|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
79338452|NCT03753607|Other|No intervention|No intervention
79488583|NCT00373867|Behavioral|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
79488584|NCT00373867|Other|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
79488585|NCT02983448|Device|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
79488586|NCT03061513|Drug|Ubiquinol|Ubiquinol caplets 600mg/day
79488587|NCT03061513|Dietary Supplement|Placebo|placebo
79983428|NCT04541979|Drug|aerosolized DNase|DNase
79983429|NCT04541979|Drug|NaCl|NaCl 0.9%, isotonic saline
79983430|NCT02454166|Other|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
79653675|NCT04587895|Behavioral|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
79653676|NCT04587895|Behavioral|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
79653677|NCT04587895|Behavioral|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
79653678|NCT00249678|Behavioral|Behavior Therapy|
79983431|NCT02454166|Other|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
79338453|NCT03981445|Behavioral|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
79338454|NCT03981445|Behavioral|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
79338455|NCT05483647|Procedure|Local infiltrative anaesthesia|In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.
79338456|NCT05483647|Procedure|Erector spine plane block|The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
79653679|NCT04588168|Drug|Chemotherapy|Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
79653680|NCT04588168|Diagnostic Test|Immediate Multiparametric MRI|Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
79653681|NCT04588168|Procedure|Cystectomy and Lymphadenectomy|The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
79983432|NCT03243994|Diagnostic Test|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
79653682|NCT04588168|Diagnostic Test|conventional Multiparametric MRI|After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
79338457|NCT05478577|Other|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
79653683|NCT04588168|Diagnostic Test|Baseline Multiparametric MRI|Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
79653684|NCT04587817|Combination Product|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
79653685|NCT00253617|Drug|porfimer sodium|
79653686|NCT00253617|Procedure|adjuvant therapy|
79653687|NCT00253617|Procedure|laser therapy|
79653688|NCT00253617|Procedure|photodynamic therapy|
79653689|NCT00253617|Procedure|phototherapy|
79653690|NCT04587778|Drug|Ketamine Hydrochloride|intravenous infusion
79338458|NCT05486299|Procedure|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
79338459|NCT05478421|Procedure|Collagen sponge|The bone cavity will be filled with collagen sponge.
79653691|NCT04587778|Drug|Esketamine|intravenous infusion
79653692|NCT04587778|Drug|Placebo|intravenous infusion
79653693|NCT04139564|Device|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
79813245|NCT00655564|Drug|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
79813246|NCT00447421|Drug|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
79338460|NCT05478421|Procedure|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
79338461|NCT05478421|Procedure|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
79338462|NCT05483569|Other|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
79338463|NCT05483569|Other|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
79653694|NCT04139564|Device|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
79653695|NCT04587505|Procedure|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
79653696|NCT04587505|Drug|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
79653697|NCT04587505|Procedure|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
79813247|NCT00447421|Drug|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
79813248|NCT00447421|Radiation|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
79813249|NCT00651118|Drug|Placebo|placebo
79653698|NCT04587505|Drug|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
79653699|NCT00249717|Behavioral|Contingency management|Receive rewards (prizes) abstinence and attendance
79813250|NCT00651118|Drug|azelastine Hcl|azelastine Hcl 548 mcg
79813251|NCT00651118|Drug|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
79813252|NCT00651118|Drug|fluticasone propionate|fluticasone propionate 200 mcg
79813253|NCT00447265|Drug|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
79813254|NCT00447265|Drug|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
79653700|NCT04587544|Behavioral|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
79338464|NCT05483569|Other|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
79338465|NCT04273087|Other|Observation|Clinical signs and symptoms
79338466|NCT05478343|Biological|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
79338467|NCT05478187|Device|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
79338468|NCT05478187|Other|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
79488588|NCT03046472|Other|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
79338469|NCT05478109|Drug|[14C]XZP-3287|360 mg suspension containing 50µCi of [14C] XZP-3287
79338470|NCT05475535|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
79338471|NCT05475535|Behavioral|Self-Compassion|Self-Compassion focused exercises
79338472|NCT05475535|Behavioral|Active Control|Engagement in a mobile application (Cooperation skills)
79488589|NCT03062605|Drug|Iodine (Betadine)|
79488590|NCT03062605|Biological|NaOCL|
79488591|NCT03062917|Diagnostic Test|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
79488592|NCT03047174|Other|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
79488593|NCT03047174|Other|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
79653701|NCT00249756|Behavioral|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
79813255|NCT00447265|Drug|Placebo|
79813256|NCT03641755|Drug|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
79813257|NCT03641755|Drug|Olaparib|Olaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working
79813258|NCT00657358|Drug|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
79338473|NCT05475457|Behavioral|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
79338474|NCT05475379|Biological|Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)|"Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited"
79488594|NCT02829307|Drug|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
79488595|NCT02985710|Device|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
79488596|NCT02985710|Procedure|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
79488597|NCT02985710|Procedure|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
79338475|NCT05483257|Device|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
79338476|NCT05475223|Diagnostic Test|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
79488598|NCT03063385|Behavioral|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
79338477|NCT03699553|Behavioral|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
79338478|NCT03699553|Behavioral|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
79338479|NCT05474677|Procedure|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\0 sutures and size zero in control group.
79338480|NCT04424017|Biological|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
79488599|NCT03063385|Behavioral|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
79488600|NCT02931565|Drug|Olinciguat|oral tablet
79488601|NCT02931565|Drug|Matching Placebo|oral tablet
79488602|NCT02986958|Other|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
79653702|NCT00249756|Behavioral|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
79653703|NCT04587349|Other|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
79653704|NCT04587349|Other|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
79813259|NCT00457639|Drug|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
79813260|NCT00800202|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
79813261|NCT00800202|Drug|carboplatin|AUC6 iv every 3 weeks for 6 cycles
79813262|NCT00800202|Drug|erlotinib [Tarceva]|150mg/day po
79813263|NCT00800202|Drug|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
79813264|NCT00811096|Drug|Tinidazole|2gms, p.o. q.d. for 5 days
79813265|NCT00811096|Drug|chloroquine|
79338481|NCT05477797|Drug|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
79338482|NCT05483179|Diagnostic Test|CPET|Cardiopulmonary exercise test
79488603|NCT02986958|Other|Usual care|routine primary care
79488604|NCT02829463|Radiation|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
79813266|NCT00805402|Other|flow cytometry|flow cytometry
79338483|NCT05477641|Procedure|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
79338484|NCT05477641|Procedure|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
79338485|NCT05472259|Drug|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
79338486|NCT05472259|Drug|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
79338487|NCT05472259|Drug|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
79338488|NCT05472259|Drug|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
79983433|NCT03312309|Procedure|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
79338489|NCT04266145|Drug|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
79338490|NCT04266145|Drug|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
79338491|NCT05477329|Device|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
79338492|NCT05477251|Procedure|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
79338493|NCT05477251|Procedure|lobectomy|lobectomy for GGOs located in hilar regions
79338494|NCT02554513|Device|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
79653705|NCT04587349|Other|Physiotherapy|Physiotherapy 2-years-long (3/week)
79653706|NCT00253695|Device|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
79338495|NCT02554513|Behavioral|SPT|A treatment hierarchy involving integral stimulation
79653707|NCT04587310|Diagnostic Test|Laparoscopic Sleeve Gastrectomy|bariatric surgery
79653708|NCT00403208|Procedure|Analgesia based sedation in ICU patients|
79983434|NCT02454868|Drug|Remifentanil|Remifentanil for intubation without neuromuscular blockade
79338496|NCT05477173|Behavioral|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
79338497|NCT04570969|Procedure|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
79338498|NCT05471635|Biological|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
79338499|NCT03383419|Drug|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
79488605|NCT03050294|Behavioral|Phone calls|Phone calls twice daily
79488606|NCT03050294|Drug|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
79653709|NCT04586998|Device|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
79653710|NCT00253734|Biological|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
79653711|NCT00253734|Biological|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
79338500|NCT05477017|Drug|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
79338501|NCT02554903|Drug|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
79338502|NCT02554903|Drug|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
79338503|NCT03329131|Device|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
79983435|NCT03243760|Drug|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
79338504|NCT03328195|Device|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
79338505|NCT03328195|Device|Sham|Twenty minutes, six days per week for 12 weeks with sham device
79338506|NCT03328195|Device|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
79338507|NCT05482087|Drug|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
79338508|NCT02332707|Drug|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
79338509|NCT02332707|Drug|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
79338510|NCT02332707|Drug|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
79338511|NCT02332707|Drug|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
79338512|NCT02332707|Drug|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
79338513|NCT02332707|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
79338514|NCT02370615|Drug|TAK-272|TAK-272 tablet.
79338515|NCT02370615|Drug|Digoxin|Digoxin tablet.
79338516|NCT02370615|Drug|Itraconazole|Itraconazole oral solution
79338517|NCT02370615|Drug|Midazolam|Midazolam syrup.
79338518|NCT02307513|Drug|Apremilast|Tablets for oral administration
79338519|NCT02307513|Drug|Placebo|Tablets for oral administration
79338520|NCT02332239|Behavioral|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored text-message program"
79338521|NCT02332239|Behavioral|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
79338522|NCT02370537|Drug|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
79338523|NCT02370537|Drug|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
79983436|NCT03243760|Drug|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
79338524|NCT02330055|Procedure|Forty-five degrees elevated upper body position|
79338525|NCT02330055|Procedure|non-elevated upper body position|
79338526|NCT02330055|Device|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
79338527|NCT02330055|Other|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
79338528|NCT02330055|Other|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
79338529|NCT02330055|Other|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
79338530|NCT02330055|Other|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
79338531|NCT02306265|Device|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
79338532|NCT02306265|Device|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
79338533|NCT02329743|Drug|RX-10045|topical therapy
79338534|NCT04896567|Diagnostic Test|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
79983437|NCT03243760|Drug|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
79338535|NCT02329431|Behavioral|activation curriculum|psychosocial activation curriculum
79653712|NCT04587115|Drug|Risperidone|Risperidone 1mg to be used in combination with other drugs
79653713|NCT04587115|Drug|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
79338536|NCT02329431|Behavioral|support group|parent directed support group
79983438|NCT02454400|Other|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~Active physiotherapy according to a treatment based classification:~Specific exercises and mobilization~Motor control exercises~Traction~Tailor-made general supervised exercise program~Behavioral approach to reduce fear avoidance and increase activity level.~Standardized information about:~the surgery~post-surgery rehabilitation~to stay active"
79983439|NCT02454400|Other|Waiting-list|"Standardized information about:~the surgery~post-surgery rehabilitation~to stay active"
79983440|NCT03753087|Drug|Empagliflozin|10 mg tablet
79338537|NCT02328105|Drug|Carboplatin|Dosing: AUC = 6; on Day 1
79338538|NCT02328105|Drug|Abraxane|100 mg/m^2; Days 1, 8, 15
79338539|NCT02305797|Drug|Extended-release lorazepam|Extended-release lorazepam capsules
79983441|NCT03753087|Other|Standard care|Standard care with no SGLT-2 inhibitors
79338540|NCT02305797|Drug|Placebo|Placebo capsules
79338541|NCT01646073|Biological|Adalimumab|adalimumab eow
79338542|NCT01646073|Biological|placebo|placebo
79338543|NCT02328027|Drug|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
79338544|NCT02551159|Biological|MEDI4736|Anti-PD-L1 antibody
79338545|NCT02551159|Biological|Tremelimumab|Anti-CTLA-4 Antibody
79338546|NCT02551159|Biological|MEDI4736+Tremelimumab|
79338547|NCT02551159|Biological|Cetuximab|Monoclonal Antibody
79338548|NCT02551159|Drug|5-fluorouracil (5FU)|Chemotherapy Agent
79338549|NCT02551159|Drug|Cisplatin|Chemotherapy agent
79338550|NCT02551159|Drug|Carboplatin|Chemotherapy Agent
79488607|NCT02831569|Drug|Loxoprofen sodium|
79488608|NCT02831569|Drug|Methocarbamol|
79653714|NCT04587115|Drug|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
79653715|NCT00403247|Dietary Supplement|Capsule with folate, Vitamin B12 & pyridoxine|
79653716|NCT00403247|Other|placebo|placebo capsule
79653717|NCT04587037|Procedure|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
79653718|NCT04587037|Procedure|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
79653719|NCT04586725|Other|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
79653720|NCT04586725|Other|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
79653721|NCT00253773|Drug|acetominophen, sulfer amino acids; cysteine and methionine|
79983442|NCT02454712|Drug|PF614|PF614 is an oxycodone prodrug
79983443|NCT02454712|Drug|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
79983444|NCT02454712|Drug|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
79983445|NCT03249064|Diagnostic Test|CD 91 levels|
79983446|NCT03249064|Diagnostic Test|Tregs|
79983447|NCT00832455|Drug|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
79338551|NCT05482009|Other|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
79488609|NCT03050918|Behavioral|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
79488610|NCT03065179|Drug|Nivolumab/Ipilimumab|IV immunotherapy
79338552|NCT05481853|Procedure|One Anastomosis Gastric Bypass|
79338553|NCT04539379|Drug|Magnesium sulfate|intravenous infusion
79338554|NCT04539379|Drug|Labetolol|intravenous infusion
79338555|NCT04529473|Dietary Supplement|Eubacterium hallii|Eubacterium hallii, ≥ 1x10^9 live bacterial cells (per capsule)
79338556|NCT04529473|Other|Placebo|Placebo capsules are identical to the active treatment
79338557|NCT05470153|Device|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
79488611|NCT03065179|Radiation|SBRT|SBRT will be delivered in conjunction with immunotherapy
79488612|NCT02988050|Drug|Remifentanil|Remifentanil used for conscious sedation.
79488613|NCT02988050|Drug|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
79983448|NCT03248986|Other|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
79488614|NCT02988050|Drug|Propofol|Used for conscious sedation.
79338558|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
79338559|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
79338560|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
79488615|NCT02988050|Drug|Bupivacaine|Local anaesthetics
79488616|NCT02988050|Drug|Lidocaine|Local anaesthetic
79488617|NCT02988050|Drug|Epinephrine|With local anaesthetic for skin infiltration.
79488618|NCT03065647|Device|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
79488619|NCT02988986|Drug|TAK-228|MTORC1/2 inhibitor
79488620|NCT02988986|Drug|Tamoxifen|Non-steroidal anti-estrogen
79488621|NCT02832115|Drug|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
79488622|NCT02832115|Drug|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
79488623|NCT02862080|Device|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
79488624|NCT02862080|Device|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
79338561|NCT05470075|Drug|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
79338562|NCT05470075|Drug|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
79488625|NCT02862080|Device|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
79653722|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
79983449|NCT01350765|Behavioral|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
79983450|NCT01350765|Behavioral|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
79983451|NCT01350843|Dietary Supplement|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
79983452|NCT03248830|Device|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
79338563|NCT05476627|Diagnostic Test|Biomarkers|Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
79338564|NCT05481619|Drug|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
79488626|NCT00373945|Drug|Observational Study|
79488627|NCT03054506|Device|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
79488628|NCT03054506|Device|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
79653723|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
79653724|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
79338565|NCT05476471|Behavioral|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
79338566|NCT05481385|Behavioral|Reference preparation-Reference preparation-Test Preparation|Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
79338567|NCT05481385|Behavioral|Reference preparation-Test Preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
79338568|NCT05481385|Behavioral|Test Preparation-Reference preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
79338569|NCT02305563|Drug|BMS-936564|
79338570|NCT02305563|Drug|Cytarabine|
79338571|NCT02327325|Behavioral|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
79338572|NCT02327325|Behavioral|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
79653725|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
79488629|NCT03054506|Device|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
79488630|NCT03068611|Behavioral|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
79338573|NCT02304705|Drug|Sildenafil|20 mg three times daily by mouth for 90 days
79488631|NCT03068611|Behavioral|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
79488632|NCT02835625|Radiation|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
79488633|NCT02835625|Radiation|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
79653726|NCT00403286|Drug|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
79653727|NCT00403286|Drug|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
79338574|NCT02304705|Drug|Placebo|One capsule three times daily by mouth for 90 days
79488634|NCT03071887|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
79653728|NCT00403286|Drug|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
79983453|NCT03248752|Behavioral|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
79488635|NCT02935699|Drug|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
79338575|NCT02553499|Biological|MK-1248|IV infusion
79338576|NCT02553499|Biological|pembrolizumab|IV infusion
79338577|NCT04507009|Device|Ozone|topical gaseous ozone application
79338578|NCT04507009|Other|CGF|concentrated growth factor (CGF) application
79338579|NCT04507009|Other|Traditional treatment|Alvogyl application
79338580|NCT04468789|Other|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
79338581|NCT05476315|Other|Emergency surgery during covid-19 pandemic|Patients undergoing emergency surgery during the covid period and compared with emergency interventions before the pandemic
79338582|NCT02553421|Device|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
79338583|NCT04270591|Drug|Glumetinib|The investigational product will be orally administrated when fasting at dose level of 300mg QD
79338584|NCT02549287|Behavioral|SafeCare|An evidence-based home visiting program
79338585|NCT02549287|Behavioral|Supportive Case Management|Child welfare services as usual
79488636|NCT02935699|Drug|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
79653729|NCT00403286|Drug|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
79653730|NCT04587232|Diagnostic Test|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
79653731|NCT04587232|Diagnostic Test|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
79653732|NCT04587232|Diagnostic Test|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
79653733|NCT04587232|Diagnostic Test|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
79983454|NCT03248752|Behavioral|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
79338586|NCT05469451|Procedure|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
79488637|NCT04333381|Other|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~The educational intervention will consist:~Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~The organizational intervention will consist:~Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~Review organizational strategies and definition of new improvement measures~Audit the delays in STEMI~Periodic multi-disciplinary update sessions"
79488638|NCT04333381|Other|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
79488639|NCT03073759|Device|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
79488640|NCT03073759|Device|Sham device|The device will administer a sham.
79488641|NCT02936479|Drug|C1-INH (Berinert)|
79488642|NCT02841241|Drug|Esmolol|Esmolol infusion
79488643|NCT00374881|Drug|Morphine|Morphine
79488644|NCT00374881|Drug|Morphine|Morphine low dose
79488645|NCT00374881|Drug|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
79488646|NCT00374881|Drug|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
79338587|NCT04505527|Behavioral|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
79338588|NCT04505527|Behavioral|Forward walking|Subjects will have a typical forward walking
79653734|NCT00253812|Procedure|flexible sigmoidoscopy|
79653735|NCT04586764|Device|Non-Invasive Cardiac System|Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.
79653736|NCT04586803|Drug|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
79983455|NCT00687531|Drug|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
79983456|NCT01347411|Procedure|CPAP|Treatment with CPAP
79983457|NCT03243526|Other|fluid therapy|fluid resuscitation guided by CVP or PPV
79338589|NCT05476159|Drug|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
79338590|NCT05476159|Device|Gastric bypass|Roux and Y Gastric bypass
79338591|NCT02553265|Drug|Carbidopa Low-Dose|300 mg/day
79338592|NCT02553265|Other|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
79488647|NCT00374881|Drug|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
79488648|NCT00374959|Drug|ceftriaxone|
79488649|NCT00374959|Device|Endotracheal tube for aspiration of subglottic secretions.|
79488650|NCT02865434|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
79983458|NCT04487002|Procedure|surgical resection|
79983459|NCT01350921|Drug|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
79983460|NCT01350921|Drug|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
79338593|NCT02553265|Drug|Carbidopa High-Dose|600 mg/day
79338594|NCT04269967|Other|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
79338595|NCT05480839|Procedure|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
79338596|NCT05480839|Procedure|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
79338597|NCT05480839|Procedure|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
79488651|NCT02865434|Procedure|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
79488652|NCT02865434|Procedure|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
79338599|NCT03215095|Drug|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
79338600|NCT03215095|Radiation|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
79338601|NCT02561195|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
79653737|NCT04586608|Dietary Supplement|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
79653738|NCT04586608|Dietary Supplement|soybean oil-based IVFE|soybean oil-based IVFE
79653739|NCT04586491|Combination Product|Oral care protocol|Oral care protocol
79653740|NCT00223067|Drug|TAIZ|
79653741|NCT04719429|Dietary Supplement|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
79653742|NCT04719429|Dietary Supplement|Beef-derived Protein|Beverage containing 25 g beef-derived protein
79338602|NCT02561195|Biological|Placebo|0.5 mL intramuscular injection
79338603|NCT01663103|Drug|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
79983461|NCT03248518|Behavioral|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
79488653|NCT02865434|Procedure|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
79983462|NCT03248518|Behavioral|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
79983463|NCT03248518|Behavioral|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
79983464|NCT00423579|Drug|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
79983465|NCT00423579|Drug|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
79983466|NCT03243682|Procedure|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
79983467|NCT03243682|Procedure|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
79983468|NCT04533945|Device|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
79488654|NCT02865434|Procedure|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
79653743|NCT04586218|Behavioral|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure > 65mmHg
79653744|NCT04586218|Behavioral|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
79653745|NCT04585867|Drug|Exparel|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
79983469|NCT03248362|Device|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
79338604|NCT01663103|Drug|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
79983470|NCT03248362|Device|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
79338605|NCT05509673|Other|Lipofilling (sublesional fat grafting)|
79488655|NCT02865434|Procedure|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
79338606|NCT05501951|Other|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
79338607|NCT05501951|Other|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
79338608|NCT05303753|Other|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
79983471|NCT03243604|Drug|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
79338609|NCT04281797|Diagnostic Test|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
79488656|NCT02865434|Procedure|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
79488657|NCT02865434|Procedure|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
79488658|NCT02865434|Procedure|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
79488659|NCT02865434|Procedure|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
79653746|NCT04585867|Drug|Bupivacaine|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
79653747|NCT00223106|Device|Vaginal Sling|
79983472|NCT01351155|Device|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
79983473|NCT03248284|Procedure|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
79983474|NCT02454556|Drug|FOLITIME®|
79983475|NCT02454556|Drug|Gonal-F®|
79983476|NCT01352481|Other|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
79338610|NCT05501639|Drug|tiotropium|tiotropium
79338611|NCT05501639|Drug|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
79338612|NCT05501639|Drug|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
79338613|NCT05501405|Other|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
79338614|NCT05509361|Biological|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
79338615|NCT05076929|Diagnostic Test|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
79338616|NCT05509205|Other|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
79488660|NCT02865434|Procedure|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
79488661|NCT02865434|Procedure|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
79983477|NCT03248050|Behavioral|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
79338617|NCT04285697|Other|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
79338618|NCT05501015|Other|Ice chips|Consuming small amounts of ice chips with supervision
79338619|NCT04535531|Drug|SB206 10.3% berdazimer|Topically once daily
79983478|NCT01352559|Drug|responders|Antidepressants administration for 6 weeks under therapeutic dose
79338620|NCT04535531|Drug|vehicle gel|Topically once daily
79338621|NCT04532645|Drug|Olaparib|Olaparib
79338622|NCT02560025|Drug|Alisertib|
79338623|NCT02560025|Drug|Cytarabine|
79338624|NCT02560025|Drug|Idarubicin|
79488662|NCT02865434|Procedure|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
79983479|NCT01352559|Drug|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
79983480|NCT01351233|Procedure|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
79488663|NCT02865434|Procedure|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
79488664|NCT00375037|Behavioral|feedback|
79983481|NCT03243292|Other|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
79983482|NCT03126513|Procedure|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
79983483|NCT03247894|Other|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
79983484|NCT03243214|Device|TMS|Real or Sham TMS will be given to the PD-MCI patient
79338625|NCT02560025|Drug|Daunorubicin|Can be used in place of idarubicin
79338626|NCT05500937|Drug|UDCA|UDCA vs. placebo together with statin in ASCVD patients
79338627|NCT04744025|Device|Microfluidics chamber|Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
79338628|NCT04744025|Other|Density Gradient Centrifugation|Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.
79338629|NCT05500781|Behavioral|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in [the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
79338630|NCT04524455|Drug|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
79338631|NCT04524455|Drug|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
79338632|NCT04524455|Drug|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
79488665|NCT00375037|Behavioral|Education|
79488666|NCT00375037|Other|usual care|
79488667|NCT02841397|Device|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
79488668|NCT02846233|Drug|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
79653748|NCT04585828|Device|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
79653749|NCT04585828|Device|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
79813267|NCT04045756|Device|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
79813268|NCT05608278|Behavioral|Bergen 4-Day Treatment (B4DT)|Novel CBT treatment
79983485|NCT03243214|Device|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
79983486|NCT01346319|Drug|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
79338633|NCT05508893|Radiation|CT Angiography|A CTA will be performed on asymptomatic individuals
79488669|NCT02846233|Drug|basal insulin|The participant will continue with the basal insulin.
79488670|NCT02846233|Drug|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
79813269|NCT05608278|Behavioral|Gold standard cognitive behavioral therapy (gold standard CBT)|Gold standard CBT treatment
79338634|NCT05508893|Diagnostic Test|Exercise stress test|A routine exercise stress test will be performed on a bicycle
79813270|NCT05146804|Other|BroccoCress|BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.
79488671|NCT02846233|Drug|Metformin|The participant will continue with metformin.
79488672|NCT02865590|Device|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
79488673|NCT02865590|Device|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
79488674|NCT02867150|Device|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
79488675|NCT03075085|Behavioral|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
79488676|NCT02867618|Drug|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
79488677|NCT02867618|Drug|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
79488678|NCT02868242|Drug|LDV/SOF|Tablet(s) administered orally once daily
79488679|NCT03075553|Other|Laboratory Biomarker Analysis|Correlative studies
79813271|NCT05146804|Other|Affilla Cress|Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.
79813272|NCT00655486|Drug|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
79338635|NCT05500625|Procedure|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
79338636|NCT05500625|Procedure|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
79338637|NCT04789889|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
79338638|NCT04789889|Radiation|postoperative radiotherapy|postoperative radiotherapy
79338639|NCT04640519|Other|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
79338640|NCT04640519|Other|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
79338641|NCT04411901|Drug|Cholecalciferol (vitaminD3)|Theraputic vitamin D3 for CF and non CF bronchiectasis children
79338642|NCT05500547|Other|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
79338643|NCT05508737|Drug|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|Single arm: Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
79338644|NCT04281329|Procedure|Magnetic resonance imaging|Cardiac magnetic resonnance imaging before catheter ablation.
79338645|NCT04333511|Device|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
79338646|NCT04333511|Device|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
79338647|NCT04231799|Procedure|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
79338648|NCT05508659|Drug|Duvelisib|Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
79338649|NCT05508659|Drug|SG001|240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
79338650|NCT05508581|Procedure|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
79338651|NCT05500157|Procedure|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
79338652|NCT05499923|Device|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
79338653|NCT05508425|Diagnostic Test|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
79488680|NCT03075553|Biological|Nivolumab|Given IV
79653750|NCT00253851|Drug|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
79653751|NCT04585672|Other|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
79488681|NCT03076333|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
79338654|NCT05508425|Diagnostic Test|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
79338655|NCT05508425|Diagnostic Test|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
79338656|NCT05508425|Diagnostic Test|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
79338657|NCT05508425|Diagnostic Test|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
79338658|NCT05508425|Diagnostic Test|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
79338659|NCT05508425|Diagnostic Test|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
79338660|NCT05508425|Diagnostic Test|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
79338661|NCT05508347|Drug|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
79338662|NCT05499845|Diagnostic Test|butanol threshold test and smell identification tests|no additional intervention
79338663|NCT05508113|Other|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
79338664|NCT05499533|Procedure|implant site preparation|a hole were created in the edentulous ridge area before implant placement
79488682|NCT02869334|Device|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
79813273|NCT04111302|Other|IV-PCA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.
79338665|NCT05508035|Drug|Sacubitril / Valsartan|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
79813274|NCT04111302|Other|IV-dezocine|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.
79813275|NCT04111302|Other|IV-PCA+AA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
79488683|NCT02869334|Device|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
79488684|NCT02869334|Behavioral|Auditory Remediation|Computer program designed to improve discrimination between sounds
79488685|NCT02869334|Behavioral|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
79983487|NCT01346319|Drug|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
79983488|NCT01350609|Drug|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
79983489|NCT01350609|Drug|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
79813276|NCT04111302|Other|IV-dezocine+AA|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
79813277|NCT00457249|Biological|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
79983490|NCT01351311|Other|Exercise|Resistance Training exercise with swiss ball
79338666|NCT05508035|Drug|Ramipril|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
79983491|NCT01351311|Other|Drug treatment|Drug treatment
79338667|NCT04411355|Dietary Supplement|control by dietitian|
79983492|NCT03269409|Other|Lactated Ringers|Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
79338668|NCT04411355|Other|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
79338669|NCT04411355|Behavioral|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
79983493|NCT03269409|Device|The Celution 800/GP System (Cytori Therapeutics)|The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
79488686|NCT03077893|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
79338670|NCT04390139|Drug|XCEL-UMC-BETA|Administration on top of the standard administered treatment
79338671|NCT04390139|Other|Placebo|Administration on top of the standard administered treatment
79338672|NCT04381637|Device|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
79813278|NCT00457249|Biological|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
79488687|NCT03077893|Device|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
79488688|NCT03054740|Drug|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
79488689|NCT03054740|Drug|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
79488690|NCT02997722|Drug|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
79813279|NCT02552290|Other|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
79813280|NCT02552290|Other|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
79983494|NCT03269409|Biological|Adipose Derived Regenerative Cells (ADRC)|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
79338673|NCT04381637|Procedure|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
79488691|NCT02997722|Drug|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
79338674|NCT02566889|Drug|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
79488692|NCT03078127|Other|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
79488693|NCT03078127|Device|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
79488694|NCT03078127|Device|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
79338675|NCT05564585|Other|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
79488695|NCT03078127|Device|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
79338676|NCT05564585|Other|Sham Taping|The sham tape was applied over the calf muscle of either leg.
79338677|NCT05564507|Diagnostic Test|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~a traditional didactic training using e-learning with a national free-access online course;~two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
79338678|NCT03713255|Procedure|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
79488696|NCT03056144|Device|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min >5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
79653752|NCT04585555|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
79653753|NCT04585282|Behavioral|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
79338679|NCT03713255|Procedure|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
79338680|NCT03713255|Procedure|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
79338681|NCT05564351|Other|eye mask and ear plug|black eye mask and silicon ear plug
79338682|NCT04283201|Other|Physical activity|Moderate activity 150 min per week
79813281|NCT02552290|Other|No intervention|Wait
79813282|NCT04111848|Drug|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
79488697|NCT02943499|Behavioral|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
79338683|NCT04283201|Other|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
79338684|NCT03673553|Other|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
79488698|NCT02943499|Behavioral|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
79488699|NCT02943499|Device|Smartphone|
79488700|NCT03000608|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
79338685|NCT03673553|Other|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
79488701|NCT03000608|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
79488702|NCT02847169|Device|filcon IV1 toric lens|toric contact lens
79983495|NCT03248206|Behavioral|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
79813283|NCT04111848|Drug|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
79488703|NCT02847169|Device|ocufilcon D toric lens|toric contact lens
79813284|NCT05656482|Other|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
79488704|NCT00374582|Device|Bodystat Quadscan 4000|device determining body composition and nutritional status
79488705|NCT00374582|Device|bodystat quadscan 400|device determining body composition and nutritional status
79488706|NCT03108482|Drug|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
79488707|NCT03108482|Drug|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
79813285|NCT00457015|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
79813286|NCT00457015|Drug|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
79813287|NCT00654940|Drug|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
79983496|NCT01351389|Behavioral|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
79813288|NCT00654940|Drug|Placebo|Oral, matched capsules, BID
79813289|NCT00588666|Drug|Bevacizumab|
79488708|NCT03108482|Drug|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
79488709|NCT03108482|Drug|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
79813290|NCT00588666|Drug|Carboplatin|
79813291|NCT00588666|Drug|Gemcitabine|
79813292|NCT03835351|Device|Urinary Catheter|An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
79813293|NCT00807430|Device|Grindcare (Active)|Active treatment
79813294|NCT00807430|Device|Grindcare (Placebo - the device is not activated)|Placebo treatment
79983497|NCT01351389|Behavioral|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
79653754|NCT04585282|Behavioral|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
79653755|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
79653756|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
79653757|NCT00249912|Drug|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
79813295|NCT00805558|Drug|moxifloxacin|400 mg moxifloxacin once daily for 7 days
79813296|NCT00805558|Drug|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
79983498|NCT03243136|Other|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
79338686|NCT05507957|Diagnostic Test|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
79813297|NCT01019785|Dietary Supplement|Ergocalciferol|100 000 U drops is given once
79983499|NCT03242902|Device|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
79983500|NCT03242902|Device|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
79983501|NCT02454634|Drug|IDH1 peptide vaccine|
79338687|NCT02566577|Biological|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
79338688|NCT02566577|Biological|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
79653758|NCT04585438|Drug|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
79653759|NCT00567853|Device|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
79653760|NCT00223223|Drug|Levetiracetam, Keppra|
79653761|NCT00567931|Drug|1-methyl-d-tryptophan|Given orally
79813298|NCT01019785|Dietary Supplement|Ergocalciferol|500 U drops given once
79813299|NCT02604186|Other|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
79813300|NCT02604186|Other|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
79813301|NCT01024543|Drug|Angiotensin II|Angiotensin II
79813302|NCT01024543|Drug|Phenylephrine|Phenylephrine
79813303|NCT01024543|Drug|Placebo|
79488710|NCT03079375|Other|basic intervention|medication review
79338689|NCT02566577|Device|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
79488711|NCT03079375|Other|extended intervention|medication review, medication interview before discharge and follow-up
79488712|NCT02871128|Dietary Supplement|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
79653762|NCT00567931|Other|pharmacological study|Correlative studies
79653763|NCT00567931|Other|laboratory biomarker analysis|Correlative studies
79653764|NCT00567970|Procedure|quality-of-life assessment|
79338690|NCT05481229|Other|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
79338691|NCT05507801|Other|High Protein Milkshake|A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
79338692|NCT05507801|Other|Normal Milkshake|A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
79488713|NCT02871128|Dietary Supplement|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
79653765|NCT00567970|Radiation|stereotactic body radiation therapy|
79653766|NCT00568009|Drug|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
79653767|NCT00223301|Drug|Mycophenolate Mofetil (cellcept)|
79653768|NCT04585516|Procedure|endoscopy|Colonoscopy or gastroscopy
79653769|NCT04585321|Drug|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
79653770|NCT04585321|Drug|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
79653771|NCT00249951|Drug|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
79338693|NCT03300713|Other|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
79338694|NCT03300713|Other|usual follow-up|usual follow-up
79653772|NCT04585360|Other|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~quality of life (SF36 self-assessment questionnaire)"
79488714|NCT02871128|Drug|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
79488715|NCT02850601|Drug|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
79488716|NCT02871440|Drug|Omega 3|
79488717|NCT02871440|Drug|Optive Advanced|
79488718|NCT02871440|Drug|Optive|
79488719|NCT03079531|Drug|Secukinumab|Secukinumab 300 mg administered subcutaneously.
79488720|NCT03056456|Drug|LY900014|Administered subcutaneously (SC)
79488721|NCT03056456|Drug|Insulin Lispro (Humalog)|Administered SC
79488722|NCT03057704|Drug|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
79488723|NCT03057704|Drug|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
79488724|NCT02874092|Drug|Ticagrelor|
79488725|NCT02874092|Drug|MTX therapy|
79488726|NCT03059810|Device|etafilcon A|Investigational Contact Lens
79488727|NCT02876900|Drug|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
79488728|NCT02876900|Drug|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
79488729|NCT02876900|Drug|Placebo|The study will evaluate placebo transdermal patch.
79338695|NCT05563883|Other|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
79488730|NCT03063476|Drug|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
79488731|NCT03063476|Drug|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
79488732|NCT02878382|Other|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
79488733|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
79488734|NCT02880176|Other|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
79338696|NCT04424693|Drug|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
79488735|NCT02880254|Device|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
79488736|NCT02880254|Device|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
79488737|NCT03115580|Device|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
79653773|NCT00412997|Drug|LBH589|
79653774|NCT04585048|Behavioral|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
79653775|NCT00253929|Drug|Intra-arterial infusion of adenosine|
79653776|NCT00253929|Drug|intra-arterial infusion of caffeine|
79653777|NCT00253929|Drug|intra-arterial infusion of acetylcholine|
79653778|NCT00253929|Drug|intra-arterial infusion of sodium nitroprusside|
79653779|NCT00253929|Procedure|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
79983502|NCT04487158|Behavioral|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
79338697|NCT05563571|Drug|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
79338698|NCT05563571|Other|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
79338699|NCT02489903|Drug|RRx-001|
79338700|NCT02489903|Drug|Cisplatin|
79338701|NCT02489903|Drug|Etoposide|
79338702|NCT02489903|Drug|Carboplatin|
79338703|NCT02489903|Drug|Irinotecan|
79338704|NCT02489903|Drug|Vinorelbine|
79338705|NCT02489903|Drug|Doxil|
79338706|NCT02489903|Drug|Gemcitabine|
79983503|NCT04487158|Behavioral|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
79983504|NCT03247426|Other|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
79653780|NCT04584931|Procedure|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
79653781|NCT04584931|Procedure|restorative intervention|colored composite restoration to camouflage the gingival recession defect
79653782|NCT00223340|Behavioral|Patient Activation and Diabetes Registry|
79338707|NCT02489903|Drug|Taxane|
79338708|NCT02489903|Drug|Paclitaxel|
79338709|NCT02489903|Drug|Nab-Paclitaxel|
79338710|NCT02489903|Drug|Pemetrexed|
79338711|NCT01815281|Device|Foot Mechanical Stimulation (GONDOLA)|
79338712|NCT01658111|Device|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
79338713|NCT01658111|Procedure|Traditional physiotherapy|Active or passive exercises.
79338714|NCT01174199|Drug|vorinostat|Given orally
79338715|NCT01174199|Drug|temsirolimus|Given IV
79338716|NCT01174199|Other|laboratory biomarker analysis|Correlative study
79338717|NCT01174199|Procedure|positron emission tomography/computed tomography|PET scan
79338718|NCT04475549|Drug|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
79653783|NCT04585126|Drug|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
79653784|NCT00568048|Biological|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
79653785|NCT00568048|Drug|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
79653786|NCT00249990|Drug|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
79338719|NCT05497895|Biological|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
79338720|NCT05497895|Biological|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
79488738|NCT03115580|Device|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
79338721|NCT05497895|Procedure|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
79338722|NCT04471337|Drug|BAY1817080|BAY1817080 will be administered orally as tablet.
79338723|NCT04356599|Other|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
79338724|NCT05562869|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
79338725|NCT05497661|Other|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
79338726|NCT05497661|Other|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
79338727|NCT04080869|Drug|retinyl palmitate|topical retinyl palmitate loaded ethosomes
79338728|NCT04080869|Drug|Tretinoin|topical tretinoin
79338729|NCT05562791|Drug|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
79338730|NCT05562791|Diagnostic Test|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
79338731|NCT00560495|Drug|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
79338732|NCT00560495|Other|immunoenzyme technique|
79338733|NCT00560495|Other|laboratory biomarker analysis|
79338734|NCT00560495|Radiation|Tc 99m sestamibi|
79338735|NCT00560495|Radiation|radiation therapy|once daily, 5 days a week, for 6-7 weeks
79488739|NCT03117140|Drug|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
79488740|NCT03117140|Drug|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
79488741|NCT03117140|Drug|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
79653787|NCT04584775|Other|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
79653788|NCT04584775|Other|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
79653789|NCT00223379|Procedure|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
79488742|NCT03117140|Drug|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
79488743|NCT03118466|Drug|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
79488744|NCT03118466|Drug|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
79338736|NCT05497505|Device|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
79338737|NCT05499299|Behavioral|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
79338738|NCT05499221|Device|Carriere motion appliance|The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
79338739|NCT02559713|Drug|Vedolizumab|Vedolizumab IV infusion
79338740|NCT01358981|Drug|LY2881835|Administered orally
79488745|NCT03118466|Drug|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
79488746|NCT03118466|Drug|Mitoxantrone|It interfere with cell reproduction
79338741|NCT01358981|Drug|Placebo|Administered orally
79338742|NCT05499065|Procedure|Fluorescence guided detection of tumor positive margins|To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively
79338743|NCT05499065|Drug|Cetuximab-IRDye800|Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
79338744|NCT04317599|Other|Non Interventional study|Non Interventional study
79338745|NCT04230161|Other|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
79338746|NCT04230161|Other|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
79338747|NCT04230161|Other|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
79338748|NCT05498909|Other|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
79653790|NCT00568165|Procedure|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
79338749|NCT04038437|Drug|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
79488747|NCT03068312|Drug|Ivacaftor|IVA 150 mg tablet.
79488748|NCT03068312|Drug|Placebo|Placebo matched to IVA tablet.
79653791|NCT00568165|Procedure|Standard care|Standard care
79338750|NCT04038437|Drug|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
79338751|NCT05491577|Other|Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire|The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
79488749|NCT03119168|Drug|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
79488750|NCT03119168|Other|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
79488751|NCT02881112|Device|Provant Therapy System|Treatment with the Provant Therapy System
79338752|NCT05491343|Drug|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
79338753|NCT05491343|Device|Other|Follow up using US
79338754|NCT05498285|Behavioral|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
79488752|NCT02881658|Dietary Supplement|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
79653792|NCT04584424|Other|The study does not required|The study is prospective multi-center COVID-19 patient cohort
79338755|NCT05498363|Biological|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
79653793|NCT04584580|Drug|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
79653794|NCT00250029|Drug|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion & the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 & the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
79338756|NCT05491265|Behavioral|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
79653795|NCT04584658|Diagnostic Test|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
79653796|NCT04584658|Diagnostic Test|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
79983505|NCT03242980|Behavioral|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
79983506|NCT03242668|Procedure|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
79983507|NCT03242668|Procedure|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
79338757|NCT05497193|Drug|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
79338758|NCT05486195|Drug|SDI-118|SDI-118 Powder in Capsule
79338759|NCT05486195|Drug|Placebo|Matching Placebo
79338760|NCT05486039|Behavioral|Changing behaviour|Changing the lying position and mattress system
79338761|NCT05497739|Drug|Intraperitoneal chemotherapy|5-Fu 1 g/m^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
79338762|NCT05497739|Drug|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA < 1.25 m^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m^2), 60 mg Bid, Days 1-10 (BSA > 1.50 m^2).
79338763|NCT04276727|Drug|MINT study IMP|Application of gel for 6 weeks.
79338764|NCT05485883|Drug|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
79338765|NCT05485727|Other|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
79338766|NCT05485727|Other|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
79338767|NCT04273607|Drug|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
79983508|NCT03242668|Drug|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
79983509|NCT03247192|Dietary Supplement|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
79338768|NCT02548585|Drug|MEDI0382|MEDI0382 administered subcutaneously.
79338769|NCT02548585|Drug|Placebo|Placebo administered subcutaneously.
79338770|NCT05480371|Device|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
79813304|NCT00805636|Drug|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|[18F]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for [18F]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of [18F]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
79813305|NCT00805636|Radiation|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
79813306|NCT00805636|Procedure|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of [18F]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
79338771|NCT05480371|Device|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
79338772|NCT05476081|Drug|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
79338773|NCT05476081|Drug|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
79338774|NCT05476081|Drug|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
79338775|NCT05480215|Device|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
79338776|NCT04479553|Drug|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
79488753|NCT02881658|Dietary Supplement|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
79488754|NCT05405972|Behavioral|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
79488755|NCT03070730|Drug|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
79813307|NCT00793182|Drug|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
79488756|NCT03070730|Drug|Atenolol|Atenolol: 50 mg Q.D.
79813308|NCT00793182|Drug|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
79813309|NCT01024621|Device|Endomicroscope|Pentax EC3870K, Tokyo, Japan
79338777|NCT05476003|Procedure|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
79338778|NCT05476003|Drug|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
79338779|NCT02547649|Biological|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
79338780|NCT02547649|Biological|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
79338781|NCT02547649|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
79488757|NCT03070730|Drug|Placebos|Placebo: t.i.d
79653797|NCT04584658|Other|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
79653798|NCT04584658|Other|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
79653799|NCT00223418|Drug|aripiprazole|
79653800|NCT04584697|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
79653801|NCT04584697|Drug|Placebo|Diluent solution
79653802|NCT04584736|Drug|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
79653803|NCT00250068|Drug|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
79653804|NCT04584268|Behavioral|mindfulness|in person and smart phone application mindfulness practice
79653805|NCT04584268|Other|standard medical education|standard medical education / control
79653806|NCT04584307|Drug|Elotuzumab|Elotuzumab 10-20mg/kg
79653807|NCT04584307|Drug|Pomalidomide|Pomalidomide 2mg
79653808|NCT00223457|Behavioral|Factors that influence compliance|
79813310|NCT01024621|Device|Standard endoscopy|Pentax EG-2931 gastroscope
79813311|NCT00811330|Drug|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
79813312|NCT04110912|Other|This is a registry and no interventions are taking place.|
79813313|NCT00811408|Drug|carboplatin|
79813314|NCT00811408|Drug|cidofovir|
79813315|NCT00811408|Genetic|protein expression analysis|
79813316|NCT00811408|Other|laboratory biomarker analysis|
79338782|NCT05460949|Other|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
79983510|NCT03247192|Dietary Supplement|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
79653809|NCT04720521|Diagnostic Test|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
79983511|NCT03247192|Dietary Supplement|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
79338783|NCT05460949|Other|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
79338784|NCT03097081|Other|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
79338785|NCT03097081|Device|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
79338786|NCT03079297|Drug|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
79653810|NCT04584034|Drug|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
79813317|NCT00811408|Radiation|brachytherapy|
79813318|NCT00811408|Radiation|radiation therapy|
79813319|NCT00813514|Genetic|VEGF genotyping|blood sample for gene analysis
79983512|NCT03242512|Biological|TK006|Subcutaneous injection
79983513|NCT03247270|Behavioral|Intervention I|Low intensive physical exercise
79983514|NCT03247270|Behavioral|Intervention II|High intensive physical exercise
79813320|NCT00793104|Procedure|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
79813321|NCT00807508|Dietary Supplement|placebo|wheat meal capsules with each main meal
79983515|NCT03247348|Behavioral|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
79983516|NCT03242356|Other|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~oral intake of clear fluid during the labor~oral intake of solid meal during the labor~fasting duration for solid and liquids~instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)~discomfort related to thirst during labor~discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
79983517|NCT03778372|Drug|Methadone|see desc above
79983518|NCT03242200|Other|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
79983519|NCT04486846|Other|eVisit|electronic surveillance program in lieu of in-person clinic visit
79983520|NCT03247114|Other|Water|Water, 300 ml at room temperature
79983521|NCT03247114|Other|Glucose|Glucose, 50 grams in 300 ml water at room temperature
79338787|NCT03079297|Other|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
79338788|NCT05475847|Biological|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
79653811|NCT04584034|Drug|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
79653812|NCT04584229|Other|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
79653813|NCT04584073|Procedure|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
79653814|NCT00223535|Behavioral|Cognitive Remediation|
79653815|NCT00223535|Behavioral|Social Skills Training|
79653816|NCT00250146|Behavioral|Gluten (behaviour)|
79653817|NCT04583722|Dietary Supplement|AX-olive oil-PP emulsion|single dose and plasma samples
79813322|NCT00807508|Dietary Supplement|leucine|daily leucine capsules with each main meal
79813323|NCT00446797|Drug|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
79813324|NCT00446797|Drug|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
79338789|NCT02535715|Drug|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
79338790|NCT02535715|Drug|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
79338791|NCT02535715|Drug|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
79338792|NCT05460247|Dietary Supplement|Protein|Participants will receive a diet supplemented by the above protein
79338793|NCT02336815|Drug|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
79983522|NCT03247114|Other|Fructose|Fructose, 50 grams in 300 ml water at room temperature
79338794|NCT02336815|Drug|Dexamethasone|20 mg was given with each dose of Selinexor.
79338795|NCT05466643|Drug|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
79488758|NCT04736498|Other|Inferior venacava Ultrasonography (IVC USG) guided fluid management|The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = [(dIVCmax - dIVCmin)/dIVCmax] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
79488759|NCT05405348|Behavioral|Intervention|The patients did not eat anything during hemodialysis.
79488760|NCT03121820|Drug|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
79488761|NCT03121820|Drug|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
79488762|NCT03123614|Drug|Loteprednol Etabonate 0.5% Oph Gel|
79488763|NCT03123614|Drug|Prednisolone Acetate 1% Oph Susp|
79653818|NCT04583683|Behavioral|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
79653819|NCT04583683|Procedure|Metabolic Surgery|Patients will undergo metabolic surgery
79653820|NCT04583605|Device|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
79653821|NCT04583566|Genetic|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
79653822|NCT04583410|Drug|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
79653823|NCT04583410|Drug|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
79338796|NCT05466643|Drug|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
79653824|NCT00223574|Drug|Control - high carbohydrate, high glycemic index foods|
79653825|NCT00223574|Drug|high carbohydrate, low glycemic index foods|
79653826|NCT00223574|Drug|low carbohydrate, high monounsaturate fat foods|
79653827|NCT00254007|Drug|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
79338797|NCT02543203|Biological|Reconnect|Topical Essential Oils mixture and aromatic method
79338798|NCT02543203|Biological|Coconut oil Comparator|Topical Essential Oils mixture and aromatic method
79338799|NCT05434039|Other|diclofenac phonophoresis|the patients will be in comfortable position and apply diclofenac phonophoresis on upper trapezius and suboccipital muscle by ultrasound device. diclofenac gel was applied circularly with a thickness of 2-3 mm. Then ultrasound with was applied with 1 MHz frequency and 1.5 Wt/cm2 power over the trigger points on the trapezius and suboccipital muscle, for 10 min.
79488764|NCT03123848|Drug|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
79488765|NCT03124550|Behavioral|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
79653828|NCT00223613|Drug|daily intranasal administration of insulin|
79813325|NCT00855335|Drug|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
79813326|NCT00855335|Drug|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
79338800|NCT05434039|Other|high power pain threshold ultrasound|the patients will be in comfortable position and The frequency was set to 1 MHz, and the intensity will be increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe was held there for 4 s; then, the intensity was reduced by 50%, and the probe will be moved over and around the trigger point. This process is done several times for three minutes
79338801|NCT05434039|Other|conventional therapy|the patient will receive an active range of motion exercise, stretching and strengthening of all cervical muscles
79338802|NCT05466175|Drug|Olverembatinib|Given PO
79338803|NCT05466175|Drug|Prednisone|Given Intravenous
79338804|NCT05466175|Drug|Vincristine|Given Intravenous
79338805|NCT02546323|Drug|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
79338806|NCT02546323|Drug|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
79338807|NCT02545933|Drug|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
79338808|NCT02545933|Drug|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
79338809|NCT02545933|Drug|Aspirin|Aspirin will be administered at the dose of 81mg once daily
79338810|NCT02545933|Drug|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
79338811|NCT01661179|Drug|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
79338812|NCT05457517|Drug|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
79338813|NCT02545543|Biological|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
79338814|NCT02545543|Biological|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
79813327|NCT00855335|Drug|Etravirine|200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
79983523|NCT03247114|Other|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
79338815|NCT02545075|Drug|Ipilimumab|
79983524|NCT03247114|Other|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
79488766|NCT02946073|Drug|buprenorphine|
79983525|NCT03246880|Drug|Tamsulosin 0.2mg|per oral for 12weeks after 2~4weeks run-in period
79338816|NCT02545075|Drug|Dacarbazine|
79338817|NCT03007537|Drug|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
79338818|NCT03007537|Drug|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
79983526|NCT03246880|Drug|Tadalafil 5mg|per oral for 12weeks after 2~4weeks run-in period
79983527|NCT03242044|Procedure|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
79338819|NCT03007537|Procedure|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
79338820|NCT02544763|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
79338821|NCT02544763|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
79488767|NCT02946073|Other|Placebo|
79338822|NCT05464771|Procedure|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
79338823|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
79338824|NCT02556203|Drug|Acetylsalicylic Acid (ASA)|75-100mg OD
79338825|NCT02556203|Drug|Clopidogrel|75mg OD
79338826|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
79338827|NCT02556203|Drug|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
79488768|NCT03071744|Drug|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
79488769|NCT03073148|Device|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
79488770|NCT03073148|Other|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
79813328|NCT00855335|Drug|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
79813329|NCT00855335|Drug|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
79813330|NCT00811486|Drug|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
79488771|NCT02946229|Device|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
79653829|NCT04583371|Other|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
79813331|NCT00813670|Drug|XPF-001|Single oral dose, or 6 days of repeated oral doses.
79813332|NCT04114188|Drug|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA < 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
79338828|NCT05485571|Device|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
79338829|NCT05485337|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
79338830|NCT05496803|Other|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
79488772|NCT03074630|Drug|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
79488773|NCT03074630|Drug|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
79338831|NCT05496803|Other|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
79338832|NCT05496725|Drug|Micafungin|Pharmacokinetic study under fasting conditions
79813333|NCT00811876|Other|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
79813334|NCT00915252|Drug|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
79813335|NCT00915252|Drug|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
79813336|NCT00813826|Drug|SLC022|SLC022 150 mg capsule, 900mg daily dose
79813337|NCT00813826|Drug|Placebo|Placebo capsule, TID
79813338|NCT00799422|Device|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
79813339|NCT00799422|Device|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
79813340|NCT00799422|Device|Clear Care|Commercially marketed contact lens solution for contact lens care
79338833|NCT05490719|Drug|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
79338834|NCT04424459|Drug|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
79488774|NCT03086707|Other|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
79488775|NCT03125018|Device|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
79488776|NCT05404334|Diagnostic Test|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
79488777|NCT00374894|Drug|2,3-dimercaptosuccinic acid|
79488778|NCT03088267|Drug|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
79488779|NCT03088267|Drug|Placebo extended-release oral suspension|6, 7 or 8 mL PO
79488780|NCT03127358|Device|AiCure|Smartphone App
79488781|NCT03127358|Device|AiCure with gamification|Smartphone App with gaming.
79488782|NCT03088345|Drug|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
79813341|NCT00799422|Device|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
79338835|NCT05496569|Drug|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
79983528|NCT02711644|Behavioral|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
79983529|NCT02711644|Behavioral|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
79983530|NCT02690584|Behavioral|Metacognitive therapy|
79983531|NCT03242122|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
79983532|NCT03242122|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
79983533|NCT03242122|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
79653830|NCT04583332|Other|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
79653831|NCT04583332|Other|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
79983534|NCT03242122|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
79653832|NCT04583332|Other|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
79653833|NCT04583137|Drug|Lidocain|Layngeal direct fiberoptic examination transnasaly
79653834|NCT00223691|Drug|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
79338836|NCT05496569|Drug|TQB3616 placebo|Placebo
79338837|NCT04179383|Other|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
79338838|NCT05485259|Dietary Supplement|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
79653835|NCT00223691|Drug|Acarbose|25-100 mg, PO. Single dose.
79338839|NCT05485259|Other|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
79653836|NCT00223691|Drug|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
79653837|NCT00223691|Drug|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
79653838|NCT00223691|Drug|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
79653839|NCT00223691|Drug|placebo|PO.Single dose.
79983535|NCT03242122|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
79983536|NCT03246412|Diagnostic Test|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
79983537|NCT03258034|Drug|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
79983538|NCT03258190|Drug|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
79983539|NCT03258112|Procedure|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
79983540|NCT03257722|Drug|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
79983541|NCT03257722|Drug|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
79488783|NCT03088345|Drug|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
79488784|NCT02855437|Device|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
79983542|NCT03268005|Drug|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
79488785|NCT02855437|Device|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
79488786|NCT02948257|Device|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
79983543|NCT03268005|Drug|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
79488787|NCT03127514|Drug|AMX0035|AMX0035
79653840|NCT00223691|Drug|Modafinil|50-400 mg PO. Single dose
79338840|NCT04027049|Device|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
79983544|NCT03268005|Drug|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
79983545|NCT03268005|Drug|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
79983546|NCT03239314|Drug|Saline Solution|Injected in the adductor canal
79983547|NCT03239314|Drug|Dexamethasone|Injected in the adductor canal
79338841|NCT05490407|Drug|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
79338842|NCT04424849|Diagnostic Test|CT-Scan|Chest CT scan on admission to the intensive care unit
79338843|NCT05490173|Other|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
79338844|NCT05485025|Behavioral|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
79338845|NCT05485025|Behavioral|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
79983548|NCT02454244|Behavioral|ART with Mindfulness|"Introduction of ART with Mindfulness. Visualization of 100% recovery~Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~The ART. Breaking the negative thoughts related to the illness. Walking meditation~Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~Mindfulness and self-compassion. Kindly awareness meditation~The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~Return to regular life. Mindfulness practice"
79338846|NCT05484947|Diagnostic Test|Elisa HIV testing|HIV testing on a voluntary basis
79488788|NCT03127514|Other|Placebo|Matching Placebo Comparator
79653841|NCT00223691|Drug|Octreotide|5-50 µg, S.C. Single dose.
79653842|NCT00223691|Other|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
79653843|NCT00223691|Drug|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
79653844|NCT00223691|Drug|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
79653845|NCT00223691|Drug|Tranylcypromine|5 - 40 mg PO. Single dose
79983549|NCT02454244|Behavioral|Mindfulness Compassion|"Introduction.Definition of Compassion~Self-Esteemed and Compassion~Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~Love,affection and self-compassion.How participants connect with the suffering of others~Equanimity~Forgiveness~Interdependence. Gratitude.Affection to unknown people~Developing affection and empathy.Empathy and burn out~Review of the practices and meditations"
79983550|NCT02454244|Behavioral|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
79983551|NCT03257644|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
79983552|NCT03257878|Other|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
79983553|NCT03241888|Drug|Megestrol Acetate|At a dosage of 160 mg/day
79488789|NCT02858713|Drug|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
79488790|NCT02858713|Device|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
79488791|NCT00375050|Drug|Riluzole|
79983554|NCT03241888|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
79983555|NCT02454088|Other|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
79983556|NCT02454088|Device|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
79983557|NCT02456116|Device|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
79983558|NCT02456116|Device|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
79983559|NCT02456116|Other|PCA/NSAID|standard boli of morphine by pressing a button of PCA
79983560|NCT04481607|Drug|TQB3454|TQB3454 tablets is a small molecule oral drug.
79488792|NCT00375050|Drug|Placebo|placebo
79488793|NCT03128372|Device|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
79488794|NCT02860507|Drug|sugammadex|
79488795|NCT02860507|Drug|Neostigmine|
79488796|NCT02860507|Drug|Glycopyrrolate|
79488797|NCT03082196|Drug|Test varnish|Topical application of test varnish to the teeth 4 times per year.
79488798|NCT03082196|Drug|Standard varnish|Topical application of test varnish to the teeth 4 times per year
79488799|NCT03092089|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
79653846|NCT00223691|Drug|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
79653847|NCT00223691|Drug|Celecoxib|50-200 mg PO. Single dose
79653848|NCT00223691|Drug|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
79653849|NCT00223691|Drug|Methylphenidate|5 or 10 mg PO. Single dose.
79653850|NCT00223691|Drug|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
79338847|NCT05484791|Other|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
79488800|NCT03092089|Device|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
79488801|NCT03092089|Procedure|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
79488802|NCT03134144|Device|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
79488803|NCT02861131|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
79983561|NCT01352871|Behavioral|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
79653851|NCT00223691|Drug|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
79983562|NCT01352871|Drug|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
79653852|NCT00223691|Drug|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
79653853|NCT00223691|Dietary Supplement|Bovril|6-10 g, PO. Single dose.
79983563|NCT03239236|Procedure|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
79983564|NCT03239236|Procedure|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
79983565|NCT03239236|Procedure|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
79983566|NCT03239236|Procedure|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
79983567|NCT03239236|Procedure|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
79653854|NCT00223691|Drug|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
79653855|NCT00223691|Drug|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
79653856|NCT00223691|Drug|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
79653857|NCT00223691|Device|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
79653858|NCT00223691|Device|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
79653859|NCT04583020|Drug|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
79653860|NCT04583020|Radiation|radiation|60Gy/30
79653861|NCT04583020|Drug|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
79653862|NCT04583059|Other|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
79653863|NCT04582552|Drug|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
79653864|NCT00568204|Device|Mexyn-A|Atomised topical self-chilled pressurised spray
79653865|NCT04582747|Diagnostic Test|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
79653866|NCT00223730|Drug|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
79653867|NCT00223730|Drug|Placebo|
79653868|NCT04582630|Dietary Supplement|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
79653869|NCT04582786|Drug|Morphine|Repeated bolus according to pain score
79653870|NCT04582786|Drug|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
79653871|NCT04582786|Drug|STR-324|Infusion of solution for intravenous administration
79653872|NCT04582513|Other|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
79653873|NCT00223769|Drug|Oxandrolone|
79653874|NCT04583449|Behavioral|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
79653875|NCT04582474|Other|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
79653876|NCT04582123|Procedure|crossed pin configuration|comparison of two crossed pin fixation methods
79653877|NCT04582084|Drug|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
79653878|NCT00254046|Drug|TMC125|2 X100 mg tablets b.i.d.96 weeks
79653879|NCT00254046|Drug|Placebo|2 tablets b.i.d.96 weeks
79653880|NCT00568360|Device|Oximeter|
79653881|NCT00223847|Behavioral|Constraint Induced Language Therapy|
79653882|NCT04582162|Other|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
79653883|NCT04582162|Other|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
79653884|NCT04582396|Procedure|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
79653885|NCT04582396|Procedure|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
79983568|NCT03239236|Drug|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
79338848|NCT05496413|Device|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
79653886|NCT04582396|Behavioral|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
79653887|NCT04582240|Other|no intervention|no intervention
79653888|NCT04581772|Drug|DNL343|Multiple oral doses
79653889|NCT04581772|Drug|Placebo|Single oral dose
79653890|NCT04581772|Drug|DNL343|Single oral dose
79983569|NCT03239236|Diagnostic Test|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
79338849|NCT05496257|Other|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
79338850|NCT05490095|Drug|SVG101 (T)|5mg of SVG101
79983570|NCT03239236|Diagnostic Test|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
79338851|NCT05490095|Drug|Afinitor (R)|5mg of Afinitor
79653891|NCT00223925|Drug|Maribavir|
79653892|NCT00223925|Drug|Placebo|
79653893|NCT00254085|Drug|Insulin Aspart|
79653894|NCT04582006|Procedure|Bariatric surgery|Surgical treatment of morbid obesity.
79653895|NCT04581967|Genetic|polymorphism analysis|"DNA will be purified from whole blood samples by commercial DNA isolation kits.~Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
79338852|NCT05484635|Procedure|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
79653896|NCT04581967|Drug|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
79653897|NCT04581577|Other|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
79653898|NCT00223964|Drug|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
79653899|NCT04581694|Diagnostic Test|TAVI without contrast|TAVI without contrast
79653900|NCT00254124|Device|The Diet Plate (R) TM portion control plate and bowl|
79653901|NCT00224081|Drug|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
79653902|NCT04581265|Drug|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
79653903|NCT04581187|Other|Quality of life assessment|Quality of life questionnaires
79653904|NCT00414999|Drug|TG100801|
79983571|NCT03239236|Diagnostic Test|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
79983572|NCT01353027|Drug|Placebo|Normal saline
79488804|NCT02861131|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
79488805|NCT03134768|Other|This is not an interventional study|This is an observational study
79488806|NCT05172206|Other|symptom-focused rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
79983573|NCT01353027|Drug|AVI-6002|Single intravenous administration
79338853|NCT05484635|Procedure|Diagnostic laparoscopy|Surgical examination through laparoscopy without removal of mesh
79338854|NCT04424381|Drug|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet [Xarelto].
79338855|NCT04424381|Drug|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
79338856|NCT05496179|Drug|Prucalopride|Prokinetic
79488807|NCT05172206|Other|usual care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
79653905|NCT04580875|Procedure|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
79983574|NCT01343121|Other|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
79983575|NCT01343121|Other|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
79983576|NCT01343121|Other|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
79983577|NCT03239392|Drug|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
79338857|NCT05496179|Drug|Metoclopramide|Prokinetic
79338858|NCT04157621|Device|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
79338859|NCT04157621|Device|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
79338860|NCT05496101|Procedure|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
79488808|NCT05098886|Drug|DA-5210 10/1000mg|single dose administration (one tablet once a day)
79983578|NCT01353105|Procedure|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
79338861|NCT05496023|Device|Percutaneous coronary intervention|"Pre-PCI angio-FFR was calculated and virtual pullback was generated~Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~PCI was performed using 2nd generation DES"
79338862|NCT05489939|Drug|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
79488809|NCT05098886|Drug|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
79488810|NCT03093025|Drug|TS-121 10 mg|Orally taken once daily
79488811|NCT03093025|Drug|TS-121 50 mg|Orally taken once daily
79338863|NCT05484323|Other|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
79983579|NCT03239158|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
79983580|NCT03239158|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
79338864|NCT05484323|Other|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
79488812|NCT03093025|Drug|Placebo|Orally taken once daily
79488813|NCT05098262|Drug|DA-5210 10/500mg|single dose administration (one tablet once a day)
79488814|NCT05098262|Drug|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
79488815|NCT02950753|Drug|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
79488816|NCT02950753|Drug|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
79488817|NCT03082586|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
79488818|NCT03082586|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
79488819|NCT03082586|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
79488820|NCT03082586|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
79983581|NCT01353183|Procedure|colonoscopy or rectosigmoidoscopy|Usual procedure
79983582|NCT03257800|Drug|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
79983583|NCT03257800|Drug|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
79983584|NCT01351857|Other|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
79983585|NCT03241654|Procedure|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
79983586|NCT01351935|Drug|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
79983587|NCT01352013|Dietary Supplement|Omega-3 (oil)|5ml daily with breakfast for 56 days.
79488821|NCT03082586|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
79488822|NCT03082586|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
79488823|NCT03086408|Device|THRIVE|active nasal oxygen delivery system
79488824|NCT03086408|Device|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
79488825|NCT02951143|Drug|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
79488826|NCT02951143|Drug|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
79488827|NCT05040152|Behavioral|Dietary Counseling and Surveillance|Receive dietary recommendations
79488828|NCT05040152|Other|Exercise Intervention|Complete home exercises
79653906|NCT04581109|Biological|Blood sample|Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
79653907|NCT02962466|Other|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
79653908|NCT04580797|Drug|PF-06700841 IR|Immediate release formulation
79653909|NCT04580797|Drug|PF-06700841 MR1|Modified release formulation 1
79653910|NCT04580797|Drug|PF-06700841 MR2|Modified release formulation 2
79983588|NCT01352013|Dietary Supplement|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
79338865|NCT05484323|Diagnostic Test|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
79338866|NCT05484323|Other|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
79338867|NCT05495867|Procedure|implant placement|implant placement in edentulous area
79983589|NCT03241576|Behavioral|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
79983590|NCT03241576|Behavioral|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
79983591|NCT01353339|Drug|Levofloxacin|500mg, PO, once daily for 3 months
79338868|NCT05489861|Behavioral|M-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
79338869|NCT05489861|Behavioral|F-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
79338870|NCT04423991|Device|COViage|Machine learning intervention
79488829|NCT05040152|Other|Informational Intervention|Receive education brochures
79488830|NCT05040152|Other|Questionnaire Administration|Ancillary studies
79983592|NCT03241498|Other|Medicines optimisation|
79983593|NCT03239080|Drug|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
79488831|NCT05040152|Behavioral|Telephone-Based Intervention|Receive telephone-based weight loss intervention
79488832|NCT04707404|Procedure|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
79488833|NCT04707092|Drug|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
79488834|NCT04707014|Behavioral|Hypnosis|Rapid conversational hypnosis
79488835|NCT04707014|Behavioral|Attention-distracting techniques|i-pad with movies, games and music
79653911|NCT04580797|Drug|PF-06700841 MR3|Modified release formulation 3
79653912|NCT04580797|Other|Placebo|Matching placebo
79653913|NCT00415038|Drug|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
79653914|NCT00415038|Drug|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
79653915|NCT00415038|Drug|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
79653916|NCT00415038|Drug|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
79653917|NCT00415038|Drug|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
79653918|NCT00224159|Behavioral|Drug and Dietary behavior|
79653919|NCT00568477|Drug|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
79983594|NCT03239080|Other|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
79653920|NCT04580836|Procedure|Magnetic Resonance Imaging|Undergo MRI
79653921|NCT04580836|Other|Questionnaire Administration|Ancillary studies
79653922|NCT04580836|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79653923|NCT00415077|Procedure|PRK|PRK
79653924|NCT00415077|Procedure|MMC PRK|mitomycin C PRK
79653925|NCT00415077|Procedure|LASEK|LASEK
79653926|NCT00568516|Drug|ASP3550|subcutaneous administration
79983595|NCT03149055|Drug|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
79983596|NCT03257488|Device|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
79983597|NCT01317693|Device|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
79983598|NCT03241264|Drug|ND-L02-s0201|Specified dose on specified day
79983599|NCT01353417|Other|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
79983600|NCT03257332|Procedure|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
79653927|NCT00224198|Procedure|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
79653928|NCT00568711|Drug|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
79653929|NCT00568711|Drug|rifampin|a 5-day course of daily 600-mg doses of rifampin
79983601|NCT01317771|Procedure|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
79983602|NCT03257176|Behavioral|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
79983603|NCT01352091|Drug|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
79983604|NCT01352091|Drug|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
79983605|NCT03257098|Biological|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
79983606|NCT01353573|Radiation|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
79653930|NCT04580758|Combination Product|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
79653931|NCT04580641|Other|Questionnaire|A self-administered questionnaire will be completed by each study subject
79653932|NCT00415116|Drug|carboplatin|
79653933|NCT00415116|Drug|docetaxel|
79653934|NCT00415116|Drug|lenalidomide|
79653935|NCT00568750|Drug|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
79653936|NCT00568789|Drug|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
79653937|NCT00254202|Drug|iloperidone|
79653938|NCT00254202|Drug|active comparator|
79653939|NCT00254202|Drug|placebo|
79653940|NCT00568945|Drug|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
79488836|NCT02867059|Drug|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
79983607|NCT01353573|Radiation|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
79983608|NCT03257020|Diagnostic Test|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
79653941|NCT00568984|Drug|repaglinide|
79653942|NCT00568984|Drug|metformin|
79653943|NCT00568984|Drug|glicazide|
79653944|NCT00254241|Drug|Seroquel and Risperidone|
79983609|NCT02964897|Behavioral|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
79983610|NCT02964897|Behavioral|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
79338871|NCT05483699|Other|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
79338872|NCT05483699|Other|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
79338873|NCT05483699|Other|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
79338874|NCT05489315|Device|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
79653945|NCT00569023|Dietary Supplement|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
79338875|NCT05489315|Other|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
79338876|NCT05495477|Device|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
79653946|NCT00224315|Drug|ziprasidone|
79653947|NCT00224315|Drug|risperidone|
79653948|NCT00569101|Drug|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg ~0.02 mg/kg + prednisolone tapering
79653949|NCT00569179|Device|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
79653950|NCT00569257|Drug|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
79338877|NCT05483543|Drug|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
79653951|NCT00224354|Biological|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
79653952|NCT00224354|Biological|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
79653953|NCT00224354|Biological|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
79338878|NCT04139213|Drug|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
79338879|NCT04139213|Drug|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
79338880|NCT04139213|Other|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
79488837|NCT04985708|Other|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
79488838|NCT03088748|Device|Journey II posterior cruciate retaining total knee arthroplasty|
79653954|NCT00224354|Drug|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
79338881|NCT04139213|Drug|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
79653955|NCT00224354|Biological|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
79488839|NCT03088748|Device|Journey II posterior bi-cruciate retaining total knee arthroplasty|
79488840|NCT02953561|Drug|Avelumab|Given IV
79488841|NCT02953561|Drug|Azacitidine|Given SC or IV
79653956|NCT00254280|Procedure|Intense Pulsed Light + paring versus paring alone|
79983611|NCT03256942|Device|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
79983612|NCT03238846|Other|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
79983613|NCT03238846|Other|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
79488842|NCT02953561|Other|Laboratory Biomarker Analysis|Correlative studies
79338882|NCT05495165|Other|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
79488843|NCT03090620|Drug|Physostigmine|Administration of physostigmine bolus followed by an infusion
79488844|NCT03090620|Drug|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
79488845|NCT04938752|Drug|DA-2811|single dose administration (one tablet once a day)
79488846|NCT04938752|Drug|DA-2811-R|single dose administration (one tablet once a day)
79653957|NCT00569296|Biological|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
79653958|NCT00569296|Biological|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
79653959|NCT00569296|Biological|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
79653960|NCT00569335|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
79653961|NCT00254319|Drug|Avastin, Alimta|
79488847|NCT02953873|Drug|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
79653962|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|One basal rate
79653963|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|Multiple basal rates
79653964|NCT00569491|Device|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
79488848|NCT02953873|Drug|Mycophenolate mofetil|≥500mg twice a day
79488849|NCT02953873|Drug|Prednisone|goal dose 5mg daily
79488850|NCT02953873|Drug|Mycophenolate Sodium|≥360mg twice a day
79488851|NCT03141242|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
79653965|NCT00569569|Drug|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
79653966|NCT00224432|Drug|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
79653967|NCT00569608|Other|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
79653968|NCT00569647|Device|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
79653969|NCT00569647|Device|Placebo|no use of device
79983614|NCT02954523|Drug|Dasatinib|oral every day
79338883|NCT04112849|Diagnostic Test|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
79338884|NCT05495009|Other|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
79338885|NCT05494931|Procedure|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
79488852|NCT03141242|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
79653970|NCT00569686|Drug|lovaza|lovaza 4 gm po daily
79653971|NCT00569686|Drug|placebo|placebo
79653972|NCT00569881|Drug|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
79338886|NCT04071587|Device|Brain Computer Interface training|Training with RecoveriX system.
79338887|NCT04071587|Behavioral|Control|Standard physiotherapy and occupational therapy according to clinical routines.
79653973|NCT00224471|Biological|GSK208141 vaccine|3 IM doses
79653974|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
79653975|NCT00569920|Drug|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
79653976|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
79983615|NCT02954523|Drug|Osimertinib|oral every day
79983616|NCT01343355|Drug|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
79338888|NCT05494775|Drug|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
79338889|NCT03937037|Procedure|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
79338890|NCT04272203|Drug|ABBV-184|Intravenous (IV) infusion
79983617|NCT03238768|Other|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
79653977|NCT00569959|Other|fasting 12+ hours|fasting 12+ hours
79653978|NCT00569959|Other|Non-fasting|Non-fasting
79653979|NCT00569998|Device|NovoPen™ 4|
79653980|NCT00569998|Device|NovoPen® 3|
79653981|NCT00224510|Drug|lamotrigine|
79653982|NCT00570193|Drug|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
79653983|NCT00570193|Drug|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
79653984|NCT00570271|Other|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
79653985|NCT00570271|Other|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
79653986|NCT00570271|Other|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
79983618|NCT03238768|Other|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
79983619|NCT01352247|Procedure|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
79983620|NCT01352247|Procedure|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
79983621|NCT04486612|Other|spinal anesthesia|prospective observational study
79983622|NCT03241108|Drug|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
79983623|NCT03241108|Other|Placebo|Placebo
79488853|NCT03095053|Procedure|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
79488854|NCT00375115|Drug|Sambucol|
79488855|NCT03098173|Procedure|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
79488856|NCT03098173|Procedure|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
79488857|NCT03091478|Drug|Pembrolizumab|200mg every 3 weeks
79488858|NCT02867605|Dietary Supplement|Hyaluronan|
79488859|NCT03092024|Other|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
79338892|NCT05494463|Device|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
79338893|NCT05488925|Drug|Vitamin E|Evion, 400 mg
79488860|NCT03092960|Behavioral|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
79983624|NCT01353651|Device|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
79488861|NCT03092960|Behavioral|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
79488862|NCT02870101|Diagnostic Test|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
79488863|NCT02870101|Diagnostic Test|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
79488864|NCT02870101|Diagnostic Test|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
79488865|NCT00375596|Drug|Ketotifen/vasoconstrictor|
79488866|NCT03143894|Device|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
79488867|NCT03143894|Other|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
79488868|NCT03144518|Other|Positive Affect Intervention|See Previous Description
79488869|NCT03144518|Other|Neutral Control Intervention|See Previous Description
79488870|NCT03144518|Biological|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
79488871|NCT03148262|Device|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
79983625|NCT01353651|Device|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
79338894|NCT05488925|Drug|Diclofenac Sodium|Voltral SR100, 100 mg
79338895|NCT05488925|Drug|Piroxicam|Feldene, 20 mg
79338896|NCT05488925|Drug|Tramadol|Tramal, 50 mg
79488872|NCT03148262|Device|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
79338897|NCT05482763|Drug|Terbinafine Topical Gel|Topical application of terbinafine
79338898|NCT05482763|Drug|Itraconazole 200 mg|systemic itraconazole pulse therapy
79338899|NCT05482763|Drug|Terbinafine 250 mg|systemic terbinafine
79338900|NCT05482763|Drug|Ciclopirox Topical Gel|Topical application of ciclopirox
79338901|NCT05482763|Drug|Amorolfine 50 MG/ML|Topical application of amorolfine
79338902|NCT05482685|Behavioral|Questionnaire|Conduct a 10-minute survey
79338903|NCT05482529|Other|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
79488873|NCT03099655|Device|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
79488874|NCT03093272|Drug|Leuprolide Acetate|a GnRH agonist
79983626|NCT01343511|Biological|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
79488875|NCT03093272|Drug|Prednisone|Prednisone is a corticosteroid
79488876|NCT03093272|Drug|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
79488877|NCT03093272|Drug|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
79488878|NCT03093662|Device|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
79488879|NCT03093662|Device|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
79488880|NCT03100123|Drug|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
79488881|NCT03100123|Drug|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
79488882|NCT04700150|Other|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
79653987|NCT00570271|Other|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
79488883|NCT04700150|Other|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
79488884|NCT03097484|Drug|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
79488885|NCT02872909|Device|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
79488886|NCT04695236|Device|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
79488887|NCT04695236|Other|Standard Treatment|Standard Treatment for Ischemic Strokre
79488888|NCT02957305|Drug|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
79488889|NCT02957305|Drug|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
79488890|NCT02873923|Drug|undefined|Chemotherapy drug (meta-analyses of randomized trials)
79488891|NCT04590092|Device|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
79488892|NCT03104647|Other|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
79488893|NCT03104725|Drug|N-Acetylcysteine|Oral
79488894|NCT03104725|Procedure|Lumbar Puncture|Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
79488895|NCT03104725|Radiation|Fluoroscopy|If needed for lumbar puncture
79488896|NCT03153956|Device|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
79488897|NCT03153956|Device|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
79653988|NCT00570271|Other|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
79653989|NCT00570271|Other|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
79983627|NCT01343511|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
79983628|NCT03240718|Procedure|Laser treatment|CORE fractional CO2 laser treatment
79983629|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
79983630|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
79338904|NCT05482373|Dietary Supplement|Oleuropein from olive tree|The capsules intake will last for a total of 4 months.
79338905|NCT05482373|Dietary Supplement|Placebo|The capsules intake will last for a total of 4 months.
79488898|NCT02876575|Device|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
79488899|NCT03154658|Drug|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
79488900|NCT03157232|Device|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
79653990|NCT00570388|Drug|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
79983631|NCT03238456|Behavioral|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
79488901|NCT02958787|Radiation|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
79983632|NCT01353729|Drug|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
79983633|NCT01353729|Drug|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
79983634|NCT01353729|Drug|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
79488902|NCT03098420|Drug|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
79488903|NCT03098420|Drug|4mg Dexamethasone|1 mL (4mg) of dexamethasone
79488904|NCT03098420|Drug|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
79983635|NCT01353729|Drug|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
79983636|NCT03238378|Radiation|Brachytherapy|Brachytherapy d 1-5(6)
79338906|NCT05482295|Biological|Hepatitis B vaccine lot 1|3 doses of Hepatitis B vaccine lot 1
79338907|NCT05482295|Biological|Hepatitis B vaccine lot 2|3 doses of Hepatitis B vaccine lot 2
79338908|NCT05482295|Biological|Hepatitis B vaccine lot 3|3 doses of Hepatitis B vaccine lot 3
79338909|NCT05482295|Biological|Hepatitis B vaccine (registered)|3 doses of Hepatitis B vaccine (registered)
79488905|NCT03098420|Drug|Morphine|
79488906|NCT03098420|Drug|Bupivacaine Hydrochloride|
79488907|NCT03098420|Drug|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
79488908|NCT03098420|Drug|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
79488909|NCT02876887|Drug|Cocoa|
79488910|NCT02876887|Drug|Placebo|
79488911|NCT03158714|Behavioral|Couples Connecting Mindfully|
79488912|NCT03158714|Behavioral|ELEVATE|
79488913|NCT03108469|Drug|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
79488914|NCT03108469|Other|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
79653991|NCT00570427|Behavioral|Problem Solving Therapy (PST)|Counseling
79983637|NCT03238378|Other|Hyperthermia|Hyperthermia d 2 + 5
79983638|NCT02453854|Behavioral|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
79488915|NCT03159260|Device|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
79488916|NCT03159260|Other|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
79488917|NCT02878057|Drug|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
79488918|NCT00422617|Drug|Alefacept (Amevive)|
79653992|NCT00570427|Behavioral|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
79338910|NCT05482217|Behavioral|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
79653993|NCT00570466|Behavioral|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
79653994|NCT00570466|Behavioral|Web and DVD knowledge|Web and DVD based knowledge games
79653995|NCT00224549|Drug|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
79653996|NCT00570544|Drug|tiotropium|18ug capsule daily for 30 days
79983639|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
79983640|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
79983641|NCT01357317|Drug|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
79338911|NCT05482139|Procedure|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
79983642|NCT03238612|Drug|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
79983643|NCT03238612|Drug|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
79983644|NCT03137121|Drug|Olanzapine|Olanzapine is used as an anti-emetic.
79983645|NCT03137121|Other|Placebo|The placebo is a non-anti-emetic.
79338912|NCT04069091|Behavioral|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
79338913|NCT05494307|Drug|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
79983646|NCT02453776|Drug|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
79338914|NCT05494307|Drug|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
79338915|NCT05488379|Other|Group well child care|Beginning with the 1-month well child care visit, mother-infant dyads will participate in well child care together, with subsequent visits occurring at the American Academy of Pediatrics recommended intervals (2, 4, 6, 9, 12, 15, and 18 months of age).
79338916|NCT05494151|Diagnostic Test|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
79488919|NCT03104738|Other|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
79653997|NCT04580329|Procedure|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
79653998|NCT04580329|Procedure|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
79653999|NCT00254436|Drug|Procrit (epoetin alfa)|Weekly dose
79983647|NCT02915679|Other|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~Thermal stimulation for pain assessment~Computer game named Cyberball: test of social exclusion~Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~Routine blood sampling"
79983648|NCT03256864|Drug|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
79983649|NCT01317849|Drug|Folic Acid|0.8mg
79983650|NCT01317849|Drug|Vitamin B6|10mg
79983651|NCT01317849|Drug|Vitamin B12|500ug
79983652|NCT01317849|Drug|placebo|0.8 mg
79983653|NCT01317849|Drug|placebo|10mg
79983654|NCT01317849|Drug|placebo|500ug
79983655|NCT03754036|Behavioral|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
79983656|NCT01317927|Drug|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
79338917|NCT05482061|Other|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
79338918|NCT05481983|Other|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
79338919|NCT05481983|Other|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
79654000|NCT00224588|Drug|Ketamine (or placebo : isotonic saline solution)|
79654001|NCT00570622|Drug|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
79338920|NCT05488223|Dietary Supplement|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
79654002|NCT00570622|Drug|Placebo|Patients receive placebo once a day orally for 9 days
79338921|NCT05488223|Dietary Supplement|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
79654003|NCT00254475|Drug|simvastatin|
79813342|NCT00593489|Other|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
79654004|NCT00254475|Drug|valsartan|
79654005|NCT00570817|Other|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
79654006|NCT00570856|Drug|Folic acid|Folic acid 5 mg/day
79983657|NCT03256786|Behavioral|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
79983658|NCT03256708|Dietary Supplement|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
79983659|NCT03256708|Dietary Supplement|Placebo|Inactive ingredients
79983660|NCT03240796|Procedure|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
79983661|NCT03240796|Procedure|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
79983662|NCT03256474|Other|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
79983663|NCT04461483|Drug|TAK-935|TAK-935 Tablets
79983664|NCT04461483|Drug|Placebo|TAK-935 placebo-matching tablets
79983665|NCT03256084|Procedure|Blood and tumor samples|Blood and tumor samples
79654007|NCT00570856|Drug|Placebo|Placebo similar to the folic acid tablets, 1/day
79983666|NCT04486300|Procedure|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
79338922|NCT05488223|Dietary Supplement|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
79338923|NCT05493917|Biological|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
79983667|NCT04486534|Other|Musculoskeletal ultrasound|Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
79983668|NCT03240484|Diagnostic Test|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
79983669|NCT03240484|Other|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
79338924|NCT05481515|Device|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
79983670|NCT01353807|Dietary Supplement|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
79983671|NCT01353807|Dietary Supplement|Olive oil|4 1-g gelatine capsules with virgin olive oil
79338925|NCT05481515|Device|Spectrophotometry|Spectrophotometry will be used to measure skin tone
79983672|NCT03238066|Radiation|Brachytherapy|HDR/PDR brachytherapy
79983673|NCT03238066|Other|Hyperthermia|Interstitial hyperthermia
79338926|NCT03906227|Device|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
79338927|NCT05487521|Drug|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
79983674|NCT02901483|Drug|PEP503|PEP503 will be administered by intratumoral route as slow injection
79983675|NCT02901483|Drug|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7~8 weeks' radiation period.
79983676|NCT02901483|Radiation|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7~8 weeks.
79983677|NCT03256396|Procedure|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
79338928|NCT05481281|Drug|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
79654008|NCT00570895|Dietary Supplement|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
79983678|NCT03256318|Other|No intervention|No intervention; surveys/questionnaires only
79983679|NCT02874651|Drug|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
79983680|NCT02874651|Drug|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
79338929|NCT05481281|Drug|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
79338930|NCT05487443|Drug|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
79338931|NCT05481203|Behavioral|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
79338932|NCT05481203|Behavioral|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
79654009|NCT00254514|Drug|somatropin|
79654010|NCT00570934|Dietary Supplement|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
79654011|NCT00570934|Dietary Supplement|Calcium|1 gm calcium as calcium carbonate
79654012|NCT00570934|Dietary Supplement|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
79654013|NCT00570934|Drug|Placebo|Placebo
79654014|NCT00570973|Procedure|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
79983681|NCT03256006|Other|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
79983682|NCT01343589|Dietary Supplement|milk fat|39 g milk fat per day in 12 weeks
79654015|NCT00570973|Procedure|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
79983683|NCT02453932|Drug|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
79983684|NCT02453932|Drug|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
79338933|NCT05493527|Device|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~a frequency of 10 Hertz ( range, 8-12 Hz);~an inspiratory time of 50% (1:1)~an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
79338934|NCT05493527|Device|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~Peep ranging from 5 to 10 cmH2O,~Peak inspiratory pressure range 15-25 cmH2O~Rate range 40-50 breath/minute~FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
79338935|NCT02558231|Drug|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
79338936|NCT02558231|Drug|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
79983685|NCT02453932|Drug|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
79983686|NCT04387851|Behavioral|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
79338937|NCT02558231|Drug|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
79488920|NCT03162458|Drug|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
79488921|NCT03162458|Drug|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
79983687|NCT04387851|Behavioral|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
79983688|NCT04387851|Behavioral|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
79983689|NCT00700570|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
79983690|NCT00700570|Drug|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
79488922|NCT03163472|Procedure|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
79488923|NCT03163472|Procedure|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
79488924|NCT02880475|Drug|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
79654016|NCT00571051|Behavioral|Mindfulness Based Stress Reduction|8 week course in mindfulness training
79983691|NCT00700570|Drug|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
79983692|NCT02453698|Drug|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, & Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
79983693|NCT02453698|Other|Placebo|Lactose Placebo
79654017|NCT00571090|Procedure|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
79654018|NCT00254553|Drug|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
79654019|NCT00254553|Drug|Placebo|two tubes of placebo per day
79654020|NCT00571129|Procedure|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
79983694|NCT01744041|Behavioral|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
79983695|NCT01744041|Other|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
79983696|NCT03255694|Drug|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
79983697|NCT02840643|Behavioral|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
79654021|NCT00224627|Procedure|Capsule GIVEN IMAGING LTD|
79983698|NCT02840643|Behavioral|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
79983699|NCT03238144|Other|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
79338938|NCT05487365|Device|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
79338939|NCT05487365|Other|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
79338940|NCT05487287|Device|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~Finger extension~Wrist extension~Finger separation~Finger clamp"
79338941|NCT04269785|Device|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
79983700|NCT01354041|Behavioral|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
79983701|NCT03238222|Behavioral|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
79338942|NCT04269785|Device|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
79983702|NCT01354119|Procedure|Aortic stent-graft|Early intervention with aortic stent-graft
79338943|NCT04275011|Other|Progressive Resistance and Impact Exercise|Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (~80% 1RM) or 6 (~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
79338944|NCT04275011|Other|Static Balance and Postural Exercise|Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
79338945|NCT05481047|Device|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
79488925|NCT04468568|Drug|Atosiban|Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
79488926|NCT04468568|Drug|Terbutaline|Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
79654022|NCT00571168|Drug|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
79654023|NCT00571168|Drug|Placebo|Placebo capsules on day 1-4
79654024|NCT00571207|Device|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
79983703|NCT03240562|Procedure|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
79983704|NCT03240562|Drug|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
79654025|NCT00571207|Behavioral|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
79983705|NCT01354275|Other|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
79338946|NCT05480969|Other|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
79338947|NCT05480813|Device|Automated KINCISE™ impaction system versus handheld traditional mallet|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
79488927|NCT03106844|Drug|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
79338948|NCT05480813|Other|Efficiency and ergonomics analysis and physical assessments|Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
79488928|NCT03168308|Drug|Sugammadex|Sugammadex 2 mg/kg
79488929|NCT03168308|Drug|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
79488930|NCT00375128|Biological|FP9-PP (FP9 polyprotein)|
79488931|NCT00375128|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
79488932|NCT03168542|Device|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
79488933|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
79654026|NCT00571246|Drug|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
79488934|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
79654027|NCT00571246|Drug|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
79654028|NCT00571246|Other|Placebo|Participants are randomized to take placebo
79488935|NCT04253756|Device|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
79488936|NCT00375206|Biological|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
79654029|NCT00254631|Drug|Oxycodone hydrochloride|
79654030|NCT00571285|Dietary Supplement|Vitamin D3|600 IU Vitamin D3 capsule daily
79654031|NCT00571285|Dietary Supplement|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
79654032|NCT00571285|Dietary Supplement|Placebo|Placebo capsule given once a week
79654033|NCT00224666|Device|Cortex stimulation|
79654034|NCT00571363|Procedure|standard surgery|excision with 4 mm margins
79654035|NCT00571363|Procedure|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
79654036|NCT00571402|Behavioral|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
79983706|NCT01354275|Other|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
79983707|NCT01318161|Drug|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
79983708|NCT01318161|Drug|Morphine|Morphine via PCA pump
79983709|NCT03255538|Other|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
79983710|NCT03255538|Other|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
79983711|NCT03255538|Other|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
79983712|NCT03255226|Drug|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
79983713|NCT03237988|Drug|CPI-444 Capsules|100mg Capsule
79983714|NCT03237988|Drug|CPI-444 Tablets|100mg Tablets
79983715|NCT03237832|Drug|ARN-6039|Ascending doses per Cohort
79983716|NCT03237832|Other|Placebo|Placebo to match ARN-6039
79983717|NCT03237676|Other|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
79488937|NCT04706780|Other|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
79654037|NCT00571402|Behavioral|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
79654038|NCT00571480|Other|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
79654039|NCT00571480|Other|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
79654040|NCT00571480|Other|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
79338949|NCT05480501|Biological|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
79338950|NCT05486819|Drug|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
79338951|NCT05480423|Behavioral|Mindfulness-based intervention|1. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
79654041|NCT00224705|Device|Molecular Adsorbent Recirculating System (MARS®)|
79654042|NCT00571558|Drug|aminolevulinic acid hydrochloride|Given PO
79654043|NCT00571558|Drug|photodynamic therapy|Undergo photodynamic therapy
79654044|NCT00571558|Other|laboratory biomarker analysis|Correlative studies
79338952|NCT05480345|Diagnostic Test|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
79338953|NCT02554877|Drug|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
79654045|NCT02961231|Biological|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
79654046|NCT02961231|Biological|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
79654047|NCT02961231|Biological|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
79654048|NCT02961231|Biological|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
79654049|NCT00571636|Drug|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
79654050|NCT00571636|Drug|5% glucose solution|ev continuous infusion
79654051|NCT00224744|Device|ultracision|Surgery by Ultracision
79338954|NCT02554877|Drug|Placebo|oral tablet
79338955|NCT05486741|Other|Optical cehernce tomography|OCT macula and disc
79488938|NCT03115177|Drug|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
79338956|NCT05493137|Other|No intervention will be provided|No intervention will be provided, this is an observational study
79338957|NCT05480267|Procedure|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
79338958|NCT05480189|Other|Non-intervention|Non-intervention,with real world study
79488939|NCT03115177|Drug|Cefazolin|
79488940|NCT04201418|Drug|Patisiran|Patisiran-lipid complex injection, for intravenous use
79654052|NCT00224744|Device|classical lymphadenectomy|classical lymphadenectomy
79338959|NCT05493059|Other|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
79654053|NCT00571675|Drug|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
79338960|NCT05493059|Other|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~Dermatology Life Quality Index (DLQI)~Treatment Satisfaction Questionnaire for Medication (TSQM)"
79654054|NCT00571675|Drug|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
79654055|NCT02961270|Drug|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
79338961|NCT05492981|Behavioral|Enhanced (intervention) education|See arm description
79338962|NCT04235465|Other|Dynamic Gait Index|The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
79338963|NCT05486429|Combination Product|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~Complete history taking with stress on:~Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~History of intake of lipid lowering drugs.~Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~Laboratory Investigation:~1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~.2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~Radiological Investigation:~1.Abdominal ultrasound.~FIB - 4 it combines platelets count, ALI, AST and age.~AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10^9/L) ×100."
79654056|NCT00571753|Drug|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
79654057|NCT00571753|Drug|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
79983718|NCT03237676|Other|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
79983719|NCT03240250|Procedure|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
79654058|NCT00224783|Biological|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
79654059|NCT00224783|Biological|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
79654060|NCT04580173|Diagnostic Test|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
79654061|NCT00254709|Drug|Sirolimus|
79654062|NCT00571831|Procedure|intraocular lens implantation|Intraocular lens implantation
79654063|NCT00224822|Drug|Aripiprazole|
79654064|NCT00571870|Drug|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
79983720|NCT03240250|Procedure|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
79654065|NCT00254748|Drug|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
79654066|NCT00254748|Drug|Placebo|placebo
79654067|NCT00571909|Procedure|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
79654068|NCT00224861|Behavioral|Self-Management|
79654069|NCT00224861|Behavioral|Adherence|
79983721|NCT03237598|Other||
79983722|NCT03239782|Behavioral|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
79983723|NCT02455726|Dietary Supplement|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
79338964|NCT05492903|Behavioral|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
79654070|NCT00572026|Drug|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
79338965|NCT05486351|Other|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
79488941|NCT02962609|Other|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
79654071|NCT00572065|Drug|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
79813343|NCT02551900|Other|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
79983724|NCT02455726|Dietary Supplement|Fructose|Oral fructose 10 g twice a day
79983725|NCT02455726|Drug|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
79983726|NCT02455726|Drug|Pregabalin|Pregabalin 25 mg at 8 pm
79983727|NCT04488328|Other|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
79983728|NCT04488172|Dietary Supplement|Multi-vitamin supplementation|Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
79983729|NCT03237520|Other|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
79983730|NCT03237520|Other|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
79983731|NCT03237754|Device|tDCS device from neuroConn|weak electrical direct current stimulation
79983732|NCT03237442|Biological|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2*10^6 cells) subconjunctival injection
79983733|NCT03237442|Biological|placebo|Saline injection
79983734|NCT04488016|Drug|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
79983735|NCT04488016|Drug|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
79983736|NCT04488016|Drug|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
79983737|NCT04488016|Drug|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
79983738|NCT04488016|Drug|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
79338966|NCT05475587|Other|Routine care|Both two groups received the same routine care.
79338967|NCT05480033|Behavioral|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
79983739|NCT04488016|Drug|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
79983740|NCT04488016|Drug|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
79983741|NCT04488016|Drug|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
79338968|NCT05479955|Other|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
79488942|NCT02962609|Other|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
79983742|NCT03239704|Behavioral|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
79338969|NCT05479955|Other|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
79338970|NCT05479877|Drug|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
79338971|NCT05479877|Drug|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
79338972|NCT05492747|Other|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
79338973|NCT05492669|Drug|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
79338974|NCT05492669|Drug|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
79338975|NCT02554721|Drug|Cilostazol|
79338976|NCT02554721|Drug|Acetylsalicylic acid|
79338977|NCT02554721|Drug|Clopidogrel|
79338978|NCT03810911|Drug|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
79488943|NCT02962687|Behavioral|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
79488944|NCT02962687|Behavioral|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
79813344|NCT02551900|Other|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
79983743|NCT03239704|Other|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
79488945|NCT03174158|Drug|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
79654072|NCT00572065|Drug|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
79654073|NCT00234897|Drug|adalimumab|
79488946|NCT03174158|Behavioral|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
79338979|NCT03801005|Biological|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
79338980|NCT02552225|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
79338981|NCT02552225|Other|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
79654074|NCT00572104|Other|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
79654075|NCT00572104|Other|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
79813345|NCT02551900|Other|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
79813346|NCT00446641|Drug|Cilostazol|cilostazol 100mg twice a day for 4 weeks
79813347|NCT00446641|Drug|placebo|placebo 1 tablet twice a day matching for cilostazol
79488947|NCT03174158|Behavioral|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
79488948|NCT04736641|Other|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
79654076|NCT00572143|Other|ca coli follow-up by GP|patients randomized to follow up by GP
79654077|NCT00572182|Drug|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
79338982|NCT05474261|Procedure|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
79338983|NCT05473949|Drug|Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
79338984|NCT05473949|Drug|Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
79654078|NCT02961153|Other|death|
79654079|NCT00224939|Drug|Potassium Chloride|
79813348|NCT00646282|Drug|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH <300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
79813349|NCT02551588|Procedure|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
79813350|NCT00814060|Drug|neratinib|HKI-272
79813351|NCT00792636|Drug|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
79813352|NCT00792636|Drug|sumatriptan tablet|sumatriptan 85mg
79813353|NCT00792636|Drug|naproxen sodium tablet|Naproxen sodium 500mg
79813354|NCT00446563|Drug|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
79813355|NCT00446563|Drug|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
79488949|NCT00422630|Behavioral|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
79488950|NCT00422630|Behavioral|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
79338985|NCT04424069|Procedure|Refractive surgery|Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
79338986|NCT05492279|Dietary Supplement|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
79338987|NCT05492279|Dietary Supplement|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
79338988|NCT02552147|Drug|Transdermal nicotine|
79654080|NCT00572221|Behavioral|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
79338989|NCT02552147|Other|Transdermal placebo|
79654081|NCT00572221|Behavioral|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
79654082|NCT00572299|Drug|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
79654083|NCT00572338|Other|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
79654084|NCT00234936|Drug|Adalimumab|
79654085|NCT00234936|Drug|Methotrexate|
79654086|NCT00572377|Drug|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
79654087|NCT00572377|Drug|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
79654088|NCT00413075|Drug|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
79654089|NCT00572494|Device|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
79813356|NCT00446563|Drug|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
79338990|NCT05479487|Drug|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
79338991|NCT05479487|Drug|Fluzoparib Monotherapy|Fluzoparib 150mg bid
79338992|NCT05479409|Radiation|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
79338993|NCT05479253|Diagnostic Test|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
79338994|NCT05479175|Drug|Ibuprofen|Ibuprofen
79338995|NCT05479175|Device|Diode laser|Diode laser
79338996|NCT05479175|Device|Nonactive Diode laser|Nonactive Diode laser
79338997|NCT05472857|Biological|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
79338998|NCT05491889|Biological|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
79338999|NCT02534935|Biological|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
79339000|NCT02534935|Biological|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
79339001|NCT05430295|Procedure|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
79813357|NCT00446563|Drug|Losartan|100 mg tablets taken orally once daily in the morning.
79339002|NCT05430295|Procedure|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
79339003|NCT05429359|Other|CPET: CardioPulmonary Exercise Test for CSII users|"Baseline~VO2peak measurement~Breakfast~100% bolus insulin~CSII users: 100% basal"
79339004|NCT05429359|Other|AEX1: Aerobic Exercise Test 1 for CSII users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~CSII users: -2h target 150 mg/dL"
79488951|NCT00422630|Behavioral|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
79488952|NCT03115411|Device|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
79488953|NCT03176654|Procedure|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
79488954|NCT03176654|Procedure|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
79488955|NCT03115801|Drug|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
79654090|NCT00572494|Device|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
79654091|NCT00572611|Drug|[14C]-bilastine|Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only
79339005|NCT05429359|Other|AEX2: Aerobic Exercise Test 2 for CSII users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~CSII users: -1h target 150 mg/dL"
79654092|NCT00572650|Drug|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
79339006|NCT05429359|Other|CPET: CardioPulmonary Exercise Test for MDI users|"Baseline~VO2peak measurement~Breakfast~100% bolus insulin~MDI users: 100% basal"
79339007|NCT05429359|Other|AEX1: Aerobic Exercise Test 1 for MDI users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~MDI users: 50% basal"
79654093|NCT00413270|Drug|nilotinib|
79654094|NCT00572689|Drug|Exenatide|10 microgram injected sub-cutaneously once
79654095|NCT00572689|Genetic|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
79339008|NCT05429359|Other|AEX2: Aerobic Exercise Test 2 for MDI users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~MDI users: 80% basal"
79339009|NCT02544451|Drug|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
79339010|NCT02544451|Drug|LUM/IVA|LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
79339011|NCT05455333|Other|Questionnaires|Sends and returns questionnaires to families.
79339012|NCT02544373|Device|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
79813358|NCT00650806|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
79339013|NCT02551991|Drug|nal-IRI|
79339014|NCT02551991|Drug|5 fluorouracil|
79339015|NCT02551991|Drug|Leucovorin|
79339016|NCT02551991|Drug|Oxaliplatin|
79339017|NCT04268615|Other|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
79339018|NCT04268615|Other|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
79339019|NCT04268615|Other|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
79488956|NCT03115801|Drug|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
79488957|NCT03115801|Radiation|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
79488958|NCT03115801|Drug|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
79488959|NCT00422708|Procedure|Local anesthesia|
79654096|NCT00572767|Drug|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
79654097|NCT00572767|Other|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
79654098|NCT00572806|Drug|insulin aspart|
79813359|NCT00650806|Drug|Placebo|One matching placebo capsule orally once daily for 12 weeks.
79488960|NCT03177512|Behavioral|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
79488961|NCT03117517|Drug|Metformin|Metformin (1000 mg)
79654099|NCT00572845|Other|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
79654100|NCT00224978|Drug|Chloroquine|
79654101|NCT00572884|Other|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
79654102|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
79813360|NCT00863057|Drug|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
79813361|NCT00863057|Drug|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
79813362|NCT00863057|Drug|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
79488962|NCT03117517|Drug|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
79339020|NCT05472389|Other|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
79488963|NCT00375284|Drug|Pramipexole|
79488964|NCT02966275|Device|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
79488965|NCT02966275|Device|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
79488966|NCT02967367|Device|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
79488967|NCT02967367|Device|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
79488968|NCT02967367|Device|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
79654103|NCT00573001|Drug|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
79654104|NCT00573001|Drug|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
79339021|NCT05472389|Other|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children < 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
79339022|NCT05491811|Drug|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
79339023|NCT05491811|Drug|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
79339024|NCT05472233|Procedure|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
79654105|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
79813363|NCT00863057|Drug|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
79339025|NCT05491733|Drug|APX001|Low-load oral tablet
79339026|NCT05491733|Drug|APX001A|High-load oral tablet
79339027|NCT05478785|Drug|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
79339028|NCT05471297|Other|There is no intervention|There is no any intervention
79339029|NCT05478395|Other|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
79813364|NCT02552602|Dietary Supplement|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
79339030|NCT05478317|Procedure|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
79339031|NCT05478317|Procedure|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
79488969|NCT05405101|Procedure|ablation of aldosterone secreting adenoma|Radio frequency ablation to Conn's adenoma(s)
79488970|NCT05405101|Procedure|Unilateral adrenalectomy|Unilateral adrenalectomy for aldosterone secreting adenoma
79488971|NCT03795350|Drug|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
79488972|NCT03118843|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
79654106|NCT00254787|Drug|IR (Immediate-Release) quetiapine fumarate (drug)|
79654107|NCT03453853|Device|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
79654108|NCT03453775|Device|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
79813365|NCT02552602|Dietary Supplement|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
79488973|NCT03724370|Behavioral|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
79654109|NCT03453775|Device|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
79654110|NCT00225056|Drug|docetaxel and capecitabine|
79654111|NCT03453736|Other|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
79813366|NCT02552602|Dietary Supplement|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
79813367|NCT00814216|Drug|QAV680|
79813368|NCT00814216|Drug|Matching placebo for QAV680|
79813369|NCT00814216|Drug|Fluticasone Propionate|
79813370|NCT00829166|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
79983744|NCT03239704|Behavioral|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
79983745|NCT03239860|Drug|GNbAC1 Monoclonal Antibody|Monthly IV
79983746|NCT04486690|Drug|Ketofol (propofol to ketamine ratio 1:1)|"Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min"
79339032|NCT01661933|Biological|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
79339033|NCT01661933|Biological|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
79339034|NCT02865551|Device|Foley catheter|Extended bladder catheterization after epidural anesthesia.
79488974|NCT03724370|Other|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
79654112|NCT00254826|Biological|YF-VAX® plus saline|YF-VAX® plus saine
79654113|NCT00254826|Biological|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
79654114|NCT03453697|Device|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
79654115|NCT00225173|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
79654116|NCT00225173|Drug|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
79983747|NCT04486690|Drug|propofol|"Propofol infusion, 25-150 mcg/kg/min.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min."
79983748|NCT03237364|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
79983749|NCT03240094|Other|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
79488975|NCT04736732|Other|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
79983750|NCT03255304|Behavioral|health mindest|groups be confronted with health aspects of food items
79813371|NCT00829166|Drug|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
79813372|NCT00829166|Drug|Capecitabine|Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
79813373|NCT00799266|Drug|Zoledronic acid|intravenous infusion
79813374|NCT00799266|Drug|Placebo|intravenous infusion
79813375|NCT00650104|Drug|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
79488976|NCT05401513|Other|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
79983751|NCT03255304|Behavioral|palatability mindset|groups be confronted with palatability aspects of food items
79654117|NCT00225173|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
79654118|NCT00225173|Drug|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
79654119|NCT00225173|Drug|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
79339035|NCT02865551|Device|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
79339036|NCT02865551|Drug|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
79339037|NCT02797769|Drug|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
79339038|NCT02797769|Drug|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
79488977|NCT05365022|Device|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
79488978|NCT03119389|Behavioral|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
79654120|NCT00225173|Drug|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
79654121|NCT00225173|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
79654122|NCT00225173|Drug|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
79654123|NCT00225173|Drug|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
79654124|NCT00234975|Drug|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
79654125|NCT00573196|Radiation|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
79654126|NCT00573274|Device|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
79654127|NCT00235014|Drug|trandolapril|2 mg QD
79654128|NCT00235014|Drug|trandolapril/verapamil|180/2 mg QD
79654129|NCT00235014|Drug|placebo|1 tablet QD
79654130|NCT00235014|Drug|verapamil|SR 240 mg QD
79654131|NCT00225290|Drug|Thalidomide(Thado)|
79654132|NCT00573352|Radiation|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
79488979|NCT02967991|Device|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
79654133|NCT00573547|Drug|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
79654134|NCT00573586|Device|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
79654135|NCT00225329|Procedure|Labour assessment and support|
79654136|NCT00573664|Drug|Gabapentin|single oral dose of 600mg gabapentin
79654137|NCT00573664|Other|lactose|Single dose
79813376|NCT00808054|Drug|EMLA|0.5g topical EMLA
79813377|NCT02552134|Other|exercise training|
79983752|NCT03255148|Drug|Oxytocin|Syntocinon nasal spray
79983753|NCT03255148|Drug|Placebo|Placebo nasal spray
79339039|NCT05471219|Other|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
79488980|NCT05400421|Device|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
79813378|NCT02552134|Other|recommendation to be active|
79339040|NCT05478083|Drug|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
79339041|NCT02750657|Genetic|Molecular Profiling|Whole Genome Sequencing
79339042|NCT02544217|Drug|KH176|
79339043|NCT02544217|Drug|placebo|
79339044|NCT05427565|Other|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
79339045|NCT05427565|Other|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
79339046|NCT02533999|Device|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
79339047|NCT02533999|Device|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
79339048|NCT02306551|Other|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
79813379|NCT04108806|Procedure|Endovascular therapy|Ballon dialtation of the diseased artery
79654138|NCT00573703|Procedure|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
79654139|NCT00573703|Procedure|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
79488981|NCT02222922|Drug|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
79488982|NCT02222922|Drug|fluconazole|combination drug used for drug-drug interaction sub-study
79654140|NCT00573742|Drug|Candesartan Cilexeotil 16mg|
79488983|NCT02222922|Drug|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
79654141|NCT00254865|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
79488984|NCT02222922|Drug|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
79488985|NCT03503942|Behavioral|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
79654142|NCT00573781|Dietary Supplement|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
79654143|NCT00573781|Dietary Supplement|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
79654144|NCT00573781|Dietary Supplement|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
79488986|NCT03503942|Drug|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
79654145|NCT00225368|Device|Insecticide treated bednets|
79654146|NCT00573820|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
79654147|NCT04579822|Biological|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
79488987|NCT03503942|Other|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
79488988|NCT03122587|Device|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
79654148|NCT04579861|Other|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
79654149|NCT00225407|Drug|Smoking of cannabis cigarettes (different strength)|
79654150|NCT04580056|Procedure|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
79654151|NCT04719468|Other|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
79654152|NCT04579744|Other|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
79654153|NCT00225446|Device|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
79488989|NCT03122587|Device|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
79488990|NCT03122587|Device|Active sham transcranial alternating current stimulation|Active sham (placebo)
79488991|NCT03791138|Other|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
79654154|NCT00574015|Drug|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
79654155|NCT00574015|Drug|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
79654156|NCT00574054|Radiation|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
79983754|NCT04487626|Device|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
79654157|NCT00255021|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
79339049|NCT05455177|Other|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
79654158|NCT00225485|Drug|Effexor XR|
79339050|NCT02533531|Device|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
79654159|NCT00574093|Drug|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
79654160|NCT00574210|Drug|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
79813380|NCT00814450|Device|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
79983755|NCT03234946|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
79339051|NCT05426707|Device|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
79654161|NCT00574210|Drug|Placebo|Placebo Tablets administered twice per day
79654162|NCT00574366|Drug|erlotinib|"Levels:~1 Erlotinib 50 mg/d~2 Erlotinib 50 mg/d~1 Erlotinib 100 mg/d~2 Erlotinib 100 mg/d~3 Erlotinib 150 mg/d~4 Erlotinib 150 mg/d"
79654163|NCT00574366|Drug|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~RAD001 2.5 mg per day~RAD001 5 mg per day~RAD001 10 mg per day~RAD001 10 mg per day"
79983756|NCT03254914|Procedure|Home Blood Pressure|Measure Home Blood Pressure
79983757|NCT03237130|Procedure|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
79983758|NCT03234868|Device|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
79488992|NCT05364398|Procedure|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
79488993|NCT02161146|Drug|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
79654164|NCT00225524|Drug|Effexor XR|
79654165|NCT00574444|Procedure|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
79339052|NCT05426707|Device|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
79488994|NCT02161146|Drug|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
79488995|NCT02161146|Drug|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
79654166|NCT00574483|Drug|quinacrine|100 mg day
79654167|NCT00235092|Device|Cypher Sirolimus-Eluting Stent|
79654168|NCT00235092|Device|Taxus Paclitaxel-Eluting Stent|
79813381|NCT05102734|Drug|Nitroglycerin Topical Product|Topical nitroglycerin solution
79813382|NCT05621226|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
79813383|NCT00812188|Other|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
79813384|NCT00812188|Other|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
79654169|NCT00574522|Radiation|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
79813385|NCT00814528|Drug|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
79654170|NCT00225563|Device|Electronic Health Record|e-prescribing methods
79654171|NCT00574600|Biological|SAAVI DNA-C2 vaccine|DNA vaccine
79339053|NCT02533453|Biological|Bydureon|exenatide once weekly
79339054|NCT05424835|Drug|SHR-A1811|SHR-A1811
79654172|NCT00574600|Biological|SAAVI MVA-C vaccine|Boost vaccine
79654173|NCT00574600|Biological|Placebo|Placebo vaccine
79339055|NCT05424835|Drug|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
79654174|NCT00574639|Drug|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
79654175|NCT00574639|Drug|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
79339056|NCT05424601|Behavioral|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
79488996|NCT03447782|Drug|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
79654176|NCT00574678|Other|Tear collection|"A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
79654177|NCT00574717|Procedure|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
79339057|NCT05424601|Behavioral|PsyPills|PsyPills is a mobile app designed to provide personalized psychological pills
79339058|NCT02533375|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79339059|NCT05410873|Drug|MitoQ Compound|Mitoquinol mesylate
79339060|NCT05410873|Drug|Placebo|Placebo
79339061|NCT05410795|Diagnostic Test|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
79339062|NCT02551055|Drug|MLN1117|MLN1117 Tablets
79339063|NCT02551055|Drug|TAK-659|TAK-659 Tablets
79488997|NCT03109951|Drug|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
79654178|NCT00225602|Behavioral|Assertive Community Treatment|
79654179|NCT00225602|Behavioral|Treatment in Community Mental Health Center|
79654180|NCT00255255|Drug|Budesonide/Formoterol|
79654181|NCT00574756|Drug|ranolazine|extended release 500 mg twice a day for two weeks
79654182|NCT03453658|Procedure|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
79654183|NCT03453658|Procedure|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
79339064|NCT02551055|Drug|Alisertib|Alisertib Tablets
79339065|NCT02551055|Drug|Paclitaxel|Paclitaxel intravenous infusion
79339066|NCT02551055|Drug|Docetaxel|Docetaxel intravenous infusion
79488998|NCT03408704|Other|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~The Swedish guidelines~Example of cases~Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
79488999|NCT03123055|Drug|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
79489000|NCT03123055|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
79983759|NCT03234868|Device|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
79983760|NCT03237052|Other|model|a model that has been established in advance.
79983761|NCT03237052|Other|non-model|real-world psychiatrist decision
79654184|NCT03453424|Procedure|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
79489001|NCT03340532|Other|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
79983762|NCT03237208|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
79983763|NCT03237208|Device|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
79983764|NCT04487938|Other|No intervention utilised|No intervention utilised
79983765|NCT03234712|Drug|ABBV-321|Intravenous infusion
79983766|NCT04876794|Device|ABLE Exoskeleton|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
79983767|NCT02455960|Dietary Supplement|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
79983768|NCT02455960|Dietary Supplement|Placebo|
79983769|NCT03236818|Drug|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
79983770|NCT04809246|Other|'One-stop-shop' hepatitis clinic|Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
79983771|NCT04486144|Other|Proprietary extract of Nerium oleander|This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
79983772|NCT04760808|Diagnostic Test|Baseline Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
79983773|NCT04760808|Radiation|Initial 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
79339067|NCT05470673|Procedure|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
79339068|NCT05470673|Procedure|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
79339069|NCT05470361|Procedure|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
79339070|NCT05459285|Biological|14028 injection|14028 injection, single dose, s.c. injection
79983774|NCT04760808|Diagnostic Test|6-month Follow-up Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
79983775|NCT04760808|Radiation|6-month Follow-up 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
79983776|NCT03236896|Behavioral|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
79983777|NCT03236896|Behavioral|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
79339071|NCT05459285|Biological|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
79489002|NCT03340532|Other|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
79813386|NCT00814528|Drug|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
79339072|NCT02542943|Device|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
79339073|NCT02542943|Device|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
79339074|NCT02542943|Other|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
79339075|NCT02542943|Drug|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
79339076|NCT03284957|Drug|Amcenestrant|"Pharmaceutical form: capsule~Route of administration: oral"
79339077|NCT03284957|Drug|Palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
79339078|NCT03284957|Drug|Alpelisib|"Pharmaceutical form: tablet~Route of administration: oral"
79339079|NCT03284957|Drug|Everolimus|Pharmaceutical form: tablet
79339080|NCT03284957|Drug|Abemaciclib|Pharmaceutical form: tablet
79339081|NCT02542865|Dietary Supplement|Fortified malt based food|Fortified malt based food
79489003|NCT03340532|Other|Sleep hygiene video|Contain information on better sleep hygiene
79489004|NCT03124069|Device|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
79489005|NCT02969317|Drug|Tiotropium|Fixed dose combination
79489006|NCT02969317|Drug|Olodaterol|Fixed dose combination
79489007|NCT03314168|Other|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
79813387|NCT00915174|Drug|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
79813388|NCT00814606|Drug|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
79654185|NCT03453424|Procedure|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
79813389|NCT00814606|Drug|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
79813390|NCT00814606|Drug|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
79339082|NCT05477771|Procedure|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
79489008|NCT03314168|Other|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
79489009|NCT00375362|Drug|Nitroderm patch|
79489010|NCT03307226|Behavioral|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
79654186|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
79654187|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
79654188|NCT00235131|Device|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
79654189|NCT00235131|Device|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
79654190|NCT03453346|Drug|Sofosbuvir|Generic sofosbuvir tablet 400 mg
79654191|NCT03453346|Drug|Ribavirin|Ribavirin was provided in 100-mg tablets.
79813391|NCT00814762|Biological|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
79813392|NCT00814762|Biological|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
79813393|NCT00654238|Drug|sorafenib|400mg PO BID daily
79813394|NCT00862979|Drug|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
79489011|NCT03307226|Behavioral|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
79489012|NCT03124693|Device|Rainbow DCI pulse oximeter sensor|
79489013|NCT03288194|Behavioral|Problem-Solving Treatment|
79489014|NCT03288194|Behavioral|Time Management|
79654192|NCT00575068|Drug|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A & II-B - Dosage start at the MTD (up to 375 mg/m2)
79813395|NCT00862979|Drug|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
79339083|NCT03644927|Behavioral|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
79489015|NCT03124771|Device|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
79489016|NCT05357300|Device|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
79489017|NCT05347082|Drug|Cholecalciferol|Tablets of 4000 IU
79489018|NCT05235139|Device|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
79489019|NCT05235139|Device|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
79489020|NCT03124927|Device|DCI pulse oximeter sensor|
79489021|NCT03125005|Device|Rainbow Universal Pulse Oximeter Sensor|
79654193|NCT00575107|Other|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
79489022|NCT03087578|Other|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
79489023|NCT03087578|Drug|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
79489024|NCT02971735|Other|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
79489025|NCT02907086|Other|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
79489026|NCT05339282|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
79489027|NCT02975557|Drug|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
79654194|NCT00575107|Other|Exercise|Standard training of leg extension
79654195|NCT00225680|Device|drug eluting coronary stent|
79813396|NCT00862979|Drug|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
79813397|NCT00862979|Drug|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
79813398|NCT00862979|Drug|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
79489028|NCT02975557|Drug|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
79654196|NCT00575224|Drug|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
79654197|NCT00235170|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
79654198|NCT00590941|Procedure|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
79983778|NCT03236974|Drug|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
79983779|NCT03236974|Drug|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
79983780|NCT03748043|Drug|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
79654199|NCT00225719|Drug|rHDL|
79654200|NCT00255294|Drug|Cellulose sulfate vaginal gel|
79654201|NCT00591058|Drug|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
79654202|NCT00591136|Drug|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
79654203|NCT00591292|Drug|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
79654204|NCT00591331|Drug|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
79654205|NCT00591331|Drug|placebo|
79654206|NCT00591448|Other|Virtual Reality (VR)|See above
79654207|NCT00235209|Device|Collagen ORC Antimicrobial Matrix (CAM)|
79654208|NCT00225836|Device|OVA (TENS apparatus)|
79654209|NCT00591487|Drug|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
79654210|NCT03452215|Behavioral|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
79654211|NCT03452215|Behavioral|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
79489029|NCT02975557|Drug|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
79654212|NCT00255333|Drug|INNO-105|
79654213|NCT03452059|Device|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
79654214|NCT00225875|Drug|Mabthéra|
79654215|NCT03452020|Device|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
79654216|NCT03451981|Procedure|mechanical debridement and chemical decontamination|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.
79813399|NCT00862979|Drug|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
79813400|NCT02605356|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
79813401|NCT02605356|Drug|Placebo|
79983781|NCT03748043|Drug|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
79983782|NCT03254992|Device|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
79983783|NCT03254992|Device|ASD - Tangible task|Experimental group using Keyboard with more real activity.
79983784|NCT03254992|Device|TD - Abstract task|Control group using Kinect with more virtual activity.
79983785|NCT03254992|Device|TD - Tangible task|Control group using Keyboard with more real activity.
79983786|NCT03750773|Drug|Gabapentin 600mg|Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
79983787|NCT03750773|Drug|Placebo oral capsule|Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
79983788|NCT02874924|Drug|Rapamycin|treatment
79983789|NCT02874924|Drug|Placebo|control
79983790|NCT02874924|Drug|Rapamycin|No placebo control in this substudy group
79983791|NCT03254836|Other|Standard of care|Elective radical surgery for adenocarcinoma.
79339084|NCT03644927|Behavioral|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
79983792|NCT04425863|Drug|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
79983793|NCT04425863|Other|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
79983794|NCT04425863|Other|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
79339085|NCT03611153|Drug|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
79339086|NCT03611153|Drug|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
79339087|NCT02542631|Device|Bolus Insulin Patch (Calibra Finesse)|
79654217|NCT03451981|Procedure|Er:YAG laser|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
79983795|NCT01370772|Drug|Rituximab|"Cycle 1 Rituximab : 375 mg/m² i.v on day 1~Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
79983796|NCT01370772|Drug|Rituximab|"Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
79983797|NCT01370772|Drug|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
79983798|NCT01370772|Drug|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
79983799|NCT03254524|Other|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
79813402|NCT02605356|Drug|Bortezomib|
79813403|NCT02605356|Drug|Dexamethasone|
79339088|NCT02542631|Device|Insulin Pen (Novo-Nordisk FlexPen®)|
79339089|NCT05459051|Diagnostic Test|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and iFR.
79339090|NCT05459051|Diagnostic Test|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and iFR.
79654218|NCT03451981|Procedure|Air Powder|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
79654219|NCT03451942|Drug|FLOT regimen chemotherapy|FLOT regimen chemotherapy
79654220|NCT03451942|Procedure|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
79654221|NCT00255372|Drug|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
79654222|NCT00255372|Drug|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
79654223|NCT00225914|Drug|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
79654224|NCT00225914|Drug|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
79654225|NCT03451903|Drug|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
79654226|NCT03451903|Procedure|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
79654227|NCT03451864|Procedure|Vaginal delivery|classic vaginal delivery
79983800|NCT03747965|Biological|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
79983801|NCT03254446|Drug|TRC150094|TRC150094 Tablet 45 mg
79654228|NCT03451864|Procedure|Cesarean Section|routine lower segment cesarean scetion
79654229|NCT00235248|Drug|Warfarin|Warfarin
79983802|NCT03254446|Drug|Placebo|Matching Placebo Tablet
79983803|NCT01365078|Dietary Supplement|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
79654230|NCT00235248|Drug|Clopidogrel-aspirin|Clopidogrel-aspirin
79654231|NCT04574323|Radiation|Curative radiotherapy|Standard curative radiotherapy
79654232|NCT04574323|Other|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
79654233|NCT00225992|Drug|Arsenic Trioxide|
79654234|NCT03451435|Drug|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
79813404|NCT00812266|Drug|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
79813405|NCT00812266|Drug|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
79813406|NCT00814840|Device|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
79983804|NCT01365078|Dietary Supplement|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
79339091|NCT02542397|Genetic|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
79654235|NCT04719195|Other|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
79654236|NCT04574596|Other|no Intervention|This is an observational study. There is no intervention
79654237|NCT04575064|Other|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
79339092|NCT05457491|Biological|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
79654238|NCT04575064|Drug|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
79654239|NCT03451318|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
79654240|NCT03451318|Procedure|tonsillar adenoidectomy|tonsillar adenoidectomy
79654241|NCT03451318|Procedure|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
79654242|NCT03451240|Behavioral|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
79813407|NCT00814840|Device|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
79339093|NCT05457491|Other|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
79339094|NCT05457491|Other|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
79339095|NCT05457491|Other|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
79339096|NCT05457491|Other|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
79339097|NCT05477615|Drug|Lazertinib|- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
79339098|NCT05477615|Drug|Pemetrexed|- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
79339099|NCT05477615|Drug|Carboplatin|- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
79339100|NCT05477537|Other|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
79654243|NCT04573894|Diagnostic Test|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
79654244|NCT04574284|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79654245|NCT04574284|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
79489030|NCT02642588|Dietary Supplement|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
79489031|NCT02976181|Device|IPG|Patient might require IPG device to be implanted under standard of care
79654246|NCT04574050|Other|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
79654247|NCT00255450|Drug|ferumoxytol or placebo|
79983805|NCT03234634|Procedure|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
79654248|NCT04574128|Procedure|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
79654249|NCT00226031|Procedure|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
79654250|NCT04573855|Biological|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
79654251|NCT04574206|Behavioral|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
79339101|NCT05477537|Other|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
79813408|NCT00483379|Biological|alglucosidase alfa|intravenous infusion
79339102|NCT02549339|Drug|LEO 43204 gel|
79983806|NCT01370928|Device|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
79983807|NCT01370928|Device|Standard colonoscope|Screening colonoscopy
79654252|NCT04574206|Behavioral|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
79654253|NCT04574011|Diagnostic Test|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
79654254|NCT04721379|Behavioral|Meditation|"Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
79654255|NCT00226109|Drug|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
79654256|NCT04573426|Drug|Acetaminophen|1,000mg liquid acetaminophen
79654257|NCT04573426|Drug|Placebo|Liquid placebo solution
79654258|NCT04573426|Behavioral|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
79339103|NCT02549339|Drug|Vehicle gel|
79339104|NCT05469503|Dietary Supplement|TOTUM-854|12 weeks of TOTUM-854 supplementation
79339105|NCT05469503|Dietary Supplement|Placebo|12 weeks of placebo supplementation
79339106|NCT02549027|Drug|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
79339107|NCT02549027|Drug|MK-6096|Oral MK-6096 tablets (5 mg strength)
79489032|NCT04736810|Biological|AK105|IV infusion
79489033|NCT04736810|Drug|Cisplatin|IV infusion
79489034|NCT04736810|Drug|Gemcitabine|IV infusion
79489035|NCT04736810|Drug|Anlotinib hydrochloride|Oral administration
79489036|NCT05267990|Diagnostic Test|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
79489037|NCT03132571|Drug|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
79489038|NCT03132571|Drug|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
79489039|NCT03132571|Other|Placebo|Oral placebo taken once daily for the course of the study (16 week)
79489040|NCT02735720|Other|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
79489041|NCT02735720|Other|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
79489042|NCT02374424|Drug|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~Dexamethasone 40 mg day 1-4 of every cycles~Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
79489043|NCT03134209|Device|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
79489044|NCT03134209|Other|Monocryl + Dermabond|conventional sutures and skin adhesive glue
79489045|NCT03134209|Other|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
79339108|NCT02549027|Drug|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
79339109|NCT05477303|Other|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
79339110|NCT05478629|Other|Survey|Questioning through google forms
79339111|NCT02709395|Device|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
79339112|NCT02529553|Drug|LY3076226|Administered IV
79983808|NCT03234244|Drug|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
79339113|NCT02547935|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
79489046|NCT02596412|Other|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
79983809|NCT03234244|Drug|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
79983810|NCT03234244|Drug|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
79983811|NCT03254680|Dietary Supplement|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
79339114|NCT02547935|Drug|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
79339115|NCT02547935|Drug|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
79489047|NCT03134989|Device|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
79489048|NCT02002130|Drug|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
79654259|NCT04573426|Behavioral|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
79983812|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
79339116|NCT04258111|Biological|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
79339117|NCT04258111|Biological|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
79339118|NCT02554019|Biological|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
79339119|NCT02554019|Biological|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
79489049|NCT02002130|Drug|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
79489050|NCT02002130|Drug|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
79489051|NCT03135379|Device|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
79339120|NCT05468411|Other|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
79339121|NCT05468411|Other|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
79654260|NCT00235287|Drug|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
79654261|NCT00235287|Drug|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
79654262|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
79339122|NCT05476835|Combination Product|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
79339123|NCT02327169|Drug|MLN2480|MLN2480 tablets.
79654263|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
79654264|NCT00226148|Procedure|Use of a membrane to cover bonedefects around implant|
79654265|NCT00226148|Device|Use of bonechips to fill up defects around implant|
79339124|NCT02327169|Drug|MLN0128|MLN0128 capsules.
79339125|NCT02327169|Drug|Alisertib|Alisertib tablets.
79339126|NCT02327169|Drug|Paclitaxel|Paclitaxel IV infusion.
79654266|NCT00226148|Procedure|Use of membrane and bonechips to manage defects|
79654267|NCT04573348|Diagnostic Test|Savicell's ImmunoBiopsy™|ImmunoBiopsy and ELISA
79654268|NCT04573621|Procedure|Pelvic drain|A pelvic drain is placed
79654269|NCT04573621|Other|No pelvic drain is placed|A pelvic drain is not placed
79654270|NCT04573465|Behavioral|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
79654271|NCT04573465|Behavioral|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
79983813|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
79339127|NCT02327169|Drug|Cetuximab|Cetuximab IV infusion.
79339128|NCT02327169|Drug|Irinotecan|Irinotecan IV infusion.
79339129|NCT02327013|Drug|vortioxetine 10 mg tablet|Oral tablets, once daily
79339130|NCT02327013|Drug|vortioxetine 20 mg tablet|Oral tablets, once daily
79339131|NCT02327013|Other|Placebo tablet|Oral tablets, once daily
79339132|NCT02301975|Drug|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
79654272|NCT04573465|Behavioral|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
79654273|NCT00255489|Drug|Gefitinib|
79339133|NCT02301975|Drug|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
79654274|NCT00255489|Procedure|palliative thoracic radiotherapy|
79654275|NCT04573153|Drug|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
79654276|NCT04573153|Drug|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
79339134|NCT02301975|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
79339135|NCT02301975|Drug|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
79339136|NCT02301975|Drug|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
79654277|NCT00226187|Procedure|Supplement of fatty acid (DHA and AA)|
79654278|NCT02277418|Device|VAVL|Videolaryngoscope
79654279|NCT02277418|Device|MIL|Direct laryngoscopy
79654280|NCT00255528|Drug|metoprolol succinate|
79654281|NCT04573270|Biological|PrimePro|Intravenous Injection
79654282|NCT04573270|Other|Placebo|Intravenous Injection
79654283|NCT00226226|Procedure|Peripherally Inserted Central Catheter Placement|
79654284|NCT04572919|Procedure|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
79654285|NCT04572919|Procedure|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
79654286|NCT04572685|Drug|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
79339137|NCT02301897|Drug|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
79339138|NCT02301897|Drug|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
79339139|NCT02301429|Device|Model 20105|implant and follow-up of study device
79339140|NCT04883385|Other|medical data collection|collection of medical data from patients' medical records
79489052|NCT03135379|Device|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
79489053|NCT01306994|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
79489054|NCT01306994|Procedure|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
79654287|NCT04572724|Drug|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
79339141|NCT04883229|Device|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
79339142|NCT04882839|Combination Product|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
79654288|NCT04572724|Drug|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
79339143|NCT02300259|Drug|LY2623091|Administered orally
79339144|NCT02300259|Drug|Itraconazole|Administered orally
79339145|NCT02300259|Drug|Simvastatin|Administered orally
79339146|NCT02300259|Drug|Tadalafil|Administered orally
79339147|NCT02300259|Drug|Diltiazem|Administered orally
79339148|NCT02367885|Drug|TAK-850 0.5 mL injection|TAK-850 injection
79339149|NCT02367885|Drug|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
79983814|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
79983815|NCT04360187|Drug|Crisaborole Ointment|Crisaborole ointment 2%
79339150|NCT02367729|Device|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
79339151|NCT02367729|Device|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
79339152|NCT02366637|Drug|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
79339153|NCT02366637|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
79339154|NCT02300103|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79339155|NCT02300103|Drug|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79339156|NCT02326467|Drug|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
79339157|NCT02299635|Drug|PF-03084014|Tablet, 10 mg, twice a day.
79654289|NCT00255567|Drug|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
79654290|NCT00255567|Drug|Paromomycin sulphate|Paromomycin sulphate
79654291|NCT00255567|Drug|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
79654292|NCT04572607|Dietary Supplement|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
79983816|NCT04360187|Drug|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
79983817|NCT03234322|Other|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
79489055|NCT01306994|Other|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
79983818|NCT03254290|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
79339158|NCT02299635|Drug|PF-03084014|Tablet, 50 mg, twice a day
79339159|NCT02299635|Drug|PF-03084014|Tablet, 100 mg, twice a day
79339160|NCT02366091|Drug|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
79339161|NCT02366091|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
79489056|NCT01306994|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
79489057|NCT01306994|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
79983819|NCT03254290|Biological|Formocresol|Control group
79983820|NCT03254368|Drug|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
79339162|NCT02366091|Drug|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
79983821|NCT03254368|Drug|Placebo|Placebo has the same excipients and appearance as ZGN-1061
79983822|NCT04498169|Drug|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
79339163|NCT02299167|Drug|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
79339164|NCT01647711|Drug|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
79339165|NCT05476757|Biological|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
79339166|NCT02547233|Drug|LEO 43204 gel|
79339167|NCT02547233|Drug|Vehicle gel|
79339168|NCT05476679|Drug|RZL-012|50mg/ml drug formulation
79339169|NCT05476679|Drug|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
79489058|NCT01306994|Other|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
79489059|NCT01306994|Other|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
79813409|NCT00814918|Drug|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
79813410|NCT00814918|Drug|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
79813411|NCT04113954|Drug|Mepivacaine Injection|Injection of 0.375% mepivacaine in nerve block
79339170|NCT05476679|Drug|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
79339171|NCT05476679|Drug|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
79339172|NCT05476679|Drug|RZL-012+facial and neck wrap|Universal Facial Band
79339173|NCT02546765|Drug|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
79339174|NCT02546765|Drug|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
79339175|NCT02546765|Drug|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
79339176|NCT02546765|Drug|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
79339177|NCT02553629|Drug|Rocuronium|
79339178|NCT05453981|Behavioral|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
79339179|NCT03073031|Device|Tablet: Samsung Galaxy Tab A|
79339180|NCT05476445|Procedure|Control|Root canal treatment
79489060|NCT03135535|Device|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
79813412|NCT04113954|Drug|Mepivacaine Injection|Injection of 1.5% mepivacaine in nerve block
79813413|NCT00812344|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
79813414|NCT00812344|Drug|Ketoconazole|tablets, orally, once daily for 3 days
79339181|NCT05476445|Procedure|Laser|Root canal treatment+Laser application
79339182|NCT05476445|Procedure|Cryotherapy|Root canal treatment + Cryotherapy application
79339183|NCT05466461|Procedure|Beautifil Flow Plus X.|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed
79339184|NCT05466461|Procedure|Activa bioactive restorative|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
79813415|NCT00812344|Drug|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
79339185|NCT02546609|Drug|Leu-Met-Sil 0.5|NS-0200 low dose
79339186|NCT02546609|Drug|Leu-Met-Sil 1.0|NS-200 high dose
79339187|NCT02546609|Drug|Placebo|Placebo
79339188|NCT02534909|Biological|LFG316|"LFG316 will be administered to all patients enrolled in the study~LFG316: Treatment periods 1-3 and first 4 weeks of period 4. LNP023: Treatment Period 4"
79339189|NCT02534909|Drug|LNP023|LNP023 will be administered in period 4 to patients who participate in period 3 of this study and are willing to join long term extension study with LNP023.
79339190|NCT03030755|Other|Optical coherence tomography|
79489061|NCT02979301|Drug|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
79489062|NCT01930136|Behavioral|Calorie restriction (25%)|
79489063|NCT01930136|Behavioral|Ad libitum health diet|
79489064|NCT02979925|Device|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
79489065|NCT02979925|Device|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
79813416|NCT00446251|Drug|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
79813417|NCT00446251|Drug|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
79813418|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
79813419|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
79813420|NCT00812422|Drug|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
79339191|NCT02553317|Biological|Caplacizumab|"First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
79339192|NCT02553317|Biological|Placebo|"First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
79339193|NCT03029351|Drug|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
79339194|NCT03029351|Drug|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
79339195|NCT02325219|Drug|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
79339196|NCT02325219|Drug|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
79339197|NCT02325219|Drug|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
79339198|NCT02325219|Drug|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
79983823|NCT04498169|Drug|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
79489066|NCT05171114|Diagnostic Test|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
79983824|NCT03236740|Drug|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
79983825|NCT03236740|Drug|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
79983826|NCT02453464|Drug|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
79983827|NCT02453464|Drug|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
79983828|NCT02453464|Drug|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
79983829|NCT02453464|Drug|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
79983830|NCT03695393|Behavioral|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
79983831|NCT03233932|Drug|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
79983832|NCT03233932|Drug|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
79983833|NCT03236584|Drug|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
79983834|NCT03236584|Drug|Tenofovir Disoproxil Fumarate|switching to tenofovir
79489067|NCT04954651|Biological|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
79983835|NCT01562093|Drug|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
79654293|NCT03450967|Drug|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
79339199|NCT02297841|Device|Experimental: Novel lubricant Miami Fragrance|
79339200|NCT02297841|Device|Experimental: Novel lubricant Miami no Fragrance|
79339201|NCT02297841|Device|KY Liquid lubricant|
79983836|NCT01562093|Drug|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
79983837|NCT03254056|Procedure|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
79983838|NCT03254056|Procedure|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
79339202|NCT02297841|Device|Astroglide Gel lubricant|
79339203|NCT02324361|Other|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
79339204|NCT02324361|Behavioral|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
79339205|NCT02365233|Drug|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
79339206|NCT02365233|Drug|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
79339207|NCT02365233|Drug|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
79339208|NCT02324205|Device|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
79339209|NCT02324049|Drug|SBC-103|
79339210|NCT02364999|Drug|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
79339211|NCT02364999|Drug|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
79489068|NCT00375440|Drug|Tranexamic Acid|
79983839|NCT03694925|Diagnostic Test|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
79983840|NCT03234088|Behavioral|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
79983841|NCT03233776|Drug|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
79339212|NCT02364999|Drug|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
79339213|NCT02364999|Drug|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
79339214|NCT02322879|Drug|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
79339215|NCT02322879|Other|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
79489069|NCT02983825|Device|Continuous positive airway pressure (CPAP); level changes|as per arm description
79489070|NCT01818986|Drug|Sipuleucel-T|
79489071|NCT01818986|Radiation|Stereotactic Ablative Body Radiation|
79654294|NCT03450928|Procedure|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
79654295|NCT00235365|Behavioral|meta-cognitive therapy|Meta-cognitive therapy
79654296|NCT00235365|Other|waiting list|waiting list control
79339216|NCT02322879|Drug|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
79339217|NCT02322411|Device|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
79339218|NCT02322411|Behavioral|Compensatory approaches|
79339219|NCT02322021|Drug|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
79339220|NCT02322021|Drug|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
79339221|NCT02363439|Drug|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
79339222|NCT02363283|Drug|Glembatumumab Vedotin|Given IV
79654297|NCT03450889|Procedure|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
79654298|NCT03450616|Device|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
79654299|NCT03450616|Procedure|Compression Dressing|Standard of Care Compression Dressing
79813421|NCT03995407|Dietary Supplement|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
79339223|NCT02363283|Other|Laboratory Biomarker Analysis|Correlative studies
79339224|NCT02363283|Other|Pharmacological Study|Correlative studies
79339225|NCT02321319|Drug|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
79339226|NCT02294175|Device|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
79339227|NCT02294175|Procedure|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
79339228|NCT02088541|Drug|Selinexor|Selinexor oral tablet.
79339229|NCT02088541|Drug|Hydroxyurea|
79339230|NCT02088541|Drug|Ara-C|Ara-C Subcutaneous Injection.
79339231|NCT02294019|Drug|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
79654300|NCT04572529|Procedure|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
79654301|NCT04572334|Other|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
79654302|NCT00255606|Drug|docetaxel|Given in 3- or 4- week courses
79654303|NCT00255606|Drug|prednisone|Given in 3- or 4- week courses
79654304|NCT03450577|Procedure|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
79654305|NCT00226343|Drug|Depakote-ER|
79654306|NCT03450499|Drug|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
79339232|NCT02320149|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
79654307|NCT03450499|Drug|Placebo|the analgesic requirement will be calculated in placebo group.
79339233|NCT02320149|Drug|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
79654308|NCT03450460|Behavioral|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
79339234|NCT05407909|Drug|SYHX2001|SYHX2001 tablets, oral
79654309|NCT03450421|Device|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
79654310|NCT00235404|Other|Multicomponent treatment|Specialized care in preparing recharge to home
79339235|NCT05423509|Other|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
79339236|NCT05423509|Other|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
79339237|NCT05422417|Device|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
79339238|NCT05422417|Device|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
79489072|NCT03138577|Diagnostic Test|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
79489073|NCT03138577|Drug|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
79339239|NCT05422417|Device|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
79339240|NCT05450653|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR <25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
79339241|NCT05405725|Biological|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
79339242|NCT05405725|Biological|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
79339243|NCT02540083|Device|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
79489074|NCT03138577|Other|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
79489075|NCT03181724|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
79339244|NCT02293863|Drug|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
79339245|NCT02293863|Drug|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
79339246|NCT02293863|Drug|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
79339247|NCT02293395|Drug|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
79489076|NCT05113004|Drug|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
79489077|NCT05113004|Drug|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
79339248|NCT02293395|Drug|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
79339249|NCT02293395|Drug|Clopidogrel|Clopidogrel 75 mg once daily orally.
79339250|NCT02293395|Drug|Ticagrelor|Ticagrelor 90 mg twice daily orally.
79339251|NCT02025985|Drug|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m^2 BIW, 35 mg/m^2 QW, 50 mg/m^2 BIW, 50 mg/m^2 QW, 60 mg/m^2 BIW, 60 mg/m^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
79339252|NCT05450341|Device|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
79339253|NCT05450341|Device|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
79339254|NCT04423081|Other|EXIT scale|completion of EXIT scale translated in french
79339255|NCT02528305|Other|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12.
79339256|NCT05450263|Behavioral|Interoceptive exposure|A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
79654311|NCT00235404|Other|usual care|Usual recharge directly from hospital to home
79654312|NCT00226382|Drug|Pegylated Interferon-alfa-2a|Pegasys once weekly
79339257|NCT05403775|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
79654313|NCT01580839|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
79654314|NCT01580839|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
79339258|NCT05403775|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
79813422|NCT03995407|Other|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
79339259|NCT05420701|Procedure|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
79654315|NCT03450382|Other|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
79654316|NCT03450265|Device|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
79339260|NCT05420311|Other|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
79339261|NCT05420311|Other|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
79489078|NCT05113004|Drug|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
79489079|NCT05113004|Drug|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
79654317|NCT03450265|Device|Tachosil|Applied according to the current instruction for use (IFU).
79654318|NCT00235482|Drug|Coxsackievirus A21|
79813423|NCT04110834|Drug|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
79339262|NCT05420311|Other|IF Arm|An intermittent fasting (IF) approach
79339263|NCT05402761|Behavioral|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
79339264|NCT05402761|Behavioral|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
79654319|NCT03450226|Drug|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
79339265|NCT05447065|Dietary Supplement|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
79813424|NCT04110834|Drug|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
79339266|NCT05402605|Procedure|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
79339267|NCT05402605|Procedure|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
79339268|NCT05401357|Drug|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
79339269|NCT05401357|Drug|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
79339270|NCT05401279|Drug|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
79339271|NCT05401279|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
79339272|NCT05401279|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four to six 21-day cycles.
79339273|NCT05420077|Biological|RVM-V001 10 µg|Low Dose
79654320|NCT04572373|Dietary Supplement|SMOFlipid|
79339274|NCT05420077|Biological|RVM-V001 30 µg|Mid Dose
79654321|NCT03450148|Other|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
79339275|NCT05420077|Biological|RVM-V001 60 µg|High Dose
79339276|NCT02532517|Device|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
79339277|NCT05418595|Other||
79813425|NCT04110834|Drug|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
79813426|NCT00812500|Other|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
79813427|NCT00812500|Other|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
79339278|NCT02545049|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
79654322|NCT03450148|Other|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
79339279|NCT02545049|Drug|Placebo|Matching placebo to be taken orally, once daily.
79339280|NCT05451095|Drug|BI 474121|BI 474121
79339281|NCT05451095|Drug|Placebo|Placebo
79983842|NCT03253588|Procedure|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
79339282|NCT05451095|Drug|Ketamine hydrochloride|Ketamine hydrochloride
79339283|NCT05476133|Other|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
79983843|NCT03253900|Device|Stable rowing simulator|a standard stable/fixed rowing simulator
79339284|NCT05476055|Genetic|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
79983844|NCT03253900|Device|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
79339285|NCT04423835|Procedure|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
79339286|NCT05450705|Biological|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
79654323|NCT03450109|Drug|LY01005|One gluteal IM injection
79654324|NCT03450109|Drug|Zoladex|One Subcutaneous injection in the abdominal wall
79654325|NCT03450031|Other|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
79983845|NCT03253900|Device|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
79339287|NCT02954081|Drug|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
79339288|NCT02517125|Device|Transoral robotic-assisted surgery with Da Vinci Xi|
79339289|NCT02532283|Drug|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
79339290|NCT02532283|Drug|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
79339291|NCT02532283|Drug|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
79654326|NCT00226460|Drug|Fetal porcine cells, Neurocell-PD|
79813428|NCT00812500|Other|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
79813429|NCT04108494|Procedure|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.Control group with total omentectomy.
79339292|NCT01807897|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
79983846|NCT04614168|Procedure|Stepped hyperinsulinaemic-hypoglycaemic clamp study|Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
79654327|NCT03459781|Behavioral|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
79654328|NCT03459781|Behavioral|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
79654329|NCT03458767|Behavioral|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
79654330|NCT00413309|Procedure|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
79654331|NCT03457519|Device|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
79654332|NCT03451552|Behavioral|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
79654333|NCT00413348|Drug|Lactobacillus acidophilus NCFM|
79654334|NCT00413387|Drug|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
79654335|NCT00413387|Drug|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
79654336|NCT04572490|Diagnostic Test|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
79654337|NCT03458845|Diagnostic Test|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
79654338|NCT00413426|Drug|Darifenacin (DAR328)|
79339293|NCT01807897|Device|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
79654339|NCT00255762|Drug|carboplatin|Given IV
79983847|NCT04614168|Device|Insulin pump|Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
79654340|NCT00255762|Drug|paclitaxel|Given IV
79654341|NCT00255762|Biological|bevacizumab|Given IV
79654342|NCT00255762|Other|laboratory biomarker analysis|Correlative studies
79654343|NCT03456583|Device|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
79654344|NCT03455998|Other|questionnaires|
79983848|NCT04614168|Device|Continuous glucose monitor|Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
79983849|NCT04614168|Other|Low carbohydrate diet|30-40g of carbohydrate per main meal portion.
79983850|NCT04614168|Device|Blinded continuous glucose monitor|Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
79983851|NCT04614168|Procedure|Stable isotope studies- D2 Glucose and D5 Glycerol|These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
79983852|NCT02453230|Behavioral|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
79983853|NCT02453152|Other|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
79983854|NCT02453152|Other|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
79983855|NCT02453152|Other|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
79983856|NCT02453152|Other|Peak cough flow|Subjects' strongest coughs will be measured.
79983857|NCT02453152|Other|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
79654345|NCT02277457|Radiation|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
79339294|NCT01807897|Behavioral|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
79339295|NCT05446831|Drug|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
79339296|NCT02431351|Drug|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
79339297|NCT01295125|Device|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
79339298|NCT01295125|Procedure|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
79339299|NCT05398705|Drug|Cepharanthine|Low-dose: Day 1~5: 20mg, Q8H X 5 days (60mg/day)+SMT
79339300|NCT05398705|Drug|Placebo|"Day 1~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
79339301|NCT05398705|Drug|Cepharanthine|"High-dose: Day 1~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
79339302|NCT02540291|Drug|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
79339303|NCT05397769|Drug|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
79339304|NCT05475977|Diagnostic Test|MSCT chest|Multi slice Computed Tomography of the chest
79654346|NCT02277457|Drug|Erlotinib|150 mg once daily
79654347|NCT02277457|Drug|Crizotinib|250 mg twice daily
79654348|NCT00255879|Drug|Quetiapine|
79654349|NCT00255879|Drug|Risperidone|
79654350|NCT00255879|Drug|Olanzapine|
79654351|NCT00413465|Drug|Escherichia Coli Endotoxin|
79654352|NCT00199888|Drug|124-Iodine-cG250 (124I-cG250)|
79654353|NCT00413504|Drug|Fondaparinux|
79489080|NCT05113004|Drug|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
79489081|NCT05113004|Drug|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
79489082|NCT04707079|Drug|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
79654354|NCT04721223|Drug|JAB-3068|JAB-3068 administrated orally as a tablet.
79339305|NCT05464043|Diagnostic Test|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
79489083|NCT02983981|Drug|Topicort Topical Spray|open label Topicort spray
79489084|NCT03182582|Device|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
79489085|NCT03182582|Procedure|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
79339306|NCT05475899|Device|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
79339307|NCT05416255|Diagnostic Test|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
79339308|NCT02540213|Device|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
79489086|NCT00375583|Drug|DEC/Albendazole|
79654355|NCT04721223|Drug|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
79654356|NCT00226538|Drug|Phenytoin|
79339309|NCT05444413|Biological|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
79339310|NCT05415865|Combination Product|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
79339311|NCT05415865|Drug|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
79339312|NCT05463887|Behavioral|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
79489087|NCT05081726|Diagnostic Test|Functional MRI|Series of MRI scans of the brain
79489088|NCT04740229|Behavioral|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
79489089|NCT02986711|Behavioral|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
79489090|NCT02986711|Behavioral|Control|Only survey questions about smoking status
79489091|NCT00374569|Procedure|Gymnastic Routine|A combination of gymnastic movements are performed
79654357|NCT00226538|Drug|Rifampicin|
79654358|NCT00226538|Drug|Diclophenac|
79654359|NCT00226538|Drug|Fluconazole|
79654360|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
79654361|NCT00255918|Drug|Placebo|Placebo dosed to match active medication
79654362|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
79654363|NCT00226616|Drug|Zinc|
79654364|NCT00199849|Biological|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
79654365|NCT00255957|Drug|HES administration|
79654366|NCT00255957|Drug|Hydroxy Ethyl Starch administration to stroke patients|
79654367|NCT00226694|Drug|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
79654368|NCT00226694|Other|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
79339313|NCT05463575|Drug|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
79339314|NCT05463575|Other|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
79339315|NCT05415553|Procedure|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
79339316|NCT05415553|Procedure|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
79489092|NCT03141931|Dietary Supplement|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
79489093|NCT03141931|Dietary Supplement|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
79489094|NCT03143569|Device|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
79339317|NCT05394649|Device|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
79339318|NCT05394649|Device|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
79654369|NCT00255996|Drug|linezolid|
79339319|NCT02552303|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
79339320|NCT02552303|Drug|Armodafinil|Active medication
79654370|NCT00226733|Behavioral|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
79654371|NCT00226733|Behavioral|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
79654372|NCT00415155|Drug|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
79654373|NCT00226850|Behavioral|hypnosis|
79654374|NCT00226889|Drug|bosentan|
79654375|NCT00415272|Behavioral|Pulmonary Rehabilitation|
79654376|NCT00226928|Behavioral|Supportive-Expressive Group Therapy plus education|
79654377|NCT00226928|Behavioral|Education|
79983858|NCT02453152|Other|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
79339321|NCT02552303|Drug|Placebo|Placebo for Nuvigil (armodafinil)
79339322|NCT01660711|Drug|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
79339323|NCT01660711|Drug|Leucovorin|400 mg/m2 by IV infusion over 2 hours
79339324|NCT01660711|Drug|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
79339325|NCT01660711|Drug|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
79339326|NCT02544113|Drug|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
79339327|NCT02544113|Drug|Placebo|Normal transplant immunosuppression
79339328|NCT02538965|Drug|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
79339329|NCT02543801|Drug|Liposomal Bupivacaine|Periarticular injection
79654378|NCT04710225|Procedure|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= [SBP+10]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
79339330|NCT02543801|Drug|Ropivacaine|Periarticular injection
79339331|NCT02543801|Drug|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
79654379|NCT00226967|Drug|Sandostatin|Calculated per patient
79654380|NCT04709913|Drug|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
79654381|NCT00199381|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
79654382|NCT00227006|Behavioral|Behavioral lifestyle/weight-loss intervention|
79339332|NCT02543801|Drug|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
79654383|NCT04710069|Behavioral|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
79983859|NCT02453152|Other|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
79339333|NCT02543801|Drug|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
79339334|NCT02543801|Drug|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
79339335|NCT02481635|Drug|Gemcitabine|
79339336|NCT02481635|Drug|Nab-paclitaxel|
79339337|NCT02481635|Radiation|Radiation Therapy|
79339338|NCT02481635|Procedure|Surgical Resection|
79339339|NCT02535065|Device|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
79339340|NCT05461313|Other|Constrained Liner|Subjects in this arm will receive a constrained liner (Freedom or G7 Freedom Constrained Acetabular Liner, Zimmer Biomet)
79339341|NCT05461313|Other|Dual Mobility|Subjects in this arm will receive a dual mobility cup (Avantage Dual Mobility Liner, Zimmer Biomet)
79489095|NCT03143569|Device|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
79489096|NCT04631497|Diagnostic Test|test|"Beck's Test~Test STAI~Test PSS~the scale of the fascination with death~COPE"
79489097|NCT02222688|Drug|cirmtuzumab|
79489098|NCT03149887|Drug|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
79983860|NCT01372488|Procedure|Suture self removal|Suture self removal
79983861|NCT01372488|Procedure|Suture removal by family doctor or clinic|As above
79339342|NCT05411159|Procedure|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
79339343|NCT05411159|Procedure|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
79339344|NCT05431907|Drug|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
79339345|NCT05448911|Procedure|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
79339346|NCT05448911|Procedure|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
79339347|NCT02530619|Drug|Alisertib|Given PO
79339348|NCT02530619|Other|Laboratory Biomarker Analysis|Correlative studies
79339349|NCT02530619|Other|Pharmacological Study|Correlative studies
79339350|NCT02530385|Other|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
79339351|NCT02530385|Biological|FMT Capsules|Capsules will be generated as per FDA-approved procedures
79339352|NCT02362425|Drug|N-acetylcysteine|
79339353|NCT02362425|Drug|Placebo|
79339354|NCT02362269|Dietary Supplement|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
79489099|NCT03149887|Drug|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
79489100|NCT04759404|Other|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
79489101|NCT04759404|Other|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
79489102|NCT02988193|Device|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
79489103|NCT02988349|Other|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
79489104|NCT04541329|Biological|Tildrakizumab|IL-23 inhibitor
79654384|NCT04709991|Procedure|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
79654385|NCT00227084|Drug|Arista AH hemostasis powder|
79654386|NCT04709952|Device|Transcranial direct current stimulation_High real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
79983862|NCT03234010|Other|FT21092|An electronic cigarette
79983863|NCT03234010|Other|FT21093|An electronic cigarette
79339355|NCT02529995|Drug|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
79339356|NCT02529995|Drug|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
79654387|NCT04709952|Device|Transcranial direct current stimulation_Low real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
79654388|NCT04709952|Device|Transcranial direct current stimulation_Sham|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
79983864|NCT03234010|Other|FT21096|An electronic cigarette
79983865|NCT03234010|Other|FT21097|An electronic cigarette
79983866|NCT01365234|Device|Pacing Lead|Implant and follow up of Model 20066 lead
79983867|NCT02453308|Drug|ACT|"Artemether-lumefantrine for 3 days~Dihydroartemisinin-piperaquine for 3 days.~Artesunate-mefloquine for 3 days"
79983868|NCT02453308|Drug|TACT|"Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
79489105|NCT03150043|Device|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
79654389|NCT00227123|Drug|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
79654390|NCT00256035|Procedure|Measuring IL-4 levels|
79983869|NCT04258020|Device|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
79983870|NCT04258020|Device|HFNC|Heated High Flow Nasal Cannula oxygen administration
79983871|NCT03236350|Device|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
79983872|NCT03236350|Device|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
79339357|NCT05431517|Procedure|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
79339358|NCT04260425|Other|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
79489106|NCT02159352|Drug|Daclatasvir|
79489107|NCT02159352|Drug|Darunavir|
79489108|NCT02159352|Drug|Ritonavir|
79489109|NCT02159352|Drug|Lopinavir/Ritonavir|
79489110|NCT04499833|Procedure|liver transplant|liver transplant
79654391|NCT00227162|Behavioral|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
79654392|NCT00227162|Behavioral|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
79654393|NCT00227162|Behavioral|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
79654394|NCT00235521|Drug|aerosolized iloprost|
79654395|NCT00227201|Behavioral|Self-affirmation intervention|
79654396|NCT00235560|Drug|rapamycin|sirolimus
79339359|NCT04260425|Other|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
79339360|NCT05408897|Diagnostic Test|liquid biopsy|A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
79339361|NCT05447819|Procedure|Reverse shoulder arthroplsaty|Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
79983873|NCT01365312|Drug|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
79339362|NCT05447585|Device|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
79489111|NCT03150199|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
79489112|NCT03150199|Behavioral|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
79983874|NCT01365312|Drug|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
79339363|NCT05447585|Device|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
79489113|NCT02187744|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
79339364|NCT05447117|Procedure|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
79339365|NCT05429021|Drug|IMM-BCP-01|Single dose of IMM-BCP-01
79339366|NCT05429021|Drug|Placebo|Placebo matching single dose of IMM-BCP-01
79339367|NCT02319759|Drug|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
79489114|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
79654397|NCT00256074|Procedure|Enteral feeding formula|
79654398|NCT00227279|Biological|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
79654399|NCT00235599|Procedure|IGFBP-3 Stimulation Test|
79654400|NCT00227318|Drug|ATACAND|
79654401|NCT00227357|Drug|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
79654402|NCT00227357|Drug|Off-site - methadone or no agonist|
79654403|NCT00198133|Drug|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
79654404|NCT00256113|Drug|Saredutant succinate (SR48968C)|
79654405|NCT00227435|Drug|val-mCyd|
79983875|NCT04495283|Drug|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
79983876|NCT04495283|Drug|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
79983877|NCT04495283|Other|Placebo 1|Placebo for APAP
79983878|NCT04495283|Other|Placebo 2|Placebo for combination
79489115|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
79813430|NCT04045444|Other|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
79813431|NCT04045444|Other|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
79654406|NCT00235677|Procedure|Endoscopic gastroplication|
79654407|NCT00227474|Drug|recombinant modified vaccinia Ankara-5T4 vaccine|
79654408|NCT00227474|Procedure|adjuvant therapy|
79813432|NCT04108572|Behavioral|Infant feeding|Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
79813433|NCT00815074|Other|No intervention|no intervention
79489116|NCT02187744|Biological|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
79654409|NCT00227474|Procedure|recombinant viral vaccine therapy|
79654410|NCT00197236|Biological|Havrix™|2 intramuscular injections, 6 months apart
79654411|NCT00197236|Biological|Infanrix™|1 intramuscular injection
79654412|NCT00197236|Biological|ActHIB™|1 intramuscular injection
79654413|NCT00256152|Device|AF Suppression Pacing Algorithm|
79654414|NCT00227513|Drug|bortezomib|Given IV
79654415|NCT00227513|Drug|vorinostat|Given orally
79654416|NCT04709445|Diagnostic Test|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
79339368|NCT02319759|Drug|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
79339369|NCT02319759|Drug|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
79339370|NCT02293005|Drug|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
79489117|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
79813434|NCT04110678|Drug|NeuroEPO|NeuroEPO [CIMAB S.A, Havana, Cuba]
79813435|NCT00812578|Drug|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
79813436|NCT00815152|Behavioral|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
79813437|NCT00815152|Behavioral|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
79654417|NCT00256191|Drug|TPI 287 Injection|
79654418|NCT00227630|Drug|cisplatin|
79654419|NCT00227630|Drug|pemetrexed disodium|
79654420|NCT00227630|Procedure|adjuvant therapy|
79654421|NCT00227630|Procedure|conventional surgery|
79654422|NCT00227630|Procedure|neoadjuvant therapy|
79983879|NCT03253822|Other|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
79983880|NCT01365390|Other|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to < 6 years) or since birth (for subjects aged < 1 year) will be recorded in the electronic case report form.
79489118|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
79489119|NCT03154333|Drug|diacerein 1% ointment|diacerein 1% ointment administered topically
79654423|NCT00227630|Radiation|radiation therapy|
79654424|NCT00256230|Drug|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
79654425|NCT00227669|Drug|docetaxel|
79654426|NCT00227669|Drug|gemcitabine hydrochloride|
79654427|NCT00235794|Drug|temsirolimus|
79654428|NCT00256269|Drug|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
79654429|NCT00256269|Drug|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
79654430|NCT00197002|Biological|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
79654431|NCT00197002|Biological|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
79654432|NCT00227708|Drug|docetaxel|
79654433|NCT00227708|Procedure|quality-of-life assessment|
79654434|NCT00235911|Drug|budesonide/formoterol Turbuhaler|
79654435|NCT00196105|Device|6 mm Nitinol Zilver Stent|
79654436|NCT00196105|Device|10 mm Nitinol Zilver Stent|
79654437|NCT00196105|Device|10 mm Stainless Steel Wallstent|
79654438|NCT04722068|Other|Kinetics test|Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
79654439|NCT00256347|Drug|intramuscular injections of morphine|
79654440|NCT00227747|Drug|capecitabine|
79654441|NCT00227747|Drug|oxaliplatin|
79654442|NCT00227747|Procedure|conventional surgery|
79654443|NCT00227747|Procedure|neoadjuvant therapy|
79654444|NCT00227747|Radiation|radiation therapy|
79654445|NCT00235950|Drug|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
79654446|NCT00227786|Behavioral|smoking cessation intervention|
79654447|NCT00227786|Other|counseling intervention|
79654448|NCT02962089|Dietary Supplement|Branched chain amino acids (BCAA)|
79654449|NCT02962089|Dietary Supplement|Placebo|
79654450|NCT00256386|Device|Electronic Medical Record (EMR) to clinician's in-basket|
79489120|NCT03154333|Drug|A placebo ointment|vehicle ointment administered topically
79339371|NCT02319525|Other|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
79813438|NCT00796224|Drug|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
79654451|NCT00256386|Device|Automated Voice Message (AVM) reminder to patient's phone|
79654452|NCT00256386|Procedure|Pharmacy Team phone call-letter followup|
79654453|NCT00227825|Behavioral|Motivational interviewing|
79654454|NCT00227864|Behavioral|Behavior Therapy|
79654455|NCT00227864|Other|Treatment as Usual|
79654456|NCT00256425|Behavioral|Cognitive rehabilitation|
79339372|NCT02319525|Other|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology [ACR]) regarding lupus and its treatments, that explained risks and benefits of various treatments
79654457|NCT04721990|Device|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
79813439|NCT00796224|Drug|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
79813440|NCT00808366|Drug|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
79813441|NCT00808366|Drug|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
79813442|NCT04113798|Other|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
79339373|NCT02292927|Behavioral|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
79339374|NCT02292849|Behavioral|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
79339375|NCT02292849|Other|Standard Mental Health Referral|Standard mental health referral to a community agency
79654458|NCT00256464|Behavioral|Multi-component Yoga Intervention|
79654459|NCT00227942|Drug|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
79654460|NCT00227942|Drug|Zolpidem|10 mg/day, po qhs
79654461|NCT00227942|Drug|placebo|placebo
79654462|NCT00256503|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
79654463|NCT00227981|Behavioral|Interpersonal Psychotherapy|
79654464|NCT00227981|Drug|Fluoxetine|
79654465|NCT00236028|Drug|Infliximab|
79654466|NCT00256542|Drug|Alkalinized Lidocaine-Heparin|
79654467|NCT00228020|Drug|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
79654468|NCT00228020|Drug|MMF, cyclosporine, steroids|
79654469|NCT00236067|Drug|Gabitril|
79654470|NCT00228059|Drug|Licarbazepine|
79654471|NCT00195715|Biological|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
79654472|NCT00236106|Drug|tacrolimus ointment 0.1%|
79654473|NCT00236106|Drug|mometasone furoate 0.1%|
79654474|NCT00228098|Behavioral|Smoking cessation|
79654475|NCT00236145|Drug|ACTIQ (Oral transmucosal fentanyl citrate)|
79654476|NCT00413543|Other|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
79654477|NCT00256581|Procedure|Additional rest and stress image sets on new camera|
79654478|NCT00228215|Behavioral|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
79654479|NCT00228254|Drug|Zinc (12.5 mg/day)|
79654480|NCT00228254|Drug|vitamin A 10,000 IU per week|
79489121|NCT04473625|Other|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
79813443|NCT04113798|Other|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
79489122|NCT04393441|Drug|011516X (New Artificial Tear Formulation)|Topical eye drops
79654481|NCT00228293|Device|investigational monitor/defibrillator with CPR feedback|
79654482|NCT00195676|Drug|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
79813444|NCT04113798|Other|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
79339376|NCT02318667|Biological|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
79339377|NCT02292771|Drug|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
79339378|NCT02292771|Drug|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
79339379|NCT02292771|Drug|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
79654483|NCT00228332|Drug|Administration of zinkgluconaat or placebo|
79339380|NCT02292771|Drug|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
79339381|NCT04880187|Drug|AXA1125|AXA1125 administered BID with or without food
79339382|NCT04880187|Drug|Placebo|Matching Placebo administered BID with or without food
79339383|NCT02291913|Drug|Everolimus|
79654484|NCT00194077|Drug|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
79654485|NCT00194077|Drug|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
79654486|NCT00228371|Device|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
79654487|NCT00193609|Drug|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
79813445|NCT04113798|Behavioral|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
79339384|NCT02291913|Drug|Exemestane|Anti-estrogen therapy
79339385|NCT02291913|Drug|Tamoxifen|Anti-estrogen therapy
79339386|NCT02291913|Drug|Fulvestrant|Anti-estrogen therapy
79339387|NCT02291913|Drug|Anastrozole|Anti-estrogen therapy
79339388|NCT02291913|Drug|Letrozole|Anti-estrogen therapy
79489123|NCT04393441|Drug|Systane Ultra Multidose|Topical eye drops
79489124|NCT04393441|Drug|REFRESH PLUS®|Topical eye drops
79489125|NCT03160027|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
79654488|NCT00193609|Drug|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
79654489|NCT00228410|Drug|Tigecycline|
79654490|NCT00228410|Drug|vancomycin with aztreonam|
79654491|NCT00228449|Drug|peginesatide|
79654492|NCT00193180|Drug|Imatinib|Imatinib
79654493|NCT00193180|Drug|Docetaxel|Docetaxel
79654494|NCT00193063|Drug|Trastuzumab|Trastuzumab
79654495|NCT00193063|Drug|Gemcitabine|Gemcitabine
79654496|NCT00228488|Drug|Gefitinib|
79654497|NCT00228527|Drug|Esomeprazole (Nexium)|
79654498|NCT00191854|Drug|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
79654499|NCT00191854|Drug|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
79813446|NCT04113798|Behavioral|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for the full duration of 30 minutes.
79489126|NCT02994979|Other|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
79489127|NCT02994979|Other|Sham comparator|Usual care plus sham visits by CNA
79654500|NCT00191854|Drug|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
79654501|NCT00191854|Drug|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
79654502|NCT00228605|Drug|OraVescent Fentanyl|
79654503|NCT00191815|Drug|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
79654504|NCT00191815|Drug|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
79339389|NCT02291913|Drug|Toremifine|Anti-estrogen therapy
79339390|NCT02291679|Drug|Linaclotide|
79339391|NCT02291679|Drug|Matching Placebo|
79339392|NCT02291601|Drug|Chlorhexidine Gluconate|comparison with other CHG products
79654505|NCT00191386|Drug|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
79654506|NCT00228683|Procedure|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
79654507|NCT00191308|Drug|pemetrexed|500 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
79339393|NCT02291601|Other|Vehicle|Excipients of CHG product only.
79489128|NCT02995915|Other|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
79654508|NCT00191308|Drug|cisplatin|75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
79654509|NCT00191308|Procedure|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
79339394|NCT02291601|Drug|DynaHex-2|2% CHG solution
79339395|NCT02360475|Biological|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79339396|NCT02360475|Biological|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79339397|NCT02360475|Biological|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79339398|NCT02360475|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
79339399|NCT02360397|Drug|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
79339400|NCT02317809|Drug|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
79339401|NCT02317809|Drug|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
79654510|NCT00256620|Procedure|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
79654511|NCT00228839|Drug|Infliximab|
79654512|NCT00191269|Drug|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
79654513|NCT00191269|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
79654514|NCT00256659|Behavioral|Early assessment and referral to ancillary care services vs. standard care|
79654515|NCT00228878|Procedure|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
79654516|NCT00413868|Procedure|LASIK|
79654517|NCT00413868|Procedure|PRK|
79339402|NCT02359851|Biological|Pembrolizumab|Given IV
79339403|NCT02359851|Other|Laboratory Biomarker Analysis|Correlative studies
79489129|NCT02995915|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
79489130|NCT02995915|Behavioral|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
79339404|NCT01607905|Drug|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
79654518|NCT00413868|Behavioral|Small target contrast sensitivity and disability glare|
79654519|NCT00228956|Drug|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
79654520|NCT00228995|Drug|epoetin alfa|
79339405|NCT01607905|Drug|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
79654521|NCT00413946|Drug|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
79813447|NCT04113798|Other|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur ~24 hours following Day 3, and lasts about 30 minutes.
79339406|NCT02389543|Drug|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
79339407|NCT02389543|Drug|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
79339408|NCT02389543|Drug|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
79339409|NCT02536963|Device|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
79489131|NCT02995915|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
79489132|NCT02995915|Behavioral|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
79489133|NCT04376515|Behavioral|HOPE intervention|Online peer support community of peers trained in behavior change science
79654522|NCT00413946|Drug|saline|three doses of 1.0 ml saline per body weight
79654523|NCT00229073|Drug|dapoxetine|
79654524|NCT00413985|Drug|Nutrient-enriched human milk|
79654525|NCT00229112|Drug|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
79654526|NCT00229112|Drug|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
79654527|NCT00256737|Drug|Omeprazole|
79654528|NCT00191191|Drug|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
79339410|NCT02536963|Other|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
79339411|NCT00843037|Drug|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
79339412|NCT05392543|Other|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
79339413|NCT05392543|Other|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
79339414|NCT05414773|Other|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
79339417|NCT05391919|Other|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
79339418|NCT05391919|Other|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
79339419|NCT05440435|Diagnostic Test|digital radiography (DR)|Patients with bone injury received routine and mobile DR sequential examination.
79339420|NCT05440045|Drug|6MW3211|6MW3211 injection, 30mg/kg, Q2W
79339421|NCT02531035|Drug|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
79339422|NCT02531035|Drug|Placebo|Placebo, once daily, before the first meal of the day
79339423|NCT05389111|Other|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
79339424|NCT05389111|Other|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
79339425|NCT05387395|Other|NO intervention|no intervention
79339426|NCT05004805|Drug|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
79339427|NCT05004805|Drug|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
79654529|NCT00191191|Drug|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
79654530|NCT00229151|Behavioral|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
79654531|NCT00229151|Other|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
79654532|NCT00414024|Drug|Tegaserod|
79654533|NCT00229190|Procedure|Nasal lavage|
79654534|NCT00229190|Procedure|Allergy skin testing|
79654535|NCT00229190|Procedure|Peak nasal inspiratory flow|
79983881|NCT01365390|Other|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
79983882|NCT03253510|Other|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
79654536|NCT00229190|Procedure|Acoustic rhinometry|
79654537|NCT00229190|Procedure|Nasal examination|
79983883|NCT03253510|Other|Poly-methyl methacrylate|Gold standard denture base material
79339428|NCT05412745|Device|Kaloidon Plus|topical application; twice daily
79654538|NCT00229190|Procedure|Quality of Life Questionnaire|
79654539|NCT00229190|Procedure|Physical examination|
79654540|NCT00256815|Drug|chemotherapy|
79654541|NCT00256815|Procedure|Radiation|
79339429|NCT05412745|Device|silicone gel|topical application; twice daily
79339430|NCT04261387|Drug|LUT014 Gel|Topical application qd for 28 days
79339431|NCT04261387|Drug|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
79654542|NCT00229229|Other|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
79654543|NCT00229229|Other|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
79654544|NCT00229229|Other|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
79654545|NCT00229229|Other|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
79654546|NCT00414102|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
79654547|NCT00414102|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
79654548|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|20 minutes exposure
79654549|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|40 minutes exposure
79339432|NCT05412199|Device|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
79339433|NCT05412199|Device|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
79654550|NCT00256893|Drug|ropinirole|
79339434|NCT05412199|Other|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
79339435|NCT05411965|Drug|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
79339436|NCT05411965|Drug|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
79339437|NCT05411965|Drug|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
79489134|NCT02997085|Device|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
79489135|NCT02997085|Device|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
79654551|NCT00229385|Drug|Ziprasidone|40-80 mg BID
79489136|NCT03163303|Behavioral|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
79489137|NCT03163303|Behavioral|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
79489138|NCT03163303|Drug|nicotine patch|14-day supply of nicotine patch
79489139|NCT04349995|Device|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
79654552|NCT00236223|Drug|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
79654553|NCT00236223|Drug|Placebo|Matching placebo
79654554|NCT00229424|Drug|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
79654555|NCT00229424|Drug|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
79339438|NCT04261075|Biological|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
79339439|NCT04261075|Biological|durvalumab|Durvalumab Q3W for a maximum of 2 years
79339440|NCT04261075|Biological|oleclumab|Oleclumab Q3W for a maximum of 2 years
79339441|NCT04452019|Device|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
79339442|NCT04452019|Device|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
79339443|NCT04451473|Procedure|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
79339444|NCT04451473|Procedure|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
79339445|NCT05438017|Device|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
79339446|NCT05436769|Drug|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
79983884|NCT03744845|Other|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
79339447|NCT05436769|Drug|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
79339448|NCT03937999|Drug|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
79339449|NCT05436067|Device|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
79339450|NCT05377567|Behavioral|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
79339451|NCT05377567|Behavioral|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
79339452|NCT05377567|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
79489140|NCT03165175|Behavioral|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
79654556|NCT00229424|Other|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
79983885|NCT03634020|Device|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
79654557|NCT00256932|Drug|alvimopan|0.5 mg
79654558|NCT00256932|Drug|Placebo|
79654559|NCT00256971|Procedure|meniscectomy|
79654560|NCT00229541|Procedure|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
79339453|NCT01659853|Drug|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
79339454|NCT01659853|Drug|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
79339455|NCT05376631|Procedure|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
79339456|NCT05376631|Procedure|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
79654561|NCT00236262|Device|ventilatory strategies with pressure|
79654562|NCT00191152|Drug|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
79654563|NCT00191152|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
79654564|NCT00191152|Drug|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
79654565|NCT00229580|Behavioral|3 session brief intervention with health behavior feedback|
79654566|NCT00229580|Other|treatment as usual|
79654567|NCT00257049|Drug|levofloxacin|
79654568|NCT01059188|Drug|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
79983886|NCT03253666|Other|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
79489141|NCT03000283|Drug|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
79489142|NCT03855163|Behavioral|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
79489143|NCT03855163|Behavioral|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
79489144|NCT03855163|Behavioral|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
79489145|NCT03164629|Device|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
79489146|NCT03168295|Drug|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
79654569|NCT01059188|Drug|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
79339457|NCT05610553|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
79339458|NCT05610553|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
79489147|NCT03168295|Drug|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
79654570|NCT01059188|Drug|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
79654571|NCT01059188|Radiation|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
79654572|NCT01059188|Procedure|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
79489148|NCT03168841|Drug|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
79489149|NCT03822949|Device|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
79489150|NCT03822949|Device|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
79489151|NCT03822949|Device|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
79489152|NCT03822949|Device|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
79489153|NCT04068493|Behavioral|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
79489154|NCT03815227|Other|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
79654573|NCT00236301|Drug|CLIMASTON (drug)|CLIMASTON(drug)
79654574|NCT00236301|Drug|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
79654575|NCT00236301|Drug|placebo|placebo
79654576|NCT00236340|Device|syringe aspiration|
79654577|NCT00236340|Device|Wall suction|
79654578|NCT00229697|Drug|Gefitinib|
79654579|NCT00229697|Drug|Tamoxifen|
79654580|NCT00236379|Drug|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
79654581|NCT00236379|Drug|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
79654582|NCT00229736|Genetic|AAV-hAADC-2|9 x 10^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
79654583|NCT00229736|Genetic|AAV-hAADC-2|3 x 10^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
79654584|NCT00257088|Behavioral|whole day first grade program|
79654585|NCT00229775|Drug|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
79654586|NCT00257127|Biological|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
79339459|NCT05593393|Device|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
79339460|NCT05376163|Other|Survey Study|Headache Disabilty Index (HDI) will be applied.
79339461|NCT05374369|Diagnostic Test|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
79339462|NCT05374369|Procedure|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
79489155|NCT04058587|Drug|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
79489156|NCT00375271|Procedure|perioperative hemodynamic optimization protocol|
79489157|NCT00375349|Procedure|Ultrasound to demonstrate existence of fatty liver|
79489158|NCT03865615|Drug|Oxytocin|intranasal oxytocin 40IU/mL
79654587|NCT00257127|Biological|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
79654588|NCT00257127|Biological|Hepatitis B vaccine|0.5 mL administered intramuscularly
79654589|NCT00257127|Biological|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
79813448|NCT00812734|Procedure|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
79339463|NCT05610475|Diagnostic Test|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
79813449|NCT04113486|Other|Blood test|About 4 ml of blood draw
79813450|NCT04045522|Drug|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
79813451|NCT04113564|Drug|Remimazolam|
79813452|NCT04108650|Other|Fit & Strong! group|Consistent with the original format of F&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
79339464|NCT05576389|Drug|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
79654590|NCT00190684|Drug|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
79813453|NCT02551276|Drug|Salbutamol|
79339465|NCT04252807|Behavioral|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
79339466|NCT04252807|Other|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
79339467|NCT05568511|Other|App-based exercise program|Remotely-controlled, app-guided exercise program
79489159|NCT03865615|Drug|Placebo|Placebo
79654591|NCT00236418|Drug|topiramate|
79654592|NCT00257283|Drug|Omega-3-acid ethyl esters 90|
79654593|NCT00236457|Drug|risperidone|
79654594|NCT04721834|Device|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
79813454|NCT02551276|Drug|Placebo|
79813455|NCT02551276|Other|Resistance training|
79813456|NCT00815386|Device|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
79813457|NCT00791934|Device|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
79654595|NCT04721834|Device|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
79654596|NCT00236496|Drug|topiramate|
79654597|NCT00199277|Drug|i.v. iron sucrose|
79654598|NCT00199277|Drug|Oral iron|
79654599|NCT00236535|Drug|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
79654600|NCT00193219|Drug|Bevacizumab|5 mg/kg IV
79813458|NCT00848081|Drug|Tadalafil|5 mg taken by mouth once daily for 12 weeks
79813459|NCT00848081|Drug|Placebo|By mouth once daily for 12 weeks
79339468|NCT05568511|Other|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
79654601|NCT00193219|Drug|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
79654602|NCT00193219|Drug|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
79813460|NCT02551978|Other|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
79813461|NCT02605278|Other|Clinical program for pain and depression|Already described
79813462|NCT02605278|Other|Control|Care as usual
79813463|NCT00815464|Device|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
79654603|NCT00193219|Drug|Leucovorin|350 mg IV
79302434|NCT02486315|Device|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
79654604|NCT00193219|Drug|Oxaliplatin|85 mg/m2 IV
79813464|NCT04111380|Drug|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
79813465|NCT02552056|Other|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
79813466|NCT04117919|Drug|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
79813467|NCT04117919|Drug|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
79339469|NCT05372341|Other|descriptive|posotcovid patients will be elective surgery postoperative outcomes
79339470|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
79339471|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
79339472|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
79339473|NCT01660243|Drug|Placebo|Placebo (2capsules) once daily for 8 weeks
79654605|NCT00199316|Drug|spinal morphine|
79654606|NCT00196339|Drug|Cyproterone acetate 5|Cyproterone acetate 5 mg
79654607|NCT00196339|Drug|Placebo|Matching placebo
79654608|NCT00196339|Drug|Cyproterone acetate 15|Cyproterone acetate 15 mg
79654609|NCT00196339|Drug|Cyproterone acetate 25|Cyproterone acetate 25 mg
79654610|NCT00257361|Drug|D-Cycloserine|
79654611|NCT00199355|Drug|Istradefylline (KW-6002)|
79654612|NCT00179959|Drug|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
79654613|NCT00179959|Drug|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
79654614|NCT00179959|Drug|Water|Water baths twice weekly for three months
79654615|NCT00179959|Drug|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
79654616|NCT00199394|Drug|Istradefylline (KW-6002)|
79654617|NCT02961933|Other|Apneic oxygenation|Nasal cannula apneic oxygenation
79813468|NCT04108338|Other|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
79813469|NCT02551510|Procedure|Suture|Skin incision closure with standard subcuticular technique
79339474|NCT05604703|Diagnostic Test|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
79339475|NCT05341687|Other|No applicable|No applicable
79339476|NCT05567263|Procedure|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
79339477|NCT05567263|Procedure|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
79339478|NCT05341609|Drug|JT001|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
79339479|NCT05341609|Drug|Paxlovid|Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
79339480|NCT05604391|Procedure|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
79654618|NCT02961933|Other|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
79983887|NCT03253432|Other|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
79339481|NCT05604391|Procedure|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
79339482|NCT05565079|Biological|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
79339483|NCT05565079|Biological|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
79339484|NCT05341453|Procedure|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
79489160|NCT03180385|Device|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
79489161|NCT03180385|Device|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
79654619|NCT00257400|Behavioral|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
79654620|NCT00257400|Behavioral|Individual Psychotherapy|Individual Psychotherapy
79654621|NCT00236574|Drug|Galantamine hydrobromide|
79654622|NCT00199433|Drug|Istradefylline (KW-6002)|
79654623|NCT00199472|Procedure|Dynamic Contrast Enhanced CT & Diuretic Renogram|
79654624|NCT02961972|Dietary Supplement|monohydrate and micronized creatine|oral supplementation with creatine
79654625|NCT02961972|Other|placebo|oral supplementation with maltodextrin (control group)
79654626|NCT00199511|Drug|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
79654627|NCT00236613|Drug|topiramate|
79339485|NCT05341453|Procedure|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
79339486|NCT05341453|Procedure|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
79339487|NCT05538013|Other|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
79339488|NCT05371015|Procedure|quadratus lumborum nerve block (ropivacaine )|Echo guided quadratus lumborum nerve block with ropivacaine
79339489|NCT05371015|Procedure|quadratus lumborum nerve block (normal saline)|Echo guided quadratus lumborum nerve block with normal saline
79339490|NCT05598463|Device|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
79339491|NCT05340907|Device|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
79339492|NCT05309161|Dietary Supplement|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
79489162|NCT03859297|Behavioral|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
79339493|NCT05339659|Device|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
79339494|NCT02531113|Drug|RPC1063|
79339495|NCT05308069|Device|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
79339496|NCT05308069|Device|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
79489163|NCT03859297|Behavioral|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
79654628|NCT00257478|Drug|YM155|
79339497|NCT05368519|Device|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
79339498|NCT04255693|Behavioral|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
79339499|NCT04255693|Behavioral|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
79339500|NCT04255693|Behavioral|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
79339501|NCT04255693|Behavioral|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
79339502|NCT04255693|Behavioral|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
79339503|NCT04255693|Behavioral|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
79339504|NCT04248595|Drug|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
79339505|NCT04248595|Drug|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
79339506|NCT04247425|Other|Exercise Counseling|Receive instructional guidance
79339507|NCT04247425|Other|Quality-of-Life Assessment|Ancillary studies
79339508|NCT04247425|Other|Questionnaire Administration|Ancillary studies
79339509|NCT04247425|Other|Resistance Training|Complete progressive resistance training
79489164|NCT03735823|Other|No intervention, just collect blood samples and CSF samples|No intervention
79654629|NCT00199550|Procedure|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
79654630|NCT00199550|Procedure|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
79654631|NCT04721340|Other|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
79339510|NCT05337709|Other|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
79339511|NCT05337397|Procedure|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
79339512|NCT05337241|Device|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
79339513|NCT05336617|Procedure|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
79489165|NCT03185546|Other|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
79654632|NCT04721340|Other|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
79654633|NCT00199589|Drug|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
79654634|NCT00236652|Drug|levofloxacin|
79654635|NCT00257595|Drug|Cetirizine Dry Syrup|
79654636|NCT00199667|Drug|Mycophenolate Mofetil|
79654637|NCT00236691|Drug|topiramate|
79654638|NCT00199706|Drug|7.2% NaCl in 6% hydroxyethyl starch solution|
79654639|NCT00236730|Drug|topiramate|
79654640|NCT00199745|Drug|atorvastatin|
79654641|NCT04709172|Drug|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
79654642|NCT00199784|Drug|Phenylephrine|
79654643|NCT00236769|Drug|norelgestromin + ethinyl estradiol|
79654644|NCT00199823|Genetic|Intracoronary aotologous stem cell transplantation|
79654645|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
79339514|NCT05366335|Drug|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
79339515|NCT05366335|Drug|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
79339516|NCT05366335|Drug|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
79339517|NCT05530915|Other|Gel capsule|Single capsule per dose
79339518|NCT05365399|Device|smartphone-based screening tool for neonatal jaundice|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
79339519|NCT05334277|Drug|Furmonertinib|Furmonertinib 80mg QD
79339520|NCT05334277|Drug|Furmonertinib|Furmonertinib 80mg QD
79339521|NCT05334277|Drug|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
79339522|NCT05334277|Drug|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
79339523|NCT05363371|Behavioral|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
79339524|NCT05363371|Behavioral|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
79339525|NCT05363137|Other|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
79654646|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
79654647|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
79339526|NCT05363137|Other|Standard care|The physiotherpy treatment will be standard care
79339527|NCT05332717|Dietary Supplement|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
79489166|NCT03185546|Other|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
79489167|NCT03185546|Other|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
79654648|NCT00199940|Drug|Ziprasidone|
79813470|NCT02551510|Device|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
79813471|NCT00701285|Drug|pitavastatin|pitavastatin 4mg once daily
79813472|NCT00701285|Drug|pravastatin|pravastatin 10mg once daily
79339528|NCT05332717|Dietary Supplement|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
79339529|NCT05506813|Other|cognitive training and conventional training|cognitive training along with conventional therapy
79489168|NCT03185546|Other|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
79489169|NCT03185546|Other|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
79489170|NCT03185546|Other|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
79489171|NCT05365009|Diagnostic Test|Multidisciplinary aproach|regular tests
79489172|NCT05058482|Device|embolism|Cerebral arteriovenous malformation embolism
79489173|NCT03657511|Behavioral|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
79489174|NCT04613882|Device|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
79489175|NCT04613882|Device|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
79489176|NCT04613882|Device|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
79489177|NCT03713203|Device|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
79489178|NCT02186652|Drug|Pantoprazole|
79489179|NCT03677791|Other|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
79654649|NCT00236808|Drug|levofloxacin|
79654650|NCT00199979|Drug|Nevirapine|
79654651|NCT02961114|Procedure|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
79654652|NCT02961114|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
79654653|NCT02961114|Biological|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
79654654|NCT00200018|Device|Enterra Therapy System (H9900014)|
79654655|NCT00257634|Drug|dexamethasone to injury site|
79654656|NCT00236847|Drug|topiramate|
79654657|NCT00410228|Drug|AHT956|
79654658|NCT00257673|Drug|MEM 1003|30 mg twice a day
79489180|NCT03677791|Other|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
79654659|NCT00257673|Drug|MEM 1003|90 mg MEM 1003 twice a day
79654660|NCT00257673|Drug|Placebo for MEM 1003|Placebo twice a day
79654661|NCT00410306|Drug|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
79654662|NCT00257712|Drug|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
79654663|NCT00179647|Drug|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
79489181|NCT03187418|Device|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
79489182|NCT03646981|Device|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
79489183|NCT03606889|Diagnostic Test|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
79489184|NCT03606889|Diagnostic Test|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
79489185|NCT03606889|Drug|Bupivacaine|0.2 ml/kg bupivicaine
79489186|NCT03283969|Other|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
79339530|NCT05506813|Other|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
79654664|NCT00179647|Drug|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
79654665|NCT00257751|Procedure|Aprotinine|
79813473|NCT05617638|Behavioral|Intervention|Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
79813474|NCT02613767|Other|Protein meal|Ingestion of protein
79813475|NCT02613767|Other|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
79339531|NCT05300269|Drug|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m^2, day1, iv, q3w"
79339532|NCT05329285|Procedure|Percutaneous Coronary Intervention (PCI)|Alternative treatment
79339533|NCT05356507|Other|Patient population|Questionnaires, standard of care
79339534|NCT05356273|Procedure|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
79339535|NCT05299177|Device|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
79489187|NCT03283969|Other|Isocaloric powder|Isocaloric powder
79489188|NCT05363917|Drug|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
79339536|NCT05327569|Other|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
79489189|NCT05363917|Drug|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
79489190|NCT03187730|Behavioral|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
79489191|NCT03187730|Behavioral|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
79489192|NCT03187730|Drug|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
79654666|NCT00200096|Procedure|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
79339537|NCT04254367|Behavioral|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
79489193|NCT05363761|Combination Product|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
79489194|NCT03189134|Drug|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
79489195|NCT03189134|Device|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
79489196|NCT03261193|Drug|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
79489197|NCT03261193|Drug|ITM + Bupivacaine QLB|QL plane block with local anesthesia
79489198|NCT05359705|Device|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
79339538|NCT05326945|Other|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
79489199|NCT05359705|Device|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
79489200|NCT05359705|Device|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
79489201|NCT05359705|Device|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
79489202|NCT00375661|Drug|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
79489203|NCT04736186|Drug|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
79489204|NCT04736186|Drug|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
79489205|NCT04736186|Drug|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
79489206|NCT02185794|Drug|Voxilaprevir|Voxilaprevir tablets administered orally once daily
79489207|NCT02185794|Drug|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
79489208|NCT02185794|Drug|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
79339539|NCT05354167|Other|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
79339540|NCT05354167|Other|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
79654667|NCT00200096|Procedure|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
79654668|NCT00179413|Drug|PEG -Intron|
79654669|NCT00179413|Drug|Colchicine|0.6mg twice a day
79654670|NCT00236886|Drug|topiramate|
79654671|NCT00178633|Procedure|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
79654672|NCT04571866|Other|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
79654673|NCT00257790|Drug|Tobramycin once a day|
79654674|NCT00178399|Procedure|Stereotactic Body Radiation Therapy|
79654675|NCT00178126|Device|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
79983888|NCT04466592|Behavioral|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
79489209|NCT04941170|Drug|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
79654676|NCT00178126|Device|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
79654677|NCT00236925|Drug|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
79654678|NCT00236925|Drug|Placebo|Placebo
79654679|NCT00200213|Behavioral|portion or unportioned food|
79654680|NCT00236964|Drug|Iron Sucrose + Erythropoietin|
79654681|NCT00236964|Drug|Ferrous Sulfate + Erythropoietin|
79654682|NCT00200252|Drug|oxytocin|
79654683|NCT00177307|Drug|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
79654684|NCT00177307|Drug|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
79654685|NCT00177307|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
79654686|NCT00257829|Drug|Methazolamide|
79654687|NCT00257829|Drug|Cisplatin|
79654688|NCT04571983|Other|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
79983889|NCT03233620|Other|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
79983890|NCT04445220|Biological|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
79339541|NCT05353933|Other|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
79339542|NCT05353933|Drug|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
79339543|NCT05325463|Procedure|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
79983891|NCT03253276|Drug|Obeticholic acid|Placebo-controlled
79339544|NCT05325463|Procedure|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
79489210|NCT04941170|Drug|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
79489211|NCT05357911|Drug|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
79489212|NCT05355883|Behavioral|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
79339545|NCT05353855|Other|No intervention|No intervention
79489213|NCT05355883|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
79654689|NCT00200291|Behavioral|hypocaloric, low-fat diet|hypocaloric, low-fat diet
79654690|NCT00237003|Behavioral|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
79654691|NCT02277535|Other|Feedback/Reminder email.|
79813476|NCT04001166|Other|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
79813477|NCT00812890|Device|semi-quantitative pregnancy test|
79813478|NCT02604498|Drug|Nemonoxacin|Single dose 500mg oral
79813479|NCT00700037|Drug|high-dose atorvastatin|20mg/day
79813480|NCT00700037|Drug|low-dose atorvastatin|5mg/day
79813481|NCT00808522|Drug|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
79813482|NCT00815542|Device|double balloon catheter|cervical ripening using double balloon catheter
79983892|NCT03253276|Drug|Placebos|
79813483|NCT00815542|Drug|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
79983893|NCT01372644|Drug|SOM 230 / Pasireotide|
79983894|NCT01371084|Behavioral|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
79983895|NCT01371084|Behavioral|Pedal@Work|Worksite wellness program.
79983896|NCT03233386|Behavioral|Mantente REAL|substance abuse prevention curriculum for adolescents
79339546|NCT05352685|Drug|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
79489214|NCT05355883|Behavioral|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
79489215|NCT05355883|Behavioral|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
79339547|NCT05321875|Drug|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
79339548|NCT05346367|Radiation|SRT|SRT
79339549|NCT05346367|Radiation|fSRT|fSRT
79339550|NCT02522767|Drug|Mesalamine|
79339551|NCT02522767|Drug|Placebo|
79339552|NCT05319847|Dietary Supplement|Daily Skin Supplement - Fountain of Youth|Skincare supplement
79339553|NCT02522377|Drug|Ketamine|inter venous injections
79489216|NCT05355883|Behavioral|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
79339554|NCT02522377|Drug|Midazolam|inter venous injections
79339555|NCT05319613|Other|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
79489217|NCT03374839|Drug|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
79489218|NCT04848272|Drug|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
79339556|NCT05318599|Device|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
79654692|NCT02484664|Drug|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
79654693|NCT00200330|Behavioral|Behavioral weight loss treatment|
79983897|NCT03253198|Drug|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
79983898|NCT03253198|Drug|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
79339557|NCT05318599|Device|Lung ultrasound|Lung ultrasonography
79339558|NCT05318599|Other|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
79339559|NCT05318599|Diagnostic Test|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
79339560|NCT04422691|Diagnostic Test|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
79339561|NCT05268757|Behavioral|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
79489219|NCT04848272|Other|Saline control|Saline control
79489220|NCT02221674|Drug|Tapentadol|
79654694|NCT00200330|Behavioral|Behavioral and home environment weight loss treatment|
79654695|NCT00257868|Drug|Rivastigmine prevention of delirium|
79654696|NCT00176605|Drug|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
79813484|NCT00791778|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
79489221|NCT04520906|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
79489222|NCT04736719|Drug|Apixaban|Apixaban dispensing claim is used as the exposure group
79489223|NCT04736719|Drug|Warfarin|Warfarin dispensing claim is used as the reference group
79489224|NCT04736563|Device|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
79489225|NCT04429646|Device|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
79654697|NCT00176605|Drug|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
79654698|NCT00200369|Device|MEMS cap|
79654699|NCT00176488|Drug|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
79654700|NCT00176488|Drug|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
79654701|NCT00200447|Drug|carbidopa/l-dopa|
79654702|NCT00200447|Drug|carbidopa/l-dopa/entacapone|
79339562|NCT05267743|Drug|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
79489226|NCT04429646|Device|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
79489227|NCT02221284|Drug|Alogliptin|Alogliptin tablets
79489228|NCT04736407|Other|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
79654703|NCT00200447|Drug|Stalevo|
79654704|NCT00200447|Procedure|[123I]-IBZM imaging|
79813485|NCT00791778|Drug|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
79813486|NCT04108260|Drug|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
79813487|NCT00798174|Device|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
79983899|NCT03253042|Other|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
79339563|NCT05267743|Drug|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
79339564|NCT05291845|Biological|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
79339565|NCT05291845|Biological|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
79339566|NCT05317195|Other|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
79339567|NCT05317195|Other|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
79339568|NCT05317195|Other|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
79339569|NCT05317195|Other|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
79339570|NCT05317195|Other|Velo-NP|Velo-NP; 10 mg nicotine;
79339571|NCT05317195|Other|Zyn-NP|Zyn-NP; 3 mg nicotine;
79654705|NCT00237120|Drug|Imatinib|
79654706|NCT00175825|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
79654707|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
79654708|NCT04710329|Drug|Ascorbic acid|The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
79654709|NCT00257946|Procedure|Repair of CDH w/SIS Gold|
79654710|NCT00257946|Procedure|Repair of CDH w/Alloderm|
79489229|NCT04736108|Drug|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
79489230|NCT04736108|Drug|Prednisolone|5 mg oral low dose prednisone, once daily
79489231|NCT04736108|Drug|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
79489232|NCT03196076|Drug|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
79654711|NCT00257985|Drug|GTN|
79339572|NCT05317117|Diagnostic Test|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|"The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
79339573|NCT05314621|Drug|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
79339574|NCT05314621|Drug|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
79489233|NCT02971033|Drug|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
79489234|NCT02971033|Drug|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
79983900|NCT03253042|Other|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
79339575|NCT05314621|Drug|Tears Naturale|Tears Naturale® II (eye drop)
79489235|NCT02971033|Drug|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
79489236|NCT05406674|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
79489237|NCT05406674|Drug|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
79489238|NCT05341375|Procedure|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
79983901|NCT03252730|Other|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
79654712|NCT00200525|Drug|apomorphine HCl injection|
79654713|NCT00174967|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
79654714|NCT00174967|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
79654715|NCT00174967|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
79654716|NCT00174967|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
79489239|NCT05341375|Drug|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
79489240|NCT05341375|Behavioral|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
79654717|NCT00200564|Drug|ketamine|
79654718|NCT00174265|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
79654719|NCT00174265|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
79654720|NCT00200603|Device|calcium phosphate macroporous bioceramics|
79654721|NCT00258024|Drug|IPT-sulphadoxinepyrimethamine|
79654722|NCT00200642|Device|Stretta® System|
79339576|NCT05314621|Drug|Saline nasal spray|Saline nasal spray (nasal spray)
79339577|NCT05290597|Biological|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
79339578|NCT05314465|Other|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times & repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
79339579|NCT05314075|Procedure|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
79339580|NCT05314075|Procedure|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
79339581|NCT05263609|Drug|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
79339582|NCT05263609|Drug|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
79983902|NCT03252886|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
79339583|NCT05263375|Device|Innovalve TMVR system|Innovalve TMVR system
79339584|NCT05313997|Drug|Diclofenac Sodium|"at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program."
79339585|NCT05259241|Diagnostic Test|activated partial thrombin time|This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
79339586|NCT05219227|Other|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~Static abdominal exercises:~Dynamic abdominal exercises:~Hip shrugging exercise from crook lying position:~Lateral flexion of the trunk from crook lying position:~Antero-posterior flexion of the trunk from crook lying position:"
79339587|NCT01657903|Drug|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
79654723|NCT00200681|Drug|Velcade|
79654724|NCT00258063|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
79654725|NCT00200720|Behavioral|Atkins diet (low carbohydrate diet)|
79654726|NCT00200720|Behavioral|DASH diet (high carbohydrate diet)|
79654727|NCT00258102|Drug|Levofloxacin|
79654728|NCT00200759|Drug|Cranberry juice and capsules|
79983903|NCT03117738|Drug|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
79983904|NCT03117738|Other|Placebo-Control|Saline with 30% auto-serum
79654729|NCT00265278|Drug|Modafinil|
79983905|NCT03252652|Radiation|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
79983906|NCT03229330|Procedure|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
79983907|NCT03229330|Combination Product|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
79983908|NCT03236038|Diagnostic Test|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
79339588|NCT01657903|Drug|Potassium nitrate|All study treatments contain 5% w/w KNO3.
79339589|NCT05256823|Drug|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
79339590|NCT05256823|Drug|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
79339591|NCT05218681|Other|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
79339592|NCT05218681|Other|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
79654730|NCT00258141|Drug|Rupatadine|
79654731|NCT00258141|Drug|Placebo|
79654732|NCT00265356|Procedure|PET diagnostic imaging|PET diagnostic imaging
79339593|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
79489241|NCT05341375|Behavioral|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
79489242|NCT00375817|Procedure|Myoblasts injection with MyoCath catheter|
79489243|NCT02796001|Biological|human rhinovirus|human rhinovirus
79489244|NCT02796001|Other|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
79654733|NCT00200876|Procedure|Hypertonic saline|To elicit pain
79654734|NCT00200876|Procedure|Isotonic saline|Non-painful control
79654735|NCT00258258|Drug|paricalcitol|
79654736|NCT00258258|Drug|zoledronic acid|
79654737|NCT00200954|Dietary Supplement|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
79654738|NCT00200954|Dietary Supplement|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
79654739|NCT00265434|Drug|Pulmozyme|
79983909|NCT04292106|Dietary Supplement|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
79813488|NCT04113642|Other|ultrasonographic measurement of abdominal muscle thickness at four positions|Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
79813489|NCT04113174|Other|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
79489245|NCT04736264|Other|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
79654740|NCT00172042|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
79654741|NCT00200993|Behavioral|physical activity|
79654742|NCT00258297|Drug|gefitinib|
79654743|NCT00258297|Procedure|conventional surgery|
79654744|NCT00258297|Procedure|enzyme inhibitor therapy|
79654745|NCT00258297|Procedure|neoadjuvant therapy|
79654746|NCT00258297|Procedure|protein tyrosine kinase inhibitor therapy|
79654747|NCT00258297|Procedure|surgery|
79654748|NCT00201110|Behavioral|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
79654749|NCT00201110|Behavioral|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
79983910|NCT04292106|Dietary Supplement|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
79983911|NCT03235882|Diagnostic Test|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
79983912|NCT03236116|Other|Almonds|Participants will consume almonds everyday for 6 months.
79339594|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
79339595|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
79339596|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
79489246|NCT04736264|Other|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
79489247|NCT04736264|Other|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
79983913|NCT03236116|Other|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
79983914|NCT04485988|Drug|Beta blocker|Duration of medication
79983915|NCT04163484|Other|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
79489248|NCT05406518|Other|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
79813490|NCT02604576|Drug|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
79983916|NCT03235960|Device|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
79983917|NCT04234464|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
79983918|NCT04234464|Combination Product|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
79983919|NCT04485910|Other|Single step media|Usage of single step media in embryo culture
79983920|NCT04485910|Other|Sequential media|Usage of sequential media in embryo culture
79983921|NCT03235570|Drug|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
79983922|NCT01371162|Drug|RO5428029|Multiple ascending doses
79983923|NCT01371162|Drug|placebo|multiple doses
79339597|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
79339598|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
79489249|NCT04373252|Biological|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
79489250|NCT03235687|Diagnostic Test|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
79489251|NCT03200587|Drug|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
79654750|NCT00201149|Behavioral|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
79489252|NCT03200587|Drug|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
79489253|NCT03198884|Drug|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
79489254|NCT01801189|Drug|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
79489255|NCT01801189|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
79654751|NCT00201188|Behavioral|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
79654752|NCT00258336|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
79654753|NCT00258336|Biological|rituximab|
79654754|NCT00258336|Biological|sargramostim|
79813491|NCT02604576|Drug|Bromopride 10 mg|Bromopride 10 mg
79983924|NCT04485832|Device|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
79983925|NCT04485832|Diagnostic Test|Weekly CAT measurement|
79983926|NCT03235648|Procedure|cardiophrenic lymph nodes resection|surgical resection
79339599|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
79339600|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
79654755|NCT00171925|Drug|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg*hr/l).
79339601|NCT05284201|Device|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
79654756|NCT00171925|Dietary Supplement|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
79654757|NCT00201227|Other|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
79339602|NCT05492149|Other|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
79339603|NCT05255263|Other|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
79339604|NCT05255263|Other|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
79654758|NCT00258453|Other|metabolic assessment|
79339605|NCT05254717|Other|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
79489256|NCT05440838|Diagnostic Test|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
79489257|NCT04275362|Device|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
79654759|NCT00258453|Other|physiologic testing|
79654760|NCT00258453|Procedure|biopsy|
79654761|NCT00258453|Procedure|computed tomography|
79654762|NCT00258453|Procedure|conventional surgery|
79654763|NCT00258453|Procedure|magnetic resonance imaging|
79654764|NCT00258453|Procedure|management of therapy complications|
79654765|NCT00258453|Procedure|psychosocial assessment and care|
79654766|NCT00258453|Procedure|quality-of-life assessment|
79654767|NCT00258453|Radiation|radiation therapy|
79654768|NCT00201266|Procedure|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
79654769|NCT00201305|Drug|Gemcitabine+5FU+Leucovorin|
79654770|NCT00258492|Behavioral|Aerobic exercise|
79654771|NCT00265551|Drug|SCA-136 (200 mg)|
79654772|NCT00265551|Drug|SCA-136 (400 mg)|
79654773|NCT00265551|Drug|olanzapine (15 mg)|
79654774|NCT00265551|Drug|placebo|
79654775|NCT00201344|Drug|Cisplatin,5-FU,Leucovorin|
79489258|NCT04275362|Device|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
79339606|NCT05253937|Drug|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
79339607|NCT05253703|Other|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
79339608|NCT05218603|Drug|Bortezomib|Maintenance: Administration as per routine clinical practice.
79489259|NCT04275362|Device|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
79654776|NCT00265629|Device|RF catheter ablation|RF ablation using mesh device
79654777|NCT00201383|Drug|cisplatin|
79339609|NCT05218603|Drug|Daratumumab|Maintenance: Administration as per routine clinical practice.
79339610|NCT05217121|Other|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
79654778|NCT00201422|Other|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
79654779|NCT00258531|Device|Olympus ScopeGuide®, 3-dimentional magnetic imager|
79489260|NCT04275362|Device|Control|No total knee replacement
79489261|NCT05406206|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
79489262|NCT05406206|Procedure|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m*2 + 5-FU 2000 mg/m*2, Q4W
79489263|NCT00716755|Drug|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, [11C]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
79654780|NCT00201461|Device|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
79654781|NCT00201461|Drug|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
79654782|NCT00258609|Drug|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
79654783|NCT00265707|Device|Blood pressure measurement|
79489264|NCT05406128|Other|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
79489265|NCT05406128|Other|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
79654784|NCT04709367|Other|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
79654785|NCT00265746|Drug|Metformin|
79654786|NCT00265746|Behavioral|Lifestyle intervention - diet, physical activity|
79654787|NCT00201539|Drug|single dose Morphine|
79654788|NCT00201539|Drug|double dose Morphine|
79654789|NCT00201539|Drug|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
79654790|NCT04709055|Other|Co-management|Personalized and intensive geriatric peri-operative care
79654791|NCT04709055|Other|Usual care|Pre-operative and post-operative geriatric care as per usual practice
79654792|NCT00201617|Device|Bone-anchored hearing aid|
79654793|NCT04709328|Drug|SCTA01|Diluted by 0.9% normal saline，IV
79654794|NCT04709328|Other|Placebo|IV
79339611|NCT05217121|Other|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
79339612|NCT05252377|Other|Breathing Exercise|"The patient will be asked to close their eyes~He will be asked to relax his head and neck in a semi-sitting position in bed~The patient will be asked to breathe through the nose for 3 seconds by counting~Then he will be told to hold his breath for 3 seconds~As the last step, he will be asked to breathe out again in 3 seconds."
79339613|NCT04900831|Diagnostic Test|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
79339614|NCT05251519|Other|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
79654795|NCT00258687|Biological|GVAX|4 vaccines every two weeks
79339615|NCT05251519|Other|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
79339616|NCT05214001|Drug|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
79339617|NCT05214001|Drug|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
79339618|NCT05249881|Drug|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
79339619|NCT05279989|Other|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
79654796|NCT00201656|Procedure|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
79654797|NCT00201656|Procedure|Removal of Cerclage|Immediate removal of Cerclage following randomization
79654798|NCT00201656|Procedure|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
79654799|NCT00265824|Drug|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
79654800|NCT00265824|Drug|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
79654801|NCT00201695|Drug|Doxil®|40 mg/m2 IV day 1
79654802|NCT00201695|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
79654803|NCT00201695|Drug|Dexamethasone|40 mg PO days 1-4
79339620|NCT05279989|Other|Health Information Videos|Participants will receive videos of health information.
79339621|NCT05279677|Drug|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
79489266|NCT05406050|Drug|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
79489267|NCT05406050|Drug|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
79654804|NCT00201695|Drug|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
79654805|NCT00258726|Biological|MMR-II|
79654806|NCT00258726|Biological|Pro-Quad|
79654807|NCT00258726|Biological|Varivax|
79339622|NCT05278117|Procedure|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
79339623|NCT05248945|Drug|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
79339624|NCT05248945|Drug|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
79339625|NCT05248711|Behavioral|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
79339626|NCT04239313|Biological|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
79339627|NCT04239313|Biological|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
79339628|NCT04239313|Biological|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
79339629|NCT05276167|Device|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
79339630|NCT05211973|Device|Wrist Actigraphy Device|a watch like wearable sensor
79339631|NCT05211973|Device|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
79339632|NCT05211973|Device|Chair Scale|a wheel-chair compatible scale to measure body weight
79339633|NCT05211973|Device|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
79339634|NCT05211973|Device|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
79489268|NCT04736095|Diagnostic Test|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
79489269|NCT04736095|Diagnostic Test|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
79489270|NCT03199118|Procedure|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
79489271|NCT03199118|Other|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
79489272|NCT03202472|Device|Implanted Medical Device|Radiofrequency tag
79489273|NCT03202472|Procedure|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
79489274|NCT03202472|Other|Questionnaire Administration|Ancillary studies
79489275|NCT03202472|Procedure|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
79489276|NCT03202472|Procedure|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
79489277|NCT04200404|Drug|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
79489278|NCT04200404|Drug|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
79654808|NCT00410345|Drug|Mifepristone|
79654809|NCT00265863|Drug|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
79654810|NCT00410462|Drug|brostallicin|
79654811|NCT00410462|Drug|doxorubicin hydrochloride|
79654812|NCT00258765|Drug|Zoledronic Acid|
79654813|NCT00258765|Drug|Docetaxel|
79654814|NCT00410501|Drug|Indacaterol (QAB149)|
79654815|NCT00265902|Procedure|diagnostic imaging|
79654816|NCT00410540|Drug|OROS hydromorphone HCL ; Morphine sulfate|
79654817|NCT00258804|Drug|Insulin glargine|
79654818|NCT00201812|Drug|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
79654819|NCT00201812|Drug|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
79654820|NCT00201812|Drug|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
79339635|NCT05273983|Behavioral|Behavioural Activation|The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
79654821|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
79654822|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, IM
79654823|NCT00201890|Procedure|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
79654824|NCT04709094|Drug|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
79654825|NCT04709094|Drug|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
79654826|NCT04709094|Drug|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
79654827|NCT04709094|Drug|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
79654828|NCT00201929|Procedure|Standard Decision Board|
79654829|NCT00201929|Procedure|Computer Decision Board|
79654830|NCT00201929|Procedure|Paper Decision Board|
79654831|NCT00171340|Drug|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
79654832|NCT00171340|Drug|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
79654833|NCT00266019|Behavioral|Weight Management (diet, exercise, and behavior modification)|
79813492|NCT04110600|Other|Coffee effect on early gastric motility|this group 100ml coffee after two hours
79339636|NCT05273515|Other|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
79654834|NCT00201968|Device|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
79654835|NCT00201968|Device|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
79339637|NCT05273437|Behavioral|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
79654836|NCT00201968|Other|Conventional Exercise|An aerobic and resistance training program.
79654837|NCT00171301|Drug|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
79654838|NCT00266058|Drug|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
79654839|NCT00171223|Drug|STI571|STI571 oral capsules or tablets.
79654840|NCT00202124|Drug|Tryptophan|
79339638|NCT05481073|Device|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
79339639|NCT05209711|Procedure|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
79983927|NCT03229096|Drug|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
79983928|NCT03232996|Other|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
79489279|NCT04171778|Other|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
79489280|NCT04135742|Device|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
79489281|NCT04135742|Behavioral|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
79654841|NCT04571905|Device|Osteosynthesis with resorbable Material|Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
79654842|NCT00266097|Drug|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
79654843|NCT00266097|Drug|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
79654844|NCT00266097|Drug|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
79489282|NCT03202550|Drug|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
79654845|NCT00266097|Radiation|radiation therapy|5040 cGy, every week, up to 6 weeks
79654846|NCT00266097|Drug|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
79654847|NCT00266097|Drug|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
79339640|NCT05209711|Procedure|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
79654848|NCT00470236|Radiation|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
79654849|NCT00470236|Radiation|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
79339641|NCT05272969|Diagnostic Test|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
79339642|NCT05272969|Diagnostic Test|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
79339643|NCT05272969|Diagnostic Test|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
79654850|NCT00470236|Radiation|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
79654851|NCT00470236|Radiation|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
79654852|NCT00202163|Drug|DHEA|
79654853|NCT00202163|Drug|Testosterone|
79654854|NCT00258999|Device|Skin Cholesterol Testing|
79654855|NCT00476554|Drug|Sapacitabine|Sapacitabine
79339644|NCT05272969|Diagnostic Test|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
79339645|NCT05272969|Diagnostic Test|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
79654856|NCT00202202|Procedure|consultation format|
79654857|NCT04709289|Other|Aminolevulinic acid, photodynamic therapy|Aminolevulinic acid, photodynamic therapy
79654858|NCT00202241|Procedure|testosterone injection|
79654859|NCT00266136|Drug|Cytarabine|see protocol
79654860|NCT00266136|Drug|Thioguanine|see protocol
79654861|NCT00266136|Drug|Daunorubicin|see protocol
79654862|NCT00266136|Drug|Cyclophosphamide|see protocol
79654863|NCT00266136|Drug|G-CSF|see protocol
79654864|NCT00266136|Procedure|Autologous stem cell transplantation|for details see protocol
79654865|NCT00266136|Procedure|Allogeneic stem cell transplantation|for details see protocol
79654866|NCT00230555|Behavioral|professional support model|
79654867|NCT00259038|Drug|Carperitide|
79654868|NCT00259038|Drug|Placebo|
79654869|NCT00230594|Drug|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
79654870|NCT00230594|Drug|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
79654871|NCT00259077|Drug|Omeprazole|
79654872|NCT00479674|Drug|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
79654873|NCT00479674|Drug|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
79654874|NCT00479674|Drug|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
79654875|NCT02962310|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
79339646|NCT05272969|Diagnostic Test|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
79339647|NCT05272969|Diagnostic Test|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
79339648|NCT05272969|Diagnostic Test|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
79339649|NCT05272969|Diagnostic Test|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
79654876|NCT02962310|Drug|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
79983929|NCT03123588|Drug|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
79983930|NCT03123588|Drug|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
79489283|NCT03202550|Drug|Placebo Comparator|Placebo oral pills
79489284|NCT03203564|Drug|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
79654877|NCT00259116|Drug|Relaxin|
79654878|NCT00415779|Drug|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
79654879|NCT00415779|Drug|zoledronic acid|2 mg IV every 2 weeks
79654880|NCT00230711|Behavioral|Physical activity counseling|
79654881|NCT00259155|Drug|Rifaximin|
79654882|NCT00230750|Biological|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
79654883|NCT00230750|Drug|Placebo|Saline placebo.
79654884|NCT00479401|Drug|Pramipexol Extended Release|
79654885|NCT00479401|Drug|Pramipexol Immediate Release|
79654886|NCT00479401|Drug|Placebo|
79983931|NCT03123588|Drug|Placebo|Anagrelide-placebo administered orally BID
79983932|NCT03123588|Drug|Placebo|Ruxolitinib-placebo administered orally BID.
79983933|NCT02453074|Other|Online survey - Follow up for Better Care|
79489285|NCT04123886|Drug|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
79339650|NCT05272969|Diagnostic Test|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
79339651|NCT05272969|Diagnostic Test|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
79339652|NCT05272969|Diagnostic Test|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
79489286|NCT03285542|Device|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
79489287|NCT03285542|Device|Staples|staples for skin closure
79489288|NCT03207074|Diagnostic Test|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
79654887|NCT00415818|Biological|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
79489289|NCT04095806|Other|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
79489290|NCT04088786|Drug|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
79489291|NCT03207386|Behavioral|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
79489292|NCT00392821|Drug|Sorafenib|Sorafenib
79489293|NCT00392821|Drug|RAD001|RAD001
79489294|NCT03208166|Device|Doctormate|Ischemic conditioning device
79654888|NCT00415818|Drug|1st line Chemotherapy|
79654889|NCT00230789|Drug|Tolterodine ER 4 mg QD|
79654890|NCT00230789|Behavioral|OAB Patient Behavioral Training Material|
79654891|NCT00230828|Drug|bifeprunox|
79813493|NCT04110600|Other|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
79489295|NCT03208166|Other|Usual Care|Standard medical care
79489296|NCT04051112|Drug|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
79339653|NCT05272969|Diagnostic Test|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
79339654|NCT05272969|Diagnostic Test|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
79339655|NCT05272969|Diagnostic Test|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
79489297|NCT04708171|Procedure|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
79489298|NCT04708171|Procedure|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
79489299|NCT04708171|Procedure|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
79489300|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
79489301|NCT02187042|Other|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
79489302|NCT03209882|Device|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
79489303|NCT03209882|Device|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
79654892|NCT02962544|Procedure|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
79339656|NCT05272969|Diagnostic Test|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
79339657|NCT05272969|Diagnostic Test|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
79339658|NCT05272969|Diagnostic Test|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
79339659|NCT05272969|Genetic|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
79489304|NCT03290378|Drug|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
79339660|NCT05272969|Genetic|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
79339661|NCT05272969|Genetic|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
79339662|NCT05272033|Device|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
79339663|NCT05243173|Other|Sequencing|Laboratory analysis of samples
79339664|NCT05207917|Procedure|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
79339665|NCT05207917|Procedure|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
79339666|NCT05207917|Procedure|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
79339667|NCT05269147|Procedure|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
79489305|NCT03290378|Other|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
79654893|NCT02962544|Procedure|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
79654894|NCT02962544|Device|Visumax device|
79654895|NCT02962544|Device|FS 200 device|
79654896|NCT00415896|Device|positive pressure ventilation|
79654897|NCT00478777|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
79654898|NCT00478777|Drug|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
79489306|NCT04659967|Behavioral|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
79489307|NCT02076217|Drug|Copper T-380 IUD|
79339668|NCT05241691|Device|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
79489308|NCT02076217|Drug|LNG IUD|
79654899|NCT00477607|Drug|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
79339669|NCT05206747|Device|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
79654900|NCT00477607|Behavioral|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
79339670|NCT05206747|Device|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
79339671|NCT05205811|Drug|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
79339672|NCT05205811|Drug|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
79489309|NCT02076217|Device|Contraceptive implant Nexplanon|
79489310|NCT02076217|Drug|Depo-Provera|
79489311|NCT03290768|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
79654901|NCT00477607|Biological|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
79654902|NCT00477607|Drug|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
79654903|NCT00259194|Behavioral|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
79654904|NCT00259194|Behavioral|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
79654905|NCT00259233|Drug|peripheral Peptide YY administration|
79339673|NCT05205811|Drug|Placebo bupropion|Placebo bupropion for 7 weeks.
79339674|NCT05205811|Drug|Placebo zonisamide|Placebo zonisamide for 7 weeks.
79654906|NCT00230867|Device|iontophoretic acyclovir|
79654907|NCT00259311|Drug|LY2422347|
79654908|NCT00259311|Drug|placebo|
79654909|NCT00230906|Procedure|Haemodialysis with either low or high flux membranes|
79654910|NCT00266214|Drug|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
79654911|NCT00259350|Drug|Skin disinfection|
79339675|NCT05205811|Other|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
79339676|NCT05166967|Drug|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
79339677|NCT05166967|Drug|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
79489312|NCT03290768|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
79489313|NCT03290768|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
79813494|NCT05615610|Device|spine TENS|The participants in Group A will receive TENS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
79339679|NCT05238337|Drug|[14C]-PBI-200|[14C]-radio-labeled-PBI-200
79339680|NCT05205421|Biological|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
79339681|NCT05166109|Drug|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
79339682|NCT05166109|Drug|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
79339683|NCT05204407|Dietary Supplement|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
79339684|NCT05204407|Dietary Supplement|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
79339685|NCT01656733|Drug|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
79339686|NCT01656733|Drug|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
79339687|NCT05236543|Drug|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
79339688|NCT05236543|Drug|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
79339689|NCT05163769|Device|NeeuroCycle Physical and Cognitive Training System|The NeeuroCycle Physical and Cognitive Training System is a novel multimodal electroencephalogram (EEG)-based physical and cognitive training device. The system mainly comprises of a recumbent bicycle device and a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
79654912|NCT00230945|Behavioral|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
79339690|NCT05163769|Device|NeeuroCycle Cognitive Training System|The NeeuroCycle Cognitive Training System is a novel electroencephalogram (EEG)-based cognitive training device. The system mainly comprises of a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
79489314|NCT04626661|Device|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
79489315|NCT04976647|Drug|HLX10+chemo|HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
79489316|NCT04976647|Drug|HLX10+HLX07+chemo|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
79654913|NCT00266253|Drug|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
79489317|NCT04976647|Drug|HLX10+HLX07|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
79489318|NCT03291080|Drug|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
79654914|NCT00266253|Drug|Metformin|As prescribed, for 12 weeks
79489319|NCT03291080|Drug|Extracted capsules 13-CRA|Extracted capsules 13-CRA
79489320|NCT04933123|Device|indirect restorative treatement with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
79654915|NCT00230984|Behavioral|education|
79654916|NCT00230984|Drug|Oral dietary supplements (563 kcal/d), RESPIFOR|
79654917|NCT00230984|Behavioral|exercises on an ergometric bicycle 3 to 5 times a week|
79654918|NCT00230984|Drug|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
79654919|NCT00266292|Behavioral|Fish oil (Bio-Marine, Pharma Nord)|
79654920|NCT00266292|Behavioral|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
79654921|NCT04721678|Behavioral|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
79654922|NCT00415350|Drug|Azithromycin|Azithromycin Tablet 250 mg daily
79654923|NCT00415350|Other|Placebo|Placebo tablet 1 daily
79654924|NCT00231023|Drug|Peribulbar Triamcinolone Acetonide|
79983934|NCT04114812|Other|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
79489321|NCT03292562|Device|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
79489322|NCT03292562|Device|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
79654925|NCT00266331|Drug|Reduced glutathione|
79654926|NCT00231101|Drug|Quetiapine|
79654927|NCT00231140|Drug|Thalidomide (drug)|
79654928|NCT00415389|Behavioral|interactive educational program|2-session interactive stroke educational program
79654929|NCT00415389|Behavioral|usual medical care|standard educational materials and usual care
79654930|NCT00231218|Drug|dietary supplement--echinacea, propolis, and vitamin c|
79654931|NCT02961192|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
79654932|NCT02961192|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
79654933|NCT02961192|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
79654934|NCT00231296|Device|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
79983935|NCT04114812|Other|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
79983936|NCT03232762|Dietary Supplement|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
79489323|NCT04874545|Drug|Propofol|Total intravenous inhalational anesthesia
79489324|NCT00368095|Behavioral|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
79489325|NCT03216200|Device|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
79489326|NCT04735939|Radiation|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
79654935|NCT00231296|Drug|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
79654936|NCT00266448|Drug|Chlorhexidine solution 4%|
79654937|NCT00415428|Behavioral|Patient adherence to national educational guidelines.|
79654938|NCT00231335|Drug|escitalopram|
79654939|NCT00266487|Drug|Folic acid|
79654940|NCT00266487|Drug|Vitamin B12|
79654941|NCT00266487|Drug|Vitamin B6|
79654942|NCT00231374|Procedure|Myelogram|
79983937|NCT03232762|Dietary Supplement|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
79983938|NCT01372722|Device|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
79489327|NCT03888092|Drug|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
79489328|NCT04440865|Other|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
79489329|NCT04440865|Other|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
79654943|NCT00415467|Device|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
79654944|NCT00231452|Drug|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
79654945|NCT00266526|Biological|Recombinant birch pollen|
79654946|NCT00231491|Drug|Botulinum Toxin A (Botox )|
79654947|NCT00477490|Drug|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
79654948|NCT00477490|Drug|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
79983939|NCT01372722|Device|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
79983940|NCT02821026|Procedure|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
79489330|NCT03418064|Device|Fanfilcon A toric lens|Contact lens
79489331|NCT03418064|Device|Lotrafilcon B toric lens|Contact lens
79489332|NCT03181009|Drug|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
79489333|NCT03181009|Drug|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
79654949|NCT00415545|Behavioral|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
79983941|NCT02821026|Drug|Anti-Thymocyte Globulin|
79983942|NCT02821026|Drug|Mycophenolate mofetil|
79983943|NCT02821026|Drug|Tacrolimus|
79983944|NCT02821026|Drug|Etanercept|
79983945|NCT02821026|Drug|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
79654950|NCT00415545|Behavioral|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
79654951|NCT00231530|Drug|topiramate|
79654952|NCT00259389|Behavioral|Directly observed therapy (DOT)|
79654953|NCT00231569|Drug|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
79654954|NCT00231569|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
79339691|NCT05161663|Behavioral|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
79654955|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
79489334|NCT03292952|Drug|KP415 oral capsule|Daily dose
79489335|NCT03292952|Drug|Placebo oral capsule|Daily dose
79654956|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
79654957|NCT00231569|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
79654958|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
79654959|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
79654960|NCT00477334|Drug|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
79654961|NCT00477334|Drug|Placebo|oral; two tablets twice a day; single day treatment
79654962|NCT00266565|Drug|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
79654963|NCT02211859|Drug|BI 2536|
79654964|NCT00231608|Drug|topiramate|
79654965|NCT00266604|Drug|Topiramate|
79654966|NCT04560985|Other|Hydrophilic fissure sealant|Hydrophilic fissure sealant on first molars
79654967|NCT04560985|Other|Hydrophobic fissure sealant|Hydrophobic fissure sealant on first molars
79654968|NCT04721483|Procedure|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
79654969|NCT04560946|Behavioral|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
79654970|NCT04560946|Behavioral|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
79654971|NCT04561024|Diagnostic Test|AI model|Deep Learning CNN model
79339692|NCT05161117|Behavioral|Virtual reality simulation app for caregiver education|"Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve."
79339693|NCT05161117|Behavioral|online fall prevention education module|Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
79339694|NCT05202535|Other|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
79339695|NCT05202535|Other|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
79339696|NCT05201911|Drug|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
79654972|NCT04561336|Drug|Avelumab|avelumab in combination with cetuximab
79654973|NCT04561336|Drug|Cetuximab|avelumab in combination with cetuximab
79339697|NCT05201755|Device|CPAP|Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
79339698|NCT04232371|Procedure|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
79339699|NCT04232371|Procedure|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
79339700|NCT05230381|Drug|Continous infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
79339701|NCT05230381|Drug|Single infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.
79339702|NCT05230381|Drug|Placebo|The 0.9% saline is administered with the same volume at the same speed as the other group.
79339703|NCT05227417|Behavioral|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
79339704|NCT05157841|Drug|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
79339705|NCT05157841|Drug|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
79339706|NCT05157841|Drug|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
79339707|NCT04241965|Drug|OPC-214870|Tablet(s)
79339708|NCT04241965|Other|Placebo|Tablet(s)
79339709|NCT05193643|Device|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
79339710|NCT05225155|Drug|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
79339711|NCT05192239|Drug|THC 5|5 milligrams of THC in gummy form
79339712|NCT05192239|Drug|Placebo|Commercially available non-THC fruit snack
79339713|NCT05190445|Drug|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|HER2/4-1BB
79339714|NCT05190445|Drug|Cinrebafusp alfa (PRS-343) in combination with tucatinib|HER2/4-1BB
79654974|NCT00259428|Drug|Dronedarone (SR33589)|oral administration
79654975|NCT00259428|Drug|placebo|oral administration
79654976|NCT04560907|Procedure|Aquablation|"By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated."
79654977|NCT04560907|Procedure|HoLEP|This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
79654978|NCT00231647|Drug|topiramate|
79654979|NCT02211898|Drug|BNS003|
79339715|NCT05149417|Other|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
79339716|NCT05149417|Other|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
79339717|NCT05148949|Biological|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
79654980|NCT04560751|Drug|Lenvatinib|Lenvatinib capsules will be administered orally, once daily (for patients <60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
79339718|NCT05148949|Biological|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
79339719|NCT04422067|Other|Fetal cephalometry|Fetal cephalometry
79339720|NCT05219851|Radiation|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
79654981|NCT04560751|Procedure|TACE|TACE will be performed as needed.
79654982|NCT00259467|Behavioral|Home-Based Behavorial Intervention|
79654983|NCT00231686|Behavioral|Supervised aerobic training|
79654984|NCT00231686|Behavioral|Supervised strength training|
79654985|NCT00231686|Behavioral|Unsupervised training|
79339721|NCT04422301|Other|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
79654986|NCT04560478|Device|Pro Seal Sealant|Sealant was reapplied every 3 months
79339722|NCT05107999|Drug|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
79339723|NCT05107999|Drug|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
79339724|NCT05146921|Dietary Supplement|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
79339725|NCT05146921|Other|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
79339726|NCT05186545|Drug|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
79654987|NCT04560478|Device|MI Varnish|Fluoride varnish was applied every 4-6 weeks
79654988|NCT04560244|Drug|SHR1701|PD-L1 / TGF-β RII double antibody
79654989|NCT04559854|Behavioral|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
79654990|NCT00266643|Drug|duloxetine hydrochloride|
79654991|NCT00231725|Drug|insulin lispro injection [rDNA origin] Low Mix|
79654992|NCT04560205|Drug|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
79654993|NCT04559971|Drug|SLN124|SLN124 for subcutaneous (s.c.) injection
79654994|NCT04559971|Drug|Placebo|Sodium chloride for s.c. injection
79654995|NCT04560049|Drug|Silver Nitrate|application of silver nitrate to sinus tract
79654996|NCT04560049|Drug|Phenol|phenolisation of sinus tract
79654997|NCT04559425|Drug|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
79654998|NCT04559425|Other|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
79654999|NCT00231764|Drug|daclizumab|
79655000|NCT00259506|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|
79655001|NCT04559503|Other|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
79655002|NCT04559776|Other|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
79655003|NCT04559308|Drug|Metformin|first-line anti-diabetic drug
79655004|NCT04559308|Drug|Chemotherapy|First line neoadjuvant chemotherapy protocol
79339727|NCT05107765|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
79339728|NCT05107765|Drug|Placebo|Pill capsules will look same as that of active drug.
79339729|NCT05146141|Other|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
79339730|NCT05144971|Diagnostic Test|Glucose, Creatinine|Compare diagnostic tests to reference methods
79339731|NCT05106985|Device|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
79489336|NCT03296072|Drug|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres [mL] of tap water for 10 seconds before expectorating again.
79489337|NCT03296072|Drug|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
79489338|NCT03296072|Drug|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
79489339|NCT03182725|Drug|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
79489340|NCT03182725|Drug|Placebo|A substance that has no therapeutic effect and will act as a control.
79655005|NCT00266682|Device|Pacing Lead|
79655006|NCT04559191|Device|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
79655007|NCT00231803|Other|Combined CKD and CVD Prevention|Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
79655008|NCT00231803|Other|Cardiovascular Disease prevention|Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
79655009|NCT00231803|Other|Treatment of Chronic Kidney Disease complications|Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
79655010|NCT00231803|Other|Usual care|No prescribed intervention, just those that the patient's own family physician thought indicated
79655011|NCT04559113|Drug|Methylprednisolone Injectable Product|"0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
79655012|NCT02211937|Drug|BI 44847 solution, low dose|
79655013|NCT02211937|Drug|BI 44847 suspension, high dose|
79655014|NCT02211937|Drug|BI 44847 tablet, low dose|
79339732|NCT04421833|Behavioral|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
79339733|NCT04421833|Behavioral|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
79339734|NCT05106283|Procedure|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
79339735|NCT05184205|Device|Nasal Photodisinfection|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
79339736|NCT05184205|Device|Sham Comparator: Control|Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
79339737|NCT05183581|Device|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
79489341|NCT03216512|Other|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
79339738|NCT05183347|Drug|BI 1291583|BI 1291583
79339739|NCT05183347|Drug|Placebo|Placebo
79339740|NCT05182411|Other|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
79339741|NCT05102851|Diagnostic Test|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
79339742|NCT01656967|Device|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
79339743|NCT01656967|Device|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
79339744|NCT05180539|Behavioral|SPLASH Intervention Condition|Two-session in person group discussions focusing on behaviors in drinking contexts
79339745|NCT05180539|Behavioral|Control Condition|Two-session in person group discussions focusing on college health behaviors
79339746|NCT05100589|Dietary Supplement|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
79489342|NCT03185065|Drug|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
79489343|NCT03185065|Drug|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
79339747|NCT05100589|Dietary Supplement|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
79339748|NCT05142397|Procedure|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
79339749|NCT05142007|Behavioral|Hypnosis|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
79339750|NCT05142007|Behavioral|Mindfulness-based stress reduction|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
79489344|NCT03185065|Drug|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
79489345|NCT03185065|Drug|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
79489346|NCT03419780|Biological|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
79489347|NCT05406271|Diagnostic Test|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
79489348|NCT04415671|Biological|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
79489349|NCT04415671|Other|Placebo|Placebo
79655015|NCT02211937|Drug|BI 44847 tablet, high dose|
79655016|NCT02211937|Other|high fat breakfast|
79655017|NCT00266721|Drug|Pancrelipase (Creon) 2 tablets with each meal|
79655018|NCT04559269|Other|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
79339751|NCT05141695|Device|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
79983946|NCT03107494|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
79813495|NCT05615610|Device|tVNS|The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
79339752|NCT05141695|Device|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
79339753|NCT05141071|Drug|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
79983947|NCT03123354|Device|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
79813496|NCT05615610|Device|Control|The participants in Group C will receive placebo tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
79813497|NCT02604654|Drug|Yiqitongluo granule|administered after dissolved
79813498|NCT04107792|Behavioral|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
79983948|NCT03235102|Other|No treatment given|Completion of a survey
79983949|NCT02452996|Drug|GNbAC1|Single dose of IMP, IV infusion
79983950|NCT04421027|Drug|Baricitinib|Given orally
79983951|NCT04421027|Drug|Placebo|Given orally
79983952|NCT03228784|Procedure|LASIK|
79983953|NCT03228628|Drug|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
79339754|NCT05141071|Drug|Placebo|50 ml of saline will be administrated enterally
79339755|NCT01656889|Biological|HP-802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
79489350|NCT04398199|Drug|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
79489351|NCT04398199|Radiation|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
79489352|NCT00375739|Drug|PEP005|
79983954|NCT03228628|Other|Placebo|inhale medical air (22% O2 - 78% N2)
79983955|NCT03228550|Dietary Supplement|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
79813499|NCT00798096|Drug|Fostamatinib Disodium|200 mg PO BID
79813500|NCT05297214|Diagnostic Test|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
79983956|NCT03228550|Behavioral|Aerobic exercise|Static exercise cycle
79983957|NCT03228550|Dietary Supplement|Placebo multinutrient|Placebo multinutrient supplement
79813501|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
79813502|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
79813503|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
79489353|NCT05406037|Biological|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
79813504|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
79983958|NCT03228706|Behavioral|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska & Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen & Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
79489354|NCT04396249|Device|Active tVNS|One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
79983959|NCT03232684|Diagnostic Test|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
79489355|NCT04396249|Device|Sham tVNS|Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
79489356|NCT03285061|Device|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
79489357|NCT02219334|Device|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
79489358|NCT03285373|Drug|NOAC|New Oral Anticoagulant
79489359|NCT02159040|Drug|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
79489360|NCT02159040|Drug|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
79489361|NCT03285529|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
79489362|NCT03285529|Device|VICRYL|Vicryl #1
79489363|NCT03189589|Drug|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
79489364|NCT03189589|Drug|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
79489365|NCT02218008|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79489366|NCT02218008|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79489367|NCT03216902|Drug|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
79489368|NCT03216902|Drug|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
79489369|NCT03216902|Drug|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
79983960|NCT04419311|Device|Vanguard® Knee System|Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
79983961|NCT03232528|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
79489370|NCT03216902|Drug|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
79489371|NCT03216902|Drug|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
79655019|NCT04559152|Dietary Supplement|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
79655020|NCT04559152|Dietary Supplement|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
79655021|NCT00231920|Biological|Fluzone|
79655022|NCT00259545|Drug|Retarded Release Phosphatidylcholine (rPC)|
79655023|NCT02211976|Drug|Bisacodyl|
79655024|NCT02211976|Drug|Simeticone|
79339756|NCT01656889|Biological|Vehicle|(fibrinogen solution & thrombin solution without cells)
79339757|NCT05097001|Other|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
79339758|NCT05139745|Device|BTL-899|BTL-899 treatment
79339759|NCT04229329|Combination Product|Intensive Finger Individuation Therapy|Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
79339760|NCT04229329|Combination Product|Intensive non-directed finger movement therapy|Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
79655025|NCT04558606|Device|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
79655026|NCT04558606|Device|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
79655027|NCT04558645|Other|Online Survey|Online surveys will be applied to all participants
79655028|NCT04558684|Drug|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
79655029|NCT04558684|Drug|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
79655030|NCT04558684|Radiation|IMRT|Radiotherapy (5 Gy x 5 fractions)
79655031|NCT00231959|Drug|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
79655032|NCT00231959|Drug|Placebo|sugar pill
79655033|NCT02278393|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
79489372|NCT03216902|Drug|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
79489373|NCT03190213|Drug|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
79339761|NCT05094427|Procedure|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
79489374|NCT03190993|Other|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
79489375|NCT03190993|Other|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
79489376|NCT03194503|Device|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
79655034|NCT02278393|Other|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
79655035|NCT00259584|Behavioral|Management and Outcome of SVCO|
79655036|NCT04558411|Behavioral|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
79655037|NCT00231998|Drug|Pimecrolimus|Pimecrolimus cream 1 %
79655038|NCT04558333|Other|blood and exhaled breath specimens|identification of possible biomarkers
79339762|NCT05092711|Behavioral|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
79489377|NCT03219320|Drug|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
79489378|NCT03219320|Drug|Placebo|Matching Placebo capsules.
79655039|NCT02212054|Behavioral|conservative|anal dilatation; colonic lavage; oral probiotic
79655040|NCT02212054|Procedure|operative|one stage pull through radical colectomy
79489379|NCT03194737|Device|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
79489380|NCT01632150|Biological|Elotuzumab|Powder for solution, 400-mg vials, for infusion
79489381|NCT01632150|Biological|Thalidomide|50-mg capsules administered orally
79655041|NCT00266838|Drug|Maxidex; Lacrystat|6 times daily, for 20 weeks.
79655042|NCT00232037|Drug|Tegaserod|
79655043|NCT02212132|Other|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
79655044|NCT02212171|Other|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~Administrative staff:~Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~Nursing staff:~They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
79339763|NCT05092711|Drug|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
79489382|NCT01632150|Biological|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
79489383|NCT01632150|Biological|Cyclophosphamide|50-mg tablets administered orally
79489384|NCT03421886|Device|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
79489385|NCT03421886|Device|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
79489386|NCT03286465|Device|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
79339764|NCT05176405|Behavioral|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
79339765|NCT05176405|Behavioral|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
79339766|NCT05175781|Drug|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
79339767|NCT05175781|Drug|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
79489387|NCT03286465|Device|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
79489388|NCT02185014|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79655045|NCT02212210|Drug|Methylprednisolone|
79655046|NCT02212210|Drug|Normal saline|
79655047|NCT00232076|Drug|ciclosporin|
79655048|NCT04558099|Behavioral|MBSR|Described previously
79339768|NCT05175781|Drug|Placebo|Normal saline
79489389|NCT03297944|Drug|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
79489390|NCT03297944|Drug|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
79655049|NCT04558255|Diagnostic Test|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
79655050|NCT00259623|Device|Radiofrequency ablation|
79655051|NCT04558060|Other|Virtual Standardized Patient|Computer program that presented a virtual human patient
79655052|NCT04558060|Other|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
79655053|NCT00232115|Drug|Pimecrolimus|Pimecrolimus cream 1 %
79655054|NCT00232115|Drug|Placebo|Vehicle cream (placebo)
79655055|NCT02212249|Biological|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
79655056|NCT04558372|Other|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
79339769|NCT04421911|Drug|Ketoprofen topical|Ketoprofen topical for 21days
79339770|NCT04421911|Drug|Diclofenac Topical|Diclofenac topical for 21days
79339771|NCT05174611|Dietary Supplement|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
79339772|NCT05174611|Other|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
79339773|NCT05173753|Other|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
79339774|NCT04226209|Other|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
79983962|NCT03232528|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
79339775|NCT05173207|Diagnostic Test|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
79983963|NCT03232450|Drug|Aspirin|Subjects will receive 81 mg enteric coated aspirin
79339776|NCT05173129|Diagnostic Test|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
79983964|NCT03232450|Device|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
79655057|NCT04558372|Other|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
79339777|NCT05172349|Biological|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
79489391|NCT03297944|Drug|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
79489392|NCT03297944|Drug|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
79489393|NCT03297944|Drug|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
79655058|NCT04558372|Other|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
79655059|NCT04558021|Drug|Niclosamide suspension|200mg/10ml
79655060|NCT04558021|Other|Placebo|10ml placebo(absent of niclosamide)
79655061|NCT00232154|Drug|Zithromax&#153; (azithromycin) 500mg tablets|
79655062|NCT00232154|Procedure|Endoscopic Sinus Surgery|
79655063|NCT00232154|Procedure|Blood sampling for hematology|
79655064|NCT00232154|Procedure|Blood sampling for plasma chemistry profile|
79655065|NCT00232154|Procedure|Serum pregnancy test (for women of child-bearing potential)|
79655066|NCT02212288|Other|Blood sample|Blood samples are for metabolic and genetic and biological investigation
79339778|NCT05133973|Device|FiberSense CGM|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
79339779|NCT05133817|Drug|Normal saline|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
79339780|NCT05133817|Drug|Norepinephrine (0.025 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
79339781|NCT05133817|Drug|Norepinephrine (0.05 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
79489394|NCT03297944|Drug|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
79489395|NCT04333004|Drug|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
79489396|NCT03298880|Device|Supine VM VAD|Valsalva strain delivered using VAD
79489397|NCT03298880|Device|Supine VAD manometer|supine Valsalva strain delivered using manometer
79489398|NCT03298880|Other|Modified VM VAD|modified VM using VAD
79489399|NCT03298880|Other|Modified VM Manonmeter|Postural modified position VM using manometer
79489400|NCT03219866|Device|Nebulizers|Patients treated and discharged on nebulized bronchodilators
79655067|NCT02212288|Other|Urine sample|Urine sample for biological investigation
79813505|NCT04113096|Drug|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
79983965|NCT03232450|Device|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
79983966|NCT03228316|Procedure|superior hypogastric plexus block|nerve plexus block
79983967|NCT03228316|Radiation|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
79983968|NCT04411667|Drug|Octagam|Standard of Care plus Octagam infusion for 3 days.
79983969|NCT03232372|Device|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
79983970|NCT03232372|Device|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
79983971|NCT03232372|Device|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
79983972|NCT03750617|Diagnostic Test|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
79489401|NCT03219866|Device|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
79983973|NCT03222622|Drug|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
79489402|NCT03219866|Drug|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
79655068|NCT04557826|Device|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
79655069|NCT00259662|Drug|atorvastatin|
79655070|NCT04557943|Drug|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
79655071|NCT04557943|Drug|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
79655072|NCT04709133|Procedure|multi-ligament knee surgery|a chart review will be performed to identify patients who underwent surgical treatment for multi-ligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
79655073|NCT00232232|Drug|Fish oil|
79813506|NCT04113096|Drug|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
79339782|NCT05133817|Drug|Norepinephrine (0.075 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
79339783|NCT05133817|Drug|Norepinephrine (0.1 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
79489403|NCT03219866|Drug|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
79489404|NCT03219866|Drug|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
79489405|NCT03219866|Drug|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
79489406|NCT03219866|Drug|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
79489407|NCT03291379|Drug|BTG-002814|BTG-002814 containing 100 mg vandetanib
79489408|NCT03300674|Drug|Hydromorphone|Hydromorphone intravenous infusion
79813507|NCT04113096|Drug|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
79813508|NCT04113096|Drug|Cancer of the Prostate Placebo|20 mg once daily for 6 months
79813509|NCT00795600|Drug|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
79813510|NCT00795600|Drug|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
79983974|NCT03222622|Drug|Placebo cream|Apply topically twice daily for 12 consecutive weeks
79983975|NCT03752021|Procedure|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
79983976|NCT03751943|Device|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
79983977|NCT04358549|Drug|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
79983978|NCT04358549|Other|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
79983979|NCT01562483|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
79983980|NCT01562483|Drug|Placebo|Identical to the Namisol arm.
79339784|NCT05172193|Biological|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
79489409|NCT03300674|Drug|Lidocaine|Lidocaine intravenous infusion
79489410|NCT02184156|Biological|4 mL injection of Ampion|4 mL injection of Ampion
79489411|NCT02184156|Drug|4 mL injection of Placebo|
79489412|NCT03291613|Other|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
79489413|NCT03300752|Behavioral|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
79489414|NCT03300752|Behavioral|Control Intervention|PCP will provide discussion of healthy lifestyles.
79489415|NCT04059913|Drug|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
79489416|NCT02158884|Device|IDEO brace|All participants will receive the IDEO brace.
79983981|NCT00700180|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
79983982|NCT00700180|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
79983983|NCT00700180|Drug|Carboplatin-based chemotherapy|As prescribed
79983984|NCT03222544|Combination Product|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
79489417|NCT03220412|Behavioral|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
79489418|NCT04028557|Other|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
79489419|NCT03195517|Other|Physical exercise|
79983985|NCT03222544|Combination Product|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
79983986|NCT03228862|Drug|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
79983987|NCT03228238|Drug|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
79983988|NCT03228238|Drug|Statin|Atorvastatin calcium 10mg
79983989|NCT03228238|Drug|Standard medication for variant angina|Calcium Channel blocker or NG
79489420|NCT04333069|Procedure|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
79489421|NCT02158806|Drug|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
79489422|NCT02158806|Drug|Placebo|Matching placebo capsule containing inert bulking agent
79489423|NCT03197389|Drug|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
79983990|NCT03232216|Dietary Supplement|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
79983991|NCT03232216|Dietary Supplement|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
79983992|NCT03228082|Device|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
79983993|NCT03222700|Procedure|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
79983994|NCT03231982|Drug|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
79983995|NCT03231982|Drug|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
79339785|NCT05171335|Drug|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of <60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
79339786|NCT05171335|Procedure|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
79489424|NCT03198871|Drug|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
79489425|NCT03198871|Drug|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
79489426|NCT03301298|Drug|SXC-2023|Oral capsule
79489427|NCT03301298|Drug|Placebo oral capsule|Placebo given as oral capsule.
79489428|NCT02157948|Drug|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
79489429|NCT02157948|Drug|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
79655074|NCT04557904|Other|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
79655075|NCT04557904|Other|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
79655076|NCT04557475|Drug|Aspirin|Two tablets daily with dinner
79655077|NCT00232271|Drug|Clexane|
79655078|NCT04557397|Drug|Fruquintinib|oral VEGFR inhibitor
79655079|NCT04557397|Drug|Itraconazole|a synthetic triazole antifungal agent
79983996|NCT03222466|Other|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
79983997|NCT03222154|Device|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
79489430|NCT03302767|Other|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
79489431|NCT03220958|Drug|Metoclopramide|Metoclopramide 20mg
79489432|NCT03220958|Drug|Diphenhydramine|Diphenhydramine 25mg
79489433|NCT03220958|Drug|Normal saline|100ml normal saline
79489434|NCT03420625|Device|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
79489435|NCT03420625|Device|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
79489436|NCT03420625|Device|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
79489437|NCT03420625|Device|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
79655080|NCT04557397|Drug|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
79983998|NCT03222154|Device|Placebo - Shock wave therapy|Simulation of shock wave therapy
79339787|NCT02522299|Drug|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
79489438|NCT03221192|Other|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, >3-7 (or >30-70) as moderate disease and >7-10 (or >70-100) as severe disease.
79983999|NCT03222388|Other|Questionnaire - IIEF 5/15|International Index of Erectile Function
79489439|NCT03221192|Other|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
79984000|NCT03227848|Device|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
79339788|NCT02522299|Drug|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
79339789|NCT02522299|Device|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
79339790|NCT02522299|Device|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
79489440|NCT03221192|Other|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
79489441|NCT02182830|Drug|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
79339791|NCT05170945|Other|Early bowel preparation for colonoscopy|Early (<24 hours) bowel cleansing prior to colonoscopy.
79339792|NCT05130307|Behavioral|virtual reality game|participants interact with a computer generated world
79489442|NCT02182830|Drug|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
79489443|NCT02182830|Drug|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
79489444|NCT03424681|Drug|Modafinil|Modafinil 300 mg by mouth daily
79489445|NCT03424681|Other|Placebo|Placebo
79655081|NCT04557241|Behavioral|Brief informational infographic|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).
79984001|NCT03231904|Diagnostic Test|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
79984002|NCT03120130|Biological|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
79984003|NCT03231670|Procedure|Blood sampling|5ml blood will be taken in addition to standard sampling
79984004|NCT03119974|Drug|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (> 2 months) complete response (platelets counts > 100 x 109/L) period on Tpo-RA treatment.
79339793|NCT01365091|Drug|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
79339794|NCT01365091|Drug|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
79489446|NCT03305653|Device|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
79339795|NCT01365091|Drug|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
79339796|NCT01365091|Drug|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
79339797|NCT01365091|Drug|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
79339798|NCT05082571|Drug|vadadustat|Vadadustat tablet orally once a day for 52 weeks
79339799|NCT04422145|Behavioral|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
79489447|NCT03431012|Other|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
79984005|NCT03119896|Other|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
79984006|NCT03231592|Other|CSA Group|Already included in the arm descriptions.
79339800|NCT04422145|Other|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
79489448|NCT03431012|Other|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
79489449|NCT03427177|Behavioral|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
79489450|NCT03302780|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
79489451|NCT03302780|Device|tDCS active|tDCS will be applied for 20 minutes.
79489452|NCT03302780|Device|tDCS sham|
79489453|NCT04332848|Drug|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
79655082|NCT04557241|Behavioral|Placebo control (non-behavioral infographic)|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style."
79984007|NCT03231592|Other|Enhanced Usual Care Group|Already included in the arm descriptions.
79339801|NCT05081869|Other|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
79339802|NCT05081869|Other|Education Program|There will be video training on the subject for both groups.
79489454|NCT04332848|Drug|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
79489455|NCT03305887|Device|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
79489456|NCT03305887|Device|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
79489457|NCT03305887|Device|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
79489458|NCT03305887|Device|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
79984008|NCT03228004|Behavioral|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
79984009|NCT03222310|Drug|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
79984010|NCT03222310|Drug|Itraconazole|Itraconazole 100 mg capsules orally once daily.
79984011|NCT03222232|Behavioral|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
79984012|NCT04485520|Other|CARICA PAPAYA MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
79984013|NCT04485520|Other|CHLORHEXIDINE MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
79339803|NCT05053711|Device|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79655083|NCT04557319|Biological|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
79813511|NCT00795132|Drug|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
79339804|NCT05053711|Device|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79339805|NCT05053711|Device|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
79489459|NCT03221738|Behavioral|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
79489460|NCT03306199|Device|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
79489461|NCT03303404|Device|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
79655084|NCT04557319|Biological|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
79655085|NCT04557319|Biological|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
79655086|NCT00232310|Drug|CELIVARONE (SSR149744C)|
79813512|NCT00795132|Drug|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
79655087|NCT04557514|Procedure|platelet rich plasma injection in post burn facial scar|"2 spins>>>~st spin (separate plasma from blood) 2500 for 10 minutes~nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
79655088|NCT04557514|Procedure|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
79655089|NCT02212366|Device|Active TDCS|Active Stimulation
79655090|NCT02212366|Device|Sham TDCS|Sham Stimulation
79655091|NCT04557202|Drug|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
79813513|NCT00795132|Drug|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
79984014|NCT03231514|Dietary Supplement|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
79339806|NCT05053711|Device|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79339807|NCT05053711|Device|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79339808|NCT05053711|Device|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
79489462|NCT03224390|Other|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
79489463|NCT03303794|Drug|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
79489464|NCT03303794|Drug|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
79489465|NCT03304106|Device|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
79339809|NCT04421287|Drug|Zhenyuan capsule|0.25g/ tablets, 2 tablets / TID, for 12 weeks
79339810|NCT03824275|Drug|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
79339811|NCT05126329|Drug|amcenestrant|tablet for oral use
79984015|NCT03231514|Other|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
79339812|NCT05053165|Drug|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
79489466|NCT03305822|Drug|LY900014|Administered SC
79489467|NCT03305822|Drug|Insulin Lispro|Administered SC
79489468|NCT04706858|Dietary Supplement|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
79489469|NCT04706702|Behavioral|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
79489470|NCT03435614|Drug|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
79655092|NCT04557202|Drug|Placebo|Placebo - control group
79655093|NCT00232349|Drug|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
79655094|NCT00259701|Device|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
79655095|NCT02212405|Device|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
79655096|NCT02212405|Other|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
79984016|NCT03231514|Other|Exercise|All groups will participate in a standardized exercise intervention.
79984017|NCT03231436|Drug|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
79339813|NCT05053165|Drug|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
79339814|NCT05053165|Drug|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
79339815|NCT05079763|Other|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
79339816|NCT05079763|Other|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
79339817|NCT04421521|Procedure|Acupuncture|Acupuncture with disposable needles will be implemented
79339818|NCT05050981|Drug|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
79339819|NCT05050981|Drug|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
79489471|NCT03437564|Drug|Vortioxetine|Vortioxetine tablet
79489472|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
79489473|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
79489474|NCT03438578|Device|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
79489475|NCT03315104|Biological|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
79489476|NCT03315104|Other|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
79339820|NCT05078983|Diagnostic Test|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
79339821|NCT05050903|Other|Rhinovirus infection|Inoculation with rhinovirus-16
79339822|NCT05049889|Other|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~Continuous 12-lead electrocardiogram~Continuous monitoring of blood pressure and ventilation."
79489477|NCT03228914|Drug|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
79489478|NCT03228914|Drug|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
79984018|NCT03231436|Drug|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
79339823|NCT05049889|Other|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~Continuous 12-lead electrocardiogram~Continuous monitoring of blood pressure and ventilation."
79339824|NCT05049889|Device|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
79339825|NCT05049889|Device|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
79489479|NCT03315572|Other|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
79489480|NCT03315572|Other|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
79489481|NCT03315572|Other|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
79489482|NCT03232580|Drug|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
79489483|NCT03316976|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
79984019|NCT02452450|Drug|Ibuprofen Acid|
79984020|NCT02452450|Drug|Ibuprofen Lysine|
79984021|NCT02452450|Drug|Ibuprofen Sodium|
79984022|NCT02452450|Drug|Ibuprofen Liquid Capsules|
79984023|NCT02452450|Drug|Paracetamol|
79984024|NCT02452372|Drug|givosiran (ALN-AS1)|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
79489484|NCT03317288|Device|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
79655097|NCT04556929|Diagnostic Test|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
79984025|NCT02452372|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
79984026|NCT03221920|Other|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
79984027|NCT01204684|Biological|autologous tumor lysate-pulsed DC vaccination|
79984028|NCT01204684|Biological|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
79984029|NCT01204684|Biological|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
79984030|NCT03227302|Procedure|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
79984031|NCT03227302|Procedure|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
79339826|NCT05049889|Biological|Blood collection|Several blood samples will be collected at visit 1 and 2.
79339827|NCT04421599|Other|The Necessity of Aspiration|"The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered."
79339828|NCT05074459|Drug|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
79489485|NCT03317444|Drug|TRC101|Oral suspension
79489486|NCT03317444|Drug|Placebo|Oral suspension
79339829|NCT05074459|Drug|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
79489487|NCT03442868|Device|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
79984032|NCT03227302|Procedure|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
79984033|NCT00594334|Drug|Risedronate|Weekly Risedronate
79984034|NCT03227380|Other|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
79984035|NCT03229018|Diagnostic Test|Voxel size|200 μm and 300 μm Voxel Sizes
79984036|NCT00238420|Drug|Paclitaxel|Given IV
79984037|NCT00238420|Radiation|Radiation Therapy|Undergo radiation therapy
79984038|NCT00238420|Biological|Trastuzumab|Given IV
79984039|NCT03221998|Drug|IV paracetamol|100 gram paracetamol infusion for moderate pain management
79984040|NCT03221998|Drug|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
79984041|NCT03221686|Dietary Supplement|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
79984042|NCT03221686|Dietary Supplement|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
79984043|NCT03231280|Device|SB-061|delivered via intra-articular injection
79984044|NCT03231280|Other|Placebo|Placebo delivered via intra-articular injection
79984045|NCT03231202|Procedure|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist."
79984046|NCT03221530|Behavioral|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
79984047|NCT03221530|Behavioral|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
79984048|NCT02452294|Drug|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
79655098|NCT04556929|Diagnostic Test|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
79339830|NCT05120557|Device|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
79655099|NCT04556929|Diagnostic Test|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
79655100|NCT04566406|Procedure|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
79655101|NCT00232388|Procedure|Blood draw|
79655102|NCT00267033|Procedure|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
79655103|NCT04566055|Device|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
79655104|NCT04566211|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
79984049|NCT03221608|Procedure|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
79813514|NCT00795132|Drug|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
79984050|NCT03221608|Procedure|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
79339831|NCT05120011|Dietary Supplement|L-carnitine|L-carnitine-L-tartrate
79339832|NCT05120011|Dietary Supplement|L-leucine|L-leucine
79339833|NCT05043259|Biological|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
79339834|NCT05043259|Biological|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
79489488|NCT03234374|Combination Product|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
79489489|NCT03234374|Drug|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
79489490|NCT04332536|Other|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
79489491|NCT03236168|Drug|Ivermectin|A single weight based dose of ivermectin
79489492|NCT03236168|Drug|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
79489493|NCT03236168|Drug|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
79489494|NCT03306589|Biological|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
79655105|NCT04566211|Drug|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
79655106|NCT00232427|Procedure|Hemodynamic monitoring system PiCCO|
79655107|NCT04565626|Other|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
79339835|NCT05043259|Biological|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
79339836|NCT05071495|Device|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
79339837|NCT05069311|Drug|Multimodal analgesia|"Multimodal analgesia includes the combination of:~morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
79339838|NCT05069311|Drug|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
79489495|NCT03306589|Biological|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
79489496|NCT03306589|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
79655108|NCT04565587|Other|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
79655109|NCT00232466|Procedure|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
79489497|NCT03306589|Drug|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
79489498|NCT03320096|Device|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
79489499|NCT03309787|Behavioral|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
79489500|NCT00376207|Behavioral|Physical exercise|
79984051|NCT04492475|Drug|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
79984052|NCT04492475|Other|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
79655110|NCT02211040|Behavioral|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
79655111|NCT00259779|Drug|budesonide/formoterol|
79339839|NCT05036863|Behavioral|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
79339840|NCT05065645|Drug|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
79339841|NCT05065645|Drug|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
79339842|NCT05063383|Other|This study does not involve any interventions|This study does not involve any interventions
79339843|NCT01364467|Drug|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
79339844|NCT01364467|Drug|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
79339845|NCT05470387|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
79489501|NCT03446846|Drug|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
79655112|NCT00259779|Drug|Prednisolone|
79339846|NCT05470387|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
79339847|NCT05468125|Procedure|guidance|either follow the care bundle or the best evidence practice
79489502|NCT03446846|Drug|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
79489503|NCT03446846|Drug|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
79655113|NCT02211079|Drug|JNJ-54861911|JNJ-54861911, 50 mg (2*25 mg tablets) orally once daily from Day 2 to Day 9.
79655114|NCT02211079|Drug|Caffeine|Single oral dose of caffeine 100 mg (2*50 mg tablets), on Day 1, 2, and 9.
79655115|NCT02211079|Drug|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
79655116|NCT02211079|Drug|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
79489504|NCT03312517|Drug|Suvorexant 10 mg|Subject will receive suvorexant 10mg
79655117|NCT04565860|Other|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
79655118|NCT00232622|Drug|Streptokinase|Accelerated infusion of streptokinase
79655119|NCT00232622|Drug|Streptokinase|Standard dose streptokinase
79339848|NCT05033899|Other|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
79339849|NCT05110417|Drug|Pyridostigmine Bromide 60 Milligrams (mg)|One tablet will be provided to patients during the second visit.
79339850|NCT02520661|Behavioral|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
79339851|NCT05109871|Other|KForce Link|Traction (pull-type) dynamometer
79489505|NCT03312517|Drug|Suvorexant 20 mg|Subject will receive suvorexant 20mg
79339852|NCT05061199|Procedure|approach of anastomosis|The approach of anastomosis
79339853|NCT05031481|Drug|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
79489506|NCT03312517|Drug|Placebo oral capsule|Subject will receive placebo.
79489507|NCT03449342|Drug|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
79489508|NCT03312595|Device|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
79489509|NCT03315559|Drug|[14C]-GSK2269557 IV infusion|The [14C]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
79489510|NCT03315559|Drug|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
79489511|NCT03315559|Drug|[14C]-GSK2269557 oral solution|The [14C]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving [14C]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
79489512|NCT03239522|Drug|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of [14C]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
79489513|NCT03239522|Drug|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of [14C]-GSK1278863 oral solution (total dose: 25 mg).
79489514|NCT03239522|Drug|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
79489515|NCT03315949|Drug|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
79489516|NCT03241862|Device|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
79984053|NCT04492475|Drug|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
79339854|NCT05031481|Drug|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
79489517|NCT04332770|Other|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
79489518|NCT03328208|Other|Comfort Talk® app|Test app
79489519|NCT03328208|Other|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
79489520|NCT03210337|Drug|A-101 Topical Solution|A-101 Topical Solution
79489521|NCT03210337|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
79489522|NCT03242408|Drug|LPCN 1021|Oral testosterone undecanoate
79339855|NCT05031481|Drug|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
79339856|NCT05031481|Drug|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
79339857|NCT05061121|Other|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
79339858|NCT05109559|Biological|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
79489523|NCT03242954|Other|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
79489524|NCT03242954|Other|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
79489525|NCT03242954|Other|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
79489526|NCT03459794|Drug|Ivermectin|150 mcg/kg ivermectin, by mouth.
79489527|NCT03459794|Other|Placebo|An oral placebo will be administered, once
79489528|NCT03211117|Drug|Docetaxel|Given IV
79489529|NCT03211117|Drug|Doxorubicin Hydrochloride|Given IV
79489530|NCT03211117|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79984054|NCT03231124|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
79984055|NCT03231124|Drug|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
79339859|NCT05109559|Biological|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
79339860|NCT05109559|Biological|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
79489531|NCT03211117|Other|Laboratory Biomarker Analysis|Correlative studies
79984056|NCT03227068|Other|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
79489532|NCT03211117|Biological|Pembrolizumab|Given IV
79489533|NCT03211117|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79655120|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Enamel (30sec) and dentin (15sec) etching with phosphoric acid~Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~Finishing and polishing"
79489534|NCT03436147|Other|POP-Q|Pelvic Organ Prolapse Quantification
79489535|NCT03245372|Procedure|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
79655121|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~Composite-resin application using a transparent cervical matrix and curing for 40sec~Finishing and polishing"
79655122|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Enamel (30sec) etching with phosphoric acid~Application of AdheSE One and curing for 10sec~Composite-resin application using a transparent cervical matrix and curing for 40sec~Finishing and polishing"
79339861|NCT05031247|Other|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
79339862|NCT05059093|Diagnostic Test|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
79489536|NCT03245372|Procedure|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
79489537|NCT03317431|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
79489538|NCT00376285|Drug|CP-742,033|
79489539|NCT00376285|Drug|Fenofibrate|
79489540|NCT03460652|Drug|KP415 oral capsule|Once-daily oral dose
79339863|NCT04218097|Other|Study questionnaire|Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
79339864|NCT05057767|Drug|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
79339865|NCT04997317|Drug|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
79339866|NCT04997317|Drug|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= [Tyr]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
79339867|NCT04997317|Drug|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
79339868|NCT04997239|Biological|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
79655123|NCT04565548|Other|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
79655124|NCT04565548|Other|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
79655125|NCT04565314|Dietary Supplement|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
79339869|NCT04997239|Biological|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
79339870|NCT04216693|Drug|Digoxin tablet|The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.
79339871|NCT04216693|Other|Placebo|The control group will receive the digoxin-like placebo treatment.
79339872|NCT05057611|Other|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
79339873|NCT05057611|Other|Usual care (UC)|- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, heart rate (HR) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
79339874|NCT01364389|Drug|AIN457|3 mg/kg
79339875|NCT01364389|Drug|ACZ885|3 mg/kg
79339876|NCT01364389|Drug|Prednisone|20 mg
79339877|NCT01364389|Drug|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
79655126|NCT04565002|Device|Transcutaneous Electrical Diaphragmatic Stimulation|The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
79655127|NCT00259818|Drug|EM-1421|
79489541|NCT03321097|Device|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
79489542|NCT03321097|Device|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
79489543|NCT03245762|Drug|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
79489544|NCT03245762|Drug|Placebo|4 IU/day of placebo administered via nasal spray device each morning
79489545|NCT03321253|Device|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
79489546|NCT03322657|Drug|Neostigmine|Neostigmine injection
79655128|NCT04565197|Biological|convalescent plasma|"Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
79339878|NCT04996381|Diagnostic Test|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
79489547|NCT03322657|Drug|Glycopyrrolate|Glycopyrrolate injection
79489548|NCT03322657|Drug|Sugammadex|Sugammadex injection
79489549|NCT03247322|Other|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
79655129|NCT00232661|Drug|ARIMIDEX (anastrazole)|
79655130|NCT00232661|Drug|NOLVADEX (tamoxifen)|
79655131|NCT04564924|Radiation|DXA|Bone mineral density was examined in all cases and controls
79489550|NCT04332679|Device|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
79489551|NCT04332679|Device|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
79489552|NCT03324451|Behavioral|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
79655132|NCT00267267|Drug|torcetrapib/atorvastatin|
79655133|NCT00267267|Drug|ezetimibe/simvastatin|
79655134|NCT04564729|Other|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
79655135|NCT04564651|Other|platelet transfusion|when the ADP inhibition >70%, give one unit platelet tansfusion
79489553|NCT03324451|Behavioral|Usual care|Regular patient education on insulin injection at the control arm hospital.
79655136|NCT04564690|Dietary Supplement|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
79655137|NCT04564690|Dietary Supplement|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
79655138|NCT00232700|Drug|Escitalopram|
79489554|NCT03324607|Drug|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
79655139|NCT04564456|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
79655140|NCT04564456|Drug|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
79655141|NCT04564144|Drug|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
79339879|NCT05027737|Procedure|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
79339880|NCT05054881|Other|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
79339881|NCT05054881|Other|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
79339882|NCT04950283|Diagnostic Test|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
79489555|NCT03324607|Drug|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
79489556|NCT03247790|Drug|Lasmiditan|Administered orally
79489557|NCT03249116|Other|animal-assisted intervention|Interaction with a therapy dog
79489558|NCT03249116|Other|active control|Interaction with a stuffed dog
79489559|NCT03437863|Device|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
79489560|NCT03467048|Device|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
79489561|NCT03467048|Device|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
79489562|NCT03249272|Drug|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
79489563|NCT03249272|Drug|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
79489564|NCT03249584|Device|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
79489565|NCT02182440|Biological|recAP|One hour infusions once daily for three days
79489566|NCT02182440|Other|Placebo|1 hour IV infusion once daily for 3 days
79489567|NCT03255902|Behavioral|Parenting classes|Parenting Classes:The Incredible Years curriculum
79489568|NCT03468920|Drug|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
79489569|NCT03468920|Drug|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
79489570|NCT03468920|Drug|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
79489571|NCT03468920|Drug|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
79339883|NCT05024383|Other|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
79339884|NCT05024383|Other|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
79489572|NCT03470012|Device|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
79489573|NCT04758624|Device|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
79489574|NCT03339206|Behavioral|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
79489575|NCT03339206|Behavioral|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
79339885|NCT04949425|Drug|Adavosertib|Patients will receive Adavosertib orally.
79489576|NCT03339206|Behavioral|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
79489577|NCT02181816|Drug|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD & HD
79489578|NCT03256136|Drug|Carboplatin|Chemotherapy
79489579|NCT03256136|Drug|Nivolumab|will allow the body's immune system to work against tumor cells
79339886|NCT05023603|Diagnostic Test|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
79489580|NCT03256136|Drug|pemetrexed|Chemo therapy
79489581|NCT03256136|Drug|Ipilimumab|will allow the body's immune system to work against tumor cells
79489582|NCT04735328|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
79655142|NCT00267306|Drug|Visilizumab|
79655143|NCT04563949|Other|Repeat Testing|Repeat Testing with the PLA will be conducted
79339887|NCT05023525|Drug|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
79339888|NCT05023525|Drug|Placebo, tablet|Matching placebo
79339889|NCT05022589|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, ~30 minutes per session.
79339890|NCT04421209|Drug|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
79339891|NCT04421209|Drug|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
79339892|NCT05020249|Drug|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
79339893|NCT05020249|Other|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
79339894|NCT04986397|Device|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
79339895|NCT04986397|Other|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
79489583|NCT04735328|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
79489584|NCT04735328|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
79489585|NCT03260426|Dietary Supplement|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
79489586|NCT03260426|Dietary Supplement|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
79489587|NCT03260426|Device|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
79489588|NCT03340610|Drug|Alflibercept|Intravitreal Injection
79655144|NCT00232778|Device|GAMMA-Iridium-192 catheter|
79489589|NCT03341546|Other|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
79655145|NCT04674787|Other|Peripheral nerve stimulation provocation study|Study which measures stimulation thresholds in volunteers induced by low frequency electromagnetic gradients used in MRI scanners.
79655146|NCT04563910|Other|young mania rating scale|questionnaires to the patients and their family after their written consent
79655147|NCT00259896|Drug|exenatide|
79655148|NCT04675021|Drug|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
79655149|NCT04675021|Drug|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
79655150|NCT04675021|Drug|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
79655151|NCT04564066|Biological|efgartigimod IV|intravenous infusions of efgartigimod
79655152|NCT04564066|Biological|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
79655153|NCT04564222|Dietary Supplement|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
79984057|NCT03227068|Other|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
79339896|NCT04944199|Other|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
79339897|NCT01364233|Device|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
79339898|NCT04985539|Device|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
79489590|NCT03344510|Device|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
79489591|NCT03344510|Other|Control|One injection will be administered without the kinetic anesthesia device.
79489592|NCT03264092|Procedure|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
79489593|NCT03346850|Device|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
79489594|NCT03346850|Device|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
79489595|NCT03478904|Drug|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
79489596|NCT03478904|Drug|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
79489597|NCT03478982|Drug|Staccato Alprazolam|single dose for inhalation
79489598|NCT03478982|Drug|Placebos|single dose for inhalation
79339899|NCT05014945|Procedure|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
79984058|NCT03231046|Device|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
79339900|NCT04983355|Dietary Supplement|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
79655154|NCT04564222|Dietary Supplement|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
79655155|NCT00232817|Drug|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
79489599|NCT03264248|Device|E-Scale|Daily bodyweight system used under legs of bed
79655156|NCT04674865|Other|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
79655157|NCT04674865|Other|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
79655158|NCT04674943|Other|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
79655159|NCT00267384|Drug|Oral N-Acetylcysteine|
79655160|NCT04674904|Other|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
79655161|NCT04674904|Other|Hot pack , TENS , Stretching|"Treatments are~Hot Pack for 15 minutes~TENS for 10 minutes~Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
79655162|NCT04675060|Drug|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
79984059|NCT03231046|Procedure|Hepatic Biopsy or Ablation|Standard of Care
79489600|NCT03270332|Drug|Albuterol|inhalation of 270μg albuterol through a spacer
79489601|NCT03270332|Drug|Placebo|inhalation of placebo through a spacer
79489602|NCT03349892|Radiation|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
79489603|NCT03483506|Drug|BI 1467335|Film-coated tablet
79489604|NCT03483506|Drug|BI 1467335 (C-14) intravenous solution|Intravenous solution
79489605|NCT03271424|Diagnostic Test|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
79655163|NCT04674982|Device|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
79655164|NCT00259935|Drug|topotecan|topotecan
79655165|NCT00424736|Procedure|whole body CT scan|
79655166|NCT04674709|Drug|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
79984060|NCT03230812|Drug|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
79984061|NCT03226990|Other|impression technique|impression technique with and without wax spacer
79984062|NCT03221452|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
79339901|NCT04983355|Dietary Supplement|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
79489606|NCT03271424|Diagnostic Test|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
79489607|NCT03271424|Diagnostic Test|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
79489608|NCT03483896|Other|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
79489609|NCT02156466|Drug|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
79489610|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
79489611|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
79489612|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
79489613|NCT02156466|Drug|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
79489614|NCT03353246|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
79489615|NCT03274856|Drug|GLWL-01|Oral administration of 3 capsules, twice a day
79489616|NCT03274856|Drug|Placebo|Oral administration of 3 capsules, twice a day
79489617|NCT02216526|Other|Cetaphil® Restoraderm|
79489618|NCT02216526|Other|Excipial|
79655167|NCT04674709|Drug|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
79984063|NCT04936763|Device|Janesse 20 (Cross-linked Hyaluronic Acid)|Janesse 20 will be administered at baseline (visit 2, day 0) and, if the Investigator will evaluate necessary, also at day 30 (visit 3). The Investigational device will be injected with retrograde technique (moving backward) with homogeneous amount on the length of each side of Labia Majora. The Janesse 20 dosage administered will be 1 ml in left labia and 1 ml in right labia for each session.
79984064|NCT03221296|Behavioral|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
79655168|NCT04674709|Drug|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
79489619|NCT03355820|Procedure|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (~5 mL) will be taken from all the subjects, at Day 1.
79489620|NCT03357614|Drug|Sulopenem|Antibiotic therapy for complicated UTI
79489621|NCT03357614|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
79489622|NCT03357614|Drug|Ertapenem|Antibiotic therapy for complicated UTI
79489623|NCT03357614|Drug|Ciprofloxacin|Antibiotic therapy for complicated UTI
79489624|NCT03357614|Drug|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
79984065|NCT03230656|Other|Early cognitive-communication therapy|
79489625|NCT03487718|Biological|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
79489626|NCT03487718|Device|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
79489627|NCT03275870|Drug|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
79489628|NCT03276494|Device|Intraosseous|Intraosseous administration of hypertonic saline
79489629|NCT03276494|Drug|Hypertonic saline|Intraosseous administration of hypertonic saline
79489630|NCT02216214|Drug|Mirabegron|oral tablet
79489631|NCT02216214|Drug|Placebo|oral tablet
79489632|NCT03277274|Drug|TAK-954|TAK-954 intravenous infusion.
79655169|NCT04674709|Drug|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
79655170|NCT00555841|Drug|ALC and Placebo|ALC and Placebo
79655171|NCT00232856|Device|drug-eluting stent|PCI
79655172|NCT00259974|Drug|Rituximab|Rituximab
79655173|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
79655174|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
79655175|NCT00555958|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
79655176|NCT04674475|Device|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
79984066|NCT03751865|Behavioral|CBT|A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
79984067|NCT03751865|Behavioral|Psychoeducation|A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
79339902|NCT04983121|Drug|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
79339903|NCT04420897|Procedure|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
79339904|NCT04208971|Other|AI-enabled ECG-based Screening Tool for AF|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
79339905|NCT02291289|Drug|Cetuximab|500 mg/m^2 via IV infusion on Day 1 of every 2-week cycle
79339906|NCT02291289|Drug|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
79655177|NCT00232895|Drug|lipuro propofol|
79655178|NCT00232895|Drug|standard formulation propofol|
79984068|NCT03221062|Device|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
79984069|NCT04486235|Behavioral|Brief waiting room pamphlet|An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
79339907|NCT02291289|Drug|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 1600-2400 mg/m^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
79655179|NCT04674280|Procedure|aHSCT|Autologous haematopoietic stem cell transplantation
79655180|NCT04673968|Other|prehabilitation|inhospital exercise training 5 times/week, 5~6 weeks during nCRT; home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
79655181|NCT04674046|Device|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
79984070|NCT03747653|Drug|ADVATE|Patients will be administered a single dose of ADVATE.
79984071|NCT03747653|Drug|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
79655182|NCT04674046|Procedure|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
79984072|NCT03226834|Device|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
79984073|NCT03226834|Other|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
79984074|NCT03230968|Behavioral|Integral Action Program for Respiration|
79984075|NCT03230578|Other|Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
79984076|NCT03226600|Device|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
79984077|NCT03226600|Device|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
79984078|NCT03227614|Behavioral|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
79339908|NCT02291289|Drug|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
79339909|NCT02291289|Drug|Vemurafenib|960 mg vermurafenib BID by mouth
79339910|NCT02291289|Drug|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
79489633|NCT03279458|Device|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
79339911|NCT02291289|Drug|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
79339912|NCT02291289|Drug|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
79339913|NCT02291289|Drug|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
79339914|NCT02291289|Drug|5-FU/LV|1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.
79339915|NCT02317575|Biological|LY900014|Administered SC
79339916|NCT02317575|Biological|Insulin Lispro|Administered SC
79339917|NCT02316717|Biological|IMM-124E|IMM-124E
79339918|NCT02316717|Other|Placebo|Matched placebo
79489634|NCT02214186|Other|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
79489635|NCT03492398|Drug|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
79339919|NCT02290821|Drug|placebo|
79339920|NCT02290821|Drug|Placebos|
79339921|NCT02289963|Drug|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
79339922|NCT02289963|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
79339923|NCT02289963|Drug|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
79339924|NCT02358369|Drug|Bimatoprost|Bimatoprost sustained release Ocular Insert
79339925|NCT02358369|Drug|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
79339926|NCT02358369|Device|Placebo Ocular Insert|Placebo ocular insert OU.
79339927|NCT02358369|Drug|Placebo Eye Drops|Placebo eye drops BID OU.
79339928|NCT02316171|Biological|CVA21|CAVATAK is a purified preparation of CVA21
79339929|NCT02316171|Drug|Mitomycin C|Chemotherapy
79339930|NCT02315625|Drug|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
79984079|NCT03220984|Biological|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
79339931|NCT02315625|Drug|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
79984080|NCT03220594|Procedure|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
79984081|NCT03220828|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets)
79984082|NCT03220906|Other|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
79984083|NCT03226444|Drug|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
79984084|NCT03226444|Drug|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
79984085|NCT03226444|Drug|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
79984086|NCT04358081|Drug|HCQ|Hydroxychloroquine Monotherapy
79984087|NCT04358081|Drug|HCQ+AZT|Hydroxychloroquine with azithromycin
79984088|NCT04358081|Drug|Placebo|Placebo
79984089|NCT03220672|Behavioral|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
79984090|NCT03230500|Procedure|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
79339932|NCT02357979|Device|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
79489636|NCT04758546|Diagnostic Test|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
79489637|NCT03496220|Device|Angulus|Feedback on patient recumbency
79984091|NCT03222934|Device|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
79984092|NCT02452138|Other|Severe sepsis management|
79984093|NCT03230344|Procedure|open flap debridement|open flap debridement simultaneously with root canal treatment
79984094|NCT03230344|Procedure|open flap debridement|open flap debridement and delayed root canal treatment
79984095|NCT03230422|Device|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
79984096|NCT03230422|Device|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
79984097|NCT04355663|Behavioral|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
79339933|NCT02357979|Other|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
79339934|NCT04886973|Other|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
79489638|NCT00376376|Drug|levofloxacin at 250, 500, 750, and 1000 mg doses|
79489639|NCT00376454|Drug|GW493838|
79984098|NCT04355663|Behavioral|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
79489640|NCT02181504|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
79489641|NCT02181504|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
79489642|NCT02181504|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
79489643|NCT03360110|Device|Phoebe test lens|Daily disposable contact lens
79489644|NCT03360110|Device|stenfilcon A lens (control)|Daily disposable contact lens
79984099|NCT04355663|Behavioral|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
79984100|NCT03220360|Procedure|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
79984101|NCT03220360|Procedure|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
79984102|NCT03220360|Procedure|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
79984103|NCT03230188|Other|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
79984104|NCT03230188|Other|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
79984105|NCT03230188|Other|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
79984106|NCT03751787|Other|cranial osteopathy|two sessions at three weeks intervals
79984107|NCT03751787|Other|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
79984108|NCT03220438|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
79489645|NCT02179398|Biological|Allocation to the Lab-score group|
79984109|NCT03750383|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
79984110|NCT03750383|Drug|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
79984111|NCT03750383|Drug|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
79984112|NCT03750383|Drug|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
79984113|NCT03220516|Procedure|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
79984114|NCT03220516|Procedure|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
79984115|NCT03220516|Procedure|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
79489646|NCT02179398|Biological|Allocation to the control group|
79339935|NCT02357901|Drug|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
79489647|NCT02156076|Drug|BMS-919373|
79489648|NCT02156076|Drug|Placebo (Matching with BMS-919373)|
79489649|NCT02213094|Drug|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
79339936|NCT02357901|Drug|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
79339937|NCT02357901|Drug|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
79655183|NCT04674046|Behavioral|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
79655184|NCT00260013|Procedure|program of care delivery|
79655185|NCT00232934|Drug|Thalidomide|
79655186|NCT04673812|Drug|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
79655187|NCT00260052|Drug|Erythropoietin administration|
79655188|NCT00232973|Drug|ICXP007|
79655189|NCT04673500|Drug|Propofol lidocaine through large vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
79339938|NCT01601847|Dietary Supplement|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
79339939|NCT01601847|Drug|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
79339940|NCT04886739|Drug|CGB-400|Topical gel
79339941|NCT04886739|Drug|Vehicle Gel|Topical gel
79489650|NCT02213094|Drug|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
79489651|NCT02155608|Device|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
79489652|NCT02155608|Device|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
79489653|NCT01629966|Drug|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
79339942|NCT02515669|Drug|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
79339943|NCT02515669|Drug|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
79339944|NCT02515279|Drug|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
79339945|NCT02515279|Drug|Ribavirin|1000-1600 mg day orally for 48 weeks.
79339946|NCT02515045|Drug|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
79339947|NCT02515045|Drug|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
79339948|NCT02515045|Drug|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
79489654|NCT01629966|Drug|Vilazodone|Vilazodone, 20mg, oral administration once per day.
79984116|NCT03226210|Drug|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan & Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
79984117|NCT03750305|Other|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
79339949|NCT02515045|Drug|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
79489655|NCT01629966|Drug|Vilazodone|Vilazodone, 40mg, oral administration once per day.
79489656|NCT03363854|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
79489657|NCT03363854|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
79339950|NCT02514577|Drug|IDP-122 Lotion|Topical lotion
79339951|NCT02514577|Drug|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
79339952|NCT04943887|Behavioral|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
79489658|NCT02177838|Biological|cetuximab|Given IV
79489659|NCT02177838|Drug|cisplatin|Given IV
79489660|NCT02177838|Radiation|external beam radiation therapy|Undergo EBRT
79489661|NCT02177838|Other|laboratory biomarker analysis|Correlative studies
79489662|NCT03369158|Procedure|patient specific pedicle screw positioning guide|
79489663|NCT03369158|Procedure|Free hand technique pedicle screw positioning|
79489664|NCT03369158|Device|MUST pedicle screw|
79489665|NCT03372434|Device|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
79489666|NCT03372434|Device|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
79489667|NCT03372434|Device|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
79339953|NCT05463055|Radiation|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
79339954|NCT02513485|Drug|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
79339955|NCT02513485|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
79339956|NCT02289417|Drug|Apremilast|
79489668|NCT03376256|Device|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
79489669|NCT03283436|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
79489670|NCT00375986|Procedure|Manual placental removal at Cesarean delivery|
79489671|NCT00375986|Procedure|Spontaneous placental removal at Cesarean delivery|
79984118|NCT03750305|Other|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, & van Gent, 2008).
79489672|NCT03380624|Drug|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
79489673|NCT03380624|Drug|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
79489674|NCT03380780|Drug|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
79655190|NCT04673500|Drug|Propofol lidocaine through small vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
79655191|NCT04673695|Drug|Lixiana(D006)|NOAC(Factor Xa inhibitor)
79655192|NCT04673695|Drug|CKD-344|NOAC(Factor Xa inhibitor)
79339957|NCT02289417|Drug|Placebo|
79339958|NCT02512861|Drug|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs"
79339959|NCT02512861|Drug|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs"
79489675|NCT00376064|Drug|Octreotide acetate and cabergoline/Octrotide and Somavert|
79489676|NCT00376142|Behavioral|Psychological theory-based behaviour change interventions|
79984119|NCT03226054|Behavioral|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
79984120|NCT03750149|Device|EyeTracker|Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
79489677|NCT03581084|Drug|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
79984121|NCT03225976|Device|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
79984122|NCT03225976|Device|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
79489678|NCT03383588|Drug|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
79489679|NCT03383588|Drug|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
79489680|NCT03383588|Drug|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
79489681|NCT03383588|Drug|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
79489682|NCT03383588|Other|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
79489683|NCT03388268|Drug|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
79489684|NCT03388268|Drug|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
79489685|NCT03388268|Device|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
79655193|NCT04673305|Other|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
79655194|NCT04673344|Device|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
79984123|NCT03225898|Other|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
79984124|NCT03225898|Other|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
79984125|NCT03229954|Drug|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
79984126|NCT03229954|Drug|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
79984127|NCT03230110|Diagnostic Test|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
79984128|NCT03226132|Behavioral|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
79984129|NCT03226132|Behavioral|Repeated Contact|Repeated Contact
79984130|NCT03220126|Biological|LY3074828|Administered IV
79984131|NCT03220126|Biological|LY900021|Administered SC
79489686|NCT03388268|Device|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
79489687|NCT00422786|Drug|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
79489688|NCT03581474|Device|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
79489689|NCT03390842|Drug|TRC101|Oral suspension
79489690|NCT03390842|Drug|Placebo|Oral suspension
79489691|NCT02177136|Drug|Obeticholic Acid (OCA)|
79489692|NCT02177136|Drug|Placebo|
79489693|NCT03393494|Drug|Adapalene and Benzoyl Peroxide Topical Gel|Test product
79489694|NCT03393494|Drug|Epiduo Topical Product|RLD product
79489695|NCT03393494|Drug|Placebo|Placebo gel
79489696|NCT03588806|Drug|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
79489697|NCT02176356|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
79489698|NCT02176356|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
79489699|NCT02176356|Device|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
79489700|NCT02176356|Device|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
79489701|NCT02176356|Device|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
79489702|NCT03591068|Drug|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
79655195|NCT00233012|Drug|Topiramate|
79655196|NCT04673110|Diagnostic Test|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
79813515|NCT00795132|Drug|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
79489703|NCT02210208|Device|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
79489704|NCT02210208|Device|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
79489705|NCT03395990|Procedure|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
79489706|NCT03395990|Procedure|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
79813516|NCT02604420|Drug|eculizumab|
79984132|NCT02452684|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
79339961|NCT04979299|Other|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
79984133|NCT03119428|Drug|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
79339962|NCT05012761|Drug|SR419 capsules|Ascending single and multiple doses of SR419 orally
79984134|NCT03119428|Drug|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
79984135|NCT03119818|Device|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
79339963|NCT05012761|Drug|Placebo|Ascending single and multiple doses of placebo orally
79339964|NCT04979065|Dietary Supplement|Probiotics, Vitamin D|Combination of two supplement that given separately
79339965|NCT04979065|Other|Placebo|Placebo with inactive ingredient
79339966|NCT02288559|Other|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
79339967|NCT02288559|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
79339968|NCT02288325|Drug|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
79339969|NCT02288325|Drug|Placebo|Dose-matched placebo taken orally once daily.
79339970|NCT02509117|Drug|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
79339971|NCT02509117|Drug|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
79339972|NCT02509117|Drug|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
79339973|NCT02509117|Drug|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
79339974|NCT02509117|Drug|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
79489707|NCT00376922|Procedure|music therapy|music played for patient during bone marrow biopsy collection
79489708|NCT02209506|Drug|MLN3126|MLN3126 tablets
79489709|NCT02209506|Drug|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
79984136|NCT03119818|Other|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
79339975|NCT02509117|Drug|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
79339976|NCT01654549|Drug|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
79489710|NCT02153736|Behavioral|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
79489711|NCT02175966|Drug|DCV/ASV/BMS-791325|
79655197|NCT00267540|Behavioral|cholecalciferol (D3) (vitamin)|
79655198|NCT04672954|Drug|BI 474121|BI 474121
79655199|NCT04672954|Drug|Placebo|Placebo
79655200|NCT04673188|Procedure|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
79655201|NCT00233051|Drug|Salmeterol or Salmeterol/Fluticasone|
79655202|NCT04673227|Diagnostic Test|Blood draw|Blood draw and the analysis of blood in laboratory
79655203|NCT00260091|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
79655204|NCT00260091|Procedure|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
79984137|NCT03229642|Device|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
79339977|NCT04978051|Drug|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
79339978|NCT04978051|Other|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
79339979|NCT04214353|Diagnostic Test|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
79339980|NCT04214353|Diagnostic Test|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
79489712|NCT02175966|Drug|Ribavirin|
79489713|NCT02175966|Drug|Sofosbuvir|
79655205|NCT04673071|Other|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
79655206|NCT04673071|Other|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
79655207|NCT04672642|Device|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
79489714|NCT02175966|Drug|Peginterferon α-2a|
79489715|NCT02153346|Other|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
79489716|NCT02153346|Other|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
79489717|NCT04750512|Procedure|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
79655208|NCT00233129|Behavioral|Top Down|Six months
79655209|NCT00233129|Other|cognitive rehabilitation day treatment program|six months
79655210|NCT00260130|Other|food in fluid form|dietary intake of fluid forms of vegetables
79655211|NCT00260130|Other|food in solid form|dietary intake of solid forms of vegetables
79655212|NCT04672603|Procedure|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
79655213|NCT00233168|Behavioral|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
79655214|NCT00233168|Behavioral|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
79655215|NCT04672837|Procedure|Pediatric Integrative Manual Therapy and educational therapy|Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
79339981|NCT04977817|Dietary Supplement|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
79655216|NCT04672837|Procedure|Stretching and educational therapy|It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
79655217|NCT00267579|Behavioral|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
79339982|NCT04977739|Diagnostic Test|No intervention|No intervention
79655218|NCT04672759|Drug|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
79655219|NCT04672759|Drug|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
79655220|NCT04672408|Device|His bundle pacing|Pacing with capture of the His bundle
79339983|NCT04976803|Other|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
79339984|NCT02508649|Drug|selepressin|
79655221|NCT04672408|Device|Right ventricular pacing|Pacing from the right ventricular lead (septal or apical)
79655222|NCT04672096|Device|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
79655223|NCT00260169|Behavioral|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
79339985|NCT02508649|Drug|placebo|
79339986|NCT05010421|Drug|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
79339987|NCT05010421|Device|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
79339988|NCT02504827|Drug|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
79339989|NCT02504671|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
79339990|NCT02504671|Drug|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
79339991|NCT02504671|Drug|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
79339992|NCT02504671|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
79339993|NCT02314143|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
79339994|NCT02314143|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
79489718|NCT04750512|Procedure|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
79489719|NCT02174562|Behavioral|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
79489720|NCT02174562|Behavioral|Enhanced Usual Care|Usual care enhanced with education and attention
79655224|NCT00260169|Behavioral|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
79655225|NCT00233207|Drug|IC14|
79655226|NCT04672057|Other|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
79984138|NCT03229642|Device|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
79655227|NCT00260247|Drug|carbamazepine oxcarbazepine|
79984139|NCT03119506|Behavioral|Recess|Recess timing and duration effects on lunch intake
79984140|NCT03219814|Other|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
79984141|NCT03219814|Other|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
79984142|NCT04345367|Drug|Abrocitinib 200 mg|Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
79984143|NCT04345367|Combination Product|Dupilumab 300 mg|Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
79984144|NCT03229720|Device|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
79339995|NCT02288091|Drug|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
79339996|NCT04420065|Device|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
79339997|NCT04420065|Device|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
79489721|NCT05138406|Other|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
79655228|NCT04671979|Diagnostic Test|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
79655229|NCT00233246|Procedure|FFP Infusion|
79655230|NCT04671745|Behavioral|Music|patient receiving care with interactive music
79655231|NCT04671745|Behavioral|No music|patient receiving care without interactive music
79984145|NCT03225742|Diagnostic Test|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
79984146|NCT02452606|Drug|Stalevo®|"Sleep disorders in Parkinson's disease~Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
79984147|NCT03225352|Drug|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
79984148|NCT03225352|Drug|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
79984149|NCT03225352|Drug|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
79339998|NCT04973527|Drug|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
79655232|NCT00260286|Behavioral|Energy availability|
79655233|NCT04671589|Drug|Meropenem Injection|"Administration Intravenous meropenem 1gram every 8 hours together with standard care;~."
79655234|NCT04671199|Other|MP 3000 monitor|Additional monitoring
79655235|NCT00260325|Drug|valdecoxib|
79984150|NCT03225352|Drug|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
79655236|NCT04671277|Other|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
79984151|NCT03217240|Procedure|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
79813517|NCT04110210|Drug|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
79984152|NCT03217240|Other|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
79339999|NCT05009329|Drug|JAB-21822|JAB-21822 will be administered orally
79655237|NCT00233441|Drug|CELIVARONE (SSR149744C)|
79655238|NCT04671160|Diagnostic Test|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
79340000|NCT05009329|Drug|JAB-21822|JAB-21822 will be administered orally
79340001|NCT04972279|Behavioral|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
79655239|NCT04671394|Procedure|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
79655240|NCT04671394|Procedure|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
79340002|NCT02503501|Drug|Insulin glulisine|
79340003|NCT02503501|Drug|Placebo|Bacteriostatic 0.9% Sodium Chloride
79340004|NCT04971889|Behavioral|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
79340005|NCT04971889|Behavioral|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
79340006|NCT05007613|Drug|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
79340007|NCT05007613|Drug|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
79340008|NCT04971265|Behavioral|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
79489722|NCT05138406|Other|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
79655241|NCT04671550|Diagnostic Test|questionnaire|"Questionnaire on Driving performances and Visual Field"
79655242|NCT00233558|Drug|adalimumab (up to 9 months exposure)|
79655243|NCT00233558|Drug|methotrexate|
79655244|NCT00267618|Behavioral|FHP Pain|Evidence-based psychological and behavioural Intervention
79655245|NCT04670926|Diagnostic Test|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of > 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of > 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
79655246|NCT04670926|Other|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
79655247|NCT00233636|Drug|Iressa (Gefitinib)|
79984153|NCT03217240|Other|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
79340009|NCT04971265|Behavioral|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
79340010|NCT04971265|Behavioral|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
79340011|NCT04971265|Behavioral|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
79340012|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
79340013|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
79340014|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
79655248|NCT00233636|Procedure|Radiotherapy|
79655249|NCT04670887|Procedure|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
79340015|NCT02502097|Drug|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
79655250|NCT04670887|Procedure|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
79655251|NCT04671121|Procedure|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
79655252|NCT04671121|Procedure|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
79655253|NCT04671316|Drug|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
79340016|NCT02502097|Other|Placebo|Matching placebo to gefapixant, tablet administered by mouth
79340017|NCT02501629|Drug|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
79489723|NCT02136576|Device|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
79489724|NCT02136576|Device|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
79655254|NCT04671316|Drug|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
79655255|NCT04671316|Drug|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
79984154|NCT02451280|Procedure|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
79655256|NCT04670614|Procedure|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
79655257|NCT04670614|Procedure|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
79655258|NCT04670692|Other|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
79340018|NCT02501629|Drug|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
79489725|NCT02136576|Device|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
79655259|NCT04670692|Other|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
79655260|NCT00267657|Drug|Reserpine|
79655261|NCT04670809|Drug|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
79655262|NCT04670809|Drug|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
79655263|NCT04670575|Procedure|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
79655264|NCT04670341|Other|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
79655265|NCT04670341|Other|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
79655266|NCT00267735|Behavioral|Use of Computerized Decision Aid on Childbirth|
79655267|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
79655268|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
79984155|NCT02451280|Procedure|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
79340019|NCT02501629|Drug|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
79340020|NCT02501629|Drug|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
79984156|NCT02451280|Procedure|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
79340021|NCT02501473|Drug|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
79340022|NCT02501473|Drug|Pembrolizumab|PD-1 Inhibitor
79984157|NCT03120208|Behavioral|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
79655269|NCT04670497|Procedure|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
79655270|NCT04670302|Procedure|Tendon repair procedure|"Tendon repair procedure:~Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~Then, double suturing of the supraspinatus tendon is performed."
79655271|NCT04670302|Procedure|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
79655272|NCT04670107|Drug|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
79655273|NCT00260364|Drug|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
79984158|NCT03120208|Behavioral|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
79984159|NCT03120208|Behavioral|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
79984160|NCT03120208|Behavioral|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
79340023|NCT02501473|Drug|Rituximab|Rituximab (anti-CD20 antibody)
79984161|NCT03120208|Behavioral|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
79984162|NCT03225040|Drug|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
79340024|NCT02501161|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
79489726|NCT03600194|Device|PowerSleep Stim|The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
79340025|NCT02501161|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
79340026|NCT02500537|Device|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
79340027|NCT05003635|Device|EVEBRA device|Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
79655274|NCT00260364|Drug|Capecitabine orally days 1 -21|
79655275|NCT00260364|Drug|Erlotinib 100 mg orally days 1-28|
79655276|NCT00260364|Drug|Bevacizumab 5 mg/kg intravenously every 2 weeks|
79655277|NCT00233753|Device|Cordis Neurovascular Self-Expanding Stent|
79655278|NCT04557007|Drug|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
79655279|NCT04670458|Other|no intervention|no intervention
79655280|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - fast release|
79655281|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - slow release|
79655282|NCT00260403|Procedure|Photodynamic therapy versus Transpupillary thermotherapy|
79655283|NCT04556812|Procedure|Four-in-one procedure|"four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
79655284|NCT04556812|Procedure|soft-tissue surgery|traditional soft-tissue surgery
79655285|NCT04670380|Other|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
79984163|NCT04404725|Device|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
79984164|NCT04404725|Device|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
79489727|NCT03600194|Device|Northwestern Stim|The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
79984165|NCT03208348|Other|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
79984166|NCT03208270|Drug|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
79340028|NCT04966819|Other|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
79340029|NCT02498821|Device|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
79340030|NCT02498821|Device|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
79984167|NCT03208270|Drug|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
79984168|NCT04343261|Biological|Convalescent Plasma|treatment with 2 Units of convalescent plasma
79984169|NCT03208426|Drug|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
79984170|NCT03208426|Drug|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
79984171|NCT03208426|Drug|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
79984172|NCT03208426|Drug|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
79984173|NCT03208426|Drug|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
79984174|NCT03208426|Drug|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
79984175|NCT03208426|Drug|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
79984176|NCT03208426|Drug|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
79984177|NCT04336475|Other|orofacial exercise program|combined stretching&strengthening exercise regimen
79984178|NCT03224962|Device|fluorescence camera|drug - diagnostic test
79984179|NCT03216070|Drug|Dasatinib 50 MG|50mg of dasatinib orally daily
79984180|NCT04335929|Behavioral|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
79984181|NCT03215602|Other|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
79340031|NCT02498821|Procedure|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
79984182|NCT03215602|Other|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
79984183|NCT03207646|Other|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
79340032|NCT04205539|Drug|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
79340033|NCT02313909|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
79340034|NCT02313909|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
79655286|NCT00556153|Drug|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
79489728|NCT03600194|Device|PowerSleep Sham|The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
79655287|NCT00556192|Drug|rituximab|"Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
79655288|NCT00233831|Device|Generator of electromagnetic millimeter waves|
79984184|NCT05115383|Other|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
79984185|NCT02450968|Drug|Dexamethasone|
79984186|NCT02450968|Drug|Placebo|
79984187|NCT03749993|Other|Screening|Use of bpMRI for opportunistic prostate cancer screening.
79984188|NCT03749915|Device|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
79340035|NCT02313909|Other|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
79655289|NCT00260442|Behavioral|Resistance Training|12 weeks, 3 times a week whole body resistance training
79655290|NCT00260442|Behavioral|Sedentary|Absence of physical activity
79655291|NCT00556270|Drug|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
79655292|NCT00260481|Drug|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
79655293|NCT00260481|Drug|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
79655294|NCT00233870|Drug|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
79655295|NCT00260520|Drug|Dalteparin|
79655296|NCT00233909|Drug|Zosuquidar|
79655297|NCT00233909|Drug|gemtuzumab ozogamicin|
79984189|NCT03749915|Drug|Ametop|Tetracaine Hydrochloride Gel 4%
79984190|NCT03207724|Drug|Xilonix plus Onivyde and 5FU|Xilonix by IV
79340036|NCT02313909|Other|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
79340037|NCT02287467|Biological|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
79340038|NCT02287467|Biological|Placebo for IVIG|Administered IV as 500 mL of normal saline
79489729|NCT03600194|Device|NorthWestern Sham|The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
79340039|NCT02287233|Drug|Venetoclax|Venetoclax will be taken orally once daily.
79340040|NCT02287233|Drug|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
79489730|NCT03398330|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
79489731|NCT03398330|Drug|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
79489732|NCT03398798|Device|".014"|".014 CuNiTi orthodontic arch wire"
79489733|NCT03398798|Device|".016"|".016 CuNiTi orthodontic arch wire"
79489734|NCT03398798|Device|Twin brackets|Ormco Insignia Metal Twin brackets
79489735|NCT03398798|Device|Self-ligating brackets|Ormco Insignia SL brackets
79489736|NCT03400748|Device|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
79489737|NCT03505190|Drug|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
79340041|NCT01646385|Drug|etanercept|use as per routine clinical practice
79489738|NCT03505190|Drug|Placebo|Matching placebo will be administered subcutaneously (SC).
79489739|NCT04734704|Procedure|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
79489740|NCT04734704|Procedure|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
79489741|NCT03513848|Device|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
79489742|NCT03513848|Device|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
79340042|NCT01646385|Drug|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
79340043|NCT02286843|Radiation|89Zr-trastuzumab|
79340044|NCT02286843|Device|PET/CT scan|
79340045|NCT02286843|Radiation|89Zr-pertuzumab|
79340046|NCT02282163|Drug|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
79340047|NCT02281773|Drug|BI 409306 100 mg QD|
79340048|NCT02281773|Drug|BI 498306 50 mg QD|
79340049|NCT02281773|Drug|Placebo|
79340050|NCT02281773|Drug|BI 498306 25 mg QD|
79340051|NCT02281773|Drug|BI 409306 10 mg QD|
79340052|NCT02285361|Drug|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
79340053|NCT02285361|Drug|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
79340054|NCT02285361|Drug|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
79340055|NCT02354235|Drug|Teneligliptin|
79655298|NCT00267813|Drug|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
79655299|NCT00234026|Drug|gemcitabine hydrochloride|
79340056|NCT02354235|Drug|Canagliflozin|
79340057|NCT02354235|Drug|Placebo|
79340058|NCT02280291|Drug|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
79489743|NCT03402932|Other|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
79489744|NCT03402932|Other|Visual|The cognitive test will be administered visually by using timed computer slides.
79489745|NCT03402932|Other|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
79489746|NCT00376610|Device|ASR/Re-cap|
79489747|NCT03621878|Other|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
79489748|NCT03621878|Other|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
79489749|NCT03621878|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
79489750|NCT00376766|Drug|levetiracetam|
79340059|NCT02280291|Drug|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
79340060|NCT02280291|Drug|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
79340061|NCT02280291|Drug|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
79489751|NCT03403712|Drug|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
79655300|NCT00267852|Other|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
79655301|NCT00234143|Behavioral|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
79340062|NCT02284893|Drug|Saxagliptin|administered orally once daily
79489752|NCT03403712|Drug|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
79489753|NCT03403712|Drug|dexamethasone|Oral dexamethasone (12 mg)
79489754|NCT03404648|Drug|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
79489755|NCT03404648|Drug|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
79340063|NCT02284893|Drug|Dapagliflozin|administered orally once daily
79489756|NCT03404648|Device|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
79489757|NCT03383198|Drug|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
79489758|NCT03383198|Drug|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
79489759|NCT03407612|Device|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
79340064|NCT02284893|Drug|Sitagliptin|administered orally once daily
79340065|NCT02284893|Drug|Placebo matching with Saxagliptin|administered orally once daily
79489760|NCT03408392|Drug|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
79489761|NCT03408392|Drug|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
79489762|NCT04735484|Device|Gait analysis|Collecting movement data whilst participants walk
79489763|NCT03413618|Drug|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
79340066|NCT02284893|Drug|Placebo matching with Dapagliflozin|administered orally once daily
79489764|NCT03413618|Drug|Diosmin|600 mg q.d. for 12 month
79340067|NCT02284893|Drug|Placebo matching with Sitagliptin|administered orally once daily
79340068|NCT02284347|Device|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
79340069|NCT02279043|Behavioral|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
79489765|NCT03413618|Other|compression stockings|above knee stocking for 12 month
79489766|NCT03522350|Device|EmbryoScope|Standard of care arm
79489767|NCT03522350|Device|EmbryoScope+|Experimental arm
79489768|NCT03523988|Drug|Acetaminophen|Acetaminophen gel capsule
79489769|NCT03523988|Drug|Ibuprofen|Ibuprofen gel capsule
79489770|NCT03525548|Drug|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
79489771|NCT03525548|Drug|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
79489772|NCT03525548|Drug|IVA|Participants received IVA orally once daily in the evening.
79489773|NCT03525548|Drug|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
79489774|NCT03525548|Drug|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
79489775|NCT03528512|Drug|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
79489776|NCT03528512|Drug|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
79489777|NCT03531710|Biological|UB-311|Intramuscular injection
79489778|NCT03531710|Drug|Placebo|Intramuscular injection
79655302|NCT00234143|Drug|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
79489779|NCT03533036|Device|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
79340070|NCT02279043|Behavioral|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
79813518|NCT04110210|Drug|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
79489780|NCT02153112|Biological|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
79489781|NCT02153112|Biological|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
79489782|NCT02153112|Biological|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
79489783|NCT02153112|Biological|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
79489784|NCT02153112|Drug|Placebo|Placebo saline solution
79489785|NCT03534986|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
79489786|NCT03534986|Device|Hill-Rom The Vest|High-frequency chest wall oscillation vest
79489787|NCT03534986|Device|Respirtech inCourage|High-frequency chest wall oscillation vest
79489788|NCT03534986|Device|Electromed SmartVest|High-frequency chest wall oscillation vest
79489789|NCT03536702|Other|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
79489790|NCT03536702|Other|Independent Writing - Control Group|This group will receive a book for a self writing session.
79489791|NCT03537092|Device|Vaginal Film|"2 x 2 vaginal film with no active drug"
79489792|NCT02133924|Drug|natalizumab|Natalizumab 300mg on days 0 and 14.
79489793|NCT02133924|Drug|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
79340071|NCT02283411|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
79340072|NCT02351817|Device|Test A|Ostomy appliance
79340073|NCT02351817|Device|Test B|Ostomy appliance
79340074|NCT02351817|Device|Baseline|Ostomy appliance
79340075|NCT02351349|Other|multidisciplinary intervention|multidisciplinary intervention
79489794|NCT03624920|Drug|THN102 Dosage A|THN102 Dosages A: placebo
79489795|NCT03624920|Drug|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
79489796|NCT03624920|Drug|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
79489797|NCT03537404|Drug|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
79489798|NCT03537404|Drug|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
79489799|NCT03537404|Drug|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
79489800|NCT03537404|Drug|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
79489801|NCT03417752|Other|Exposure to firearm safety PSA|Exposed to firearm safety PSA
79489802|NCT03417752|Other|Exposure to health promotion PSA|Exposed to general health promotion PSA
79489803|NCT03626714|Drug|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
79489804|NCT04332380|Drug|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
79340076|NCT02484547|Drug|Aducanumab (BIIB037)|Low dose
79340077|NCT02484547|Drug|Aducanumab (BIIB037)|High dose
79340078|NCT02484547|Drug|Placebo|Placebo
79340079|NCT02517541|Device|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
79489805|NCT03538808|Drug|Varenicline|Participants will be provided varenicline medication
79813519|NCT00647296|Drug|Placebo|Placebo: 2 tablets taken orally twice daily
79984191|NCT03225274|Other|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
79984192|NCT05050409|Behavioral|Brief mindfulness|A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
79340080|NCT02496091|Device|ATLANTIS Abutment|
79489806|NCT03538808|Other|Placebo|Participants will be provided placebo medication
79340081|NCT02483611|Drug|Magnesium Sulfate|
79340082|NCT02483611|Drug|Lidocaine|
79340083|NCT02483611|Drug|Isotonic Solution|
79340084|NCT02483611|Drug|Cisatracurium|
79340085|NCT04963933|Device|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
79340086|NCT02483533|Drug|LIPO-202|
79340087|NCT02483533|Drug|Placebo|
79340088|NCT02482129|Drug|LME636 60 mg/mL ophthalmic solution|
79340089|NCT02482129|Drug|Dexamethasone 0.1% ophthalmic solution|
79340090|NCT02482129|Drug|LME636 Vehicle|Inactive ingredients used for masking purposes
79489807|NCT03540134|Device|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
79489808|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% gel pump|
79489809|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% tube|
79489810|NCT02173704|Biological|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
79489811|NCT02173704|Biological|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
79489812|NCT03542474|Behavioral|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
79489813|NCT03543176|Other|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
79489814|NCT03543176|Other|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
79489815|NCT03543176|Other|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
79813520|NCT00647296|Drug|Dexpramipexole 50 mg/day|Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
79813521|NCT00647296|Drug|Dexpramipexole 150 mg/day|Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
79340091|NCT04962529|Procedure|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
79340092|NCT02495857|Device|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
79340093|NCT02495857|Device|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
79984193|NCT05050409|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
79984194|NCT05050409|Other|Standard care|Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
79340094|NCT02495857|Device|Placebo|0.9% sodium chloride, sterile
79340095|NCT02495389|Drug|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
79340096|NCT02495233|Drug|Gilteritinib|oral
79340097|NCT02495233|Drug|Erlotinib|oral
79340098|NCT02495077|Biological|Infliximab|A single dose, of 3mg/kg infusion
79340099|NCT02495077|Drug|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
79340100|NCT02495077|Drug|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
79340101|NCT02495077|Drug|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
79340102|NCT02495077|Biological|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
79489816|NCT03543176|Other|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
79489817|NCT03543176|Device|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
79655303|NCT04670419|Other|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
79340103|NCT02495077|Drug|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~Tylenol, 600 to 1000mg by mouth or~Suppository form"
79340104|NCT02495077|Drug|Loratadine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
79655304|NCT04670185|Behavioral|BIP SAMBA|Behavioral parent management training
79655305|NCT04670146|Diagnostic Test|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
79655306|NCT00234182|Drug|Interferon alpha-2b|
79655307|NCT04669873|Radiation|Active Comparator: Standard|Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks
79655308|NCT04669873|Radiation|Experimental 1: Hypofractionated radiotherapy|Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week
79489818|NCT03543176|Device|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
79340105|NCT02495077|Biological|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
79340106|NCT02495077|Drug|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
79340107|NCT02495077|Drug|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
79340108|NCT02278341|Drug|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
79489819|NCT02173548|Drug|Anakinra|
79489820|NCT02173548|Drug|Placebo|
79489821|NCT03543878|Device|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
79489822|NCT02173158|Drug|lomitapide|
79655309|NCT04669873|Radiation|Experimental 2: Accelerated Partial Breast Irradiation|Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
79655310|NCT04669756|Procedure|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
79489823|NCT04501640|Drug|mirabegron|Oral adminstration
79489824|NCT02152566|Device|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
79655311|NCT04669756|Procedure|placebo operation|in arm D sutures are transabdominal only
79655312|NCT00260598|Procedure|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
79655313|NCT04669912|Other|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
79655314|NCT04669795|Drug|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
79655315|NCT04670029|Other|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
79655316|NCT04669951|Other|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
79655317|NCT00234221|Behavioral|Strengths Based Case Management|
79655318|NCT00234221|Behavioral|Motivational Enhancement Therapy|
79655319|NCT00234221|Behavioral|Brief Informational Feedback|
79655320|NCT04669990|Drug|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
79340109|NCT02278341|Drug|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
79340110|NCT02278341|Drug|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
79340111|NCT02278341|Drug|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was < 100 ng/mL (< 220 pmol/L) or TSAT < 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
79489825|NCT04758390|Behavioral|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
79489826|NCT04758390|Behavioral|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
79655321|NCT00267930|Drug|Vernakalant (oral)|
79655322|NCT00267930|Drug|Placebo comparator|
79655323|NCT04669405|Device|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
79489827|NCT03632954|Device|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
79489828|NCT04559282|Device|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
79489829|NCT04734470|Diagnostic Test|Flow cytometry|The study of CD19 complex expression in lymphoproliferative disorders by flowcytometry
79489830|NCT03633344|Drug|Carbowhite|
79489831|NCT03633344|Drug|Carbowhite placebo|
79489832|NCT02171130|Drug|Nasal Glucagon|3 mg nasal glucagon powder
79489833|NCT04777214|Device|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
79489834|NCT04777214|Device|Sham TMS|Sham TMS will be administered
79489835|NCT04749810|Drug|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
79489836|NCT00377078|Drug|recombinant human lactoferrin|
79489837|NCT04495712|Drug|spironolactone|aldosterone blocker
79489838|NCT04495712|Drug|placebo|identical in appearance to spironolactone study drug
79489839|NCT04474496|Other|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
79489840|NCT03552536|Drug|MK-8583|A single oral dose of MK-8583 in capsule form
79489841|NCT03553940|Biological|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
79813522|NCT00647296|Drug|Dexpramipexole 300 mg/day|Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
79489842|NCT03553940|Other|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
79489843|NCT03553940|Biological|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
79489844|NCT04448210|Behavioral|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
79489845|NCT03640832|Other|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
79340112|NCT02282631|Behavioral|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
79340113|NCT02278263|Drug|Tranexamic Acid|Given intravenously or topically
79489846|NCT03640832|Other|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
79489847|NCT04458818|Procedure|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
79489848|NCT04456634|Drug|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
79489849|NCT04456634|Other|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
79813523|NCT00644878|Drug|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
79340114|NCT02278263|Drug|Normal saline (0.9% NaCl)|Administered in all 3 groups
79340115|NCT02349711|Dietary Supplement|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
79340116|NCT02349711|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
79340117|NCT02494921|Drug|Docetaxel-PNP|Given IV
79340118|NCT02494921|Drug|Ribociclib|Given Orally
79340119|NCT02494921|Drug|Prednisone|Given Orally
79340120|NCT02494921|Drug|Filgrastim|Given IV
79340121|NCT01653847|Drug|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
79489850|NCT04454138|Device|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
79340122|NCT01653847|Drug|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is < 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
79489851|NCT04431908|Device|olfactory device|A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
79489852|NCT00377624|Drug|sodium hyaluronate|
79489853|NCT03558074|Drug|ALK4290|ALK4290 400 mg tablet twice a day
79489854|NCT03558230|Behavioral|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
79489855|NCT03558230|Behavioral|Vibration|Vibration applied to the wrist.
79489856|NCT03558230|Behavioral|Placebo (for vibration)|No vibration applied to the wrist.
79489857|NCT03560102|Device|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
79489858|NCT03562988|Dietary Supplement|Vitamin C gummy|vitamin C
79489859|NCT03562988|Dietary Supplement|Vitamin C tablet|vitamin C
79489860|NCT03644108|Drug|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
79489861|NCT04713956|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
79489862|NCT04713956|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
79489863|NCT04713956|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
79489864|NCT04713956|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79984195|NCT03207880|Device|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
79489865|NCT04713956|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
79489866|NCT03565874|Device|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
79489867|NCT03569618|Device|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
79489868|NCT04425746|Drug|Afamelanotide|
79984196|NCT03214822|Dietary Supplement|H2MF|As described in the Experimental Arm description.
79984197|NCT04333199|Behavioral|Timely|Email
79984198|NCT04333199|Behavioral|Transparency|Email
79984199|NCT04333199|Behavioral|Foot-in-the-door|Email
79984200|NCT03119116|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
79984201|NCT03119116|Drug|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
79984202|NCT03119116|Drug|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
79984203|NCT03207802|Device|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
79984204|NCT04332419|Device|PET/CT|Standard Imaging
79489869|NCT04425746|Drug|Placebo|
79984205|NCT04332419|Device|PET/MR|Additional Imaging
79489870|NCT04402970|Drug|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
79655324|NCT04669405|Other|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
79984206|NCT04332419|Radiation|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
79984207|NCT02450734|Procedure|Ultrasound-guided intermediate cervical plexus block|
79984208|NCT03224806|Other|Wholegrain bread|156.8g wholegrain bread
79489871|NCT04392362|Drug|Adenosine|A vial of adenosine with 6mg
79340123|NCT02493751|Drug|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
79489872|NCT04734782|Diagnostic Test|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
79489873|NCT04714034|Diagnostic Test|"to develop and validate a scale measuring online dating addiction (ODA) in sexual minorities - the ODA Scale"|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of ODA Scale scores with sexual health and mental health outcomes."
79489874|NCT04390022|Drug|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
79489875|NCT04390022|Drug|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
79655325|NCT02962271|Device|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
79340124|NCT02493751|Drug|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
79655326|NCT00556348|Drug|bevacizumab|1.25mg
79655327|NCT04556539|Drug|SC10914|400mg TID, oral admination on fasting condition
79655328|NCT00556387|Drug|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
79984209|NCT03224806|Other|White bread|122.6g white bread
79984210|NCT03224806|Other|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
79984211|NCT03224806|Other|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
79984212|NCT03207568|Device|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
79984213|NCT03224884|Procedure|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
79984214|NCT03224884|Procedure|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
79340125|NCT02493517|Drug|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
79340126|NCT02493517|Drug|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
79984215|NCT04329923|Drug|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
79984216|NCT04329923|Drug|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
79984217|NCT04329923|Drug|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
79340127|NCT02493361|Drug|Pembrolizumab|
79340128|NCT02493361|Drug|pIL-12|
79340129|NCT04959799|Drug|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
79984218|NCT04329923|Drug|Placebo oral tablet|Placebo
79340130|NCT02493127|Other|Standard PCS|Subject completes the standard version of the PCS Questionnaire
79489876|NCT04370834|Biological|Tocilizumab|Given IV
79489877|NCT03570476|Drug|Olaparib|Given orally
79489878|NCT03570476|Procedure|Radical Prostatectomy|Undergo surgery
79489879|NCT03571724|Other|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
79489880|NCT03571724|Other|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
79489881|NCT03571724|Other|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
79489882|NCT03571724|Other|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
79489883|NCT03572972|Drug|Apixaban|Treatment for NVAF patients
79489884|NCT03572972|Drug|Dabigatran|Treatment for NVAF patients
79489885|NCT03572972|Drug|Rivaroxaban|Treatment for NVAF patients
79489886|NCT03572972|Drug|warfarin|Treatment for NVAF patients
79489887|NCT03572972|Drug|Antiplatelets|Treatment for NVAF patients
79489888|NCT05314790|Other|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
79489889|NCT04352660|Drug|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
79489890|NCT04352660|Drug|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
79340131|NCT02493127|Other|Grip Strength|Research Assistant takes Grip Strength Measurements
79489891|NCT03650192|Device|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
79489892|NCT04342130|Drug|Morphine|30 mg oral tablet
79489893|NCT04338074|Drug|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
79489894|NCT04338074|Drug|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
79489895|NCT03964220|Drug|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
79655329|NCT00556387|Drug|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
79655330|NCT00260637|Procedure|Acupuncture|
79489896|NCT03964220|Drug|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
79984219|NCT03207178|Biological|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5*10^6 cells/kg body weight,separately.
79340132|NCT02493127|Other|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
79489897|NCT04337138|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
79984220|NCT03213496|Behavioral|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
79984221|NCT03213496|Other|Conventional care|Patient do not walk before surgery
79984222|NCT03224728|Device|intraocular lens|
79984223|NCT03207412|Biological|hAECs|human amniotic epithelial cells
79984224|NCT03207412|Procedure|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
79984225|NCT04403399|Drug|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
79340133|NCT02478463|Drug|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
79984226|NCT04403399|Drug|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
79984227|NCT03224572|Drug|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
79340134|NCT02478463|Drug|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL [600 mg] total) IM given once on Day 1 of injection phase
79340135|NCT02491411|Drug|Dexamethasone|Given PO
79340136|NCT02491411|Drug|Enzalutamide|Given PO
79340137|NCT02491411|Other|Laboratory Biomarker Analysis|Correlative studies
79340138|NCT02491411|Other|Quality-of-Life Assessment|Ancillary studies
79489898|NCT03657134|Diagnostic Test|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
79489899|NCT04332614|Behavioral|Less-is-better|Email
79489900|NCT04332614|Behavioral|Social proof|Email
79489901|NCT04332614|Behavioral|Endowment / decision staging|Email
79655331|NCT04556422|Other|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
79655332|NCT04556422|Other|Sauna bathing|Passive heat exposure
79813524|NCT04045288|Behavioral|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
79984228|NCT03224572|Other|normal saline|500ml normal saline, once per week, and total 4-week treatment
79984229|NCT02452216|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
79984230|NCT02452216|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
79984231|NCT02452216|Procedure|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
79489902|NCT04332614|Behavioral|Standard email|Email
79489903|NCT04332757|Other|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
79489904|NCT00422773|Drug|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
79340139|NCT02517463|Drug|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
79984232|NCT03749759|Procedure|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
79489905|NCT04326842|Procedure|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
79984233|NCT03207334|Drug|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
79489906|NCT04326842|Device|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
79340140|NCT02516605|Drug|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
79489907|NCT03329209|Drug|Vedolizumab|Vedolizumab intravenous infusion.
79813525|NCT04045288|Behavioral|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
79813526|NCT00813046|Biological|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
79813527|NCT00813202|Drug|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
79813528|NCT00646906|Drug|Aspirin First|Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
79813529|NCT00646906|Drug|Aspirin Last|Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
79984234|NCT03207334|Drug|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
79340141|NCT02516605|Drug|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
79340142|NCT02516605|Drug|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
79340143|NCT02516605|Drug|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
79340144|NCT02516605|Drug|Part 2: LJN452 Dose level 2|LJN452
79340145|NCT02490475|Drug|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
79489908|NCT03661346|Drug|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
79489909|NCT03661346|Drug|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
79489910|NCT03329911|Drug|EU Avastin®|100 mg/4 mL
79489911|NCT03329911|Drug|BAT1706|100 mg/4 mL
79489912|NCT03329911|Drug|Paclitaxel|200 mg/m²
79489913|NCT03329911|Drug|carboplatin|target area under the curve [AUC] 6 mg/mL•minute
79489914|NCT04322396|Drug|Azithromycin|Azithromycin
79489915|NCT04322396|Drug|Hydroxychloroquine|Hydroxychloroquine
79489916|NCT04322396|Drug|Placebo oral tablet|Placebo Azithromycin
79489917|NCT04322396|Drug|Placebo oral tablet|Placebo Hydroxychloroquine
79489918|NCT03222037|Device|senofilcon A|Acuvue Oasys 1-Day
79489919|NCT03222037|Device|Control|Trial Frame with best spherocylindrical refraction (SCR)
79489920|NCT03961100|Drug|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
79489921|NCT03961100|Drug|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
79813530|NCT00646906|Drug|Acetaminophen 1000 mg/d|Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
79489922|NCT03961100|Drug|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
79813531|NCT00646906|Drug|Acetaminophen 4000 mg/d|Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
79813532|NCT00646906|Drug|Ibuprofen 800 mg/d|Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
79813533|NCT00808600|Behavioral|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
79813534|NCT00808600|Behavioral|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
79813535|NCT00808600|Behavioral|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
79489923|NCT03961100|Drug|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
79489924|NCT03222427|Drug|LY3314814|Administered orally
79489925|NCT03222427|Drug|[13C415N3] LY3314814|Administered as an IV infusion
79489926|NCT03442699|Behavioral|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
79489927|NCT03954158|Drug|Crisaborole ointment 2%|BID regimen
79489928|NCT03954158|Drug|Vehicle|BID regimen
79489929|NCT03954158|Drug|Crisaborole ointment 2%|QD regimen
79489930|NCT03954158|Drug|Vehicle|QD regimen
79489931|NCT03222505|Device|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
79489932|NCT03222505|Other|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
79489933|NCT03224299|Drug|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
79489934|NCT03224299|Drug|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
79489935|NCT03224299|Other|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
79489936|NCT03224299|Other|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
79489937|NCT03333577|Device|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
79489938|NCT03334825|Other|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
79489939|NCT03334825|Other|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
79489940|NCT03442933|Other|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
79489941|NCT03442933|Other|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
79489942|NCT03444961|Device|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
79489943|NCT03661814|Device|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
79489944|NCT03335761|Device|InterStim Therapy|Device Programming
79489945|NCT03662282|Drug|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
79489946|NCT03336853|Device|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
79655333|NCT04669483|Other|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
79340146|NCT02490475|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
79655334|NCT04552093|Drug|Floxuridine|Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
79655335|NCT04552093|Device|Tricumed IP2000V infusion pump|Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
79655336|NCT00260676|Procedure|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
79340147|NCT02477839|Drug|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
79340148|NCT02477839|Other|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
79340149|NCT04939987|Drug|Tramadol|Opioid Control Cohort (One treatment selected)
79340150|NCT04939987|Drug|Gabapentin|Experimental Cohort (Multimodal Approach)
79489947|NCT03336853|Other|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
79984235|NCT03751475|Other|Nutritional Strategy - OptiMA|"All children with a MUAC<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
79984236|NCT03751475|Other|Effective nutritional standard strategy|"Children presenting with MUAC<115 or WHZ<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
79984237|NCT03212950|Drug|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
79984238|NCT03212950|Drug|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
79984239|NCT03207490|Device|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
79984240|NCT03212248|Diagnostic Test|Thoracic Ultrasound (TUS)|
79984241|NCT03207100|Combination Product|Analgesia-first minimal sedation|Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
79489948|NCT03954626|Biological|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
79340151|NCT04939987|Drug|Hydrocodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
79489949|NCT04332835|Drug|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
79340152|NCT04939987|Drug|Oxycodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
79340153|NCT04939987|Drug|Ketorolac|Experimental Cohort (Multimodal Approach)
79340154|NCT04939987|Drug|Acetaminophen|Experimental Cohort (Multimodal Approach)
79340155|NCT04939987|Drug|Ketorolac tromethamine|Experimental Cohort (Multimodal Approach)
79340156|NCT04939987|Drug|Ketamine|Experimental Cohort (Multimodal Approach)
79340157|NCT04953559|Device|Active cTBS|Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
79489950|NCT04332835|Drug|Standard Therapy|Standard therapy defined by institutional protocol.
79340158|NCT04953559|Device|Sham cTBS|Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
79340159|NCT02488915|Device|EmboTrap® Revascularization Device|
79340160|NCT02488681|Device|Micra Pacemaker Implant|
79340161|NCT02477605|Device|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
79489951|NCT03662360|Other|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
79489952|NCT03225001|Device|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
79489953|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
79984242|NCT03207100|Combination Product|Antihypertensive treatment|Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
79984243|NCT03212092|Dietary Supplement|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
79489954|NCT03225313|Drug|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound & locally surrounding the hernia
79655337|NCT04556110|Drug|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
79655338|NCT04556110|Drug|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
79655339|NCT00234299|Drug|Aspirin|325mg, one tablet orally, six months
79655340|NCT00234299|Drug|Placebo|325mg, one tablet orally every day, 6 months
79655341|NCT04556227|Behavioral|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
79984244|NCT03212092|Dietary Supplement|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
79655342|NCT04556032|Dietary Supplement|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
79655343|NCT04556032|Dietary Supplement|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
79655344|NCT04556032|Other|Placebo|0 mg/d L-Ergothioneine
79655345|NCT00260715|Behavioral|Community-Popular Opinion Leader Model|
79489955|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
79655346|NCT00260715|Behavioral|Diffusion of Innovations|
79984245|NCT03211390|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
79984246|NCT03211390|Diagnostic Test|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
79489956|NCT03949244|Drug|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
79984247|NCT01561937|Drug|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
79340162|NCT02477605|Device|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
79489957|NCT03949244|Drug|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
79340163|NCT02477605|Procedure|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
79489958|NCT03949244|Drug|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
79489959|NCT03949244|Diagnostic Test|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
79489960|NCT03225859|Behavioral|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
79340164|NCT02477527|Drug|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
79489961|NCT05313932|Other|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
79489962|NCT03948386|Drug|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
79489963|NCT03948386|Drug|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
79489964|NCT03948386|Drug|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
79655347|NCT04556149|Device|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
79655348|NCT04556149|Device|Philips Lumify Ultrasound System|Point-of-care ultrasound
79340165|NCT02477215|Drug|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
79340166|NCT02477215|Drug|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
79340167|NCT02477215|Drug|Bendamustine (multiple dose levels)|70 mg/m^2, 80 mg/m^2, or 90 mg/m^2 on days 1 and 2
79489965|NCT03445195|Drug|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
79489966|NCT03445195|Drug|Placebo|Matching 1g IV solution.
79489967|NCT03445195|Drug|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
79489968|NCT04289714|Device|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
79489969|NCT04277936|Drug|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
79489970|NCT03666026|Behavioral|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
79489971|NCT03666026|Behavioral|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
79489972|NCT03666026|Behavioral|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
79655349|NCT04556071|Drug|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight<77 kg and/or basal platelet count <150,000/μL will take 200 mg daily.
79655350|NCT04556071|Drug|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
79340168|NCT02477215|Drug|Bendamustine (MTD)|80 mg/m^2 on days 1 and 2
79340169|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
79655351|NCT04563676|Biological|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
79655352|NCT00234377|Drug|Seroquel SR|
79655353|NCT04563286|Other|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
79655354|NCT00260754|Behavioral|Community-Popular Opinion Leader Model|
79655355|NCT00260754|Behavioral|Diffusion of Innovations|
79655356|NCT02211118|Drug|Intranasal dexemdetomidine (IN-DEX)|
79655357|NCT02211157|Drug|BIBR 796 BS|
79655358|NCT02211157|Drug|Placebo|
79655359|NCT02211157|Other|high fat breakfast|
79655360|NCT00234416|Drug|Gefitinib|
79655361|NCT00234416|Drug|Gemcitabine|
79655362|NCT02211196|Behavioral|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
79655363|NCT02211196|Other|survey administration|Ancillary studies
79489973|NCT03936608|Device|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
79489974|NCT03936608|Device|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
79489975|NCT03670160|Drug|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
79655364|NCT02211196|Other|questionnaire administration|Ancillary studies
79984248|NCT01561937|Drug|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
79984249|NCT01561937|Drug|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
79340170|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
79340171|NCT02475733|Drug|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
79340172|NCT02475733|Drug|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
79340173|NCT02475733|Drug|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
79340174|NCT04925947|Drug|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
79655365|NCT04563364|Other|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
79489976|NCT03670160|Drug|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
79489977|NCT03672032|Device|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
79340175|NCT04942639|Device|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
79489978|NCT03672032|Device|Franseen Needle|Franseen Needle will be used to obtain biopsy
79489979|NCT03446053|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
79489980|NCT03446053|Other|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
79489981|NCT00375895|Drug|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
79489982|NCT05314322|Procedure|Deep brain stimulation with high frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
79489983|NCT05314322|Procedure|Deep brain stimulation with low frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
79489984|NCT03338803|Drug|Linagliptin|drug
79655366|NCT04563364|Other|Convencional treatment|Control group will receive a conventional treatment given by the institutions
79655367|NCT04562857|Behavioral|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
79655368|NCT04563052|Behavioral|Educational Program on Air Pollution as a Health Risk Reduction Strategy|A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
79655369|NCT00234455|Device|drug eluting-stent|PCI
79655370|NCT00234455|Device|drug-eluting stent|PCI
79655371|NCT04563169|Other|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (>6 hours per night); 2) rest AHI < 5 (or <10 if age >70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
79984250|NCT03210766|Drug|Nabilone|
79489985|NCT05314244|Procedure|Pylorus resecting pancreaticoduodenectomy|The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
79489986|NCT03452371|Behavioral|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
79489987|NCT03452371|Behavioral|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
79489988|NCT03906968|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
79489989|NCT05314634|Behavioral|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
79489990|NCT05314634|Behavioral|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
79984251|NCT03210766|Drug|THC/CBD|
79489991|NCT04206800|Diagnostic Test|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
79489992|NCT03689504|Dietary Supplement|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
79489993|NCT03689504|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
79489994|NCT03689504|Behavioral|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
79655372|NCT04563091|Device|Hemodialysis with online HFR|"Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values > 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
79489995|NCT03455491|Drug|XC221 100 mg|once daily during 3 days.
79340176|NCT02486653|Drug|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: tamsulosin 0.4mg in the evening~Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
79340177|NCT02486653|Drug|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: placebo in the evening~Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
79655373|NCT00234572|Drug|Lanreotide (Autogel formulation)|
79984252|NCT03747341|Drug|Buprenorphine Injectable Solution - Part A|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."
79340178|NCT02475655|Drug|Ruxolitinib|10 mg orally twice daily for 5 weeks
79340179|NCT02475265|Drug|estradiol 0.045 mg/levonorgestrel 0.015mg|
79340180|NCT02485717|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
79489996|NCT03455491|Drug|XC221 200 mg|once daily during 3 days.
79489997|NCT03455491|Drug|Placebo|once daily during 3 days.
79489998|NCT03349567|Behavioral|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
79489999|NCT03691844|Drug|AMZ001|diclofenac gel
79490000|NCT03691844|Drug|Placebo|Placebo
79490001|NCT03691844|Drug|Comparator|diclofenac gel
79655374|NCT04562818|Diagnostic Test|Diagnosis|Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
79655375|NCT04562818|Diagnostic Test|Molecular and Karyotype|To realize the need of having more center we the technology to perform all of these tests
79655376|NCT04562818|Diagnostic Test|Leucocytes|
79655377|NCT00260793|Drug|Ropinirole Hydrochloride|
79340181|NCT02485717|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
79490002|NCT03456427|Device|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) & Mediolateral Oblique (MLO).
79984253|NCT03747341|Drug|Placebo - Parts A + B|0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
79340182|NCT05460559|Procedure|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
79984254|NCT03747341|Drug|Fentanyl - Part A|Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
79340183|NCT05460559|Procedure|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
79340184|NCT02451007|Drug|lurbinectedin (PM01183)|
79340185|NCT02473471|Device|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
79490003|NCT03456427|Device|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
79490004|NCT04195880|Other|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
79340186|NCT02450539|Drug|Abemaciclib|Administered orally
79655378|NCT04562506|Device|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
79984255|NCT03747341|Drug|Ondansetron - Parts A + B|A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.
79340187|NCT02450539|Drug|Docetaxel|Administered IV
79340188|NCT02449915|Drug|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
79340189|NCT02449915|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
79340190|NCT02420119|Other|non interventional|
79340191|NCT02473393|Drug|OPS-2071 tablet|
79340192|NCT02419573|Device|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
79340193|NCT02419573|Device|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
79490005|NCT03352609|Device|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
79490006|NCT03352609|Device|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
79490007|NCT04191668|Device|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
79490008|NCT03354325|Behavioral|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
79490009|NCT03354325|Behavioral|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
79490010|NCT03892460|Device|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
79490011|NCT03232645|Device|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
79490012|NCT00377936|Drug|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
79490013|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
79490014|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
79490015|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
79490016|NCT03457909|Device|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
79490017|NCT03696758|Procedure|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
79490018|NCT03696758|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
79490019|NCT03696758|Procedure|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
79490020|NCT03696758|Drug|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
79490021|NCT03696758|Drug|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
79490022|NCT03461965|Behavioral|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
79490023|NCT03461965|Behavioral|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
79490024|NCT03702608|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - (PBMA) and CarboSil®~Ridaforolimus drug"
79490025|NCT03233737|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
79655379|NCT04562506|Device|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
79984256|NCT03747341|Drug|Buprenorphine Injectable Solution - Part B|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."
79340194|NCT02472847|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
79340195|NCT02472847|Drug|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
79340196|NCT02472145|Drug|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/[m^2]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
79340197|NCT02472145|Drug|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
79340198|NCT02448043|Drug|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
79490026|NCT03233737|Device|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
79490027|NCT03233737|Device|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
79490028|NCT05440747|Other|TFR(Treatment-Free Remission)|Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
79490029|NCT04144088|Drug|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
79813536|NCT00808600|Behavioral|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
79813537|NCT00813436|Drug|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
79813538|NCT00813436|Drug|Placebo|saline liquid, intranasally administered
79984257|NCT03747341|Drug|Fentanyl - Part B|"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."
79984258|NCT03747341|Drug|Oxycodone - Part B|All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.
79984259|NCT03210298|Combination Product|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
79984260|NCT04401293|Drug|Enoxaparin|Full Dose LMWH anticoagulation therapy
79984261|NCT04401293|Drug|Prophylactic/Intermediate Dose Enoxaparin|Prophylactic/Intermediate Dose LMWH or UFH therapy
79340199|NCT02448043|Other|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
79340200|NCT02447887|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
79490030|NCT04144088|Drug|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
79490031|NCT04144088|Drug|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
79490032|NCT03359629|Device|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
79490033|NCT03359629|Device|YSI 2300 Stat Plus|Reference commercial glucometer
79490034|NCT03462745|Device|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
79490035|NCT03711578|Drug|Tenalisib,|BID, Orally
79490036|NCT03463915|Drug|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
79490037|NCT03463915|Drug|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
79984262|NCT03209830|Drug|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
79984263|NCT03209830|Drug|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
79984264|NCT03209986|Procedure|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
79340201|NCT02447887|Drug|Pegylated IFN-alpha 2b|Weekly injection
79490038|NCT00376441|Procedure|Vaginal Surgery|patients undergoing vaginal surgery
79490039|NCT04147442|Device|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
79490040|NCT03237871|Behavioral|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
79490041|NCT04146272|Device|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
79490042|NCT04146272|Device|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
79490043|NCT04146272|Device|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
79490044|NCT04146272|Device|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
79490045|NCT03473665|Drug|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
79490046|NCT03473665|Drug|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
79490047|NCT03473665|Drug|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
79490048|NCT03473665|Drug|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
79490049|NCT03863210|Other|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
79490050|NCT03239665|Behavioral|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
79490051|NCT03239665|Behavioral|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
79490052|NCT03717506|Drug|GDC 268 Lotion|GDC 268 is a topical lotion
79984265|NCT03209986|Other|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
79490053|NCT03717506|Drug|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
79984266|NCT03209908|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
79490054|NCT03717506|Drug|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
79490055|NCT03861338|Drug|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
79490056|NCT03851744|Other|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
79490057|NCT03851744|Other|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
79490058|NCT00377780|Drug|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
79490059|NCT03242941|Procedure|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
79655380|NCT04562545|Device|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
79490060|NCT03719300|Drug|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
79490061|NCT00376519|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
79490062|NCT00376519|Drug|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
79490063|NCT00376519|Drug|fludarabine phosphate|Fludarabine 25 mg/m^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
79490064|NCT00376519|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
79655381|NCT04562545|Device|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
79655382|NCT00234611|Procedure|Echocardiogram guided left ventricular lead placement|
79655383|NCT00415935|Drug|methotrexate|
79813539|NCT00642772|Other|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
79813540|NCT00808678|Drug|ABT-143|once, see arm description for more information
79813541|NCT00808678|Drug|ABT-335|once, see arm description for more information
79813542|NCT00808678|Drug|rosuvastatin|once, see arm description for more detail
79813543|NCT04045366|Other|Sample collection|Plasma and BAL sample collection
79984267|NCT03209440|Behavioral|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
79490065|NCT00376519|Procedure|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10^6/kg, 0.3 x 10^6/kg, 1 x 10^6/kg and 3 x 10^6/kg weight (determined on the day prior to administration of the preparative therapy).
79490066|NCT00376519|Procedure|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
79490067|NCT00376519|Radiation|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
79490068|NCT00422864|Drug|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
79490069|NCT00422864|Drug|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
79490070|NCT00422864|Drug|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
79655384|NCT02211274|Other|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
79655385|NCT02211352|Drug|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
79813544|NCT00815854|Dietary Supplement|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
79813545|NCT00815854|Other|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
79340202|NCT02471755|Device|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
79813546|NCT02551354|Device|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
79490071|NCT00422864|Procedure|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
79490072|NCT03719378|Other|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
79490073|NCT03368053|Procedure|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
79490074|NCT03719612|Drug|DEFINITY®|All subjects will receive a single dose of DEFINITY®
79655386|NCT02211352|Drug|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
79655387|NCT00413738|Device|Antiseptic-coated central venous catheters|
79655388|NCT02211391|Other|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
79813547|NCT02551198|Drug|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
79813548|NCT02551198|Drug|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]
79490075|NCT04706611|Procedure|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
79490076|NCT03373591|Drug|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
79490077|NCT03373591|Drug|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
79490078|NCT03720938|Other|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
79813549|NCT00446095|Drug|fostamatinib|200 mg PO BID
79655389|NCT02211391|Other|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
79340203|NCT02471755|Device|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
79655390|NCT02211469|Drug|BMS-986104|
79340204|NCT02470429|Device|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
79340205|NCT02470429|Device|Hyabak 0.15% eye drops|Preservative-free
79340206|NCT02470429|Drug|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
79340207|NCT02447497|Drug|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
79340208|NCT02447497|Other|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
79655391|NCT02211469|Drug|Placebo|
79655392|NCT00415974|Behavioral|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
79340209|NCT02447497|Drug|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
79340210|NCT02447497|Other|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
79340211|NCT02417935|Drug|Duloxetine|Administered orally
79340212|NCT02417935|Drug|Pregabalin|Administered orally
79655393|NCT00415974|Behavioral|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
79813550|NCT00815932|Device|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
79340213|NCT02417935|Drug|Placebo|Administered orally
79340214|NCT02417233|Behavioral|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
79340215|NCT02417233|Behavioral|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
79340216|NCT04938661|Other|Center-Based Cardiac Rehab|36 center-Based Cardiac Rehab Sessions
79340217|NCT04938661|Other|mHealth|Mobile Health Platform
79340218|NCT04938661|Other|Home-Based Cardiac Rehab|Encouraged to exercise 3 times per week at home
79340219|NCT02416453|Biological|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
79340220|NCT02416453|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
79340221|NCT02416453|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
79340222|NCT02469961|Drug|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
79340223|NCT02469961|Drug|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
79340224|NCT02469961|Other|Interscalene block|Interscalene block is used for the main anesthetic for the case
79340225|NCT02415595|Drug|BMS-955176|HIV Maturation Inhibitor
79340226|NCT02415595|Drug|EFV|EFV
79340227|NCT02415595|Drug|TDF/FTC|TDF/FTC
79340228|NCT02446717|Drug|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
79340229|NCT02446717|Drug|ribavirin (RBV)|Tablet
79340230|NCT02446717|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
79490079|NCT03374683|Behavioral|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
79490080|NCT03374683|Behavioral|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
79340231|NCT02469415|Drug|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
79340232|NCT02469415|Drug|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
79340233|NCT02469415|Drug|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
79340234|NCT02446171|Drug|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
79340235|NCT02446171|Drug|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
79655394|NCT00415974|Behavioral|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
79813551|NCT00817648|Drug|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
79813552|NCT00817648|Drug|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
79813553|NCT00808756|Dietary Supplement|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
79813554|NCT00808756|Other|Standard infant formula.|Standard infant formula.
79340236|NCT02446171|Drug|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
79340237|NCT02446171|Drug|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
79340238|NCT02446015|Drug|SYSTANE® ULTRA Lubricant Eye Drops|
79340239|NCT02415127|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
79813555|NCT04045054|Behavioral|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
79490081|NCT03374683|Behavioral|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
79490082|NCT03480685|Device|IVUS and OCT Imaging|Use of an imaging catheter
79490083|NCT03378973|Drug|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
79490084|NCT03380845|Device|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
79490085|NCT03380845|Device|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
79340240|NCT02415127|Drug|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
79340241|NCT02468557|Drug|Idelalisib|Tablets administered orally twice daily
79340242|NCT02468557|Drug|Nab-paclitaxel|125 mg/m^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
79340243|NCT02468557|Drug|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m^2) or racemic leucovorin 400 mg/m^2, oxaliplatin 85 mg/m^2, bolus 5-fluorouracil 400 mg/m^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m^2.
79340244|NCT02413489|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
79490086|NCT04121078|Drug|TAK-906|TAK-906 capsule.
79490087|NCT04121078|Drug|Rifampin|Rifampin infusion.
79813556|NCT00829010|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
79813557|NCT00829010|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
79813558|NCT00829010|Biological|measles|Intramuscular injection, 2 doses
79813559|NCT00829010|Biological|Rotarix|Oral, 2 doses
79490088|NCT03248947|Drug|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
79490089|NCT03248947|Other|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
79490090|NCT04114058|Drug|liposomal bupivicaine|local field infiltration
79490091|NCT04114058|Procedure|Fascia iliaca blockade|fascia iliaca compartment blockade
79490092|NCT03480919|Device|Shen Men acupuncture|20-minute acupuncture session
79490093|NCT03480919|Procedure|Epidural injection|Epidural injection for the relief of back pain
79490094|NCT03817580|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
79490095|NCT03817580|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
79490096|NCT03817580|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
79490097|NCT03862040|Drug|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
79340245|NCT02413333|Device|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
79340246|NCT02413333|Device|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
79340247|NCT02413333|Device|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
79340248|NCT02413255|Drug|TAK-020|TAK-020 oral solution
79340249|NCT02413255|Drug|TAK-020 Placebo|TAK-020 placebo-matching oral solution
79340250|NCT02444533|Drug|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
79655395|NCT00415974|Behavioral|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
79655396|NCT04562584|Device|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
79340251|NCT05458219|Drug|IBI343|IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
79340252|NCT01651039|Drug|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
79490098|NCT03862040|Drug|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
79813560|NCT00829010|Biological|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
79813561|NCT00817882|Other|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
79490099|NCT03482713|Drug|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
79813562|NCT00817882|Other|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
79490100|NCT03482713|Drug|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
79490101|NCT00376831|Drug|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
79813563|NCT04632784|Device|Artiflex Presbyopic implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL
79813564|NCT00706316|Biological|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
79655397|NCT04562350|Other|XatJove Anoia Aplication|All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
79340253|NCT01651039|Drug|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
79340254|NCT01651039|Drug|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
79340255|NCT02349633|Drug|PF-06747775|
79655398|NCT04562311|Drug|Chidamide with tislelizumab|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
79340256|NCT02349633|Drug|Palbociclib|
79490102|NCT00376831|Drug|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
79490103|NCT03857750|Drug|Rocuronium|0.6 mg/kg
79490104|NCT03491917|Device|DBT plus S-View|DBT plus S-View images
79490105|NCT03491917|Device|FFDM alone|FFDM alone images
79490106|NCT03828422|Diagnostic Test|imaging|
79490107|NCT03254719|Other|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
79655399|NCT00234650|Procedure|Colonoscopy|
79655400|NCT02211547|Device|Epic 10 Diode Laser by Biolase Inc.|
79655401|NCT02211547|Other|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
79655402|NCT04562272|Procedure|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
79655403|NCT04561843|Diagnostic Test|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
79655404|NCT00234689|Drug|Naltrexone|
79655405|NCT04561960|Drug|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
79655406|NCT04561960|Drug|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
79655407|NCT04561960|Device|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
79340257|NCT02349633|Drug|Avelumab|
79340258|NCT05650125|Other|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
79340259|NCT02275611|Drug|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
79340260|NCT02275611|Drug|Intranasal Placebo Spray|Intranasal Placebo Spray
79340261|NCT05649891|Other|Emergency Manual|Collection of crisis checklists and fact sheets
79340262|NCT05649735|Device|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
79655408|NCT04561960|Device|Miswak Stick|A miswak stick of 15 cm length
79813565|NCT00644332|Drug|Ranolazine|Oral dosage form.
79813566|NCT00808912|Drug|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
79813567|NCT00808912|Other|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
79813568|NCT02551042|Drug|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
79490108|NCT04084028|Behavioral|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
79490109|NCT04084028|Behavioral|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
79490110|NCT04084028|Behavioral|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
79490111|NCT03387319|Behavioral|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
79490112|NCT03387319|Behavioral|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
79490113|NCT03852524|Drug|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
79490114|NCT03852524|Other|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
79490115|NCT03388645|Biological|10^6.3 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
79655409|NCT04561804|Procedure|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
79655410|NCT00234728|Device|Occlusive dressing|
79813569|NCT02551042|Drug|0.9% sodium chloride|IV infusion
79490116|NCT03388645|Biological|10^7 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
79490117|NCT04081610|Drug|lagricel ofteno multidose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
79490118|NCT04081610|Drug|lagricel ofteno single dose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
79490119|NCT03390907|Device|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
79490120|NCT04713878|Other|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
79490121|NCT03840278|Device|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
79490122|NCT03840278|Device|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
79490123|NCT03840278|Drug|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
79655411|NCT04561921|Drug|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
79655412|NCT04561921|Drug|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
79655413|NCT04561882|Device|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
79490124|NCT04735783|Dietary Supplement|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
79490125|NCT04735783|Dietary Supplement|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
79490126|NCT04735783|Dietary Supplement|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
79490127|NCT03838874|Drug|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
79490128|NCT03838874|Drug|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
79490129|NCT04332302|Other|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
79490130|NCT03815240|Other|No dressing|no dressing at sacrum
79490131|NCT03815240|Other|Mepilex® Border Sacrum|adhesive sacrum dressing
79490132|NCT03815240|Other|ALLEVYN Life Sacrum|adhesive sacrum dressing
79490133|NCT03815240|Other|Optifoam® Gentle Sacrum|adhesive sacrum dressing
79655414|NCT04561999|Device|Elastography|Performance of Ultrasound, Elastography
79490134|NCT04071392|Procedure|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
79340263|NCT05649735|Device|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
79490135|NCT04045964|Drug|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
79490136|NCT04045964|Behavioral|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
79490137|NCT04045964|Behavioral|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
79490138|NCT03941912|Device|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
79490139|NCT04048460|Device|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
79340264|NCT05649735|Other|Placebo|Sterile saline solution
79490140|NCT04016324|Device|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
79490141|NCT04039412|Drug|Hybrid regimen|two-step (dual-quadruple) treatment
79490142|NCT04039412|Drug|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
79655415|NCT04561687|Drug|Montelukast|Montelukast and nasal budesonide
79655416|NCT04561687|Drug|Azelastine|Azelastine and nasal budesonide
79655417|NCT04561687|Drug|Budesonide|To all groups
79655418|NCT04561687|Drug|Placebo|Placebo and nasal budesonide
79655419|NCT00234767|Device|Pulmonary Artery Catheter|
79655420|NCT00234767|Behavioral|Protocolized Fluid Management|
79813570|NCT00808990|Dietary Supplement|BioFemale|BioFemale 6 months.
79813571|NCT00445939|Biological|adalimumab|160 mg at Week 0, 80 mg at Week 2
79813572|NCT00445939|Biological|adalimumab|80 mg at Week 0, 40 mg at Week 2
79813573|NCT00445939|Biological|placebo|Placebo at Week 0 and Week 2
79490143|NCT04039412|Drug|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
79490144|NCT04036838|Combination Product|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
79490145|NCT04036838|Diagnostic Test|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
79490146|NCT04036838|Diagnostic Test|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
79490147|NCT04036838|Diagnostic Test|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
79490148|NCT03831854|Drug|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P<.05).
79490149|NCT03831854|Drug|Placebo|300 mg of oral Placebo
79490150|NCT03831854|Drug|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
79490151|NCT03806270|Drug|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
79813574|NCT00816244|Drug|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
79340265|NCT05649657|Other|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2~3 sessions per week and about 70 sessions in total.
79655421|NCT04561414|Device|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
79340266|NCT02275065|Drug|Bictegravir|Bictegravir tablet(s) administered orally once daily
79340267|NCT02275065|Drug|Placebo|Placebo to match bictegravir administered orally once daily
79340268|NCT04875585|Drug|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
79340269|NCT04875585|Procedure|Surgery|surgical resection of primary tumor and lymph-node-dissection.
79340270|NCT04875585|Drug|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
79813575|NCT00817960|Drug|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
79813576|NCT00816322|Dietary Supplement|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
79340271|NCT02273973|Drug|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
79813577|NCT00816322|Dietary Supplement|Placebo|high oleic oil
79340272|NCT02273973|Other|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
79340273|NCT02273973|Drug|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
79490152|NCT03806270|Drug|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
79655422|NCT04561414|Device|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
79655423|NCT04561726|Other|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
79655424|NCT04561726|Other|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
79984268|NCT03209440|Behavioral|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
79984269|NCT03209440|Behavioral|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
79340274|NCT02273739|Drug|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
79340275|NCT05649111|Drug|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
79655425|NCT04561531|Other|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
79655426|NCT00234806|Other|Health-e-Access|telemedicine intervention
79655427|NCT04561219|Drug|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
79655428|NCT04561219|Drug|Placebo|Placebo three times a day for 5 days
79340276|NCT02273037|Device|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
79340277|NCT02273037|Procedure|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
79340278|NCT02465515|Biological|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
79340279|NCT02465515|Biological|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
79340280|NCT02465515|Biological|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
79490153|NCT03828734|Device|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
79490154|NCT03828734|Device|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
79490155|NCT03828734|Device|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
79490156|NCT04033640|Diagnostic Test|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
79490157|NCT04033640|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
79984270|NCT03224494|Device|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
79655429|NCT04561609|Other|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
79655430|NCT04561609|Other|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
79655431|NCT00424866|Drug|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
79655432|NCT00424866|Drug|Placebo|Vehicle: 0 µg/kg
79655433|NCT00234845|Drug|adalimumab|
79655434|NCT00234845|Drug|methotrexate|
79984271|NCT03224494|Other|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
79984272|NCT03224494|Other|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
79984273|NCT04319159|Combination Product|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
79655435|NCT02211625|Drug|Open-label TRV734 125 mg|125 mg
79655436|NCT02211625|Drug|TRV734 blinded|blinded, multiple ascending dose
79655437|NCT02211625|Drug|Oxycodone IR 10 mg|
79655438|NCT02211625|Drug|Placebo|TRV734-matched and oxycodone placebo
79984274|NCT02451904|Other|Observation|
79655439|NCT02211664|Device|Passeo-18 balloon|
79655440|NCT02211664|Device|Passeo-18 Lux drug releasing balloon|
79655441|NCT02211664|Device|Pulsar-18 stent|
79655442|NCT00234923|Drug|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
79655443|NCT00234923|Drug|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
79655444|NCT04551937|Other|Lactose Free 1% Milk|8 oz of study beverage daily
79655445|NCT04551937|Other|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
79490158|NCT04033640|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
79490159|NCT04033640|Diagnostic Test|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
79655446|NCT00268125|Device|Acupression's bracelet|
79340281|NCT05561361|Procedure|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
79655447|NCT00268125|Behavioral|Hygiene and dietetic advices|
79655448|NCT04552054|Device|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
79340282|NCT05561361|Drug|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
79490160|NCT03497845|Biological|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79655449|NCT04552054|Device|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
79655450|NCT02213887|Drug|Pantoprazole|40 mg PO QAM
79984275|NCT03224338|Drug|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B*5701 allele screening assessment.
79655451|NCT02213887|Drug|Pantoprazole|0 mg PO QAM
79984276|NCT03224260|Drug|BMS-986177|Oral Suspension
79655452|NCT00234962|Drug|Lopinavir/Ritonavir|
79984277|NCT03224260|Other|Matched Placebo|Oral Suspension
79984278|NCT04318535|Drug|Griseofulvin 500 mg|Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
79984279|NCT04318535|Drug|Griseofulvin 250 mg|Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
79984280|NCT04318535|Drug|Reference Griseofulvin 500 mg|Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
79340283|NCT02412631|Drug|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
79655453|NCT04551859|Other|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
79340284|NCT02412631|Drug|Varenicline|Chantix is an FDA approved medication for smoking cessation
79340285|NCT02412631|Drug|Placebo|Placebo for lorcaserin
79340286|NCT02272803|Drug|Lenalidomide|
79340287|NCT02272803|Drug|Dexamethasone|
79340288|NCT02272803|Biological|Elotuzumab (BMS-901608)|
79340289|NCT02272725|Drug|Ibuprofen|Ibuprofen
79340290|NCT02272725|Drug|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
79340291|NCT01650805|Drug|ponatinib|45 mg tablet, taken orally once daily
79655454|NCT00424905|Drug|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
79655455|NCT04551703|Drug|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
79984281|NCT02451826|Drug|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
79340292|NCT01650805|Drug|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
79340293|NCT02442349|Drug|AZD9291|Once daily tablet 80 mg
79490161|NCT03497845|Biological|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79490162|NCT03497845|Biological|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79490163|NCT03497845|Biological|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79490164|NCT03497845|Biological|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79490165|NCT03497845|Biological|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79490166|NCT03497845|Biological|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
79984282|NCT03224416|Other|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
79490167|NCT04036292|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
79340294|NCT02411539|Biological|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
79490168|NCT04036292|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
79490169|NCT03501043|Drug|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
79490170|NCT00377390|Biological|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
79655456|NCT04551976|Behavioral|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
79655457|NCT00235001|Drug|trandolapril/verapamil|180/2 mg QD
79655458|NCT04551781|Drug|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
79655459|NCT04551781|Drug|control|symptomatic ttt
79655460|NCT00424944|Biological|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
79655461|NCT00424944|Biological|GMZ2 malaria vaccine|100 micrograms of GMZ2
79655462|NCT00424944|Biological|Verorab vaccine|Anti-rabies vaccine
79655463|NCT04551625|Device|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
79655464|NCT02214004|Drug|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks~Trastuzumab 8mg/kg on Day 1 of Cycle 1~Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
79655465|NCT02214004|Drug|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
79655466|NCT04551274|Behavioral|Music Therapy|Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
79655467|NCT00268164|Drug|lactobacilus acidophilus & bifidobacterium animalis/lactis|
79655468|NCT04551118|Device|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
79655469|NCT04551118|Device|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
79655470|NCT04551118|Device|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
79340295|NCT02411539|Biological|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
79340296|NCT02465437|Drug|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
79340297|NCT02465437|Drug|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
79340298|NCT02465437|Drug|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
79340299|NCT02442271|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
79340300|NCT02442271|Drug|ribavirin|Tablet
79340301|NCT02465203|Drug|Previous treatment in DEB025 study|Follow-up after DEB025 active study
79340302|NCT02463409|Drug|Theophylline|24 hour infusion of IV theophylline
79490171|NCT03261973|Device|DV8|DV8 esophageal deviation tool
79490172|NCT03820388|Drug|Propofol 2mg/kg|2 mg/kg
79490173|NCT03820388|Drug|Etomidate 0.3 mg/kg|0.3 mg/kg
79490174|NCT03820388|Drug|Propofol 1 mg/kg|1 mg/kg Propofol
79490175|NCT03820388|Drug|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
79490176|NCT03264157|Drug|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
79490177|NCT03264157|Drug|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
79490178|NCT03264157|Biological|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
79490179|NCT03820544|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
79490180|NCT03820544|Other|Standard of care|Undergo standard of care surgical resection
79490181|NCT03400579|Device|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
79490182|NCT03801044|Diagnostic Test|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
79490183|NCT03801044|Diagnostic Test|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
79655471|NCT04551079|Drug|TAK-994|TAK-994 tablets.
79490184|NCT03801044|Radiation|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
79655472|NCT04551079|Drug|Placebo|TAK-994 placebo-matching tablets.
79655473|NCT00235040|Behavioral|Smart Form|Computer Decision Support System
79984283|NCT03224416|Other|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
79984284|NCT03224416|Other|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
79340303|NCT02528357|Drug|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to <=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
79655474|NCT00260949|Procedure|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
79655475|NCT02214082|Other|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
79655476|NCT00235079|Drug|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
79655477|NCT00235079|Drug|Placebo|Placebo comparator
79655478|NCT00268281|Device|Left Ventricular Capture Management Software|
79655479|NCT00235118|Device|Cordis AAA Bilateral Device|
79655480|NCT04550884|Diagnostic Test|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
79655481|NCT00260988|Drug|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
79655482|NCT00260988|Drug|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
79655483|NCT04550416|Other|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
79655484|NCT04550533|Other|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
79655485|NCT00235157|Device|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
79984285|NCT04400903|Device|Activity Monitor|Undergo HRV monitoring via WHOOP device
79984286|NCT04400903|Other|Quality-of-Life Assessment|Ancillary studies
79984287|NCT04400903|Other|Questionnaire Administration|Complete questionnaires
79340304|NCT02528357|Drug|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
79340305|NCT04910425|Drug|Fluorine F 18 DCFPyL|Given IV
79340306|NCT04910425|Drug|Gadobenate Dimeglumine|Given IV
79340307|NCT04910425|Drug|Gadobutrol|Given IV
79340308|NCT04910425|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79340309|NCT04910425|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79340310|NCT04910425|Procedure|Positron Emission Tomography|Undergo PET/MRI
79340311|NCT04910425|Procedure|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-guided biopsy
79490185|NCT03801044|Diagnostic Test|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
79490186|NCT03801044|Diagnostic Test|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG & Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
79655486|NCT04550338|Drug|Tranexamic acid|Oral administration of blinded medications
79655487|NCT04550338|Drug|Placebo|Oral administration of blinded medications
79655488|NCT02214199|Other|Manipulative Therapy Techniques|
79655489|NCT02214199|Other|Home Exercises|
79655490|NCT00268320|Device|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
79984288|NCT03223948|Device|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
79984289|NCT03223870|Diagnostic Test|Diagnostic|Diagnostic
79984290|NCT03223792|Other|Control|Routine cow's milk-based infant formula
79655491|NCT04550611|Other|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
79340312|NCT02463331|Drug|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
79490187|NCT04029584|Drug|rifampin IV|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
79340313|NCT02463331|Drug|prednisone|Prednisone 5-15 mg/day until the end of the study
79984291|NCT03223792|Other|Investigational|Partially-hydrolyzed cow's milk protein infant formula
79340314|NCT02463331|Drug|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
79340315|NCT02410837|Procedure|Electromagnetic Navigation Bronchoscopy|
79655492|NCT04550611|Other|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
79655493|NCT00235196|Device|Collagen ORC Antimicrobial Matrix (CAM)|
79655494|NCT04550026|Other|HTP inhalation|Sham inhalation for 30 minutes
79655495|NCT04550299|Other|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
79655496|NCT00261027|Drug|Exemestane|
79655497|NCT00235235|Procedure|Biopsy|core biopsy
79340316|NCT02314247|Drug|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
79340317|NCT02463097|Device|Insulin Pump|Closed Loop Algorithm
79655498|NCT00235235|Procedure|Serum Collection|serum collection
79655499|NCT00235235|Procedure|Urine Collection|urine collection
79340318|NCT05427149|Drug|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
79340319|NCT02441179|Other|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
79490188|NCT04029584|Drug|Rifadin 300Mg Capsule|Rifadin 600mg by mouth as two 300mg rifadin capsules
79490189|NCT04029584|Drug|Fluvastatin 20 MG|one oral dose of fluvastatin (Lescol ) 20mg capsule
79655500|NCT00235235|Drug|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
79655501|NCT00235235|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
79655502|NCT00235235|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
79655503|NCT00235235|Drug|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
79655504|NCT00235235|Drug|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
79984292|NCT03747263|Procedure|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
79984293|NCT01562561|Drug|repaglinide|2 mg at each main meal
79984294|NCT01562561|Drug|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
79340320|NCT02441179|Other|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
79340321|NCT02441179|Other|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
79490190|NCT04028960|Drug|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
79655505|NCT04549714|Procedure|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
79340322|NCT05406167|Device|Registry - Observational|Observation Registry for Medical Device
79490191|NCT04028960|Device|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
79490192|NCT03401671|Drug|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
79490193|NCT04023578|Device|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
79490194|NCT03502915|Drug|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
79490195|NCT03502915|Other|Placebo|100% oxygen via Nitronox delivery device
79655506|NCT04549714|Procedure|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
79655507|NCT04549714|Procedure|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
79490196|NCT03506347|Drug|Vancomycin|Antibiotic
79490197|NCT04210232|Device|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
79655508|NCT04549909|Other|collect retrospectively data|Analyse the incidence of BPL in these populations
79490198|NCT04019990|Other|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
79655509|NCT04549675|Behavioral|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
79984295|NCT03206944|Drug|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
79340323|NCT02462473|Drug|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
79340324|NCT02462473|Drug|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
79340325|NCT02462473|Drug|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
79340326|NCT02462473|Drug|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
79340327|NCT02462473|Drug|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
79490199|NCT03266419|Drug|Deep NMB using rocuronium|"Drug: rocuronium~Bolus dose: 0.7 mg/kg~Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
79490200|NCT03266419|Drug|Moderate NMB using rocuronium|"Drug: rocuronium~Bolus dose: none~Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
79490201|NCT03270943|Behavioral|MFY|Mindful Self-Compassion course for teens
79490202|NCT03270943|Behavioral|HLG|Healthy Lifestyles course for teens
79490203|NCT03800030|Device|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
79490204|NCT03800030|Device|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
79655510|NCT04549675|Behavioral|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
79655511|NCT04549948|Procedure|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
79340328|NCT04465799|Behavioral|ENTREN|ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
79340329|NCT04465799|Behavioral|ENTREN-F|ENTREN intervention for children + family intervention.
79490205|NCT03800030|Device|Sham tACS|NeuroConn technologies, direct current-stimulator plus
79490206|NCT00377468|Drug|Delta9-Tetrahydrocannabinol|
79490207|NCT03799484|Drug|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
79490208|NCT03799484|Drug|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
79490209|NCT03799484|Device|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
79490210|NCT04012970|Other|Manual spinal mobilisations|
79490211|NCT03508687|Drug|300mg Gemcabene|300mg Gemcabene
79655512|NCT04549948|Procedure|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
79655513|NCT04549948|Procedure|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
79655514|NCT00268359|Biological|bevacizumab|
79655515|NCT00268359|Drug|irinotecan hydrochloride|
79655516|NCT00235274|Drug|Subcutaneous Secretin|
79655517|NCT04549987|Device|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
79655518|NCT04549987|Device|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
79655519|NCT04549636|Other|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
79655520|NCT04549636|Other|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
79340330|NCT04465799|Behavioral|Control group|Behavioral modification of habits
79340331|NCT01462097|Behavioral|Aerobic exercise training|12 months of aerobic exercise
79340332|NCT01462097|Behavioral|Health Education|12 months of health education sessions
79490212|NCT03508687|Drug|600mg Gemcabene|600mg Gemcabene
79490213|NCT03999944|Device|positive airway pressure system|Positive Airway Pressure System
79490214|NCT03273283|Behavioral|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
79490215|NCT00377546|Drug|Nepafenac|
79490216|NCT00377546|Drug|Ketorolac LS, Bromfenac|
79490217|NCT04290494|Drug|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
79490218|NCT04005404|Drug|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
79490219|NCT04005404|Drug|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
79490220|NCT04005404|Drug|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
79490221|NCT03232892|Drug|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
79490222|NCT03787472|Device|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
79490223|NCT03787472|Device|JJV Investigational senofilcon A Multifocal Lens2|TEST
79490224|NCT03778190|Procedure|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
79490225|NCT03510481|Biological|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
79813834|NCT04107480|Drug|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
79813835|NCT00915408|Drug|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
79998519|NCT03744390|Drug|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
79813836|NCT00915408|Drug|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
79340474|NCT04855773|Other|PrEPmate|"PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators."
79524719|NCT03830424|Dietary Supplement|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
79813837|NCT00915408|Drug|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
79998520|NCT03644316|Device|BandGrip skin closure device|topical skin closure device
79998521|NCT03629145|Behavioral|Live Music Therapy|Investigator will begin play live guitar and voice music.
79998522|NCT03629145|Behavioral|Recorded Music Therapy|Investigator will play recorded music.
79227921|NCT02228109|Device|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
79227922|NCT02228109|Device|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
79679418|NCT00516191|Drug|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
79998523|NCT05759715|Other|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
79340475|NCT04855773|Device|Dot Diary|Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
79340476|NCT02260791|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
79340477|NCT02260791|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
79340478|NCT02260635|Drug|Evacetrapib|Administered orally
79998524|NCT03644784|Diagnostic Test|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
79340479|NCT02260635|Drug|Placebo|Administered orally
79340480|NCT04872855|Device|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
79679419|NCT05319483|Other|No intervention|No intervention.
79679420|NCT00516308|Device|NightHawk|
79998525|NCT05283798|Device|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
79655830|NCT04541524|Device|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
79340481|NCT05466201|Drug|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
79340482|NCT05466201|Drug|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
79655831|NCT04541563|Device|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
79340483|NCT02258529|Drug|Idelalisib|150 tablets administered orally twice daily
79998526|NCT02896296|Drug|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
79679421|NCT00515333|Drug|TRx0014|Hard capsule; 60 milligrams; t.i.d.
79490412|NCT02367170|Device|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
79655832|NCT02214706|Drug|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
79655833|NCT02214706|Other|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
79655834|NCT02214706|Device|Pulsed Dye Laser|
79655835|NCT04541485|Drug|DWRX2003|Intramuscularly injection at pre-defined injection sites
79655836|NCT04541485|Drug|Placebo|Intramuscularly injection at pre-defined injection sites
79227923|NCT02228109|Device|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
79340484|NCT02258529|Biological|Rituximab|375 mg/m^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
79679422|NCT00515333|Drug|TRx0014|Hard capsule; 30 milligrams; t.i.d.
79655837|NCT02214745|Other|Questionnaire|Questionnaire developed for this purpose by the investigators
79655838|NCT02214784|Device|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
79655839|NCT02214784|Device|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
79655840|NCT02214862|Drug|[F18]-FDDNP|radiopharmaceutical tracer
79655841|NCT00236600|Drug|topiramate|
79655842|NCT00269295|Biological|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10^7 cfu, 5 X 10^8 cfu, and 5 X 10^9 cfu.
79655843|NCT00269295|Drug|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
79679423|NCT00515333|Drug|Placebo|Hard capsule; 0 milligrams; t.i.d.
79490413|NCT02367170|Device|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
79655844|NCT04541134|Drug|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
79655845|NCT04541134|Drug|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
79655846|NCT00236639|Drug|topiramate|
79490414|NCT02367170|Procedure|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
79655847|NCT04541368|Drug|CS1 Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
79998527|NCT03643614|Procedure|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
79655848|NCT00261924|Device|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
79679424|NCT00515333|Drug|TRx0014|Hard capsule, 100 milligrams, t.i.d.
79655849|NCT04545463|Dietary Supplement|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
79655850|NCT04545463|Dietary Supplement|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
79655851|NCT04545463|Dietary Supplement|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
79655852|NCT04545697|Other|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
79655853|NCT02214901|Drug|BIBW 2948 BS for oral inhalation|
79655854|NCT02214901|Drug|Placebo|
79655855|NCT00236678|Drug|Epoetin alfa|
79655856|NCT00269334|Drug|Using Citalopram(drug) or Paroxetine(drug)|
79655857|NCT04541251|Drug|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
79655858|NCT04540783|Device|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
79655859|NCT04545034|Other|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
79655860|NCT00236717|Drug|Topiramate; Carbamazepine; Valproate|
79655861|NCT00269373|Procedure|PET-CT|no drugs included
79655862|NCT04540549|Behavioral|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
79655863|NCT04545073|Device|PanOptix|Trifocal IOL with ORA in post refractive patients
79655864|NCT00236756|Drug|topiramate|
79655865|NCT04545307|Biological|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
79655866|NCT00269412|Drug|Rifaximin|
79655867|NCT04545190|Dietary Supplement|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
79655868|NCT00236795|Drug|norelgestromin + ethinyl estradiol; triphasil.|
79655869|NCT04545268|Device|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
79655870|NCT04545268|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
79340485|NCT05646225|Other|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
79490415|NCT02367170|Other|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
79490416|NCT01104116|Radiation|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
79490417|NCT03579433|Device|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
79490418|NCT03579433|Other|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
79490419|NCT03579433|Device|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
79490420|NCT03534427|Other|Jump rope exercise intervention|12-week jump rope exercise program
79490421|NCT02340728|Device|ERCP with SEMS plus radiofrequency ablation|
79655871|NCT04544644|Drug|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
79655872|NCT00261963|Device|ultraviolet light|
79655873|NCT04540627|Drug|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
79490422|NCT02340728|Device|ERCP with SEMS alone (standard of care)|
79490423|NCT00376909|Other|educational intervention|
79490424|NCT00376909|Other|study of socioeconomic and demographic variables|
79490425|NCT01078844|Drug|memantine|memantine 5-20 mg daily
79490426|NCT01078844|Drug|Placebo|Look-alike placebo
79490427|NCT00376051|Drug|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
79490428|NCT01072526|Drug|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
79490429|NCT01072526|Drug|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
79490430|NCT03536923|Device|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
79490431|NCT05312840|Drug|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
79490432|NCT00376129|Drug|Alefacept|15 mg i.m. once weekly for 12 weeks
79490433|NCT02307188|Device|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
79490434|NCT01035944|Device|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
79655874|NCT04540627|Drug|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
79655875|NCT04540627|Other|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
79490435|NCT01035944|Device|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
79490436|NCT00378638|Drug|bevacizumab combined with dose dense chemotherapy|
79655876|NCT00236834|Drug|levofloxacin; imipenem/cilastitin|
79655877|NCT04540393|Biological|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) > 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
79655878|NCT04544722|Behavioral|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
79340486|NCT05646225|Other|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
79655879|NCT04544722|Behavioral|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
79340487|NCT05449275|Other|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
79340488|NCT05449275|Other|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
79340489|NCT02256969|Drug|Blephamide|
79340490|NCT02256969|Drug|GenTeal PM Night-Time|
79655880|NCT00236873|Drug|topiramate|
79655881|NCT04544566|Device|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
79490437|NCT03582553|Dietary Supplement|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
79490438|NCT03582553|Other|Placebo|Cellulose
79490439|NCT01025492|Drug|Trilipix|135 mg po daily
79655882|NCT04544566|Device|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
79490440|NCT01025492|Drug|placebo|one tablet po daily
79490441|NCT04331834|Drug|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months"
79490442|NCT04331834|Drug|Placebos|"Placebo with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months"
79490443|NCT04735159|Device|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
79655883|NCT04544566|Device|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
79655884|NCT00269490|Behavioral|Yoga Nidra|
79227924|NCT03309956|Device|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
79490444|NCT02202044|Device|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
79655885|NCT04540510|Device|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
79655886|NCT04540510|Other|Standard care|Standard pneumonia care
79655887|NCT00236912|Drug|levofloxacin; metronidazole|
79655888|NCT00269529|Procedure|femoral nerve block|
79655889|NCT00269529|Procedure|knee infiltration and injection via catheter|
79655890|NCT04540471|Other|music|MT group receives additional music therapy
79655891|NCT04540471|Other|comprehensive in-patient education program|comprehensive in-patient education program
79490445|NCT03538795|Combination Product|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
79490446|NCT01023620|Drug|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
79655892|NCT04544605|Other|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
79655893|NCT04540237|Diagnostic Test|Flow-cytometric analysis|Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
79655894|NCT02215447|Drug|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
79655895|NCT02215447|Drug|Carboplatin|
79655896|NCT00236990|Drug|pentosan polysulfate sodium|
79227925|NCT03309956|Device|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
79227926|NCT04458558|Drug|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
79227927|NCT04872777|Behavioral|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~Noom application set-up and troubleshooting on smartphone (license provided)~Digital scale provision (subjects may keep the scale)~Capture of available clinical information over preceding 28-days."
79340491|NCT02256969|Procedure|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
79655897|NCT02215486|Other|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
79655898|NCT02215486|Other|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
79655899|NCT04540276|Drug|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
79655900|NCT04544371|Device|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
79655901|NCT04544371|Procedure|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
79490447|NCT01023620|Other|Observation|Participants will be observed for 16 weeks but will not receive drug
79655902|NCT00237068|Drug|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
79655903|NCT04539925|Other|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
79490448|NCT03595579|Drug|AXS-05|AXS-05 taken twice daily for 6 weeks.
79490449|NCT03595579|Drug|Bupropion|Bupropion taken twice daily for 6 weeks.
79490450|NCT02200328|Drug|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
79655904|NCT00269568|Drug|mifepristone and misoprostol|
79655905|NCT02215603|Behavioral|Breaking prolonged sitting with physical activity|
79340492|NCT02256969|Procedure|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
79340493|NCT05438121|Device|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
79340494|NCT05645991|Dietary Supplement|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
79340495|NCT05645991|Dietary Supplement|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
79340496|NCT02256891|Device|PRFM|
79340497|NCT02256891|Procedure|Double Row|
79340498|NCT02256267|Drug|LY2835219|Administered orally
79340499|NCT02256267|Drug|Rifampin|Administered orally
79340500|NCT01641471|Device|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
79655906|NCT04544215|Biological|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
79655907|NCT04544215|Biological|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
79655908|NCT04544215|Biological|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
79655909|NCT00237107|Procedure|Curretage|
79490451|NCT02200328|Drug|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
79340501|NCT01641471|Device|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
79340502|NCT05429463|Biological|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
79340503|NCT05429463|Drug|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
79340504|NCT05429463|Drug|Albumin-Bound Paclitaxel|260 mg/m^2 by IV infusion Q3W, given on cycle day 1.
79340505|NCT02255565|Drug|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
79340506|NCT02255565|Drug|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
79655910|NCT00262197|Behavioral|Customized Physician Intervention|
79655911|NCT00262197|Behavioral|Customized Patient Intervention|
79655912|NCT02215681|Device|acupuncture|
79655913|NCT00237146|Drug|Zoledronic acid|
79679425|NCT02943174|Behavioral|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
79679426|NCT02943174|Other|Treatment as Usual (TAU)|Standard personalized treatment of cancer
79340507|NCT02255565|Drug|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
79340508|NCT01640301|Biological|Aldesleukin|Given SC
79340509|NCT01640301|Drug|Cyclophosphamide|Given IV
79340510|NCT01640301|Drug|Fludarabine Phosphate|Given IV
79679427|NCT02941887|Behavioral|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
79340511|NCT01640301|Other|Laboratory Biomarker Analysis|Correlative studies
79340512|NCT01640301|Biological|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
79340513|NCT01642407|Drug|Sildenafil|Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
79340514|NCT02255097|Biological|pembrolizumab|
79340515|NCT02254551|Drug|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
79340516|NCT02254551|Drug|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
79340517|NCT05651139|Device|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
79340518|NCT05642793|Drug|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
79679428|NCT00515450|Biological|GB-0998 (Intravenous immunoglobulin)|
79679429|NCT00515450|Procedure|Plasmapheresis|
79679430|NCT00516347|Genetic|comparative genomic hybridization|
79679431|NCT00516347|Genetic|genetic linkage analysis|
79340519|NCT05642793|Drug|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
79679432|NCT00516347|Other|laboratory biomarker analysis|
79340520|NCT05642013|Procedure|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
79340521|NCT05642013|Other|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
79340522|NCT05650983|Behavioral|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum & repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
79340523|NCT05405985|Drug|Nemolizumab|Nemolizumab with Auto-Injector (AI).
79340524|NCT05405985|Drug|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
79340525|NCT05640375|Drug|Methylprednisolone|Single dose, 1 mg/kg
79340526|NCT05650671|Device|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
79679433|NCT00516347|Other|questionnaire administration|
79679434|NCT00516347|Procedure|study of high risk factors|
79679435|NCT02941848|Drug|HGP0816|
79679436|NCT02941848|Drug|HGP1404|
79679437|NCT02941848|Drug|HCP1306|
79655914|NCT04544137|Behavioral|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
79490452|NCT04327843|Behavioral|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
79490453|NCT04327843|Drug|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
79490454|NCT02147834|Drug|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
79490455|NCT02147834|Drug|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
79490456|NCT04343287|Drug|BRM421|The active control with BRM421 solution
79490457|NCT04343287|Drug|Placebo|The vehicle solution
79490458|NCT04369885|Device|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
79490459|NCT00979550|Drug|Imiquimod|commercially available topical antiviral drug
79679438|NCT00515489|Drug|Risperidone|as prescribed
79998528|NCT05262348|Device|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
79340527|NCT01641237|Drug|sodium fluoride|fluoride as sodium fluoride
79340528|NCT01641237|Drug|no added fluoride in a silica base|no added fluoride
79340529|NCT04861779|Drug|HSK29116|Oral HSK29116
79340530|NCT05623605|Drug|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
79340531|NCT05623605|Drug|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
79340532|NCT05623605|Drug|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
79340533|NCT05617209|Other|thrombin generation measurement|Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
79340534|NCT01639833|Device|Veriset Hemostatic Patch|Topical hemostat
79340535|NCT01639833|Device|TachoSil®|Topical Hemostat
79340536|NCT01639131|Drug|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
79340537|NCT01639131|Drug|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
79490460|NCT00979550|Drug|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
79340538|NCT01639131|Drug|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor [G-CSF]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
79340539|NCT01641159|Drug|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
79340540|NCT01641159|Drug|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
79490461|NCT04394845|Diagnostic Test|[18F]GTP1|[18F]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]), with a maximum drug mass dose of 10 microgram (μg).
79490462|NCT00966992|Drug|Zoledronic acid|
79490463|NCT02099318|Other|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
79490464|NCT02099318|Other|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
79490465|NCT04418947|Other|Communication type|Control letter vs. intervention letter
79823592|NCT00789945|Other|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
79998529|NCT05262348|Device|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
79998530|NCT03643536|Other|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
79340541|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
79340542|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
79490466|NCT00379730|Drug|Prednisolone|
79490467|NCT02074904|Drug|Topiramate|
79490468|NCT02074904|Drug|Placebo|
79490469|NCT03542305|Drug|Lorlatinib|Lorlatinib single oral dose
79490470|NCT02057276|Device|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
79490471|NCT02057276|Device|Sham Repetitive Transcranial Magnetic Stimulation|
79490472|NCT02057276|Other|Occupational Therapy|
79490473|NCT04420273|Behavioral|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
79490474|NCT04420273|Behavioral|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
79490475|NCT05572892|Other|FAC scale|"Measurement of walking dependency according to the FAC scale :~in the first week after stroke (in neurology by physiotherapists),~then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
79679439|NCT02941653|Device|Potassium nitrate 2% gel|"Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
79984759|NCT03744923|Procedure|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
79227928|NCT02228187|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
79984760|NCT03193138|Drug|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
79984761|NCT03625310|Drug|Sodium Fluoride|
79984762|NCT03625310|Drug|Sodium Fluoride with TCP|
79984763|NCT03625310|Drug|Sodium Fluoride with CXP|
79655915|NCT04544059|Drug|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
79655916|NCT00269607|Drug|Implantation of naltrexone implants|
79340543|NCT01641081|Drug|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
79655917|NCT04544176|Other|Observational|There will be no interventions in this study, it is purely observational using data already collected.
79655918|NCT04539769|Procedure|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
79655919|NCT04539769|Procedure|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
79340544|NCT01641081|Drug|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
79340545|NCT01641081|Drug|Placebo|Placebo in the Pressair for 14 days
79655920|NCT04539769|Procedure|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
79655921|NCT00237224|Drug|Letrozole|
79227929|NCT03309800|Drug|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
79227930|NCT03309800|Drug|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
79490476|NCT05554796|Procedure|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
79490477|NCT05554796|Procedure|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
79490478|NCT00929474|Device|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
79490479|NCT00929474|Device|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
79490480|NCT04734457|Drug|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
79490481|NCT02043860|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
79340546|NCT01640925|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
79340547|NCT01640925|Other|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
79655922|NCT04543747|Device|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
79655923|NCT04539847|Device|High-end hearing aid|hearing aid with premium level of technology
79813838|NCT00590954|Drug|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
79340548|NCT05369481|Drug|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
79340549|NCT05369481|Drug|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
79340550|NCT04853979|Other|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
79490482|NCT02043860|Procedure|Autologous Transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
79655924|NCT04539847|Device|Basic hearing aid|hearing aid with basic level of technology
79655925|NCT00262236|Drug|Aliskiren|
79813839|NCT04030286|Other|Observation|Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
79490483|NCT02043860|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
79340551|NCT04853589|Device|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
79340552|NCT04853589|Device|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
79340553|NCT01638429|Drug|Neomycin|Neomycin: 500mg po bid for 10 days
79340554|NCT01638429|Drug|Rifaximin|Rifaximin: 550mg po tid for 10 days
79340555|NCT04847973|Other|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
79340556|NCT04847973|Dietary Supplement|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
79340557|NCT05058807|Other|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
79340558|NCT05058807|Other|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
79490484|NCT02043860|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
79490485|NCT03606187|Device|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
79490486|NCT03606187|Device|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
79340559|NCT04853511|Device|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
79490487|NCT01974284|Drug|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
79490488|NCT03543085|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
79340560|NCT04853355|Drug|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
79340561|NCT04419285|Behavioral|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
79490489|NCT03606343|Behavioral|Teaching Academic Skills to Kids|Group treatment
79490490|NCT00869414|Drug|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
79340562|NCT04419285|Behavioral|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
79340563|NCT04419285|Behavioral|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
79490491|NCT00869414|Drug|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
79490492|NCT00869414|Drug|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
79655926|NCT04539886|Device|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
79813840|NCT05753540|Other|Laser therapy|Multiwave locked system laser therapy
79490493|NCT04734769|Other|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
79490494|NCT04536571|Device|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
79490495|NCT04536571|Device|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
79340564|NCT01639755|Device|new texture shaped breast implants|breast implant surgery
79813841|NCT05753540|Other|Sham laser therapy|Sham laser therapy
79813842|NCT02602548|Other|Culture|Specimens will be obtained and sent to the lab for cultures.
79813843|NCT00791076|Drug|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
79340565|NCT04844853|Device|electroencephalography|128-channel electroencephalography
79340566|NCT04844853|Device|Tactile stimulation|Vibrotactile sequence on the forearm
79340567|NCT04844853|Behavioral|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
79340568|NCT04844853|Behavioral|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
79340569|NCT04844853|Behavioral|Laby 5-12|Test of motor planning using labyrinths
79490496|NCT00843986|Drug|conivaptan|Premix bag
79490497|NCT00843986|Drug|placebo|Premix bag
79490498|NCT05514158|Drug|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
79490499|NCT05514158|Drug|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
79490500|NCT01965782|Drug|[^14C]-LY3023703|Administered orally
79490501|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
79490502|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
79655927|NCT04539886|Device|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
79655928|NCT04543981|Diagnostic Test|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
79655929|NCT04543864|Device|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
79655930|NCT04543864|Device|casting|casting the metal framework
79813844|NCT00791076|Drug|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
79813845|NCT05757518|Other|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
79655931|NCT04539613|Drug|HPFSH & HMG|. Various gonadotropin preparations
79340570|NCT04844853|Behavioral|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
79340571|NCT04844853|Behavioral|Stroop animals|Stroop test for preK children using animals instead of words
79655932|NCT00269646|Behavioral|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
79655933|NCT04543669|Biological|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
79655934|NCT00237302|Drug|topiramate|
79655935|NCT04539691|Device|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
79655936|NCT02214940|Drug|BI 11634|
79655937|NCT02214940|Drug|Placebo|
79984764|NCT03625310|Drug|Sodium Fluoride with CPP-ACP|
79984765|NCT03192982|Device|A-V impulse 6000 Series|foot pad and pump
79490503|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
79490504|NCT05503160|Behavioral|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
79490505|NCT03544879|Behavioral|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
79655938|NCT00262275|Drug|Aspirin, Clopidogrel|
79655939|NCT04539652|Drug|Experimental|Experimental group are treated with TenofoBell®
79655940|NCT02214979|Drug|Telmisartan/Ramipril|fixed dose combination tablet
79655941|NCT02214979|Drug|Telmisartan|
79655942|NCT02214979|Drug|Ramipril capsule|
79655943|NCT02214979|Drug|Ramipril tablet|
79655944|NCT00237341|Drug|fentanyl|
79655945|NCT04539496|Drug|XZP-3287|a small molecular, oral potent, selective CDK4/6 inhibitor
79490506|NCT03544879|Behavioral|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works & What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
79490507|NCT05486468|Drug|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
79490508|NCT05486468|Other|Sham Injection|Sham injection
79813846|NCT04785560|Device|Initial shunt setting post-operatively of the Certas Plus shunt valve.|The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
79490509|NCT00845702|Drug|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
79490510|NCT00845702|Other|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
79490511|NCT03610399|Drug|Primaquine|Different total dose and supervision.
79655946|NCT04539301|Diagnostic Test|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
79655947|NCT04539535|Other|General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day|Different surface
79655948|NCT00237380|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
79655949|NCT04543708|Procedure|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
79984766|NCT03192982|Device|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
79340572|NCT05310981|Behavioral|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
79340573|NCT05369091|Drug|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
79340574|NCT04652037|Device|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
79655950|NCT04543708|Procedure|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
79655951|NCT00262353|Device|Dialysis with different artificial devices|
79340575|NCT01601535|Drug|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
79340576|NCT01601535|Drug|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
79340577|NCT01601535|Drug|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
79340578|NCT05422365|Drug|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
79340579|NCT04641273|Drug|BAY1817080|Tablet, intake orally.
79340580|NCT04641273|Drug|Placebo for BAY1817080|Tablet, intake orally.
79490512|NCT00843830|Radiation|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
79340581|NCT04641273|Drug|Placebo for Pregabalin|Capsule, intake orally.
79655952|NCT04539145|Device|Chocolate PTA Balloon|Chocolate PTA Balloon
79655953|NCT04539145|Device|conventional balloon angioplasty|conventional bal-loon angioplasty
79679440|NCT02941653|Device|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
79340582|NCT04641273|Drug|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
79340583|NCT04832763|Procedure|Biospecimen Collection|Undergo collection of blood sample
79340584|NCT04832763|Other|Medical Chart Review|Review of medical charts
79340585|NCT04832763|Other|Physical Performance Testing|Undergo physical function testing
79340586|NCT04832763|Other|Quality-of-Life Assessment|Ancillary studies
79340587|NCT04832763|Other|Questionnaire Administration|Complete questionnaire
79340588|NCT04852731|Procedure|Cardiac MRI|Injected cardiac MRI
79340589|NCT04852731|Other|Blood collection|Blood collection (including genetics at the inclusion visit)
79490513|NCT00843830|Biological|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
79490514|NCT03610633|Drug|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
79490515|NCT03610633|Drug|Placebo|Saline solution.
79490516|NCT00832520|Drug|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance < 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.~Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~Dose modifications: None"
79490517|NCT03545893|Drug|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
79490518|NCT03545893|Drug|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
79490519|NCT03551821|Drug|ATI-50002|Topical Solution
79490520|NCT04734691|Procedure|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
79490521|NCT00843050|Drug|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
79655954|NCT04543318|Procedure|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
79813847|NCT05757440|Other|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
79813848|NCT02609126|Drug|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
79340590|NCT04852731|Procedure|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
79340591|NCT05000853|Drug|Iron Carboxymaltose|Iron supplementation when is needed according to usual care
79227931|NCT04035174|Diagnostic Test|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (< 50% skin surface under the patch), medium reaction (> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
79227932|NCT04035174|Diagnostic Test|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
79340592|NCT04832529|Procedure|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
79340593|NCT04998591|Behavioral|Fasting|fasting for 7 days (caloric intake <500 kcal in liquid form)
79340594|NCT04419129|Device|Oxford UKA|knee arthroplasty
79340595|NCT04419129|Device|Vanguard TKA|knee arthroplasty
79340596|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
79340597|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
79340598|NCT04586985|Drug|FTX-6058 - Two Dosing Periods|Subjects will receive FTX-6058
79340599|NCT04586985|Drug|FTX-6058 / Midazolam Syrup|Subjects will receive FTX-6058 and midazolam syrup
79340600|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
79340601|NCT05260749|Procedure|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
79340602|NCT05260749|Procedure|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
79340603|NCT04852419|Drug|ZN-c5|ZN-c5
79340604|NCT05249673|Other|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
79340605|NCT05249673|Other|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
79340606|NCT05245539|Drug|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
79490522|NCT04658797|Device|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
79490523|NCT04658797|Device|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
79490524|NCT04658797|Other|Personal Facemask|Personal Facemask
79490525|NCT05290844|Other|cricoid pressure|cricoid force in pediatric patients
79490526|NCT01954160|Device|Symplicity Renal Denervation|Renal denervation
79340607|NCT04840875|Biological|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
79340608|NCT05408403|Other|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
79490527|NCT03552289|Device|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
79490528|NCT03552289|Device|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
79490529|NCT03615001|Device|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
79490530|NCT01877564|Drug|Metformin|
79490531|NCT03615079|Behavioral|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
79490532|NCT03556579|Device|senofilcon A with new UV blocker|Test Lens
79490533|NCT03556579|Device|senofilcon A|Control Lens
79655955|NCT04543318|Procedure|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
79655956|NCT00237419|Drug|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
79655957|NCT04539340|Biological|GNR-055|Single intravenous administration
79490534|NCT00835328|Drug|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
79490535|NCT00835328|Drug|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
79490536|NCT00376987|Dietary Supplement|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
79655958|NCT04539106|Drug|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
79227933|NCT02232477|Drug|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
79227934|NCT03478332|Drug|Yangxinshi pill|0.6g/tablet
79227935|NCT03478332|Drug|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
79340609|NCT05408403|Other|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
79340610|NCT05620797|Other|Immediate loading of the implants|Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
79340611|NCT05620797|Other|Delayed loading of the implant|Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
79490537|NCT00832598|Radiation|[18F]FACBC PET and [18F]FLT PET imaging|[18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
79490538|NCT04499599|Other|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
79490539|NCT04499599|Other|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
79655959|NCT04543552|Device|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
79679441|NCT02941575|Other|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
79679442|NCT02941575|Other|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
79813849|NCT02609126|Drug|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
79655960|NCT04543474|Other|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
79340612|NCT04916223|Other|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
79679443|NCT00515606|Drug|helium:oxygen|
79679444|NCT02941731|Drug|HIP1403|Oseltamivir 6mg/mL
79340613|NCT04830735|Drug|Dasatinib Anhydrous|Given PO
79679445|NCT02941731|Drug|HGP0919|Oseltamivir phosphate 6mg/mL
79679446|NCT05319210|Procedure|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
79227936|NCT03478332|Drug|Placebos|Yangxinshi simulant
79227937|NCT04105062|Drug|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
79227938|NCT04105062|Device|Cancer Vision Goggles|-Non-significant risk device
79227939|NCT02223741|Other|Korean medical treatment|acupuncture and herbal drugs
79340614|NCT04830735|Drug|Placebo Administration|Given PO
79227940|NCT03930498|Drug|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
79227941|NCT03930498|Drug|Chemotherapy|Cisplatin and Gemcitabine
79227942|NCT03930498|Radiation|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
79490540|NCT04499599|Other|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
79490541|NCT04512703|Device|µCor|Sensor Monitor for arrhythmia and other bio-metric markers
79490542|NCT01889420|Drug|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~Everolimus daily for 28 days of a 28 day cycle;~Pomalidomide daily for 21 days of a 28 day cycle~Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
79490543|NCT03557125|Other|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
79490544|NCT03557125|Other|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
79490545|NCT03616171|Behavioral|SLEEP-Extend intervention|"One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
79490546|NCT03616171|Other|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
79490547|NCT00379028|Drug|Budesonide/Formoterol Turbuhaler|
79490548|NCT00379028|Drug|Salmeterol/Fluticasone Diskus|
79490549|NCT03558061|Drug|ALK4290|ALK4290 400 mg tablet twice a day
79490550|NCT01881932|Device|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
79490551|NCT01881932|Device|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
79490552|NCT03617419|Device|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
79490553|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
79490554|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
79490555|NCT00379106|Procedure|Arm exercises.|Basic active exercise program at home.
79490556|NCT00379106|Procedure|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
79340615|NCT04489095|Diagnostic Test|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
79340616|NCT04840173|Behavioral|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
79490557|NCT03619135|Device|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
79490558|NCT03619135|Other|Placebo|No use of the Buzzy (standard IV access techniques)
79490559|NCT04706312|Other|stem cells|hAMSCs injection via venous in the dorsum of hand
79490560|NCT03559933|Device|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
79490561|NCT00379262|Drug|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
79490562|NCT00379262|Drug|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
79490563|NCT00379262|Drug|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
79655961|NCT04543474|Other|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
79655962|NCT00237497|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
79655963|NCT00237497|Drug|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
79984767|NCT03118336|Drug|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
79490564|NCT03620383|Procedure|Topical Heat|Warm heat pack applied topically in participant hand.
79490565|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
79490566|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
79490567|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
79655964|NCT00237497|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
79655965|NCT00416130|Drug|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
79655966|NCT04539028|Procedure|Emergency Abdominal surgery|Emergency Abdominal surgery
79984768|NCT02444572|Drug|Enoxaparin 4000 IU|
79984769|NCT03196726|Behavioral|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
79984770|NCT03196726|Behavioral|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
79984771|NCT04165031|Drug|LY3499446|Administered orally
79490568|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
79490569|NCT03621085|Drug|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
79490570|NCT03621085|Other|Placebo|Subjects will receive placebo
79490571|NCT00795236|Drug|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
79490572|NCT04490863|Device|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
79490573|NCT00790478|Drug|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
79984772|NCT04165031|Drug|Abemaciclib|Administered orally
79984773|NCT04165031|Drug|Cetuximab|Administered IV
79984774|NCT04165031|Drug|Erlotinib|Administered orally
79984775|NCT04165031|Drug|Docetaxel|Administered IV
79490574|NCT00790478|Other|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
79490575|NCT04490239|Drug|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
79490576|NCT00791336|Drug|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
79490577|NCT03621787|Device|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
79490578|NCT03562663|Device|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
79490579|NCT03562663|Device|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
79490580|NCT00771602|Drug|Rituximab|375 mg/m^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
79490581|NCT00771602|Drug|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
79490582|NCT04332146|Behavioral|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
79490583|NCT04332146|Behavioral|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
79490584|NCT05277818|Procedure|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
79490585|NCT05246384|Drug|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
79490586|NCT03626623|Device|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
79490587|NCT03626623|Other|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
79370697|NCT04362202|Other|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
79490588|NCT05149742|Behavioral|Cognitive and audiometry evaluation|"For both Patients and controls:~Cognitive functions evaluation~Tonal and vocal audiometry~Self questionnaires"
79490589|NCT01804166|Drug|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
79490590|NCT01804166|Drug|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
79490591|NCT04459585|Drug|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
79490592|NCT04459585|Drug|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
79655967|NCT04543084|Behavioral|Logbook|Participants will record practice in a logbook.
79655968|NCT00416169|Drug|galantamine hydrobromide|
79655969|NCT00237536|Drug|Lonidamine|
79655970|NCT04543240|Device|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
79227943|NCT02228265|Other|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
79227944|NCT02228265|Drug|Enzalutamide|Given PO
79227945|NCT02228265|Other|Laboratory Biomarker Analysis|Correlative studies
79227946|NCT03130920|Procedure|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
79655971|NCT02215720|Drug|Cetuximab|
79655972|NCT02215720|Drug|Temsirolimus|
79655973|NCT02215759|Drug|BI 44370 TA|
79984776|NCT03118258|Behavioral|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
79655974|NCT02215759|Drug|Placebo|
79655975|NCT00416208|Drug|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
79655976|NCT02215798|Drug|Cymbalta|
79655977|NCT02215018|Drug|BI 44370 TA solution|
79655978|NCT02215018|Drug|BI 44370 TA tablet|
79998531|NCT03644706|Drug|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
79227947|NCT03817554|Drug|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
79227948|NCT03817554|Other|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
79227949|NCT02223897|Drug|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
79227950|NCT02223897|Drug|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
79227951|NCT02723630|Drug|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level <12%~Treatment 2: reference* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level >26%"
79227952|NCT04459962|Diagnostic Test|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
79227953|NCT02228655|Drug|FMX-8|
79227954|NCT02866227|Drug|TOL-463|TOL-463 vaginal gel
79227955|NCT02866227|Drug|TOL-463|TOL-463 vaginal insert
79227956|NCT05258136|Drug|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
79227957|NCT02228733|Drug|KBP-5074|Comparisons of different doses of study drug
79227958|NCT02224131|Drug|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
79227959|NCT02224131|Drug|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
79227960|NCT02469584|Procedure|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
79227961|NCT03474120|Procedure|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
79227962|NCT03474042|Drug|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
79227963|NCT03474042|Drug|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
79227964|NCT03309722|Other|biomarker study|
79227965|NCT02810184|Radiation|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
79340617|NCT05335317|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
79655979|NCT02215018|Drug|Placebo solution|
79340618|NCT05335317|Drug|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
79340619|NCT05335317|Diagnostic Test|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
79340620|NCT05335317|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
79340621|NCT05335317|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
79340622|NCT05335317|Diagnostic Test|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
79340623|NCT05335317|Diagnostic Test|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
79340624|NCT05335317|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
79340625|NCT05335317|Other|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
79227966|NCT03473964|Drug|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
79340626|NCT05335317|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
79655980|NCT02215018|Drug|Placebo tablet|
79655981|NCT02215837|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
79655982|NCT02215837|Biological|Ag-D-CIK|8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
79655983|NCT02215057|Drug|topical anesthesia|topical anesthetic drops and Group 2
79227967|NCT03309644|Other|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
79340627|NCT05335317|Diagnostic Test|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
79655984|NCT02215057|Drug|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
79813850|NCT04107402|Other|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
79813851|NCT02603718|Other|Rehabilitation treatment|
79340628|NCT05335317|Diagnostic Test|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
79340629|NCT05335317|Diagnostic Test|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
79340630|NCT05335317|Diagnostic Test|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
79340631|NCT05335317|Diagnostic Test|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
79340632|NCT04829721|Other|Educational Intervention with video|Women randomized to an educational video workshop group.
79340633|NCT04419441|Drug|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
79655985|NCT00269685|Drug|vasopressin|
79655986|NCT04710095|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.
79813852|NCT02610062|Drug|AGS67E|Intravenous (IV) infusion
79813853|NCT05757284|Diagnostic Test|Lower Limb Lymhedema assessment|assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
79823593|NCT00789945|Other|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
79490593|NCT05080556|Drug|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
79490594|NCT00746018|Device|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
79490595|NCT01797380|Drug|Placebo|Placebo daily for duration of double-blind portion of trial
79490596|NCT01797380|Drug|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
79998532|NCT03644706|Drug|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
79340634|NCT05329779|Drug|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
79490597|NCT03571555|Behavioral|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
79340635|NCT05329779|Drug|placebo|The placebo is a 0.45% sodium chloride infusion.
79340636|NCT04419753|Behavioral|attention focus walking training|Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
79340637|NCT04850937|Drug|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
79490598|NCT00737594|Drug|Placebo|Matching placebo capsules for oral administration
79340638|NCT04850937|Drug|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
79490599|NCT00737594|Drug|Cobiprostone|Cobiprostone capsules for oral administration
79490600|NCT00732680|Drug|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
79490601|NCT04441255|Drug|TAK-788|TAK-788 Capsule.
79490602|NCT00726830|Drug|methadone hydrochloride|Given orally
79490603|NCT00726830|Drug|morphine sulfate|Given orally
79490604|NCT00726830|Drug|oxycodone hydrochloride|Given orally
79490605|NCT03628885|Behavioral|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
79490606|NCT03628885|Behavioral|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
79490607|NCT00691652|Biological|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
79490608|NCT00691652|Drug|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
79490609|NCT00691652|Genetic|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
79490610|NCT00691652|Genetic|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
79998533|NCT03740919|Drug|LY900014|Administered SC
79490611|NCT00691652|Genetic|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals << 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
79340639|NCT04851717|Drug|Remimazolam|Remimazolam for intravenous sedation
79490612|NCT00691652|Genetic|polymerase chain reaction|
79655987|NCT04710095|Behavioral|Control Condition|The attention-matched control condition consisting of a 30-min video about astronomy.
79984777|NCT03118258|Behavioral|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
79679447|NCT02951039|Drug|Edoxaban|Prescribed according to approved label
79984778|NCT05480150|Drug|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
79984779|NCT05480150|Drug|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
79679448|NCT02951117|Drug|Venetoclax|Tablet
79984780|NCT05480150|Drug|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
79340640|NCT04464057|Dietary Supplement|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
79984781|NCT03196570|Behavioral|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
79984782|NCT03196570|Behavioral|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
79998534|NCT03740919|Drug|Insulin Lispro|Administered SC
79340641|NCT01638819|Biological|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
79340642|NCT01638819|Biological|Placebo|Saline
79370698|NCT04762641|Drug|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
79813854|NCT02610218|Other|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
79984783|NCT05464628|Drug|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
79340643|NCT04849143|Other|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
79340644|NCT04849143|Other|Gel dressing|Smith-Nephew's Intrasite gel
79340645|NCT01363713|Drug|DE-114 ophthalmic solution|
79340646|NCT04414917|Drug|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
79340647|NCT04414917|Device|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
79340648|NCT04411329|Drug|Bupivacaine|local anesthetics, steriod, alpha 2 blockers
79340649|NCT04411329|Drug|Dexamethasone|dexamethazone
79340650|NCT04411329|Drug|Dexmedetomidine|dexmedetomidine
79340651|NCT04411329|Drug|Hyalouridinase|hyalouridinase
79340652|NCT05171673|Drug|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
79340653|NCT04811937|Diagnostic Test|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
79340654|NCT05147415|Other|Placebo|Inactive comparator
79340655|NCT05147415|Drug|Tesomet|Fixed-dose combination
79984784|NCT05464628|Drug|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
79984785|NCT03196492|Other|No intervention|No intervention
79998535|NCT03740919|Drug|Insulin Glargine|Administered SC
79227968|NCT03309644|Other|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
79227969|NCT04319445|Behavioral|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
79227970|NCT04459572|Diagnostic Test|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
79340656|NCT04827069|Drug|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
79340657|NCT04786743|Other|endoscopic intervention|performing endoscopy
79340658|NCT04390581|Device|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
79340659|NCT01637961|Drug|Alisertib|Given PO
79340660|NCT01637961|Other|Laboratory Biomarker Analysis|Correlative studies
79370699|NCT01543087|Procedure|blood sampling|Blood sample collection at different time points
79679449|NCT02951117|Drug|ABBV-838|Intravenous infusion
79679450|NCT02951117|Drug|Dexamethasone|Tablet or intravenous infusion
79998536|NCT03740919|Drug|Insulin Degludec|Administered SC
79655988|NCT02215135|Drug|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
79655989|NCT04543123|Device|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
79340661|NCT05114577|Behavioral|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
79340662|NCT05114577|Behavioral|Email recommendations|Receive recommendations (via email) to help improve sleep
79340663|NCT05114265|Drug|KUR-101|Single oral dose of KUR-101
79340664|NCT05114265|Drug|OxyNorm|Single oral dose of OxyNorm
79340665|NCT05114265|Drug|Placebo|Single oral dose of placebo
79655990|NCT04543123|Drug|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
79340666|NCT04419051|Other|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
79340667|NCT04277715|Behavioral|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
79984786|NCT04829630|Biological|rabies vaccine|"day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~day 7 : questionnaire and blood sampling"
79984787|NCT02712424|Biological|DAR-901|
79984788|NCT02712424|Biological|Sterile saline placebo|
79655991|NCT04539418|Drug|Vitamin K 2|Patients will be monitored during the whole protocol.
79655992|NCT00269724|Drug|OROS® oxybutynin|
79655993|NCT04542928|Behavioral|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
79655994|NCT04543006|Diagnostic Test|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
79655995|NCT04710017|Drug|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
79655996|NCT04710017|Drug|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
79984789|NCT03196414|Biological|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
79984790|NCT02449408|Other|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
79984791|NCT02449330|Drug|Teneligliptin|
79984792|NCT03648814|Procedure|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
79984793|NCT03648814|Procedure|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
79340668|NCT04183335|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79340669|NCT04183335|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79340670|NCT04183335|Drug|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
79340671|NCT04183335|Drug|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
79813855|NCT00590720|Biological|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
79984794|NCT03192592|Other|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
79340672|NCT04183335|Drug|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
79340673|NCT04419363|Drug|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
79340674|NCT04825431|Drug|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
79340675|NCT04241679|Device|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
79340676|NCT04225767|Combination Product|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
79490613|NCT00691652|Other|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
79490614|NCT00691652|Other|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
79490615|NCT00691574|Dietary Supplement|Melatonin|up to 3 mg, daily, for up to 1 year
79490616|NCT00691574|Device|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
79490617|NCT03631927|Other|Observation|Observation
79490618|NCT00685880|Drug|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
79490619|NCT00685880|Drug|Betamethasone|CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
79490620|NCT00681044|Biological|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
79655997|NCT04538521|Dietary Supplement|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
79655998|NCT00269763|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
79655999|NCT04543630|Procedure|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
79656000|NCT04542967|Biological|Biological|"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."
79656001|NCT00237575|Drug|gemcitabine|
79656002|NCT00237575|Drug|cisplatin|
79656003|NCT00237575|Drug|sargramostim|
79656004|NCT00237575|Drug|filgrastim|
79656005|NCT04542811|Other|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
79656006|NCT00269802|Drug|OROS methylphenidate HCl|
79656007|NCT00269802|Drug|Ritalin|
79340677|NCT04212273|Diagnostic Test|Diagnostic Sonazoid-CEUS and EOB-MRI|Undergo Sonazoid-CEUS and EOB-MRI
79490621|NCT00681044|Drug|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
79490622|NCT00681044|Procedure|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
79490623|NCT03632083|Device|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
79656008|NCT00269802|Drug|Placebo|
79656009|NCT02215174|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
79656010|NCT00237614|Drug|intravenous and oral N-acetylcysteine|
79656011|NCT04538326|Behavioral|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
79490624|NCT03632083|Device|Lite Contact Lens Solution|Lite Contact Lens Solution
79490625|NCT03632083|Device|fanfilcon A soft contact lens|fanfilcon A soft contact lens
79490626|NCT03632083|Device|comfilcon A soft contact lens|comfilcon A soft contact lens
79490627|NCT05010980|Other|CMR|clinical indication
79984795|NCT03705260|Other|Usual Care|Usual care from Primary Care Physician and dietitian.
79490628|NCT05010980|Other|scintigraphy|clinical indication
79984796|NCT03705260|Behavioral|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
79984797|NCT03705260|Other|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
79490629|NCT03633487|Drug|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
79490630|NCT04929002|Other|No intervention|No intervention
79490631|NCT03574441|Device|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
79490632|NCT03574441|Device|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
79490633|NCT03574441|Device|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
79490634|NCT00423020|Drug|Erythropoietin|
79490635|NCT00671606|Procedure|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
79490636|NCT01756586|Drug|Dexamethasone|
79490637|NCT01756586|Drug|Bupivacaine|Control
79490638|NCT03636061|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
79490639|NCT03636061|Drug|Placebo (vehicle) nasal spray|Placebo
79490640|NCT04404907|Other|no intervention|This is a secondary analysis of registry data.
79490641|NCT00661466|Drug|Bupivacaine Collagen Sponge|
79490642|NCT00661466|Drug|Placebo|placebo
79490643|NCT04403113|Other|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
79490644|NCT04403113|Other|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
79490645|NCT04403113|Other|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
79490646|NCT00639626|Drug|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
79490647|NCT01718444|Drug|Progestin|
79490648|NCT01718444|Drug|Clomiphene Citrate|
79490649|NCT00641108|Drug|ADAM SPECT plus Cognitive Therapy|
79490650|NCT00641108|Drug|ADAM SPECT plus No Therapy|
79656012|NCT00269841|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
79984798|NCT03118180|Biological|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
79984799|NCT03705182|Device|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
79984800|NCT03193762|Other|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
79984801|NCT05455502|Drug|VX-548|Tablet for oral administration.
79984802|NCT03193918|Drug|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
79984803|NCT03193918|Drug|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
79490651|NCT00638222|Other|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
79490652|NCT00634322|Drug|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
79490653|NCT00634322|Drug|leucovorin|IV or po given every 6 hours
79490654|NCT00379886|Drug|Propofol Thiopental|
79490655|NCT01705106|Drug|capecitabine|Given PO
79656013|NCT00269841|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
79813856|NCT00590720|Other|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
79370700|NCT01543087|Drug|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
79490656|NCT01705106|Drug|celecoxib|Given PO
79490657|NCT01705106|Other|pharmacological study|Correlative studies
79490658|NCT01705106|Other|laboratory biomarker analysis|Correlative studies
79490659|NCT01705106|Other|pharmacogenomic studies|Correlative studies
79490660|NCT00626444|Drug|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
79490661|NCT00624650|Drug|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~Continuous IV furosemide at 3mg/hour or last known protocol specified dose~Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~Do not exceed 30mg/hour~Furosemide Bolus:~If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
79370701|NCT04368598|Drug|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
79370702|NCT04368598|Drug|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
79370703|NCT05347641|Drug|Penpulimab|"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine * (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"
79370704|NCT01696058|Drug|Tiotropium|marketed product
79370705|NCT01696058|Drug|Placebo matching Olodaterol|one dose
79370706|NCT01696058|Drug|Tiotropium|marketed product
79370707|NCT01696058|Drug|Olodaterol|one dose
79656014|NCT00269841|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
79656015|NCT04538443|Other|functional capacity|impact of hemodialysis on functional capacity in children with CKD
79656016|NCT04538443|Other|muscle strength|impact of hemodialysis on muscle strength in children with CKD
79656017|NCT04538443|Other|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
79656018|NCT04538443|Other|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
79656019|NCT04538404|Procedure|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
79813857|NCT00625378|Drug|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
79813858|NCT00822250|Other|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
79823594|NCT00785187|Device|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
79984804|NCT03193918|Drug|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
79370708|NCT04368520|Dietary Supplement|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
79370709|NCT04368520|Dietary Supplement|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
79656020|NCT04538872|Behavioral|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
79340678|NCT04824183|Other|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
79340679|NCT04199793|Device|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
79340680|NCT04199793|Device|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
79656021|NCT04538872|Behavioral|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
79656022|NCT00414128|Drug|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
79656023|NCT00414128|Drug|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
79656024|NCT04538677|Device|Video consultation|A two-way audio and visual connection between patients and surgeons
79656025|NCT04538365|Drug|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
79656026|NCT04538365|Drug|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
79656027|NCT00414245|Drug|metformin|
79823595|NCT00785265|Behavioral|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
79340681|NCT04823871|Procedure|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
79340682|NCT04820673|Drug|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
79823596|NCT00785265|Behavioral|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
79823597|NCT05013645|Other|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
79340683|NCT05298579|Other|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
79340684|NCT03280719|Device|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
79340685|NCT03280719|Radiation|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
79340686|NCT03280719|Device|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
79340687|NCT03280719|Radiation|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
79340688|NCT04699929|Drug|YH001|YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
79340689|NCT03256149|Drug|Dexamethasone|
79340690|NCT03256149|Drug|Placebo|Normal saline (IV placebo)
79340691|NCT04105257|Diagnostic Test|All patients|Comparison of the results of the CTP with MRI
79823598|NCT05013645|Other|Placebo|Gel control product
79823599|NCT00782145|Other|educational intervention|
79823600|NCT00782145|Other|informational intervention|
79340692|NCT04097769|Drug|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
79340693|NCT04089033|Procedure|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
79340694|NCT04089033|Procedure|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
79813859|NCT00819364|Behavioral|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
79340695|NCT03253263|Drug|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
79340696|NCT04797117|Diagnostic Test|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
79340697|NCT03180411|Behavioral|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
79656028|NCT04542772|Other|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
79656029|NCT04542772|Other|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
79656030|NCT00269880|Drug|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
79656031|NCT00269880|Drug|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
79656032|NCT00269880|Drug|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
79370710|NCT04368520|Other|Placebo|Hypromellose capsules, given daily for 3 months
79370711|NCT04762797|Other|Non|This is a retrospective study, without intervention.
79656033|NCT04542655|Other|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
79656034|NCT04542655|Other|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
79823601|NCT00782145|Other|internet-based intervention|
79823602|NCT00782145|Other|questionnaire administration|
79823603|NCT00782145|Other|study of socioeconomic and demographic variables|
79823604|NCT00782145|Other|survey administration|
79823605|NCT00782145|Procedure|psychosocial assessment and care|
79490662|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP<8 or measured PaOP <12mmHg in addition to concurrent urine output of <0.5 ml/kg/hr
79340698|NCT03180411|Behavioral|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
79490663|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map < 60 or who are on vasopressors that also have a measured GEDI less than goal"
79656035|NCT04542655|Other|Rest|The participants undergo ergometer cycling, treadmill running and rest.
79656036|NCT04542538|Other|No intervention, observational study|
79984805|NCT05427812|Drug|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
79340699|NCT03107247|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
79340700|NCT05652777|Device|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
79340701|NCT05652621|Dietary Supplement|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
79490664|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
79656037|NCT04539067|Drug|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
79656038|NCT00237653|Drug|Valganciclovir|
79656039|NCT00269958|Drug|epoetin alfa|
79656040|NCT04538248|Other|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
79998537|NCT01335685|Drug|Ixazomib|Ixazomib capsules
79656041|NCT04538014|Drug|Lu AF88434|Oral solution
79656042|NCT04538014|Drug|[11C]-Lu AF88434|[11C]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
79656043|NCT04538209|Radiation|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
79340702|NCT01636947|Drug|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
79340703|NCT01636947|Drug|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
79370712|NCT04762563|Other|IASTM application|IASTM application .
79656044|NCT02215876|Drug|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
79656045|NCT02215876|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
79656046|NCT02215876|Drug|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
79656047|NCT00269997|Drug|epoetin alfa|
79656048|NCT00237731|Drug|morphine|morphine 0.05
79656049|NCT00237731|Drug|morphine|morphine 0.10
79656050|NCT04542226|Drug|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
79656051|NCT00270036|Drug|epoetin alfa|
79656052|NCT01641874|Procedure|Exercise|Directional specific exercise
79656053|NCT01641874|Procedure|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
79656054|NCT00237848|Drug|D-serine|
79656055|NCT00237848|Behavioral|Cognitive retraining|
79998538|NCT01335685|Drug|Melphalan|Melphalan tablets
79340704|NCT01636947|Drug|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
79656056|NCT04537975|Device|C2Rx|Hemofiltration
79813860|NCT00819364|Behavioral|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
79656057|NCT04537975|Other|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
79340705|NCT01636947|Drug|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
79340706|NCT01636947|Drug|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
79340707|NCT01636947|Drug|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
79340708|NCT05652387|Behavioral|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
79340709|NCT05214027|Other|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
79340710|NCT05214027|Other|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
79340711|NCT01635933|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
79340712|NCT01635933|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
79340713|NCT01635855|Device|Belotero®|Hyaluronic acid dermal filler
79656058|NCT04538131|Device|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
79656059|NCT04538131|Device|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
79656060|NCT00262392|Drug|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
79656061|NCT04537780|Other|Placebo|Placebo tabled every day
79656062|NCT04537780|Drug|Montelukast|Montelukast 10 mg daily at bed time.
79340714|NCT04808115|Drug|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
79656063|NCT00237887|Drug|adalimumab|
79656064|NCT04537858|Device|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
79656065|NCT04537858|Device|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
79656066|NCT04537819|Drug|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
79656067|NCT04537819|Drug|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
79998539|NCT01335685|Drug|Prednisone|Prednisone tablets
79340715|NCT05652309|Procedure|spinal block and obturator nerve block|spinal block and obturator nerve block
79340716|NCT03052725|Drug|reslizumab|Reslizumab was provided in a pre-filled syringe.
79370713|NCT04762563|Other|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
79656068|NCT02215915|Procedure|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
79813861|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
79813862|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
79340717|NCT04818801|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
79490665|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of < 60"
79490666|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index < 2.5"
79656069|NCT02215915|Procedure|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
79656070|NCT02215915|Procedure|DES implantation|
79656071|NCT00262431|Procedure|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
79656072|NCT00237926|Behavioral|Exercise|aerobic or resistance training
79656073|NCT02215993|Drug|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
79656074|NCT02215993|Drug|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
79656075|NCT04537546|Device|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
79656076|NCT04537702|Behavioral|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
79656077|NCT04537702|Behavioral|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
79813863|NCT00806624|Drug|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
79340718|NCT04818801|Other|Placebo|Normal saline (0.9% sodium chloride solution),
79340719|NCT04793919|Drug|Mylotarg|See the protocol
79340720|NCT04793919|Drug|Arsenic Trioxide|See the protocol
79340721|NCT04793919|Drug|All-trans retinoic acid|See the protocol
79340722|NCT05356767|Procedure|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
79340723|NCT05651763|Other|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
79340724|NCT05651763|Other|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
79340725|NCT02837445|Device|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
79490667|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
79490668|NCT00624650|Other|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal."
79490669|NCT00624650|Drug|Diuresis (furosemide) part II|"Withhold furosemide if:~Significant hypokalemia (K+ <= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~Dialysis dependence~Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF~More than 800mg has been given in less then 24 hours~Creatinine increases > 1.5 mg/dl in any 24 hour period"
79490670|NCT00624650|Procedure|Dialysis|"Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~EVLW arm: Fluid balance as per algorithm~When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
79490671|NCT03965533|Drug|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
79340726|NCT02837445|Device|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
79340727|NCT02817633|Drug|TSR-022|TSR-022 will be administered.
79490672|NCT03965533|Drug|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
79490673|NCT01693484|Drug|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
79490674|NCT03637699|Behavioral|Positive Psychology|5-week positive psychology intervention
79490675|NCT01690910|Device|Rifton Gait Trainer|
79490676|NCT01690910|Device|Front Wheeled Walker|
79490677|NCT00377065|Drug|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
79490678|NCT00377143|Drug|Warfarin Dosing|
79656078|NCT04719351|Behavioral|The DIARY mobile application|The mobile application has two main functionalities. First, it will remind the user to report in regular time periods on their mental health status (e.g., sleep disturbances, stress). The assessment is done daily for four weeks. Second, some completed assessments will be combined with a behavioral prompt i.e. short message encouraging the user to engage in one of the strategies that can help coping with stress at work, e.g. remember to take short breaks, exercise in daylight, summarize a day with a colleague after a finished shift.
79656079|NCT04537585|Combination Product|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
79340728|NCT02817633|Drug|Nivolumab|Nivolumab will be administered.
79340729|NCT02817633|Drug|TSR-042|TSR-042 will be administered.
79340730|NCT02817633|Drug|TSR-033|TSR-033 will be administered.
79340731|NCT02817633|Drug|Docetaxel|Docetaxel will be administered.
79340732|NCT02817633|Drug|Pemetrexed|Pemetrexed will be administered.
79340733|NCT02817633|Drug|Cisplatin|Cisplatin will be administered.
79340734|NCT02817633|Drug|Carboplatin|Carboplatin will be administered.
79340735|NCT02817399|Device|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
79656080|NCT04537585|Drug|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
79656081|NCT00237965|Behavioral|Mole Mapping Diagram|
79490679|NCT00613886|Device|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
79656082|NCT02216110|Procedure|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
79656083|NCT02216149|Drug|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
79656084|NCT02216149|Drug|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
79656085|NCT02216149|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
79656086|NCT00238004|Drug|Nicotinic acid|
79656087|NCT04537468|Other|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
79340736|NCT02817399|Device|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
79340737|NCT02817399|Procedure|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
79340738|NCT05651529|Dietary Supplement|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
79340739|NCT05651529|Dietary Supplement|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
79227971|NCT02470598|Other|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
79227972|NCT03478020|Drug|AQX-1125|Investigational Drug
79227973|NCT03478020|Drug|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
79227974|NCT02224209|Device|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;~After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
79227975|NCT02224209|Device|a balloon, stent|"Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;~After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
79227976|NCT03481764|Genetic|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
79490680|NCT00613886|Behavioral|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
79823606|NCT00782145|Procedure|quality-of-life assessment|
79340740|NCT05651451|Device|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
79823607|NCT00782145|Procedure|standard follow-up care|
79340741|NCT05651451|Dietary Supplement|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
79340742|NCT05651373|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
79340743|NCT05651373|Drug|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
79490681|NCT03947983|Behavioral|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
79490682|NCT03947983|Behavioral|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
79490683|NCT00610532|Drug|phenytoin|intravenous phenytoin (15 mg/kg) single dose
79490684|NCT00610532|Drug|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
79490685|NCT01669148|Device|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
79490686|NCT01669148|Device|Conventional|conventional (2D) imaging (standard mammography)
79490687|NCT03638323|Other|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
79823608|NCT00790101|Drug|Risedronate|
79823609|NCT00790101|Drug|Raloxifene|
79340744|NCT05651373|Drug|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
79340745|NCT05198583|Other|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
79340746|NCT02607033|Other|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
79490688|NCT03642457|Drug|Bupivacaine|20 cc 0.5%
79490689|NCT03642457|Drug|Bupivacaine liposome|133mg liposomal bupivacaine
79656088|NCT04537468|Other|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
79813864|NCT05753228|Other|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
79490690|NCT00379418|Drug|Abciximab|
79490691|NCT00379496|Procedure|Antidepressants|
79490692|NCT00379496|Procedure|acupuncture|
79813865|NCT05753228|Other|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
79490693|NCT00378716|Drug|5-fluorouracil|
79490694|NCT00378716|Drug|leucovorin calcium|
79490695|NCT00378716|Drug|tegafur|
79813866|NCT05753228|Other|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
79823610|NCT00790101|Other|Placebo|
79340747|NCT02607033|Other|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
79340748|NCT03905889|Drug|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
79340749|NCT03905889|Drug|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
79490696|NCT00378716|Drug|uracil|
79490697|NCT03644095|Drug|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
79490698|NCT03644095|Drug|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
79490699|NCT01633814|Drug|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
79490700|NCT01633814|Drug|Placebo|placebo patch.
79490701|NCT04332133|Procedure|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
79490702|NCT04713943|Dietary Supplement|>Your< Iron Syrup|Once daily dose of >Your< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
79490703|NCT04713943|Other|Placebo|Once daily dose of placebo syrup for 12 weeks
79490704|NCT04713865|Procedure|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
79490705|NCT04713865|Procedure|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
79490706|NCT04713865|Procedure|endovascular treatment|The bare metal stent totally covers the deep femoral artery
79490707|NCT04714099|Drug|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution [200mg cyclosporine in 8 ml ethanol (96%)] under laminar flow.
79490708|NCT04714099|Drug|Placebo|Placebo
79490709|NCT04566770|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
79490710|NCT04566770|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
79490711|NCT04350307|Device|22-gauge needle|22-gauge Quincke needle used for epidural injection
79490712|NCT04350307|Device|25-gauge needle|25-gauge Quincke needle used for epidural injection
79490713|NCT04348357|Other|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
79490714|NCT04348357|Other|Office visit|Patient comes to the office to receive routine postoperative care
79490715|NCT04342663|Drug|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
79490716|NCT04342663|Drug|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
79823611|NCT02555085|Biological|BIIB063|Single ascending IV dose
79340750|NCT05582187|Drug|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
79490717|NCT00589550|Biological|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
79490718|NCT00589550|Drug|Sorafenib|
79490719|NCT00589550|Genetic|gene expression analysis|
79490720|NCT00589550|Genetic|polymerase chain reaction|
79490721|NCT00589550|Genetic|reverse transcriptase-polymerase chain reaction|
79490722|NCT00589550|Other|flow cytometry|
79490723|NCT00589550|Other|immunoenzyme technique|
79490724|NCT00589550|Other|laboratory biomarker analysis|
79490725|NCT01636466|Drug|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
79490726|NCT00583466|Drug|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
79490727|NCT00583466|Drug|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
79656089|NCT04537468|Other|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
79340751|NCT04804059|Drug|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
79656090|NCT00262548|Drug|Rosuvastatin; improvement of lipid profile|
79490728|NCT00583466|Drug|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
79490729|NCT00568802|Drug|Hydroxyurea|
79490730|NCT00568802|Drug|Placebo to match hydroxyurea|
79490731|NCT00576524|Device|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
79490732|NCT00576524|Device|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
79490733|NCT03949621|Drug|Vedolizumab SC|Vedolizumab SC liquid.
79490734|NCT04474730|Device|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
79656091|NCT04537390|Diagnostic Test|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
79656092|NCT04536883|Procedure|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
79656093|NCT00238043|Drug|Biogeneric Epoetin|
79813867|NCT05753228|Other|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
79340752|NCT04804059|Drug|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
79340753|NCT03846765|Drug|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
79490735|NCT04474730|Other|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
79490736|NCT05313919|Diagnostic Test|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~echocardiography with assessment of diastolic function~flow-mediated dilation of brachial artery~coronary angiography~functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~serum level of inflammatory cytokines and chemokines"
79490737|NCT04429880|Drug|Oxytocin|Oxytocin given by intravenous route
79490738|NCT03645811|Behavioral|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
79490739|NCT03645811|Behavioral|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
79490740|NCT05600738|Device|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
79490741|NCT04706078|Diagnostic Test|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
79490742|NCT01692158|Drug|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
79490743|NCT01570634|Drug|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
79490744|NCT03928327|Drug|TAK-788|TAK-788 Capsules
79813868|NCT00806546|Drug|NP101|NP101 study patch four hour application
79490745|NCT03928327|Drug|Itraconazole|Itraconazole Oral solution
79490746|NCT03928327|Drug|Rifampin|Rifampin Capsules
79490747|NCT01055756|Drug|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
79656094|NCT04536844|Device|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
79656095|NCT04536844|Other|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
79656096|NCT00415584|Drug|Cinacalcet HCl|
79656097|NCT04537273|Other|Descriptive and analytical|
79656098|NCT04536922|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
79656099|NCT04536922|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
79227977|NCT05235360|Behavioral|Episodic future thinking|Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
79490748|NCT03648853|Device|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
79490749|NCT00652574|Drug|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
79490750|NCT04240184|Other|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
79490751|NCT03649867|Other|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
79656100|NCT04536922|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
79656101|NCT04536922|Drug|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
79656102|NCT04536922|Biological|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
79656103|NCT04536961|Drug|Reference Treatment- BMS-986165-01|Specified dose on specified days
79656104|NCT04536961|Drug|Prototype BMS-986165|Specified dose on specified days
79656105|NCT04536961|Drug|Famotidine|Specified dose on specified days
79656106|NCT04536961|Other|Alcohol|Specified quantity on specified days
79656107|NCT04537117|Other|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
79813869|NCT00624832|Drug|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
79813870|NCT00624832|Drug|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
79823612|NCT02555085|Other|Placebo|Single dose
79490752|NCT01550510|Drug|Ascorbic Acid|3x a week for 9 weeks
79490753|NCT01550510|Drug|Irinotecan|350mg/m2 once a week every 3 weeks
79490754|NCT04333225|Drug|Hydroxychloroquine|Weekly treatment in individuals at high risk
79490755|NCT00566462|Drug|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
79490756|NCT00566462|Drug|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
79490757|NCT00556400|Drug|Lo-Ovral Oral Contraceptive Pills|
79490758|NCT00556400|Drug|Placebo - sugar pill|
79490759|NCT03918811|Procedure|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
79340754|NCT03846765|Drug|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
79340755|NCT05163405|Drug|Bortezomib|Self-administration of subcutaneously Velcade.
79340756|NCT05474469|Other|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
79340757|NCT05474469|Other|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
79490760|NCT03918811|Procedure|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
79490761|NCT00521924|Biological|infliximab|infliximab 3 mg/kg and basic treatment
79656108|NCT04542265|Combination Product|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
79656109|NCT00415662|Device|Pulsed Signal Therapy (PST)|
79340758|NCT02426307|Procedure|TAVR|TAVR: Transcatheter Aortic Valve Replacement
79340759|NCT02426307|Procedure|SAVR|SAVR: surgical Aortic Valve Replacement
79340760|NCT02325531|Other|Low support|"EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
79490762|NCT00521924|Drug|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
79490763|NCT03927781|Drug|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
79656110|NCT04536610|Behavioral|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
79490764|NCT01553240|Device|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
79656111|NCT04536610|Behavioral|Giving informative leaflet|Leaflets containe the same information as the OP education program
79490765|NCT03907579|Behavioral|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
79984806|NCT05427812|Drug|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
79490766|NCT00379964|Drug|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC>500/mm3), and for up to 72 hours later.
79490767|NCT01545518|Drug|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
79490768|NCT04320823|Device|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
79490769|NCT04320823|Device|Current Plasma Collection Approach|Plasma collection using the current collection approach.
79490770|NCT01539590|Drug|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
79490771|NCT01539590|Drug|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
79490772|NCT00380042|Device|Cortical Stimulation|Cortical stimulation of prefrontal cortex
79490773|NCT00380042|Device|Sham|Sham stimulation
79490774|NCT04313647|Biological|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
79490775|NCT04313647|Biological|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
79490776|NCT04313647|Biological|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
79656112|NCT00238160|Drug|cisplatin|
79656113|NCT00238160|Drug|fluorouracil|
79813871|NCT04029662|Behavioral|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
79984807|NCT02449096|Device|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
79227978|NCT05235360|Behavioral|Positive affect imagery|Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
79227979|NCT05235360|Behavioral|Action planning|Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
79227980|NCT05235360|Behavioral|High dose|Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
79490777|NCT04313647|Biological|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
79490778|NCT04313647|Biological|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
79490779|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
79490780|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
79490781|NCT01526408|Drug|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
79490782|NCT01526408|Drug|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
79490783|NCT03660787|Drug|Seroguard|Seroguard 0.41 g/L solution
79490784|NCT03660787|Drug|Placebo|Saline
79656114|NCT00238160|Procedure|adjuvant therapy|
79656115|NCT00238160|Procedure|chemotherapy|
79656116|NCT00238160|Procedure|conventional surgery|
79656117|NCT00238160|Procedure|hepatic arterial infusion|
79656118|NCT00238160|Procedure|surgery|
79656119|NCT04536649|Radiation|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
79656120|NCT04536454|Drug|[18F]FPyGal|Radiotracer for PET-imaging
79656121|NCT00415701|Drug|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
79656122|NCT00415701|Drug|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
79656123|NCT00415701|Drug|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
79984808|NCT02449096|Other|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
79490785|NCT04713644|Drug|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
79490786|NCT00000734|Drug|Sulfamethoxazole-Trimethoprim|
79490787|NCT00000734|Drug|Zidovudine|
79490788|NCT03926065|Other|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
79656124|NCT00415701|Drug|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
79656125|NCT00415701|Other|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
79656126|NCT02961998|Drug|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
79340761|NCT02325531|Other|Medium support|"Same as provided to the low support arm, PLUS~STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 & 3."
79490789|NCT03926065|Other|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
79490790|NCT03926065|Other|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
79490791|NCT03926065|Other|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
79490792|NCT03663283|Drug|Liposomal Bupivacaine|Interscalene Nerve Blocks
79490793|NCT03663283|Drug|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
79490794|NCT00380198|Drug|Apadenoson|
79490795|NCT00000764|Drug|Isotretinoin|
79490796|NCT00000764|Drug|Interferon alfa-2a|
79490797|NCT03909763|Drug|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
79490798|NCT00484718|Drug|celecoxib|oral, 100 mg bid
79490799|NCT00484718|Drug|Oxycodone|oral, 20 mg bid
79490800|NCT00484718|Drug|placebo|oral bid
79490801|NCT03665155|Drug|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
79490802|NCT03665155|Device|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
79490803|NCT03665155|Other|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
79490804|NCT00477230|Device|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
79656127|NCT02961998|Drug|Sorafenib|Each group will receive sorafenib as basic treatment.
79656128|NCT04536727|Behavioral|Fit & Strong!|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
79656129|NCT04536727|Behavioral|Wait list|Participants randomized to the wait list group receive the 8-week Fit & Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
79656130|NCT04536415|Drug|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
79656131|NCT04536415|Drug|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
79656132|NCT04536220|Diagnostic Test|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
79656133|NCT00262587|Drug|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
79656134|NCT00262587|Drug|Placebo|Inhaled sugar powder in a placebo inhaler
79656135|NCT00238199|Dietary Supplement|calcitriol|
79656136|NCT00238199|Drug|docetaxel|
79656137|NCT04536259|Behavioral|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
79656138|NCT04536259|Behavioral|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
79813872|NCT00826774|Behavioral|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
79813873|NCT00826774|Behavioral|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
79813874|NCT00826774|Behavioral|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
79823613|NCT00782301|Drug|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
79340762|NCT02325531|Other|High support|"Same as provided to the low and medium support arms, PLUS~- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
79823614|NCT00782301|Drug|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
79340763|NCT02325531|Other|Comparison|No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
79490805|NCT00477230|Drug|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
79490806|NCT03901105|Drug|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
79490807|NCT03901105|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
79490808|NCT00448682|Drug|Docetaxel|
79813875|NCT02550730|Behavioral|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
79340764|NCT05366985|Procedure|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
79490809|NCT00448682|Drug|Floxuridine|
79813876|NCT02550730|Other|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
79813877|NCT00826852|Drug|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
79813878|NCT00826930|Drug|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
79227981|NCT05235360|Behavioral|Recent thinking|Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
79227982|NCT05235360|Behavioral|Neutral imagery|Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
79227983|NCT05235360|Behavioral|Low dose|Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
79227984|NCT01733433|Procedure|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
79227985|NCT02008292|Drug|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
79227986|NCT02228811|Drug|DCC-2701 tablet|
79227987|NCT02224287|Procedure|Technologist control of fluoroscopy|Technologist control of fluoroscopy
79227988|NCT02224287|Procedure|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
79227989|NCT04809519|Other|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
79227990|NCT04809519|Other|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
79227991|NCT03477864|Biological|Ipilimumab|Given via intraprostatic injection
79227992|NCT03477864|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
79227993|NCT03477864|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
79227994|NCT03477864|Biological|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
79227995|NCT02229045|Drug|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
79227996|NCT02229045|Drug|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
79227997|NCT02682810|Device|DNA PCR HIV diagnostic test|standard of care
79227998|NCT02682810|Device|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
79490810|NCT00448682|Drug|Leucovorin|
79490811|NCT00448682|Drug|Oxaliplatin|
79490812|NCT04713488|Biological|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
79490813|NCT03675451|Drug|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
79490814|NCT03675451|Drug|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
79490815|NCT03870152|Procedure|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
79490816|NCT00380120|Drug|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
79490817|NCT00380120|Drug|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
79490818|NCT03675685|Biological|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
79656139|NCT04536259|Behavioral|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
79813879|NCT00913796|Drug|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
79813880|NCT00913796|Drug|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
79813881|NCT00822406|Drug|homeopathic medicine|individualized homeopathic medicine
79227999|NCT02229201|Drug|Propofol|4-6 mg/kg/h during anaesthesia
79228000|NCT02229201|Drug|Sevoflurane|0.8 MAC
79228001|NCT03164226|Device|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
79340765|NCT02204787|Device|transcranial direct current stimulation|
79340766|NCT05393895|Drug|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
79813882|NCT00822406|Drug|placebo|placebo - 6 months
79340767|NCT05393895|Drug|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
79340768|NCT05365737|Other|Oral rinse|Participants use mouthwasher for a given time.
79340769|NCT05365737|Other|Saliva harvest|Non-stimulated saliva harvesting
79490819|NCT00000770|Drug|Nevirapine|
79813883|NCT02550574|Procedure|Wound Closure with 2-octylcyanoacrylate|
79340770|NCT05355831|Device|Active Transcranial Direct Current Stimulation|See arm/group description
79340771|NCT05355831|Device|Sham stimulation|See arm/group description
79490820|NCT00000770|Drug|Zidovudine|
79490821|NCT00000770|Drug|Didanosine|
79490822|NCT03677089|Behavioral|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
79490823|NCT03677245|Other|Strider Balance Bike|Learning to ride a Strider balance bike
79490824|NCT00383630|Biological|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
79656140|NCT04536064|Procedure|LVA and liposuction|"Tumescent technique in lymph-sparing fashion was adopted. Areas were infiltrated with a mix of a standard tumescent solution consisting for each liter of in 1000 ml of saline solution, 50 ml lidocaine 1%, 1 ml epinephrine 1:1000, 10 ml bicarbonate 8,4%. Infiltration volume was approximately from 0,5 to 1 liter for the upper extremities and 1-2 liters for lowers. Three to 4 mm 3 holes blunt cannulas were employed. Aspiration technique was as parallel as possible along the lymphatic network pattern and from superficial to deep layers.~Lymphatic vessels identified at ICG lymphography were spared. Volume of the aspirate was aimed to approximate 80 percent of the volume difference between the affected and non affected side.~The number and type of anastomosis were recorded as well as amount of removed lipoaspirate versus the excess limb volume."
79656141|NCT04536493|Drug|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
79490825|NCT00383630|Biological|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
79490826|NCT00383630|Device|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
79656142|NCT04536493|Drug|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
79656143|NCT04536181|Drug|Prednisolone|12 weeks prednisolone treatment
79656144|NCT04536181|Drug|Placebo|12 weeks simulated tablets
79490827|NCT04285411|Device|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
79656145|NCT00262626|Drug|Intraocular pressure reduction|
79490828|NCT00368654|Drug|Methotrexate|Initial dose 5 mg, then 15 mg per week
79656146|NCT00262626|Procedure|Argon laser trabeculoplasty|
79813884|NCT02550574|Procedure|Wound Closure with 5-0 Vicryl Sutures|
79656147|NCT00262626|Procedure|Trabeculectomy|
79656148|NCT04535869|Drug|Sofosbuvir 400 MG plus Daclatasvir 200mg|This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
79490829|NCT00368654|Drug|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
79490830|NCT03888469|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
79490831|NCT03888469|Device|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
79656149|NCT02216188|Biological|AFFITOPE® PD01A|s.c. injection
79656150|NCT02216188|Other|Control|Untreated control group
79656151|NCT02216227|Drug|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
79656152|NCT02216227|Drug|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
79656153|NCT02216227|Drug|Cefazolin|All patients will receive Cefazolin during surgery
79656154|NCT02216227|Drug|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
79813885|NCT02550340|Other|acute alcohol intake|Smart phone based ECG recording
79813886|NCT05123768|Diagnostic Test|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
79813887|NCT00819442|Procedure|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
79823615|NCT00785343|Device|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
79340772|NCT04787367|Procedure|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
79656155|NCT02216227|Drug|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
79340773|NCT02061891|Procedure|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
79340774|NCT02061891|Procedure|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
79490832|NCT00000776|Drug|Flucytosine|
79490833|NCT00000776|Drug|Fluconazole|
79340775|NCT03797157|Dietary Supplement|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
79490834|NCT00000776|Drug|Amphotericin B|
79490835|NCT00000776|Drug|Dexamethasone|
79490836|NCT04283773|Combination Product|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
79490837|NCT04283773|Combination Product|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
79656156|NCT00238277|Drug|temozolomide|
79656157|NCT00238277|Procedure|adjuvant therapy|
79656158|NCT00238277|Procedure|chemotherapy|
79656159|NCT00238277|Procedure|radiation therapy|
79490838|NCT00329732|Drug|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
79490839|NCT00329732|Drug|Saline placebo|matching volume of saline (placebo)
79490840|NCT03438500|Device|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
79490841|NCT04281901|Drug|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
79490842|NCT04281901|Drug|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
79656160|NCT00262665|Drug|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
79656161|NCT00262665|Drug|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
79490843|NCT00000782|Biological|gp160 Vaccine (Immuno-AG)|
79490844|NCT00000782|Biological|gp160 Vaccine (MicroGeneSys)|
79340776|NCT03797157|Dietary Supplement|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
79340777|NCT02039739|Device|Orsiro™ Drug Eluting Stent group|
79340778|NCT05210049|Diagnostic Test|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
79340779|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
79340780|NCT03766113|Other|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
79340781|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
79340782|NCT04785339|Behavioral|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
79813888|NCT04704986|Device|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
79490845|NCT04280653|Device|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
79490846|NCT00000800|Drug|Methadone hydrochloride|
79490847|NCT00000800|Drug|Zidovudine|
79656162|NCT02216266|Drug|Physostigmine|
79656163|NCT02216266|Other|Sodium Chloride solution|
79656164|NCT04535830|Device|Flash Glucose Monitoring System|During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
79656165|NCT00262704|Behavioral|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
79490848|NCT00000806|Drug|Telinavir|
79490849|NCT03679975|Drug|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
79656166|NCT00262704|Behavioral|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
79656167|NCT04535752|Drug|ANX009|Single or multiple ascending dose
79656168|NCT04535752|Drug|Placebo|Single or multiple ascending dose
79656169|NCT00238316|Drug|letrozole|2.5 mg PO daily for 1 year
79656170|NCT00238316|Other|Placebo|2.5 mg PO daily for one 1 year
79656171|NCT04535518|Drug|IVIG|IVIG at a single dose of 2 g/kg
79656172|NCT04535518|Drug|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
79656173|NCT04535518|Drug|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
79656174|NCT02216383|Drug|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
79656175|NCT02216383|Drug|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
79656176|NCT02216383|Drug|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
79813889|NCT04704986|Drug|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
79340783|NCT03757377|Device|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
79340784|NCT03757377|Device|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
79340785|NCT04418505|Device|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
79340786|NCT03746847|Drug|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
79228002|NCT02224365|Dietary Supplement|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
79340787|NCT01635153|Dietary Supplement|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
79340788|NCT01635153|Dietary Supplement|Micronutrient|Dar-vite Multivitamin
79813890|NCT00822484|Biological|ILV-095|
79813891|NCT00822484|Other|Placebo|
79340789|NCT04446039|Drug|Escitalopram|Treatment for depression
79340790|NCT04446039|Drug|Paroxetine|Treatment for depression
79490850|NCT03887299|Combination Product|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
79490851|NCT03887299|Other|Standard Wound Care|Wound care will be administered as standard protocol in our institution
79490852|NCT00244010|Device|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
79490853|NCT03684265|Drug|Meloxicam Capsule (Test)|single dose
79490854|NCT03684265|Drug|Meloxicam Tablet (Reference)|single dose
79490855|NCT00218036|Drug|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
79490856|NCT00218036|Drug|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
79490857|NCT00218036|Drug|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
79490858|NCT00218036|Drug|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
79490859|NCT00218036|Drug|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
79490860|NCT03848221|Drug|Systane Complete|Systane Complete is an artificial tear.
79490861|NCT03848221|Drug|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
79490862|NCT05314699|Behavioral|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
79490863|NCT05314699|Behavioral|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
79490864|NCT00205868|Device|Precision Spinal Cord Stimulation System|Stimulation on throughout study
79490865|NCT04271761|Other|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
79490866|NCT00233090|Drug|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
79490867|NCT00233090|Drug|Placebo|daily dose of placebo for four weeks.
79490868|NCT04266925|Behavioral|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
79490869|NCT04266925|Other|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
79490870|NCT05182502|Device|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
79490871|NCT04247581|Device|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
79340791|NCT04446039|Drug|Fluoxetine|Treatment for depression
79340792|NCT04446039|Drug|Mirtazapine|Treatment for depression
79340793|NCT04446039|Drug|Duloxetine|Treatment for depression
79340794|NCT04446039|Drug|Sertraline|Treatment for depression
79340795|NCT04446039|Drug|Venlafaxine|Treatment for depression
79340796|NCT04446039|Drug|Tianeptine|Treatment for depression
79340797|NCT04446039|Drug|Vortioxetine|Treatment for depression
79340798|NCT04446039|Drug|Desvenlafaxine|Treatment for depression
79340799|NCT04446039|Drug|Bupropion|Treatment for depression
79340800|NCT05087979|Device|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
79490872|NCT02921906|Other|High protein meal|Breakfast with high protein / low carbohydrate content
79490873|NCT02921906|Other|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
79490874|NCT02921906|Drug|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
79490875|NCT02921906|Other|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
79490876|NCT04243369|Device|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
79490877|NCT00000812|Drug|Thalidomide|
79490878|NCT03849937|Behavioral|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
79490879|NCT00000818|Drug|Zidovudine|
79340801|NCT05036967|Drug|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
79340802|NCT03647007|Other|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
79340803|NCT02014311|Procedure|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
79340804|NCT02014311|Procedure|CTA guided treatment strategy|CTA guided treatment strategy
79490880|NCT00377689|Behavioral|high intensity functional exercise|high intensity functional exercise
79490881|NCT00177866|Drug|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
79490882|NCT00177866|Drug|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
79490883|NCT03693937|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
79490884|NCT03696589|Behavioral|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
79490885|NCT00089414|Drug|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
79340805|NCT05034861|Device|cCTG|Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
79340806|NCT05034861|Diagnostic Test|Doppler|Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
79490886|NCT00089414|Drug|Placebo|
79490887|NCT00089414|Drug|CDB 2914|
79490888|NCT00000824|Drug|Lymphocytes, Activated|
79813892|NCT02608814|Procedure|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
79813893|NCT02608814|Other|Ultrasound|
79340807|NCT05032677|Procedure|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
79340808|NCT05032677|Procedure|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
79340809|NCT05002959|Device|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
79813894|NCT00633880|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
79813895|NCT00633880|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
79656177|NCT00262782|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
79340810|NCT05002959|Device|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
79340811|NCT01871727|Drug|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
79340812|NCT05266989|Other|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
79340813|NCT01636713|Drug|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
79340814|NCT01636713|Drug|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
79340815|NCT01636713|Drug|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
79340816|NCT04801095|Drug|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
79340817|NCT04800237|Drug|VQW-765|oral capsule
79340818|NCT04800237|Drug|Placebo|oral capsule
79340819|NCT03591861|Procedure|Ketogenic diet|"Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
79490889|NCT00075608|Biological|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
79490890|NCT00075608|Drug|melphalan|140-200 mcg/kg IV over two days
79490891|NCT00075608|Procedure|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
79490892|NCT00075608|Procedure|stem cell infusion|infusion of previously collected stem cells on Day 0
79656178|NCT00238394|Drug|cediranib maleate|Given orally
79340820|NCT03591861|Drug|BCNU|-Standard of care
79490893|NCT03704467|Drug|M6620|Participants received 90 milligrams per square meter (mg/m^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m^2, or 40 mg/m^2.
79490894|NCT03704467|Drug|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
79656179|NCT00238394|Other|laboratory biomarker analysis|Correlative studies
79656180|NCT04535284|Behavioral|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
79813896|NCT04029428|Drug|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
79340821|NCT04832919|Behavioral|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
79656181|NCT02216461|Drug|Low dose of BIBW 2948 BS for oral inhalation|
79656182|NCT02216461|Drug|Medium dose of BIBW 2948 BS for oral inhalation|
79656183|NCT02216461|Drug|High dose of BIBW 2948 BS for oral inhalation|
79656184|NCT02216461|Drug|Placebo|
79656185|NCT00238472|Drug|nateglinide|
79813897|NCT04029428|Drug|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
79823616|NCT00785343|Procedure|Conventional Therapy|Occupational therapy that is the current standard of care
79490895|NCT03704467|Drug|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
79490896|NCT03705481|Device|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
79656186|NCT04535206|Diagnostic Test|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
79656187|NCT04534621|Other|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
79656188|NCT00262899|Behavioral|counseling intervention|
79813898|NCT04029428|Drug|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
79984809|NCT03117790|Drug|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
79984810|NCT03117790|Drug|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
79228003|NCT02224365|Dietary Supplement|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
79228004|NCT03477786|Combination Product|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
79490897|NCT00000836|Drug|Sevirumab|
79490898|NCT05177900|Device|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
79656189|NCT00262899|Other|educational intervention|
79656190|NCT00262899|Procedure|psychosocial assessment and care|
79656191|NCT04534855|Drug|Treprilimab|Treprilimab 240mg Q3W until progression or unacceptable toxicity
79656192|NCT00238511|Drug|SPM 927|
79656193|NCT02216539|Behavioral|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
79656194|NCT02216539|Procedure|Lung transplantation|
79656195|NCT02216539|Other|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
79984811|NCT03117712|Diagnostic Test|Delirium Scores|"Confusion Assessment method for the ICU (CAM-ICU) and~The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~Postoperative day (POD) 1~POD 2~POD 5"
79984812|NCT03117712|Diagnostic Test|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~Before induction of anaesthesia~Before going on cardiopulmonary bypass (CBP)~During CPB, 5 min after aortic cross clamping~After CPB~24 hours after CPB"
79340822|NCT01600053|Drug|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
79340823|NCT04821297|Other|Health Promotion and Education|Receive messages
79340824|NCT04821297|Other|Survey Administration|Complete survey
79340825|NCT04821297|Other|Interview|Participate in an interview
79340826|NCT03569241|Radiation|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
79490899|NCT00000842|Drug|Nerve Growth Factor, Recombinant Human|
79490900|NCT02145260|Drug|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
79490901|NCT02145260|Drug|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
79490902|NCT00000848|Drug|Indinavir sulfate|
79490903|NCT00000848|Drug|Saquinavir|
79490904|NCT01795586|Drug|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m^2; Level 2: 1.1 mg/m^2; Level 3: 1.4 mg/m^2"
79490905|NCT01795586|Drug|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
79656196|NCT04534816|Diagnostic Test|Indocyanine Green|Perfusion assessments
79813899|NCT02608424|Device|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
79984813|NCT03117712|Diagnostic Test|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~During cannulation of the ascending aorta~After aortic cross-clamp~After opening of the aortic cross-clamp~During decannulation"
79984814|NCT03193372|Drug|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
79984815|NCT03034772|Drug|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
79984816|NCT03034772|Other|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
79228005|NCT02224443|Drug|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
79228006|NCT02224443|Drug|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
79228007|NCT02224443|Drug|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
79228008|NCT02224443|Drug|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4~5μg.kg-1 fentanyl,1.0~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
79340827|NCT03569241|Radiation|metastasis-directed treatment|stereotactic body radiotherapy
79340828|NCT03569241|Procedure|salvage Lymph Node Dissection|metastasis-directed treatment
79340829|NCT03569241|Drug|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
79340830|NCT04716387|Other|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
79490906|NCT03707041|Drug|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
79490907|NCT03707041|Drug|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
79490908|NCT03707041|Drug|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
79490909|NCT03707041|Biological|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
79490910|NCT03879044|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
79490911|NCT02212574|Drug|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
79490912|NCT02212574|Drug|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
79490913|NCT02212574|Drug|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
79490914|NCT02212574|Drug|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
79490915|NCT02212574|Drug|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
79490916|NCT02212574|Drug|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
79490917|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
79490918|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
79490919|NCT00000854|Drug|Nandrolone decanoate|
79656197|NCT00262938|Behavioral|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
79340831|NCT04716387|Other|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
79340832|NCT04716387|Other|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
79340833|NCT04716387|Other|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
79490920|NCT03862027|Device|Esophageal Balloon catheter|"Pressures [Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
79490921|NCT03856255|Device|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
79490922|NCT04298918|Drug|Placebo|Participants will receive oral placebo in combination with trastuzumab emtansine.
79490923|NCT04298918|Drug|Venetoclax|Participants will receive oral venetoclax.
79490924|NCT04298918|Drug|Trastuzumab emtansine|Participants will receive intravenous (IV) trastuzumab emtansine.
79490925|NCT00001676|Drug|SQ Fludarabine|
79490926|NCT03714919|Drug|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
79490927|NCT03714919|Drug|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
79490928|NCT03714919|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
79490929|NCT03714919|Drug|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
79490930|NCT00000866|Biological|MN rgp120/HIV-1|
79490931|NCT00000866|Biological|TBC-3B Vaccine|
79490932|NCT03863522|Procedure|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
79490933|NCT03863522|Device|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
79656198|NCT00262938|Other|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
79656199|NCT00262938|Other|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
79656200|NCT00262938|Other|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
79340834|NCT01068249|Drug|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
79340835|NCT01068249|Drug|RAD001 (Everolimus)|10 mg by mouth daily
79340836|NCT01035099|Drug|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;"
79340837|NCT01035099|Drug|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
79490934|NCT04223635|Drug|Pexidartinib|Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
79490935|NCT00000872|Drug|Abacavir sulfate|
79490936|NCT00000872|Drug|Nelfinavir mesylate|
79490937|NCT00000872|Drug|Nevirapine|
79490938|NCT00000872|Drug|Lamivudine|
79490939|NCT00000872|Drug|Stavudine|
79490940|NCT00000872|Drug|Zidovudine|
79490941|NCT04232137|Behavioral|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
79490942|NCT00000878|Drug|Lamivudine|
79490943|NCT00000878|Drug|Stavudine|
79490944|NCT00000878|Drug|Zidovudine|
79490945|NCT04204057|Drug|Tenalisib|Tenalisib 800 mg BID, Orally
79490946|NCT00000104|Procedure|ERP measures of attention and memory|
79490947|NCT00001736|Drug|Cysteamine|
79490948|NCT00000884|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
79490949|NCT00000884|Biological|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
79490950|NCT00000884|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
79490951|NCT00001748|Procedure|Peripheral blood progenitor cell transplant|
79490952|NCT00000110|Procedure|magnetic resonance spectroscopy|
79490953|NCT00000110|Drug|dietary fat|
79490954|NCT00000896|Drug|Indinavir sulfate|
79490955|NCT00000896|Drug|Lamivudine/Zidovudine|
79490956|NCT00000896|Biological|Hepatitis A Vaccine (Inactivated)|
79490957|NCT00000896|Drug|Interleukin-12|
79490958|NCT00000896|Drug|Nevirapine|
79490959|NCT00000896|Drug|Stavudine|
79490960|NCT00000896|Drug|Sargramostim|
79490961|NCT00001790|Drug|FK463|
79490962|NCT00000902|Drug|Ritonavir|
79490963|NCT00000902|Drug|Nelfinavir mesylate|
79656201|NCT00262938|Procedure|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
79656202|NCT04534894|Diagnostic Test|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
79340838|NCT05362383|Device|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
79340839|NCT00973011|Drug|FCFD4514S|Intravitreal escalating dose
79340840|NCT03560349|Drug|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
79490964|NCT00000902|Drug|Nevirapine|
79490965|NCT00000902|Drug|Lamivudine|
79490966|NCT00000902|Drug|Stavudine|
79490967|NCT00000902|Drug|Zidovudine|
79490968|NCT00000902|Drug|Zalcitabine|
79490969|NCT00000902|Drug|Didanosine|
79490970|NCT04331600|Drug|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
79490971|NCT04331600|Other|Telemedicine|Telemedical supervision for 42 days
79490972|NCT03844321|Behavioral|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
79656203|NCT00238628|Drug|Bexarotene|
79813900|NCT00819520|Drug|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
79490973|NCT03844321|Behavioral|Brief Mindfulness|3 sessions of online mindfulness therapy
79490974|NCT00000128|Device|Bifocal Spectacle Lenses|
79490975|NCT04331678|Behavioral|Comparator App|"Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment."
79490976|NCT00000188|Drug|Selegiline|
79490977|NCT00000914|Drug|Indinavir sulfate|
79490978|NCT00000914|Drug|Ritonavir|
79490979|NCT00000914|Drug|Nelfinavir mesylate|
79490980|NCT00000914|Drug|Efavirenz|
79490981|NCT00000920|Drug|Ritonavir|
79490982|NCT00000920|Drug|Saquinavir|
79490983|NCT00000920|Drug|Lamivudine|
79490984|NCT00000920|Drug|Zidovudine|
79490985|NCT00000938|Drug|ceftriaxone|
79490986|NCT00000938|Drug|doxycycline|
79490987|NCT00001862|Drug|Enbrel|
79490988|NCT00000194|Drug|Cycloserine|
79490989|NCT00000200|Drug|Methadone|normal maintenance dose
79490990|NCT05440682|Procedure|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
79490991|NCT00000206|Drug|Buprenorphine|
79490992|NCT00000944|Drug|Indinavir sulfate|
79490993|NCT00000944|Drug|Lamivudine|
79490994|NCT00000944|Drug|Zidovudine|
79490995|NCT00000950|Drug|Ethambutol hydrochloride|
79490996|NCT00000950|Drug|Isoniazid|
79490997|NCT00000950|Drug|Pyrazinamide|
79490998|NCT00000950|Drug|Pyridoxine hydrochloride|
79490999|NCT00000950|Drug|Rifampin|
79491000|NCT00000218|Drug|Carbamazepine|
79984817|NCT03196336|Other|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
79340841|NCT03560349|Drug|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
79340842|NCT04812639|Other|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
79340843|NCT04812639|Other|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
79491001|NCT00000224|Drug|Buprenorphine|
79491002|NCT00001886|Procedure|Real time 3-dimensional stress echocardiography|
79491003|NCT04332991|Drug|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
79998540|NCT01335763|Drug|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
79228009|NCT02224443|Drug|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05~0.1mg.kg-1.h-1cisatracurium besylate,4~8mg.kg-1.h-1propofol,0.1~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%~1.0%
79656204|NCT00238628|Drug|Iressa|
79656205|NCT02216617|Drug|Taxotere, Cisplatin, Afatinib|
79340844|NCT04418583|Diagnostic Test|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
79340845|NCT05157399|Device|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
79491004|NCT04332991|Drug|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
79340846|NCT05157399|Device|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
79340847|NCT04418973|Other|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
79984818|NCT03196258|Behavioral|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
79656206|NCT00262977|Behavioral|Electronic prompt plus patient-directed intervention|
79813901|NCT00819520|Drug|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
79823617|NCT00785421|Drug|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
79340848|NCT00434343|Other|Global Therapeutic Massage (GTM)|
79340849|NCT00434343|Other|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
79340850|NCT04435431|Drug|Mesdopetam|Oral use
79340851|NCT04435431|Drug|Placebo|Oral use
79340852|NCT02246673|Drug|RDEA3170 15 mg|
79340853|NCT02246673|Drug|RDEA3170 10 mg|
79340854|NCT02246673|Drug|RDEA3170 2.5|
79656207|NCT00262977|Behavioral|Electronic prompt to clinician to prescribe aspirin|
79656208|NCT04534504|Procedure|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
79656209|NCT00238667|Drug|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
79340855|NCT02246673|Drug|RDEA3170 5 mg|
79340856|NCT02246673|Drug|Febuxostat 40 mg|
79340857|NCT02246673|Drug|Febuxostat 80 mg|
79340858|NCT03532425|Drug|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
79340859|NCT03532425|Drug|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
79340860|NCT03532425|Drug|B/F/TAF Placebo|Tablet taken orally once daily
79656210|NCT00238667|Drug|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
79340861|NCT03532425|Drug|Atripla Placebo|Tablet taken orally once daily
79340862|NCT03503877|Device|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
79340863|NCT03503877|Other|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
79340864|NCT03503877|Other|SAGE MEDIA|Embryos will be cultured in SAGE media
79340865|NCT04811469|Drug|CBP-174|CBP-174 oral solution, given once
79340866|NCT04811469|Drug|Placebo|Placebo oral solution, given once
79340867|NCT02246439|Drug|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
79340868|NCT02246439|Drug|Placebo Oral Tablet|Placebo
79340869|NCT02245737|Drug|Lanabecestat|Administered orally
79340870|NCT02245737|Drug|Placebo|Administered orally
79340871|NCT04191447|Drug|Flamboyant 200/12|Flamboyant 200/12 capsule
79340872|NCT04191447|Drug|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
79340873|NCT04191447|Other|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
79491005|NCT00000956|Biological|gp160 Vaccine (MicroGeneSys)|
79340874|NCT04191447|Other|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
79491006|NCT00000230|Drug|Buprenorphine|
79340875|NCT02244957|Device|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations <88% while on stable bi-level settings.
79491007|NCT00000236|Drug|Buprenorphine/naloxone|
79491008|NCT00000974|Drug|Pentamidine isethionate|
79491009|NCT00000242|Drug|Carbamazepine|
79491010|NCT03719677|Behavioral|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
79491011|NCT00000980|Drug|Spiramycin|
79491012|NCT03831451|Behavioral|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
79491013|NCT03831451|Behavioral|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
79656211|NCT04534426|Drug|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
79823618|NCT00785421|Drug|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
79340876|NCT02244957|Drug|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
79491014|NCT00000992|Drug|Itraconazole|
79491015|NCT03721549|Biological|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
79491016|NCT00000254|Drug|40% Nitrous oxide|Used as pain assay positive control
79823619|NCT00785421|Drug|only chemotherapy|observation, no treatment with LMWH
79340877|NCT02243865|Device|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
79491017|NCT00000254|Other|Sham comparator|0% isoflurane in oxygen
79491018|NCT00000254|Drug|0.2% isoflurane|
79491019|NCT00000254|Drug|0.4% isoflurane|
79491020|NCT00000254|Drug|0.6% isoflurane|
79491021|NCT03834025|Behavioral|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
79491022|NCT03834025|Behavioral|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
79984819|NCT03704870|Diagnostic Test|Chest Xray|Daily chest xray
79491023|NCT03834025|Behavioral|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
79491024|NCT03834025|Behavioral|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
79984820|NCT03704870|Diagnostic Test|No daily chest xray|Chest xray will be done post chest tube removal only
79998541|NCT02926209|Device|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
79340878|NCT02243865|Device|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
79340879|NCT03443739|Other|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
79340880|NCT02243631|Drug|Probenecid|Treatment
79340881|NCT04183413|Other|DSD|This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
79340882|NCT04183413|Other|CDP|Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
79340883|NCT03986229|Other|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~Evaluation of the pain~Berg test~One test per condition starting with open eyes~Standardized instructions:~Break about 15 minutes (wash-out) between each test.~Both conditions will be tested on the same day.~Evaluation in an environment free from visual and audible interference."
79340884|NCT03396783|Biological|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
79340885|NCT03396783|Other|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
79340886|NCT05233449|Device|NoL monitor|NoL monitor : non invasive, adhesive digital device
79491025|NCT03834025|Behavioral|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
79491026|NCT03834025|Behavioral|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
79813902|NCT00590564|Drug|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
79491027|NCT03834025|Behavioral|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
79491028|NCT00000260|Drug|Nitrous oxide|
79491029|NCT00000266|Drug|Flupenthixol|
79813903|NCT00827164|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
79823620|NCT00790179|Procedure|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
79823621|NCT00790257|Device|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
79823622|NCT00785499|Behavioral|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
79823623|NCT00782457|Procedure|RECTAL CANCER RESECTION|
79823624|NCT00790413|Drug|iodine I 131 metaiodobenzylguanidine|
79823625|NCT00790413|Drug|Fludarabine|
79656212|NCT04534426|Drug|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
79340887|NCT05233449|Procedure|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
79340888|NCT02242305|Drug|Hyoscine Butylbromide - Tablet|
79340889|NCT02242305|Drug|Hyoscine Butylbromide - Capsule|
79340890|NCT02242305|Drug|Placebo|
79340891|NCT02240121|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
79340892|NCT02240121|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
79340893|NCT04780425|Behavioral|DESMOND|as previously described
79340894|NCT04780425|Other|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
79340895|NCT02239263|Device|Nucleus 6 Sound Processor|
79340896|NCT02238483|Drug|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
79491030|NCT03748771|Device|ApneaLink Air|"The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP."
79491031|NCT00001016|Drug|Trimetrexate glucuronate|
79656213|NCT04534426|Other|Control group|In Control group, only standard therapy was performed after surgery
79656214|NCT00263016|Drug|Docetaxel|
79656215|NCT00238706|Device|Radiofrequency ablation|
79998542|NCT02926209|Procedure|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
79491032|NCT00001016|Drug|Leucovorin calcium|
79491033|NCT05228912|Drug|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
79491034|NCT03836989|Device|Electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
79656216|NCT04534465|Drug|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
79656217|NCT04534465|Drug|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
79656218|NCT02216656|Drug|Placebo|Oral administration
79340897|NCT02238483|Drug|Placebo|Inhaled placebo solution
79340898|NCT01632891|Drug|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
79340899|NCT01632891|Drug|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
79340900|NCT01632891|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
79340901|NCT01632891|Drug|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
79656219|NCT02216656|Drug|KHK7580 low dose|Oral administration
79340902|NCT01632891|Drug|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
79340903|NCT02208999|Device|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
79340904|NCT02208843|Drug|Afatinib|Afatinib tablet once daily until progression
79340905|NCT02208063|Drug|Telavancin|
79340906|NCT02208063|Drug|Vancomycin|
79340907|NCT02208063|Drug|Daptomycin|
79340908|NCT02208063|Drug|Synthetic penicillin|
79340909|NCT02208063|Drug|Cefazolin|
79340910|NCT02207907|Drug|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
79340911|NCT02207907|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
79340912|NCT02207829|Drug|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
79340913|NCT02207829|Drug|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
79340914|NCT02207829|Drug|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
79340915|NCT02207829|Drug|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
79340916|NCT02237157|Drug|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
79340917|NCT02237001|Device|Suture-based meniscal repair|Suture-based meniscal repair
79340918|NCT02236611|Drug|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
79656220|NCT02216656|Drug|KHK7580 middle dose|Oral administration
79656221|NCT02216656|Drug|KHK7580 high dose|Oral administration
79656222|NCT02216656|Drug|KRN1493|Oral administration
79491035|NCT03811951|Drug|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
79491036|NCT04816526|Biological|Descartes 08|Car T-cells
79491037|NCT04332289|Other|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
79491038|NCT00001022|Drug|Zidovudine|
79491039|NCT00001022|Drug|Zalcitabine|
79491040|NCT00001022|Drug|Didanosine|
79491041|NCT03816709|Device|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
79491042|NCT05218148|Drug|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
79491043|NCT05218148|Drug|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
79491044|NCT05218148|Drug|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) < 1.25 m2, 50 mg for BSA 1.25 to <1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area &lt;1.25m2: Tegio 40mg bid day 1 ~ 14; Body surface area 1.25 ~ &lt;1.5m2: Tegio 50mg bid day 1 ~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 ~ 14; 3 cycles before surgery and 3 cycles after surgery."
79491045|NCT00001934|Drug|Zenapax|
79491046|NCT04183231|Drug|Anti-caries varnish|topical tooth varnish
79491047|NCT00000278|Drug|Disulfiram|
79491048|NCT00001028|Drug|Pentamidine isethionate|
79491049|NCT00001028|Drug|Dapsone|
79491050|NCT03890419|Device|Green light|Green light exposure
79491051|NCT03890419|Device|Clear light|Full spectrum light exposure
79491052|NCT03890419|Device|Blue Light|Blue light exposure
79491053|NCT00000284|Drug|Cotinine fumarate|
79491054|NCT00001940|Drug|Voriconazole|
79656223|NCT00263055|Drug|oxaliplatin|
79491055|NCT03907033|Drug|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
79656224|NCT00238745|Drug|Bazedoxifene|
79491056|NCT03907033|Drug|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
79491057|NCT00001946|Procedure|Magnetic resonance angiography|
79491058|NCT00001034|Drug|Ganciclovir|
79491059|NCT00001046|Biological|MF59|
79491060|NCT00001046|Biological|rgp120/HIV-1 SF-2|
79491061|NCT03818815|Combination Product|OP0201|OP0201 20mg per day in two divided doses for 10 days
79491062|NCT03818815|Combination Product|Placebo|Placebo 0mg per day in two divided doses for 10 days
79491063|NCT03818815|Drug|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
79491064|NCT00001958|Drug|Hydroxyurea|
79491065|NCT00001964|Drug|Cyclosporine A|Cyclosporine A
79491066|NCT00001964|Drug|ATG|ATG
79491067|NCT00001964|Drug|MMF|MMF
79491068|NCT03801265|Procedure|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
79656225|NCT00238745|Drug|Placebo|
79656226|NCT04534348|Device|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
79656227|NCT04534231|Drug|Nicotine patch|Nicotine transdermal patches as per product monograph
79656228|NCT00263094|Drug|Rofecoxib|
79656229|NCT04534192|Device|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
79656230|NCT00238784|Drug|Budesonide/formoterol Turbuhaler|
79656231|NCT04534036|Dietary Supplement|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
79656232|NCT04534036|Other|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
79656233|NCT00263133|Drug|Sertraline|
79823626|NCT00790413|Drug|Thiotepa|
79823627|NCT00790413|Procedure|T-cell depletion|
79823628|NCT00790413|Procedure|Haploidentical stem cell transplantation|
79491069|NCT03801265|Procedure|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
79491070|NCT03801265|Drug|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
79491071|NCT00000290|Drug|Cocaine|
79491072|NCT00000296|Drug|Cotinine fumarate|
79491073|NCT00000212|Drug|Desipramine|
79491074|NCT00000302|Drug|Buprenorphine|
79491075|NCT00001052|Biological|Aluminum hydroxide|
79491076|NCT00001052|Biological|QS-21|
79491077|NCT00001052|Biological|rgp120/HIV-1MN|
79491078|NCT00001058|Drug|Indinavir sulfate|
79491079|NCT00001058|Drug|Ritonavir|
79491080|NCT00001058|Drug|Ethambutol hydrochloride|
79491081|NCT00001058|Drug|Clarithromycin|
79491082|NCT00001058|Drug|Rifabutin|
79491083|NCT00000308|Drug|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
79656234|NCT04533724|Drug|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
79656235|NCT04533685|Behavioral|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
79340919|NCT02236611|Drug|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
79491084|NCT00000308|Drug|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
79656236|NCT04533685|Behavioral|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
79656237|NCT04533685|Behavioral|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
79340920|NCT02234583|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
79491085|NCT00000308|Drug|placebo|placebo
79998543|NCT04466163|Behavioral|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen & Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
79340921|NCT03705663|Behavioral|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
79340922|NCT03686397|Drug|SVT-15652|1 vial twice daily
79491086|NCT03968965|Device|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
79491087|NCT03968965|Other|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
79340923|NCT03686397|Drug|Placebo|1 vial twice daily
79491088|NCT00001064|Drug|Allogenic Dendritic Cells|
79491089|NCT00001994|Drug|Atovaquone|
79491090|NCT00000314|Drug|M-CPP|
79491091|NCT00000320|Drug|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
79491092|NCT00000326|Drug|Heroin Dependence|
79491093|NCT03978403|Drug|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
79491094|NCT03978403|Drug|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
79998544|NCT03635671|Diagnostic Test|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
79491095|NCT03978403|Drug|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
79491096|NCT03978403|Drug|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
79491097|NCT00002000|Drug|Valacyclovir hydrochloride|
79491098|NCT00002000|Drug|Acyclovir|
79491099|NCT03979807|Drug|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
79491100|NCT03979807|Drug|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
79491101|NCT00001082|Drug|Levocarnitine|500 mg tablet taken orally daily
79491102|NCT00001082|Drug|Adefovir dipivoxil|120 mg tablet taken orally daily
79491103|NCT00001082|Drug|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
79491104|NCT00002006|Drug|Zidovudine|
79491105|NCT00002006|Drug|Sargramostim|
79491106|NCT04169113|Other|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
79491107|NCT04169113|Other|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
79491108|NCT00002012|Drug|Interferon alfa-n3|
79984821|NCT03196102|Behavioral|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
79491109|NCT00380276|Drug|MPC-7869|800 mg BID Oral dosing
79491110|NCT04149925|Device|AEON Endostapler|Surgery with AEON Endostapler
79491111|NCT04149925|Device|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
79491112|NCT00380354|Drug|GSK256066|
79491113|NCT03799783|Drug|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
79491114|NCT00001088|Biological|APL 400-047|
79491115|NCT00001088|Drug|Bupivacaine hydrochloride|
79656238|NCT04533685|Behavioral|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
79998545|NCT04462965|Combination Product|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
79656239|NCT00263172|Behavioral|behavior modification for weight loss|
79656240|NCT00238901|Drug|Basiliximab|
79656241|NCT04533490|Drug|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
79656242|NCT00263250|Procedure|watchful waiting or tension-free hernia repair|
79340924|NCT02233803|Drug|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
79340925|NCT02233803|Drug|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
79340926|NCT02233803|Drug|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
79340927|NCT02233803|Drug|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
79340928|NCT02233647|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
79491116|NCT04713566|Other|oral rinces|natural and commercial oral rinses were compared for efficacy
79491117|NCT00001094|Drug|Lamivudine/Zidovudine|
79491118|NCT00001094|Drug|Nelfinavir mesylate|
79491119|NCT00001094|Drug|Saquinavir|
79491120|NCT00001094|Drug|Delavirdine mesylate|
79491121|NCT00001100|Drug|ganciclovir|
79491122|NCT00000332|Drug|Nimodipine|
79491123|NCT00000338|Drug|Lisuride|
79491124|NCT04085341|Drug|GB-102|Intravitreal injection of GB-102
79491125|NCT00002018|Drug|Interferon alfa-n3|
79491126|NCT00002024|Drug|Ganciclovir|
79491127|NCT00001106|Drug|Zidovudine|
79491128|NCT00000344|Drug|Buprenorphine/naloxone|
79491129|NCT04103515|Device|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
79491130|NCT04103515|Device|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
79491131|NCT05075018|Other|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
79491132|NCT00002030|Drug|Pentamidine isethionate|
79491133|NCT00377377|Drug|EP1572 (ghrelin agonist) oral and duodenal application|
79491134|NCT00001112|Drug|Zidovudine|
79491135|NCT00001112|Drug|Interferon gamma-1b|
79491136|NCT00377767|Behavioral|To change structure and roles of primary care teams to optimize prevention of obesity|
79491137|NCT00002036|Drug|Anti-HIV Immune Serum Globulin (Human)|
79491138|NCT00000350|Procedure|radioactive substance|
79491139|NCT03782701|Drug|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
79656243|NCT00238940|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79823629|NCT00790413|Procedure|Donor Lymphocyte Infusion|
79823630|NCT00790413|Drug|Rituximab|
79823631|NCT00790413|Procedure|Co-transplantation of mesenchymal stem cells|
79823632|NCT00785655|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
79823633|NCT00790491|Behavioral|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
79656244|NCT04533139|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
79491140|NCT03782701|Other|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
79491141|NCT05314387|Device|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
79491142|NCT05314387|Device|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
79656245|NCT04533256|Procedure|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
79656246|NCT04533217|Procedure|Vertebroplasty|Injection of cement into vertebral lesion(s)
79656247|NCT04533178|Device|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
79656248|NCT04533178|Other|Resting from all sports activities|Resting from all sports activities
79656249|NCT00263289|Procedure|preprocedural fasting|
79656250|NCT00238979|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79656251|NCT04533295|Device|acupuncture and IVF|Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
79813904|NCT00827164|Behavioral|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
79340929|NCT02233647|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
79340930|NCT02233413|Device|Active LLLT helmet application|LED helmet applied with light activated
79340931|NCT02233413|Device|Non-active LLLT helmet application|LED helmet applied without light activated
79340932|NCT04778631|Device|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
79340933|NCT04778631|Device|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
79340934|NCT01632579|Drug|LY3023703|Administered orally
79491143|NCT00000356|Drug|LAAM|
79491144|NCT04143373|Procedure|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
79491145|NCT00000374|Drug|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
79491146|NCT00000374|Drug|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
79656252|NCT04533295|Device|sham acupuncture and IVF|Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
79656253|NCT04532944|Diagnostic Test|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
79998546|NCT04462965|Combination Product|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
79491147|NCT00002042|Drug|Epoetin alfa|
79823634|NCT00790725|Other|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
79823635|NCT00790725|Other|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
79656254|NCT04533061|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
79656255|NCT00239018|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79656256|NCT04532905|Other|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
79340935|NCT01632579|Drug|Placebo|Administered orally
79491148|NCT03789175|Dietary Supplement|Nicotinamide Riboside (NR)|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
79656257|NCT02216734|Behavioral|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
79656258|NCT02216890|Drug|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
79340936|NCT01632579|Drug|Celecoxib|Administered orally
79340937|NCT01632345|Drug|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
79340938|NCT01632345|Drug|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
79491149|NCT00381056|Behavioral|Labor and Delivery Team Coordination Course|
79491150|NCT00002048|Drug|Zidovudine|
79491151|NCT04130425|Device|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
79491152|NCT04130425|Device|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
79491153|NCT04130425|Device|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
79491154|NCT00001136|Biological|ALVAC-HIV MN120TMG (vCP205)|
79491155|NCT00002054|Drug|Pentamidine isethionate|
79491156|NCT00000386|Behavioral|Exposure and Response Prevention|
79491157|NCT00000386|Behavioral|Family Treatment Program|
79491158|NCT00000386|Behavioral|Relaxation Training|
79491159|NCT00000386|Behavioral|Behavior therapy|
79491160|NCT00000386|Behavioral|Family Counseling|
79491161|NCT00000398|Behavioral|Coping skills training|
79491162|NCT00000398|Behavioral|Physical exercise training|
79491163|NCT00000398|Behavioral|Coping skills training plus physical exercise training|
79491164|NCT00002060|Drug|Inosine pranobex|
79491165|NCT00002066|Drug|Thymopentin|
79491166|NCT00002072|Drug|Epoetin alfa|
79491167|NCT00002078|Drug|Interferon alfa-n3|
79491168|NCT00000404|Behavioral|Patient education in self-care of knee OA|
79491169|NCT00000434|Behavioral|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
79491170|NCT00000440|Drug|naltrexone (Revia)|
79656259|NCT04532983|Procedure|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
79656260|NCT04532983|Procedure|mesh placement without fixation|mesh placement in preperitoneal space without fixation
79656261|NCT04532476|Device|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH & Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
79656262|NCT04532671|Other|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
79340939|NCT01632345|Drug|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
79656263|NCT04532671|Other|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
79656264|NCT04532671|Other|indirect resin composite|CADCAM resin composite blocks using milling process
79491171|NCT00000440|Drug|sertraline (Zoloft)|
79491172|NCT00002084|Drug|Valacyclovir hydrochloride|
79491173|NCT00002084|Drug|Acyclovir|
79491174|NCT00000446|Drug|sertraline (Zoloft)|
79340940|NCT01632345|Drug|Placebo for Doravirine|Placebo tablets matching doravirine
79340941|NCT01632345|Drug|Placebo for Efavirenz|Placebo tablets matching efavirenz
79491175|NCT04131517|Drug|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
79491176|NCT04131517|Drug|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
79491177|NCT00001256|Drug|prednisone and methotrexate|
79491178|NCT00000452|Drug|naltrexone (Revia)|
79340942|NCT02232243|Drug|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
79340943|NCT02232243|Drug|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
79340944|NCT04776837|Behavioral|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
79340945|NCT02205333|Biological|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
79340946|NCT02205333|Biological|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
79491179|NCT00000452|Behavioral|Compliance Enhancement Tech.|
79491180|NCT00000452|Behavioral|Cognitive Behavior Therapy|
79491181|NCT00377533|Device|wheelchair rear anti-tip device|assistive device
79491182|NCT00000458|Drug|sertraline (Zoloft)|
79491183|NCT00000458|Behavioral|cognitive behavior therapy|
79491184|NCT00000470|Procedure|cardiac surgical procedures|
79491185|NCT00000470|Procedure|cardiopulmonary bypass|
79491186|NCT03782233|Drug|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
79491187|NCT03782233|Drug|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
79491188|NCT00002090|Drug|Azithromycin|
79491189|NCT00002096|Drug|Zidovudine|
79491190|NCT00002096|Drug|Didanosine|
79491191|NCT00002096|Drug|Ganciclovir|
79491192|NCT04285489|Device|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
79491193|NCT00002102|Drug|Trimetrexate glucuronate|
79491194|NCT00002102|Drug|Leucovorin calcium|
79491195|NCT00380666|Procedure|PET/CT scan|
79491196|NCT00002108|Drug|Lamivudine|
79491197|NCT00002108|Drug|Zidovudine|
79491198|NCT04317313|Other|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
79491199|NCT00381134|Drug|losartan 100 mg orally once daily|
79491200|NCT00381134|Drug|spironolactone 25 mg orally once daily|
79491201|NCT00381134|Drug|placebo once orally once daily|
79491202|NCT04714021|Other|CO2|to insufflate CO2 into the stomach instead of air during the PEG
79340947|NCT02205333|Biological|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
79491203|NCT04714021|Other|air|to insufflate air into the stomach instead of CO2 during the PEG
79491204|NCT00002114|Drug|Procysteine|
79491205|NCT00378001|Drug|FSH-IBSA|
79491206|NCT00378001|Drug|GONAL-F|
79491207|NCT00000506|Drug|fenfluramine|
79491208|NCT00000506|Drug|phentermine|
79656265|NCT00239057|Drug|Enteric-Coated Mycophenolate Sodium|
79656266|NCT04532593|Procedure|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
79656267|NCT04532593|Procedure|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
79656268|NCT02216968|Behavioral|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
79340948|NCT02205333|Biological|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
79656269|NCT00238082|Drug|HFA-134A Beclomethasone DIpropionate (QVAR)|
79656270|NCT02217007|Drug|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
79656271|NCT02217046|Procedure|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
79656272|NCT02217124|Other|dried apples|120 calories
79656273|NCT02217124|Other|muffin|120 calories
79823636|NCT00785811|Drug|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
79340949|NCT04776369|Drug|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
79340950|NCT04776369|Drug|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
79340951|NCT04776369|Drug|IV saline|Saline IV 50 ml
79340952|NCT02230683|Drug|IDN-6556|25 mg BID
79340953|NCT02230527|Drug|Ticagrelor|90mg twice a day by mouth
79340954|NCT02230527|Drug|Clopidogrel|75mg once a day by mouth
79340955|NCT02204319|Device|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
79491209|NCT00000512|Drug|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
79491210|NCT00000512|Drug|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
79491211|NCT00000512|Drug|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
79491212|NCT00000512|Other|Placebo for colestipol|Placebo for colestipol.
79491213|NCT00000512|Other|Placebo for lovastatin|Placebo for lovastatin
79491214|NCT00000536|Behavioral|sodium, dietary|
79491215|NCT00380822|Drug|miglitol|
79491216|NCT03777865|Biological|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
79491217|NCT00000542|Drug|Inhibitors, ACE|
79491218|NCT00000542|Drug|amlodipine|
79491219|NCT00000542|Drug|lisinopril|
79491220|NCT00000542|Drug|doxazosin|
79491221|NCT00000542|Drug|chlorthalidone|
79491222|NCT00000542|Drug|pravastatin|
79491223|NCT00000542|Behavioral|diet, fat-restricted|
79491224|NCT04109443|Behavioral|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
79491225|NCT04109443|Behavioral|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
79656274|NCT05897879|Biological|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
79491226|NCT00000548|Procedure|mechanical ventilation|
79491227|NCT04107493|Device|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
79491228|NCT04107493|Device|Mobi|ResMed's variant of POC
79491229|NCT00002120|Drug|Trimetrexate glucuronate|
79491230|NCT00002120|Drug|Trimethoprim|
79656275|NCT05897879|Biological|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
79656276|NCT05897762|Behavioral|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
79340956|NCT02204007|Device|3D imaging & surrogate bone model|3D imaging & surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
79340957|NCT02203851|Drug|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
79340958|NCT02228967|Behavioral|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
79491231|NCT00002120|Drug|Sulfamethoxazole|
79656277|NCT05897749|Other|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
79340959|NCT03155061|Drug|ONO-4578|ONO-4578 specified dose on specified days
79491232|NCT00002120|Drug|Dapsone|
79491233|NCT00002120|Drug|Leucovorin calcium|
79491234|NCT00002126|Drug|Filgrastim|
79656278|NCT05897749|Other|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
79656279|NCT05897723|Device|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
79340960|NCT03155061|Drug|ONO-4538|ONO-4538 specified dose on specified days
79656280|NCT05897710|Other|Virtual World-Based Cardiac Rehabilitation (VWCR)|12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.
79823637|NCT00785811|Drug|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
79340961|NCT02985411|Behavioral|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
79491235|NCT03231397|Drug|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
79491236|NCT03231397|Drug|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
79491237|NCT03231397|Diagnostic Test|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
79491238|NCT03189433|Drug|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
79491239|NCT00002132|Drug|Itraconazole|
79491240|NCT00002132|Drug|Fluconazole|
79491241|NCT00002138|Drug|Tecogalan sodium|
79491242|NCT03776539|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
79491243|NCT00002144|Drug|Foscarnet sodium|
79491244|NCT00000578|Drug|theophylline|
79491245|NCT00000578|Drug|beclomethasone|
79491246|NCT03774745|Drug|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
79491247|NCT03774745|Drug|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
79491248|NCT03774745|Drug|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
79491249|NCT00000584|Drug|immunoglobulins|
79491250|NCT00000590|Drug|immunoglobulins|
79491251|NCT03769207|Device|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
79998547|NCT01339585|Device|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
79998548|NCT04004325|Drug|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
79491252|NCT00000614|Drug|warfarin|
79491253|NCT02973464|Drug|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
79998549|NCT04004325|Drug|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
79491254|NCT02973464|Drug|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
79491255|NCT00000626|Drug|Vinblastine sulfate|
79491256|NCT00000626|Drug|Dacarbazine|
79491257|NCT00000626|Drug|Filgrastim|
79340962|NCT02985411|Other|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
79340963|NCT02227875|Drug|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
79340964|NCT02227875|Drug|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
79340965|NCT02203149|Drug|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
79340966|NCT02203149|Drug|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
79340967|NCT02203149|Drug|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
79340968|NCT02203149|Drug|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
79340969|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
79340970|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
79340971|NCT02202759|Drug|MLN0264|MLN0264 IV infusion
79340972|NCT02226549|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
79340973|NCT02226549|Drug|VDV|VDV 80 mg tablet administered orally once daily
79340974|NCT02226549|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79340975|NCT02226003|Drug|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
79340976|NCT02226003|Drug|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
79340977|NCT02226003|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
79340978|NCT02226003|Drug|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
79340979|NCT02226003|Drug|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
79340980|NCT02225223|Device|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
79491258|NCT00000626|Drug|Bleomycin sulfate|
79340981|NCT02225223|Device|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
79340982|NCT02469519|Drug|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
79340983|NCT02469519|Other|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
79340984|NCT01634139|Drug|Tiotropium low dose QD|2 actuations once daily in the evening
79491259|NCT00000626|Drug|Doxorubicin hydrochloride|
79491260|NCT03766165|Behavioral|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
79491261|NCT03766165|Behavioral|Control|Participants will receive job announcements only.
79823638|NCT00782613|Drug|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
79340985|NCT01634139|Drug|Tiotropium high dose QD|2 actuations once daily in the evening
79340986|NCT01634139|Drug|Placebo|2 actuations once daily in the evening
79491262|NCT00002150|Drug|Celgosivir hydrochloride|
79491263|NCT00001382|Biological|PROSTVAC|
79491264|NCT03109873|Radiation|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
79491265|NCT03109873|Drug|Metformin Hydrochloride|Given orally
79491266|NCT03109873|Other|Placebo|Given orally
79340987|NCT02224755|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
79340988|NCT02224755|Device|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
79340989|NCT02404441|Biological|PDR001|anti-PD1 antibody
79340990|NCT02101281|Drug|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
79340991|NCT02101281|Drug|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
79340992|NCT02224599|Biological|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
79340993|NCT02224599|Drug|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
79340994|NCT02224599|Drug|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
79340995|NCT02201901|Drug|SOF/VEL|400/100 mg tablets administered orally once daily
79340996|NCT02201901|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79340997|NCT04775043|Diagnostic Test|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
79340998|NCT02201277|Device|Filter Placed|
79340999|NCT02224053|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
79491267|NCT04713254|Drug|Lu AG06466|10, 20, 30 mg/day oral capsules on Day 5-18
79491268|NCT04713254|Other|Midazolam|4 mg syrup, oral single dose on Day 1 and Day 15
79491269|NCT04713254|Other|Metoprolol|100 mg tablets, oral single dose on Day 1 and Day 15
79491270|NCT04713254|Other|Bupropion|100 mg tablets, oral single dose on Day 3 and Day 17
79491271|NCT00002156|Drug|Fomivirsen sodium|
79491272|NCT00002156|Drug|Ganciclovir|
79491273|NCT04092907|Drug|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
79491274|NCT04092907|Drug|placebo|Ophthalmic Solution
79491275|NCT00002162|Drug|Saquinavir|
79491276|NCT00002162|Drug|Lamivudine|
79491277|NCT00002162|Drug|Stavudine|
79491278|NCT00002162|Drug|Zidovudine|
79491279|NCT00002162|Drug|Zalcitabine|
79491280|NCT00002162|Drug|Didanosine|
79491281|NCT00000638|Drug|Isoniazid|
79491282|NCT00000638|Drug|Pyrazinamide|
79491283|NCT00000638|Drug|Pyridoxine hydrochloride|
79491284|NCT00000638|Drug|Rifampin|
79491285|NCT04086433|Device|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
79491286|NCT00000650|Drug|Ditiocarb sodium|
79491287|NCT00000656|Drug|Zidovudine|
79491288|NCT00000656|Drug|Didanosine|
79491289|NCT00001430|Procedure|PBSC|
79491290|NCT00001430|Drug|IL-2|
79491291|NCT00001430|Drug|EPOCH II|
79491292|NCT00000662|Drug|Zidovudine|
79491293|NCT00002168|Drug|Indinavir sulfate|
79491294|NCT00002168|Drug|Lamivudine|
79491295|NCT00002168|Drug|Stavudine|
79491296|NCT00002168|Drug|Zidovudine|
79491297|NCT00002168|Drug|Didanosine|
79491298|NCT00001442|Drug|paclitaxel concurrent with radiation therapy|
79491299|NCT00002174|Drug|Thalidomide|
79491300|NCT04710212|Other|No intervention.|Observational study with no intervention.
79491301|NCT00000668|Drug|Ganciclovir|
79491302|NCT00000680|Drug|Zidovudine|
79491303|NCT00000680|Drug|Aldesleukin|
79341000|NCT02224053|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
79341001|NCT02224053|Drug|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
79341002|NCT02224053|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
79341003|NCT04774731|Other|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
79341004|NCT04774107|Drug|P1101 + Ribavirin|P1101 400 µg SC
79341005|NCT02457793|Drug|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
79341006|NCT02457793|Drug|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
79341007|NCT01650259|Drug|OAD|OAD except Trazenta tablets
79656281|NCT05897710|Other|Center-Based Cardiac Rehabilitation (CBCR)|Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
79656282|NCT05897645|Other|Registration|collect clinical date, assess the morphologic characteristics of plaque
79341008|NCT01650259|Drug|Trazenta|Linagliptin
79341009|NCT04908085|Behavioral|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
79341010|NCT02434939|Drug|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
79341011|NCT02434939|Drug|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
79341012|NCT02434471|Device|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~Respiratory-triggered T1w DISCO LAVA precontrast~Respiratory-triggered T1w DISCO LAVA in the portal venous phase~Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
79341013|NCT02457637|Other|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
79341014|NCT02457325|Drug|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
79341015|NCT02457325|Drug|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
79341016|NCT02434081|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
79491304|NCT00000692|Drug|Butyldeoxynojirimycin|
79491305|NCT00001460|Behavioral|inpatient evaluation and management|
79656283|NCT05897606|Combination Product|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
79656284|NCT05897606|Combination Product|Placebo|Placebo
79656285|NCT05897580|Behavioral|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
79341017|NCT02222493|Biological|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
79341018|NCT02222493|Biological|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
79341019|NCT02433379|Device|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
79341020|NCT01439997|Drug|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
79341021|NCT02199795|Device|Contralaterally Controlled Neuromuscular Electrical Stimulation|
79341022|NCT02199795|Device|Cyclic Neuromuscular Electrical Stimulation|
79341023|NCT02403817|Behavioral|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
79341024|NCT02403817|Behavioral|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
79491306|NCT00000698|Drug|Ganciclovir|
79491307|NCT03764449|Drug|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
79491308|NCT03764449|Drug|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
79656286|NCT05897580|Behavioral|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
79656287|NCT05897567|Other|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
79656288|NCT05897567|Other|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
79823639|NCT00782613|Drug|Placebo|Placebo in a cream formulation
79341025|NCT02403817|Behavioral|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
79341026|NCT04773249|Device|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
79491309|NCT00002180|Drug|Tenofovir|
79491310|NCT00002186|Drug|Crofelemer|
79491311|NCT00002186|Drug|Acyclovir|
79491312|NCT00001502|Drug|RMP-7 and carboplatin|
79491313|NCT04084015|Device|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
79491314|NCT00002192|Drug|Rifapentine|
79491315|NCT00002192|Drug|Ethambutol hydrochloride|
79491316|NCT00002192|Drug|Clarithromycin|
79491317|NCT00002192|Drug|Azithromycin|
79491318|NCT00002198|Drug|Abacavir sulfate|
79491319|NCT00000704|Drug|Zalcitabine|
79491320|NCT03061279|Device|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
79491321|NCT03061279|Device|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
79491322|NCT00000728|Drug|Zidovudine|
79491323|NCT00000728|Drug|Aldesleukin|
79491324|NCT00001520|Drug|neostigmine|
79998550|NCT04004325|Other|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
79491325|NCT03763747|Device|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
79656289|NCT05897567|Other|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
79656290|NCT05897528|Other|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
79341027|NCT04773249|Device|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
79823640|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
79998551|NCT05208489|Other|there is no intervention involved in this study|there is no intervention involved in this study.
79341028|NCT04189653|Other|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
79341029|NCT02403271|Drug|Ibrutinib|BTK Inhibitor
79341030|NCT02403271|Drug|Durvalumab|Anti PDL-1
79341031|NCT02219685|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79341032|NCT02219685|Drug|Placebo|Tablet administered orally once daily
79491326|NCT00002204|Biological|HIV p24/MF59 Vaccine|
79491327|NCT00001526|Drug|Daclizumab (Zenapax)|
79491328|NCT00002294|Drug|Fluconazole|
79491329|NCT03758365|Drug|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79491330|NCT03758365|Drug|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79491331|NCT03758365|Drug|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79491332|NCT03758365|Drug|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79491333|NCT03758365|Drug|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79491334|NCT03758365|Drug|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79491335|NCT03758365|Drug|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
79823641|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
79823642|NCT00790881|Drug|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
79823643|NCT00790881|Drug|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
79491336|NCT00002300|Drug|Megestrol acetate|
79491337|NCT00001538|Biological|APL 400-003|
79656291|NCT05897515|Diagnostic Test|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B & COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
79656292|NCT05897476|Other|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
79341033|NCT02457247|Drug|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
79341034|NCT02457247|Drug|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
79341035|NCT02457247|Drug|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
79341036|NCT04929535|Drug|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
79341037|NCT02402647|Behavioral|CREST|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
79341038|NCT02402647|Behavioral|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
79341039|NCT00752583|Procedure|Peritoneal dialysis|Blood, urine and dialysate sampling
79341040|NCT00752583|Procedure|Haemodialysis|Blood, urine and dialysate sampling
79341041|NCT02198235|Drug|Dexamethasone|
79341042|NCT02198235|Drug|Buprenorphine|
79491338|NCT03757039|Device|Multifocal soft contact lenses|Commercially available contact lenses
79491339|NCT03757039|Other|Progressive addition lens spectacles|Per subject's habitual prescription
79491340|NCT00002306|Drug|Fluconazole|
79491341|NCT00002210|Drug|Delavirdine mesylate|
79491342|NCT00381212|Biological|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
79491343|NCT00002216|Drug|Lamivudine/Zidovudine|
79491344|NCT00002216|Drug|Abacavir sulfate|
79491345|NCT00002216|Drug|Amprenavir|
79491346|NCT00002216|Drug|Nelfinavir mesylate|
79491347|NCT00002222|Drug|Valganciclovir|
79491348|NCT00002312|Drug|Delavirdine mesylate|
79491349|NCT00002312|Drug|Zidovudine|
79656293|NCT05897424|Drug|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
79491350|NCT04072237|Biological|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
79491351|NCT00002318|Drug|Doxorubicin hydrochloride (liposomal)|
79491352|NCT00002318|Drug|Bleomycin sulfate|
79491353|NCT00002318|Drug|Vincristine sulfate|
79491354|NCT00002318|Drug|Doxorubicin hydrochloride|
79656294|NCT05897411|Behavioral|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
79984822|NCT03196102|Behavioral|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
79984823|NCT03196102|Behavioral|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
79341043|NCT04917133|Behavioral|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
79341044|NCT04917133|Other|Control|classic 4-week rehabilitation program (standard care)
79341045|NCT04916431|Drug|mRNA-6231|Sterile frozen liquid dispersion for injection
79341046|NCT00346125|Biological|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
79341047|NCT00346125|Drug|doxorubicin hydrochloride|65 mg/m^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
79984824|NCT03192514|Other|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
79656295|NCT05897411|Behavioral|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
79341048|NCT00346125|Drug|ifosfamide|9 g/m^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m^2 by continuous IV infusion over 7 days beginning on day 1
79823644|NCT00782691|Other|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
79341049|NCT00346125|Drug|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
79341050|NCT00346125|Procedure|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
79341051|NCT00346125|Radiation|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
79491355|NCT00381290|Behavioral|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
79491356|NCT00381290|Behavioral|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
79491357|NCT03743311|Procedure|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
79491358|NCT03743311|Drug|Detralex|Conservative treatment of Hemorhoid
79491359|NCT03743311|Other|Combined therapy|Surgical + conservative treatment of Hemorhoid
79491360|NCT00380900|Drug|AGG-523|
79491361|NCT00002228|Drug|Enfuvirtide|
79491362|NCT04714177|Drug|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
79823645|NCT01029769|Drug|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
79823646|NCT02557945|Drug|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
79823647|NCT02557945|Drug|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
79984825|NCT02448940|Dietary Supplement|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
79984826|NCT02448940|Dietary Supplement|lactose|2 capsule a day containing lactose
79341052|NCT04418349|Procedure|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
79656299|NCT05897372|Drug|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
79984827|NCT03193294|Diagnostic Test|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
79341053|NCT02253147|Device|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
79341054|NCT02217501|Drug|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
79341055|NCT02217501|Drug|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
79656300|NCT05897359|Behavioral|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
79823648|NCT03268070|Device|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
79984828|NCT03193450|Behavioral|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
79341056|NCT01649869|Other|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
79341057|NCT01649869|Drug|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
79341058|NCT02197377|Device|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
79491363|NCT04714177|Drug|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
79491364|NCT00001628|Drug|Angiotensin II type 1 receptor antagonists|
79491365|NCT00002234|Drug|Efavirenz|
79491366|NCT00002234|Drug|Adefovir dipivoxil|
79491367|NCT00002234|Drug|Lamivudine|
79491368|NCT00002234|Drug|Didanosine|
79656301|NCT05897359|Behavioral|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
79823649|NCT03268070|Device|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
79491369|NCT00002324|Drug|Nevirapine|
79491370|NCT00002324|Drug|Zidovudine|
79491371|NCT00002330|Drug|Ganciclovir|
79491372|NCT03740659|Drug|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
79491373|NCT03740659|Drug|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
79491374|NCT03740659|Drug|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
79491375|NCT00002336|Drug|Clarithromycin|
79491376|NCT00001646|Drug|Voriconazole|
79491377|NCT00001646|Drug|Amphotericin B|
79491378|NCT00001658|Drug|Amoxicillin|
79491379|NCT00378469|Behavioral|45 minute exercise on ergocycle|
79491380|NCT00002252|Drug|Octreotide|
79491381|NCT03738163|Device|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
79491382|NCT00002342|Drug|Tecogalan sodium|
79491383|NCT02757547|Device|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
79341059|NCT02197377|Device|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
79341060|NCT02400307|Drug|Bictegravir|75 mg tablet administered orally
79341061|NCT02196675|Device|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
79491384|NCT02757547|Device|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
79656302|NCT05897346|Other|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
79341062|NCT04772703|Diagnostic Test|COMET ASSAY|The description in the detailed description of the study
79341063|NCT02399449|Drug|Brand sodium ferric gluconate|brand product
79341064|NCT02399449|Drug|Generic sodium ferric gluconate|generic product
79341065|NCT02217345|Drug|Growth hormone|growth hormone, Genotropin (Pfizer)
79491385|NCT00378157|Behavioral|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
79491386|NCT00002348|Drug|Mitoguazone|
79341066|NCT02217345|Drug|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
79491387|NCT02721277|Drug|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
79491388|NCT00002258|Drug|Interleukin-3|
79656303|NCT05897346|Other|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
79656304|NCT05897294|Drug|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
79656305|NCT05897255|Device|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
79656306|NCT05897203|Drug|TAZCOV|Herbal Syrup
79656307|NCT05897203|Drug|Vidicine|Herbal Syrup
79656308|NCT05897112|Drug|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
79656309|NCT05897112|Drug|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
79656310|NCT05897060|Device|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
79656311|NCT05897047|Combination Product|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
79984829|NCT03193450|Behavioral|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
79998552|NCT05185063|Diagnostic Test|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
79998553|NCT01339663|Drug|cyclophosphamide|Given IV
79998554|NCT01339663|Biological|aldesleukin|Given SC
79491389|NCT00002264|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
79491390|NCT00378235|Drug|IL13-PE38QQR|
79491391|NCT00002270|Drug|Interferon alfa-2b|
79491392|NCT00002270|Drug|Zidovudine|
79491393|NCT00002354|Drug|Indinavir sulfate|
79491394|NCT00002354|Drug|Stavudine|
79491395|NCT00002360|Drug|Didanosine|
79656312|NCT05896982|Other|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
79656313|NCT05896982|Other|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
79656314|NCT05896982|Other|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
79656315|NCT05896956|Other|no interventions|no interventions
79656317|NCT05896930|Drug|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
79813905|NCT04029740|Behavioral|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert & Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
79813906|NCT04029740|Other|No intervention|Healthy controls will not receive any intervention.
79998555|NCT01339663|Biological|autologous tumor cell vaccine|Receive T-APC via IV
79341067|NCT01652287|Drug|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
79656318|NCT05896930|Drug|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
79998556|NCT01339663|Other|laboratory biomarker analysis|Correlative studies
79998557|NCT01339663|Other|immunologic technique|Correlative studies
79656319|NCT05896930|Drug|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
79998558|NCT01339663|Other|immunohistochemistry staining method|Correlative studies
79998559|NCT01339663|Genetic|polymerase chain reaction|Correlative studies
79341068|NCT01652287|Other|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
79341069|NCT02251743|Device|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~Average voltage of theta waves~Average voltage of beta~Average ratio of theta to beta power (TBR)"
79341070|NCT04189575|Other|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
79656320|NCT05896930|Drug|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
79341071|NCT02428855|Drug|Dasatinib|
79341072|NCT02428699|Other|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
79341073|NCT02428699|Other|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
79656321|NCT05896930|Drug|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
79656322|NCT05896930|Drug|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
79813907|NCT00631696|Drug|Pregabalin|pregabalin 600 mg given twice a day
79341074|NCT02428231|Drug|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
79341075|NCT02397889|Drug|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
79341076|NCT02397889|Drug|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
79341077|NCT02396953|Drug|Lanreotide PRF|
79341078|NCT04905589|Dietary Supplement|BetaQuik™|MCT (Medium chain triglycerides)
79341079|NCT04905589|Dietary Supplement|WheyBasics|Whey Protein Isolate
79341080|NCT04905589|Other|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
79341081|NCT02387983|Drug|Posaconazole|Posaconazole 300 mg solid oral tablet
79341082|NCT02395627|Drug|Tamoxifen|
79656323|NCT05896930|Drug|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
79656324|NCT05896930|Drug|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
79813908|NCT00631696|Drug|Placebo|Placebo
79341083|NCT02395627|Drug|Vorinostat|
79341084|NCT02395627|Drug|Pembrolizumab|
79341085|NCT02395471|Device|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
79341086|NCT02395081|Dietary Supplement|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
79341087|NCT02395081|Dietary Supplement|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
79341088|NCT02395081|Dietary Supplement|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
79341089|NCT02394925|Device|Multifocal Test Contact lens|Used in a daily wear modality
79341090|NCT02427607|Drug|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
79341091|NCT02425111|Drug|Vedolizumab|Vedolizumab intravenous injection
79341092|NCT04916119|Drug|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
79341093|NCT02424565|Drug|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
79341094|NCT02424565|Other|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
79341095|NCT02424253|Drug|ZPL-3893787|ZPL-3893787
79656325|NCT05896930|Drug|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
79656326|NCT05896930|Drug|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
79656327|NCT05896904|Diagnostic Test|Echocardiography|Echocardiography
79656328|NCT05896852|Behavioral|physical activity|Participants will increase their physical activity through walking.
79656329|NCT05896826|Device|Magnetometer|inspection equipment for magnetocardiography
79341096|NCT02424253|Drug|Placebo|Matched Placebo
79341097|NCT02393755|Drug|Capecitabine|Given PO
79813909|NCT04021628|Other|No intervention- not applicable|No intervention - not applicable
79341098|NCT02393755|Other|Laboratory Biomarker Analysis|Correlative studies
79341099|NCT02393755|Drug|Nintedanib|Given PO
79341100|NCT02393755|Other|Pharmacological Study|Correlative studies
79341101|NCT05454319|Device|Biofeedback|Home-based biofeedback with medical device
79341102|NCT02393209|Drug|Docetaxel|Docetaxel intravenous infusion
79341103|NCT02393209|Drug|TAK-117|TAK-117 Tablets
79491396|NCT03733483|Behavioral|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
79491397|NCT00002276|Drug|Ibuprofen|
79491398|NCT00002276|Drug|Zidovudine|
79656330|NCT05896813|Drug|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
79656331|NCT05896787|Drug|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
79656332|NCT05896722|Other|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
79656333|NCT05896722|Other|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
79656334|NCT05896722|Other|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
79656335|NCT05896722|Other|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
79813910|NCT04021004|Other|Survey Questionnaire|Survey Questionnaire
79813911|NCT04430140|Device|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
79341104|NCT02424097|Drug|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste & MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
79341105|NCT02424097|Drug|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
79341106|NCT02392507|Drug|Necitumumab|Administered IV
79341107|NCT02392507|Drug|Nab-Paclitaxel|Administered IV
79341108|NCT02392507|Drug|Carboplatin|Administered IV
79341109|NCT04904341|Drug|Cerebrolysin|neuroprotection treatment
79341110|NCT01651117|Behavioral|Peer Mentoring|Patients will receive peer mentoring.
79341111|NCT02386189|Behavioral|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
79341112|NCT02385799|Drug|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
79341113|NCT02385799|Drug|Sertraline|Active medication
79341114|NCT02422303|Drug|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
79341115|NCT02392195|Other|Non-interventional|Observational
79341116|NCT02391961|Drug|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
79491399|NCT05752370|Device|High flow oxygen|Use of HFO
79491400|NCT05752370|Other|Usual care|Room air or normal flow oxygen
79813912|NCT00822562|Other|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
79813913|NCT00822562|Procedure|surgery|only surgery
79813914|NCT00631540|Device|Formula Balloon-Expandable Stent|renal artery stenting
79341117|NCT02391961|Drug|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
79491401|NCT00378547|Drug|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
79491402|NCT00378547|Drug|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
79491403|NCT00378547|Drug|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
79341118|NCT02384941|Drug|Placebo|Placebo once daily, before first meal of the day.
79491404|NCT00002282|Drug|Clotrimazole|
79491405|NCT00002282|Drug|Fluconazole|
79341119|NCT02384941|Drug|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
79341120|NCT02384551|Other|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
79341121|NCT02384395|Drug|Dolutegravir 50 mg|Initial therapy for AHI
79491406|NCT02658877|Drug|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
79491407|NCT02658877|Drug|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
79491408|NCT00002288|Drug|Zidovudine|
79491409|NCT00002366|Drug|Ritonavir|
79491410|NCT00378313|Drug|gemcitabine, epirubicin, paclitaxel|
79491411|NCT00002372|Drug|Indinavir sulfate|
79341122|NCT02384395|Drug|Lamivudine 300 mg|Initial therapy for AHI
79813915|NCT02608112|Drug|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
79341123|NCT02384395|Drug|Abacavir 600 mg|Initial therapy for AHI
79341124|NCT02420353|Drug|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
79341125|NCT02420353|Drug|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
79341126|NCT02391337|Drug|Bisoprolol|Drug intervention
79341127|NCT02391337|Drug|Digoxin|Drug intervention
79341128|NCT02382991|Device|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
79491412|NCT00002372|Drug|Amprenavir|
79491413|NCT00002372|Drug|Nelfinavir mesylate|
79491414|NCT00002372|Drug|Saquinavir|
79341129|NCT02382991|Device|NMPK-3C60|1 month with NMPK - 3 months with 3C60
79341130|NCT02390557|Other|Survey|PDQS survey reports only
79341131|NCT02390557|Other|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
79341132|NCT01649791|Drug|lenalidomide|Given orally
79341133|NCT01649791|Other|laboratory biomarker analysis|Correlative study
79341134|NCT01649791|Procedure|lymph node biopsy|Correlative study
79341135|NCT01649791|Procedure|bone marrow aspiration|Correlative study
79341136|NCT01649791|Other|pharmacological study|Correlative study
79341137|NCT01649791|Other|flow cytometry|Correlative study
79341138|NCT01649557|Drug|OPC-34712|oral administered once daily
79341139|NCT02390245|Other|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
79491415|NCT00002378|Drug|Ritonavir|
79491416|NCT00002378|Drug|Nelfinavir mesylate|
79491417|NCT00002378|Drug|Saquinavir|
79491418|NCT00002378|Drug|Delavirdine mesylate|
79491419|NCT00002378|Drug|Lamivudine|
79491420|NCT00002378|Drug|Stavudine|
79491421|NCT00002378|Drug|Zidovudine|
79491422|NCT02589145|Drug|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
79491423|NCT02589145|Drug|Vorinostat|1000 mg by mouth on Days -9 to -2.
79491424|NCT02589145|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
79491425|NCT02589145|Drug|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
79491426|NCT02589145|Drug|Melphalan|60 mg/m2 by vein on days -3 and -2.
79491427|NCT02589145|Drug|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
79491428|NCT02589145|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
79491429|NCT02589145|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
79491430|NCT02589145|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
79491431|NCT02589145|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
79341140|NCT02390245|Other|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
79656336|NCT05896722|Other|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
79341141|NCT02390245|Other|Usual Care|This group will receive ophthalmic referral.
79341142|NCT02390167|Device|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
79341143|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
79341144|NCT02347657|Drug|Ivacaftor|Tablet, oral use
79341145|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
79341146|NCT02347657|Drug|Ivacaftor placebo|Tablet, oral use
79341147|NCT02347189|Device|Melody Transcatheter Pulmonary Valve PB1016|
79341148|NCT02382133|Device|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
79341149|NCT02346877|Behavioral|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
79341150|NCT02346721|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
79341151|NCT02389621|Drug|Lusutrombopag|Tablets for oral administration
79341152|NCT02389621|Drug|Placebo|Tablets for oral administration
79341153|NCT02388997|Drug|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
79984830|NCT03193606|Other|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
79984831|NCT03032198|Device|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
79998560|NCT01339663|Biological|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
79341154|NCT02388997|Biological|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
79341155|NCT02388763|Device|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
79341156|NCT02388763|Device|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
79341157|NCT02388295|Drug|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
79341158|NCT02388295|Drug|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
79341159|NCT02345161|Drug|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
79341160|NCT02345161|Drug|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
79341161|NCT02345161|Drug|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
79341162|NCT02345161|Drug|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
79491432|NCT02589145|Drug|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
79491433|NCT02589145|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
79656337|NCT05896657|Dietary Supplement|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9 log10 cfu of the strain.
79984832|NCT02448784|Drug|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
79984833|NCT04050488|Drug|Zinc Sulfate|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
79341163|NCT02345161|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
79341164|NCT02251275|Drug|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
79341165|NCT02379637|Drug|N-acetylcysteine|
79341166|NCT02379637|Drug|Placebo|
79341167|NCT02195583|Drug|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
79341168|NCT02195583|Drug|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
79341169|NCT02195583|Drug|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
79341170|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
79341171|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
79984834|NCT04050488|Drug|Placebos|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
79341172|NCT02195583|Drug|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
79341173|NCT02379091|Drug|Namilumab|Namilumab subcutaneous injection
79656338|NCT05896657|Dietary Supplement|Placebo|Oral administration of a capsule containing maltodextrin.
79656339|NCT05896631|Other|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
79656340|NCT05896631|Other|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
79813916|NCT02608112|Drug|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
79341174|NCT02379091|Drug|Placebo|Namilumab placebo-matching subcutaneous injection
79341175|NCT02379091|Drug|Methotrexate|Methotrexate tablets
79341176|NCT02379091|Drug|Folic/folinic acid|Folic/folinic acid tablets
79341177|NCT02378935|Drug|VOX|100 mg tablet(s) administered orally once daily with food
79341178|NCT02378935|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
79813917|NCT00630916|Device|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
79984835|NCT02448628|Drug|CS-3150|
79984836|NCT02449252|Radiation|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
79984837|NCT02449252|Radiation|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
79984838|NCT02449252|Drug|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
79984839|NCT02449252|Drug|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
79984840|NCT02449252|Drug|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
79984841|NCT02449252|Drug|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
79998561|NCT03066999|Procedure|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
79341179|NCT02378935|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79656341|NCT05896605|Drug|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
79656342|NCT05896553|Drug|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
79813918|NCT02549326|Dietary Supplement|vitamin D|
79813919|NCT02549326|Dietary Supplement|Placebo|
79813920|NCT02549404|Drug|KHK7580|Oral administration
79813921|NCT00819598|Procedure|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
79984842|NCT04779554|Drug|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
79341180|NCT02250651|Drug|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
79984843|NCT04779554|Drug|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
79984844|NCT02444260|Drug|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
79341181|NCT02250651|Other|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
79341182|NCT02250651|Drug|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
79491434|NCT02589145|Drug|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
79491435|NCT00002384|Drug|Cidofovir|
79491436|NCT02568007|Drug|Cyproheptadine|
79491437|NCT00002390|Drug|Abacavir sulfate|
79491438|NCT00002396|Drug|Tenofovir disoproxil fumarate|
79491439|NCT02549755|Drug|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
79491440|NCT00002402|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
79491441|NCT00002402|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
79491442|NCT00002402|Biological|Aluminum hydroxide|
79341183|NCT02250651|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
79491443|NCT00002408|Drug|Crofelemer|
79491444|NCT00002414|Drug|CPI-1189|
79491445|NCT00002420|Drug|Emivirine|
79491446|NCT00002420|Drug|Hydroxyurea|
79341184|NCT02377921|Drug|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
79341185|NCT02377921|Drug|Placebo|tablets for oral use
79813922|NCT00819598|Procedure|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
79341186|NCT02311153|Device|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
79341187|NCT02311153|Device|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
79491447|NCT00002420|Drug|Delavirdine mesylate|
79491448|NCT00002420|Drug|Stavudine|
79491449|NCT00002420|Drug|Didanosine|
79491450|NCT00381368|Drug|Ibandronic acid|
79491451|NCT04024501|Drug|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
79491452|NCT04024501|Drug|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
79491453|NCT04024501|Drug|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
79491454|NCT04024501|Drug|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
79491455|NCT04024501|Drug|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
79491456|NCT05717348|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79491457|NCT05709626|Drug|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
79491458|NCT05709626|Drug|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
79656343|NCT05896553|Drug|intranasal Placebo|Administration of intranasal Placebo
79813923|NCT02549248|Other|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
79984845|NCT02444260|Drug|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
79341188|NCT02195427|Device|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
79341189|NCT02195427|Device|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
79341190|NCT02214225|Biological|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
79341191|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
79341192|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
79341193|NCT02250183|Device|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
79984846|NCT02444260|Drug|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
79341194|NCT02250183|Device|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
79341195|NCT02249949|Drug|efatutazone|Given PO
79679451|NCT02941809|Behavioral|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
79679452|NCT02951000|Procedure|platysma suture|
79679453|NCT02951000|Procedure|no platysma suture|
79341196|NCT02249091|Drug|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m^2 or 6 doses of 60 mg per induction cycle).
79341197|NCT02249091|Drug|Idarubicin|Infusion, iv, 10 mg/m^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
79341198|NCT02249091|Drug|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m^2, iv,
79341199|NCT02248857|Other|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
79341200|NCT02248857|Other|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
79341201|NCT02213055|Drug|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
79813924|NCT02549248|Other|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
79984847|NCT02444260|Drug|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
79984848|NCT03010930|Other|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
79998562|NCT03066999|Device|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
79998563|NCT00092599|Drug|MK0653, ezetimibe|
79491459|NCT05707364|Behavioral|Pre-visit Lab Workflow|"Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~Patient contacted to complete labs prior to the scheduled routine physical.~Resulted labs are triaged based on urgency.~After Visit Summary used to communicate about labs and surveys."
79341202|NCT02213055|Drug|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
79341203|NCT02310763|Biological|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
79491460|NCT03538015|Drug|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
79491461|NCT03538015|Drug|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
79491462|NCT03538015|Drug|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
79491463|NCT05752214|Other|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
79491464|NCT00381446|Device|Marketed contact lens care products|
79656344|NCT05896540|Behavioral|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
79656345|NCT05896462|Other|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
79656346|NCT05896449|Diagnostic Test|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of [68Ga]Ga-PSMA-11 (2 MBq per kg body weight).
79656347|NCT05896345|Device|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
79656348|NCT05896345|Combination Product|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
79491465|NCT03342157|Drug|senna/docusate|Stimulant laxative
79656349|NCT05896319|Device|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
79341204|NCT02310763|Drug|Placebo|
79341205|NCT02342743|Device|CEFALY|
79341206|NCT04891315|Diagnostic Test|Blood test for soluble VAP-1 (sVAP-1).|~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
79341207|NCT02377063|Dietary Supplement|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
79341208|NCT02309515|Other|Laboratory Biomarker Analysis|Correlative studies
79341209|NCT02309515|Drug|Lenalidomide|Given PO
79341210|NCT02309515|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
79656350|NCT05896241|Other|non-interventional study|non-interventional study
79813925|NCT02549248|Other|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
79341211|NCT02309359|Biological|ALX-0061|
79341212|NCT02309359|Other|Placebo|
79491466|NCT04331210|Drug|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
79491467|NCT00381524|Behavioral|Increase condom use|Voluntary increase in condom use
79491468|NCT04016077|Drug|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
79491469|NCT00002426|Drug|Adefovir dipivoxil|
79656351|NCT05896176|Diagnostic Test|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
79341213|NCT02309359|Drug|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
79341214|NCT02247531|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
79491470|NCT04021771|Other|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
79656352|NCT05896111|Procedure|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
79341215|NCT02247531|Other|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
79341216|NCT02375971|Drug|Ranibizumab|Administered as an intravitreal injection
79341217|NCT02375971|Procedure|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
79656353|NCT05896072|Procedure|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
79656354|NCT05896072|Procedure|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
79656355|NCT05896059|Drug|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
79813926|NCT02549248|Other|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
79998564|NCT00092599|Drug|Comparator: ezetimibe, placebo|
79341218|NCT02308735|Other|N/A - No intervention|
79491471|NCT00002432|Drug|Foscarnet sodium|
79491472|NCT05701436|Drug|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
79656356|NCT05896059|Drug|Anlotinib|Anlotinib，12mg，oral administration，QD.
79656357|NCT05895994|Drug|RD13-02 cell infusion|CAR-T cells
79813927|NCT02549248|Other|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
79813928|NCT00630292|Other|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
79813929|NCT00822640|Device|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
79813930|NCT00819676|Other|analysis of exhaled breath by biosensors|
79813931|NCT00819676|Other|measurement of exhaled nitric oxide|
79341219|NCT02212197|Drug|leuprolide acetate FluidCrystal® injection depot|
79341220|NCT02212197|Drug|leuprolide acetate|
79656358|NCT05895942|Drug|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
79656359|NCT05895916|Behavioral|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
79656360|NCT05895877|Drug|Goofice®|Once daily before breakfast.
79656361|NCT05895877|Drug|Goofice® Placebo|Once daily before breakfast.
79491473|NCT05701436|Drug|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
79656362|NCT05895864|Drug|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
79984849|NCT03010930|Other|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
79984850|NCT02448472|Other|Observational study, none intervention|
79341221|NCT02193165|Drug|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
79341222|NCT02193165|Drug|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
79491474|NCT05701436|Drug|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
79491475|NCT05701436|Drug|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
79491476|NCT05701436|Drug|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
79491477|NCT05701436|Drug|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
79491478|NCT02487277|Drug|PEGPH20|
79491479|NCT02487277|Drug|Gemcitabine|
79656363|NCT05895851|Radiation|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
79656364|NCT05895812|Drug|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
79679454|NCT02941770|Behavioral|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
79813932|NCT00827320|Drug|Levetiracetam|1000 mg tablet
79813933|NCT00827398|Biological|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
79813934|NCT00626548|Drug|ZD4054|10 mg once daily oral dose
79984851|NCT03195634|Drug|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day
79341223|NCT02193165|Drug|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
79341224|NCT01617460|Drug|Aripiprazole|Flexibly dose administered orally once daily
79341225|NCT01890148|Drug|AZD5069|oral BD administration of 45 mg AZD5069
79656365|NCT05895799|Other|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
79813935|NCT00626548|Drug|Palcebo|Matching Plcebo oral tablet once daily
79813936|NCT00819754|Drug|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
79341226|NCT01889602|Drug|Lorazepam|Lorazepam: 2mg, po, 1x
79341227|NCT01889602|Other|Placebo|Non-active placebo, po, 1x
79341228|NCT01889602|Drug|Topiramate 100mg|Topiramate: 100 mg, po, 1x
79341229|NCT01889602|Drug|Topiramate 150mg|Topiramate: 150 mg, po, 1x
79341230|NCT01889602|Drug|Topiramate 200mg|Topiramate: 200 mg, po, 1x
79341231|NCT01935700|Drug|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
79341232|NCT01618162|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
79491480|NCT02487277|Drug|Nab-paclitaxel|
79491481|NCT00002438|Drug|Itraconazole|
79491482|NCT00002444|Drug|Nitazoxanide|
79491483|NCT02436265|Drug|Dexamethasone|IV dexamethasone
79491484|NCT02436265|Drug|Ropivacaine|Ropivacaine only
79491485|NCT04016623|Device|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
79491486|NCT04016623|Device|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
79491487|NCT05751746|Drug|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
79491488|NCT02973230|Other|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
79491489|NCT03316105|Device|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
79813937|NCT00827476|Procedure|ovarian transplantation|ovarian xenotransplantation or in vitro culture
79491490|NCT00002450|Drug|Tenofovir disoproxil fumarate|
79491491|NCT03277183|Drug|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
79491492|NCT03277183|Drug|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
79491493|NCT00002456|Drug|cyclosporine|
79341233|NCT01618162|Drug|placebo|Injected subcutaneously (under the skin) once daily.
79491494|NCT00002456|Drug|methotrexate|
79491495|NCT00002456|Procedure|allogeneic bone marrow transplantation|
79491496|NCT01525927|Drug|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
79491497|NCT01525927|Radiation|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
79491498|NCT01525927|Radiation|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
79491499|NCT00002474|Drug|carboplatin|
79491500|NCT00002474|Drug|cyclophosphamide|
79491501|NCT00002474|Drug|mitoxantrone hydrochloride|
79491502|NCT00002474|Procedure|autologous bone marrow transplantation|
79491503|NCT00002474|Procedure|bone marrow ablation with stem cell support|
79491504|NCT00002480|Radiation|radiation therapy|
79491505|NCT04013737|Device|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
79491506|NCT05670470|Drug|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
79491507|NCT05670470|Drug|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
79491508|NCT04011631|Procedure|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
79491509|NCT00002492|Drug|cisplatin|
79491510|NCT00002492|Drug|doxorubicin hydrochloride|
79491511|NCT00002492|Drug|isolated limb perfusion|
79491512|NCT00002492|Procedure|conventional surgery|
79491513|NCT00002492|Radiation|brachytherapy|
79491514|NCT00002492|Radiation|radiation therapy|
79491515|NCT05751512|Drug|MRG003|Administered intravenously
79491516|NCT05751512|Drug|Cetuximab injection|Administered intravenously
79491517|NCT05751512|Drug|Methotrexate Injection|Administered intravenously
79491518|NCT02373865|Drug|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
79656366|NCT05895760|Other|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
79813938|NCT00819988|Drug|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
79341234|NCT02193087|Drug|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
79341235|NCT02193087|Drug|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
79341236|NCT02193087|Drug|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
79491519|NCT02373865|Drug|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
79341237|NCT02193087|Drug|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
79341238|NCT01617070|Drug|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
79341239|NCT01617070|Dietary Supplement|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
79341240|NCT04771767|Drug|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
79341241|NCT04771767|Behavioral|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
79491520|NCT02373865|Drug|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
79491521|NCT02373865|Drug|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
79491522|NCT00002498|Drug|CMF regimen|
79491523|NCT00002498|Drug|cyclophosphamide|
79491524|NCT00002498|Drug|fluorouracil|
79491525|NCT00002498|Drug|methotrexate|
79491526|NCT00002498|Drug|mitoxantrone hydrochloride|
79491527|NCT00002504|Biological|aldesleukin|
79491528|NCT00002504|Biological|recombinant interferon alfa|
79491529|NCT02360059|Drug|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
79491530|NCT02360059|Other|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
79491531|NCT02360059|Behavioral|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
79491532|NCT02360059|Other|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
79491533|NCT04006795|Other|Serum|Participants will be topically applied adhesive patch containing developmental serum
79491534|NCT04006795|Other|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
79341242|NCT02341417|Drug|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
79341243|NCT01888900|Drug|DUAL|Asunaprevir and Daclatsvir
79491535|NCT04006795|Other|Cream|Participants will be topically applied adhesive patch containing developmental cream
79491536|NCT04006795|Other|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
79491537|NCT05665790|Radiation|radiotherapy|radiotherapy
79656367|NCT05895708|Other|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
79656368|NCT05895708|Other|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
79341244|NCT01888900|Drug|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
79656369|NCT05895422|Procedure|pyeloplasty|repair of the uPJO
79656370|NCT05895331|Diagnostic Test|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
79984852|NCT02448394|Other|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
79341245|NCT02340949|Drug|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
79341246|NCT02340949|Drug|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
79341247|NCT02340949|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
79341248|NCT02340949|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
79341249|NCT01646203|Biological|IMC-TR1|Administered intravenously
79656371|NCT05894759|Behavioral|Psychological stress relief techniques|Psychological stress relief techniques
79341250|NCT02375347|Other|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
79341251|NCT02374957|Drug|Cilostazol|100 mg twice daily for 90 days
79341252|NCT02374255|Behavioral|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
79341253|NCT02308033|Drug|Metronidazole|
79341254|NCT02308033|Drug|Gel vehicle|
79341255|NCT02339155|Biological|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
79341256|NCT02339155|Biological|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
79341257|NCT02339155|Drug|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
79341258|NCT02211261|Biological|PF-06293620|subcutaneous, single dose 0.3 mg/kg
79813939|NCT00819988|Other|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
79813940|NCT02549482|Other|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
79813941|NCT00827554|Drug|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
79984853|NCT02448550|Drug|Bivalirudin|
79984854|NCT02448550|Drug|Unfractionated heparin|
79984855|NCT02431364|Drug|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
79341259|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
79491538|NCT05665790|Procedure|palliative surgery|palliative surgery
79491539|NCT00002510|Biological|filgrastim|
79491540|NCT00002510|Drug|cyclophosphamide|
79491541|NCT00002510|Drug|etoposide|
79491542|NCT00002510|Drug|mesna|
79491543|NCT00002510|Procedure|peripheral blood stem cell transplantation|
79491544|NCT00002510|Radiation|radiation therapy|
79341260|NCT02211261|Biological|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
79491545|NCT01500109|Drug|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
79491546|NCT01500109|Drug|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
79491547|NCT01500109|Drug|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
79491548|NCT00002516|Biological|dactinomycin|
79491549|NCT00002516|Drug|cyclophosphamide|
79491550|NCT00002516|Drug|doxorubicin hydrochloride|
79491551|NCT00002516|Drug|etoposide|
79491552|NCT00002516|Drug|ifosfamide|
79491553|NCT00002516|Drug|mesna|
79491554|NCT00002516|Drug|vincristine sulfate|
79491555|NCT00002516|Procedure|conventional surgery|
79491556|NCT00002516|Radiation|low-LET cobalt-60 gamma ray therapy|
79491557|NCT00002516|Radiation|low-LET photon therapy|
79491558|NCT00377845|Procedure|Regular Tampax used in 3 hours|
79491559|NCT00002522|Drug|cisplatin|
79491560|NCT00002522|Drug|cyclophosphamide|
79491561|NCT00002522|Drug|etoposide|
79491562|NCT00002522|Procedure|autologous bone marrow transplantation|
79813942|NCT00827554|Procedure|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
79813943|NCT00822796|Device|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
79813944|NCT00822796|Device|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
79984856|NCT02431364|Other|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
79984857|NCT03701750|Drug|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
79341261|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
79341262|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 3 mg/kg
79341263|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
79341264|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 6 mg/kg
79341265|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
79341266|NCT02211261|Biological|PF-06293620|Intravenous infusion single dose 1 mg/kg
79341267|NCT02211261|Biological|Placebo|Intravenous infusion normal saline single dose
79341268|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
79341269|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
79491563|NCT00002522|Procedure|bone marrow ablation with stem cell support|
79491564|NCT00002522|Procedure|peripheral blood stem cell transplantation|
79491565|NCT00002522|Procedure|syngeneic bone marrow transplantation|
79491566|NCT00002522|Radiation|radiation therapy|
79984858|NCT03704402|Other|Alcohol policy|Introduction of new mutual alcohol policy
79491567|NCT02350777|Procedure|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
79491568|NCT02350777|Device|CliniMACS Cell Selection System|
79491569|NCT01482325|Device|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
79491570|NCT00002528|Drug|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
79984859|NCT03704246|Drug|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
79341270|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
79341271|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
79341272|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
79984860|NCT05273684|Other|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
79341273|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
79341274|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
79341275|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
79341276|NCT02170077|Drug|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
79984861|NCT05239910|Drug|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
79984862|NCT03701672|Other|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
79341277|NCT02170077|Drug|Placebo|Placebo tablets administered orally
79341278|NCT02210091|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
79341279|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
79341280|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
79341281|NCT02338999|Radiation|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
79341282|NCT02338999|Drug|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
79341283|NCT02338999|Drug|Placebo|
79341284|NCT02169219|Drug|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~60mg for 2 weeks~40mg for 2 weeks~30mg for 1 week~20mg for 1 week~10mg for 1 week~5mg for 1 week"
79341285|NCT02169219|Drug|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
79341286|NCT02191605|Behavioral|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
79341287|NCT02191605|Behavioral|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
79341288|NCT02191137|Drug|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
79341289|NCT02168439|Drug|Dexmedetomidine|
79341290|NCT02168439|Drug|Midazolam|
79341291|NCT02190591|Device|Peanut Labor Ball|Peanut Labor Ball
79341292|NCT02190435|Device|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
79341293|NCT02190435|Device|Conventional technique|Conventional Technique
79341294|NCT02338843|Drug|LJPC-501|Treatment arm
79341295|NCT02338843|Drug|Placebo|PBO
79341296|NCT02190279|Drug|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
79341297|NCT02190279|Drug|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
79341298|NCT02135445|Drug|TAK-385|TAK-385 tablet
79984863|NCT03624998|Other|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
79984864|NCT03704090|Behavioral|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
79341299|NCT02135445|Drug|Degarelix|Degarelix injection
79656372|NCT05894187|Other|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
79656373|NCT05892965|Other|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
79984865|NCT03704090|Behavioral|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
79984866|NCT03704012|Behavioral|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
79984867|NCT03034460|Drug|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
79341300|NCT02374099|Drug|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
79341301|NCT02374099|Drug|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
79341302|NCT02134977|Drug|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
79341303|NCT02374021|Drug|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
79341304|NCT02374021|Drug|Sulfasalazine|1 gm bid
79341305|NCT02374021|Drug|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
79984868|NCT03034460|Drug|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
79341306|NCT02374021|Drug|Etanercept|50 mg SC weekly
79341307|NCT02374021|Drug|Adalimumab|40 mg SQ every other week
79984869|NCT03034460|Drug|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
79984870|NCT03034460|Drug|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
79341308|NCT02372383|Drug|Ethambutol|Anti-mycobacterial oral drug
79341309|NCT02372383|Drug|Rifampin|Anti-mycobacterial oral drug
79341310|NCT02372383|Drug|Azithromycin|Anti-mycobacterial oral drug
79341311|NCT02372383|Drug|Pancrelipase|Pancreatic enzyme replacement therapy
79341312|NCT01648699|Drug|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
79341313|NCT02134353|Drug|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
79341314|NCT02134353|Drug|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
79341315|NCT01646125|Drug|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
79341316|NCT01646125|Drug|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
79341317|NCT01646125|Drug|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
79341318|NCT01362790|Drug|Pentostatin|Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle
79656374|NCT05892640|Other|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
79984871|NCT04162769|Drug|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
79341319|NCT01362790|Drug|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
79984872|NCT04162769|Drug|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
79341320|NCT01362790|Biological|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
79341321|NCT01362790|Biological|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
79341322|NCT02167893|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
79341323|NCT04759989|Procedure|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
79341324|NCT04759989|Procedure|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
79341325|NCT04759989|Procedure|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
79341326|NCT02167035|Drug|Combigan Two Times Daily (BID)|
79341327|NCT02167035|Drug|Simbrinza Three Times Daily (TID)|
79341328|NCT01615198|Drug|Olmesartan|10 mg, 20 mg, 40 mg capsules
79341329|NCT01615198|Drug|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
79341330|NCT01615198|Drug|LCZ696|100 mg, 200 mg tablets
79341331|NCT02337907|Drug|Placebo|for blinding purposes
79341332|NCT02337907|Drug|Placebo|
79341333|NCT02337907|Drug|BI 409306|
79341334|NCT02337907|Drug|Donepezil|
79341335|NCT01913470|Drug|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
79491571|NCT00002528|Procedure|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
79491572|NCT00002528|Radiation|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
79984873|NCT04162769|Drug|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
79984874|NCT04593602|Behavioral|Early Mobilization|Nurse-driven early mobilization activities twice daily
79984875|NCT04593602|Behavioral|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
79341336|NCT02372071|Device|BiliCare|Two measurements with the BiliCare device
79341337|NCT02337751|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
79341338|NCT02166333|Dietary Supplement|200 IU/d cholecalciferol|
79341339|NCT02166333|Dietary Supplement|1000 IU/d cholecalciferol|
79341340|NCT02166333|Dietary Supplement|2000 IU/d cholecalciferol|
79341341|NCT02166333|Dietary Supplement|4000 IU/d cholecalciferol|
79341342|NCT02132949|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m^2 IV on Day 1 of each cycle q3w.
79341343|NCT02132949|Drug|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m^2) intravenous (IV) given on Day 1 of each cycle q2w.
79341344|NCT02132949|Drug|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m^2 IV for the first cycle and the dose may be escalated to 100 mg/m^2 for subsequent cycles q3w.
79341345|NCT02132949|Drug|Doxorubicin|Participants will receive doxorubicin 60 mg/m^2 IV on Day 1 of each cycle q2w.
79341346|NCT02132949|Drug|Epirubicin|Participants will receive epirubicin 100 mg/m^2 IV on Day 1 of each cycle q3w.
79341347|NCT02132949|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV given weekly.
79341348|NCT02132949|Drug|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
79341349|NCT02132949|Drug|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
79341350|NCT02165397|Drug|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
79341351|NCT02165397|Drug|Placebo|Participants will receive placebo capsules orally.
79341352|NCT02165397|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV.
79341353|NCT02132637|Drug|Insulin Peglispro|Administered SQ
79341354|NCT02132637|Drug|Insulin Glargine|Administered SQ
79341355|NCT02164929|Procedure|TAP block|
79341356|NCT02164929|Procedure|Epidural|
79341357|NCT02164929|Procedure|Paravertebral block|
79341358|NCT02164929|Drug|Acetaminophen 1g IV|
79341359|NCT02164929|Drug|Dexamethasone 4mg|
79341360|NCT02164929|Drug|Midazolam up to 2mg|
79341361|NCT02164929|Drug|Propofol 1-2.5 mg/kg|
79341362|NCT02164929|Drug|Sevoflurane to keep a bispectral index of between 40-60|
79984876|NCT04161131|Behavioral|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
79656375|NCT05892458|Behavioral|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
79984877|NCT03703700|Drug|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
79984878|NCT03703700|Drug|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
79341363|NCT02164929|Drug|Local infiltration with 10 mL of plain ropivacaine 0.25%|
79491573|NCT00002528|Procedure|Axillary clearance|Axillary node dissection.
79656376|NCT05892419|Other|No intervention|There is no intervention
79984879|NCT04743518|Other|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
79984880|NCT04743518|Other|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
79984881|NCT04155047|Combination Product|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
79984882|NCT04155047|Drug|Placebo administered by Magnair|Placebo Inhalation Solution
79984883|NCT03624530|Drug|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
79984884|NCT03624452|Other|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
79984885|NCT03624452|Other|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
79984886|NCT03746327|Drug|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
79984887|NCT03746249|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79984888|NCT03746249|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
79984889|NCT03624686|Other|peripheral blood|draw peripheral blood
79341364|NCT02164929|Drug|Lidocaine|1.5% lidocaine
79341365|NCT02164929|Drug|Epinephrine|1:200,000 epinephrine
79341366|NCT02164929|Drug|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
79491574|NCT02341495|Drug|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
79984890|NCT04152083|Drug|Eptinezumab|Injection for IV administration
79984891|NCT04152083|Drug|Placebo|Injection for IV administration
79984892|NCT03698474|Drug|Natrium picosulfate / Magnesium citrate|bowel preparation formula
79341367|NCT04749615|Drug|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
79341368|NCT04749615|Drug|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
79491575|NCT02341495|Drug|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
79491576|NCT02341495|Drug|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
79491577|NCT00002534|Biological|anti-thymocyte globulin|
79491578|NCT00002534|Drug|cyclophosphamide|
79491579|NCT00002534|Drug|cytarabine|
79491580|NCT00002534|Drug|methylprednisolone|
79491581|NCT00002534|Drug|thiotepa|
79341369|NCT01888432|Drug|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
79341370|NCT01888432|Drug|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
79341371|NCT02188719|Biological|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is <50/mm^3 or when the maximal dose of 4.5/mg/kg has been given.
79341372|NCT02188719|Biological|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
79341373|NCT02188719|Drug|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
79341374|NCT02188719|Drug|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
79341375|NCT02188719|Drug|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
79341376|NCT02188719|Drug|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
79341377|NCT02188719|Drug|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
79341378|NCT02188719|Drug|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
79341379|NCT02188719|Drug|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
79656377|NCT05891015|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
79656378|NCT05887752|Other|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~physiotherapy;~occupational therapy;~sports rehabilitation."
79656379|NCT05887752|Device|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
79813945|NCT00822874|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
79813946|NCT00847379|Drug|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
79813947|NCT02549560|Device|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
79984893|NCT03698474|Drug|Polyethylene glycol / Ascorbic acid|bowel preparation formula
79491582|NCT00002534|Procedure|allogeneic bone marrow transplantation|
79656380|NCT05882552|Diagnostic Test|Tilted Gaze Target Tast|Tilted gaze target tast is playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position.It will be conducted during the first visit. Preoperative intervention will also be conducted before surgery. Postoperative interventions will be conducted at one day, one month, and six months after surgery.
79813948|NCT00820144|Biological|CTB by nasal way|
79341380|NCT02188719|Procedure|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level </=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
79984894|NCT03698474|Drug|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
79341381|NCT02188719|Procedure|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
79341382|NCT02188719|Procedure|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
79984895|NCT02711956|Drug|ZEN003694|
79341383|NCT02188719|Procedure|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
79341384|NCT01934140|Biological|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
79341385|NCT04416100|Diagnostic Test|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
79984896|NCT02711956|Drug|Enzalutamide|
79984897|NCT03698396|Biological|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
79998565|NCT01335841|Device|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
79998566|NCT03737565|Device|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
79341386|NCT04416100|Diagnostic Test|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
79341387|NCT04416100|Biological|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
79341388|NCT01933672|Drug|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
79341389|NCT01933672|Drug|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
79491583|NCT00002534|Procedure|in vitro-treated bone marrow transplantation|
79491584|NCT00002534|Radiation|low-LET electron therapy|
79491585|NCT00002534|Radiation|low-LET photon therapy|
79491586|NCT02320825|Radiation|single-fraction SRS|
79491587|NCT02320825|Radiation|high-dose hypofractionated SRS|
79813949|NCT00820144|Biological|absorption of CTB by oral way|absorption of CTB by oral way
79813950|NCT00820144|Biological|absorption of dukoral by oral way|absorption of dukoral by oral way
79813951|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
79491588|NCT02320825|Behavioral|Quality of Life Measures|
79491589|NCT00002546|Drug|cisplatin|
79491590|NCT00002546|Drug|ifosfamide|
79491591|NCT00002546|Procedure|adjuvant therapy|
79998567|NCT02889133|Drug|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
79491592|NCT00002546|Radiation|radiation therapy|
79491593|NCT01477177|Device|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
79491594|NCT05655884|Other|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
79656381|NCT05882552|Diagnostic Test|Conventional Examination Methods|The conventional examination methods include oculomotor examination, Bielschowsky head tilt test, alternate prism cover test, prism adaptation test, and monocular cover test. They will be conducted during the first visit. Preoperative intervention will also be conducted before surgery.Postoperative interventions will be conducted at one day, one month, and six months after surgery.
79491595|NCT05655884|Other|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
79341390|NCT01933672|Drug|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
79341391|NCT02164539|Drug|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
79341392|NCT02164539|Drug|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
79341393|NCT02164539|Drug|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
79341394|NCT02188485|Behavioral|ENGAGE|Up to 10 sessions delivered in the home.
79491596|NCT00378625|Drug|Artesunate|
79656382|NCT05876715|Drug|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
79491597|NCT00378859|Behavioral|Skim milk|
79491598|NCT00378859|Behavioral|Lean meat|
79491599|NCT04005391|Other|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
79491600|NCT00002552|Biological|filgrastim|
79656383|NCT05859048|Diagnostic Test|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
79656384|NCT05859048|Diagnostic Test|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
79491601|NCT00002552|Biological|sargramostim|
79491602|NCT00002552|Drug|carmustine|
79998568|NCT02889133|Drug|Saline|Salt water IV - 500 mL, one pint normal saline.
79998569|NCT02889133|Procedure|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
79341395|NCT02132247|Drug|Diclofenac hydroxyethylpyrrolidine|
79341396|NCT01629381|Drug|Rivaroxaban|10 mg os once daily for 1 week
79491603|NCT00002552|Drug|cyclophosphamide|
79656385|NCT05859048|Diagnostic Test|electrocardiogram|tracing of electrical cardiac activity of the heart
79984898|NCT03703622|Behavioral|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, & OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
79491604|NCT00002552|Drug|cytarabine|
79491605|NCT00002552|Drug|etoposide|
79341397|NCT01629381|Drug|placebo|10 mg os once daily for 1 week
79341398|NCT02131311|Device|disposable, single-use pessary|
79341399|NCT05269017|Drug|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
79341400|NCT05269017|Drug|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
79656386|NCT05859048|Other|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
79656387|NCT05853120|Drug|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
79341401|NCT01628913|Drug|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
79341402|NCT01628913|Drug|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
79341403|NCT02164383|Drug|Nicotine patch|4-week starter kit of nicotine patch
79341404|NCT02164383|Behavioral|Cessation Counseling|5 brief counseling sessions
79341405|NCT02164383|Device|Mobile Games|
79491606|NCT00002552|Drug|leucovorin calcium|
79491607|NCT00002552|Drug|methotrexate|
79491608|NCT00002552|Drug|perfosfamide|
79491609|NCT00002552|Drug|therapeutic hydrocortisone|
79491610|NCT00002552|Procedure|allogeneic bone marrow transplantation|
79491611|NCT00002552|Procedure|autologous bone marrow transplantation|
79491612|NCT00002552|Procedure|in vitro-treated bone marrow transplantation|
79491613|NCT00002552|Procedure|peripheral blood stem cell transplantation|
79491614|NCT00002552|Procedure|syngeneic bone marrow transplantation|
79491615|NCT00002552|Radiation|radiation therapy|
79491616|NCT00378781|Drug|Heparin|Heparin flush solution into CVC once daily.
79491617|NCT00378781|Drug|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
79491618|NCT00002564|Other|educational intervention|
79491619|NCT00002564|Procedure|therapeutic dietary intervention|
79491620|NCT00377923|Drug|Progesterone|
79491621|NCT05750888|Behavioral|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
79341406|NCT02131233|Drug|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
79341407|NCT02131233|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily
79341408|NCT02131233|Drug|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
79491622|NCT05750888|Behavioral|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
79491623|NCT03990415|Behavioral|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
79491624|NCT00002570|Drug|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
79341409|NCT02131233|Drug|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
79341410|NCT02131233|Drug|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
79341411|NCT02131155|Drug|Placebo|Once daily
79341412|NCT02131155|Drug|Afatinib|Once daily
79341413|NCT01933594|Drug|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
79491625|NCT00002570|Drug|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
79656388|NCT05841160|Drug|Ecopipam Hydrochloride|oral tablets
79656389|NCT05841160|Drug|Moxifloxacin|oral tablet
79491626|NCT05750810|Other|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
79491627|NCT04002973|Device|INVSENSOR00037|Noninvasive regional oximeter.
79491628|NCT00002576|Drug|cyclophosphamide|
79491629|NCT00002576|Drug|doxorubicin hydrochloride|
79491630|NCT00002576|Drug|mitoxantrone hydrochloride|
79491631|NCT00002576|Drug|prednisolone|
79491632|NCT00002576|Drug|vincristine sulfate|
79491633|NCT03977935|Device|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
79491634|NCT03985657|Device|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
79491635|NCT00002582|Drug|CMF regimen|
79491636|NCT00002582|Drug|cyclophosphamide|
79491637|NCT00002582|Drug|doxorubicin hydrochloride|
79491638|NCT00002582|Drug|fluorouracil|
79491639|NCT00002582|Drug|goserelin acetate|
79491640|NCT00002582|Drug|leuprolide acetate|
79491641|NCT00002582|Drug|methotrexate|
79491642|NCT00002582|Drug|tamoxifen citrate|
79491643|NCT00002582|Procedure|oophorectomy|
79491644|NCT00002582|Radiation|radiation therapy|
79491645|NCT02249377|Other|Platelets-Rich-Plasma|Platelet-Rich Plasma
79491646|NCT02249377|Drug|Corticosteroid|Corticosteroid
79491647|NCT05750654|Device|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
79491648|NCT05750654|Device|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
79491649|NCT00002588|Drug|etoposide|
79656390|NCT05841160|Drug|Placebo|oral tablet
79813952|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
79491650|NCT00002588|Drug|topotecan hydrochloride|
79491651|NCT02239627|Drug|Epidural steroid|
79491652|NCT02239627|Drug|Clonidine|
79491653|NCT05750576|Device|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
79491654|NCT05750576|Device|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
79491655|NCT00002594|Biological|Sargramostim|Given IV
79491656|NCT00002594|Drug|cyclophosphamide|Given IV
79491657|NCT00002594|Drug|melphalan|Given IV
79491658|NCT00002594|Procedure|autologous bone marrow transplantation|
79491659|NCT00002594|Procedure|bone marrow ablation with stem cell support|
79491660|NCT00002594|Procedure|peripheral blood stem cell transplantation|
79491661|NCT02234011|Drug|Ketamine|
79491662|NCT02234011|Drug|Placebo|
79491663|NCT02198833|Biological|Urine Culture|Obtain urine culture every third day
79491664|NCT02198833|Device|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
79491665|NCT02198833|Device|Scanning Electron Microscopy|Houston Site Only
79491666|NCT02198833|Procedure|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
79491667|NCT02198833|Procedure|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
79491668|NCT00002600|Biological|filgrastim|
79491669|NCT00002600|Drug|carboplatin|
79491670|NCT00002600|Drug|cyclophosphamide|
79491671|NCT00002600|Procedure|autologous bone marrow transplantation|
79491672|NCT00002600|Procedure|peripheral blood stem cell transplantation|
79491673|NCT02177773|Procedure|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
79491674|NCT02177773|Drug|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
79491675|NCT02177773|Procedure|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
79491676|NCT02177773|Procedure|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
79491677|NCT00382226|Drug|Azopt|
79491678|NCT02144155|Drug|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
79491679|NCT02144155|Drug|Placebo|placebo drug
79491680|NCT00002618|Biological|filgrastim|
79491681|NCT00002618|Drug|cytarabine|
79491682|NCT00002618|Drug|doxorubicin hydrochloride|
79491683|NCT00002618|Drug|leucovorin calcium|
79491684|NCT00002618|Drug|mercaptopurine|
79491685|NCT00002618|Drug|methotrexate|
79491686|NCT00002618|Drug|prednisone|
79491687|NCT00002618|Drug|vincristine sulfate|
79491688|NCT00002618|Radiation|low-LET cobalt-60 gamma ray therapy|
79491689|NCT00002618|Radiation|low-LET electron therapy|
79491690|NCT00002618|Radiation|low-LET photon therapy|
79491691|NCT02145169|Drug|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
79491692|NCT00002624|Procedure|adjuvant therapy|
79984899|NCT04149353|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
79813953|NCT00827710|Behavioral|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
79491693|NCT00002624|Procedure|diagnostic thoracoscopy|
79491694|NCT00002624|Procedure|therapeutic thoracoscopy|
79491695|NCT00002624|Procedure|video-assisted surgery|
79656391|NCT05815758|Drug|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
79656392|NCT05815758|Drug|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
79813954|NCT00827710|Behavioral|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
79341414|NCT01933594|Drug|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
79656393|NCT05813613|Other|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
79984900|NCT02711800|Drug|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
79341415|NCT04623190|Behavioral|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
79341416|NCT04623190|Behavioral|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
79813955|NCT00624520|Behavioral|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
79491696|NCT00002624|Radiation|radiation therapy|
79491697|NCT00002630|Biological|filgrastim|
79491698|NCT00002630|Drug|cyclophosphamide|
79491699|NCT00002630|Drug|melphalan|
79491700|NCT00002630|Procedure|peripheral blood stem cell transplantation|
79491701|NCT00002630|Radiation|low-LET cobalt-60 gamma ray therapy|
79491702|NCT00002630|Radiation|low-LET photon therapy|
79491703|NCT02047747|Drug|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
79491704|NCT05750186|Other|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
79491705|NCT00002642|Drug|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
79491706|NCT00002642|Drug|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
79491707|NCT00002642|Procedure|conventional surgery|surgery some time between weeks 9 and 12
79491708|NCT00002642|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
79491709|NCT03983941|Drug|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
79491710|NCT01434511|Biological|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
79491711|NCT02973074|Dietary Supplement|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
79491712|NCT05750108|Device|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
79813956|NCT00624520|Other|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
79813957|NCT04118075|Drug|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
79491713|NCT05750108|Device|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
79491714|NCT02020837|Procedure|Lymphaticovenous Micro-Anastomosis|
79491715|NCT02006407|Radiation|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
79984901|NCT03701594|Other|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
79984902|NCT03701594|Other|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
79984903|NCT03701594|Other|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
79984904|NCT02091154|Behavioral|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~Fruit or vegetable on every tray~Meet requirements for vegetable varieties~50% of all grains must be whole grain~Milk must be 1% or skim; flavored milk must be skim"
79984905|NCT02091154|Behavioral|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~56''x72'' vinyl sign with the words [school mascot] Cafe~8.5''x11'' signs describing the foods offered on a specific day~2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
79984906|NCT02091154|Behavioral|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
79984907|NCT02444026|Behavioral|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
79984908|NCT01526668|Behavioral|Follow-up strategy|Comparison of different follow-up strategies
79341417|NCT01932970|Drug|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
79341418|NCT01912768|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
79491716|NCT02006407|Device|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
79491717|NCT02006407|Behavioral|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
79491718|NCT04331054|Drug|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
79491719|NCT04331054|Other|1: Usual practice|Usual practice
79341419|NCT01912768|Device|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
79491720|NCT00002654|Drug|chemotherapy|
79491721|NCT00002654|Drug|cisplatin|
79491722|NCT00002654|Radiation|low-LET cobalt-60 gamma ray therapy|
79491723|NCT00002654|Radiation|low-LET electron therapy|
79491724|NCT00002654|Radiation|low-LET photon therapy|
79491725|NCT02973308|Other|Observer|Observer A and observer B
79491726|NCT01426555|Other|FES-Rowing|FES- Rowing Exercise
79491727|NCT01426555|Drug|Zoledronic acid|5 mg IV single dose
79491728|NCT01434745|Drug|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
79491729|NCT01434745|Dietary Supplement|Lactose|Lactose will be administered in a capsule formula.
79491730|NCT01401049|Drug|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
79341420|NCT01912768|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
79491731|NCT01401049|Drug|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
79491732|NCT00381758|Drug|Methylphenidate Extended Release Capsules|
79491733|NCT01402531|Drug|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
79491734|NCT00381836|Drug|Darbepoetin Alfa|
79491735|NCT01971853|Drug|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
79491736|NCT01971853|Drug|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
79491737|NCT00002678|Drug|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
79656394|NCT05788978|Other|Scale development|Scale development
79656395|NCT05782179|Biological|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
79984909|NCT01526668|Behavioral|No contact after discharge|
79341421|NCT02305849|Drug|Peficitinib|oral tablet
79984910|NCT01194622|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
79984911|NCT01194622|Drug|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
79984912|NCT01194622|Drug|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
79341422|NCT02305849|Drug|Placebo|oral tablet
79984913|NCT02448316|Procedure|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
79984914|NCT02448316|Drug|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
79341423|NCT02305849|Drug|Methotrexate|Oral tablet/capsule
79341424|NCT02371759|Drug|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
79491738|NCT00002678|Drug|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
79491739|NCT00002678|Drug|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
79491740|NCT01397695|Drug|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
79491741|NCT00002684|Drug|cisplatin|
79656396|NCT05782179|Biological|Placebo|Normal Saline 0.9 %
79341425|NCT02371759|Drug|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
79341426|NCT02371759|Drug|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
79341427|NCT02371759|Drug|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
79341428|NCT02531633|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
79341429|NCT02531633|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
79341430|NCT02531633|Drug|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
79341431|NCT02531633|Drug|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
79491742|NCT00002684|Drug|ifosfamide|
79491743|NCT00002684|Drug|paclitaxel|
79656397|NCT05755373|Other|No treatment given|No treatment given
79656398|NCT05729997|Other|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
79656399|NCT05726604|Other|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
79656400|NCT05726058|Device|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
79341432|NCT05415605|Device|Lung Strain|The main objective of this study is to describe the physiological values of lung strain in healthy volunteers as well as its variations induced by non-invasive positive pressure ventilation and their correlation with tidal volume.
79341433|NCT02536313|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
79341434|NCT02536313|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79491744|NCT01982383|Device|Micropulse Laser Treatment|
79491745|NCT01982383|Other|No treatment|
79491746|NCT05600647|Device|Electromagnetic Field therapy with an exercise program|"The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
79491747|NCT05600647|Other|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
79491748|NCT01356667|Behavioral|DARTNA|3-hour protocol provided 2x/week over 12 weeks
79491749|NCT01356667|Behavioral|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
79656401|NCT05723913|Dietary Supplement|Dietary Supplement: A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
79656402|NCT05709743|Behavioral|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
79656403|NCT05694533|Drug|INDV-2000|Capsules administered orally twice a day
79656404|NCT05694533|Drug|Midazolam|Midazolam syrup administered orally on Days 1 and 15
79656405|NCT05681390|Drug|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
79341435|NCT05415059|Device|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
79491750|NCT02972918|Drug|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
79656406|NCT05669547|Device|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
79656407|NCT05669261|Procedure|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
79656408|NCT05669261|Biological|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
79656409|NCT05669079|Drug|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
79984915|NCT02448316|Drug|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
79984916|NCT02448316|Behavioral|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
79491751|NCT05600491|Drug|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
79491752|NCT05749484|Other|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
79491753|NCT05600413|Dietary Supplement|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
79656410|NCT05669079|Biological|umbilical cord blood|MNC ≥ 3*108 cells; HLA compatibility ≥ 5/6
79656411|NCT05669079|Drug|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
79656412|NCT05669079|Drug|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
79491754|NCT05600413|Dietary Supplement|Placebo|4 weeks of Placebo (crystalline cellulose)
79491755|NCT01934647|Drug|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
79491756|NCT05440526|Procedure|Herbst Group|"Herbst Group:~Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
79491757|NCT05440526|Device|TFBC Group|"TFBC Group:~The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
79491758|NCT01354951|Other|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
79984917|NCT03698318|Dietary Supplement|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
79984918|NCT03698318|Dietary Supplement|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
79984919|NCT03698318|Dietary Supplement|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
79984920|NCT03698318|Dietary Supplement|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
79984921|NCT03698318|Dietary Supplement|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
79491759|NCT00379561|Drug|PSA-Activated PSA-PAH1|
79491760|NCT00002696|Drug|CAF regimen|
79491761|NCT00002696|Drug|CMF regimen|
79491762|NCT00002696|Drug|cyclophosphamide|
79491763|NCT00002696|Drug|doxorubicin hydrochloride|
79491764|NCT00002696|Drug|fluorouracil|
79491765|NCT00002696|Drug|methotrexate|
79491766|NCT00002696|Procedure|adjuvant therapy|
79491767|NCT00002696|Procedure|conventional surgery|
79656413|NCT05669079|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
79656414|NCT05630625|Behavioral|Drinking Dashboard|Day-level feedback on alcohol use and consequences
79491768|NCT00002696|Procedure|neoadjuvant therapy|
79491769|NCT00002696|Radiation|radiation therapy|
79491770|NCT01350583|Drug|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
79491771|NCT00002702|Biological|aldesleukin|
79370714|NCT04356820|Other|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
79491772|NCT00002702|Procedure|adjuvant therapy|
79491773|NCT00002702|Procedure|conventional surgery|
79984922|NCT03698240|Behavioral|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
79984923|NCT05200858|Device|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device (delivers 100% of the dose) to wear for 1 hour daily for up to 4 weeks.
79491774|NCT00002702|Procedure|neoadjuvant therapy|
79491775|NCT00002702|Radiation|radiation therapy|
79984924|NCT05200858|Device|Electrical Stimulation - Placebo|Subjects will receive a placebo electrical stimulation device (delivers 10% of the dose) to wear for 1 hour daily for up to 4 weeks.
79984925|NCT05178238|Other|Fecal sample|Fecal sample taken to investigate intestinal microbiota
79491776|NCT01890577|Drug|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
79491777|NCT05749406|Other|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
79491778|NCT05749406|Other|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
79491779|NCT00002708|Procedure|surgical procedure|
79491780|NCT00002708|Radiation|radiation therapy|
79491781|NCT00002708|Radiation|stereotactic radiosurgery|
79491782|NCT01315873|Drug|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m^2 after bortezomib . Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
79984926|NCT03697928|Other|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
79984927|NCT03703388|Dietary Supplement|Arctigenin|Arctigenin capsule
79984928|NCT02443714|Device|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
79984929|NCT02443714|Device|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
79984930|NCT03703310|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
79984931|NCT03703310|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
79984932|NCT03190408|Other|Fluids|Fluids Administered in Shock
79491783|NCT01315873|Drug|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m^2 followed by bendamustine given at 90 mg/m^2. Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
79656415|NCT05611905|Combination Product|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
79656416|NCT05611905|Drug|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
79656417|NCT05607173|Drug|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
79656418|NCT05586373|Drug|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
79491784|NCT01895959|Drug|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
79491785|NCT01895959|Device|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
79491786|NCT01303003|Drug|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
79491787|NCT01303003|Procedure|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
79656419|NCT05586373|Drug|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
79656420|NCT05549401|Drug|CKD-348(4) F1|QD, PQ
79656421|NCT05549401|Drug|CKD-348(4) F2|QD, PQ
79656422|NCT05549401|Drug|CKD-828, D097, D337|QD, PQ
79656423|NCT05491668|Diagnostic Test|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
79491788|NCT01256281|Procedure|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
79491789|NCT00002714|Biological|bleomycin sulfate|
79656424|NCT05472519|Biological|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~Medical examination : weight, gender, blood pressure, medical history~Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
79656425|NCT05472519|Biological|blood samples|"Only one visit for each participant:~Medical examination : weight, gender, blood pressure, medical history~Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
79984933|NCT03703232|Device|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
79656426|NCT05434546|Drug|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
79491790|NCT00002714|Drug|Stanford V regimen|
79491791|NCT00002714|Drug|doxorubicin hydrochloride|
79491792|NCT00002714|Drug|etoposide|
79491793|NCT00002714|Drug|mechlorethamine hydrochloride|
79491794|NCT00002714|Drug|prednisone|
79491795|NCT00002714|Drug|vinblastine sulfate|
79656427|NCT05433090|Behavioral|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
79491796|NCT00002714|Drug|vincristine sulfate|
79491797|NCT00002714|Radiation|radiation therapy|
79656428|NCT05419622|Biological|bronchial biopsies|This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
79656429|NCT05405998|Other|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~after the installation of the pump following the above mentioned hospitalization."
79656430|NCT05376917|Device|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
79656431|NCT05376917|Device|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
79656432|NCT05376917|Device|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
79491798|NCT05313061|Drug|MTX|MTX continuation
79491799|NCT00002720|Drug|tamoxifen citrate|
79491800|NCT00002720|Procedure|conventional surgery|
79656433|NCT05376917|Device|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
79656434|NCT05372055|Other|Semi-structure interviews|Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
79984934|NCT04483570|Procedure|Redo-tethering operation|
79491801|NCT01821859|Drug|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
79656435|NCT05367778|Drug|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
79491802|NCT01821859|Drug|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
79491803|NCT05749328|Dietary Supplement|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
79491804|NCT05600023|Drug|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
79491805|NCT05600023|Drug|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
79656436|NCT05362981|Other|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
79656437|NCT05359939|Diagnostic Test|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
79823650|NCT03268070|Device|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
79491806|NCT05599867|Behavioral|quality of life|to assess quality among patients with patients with IBD
79656438|NCT05354934|Other|quetionnaire|"The questionnaire includes the following modules~Demography and socio-economic conditions~Screening and modalities of discovery and announcement of HIV infection~Time and modalities of introduction of antiretroviral drugs after diagnosis~Knowledge of HIV infection~The perception of follow-up in the health care service~Experiences of stigma~Barriers to accessing care~Periods of loss of sight and reasons for this~Perceived health status, mental health (PHQ4), chronic illness, functional limitations~Addictions~Social network and support~Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
79491807|NCT05566184|Device|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
79491808|NCT01194427|Drug|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
79491809|NCT05749250|Device|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
79491810|NCT05599555|Biological|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
79491811|NCT05599555|Biological|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
79491812|NCT00002738|Drug|leucovorin calcium|
79656439|NCT05335044|Drug|CKD-331|QD, PO
79656440|NCT05335044|Drug|EX5619|QD, PO
79656441|NCT05332275|Behavioral|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
79656442|NCT05332275|Behavioral|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
79370715|NCT04356274|Other|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
79370716|NCT04356274|Other|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
79491813|NCT00002738|Drug|trimetrexate glucuronate|
79491814|NCT04706455|Device|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
79656443|NCT05312047|Procedure|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
79823651|NCT03268070|Device|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
79491815|NCT04706455|Device|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
79491816|NCT00002744|Drug|asparaginase|
79491817|NCT00002744|Drug|cyclophosphamide|
79491818|NCT00002744|Drug|cytarabine|
79491819|NCT00002744|Drug|daunorubicin hydrochloride|
79491820|NCT00002744|Drug|dexamethasone|
79491821|NCT00002744|Drug|doxorubicin hydrochloride|
79491822|NCT00002744|Drug|mercaptopurine|
79341436|NCT05610761|Behavioral|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
79656444|NCT05286177|Procedure|Volume-based EN|Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for > 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.
79656445|NCT05286177|Procedure|Rate-based EN|Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
79341437|NCT05610761|Behavioral|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
79491823|NCT00002744|Drug|methotrexate|
79656446|NCT05250947|Device|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
79341438|NCT05414825|Other|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
79341439|NCT04423133|Behavioral|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
79341440|NCT04423289|Other|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
79341441|NCT05413499|Other|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
79341442|NCT04423445|Other|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
79656447|NCT05250791|Drug|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
79341443|NCT02187861|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
79341444|NCT02187861|Drug|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
79491824|NCT00002744|Drug|pegaspargase|
79656448|NCT05250791|Drug|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
79656449|NCT05230342|Dietary Supplement|A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
79656450|NCT05230342|Other|Placebo ingredient group|The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
79823652|NCT03268070|Device|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
79823653|NCT03241082|Device|ultrasound|validation of portable ultrasound to measure body composition
79341445|NCT02187861|Drug|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
79370717|NCT04104763|Behavioral|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
79491825|NCT00002744|Drug|prednisone|
79491826|NCT00002744|Drug|therapeutic hydrocortisone|
79491827|NCT00002744|Drug|thioguanine|
79491828|NCT00002744|Drug|vincristine sulfate|
79491829|NCT00002744|Radiation|low-LET cobalt-60 gamma ray therapy|
79491830|NCT00002744|Radiation|low-LET photon therapy|
79491831|NCT01788475|Drug|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
79491832|NCT01183897|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
79491833|NCT00381914|Drug|Vitamin D|400 IU vitamin D / day
79656451|NCT05200520|Behavioral|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
79370718|NCT01695746|Drug|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
79984935|NCT03703154|Drug|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
79491834|NCT00381914|Drug|Vitamin D|800 IU vitamin D / day
79491835|NCT00381914|Drug|Vitamin D|1200 IU vitamin D / day
79491836|NCT00423007|Drug|Bromfenac|
79656452|NCT05197322|Drug|Pembrolizumab|Dose: 200mg by IV infusion on Day 1 of each treatment cycle
79656453|NCT05192356|Drug|CKD-348(3)|QD, PO
79813958|NCT00698711|Biological|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
79656454|NCT05192356|Drug|CKD-828, D097, D337|QD, PO
79656455|NCT05187000|Device|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
79656456|NCT05187000|Device|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
79813959|NCT04122209|Other|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
79813960|NCT04122209|Other|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
79813961|NCT00847145|Biological|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
79813962|NCT00847145|Biological|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
79984936|NCT03703154|Drug|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
79491837|NCT00423007|Drug|Placebo|
79491838|NCT00002750|Drug|melphalan|
79491839|NCT00002756|Biological|filgrastim|
79491840|NCT00002756|Drug|asparaginase|
79491841|NCT00002756|Drug|cyclophosphamide|
79491842|NCT00002756|Drug|cytarabine|
79491843|NCT00002756|Drug|daunorubicin hydrochloride|
79491844|NCT00002756|Drug|etoposide|
79491845|NCT00002756|Drug|leucovorin calcium|
79491846|NCT00002756|Drug|mercaptopurine|
79491847|NCT00002756|Drug|methotrexate|
79491848|NCT00002756|Drug|prednisone|
79491849|NCT00002756|Drug|therapeutic hydrocortisone|
79491850|NCT00002756|Drug|vincristine sulfate|
79491851|NCT05599477|Device|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
79491852|NCT01183429|Drug|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. *High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
79491853|NCT01157533|Drug|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
79656457|NCT05160012|Behavioral|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~If HTN control rate <50th percentile, PCP is told they are below median~If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
79656458|NCT05148065|Device|BIS|Bispectral index monitoring
79491854|NCT01760941|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
79656459|NCT05148065|Device|PSi|Patient state index monitoring
79656460|NCT05145764|Drug|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
79656461|NCT05145764|Drug|Placebo|Encapsulated placebo (matched for color, weight, and size)
79656462|NCT05142826|Behavioral|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
79656463|NCT05142826|Other|School as Usual|Interventions and supports as provided through usual care
79656464|NCT05128812|Dietary Supplement|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
79656465|NCT05123235|Behavioral|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
79491855|NCT01760941|Other|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
79491856|NCT01760941|Other|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
79491857|NCT05556668|Device|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
79491858|NCT05749016|Drug|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
79491859|NCT01756573|Drug|Dexamthsone|
79491860|NCT01756573|Drug|Bupivacaine|
79491861|NCT00382304|Drug|tolevamer potassium-sodium (GT267-004)|
79656466|NCT05113693|Drug|CKD-393|QD, PO
79656467|NCT05113693|Drug|CKD-501, D759, H053|QD, PO
79656468|NCT05087342|Drug|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
79656469|NCT05087342|Drug|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
79656470|NCT05086432|Other|Sputum-guided management|As previously described.
79656471|NCT05086432|Other|Standard of Care|As previously described.
79656472|NCT05078476|Other|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
79491862|NCT01126801|Drug|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
79656473|NCT05078476|Other|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
79341446|NCT03958487|Behavioral|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
79656474|NCT05060146|Other|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
79656475|NCT05044715|Behavioral|Treatment as Usual|"Treatment as usual-TAU groups include:~Mood Groups - General Process Groups~Anxiety Groups - Cognitive Behavioral Therapy~Body Image and Eating Concerns Groups~Reconciling Faith and Sexuality Groups"
79656476|NCT05044715|Behavioral|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
79656477|NCT05035095|Drug|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
79656478|NCT05035095|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
79656479|NCT04983836|Procedure|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
79656480|NCT04983836|Procedure|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
79984937|NCT03188380|Diagnostic Test|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
79341447|NCT05435261|Procedure|BKA|"Below Knee Amputation:~Under spinal anesthesia~BKA~closure in layers (terminal closure) with suction drain."
79491863|NCT01126801|Other|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
79491864|NCT00002762|Behavioral|patient interviewing to obtain menstrual history|
79491865|NCT00002762|Procedure|blood sampling|
79491866|NCT01727167|Drug|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
79491867|NCT01727167|Other|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
79491868|NCT05748938|Biological|RD14-01|ROR1 Targeted CAR-T cells
79491869|NCT01702909|Drug|Interleukin-2|Interleukin-2
79491870|NCT00002768|Biological|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
79491871|NCT00002768|Drug|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
79491872|NCT00002768|Drug|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
79491873|NCT00002768|Drug|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
79984938|NCT03188380|Diagnostic Test|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
79341448|NCT05435261|Procedure|Debridement with Ex_Fix (salvage)|"Debridement and External Fixation (salvage):~Under spinal anesthesia~wound debridement and wash.~external fixation."
79341449|NCT05434091|Drug|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
79341450|NCT05434091|Drug|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
79341451|NCT05610605|Other|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
79341452|NCT05378477|Device|X92001752|The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
79341453|NCT05378477|Device|RID Super Max Solution|RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
79341454|NCT05378477|Drug|Nix Crème|Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
79823654|NCT00664521|Biological|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
79656481|NCT04971967|Combination Product|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
79341455|NCT05378477|Device|Pouxit Végétal|Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
79341456|NCT05377385|Behavioral|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
79341457|NCT02163993|Drug|Galcanezumab|Administered SQ
79341458|NCT02163993|Drug|Placebo|Administered SQ
79341459|NCT05383001|Drug|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
79341460|NCT05383001|Drug|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
79341461|NCT02527421|Drug|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
79656482|NCT04950985|Other|Observational Study|Observational study
79656483|NCT04933383|Drug|AQ001S 0.125 mg/ml|administered by nebulization once daily
79341462|NCT02163915|Drug|TAK-137|TAK-137 tablets
79656484|NCT04933383|Drug|Budesonide 0.125 mg/ml inhalation suspension|administered by nebulization once daily
79656485|NCT04923906|Drug|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4~6 cycles, followed by Aumolertinib daily with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
79984939|NCT02443558|Other|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
79491874|NCT00002768|Drug|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
79491875|NCT00002768|Procedure|peripheral blood stem cell transplantation|Infusion on Day 0
79524720|NCT03830346|Other|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
79341463|NCT02163915|Drug|TAK-137 Placebo|TAK-137 placebo-matching tablets
79656486|NCT04923906|Drug|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
79656487|NCT04923776|Drug|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
79656488|NCT04923776|Drug|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
79656489|NCT04923776|Drug|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
79656490|NCT04923776|Radiation|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
79656491|NCT04903691|Behavioral|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
79656492|NCT04902521|Device|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
79656493|NCT04902521|Device|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
79656494|NCT04902144|Other|Electronic Health Record Review|Medical data collected
79656495|NCT04902144|Other|Questionnaire Administration|Complete questionnaires
79656496|NCT04902144|Behavioral|Behavioral Intervention|Receive coaching
79656497|NCT04871542|Procedure|Biospecimen Collection|Undergo collection of blood sample
79656498|NCT04871542|Other|Questionnaire Administration|Complete questionnaires
79813963|NCT00847145|Biological|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
79813964|NCT00847145|Biological|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
79656499|NCT04826718|Other|Questionaire|"A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls)."
79341464|NCT05610371|Drug|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
79341465|NCT05610371|Drug|Saline|The control group underwent hysteroscopy using a saline distension medium.
79656500|NCT04822311|Behavioral|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
79341466|NCT02163759|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
79341467|NCT02163759|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
79341468|NCT02163759|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
79656501|NCT04815824|Behavioral|Exercise Mode|Stationary cycling or treadmill walking
79341469|NCT02163759|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
79341470|NCT02371369|Drug|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
79491876|NCT00002774|Drug|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
79491877|NCT00002774|Drug|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
79491878|NCT00002774|Drug|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
79813965|NCT00847145|Biological|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
79823655|NCT00664521|Drug|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
79341471|NCT02371369|Drug|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
79341472|NCT02187783|Drug|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
79341473|NCT02337361|Behavioral|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
79341474|NCT02336737|Device|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
79341475|NCT02336737|Drug|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
79341476|NCT02336737|Drug|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
79341477|NCT02130765|Device|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
79341478|NCT02305381|Drug|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
79341479|NCT02305381|Drug|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
79341480|NCT02336425|Drug|QGE031|QGE031 120 mg per 1 mL liquid in vial
79341481|NCT02336425|Drug|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
79341482|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
79341483|NCT02163447|Drug|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
79341484|NCT02163447|Drug|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
79341485|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
79341486|NCT02163447|Drug|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
79524721|NCT03830112|Behavioral|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
79656502|NCT04791215|Other|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
79341487|NCT02370667|Other|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
79341488|NCT02370667|Other|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
79341489|NCT02370667|Other|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
79341490|NCT02130297|Device|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
79524722|NCT03830112|Behavioral|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
79491879|NCT00002774|Radiation|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
79491880|NCT05599165|Other|Different signal processing for consonant recognition|Consonant recognition will be measured in noise with three different signal processing conditions: control (no signal processing), important frequency regions enhanced by signal processing, and combined conditions of important frequency regions enhanced and confused frequency regions removed by signal processing.
79491881|NCT00002780|Biological|aldesleukin|
79656503|NCT04744051|Drug|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
79656504|NCT04744051|Drug|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
79656505|NCT04744051|Drug|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
79341491|NCT01931956|Device|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
79341492|NCT01887418|Drug|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
79491882|NCT00002780|Biological|cytokine therapy|
79491883|NCT00002780|Biological|sargramostim|
79656506|NCT04744051|Drug|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
79491884|NCT00002780|Drug|carboplatin|
79491885|NCT00002780|Drug|cyclophosphamide|
79491886|NCT00002780|Drug|thiotepa|
79656507|NCT04743856|Behavioral|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
79656508|NCT04743856|Behavioral|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
79656509|NCT04715074|Behavioral|Interviews|We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
79341493|NCT01887418|Drug|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
79341494|NCT01887418|Drug|Delatestryl 200 mg IM Treatment C|Standard of care
79341495|NCT01886716|Behavioral|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
79341496|NCT01886716|Behavioral|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
79656510|NCT04715074|Behavioral|Pilot|Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
79813966|NCT00847145|Biological|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
79341497|NCT01886716|Behavioral|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
79341498|NCT01912612|Drug|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
79341499|NCT02370511|Device|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
79341500|NCT02303041|Drug|Buparlisib|Administered orally at starting dose of 80 mg/day
79341501|NCT02303041|Drug|Sonidegib|Administered orally at starting dose of 200 mg/day
79491887|NCT00002780|Procedure|peripheral blood stem cell transplantation|
79491888|NCT01692691|Drug|Dacarbazine|Dacarbazine IV - Day 1
79491889|NCT01692691|Drug|Carmustine|Carmustine IV- Day 2
79491890|NCT01692691|Drug|Neulasta|Neulasta SC - Day 3
79491891|NCT01127503|Drug|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day [2000 mg/day if metyrosine]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
79656511|NCT04655937|Other|Acceptance and Commitment Therapy|none two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
79656512|NCT04652479|Drug|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
79656513|NCT04642599|Device|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
79656514|NCT04634617|Other|Questionnaire Administration|Complete questionnaires
79656515|NCT04582266|Drug|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
79656516|NCT04535648|Other|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
79341502|NCT02302807|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
79341503|NCT02302807|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
79341504|NCT02302807|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
79341505|NCT02302807|Drug|Vinflunine|Vinflunine 320 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
79341506|NCT02335489|Device|Implantation with the commercially available Axium neurostimulator|
79341507|NCT02527343|Drug|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
79491892|NCT01127503|Drug|Placebo|Placebo capsules were identically matched to Metyrosine.
79656517|NCT04528134|Device|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
79656518|NCT04528134|Device|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
79656519|NCT04521920|Drug|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
79656520|NCT04521920|Drug|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
79341508|NCT02527343|Drug|Placebo|Volanesorsen-matching placebo administered SC injection.
79341509|NCT05582057|Behavioral|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
79341510|NCT05373875|Diagnostic Test|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
79341511|NCT05538065|Other|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
79341512|NCT05538065|Other|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
79341513|NCT05538065|Other|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory [BPA]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
79491893|NCT01122511|Drug|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
79341514|NCT05308277|Device|Leo device monitoring|After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
79341515|NCT05307887|Device|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
79491894|NCT01122511|Biological|ranibizumab|Intravitreal injection of ranibizumab into study eye
79341516|NCT01931566|Drug|Pioglitazone|Pioglitazone SR tablets
79491895|NCT01122511|Other|sham|Sham needle-less injection administered in the study eye
79491896|NCT05535218|Drug|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|"Neoadjuvant treatment: 10 mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
79491897|NCT05531708|Biological|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
79491898|NCT05531708|Drug|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m^2/day) will be administered intravenously for 5 days.
79656521|NCT04521894|Device|Positron emission tomography/computerized tomography (PET/CT)|"Genetic factors and age:~Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~Infection:~Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~Daily diet: The corrective mechanism of diet in PCa is not very clear.~Drinking history:"
79341517|NCT01931566|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets
79341518|NCT05511077|Other|Diet|Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
79341519|NCT04248725|Behavioral|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
79341520|NCT05372939|Drug|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
79491899|NCT05531708|Drug|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
79491900|NCT01663285|Drug|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
79491901|NCT00002786|Biological|aldesleukin|
79491902|NCT00002786|Biological|therapeutic tumor infiltrating lymphocytes|
79491903|NCT00378937|Drug|acetaminophen|
79491904|NCT00378937|Drug|codeine phosphate|
79656522|NCT04475510|Other|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
79341521|NCT05372939|Other|Placebo (oral)|Orally administered placebo comparator taken once daily
79341522|NCT05372939|Combination Product|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
79491905|NCT00378937|Drug|dextropropoxyphene hydrochloride|
79491906|NCT00378937|Drug|morphine sulfate|
79341523|NCT05372705|Behavioral|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
79341524|NCT04247477|Other|Ventilation strategy|Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
79341525|NCT01912456|Biological|Low-volume C1-esterase inhibitor|
79341526|NCT01912456|Biological|Higher-volume C1-esterase inhibitor|
79491907|NCT00378937|Drug|oxycodone hydrochloride|
79491908|NCT00378937|Procedure|management of therapy complications|
79491909|NCT00378937|Procedure|quality-of-life assessment|
79491910|NCT00002792|Drug|busulfan|
79491911|NCT00002792|Drug|cyclophosphamide|
79491912|NCT00002792|Drug|cyclosporine|
79491913|NCT00002792|Drug|methotrexate|
79491914|NCT00002792|Drug|tacrolimus|
79491915|NCT00002792|Procedure|allogeneic bone marrow transplantation|
79491916|NCT00002792|Procedure|peripheral blood stem cell transplantation|
79491917|NCT01673425|Drug|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
79491918|NCT05599087|Biological|Acellular system|Regenerative Endodontic Procedure Tissue engineering procedure
79491919|NCT05748704|Other|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
79491920|NCT05598307|Drug|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
79491921|NCT05598307|Drug|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
79491922|NCT05598307|Drug|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
79491923|NCT05747612|Other|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
79491924|NCT01090141|Drug|Micafungin|100 mg IV infusion over 1 hour
79491925|NCT01090141|Drug|Micafungin|300 mg IV infusion over 1 hour
79491926|NCT05597293|Device|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
79491927|NCT05597293|Device|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
79491928|NCT05597059|Diagnostic Test|Machine Learning Prediction|Machine Learning Prediction
79341527|NCT01912456|Biological|Low-volume placebo|
79341528|NCT01912456|Biological|Higher-volume placebo|
79341529|NCT05307653|Procedure|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
79341530|NCT05307653|Procedure|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
79341531|NCT05307653|Procedure|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
79491929|NCT01048723|Drug|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
79491930|NCT05513612|Biological|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
79491931|NCT05513612|Drug|Fludarabine|Administered according to package insert
79491932|NCT05513612|Drug|Cyclophosphamide|Administered according to package insert
79491933|NCT05596045|Drug|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
79491934|NCT05596045|Drug|Placebo|Participants will be randomized to receive placebo
79491935|NCT05594407|Drug|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
79491936|NCT05594407|Drug|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
79491937|NCT00379717|Drug|Cisplatinum|
79656523|NCT04459338|Biological|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
79656524|NCT04459338|Other|Saline|Placebo comparator
79341532|NCT05340491|Drug|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
79491938|NCT00379717|Drug|Docetaxel|
79491939|NCT00379717|Device|Tomotherapy|
79491940|NCT04706377|Dietary Supplement|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
79491941|NCT04706377|Other|Placebo|Placebo tablet
79341533|NCT05340491|Drug|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
79341534|NCT05340491|Radiation|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
79341535|NCT05306093|Dietary Supplement|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
79341536|NCT05306093|Dietary Supplement|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
79656525|NCT04457687|Drug|Lorcaserin|Lorcaserin 10 milligram (mg) tablets orally.
79656526|NCT04381143|Drug|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablets daily
79656527|NCT04370093|Drug|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
79341537|NCT04251065|Drug|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade > 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
79491942|NCT04706299|Other|Resistance Exercise|Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
79491943|NCT04450004|Biological|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
79491944|NCT01583647|Drug|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
79491945|NCT01583647|Drug|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
79491946|NCT05745428|Other|molecular and cellular analyses|sample blood
79656528|NCT04370093|Behavioral|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
79656529|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
79656530|NCT04298229|Drug|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
79656531|NCT04298229|Other|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
79656532|NCT04278118|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
79984940|NCT02443558|Device|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
79984941|NCT04701164|Drug|ANX005|Solution for intravenous infusion
79984942|NCT04701164|Drug|Placebo|Solution for intravenous infusion
79341538|NCT01885936|Drug|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
79341539|NCT01885936|Drug|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
79341540|NCT05509127|Drug|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
79341541|NCT05509127|Drug|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
79341542|NCT05338229|Device|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
79341543|NCT05336591|Other|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
79491947|NCT04403516|Drug|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
79491948|NCT04403516|Drug|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
79491949|NCT01555489|Drug|Ascorbic Acid|3x per week
79491950|NCT01035073|Drug|Duloxetine|30-60 mg daily for 8 weeks
79491951|NCT05236868|Drug|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
79491952|NCT01561495|Radiation|Proton Therapy|
79491953|NCT04330976|Behavioral|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
79656533|NCT04278118|Radiation|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
79656534|NCT04278118|Radiation|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
79656535|NCT04278118|Other|Quality-of-Life Assessment|Ancillary studies
79656536|NCT04278118|Other|Questionnaire Administration|Ancillary studies
79656537|NCT04273269|Genetic|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
79656538|NCT04234646|Behavioral|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
79656539|NCT04234646|Behavioral|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
79308199|NCT02505971|Drug|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
79370719|NCT03790137|Drug|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
79491954|NCT04330976|Behavioral|Control|Messages sent on general health during pregnancy
79491955|NCT04331743|Drug|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
79491956|NCT05296759|Drug|botulinum toxin A|botulinum toxin A injection
79491957|NCT05296759|Drug|Gabapentin|Gabapentin oral intake
79656540|NCT04202445|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
79491958|NCT05296759|Drug|Duloxetine|Duloxetine oral drug intake
79491959|NCT05546047|Drug|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
79656541|NCT04177433|Drug|Depo-Medrol Injectable Product|Corticosteroid
79656542|NCT04177433|Drug|Saline|Placebo
79656543|NCT04141748|Device|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
79656544|NCT04141748|Procedure|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
79656545|NCT04132895|Other|observational only, no interventions are prescribed in protocol.|"Treatment will be given as per usual standard of care.~No treatments are specified by this protocol."
79656546|NCT04131842|Other|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
79491960|NCT05743556|Device|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
79491961|NCT05743556|Device|TRT therapy|application of radiofrekvention therapy on cervical muscles
79491962|NCT05234762|Drug|ES-481|Dose escalation during two Treatment Periods
79491963|NCT05234762|Other|Placebo|Placebo dosed at same dosing as ES-481
79491964|NCT01532635|Radiation|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
79656547|NCT04131842|Other|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
79656548|NCT04131842|Other|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
79656549|NCT04131842|Other|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
79491965|NCT01532635|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
79813967|NCT00847145|Biological|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
79491966|NCT01532635|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
79813968|NCT00847145|Biological|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
79341544|NCT05301491|Other|Dance Therapy Group|"Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions."
79370720|NCT04795076|Dietary Supplement|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
79491967|NCT01532635|Drug|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
79491968|NCT01532635|Drug|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
79491969|NCT01532635|Biological|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
79370721|NCT04368286|Behavioral|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
79491970|NCT01085773|Behavioral|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
79813969|NCT00701597|Drug|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
79813970|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
79823656|NCT00664521|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
79341545|NCT05301491|Other|Exercise Group|"The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~Unilateral hip-knee flexion (self-assisted exercise)~Bilateral hip-knee flexion (self-assisted exercise)~Straight leg lifting with the aid of a sheet/rigid band~Posterior pelvic tilt~Bridge building exercise~Cat-camel exercise~Half shuttle in sagittal plane~Right and left rotational shuttle~Trunk hyperextension in prone position~Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased."
79491971|NCT01085773|Behavioral|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
79491972|NCT05295511|Other|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
79491973|NCT00986947|Drug|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
79491974|NCT00559897|Other|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
79679455|NCT02941770|Other|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
79491975|NCT00559897|Procedure|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
79491976|NCT00979147|Procedure|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
79491977|NCT00979147|Procedure|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
79491978|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
79984943|NCT03192670|Device|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
79341546|NCT05301491|Other|Pyhsiotherapy Modalities|20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
79491979|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
79491980|NCT00539617|Drug|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
79491981|NCT00539617|Drug|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
79984944|NCT03703544|Other|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
79491982|NCT00539617|Drug|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
79491983|NCT00539617|Drug|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
79491984|NCT05182580|Diagnostic Test|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
79491985|NCT05467514|Drug|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
79491986|NCT00976339|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
79491987|NCT05456828|Biological|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
79491988|NCT04579640|Dietary Supplement|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
79656550|NCT04130711|Other|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
79679456|NCT02950181|Device|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
79341547|NCT05368415|Drug|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
79341548|NCT05335109|Drug|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
79341549|NCT05335109|Drug|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
79341550|NCT05300399|Device|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
79370722|NCT01694420|Drug|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
79370723|NCT04347148|Procedure|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
79341551|NCT04137575|Behavioral|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
79341552|NCT04137575|Behavioral|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
79341553|NCT05299229|Diagnostic Test|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
79341554|NCT05333237|Dietary Supplement|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
79341555|NCT05333237|Dietary Supplement|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
79341556|NCT05333237|Dietary Supplement|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
79341557|NCT01912222|Drug|IXAZOMIB|
79341558|NCT05367791|Other|POSTUR|Training sessions without any stimulation
79341559|NCT05367791|Other|Localised Vibration|Training sessions with localized vibration
79341560|NCT05367791|Other|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
79341561|NCT05366855|Biological|Imsidolimab|Solution for infusion Solution for injection
79341562|NCT05366855|Other|Placebo|Solution for injection
79341563|NCT05332301|Other|High-fat test meal|Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
79679457|NCT02941536|Diagnostic Test|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
79679458|NCT02951078|Procedure|Thulium Laser en Bloc Resection of bladder tumor|
79491989|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
79491990|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
79491991|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
79491992|NCT00517075|Device|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
79656551|NCT04130711|Other|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
79984945|NCT03703544|Other|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
79656552|NCT04130711|Other|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
79656553|NCT04120285|Behavioral|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
79984946|NCT02434276|Biological|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
79984947|NCT02434276|Biological|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
79984948|NCT03624842|Drug|Trappsol (R) Cyclo (TM)|
79341564|NCT04250207|Drug|K-321 Solution|K-321 solution drops
79341565|NCT04250207|Drug|Placebo Solution|Placebo solution drops for K-321
79341566|NCT05500703|Drug|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
79341567|NCT05500703|Drug|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
79984949|NCT03697694|Dietary Supplement|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
79341568|NCT05331833|Radiation|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
79491993|NCT04579172|Procedure|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
79491994|NCT04579172|Procedure|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
79491995|NCT00523939|Drug|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
79491996|NCT00382538|Drug|Addition of mifepristone 200 mg 24 hours before induction|
79491997|NCT00954187|Drug|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
79656554|NCT04108897|Drug|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
79656555|NCT04108897|Drug|Ivermectin Topical|1% topical ivermectin.
79656556|NCT04101877|Drug|Bevacizumab Injection|25 mg/ml
79341569|NCT05366231|Drug|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
79370724|NCT04347148|Procedure|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
79656557|NCT04101877|Drug|Aflibercept Injection|40 mg/ml
79656558|NCT04101838|Drug|Fluzone|inactivated seasonal influenza vaccine
79656559|NCT04101838|Drug|Flucelvax|inactivated seasonal influenza vaccine
79341570|NCT05366231|Drug|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
79491998|NCT00954187|Drug|pregabalin|50 mg PO TID
79491999|NCT04802018|Device|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
79492000|NCT00947791|Drug|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
79492001|NCT00947791|Drug|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
79492002|NCT05139992|Biological|COVID-19 Vaccine|Vaccination against SARS-CoV-2
79492003|NCT00504985|Behavioral|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
79492004|NCT05136326|Radiation|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
79492005|NCT05136326|Drug|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
79984950|NCT03697694|Other|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
79984951|NCT03190642|Drug|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
79492006|NCT05136326|Drug|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
79492007|NCT05387941|Drug|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
79656560|NCT04101838|Drug|Fluzone High-Dose|inactivated seasonal influenza vaccine
79656561|NCT04101838|Drug|Fluad|inactivated seasonal influenza vaccine
79656562|NCT04061044|Drug|Ophthalmic Insert|Travoprost, 0.32 mg
79656563|NCT04026958|Drug|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
79656564|NCT04026958|Drug|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
79656565|NCT04024254|Drug|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
79492008|NCT00382772|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
79492009|NCT00379015|Biological|trastuzumab|
79492010|NCT00379015|Drug|cyclophosphamide|
79492011|NCT00379015|Drug|docetaxel|
79492012|NCT00379015|Drug|epirubicin hydrochloride|
79492013|NCT00379015|Procedure|conventional surgery|
79492014|NCT00379015|Procedure|neoadjuvant therapy|
79492015|NCT05447000|Behavioral|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
79492016|NCT05447000|Behavioral|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
79492017|NCT05447000|Other|No Intervention|No Intervention
79492018|NCT00930787|Device|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
79492019|NCT00930787|Device|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
79492020|NCT00382382|Other|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
79492021|NCT05438030|Diagnostic Test|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
79492022|NCT05438030|Diagnostic Test|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
79813971|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
79341571|NCT05365295|Other|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
79341572|NCT05330585|Device|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
79341573|NCT05330585|Other|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
79341574|NCT05295407|Genetic|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
79492023|NCT05352061|Behavioral|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
79341575|NCT05295251|Other|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
79492024|NCT05119088|Other|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
79492025|NCT00911053|Drug|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
79492026|NCT00911053|Behavioral|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
79656566|NCT04016376|Drug|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
79656567|NCT04016376|Drug|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
79656568|NCT04016376|Drug|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
79656569|NCT03939481|Drug|Chemotherapy|Given chemotherapy regimen
79341576|NCT02525861|Biological|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
79656570|NCT03939481|Other|Functional Assessment|Functional and sensory clinician assessments
79813972|NCT04117529|Other|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
79813973|NCT02612987|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|
79341577|NCT05293613|Device|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
79341578|NCT02524847|Drug|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
79341579|NCT02524847|Procedure|Extracorporeal Photopheresis (ECP)|
79341580|NCT05526365|Other|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
79341581|NCT04422275|Drug|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
79492027|NCT00911053|Behavioral|Light|Subjects will be exposed to light.
79492028|NCT04755530|Dietary Supplement|Regular whole milk|400 g/day of regular whole milk
79492029|NCT04755530|Dietary Supplement|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
79492030|NCT04755530|Dietary Supplement|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
79492031|NCT04755530|Dietary Supplement|Acidified whole milk|400 g/day of yogurt with acidified whole milk
79492032|NCT04330508|Other|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
79492033|NCT05424926|Other|collection of clinical parameters and blood sample|"A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
79341582|NCT04422275|Behavioral|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
79656571|NCT03939481|Other|Questionnaire Administration|Patient and physician reported responses
79341583|NCT04422275|Drug|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
79656572|NCT03939182|Drug|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
79341584|NCT04422275|Behavioral|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
79341585|NCT04422587|Other|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
79341586|NCT02129205|Drug|PF-06650808|Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
79341587|NCT02129205|Drug|PF-06650808|Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
79492034|NCT05423912|Behavioral|Couple in Control Intervention|To assess the acceptability, feasibility, and preliminary efficacy in 4 cohorts of 6 MCI dyads each (N-48 individuals) to take part in a trial of the CiC program. Participants engaging in the pilot testing aim of the project will meet in 90-120-minute virtual intervention group meetings over the course of 8-9 consecutive weeks (depending on the program finalization to occur through Objective 1 activities). They will be asked to take part in structured quantitative interviews pre-intervention and then 4 and 8 weeks post-intervention. A purposive convenience subsample of intervention participants will be interviewed virtually over Zoom videoconference for one 30-60 minute discussion on their experiences in and perceptions of the intervention. Interview durations will be based on the participant's verbosity of response, and participants can end the interview at any point or choose to schedule a follow up call to continue the interview later should they become fatigued.
79492035|NCT05097170|Procedure|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
79492036|NCT05095532|Biological|Bone marrow-derived mesenchymal stem cells|MSC transplantation
79492037|NCT05095532|Other|Placebo|Standard of Care
79492038|NCT04330352|Behavioral|"Mindfulness-based STOP touching your face practice"|1. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
79492039|NCT04713410|Drug|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
79656573|NCT03939182|Drug|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
79656574|NCT03935633|Drug|CN128 Tablets|Iron chelator， oral tablets
79656575|NCT03901807|Device|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
79656576|NCT03887702|Other|Best Practice|Receive best practice
79656577|NCT03887702|Drug|Entecavir|Given PO
79341588|NCT05289479|Procedure|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
79341589|NCT05289479|Procedure|no pre-heating of resin composite before application|The control group
79341590|NCT05360693|Procedure|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done & patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
79341591|NCT05360693|Procedure|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
79341592|NCT04245605|Procedure|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
79341593|NCT05324969|Behavioral|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
79341594|NCT05324969|Other|healthy education|9 health education emails will be sent to participating parents in the control group
79341595|NCT02128269|Biological|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
79492040|NCT04713332|Dietary Supplement|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
79656578|NCT03887702|Drug|Tenofovir Alafenamide|Given PO
79656579|NCT03887702|Drug|Tenofovir Disoproxil Fumarate|Given PO
79656580|NCT03878589|Drug|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
79656581|NCT03878589|Drug|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
79656582|NCT03875326|Device|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
79656583|NCT03875326|Device|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
79656584|NCT03875326|Device|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
79656585|NCT03875326|Device|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
79656586|NCT03843190|Behavioral|Take of Pounds Sensibly (TOPS)|Experimental arm: Dietician-facilitated Wait-list control arm: Peer-led
79813974|NCT00846521|Drug|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
79341596|NCT05324735|Drug|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
79341597|NCT05324735|Drug|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
79656588|NCT03832829|Device|Indirect composite restoration|Restoration of tooth with extensive substance loss
79656589|NCT03827850|Drug|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
79341598|NCT05360459|Radiation|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
79341599|NCT01626885|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
79341600|NCT05360225|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
79341601|NCT05359055|Drug|SPH3127 tablet|100mg once daily on Day 1 and Day 8
79492041|NCT04713332|Dietary Supplement|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
79492042|NCT04713332|Dietary Supplement|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
79492043|NCT05087186|Behavioral|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~Sessions 1 and 2: Guided imagery~Sessions 3 and 4: FLASH technique~Session 5: Refresher on guided imagery and FLASH technique"
79492044|NCT00476827|Drug|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
79492045|NCT00476827|Drug|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
79492046|NCT00476827|Drug|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
79492047|NCT00476827|Drug|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
79341602|NCT05359055|Drug|Itraconazole|200mg once daily from Day 3 to Day10.
79492048|NCT00476827|Drug|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
79492049|NCT00476827|Drug|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
79492050|NCT05084300|Other|Pain Neuroscience Education|A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
79492051|NCT05084300|Other|Usual care|The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
79341603|NCT05359055|Drug|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
79341604|NCT05359055|Drug|Rifampin|600mg once daily from Day 3 to Day13.
79341605|NCT02524379|Drug|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
79341606|NCT02524145|Other|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
79341607|NCT02524145|Drug|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
79656590|NCT03813836|Drug|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
79341608|NCT02524145|Drug|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
79341609|NCT02524145|Drug|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
79341610|NCT05357417|Drug|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
79656591|NCT03801330|Other|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
79656592|NCT03801330|Other|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
79341611|NCT05357417|Drug|Bevacizumab|15mg/kg, day 1
79341612|NCT01658813|Drug|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
79341613|NCT02187471|Drug|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
79492052|NCT04330898|Device|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
79679459|NCT02951078|Procedure|Electrical transurethral resection of bladder tumor|
79492053|NCT00901303|Drug|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
79492054|NCT05083676|Behavioral|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
79492055|NCT00459121|Drug|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
79679460|NCT05319171|Device|TAVR|TAVR
79341614|NCT02187471|Drug|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
79341615|NCT02187471|Drug|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
79492056|NCT00459121|Drug|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
79492057|NCT00459121|Drug|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
79492058|NCT00459121|Procedure|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
79656593|NCT03796988|Device|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
79656594|NCT03740048|Other|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
79341616|NCT02187471|Drug|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
79341617|NCT02525471|Drug|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
79341618|NCT05285423|Procedure|Novel technique of Vocal cord Laterlization with Prolene suture.|The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
79341619|NCT05284409|Drug|Pethidine|36 patients will receive 0.5 mg/kg Pethidine IVI
79341620|NCT05284409|Drug|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI
79492059|NCT04696796|Procedure|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
79656595|NCT03740048|Drug|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
79656596|NCT03733951|Drug|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
79341621|NCT05284409|Drug|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI
79341622|NCT01658735|Device|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
79341623|NCT01658735|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
79341624|NCT01658735|Device|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
79341625|NCT02523599|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
79341626|NCT02523599|Other|Placebo|Plain collagen implant (vehicle)
79341627|NCT05492357|Other|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
79341628|NCT05492357|Other|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
79341629|NCT05490797|Other|app based training with conventional therapy|The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.
79341630|NCT05490797|Other|conventional therapy|conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
79492060|NCT04696796|Procedure|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
79492061|NCT00432445|Radiation|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
79492062|NCT00432445|Procedure|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
79492063|NCT05061680|Device|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
79492064|NCT05347303|Other|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
79492065|NCT05347303|Other|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
79492066|NCT05343403|Other|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
79492067|NCT04691024|Other|Exercise|Spinal stabilization exercises
79492068|NCT00904423|Drug|Vitamin D|up to 2400 mg; oral tablet
79656597|NCT03730649|Drug|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
79656598|NCT03730649|Radiation|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
79341631|NCT05321303|Other|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
79341632|NCT05321303|Other|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
79656599|NCT03683355|Radiation|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
79813975|NCT00698945|Drug|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
79341633|NCT04422353|Other|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
79341634|NCT04422353|Other|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
79656600|NCT03645031|Other|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
79656601|NCT03645031|Other|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
79656602|NCT03612596|Behavioral|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
79656603|NCT03612596|Behavioral|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
79813976|NCT00698945|Drug|Alphagan|Alphagan: two drops a day for 28 days
79813977|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
79813978|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
79813979|NCT00790842|Drug|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
79813980|NCT00790842|Drug|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
79341635|NCT05354999|Dietary Supplement|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
79341637|NCT02187159|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
79492069|NCT04689698|Diagnostic Test|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
79341638|NCT02187159|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
79492070|NCT00904189|Radiation|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
79656604|NCT03598426|Drug|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
79656605|NCT03561805|Device|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
79341639|NCT02187159|Drug|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
79341640|NCT02187159|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
79656606|NCT03558204|Procedure|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
79341641|NCT02335411|Biological|pembrolizumab|IV infusion
79341642|NCT02335411|Drug|cisplatin|IV infusion
79341643|NCT02335411|Drug|5-FU|IV infusion
79341644|NCT02335411|Drug|capecitabine|oral tablets
79656607|NCT03558204|Procedure|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
79656608|NCT03521037|Drug|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
79998570|NCT02889133|Procedure|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
79492071|NCT05328895|Other|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
79341645|NCT02186301|Drug|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
79341646|NCT02186301|Drug|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
79341647|NCT02186223|Device|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
79341648|NCT02163057|Biological|INO-3112|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
79341649|NCT02163057|Device|CELLECTRA™-5P|CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
79656609|NCT03507777|Device|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
79656610|NCT03507777|Device|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
79656611|NCT03499444|Drug|Rucaparib|Rucaparib will be administered twice daily
79656612|NCT03494322|Drug|Avelumab|Avelumab 10 mg/kg given IV
79492072|NCT00399841|Device|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
79341650|NCT02185521|Other|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
79492073|NCT00387673|Behavioral|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
79492074|NCT04669808|Drug|STP705|Dry powder for intra-and peri-lesional injection.
79492075|NCT00879619|Drug|sunitinib malate|Given PO
79492076|NCT00879619|Drug|docetaxel|Given IV
79492077|NCT00879619|Drug|prednisone|Given PO
79341651|NCT01599585|Behavioral|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
79492078|NCT05040698|Drug|Fostamatinib|Open label Fostamatinib
79492079|NCT00382616|Drug|Phosphatidylserine-Omega3|
79492080|NCT00878605|Drug|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
79341652|NCT02185053|Drug|CPC-201|
79492081|NCT00878605|Drug|Placebo|Placebo control
79492082|NCT04529174|Dietary Supplement|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
79492083|NCT04529174|Dietary Supplement|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
79492084|NCT00353275|Drug|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
79492085|NCT00353275|Drug|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
79492086|NCT00822679|Drug|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
79998571|NCT01333423|Drug|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
79341653|NCT02161731|Drug|Evacetrapib|Oral administration
79341654|NCT02161731|Drug|Warfarin|Oral administration
79341655|NCT02124759|Drug|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
79341656|NCT02124759|Drug|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
79341657|NCT02124759|Drug|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
79341658|NCT02124759|Other|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
79341659|NCT02124759|Other|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
79341660|NCT02302339|Drug|glembatumumab vedotin|
79492087|NCT00822679|Other|Placebo|Subjects are given placebo for 3 consecutive nights
79492088|NCT04652180|Procedure|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
79492089|NCT05034614|Diagnostic Test|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
79492090|NCT05034614|Diagnostic Test|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
79492091|NCT00323635|Drug|tolterodine|tablet, 4 mg, daily, 1 month
79492092|NCT00314353|Drug|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles*~*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
79492093|NCT00314353|Drug|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
79492094|NCT00314353|Drug|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles*#~*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
79492095|NCT00314353|Drug|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
79492096|NCT04642976|Device|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
79492097|NCT00279409|Drug|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
79492098|NCT00279409|Drug|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
79492099|NCT00253981|Device|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
79492100|NCT05235919|Device|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
79492101|NCT05235919|Other|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
79998572|NCT01333423|Drug|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
79341661|NCT02302339|Drug|glembatumumab vedotin and varlilumab|
79341662|NCT02302339|Drug|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
79341663|NCT02302339|Drug|glembatumumab vedotin and CDX-301|
79341664|NCT04895917|Drug|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
79341665|NCT02161575|Drug|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
79341666|NCT02370121|Drug|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
79492102|NCT00804349|Device|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
79492103|NCT00178477|Procedure|MRI with breath-holding|Breath holding for diminished tumor motion.
79492104|NCT00379093|Behavioral|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~A personalized risk report;~An educational booklet titled Healthy Drinking as You Age;~A drinking diary;~Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
79492105|NCT00379171|Behavioral|Cow's milk with fish oil|
79492106|NCT00379171|Behavioral|Cow's milk without fish oil|
79492107|NCT00379171|Behavioral|Formula with fish oil|
79341667|NCT02370121|Drug|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
79492108|NCT00379171|Behavioral|Formula without fish oil|
79341668|NCT02161185|Drug|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
79492109|NCT02973373|Device|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
79492110|NCT02973373|Other|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
79492111|NCT00379249|Drug|Rosuvastatin|
79492112|NCT00801931|Drug|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
79656613|NCT03494322|Drug|Cetuximab|"Cetuximab 500* mg/m2 given IV~*Cetuximab dose will be dependent on outcome of safety run-in."
79492113|NCT00801931|Radiation|Total Body Irradiation|
79492114|NCT00801931|Drug|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
79492115|NCT00801931|Drug|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
79492116|NCT00801931|Drug|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
79492117|NCT00801931|Drug|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
79492118|NCT00801931|Drug|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
79492119|NCT00801931|Drug|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG [horse]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
79492120|NCT00801931|Drug|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
79492121|NCT00801931|Drug|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
79656614|NCT03441633|Drug|apixaban|current or new medication
79656615|NCT03441633|Drug|dabigatran|current or new medication
79492122|NCT00382850|Procedure|Nissen fundoplication|
79492123|NCT05348642|Dietary Supplement|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
79492124|NCT05348642|Dietary Supplement|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
79656616|NCT03441633|Drug|VKA|current or new medication
79656617|NCT03441633|Drug|rivaroxaban|current or new medication
79656618|NCT03397394|Drug|Rucaparib|Rucaparib will be administered daily.
79656619|NCT03373760|Biological|Durvalumab|Given IV
79656620|NCT03373760|Other|Laboratory Biomarker Analysis|Correlative studies
79656621|NCT03373760|Biological|Tremelimumab|Given IV
79656622|NCT03324880|Biological|rhPTH (1-84)|rhPTH (1-84) SC injection.
79656623|NCT03324880|Biological|Placebo|Placebo QD SC injection.
79656624|NCT03290794|Drug|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
79341669|NCT02159469|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
79341670|NCT02123511|Drug|acetylcysteine|Oral rinse
79341671|NCT02123511|Other|placebo|Oral rinse
79341672|NCT02123511|Other|quality-of-life assessment|Ancillary studies
79341673|NCT02123511|Other|questionnaire administration|Ancillary studies
79341674|NCT04746339|Drug|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
79341675|NCT04746339|Drug|Placebo|placebo twice daily for 30 days
79341676|NCT02122887|Behavioral|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
79492125|NCT00780481|Drug|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
79341677|NCT02182947|Device|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
79341678|NCT04755075|Drug|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
79341679|NCT04755075|Drug|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
79341680|NCT02370043|Drug|KQ-791|Capsules administered orally while fasting, in up to 3 periods
79341681|NCT02370043|Drug|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
79492126|NCT04278326|Procedure|Vaginal Biopsy|"Vaginal biopsies~Additional cervical and vaginal biopsies~Non invasive cervico-vaginal swab like a smear"
79492127|NCT00019747|Drug|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
79492128|NCT00019747|Procedure|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
79492129|NCT00019747|Other|Placebo|oral placebo once daily
79492130|NCT02970799|Device|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
79341682|NCT02370043|Drug|Placebo|Capsules, administered orally, in 1 period
79341683|NCT02301403|Drug|Nicotine patch|8 weeks of nicotine patch
79656625|NCT03107897|Other|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
79656626|NCT03059342|Procedure|single event multilevel surgery|
79656627|NCT03053440|Drug|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
79656628|NCT03053440|Drug|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
79341684|NCT02301403|Behavioral|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
79656629|NCT02986100|Drug|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and [14C]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of [14C]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of [14C]-rucaparib
79656630|NCT02986100|Drug|Rucaparib|200 & 300 mg tablet
79341685|NCT02301403|Drug|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
79492131|NCT00759577|Drug|Solifenacin|5mg and 10 mg, oral once daily
79492132|NCT05338112|Diagnostic Test|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
79492133|NCT00748579|Drug|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
79492134|NCT00748579|Drug|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
79492135|NCT05329922|Behavioral|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
79492136|NCT04524962|Biological|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
79492137|NCT00746239|Drug|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
79492138|NCT00746239|Drug|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
79492139|NCT04977674|Drug|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
79492140|NCT04977674|Drug|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
79492141|NCT04977674|Drug|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
79341686|NCT02301403|Drug|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
79656631|NCT02985684|Device|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
79341687|NCT02301403|Behavioral|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
79341688|NCT02301403|Behavioral|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
79341689|NCT02301403|Behavioral|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
79341690|NCT02301169|Behavioral|Heat pain stimuli A|
79341691|NCT02301169|Behavioral|Video A|
79492144|NCT04963790|Behavioral|Tailored COVID-19 vaccine messages|Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
79492145|NCT04963790|Other|Other health messages|Other health messages unrelated to COVID-19 will be sent to participants in the control arm
79492146|NCT04960124|Drug|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
79656632|NCT02965027|Drug|Prazosin|
79656633|NCT02965027|Drug|Placebos|
79679461|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
79492147|NCT00402883|Drug|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
79492148|NCT00402883|Drug|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
79492149|NCT00402883|Procedure|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
79492150|NCT00402883|Other|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
79492151|NCT00402883|Other|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
79492152|NCT00402883|Drug|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
79813981|NCT00790842|Drug|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
79341692|NCT02301169|Drug|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
79341693|NCT02301169|Behavioral|Heat pain stimuli B|
79341694|NCT02301169|Behavioral|Video B|
79341695|NCT02301169|Drug|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
79341696|NCT02333383|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79341697|NCT02332915|Behavioral|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
79341698|NCT02369341|Biological|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
79341699|NCT02121795|Drug|FTC/TDF|200/300 mg FDC tablets administered orally once daily
79341700|NCT02121795|Drug|F/TAF|Tablets administered orally once daily
79341701|NCT02121795|Drug|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
79341702|NCT02121795|Drug|FTC/TDF Placebo|Tablets administered orally once daily
79341703|NCT02121795|Drug|F/TAF Placebo|Tablets administered orally once daily
79341704|NCT02158533|Drug|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79341705|NCT02158533|Drug|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79341706|NCT02158533|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79679462|NCT02950376|Other|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
79813982|NCT04107012|Device|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
79813983|NCT04104204|Drug|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
79813984|NCT04104204|Drug|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
79341707|NCT02120781|Biological|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
79492153|NCT05311826|Procedure|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
79813985|NCT04107324|Procedure|ARAPS|In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
79341708|NCT02120781|Drug|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
79341709|NCT02120625|Device|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
79341710|NCT02120469|Drug|everolimus|Given PO
79341711|NCT02120469|Drug|eribulin mesylate|Given IV
79341712|NCT02120469|Other|pharmacological study|Correlative studies
79492154|NCT05311826|Procedure|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
79492155|NCT04940312|Behavioral|App-based physical activity coaching|Individualized app-based coaching via a smartphone
79813986|NCT04107324|Procedure|PVE|Portal vein embolisation
79341713|NCT02120469|Other|laboratory biomarker analysis|Optional correlative studies
79341714|NCT02157519|Other|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
79341715|NCT02180061|Biological|Pembrolizumab|IV infusion
79341716|NCT02179515|Biological|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
79341717|NCT02120157|Drug|Cyclophosphamide|Chemotherapy administration
79813987|NCT00915486|Procedure|Good Standard of Care (GSoC)|Procedural treatment twice per week
79813988|NCT00915486|Biological|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
79813989|NCT00915486|Biological|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
79492156|NCT04939844|Drug|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
79341718|NCT02120157|Radiation|TBI|Radiation Therapy
79341719|NCT02120157|Drug|Busulfan|Chemotherapy Administered
79492157|NCT04936568|Other|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
79492158|NCT05295212|Drug|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
79341720|NCT02120157|Other|Unmanipulated Bone Marrow|Bone Marrow Transplant
79341721|NCT02120157|Drug|Tacrolimus|Immunosuppressive Drug Administered
79341722|NCT02120157|Drug|Mycophenolate mofetil|Immunosuppressive Drug Administered
79341723|NCT02119299|Device|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
79341724|NCT04753827|Other|Drug eluting stent|Put a Drug eluting stent in the blood vessel
79341725|NCT04753827|Other|Durg coated balloon|Put a Durg coated balloon in the blood vessel
79341726|NCT02156271|Drug|ramelteon|
79341727|NCT02156271|Drug|placebo|
79341728|NCT01365455|Drug|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
79492159|NCT05287178|Behavioral|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
79492160|NCT04328948|Radiation|Chemoradiotherapy|Chemoradiotherapy
79492161|NCT05286320|Drug|Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
79492162|NCT00728845|Biological|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
79492163|NCT00728845|Drug|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
79492164|NCT00728845|Drug|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
79492165|NCT00728845|Drug|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
79813990|NCT02602392|Behavioral|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
79341729|NCT01365455|Drug|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
79341730|NCT02155881|Drug|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
79341731|NCT02155881|Drug|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
79341732|NCT05279807|Drug|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
79341733|NCT05279807|Drug|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
79341734|NCT05319431|Biological|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
79341735|NCT05319431|Drug|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
79341736|NCT05319431|Procedure|TACE|On demand TACE
79341737|NCT05276531|Drug|subcutaneous progesterone|clinical pregnancy rates
79341738|NCT05276531|Drug|vaginal progesterone|clinical pregnancy rates
79341739|NCT05352581|Diagnostic Test|BD Veritor At-Home|BD Veritor At-Home rapid self testing
79341740|NCT05352581|Diagnostic Test|BD Veritor Professional|BD Veritor Professional rapid test
79341741|NCT05318651|Device|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
79341742|NCT01658579|Drug|HOE901-U300 (new formulation of insulin glargine)|
79341743|NCT01658579|Drug|Lantus (insulin glargine)|
79492166|NCT04306016|Other|Sensory stimulation|Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
79492167|NCT00379873|Device|ProAdjuster|
79341744|NCT05561309|Drug|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
79341745|NCT05352503|Device|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
79341746|NCT05270525|Drug|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
79341747|NCT05270525|Drug|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
79341748|NCT05317013|Drug|CBD|CBD
79341749|NCT05317013|Other|Placebo|Placebo
79341750|NCT04949555|Other|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
79492168|NCT00726037|Drug|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
79492169|NCT04890860|Other|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
79492170|NCT04928053|Genetic|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
79341751|NCT04422509|Biological|lanadelumab|single dose, or two doses administered iv
79341752|NCT04422509|Other|regular care|no lanadelumab administration, treated according to regular care
79341753|NCT05313893|Biological|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
79679463|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
79679464|NCT02942901|Procedure|PET-CT|
79984952|NCT03697616|Device|Ridge augmentation with sticky bone and GBR|"Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~Periosteal releasing incision will be done to provide flap advancement for tension free closure~Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
79341754|NCT05349773|Procedure|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
79341755|NCT05268497|Drug|Esketamine|Esketamine will be self-administered as nasal spray.
79341756|NCT05268497|Behavioral|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
79341757|NCT05268497|Drug|Antidepressant|Antidepressant will be administered orally.
79341758|NCT05311943|Drug|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
79341759|NCT05557175|Device|Repetitive transcranial magnetic stimulation|The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
79341760|NCT05557175|Device|Sham rTMS|The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
79341761|NCT05266859|Other|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
79341762|NCT05266859|Other|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
79341763|NCT05266859|Other|PRF|PRF will be placed directly over the exposed pulp
79341764|NCT05310851|Other|PIOMI and non-nutritive sucking|"PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes."
79341765|NCT02154087|Biological|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
79492171|NCT00703885|Drug|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
79813991|NCT02602392|Behavioral|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
79813992|NCT00574288|Drug|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
79813993|NCT00574288|Drug|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
79984953|NCT02439892|Behavioral|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
79492172|NCT00703885|Drug|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
79341766|NCT05219201|Device|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~at -30°C for sham cryotherapy session~at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
79341767|NCT05346731|Drug|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
79341768|NCT05346731|Drug|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
79656634|NCT02959450|Dietary Supplement|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
79656635|NCT02952534|Drug|Rucaparib|Rucaparib will be administered daily
79813994|NCT00574288|Other|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
79341769|NCT05346731|Drug|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight > 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
79492173|NCT00703885|Drug|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
79656636|NCT02949934|Drug|Tolcapone|
79656637|NCT02949934|Drug|Placebo|
79813995|NCT00574288|Other|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
79656638|NCT02935634|Biological|Nivolumab|Specified dose on specified days
79656639|NCT02935634|Biological|Ipilimumab|Specified dose on specified days
79656640|NCT02935634|Biological|Relatlimab|Specified dose on specified days
79341770|NCT05346731|Drug|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
79341771|NCT02118597|Drug|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
79341772|NCT02118597|Drug|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
79492174|NCT00703339|Drug|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~Cohort 1: dosed at 3 breaths (18 mcg)~Cohort 2: dosed at 6 breaths (36 mcg)~Cohort 3: dosed at 9 breaths (54 mcg)~Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
79492175|NCT04330586|Drug|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
79341773|NCT02118597|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
79341774|NCT02118597|Drug|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
79492176|NCT00382694|Drug|Fludarabine|
79492177|NCT04508036|Diagnostic Test|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
79492178|NCT04508036|Diagnostic Test|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
79492179|NCT04508036|Diagnostic Test|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
79492180|NCT04495556|Diagnostic Test|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
79492181|NCT04828057|Drug|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
79492182|NCT04857866|Drug|XmAb27564|Single ascending dose of XmAb27564
79492183|NCT04857866|Drug|Placebo|Single dose of placebo
79492184|NCT00000127|Procedure|Optic Nerve Sheath Decompression Surgery|
79341775|NCT01659125|Behavioral|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
79492185|NCT04495400|Procedure|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
79492186|NCT02973451|Drug|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
79492187|NCT02973451|Drug|local Bupivacaine|Bupivacaine Trocar Site Infiltration
79492188|NCT00000193|Drug|Gamma hydroxybutyric|
79492189|NCT00000199|Drug|Piracetam|
79492190|NCT00668785|Drug|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
79492191|NCT04844840|Drug|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
79492192|NCT04844840|Other|Placebo|Saline
79492193|NCT00655057|Drug|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
79492194|NCT00655057|Behavioral|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
79492195|NCT00655057|Procedure|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using [99mTc]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
79341776|NCT05218889|Drug|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40-60mg bid, according to BSA, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
79492196|NCT00000211|Drug|Buprenorphine|
79341777|NCT05218889|Drug|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
79341778|NCT05262569|Other|ileus|retrospectively allocation according to a postoperative outcome-ileus
79341779|NCT01657253|Drug|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
79341780|NCT01657253|Drug|Systane|Instill 1 drop in each eye four times a day, for 60 days
79341781|NCT02117427|Biological|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
79492197|NCT04358432|Drug|AK102|Administered by subcutaneous injection
79492198|NCT04358432|Drug|Placebos|Administered by subcutaneous injection
79492199|NCT04358432|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
79492200|NCT00635167|Drug|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline [Visit 2]); week 5 (middle of treatment [Visit 3]); week 10 (end of treatment [Visit 4]); week 18 (2 months after end of EBRT [Visit 5]); week 26 (4 months after end of EBRT [Visit 6]); and week 36 (6 months after end of EBRT [Visit 7]).
79492201|NCT04353830|Drug|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
79492202|NCT04353830|Drug|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
79341782|NCT02117349|Drug|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
79341783|NCT02117349|Device|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
79341784|NCT02117349|Drug|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
79341785|NCT05213663|Other|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
79492203|NCT04353830|Drug|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
79492204|NCT00000217|Drug|Carbamazepine|
79492205|NCT00000223|Drug|Buprenorphine|
79492206|NCT00630487|Drug|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
79492207|NCT00630487|Drug|Somatropin|Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
79492208|NCT00000229|Drug|Buprenorphine|
79492209|NCT00000235|Drug|Buprenorphine|
79492210|NCT03659240|Other|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
79492211|NCT03659240|Other|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
79341786|NCT05167253|Biological|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
79341787|NCT01626495|Biological|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
79341788|NCT02177175|Drug|Carvedilol|
79341789|NCT02177175|Other|placebo|
79341790|NCT02153073|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
79341791|NCT01657877|Drug|Calcium sodium phosphosilicate|CSP high percentage weight by weight
79656641|NCT02935634|Biological|BMS-986205|Specified dose on specified days
79656642|NCT02935634|Drug|Rucaparib|Specified dose on specified days
79341792|NCT01657877|Drug|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
79341793|NCT01657877|Drug|Placebo|No CSP and no fluoride
79341794|NCT05254925|Drug|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
79341795|NCT05254925|Other|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
79341796|NCT05254925|Drug|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
79341797|NCT05254925|Other|Petrolatum vehicle|Petrolatum vehicle
79341798|NCT05205941|Drug|MMV688533|Not exceeding 200mg
79341799|NCT05205473|Procedure|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
79341800|NCT05205473|Procedure|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
79341801|NCT05160935|Behavioral|Education|"Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken."
79656643|NCT02864992|Drug|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
79656644|NCT02740712|Drug|Caffeine|200 mg (4 x 50mg) Tablet
79341802|NCT04422197|Biological|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
79341803|NCT04422197|Procedure|surgery without botox injection|surgery without botox injection
79656645|NCT02740712|Drug|Warfarin|10 mg (2 x 5mg) Tablet
79341804|NCT05204303|Diagnostic Test|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
79341805|NCT05204303|Other|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
79656646|NCT02740712|Drug|Omeprazole|40 mg Tablet
79656647|NCT02740712|Drug|Midazolam|5 mg/mL
79656648|NCT02740712|Drug|digoxin|.25 mg Tablet
79341806|NCT05204303|Other|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
79341807|NCT05203367|Drug|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
79492212|NCT00379327|Procedure|Acupuncture|Acupuncture administered in last three weeks of pregnancy
79492213|NCT00379327|Device|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
79492214|NCT00000241|Drug|Flupenthixol|
79492215|NCT00000253|Drug|10% N2O|
79492216|NCT00000253|Drug|20% N2O|
79492217|NCT00000253|Drug|30% N2O|
79492218|NCT00000253|Drug|40% N2O|
79492219|NCT00000259|Drug|15 % Nitrous oxide|
79341808|NCT05203367|Drug|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
79656649|NCT02740712|Drug|Vitamin K|10 mg Tablet
79492220|NCT00000259|Drug|0.3 % Sevoflurane|
79492221|NCT00000259|Drug|30% Nitrous oxide|
79492222|NCT00000259|Drug|0.6% Sevoflurane|
79656650|NCT02740712|Drug|Rucaparib|200 & 300 mg tablet
79656651|NCT02684578|Drug|Metformin|
79656652|NCT02612129|Drug|arimoclomol|
79656653|NCT02612129|Drug|Placebo|
79341809|NCT05203289|Drug|BI 695501 - higher concentration|BI 695501 - higher concentration
79656654|NCT02580305|Drug|SUVN-502|Once-daily, tablets, orally
79492223|NCT00000259|Other|Placebo|
79656655|NCT02580305|Drug|Placebo|Once-daily, tablets, orally
79656656|NCT02580305|Drug|Donepezil|Donepezil HCl (10 mg, once a day)
79341810|NCT05203289|Drug|BI 695501 - lower concentration|BI 695501 - lower concentration
79341811|NCT05370755|Drug|ICP-189|Administered orally
79492224|NCT04331665|Drug|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
79492225|NCT00379405|Drug|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
79492226|NCT04321538|Device|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
79492227|NCT04321538|Device|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
79492228|NCT04321538|Diagnostic Test|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
79656657|NCT02580305|Drug|Memantine|Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
79656658|NCT02279394|Drug|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
79656659|NCT02279394|Drug|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
79656660|NCT02279394|Drug|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
79656661|NCT02229578|Drug|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
79656662|NCT02229578|Drug|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
79656663|NCT02151513|Device|Intrathecal Pump Placement|
79656664|NCT02054741|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
79656665|NCT02054741|Other|Quality-of-Life Assessment|Ancillary studies
79656666|NCT02054741|Other|Survey Administration|Ancillary studies
79492229|NCT00379483|Drug|Deferasirox|
79492230|NCT00607477|Drug|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
79656667|NCT01821781|Drug|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
79492231|NCT00607477|Drug|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
79492232|NCT03603314|Drug|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
79492233|NCT03603314|Other|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
79656668|NCT01555463|Drug|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
79656669|NCT01555463|Drug|Vehicle foam|twice daily topical application
79813996|NCT05568654|Diagnostic Test|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen and UAT testing.
79813997|NCT05568654|Other|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
79813998|NCT00827788|Drug|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
79813999|NCT00827788|Drug|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
79341812|NCT02175771|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
79341813|NCT02175771|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
79814000|NCT00827866|Other|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
79341814|NCT02175771|Drug|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
79341815|NCT02175771|Drug|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
79492234|NCT03603314|Drug|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
79492235|NCT04423861|Drug|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
79492236|NCT04423861|Drug|Placebo|Patients will receive matching placebo BID for 7 days.
79492237|NCT04418869|Other|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
79492238|NCT04330196|Diagnostic Test|Oral glucose tolerance test|Participant ingests 75g of glucose
79492239|NCT04330196|Diagnostic Test|Ingestion of placebo|Participant ingests 700mg of aspartame
79492240|NCT00000271|Drug|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
79492241|NCT00000271|Drug|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
79341816|NCT02175771|Drug|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
79341817|NCT01657799|Drug|Veliparib|Veliparib capsules for oral administration
79341818|NCT01657799|Drug|Placebo|Placebo to veliparib capsules for oral administration
79341819|NCT01657799|Radiation|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
79341820|NCT05249777|Drug|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
79341821|NCT05249777|Drug|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
79341822|NCT02116803|Drug|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
79341823|NCT02116803|Drug|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
79341824|NCT05201027|Device|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
79341825|NCT05156411|Other|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
79341826|NCT02115321|Drug|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
79814001|NCT00827866|Other|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
79814002|NCT00790452|Drug|Aspirin|325 mg daily by mouth
79341827|NCT02115321|Drug|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
79341828|NCT02115321|Drug|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
79341829|NCT05248841|Drug|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
79341830|NCT05248841|Drug|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
79341831|NCT05248139|Drug|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
79341832|NCT05248139|Drug|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
79341833|NCT04230239|Drug|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
79341834|NCT05199389|Device|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
79814003|NCT00790452|Drug|Placebo|Tablet daily by mouth
79814004|NCT00823030|Procedure|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
79814005|NCT00823030|Drug|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
79492242|NCT00000277|Drug|Mazindol|
79814006|NCT00823030|Other|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
79341839|NCT05154851|Biological|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
79341840|NCT05154383|Biological|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
79341841|NCT05154383|Biological|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
79341842|NCT05245877|Drug|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
79341843|NCT05194475|Other|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
79492243|NCT04444544|Other|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
79492244|NCT00599131|Drug|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a < 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
79341844|NCT05194475|Other|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
79341845|NCT05245175|Other|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
79492245|NCT00599131|Drug|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
79492246|NCT00599131|Drug|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
79656670|NCT01534104|Procedure|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI & DSI, neurological/physical testing & brain MRI showing tumor &/or edema located in or near (<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), &/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately <48 hours before surgery*) fMRI to localize gray matter DTI, DSI & tractography to localize white matter, DSI & updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray &/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (<48 hours after surgery)
79679465|NCT00515645|Other|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
79341846|NCT05245175|Other|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
79341847|NCT05245175|Other|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
79341848|NCT05245175|Other|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
79341849|NCT05245175|Other|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
79341850|NCT05152277|Drug|HRS9531|Administered SC once
79492247|NCT00599131|Drug|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
79524723|NCT03830034|Drug|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins & milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline & then 4, 8 & 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
79341851|NCT05152277|Other|placebo|Administered SC once
79341852|NCT05152277|Drug|HRS9531|Administered SC for multiple dose
79341853|NCT05152277|Other|placebo|Administered SC for multiple dose
79341854|NCT05243381|Biological|20 ml blood test|20 ml blood test
79679466|NCT02950220|Drug|Ibrutinib|Given PO
79679467|NCT02950220|Other|Laboratory Biomarker Analysis|Correlative studies
79492248|NCT04302350|Procedure|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
79492249|NCT00584935|Drug|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
79341855|NCT05150171|Other|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
79492250|NCT04297358|Drug|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
79492251|NCT04295486|Drug|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
79492252|NCT00000289|Drug|Ondansetron|
79492253|NCT00000295|Drug|Micronized Progesterone|
79492254|NCT04384939|Device|magnetic-end Double-J ureteral stent|"Inserting the ureteral stent with magnet (same process as classic ureteral stent)~Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
79492255|NCT00000733|Drug|Ribavirin|
79656671|NCT01482715|Drug|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
79656672|NCT01378871|Drug|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
79492256|NCT04246723|Drug|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
79492257|NCT04246723|Drug|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
79492258|NCT04246723|Drug|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
79341856|NCT05149157|Other|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
79492259|NCT00000301|Drug|Amantadine|
79492260|NCT00000307|Drug|Naltrexone|
79492261|NCT00000313|Drug|Fenfluramine|
79492262|NCT00000757|Biological|gp160 Vaccine (MicroGeneSys)|
79492263|NCT00000319|Drug|Buprenorphine|
79492264|NCT00000325|Behavioral|Gonadorelin|
79656673|NCT01360606|Radiation|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
79656674|NCT01257919|Drug|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
79656675|NCT01257919|Drug|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
79679468|NCT02950220|Biological|Pembrolizumab|Given IV
79492265|NCT04415996|Other|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
79492266|NCT04415996|Other|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 90 seconds each side.
79656676|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
79656677|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
79656678|NCT00239096|Drug|losartan (drug)|
79341857|NCT05148845|Biological|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
79492267|NCT04181203|Drug|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
79656679|NCT04532398|Other|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
79656680|NCT04532398|Other|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
79656681|NCT04532554|Drug|Growth Hormone|Recombinant growth hormone will be used
79656682|NCT04532554|Drug|Placebo|Saline injection with the same amount
79679469|NCT00515684|Drug|bevacizumab (Avastin)|
79814007|NCT00823186|Drug|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
79656683|NCT04532281|Drug|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
79341858|NCT05192837|Behavioral|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~Informative content about advantages of smoking cessation~Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
79341859|NCT05192525|Device|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
79341860|NCT05475197|Device|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
79341861|NCT02367781|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
79341862|NCT02367781|Drug|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
79341863|NCT02367781|Drug|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
79656684|NCT00239135|Drug|PEP005|
79656685|NCT04532086|Diagnostic Test|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks & evaluation of dilatation of internal os & measurement of uterocervical angle between(18-28)weeks gestational age.
79656686|NCT04532203|Drug|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
79814008|NCT00820378|Other|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
79814009|NCT02550496|Device|Dermoscopy|
79341864|NCT02367781|Drug|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
79341865|NCT02152761|Drug|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
79492268|NCT04181203|Radiation|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
79656687|NCT04532203|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
79814010|NCT00626392|Drug|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
79814011|NCT00626392|Drug|aspirin (ASA)|325 mg tablets administered once daily
79814012|NCT00626392|Drug|aspirin placebo (ASA Pbo)|Tablets administered once daily
79814013|NCT00828022|Biological|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
79823657|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
79656688|NCT02217163|Drug|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
79492269|NCT04181203|Drug|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
79656689|NCT02217202|Device|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
79656690|NCT00239174|Drug|SR147778|
79984954|NCT02439892|Behavioral|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
79984955|NCT03702686|Device|FEEDBACK System|Smart Nipple Shield and Monitor Unit
79984956|NCT03701438|Biological|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
79984957|NCT02440048|Device|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
79984958|NCT02440048|Device|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
79984959|NCT04050332|Behavioral|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
79656691|NCT04531852|Other|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
79656692|NCT04531852|Behavioral|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
79984960|NCT03188458|Other|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 [approximately 4-8 weeks of age]).
79984961|NCT03702530|Biological|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
79984962|NCT03702530|Other|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
79984963|NCT03702530|Biological|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
79984964|NCT02443246|Drug|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
79984965|NCT02443246|Drug|Placebo|
79984966|NCT03702452|Other|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
79984967|NCT03702452|Other|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
79302547|NCT04992663|Device|PICO glasses and controller with BirthVR|"PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~Counseling video (cesarean section, epidural anesthesia)"
79492270|NCT03521102|Drug|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
79492271|NCT03521102|Drug|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
79492272|NCT00000763|Drug|TNP-470|
79492273|NCT00380263|Drug|PACAP38|10 pmol/kg/min given one time
79492274|NCT00000769|Drug|Interleukin-4|
79492275|NCT00380341|Procedure|Instrument-applied spinal manipulative therapy|
79492276|NCT05440591|Drug|Dapagliflozin|Dapagliflozin 10mg tablets
79656693|NCT04531774|Behavioral|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
79823658|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
79984968|NCT03188302|Other|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
79984969|NCT02443168|Drug|AG-221|Part 1: oral solution containing 100 mg [14C]-AG-221
79984970|NCT02443168|Radiation|14C AG-221|5 mL of 100 micrograms [14C] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
79341866|NCT02152761|Other|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
79341867|NCT05191277|Drug|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
79341868|NCT05191277|Drug|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
79341869|NCT05191277|Behavioral|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
79341870|NCT05191277|Behavioral|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
79341871|NCT04242173|Drug|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
79656694|NCT04531774|Behavioral|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
79656695|NCT00239213|Drug|catechin extracts (health food)|
79823659|NCT02581046|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
79823660|NCT02580890|Device|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
79823661|NCT02580890|Device|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
79823662|NCT00664209|Drug|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
79823663|NCT00664209|Drug|placebo|placebo therapy
79341872|NCT02152605|Drug|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
79341873|NCT02152605|Drug|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
79341874|NCT02152371|Drug|Dulaglutide|Administered SQ
79341875|NCT02152371|Drug|Placebo|Administered SQ
79341876|NCT02152371|Drug|Insulin Glargine|Administered SQ
79341877|NCT02152371|Drug|Metformin|Administered orally
79341878|NCT02332291|Drug|Escitalopram|Escitalopram 10-20mg daily
79341879|NCT02332291|Drug|Bupropion XL|Bupropion XL 150-450mg daily
79341880|NCT01656395|Drug|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
79341881|NCT01656395|Drug|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
79823664|NCT05254977|Drug|Standard Preparation|Any kind of intervention received to reduce adverse effects
79984971|NCT02443948|Other|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
79984972|NCT02439580|Dietary Supplement|Annona muricata extract|ethanol-soluble fraction of water extract
79984973|NCT02439580|Dietary Supplement|Placebo|maltose
79656696|NCT04531930|Procedure|surgery|Colorectal surgery, mainly total proctocolectomy.
79656697|NCT04531930|Procedure|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
79656698|NCT04531930|Other|self choosed methods|A patient chooses a method for himself other than surgery.
79656699|NCT04532008|Behavioral|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
79656700|NCT00263367|Other|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
79656701|NCT04531423|Drug|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
79656702|NCT04531423|Other|SSRI + placebo|placebo
79656703|NCT04531657|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
79341882|NCT01656395|Drug|Placebo|Parts I-II: Participants will receive Placebo tablets QD
79656704|NCT00239252|Drug|Interferon alfacon-1|
79656705|NCT04531306|Other|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
79823665|NCT04074434|Device|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
79823666|NCT00785889|Procedure|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
79656706|NCT00263406|Drug|Administration of an ACE-inhibitor or not|
79656707|NCT04531267|Dietary Supplement|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
79656708|NCT04531228|Procedure|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight <60kg, or 12mg for patients weight more than 60Kg.
79656709|NCT04531150|Drug|INV-101|Subjects will be randomized to receive INV-101 tablets
79656710|NCT04531150|Drug|Placebo|Subjects will be randomized to receive placebo tablets
79823667|NCT03192332|Device|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
79823668|NCT03192332|Drug|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
79823669|NCT02555943|Drug|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
79823670|NCT02555943|Drug|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
79656711|NCT00414284|Drug|Increased dose of Kaletra|
79656712|NCT04531345|Diagnostic Test|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
79656713|NCT04531072|Drug|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
79656714|NCT04531072|Drug|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
79984974|NCT03031496|Drug|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
79984975|NCT03031496|Drug|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
79814014|NCT00828100|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
79984976|NCT03190486|Other|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
79984977|NCT03187990|Drug|[68Ga]PSMA-11|PET/MRI with [68Ga]PSMA will be compared to mpMRI for biopsy guidance.
79984978|NCT03187990|Drug|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
79341883|NCT02114931|Biological|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
79341884|NCT05185739|Drug|Pembrolizumab|Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
79341885|NCT05185739|Drug|Lenvatinib|Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight <60gk≥) for 6 weeks
79341886|NCT05185739|Drug|Pembrolizumab and Lenvatinib|Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
79341887|NCT05184881|Other|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
79341888|NCT05184881|Other|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
79341889|NCT05144711|Procedure|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
79341890|NCT05144711|Procedure|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
79341891|NCT05238935|Other|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
79492277|NCT05440591|Drug|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
79492278|NCT05440591|Drug|Dapagliflozin / metFORMIN Pill|Combination pill
79656715|NCT04530955|Device|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
79656716|NCT00414323|Drug|Duloxetine|
79984979|NCT03697382|Behavioral|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
79302548|NCT02485067|Drug|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
79302549|NCT02485067|Drug|Placebo(For THVD-201)|
79302550|NCT02485067|Drug|Detrusitol 2mg tablet|Tolterodine 2mg
79656717|NCT00414323|Drug|Escitalopram|
79656718|NCT00414323|Drug|Placebo|
79656719|NCT00263484|Drug|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
79656720|NCT00263484|Drug|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
79656721|NCT00263484|Drug|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
79656722|NCT04531033|Dietary Supplement|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
79341892|NCT05184725|Device|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
79341893|NCT05238623|Diagnostic Test|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
79341894|NCT05184413|Other|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
79341895|NCT05184413|Other|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
79656723|NCT04531033|Dietary Supplement|Placebo|placebo made to match dietary supplement being tested.
79656724|NCT04530721|Other|no intervention|we don't do any intervention
79656725|NCT00263523|Drug|[11C] (-)-RWAY|
79656726|NCT04530370|Biological|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
79656727|NCT00414401|Behavioral|Clinical Reminder|
79656728|NCT04530331|Behavioral|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
79656729|NCT02217319|Drug|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
79656730|NCT02217319|Drug|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
79656731|NCT00263601|Biological|Allergovit 6-grasses|Subcutaneous injections
79656732|NCT00263601|Other|Placebo|Subcutaneous injections
79656733|NCT02217397|Device|OA, CPAP, combination therapy|
79656734|NCT00414479|Drug|praziquantl, iron, ACT|
79656735|NCT02217514|Drug|Midazolam|
79656736|NCT02217514|Drug|BI 44370 low dose|
79656737|NCT02217514|Drug|BI 44370 medium dose|
79302551|NCT02485067|Drug|Placebo(For Detrusitol 2mg tablet)|
79341896|NCT05183789|Diagnostic Test|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
79341897|NCT01657019|Drug|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
79656738|NCT02217514|Drug|BI 44370 high dose|
79656739|NCT02217553|Drug|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
79656740|NCT04719312|Procedure|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
79656741|NCT02217631|Drug|BI 653048 BS H3PO4|
79656742|NCT02217631|Drug|Prednisolone low dose|
79656743|NCT02217631|Drug|Prednisolone high dose|
79656744|NCT02217631|Drug|Placebo|
79656745|NCT02217670|Drug|Metformin 1000 mg granules|
79656746|NCT02217670|Drug|Metformin 1000 mg film-coated tablets|
79656747|NCT00239291|Drug|Gefitinib, radiotherapy|
79656748|NCT02217748|Other|Survey questionnaire|
79656749|NCT00263640|Biological|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
79656750|NCT00263640|Drug|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
79656751|NCT02217826|Drug|DG3173|
79341898|NCT02329327|Biological|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
79656752|NCT02217826|Drug|Saline|
79656753|NCT02217826|Drug|Octreotide|
79984980|NCT03697382|Behavioral|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
79984981|NCT03697382|Behavioral|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
79984982|NCT03187912|Drug|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
79656754|NCT00239330|Drug|Rosuvastatin|
79656755|NCT00239330|Drug|Atorvastatin|
79656756|NCT04530097|Procedure|RFA|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
79341899|NCT05235269|Drug|I124-AT01 only|Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
79656757|NCT02218021|Drug|Samidorphan|
79656758|NCT02218021|Drug|Placebo|
79656759|NCT02218021|Drug|Oxycodone|
79656760|NCT04719234|Device|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
79656761|NCT02218060|Procedure|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
79656762|NCT02218060|Procedure|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
79814015|NCT00828100|Device|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
79814016|NCT00820690|Drug|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
79341900|NCT02328937|Device|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
79341901|NCT02328937|Device|lotrafilcon B|
79341902|NCT02328937|Device|comfilcon A|
79341903|NCT05181605|Drug|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
79341904|NCT02328547|Drug|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
79814017|NCT00820690|Drug|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
79814018|NCT00820690|Drug|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
79814019|NCT00820690|Procedure|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
79814020|NCT00828256|Procedure|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
79341905|NCT02328547|Drug|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
79341906|NCT02300311|Drug|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
79656763|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
79656764|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
79656765|NCT04529746|Behavioral|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
79656766|NCT04529668|Drug|vitamin D supplementation|vitamin D supplementation
79656767|NCT04529668|Drug|usual therapy for nasal polyposis|steroids ( systemic and local )
79656768|NCT00263679|Biological|Prophylaxis: Diphtheria, tetanus and pertussis|
79656769|NCT02218099|Drug|ASP8232|Oral
79656770|NCT02218099|Drug|Placebo|Oral
79656771|NCT00239408|Device|Pulmonary function Testing|
79656772|NCT00239408|Drug|tiotropium bromide|
79656773|NCT02218138|Behavioral|Learning 2 BREATHE|Mindfulness-based group program
79656774|NCT02218138|Behavioral|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
79656775|NCT02218177|Drug|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
79656776|NCT02218177|Drug|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
79656777|NCT02218177|Procedure|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
79656778|NCT00263718|Drug|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
79656779|NCT02218255|Device|Eeva™ results|
79656780|NCT02218294|Drug|BCX4161|
79656781|NCT02218333|Dietary Supplement|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
79656782|NCT02218333|Dietary Supplement|Placebo|
79656783|NCT02218528|Dietary Supplement|Plant-based ingredient|
79656784|NCT02218528|Dietary Supplement|No Plant-based ingredient|
79656785|NCT02218567|Behavioral|questionnaire qualilty of life|
79656786|NCT02218567|Behavioral|psychological interview|
79341907|NCT02300311|Drug|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
79341908|NCT05141903|Dietary Supplement|Dietary supplement, probiotic, antibiotic conditioning -all groups|Dietary supplement, probiotic, antibiotic conditioning -all groups
79341909|NCT05140499|Drug|Liposomal bupivacaine|Popliteal nerve block
79341910|NCT05140499|Drug|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
79341911|NCT05233631|Procedure|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
79341912|NCT04229381|Procedure|Physical Therapy|Undergo physical therapy
79492279|NCT04099303|Biological|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
79492280|NCT04099303|Biological|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
79492281|NCT04099303|Biological|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
79814021|NCT00828334|Device|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter < 4 mm.
79492282|NCT04099303|Biological|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
79492283|NCT00000775|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
79492284|NCT00379951|Drug|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
79492285|NCT00000331|Drug|Test Drug|
79656787|NCT02218567|Behavioral|psychological tests|
79656788|NCT02218567|Other|Motor evaluation|
79656789|NCT02218567|Behavioral|Behavioral evaluation|
79656790|NCT02218567|Behavioral|cognitive tests|
79814022|NCT00624286|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
79341913|NCT04229381|Other|Quality-of-Life Assessment|Ancillary studies
79341914|NCT04229381|Other|Questionnaire Administration|Ancillary studies
79341915|NCT04229381|Procedure|Relaxation Therapy|Undergo progressive muscle relaxation
79341916|NCT05178485|Drug|Bupivacain|FDA approved drug
79341917|NCT05178485|Other|Normal Saline|FDA approved
79341918|NCT05229185|Device|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
79492286|NCT00000331|Drug|Placebo Drug|
79492287|NCT03492476|Device|Circaid|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
79492288|NCT03492476|Device|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
79492289|NCT00000337|Drug|Selegiline|
79492290|NCT00000781|Drug|Nevirapine|
79656791|NCT02218645|Drug|WE 941 OD tablets|
79656792|NCT02218645|Drug|Brotizolam|
79656793|NCT02218684|Drug|Telmisartan|
79656794|NCT02218684|Drug|Lacidipine|
79656795|NCT02218684|Drug|Placebo|
79656796|NCT02278822|Other|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
79656797|NCT02278822|Other|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
79656798|NCT02278861|Drug|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
79656799|NCT02278861|Drug|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
79492291|NCT00000781|Drug|Zidovudine|
79341919|NCT05175365|Behavioral|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
79341920|NCT05228951|Drug|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
79492292|NCT00000781|Drug|Zalcitabine|
79492293|NCT00000781|Drug|Didanosine|
79492294|NCT04712708|Device|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
79492295|NCT04712708|Other|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
79492296|NCT00000343|Behavioral|counseling|
79492297|NCT00000787|Behavioral|Pre- and post-test counseling|
79492298|NCT00000349|Drug|Flupenthixol|
79492299|NCT00000805|Drug|Ganciclovir|
79492300|NCT00000355|Drug|Buprenorphine|
79492301|NCT04022785|Drug|Azacitidine|Given IV or SC
79492302|NCT04022785|Drug|BRD4 Inhibitor PLX51107|Given PO
79492303|NCT00383006|Behavioral|Skills for affect regulation (behavior)|
79492304|NCT00000361|Drug|Corticosteroids|
79656800|NCT02278861|Drug|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
79492305|NCT00000361|Drug|Methotrexate|
79492306|NCT00000811|Drug|Azithromycin|
79492307|NCT00000811|Drug|Atovaquone|
79492308|NCT00000811|Drug|Sulfamethoxazole-Trimethoprim|
79492309|NCT00000367|Drug|Treatment of depression|
79492310|NCT00000367|Behavioral|Suicide prevention intervention|
79492311|NCT00000367|Drug|Suicide prevention treatment|
79341921|NCT05174039|Drug|Miglustat 100Mg Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
79984983|NCT03701204|Behavioral|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~App on their smartphone~Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~Next Step debit card to receive financial incentives~Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~The amount of coins and funds are available on a progressive variable reward schedule."
79984984|NCT03188224|Other|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
79656801|NCT02278900|Other|Communication aids|Question Prompt list Audiofile
79341922|NCT04422119|Procedure|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
79656802|NCT01641913|Other|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
79984985|NCT03697226|Drug|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
79302552|NCT03075813|Other|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
79341923|NCT04422119|Procedure|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
79341924|NCT02300233|Drug|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
79341925|NCT02300233|Drug|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
79341926|NCT05137379|Behavioral|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
79656803|NCT01642030|Drug|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
79656804|NCT01642030|Drug|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
79656805|NCT01642030|Drug|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
79656806|NCT01642069|Other|laboratory biomarker analysis|Correlative studies
79341927|NCT02175225|Drug|Deferoxamine Mesylate|
79341928|NCT02175225|Drug|Placebo (for Deferoxamine Mesylate)|
79341929|NCT05170841|Drug|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 MG|Administered as one single tablet to be taken every 8 hours
79524833|NCT05767710|Behavioral|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
79341930|NCT05170841|Drug|Tramadol Hydrochloride 100 MG|Administered as two capsules with 50 mg each to be taken every 8 hours
79656807|NCT00263796|Drug|Oxytocin|10 international units = 1 cc, IV over 4 hours
79656808|NCT00263796|Drug|Placebo|Normal Saline, IV over 4 hours
79656809|NCT01642108|Drug|Sitagliptin|50 mg once per day
79656810|NCT01642264|Behavioral|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
79656811|NCT01642303|Other|vodcasting|listening to downloaded vodcasting files
79656812|NCT01642303|Other|no intervension|Listen to student book listening files
79656813|NCT00250185|Drug|Sodium Nitrate|
79656814|NCT00250185|Drug|Acetylcholine|
79656815|NCT01642381|Behavioral|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
79524834|NCT05767710|Behavioral|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
79341931|NCT05170841|Drug|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 MG or two capsules if matching Tramadol Hydrochloride 100 MG
79984986|NCT03189940|Behavioral|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
79341932|NCT05169671|Drug|ATH-1020|ATH-1020 in oral capsule form
79656816|NCT01642381|Behavioral|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
79984987|NCT03189940|Behavioral|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
79341933|NCT05169671|Drug|Placebo|Placebo in oral capsule form
79656817|NCT00239486|Drug|Pramipexole|
79341934|NCT05109221|Device|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
79341935|NCT05107583|Behavioral|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
79341936|NCT05107583|Behavioral|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
79341937|NCT05107583|Behavioral|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
79341938|NCT05106491|Device|Synchronized Cardiac Support with the icor kit|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
79656818|NCT01642459|Other|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
79656819|NCT01642459|Other|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
79656820|NCT01642498|Device|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
79656821|NCT01642537|Device|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
79656822|NCT00263835|Behavioral|Empowerment|
79998573|NCT03554187|Device|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
79341939|NCT05135273|Biological|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
79341940|NCT05135273|Biological|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
79341941|NCT05133713|Device|Catheter directed therapy|Thrombectomy
79656823|NCT00239525|Device|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
79656824|NCT00239525|Drug|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
79998574|NCT03554187|Biological|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
79341942|NCT05133713|Drug|Systemic anticoagulation|Conservative therapy
79492312|NCT04246970|Other|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device [2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
79341943|NCT05133089|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
79341944|NCT05224427|Behavioral|Near-Peer Coaching|Targeted coaching by near-peer medical students
79341945|NCT05129423|Drug|MTPS9579A|MTPS9579A will be administered.
79341946|NCT05129423|Drug|Placebo|Placebo matched with MTPS9579A will be administered.
79492313|NCT04246970|Other|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
79341947|NCT05129189|Drug|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
79341948|NCT02299375|Drug|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
79492314|NCT00000373|Drug|olanzapine + fluoxetine|
79998575|NCT03554187|Genetic|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
79998576|NCT03554187|Biological|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
79998577|NCT03554187|Device|Halitosis measure|With appropriate device : halimeter
79998578|NCT01333579|Other|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
79998579|NCT00092209|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium|
79998580|NCT00092209|Drug|Comparator: placebo, losartan, hydrochlorothiazide|
79341949|NCT02299375|Drug|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
79341950|NCT02299375|Drug|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
79341951|NCT04421651|Behavioral|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
79341952|NCT05223959|Behavioral|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
79341953|NCT02151903|Drug|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
79341954|NCT05221307|Other|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
79341955|NCT05102201|Device|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
79341956|NCT02151591|Drug|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
79341957|NCT05101421|Dietary Supplement|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
79341958|NCT02174523|Drug|40mg lurasidone|
79341959|NCT02174523|Drug|placebo|
79656825|NCT01642576|Behavioral|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
79656826|NCT01642654|Other|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
79656827|NCT01642654|Other|Educational lectures|Educational lectures
79656828|NCT01642693|Radiation|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
79656829|NCT01642693|Other|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
79656830|NCT01642810|Behavioral|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
79656831|NCT01642810|Other|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
79656832|NCT00239564|Drug|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
79656833|NCT00239564|Drug|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
79814023|NCT00624286|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
79341960|NCT05099783|Diagnostic Test|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
79341961|NCT05128877|Other|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
79341962|NCT02297815|Drug|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
79341963|NCT02297815|Drug|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
79341964|NCT02114385|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
79341965|NCT02114385|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
79341966|NCT05220605|Drug|BromAc|Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
79341967|NCT05098457|Device|GP0112|Injectable gel
79341968|NCT05098457|Device|Restylane Lyft Lidocaine|Injectable gel
79341969|NCT02114151|Drug|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
79492315|NCT00000373|Drug|placebo + fluoxetine|
79656834|NCT00239564|Drug|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
79656835|NCT00239564|Drug|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
79656836|NCT00239564|Drug|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
79656837|NCT02961036|Other|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
79492316|NCT00000823|Drug|Zidovudine|
79341970|NCT02114151|Drug|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
79341971|NCT05098379|Behavioral|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
79341972|NCT05220293|Drug|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
79341973|NCT05220293|Device|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
79341974|NCT04752189|Behavioral|Enhanced Replicating Effective Programs (Enhanced REP)|Deploy Enhanced REP to optimize the delivery of a drug use prevention intervention in community schools and test its feasibility, acceptability, and appropriateness; Enhanced REP includes tailoring the curriculum, training, and providing ongoing provider consultation, or facilitation, to support implementation.
79341975|NCT04752189|Behavioral|Standard implementation|Standard implementation of the Michigan Model for Health is akin to Standard REP and includes the curriculum materials, standard training and as-needed technical assistance.
79341976|NCT02297503|Drug|Azzalure|Glabellar lines
79341977|NCT02297503|Device|Restylane/Emervel filler|Facial tissue augmentation
79341978|NCT02297503|Device|Restylane Skinbooster|Facial skin rejuvenation
79341979|NCT04421885|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
79492317|NCT00000823|Drug|Didanosine|
79492318|NCT00000379|Drug|Fluoxetine|
79656838|NCT02961036|Other|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
79656839|NCT02961036|Other|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
79656840|NCT02961036|Other|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
79341980|NCT04421885|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
79341981|NCT02113449|Drug|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
79341982|NCT02366923|Device|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
79341983|NCT02366923|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
79341984|NCT02326597|Other|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
79492319|NCT00000379|Behavioral|EMDR|
79492320|NCT03367364|Behavioral|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
79492321|NCT03367364|Behavioral|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
79492322|NCT00000385|Drug|Lithium|Lithium 600 mg to 2700 mg per day
79492323|NCT00000385|Drug|Placebo|Matching placebo
79656841|NCT02961036|Other|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
79656842|NCT02961036|Other|Group A Reminder|One survey reminder at 14 days
79656843|NCT02961036|Other|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
79656844|NCT01642849|Dietary Supplement|high protein diet|6 months on HP diet
79656845|NCT01642849|Dietary Supplement|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
79656846|NCT01642888|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
79656847|NCT01642888|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
79341985|NCT02326597|Other|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
79492324|NCT04365920|Combination Product|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
79656848|NCT00239603|Device|OV-Watch|
79656849|NCT01642966|Drug|Prasugrel|Prasugrel 10mg/day for 15 days
79656850|NCT01642966|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
79341986|NCT02366767|Device|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
79341987|NCT02366767|Device|Control|Threshold suspend
79302553|NCT03203395|Behavioral|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
79341988|NCT02150343|Drug|HDM-SPIRE|1 dose every 4 weeks
79341989|NCT02150343|Drug|Placebo|1 dose every 4 weeks
79302554|NCT03075579|Drug|Medication Other|medication of atomoxetine
79341990|NCT02149875|Drug|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
79341991|NCT02149875|Drug|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
79341992|NCT02149875|Drug|Placebo|100 ml saline intravenous infusion once daily for 10 days.
79341993|NCT05096507|Procedure|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
79341994|NCT05125367|Procedure|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
79341995|NCT05125367|Procedure|bypass grafting|coronary artery bypass graft
79341996|NCT05124899|Drug|CAP UnScented|Sunscreen lip balm.
79341997|NCT05124899|Drug|CAP Herbal Mint Flavour|Sunscreen lip balm.
79341998|NCT05124899|Drug|CAP Mountain Berry Flavour|Sunscreen lip balm.
79341999|NCT05124899|Drug|SPF Standard Sunscreen|SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)
79342000|NCT05122013|Behavioral|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
79342001|NCT05122013|Behavioral|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
79342002|NCT02112045|Drug|Granix|
79342003|NCT02112045|Drug|High dose melphalan (HDR)|
79342004|NCT02112045|Procedure|Autologous Stem Cell Transplant (ASCT)|
79342005|NCT01629693|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
79342006|NCT01629693|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
79342007|NCT02147691|Drug|Azelaic acid 15%|Applied to the face each AM and PM
79492325|NCT04365920|Combination Product|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
79492326|NCT00000391|Drug|Peptide T|
79492327|NCT00002894|Drug|carboplatin|
79492328|NCT00002894|Drug|cisplatin|
79492329|NCT00002894|Drug|paclitaxel|
79492330|NCT00000829|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
79492331|NCT00000829|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
79492332|NCT00000829|Biological|Placebo|Administered at 0, 2, 4, and 15 months of age
79492333|NCT03282344|Drug|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
79492334|NCT03282344|Drug|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
79656851|NCT01643005|Behavioral|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
79656852|NCT01643005|Behavioral|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
79998581|NCT04399473|Behavioral|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
79342008|NCT02147691|Drug|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
79342009|NCT02111811|Other|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
79492335|NCT03889093|Other|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
79492336|NCT00000403|Drug|Doxycycline|
79492337|NCT00000841|Drug|Indinavir sulfate|
79492338|NCT00000841|Drug|Lamivudine|
79656853|NCT04529317|Dietary Supplement|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
79342010|NCT01655693|Drug|Doxorubicin 20 mg/m2|
79342011|NCT01655693|Drug|Doxorubicin 30 mg/m2|
79492339|NCT00000841|Drug|Stavudine|
79656854|NCT01643083|Drug|Rifaximin|Rifaximin 400mg tid for 2 wk
79656855|NCT01643083|Drug|Placebo|Placebo for 2 week
79656856|NCT01643122|Other|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
79998582|NCT01339741|Dietary Supplement|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
79998583|NCT01339741|Drug|Placebo|Placebo, oral route, 12 weeks
79998584|NCT05184829|Other|selective lymph node dissection|selective lymph node dissection
79342012|NCT01655693|Drug|Best Standard of Care|
79342013|NCT05090657|Combination Product|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
79342014|NCT05120765|Behavioral|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
79342015|NCT05089019|Drug|Selpercatinib|Administered orally
79492340|NCT00000841|Drug|Zidovudine|
79492341|NCT00002900|Procedure|management of therapy complications|
79492342|NCT00000415|Procedure|Physical activity|
79492343|NCT00000415|Drug|Calcium supplement|
79492344|NCT00000847|Biological|ALVAC-HIV MN120TMG (vCP205)|
79492345|NCT00000847|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
79492346|NCT00000847|Biological|rgp120/HIV-1 SF-2|
79492347|NCT00000439|Drug|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
79998585|NCT05184829|Other|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
79492348|NCT00002912|Drug|etoposide|
79492349|NCT00002912|Drug|mitoxantrone hydrochloride|
79492350|NCT00002912|Drug|valspodar|
79492351|NCT00000853|Biological|rgp120/HIV-1MN|
79492352|NCT03731845|Genetic|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
79492353|NCT03731845|Biological|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
79492354|NCT03731845|Other|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
79492355|NCT00000445|Drug|naltrexone (Revia)|
79492356|NCT00002924|Other|mutation analysis|
79492357|NCT00000451|Drug|sertraline|16 week outpatient study
79492358|NCT00000451|Drug|naltrexone|16 week outpatient study
79656857|NCT01643122|Other|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
79814024|NCT00823420|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
79814025|NCT00820768|Drug|ABI-010|17-AAG and ABI-007
79342016|NCT04226339|Procedure|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
79342017|NCT04226339|Procedure|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
79814026|NCT00624052|Drug|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
79814027|NCT00624052|Drug|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
79814028|NCT00821080|Drug|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
79814029|NCT00821080|Drug|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
79814030|NCT00828490|Behavioral|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
79814031|NCT00828490|Behavioral|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
79342018|NCT05048849|Biological|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
79492359|NCT00000865|Drug|Abacavir sulfate|
79492360|NCT00000865|Drug|Lamivudine|
79492361|NCT00000865|Drug|Stavudine|
79492362|NCT00000865|Drug|Zidovudine|
79492363|NCT00000865|Drug|Didanosine|
79492364|NCT00000469|Drug|aspirin|
79492365|NCT00000469|Drug|lovastatin|
79492366|NCT00000889|Drug|Aldesleukin|
79492367|NCT00000505|Drug|tissue plasminogen activator|
79492368|NCT00000505|Procedure|angioplasty, transluminal, percutaneous coronary|
79492369|NCT04169672|Drug|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
79492370|NCT04169672|Drug|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
79492371|NCT00380419|Behavioral|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
79492372|NCT00000511|Dietary Supplement|mineral supplements|
79492373|NCT00000511|Dietary Supplement|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
79492374|NCT00000511|Behavioral|dietary supplements|
79492375|NCT03344731|Behavioral|Cognitive evaluation|Cognitive task
79492376|NCT03344731|Device|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
79342019|NCT01655381|Drug|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
79342020|NCT05117333|Other|Reminder (information letter)|Reminders
79342021|NCT05048537|Radiation|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
79342022|NCT01656161|Drug|Triptorelin embonate 22.5 mg|
79492377|NCT00000901|Drug|Indinavir sulfate|
79492378|NCT00000901|Drug|Lamivudine|
79492379|NCT00000901|Drug|Stavudine|
79492380|NCT00000523|Behavioral|exercise|
79492381|NCT00000541|Behavioral|dietary supplements|
79492382|NCT00000541|Drug|vitamin C|
79492383|NCT00000541|Drug|vitamin E|
79492384|NCT00000541|Drug|beta-carotene|
79492385|NCT00000541|Drug|folic acid/Vitamin B6/Vitamin B12|
79492386|NCT00000913|Drug|Ritonavir|
79492387|NCT00000913|Drug|Nelfinavir mesylate|
79492388|NCT00000913|Drug|Saquinavir|
79492389|NCT03111290|Device|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
79492390|NCT03111290|Device|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
79342023|NCT05048381|Diagnostic Test|Next Generation Sequencing|Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.
79342024|NCT05081141|Diagnostic Test|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
79342025|NCT05114993|Device|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
79342026|NCT05080283|Device|CP1110 Sound Processor System|Sound Processor
79492391|NCT00000547|Drug|enalapril|
79492392|NCT00002930|Procedure|positron emission tomography|
79492393|NCT00002930|Radiation|fludeoxyglucose F 18|
79492394|NCT00000565|Procedure|intermittent positive-pressure breathing|
79656858|NCT01643161|Behavioral|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
79656859|NCT01643161|Behavioral|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
79342027|NCT05080283|Device|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
79492395|NCT03061526|Other|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
79492396|NCT00000577|Drug|Albuterol|
79492397|NCT00000577|Drug|Colchicine|
79492398|NCT00000577|Drug|Adrenal Cortex Hormones|
79656860|NCT01643239|Other|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
79656861|NCT01643239|Other|Hospital-based mCIT|the mCIT group with individualized intervention
79656862|NCT01643239|Other|Hospital-based TR|OT or PT or therapist-based training
79342028|NCT04422041|Other|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
79342029|NCT04422041|Other|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
79656863|NCT01643278|Drug|Dasatinib|Given PO
79656864|NCT01643278|Biological|Ipilimumab|Given IV
79656865|NCT01643278|Other|Laboratory Biomarker Analysis|Correlative studies
79492399|NCT00000577|Drug|Adrenergic-Beta Agonists|
79492400|NCT03321799|Device|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
79492401|NCT03321799|Device|Sterile Antimicrobial Dressings|Control group, current hospital standard.
79492402|NCT03278119|Diagnostic Test|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
79492403|NCT03015896|Other|Laboratory Biomarker Analysis|Correlative studies
79492404|NCT03015896|Drug|Lenalidomide|Given PO
79492405|NCT03015896|Biological|Nivolumab|Given IV
79492406|NCT00000925|Drug|Optimune oral nutritional supplement|
79492407|NCT00000583|Biological|hepatitis B vaccines|
79492408|NCT02994836|Biological|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
79656866|NCT01643278|Other|Pharmacological Study|Correlative studies
79656867|NCT01643356|Behavioral|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
79656868|NCT01643395|Other|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
79656869|NCT01643395|Other|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
79656870|NCT01643590|Biological|JVS-100 15 mg dose Injection|Intramyocardial Injection
79656871|NCT01643590|Biological|Placebo Injection|Intramyocardial Injection
79656872|NCT01643590|Biological|JVS-100 30 mg dose injection|Intramyocardial Injection
79656873|NCT01643629|Biological|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
79656874|NCT01643629|Other|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
79814032|NCT00828490|Behavioral|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
79814033|NCT00823498|Behavioral|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
79342030|NCT05045027|Procedure|Biospecimen Collection|Undergo collection of tissue samples
79656875|NCT01643746|Device|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
79656876|NCT01643746|Device|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
79656877|NCT04529200|Other|electrotherapy treatment|physical therapy management like EMS IFT
79814034|NCT00823498|Behavioral|Interview|Interview with a member of study staff at housing development site.
79656878|NCT01643785|Drug|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
79656879|NCT01643824|Radiation|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
79814035|NCT00823498|Other|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
79814036|NCT04044430|Drug|Binimetinib|Given PO
79814037|NCT04044430|Drug|Encorafenib|Given PO
79342031|NCT05045027|Procedure|Diagnostic Imaging|Undergo multinuclear metabolic imaging
79342032|NCT05045027|Procedure|Magnetic Resonance Imaging|Undergo MRI
79814038|NCT04044430|Biological|Nivolumab|Given IV
79814039|NCT04044430|Other|Questionnaire Administration|Ancillary studies
79814040|NCT00821158|Drug|Antioxidant|Antioxidant iv bolus
79814041|NCT00821158|Other|Placebo|Placebo tablet and iv
79656880|NCT04529161|Dietary Supplement|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
79656881|NCT04529161|Dietary Supplement|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
79984988|NCT04681742|Behavioral|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
79984989|NCT03192124|Device|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
79342033|NCT05043857|Radiation|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
79342034|NCT04421807|Other|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
79342035|NCT04421807|Other|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
79342036|NCT02111577|Biological|DCVAC/PCa|DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
79342037|NCT02111577|Biological|Placebo|Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
79342038|NCT05111795|Device|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
79492409|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
79492410|NCT02994836|Biological|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
79492411|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
79656882|NCT04528966|Other|Whole-Body Vibration|Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.
79656883|NCT04528966|Other|Conventional Physiotherapy|conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
79656884|NCT01644019|Procedure|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
79492412|NCT00000937|Drug|Antibiotics|
79492413|NCT00000613|Behavioral|dietary supplements|
79492414|NCT00000613|Drug|genistein|
79492415|NCT00000613|Behavioral|diet, soy proteins|
79492416|NCT00000619|Procedure|catheterization, Swan-Ganz|
79492417|NCT02909348|Drug|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
79492418|NCT02973529|Device|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
79492419|NCT02973529|Device|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
79656885|NCT01644097|Dietary Supplement|Lactobacillus plantarum strain 299v|Given PO
79656886|NCT01644097|Dietary Supplement|Lactobacillus acidophilus probiotic|Given PO
79656887|NCT01644097|Dietary Supplement|placebo|Given PO
79656888|NCT01644097|Other|laboratory biomarker analysis|Correlative studies
79656889|NCT01644097|Other|questionnaire administration|Ancillary studies
79656890|NCT01644097|Procedure|quality-of-life assessment|Ancillary studies
79342039|NCT05216445|Behavioral|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
79342040|NCT04751877|Drug|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
79342041|NCT04751877|Drug|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
79342042|NCT04751877|Drug|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
79656891|NCT01644097|Dietary Supplement|Bifidobacterium lactis probiotic supplement|Given PO
79656892|NCT01644136|Procedure|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
79984990|NCT03190252|Other|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
79342043|NCT04751877|Drug|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
79656893|NCT01644136|Procedure|regional lymph node dissection|Undergo pelvic lymph node dissection
79656894|NCT01644136|Device|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
79656895|NCT01644253|Biological|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
79656896|NCT01644253|Biological|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
79984991|NCT03190252|Other|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
79342044|NCT02170779|Behavioral|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
79814042|NCT00821158|Drug|Anti-inflammatory drug|Anti-inflammatory tablet
79814043|NCT00830674|Drug|Placebo|single dose IV or SC administration
79984992|NCT03702296|Other|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
79984993|NCT03192280|Drug|Leukotriene B4|Leukotriene B4 (LTB4)
79984994|NCT03192280|Device|FLIR One|Thermal imaging attachment to iPhone
79342045|NCT02170779|Other|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
79492420|NCT04329416|Other|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
79492421|NCT04329416|Other|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
79492422|NCT04329416|Other|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
79492423|NCT02859727|Drug|CDZ173|140 mg/day
79492424|NCT04329338|Other|Lactobacillus pentosus KCA1|Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
79342046|NCT04751799|Device|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
79342047|NCT04751799|Device|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
79492425|NCT00000949|Drug|Aldesleukin|
79656897|NCT01644253|Biological|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
79984995|NCT03192280|Device|SCIO|Handheld near-IR molecular spectroscopy device
79342048|NCT02147067|Drug|Ranolazine|Ranolazine 1,000 mg twice daily
79342049|NCT02147067|Drug|Placebo|Placebo
79814044|NCT00830674|Drug|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
79814045|NCT00823732|Other|educational intervention|Undergo individualized interdisciplinary palliative care intervention
79342050|NCT02170389|Other|Laboratory Biomarker Analysis|Correlative studies
79342051|NCT02170389|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
79342052|NCT02170389|Biological|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
79342053|NCT02146599|Other|Administration of patient self-assessment|
79342054|NCT02146131|Device|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
79342055|NCT02146131|Device|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
79342056|NCT02107131|Drug|Intravitreal ranibizumab 0.3mg|
79342057|NCT02106975|Drug|Ascorbic Acid|Intervention
79342058|NCT02106975|Drug|Placebo: 5% Dextrose in water|Placebo
79492426|NCT00002936|Drug|altretamine|
79492427|NCT00002936|Drug|etoposide|
79492428|NCT00000649|Drug|Nevirapine|
79492429|NCT00000649|Drug|Zidovudine|
79492430|NCT00002942|Procedure|autologous bone marrow transplantation|
79492431|NCT00002942|Procedure|peripheral blood stem cell transplantation|
79492432|NCT00000955|Drug|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
79492433|NCT02789384|Other|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
79656898|NCT01644253|Biological|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
79656899|NCT01644253|Biological|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
79814046|NCT00823732|Other|medical chart review|Ancillary studies
79342059|NCT02145429|Behavioral|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
79492434|NCT00000961|Drug|Anti-HIV Immune Serum Globulin (Human)|
79492435|NCT00000961|Drug|Zidovudine|
79492436|NCT04048304|Drug|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
79492437|NCT00000655|Drug|Atovaquone|
79492438|NCT00000655|Drug|Sulfamethoxazole-Trimethoprim|
79814047|NCT00823732|Other|questionnaire administration|Ancillary studies
79814048|NCT00823732|Procedure|end-of-life treatment/management|Undergo end-of-life treatment/management
79302555|NCT03075579|Device|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
79302556|NCT03203317|Drug|Insulin|2 h insulin clamp
79302557|NCT03203317|Other|Exercise|Cycling exercise
79302558|NCT03316313|Diagnostic Test|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
79492439|NCT00002948|Biological|filgrastim|
79492440|NCT00002948|Drug|topotecan hydrochloride|
79814049|NCT00823732|Procedure|psychosocial assessment and care|Undergo psychosocial assessment and care
79492441|NCT00002948|Procedure|bone marrow ablation with stem cell support|
79492442|NCT00002948|Procedure|peripheral blood stem cell transplantation|
79492443|NCT04009148|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
79492444|NCT02594293|Drug|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
79656900|NCT01644253|Biological|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
79656901|NCT01644370|Drug|HAART|as per Thai HIV Treatment guidelines
79492445|NCT00000967|Drug|Interferon alfa-2a|
79492446|NCT00000967|Drug|Zidovudine|
79492447|NCT00000661|Drug|Oxazepam|
79492448|NCT00000661|Drug|Zidovudine|
79492449|NCT02749058|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
79656902|NCT01644448|Other|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
79656903|NCT01644448|Other|Standard Therapy|Topical Applications as directed by the investigator
79656904|NCT01644487|Device|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
79656905|NCT01644487|Device|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
79656906|NCT01644526|Device|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
79656907|NCT01644604|Device|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
79814050|NCT00823732|Procedure|quality-of-life assessment|Ancillary studies
79492450|NCT02749058|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
79492451|NCT00000979|Drug|Zidovudine|
79492452|NCT00000979|Drug|Didanosine|
79492453|NCT00002960|Biological|recombinant adenovirus-p53 SCH-58500|
79492454|NCT00000667|Biological|gp160 Vaccine (MicroGeneSys)|
79492455|NCT00000991|Drug|Pentamidine isethionate|
79492456|NCT00000991|Drug|Sulfamethoxazole-Trimethoprim|
79492457|NCT00000991|Drug|Dapsone|
79814051|NCT00823732|Procedure|management of therapy complications|Undergo management of therapy complications
79492458|NCT00000991|Drug|Zidovudine|
79492459|NCT00000673|Drug|Ganciclovir|
79492460|NCT00000685|Drug|Zidovudine|
79492461|NCT00002972|Drug|paclitaxel|
79492462|NCT00000691|Drug|Foscarnet sodium|
79492463|NCT00002984|Drug|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
79492464|NCT00002984|Drug|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
79492465|NCT00002984|Drug|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
79492466|NCT00002984|Procedure|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
79492467|NCT00002984|Radiation|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
79492468|NCT02341807|Biological|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
79492469|NCT00002990|Biological|BCG vaccine|
79492470|NCT00000997|Drug|Zalcitabine|
79492471|NCT00000697|Drug|Foscarnet sodium|
79492472|NCT00001009|Drug|Dextran sulfate|
79492473|NCT00000703|Drug|Bleomycin sulfate|
79492474|NCT00000703|Drug|Vincristine sulfate|
79492475|NCT00000703|Drug|Doxorubicin hydrochloride|
79492476|NCT00000703|Drug|Cyclophosphamide|
79492477|NCT00000703|Drug|Allopurinol|
79492478|NCT00000703|Drug|Methotrexate|
79492479|NCT00000703|Drug|Cytarabine|
79492480|NCT00000703|Drug|Leucovorin calcium|
79492481|NCT00000703|Drug|Zidovudine|
79492482|NCT00000703|Drug|Dexamethasone|
79492483|NCT00001015|Drug|Ribavirin|
79492484|NCT00000709|Drug|Zidovudine|
79492485|NCT00001027|Drug|Pentamidine isethionate|
79492486|NCT00000721|Drug|CD4 Antigens|
79656908|NCT01644682|Other|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
79656909|NCT01644682|Other|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
79656910|NCT01644682|Other|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
79656911|NCT01644760|Procedure|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
79656912|NCT01644799|Drug|idelalisib|oral
79656913|NCT01644799|Drug|lenalidomide|oral
79492487|NCT00000727|Drug|Pentamidine isethionate|
79656914|NCT01644838|Drug|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
79492488|NCT00000727|Drug|Pyrimethamine|
79656915|NCT01644838|Drug|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
79656916|NCT01644877|Drug|DAS181 dry powder, formulation F02|
79656917|NCT01644877|Drug|Lactose Placebo|
79302559|NCT02484131|Behavioral|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
79302560|NCT02484131|Behavioral|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
79492489|NCT00000727|Drug|Sulfamethoxazole/Trimethoprim|
79492490|NCT00000727|Drug|Sulfadoxine/Pyrimethamine|
79492491|NCT00000727|Drug|Zidovudine|
79656918|NCT01644955|Drug|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
79656919|NCT01644955|Procedure|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
79656920|NCT01644994|Combination Product|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
79656921|NCT00263874|Drug|UK-500,001|
79656922|NCT01645033|Other|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
79656923|NCT01645033|Other|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
79656924|NCT01645150|Behavioral|Progressive strength training|12 weeks of supervised progressive strength training
79656925|NCT01645189|Biological|Hunterase|once weekly, 0.5mg/kg IV infusion
79984996|NCT03192280|Device|MS Band 2|"Wearable watch-like device with multiple sensors"
79492492|NCT00001039|Drug|Ethambutol hydrochloride|
79492493|NCT00001039|Drug|Clarithromycin|
79492494|NCT00001057|Drug|Zidovudine|
79656926|NCT04528888|Drug|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
79656927|NCT04528888|Drug|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
79656928|NCT04528888|Drug|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
79656929|NCT00250224|Device|Radiotherapy stent|
79656930|NCT04528615|Behavioral|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
79656931|NCT04528615|Behavioral|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
79656932|NCT01645267|Procedure|Hydroxyapatite|Use of artifical bonegraft material
79342060|NCT05133765|Device|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
79342061|NCT02144337|Behavioral|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
79656933|NCT01645345|Device|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
79814052|NCT00823732|Procedure|assessment of therapy complications|Undergo assessment of therapy complications
79814053|NCT00828646|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
79984997|NCT03192280|Device|AGE reader|Portable bench top device for in-clinic near UV assessment
79342062|NCT04417881|Other|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
79342063|NCT02520011|Drug|Alvocidib|
79342064|NCT02520011|Drug|Cytarabine|
79342065|NCT02520011|Drug|Mitoxantrone|
79342066|NCT05110625|Behavioral|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
79342067|NCT05110625|Other|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
79492495|NCT00001057|Drug|Didanosine|
79492496|NCT00001705|Drug|GP100 peptide|
79492497|NCT00001705|Drug|IL-2|
79492498|NCT00002293|Drug|Nystatin|
79492499|NCT00002299|Drug|Interferon beta-1b|
79492500|NCT00002299|Drug|Ganciclovir|
79492501|NCT00380497|Drug|PEG-Lyte®|
79492502|NCT00380497|Drug|Pico-Salax®|
79492503|NCT00001063|Drug|Stavudine|
79492504|NCT00001063|Drug|Zidovudine|
79492505|NCT00001063|Drug|Didanosine|
79492506|NCT00002305|Drug|Flucytosine|
79492507|NCT00002305|Drug|Fluconazole|
79492508|NCT00002305|Drug|Amphotericin B|
79492509|NCT00001753|Procedure|Magnetic resonance imaging|
79492510|NCT00001765|Device|Nexell Isolex with T-cell Depletion|
79492511|NCT00001765|Device|Baxter isolex 300i|
79492512|NCT00001081|Drug|Nitazoxanide|
79492513|NCT00002311|Drug|Wobenzym|
79492514|NCT00002317|Drug|Trimetrexate glucuronate|
79492515|NCT00002317|Drug|Leucovorin calcium|
79492516|NCT00001123|Drug|Ribavirin|
79492517|NCT00002323|Drug|Nevirapine|
79492518|NCT00002323|Drug|Zidovudine|
79656934|NCT00263952|Biological|bee venom|
79656935|NCT01645384|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
79656936|NCT00239798|Drug|FTY720|
79656937|NCT01645423|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
79656938|NCT01645774|Procedure|10s injections duration|10s injections duration
79492519|NCT00002329|Drug|Celgosivir hydrochloride|
79492520|NCT00001873|Device|Isolex 300i plus MoAbs|
79656939|NCT01645774|Procedure|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
79656940|NCT01645774|Procedure|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
79656941|NCT01645774|Procedure|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
79492521|NCT00380965|Drug|Cesamet™ (nabilone)|
79492522|NCT00001129|Device|Electronic Medication Reminder System|
79492523|NCT00001129|Behavioral|Medication Manager|
79492524|NCT00001135|Drug|Nevirapine|
79492525|NCT00003002|Biological|HER-2/neu peptide vaccine|
79492526|NCT00003002|Biological|sargramostim|
79492527|NCT00001891|Procedure|Myocardial contrast echocardiography|
79492528|NCT00001891|Procedure|Dobutamine echocardiography|
79656942|NCT00263991|Device|EEC-techniques|
79656943|NCT01645852|Dietary Supplement|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
79656944|NCT00239876|Drug|FTY720|
79656945|NCT01646008|Other|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
79656946|NCT01646008|Other|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
79656947|NCT01646047|Dietary Supplement|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
79656948|NCT01646047|Dietary Supplement|multi-component dietary supplement|placebo capsules
79656949|NCT00264030|Device|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
79656950|NCT00264030|Other|PTCA|PTCA
79814054|NCT00828646|Drug|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
79814055|NCT00828646|Drug|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
79814056|NCT00828646|Drug|Placebo|Capsules, Oral, once daily, 14 days
79814057|NCT02548936|Drug|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
79984998|NCT03192280|Device|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
79492529|NCT00383864|Drug|Pegylated interferon and ribavirin|
79492530|NCT00001903|Drug|RSV Polyclonal Immunoglobulin|
79492531|NCT00002335|Drug|Emtricitabine|
79492532|NCT00002341|Drug|Itraconazole|
79814058|NCT02548858|Procedure|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
79492533|NCT04331431|Procedure|Spinal cord tumor resection|Excision of intradural tumors
79814059|NCT02548858|Procedure|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
79814060|NCT00828724|Drug|Lorcaserin 10mg|
79984999|NCT03192280|Device|iPhone 7|Smart phone
79302561|NCT04992351|Procedure|WALANT|WALANT as anesthesia method for upper and lower limb palstic surgery operations
79302562|NCT03201601|Drug|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
79302563|NCT03201601|Drug|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
79492534|NCT00001909|Drug|Soluble recombinantly produced IL-4R|
79492535|NCT00001189|Procedure|radiotherapy|
79492536|NCT00002347|Drug|Saquinavir|
79492537|NCT00002347|Drug|Nevirapine|
79492538|NCT00002347|Drug|Zidovudine|
79492539|NCT00002347|Drug|Zalcitabine|
79492540|NCT00001237|Drug|granulocyte-macrophage colony stimulating factor (GM-CSF)|
79492541|NCT00002353|Biological|P3C541b Lipopeptide|
79492542|NCT00002359|Biological|HIV-1 Immunogen|
79492543|NCT04925713|Biological|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~Immunomodulatory Agent~Route of Administration:~Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
79985000|NCT03190018|Device|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
79492544|NCT00001933|Drug|Nefiracetam|
79985001|NCT02443012|Drug|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
79492545|NCT00001249|Drug|Yttrium-90 radiolabeled anti-Tac antibody|
79492546|NCT00380575|Drug|YM087|
79492547|NCT00001951|Drug|TMTDS|
79492548|NCT00001963|Procedure|hemoglobin-transported nitric oxide|
79656951|NCT01646086|Behavioral|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
79656952|NCT04709510|Diagnostic Test|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
79985002|NCT02443012|Procedure|Laser|Grid/Focal Laser Photocoagulation
79985003|NCT02443090|Drug|fispemifene|
79492549|NCT00002365|Drug|LXR015-1|
79492550|NCT00380731|Behavioral|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
79492551|NCT00002377|Drug|Valganciclovir|
79492552|NCT00002377|Drug|Ganciclovir|
79492553|NCT00380809|Procedure|Rotational Atherectomy + PES|
79492554|NCT00380809|Procedure|Standard Treatment (PES without Rotational Atherectomy)|
79492555|NCT00001339|Drug|doxorubicin, vincristine, and etoposide with mitotane|
79492556|NCT00001993|Drug|Butyldeoxynojirimycin|
79492557|NCT00001993|Drug|Zidovudine|
79492558|NCT00001999|Drug|Globulin, Immune|
79492559|NCT00001999|Drug|Ganciclovir|
79492560|NCT00002383|Drug|Saquinavir|
79492561|NCT00002389|Drug|Abacavir sulfate|
79492562|NCT00002389|Drug|Lamivudine|
79492563|NCT00002389|Drug|Zidovudine|
79492564|NCT00001357|Drug|Interleukin-2|
79492565|NCT00001381|Drug|suramin|
79492566|NCT00002005|Drug|CD4 Antigens|
79492567|NCT00002011|Drug|Methoxsalen|
79492568|NCT00002017|Drug|Interleukin-2, Polyethylene Glycolated|
79492569|NCT00002023|Drug|Zidovudine|
79492570|NCT00002029|Drug|Fat Emulsion 2%|
79985004|NCT02443090|Other|Placebo|
79985005|NCT03624764|Procedure|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
79985006|NCT03624764|Procedure|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
79656953|NCT01646242|Procedure|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
79656954|NCT01646242|Procedure|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
79656955|NCT02961075|Other|local surface anesthesia|Airway anesthesia for Bronchoscopy
79985007|NCT03701126|Procedure|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
79302564|NCT03316157|Dietary Supplement|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
79302565|NCT03316157|Behavioral|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
79492571|NCT00002029|Drug|Fat Emulsion 20%|
79492572|NCT00002035|Drug|Zidovudine|
79492573|NCT00002035|Drug|Didanosine|
79492574|NCT00002041|Drug|Amphotericin B|
79492575|NCT04716907|Genetic|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
79492576|NCT04716907|Biological|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
79492577|NCT04716907|Diagnostic Test|CT Scan|Thymus and lung imaging
79492578|NCT04716907|Biological|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
79656956|NCT02961075|Device|Laryngeal tube|
79656957|NCT01646281|Drug|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
79814061|NCT00828802|Drug|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
79814062|NCT00823810|Other|PET/CT|18F-FDG PET/CT
79492579|NCT00002047|Drug|Zidovudine|
79492580|NCT00002053|Drug|Pentamidine isethionate|
79492581|NCT00002059|Drug|Inosine pranobex|
79492582|NCT00002065|Drug|Disulfiram|
79492583|NCT00002071|Drug|Epoetin alfa|
79492584|NCT00002395|Drug|Topotecan|
79492585|NCT00002401|Drug|Indinavir sulfate|
79492586|NCT00002401|Drug|Delavirdine mesylate|
79492587|NCT00002401|Drug|Lamivudine|
79492588|NCT00002401|Drug|Zidovudine|
79814063|NCT00823888|Device|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
79814064|NCT00785577|Drug|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
79492589|NCT00002407|Drug|Indinavir sulfate|
79492590|NCT00002407|Drug|Nevirapine|
79985008|NCT03701126|Procedure|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
79492591|NCT00002407|Drug|Lamivudine|
79985009|NCT03701126|Drug|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
79985010|NCT03701126|Device|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
79342068|NCT04224233|Other|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
79342069|NCT04224233|Other|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
79342070|NCT04222829|Procedure|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
79492592|NCT00002407|Drug|Stavudine|
79492593|NCT00002407|Drug|Didanosine|
79492594|NCT00002413|Drug|Emivirine|
79492595|NCT00002419|Drug|Abacavir sulfate|
79492596|NCT00002419|Drug|Amprenavir|
79492597|NCT00002419|Drug|Efavirenz|
79492598|NCT00002419|Drug|Adefovir dipivoxil|
79492599|NCT00381355|Procedure|Written Action Plan for Acute Asthma|
79492600|NCT00381433|Drug|AVI-4065 Injection|
79492601|NCT00381511|Drug|low molecular weight heparin|
79492602|NCT00002425|Drug|Saquinavir|
79492603|NCT00002431|Drug|Chlorhexidine gluconate|
79492604|NCT00002077|Drug|Fluconazole|
79492605|NCT00002083|Drug|Peptide T|
79492606|NCT00002089|Drug|Azithromycin|
79492607|NCT00002095|Drug|Ganciclovir|
79492608|NCT00002101|Drug|Ethambutol hydrochloride|
79492609|NCT00002101|Drug|Clarithromycin|
79814065|NCT00785577|Drug|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
79814066|NCT00785577|Drug|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
79985011|NCT02439736|Other|Blood draw within 12 hours of head injury|
79985012|NCT02442934|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
79492610|NCT00002101|Drug|Rifabutin|
79492611|NCT02335424|Biological|pembrolizumab|IV infusion
79492612|NCT00002107|Drug|Aldesleukin|
79492613|NCT00002113|Drug|Flucytosine|
79492614|NCT00002113|Drug|Fluconazole|
79492615|NCT00002119|Drug|WF10|
79492616|NCT00383318|Procedure|Gene mutation sample|
79492617|NCT00002437|Drug|Cidofovir|
79492618|NCT00002437|Drug|Probenecid|
79492619|NCT00002443|Drug|Indinavir sulfate|
79492620|NCT00002443|Drug|Zidovudine|
79492621|NCT00001561|Drug|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
79492622|NCT00001561|Drug|GM-CSF|
79492623|NCT00002449|Drug|Aldesleukin|
79492624|NCT00003014|Drug|carboplatin|
79492625|NCT00003014|Radiation|radiation therapy|
79492626|NCT00002125|Drug|Foscarnet sodium|
79492627|NCT00001579|Drug|5-Fluorouracil|
79492628|NCT00001579|Drug|Ethynyluracil|
79492629|NCT00001579|Drug|Leucovorin|
79492630|NCT00003020|Biological|LMB-7 immunotoxin|
79492631|NCT00002131|Drug|Vesnarinone|
79492632|NCT00001615|Drug|Corticosteroid|
79492633|NCT00002137|Drug|Tecogalan sodium|
79492634|NCT00002455|Biological|Corynebacterium granulosum P40|
79985013|NCT02442934|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
79656958|NCT01646281|Drug|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
79656959|NCT01646359|Device|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
79302566|NCT04992585|Device|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
79814067|NCT00785577|Drug|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
79814068|NCT00785577|Drug|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
79814069|NCT00830830|Drug|Hyalgan (sodium hyaluronate)|
79814070|NCT00828880|Device|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
79814071|NCT02548390|Drug|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
79656960|NCT01646359|Device|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
79656961|NCT00239915|Drug|Pagoclone|
79814072|NCT00830908|Device|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
79814073|NCT00828958|Drug|Risperidone long-acting injectable|
79814074|NCT04105101|Device|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
79342071|NCT05037539|Drug|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
79342072|NCT05037539|Drug|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
79492635|NCT00002455|Procedure|adjuvant therapy|
79656962|NCT01646476|Device|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
79814075|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
79814076|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
79342073|NCT02519231|Drug|Naproxen|Naproxen 440mg 1x pid
79342074|NCT02519231|Drug|Placebo|Placebo tablet 440mg 1x pid
79342075|NCT02106351|Biological|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
79342076|NCT04998539|Other|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
79492636|NCT00380887|Drug|Premarin|
79823671|NCT02555943|Drug|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
79342077|NCT04998539|Other|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
79814077|NCT02548780|Device|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
79823672|NCT02555943|Drug|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
79342078|NCT04998539|Other|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
79492637|NCT00002461|Biological|filgrastim|
79342079|NCT04998539|Other|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
79342080|NCT04998539|Other|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
79492638|NCT00002461|Biological|sargramostim|
79492639|NCT00002461|Drug|carmustine|
79342081|NCT05036603|Other|chest physiotherapy|diffferent chest physiotherapy methods
79342082|NCT02143947|Device|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
79342083|NCT02143947|Device|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
79342084|NCT02075073|Biological|SB3|
79656963|NCT01646476|Device|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
79656964|NCT01646554|Drug|Modified FOLFOX6|
79656965|NCT01646554|Biological|Aflibercept|Targeted therapy
79342085|NCT02075073|Biological|EU sourced Herceptin®|
79656966|NCT01646554|Procedure|Surgery|
79823673|NCT02555943|Drug|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
79998586|NCT01482195|Biological|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
79342086|NCT02075073|Biological|US sourced Herceptin®|
79342087|NCT02074059|Drug|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
79342088|NCT02074059|Device|nCPAP alone|nCPAP therapy
79342089|NCT02143713|Drug|Elagolix|Elagolix tablets administered orally
79342090|NCT04738149|Drug|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
79342091|NCT04738149|Device|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
79342092|NCT04738149|Device|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
79342093|NCT02519855|Biological|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
79342094|NCT02519855|Biological|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
79342095|NCT02519855|Biological|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
79492640|NCT00002461|Drug|cisplatin|
79492641|NCT00002461|Drug|cyclophosphamide|
79492642|NCT00002461|Drug|etoposide|
79342096|NCT02142387|Other|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
79492643|NCT00002461|Procedure|autologous bone marrow transplantation|
79492644|NCT00002461|Procedure|in vitro-treated bone marrow transplantation|
79814078|NCT02548780|Other|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
79814079|NCT04105023|Dietary Supplement|genistein|Administered orally once every 12 hours
79814080|NCT04105023|Dietary Supplement|Placebo|Administered orally once every 12 hours
79492645|NCT00002461|Procedure|peripheral blood stem cell transplantation|
79814081|NCT00831064|Procedure|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
79985014|NCT02442934|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
79985015|NCT02439502|Device|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
79985016|NCT03187600|Procedure|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
79985017|NCT03187600|Procedure|Standard of Care Pharyngeal Flap|Included in study arm description
79985018|NCT03696836|Device|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
79342097|NCT05070455|Biological|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
79342098|NCT05034575|Other|Eye Tracking Technology Sensor|Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
79342099|NCT05069987|Other|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax & Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
79492646|NCT00002461|Radiation|radiation therapy|
79492647|NCT00003026|Drug|bicalutamide|
79492648|NCT00003026|Drug|flutamide|
79492649|NCT00003026|Drug|triptorelin|
79492650|NCT00003026|Radiation|radiation therapy|
79492651|NCT00002143|Drug|Acitretin|
79492652|NCT00002149|Drug|Clavulanate potassium|
79492653|NCT00002149|Drug|Pseudoephedrine hydrochloride|
79492654|NCT00002149|Drug|Amoxicillin trihydrate|
79492655|NCT03868046|Drug|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
79492656|NCT03868046|Diagnostic Test|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
79492657|NCT02973295|Drug|Silymarin|Capsules contains 100 mg of silymarin
79492658|NCT02973295|Other|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
79492659|NCT04329884|Procedure|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
79492660|NCT04329884|Drug|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
79492661|NCT00003032|Biological|filgrastim|
79492662|NCT00003032|Drug|cisplatin|
79492663|NCT00003032|Drug|cyclophosphamide|
79492664|NCT00003032|Drug|mitoxantrone hydrochloride|
79492665|NCT00003032|Drug|tamoxifen citrate|
79492666|NCT00002155|Drug|Indinavir sulfate|
79492667|NCT00002155|Drug|Lamivudine|
79492668|NCT00002155|Drug|Zidovudine|
79492669|NCT00003038|Drug|doxorubicin hydrochloride|
79492670|NCT00003038|Drug|suramin|
79492671|NCT00001633|Procedure|Coronary magnetic resonance angiography imaging|
79492672|NCT00002473|Procedure|conventional surgery|
79492673|NCT05752591|Diagnostic Test|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
79492674|NCT00003044|Drug|cisplatin-e therapeutic implant|
79492675|NCT00002485|Procedure|psychosocial assessment and care|
79985019|NCT02442544|Dietary Supplement|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
79492676|NCT02047994|Drug|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~Esomeprazole 40 mg bid for 10 days~Clarithromycin 500 mg bid for 10 days~Amoxicillin 1000 mg bid for 10 days"
79492677|NCT00002161|Drug|Adefovir dipivoxil|
79814082|NCT04104867|Drug|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
79814083|NCT04104867|Drug|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
79492678|NCT03836378|Procedure|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
79492679|NCT03833804|Other|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
79524835|NCT05767710|Behavioral|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
79814084|NCT04104867|Other|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
79814085|NCT04024605|Dietary Supplement|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
79814086|NCT04024605|Dietary Supplement|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
79342100|NCT05069207|Other|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
79342101|NCT05068817|Other|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
79342102|NCT05068817|Other|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
79342103|NCT05068817|Other|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
79342104|NCT04421183|Diagnostic Test|draw blood|draw blood from the all of patients
79342105|NCT04219319|Drug|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
79814087|NCT04024605|Dietary Supplement|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
79814088|NCT04024605|Dietary Supplement|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
79985020|NCT02442544|Dietary Supplement|Placebo|maltodextrin 3.3g orally/day
79342106|NCT04996121|Drug|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
79302567|NCT02450227|Dietary Supplement|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
79302568|NCT02450227|Dietary Supplement|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
79302569|NCT02484989|Other|Surviellance card|
79814089|NCT00789828|Drug|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
79342107|NCT02518919|Other|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
79342108|NCT02518919|Other|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
79342109|NCT04995887|Device|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
79342110|NCT04995731|Behavioral|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
79342111|NCT04995731|Procedure|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
79342112|NCT05066321|Behavioral|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
79342113|NCT05063279|Other|Progressive resistance training|Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
79342114|NCT05060627|Drug|Belantamab mafodotin|"In phase 1:~Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
79342115|NCT05060627|Drug|Carfilzomib|"In phase 1:~Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
79342116|NCT05060627|Drug|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients > 75 years old., Q4W
79814090|NCT00789828|Drug|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
79814091|NCT04044118|Behavioral|Low Calorie Diet|Low Calorie Diet consisted of ~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
79814092|NCT04024839|Other|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
79985021|NCT03187522|Device|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
79814093|NCT04024839|Other|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
79814094|NCT02550262|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
79814095|NCT02550262|Drug|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
79985022|NCT03702140|Drug|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
79985023|NCT02433886|Procedure|Gamma Ventral Capsulotomy|
79985024|NCT03700814|Drug|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
79985025|NCT02433964|Other|Grupo LED|
79342117|NCT04421105|Drug|Lysergic acid diethylamide (LSD) 5µg|
79342118|NCT04421105|Drug|Lysergic acid diethylamide (LSD) 10µg|
79342119|NCT04421105|Drug|Lysergic acid diethylamide (LSD)20 µg|
79342120|NCT04421105|Drug|Placebo|
79342121|NCT02518685|Device|TransPyloric Shuttle|
79342122|NCT02518685|Device|Sham procedure|
79342123|NCT02518685|Behavioral|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
79814096|NCT02550262|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
79342124|NCT05024747|Drug|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm^2) surface area will be placed topically.
79342125|NCT05024747|Drug|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm^2 surface area will be placed topically.
79342126|NCT05058833|Diagnostic Test|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
79656967|NCT00250263|Drug|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
79814097|NCT04024449|Other|Group A|ovarian function test in control group
79814098|NCT02550418|Drug|Budesonide|
79814099|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
79814100|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
79302570|NCT03216577|Other|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
79302571|NCT03316079|Other|Chest physiotherapy techniques|Respiratory manual CPT
79342127|NCT05058833|Diagnostic Test|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
79342128|NCT02520089|Procedure|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
79342129|NCT02520089|Procedure|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
79342130|NCT05056883|Drug|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
79342131|NCT05056883|Drug|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
79342132|NCT04991597|Other|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
79342133|NCT04991597|Other|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
79656968|NCT00250263|Drug|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
79656969|NCT02279368|Behavioral|Family Counselling and safeguarding|
79656970|NCT02279446|Other|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
79656971|NCT02279485|Drug|Perampanel|
79656972|NCT01646593|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
79814101|NCT00790296|Drug|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
79656973|NCT00264069|Drug|antipsychotic|as prescribed
79656974|NCT00264069|Drug|antidepressants|as prescribed
79656975|NCT01646632|Behavioral|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
79814102|NCT00790296|Drug|Placebo|Saline
79302572|NCT03316079|Device|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
79302573|NCT02637063|Behavioral|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
79342134|NCT04991597|Drug|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
79656976|NCT01646632|Behavioral|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
79656977|NCT01646710|Behavioral|Pretesting food based recommendations|
79656978|NCT01646788|Device|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
79814103|NCT02548702|Behavioral|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
79814104|NCT00829192|Drug|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
79814105|NCT00829192|Drug|Placebo|Placebo subcutaneous implant administered every 60 days
79814106|NCT00623194|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
79342135|NCT04991597|Drug|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
79656979|NCT01647178|Procedure|TORQ assisted sternal closure|
79656980|NCT01647178|Procedure|Conventional closure|
79656981|NCT02961699|Device|Transpose ® RT System|adipose-derived stem cell therapy
79656982|NCT02961699|Other|debridement/dressing of wound|standard of care debridement and wound dressing
79656983|NCT01647256|Drug|Nikkomycin Z|Capsule, 500 mg, single-dose
79656984|NCT00239954|Drug|Escitalopram|
79656985|NCT04528927|Drug|HCQ|600 mg on the 1st day as a starting dose then 200 mg * 2 /D for 9 days
79814107|NCT00623194|Drug|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
79814108|NCT00829348|Other|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
79985026|NCT02433964|Other|Placebo|ledterapia off + price
79656986|NCT04528927|Drug|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
79492680|NCT04713397|Diagnostic Test|Leg Length Discrepancy Scoliometer Test|"A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated."
79492681|NCT00002167|Drug|Tin ethyl etiopurpurin|
79492682|NCT03805412|Device|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
79492683|NCT05752513|Procedure|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
79492684|NCT05752513|Procedure|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
79492685|NCT00002173|Biological|HIV-1 Immunogen|
79492686|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
79342136|NCT02105961|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
79302574|NCT02637063|Behavioral|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
79492687|NCT03805022|Drug|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
79492688|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
79342137|NCT02105961|Drug|Placebo|Sterile 0.9percent sodium chloride solution
79492689|NCT03805022|Drug|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
79342138|NCT04950101|Other|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
79342139|NCT04949867|Drug|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
79342140|NCT04949867|Device|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
79492690|NCT03805022|Drug|At the discretion of the investigator|Drug at the discretion of the investigator.
79492691|NCT05752435|Procedure|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
79492692|NCT00003050|Drug|cyclophosphamide|
79492693|NCT00003050|Drug|doxorubicin hydrochloride|
79656987|NCT04528927|Drug|Doxycycline|200 mg per day for 10 days
79985027|NCT02433808|Drug|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
79342141|NCT05018897|Behavioral|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
79492694|NCT00003050|Drug|paclitaxel|
79342142|NCT05018897|Behavioral|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
79342143|NCT05018117|Drug|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
79342144|NCT05018117|Other|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
79342145|NCT04203329|Device|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
79342146|NCT05016869|Drug|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
79342147|NCT02141997|Biological|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
79342148|NCT02141997|Biological|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
79492695|NCT00003050|Drug|tamoxifen citrate|
79492696|NCT00003050|Procedure|surgical procedure|
79492697|NCT00003050|Radiation|radiation therapy|
79492698|NCT03798860|Diagnostic Test|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
79656988|NCT04528927|Dietary Supplement|Zinc|220 mg per day for 10 days
79656989|NCT04720287|Drug|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
79656990|NCT04720287|Drug|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
79656991|NCT04528654|Other|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
79985028|NCT02433808|Other|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
79302575|NCT02637063|Other|Usual care|No intervention beyond participants' own medical care.
79302576|NCT02480387|Drug|Ledipasvir/Sofosbuvir FDC|
79342149|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
79656992|NCT00239993|Drug|glatiramer acetate|
79656993|NCT00239993|Procedure|Warm compress prior to injection of glatiramer acetate|
79342150|NCT04411433|Drug|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
79492699|NCT00002179|Drug|Indinavir sulfate|
79492700|NCT00002179|Drug|Lamivudine|
79656994|NCT01647334|Radiation|Adaptive radiotherapy|
79656995|NCT00264108|Drug|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
79656996|NCT00264108|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length.
79656997|NCT01647412|Drug|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
79656998|NCT01647412|Dietary Supplement|Nutraceutical Combination|
79656999|NCT01647412|Other|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
79657000|NCT01647412|Other|Placebo Growth Hormone|
79657001|NCT01647529|Drug|Ganciclovir|Treatment with topical ganciclovir ointment
79657002|NCT00240032|Drug|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
79657003|NCT00240032|Drug|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
79657004|NCT01647607|Behavioral|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
79985029|NCT02434042|Dietary Supplement|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
79985030|NCT02434042|Other|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
79985031|NCT02439346|Drug|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
79492701|NCT00002179|Drug|Zidovudine|
79492702|NCT00003056|Drug|cyclosporine|
79492703|NCT00003056|Drug|cyclosporine and methotrexate|
79492704|NCT00002185|Drug|Nelfinavir mesylate|
79492705|NCT01923506|Radiation|stereotactic body radiation therapy|Undergo SBRT
79492706|NCT01923506|Procedure|quality-of-life assessment|Ancillary studies
79342151|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
79342152|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
79657005|NCT01647607|Behavioral|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
79657006|NCT00250302|Procedure|autologous mesenchymal stem cells implantation|
79657007|NCT04528849|Drug|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
79657008|NCT00240149|Drug|Regular Insulin via Insulin-Glucose Algorithm|
79657009|NCT01647646|Drug|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
79814109|NCT00829348|Behavioral|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
79985032|NCT03702062|Diagnostic Test|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
79342153|NCT04411433|Drug|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
79492707|NCT01923506|Other|laboratory biomarker analysis|Correlative studies
79492708|NCT00003062|Drug|temozolomide|
79492709|NCT00002191|Drug|Albendazole|
79657010|NCT01647685|Drug|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
79657011|NCT01647685|Drug|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
79657012|NCT01647685|Drug|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
79657013|NCT00240188|Procedure|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
79657014|NCT00240188|Procedure|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
79657015|NCT01647802|Device|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
79814110|NCT02548000|Other|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
79814111|NCT02548000|Other|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
79814112|NCT00829582|Drug|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
79814113|NCT00829582|Other|placebo|single intravenous infusion
79657016|NCT01647802|Device|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
79814114|NCT00831298|Other|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
79985033|NCT02439424|Device|Reactive ATP|"Reactive ATP turned to on"
79998587|NCT01341613|Dietary Supplement|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
79998588|NCT01341613|Dietary Supplement|Placebo capsule|Twice per day (BID), 9 weeks
79998589|NCT00003777|Drug|amifostine trihydrate|
79492710|NCT00383396|Drug|Topical Cyclosporine|
79492711|NCT00002197|Drug|Abacavir sulfate|
79492712|NCT00003068|Drug|amifostine trihydrate|
79492713|NCT00003068|Drug|cyclophosphamide|
79492714|NCT00003068|Drug|mitoxantrone hydrochloride|
79342154|NCT04411433|Drug|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
79342155|NCT01628367|Procedure|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
79342156|NCT01628367|Device|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
79342157|NCT01628367|Biological|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
79342158|NCT01628367|Biological|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
79342159|NCT01628367|Biological|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
79492715|NCT00003068|Drug|thiotepa|
79492716|NCT00003068|Procedure|peripheral blood stem cell transplantation|
79492717|NCT00002503|Radiation|strontium chloride Sr 89|
79492718|NCT01719458|Drug|(S,S)-[11C]MRB|PET radioligand
79657017|NCT01647802|Device|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
79492719|NCT00003080|Drug|endocrine-modulating drug therapy|
79492720|NCT00003080|Drug|melphalan|
79492721|NCT00003080|Drug|mitoxantrone hydrochloride|
79492722|NCT00003080|Drug|tamoxifen citrate|
79492723|NCT00003080|Drug|thiotepa|
79492724|NCT00003080|Procedure|peripheral blood stem cell transplantation|
79492725|NCT00002203|Drug|Lamivudine/Zidovudine|
79492726|NCT00002203|Drug|Lamivudine|
79492727|NCT00002203|Drug|Zidovudine|
79492728|NCT01568918|Drug|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
79492729|NCT01568918|Other|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
79985034|NCT03701984|Drug|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
79342160|NCT01628367|Drug|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
79492730|NCT02973139|Other|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
79492731|NCT02973139|Other|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
79492732|NCT00003086|Biological|filgrastim|
79492733|NCT00003086|Drug|CAF regimen|
79657018|NCT01647919|Dietary Supplement|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
79657019|NCT01647919|Dietary Supplement|Placebo|4 capsules of placebo identical to cogniVida™ once a day
79657020|NCT00240266|Drug|Rosuvastatin|
79657021|NCT01648036|Drug|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
79814115|NCT00784368|Drug|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
79657022|NCT01648036|Drug|Dalteparin|Dose 5000 IU, subcutaneous, daily
79814116|NCT00784368|Drug|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
79814117|NCT02548468|Drug|Fludarabine|Given IV
79814118|NCT02548468|Radiation|Total-Body Irradiation|Undergo TBI
79814119|NCT02548468|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
79814120|NCT02548468|Drug|Cyclophosphamide|Given IV
79814121|NCT02548468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
79814122|NCT02548468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
79814123|NCT02548468|Drug|Mycophenolate mofetil|Given IV
79814124|NCT02548468|Drug|Tacrolimus|Given IV
79998590|NCT00003777|Drug|cisplatin|
79342161|NCT01627899|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
79342162|NCT05012735|Drug|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
79492734|NCT00003086|Drug|carboplatin|
79492735|NCT00003086|Drug|cisplatin|
79492736|NCT00003086|Drug|cyclophosphamide|
79492737|NCT00003086|Drug|doxorubicin hydrochloride|
79492738|NCT00003086|Drug|fluorouracil|
79492739|NCT00003086|Drug|ifosfamide|
79492740|NCT00003086|Drug|melphalan|
79492741|NCT00003086|Drug|paclitaxel|
79492742|NCT00003086|Drug|thiotepa|
79492743|NCT00003086|Procedure|peripheral blood stem cell transplantation|
79657023|NCT01648075|Dietary Supplement|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
79985035|NCT03701984|Drug|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
79657024|NCT01648114|Other|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
79814125|NCT00829660|Drug|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
79814126|NCT00829660|Drug|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
79814127|NCT00915564|Drug|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
79985036|NCT03701984|Drug|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
79492744|NCT00003086|Radiation|samarium Sm 153 lexidronam pentasodium|
79492745|NCT01334450|Device|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
79985037|NCT03190096|Procedure|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
79985038|NCT02439190|Drug|BMS-986120|
79985039|NCT02439190|Drug|Aspirin|
79985040|NCT02439190|Drug|Clopidogrel|
79342163|NCT05012735|Device|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
79492746|NCT00002209|Drug|CPI-1189|
79492747|NCT00003092|Drug|paclitaxel|
79492748|NCT00381199|Drug|Amitriptyline Hydrochloride|
79492749|NCT00381199|Drug|Nabilone|
79657025|NCT04528537|Other|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
79657026|NCT00240305|Drug|Rosuvastatin|
79657027|NCT01648192|Drug|Losmapimod for single dose|Film coated white tablet
79657028|NCT01648192|Drug|Losmapimod for repeat dose|Film coated white tablet
79302577|NCT03203161|Procedure|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
79342164|NCT04946903|Drug|RLD2007|Take it once per period.
79342165|NCT04946903|Drug|RLD2008|Take it once per period.
79342166|NCT04946903|Drug|HCP1902|Take it once per period.
79342167|NCT04985825|Drug|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
79342168|NCT02519777|Drug|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
79342169|NCT02519777|Drug|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
79492750|NCT00002509|Biological|filgrastim|
79657029|NCT01648231|Drug|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
79657030|NCT01648231|Drug|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
79657031|NCT01648231|Drug|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
79657032|NCT01648309|Other|Neuropsychological testing|This is an observational study
79657033|NCT01648504|Other|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
79985041|NCT02442466|Drug|Endothelin Receptor B inhibitor BQ788|
79492751|NCT00002509|Drug|carboplatin|
79492752|NCT00002509|Drug|cyclophosphamide|
79492753|NCT00002509|Drug|etoposide|
79492754|NCT00002509|Drug|mesna|
79492755|NCT00002509|Procedure|autologous bone marrow transplantation|
79492756|NCT00002509|Procedure|peripheral blood stem cell transplantation|
79492757|NCT00002515|Biological|filgrastim|
79492758|NCT00002515|Drug|carboplatin|
79492759|NCT00002515|Drug|thiotepa|
79342170|NCT02519777|Drug|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
79342171|NCT02519777|Drug|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
79342172|NCT05008913|Drug|[14C]Adavosertib|Patients will receive a single administration of [14C]Adavosertib as an oral solution on Day 1.
79342173|NCT04982705|Drug|[Part 1.1] IDG-16177|[Part 1.1] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
79492760|NCT00002515|Drug|topotecan hydrochloride|
79492761|NCT00002515|Procedure|autologous bone marrow transplantation|
79492762|NCT00002515|Procedure|bone marrow ablation with stem cell support|
79492763|NCT00002515|Procedure|in vitro-treated bone marrow transplantation|
79492764|NCT00003098|Other|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
79492765|NCT00003098|Other|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
79492766|NCT00381277|Drug|Gatorade|
79492767|NCT00381277|Drug|Performance|
79492768|NCT04712630|Procedure|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
79657034|NCT01648543|Procedure|lumbar sympathetic ganglion block|
79657035|NCT01648660|Dietary Supplement|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
79985042|NCT02442466|Drug|PBS|
79985043|NCT02439034|Drug|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
79342174|NCT04982705|Drug|[Part 1.1] Placebo of IDG-16177|[Part 1.1] subjects will receive a single oral dose of IMP.
79342175|NCT04982705|Drug|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
79342176|NCT04982705|Drug|[Part1.2] IDG-16177|[Part 1.2] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
79342177|NCT04982705|Drug|[Part 2] IDG-16177|[Part 2] Administration once daily for 4 weeks.
79342178|NCT04982705|Drug|[Part 1.2] Placebo of IDG-16177|[Part 1.2] Administration once daily for 14 days.
79342179|NCT04982705|Drug|[Part 2] Placebo of IDG-16177|[Part 2] Administration once daily for 4 weeks.
79342180|NCT04202783|Other|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
79342181|NCT04944095|Other|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
79342182|NCT02515331|Drug|LHW090|Capsule - oral dose
79342183|NCT02515331|Drug|Placebo|Capsule - oral dose
79342184|NCT02515097|Drug|IDP-122 Lotion|Medicated topical lotion
79657036|NCT00264186|Drug|LPS 2 ng/kg intravenous (IV) bolus|
79657037|NCT00264186|Drug|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
79342185|NCT02515097|Drug|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
79342186|NCT02141295|Drug|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
79492769|NCT04712630|Procedure|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
79492770|NCT00002521|Drug|cisplatin|
79492771|NCT00002521|Drug|cyclophosphamide|
79492772|NCT00002521|Drug|etoposide|
79492773|NCT00002521|Procedure|autologous bone marrow transplantation|
79342187|NCT02141295|Drug|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
79492774|NCT00002521|Procedure|bone marrow ablation with stem cell support|
79492775|NCT00002521|Procedure|peripheral blood stem cell transplantation|
79492776|NCT00002521|Procedure|syngeneic bone marrow transplantation|
79657038|NCT00264186|Drug|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
79657039|NCT00264186|Drug|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
79657040|NCT00264186|Drug|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
79342188|NCT02141295|Drug|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
79342189|NCT02141295|Drug|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
79342190|NCT02141295|Drug|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
79342191|NCT02514551|Drug|Ramucirumab|Administered IV
79342192|NCT02514551|Drug|Paclitaxel|Administered IV
79342193|NCT02141217|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
79342194|NCT02141217|Drug|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
79492777|NCT00002521|Radiation|radiation therapy|
79657041|NCT01648738|Other|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
79657042|NCT01648738|Other|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
79342195|NCT02138253|Drug|IDN-6556|
79342196|NCT02138253|Drug|Placebo|Placebo control
79342197|NCT02514473|Drug|VX-809|
79342198|NCT02514473|Drug|Placebo|
79342199|NCT02514473|Drug|VX-770|
79342200|NCT02513771|Drug|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
79342201|NCT02513771|Drug|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
79342202|NCT02104947|Drug|idarucizumab|idarucizumab
79342203|NCT02513459|Drug|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
79492778|NCT00581906|Radiation|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) & group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite & will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st & 2nd weeks of treatment & the 2nd intra-treatment DCE-MRI is recommended between the 3rd & 4th weeks of treatment.
79492779|NCT00003104|Radiation|radiation therapy|
79492780|NCT05751889|Behavioral|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
79492781|NCT05751889|Behavioral|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
79492782|NCT00003110|Biological|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
79492783|NCT00002215|Drug|Emivirine|
79492784|NCT00002215|Drug|Nelfinavir mesylate|
79657043|NCT01648855|Other|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
79657044|NCT01648933|Radiation|Rubidium PET|Myocardial Perfusion Imaging
79657045|NCT01648972|Drug|Gastrografin|
79657046|NCT01648972|Drug|Placebo|
79657047|NCT00240422|Drug|Telmisartan|
79657048|NCT00240422|Drug|Ramipril|
79492785|NCT00003116|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
79492786|NCT00003116|Drug|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
79492787|NCT00003116|Drug|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
79492788|NCT00003116|Drug|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
79492789|NCT00003116|Procedure|bone marrow ablation with stem cell support|
79492790|NCT00003116|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
79657049|NCT00264225|Drug|Lamaline® , 3 different doses, Dafalgan codeine|
79342204|NCT02513459|Drug|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
79342205|NCT02104557|Other|Non intervention|Non intervention
79342206|NCT02104557|Other|Non intervention|Non intervention
79492791|NCT00002221|Drug|Peripheral blood stem cells|
79492792|NCT00002227|Drug|Efavirenz|
79492793|NCT00002227|Drug|Lamivudine|
79492794|NCT00002227|Drug|Stavudine|
79492795|NCT00002233|Drug|Indinavir sulfate|
79657050|NCT01649011|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
79998591|NCT00003777|Drug|fluorouracil|
79492796|NCT00002233|Drug|Abacavir sulfate|
79492797|NCT00002233|Drug|Amprenavir|
79492798|NCT00002233|Drug|Lamivudine|
79492799|NCT00002527|Drug|aspirin|
79492800|NCT00002527|Other|placebo|
79492801|NCT00002533|Drug|fluconazole|
79492802|NCT00002533|Radiation|radiation therapy|
79492803|NCT00003122|Procedure|surgical procedure|
79492804|NCT02973217|Device|Immunostimulating Interstitial Laser Thermotherapy|
79492805|NCT00002539|Biological|filgrastim|
79492806|NCT00002539|Drug|cisplatin|
79492807|NCT00002539|Drug|doxorubicin hydrochloride|
79492808|NCT00002539|Procedure|conventional surgery|
79492809|NCT00381589|Drug|ipratropium bromide 0.03% spray|
79492810|NCT00002239|Drug|Enfuvirtide|
79492811|NCT00002239|Drug|Ritonavir|
79492812|NCT00002239|Drug|Abacavir sulfate|
79492813|NCT00002239|Drug|Amprenavir|
79492814|NCT00002239|Drug|Efavirenz|
79492815|NCT00383474|Drug|Bortezomib|Given IV
79492816|NCT00383474|Other|Laboratory Biomarker Analysis|Correlative studies
79492817|NCT00383474|Drug|Tipifarnib|Given orally
79492818|NCT00002245|Drug|Abacavir sulfate|
79492819|NCT00002245|Drug|Amprenavir|
79657051|NCT01649011|Behavioral|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
79657052|NCT01649050|Drug|BGG492|
79657053|NCT01649050|Drug|Placebo|
79342207|NCT04209023|Device|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
79342208|NCT04982081|Biological|hiPSC-CM therapy|20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
79342209|NCT05006105|Device|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
79342210|NCT05006105|Device|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
79342211|NCT05006105|Other|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
79657054|NCT02279563|Drug|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
79657055|NCT02279563|Drug|Dymista™ Nasal Spray|
79342212|NCT05006105|Other|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
79342213|NCT05006105|Device|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
79657056|NCT02279563|Drug|Placebo|
79657057|NCT00240461|Dietary Supplement|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
79657058|NCT00240461|Dietary Supplement|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
79342214|NCT02069379|Drug|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
79657059|NCT00240461|Other|Placebo|crystalline substance 200 mg twice daily for 6 months
79657060|NCT02279680|Device|Electroencephalography|
79657061|NCT02279680|Behavioral|Neuropsychological assesments|
79657062|NCT02279758|Drug|Metformin|
79657063|NCT00264264|Procedure|Closure Device|
79657064|NCT00264264|Procedure|Direct Compression|
79657065|NCT01649206|Procedure|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
79985044|NCT02439034|Drug|Ketoprofen|Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
79814128|NCT00915564|Other|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily [extremes included]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
79657066|NCT01649245|Drug|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
79342215|NCT02069379|Drug|Placebo|Placebo capsules prepared identically to Metformin capsules
79342216|NCT02511431|Drug|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
79342217|NCT02511431|Drug|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
79342218|NCT02511431|Other|Placebo|Placebo
79342219|NCT05005247|Biological|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
79657067|NCT04721210|Other|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
79657068|NCT01649284|Drug|afatinib|40, 30, and 20 mg film-coated tablets
79657069|NCT00250419|Biological|V930|
79342220|NCT02137785|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
79342221|NCT02137785|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
79342222|NCT02137785|Device|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
79342223|NCT01655069|Drug|Solifenacin succinate suspension|Oral suspension
79342224|NCT02068599|Drug|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
79342225|NCT02068599|Drug|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
79342226|NCT04708509|Device|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
79342227|NCT01654601|Drug|DWCZP|Multiple dose
79657070|NCT01649401|Device|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
79657071|NCT01649401|Device|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
79657072|NCT00415740|Drug|ELC200 (carbidopa+levodopa+entacapone)|
79657073|NCT01649479|Biological|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
79657074|NCT01649479|Biological|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~antithrombin, protein C, protein S~Factor V Leiden polymorphisms (F5 1691A)~prothrombin 20210A gene polymorphism (F2 20210A)~JAK2 617F Mutation~Homocysteine~Factor VIII"
79814129|NCT02603406|Drug|erythropoietin|
79814130|NCT04106700|Drug|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
79814131|NCT04107090|Other|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
79814132|NCT04107090|Other|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
79998592|NCT00003777|Procedure|surgical procedure|
79998593|NCT00003777|Radiation|radiation therapy|
79492820|NCT00002245|Drug|Lamivudine|
79302578|NCT04999293|Drug|Ticagrelor|Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
79342228|NCT01654601|Drug|Clozaril|multiple-dose
79342229|NCT01654523|Device|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
79342230|NCT05001113|Procedure|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
79342231|NCT05001113|Procedure|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
79342232|NCT04978649|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
79342233|NCT04978649|Drug|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
79342234|NCT04978415|Procedure|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
79492821|NCT00003128|Biological|filgrastim|
79492822|NCT00003128|Drug|ifosfamide|
79657075|NCT01649479|Other|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
79657076|NCT01649635|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
79657077|NCT01649635|Drug|Prednisone|Pharmaceutical form: tablet Route of administration: oral
79492823|NCT00003128|Drug|paclitaxel|
79657078|NCT01649635|Drug|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
79492824|NCT04331197|Drug|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
79657079|NCT01649635|Drug|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
79657080|NCT00250536|Drug|nandrolone decanoate|
79492825|NCT04331197|Drug|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
79492826|NCT05751733|Drug|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
79492827|NCT05751733|Drug|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
79492828|NCT00002798|Drug|asparaginase|
79492829|NCT00002798|Drug|daunorubicin hydrochloride|
79492830|NCT00002798|Drug|fludarabine phosphate|
79657081|NCT00250536|Behavioral|resistance exercise training|
79657082|NCT00240617|Drug|sumatriptan succinate/naproxen sodium|comparator
79657083|NCT00240617|Drug|placebo|placebo to match
79657084|NCT01649713|Drug|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
79657085|NCT01649752|Biological|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
79657086|NCT01649752|Biological|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
79657087|NCT01649830|Radiation|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
79657088|NCT01649830|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
79492831|NCT00002798|Drug|therapeutic hydrocortisone|
79492832|NCT00002798|Procedure|allogeneic bone marrow transplantation|
79492833|NCT00002798|Radiation|3-dimensional conformal radiation therapy|
79492834|NCT00002798|Biological|filgrastim|Given SC
79492835|NCT00002798|Drug|cytarabine|Given IV or IT
79492836|NCT00002798|Drug|idarubicin|Given IV
79492837|NCT00002798|Drug|dexamethasone|Given PO
79492838|NCT00002798|Drug|thioguanine|Given PO
79492839|NCT00002798|Drug|etoposide|Given IV
79492840|NCT00002798|Drug|methotrexate|Given IT
79492841|NCT00002798|Drug|cyclophosphamide|Given IV
79492842|NCT00002798|Biological|aldesleukin|
79657089|NCT04708743|Diagnostic Test|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
79657090|NCT01649986|Behavioral|Non-pharmacologic intervention|Diet and physical exercise
79657091|NCT01649986|Drug|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
79657092|NCT00240656|Drug|spironolactone captopril carvedilol|
79657093|NCT01645696|Device|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
79657094|NCT01645696|Device|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
79657095|NCT01645696|Device|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
79657096|NCT01647451|Drug|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
79342235|NCT02508935|Drug|XARTEMIS XR|XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets
79657097|NCT01647451|Drug|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
79657098|NCT00250575|Drug|Clozapine|
79657099|NCT01640899|Device|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
79657100|NCT00240695|Drug|galantamine hydrobromide|
79302579|NCT03316001|Other|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
79302580|NCT02451241|Other|acupuncture|electroacupuncture
79342236|NCT02508701|Behavioral|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
79342237|NCT05000333|Other|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
79657101|NCT04528381|Procedure|Laparoscopy|Laparoscopic orchiopexy
79657102|NCT00250614|Drug|Saredutant succinate (SR48968C)|
79657103|NCT04528186|Diagnostic Test|Maternal thyroid volume|Maternal thyroid volume measurement
79657104|NCT00240734|Drug|Epoetin alfa|
79657105|NCT01645072|Other|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
79657106|NCT01645072|Other|Control group|The ongoing anti epileptic drug treatment will be continued without change.
79814133|NCT04107090|Other|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
79814134|NCT00831376|Drug|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
79342238|NCT02507375|Drug|Erlotinib|Erlotinib will be administered as oral tablets.
79342239|NCT02507375|Drug|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
79492843|NCT00002798|Drug|busulfan|
79492844|NCT00002251|Drug|Ganciclovir|
79492845|NCT00002257|Drug|Ganciclovir|
79492846|NCT00003134|Drug|irinotecan hydrochloride|
79492847|NCT00002545|Drug|carmustine|
79492848|NCT00002545|Radiation|low-LET photon therapy|
79492849|NCT00002804|Biological|filgrastim|
79492850|NCT00002804|Drug|doxorubicin hydrochloride|
79492851|NCT00002804|Drug|ifosfamide|
79492852|NCT00002804|Drug|mesna|
79492853|NCT00002804|Drug|vincristine sulfate|
79492854|NCT00002804|Procedure|conventional surgery|
79492855|NCT00002804|Radiation|brachytherapy|
79492856|NCT00002804|Radiation|low-LET cobalt-60 gamma ray therapy|
79492857|NCT00002804|Radiation|low-LET electron therapy|
79492858|NCT00002804|Radiation|low-LET photon therapy|
79492859|NCT00002810|Biological|filgrastim|
79342240|NCT05000177|Other|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
79342241|NCT05000177|Other|30-minute rest|Rest for 30 minutes
79342242|NCT02507219|Drug|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
79342243|NCT02483975|Drug|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
79342244|NCT02483975|Drug|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
79342245|NCT02483975|Drug|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
79342246|NCT02483975|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
79342247|NCT02047227|Drug|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
79492860|NCT00002810|Drug|melphalan|
79492861|NCT00002810|Procedure|bone marrow ablation with stem cell support|
79492862|NCT00002810|Procedure|peripheral blood stem cell transplantation|
79492863|NCT00003140|Drug|letrozole|Given orally
79492864|NCT00003140|Other|placebo|Given orally
79814135|NCT00831376|Drug|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
79492865|NCT00003392|Biological|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
79492866|NCT00003392|Drug|carboplatin|18 AUC IV, approximately days 21, 42
79492867|NCT00003392|Drug|cyclophosphamide|4 gm/m2 IV, day 1
79492868|NCT00003392|Drug|melphalan|140 mg/m2 IV , approximately day 63
79492869|NCT00003392|Drug|paclitaxel|170 mg/m2 IV day 1
79492870|NCT00003392|Procedure|bone marrow ablation with stem cell support|
79492871|NCT00003392|Procedure|peripheral blood stem cell transplantation|
79492872|NCT00002551|Drug|fluorouracil|See arm assignments.
79492873|NCT00002551|Drug|leucovorin calcium|See arm assignments.
79492874|NCT00002551|Drug|levamisole hydrochloride|See arm assignments.
79492875|NCT00002551|Radiation|radiation therapy|See arm assignments.
79492876|NCT00003146|Drug|busulfan|
79492877|NCT00003146|Drug|melphalan|
79492878|NCT00003146|Drug|thiotepa|
79492879|NCT00003146|Procedure|bone marrow transplantation|
79492880|NCT00003146|Procedure|peripheral blood stem cell transplantation|
79492881|NCT00003398|Biological|anti-thymocyte globulin|
79814136|NCT00831376|Drug|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
79814137|NCT02602470|Drug|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser & Moisturizing
79492882|NCT00003398|Biological|filgrastim|
79492883|NCT00003398|Drug|cyclophosphamide|
79492884|NCT00003398|Drug|thiotepa|
79492885|NCT00003398|Procedure|allogeneic bone marrow transplantation|
79492886|NCT00003398|Procedure|bone marrow ablation with stem cell support|
79492887|NCT00003398|Radiation|radiation therapy|
79492888|NCT00002263|Drug|Zidovudine|
79492889|NCT00002263|Drug|Sargramostim|
79492890|NCT00002816|Drug|cytarabine|Given IV
79492891|NCT00002816|Drug|dexamethasone|Given IV
79492892|NCT00002816|Drug|etoposide|Given IV
79985045|NCT03700580|Drug|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
79342248|NCT02047227|Drug|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
79342249|NCT02047227|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
79985046|NCT03700580|Drug|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
79998594|NCT01339819|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
79342250|NCT02483585|Drug|Erenumab|Administered once a month by subcutaneous injection
79342251|NCT02483585|Drug|Placebo|Administered once a month by subcutaneous injection
79342252|NCT02046993|Behavioral|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
79342253|NCT02046993|Behavioral|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
79342254|NCT02101983|Drug|Cytosine Arabinoside|
79342255|NCT04974593|Other|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
79342256|NCT04974281|Combination Product|PD-1 and Lenvatinib Plus TACE|PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
79342257|NCT02482805|Behavioral|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
79342258|NCT02503865|Drug|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
79342259|NCT02503865|Dietary Supplement|"Analimentary detoxication"|Vegetable and salt diet
79342260|NCT01623531|Drug|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
79342261|NCT02503787|Device|Spinal Cord Stimulation (SCS)|SCS programming options
79657107|NCT01645891|Device|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
79492893|NCT00002816|Drug|idarubicin|Given IV
79492894|NCT00002816|Drug|ifosfamide|Given IV
79492895|NCT00002816|Drug|leucovorin calcium|
79998595|NCT01339819|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
79492896|NCT00002816|Drug|mesna|Given IV
79492897|NCT00002816|Drug|pegaspargase|Given IV
79492898|NCT00002816|Drug|therapeutic hydrocortisone|
79492899|NCT00002816|Drug|thioguanine|
79492900|NCT00002816|Drug|vincristine sulfate|Given IV
79492901|NCT00002816|Radiation|low-LET cobalt-60 gamma ray therapy|
79492902|NCT00002816|Radiation|low-LET electron therapy|
79657108|NCT01645891|Device|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
79492903|NCT00002816|Radiation|low-LET photon therapy|
79657109|NCT04720248|Drug|Metamizole|Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
79657110|NCT01646515|Drug|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
79657111|NCT01646515|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
79657112|NCT00240773|Drug|acetaminophen|4 grams daily for six months
79657113|NCT00240773|Drug|naproxen|750 mg daily for 12 months
79657114|NCT00240773|Drug|acetaminophen|4 grams daily for 12 months
79657115|NCT00240773|Drug|naproxen|750 mg daily for six months
79342262|NCT04943471|Other|Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire|Questionnaire
79342263|NCT02482571|Device|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
79342264|NCT02481947|Drug|BLI400 Laxative|21 gm BLI400 powder
79342265|NCT02481947|Drug|Lubiprostone|24 mcg capsule bid
79342266|NCT02503085|Drug|Nurofen for Children®|
79342267|NCT02503085|Drug|Algifor Dolo Junior®|
79492904|NCT00002816|Drug|Methotrexate|Given IV
79657116|NCT02279797|Behavioral|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
79492905|NCT05751499|Diagnostic Test|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"Low Back Outcome Scale~Center for Epidemiological Studies-Depression Scale (CES-D)~International Physical Activity Questionnaire~Roland-Morris Disability Questionnaire~Force Platform~Pain Self-Efficacy Questionnaire (PSEQ)~Numeric Rating Scale~Job Content Questionnaire~Pits Burgh Sleep Quality Index (PSQI)~Orebo Musculoskeletal Pain Screening Questionnaire~Gait & Balance App~Keele STarT Back Screening Tool (SBST)~Fear-Avoidance Beliefs Questionnaire (FABQ)~Pain Catastrophizing Scale"
79492906|NCT00002269|Drug|Ampligen|
79492907|NCT00002269|Drug|Zidovudine|
79657117|NCT01688401|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
79492908|NCT00002275|Drug|Fat Emulsion 2%|
79657118|NCT04708821|Drug|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
79657119|NCT04708821|Drug|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
79657120|NCT04708821|Drug|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
79657121|NCT01688440|Other|#1 Respiratory Care Solution|Respiratory care solution.
79657122|NCT00240812|Drug|ibuprofen; pseudoephedrine HCl|
79657123|NCT01688479|Drug|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
79657124|NCT01688479|Drug|Essex® cream (Schering-Plough), aqueous cream without parabens|
79657125|NCT01688518|Drug|Heated Lidocaine/Tetracaine Patch|
79657126|NCT01688518|Drug|5% Lidocaine Patch|
79657127|NCT00250653|Drug|Saredutant succinate (SR48968C)|
79814138|NCT02602470|Drug|Azelaic Acid Cream|Azelaic Acid Cream 20%
79342268|NCT02481869|Biological|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
79342269|NCT02481869|Drug|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
79342270|NCT02502149|Biological|rFVIIIFc|As per arm description
79342271|NCT02480621|Drug|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
79492909|NCT00002275|Drug|Fat Emulsion 20%|
79657128|NCT05140681|Procedure|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
79657129|NCT05140681|Procedure|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
79657130|NCT00240851|Drug|acetaminophen extended release|
79657131|NCT01688557|Device|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
79657132|NCT01688557|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
79657133|NCT01688674|Drug|10% dextrose|
79657134|NCT04708977|Procedure|One-level lateral lumbar interbody fusion with Indirect Decompression|One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
79657135|NCT04708977|Procedure|One-level lateral lumbar interbody fusion with Direct Decompression|"One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed."
79657136|NCT05140486|Procedure|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
79657137|NCT00240929|Drug|MEDI-493|Active Comparator
79814139|NCT02602470|Drug|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
79342272|NCT02046603|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
79342273|NCT02046603|Drug|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
79342274|NCT02046603|Drug|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
79342275|NCT02046603|Drug|Methotrexate|Methotrexate per investigator's discretion.
79342276|NCT01885078|Drug|Baricitinib|Administered orally
79342277|NCT01885078|Drug|Placebo|Administered orally
79342278|NCT02046369|Drug|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
79342279|NCT02046369|Drug|Placebo|Placebo Comparator once daily
79342280|NCT02101359|Drug|T2380|200 microlitres of T2380 will be administrated intracamerally
79342281|NCT02101359|Drug|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
79342282|NCT02101359|Drug|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
79342283|NCT02100969|Drug|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
79342284|NCT01885000|Drug|Brimonidine tartrate was applied cutaneously once daily for 8 days.|
79342285|NCT01885000|Drug|Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.|
79342286|NCT04735341|Device|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
79492910|NCT00003152|Biological|filgrastim|
79492911|NCT00003152|Biological|recombinant interferon alfa|
79492912|NCT00003152|Drug|cyclophosphamide|
79492913|NCT00003152|Drug|prednisone|
79492914|NCT00003152|Drug|vincristine sulfate|
79492915|NCT00003152|Procedure|autologous bone marrow transplantation|
79492916|NCT00003152|Procedure|bone marrow ablation with stem cell support|
79492917|NCT00003152|Procedure|peripheral blood stem cell transplantation|
79492918|NCT00003152|Radiation|radiation therapy|
79492919|NCT05751421|Drug|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
79342287|NCT04171960|Other|Blood Draw Within 12 Hours of Injury|- Specimens collected for i-STAT testing and, if applicable, for optional collection of DNA for possible future genetic testing.
79342288|NCT04171960|Other|3T MRI|- 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury.
79492920|NCT05751421|Drug|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
79657138|NCT05140447|Other|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
79657139|NCT01688713|Drug|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
79657140|NCT00250692|Drug|Nitrous Oxide|
79657141|NCT01688791|Drug|Vintafolide|
79657142|NCT01688791|Drug|Carboplatin|
79657143|NCT01688791|Drug|Paclitaxel|
79657144|NCT01688908|Procedure|Endoscopic Screening|"Upper G.I. endoscopic examination with Lugols Iodine in esophagus~Biopsy at the visually abnormal sites~Pathologic examination of all biopsy tissue specimens~Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
79657145|NCT00240968|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
79657146|NCT01688947|Drug|V116517 50-mg tablets|Taken orally twice daily
79657147|NCT01688947|Drug|V116517 30-mg tablets|Taken orally twice daily
79342289|NCT04171960|Other|In-Person Outcome Assessment at Baseline|-3 Outcome Assessments administered at Baseline.
79342290|NCT04171960|Other|In-Person Outcome Assessment at Follow-Up|- Full set of Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury.
79657148|NCT01688947|Drug|Pregabalin capsules|1-2 capsules taken orally twice daily
79657149|NCT01688947|Drug|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
79657150|NCT00250731|Behavioral|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
79657151|NCT00250731|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
79657152|NCT00241007|Drug|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
79657153|NCT01689025|Drug|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
79657154|NCT01689025|Drug|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
79342291|NCT04171960|Other|Phone Outcome Assessment|- 6 Outcome Assessments administered at 3 months following injury by Phone.
79342292|NCT04171960|Other|Blood Draw After 12 Hours of Injury|- Specimens collected at 12-24 hours, 2 weeks, and 6 month following injury then processed for storage for future use.
79342293|NCT01884688|Drug|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
79342294|NCT01883362|Drug|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
79492921|NCT05751421|Procedure|primary total knee replacement|primary total knee replacement
79492922|NCT00002822|Drug|carboplatin|
79492923|NCT00002822|Drug|cisplatin|
79492924|NCT00002822|Drug|cyclophosphamide|
79492925|NCT00002822|Drug|doxorubicin hydrochloride|
79492926|NCT00002822|Drug|etoposide|
79492927|NCT00002822|Drug|ifosfamide|
79492928|NCT00002822|Drug|mesna|
79492929|NCT00002822|Drug|vincristine sulfate|
79492930|NCT00002822|Radiation|radiation therapy|
79492931|NCT00002281|Drug|Filgrastim|
79492932|NCT00002281|Drug|Epoetin alfa|
79492933|NCT00002281|Drug|Zidovudine|
79657155|NCT01689142|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
79657156|NCT01689142|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
79657157|NCT00241046|Drug|Letrozole|
79657158|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
79657159|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
79657160|NCT01689259|Drug|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
79657161|NCT01689259|Drug|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
79492934|NCT00002287|Drug|Zidovudine|
79492935|NCT00002828|Drug|fluorouracil|
79492936|NCT00002828|Drug|raltitrexed|
79492937|NCT00003410|Drug|motexafin gadolinium|
79492938|NCT00003410|Procedure|magnetic resonance imaging|
79657162|NCT01689259|Drug|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
79657163|NCT01689259|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
79657164|NCT01689298|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
79657165|NCT01689298|Drug|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
79657166|NCT00241085|Drug|valsartan|
79657167|NCT01689376|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
79657168|NCT02272075|Device|Mobile OCT M3 scope|
79342295|NCT01883362|Other|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
79342296|NCT02100813|Drug|LEO 43204|
79342297|NCT02100813|Drug|Placebo|
79657169|NCT00241124|Drug|valsartan|
79657170|NCT00241124|Drug|lisinopril|
79657171|NCT00241163|Procedure|Fibrinogen (human) + thrombin (human) (TachoSil)|
79657172|NCT00241202|Behavioral|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
79657173|NCT02277106|Drug|SAGE-547|
79657174|NCT02277106|Drug|Placebo|
79657175|NCT00241241|Drug|pegylated interferon-alfa 2a|
79342298|NCT04724967|Drug|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
79657176|NCT00241319|Drug|R89674 (generic name not yet established)|
79657177|NCT00414804|Device|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
79657178|NCT00414804|Procedure|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
79657179|NCT02279602|Drug|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
79657180|NCT02276209|Drug|Dasotraline|Dasotraline 4 mg once daily
79342299|NCT04724967|Drug|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
79342300|NCT01930162|Drug|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
79342301|NCT04630912|Other|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
79342302|NCT02045979|Drug|BI 695501|BI 695501 single s.c. injection
79342303|NCT02045979|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
79342304|NCT02045979|Drug|adalimumab-US source|adalimumab-US source single s.c. injection.
79492939|NCT00003410|Procedure|surgical procedure|
79492940|NCT00384020|Drug|Paroxetine (Seroxat)|
79492941|NCT00384020|Drug|Escitalopram (Lexapro)|
79492942|NCT00384098|Drug|CTA018 cream|
79492943|NCT00002557|Drug|CHOP regimen|
79492944|NCT00002557|Drug|doxorubicin hydrochloride|
79492945|NCT00002557|Drug|etoposide|
79492946|NCT00002557|Drug|leucovorin calcium|
79492947|NCT00002557|Drug|methotrexate|
79492948|NCT00003158|Drug|carboplatin|
79492949|NCT00003158|Drug|etoposide|
79492950|NCT00003158|Drug|paclitaxel|
79492951|NCT00003158|Radiation|radiation therapy|
79492952|NCT00002563|Procedure|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
79342305|NCT01929226|Biological|ETI-204|Monoclonal Antibody
79342306|NCT01929226|Other|Placebo|Placebo for ETI-204
79492953|NCT00002563|Procedure|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
79342307|NCT04703751|Device|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
79492954|NCT00003416|Biological|filgrastim|
79492955|NCT00003416|Biological|recombinant interferon alfa|
79492956|NCT00003416|Drug|dexamethasone|
79342308|NCT05122702|Drug|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
79492957|NCT00003416|Drug|melphalan|
79657181|NCT02276209|Drug|Dasotraline|Dasotraline 6 mg once daily
79342309|NCT05122702|Other|Placebo|Placebo granules, twice daily for 12 weeks.
79342310|NCT04734405|Drug|Prof-001|Prof-001 cream
79342311|NCT04734405|Drug|Fluconazole 150 mg|Fluconazole capsule
79342312|NCT04734405|Drug|Placebo cream|ointment base to mimic Prof-001
79342313|NCT04734405|Drug|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
79342314|NCT02045433|Radiation|SABR Boost Therapy|"Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
79657182|NCT02276209|Other|Placebo|Placebo once daily
79657183|NCT01689493|Behavioral|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
79657184|NCT01689571|Drug|CHF6001|
79657185|NCT01689571|Drug|Placebo|
79657186|NCT00241436|Drug|Anastrozole (ARIMIDEX™)|
79342315|NCT01911442|Drug|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
79342316|NCT01911442|Drug|Lurasidone|Lurasidone 60 mg once daily
79342317|NCT01911442|Drug|Placebo|Placebo
79342318|NCT01928758|Drug|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
79492958|NCT00003416|Procedure|peripheral blood stem cell transplantation|
79492959|NCT00002569|Drug|lomustine|
79657187|NCT00264420|Drug|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
79657188|NCT00241475|Drug|Gefitinib|
79657189|NCT01689844|Behavioral|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
79657190|NCT01689844|Behavioral|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
79657191|NCT01689883|Device|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
79342319|NCT01928758|Drug|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
79342320|NCT01910116|Drug|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
79342321|NCT01910116|Drug|Placebo|The study medication and placebo were identical in appearance.
79342322|NCT01614886|Drug|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
79342323|NCT01614886|Drug|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
79492960|NCT00002569|Drug|procarbazine hydrochloride|
79492961|NCT00002569|Drug|vincristine sulfate|
79492962|NCT00002569|Radiation|radiation therapy|
79492963|NCT00002840|Drug|lomustine|
79492964|NCT00002840|Drug|procarbazine hydrochloride|
79492965|NCT00002840|Drug|vincristine sulfate|
79492966|NCT00002840|Radiation|radiation therapy|
79492967|NCT00002846|Biological|aldesleukin|
79492968|NCT00002846|Procedure|conventional surgery|
79492969|NCT05720767|Drug|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
79814140|NCT02602470|Drug|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
79814141|NCT02602470|Drug|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
79492970|NCT05720767|Drug|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
79814142|NCT02602470|Drug|Metronidazole Lotion|Metronidazole Lotion 0,75%
79342324|NCT04622254|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79342325|NCT04622254|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79342326|NCT01880554|Device|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
79492971|NCT05720767|Drug|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
79492972|NCT00003170|Dietary Supplement|glutamine|
79657192|NCT01689922|Other|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
79657193|NCT01689961|Behavioral|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
79657194|NCT01686061|Other|No intervention- only one time survey|
79657195|NCT01685359|Drug|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
79657196|NCT01682824|Other|Nutritional Assessment|Complete dietary intake assessment
79814143|NCT02602470|Drug|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
79814144|NCT00829816|Drug|Dimebon|
79492973|NCT00003170|Other|placebo|
79342327|NCT04171726|Drug|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
79492974|NCT05751031|Drug|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
79657197|NCT01682824|Other|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
79657198|NCT01682824|Other|Questionnaire Administration|Complete EQ-EMA questionnaire
79814145|NCT00829816|Drug|Placebo|
79814146|NCT00824200|Behavioral|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema.
79342328|NCT02100657|Drug|Plitidepsin|
79342329|NCT02100657|Drug|Bortezomib|
79342330|NCT02100657|Drug|Dexamethasone|
79814147|NCT00824200|Drug|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
79814148|NCT00824200|Drug|placebo|tamsulosin placebo
79814149|NCT00824200|Behavioral|placebo|placebo behavioral intervention
79814150|NCT04043884|Other|sEmg biofeedback training|Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
79814151|NCT04043884|Other|Strength training|The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
79342331|NCT02067663|Device|Paragard|The IUD will be placed as part of standard clinical care.
79342332|NCT02067663|Drug|Mirena|The IUD will be placed as part of standard clinical care.
79342333|NCT01909804|Drug|SOF|400 mg tablet administered orally once daily
79342334|NCT01909804|Drug|VEL|Tablet administered orally once daily
79342335|NCT01909804|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79342336|NCT01880086|Drug|Clomiphene citrate|
79342337|NCT01880086|Drug|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
79342338|NCT01879852|Behavioral|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
79342339|NCT01879852|Behavioral|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
79342340|NCT01879618|Drug|Fragmin|variable dosing regimen
79342341|NCT01926886|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
79657199|NCT01687738|Other|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
79657200|NCT01687738|Other|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
79657201|NCT02278978|Drug|BIBF1120|BIBF1120 200 mg two times per day orally
79814152|NCT04103736|Dietary Supplement|Beet It Sport Shot|Source of naturally occurring dietary nitrates
79342342|NCT01909336|Drug|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
79342343|NCT01909336|Drug|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
79342344|NCT01909336|Drug|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
79342345|NCT01926028|Biological|NDV-3A|0.5mL injection IM
79342346|NCT01926028|Biological|NDV-3|0.5mL injection IM
79657202|NCT02218723|Drug|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
79657203|NCT02218723|Drug|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
79814153|NCT04103736|Dietary Supplement|Nitrate-depleted placebo|Placebo
79342347|NCT01926028|Biological|Placebo|aluminum hydroxide and buffered saline
79342348|NCT01925950|Drug|orBec|
79342349|NCT01925950|Drug|Placebo|
79342350|NCT04415320|Drug|X-396(Ensartinib)|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
79814154|NCT00829894|Drug|Risperidone|1 mg Tablet
79814155|NCT00829894|Drug|Risperidone|1 mg Tablet
79814156|NCT00622726|Drug|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
79342351|NCT01878292|Drug|Placebo|Dose matched placebo tablets, once per day, oral administration.
79342352|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
79342353|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
79342354|NCT01908634|Dietary Supplement|Milk-based Strawberry Beverage without meal|
79342355|NCT01908634|Dietary Supplement|Water-Based Strawberry Beverage without meal|
79342356|NCT01908634|Dietary Supplement|Milk-based strawberry Beverage with meal|
79342357|NCT01908634|Dietary Supplement|Water-Based strawberry Beverage with meal|
79492975|NCT00002852|Drug|paclitaxel|Given IV
79492976|NCT00002852|Drug|carboplatin|Given IV
79342358|NCT01878214|Behavioral|Targeted messaging|6 targeted mailed messages and 6 booster text messages
79492977|NCT00002852|Procedure|therapeutic conventional surgery|Undergo surgery
79492978|NCT05750719|Genetic|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
79492979|NCT00003422|Drug|fluorouracil|
79492980|NCT00003422|Drug|leucovorin calcium|
79657204|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
79342359|NCT01878214|Behavioral|Standard messaging|1 informational letter
79342360|NCT01907854|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
79492981|NCT00003422|Procedure|adjuvant therapy|
79657205|NCT02218762|Drug|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
79657206|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
79492982|NCT00003422|Procedure|conventional surgery|
79657207|NCT02218762|Drug|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
79657208|NCT00264459|Biological|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
79657209|NCT00264459|Other|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
79492983|NCT00003422|Procedure|neoadjuvant therapy|
79492984|NCT00003422|Radiation|radiation therapy|
79657210|NCT00241514|Drug|Esomeprazole|
79657211|NCT02218879|Drug|Tecfidera|Oral Tecfidera 240 mg bid
79657212|NCT02218918|Behavioral|Ground walk training|3 times a week and 6 weeks
79814157|NCT00622726|Procedure|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
79342361|NCT01907854|Drug|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
79342362|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
79342363|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
79342364|NCT02480153|Biological|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
79342365|NCT02480153|Biological|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
79342366|NCT04972253|Drug|Infigratinib|Oral, dosage per protocol
79342367|NCT02500979|Drug|Pramlintide acetate|Pramlintide acetate administered by a separate pump
79492985|NCT00003176|Drug|carmustine|
79492986|NCT00003176|Drug|temozolomide|
79492987|NCT00003428|Drug|arzoxifene hydrochloride|
79492988|NCT00002858|Drug|cisplatin|
79492989|NCT00002858|Drug|cyclophosphamide|
79492990|NCT00002858|Drug|doxorubicin hydrochloride|
79492991|NCT00002858|Drug|etoposide|
79492992|NCT00002858|Radiation|radiation therapy|
79492993|NCT00002575|Procedure|conventional surgery|
79492994|NCT00002575|Procedure|laparoscopic surgery|
79492995|NCT00002864|Drug|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
79492996|NCT00002864|Drug|tamoxifen citrate|20 mg PO for 5 years
79492997|NCT00002870|Biological|filgrastim|
79492998|NCT00002870|Drug|cyclophosphamide|
79492999|NCT00002870|Drug|epirubicin hydrochloride|
79493000|NCT00002870|Drug|fluorouracil|
79493001|NCT00002870|Drug|thiotepa|
79657213|NCT02218918|Behavioral|Supervised Treadmill Walk training|3 times a week and 6 weeks
79657214|NCT02218957|Procedure|Extended Pouch RYGB|
79493002|NCT00002870|Procedure|peripheral blood stem cell transplantation|
79657215|NCT02218957|Procedure|Standard RYGB|
79657216|NCT00241553|Drug|Esomeprazole|
79657217|NCT02219074|Device|Sebacia microparticle and laser treatment|
79657218|NCT02219074|Device|Vehicle and laser treatment|
79342368|NCT02500979|Drug|Placebo|Placebo administered by separate pump
79342369|NCT02500979|Drug|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
79493003|NCT00002581|Drug|cyclophosphamide|
79493004|NCT00002581|Drug|fluorouracil|
79493005|NCT00002581|Drug|methotrexate|
79493006|NCT00002581|Drug|tamoxifen citrate|
79493007|NCT00002581|Procedure|conventional surgery|
79493008|NCT00002581|Radiation|radiation therapy|
79493009|NCT00003182|Drug|cisplatin|
79493010|NCT00003182|Drug|gemcitabine hydrochloride|
79493011|NCT00002587|Drug|paclitaxel|
79493012|NCT00002587|Drug|topotecan hydrochloride|
79657219|NCT00250887|Drug|Gefitnib|
79657220|NCT02219113|Procedure|Arthroscopic surgery|
79657221|NCT02219113|Procedure|Liposuction|
79493013|NCT00003434|Biological|carcinoembryonic antigen peptide 1|
79493014|NCT00003434|Biological|hepatitis B antigen peptide|
79493015|NCT05750641|Other|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
79493016|NCT05750641|Other|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
79493017|NCT00002876|Drug|cisplatin|
79657222|NCT02219113|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
79657223|NCT02219113|Other|Intraarticular administration of autologous ADRC|
79657224|NCT02279017|Behavioral|mHealth Texting for Weight Loss|
79657225|NCT02219152|Drug|tranexamic acid|
79657226|NCT02219152|Drug|saline|
79493018|NCT00002876|Drug|etoposide|
79493019|NCT00002593|Drug|fluorouracil|Given IV as described in Arm Description
79493020|NCT00002593|Drug|leucovorin calcium|Given IV as described in Arm description.
79814158|NCT00831610|Procedure|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
79814159|NCT00831610|Procedure|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
79493021|NCT00002593|Drug|levamisole hydrochloride|Given as described in arm description
79493022|NCT00003194|Biological|filgrastim|
79493023|NCT00003194|Drug|carboplatin|
79493024|NCT00003194|Drug|cyclophosphamide|
79657227|NCT00264615|Drug|lamotrigine extended-release|
79657228|NCT02219191|Drug|puerarin tablet 50 mg|
79657229|NCT02219191|Drug|Atorvastatin tablet 20 mg|Approval No.: H19990258
79657230|NCT02219347|Drug|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
79657231|NCT04529512|Drug|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
79814160|NCT00830050|Drug|Naproxen|500 mg BID 7 days
79342370|NCT02500979|Drug|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
79342371|NCT02500901|Drug|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
79342372|NCT02500901|Drug|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
79342373|NCT02479139|Biological|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
79342374|NCT02479139|Biological|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
79493025|NCT00003194|Drug|etoposide|
79493026|NCT00003194|Drug|thiotepa|
79493027|NCT00003194|Drug|topotecan hydrochloride|
79493028|NCT00003194|Procedure|peripheral blood stem cell transplantation|
79493029|NCT00002882|Biological|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
79493030|NCT00002882|Biological|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
79657232|NCT00241592|Drug|Cannabis|
79657233|NCT02219386|Other|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
79657234|NCT02219386|Other|group 2. Passive analitical stretch (performed in both groups)|
79657235|NCT02219425|Procedure|endometrial biopsy|
79657236|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
79657237|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
79657238|NCT02219620|Behavioral|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
79814161|NCT00830050|Drug|Placebo|BID 7 days
79814162|NCT00623428|Drug|peginterferon alfa-2a|
79493031|NCT00002882|Drug|Cisplatin|IV Days 1-4
79493032|NCT00002882|Drug|Dacarbazine|IVPB on day 1
79493033|NCT00002882|Drug|Vinblastine|IVPB on days 1-4
79657239|NCT02219620|Behavioral|Social Control|social conversational group facilitated by care counselor
79985047|NCT02439112|Other|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly >65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
79985048|NCT03696602|Diagnostic Test|bronchial provocation test|
79657240|NCT00241670|Drug|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
79657241|NCT02219737|Drug|Carboplatin|Given IVPB
79985049|NCT03701906|Dietary Supplement|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1*10E9 CFU of L.salivarius PS11603 and 1*10E8 CFU of B.longum PS10402.
79493034|NCT00002882|Procedure|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
79814163|NCT00623428|Drug|Ribavirin|
79814164|NCT00831688|Device|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
79814165|NCT00831688|Device|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
79814166|NCT00824356|Drug|GSK1004723 (200mg)|Intranasal antihistamine.
79985050|NCT03701906|Dietary Supplement|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
79985051|NCT02438956|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
79493035|NCT05750563|Dietary Supplement|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
79493036|NCT05750563|Other|Placebo|Use as comparator
79493037|NCT00002888|Drug|cisplatin|
79657242|NCT02219737|Drug|Etoposide|Given IVPB
79657243|NCT02219737|Drug|Ibrutinib|Given PO
79657244|NCT02219737|Drug|Ifosfamide|Given IV
79657245|NCT02219737|Other|Laboratory Biomarker Analysis|Correlative studies
79657246|NCT02219737|Other|Pharmacological Study|Correlative studies
79657247|NCT02219737|Biological|Rituximab|Given IV
79657248|NCT02219854|Procedure|Laparoscopic gastrectomy|
79657249|NCT02219854|Procedure|Open gastrectomy|
79657250|NCT02219893|Drug|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
79657251|NCT02219971|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
79814167|NCT00824356|Other|Placebo|Equivalent to GSK1004723 in presentation etc.
79985052|NCT02438956|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
79493038|NCT00002888|Drug|fluorouracil|
79493039|NCT00002888|Drug|paclitaxel|
79493040|NCT00002599|Biological|filgrastim|
79493041|NCT00002599|Biological|recombinant interferon alfa|
79493042|NCT00002599|Biological|sargramostim|
79342375|NCT02478359|Behavioral|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
79493043|NCT00002599|Drug|carmustine|
79493044|NCT00002599|Drug|cyclophosphamide|
79493045|NCT00002599|Drug|doxorubicin hydrochloride|
79493046|NCT00002599|Drug|melphalan|
79657252|NCT04720170|Procedure|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
79657253|NCT02218801|Other|Evaluation of treatment for liver metastasis|
79493047|NCT00002599|Drug|methylprednisolone|
79493048|NCT00002599|Drug|prednisone|
79302581|NCT03315923|Drug|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
79493049|NCT00002599|Drug|vincristine sulfate|
79657254|NCT02217865|Behavioral|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
79657255|NCT02217865|Behavioral|Questionnaire|Questionnaire completion asking general health and demographic questions.
79342376|NCT01877668|Drug|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
79342377|NCT01877668|Drug|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
79493050|NCT00002599|Radiation|low-LET cobalt-60 gamma ray therapy|
79493051|NCT00002599|Radiation|low-LET photon therapy|
79493052|NCT00003440|Drug|paclitaxel|Given IV over 1 hour or 3 hours
79493053|NCT00003440|Biological|trastuzumab|Given IV
79493054|NCT00003440|Procedure|quality-of-life assessment|Ancillary studies
79814168|NCT00824356|Drug|GSK1004723 (1000mg)|Intranasal antihistamine.
79493055|NCT00003440|Other|laboratory biomarker analysis|Correlative studies
79493056|NCT00003200|Drug|Taxotere|
79493057|NCT00003200|Radiation|Radiation therapy|
79493058|NCT05750485|Other|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
79493059|NCT05750407|Behavioral|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
79493060|NCT00003446|Drug|fluorouracil|
79493061|NCT00003446|Drug|leucovorin calcium|
79493062|NCT00003446|Drug|trimetrexate glucuronate|
79493063|NCT00003938|Drug|liposomal amphotericin B|
79493064|NCT05750251|Procedure|levator muscle resection surgery|conventional ptosis surgery
79493065|NCT05750251|Procedure|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
79493066|NCT05750251|Procedure|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
79493067|NCT00003212|Drug|doxorubicin hydrochloride|
79493068|NCT00003212|Drug|ifosfamide|
79493069|NCT00002611|Biological|dactinomycin|
79342378|NCT01877668|Drug|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
79342379|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
79342380|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
79342381|NCT01877278|Device|Wearable pulsed electromagnetic fields|
79657256|NCT02217865|Behavioral|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
79657257|NCT02217865|Behavioral|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
79657258|NCT02210650|Procedure|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
79342382|NCT01906372|Drug|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
79342383|NCT01925170|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
79342384|NCT01925170|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
79493070|NCT00002611|Biological|filgrastim|
79493071|NCT00002611|Drug|cyclophosphamide|
79493072|NCT00002611|Drug|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; <5% in the urine. The drug has a very short initial t½ of <20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
79493073|NCT00002611|Drug|etoposide|
79493074|NCT00002611|Drug|vincristine sulfate|
79657259|NCT02210650|Procedure|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
79657260|NCT04720014|Behavioral|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~an understanding of stress physiology and the physiology of the relaxation response;~a regular practice of eliciting the relaxation response; and~cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
79657261|NCT02212951|Drug|BIOD-531|
79657262|NCT02212951|Drug|Humalog Mix 75/25|
79657263|NCT02212951|Drug|Humulin R U-500|
79657264|NCT02211508|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
79657265|NCT00250965|Drug|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
79657266|NCT00241826|Procedure|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
79657267|NCT00241826|Procedure|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
79657268|NCT02210806|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
79657269|NCT02210806|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
79657270|NCT02210806|Other|Placebo DPI|Placebo, 1 inhalation
79657271|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
79657272|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
79814169|NCT00831922|Drug|masitinib (AB1010)|3 mg/kg/day
79493075|NCT00002611|Procedure|conventional surgery|
79493076|NCT00002611|Radiation|radiation therapy|
79657273|NCT02210026|Device|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
79657274|NCT00264654|Drug|BRL29060A|
79493077|NCT00003944|Biological|filgrastim|
79985053|NCT02438800|Behavioral|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
79657275|NCT00264654|Drug|paroxetine hydrochloride hydrate|
79657276|NCT00241943|Procedure|Hepatitis C educational video|
79657277|NCT02219230|Device|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
79985054|NCT03692858|Drug|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
79985055|NCT03692858|Drug|Adductor Canal Block|Adductor Canal Block using Ropivacaine
79657278|NCT02219230|Device|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
79657279|NCT02219230|Device|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
79657280|NCT02219659|Drug|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
79657281|NCT02219659|Drug|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
79814170|NCT00831922|Drug|masitinib (AB1010)|6 mg/kg/day
79814171|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
79814172|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
79985056|NCT03692780|Drug|Careseng 1370|4,000mg granules in sachet
79985057|NCT03692780|Drug|Placebo|4,000mg granules in sachet
79985058|NCT04483492|Drug|Caffeine citrate|diaphragm contractility after administration
79985059|NCT02442154|Procedure|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
79985060|NCT04483336|Other|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
79985061|NCT04483336|Other|TV Screen Distraction|A cartoon video was played on a regular TV screen.
79985062|NCT02438878|Behavioral|Baby Behavior|
79985063|NCT03186976|Behavioral|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%"
79342385|NCT01925170|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
79342386|NCT01925014|Diagnostic Test|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
79342387|NCT01925014|Diagnostic Test|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
79342388|NCT01876810|Drug|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
79342389|NCT01876810|Drug|Placebo|One lactose pill twice a day for two weeks.
79493078|NCT00003944|Drug|carboplatin|
79493079|NCT00003944|Drug|cyclophosphamide|
79493080|NCT00003944|Drug|paclitaxel|
79493081|NCT00003944|Drug|topotecan hydrochloride|
79493082|NCT00003944|Procedure|peripheral blood stem cell transplantation|
79493083|NCT00003950|Drug|cyclosporine|
79493084|NCT00003950|Drug|CPT-11|
79985064|NCT03186976|Other|Standard of Care|Recommendations based on current guidelines
79985065|NCT02442388|Procedure|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
79342390|NCT01876732|Drug|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
79342391|NCT01905592|Drug|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
79342392|NCT01905592|Drug|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
79342393|NCT01876420|Device|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
79342394|NCT04608682|Drug|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
79342395|NCT04608682|Drug|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
79342396|NCT01875874|Biological|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
79342397|NCT04619446|Device|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
79342398|NCT04619446|Device|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
79342399|NCT02500121|Other|Placebo|Normal saline
79985066|NCT02442388|Procedure|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
79985067|NCT02442388|Procedure|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
79342400|NCT02500121|Drug|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
79342401|NCT01875250|Biological|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
79342402|NCT01875250|Biological|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
79342403|NCT01875250|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
79985068|NCT03186742|Drug|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
79342404|NCT01904032|Drug|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
79342405|NCT01904032|Drug|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
79493085|NCT00003452|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79493086|NCT00003464|Drug|temozolomide|
79493087|NCT00003464|Radiation|radiation therapy|
79493088|NCT00003230|Drug|paclitaxel|
79985069|NCT02441998|Other|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
79493089|NCT00003956|Drug|fluorouracil|
79493090|NCT00003956|Drug|leucovorin calcium|
79493091|NCT00003956|Drug|lonafarnib|
79657282|NCT02219659|Drug|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
79657283|NCT00241982|Drug|long-circulating liposomal prednisolone|
79342406|NCT01903876|Behavioral|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
79342407|NCT01903876|Behavioral|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
79342408|NCT01921348|Device|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
79342409|NCT01921348|Device|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
79657284|NCT02212015|Drug|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
79342410|NCT01921270|Drug|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
79342411|NCT02325739|Drug|FGF401|FGF401 is a FGFR4 inhibitor.
79493092|NCT00002623|Drug|carboplatin|
79493093|NCT00002623|Drug|cisplatin|
79493094|NCT00002623|Procedure|conventional surgery|
79493095|NCT00002623|Radiation|radiation therapy|
79493096|NCT00003962|Biological|aldesleukin|
79493097|NCT00003968|Drug|bryostatin 1|
79493098|NCT00003974|Biological|lung tumor associated antigen|
79493099|NCT00003974|Drug|DetoxPC|
79493100|NCT00003974|Drug|chemotherapy|
79493101|NCT00003974|Drug|cyclophosphamide|
79493102|NCT00002635|Biological|filgrastim|
79493103|NCT00002635|Drug|aminocamptothecin|
79985070|NCT03186664|Device|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
79342412|NCT02325739|Biological|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
79657285|NCT04720859|Drug|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
79657286|NCT00272727|Behavioral|Dialog tool for caregivers|
79657287|NCT02279056|Behavioral|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
79657288|NCT02279056|Behavioral|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
79342413|NCT05121922|Behavioral|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
79493104|NCT00003494|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79657289|NCT00272766|Drug|pegaptanib sodium|
79657290|NCT00242060|Procedure|MRI|
79657291|NCT02961842|Drug|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
79657292|NCT02961842|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
79657293|NCT02961842|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
79657294|NCT02961842|Drug|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
79342414|NCT01903720|Drug|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
79342415|NCT02366689|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
79342416|NCT02366689|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
79342417|NCT02366689|Drug|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
79342418|NCT02366689|Drug|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
79657295|NCT02961842|Drug|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
79657296|NCT02961842|Drug|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
79657297|NCT02961842|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
79657298|NCT02961842|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
79657299|NCT02961842|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
79657300|NCT00272805|Drug|carvedilol|
79657301|NCT00242099|Procedure|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
79657302|NCT00242138|Behavioral|Erectile Dysfunction|
79657303|NCT00242177|Drug|ACTOS (Pioglitazone)|
79657304|NCT00264888|Drug|PTC124|
79985071|NCT03186664|Drug|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
79493105|NCT00003500|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79493106|NCT00003512|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79493107|NCT00003242|Drug|bryostatin 1|
79657305|NCT00416481|Behavioral|quality of life questionnaires|
79657306|NCT00264927|Drug|SR121463B|
79657307|NCT00242294|Drug|Roflumilast|
79657308|NCT00242333|Drug|AD 237|
79342419|NCT02366689|Drug|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
79342420|NCT01903252|Drug|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
79342421|NCT01903252|Drug|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
79493108|NCT00003242|Drug|cisplatin|
79493109|NCT00003242|Drug|paclitaxel|
79657309|NCT00416559|Other|clinical observation|
79657310|NCT00264966|Drug|ASM8|
79493110|NCT00003980|Drug|BIBX 1382|
79657311|NCT00242372|Drug|Tesaglitazar 0.5|
79657312|NCT00242372|Drug|Insulin at least 30 units/day|
79657313|NCT00265005|Drug|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
79657314|NCT00242411|Drug|Budesonide/Formoterol Turbuhaler|
79657315|NCT00242411|Drug|Conventional Best Asthma Therapy|
79657316|NCT00272922|Device|hernia repair|
79342422|NCT01920958|Other|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
79342423|NCT04415398|Device|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
79657317|NCT00265044|Behavioral|Provider Education|
79657318|NCT00265044|Behavioral|Hypertension Alert|
79657319|NCT00265044|Behavioral|Patient Education|
79657320|NCT02962037|Other|Melatonin and light therapy|
79657321|NCT00273000|Drug|GLP-2|
79657322|NCT04720586|Procedure|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
79657323|NCT04720586|Procedure|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
79657324|NCT00282399|Drug|Subcutaneous Decitabine|
79657325|NCT00242450|Drug|Metoclopramide|
79657326|NCT00273039|Drug|paroxetine|
79493111|NCT05664061|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
79657327|NCT00242528|Drug|Zoledronic acid|
79657328|NCT00273117|Procedure|transnasal gastroscopy|
79657329|NCT00273156|Behavioral|Telephone quitline|
79985072|NCT03189784|Other|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
79657330|NCT00242606|Drug|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
79657331|NCT00242606|Drug|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
79657332|NCT00242645|Behavioral|Health Information|
79657333|NCT00242645|Behavioral|Preventive Services|
79657334|NCT00242645|Behavioral|Computer tailored information|
79657335|NCT00273195|Device|Implantable Cardioverter Defibrillator|
79657336|NCT00242762|Drug|ZD1839 (IRESSA™)|
79302582|NCT03315923|Drug|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
79302583|NCT02451085|Behavioral|training with video therapy|training with video therapy
79302584|NCT02451085|Behavioral|conventional exercise|training in conventional way
79985073|NCT02441842|Drug|atenolol|administered 60 minutes pre procedure
79342424|NCT01613716|Drug|Ozurdex|Ozurdex .7 mg injected into the treated eye
79342425|NCT01872910|Drug|Placebo|Administered orally
79342426|NCT01872910|Drug|LY3023703|Administered orally
79342427|NCT01872910|Drug|Celecoxib|Administered orally
79342428|NCT01920568|Biological|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
79342429|NCT01920568|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance <=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
79342430|NCT01920568|Drug|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
79342431|NCT01920568|Drug|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
79657337|NCT00242762|Drug|Docetaxel|
79985074|NCT02441842|Drug|lisinopril|administered 60 minutes pre procedure
79342432|NCT01920568|Dietary Supplement|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
79342433|NCT01920568|Dietary Supplement|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
79493112|NCT05664061|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
79493113|NCT05664061|Drug|Placebo|twice daily inhalation throughout the treatment period
79657338|NCT00242762|Drug|Cisplatin|
79657339|NCT00282516|Procedure|In-home telemonitoring of pediatric patients with persistent asthma|
79657340|NCT00242801|Drug|Gefitinib|
79657341|NCT00273234|Procedure|Autologous Platelet Gel (APG)|
79657342|NCT00282555|Drug|S-Tenatoprazole-Na (STU-Na)|
79657343|NCT00242840|Drug|No intervention; Observational study|
79657344|NCT00273273|Procedure|blood draw|
79657345|NCT00242879|Drug|Physician determined comparator PI + ritonavir|
79657346|NCT00242879|Drug|GW640385 + ritonavir|
79657347|NCT00282594|Drug|Novolin R (human recombinant Insulin)|
79657348|NCT00242918|Drug|docetaxel|
79985075|NCT02441842|Other|glucose|administered 60 minutes pre procedure
79657349|NCT00242918|Drug|ZD1839|
79657350|NCT00282633|Device|Dermabond|
79985076|NCT02438566|Drug|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
79985077|NCT02438566|Drug|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
79985078|NCT02433652|Biological|Recombinant live attenuated trivalent dengue vaccine|Contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10^3.0 PFU of each component.
79814173|NCT02548624|Device|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
79657351|NCT00242957|Behavioral|Intervention with Microfinance for AIDS and Gender Equity|
79342434|NCT01920178|Device|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
79985079|NCT02433652|Biological|Placebo|
79985080|NCT02433652|Biological|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10^3 PFU
79342435|NCT01901848|Behavioral|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
79657352|NCT00273312|Drug|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
79342436|NCT01901848|Drug|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
79657353|NCT00242996|Biological|filgrastim|
79985081|NCT03186586|Drug|Ulipristal acetate|5mg/day/five days
79985082|NCT03186586|Drug|Placebo|Placebo one pill a day for 5 days at the bleeding episode
79985083|NCT02441608|Device|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
79985084|NCT02433574|Radiation|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
79657354|NCT00242996|Biological|rituximab|
79657355|NCT00242996|Biological|sargramostim|
79657356|NCT00242996|Drug|carmustine|
79657357|NCT00242996|Drug|cyclophosphamide|
79657358|NCT00242996|Drug|etoposide|
79657359|NCT00242996|Procedure|adjuvant therapy|
79657360|NCT00242996|Procedure|bone marrow ablation with stem cell support|
79657361|NCT00242996|Procedure|peripheral blood stem cell transplantation|
79657362|NCT00273390|Drug|Remicade (infliximab)|
79657363|NCT00243035|Drug|bortezomib|Given IV
79657364|NCT00243035|Drug|tipifarnib|Given orally
79657365|NCT00243035|Other|laboratory biomarker analysis|Correlative studies
79657366|NCT00243113|Drug|docetaxel|
79985085|NCT02438176|Procedure|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
79985086|NCT02438176|Procedure|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
79985087|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
79493114|NCT00003248|Biological|rituximab|
79493115|NCT00003248|Drug|fludarabine phosphate|
79493116|NCT00002641|Biological|filgrastim|
79493117|NCT00002641|Drug|doxorubicin hydrochloride|
79493118|NCT00002641|Drug|ifosfamide|
79493119|NCT00002641|Drug|isolated perfusion|
79493120|NCT00002641|Procedure|adjuvant therapy|
79493121|NCT00002641|Procedure|conventional surgery|
79493122|NCT00002641|Radiation|radiation therapy|
79493123|NCT00003992|Biological|trastuzumab|
79493124|NCT00003992|Drug|cyclophosphamide|
79493125|NCT00003992|Drug|doxorubicin hydrochloride|
79493126|NCT00003992|Drug|paclitaxel|
79493127|NCT00003992|Drug|tamoxifen citrate|
79657367|NCT00243113|Radiation|radiation therapy|
79657368|NCT00273429|Drug|timolol maleate 0.5%|
79985088|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
79985089|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
79985090|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
79985091|NCT02433418|Procedure|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
79493128|NCT00002647|Drug|verteporfin|
79657369|NCT00273429|Drug|dorzolamide/timolol maleate fixed combination|
79657370|NCT00273429|Drug|latanoprost 0.005%|
79657371|NCT00273429|Drug|placebo|
79657372|NCT00243308|Drug|Serine proteinase-1 (Serp-1)|
79985092|NCT02433418|Drug|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
79493129|NCT00002647|Procedure|conventional surgery|
79493130|NCT00003524|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79493131|NCT00003530|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79493132|NCT00002653|Drug|carmustine|
79493133|NCT00002653|Drug|cyclophosphamide|
79493134|NCT00002653|Drug|doxorubicin hydrochloride|
79493135|NCT00002653|Drug|melphalan|
79493136|NCT00002653|Drug|prednisone|
79493137|NCT00002653|Radiation|radiation therapy|
79493138|NCT00003254|Drug|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
79493139|NCT00003254|Drug|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
79493140|NCT05749549|Drug|BR1733|Subjects will receive oral administration of BR1733.
79493141|NCT00002659|Drug|cisplatin-e therapeutic implant|
79493142|NCT00003998|Drug|carboplatin|
79493143|NCT00003998|Drug|docetaxel|
79493144|NCT00003998|Drug|paclitaxel|
79493145|NCT00003998|Procedure|surgical procedure|
79493146|NCT00004004|Drug|procarbazine hydrochloride|
79493147|NCT05749471|Diagnostic Test|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of > 19, any one item with a score of > 5, or any three items with a score of > 4 would have sexual dysfunction.
79493148|NCT00003260|Drug|FOLFIRI regimen|
79493149|NCT00003260|Drug|FOLFOX regimen|
79493150|NCT00003260|Drug|fluorouracil|
79493151|NCT00003260|Drug|irinotecan hydrochloride|
79493152|NCT00003260|Drug|leucovorin calcium|
79493153|NCT00003260|Drug|oxaliplatin|
79493154|NCT00002665|Drug|asparaginase|10,000 units/d IV or IM 15 - 24
79493155|NCT00002665|Drug|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
79657373|NCT00273468|Drug|Granisetron|
79657374|NCT00243425|Procedure|Standard Quality Improvement|
79657375|NCT00243425|Procedure|Patient-centered Intervention|
79657376|NCT00282750|Device|Bar coded sponge and scanner|
79657377|NCT00243464|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
79657378|NCT00282789|Device|bilevel positive airway pressure|
79657379|NCT00282789|Device|bilevel positive airway pressure (Device)|
79657380|NCT00243542|Drug|ACZONE Gel, 5%|
79657381|NCT00243542|Drug|Vehicle|
79657382|NCT00282906|Device|hybrid PET-CT imaging system|15 mCi of FDG
79814174|NCT00837304|Device|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
79657383|NCT00243581|Behavioral|Dean Ornish Heart Disease Reversing Program|
79657384|NCT00273507|Drug|Carboplatin and Paclitaxel|
79657385|NCT02962154|Radiation|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
79657386|NCT02962154|Other|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
79657387|NCT02962154|Other|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
79657388|NCT02962154|Other|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
79814175|NCT00837304|Procedure|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
79493156|NCT00002665|Drug|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
79342437|NCT01901848|Drug|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
79493157|NCT00002665|Drug|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
79493158|NCT00002665|Drug|dexamethasone|main: 10 mg/m2/day PO 1 - 28
79342438|NCT01901848|Behavioral|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
79493159|NCT00002665|Drug|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
79493160|NCT00002665|Drug|etoposide|60 mg/kg based on ideal body weight day -3
79493161|NCT00002665|Drug|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC < 3,000 /μl
79493162|NCT00002665|Drug|mercaptopurine|con: 60 mg/m2 PO 1 - 28
79342439|NCT01901848|Behavioral|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
79493163|NCT00002665|Drug|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
79493164|NCT00002665|Drug|prednisone|"ind: 60 mg/m2/d PO 1 - 21*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
79493165|NCT00002665|Drug|thioguanine|main: 60 mg/m2/day PO 1 - 14
79342440|NCT04415632|Other|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
79342441|NCT04415632|Other|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
79493166|NCT00002665|Drug|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
79493167|NCT00002665|Procedure|allogeneic bone marrow transplantation|day 0
79493168|NCT00002665|Radiation|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
79493169|NCT00003536|Drug|antineoplaston A10|
79493170|NCT00003536|Drug|methotrexate|
79493171|NCT00003536|Procedure|alternative product therapy|
79493172|NCT00003536|Procedure|biological therapy|
79493173|NCT00003536|Procedure|biologically based therapies|
79493174|NCT00003536|Procedure|cancer prevention intervention|
79302585|NCT03315845|Other|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
79493175|NCT00003536|Procedure|chemotherapy|
79493176|NCT00003536|Procedure|complementary and alternative therapy|
79493177|NCT00003536|Procedure|differentiation therapy|
79493178|NCT00003542|Biological|pegylated interferon alfa|
79493179|NCT00381667|Drug|GW642444M|M salt
79493180|NCT00381667|Drug|GW642444H|H salt
79493181|NCT00381667|Other|placebo|placebo
79493182|NCT00003548|Drug|aminocamptothecin colloidal dispersion|
79493183|NCT00381823|Behavioral|Cognitive Behavioral Therapy|
79493184|NCT00004010|Biological|bleomycin sulfate|
79493185|NCT00004010|Biological|filgrastim|
79493186|NCT00004010|Drug|ABVD regimen|
79493187|NCT00004010|Drug|cyclophosphamide|
79493188|NCT00004010|Drug|dacarbazine|
79493189|NCT00004010|Drug|doxorubicin hydrochloride|
79493190|NCT00004010|Drug|etoposide|
79493191|NCT00004010|Drug|prednisone|
79493192|NCT00004010|Drug|procarbazine hydrochloride|
79493193|NCT00004010|Drug|vinblastine sulfate|
79493194|NCT00004010|Drug|vincristine sulfate|
79493195|NCT00004010|Radiation|radiation therapy|
79493196|NCT05646979|Behavioral|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
79493197|NCT00004016|Biological|recombinant interferon gamma|
79493198|NCT05749315|Other|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
79493199|NCT05749315|Other|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
79493200|NCT00004022|Biological|aldesleukin|
79493201|NCT00004022|Biological|autologous tumor cell vaccine|
79493202|NCT00004022|Biological|muromonab-CD3|
79493203|NCT00004022|Biological|therapeutic autologous lymphocytes|
79493204|NCT00004022|Procedure|surgical procedure|
79493205|NCT00381901|Biological|trastuzumab|
79493206|NCT00381901|Genetic|polymorphism analysis|
79493207|NCT00381901|Procedure|adjuvant therapy|
79342442|NCT01901614|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
79493208|NCT00003278|Drug|dexamethasone|
79493209|NCT00003278|Radiation|radiation therapy|
79493210|NCT00004028|Drug|carmustine|
79493211|NCT00004028|Procedure|conventional surgery|
79493212|NCT00003554|Biological|rituximab|
79493213|NCT00003554|Drug|melphalan|
79493214|NCT00003554|Drug|prednisone|
79657389|NCT02962154|Other|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
79657390|NCT02962154|Other|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
79493217|NCT00003284|Biological|filgrastim|
79493218|NCT00003284|Drug|carboplatin|
79493219|NCT00003284|Drug|etoposide|
79493220|NCT00003284|Drug|ifosfamide|
79493221|NCT00003284|Drug|paclitaxel|
79493222|NCT00003284|Procedure|peripheral blood stem cell transplantation|
79493223|NCT00003284|Radiation|radiation therapy|
79493224|NCT05749237|Other|respiratory exercises|respiratory exercises
79493225|NCT05749237|Other|relaxation exercises|relaxation exercises
79493226|NCT00384410|Drug|Nabilone|
79493227|NCT00384488|Behavioral|Interactive Voice Response System (IVR)|
79493228|NCT00004040|Biological|recombinant interferon alfa|
79493229|NCT00004040|Biological|rituximab|
79493230|NCT00384254|Behavioral|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
79493231|NCT00384254|Behavioral|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
79493232|NCT05630911|Other|Standing tasks with different task difficulty|The three different standing positions will include wide-base standing on foam (WBF) with low-level of task difficulty, narrow-base standing on foam (NBF) with moderate-level of task difficulty, and tandem standing on foam (TAF) with high-level of task difficulty.
79493233|NCT00004046|Drug|exatecan mesylate|
79493234|NCT00003560|Drug|carboplatin|
79493235|NCT00003560|Drug|docetaxel|
79493236|NCT00002671|Drug|aminocamptothecin|
79493237|NCT00003290|Biological|gonadotrophin releasing hormone|
79493238|NCT00003290|Radiation|radiation therapy|
79493239|NCT00002677|Drug|chemotherapy|
79493240|NCT00002677|Drug|tributyrin|
79493241|NCT05749003|Other|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
79493242|NCT05749003|Other|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
79493243|NCT00003566|Procedure|videothoracoscopy|
79342443|NCT01901614|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
79814176|NCT00832156|Biological|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
79342444|NCT01901614|Drug|Retrobulbar Block or General Anesthesia|
79342445|NCT01901614|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
79342446|NCT01901614|Drug|Topical Anesthesia|
79342447|NCT01901614|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
79342448|NCT01901302|Drug|CB-5945|
79342449|NCT01901302|Drug|Placebo|
79493244|NCT05748925|Drug|dapagliflozin|The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.
79493245|NCT05748925|Drug|placebo|Control group: will be maintained on their medication
79493246|NCT00003572|Biological|peripheral blood lymphocyte therapy|
79493247|NCT00003572|Drug|mycophenolate mofetil|
79814177|NCT00837382|Behavioral|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
79814178|NCT00837382|Behavioral|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
79814179|NCT00837460|Other|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
79814180|NCT04043338|Drug|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
79814181|NCT04043338|Drug|Placebo|Placebo supplied as matching capsules or tablets
79814182|NCT00824668|Drug|biphasic insulin aspart 30|
79814183|NCT00824668|Drug|insulin glargine|
79370725|NCT03580317|Other|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
79493248|NCT00003572|Drug|tacrolimus|
79493249|NCT00003572|Procedure|allogeneic bone marrow transplantation|
79493250|NCT00003572|Radiation|radiation therapy|
79493251|NCT00004052|Biological|QS21|
79814184|NCT00824668|Drug|insulin glulisine|
79493252|NCT00004052|Biological|bcr-abl peptide vaccine|
79493253|NCT00004058|Drug|tetradecanoylphorbol acetate|
79493254|NCT00002689|Drug|dexamethasone|
79493255|NCT00002689|Drug|fluorouracil|
79493256|NCT00002689|Radiation|brachytherapy|
79493257|NCT00002689|Radiation|phosphorus P32|
79493258|NCT00002689|Radiation|radiation therapy|
79493259|NCT00003296|Biological|filgrastim|
79493260|NCT00003296|Drug|pegylated liposomal doxorubicin hydrochloride|
79493261|NCT00004064|Biological|oregovomab|
79493262|NCT00003302|Procedure|biopsy|
79493263|NCT00003302|Diagnostic Test|magnetic resonance imaging|
79493264|NCT00003302|Diagnostic Test|mammography|
79493265|NCT00382057|Drug|Testosterone|
79493266|NCT00382057|Drug|Anastrozole|
79493267|NCT00382057|Drug|Goserelin|
79493268|NCT00003578|Drug|CHOP regimen|
79657391|NCT02962154|Other|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
79342450|NCT04606420|Behavioral|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds & nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
79493269|NCT00003578|Drug|carmustine|
79493270|NCT00003578|Drug|cyclophosphamide|
79493271|NCT00003578|Drug|cytarabine|
79657392|NCT00282945|Drug|Rosiglitazone|
79493272|NCT00003578|Drug|doxorubicin hydrochloride|
79493273|NCT00003578|Drug|etoposide|
79493274|NCT00003578|Drug|melphalan|
79493275|NCT00003578|Drug|prednisone|
79493276|NCT00003578|Drug|vincristine sulfate|
79493277|NCT00003578|Procedure|autologous bone marrow transplantation|
79493278|NCT00003578|Procedure|peripheral blood stem cell transplantation|
79493279|NCT05617651|Drug|IY-NT-T|Ilaprazole 20mg
79493280|NCT05617651|Drug|IY-NT-R|Ilaprazole 10mg
79657393|NCT00282945|Drug|Metformin|
79657394|NCT00243620|Device|Vacuum therapy (device)|
79657395|NCT00273546|Drug|XRP6976 (Docetaxel/Taxotere)|
79657396|NCT00273585|Device|Personally-tailored educational software program|
79493281|NCT05615857|Device|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
79493282|NCT05748691|Diagnostic Test|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
79493283|NCT00003584|Drug|estramustine phosphate sodium|
79493284|NCT00003584|Drug|prednisone|
79985093|NCT04484038|Radiation|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
79814185|NCT00832234|Drug|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
79342451|NCT04415242|Other|positioning|different positioning prior surgery
79493285|NCT00003584|Drug|vinorelbine tartrate|
79493286|NCT00002701|Drug|busulfan|
79493287|NCT00002701|Drug|cyclophosphamide|
79814186|NCT05036980|Drug|Trans Sodium Crocetinate|Single IV bolus
79342452|NCT01919398|Drug|LY2940680|Administered orally
79342453|NCT04626154|Diagnostic Test|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
79342454|NCT02500043|Drug|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
79342455|NCT02500043|Drug|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
79342456|NCT02499575|Drug|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
79493288|NCT00002701|Drug|cytarabine|
79493289|NCT00002701|Drug|etoposide|
79493290|NCT00002701|Drug|idarubicin|
79985094|NCT02433730|Drug|Testosterone|intramuscular injection
79342457|NCT02499575|Drug|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
79657397|NCT00283023|Procedure|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
79814187|NCT00837772|Device|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
79985095|NCT02433730|Drug|placebo|intramuscular injection
79985096|NCT02438098|Drug|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
79342458|NCT02065791|Drug|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
79342459|NCT02065791|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily
79342460|NCT01654289|Other|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
79370726|NCT03580317|Other|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
79657398|NCT00283101|Drug|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
79657399|NCT00243698|Drug|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
79657400|NCT00273663|Device|TCES|
79657401|NCT00243737|Drug|Artesunate-Mefloquine|
79657402|NCT00273702|Drug|N-Acetyl Cysteine|
79657403|NCT00243815|Drug|ibuprofen|
79657404|NCT00283179|Drug|Aripiprazole|
79657405|NCT00283179|Drug|Risperidone|
79657406|NCT00243854|Drug|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
79985097|NCT02433262|Other|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
79814188|NCT00837772|Device|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
79814189|NCT00832312|Other|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
79493291|NCT00002701|Drug|mercaptopurine|
79493292|NCT00002701|Drug|methotrexate|
79493293|NCT00002701|Drug|mitoxantrone hydrochloride|
79493294|NCT00002701|Drug|thioguanine|
79493295|NCT00002701|Drug|tretinoin|
79493296|NCT00002701|Procedure|allogeneic bone marrow transplantation|
79493297|NCT00002701|Procedure|autologous bone marrow transplantation|
79814190|NCT00832312|Other|placebo (saline)|Injection of 1cc of saline into the knee joint
79814191|NCT02547532|Other|collection of sputum|
79814192|NCT00837850|Device|Bone cement 1|Bone cement SmartSet® HV
79814193|NCT00837850|Device|Bone cement 2|Bone cement Palacos R
79342461|NCT01654289|Other|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
79342462|NCT02499029|Drug|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
79985098|NCT02433262|Other|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
79657407|NCT00273741|Drug|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
79814194|NCT00784134|Drug|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
79342463|NCT02499029|Drug|Placebo|Identical looking placebo pills were administered each week.
79342464|NCT04968353|Device|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
79342465|NCT04968353|Device|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
79342466|NCT04968353|Device|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
79657408|NCT00273741|Drug|placebo comparator|placebo capsules
79814195|NCT00784134|Other|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
79985099|NCT02441530|Dietary Supplement|Vitamin D|
79985100|NCT02441530|Dietary Supplement|Vitamin E|
79985101|NCT02441530|Drug|Ibuprofen|
79985102|NCT02433184|Drug|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
79493298|NCT00002701|Radiation|radiation therapy|
79493299|NCT00004070|Biological|IL-12|
79342467|NCT04968353|Device|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
79342468|NCT02065713|Drug|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
79493300|NCT00003320|Procedure|surgical procedure|
79493301|NCT00003320|Radiation|radiation therapy|
79493302|NCT00003320|Radiation|stereotactic radiosurgery|
79493303|NCT00004076|Drug|mureletecan|
79493304|NCT00004082|Drug|carboplatin|
79493305|NCT00004082|Drug|docetaxel|
79493306|NCT00004082|Drug|gemcitabine hydrochloride|
79985103|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
79342469|NCT02065713|Drug|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
79342470|NCT02065713|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
79493307|NCT00002707|Drug|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
79814196|NCT00832468|Other|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
79985104|NCT02433184|Drug|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
79985105|NCT02433184|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
79342471|NCT04701489|Device|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
79342472|NCT02497781|Drug|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
79342473|NCT02497781|Drug|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
79342474|NCT02497469|Drug|Vedolizumab|Vedolizumab infusion
79342475|NCT02497469|Drug|Adalimumab placebo|Adalimumab placebo-matching injection
79342476|NCT02497469|Drug|Adalimumab|Adalimumab injection
79342477|NCT02497469|Drug|Vedolizumab placebo|Vedolizumab placebo-matching infusion
79342478|NCT02497391|Drug|Evacetrapib|administered orally
79493308|NCT00002707|Drug|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
79493309|NCT00002707|Drug|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
79493310|NCT00002707|Drug|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
79493311|NCT00003596|Drug|cisplatin|
79493312|NCT00003596|Drug|fluorouracil|
79493313|NCT00003596|Drug|mitomycin C|
79493314|NCT00003596|Radiation|radiation therapy|
79493315|NCT05608993|Other|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
79493316|NCT05608993|Other|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
79493317|NCT05747365|Diagnostic Test|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
79493318|NCT00002719|Biological|filgrastim|
79493319|NCT00002719|Drug|amsacrine|
79493320|NCT00002719|Drug|carmustine|
79493321|NCT00002719|Drug|cytarabine|
79493322|NCT00002719|Drug|etoposide|
79493323|NCT00002719|Drug|idarubicin|
79493324|NCT00002719|Drug|mitoxantrone hydrochloride|
79493325|NCT00002719|Procedure|peripheral blood stem cell transplantation|
79493326|NCT00003326|Drug|paclitaxel|
79493327|NCT00002725|Drug|bryostatin 1|
79493328|NCT00002725|Drug|chemotherapy|
79493329|NCT00003602|Drug|cytarabine|
79493330|NCT00003602|Drug|etoposide|
79493331|NCT00003602|Drug|idarubicin|
79493332|NCT00003602|Drug|mitoxantrone hydrochloride|
79985106|NCT02433184|Drug|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
79985107|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
79985108|NCT02433106|Other|GAA 15|Neuromuscular injury prevention training
79985109|NCT02433106|Other|Control|Usual training
79985110|NCT02438020|Drug|Metformin|One tablet of 500 mg will be ingested before the main meal
79985111|NCT02438020|Other|Placebo|A placebo tablet will be ingested daily before main meal.
79985112|NCT02437942|Other|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
79342479|NCT02476175|Drug|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
79985113|NCT02441452|Other|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
79985114|NCT02441140|Procedure|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
79985115|NCT02441140|Procedure|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
79985116|NCT02441140|Procedure|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
79342480|NCT02065557|Biological|Adalimumab|Subcutaneous (SC) injection
79342481|NCT02065557|Biological|Placebo|Subcutaneous (SC) injection
79342482|NCT02065245|Biological|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
79985117|NCT02441140|Procedure|Blood collection|Intravenous blood collection will be drawn from an IV
79342483|NCT02065245|Biological|Placebo|Placebo administered by peripheral intravenous infusion.
79493333|NCT04609423|Dietary Supplement|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
79493334|NCT04609423|Dietary Supplement|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
79493335|NCT00003332|Drug|cisplatin|
79493336|NCT00003332|Drug|gemcitabine hydrochloride|
79493337|NCT00003332|Procedure|surgical procedure|
79814197|NCT00832468|Other|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
79342484|NCT02065245|Biological|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
79342485|NCT02043015|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
79342486|NCT02043015|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
79342487|NCT02043015|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
79342488|NCT02043015|Drug|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
79342489|NCT02043015|Other|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
79493338|NCT00003332|Radiation|radiation therapy|
79493339|NCT00004094|Drug|carboplatin|
79493340|NCT00004094|Drug|fluorouracil|
79493341|NCT00004094|Drug|hydroxyurea|
79493342|NCT00004094|Drug|paclitaxel|
79493343|NCT00004094|Procedure|conventional surgery|
79493344|NCT00004094|Radiation|radiation therapy|
79493345|NCT05745571|Other|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
79493346|NCT05592769|Device|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~The HealthBeacon Smart Sharps Bin~The HealthBeacon Companion App~HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
79493347|NCT00004100|Drug|cisplatin|
79493348|NCT00004100|Drug|gemcitabine hydrochloride|
79493349|NCT00004100|Drug|vinorelbine tartrate|
79814198|NCT00832546|Drug|Placebo|
79814199|NCT00832546|Drug|Oral NGX426 (Powder in solution)|
79493350|NCT00002737|Biological|recombinant interferon alfa|
79493351|NCT00002737|Drug|chemotherapy|
79493352|NCT00002737|Drug|isotretinoin|
79342490|NCT02043015|Behavioral|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
79493353|NCT00003338|Procedure|immunoscintigraphy|
79342491|NCT02043015|Behavioral|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
79342492|NCT02064231|Device|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
79493354|NCT00003338|Radiation|technetium Tc 99m epratuzumab|
79493355|NCT05744947|Other|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
79985118|NCT02441140|Procedure|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
79985119|NCT02437786|Drug|GRAZAX|GRAZAX
79985120|NCT02437552|Device|ergometer cycle exercise|
79342493|NCT02064231|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
79342494|NCT02064231|Device|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
79342495|NCT02064231|Device|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
79342496|NCT02064231|Device|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
79342497|NCT02063217|Drug|Sodium Oxybate|Sodium oxybate h.s.
79342498|NCT02063217|Behavioral|Sleep deprivation|36hr sleep deprivation
79657409|NCT02279134|Radiation|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
79657410|NCT02279134|Radiation|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
79657411|NCT02279134|Drug|Paclitaxel|135-150mg/m2 (D1 and D29)
79657412|NCT02279134|Drug|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
79985121|NCT02437552|Other|routine physiotherapy|routine physiotherapy
79342499|NCT02497001|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])
79342500|NCT02497001|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
79342501|NCT02497001|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
79342502|NCT02497001|Drug|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
79493356|NCT00003620|Drug|alvocidib|Given IV
79493357|NCT00003620|Other|laboratory biomarker analysis|Correlative studies
79493358|NCT00003344|Drug|irinotecan hydrochloride|
79493359|NCT00003344|Radiation|radiation therapy|
79493360|NCT00003626|Drug|dolastatin 10|
79493361|NCT00003632|Biological|filgrastim|
79985122|NCT02441296|Other|Formula with lactose|
79985123|NCT02441296|Other|Formula with maltodextrins|
79985124|NCT03189628|Biological|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
79985125|NCT03189628|Drug|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
79493362|NCT00003632|Drug|carmustine|
79493363|NCT00003632|Drug|cytarabine|
79493364|NCT00003632|Drug|etoposide|
79493365|NCT00003632|Drug|melphalan|
79493366|NCT00003632|Drug|methotrexate|
79493367|NCT00003632|Procedure|peripheral blood stem cell transplantation|
79493368|NCT05743465|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
79493369|NCT00003350|Drug|paclitaxel|Given IV
79493370|NCT00003350|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
79493371|NCT00003350|Other|laboratory biomarker analysis|Correlative studies
79493372|NCT00003350|Procedure|quality-of-life assessment|Ancillary studies
79493373|NCT00003356|Biological|aldesleukin|
79493374|NCT00003356|Biological|rituximab|
79493375|NCT00004136|Procedure|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
79493376|NCT00003638|Biological|Detox-B adjuvant|
79493377|NCT00003638|Biological|THERATOPE STn-KLH vaccine|
79657413|NCT00243893|Drug|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
79657414|NCT00243893|Drug|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
79657415|NCT00243971|Drug|SPM 962|
79657416|NCT00283218|Drug|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
79657417|NCT00244049|Behavioral|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
79985126|NCT03186820|Other|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
79342503|NCT04182555|Device|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
79493378|NCT00003638|Biological|keyhole limpet hemocyanin|
79985127|NCT02441374|Device|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
79342504|NCT04182555|Diagnostic Test|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
79493379|NCT00003638|Drug|cyclophosphamide|
79493380|NCT00004142|Drug|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
79657418|NCT00244049|Other|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
79985128|NCT02441374|Other|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
79342505|NCT04182555|Device|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
79985129|NCT03186274|Behavioral|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
79985130|NCT03186274|Behavioral|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
79342506|NCT04182555|Other|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
79342507|NCT04733079|Other|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
79342508|NCT04733079|Other|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
79342509|NCT02366143|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
79342510|NCT02366143|Drug|Bevacizumab|Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
79342511|NCT02366143|Drug|Carboplatin|Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
79342512|NCT02366143|Drug|Paclitaxel|Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
79342513|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
79342514|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
79342515|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
79342516|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
79342517|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
79493381|NCT00004142|Drug|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
79342518|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
79657419|NCT00273780|Behavioral|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
79657420|NCT00273780|Device|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
79657421|NCT00244127|Drug|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
79342519|NCT02041923|Behavioral|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
79493382|NCT00004142|Procedure|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
79493383|NCT00004142|Procedure|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
79493384|NCT00002749|Drug|carboplatin|
79657422|NCT00273819|Procedure|CT angiography|
79657423|NCT00414557|Procedure|Quadriceps strengthening|
79657424|NCT00273897|Device|Phoresor II|
79657425|NCT00244166|Drug|prednisolone|
79657426|NCT00273936|Drug|AVN-944 capsules for oral administration|
79657427|NCT00244205|Procedure|Identifying genes methylated in urine|
79985131|NCT02437474|Behavioral|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
79342520|NCT02041923|Other|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
79657428|NCT00283257|Behavioral|Patients and caregivers are taught problem solving skills|
79657429|NCT00244244|Drug|arimoclomol|
79814200|NCT00837928|Drug|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
79985132|NCT02437474|Behavioral|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
79342521|NCT02365519|Biological|LME636 ophthalmic solution|
79342522|NCT02365519|Biological|LME636 Vehicle|Inactive ingredients used as a placebo comparator
79342523|NCT04700163|Biological|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
79657430|NCT00273975|Drug|Nevirapine|
79657431|NCT00273975|Drug|Lamivudine|
79657432|NCT00273975|Drug|Zidovudine|
79657433|NCT00244283|Drug|Sevoflurane|
79657434|NCT00244283|Procedure|High thoracic epidural analgesia|
79657435|NCT00283335|Drug|gemfibrozil|
79657436|NCT00283335|Other|Placebo|Matching placebo tablets taken once per day
79814201|NCT00837928|Other|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
79342524|NCT02061813|Drug|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
79342525|NCT02061813|Drug|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
79342526|NCT02061813|Drug|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
79342527|NCT02061813|Drug|Placebo|
79493385|NCT00003362|Biological|QS21|
79493386|NCT00003362|Biological|gp100 antigen|
79657437|NCT00244322|Drug|LY450139 dihydrate|
79657438|NCT00244322|Drug|placebo|
79657439|NCT00283374|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
79657440|NCT00244361|Drug|rituximab|
79657441|NCT00274014|Drug|Tiotropium|
79657442|NCT00244439|Drug|MALG|30 minute application
79657443|NCT00244439|Drug|Ovide (malathion) lotion 0.05%|8-12 hour application
79657444|NCT00244439|Drug|Permethrin 1%|10 minute application
79657445|NCT00417144|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
79657446|NCT00417144|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
79657447|NCT00244478|Dietary Supplement|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
79657448|NCT00244478|Dietary Supplement|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
79657449|NCT00274053|Drug|tiotropium|
79814202|NCT00837928|Procedure|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
79985133|NCT02437474|Behavioral|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
79985134|NCT02437708|Procedure|REP with L-PRF|
79985135|NCT02437708|Procedure|REP|
79985136|NCT02437708|Biological|stem and progenitor cells|
79493387|NCT00003362|Biological|incomplete Freund's adjuvant|
79493388|NCT00003362|Biological|sargramostim|
79493389|NCT00003362|Biological|tyrosinase peptide|
79657450|NCT04709588|Dietary Supplement|placebo group|subjects drank 50 ml every night for 14, 28 days
79985137|NCT03186430|Behavioral|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
79985138|NCT02440984|Procedure|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
79342528|NCT02096835|Device|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
79342529|NCT02096835|Device|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
79657451|NCT04709588|Dietary Supplement|collagen drinkss|subjects drank 50 ml every night for 14, 28 days
79342530|NCT02096835|Drug|Tropisetron|will be given at the start of skin closure
79342531|NCT02096835|Drug|Dexamethasone|will be given after induction
79342532|NCT02294773|Procedure|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
79342533|NCT02294773|Drug|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
79493390|NCT00004148|Biological|recombinant vaccinia-B7.1 vaccine|
79493391|NCT00003650|Drug|asparaginase|
79493392|NCT00003650|Drug|cyclophosphamide|
79493393|NCT00003650|Drug|cytarabine|
79493394|NCT00003650|Drug|daunorubicin hydrochloride|
79657452|NCT00417183|Drug|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
79493395|NCT00003650|Drug|dexamethasone|
79493396|NCT00003650|Drug|etoposide|
79493397|NCT00003650|Drug|mercaptopurine|
79493398|NCT00003650|Drug|methotrexate|
79493399|NCT00003650|Drug|methylprednisolone|
79493400|NCT00003650|Drug|mitoxantrone hydrochloride|
79493401|NCT00003650|Drug|prednisone|
79493402|NCT00003650|Drug|vincristine sulfate|
79493403|NCT00003650|Radiation|radiation therapy|
79493404|NCT00002755|Biological|filgrastim|
79493405|NCT00002755|Drug|CMF regimen|
79493406|NCT00002755|Drug|cyclophosphamide|
79493407|NCT00002755|Drug|doxorubicin hydrochloride|
79493408|NCT00002755|Drug|fluorouracil|
79493409|NCT00002755|Drug|methotrexate|
79493410|NCT00002755|Drug|tamoxifen citrate|
79493411|NCT00002755|Drug|thiotepa|
79493412|NCT00002755|Procedure|autologous bone marrow transplantation|
79493413|NCT00002755|Procedure|peripheral blood stem cell transplantation|
79493414|NCT00002755|Radiation|low-LET cobalt-60 gamma ray therapy|
79493415|NCT00002755|Radiation|low-LET electron therapy|
79493416|NCT00002755|Radiation|low-LET photon therapy|
79657453|NCT00417183|Drug|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
79657454|NCT00244517|Drug|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
79985139|NCT02432794|Procedure|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
79985140|NCT02440906|Behavioral|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
79342534|NCT02294773|Drug|Letrozole|Patient is to take letrozole during cycle days 3-7.
79985141|NCT02440906|Behavioral|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
79342535|NCT02365285|Drug|Galantamine|16 mg po prior to the infusion of intralipid
79342536|NCT02365285|Drug|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
79342537|NCT02365285|Drug|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
79342538|NCT02365285|Drug|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
79342539|NCT02041299|Drug|Deferiprone|
79493417|NCT04207424|Procedure|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
79493418|NCT00002761|Biological|filgrastim|
79493419|NCT00002761|Biological|recombinant interferon gamma|
79657455|NCT00244517|Drug|Sevoflurane, Isoflurane, Desflurane|1 MAC
79657456|NCT00274092|Drug|tiotropium inhalation capsules (18 mcg once daily)|
79657457|NCT00274092|Drug|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
79302586|NCT03201133|Diagnostic Test|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
79342540|NCT02041299|Drug|Deferoxamine|
79342541|NCT01645735|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
79342542|NCT01645735|Drug|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
79342543|NCT02365207|Drug|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
79342544|NCT01645111|Drug|Clevidipine|
79493420|NCT00002761|Drug|busulfan|
79493421|NCT00002761|Drug|cyclophosphamide|
79493422|NCT00002761|Drug|cyclosporine|
79342545|NCT02364037|Behavioral|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
79342546|NCT02364037|Behavioral|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
79493423|NCT00002761|Drug|cytarabine|
79493424|NCT00002761|Drug|idarubicin|
79493425|NCT00002761|Procedure|peripheral blood stem cell transplantation|
79493426|NCT04191122|Other|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
79493427|NCT00382135|Drug|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
79493428|NCT00382135|Drug|placebo|Placebo tablet taken by mouth once a day for 40 weeks
79493429|NCT00003662|Biological|anti-thymocyte globulin|
79493430|NCT00003662|Drug|busulfan|
79493431|NCT00003662|Drug|cyclophosphamide|
79493432|NCT00003662|Drug|cyclosporine|
79657458|NCT00244556|Drug|Methotrexate plus ENBREL or ENBREL alone|
79657459|NCT00283413|Device|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
79657460|NCT00283413|Device|Bare metal stent|Any commercially available bare metal stent for coronary indication
79657461|NCT00244595|Drug|candsartan cilexetil|
79657462|NCT00274131|Drug|Pramipexole 0.125 mg tablets|
79657463|NCT00274131|Drug|Pramipexole 0.5 mg tablets|
79657464|NCT00244634|Drug|candsartan cilexetil|
79657465|NCT00274170|Drug|Octreotide|
79657466|NCT00244673|Biological|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
79342547|NCT02364037|Device|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
79342548|NCT01919164|Drug|Sprifermin|Participants received Sprifermin as intra-articular injection.
79342549|NCT01919164|Drug|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
79342550|NCT01901224|Drug|Metformin 1000 mg|
79342551|NCT01901224|Drug|Placebo|
79342552|NCT05109676|Other|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
79657467|NCT00244790|Behavioral|Diet|crossover low vs high protein diet before and after weight loss
79342553|NCT01901146|Drug|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
79342554|NCT01901146|Drug|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
79342555|NCT01901146|Drug|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
79657468|NCT00283452|Behavioral|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
79342556|NCT01901146|Procedure|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
79657469|NCT02961530|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
79342557|NCT01644643|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
79342558|NCT01644643|Drug|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
79493433|NCT00003662|Drug|melphalan|
79493434|NCT00003662|Drug|methylprednisolone|
79657470|NCT02961530|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
79985142|NCT02437630|Procedure|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
79985143|NCT02437630|Procedure|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
79657471|NCT00283491|Behavioral|Active Lactobacillus plantarum 299v|10^11 cfu/meal in 2 meals on 2 consecutive days
79342559|NCT01644643|Drug|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
79342560|NCT01864564|Other|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
79302587|NCT02480075|Other|Observational|Observational Study only
79342561|NCT01864174|Drug|Metformin XR|
79342562|NCT01864174|Drug|Metformin IR|
79342563|NCT01864174|Drug|Placebo matching with Metformin XR|
79342564|NCT01864174|Drug|Placebo matching with Metformin IR|
79342565|NCT01900444|Biological|IMOJEV|0.5 mL, Subcutaneous
79342566|NCT02294227|Biological|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
79342567|NCT02294227|Other|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
79342568|NCT02496767|Drug|Tirasemtiv|
79342569|NCT02496767|Drug|Placebo tablets|
79342570|NCT02496533|Procedure|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
79493435|NCT00003662|Procedure|umbilical cord blood transplantation|
79493436|NCT00003662|Radiation|radiation therapy|
79302588|NCT03201055|Device|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
79342571|NCT02496221|Drug|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
79342572|NCT02496221|Drug|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
79342573|NCT02496221|Drug|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
79342574|NCT02475629|Biological|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
79342575|NCT02475629|Drug|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
79342576|NCT02475395|Device|TRAK device|Use of TRAK to attain sperm concentration measurement
79342577|NCT01653743|Drug|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
79342578|NCT01653743|Drug|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
79493437|NCT00004154|Drug|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
79493438|NCT00004154|Other|Placebo|Two placebo capsules for 25 days of 28 day cycle.
79493439|NCT00002767|Biological|Detox-B adjuvant|
79493440|NCT00002767|Biological|recombinant interferon alfa|
79493441|NCT04133324|Diagnostic Test|C-reactive protein|C-reactive protein at postoperative days four and two.
79493442|NCT00002773|Biological|allogeneic tumor cell vaccine|
79493443|NCT00002773|Biological|recombinant interferon alfa|
79493444|NCT00002773|Biological|sargramostim|
79493445|NCT00002773|Drug|cyclophosphamide|
79493446|NCT00004160|Drug|cisplatin|
79493447|NCT00004160|Drug|gemcitabine hydrochloride|
79493448|NCT00004160|Drug|paclitaxel|
79493449|NCT00004160|Radiation|radiation therapy|
79493450|NCT05562115|Other|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
79493451|NCT00003368|Drug|irinotecan hydrochloride|
79493452|NCT05562037|Other|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
79493453|NCT05509543|Drug|IY-NT-T|Ilaprazole 20mg
79493454|NCT05509543|Drug|IY-NT-R|Ilaprazole 10mg
79493455|NCT00003674|Drug|dalteparin|
79342579|NCT01653743|Drug|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
79342580|NCT02293993|Drug|SGI-110|
79342581|NCT02322775|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
79493456|NCT00003674|Drug|standard therapy|
79493457|NCT05561101|Other|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
79493458|NCT00003380|Drug|etoposide|
79342582|NCT02322775|Biological|Placebo|Placebo administered subcutaneously every 4 weeks
79342583|NCT04888273|Behavioral|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
79342584|NCT02322229|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
79342585|NCT02362789|Biological|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
79493459|NCT00003380|Drug|pegylated liposomal doxorubicin hydrochloride|
79493460|NCT00002779|Drug|fludarabine phosphate|
79493461|NCT00002779|Drug|octreotide acetate|
79493462|NCT00003680|Drug|CMF regimen|
79493463|NCT00003680|Drug|cyclophosphamide|
79493464|NCT00003680|Drug|fluorouracil|
79493465|NCT00003680|Drug|methotrexate|
79493466|NCT00003680|Drug|tamoxifen citrate|
79493467|NCT00003680|Drug|thiotepa|
79493468|NCT00003680|Procedure|peripheral blood stem cell transplantation|
79493469|NCT00003680|Radiation|radiation therapy|
79493470|NCT00002785|Biological|filgrastim|
79493471|NCT00002785|Drug|asparaginase|
79493472|NCT00002785|Drug|cyclophosphamide|
79493473|NCT00002785|Drug|cyclosporine|
79657472|NCT00283491|Dietary Supplement|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
79657473|NCT00244829|Drug|imatinib mesylate|
79493474|NCT00002785|Drug|cytarabine|
79493475|NCT00002785|Drug|daunorubicin hydrochloride|
79493476|NCT00002785|Drug|dexamethasone|
79493477|NCT00002785|Drug|etoposide|
79493478|NCT00002785|Drug|leucovorin calcium|
79493479|NCT00002785|Drug|mercaptopurine|
79493480|NCT00002785|Drug|mesna|
79493481|NCT00002785|Drug|methotrexate|
79493482|NCT00002785|Drug|methylprednisolone|
79493483|NCT00002785|Drug|pegaspargase|
79493484|NCT00002785|Drug|prednisone|
79493485|NCT00002785|Drug|therapeutic hydrocortisone|
79493486|NCT00002785|Drug|vincristine sulfate|
79493487|NCT00002785|Procedure|allogeneic bone marrow transplantation|
79493488|NCT00002785|Radiation|low-LET cobalt-60 gamma ray therapy|
79493489|NCT00002785|Radiation|low-LET photon therapy|
79493490|NCT00004178|Biological|therapeutic autologous lymphocytes|
79493491|NCT00004184|Biological|monoclonal antibody 4B5 anti-idiotype vaccine|
79493492|NCT00004184|Biological|sargramostim|
79493493|NCT00004184|Drug|alum adjuvant|
79493494|NCT00003386|Biological|BCG vaccine|
79493495|NCT00003386|Biological|autologous tumor cell vaccine|
79493496|NCT00003386|Drug|carboplatin|
79493497|NCT00003386|Drug|cisplatin|
79493498|NCT00003386|Drug|cyclophosphamide|
79493499|NCT00003386|Drug|paclitaxel|
79493500|NCT00003386|Other|dinitrophenyl|
79493501|NCT00003386|Procedure|surgical procedure|
79493502|NCT00384566|Drug|Carvedilol|anit hypertensive medication
79493503|NCT00384566|Drug|Metoprolol|Anti hypertensive medication
79493504|NCT00004832|Drug|3,4-diaminopyridine|
79493505|NCT00384644|Device|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
79493506|NCT00002791|Biological|filgrastim|
79493507|NCT00002791|Drug|dacarbazine|
79493508|NCT00002791|Drug|doxorubicin hydrochloride|
79493509|NCT00002791|Drug|ifosfamide|
79493510|NCT00002791|Drug|mesna|
79493511|NCT00002791|Procedure|conventional surgery|
79493512|NCT00002791|Radiation|brachytherapy|
79493513|NCT00002791|Radiation|intraoperative radiation therapy|
79657474|NCT00244829|Procedure|adjuvant therapy|
79657475|NCT00283530|Procedure|Tumor biopsy|
79342586|NCT02362789|Biological|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
79342587|NCT01646827|Drug|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
79493514|NCT00002791|Radiation|radioisotope therapy|
79493515|NCT00384722|Device|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
79493516|NCT00004190|Drug|gemcitabine hydrochloride|
79493517|NCT00004190|Drug|oxaliplatin|
79493518|NCT00004196|Biological|recombinant interferon alfa|
79493519|NCT00004196|Procedure|lymphangiography|
79493520|NCT00004196|Drug|Observation|
79493521|NCT00385034|Device|Interactive computer based health-risk survey before doctor's visit|
79342588|NCT02293837|Drug|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
79342589|NCT02293837|Drug|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
79493522|NCT00004838|Drug|succimer|
79342590|NCT02293837|Other|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
79342591|NCT02361307|Procedure|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
79342592|NCT02361307|Procedure|Conventional ADL training|The control group receive the conventional ADL training programme
79342593|NCT02320903|Device|VillageWhere App|
79342594|NCT02320123|Behavioral|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
79493523|NCT00381979|Other|Supportive Expressive Therapy|
79493524|NCT00004844|Procedure|tissue implantation|
79493525|NCT05500807|Drug|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
79493526|NCT00004202|Drug|carboplatin|
79493527|NCT00004202|Drug|chemotherapy|
79493528|NCT00004202|Drug|efaproxiral|
79493529|NCT00004202|Drug|paclitaxel|
79493530|NCT00004202|Radiation|radiation therapy|
79493531|NCT00003686|Drug|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
79493532|NCT00003686|Drug|Placebo|Placebo 5 mg po qid x 4 weeks
79493533|NCT05495035|Drug|Olverembatinib, APG-2575, Dexamethasone|"Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~2) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~3) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
79493534|NCT00004856|Biological|trastuzumab|Given IV
79493535|NCT04438057|Biological|CCP|Randomized open label study to receive 2:1 CCP to standard of care
79493536|NCT00003698|Drug|fosbretabulin disodium|
79493537|NCT04600375|Behavioral|Verbal consultation|Verbal consultation only without written information before receiving written action plan
79493538|NCT04600375|Behavioral|Written Action Plan|Written handout of treatment plan and disease management strategies
79493539|NCT00004208|Drug|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
79493540|NCT00004208|Behavioral|Supportive care|Patients randomized to this arm will be treated as outpatients.
79493541|NCT00004862|Biological|filgrastim|
79493542|NCT00004862|Biological|oblimersen sodium|
79493543|NCT00004862|Drug|cytarabine|
79493544|NCT00004862|Drug|fludarabine phosphate|
79493545|NCT05533333|Behavioral|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
79493546|NCT00004220|Drug|gemcitabine hydrochloride|
79493547|NCT00004220|Drug|oxaliplatin|
79493548|NCT05492071|Device|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
79493549|NCT05492071|Other|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
79493550|NCT00003704|Drug|capecitabine|
79493551|NCT00003704|Radiation|radiation therapy|
79493552|NCT00004868|Drug|semaxanib|
79493553|NCT00003710|Drug|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
79342595|NCT02360995|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
79814203|NCT00837928|Radiation|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
79814204|NCT02550184|Other|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
79985144|NCT02437630|Other|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
79985145|NCT02437630|Procedure|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
79342596|NCT02360995|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
79342597|NCT02360995|Drug|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
79342598|NCT02360995|Drug|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
79493554|NCT00003710|Drug|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
79493555|NCT05232097|Behavioral|Behavioral therapy|Diaphragmatic breathing exercises
79493556|NCT05232097|Behavioral|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
79493557|NCT00004226|Radiation|radiation therapy|
79493558|NCT05485675|Behavioral|Stand & Move at Work|Web-based platform only.
79814205|NCT03996174|Other|Interview|Interview bases on the use of an interview guide, during one hour maximum
79493559|NCT05485675|Behavioral|Stand & Move at Work+|Web-based platform and support from an expert facilitator
79342599|NCT02360995|Drug|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
79342600|NCT04197037|Procedure|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
79493560|NCT00004232|Biological|filgrastim|
79493561|NCT00004232|Drug|cyclosporine|
79493562|NCT00004232|Drug|methylprednisolone|
79493563|NCT00004232|Drug|prednisone|
79493564|NCT00004232|Procedure|allogeneic bone marrow transplantation|
79493565|NCT00004232|Procedure|peripheral blood stem cell transplantation|
79493566|NCT00004238|Drug|pralatrexate|
79493567|NCT00004874|Radiation|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
79814206|NCT04106622|Procedure|electrophysiological study|"To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF."
79493568|NCT05230927|Other|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
79493569|NCT00004244|Biological|recombinant interferon alfa|
79493570|NCT00004244|Biological|recombinant interleukin-12|
79493571|NCT00004880|Biological|dendritic cell vaccine therapy|
79493572|NCT00004880|Procedure|conventional surgery|
79493573|NCT00004250|Biological|dactinomycin|
79493574|NCT00004250|Drug|isolated limb perfusion|
79493575|NCT00004250|Drug|melphalan|
79493576|NCT00003728|Drug|asparaginase|
79342601|NCT02360605|Behavioral|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
79342602|NCT02360605|Behavioral|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
79493577|NCT00003728|Drug|cyclophosphamide|
79493578|NCT00003728|Drug|cytarabine|
79493579|NCT00003728|Drug|daunorubicin hydrochloride|
79493580|NCT00003728|Drug|dexamethasone|
79493581|NCT00003728|Drug|doxorubicin hydrochloride|
79493582|NCT00003728|Drug|etoposide|
79493583|NCT00003728|Drug|leucovorin calcium|
79493584|NCT00003728|Drug|mercaptopurine|
79493585|NCT00003728|Drug|methotrexate|
79657476|NCT00244868|Other|counseling intervention|
79657477|NCT00244868|Other|educational intervention|
79657478|NCT00274209|Procedure|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
79657479|NCT00244907|Dietary Supplement|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
79493586|NCT00003728|Drug|methylprednisolone|
79493587|NCT00003728|Drug|mitoxantrone hydrochloride|
79493588|NCT00003728|Drug|prednisolone|
79493589|NCT00003728|Drug|therapeutic hydrocortisone|
79493590|NCT00003728|Drug|thioguanine|
79493591|NCT00003728|Drug|vincristine sulfate|
79493592|NCT00003728|Drug|vindesine|
79493593|NCT00003728|Procedure|allogeneic bone marrow transplantation|
79493594|NCT00003728|Procedure|peripheral blood stem cell transplantation|
79493595|NCT00004886|Drug|docetaxel|
79493596|NCT00004886|Drug|dofequidar fumarate|
79493597|NCT00382759|Procedure|stem cell transplant|
79493598|NCT00003734|Drug|flutamide|
79493599|NCT00003734|Drug|triptorelin|
79493600|NCT00003734|Radiation|radiation therapy|
79493601|NCT04812847|Diagnostic Test|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
79493602|NCT00003740|Biological|trastuzumab|
79493603|NCT00004256|Biological|sargramostim|
79493604|NCT00004256|Procedure|quality-of-life assessment|
79493605|NCT00004256|Radiation|radiation therapy|
79493606|NCT00382525|Device|Cardiac Rhythm Management device|
79493607|NCT00004262|Procedure|conventional surgery|
79493608|NCT00004262|Radiation|3-dimensional conformal radiation therapy|
79493609|NCT00004262|Radiation|stereotactic radiosurgery|
79493610|NCT00004262|Drug|motexafin gadolinium|Given IV
79493611|NCT00004262|Procedure|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
79493612|NCT00004262|Procedure|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
79493613|NCT05471791|Device|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
79493614|NCT00004892|Drug|O6-benzylguanine|
79657480|NCT00283569|Other|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
79657481|NCT00274248|Drug|MLN518|
79657482|NCT00244946|Biological|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
79657483|NCT00244946|Drug|carmustine|
79657484|NCT00244946|Drug|cytarabine|
79657485|NCT00244946|Drug|etoposide|
79657486|NCT00244946|Drug|melphalan|
79657487|NCT00244946|Procedure|peripheral blood stem cell transplantation (PBSCT)|
79657488|NCT00283608|Genetic|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
79493615|NCT00004892|Drug|polifeprosan 20 with carmustine implant|
79342603|NCT02360605|Behavioral|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
79657489|NCT00283608|Other|high performance liquid chromatography|analysis of plasma concentrations of drugs
79657490|NCT00283608|Other|measurements by DXA|determine bone mineral density (BMD)
79657491|NCT00283608|Other|questionnaire administration|determine attitude changes
79657492|NCT00245024|Drug|sulindac|
79985146|NCT02437630|Procedure|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
79985147|NCT02437630|Other|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
79985148|NCT02440750|Procedure|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
79342604|NCT02360293|Behavioral|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
79493616|NCT00004892|Procedure|conventional surgery|
79493617|NCT00004268|Drug|midodrine|
79493618|NCT00004274|Drug|Estrogen|
79493619|NCT00004904|Biological|anti-thymocyte globulin|
79493620|NCT00004904|Biological|filgrastim|
79493621|NCT00004904|Drug|cladribine|
79657493|NCT00245024|Other|laboratory biomarker analysis|
79657494|NCT00274326|Drug|SR121463B|
79657495|NCT00245141|Biological|dactinomycin|
79493622|NCT00004904|Drug|cyclophosphamide|
79493623|NCT00004904|Drug|etoposide|
79493624|NCT00004904|Drug|methylprednisolone|
79493625|NCT00004904|Drug|tacrolimus|
79493626|NCT00004904|Procedure|allogeneic bone marrow transplantation|
79493627|NCT00004904|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79493628|NCT00004286|Drug|immune globulin|
79657496|NCT00245141|Drug|cyclophosphamide|
79657497|NCT00245141|Drug|vincristine sulfate|
79657498|NCT00245141|Radiation|radiation therapy|
79657499|NCT00245180|Behavioral|Diet|
79657500|NCT00245180|Behavioral|Exercise|
79657501|NCT00416637|Biological|Bevacizumab (Avastin)|
79657502|NCT00245258|Drug|Sildenafil Citrate|
79657503|NCT00283725|Other|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
79657504|NCT02961803|Drug|MD1003 100 mg capsule|
79657505|NCT02961803|Drug|Placebo|
79657506|NCT00274365|Procedure|videoconference|
79657507|NCT00245297|Drug|Kogenate FS, reconstituted in a suspension of liposomes|
79657508|NCT00274404|Drug|valacyclovir|
79657509|NCT00283764|Drug|Xalatan|
79342605|NCT02360293|Behavioral|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
79342606|NCT02359903|Drug|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
79342607|NCT02359903|Drug|Infliximab (Remicade)|
79493629|NCT00003746|Drug|2-chlorodeoxyadenosine (CDA) daily|Daily administration
79985149|NCT02440750|Drug|Dienogest|21 days administration of dienogest 2 mg/die
79493630|NCT00003746|Drug|2-chlorodeoxyadenosine weekly|Weekly administration
79493631|NCT00003752|Drug|bexarotene|
79493632|NCT02973152|Procedure|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
79985150|NCT02440750|Drug|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
79342608|NCT02291419|Drug|ticagrelor|ticagrelor 90 mg bid
79342609|NCT02291419|Drug|aspirin|aspirin 81 mg daily
79342610|NCT02319031|Drug|Daclatasvir|
79342611|NCT02319031|Drug|Sofosbuvir|
79342612|NCT02319031|Drug|Ribavirin|
79342613|NCT02318797|Behavioral|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
79342614|NCT02318797|Behavioral|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
79342615|NCT02359435|Drug|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
79342616|NCT02359435|Drug|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
79342617|NCT02318719|Drug|Placebo|Placebo
79342618|NCT02318719|Drug|DS-5565|
79342619|NCT01870726|Drug|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
79342620|NCT01870726|Drug|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
79493633|NCT02973152|Procedure|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
79493634|NCT04092842|Device|Silicone prosthesis|Silicone prosthesis
79493635|NCT04092842|Procedure|Usual practice|Usual surgery
79493636|NCT00003758|Drug|cytarabine|
79493637|NCT00003758|Drug|idarubicin|
79493638|NCT00003758|Procedure|allogeneic bone marrow transplantation|
79493639|NCT00003758|Procedure|autologous bone marrow transplantation|
79493640|NCT00003758|Procedure|peripheral blood stem cell transplantation|
79493641|NCT00004310|Drug|Clomipramine|
79493642|NCT00004922|Drug|irinotecan hydrochloride|
79493643|NCT00004316|Drug|capsaicin|
79493644|NCT04712786|Other|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
79493645|NCT00004928|Dietary Supplement|calcitriol|
79493646|NCT00004928|Drug|zoledronic acid|
79493647|NCT00004328|Drug|enalapril|
79985151|NCT03186196|Dietary Supplement|Diet containing Folate|
79493648|NCT00004328|Drug|polystyrene sulfonate|
79814207|NCT04102566|Drug|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
79814208|NCT04102566|Behavioral|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
79342621|NCT04599868|Drug|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
79342622|NCT01900054|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
79342623|NCT01612156|Drug|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
79342624|NCT01612156|Drug|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
79342625|NCT01899742|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
79342626|NCT01899742|Drug|Tiotropium 18 mcg|Inhalation Powder
79342627|NCT04602988|Device|EEG|EEG monitoring of brain rhythms
79342628|NCT01615822|Drug|OZ439 100mg|OZ439 100mg oral suspension, single dose
79342629|NCT01615822|Drug|OZ439 400mg|OZ439 400mg oral suspension, single dose
79342630|NCT01615822|Drug|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
79342631|NCT01615822|Drug|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
79342632|NCT01615822|Drug|Placebo|
79342633|NCT01898884|Drug|VP 20629|
79342634|NCT01898884|Drug|Placebo|
79342635|NCT01613326|Drug|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
79342636|NCT01613326|Drug|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
79342637|NCT01613326|Drug|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
79342638|NCT01613326|Drug|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
79342639|NCT01613326|Drug|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
79493649|NCT02972684|Device|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
79814209|NCT04106778|Drug|DMT310|Topical Powder
79814210|NCT04106778|Drug|Placebo|Placebo Topical Powder
79814211|NCT00916110|Drug|ATN-103|1.5 mg solution, single subcutaneous injection
79814212|NCT00916110|Drug|ATN-103|4 mg solution, single subcutaneous injection
79814213|NCT00916110|Drug|ATN-103|10 mg solution, single subcutaneous injection
79342640|NCT01613248|Drug|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
79493650|NCT00004934|Drug|carboplatin|
79493651|NCT00004934|Drug|epirubicin hydrochloride|
79493652|NCT00004934|Drug|paclitaxel|
79493653|NCT00004934|Procedure|conventional surgery|
79493654|NCT00003776|Biological|filgrastim|
79493655|NCT00003776|Drug|cisplatin|
79493656|NCT00003776|Drug|doxorubicin hydrochloride|
79493657|NCT00003776|Drug|ifosfamide|
79493658|NCT00003776|Drug|leucovorin calcium|
79814214|NCT00916110|Drug|ATN-103|25 mg solution, single subcutaneous injection
79814215|NCT00916110|Drug|ATN-103|25 mg solution, single intravenous injection
79814216|NCT00916110|Drug|ATN-103|50 mg solution, single subcutaneous injection
79493659|NCT00003776|Drug|methotrexate|
79814217|NCT00916110|Drug|ATN-103|100 mg solution, single subcutaneous injection
79493660|NCT00003776|Drug|trimetrexate glucuronate|
79493661|NCT00003776|Procedure|surgical procedure|
79493662|NCT00004940|Drug|cysteine hydrochloride|
79657510|NCT00245336|Biological|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
79342641|NCT01613248|Drug|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
79342642|NCT01613248|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded."
79342643|NCT01898806|Drug|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
79493663|NCT00003788|Drug|carmustine|
79493664|NCT00003788|Drug|lomustine|
79493665|NCT00003788|Drug|porfimer sodium|
79493666|NCT00003788|Drug|procarbazine hydrochloride|
79493667|NCT00003788|Procedure|neoadjuvant therapy|
79493668|NCT00003788|Procedure|surgical procedure|
79493669|NCT00003788|Radiation|radiation therapy|
79493670|NCT00385112|Procedure|Echocardiogram|2D echocardiogram with Doppler flow
79657511|NCT00245336|Drug|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
79493671|NCT00004340|Drug|calcitriol|
79493672|NCT00004340|Drug|growth hormone|
79493673|NCT00004982|Drug|Combination Iron Chelation Therapy|
79493674|NCT00004346|Drug|chenodeoxycholic acid|
79493675|NCT00004346|Drug|lovastatin|
79493676|NCT00003794|Procedure|psychosocial assessment and care|
79657512|NCT00274443|Drug|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
79657513|NCT00245375|Drug|Tylenol #3|
79657514|NCT00245375|Drug|Combination Tylenol and Ibuprofen|
79657515|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 48 weeks
79657516|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 24 weeks
79657517|NCT00274521|Drug|Tiotropium|
79493677|NCT00003794|Procedure|quality-of-life assessment|
79493678|NCT00384800|Drug|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
79493679|NCT00384878|Drug|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
79493680|NCT02972762|Drug|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
79493681|NCT00004988|Drug|VNP20009|
79493682|NCT00004358|Drug|calcitonin|
79493683|NCT00004364|Drug|desmopressin|
79493684|NCT00005000|Drug|Nelfinavir mesylate|
79493685|NCT00005000|Drug|Efavirenz|
79493686|NCT00005000|Drug|Lamivudine|
79493687|NCT00005000|Drug|Keyhole-Limpet Hemocyanin|
79493688|NCT00005000|Drug|Stavudine|
79493689|NCT00005000|Drug|Zidovudine|
79493690|NCT00005000|Drug|Didanosine|
79493691|NCT00004376|Drug|guanfacine|
79493692|NCT00005006|Drug|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
79493693|NCT00005006|Drug|Alendronate|Alendronate 70mg/week
79657518|NCT00245453|Drug|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
79657519|NCT00245453|Drug|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
79657520|NCT00245453|Drug|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
79657521|NCT00245492|Procedure|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
79657522|NCT00283920|Drug|[(11)C] PBR28|
79657523|NCT00245609|Drug|Pregabalin|
79657524|NCT00245609|Drug|Alprazolam|
79493694|NCT00005006|Drug|Teriparatide|Teriparatide 20mcg/day
79342644|NCT01898806|Drug|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
79342645|NCT01898806|Drug|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
79342646|NCT01898806|Drug|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
79342647|NCT02291029|Drug|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
79814218|NCT00916110|Drug|ATN-103|200 mg solution, single subcutaneous injection
79342648|NCT02291029|Drug|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
79342649|NCT02291029|Drug|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
79342650|NCT02291029|Drug|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
79342651|NCT02291029|Drug|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
79342652|NCT02291029|Drug|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
79342653|NCT02290873|Drug|Remimazolam|For induction and maintenance of sedation
79342654|NCT02290873|Drug|Midazolam|For induction of maintenance and sedation
79342655|NCT02290873|Drug|Placebo|Inactive control arm
79493695|NCT00004382|Drug|tin mesoporphyrin|
79493696|NCT00004382|Procedure|Phototherapy|
79493697|NCT00005012|Drug|Peginterferon alfa-2b|
79493698|NCT00004400|Drug|testosterone|
79493699|NCT00003812|Biological|filgrastim|
79493700|NCT00003812|Drug|carboplatin|
79493701|NCT00003812|Drug|etoposide|
79493702|NCT00003812|Drug|paclitaxel|
79342656|NCT02290405|Behavioral|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
79342657|NCT02359045|Drug|D1400147|Treatment A
79342658|NCT02359045|Drug|D14000136|Treatment B
79342659|NCT02359045|Drug|D14000137|Treatment C
79342660|NCT02359045|Drug|Epanova®|Treatment D
79342661|NCT02358343|Behavioral|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
79342662|NCT02358343|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
79814219|NCT00916110|Drug|ATN-103|200 mg solution, single intravenous injection
79342663|NCT02358343|Drug|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
79342664|NCT02356783|Device|Pedometer|Wireless pedometer
79493703|NCT00003812|Drug|topotecan hydrochloride|
79493704|NCT00003812|Radiation|radiation therapy|
79493705|NCT00005018|Drug|Hydroxyurea|
79493706|NCT00005018|Drug|Abacavir sulfate|
79493707|NCT00005018|Drug|Efavirenz|
79493708|NCT00005018|Drug|Didanosine|
79493709|NCT00003824|Drug|cephalexin|500 mg oral bid for 3 days starting the night before resection
79657525|NCT00245609|Drug|Placebo|
79814220|NCT00776100|Other|clinical observation|Patients undergo observation for 6 weeks.
79342665|NCT02289469|Other|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
79342666|NCT02318095|Drug|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
79657526|NCT00283998|Procedure|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
79657527|NCT00245648|Drug|fibrinolytic therapy or combination reduced fibrinolytic therapy|
79657528|NCT00245687|Device|Tiger Tube|
79657529|NCT00245726|Device|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
79814221|NCT00776100|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
79493710|NCT00003824|Procedure|surgical procedure|
79493711|NCT00003824|Drug|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
79493712|NCT04791319|Drug|Placebo|Placebo will be administered subcutaneously.
79493713|NCT04791319|Drug|Bermekimab|Bermekimab will be administered subcutaneously.
79493714|NCT04791319|Drug|Dupilumab|Dupilumab will be administered subcutaneously.
79493715|NCT00004406|Drug|human parathyroid hormone|
79493716|NCT00005024|Drug|carboplatin|
79493717|NCT00005024|Drug|cyclophosphamide|
79493718|NCT00005024|Drug|doxorubicin hydrochloride|
79493719|NCT00005024|Drug|granisetron hydrochloride|
79493720|NCT00005030|Drug|SCH 66336|
79493721|NCT00005030|Procedure|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
79493722|NCT00004424|Drug|fentanyl|
79493723|NCT00004424|Drug|Midazolam|
79493724|NCT00004424|Drug|propofol|
79493725|NCT05196373|Drug|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
79493726|NCT00004430|Drug|Dihematoporphyrin derivative|
79493727|NCT00004430|Drug|prednisolone|
79493728|NCT00004430|Procedure|Laser surgery|
79493729|NCT00003842|Biological|interleukin-4 PE38KDEL cytotoxin|
79493730|NCT00003842|Drug|isolated perfusion|
79657530|NCT00245726|Device|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
79657531|NCT00245726|Device|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
79657532|NCT00274638|Drug|Telmisartan & Hydrochlorothiazide|
79657533|NCT00274638|Drug|Losartan & Hydrochlorothiazide|
79814222|NCT04103658|Radiation|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
79814223|NCT02602236|Device|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
79342667|NCT02318095|Radiation|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
79342668|NCT02318095|Other|Sugical resection|Surgical resection of the pancreas post radiation therapy
79493731|NCT00003842|Procedure|surgical procedure|
79657534|NCT00274638|Procedure|ABPM|
79342669|NCT02318095|Drug|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
79342670|NCT02317705|Drug|OTL38|
79342671|NCT02317705|Device|Near infrared camera imaging system|Near infrared camera imaging system
79342672|NCT02317705|Procedure|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
79493732|NCT00005036|Drug|irinotecan hydrochloride|Given IV
79493733|NCT00005036|Drug|oxaliplatin|Given IV
79493734|NCT00005036|Drug|leucovorin calcium|Given IV
79493735|NCT00005036|Drug|fluorouracil|Given IV
79493736|NCT00005036|Procedure|quality-of-life assessment|Ancillary studies
79493737|NCT05454007|Behavioral|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
79657535|NCT02961569|Procedure|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
79342673|NCT02474069|Drug|Secukinumab|
79342674|NCT02317627|Drug|KD025|
79493738|NCT00003854|Other|immunohistochemistry staining method|
79657536|NCT00274677|Drug|Placebo|Experimental treatment arm
79342675|NCT02517905|Drug|Bupivacaine liposome|Local administration
79342676|NCT02517905|Drug|Placebo|Local administration
79657537|NCT00274677|Drug|lamotrigine|Experimental treatment
79814224|NCT04102176|Other|stopping nucleos(t)ide therapy|patients taking nucleoside(t)ide therapy will stop treatment
79342677|NCT02473913|Drug|Milk Thistle|
79814225|NCT04102176|Other|Continue nucleos(t)ide analogue|Continue nucleos(t)ide analogue
79814226|NCT04101864|Procedure|Electromagnetic navigation|Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.
79814227|NCT04101864|Procedure|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
79814228|NCT00783432|Drug|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
79342678|NCT02473913|Drug|Placebo|
79342679|NCT02316847|Drug|diazepam nasal spray|
79342680|NCT02473523|Other|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
79342681|NCT02473523|Other|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
79493739|NCT00003854|Procedure|lymphangiography|
79493740|NCT00003854|Procedure|sentinel lymph node biopsy|
79493741|NCT00003854|Procedure|therapeutic conventional surgery|
79493742|NCT00003854|Radiation|whole breast irradiation|
79493743|NCT05450107|Procedure|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
79657538|NCT00245843|Behavioral|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
79493744|NCT05450107|Procedure|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
79493745|NCT05449639|Device|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
79493746|NCT00004436|Drug|leuprolide|
79493747|NCT00004436|Drug|prednisone|
79493748|NCT00005042|Drug|semaxanib|
79493749|NCT00004442|Drug|chenodeoxycholic acid|
79493750|NCT00004442|Drug|cholic acid|
79493751|NCT00004442|Drug|ursodiol|
79493752|NCT05444569|Drug|LY3537021|Administered SC.
79493753|NCT05444569|Drug|Liraglutide|Administered SC.
79493754|NCT05444569|Drug|Placebo|Administered SC.
79342682|NCT02473523|Device|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
79342683|NCT02473523|Device|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
79493755|NCT00004448|Drug|omega-3 fatty acids|
79814229|NCT00783432|Drug|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
79493756|NCT00004448|Drug|prednisone|
79493757|NCT00003860|Biological|filgrastim|
79493758|NCT00003860|Drug|carboplatin|
79493759|NCT00003860|Drug|etoposide|
79493760|NCT00003860|Drug|ifosfamide|
79493761|NCT00003860|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79493762|NCT00005048|Drug|estramustine phosphate sodium|
79493763|NCT00005048|Drug|paclitaxel|
79493764|NCT00004454|Genetic|lymphocyte gene therapy|
79493765|NCT04756765|Drug|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
79493766|NCT00004466|Drug|Atorvastatin|
79493767|NCT00004466|Drug|Placebo|
79493768|NCT00005054|Drug|temozolomide|
79493769|NCT00385346|Behavioral|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
79493770|NCT00004478|Drug|droxidopa|
79493771|NCT00003878|Drug|polifeprosan 20 with carmustine implant|
79493772|NCT00003878|Procedure|conventional surgery|
79493773|NCT00005060|Drug|Taxotere-Cisplatin-5FU|Preoperatively
79493774|NCT00005060|Drug|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
79493775|NCT04723927|Other|Older adults|The data for motor function and gait pattern analysis was obtained.
79493776|NCT00003884|Drug|zoledronic acid|
79493777|NCT00003884|Procedure|quality-of-life assessment|
79493778|NCT00003890|Drug|MG 98|
79493779|NCT00385190|Drug|HCV-796|
79657539|NCT00284037|Device|continuous positive airway pressure therapy|
79657540|NCT00245882|Behavioral|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
79657541|NCT00245882|Behavioral|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
79657542|NCT00274755|Drug|chemotherapy|
79985152|NCT03186352|Procedure|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
79493780|NCT04717297|Behavioral|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
79493781|NCT04717297|Behavioral|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
79493782|NCT04717297|Behavioral|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
79493783|NCT00005066|Drug|O6-benzylguanine|
79342684|NCT02473523|Other|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
79493784|NCT00005066|Drug|carmustine|
79493785|NCT00004490|Drug|sodium dichloroacetate|
79493786|NCT00005072|Biological|Leuvectin|1000 ug of Leuvectin injected intratumorally
79493787|NCT00004496|Drug|alpha-melanocyte stimulating hormone|
79493788|NCT05138653|Drug|Drug: CVL-354|Oral solution/suspension
79493789|NCT05138653|Drug|Drug: Placebo|Oral solution/suspension
79493790|NCT05133895|Drug|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
79493791|NCT00382603|Device|OptiFree Multi-Purpose Disinfecting Solution|
79493792|NCT00003902|Drug|capecitabine|
79493793|NCT00003902|Drug|vinorelbine tartrate|
79493794|NCT00003908|Drug|carboplatin|
79493795|NCT00003908|Drug|docetaxel|
79493796|NCT00382837|Drug|Epratuzumab|
79493797|NCT00003914|Drug|dolastatin 10|
79493798|NCT00005078|Drug|carboplatin|
79493799|NCT00005078|Drug|paclitaxel|
79814230|NCT00783198|Biological|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
79985153|NCT02432872|Drug|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
79493800|NCT00005078|Drug|tirapazamine|
79657543|NCT00274755|Procedure|conventional surgery|
79657544|NCT00274755|Procedure|magnetic resonance imaging|
79657545|NCT00274755|Procedure|magnetic resonance spectroscopic imaging|
79657546|NCT00274755|Radiation|radiation therapy|
79985154|NCT02432872|Drug|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
79814231|NCT00783198|Biological|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
79342685|NCT02473523|Other|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
79342686|NCT02473523|Other|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
79342687|NCT02473523|Other|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
79342688|NCT02316769|Procedure|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
79342689|NCT02316769|Procedure|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
79657547|NCT00245921|Drug|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
79657548|NCT00284076|Drug|L-arginine|
79657549|NCT00246038|Device|Boston Scientific ENOVUS AAA Endograft|
79657550|NCT00274794|Biological|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
79657551|NCT00274794|Biological|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
79657552|NCT00246155|Biological|Botulinum toxin type A|
79342690|NCT02473445|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
79493803|NCT00003920|Biological|filgrastim|
79493804|NCT00003920|Drug|cyclosporine|
79493805|NCT00003920|Procedure|peripheral blood stem cell transplantation|
79493806|NCT00003920|Radiation|indium In 111 monoclonal antibody m170|
79493807|NCT00003920|Radiation|yttrium Y 90 monoclonal antibody m170|
79493808|NCT00005084|Procedure|conventional surgery|
79657553|NCT00284193|Drug|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
79814232|NCT00783198|Biological|Placebo|matching placebo sublingual tablets administered once daily
79342691|NCT02473367|Drug|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
79657554|NCT00284193|Drug|FEIBA- Activated Prothrombin Complexes|
79342692|NCT02473367|Drug|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
79342693|NCT02473367|Drug|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
79342694|NCT02316613|Drug|Rituximab|
79342695|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
79342696|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
79342697|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
79342698|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
79493809|NCT00005084|Procedure|magnetic resonance spectroscopic imaging|
79493810|NCT00005084|Radiation|radiation therapy|
79493811|NCT00003926|Drug|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
79814233|NCT00789360|Drug|Inhaled Placebo|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
79493812|NCT00003926|Drug|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
79493813|NCT00003926|Drug|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
79493814|NCT00003926|Drug|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
79493815|NCT00003926|Drug|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
79493816|NCT00003926|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
79493817|NCT05122819|Procedure|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
79493818|NCT00005090|Biological|bleomycin sulfate|10 U/m^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
79493819|NCT00005090|Drug|carmustine|150/m^2 on days -6 to -4 (4-6 days before transplant).
79493820|NCT00005090|Drug|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
79657555|NCT00246194|Drug|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
79657556|NCT00284232|Behavioral|Use and interpretation of blood glucose results|
79657557|NCT00284232|Drug|Insulin dosing based on SMBG chart and education|
79657558|NCT00246233|Drug|methylphenidate|
79342699|NCT02355691|Device|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
79342700|NCT02473289|Drug|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
79342701|NCT02473289|Drug|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
79342702|NCT02354599|Drug|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
79493821|NCT00005090|Drug|dacarbazine|375 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
79657559|NCT00274833|Drug|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
79657560|NCT00274833|Drug|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
79342703|NCT02354599|Drug|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
79342704|NCT02354599|Drug|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
79493822|NCT00005090|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
79493823|NCT00005090|Drug|etoposide|60 mg/kg on day -4 (4 days before transplant).
79493824|NCT00005090|Drug|vinblastine|6 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
79493825|NCT00005090|Procedure|peripheral blood stem cell transplantation|2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight
79493826|NCT00004580|Drug|Lopinavir/Ritonavir|
79493827|NCT00004580|Drug|Nevirapine|
79493828|NCT00005096|Drug|docetaxel|
79493829|NCT00004604|Biological|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
79493830|NCT05421013|Drug|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
79657561|NCT00274833|Radiation|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
79657562|NCT04709666|Procedure|Endsocopic Retrograde ColangioPancreatography (ERCP)|
79657563|NCT00274872|Drug|fluorouracil|
79657564|NCT00274872|Drug|leucovorin calcium|
79342705|NCT02316223|Behavioral|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
79493831|NCT00004640|Drug|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
79493832|NCT05104099|Drug|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
79493833|NCT00004646|Drug|prednisone|
79657565|NCT00274872|Drug|oxaliplatin|
79493834|NCT04330651|Procedure|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
79493835|NCT00005108|Drug|Estradiol|
79657566|NCT00246272|Drug|risperidone|
79657567|NCT00284271|Drug|Cyclophosphamide|
79657568|NCT00284271|Drug|Adramycin|
79657569|NCT00284271|Drug|Procarbacine|
79657570|NCT00284271|Drug|Prednisone|
79657571|NCT00284271|Drug|Vincristine|
79657572|NCT00284271|Drug|Bleomycin|
79657573|NCT00284271|Drug|Erythropoietin beta|
79657574|NCT00284115|Device|Gait trainer|Mechanical gait repetitive training
79657575|NCT00284115|Device|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
79814234|NCT00789360|Drug|Inhaled Loxapine|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
79657576|NCT00246350|Procedure|massage|8 light massage treatments and hot pack
79342706|NCT02286895|Biological|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
79342707|NCT02286895|Biological|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
79342708|NCT02286895|Biological|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
79342709|NCT02286895|Biological|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
79342710|NCT02472977|Drug|Ulocuplumab|
79342711|NCT02472977|Drug|Nivolumab|
79342712|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
79342713|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
79493836|NCT00005108|Drug|Progesterone|
79493837|NCT04648579|Device|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
79493838|NCT04648579|Other|Control|Hospital usual care regarding vital signs collection and TRR activation.
79493839|NCT00004652|Drug|pimozide|
79493840|NCT00004658|Drug|ribose|
79493841|NCT00004658|Drug|thymidine|
79342714|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
79493842|NCT00004658|Drug|uridine|
79657577|NCT00246350|Procedure|massage|16 light massage treatments and hot packs
79657578|NCT00246350|Procedure|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
79342715|NCT02059395|Other|Mastery based learning|Participants are allowed to follow the course content at their own speed
79493843|NCT00005120|Drug|Calanolide A|
79493844|NCT04624321|Behavioral|Health and lifestyle tool|Health and lifestyle tool used online
79493845|NCT04624321|Other|Usual care|Usual care at ordinary healthcare provider
79493846|NCT00004664|Drug|megestrol|
79493847|NCT00004664|Behavioral|Exercise|
79493848|NCT00004670|Procedure|pallidotomy|
79493849|NCT05396755|Procedure|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
79493850|NCT00004682|Drug|immune globulin|
79493851|NCT00004688|Drug|carmustine|
79493852|NCT00004688|Drug|mercaptopurine|
79493853|NCT00004688|Drug|streptozocin|
79657579|NCT00246350|Procedure|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
79985155|NCT03189472|Device|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
79493854|NCT00004694|Drug|heparin|
79657580|NCT00246389|Drug|cyclobenzaprine hydrochloride|
79657581|NCT00274911|Drug|cisplatin|
79657582|NCT00274911|Drug|lomustine|
79657583|NCT00274911|Drug|vincristine sulfate|
79657584|NCT00274911|Procedure|adjuvant therapy|
79657585|NCT00274911|Radiation|radiation therapy|
79657586|NCT00246428|Behavioral|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
79657587|NCT00284349|Device|Use of a rehabilitation brace instead of a plaster|
79657588|NCT00246467|Biological|Alhydrogel|
79657589|NCT00246467|Biological|rF1 and rV protein antigens|
79342716|NCT02059395|Other|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
79342717|NCT02059239|Drug|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
79493855|NCT04608409|Drug|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
79493856|NCT05091853|Device|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
79493857|NCT04607551|Procedure|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
79814235|NCT04022538|Procedure|Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
79342718|NCT02059239|Drug|Carmustine|300 mg/m2 on Day -6
79342719|NCT02059239|Drug|Etoposide|100 mg/m2 on days -5 to -2
79342720|NCT02059239|Drug|Melphalan|140mg/m2 on Day -1
79342721|NCT02059239|Drug|Cytarabine|200 mg/m2 on days -5 to -2
79342722|NCT02059239|Drug|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
79342723|NCT02059239|Biological|Autologous Stem Cell Transplantation|
79342724|NCT02059239|Biological|Allogeneic Stem Cell Transplantation|
79342725|NCT02059239|Drug|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
79493858|NCT04607551|Procedure|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
79493859|NCT00004700|Drug|insulin-like growth factor I|
79493860|NCT00004730|Drug|magnesium sulfate|
79493861|NCT00004736|Drug|Nelfinavir mesylate|
79493862|NCT00004736|Drug|Ethambutol hydrochloride|
79493863|NCT00004736|Drug|Isoniazid|
79493864|NCT00004736|Drug|Pyrazinamide|
79493865|NCT00004736|Drug|Lamivudine|
79493866|NCT00004736|Drug|Rifabutin|
79493867|NCT00004736|Drug|Stavudine|
79493868|NCT00004736|Drug|Zidovudine|
79657590|NCT00277173|Behavioral|Adoption of Crew Resource Management approach|
79657591|NCT00246506|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
79657592|NCT00246506|Procedure|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
79493869|NCT04592731|Drug|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
79657593|NCT00246545|Behavioral|exercise|
79657594|NCT00277251|Drug|Alendronate|
79657595|NCT00246584|Drug|SPP100|
79657596|NCT00416676|Drug|carboplatin|
79657597|NCT00416676|Drug|cisplatin|
79657598|NCT00416676|Drug|cyclophosphamide|
79657599|NCT00416676|Drug|etoposide|
79657600|NCT00416676|Drug|vincristine sulfate|
79493870|NCT04592731|Drug|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
79493871|NCT00004748|Drug|colchicine|
79493872|NCT00004748|Drug|methotrexate|
79493873|NCT00004748|Drug|ursodiol|
79493874|NCT00004754|Drug|epoprostenol|
79342726|NCT04722783|Behavioral|Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, & Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
79493875|NCT00005576|Biological|monoclonal antibody Ch14.18|Given IV
79493876|NCT00005576|Drug|isotretinoin|Given orally
79493877|NCT00005576|Biological|aldesleukin|Given IV
79493878|NCT00005576|Biological|sargramostim|Given IV
79493879|NCT00386204|Device|Q-switched Ruby Laser|
79657601|NCT00416676|Procedure|adjuvant therapy|
79657602|NCT00416676|Procedure|conventional surgery|
79657603|NCT00416676|Procedure|neoadjuvant therapy|
79657604|NCT00416676|Radiation|radiation therapy|
79493880|NCT00004760|Behavioral|Exercise|
79493881|NCT04713163|Drug|covid19 vaccine|Vaccine
79493882|NCT00004772|Drug|Immune globulin|
79493883|NCT04712929|Other|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
79493884|NCT05082961|Other|Collection of blood samples|Samples to evaluate the circulating CD8+ T cell count.
79493885|NCT00004784|Drug|methotrexate|
79493886|NCT00004784|Drug|ursodiol|
79493887|NCT00004796|Drug|lactulose|
79493888|NCT00004802|Drug|dichlorphenamide|
79493889|NCT00004808|Drug|fluconazole|
79493890|NCT00004814|Drug|copolymer 1|
79493891|NCT00004826|Drug|clozapine|
79493892|NCT00423254|Biological|PSMA/PRAME|Low dose
79493893|NCT00423254|Biological|PSMA/PRAME|high dose
79493894|NCT04552327|Device|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
79657605|NCT00284388|Procedure|Simultaneous controlled power measurement|
79657606|NCT00284388|Procedure|Surface EMG measurement|
79657607|NCT00246623|Drug|Exubera (inhaled insulin)|
79493895|NCT04552327|Device|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
79493896|NCT04552327|Drug|Solaraze|Twice daily application for a duration of 60 days
79493897|NCT00005588|Radiation|radiation therapy|
79493898|NCT04552015|Diagnostic Test|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
79493899|NCT00004778|Drug|betamethasone|
79493900|NCT00004778|Drug|dexamethasone|
79493901|NCT00004778|Drug|thyrotropin-releasing hormone|
79493902|NCT00005594|Drug|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
79493903|NCT00005600|Procedure|management of therapy complications|
79493904|NCT00005612|Biological|filgrastim|
79493905|NCT00005612|Drug|carboplatin|
79493906|NCT00005612|Drug|cyclophosphamide|
79493907|NCT00005612|Drug|etoposide|
79493908|NCT00005612|Drug|paclitaxel|
79657608|NCT00246623|Procedure|8-point glucose diary (to assess pre- and post prandial glucoses)|
79657609|NCT00246623|Procedure|Meal Tolerance Test|
79657610|NCT00246623|Procedure|24-hour continuous glucose monitoring (at select sites)|
79657611|NCT00246623|Procedure|Pulmonary Function Testing|
79657612|NCT00246623|Procedure|Hypoglycemic Event Monitoring|
79370727|NCT03580317|Other|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
79493909|NCT00005612|Drug|topotecan hydrochloride|
79493910|NCT00005612|Procedure|peripheral blood stem cell transplantation|
79493911|NCT00005618|Drug|arsenic trioxide|
79493912|NCT00005624|Drug|CI-994|CI-994 as outlined in treatment arm.
79657613|NCT00246623|Procedure|Laboratory Assessments|
79657614|NCT00246623|Behavioral|Nutritional Counseling and Diabetes Education|
79657615|NCT00284427|Drug|vitamin C|IV Vitamin C given 2-3 times a week
79657616|NCT00246662|Drug|Vosaroxin|All patients receive vosaroxin Injection
79657617|NCT00277290|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
79657618|NCT00246701|Drug|Simvastatin|Simvastatin
79657619|NCT00246701|Drug|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
79985156|NCT03189472|Device|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
79342727|NCT04722783|Behavioral|Early Start Denver Model (ESDM) intervention|ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
79342728|NCT04722783|Behavioral|1-hour ESDM|The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).
79342729|NCT04722783|Behavioral|Early special needs education (ESNE)|The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
79342730|NCT02059161|Drug|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
79342731|NCT02059161|Drug|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
79342732|NCT02059161|Drug|Prandial Insulin|Participants will continue their prandial insulin during the study.
79342733|NCT04417647|Device|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
79342734|NCT04417647|Procedure|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
79342735|NCT01897714|Drug|Melflufen|
79342736|NCT01897714|Drug|Dexamethasone|
79342737|NCT05131737|Procedure|High altitude exposure|Exposure to 2500m of altitude
79342738|NCT05131737|Procedure|Low altitude exposure|Exposure to 490 m
79342739|NCT01861522|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
79342740|NCT01861522|Drug|Placebo|Two Placebo tablets will be taken orally twice a day
79342741|NCT01860976|Drug|Abatacept|
79342742|NCT01860976|Drug|Placebo|
79342743|NCT01860040|Drug|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
79342744|NCT01860040|Drug|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
79342745|NCT01860040|Drug|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
79657620|NCT00284466|Procedure|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
79342746|NCT04618744|Drug|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
79342747|NCT04618744|Other|Placebo|Matching Placebo
79493913|NCT00382915|Device|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
79342748|NCT01896934|Drug|Sertraline|50-200mg daily
79342749|NCT02039505|Drug|Vedolizumab|Vedolizumab intravenous infusion
79342750|NCT02039505|Drug|Vedolizumab placebo|Vedolizumab placebo
79342751|NCT02095197|Drug|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
79493914|NCT00385502|Drug|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
79342752|NCT02039427|Drug|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
79342753|NCT02039427|Other|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
79342754|NCT02039427|Drug|Placebo|Normal saline 2 ml
79342755|NCT02094885|Biological|Bioseal Fibrin Sealant|
79657621|NCT00246779|Procedure|Modified ultrafiltration|
79657622|NCT00277329|Drug|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
79657623|NCT00246818|Procedure|Tai Chi Chuan|
79657624|NCT00277368|Other|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
79657625|NCT00246896|Behavioral|care management|
79657626|NCT00284505|Drug|thalidomide|
79657627|NCT00246935|Drug|Roflumilast|
79657628|NCT00277407|Procedure|NAET with acupressure and/or chiropractic procedures|
79342756|NCT02094885|Other|Manual Compression|
79342757|NCT01896856|Drug|SGI-110 Dose Escalation|"Dose level 1 (DL1): 45 mg/m^2 administered as a subcutaneous injection~Dose level 1G (DL1G): 45 mg/m^2 administered as a subcutaneous injection + growth factor support~Dose level -1 (DL-1): 30 mg/m^2 administered as a subcutaneous injection~Dose level -1G (DL-1G): 30 mg/m^2 administered as a subcutaneous injection + growth factor support"
79342758|NCT01896856|Drug|Regorafenib|160 mg taken orally
79342759|NCT01896856|Drug|TAS-102|35 mg/m^2 taken orally
79342760|NCT01896856|Drug|SGI-110|45 mg/m^2 administered as a subcutaneous injection
79342761|NCT01896856|Drug|Irinotecan|125 mg/m^2 administered IV
79342762|NCT02038959|Other|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
79342763|NCT01896700|Drug|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
79342764|NCT01896700|Drug|Placebo|Escalating matched dose of placebo
79493915|NCT00005630|Biological|ras peptide cancer vaccine|
79493916|NCT00005630|Biological|sargramostim|
79493917|NCT00005636|Drug|cisplatin|
79493918|NCT00005636|Drug|pemetrexed disodium|
79657629|NCT00246974|Drug|Gemcitabine|intravenous
79657630|NCT00246974|Drug|Cisplatin|intravenous
79657631|NCT00246974|Drug|Gefitinib|oral
79657632|NCT00284583|Drug|Injection of Steroid into Foot|
79657633|NCT00284583|Drug|Injection of Alcohol into Foot|
79657634|NCT00284583|Drug|Injection of Lidocaine into Foot|
79657635|NCT00247013|Behavioral|Breast Cancer Screening Compliance|
79657636|NCT00277563|Device|reduction of pain scores by magnetic energy|
79657637|NCT00247052|Drug|diclofenac|diclofenac 50 mg bid versus placebo bid
79657638|NCT00247052|Drug|diclofenac|diclofenac 100 mg per day for 14 days
79657639|NCT00247052|Drug|matching placebo|
79657640|NCT00284622|Procedure|Arthroscopy|HTO with pre-scope
79657641|NCT00247091|Biological|standard-titer measles vaccine|
79493919|NCT00005642|Drug|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
79342765|NCT02352493|Drug|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
79342766|NCT02352493|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
79342767|NCT02286193|Behavioral|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
79342768|NCT01896232|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
79342769|NCT01896232|Drug|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
79342770|NCT01896232|Drug|Oral Placebo|Administered orally once a day.
79342771|NCT01896232|Drug|Intravenous Placebo|Administered intravenously (IV) three times per week.
79342772|NCT02460224|Drug|LAG525|LAG525 was administered via intravenous (i.v.) infusion
79493923|NCT00005648|Drug|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
79493924|NCT00005648|Drug|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
79493925|NCT00005654|Drug|clomiphene citrate|
79493926|NCT00005654|Drug|metformin|
79493927|NCT00005666|Procedure|PET scan use in radiotherapy planning|
79493928|NCT00382447|Device|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
79342773|NCT02460224|Drug|PDR001|PDR001 was administered via i.v. infusion
79342774|NCT02094573|Drug|Brigatinib|Brigatinib tablets
79342775|NCT01859494|Device|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
79342776|NCT01858636|Device|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
79342777|NCT02058849|Drug|Beetroot|10g Beetroot powder mixed with 4-8 oz.
79342778|NCT02058849|Other|Placebo|Placebo
79342779|NCT01858558|Biological|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
79342780|NCT01858558|Drug|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
79493929|NCT00382447|Device|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
79493930|NCT04504747|Other|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
79493931|NCT00005684|Drug|warfarin|
79493932|NCT00005684|Drug|heparin|
79657642|NCT00277602|Drug|Riluzole|
79493933|NCT00386282|Drug|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
79493935|NCT05324683|Other|No intervention planned|No intervention planned; study is observational
79342781|NCT02058537|Drug|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
79342782|NCT01612000|Biological|PanBlok|Intramuscular injection
79342783|NCT01612000|Biological|rHA adjuvant|Intramuscular injection
79342784|NCT01895608|Behavioral|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
79342785|NCT01895608|Behavioral|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
79342786|NCT01895608|Behavioral|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
79342787|NCT01895608|Behavioral|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
79493936|NCT05323903|Other|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
79493937|NCT05323903|Other|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
79493938|NCT00385658|Drug|Fluvastatin extended release, fenofibrate|
79493939|NCT00385658|Drug|Fixed combination simvastatin/ezetimibe|
79493940|NCT04452955|Biological|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
79493941|NCT05305573|Biological|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
79493942|NCT05305573|Biological|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
79493943|NCT00005762|Drug|Indinavir sulfate|
79493944|NCT00005762|Drug|Ritonavir|
79493945|NCT00005762|Drug|Amprenavir|
79493946|NCT00005762|Drug|Nelfinavir mesylate|
79493947|NCT00005762|Drug|Efavirenz|
79493948|NCT00005762|Drug|Saquinavir|
79493949|NCT04447807|Behavioral|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
79493950|NCT04447807|Other|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
79493951|NCT00005768|Drug|Estrogen|
79493952|NCT00005774|Drug|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
79657643|NCT00277641|Drug|Lamotrigine|25 mg or 100 mg
79657644|NCT00277641|Drug|placebo|identical tablets to study drug
79657645|NCT00284661|Procedure|FAST FIX|Fast fix repair of a meniscal tear
79657646|NCT00284661|Procedure|Meniscal suturing|standard suturing of meniscal tear
79657647|NCT00247130|Drug|Omeprazole|
79657648|NCT00247130|Drug|Ranitidine|
79657649|NCT00277680|Procedure|Laparoscopic bilateral occlusion of uterine artery|
79657650|NCT00277680|Procedure|Radiological embolization (UFE)|
79985157|NCT03189550|Procedure|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
79342788|NCT02409680|Drug|Low dose aspirin|Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
79985158|NCT03189550|Procedure|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
79342789|NCT02409680|Drug|Placebo|Placebo
79342790|NCT04618354|Other|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
79342791|NCT01895452|Drug|ALKS 9072, Low Dose|Intramuscular injection, given monthly
79493953|NCT00005774|Drug|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
79493954|NCT00005786|Drug|arsenic trioxide|Given IV
79657651|NCT00247169|Drug|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
79657652|NCT00247208|Device|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
79342792|NCT01895452|Drug|ALKS 9072, High Dose|Intramuscular injection, given monthly
79342793|NCT02094417|Drug|AMG531|Subcutaneous, weekly injection
79493955|NCT00005786|Other|laboratory biomarker analysis|Correlative studies
79814236|NCT04022538|Procedure|Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
79493956|NCT00005792|Drug|etoposide phosphate|Etoposide phosphate 1363 mg/m^2/day IV over 4 hours (total dose 2726 mg/m^2, or 2400 mg/m^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
79814237|NCT00782496|Device|Education + new meter|Diabetes education and a new meter with basic features
79814238|NCT00782496|Device|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
79814239|NCT00782418|Drug|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
79342794|NCT01894984|Drug|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
79493957|NCT00005792|Drug|melphalan|Melphalan 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2), followed immediately by topotecan. Days -7, -6, -5
79814240|NCT00782418|Drug|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
79493958|NCT00005792|Drug|topotecan|Topotecan 3.3 mg/m^2/day (starting total dose = 10 mg/m^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
79493959|NCT00005792|Procedure|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
79493960|NCT00005798|Drug|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
79493961|NCT00005798|Drug|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
79657653|NCT00247208|Device|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
79657654|NCT00284778|Drug|Alimta®|
79657655|NCT00284778|Drug|Taxotere®|
79657656|NCT00247247|Drug|Comtess®|
79657657|NCT00277758|Biological|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
79657658|NCT00277758|Drug|Ribavirin|Ribavirin @ 800 mg daily (< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
79985159|NCT03189550|Procedure|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
79342795|NCT01894984|Drug|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
79657659|NCT00277758|Biological|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
79342796|NCT02375672|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
79342797|NCT02375672|Drug|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~Oxaliplatin 85 mg/m^2 IV with~Leucovorin 400 mg/m^2 IV followed by~5FU 400 mg/m^2 bolus and then 2400 mg/m^2 via continuous infusion"
79985160|NCT03189394|Behavioral|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
79342798|NCT01894516|Drug|GLPG0634|GLPG0634 capsules.
79342799|NCT01894516|Drug|Placebo|Placebo capsules.
79342800|NCT02491463|Biological|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
79342801|NCT02491463|Biological|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
79342802|NCT02491463|Biological|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
79342803|NCT02491463|Drug|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
79342804|NCT02038881|Biological|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
79342805|NCT01857622|Drug|DU-176b 15mg|oral DU-176b 15mg once daily
79342806|NCT01857622|Drug|DU-176b 30mg|oral DU-176b 30mg once daily
79342807|NCT01857622|Drug|DU-176b 60mg|oral DU-176b 60mg once daily
79657660|NCT00277758|Biological|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
79657661|NCT00277758|Drug|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight <65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
79657662|NCT00247286|Behavioral|weighted vaginal cones|
79657663|NCT00247286|Behavioral|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
79985161|NCT03189394|Behavioral|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
79342808|NCT01857310|Dietary Supplement|5 mg folic acid and 30 mg elemental zinc|
79342809|NCT01857310|Drug|Placebo Comparator: Placebo|
79342810|NCT02472353|Drug|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
79342811|NCT02472353|Drug|Doxorubicin|Standard of care treatment with doxorubicin
79342812|NCT02491073|Other|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
79342813|NCT02314117|Drug|Ramucirumab|Administered IV
79342814|NCT02314117|Drug|Capecitabine|Administered orally
79342815|NCT02314117|Drug|Cisplatin|Administered IV
79342816|NCT02314117|Drug|Placebo|Administered IV
79342817|NCT02314117|Drug|Fluorouracil|Administered IV
79342818|NCT01893346|Drug|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
79342819|NCT02490371|Device|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
79342820|NCT02490371|Behavioral|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
79342821|NCT02058147|Drug|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
79342822|NCT02058147|Drug|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
79493962|NCT00005798|Drug|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
79493963|NCT00005810|Biological|filgrastim|
79493964|NCT00005810|Drug|carboplatin|
79657664|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
79493965|NCT00005810|Drug|docetaxel|
79657665|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
79657666|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
79657667|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
79657668|NCT00284817|Drug|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
79657669|NCT00247325|Drug|Iodixanol(Drug)|
79985162|NCT03189394|Behavioral|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
79985163|NCT02437006|Other|exercise|cycle ergometry
79493966|NCT00005810|Drug|estramustine phosphate sodium|
79493967|NCT00005816|Biological|therapeutic autologous dendritic cells|
79657670|NCT00277797|Device|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
79657671|NCT00277797|Device|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
79985164|NCT02437240|Behavioral|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
79985165|NCT02437240|Behavioral|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
79985166|NCT02436850|Procedure|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
79985167|NCT02436928|Biological|AT-501 High Dose vaccine|Comparison of each dose of vaccine
79985168|NCT02436928|Biological|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
79342823|NCT02058147|Drug|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
79342824|NCT02058147|Drug|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
79342825|NCT02489981|Drug|Spiriva|60 puffs
79342826|NCT04205045|Diagnostic Test|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
79342827|NCT04205045|Other|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
79342828|NCT04205045|Other|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
79342829|NCT04415554|Diagnostic Test|echocardiography|echocardiography exam of the infant
79342830|NCT02471183|Drug|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
79342831|NCT01855828|Drug|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
79342832|NCT01855828|Drug|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
79342833|NCT01855828|Drug|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
79493968|NCT00005816|Procedure|conventional surgery|
79493969|NCT05303623|Other|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
79493970|NCT05303623|Other|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
79657672|NCT00247364|Drug|Levetiracetam (Keppra)|
79657673|NCT00247403|Drug|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
79657674|NCT00277836|Drug|MST-997|
79985169|NCT02436928|Biological|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
79342834|NCT01855828|Drug|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
79657675|NCT00247442|Behavioral|Decision aid|
79657676|NCT00277875|Drug|ALT-711 (alagebrium chloride)|
79657677|NCT00424814|Drug|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
79985170|NCT02436928|Biological|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
79985171|NCT02436538|Other|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
79985172|NCT02432014|Behavioral|PMTO-PTC Group clinic-based|
79985173|NCT02432014|Behavioral|PMTO Individual home-based|
79985174|NCT02432014|Behavioral|PMTO Individual clinic-based|
79657678|NCT00424814|Drug|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
79657679|NCT00284973|Biological|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
79657680|NCT00247481|Drug|Gefitinib|
79657681|NCT00247481|Drug|Docetaxel|
79657682|NCT00277914|Drug|Flibanserin|flibanserin flexible dosing
79657683|NCT00247520|Drug|topical nasal rEV131|
79985175|NCT02432014|Behavioral|Services as Usual|
79814241|NCT00782418|Drug|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
79342835|NCT01855828|Drug|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
79342836|NCT01855828|Drug|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
79342837|NCT04417335|Biological|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
79342838|NCT04417335|Biological|Placebo|0.9% NaCl
79342839|NCT02489279|Behavioral|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
79342840|NCT02489279|Behavioral|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
79657684|NCT04719039|Behavioral|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
79657685|NCT00247559|Biological|Botulinum toxin type A|
79657686|NCT00285051|Drug|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
79342841|NCT04417491|Device|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
79342842|NCT04417491|Device|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
79657687|NCT02961725|Biological|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml
79657688|NCT00247715|Drug|algeldrate/magnesium oxide|
79657689|NCT00247715|Drug|ranitidine|
79657690|NCT00247715|Drug|pantoprazole|
79657691|NCT00247754|Behavioral|Cognitive Behaviour Treatment|
79814242|NCT00782340|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
79814243|NCT00782340|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
79814244|NCT00916188|Dietary Supplement|Black Tea Extract|Amount/dose depends on Arm assignment.
79985176|NCT03191968|Behavioral|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
79985177|NCT03191968|Behavioral|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
79657692|NCT00285090|Dietary Supplement|Calcium, Vitamin D|
79657693|NCT00285090|Dietary Supplement|Calcium,Vitamin D|
79657694|NCT00285090|Dietary Supplement|Calcium, VitaminD|
79657695|NCT00285090|Other|Sugar Pill|
79657696|NCT00247793|Drug|Oral Impact (preoperative enteral nutritional supplement)|
79657697|NCT00417222|Drug|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
79814245|NCT00774852|Drug|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
79493971|NCT05303623|Other|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
79493972|NCT00385892|Device|Abdominal binder|
79493973|NCT00385970|Drug|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
79493974|NCT00385970|Drug|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
79657698|NCT00247832|Behavioral|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
79814246|NCT00774852|Drug|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
79814247|NCT00774852|Drug|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
79814248|NCT00774852|Drug|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
79342843|NCT02489045|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
79342844|NCT02488109|Other|Higher Calorie Refeeding|
79985178|NCT02436694|Drug|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
79342845|NCT02488109|Other|Lower Calorie Refeeding|
79342846|NCT02351167|Drug|Combination NRT (Nicotine patch, Nicotine lozenge)|
79342847|NCT02351167|Drug|Varenicline|
79342848|NCT02351167|Drug|Placebo|
79342849|NCT02351167|Behavioral|Intensive smoking counseling|
79342850|NCT02350309|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablet.
79342851|NCT02350309|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablet.
79342852|NCT02350309|Drug|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
79342853|NCT02350309|Drug|Flurazepam 30 mg|Flurazepam 30 mg capsule.
79342854|NCT02038647|Drug|Alisertib|Alisertib tablets
79342855|NCT02038647|Drug|Placebo|Placebo matching tablets
79342856|NCT02038647|Drug|Paclitaxel|Paclitaxel intravenous injection
79342857|NCT02058069|Device|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
79342858|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
79342859|NCT02057835|Drug|BI 691751 high dose|BI 691751 high dose
79342860|NCT02057835|Drug|BI 691751 middle dose|BI 691751 middle dose
79342861|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
79493975|NCT00385970|Drug|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
79493976|NCT05006677|Drug|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
79493977|NCT05006677|Drug|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
79493978|NCT05006677|Drug|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
79493979|NCT05006677|Other|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
79657699|NCT00247832|Behavioral|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
79342862|NCT02057835|Drug|BI 691751 low dose 1|BI 691751 low dose 1
79342863|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
79342864|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
79342865|NCT02057835|Drug|BI 691751 low dose 2|BI 691751 low dose 2
79370728|NCT03580317|Other|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
79657700|NCT00278070|Drug|vinorelbine oral formulation|Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
79657701|NCT00417261|Drug|ATF936|
79657702|NCT00417261|Drug|AXT914|
79342866|NCT02057757|Drug|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
79342867|NCT02057757|Drug|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
79342868|NCT02037477|Drug|Vonoprazan|Vonoprazan tablets
79342869|NCT02037477|Drug|Esomeprazole|Esomeprazole capsules
79342870|NCT02037477|Drug|Rabeprazole sodium|Rabeprazole sodium tablets
79342871|NCT02057523|Drug|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
79342872|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
79657703|NCT00424983|Drug|Zoledronic acid|
79657704|NCT00247910|Drug|Hydrochlorothiazide|Not recorded in detailed description.
79985179|NCT02436694|Drug|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
79342873|NCT02037165|Drug|Pregabalin|Pregabalin hard capsule
79342874|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
79342875|NCT02037165|Drug|Celecoxib|Celecoxib hard capsule
79342876|NCT02470403|Drug|LIK066|LIK066 25 mg tablets
79342877|NCT02470403|Drug|Placebo|Matching placebo tablets
79342878|NCT01855750|Drug|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
79342879|NCT01855750|Drug|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
79342880|NCT01855750|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
79342881|NCT01855750|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
79342882|NCT01855750|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
79342883|NCT01855750|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
79342884|NCT01855750|Drug|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
79342885|NCT04963439|Drug|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
79342886|NCT04939103|Device|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
79657705|NCT00278187|Biological|volociximab|
79657706|NCT00278187|Drug|erlotinib hydrochloride|
79657707|NCT04718610|Other|Osteopathic intervention|Nerve vagus stimulation
79657708|NCT04718610|Biological|CRP assessment|Blood CRP will be assessed during trial
79657709|NCT04718610|Behavioral|QLQ-C30 questionnaire|Completion of QLQ-C30
79657710|NCT00247988|Drug|Weekly Taxotere with weekly carboplatin|
79657711|NCT00425022|Procedure|thoracoscopy|
79657712|NCT00248066|Drug|RESTEN-MP|
79657713|NCT00285129|Device|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
79657714|NCT00248105|Behavioral|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
79342887|NCT01855126|Other|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
79657715|NCT00278226|Behavioral|smoking cessation intervention|
79985180|NCT02436616|Device|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
79985181|NCT02436460|Biological|AbGn-168H|Humanized monoclonal antibody
79985182|NCT03191422|Behavioral|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
79342888|NCT01855126|Other|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
79342889|NCT01622673|Drug|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
79342890|NCT01622673|Drug|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
79342891|NCT01622673|Drug|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
79493980|NCT00386048|Behavioral|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
79493981|NCT00386126|Drug|Iron Sucrose IV 200mg, once a week, for 5 weeks|
79493982|NCT00386126|Drug|Ferrous sulfate 200mg PO TID, for 8 weeks|
79657716|NCT00278226|Other|educational intervention|
79657717|NCT00248144|Drug|Famciclovir|
79657718|NCT00278265|Drug|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
79985183|NCT03186040|Drug|Lacosamide|Sodium channel blocker
79342892|NCT01855048|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
79342893|NCT01855048|Other|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
79657719|NCT00248183|Drug|PRX-00023|
79657720|NCT00278304|Radiation|brachytherapy|
79657721|NCT00278304|Radiation|radiation therapy|
79657722|NCT00248222|Behavioral|Supervised aerobic training|
79657723|NCT00278343|Drug|cediranib maleate|30mg given PO, daily
79657724|NCT00278343|Other|laboratory biomarker analysis|Correlative studies
79657725|NCT00248261|Drug|ziprasidone, sertraline|
79657726|NCT00285168|Behavioral|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
79657727|NCT00248300|Other|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
79657728|NCT00278382|Drug|sorafenib tosylate|Given orally
79657729|NCT00278382|Other|laboratory biomarker analysis|Correlative studies
79657730|NCT00248339|Drug|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
79657731|NCT00248339|Drug|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
79657732|NCT00248339|Drug|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
79985184|NCT03191734|Device|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
79342894|NCT02469857|Drug|AB103 0.5 mg/kg|
79657733|NCT00278421|Biological|rituximab|
79657734|NCT00278421|Drug|cyclophosphamide|
79657735|NCT00278421|Drug|doxorubicin hydrochloride|
79657736|NCT00278421|Drug|prednisone|
79657737|NCT00278421|Drug|vincristine sulfate|
79657738|NCT00248378|Drug|Smoked Cannabis|
79657739|NCT00248456|Drug|Calcipotriol plus betamethasone dipropionate ointment|
79985185|NCT03191500|Device|steerable catheter|peripheral vascular disease
79342895|NCT02469857|Other|NaCl 0.9%|
79342896|NCT04960865|Other|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
79342897|NCT04960865|Other|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
79342898|NCT04960865|Other|Rigid Taping|Rigid Taping will be applied.
79342899|NCT02036853|Drug|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
79657740|NCT00285285|Device|Point of Care Device; i-Stat Analyzer|
79657741|NCT00248690|Device|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
79493983|NCT04421443|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups every three months until two years after post-treatment, all of them will be conducted online.
79985186|NCT02432170|Device|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
79342900|NCT02469623|Device|Dipole Density Mapping with AcQMap followed by ablation|
79342901|NCT02469077|Behavioral|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
79342902|NCT02469077|Drug|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
79342903|NCT02469077|Drug|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
79342904|NCT02469077|Drug|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
79342905|NCT02486627|Drug|plazomicin|
79493984|NCT04405297|Device|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
79657742|NCT00278460|Drug|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
79657743|NCT00278460|Drug|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
79657744|NCT00248729|Drug|Etomidate (20mg) or Midazolam (7mg)|
79657745|NCT00248768|Device|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
79657746|NCT00278499|Behavioral|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
79657747|NCT00278499|Behavioral|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
79985187|NCT02440516|Other|Early treatment group|Physical- and occupational Therapy
79985188|NCT02440516|Other|Late treatment group|Waiting list - then Physical- and occupational Therapy
79985189|NCT02659020|Drug|Olaratumab|Administered IV
79985190|NCT02659020|Drug|Gemcitabine|Administered IV
79985191|NCT02659020|Drug|Docetaxel|Administered IV
79985192|NCT02659020|Drug|Placebo|Administered IV
79342906|NCT02486627|Drug|meropenem|
79493985|NCT04399993|Other|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
79493986|NCT04399993|Other|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
79657748|NCT00248846|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
79657749|NCT00278577|Biological|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
79814249|NCT00774852|Drug|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
79814250|NCT00774852|Drug|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
79985193|NCT02436382|Other|change in temperature|increase in ambient room temperature
79342907|NCT02486627|Drug|levofloxacin (oral)|
79342908|NCT01644565|Biological|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
79342909|NCT01644565|Biological|Recombinant fimbrial adhesin dscCfaE|
79342910|NCT01644565|Biological|Modified E. coli heat labile enterotoxin LTR192G|
79985194|NCT03482011|Drug|Mirikizumab|Administered SC
79342911|NCT02485925|Device|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
79342912|NCT04936217|Other|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
79342913|NCT04936217|Other|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
79342914|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
79342915|NCT02282293|Drug|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
79342916|NCT01854658|Drug|GFF MDI (PT003)|GFF MDI administered as two puffs BID
79342917|NCT01854658|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
79985195|NCT03482011|Drug|Placebo|Administered SC
79493987|NCT05293093|Other|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
79342918|NCT01854658|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
79493988|NCT04568330|Other|best support care|Best support care
79985196|NCT02436148|Other|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
79985197|NCT02436070|Behavioral|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
79985198|NCT02436070|Behavioral|General text messages|Subjects received text messages generalized to children with asthma
79985199|NCT03189238|Biological|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
79985200|NCT03189082|Procedure|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
79985201|NCT02431858|Device|E-Catheter (Pajunk)|
79985202|NCT02431858|Device|Sonolong Catheter (Pajunk)|
79985203|NCT01374126|Drug|Artesunate|Artesunate alone
79985204|NCT01374126|Drug|Azithromycin + Artesunate|Combination of azithromycin + artesunate
79342919|NCT01854658|Drug|Placebo|
79342920|NCT01892020|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
79342921|NCT01892020|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
79342922|NCT02485691|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
79342923|NCT02485691|Drug|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
79342924|NCT02485691|Drug|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
79493989|NCT04568330|Other|moisture cream|BSC plus moisture cream
79985205|NCT02431624|Drug|BTDS|
79985206|NCT02584920|Drug|HLX01|
79985207|NCT02584920|Drug|Rituximab|
79985208|NCT03185650|Device|tPAD Device|A novel, transnasal aerosol generator
79985209|NCT03185650|Device|PARI LC Star Nebulizer|Standard oral nebulizer
79985210|NCT01371318|Other|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
79985211|NCT03639103|Procedure|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
79985212|NCT02431936|Drug|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
79985213|NCT02431936|Drug|Placebo|Sugar pill made to look identical to Prazosin intervention.
79985214|NCT03916770|Device|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
79985215|NCT03916770|Device|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
79985216|NCT03185806|Device|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
79985217|NCT03481309|Device|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
79657750|NCT00248885|Procedure|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
79657751|NCT00285402|Drug|AST-726 Low dose|
79657752|NCT00285402|Drug|AST-726 High dose|
79985218|NCT03481309|Device|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
79657753|NCT00285402|Drug|AST-726 Placebo|
79985219|NCT03481309|Device|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
79493990|NCT04568330|Other|10% urea-based cream|BSC plus 10% urea-based cream.
79493991|NCT04569890|Drug|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
79493992|NCT04569890|Drug|Hydroxychloroquine|400mg HCQ orally daily
79657754|NCT00248924|Behavioral|Social Services|
79657755|NCT00278616|Biological|Stem Cell Transplantation|Autologous Stem Cell Transplantation
79985220|NCT03185884|Other|Control|control carbohydrate blend
79342925|NCT02485691|Drug|prednisone|Pharmaceutical form: tablet Route of administration: oral
79342926|NCT02517515|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
79342927|NCT02517515|Drug|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
79342928|NCT02466659|Device|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
79342929|NCT01891864|Drug|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
79342930|NCT01891864|Drug|Enbrel|Enbrel is used as reference product to GP2015.
79342931|NCT02485301|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
79342932|NCT02485301|Drug|Placebo|A single dose administrated intramuscular
79493993|NCT04569890|Drug|Prednisone|10mg GC orally daily
79493994|NCT04569500|Other|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
79493995|NCT04485637|Other|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
79657756|NCT00278694|Drug|Oxaliplatin|
79657757|NCT00278694|Drug|Chemoradiation|
79657758|NCT00278694|Drug|5-FU|
79657759|NCT00278694|Radiation|Preoperative chemoradiation|
79657760|NCT00278694|Procedure|Pelvic surgery|
79657761|NCT00278694|Drug|Neoadjuvant oxaliplatin|
79657762|NCT00248963|Drug|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
79657763|NCT00278733|Behavioral|Brief intervention (physician advice)|
79657764|NCT04720508|Diagnostic Test|blood sample collection.|venipuncture procedure
79985221|NCT03185884|Other|Experimental|experimental carbohydrate blend
79985222|NCT03185494|Biological|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
79493996|NCT04485637|Other|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
79493997|NCT04485637|Other|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
79342933|NCT02484911|Drug|Olanzapine|5mg,twice a day orally on day 1 to day 4
79985223|NCT03480841|Behavioral|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
79342934|NCT02484911|Drug|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
79493998|NCT04569812|Procedure|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
79493999|NCT00423163|Drug|micafungin|
79494000|NCT00423163|Drug|voriconazole|
79494001|NCT04569656|Drug|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
79657765|NCT00249041|Drug|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
79985224|NCT02440828|Drug|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
79985225|NCT02440828|Drug|placebo|NaCl 0.9% inhalation 4 ml twice daily
79985226|NCT01311037|Other|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
79985227|NCT02431390|Device|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
79985228|NCT02431390|Behavioral|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
79342935|NCT02484911|Drug|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
79342936|NCT02484911|Drug|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
79342937|NCT04306367|Drug|Pembrolizumab|200 mg given intravenously.
79342938|NCT04306367|Drug|Olaparib|300 mg given orally.
79342939|NCT04925609|Drug|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
79342940|NCT02466425|Drug|SHP465|12.5mg and 25mg capsules (one capsule daily)
79342941|NCT02466425|Drug|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
79370729|NCT04362124|Biological|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
79494002|NCT04569578|Other|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~At least 10 minutes teacher-led active play per day~A minimum of 1 weekly outdoor excursion~Meet the children outdoors when they arrive at preschool and/or picked up by their parents~Only use screen tablets and computers for educational teaching purposes~Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
79494003|NCT04569188|Biological|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
79494004|NCT04568876|Dietary Supplement|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
79494005|NCT04568876|Combination Product|Standard Therapy|Standard therapy established for individual patients
79494006|NCT04375657|Combination Product|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
79494007|NCT04375657|Combination Product|Active Control|Metformin and DHEA
79494008|NCT02210468|Device|APIC-CF, 4 cc|
79494009|NCT02210468|Device|APIC-CF, 2 cc|
79494010|NCT02210468|Other|Placebo Comparator: Saline|Placebo Comparator: Saline
79494011|NCT04265287|Other|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
79494012|NCT02210546|Other|Magnetic Resonance Imaging (MRI)|
79342942|NCT04925453|Combination Product|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
79342943|NCT04925453|Combination Product|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
79494013|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|
79985229|NCT02440438|Biological|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
79494014|NCT02210624|Biological|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
79494015|NCT04569110|Other|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
79494016|NCT04567472|Behavioral|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
79494017|NCT04330573|Other|No intervention. Observational study|Observational study
79494018|NCT04567316|Drug|[14C]-radiolabelled BI 1358894|Part 1
79494019|NCT04567316|Drug|BI 1358894|Part 2
79494020|NCT04569422|Drug|Benoxyl|reduce pain
79494021|NCT04568720|Diagnostic Test|blood sample|Isolated the blood sample and detected the CTC
79494022|NCT02210702|Drug|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
79494023|NCT02210702|Drug|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
79494024|NCT04568096|Combination Product|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
79657766|NCT00249041|Drug|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
79657767|NCT00285519|Drug|Doxazosin (drug)|
79657768|NCT00278772|Drug|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
79657769|NCT00278772|Other|Placebo|oral dose, placebo
79657770|NCT00249119|Drug|risperidone|
79657771|NCT00278811|Procedure|mobile crisis team|
79657772|NCT00285558|Behavioral|CBT with peer-enhanced activities|
79657773|NCT00285558|Behavioral|CBT with supervised aerobic exercise|
79342944|NCT04616014|Drug|ORMD-0801 QD|8 mg, QD
79342945|NCT04616014|Drug|ORMD-0801 BD|8 mg, BD
79494025|NCT04568096|Other|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
79342946|NCT02451917|Drug|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
79494026|NCT04568018|Drug|Surfactant|Inhalation of surfactant emulsion at 150 mg
79494027|NCT04334317|Drug|TAK-071|TAK-071 tablet.
79494028|NCT04334317|Drug|Placebo|TAK-071 placebo-matching tablet.
79342947|NCT02451917|Drug|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
79494029|NCT02210390|Behavioral|Psycho education|Psycho-education Sessions will be offered weekly basis
79494030|NCT02278094|Device|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
79494031|NCT02278094|Device|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
79494032|NCT02278094|Procedure|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
79494033|NCT02278094|Device|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
79494034|NCT04985071|Procedure|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
79494035|NCT02278172|Dietary Supplement|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
79494036|NCT02278172|Dietary Supplement|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
79494037|NCT04983667|Dietary Supplement|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
79494038|NCT04971031|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
79342948|NCT02349451|Biological|adalimumab|
79342949|NCT02349451|Biological|ABT-122|
79342950|NCT04956731|Other|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
79342951|NCT04956263|Drug|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
79342952|NCT04956263|Drug|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
79342953|NCT02409368|Drug|Nivolumab|
79342954|NCT01853878|Biological|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
79494039|NCT04971031|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
79494040|NCT04566614|Other|ctDNA blood sampling|Screening/baseline blood sample to be analysed for ctDNA
79494041|NCT04970641|Behavioral|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
79494042|NCT04566224|Device|Macintosh size 2 blade|intubate with Macintosh size 2 blade
79494043|NCT04566224|Device|Macintosh size 3 blade|intubate with Macintosh size 3 blade
79342955|NCT01853878|Biological|Placebo|Intramuscular administration
79342956|NCT04891484|Drug|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
79342957|NCT04891484|Drug|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
79342958|NCT02342678|Behavioral|Yoga Therapy|
79494044|NCT04566458|Other|No intervention|retrospective chart review study
79494045|NCT02210858|Other|Laboratory Biomarker Analysis|Correlative studies
79494046|NCT02210858|Drug|Tipifarnib|Given PO
79494047|NCT04564586|Behavioral|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
79657774|NCT00414713|Procedure|red blood cell transfusion|red blood cell transfusion
79342959|NCT02342678|Behavioral|Physical Conditioning|
79342960|NCT02342288|Procedure|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
79494048|NCT04566146|Other|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
79494049|NCT04563104|Diagnostic Test|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
79494050|NCT04565912|Drug|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
79657775|NCT00278850|Behavioral|Educational|three 1 hour long educational seminars
79657776|NCT00414752|Drug|AFQ065|
79657777|NCT00285597|Drug|Ursodeoxycholic Acid|
79657778|NCT00249158|Drug|Risperidone|
79657779|NCT00278928|Drug|Liposyn III 20% (lipid infusion)|
79657780|NCT00278928|Drug|Intralipid 20% (lipid infusion)|
79342961|NCT02342288|Procedure|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
79494051|NCT04565912|Drug|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
79494052|NCT04281199|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
79494053|NCT04281199|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79657781|NCT00249197|Drug|levofloxacin|
79342962|NCT01853644|Drug|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
79342963|NCT01853254|Drug|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
79342964|NCT01853254|Drug|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing < 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
79342965|NCT02373098|Drug|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
79494054|NCT04281199|Radiation|Tomotherapy|Undergo IMRT with tomotherapy
79494055|NCT04281199|Radiation|Total-Body Irradiation|Undergo TBI
79494056|NCT04281199|Radiation|Volume Modulated Arc Therapy|Undergo IMRT with VMAT
79494057|NCT04565678|Drug|Mitapivat tablets|Oral tablets
79657782|NCT00278967|Drug|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
79657783|NCT00278967|Drug|HalfLytely - Reformulation|
79814251|NCT02602158|Dietary Supplement|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
79342966|NCT01853176|Drug|Liposomal Injection Bupivacaine (Exparel)|
79342967|NCT01853176|Drug|Standard bupivicaine|
79370730|NCT04362124|Other|Placebo|A single dose intradermal application of normal saline solution.
79494058|NCT04565678|Drug|Mitapivat coated granules|Oral coated granules
79494059|NCT04279483|Behavioral|7-11|Assigned to make a small (~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit
79494060|NCT04279483|Behavioral|CVS|Assigned to make a small (~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
79494061|NCT02210936|Other|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
79494062|NCT04564352|Dietary Supplement|Adansonia digitata|Juice of AD fruit
79494063|NCT04564430|Drug|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
79494064|NCT04564430|Other|Saline|controlgroup receiving saline
79494065|NCT04564118|Drug|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
79657784|NCT00249236|Drug|Risperidone, oral tablets|
79657785|NCT00249275|Device|spectacles|
79657786|NCT00279006|Procedure|Percutaneous coronary intervention|
79657787|NCT00285675|Drug|DN-101 (calcitriol) - Drug|
79657788|NCT02215096|Drug|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
79657789|NCT02215096|Drug|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
79342968|NCT02372396|Behavioral|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
79494066|NCT04274101|Other|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
79494067|NCT04274101|Diagnostic Test|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
79494068|NCT04274101|Diagnostic Test|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
79494069|NCT04274101|Behavioral|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
79494070|NCT04564040|Drug|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
79494071|NCT04564040|Drug|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
79494072|NCT04564040|Drug|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
79657790|NCT02961647|Procedure|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
79657791|NCT00279045|Drug|Rosiglitazone|
79657792|NCT00279045|Drug|glyburide|
79657793|NCT00279045|Drug|metformin|
79657794|NCT00249353|Drug|methylphenidate hydrochloride|
79657795|NCT02215408|Behavioral|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
79342969|NCT02372396|Behavioral|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
79494073|NCT04564040|Drug|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
79494074|NCT00005804|Drug|cyclophosphamide|
79342970|NCT01835548|Drug|NT0102|NT0102 (methylphenidate polistirex [MPP] extended release [XR] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
79342971|NCT01835548|Drug|Placebo|Matching ODT placebo was given once daily.
79342972|NCT01852942|Drug|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
79342973|NCT01852942|Drug|Placebo|one tablet by mouth daily
79342974|NCT01852162|Drug|Dabigatran|Dabigatran 150mg
79342975|NCT01852162|Drug|Placebo|Matching placebo tablets
79494075|NCT00005804|Procedure|allogeneic bone marrow transplantation|
79342976|NCT04596124|Device|fitostimoline plus|randomized controlled multicentric study
79494076|NCT00005804|Radiation|radiation therapy|
79494077|NCT04563962|Behavioral|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
79494078|NCT04563962|Behavioral|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
79494079|NCT04563650|Biological|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
79657796|NCT00249431|Drug|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
79657797|NCT00249431|Behavioral|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
79657798|NCT00285714|Procedure|3D stereophotogrammetric imaging|
79657799|NCT00285714|Procedure|3D CT-imaging with cone-beam CT|
79657800|NCT00285714|Procedure|Case report form|
79657801|NCT00249509|Drug|Nefazodone|
79657802|NCT00249509|Drug|Bupropion|
79657803|NCT00279084|Drug|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
79657804|NCT00279084|Drug|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
79657805|NCT00249548|Behavioral|Contingency management|
79657806|NCT00285753|Behavioral|support groups|cognitive behavioral intervention with psychoeducation
79657807|NCT00249587|Drug|Methadone|dosed to effect, every six hours
79657808|NCT00279123|Drug|pantoprazole infusion|
79657809|NCT00279123|Drug|pantoprazole bolus|
79657810|NCT00279123|Drug|no treatment|
79342977|NCT01835470|Drug|Abatacept|
79494080|NCT02211092|Behavioral|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
79494081|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
79494082|NCT04565444|Dietary Supplement|Ketone|"Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~Isocaloric carbohydrate control: dextrose + vanilla flavouring"
79494083|NCT04565444|Dietary Supplement|Ketone + Protein|"Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~10g Whey Protein~L-[ring-2H5]-phenylalanine tracer (enriched to 4%)"
79494084|NCT04565444|Dietary Supplement|Protein|"Isocaloric carbohydrate control: dextrose + stevia~10g Whey Protein~L-[ring-2H5]-phenylalanine tracer (enriched to 4%)"
79494085|NCT02211248|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
79494086|NCT02211248|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
79494087|NCT04565132|Device|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
79814252|NCT02602158|Dietary Supplement|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
79814253|NCT02603016|Drug|GLSE compound|
79342978|NCT02451137|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79342979|NCT02451137|Drug|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79342980|NCT02451137|Drug|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79342981|NCT02451137|Drug|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
79342982|NCT02372006|Drug|afatinib|
79342983|NCT02406248|Drug|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
79342984|NCT02450903|Drug|LDK378|Oral LDK378 750mg once daily
79342985|NCT02371616|Device|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
79342986|NCT02371616|Other|Sodium fluoride|1426 ppm fluoride as sodium fluoride
79342987|NCT02371616|Other|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
79342988|NCT02370914|Device|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
79342989|NCT02370914|Behavioral|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
79342990|NCT02370602|Drug|TAK-063|TAK-063 tablets
79494088|NCT04564664|Drug|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
79494089|NCT02211482|Drug|dolutegravir, lamivudine|single arm
79494090|NCT04562636|Other|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
79657811|NCT00249626|Behavioral|Contingency management|Rewards (prizes) for abstinence
79657812|NCT00279162|Drug|Calcipotriene/betamethasone gel and ointment|
79814254|NCT02603016|Drug|Maitake mushroom extract compound|
79814255|NCT02603016|Drug|Ginseng compound|
79814256|NCT04101942|Behavioral|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
79814257|NCT04106310|Device|High-flux dialyzer|a dialyzer meeting the definition of high-flux
79814258|NCT04106310|Device|Theranova dialyzer|a middle cut-off dialyzer
79814259|NCT04106076|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
79342991|NCT02370602|Drug|[^11C]T-773|[^11C]T-773 IV solution
79342992|NCT02370368|Device|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
79342993|NCT02370368|Other|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
79342994|NCT04897256|Behavioral|TURN-IT exercise program|Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
79494091|NCT04562636|Other|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
79814260|NCT00774306|Drug|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
79342995|NCT02340806|Device|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
79657813|NCT04720352|Device|Active treatment|Active treatment delivers radiofrequency and cryogen
79814261|NCT00774306|Drug|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
79814262|NCT00774306|Drug|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
79657814|NCT04720352|Device|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
79814263|NCT04105764|Drug|Rocuronium|DEEP block to PTC 1-3
79814264|NCT04105764|Drug|Rocuronium bromide|MODERATE block to TOF1-2
79985230|NCT02431546|Behavioral|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
79814265|NCT04105608|Dietary Supplement|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
79814266|NCT04105608|Dietary Supplement|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
79814267|NCT04105686|Other|Control Infant Formula|Ready to feed infant formula, feed ad libitum
79985231|NCT03191110|Other|No intervention: observational study|
79985232|NCT02431312|Biological|INO-1800|INO-1800 delivered by EP
79342996|NCT01835158|Drug|Cabozantinib S-malate|Given PO
79657815|NCT00285792|Behavioral|Physical Activity|
79657816|NCT00249704|Drug|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
79342997|NCT01835158|Other|Laboratory Biomarker Analysis|Correlative studies
79342998|NCT01835158|Drug|Sunitinib Malate|Given PO
79342999|NCT02337764|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
79343000|NCT04420442|Procedure|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
79657817|NCT00249704|Procedure|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
79657818|NCT00249704|Procedure|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
79657819|NCT00249704|Drug|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
79814268|NCT04105686|Other|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
79814269|NCT00781326|Drug|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
79985233|NCT02431312|Biological|INO-9112|INO-9112 delivered by EP
79985234|NCT02431312|Drug|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
79985235|NCT02431234|Other|serum RANKL|
79985236|NCT03191344|Behavioral|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
79343001|NCT01834222|Biological|Non-intervention|Non-intervention
79494092|NCT04562636|Other|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
79814270|NCT00781326|Drug|Placebo|Placebo will be given in doses matching those of nimodipine.
79814271|NCT02603094|Procedure|clear fluid ingestion|drinking of clear fluid in preoperative period
79814272|NCT00916266|Procedure|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
79494093|NCT04562168|Diagnostic Test|Autoderm® dermatology search engine (ML model) testing|GP using a smartphone camera will take an image of the skin problem and will use the Autoderm ML interface to upload the anonymized image. The obtained predicted diagnosis will be recorded in case report form.
79494094|NCT04929847|Other|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
79494095|NCT04561934|Drug|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
79343002|NCT01833832|Drug|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
79343003|NCT01833832|Procedure|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
79814273|NCT00787800|Device|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
79814274|NCT00787800|Device|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
79343004|NCT01833832|Drug|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
79343005|NCT01833520|Drug|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
79343006|NCT01850602|Drug|PA21|
79494096|NCT04561934|Other|resin modified glassionomer cement|resin modified glassionomer cement
79494097|NCT04562402|Procedure|Phacoemulsification|cataract surgery via phacoemulsification
79494098|NCT04562402|Procedure|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
79494099|NCT04330495|Drug|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
79343007|NCT01850602|Drug|Sevelamer hydrochloride|
79494100|NCT04330495|Drug|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
79494101|NCT04563260|Drug|Normal saline injection|Normal saline 2 mL, intravenous injection
79657820|NCT00249743|Device|FallSaver (formerly called NOCwatch)|
79814275|NCT00773838|Drug|Vorinostat|Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
79814276|NCT00773838|Drug|Bortezomib|Bortezomib 1.3 mg/m^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
79814277|NCT00773838|Drug|Dexamethasone|Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
79494102|NCT04563260|Drug|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
79343008|NCT01832818|Device|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
79343009|NCT02405780|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
79343010|NCT02405780|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
79343011|NCT02369510|Drug|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
79343012|NCT02369510|Drug|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
79343013|NCT02369510|Drug|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
79343014|NCT01650194|Drug|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
79343015|NCT01650194|Drug|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
79343016|NCT01650194|Drug|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
79494103|NCT02211170|Drug|BIBR 796 BS, low dose|
79494104|NCT02211170|Drug|BIBR 796 BS, high dose|
79494105|NCT02211170|Drug|Placebo|
79494106|NCT02211170|Drug|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
79814278|NCT00787644|Drug|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
79814279|NCT00787644|Drug|Placebo|Matching placebo (inert tablet)
79494107|NCT04180189|Other|Weighted fiber blanket|Using weighted blanket for four weeks
79494108|NCT02211560|Other|Phosphatidylserine|
79494109|NCT02211560|Other|Placebo|
79657821|NCT00249782|Drug|Vehicle control, 2x/day|
79657822|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 2x/day|
79657823|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day|
79657824|NCT00249782|Drug|MetroGel® (metronidazole gel), 1.0% 1x/day|
79657825|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
79657826|NCT00279240|Drug|Metformin|
79657827|NCT00249860|Drug|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
79814280|NCT02602002|Drug|Remifentanil|IV
79814281|NCT02602002|Drug|Placebo|Placebo
79814282|NCT00787566|Drug|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
79985237|NCT02431156|Other|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
79343017|NCT02367716|Device|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
79343018|NCT02366936|Device|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
79343019|NCT05369936|Other|Aromatherapy|Lavender will be inhaled through three phases
79343020|NCT05369936|Other|Placebo|Vapors of the distal water will be inhaled through three phases
79494110|NCT04173793|Drug|AK102|Administered by subcutaneous injection
79343021|NCT01648166|Other|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
79494111|NCT04173793|Drug|Placebo|Administered by subcutaneous injection
79494112|NCT04173793|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
79814283|NCT04103112|Device|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
79343022|NCT02404220|Drug|Entospletinib|
79343023|NCT02404220|Drug|Vincristine|
79343024|NCT02404220|Drug|Dexamethasone|
79343025|NCT02404220|Drug|CNS Prophylaxis|
79343026|NCT02335658|Drug|DSP-5423P|40-80mg/day
79494113|NCT04173637|Biological|AK101|an anti-IL-12/23p40 monoclonal antibody
79494114|NCT04173637|Biological|Placebo|matching placebo
79814284|NCT04101552|Procedure|socket shield technique with xenophobic graft particulate and without the use of graft|the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
79494115|NCT04561856|Drug|Dexamethasone|Intravenous 4mg
79985238|NCT02709538|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
79985239|NCT02709538|Drug|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
79343027|NCT02366468|Drug|ranibizumab 0.5 mg|intravitreal injection
79343028|NCT02366312|Drug|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
79343029|NCT05370560|Other|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
79343030|NCT02335346|Drug|Duloxetine|Administered orally
79494116|NCT04561856|Drug|Dexamethasone|Perineural 4mg
79494117|NCT04561856|Drug|Placebo|Normal Saline 2ml
79494118|NCT02211716|Device|BeGraft Peripheral Stent Graft System|
79494119|NCT04912687|Diagnostic Test|EGFR gene mutation analysis on liquid biopsy|Blood samples will be collected at inclusion for plasma DNA collection and analysis.
79494120|NCT00382681|Device|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
79985240|NCT02709538|Drug|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
79985241|NCT03789318|Drug|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
79985242|NCT03789318|Drug|Placebo|Each cohort will use placebo reconstituted in saline.
79343031|NCT04908020|Other|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
79343032|NCT02403206|Device|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
79343033|NCT02403206|Procedure|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
79494121|NCT00382681|Device|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
79494122|NCT04173403|Drug|450mg AK102|AK102 Q4W
79494123|NCT04173403|Drug|300mg AK102|AK102 Q4W
79494124|NCT04173403|Drug|150mg AK102|AK102 Q2W
79494125|NCT04173403|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
79494126|NCT03541369|Drug|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
79657828|NCT00249860|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
79657829|NCT00249860|Drug|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
79814285|NCT04017234|Other|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
79985243|NCT03789318|Drug|Bupivacaine Hydrochloride|0.25% administered pre-surgery
79343034|NCT02333630|Other|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
79343035|NCT02333630|Other|Asthma education|A website with links to written asthma education and videos
79343036|NCT02401412|Device|Test Ostomy Barrier|
79343037|NCT02401412|Device|Control Ostomy Barrier|
79343038|NCT02365298|Device|etafilcon A|etafilcon A soft contact lens
79343039|NCT02365298|Device|nelfilcon A|nelfilcon A
79343040|NCT02365064|Device|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
79814286|NCT02602938|Drug|Aspirin|Take aspirin (100mg) orally once a day for 2 months
79343041|NCT02401256|Drug|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
79343042|NCT02401256|Drug|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
79814287|NCT00787254|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
79814288|NCT00787254|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
79814289|NCT00625846|Other|Laboratory Biomarker Analysis|Correlative studies
79814290|NCT00625846|Drug|Pazopanib Hydrochloride|Given PO
79343043|NCT02401256|Drug|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
79985244|NCT03789318|Drug|Hydromorphone|0.02 mg/kg IV administered intraoperatively
79370731|NCT04361968|Other|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
79985245|NCT03789318|Drug|Fentanyl|100 mcg IV administered intraoperatively
79657830|NCT00249899|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
79657831|NCT00249899|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
79657832|NCT00249938|Drug|Minute Maid Heart Wise orange juice|
79657833|NCT00249938|Drug|Welchol|
79657834|NCT00279279|Device|Implanted Device|
79814291|NCT00824902|Procedure|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
79814292|NCT00922402|Procedure|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
79814293|NCT04101786|Other|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
79814294|NCT00824980|Drug|IP10.C8|IP10.C8 Gel 1%
79814295|NCT04105374|Drug|Extended Release Flucytosine|Given PO
79814296|NCT04105374|Device|NovoTTF-100A Device|Receive Optune device
79985246|NCT03789318|Drug|Acetaminophen|1000 mg IV administered intraoperatively
79343044|NCT02401256|Drug|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
79494127|NCT03539887|Drug|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
79494128|NCT03539887|Drug|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
79494129|NCT04123717|Drug|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
79657835|NCT00249977|Drug|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
79814297|NCT04105374|Other|Quality-of-Life Assessment|Ancillary studies
79343045|NCT02349295|Drug|Placebo|Administered SC
79494130|NCT03472495|Drug|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is <60 kg)
79814298|NCT04105374|Other|Questionnaire Administration|Ancillary studies
79343046|NCT02349295|Drug|Ixekizumab 80 mg Q4W|Administered SC
79343047|NCT02349295|Drug|Ixekizumab 80 mg Q2W|Administered SC
79343048|NCT04877587|Drug|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~2 60 g/m2 IV Days (1,2,8,9,15,16)~1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~1 30 g/m2 IV Days (1,2,8,9,15,16)"
79343049|NCT04877587|Drug|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
79494131|NCT03472495|Drug|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
79494132|NCT04094701|Other|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
79494133|NCT04094701|Other|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
79657836|NCT00285909|Behavioral|Alcohol: 25 gday (white wine)|
79657837|NCT00285948|Device|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
79343050|NCT02281357|Biological|Tralokinumab|Tralokinumab dose
79657838|NCT00279357|Procedure|Narrow Band Imaging|
79814299|NCT04105374|Radiation|Radiation Therapy|Undergo radiation
79343051|NCT02281357|Other|Placebo|Placebo dose
79343052|NCT02284243|Drug|Intranasal Dexmedetomidine|
79343053|NCT02284243|Drug|Intranasal Placebo|
79814300|NCT04105374|Drug|Temozolomide|Given PO
79814301|NCT04105374|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
79814302|NCT04105374|Biological|Vocimagene Amiretrorepvec|Given via intracranial injection
79370732|NCT04361968|Other|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
79814303|NCT04102722|Device|MUST device|Imaging with MUST device
79985247|NCT03789318|Drug|Oxycodone|5-10 mg PO administered post-surgery
79985248|NCT03789318|Drug|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
79343054|NCT02284009|Biological|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
79343055|NCT02284009|Biological|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
79657839|NCT00250094|Drug|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is >1,500 and platelets > 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
79657840|NCT00285987|Procedure|Reconstruction of the cruciate ligament|
79657841|NCT00250133|Procedure|Blood draws|
79657842|NCT00279435|Drug|visilizumab|
79814304|NCT02601846|Other|No intervention|This is an observational study, without any specific intervention.
79814305|NCT04102878|Drug|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
79814306|NCT04102878|Procedure|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
79814307|NCT04102878|Procedure|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
79343056|NCT02284009|Biological|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
79343057|NCT02280499|Device|standard PROMOS prosthesis|
79814308|NCT04102878|Other|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
79814309|NCT04102878|Other|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
79814310|NCT04102878|Procedure|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
79985249|NCT03789318|Drug|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
79343058|NCT02400476|Drug|Neratinib|
79343059|NCT02400476|Drug|Loperamide|
79343060|NCT02400476|Drug|Colestipol|2 g twice daily with or without food for one 28 day cycle
79343061|NCT02400476|Drug|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
79343062|NCT02363738|Drug|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
79657843|NCT00286026|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
79657844|NCT00250172|Drug|[C-11](R)-rolipram|
79657845|NCT00279474|Behavioral|cognitive-behavior groups|
79657846|NCT00286065|Drug|AeroLEF|
79657847|NCT00250211|Procedure|Functional MRI imaging and tomotherapy|
79657848|NCT00279513|Drug|Traumeel S|
79657849|NCT00250250|Drug|ZOMACTON|
79657850|NCT00279552|Drug|Recombinant human intrinsic factor|
79657851|NCT02961608|Drug|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
79814311|NCT00825136|Behavioral|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
79814312|NCT00825136|Behavioral|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
79814313|NCT00838084|Drug|LY2811376|Oral capsules
79814314|NCT00838084|Drug|Placebo|Oral capsules
79814315|NCT00838240|Drug|clofarabine|Given IV
79814316|NCT00838240|Drug|cytarabine|Given IV
79814317|NCT00838240|Drug|idarubicin|Given IV
79814318|NCT00773292|Drug|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
79814319|NCT00838318|Behavioral|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
79814320|NCT00786864|Other|exercise programme|Specific low back pain exercise programme for children
79814321|NCT00838396|Drug|XP19986 CR|
79814322|NCT00838396|Drug|Placebo for XP19986 CR|
79657852|NCT00286104|Device|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
79657853|NCT00286104|Device|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
79343063|NCT02363738|Other|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
79494134|NCT04092829|Procedure|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
79494135|NCT03459469|Drug|Tegavivint|This is an Investigational drug
79657854|NCT00250289|Device|a mucosal sticker with herbal formula|
79657855|NCT00286143|Drug|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
79985250|NCT02431078|Procedure|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
79343064|NCT04894526|Other|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
79814323|NCT00838474|Other|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
79814324|NCT00838708|Drug|SRD174 Cream|topical SRD174 Cream
79343065|NCT04894526|Other|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
79343066|NCT02331680|Drug|OPC-41061|
79343067|NCT02331680|Drug|OPC-41061|
79343068|NCT02331680|Drug|Placebo|
79343069|NCT02331446|Behavioral|Physical exercise intervention|
79343070|NCT02349061|Drug|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
79343071|NCT02349061|Drug|Placebo Infusion|Placebo intravenously at Week 0.
79343072|NCT02349061|Drug|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
79343073|NCT02349061|Drug|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
79343074|NCT02349061|Other|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
79343075|NCT02331368|Procedure|Autologous Stem Cell Transplant|
79343076|NCT02331368|Drug|Melphalan|140-200 mg/m^2
79343077|NCT02331368|Drug|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
79343078|NCT02331368|Drug|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
79343079|NCT02362724|Device|Sapphire|silicone hydrogel contact lens
79343080|NCT02362724|Device|Pearl|silicone hydrogel contact lens
79494136|NCT03428659|Other|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
79814325|NCT00838708|Other|vehicle cream|topical vehicle cream
79814326|NCT00833014|Device|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
79814327|NCT00838864|Drug|ceftrioxone|500 mg iv q12h for 3 days
79814328|NCT00838864|Drug|ceftrioxone|500 mg q12h for 7 days
79814329|NCT00838942|Behavioral|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
79985251|NCT02435602|Procedure|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
79343081|NCT02362646|Biological|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
79985252|NCT02435602|Procedure|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
79343082|NCT02362646|Drug|Control Solution|
79657856|NCT00250328|Device|LapCAC Laparoscopic Compression Anastomosis Clip|
79657857|NCT00286260|Drug|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
79657858|NCT00250367|Drug|risperidone|
79985253|NCT03773952|Drug|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
79985254|NCT03773952|Drug|Placebo oral capsule|Oral capsules
79343083|NCT04907162|Diagnostic Test|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
79985255|NCT02431000|Procedure|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
79657859|NCT00279630|Procedure|Orthoses and Exercise|orthrose and exercise - daily
79657860|NCT00250406|Device|Ureteral Stent|triclosan-eluting ureteral stent
79985256|NCT03191188|Drug|Levothyroxine Sodium|Thyroid hormone supplement
79985257|NCT03191188|Drug|Placebo Oral Tablet|Placebo
79985258|NCT02435446|Device|Cone-beam computed tomography|Cone-beam computed tomography
79985259|NCT03613662|Drug|SP-102|Injection
79985260|NCT02435368|Drug|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
79985261|NCT01698294|Other|Clinical Observation|Participants maintain usual diet and undergo clinical observation
79985262|NCT01698294|Dietary Supplement|Flaxseed|Given PO
79343084|NCT04907162|Diagnostic Test|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
79985263|NCT01698294|Other|Laboratory Biomarker Analysis|Correlative studies
79985264|NCT01698294|Other|Questionnaire Administration|Ancillary studies
79343085|NCT04907162|Diagnostic Test|Brief Pain Inventory|Validated questionnaire for pain.
79343086|NCT04907162|Diagnostic Test|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
79343087|NCT04907162|Diagnostic Test|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
79985265|NCT03191032|Other|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
79343088|NCT04907162|Diagnostic Test|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
79343089|NCT04907162|Diagnostic Test|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
79657861|NCT00250406|Device|Ureteral Stent|Percuflex Plus Stent as the control
79657862|NCT02960841|Other|Intracavitary Manual Lymphatic Drainage|
79657863|NCT02960841|Other|Conventional treatment|
79657864|NCT04720235|Device|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
79657865|NCT00279669|Procedure|Ultrasound examination|contact ultrasound examination
79657866|NCT02960724|Other|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
79985266|NCT03190876|Procedure|Variable drain usage|Influence of drain usage on seroma formation rate
79985267|NCT05160090|Drug|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
79985268|NCT03190720|Device|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
79985269|NCT03538002|Device|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
79985270|NCT03692702|Behavioral|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
79657867|NCT00250562|Drug|valsartan plus hydrochlorothiazide|
79657868|NCT00286299|Other|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
79657869|NCT00286299|Other|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
79657870|NCT00286299|Other|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
79657871|NCT02960880|Drug|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
79985271|NCT03117946|Other|Biological samples|blood and tumor tissue sample
79985272|NCT04516616|Drug|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
79343090|NCT04907162|Diagnostic Test|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
79657872|NCT02960880|Drug|Phenprocoumon (branded and generics)|Individually adjusted dose
79343091|NCT04907162|Diagnostic Test|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
79657873|NCT00279747|Drug|meloxicam 0.25 mg/kg|
79343092|NCT04907162|Diagnostic Test|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
79494137|NCT04067089|Procedure|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
79494138|NCT04067089|Procedure|Surgical aortic valve replacement|Surgical aortic valve replacement
79657874|NCT00279747|Drug|meloxicam 0.125 mg/kg|
79657875|NCT00279747|Drug|naproxen 10 mg/kg|
79657876|NCT00250601|Drug|Saredutant succinate (SR48968C)|
79657877|NCT00286377|Drug|prosaptide|
79657878|NCT02961686|Radiation|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
79657879|NCT00250640|Drug|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
79985273|NCT00511134|Drug|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
79985274|NCT00511134|Drug|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
79985275|NCT02435056|Other|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~Minimum Data Set for supporting the diagnosis~Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~Second opinion system for improving the management"
79985276|NCT02435134|Other|no intervention|
79985277|NCT03634722|Device|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
79985278|NCT03118024|Drug|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
79985279|NCT03118024|Drug|Catecholamines|catecholamine restrictive anesthesia protocol
79985280|NCT03117868|Other|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
79985281|NCT03634644|Drug|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
79343093|NCT04907162|Diagnostic Test|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
79343094|NCT02280421|Drug|ASP2151 400mg + 100mg ciclosporin|
79343095|NCT02280421|Drug|ASP2151 1200mg + 100mg ciclosporin|
79343096|NCT04906382|Procedure|Biopsy|Undergo biopsy
79343097|NCT04906382|Drug|Carboplatin|Given IV
79343098|NCT04906382|Drug|Paclitaxel|Given IV
79343099|NCT04906382|Biological|Tislelizumab|Given IV
79343100|NCT04892719|Diagnostic Test|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
79343101|NCT02362412|Drug|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
79657880|NCT00250796|Drug|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
79657881|NCT00250796|Drug|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
79657882|NCT00286416|Drug|omalizumab (Xolair)|
79814330|NCT03855748|Other|Healthy group|"Subjects undergo the following activities:~Walking~Jogging (8-11 km/h)~Maximal 5 meters sprint acceleration~Single leg drop jump from 35 cm height~Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~Maximal change of direction at 45, 135, 180 degrees~Single-leg cross-country skiing exercise"
79657883|NCT00250874|Drug|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
79657884|NCT00279825|Drug|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
79657885|NCT00279825|Drug|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
79657886|NCT00279825|Drug|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
79657887|NCT00279825|Drug|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
79657888|NCT00279825|Drug|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
79657889|NCT00279825|Drug|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
79985282|NCT03634644|Drug|Placebo oral capsule|mainly composed of corn oil
79343102|NCT02280187|Procedure|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
79343103|NCT02347813|Drug|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
79657890|NCT00279825|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
79657891|NCT00279825|Drug|CD-LD CR Placebo|Placebo to match CD-LD CR
79657892|NCT00250913|Behavioral|Telephone-based physical activity counseling program|
79657893|NCT00250952|Drug|Botox Cosmetic™|
79657894|NCT00250991|Drug|activase|
79657895|NCT00250991|Drug|integrilin|
79985283|NCT05103228|Drug|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
79343104|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
79343105|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
79985284|NCT05103228|Drug|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
79343106|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
79343107|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
79343108|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
79343109|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
79343110|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
79343111|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
79343112|NCT02328326|Other|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
79343113|NCT02328326|Other|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
79343114|NCT01649804|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
79343115|NCT02397278|Drug|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
79343116|NCT02360228|Device|tACS (alpha)|
79494139|NCT03351361|Drug|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
79657896|NCT00416754|Other|counseling intervention|subjects will receive genetic counseling
79657897|NCT00286611|Procedure|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
79657898|NCT04719962|Procedure|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
79657899|NCT00416832|Drug|cyclophosphamide|
79657900|NCT00416832|Drug|dacarbazine|
79985285|NCT05103228|Drug|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
79985286|NCT01372384|Drug|erlotinib [Tarceva]|150 mg orally daily
79657901|NCT00416832|Drug|doxorubicin hydrochloride|
79985287|NCT03185416|Other|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
79814331|NCT00825214|Device|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
79343117|NCT02360228|Device|tDCS|
79343118|NCT02359994|Device|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
79343119|NCT02359994|Device|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
79657902|NCT00416832|Drug|etoposide|
79343120|NCT02326298|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
79657903|NCT00416832|Drug|prednisone|
79657904|NCT00416832|Drug|procarbazine hydrochloride|
79657905|NCT00416832|Drug|vincristine sulfate|
79657906|NCT00416832|Radiation|radiation therapy|
79343121|NCT02326298|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
79343122|NCT02396420|Device|Embosphere Microspheres|
79343123|NCT02279719|Drug|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
79657907|NCT00251030|Drug|Nelfinavir and Omeprazole|
79657908|NCT00286650|Procedure|3rd molar teeth extraction|
79657909|NCT00251069|Drug|Glucosamine sulphate|
79657910|NCT00286689|Drug|Growth Hormone|
79814332|NCT00825214|Device|Inactivated zapperclick device|placebo
79814333|NCT00839020|Procedure|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
79814334|NCT00839020|Procedure|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
79494140|NCT03351361|Drug|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
79657911|NCT00286689|Procedure|Whole body Protein turnover|
79657912|NCT00286689|Procedure|DEXA scan|
79985288|NCT03190798|Drug|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
79657913|NCT02961491|Drug|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
79343124|NCT02279719|Drug|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
79343125|NCT02279719|Drug|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
79343126|NCT02279407|Drug|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
79343127|NCT02279407|Drug|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
79343128|NCT02279407|Drug|Dapagliflozin|10 mg administered as 10 mg tablet
79343129|NCT02279407|Drug|Placebo|Placebo matching to dapagliflozin 10 mg
79494141|NCT04056715|Device|Zio XT|ambulatory cardiac monitoring device
79985289|NCT03190798|Drug|Placebo|Placebo for Canagliflozin
79985290|NCT03117478|Other|Magneto-encephalography (MEG)|Magneto-encephalography
79343130|NCT02326220|Drug|Placebo|
79343131|NCT02326220|Drug|Alirocumab|
79343132|NCT02279173|Drug|Romiplostim|Romiplostim subcutaneous weekly injection
79343133|NCT02282917|Drug|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
79657914|NCT01640002|Drug|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
79657915|NCT01640002|Drug|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
79657916|NCT01640041|Device|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
79814335|NCT00833326|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
79814336|NCT00833326|Drug|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
79985291|NCT03117478|Other|Electro-encephalography (EEG)|Electro-encephalography
79985292|NCT03117478|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
79494142|NCT04863781|Behavioral|Mobile cognitive-behavioral stress management intervention|Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
79494143|NCT04863781|Behavioral|Control|The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
79494144|NCT03234907|Drug|Vedolizumab IV|Vedolizumab IV infusion
79494145|NCT03234907|Drug|Placebo|Vedolizumab placebo-matching
79657917|NCT00279903|Drug|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
79343134|NCT02358668|Drug|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
79343135|NCT02358668|Drug|BTI320 matching placebo|Placebo
79343136|NCT02282605|Drug|XF-73 nasal gel|
79343137|NCT02282605|Drug|Placebo nasal gel|
79343138|NCT02282605|Other|Chlorhexidine gluconate 2% topical cloths|
79343139|NCT02282527|Biological|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
79343140|NCT02282527|Biological|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
79494146|NCT04000243|Diagnostic Test|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
79494147|NCT04844983|Drug|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
79494148|NCT04844983|Other|Placebo Saline|Normal Saline
79494149|NCT04330027|Biological|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
79494150|NCT04330027|Other|Saline|0.9% Sodium Chloride
79494151|NCT00002893|Drug|fluorouracil|
79494152|NCT00002893|Drug|leucovorin calcium|
79494153|NCT00002893|Drug|raltitrexed|
79657918|NCT00279903|Drug|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
79657919|NCT02961452|Other|Cross reaction detection|
79657920|NCT01640275|Drug|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
79657921|NCT01640275|Drug|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
79657922|NCT01640392|Behavioral|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
79814337|NCT00833326|Drug|Prophylactic growth factors; subcutaneous|standard of care
79814338|NCT00839176|Drug|RX-10100|Extended-release tablet, 5~15mg, twice day (morning & evening) at least 30 min before meal, 8 weeks
79657923|NCT01640470|Device|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
79657924|NCT01640470|Device|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
79814339|NCT00825292|Procedure|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
79814340|NCT00825292|Procedure|colon polyp removal|identify and remove polyp
79985293|NCT03117478|Other|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
79985294|NCT03117478|Other|Meditation|Meditation
79985295|NCT03115476|Drug|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
79343141|NCT05650099|Device|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
79343142|NCT02278939|Behavioral|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
79343143|NCT02278471|Drug|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
79343144|NCT05565235|Drug|patients will receive intraoperative serratus block with bupivacaine|no additives
79343145|NCT05565235|Drug|serratus block with bupivacaine /magnesium|magnesium added
79343146|NCT05565235|Drug|serratus block with bupivacaine with nalbuphine|nalbuphine added
79343147|NCT04420039|Device|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
79343148|NCT02278003|Other|memory test|
79343149|NCT02278003|Drug|Propofol|
79343150|NCT02277769|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
79343151|NCT02277769|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
79985296|NCT03115476|Drug|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
79985297|NCT03115476|Other|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
79657925|NCT01640509|Radiation|treated by synchrotron radiation|treated by synchrotron radiation
79657926|NCT04719923|Behavioral|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
79657927|NCT04529356|Device|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
79814341|NCT00825292|Procedure|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
79814342|NCT00833404|Drug|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
79814343|NCT00833716|Drug|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
79814344|NCT02549794|Procedure|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
79494154|NCT03053245|Behavioral|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
79494155|NCT03053245|Behavioral|Attention Control|Patients in this group will receive regular wellness calls from the research team.
79494156|NCT00002899|Procedure|adjuvant therapy|
79494157|NCT00002899|Radiation|radiation therapy|
79494158|NCT00002899|Radiation|stereotactic radiosurgery|
79494159|NCT00383227|Biological|Hepatitis B adjuvanted vaccine|
79657928|NCT04529356|Drug|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
79657929|NCT04529083|Device|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
79343152|NCT01641991|Biological|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
79343153|NCT01641991|Biological|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
79657930|NCT01640626|Other|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
79657931|NCT00279942|Dietary Supplement|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
79343154|NCT05649709|Drug|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
79657932|NCT00279942|Other|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
79343155|NCT05649709|Drug|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
79343156|NCT05649631|Dietary Supplement|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
79343157|NCT02277691|Drug|TAK-536TCH tablet|TAK-536TCH tablets
79343158|NCT02277691|Drug|TAK-536CCB tablet|TAK-536CCB tablets
79343159|NCT02277691|Drug|HCTZ 12.5 mg tablet|HCTZ tablets
79343160|NCT02395172|Drug|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
79494160|NCT02775331|Other|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
79494161|NCT02775331|Other|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
79657933|NCT01640665|Drug|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
79657934|NCT01640665|Drug|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
79343161|NCT02395172|Drug|Docetaxel|Participants received 75 mg per square meter (m^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
79343162|NCT04876027|Drug|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
79343163|NCT04876027|Other|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
79343164|NCT04859101|Other|Gum|2 minutes of gum chewing prior to procedure
79657935|NCT00251108|Procedure|Cardiorespiratory fitness training|
79343165|NCT04859101|Other|Control|2 swallows prior to procedure
79657936|NCT01640704|Behavioral|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
79657937|NCT01640782|Drug|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
79343166|NCT02275819|Other|Exercise|Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
79343167|NCT02358044|Drug|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
79343168|NCT02358044|Biological|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
79657938|NCT01640782|Drug|Leucovorin, 5-Fluorouracil|"Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
79657939|NCT00279981|Device|Diagnostic|
79343169|NCT02358044|Drug|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
79494162|NCT03841981|Diagnostic Test|Anthropometric and physical examination|"Weight and height.~Waist-to-hip ratio.~Body composition: Bioelectrical impedance and [Dual energy X-ray absorptiometry (DEXA)]."
79494163|NCT03841981|Diagnostic Test|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
79657940|NCT00251147|Procedure|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
79343170|NCT02358044|Drug|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
79343171|NCT02275117|Biological|ALD403|
79814345|NCT02549794|Procedure|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
79814346|NCT02549794|Procedure|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
79814347|NCT00825448|Procedure|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
79343172|NCT02275117|Biological|Placebo|
79494164|NCT03841981|Diagnostic Test|Biochemical, hormonal and metabolic phenotyping|"Lipid profile.~Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~Sex steroid profile.~Hypothalamic-pituitary-adrenal axis study.~Ferrokinetic study.~Subclinical chronic inflammatory markers."
79494165|NCT03841981|Diagnostic Test|Sonographic studies|"Polycystic ovarian morphology.~Carotid intima-media thickness.~Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
79494166|NCT03841981|Diagnostic Test|24-hour Ambulatory blood pressure monitoring|A&D TM2430EX oscillometric devices (A&D Company Limited, Tokyo, Japan).
79343173|NCT04869553|Other|Management pain with distraction methods ABC|"Every patient will receive :~The usual pain management of their ward (Treatment A),~The usual pain management of their ward with a hypnosis session (Treatment B)~The usual pain management of their ward with a virtual reality session (Treatment C)"
79494167|NCT03841981|Procedure|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
79343174|NCT04869553|Other|Management pain with distraction methods BCA|"Every patient will receive :~The usual pain management of their ward with a hypnosis session (Treatment B)~The usual pain management of their ward with a virtual reality session (Treatment C)~The usual pain management of their ward (Treatment A)"
79343175|NCT04869553|Other|Management pain with distraction methods CAB|"Every patient will receive :~The usual pain management of their ward with a virtual reality session (Treatment C)~The usual pain management of their ward (Treatment A)~The usual pain management of their ward with a hypnosis session (Treatment B)"
79343176|NCT05649319|Procedure|ERAS protocol|The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
79494168|NCT03841981|Diagnostic Test|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
79494169|NCT03841981|Diagnostic Test|Oral smear and feces specimen|Microbiome studies.
79494170|NCT03818581|Drug|Suvorexant|10-mg or 20-mg Suvorexant capsules
79494171|NCT03818581|Other|Placebo|Matching placebo capsules
79657941|NCT00251147|Procedure|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
79343177|NCT05649241|Drug|Nicotine patch|Nicotine replacement therapy patch
79343178|NCT05649241|Drug|Nicotine gum|Nicotine replacement therapy gum
79494172|NCT03793855|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
79494173|NCT03793855|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
79814348|NCT00621322|Biological|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
79814349|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
79343179|NCT05649241|Behavioral|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
79343180|NCT05649007|Device|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
79343181|NCT02274493|Device|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
79343182|NCT02274493|Procedure|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
79343183|NCT02274493|Procedure|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
79343184|NCT02274493|Behavioral|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
79343185|NCT02273167|Drug|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
79343186|NCT02273167|Drug|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
79494174|NCT00002905|Drug|cyclophosphamide|
79494175|NCT00002905|Drug|didanosine|
79494176|NCT00002905|Drug|doxorubicin hydrochloride|
79494177|NCT00002905|Drug|etoposide|
79494178|NCT00002905|Drug|mitoxantrone hydrochloride|
79494179|NCT00002905|Drug|prednimustine|
79494180|NCT00002905|Drug|zidovudine|
79494181|NCT00002911|Drug|marimastat|
79343187|NCT02273167|Drug|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
79343188|NCT02272777|Drug|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
79343189|NCT02272777|Drug|Nilotinib|Nilotinib 300mg BID or 400mg QD
79494182|NCT00002917|Drug|paclitaxel|
79494183|NCT00383695|Biological|cetuximab|
79494184|NCT00383695|Drug|capecitabine|
79494185|NCT00383695|Drug|oxaliplatin|
79494186|NCT00383695|Procedure|adjuvant therapy|
79494187|NCT00383695|Procedure|conventional surgery|
79657942|NCT01640821|Behavioral|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
79814350|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
79343190|NCT05648929|Other|Patient Satisfaction Questionnaire|During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders
79343191|NCT05648929|Diagnostic Test|Pregnancy test|Pre-op; to sufficiently check pregnancy as exclusion criteria
79343192|NCT05648929|Procedure|Blood draw|pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed
79343193|NCT05648929|Procedure|Expander based breast reconstruction|implantation of 2 different expanders intraindividually
79494188|NCT00383695|Procedure|neoadjuvant therapy|
79494189|NCT00383695|Radiation|radiation therapy|
79494190|NCT00383773|Procedure|Retinal endo vascular surgery|
79494191|NCT00383851|Drug|ATN-224|
79494192|NCT00383851|Drug|Temozolomide|
79494193|NCT00002923|Drug|KRN5500|
79494194|NCT03779581|Other|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
79494195|NCT03779581|Device|orthotic devices|the orthotic devices designed to correct the scoliosis curve
79494196|NCT03766321|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
79494197|NCT03766321|Biological|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
79494198|NCT02636569|Drug|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
79814351|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
79814352|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
79343194|NCT05648929|Procedure|Ultrasound of breast|Measurement of capsular thickness pre- expander removal
79494199|NCT02636569|Drug|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
79814353|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
79985298|NCT03117556|Procedure|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
79343195|NCT05648929|Other|S(AE )monitoring|(S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
79343196|NCT02357810|Drug|Pazopanib Hydrochloride|Given PO
79814354|NCT00833872|Drug|LEO 22811|First-in-man
79814355|NCT00833872|Drug|placebo solution|
79814356|NCT00839488|Drug|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
79343197|NCT02357810|Drug|Oral Topotecan Hydrochloride|Given PO
79343198|NCT02357810|Other|Laboratory Biomarker Analysis|Correlative studies
79343199|NCT04858243|Other|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
79494200|NCT03736447|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
79494201|NCT03736447|Biological|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
79657943|NCT01640977|Procedure|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
79657944|NCT01640977|Procedure|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
79343200|NCT04858243|Other|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
79657945|NCT00251186|Drug|Capecitabine and Cetuximab|
79657946|NCT01641172|Procedure|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
79657947|NCT01641172|Procedure|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
79657948|NCT01641172|Procedure|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
79657949|NCT01641172|Procedure|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
79814357|NCT00839488|Drug|famotidine 20 mg iv|famotidine 20 mg q12h
79814358|NCT00839566|Procedure|Ablation|AV-node ablation
79814359|NCT00839566|Other|Rate Control|Rate control by drug
79343201|NCT02357576|Drug|Intralipid 20% I.V. Fat Emulsion|
79343202|NCT01850446|Drug|Ergoferon|Safety and Efficacy
79343203|NCT01850446|Drug|Oseltamivir|Safety and Efficacy
79343204|NCT02465567|Drug|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
79343205|NCT02465567|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
79343206|NCT02465567|Drug|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
79494202|NCT03723655|Drug|mavacamten|mavacamten capsules
79494203|NCT00002935|Drug|porfimer sodium|
79494204|NCT00002941|Drug|carmustine|
79494205|NCT00002941|Drug|cyclophosphamide|
79494206|NCT00002941|Drug|etoposide|
79494207|NCT00002941|Drug|mesna|
79494208|NCT00002941|Procedure|peripheral blood stem cell transplantation|
79814360|NCT00833950|Device|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
79343207|NCT02465567|Drug|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
79343208|NCT01644175|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
79343209|NCT01644175|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
79343210|NCT01644175|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
79343211|NCT02357420|Drug|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
79343212|NCT02357420|Drug|Placebo|Placebo given subcutaneously for 12 weeks.
79343213|NCT05648461|Radiation|Five fraction of post operative radiotherapy|Target volume will include tumor bed & ipsilateral level I-III levels.
79343214|NCT04856761|Drug|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
79343215|NCT04856761|Drug|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
79343216|NCT01832038|Drug|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 [NCT01710657], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
79494209|NCT04329793|Device|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
79343217|NCT05648383|Behavioral|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
79494210|NCT04329793|Other|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
79494211|NCT00383305|Device|Cool-Cap|
79343218|NCT05648383|Behavioral|Standard care|Participants will receive standard care, including lifestyle recommendations.
79343219|NCT05369689|Other|No interventions|As this is a prognosis evaluation study, there are no interventions.
79343220|NCT01849588|Drug|Sorafenib|
79343221|NCT05648305|Procedure|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
79343222|NCT02357342|Drug|Sirolimus|intravitreal injection
79343223|NCT02357342|Drug|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
79494212|NCT04329637|Other|Integrative healt care|Meditation and use of a care cordinator
79494213|NCT00002953|Drug|cyclophosphamide|
79494214|NCT00002953|Drug|epirubicin hydrochloride|
79494215|NCT00002953|Drug|paclitaxel|
79494216|NCT03705637|Drug|Exparel|"Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
79343224|NCT02271529|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
79343225|NCT02325518|Drug|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
79343226|NCT02325518|Drug|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
79494217|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
79343227|NCT02325518|Drug|Subject's habitual PGA monotherapy|
79343228|NCT02270983|Drug|Linaclotide 145 micrograms|
79343229|NCT02270983|Drug|Linaclotide 290 micrograms|
79343230|NCT02270983|Drug|Placebo|Matching placebo
79343231|NCT02449889|Drug|highly purified human chorionic gonadotropin|
79343232|NCT02449889|Drug|recombinant human chorionic gonadotropin|
79343233|NCT01831804|Drug|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
79343234|NCT01831804|Drug|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
79343235|NCT02270671|Behavioral|ABMT|Attention Bias Modification Training
79343236|NCT02270671|Other|Placebo|Placebo Training
79343237|NCT04415164|Drug|Xueshuantong lyophilized powder|Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
79494218|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
79814361|NCT00825526|Behavioral|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
79814362|NCT00839644|Device|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
79343238|NCT04415164|Drug|Placebo|Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
79343239|NCT04415164|Other|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
79343240|NCT04875481|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
79343241|NCT04875481|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
79494219|NCT03693781|Drug|Placebo Oral Tablet|Corresponding tablets for 30 weeks
79494220|NCT02283853|Drug|dimethyl fumarate|administered orally
79494221|NCT02283853|Drug|Interferon β-1a|administered by intramuscular injection
79343242|NCT02324270|Drug|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
79343243|NCT02324270|Other|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
79343244|NCT02270515|Other|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
79494222|NCT03670849|Device|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
79343245|NCT02448875|Device|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
79343246|NCT02448875|Device|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
79343247|NCT05648149|Behavioral|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
79343248|NCT05648071|Drug|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
79343249|NCT01831726|Drug|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
79343250|NCT04868617|Device|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
79657950|NCT01641172|Dietary Supplement|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
79657951|NCT01641172|Behavioral|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
79343251|NCT05464069|Device|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
79494223|NCT02401789|Device|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
79494224|NCT04329247|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
79494225|NCT02263417|Device|Deep Brain Stimulation (DBS) of Gpi|
79494226|NCT02263417|Device|Deep Brain Stimulation (DBS) of STN|
79494227|NCT02116699|Other|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
79657952|NCT01641172|Behavioral|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
79657953|NCT00286845|Drug|Standard Chemotherapy|physician determined
79657954|NCT01641211|Behavioral|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
79814363|NCT00839644|Device|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
79494228|NCT02116699|Other|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
79494229|NCT00002971|Drug|O6-benzylguanine|
79814364|NCT00839644|Other|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
79657955|NCT01641211|Other|Nutrition video|Children in this group will watch a 2-minute nutrition video.
79657956|NCT01641250|Drug|RO5429083|Multiple escalating doses
79657957|NCT01641250|Drug|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
79814365|NCT00834184|Drug|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
79814366|NCT00839722|Procedure|embolization|fertility after embolization
79343252|NCT01831258|Device|SensAwake On|
79494230|NCT00002977|Biological|filgrastim|
79494231|NCT00002977|Drug|melphalan|
79494232|NCT00002977|Drug|thiotepa|
79494233|NCT00002977|Procedure|peripheral blood stem cell transplantation|
79494234|NCT00003391|Biological|monoclonal antibody muJ591|
79494235|NCT00003397|Biological|filgrastim|
79494236|NCT00003397|Biological|rituximab|
79494237|NCT00003397|Biological|sargramostim|
79494238|NCT00003397|Drug|carmustine|
79494239|NCT00003397|Drug|cisplatin|
79494240|NCT00003397|Drug|cyclophosphamide|
79494241|NCT00003397|Drug|dexamethasone|
79494242|NCT00003397|Drug|etoposide|
79494243|NCT00003397|Drug|gemcitabine hydrochloride|
79494244|NCT00003397|Drug|melphalan|
79494245|NCT00003397|Drug|paclitaxel|
79494246|NCT00003397|Procedure|bone marrow ablation with stem cell support|
79494247|NCT00003397|Procedure|peripheral blood stem cell transplantation|
79814367|NCT00825604|Procedure|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
79814368|NCT02549950|Procedure|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
79814369|NCT02549950|Procedure|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
79343253|NCT01831258|Device|SensAwake Off|
79494248|NCT00384319|Device|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
79494249|NCT00003403|Drug|GPX-100|
79814370|NCT00834262|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79814371|NCT00834262|Drug|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79814372|NCT00834262|Drug|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79343254|NCT01849276|Drug|metformin hydrochloride|Given orally
79343255|NCT01849276|Drug|cytarabine|Given IV
79343256|NCT01849276|Other|laboratory biomarker analysis|Correlative studies
79343257|NCT02465489|Drug|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
79343258|NCT02465489|Drug|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
79343259|NCT01829464|Drug|Placebo|TAK-875 placebo-matching tablets
79343260|NCT01829464|Drug|TAK-875|TAK-875 tablets
79343261|NCT01829464|Drug|TAK-875|TAK-875 tablets
79343262|NCT04953923|Drug|Cedazuridine|Tablet for oral administration
79343263|NCT04953923|Drug|Placebo|Capsule for oral administration
79343264|NCT04953923|Drug|Moxifloxacin|Tablet for oral administration
79343265|NCT01847092|Drug|AZD1722|
79343266|NCT01847092|Drug|Placebo|Placebo for AZD1722
79343267|NCT01601821|Drug|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
79494250|NCT00383383|Biological|Hepatitis B adjuvanted vaccine|
79494251|NCT00383383|Biological|Engerix-B|
79494252|NCT00003409|Drug|motexafin gadolinium|
79494253|NCT00003409|Radiation|radiation therapy|
79494254|NCT00003415|Drug|amifostine trihydrate|
79494255|NCT00003415|Drug|topotecan hydrochloride|
79494256|NCT00002989|Drug|busulfan|
79494257|NCT00002989|Drug|cyclophosphamide|
79494258|NCT00002989|Drug|idarubicin|
79494259|NCT00002989|Drug|melphalan|
79494260|NCT00002989|Radiation|radiation therapy|
79494261|NCT00002995|Biological|dactinomycin|
79494262|NCT00002995|Biological|filgrastim|
79494263|NCT00002995|Biological|sargramostim|
79494264|NCT00002995|Drug|cyclophosphamide|
79494265|NCT00002995|Drug|vincristine sulfate|
79494266|NCT00002995|Radiation|radiation therapy|
79494267|NCT00003001|Drug|fluorouracil|
79494268|NCT00003001|Drug|gemcitabine hydrochloride|
79494269|NCT00003001|Drug|leucovorin calcium|
79494270|NCT00003421|Biological|bleomycin sulfate|
79494271|NCT00003421|Drug|ABVD regimen|
79494272|NCT00003421|Drug|chlorambucil|
79494273|NCT00003421|Drug|dacarbazine|
79494274|NCT00003421|Drug|doxorubicin hydrochloride|
79343268|NCT01601821|Drug|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
79985299|NCT02435290|Behavioral|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
79494275|NCT00003421|Drug|etoposide|
79814373|NCT00853385|Drug|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
79814374|NCT00853385|Drug|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
79985300|NCT02434978|Device|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
79814375|NCT00853385|Other|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
79814376|NCT00853385|Other|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
79985301|NCT02434978|Drug|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
79343269|NCT02323646|Drug|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
79343270|NCT02323646|Drug|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
79343271|NCT01846624|Drug|Decitabine|Given IV
79343272|NCT01846624|Drug|Midostaurin|Given PO
79494276|NCT00003421|Drug|prednisolone|
79494277|NCT00003421|Drug|procarbazine hydrochloride|
79494278|NCT00003421|Drug|vinblastine sulfate|
79494279|NCT00003421|Drug|vincristine sulfate|
79494280|NCT00003421|Radiation|radiation therapy|
79494281|NCT00003427|Drug|irinotecan hydrochloride|
79494282|NCT00003427|Drug|oxaliplatin|
79494283|NCT00002947|Radiation|indium In 111 pentetreotide|
79494284|NCT00003433|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
79494285|NCT00003439|Biological|recombinant interleukin-12|
79494286|NCT00003007|Biological|recombinant interferon alfa|
79494287|NCT00003007|Biological|sargramostim|
79494288|NCT00003007|Drug|cyclophosphamide|
79494289|NCT00003007|Drug|dexamethasone|
79494290|NCT00003007|Drug|melphalan|
79494291|NCT00003007|Procedure|peripheral blood stem cell transplantation|
79814377|NCT00853385|Biological|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
79814378|NCT00622336|Drug|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
79814379|NCT00622336|Drug|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
79814380|NCT00779766|Biological|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
79814381|NCT00779766|Biological|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
79814382|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
79814383|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
79985302|NCT02434978|Other|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
79494292|NCT01478035|Drug|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
79814384|NCT00846365|Drug|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
79814385|NCT00839878|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
79814386|NCT00834496|Procedure|Liver biopsy|percutaneous liver biopsy
79985303|NCT01371396|Other|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
79343273|NCT05647915|Drug|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
79343274|NCT05647915|Behavioral|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
79343275|NCT01829230|Device|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
79343276|NCT02269657|Device|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
79343277|NCT04588714|Behavioral|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
79494293|NCT01478035|Drug|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
79494294|NCT00003013|Drug|CMF regimen|
79814387|NCT00834730|Drug|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
79814388|NCT02601924|Drug|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
79985304|NCT01371396|Other|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
79985305|NCT03696290|Drug|Aztreonam lysine|Nebulised aztreonam lysine 75mg
79985306|NCT03696290|Other|Placebo|Nebulised lactose monohydrate 5mg
79494295|NCT00003013|Drug|cyclophosphamide|
79985307|NCT03633942|Device|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
79494296|NCT00003013|Drug|doxorubicin hydrochloride|
79494297|NCT00003013|Drug|fluorouracil|
79494298|NCT00003013|Drug|methotrexate|
79494299|NCT00003013|Drug|paclitaxel|
79494300|NCT00003013|Drug|tamoxifen citrate|
79494301|NCT00003013|Procedure|conventional surgery|
79985308|NCT02434666|Drug|CPC-201|
79985309|NCT03696212|Drug|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
79494302|NCT00003013|Radiation|radiation therapy|
79494303|NCT00003445|Drug|docetaxel|
79494304|NCT00003451|Biological|recombinant interferon alfa|
79814389|NCT02601924|Other|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
79343278|NCT02269423|Biological|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
79343279|NCT02269423|Other|Placebo|Normal saline placebo.
79494305|NCT00003451|Biological|recombinant interleukin-12|
79494306|NCT00003463|Drug|carmustine|
79494307|NCT00003463|Drug|irinotecan hydrochloride|
79494308|NCT00003463|Drug|polifeprosan 20 with carmustine implant|
79494309|NCT00003463|Procedure|surgical procedure|
79494310|NCT01338649|Device|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
79494311|NCT01338649|Device|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
79343280|NCT05647837|Diagnostic Test|lumper puncture|lumper puncture
79494312|NCT00003019|Drug|methotrexate|
79657958|NCT00251264|Procedure|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
79985310|NCT05048160|Drug|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
79985311|NCT03803280|Procedure|ERAS program|ERAS pathway according to the Spanish Via RICA
79985312|NCT03692624|Behavioral|Biofeedback|Heart Rate Variability Biofeedback
79985313|NCT02430922|Device|iVolution nitinol stent|
79343281|NCT01827670|Drug|Stannous fluoride|Test dentifrice containing 0.454% SnF
79343282|NCT01827670|Drug|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate [1000 parts per million (ppm) fluoride]
79343283|NCT02267317|Drug|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
79343284|NCT02267317|Drug|D5W|5% Dextrose Water = Vehicle
79343285|NCT01844830|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
79343286|NCT01844830|Drug|Placebo|Inactive ingredients supplied in identical nasal sprayer
79343287|NCT05426473|Other|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
79343288|NCT04874467|Procedure|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
79343289|NCT01827592|Drug|Elobixibat 10 mg|Elobixibat 10 mg/day
79343290|NCT01827592|Drug|Elobixibat 5 mg|Elobixibat 5 mg/day
79343291|NCT01827592|Drug|Placebo|Placebo
79343292|NCT02323334|Drug|LY3202626|administered orally
79494313|NCT00003019|Drug|vinblastine sulfate|
79494314|NCT01247233|Radiation|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
79494315|NCT01247233|Radiation|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
79494316|NCT00003493|Drug|dexamethasone|
79494317|NCT00003493|Drug|pegylated liposomal doxorubicin hydrochloride|
79494318|NCT00003493|Drug|vincristine sulfate|
79494319|NCT00003505|Drug|antineoplaston A10|
79494320|NCT00003505|Drug|antineoplaston AS2-1|
79494321|NCT00003505|Procedure|alternative product therapy|
79494322|NCT00003505|Procedure|biological therapy|
79494323|NCT00003505|Procedure|biologically based therapies|
79494324|NCT00003505|Procedure|cancer prevention intervention|
79494325|NCT00003505|Procedure|complementary and alternative therapy|
79494326|NCT00003505|Procedure|differentiation therapy|
79494327|NCT00003025|Biological|vitespen|
79494328|NCT00003031|Drug|amphotericin B deoxycholate|
79494329|NCT00003031|Drug|voriconazole|
79494330|NCT00003517|Drug|antineoplaston A10|
79494331|NCT00003517|Drug|antineoplaston AS2-1|
79494332|NCT00003517|Drug|bicalutamide|
79494333|NCT00003517|Drug|flutamide|
79494334|NCT00003517|Drug|leuprolide acetate|
79494335|NCT00003517|Procedure|alternative product therapy|
79494336|NCT00003517|Procedure|antiandrogen therapy|
79494337|NCT00003517|Procedure|biological therapy|
79343293|NCT02323334|Drug|Placebo (Part A, B, C)|administered orally
79343294|NCT02323334|Drug|Itraconazole|administered orally
79494338|NCT00003517|Procedure|biologically based therapies|
79494339|NCT00003517|Procedure|cancer prevention intervention|
79494340|NCT00003517|Procedure|complementary and alternative therapy|
79494341|NCT00003517|Procedure|differentiation therapy|
79494342|NCT00003517|Procedure|endocrine therapy|
79494343|NCT00003517|Procedure|hormone therapy|
79985314|NCT03692546|Drug|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
79343295|NCT02448719|Drug|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
79343296|NCT02448719|Drug|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
79343297|NCT02448719|Drug|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
79343298|NCT02448719|Drug|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
79343299|NCT02448719|Drug|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
79343300|NCT02448719|Drug|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
79343301|NCT02448719|Drug|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
79343302|NCT02448719|Drug|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
79343303|NCT02448719|Drug|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
79494344|NCT00003523|Drug|aminocamptothecin colloidal dispersion|
79343304|NCT02448719|Drug|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
79494345|NCT00383461|Behavioral|smoking cessation intervention|
79494346|NCT00383461|Other|counseling intervention|
79494347|NCT00003037|Drug|cisplatin|
79494348|NCT00003037|Drug|docetaxel|
79494349|NCT00003037|Drug|gemcitabine hydrochloride|
79343305|NCT02448719|Drug|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
79343306|NCT02448719|Drug|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
79343307|NCT02322866|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
79343308|NCT02322866|Drug|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
79494350|NCT00002803|Drug|cyclophosphamide|
79494351|NCT00002803|Drug|doxorubicin hydrochloride|
79494352|NCT00002803|Drug|vincristine sulfate|
79494353|NCT00002803|Procedure|conventional surgery|
79494354|NCT00383929|Drug|Candesartan cilexetil|32mg oral
79494355|NCT00383929|Drug|Hydrochlorothiazide|12.5 mg oral
79494356|NCT00383929|Drug|Hydrochlorothiazide|25 mg oral
79494357|NCT00003541|Biological|filgrastim|
79494358|NCT00003541|Drug|CHOP regimen|
79494359|NCT00003541|Drug|carboplatin|
79494360|NCT00003541|Drug|cyclophosphamide|
79494361|NCT00003541|Drug|doxorubicin hydrochloride|
79494362|NCT00003541|Drug|etoposide|
79494363|NCT00003541|Drug|ifosfamide|
79494364|NCT00003541|Drug|prednisone|
79494365|NCT00003541|Drug|vincristine sulfate|
79494366|NCT00003541|Procedure|peripheral blood stem cell transplantation|
79494367|NCT00003541|Radiation|radiation therapy|
79494368|NCT00002809|Biological|anti-thymocyte globulin|
79494369|NCT00002809|Biological|filgrastim|
79494370|NCT00002809|Biological|sargramostim|
79494371|NCT00002809|Biological|therapeutic immune globulin|
79494372|NCT00002809|Drug|cyclophosphamide|
79494373|NCT00002809|Drug|methotrexate|
79494374|NCT00002809|Drug|tacrolimus|
79494375|NCT00002809|Procedure|allogeneic bone marrow transplantation|
79494376|NCT00002809|Radiation|radiation therapy|
79494377|NCT00003553|Other|HLA Matched Peripheral BLood Stem Cells|Cell Product
79494378|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
79494379|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
79494380|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
79494381|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Control Vaccine
79494382|NCT00002827|Biological|bleomycin sulfate|Given IV
79494383|NCT00002827|Biological|filgrastim|Given IV
79494384|NCT00002827|Drug|dexrazoxane hydrochloride|Given IV
79494385|NCT00002827|Drug|doxorubicin hydrochloride|Given IV
79494386|NCT00002827|Drug|etoposide|Given IV
79494387|NCT00002827|Drug|vincristine sulfate|Given IV
79494388|NCT00002827|Radiation|low-LET cobalt-60 gamma ray therapy|
79494389|NCT00002827|Radiation|low-LET electron therapy|
79494390|NCT00002827|Radiation|low-LET photon therapy|
79494391|NCT00384475|Drug|Ciclesonide Nasal Spray|
79494392|NCT00003565|Drug|docetaxel|
79343309|NCT04198376|Procedure|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
79343310|NCT04198376|Procedure|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
79343311|NCT02463071|Drug|AZD0585|1g soft capsule
79985315|NCT03248388|Device|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
79343312|NCT02463071|Drug|AZD0585 placebo|1g soft capsule
79494393|NCT00003049|Drug|fluorouracil|
79494394|NCT00003049|Drug|leucovorin calcium|
79494395|NCT00003049|Procedure|conventional surgery|
79494396|NCT00003049|Radiation|radiation therapy|
79343313|NCT02266381|Procedure|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
79494397|NCT00003055|Drug|cisplatin|
79494398|NCT00003055|Drug|irinotecan hydrochloride|
79343314|NCT02266381|Procedure|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
79343315|NCT02266381|Procedure|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
79494399|NCT00002833|Biological|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
79494400|NCT00002833|Drug|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
79985316|NCT03248388|Device|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
79494401|NCT00002833|Drug|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
79985317|NCT02434588|Device|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
79494402|NCT00002833|Drug|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
79494403|NCT00002833|Drug|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
79494404|NCT00002833|Drug|Idarubicin|IV Days -6, -5 and -4.
79494405|NCT00002833|Drug|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
79494406|NCT00002833|Procedure|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
79494407|NCT00003061|Drug|cytarabine|
79494408|NCT00003061|Drug|methotrexate|
79494409|NCT00003061|Radiation|radiation therapy|
79494410|NCT00003571|Genetic|mutation analysis|
79494411|NCT00003571|Genetic|tumor replication error analysis|
79494412|NCT00003577|Drug|CMF regimen|
79494413|NCT00003577|Drug|cyclophosphamide|
79494414|NCT00003577|Drug|epirubicin hydrochloride|
79494415|NCT00003577|Drug|fluorouracil|
79494416|NCT00003577|Drug|methotrexate|
79494417|NCT00003577|Procedure|adjuvant therapy|
79494418|NCT00003577|Radiation|radiation therapy|
79494419|NCT00002839|Drug|cisplatin|
79494420|NCT00002839|Drug|fluorouracil|
79494421|NCT00002839|Procedure|conventional surgery|
79494422|NCT00002839|Procedure|neoadjuvant therapy|
79343316|NCT01827046|Drug|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
79494423|NCT00002839|Radiation|radiation therapy|
79343317|NCT02356562|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
79343318|NCT02356562|Drug|Sofosbuvir|tablet
79657959|NCT00251264|Procedure|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
79343319|NCT02356562|Drug|Ribavirin|tablet
79343320|NCT02448563|Behavioral|Nutrition and physical activity education|Eight weekly in-person groups
79343321|NCT02266225|Other|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
79343322|NCT02354690|Drug|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
79494424|NCT00003583|Drug|amifostine trihydrate|
79657960|NCT01641289|Drug|Paracetamol|>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate <50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
79814390|NCT00840112|Dietary Supplement|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
79985318|NCT03480763|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
79343323|NCT02354690|Drug|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
79343324|NCT02354690|Drug|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
79343325|NCT02354690|Drug|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
79343326|NCT02354222|Drug|Canagliflozin|
79343327|NCT02354222|Drug|Teneligliptin|
79494425|NCT00003583|Drug|cisplatin|
79494426|NCT00003583|Drug|etoposide|
79494427|NCT00003583|Radiation|radiation therapy|
79494428|NCT00002845|Biological|aldesleukin|
79494429|NCT00003067|Biological|aldesleukin|
79494430|NCT00003067|Biological|lymphokine-activated killer cells|
79343328|NCT02354222|Drug|Placebo|
79343329|NCT04904276|Drug|Fostamatinib|Fostamatinib disodium
79494431|NCT00003589|Drug|cisplatin|
79494432|NCT00003589|Drug|gemcitabine hydrochloride|
79494433|NCT00003589|Drug|paclitaxel|
79494434|NCT00002851|Procedure|adjuvant therapy|
79494435|NCT00002851|Radiation|low-LET electron therapy|
79494436|NCT00002851|Radiation|low-LET photon therapy|
79494437|NCT00003595|Biological|filgrastim|
79494438|NCT00003595|Biological|rituximab|
79494439|NCT00003595|Drug|CHOP regimen|
79494440|NCT00003595|Drug|cyclophosphamide|
79494441|NCT00003595|Drug|doxorubicin hydrochloride|
79494442|NCT00003595|Drug|prednisone|
79494443|NCT00003595|Drug|vincristine sulfate|
79494444|NCT00003073|Drug|liposomal cytarabine|
79494445|NCT00002863|Drug|chemotherapy|
79494446|NCT00002863|Procedure|conventional surgery|
79494447|NCT00002863|Procedure|cryosurgery|
79494448|NCT00003079|Drug|bryostatin 1|
79494449|NCT00003079|Drug|cytarabine|
79494450|NCT00002869|Biological|recombinant interferon alfa|
79494451|NCT00002869|Drug|cytarabine|
79494452|NCT00002869|Drug|hydroxyurea|
79494453|NCT00002875|Biological|filgrastim|
79494454|NCT00002875|Drug|cisplatin|
79494455|NCT00002875|Drug|cyclophosphamide|
79985319|NCT03480763|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
79985320|NCT03480763|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
79985321|NCT02434432|Behavioral|music therapy selected by mothers|mothers' choice of music
79985322|NCT02434432|Behavioral|Music therapy recorded lullaby|recorded lullaby
79985323|NCT04223804|Drug|ABBV-181|Intravenous (IV) Infusion
79985324|NCT04223804|Drug|Placebo|Intravenous (IV) infusion
79985325|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
79985326|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
79343330|NCT02353442|Other|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
79494456|NCT00002875|Drug|lomustine|
79985327|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
79985328|NCT03692390|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
79985329|NCT02430766|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
79343331|NCT02353442|Other|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
79343332|NCT02353442|Other|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
79343333|NCT02353442|Other|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
79343334|NCT02353442|Other|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
79985330|NCT02430766|Device|NanoKnife|
79985331|NCT03700502|Diagnostic Test|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
79985332|NCT03123120|Drug|Spesolimab|12 weeks treatment
79985333|NCT03123120|Drug|Placebo|12 weeks treatment
79985334|NCT03692234|Dietary Supplement|125 mg L-homoarginine|capsules for oral supplementation
79985335|NCT03692234|Other|placebo|capsules for oral supplementation
79985336|NCT02430688|Procedure|Irreversible electroporation (IRE)|
79985337|NCT02430688|Device|NanoKnife|
79985338|NCT03185338|Behavioral|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
79343335|NCT02353442|Other|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
79343336|NCT02351960|Drug|Dexlansoprazole|Dexlansoprazole capsules
79494457|NCT00002875|Drug|mesna|
79494458|NCT00002875|Drug|vincristine sulfate|
79494459|NCT00002875|Radiation|low-LET electron therapy|
79494460|NCT00002875|Radiation|low-LET photon therapy|
79494461|NCT00003607|Radiation|radiation therapy|
79814391|NCT04101474|Drug|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
79343337|NCT02351180|Drug|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
79343338|NCT02351180|Drug|Placebo|Placebo will serve as a control treatment
79343339|NCT02350478|Drug|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
79343340|NCT02350478|Drug|Placebo|The subject will receive placebo orally once daily for 12 weeks.
79494462|NCT00003613|Drug|O6-benzylguanine|Given IV
79494463|NCT00003613|Drug|carmustine|Given topically
79494464|NCT00003613|Other|laboratory biomarker analysis|Correlative studies
79494465|NCT00003085|Procedure|laparoscopy|
79494466|NCT00003085|Procedure|ultrasound imaging|
79494467|NCT00002881|Drug|flutamide|
79494468|NCT00002881|Drug|goserelin acetate|
79494469|NCT00002881|Drug|leuprolide acetate|
79494470|NCT00002881|Drug|suramin|
79494471|NCT00002881|Drug|therapeutic hydrocortisone|
79494472|NCT00002881|Procedure|orchiectomy|
79494473|NCT00003091|Biological|aldesleukin|
79494474|NCT00003091|Biological|recombinant interferon alfa|
79494475|NCT00003619|Biological|filgrastim|
79494476|NCT00003619|Dietary Supplement|vitamin E|
79343341|NCT02349542|Drug|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
79343342|NCT02321930|Drug|tofacitinib 5mg po bid|
79343343|NCT01647542|Drug|TAK-875|TAK-875 tablets
79343344|NCT01647542|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
79343345|NCT02321462|Drug|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
79343346|NCT02321462|Drug|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
79494477|NCT00003619|Drug|busulfan|
79494478|NCT00003619|Drug|cytarabine|
79494479|NCT00003619|Drug|etoposide|
79494480|NCT00003619|Drug|fludarabine phosphate|
79494481|NCT00003619|Drug|isotretinoin|
79494482|NCT00003619|Drug|topotecan hydrochloride|
79494483|NCT00003619|Procedure|bone marrow ablation with stem cell support|
79494484|NCT00003619|Procedure|peripheral blood stem cell transplantation|
79494485|NCT00002887|Drug|cisplatin|
79494486|NCT00002887|Drug|etoposide|
79494487|NCT00002887|Drug|hydroxyurea|
79494488|NCT00002887|Drug|vinblastine sulfate|
79814392|NCT00840190|Drug|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
79343347|NCT02391584|Device|XprESS|Balloon dilation of the Eustachian tube
79494489|NCT00002887|Drug|vindesine|
79494490|NCT00002887|Drug|vinorelbine tartrate|
79494491|NCT00002887|Procedure|drug resistance inhibition treatment|
79494492|NCT00003937|Drug|cisplatin|
79494493|NCT00003937|Drug|dexrazoxane hydrochloride|
79985339|NCT03185338|Behavioral|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
79985340|NCT03185338|Behavioral|Active school recess|Teachers will design games and activities and will encourage children for being active
79985341|NCT03185338|Behavioral|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
79985342|NCT03185338|Behavioral|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
79985343|NCT03624296|Device|MRI 7T|MRI 7T
79985344|NCT03624296|Other|TEST EDSS|EDSS - Expanded Disability Status Scale
79494494|NCT00003937|Drug|doxorubicin hydrochloride|
79494495|NCT00003937|Drug|etoposide|
79494496|NCT00003937|Drug|ifosfamide|
79494497|NCT00003937|Drug|methotrexate|
79343348|NCT02391584|Other|Control|Continued medical management
79343349|NCT02266147|Drug|SD-101|
79343350|NCT02266147|Radiation|Radiation therapy|
79494498|NCT00003937|Procedure|conventional surgery|
79494499|NCT00003625|Drug|cyclosporine|
79494500|NCT00003625|Drug|etoposide|
79343351|NCT04873843|Behavioral|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
79343352|NCT04873843|Behavioral|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
79343353|NCT05647135|Other|Medical food|enteral formulas with different protein composition
79494501|NCT00003625|Drug|vincristine sulfate|
79494502|NCT00003625|Radiation|radiation therapy|
79494503|NCT00003637|Drug|cisplatin|
79494504|NCT00003637|Drug|fluorouracil|
79494505|NCT00003637|Radiation|radiation therapy|
79494506|NCT00003097|Other|preventative dietary intervention|
79494507|NCT00003943|Biological|filgrastim|5 ug/kg
79494508|NCT00003943|Drug|carboplatin|AUC 5
79494509|NCT00003943|Drug|cyclophosphamide|3 gm/m2
79494510|NCT00003943|Drug|paclitaxel|250 mg/m2
79494511|NCT00003943|Drug|topotecan hydrochloride|10 mg/m2
79494512|NCT00003943|Procedure|peripheral blood stem cell transplantation|harvest via apheresis
79494513|NCT00003955|Biological|dactinomycin|
79494514|NCT00003955|Biological|filgrastim|
79494515|NCT00003955|Biological|pegfilgrastim|
79494516|NCT00003955|Biological|sargramostim|
79494517|NCT00003955|Drug|cyclophosphamide|
79494518|NCT00003955|Drug|irinotecan hydrochloride|
79494519|NCT00003955|Drug|vincristine sulfate|
79494520|NCT00003955|Radiation|radiation therapy|
79494521|NCT00003103|Biological|oblimersen sodium|
79494522|NCT00003103|Drug|docetaxel|
79494523|NCT00003109|Drug|irinotecan hydrochloride|
79985345|NCT03624296|Other|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
79985346|NCT03692832|Procedure|LH|Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
79985347|NCT03692832|Procedure|VH|Vaginal hysterectomy following Heaney technique
79814393|NCT04101708|Drug|Lansoprazole, Amoxicillin|high dose dual regimen
79343354|NCT05402917|Procedure|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
79343355|NCT02264977|Device|GORE® TAG® Thoracic Branch Endoprosthesis|
79343356|NCT02264821|Drug|ropivacaine infiltration|wound infiltration
79343357|NCT02264821|Drug|intrathecal morphine|100 µg added to the spinal anaesthesia
79343358|NCT02264821|Drug|placebo|placebo in spinal anaesthesia and in wound infiltration
79343359|NCT05386147|Device|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
79343360|NCT04854889|Drug|Decitabine|Demethylating agents
79343361|NCT02261467|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
79814394|NCT04101708|Drug|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
79814395|NCT00825760|Drug|Topical PPA904 gel and light|
79814396|NCT00825760|Drug|Topical placebo gel plus light|
79343362|NCT02261467|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
79494524|NCT00003109|Drug|raltitrexed|
79494525|NCT00003643|Biological|bleomycin sulfate|
79494526|NCT00003643|Biological|filgrastim|
79814397|NCT00779142|Drug|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
79814398|NCT00840346|Drug|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
79985348|NCT03696134|Other|questionnaire|questionnaire
79494527|NCT00003643|Drug|cisplatin|
79494528|NCT00003643|Drug|etoposide|
79657961|NCT01641289|Drug|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
79657962|NCT01641328|Behavioral|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
79814399|NCT04105140|Drug|Oxytocin|intranasal administration of oxytocin (24 IU)
79343363|NCT05646823|Dietary Supplement|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
79343364|NCT05646823|Dietary Supplement|Placebo|vehicle only - Maltodextrin gluten free
79343365|NCT05646667|Other|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
79343366|NCT05646667|Other|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
79494529|NCT00003643|Drug|paclitaxel|
79494530|NCT00003961|Biological|sargramostim|
79494531|NCT00003661|Biological|anti-thymocyte globulin|
79494532|NCT00003661|Drug|busulfan|
79494533|NCT00003661|Drug|cyclosporine|
79494534|NCT00003661|Drug|melphalan|
79494535|NCT00003661|Drug|methylprednisolone|
79494536|NCT00003661|Procedure|umbilical cord blood transplantation|
79494537|NCT00003661|Radiation|radiation therapy|
79494538|NCT00003967|Drug|etoposide|
79494539|NCT00003967|Drug|topotecan hydrochloride|
79494540|NCT00003115|Drug|hydromorphone hydrochloride|
79814400|NCT04105140|Drug|Placebo|intranasal administration of placebo (24 IU)
79494541|NCT00003667|Drug|cyclophosphamide|
79494542|NCT00003667|Drug|dexrazoxane hydrochloride|
79494543|NCT00003667|Drug|disaccharide tripeptide glycerol dipalmitoyl|
79494544|NCT00003667|Drug|doxorubicin hydrochloride|
79494545|NCT00003667|Drug|vincristine sulfate|
79494546|NCT00003667|Procedure|surgical procedure|
79494547|NCT00003667|Radiation|radiation therapy|
79494548|NCT00003979|Drug|CHS 828|
79494549|NCT00003673|Drug|chemotherapy|
79657963|NCT01641328|Behavioral|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
79814401|NCT00622180|Device|NBUVB|NBUVB hand foot box
79494550|NCT00003673|Drug|gemtuzumab ozogamicin|
79657964|NCT00280020|Behavioral|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
79985349|NCT01371474|Drug|Paroxetine|
79343367|NCT01643473|Behavioral|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
79985350|NCT03184948|Device|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
79985351|NCT03696056|Behavioral|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
79343368|NCT01643473|Other|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
79343369|NCT05646277|Other|e-Consultation|first orthodontic consultation in remote
79343370|NCT05646277|Other|Consultation|first orthodontic consultation in face-to-face
79814402|NCT00622180|Device|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
79814403|NCT02601768|Device|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
79343371|NCT05344651|Device|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
79343372|NCT05341843|Drug|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
79343373|NCT05341843|Drug|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
79343374|NCT02320058|Drug|Ipilimumab|
79343375|NCT02320058|Drug|Nivolumab|
79343376|NCT02319668|Drug|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
79814404|NCT00840580|Drug|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
79814405|NCT00840580|Drug|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
79814406|NCT00773136|Drug|Bimatoprost Suspension|see prior
79814407|NCT00843388|Drug|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
79814408|NCT00843388|Drug|placebo tablet|placebo tablet 25 mg OD
79814409|NCT04101084|Other|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
79343377|NCT02319668|Drug|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
79343378|NCT02092467|Drug|tofacitinib|Oral tablet, 5 mg BID
79343379|NCT02092467|Drug|tofacitinib|Oral tablet, 10 mg BID
79343380|NCT02092467|Biological|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
79343381|NCT02092467|Biological|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
79343382|NCT02462759|Drug|Nusinersen|Administered by intrathecal injection.
79343383|NCT02462759|Procedure|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
79494551|NCT00003679|Drug|cyclophosphamide|
79494552|NCT00003679|Drug|docetaxel|
79494553|NCT00003679|Drug|doxorubicin hydrochloride|
79494554|NCT00003679|Drug|tamoxifen citrate|
79657965|NCT00280020|Behavioral|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
79657966|NCT00280020|Behavioral|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
79494555|NCT00003679|Procedure|conventional surgery|
79494556|NCT00003679|Radiation|radiation therapy|
79494557|NCT00003985|Drug|KRN7000|
79494558|NCT00384553|Drug|Rituximab|
79343384|NCT04420871|Drug|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
79494559|NCT00384553|Drug|DHAP|
79985352|NCT03696056|Behavioral|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
79343385|NCT04420871|Drug|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
79343386|NCT02349386|Drug|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
79343387|NCT02349386|Drug|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
79494560|NCT00384553|Drug|TEC|
79494561|NCT00384553|Drug|autologous stem cell transplantation|
79494562|NCT00003991|Biological|aldesleukin|
79985353|NCT03185104|Drug|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
79494563|NCT00003991|Drug|histamine dihydrochloride|
79494564|NCT00003997|Drug|irofulven|
79494565|NCT00384631|Other|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
79494566|NCT00384631|Drug|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
79494567|NCT00003127|Drug|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
79494568|NCT00003127|Drug|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
79494569|NCT00003127|Drug|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
79494570|NCT00004003|Drug|cisplatin|
79494571|NCT00004003|Drug|fluorouracil|
79494572|NCT00004003|Drug|gemcitabine hydrochloride|
79494573|NCT00004009|Drug|tipifarnib|
79494574|NCT00003133|Biological|filgrastim|
79494575|NCT00003133|Drug|cisplatin|
79494576|NCT00003133|Drug|doxorubicin hydrochloride|
79494577|NCT00003133|Drug|gemcitabine hydrochloride|
79494578|NCT00003133|Drug|paclitaxel|
79494579|NCT00003685|Procedure|fatigue assessment and management|
79494580|NCT00003685|Procedure|nausea and vomiting therapy|
79494581|NCT00003685|Procedure|pain therapy|
79494582|NCT00003685|Procedure|quality-of-life assessment|
79494583|NCT00003685|Radiation|radiation therapy|
79494584|NCT00004015|Drug|sodium borocaptate|
79343388|NCT04935047|Other|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
79343389|NCT04934891|Drug|ION547|ION547 will be administered by SC injection.
79343390|NCT04934891|Drug|Placebo|ION547-matching placebo will be administered by SC injection.
79494585|NCT00004015|Procedure|adjuvant therapy|
79494586|NCT00003691|Biological|filgrastim|
79343391|NCT04892888|Biological|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
79343392|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
79343393|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
79494587|NCT00003691|Drug|cisplatin|
79494588|NCT00003691|Drug|doxorubicin hydrochloride|
79494589|NCT00003691|Drug|paclitaxel|
79494590|NCT00003139|Drug|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
79494591|NCT00003139|Other|Placebo|
79343394|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
79343395|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
79343396|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
79343397|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
79494592|NCT00003697|Drug|vadimezan|
79494593|NCT00004033|Drug|liposomal NDDP|
79494594|NCT00004033|Procedure|therapeutic thoracoscopy|
79494595|NCT00003703|Drug|SarCNU|
79494596|NCT02972983|Drug|Daptomycin|Adjuvant therapy for up to five days
79494597|NCT02972983|Other|Placebo|Placebo
79985354|NCT03185104|Drug|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
79814410|NCT00843544|Behavioral|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
79814411|NCT02548234|Other|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
79343398|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
79343399|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
79343400|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
79343401|NCT02036775|Drug|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
79343402|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
79343403|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
79343404|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
79343405|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
79343406|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
79494598|NCT00003709|Drug|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
79494599|NCT00003145|Drug|Fludarabine Phosphate|Given IV
79343407|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
79343408|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
79343409|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
79343410|NCT02034591|Drug|Apixaban|
79343411|NCT02034591|Dietary Supplement|Boost Plus|
79494600|NCT00003145|Radiation|Total-Body Irradiation|Undergo TBI
79494601|NCT00003145|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
79494602|NCT00003145|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
79494603|NCT00003145|Drug|Cyclosporine|Given PO or IV
79494604|NCT00003145|Drug|Mycophenolate Mofetil|Given PO or IV
79494605|NCT00003145|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
79494606|NCT00003145|Other|Laboratory Biomarker Analysis|Correlative studies
79494607|NCT00004039|Biological|recombinant interferon alfa|
79494608|NCT00004039|Biological|rituximab|
79494609|NCT00004039|Drug|cyclophosphamide|
79985355|NCT03700424|Drug|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
79494610|NCT00004039|Drug|doxorubicin hydrochloride|
79343412|NCT02391116|Drug|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
79343413|NCT02091921|Drug|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
79343414|NCT02447081|Device|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
79343415|NCT02391038|Drug|MLN0264|MLN0264 IV.
79343416|NCT02260921|Device|iovera°|
79343417|NCT02260921|Device|Sham Comparator|
79343418|NCT02462603|Drug|PTC-589|PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
79494611|NCT00004039|Drug|prednisone|
79494612|NCT00004039|Drug|vincristine sulfate|
79985356|NCT03700424|Drug|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
79985357|NCT01319994|Drug|Metformin|Metformin 850mg TDS (12 weeks)
79343419|NCT02034513|Drug|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
79343420|NCT02034513|Drug|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
79985358|NCT01319994|Drug|Placebo|Placebo 850mg TDS (12 weeks)
79343421|NCT02034513|Drug|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
79343422|NCT05370248|Other|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
79343423|NCT05370248|Other|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
79343424|NCT02348840|Device|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
79985359|NCT02430298|Drug|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
79985360|NCT02430298|Drug|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
79343425|NCT02462057|Other|Email message regarding the HealthyFood benefit|
79343426|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
79343427|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
79343428|NCT02034435|Other|Low Salt diet plus Placebo tablet|
79343429|NCT02034435|Other|Low Sodium diet plus Salt tablet|
79494613|NCT00003151|Dietary Supplement|bismuth subcitrate|
79494614|NCT00003151|Drug|amoxicillin|
79494615|NCT00003151|Drug|clarithromycin|
79494616|NCT00003151|Drug|metronidazole hydrochloride|
79494617|NCT00003151|Drug|omeprazole|
79494618|NCT00003151|Drug|tetracycline hydrochloride|
79494619|NCT00004045|Drug|exatecan mesylate|
79494620|NCT00003715|Biological|BCG vaccine|
79494621|NCT00003715|Biological|autologous tumor cell vaccine|
79494622|NCT00003715|Biological|recombinant interferon alfa|
79494623|NCT00003715|Drug|chemotherapy|
79494624|NCT00003715|Drug|cyclophosphamide|
79494625|NCT00004051|Drug|irinotecan hydrochloride|
79814412|NCT02548234|Other|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
79814413|NCT02602860|Radiation|[11C]UCB-J|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 20 mCi~Route of Administration: iv"
79343430|NCT02034435|Drug|Epleronone|50mg daily
79343431|NCT02034435|Drug|Amlodipine|5mg daily
79343432|NCT04691427|Device|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
79343433|NCT02033889|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
79343434|NCT02033889|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
79343435|NCT02033889|Drug|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
79343436|NCT02033889|Other|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
79343437|NCT02033889|Drug|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
79985361|NCT03624218|Behavioral|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
79985362|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
79343438|NCT02033889|Biological|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
79343439|NCT02033889|Drug|Metformin|Metformin >=1500 mg/day, orally, once a day
79343440|NCT02447003|Biological|Pembrolizumab|IV infusion of 200 mg.
79343441|NCT01844284|Device|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
79343442|NCT01844284|Device|Absorb™ BVS|Subjects receiving Absorb™ BVS
79494626|NCT00003721|Drug|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
79343443|NCT02054715|Behavioral|print educational intervention|print educational intervention
79343444|NCT02054715|Behavioral|multimedia psychoeducational intervention|multimedia psychoeducational intervention
79343445|NCT02446769|Device|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
79343446|NCT02420093|Device|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
79343447|NCT02419937|Drug|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
79343448|NCT02419937|Drug|Placebo|Saline injection
79343449|NCT02054481|Drug|BI 655066|Medium dose
79343450|NCT02054481|Drug|BI 655066|High dose
79494627|NCT00003727|Biological|filgrastim|
79494628|NCT00003727|Biological|recombinant interferon alfa|
79343451|NCT02054481|Drug|Ustekinumab|
79343452|NCT02054481|Drug|BI 655066|Low dose
79494629|NCT00003727|Biological|sargramostim|
79494630|NCT00003727|Biological|therapeutic autologous lymphocytes|
79494631|NCT00003727|Drug|carmustine|
79494632|NCT00003727|Drug|cyclophosphamide|
79494633|NCT00003727|Drug|etoposide|
79494634|NCT00003727|Drug|gemcitabine hydrochloride|
79343453|NCT01610752|Behavioral|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
79343454|NCT02054325|Drug|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
79343455|NCT02054325|Drug|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
79343456|NCT02446691|Biological|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
79343457|NCT02091375|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
79343458|NCT02091375|Drug|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
79343459|NCT04690335|Biological|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
79343460|NCT04690335|Other|Placebo|Saline solution
79657967|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
79343461|NCT02032875|Drug|Daclatasvir|
79343462|NCT02032875|Drug|Sofosbuvir|
79343463|NCT02032875|Drug|Ribavirin|
79343464|NCT02032407|Drug|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
79343465|NCT04689867|Behavioral|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
79343466|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 6
79343467|NCT01843972|Drug|BI 691751|oral solution
79343468|NCT01843972|Drug|Placebo|placebo solution
79343469|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 2
79343470|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 5
79343471|NCT01843972|Drug|BI 691751|1 tablet
79343472|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 3
79343473|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 4
79343474|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 7
79343475|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 1
79343476|NCT01826422|Dietary Supplement|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
79343477|NCT01826422|Dietary Supplement|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
79343478|NCT01843660|Drug|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
79343479|NCT02090283|Drug|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
79343480|NCT02032173|Drug|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
79343481|NCT04712409|Procedure|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
79657968|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
79343482|NCT04712409|Procedure|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
79343483|NCT04712409|Procedure|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
79494635|NCT00003727|Drug|melphalan|
79494636|NCT00003727|Procedure|bone marrow ablation with stem cell support|
79343484|NCT04712409|Procedure|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
79343485|NCT04689477|Device|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
79814414|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 10 mg/ml~Route of Administration: iv"
79343486|NCT02031471|Drug|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
79343487|NCT02461589|Drug|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
79343488|NCT02461589|Drug|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
79494637|NCT00003727|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79494638|NCT00003157|Drug|cisplatin|
79985363|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
79343489|NCT02461589|Drug|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
79343490|NCT04420793|Other|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
79343491|NCT04934189|Behavioral|Empowerment Self Defense Training|We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists [PI and Co-I] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
79343492|NCT02089737|Drug|Panitumumab|Panitumumab for intravenous infusion
79494639|NCT00003157|Drug|gemcitabine hydrochloride|
79494640|NCT00003157|Radiation|radiation therapy|
79494641|NCT00384007|Procedure|Hydrodiscectomy with Spinejet|
79814415|NCT02602860|Drug|Levetiracetam|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 100 mg/ml~Route of Administration: iv"
79494642|NCT00004057|Drug|L-778,123|
79494643|NCT00004057|Drug|paclitaxel|
79494644|NCT00004063|Biological|recombinant interferon alfa|
79494645|NCT00004063|Drug|cisplatin|
79494646|NCT00004063|Drug|gemcitabine hydrochloride|
79494647|NCT00004063|Procedure|hyperthermia treatment|
79494648|NCT00003733|Drug|carboplatin|
79494649|NCT00003733|Drug|paclitaxel|
79494650|NCT00003733|Drug|topotecan hydrochloride|
79494651|NCT00003739|Biological|filgrastim|
79494652|NCT00004075|Drug|tanespimycin|
79494653|NCT00003745|Drug|topotecan hydrochloride|
79494654|NCT00003163|Biological|filgrastim|
79494655|NCT00003163|Biological|sargramostim|
79494656|NCT00003163|Drug|cyclophosphamide|
79494657|NCT00003163|Drug|melphalan|
79494658|NCT00003163|Procedure|autologous bone marrow transplantation|
79494659|NCT00003163|Procedure|peripheral blood stem cell transplantation|
79494660|NCT00003163|Radiation|radiation therapy|
79494661|NCT00004081|Drug|docetaxel|
79494662|NCT00003751|Drug|penicillamine|
79494663|NCT00003751|Radiation|radiation therapy|
79494664|NCT04097119|Dietary Supplement|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
79814416|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Tablets for oral intake~Concentration: 25 mg~Route of Administration: oral"
79814417|NCT00840736|Procedure|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
79343493|NCT04688853|Biological|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
79343494|NCT02460575|Biological|Lactobacillus reuteri 17938|probiotic
79657969|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is >5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is <5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
79494665|NCT00004087|Biological|filgrastim|as prescribed by physician
79657970|NCT01641484|Procedure|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
79343495|NCT02460575|Biological|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
79343496|NCT02089347|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
79343497|NCT02089347|Biological|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
79343498|NCT02419469|Drug|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
79657971|NCT01641523|Device|CustomBone Service|customized hydroxyapatite cranial prosthesis
79343499|NCT02419469|Drug|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
79343500|NCT02419469|Drug|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
79343501|NCT02419469|Drug|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
79343502|NCT02419469|Drug|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
79343503|NCT02419469|Drug|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
79494666|NCT00004087|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
79494667|NCT00004087|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
79494668|NCT00004087|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
79494669|NCT00004087|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
79494670|NCT00003757|Biological|rituximab|
79494671|NCT00003175|Drug|fluorouracil|
79494672|NCT00004099|Drug|cisplatin|
79494673|NCT00004099|Drug|fluorouracil|
79494674|NCT00004099|Drug|leucovorin calcium|
79657972|NCT00417339|Procedure|hemodialysis|individualised
79657973|NCT00251342|Procedure|Edinburgh Postnatal Depression Scale|
79657974|NCT01641796|Drug|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
79657975|NCT00280098|Drug|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
79494675|NCT00004099|Procedure|neoadjuvant therapy|
79657976|NCT01681147|Behavioral|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
79494676|NCT00003763|Procedure|radionuclide imaging|
79343504|NCT02419469|Drug|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
79343505|NCT02419469|Drug|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
79343506|NCT02419469|Drug|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
79343507|NCT02419469|Drug|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
79343508|NCT02419469|Drug|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
79343509|NCT02419469|Drug|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
79343510|NCT02419469|Drug|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
79343511|NCT04687761|Drug|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle
79343512|NCT04687761|Drug|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
79343513|NCT04687761|Drug|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
79343514|NCT04687761|Drug|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
79343515|NCT04687761|Drug|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
79343516|NCT04687761|Drug|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
79343517|NCT02419313|Drug|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
79657977|NCT01681147|Behavioral|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
79657978|NCT00251381|Drug|Cetuximab|
79657979|NCT01685827|Drug|Fexinidazole|
79657980|NCT01685827|Drug|Nifurtimox|
79343518|NCT02419313|Drug|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
79657981|NCT01685827|Drug|Eflornithine|
79657982|NCT00251420|Procedure|writing about disease|writing about physical or emotional consequences of pulmonary disease
79657983|NCT05108584|Procedure|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
79814418|NCT00840736|Procedure|vertical banded gastroplasty|vertical banded gastroplasty
79985364|NCT03714139|Procedure|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden & Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
79494677|NCT00003763|Radiation|indium In 111 folic acid|
79343519|NCT04730193|Drug|Caffeine|Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
79343520|NCT04730193|Drug|Placebo|Placebo pill will be formulated with a non active ingredient such as rice flour powder
79494678|NCT04712695|Other|Exercise Based Interventions|Proprioception Training Interventions
79657984|NCT05108584|Procedure|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
79657985|NCT05108584|Procedure|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
79343521|NCT02419001|Drug|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
79343522|NCT02419001|Drug|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
79343523|NCT02419001|Drug|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
79657986|NCT01686841|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79657987|NCT00417378|Device|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
79985365|NCT03714139|Procedure|non implant loading|Control implants will receive a healing screw and will remain unloaded
79343524|NCT02419001|Drug|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
79343525|NCT02031237|Radiation|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
79343526|NCT02031237|Radiation|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
79343527|NCT02031237|Radiation|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
79343528|NCT02031237|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
79343529|NCT02088957|Drug|Brivaracetam intravenous solution|"Active Substance: Brivaracetam~Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/mL~Route of Administration: Intravenous bolus use"
79494679|NCT00003181|Biological|aldesleukin|
79494680|NCT00003181|Biological|sargramostim|
79494681|NCT00003181|Drug|vinblastine sulfate|
79494682|NCT00004105|Drug|estramustine phosphate sodium|
79494683|NCT00004105|Drug|paclitaxel|
79494684|NCT00004105|Drug|vinorelbine ditartrate|
79494685|NCT00003187|Biological|filgrastim|
79494686|NCT00003187|Drug|cyclophosphamide|
79494687|NCT00003187|Drug|cyclosporine|
79494688|NCT00003187|Drug|cytarabine|
79494689|NCT00003187|Drug|methotrexate|
79494690|NCT00003187|Drug|methylprednisolone|
79494691|NCT00003187|Procedure|allogeneic bone marrow transplantation|
79494692|NCT00003187|Procedure|in vitro-treated bone marrow transplantation|
79494693|NCT00003187|Radiation|radiation therapy|
79657988|NCT00417378|Device|Intraaortic Balloon Pump|Counterpulsation
79657989|NCT05140096|Drug|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
79814419|NCT00853307|Drug|Alisertib|Alisertib capsules
79985366|NCT02430454|Behavioral|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
79343530|NCT02088957|Drug|Brivaracetam oral tablets|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~Route of Administration: Oral use"
79494694|NCT00003769|Drug|perillyl alcohol|
79494695|NCT00003769|Procedure|surgical procedure|
79494696|NCT00003775|Drug|leflunomide|
79494697|NCT00004123|Drug|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
79657990|NCT05140096|Drug|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
79985367|NCT03700346|Device|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
79343531|NCT02088957|Drug|Phenytoin intravenous solution|"Active Substance: Phenytoin~Pharmaceutical Form: Solution for infusion~Concentration: 50 mg/mL~Route of Administration: Intravenous use"
79343532|NCT02088957|Drug|Phenytoin oral tablets|"Active Substance: Phenytoin~Pharmaceutical Form: Tablet~Concentration: Weight based~Route of Administration: Oral use"
79343533|NCT02418845|Drug|SYM-1219|
79343534|NCT02418845|Drug|Placebo|
79494698|NCT00004123|Procedure|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
79657991|NCT05140096|Drug|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
79657992|NCT00251459|Drug|rhuFab V2 (ranibizumab)|
79657993|NCT04823065|Drug|Loperamide Pill|4 mg Imodium, per os
79343535|NCT02088177|Drug|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
79343536|NCT02030535|Drug|olodaterol|free combination with tiotropium
79494699|NCT00004123|Radiation|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
79494700|NCT00004123|Radiation|Radiation Therapy (RT)|5 days a week for 4 weeks
79494701|NCT00003781|Drug|docetaxel|
79657994|NCT04823065|Drug|hyoscine-n-butylbromide|3 X 20 mg Buscopan, intravenous
79985368|NCT01373034|Dietary Supplement|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
79985369|NCT01373034|Dietary Supplement|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
79343537|NCT02030535|Drug|tiotropium|free combination with olodaterol
79343538|NCT02030535|Drug|Placebo|
79343539|NCT02030535|Drug|tiotropium|fixed dose combination with olodaterol
79343540|NCT02030535|Drug|olodaterol|fixed dose combination with tiotropium
79494702|NCT00003781|Procedure|pain therapy|
79494703|NCT00003781|Procedure|quality-of-life assessment|
79494704|NCT00003787|Behavioral|educational/counseling intervention|
79494705|NCT00003787|Behavioral|therapeutic dietary intervention|
79494706|NCT00003193|Drug|amifostine trihydrate|
79494707|NCT00003193|Drug|paclitaxel|
79494708|NCT00003193|Procedure|conventional surgery|
79494709|NCT00003193|Radiation|radiation therapy|
79494710|NCT00004129|Radiation|brachytherapy|
79494711|NCT00004129|Radiation|phosphorus P32|
79494712|NCT00003793|Genetic|clonality analysis|
79494713|NCT00003793|Genetic|microsatellite instability analysis|
79494714|NCT00003793|Genetic|mutation analysis|
79494715|NCT00384787|Biological|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
79494716|NCT00384787|Biological|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
79494717|NCT00004135|Biological|filgrastim|
79814420|NCT00835432|Device|Ossix|Test group
79814421|NCT00835432|Device|Biogide|controls
79985370|NCT03189316|Other|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
79985371|NCT05631613|Procedure|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
79985372|NCT03624608|Device|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
79985373|NCT02430064|Other|Low PAMP diet|
79343541|NCT04710537|Other|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
79494718|NCT00004135|Biological|therapeutic allogeneic lymphocytes|
79343542|NCT04710537|Other|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
79494719|NCT00004135|Drug|cyclophosphamide|
79494720|NCT00004135|Drug|fludarabine phosphate|
79343543|NCT02029989|Device|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
79494721|NCT00004135|Procedure|peripheral blood stem cell transplantation|
79494722|NCT00384943|Behavioral|Moderate-intensity Exercise|
79494723|NCT00004141|Drug|Cisplatin|
79494724|NCT00004141|Drug|dacarbazine|
79494725|NCT00004141|Drug|Granulocyte-macrophage colony-stimulating factor|
79494726|NCT02972905|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
79657995|NCT00280176|Drug|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
79657996|NCT00280176|Drug|fluorouracil|225mg/m2 given weekly, up to 6 weeks
79494727|NCT02972905|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
79657997|NCT00280176|Radiation|radiation therapy|180 cGy, every 5 days, up to six weeks
79343544|NCT02029989|Device|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
79494728|NCT00004147|Drug|incyclinide|
79343545|NCT02029989|Device|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
79343546|NCT02029989|Device|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
79657998|NCT02961179|Behavioral|Increased dairy product|
79657999|NCT02961179|Behavioral|Dietary counselling|
79658000|NCT04829305|Drug|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
79343547|NCT02029989|Device|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
79343548|NCT02029989|Behavioral|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
79343549|NCT02048241|Behavioral|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
79343550|NCT02048241|Other|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
79343551|NCT02048241|Drug|Intuniv|Weekly administration of medication in doses as per protocol
79343552|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
79343553|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
79343554|NCT02087943|Drug|Placebo|Orally twice a day (BID)
79494729|NCT00003799|Drug|fluorouracil|Given IV
79494730|NCT00003799|Drug|oxaliplatin|Given IV
79494731|NCT00003799|Radiation|radiation therapy|Undergo radiotherapy
79494732|NCT00003799|Drug|leucovorin calcium|Given IV
79494733|NCT00003799|Procedure|therapeutic conventional surgery|Undergo surgery
79494734|NCT00003205|Drug|bryostatin 1|
79494735|NCT00004153|Genetic|reverse transcriptase-polymerase chain reaction|
79494736|NCT00004153|Procedure|sentinel lymph node biopsy|
79494737|NCT00003211|Biological|filgrastim|
79494738|NCT00003211|Drug|amifostine trihydrate|
79494739|NCT00003211|Drug|cisplatin|
79494740|NCT00003211|Drug|cyclophosphamide|
79494741|NCT00003211|Drug|vincristine sulfate|
79494742|NCT00003211|Procedure|peripheral blood stem cell transplantation|
79494743|NCT00003211|Radiation|radiation therapy|
79494744|NCT00003805|Drug|piperacillin sodium|
79494745|NCT00003805|Drug|piperacillin-tazobactam|
79494746|NCT00003805|Drug|tazobactam sodium|
79494747|NCT00003805|Drug|vancomycin|
79494748|NCT00004159|Drug|gemcitabine hydrochloride|
79494749|NCT00004159|Drug|paclitaxel|
79494750|NCT00003811|Biological|bleomycin sulfate|
79494751|NCT00003811|Drug|amifostine trihydrate|
79494752|NCT00003811|Drug|cisplatin|
79494753|NCT00003811|Drug|etoposide|
79494754|NCT00003811|Procedure|conventional surgery|
79494755|NCT00004177|Biological|filgrastim|as prescribed by physician
79494756|NCT00004177|Procedure|peripheral blood stem cell transplantation|1-2 weeks from treatment
79494757|NCT00004177|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
79494758|NCT00004177|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
79494759|NCT00003817|Drug|dolasetron mesylate|
79494760|NCT00003817|Drug|granisetron hydrochloride|
79494761|NCT00003817|Drug|ondansetron|
79494762|NCT00003817|Drug|tropisetron|
79814422|NCT00825058|Drug|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
79814423|NCT00825058|Drug|placebo|oral administration 12 hours intervals
79814424|NCT00825058|Drug|paroxetine|oral 20 mg/day
79814425|NCT00701831|Drug|Insulin glargine|The dose is titrated according to patient needs
79494763|NCT00003817|Procedure|quality-of-life assessment|
79494764|NCT00003829|Drug|cyclophosphamide|
79494765|NCT00003829|Drug|fludarabine phosphate|
79658001|NCT00280215|Drug|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
79658002|NCT00280215|Drug|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
79343555|NCT02087943|Drug|Placebo|Orally twice a day (BID)
79658003|NCT00280215|Drug|Placebo|Patients will receive placebo for 24 months
79658004|NCT04720118|Other|No Intervention|There is no intervention for this study.
79343556|NCT02029521|Dietary Supplement|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
79343557|NCT02029521|Dietary Supplement|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
79343558|NCT04685811|Drug|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
79658005|NCT04826029|Other|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
79814426|NCT00840892|Other|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
79814427|NCT00835744|Drug|clomiphene citrate|ovulation induction
79814428|NCT00835744|Drug|gonadotropins|ovulation induction
79343559|NCT04709211|Procedure|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
79343560|NCT04709211|Procedure|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
79343561|NCT04709211|Drug|bupivacaine|bupivacaine
79343562|NCT02443883|Drug|Ramucirumab|Administered IV
79343563|NCT02460263|Device|Tablo Hemodialysis System|
79343564|NCT02443805|Biological|300 IR|300 IR tablet of HDM Allergen Extracts
79343565|NCT02443805|Biological|Placebo|Placebo tablet
79343566|NCT01652885|Drug|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
79343567|NCT02459951|Other|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
79343568|NCT04931927|Behavioral|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) [MCI-T +TAU]
79494766|NCT04329403|Drug|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
79494767|NCT04329403|Drug|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
79814429|NCT00841048|Drug|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
79343569|NCT04931927|Behavioral|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
79343570|NCT04922957|Drug|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
79343571|NCT04922957|Other|Placebo|Ringer's lactate solution
79343572|NCT02087241|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
79494768|NCT04329403|Other|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
79494769|NCT00003217|Biological|filgrastim|
79494770|NCT00003217|Drug|cyclophosphamide|
79494771|NCT00003217|Drug|cytarabine|
79494772|NCT00003217|Drug|dexamethasone|
79494773|NCT00003217|Drug|doxorubicin hydrochloride|
79494774|NCT00003217|Drug|methotrexate|
79494775|NCT00003217|Drug|vincristine sulfate|
79494776|NCT00004183|Drug|capecitabine|
79494777|NCT00003223|Drug|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
79494778|NCT00004189|Biological|filgrastim|
79494779|NCT00004189|Drug|becatecarin|
79343573|NCT02087241|Drug|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
79494780|NCT00004189|Drug|cisplatin|
79494781|NCT00003229|Biological|aldesleukin|
79494782|NCT00003229|Biological|gp100 antigen|
79343574|NCT02087241|Drug|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
79494783|NCT00003229|Biological|tyrosinase peptide|
79343575|NCT02087241|Drug|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
79494784|NCT00003835|Drug|leucovorin calcium|Given IV
79658006|NCT04826029|Other|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
79814430|NCT00841048|Drug|Placebo|
79985374|NCT03716089|Procedure|Laparoscopic resection|Laparoscopic surgery under general anesthesia
79343576|NCT02087085|Drug|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
79343577|NCT02087085|Other|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
79343578|NCT02443337|Drug|LY3023414|Administered orally
79343579|NCT02443337|Drug|Necitumumab|Administered IV
79343580|NCT04684251|Procedure|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
79494785|NCT00003835|Drug|fluorouracil|Given IV
79494786|NCT00003835|Drug|irinotecan hydrochloride|Given IV
79343581|NCT02443103|Drug|Guanabenz acetate|
79343582|NCT02022657|Drug|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
79343583|NCT02418455|Drug|UX003|solution for intravenous infusion
79494787|NCT00003835|Other|laboratory biomarker analysis|Correlative studies
79494788|NCT00003847|Drug|biricodar dicitrate|
79343584|NCT02417753|Drug|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
79494789|NCT00003847|Drug|doxorubicin hydrochloride|
79494790|NCT00003847|Drug|vincristine sulfate|
79494791|NCT00004195|Drug|eniluracil|Will be given to either subject pre-operative and metastatic disease
79494792|NCT00004195|Procedure|conventional colon surgery|Only if the subject is amenable to surgical resections
79494793|NCT00003853|Drug|4'-iodo-4'-deoxydoxorubicin|
79494794|NCT00385021|Drug|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
79494795|NCT00004201|Drug|carboplatin|
79494796|NCT00004201|Drug|cisplatin|
79494797|NCT00004201|Drug|gemcitabine hydrochloride|
79494798|NCT00003241|Drug|phenylacetate|
79494799|NCT00003859|Drug|carboplatin|
79494800|NCT00003859|Drug|cyclophosphamide|
79494801|NCT00003859|Drug|etoposide|
79494802|NCT00003859|Drug|vincristine sulfate|
79494803|NCT00003859|Procedure|surgical procedure|
79494804|NCT00003859|Radiation|radiation therapy|
79494805|NCT00003865|Drug|toremifene|
79494806|NCT00004207|Drug|liposomal daunorubicin citrate|
79494807|NCT00004213|Drug|triapine|
79494808|NCT00004219|Drug|granisetron hydrochloride|
79494809|NCT00004219|Drug|lerisetron|
79494810|NCT00004219|Radiation|radiation therapy|
79343585|NCT02417441|Device|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
79494811|NCT00003877|Biological|filgrastim|
79494812|NCT00003877|Drug|carboplatin|
79658007|NCT00251498|Drug|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
79658008|NCT00417456|Other|Evisit|Asynchronous,remote care delivery via a secure web platform
79658009|NCT00417456|Other|Office visit|Conventional office-based care
79985375|NCT03692078|Other|OTDN product 1|Oral tobacco-derived nicotine product
79985376|NCT03692078|Other|OTDN product 2|Oral tobacco-derived nicotine product
79985377|NCT03692078|Other|Tobacco Cessation|Tobacco Cessation
79985378|NCT03189160|Biological|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
79985379|NCT03189160|Biological|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
79985380|NCT03189160|Other|Non-treatment control group|
79985381|NCT03208530|Behavioral|Brief motivational interview intervention|A brief (<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
79343586|NCT02021643|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
79343587|NCT02021643|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79343588|NCT02021643|Drug|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
79343589|NCT02415959|Drug|Creon IR|
79985382|NCT03695822|Drug|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
79985383|NCT03718507|Drug|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
79985384|NCT03718507|Drug|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
79985385|NCT03700268|Other|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
79343590|NCT02415959|Drug|Creon® (DR/GR)|
79343591|NCT02021565|Behavioral|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
79343592|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
79494813|NCT00003877|Drug|cyclophosphamide|
79494814|NCT00003877|Drug|paclitaxel|
79494815|NCT00003877|Drug|thiotepa|
79985386|NCT03188692|Biological|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
79494816|NCT00003877|Procedure|in vitro-treated bone marrow transplantation|
79494817|NCT00003877|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79494818|NCT00003883|Drug|fluconazole|
79494819|NCT00003883|Drug|itraconazole|
79494820|NCT00003253|Drug|paclitaxel|
79494821|NCT00003253|Other|antitumor drug screening assay|
79494822|NCT00004225|Biological|Ad5CMV-p53 gene|
79494823|NCT00004225|Radiation|radiation therapy|
79494824|NCT00004237|Drug|cyclophosphamide|
79494825|NCT00004237|Drug|doxorubicin hydrochloride|
79494826|NCT00004237|Drug|epirubicin hydrochloride|
79494827|NCT00004237|Drug|mitoxantrone hydrochloride|
79494828|NCT00004237|Drug|vinorelbine tartrate|
79985387|NCT03716011|Device|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
79985388|NCT04940832|Device|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
79985389|NCT02430610|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
79985390|NCT02430610|Device|NanoKnife|
79343593|NCT05370677|Genetic|ARMS|amplification refractory mutation system
79343594|NCT02021331|Device|immediate implant placement without provisionalization|
79343595|NCT02021331|Device|immediate implant placement with immediate provisionalization|
79343596|NCT04682535|Other|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
79494829|NCT00004237|Procedure|conventional surgery|
79494830|NCT00004237|Radiation|radiation therapy|
79494831|NCT00003259|Drug|vinorelbine tartrate|
79658010|NCT00280254|Procedure|Hemodynamically Oriented Echocardiography-based Strategy|
79658011|NCT02275351|Drug|SM04554|Topical solution, applied once a day
79658012|NCT02275351|Drug|Vehicle|Topical solution, applied once a day
79658013|NCT04720040|Device|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79343597|NCT02085135|Drug|ALKS 5461|Sublingual tablet taken once daily
79343598|NCT02441309|Drug|Mifamurtide|
79343599|NCT02441309|Drug|Ifosfamide|
79658014|NCT00417495|Behavioral|Sentinel Lymph Node Technique|
79658015|NCT05140057|Combination Product|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
79343600|NCT02027025|Drug|SPARC1103 low dose|once daily
79658016|NCT00251537|Drug|LTB4|
79658017|NCT02271334|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
79658018|NCT02271334|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
79658019|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
79343601|NCT02027025|Drug|SPARC1103 high dose|once daily
79343602|NCT02027025|Drug|SPARC Placebo|
79343603|NCT01652729|Drug|Exenatide once weekly suspension|
79343604|NCT01652729|Drug|Sitagliptin|
79343605|NCT01652729|Drug|Placebo|Placebo oral capsule once daily
79343606|NCT02083965|Biological|rFVIIIFc|Administered as specified in the treatment arm.
79343607|NCT02438813|Drug|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
79343608|NCT02438813|Procedure|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
79343609|NCT02438813|Procedure|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
79494832|NCT00003913|Biological|anti-thymocyte globulin|
79494833|NCT00003913|Biological|filgrastim|
79494834|NCT00003913|Drug|busulfan|
79494835|NCT00003913|Drug|cyclophosphamide|
79494836|NCT00003913|Drug|methylprednisolone|
79494837|NCT00003913|Procedure|umbilical cord blood transplantation|
79494838|NCT00003913|Radiation|radiation therapy|
79494839|NCT00004243|Drug|docetaxel|
79494840|NCT00004243|Drug|oxaliplatin|
79494841|NCT00004249|Biological|QS21|
79494842|NCT00004249|Biological|keyhole limpet hemocyanin|
79494843|NCT00004249|Drug|polysialic acid|
79494844|NCT00003925|Drug|gemcitabine hydrochloride|
79494845|NCT00003925|Drug|leucovorin calcium|
79494846|NCT00003925|Drug|tegafur-uracil|
79494847|NCT00004255|Biological|anti-thymocyte globulin|
79658020|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
79658021|NCT00280332|Procedure|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
79658022|NCT02276755|Dietary Supplement|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
79658023|NCT02276755|Other|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
79658024|NCT02278198|Drug|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
79658025|NCT00286884|Procedure|Monitoring of heart rate variability|
79658026|NCT02279290|Behavioral|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
79494848|NCT00004255|Biological|filgrastim|
79494849|NCT00004255|Drug|cyclophosphamide|
79494850|NCT00004255|Drug|fludarabine phosphate|
79343610|NCT02438813|Device|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
79343611|NCT02438813|Other|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
79343612|NCT02437409|Device|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
79343613|NCT02459093|Device|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
79343614|NCT02459093|Device|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
79494851|NCT00004255|Drug|methylprednisolone|
79494852|NCT00004255|Drug|tacrolimus|
79494853|NCT00004255|Procedure|allogeneic bone marrow transplantation|
79494854|NCT00004255|Procedure|in vitro-treated bone marrow transplantation|
79494855|NCT00004255|Radiation|radiation therapy|
79494856|NCT00003931|Genetic|reverse transcriptase-polymerase chain reaction|
79494857|NCT00004261|Drug|EF5|
79494858|NCT00004261|Other|flow cytometry|
79494859|NCT00004261|Other|fluorescent antibody technique|
79494860|NCT00004261|Other|immunohistochemistry staining method|
79494861|NCT00004261|Procedure|biopsy|
79494862|NCT00004831|Drug|cysteine hydrochloride|
79494863|NCT00004285|Device|Standard dose, low flux hemodialysis|
79494864|NCT00004285|Device|Standard dose, high flux hemodialysis|
79494865|NCT00004285|Device|High dose, low flux hemodialysis|
79494866|NCT00004285|Device|High dose, high flux hemodialysis|
79494867|NCT00004843|Procedure|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
79494868|NCT00004843|Other|Observation|Usual care
79494869|NCT00004297|Drug|diazepam|
79494870|NCT00004297|Drug|lorazepam|
79494871|NCT00004855|Drug|Lopinavir/Ritonavir|
79494872|NCT00004855|Drug|Abacavir sulfate|
79494873|NCT00004855|Drug|Nevirapine|
79494874|NCT00004855|Drug|Lamivudine|
79494875|NCT00004855|Drug|Stavudine|
79494876|NCT00003289|Drug|7-hydroxystaurosporine|
79494877|NCT00004861|Drug|gemcitabine hydrochloride|
79494878|NCT00004861|Drug|tacedinaline|
79494879|NCT00004315|Drug|ursodiol|
79494880|NCT00003301|Drug|irinotecan hydrochloride|
79814431|NCT00778830|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
79494881|NCT00003307|Drug|amifostine trihydrate|
79494882|NCT00003307|Radiation|radiation therapy|
79494883|NCT00004327|Drug|octreotide|
79494884|NCT00003313|Biological|filgrastim|
79494885|NCT00003313|Drug|amifostine trihydrate|
79494886|NCT00003313|Drug|carboplatin|
79494887|NCT00003313|Drug|paclitaxel|
79494888|NCT00003313|Radiation|radiation therapy|
79494889|NCT00004867|Procedure|conventional surgery|
79494890|NCT00004867|Procedure|positron emission tomography|
79494891|NCT00004867|Procedure|radionuclide imaging|
79494892|NCT00004867|Radiation|fludeoxyglucose F 18|
79494893|NCT00004867|Drug|chemotherapy|
79494894|NCT00004867|Radiation|Radiotherapy|
79494895|NCT00004873|Drug|cisplatin|
79494896|NCT00004873|Drug|docetaxel|
79494897|NCT00004873|Drug|epirubicin hydrochloride|
79494898|NCT00004873|Drug|fluorouracil|
79494899|NCT00004333|Drug|NTBC|
79494900|NCT00004879|Biological|panitumumab|
79494901|NCT00003325|Procedure|Sentinel lymph node mapping|Sentinel lymph node mapping
79494902|NCT00004339|Drug|tetrathiomolybdate|
79494903|NCT00004339|Drug|trientine|
79494904|NCT00385099|Drug|GW876008|
79494905|NCT00003331|Drug|fluorouracil|
79494906|NCT00003331|Drug|leucovorin calcium|
79494907|NCT00003331|Drug|topotecan hydrochloride|
79494908|NCT00004885|Drug|FOLFIRI regimen|
79494909|NCT00004885|Drug|fluorouracil|
79494910|NCT00004885|Drug|irinotecan hydrochloride|
79494911|NCT00004885|Drug|leucovorin calcium|
79494912|NCT00004891|Drug|chemotherapy|
79494913|NCT00004891|Procedure|computed tomography|
79494914|NCT00004891|Procedure|conventional surgery|
79494915|NCT00004891|Procedure|neoadjuvant therapy|
79494916|NCT00004891|Procedure|positron emission tomography|
79494917|NCT00004891|Procedure|radionuclide imaging|
79494918|NCT00004891|Radiation|fludeoxyglucose F 18|
79494919|NCT00004891|Radiation|radiation therapy|
79494920|NCT00003337|Procedure|immunoscintigraphy|
79494921|NCT00003337|Radiation|technetium Tc 99m epratuzumab|
79494922|NCT00003343|Drug|endocrine-modulating drug therapy|
79343615|NCT02458469|Drug|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
79343616|NCT02458469|Drug|Trazodone|100 mg dose before bed-time
79494923|NCT00003343|Drug|mitoxantrone hydrochloride|
79494924|NCT00003343|Drug|prednisone|
79494925|NCT00003343|Drug|prinomastat|
79494926|NCT00004903|Biological|filgrastim|
79494927|NCT00004903|Biological|recombinant interferon alfa|
79494928|NCT00004903|Drug|cisplatin|
79494929|NCT00004903|Drug|cyclophosphamide|
79494930|NCT00004903|Drug|cytarabine|
79494931|NCT00004903|Drug|etoposide|
79494932|NCT00004903|Drug|melphalan|
79494933|NCT00004903|Procedure|peripheral blood stem cell transplantation|
79494934|NCT00004357|Drug|Methylprednisolone|IV
79494935|NCT00004357|Drug|Prednisolone|Oral
79494936|NCT00004363|Drug|chlorpropamide|
79494937|NCT00004363|Drug|desmopressin|
79494938|NCT04069117|Drug|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
79494939|NCT00004921|Biological|filgrastim|
79494940|NCT00004921|Drug|carboplatin|
79494941|NCT00004921|Drug|cyclophosphamide|
79494942|NCT00004921|Drug|melphalan|
79494943|NCT00004921|Drug|paclitaxel|
79494944|NCT00004921|Procedure|adjuvant therapy|
79494945|NCT00004921|Procedure|bone marrow ablation with stem cell support|
79494946|NCT00004921|Procedure|peripheral blood stem cell transplantation|
79494947|NCT00004375|Procedure|ultraviolet A-1 light treatment|
79494948|NCT00004927|Drug|ixabepilone|
79494949|NCT00004933|Drug|hydroxyurea|0.5 to 5 grams PO per day
79494950|NCT00004933|Drug|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
79494951|NCT00004939|Drug|,4-diaminopyridine|
79343617|NCT02458469|Drug|Placebo|One placebo pill before bed-time
79343618|NCT01843348|Drug|Everolimus|
79343619|NCT01843348|Drug|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
79343620|NCT01843348|Drug|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
79343621|NCT01843348|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
79494952|NCT00004981|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
79494953|NCT00004981|Drug|Lamivudine/Zidovudine|
79494954|NCT00004981|Drug|Abacavir sulfate|
79494955|NCT00004987|Drug|Dextrin 2-sulfate|
79494956|NCT00004993|Drug|Parathyroid hormone (hPTH 1-34)|
79494957|NCT00004999|Drug|Lamivudine/Zidovudine|
79494958|NCT00004999|Drug|Capravirine|
79494959|NCT00004999|Drug|Nelfinavir mesylate|
79494960|NCT00003361|Drug|decitabine|
79494961|NCT00003367|Dietary Supplement|green tea|
79494962|NCT00003367|Dietary Supplement|soy protein isolate|
79494963|NCT00003367|Dietary Supplement|vitamin E|
79494964|NCT00003379|Drug|cisplatin|
79494965|NCT00003379|Drug|paclitaxel|
79494966|NCT00003379|Radiation|brachytherapy|
79494967|NCT00003379|Radiation|radiation therapy|
79494968|NCT00003385|Drug|carboplatin|
79494969|NCT00003385|Drug|paclitaxel|
79494970|NCT00003385|Drug|pegylated liposomal doxorubicin hydrochloride|
79494971|NCT00004381|Drug|tin mesoporphyrin|
79494972|NCT00005005|Drug|PTH|
79494973|NCT00005005|Drug|Alendronate|
79494974|NCT00004387|Procedure|fetal nigral transplantation|
79494975|NCT00004393|Drug|risperidone|
79494976|NCT00004399|Drug|magnesium sulfate|
79494977|NCT00004399|Drug|nimodipine|
79494978|NCT00004423|Drug|-aminosalicylic acid|
79494979|NCT00005017|Drug|Ritonavir|
79494980|NCT00005017|Drug|Abacavir sulfate|
79494981|NCT00005017|Drug|Amprenavir|
79494982|NCT00005017|Drug|Efavirenz|
79494983|NCT00005017|Drug|Lamivudine|
79494984|NCT00005017|Drug|Stavudine|
79494985|NCT00005023|Biological|HER-2/neu peptide vaccine|
79343622|NCT01843348|Drug|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
79343623|NCT01843348|Drug|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
79494986|NCT00005023|Biological|sargramostim|
79658027|NCT02279290|Behavioral|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
79985391|NCT03714061|Other|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
79658028|NCT04826419|Other|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
79658029|NCT00280371|Drug|Formoterol Fumarate|
79343624|NCT01843348|Drug|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
79343625|NCT01843192|Device|Endocutter|
79343626|NCT01825876|Drug|Evacetrapib|Oral administration
79343627|NCT01825876|Drug|Warfarin|Oral administration
79343628|NCT01842958|Device|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
79343629|NCT01842958|Device|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
79343630|NCT02413229|Drug|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
79494987|NCT00005029|Drug|topotecan hydrochloride|
79494988|NCT00005035|Drug|oxaliplatin|
79494989|NCT00004429|Drug|growth hormone|
79343631|NCT02413229|Drug|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
79343632|NCT01825798|Drug|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
79494990|NCT00005041|Drug|tipifarnib|
79494991|NCT00004441|Drug|tauroursodeoxycholic acid|
79494992|NCT00004441|Drug|ursodiol|
79494993|NCT00005053|Drug|glufosfamide|
79494994|NCT00004465|Drug|SYNSORB Pk|
79494995|NCT00004465|Drug|Placebo|
79494996|NCT00005569|Drug|SLPI (Secretory Leukocyte Protease Inhibitor)|
79494997|NCT00005575|Drug|Imipramine|
79814432|NCT00778830|Drug|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
79494998|NCT00005575|Behavioral|Cognitive-behavior therapy|
79494999|NCT00385333|Procedure|Feasibility Study - Imaging System|
79495000|NCT00004471|Genetic|pGT-1 gene lipid complex|
79495001|NCT00005059|Drug|carboplatin|
79495002|NCT00005059|Drug|paclitaxel|
79495003|NCT00005065|Drug|paclitaxel|Given IV
79495004|NCT00005065|Drug|carboplatin|Given IV
79495005|NCT00005065|Drug|motexafin gadolinium|Given IV
79495006|NCT00005065|Procedure|conventional surgery|Undergo complete surgical resection
79495007|NCT00005065|Radiation|radiation therapy|Undergo radiation therapy
79343633|NCT01825798|Drug|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
79343634|NCT01824472|Device|CPAP|Treatment for sleep apnea
79343635|NCT01824472|Behavioral|CBT|Treatment for insomnia
79343636|NCT01824472|Device|sham CPAP|Placebo for sleep apnea
79343637|NCT01824472|Behavioral|CC|Placebo (sham) for insomnia
79495008|NCT00386191|Drug|clopidogrel (SR25990C)|oral administration
79495009|NCT00386269|Drug|Codeine Phosphate Analgesia|
79658030|NCT04822480|Behavioral|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
79985392|NCT03714061|Other|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
79343638|NCT02412761|Drug|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
79343639|NCT02412761|Drug|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
79343640|NCT02412761|Drug|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
79343641|NCT01842334|Behavioral|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
79343642|NCT01842334|Drug|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
79495010|NCT00005071|Procedure|biopsy|
79343643|NCT02457611|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79495011|NCT00005071|Procedure|bronchoscopy|
79495012|NCT00005071|Procedure|computed tomography|
79495013|NCT00005071|Procedure|quality-of-life assessment|
79495014|NCT00423241|Device|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
79495015|NCT00423241|Device|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
79495016|NCT00385177|Drug|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
79495017|NCT00005581|Drug|cyclophosphamide|
79495018|NCT00005581|Drug|epirubicin hydrochloride|
79495019|NCT00005581|Drug|fluorouracil|
79495020|NCT00005581|Drug|paclitaxel|
79495021|NCT00005077|Drug|oxaliplatin|
79495022|NCT00004489|Drug|alendronate sodium|
79658031|NCT04826926|Procedure|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
79814433|NCT00778830|Drug|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
79495023|NCT00004489|Drug|calcium carbonate|
79814434|NCT04102332|Device|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
79495024|NCT00004489|Drug|cholecalciferol|
79495025|NCT00005083|Procedure|conventional surgery|
79495026|NCT00005083|Procedure|magnetic resonance imaging|
79495027|NCT00005083|Procedure|magnetic resonance spectroscopic imaging|
79495028|NCT00005587|Radiation|radiation therapy|
79495029|NCT00005593|Drug|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
79495030|NCT00005593|Drug|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
79495031|NCT00005593|Drug|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
79658032|NCT00280410|Drug|E7337|
79814435|NCT00772668|Drug|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
79814436|NCT00772668|Drug|Bortezomib|Administered intravenously per protocol.
79814437|NCT00772668|Drug|Cyclophosphamide|Administered intravenously per protocol.
79814438|NCT00772668|Drug|Prednisone|Administered orally (PO) per protocol.
79814439|NCT00786474|Drug|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
79343644|NCT04593628|Behavioral|Connect for Caregivers|The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
79658033|NCT04900246|Procedure|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
79814440|NCT00786474|Drug|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
79343645|NCT04931381|Other|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
79814441|NCT00784875|Drug|LY2624803|1 mg, oral capsule, once nightly before bedtime
79343646|NCT02457065|Behavioral|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
79343647|NCT02083653|Drug|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
79343648|NCT02083653|Drug|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
79343649|NCT02083653|Other|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
79343650|NCT02083653|Drug|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
79343651|NCT02083653|Drug|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
79343652|NCT02436239|Drug|Vilazodone|Vilazodone tablets, once daily, oral administration
79495032|NCT00004495|Drug|cyanocobalamin|
79495033|NCT00004495|Drug|folic acid|
79495034|NCT00004495|Drug|pyridoxine|
79495035|NCT00005089|Biological|rituximab|375 mg/m^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
79495036|NCT00005089|Drug|cyclophosphamide|750 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
79495037|NCT00005089|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
79495038|NCT00005089|Drug|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
79495039|NCT00005089|Drug|vincristine sulfate|1.4 mg/m^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
79495040|NCT00005089|Radiation|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
79495041|NCT00004549|Procedure|Magnetic resonance imaging|
79495042|NCT00005599|Drug|bryostatin 1|
79495043|NCT00005599|Drug|paclitaxel|
79343653|NCT02026011|Drug|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
79343654|NCT02026011|Drug|Placebo|Sugar pill, matched to the active study medication in capsule size and color
79343655|NCT02436005|Device|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
79343656|NCT02436005|Device|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
79343657|NCT02456909|Device|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
79343658|NCT02456909|Device|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
79495044|NCT00004561|Behavioral|exercise|
79495045|NCT00005611|Drug|BMS-188797|
79343659|NCT02456909|Drug|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
79495046|NCT00004567|Drug|Mycophenolate Mofetil|
79495047|NCT00005113|Drug|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
79495048|NCT00005113|Drug|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
79495049|NCT00005113|Drug|Tacrolimus|dosage is in oral form titrated to target trough level
79495050|NCT00005617|Biological|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
79343660|NCT04199273|Procedure|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
79495051|NCT00005617|Procedure|leukapheresis|Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
79343661|NCT04199273|Procedure|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
79343662|NCT02025621|Drug|Levosimendan|
79343663|NCT02025621|Drug|Placebo|matching placebo
79658034|NCT04900246|Radiation|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
79814442|NCT00784875|Drug|LY2624803|3 mg, oral capsule, once nightly before bedtime
79495052|NCT00004573|Drug|ganciclovir|
79495053|NCT00005623|Drug|cyproterone acetate|
79495054|NCT00005623|Procedure|quality-of-life assessment|
79343664|NCT04729023|Procedure|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
79343665|NCT04729023|Procedure|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
79495055|NCT00005119|Procedure|Measures of calcium and bone turnover|
79343666|NCT02020941|Drug|carfilzomib|Given IV
79343667|NCT02020941|Drug|dexamethasone|Given IV or PO
79343668|NCT02020941|Other|laboratory biomarker analysis|Correlative studies
79343669|NCT02024529|Biological|4 mL injection of Ampion|4 mL injection of Ampion
79495056|NCT02972749|Behavioral|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
79495057|NCT00005629|Biological|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
79495058|NCT00004579|Biological|gp160 MN/LAI-2|
79495059|NCT00004579|Biological|ALVAC-HIV MN120TMG (vCP205)|
79495060|NCT00004585|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
79495061|NCT00004585|Drug|Lamivudine/Zidovudine|
79495062|NCT00004585|Drug|Abacavir sulfate|
79495063|NCT00004585|Drug|Efavirenz|
79495064|NCT00005635|Biological|trastuzumab|
79495065|NCT00005635|Drug|paclitaxel|
79814443|NCT00784875|Drug|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
79814444|NCT00784875|Drug|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
79814445|NCT04104711|Other|Home visits, health education|
79814446|NCT02602665|Procedure|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
79814447|NCT02602665|Procedure|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
79814448|NCT02602431|Device|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
79495066|NCT00005137|Other|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
79495067|NCT00004639|Procedure|Furlow double z-plasty palatoplasty palate repair|
79658035|NCT04900246|Device|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
79985393|NCT01373112|Procedure|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
79658036|NCT00280449|Behavioral|strengths-based case managed proactive service model|
79343670|NCT02024529|Drug|4 mL Injection of Placebo|4 mL Injection of Placebo
79343671|NCT02020863|Device|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
79343672|NCT01824394|Device|nMARQ Navigation Catheters|
79343673|NCT01824394|Device|NaviStar ThermoCool Catheters|
79343674|NCT01823536|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
79495068|NCT00004639|Procedure|Von Langenbeck palatoplasty palate repair|
79495069|NCT00005641|Biological|anti-thymocyte globulin|
79658037|NCT00251654|Procedure|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
79658038|NCT04335019|Other|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
79658039|NCT00286923|Drug|Topiramate|
79658040|NCT04822168|Other|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
79658041|NCT04822168|Other|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
79343675|NCT01841554|Device|Cardioband|
79495070|NCT00005641|Drug|busulfan|
79495071|NCT00005641|Drug|cyclophosphamide|
79495072|NCT00005641|Drug|cyclosporine|
79495073|NCT00005641|Drug|leucovorin calcium|
79495074|NCT00005641|Drug|methotrexate|
79495075|NCT00005641|Drug|methylprednisolone|
79495076|NCT00005641|Procedure|allogeneic bone marrow transplantation|
79495077|NCT00005641|Procedure|in vitro-treated bone marrow transplantation|
79495078|NCT00005641|Radiation|radiation therapy|
79495079|NCT00004645|Procedure|Plasma exchange|
79495080|NCT00005647|Drug|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
79658042|NCT00251732|Drug|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
79495081|NCT00005647|Drug|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
79495082|NCT00005665|Drug|interferon alpha|
79495083|NCT00004669|Drug|hydrocortisone|
79495084|NCT00385411|Drug|valproate microgranules|20 to 30 mg/kg/day
79495085|NCT00004699|Drug|insulin-like growth factor I|
79495086|NCT00385489|Drug|LXR-623|
79495087|NCT00004705|Drug|amiloride|
79495088|NCT00004705|Drug|uridine|
79495089|NCT00004729|Behavioral|Ketogenic diet|
79495090|NCT00004735|Biological|Tetanus toxoid|
79495091|NCT00004735|Biological|Hepatitis A Vaccine (Inactivated)|
79495092|NCT00004747|Drug|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
79495093|NCT00004759|Drug|methylprednisolone|
79495094|NCT00004759|Drug|tirilazad|
79658043|NCT00251732|Drug|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
79658044|NCT00251732|Drug|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
79495095|NCT00005713|Behavioral|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
79658045|NCT04088539|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
79814449|NCT02602431|Device|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
79814450|NCT02602431|Device|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
79343676|NCT01823224|Drug|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
79343677|NCT01823224|Drug|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
79343678|NCT01840228|Drug|Micronized progesterone suppository|
79343679|NCT01839916|Biological|therapeutic allogeneic lymphocytes|Given IV
79343680|NCT01839916|Other|laboratory biomarker analysis|Correlative studies
79343681|NCT01823146|Drug|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
79343682|NCT01823146|Drug|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
79343683|NCT02083185|Drug|Relugolix|Relugolix tablets
79343684|NCT02083185|Drug|Leuprorelin|Leuprorelin subcutaneous injection
79343685|NCT04417023|Other|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
79495096|NCT02972827|Device|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
79658046|NCT04088539|Behavioral|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
79814451|NCT02602431|Device|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
79814452|NCT00592553|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
79814453|NCT00592553|Drug|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
79814454|NCT00701909|Drug|morphine plus saline|During the first wound care procedure, some patients will receive morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS), according to randomization, while other patients will receive morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg
79495097|NCT02972827|Other|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
79343686|NCT02019927|Device|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
79343687|NCT02019927|Device|Sham|Sham
79343688|NCT04185441|Drug|Tanzânia association|Tanzânia association capsule
79343689|NCT04185441|Drug|Omnic Ocas|Tamsulosin 0,4 mg
79343690|NCT04185441|Other|Omnic Ocas placebo|Tamsulosin placebo
79343691|NCT04185441|Other|Tanzânia association placebo|EMS association placebo
79343692|NCT04416945|Other|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
79343693|NCT04416945|Other|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
79495098|NCT00004771|Drug|leuprolide|
79495099|NCT00004771|Drug|testosterone|
79495100|NCT00004789|Drug|heme arginate|
79814455|NCT00701909|Drug|morphine plus ketamine|Patients who received morphine 0.1 mg/kg (maximum dose of 8 mg)plus saline during the first wound care procedure will now receive ketamine 0.25 mg/kg IV plus morphine 0.05 mg/kg
79495101|NCT00004789|Drug|tin mesoporphyrin|
79495102|NCT00004795|Drug|dehydroepiandrosterone|
79495103|NCT00005743|Behavioral|exercise|
79495104|NCT00005743|Behavioral|weight loss|
79495105|NCT00004801|Drug|monoclonal factor IX replacement therapy|
79495106|NCT00004807|Drug|dextromethorphan|
79495107|NCT00004807|Drug|topiramate|
79495108|NCT00004807|Drug|Donepezil|
79495109|NCT00004825|Drug|recombinant human insulin-like growth factor I|
79495110|NCT00385567|Drug|PEHRG214|
79495111|NCT00385645|Drug|Combivir+Kaletra|
79495112|NCT00385645|Drug|Combivir+Reyataz|
79495113|NCT00385879|Behavioral|Case management|
79495114|NCT00005305|Other|No interventions - observational study|
79814456|NCT00699023|Drug|ezetimibe tablets|ezetimibe tablets 10 mg/die
79814457|NCT00699023|Drug|simvastatin tablets|simvastatin tablets 20 mg/die
79814458|NCT00699023|Drug|placebo|placebo
79814459|NCT00853229|Drug|pregabalin|pregabalin 150mg twice daily for 4 weeks
79814460|NCT02612753|Procedure|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
79495115|NCT00385957|Drug|AZT+3TC+IDV+RTV|
79495116|NCT00385957|Drug|AZT+3TC+EFV|
79495117|NCT00386035|Drug|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
79814461|NCT02612753|Device|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
79814462|NCT02612753|Device|tDCs|
79814463|NCT00853151|Drug|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
79814464|NCT00853151|Drug|TT223|subcutaneous injection once a day for 4 weeks
79658047|NCT04042792|Other|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
79343694|NCT04416945|Other|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
79658048|NCT00286962|Device|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
79343695|NCT02412371|Drug|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
79495118|NCT00386035|Drug|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
79495119|NCT00386113|Biological|Fluarix and adjuvanted influenza vaccine|
79495120|NCT00005107|Drug|N-monomethyl-L-arginine|
79495121|NCT00005773|Drug|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had <=20 mm Hg increase in PaO2 (less than full response).
79495122|NCT00005773|Drug|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
79495123|NCT00005779|Drug|Interleukin-12|
79495124|NCT00005779|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
79495125|NCT00005785|Drug|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
79495126|NCT00005791|Drug|cisplatin|
79658049|NCT00286962|Device|continuous subcutaneous insulin infusion (CSII) or MDI|
79658050|NCT04011826|Device|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
79658051|NCT04006756|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
79658052|NCT04006756|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
79658053|NCT00251771|Procedure|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
79343696|NCT02412371|Drug|Placebo for Veliparib|Capsule for oral administration
79658054|NCT03946462|Drug|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
79343697|NCT02412371|Drug|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
79495127|NCT00005791|Drug|fluorouracil|
79658055|NCT03946462|Other|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
79658056|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
79658057|NCT00280488|Behavioral|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
79658058|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
79658059|NCT00251810|Device|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
79658060|NCT03531580|Device|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
79658061|NCT03488641|Diagnostic Test|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
79658062|NCT00287001|Device|Cold air cooling|
79495128|NCT00005791|Drug|irinotecan hydrochloride|
79658063|NCT03439930|Other|Balance training|6 weeks lasting balance training program
79658064|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
79658065|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
79495129|NCT00005797|Drug|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
79495130|NCT00005797|Drug|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
79658066|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
79658067|NCT04719650|Drug|Placebo|Infusion normal saline once.
79343698|NCT02412371|Drug|Veliparib|Capsule for oral administration
79343699|NCT02412371|Radiation|Radiotherapy|Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
79343700|NCT02411747|Behavioral|Testing|
79343701|NCT02411747|Behavioral|Directed self-regulated simulation training|
79343702|NCT01822756|Drug|ruxolitinib|
79343703|NCT01822756|Drug|gemcitabine|Other names: Gemzar®
79343704|NCT01822756|Drug|nab-paclitaxel|Other names: Abraxane®
79343705|NCT01822756|Drug|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
79495131|NCT00005797|Drug|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
79343706|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
79495132|NCT00005797|Radiation|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
79495133|NCT00386347|Drug|GSK364735 oral solution and oral tablets|
79495134|NCT00005809|Procedure|computed tomography|
79658068|NCT03406312|Diagnostic Test|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
79343707|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
79343708|NCT01822678|Drug|Placebo|Placebo
79343709|NCT01822366|Behavioral|Trauma-focused Cognitive Behavioral Therapy|
79495135|NCT00005809|Procedure|diagnostic colonoscopy|
79495136|NCT00005815|Drug|temozolomide|
79495137|NCT00005815|Drug|thalidomide|
79495138|NCT02132754|Biological|MK-4166|
79495139|NCT02132754|Biological|Pembrolizumab|
79495140|NCT02151786|Drug|Lansoprazole|Lansoprazole intravenous 30 mg
79658069|NCT03218605|Other|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
79658070|NCT00251849|Drug|Rifalazil|
79658071|NCT03189862|Behavioral|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
79658072|NCT02960802|Procedure|kidney transplantation|
79658073|NCT00251888|Drug|campto (irinotecan)|
79658074|NCT00251888|Drug|cisplatin (cisplatyl)|
79814465|NCT00853151|Drug|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
79658075|NCT04823221|Device|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
79343710|NCT01838590|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79343711|NCT01838590|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79658076|NCT01600027|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
79658077|NCT01600027|Procedure|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
79658078|NCT00251966|Drug|Esomeprazole|
79343712|NCT01611454|Device|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
79343713|NCT01611454|Device|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
79495141|NCT02132130|Drug|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
79495142|NCT02131662|Drug|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
79495143|NCT02131662|Drug|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
79495144|NCT02131662|Drug|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
79658079|NCT02699086|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
79658080|NCT00252044|Drug|Pergolide|
79658081|NCT01805284|Drug|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
79658082|NCT01337128|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
79658083|NCT01337128|Procedure|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
79658084|NCT01337128|Procedure|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
79814466|NCT00853151|Drug|Placebo for TT223|subcutaneous injection once a day for 4 weeks
79814467|NCT00700349|Other|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
79814468|NCT02612675|Other|ONS|
79985394|NCT01373112|Procedure|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
79985395|NCT03695666|Other|Clerical policy|Clerical policy introduction
79343714|NCT01611298|Biological|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
79343715|NCT01822132|Drug|Extended release naltrexone|
79343716|NCT01822132|Drug|Placebo|
79343717|NCT04593004|Device|Teledermatology|Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
79343718|NCT04593004|Other|Face-to-face consultation|Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
79343719|NCT01821898|Drug|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
79343720|NCT01821898|Other|Elimination diet|This group will receive an elimination diet
79343721|NCT02411591|Drug|Necitumumab|Administered IV.
79658085|NCT01337128|Procedure|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
79985396|NCT03188848|Drug|BPI-3016|Single-dose subcutaneous injection of BPI-3016
79343722|NCT02411591|Drug|Abemaciclib|Administered orally.
79495145|NCT02131662|Drug|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
79495146|NCT02131662|Drug|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
79658086|NCT01337128|Procedure|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
79658087|NCT01337128|Procedure|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
79814469|NCT00853073|Drug|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
79985397|NCT03188848|Drug|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
79985398|NCT01311271|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~Real: unaffected M1 hotspot~Sham: coil perpendicular to scalp"
79985399|NCT01374282|Drug|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
79985400|NCT02429986|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
79814470|NCT00853073|Other|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
79985401|NCT03691922|Procedure|Erector Spinae Plane (ESP) Block|"Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
79985402|NCT03691922|Procedure|Periarticular Infiltration (PAI)|"Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
79985403|NCT03453151|Drug|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
79985404|NCT03433248|Drug|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
79814471|NCT00846053|Diagnostic Test|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, [18F]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue [18F] FDG uptake. Patlak graphical analysis was used to determine the rate of [18F]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
79343723|NCT02454959|Device|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
79343724|NCT02454959|Device|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
79343725|NCT01821118|Biological|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
79343726|NCT01821118|Other|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
79343727|NCT01650779|Biological|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
79343728|NCT02411201|Drug|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
79658088|NCT04719884|Procedure|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) >10% and SI and CI >10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of >10% and the SVV still >10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI <10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
79658089|NCT01191073|Device|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
79658090|NCT01191073|Device|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
79658091|NCT00280605|Drug|Alfuzosin|
79814472|NCT00700505|Device|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
79658092|NCT01134601|Procedure|Radiation Therapy|
79658093|NCT01134601|Drug|Capecitabine|
79658094|NCT01134601|Drug|AZD6244|
79658095|NCT00252083|Behavioral|Popular Opinion Leader|
79658096|NCT00287040|Behavioral|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
79658097|NCT00252122|Drug|Ketamine|Ketamine. 0.2 mg/kg, intravenously
79658098|NCT00287157|Drug|Sublingual Tizanidine HCl|
79658099|NCT00252161|Procedure|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
79658100|NCT00252161|Drug|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
79658101|NCT00280644|Drug|Leflunomide|
79658102|NCT00252200|Drug|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
79814473|NCT00845897|Drug|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
79814474|NCT00845897|Drug|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
79658103|NCT00280722|Behavioral|patient information leaflet|
79658104|NCT00252278|Drug|atomoxetine|
79343729|NCT01838044|Drug|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
79658105|NCT00287196|Radiation|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
79658106|NCT00252317|Drug|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
79658107|NCT00252317|Drug|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
79814475|NCT04115891|Other|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
79814476|NCT04115891|Other|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
79814477|NCT04115891|Other|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
79985405|NCT03433248|Drug|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
79343730|NCT01838044|Drug|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
79343731|NCT02410811|Other|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
79343732|NCT02435381|Drug|Carisbamate|600mg Orally on days 2-4
79343733|NCT02435381|Drug|Placebo|Placebo treatment only
79343734|NCT01837966|Other|Lavender oil|2 drops for aromatherapy
79985406|NCT03433248|Drug|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
79985407|NCT02430142|Other|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
79985408|NCT03691766|Other|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
79985409|NCT03691766|Other|Placebo|Device with sham light source
79985410|NCT03691688|Drug|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
79343735|NCT01837966|Other|Placebo|2 drops unscented mineral oil for aromatherapy
79658108|NCT01118026|Drug|ABVD|doxorubicin 25 mg/m^2 IV bleomycin 10 units/m^2 IV vinblastine 6 mg/m^2 IV dacarbazine 375 mg/m^2 IV
79658109|NCT01118026|Drug|BEACOPP|bleomycin 10 units/m^2 IV on Day 8 etoposide 200 mg/m^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m^2 IV on Day 1 cyclophosphamide 1250 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 8 procarbazine 100 mg/m^2 orally on Days 1-7 prednisone 40 mg/m^2 orally on Days 1-14
79658110|NCT01118026|Radiation|radiation therapy|
79658111|NCT00280800|Device|constant CPAP devices|different CPAP mode
79658112|NCT00280800|Device|automatic CPAP devices|different CPAP mode
79658113|NCT00252356|Drug|SR58611A|
79814478|NCT04115891|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
79814479|NCT00862277|Biological|Menactra®|0.5 mL, Intramuscular (from a previous study)
79343736|NCT02435147|Drug|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
79343737|NCT02435069|Drug|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
79658114|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
79985411|NCT03691688|Drug|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
79985412|NCT03619304|Dietary Supplement|coffee|coffee beverage
79495147|NCT04188366|Behavioral|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
79495148|NCT04188366|Behavioral|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
79495149|NCT02106156|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
79495150|NCT02106156|Drug|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
79495151|NCT05137002|Drug|CIN-107|CIN-107 tablets by mouth once daily
79495152|NCT05137002|Drug|Placebo|Placebo tablets by mouth once daily
79658115|NCT01648153|Other|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
79658116|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
79985413|NCT02425462|Drug|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
79814480|NCT00862277|Biological|Menomune®|0.5 mL, Intramuscular (from a previous study)
79985414|NCT03700112|Other|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
79495153|NCT01598610|Device|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
79495154|NCT04738812|Drug|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
79495155|NCT04738812|Drug|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
79495156|NCT04737954|Diagnostic Test|Venepuncture|Venous blood draw
79495157|NCT04737954|Diagnostic Test|Fingerstick|Capillary blood draw
79658117|NCT02753998|Combination Product|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
79658118|NCT02753998|Combination Product|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
79658119|NCT02753998|Procedure|Conventional angioplasty|
79343738|NCT02435069|Drug|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
79343739|NCT04917731|Drug|Botulinum toxin type A|Botox injected at digital artery
79343740|NCT02454101|Procedure|cord milking|milking of the cord 5 times toward the neonate
79343741|NCT02454101|Procedure|delayed cord clamping|delay clamping of the cord for 120 seconds
79658120|NCT02279836|Device|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
79658121|NCT00287235|Device|MARS|
79343742|NCT02409719|Other|Schedule|Illustrative daily planner to point the day that the exercise was performed
79343743|NCT02409719|Other|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
79495158|NCT01625988|Drug|LY2951742|
79658122|NCT00287235|Drug|Standard Medical Therapy|
79658123|NCT00252395|Device|PDA-based Electronic Prescribing Software|
79658124|NCT02753452|Behavioral|Residential Immersive Life Skills programming|
79343744|NCT01820572|Drug|Belatacept|
79495159|NCT01625988|Drug|Placebo|
79658125|NCT02753452|Behavioral|Non-residential life skills programming|
79343745|NCT01820572|Drug|Tacrolimus|
79343746|NCT01820572|Drug|Cyclosporine|
79343747|NCT01820260|Drug|Ingenol mebutate gel|
79343748|NCT01820260|Drug|placebo|
79343749|NCT01610596|Drug|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
79343750|NCT01610596|Drug|Placebo|
79343751|NCT01818700|Drug|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
79495160|NCT02131272|Drug|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
79658126|NCT02754154|Drug|Warfarin|
79658127|NCT02754154|Drug|Apixaban|
79658128|NCT02754154|Drug|Dabigatran|
79658129|NCT02754154|Drug|Rivaroxaban|
79658130|NCT00252434|Behavioral|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
79658131|NCT00280839|Drug|Topiramate|
79658132|NCT00280839|Drug|Placebo|
79658133|NCT04719728|Diagnostic Test|Aided pure tone audiometry|aided response, speech, evoked potential
79658134|NCT00287274|Device|computerized physician order entry|
79658135|NCT00414869|Drug|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
79658136|NCT00414869|Drug|Placebo|Inactive powder matching NCX-1000
79658137|NCT00280878|Drug|gemcitabine|
79658138|NCT00280878|Drug|vinorelbine|
79658139|NCT00280878|Drug|ifosfamide|
79658140|NCT00280878|Drug|rituximab|
79658141|NCT00252473|Device|MedTec S-frame Immobilization Masks|
79658142|NCT00287313|Drug|Vitamin K|
79658143|NCT01680133|Other|Hyperinsulinemic euglycemic clamp|
79985415|NCT03700112|Other|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
79495161|NCT02131272|Drug|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
79985416|NCT03700112|Other|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
79343752|NCT01817764|Drug|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
79343753|NCT01817764|Drug|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
79495162|NCT02131272|Behavioral|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
79985417|NCT03700112|Other|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
79495163|NCT02130882|Drug|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
79658144|NCT01680211|Dietary Supplement|Salacia bark extract|
79658145|NCT01680211|Dietary Supplement|Salacia leaf extract|
79658146|NCT01680211|Dietary Supplement|Sesame seed extract|
79985418|NCT03700112|Other|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
79985419|NCT03700112|Other|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
79985420|NCT03700112|Other|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
79985421|NCT03700112|Other|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
79985422|NCT04482868|Procedure|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
79343754|NCT01817764|Drug|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
79985423|NCT03452527|Biological|ICON-1|ICON-1 0.6 mg by intravitreal injection
79985424|NCT03452527|Biological|aflibercept|aflibercept 2 mg by intravitreal injection
79495164|NCT02130882|Other|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
79495165|NCT02130570|Other|Multi-Model Intensive Discharge Intervention|"Inpatient medication safety interventions~Inpatient discharge advocate~Structured visiting nurse (VNA) appointments~Post-discharge phone call by primary care personnel within 2 business days of discharge~Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~Improved communication between inpatient and primary care teams~High-risk patients will receive additional interventions as needed:~Home pharmacist visit~Enrollment in the Partners integrated Care Management Program (iCMP)~Enrollment in telemedicine programs for patients with CHF~Palliative care consultation regarding goals of care~Novel health information technology to facilitate communication and transfer of clinical information"
79658147|NCT01680211|Behavioral|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
79658148|NCT01680211|Other|Placebo|
79658149|NCT01680250|Drug|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
79658150|NCT00280956|Drug|natalizumab|
79658151|NCT02279875|Drug|Linezolid|
79658152|NCT02279875|Drug|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
79658153|NCT04824508|Behavioral|position|teamleaders are instructed to allocated position
79658154|NCT00252551|Procedure|Osteosynthesis|
79658155|NCT00252551|Procedure|Simple surgery|Surgery without device
79658156|NCT00280995|Drug|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
79658157|NCT00280995|Drug|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
79343755|NCT04726618|Drug|Hyperpolarized 129-xenon gas and Perfluoropropane gas|"Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane)."
79343756|NCT01803880|Device|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
79495166|NCT02149836|Drug|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
79495167|NCT02130024|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
79495168|NCT02130024|Drug|Aflibercept 2.0 mg|Administered as an intravitreal injection
79495169|NCT02105688|Drug|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
79495170|NCT02105688|Drug|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
79495171|NCT02105454|Drug|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
79985425|NCT02429908|Device|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
79985426|NCT03226470|Biological|T512|T512 suppository contain 500 µg of T512 and suppocire.
79985427|NCT03188926|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
79985428|NCT03718351|Procedure|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
79985429|NCT03718351|Procedure|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
79985430|NCT03713827|Device|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
79343757|NCT01803880|Device|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
79343758|NCT01803646|Drug|AM-101|AM-101 gel for intratympanic injection
79343759|NCT01803646|Drug|Placebo|Placebo gel for intratympanic injection
79343760|NCT01817530|Other|Elagolix placebo|oral coated tablet
79343761|NCT01817530|Drug|Elagolix|oral coated tablet
79495172|NCT02105454|Drug|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
79495173|NCT02105454|Drug|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
79495174|NCT01625910|Behavioral|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
79495175|NCT02104752|Drug|Curcumin|360 mg/day (divided into twice daily oral doses)
79495176|NCT02104752|Drug|Placebo|"Inactive, matched placebo (Sugar Pill)"
79495177|NCT02102724|Dietary Supplement|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
79658158|NCT00280995|Drug|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
79658159|NCT00280995|Drug|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
79658160|NCT04822675|Procedure|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
79814481|NCT04120337|Device|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
79343762|NCT01817530|Drug|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
79343763|NCT01817530|Drug|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
79343764|NCT01817530|Drug|E2/NETA placebo|oral hard capsule
79343765|NCT01816984|Drug|PI3K inhibitor BKM120|Given PO
79343766|NCT01816984|Biological|cetuximab|Given IV
79343767|NCT01816906|Device|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
79495178|NCT02102724|Dietary Supplement|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
79495179|NCT02102490|Drug|Abemaciclib|Administered orally
79495180|NCT02101554|Drug|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
79495181|NCT02101554|Drug|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
79495182|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
79495183|NCT02128932|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
79658161|NCT04822675|Procedure|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
79814482|NCT04120337|Procedure|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
79814483|NCT04120337|Device|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
79985431|NCT02429674|Behavioral|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
79985432|NCT03028142|Drug|1.5 mg RPL554 plus tiotropium|
79495184|NCT02128542|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
79658162|NCT05139667|Drug|Corticosteroid Topical|topical tacrolimus and corticosteroids
79658163|NCT02271061|Device|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
79658164|NCT02271061|Device|Control tape|Apply tape in same technique without tension.
79985433|NCT03028142|Drug|6 mg RPL554 plus tiotropium|
79985434|NCT03028142|Drug|Placebo plus tiotropium|
79658165|NCT00287352|Drug|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
79658166|NCT00287352|Drug|Olanzapine and placebo|Olanzapine continuing as clinically indicated
79658167|NCT04823962|Drug|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
79985435|NCT03188614|Drug|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
79985436|NCT02866812|Other|questionnaires assessing the state of fatigue, depression and anxiety|
79985437|NCT03713749|Device|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
79985438|NCT03182842|Device|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
79343768|NCT01816906|Device|Footwear: MCP|One group of patients will receive footwear with MCP insoles
79495185|NCT02128542|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79495186|NCT02127372|Drug|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
79495187|NCT02127372|Drug|Docetaxel|
79658168|NCT04823962|Drug|Placebo hydrogel|Placebo hydrogel
79658169|NCT04823962|Other|Standard care|Compression therapy and neutral dressings
79658170|NCT00252668|Drug|Etanercept|
79658171|NCT00252668|Drug|Methotrexate|
79658172|NCT02271997|Drug|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
79814484|NCT00852995|Biological|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
79814485|NCT00852995|Biological|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
79814486|NCT00701987|Drug|ALS-357|Topical application of ALS-357
79814487|NCT04117061|Procedure|Observation|Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
79814488|NCT00592319|Drug|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
79495188|NCT02127372|Drug|Cisplatin|
79343769|NCT01816594|Drug|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
79495189|NCT04747548|Behavioral|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
79495190|NCT04747548|Behavioral|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
79495191|NCT04751682|Biological|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10^10 Virus Particle.
79495192|NCT04751682|Biological|Placebo|Placebo
79495193|NCT02126826|Drug|BI 1026706|Multiple Rising Doses (oral solution, tablet)
79495194|NCT02126826|Drug|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
79495195|NCT02126670|Drug|ACT01|
79495196|NCT02126670|Drug|Comp01|
79495197|NCT02126670|Drug|Comp02|
79495198|NCT02126670|Drug|Comp03|
79495199|NCT02126670|Drug|Comp04|
79495200|NCT02125734|Drug|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
79495201|NCT02125734|Drug|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
79495202|NCT02124798|Device|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
79495203|NCT02146326|Behavioral|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
79495204|NCT02146326|Behavioral|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
79495205|NCT02146248|Drug|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
79495206|NCT02146248|Drug|DepoProvera|injectable hormonal contraceptive
79343770|NCT01816594|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
79343771|NCT01816594|Drug|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
79495207|NCT02145468|Drug|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
79495208|NCT02145468|Drug|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
79495209|NCT02145468|Drug|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
79495210|NCT02124564|Drug|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
79495211|NCT02145390|Procedure|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~Cystoscopic evaluation~Bimanual examination under anesthesia,~Transurethral resection of the bladder tumor,~Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
79302589|NCT03072693|Procedure|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
79495212|NCT02145390|Radiation|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
79495213|NCT02145390|Behavioral|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
79985439|NCT03182842|Device|SMBG - Blinded Sensor|Insulin dosing based on SMBG
79985440|NCT02800824|Drug|Budesonide|
79343772|NCT01816594|Drug|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
79343773|NCT01802320|Drug|Akt Inhibitor MK2206|Given PO
79343774|NCT01802320|Other|Laboratory Biomarker Analysis|Correlative studies
79343775|NCT01802320|Other|Pharmacological Study|Correlative studies
79658173|NCT02271997|Drug|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
79343776|NCT02453711|Drug|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
79343777|NCT02453711|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
79343778|NCT02453711|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
79495214|NCT02145390|Behavioral|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
79343779|NCT02453555|Drug|Linagliptin|
79495215|NCT02100696|Drug|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
79985441|NCT02800824|Drug|Uceris|
79343780|NCT02453555|Drug|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
79495216|NCT02100696|Drug|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
79495217|NCT02145156|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
79658174|NCT02271997|Drug|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
79985442|NCT03695588|Procedure|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
79658175|NCT04821076|Other|Diet intervention - caloric restriction|Energy restriction is set to 25 kcal / kg fat-free mass
79658176|NCT04821076|Other|Exercise intervention|Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
79343781|NCT02453555|Drug|Empagliflozin + linagliptin low dose|tablet
79343782|NCT02453555|Drug|Linagliptin placebo|Matching placebo linagliptin
79985443|NCT03695588|Procedure|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
79985444|NCT04806360|Procedure|ACRF surgery|A new surgical procedure that previously proposed by our team.
79985445|NCT04806360|Procedure|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
79985446|NCT04806360|Procedure|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
79985447|NCT02429752|Other|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
79985448|NCT03713359|Biological|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
79985449|NCT03713359|Biological|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
79343783|NCT02453555|Drug|Empagliflozin + linagliptin high dose|tablet
79343784|NCT02453555|Drug|Empa + lina highdose placebo|
79343785|NCT02453321|Procedure|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
79343786|NCT02453321|Procedure|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
79658177|NCT04821076|Other|Diet intervention - Energy balance|Energy balance is set to 50 kcal / kg fat-free mass
79985450|NCT03695432|Biological|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
79495218|NCT02145156|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
79495219|NCT02145156|Behavioral|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
79495220|NCT02123472|Drug|Cephalexin|Administered Orally
79495221|NCT02145078|Drug|docetaxel|Given IV
79814489|NCT00592319|Device|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
79985451|NCT03695432|Dietary Supplement|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
79495222|NCT02145078|Drug|pemetrexed disodium|Given IV
79495223|NCT02145078|Drug|gemcitabine hydrochloride|Given IV
79495224|NCT02145078|Other|laboratory biomarker analysis|Correlative studies
79658178|NCT05139394|Procedure|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
79658179|NCT05139082|Drug|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
79814490|NCT00592319|Procedure|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
79985452|NCT03695432|Other|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
79985453|NCT03695432|Other|Placebo probiotic|Capsul
79495225|NCT02144610|Biological|HGF Plasmid (AMG0001)|IM
79495226|NCT02144610|Biological|Matching Placebo|IM
79495227|NCT02100228|Drug|Apixaban|Oral, 2.5 or 5 mg BID
79985454|NCT03715777|Drug|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
79495228|NCT02100228|Drug|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
79495229|NCT02099838|Drug|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
79495230|NCT02099838|Drug|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
79495231|NCT02144220|Other|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
79495232|NCT02099682|Drug|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
79495233|NCT05182944|Drug|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
79343787|NCT02453321|Procedure|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
79343788|NCT02453321|Drug|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
79814491|NCT04115813|Behavioral|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
79985455|NCT03695354|Device|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
79343789|NCT01610284|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
79343790|NCT01610284|Drug|BKM120|BKM120 100 mg once daily
79343791|NCT01610284|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
79343792|NCT02452463|Biological|Durvalumab|Given IV
79343793|NCT02452463|Drug|Nintedanib|Given PO
79343794|NCT02452463|Other|Placebo|Given PO
79343795|NCT02452463|Procedure|Quality-of-Life Assessment|Ancillary studies
79343796|NCT02432105|Drug|EXE844 Sterile Otic Suspension, 0.3%|
79343797|NCT02432105|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
79814492|NCT00862121|Drug|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
79985456|NCT03695354|Procedure|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
79343798|NCT02431793|Behavioral|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
79343799|NCT02431793|Behavioral|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
79343800|NCT03628391|Drug|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
79343801|NCT03628391|Drug|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
79343802|NCT01801930|Drug|OCV-103 and OCV-104|0.3 mg of each
79343803|NCT01801930|Drug|OCV-103 and OCV-104|1 mg of each
79343804|NCT01801930|Drug|OCV-103 and OCV-104|3 mg of each
79343805|NCT01801930|Drug|OCV-103 and OCV-104|6 mg of each
79985457|NCT03715699|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
79658180|NCT04719767|Device|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
79658181|NCT05138926|Other|Cervical Manipulation|high speed, low amplitude cervical manipulation
79985458|NCT03715699|Drug|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
79658182|NCT05138926|Other|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
79985459|NCT02708524|Device|Senofilcon C Contact Lens|
79985460|NCT02708524|Device|Comfilcon A Contact Lens|
79658183|NCT00287391|Drug|Rabeprazole|
79658184|NCT05138536|Procedure|Pan-Computer Tomography|trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma.
79658185|NCT00252707|Drug|Gefitinib or Docetaxel|
79658186|NCT01680367|Procedure|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
79658187|NCT01680367|Procedure|wound care management|Receive native collagen wound dressing
79658188|NCT01680367|Other|questionnaire administration|Ancillary studies
79343806|NCT01610206|Drug|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
79343807|NCT01610206|Drug|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
79343808|NCT04414462|Other|exergaming training|"HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
79658189|NCT00281073|Device|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
79658190|NCT00281073|Device|Intracardiac Echo|Intracardiac Echo Viewmate
79658191|NCT00281073|Device|ICE|ICE or TEE
79658192|NCT01680406|Drug|Artemether-lumefantrine combination|
79658193|NCT01680406|Drug|Primaquine|
79985461|NCT02708524|Device|Lotrafilcon B Contact Lens|
79658194|NCT01680406|Drug|Chloroquine|
79658195|NCT00252746|Drug|ZD6474 (vandetanib) 100mg|once daily oral dose
79658196|NCT00252746|Drug|ZD6474 (vandetanib) 200mg|once daily oral dose
79658197|NCT00252746|Drug|ZD6474 (vandetanib) 300mg|once daily oral dose
79658198|NCT01680484|Dietary Supplement|Bitter chocolate|
79985462|NCT02708524|Device|Samfilcon A Contact Lens|
79985463|NCT03699800|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
79658199|NCT01680484|Dietary Supplement|Orange juice|
79658200|NCT01680523|Procedure|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
79658201|NCT01680523|Radiation|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
79658202|NCT01680523|Radiation|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
79658203|NCT00287430|Drug|Growth Hormone|
79658204|NCT00287430|Procedure|Whole body Protein Turnover Study|
79985464|NCT04776408|Device|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
79985465|NCT04776408|Device|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
79814493|NCT00862121|Drug|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
79343809|NCT04414462|Other|training - Group II|"Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
79495234|NCT05182944|Drug|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
79658205|NCT00287430|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
79658206|NCT01680562|Other|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
79658207|NCT04528147|Behavioral|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
79814494|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
79658208|NCT04528147|Behavioral|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
79343810|NCT01816048|Drug|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
79343811|NCT01816048|Radiation|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
79658209|NCT01680601|Procedure|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
79658210|NCT01680601|Procedure|Placebo|
79658211|NCT01680679|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
79658212|NCT01680679|Biological|Inactivated poliovirus vaccine (IPV), trivalent|
79658213|NCT01680718|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
79658214|NCT01680718|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
79985466|NCT03695198|Drug|LY3361237 - SC|LY3361237 administered SC
79658215|NCT01680718|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
79658216|NCT01680757|Device|LARIAT Suture Delivery Device and Accessories|
79985467|NCT03695198|Drug|LY3361237 - IV|LY3361237 administered IV
79343812|NCT01816048|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
79343813|NCT01816048|Procedure|Computed Tomography|Undergo 18F NaF PET/CT scan
79658217|NCT01680796|Drug|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
79658218|NCT01680796|Drug|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
79814495|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
79814496|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
79814497|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
79814498|NCT00784719|Drug|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
79814499|NCT00784719|Drug|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
79985468|NCT03695198|Drug|Placebo - SC|Placebo administered SC
79985469|NCT03695198|Drug|Placebo - IV|Placebo administered IV
79985470|NCT02773524|Drug|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
79495235|NCT05182944|Drug|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
79343814|NCT01612858|Drug|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
79343815|NCT01612858|Drug|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
79343816|NCT04585984|Dietary Supplement|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
79343817|NCT04585984|Dietary Supplement|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
79343818|NCT01612780|Device|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
79343819|NCT01612702|Drug|Dexamethasone|Dexamethasone 10 mg intravenous administration
79658219|NCT01680796|Drug|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
79658220|NCT00252785|Drug|Budesonide/Formoterol|
79343820|NCT02431559|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
79343821|NCT02431559|Drug|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
79343822|NCT02431559|Drug|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
79343823|NCT02388269|Device|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
79343824|NCT01652573|Drug|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
79343825|NCT01652573|Drug|Saline Nasal Spray Placebo|
79343826|NCT02388191|Drug|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
79658221|NCT00252785|Drug|Budesonide|
79495236|NCT05182944|Drug|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
79495237|NCT02142894|Device|CST001|
79814500|NCT04120103|Behavioral|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
79814501|NCT04120103|Other|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
79343827|NCT02388191|Other|Placebo tablet|
79343828|NCT01815736|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
79343829|NCT01815736|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
79343830|NCT01815736|Drug|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
79343831|NCT01815736|Drug|RTV|100 mg tablet administered orally once daily
79343832|NCT01815736|Drug|ATV|300 mg capsule administered orally once daily
79343833|NCT01815736|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
79343834|NCT01815736|Drug|COBI|150 mg tablet administered orally once daily
79343835|NCT01651949|Biological|9vHPV Vaccine|9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
79343836|NCT01800916|Device|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
79343837|NCT01800916|Device|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
79343838|NCT01800916|Device|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
79343839|NCT01800916|Device|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
79343840|NCT01815580|Drug|Atripla or Stribild|Antiretroviral therapy
79343841|NCT01799590|Drug|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
79343842|NCT04902131|Drug|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
79658222|NCT00252785|Drug|Theophylline|
79658223|NCT01680874|Dietary Supplement|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
79495238|NCT02098746|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
79985471|NCT02773524|Other|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
79985472|NCT02429596|Drug|Experimental|Switch from brand to generic
79985473|NCT03418675|Drug|Rexulti|Atypical antipsychotic
79985474|NCT03418675|Drug|Placebo|Pill that contains no medicine
79985475|NCT03695120|Other|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
79985476|NCT03694964|Drug|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
79343843|NCT04902131|Drug|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
79495239|NCT02122770|Drug|MLN4924|MLN4924 intravenous solution.
79985477|NCT03694964|Drug|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
79495240|NCT02122770|Drug|Fluconazole|Fluconazole tablets.
79495241|NCT02122770|Drug|Itraconazole|Itraconazole oral solution.
79495242|NCT02122770|Drug|Docetaxel|Docetaxel intravenous solution.
79495243|NCT02122770|Drug|Carboplatin|Carboplatin intravenous solution.
79495244|NCT02122770|Drug|Paclitaxel|Paclitaxel intravenous solution.
79343844|NCT01815424|Drug|placebo|placebo BID for 16 weeks and then re-randomized into active groups
79343845|NCT01815424|Drug|CP-690,550|CP-690,550 5mg BID for 52 weeks
79343846|NCT01815424|Drug|CP-690,550|CP-690,550 10mg BID for 52 weeks
79343847|NCT02431247|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
79343848|NCT02431247|Drug|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
79343849|NCT02431247|Drug|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
79343850|NCT02431247|Drug|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
79495245|NCT02122380|Drug|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
79495246|NCT02122380|Drug|Placebo|1 placebo pill by mouth per day for 30 days
79495247|NCT02122146|Drug|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
79495248|NCT02122146|Drug|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
79495249|NCT02121834|Drug|LY3050258|
79495250|NCT02121834|Drug|Placebo|
79495251|NCT02121756|Drug|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
79495252|NCT02121756|Drug|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
79343851|NCT02431247|Drug|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
79495253|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
79495254|NCT02142504|Drug|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
79814502|NCT00852917|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
79814503|NCT00852917|Drug|Placebo|One Placebo tablet daily.
79343852|NCT02431247|Drug|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
79343853|NCT01814878|Drug|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl [75 mg]/acetaminophen [650 mg]) will be administered at 0, 12, 24 and 36 hours
79343854|NCT01814878|Drug|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl [37.5 mg]/acetaminophen [325 mg]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
79343855|NCT02407457|Device|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
79343856|NCT02407457|Device|FDA Approved EVAR AAA Graft Systems|
79343857|NCT01814800|Biological|RI-002|Immune Globulin Intravenous (IGIV)
79343858|NCT01814332|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
79343859|NCT01814332|Drug|Placebo|Placebo compound treatment for comparison with IP
79343860|NCT02407223|Drug|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
79343861|NCT02407223|Drug|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
79495255|NCT02121522|Drug|BI 144807|twice daily
79495256|NCT02121210|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
79658224|NCT01680874|Dietary Supplement|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
79495257|NCT02141490|Drug|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
79495258|NCT02141490|Diagnostic Test|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
79495259|NCT02097108|Drug|Raltegravir|
79495260|NCT02097030|Device|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
79814504|NCT00700583|Drug|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
79814505|NCT00913055|Drug|octreotide acetate|subcutaneous implant
79495261|NCT02097030|Device|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
79495262|NCT02097030|Device|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
79495263|NCT02096952|Drug|Methylphenidate extended-release liquid formulation|
79658225|NCT01680913|Procedure|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
79495264|NCT02120898|Drug|Imiquimod|Cream, generic formulation of the brand product.
79495265|NCT02120898|Drug|Zyclara®|Cream, brand product.
79495266|NCT02120898|Drug|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
79495267|NCT02120664|Drug|Florbetapir (18F)|
79495268|NCT02120664|Drug|11C-PiB|
79495269|NCT01627860|Drug|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
79495270|NCT01627860|Drug|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
79495271|NCT01627782|Drug|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
79658226|NCT01680913|Procedure|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
79658227|NCT01680913|Procedure|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
79658228|NCT00287508|Device|Carotid artery stenting with filter (interventional)|
79658229|NCT01680952|Drug|A) TEST|"Extended Release Tacrolimus (Advagraf®)~① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
79658230|NCT01680952|Drug|B) CONTROL|"Extended Release Tacrolimus (Advagraf®)~: Same as above.~Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
79658231|NCT01681108|Behavioral|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
79658232|NCT01681303|Drug|AST-120|
79658233|NCT00252824|Drug|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
79814506|NCT04117139|Diagnostic Test|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
79814507|NCT02612597|Other|Bedrest|
79814508|NCT02612597|Other|Exercise Training|
79814509|NCT00845429|Biological|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
79814510|NCT00845429|Biological|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
79495272|NCT01627782|Drug|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
79495273|NCT01598532|Device|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
79495274|NCT02119650|Drug|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
79495275|NCT02119650|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
79495276|NCT02119650|Drug|Pemetrexed|500 mg/m^2 administered as an intravenous infusion over 10 minutes
79495277|NCT02119650|Drug|Cisplatin|75 mg/m^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
79495278|NCT02119416|Drug|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
79495279|NCT02119416|Drug|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
79495280|NCT02119416|Drug|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
79495281|NCT02140164|Drug|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
79495282|NCT04745208|Behavioral|Simulation based education|high fidelity simulation with moulage
79814511|NCT00845429|Biological|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
79814512|NCT00699101|Device|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
79814513|NCT00593333|Device|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
79343862|NCT02407223|Drug|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
79343863|NCT01797562|Diagnostic Test|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
79658234|NCT04528420|Other|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
79658235|NCT01681381|Device|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
79814514|NCT00593333|Device|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
79302590|NCT03072693|Procedure|Home-based physiological parameter recording only|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
79343864|NCT01813474|Drug|olaparib|tablet oral
79343865|NCT01868542|Drug|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
79343866|NCT01797094|Biological|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
79495283|NCT02119260|Drug|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
79495284|NCT02119260|Drug|GSK2798745 suspension|Aqueous suspension of GSK2798745 (>=0.5 mg)
79814515|NCT04117217|Diagnostic Test|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
79814516|NCT02613533|Other|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
79814517|NCT00844883|Drug|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
79814518|NCT00844883|Procedure|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
79495285|NCT02119260|Drug|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
79495286|NCT02119260|Drug|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
79495287|NCT02119260|Drug|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
79814519|NCT00851903|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
79814520|NCT00851903|Drug|Sitagliptin|Oral administration. 100mg film-coated tablets.
79302591|NCT02480231|Device|Retropubic Midurethral Sling|
79302592|NCT03201367|Drug|Rivaroxaban|Rivaroxaban 10 mg/12 hour
79302593|NCT03201367|Other|symptomatic therapy for ascites, abdominal pain|
79495288|NCT02119260|Drug|Placebo capsule|Matching white opaque placebo blend filled capsule
79495289|NCT02119104|Drug|Prevenar (13v)|Prevenar (13v)
79495290|NCT02119026|Drug|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
79658236|NCT01681381|Device|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
79985478|NCT02421406|Behavioral|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
79985479|NCT02421406|Behavioral|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
79658237|NCT01681420|Behavioral|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
79985480|NCT02653092|Drug|Insulin|
79658238|NCT01681420|Behavioral|Blood Donation|Blood donation without HIV counseling
79985481|NCT02653092|Drug|Intralipid|
79985482|NCT02653092|Drug|Dextrose|
79985483|NCT02653092|Drug|Heparin|
79985484|NCT02653092|Drug|GnRH|
79343867|NCT01797094|Biological|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
79343868|NCT02383589|Drug|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
79343869|NCT02383589|Drug|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
79343870|NCT02383589|Drug|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
79985485|NCT02653092|Procedure|Hyperinsulinemic Euglycemic Clamp|
79985486|NCT03691454|Drug|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
79985487|NCT03691454|Drug|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
79985488|NCT02421484|Biological|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
79985489|NCT02736318|Biological|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
79985490|NCT03182764|Other|No intervention|No intervention
79985491|NCT03691142|Other|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
79985492|NCT03699722|Behavioral|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
79343871|NCT02383589|Drug|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
79985493|NCT03699722|Behavioral|Information|Format: Information handouts
79985494|NCT02425228|Device|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
79495291|NCT02119026|Drug|Capecitabine|1000mg/m2 bid d1-14,
79985495|NCT03715543|Procedure|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
79658239|NCT00281190|Procedure|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
79985496|NCT03690908|Other|no intervention (descriptive study)|no intervention (descriptive study)
79658240|NCT00281190|Procedure|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
79658241|NCT00252863|Drug|Symbicort, used twice daily (b.i.d) and as needed (prn)|
79658242|NCT00252863|Drug|Budesonide Turbuhaler 200 µg|
79658243|NCT00252863|Drug|Fluticasone Discus 250 µg|
79343872|NCT01810432|Drug|Evacetrapib|Administered orally
79658244|NCT00252863|Drug|Formoterol Turbuhaler 4.5 µg|
79658245|NCT00252863|Drug|Terbutaline Turbuhaler 0.5 mg|
79814521|NCT00851903|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
79343873|NCT01810432|Other|High-fat Meal|Administered orally, at breakfast.
79343874|NCT01796860|Other|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
79343875|NCT01796548|Drug|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
79343876|NCT02406677|Other|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
79343877|NCT02404805|Drug|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
79343878|NCT02404805|Drug|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
79658246|NCT00252863|Drug|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
79658247|NCT00252863|Drug|Salmeterol Discus 50 µg|
79658248|NCT00252863|Drug|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
79658249|NCT00252863|Drug|Fluticasone/Salmeterol Discus 250/50 µg|
79658250|NCT00252863|Drug|Fluticasone/Salmeterol Discus 500/50 µg|
79658251|NCT00252863|Drug|Theophylline 200 mg|
79302594|NCT02479685|Procedure|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
79495292|NCT02119026|Drug|Bevacizumab|7,5 mg/kg given on d1 q3w
79495293|NCT02119026|Drug|Oxaliplatin|130mg/m2 iv. d 1 q3w
79495294|NCT02119026|Drug|Irinotecan|200mg/m2 iv. d 1 q3w .
79495295|NCT02095158|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
79658252|NCT00252863|Drug|Theophylline 300 mg|
79658253|NCT00252863|Drug|Singulair 10 mg|
79658254|NCT01681537|Drug|Lenalidomide|
79814522|NCT02612441|Device|real Acupuncture Needles|Acupuncture needles
79814523|NCT02612441|Device|sham Acupuncture Needles|sham Acupuncture Needles
79814524|NCT00587457|Drug|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
79814525|NCT00587457|Drug|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
79343879|NCT02430311|Drug|Olaparib|Tablet-150mg, Oral
79495296|NCT02094612|Device|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
79495297|NCT02094612|Behavioral|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
79658255|NCT01681537|Drug|Mitoxantrone|
79658256|NCT01681537|Drug|Etoposide|
79658257|NCT01681537|Drug|Cytarabine|
79985497|NCT03718273|Drug|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
79985498|NCT03718273|Drug|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance <60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
79985499|NCT03690830|Other|metabolomics analysis|collect blood samples and endometrial cells
79658258|NCT00287625|Procedure|Pulmonary rehabilitation|Pulmonary rehabilitation
79985500|NCT02421640|Drug|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
79985501|NCT02421640|Drug|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
79985502|NCT01311193|Other|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
79985503|NCT03417505|Device|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
79985504|NCT03417505|Device|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
79985505|NCT02421562|Procedure|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
79985506|NCT02421328|Device|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
79985507|NCT02421328|Device|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
79985508|NCT02425150|Procedure|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
79985509|NCT02425150|Procedure|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
79658259|NCT01681654|Behavioral|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
79658260|NCT01681654|Behavioral|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
79658261|NCT01681693|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
79658262|NCT01681732|Other|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
79658263|NCT01681732|Other|Control Standard Care|This is the standard care arm
79985510|NCT03715387|Drug|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
79985511|NCT03715387|Drug|Polysporin Ointment|Polysporin ointment
79985512|NCT02425072|Device|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
79343880|NCT02430311|Drug|Paclitaxel|Injection
79343881|NCT02430311|Drug|Olaparib|Tablet-100mg, Oral
79343882|NCT02404649|Device|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
79343883|NCT02404649|Device|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
79343884|NCT02383355|Drug|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
79495298|NCT02139306|Drug|Ataluren (PTC124®)|Oral Ataluren TID
79495299|NCT02139306|Drug|Placebo|Oral Placebo TID
79495300|NCT02094300|Device|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
79495301|NCT02118792|Drug|AN2728 Topical Ointment, 2%|
79985513|NCT03715309|Drug|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
79658264|NCT01681888|Device|Sanger EMG Biofeedback Device|
79985514|NCT02424994|Other|No intervention|
79985515|NCT02429206|Other|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
79343885|NCT02383355|Drug|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
79658265|NCT00252902|Behavioral|Behavior change counseling|
79658266|NCT04528264|Device|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
79343886|NCT02381795|Drug|Nasal Carbon Dioxide|
79343887|NCT02404493|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
79495302|NCT02118792|Drug|Matching vehicle control|
79658267|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction technique
79658268|NCT01681966|Drug|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
79658269|NCT01682161|Drug|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
79658270|NCT01682200|Drug|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
79814526|NCT00587457|Drug|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
79985516|NCT02429206|Other|standard moisturizing cream (Glaxal Base)|
79985517|NCT03182608|Diagnostic Test|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
79985518|NCT03182530|Device|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
79302595|NCT03202927|Drug|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
79302596|NCT03215563|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
79302597|NCT03215563|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
79343888|NCT02404493|Drug|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
79343889|NCT02380859|Behavioral|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
79495303|NCT02118714|Drug|Atrasentan|Atrasentan
79495304|NCT02138916|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
79495305|NCT02138916|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
79495306|NCT02138916|Drug|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
79495307|NCT02118012|Drug|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
79495308|NCT02118012|Drug|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily<75 kg and 1200 mg daily ≥75 kg.
79495309|NCT02093520|Procedure|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
79495310|NCT02093520|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
79495311|NCT02138838|Drug|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
79658271|NCT01682395|Procedure|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
79658272|NCT01682395|Procedure|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
79658273|NCT01682395|Procedure|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
79658274|NCT01682434|Procedure|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
79343890|NCT02380703|Behavioral|Aggression Prevention Training (APT)|
79985519|NCT03182530|Device|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
79658275|NCT01682473|Drug|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
79658276|NCT00252941|Device|Memokath 028SW Urethral Stent|
79985520|NCT03182530|Device|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
79343891|NCT02380703|Other|Enhanced Usual Primary Care (EU-PC)|
79658277|NCT01682551|Drug|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
79658278|NCT01682551|Drug|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
79985521|NCT03179254|Drug|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
79985522|NCT03179254|Drug|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
79343892|NCT02379923|Device|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
79343893|NCT04916171|Other|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
79343894|NCT02379221|Drug|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
79343895|NCT02379221|Drug|Topical|4% Topicaine gel
79343896|NCT02404103|Drug|Flunisolide HFA|
79495312|NCT02138838|Dietary Supplement|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
79658279|NCT00281268|Procedure|pulmonary artery catheter|
79658280|NCT00281268|Procedure|central venous catheter|
79658281|NCT00281268|Procedure|fluid management|
79658282|NCT02279914|Drug|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D&E procedure
79985523|NCT02953639|Drug|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
79985524|NCT02953639|Drug|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
79985525|NCT04147715|Drug|S-648414|Tablet for oral administration
79343897|NCT02404025|Drug|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
79658283|NCT02279914|Drug|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D&E procedure
79658284|NCT01682590|Procedure|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output > 1000ml/24 hr or >2000ml/24hr with diuretics), RRT is not mandatory."
79658285|NCT00281307|Drug|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
79814527|NCT00851747|Drug|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
79985526|NCT04147715|Drug|Placebo|Tablet for oral administration
79985527|NCT04147715|Drug|Midazolam|Solution for oral administration
79985528|NCT04147715|Drug|Dolutegravir|Tablet for oral administration
79985529|NCT02420938|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
79985530|NCT02420938|Drug|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
79343898|NCT02404025|Drug|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
79985531|NCT02429440|Biological|peptide vaccine|subcutaneous
79985532|NCT02429440|Drug|Granulocyte Macrophage Colony Stimulating Factor|intradermal
79985533|NCT02429440|Drug|Montanide ISA-51|subcutaneous
79985534|NCT03182452|Other|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
79985535|NCT02429518|Drug|Miltefosine|
79985536|NCT00708526|Other|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
79985537|NCT00708526|Device|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
79343899|NCT02404025|Drug|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
79495313|NCT02138214|Procedure|Thyroidectomy|Undergo total thyroidectomy
79302598|NCT04991961|Diagnostic Test|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
79343900|NCT02377817|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
79985538|NCT03712735|Drug|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
79343901|NCT02377817|Device|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
79495314|NCT02138214|Procedure|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
79495315|NCT02138214|Other|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
79658286|NCT01682629|Other|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
79658287|NCT01682629|Other|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
79985539|NCT02428816|Other|MRI acquisition|MRI acquisitions
79343902|NCT02403635|Drug|Midazolam|
79985540|NCT02428816|Behavioral|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
79985541|NCT03718195|Other|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
79985542|NCT03182218|Drug|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
79985543|NCT02452554|Other|Laboratory Biomarker Analysis|Correlative studies
79343903|NCT02403635|Drug|ASP2151|
79495316|NCT02092662|Other|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
79495317|NCT02092662|Other|Healthy controls|no treatment
79495318|NCT02092350|Drug|Grazoprevir|Grazoprevir 100 mg tablet
79495319|NCT02092350|Drug|Elbasvir|Elbasvir 50 mg tablet
79495320|NCT02092350|Drug|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
79495321|NCT02092350|Drug|Placebo to Elbasvir|Placebo tablet matched to elbasvir
79495322|NCT02117544|Device|Lotrafilcon B multifocal contact lenses (new)|
79495323|NCT02117544|Device|Lotrafilcon B multifocal contact lenses|
79495324|NCT02138136|Drug|Lubiprostone|12 or 24 mcg soft capsules for oral administration
79495325|NCT04726020|Other|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
79495326|NCT04726020|Other|Standard monitoring|standard monitoring of adverse event reaction
79985544|NCT02452554|Biological|Lorvotuzumab Mertansine|Given IV
79985545|NCT02452554|Other|Pharmacological Study|Correlative studies
79985546|NCT03712501|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
79985547|NCT03182374|Device|nSTRIDE APS|Intra-articular injection
79985548|NCT03182374|Device|Synvisc-One|Intra-articular injection
79495327|NCT01626690|Device|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
79495328|NCT01626690|Device|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
79495329|NCT01626456|Drug|ALKS 9072, Low|IM injection, given monthly
79985549|NCT01319682|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
79495330|NCT01626456|Drug|ALKS 9072, High|IM injection, given monthly
79495331|NCT02116608|Drug|Betadine|Apply locally as needed.
79343904|NCT04907903|Other|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
79343905|NCT02402933|Drug|Nasal Glucagon|3 mg nasal glucagon powder
79495332|NCT02116608|Drug|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
79495333|NCT02116608|Drug|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
79495334|NCT04742088|Device|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
79985550|NCT01319682|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
79985551|NCT03715075|Procedure|Caesarean Section|Caesarean Section
79985552|NCT03182062|Procedure|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
79302599|NCT03203005|Drug|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms [µg] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
79302600|NCT02484209|Drug|Metformin|Metformin 1500 mg daily for 16 weeks
79343906|NCT05370365|Procedure|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
79343907|NCT01796470|Drug|Entospletinib|Entospletinib tablets administered orally twice daily
79343908|NCT01796470|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
79495335|NCT02092116|Drug|Romidepsin|Latency reversing agent
79495336|NCT02092116|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
79495337|NCT02092116|Biological|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
79495338|NCT02091726|Procedure|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
79495339|NCT02091414|Drug|mycophenolate mofetil (MMF)|1.0 g PO BID
79495340|NCT02091414|Drug|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
79495341|NCT02091414|Drug|corticosteroids|As per the practice of each participating center
79495342|NCT04731558|Drug|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
79495343|NCT04731558|Drug|No intervention|No preoperative thromboprophylaxis.
79495344|NCT02116530|Drug|Olanzapine|oral
79495345|NCT02116530|Drug|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
79495346|NCT02116530|Drug|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
79343909|NCT05102890|Other|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
79495347|NCT02116530|Other|Placebo|oral
79985553|NCT03182062|Procedure|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
79985554|NCT03182062|Procedure|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
79343910|NCT01868074|Device|Insole|Custom-molded arch-supporting insole
79495348|NCT02072226|Drug|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
79495349|NCT02072226|Drug|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
79985555|NCT02424916|Biological|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
79495350|NCT02072226|Drug|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
79495351|NCT02072226|Drug|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
79495352|NCT04730856|Drug|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
79495353|NCT02090634|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
79495354|NCT02090634|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
79495355|NCT02114892|Drug|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
79985556|NCT04009577|Drug|LEM 5 mg|LEM tablet.
79343911|NCT04414852|Drug|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
79495356|NCT02114892|Drug|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
79495357|NCT02070978|Drug|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
79495358|NCT02070978|Drug|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
79495359|NCT02070978|Drug|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
79495360|NCT04725630|Behavioral|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
79495361|NCT04725630|Behavioral|Healthy food prescription|A one-time healthy food prescription pamphlet
79985557|NCT04009577|Drug|LEM 10 mg|LEM tablet.
79343912|NCT04171024|Device|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
79495362|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
79495363|NCT02114268|Drug|Placebo|Participants received placebo on Day 1.
79495364|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
79495365|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
79495366|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
79495367|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
79495368|NCT02089230|Drug|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
79495369|NCT02070744|Drug|VX-661|Tablet, oral use
79495370|NCT02070744|Drug|Ivacaftor|Film coated tablet, oral use
79495371|NCT02070744|Drug|Placebo matched to VX-661|Tablet, oral use
79985558|NCT03714841|Other|CRP|Knowledge of CRP value
79985559|NCT02176668|Drug|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
79985560|NCT02176668|Drug|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
79985561|NCT02176668|Drug|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
79985562|NCT02176668|Drug|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
79985563|NCT02424838|Procedure|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
79985564|NCT02424838|Device|22 gauge needle|
79495372|NCT02070744|Drug|Placebo matched to Ivacaftor|Film coated tablet, oral use
79985565|NCT02424838|Device|25 gauge needle|
79495373|NCT02113956|Behavioral|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
79495374|NCT02070588|Device|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
79343913|NCT04171024|Device|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
79495375|NCT04741698|Drug|Propranolol|Propranolol 2mg IV
79495376|NCT02111850|Biological|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
79495377|NCT02111850|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
79495378|NCT02111850|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
79495379|NCT02111850|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
79343914|NCT01810042|Drug|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
79343915|NCT02424539|Drug|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
79343916|NCT02424539|Other|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
79343917|NCT01809262|Drug|single dose of 5 mcg|solution for inhalation
79343918|NCT01809262|Drug|single dose of placebo|solution for inhalation
79495380|NCT02087904|Biological|ABT-981|
79495381|NCT02087904|Other|Placebo|
79495382|NCT02087670|Other|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
79495383|NCT02087670|Other|exercise protocol no supervised|Exercise program at the community
79495384|NCT04729530|Device|Dyson Pure Cool - Active Purifier|Free standing air purifier
79495385|NCT04729530|Device|Dyson Pure Cool - Placebo purifier|Placebo air purifier
79495386|NCT02086968|Drug|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
79495387|NCT02086968|Drug|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
79495388|NCT04729218|Behavioral|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
79495389|NCT02086110|Dietary Supplement|Synbiotic|
79495390|NCT02086110|Dietary Supplement|Prebiotic|
79343919|NCT01809262|Drug|single dose of 40 mcg|solution for inhalation
79495391|NCT02085252|Drug|Leuprorelin|Solution for injection
79495392|NCT02085252|Drug|Bicalutamide|Bicalutamide tablets
79495393|NCT04417686|Procedure|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
79343920|NCT01809262|Drug|single dose of 20 mcg|solution for inhalation
79343921|NCT01809262|Drug|single dose of 2 mcg|solution for inhalation
79343922|NCT01809262|Drug|single dose of 10 mcg|solution for inhalation
79343923|NCT04915703|Procedure|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
79343924|NCT01808248|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79343925|NCT01808248|Drug|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
79343926|NCT01808248|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79495394|NCT02084238|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
79495395|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
79495396|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
79495397|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
79495398|NCT02083926|Drug|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
79495399|NCT02083926|Other|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
79495400|NCT02083380|Drug|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
79343927|NCT02424383|Device|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
79495401|NCT02083380|Drug|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
79495402|NCT02083380|Drug|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
79985566|NCT03714763|Drug|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
79343928|NCT01867294|Drug|Doxycycline|Given PO
79343929|NCT01867294|Procedure|Management of Therapy Complications|Moisturizer given topically
79343930|NCT01867294|Other|Placebo|Given topically
79495403|NCT02109744|Drug|Decitabine|
79495404|NCT02109432|Behavioral|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
79495405|NCT02109432|Behavioral|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
79985567|NCT03714763|Other|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
79985568|NCT04640532|Drug|KRT-232|KRT-232, administered by mouth
79343931|NCT01867294|Other|Questionnaire Administration|Ancillary studies
79343932|NCT01867294|Drug|Spironolactone|Given topically
79343933|NCT01867294|Drug|Sunscreen|Given topically
79495406|NCT02109432|Behavioral|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
79495407|NCT04723602|Biological|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
79495408|NCT04723602|Biological|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
79985569|NCT04640532|Drug|TL-895|TL-895, administered by mouth
79985570|NCT03712423|Drug|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
79985571|NCT02424760|Device|Shoulder hemi-arthroplasty|
79985572|NCT03717805|Other|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
79985573|NCT02421016|Device|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
79302601|NCT02484209|Drug|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
79302602|NCT02484209|Drug|Metformin|metformin 1500 mg daily for 16 weeks
79302603|NCT04991727|Behavioral|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
79302604|NCT02484365|Other|No treatment|Attach adhesive probe on thumb or index finger
79343934|NCT01867294|Drug|Therapeutic Hydrocortisone|Given topically
79343935|NCT02424149|Drug|Phenazopyridine|
79343936|NCT02423291|Drug|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
79343937|NCT02401529|Drug|IV dexamethasone|0.15 mg/kg
79343938|NCT02401529|Drug|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
79495409|NCT02109042|Drug|Blosozumab|Administered subcutaneously
79495410|NCT02066922|Device|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
79495411|NCT02066922|Device|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
79495412|NCT02066922|Device|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
79495413|NCT02108262|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
79495414|NCT02108262|Biological|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
79495415|NCT02107482|Device|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
79495416|NCT02107482|Device|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
79495417|NCT02066298|Drug|Mometasone 220mcg BID|Mometasone is an ICS
79495418|NCT02066298|Drug|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
79495419|NCT02066298|Drug|Placebo|
79495420|NCT02082912|Drug|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
79495421|NCT02082912|Other|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
79985574|NCT02421016|Device|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
79985575|NCT04620252|Drug|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
79495422|NCT02082912|Device|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
79495423|NCT02082522|Drug|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
79985576|NCT04620252|Drug|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
79985577|NCT04620252|Drug|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
79985578|NCT04620252|Drug|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
79985579|NCT04620252|Drug|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
79302605|NCT03119467|Drug|RP4010|Escalating doses starting at 25 mg
79343939|NCT02401529|Drug|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
79343940|NCT02401529|Drug|IV saline|IV saline
79343941|NCT01867216|Drug|Placebo|Administered orally as capsules
79343942|NCT01867216|Drug|LY2922470|Administered orally as capsules
79343943|NCT01866826|Drug|Rifaximin|subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
79343944|NCT01866826|Other|Placebo|subject will receive three capsules of placebo by mouth twice daily.
79343945|NCT04579276|Procedure|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
79343946|NCT04579276|Procedure|thoracic epidural analgesia|locoregional analgesia under ultrasound control
79343947|NCT04584970|Device|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
79343948|NCT04584970|Device|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
79343949|NCT01791244|Drug|Rebif®|
79985580|NCT04620252|Drug|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
79343950|NCT01865812|Drug|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily [QD]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
79985581|NCT04620252|Drug|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
79343951|NCT04600258|Dietary Supplement|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
79343952|NCT01808092|Drug|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
79343953|NCT01808092|Drug|meropenem (active comparator)|1000mg of Meropenem
79814528|NCT00851747|Drug|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
79814529|NCT04099875|Diagnostic Test|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
79814530|NCT04100031|Device|bandage contact lenses|wear bandage contact lensesfor a week after cataract surgery.
79985582|NCT03694886|Drug|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
79985583|NCT03694886|Other|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
79985584|NCT03694886|Drug|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
79985585|NCT03694886|Other|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
79985586|NCT04146467|Device|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
79985587|NCT02429128|Other|14 weeks exercise training|
79343954|NCT04584814|Device|No intervention|Basal analysis
79985588|NCT05602675|Drug|LY3871801|Administered orally.
79302606|NCT04991883|Other|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
79302607|NCT03315767|Diagnostic Test|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
79302608|NCT03315767|Diagnostic Test|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
79343955|NCT04584814|Device|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
79343956|NCT04584814|Device|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
79343957|NCT01774084|Dietary Supplement|Experimental: PreOp, NutriciaNordica AB|
79343958|NCT01774084|Dietary Supplement|Placebo Comparator: Water|
79343959|NCT01807234|Drug|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
79343960|NCT01807234|Drug|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
79985589|NCT05602675|Drug|Methotrexate|Administered orally.
79343961|NCT01807234|Drug|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
79343962|NCT01790932|Drug|BKM120|
79343963|NCT02377427|Drug|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
79814531|NCT04100031|Procedure|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
79814532|NCT02612519|Device|Alfapump|Implantation of Alfapump
79814533|NCT02612519|Device|TIPS|Implantation of TIPS
79658288|NCT01682746|Drug|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
79985590|NCT05602675|Drug|Warfarin|Administered orally.
79495424|NCT02082522|Procedure|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
79495425|NCT02082522|Drug|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
79658289|NCT00287664|Drug|terlipressin|
79495426|NCT02082210|Drug|Emibetuzumab|Administered Intravenously (IV)
79495427|NCT02082210|Drug|Ramucirumab|Administered Intravenously (IV)
79985591|NCT05602675|Drug|Dextromethorphan|Administered orally.
79985592|NCT05602675|Drug|Midazolam|Administered orally.
79985593|NCT05602675|Drug|Repaglinide|Administered orally.
79985594|NCT02421250|Device|Radical-7 Noninvasive Hgb Monitor|
79985595|NCT03714685|Drug|Firibastat|Firibastat (QGC001) 500 mg
79985596|NCT03699566|Other|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
79985597|NCT03699566|Other|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
79343964|NCT02421887|Drug|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
79343965|NCT02421887|Other|Placebo|Placebo
79343966|NCT01609582|Drug|TAK-875|TAK-875 tablets
79343967|NCT01609582|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
79343968|NCT01789606|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
79343969|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
79343970|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
79343971|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
79495428|NCT02107092|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
79495429|NCT02107014|Drug|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
79495430|NCT01624974|Drug|MK-1029|MK-1029 150 mg tablets taken QD
79495431|NCT01624974|Drug|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
79495432|NCT01624974|Drug|Montelukast (ML)|ML 10 mg tablets QD
79495433|NCT02065518|Device|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
79658290|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
79658291|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
79814534|NCT04099563|Drug|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
79985598|NCT03699566|Other|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
79985599|NCT03714607|Device|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
79985600|NCT03694730|Other|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
79985601|NCT03694730|Other|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
79658292|NCT01682902|Drug|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
79814535|NCT02613689|Behavioral|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
79814536|NCT02613689|Behavioral|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
79985602|NCT03444181|Behavioral|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
79658293|NCT01683097|Other|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
79814537|NCT00767325|Drug|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
79814538|NCT00767325|Drug|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
79814539|NCT00851591|Drug|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
79814540|NCT00851591|Drug|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
79814541|NCT04119947|Drug|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
79814542|NCT04115579|Other|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
79814543|NCT04115579|Other|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
79814544|NCT00702455|Behavioral|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
79343972|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
79343973|NCT01773226|Device|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
79985603|NCT03444181|Behavioral|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
79343974|NCT01773070|Drug|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
79343975|NCT01773070|Drug|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
79343976|NCT01773070|Drug|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
79343977|NCT01772368|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
79343978|NCT01772368|Drug|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
79495434|NCT02065518|Behavioral|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
79495435|NCT02065518|Behavioral|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
79495436|NCT01624662|Drug|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
79343979|NCT01772368|Drug|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
79658294|NCT01683136|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
79658295|NCT01683175|Drug|Erlotinib|
79658296|NCT01683175|Drug|cis-platinum|
79814545|NCT00702455|Behavioral|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
79658297|NCT01683175|Drug|Vinorelbine|
79658298|NCT00252980|Behavioral|Psychotherapy|
79985604|NCT03690752|Device|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
79985605|NCT03690752|Device|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
79985606|NCT02705716|Other|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
79985607|NCT02705716|Other|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
79343980|NCT01772368|Drug|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
79343981|NCT01788046|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
79343982|NCT01788046|Drug|Placebo|Administered intravenously (IV) three times per week.
79658299|NCT00281346|Procedure|Doppler echocardiography|Echocardiography
79343983|NCT01806298|Drug|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
79343984|NCT01772134|Drug|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
79343985|NCT01772134|Drug|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
79343986|NCT01772134|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
79343987|NCT01772134|Drug|Placebo|Inhalation Powder, Placebo
79343988|NCT01994889|Drug|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
79495437|NCT02106390|Biological|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
79495438|NCT02106390|Biological|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
79495439|NCT02064894|Drug|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
79658300|NCT01683253|Drug|Levodopa/Carbidopa(200mg/50mg)|
79658301|NCT01683253|Drug|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
79658302|NCT01683292|Drug|Inhaled VR040|
79658303|NCT01683292|Drug|Placebo for VR040|Placebo arm
79658304|NCT00253058|Drug|Cetirizine Dry Syrup|
79658305|NCT00281385|Behavioral|traditional vs. lifestyle exercise|
79343989|NCT01994889|Drug|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
79343990|NCT01994889|Drug|Placebo|Placebo in soft gel capsules administered once a day for 30 months
79495440|NCT02064894|Drug|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
79495441|NCT02064894|Drug|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
79495442|NCT04707768|Drug|Vadadustat|oral tablets
79495443|NCT04707768|Drug|Mircera®|intravenous administration
79658306|NCT01683487|Procedure|Observation|Observational study only, no intervention.
79658307|NCT01683682|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
79658308|NCT01683682|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
79658309|NCT01683682|Drug|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
79658310|NCT00287703|Device|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
79658311|NCT00287703|Device|Pulsating Electro-Magnetic Fields sham|sham PEMF
79658312|NCT00253097|Behavioral|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
79658313|NCT01683799|Behavioral|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
79658314|NCT00287742|Drug|risperidone|
79814546|NCT04116905|Behavioral|Intensive Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
79495444|NCT02081586|Behavioral|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
79495445|NCT02081586|Device|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
79343991|NCT02082483|Other|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
79495446|NCT02081586|Other|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
79495447|NCT02081196|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79495448|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
79495449|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
79495450|NCT02080260|Drug|regorafenib|Single agent drug therapy with regorafenib
79495451|NCT01624194|Drug|Oxytocin nasal spray|24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.
79495452|NCT01624194|Drug|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
79495453|NCT02079636|Drug|Abemaciclib|Administered orally
79495454|NCT02079636|Drug|Pemetrexed|Administered IV
79495455|NCT02079636|Drug|Gemcitabine|Administered IV
79495456|NCT02079636|Drug|Ramucirumab|Administered IV
79495457|NCT02079636|Drug|LY3023414|Administered orally
79495458|NCT02079636|Drug|Pembrolizumab|Administered IV
79495459|NCT02079246|Drug|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
79495460|NCT02077374|Drug|IDN-6556|25 mg BID for 28 days
79495461|NCT02077374|Other|Placebo|Placebo BID for 28 Days
79495462|NCT02077140|Drug|MDT-10013|
79814547|NCT04116905|Behavioral|Conventional Treatment|Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
79302609|NCT04999137|Drug|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
79495463|NCT02077140|Drug|Standard of care for pain|
79495464|NCT02047110|Drug|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
79495465|NCT02047110|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
79985608|NCT01374672|Other|laboratory biomarker analysis|Correlative studies
79343992|NCT02017899|Biological|S. sonnei 1790GAHB|
79343993|NCT02017899|Biological|Placebo|
79343994|NCT01993329|Drug|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
79343995|NCT01993329|Drug|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
79343996|NCT01993329|Drug|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
79495466|NCT02046564|Drug|ASC-01|
79495467|NCT02046564|Drug|Placebo|
79495468|NCT02046174|Biological|RENCA macrobeads|
79495469|NCT02045862|Drug|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
79495470|NCT02045862|Drug|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
79495471|NCT02045862|Drug|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
79495472|NCT02045862|Drug|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
79495473|NCT02075658|Device|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
79495474|NCT02075658|Device|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
79495475|NCT02063880|Other|Urgent ART|Children will be started on HAART <48 hours after enrollment.
79495476|NCT02063880|Other|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
79495477|NCT02044848|Drug|Secukinumab|
79495478|NCT02044848|Drug|Placebo|Placebo
79495479|NCT02044458|Device|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
79495480|NCT04182984|Drug|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
79495481|NCT02044302|Drug|Bupivacaine|
79495482|NCT02044302|Drug|Botulinum Toxins|
79495483|NCT02044302|Drug|Analgesics|
79495484|NCT02062944|Drug|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
79343997|NCT01993329|Drug|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
79495485|NCT02062632|Drug|Doxepin Hydrochloride|Given orally
79495486|NCT02062632|Other|Placebo|Given orally
79658315|NCT04527640|Dietary Supplement|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
79658316|NCT04527640|Other|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
79658317|NCT04527562|Drug|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
79495487|NCT02062632|Other|Quality-of-Life Assessment|Ancillary studies
79495488|NCT02062632|Other|Questionnaire Administration|Ancillary studies
79495489|NCT02062398|Device|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
79343998|NCT04417101|Drug|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
79343999|NCT02016183|Drug|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
79344000|NCT02377349|Biological|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
79344001|NCT02377349|Drug|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
79344002|NCT02421419|Drug|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
79344003|NCT02421419|Drug|Xylocaine|a local anesthetic agent
79495490|NCT02061540|Drug|LUM001|LUM001 oral dose
79495491|NCT02043366|Drug|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
79495492|NCT02043366|Drug|Butorphanol|Butorphanol is intravenously administrated
79658318|NCT04527562|Drug|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
79658319|NCT00281424|Device|pedometer|gave pedometer and info
79985609|NCT03714529|Biological|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
79985610|NCT04138043|Drug|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
79985611|NCT04138043|Drug|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
79985612|NCT03699488|Behavioral|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
79495493|NCT02043366|Drug|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
79495494|NCT02043366|Drug|Remifentanil|Remifentanil is intravenously administrated
79495495|NCT02043366|Drug|Sufentanil|Sufentanil is intravenously administrated
79495496|NCT02060370|Drug|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
79495497|NCT02060370|Behavioral|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
79985613|NCT03116620|Other|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
79985614|NCT02429050|Drug|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
79495498|NCT01622088|Drug|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
79495499|NCT01621542|Biological|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
79302610|NCT04999137|Drug|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
79302611|NCT02451163|Dietary Supplement|wheat polysaccharides|Consumed once daily for 12 weeks.
79302612|NCT02451163|Dietary Supplement|maltodextrin|Consumed once daily for 12 weeks.
79495500|NCT02021292|Drug|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
79495501|NCT02021292|Drug|Placebo|Matching placebo oral tablet, to be taken once daily.
79495502|NCT02059980|Behavioral|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
79495503|NCT02059980|Behavioral|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
79658320|NCT01684072|Biological|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
79658321|NCT01684072|Biological|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
79344004|NCT02421419|Drug|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
79344005|NCT02016105|Drug|GP2017 Adalimumab|
79344006|NCT02016105|Drug|Humira ® Adalimumab|
79344007|NCT02400905|Device|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
79495504|NCT02043132|Drug|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
79495505|NCT02043132|Drug|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
79495506|NCT02059434|Drug|LAS190792 Dose 1|
79495507|NCT02059434|Drug|LAS190792 Dose 2|
79495508|NCT02059434|Drug|LAS190792 Dose 3|
79658322|NCT01684111|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
79344008|NCT02400749|Drug|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
79344009|NCT02400749|Drug|Placebo|Placebo tablets will be provided to sites in blister cards.
79344010|NCT02420327|Drug|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
79344011|NCT02420327|Drug|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
79344012|NCT02420327|Drug|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
79495509|NCT02059434|Drug|LAS190792 Dose 4|
79495510|NCT02059434|Drug|LAS190792 Dose 5|
79495511|NCT02059434|Drug|LAS190792 Dose 6|
79495512|NCT02059434|Drug|LAS190792 Dose 1 (Part 2)|
79495513|NCT02059434|Drug|LAS190792 Dose 2 (Part 2)|
79495514|NCT02059434|Drug|Tiotropium 18 μg|
79495515|NCT02059434|Drug|Indacaterol 150 μg|
79495516|NCT02059434|Drug|Placebo|
79495517|NCT02059278|Drug|T-2345|T-2345 Ophthalmic Solution
79495518|NCT02059278|Drug|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
79495519|NCT04680780|Other|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
79495520|NCT04680780|Other|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
79495521|NCT04680780|Other|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (< 5-7 g/day) and sufficient fluid intake (>3 l/day) which is considered beneficial in ADPKD.
79495522|NCT02020512|Drug|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
79658323|NCT01684111|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
79658324|NCT01684189|Other|Patient registry|Patient registry without study intervention
79658325|NCT00253136|Drug|risperidone|
79658326|NCT02960529|Procedure|extra-peritoneal high ligation of hernia|
79658327|NCT02960529|Procedure|intraabdominal high ligation of hernia|
79658328|NCT01684267|Device|Robotic Gait Rehabilitation (RGR) Trainer|
79344013|NCT02420327|Drug|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
79344015|NCT04420559|Other|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
79658329|NCT01684306|Drug|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
79658330|NCT01684306|Drug|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
79985615|NCT02429050|Drug|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
79985616|NCT04479488|Other|Hospital admission|Usual care.
79495523|NCT02041962|Behavioral|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
79658331|NCT01684345|Drug|Placebo|Solution for subcutaneous injection
79658332|NCT01684345|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
79658333|NCT01684345|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
79658334|NCT00287781|Drug|Lidocaine|
79658335|NCT01684384|Radiation|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
79985617|NCT04479488|Other|Non-hospitalization procedures|Usual care.
79344016|NCT02374853|Drug|Vancomycin|Topical prophylactic antibiotic
79344017|NCT02374853|Other|No Vancomycin|Placebo: Sterile water. No Vancomycin.
79495524|NCT02041962|Other|Educational Control|
79658336|NCT01684462|Biological|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset
79658337|NCT01684462|Drug|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset
79658338|NCT00416871|Biological|aldesleukin|
79658339|NCT00416871|Biological|recombinant interferon alfa|
79658340|NCT01684540|Other|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
79658341|NCT01684540|Drug|Sinupret forte|
79985618|NCT01311427|Behavioral|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
79985619|NCT01311427|Behavioral|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
79985620|NCT02417142|Drug|Exenatide|Exenatide SQ 2mg/week for 24 weeks.
79985621|NCT02417142|Drug|Placebo|Placebo SQ 1x/week for 24 weeks.
79495525|NCT02041494|Device|Ventralight|
79495526|NCT02041494|Device|Strattice|
79495527|NCT04722042|Other|place-based mapping|Adjusting the electric frequency filters to align with the cochlear place frequency
79495528|NCT04722042|Other|default mapping|Default frequency filter assignments
79344018|NCT02015793|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
79344019|NCT02015793|Biological|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
79344020|NCT02347631|Device|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
79344021|NCT02347631|Device|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
79658342|NCT01684579|Behavioral|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
79658343|NCT01684579|Behavioral|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
79658344|NCT01684579|Behavioral|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
79658345|NCT01684618|Procedure|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
79658346|NCT01684657|Drug|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
79658347|NCT00416910|Biological|Filgrastim|
79658348|NCT00416910|Drug|Fludarabine|
79658349|NCT00416910|Drug|Cyclophosphamide|
79658350|NCT00416910|Drug|Mitoxantrone|
79658351|NCT01684696|Behavioral|Virtual experience|
79814548|NCT02612363|Drug|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~Analgesia~Propofol at lowest dosage.~Dose range: 0.1- 0.7 u/kg/hour~Target RASS score of -2 to +1~Supplemental other sedatives at lowest effective dose"
79344022|NCT02015637|Drug|Delafloxacin|single dose
79658352|NCT01684696|Behavioral|Videos|
79344023|NCT02015637|Drug|Ceftriaxone|single dose
79344024|NCT02347085|Drug|GFF MDI (PT003)|
79344025|NCT02347085|Drug|Placebo MDI|
79495529|NCT04699812|Device|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
79658353|NCT01684774|Drug|Bupivacaine|
79658354|NCT02279992|Drug|Vardenafil|
79658355|NCT02279992|Drug|Carboplatin|
79658356|NCT00253175|Drug|topiramate|
79658357|NCT00287820|Drug|Olanzapine|olanzapine 5-40 mg/day
79658358|NCT00287820|Drug|olanzapine|olanzapine 5-40 ,mg/day
79658359|NCT00287820|Drug|risperidone|risperidone 1-12 mg/day
79658360|NCT02272348|Other|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
79658361|NCT02272348|Other|Usual diabetes management.|
79658362|NCT02279095|Drug|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
79658363|NCT02279095|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
79658364|NCT02279095|Drug|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
79658365|NCT02279095|Drug|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
79658366|NCT01684852|Other|Medical device, drug-like|
79658367|NCT00253214|Drug|galantamine hydrobromide|
79814549|NCT00913211|Device|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
79344026|NCT02374463|Behavioral|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
79344027|NCT02374463|Behavioral|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
79344028|NCT02015481|Drug|Cabaletta|
79658368|NCT00287859|Drug|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
79658369|NCT01684891|Drug|RG1662|multiple doses of RG1662
79302613|NCT02484053|Drug|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
79344029|NCT02374307|Other|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
79344030|NCT02397473|Drug|Galcanezumab|Administered SC
79302614|NCT03200821|Biological|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
79658370|NCT01684969|Drug|Haloperidol|0.5 mg iv x one dose
79658371|NCT01684969|Drug|Placebo|0.5 mg iv , one dose
79344031|NCT02397473|Drug|Placebo|Administered SC
79985622|NCT03179098|Other|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
79985623|NCT03179098|Other|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
79344032|NCT02344745|Other|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
79344033|NCT02344745|Other|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
79344034|NCT02370641|Dietary Supplement|PomX|1000 mg POMx daily for 4 weeks
79344035|NCT01621191|Drug|Duloxetine|Administered Orally
79658372|NCT01685125|Drug|abiraterone acetate|Given PO
79658373|NCT01685125|Drug|dasatinib|Given PO
79658374|NCT01685125|Drug|prednisone|Given PO
79658375|NCT00416988|Other|educational intervention|
79658376|NCT04527679|Drug|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
79658377|NCT01685164|Other|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
79658378|NCT01685281|Drug|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
79658379|NCT01685281|Drug|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
79658380|NCT00417066|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
79344036|NCT02343263|Drug|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
79985624|NCT03179098|Other|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
79495530|NCT04699266|Device|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
79495531|NCT04698252|Radiation|Radiotherapy|Radiation therapy for oligometastatic sites
79658381|NCT00417066|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
79344037|NCT02343263|Biological|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
79658382|NCT04527952|Behavioral|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
79658383|NCT01682005|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
79658384|NCT01685398|Drug|0.5% timolol maleate eye drop|
79658385|NCT01685398|Drug|Normal saline|
79344038|NCT02081859|Device|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
79344039|NCT02081859|Other|Conventional Criteria|
79344040|NCT04420715|Other|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
79344041|NCT04897451|Other|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
79344042|NCT02342639|Drug|Rifaximin|550mg pills
79658386|NCT01685476|Device|Echodia® hand-held equipment|
79658387|NCT01685515|Drug|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
79658388|NCT01685515|Drug|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
79658389|NCT00281502|Drug|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
79658390|NCT00253331|Drug|topical organogel with nitroglycerin|
79658391|NCT04527250|Drug|ASC41|ASC41,1mg/table;5mg/table
79495532|NCT04698252|Procedure|Surgery|Surgery for oligometastatic sites
79495533|NCT04698252|Other|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
79658392|NCT04527250|Drug|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
79658393|NCT04527484|Drug|SHR-1314|each group subjects will be given different formulations of SHR-1314
79814550|NCT00913211|Procedure|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
79814551|NCT00913211|Procedure|rTMS and Tracking|Combination of rTMS and finger tracking
79495534|NCT02041104|Dietary Supplement|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
79495535|NCT02041104|Dietary Supplement|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
79495536|NCT02019420|Drug|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
79658394|NCT04527835|Diagnostic Test|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
79985625|NCT04477928|Diagnostic Test|Sera and whole blood sampling|"Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~5 years old: T1D and celiac autoantibodies~9-16 year old: one-time T1D and celiac autoantibodies~Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
79985626|NCT04477928|Diagnostic Test|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
79985627|NCT01374750|Drug|Sirolimus|Sirolimus
79344043|NCT02342639|Drug|Placebo|Placebo pill
79344044|NCT01625091|Drug|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
79344045|NCT01625091|Drug|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
79658395|NCT01685554|Device|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
79658396|NCT01685554|Device|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
79658397|NCT01685593|Device|abdominal binder|
79985628|NCT01374750|Drug|m-TOR inhibitor free|calcineurin inhibitors
79985629|NCT03106792|Dietary Supplement|Hairfinity #1|Main Hairfinity formulation
79985630|NCT03106792|Dietary Supplement|Hairfinity #2|Variation to main formulation
79344046|NCT02396849|Device|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
79985631|NCT03106792|Dietary Supplement|Hairfinity #3|Variation to main formulation
79985632|NCT03106792|Dietary Supplement|Placebo|No active ingredients
79985633|NCT03443713|Device|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
79985634|NCT03106558|Device|Total Knee Arthroplasty using Manual Instrumentation|
79344047|NCT02396849|Device|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
79344048|NCT02370251|Drug|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB <2 mg/dL) occurs.
79344049|NCT02396537|Drug|Lidocaine|Administered intranasally prior to Midazolam administration.
79495537|NCT02019420|Drug|Linezolid|Linezolid IV 600 mg twice daily
79495538|NCT02019264|Drug|Lorcaserin hydrochloride|APD356 10 mg twice daily
79985635|NCT03106558|Device|Total Knee Arthroplasty using Robotic Arm|
79985636|NCT03694574|Behavioral|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, & Hoffmann, 2011)"
79495539|NCT02019264|Drug|Placebo|Placebo twice daily
79658398|NCT01685593|Other|no binder|
79658399|NCT00253409|Drug|chemotherapy|
79658400|NCT00253409|Procedure|adjuvant therapy|
79658401|NCT00253409|Procedure|conventional surgery|
79658402|NCT00253409|Procedure|neoadjuvant therapy|
79658403|NCT00253409|Radiation|radiation therapy|
79814552|NCT00913211|Device|Sham rTMS|Sham treatment of rTMS
79495540|NCT02019108|Other|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
79658404|NCT01685632|Procedure|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
79814553|NCT00702611|Device|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
79344050|NCT02396537|Drug|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
79344051|NCT02396537|Drug|0.9% Saline|Administered intranasally prior to Midazolam administration.
79344052|NCT04891367|Other|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
79814554|NCT00702767|Drug|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
79814555|NCT04119869|Other|iaya|The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.
79344053|NCT02342171|Other|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
79344054|NCT01624467|Biological|Necitumumab|800 mg necitumumab, administered once per week IV
79344055|NCT01624233|Drug|80 mg ixekizumab|Administered SC
79344056|NCT01993017|Other|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
79495541|NCT02019108|Other|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
79814556|NCT00912899|Drug|Noscapine HCl|Escalating doses given twice per day
79814557|NCT00700895|Drug|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
79814558|NCT00861341|Drug|Aspirin|81 mg
79814559|NCT00861341|Drug|Pioglitazone|30mg Pioglitazone x1
79814560|NCT00766467|Drug|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
79814561|NCT00766467|Other|Placebo|Placebo taken once a day in the morning
79814562|NCT00850499|Drug|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
79814563|NCT00850499|Drug|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
79344057|NCT01993017|Drug|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
79814564|NCT00850499|Drug|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
79814565|NCT00860951|Device|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
79344058|NCT01993017|Other|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
79344059|NCT01993017|Other|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
79814566|NCT03123549|Device|Simplify Disc|Simplify Disc at two levels of the cervical spine
79344060|NCT01993017|Other|No intervention|
79344061|NCT01992549|Biological|Human-cl rhFVIII|
79344062|NCT01992159|Drug|Romosozumab|Administered by subcutaneous injection
79495542|NCT02018562|Device|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
79495543|NCT02058966|Drug|Entacapone|Entacapone 200 mg oral dose
79495544|NCT02058966|Drug|Methamphetamine|Methamphetamine 20 mg oral dose
79495545|NCT02058966|Drug|Placebo|capsules compounded to be of similar appearance to the active drugs
79495546|NCT02017860|Drug|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
79495547|NCT02040870|Drug|LDK378|750 mg once daily
79495548|NCT04697472|Device|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
79495549|NCT04720716|Drug|IBI310|IBI310 IV d1, Q6W
79495550|NCT04720716|Drug|Sintilimab|sintilimab IV d1, Q3W
79495551|NCT04720716|Drug|Sorafenib|Sorafenib 400mg po
79344063|NCT01992159|Drug|Placebo|Administered by subcutaneous injection
79344064|NCT01988493|Drug|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
79495552|NCT04719624|Device|Adaptos®-Si [0.5-1 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
79495553|NCT04719624|Device|Adaptos®-Si [1-2 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
79658405|NCT01685632|Procedure|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
79658406|NCT00281541|Drug|YM155|
79658407|NCT01685671|Drug|NESP 60μg|Administrated NESP 60μg once subcutaneously
79814567|NCT00844805|Drug|Infliximab|
79814568|NCT00844805|Drug|Placebo|
79814569|NCT00844805|Drug|Naproxen|
79814570|NCT04022265|Device|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
79814571|NCT03043209|Genetic|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
79814572|NCT00765999|Drug|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
79814573|NCT00765843|Device|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
79814574|NCT04099407|Drug|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
79814575|NCT04099407|Other|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
79344065|NCT01988493|Drug|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
79495554|NCT04719624|Device|Geistlich Bio-Oss (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
79344066|NCT01988493|Drug|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
79344067|NCT01988493|Drug|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
79495555|NCT04719624|Procedure|Tooth extraction without bone graft material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
79495556|NCT04719624|Device|Adaptos® (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
79495557|NCT04696068|Other|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
79495558|NCT02016300|Device|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
79495559|NCT02016300|Device|Non-Bracing|Microfracture performed with no post-operative unloader bracing
79495560|NCT02040090|Drug|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
79658408|NCT01685671|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
79658409|NCT01685710|Drug|GTN patch|
79344068|NCT01988493|Drug|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
79344069|NCT02081079|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
79344070|NCT02081001|Drug|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
79344071|NCT02081001|Drug|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
79344072|NCT02080221|Drug|FOLFOXA|
79344073|NCT02079909|Drug|T-817MA-H|224 mg or 448 mg T-817 MA once daily
79495561|NCT02058498|Behavioral|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
79344074|NCT02079909|Drug|T-817MA-L|224 mg T-817 MA once daily
79344075|NCT02079909|Drug|Placebo|Placebo
79344076|NCT04178031|Device|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
79344077|NCT02014467|Drug|Denosumab|Injection
79658410|NCT01685710|Drug|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
79344078|NCT02014467|Drug|Placebo|Injection
79344079|NCT02014467|Dietary Supplement|Elemental Calcium|Oral, at least 600 mg
79344080|NCT02014467|Dietary Supplement|Vitamin D|Oral, at least 400 IU
79658411|NCT00253487|Drug|O6-benzylguanine|
79658412|NCT00253487|Drug|busulfan|
79658413|NCT00253487|Drug|temozolomide|
79658414|NCT00253487|Procedure|adjuvant therapy|
79495562|NCT02039778|Radiation|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin & the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
79658415|NCT00253487|Procedure|autologous bone marrow transplantation|
79814576|NCT00765063|Drug|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
79495563|NCT02015754|Drug|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
79814577|NCT04098939|Diagnostic Test|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
79495564|NCT02015754|Device|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
79495565|NCT02015754|Procedure|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
79495566|NCT04441944|Other|Telemedicine|Use of provider-to-provider telemedicine
79495567|NCT02015676|Drug|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
79495568|NCT02015676|Drug|paclitaxel|60 mg/m^2 IV weekly; dose increased to 70 mg/m^2, and subsequently 80 mg/m^2, after 2 treatment cycles with no evidence of DLT until disease progression
79495569|NCT02015676|Drug|Myocet|40 mg/m^2 IV weekly; dose increased to 50 mg/m^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
79658416|NCT00253487|Procedure|conventional surgery|
79658417|NCT00253487|Procedure|peripheral blood stem cell transplantation|
79814578|NCT00764751|Drug|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
79495570|NCT02015520|Drug|Clazakizumab|
79495571|NCT02015520|Drug|Placebo (Matching with Clazakizumab)|
79658418|NCT00253487|Radiation|radiation therapy|
79658419|NCT01685788|Other|No intervention|
79658420|NCT00281619|Drug|CellCept (mycophenolate mofetil)|
79658421|NCT00281619|Behavioral|Dietary Monitoring|
79658422|NCT00281619|Behavioral|Drug Diary|
79658423|NCT00281619|Procedure|Blood Sampling|
79814579|NCT00764751|Drug|Dovonex® cream|Twice daily application
79814580|NCT00764751|Drug|Cream vehicle|Twice daily application
79814581|NCT00764673|Device|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
79814582|NCT00764517|Drug|Cladribine|Given IV
79344081|NCT02013765|Drug|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
79344082|NCT02013687|Biological|Pfs25 VLP- FhCMB|
79495572|NCT02058108|Drug|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
79658424|NCT04527211|Drug|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
79495573|NCT02058108|Drug|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
79495574|NCT04417374|Other|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
79495575|NCT04678362|Drug|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
79495576|NCT02057874|Device|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
79658425|NCT01685866|Device|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
79658426|NCT00253526|Drug|bevacizumab|
79658427|NCT00253526|Drug|gemcitabine hydrochloride|
79814583|NCT00764517|Other|Laboratory Biomarker Analysis|Correlative studies
79344083|NCT02013609|Drug|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
79344084|NCT01988337|Device|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
79344085|NCT01988337|Other|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
79344086|NCT02013531|Drug|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
79658428|NCT00253526|Procedure|adjuvant therapy|
79658429|NCT00253526|Procedure|anti-cytokine therapy|
79658430|NCT00253526|Procedure|antiangiogenesis therapy|
79344087|NCT01988103|Drug|Apremilast|20 mg tablet BID for 68 weeks
79344088|NCT01988103|Drug|Apremilast|20 mg tablet BID for 68 weeks
79658431|NCT00253526|Procedure|antibody therapy|
79658432|NCT00253526|Procedure|biological therapy|
79814584|NCT00764517|Biological|Rituximab|Given IV
79814585|NCT00764517|Drug|Vorinostat|Given PO
79814586|NCT00764361|Drug|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
79658433|NCT00253526|Procedure|chemotherapy|
79658434|NCT00253526|Procedure|conventional surgery|
79658435|NCT00253526|Procedure|growth factor antagonist therapy|
79658436|NCT00253526|Procedure|monoclonal antibody therapy|
79658437|NCT00253526|Procedure|surgery|
79658438|NCT01685944|Dietary Supplement|Live Pediococcus pentosaceus LP28|
79658439|NCT01685944|Dietary Supplement|Heat-killed Pediococcus pentosaceus LP28|
79344089|NCT01988103|Drug|Placebo|Placebo tablet BID for 16 weeks
79344090|NCT02013375|Procedure|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
79344091|NCT02013375|Drug|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
79344092|NCT02013375|Radiation|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
79495577|NCT02057874|Drug|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
79658440|NCT01685944|Dietary Supplement|Placebo|
79658441|NCT01686022|Other|Immunoblot|serum specific IgE binds to grass extract by immunoblot
79302615|NCT03200821|Drug|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
79344093|NCT02013375|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
79344094|NCT02013375|Drug|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
79344095|NCT02079519|Drug|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
79344096|NCT01987557|Behavioral|rate group|walking with a high cadence (steps per minute)
79344097|NCT01987557|Behavioral|magnitude treadmill group|
79344098|NCT01987557|Behavioral|regular treadmill walking|
79344099|NCT02078817|Drug|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
79344100|NCT02011893|Device|Tonic Stimulation|Prodigy Neurostimulation System with associated components
79344101|NCT02011893|Device|Burst Stimulation|Prodigy Neurostimulation System with associated components
79344102|NCT02011113|Drug|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
79344103|NCT02011113|Drug|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
79344104|NCT01807156|Drug|Tivozanib|Oral medication given daily. No placebo.
79344105|NCT01987479|Drug|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
79658442|NCT01686217|Drug|ASP015K ER|oral extended release (ER) at three dosing levels
79658443|NCT01686217|Drug|ASP015K IR|oral immediate release (IR)
79658444|NCT04719572|Other|Basic treatment group|A total of 60 subjects were recruited in the group.
79814587|NCT00764361|Drug|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
79814588|NCT00763971|Drug|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
79814589|NCT00763971|Drug|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
79814590|NCT00763971|Drug|Placebo|Placebo capsule once per day (Overencapsulated)
79814591|NCT00763815|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
79658445|NCT04719572|Other|Basic treatment+ anti-osteoporosis drug group|A total of 60 subjects were recruited in the group.
79658446|NCT04719572|Other|Basic treatment + non-drug treatment group|A total of 60 subjects were recruited in the group.
79658447|NCT01686295|Device|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
79495578|NCT04678050|Drug|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
79344106|NCT01987479|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
79344107|NCT01987479|Drug|Methotrexate|Methotrexate will be administered per investigator's discretion.
79344108|NCT01620489|Drug|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
79344109|NCT01620489|Drug|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
79495579|NCT04678050|Drug|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
79495580|NCT04677426|Drug|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
79495581|NCT02038920|Drug|Vedolizumab|Vedolizumab IV injection
79495582|NCT02038920|Drug|Vedolizumab placebo|Vedolizumab placebo-matching IV infusion
79495583|NCT02038764|Drug|Placebo|Placebo
79658448|NCT01686295|Device|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
79985637|NCT03694574|Behavioral|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
79495584|NCT02038764|Biological|PF-06342674 Dose A|Multiple SC Doses
79495585|NCT02038764|Biological|PF-06342674 Dose B|Multiple SC Doses
79495586|NCT02038764|Biological|PF-06342674 Dose C|Multiple SC Doses
79495587|NCT02038764|Biological|PF-06342674 Dose D|Multiple SC Doses
79658449|NCT04528030|Device|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
79814592|NCT00763815|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
79814593|NCT00763815|Device|Pen auto-injector|
79814594|NCT00763815|Drug|Pioglitazone|Dose to be kept stable.
79302616|NCT02635737|Device|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
79302617|NCT03072615|Diagnostic Test|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
79495588|NCT04693260|Device|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
79814595|NCT00763815|Drug|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
79985638|NCT03694574|Behavioral|control|No instruction
79495589|NCT04177836|Behavioral|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
79495590|NCT02014740|Drug|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
79495591|NCT02014740|Drug|Metformin|
79495592|NCT02014584|Drug|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
79495593|NCT02014584|Drug|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
79495594|NCT02014272|Drug|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
79495595|NCT02014272|Drug|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
79344110|NCT02076165|Behavioral|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
79344111|NCT02076165|Behavioral|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
79344112|NCT01620255|Drug|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
79344113|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
79344114|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
79344115|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
79344116|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
79344117|NCT02010567|Drug|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
79344118|NCT02010567|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
79344119|NCT02010567|Radiation|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if <T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
79344120|NCT02010567|Procedure|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
79344121|NCT01806064|Drug|TRC105 and Axitinib|
79344122|NCT01806064|Drug|Axitinib|
79495596|NCT04963452|Other|Dural puncture epidural|Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
79495597|NCT02037984|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
79495598|NCT02037984|Biological|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
79495599|NCT02037984|Biological|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
79495600|NCT02037984|Biological|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
79495601|NCT02037984|Biological|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
79495602|NCT02037984|Biological|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
79495603|NCT02057406|Drug|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
79495604|NCT02057406|Drug|High EPA|
79495605|NCT02057406|Other|Placebo|
79344123|NCT01804582|Other|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
79985639|NCT01977144|Other|Comprehensive Chromosomal Screening|
79985640|NCT03717649|Device|Conventional 2-stage venous cannula|venous cannula
79344124|NCT01787188|Drug|Meloxicam Test Capsules|
79344125|NCT01787188|Drug|Meloxicam Test Capsules|
79495606|NCT02036580|Biological|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
79495607|NCT02036580|Biological|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
79495608|NCT02036580|Other|Placebo|
79495609|NCT02014116|Drug|LY3009120 capsule|Administered orally.
79495610|NCT02057250|Drug|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
79495611|NCT02057250|Device|Auto-Injector Device (AID)|
79814596|NCT00763269|Drug|Triclosan, Silicon dioxide, fluoride|Brush twice daily
79814597|NCT00763269|Drug|Triclosan, fluoride|Brush twice daily
79814598|NCT00763035|Drug|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
79814599|NCT00763035|Drug|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
79814600|NCT00844649|Drug|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m^2 administered by intravenous infusion
79985641|NCT03717649|Device|Conventional 3-stage venous cannula|venous cannula
79985642|NCT03717649|Device|Fenestrated 3-stage venous cannula|venous cannula
79985643|NCT03182140|Drug|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
79344126|NCT01787188|Drug|Placebo Capsules|
79344127|NCT01787032|Drug|BI 113608|tablet
79344128|NCT01787032|Drug|BI 113608|tablet
79344129|NCT01787032|Drug|BI 113608|tablet
79344130|NCT01787032|Drug|Ketoconazole|tablet
79344131|NCT01787032|Drug|Voriconazole|tablet
79344132|NCT01737268|Drug|FK949E|Oral tablet
79344133|NCT01769404|Biological|LY2605541|
79985644|NCT03694496|Behavioral|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
79344134|NCT01769404|Biological|Insulin Glargine|
79344135|NCT04562662|Device|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
79344136|NCT01769326|Other|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
79495612|NCT02057250|Device|Pre-filled Syringe (PFS)|
79495613|NCT02057250|Drug|Methotrexate|Dispensed according to local practice.
79495614|NCT02057250|Drug|Sulfasalazine|Dispensed according to local practice.
79495615|NCT02057250|Drug|Leflunomide|Dispensed according to local practice.
79495616|NCT02057250|Drug|Hydroxychloroquine|Dispensed according to local practice.
79495617|NCT02036502|Biological|Pembrolizumab|Intravenous (IV) infusion
79495618|NCT02036502|Drug|Lenalidomide|Oral capsule
79495619|NCT02036502|Drug|Dexamethasone|Oral tablet IV infusion
79495620|NCT02036502|Drug|Carfilzomib|IV infusion
79495621|NCT02056626|Drug|carvedilol|
79495622|NCT02035332|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
79495623|NCT02056392|Drug|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
79985645|NCT01374828|Drug|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
79658450|NCT01686412|Device|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
79814601|NCT00844649|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
79344137|NCT01769326|Device|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
79985646|NCT04133519|Device|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
79985647|NCT04133519|Device|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
79495624|NCT02056392|Drug|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
79495625|NCT02056392|Drug|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
79814602|NCT04098861|Drug|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
79344138|NCT01769326|Other|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
79344139|NCT01769326|Device|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
79495626|NCT04716270|Procedure|Electrophysiology Study and Ablation|Electrophysiology Study and Ablation of Supraventricular Arrhythmias
79814603|NCT00762723|Device|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
79985648|NCT05567497|Procedure|trigeminal nerve block|ultrasound guided trigeminal nerve block
79985649|NCT03181906|Other|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
79985650|NCT03714295|Other|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
79985651|NCT02424682|Other|No intervention|No intervention administered in this study
79302618|NCT02483897|Drug|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
79302619|NCT02483897|Drug|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
79344140|NCT01786330|Device|Procare abdominal binder|
79344141|NCT01786330|Other|Standard of Care|
79344142|NCT01786174|Drug|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
79344143|NCT01786174|Other|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
79344144|NCT01736566|Other|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
79344145|NCT01736566|Other|Family History Only|Doctors and their patients receive a Family History report.
79495627|NCT02034708|Drug|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
79495628|NCT02034708|Drug|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
79658451|NCT01686490|Behavioral|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
79985652|NCT01373502|Device|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
79344146|NCT01768858|Drug|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
79344147|NCT01736254|Drug|Evacetrapib|
79344148|NCT01736254|Drug|Gemfibrozil|
79344149|NCT01767376|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
79344150|NCT01767376|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
79344151|NCT01767142|Device|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79495629|NCT02034552|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST [National Institute of Standards and Technology] update) every 4 weeks x 6 doses intravenous slow bolus
79495630|NCT02034552|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
79495631|NCT02034552|Drug|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
79344152|NCT01785628|Dietary Supplement|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
79985653|NCT01373502|Device|Taxus Liberté Stent|Taxus Liberté Coronary Stent
79985654|NCT03690362|Drug|VNRX-5133 and VNRX-5022|intravenous infusion
79985655|NCT03714217|Behavioral|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
79985656|NCT03746171|Diagnostic Test|Colonic polyp characterization by BLI|"All rectosigmoid <5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
79495632|NCT02034552|Drug|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
79495633|NCT02034474|Drug|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
79495634|NCT02034474|Drug|Placebo|intravenously via iv drip over 60 min
79814604|NCT04098705|Other|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
79495635|NCT02011542|Drug|VSL#3|This is a probiotic mixture
79344153|NCT01785628|Dietary Supplement|Placebo Capsule|Placebo is dextrin composition.
79344154|NCT01785472|Drug|LCZ696|LCZ696 200 mg tablet
79344155|NCT01785472|Drug|Olmesartan|Olmesartan 20 mg capsule
79344156|NCT01785472|Drug|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
79344157|NCT01785472|Drug|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
79344158|NCT01785160|Drug|Raltegravir|low dose oral administration
79344159|NCT01785160|Drug|Raltegravir|low dose oral administration
79344160|NCT01785160|Drug|Faldaprevir|medium dose oral administration
79344161|NCT01736176|Drug|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
79344162|NCT01736176|Procedure|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
79344163|NCT01736176|Drug|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
79344164|NCT01735630|Drug|ELND005|
79344165|NCT01735630|Drug|Placebo|
79495636|NCT02011542|Drug|Placebo|This is a pill with inactive ingredients.
79495637|NCT02011386|Drug|Treatment|
79814605|NCT00850343|Drug|Certolizumab pegol|Subcutaneous (SC) injection
79814606|NCT00849875|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
79814607|NCT00849875|Drug|Dacarbazine|Intravenous administration Chemotherapy
79814608|NCT00844415|Drug|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
79814609|NCT00843635|Drug|Tadalafil|Given orally
79814610|NCT00843635|Other|Placebo|Given orally
79344166|NCT04575922|Drug|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
79495638|NCT02010684|Behavioral|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
79495639|NCT02034162|Drug|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
79985657|NCT03717493|Behavioral|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking & Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
79344167|NCT04575922|Drug|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
79344168|NCT04575922|Radiation|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
79344169|NCT01735396|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
79344170|NCT01766206|Biological|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
79658452|NCT01686490|Behavioral|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
79344171|NCT01734850|Drug|Busulfan|Intravenous busulfan
79658453|NCT00281736|Drug|HPPH|Given IV
79658454|NCT00253565|Drug|capecitabine|
79344172|NCT01734850|Biological|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
79495640|NCT02034162|Drug|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
79658455|NCT00253565|Drug|imatinib mesylate|
79658456|NCT01686529|Procedure|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
79985658|NCT04477694|Procedure|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
79344173|NCT01734850|Biological|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
79344174|NCT01766050|Drug|Caffeine|
79344175|NCT01766050|Drug|Losartan|
79344176|NCT01766050|Drug|Omeprazole|
79344177|NCT01766050|Drug|Dextromethorphan|
79344178|NCT01766050|Drug|Midazolam|
79344179|NCT01766050|Biological|Belatacept|
79344180|NCT02341625|Drug|BMS-986148|
79344181|NCT02341625|Biological|Nivolumab|
79344182|NCT02370095|Drug|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
79344183|NCT02370095|Drug|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
79344184|NCT05370053|Diagnostic Test|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
79344185|NCT01783678|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
79344186|NCT01783678|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79344187|NCT01734772|Drug|dabigatran etexilate|multiple doses of dabigatran
79344188|NCT01734772|Drug|dabigatran etexilate|medium dose dabigatran
79495641|NCT02034006|Drug|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
79814611|NCT00699179|Drug|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
79985659|NCT03634332|Drug|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
79495642|NCT02054910|Procedure|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
79814612|NCT04116827|Drug|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
79814613|NCT00843167|Dietary Supplement|broccoli sprout extract|Given orally
79495643|NCT02054910|Procedure|Sham|Patients will not receive celiac plexus block during endoscopy.
79495644|NCT04714398|Behavioral|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
79344189|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
79344190|NCT01734772|Drug|ticagrelor|multiple doses of ticagrelor
79344191|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
79344192|NCT01734772|Drug|dabigatran etexilate|single dose of dabigatran
79344193|NCT02340221|Drug|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
79344194|NCT02340221|Drug|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
79344195|NCT02340221|Drug|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
79344196|NCT02395133|Drug|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
79344197|NCT02395133|Drug|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
79658457|NCT01686529|Drug|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
79658458|NCT01686607|Drug|Parenteral micafungin application|Parenteral
79658459|NCT01686607|Drug|Other parenteral antifungal drugs|Parenteral
79658460|NCT05140720|Biological|PNEUMOSIL®|"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval > 1 month Group 3: 2 doses, dose interval > 2 months"
79658461|NCT00281814|Procedure|psychosocial assessment and care|psychosocial assessment and care
79658462|NCT01686724|Behavioral|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
79344198|NCT02395055|Drug|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
79344199|NCT02395055|Drug|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
79344200|NCT02369159|Drug|Peramivir|
79344201|NCT02369159|Drug|Oseltamivir|
79344202|NCT02368691|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
79344203|NCT02394665|Radiation|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
79344204|NCT02394665|Drug|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~Concurrent during Radiation Therapy: 75 mg/m^2 orally for 6 weeks;~Post-radiation, adjuvant therapy: 150 mg/m^2 - 200 mg/m^2 orally daily on days 1 - 5 of each cycle."
79344205|NCT02394665|Behavioral|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
79344206|NCT02394665|Radiation|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
79658463|NCT01686724|Other|Business As Usual|
79658464|NCT01686802|Drug|oral morphine|
79658465|NCT01686802|Drug|Ibuprofen|
79814614|NCT00843167|Other|placebo|Given orally
79814615|NCT00849017|Biological|albiglutide|albiglutide weekly injection
79814616|NCT00849017|Biological|albiglutide uptitration|albiglutide uptitration at week 12
79814617|NCT00849017|Biological|placebo|matching albiglutide placebo weekly injection
79814618|NCT00842543|Dietary Supplement|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
79814619|NCT00842543|Dietary Supplement|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
79985660|NCT03634332|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
79985661|NCT03744767|Drug|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
79814620|NCT00785928|Biological|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
79344207|NCT02394665|Radiation|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
79495645|NCT04714398|Behavioral|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
79658466|NCT00281853|Procedure|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
79814621|NCT00785928|Drug|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
79344208|NCT02394665|Device|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
79344209|NCT02367911|Drug|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
79344210|NCT02367911|Drug|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
79495646|NCT02033850|Behavioral|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
79495647|NCT02054130|Drug|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
79814622|NCT00842309|Drug|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
79495648|NCT02054130|Drug|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
79658467|NCT01686880|Device|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
79658468|NCT00253721|Drug|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
79985662|NCT02428972|Drug|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
79985663|NCT02428972|Drug|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
79302620|NCT03203083|Other|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
79302621|NCT03200899|Behavioral|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
79302622|NCT03200899|Other|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
79302623|NCT02636907|Drug|BI 695501 Autoinjector|
79302624|NCT02636907|Drug|BI 695501 Prefilled syringe|
79302625|NCT03200665|Diagnostic Test|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
79344211|NCT02339285|Device|tACS (alpha)|
79658469|NCT01686919|Dietary Supplement|milk-free|milk-free diet during 8 preoperative weeks
79814623|NCT00842309|Drug|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
79814624|NCT04119401|Procedure|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
79985664|NCT03634254|Other|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
79985665|NCT02428660|Genetic|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
79985666|NCT02428660|Other|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
79985667|NCT02428660|Other|MTM|Medication Therapy Management
79985668|NCT03694340|Other|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
79985669|NCT03699332|Drug|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
79985670|NCT03699332|Radiation|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
79344212|NCT02339285|Device|tACS (gamma)|
79495649|NCT02054130|Drug|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
79658470|NCT01686997|Procedure|Roux-en-Y Gastric Bypass|
79495650|NCT02054130|Drug|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
79985671|NCT03699332|Procedure|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
79495651|NCT04673682|Drug|D309|D309(Testosterone) 1 vial, Once, IM injection
79658471|NCT01687075|Device|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
79658472|NCT00253760|Drug|dietary amino acids; cysteine and methionine|
79985672|NCT04007159|Other|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square [mL/cm^2] of serum in an individual cell of patch)
79344213|NCT02367833|Drug|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
79344214|NCT02367833|Drug|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
79495652|NCT04673682|Drug|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
79495653|NCT02009046|Behavioral|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
79495654|NCT02009046|Behavioral|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
79524836|NCT05767710|Behavioral|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
79524837|NCT05767710|Behavioral|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
79658473|NCT00281892|Biological|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
79985673|NCT04007159|Other|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of lotion in an individual cell of patch)
79344215|NCT02367833|Drug|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
79814625|NCT04119401|Procedure|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
79814626|NCT02613065|Dietary Supplement|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
79344216|NCT02367521|Combination Product|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
79658474|NCT00281892|Drug|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
79814627|NCT02613065|Dietary Supplement|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
79814628|NCT00842153|Drug|Clobetasol propionate foam|Topical Clobetasol propionate foam
79814629|NCT00842153|Drug|Vehicle foam|Vehicle foam does not include the active drug.
79814630|NCT00762411|Drug|LY450139|Administered orally once daily.
79814631|NCT00762411|Drug|Placebo|Administered orally once daily.
79814632|NCT00761865|Device|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
79985674|NCT04007159|Other|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of cream in an individual cell of patch)
79344217|NCT02367521|Device|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
79985675|NCT04007159|Other|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of normal saline in an individual cell of patch)
79985676|NCT04483024|Dietary Supplement|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
79344218|NCT02338193|Drug|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
79985677|NCT03690128|Behavioral|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
79495655|NCT02009046|Behavioral|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
79658475|NCT02274571|Drug|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
79658476|NCT02274571|Other|Placebo|non active
79344219|NCT02338193|Drug|DAPA|10 mg dapagliflozin QD for 20-24 weeks
79344220|NCT02338193|Drug|MET XR|1000 mg Metformin XR BID for 20-24 weeks
79658477|NCT00253799|Device|Hylan GF-20|
79658478|NCT01687231|Other|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
79344221|NCT01783444|Drug|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
79658479|NCT00281931|Biological|rituximab|
79658480|NCT00281931|Drug|cyclophosphamide|
79344222|NCT01783444|Drug|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
79658481|NCT00281931|Drug|fludarabine phosphate|
79658482|NCT01687309|Drug|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
79344223|NCT01783444|Drug|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
79344224|NCT02367131|Drug|Jardiance|Empagliflozin
79344225|NCT02394275|Biological|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
79344226|NCT01608724|Drug|Saxagliptin|oral, 5 mg once a day (Q.D.)
79344227|NCT02366195|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10^8 PFU/mL.
79344228|NCT04905251|Drug|Mifepristone-Misoprostol|Non interventional design.
79658483|NCT01687309|Drug|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
79658484|NCT01687309|Other|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
79344229|NCT02364947|Drug|Nalmefene hydrochloride|As-needed; tablets, orally
79344230|NCT02364947|Drug|Placebo|As-needed; tablets, orally
79344231|NCT02392481|Procedure|Biofluid sampling|
79344232|NCT02392403|Device|Nucleus CI532 cochlear implant|
79658485|NCT01687309|Other|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
79658486|NCT01687348|Drug|lidocaine aguettant|
79658487|NCT01687426|Drug|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
79658488|NCT01687426|Drug|Vehicle|1 drop in each eye daily four times a day for 14 days
79814633|NCT00841763|Biological|Placebo (PL)|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.
79985678|NCT03690128|Behavioral|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
79985679|NCT03119688|Other|Test Product|Micellar cleanser (0.09 ml)
79985680|NCT03119688|Other|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
79985681|NCT03119688|Other|Reference Product|Sterile Water (0.09 ml)
79985682|NCT03119688|Other|No Treatment|Unwashed area of the forearm
79985683|NCT03389893|Drug|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
79985684|NCT03389893|Drug|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
79985685|NCT03178708|Drug|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
79985686|NCT03178708|Other|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
79985687|NCT03694106|Behavioral|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
79495656|NCT02009046|Behavioral|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
79985688|NCT02424292|Other|Physical activity|Physical activity in a personalised program.
79985689|NCT04473872|Other|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
79344233|NCT02392247|Device|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
79495657|NCT02052960|Drug|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
79985690|NCT01373658|Device|Yinyi stent|subjects with Yinyi stent implantation
79985691|NCT04128293|Drug|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
79985692|NCT04128293|Drug|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
79985693|NCT02428582|Device|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
79985694|NCT02428582|Device|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
79985695|NCT05197686|Device|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
79985696|NCT05197686|Device|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
79985697|NCT03179020|Other|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
79985698|NCT03179020|Other|Usual care|Management of the potential donor according usual care.
79985699|NCT02428894|Device|LVAD|
79344234|NCT02337725|Drug|TVP-1012|TVP-1012 1mg Tablets
79344235|NCT02337725|Drug|Placebo|Placebo tablets
79344236|NCT02337491|Drug|Pembrolizumab|
79344237|NCT02337491|Drug|Bevacizumab|
79344238|NCT01765582|Drug|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
79344239|NCT01765582|Drug|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
79344240|NCT01765582|Drug|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
79495658|NCT02052960|Drug|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
79495659|NCT02052960|Drug|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
79985700|NCT00787176|Drug|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
79495660|NCT02008890|Biological|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
79814634|NCT00841763|Biological|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
79814635|NCT00841763|Biological|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
79814636|NCT00841763|Biological|Adjuvanted trivalent influenza virus vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
79344241|NCT01765582|Drug|irinotecan|Participants will receive IV infusion of 165 mg/m^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
79344242|NCT01765582|Drug|folinic acid|Participants will receive IV infusion of 200 mg/m^² (Arm A) or 400 mg/m^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m^2 in the maintenance therapy.
79495661|NCT02008890|Biological|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
79495662|NCT02008890|Biological|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
79495663|NCT02052414|Drug|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
79495664|NCT02007954|Device|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
79495665|NCT02049450|Drug|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
79495666|NCT02031432|Drug|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
79658489|NCT04719689|Other|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
79814637|NCT00838331|Biological|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
79814638|NCT00838331|Biological|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (< 7 days) and impaired (> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (> 28 days; washed or rejuvenated) RBC transfusions."
79814639|NCT00703001|Behavioral|Educational Intervention|students in this arm will receive several oral health educational modules in class
79814640|NCT00703001|Behavioral|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
79344243|NCT01765582|Drug|oxaliplatin|Participants will receive 85 mg/m^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
79344244|NCT04413838|Drug|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
79344245|NCT04413838|Other|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
79344246|NCT01649375|Drug|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
79344247|NCT01649375|Drug|Placebo|Placebo
79344248|NCT01649375|Drug|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
79658490|NCT04719689|Other|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
79344249|NCT02336555|Drug|MK-8291|MK-8291 oral tablets
79344250|NCT02336555|Drug|Placebo|Placebo oral tablets
79344251|NCT01648283|Drug|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
79495667|NCT02031276|Drug|risankizumab IV|risankizumab administered by IV infusion
79495668|NCT02031276|Drug|risankizumab SC|risankizumab administered by SC injection
79495669|NCT02031276|Drug|Placebo|Placebo for risankizumab administered by IV infusion
79495670|NCT04686864|Behavioral|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
79495671|NCT02007720|Drug|Serelaxin|Intravenous infusion
79495672|NCT02007720|Drug|Placebo|Intravenous infusion
79658491|NCT01687543|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
79344252|NCT01648283|Drug|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
79344253|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
79344254|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
79344255|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
79344256|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
79344257|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
79344258|NCT01649297|Drug|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
79344259|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
79344260|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
79495673|NCT02007720|Other|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
79495674|NCT01363440|Drug|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
79495675|NCT01363440|Procedure|Macular Laser Photocoagulation|Laser therapy
79495676|NCT02007252|Drug|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
79495677|NCT02007252|Drug|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
79495678|NCT02007096|Drug|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight <100kg: 50ml total; weight >100kg: 60ml total
79495679|NCT02007096|Drug|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight <100kg: 50ml; weight >100kg: 60ml
79495680|NCT02006706|Drug|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
79495681|NCT02006706|Drug|methotrexate|10 - 25 mg/week
79495682|NCT02006706|Drug|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
79658492|NCT01687543|Other|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
79985701|NCT00787176|Drug|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
79985702|NCT00787176|Drug|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
79985703|NCT00787176|Drug|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
79344261|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
79344262|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
79344263|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
79658493|NCT00287898|Behavioral|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
79658494|NCT00287898|Behavioral|Usual Care|subjects will receive standard in-person genetic counseling
79658495|NCT01687582|Drug|GLP-1 analog|GLP-1 analog treatment
79344264|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
79658496|NCT01687621|Procedure|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
79344265|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
79344266|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
79344267|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
79658497|NCT01687660|Other|acupuncture|apply acupuncture to prevent the migraine attack
79344268|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
79344269|NCT01649297|Drug|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
79344270|NCT01649297|Drug|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
79344271|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
79344272|NCT01649297|Drug|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
79344273|NCT01648205|Drug|Placebo|Matching Placebo will be given for first month.
79495683|NCT02049138|Drug|Upadacitinib|Tablet taken orally
79495684|NCT02049138|Biological|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
79524838|NCT05767710|Behavioral|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
79524839|NCT05767632|Drug|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg & 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
79344274|NCT01648205|Drug|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
79985704|NCT03711487|Drug|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
79344275|NCT04894253|Biological|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
79495685|NCT04686318|Diagnostic Test|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
79985705|NCT02424370|Procedure|TAVR|Percutaneous aortic valve replacement
79985706|NCT03633864|Biological|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
79985707|NCT05560555|Drug|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
79344276|NCT02362451|Biological|Autologus elutriated monocyte placebo vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
79344277|NCT02362451|Biological|Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
79344278|NCT01734382|Drug|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants < 30 kg) or 8 mg/kg (for participants >/=30 kg) Q2W/Q3W/Q4W.
79344279|NCT02391311|Device|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
79344280|NCT01765426|Biological|TDV|TDV suspension for intradermal administration
79344281|NCT01765426|Drug|Placebo|Phosphate buffered saline (PBS)
79344282|NCT01765270|Drug|Saxagliptin|one 5-mg saxagliptin tablet daily
79985708|NCT03744689|Procedure|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
79344283|NCT01765270|Drug|Placebo|5mg placebo tablet daily
79344284|NCT01733758|Drug|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
79344285|NCT01733758|Drug|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
79985709|NCT03744689|Procedure|Sham block|Sham block will be done with serum physiologic.
79985710|NCT03744689|Drug|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
79985711|NCT03744689|Device|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
79985712|NCT02424214|Other|Artificial Oocyte activation|
79985713|NCT02424214|Drug|Ca Ionophore|
79985714|NCT02424214|Drug|Strontium Chloride|
79985715|NCT05559541|Drug|AK119|AK119 is an anti-CD73 monoclonal antibody.
79985716|NCT05559541|Drug|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
79985717|NCT02428426|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
79985718|NCT03691571|Device|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
79985719|NCT03691571|Device|Control|Standard of care involves standard temperature probe monitoring.
79985720|NCT03113916|Behavioral|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
79985721|NCT03712111|Drug|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
79985722|NCT03712111|Drug|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
79495686|NCT02048904|Drug|Sitagliptin|Sitagliptin 100 mg/day for 3 months
79495687|NCT02048904|Drug|Placebo|Placebo 1 pill/day for 3 months
79985723|NCT03712111|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
79344286|NCT01733758|Drug|Placebo|Albiglutide matching placebo will be available as a pen injector
79495688|NCT02006628|Drug|Placebo|Placebo oral solution (0 milligrams [mg]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
79495689|NCT02006628|Drug|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
79495690|NCT02048826|Device|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
79495691|NCT02048826|Device|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
79985724|NCT03712111|Drug|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
79344287|NCT01733758|Drug|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
79344288|NCT01607554|Drug|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
79344289|NCT01607476|Drug|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
79985725|NCT02925494|Drug|Estradiol/Norethindrone Acetate|capsules
79985726|NCT02925494|Drug|Elagolix|film-coated tablets
79985727|NCT03711409|Other|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
79344290|NCT01607476|Drug|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
79344291|NCT01765192|Drug|Roflumilast|Roflumilast was supplied in tablets.
79344292|NCT01765192|Drug|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
79344293|NCT01765192|Drug|Montelukast|Montelukast was supplied in tablets.
79344294|NCT01733680|Drug|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
79344295|NCT01733680|Behavioral|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
79344296|NCT04892498|Radiation|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
79344297|NCT04892498|Drug|PD-1 inhibitor|q3w, until PD
79344298|NCT04892498|Drug|GM-CSF|200μg, D1-D7, ≥8 cycles
79344299|NCT04892498|Drug|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
79344300|NCT02336165|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
79344301|NCT02336165|Radiation|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
79495692|NCT02006472|Drug|Pridopidine|22.5 mg and 45 mg capsules
79495693|NCT02006472|Other|Placebo|Capsules matching drug
79495694|NCT02005692|Device|DynaSense sensor|
79495695|NCT02029638|Biological|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
79495696|NCT02029638|Drug|Fludarabine|Fludarabine at dose 30 mg/m^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
79495697|NCT02029638|Drug|Cyclophosphamide|"Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~High dose cyclophosphamide [50mg/kg (Ideal Body Weight)] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
79658498|NCT01687699|Drug|Spironolactone|
79985728|NCT03711409|Other|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
79985729|NCT02428348|Other|Interview about prototype EEG-cap|
79344302|NCT02336165|Biological|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
79344303|NCT02360111|Drug|Cyclophosphamide|
79344304|NCT02334683|Device|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
79344305|NCT02334683|Device|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
79495698|NCT02029638|Radiation|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
79344306|NCT02319044|Drug|MEDI4736|MEDI4736 monotherapy
79344307|NCT02319044|Drug|Tremelimumab|Tremelimumab monotherapy
79344308|NCT02319044|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
79495699|NCT02029638|Drug|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
79344309|NCT01649765|Drug|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
79495700|NCT02029638|Drug|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
79344310|NCT01649765|Other|placebo|Normal Saline 250 ml
79658499|NCT00287937|Drug|vorinostat|Given orally
79658500|NCT00287937|Drug|paclitaxel|Given IV
79658501|NCT00287937|Drug|carboplatin|Given IV
79658502|NCT00287937|Other|laboratory biomarker analysis|Correlative studies
79658503|NCT00287937|Other|pharmacological study|Correlative studies
79658504|NCT01687855|Device|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
79344311|NCT02317562|Drug|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
79658505|NCT00253838|Procedure|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
79344312|NCT02317016|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
79495701|NCT02029638|Drug|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
79495702|NCT02029638|Biological|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
79495703|NCT02029638|Drug|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
79495704|NCT02029638|Drug|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
79658506|NCT00253838|Procedure|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
79658507|NCT01687894|Drug|Vasopressins|Vasopressins propofol vasopressins sevoflurane
79658508|NCT01687894|Drug|Placebo|Placebo propofol & placebo sevoflurane
79658509|NCT01687894|Drug|propofol|vasopressin propofol & placebo propofol
79658510|NCT01687894|Drug|sevoflurane|vasopressins sevoflurane placebo sevoflurane
79658511|NCT00287976|Drug|irinotecan hydrochloride|
79658512|NCT01687933|Device|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
79658513|NCT01687933|Other|usual care|Women in Control group did not use the glasses.
79344313|NCT02317016|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
79344314|NCT02317016|Drug|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
79344315|NCT02317016|Procedure|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
79344316|NCT02317016|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
79344317|NCT02311478|Device|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
79344318|NCT02388932|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79344319|NCT02388932|Device|Positron Emission Tomography|Undergo PET/CT
79344320|NCT02388932|Device|Computed Tomography|Undergo PET/CT
79344321|NCT02388932|Other|Quality-of-Life Assessment|Ancillary studies
79344322|NCT02388776|Device|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
79495705|NCT02029638|Drug|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
79495706|NCT02029638|Drug|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
79495707|NCT04710654|Other|connective tissue manipulation|Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
79495708|NCT04710654|Other|Interferential current stimulation (100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
79658514|NCT01688089|Drug|ODM103|
79658515|NCT01688089|Drug|Placebo|
79658516|NCT01688089|Drug|Entacapone|
79658517|NCT01688089|Drug|Levodopa/carbidopa|
79658518|NCT00253877|Other|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
79658519|NCT01688128|Device|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
79658520|NCT01688128|Other|Washout (2 wks)|2-weeks wash out period in both arms
79658521|NCT01688128|Device|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
79658522|NCT01688206|Biological|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
79658523|NCT01688206|Biological|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram [mg] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
79658524|NCT01688245|Behavioral|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
79658525|NCT01688245|Behavioral|SMS Assessments|Weekly post-weekend drinking outcome assessments
79814641|NCT00785538|Biological|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
79814642|NCT00785538|Biological|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
79344323|NCT02316548|Radiation|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
79344324|NCT02281760|Drug|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
79344325|NCT02281760|Drug|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
79344326|NCT02390531|Drug|Bevacizumab|Varying dosages in 10µl
79344327|NCT02390219|Drug|Lumacaftor|
79344328|NCT02390219|Drug|Ivacaftor|
79344329|NCT02334215|Drug|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
79495709|NCT04710654|Other|Interferential current stimulation (0-100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
79495710|NCT04710654|Other|behavioural therapy|"The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy."
79985730|NCT03744533|Other|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
79495711|NCT04710654|Other|exercise program|"Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training."
79658526|NCT01688284|Device|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
79658527|NCT01688323|Other|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
79658528|NCT00288093|Radiation|3-Dimensional Conformal Radiation Therapy|
79658529|NCT00288093|Drug|Triapine|
79658530|NCT04525339|Procedure|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
79658531|NCT00288132|Behavioral|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
79658532|NCT00288132|Behavioral|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
79658533|NCT04519840|Other|nill|nill
79658534|NCT04519372|Diagnostic Test|Testing for SARS-CoV-2|All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.
79814643|NCT00785538|Biological|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
79814644|NCT00785538|Biological|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
79814645|NCT00785538|Biological|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
79985731|NCT03744533|Other|guideline-based treatment|guideline-based treatment
79985732|NCT02420704|Procedure|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
79985733|NCT03744455|Biological|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
79495712|NCT02047734|Drug|Ozanimod|Oral capsule, daily for 24 months
79495713|NCT02047734|Drug|Ozanimod placebo|Oral capsule, daily for 24 months
79658535|NCT00253916|Behavioral|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
79658536|NCT00253916|Behavioral|Resistance Exercise Program|Resistance Exercise Program
79658537|NCT00288171|Drug|Placebo|placebo capsule twice daily for one month
79658538|NCT00288171|Drug|Allopurinol|Allopurinol 200mg twice daily for one month
79658539|NCT00253955|Drug|Levofloxacin|
79344330|NCT02334215|Behavioral|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
79344331|NCT02334215|Behavioral|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
79344332|NCT02359877|Drug|BCD-054|
79344333|NCT02359877|Drug|Rebif|
79495714|NCT02047734|Drug|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
79495715|NCT02047734|Drug|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
79495716|NCT02053350|Drug|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
79658540|NCT00253955|Drug|Piperacillin/Tazobactam|
79658541|NCT00288210|Procedure|Primary angioplasty in acute myocardial infarction|
79658542|NCT00253994|Procedure|Acupuncture|
79658543|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
79658544|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
79658545|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
79658546|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
79344334|NCT02359877|Drug|Avonex|
79344335|NCT02389829|Drug|Hydromorphone|
79344336|NCT02389829|Drug|Prochlorperazine|
79814646|NCT00785538|Biological|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
79344337|NCT02389829|Drug|Diphenhydramine|
79344338|NCT02358863|Drug|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
79344339|NCT02358863|Drug|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
79495717|NCT04684914|Biological|HepTcell|Intramuscular injection
79495718|NCT04684914|Drug|Placebo|Intramuscular injection
79495719|NCT04709016|Behavioral|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
79495720|NCT04417140|Biological|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
79658547|NCT00254033|Drug|Dextroamphetamine|
79658548|NCT00254033|Drug|Methylphenidate|
79658549|NCT01600573|Drug|pazopanib in combination with weekly topotecan|"Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
79658550|NCT01600612|Drug|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
79658551|NCT01600612|Drug|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
79658552|NCT01600612|Drug|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
79658553|NCT01600651|Other|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
79985734|NCT03181672|Procedure|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
79985735|NCT03181672|Procedure|control group|Deltoid muscle injection with 1% lidocaine 10ml
79985736|NCT05658445|Other|evacuation|after complete evacuation of uterus follow abortion
79985737|NCT04006145|Drug|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
79495721|NCT01994850|Drug|brentuximab vedotin|Trade name: Adcetris
79495722|NCT02027844|Behavioral|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
79344340|NCT02358863|Drug|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
79344341|NCT02358863|Drug|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
79344342|NCT02358863|Drug|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
79658554|NCT01600651|Other|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
79658555|NCT00288288|Procedure|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
79658556|NCT00288288|Procedure|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
79658557|NCT00254111|Device|Ultra Probe Laser System|
79814647|NCT04102488|Procedure|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
79814648|NCT04102488|Procedure|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
79985738|NCT04006145|Drug|Placebo oral tablet|Placebo identical in appearance to active drug
79985739|NCT03717337|Procedure|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
79344343|NCT02358863|Drug|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
79344344|NCT02358863|Drug|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
79344345|NCT02358863|Drug|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
79344346|NCT02358473|Biological|mogamulizumab|Mogamulizumab will be administered by IV infusion.
79344347|NCT02358473|Drug|Docetaxel|Docetaxel will be administered by IV infusion.
79344348|NCT02357459|Drug|FX006|Single 5 mL IA injection
79344349|NCT02357459|Drug|Placebo|Single 5 mL IA injection
79344350|NCT02357459|Drug|TCA IR 40|Single 1 mL IA injection
79344351|NCT04902599|Procedure|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
79344352|NCT04902599|Procedure|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
79495723|NCT02027844|Behavioral|parental presence|parental presence during inhalational induction of sevoflurane
79495724|NCT04671576|Other|Control Infant Formula|Powder, standard commercial infant formula.
79495725|NCT04671576|Other|Organic Infant Formula|Powder, organic milk-based infant formula.
79495726|NCT01994382|Drug|Cerdulatinib|Oral capsule
79495727|NCT01994382|Biological|Rituximab|IV infusion
79495728|NCT02003898|Device|Medtronic MiniMed 530G Insulin Pump|
79495729|NCT01994226|Drug|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
79658558|NCT01600690|Other|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
79658559|NCT01600768|Drug|Beta-Lactams|infusion time: 30 mins or 1 hr
79658560|NCT01600768|Drug|Beta-Lactams|infusion time 4 hrs
79658561|NCT00288327|Behavioral|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
79658562|NCT00288327|Behavioral|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
79658563|NCT04467112|Device|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
79658564|NCT00414947|Drug|Vildagliptin (LAF237)|
79658565|NCT04465747|Other|Publications|Reviewing published evidence
79985740|NCT03717337|Procedure|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
79985741|NCT03689816|Procedure|sleeve gastrectomy|sleeve gastrectomy
79985742|NCT03689816|Procedure|gastric bypass|gastric bypass
79985743|NCT03386773|Behavioral|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
79658566|NCT04464772|Device|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
79658567|NCT00288405|Device|Cordis Self Expanding Stent|
79344353|NCT02332889|Biological|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be > 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
79344354|NCT02332889|Drug|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
79344355|NCT02357147|Drug|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
79344356|NCT02357147|Drug|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
79495730|NCT01994226|Drug|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
79344357|NCT02357147|Drug|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
79344358|NCT02357147|Drug|Cisplatin|Combination Phase - Cisplatin 75 mg/m^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
79658568|NCT04462744|Other|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
79658569|NCT00414986|Behavioral|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
79658570|NCT00414986|Behavioral|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
79658571|NCT00414986|Behavioral|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
79658572|NCT00288444|Drug|Lonafarnib|
79658573|NCT00288444|Drug|Docetaxel|
79495731|NCT02002884|Drug|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
79495732|NCT02002884|Drug|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
79524840|NCT05767632|Drug|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg & Mirabegron 50 mg orally administrated followed by 240 ml of water
79524841|NCT05767632|Drug|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg & 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
79524842|NCT05767593|Device|Wearing Samsung smartwatch and filling out daily surveys|Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
79658574|NCT04460716|Procedure|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
79658575|NCT00415025|Procedure|adjuvant therapy|
79658576|NCT00415025|Procedure|management of therapy complications|
79344359|NCT02356211|Other|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
79344360|NCT02332655|Drug|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
79344361|NCT02388737|Drug|Vonoprazan|Vonoprazan tablets
79658577|NCT00415025|Procedure|quality-of-life assessment|
79658578|NCT00415025|Radiation|intensity-modulated radiation therapy|
79658579|NCT04460404|Behavioral|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~Basic information~Digestive tract symptoms:~A constipation-related symptoms B abnormal symptoms~Fecal traits~Lifestyle habits~Others"
79658580|NCT04459819|Other|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~patients positioning~non-invasive mechanical ventilation / CPAP~tracheostomy management~invasive mechanical ventilation weaning~airway clearance~oxygen titration"
79658581|NCT00417573|Drug|IV Gamunex 10%|
79658582|NCT00415064|Drug|Perifosine|Perifosine given in either 50 mg or 100 mg / day
79658583|NCT00415064|Drug|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
79658584|NCT00415064|Drug|Dexamethasone|Dexamethasone given in 20 mg / day
79985744|NCT03386773|Behavioral|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
79985745|NCT04207866|Other|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
79344362|NCT02388737|Drug|Lansoprazole|Lansoprazole capsules or tablets
79658585|NCT04456465|Other|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
79658586|NCT04455685|Other|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
79344363|NCT02388737|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
79344364|NCT02388737|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
79524843|NCT05767580|Other|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
79524844|NCT05767541|Other|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
79524845|NCT05767541|Other|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
79344365|NCT02355743|Drug|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
79344366|NCT02388347|Drug|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
79344367|NCT02388347|Biological|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
79658587|NCT04455217|Other|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
79658588|NCT00415103|Drug|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
79658589|NCT00415103|Drug|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
79658590|NCT00415103|Drug|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
79985746|NCT04207866|Other|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
79985747|NCT04126343|Drug|Padsevonil|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
79985748|NCT04126343|Drug|Moxifloxacin|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive moxifloxacin once during the Treatment Period"
79658591|NCT00417690|Drug|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
79658592|NCT00417690|Drug|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
79344368|NCT02388347|Biological|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
79344369|NCT02388347|Biological|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
79658593|NCT04454320|Other|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
79658594|NCT04453540|Diagnostic Test|FilmArray PCR on respiratory samples|Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
79985749|NCT04126343|Drug|Placebo|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
79985750|NCT04207710|Drug|Gebauer Pain Ease Top Aerosol Mist Spray|Topical numbing spray
79658595|NCT00254150|Procedure|Increase oxygen extraction rate|
79658596|NCT04452994|Drug|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0*10^6 CAR-positive viable T cells/kg).
79344370|NCT02388347|Biological|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
79495733|NCT02002884|Drug|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
79495734|NCT02002182|Biological|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
79495735|NCT01990950|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
79495736|NCT02001558|Drug|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
79495737|NCT02001558|Other|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
79495738|NCT02023866|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
79495739|NCT02023242|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
79985751|NCT04207710|Drug|Gebauer Ethyl Chloride|Topical numbing spray
79985752|NCT02952313|Device|Nasal Implant|
79985753|NCT03119610|Drug|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
79985754|NCT03119610|Drug|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
79344371|NCT02355665|Drug|Nicotine Spray|Nicotine Spray
79344372|NCT02355665|Drug|Placebo|Placebo to match nicotine spray
79495740|NCT02023242|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
79495741|NCT01967940|Drug|TAF|25 mg tablet administered orally once daily with food
79495742|NCT01967940|Drug|Placebo|Tablets to match TAF administered orally once daily with food
79495743|NCT01967940|Drug|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
79814649|NCT04102488|Procedure|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
79985755|NCT03689738|Other|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
79985756|NCT03689738|Other|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
79344373|NCT02010255|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
79344374|NCT02010255|Drug|RBV|RBV tablets administered orally in a divided daily dose
79344375|NCT02354417|Biological|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
79344376|NCT02332187|Device|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
79495744|NCT01967940|Drug|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
79495745|NCT01967940|Drug|ATV|300 mg tablet administered orally once daily.
79495746|NCT01990560|Drug|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
79495747|NCT01998984|Drug|ingenol mebutate|
79495748|NCT01998984|Other|Placebo|
79495749|NCT04416594|Other|Data collection|Only data collection
79495750|NCT01967706|Other|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
79495751|NCT01967706|Other|mCC|Single use of subject's own menthol cigarette (mCC)
79495752|NCT01967706|Other|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
79495753|NCT01967628|Dietary Supplement|Vitamin D3 (cholecalciferol)|
79495754|NCT01967628|Dietary Supplement|Placebo Sugar Pill|
79495755|NCT01998906|Drug|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
79495756|NCT01998906|Drug|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
79495757|NCT01998906|Drug|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
79495758|NCT01998906|Drug|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
79495759|NCT01967550|Drug|diclofenac diethylamine, DDEA 2.32% gel|
79495760|NCT01967550|Drug|Placebo|
79495761|NCT01989546|Drug|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
79495762|NCT01989468|Biological|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
79495763|NCT01989468|Biological|Placebo|Secukinumab placebo provided in 1 mL autoinjector
79495764|NCT01989156|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
79658597|NCT00417729|Drug|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
79658598|NCT00254189|Drug|Levonorgestrel|
79658599|NCT00254189|Drug|Ethinyl Estradiol|
79658600|NCT01600807|Drug|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
79344377|NCT02332187|Device|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
79985757|NCT04005755|Drug|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
79985758|NCT03699176|Drug|Vilaprisan (BAY1002670)|2 mg, once daily, oral
79985759|NCT03699176|Drug|Placebo|Once daily, oral
79344378|NCT02330549|Drug|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
79344379|NCT02330549|Drug|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
79658601|NCT01600807|Drug|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
79658602|NCT00288483|Drug|Policosanol|
79658603|NCT00254228|Device|Electrotactile sensory substitution|
79658604|NCT01600963|Drug|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
79658605|NCT01600963|Drug|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
79658606|NCT01600963|Drug|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
79658607|NCT01600963|Drug|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
79985760|NCT03442777|Device|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith&Nephew (Allevyn® brand).
79985761|NCT03442777|Device|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
79658608|NCT01606969|Drug|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
79658609|NCT01606969|Drug|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
79985762|NCT01373736|Drug|123I-meta-iodobenzylguanidine|
79985763|NCT03746093|Dietary Supplement|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
79344380|NCT02009865|Drug|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
79985764|NCT03746093|Dietary Supplement|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
79985765|NCT03689348|Dietary Supplement|Avena sativa|A supplement derived from wild green oat
79985766|NCT03689348|Dietary Supplement|Placebo|Maltodextrin
79985767|NCT03689270|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
79985768|NCT03689270|Procedure|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
79344381|NCT02009865|Drug|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
79344382|NCT01620177|Drug|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
79495765|NCT01989156|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
79495766|NCT01989156|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
79495767|NCT01620762|Drug|Cat-PAD|1 dose every 4 weeks
79495768|NCT01620762|Drug|Placebo|1 dose every 4 weeks
79344383|NCT01620177|Drug|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
79344384|NCT02075541|Biological|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79985769|NCT01375062|Other|analyse and proliferate the cells|"Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~Digestion of the biopsies through controlled enzymes~Replication of the cells~Selection undifferentiated cells~Expansion of the purification cells population~Characterization of the cell population~Assessment of pluripotent and germinal cell potential.~Possible maturation of the cells."
79344385|NCT02075541|Drug|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79344386|NCT02330081|Device|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subject's untreated fresh whole blood."
79344387|NCT01986855|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
79344388|NCT01986855|Drug|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
79985770|NCT03401749|Drug|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
79985771|NCT03401749|Other|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
79985772|NCT03689114|Drug|Low dose carbamazepine|Carbamazepine, 300 mg/die
79985773|NCT03689114|Drug|Standard dose carbamazepine|Carbamazepine 600 mg/die
79344389|NCT01986855|Drug|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
79344390|NCT01986855|Drug|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
79985774|NCT03689114|Drug|Low dose levetiracetam|Levetiracetam 500 mg/die
79344391|NCT02075463|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
79344392|NCT02075463|Drug|Placebo|Matching placebo tablet for GSK1278863
79344393|NCT02353871|Biological|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
79344394|NCT02353871|Drug|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
79344395|NCT02009397|Drug|Ipilimumab|
79344396|NCT02009397|Drug|GM-CSF|
79495769|NCT01966068|Other|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
79658610|NCT00288522|Drug|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
79658611|NCT00254267|Drug|AMG 706|AMG 706 125mg, oral, once a day
79985775|NCT03689114|Drug|Standard dose levetiracetam|Levetiracetam 1000 mg/die
79985776|NCT03689114|Drug|Low dose valproate|Valproate 300 mg/die
79658612|NCT01601002|Drug|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
79495770|NCT01620528|Drug|elagolix|oral tablet
79495771|NCT01620528|Other|placebo|oral tablet
79495772|NCT01965834|Drug|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance < 50 mL/min will receive a reduced dose of 54 mg orally daily.
79658613|NCT00288561|Drug|ranibizumab|
79658614|NCT01607086|Drug|Cherry lamotrigine ODT|25mg, taken orally on one study visit
79985777|NCT03689114|Drug|Standard dose valproate|Valproate 600 mg/die
79495773|NCT01965600|Drug|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
79495774|NCT01965600|Drug|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
79495775|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
79495776|NCT01965600|Drug|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
79658615|NCT01607086|Drug|Cherry Placebo|Taken orally on one study visit
79658616|NCT01607125|Drug|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
79658617|NCT01607125|Drug|Placebo|capsules, orally, once daily for 13 to 14 days
79814650|NCT04102488|Procedure|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
79985778|NCT03689114|Drug|Low dose zonisamide|Zonisamide 150 mg/die
79985779|NCT03689114|Drug|Standard dose zonisamide|Zonisamide 300 mg/die
79985780|NCT03689114|Drug|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
79495777|NCT01965600|Drug|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
79495778|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
79495779|NCT01996332|Drug|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
79658618|NCT00288678|Procedure|Health Education|
79814651|NCT04101162|Diagnostic Test|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
79495780|NCT04669548|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
79495781|NCT01996254|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
79495782|NCT01987986|Biological|Collagenase Clostridium Histolyticum|injectible intervention
79495783|NCT01987986|Biological|Placebo|
79495784|NCT04659018|Biological|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
79495785|NCT01987908|Drug|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
79495786|NCT01987908|Other|Placebo|
79495787|NCT01995552|Device|External Loop Recorder|
79495788|NCT01987830|Device|MRI-PET|"[11C] temozolomide for PET scan and a contrast dye for the MRI scan~Drawing blood to assess the radioactivity of [11C] temozolomide"
79658619|NCT00254345|Procedure|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
79658620|NCT01607164|Behavioral|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
79658621|NCT01601041|Other|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
79658622|NCT00254618|Drug|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
79658623|NCT00254618|Drug|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
79814652|NCT02602704|Drug|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
79985781|NCT03689114|Drug|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
79985782|NCT03689114|Drug|Low dose topiramate|Topiramate 100 mg/die
79985783|NCT03689114|Drug|Standard dose topiramate|Topiramate 200 mg/die
79985784|NCT03689114|Drug|Low dose lamotrigine|Lamotrigine 100 mg/die
79985785|NCT03689114|Drug|Standard dose lamotrigine|Lamotrigine 200 mg/die
79985786|NCT03689114|Drug|Low dose gabapentin|Gabapentin 450 mg/die
79985787|NCT03689114|Drug|Standard dose gabapentin|Gabapentin 900 mg/die
79344397|NCT04666311|Diagnostic Test|Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|"CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel."
79344398|NCT04666311|Diagnostic Test|CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection|"CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)"
79344399|NCT02312219|Drug|Folic Acid|1 mg folic acid once daily
79344400|NCT02312219|Drug|Placebo|placebo once weekly
79495789|NCT01987830|Device|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
79814653|NCT02602704|Drug|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks
79495790|NCT01987596|Biological|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
79344401|NCT02312219|Drug|Low Dose Methotrexate|An anti-inflammatory drug
79344402|NCT01986231|Drug|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
79344403|NCT02312063|Drug|Sitagliptin|
79344404|NCT02312063|Drug|Glimepiride|
79344405|NCT02353169|Drug|Dexmedetomidine|
79344406|NCT02353169|Drug|Saline|
79344407|NCT02009163|Drug|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
79344408|NCT02009163|Other|Placebo|Placebo capsule once per day (double-blind period)
79344409|NCT01983969|Drug|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
79495791|NCT04658316|Behavioral|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
79495792|NCT01964898|Behavioral|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
79814654|NCT02601690|Other|Blood Sampling|
79344410|NCT01983969|Drug|Vorinostat|1000 mg by vein on Day -11 through Day -2.
79344411|NCT01983969|Drug|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
79814655|NCT04105296|Device|EKSO+ES|6 months of exoskeleton training with epidural stimulation.
79344412|NCT01983969|Drug|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
79495793|NCT01964898|Behavioral|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
79344413|NCT01983969|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
79344414|NCT01983969|Drug|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
79344415|NCT01983969|Other|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
79495794|NCT01964898|Drug|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
79495795|NCT01964898|Other|Printed Self-help materials for Smoking Cessation|
79495796|NCT01964352|Drug|tiotropium|fixed dose combination
79495797|NCT01964352|Drug|placebo|
79495798|NCT01964352|Drug|olodaterol|fixed dose combination
79814656|NCT00916422|Biological|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
79344416|NCT01983969|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
79344417|NCT01983969|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
79344418|NCT01983969|Drug|Rituximab|375 mg/m2 by vein on Days -9.
79344419|NCT02008773|Drug|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
79344420|NCT02008773|Drug|placebo|placebo capsules 6/day oral for 16 weeks
79344421|NCT02257567|Drug|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
79344422|NCT02257567|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
79344423|NCT02257567|Drug|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
79344424|NCT02257567|Drug|Rituximab|Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
79344425|NCT02257567|Drug|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
79495799|NCT01964352|Drug|tiotropium|fixed dose combination
79495800|NCT01964352|Drug|tiotropium|
79495801|NCT01964352|Drug|olodaterol|fixed dose combination
79495802|NCT01946412|Drug|Ivacaftor|
79344426|NCT04419961|Behavioral|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
79344427|NCT05330299|Behavioral|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
79344428|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
79495803|NCT01946178|Device|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
79495804|NCT01945944|Drug|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
79495805|NCT01945944|Drug|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
79495806|NCT01945866|Drug|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
79495807|NCT01945866|Drug|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
79658624|NCT00254618|Drug|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
79658625|NCT00288717|Drug|Candesartan|
79658626|NCT00288717|Drug|Telmisartan|
79344429|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
79344430|NCT01642615|Drug|Placebo|Dexlansoprazole placebo-matching capsules
79344431|NCT02311361|Biological|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
79344432|NCT02311361|Biological|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
79344433|NCT02311361|Radiation|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
79344434|NCT02352779|Dietary Supplement|Omega-3 Fatty Acid|Given PO
79495808|NCT01945866|Procedure|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
79495809|NCT01986114|Drug|SM-13496|
79495810|NCT01945710|Drug|Eribulin-LF|
79495811|NCT01945242|Drug|Alogliptin|Alogliptin tablets
79344435|NCT02352779|Other|Placebo|Given PO
79344436|NCT02352779|Other|Questionnaire Administration|Ancillary studies
79344437|NCT02352779|Other|Laboratory Biomarker Analysis|Correlative studies
79344438|NCT04893395|Other|Pharmacogenomic Screening|"First telehealth appointment:~Pharmacogenomics education and informed consent~Medical history~Sample collection~Second telehealth appointment:~Results of pharmacogenomic testing~Utility and limitations of pharmacogenomic testing~Patient-specific potential impacts on current or future medication therapies~Answering of patient questions~Referral to mental health provider(s) for treatment-specific recommendations"
79344439|NCT02257489|Drug|ACE-083|recombinant fusion protein
79344440|NCT05645809|Device|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
79344441|NCT05645809|Device|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
79344442|NCT02329223|Biological|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
79495812|NCT01945086|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
79495813|NCT01945086|Drug|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
79495814|NCT01945086|Other|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
79344443|NCT02329223|Other|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
79344444|NCT05645419|Behavioral|personalized chronoprevention|Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
79344445|NCT01641601|Device|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
79524846|NCT05767528|Diagnostic Test|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing|Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results
79524847|NCT05767515|Drug|metformin|Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
79814657|NCT00916422|Biological|Placebo|Subcutaneous monthly treatment
79658627|NCT01601119|Drug|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
79658628|NCT01601119|Other|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
79658629|NCT01601158|Biological|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
79658630|NCT01601158|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
79344446|NCT02350127|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
79658631|NCT01601197|Behavioral|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
79344447|NCT02350127|Behavioral|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
79344448|NCT02256553|Biological|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
79344449|NCT02256553|Biological|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
79344450|NCT02256553|Drug|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
79344451|NCT05305807|Other|Postural exercises|Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
79344452|NCT05302297|Drug|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
79344453|NCT02349425|Drug|Gefapixant|Gefapixant 7.5 and 50mg tablets administered orally
79344454|NCT02349425|Drug|Placebo (for gefapixant)|Placebo to gefapixant 7.5 and 50mg tablets administered orally
79658632|NCT01601314|Drug|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
79658633|NCT01601314|Other|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
79344455|NCT02310581|Drug|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
79658634|NCT00254657|Drug|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
79658635|NCT00254657|Drug|Placebo|
79658636|NCT00288756|Procedure|lv injection of contrast|
79344456|NCT02310581|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
79344457|NCT04892693|Drug|Talazoparib Oral Capsule|- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
79344458|NCT02309723|Device|Beta amyloid imaging|
79344459|NCT02309411|Drug|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
79344460|NCT02008227|Drug|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
79344461|NCT02008227|Drug|Docetaxel|75 mg/m^2 IV infusion on Day 1 of each 21-day cycle
79344462|NCT04867551|Drug|KDT-3594|oral administration, dose titration
79344463|NCT04862871|Behavioral|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
79344464|NCT02006979|Other|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
79344465|NCT02348723|Drug|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
79344466|NCT02348723|Drug|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
79814658|NCT00860405|Drug|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
79344467|NCT01967277|Device|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
79344468|NCT01967277|Device|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
79344469|NCT04411095|Other|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
79495815|NCT04637802|Behavioral|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
79658637|NCT01607515|Other|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
79658638|NCT02482753|Drug|Chidamide|30 mg, administered orally twice per week (BIW)
79658639|NCT02482753|Drug|exemestane|25 mg, PO daily
79658640|NCT02482753|Drug|placebo|Administered orally twice per week (BIW)
79658641|NCT00254696|Drug|Extended-Spectrum-Lactamases (ESBLs)|
79658642|NCT00288795|Other|Massage Therapy|Therapeutic Touch
79658643|NCT00288795|Other|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
79658644|NCT01607632|Behavioral|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
79658645|NCT00254735|Drug|quetiapine fumarate|
79658646|NCT00254735|Drug|SSRI/Clomipramine|
79658647|NCT00288834|Behavioral|dysphagia rehabilitation|
79814659|NCT00860405|Drug|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
79814660|NCT04104906|Other|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
79814661|NCT04104906|Other|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
79495816|NCT04637802|Behavioral|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
79495817|NCT01963728|Drug|Insulin, Isophane|daily dosing based on fasting morning glucose levels
79495818|NCT01963728|Drug|insulin glargine|daily dose based on fasting morning glucose levels
79495819|NCT01963260|Drug|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
79495820|NCT01963260|Drug|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
79495821|NCT01962948|Drug|paclitaxel|Given IV
79495822|NCT01962948|Drug|ganetespib|Given IV
79495823|NCT01962948|Other|laboratory biomarker analysis|Correlative studies
79495824|NCT01985334|Drug|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
79495825|NCT01985334|Drug|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
79658648|NCT01607827|Procedure|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
79344470|NCT02326883|Behavioral|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
79495826|NCT01985334|Drug|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
79658649|NCT01607827|Procedure|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
79495827|NCT01985334|Drug|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
79495828|NCT01985334|Drug|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
79495829|NCT01985334|Drug|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
79495830|NCT01985334|Drug|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
79495831|NCT01944774|Drug|Nemonoxacin 500 mg|IV Infusion, once daily for 7~14 days
79344471|NCT02326883|Behavioral|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
79344472|NCT02326883|Behavioral|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
79495832|NCT01944774|Drug|Nemonoxacin 650 mg|IV Infusion, once daily for 7~14 days
79495833|NCT01944774|Drug|Moxifloxacin 400 mg|IV Infusion, once daily for 7~14 days
79495834|NCT01944462|Behavioral|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
79495835|NCT01943292|Drug|Defactinib|
79344473|NCT02006667|Drug|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
79985788|NCT03634176|Diagnostic Test|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
79344474|NCT02006667|Drug|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
79344475|NCT02006667|Drug|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
79814662|NCT05542290|Procedure|Capsular tension ring implantation|Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
79985789|NCT01311583|Behavioral|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
79344476|NCT01983111|Drug|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
79344477|NCT01983111|Drug|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
79344478|NCT02348489|Drug|SGI-110 (guadecitabine)|Investigational medicinal product
79344479|NCT02348489|Drug|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
79344480|NCT02309099|Device|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
79344481|NCT01966107|Drug|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
79344482|NCT01966107|Drug|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
79344483|NCT01982331|Biological|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
79344484|NCT01982331|Other|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
79344485|NCT02326025|Drug|Olaratumab|Administered IV
79344486|NCT02326025|Drug|Doxorubicin|Administered IV
79495836|NCT01961544|Drug|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
79495837|NCT01942590|Drug|Clenbuterol|
79495838|NCT01942590|Drug|Placebo|
79495839|NCT01984242|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
79495840|NCT01984242|Drug|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
79495841|NCT01984242|Drug|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
79495842|NCT01941498|Device|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
79495843|NCT01941498|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
79495844|NCT04656132|Behavioral|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
79495845|NCT01960998|Behavioral|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
79658650|NCT01607866|Procedure|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
79814663|NCT05542290|Procedure|No capsular tension ring implantation|No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
79814664|NCT04099758|Behavioral|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
79814665|NCT04099758|Behavioral|Audio-recording control|10 minute non-fiction audio-recording delivered online
79985790|NCT03029624|Device|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
79344487|NCT01619865|Drug|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
79344488|NCT02006121|Drug|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
79495846|NCT01960998|Behavioral|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
79495847|NCT01941186|Other|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
79495848|NCT01960842|Drug|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
79344489|NCT02006121|Drug|Placebo|Sodium chloride 9 mg/ml
79495849|NCT01960842|Device|CADD-Legacy® 1400 ambulatory infusion pump|
79495850|NCT01960842|Device|PEG tube|percutaneous endoscopic gastrostomy tube
79495851|NCT01960842|Device|J-tube|jejunal tube
79495852|NCT01984164|Drug|Candesartan|blinded
79495853|NCT01984164|Drug|Lisinopril|Blinded
79495854|NCT01983930|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
79495855|NCT01983930|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
79495856|NCT04636398|Behavioral|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
79495857|NCT01983774|Drug|Esomeprazole|
79344490|NCT02005887|Drug|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
79495858|NCT01983774|Drug|Placebo|Sugar pill
79495859|NCT01982682|Radiation|Total-Body Irradiation (TBI)|Undergo TBI
79495860|NCT01982682|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
79495861|NCT01982682|Drug|Cyclophosphamide|Given IV
79658651|NCT01607866|Procedure|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
79658652|NCT00288873|Drug|Ergocalciferol|
79658653|NCT00288873|Drug|Cholecalciferol|
79985791|NCT02952001|Drug|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
79985792|NCT02952001|Drug|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
79985793|NCT05196594|Diagnostic Test|collection of stools for genetic analysis|Intestinal microbiome analysis
79985794|NCT03699098|Diagnostic Test|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
79344491|NCT02005887|Drug|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
79344492|NCT02005887|Drug|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
79344493|NCT01982253|Drug|Fasiglifam|Fasiglifam tablets
79344494|NCT01982253|Drug|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
79344495|NCT01981473|Other|no intervention|
79344496|NCT01981473|Other|no intervention|
79344497|NCT01981473|Other|no intervention|
79344498|NCT02005029|Drug|Erythromycin|
79344499|NCT02005029|Drug|placebo|
79344500|NCT02325791|Drug|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
79344501|NCT02325791|Drug|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
79344502|NCT02325791|Drug|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
79495862|NCT01982682|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
79495863|NCT01982682|Drug|Mycophenolate mofetil|Given IV
79495864|NCT01940484|Drug|Methoxy polyethylene glycol epoetin beta|
79495865|NCT01939548|Drug|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
79495866|NCT01939548|Drug|Placebo|Placebo BID until the Week 12 visit
79658654|NCT01608022|Drug|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
79658655|NCT04719494|Other|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
79814666|NCT05491434|Dietary Supplement|Protein supplement|One líquid brick every day during 3 weeks
79495867|NCT01939548|Drug|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
79495868|NCT01960296|Drug|Clopidogrel|Continue home dose of clopidogrel into surgery
79495869|NCT01960296|Drug|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
79495870|NCT01982292|Drug|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
79495871|NCT01982292|Drug|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
79495872|NCT04652778|Device|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
79495873|NCT01939314|Drug|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
79495874|NCT01939314|Drug|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
79495875|NCT01939158|Biological|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
79658656|NCT01608139|Drug|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
79985795|NCT01372020|Other|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
79344503|NCT02325791|Drug|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
79344504|NCT02004873|Device|Micra Pacemaker Implant|
79344505|NCT02347787|Behavioral|IMPaCT|"The IMPaCT intervention has three stages:~Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
79344506|NCT02347787|Other|Usual care|
79344507|NCT04416399|Drug|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
79344508|NCT01979835|Device|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
79495876|NCT01939158|Biological|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
79658657|NCT01608139|Drug|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
79658658|NCT01608139|Drug|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
79658659|NCT01607671|Drug|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
79344509|NCT02282345|Other|Laboratory Biomarker Analysis|Correlative studies
79344510|NCT02282345|Drug|Talazoparib|Given PO
79344511|NCT01732822|Drug|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
79344512|NCT01732822|Drug|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
79344513|NCT02004093|Drug|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
79495877|NCT01939002|Drug|BIIB017|
79495878|NCT01939002|Drug|naproxen|
79495879|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
79495880|NCT01938846|Drug|exemestane|exemestane once daily
79495881|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
79495882|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
79495883|NCT01938846|Drug|paclitaxel|paclitaxel once weekly
79495884|NCT01960140|Drug|Baricitinib|Administered orally
79495885|NCT01960140|Drug|Simvastatin|Administered orally
79658660|NCT00288951|Drug|Travoprost 0.004% with and without BAK|
79658661|NCT00254774|Drug|quetiapine fumarate or valproate|
79985796|NCT03744299|Other|Questionnaire|Patients and caregivers are asked to complete a questionnaire
79985797|NCT01311739|Drug|Cyanocobalamin|
79495886|NCT01981356|Behavioral|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
79658662|NCT01608334|Drug|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
79658663|NCT01608334|Drug|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
79495887|NCT01981356|Other|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
79495888|NCT01981122|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
79658664|NCT01608373|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
79658665|NCT01608373|Drug|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
79658666|NCT01608373|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
79658667|NCT01608412|Drug|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
79658668|NCT01608412|Drug|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
79658669|NCT00254813|Drug|Quetiapine|
79985798|NCT05196438|Other|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
79814667|NCT05603351|Diagnostic Test|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
79814668|NCT05603351|Diagnostic Test|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
79344514|NCT02004093|Drug|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
79344515|NCT02004093|Drug|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
79344516|NCT02004093|Drug|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
79985799|NCT03744221|Dietary Supplement|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
79985800|NCT03744221|Dietary Supplement|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
79985801|NCT03744221|Dietary Supplement|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
79985802|NCT05507359|Other|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
79985803|NCT05507359|Other|Benzocaine gel|20% Benzocaine gel (Opahl gel)
79985804|NCT05196360|Drug|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
79985805|NCT04123067|Drug|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
79985806|NCT04123067|Drug|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
79344517|NCT01641367|Drug|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day [200 mg per day])
79344518|NCT01641367|Drug|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
79344519|NCT01641367|Drug|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
79985807|NCT05193006|Other|No intervention|No intervention
79495889|NCT01981122|Drug|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
79495890|NCT01980888|Drug|Idelalisib|150 mg tablet administered orally twice daily
79495891|NCT01980888|Drug|Bendamustine|Administered intravenously at a starting dose of 90 mg/m^2 for up to 6 cycles. Dosing will be based on mg/m^2 of body surface area.
79495892|NCT01980888|Drug|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m^2 on Day 1 (Week 0) and 500 mg/m^2 thereafter for a total of 6 infusions
79495893|NCT01980888|Drug|Placebo|Placebo to match idelalisib administered orally twice daily
79495894|NCT04650282|Combination Product|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
79495895|NCT04650282|Combination Product|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
79344520|NCT01641367|Drug|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
79495896|NCT01937364|Drug|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
79344521|NCT01641367|Drug|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
79344522|NCT01641367|Drug|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
79344523|NCT01641367|Other|SOC adherence versus SOC+CPI adherence|"not participating in the adherence randomization; OR~randomized to SOC adherence; OR~randomized to SOC+CPI adherence."
79495897|NCT01937364|Drug|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
79495898|NCT01979952|Drug|Matching Placebo|twice daily dosing
79985808|NCT03711955|Other|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
79495899|NCT01979952|Drug|Nintedanib|gelating capsule
79495900|NCT01999218|Drug|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
79344524|NCT02325713|Drug|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
79344525|NCT02325713|Drug|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
79344526|NCT02325713|Drug|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
79344527|NCT02325713|Drug|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
79495901|NCT01999218|Drug|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
79495902|NCT01999218|Drug|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
79495903|NCT01999218|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
79495904|NCT01999218|Drug|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
79814669|NCT05603351|Procedure|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
79814670|NCT00703313|Drug|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
79814671|NCT00703313|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
79985809|NCT05192928|Device|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
79495905|NCT01999218|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
79985810|NCT01375218|Other|Pavlik Brace|Pavlik Brace
79344528|NCT02325713|Drug|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
79344529|NCT02325713|Drug|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
79344530|NCT04877639|Drug|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
79985811|NCT01375218|Other|Plastizote Brace|Plastizote Brace
79344531|NCT02325401|Drug|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
79344532|NCT02325401|Drug|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
79344533|NCT02325401|Radiation|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
79344534|NCT02324699|Drug|Prednisone|
79344535|NCT02324699|Drug|Placebo|
79344536|NCT02324699|Drug|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
79495906|NCT01999218|Drug|Sitagliptin|Open label, oral, once daily, rescue medication as required.
79985812|NCT05196282|Other|Smoking cessation|Patients are forced to stop smoking
79985813|NCT03688958|Drug|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
79495907|NCT01937130|Drug|IDN-6556|
79495908|NCT01937130|Other|Placebo|
79495909|NCT01936974|Drug|Gemcitabine|Patient to receive gemzar
79495910|NCT01936974|Drug|Bevacizumab|Patient to receive avastin
79495911|NCT01936974|Drug|Carboplatin|Patient to receive carboplatin
79495912|NCT01936974|Drug|Cisplatin|Patient to receive cisplatin
79495913|NCT01936974|Drug|Oxaliplatin|Patient to receive Oxaliplatin
79495914|NCT04648644|Other|Application of ERAS protocol|Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
79495915|NCT01959516|Drug|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
79495916|NCT01959516|Drug|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
79495917|NCT01959516|Drug|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
79495918|NCT01959516|Drug|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
79495919|NCT01979016|Drug|Dupilumab|
79344537|NCT01764256|Biological|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
79344538|NCT01764256|Other|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
79344539|NCT01979523|Other|Laboratory Biomarker Analysis|Correlative studies
79344540|NCT01979523|Other|Pharmacological Study|Correlative studies
79495920|NCT01979016|Drug|Placebo|Matching placebo
79495921|NCT01979016|Other|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
79658670|NCT01608529|Device|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
79985814|NCT03688958|Drug|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
79344541|NCT01979523|Drug|Trametinib|Given PO
79344542|NCT01979523|Drug|Uprosertib|Given PO
79344543|NCT02255461|Drug|palbociclib isethionate|Given PO
79344544|NCT02255461|Other|pharmacological study|Correlative studies
79344545|NCT02255461|Other|laboratory biomarker analysis|Correlative studies
79344546|NCT01764022|Drug|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
79344547|NCT01764022|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
79344548|NCT02003391|Drug|Beta-blocker monotherapy|Per participant's current prescribed therapy
79344549|NCT02003391|Drug|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
79495922|NCT01935336|Drug|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
79495923|NCT01978236|Drug|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
79658671|NCT04718454|Device|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
79985815|NCT03688958|Drug|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
79985816|NCT03688958|Drug|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
79985817|NCT05192616|Device|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
79344550|NCT04852627|Behavioral|Brisk walking|Walking
79344551|NCT04658901|Device|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
79344552|NCT04658901|Device|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
79344553|NCT02254681|Drug|Gemcitabine|
79344554|NCT02254681|Drug|Cisplatin|
79344555|NCT02254681|Radiation|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
79344556|NCT01965327|Drug|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
79344557|NCT05651191|Drug|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
79344558|NCT02002689|Drug|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
79344559|NCT01639729|Drug|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
79344560|NCT01639729|Drug|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
79344561|NCT01639729|Drug|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
79495924|NCT01978236|Drug|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
79495925|NCT01934790|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
79495926|NCT01934556|Drug|Ranibizumab 0.3 mg intravitreal injection|
79344562|NCT01639729|Drug|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
79344563|NCT02002533|Behavioral|Brief Behavioral Therapy|Undergo BBT intervention
79344564|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo BBT intervention
79344565|NCT02002533|Other|Educational Intervention|Undergo HEAL
79344566|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo HEAL
79344567|NCT02002221|Drug|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
79344568|NCT02002221|Drug|Placebo|Matching placebo of vildagliptin 50 mg twice daily
79495927|NCT01934556|Device|Guided Laser Photocoagulation|
79495928|NCT04415814|Procedure|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
79495929|NCT04415814|Procedure|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
79344569|NCT02002221|Drug|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
79344570|NCT02002221|Drug|Metformin|Patients continued their prescribed metformin dose, if applicable.
79495930|NCT04411212|Drug|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
79985818|NCT03698942|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
79985819|NCT05196204|Other|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
79344571|NCT01639495|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
79344572|NCT05651113|Other|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
79344573|NCT05262439|Device|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
79344574|NCT05640661|Device|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
79344575|NCT05640661|Device|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
79344576|NCT04871971|Dietary Supplement|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
79344577|NCT04871971|Dietary Supplement|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
79344578|NCT04871971|Dietary Supplement|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
79344579|NCT04871971|Dietary Supplement|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
79344580|NCT04871971|Dietary Supplement|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
79495931|NCT04411212|Other|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
79495932|NCT01977690|Device|Clavicle Brace|
79495933|NCT04646148|Behavioral|Yoga classes|All participants are invited to attend weekly yoga classes.
79495934|NCT01934010|Drug|AM-101|AM-101 gel for intratympanic injection
79814672|NCT00703313|Drug|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
79985820|NCT05196204|Other|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
79985821|NCT03688646|Dietary Supplement|Intensive Nutrition Intervention|
79985822|NCT05196048|Other|No Intervention|No Intervention
79344581|NCT05651035|Other|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
79344582|NCT05260177|Device|Light Therapy System (LTS): Active Setting|Exposure for 1 hour á day for consecutive days
79344583|NCT05260177|Device|Light Therapy System (LTS): Sham Setting|Exposure for 1 hour á day for consecutive days
79344584|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
79344585|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
79344586|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
79344587|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
79344588|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
79344589|NCT05650801|Other|Music Therapy|Therapy using a traditional music originally from Indonesian culture
79344590|NCT05650723|Drug|Zanubrutinib Pill|320 mg once per day by mouth
79814673|NCT00703079|Drug|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
79985823|NCT04080050|Drug|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
79985824|NCT04117607|Other|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
79344591|NCT05650723|Drug|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
79344592|NCT05650723|Drug|Obinutuzumab Injection|1000 mg IV given every 28 days
79344593|NCT05636215|Biological|IBI354|Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
79344594|NCT05249647|Other|Instrument based Fascial abrasion technique|Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place & the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
79658672|NCT01608568|Device|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
79814674|NCT00703079|Procedure|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
79814675|NCT00840827|Drug|lenalidomide|Lenalidomide 10mg po daily
79814676|NCT00840827|Drug|cyclosporine A|CSA 250mg orally twice daily
79814677|NCT00860249|Behavioral|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
79344595|NCT05249647|Other|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
79344596|NCT05247697|Drug|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
79344597|NCT05247697|Drug|Placebo oral tablet once daily at bedtime|Matching placebo
79344598|NCT05650489|Other|assessment|correlation between Autistic features, motor function and quality of life
79344599|NCT05232175|Drug|ALT-BB4|Recombinant Hyaluronidase
79344600|NCT05232175|Drug|0.9%NaCl|Normal Saline
79344601|NCT05193331|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
79344602|NCT02001987|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
79344603|NCT02001987|Drug|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
79344604|NCT02001987|Drug|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
79344605|NCT01363765|Other|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
79344606|NCT01363765|Other|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
79344607|NCT02001051|Procedure|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
79344608|NCT02001051|Other|Observation|Observation for 6 months prior to surgery
79344609|NCT05577013|Other|kinesiotaping|It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
79344610|NCT05577013|Other|motor relearning program|Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
79344611|NCT05429437|Biological|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
79344612|NCT05429437|Biological|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
79344613|NCT04850677|Other|Observational Cohort|Observational study
79495935|NCT01620138|Drug|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
79985825|NCT04117607|Drug|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
79344614|NCT01763164|Drug|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
79344615|NCT01763164|Drug|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
79658673|NCT01608646|Drug|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
79344616|NCT01782742|Drug|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
79344617|NCT01782742|Drug|Placebo|
79344618|NCT01782664|Drug|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
79344619|NCT01782664|Drug|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
79344620|NCT01782664|Drug|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
79344621|NCT01782664|Drug|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
79344622|NCT04414072|Procedure|sleeve gastrectomy with loop bipartition|operations to decrease weight
79344623|NCT01732588|Drug|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
79344624|NCT01732588|Drug|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
79495936|NCT01620138|Drug|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
79344625|NCT01732588|Drug|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
79344626|NCT01781962|Other|No Treatment|No Treatment was given in this study.
79495937|NCT01977612|Device|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
79658674|NCT00254852|Procedure|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
79658675|NCT00254852|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
79658676|NCT00254852|Procedure|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
79658677|NCT00254852|Procedure|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
79658678|NCT00254852|Procedure|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
79344627|NCT04560790|Drug|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
79344628|NCT04574830|Other|No Intervention|No Intervention
79344629|NCT01639339|Biological|Placebo plus standard therapy|Placebo plus standard therapy
79344630|NCT01639339|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
79658679|NCT01608763|Behavioral|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
79658680|NCT01608802|Other|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
79344631|NCT01639339|Drug|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
79344632|NCT02000817|Biological|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
79344633|NCT02000817|Biological|Placebo|Placebo is available 0.9% w/v sodium chloride
79495938|NCT01977612|Device|Stainless steel staples|Skin closure using stainless steel staples.
79658681|NCT01608802|Other|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
79658682|NCT01608841|Drug|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
79658683|NCT00254930|Drug|risperidone|
79658684|NCT01608919|Other|blood tests|thromboelastogram platelet mapping
79658685|NCT00289029|Drug|Iopamidol 370 mgI/mL|
79658686|NCT00254969|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
79658687|NCT02273440|Drug|BIIL 284 BS|
79658688|NCT02273440|Drug|Theophylline|
79658689|NCT02273440|Drug|Placebo|
79658690|NCT01588678|Drug|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
79658691|NCT04719455|Behavioral|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
79658692|NCT04719455|Other|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
79658693|NCT01588717|Drug|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
79658694|NCT00270075|Drug|epoetin alfa|
79658695|NCT01588756|Drug|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
79344634|NCT01641133|Biological|Synflorix (3-Dose)|3 doses administered intramuscularly
79344635|NCT01641133|Biological|Synflorix (2-Dose)|2 doses administered intramuscularly
79344636|NCT01641133|Biological|Synflorix (Single Dose)|1 dose administered intramuscularly
79658696|NCT01588756|Drug|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
79344637|NCT01641133|Biological|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
79344638|NCT01641133|Biological|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
79344639|NCT04849429|Biological|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
79344640|NCT04849429|Drug|Normal Saline|placebo : 2 ml normal saline para discal administration
79344641|NCT05112757|Other|Smartphone application use|Use of a smartphone application
79344642|NCT04419259|Drug|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
79344643|NCT04835311|Procedure|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
79344644|NCT02000427|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
79344645|NCT05382013|Drug|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
79344646|NCT05382013|Other|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
79344647|NCT05382013|Other|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
79344648|NCT04678921|Drug|TJ210001|human anti-C5aR monoclonal antibody
79344649|NCT04673851|Device|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
79344650|NCT04845217|Drug|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
79344651|NCT04845217|Drug|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
79344652|NCT04419883|Device|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
79344653|NCT05359393|Combination Product|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
79344654|NCT04833439|Other|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
79344655|NCT04178707|Device|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
79344656|NCT04650919|Procedure|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
79344657|NCT01600885|Drug|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
79344658|NCT01600885|Drug|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
79344659|NCT05369455|Procedure|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
79495939|NCT01932996|Drug|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
79658697|NCT04719104|Device|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
79658698|NCT01588795|Procedure|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
79985826|NCT04117607|Drug|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
79344660|NCT05369455|Procedure|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
79344661|NCT01732510|Drug|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
79344662|NCT01732510|Drug|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
79344663|NCT05369377|Drug|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
79344664|NCT05369377|Drug|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
79344665|NCT04832269|Other|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
79344666|NCT05353153|Other|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
79344667|NCT05353153|Other|standart care|no intervention no hypnosis
79495940|NCT01932996|Behavioral|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
79495941|NCT01932762|Drug|Grazoprevir|100 mg every day (QD) orally
79495942|NCT01932762|Drug|Elbasvir|50 mg QD orally
79495943|NCT01932762|Drug|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
79495944|NCT01618968|Drug|MTX|"Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
79658699|NCT01588795|Drug|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
79658700|NCT01588834|Procedure|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
79658701|NCT00107614|Drug|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with < 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
79658702|NCT00255242|Drug|Simvastatin treatment for 28 days|40 mg / day
79658703|NCT00270114|Drug|epoetin alfa|
79658704|NCT00255281|Drug|AZD7009, no generic name available|
79658705|NCT00107380|Biological|rituximab|
79308200|NCT02505971|Drug|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
79344668|NCT04608331|Drug|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
79344669|NCT04608331|Drug|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
79344670|NCT04065295|Drug|BI 1356225|Oral Dose
79344671|NCT04065295|Drug|Placebo|Oral dose
79344672|NCT05348941|Dietary Supplement|TECADRIOL|Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
79344673|NCT04842097|Behavioral|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
79344674|NCT01637077|Drug|pregabalin|Given PO
79344675|NCT01637077|Drug|placebo|Given PO
79344676|NCT01637077|Other|questionnaire administration|Ancillary studies
79344677|NCT02308163|Drug|Peficitinib|oral
79658706|NCT00107380|Drug|cyclophosphamide|
79344678|NCT02308163|Drug|Placebo|oral
79495945|NCT04645524|Drug|AD182|Oral capsule administered before bed
79495946|NCT04645524|Drug|AD504|Oral capsule administered before bed
79658707|NCT00107380|Drug|doxorubicin hydrochloride|
79658708|NCT00107380|Drug|prednisone|
79658709|NCT00107380|Drug|vincristine sulfate|
79658710|NCT00107380|Radiation|tositumomab and iodine I 131 tositumomab|
79658711|NCT00270153|Drug|enalapril|5mg enalapril daily for 6 months
79658712|NCT00270153|Drug|Placebo|5mg enalapril-matching placebo daily for 6 months
79658713|NCT00255320|Drug|VIP|
79658714|NCT00289224|Biological|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
79658715|NCT00289224|Biological|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
79658716|NCT00255359|Drug|XTL-2125|
79495947|NCT04645524|Drug|Placebo|Oral capsule administered before bed
79495948|NCT04645524|Diagnostic Test|Polysomnography|for all arms
79495949|NCT04662216|Procedure|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
79658717|NCT04054843|Diagnostic Test|Afamin|Plasma maternal afamin levels
79658718|NCT04055038|Drug|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
79658719|NCT04055038|Drug|Conventional chemotherapy|Conventional chemotherapy
79658720|NCT00270192|Behavioral|individual lactation counseling and educational material|
79658721|NCT00270192|Behavioral|educational material alone|
79658722|NCT00270192|Behavioral|routine antenatal care without educational intervention|
79658723|NCT04054609|Diagnostic Test|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
79658724|NCT04054531|Biological|KN046|IV infusion
79658725|NCT04054531|Drug|Paclitaxel|IV infusion
79658726|NCT04054531|Drug|Pemetrexed|IV infusion
79344679|NCT02308163|Biological|Etanercept|subcutaneous injection
79344680|NCT05347537|Other|Mulligan mobilization|Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
79344681|NCT05347537|Other|clamshell exercise|As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
79344682|NCT04819711|Behavioral|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
79495950|NCT04662216|Procedure|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
79495951|NCT01931670|Other|placebo|
79495952|NCT01931670|Drug|Elagolix|
79495953|NCT01977456|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
79495954|NCT01957644|Drug|Azacitidine|
79495955|NCT01957644|Drug|Volasertib|
79495956|NCT01931202|Drug|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
79495957|NCT01931202|Drug|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
79495958|NCT01930890|Biological|BIIB023|
79495959|NCT01930890|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
79658727|NCT04054531|Drug|Carboplatin|IV infusion
79344683|NCT04556851|Drug|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
79344684|NCT04556851|Drug|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
79495960|NCT01930890|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
79495961|NCT01930188|Drug|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
79495962|NCT01930188|Drug|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
79495963|NCT01930188|Drug|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
79495964|NCT01930188|Drug|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
79658728|NCT00289263|Drug|Paclitaxel|
79658729|NCT04054336|Behavioral|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
79658730|NCT04054336|Behavioral|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
79658731|NCT04054336|Behavioral|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
79344685|NCT04556851|Drug|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
79344686|NCT04039399|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
79344687|NCT04039399|Procedure|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
79344688|NCT04419727|Procedure|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, the arterial tissues will be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using Trizol reagent (Invitrogen, Milan Italy), according to the manufacturer's instructions. The expression of ER-alpha, ER-beta,and GPER will be quantified by real-time PCR using the Step One ™ sequence detection system (Applied Biosystems Inc. Milan, Italy), following the manufacturer's instruction
79344689|NCT04554745|Radiation|Ultrasound|ultrasound assessment of pregnant women
79344690|NCT04038697|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
79344691|NCT04038697|Procedure|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
79344692|NCT04038697|Procedure|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
79344693|NCT04819477|Behavioral|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
79344694|NCT04819477|Behavioral|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
79344695|NCT04818775|Device|HemaClear|HemaClear Model A
79344696|NCT04818775|Device|Pneumatic Tourniquet|Pneumatic Tourniquet
79495965|NCT01977222|Device|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
79658732|NCT00289302|Device|Cardiac resynchronization therapy device|
79658733|NCT04516486|Other|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
79658734|NCT04516525|Device|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
79658735|NCT00255437|Drug|ferumoxytol or oral iron|
79658736|NCT04515940|Dietary Supplement|acceptability, tolerance and palatability study|prospective acceptability study
79658737|NCT00255476|Drug|gefitinib|
79658738|NCT00255476|Drug|cisplatin|
79658739|NCT00255476|Drug|5-flourouracil|
79495966|NCT01957488|Device|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
79344697|NCT04966273|Device|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
79344698|NCT05344105|Device|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
79344699|NCT04018807|Other|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
79344700|NCT04018807|Behavioral|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
79344701|NCT04830787|Other|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
79344702|NCT04018729|Device|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
79344703|NCT04018729|Biological|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
79344704|NCT04817371|Device|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
79344705|NCT04817371|Other|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
79985827|NCT03657654|Other|No intervention: observational only|No intervention: observational only
79344706|NCT04817371|Device|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
79344707|NCT04817371|Device|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
79495967|NCT01957488|Device|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
79658740|NCT04513249|Diagnostic Test|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
79658741|NCT00270270|Drug|epoetin alfa|
79658742|NCT04512118|Diagnostic Test|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
79985828|NCT03688568|Drug|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
79495968|NCT01957488|Device|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
79344708|NCT05408533|Device|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
79658743|NCT04511143|Other|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
79344709|NCT04001647|Drug|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
79344710|NCT04001647|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
79344711|NCT04001647|Drug|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
79344712|NCT04419571|Procedure|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
79814678|NCT00860249|Behavioral|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
79495969|NCT01976364|Drug|Tofacitinib|Tofacitinib 5 mg tablet twice daily
79495970|NCT01976364|Drug|Tofacitinib|Tofactinib 10 mg tablet twice daily
79814679|NCT00840749|Radiation|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
79344713|NCT04490161|Other|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
79344714|NCT04923997|Behavioral|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
79985829|NCT05192304|Drug|TPN-672|single dose of TPN-672 maleate tablet
79344715|NCT04829461|Device|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
79495971|NCT01976364|Drug|Methotrexate|Methotrexate 7.5-20 mg weekly
79495972|NCT01976364|Drug|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
79495973|NCT01956240|Procedure|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
79658744|NCT00255515|Drug|Quetiapine fumarate|oral
79658745|NCT00255515|Drug|conventional treatment for schizophrenia|various standard therapies
79658746|NCT00270309|Behavioral|Self-management|
79658747|NCT00289419|Drug|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
79658748|NCT00289419|Drug|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
79658749|NCT01600144|Other|digital mammography|data collection
79658750|NCT00255554|Behavioral|Dialectical Behavioral Therapy|
79658751|NCT00255554|Drug|Escitalopram|
79658752|NCT00270348|Drug|ciclesonide|
79658753|NCT00255593|Drug|rituximab|
79658754|NCT00289497|Device|TempTouch®|
79495974|NCT01956240|Procedure|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
79658755|NCT04497337|Procedure|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
79985830|NCT01375296|Device|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
79658756|NCT04496869|Other|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
79658757|NCT00255671|Other|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
79658758|NCT04496206|Other|No intervention|No intervention, it is retrospective study.
79344716|NCT04829461|Device|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
79344717|NCT03876457|Device|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
79495975|NCT01929876|Drug|Cobimetinib|10 milligram (mg) (2* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
79495976|NCT01929876|Drug|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
79658759|NCT00270387|Drug|Natrecor (nesiritide)|
79985831|NCT01375296|Other|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
79658760|NCT00255710|Biological|filgrastim|
79658761|NCT00255710|Drug|cyclophosphamide|
79658762|NCT00255710|Drug|fludarabine phosphate|
79658763|NCT00255710|Drug|mycophenolate mofetil|
79658764|NCT00255710|Drug|tacrolimus|
79658765|NCT00255710|Procedure|allogeneic bone marrow transplantation|
79985832|NCT03527862|Other|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
79985833|NCT04430660|Other|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
79658766|NCT00255710|Procedure|peripheral blood stem cell transplantation|
79985834|NCT04430660|Device|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
79985835|NCT03744143|Procedure|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
79985836|NCT03744143|Procedure|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
79985837|NCT03744143|Procedure|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
79495977|NCT04630236|Diagnostic Test|Ultrasound|Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
79495978|NCT01929018|Behavioral|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
79495979|NCT01929018|Behavioral|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
79658767|NCT00255710|Radiation|radiation therapy|
79658768|NCT04493866|Other|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
79658769|NCT00270426|Drug|Benazepril|
79658770|NCT00255749|Biological|epoetin alfa|
79658771|NCT04491214|Other|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
79658772|NCT04491448|Behavioral|Social needs screening|Interview and referral for non-medical health-related social needs
79495980|NCT01929018|Behavioral|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
79495981|NCT01928940|Drug|dabrafenib|150 mg twice daily
79495982|NCT01928940|Drug|trametinib|2 mg once daily
79495983|NCT01928862|Drug|Prepopik® ½ Sachet x 2 (9-12 years)|
79495984|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (9-12 years)|
79495985|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
79495986|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (13-16 years)|
79495987|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
79495988|NCT01954056|Drug|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
79495989|NCT01954056|Drug|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
79495990|NCT01953354|Biological|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
79495991|NCT01953354|Biological|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
79495992|NCT01975272|Drug|Ferinject|
79658773|NCT00289575|Device|MBCP|
79658774|NCT01600183|Device|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
79495993|NCT01975272|Drug|Ferrous fumarate|
79495994|NCT01975272|Drug|Placebo for ferrous fumarate|
79495995|NCT01975272|Drug|Placebo for ferinject|
79495996|NCT04643886|Drug|GEM103|Biological
79495997|NCT01951638|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
79495998|NCT01951638|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
79495999|NCT01951638|Drug|Placebo|
79496000|NCT01928472|Biological|H7N9c low dose with adjuvant|
79496001|NCT01928472|Biological|H7N9c medium dose with adjuvant|
79496002|NCT01928472|Biological|H7N9c high dose with adjuvant|
79496003|NCT01928472|Biological|H7N9c high dose without adjuvant|
79496004|NCT03563183|Other|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
79496005|NCT03565679|Device|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
79496006|NCT03565679|Device|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
79496007|NCT03965039|Device|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
79496008|NCT03965039|Drug|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
79496009|NCT03965039|Drug|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
79496010|NCT03965039|Drug|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
79658775|NCT01600183|Procedure|cast|casting of the infant legs
79658776|NCT04489030|Other|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
79658777|NCT00270465|Drug|VRC-HIVDNA016-00-VP|
79814680|NCT00840749|Procedure|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
79658778|NCT00270465|Drug|VRC-HIVADV014-00-VP|
79658779|NCT04486807|Diagnostic Test|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
79658780|NCT00255827|Biological|HyperAcute-Pancreatic Cancer Vaccine|
79814681|NCT00703469|Drug|MDX1106-02|Single dose
79814682|NCT00703469|Drug|Placebo|Placebo single dose
79344718|NCT03876457|Other|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
79814683|NCT02612207|Device|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
79344719|NCT04193917|Diagnostic Test|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
79814684|NCT00859937|Drug|Dasatinib|Given PO
79814685|NCT00859937|Other|Laboratory Biomarker Analysis|Correlative studies
79814686|NCT04030715|Drug|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
79344720|NCT04828681|Diagnostic Test|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
79496011|NCT03961295|Drug|Vedolizumab SC|Vedolizumab SC liquid.
79496012|NCT00377897|Procedure|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
79496013|NCT03567005|Device|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
79496014|NCT03567005|Device|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
79496015|NCT05313971|Other|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
79496016|NCT03569033|Drug|Gefapixant|Gefapixant 45 mg will be administered orally.
79496017|NCT03569033|Drug|Placebo|Placebo tablet matching gefapixant will be administered orally.
79496018|NCT03955133|Other|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
79658781|NCT00270504|Device|Memokath stenting|Urethral Stenting
79344721|NCT04828369|Procedure|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
79344722|NCT04828369|Procedure|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
79496019|NCT03991715|Behavioral|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
79344723|NCT04408729|Other|PrEP My Way|"Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP."
79344724|NCT04402489|Drug|Placebo|Placebo
79496020|NCT04002791|Device|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
79496021|NCT05314049|Procedure|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
79344725|NCT04402489|Drug|MT-7117 Low Dose|MT-7117 Low Dose
79344726|NCT04402489|Drug|MT-7117 High Dose|MT-7117 High Dose
79344727|NCT04827199|Device|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~Perineal approach and bulbar urethral dissection~Inguinal approach~Cuff implantation around the urethra~Transmission cable passing~Surgery test procedure~Implantation of the Control Unit~Closure of the inguinal incision~Closure of the perineal incision~Implant disabled mode activation"
79344728|NCT04399369|Device|SDF|38% silver diamine fluoride solution
79496022|NCT05314049|Procedure|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
79496023|NCT05314049|Device|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
79496024|NCT05314049|Device|Heat Therapy|superficial heating for 20 minutes
79496025|NCT03935399|Drug|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
79496026|NCT03935399|Drug|Saline|1.5 ml preservative free saline for intramuscular injection
79496027|NCT03571607|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
79496028|NCT03993119|Drug|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
79496029|NCT03574181|Other|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
79658782|NCT00255866|Behavioral|Skills training for the care of dementia patients|
79658783|NCT00289614|Drug|Iopamidol 370 mgI/dL|
79658784|NCT04482361|Diagnostic Test|Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies
79658785|NCT00255905|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|
79658786|NCT00255905|Behavioral|Clinician monitoring|
79658787|NCT00270543|Drug|Taxotere, Fluorouracil, Leucovorin|
79658788|NCT04480684|Diagnostic Test|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
79985838|NCT05191992|Other|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
79658789|NCT04480684|Diagnostic Test|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
79658790|NCT04480684|Diagnostic Test|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
79985839|NCT03693638|Drug|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
79344729|NCT04399369|Device|NaF|5% sodium fluoride varnish
79344730|NCT04419415|Dietary Supplement|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
79496030|NCT03988049|Device|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
79496031|NCT03988049|Device|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
79985840|NCT03693638|Drug|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
79496032|NCT03930641|Drug|RTH258|6 mg in prefilled syringe
79985841|NCT04112303|Drug|SOF/VEL|Tablets administered orally once daily
79985842|NCT01319838|Drug|Isotretinoin|>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
79985843|NCT05195580|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
79985844|NCT03693482|Diagnostic Test|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
79985845|NCT03634566|Drug|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
79344731|NCT04419415|Other|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
79344732|NCT04419415|Other|Skipping breakfast|Participants will be asked to skip breakfast.
79344733|NCT04815109|Other|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
79344734|NCT01999335|Drug|Oprozomib|Extended release (ER) tablets administered orally
79344735|NCT01999335|Drug|Pomalidomide|Capsules for oral administration
79344736|NCT01999335|Drug|Dexamethasone|Tablets for oral administration
79344737|NCT01978119|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
79344738|NCT01978119|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
79344739|NCT01999179|Drug|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
79496033|NCT03910439|Biological|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
79496034|NCT03910439|Radiation|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
79496035|NCT03907241|Drug|Octanorm 16.5%|Human normal immunoglobulin
79496036|NCT03137225|Device|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
79496037|NCT03137225|Device|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
79496038|NCT03927209|Drug|BI 1467335|tablet
79496039|NCT03895307|Other|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
79496040|NCT03895307|Other|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
79496041|NCT03895307|Other|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
79496042|NCT01511081|Radiation|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
79496043|NCT01511081|Radiation|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
79496044|NCT03115853|Drug|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
79658791|NCT04480684|Device|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
79658792|NCT00255983|Drug|Faropenem medoxomil|600 mg BID for 5 days
79658793|NCT00255983|Drug|placebo|placebo tablets BID for 5 days
79658794|NCT04480060|Diagnostic Test|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
79985846|NCT03634566|Drug|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
79658795|NCT02960919|Drug|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
79658796|NCT02960919|Drug|parenteral ampicillin/ penicillin|
79658797|NCT02960919|Drug|gentamicin|
79658798|NCT04479124|Diagnostic Test|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
79658799|NCT04478383|Procedure|a new transosseous suture technique|a new technique using the spur base on the insertional site to drill the suture tunnel to repair Achilles sleeve avulsion.
79658800|NCT00415220|Procedure|Spinal Manipulation, Microdiscectomy|
79985847|NCT03998189|Other|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
79985848|NCT03998189|Other|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
79985849|NCT03998189|Other|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
79344740|NCT01977729|Drug|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
79344741|NCT01977729|Behavioral|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
79344742|NCT01998477|Biological|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain [A/H1N1-like, A/H3N2-like, and B-like]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
79658801|NCT00270582|Drug|Taxotere, Cisplatin, Gemcitabine|
79658802|NCT04476823|Other|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
79985850|NCT03998189|Other|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
79985851|NCT03998189|Other|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
79985852|NCT03998189|Other|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
79496045|NCT03115853|Drug|Placebo|Placebo tablet for Aliskerin
79496046|NCT03115853|Drug|HCTZ|HCTZ 25mg every day for 18 weeks
79496047|NCT03115853|Drug|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
79658803|NCT00415259|Device|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
79658804|NCT00415259|Device|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
79658805|NCT00270621|Behavioral|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
79344743|NCT01998477|Biological|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain [A/ H1N1-like, A/H3N2-like, and B-like]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
79344744|NCT01998399|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
79344745|NCT01998399|Drug|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
79344746|NCT01781572|Drug|LEE011|LEE011 will be administered orally once daily
79344747|NCT01781572|Drug|MEK162|MEK162 will be administered orally twice daily
79344748|NCT01998243|Device|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
79344749|NCT01998243|Other|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
79344750|NCT01977573|Drug|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
79344751|NCT01977573|Drug|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
79344752|NCT01963767|Drug|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract*~Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
79344753|NCT01963767|Dietary Supplement|Placebo|
79985853|NCT01372098|Behavioral|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
79985854|NCT03688412|Device|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
79985855|NCT01373892|Procedure|Bariatric surgery|
79985856|NCT03355872|Drug|HLX01|Biosimilar of Rituximab
79985857|NCT03744065|Procedure|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
79344754|NCT01731886|Procedure|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
79344755|NCT01731886|Drug|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
79344756|NCT01731886|Drug|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
79344757|NCT01731886|Procedure|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is >2500 x 109 cells/liter; platelet count is >20 x 103/mm3.
79344758|NCT01731886|Drug|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
79344759|NCT01731886|Drug|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
79344760|NCT01731886|Drug|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
79344761|NCT01731886|Drug|Mesna|Mesna will be provided with the cyclophosphamide.
79344762|NCT01759420|Drug|Ondansetron|4mg of intravenous ondansetron
79344763|NCT01781026|Drug|Vemurafenib|Single arm trial
79344764|NCT01607398|Drug|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
79344765|NCT01607398|Drug|Placebo|Placebo inhalation, twice daily, from week0 -12.
79344766|NCT01779856|Device|REVEAL Insertable Cardiac Monitor (ICM)|
79344767|NCT01729156|Drug|Metformin|1000 mg metformin twice daily in 3 months
79344768|NCT01729156|Drug|Placebo|2 tablets twice daily in 3 months
79344769|NCT01779700|Drug|Fingolimod|0.5mg each day of 8 week cycle
79658806|NCT01600300|Device|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
79985858|NCT03744065|Procedure|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
79344770|NCT01779700|Drug|placebo|1 tablet each day of 8 week cycle
79985859|NCT05191914|Drug|Chidamide+ Fulvestrant|"Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1"
79344771|NCT01778530|Drug|TRC105|Intravenous infusion.
79344772|NCT01778062|Drug|Indacaterol|Indacaterol 150µg once daily oral inhalation
79985860|NCT04060394|Drug|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
79344773|NCT01778062|Drug|Control|Placebo once daily oral inhalation
79344774|NCT01757704|Procedure|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
79344775|NCT01757704|Procedure|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
79344776|NCT01757392|Biological|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
79344777|NCT01756846|Other|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
79344778|NCT01756846|Other|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
79985861|NCT03688334|Drug|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
79985862|NCT03688334|Drug|Medical air (sham O2)|Medical air supplementation via Venturi mask
79985863|NCT05191836|Behavioral|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
79985864|NCT05191836|Behavioral|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
79344779|NCT01963611|Drug|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
79344780|NCT01963611|Drug|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
79344781|NCT01963611|Drug|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
79344782|NCT01963611|Drug|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
79344783|NCT01963611|Drug|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
79344784|NCT04662645|Other|Palliative Therapy|Undergo embedded palliative care
79344785|NCT04662645|Other|Questionnaire Administration|Ancillary studies
79344786|NCT01975701|Drug|BGJ398|Capsule for oral use.
79344787|NCT01962987|Drug|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
79658807|NCT01600300|Device|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
79344788|NCT01962987|Other|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
79344789|NCT01962441|Drug|SOF|400 mg tablet administered orally once daily
79344790|NCT01962441|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79344791|NCT01962441|Drug|Peg-IFN|180 µg administered via subcutaneous injection once weekly
79344792|NCT01638013|Drug|Peficitinib|Oral Tablet
79658808|NCT01600339|Drug|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
79658809|NCT00256022|Drug|Lactobacillus Probiotic|
79658810|NCT00256022|Other|Lactose Powder|
79344793|NCT01637623|Drug|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
79344794|NCT01637623|Drug|Allopurinol|Allopurinol 300 mg daily for 6 weeks
79658811|NCT00270660|Behavioral|biopsy, audiometry, ET function test, ear swab culture, DNE|
79344795|NCT01637623|Drug|Placebo|Placebo capsule daily for 6 weeks
79658812|NCT01600456|Behavioral|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
79658813|NCT01600456|Other|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
79658814|NCT00289809|Drug|combination of TLC D-99 and Ifosfamide|"TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
79344796|NCT01962207|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
79658815|NCT00256100|Drug|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
79658816|NCT01600534|Behavioral|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
79658817|NCT00289926|Drug|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
79658818|NCT00289926|Drug|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
79658819|NCT01609192|Drug|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
79658820|NCT01609270|Device|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
79658821|NCT00256139|Drug|Raptiva|
79658822|NCT00270699|Biological|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
79658823|NCT00270699|Biological|Placebo|Placebo for rDEN4delta30-200,201
79344798|NCT01995825|Drug|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
79344799|NCT01995825|Drug|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
79344800|NCT04829929|Device|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
79344801|NCT03777943|Procedure|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
79658824|NCT01609387|Dietary Supplement|Fit For me|
79658825|NCT01609387|Dietary Supplement|Davitamon|
79658826|NCT01609426|Genetic|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
79985865|NCT05191836|Other|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
79985866|NCT04099277|Drug|LY3435151|Administered IV
79344802|NCT01995357|Device|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
79344803|NCT01995357|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
79344804|NCT01995357|Device|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
79344805|NCT04838353|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
79344806|NCT05270239|Behavioral|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
79344807|NCT05270239|Behavioral|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
79496048|NCT01498991|Device|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
79985867|NCT04099277|Drug|Pembrolizumab|Administered IV
79985868|NCT03698786|Behavioral|Exercise|Participants will be required to complete two, 8-hours trials (exercise & control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
79344808|NCT04307563|Behavioral|Mindfulness session|1.5 hour weekly session with health educator
79496049|NCT03895853|Other|Best Practice|Receive standard of care
79496050|NCT03895853|Dietary Supplement|early metabolic resuscitation|Given Intravenous
79496051|NCT03901313|Drug|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
79496052|NCT03901313|Drug|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
79496053|NCT03901313|Drug|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
79496054|NCT03900299|Procedure|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
79985869|NCT03311256|Diagnostic Test|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
79985870|NCT03743987|Procedure|control group|a procedure used to prevent or resolves apical periodontitis.
79496055|NCT03898349|Other|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
79344809|NCT04817761|Drug|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to < 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
79496056|NCT03898349|Other|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
79658827|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
79658828|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
79658829|NCT00256178|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
79985871|NCT03743987|Procedure|MTA group|a procedure used to prevent or resolves apical periodontitis.
79985872|NCT03743987|Procedure|PRF group|a procedure that is used for wound healing
79344810|NCT03706963|Other|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
79344811|NCT04267081|Drug|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
79658830|NCT00270738|Procedure|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
79658831|NCT00270738|Procedure|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
79658832|NCT00270738|Procedure|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
79496057|NCT03898349|Other|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
79496058|NCT03894449|Combination Product|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
79496059|NCT03888755|Drug|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
79496060|NCT00378755|Drug|velcade|
79496061|NCT00378833|Drug|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
79496062|NCT00378833|Drug|niacin|Duration of Treatment: 18 Weeks
79658833|NCT01609504|Procedure|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
79658834|NCT01609504|Procedure|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
79658835|NCT01609621|Device|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
79658836|NCT02488408|Drug|Bemcentinib|
79985873|NCT03743987|Procedure|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
79985874|NCT03688256|Device|Obalon Balloon System|6 month Obalon Intragastric Balloons
79496063|NCT02995967|Procedure|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
79496064|NCT02995967|Drug|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
79658837|NCT02488408|Drug|Cytarabine|
79344812|NCT04258267|Procedure|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
79985875|NCT05171322|Device|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
79985876|NCT03990389|Device|Chatbot Intervention|a chatbot will be used to monitor depression severity
79344813|NCT04258267|Procedure|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
79344814|NCT05309005|Behavioral|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
79344815|NCT05309005|Behavioral|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
79344816|NCT04814173|Other|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
79985877|NCT03168360|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
79658838|NCT02488408|Drug|Decitabine|
79658839|NCT00270777|Drug|adrenaline, promethazine, hydrocortisone|
79658840|NCT00256256|Drug|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
79985878|NCT04037462|Drug|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
79985879|NCT05194878|Drug|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
79985880|NCT05194878|Procedure|Colectomy|Radical colectomy
79985881|NCT05194878|Drug|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
79985882|NCT03693326|Drug|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
79985883|NCT01319916|Drug|ATX-101|ATX-101 2mg/cm2
79985884|NCT03988907|Drug|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
79985885|NCT03988907|Drug|Midazolam|single dose administration of 2 mg midazolam
79985886|NCT03693248|Drug|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
79985887|NCT03987191|Drug|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
79985888|NCT04098809|Device|16 French urinary catheter|16 French urinary catheter
79985889|NCT04098809|Device|20 French urinary catheter|20 French urinary catheter
79496065|NCT03888365|Drug|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
79658841|NCT01580176|Device|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
79658842|NCT01609660|Dietary Supplement|Saccharomyces boulardii|100mg daily for seven days prior to surgery
79658843|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
79344817|NCT04814173|Other|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
79496066|NCT03888365|Drug|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
79496067|NCT00377975|Drug|Ephedrine|
79658844|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
79814687|NCT00592007|Drug|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
79814688|NCT00913289|Biological|adipose tissue derived stromal cells|dosage
79814689|NCT00837473|Device|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
79496068|NCT00377975|Drug|Pioglitazone|
79814690|NCT00703547|Drug|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
79814691|NCT00703547|Drug|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
79814692|NCT00703547|Drug|Placebo|Placebo tablets and capsules will be provided to subjects.
79814693|NCT04030793|Device|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
79814694|NCT04030793|Device|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
79814695|NCT00839423|Drug|Placebo|capsules, daily, orally
79344818|NCT04814173|Other|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
79344819|NCT03698071|Biological|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
79344820|NCT03698071|Biological|urine sample|6 ml
79344821|NCT04792567|Drug|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
79496069|NCT00377975|Drug|Caffeine|
79496070|NCT03870893|Behavioral|hippotherapy|16weeks hippotherapy program
79496071|NCT02994251|Drug|gemcitabine|1000 mg/m^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
79496072|NCT02994251|Drug|Cisplatin|25 mg/m^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
79496073|NCT02994251|Drug|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
79814696|NCT00839423|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
79814697|NCT00839423|Drug|Venlafaxine XL|capsules, daily, orally
79814698|NCT00837161|Device|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
79814699|NCT00859547|Biological|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
79814700|NCT00859469|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
79814701|NCT00859469|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
79814702|NCT00703625|Drug|Temsirolimus|
79814703|NCT00703625|Drug|Docetaxel|
79814704|NCT00703703|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
79814705|NCT00703703|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
79344822|NCT04792567|Drug|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
79344823|NCT04825171|Drug|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
79658845|NCT00289965|Behavioral|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
79344824|NCT04235335|Behavioral|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
79344825|NCT04419025|Drug|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
79496074|NCT03887429|Drug|SXC-2023|SXC-2023 oral capsules
79658846|NCT00289965|Behavioral|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
79658847|NCT00289965|Behavioral|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
79344826|NCT04837417|Diagnostic Test|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
79344827|NCT04837339|Other|Collection of biological samples|Blood sample, biopsies sample, hair sample.
79496075|NCT03887429|Drug|Placebos|Matching Placebo oral capsules
79496076|NCT02978885|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
79496077|NCT02978885|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
79814706|NCT00703703|Drug|Placebo|Placebo tablet once daily
79814707|NCT00859313|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
79344828|NCT04813003|Other|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
79496078|NCT02978885|Procedure|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
79496079|NCT02978885|Procedure|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
79658848|NCT01609738|Device|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
79308201|NCT02505503|Device|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
79658849|NCT00256334|Drug|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
79658850|NCT01609777|Procedure|SBAR|situation, background, assessment, recommendation
79658851|NCT01609855|Drug|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
79658852|NCT01609855|Drug|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
79344829|NCT01638559|Drug|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
79344830|NCT04210999|Other|Homebased resistance training|Resistance training at home instructed via a smart phone training app
79658853|NCT00256373|Procedure|Mod. functional restoration-Individ. dynamic back-muscle|
79658854|NCT00270816|Drug|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
79344831|NCT04210999|Other|Supervised heavy slow resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist
79658855|NCT00270816|Drug|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
79658856|NCT01609972|Device|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
79344832|NCT05259787|Drug|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
79344833|NCT05259787|Drug|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
79496080|NCT02936999|Drug|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
79496081|NCT01385033|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
79496082|NCT02826551|Drug|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
79496083|NCT02826551|Other|Ice|
79496084|NCT02826551|Drug|Percocet|
79496085|NCT02826551|Device|Knee Brace and Crutches|
79496086|NCT00378443|Drug|prednisone + Inhibace/Cozaar|
79496087|NCT00378443|Drug|Inhibace/Cozaar|
79496088|NCT01337609|Drug|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
79496089|NCT01337609|Other|Placebo (sugar pill)|1 pill daily for 60 days
79344834|NCT04809571|Other|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
79496090|NCT01337609|Other|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
79496091|NCT01340573|Drug|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
79496092|NCT01340573|Drug|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
79658857|NCT00256412|Drug|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
79658858|NCT00256412|Drug|Placebo|4 capsules of placebo each day
79658859|NCT01602367|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
79658860|NCT01602367|Drug|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
79658861|NCT01602367|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
79658862|NCT01602367|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
79344835|NCT05226325|Drug|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
79344836|NCT04418635|Dietary Supplement|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
79344837|NCT05394883|Behavioral|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
79496093|NCT01340885|Drug|Strattera|10-30 mg b.i.d. for 6 weeks
79496094|NCT01340885|Drug|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
79496095|NCT01340885|Other|Placebo|2-6 pills for 6 weeks
79496096|NCT01326923|Drug|Cetuximab|Single arm phase II study of chemotherapy
79496097|NCT03855059|Drug|Placebos|This will be a saline solution of given IV or perineural.
79496098|NCT03855059|Drug|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
79496099|NCT03863795|Other|Survey Administration|Respond to SurveyGizmo survey online
79496100|NCT03858335|Other|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
79496101|NCT03857243|Device|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
79496102|NCT01301963|Drug|plerixafor|Given SC
79496103|NCT01301963|Biological|filgrastim|Given SC
79496104|NCT05313737|Other|Automated message|Automated message via phone call (audiocare)
79496105|NCT05313737|Other|Opt-out scheduling|Scheduling via non-automated phone call
79658863|NCT00290004|Drug|motexafin gadolinium|
79658864|NCT01606891|Behavioral|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
79658865|NCT00256490|Procedure|PET/CT 20 days after the first cycle of chemotherapy|
79658866|NCT01609816|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
79658867|NCT00256529|Procedure|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
79658868|NCT00290043|Drug|Insulin glulisine|
79814708|NCT02611973|Other|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
79344838|NCT05394883|Behavioral|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
79344839|NCT01756300|Device|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
79344840|NCT03543631|Other|Survey|Online survey
79344841|NCT04811131|Drug|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
79344842|NCT04811131|Drug|ARQ-252 Vehicle cream|ARQ-252 Vehicle cream
79344843|NCT04811131|Device|NB-UVB phototherapy active treatment|NB-UVB phototherapy active treatment
79344844|NCT04811131|Device|NB-UVB phototherapy sham treatment|NB-UVB phototherapy sham treatment
79658869|NCT01606930|Behavioral|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
79658870|NCT00256568|Behavioral|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
79814709|NCT02611973|Other|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
79814710|NCT02611973|Other|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
79344845|NCT04724161|Diagnostic Test|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
79814711|NCT02611973|Drug|Hydroxyurea treatment (HU)|HU maintenance
79814712|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 100 ug/kg
79814713|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 300 ug/kg
79344846|NCT05221021|Drug|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
79344847|NCT05221021|Drug|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
79344848|NCT03164473|Drug|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
79344849|NCT03164473|Drug|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
79344850|NCT03164473|Drug|Placebo-rituximab|4 infusions for 18 months
79344851|NCT03164473|Drug|Placebo-azathioprine|oral tablets for 24 months
79658871|NCT02270047|Dietary Supplement|Orange nectar|Orange nectar
79658872|NCT02270047|Dietary Supplement|Orange Nectar with fibre|
79658873|NCT02960607|Drug|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
79658874|NCT02270125|Procedure|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
79658875|NCT02270164|Dietary Supplement|Artichoke Leaf Extract|Capsule
79658876|NCT02270164|Other|Placebo|Capsule
79658877|NCT00290082|Drug|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
79814714|NCT00771810|Drug|Placebo|Once daily subcutaneous injection of placebo
79814715|NCT00836927|Drug|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
79814716|NCT00836927|Drug|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
79814717|NCT00703235|Drug|Bevacizumab|
79814718|NCT02612051|Drug|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
79344852|NCT03162289|Other|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
79344853|NCT03162289|Other|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
79344854|NCT05218915|Drug|Dulaglutide|Dulaglutide once weekly subcutaneous
79344855|NCT05218915|Drug|Insulin Degludec|Insulin degludec once daily
79658878|NCT00290082|Biological|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
79658879|NCT00290082|Other|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
79658880|NCT00290082|Drug|Loxapine|Loxapine 1 mL / 10 kg
79658881|NCT00290082|Drug|Midazolam|Midazolam 1 mL / 10 Kg
79658882|NCT02270203|Radiation|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
79658883|NCT02270320|Behavioral|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
79658884|NCT02270398|Behavioral|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
79814719|NCT02612051|Drug|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
79308202|NCT02505503|Device|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
79308203|NCT04497311|Diagnostic Test|Thoraxic computed tomography|Diagnostic lung CT.
79344856|NCT05218915|Device|Continuous glucose monitor|Dexcom G6 CGM system
79344857|NCT05237089|Other|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm*40mm or 0.30mm*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
79344858|NCT05237089|Other|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
79344859|NCT05237089|Other|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
79344860|NCT03462511|Behavioral|HABIT Intervention|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
79658885|NCT02270398|Behavioral|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
79658886|NCT02270398|Behavioral|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
79658887|NCT00256646|Drug|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
79658888|NCT02270437|Drug|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
79814720|NCT02612051|Radiation|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of [18F]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
79344861|NCT03424603|Drug|STRO-001|intravenous antibody drug conjugate
79344862|NCT05384197|Drug|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
79344863|NCT05384197|Drug|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
79496106|NCT01298921|Drug|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
79496107|NCT01298921|Drug|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
79496108|NCT05313191|Radiation|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
79814721|NCT00771030|Biological|Brodalumab|Solution for subcutaneous or intravenous administration
79814722|NCT00771030|Other|Placebo|Solution for subcutaneous or intravenous administration
79814723|NCT00768300|Drug|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
79814724|NCT00768300|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
79344864|NCT01995201|Drug|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
79344865|NCT01995201|Drug|methotrexate|stable dose
79344866|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
79344867|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
79344868|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
79496109|NCT00378521|Drug|MQX-503|
79658889|NCT02270554|Device|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
79658890|NCT02270749|Drug|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
79814725|NCT00768222|Device|silk suture|skin closure
79814726|NCT00768222|Device|VICRYL* Plus suture|skin closure
79814727|NCT00768144|Drug|Sunitinib|
79814728|NCT03996330|Diagnostic Test|taqman array card|The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
79814729|NCT00784836|Drug|BG9418 (interferon beta 1-a)|
79814730|NCT04104984|Device|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
79814731|NCT04104984|Drug|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
79814732|NCT04104984|Procedure|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
79814733|NCT04104984|Other|digital vaginal exam|vaginal examination to detect short cervix
79814734|NCT04104984|Device|abdominal ultrasound|use abdominal ultrasound to measure cervical length
79814735|NCT04104984|Drug|Tocolytic Agents|a medication is given to prevent uterine contraction
79814736|NCT00784758|Device|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
79814737|NCT00784758|Device|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
79344869|NCT05383651|Device|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
79344870|NCT05383651|Device|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
79344871|NCT04690699|Biological|Lerapolturev|Lerapolturev administered via intravesical instillation once
79344872|NCT04690699|Other|5% DDM|5% DDM and saline washes
79344873|NCT04638387|Dietary Supplement|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
79344874|NCT04638387|Dietary Supplement|Placebo|Placebo comparator to P125
79658891|NCT02270749|Drug|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
79496110|NCT03870737|Device|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
79658892|NCT00256685|Drug|DVS-233 SR|
79814738|NCT00768066|Biological|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
79814739|NCT00768066|Biological|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
79344875|NCT01728454|Drug|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
79344876|NCT01728454|Drug|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
79344877|NCT04568590|Behavioral|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average > 3), they will be given the informational handout along with a brief script.
79496111|NCT01269749|Radiation|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
79344879|NCT01636687|Drug|Placebo|2 injections of placebo to secukinumab 150mg per dose
79344880|NCT01636687|Drug|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
79658893|NCT02270788|Drug|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
79658894|NCT02270788|Drug|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
79658895|NCT02270788|Drug|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
79658896|NCT02270827|Drug|Aminophylline|intravenous medication
79344881|NCT01636687|Drug|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
79658897|NCT02270827|Drug|Hydrocortisone|Intravenous medication
79344882|NCT05213377|Procedure|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
79496112|NCT01269749|Drug|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
79985890|NCT03122184|Behavioral|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
79985891|NCT03122184|Behavioral|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
79658898|NCT02270866|Device|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
79658899|NCT00290121|Drug|Olanzapine|
79985892|NCT03745781|Drug|Placebos|placebo pills
79814740|NCT00768066|Biological|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
79814741|NCT00767676|Device|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
79308204|NCT02505581|Drug|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
79814742|NCT00767520|Drug|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
79344883|NCT01634659|Device|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
79344884|NCT01634659|Device|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
79344885|NCT05652985|Behavioral|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
79344886|NCT05165641|Procedure|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally [ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
79344887|NCT04796467|Drug|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
79658900|NCT02270905|Device|dCELL® Meniscus|decellularised porcine xenograft
79658901|NCT04709744|Drug|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
79658902|NCT04709744|Diagnostic Test|ELISA|Measure vitamin D level
79658903|NCT02271022|Other|Non-Interventional Study|Non-Interventional Study
79658904|NCT02271100|Device|ultrasound guidance|use of ultrasound for entry position estimation
79658905|NCT02271100|Device|palpation guidance|use of palpation for position estimation
79308205|NCT02505581|Procedure|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
79308206|NCT02505581|Drug|Ciprofloxacin 750 mg oral|An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
79658906|NCT00270972|Device|Bilayered Cellular Matrix (OrCel)|
79658907|NCT00256802|Device|MR-angiography, GTN|
79658908|NCT02271139|Drug|Alectinib|Alectinib 600 mg administered orally with food.
79658909|NCT02271178|Other|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
79658910|NCT02271178|Other|Conventional therapy|Usual therapy
79658911|NCT00256841|Drug|Chemotherapy|
79814743|NCT00767520|Drug|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
79814744|NCT02601612|Biological|D46cpΔM2-2 vaccine|Delivered as nose drops
79814745|NCT02601612|Biological|Placebo|Delivered as nose drops
79814746|NCT00838565|Drug|Placebo|intravenous infusion on three consecutive months
79814747|NCT00838565|Drug|dose level 1|intravenous infusion on three consecutive months
79814748|NCT00838565|Drug|dose level 2|intravenous infusion on three consecutive months
79814749|NCT00838565|Drug|dose level 3|intravenous infusion on three consecutive months
79496113|NCT02757053|Device|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
79985893|NCT01372176|Other|Early Goal-Directed Nutrition|"Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
79228189|NCT03304808|Device|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
79344888|NCT04796467|Drug|68Ga-P16-093|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
79344889|NCT05814471|Device|Cable fastening system and 3d printed straps|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
79344890|NCT05814471|Device|Velcro straps system|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
79496114|NCT01270919|Device|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
79344891|NCT05814458|Device|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
79496115|NCT01262339|Drug|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
79658912|NCT00256841|Procedure|Radiation Therapy|
79658913|NCT02271295|Drug|Enoxaparine|Enoxaparine 4000UI/day during 24 months
79658914|NCT02271373|Behavioral|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
79658915|NCT02271412|Drug|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
79658916|NCT02271412|Drug|Placebo|Placebo
79658917|NCT00256880|Drug|GW786034|
79658918|NCT00271050|Other|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
79985894|NCT01372176|Other|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
79658919|NCT02271568|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
79658920|NCT02271568|Other|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
79658921|NCT02271607|Device|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
79658922|NCT00256919|Drug|GW856553|
79658923|NCT02271646|Drug|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
79658924|NCT00271089|Procedure|PBSC Collection|
79658925|NCT00271089|Procedure|Bone Marrow Harvest|
79985895|NCT04396106|Drug|AT-527|One 550 mg tablet of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
79658926|NCT00271089|Device|CliniMacs Cell Selection System|
79658927|NCT02271685|Other|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
79496116|NCT03861845|Device|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
79496117|NCT03861845|Device|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
79496118|NCT03861845|Device|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
79658928|NCT02271685|Other|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
79496119|NCT03861845|Behavioral|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
79496120|NCT03861845|Behavioral|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
79496121|NCT02708849|Drug|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
79496122|NCT02708849|Drug|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
79496123|NCT02708849|Drug|Placebo|oral dose placebo
79496124|NCT03859739|Drug|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
79496125|NCT01237613|Device|Artelon|Artelon Tissue Reinforcement
79496126|NCT01234103|Behavioral|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
79228190|NCT03304808|Behavioral|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
79344892|NCT05814458|Device|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
79496127|NCT01222871|Drug|Triamcinolone|Triamcinolone soaked nasopore dressing
79658929|NCT02271685|Other|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
79658930|NCT02271685|Other|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
79658931|NCT02271763|Other|ultrasound|subjects' neck will be scanned using ultrasound
79658932|NCT00256958|Procedure|total knee replacement|
79344893|NCT05814445|Other|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
79658933|NCT02271802|Dietary Supplement|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
79658934|NCT02271802|Dietary Supplement|NaCl|
79658935|NCT02271841|Device|PVI|Pleth Variability Index
79658936|NCT02271958|Drug|Mifepristone|
79344894|NCT05814445|Other|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
79496128|NCT01222871|Drug|Saline soaked sponge|saline soaked sponge
79496129|NCT01219673|Other|Placebo|1 by mouth twice a day.
79985896|NCT04396106|Other|Placebo|One placebo tablet administered every ~12 hours (twice a day) for a total of 5 days
79344895|NCT05814380|Radiation|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
79496130|NCT01219673|Drug|Armodafinil|150 mg by mouth once a day.
79496131|NCT01219673|Drug|Minocycline|100 mg by mouth twice a day.
79496132|NCT01219673|Drug|Bupropion|100 mg by mouth twice a day.
79814750|NCT00838565|Drug|dose level 4|intravenous infusion on 3 consecutive months
79814751|NCT00858845|Drug|Clonidine Patch|A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
79814752|NCT00858845|Other|Matching Placebo Patch|A matching placebo patch to be worn for a period of 3 months.
79228191|NCT04458636|Drug|Prednisolone|Oral
79496133|NCT01216631|Drug|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
79496134|NCT01216631|Drug|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
79496135|NCT01216631|Drug|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
79496136|NCT02693717|Other|Laboratory Biomarker Analysis|Correlative studies
79496137|NCT02693717|Drug|Pemetrexed Disodium|Given IV
79496138|NCT03860753|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
79814753|NCT00703859|Drug|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
79496139|NCT03860753|Drug|Placebo|Pill capsules will look same as that of active drug.
79658937|NCT02271958|Drug|PLACEBO|
79658938|NCT00257036|Drug|levofloxacin|
79658939|NCT02272036|Procedure|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
79658940|NCT02272036|Device|mobile phone|SMS received by mobile phone
79658941|NCT00271167|Drug|INO-1001|
79658942|NCT02272153|Other|Egg refined grain|
79658943|NCT02272153|Other|Egg Whole Grain|
79658944|NCT02272153|Other|Cereal Refined grain|
79658945|NCT00257075|Drug|Risperidone, oral tablets|
79344896|NCT05814380|Diagnostic Test|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
79496140|NCT02687165|Drug|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
79658946|NCT02272192|Behavioral|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
79344897|NCT05814328|Other|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
79344898|NCT05814302|Drug|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
79496141|NCT02672033|Radiation|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
79658947|NCT02272192|Behavioral|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
79658948|NCT00290277|Biological|HPV-16/18 L1/AS04|
79496142|NCT02672033|Radiation|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
79658949|NCT02272270|Drug|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
79814754|NCT04030949|Other|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
79814755|NCT05565287|Combination Product|ultra early physiotherapy intervention|"NBAS / NBO and GMs based guidelines in explaining neonatal signs into the NICU (lasting 15-30 minutes)~NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention upon hospital discharge (lasting one hour)~NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention every 15 to 20 days until the 3rd month of life (corrected age)."
79814756|NCT00770562|Drug|rituximab|
79814757|NCT00770562|Drug|Dexamethasone|
79814758|NCT00836693|Drug|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
79814759|NCT00836693|Drug|placebo|tablet administered orally once a day for 12 weeks.
79228192|NCT02469350|Other|Serious game|Rehabilitation with serious game
79228193|NCT05000619|Behavioral|Outreach mailer|Postcard or letter
79228194|NCT05000619|Behavioral|Humor/Salience|Funny cartoon
79228195|NCT05000619|Behavioral|Doctor's authority|Letter from a doctor
79344899|NCT05814289|Other|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
79496143|NCT02672033|Other|Laboratory Biomarker Analysis|Correlative studies
79496144|NCT02672033|Procedure|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
79496145|NCT02656199|Procedure|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
79228196|NCT05000619|Behavioral|Information|Information about benefits of the appointment
79228197|NCT03304652|Drug|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
79228198|NCT03304652|Other|Natural Sleep|Natural Sleep without medication
79228199|NCT03898323|Device|Alcohol Approach Bias Modification|Computerized training
79496146|NCT03845933|Procedure|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
79496147|NCT03817775|Other|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
79658950|NCT02272387|Dietary Supplement|Vitamin D3 (Cholecalciferol)|
79658951|NCT02272387|Other|Placebo|
79658952|NCT00257114|Drug|bortezomib|
79658953|NCT02272426|Behavioral|CARET|Combined Aerobic and Resistance Exercise Training
79658954|NCT02272426|Behavioral|CTI|Cognitive Training Intervention
79658955|NCT02272426|Behavioral|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
79658956|NCT02272426|Behavioral|Sham CTI|Sham Cognitive Training Intervention
79658957|NCT02272465|Other|No intervention|Observational study
79658958|NCT00257153|Device|Coronary thrombus aspiration catheter|
79658959|NCT00271206|Drug|Progesterone|compared to placebo
79658960|NCT00271206|Drug|sugar pill|Compared to progesterone
79658961|NCT02272543|Dietary Supplement|Fish surimi peptide|
79814760|NCT00770484|Drug|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
79814761|NCT00770484|Drug|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
79814762|NCT04099602|Other|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
79496148|NCT01169753|Drug|Placebo|Oral tablet every morning for 2 weeks
79496149|NCT01169753|Drug|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
79496150|NCT02654639|Drug|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
79496151|NCT02654639|Drug|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
79658962|NCT02272582|Device|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
79228200|NCT02722148|Device|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
79496152|NCT02634827|Drug|Decitabine|Given IV
79496153|NCT02634827|Other|Laboratory Biomarker Analysis|Correlative studies
79496154|NCT02634827|Drug|Midostaurin|Given PO
79658963|NCT02272582|Other|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
79814763|NCT04098042|Device|Scaffold|implantation of a Magmaris scaffold
79496155|NCT02506985|Drug|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
79496156|NCT02506985|Drug|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
79496157|NCT01150409|Drug|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
79658964|NCT02272621|Procedure|Minimally invasive aortic valve replacement|
79814764|NCT00835679|Biological|cetuximab|Given IV
79814765|NCT00835679|Drug|dasatinib|Given orally
79814766|NCT00835679|Procedure|therapeutic conventional surgery|Undergo surgery
79814767|NCT00835679|Other|laboratory biomarker analysis|Correlative studies
79496158|NCT01150409|Drug|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
79658965|NCT02272621|Procedure|Full sternotomy aortic valve replacement|
79814768|NCT04100070|Behavioral|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~visits with the diabetologist/pediatrician~contacts with the service provider (nurses' visits) (more in intensive group)~personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
79228201|NCT03471312|Drug|Magnesium|magnesium therapy
79496159|NCT01133639|Drug|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
79496160|NCT01133639|Drug|Placebo|Placebo plus standard of care
79496161|NCT01115699|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
79496162|NCT00378911|Drug|sunitinib malate|Given orally
79658966|NCT00290316|Procedure|Endoscopy ultrasound|
79814769|NCT04119245|Device|I-gel supraglottic airway device|After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
79814770|NCT00766506|Device|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
79985897|NCT04396106|Drug|AT-527|Two 550 mg tablets of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
79496163|NCT03819491|Dietary Supplement|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
79496164|NCT03801473|Other|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
79496165|NCT03801473|Other|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
79658967|NCT02272660|Drug|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
79985898|NCT04396106|Other|Placebo|Two placebo tablets administered every ~12 hours (twice a day) for a total of 5 days
79496166|NCT03828149|Combination Product|Drug:OP0201|Drug: OP0201
79658968|NCT02272660|Drug|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
79658969|NCT02272699|Drug|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
79496167|NCT03828149|Combination Product|Drug: Placebo|Drug: Placebo
79496168|NCT03832907|Device|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
79985899|NCT03743831|Device|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
79496169|NCT03832907|Diagnostic Test|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
79496170|NCT03831971|Drug|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
79658970|NCT02272699|Drug|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
79658971|NCT02272699|Drug|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
79658972|NCT02272699|Radiation|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
79658973|NCT02272699|Procedure|Surgery|Esophagectomy
79658974|NCT02272738|Drug|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
79658975|NCT02272738|Drug|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
79658976|NCT00271245|Dietary Supplement|200 µg selenium as selenate|200 µg selenium as selenate
79658977|NCT00271245|Dietary Supplement|400 µg selenium as selenate|400 µg selenium as selenate
79658978|NCT00271245|Dietary Supplement|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
79658979|NCT00271245|Dietary Supplement|Placebo|Placebo
79658980|NCT02272855|Biological|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
79658981|NCT02272894|Procedure|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
79985900|NCT03743831|Device|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
79658982|NCT00257270|Drug|gabapentin|
79658983|NCT02272933|Device|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
79658984|NCT02272933|Device|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
79658985|NCT00290394|Drug|rosiglitazone(drug), blood pressure lowering effect|
79658986|NCT02273011|Procedure|caesarean section|elective caesarean section under regional anesthesia
79985901|NCT01373970|Drug|Placebo|Placebo, one tablet daily for 12 weeks
79985902|NCT01373970|Drug|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
79985903|NCT03743675|Behavioral|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
79985904|NCT03743675|Behavioral|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
79985905|NCT04050098|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
79985906|NCT04050098|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
79496171|NCT03823937|Other|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
79496172|NCT03807089|Device|Conventional Pediatric Colonoscope|
79496173|NCT03807089|Device|Short-Turn Radius Colonoscope|
79496174|NCT03822377|Drug|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
79658987|NCT02273089|Device|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
79658988|NCT00416247|Behavioral|Hypnosis|Hypnosis
79658989|NCT00257348|Drug|Capecitabine|
79658990|NCT00257348|Drug|Docetaxel|
79658991|NCT01580215|Device|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
79658992|NCT02273128|Genetic|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
79658993|NCT00290550|Drug|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
79658994|NCT00257387|Drug|Cyclosporine|
79658995|NCT02273245|Radiation|Thoracic aortogram CT|With and without contrast dye
79658996|NCT02273401|Drug|BI 11054 CL|
79658997|NCT02273401|Drug|Placebo|
79658998|NCT00257426|Drug|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
79658999|NCT01601353|Device|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
79344900|NCT05814276|Behavioral|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
79496175|NCT03822377|Drug|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
79496176|NCT02501759|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
79496177|NCT02501759|Radiation|Gadodiamide|Given IV
79344901|NCT05814263|Device|HIS/LBB pacing|3830 lead to HIS or LBB
79344902|NCT05814263|Device|LV pacing|LV lead in a CS branch
79496178|NCT02501759|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
79496179|NCT02501759|Procedure|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
79496180|NCT02501759|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
79496181|NCT03808493|Drug|TAK-438 OD|TAK-438 OD tablet
79496182|NCT03808493|Drug|TAK-438|TAK-438 tablet
79659000|NCT01601392|Procedure|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
79985907|NCT03745625|Drug|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
79985908|NCT03745625|Drug|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
79985909|NCT04021706|Drug|Anamorelin Hydrochloride|Ghrelin receptor agonist
79344903|NCT05814237|Other|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
79496183|NCT00378989|Behavioral|Consultation at the occupational health services|Consultation at the occupational health services
79496184|NCT02499887|Drug|beclamethasone dipropionate|Inhaler
79496185|NCT02499887|Drug|albuterol|Inhaler
79496186|NCT02499887|Drug|Prednisone|Oral corticosteroid
79496187|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
79496188|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
79659001|NCT01601392|Procedure|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
79659002|NCT01601392|Procedure|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
79814771|NCT00766506|Device|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
79496189|NCT02504099|Drug|ribavirin|Tablet
79496190|NCT02450591|Drug|Erlotinib|
79496191|NCT02450591|Other|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
79496192|NCT01094561|Drug|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
79496193|NCT01094561|Procedure|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
79496194|NCT01094561|Procedure|Secretin-Enhanced Endoscopic Ultrasound|
79496195|NCT01074437|Drug|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
79814772|NCT04097886|Other|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
79814773|NCT04097886|Other|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
79985910|NCT04021706|Drug|Placebo|placebo is a inert substance
79344904|NCT05814224|Diagnostic Test|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
79659003|NCT01601509|Drug|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
79814774|NCT00770328|Drug|Pentoxifylline|400mg PO TID x 8 weeks
79814775|NCT00770328|Drug|Placebo|PO TID x 8 weeks
79985911|NCT05194020|Other|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
79344905|NCT05814185|Device|Periodontal distractor|different activation protocols of periodontal distractor
79985912|NCT03698630|Drug|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
79985913|NCT03698630|Drug|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon* on the other containing 2 mg dexamethasone."
79985914|NCT01375452|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
79985915|NCT03053466|Drug|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
79985916|NCT03687944|Other|Validity and reliability|Test-retest method and concurrent validity
79344906|NCT05814315|Behavioral|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
79985917|NCT05131308|Other|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
79344907|NCT05814120|Behavioral|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
79344908|NCT05814094|Other|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
79985918|NCT03624140|Device|blood measurement|Hemoglobin measurement
79985919|NCT03624140|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
79496196|NCT01074437|Drug|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
79985920|NCT03624140|Device|hemoCue|non invasive method of hemoglobin measurement
79985921|NCT04091087|Drug|crisaborole ointment|crisaborole ointment
79985922|NCT04091087|Other|vehicle ointment|vehicle ointment
79985923|NCT03687866|Genetic|non invasive prenatal testing|
79496197|NCT01074437|Drug|Placebo|Liquid placebo will be given during the two month treatment trial.
79814776|NCT04097496|Behavioral|Act Out! Intervention|Data included in the description of the intervention arm.
79814777|NCT00916500|Drug|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
79814778|NCT04100928|Other|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
79985924|NCT03046836|Drug|Oxytocin|40 IU oxytocin nasal spray
79985925|NCT03046836|Drug|Placebo|Saline
79659004|NCT01601509|Drug|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
79814779|NCT03110094|Other|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
79344909|NCT05814094|Other|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
79496198|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
79496199|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
79496200|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
79496201|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
79496202|NCT02461355|Behavioral|Aphasia therapy|Aphasia therapy using a computerized scripting program
79496203|NCT02461355|Device|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
79496204|NCT02461355|Device|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
79496205|NCT02410577|Drug|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
79344910|NCT05814081|Procedure|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
79344911|NCT05814068|Drug|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
79496206|NCT02410577|Device|PET/CT Scan|
79496207|NCT02410577|Device|MRI|
79659005|NCT00416325|Dietary Supplement|lycopene|
79659006|NCT00416325|Other|laboratory biomarker analysis|
79344912|NCT05814003|Drug|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
79496208|NCT02410577|Other|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
79659007|NCT00257465|Biological|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
79496209|NCT01066637|Drug|[18F](+/-)NOS|Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis
79496210|NCT03796013|Drug|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
79496211|NCT03796013|Drug|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
79659008|NCT00257465|Biological|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
79659009|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|2.5 million cells
79814780|NCT03110094|Other|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
79814781|NCT02600988|Drug|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
79814782|NCT02600988|Drug|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
79814783|NCT05499078|Device|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
79814784|NCT04097574|Drug|NPO-13: l-menthol|20 mL/site
79985926|NCT03687788|Behavioral|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
79985927|NCT03400033|Drug|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
79985928|NCT03400033|Drug|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
79496212|NCT02399111|Device|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
79344913|NCT05814003|Other|Placebo|Dough inert material without any therapeutic action
79344914|NCT05813977|Device|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
79496213|NCT03793751|Drug|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
79496214|NCT01030757|Radiation|Tomotherapy treatment|"A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~Dose will be prescribed to the isodose line which covers at least 90% of the PTV~Dose homogeneity +/- 5%"
79496215|NCT01016561|Radiation|intracavitary balloon brachytherapy|
79344915|NCT05813951|Drug|Linezolid|linezolid either continues infusion or standard intermittent dose
79496216|NCT01016561|Radiation|external beam radiation therapy|
79496217|NCT01016561|Radiation|intensity-modulated radiation therapy|
79496218|NCT01016561|Radiation|radiation therapy treatment planning/simulation|
79496219|NCT01016561|Radiation|3-dimensional conformal radiation therapy|
79496220|NCT01016561|Drug|Cisplatin|
79496221|NCT01009931|Drug|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
79659010|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0.5 million cells
79659011|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0 cells
79814785|NCT04099680|Procedure|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
79344916|NCT05813938|Device|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
79344917|NCT05813886|Other|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
79344918|NCT05813821|Behavioral|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment >7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
79344919|NCT05813808|Diagnostic Test|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
79344920|NCT05813782|Behavioral|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
79344921|NCT05813756|Other|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+~2.5 months), at the end of the intervention (T2 : T0+~5 months) and 3 months after the intervention (T3 : T0+~8 months). At the same time psychological questionnaires and scales will be completed
79344922|NCT05813704|Device|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
79344923|NCT05813691|Diagnostic Test|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
79344924|NCT05813665|Drug|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
79496222|NCT01009931|Drug|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
79496223|NCT01009931|Drug|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
79496224|NCT03792191|Radiation|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
79496225|NCT03792191|Radiation|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
79496226|NCT03792191|Procedure|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
79496227|NCT03792191|Procedure|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
79496228|NCT03792191|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
79496229|NCT03792191|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
79496230|NCT03791489|Device|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
79496231|NCT03790865|Drug|Livoletide|Daily subcutaneous injection
79496232|NCT03790865|Drug|Placebo|Daily subcutaneous injection
79496233|NCT00986999|Drug|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
79496234|NCT02345369|Device|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
79659012|NCT01601548|Behavioral|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
79659013|NCT01601665|Device|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
79659014|NCT01601665|Device|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
79344925|NCT05813665|Drug|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
79496235|NCT02345369|Device|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
79659015|NCT01601665|Device|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
79985929|NCT03400033|Drug|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
79344926|NCT05813652|Other|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
79344927|NCT05813652|Other|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
79344928|NCT05813639|Procedure|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
79344929|NCT05813639|Procedure|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
79496236|NCT03784001|Behavioral|Gratitude + No Expectations Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
79496237|NCT03784001|Behavioral|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
79496238|NCT03784001|Behavioral|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
79496239|NCT03781037|Behavioral|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
79496240|NCT02319005|Drug|Revusiran (ALN-TTRSC)|
79496241|NCT02319005|Drug|Sterile Normal Saline (0.9% NaCl)|
79496242|NCT03784079|Drug|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
79496243|NCT03784079|Drug|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
79496244|NCT00983645|Drug|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
79496245|NCT00983645|Drug|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
79496246|NCT02308475|Device|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
79496247|NCT02234687|Drug|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
79496248|NCT02234687|Drug|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
79496249|NCT02234687|Drug|Placebo|Placebo, one dose, one time
79496250|NCT00978419|Drug|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
79659016|NCT01601665|Device|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
79659017|NCT01601665|Device|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
79659018|NCT01601743|Behavioral|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
79814786|NCT04099680|Procedure|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
79814787|NCT04099680|Device|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
79814788|NCT04099680|Procedure|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
79814789|NCT04099680|Procedure|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
79496251|NCT00978419|Drug|Placebo|Placebo administered every day for up to 28 days
79496252|NCT00957827|Drug|keflex|keflex 500 mg BID 5 days
79496253|NCT00957827|Drug|placebo|placebo BID for five days
79496254|NCT00962429|Drug|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
79496255|NCT00950183|Device|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
79496256|NCT00950183|Other|Ice|postoperative cold therapy
79496257|NCT00949403|Drug|Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate|injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
79496258|NCT03767153|Device|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
79496259|NCT03766373|Combination Product|Drug: OP0201 20mg|OP0201
79496260|NCT03766373|Combination Product|Drug: Placebo 0mg|Placebo
79659019|NCT01601743|Behavioral|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
79659020|NCT01601743|Behavioral|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
79659021|NCT01601899|Drug|Stavudine|30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
79659022|NCT01601899|Drug|Stavudine|20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
79659023|NCT01601899|Drug|Tenofovir|300 mg po QD
79659024|NCT01601938|Dietary Supplement|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
79659025|NCT01601938|Dietary Supplement|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
79814790|NCT04099680|Procedure|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
79814791|NCT00766038|Drug|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
79814792|NCT00766038|Drug|Placebo|SC injection daily
79814793|NCT04100304|Diagnostic Test|resection|CT volumetry,liver function,biopsy before resection
79814794|NCT00765882|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
79814795|NCT00765882|Drug|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
79344930|NCT05813639|Procedure|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
79344931|NCT05813626|Drug|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
79344932|NCT05813600|Drug|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature >38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
79344933|NCT05813561|Drug|DWP14012|DWP14012 40mg
79344934|NCT05813522|Drug|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
79344935|NCT05813509|Device|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
79344936|NCT05813496|Drug|Alpha-Lipoic Acid (ALA)|Oral tablet
79659026|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
79814796|NCT00765882|Drug|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
79814797|NCT05297136|Procedure|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
79496261|NCT02110277|Device|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
79496262|NCT03760913|Drug|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
79814798|NCT05297136|Procedure|No Stent|No preoperative stenting with distal pancreatectomy alone
79496263|NCT03760913|Drug|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
79659027|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
79814799|NCT00769860|Drug|Arimoclomol|Arimoclomol 100 mg TID for 4 months
79814800|NCT00769860|Other|Placebo|Placebo for 4 months
79659028|NCT00257543|Procedure|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
79659029|NCT01602133|Procedure|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
79659030|NCT00416403|Drug|fluvastatin sodium|Given orally
79814801|NCT02600754|Behavioral|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
79496264|NCT03760913|Other|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
79496265|NCT03760913|Other|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
79496266|NCT00920309|Drug|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
79496267|NCT00920309|Other|Standard of Care-Placebo|
79496268|NCT00928499|Device|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
79496269|NCT02109809|Radiation|total nodal irradiation|Undergo TLI
79496270|NCT02109809|Other|laboratory biomarker analysis|Correlative studies
79496271|NCT02109809|Other|questionnaire administration|Ancillary studies
79496272|NCT02075411|Drug|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
79659031|NCT00416403|Procedure|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
79659032|NCT01602211|Other|Internet-Based Intervention|Receive full access to INSPIRE
79659033|NCT01602211|Other|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
79659034|NCT01602211|Other|Medical Chart Review|Ancillary studies
79659035|NCT01602211|Other|Quality-of-Life Assessment|Ancillary studies
79659036|NCT01602211|Other|Questionnaire Administration|Ancillary studies
79659037|NCT01602250|Drug|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
79814802|NCT02600754|Behavioral|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
79814803|NCT00858143|Other|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
79814804|NCT04118933|Drug|JS001|JS001 240mg, Q3W
79496273|NCT02075411|Drug|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
79344937|NCT05813496|Drug|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
79344938|NCT05813483|Other|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
79344939|NCT05813483|Other|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
79496274|NCT02075411|Device|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
79496275|NCT02075411|Device|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
79496276|NCT03753113|Drug|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
79344940|NCT05813470|Biological|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
79344941|NCT05813470|Biological|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
79496277|NCT03753113|Drug|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
79496278|NCT02084147|Device|positron emission tomography|Undergo PET
79496279|NCT02084147|Device|computed tomography|Undergo CT
79496280|NCT02084147|Device|magnetic resonance imaging|Undergo MRI
79496281|NCT02067611|Drug|X0002|Parallel Assignment
79496282|NCT02067611|Drug|Placebo|Parallel Assignment
79496283|NCT02075021|Drug|Lenalidomide|
79496284|NCT02075021|Drug|nab-paclitaxel|
79496285|NCT02057237|Drug|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
79496286|NCT03752567|Other|Follow up|like group descriptions
79496287|NCT00378677|Drug|Cyclosporine A dry powder inhalation (Drug)|
79496288|NCT03748979|Drug|TAK-925|TAK-925
79496289|NCT03748979|Drug|Placebo|TAK-925 Placebo
79496290|NCT00850421|Drug|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
79496291|NCT02017379|Drug|Erythromycin|
79496292|NCT02017379|Drug|Metoclopromide|
79659038|NCT01602250|Drug|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
79659039|NCT00257582|Drug|Cetirizine Dry Syrup|
79659040|NCT01602289|Biological|LY2875358|Administered IV
79659041|NCT01602289|Drug|Erlotinib|Administered orally
79659042|NCT01602289|Drug|Gefitinib|Administered orally
79659043|NCT00416442|Drug|RSV604|
79659044|NCT01602328|Biological|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
79659045|NCT01602328|Biological|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
79659046|NCT00257621|Drug|GW640385|
79659047|NCT00257621|Drug|Ritonavir|
79659048|NCT01602406|Drug|LJM716|LJM716
79659049|NCT01602406|Drug|Trastuzumab|Trastuzumab
79659050|NCT00290628|Drug|anti-thymocyte globulin|
79659051|NCT00290628|Drug|busulfan|
79659052|NCT00290628|Drug|cyclophosphamide|
79659053|NCT00290628|Drug|cyclosporine|
79659054|NCT00290628|Drug|filgrastim|
79659055|NCT00290628|Drug|melphalan|
79659056|NCT00290628|Drug|methylprednisolone|
79659057|NCT00290628|Drug|mycophenolate mofetil|
79344942|NCT05813405|Other|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
79344943|NCT05813379|Combination Product|exosime injection|Treatment- exosome injection
79344944|NCT05813366|Other|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
79344945|NCT05813366|Other|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
79496293|NCT04332263|Other|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
79496294|NCT01997567|Drug|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
79496295|NCT01997567|Drug|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
79496296|NCT03742973|Drug|Baricitinib|Administered orally.
79659058|NCT00290628|Procedure|radiation therapy|
79659059|NCT00290628|Procedure|umbilical cord blood transplantation|
79814805|NCT00913367|Drug|glimepiride + insulin glargine (Amaryl + Lantus)|"Amaryl® 4 mg at breakfast + Lantus® at dinner~The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
79659060|NCT01602523|Drug|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
79659061|NCT01602523|Drug|Placebo|Placebo inhaler once daily 28 days
79659062|NCT00415298|Drug|DACH polymer platinate AP5346|
79659063|NCT00415298|Drug|oxaliplatin|
79659064|NCT00415298|Genetic|gene expression analysis|
79659065|NCT00415298|Other|immunohistochemistry staining method|
79659066|NCT00415298|Other|pharmacological study|
79659067|NCT00415298|Procedure|biopsy|
79659068|NCT01602601|Drug|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
79659069|NCT01602601|Drug|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
79659070|NCT01602640|Drug|Morphine infusion|Conventional dose
79659071|NCT01602640|Drug|Fentanyl and Midazolam infusion|Conventional dose
79659072|NCT00290667|Biological|pegfilgrastim|
79659073|NCT00290667|Biological|rituximab|
79659074|NCT00290667|Drug|cyclophosphamide|
79659075|NCT00290667|Drug|doxorubicin hydrochloride|
79659076|NCT00290667|Drug|prednisone|
79659077|NCT00290667|Drug|vincristine sulfate|
79659078|NCT00290667|Other|pharmacological study|
79659079|NCT00290667|Radiation|radiation therapy|
79659080|NCT01602757|Drug|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
79659081|NCT02961101|Drug|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
79496297|NCT03742973|Drug|Placebo|Administered orally.
79496298|NCT03742427|Diagnostic Test|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
79344946|NCT05813366|Other|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
79496299|NCT03741725|Other|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
79496300|NCT03741725|Other|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
79659082|NCT02961101|Drug|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
79659083|NCT02961101|Drug|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
79659084|NCT01602913|Drug|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
79659085|NCT01602913|Drug|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
79814806|NCT00913367|Drug|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
79814807|NCT00922805|Dietary Supplement|guar gum|guar gum (20 g/l of formula) for one week
79814808|NCT00704015|Behavioral|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
79814809|NCT00828113|Drug|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
79344947|NCT05813340|Procedure|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
79344948|NCT05813249|Drug|Rybelsus Oral Product|Oral Semaglutide
79344949|NCT05813249|Drug|Ozempic Injectable Product|Subcutaneous Semaglutide
79344950|NCT05813249|Drug|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
79496301|NCT00825227|Drug|Armodafinil 150 mg/day|"150 mg/day armodafinil~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
79496302|NCT00825227|Drug|Placebo,|"placebo~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
79496303|NCT01978535|Drug|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
79496304|NCT01978535|Drug|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
79496305|NCT00808769|Drug|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
79496306|NCT00808769|Drug|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
79496307|NCT00378131|Drug|RC-1291|
79496308|NCT00378131|Drug|placebo|
79814810|NCT00828113|Drug|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
79814811|NCT00828113|Behavioral|Individual smoking cessation counseling|Brief (<10 minutes) smoking cessation counseling delivered at clinic visits
79814812|NCT00704093|Device|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
79814813|NCT00707135|Drug|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
79814814|NCT00769704|Biological|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
79344951|NCT05813210|Diagnostic Test|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
79496309|NCT01974635|Device|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
79344952|NCT05813197|Behavioral|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
79344953|NCT05813197|Behavioral|Usual services|Usual services
79344954|NCT05813184|Drug|Antibiotics|Any antibiotic therapy administered > 7 days
79344955|NCT05813171|Dietary Supplement|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
79344956|NCT05813171|Drug|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
79496310|NCT00379067|Drug|Tamsulosin OCAS|Adrenoceptor antagonist
79496311|NCT00379067|Drug|Placebo|placebo
79496312|NCT01937507|Drug|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
79496313|NCT00379223|Procedure|vitrectomy with radial optic neurotomy|
79659086|NCT01602913|Drug|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
79496314|NCT00378287|Drug|rabeprazole sodium|
79814815|NCT00769704|Biological|GM-CSF|125 µg/m² subcutaneous injection
79344957|NCT05813145|Drug|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
79496315|NCT01938833|Drug|Romidepsin|
79496316|NCT01938833|Drug|Abraxane|
79659087|NCT01602952|Drug|Radotinib|50mg, 100mg or 200mg Capsule BID
79659088|NCT01602991|Procedure|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
79814816|NCT00818753|Drug|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
79814817|NCT00818753|Drug|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
79344958|NCT05813145|Drug|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
79344959|NCT05813106|Drug|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
79344960|NCT05813106|Drug|normal saline|normal saline
79344961|NCT05813093|Device|rTMS|Accelerated iTBS treatment
79496317|NCT01893359|Drug|riboflavin ophthalmic solution, 0% dextran|
79814818|NCT00818753|Drug|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
79814819|NCT00704249|Drug|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
79814820|NCT00704249|Drug|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
79814821|NCT00765726|Biological|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
79814822|NCT00765726|Procedure|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
79344962|NCT05813054|Dietary Supplement|HA matrix ingredient|1 capsule/day
79344963|NCT05813054|Dietary Supplement|Placebo|1 capsule/day
79496318|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
79496319|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
79496320|NCT01893359|Procedure|Laser-assisted in situ keratomileusis|
79496321|NCT05313503|Other|ketogenic diet|We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
79496322|NCT00795665|Drug|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
79344964|NCT05813028|Other|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
79659089|NCT01602991|Procedure|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
79659090|NCT00257699|Drug|Metronidazole placebo|
79659091|NCT00257699|Drug|ciprofloxacin placebo|
79659092|NCT00257699|Drug|ciprofloxacin|500 mg bid po
79659093|NCT00257699|Drug|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
79659094|NCT01603030|Drug|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
79659095|NCT01603030|Drug|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
79228202|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
79344965|NCT05813015|Drug|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
79344966|NCT05813015|Drug|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
79659096|NCT01603069|Drug|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
79659097|NCT01603069|Drug|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
79659098|NCT01603069|Drug|Placebo|Placebo to AZD3241 BID
79659099|NCT00257738|Biological|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
79659100|NCT00257738|Biological|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
79659101|NCT01603108|Drug|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
79659102|NCT01603108|Drug|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
79659103|NCT00290823|Drug|Albendazole|400 mg tablet taken orally twice daily
79659104|NCT00290823|Drug|Dexamethasone|6mg or 8mg taken daily
79659105|NCT00290823|Drug|Omeprazole|20 mg tablet taken orally daily
79659106|NCT01603186|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
79659107|NCT01603186|Drug|Quetiapine Fumarate|25 mg tablet once a day
79659108|NCT02484937|Other|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
79228203|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
79659109|NCT02484937|Other|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
79659110|NCT00257777|Procedure|Myocardial protection techniques|
79659111|NCT00271284|Drug|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
79659112|NCT00271284|Drug|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
79659113|NCT02480257|Behavioral|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
79659114|NCT02487043|Behavioral|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
79228204|NCT03162783|Drug|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
79228205|NCT02523144|Drug|Chloral Hydrate|70mg/kg chloral hydrate
79228206|NCT02523144|Drug|Dexmedetomidine|2mcg/kg
79228207|NCT02523144|Drug|Dexmedetomidine|3mcg/kg
79228208|NCT02523144|Drug|Placebo|Flavored placebo syrup
79308207|NCT02505581|Drug|Metronidazole 250 mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
79659115|NCT00257816|Drug|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
79344967|NCT05813002|Other|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
79344968|NCT05813002|Other|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
79496323|NCT00795665|Drug|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
79496324|NCT00791843|Drug|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
79496325|NCT01836809|Drug|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
79496326|NCT01836809|Drug|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
79659116|NCT00257816|Drug|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
79659117|NCT01603303|Behavioral|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
79659118|NCT01603303|Other|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
79659119|NCT01603303|Other|Luvena|Use vaginally 2 or 3 times a week.
79659120|NCT01603303|Other|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
79659121|NCT01603303|Other|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
79659122|NCT01603303|Behavioral|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
79814823|NCT04100226|Dietary Supplement|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
79814824|NCT00765336|Drug|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
79344969|NCT05813002|Other|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
79496327|NCT00780455|Drug|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
79496328|NCT00780455|Drug|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
79496329|NCT00755261|Drug|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
79496330|NCT00755261|Drug|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
79985930|NCT03400033|Drug|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
79344970|NCT05812937|Procedure|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
79344971|NCT05812872|Drug|Toothgraft|Particulate dentin
79985931|NCT02995902|Device|FLT-PET|
79985932|NCT02995902|Device|MRI|
79344972|NCT05812872|Drug|Allograft|Mineralized corticocancellous allograft
79344973|NCT05812872|Drug|Alloplast|Beta tri-calcuim phosphate
79659123|NCT01603303|Behavioral|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
79659124|NCT00271323|Drug|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
79659125|NCT00271323|Radiation|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
79814825|NCT00765336|Drug|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
79814826|NCT00818519|Drug|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
79814827|NCT00818519|Drug|Placebo|Inert tablet
79814828|NCT00827567|Drug|RAD 001|RAD 001-10 mg by mouth once everyday
79814829|NCT00765102|Drug|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
79308208|NCT02505581|Drug|Cefuroxime 1.5 g Intravenous|An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
79308209|NCT02505581|Drug|Metronidazole 1 g Intravenous|An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
79344974|NCT05812833|Behavioral|Education|Pregnant women will be given online baby care training
79344975|NCT05812781|Drug|VTX2735|Dose A
79344976|NCT05812781|Drug|VTX2735|Dose B
79344977|NCT05812729|Behavioral|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
79344978|NCT05812716|Behavioral|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
79344979|NCT05812677|Drug|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
79814830|NCT00765102|Drug|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m^2.
79814831|NCT00809354|Drug|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
79985933|NCT05123820|Drug|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
79985934|NCT05123820|Drug|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
79985935|NCT04089761|Device|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
79985936|NCT03118518|Device|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
79496331|NCT00748085|Device|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
79496332|NCT03725033|Drug|Subetta|Oral administration.
79496333|NCT03725033|Drug|Placebo|Oral administration.
79496334|NCT03724877|Drug|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
79496335|NCT03724877|Drug|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
79496336|NCT03724253|Drug|[68Ga]-NeoBOMB1|[68Ga]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
79344980|NCT05811624|Behavioral|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
79496337|NCT05313113|Behavioral|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
79496338|NCT01809899|Behavioral|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
79496339|NCT01809899|Behavioral|Consent as Usual|Routine informed consent procedures
79496340|NCT00746603|Drug|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
79496341|NCT05312957|Other|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
79496342|NCT04713527|Diagnostic Test|Cultivation and PCR within 24 hours|During operation for appendicitis peritoneal fluid will be extracted. This is sent to cultivation and PCR analysis to determine if there is bacteria within the peritoneal cavity.
79496343|NCT04713527|Drug|Enteral antibiotics|Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
79814832|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
79814833|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
79814834|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
79496344|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
79496345|NCT00716807|Drug|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
79814835|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
79496346|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
79496347|NCT00716807|Drug|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
79496348|NCT03461705|Device|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
79814836|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
79814837|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
79344981|NCT05811624|Behavioral|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
79496349|NCT03461705|Device|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
79496350|NCT03426137|Drug|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
79496351|NCT03426137|Drug|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
79344982|NCT05810987|Other|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~Introduction~Preparing for and introducing a conversation [Consider personal bias /Building rapport /Ask permission]~Assessing understanding [Avoid correcting /Open ended questions]~Giving information [Give a warning shot /Using silence /Wish/worry/wonder]~Explore goals [Reflective listening /Naming, validating emotion~Summarizing and recommending a plan [Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)]"
79496352|NCT03426137|Other|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
79496353|NCT04706351|Other|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
79496354|NCT05283863|Device|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
79659126|NCT01603342|Drug|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
79344983|NCT05810987|Behavioral|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
79344984|NCT05810025|Behavioral|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
79496355|NCT05283863|Device|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
79659127|NCT01603342|Drug|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
79659128|NCT01603381|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
79659129|NCT00257855|Drug|Lamotrigine|
79659130|NCT00290862|Device|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
79659131|NCT01603498|Drug|Dexamethasone|Dexamethasone 8mg
79496356|NCT05283863|Device|Conventional spinal cord stimulation|Patients will receive conventional spinal cord stimulation (aka 60Hz, aka tonic stimulation, aka paresthesia-based stimulation) for 2 weeks
79496357|NCT01760993|Drug|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
79496358|NCT00669461|Drug|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
79659132|NCT01603498|Drug|Methylprednisolone|Methylprednisolone 40mg
79659133|NCT01603576|Device|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
79814838|NCT00834899|Drug|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
79496359|NCT00673595|Drug|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
79496360|NCT00673595|Drug|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
79344985|NCT05809570|Diagnostic Test|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
79344986|NCT05809531|Drug|Pegcetacoplan|Complement (C3) Inhibitor
79659134|NCT01603654|Drug|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
79344987|NCT05808582|Drug|chidamide，fulvestrant|chidamide combined with fulvestrant
79496361|NCT00670631|Combination Product|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 & 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
79496362|NCT03248141|Drug|Hemophilia B standard half-life|Benefix
79659135|NCT01603654|Drug|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
79344988|NCT05808400|Biological|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1*10^9 particles/ml.
79344989|NCT05805787|Other|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
79344990|NCT05800002|Procedure|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
79344991|NCT05800002|Procedure|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
79344992|NCT05796804|Procedure|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
79659136|NCT00257972|Drug|aripiprazole|
79659137|NCT00271362|Behavioral|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
79344993|NCT05796804|Procedure|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
79344994|NCT05796804|Procedure|spinal anesthesia|bupivacaine 0.5% 2.2 ml
79344995|NCT05788887|Other|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
79659138|NCT00271362|Procedure|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
79659139|NCT01603693|Device|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
79814839|NCT00834899|Drug|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
79814840|NCT04100460|Dietary Supplement|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
79308210|NCT03343847|Biological|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
79308211|NCT03343847|Other|Placebo|Placebo Comparator
79344996|NCT05788887|Other|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
79344997|NCT05788874|Diagnostic Test|18F-FAPI and 18F-FDG PET/CT|18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
79344998|NCT05788289|Drug|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
79344999|NCT05788289|Drug|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
79345000|NCT05775887|Biological|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
79496363|NCT03248141|Drug|Hemophilia B extended half-life|Alprolix
79345001|NCT05775887|Biological|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
79345002|NCT05774431|Other|There was no intervention necessary.|There was no intervention necessary.
79345003|NCT05766189|Behavioral|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
79496364|NCT03248141|Drug|Hemophilia A standard half-life|Xyntha and other standard half-life agents
79496365|NCT03248141|Drug|Hemophilia A extended half-life|Eloctate and Adynovate
79496366|NCT00378365|Procedure|Arsenic trioxide|Arsenic trioxide
79496367|NCT00378365|Procedure|ATRA|ATRA
79496368|NCT05313425|Other|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
79345004|NCT05760560|Drug|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
79345005|NCT05758090|Procedure|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score > 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score < 50 indicates inadequate narcotic and narcotic should be given.
79345006|NCT05758090|Procedure|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
79496369|NCT01754987|Drug|Ascorbic Acid + Sorafenib|
79496370|NCT01754987|Drug|Sorafenib|
79496371|NCT01732211|Biological|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
79496372|NCT01732211|Other|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
79496373|NCT05600153|Procedure|implant exchange operation|To perform implant exchange via axillary incision.
79496374|NCT00652457|Drug|Memantine|10 mg BID x 3 months
79496375|NCT00645359|Procedure|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
79496376|NCT01681589|Device|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
79496377|NCT01681589|Device|Control Group|This group will receive Sham TDCS
79496378|NCT01681589|Other|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
79496379|NCT00625703|Drug|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
79496380|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
79496381|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
79496382|NCT00616577|Drug|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
79985937|NCT03118518|Drug|Antiarrhythmic drug|Antiarrhythmic drug initiation
79345007|NCT05757388|Drug|Parecoxib + paracetamol|Administers after induction of anesthesia.
79496383|NCT00616343|Drug|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
79814841|NCT04100460|Dietary Supplement|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
79496384|NCT05599997|Drug|Pecavaptan (BAY1753011)|30 mg, immediate release tablet, single dose, oral
79345008|NCT05757388|Drug|Normal saline|Administers after induction of anesthesia.
79345009|NCT05755334|Drug|Ropivacaine|Administration of Ropivacaine
79496385|NCT05599997|Drug|Pecavaptan (BAY1753011)|15 mg, immediate release tablet, single dose, oral
79496386|NCT05599919|Drug|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
79814842|NCT04100460|Dietary Supplement|Control - No Arabinoxylan|Participants are given no Arabinoxylan
79814843|NCT00764946|Drug|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
79345010|NCT05746299|Behavioral|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
79496387|NCT05599607|Dietary Supplement|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
79659140|NCT01603693|Device|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
79985938|NCT03984305|Device|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording."
79496388|NCT05599607|Dietary Supplement|Placebo|Maltodextrin
79496389|NCT01645709|Drug|Verapamil|
79496390|NCT01645709|Drug|Placebo|
79228209|NCT03304574|Behavioral|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
79228210|NCT02469272|Drug|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
79228211|NCT05154942|Device|DOXO+electroacupuncture|DOXO+electroacupuncture
79228212|NCT03894306|Other|Medication lock box|given a lock box and instructed on how to use the device.
79228213|NCT03894306|Other|medication lock bag|given a lock bag and instructed on how to use the device.
79228214|NCT03894306|Other|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
79228215|NCT00704132|Drug|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
79228216|NCT00704132|Drug|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
79228217|NCT03304496|Drug|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
79228218|NCT03304496|Drug|Saline Solution|Previously described.
79345011|NCT05746299|Behavioral|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
79814844|NCT00764868|Drug|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
79814845|NCT00764790|Biological|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
79814846|NCT00764790|Biological|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
79823674|NCT00790959|Behavioral|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
79496391|NCT05599529|Other|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
79345012|NCT05746299|Behavioral|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
79496392|NCT05270993|Behavioral|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
79345013|NCT05741606|Drug|Sodium pentaborate pentahydrate|Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
79496393|NCT05270993|Behavioral|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
79659141|NCT01603771|Other|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
79659142|NCT02960685|Procedure|Echocardiography|
79345014|NCT05741606|Drug|Placebo|Placebo capsules
79659143|NCT01603810|Other|OCT|Optical coherence tomography of periocular basal cell carcinoma
79345015|NCT05729334|Device|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~for EUCLIDES 3D, a two reference points selected by the investigator."
79659144|NCT00258050|Drug|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
79659145|NCT00258050|Drug|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
79659146|NCT01603888|Other|no intervention|
79659147|NCT00271401|Other|Angioplasty|
79345016|NCT05717205|Diagnostic Test|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
79345017|NCT05707182|Drug|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
79345018|NCT05704322|Other|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
79345019|NCT05701891|Combination Product|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
79345020|NCT05701891|Other|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
79345021|NCT05692921|Other|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
79345022|NCT05692921|Other|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
79345023|NCT05691140|Other|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
79345024|NCT05688735|Other|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
79496394|NCT05267483|Other|No intervention|No intervention
79496395|NCT00608465|Drug|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
79496396|NCT00608465|Drug|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
79496397|NCT00608777|Drug|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
79659148|NCT00271401|Other|Intracoronary Stent|
79659149|NCT00271401|Drug|Abxicimab|
79659150|NCT00271401|Drug|Heparin|
79659151|NCT00271401|Drug|Placebo|
79659152|NCT01604005|Radiation|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
79659153|NCT00258089|Drug|Levofloxacin|
79659154|NCT01604044|Drug|Meropur 150 a day|one subcutaneous injection a day
79659155|NCT01604044|Drug|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
79659156|NCT01604161|Drug|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
79345025|NCT05688735|Other|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
79345026|NCT05627596|Behavioral|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
79496398|NCT00379301|Procedure|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
79496399|NCT00379379|Device|electroacupuncture|
79659157|NCT00290901|Drug|Tramadol Hydrochloride 50mg|
79496400|NCT00379457|Biological|dactinomycin|
79496401|NCT00379457|Drug|carboplatin|
79659158|NCT00290901|Drug|Celebrex 200mg|
79659159|NCT00258167|Behavioral|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
79814847|NCT05748548|Other|Thoracic kyphosis- Lumbal Lordosis angle measurement|In order to determine the kyphosis, the degrees determined by measuring the spinous processes of the T12 T1, T2 and L1 vertebrae with an inclinometer while the individuals are standing will be collected. In order to determine the degree of lumbar lordosis, the measurement between the spinous processes of the T12L1 and S2S3 vertebrae will be made and the degree of lordosis will be determined by adding the degrees found. While the reference values for thoracic kyphosis are 20-45 degrees, this value is 20-40 degrees for lordosis. These measurements will be made with an inclinometer. Measurements will be repeated 3 times and the results will be recorded by taking the average of the measurements.
79814848|NCT05748548|Other|Back Muscle Endurance Test - Sorenson Test|The endurance of the back muscles will be evaluated with the Biering Sorensen Test (Static Back Endurance Test).
79814849|NCT05748548|Other|Surface EMG activation|We will try to find out which of the exercises such as pressing back the back, waist extension on the balance ball, lumbar extension while in the active prone position, Superman exercises have better lumbar extensor muscle activations.Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
79496402|NCT00379457|Drug|cyclophosphamide|
79496403|NCT00379457|Drug|doxorubicin hydrochloride|
79496404|NCT00379457|Drug|etoposide|
79496405|NCT00379457|Drug|ifosfamide|
79308212|NCT02451293|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|
79345027|NCT05627596|Drug|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
79345028|NCT05627596|Drug|Nicotine lozenge|4mg nicotine lozenge
79496406|NCT00379457|Drug|topotecan hydrochloride|
79496407|NCT00379457|Drug|vincristine sulfate|
79496408|NCT00379457|Drug|vinorelbine tartrate|
79496409|NCT00379457|Procedure|conventional surgery|
79496410|NCT00379457|Radiation|radiation therapy|
79496411|NCT01643525|Device|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
79496412|NCT01629329|Drug|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
79496413|NCT01629329|Drug|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
79496414|NCT01606709|Drug|GnRH agonist|GnRH agonist 1mg one dose
79496415|NCT01606709|Drug|hCG|5,000 IU one dose
79496416|NCT00423059|Drug|bevacizumab|
79496417|NCT00585611|Drug|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
79496418|NCT00585611|Other|placebo|placebo
79496419|NCT00379535|Drug|potassium iodide|per os
79496420|NCT00379535|Drug|placebo|per os
79659160|NCT01604200|Behavioral|focus group|key informant review
79659161|NCT01604239|Drug|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
79659162|NCT01604356|Procedure|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
79659163|NCT04708314|Drug|Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]|Vyondys 53
79659164|NCT00258245|Dietary Supplement|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11
79659165|NCT00258245|Drug|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
79659166|NCT00258245|Drug|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
79345029|NCT05619198|Behavioral|High Intensity Interval Exercise|"High Intensity Interval Exercise:~5 minutes resting phase @ 0 watts.~5-minute warm up phase @ 20 watts.~40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to ~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~5 minutes resting phase @ 0 watts."
79345030|NCT05619198|Behavioral|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~5 minutes resting phase @ 0 watts.~5-minute warm up phase @ 20 watts.~40 minutes of MICE 65% VO2max.~5 minutes resting phase @ 0 watts."
79496421|NCT05596253|Procedure|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
79345031|NCT05593588|Drug|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
79496422|NCT01557881|Device|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center [SCC] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
79345032|NCT05593588|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
79814850|NCT03990896|Drug|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
79814851|NCT00756444|Drug|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
79345035|NCT05590871|Device|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
79496423|NCT00379613|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
79496424|NCT00379613|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
79496425|NCT00379691|Drug|phenylephrine|
79496426|NCT01685333|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
79496427|NCT01648907|Other|Imaging exams|"Radiological examinations:~Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
79496428|NCT01556009|Drug|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
79496429|NCT01556009|Drug|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
79659167|NCT00258245|Drug|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
79659168|NCT00258245|Drug|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
79659169|NCT00258245|Drug|Aspirin|Aspirin - 325 mg by mouth (PO) every day
79659170|NCT01604434|Procedure|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
79659171|NCT01604434|Procedure|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
79659172|NCT01604590|Radiation|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
79814852|NCT00756444|Drug|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
79345036|NCT05588882|Procedure|Wavefront-guided LASIK|Topography-guided utilizes topography mapping to perform the ablation
79345037|NCT05588882|Procedure|Wavefront-guided|Wavefront-guided utilizes aberrometry to perform the ablation
79496430|NCT04331951|Diagnostic Test|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
79345038|NCT05585294|Behavioral|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
79496431|NCT01521143|Biological|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
79496432|NCT01521143|Biological|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
79496433|NCT05529953|Dietary Supplement|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
79659173|NCT00271440|Procedure|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
79345039|NCT05582798|Drug|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
79345040|NCT05582798|Drug|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
79345041|NCT05582798|Drug|Sodium chloride|Sodium chloride 09.% intravenous infusion
79345042|NCT05574322|Other|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~Maximum muscle strength of the foot~Foot muscle morphology"
79496434|NCT05529953|Dietary Supplement|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
79496435|NCT00546455|Drug|Fenretinide|200 mg/day
79345043|NCT05574322|Other|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
79496436|NCT00546455|Drug|Placebo|2 capsules/day
79496437|NCT01525745|Radiation|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
79659174|NCT01604629|Drug|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
79659175|NCT01604629|Drug|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
79659176|NCT00258284|Drug|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
79659177|NCT00258284|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
79659178|NCT00290940|Drug|CS-917|
79659179|NCT00290940|Drug|metformin hydrochloride|
79659180|NCT00290940|Drug|pioglitazone|
79496438|NCT01525745|Radiation|External Beam Radiation Therapy|10 consecutive days of standard radiation
79496439|NCT05231057|Other|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
79496440|NCT05231057|Other|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
79659181|NCT01604707|Other|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
79659182|NCT00258323|Drug|cisplatin|20mg/m2d/IV continuous infusion x days
79659183|NCT00258323|Drug|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
79308213|NCT02451293|Drug|Placebo|
79496441|NCT00000737|Drug|Dronabinol|
79496442|NCT00000737|Drug|Megestrol acetate|
79496443|NCT00533351|Drug|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
79496444|NCT00533351|Drug|placebo|placebo 50 mg capsules three-times daily for 2 weeks
79496445|NCT00528437|Drug|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
79814853|NCT00756444|Drug|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
79814854|NCT04100616|Other|No intervention|There is no intervention for this study
79345044|NCT05574309|Device|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
79814855|NCT00769002|Biological|FluShield|Flu vaccine
79814856|NCT00769002|Biological|FluShield - same arm|Flu vaccine
79814857|NCT00769002|Biological|FluShield - opposite arm|Flu vaccine
79814858|NCT00769002|Procedure|Blood Draws|50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
79814859|NCT00769002|Procedure|FDG PET-CT Scan|PET scan
79814860|NCT00769002|Genetic|Cytokine Profiling|Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
79345045|NCT05574309|Device|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
79814861|NCT04100382|Device|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
79985939|NCT03984305|Device|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
79985940|NCT03397771|Drug|Litoxetine|oral study medication provided in a dose titration manner
79985941|NCT03397771|Drug|placebo|placebo medication provided in a dose titration manner
79308214|NCT03343769|Other|BERG scale|Complete the BERG balance scale
79308215|NCT03343769|Other|Functional tests|timed up and go, Mini motor test, retropulsion test
79345046|NCT05567640|Behavioral|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
79345047|NCT05567640|Behavioral|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
79345048|NCT05567640|Behavioral|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
79345049|NCT05552196|Drug|Ponesimod|Ponesimod tablet will be administered orally.
79496446|NCT05480735|Behavioral|Prehabilitation|Multimodal prehabilitation program
79659184|NCT00258323|Drug|Iressa|250mg po qd days 1-28 then x 2 years
79659185|NCT00258323|Procedure|conventional surgery|conventional surgery
79659186|NCT00258323|Radiation|radiation therapy|150 cGy bid
79345050|NCT05552196|Drug|Carbamazepine|Carbamazepine tablet will be administered orally.
79345051|NCT05538247|Drug|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
79496447|NCT00000743|Drug|Alvircept sudotox|
79496448|NCT00000743|Drug|Zidovudine|
79496449|NCT00506909|Drug|Oxytocin|20 IU BID or 40 IU BID
79496450|NCT00506909|Drug|Placebo|20 IU BID or 40 IU BID
79496451|NCT00500045|Drug|nicotinic acid|niacin 1500 mg po qd
79496452|NCT00000749|Biological|rgp120/HIV-1 SF-2|
79659187|NCT01604746|Biological|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
79659188|NCT01604863|Drug|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
79659189|NCT01604863|Drug|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
79659190|NCT01604863|Drug|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
79659191|NCT00290979|Drug|insulin glulisine|
79659192|NCT00258401|Dietary Supplement|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
79659193|NCT00258401|Procedure|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
79985942|NCT05009160|Device|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
79496453|NCT05404685|Device|Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 7 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
79345052|NCT05538247|Dietary Supplement|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
79823675|NCT00790959|Other|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
79496454|NCT05404685|Device|Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 12 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
79496455|NCT05204225|Other|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
79345053|NCT05538247|Drug|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
79345054|NCT05536258|Other|Fluid|The investigators will titrate fluid administration to maintain a RI > 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI > 90 over at least 85% of the intraoperative period.
79659194|NCT00258401|Procedure|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
79659195|NCT01604902|Other|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
79659196|NCT01604980|Dietary Supplement|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
79659197|NCT00271479|Biological|A, C, Y, W135 meningococcal polysaccharide vaccine|
79659198|NCT01605331|Drug|sustained-release recombinant human GH (SR-rhGH)|
79659199|NCT01605409|Procedure|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
79308216|NCT03343769|Other|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
79345056|NCT05531916|Other|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
79345057|NCT05496192|Drug|Nivolumab/rHuPH20|Specified dose on specified days
79345058|NCT05496192|Drug|Nivolumab|Specified dose on specified days
79659200|NCT01605409|Procedure|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
79496456|NCT05204225|Other|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
79496457|NCT00000767|Biological|TBC-3B Vaccine|
79496458|NCT00000767|Biological|Smallpox Vaccine|
79345059|NCT05493072|Other|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
79496459|NCT05383547|Drug|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
79496460|NCT00456989|Drug|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
79496461|NCT00456989|Drug|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
79496462|NCT00000773|Drug|Atovaquone|
79814862|NCT00753012|Drug|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
79814863|NCT00806156|Drug|NKTR-102 q14d|NKTR-102 given on a q14 day schedule
79496463|NCT00428207|Drug|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
79985943|NCT03711721|Dietary Supplement|Food basket|
79985944|NCT03711721|Dietary Supplement|Ready-to-Use Therapeutic Food|
79985945|NCT02876835|Drug|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
79496464|NCT00428207|Drug|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
79496465|NCT00000791|Drug|Glycovir|
79496466|NCT00000791|Drug|Zidovudine|
79496467|NCT00379847|Drug|conivaptan|IV
79496468|NCT05252741|Other|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
79496469|NCT00374543|Drug|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
79496470|NCT00374543|Drug|Placebo|Placebo administered daily for 8 weeks
79496471|NCT00000803|Drug|Delavirdine mesylate|
79496472|NCT00000803|Drug|Zidovudine|
79496473|NCT00000803|Drug|Didanosine|
79496474|NCT00314093|Drug|RFT5pdgA|
79496475|NCT00299195|Drug|sulindac|Sulindac 150 mg po bid x 24 weeks
79496476|NCT00299195|Drug|Placebo|Placebo bid x 24 weeks
79496477|NCT01351415|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
79496478|NCT01351415|Drug|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m^2) on Day 1 every 21 days.
79496479|NCT01351415|Drug|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
79496480|NCT01351415|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV over 10 minutes on Day 1 every 21 days.
79496481|NCT00281879|Biological|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
79496482|NCT00281879|Biological|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
79496483|NCT00281879|Drug|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
79496484|NCT00281879|Drug|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
79496485|NCT00281879|Drug|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
79496486|NCT00281879|Drug|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
79496487|NCT00281879|Drug|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
79496488|NCT00281879|Drug|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
79496489|NCT00281879|Drug|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
79496490|NCT00281879|Drug|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
79496491|NCT00281879|Drug|methotrexate|Administered on days +1, +3, and +7.
79496492|NCT00281879|Drug|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
79496493|NCT00281879|Drug|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
79814864|NCT00806156|Drug|NKTR-102 q21d|NKTR-102 given on a q21 day schedule
79814865|NCT00764478|Drug|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
79814866|NCT00764478|Drug|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
79308217|NCT03343769|Other|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
79308218|NCT03343769|Other|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
79308219|NCT03220139|Other|fat intake|Observational study on fat intake and mortality
79308220|NCT02505191|Drug|St. John's wort prolonged-release tablet 500 mg|
79308221|NCT02505191|Drug|St. John's wort film coated tablets 250 mg|
79308222|NCT04497077|Dietary Supplement|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
79308223|NCT04497077|Dietary Supplement|placebo|either cornstarch capsule or kool-aid
79308224|NCT02505035|Behavioral|Default ordering of palliative consult|
79308225|NCT03119753|Device|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
79308226|NCT03119753|Device|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
79308227|NCT03220061|Behavioral|music therapy|
79308228|NCT02505113|Drug|Montelukast|Montelukast (10mg, q.d., p.o.)
79308229|NCT02504957|Procedure|Photodynamic therapy using polyhematoporphyrin|
79308230|NCT03343691|Diagnostic Test|Screening Population|Blood samples taken from screening population
79308231|NCT03343691|Diagnostic Test|Breast Cancer Population|Blood samples taken from Breast Cancer population
79308232|NCT03219515|Drug|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
79308233|NCT03219515|Drug|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
79308234|NCT03216317|Behavioral|Intervention Group|Isometric handgrip training consisting of four series
79345060|NCT05477758|Behavioral|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
79345061|NCT05477758|Other|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
79345062|NCT05477758|Behavioral|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
79345063|NCT05472623|Drug|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
79345064|NCT05472623|Combination Product|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
79345065|NCT05466110|Device|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
79345066|NCT05466110|Procedure|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
79345067|NCT05442775|Drug|Reldesemtiv|Oral tablet
79345068|NCT05438394|Drug|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
79345069|NCT05407610|Procedure|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
79345070|NCT05407610|Procedure|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
79496494|NCT00281879|Drug|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
79814867|NCT00764478|Drug|Placebo|placebo sublingual tablet, administered BID for 21 days
79345071|NCT05407610|Procedure|Sham procedure|Sham procedure with placing of needles subcutaneously.
79345072|NCT05386030|Combination Product|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
79345073|NCT05386030|Combination Product|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
79345074|NCT05368493|Other|MRI task|Task fMRI (Simon) [ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. ] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
79345075|NCT05349331|Procedure|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
79345076|NCT05345730|Diagnostic Test|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
79496495|NCT00281879|Procedure|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
79814868|NCT05755022|Procedure|Maxillary Segment Repositioning|"Le-Fort I osteotomy will be made using the cutting guide.~Mobilization of the maxilla will be done.~The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~While the guide in place, the plates will be fixed into their intended position.~After fixation of the plates, the guide will be removed."
79496496|NCT00281879|Procedure|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
79496497|NCT00281879|Radiation|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
79823676|NCT02580812|Other|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
79985946|NCT02876835|Drug|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
79985947|NCT02876835|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
79345077|NCT05330611|Device|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
79496498|NCT05153057|Other|Observational study|The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
79496499|NCT00000809|Biological|Aluminum hydroxide|
79496500|NCT00000809|Biological|QS-21|
79496501|NCT00000809|Biological|MN rsgp120/HIV-1|
79496502|NCT00000815|Biological|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
79496503|NCT00000815|Biological|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
79496504|NCT00240227|Drug|Prazosin|FDA approved medication for hypertension
79496505|NCT00240227|Drug|placebo|
79659201|NCT00258479|Drug|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
79659202|NCT00258479|Drug|Modafinil|See Modafinil Intervention Description above.
79659203|NCT00271518|Drug|growth hormone (somatropin)|dosing regimen is weight based.
79659204|NCT01340014|Drug|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
79659205|NCT01340014|Drug|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
79659206|NCT00258518|Procedure|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
79659207|NCT00291057|Drug|MALG|30 minute application
79659208|NCT00258557|Drug|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
79659209|NCT00258557|Drug|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
79659210|NCT00271557|Drug|nesiritide|
79496506|NCT00205049|Drug|pentoxifylline|daily dosing
79496507|NCT00000833|Drug|Ribavirin|
79496508|NCT00000833|Drug|Didanosine|
79496509|NCT00176501|Biological|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
79496510|NCT00000839|Drug|Didanosine|
79496511|NCT00133679|Drug|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
79496512|NCT00133679|Drug|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
79496513|NCT00000845|Biological|P3C541b Lipopeptide|
79496514|NCT00000875|Drug|Indinavir sulfate|
79496515|NCT00000875|Drug|Diphenhydramine hydrochloride|
79496516|NCT00000875|Drug|Lymphocytes, Activated|
79496517|NCT00000875|Drug|Lamivudine|
79496518|NCT00000875|Drug|Zidovudine|
79496519|NCT00000875|Drug|Acetaminophen|
79496520|NCT00000875|Drug|Aldesleukin|
79496521|NCT04941833|Drug|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
79496522|NCT04890041|Drug|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10^9/L and 150×10^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10^9/L, the treatment was stopped. If the platelet count is more than 400×10^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
79496523|NCT04874909|Other|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~subject less than 5 kg : 1.8 to 4.5 ml max~subject 5 kg to 10 kg : 4.5 to 9 ml max~subject 10 kg to 15 kg : 9 to 13.5 ml~subject 15 kg to 20 kg : 13.5 to 15 ml max"
79496524|NCT04874909|Other|Urine sample|Urine sample (500 ml) once time
79496525|NCT04841369|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
79496526|NCT04841369|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
79496527|NCT00379925|Behavioral|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
79496528|NCT00002975|Drug|aminolevulinic acid|
79985948|NCT02876835|Drug|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
79496529|NCT02221817|Procedure|Trochanter bursa injections|
79496530|NCT02221817|Device|Ultrasound|
79659211|NCT01339897|Drug|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
79659212|NCT01339897|Drug|Placebo|Same administration procedures as active
79496531|NCT00521885|Drug|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
79985949|NCT04086641|Device|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
79308235|NCT02504801|Drug|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
79308236|NCT02504567|Device|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
79308237|NCT02504567|Device|RF ablation|Pulmonary vein isolation using the RF ablation catheter
79308238|NCT02504411|Device|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
79308239|NCT02504411|Device|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
79496532|NCT00521885|Drug|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
79496533|NCT05239013|Drug|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
79985950|NCT04086641|Device|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
79659213|NCT01339897|Drug|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
79659214|NCT01339897|Drug|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
79659215|NCT00271635|Drug|Placebo|Placebo 4 capsules b.i.d. during 1 year
79659216|NCT00271635|Drug|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
79659217|NCT01339429|Device|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
79659218|NCT00258596|Device|sirolimus-eluting stent|
79659219|NCT01339390|Behavioral|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
79659220|NCT01339390|Behavioral|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
79659221|NCT01339273|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
79985951|NCT03503318|Drug|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm.
79345078|NCT05330611|Other|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
79345079|NCT05289089|Behavioral|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
79496534|NCT00000881|Drug|Cidofovir|
79496535|NCT00000881|Drug|Probenecid|
79496536|NCT00000887|Drug|Nelfinavir mesylate|
79496537|NCT00000887|Drug|Lamivudine|
79659222|NCT01339273|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
79659223|NCT00271674|Device|Q-switched YAG laser|
79659224|NCT01334866|Procedure|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
79496538|NCT00000887|Drug|Zidovudine|
79985952|NCT03503318|Drug|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm.
79345080|NCT05287191|Drug|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast AF persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance <60 ml/min measured by the MDRD formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone will be administered as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
79659225|NCT04709315|Drug|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
79496539|NCT03979079|Radiation|external beam radiation therapy|
79496540|NCT02973347|Other|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
79659226|NCT04709315|Drug|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
79659227|NCT01334710|Drug|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
79659228|NCT00271713|Drug|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
79659229|NCT00271713|Drug|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
79659230|NCT00258713|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
79659231|NCT01334554|Drug|Sildenafil|20 mg three times a day.
79659232|NCT01334554|Drug|Placebo|No active drug
79659233|NCT00291213|Drug|levetiracetam|
79814869|NCT05755022|Procedure|Maxillary Segment Repositioning|"Le-Fort I osteotomy will be made using the cutting guide.~Mobilization of the maxilla will be done.~The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~While the guide in place, the plates will be fixed into their intended position.~After fixation of the plates, the guide will be removed."
79659234|NCT00291213|Drug|placebo|
79659235|NCT01332799|Drug|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
79985953|NCT03396913|Device|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
79659236|NCT01332799|Other|Placebo|Sugar pill administered orally for 3 years.
79985954|NCT03396913|Device|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
79659237|NCT00258752|Behavioral|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
79659238|NCT00258752|Other|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
79496541|NCT02973347|Other|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
79659239|NCT00258752|Other|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
79659240|NCT00271752|Procedure|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
79659241|NCT00258791|Drug|Ibuprofen|
79659242|NCT00291369|Drug|Interleukin-2|
79659243|NCT00291369|Drug|Interferon alfa|
79659244|NCT00291369|Drug|medroxyprogesterone acetate|
79659245|NCT00291408|Procedure|Skin Prick Test|
79823677|NCT04047459|Other|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
79823678|NCT00782847|Behavioral|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
79496542|NCT04618991|Other|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
79496543|NCT00000119|Device|Heparin Surface-Modified Intraocular Lens|
79496544|NCT00000923|Drug|Indinavir sulfate|
79496545|NCT00000923|Drug|Lamivudine|
79496546|NCT00000923|Drug|Stavudine|
79496547|NCT00000923|Drug|Zidovudine|
79496548|NCT00000923|Drug|Didanosine|
79496549|NCT00000923|Drug|Aldesleukin|
79496550|NCT00000161|Drug|Aspirin|
79496551|NCT00000161|Drug|Beta-Carotene|
79496552|NCT00000161|Drug|Vitamin C|
79496553|NCT00000161|Drug|Vitamin E|
79659246|NCT00291408|Procedure|Impulse Oscillometry|
79659247|NCT00291408|Procedure|Exhaled Nitric Oxide|
79659248|NCT00291408|Procedure|Spirometry|
79659249|NCT00291408|Procedure|Reversibility|
79659250|NCT00291408|Procedure|Exhaled Breath Condensate|
79659251|NCT00291408|Procedure|Sputum Induction|
79659252|NCT00258947|Biological|Smallpox vaccine, LISTER strain, from chick embryo cells|
79659253|NCT00271791|Drug|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
79345081|NCT05287191|Drug|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
79345082|NCT05280652|Behavioral|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
79345083|NCT05280652|Behavioral|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
79496554|NCT04474145|Procedure|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
79345084|NCT05278052|Radiation|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
79345085|NCT05278052|Drug|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
79345086|NCT05268094|Device|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
79345087|NCT05268094|Procedure|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
79345088|NCT05259046|Dietary Supplement|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
79496555|NCT04474145|Procedure|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
79496556|NCT00000929|Drug|Nonoxynol-9|
79659254|NCT00271791|Drug|Prednisone|PO, Placebo, 17 days
79659255|NCT00258986|Procedure|Living donornephrectomy|
79496557|NCT00000167|Procedure|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
79659256|NCT01332331|Drug|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
79659257|NCT01332331|Drug|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
79345089|NCT05259046|Dietary Supplement|Placebo tablet|One placebo tablet per day
79345090|NCT05230212|Other|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
79345091|NCT05230212|Other|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
79345092|NCT05221632|Device|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
79345093|NCT05221632|Device|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
79345094|NCT05221632|Device|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
79345095|NCT05216042|Dietary Supplement|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
79345096|NCT05216042|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
79659258|NCT00259025|Drug|lipid emulsion with a high content of n-3 fatty acids|
79659259|NCT00291564|Device|Cardiac Resynchronization Therapy Device|
79659260|NCT00259064|Drug|Gefitinib|
79659261|NCT00259064|Other|Placebo|
79659262|NCT01332292|Drug|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
79659263|NCT01332292|Drug|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
79659264|NCT00271869|Procedure|Extracorporeal photoimmunotherapy|
79345097|NCT05216042|Other|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
79814870|NCT03968276|Other|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
79814871|NCT00805766|Drug|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
79345098|NCT05216042|Other|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
79345099|NCT05208216|Device|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
79659265|NCT00271908|Behavioral|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
79659266|NCT00291603|Device|FX-class of dialyser|
79659267|NCT00259103|Drug|Serelaxin|
79659268|NCT00259103|Drug|Placebo|
79814872|NCT02608970|Drug|BMS-986177|
79814873|NCT02608970|Other|Placebo|
79814874|NCT00805532|Behavioral|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
79659269|NCT00259142|Drug|Chloroquine, sulphadoxine-pyrimethamine|
79659270|NCT00259181|Procedure|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
79345100|NCT05208216|Device|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
79496558|NCT00000935|Biological|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
79496559|NCT00000197|Drug|Propranolol|
79659271|NCT00291720|Drug|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
79659272|NCT00291720|Drug|Placebo|matching placebo
79659273|NCT00259220|Drug|erythomycin|erythomycin
79659274|NCT00259220|Procedure|gastric lavage alone|gastric lavage alone
79659275|NCT00259220|Procedure|erythromycine and gastric lavage|erythromycine and gastric lavage
79659276|NCT00259259|Behavioral|SALATRIM|
79659277|NCT00291759|Drug|Tamoxifen|
79659278|NCT00291759|Drug|Anastrozole|
79659279|NCT00272025|Drug|Escitalopram|10mg to 20mg tablet daily for 6 weeks
79814875|NCT00805532|Other|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
79814876|NCT05752838|Other|No intervention|This is a survey study, and there were no intervention
79814877|NCT03947138|Biological|GC3107|BCG Vaccine
79659280|NCT00272025|Drug|placebo|
79659281|NCT00291798|Procedure|rate of remission|
79496560|NCT00000947|Drug|Azithromycin|
79496561|NCT04251611|Other|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
79659282|NCT04709081|Drug|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
79659283|NCT04709081|Drug|Midazolam|Midazolam was dosed at 2 mg (1 milliliter [mL] of a 2 mg/mL syrup).
79345101|NCT05207891|Device|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
79345102|NCT05206682|Drug|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
79345103|NCT05204082|Device|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
79659284|NCT04709081|Drug|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
79659285|NCT04709081|Drug|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
79659286|NCT00272064|Drug|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal < 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
79659287|NCT00272064|Drug|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) <= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
79985955|NCT03396913|Procedure|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
79345104|NCT05201937|Drug|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
79345105|NCT05192564|Other|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
79345106|NCT05192564|Other|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
79345107|NCT05153629|Device|TENS|TENS device used four times a day for 60 minutes each time
79345108|NCT05137236|Biological|mRNA-1283|Sterile liquid for injection
79345109|NCT05137236|Biological|mRNA-1283.211|Sterile liquid for injection
79345110|NCT05137236|Biological|mRNA-1273|Sterile liquid for injection
79345111|NCT05137236|Biological|mRNA-1283.529|Sterile liquid for injection
79345112|NCT05136612|Other|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
79659288|NCT00272064|Drug|Metformin|1000 mg b.i.d, since the qualification phase, oral
79814878|NCT03947138|Biological|Intradermal BCG SSI inj.|BCG Vaccine
79985956|NCT01375920|Drug|Metyrapone|500 milligrams to be taken twice a day orally
79985957|NCT01375920|Drug|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
79496562|NCT00000203|Drug|Buprenorphine|
79496563|NCT00000209|Drug|Buprenorphine|
79814879|NCT00764322|Drug|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
79985958|NCT03982433|Behavioral|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
79496564|NCT00000215|Drug|Pergolide|
79496565|NCT00000953|Drug|Sorivudine|
79659289|NCT00259337|Biological|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
79659290|NCT00259376|Drug|Dronedarone (SR33589)|oral administration
79659291|NCT00259376|Drug|placebo|oral administration
79659292|NCT00415337|Procedure|endobronchial ultrasound|EBUS
79659293|NCT01332019|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
79659294|NCT00291837|Drug|CT-2106|
79814880|NCT00764322|Genetic|gene expression analysis|Genetic analysis of blood sample.
79985959|NCT03396835|Device|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
79985960|NCT01375998|Drug|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
79345113|NCT05136612|Other|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
79659295|NCT02961140|Other|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
79659296|NCT02961140|Other|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
79659297|NCT00272103|Drug|Itopride (drug)|
79345114|NCT05130177|Drug|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
79345115|NCT05130177|Drug|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
79345116|NCT05129748|Drug|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
79345117|NCT05127746|Drug|Aricept 5mg Tablet|1 tablet once daily
79659298|NCT04718688|Other|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
79659299|NCT00415376|Drug|levetiracetam|
79985961|NCT03743597|Device|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
79985962|NCT03743597|Device|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
79345118|NCT05127746|Drug|Aricept 10mg Tablet|1 tablet once daily
79659300|NCT00415376|Procedure|quality-of-life assessment|
79814881|NCT00764322|Other|pharmacogenomic studies|Genetic analysis of blood sample.
79814882|NCT00764322|Other|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
79814883|NCT00764322|Procedure|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
79496566|NCT00000953|Drug|Acyclovir|
79496567|NCT00000983|Drug|Zidovudine|
79496568|NCT00000227|Drug|Buprenorphine|
79345119|NCT05127746|Drug|DA-5207 A|1 patch once weekly
79345120|NCT05127746|Drug|DA-5207 B|1 patch once weekly
79345121|NCT05062824|Behavioral|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. [Parental FFQ portal]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age [Clinician Portal]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component [Parent's Portal].
79659301|NCT00415454|Genetic|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
79659302|NCT00259415|Behavioral|Caregiver support via telephone|
79659303|NCT00272142|Drug|Zinc|
79659304|NCT00272142|Drug|Placebo|
79659305|NCT00259454|Behavioral|In-home intervention|occupational therapy techniques to reduce caregiver stress
79659306|NCT00291915|Drug|Adalimumab|
79659307|NCT00291915|Drug|Methotrexate|
79985963|NCT03683108|Drug|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
79985964|NCT03683108|Other|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
79345122|NCT05054218|Biological|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
79659308|NCT00259493|Procedure|Off-Pump Coronary Artery Bypass Graft Surgery|
79823679|NCT00785967|Biological|Various vaccines|VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
79345123|NCT05048316|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
79345124|NCT05007808|Drug|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
79496569|NCT00000233|Drug|Buprenorphine|
79496570|NCT00000239|Drug|Buprenorphine|
79496571|NCT00000245|Drug|Desipramine|
79496572|NCT00000263|Drug|30% Nitrous oxide|
79496573|NCT00000263|Other|0.25 g/Kg ethanol|
79496574|NCT00000263|Other|0.5 g/KG ethanol|
79496575|NCT00000263|Other|0 g/Kg ethanol|
79496576|NCT00000269|Drug|Pergolide|
79496577|NCT00380003|Drug|EVT 201|
79496578|NCT03967223|Drug|Letetresgene autoleucel (lete-cel, GSK3377794)|letetresgene autoleucel will be administered.
79659309|NCT00272181|Drug|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
79659310|NCT00259532|Procedure|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
79659311|NCT00291954|Biological|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
79496579|NCT03967223|Drug|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy
79496580|NCT03967223|Drug|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy.
79496581|NCT00000989|Drug|Zidovudine|
79496582|NCT00000989|Drug|Sargramostim|
79496583|NCT00000989|Drug|Ganciclovir|
79496584|NCT00000995|Drug|Zidovudine|
79496585|NCT00000995|Drug|Ganciclovir|
79496586|NCT00001019|Biological|rgp120/HIV-1 SF-2|
79496587|NCT00001019|Biological|MTP-PE/MF59|
79496588|NCT00001025|Drug|Zidovudine|
79496589|NCT00001025|Drug|Didanosine|
79496590|NCT00001031|Biological|rgp120/HIV-1MN|
79496591|NCT00001031|Biological|rgp120/HIV-1 SF-2|
79496592|NCT05440565|Diagnostic Test|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
79496593|NCT05440565|Diagnostic Test|APCS score|APCS score can concentrate the high-risk population.
79496594|NCT03118895|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
79659312|NCT00291954|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
79659313|NCT00259571|Drug|retarded release phosphatidylcholine|2g daily, given orally QTD
79659314|NCT00259688|Device|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
79985965|NCT05137860|Drug|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
79985966|NCT03682952|Drug|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
79985967|NCT03682952|Drug|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
79985968|NCT03682718|Device|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
79985969|NCT03682718|Drug|Misoprostol|Misoprstol inserted vaginally for induction of labor
79985970|NCT03682640|Drug|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
79985971|NCT03682640|Drug|Insulin Lispro|Solution for intravenous or subcutaneous use
79985972|NCT03682640|Behavioral|Dietician support|Dietary advice
79659315|NCT00272220|Behavioral|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
79345125|NCT05007808|Drug|Vehicle|Vehicle Gel for topical administration
79659316|NCT00272259|Procedure|Participants will interact with up to two small robots and a visual display|
79985973|NCT03682562|Diagnostic Test|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
79985974|NCT03687476|Drug|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
79496595|NCT03055247|Drug|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
79985975|NCT01376076|Drug|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
79985976|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
79985977|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
79985978|NCT03687398|Diagnostic Test|genetic testing with nanoclonal technique|endometrial sampling
79985979|NCT03121950|Other|Dance|The primary intervention is a dance class
79985980|NCT03121950|Other|Music|the secondary intervention is listening to live music
79985981|NCT03395353|Drug|Duloxetine Hydrochloride|Administered orally
79496596|NCT03055247|Drug|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
79496597|NCT03055247|Drug|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are < 10 /μL) to the day of the last LP.
79496598|NCT00001049|Drug|Zidovudine|
79345126|NCT05006040|Device|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system [25, 26]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days [30].
79496599|NCT00001049|Drug|Didanosine|
79659317|NCT00259766|Drug|Budesonide|
79659318|NCT00259766|Drug|Formoterol|
79985982|NCT03687242|Drug|SPR001|Open label SPR001
79985983|NCT05760066|Other|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
79985984|NCT05760066|Other|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
79985985|NCT03687164|Other|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
79345127|NCT04988477|Behavioral|Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 3 months.
79496600|NCT00001055|Biological|ALVAC-HIV MN120TMG (vCP205)|
79496601|NCT00001055|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
79496602|NCT00001055|Biological|rgp120/HIV-1 SF-2|
79496603|NCT00000275|Drug|Flupenthixol|
79659319|NCT00259766|Drug|Terbutaline|
79659320|NCT00292071|Drug|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
79985986|NCT05074758|Diagnostic Test|alveolar dead-space quantification|measurement of alveolar dead-space based on volumetric capnography
79823680|NCT03923504|Other|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 & 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
79985987|NCT05074758|Diagnostic Test|Coagulation activation and impaired fibrinolysis explorations|"blood sampling:~Fibrinolytic components~NETs components~Elastase-derived fragments of proteins of interest"
79985988|NCT05074758|Diagnostic Test|Endothelial activation / endothelial senescence|circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
79985989|NCT04082663|Device|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
79985990|NCT01376154|Drug|Lamivudine|
79496604|NCT00001061|Drug|Sevirumab|
79985991|NCT01562951|Drug|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
79985992|NCT01562951|Drug|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
79985993|NCT01375842|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure </= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
79985994|NCT03682367|Drug|Gabapentin|Use of Gabapentin peri- and post-operatively.
79985995|NCT03682367|Drug|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
79985996|NCT03677570|Diagnostic Test|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
79496605|NCT00001061|Drug|Foscarnet sodium|
79496606|NCT00001061|Drug|Ganciclovir|
79985997|NCT05170464|Behavioral|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
79985998|NCT05170464|Drug|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
79985999|NCT03677492|Other|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
79659321|NCT04709159|Other|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
79659322|NCT00292110|Drug|Methadone|100 mg/day orally
79659323|NCT00292110|Behavioral|Contingency Management|Incentives given for cocaine abstinence
79986000|NCT03681353|Behavioral|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
79986001|NCT03394885|Drug|Atezolizumab|1200mg IV q3weeks
79659324|NCT00292110|Drug|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
79496607|NCT00000281|Behavioral|Amantadine|
79659325|NCT00292110|Behavioral|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
79659326|NCT00259805|Drug|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
79659327|NCT00259844|Biological|TroVax|
79659328|NCT00259883|Drug|paroxetine|1 or 2 tablets once a day
79659329|NCT04718376|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
79659330|NCT02961335|Procedure|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
79659331|NCT02961335|Procedure|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
79659332|NCT02961335|Procedure|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
79659333|NCT00272415|Drug|INO-1001|Intravenous repeating dose
79659334|NCT00272415|Drug|temozolomide|Oral repeating dose
79659335|NCT00259922|Drug|Placebo|Placebo
79659336|NCT00259922|Drug|Alvimopan|0.5 mg QD
79659337|NCT00259922|Drug|Alviompan|0.5 mg BID
79986002|NCT03394885|Drug|Carboplatin|5-6mg/ML IV q3 weeks
79986003|NCT03394885|Drug|Paclitaxel|70-80 mg/m2 IV q1 week
79986004|NCT03394885|Drug|Bevacizumab|15 mg/kg IV q3 weeks
79986005|NCT03682484|Drug|MA-0211|oral
79986006|NCT03682484|Drug|Placebo|oral
79986007|NCT05168592|Behavioral|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
79986008|NCT05168592|Behavioral|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
79345128|NCT04974619|Behavioral|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
79496608|NCT02788955|Behavioral|Dietary counselling|
79496609|NCT02788955|Other|Dietary Protein|
79496610|NCT00001067|Drug|Lamivudine|
79496611|NCT00001067|Drug|Stavudine|
79496612|NCT00001067|Drug|Zidovudine|
79496613|NCT02396459|Drug|Triac|Triac, individually titrated dose
79496614|NCT00001079|Drug|Testosterone enanthate|
79659338|NCT00272454|Drug|Cilostazol|
79659339|NCT00272454|Drug|Aspirin|
79659340|NCT00272493|Biological|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
79659341|NCT00272493|Biological|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
79659342|NCT00259961|Procedure|open fundoplication|
79659343|NCT00259961|Procedure|laparoscopic fundopliaction|
79659344|NCT00292266|Drug|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
79659345|NCT00292266|Drug|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
79659346|NCT00260000|Drug|5,6,7,8-tetrahydrobiopterin|
79659347|NCT00292305|Procedure|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
79659348|NCT00260039|Biological|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
79659349|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
79659350|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
79659351|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
79659352|NCT00292344|Drug|Rifaximin and loperamide|
79659353|NCT00260117|Behavioral|Exercise|Referal to a website
79986009|NCT01361373|Drug|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
79986010|NCT01361373|Drug|placebo|placebo for 2 weeks
79345129|NCT04974619|Behavioral|Focus groups|Focus groups will be conducted in-person or remotely to evaluate the newly created educational materials about HPV vaccination. Individual interviews and/or focus groups (n=24) with young Latino men who have sex with men (YLMSM) (12 in Puerto Rico and 12 in Florida) will be conducted to gain feedback on the education intervention. The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference and aesthetics of the theoretically informed, HPV education target for Spanish-speaking YLMSM.
79659354|NCT00272532|Drug|Thiocolchicoside|
79659355|NCT00417768|Drug|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
79345130|NCT04974619|Behavioral|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
79814884|NCT00914108|Behavioral|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
79345131|NCT04944784|Drug|Reldesemtiv|Reldesemtiv Oral Tablet
79986011|NCT03677336|Drug|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
79659356|NCT00417768|Other|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
79659357|NCT00292383|Procedure|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
79986012|NCT03677336|Drug|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
79345132|NCT04944784|Drug|Placebo|Placebo Oral Tablet
79986013|NCT03677336|Drug|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
79308240|NCT02451059|Behavioral|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
79345133|NCT04936750|Other|Analysis of body composition|The cross section of the third lumbar spine in the CT scan images of the patients was analyzed to obtain the parameters related to the body composition of the patients
79345134|NCT04932486|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
79345135|NCT04930887|Drug|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
79496615|NCT00001079|Drug|Megestrol acetate|
79496616|NCT00000293|Drug|Nefazodone|
79659358|NCT00258635|Biological|RagweedMATAMPL|
79986014|NCT03677336|Drug|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
79986015|NCT03634995|Drug|BMS-986256|Specified dose on specified days
79986016|NCT03634995|Other|Placebo|Specified dose on specified days
79345136|NCT04930887|Drug|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
79496617|NCT00001091|Drug|Ritonavir|
79496618|NCT00001091|Drug|Nelfinavir mesylate|
79496619|NCT00001091|Drug|Nevirapine|
79496620|NCT00001091|Drug|Lamivudine|
79496621|NCT00001091|Drug|Stavudine|
79496622|NCT00000299|Drug|Buprenorphine|
79496623|NCT00000305|Drug|Dextroamphetamine|
79496624|NCT01771679|Biological|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
79496625|NCT00000311|Drug|Buprenorphine|Medication and Behavioral
79496626|NCT00000311|Drug|methadone|medication and behavioral
79496627|NCT00000317|Drug|Risperidone|Risperidone (4mg/day)
79659359|NCT00260234|Biological|Allogeneic Cultured Islet Cells (human); Encapsulated|
79659360|NCT00272571|Procedure|External counter pulsation therapy|
79659361|NCT00260273|Behavioral|Cognitive Behaviour Therapy|therapy
79659362|NCT00272610|Drug|0.4% Retinol Cream|
79659363|NCT00260312|Biological|Inactivated Polio Vaccine given at an accelerated schedule|
79659364|NCT00292422|Drug|BG9924|
79659365|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
79659366|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
79986017|NCT01559805|Behavioral|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
79345137|NCT04930666|Other|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
79659367|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
79345138|NCT04875065|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
79659368|NCT00292500|Device|Automated distal anastomotic device|CABG
79345139|NCT04863248|Drug|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
79345140|NCT04863248|Drug|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
79345141|NCT04863248|Drug|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
79345142|NCT04815902|Drug|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
79345143|NCT04815902|Drug|Losartan|12.5 mg oral Losartan taken for 30 days total.
79345144|NCT04815902|Drug|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
79659369|NCT00272688|Drug|Levodopa (drug), intraduodenal administration|
79659370|NCT00260390|Drug|Testoviron|
79986018|NCT01559805|Behavioral|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
79986019|NCT02877927|Drug|Omadacycline|po tablets
79986020|NCT02877927|Drug|Linezolid|po tablets
79986021|NCT02706886|Drug|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
79986022|NCT02706886|Drug|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride [NaCl]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
79986023|NCT01357707|Genetic|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
79345145|NCT04815902|Drug|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
79345146|NCT04807140|Drug|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
79345147|NCT04807140|Drug|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
79345148|NCT04807140|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
79345149|NCT04804566|Other|This is a non-interventional study|This is a non-interventional study
79496628|NCT00000317|Drug|Placebo|Placebo
79659371|NCT00292539|Device|Any pacemaker with right ventricular pacing option|
79659372|NCT00260468|Other|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
79659373|NCT00292578|Procedure|NAET Testing Modalities|
79659374|NCT00260546|Procedure|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
79659375|NCT00292656|Procedure|NAET|
79659376|NCT00260624|Drug|Escitalopram (Lexapro)|
79814885|NCT03908060|Drug|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
79814886|NCT03908060|Drug|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
79814887|NCT00752856|Drug|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
79814888|NCT00752856|Drug|Atripla|Atripla 1 tab once a day
79345150|NCT04773691|Device|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
79496629|NCT00000317|Behavioral|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
79345151|NCT04773691|Device|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
79345152|NCT04773691|Other|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
79345153|NCT04773691|Device|Breathalyzer|estimation of blood alcohol level
79345154|NCT04761575|Other|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
79345155|NCT04759248|Drug|Atezolizumab + Trastuzumab + Vinorelbine|"Atezolizumab IV 1200 mg in combination with~Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
79345156|NCT04756726|Drug|CFT7455|oral CFT7455
79345157|NCT04756726|Drug|Dexamethasone Oral|oral dexamethasone [ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; >75 Years old: 20 mg QW on days 1, 8, 15, and 22]
79345158|NCT04754932|Other|Cognitive Stimulation Therapy|Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
79345159|NCT04708275|Procedure|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
79345160|NCT04704505|Radiation|radium-223|Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
79345161|NCT04704505|Drug|Bipolar Androgen Therapy (BAT)|All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
79345162|NCT04699435|Other|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
79345163|NCT04699435|Other|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
79496630|NCT00001685|Biological|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
79496631|NCT00001115|Drug|Acyclovir|
79496632|NCT00380237|Biological|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
79496633|NCT00380315|Drug|AG1321001(drug)|
79496634|NCT00001127|Biological|Influenza virus vaccine (CAIV-T)|
79496635|NCT00001757|Drug|Voriconazole|
79659377|NCT00292695|Other|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
79659378|NCT00260663|Procedure|Group hearing aid fittings|
79496636|NCT00001133|Drug|Indinavir sulfate|
79496637|NCT00001133|Drug|Ritonavir|
79496638|NCT00000329|Drug|Opioid-Related Disorders|
79496639|NCT00000335|Drug|Morphine|
79496640|NCT00000341|Drug|Buprenorphine|
79496641|NCT00000347|Drug|Risperidone|
79496642|NCT00001781|Drug|CGP 77116|
79496643|NCT00001835|Drug|Oxaliplatin|
79659379|NCT00260663|Procedure|Group hearing aid follow-up|
79659380|NCT00292734|Drug|Zolpidem|
79659381|NCT00260702|Drug|Omalizumab (Xolair)|
79659382|NCT00260741|Drug|Smoked Cannabis|
79496644|NCT00001193|Procedure|high dose melphalan and autologous bone marrow transplantation|
79496645|NCT00000353|Drug|Buprenorphine/naloxone|
79496646|NCT00000377|Drug|Nortriptyline|
79659383|NCT00260780|Behavioral|The MISTERS Intervention for Post Jail Release Men|
79659384|NCT00260819|Drug|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
79496647|NCT00001865|Drug|Daclizumab|
79496648|NCT00000389|Drug|Fluvoxamine|
79496649|NCT00001271|Drug|IgG-RFB4-SMPT-dgA|
79496650|NCT00000401|Drug|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
79496651|NCT00000407|Behavioral|Vocational counseling intervention|
79496652|NCT00000407|Behavioral|Reading materials for control participants|
79496653|NCT00000407|Behavioral|Standard of care|No education or behavioral intervention
79496654|NCT00001877|Drug|Pentoxifylline|
79496655|NCT00380939|Drug|Atorvastatin|
79496656|NCT00380939|Drug|Pravastatin|
79496657|NCT00001889|Procedure|Myocardial contrast echocardiography|
79496658|NCT00001889|Procedure|Stress echocardiography with dobutamine|
79496659|NCT00380549|Diagnostic Test|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
79496660|NCT00001895|Drug|FDG|
79496661|NCT00001895|Drug|NH(3)|
79496662|NCT00001901|Drug|Etanercept|
79496663|NCT00000431|Drug|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
79496664|NCT00000437|Drug|Naltrexone Tablet and Nicotine Patch|
79496665|NCT00000437|Drug|Naltrexone Tablet and Placebo Patch|
79496666|NCT00000437|Drug|Placebo Tablet and Nicotine Patch|
79496667|NCT00000437|Drug|Placebo Tablet and Placebo Patch|
79496668|NCT00000443|Drug|ondansetron (Zofran)|
79496669|NCT00380783|Drug|AGN 203818|
79496670|NCT00000449|Drug|naltrexone (Revia)|
79496671|NCT00000449|Behavioral|cognitive behavioral therapy|
79496672|NCT00000449|Behavioral|cue exposure treatment|
79496673|NCT00000455|Drug|naltrexone|
79496674|NCT00000473|Behavioral|dietary supplements|
79496675|NCT00000473|Drug|fatty acids, omega-3|
79496676|NCT00000473|Behavioral|diet, fat-restricted|
79496677|NCT00001919|Drug|Hypericum (LI-160)|
79496678|NCT00001925|Drug|Alcohol|
79496679|NCT00001307|Drug|Oxygen-15 Water|
79496680|NCT00001307|Drug|Capsaicin|
79496681|NCT00001931|Drug|N-0923|
79659385|NCT00260819|Drug|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
79496682|NCT04713761|Drug|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
79496683|NCT00380471|Device|Bath PUVA|
79496684|NCT00000509|Behavioral|diet, sodium-restricted|
79496685|NCT00000509|Behavioral|diet, potassium-supplementation|
79496686|NCT00000515|Behavioral|diet, reducing|
79496687|NCT00001937|Drug|FK463|
79496688|NCT00001937|Drug|Fluconazole|
79345164|NCT04699435|Other|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
79496689|NCT00001325|Drug|18 FDG|
79496690|NCT00000545|Behavioral|exercise|
79496691|NCT00000545|Behavioral|diet|
79345165|NCT04689555|Procedure|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
79345166|NCT04689555|Procedure|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
79496692|NCT04331327|Drug|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
79496693|NCT00001955|Drug|Etanercept|
79496694|NCT00001955|Drug|Celecoxib|
79496695|NCT00000551|Behavioral|health education|
79496696|NCT04943783|Drug|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
79496697|NCT00000581|Procedure|leukocyte transfusions|
79496698|NCT00000605|Drug|hormone replacement therapy|
79496699|NCT00000605|Drug|estrogens|
79496700|NCT00000605|Drug|medroxyprogesterone|
79496701|NCT00000617|Drug|azithromycin|
79496702|NCT00000623|Drug|Deferoxamine|
79496703|NCT00000623|Drug|Deferiprone|
79496704|NCT00000623|Drug|Arginine|
79496705|NCT00000623|Drug|Sildenafil|
79496706|NCT00000623|Drug|Decitabine|
79496707|NCT00001961|Procedure|MRI|
79496708|NCT00001967|Drug|HAART|
79496709|NCT00001991|Drug|Atovaquone|
79496710|NCT00001997|Drug|Interleukin-2, Polyethylene Glycolated|
79496711|NCT00001997|Drug|Zidovudine|
79496712|NCT00001997|Drug|Didanosine|
79496713|NCT00002003|Drug|Mitoxantrone hydrochloride|
79496714|NCT00002003|Drug|Etoposide|
79496715|NCT00002009|Drug|Sargramostim|
79496716|NCT00000629|Drug|Valproic acid|
79496717|NCT00000629|Drug|Zidovudine|
79496718|NCT00000647|Drug|CD4-IgG|
79496719|NCT00000647|Drug|Zidovudine|
79496720|NCT00000647|Drug|Interferon alfa-n1|
79496721|NCT00000647|Procedure|Peripheral lymphocyte infusion|
79496722|NCT00000647|Procedure|Bone marrow transplant|
79496723|NCT00000653|Drug|Zalcitabine|
79496724|NCT00001409|Drug|Interleukin-2|
79496725|NCT00000659|Drug|CD4 Antigens|
79659386|NCT00292773|Procedure|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
79345167|NCT04683692|Device|Magnetic Resonance Imaging (MRI)|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
79345168|NCT04683692|Other|Laboratory Testing|Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
79659387|NCT00260858|Drug|Test Meal: Reference food (glucose or white bread)|
79659388|NCT00260858|Drug|Test Meal: Pirate's Booty|
79308241|NCT02451059|Behavioral|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
79345169|NCT04671186|Dietary Supplement|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
79345170|NCT04671186|Other|Placebo|Placebo group will take 1 capsule of placebo orally once daily
79345171|NCT04651270|Device|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
79345172|NCT04617197|Device|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
79345173|NCT04588038|Biological|Efineptakin alfa|Given via intramuscular injection
79659389|NCT00260858|Drug|Test Meal: Ceaprove wafer|
79986024|NCT01318239|Procedure|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
79986025|NCT01357785|Procedure|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
79496726|NCT00000659|Drug|Zidovudine|
79986026|NCT03116932|Behavioral|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
79496727|NCT00381017|Drug|Peg interferon alpha-2b|
79496728|NCT00001439|Biological|gp100 human melanoma peptide|
79496729|NCT00002015|Drug|Ganciclovir|
79986027|NCT01357863|Drug|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
79496730|NCT00002021|Drug|Foscarnet sodium|
79496731|NCT00002027|Drug|Diclazuril|
79496732|NCT00000695|Drug|Interferon beta-1b|
79986028|NCT02809131|Drug|polymixin/bacitracin|Antibacterial irrigation
79986029|NCT02809131|Drug|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
79345174|NCT04548479|Device|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
79345175|NCT04529278|Drug|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
79496733|NCT00000695|Drug|Zidovudine|
79986030|NCT02809131|Drug|Saline|Saline irrigation
79986031|NCT05046054|Device|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
79345176|NCT04503148|Drug|Propofol|Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
79345177|NCT04503148|Drug|Inhaled General Anesthetics|Sevoflurane or desflurane for induction and maintenance of anesthesia
79496734|NCT00000701|Drug|Zidovudine|
79496735|NCT00000713|Drug|Ampligen|
79496736|NCT00000725|Drug|Interferon alfa-2a|
79496737|NCT00000725|Drug|Zidovudine|
79496738|NCT00000725|Drug|Interferon alfa-n1|
79496739|NCT00002033|Drug|Zidovudine|
79496740|NCT00002033|Drug|AS-101|
79496741|NCT00002039|Drug|Foscarnet sodium|
79496742|NCT00000731|Drug|Zidovudine|
79496743|NCT00000731|Drug|Acetaminophen|
79496744|NCT00002045|Drug|Zidovudine|
79496745|NCT00001493|Genetic|peripheral blood progenitor cells carrying MDR1|
79496746|NCT00002051|Drug|Thymopentin|
79496747|NCT00001499|Drug|paclitaxel|
79496748|NCT00001499|Drug|cisplatin|
79496749|NCT00001499|Procedure|chest radiotherapy|
79496750|NCT00002057|Drug|Nystatin|
79496751|NCT00002297|Drug|Inosine pranobex|
79814889|NCT03727568|Procedure|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
79814890|NCT05745740|Drug|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
79986032|NCT05046054|Device|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
79659390|NCT00260858|Drug|Test Meal: Stretch Island Strawberry Fruit Leather|
79814891|NCT05745740|Drug|Pyrotinib|Pyrotinib 400 mg by oral once a day.
79986033|NCT03633318|Device|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
79345178|NCT04484766|Other|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~Physical examination: height, weight, BMI, blood pressure~Cardiac examination: cardiac output~Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
79986034|NCT05009628|Procedure|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
79345179|NCT04429516|Drug|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
79986035|NCT05009628|Procedure|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
79986036|NCT05009628|Procedure|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
79345180|NCT04429516|Drug|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
79496752|NCT00001535|Drug|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
79496753|NCT00002303|Drug|Epoetin alfa|
79496754|NCT00002063|Drug|Zidovudine|
79496755|NCT00002069|Drug|Ditiocarb sodium|
79659391|NCT00298311|Behavioral|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
79659392|NCT00292812|Drug|Nutritional supplementation (nucleotides)|
79659393|NCT00415571|Drug|Fispemifene (once daily for 8 weeks)|
79659394|NCT00298350|Drug|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
79659395|NCT00298428|Procedure|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
79659396|NCT02960451|Other|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
79659397|NCT02960451|Other|Usual care|Medication and psychotherapy as available form community providers
79659398|NCT00292890|Device|insulin needle|
79659399|NCT00292929|Drug|Intravenous artesunate|
79659400|NCT00298467|Drug|MDX-060|
79659401|NCT00424853|Drug|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
79659402|NCT00424853|Drug|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
79659403|NCT00298506|Drug|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
79986037|NCT02784951|Drug|Red blood cells (0Rh D-neg)|Fresh produced RBC
79986038|NCT02784951|Drug|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
79986039|NCT02784951|Drug|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
79496756|NCT00001565|Drug|phenylbutyrate|
79496757|NCT00002309|Drug|Azithromycin|
79659404|NCT00292968|Behavioral|Computer based care|
79496758|NCT00002315|Drug|Netivudine|
79659405|NCT00292968|Behavioral|Telephone counseling|
79659406|NCT00292968|Behavioral|Group visits|
79659407|NCT00292968|Behavioral|Usual care|
79659408|NCT00424892|Drug|Desvenlafaxine Sustained Release|
79659409|NCT01331239|Drug|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
79659410|NCT00424931|Drug|JNJ-17216498|50mg one time
79659411|NCT00424931|Drug|JNJ-17216498|10mg one time
79659412|NCT00424931|Drug|Modafinil|200 mg X 2
79659413|NCT00298545|Drug|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
79659414|NCT00298545|Drug|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
79659415|NCT01331161|Biological|ZOSTAVAX|shingles vaccine, one dose
79659416|NCT00424970|Drug|acetazolamide|
79659417|NCT00298584|Procedure|Percutaneous Suprapubic Aspiration|
79659418|NCT00298584|Procedure|Urethral Catheterization|
79659419|NCT01331005|Drug|nepafenac 0.1% drops|One drop three times per day for one year
79496759|NCT00002315|Drug|Acyclovir|
79496760|NCT00002075|Drug|Flucytosine|
79496761|NCT00002075|Drug|Fluconazole|
79496762|NCT00002075|Drug|Amphotericin B|
79496763|NCT00001577|Procedure|double isolated limb perfusion with melphalan alone|
79496764|NCT00002081|Drug|Zidovudine|
79496765|NCT00002081|Drug|Zalcitabine|
79659420|NCT01331005|Other|Nepafenac Vehicle|Placebo
79659421|NCT00293046|Biological|ALK Grass tablet - use of compliance device|
79659422|NCT01330459|Drug|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
79659423|NCT01330459|Drug|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
79659424|NCT01330459|Drug|Ibuprofen|800 mg oral ibuprofen
79659425|NCT01330459|Drug|Lorazepam|2 mg oral lorazepam
79496766|NCT00001637|Procedure|Blood cell transplantation|
79659426|NCT01330459|Drug|Lidocaine|20 ml 1% buffered lidocaine, injected
79659427|NCT00298623|Drug|XP13512 (GSK1838262)|
79659428|NCT00298623|Other|placebo|
79659429|NCT00293085|Drug|Docetaxel|
79814892|NCT04096404|Genetic|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
79814893|NCT04096404|Behavioral|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
79986040|NCT05002062|Device|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel & printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
79986041|NCT05002062|Other|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
79496767|NCT00002087|Drug|Alvircept sudotox|
79496768|NCT00002093|Drug|Daunorubicin (liposomal)|
79986042|NCT01442649|Drug|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
79659430|NCT00293085|Drug|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
79986043|NCT01442649|Drug|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
79986044|NCT01442649|Drug|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
79345181|NCT04417452|Other|Basic data collection (online survey or written form)|Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.
79986045|NCT01442649|Drug|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
79345182|NCT04417452|Other|Physical examination|The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.
79659431|NCT00261053|Drug|i.v. recombinant human C1 inhibitor|
79659432|NCT00298662|Drug|Interferon beta-1b and Tacrolimus|
79345183|NCT04417452|Behavioral|Psychometric examination|Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.
79345184|NCT04417452|Diagnostic Test|Recording of the adrenergic stress reaction (saliva test)|The adrenergic stress reaction is recorded by a saliva test.
79345185|NCT04371263|Other|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
79496769|NCT00002093|Drug|Bleomycin sulfate|
79496770|NCT00002093|Drug|Vincristine sulfate|
79496771|NCT00002093|Drug|Doxorubicin hydrochloride|
79496772|NCT00002099|Drug|Lentinan|
79496773|NCT00002099|Drug|Didanosine|
79496774|NCT00002321|Drug|Aldesleukin|
79496775|NCT00002327|Drug|Cidofovir|
79496776|NCT00002333|Drug|Saquinavir|
79496777|NCT00002333|Drug|Zalcitabine|
79496778|NCT00002339|Drug|Fluconazole|
79496779|NCT00002105|Drug|Doxorubicin hydrochloride (liposomal)|
79496780|NCT00002105|Drug|Bleomycin sulfate|
79986046|NCT01442649|Drug|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
79986047|NCT01442649|Drug|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
79986048|NCT05199792|Diagnostic Test|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
79496781|NCT00002105|Drug|Vincristine sulfate|
79496782|NCT00002345|Drug|Megestrol acetate|
79496783|NCT00002111|Drug|Saquinavir|
79659433|NCT01330381|Drug|prucalopride|"prucalopride~subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~subjects with weight >50 kg: prucalopride 2 mg tablet once daily"
79345186|NCT04357951|Drug|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
79814894|NCT02600832|Behavioral|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
79986049|NCT01354587|Drug|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
79986050|NCT04995120|Drug|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
79345187|NCT04357951|Drug|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
79345188|NCT04357951|Behavioral|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
79345189|NCT04323293|Other|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
79345190|NCT04323293|Other|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
79659434|NCT01330381|Drug|Placebo|Matching oral solution or oral tablets given once daily
79659435|NCT01330381|Drug|PEG 4000|
79659436|NCT00261092|Drug|Oxaliplatin|
79659437|NCT01330303|Drug|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
79986051|NCT03745469|Device|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
79986052|NCT03988998|Drug|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
79345191|NCT04285229|Drug|Ixekizumab|Administered SC
79345192|NCT04285229|Drug|Placebo|Administered SC
79986053|NCT03988998|Drug|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
79345193|NCT04282668|Drug|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
79345194|NCT04282668|Drug|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
79345195|NCT04263454|Drug|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
79345196|NCT04263454|Procedure|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
79496784|NCT05752643|Other|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
79496785|NCT00002351|Drug|Indinavir sulfate|
79496786|NCT00002357|Drug|HBY 097|
79496787|NCT00002357|Drug|Zidovudine|
79496788|NCT00002117|Drug|Zidovudine|
79659438|NCT01330303|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
79659439|NCT00293124|Drug|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
79659440|NCT01330108|Drug|ambrisentan|ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
79659441|NCT00261131|Drug|Botulinum Toxin A|
79659442|NCT00298701|Biological|ALK Grass tablet|
79659443|NCT00261170|Drug|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
79659444|NCT00261170|Other|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
79814895|NCT02600832|Behavioral|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
79496789|NCT00002117|Drug|Zalcitabine|
79659445|NCT00261209|Drug|Collagenase|Collagenase injection into adhesion restricting tendon gliding
79496790|NCT05752565|Device|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
79496791|NCT00002123|Drug|Delavirdine mesylate|
79496792|NCT00002123|Drug|Didanosine|
79345197|NCT04259060|Drug|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
79345198|NCT04259060|Drug|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
79345199|NCT04251195|Behavioral|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
79496793|NCT00381329|Behavioral|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
79496794|NCT00381329|Behavioral|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
79345200|NCT04251195|Behavioral|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
79345201|NCT04218240|Drug|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
79345202|NCT04218240|Drug|Placebo oral tablet|oral Placebo
79496795|NCT00002363|Drug|Peptide Construction 3, Synthetic|
79496796|NCT00381173|Drug|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
79496797|NCT00002129|Drug|Vesnarinone|
79496798|NCT00002135|Drug|Ganciclovir|
79496799|NCT00002141|Drug|Abacavir sulfate|
79496800|NCT00002369|Drug|Indinavir sulfate|
79659446|NCT00261209|Drug|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
79986054|NCT01318785|Other|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
79345203|NCT04218240|Drug|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
79345204|NCT04212793|Drug|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
79496801|NCT00002369|Drug|Lamivudine|
79496802|NCT00002369|Drug|Stavudine|
79496803|NCT00002369|Drug|Zidovudine|
79496804|NCT00002375|Drug|Indinavir sulfate|
79496805|NCT00002375|Drug|Nelfinavir mesylate|
79496806|NCT04636697|Drug|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
79496807|NCT04636697|Biological|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
79496808|NCT00002381|Drug|Nelfinavir mesylate|
79496809|NCT00002381|Drug|Nevirapine|
79496810|NCT00002381|Drug|Stavudine|
79496811|NCT00002387|Drug|Indinavir sulfate|
79496812|NCT00002387|Drug|Efavirenz|
79496813|NCT00002393|Drug|Indinavir sulfate|
79496814|NCT00002393|Drug|Efavirenz|
79496815|NCT00002399|Drug|Posaconazole|
79496816|NCT00002399|Drug|Fluconazole|
79496817|NCT00002405|Drug|Amprenavir|
79496818|NCT00002417|Drug|Amprenavir|
79496819|NCT00381407|Behavioral|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
79496820|NCT00381407|Behavioral|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
79659447|NCT04718298|Device|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
79659448|NCT00261248|Biological|Immunization with inactivated bacteria|
79659449|NCT00261287|Drug|Ciclesonide|
79659450|NCT00261326|Drug|simvastatin|80 mg once daily
79659451|NCT00261326|Drug|placebo|calcium tablets once daily
79659452|NCT00293163|Device|Hylaform, Hylaform Plus (hylan B gel)|
79659453|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
79986055|NCT01376232|Drug|GSK1278863|GSk1278863 100mg
79496821|NCT00002423|Drug|Indinavir sulfate|
79496822|NCT00002423|Drug|Abacavir sulfate|
79345205|NCT04212793|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
79986056|NCT01376232|Drug|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
79986057|NCT01376232|Drug|Gemfibrozil|600 mg Gemfibrozil
79986058|NCT01354665|Biological|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
79986059|NCT01354743|Drug|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
79986060|NCT01354743|Device|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
79986061|NCT01361529|Drug|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
79345206|NCT04212260|Behavioral|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
79986062|NCT05018403|Drug|Intravenous AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
79345207|NCT04212260|Behavioral|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
79345208|NCT04187547|Drug|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
79345209|NCT04187547|Drug|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
79345210|NCT04175678|Other|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
79345211|NCT04175678|Other|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
79345212|NCT04175678|Other|Standard care|Observational
79345213|NCT04159662|Behavioral|Cognitive Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
79496823|NCT00002423|Drug|Amprenavir|
79496824|NCT00002423|Drug|Nelfinavir mesylate|
79986063|NCT05018403|Drug|Intravenous placebo|Isotonic glucose solution identical in appearance to AON-D21.
79986064|NCT04944108|Procedure|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
79986065|NCT04944108|Procedure|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
79986066|NCT05008575|Biological|anti-CD33 CAR NK cells|6×10^8, 12×10^8, 18×10^8/KG Treatment follows a lymphodepletion
79986067|NCT05008575|Drug|Fludarabine|recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.
79345214|NCT04159662|Behavioral|Active Control Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
79986068|NCT05008575|Drug|Cytoxan|recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.
79986069|NCT03971994|Behavioral|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
79345215|NCT04155463|Other|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
79345216|NCT04155463|Other|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
79345217|NCT04117347|Device|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
79345218|NCT04117347|Device|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
79345219|NCT04117347|Device|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
79345220|NCT04084951|Biological|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
79496825|NCT00002423|Drug|Lamivudine|
79496826|NCT02973581|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
79496827|NCT02973581|Drug|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
79659454|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
79986070|NCT04069715|Dietary Supplement|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
79986071|NCT04069715|Other|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
79345221|NCT04084951|Drug|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
79345222|NCT04084951|Drug|Ipilimumab|cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
79345223|NCT04084951|Drug|Nivolumab|programmed cell death 1 (PD-1) blocking antibody
79345224|NCT04058665|Device|Floseal|Hemostatic agent
79345225|NCT04056611|Drug|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
79345226|NCT04056611|Drug|Placebo|Matching placebo will be administered orally.
79496828|NCT02973581|Drug|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
79986072|NCT03970512|Device|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
79345227|NCT04056611|Drug|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
79345228|NCT04040686|Drug|Injection of 99mTc-NM-02|Patient will be injected with microdose (<100ug) of 99mTc-NM-02 radiotracer
79345229|NCT04035837|Drug|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
79986073|NCT01319487|Drug|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
79986074|NCT01319487|Drug|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
79345230|NCT04022135|Dietary Supplement|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
79496829|NCT02973581|Drug|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
79496830|NCT00002435|Drug|Thymic Humoral Factor|
79345231|NCT04022135|Dietary Supplement|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
79496831|NCT00002435|Drug|Zidovudine|
79496832|NCT00002441|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
79659455|NCT00293280|Drug|lomustine|
79659456|NCT00261404|Drug|TNFerade™|
79986075|NCT01319487|Drug|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
79986076|NCT03681119|Behavioral|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
79986077|NCT03681119|Behavioral|Education and Training|Education and training
79496833|NCT00002447|Drug|Ritonavir|
79986078|NCT03111108|Drug|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
79986079|NCT03677375|Device|INVSENSOR00026|Noninvasive pulse oximeter sensor
79986080|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
79986081|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
79986082|NCT00702520|Drug|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
79986083|NCT00702520|Biological|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
79986084|NCT00702520|Biological|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
79986085|NCT05198856|Drug|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
79345232|NCT04011254|Procedure|haemodialysis|Routine haemodialysis session
79345233|NCT04001803|Drug|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
79496834|NCT00002447|Drug|Efavirenz|
79496835|NCT00002447|Drug|Saquinavir|
79659457|NCT00298779|Drug|omeprazole and bortezomib|
79659458|NCT00261482|Drug|norelgestromin + ethinyl estradiol|
79659459|NCT00261521|Drug|epoetin alfa|
79345234|NCT04001777|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
79345235|NCT04001777|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
79345236|NCT03994913|Biological|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
79496836|NCT00002453|Drug|Tenofovir disoproxil fumarate|
79496837|NCT00002459|Radiation|radiation therapy|
79496838|NCT00002465|Drug|megestrol acetate|
79496839|NCT00002471|Drug|asparaginase|
79496840|NCT00002471|Drug|cyclophosphamide|
79496841|NCT00002471|Drug|cytarabine|
79496842|NCT00002471|Drug|daunorubicin hydrochloride|
79496843|NCT00002471|Drug|dexamethasone|
79496844|NCT00002471|Drug|etoposide|
79496845|NCT00002471|Drug|leucovorin calcium|
79496846|NCT00002471|Drug|methotrexate|
79496847|NCT00002471|Drug|methylprednisolone|
79496848|NCT00002471|Drug|therapeutic hydrocortisone|
79659460|NCT00298857|Drug|Valproic acid|
79659461|NCT00261560|Drug|acetaminophen|
79659462|NCT00261599|Drug|AQUAVAN® (fospropofol disodium) Injection|
79659463|NCT00261599|Drug|Midazolam HCI|
79659464|NCT00293319|Biological|filgrastim|
79659465|NCT00293319|Radiation|iobenguane I 131|
79659466|NCT00293358|Drug|carboplatin|
79659467|NCT00293358|Drug|cisplatin|
79496849|NCT00002471|Drug|thiotepa|
79345237|NCT03987802|Drug|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
79659468|NCT00293358|Drug|etoposide phosphate|
79659469|NCT00293358|Drug|ifosfamide|
79345238|NCT03984994|Other|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
79345239|NCT03984994|Other|Strength training|3 months of center-based, supervise strength training
79345240|NCT03983668|Drug|CMP-001|Immunostimulatory therapeutic agent
79345241|NCT03983668|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy
79345242|NCT03977012|Drug|Buprenorphine|5~20 mcg
79345243|NCT03968055|Other|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
79345244|NCT03940066|Device|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
79496850|NCT00002471|Drug|vincristine sulfate|
79496851|NCT00002477|Drug|carboplatin|
79659470|NCT00293358|Procedure|adjuvant therapy|
79814896|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
79814897|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
79345245|NCT03940066|Other|No Intervention|No intervention
79345246|NCT03915964|Drug|Baricitinib|Administered orally.
79496852|NCT00002477|Drug|cisplatin|
79496853|NCT00002477|Drug|cyclophosphamide|
79496854|NCT00002477|Drug|doxorubicin hydrochloride|
79496855|NCT00002489|Biological|dactinomycin|
79496856|NCT00002489|Biological|filgrastim|
79496857|NCT00002489|Drug|carboplatin|
79496858|NCT00002489|Drug|cyclophosphamide|
79496859|NCT00002489|Drug|doxorubicin hydrochloride|
79345247|NCT03915964|Drug|TNF Inhibitor|Administered SC
79496860|NCT00002489|Drug|etoposide|
79345248|NCT03907423|Drug|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
79345249|NCT03907423|Drug|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
79345250|NCT03906409|Other|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
79345251|NCT03906409|Other|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
79345252|NCT03903874|Behavioral|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
79496861|NCT00002489|Drug|leucovorin calcium|
79496862|NCT00002489|Drug|methotrexate|
79496863|NCT00002489|Drug|vincristine sulfate|
79496864|NCT00002489|Procedure|conventional surgery|
79496865|NCT00002495|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15
79496866|NCT00002495|Drug|vinblastine|6 mg/m^2 on days 1 and 15
79496867|NCT00002495|Radiation|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
79496868|NCT00002501|Biological|filgrastim|
79659471|NCT00293358|Procedure|conventional surgery|
79659472|NCT00293358|Procedure|neoadjuvant therapy|
79659473|NCT00293358|Radiation|radiation therapy|
79659474|NCT00261677|Drug|epoetin alfa|
79659475|NCT00298935|Procedure|Osteopathic manipulative treatment (OMT)|
79659476|NCT00298974|Drug|hydrocodone / acetaminophen extended release|2 tablets twice daily
79659477|NCT00298974|Drug|Placebo|2 tablets twice daily
79814898|NCT00755196|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
79496869|NCT00002501|Drug|cyclophosphamide|
79496870|NCT00002147|Drug|Doxorubicin hydrochloride (liposomal)|
79496871|NCT00002153|Drug|A-007|
79496872|NCT00002159|Drug|Itraconazole|
79496873|NCT00002159|Drug|Amphotericin B|
79496874|NCT00002165|Drug|Nelfinavir mesylate|
79496875|NCT04713059|Genetic|FGFR2|Mutation of FGFR2
79496876|NCT00002171|Drug|Nelfinavir mesylate|
79659478|NCT00261794|Behavioral|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
79659479|NCT00261794|Behavioral|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
79659480|NCT00293436|Drug|celecoxib|
79659481|NCT00293436|Drug|erlotinib hydrochloride|
79659482|NCT00293436|Procedure|adjuvant therapy|
79814899|NCT00755196|Drug|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
79814900|NCT04020510|Drug|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
79814901|NCT00805142|Drug|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
79659483|NCT00261872|Drug|Methylphenidate|
79345253|NCT03897621|Drug|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
79345254|NCT03897621|Drug|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
79814902|NCT00761631|Biological|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
79986086|NCT04067141|Device|somofilcon A|Contact Lens
79345255|NCT03882671|Device|EpiTel Epilog|EEG recording device
79496877|NCT00002177|Drug|Hydroxyurea|
79496878|NCT00002177|Drug|Nelfinavir mesylate|
79496879|NCT00002177|Drug|Stavudine|
79496880|NCT00002177|Drug|Didanosine|
79986087|NCT04067141|Device|nelfilcon A|Contact Lens
79496881|NCT00002183|Drug|Abacavir sulfate|
79496882|NCT00002183|Drug|Amprenavir|
79496883|NCT00002183|Drug|Lamivudine|
79496884|NCT00002183|Drug|Zidovudine|
79986088|NCT03887910|Other|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
79496885|NCT00002189|Drug|Paclitaxel|
79496886|NCT00002195|Drug|Amprenavir|
79659484|NCT00293475|Drug|Carboplatin|Given IA
79659485|NCT00293475|Drug|Mannitol|Given IA
79659486|NCT00293475|Drug|Methotrexate|Given IA
79659487|NCT00293475|Other|Quality-of-Life Assessment|Ancillary studies
79659488|NCT00293475|Biological|Rituximab|Given IV
79345256|NCT03882671|Device|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
79345257|NCT03882671|Device|GENEActiv|Temperature, light level and accelerometry recording device
79496887|NCT00002195|Drug|Lamivudine|
79659489|NCT00293475|Drug|Sodium Thiosulfate|Given IV
79659490|NCT00261911|Drug|sibutramine|
79496888|NCT00002195|Drug|Zidovudine|
79496889|NCT00002201|Drug|Ritonavir|
79496890|NCT00002201|Drug|Nelfinavir mesylate|
79496891|NCT00002213|Drug|Abacavir sulfate|
79496892|NCT00002213|Drug|Amprenavir|
79496893|NCT00002213|Drug|Efavirenz|
79496894|NCT04331405|Biological|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
79496895|NCT00381251|Drug|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
79496896|NCT00002219|Drug|Nelfinavir mesylate|
79659491|NCT00299013|Drug|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
79659492|NCT00299013|Drug|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
79659493|NCT00293514|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|
79659494|NCT00299052|Device|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
79345258|NCT03874507|Other|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
79659495|NCT00299052|Biological|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
79496897|NCT00002219|Drug|Levocarnitine|
79986089|NCT03887910|Other|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
79986090|NCT03184714|Device|NIPPV|BiPAP treatment for 3 years
79986091|NCT02876601|Drug|Defibrotide|6.25mg/kg bodyweight over 2h infusion
79345259|NCT03859167|Other|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
79345260|NCT03849118|Diagnostic Test|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
79345261|NCT03846726|Procedure|standard TME surgery|radical resection for rectal cancer
79659496|NCT00293553|Procedure|Electronic Barostat|
79345262|NCT03821506|Device|Dynamic Light|Dynamic Lighting system
79986092|NCT02876601|Drug|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
79986093|NCT02876601|Drug|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
79659497|NCT00299091|Drug|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
79659498|NCT00299169|Behavioral|N of 1 Trials|N of 1 Trials of statin therapy
79659499|NCT00299208|Drug|Artesunate|
79659500|NCT00299208|Drug|Azithromycin|
79345263|NCT03821506|Device|Usual care|Standard lighting system
79986094|NCT02876601|Drug|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
79659501|NCT00299208|Drug|Quinine|
79986095|NCT04059536|Device|Roxwood Anchoring Catheters|Anchoring catheters
79986096|NCT04059536|Drug|Acetylsalicylic Acid|Oral Tablet
79986097|NCT04059536|Drug|Heparin|Intravenous Injection
79986098|NCT05714982|Other|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
79496898|NCT00002219|Drug|Adefovir dipivoxil|
79496899|NCT00002225|Drug|Efavirenz|
79496900|NCT00002225|Drug|Stavudine|
79496901|NCT00002225|Drug|Didanosine|
79496902|NCT00002231|Biological|APL 400-003|
79496903|NCT00002237|Drug|Peldesine|
79496904|NCT00002243|Drug|Calanolide A|
79496905|NCT00002249|Drug|Levofloxacin|
79496906|NCT00002255|Drug|Filgrastim|
79496907|NCT00002255|Drug|Epoetin alfa|
79496908|NCT00002255|Drug|Zidovudine|
79496909|NCT05752253|Other|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
79496910|NCT00002261|Biological|Smallpox Vaccine|
79496911|NCT00002261|Biological|HIVAC-1e|
79496912|NCT00002261|Biological|gp160 Vaccine (MicroGeneSys)|
79496913|NCT00002507|Drug|mitomycin C|
79496914|NCT00002507|Drug|porfiromycin|
79496915|NCT00002507|Radiation|brachytherapy|
79496916|NCT00002507|Radiation|radiation therapy|
79659502|NCT00262145|Drug|tea extracts|
79659503|NCT00418119|Drug|erythropoietin|
79659504|NCT00293592|Drug|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
79659505|NCT00293631|Drug|Lornoxicam 8 mg|
79659506|NCT00293631|Drug|Lornoxicam 16 mg|
79659507|NCT00293631|Drug|Ketorolac 30 mg|
79659508|NCT00293631|Drug|Placebo|
79659509|NCT00262184|Drug|Soy Isoflavone|
79345264|NCT03819192|Diagnostic Test|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~directly after hospitalization~5-7 days after beginning of antibiotic treatment~24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
79345265|NCT03819192|Diagnostic Test|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
79496917|NCT05752175|Drug|WPV01|WPV01 tablets
79496918|NCT05752175|Drug|Placebo|Placebo tablets
79496919|NCT00002519|Drug|chemotherapy|
79496920|NCT00002519|Drug|paclitaxel|
79496921|NCT00002519|Radiation|radiation therapy|
79659510|NCT00262262|Drug|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
79659511|NCT00418158|Behavioral|use of Airlife (therapy)|
79659512|NCT00262340|Other|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
79659513|NCT00293670|Drug|Goserelin (Zoladex)|
79345266|NCT03819192|Diagnostic Test|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
79986099|NCT05714982|Other|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
79986100|NCT05714982|Other|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
79659514|NCT00262379|Drug|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
79345267|NCT03809884|Behavioral|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
79659515|NCT00299247|Drug|sulfadoxine/pyrimethamine|
79345268|NCT03809884|Drug|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
79496922|NCT00002267|Drug|Rifabutin|
79496923|NCT00002273|Drug|Ganciclovir|
79659516|NCT00262418|Drug|Administration of ivermectin or permethrin|
79496924|NCT00002279|Drug|Zalcitabine|
79496925|NCT00002285|Drug|Zidovudine|
79496926|NCT00002531|Drug|asparaginase|
79496927|NCT00002531|Drug|cyclophosphamide|
79496928|NCT00002531|Drug|cytarabine|
79496929|NCT00002531|Drug|daunorubicin hydrochloride|
79496930|NCT00002531|Drug|dexamethasone|
79496931|NCT00002531|Drug|doxorubicin hydrochloride|
79496932|NCT00002531|Drug|etoposide|
79496933|NCT00002531|Drug|ifosfamide|
79496934|NCT00002531|Drug|leucovorin calcium|
79496935|NCT00002531|Drug|mercaptopurine|
79496936|NCT00002531|Drug|methotrexate|
79496937|NCT00002531|Drug|mitoxantrone hydrochloride|
79496938|NCT00002531|Drug|prednisolone|
79496939|NCT00002531|Drug|teniposide|
79496940|NCT00002531|Drug|thioguanine|
79496941|NCT00002531|Drug|vincristine sulfate|
79496942|NCT00002531|Drug|vindesine|
79496943|NCT00002531|Procedure|allogeneic bone marrow transplantation|
79496944|NCT00002531|Procedure|peripheral blood stem cell transplantation|
79496945|NCT00002531|Radiation|radiation therapy|
79496946|NCT00002537|Drug|topotecan hydrochloride|
79496947|NCT00002537|Radiation|radiation therapy|
79496948|NCT00002543|Drug|gallium nitrate|
79496949|NCT00002291|Drug|Pentamidine isethionate|
79496950|NCT00002549|Biological|filgrastim|
79496951|NCT00002549|Drug|busulfan|
79496952|NCT00002549|Drug|cyclophosphamide|
79345269|NCT03804138|Other|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
79496953|NCT00002549|Drug|cytarabine|
79496954|NCT00002549|Drug|daunorubicin hydrochloride|
79659517|NCT00299286|Drug|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
79659518|NCT00299286|Drug|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
79659519|NCT00262457|Device|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
79659520|NCT00262496|Drug|Botox|
79659521|NCT00293787|Drug|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
79659522|NCT00293787|Other|Timolol Vehicle|Placebo
79659523|NCT00293787|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
79659524|NCT00293787|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
79345270|NCT03785366|Drug|VeraCept|VeraCept Intrauterine Device (IUD)
79496955|NCT00002549|Drug|etoposide|
79659525|NCT00299364|Drug|Black Cohosh (iCR) or tibolone|
79496956|NCT00002549|Drug|idarubicin|
79345271|NCT03785366|Drug|ParaGard|ParaGard intrauterine copper contraceptive
79345272|NCT03768427|Combination Product|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
79345273|NCT03768427|Combination Product|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
79345274|NCT03768427|Drug|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
79345275|NCT03768427|Drug|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
79345276|NCT03768427|Drug|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
79345277|NCT03758781|Drug|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
79496957|NCT00002549|Drug|mesna|
79345278|NCT03758781|Drug|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
79496958|NCT00002549|Drug|mitoxantrone hydrochloride|
79496959|NCT00002549|Procedure|allogeneic bone marrow transplantation|
79496960|NCT00002549|Procedure|autologous bone marrow transplantation|
79496961|NCT00002549|Procedure|peripheral blood stem cell transplantation|
79496962|NCT00002549|Radiation|radiation therapy|
79496963|NCT00002555|Drug|cisplatin|
79496964|NCT00002555|Radiation|low-LET cobalt-60 gamma ray therapy|
79496965|NCT00002555|Radiation|low-LET electron therapy|
79496966|NCT00002555|Radiation|low-LET photon therapy|
79496967|NCT00002561|Biological|bleomycin sulfate|10 units/m2
79496968|NCT00002561|Drug|dacarbazine|375mg/m2
79659526|NCT00415649|Biological|VRC-HIVDNA016-00-VP|
79659527|NCT00415649|Biological|VRC-HIVADV014-00-VP|
79659528|NCT00415649|Biological|Vaccine placebo|Placebo comparator
79659529|NCT00293826|Drug|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
79659530|NCT00293826|Drug|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
79659531|NCT00293826|Drug|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
79659532|NCT00293826|Drug|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
79345279|NCT03747718|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
79496969|NCT00002561|Drug|doxorubicin hydrochloride|25mg/m2
79496970|NCT00002561|Drug|vinblastine|6mg/m2
79986101|NCT03178318|Procedure|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
79496971|NCT00002561|Radiation|radiation therapy|35Gy in 20 fractions (daily)
79496972|NCT05751707|Device|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
79496973|NCT05719649|Dietary Supplement|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
79496974|NCT05719649|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
79496975|NCT00002567|Biological|filgrastim|
79496976|NCT00002567|Drug|etoposide|
79496977|NCT00002567|Procedure|peripheral blood stem cell transplantation|
79659533|NCT00415688|Behavioral|Low carbohydrate, ketogenic diet|
79986102|NCT03745391|Diagnostic Test|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
79986103|NCT03745391|Diagnostic Test|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
79496978|NCT00002567|Radiation|low-LET electron therapy|
79496979|NCT00002567|Radiation|low-LET photon therapy|
79496980|NCT00002579|Drug|CMF regimen|
79496981|NCT00002579|Drug|cyclophosphamide|
79496982|NCT00002579|Drug|fluorouracil|
79496983|NCT00002579|Drug|methotrexate|
79496984|NCT00002579|Drug|tamoxifen citrate|
79496985|NCT00002579|Procedure|conventional surgery|
79496986|NCT00002579|Radiation|radiation therapy|
79496987|NCT00002585|Drug|pyrazoloacridine|
79659534|NCT00415688|Behavioral|Low glycemic index, reduced calorie diet|
79659535|NCT00299403|Procedure|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
79659536|NCT00299403|Procedure|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
79496988|NCT00382187|Biological|MF59 adjuvanted H5N1 influenza vaccine|"MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~non-adjuvanted influenza vaccine containing 15 ug of H5N1"
79496989|NCT00002609|Biological|lintuzumab|
79496990|NCT00002609|Drug|cytarabine|
79496991|NCT00002609|Drug|idarubicin|
79496992|NCT05751395|Device|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
79496993|NCT00002615|Drug|cisplatin|
79496994|NCT00002615|Drug|epirubicin hydrochloride|
79496995|NCT00002615|Drug|fluorouracil|
79496996|NCT00002615|Procedure|conventional surgery|
79496997|NCT05680103|Radiation|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
79496998|NCT00002621|Biological|recombinant interferon alfa|
79496999|NCT00002627|Biological|filgrastim|
79659537|NCT00415727|Device|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
79659538|NCT00299442|Behavioral|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
79986104|NCT03178396|Dietary Supplement|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
79986105|NCT03677258|Device|Collagen for injections 7%|Injection of medical device
79986106|NCT03677258|Device|Hyaluronic acid for injections 2%|Injection of medical device
79986107|NCT03682328|Procedure|vertebroplasty|Cement augmentation of the vertebral body
79986108|NCT03682328|Procedure|kyphoplaty|Cement augmentation of the vertebral body
79986109|NCT01361763|Drug|Dabigatran|110 mg twice daily
79659539|NCT00262574|Drug|Nesiritide,|PCI
79659540|NCT00293865|Procedure|sentinel node|detection of the sentinel node in breast cancer
79659541|NCT00293865|Procedure|GAS|
79659542|NCT00262613|Drug|sodium pyruvate in 0.9% sodium chloride solution|
79345280|NCT03747718|Other|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
79345281|NCT03746080|Drug|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
79497000|NCT00002627|Drug|carboplatin|
79497001|NCT00002627|Drug|cyclophosphamide|
79659543|NCT00293904|Biological|CYT005-AllQbG10|
79659544|NCT00262652|Drug|sodium pyruvate|
79659545|NCT00262769|Drug|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
79659546|NCT00262769|Drug|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
79345282|NCT03746080|Drug|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
79814903|NCT00763698|Device|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
79814904|NCT04620668|Device|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
79814905|NCT04098627|Behavioral|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
79345283|NCT03746080|Radiation|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
79345284|NCT03746080|Radiation|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
79345285|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
79345286|NCT03724149|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
79497002|NCT00002627|Drug|mesna|
79497003|NCT00002627|Drug|paclitaxel|
79497004|NCT00002627|Procedure|peripheral blood stem cell transplantation|
79497005|NCT00002633|Drug|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
79659547|NCT00299520|Drug|intravenous iclaprim or intravenous linezolid|
79659548|NCT00261755|Procedure|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
79659549|NCT00261755|Other|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
79659550|NCT00261755|Other|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
79814906|NCT00763386|Device|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
79814907|NCT00763386|Device|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
79814908|NCT00761319|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
79986110|NCT01361763|Drug|Antiplatelets|100mg once a day
79986111|NCT02420782|Drug|ASP6282|oral
79345287|NCT03724149|Drug|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
79659551|NCT00262808|Biological|sargramostim|
79659552|NCT00262808|Drug|fluorouracil|
79659553|NCT00262808|Drug|leucovorin calcium|
79659554|NCT00262808|Drug|oxaliplatin|
79659555|NCT00262808|Procedure|adjuvant therapy|
79659556|NCT00262808|Procedure|conventional surgery|
79659557|NCT00262808|Procedure|neoadjuvant therapy|
79659558|NCT00262886|Biological|anti-thymocyte globulin|
79659559|NCT00262886|Biological|graft-versus-tumor induction therapy|
79659560|NCT00262886|Biological|therapeutic allogeneic lymphocytes|
79659561|NCT00262886|Drug|cyclophosphamide|
79345288|NCT03720002|Dietary Supplement|HF2|placebo
79345289|NCT03595228|Biological|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
79345290|NCT03572933|Drug|ganaxolone|active drug
79345291|NCT03572933|Drug|Placebo|inactive
79345292|NCT03558152|Drug|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
79345293|NCT03558152|Drug|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
79659562|NCT00262886|Drug|fludarabine phosphate|
79814909|NCT00761319|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
79659563|NCT00262886|Drug|mycophenolate mofetil|
79659564|NCT00262886|Drug|tacrolimus|
79659565|NCT00262886|Procedure|allogeneic bone marrow transplantation|
79659566|NCT00262886|Procedure|peripheral blood stem cell transplantation|
79659567|NCT00263003|Drug|Irbesartan/hydrochlorothiazide|
79659568|NCT00263003|Drug|Irbesartan|
79659569|NCT06260007|Drug|Tribulus terrestris|Tribulus terrestris
79659570|NCT06260007|Other|Placebo|Placebo
79345294|NCT03558152|Drug|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
79345295|NCT03558152|Drug|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
79345296|NCT03768999|Diagnostic Test|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
79659571|NCT06259981|Drug|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily
79659572|NCT06259981|Drug|Placebo|4 placebo capsules orally twice daily
79659573|NCT06259968|Device|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
79659574|NCT06259968|Device|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
79814910|NCT00762996|Device|etafilcon A|contact lens
79814911|NCT00762996|Device|omafilcon A|contact lens
79986112|NCT02420782|Drug|Itraconazole|oral
79986113|NCT02420782|Drug|Pilocarpine|oral
79986114|NCT02420782|Drug|Placebo|oral
79986115|NCT02420782|Drug|Midazolam|oral
79986116|NCT03677024|Procedure|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
79345297|NCT03482141|Device|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
79345298|NCT03461406|Biological|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
79345299|NCT03461406|Biological|EVICEL|The EVICEL solution was applied topically via drip or spray application.
79345300|NCT03431974|Drug|LD-Aminopterin oral capsule|anti-folate treatment
79345301|NCT03431974|Drug|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
79345302|NCT03416335|Drug|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
79345303|NCT03416335|Drug|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
79345304|NCT03416335|Drug|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
79345305|NCT03408899|Drug|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
79345306|NCT03348956|Diagnostic Test|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
79345307|NCT03328546|Other|Dietary intake|Dietary intake converted into dietary pattern scores.
79986117|NCT04054193|Drug|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
79986118|NCT04054193|Drug|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; [5-HT]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
79345308|NCT03311308|Drug|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
79345309|NCT03311308|Drug|Metformin|500 mg, by mouth, twice a day for nine weeks.
79497006|NCT00002633|Drug|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
79497007|NCT00002633|Drug|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
79497008|NCT00002633|Drug|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
79986119|NCT04054193|Drug|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
79986120|NCT03394027|Drug|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
79986121|NCT03682172|Drug|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
79986122|NCT03682172|Drug|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
79986123|NCT03682172|Drug|Placebo|Four hour intravenous infusion with saline water
79986124|NCT03184480|Drug|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
79986125|NCT03136107|Other|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
79986126|NCT03136107|Other|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
79497009|NCT00002633|Drug|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
79497010|NCT00002633|Drug|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
79228219|NCT03313154|Other|Neuropsychiatric screening|"Psychiatric diagnosis through:~clinical interview~the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~HAM-D (Hamilton Scale for Depression);~PHQ-9 (Patient's Health Questionnaire-9 items);~MDQ (Mood Disorders Questionnaire);~YMRS (Young Mania Rating Scale);~ASRM (Altman Self Rating Mania scale);~BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~Assessment of Quality of Life:~SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
79497011|NCT00002633|Procedure|orchiectomy|Optional orchiectomy
79345310|NCT03308006|Biological|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
79497012|NCT00002633|Radiation|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
79497013|NCT00002639|Drug|chemotherapy|
79497014|NCT00002639|Drug|suramin|
79814912|NCT02601534|Behavioral|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
79345311|NCT03279393|Drug|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
79345312|NCT03270098|Behavioral|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
79986127|NCT01376466|Other|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
79345313|NCT03270098|Behavioral|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
79345314|NCT03266471|Diagnostic Test|Baseline blood sample|Blood sample for cytokine measurements and genetics.
79497015|NCT04659005|Other|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
79497016|NCT04659005|Other|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
79497017|NCT05751005|Dietary Supplement|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
79497018|NCT00002657|Biological|bleomycin sulfate|5 mg/m^2
79497019|NCT00002657|Biological|recombinant interferon alfa|3.0 x 10^6 IU/m^2
79228220|NCT03128853|Device|Rad-67 and DCI Mini Sensor|
79345315|NCT03266471|Diagnostic Test|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
79345316|NCT03266471|Other|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
79497020|NCT00002657|Drug|cyclophosphamide|650 mg/m^2
79497021|NCT00002657|Drug|cytarabine|300 mg/m^2
79497022|NCT00002657|Drug|doxorubicin hydrochloride|25 mg/m^2
79497023|NCT00002657|Drug|etoposide|120 mg/m^2
79497024|NCT00002657|Drug|methotrexate|120 mg/m^2
79497025|NCT00002657|Drug|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m^2.
79497026|NCT00002657|Drug|vincristine sulfate|1.4 mg/m^2
79497027|NCT00002657|Procedure|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
79497028|NCT00002657|Radiation|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
79497029|NCT05750927|Procedure|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
79497030|NCT00381719|Drug|AGN 203818|3 mg Capsule twice daily for 4 weeks
79497031|NCT00381719|Drug|AGN 203818|20 mg Capsule twice daily for 4 weeks
79497032|NCT00381719|Drug|AGN 203818|60 mg Capsule twice daily for 4 weeks
79497033|NCT00381719|Drug|placebo capsule|Capsule twice daily for 4 weeks
79497034|NCT05750771|Device|DES|Second-generation drug-eluting stents
79497035|NCT05750771|Device|DCB|Drug-coated balloon with paclitaxel as drug coating
79345317|NCT03266471|Diagnostic Test|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
79497036|NCT00381875|Biological|E1M184V peptide vaccine|
79497037|NCT00381875|Biological|incomplete Freund's adjuvant|
79497038|NCT00381875|Biological|sargramostim|
79497039|NCT00381875|Other|immunoenzyme technique|
79497040|NCT00002669|Biological|aldesleukin|
79345318|NCT03266471|Diagnostic Test|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
79345319|NCT03266471|Diagnostic Test|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
79497041|NCT00002669|Biological|recombinant interferon alfa|
79497042|NCT00002669|Drug|cisplatin|
79497043|NCT00002669|Drug|dacarbazine|
79497044|NCT05750693|Genetic|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
79497045|NCT00002675|Biological|filgrastim|
79497046|NCT00002675|Drug|carboplatin|
79497047|NCT00002675|Drug|cisplatin|
79814913|NCT02601534|Behavioral|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
79345320|NCT03266471|Diagnostic Test|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
79345321|NCT03179449|Diagnostic Test|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
79345322|NCT03179449|Procedure|Surgery|Undergo surgical resection
79345323|NCT03179449|Drug|Ferumoxytol|Given IV
79345324|NCT03179449|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
79345325|NCT02978196|Procedure|Injection of 99m-Tc-NM-01|Patient is injected with micro-dose of 99m-Tc-NM-01
79345326|NCT02915744|Drug|NKTR-102|
79345327|NCT02915744|Drug|Eribulin|
79345328|NCT02915744|Drug|Ixabepilone|
79345329|NCT02915744|Drug|Vinorelbine|
79345330|NCT02915744|Drug|Gemcitabine|
79345331|NCT02915744|Drug|Paclitaxel|
79497048|NCT00002675|Drug|cyclophosphamide|
79497049|NCT00002675|Drug|etoposide|
79497050|NCT00002675|Drug|mesna|
79497051|NCT00002675|Drug|vincristine sulfate|
79497052|NCT00002681|Biological|aldesleukin|
79497053|NCT00002681|Biological|daclizumab|
79497054|NCT02973113|Biological|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
79497055|NCT02973113|Biological|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
79497056|NCT05665439|Radiation|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
79497057|NCT05750615|Other|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
79497058|NCT00002687|Biological|aldesleukin|
79497059|NCT00002693|Biological|filgrastim|
79497060|NCT00002693|Drug|carboplatin|
79497061|NCT00002693|Drug|topotecan hydrochloride|
79497062|NCT05750381|Other|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
79497063|NCT05750381|Other|Placebo balm|Placebo balm formulation for topical applications.
79497064|NCT00002705|Drug|topotecan hydrochloride|
79497065|NCT00002711|Drug|chemotherapy|
79497066|NCT00002711|Drug|cisplatin|
79497067|NCT00002711|Drug|paclitaxel|
79497068|NCT00002711|Radiation|low-LET electron therapy|
79814914|NCT00762606|Procedure|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
79345332|NCT02915744|Drug|Docetaxel|
79345333|NCT02915744|Drug|Nab-paclitaxel|
79497069|NCT00002711|Radiation|low-LET photon therapy|
79497070|NCT00002717|Drug|cisplatin|
79659575|NCT06259955|Other|Mindfulness|In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat & Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat & Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
79659576|NCT06259942|Other|İntervention 1 group (underbody heater group only)|Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.
79659577|NCT06259942|Other|İntervention 2 group (group using both underbody heater and heated iv liquid)|IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.
79986128|NCT03686852|Other|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
79986129|NCT03184402|Drug|DWJ1252|tablet
79659578|NCT06259942|Other|Control Group|no active heating treatment was applied in this group
79659579|NCT06259929|Drug|Abemaciclib 150 MG + Giredestrant 30 MG|Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
79986130|NCT03184402|Drug|Gasmotin|tablet
79986131|NCT03184402|Drug|Placebo of Gasmotin|tablet
79986132|NCT03184402|Drug|Placebo of DWJ1252|tablet
79345334|NCT02885363|Other|Clinical examination|
79345335|NCT02885363|Other|Blood sample|
79345336|NCT02885363|Procedure|Echocardiography|
79345337|NCT02853643|Drug|ASN002|Single dose study with food effect
79345338|NCT02835638|Device|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
79345339|NCT02827955|Device|Gamma Knife® radiosurgery bilateral|
79345340|NCT02823327|Genetic|Laboratory Biomarker Analysis|Correlative studies
79497071|NCT00002717|Drug|paclitaxel|
79497072|NCT00002723|Drug|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
79497073|NCT00002723|Drug|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
79497074|NCT00002723|Drug|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
79986133|NCT01318395|Drug|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
79345341|NCT02823327|Other|Medical Chart Review|Medical chart review is performed
79345342|NCT02803125|Behavioral|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
79345343|NCT02803125|Behavioral|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
79345344|NCT02782949|Drug|Curcumin|Given PO
79345345|NCT02782949|Other|Laboratory Biomarker Analysis|Correlative studies
79345346|NCT02782949|Other|Placebo Administration|Given PO
79497075|NCT05648123|Behavioral|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
79497076|NCT00002735|Drug|Induction chemotherapy|Cisplatin and 5-Fluorouracil
79497077|NCT00002735|Drug|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
79497078|NCT00002735|Drug|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
79497079|NCT00002735|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
79497080|NCT00002747|Drug|cisplatin|
79497081|NCT00002747|Drug|fluorouracil|
79345347|NCT02782949|Other|Quality-of-Life Assessment|Ancillary studies
79345348|NCT02736656|Drug|SPN-812|
79659580|NCT06259916|Other|Alcohol|Participants in this condition will receive the standard alcohol dose
79659581|NCT06259916|Other|Cannabis|Participants in this group will self-administer legal-market flower cannabis
79659582|NCT06259903|Drug|MD-18|Subcutaneous Administration of MD-18 in Healthy Subjects.
79659583|NCT06259890|Other|measurement of salt intake|measurement of salt intake without intervention
79345349|NCT02528643|Drug|Enzalutamide|Oral capsule
79345350|NCT02528643|Drug|Placebo|Oral capsule
79345351|NCT02506933|Other|Laboratory Biomarker Analysis|Correlative studies
79345352|NCT02506933|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
79345353|NCT02506933|Other|Placebo|Given IM
79659584|NCT06259864|Other|EXOPULSE Mollii Suit method|EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities.
79659585|NCT06259838|Other|no intervention|no intervention
79659586|NCT06259825|Other|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
79659587|NCT06259825|Other|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
79659588|NCT06259812|Other|Parameters of Early Warning Scores|Parameters of Early Warning Scores
79814915|NCT00762606|Procedure|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
79345354|NCT02409810|Drug|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
79345355|NCT02325804|Behavioral|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
79345356|NCT02206815|Drug|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
79345357|NCT02206815|Drug|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
79345358|NCT02186691|Other|MRI|
79345359|NCT02175680|Drug|PRO 140|CCR5 Antagonist
79345360|NCT02175680|Other|Historical data|Historical data (i.e., time to HIV-1 RNA viral load > 500 copies/mL of 29 days).
79345361|NCT02151175|Device|LIFUP|
79345362|NCT02125981|Drug|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
79345363|NCT02125981|Drug|Placebo|taking placebo drug
79345364|NCT02114944|Device|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
79345365|NCT02114944|Device|CPAP|Patient treated, as per attending physician's decision, with CPAP
79345366|NCT02114944|Device|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
79659589|NCT06259773|Diagnostic Test|knee stability test (DYNEELAX)|Each knee was tested under a force 120 Newtons in a posterior to anterior direction to create anterior tibial translation at 20 degrees knee flexion. Side-to-side difference of anterior/posterior tibial translation (mm) was measured from radiographs. Measurement of rotation and translation by DYNEELAX was also recorded.
79659590|NCT06259760|Drug|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
79345367|NCT02114944|Device|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
79345368|NCT01983462|Drug|Clonidine|
79345369|NCT01983462|Drug|Hydrochlorothiazide|
79345370|NCT01983462|Drug|Placebo|
79345371|NCT01936883|Radiation|HDR|High dose rate brachytherapy
79345372|NCT01936883|Radiation|LDR|Low dose rate brachytherapy boost
79659591|NCT06259734|Behavioral|Transfusion Camp Rwanda education|Transfusion Camp Rwanda 3 day education intervention covering all aspects of safe blood transfusion practices as per the Rwanda Biomedical Centre National Transfusion Guidelines
79659592|NCT06259721|Drug|Anti-PD1 antibody, nimotuzumab and capecitabine|"Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment."
79986134|NCT01318395|Drug|Placebo|orally once per day
79345373|NCT01779375|Drug|Metformin|
79345374|NCT01779375|Drug|Glargine|
79345375|NCT01594723|Drug|120 mg LY2784544|Administered orally
79345376|NCT01559935|Drug|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
79345377|NCT01559935|Drug|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
79345378|NCT01559935|Drug|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
79345379|NCT01559935|Drug|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
79345380|NCT01559935|Drug|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
79345381|NCT01559935|Drug|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
79345382|NCT01284699|Procedure|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
79986135|NCT01376544|Device|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
79986136|NCT02329925|Device|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
79986137|NCT03686774|Drug|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
79986138|NCT03686774|Other|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
79497082|NCT00002747|Procedure|conventional surgery|
79345383|NCT00981058|Biological|Necitumumab|"800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
79345384|NCT00981058|Drug|Gemcitabine|"1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles."
79345385|NCT00981058|Drug|Cisplatin|"75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles."
79345386|NCT00979043|Behavioral|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
79345387|NCT00979043|Behavioral|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
79345388|NCT00667069|Drug|triptorelin|
79345389|NCT00667069|Procedure|adjuvant therapy|
79345390|NCT00667069|Radiation|3-dimensional conformal radiation therapy|
79497083|NCT00002747|Radiation|low-LET cobalt-60 gamma ray therapy|
79497084|NCT00002747|Radiation|low-LET photon therapy|
79497085|NCT02973035|Drug|Amlodipine|
79497086|NCT02973035|Drug|Valsartan|
79497087|NCT05749991|Device|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
79497088|NCT05749991|Device|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
79497089|NCT00002753|Radiation|iodine I 131 monoclonal antibody 81C6|
79497090|NCT00002759|Drug|cyclosporine|
79986139|NCT02420392|Drug|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
79986140|NCT01318551|Drug|BAY85-3934|single dose, 20 mg
79986141|NCT01318551|Drug|BAY85-3934|single dose, 40 mg (optional)
79345391|NCT00565851|Biological|Bevacizumab|Given IV
79345392|NCT00565851|Drug|Carboplatin|Given IV
79986142|NCT01318551|Drug|BAY85-3934|single dose, 80 mg (optional)
79986143|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
79345393|NCT00565851|Drug|Docetaxel|Given IV
79345394|NCT00565851|Drug|Gemcitabine Hydrochloride|Given IV
79345395|NCT00565851|Other|Laboratory Biomarker Analysis|Correlative studies
79345396|NCT00565851|Drug|Paclitaxel|Given IV
79497091|NCT00002759|Drug|irinotecan hydrochloride|
79497092|NCT00002759|Drug|phenobarbital|
79497093|NCT00002765|Biological|LMB-2 immunotoxin|
79497094|NCT00002771|Biological|recombinant interferon alfa|
79497095|NCT00002771|Drug|busulfan|
79497096|NCT00002771|Drug|cytarabine|
79497097|NCT00002771|Drug|hydroxyurea|
79497098|NCT00002771|Drug|idarubicin|
79497099|NCT00002771|Procedure|allogeneic bone marrow transplantation|
79497100|NCT00002771|Procedure|autologous bone marrow transplantation|
79497101|NCT00002771|Procedure|peripheral blood stem cell transplantation|
79497102|NCT00002771|Radiation|radiation therapy|
79497103|NCT00002777|Drug|exemestane|
79497104|NCT00002777|Drug|tamoxifen citrate|
79659593|NCT06259708|Device|Low intensity focused ultrasound|Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
79814916|NCT00818441|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
79986144|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
79986145|NCT01562795|Drug|corticosteroids|corticosteroids plus artificial tear substitute
79986146|NCT01562795|Drug|artificial tear substitute|artificial tear substitute alone
79345397|NCT00565851|Other|Quality-of-Life Assessment|Ancillary studies
79345398|NCT00305227|Drug|Lactin-V|
79345399|NCT00305227|Drug|Placebo|
79345400|NCT00238563|Drug|Triamcinolone injection, sub-tenon|
79345401|NCT00001070|Drug|Oral Vitamin C|
79345402|NCT04601467|Drug|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
79986147|NCT02424448|Procedure|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
79497105|NCT04611035|Device|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
79986148|NCT01311817|Biological|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
79345403|NCT04601467|Drug|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
79345404|NCT01599793|Drug|cabozantinib|Given PO
79345405|NCT01599793|Other|laboratory biomarker analysis|Correlative studies
79345406|NCT01599793|Procedure|magnetic resonance imaging|Undergo MRI
79345407|NCT05209633|Drug|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
79345408|NCT05209633|Drug|Placebo|placebo
79345409|NCT04499677|Drug|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
79345410|NCT04499677|Drug|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
79345411|NCT04499677|Other|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
79345412|NCT04499677|Other|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
79345413|NCT05652751|Drug|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
79345414|NCT05652751|Drug|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
79497106|NCT00002783|Drug|cisplatin|
79497107|NCT00002783|Drug|floxuridine|
79497108|NCT00002783|Drug|fluorouracil|
79497109|NCT00002783|Drug|leucovorin calcium|
79497110|NCT00002783|Procedure|conventional surgery|
79659594|NCT06259695|Device|Adjustable Aquatic Therapy Prosthesis|We will recruit up to three participants, who will attend up to two fitting appointments lasting up to one hour to assist in the design development. After the design of the prosthesis is completed, participants will attend three, 30-minute, aquatic therapy sessions with a physical therapist trained in aquatic therapy and utilize the prosthesis.
79659595|NCT06259682|Behavioral|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
79659596|NCT06259669|Drug|Ruxolitinib Cream|Ruxolitinib Cream
79814917|NCT00818441|Drug|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
79814918|NCT00704639|Drug|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
79814919|NCT00704639|Drug|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
79659597|NCT06259656|Diagnostic Test|COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)|Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
79659598|NCT06259643|Other|Power wheelchair soccer|Participants will practice power wheelchair soccer during the course of the power wheelchair soccer season (starting in November 2023 and ending in June 2024). Sessions are given once a week, by a coach with experience in this adaptive sport.
79659599|NCT06259630|Drug|Nicotine|Participant receives oral dose of nicotine
79659600|NCT06259630|Drug|Placebo oral capsule|Participant receives oral dose of placebo
79986149|NCT01354821|Procedure|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
79986150|NCT01354821|Procedure|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
79986151|NCT02424136|Other|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
79986152|NCT02424136|Other|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
79986153|NCT02424136|Other|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
79986154|NCT02424136|Other|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
79659601|NCT06259604|Other|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
79659602|NCT06259604|Other|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
79659603|NCT06259591|Behavioral|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
79986155|NCT02424136|Other|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
79659604|NCT06259591|Behavioral|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
79345415|NCT05652751|Device|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
79659605|NCT06259578|Biological|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|1 dose of 0.5 ml containing inactivated SARS-CoV-2 virus (5 μg ), Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride
79659606|NCT06259565|Drug|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
79986156|NCT02424136|Other|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
79986157|NCT02424136|Other|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
79986158|NCT02916056|Drug|Azeliragon 5mg|
79497111|NCT05749757|Device|Acupuncture|For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
79345416|NCT05652751|Device|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
79345417|NCT02909335|Drug|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~between 6 and 10 ng / ml during the first 2 months,~between 5 and 8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
79659607|NCT06259565|Other|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
79986159|NCT03770676|Dietary Supplement|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
79986160|NCT03181438|Procedure|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
79659608|NCT06259552|Biological|SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody|SPX- 303 Injection
79345418|NCT02909335|Drug|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~between 6 and 10 ng / ml during the first 2 months,~between 5-8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
79345419|NCT02909335|Drug|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
79345420|NCT02909335|Drug|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
79659609|NCT06259539|Behavioral|YouTube nutrition education|For those in the intervention group, the YouTube training modules had step-by-step recipe demonstrations, strategies on how to get your child to eat more new foods, social stories, First-Then visual chart, and other nutrition education materials. All the videos were less than 5 minutes long, and parents were assigned 2 videos per week for 8 consecutive weeks. Parents answered 2 open-ended questions each week related to the educational materials they reviewed.
79659610|NCT06259526|Drug|Placebo group|(1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
79659611|NCT06259526|Drug|JS1-1-01 low-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
79659612|NCT06259526|Drug|JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules|(1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
79497112|NCT05749757|Device|Sham Acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
79497113|NCT00002789|Drug|busulfan|
79659613|NCT06259526|Drug|JS1-1-01 high-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
79814920|NCT00704639|Radiation|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
79814921|NCT00826943|Drug|Cetirizine|Cetirizine 10 mg tab daily x 7 days
79986161|NCT03181438|Procedure|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
79497114|NCT00002789|Drug|cyclophosphamide|
79497115|NCT00002789|Drug|cyclosporine|
79497116|NCT00002789|Drug|methotrexate|
79497117|NCT00002789|Procedure|allogeneic bone marrow transplantation|
79497118|NCT00002789|Procedure|peripheral blood stem cell transplantation|
79497119|NCT00381953|Drug|Peginterferon alfa-2a|
79497120|NCT00381953|Drug|Interferon alfa-2a|
79497121|NCT00381953|Drug|Ribavirin|
79497122|NCT05749523|Behavioral|Exercise|Exercise vs non-exercise
79345421|NCT02893267|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
79497123|NCT05613881|Other|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
79345422|NCT02893267|Other|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
79345423|NCT02893267|Other|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
79345424|NCT02893267|Device|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
79345425|NCT04471909|Device|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
79814922|NCT00826943|Drug|Levocetirizine|5 mg tab daily x 7 days
79345426|NCT02805517|Device|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
79345427|NCT05652595|Drug|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
79345428|NCT05652595|Drug|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
79345429|NCT04418323|Procedure|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
79345430|NCT05652517|Procedure|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
79345431|NCT05163847|Biological|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
79345432|NCT05163847|Biological|Fluzone HD IIV|Administered intramuscularly on Day 1
79497124|NCT00382343|Drug|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
79497125|NCT05749445|Drug|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
79497126|NCT05749367|Drug|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
79814923|NCT00826943|Drug|Placebo|Placebo tablet daily x 7 days
79814924|NCT00707369|Drug|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
79814925|NCT00707369|Drug|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
79228221|NCT02469428|Other|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
79814926|NCT02611661|Device|PET/MRI|
79345433|NCT05163847|Other|IN Placebo|Administered intranasally on Day 1
79497127|NCT05749367|Drug|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
79497128|NCT05502887|Diagnostic Test|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
79345434|NCT05163847|Other|IM Placebo|Administered intramuscularly on Day 1
79345435|NCT05203393|Device|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
79345436|NCT04196569|Device|Alcon Trifocal and Trifocal Toric Intraocular Lenses|"Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60"
79814927|NCT02611661|Radiation|Percutaneous ablation|
79814928|NCT02611661|Radiation|Stereotactic body radiotherapy|
79986162|NCT01355133|Biological|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
79986163|NCT02424058|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
79986164|NCT02424058|Behavioral|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
79345437|NCT05651971|Behavioral|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
79497129|NCT05749289|Drug|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
79497130|NCT05501249|Behavioral|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
79345438|NCT04137211|Behavioral|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
79345439|NCT04137211|Behavioral|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
79497131|NCT05749133|Biological|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10^6/kg±20%; Low dose group: 3.0×10^6/kg±20%; High dose group: 6.0×10^6/kg±20%. Dose was weight-based."
79497132|NCT04331171|Device|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
79814929|NCT02611739|Device|Medi-Port|Treatment
79986165|NCT02420158|Device|Trans-cutaneous vagal nerve electrical stimulation|
79814930|NCT02611739|Device|Medi-Port|Control
79814931|NCT00834041|Drug|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
79814932|NCT00760929|Drug|Placebo|iv 9mg/kg weekly
79814933|NCT00760929|Drug|Placebo|iv 16mg/kg every 3 weeks
79814934|NCT00760929|Drug|RG1507|iv 9mg/kg weekly
79814935|NCT00760929|Drug|RG1507|iv 16mg/kg every 3 weeks
79814936|NCT00760929|Drug|erlotinib [Tarceva]|150mg oral daily
79814937|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
79345440|NCT04137211|Behavioral|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
79497133|NCT05590481|Device|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
79497134|NCT05590481|Behavioral|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
79345441|NCT05651815|Device|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
79345442|NCT04132219|Behavioral|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
79345443|NCT03998293|Drug|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
79345444|NCT05651503|Dietary Supplement|Prodilac Oral, Frezyderm|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
79345445|NCT05651503|Dietary Supplement|placebo lozenges|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
79345446|NCT01755598|Biological|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
79497135|NCT05490017|Drug|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
79986166|NCT01361841|Drug|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
79345447|NCT01755598|Biological|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
79345448|NCT01606306|Drug|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
79345449|NCT01606306|Drug|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
79345450|NCT01606306|Drug|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
79345451|NCT01754194|Procedure|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
79345452|NCT01754194|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
79497136|NCT05490017|Drug|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
79497137|NCT05748977|Drug|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
79497138|NCT02972957|Biological|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
79497139|NCT02972957|Drug|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
79497140|NCT05748899|Behavioral|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
79986167|NCT01361841|Drug|travoprost, latanoprost and bimatoprost|one drop once a day for life
79986168|NCT02420236|Behavioral|High-intensity resistance training|
79986169|NCT02420236|Behavioral|General physical activity|
79986170|NCT02420236|Behavioral|Multidisciplinary rehabilitation program|
79986171|NCT02583789|Drug|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
79986172|NCT02583789|Drug|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
79345453|NCT01753570|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
79345454|NCT01753570|Drug|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
79345455|NCT01753570|Drug|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
79497141|NCT05446259|Other|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
79497142|NCT05748743|Procedure|glove changing|Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
79345456|NCT01753570|Drug|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
79345457|NCT01753570|Drug|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
79345458|NCT01753336|Biological|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
79345459|NCT01777282|Drug|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
79497143|NCT05471141|Other|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
79497144|NCT05469191|Other|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
79497145|NCT05469191|Other|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
79497146|NCT04571333|Device|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
79497147|NCT05545319|Drug|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to <60 mL/min) every 12 hours
79497148|NCT05545319|Drug|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
79986173|NCT01358019|Drug|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
79345460|NCT01777282|Drug|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
79497149|NCT05545319|Drug|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to <60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
79659614|NCT06259526|Drug|Active drug group|(1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.
79659615|NCT06259513|Procedure|omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO|Omission of SLNB in cT1-2N0 or Omission of ALND in patients with </= 2 macrometastasis in SLNB
79659616|NCT06259487|Biological|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
79659617|NCT06259487|Behavioral|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
79659618|NCT06259448|Other|urine self-sampling|urine self-sampling
79345461|NCT01777282|Drug|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
79345462|NCT01777282|Drug|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
79659619|NCT06259435|Behavioral|Low-energy dense diet|Subjects will follow time-restricted eating of a low energy dense diet
79659620|NCT06259435|Behavioral|Usual diet|Subjects will follow time-restricted eating of the usual diet
79659621|NCT06259422|Drug|Iohexol|Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
79659622|NCT06259422|Diagnostic Test|125I-iothalamate and 131I-hippuran|Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
79659623|NCT06259409|Device|Regenn® Negative Pressure Therapy System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
79986174|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
79345463|NCT01777282|Drug|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
79345464|NCT01777282|Drug|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
79497150|NCT05446337|Other|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
79659624|NCT06259409|Device|Prevena™ Incision Management System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
79986175|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.
79345465|NCT04169776|Device|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
79345466|NCT04571632|Drug|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions < 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
79345467|NCT04571632|Drug|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions < 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
79497151|NCT05536427|Biological|IPM001|IPM001 will be used against tumor cells
79497152|NCT05526287|Other|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
79497153|NCT05526287|Other|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
79497154|NCT05523869|Drug|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
79497155|NCT05523869|Procedure|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
79659625|NCT06259396|Behavioral|The 8x5 Diet|A virtual, dietitian-counselled, healthy dietary pattern defined by its fat intake, its daily eating pattern, keeping adequately hydrated, having a variety of whole grains, fruit and vegetables, and use of certain plant fibres.
79659626|NCT06259383|Drug|Ivermectin|3-day 1 daily dose of 400 μg/kg oral ivermectin
79659627|NCT06259370|Behavioral|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
79986176|NCT01355367|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
79986177|NCT05759520|Biological|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
79986178|NCT05759520|Biological|Prevenar 13|the 2-month-old control group received the active control vaccine
79986179|NCT02423902|Biological|Ad-RTS-hIL-12|Approximately 1.0x10^12 viral particles (vp) per injection
79986180|NCT02423902|Drug|Veledimex|7 oral doses of veledimex
79986181|NCT02427880|Drug|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
79986182|NCT02427880|Drug|Furosemide and Hydrochlorothiazide Followed by Furosemide|
79986183|NCT02567643|Radiation|Stereotactic Radiosurgery|
79986184|NCT04789200|Drug|NX9 Oral Contrast Agent|Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
79497156|NCT05523557|Behavioral|Urban Training|1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
79497157|NCT05522465|Drug|Prednisone|Prednisone 4mg/kg.d, d1-4
79345468|NCT04571632|Drug|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
79345469|NCT04571632|Other|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions < 0,5 cm to 4.0 mL for lesions > 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
79345470|NCT01975389|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
79497158|NCT05522465|Drug|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
79497159|NCT04428047|Drug|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
79659628|NCT06259344|Behavioral|Fragmented Pain Neuroscience Education (FPNE)|Pain Neuroscience Education (PNE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 60 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
79659629|NCT06259344|Behavioral|Condensed Fragmented Pain Neuroscience Education (CPNE)|Pain Neuroscience Education (PNE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 8 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
79345471|NCT01975389|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
79345472|NCT01974141|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
79345473|NCT01974141|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
79345474|NCT01945593|Biological|BAX855|Antihemophilic Factor (Recombinant), PEGylated
79497160|NCT05248061|Other|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~- *Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
79345475|NCT01945281|Drug|Caspofungin|
79497161|NCT05248061|Other|Group B|"The same exercises as in Group 1 will be suitable for the participants.~PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
79345476|NCT01945281|Drug|Amphotericin B Deoxycholate|
79345477|NCT01961349|Drug|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
79345478|NCT01961349|Drug|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
79345479|NCT01961349|Drug|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
79345480|NCT01973595|Dietary Supplement|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
79497162|NCT05233865|Behavioral|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
79659630|NCT06259344|Other|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
79345481|NCT01973595|Other|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
79345482|NCT01944969|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
79345483|NCT01961115|Drug|Epacadostat|Given PO
79345484|NCT01961115|Biological|MELITAC 12.1 Peptide Vaccine|Given ID/SC
79345485|NCT04661397|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
79345486|NCT04661397|Drug|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
79345487|NCT04661397|Drug|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
79345488|NCT04661397|Drug|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
79345489|NCT01973439|Other|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
79345490|NCT01973439|Other|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
79345491|NCT01973283|Drug|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
79986185|NCT02423746|Behavioral|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
79497163|NCT05233865|Behavioral|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
79986186|NCT02423746|Behavioral|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
79345492|NCT01943799|Biological|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
79497164|NCT05230277|Other|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. [8] which consists in mobilizing the sacrum between the iliac bones.
79497165|NCT05230277|Other|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. [13] and proposed by others to perform simulated bone manipulations [14], will be applied to the sacrum
79497166|NCT04835675|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
79497167|NCT05218187|Device|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
79497168|NCT05218187|Other|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
79659631|NCT06259344|Other|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
79659632|NCT06259331|Drug|SPN-812 (600mg, QD)|SPN-812 (600mg, QD)
79345493|NCT01943799|Drug|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
79345494|NCT01972659|Drug|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
79345495|NCT01972659|Drug|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
79345496|NCT01972659|Drug|sugammadex|4 mg/kg iv bolus at the end of the surgery
79986187|NCT01355445|Drug|Vincristine, Irinotecan|"D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
79659633|NCT06259318|Behavioral|Kanasina Gulabi|Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
79659634|NCT06259305|Other|Creation of a memory track combined with the baby's heartbeat|This is as described above
79659635|NCT06259279|Behavioral|High intensity high impact exercise intervention|"Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes."
79345497|NCT01971723|Other|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
79659636|NCT06259266|Other|Anti-reflux valve for dialysis catheter|
79986188|NCT01355445|Drug|Vincristine, Irinotecan, Temozolomide|"D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)~D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
79345498|NCT01971723|Other|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
79986189|NCT02420080|Drug|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
79986190|NCT01355601|Other|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
79986191|NCT01355601|Other|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
79986192|NCT04772118|Other|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
79497169|NCT05217953|Device|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
79345499|NCT01942785|Drug|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
79345500|NCT01774786|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
79497170|NCT05215691|Procedure|Group I: TAPA block|Postoperative analgesia will be provided with peripheral nerve block (TAPA)
79497171|NCT05215691|Procedure|Group II: IV Morphine|Postoperative analgesia will be provided with opioids
79497172|NCT04831073|Procedure|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
79497173|NCT05204147|Drug|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
79497174|NCT05204147|Procedure|Biospecimen Collection|Correlative studies
79497175|NCT04824053|Dietary Supplement|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
79497176|NCT04824053|Dietary Supplement|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
79497177|NCT04824053|Dietary Supplement|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
79497178|NCT04824053|Dietary Supplement|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
79814938|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
79497179|NCT04824053|Dietary Supplement|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
79497180|NCT04824053|Dietary Supplement|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
79814939|NCT00704795|Other|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
79345501|NCT01774786|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
79345502|NCT01774786|Drug|Cisplatin|Participants will receive cisplatin 80 mg/m^2 IV q3w for 6 cycles.
79345503|NCT01774786|Drug|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
79345504|NCT01774786|Drug|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
79345505|NCT01774786|Drug|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
79497181|NCT05190653|Other|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
79497182|NCT04812197|Procedure|Biospecimen Collection(Punch Biopsy)|Punch Biopsy of Skin
79986193|NCT04483258|Procedure|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
79986194|NCT04483258|Procedure|intravenous sedation|midazolam +ketamine + atropine
79986195|NCT02419768|Other|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
79986196|NCT03178474|Other|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
79814940|NCT00704795|Other|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
79986197|NCT03178474|Other|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
79986198|NCT03178474|Other|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
79986199|NCT01355757|Device|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
79986200|NCT01355757|Drug|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
79345506|NCT01960725|Biological|RV5 (Pentavalent Rotavirus Vaccine)|
79345507|NCT04654845|Procedure|Pulpotomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
79497183|NCT04811339|Drug|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
79497184|NCT04811339|Other|Placebo oral tablet without BSS|Placebo Tablet made by P & G to contain everything except active ingredient ( BSS)
79497185|NCT04804631|Device|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
79986201|NCT02507505|Procedure|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
79497186|NCT05173961|Other|Internet-Based Intervention|Use oncpatient mobile application
79497187|NCT05173961|Other|Survey Administration|Complete survey
79986202|NCT02507505|Procedure|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
79497188|NCT04790123|Procedure|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
79497189|NCT04790123|Procedure|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
79497190|NCT00382577|Drug|Itopride|
79497191|NCT00382577|Drug|Placebo|
79497192|NCT05406323|Behavioral|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
79497193|NCT04331093|Drug|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
79497194|NCT05142917|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
79497195|NCT05142917|Behavioral|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
79497196|NCT04760873|Device|cryotherapy|cryotherapy is a freeze spray that will be applied to GAVE for bleeding
79497197|NCT04758767|Drug|CID-103|anti-CD38 antibody
79814941|NCT04039295|Procedure|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
79986203|NCT03181360|Drug|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
79497198|NCT05122637|Device|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
79497199|NCT05122637|Device|Standard of Care Aspiration Thrombectomy System|Commercially available aspiration catheter with commercially available aspiration pump
79814942|NCT00707525|Procedure|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
79986204|NCT03181360|Other|Control|Best standard treatment
79814943|NCT00704951|Drug|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
79497200|NCT05120297|Drug|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
79497201|NCT05120297|Drug|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
79345508|NCT04654845|Procedure|Pulpectomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
79345509|NCT01942161|Drug|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
79345510|NCT01942161|Drug|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
79345511|NCT01942161|Drug|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
79345512|NCT01971645|Drug|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
79345513|NCT01971645|Drug|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
79345514|NCT01941537|Drug|ILV-094|IV infusion of ILV-094
79345515|NCT01941537|Drug|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
79345516|NCT01971567|Device|HIRREM|
79345517|NCT01960413|Drug|Montelukast added to Hydroxyurea|
79345518|NCT01960413|Drug|Placebo added to Hydroxyurea|
79345519|NCT04661241|Other|Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches|The proposed sequence (<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
79345520|NCT04661241|Other|Routine clinical MRI protocol|MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
79345521|NCT01970475|Biological|ABP 501|Solution for subcutaneous injection in pre-filled syringe
79986205|NCT04769856|Other|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
79345522|NCT01970475|Biological|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
79345523|NCT04653753|Device|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
79497202|NCT05106881|Device|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
79659637|NCT06259240|Other|Prone plank exercises|Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.
79659638|NCT06259240|Device|Electrical Stimulation|Electrical Stimulation
79659639|NCT06259227|Other|Cardiorespiratory fitness (CRF) training|The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
79986206|NCT04769856|Other|Satisfaction scale|Satisfaction scale
79986207|NCT04275531|Drug|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
79986208|NCT04764864|Procedure|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
79986209|NCT04764864|Procedure|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
79345524|NCT01939977|Drug|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
79345525|NCT01939977|Drug|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
79497203|NCT04740359|Other|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
79497204|NCT04740359|Other|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
79345526|NCT01939899|Drug|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
79345527|NCT01970397|Device|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
79345528|NCT01970397|Device|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
79497205|NCT05104541|Other|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
79497206|NCT05362097|Other|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
79659640|NCT06259214|Other|15% HCl gel|Icon , DMG, Hamburg, Germany
79659641|NCT06259214|Other|H3PO4 gel|Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA
79659642|NCT06259214|Other|Er:YAG laser|Fotona AT Fidelis III, Ljubljana, Slovenia
79659643|NCT06259201|Device|Vagus Nerve Stimulation|Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM & PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
79814944|NCT00760617|Biological|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
79345529|NCT01970241|Drug|NPH|NPH given per study table based on steroid dose and patient weight in kg.
79345530|NCT01970241|Drug|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
79345531|NCT01939353|Drug|CTN SR|CTN SR tablets
79345532|NCT01939353|Drug|Placebo|CTN SR-matching placebo tablets
79345533|NCT01970007|Device|Zilver Vena Venous Self-Expanding Stent|stenting
79345534|NCT01728376|Drug|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
79345535|NCT01728376|Drug|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
79345536|NCT01708174|Drug|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
79345537|NCT01708174|Drug|TMZ|Temozolomide capsules were obtained locally by the Investigator
79345538|NCT01605916|Drug|AZD6244|Tablet Oral bid
79345539|NCT02416609|Radiation|LDR|LDR will be delivered during each cycle of Gem-based doublets
79345540|NCT02416609|Drug|Gem-based doublets|4 cycles of Gem-based doublets
79345541|NCT02416609|Radiation|SBRT|SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
79345542|NCT02321137|Procedure|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
79345543|NCT02321137|Procedure|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
79345544|NCT02217709|Drug|phenelzine sulfate|Given by mouth
79497207|NCT00382421|Drug|bisoprolol|
79345545|NCT02217709|Other|laboratory biomarker analysis|Correlative studies
79345546|NCT02217709|Other|questionnaire administration|Ancillary studies
79497208|NCT00382421|Drug|amlodipine|
79497209|NCT00382421|Drug|molsidomine|
79497210|NCT00382421|Drug|acetylsalicylic acid|
79497211|NCT04712825|Behavioral|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
79345547|NCT04791553|Drug|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
79659644|NCT06259188|Device|Respiratory Muscle Training Device|In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.
79497212|NCT04712825|Device|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
79497213|NCT05087849|Biological|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
79497214|NCT05075837|Biological|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
79497215|NCT05335811|Drug|4-[18F]Fluoro-1-Naphthol|By vein (IV)
79497216|NCT05068583|Other|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
79497217|NCT05314751|Behavioral|Questionnaire and interview|An online survey and an in-depth interview.
79659645|NCT06259188|Device|Personalized Breathing Exercise Device|Personalized Breathing Exercise Device
79497218|NCT05043701|Drug|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
79659646|NCT06259175|Drug|Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
79345548|NCT05651347|Other|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
79345549|NCT05651347|Drug|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
79345550|NCT05651269|Drug|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
79659647|NCT06259175|Drug|Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
79814945|NCT00760617|Biological|Fluarix|Intramuscular (IM) administration, 1 dose
79814946|NCT04098783|Other|Home visit, health education|
79345551|NCT05647525|Diagnostic Test|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
79345552|NCT04791163|Device|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
79345553|NCT05638009|Dietary Supplement|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
79345554|NCT05638009|Dietary Supplement|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
79497219|NCT05040581|Behavioral|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
79659648|NCT06259175|Drug|Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
79659649|NCT06259162|Procedure|LAG-3 expression / immune checkpoint protein expression|Evaluate the tissue and blood before and after chemotherapy
79345555|NCT05636683|Procedure|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
79659650|NCT06259149|Drug|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
79659651|NCT06259110|Diagnostic Test|Multiplex PCR|multiplex PCR is a molecular biology technique that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample
79659652|NCT06259097|Drug|Misoprostol and Pitocin|25 mcg vaginally every 6 hours (miso) and 3-6 mL intravenously every hour (pitocin)
79814947|NCT04098549|Other|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
79986210|NCT01355835|Device|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
79345556|NCT01635283|Biological|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
79345557|NCT01635283|Other|laboratory biomarker analysis|Correlative studies
79659653|NCT06259097|Drug|Pitocin only|3-6 mL intravenously every hour (pitocin)
79814948|NCT04098549|Other|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
79986211|NCT04804527|Other|Intensified physiotherapy|Physiotherapy x2
79986212|NCT04804527|Other|Usual care physiotherapy|Physiotherapy x1
79986213|NCT03384745|Drug|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
79986214|NCT03384745|Drug|Placebo|Placebo contains no active drug.
79986215|NCT03384745|Drug|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
79986216|NCT03180814|Other|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
79345558|NCT01707004|Drug|decitabine|Given IV
79345559|NCT01707004|Drug|fludarabine phosphate|Given IV
79345560|NCT01707004|Drug|busulfan|Given IV
79345561|NCT01707004|Drug|cyclophosphamide|Given IV
79345562|NCT01707004|Drug|tacrolimus|Given PO or IV
79345563|NCT01707004|Drug|mycophenolate mofetil|Given PO
79345564|NCT01707004|Biological|filgrastim|Given SC
79659654|NCT06259058|Drug|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14-day cycle
79659655|NCT06259058|Drug|Oxaliplatin|60 mg/m² on Day 1 of a 14-day cycle
79659656|NCT06259058|Drug|5-Fluorouracil|2400 mg/m² continuous IV infusion in 46 h
79659657|NCT06259058|Drug|Leucovorin|400 mg/m² on Day 1 of a 14-day cycle
79345565|NCT01707004|Radiation|total-body irradiation|Undergo total-body irradiation
79345566|NCT01707004|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
79345567|NCT01707004|Other|laboratory biomarker analysis|Correlative studies
79345568|NCT01939197|Drug|ABT-450/r/ABT-267|tablet
79345569|NCT01939197|Drug|ABT-333|tablet
79345570|NCT01939197|Drug|ribavirin|tablet
79814949|NCT04098159|Device|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
79814950|NCT00760383|Dietary Supplement|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
79986217|NCT01361997|Biological|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
79986218|NCT01361997|Biological|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
79986219|NCT03180892|Other|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
79986220|NCT04750824|Drug|Afatinib|Afatinib
79345571|NCT05182645|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
79986221|NCT04750824|Drug|other systemic therapy|other systemic therapy
79986222|NCT01362075|Procedure|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
79345572|NCT05182645|Behavioral|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
79345573|NCT01969851|Drug|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
79345574|NCT04661085|Diagnostic Test|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
79345575|NCT04659759|Other|COVID-19 exposure|COVID-19 exposure during pregnancy
79497220|NCT04281719|Other|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
79659658|NCT06259058|Radiation|SBRT|30Gy/5Fx
79659659|NCT06259032|Other|Mechanical alignment|Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.
79659660|NCT06259032|Other|Functional alignment|Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
79986223|NCT01362075|Procedure|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
79986224|NCT03180970|Drug|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
79986225|NCT03180970|Drug|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
79986226|NCT03180970|Drug|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
79986227|NCT03180970|Drug|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
79986228|NCT03180970|Drug|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
79659661|NCT06259019|Device|Liquid Biopsy System (LBS)|Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
79659662|NCT06259006|Drug|Dexamethasone Oral|4mg capsules taken orally in three divided doses to a total daily dose of 20mg/m2 (maximum dose 24mg/day) for three days
79659663|NCT06259006|Drug|Placebo|Matching capsules taken orally three times daily for three days
79986229|NCT05676528|Other|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
79345576|NCT04659759|Biological|COVID-19 vaccine|Receipt of any COVID-19 vaccine
79345577|NCT01938573|Drug|Cisplatin|Given IV
79345578|NCT01938573|Drug|Gemcitabine Hydrochloride|Given IV
79345579|NCT01938573|Drug|Sirolimus|Given PO
79986230|NCT01319097|Other|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
79345580|NCT01938573|Procedure|Cystectomy|Undergo cystectomy when appropriate
79345581|NCT05496907|Behavioral|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
79345582|NCT04777513|Procedure|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
79345583|NCT04777513|Procedure|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
79345584|NCT04777513|Procedure|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
79345585|NCT04777513|Device|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
79345586|NCT04777513|Device|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
79345587|NCT05169931|Biological|RegenerEyes|Biologic eye drop
79679470|NCT02941497|Behavioral|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
79345588|NCT04788901|Other|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
79497221|NCT05034341|Other|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
79986231|NCT03631446|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
79986232|NCT03178240|Behavioral|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
79986233|NCT03383887|Drug|Placebo oral capsule|Placebo before sleep
79986234|NCT03383887|Drug|DAW1033D oral capsule|DAW1033D before sleep
79986235|NCT03184168|Drug|[14C]lorlatinib|Extemporaneously compounded oral solution of [14C]lorlatinib (approximately 100 mg/100 µCi)
79345589|NCT01937871|Drug|5 mg Tadalafil|Administered orally
79345590|NCT01937871|Drug|Placebo|Administered orally
79345591|NCT01937871|Drug|0.2 mg Tamsulosin|Administered orally
79345592|NCT04775875|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
79345593|NCT01341535|Radiation|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
79345594|NCT01341535|Radiation|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
79345595|NCT04775407|Procedure|blood sampling|IgM og IgG analysis
79345596|NCT05380063|Drug|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
79345597|NCT05380063|Drug|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
79345598|NCT01287091|Drug|GDC-0980|Oral tablet dose
79345599|NCT01287091|Drug|GDC-0980|Oral capsule dose
79345600|NCT01287091|Drug|GDC-0980|Oral tablet dose in fed state
79345601|NCT01287091|Drug|GDC-0980|Oral repeating dose in fasting state
79345602|NCT01287091|Drug|GDC-0980|Oral repeating dose in fed state
79345603|NCT01287091|Drug|GDC-0980|Oral tablet in a fasting state
79345604|NCT01287091|Drug|rabeprazole|Oral repeating dose
79345605|NCT01269463|Drug|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
79345606|NCT01269463|Drug|Placebo|Capsule without active drug
79679471|NCT02950883|Drug|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
79345607|NCT05362825|Drug|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
79814951|NCT00760383|Dietary Supplement|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
79814952|NCT04098471|Procedure|transanal local excision following radiotherapy|transanal local excision following radiotherapy
79814953|NCT00759915|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
79814954|NCT00759915|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
79814955|NCT00759759|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
79986236|NCT04709874|Other|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
79986237|NCT04709874|Other|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
79986238|NCT01362153|Drug|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
79986239|NCT01362153|Drug|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
79345608|NCT05362825|Procedure|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
79345609|NCT02539459|Drug|Everolimus|10 mg tablets
79345610|NCT01706926|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
79345611|NCT01706926|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
79345612|NCT01706926|Biological|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
79679472|NCT02950883|Drug|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
79679473|NCT05317767|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
79814956|NCT00759759|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
79814957|NCT00759681|Device|ArterX Surgical Sealant|Apply at the suture site.
79986240|NCT03184324|Drug|DWP14012|tablet
79986241|NCT03184324|Drug|Esomeprazole|tablet
79986242|NCT03184324|Drug|DWP14012 placebo|tablet
79986243|NCT03184324|Drug|Esomeprazole placebo|tablet
79986244|NCT02427334|Drug|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
79986245|NCT02427334|Drug|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
79986246|NCT02427334|Drug|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
79345613|NCT01706926|Other|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
79345614|NCT01634113|Drug|tiotropium-bromide|IMP
79345615|NCT01634113|Drug|tiotropium-bromide|IMP
79345616|NCT01634113|Drug|placebo|placebo matching tiotropium
79345617|NCT01706770|Device|enfilcon A|
79814958|NCT00759681|Device|Gelfoam and Thrombin|Apply at the suture site.
79814959|NCT00826241|Drug|Temozolomide|Starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle.
79814960|NCT00826241|Drug|Lapatinib|Starting dose 1250 mg daily by mouth.
79814961|NCT00707681|Drug|MS-20|4 ml/vial
79814962|NCT00707681|Drug|Placebo|4ml/vial
79345618|NCT01706770|Device|galyfilcon A|
79345619|NCT01016899|Radiation|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
79497222|NCT05034341|Other|Standard Pre-Surgical Clinical Care|"Education related to preoperative activity and home-based exercise program.~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
79497223|NCT04615325|Drug|RO7303359|RO730359 will be administered as a single intravitreal injection.
79659664|NCT06258993|Behavioral|Core Exercise Promotion Program|Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
79659665|NCT06258993|Behavioral|Affect-based exercise prescription|"Participants assigned to Affect-Rx will receive instructions to select a pace of exercise that makes you feel as good as possible. The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to stay in the green zone on the Feeling Scale."
79659666|NCT06258993|Behavioral|Effort-based exercise prescription|"Participants assigned to RPE-Rx will receive instructions to select a pace that would make it challenging for you to carry on more than a short conversation. The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to stay in the green zone on the RPE Scale."
79659667|NCT06258980|Drug|Proph7|Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
79659668|NCT06258967|Drug|ciprofol|Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.
79345620|NCT04497454|Other|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP < 16 cmH2O
79497224|NCT05007509|Biological|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
79345621|NCT04497454|Other|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
79345622|NCT01937715|Drug|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
79497225|NCT05007509|Biological|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
79659669|NCT06258967|Drug|propofol|Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
79814963|NCT04097847|Drug|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
79814964|NCT05467371|Behavioral|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
79814965|NCT05467371|Behavioral|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
79814966|NCT00758589|Drug|AZD1981|Oral tablet, 50 mg twice daily
79228222|NCT02469428|Other|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
79228223|NCT03643146|Behavioral|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
79228224|NCT03643146|Behavioral|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
79228225|NCT03312998|Radiation|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
79228226|NCT04897035|Device|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
79228227|NCT03304340|Device|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
79228228|NCT03304340|Device|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device & Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
79228229|NCT03304340|Other|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
79228230|NCT03527238|Other|PPM-based Computation Assisted Drug Dosing|Tacrolimus dosing based on application of PPM.
79497226|NCT05007509|Biological|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
79814967|NCT00758589|Drug|AZD1981|Oral tablet, 400 mg twice daily
79345623|NCT01937715|Drug|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
79814968|NCT00758589|Drug|AZD1981|Oral tablet, 1000 mg twice daily
79345624|NCT01937715|Biological|Bevacizumab|5 mg/m^2 every 2 weeks or 7.5 mg/m^2 every 3 weeks
79497227|NCT05007509|Biological|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
79497228|NCT00382499|Drug|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
79659670|NCT06258954|Other|3D reconstruction|3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.
79659671|NCT06258954|Other|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and height.
79659672|NCT06258928|Diagnostic Test|Functional examination|Compared to nonoperated limb, after 6 months of early rehabilitation.
79659673|NCT06258915|Drug|Adalimumab|Adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously)
79659674|NCT06258915|Drug|Mycophenolate Mofetil|2 g/day orally for 36 weeks
79659675|NCT06258889|Behavioral|reward-focused intervention|"Participants complete three interventions based on the Positive Affect Treatment:~Finding the silver lining includes attending to and appreciating positive aspects of past events~Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session."
79659676|NCT06258889|Behavioral|cognitive flexibility intervention|"This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations."
79659677|NCT06258889|Behavioral|exposure|"All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where they give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions)."
79659678|NCT06258889|Behavioral|Psychoeducation|All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
79659679|NCT06258876|Other|PrEP in general practice|Prescription and follow-up of PrEP in general practice
79345625|NCT01937715|Drug|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
79345626|NCT01937559|Biological|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
79345627|NCT01937559|Drug|Normal saline|
79345628|NCT04634331|Behavioral|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
79345629|NCT04634331|Behavioral|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
79345630|NCT01960257|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
79345631|NCT01960257|Other|SOC DOT|
79345632|NCT01918371|Drug|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
79659680|NCT06258863|Procedure|incision type|Total mastectomy was performed using one of the four incision types
79659681|NCT06258850|Drug|Calcifediol Oral Capsule|One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
79659682|NCT06258850|Drug|Placebo|One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
79659683|NCT06258824|Diagnostic Test|Small RNA Sequencing and Validation of candidate miRNAs|Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
79814969|NCT00758589|Drug|Placebo|
79814970|NCT00833417|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
79814971|NCT00762372|Drug|desflurane|volatile liquid for inhalation
79814972|NCT00762372|Drug|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
79814973|NCT00762372|Drug|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
79814974|NCT00833261|Drug|cetuximab|cetuximab
79814975|NCT00833261|Drug|cisplatin|cisplatin
79814976|NCT00833261|Radiation|intensity-modulated radiation therapy|IMRT
79345633|NCT01917747|Behavioral|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
79345634|NCT01917747|Behavioral|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
79345635|NCT01597791|Device|Foley catheter|Foley catheter placement after CSE.
79497229|NCT04330547|Drug|Analgesic administration|"Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~Level 2: Tramadol 50mg.~Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~Increase of a prior level 3 medication :~1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
79345636|NCT01597791|Other|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
79345637|NCT01916967|Drug|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
79345638|NCT01916967|Drug|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
79345639|NCT01936623|Behavioral|Computerized Brief Intervention|No additional information needed.
79345640|NCT04625127|Device|Treadmill gait training with GaitBetter|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
79345641|NCT04625127|Other|Treadmill gait training with GaitBetter + Standard of care|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
79345642|NCT04625127|Other|Standard of care|Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
79345643|NCT01959243|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
79659684|NCT06258798|Radiation|Taking a dental X-ray|Dental X-rays taken in patients with indications confirmed by a written referral.
79497230|NCT04330547|Drug|Placebo administration|Folavit (folic acid, 0.4 mg)
79659685|NCT06258772|Drug|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
79659686|NCT06258759|Biological|autologous platelet-rich plasma supplement|the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
79659687|NCT06258759|Biological|no autologous platelet-rich plasma supplement|the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
79659688|NCT06258720|Drug|Lu AF82422|Lu AF82422 solution for intravenous infusion
79659689|NCT06258707|Device|LuxBoost IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
79228231|NCT03527238|Drug|Tacrolimus|Dosing of calcineurin inhibitor, tacrolimus
79345644|NCT01959243|Drug|Vehicle|Ophthalmic solution to be applied as directed.
79345645|NCT01959243|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
79345646|NCT01959243|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
79345647|NCT01959165|Drug|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
79345648|NCT01959165|Drug|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
79345649|NCT01959165|Drug|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
79345650|NCT01959165|Drug|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
79345651|NCT01916109|Drug|Gemcitabine|
79345652|NCT01916109|Drug|Carboplatin|
79345653|NCT01916109|Drug|Panitumumab|
79345654|NCT01916109|Procedure|radical cystectomy|
79497231|NCT00382889|Drug|beclomethasone/salbutamol combination|
79497232|NCT00382889|Drug|beclomethasone|
79497233|NCT00382889|Drug|salbutamol|
79659690|NCT06258707|Device|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
79345655|NCT01915095|Device|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
79345656|NCT01915095|Device|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
79345657|NCT01915095|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
79345658|NCT01915095|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
79345659|NCT01958619|Drug|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
79345660|NCT01958619|Drug|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
79345661|NCT01958619|Drug|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
79345662|NCT01958619|Drug|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
79345663|NCT01752634|Drug|Secukinumab (AIN457)|Secukinumab (AIN457)
79345664|NCT01752634|Drug|Placebo|Placebo PFS for s.c. administration.
79345665|NCT01726270|Drug|tamsulosin|0.4 mg
79497234|NCT04972799|Other|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
79497235|NCT04972799|Other|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
79659691|NCT06258681|Other|Incentive spirometer|The incentive spirometry group will continue training with Volumetric Triflo. It is asked to exhale at first and then hold their breath for at least 3 seconds after taking as deep a breath as possible.
79659692|NCT06258681|Other|Individualized respiratory training group|Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle.
79659693|NCT06258668|Drug|Deucravacitinib|As per product label
79659694|NCT06258655|Other|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation."
79659695|NCT06258642|Drug|Irinotecan Liposome|70 mg/m^2 , d1, Q2W, iv
79659696|NCT06258642|Drug|Anlotinib|12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
79497236|NCT05273177|Other|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
79497237|NCT04482959|Drug|Carbetocin|(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
79497238|NCT04482959|Drug|Sodium chloride 0.9%|Physiological solution will be used as placebo
79497239|NCT04571879|Drug|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
79659697|NCT06258629|Diagnostic Test|Flowcytometry on bone marrow aspiration|Flowcytometry on bone marrow aspiration
79659698|NCT06258590|Device|Transcutaneous auricular vagus nerve stimulation|Patients will receive non invasive vagus nerve stimulation via electrodes attached to the ear.
79497240|NCT04571879|Drug|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
79497241|NCT04571879|Other|Placebo|Nebulized normal saline and intranasal normal sline
79679474|NCT05317767|Biological|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
79679475|NCT02950454|Other|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
79814977|NCT00833261|Drug|Nab-Paclitaxel|Nab-Paclitaxel
79345666|NCT02102269|Device|actimove sling|
79345667|NCT02102269|Device|shoulderlift|
79345668|NCT01914393|Drug|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
79345669|NCT01545271|Drug|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
79345670|NCT01545271|Device|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
79345671|NCT00559819|Drug|placebo|Placebo (orange juice), same volume as alcohol
79345672|NCT00559819|Drug|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
79345673|NCT01931865|Drug|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
79345674|NCT04646889|Drug|AR882 Single Dose|A single dose of AR882
79345675|NCT04646889|Drug|AR882 Multiple Dose|AR882 taken once daily for 14 days
79345676|NCT01617447|Drug|Placebo of Aripiprazole|administered orally once daily
79345677|NCT01617447|Drug|Aripiprazole|Flexibly dose administered orally once daily
79345678|NCT00432679|Drug|Rosiglitazone (BRL49653C)|study drug
79345679|NCT05232487|Other|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
79497242|NCT04563533|Biological|Low-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg."
79497243|NCT04563533|Biological|High-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg."
79345680|NCT05232487|Other|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
79497244|NCT04563533|Biological|Placebo (containing aluminum)|Active ingredients: none Other ingredients: aluminum hydroxide adjuvant: 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
79497245|NCT04563533|Biological|Placebo (without aluminum)|Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
79497246|NCT04330937|Dietary Supplement|dietetics|90 days of consumption
79986247|NCT03379753|Other|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
79345681|NCT01600105|Drug|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
79345682|NCT01077895|Procedure|CVVH|"CVVH is started using following parameters:~Blood flow is started at 150 mL/min~Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
79497247|NCT04939961|Dietary Supplement|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
79497248|NCT04939961|Dietary Supplement|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
79497249|NCT04332107|Drug|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
79497250|NCT04332107|Drug|Placebos|Participants will be shipped a dose of matching placebo
79497251|NCT04328285|Drug|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
79497252|NCT04328285|Drug|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
79497253|NCT04328285|Drug|Lopinavir and ritonavir|LPV/r Oral Tablets
79497254|NCT04328285|Drug|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
79497255|NCT04308473|Other|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
79659699|NCT06258538|Device|Robots can aid in distal UE rehabilitation through exoskeleton (EXO)|Exoskeleton robot-assisted therapy Each EXO robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Hand of Hope (HOH) robotic hand system . HOH is an exoskeleton type of robot that is worn on the dorsal side of the impaired hand with 2 surface EMG sensors attached to the extensor digitorum and flexor digitorum superficialis.
79345683|NCT01077895|Procedure|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~Vasopressor or inotrope medication dose is increased by > 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV > 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
79345684|NCT01077895|Procedure|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
79497256|NCT04308473|Other|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
79659700|NCT06258538|Device|End-effector robot-assisted therapy (EE)|Each EE robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Amadeo robotic system. Amadeo is an end-effector robot with 5 finger slides, which are attached to the fingertips and the thumb via magnetic finger pads. The integrated sensor for each finger allows the robot system to provide patients with real-time visual feedback of finger strengths and range of motion
79659701|NCT06258538|Behavioral|Unilateral task-oriented therapy|The therapy will focus on task-oriented therapy with the affected UE and the training tasks involve proximal or distal UE movement, such as ringing a bell, picking up coins, grasping and releasing various cups, and other functional movements involved in daily activities. The level of challenge will be adapted according to patient ability and improvement during training.
79345685|NCT04785079|Procedure|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
79345686|NCT04797325|Drug|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
79345687|NCT04797325|Drug|Prednisolone|tablet prednisolone plus infliximab in severe cases.
79659702|NCT06258538|Behavioral|Bilateral task-oriented therapy|The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
79345688|NCT02246647|Diagnostic Test|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
79345689|NCT02246647|Procedure|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
79497257|NCT04911881|Drug|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
79497258|NCT04906187|Other|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
79679476|NCT02950454|Other|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
79345690|NCT02246647|Procedure|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
79345691|NCT00752245|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
79345692|NCT00752245|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
79345693|NCT00752245|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
79345694|NCT04771351|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
79345695|NCT04771351|Drug|Placebo|Diluent solution
79497259|NCT04906187|Other|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
79497260|NCT04354493|Device|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
79814978|NCT00833105|Device|AMES treatment|The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
79659703|NCT06258512|Other|Intervention with a narrative approach.|"Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system."
79659704|NCT06258499|Combination Product|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is manually placed into the joint fusion space during fusion surgery.
79814979|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
79497261|NCT04299269|Other|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
79497262|NCT04903457|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
79659705|NCT06258486|Drug|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
79814980|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
79814981|NCT00833027|Drug|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
79814982|NCT05758493|Diagnostic Test|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
79497263|NCT04903457|Behavioral|Motor learning|Sequential finger tapping task training is applied to stroke patients.
79814983|NCT00752622|Biological|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
79345696|NCT04770727|Behavioral|CBT workshop|The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
79345697|NCT05107687|Behavioral|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
79345698|NCT01933113|Device|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
79659706|NCT06258486|Other|Non-Injection/Control|No ICG injection
79659707|NCT06258486|Procedure|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
79659708|NCT06258473|Combination Product|Multicomponent decentralized care|"Training and support on Simple app for HTN/DM management & training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs & CHCP care coordination supported by Simple app at community clinics~CHWs assist in screening, counselling, referral, and follow-up for CHW at village level"
79659709|NCT06258473|Combination Product|mHealth|Training and support on Simple app for HTN/DM patient management & training NCD corner clinicians on clinical guidelines of Upazila Health complex
79679477|NCT02942862|Drug|Orcein staining|Prognostic value of venous emboli detected by orcein staining
79679478|NCT04695158|Drug|COVID-19 group (Group I)|Routine COVID-19 treatment
79679479|NCT04695158|Drug|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
79986248|NCT03620253|Drug|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
79345699|NCT04773067|Biological|UB-612|Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
79345700|NCT04773067|Biological|Placebo|Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
79345701|NCT04784845|Biological|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
79345702|NCT02244619|Drug|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
79497264|NCT04874519|Behavioral|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
79497265|NCT04869995|Other|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
79679480|NCT05317650|Other|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
79679481|NCT02950142|Other|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
79497266|NCT04263779|Behavioral|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
79986249|NCT03620253|Drug|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
79986250|NCT03177928|Device|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
79345703|NCT02244619|Drug|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
79345704|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6
79497267|NCT04263779|Behavioral|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
79497268|NCT04437095|Other|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
79497269|NCT04418297|Drug|CT-G20|oral tablet
79497270|NCT04418297|Drug|Placebo|oral tablet
79497271|NCT03575195|Drug|Rifaximin|Rifaximin 550mg orally
79679482|NCT02950142|Other|CPOE without order sets for lab testing|CPOE only
79986251|NCT01355991|Drug|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
79986252|NCT01355991|Drug|Salmeterol|50mcg inhalation twice daily for two weeks
79986253|NCT03180658|Procedure|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
79345705|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 1 of Cycles 3-6
79986254|NCT03180658|Procedure|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
79345706|NCT02243371|Drug|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
79345707|NCT02243371|Biological|GVAX|5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
79345708|NCT02243371|Drug|CY|200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2
79345709|NCT01931475|Drug|Duloxetine|Administered orally
79345710|NCT01931475|Drug|Placebo|Administered orally
79497272|NCT03575195|Other|Placebo|Placebo control
79497273|NCT04391777|Other|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
79497274|NCT04391777|Other|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
79679483|NCT04691310|Device|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
79679484|NCT00515762|Device|elasto-gel cap|scalp cooling cap
79986255|NCT01356069|Other|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
79679485|NCT02941341|Drug|r-hFSH|As per standard practice
79345711|NCT04622787|Other|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
79345712|NCT01929993|Procedure|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
79345713|NCT01929993|Procedure|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
79345714|NCT04630821|Other|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
79345715|NCT04645953|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3mg)
79345716|NCT04645953|Combination Product|1mg AZ010|Subject will receive a single inhaled dose (1mg)
79345717|NCT04645953|Combination Product|Staccato Placebo|Subject will receive a single inhaled dose (Staccato Placebo)
79497275|NCT03481205|Device|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
79497276|NCT04159025|Device|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
79497277|NCT00002897|Drug|cisplatin|
79497278|NCT00002897|Drug|fluorouracil|
79986256|NCT01356069|Other|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
79345718|NCT01912599|Device|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
79345719|NCT01912599|Device|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
79345720|NCT04645017|Behavioral|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
79345721|NCT01929681|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
79986257|NCT03180424|Drug|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
79986258|NCT03180424|Behavioral|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
79345722|NCT01646177|Drug|Placebo|Administered SC
79345723|NCT01646177|Drug|50 mg etanercept|Administered SC
79345724|NCT01646177|Drug|80 mg ixekizumab|Administered SC
79497279|NCT00002897|Procedure|conventional surgery|
79497280|NCT03420209|Behavioral|Group applying PNF technique|
79497281|NCT00002903|Drug|docetaxel|
79497282|NCT00002909|Drug|chemotherapy|
79497283|NCT00002909|Drug|oral sodium phenylbutyrate|
79497284|NCT00002915|Drug|penclomedine|
79497285|NCT00002921|Drug|suramin|
79497286|NCT00002921|Drug|therapeutic hydrocortisone|
79497287|NCT00383045|Drug|Buprenorphine/Subutex|
79497288|NCT00383045|Drug|Naltrexone|
79497289|NCT00383045|Procedure|Drug counseling|
79497290|NCT00383591|Biological|Hepatitis B adjuvanted vaccine|
79497291|NCT00383591|Biological|Engerix-B|
79497292|NCT00383669|Dietary Supplement|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
79497293|NCT00383669|Dietary Supplement|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
79986259|NCT03180424|Drug|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
79345725|NCT01912287|Behavioral|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
79345726|NCT01912287|Behavioral|Stress Education|Active control group (12 sessions)
79345727|NCT01912287|Behavioral|Yoga|12 sessions, mindfulness components
79659710|NCT06258434|Diagnostic Test|multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo)|Patients who are at high risk of developing CRC or confirmed CRC and willing to conduct colonoscopy examination will be asked to collect blood prior to bowl preparation for multiomics CRC screening test which using Reduced Representation Bisulfite Sequencing (RRBS) technology to obtain multidimensional variation information on cell-free DNA (cfDNA) methylation, end sequence, fragment size distribution, and copy number variation in the blood, and integrate analysis through machine learning algorithms to accurately assess the risk of colorectal cancer and advanced adenoma. and will be asked to collect stool sample for commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference. The diagnosis information of each sample was blind to the participants who conduct the multiomics profiling, as well as the informatics who perform the integrate analysis.
79345728|NCT01929135|Drug|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
79345729|NCT01929135|Drug|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
79497294|NCT00383825|Procedure|Anterior segment indocyanine green angiography|
79497295|NCT04062461|Other|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
79659711|NCT06258421|Other|No Intervention|Observatory Study
79659712|NCT06258408|Drug|BB102 tablet|BB102 tablets will be administered orally once daily(QD).
79659713|NCT06258382|Other|Questionnaires and functional test|Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
79659714|NCT06258369|Other|Patients with primary coxarthrosis (any stage).|Patients who do not undergo surgery will be called specifically for the study to attend a consultation dedicated to gait assessment.
79659715|NCT06258369|Other|Patients with primary coxarthrosis (any stage) and operated with Total Hip Prosthesis (THP).|Patients scheduled for THP (Total Hip Prosthesis) will be seen at the consultation the day before surgery, in the same hospital as the THP, or at an existing dedicated consultation scheduled for all THP patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
79659716|NCT06258369|Other|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|Patients scheduled for RTH (Hip Resurfacing) will be seen at the consultation the day before surgery, in the same hospital as the RTH, or at an existing dedicated consultation scheduled for all RTH patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
79659717|NCT06258330|Drug|AM003|Bispecific Personalized Aptamer for intratumoral administration
79986260|NCT03180424|Behavioral|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
79986261|NCT01319175|Other|Hip flexion strength training|
79986262|NCT01358253|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
79986263|NCT01358253|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
79986264|NCT01358253|Drug|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
79986265|NCT01358253|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
79986266|NCT01358253|Drug|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
79986267|NCT01358253|Drug|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
79345730|NCT01911819|Procedure|Sinus augmentation|
79345731|NCT01911819|Drug|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
79345732|NCT01911819|Drug|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
79345733|NCT01911819|Drug|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
79345734|NCT02280863|Device|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
79345735|NCT02280863|Device|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
79345736|NCT01911429|Drug|Lurasidone 40 mg|Lurasidone 40 mg once daily
79345737|NCT01911429|Drug|Lurasidone 80 mg|Lurasidone 80 mg once daily
79345738|NCT01911429|Drug|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
79497296|NCT04062461|Other|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
79497297|NCT04329455|Procedure|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
79659718|NCT06258317|Procedure|fixation of conventional polypropylene mesh|"By fixation of the polyprolene mesh,patients will be divided into two groups:~Group 1 includes patients with fixation of conventional polypropylene mesh. Group 2 includes patients without fixation of the mesh."
79497298|NCT00002933|Drug|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
79497299|NCT00002939|Drug|irinotecan hydrochloride|
79986268|NCT01358253|Drug|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
79986269|NCT01358253|Drug|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
79986270|NCT01358253|Drug|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
79986271|NCT01358253|Drug|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
79345739|NCT02324465|Device|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
79345740|NCT02324465|Device|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
79345741|NCT02324153|Drug|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
79345742|NCT02324153|Drug|Microcrystalline Cellulose|Placebo Comparator
79345743|NCT02324153|Drug|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
79345744|NCT02280473|Drug|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
79345745|NCT02280473|Drug|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
79345746|NCT04420481|Drug|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
79345747|NCT04420481|Drug|Placebo|Placebo
79497300|NCT00002939|Drug|paclitaxel|
79497301|NCT03151967|Drug|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
79497302|NCT03151967|Drug|Placebo|vaginal applicator with medium containing no drug
79659722|NCT06258278|Procedure|Arthroscopic-assisted lower trapezius tendon transfer surgery|The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
79659723|NCT06258265|Drug|TAK-279|TAK-279 capsule.
79659724|NCT06258265|Drug|TAK-279 Placebo|TAK-279 matching placebo capsule.
79659725|NCT06258265|Drug|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
79659726|NCT06258265|Drug|Moxifloxacin Placebo|Moxifloxacin matching placebo capsule.
79659727|NCT06258252|Other|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
79679486|NCT00515801|Drug|glibenclamide|glibenclamide 15 mg single dose
79986272|NCT03180346|Device|PICO|Single Use Negative Pressure Dressing
79986273|NCT03180346|Device|Aquacel|Occlusive surgical dressing infused with ionized silver
79986274|NCT03180112|Genetic|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
79986275|NCT01356225|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
79345748|NCT01911273|Drug|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
79814984|NCT00752622|Biological|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
79986276|NCT01356225|Drug|Placebo|IN placebo
79986277|NCT03379675|Drug|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
79659728|NCT06258239|Other|Communication between nursing staff and participants|The analgesic treatment that will be given are part of clinical routine - the participants will get the same exact treatment regardless if they entered the study and to which study arm they entered. The effect that we are interested to capture is the potential added value of communication between the nursing staff and participants while administrating analgesics.
79659729|NCT06258226|Drug|Conventional dosage reduction|The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.
79659730|NCT06258226|Procedure|Auricular acupressure|Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.
79659731|NCT06258226|Procedure|Sham auricular acupressure|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
79659732|NCT06258213|Drug|ABP-745|0.5, 5 or 25 mg tablet
79659733|NCT06258213|Drug|Placebo|Placebo tablet
79814985|NCT00752622|Biological|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
79986278|NCT03379675|Drug|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
79986279|NCT03379675|Drug|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
79986280|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
79986281|NCT02427412|Drug|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
79986282|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
79986283|NCT01356303|Drug|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
79986284|NCT03184012|Device|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
79986285|NCT03184012|Device|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
79345749|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
79345750|NCT01911273|Other|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
79345751|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
79345752|NCT02308007|Drug|Terconazole|
79345753|NCT02308007|Drug|Metronidazole|
79345754|NCT02308007|Drug|Terconazole/metronidazole|
79345755|NCT02278367|Drug|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
79345756|NCT02278367|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
79814986|NCT04038827|Diagnostic Test|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
79814987|NCT00913601|Device|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
79814988|NCT00754650|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
79814989|NCT00707837|Other|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
79814990|NCT00707837|Other|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
79814991|NCT02611271|Other|Monitoring of antibiotic drug removal|No study specific intervention will be performed
79986286|NCT02220309|Drug|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
79345757|NCT04886141|Behavioral|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
79659734|NCT06258200|Behavioral|Gender and immunization activities|Household visits from community mobilizers, participation in couples communication groups, and messaging from community leaders.
79659735|NCT06258200|Other|No intervention|Participants in the comparison group will not receive any intervention
79814992|NCT04093440|Other|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
79659736|NCT06258187|Device|Pedi-Cap|The neonatal resuscitation team will include or omit the use of Pedi-Cap during non-invasive positive pressure ventilation (PPV) for infants ≥30 weeks in the delivery room based on the randomized study arm each month.
79345758|NCT01910181|Drug|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
79345759|NCT04885907|Biological|mRNA-1273 vaccine|COVID vaccine 3rd dose
79814993|NCT00761748|Device|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
79814994|NCT00761748|Device|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
79814995|NCT00825305|Biological|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
79814996|NCT00825305|Biological|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
79814997|NCT00754572|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
79986287|NCT02419534|Drug|Polyethylene glycol|Laxative to treat constipation
79986288|NCT02419534|Drug|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
79986289|NCT04674852|Device|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
79345760|NCT04885907|Other|Normal Saline Placebo|Normal Saline Placebo
79659737|NCT06258174|Drug|Pirtobrutinib|Administered orally.
79659738|NCT06258161|Procedure|Spinal Fusion|Realignment and fusion of adult spinal deformity
79986290|NCT01362231|Drug|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
79345761|NCT04622241|Other|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
79659739|NCT06258148|Drug|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
79659740|NCT06258148|Drug|Placebo|Placebo, SC, once a week
79659741|NCT06258135|Dietary Supplement|Galacto-oligosaccharide|Single 7g dose daily for 28 days
79659742|NCT06258135|Dietary Supplement|Maltodextrin|Single 7g dose daily for 28 days
79986291|NCT03527316|Drug|MDMA|125 mg MDMA per os, single dose
79659743|NCT06258096|Device|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
79659744|NCT06258096|Device|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
79986292|NCT03527316|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
79986293|NCT03184246|Device|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
79986294|NCT03184246|Device|Direct laryngoscopy|direct laryngoscopy will be used for intubation
79986295|NCT01358409|Drug|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
79986296|NCT02423590|Drug|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
79345762|NCT04622241|Other|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
79345763|NCT04622241|Other|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
79345764|NCT04622241|Other|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
79345765|NCT01957215|Drug|Indomethacin|Topical indomethacin
79345766|NCT01957215|Drug|Placebo|Placebo patch
79345767|NCT02322749|Drug|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
79345768|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
79497303|NCT04226027|Behavioral|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
79497304|NCT03085823|Device|Sirolimus Coated Balloon|
79986297|NCT02423590|Drug|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
79497305|NCT04000217|Behavioral|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
79659745|NCT06258070|Other|Abobotulinumtoxin A injection for bruxism|Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
79659746|NCT06258057|Other|Not applicable / database analysis|Not applicable / database analysis
79659747|NCT06258031|Drug|Psilocybin (COMP360)|Up to 10mg on two occasions
79659748|NCT06258018|Drug|Temodal|given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
79659749|NCT06258018|Drug|Niraparib|given orally in continous
79659750|NCT06257992|Other|Dry Needling|3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.
79986298|NCT02423590|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
79986299|NCT01362309|Drug|d-cycloserine.|50 mg administered on two occasions.
79986300|NCT03710941|Drug|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
79986301|NCT03710941|Drug|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
79986302|NCT05114356|Device|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
79986303|NCT05760768|Behavioral|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
79986304|NCT03710863|Drug|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
79986305|NCT02930889|Device|Prostate Artery Embolization|Prostate Artery Embolization
79497306|NCT04000217|Behavioral|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
79497307|NCT00002945|Biological|aldesleukin|IV
79986306|NCT02423668|Procedure|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
79986307|NCT02423668|Procedure|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
79345769|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
79345770|NCT01957137|Device|InterStim® (Device Programming)|
79345771|NCT01928433|Drug|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
79345772|NCT01928433|Drug|Finafloxacin placebo i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
79345773|NCT01928433|Drug|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
79497308|NCT00002945|Biological|filgrastim|IV
79345774|NCT01928433|Drug|Finafloxacin placebo tablets once daily|Administered as four tablets
79345775|NCT01928433|Drug|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
79345776|NCT01928433|Drug|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
79345777|NCT01928433|Drug|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
79497309|NCT00002945|Drug|cyclophosphamide|IV
79497310|NCT00002945|Drug|cytarabine|IV
79497311|NCT00002945|Drug|etoposide|IV
79497312|NCT00002945|Drug|idarubicin|IV
79659751|NCT06257992|Other|Stretch|3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
79679487|NCT00515801|Drug|placebo|placebo capsules, single dose
79814998|NCT00754572|Drug|methotrexate|10-25mg oral or parenteral weekly.
79814999|NCT00824993|Drug|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
79986308|NCT02423668|Procedure|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
79986309|NCT04604496|Drug|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
79345778|NCT01928433|Drug|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
79345779|NCT02322281|Drug|Rociletinib|
79345780|NCT02322281|Drug|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
79345781|NCT02322125|Device|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
79345782|NCT02243293|Drug|ABT-493|Tablet
79345783|NCT02243293|Drug|ABT-530|Tablet
79345784|NCT02243293|Drug|ribavirin (RBV)|Tablet
79345785|NCT02243293|Drug|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
79345786|NCT02322047|Drug|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
79345787|NCT02322047|Drug|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
79345788|NCT02322047|Drug|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
79497313|NCT00002945|Drug|melphalan|IV
79497314|NCT00002945|Procedure|peripheral blood stem cell transplantation|IV
79497315|NCT00002945|Radiation|radiation therapy|delivered to the cancer cells
79497316|NCT00002951|Drug|fluorouracil|
79497317|NCT00002951|Drug|hydroxyurea|
79497318|NCT00002951|Procedure|surgical procedure|
79497319|NCT00002951|Radiation|radiation therapy|
79497320|NCT03075839|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
79497321|NCT03058289|Drug|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.~The drug is stored frozen and must be dosed at room temperature.~The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area"
79497322|NCT03058289|Biological|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
79986310|NCT03178084|Drug|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
79986311|NCT03178084|Drug|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
79345789|NCT02322047|Drug|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
79497323|NCT03058289|Biological|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
79497324|NCT00002963|Drug|aminolevulinic acid hydrochloride|
79345790|NCT02254291|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
79345791|NCT02254291|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
79815000|NCT00824993|Drug|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
79345792|NCT02254291|Drug|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
79345793|NCT02253433|Other|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
79497325|NCT00002963|Procedure|conventional surgery|
79497326|NCT00002969|Drug|paclitaxel|
79986312|NCT03178084|Drug|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
79986313|NCT02875977|Other|Educational video|A 4-minute educational video describing PFPT
79986314|NCT02875977|Other|Educational handout|A 2-page educational handout describing PFPT
79345794|NCT02253433|Other|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
79345795|NCT02242981|Drug|LY2623091|Administered orally
79345796|NCT02277743|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
79345797|NCT02277743|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
79659752|NCT06257979|Other|This study is with minimal risk and minimal constraints due to the addition of questionnaires|"In this study, the specific procedures compared to routine care are :~Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research.~The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis.~Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."
79659753|NCT06257966|Drug|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
79345798|NCT02242903|Drug|LY3079514|Administered SC
79345799|NCT02242903|Drug|LY3079514|Administered IV
79345800|NCT02242903|Drug|Placebo|Administered SC
79345801|NCT02242903|Drug|Placebo|Administered IV
79345802|NCT02320721|Drug|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
79345803|NCT02320721|Drug|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
79345804|NCT02320721|Drug|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
79497327|NCT00002987|Biological|bleomycin sulfate|
79497328|NCT00002987|Drug|cyclophosphamide|
79497329|NCT00002987|Drug|doxorubicin hydrochloride|
79497330|NCT00002987|Drug|etoposide|
79497331|NCT00002987|Drug|prednisolone|
79497332|NCT00002987|Drug|vincristine sulfate|
79497333|NCT00002987|Radiation|radiation therapy|
79497334|NCT02919683|Drug|Nivolumab|
79497335|NCT02919683|Drug|Ipilimumab|
79497336|NCT02919683|Procedure|Standard of Care Surgery|
79497337|NCT03933293|Drug|AK102|450mg, Q4W, subcutaneous injection
79497338|NCT03933293|Drug|Statins|Lipid-lowering therapies
79497339|NCT03933293|Drug|Ezetimibe|Lipid-lowering therapies
79497340|NCT03926741|Drug|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
79497341|NCT00002993|Drug|cisplatin|
79497342|NCT00002993|Drug|doxorubicin hydrochloride|
79497343|NCT00002993|Drug|mitomycin C|
79497344|NCT01928082|Drug|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
79986315|NCT02419222|Behavioral|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
79986316|NCT05122572|Biological|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
79345805|NCT02320487|Drug|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
79345806|NCT02320487|Drug|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
79345807|NCT04884659|Other|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
79345808|NCT04884659|Other|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
79345809|NCT02277119|Device|Maestro|OCT machines used for diagnostic purposes
79345810|NCT02277119|Device|iVue|OCT machines used for diagnostic purposes
79497345|NCT01972776|Drug|QBM076|Supplied in 25 mg and 75 mg capsules
79497346|NCT01972776|Drug|Placebo|Matching placebo capsules
79497347|NCT00002999|Drug|cisplatin|
79497348|NCT00002999|Drug|fluorouracil|
79497349|NCT00002999|Radiation|radiation therapy|
79345811|NCT02320253|Behavioral|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
79497350|NCT04330469|Procedure|Periodontal therapy|"Treatment will be performed by a periodontist.~Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~Polishing of the coronal and radicular surfaces of the teeth."
79497351|NCT04330469|Procedure|Oral hygiene advice|Oral hygiene advised by Periodontist
79497352|NCT00003005|Drug|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
79497353|NCT00003005|Drug|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
79497354|NCT00003011|Drug|marimastat|10 mg PO BID
79497355|NCT00003011|Drug|Placebo|10 mg PO BID
79497356|NCT00003017|Biological|recombinant interleukin-12|
79497357|NCT00003023|Biological|BCG vaccine|
79497358|NCT00003023|Biological|monoclonal antibody A1G4 anti-idiotype vaccine|
79497359|NCT03850067|Drug|CC-90011|CC-90011
79497360|NCT03850067|Drug|Cisplatin|Cisplatin
79497361|NCT03850067|Drug|Carboplatin|Carboplatin
79497362|NCT03850067|Drug|Etoposide|Etoposide
79497363|NCT03850067|Drug|Nivolumab|Nivolumab
79497364|NCT00383279|Other|counseling intervention|
79986317|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
79986318|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
79497365|NCT00383279|Other|study of socioeconomic and demographic variables|
79986319|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
79986320|NCT01356381|Drug|Vildagliptin|Dosage 50mg b.i.d.
79986321|NCT01356381|Drug|Placebo|50mg bid
79345812|NCT02320253|Behavioral|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
79986322|NCT03117166|Drug|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
79345813|NCT02320253|Behavioral|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
79345814|NCT04197089|Drug|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
79497366|NCT00003029|Drug|cisplatin|
79497367|NCT00003029|Drug|fluorouracil|
79986323|NCT03117166|Drug|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
79986324|NCT01356459|Device|Mepilex Border Dressing|Soft silicone self adherent dressing
79986325|NCT05189613|Biological|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
79986326|NCT03183700|Device|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
79986327|NCT03183700|Other|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
79986328|NCT03632928|Other|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
79986329|NCT03632928|Other|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
79986330|NCT01358487|Behavioral|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
79228232|NCT02469506|Device|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
79228233|NCT03832179|Drug|Bevacizumab|Bevacizumab
79228234|NCT03832179|Drug|Ranibizumab|Ranibizumab
79345815|NCT02276807|Behavioral|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
79345816|NCT02276807|Other|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
79345817|NCT02252965|Drug|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
79497368|NCT00003035|Biological|filgrastim|
79497369|NCT00003035|Drug|doxorubicin hydrochloride|
79497370|NCT00003035|Drug|paclitaxel|
79497371|NCT00003035|Drug|tamoxifen citrate|
79497372|NCT00003035|Procedure|surgical procedure|
79497373|NCT00003035|Radiation|radiation therapy|
79497374|NCT02579525|Other|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
79497375|NCT02579525|Other|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
79986331|NCT01358487|Behavioral|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
79986332|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
79986333|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
79986334|NCT02419300|Device|ultrasoungraphy|pelvic ultrasonography and Doppler
79497376|NCT03837431|Diagnostic Test|Skin slit|Skin slit microscopy, RDT and PCR
79986335|NCT02419144|Behavioral|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
79986336|NCT01356615|Drug|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
79345818|NCT02252965|Drug|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
79345819|NCT02242435|Biological|4 mL injection of Ampion|4 mL injection of Ampion
79345820|NCT02242435|Drug|4 mL Injection of Placebo|
79345821|NCT02251717|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79497377|NCT03837431|Diagnostic Test|Dental broach|Dental broach RDT and PCR
79497378|NCT03837431|Diagnostic Test|Tape disc|Tape disc PCR
79497379|NCT00003041|Drug|pyrazoloacridine|
79345822|NCT02242201|Drug|PNB Bupivacaine|Infusion
79345823|NCT02242201|Drug|PAI Ropivacaine|Injection
79345824|NCT02242201|Drug|PAI liposomal bupivacaine|Injection
79345825|NCT02242201|Drug|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
79345826|NCT02242201|Drug|Ketorolac|Injection, 30 mg
79345827|NCT02242045|Drug|Idelalisib|150 mg tablet(s) administered orally twice daily
79497380|NCT00383903|Biological|HRV vaccine|Two or three oral doses
79497381|NCT00003053|Drug|cisplatin|
79497382|NCT00003053|Drug|etoposide|
79345828|NCT02241889|Device|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
79345829|NCT02241889|Device|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
79345830|NCT02241733|Behavioral|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
79345831|NCT02241733|Behavioral|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
79228235|NCT03832179|Drug|Aflibercept|Aflibercept
79345832|NCT02241343|Device|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
79345833|NCT04191577|Drug|CVN424 Low Dose|CVN424
79345834|NCT04191577|Drug|CVN424 High Dose|CVN424
79345835|NCT04191577|Drug|Placebo|Placebo
79345836|NCT02241187|Drug|PEGPH20|
79345837|NCT02241187|Drug|Cetuximab|
79345838|NCT02241187|Device|DW & DCE-MRI|
79345839|NCT02241187|Other|blood draws|Blood samples will be drawn at various time points.
79345840|NCT02249767|Drug|Tretinoin|Treatment of acne once daily in evening
79345841|NCT02239939|Behavioral|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
79497383|NCT00003053|Procedure|adjuvant therapy|
79497384|NCT04329689|Other|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
79497385|NCT04329845|Procedure|open splenectomy|open splenectomy for treatment of splenic injury
79497386|NCT04329845|Procedure|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
79497387|NCT00003065|Biological|filgrastim|
79497388|NCT00003065|Drug|paclitaxel|
79497389|NCT00003065|Drug|topotecan hydrochloride|
79497390|NCT04329611|Drug|Hydroxychloroquine|COVID19
79497391|NCT00383357|Drug|zolpidem|
79497392|NCT03763331|Device|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
79497393|NCT03763331|Device|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
79497394|NCT00003077|Dietary Supplement|omega-3 fatty acid|
79345842|NCT02239939|Behavioral|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
79497395|NCT03759665|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
79497396|NCT00003089|Drug|amifostine trihydrate|
79497397|NCT00003089|Drug|carboplatin|
79497398|NCT00003089|Drug|paclitaxel|
79497399|NCT00003089|Radiation|radiation therapy|
79497400|NCT00003101|Biological|filgrastim|
79497401|NCT00003101|Drug|busulfan|
79345843|NCT02248675|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
79497402|NCT00003101|Drug|lomustine|
79497403|NCT00003101|Drug|procarbazine hydrochloride|
79497404|NCT00003101|Drug|thiotepa|
79815001|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
79228236|NCT03832179|Drug|Ozurdex|Ozurdex
79345844|NCT02248675|Other|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
79345845|NCT04783441|Device|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
79345846|NCT04783441|Device|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
79345847|NCT02238379|Drug|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
79345848|NCT02238379|Other|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
79497405|NCT00003101|Drug|vincristine sulfate|
79497406|NCT00003101|Procedure|autologous bone marrow transplantation|
79497407|NCT00003101|Procedure|peripheral blood stem cell transplantation|
79497408|NCT03692273|Procedure|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
79497409|NCT03692273|Procedure|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
79497410|NCT01866371|Procedure|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
79497411|NCT01805609|Behavioral|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture & discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff & that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
79497412|NCT01805609|Behavioral|questionnaires|
79497413|NCT00003107|Biological|recombinant interleukin-12|
79497414|NCT00383201|Device|OptiFree Multi-Purpose Disinfecting Solution|
79497415|NCT00003113|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
79497416|NCT00003113|Drug|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
79497417|NCT00003113|Drug|etoposide|Etoposide is given on days 1-3.
79497418|NCT00003113|Drug|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
79497419|NCT00003113|Drug|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
79497420|NCT00003113|Radiation|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
79497421|NCT01545557|Device|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
79497422|NCT00003119|Biological|filgrastim|
79497423|NCT00003119|Biological|sargramostim|
79497424|NCT00003119|Drug|carboplatin|
79497425|NCT00003119|Drug|cyclophosphamide|
79497426|NCT00003119|Drug|doxorubicin hydrochloride|
79497427|NCT00003119|Drug|etoposide|
79497428|NCT00003119|Procedure|adjuvant therapy|
79497429|NCT00003119|Procedure|conventional surgery|
79497430|NCT00003119|Radiation|radiation therapy|
79497431|NCT00003395|Drug|arsenic trioxide|
79497432|NCT00003401|Drug|carmustine|
79497433|NCT00003401|Drug|cisplatin|
79345849|NCT02238067|Drug|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
79497434|NCT00003401|Drug|cyclophosphamide|
79497435|NCT00003401|Drug|dexamethasone|
79345850|NCT02238067|Other|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
79497436|NCT00003401|Drug|etoposide|
79345851|NCT02237911|Other|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
79345852|NCT02237911|Other|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
79345853|NCT02234479|Biological|Hydrophor (Group A)|"Rehydrates dry, chapped or chafed skin~May be used alone as a skin lubricant or protectant"
79345854|NCT02234479|Biological|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~Maintain a balanced environment for healing.~Aids in reducing dermatitis.~Reduce affected area pH.2-3"
79345855|NCT02207491|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
79345856|NCT02207491|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
79497437|NCT00003401|Drug|gemcitabine hydrochloride|
79497438|NCT00003401|Drug|melphalan|
79497439|NCT00003401|Drug|paclitaxel|
79497440|NCT00003401|Procedure|bone marrow ablation with stem cell support|
79497441|NCT00003401|Procedure|peripheral blood stem cell transplantation|
79497442|NCT00003125|Biological|ALVAC-CEA vaccine|
79497443|NCT00003125|Biological|aldesleukin|
79497444|NCT00003125|Biological|sargramostim|
79815002|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
79815003|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
79815004|NCT04093674|Procedure|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
79815005|NCT04095390|Drug|Pyrotinib|400 mg
79497445|NCT00003125|Biological|vaccinia-CEA vaccine|
79497446|NCT04130555|Device|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
79497447|NCT00003131|Drug|chemotherapy|
79497448|NCT00003131|Drug|gemtuzumab ozogamicin|
79497449|NCT00384371|Drug|Botulinum Toxin A|Botulinum Toxin A
79497450|NCT00384371|Drug|Placebo|Placebo
79497451|NCT00423215|Drug|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
79497452|NCT00003413|Biological|filgrastim|
79497453|NCT00003413|Drug|carmustine|
79497454|NCT00003413|Drug|cisplatin|
79497455|NCT00003413|Drug|melphalan|
79497456|NCT00003413|Drug|paclitaxel|
79497457|NCT00003413|Procedure|peripheral blood stem cell transplantation|
79497458|NCT00003413|Procedure|surgical procedure|
79497459|NCT00003137|Drug|irinotecan hydrochloride|
79345857|NCT02207491|Other|Placebo|1 drop QD, AM, OU
79659754|NCT06257966|Drug|Exendin-4 Fc fusion protein injection（2.4mg）|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
79497460|NCT00003419|Procedure|antiviral therapy|
79659755|NCT06257966|Drug|Dulaglutide|1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
79659756|NCT06257966|Drug|Metformin|Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
79659757|NCT06257953|Procedure|Erector spinae plane block|Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
79659758|NCT06257927|Behavioral|Tuko Pamoja|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
79986337|NCT01356615|Drug|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
79986338|NCT03117322|Biological|agave inulin|Duration: four weeks Dosage: powder 4 g/d
79986339|NCT03117322|Biological|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
79986340|NCT03117322|Other|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
79986341|NCT03117322|Other|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
79345858|NCT02315066|Drug|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
79345859|NCT02315066|Drug|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
79345860|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
79345861|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
79497461|NCT00003425|Biological|filgrastim|
79497462|NCT00003425|Drug|amifostine trihydrate|
79497463|NCT00003425|Drug|cyclophosphamide|
79497464|NCT00003425|Drug|melphalan|
79497465|NCT00003425|Procedure|peripheral blood stem cell transplantation|
79497466|NCT00534131|Procedure|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
79497467|NCT00534131|Procedure|APPEAR Procedure|Perineal incision to reach the distal rectum
79497468|NCT00534131|Procedure|Proctectomy|standard rectal excision which does not preserve the anal canal
79497469|NCT00330551|Drug|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
79659759|NCT06257914|Diagnostic Test|Catquest-9SF|Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
79659760|NCT06257901|Other|Interviews/Focus groups/Participatory workshops|Qualitative study (no intervention delivered)
79659761|NCT06257849|Other|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
79659762|NCT06257836|Other|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
79986342|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
79986343|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
79986344|NCT03620175|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
79986345|NCT03180190|Drug|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
79497470|NCT00330551|Drug|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
79659763|NCT06257823|Other|No intervention|No intervention
79815006|NCT04095390|Drug|SHR6390|125mg
79815007|NCT04095390|Drug|Letrozole|2.5mg
79815008|NCT04095390|Drug|Capecitabine|500mg
79986346|NCT01356693|Drug|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
79497471|NCT00001259|Drug|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
79497472|NCT00001259|Drug|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
79497473|NCT00001259|Drug|Progesterone|Progesterone suppository, 200mg vaginally twice/day
79497474|NCT00001259|Drug|Placebo patch|Placebo by skin patch
79497475|NCT00001259|Drug|Placebo injection|Placebo given intramuscularly monthly
79497476|NCT00001259|Drug|Placebo suppository|Placebo vaginal suppository
79497477|NCT00003143|Drug|Amifostine|
79497478|NCT00003143|Drug|DHAP|
79497479|NCT00003431|Biological|recombinant flt3 ligand|
79986347|NCT01356693|Drug|Placebo|Placebo with mimicking characteristics of experimental drug
79986348|NCT03183856|Device|Morning walk|a end-effector typed gait robot with a saddle
79986349|NCT03183856|Other|no Morning walk|ambulation voluntary or with a help of walker
79986350|NCT03179878|Drug|Placebo|Placebo
79986351|NCT03179878|Drug|SYNB1020|Investigational Product
79986352|NCT01362387|Other|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
79345862|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
79986353|NCT04583592|Drug|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
79497480|NCT00003149|Biological|recombinant interleukin-12|
79345863|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
79345864|NCT02309372|Behavioral|Beating the Blues|Computerized depression treatment intervention
79345865|NCT02276027|Drug|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
79659764|NCT06257797|Diagnostic Test|Skin prick test|Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
79986354|NCT04583592|Drug|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
79986355|NCT01358643|Other|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
79986356|NCT03179722|Behavioral|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
79986357|NCT03179722|Behavioral|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~before the medication review (T-1week)~during the review (Tweek 3)~after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
79345866|NCT02276027|Drug|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
79497481|NCT00003437|Drug|asparaginase|
79497482|NCT00003437|Drug|cyclophosphamide|
79497483|NCT00003437|Drug|cytarabine|
79815009|NCT02599818|Behavioral|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
79497484|NCT00003437|Drug|daunorubicin hydrochloride|
79659765|NCT06257784|Procedure|Oxygen Therapy|Patients who have SpO2 < 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
79659766|NCT06257784|Procedure|Non-Invasive Ventilation (NIV)|Patients with P/F < 250 or Ph < 7,35 with PCO2 > 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
79815010|NCT04095468|Radiation|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
79497485|NCT00003437|Drug|dexamethasone|
79497486|NCT00003437|Drug|doxorubicin hydrochloride|
79986358|NCT01362465|Procedure|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
79659767|NCT06257784|Procedure|Invasive Ventilation|Patients with P/F < 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (>24 breaths/min) despite NIV for at least 2 hours or patients with Ph < 7,2 with PCO2 > 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
79659768|NCT06257758|Drug|VIO-01|"VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study."
79659769|NCT06257745|Other|Compliance with ERACS guideline as described in the current ERACS guidelines from Engelman et al. 2019|Compliance with the interventions as proposed in the ERACS guidelines and described in our previous publication (https://doi.org/10.1016/j.jtcvs.2022.07.010
79815011|NCT00832091|Drug|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
79497487|NCT00003437|Drug|mercaptopurine|
79497488|NCT00003437|Drug|methotrexate|
79497489|NCT00003437|Drug|pegaspargase|
79497490|NCT00003437|Drug|prednisolone|
79345867|NCT02276027|Drug|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
79497491|NCT00003437|Drug|thioguanine|
79497492|NCT00003437|Drug|vincristine sulfate|
79815012|NCT00832091|Drug|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
79815013|NCT00708149|Drug|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
79815014|NCT00708149|Drug|placebo|takepron placebo
79815015|NCT00916734|Procedure|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
79815016|NCT00916734|Procedure|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
79815017|NCT04016051|Drug|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
79815018|NCT04016051|Drug|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
79815019|NCT04016051|Drug|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
79986359|NCT03117088|Other|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
79345868|NCT02276027|Drug|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
79345869|NCT02309294|Device|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
79345870|NCT02309294|Device|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
79345871|NCT02309294|Device|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
79345872|NCT02309294|Device|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
79345873|NCT02309294|Device|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
79345874|NCT02233543|Drug|QVA149|Delivered once daily via single-dose dry powder inhaler
79345875|NCT02233543|Drug|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
79497493|NCT00003437|Radiation|radiation therapy|
79497494|NCT00003443|Drug|bryostatin 1|
79497495|NCT00003449|Drug|dexamethasone|
79497496|NCT00003449|Drug|gemcitabine hydrochloride|
79497497|NCT00003449|Drug|paclitaxel|
79497498|NCT00002801|Drug|leucovorin calcium|
79497499|NCT00002801|Drug|tegafur-uracil|
79497500|NCT00002801|Radiation|radiation therapy|
79497501|NCT00002807|Radiation|radiation therapy|45 Gy in 25 fractions over 5 weeks
79497502|NCT04329533|Other|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
79986360|NCT03117088|Other|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
79815020|NCT04016051|Drug|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
79986361|NCT01362543|Other|Cognitive behavioural therapy (stress management)|Following a manual
79815021|NCT04016051|Drug|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
79986362|NCT01362543|Other|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
79986363|NCT02418988|Drug|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
79986364|NCT02418988|Drug|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
79345876|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
79497503|NCT00002813|Drug|cisplatin|
79345877|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
79345878|NCT04761133|Drug|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
79345879|NCT02233309|Other|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
79345880|NCT02204917|Drug|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
79345881|NCT02280044|Biological|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
79815022|NCT04016051|Drug|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
79345882|NCT02280044|Biological|Placebo intervention|Placebo administered then Challenge with C jejuni
79659770|NCT06257732|Other|Exercise|The exercise interventions in this study include High-Intensity Interval Training (HIIT), involving brief bursts of intense exercise; Resistance Exercise, focusing on strength and muscle endurance; and Fatmax Exercise, tailored to optimize fat oxidation during aerobic activity.
79659771|NCT06257732|Behavioral|Motivational Interviewing|Motivational Interviewing will be employed as a counseling technique to elicit behavior change by fostering collaborative and empathetic conversations, enhancing motivation for positive lifestyle modifications in individuals with liver fat accumulation.
79659772|NCT06257719|Other|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
79815023|NCT00761514|Drug|Humira (adalimumab)|40 mg eow
79815024|NCT00831779|Drug|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
79228237|NCT03312764|Behavioral|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
79345883|NCT04748653|Behavioral|Multi-component reintegration intervention|The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
79345884|NCT02308748|Drug|Dofetilide|"8 am: Placebo~12 pm (noon): 250 µg~5:30 pm: 250 µg"
79345885|NCT02308748|Drug|Mexiletine|"8 am: weight x 4 mg/kg~12 pm (noon): Same as at 8 am~5:30 pm: Same as at 8 am"
79345886|NCT02308748|Drug|Lidocaine|"9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
79497504|NCT00002813|Drug|vinorelbine tartrate|
79497505|NCT00002819|Drug|carboplatin|
79815025|NCT00831779|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
79815026|NCT04098510|Dietary Supplement|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
79986365|NCT04579146|Other|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
79497506|NCT00002819|Drug|cyclophosphamide|
79497507|NCT00002819|Drug|mitoxantrone hydrochloride|
79497508|NCT00002819|Drug|paclitaxel|
79497509|NCT00002819|Procedure|autologous bone marrow transplantation|
79497510|NCT00002819|Procedure|peripheral blood stem cell transplantation|
79497511|NCT00002825|Biological|filgrastim|
79659773|NCT06257706|Biological|Vedolizumab|All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
79986366|NCT01356771|Other|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~Current and past skin cancer screening practices~Current and past sun protection practices~Attitudes about skin cancer and sun protection~Knowledge of melanoma"
79986367|NCT01358799|Device|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
79986368|NCT05189301|Diagnostic Test|first pass study|Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
79986369|NCT05189301|Diagnostic Test|cardiopulmonary exercise testing|to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
79986370|NCT01356927|Drug|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
79497512|NCT00002825|Drug|docetaxel|
79345887|NCT02308748|Drug|Moxifloxacin|"9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
79345888|NCT02308748|Drug|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
79345889|NCT02308748|Drug|Placebo|Placebo (#2 Gelcap or IV saline)
79345890|NCT04745689|Drug|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
79345891|NCT04745689|Drug|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
79497513|NCT00002831|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
79497514|NCT00002831|Drug|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
79497515|NCT00002831|Drug|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
79345892|NCT04745689|Drug|Carboplatin|IV infusions through induction phase if chosen by Investigator.
79497516|NCT00002831|Drug|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
79659774|NCT06257693|Drug|enzalutamide|Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
79345893|NCT04745689|Drug|Cisplatin|IV infusions through induction phase if chosen by Investigator.
79345894|NCT04745689|Drug|Etoposide|IV infusions through induction phase.
79345895|NCT04768543|Device|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
79345896|NCT01646216|Behavioral|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
79345897|NCT02308124|Drug|Midodrine|
79345898|NCT02308124|Drug|Pyridostigmine Bromide|
79345899|NCT02308124|Drug|Midodrine + pyridostigmine|
79345900|NCT02232061|Drug|Fingolimod|Fingolimod 0.5 mg tablet
79345901|NCT02275481|Drug|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
79345902|NCT02275481|Drug|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
79497517|NCT00002831|Drug|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
79497518|NCT00002831|Drug|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
79497519|NCT00002831|Drug|Methylprednisolone|Given according to clinical grade of GVHD procedures.
79497520|NCT00002831|Drug|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
79497521|NCT00002831|Procedure|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
79497522|NCT00002831|Procedure|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
79497523|NCT00002837|Biological|Filgrastim (G-CSF)|
79497524|NCT00002837|Drug|Cyclophosphamide|
79497525|NCT00002837|Drug|Doxorubicin Hydrochloride|
79497526|NCT00002837|Drug|Paclitaxel|
79497527|NCT00002837|Procedure|Peripheral Blood Stem Cell Transplantation|
79497528|NCT00003455|Drug|antineoplaston A10|
79497529|NCT00003455|Drug|antineoplaston AS2-1|
79497530|NCT00003455|Procedure|alternative product therapy|
79497531|NCT00003455|Procedure|biological therapy|
79497532|NCT00003455|Procedure|biologically based therapies|
79497533|NCT00003455|Procedure|cancer prevention intervention|
79497534|NCT00003455|Procedure|complementary and alternative therapy|
79497535|NCT00003455|Procedure|differentiation therapy|
79497536|NCT00003461|Procedure|surgical procedure|
79497537|NCT00003461|Radiation|astatine At 211 monoclonal antibody 81C6|
79345903|NCT02204449|Behavioral|Cardiac Rehabilitation Peer Mentorship|
79345904|NCT02308046|Drug|Terconazole|
79345905|NCT02308046|Drug|Placebo|
79497538|NCT00003467|Drug|carmustine|
79986371|NCT01356927|Drug|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
79986372|NCT02703532|Behavioral|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
79986373|NCT02703532|Behavioral|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
79659775|NCT06257680|Biological|ReT01 ACT|Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
79345906|NCT02318693|Drug|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
79345907|NCT02318693|Drug|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
79345908|NCT02230891|Drug|Carvedilol|Carvedilol is a non selective beta blocker
79345909|NCT02230891|Drug|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
79345910|NCT02230891|Other|Usual care|standard care as per primary care provider
79497539|NCT00003467|Drug|polifeprosan 20 with carmustine implant|
79497540|NCT00003467|Procedure|surgical procedure|
79659776|NCT06257667|Other|Respiratory Support|Treatment with High Flow Nasal Cannula
79659777|NCT06257628|Device|Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
79986374|NCT02703532|Behavioral|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
79986375|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
79497541|NCT00003485|Drug|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79497542|NCT00003491|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79659778|NCT06257615|Behavioral|Education provided via TeleNursing|"Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42)."
79659779|NCT06257602|Procedure|Tragal graft tympanoplasty|Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
79345911|NCT01646138|Biological|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
79986376|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
79659780|NCT06257537|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
79497543|NCT00003497|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
79659781|NCT06257537|Device|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
79659782|NCT06257537|Drug|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
79659783|NCT06257537|Other|SAM Patch|Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
79659784|NCT06257524|Other|Education and training|Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions
79659785|NCT06257511|Behavioral|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
79497544|NCT00003167|Biological|Ad5CMV-p53 gene|Given intravesically
79228238|NCT03312764|Behavioral|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
79345912|NCT02204371|Drug|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
79345913|NCT02204371|Drug|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
79345914|NCT02274857|Procedure|Standard PVI Ablation|Standard PVI procedure without FIRMap.
79345915|NCT02274857|Procedure|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
79497545|NCT00003515|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79497546|NCT00003521|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79497547|NCT00002849|Biological|recombinant interferon alfa|first 2 years
79497548|NCT00002849|Drug|dexamethasone|40 mg*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles*
79497549|NCT04329377|Diagnostic Test|blood test|complete blood count and platelet function
79345916|NCT02302859|Drug|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
79497550|NCT00002855|Drug|Bicalutamide|
79497551|NCT00002855|Drug|Doxorubicin hydrochloride|
79345917|NCT02302859|Behavioral|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
79345918|NCT02302859|Other|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
79345919|NCT02302859|Behavioral|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
79497552|NCT00002855|Drug|Estramustine Phosphate Sodium|
79497553|NCT00002855|Drug|Flutamide|
79497554|NCT00002855|Drug|Ketoconazole|
79497555|NCT00002855|Drug|Nilutamide|
79497556|NCT00002855|Drug|Therapeutic Hydrocortisone|
79497557|NCT00002855|Drug|Vinblastine|
79497558|NCT00002855|Procedure|Conventional Surgery|Surgical castration
79497559|NCT00003173|Biological|filgrastim|
79497560|NCT00003173|Drug|thiotepa|
79497561|NCT00003173|Procedure|autologous bone marrow transplantation|
79497562|NCT00003173|Procedure|peripheral blood stem cell transplantation|
79497563|NCT00003533|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79497564|NCT00003179|Drug|medroxyprogesterone|
79497565|NCT00003545|Drug|nelarabine|
79345920|NCT02302859|Other|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
79345921|NCT02302859|Device|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
79345922|NCT02274311|Drug|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
79345923|NCT02316353|Biological|C1-esterase inhibitor|
79370733|NCT04361968|Other|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
79370734|NCT04361968|Other|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
79370735|NCT04356118|Drug|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
79497566|NCT00003551|Drug|aminocamptothecin colloidal dispersion|
79497567|NCT00002873|Radiation|brachytherapy|
79497568|NCT00002879|Drug|cladribine|
79497569|NCT00003185|Biological|autologous tumor cell vaccine|
79497570|NCT00003185|Biological|sargramostim|
79497571|NCT00003185|Biological|tumor-draining lymph node lymphocyte therapy|
79497572|NCT00003185|Drug|cyclophosphamide|
79497573|NCT00003185|Procedure|conventional surgery|
79659786|NCT06257498|Procedure|MRI scan|MRI scan on open scanner and some questionnaires
79659787|NCT06257485|Diagnostic Test|99mTc-pyrophosphate Single Photon Emission Computed Tomography|All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
79659788|NCT06257472|Device|Virtual Reality Headset|Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
79370736|NCT04356118|Drug|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
79370737|NCT04356118|Drug|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
79228239|NCT05154630|Drug|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
79228240|NCT03312608|Diagnostic Test|Navigated transcranial magnetic stimulation|
79497574|NCT00003557|Drug|dolastatin 10|
79497575|NCT00003935|Drug|etoposide|
79497576|NCT00003935|Drug|vincristine sulfate|
79497577|NCT00003935|Radiation|radiation therapy|
79497578|NCT00003191|Drug|fenretinide|
79497579|NCT00003941|Biological|bleomycin sulfate|
79497580|NCT00003941|Biological|filgrastim|
79497581|NCT00003941|Drug|cisplatin|
79497582|NCT00003941|Drug|etoposide|
79497583|NCT00003941|Drug|ifosfamide|
79497584|NCT00003941|Procedure|bone marrow ablation with stem cell support|
79497585|NCT00003941|Procedure|peripheral blood stem cell transplantation|
79497586|NCT00384527|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
79497587|NCT00384527|Drug|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
79497588|NCT00003197|Dietary Supplement|green tea extract|
79497589|NCT00003563|Radiation|WBRT|3 GY of WBRT daily for a total of 10 days
79497590|NCT00003563|Drug|MGd|5.0 mg /kg MGd plus WBRT
79497591|NCT00003569|Drug|cisplatin|
79497592|NCT00003569|Drug|dimesna|
79497593|NCT00003569|Drug|paclitaxel|
79497594|NCT00003953|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
79497595|NCT00003953|Drug|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
79497596|NCT00003953|Drug|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
79497597|NCT00003953|Drug|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
79497598|NCT00003953|Drug|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
79659789|NCT06257459|Procedure|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
79659790|NCT06257446|Behavioral|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
79659791|NCT06257433|Behavioral|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
79659792|NCT06257420|Drug|Rapamycin|Once weekly oral rapamycin
79986377|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
79497599|NCT00003953|Procedure|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
79497600|NCT00003953|Procedure|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
79497601|NCT00003953|Radiation|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
79497602|NCT00003959|Biological|ras peptide cancer vaccine|
79497603|NCT00003959|Biological|sargramostim|
79345924|NCT02273141|Drug|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
79345925|NCT02273141|Drug|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
79345926|NCT02314052|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
79345927|NCT02279732|Biological|Paclitaxel|
79345928|NCT02279732|Biological|Carboplatin|
79497604|NCT02972723|Drug|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
79345929|NCT02279732|Biological|Ipilimumab|
79345930|NCT02279732|Other|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
79497605|NCT00003203|Biological|filgrastim|Given IV
79345931|NCT05650034|Radiation|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
79497606|NCT00003203|Drug|carboplatin|Given IV
79497607|NCT00003203|Drug|cisplatin|Given IV
79497608|NCT00003203|Drug|cyclophosphamide|Given IV
79497609|NCT00003203|Drug|vincristine sulfate|Given IV
79497610|NCT00003203|Procedure|adjuvant therapy|
79497611|NCT00003203|Radiation|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT*
79497612|NCT00003575|Biological|filgrastim|
79497613|NCT00003575|Biological|recombinant interleukin-12|
79823681|NCT03923504|Other|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
79345932|NCT02279498|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
79345933|NCT02279498|Drug|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
79345934|NCT02307266|Behavioral|Standard of care + supplementary education|
79497614|NCT00003575|Drug|etoposide|
79497615|NCT00003575|Drug|ifosfamide|
79497616|NCT00003539|Biological|trastuzumab|
79497617|NCT00003539|Drug|paclitaxel|
79497618|NCT00003209|Biological|bleomycin sulfate|
79497619|NCT00003209|Drug|cisplatin|
79228241|NCT05154396|Drug|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
79228242|NCT03185234|Device|anodal tDCS|2 mA, 10 min, 5 sessions
79345935|NCT02307266|Behavioral|Standard of care + additional visits|
79345936|NCT02307266|Behavioral|Standard of care|
79497620|NCT00003209|Drug|fluorouracil|
79497621|NCT00003209|Drug|ifosfamide|
79497622|NCT00003209|Drug|methotrexate|
79497623|NCT00003209|Drug|mitomycin C|
79228243|NCT03185234|Device|sham tDCS|sham stimulation, 10 min, 5 sessions
79228244|NCT02600130|Biological|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
79228245|NCT02600130|Biological|Placebo|via peripheral intravenous infusion
79228246|NCT04740645|Other|NOCDURNA Cohort|Non intervention
79228247|NCT04740645|Other|LUTS Cohort|Non intervention
79497624|NCT00003209|Drug|vinblastine sulfate|
79497625|NCT00003209|Drug|vindesine|
79497626|NCT00003209|Radiation|radiation therapy|
79497627|NCT00003587|Drug|carboplatin|AUC=5.5 day 1 every 21 days X 3
79497628|NCT00003587|Drug|cisplatin|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3
79497629|NCT00003587|Drug|docetaxel|IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
79497630|NCT00003587|Drug|gemcitabine|IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3
79497631|NCT00003587|Drug|paclitaxel|IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
79497632|NCT00003587|Drug|vinorelbine|IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3
79497633|NCT00003977|Biological|human papillomavirus 16 E7 peptide|
79497634|NCT00003977|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79497635|NCT00003215|Biological|filgrastim|
79497636|NCT00003215|Drug|CHOP regimen|
79497637|NCT00003215|Drug|cyclophosphamide|
79497638|NCT00003215|Drug|cytarabine|
79497639|NCT00003215|Drug|doxorubicin hydrochloride|
79497640|NCT00003215|Drug|etoposide|
79497641|NCT00003215|Drug|leucovorin calcium|
79497642|NCT00003215|Drug|melphalan|
79497643|NCT00003215|Drug|methotrexate|
79497644|NCT00003215|Drug|methylprednisolone|
79497645|NCT00003215|Drug|mitoxantrone hydrochloride|
79497646|NCT00003215|Drug|prednisone|
79497647|NCT00003215|Drug|therapeutic hydrocortisone|
79497648|NCT00003215|Drug|vincristine sulfate|
79497649|NCT00003215|Procedure|bone marrow ablation with stem cell support|
79497650|NCT00003215|Procedure|peripheral blood stem cell transplantation|
79497651|NCT00003215|Radiation|radiation therapy|
79823682|NCT02555553|Behavioral|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
79823683|NCT00786045|Other|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
79228248|NCT03312452|Device|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
79228249|NCT03312452|Device|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
79345937|NCT02279420|Device|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
79345938|NCT04877132|Drug|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
79345939|NCT02278328|Drug|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
79370738|NCT04361734|Other|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
79370739|NCT04361578|Diagnostic Test|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
79497652|NCT00003989|Biological|ISIS 3521|
79497653|NCT00003995|Biological|trastuzumab|
79986378|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
79986379|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
79986380|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
79986381|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
79986382|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
79497654|NCT00003995|Drug|irinotecan hydrochloride|
79497655|NCT00003593|Drug|asparaginase|Given IV
79497656|NCT00003593|Drug|cytarabine|Given IT
79497657|NCT00003593|Drug|daunorubicin hydrochloride|Given IV
79986383|NCT01357005|Other|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
79986384|NCT02930343|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
79986385|NCT02930343|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
79986386|NCT02930343|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
79986387|NCT02930343|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
79986388|NCT02930343|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
79497658|NCT00003593|Drug|methotrexate|Given IV
79497659|NCT00003593|Drug|therapeutic hydrocortisone|Given IT
79497660|NCT00003593|Drug|thioguanine|Given IV
79497661|NCT00003599|Dietary Supplement|Vitamin E (AT)|Orally daily
79345940|NCT02278328|Drug|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
79370740|NCT04361812|Drug|HS632|Subcutaneous injection of HS632
79370741|NCT04361812|Drug|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
79497662|NCT00003599|Drug|Isotretinoin|Orally daily
79497663|NCT00003605|Biological|rituximab|
79497664|NCT00003605|Drug|cyclophosphamide|
79497665|NCT04329299|Diagnostic Test|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
79497666|NCT00003611|Drug|acitretin|
79497667|NCT00003611|Other|placebo|
79497668|NCT00003617|Drug|chlorambucil|
79497669|NCT00003617|Drug|clarithromycin|
79497670|NCT00003617|Drug|omeprazole|
79497671|NCT00003617|Drug|tinidazole|
79497672|NCT00003623|Dietary Supplement|multivitamin|
79497673|NCT00003623|Other|Placebo|
79497674|NCT00003635|Drug|nelarabine|
79497675|NCT00004001|Drug|docetaxel|
79497676|NCT00004001|Drug|estramustine|
79986389|NCT02930343|Drug|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
79497677|NCT00004001|Drug|mitoxantrone|
79497678|NCT00004001|Drug|prednisone|
79497679|NCT00004013|Biological|trastuzumab|
79497680|NCT00004013|Drug|paclitaxel|
79986390|NCT03681938|Procedure|Autograft|Autograft
79986391|NCT02703454|Procedure|FIRM-guided RF ablation|
79370742|NCT04368208|Other|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
79497681|NCT00004025|Biological|aldesleukin|
79497682|NCT00004025|Biological|dendritic cell-gp100-MART-1 antigen vaccine|
79497683|NCT00004037|Drug|docetaxel|
79497684|NCT00004043|Dietary Supplement|calcitriol|
79497685|NCT00004049|Drug|apomine|
79497686|NCT00004055|Biological|filgrastim|
79497687|NCT00004055|Drug|paclitaxel|
79497688|NCT00004055|Drug|topotecan hydrochloride|
79497689|NCT00004061|Biological|filgrastim|
79497690|NCT00004061|Biological|palifermin|
79497691|NCT00004061|Drug|cyclophosphamide|
79497692|NCT00004061|Drug|etoposide|
79497693|NCT00004061|Drug|ifosfamide|
79497694|NCT00004061|Procedure|peripheral blood stem cell transplantation|
79497695|NCT00004061|Procedure|quality-of-life assessment|
79497696|NCT00004061|Radiation|radiation therapy|
79497697|NCT00004067|Biological|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
79497698|NCT00004067|Drug|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
79497699|NCT00004067|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
79497700|NCT00004067|Drug|taxol|175 mg/m2 IV every 21 days for 4 cycles
79497701|NCT00004073|Drug|suramin|
79497702|NCT00004073|Radiation|radiation therapy|
79497703|NCT00004079|Drug|SarCNU|Given PO
79497704|NCT00004079|Other|pharmacological study|Correlative studies
79497705|NCT00004079|Other|laboratory biomarker analysis|Correlative studies
79497706|NCT00004085|Biological|filgrastim|as prescribed by physician
79497707|NCT00004085|Procedure|autologous bone marrow transplantation|1-2 weeks prior to treatment
79497708|NCT00004085|Procedure|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
79497709|NCT00004085|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
79497710|NCT00004091|Other|Papanicolaou test|
79497711|NCT00004091|Other|cytology specimen collection procedure|
79497712|NCT00004091|Other|fluorescent antibody technique|
79497713|NCT00004091|Procedure|colposcopic biopsy|
79497714|NCT00004091|Procedure|study of high risk factors|
79497715|NCT00004097|Drug|fluorouracil|
79497716|NCT00004097|Drug|gemcitabine hydrochloride|
79497717|NCT00004097|Drug|paclitaxel|
79497718|NCT00004097|Radiation|radiation therapy|
79497719|NCT00004103|Drug|cisplatin|
79986392|NCT02703454|Procedure|Conventional RF ablation|
79345941|NCT02278328|Drug|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
79345942|NCT02314637|Drug|Teneligliptin|Teneligliptin for 52 weeks
79497720|NCT00004103|Drug|floxuridine|
79497721|NCT00004103|Drug|irinotecan hydrochloride|
79345943|NCT02314637|Drug|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
79497722|NCT00004103|Procedure|adjuvant therapy|
79497723|NCT00004103|Procedure|conventional surgery|
79497724|NCT00004103|Procedure|neoadjuvant therapy|
79497725|NCT00004109|Drug|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
79497726|NCT00004109|Radiation|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
79815027|NCT05441891|Other|Auditory intervention filter-modulated group|"Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH & Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz."
79815028|NCT00758043|Drug|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
79497727|NCT00003239|Biological|Recombinant Interferon Alfa|Daily by subcutaneous injection.
79497728|NCT00003239|Drug|Cytarabine|Daily by subcutaneous injection.
79815029|NCT00758043|Drug|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
79815030|NCT00758043|Biological|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
79815031|NCT00831701|Drug|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
79815032|NCT00831701|Drug|Placebo|One placebo pill per day for 21 days or until stone expulsion
79345944|NCT04877054|Behavioral|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
79345945|NCT04877054|Behavioral|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
79345946|NCT04876430|Drug|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR < 50mL/min.
79370743|NCT04368052|Diagnostic Test|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
79497729|NCT00003239|Drug|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
79497730|NCT00004115|Radiation|yttrium Y 90 monoclonal antibody HMFG1|
79497731|NCT00003245|Drug|irinotecan hydrochloride|
79497732|NCT00004127|Drug|FOLFOX regimen|
79497733|NCT00004127|Drug|fluorouracil|
79497734|NCT00004127|Drug|leucovorin calcium|
79497735|NCT00004127|Drug|oxaliplatin|
79497736|NCT00003251|Drug|amifostine trihydrate|
79497737|NCT00003251|Drug|cisplatin|
79497738|NCT00003251|Drug|paclitaxel|
79497739|NCT00003251|Radiation|radiation therapy|
79497740|NCT00004139|Drug|docetaxel|
79497741|NCT00004139|Drug|gemcitabine hydrochloride|
79497742|NCT00004139|Drug|irinotecan hydrochloride|
79497743|NCT00003257|Biological|Ad5CMV-p53 gene|
79497744|NCT00004145|Biological|anti-thymocyte globulin|
79497745|NCT00004145|Drug|cyclophosphamide|
79497746|NCT00004145|Drug|fludarabine phosphate|
79497747|NCT00004145|Procedure|peripheral blood stem cell transplantation|
79497748|NCT04212923|Behavioral|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
79497749|NCT00004151|Drug|acridine carboxamide|
79497750|NCT00003263|Biological|recombinant interferon alfa|vaccine
79497751|NCT00003263|Drug|cisplatin|
79497752|NCT00003263|Procedure|surgical procedure|
79497753|NCT00003263|Radiation|radiation therapy|
79497754|NCT00004157|Biological|filgrastim|
79497755|NCT00004157|Biological|recombinant interleukin-11|
79497756|NCT00003269|Biological|sargramostim|
79497757|NCT00003269|Drug|amifostine trihydrate|
79497758|NCT00003269|Drug|cisplatin|
79497759|NCT00003269|Drug|cyclophosphamide|
79497760|NCT00003269|Drug|etoposide|
79497761|NCT00004163|Drug|Trastuzumab|
79497762|NCT00003281|Drug|paclitaxel|
79497763|NCT00003281|Drug|topotecan hydrochloride|
79497764|NCT00003281|Radiation|radiation therapy|
79497765|NCT00003287|Drug|FOLFOX regimen|
79497766|NCT00003287|Drug|fluorouracil|
79497767|NCT00003287|Drug|leucovorin calcium|
79497768|NCT00003287|Drug|oxaliplatin|
79497769|NCT00004187|Drug|capecitabine|
79497770|NCT00004187|Drug|oxaliplatin|
79497771|NCT00384137|Drug|Tacrolimus|Immunosuppression
79497772|NCT00384215|Drug|insulin glargine [rDNA origin] injection|
79497773|NCT00004193|Drug|ISIS 2503|
79345947|NCT01646645|Biological|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
79497774|NCT00003293|Drug|leflunomide|
79497775|NCT00003293|Drug|procarbazine hydrochloride|
79815033|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
79345948|NCT02272985|Other|[15O]H2O PET-CT scan|All participants will undergo 3 [15O]H2O PET-CT scans during the hemodialysis study session
79497776|NCT00004199|Drug|cisplatin|
79497777|NCT00004199|Drug|gemcitabine hydrochloride|
79497778|NCT00004199|Drug|prinomastat|
79986393|NCT03686618|Drug|Secretin|Drug to stimulate pancreatic secretion
79228250|NCT02497248|Procedure|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
79228251|NCT04441970|Procedure|Neutral position|The cuff pressure will be recorded at the neutral head position.
79345949|NCT02272985|Other|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
79345950|NCT01644149|Device|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
79345951|NCT01644149|Device|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
79345952|NCT01644149|Biological|2011-2012 Fluzone trivalent inactivated influenza vaccine|
79370744|NCT04355962|Drug|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
79497779|NCT00384995|Drug|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
79497780|NCT00384995|Drug|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
79497781|NCT00003299|Drug|cisplatin|
79497782|NCT00003299|Drug|etoposide|
79497783|NCT00003299|Drug|paclitaxel|
79497784|NCT00004205|Drug|letrozole|Letrozole 2.5 mg daily oral administration.
79497785|NCT00004205|Drug|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
79497786|NCT00003305|Drug|aminopterin|
79659793|NCT06257394|Drug|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~If MRD & qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~If MRD & qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
79659794|NCT06257394|Drug|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
79659795|NCT06257381|Other|VO2max|"Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h)."
79659796|NCT06257043|Device|Transcatheter aortic valve replacement|A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
79659797|NCT06256705|Other|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
79345953|NCT02313233|Dietary Supplement|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
79497787|NCT00003305|Drug|leucovorin calcium|
79345954|NCT02313233|Dietary Supplement|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
79497788|NCT00004211|Biological|PSA RNA-pulsed dendritic cell vaccine|
79497789|NCT00003311|Biological|filgrastim|
79497790|NCT00003311|Drug|cyclophosphamide|
79497791|NCT00003311|Drug|cytarabine|
79659798|NCT06256666|Device|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
79659799|NCT06256445|Drug|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
79659800|NCT06256445|Drug|Matching placebo of AYP-101|Phosphate buffered saline placebo for injection
79497792|NCT00003311|Drug|dexamethasone|
79497793|NCT00003311|Drug|doxorubicin hydrochloride|
79497794|NCT00003311|Drug|methotrexate|
79497795|NCT00003311|Drug|vincristine sulfate|
79345955|NCT02313155|Drug|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
79497796|NCT00003317|Drug|carboplatin|
79497797|NCT00003317|Drug|paclitaxel|
79497798|NCT00003317|Radiation|radiation therapy|
79497799|NCT00003317|Procedure|surgery|
79497800|NCT00004217|Biological|filgrastim|5 μg/kg/day IV or SC
79497801|NCT00004217|Biological|sargramostim|5 μg/kg/day IV or SC starting d 15
79497802|NCT00004217|Drug|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
79345956|NCT02313155|Drug|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
79497803|NCT00004217|Drug|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
79497804|NCT00004217|Drug|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
79497805|NCT00003323|Drug|finasteride|5 mg/d PO
79497806|NCT00003323|Drug|flutamide|250 mg PO tid
79497807|NCT00003323|Other|quality-of-life assessment|Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
79497808|NCT00004229|Biological|recombinant human endostatin|
79497809|NCT00004235|Drug|docetaxel|
79497810|NCT00004235|Drug|irinotecan hydrochloride|
79497811|NCT00003335|Biological|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
79497812|NCT00003335|Drug|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
79497813|NCT00003335|Drug|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
79497814|NCT00003335|Drug|melphalan|melphalan IV for three days on days -4 to -2
79497815|NCT00003335|Drug|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
79497816|NCT00003335|Procedure|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
79497817|NCT00003335|Radiation|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
79497818|NCT00004241|Drug|tanespimycin|Given IV
79497819|NCT00004241|Other|pharmacological study|Correlative studies
79497820|NCT00003341|Biological|epoetin alfa|
79497821|NCT00003341|Procedure|quality-of-life assessment|
79497822|NCT00004253|Drug|carboplatin|
79497823|NCT00004253|Drug|paclitaxel|
79497824|NCT00004253|Radiation|radiation therapy|
79345957|NCT02204293|Drug|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
79497825|NCT00004265|Drug|paclitaxel|
79345958|NCT02204293|Drug|Placebo|Matching placebo administered subcutaneously.
79345959|NCT02304926|Drug|Simvastatin|simvastatin (40 mg/day) for 4 weeks
79497826|NCT00003359|Drug|batabulin sodium|
79497827|NCT00003365|Dietary Supplement|curcumin|
79497828|NCT00003365|Dietary Supplement|rutin|
79497829|NCT00003365|Drug|quercetin|
79497830|NCT00003365|Drug|sulindac|
79497831|NCT00004307|Behavioral|Protein and calorie controlled diet|
79497832|NCT00004307|Genetic|Ornithine transcarbamylase vector|
79659801|NCT06256393|Other|Collection of biological samples|Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
79659802|NCT06256354|Other|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
79815034|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
79986394|NCT03103542|Biological|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
79345960|NCT02304926|Drug|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
79345961|NCT02304926|Drug|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
79345962|NCT01646255|Drug|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
79345963|NCT01646255|Drug|Placebo Patch|"Transdermal Patch~Size:~20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
79345964|NCT01646255|Drug|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with benserazide or carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
79345965|NCT04870229|Drug|Carnosine|
79345966|NCT04870229|Drug|Placebo|Placebo
79497833|NCT00004829|Drug|tobramycin|
79497834|NCT00004313|Drug|dehydroepiandrosterone|
79497835|NCT00004853|Biological|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
79815035|NCT00705419|Drug|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
79986395|NCT02426866|Drug|Efavirenz|
79497836|NCT00004853|Biological|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
79497837|NCT00004865|Biological|cetuximab|
79497838|NCT00004865|Drug|cisplatin|
79497839|NCT00004865|Drug|fluorouracil|
79497840|NCT00004865|Drug|paclitaxel|
79497841|NCT00004361|Drug|calcium gluconate|
79497842|NCT00004361|Drug|sodium citrate|
79497843|NCT00004367|Procedure|Clinical vestibular tests|
79497844|NCT00004373|Drug|alprazolam|
79497845|NCT00004871|Drug|azacitidine|
79497846|NCT00004871|Drug|sodium phenylbutyrate|
79497847|NCT00004397|Drug|heme arginate|
79497848|NCT00004397|Drug|tin mesoporphyrin|
79497849|NCT00004877|Drug|BMS-214662|
79497850|NCT00004883|Biological|trastuzumab|Given IV
79497851|NCT00004883|Other|laboratory biomarker analysis|Correlative studies
79497852|NCT00004403|Drug|albendazole|
79497853|NCT00004403|Drug|dexamethasone|
79497854|NCT00004403|Drug|phenytoin|
79497855|NCT00004409|Drug|collagenase|
79497856|NCT00004415|Device|Medlink spinal cord electrode|
79497857|NCT00004421|Device|implanted pulse generator|
79497858|NCT00004889|Biological|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
79497859|NCT00385307|Drug|amibegron (SR58611A)|
79497860|NCT00004901|Drug|ethynyluracil|
79659803|NCT06256354|Other|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
79815036|NCT00705419|Drug|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
79815037|NCT02599935|Dietary Supplement|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
79815038|NCT02599935|Other|standard treatment|No other than standard treatment
79815039|NCT02599935|Other|educational structured counseling|Nutritional counseling leaded to patient and caregivers
79815040|NCT05426837|Behavioral|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
79228252|NCT04441970|Procedure|Head extension position|The cuff pressure will be recorded at the head extension position.
79228253|NCT04441970|Procedure|Head flexion position|The cuff pressure will be recorded at the head flexion position.
79228254|NCT04441970|Procedure|Head rotation position|The cuff pressure will be recorded at the head rotation position.
79228255|NCT02469194|Other|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
79345967|NCT05649761|Drug|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
79370745|NCT04355962|Drug|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
79370746|NCT04367662|Procedure|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
79497861|NCT00004901|Drug|fluorouracil|
79497862|NCT00004901|Drug|hydroxyurea|
79497863|NCT00004901|Radiation|radiation therapy|
79497864|NCT00004433|Drug|pergolide|
79497865|NCT00004913|Drug|cisplatin|
79497866|NCT00004913|Drug|docetaxel|
79497867|NCT00004913|Drug|fluorouracil|
79497868|NCT00004913|Drug|leucovorin calcium|
79497869|NCT00004451|Drug|Glucose|
79497870|NCT00004919|Drug|cisplatin|Given IV
79497871|NCT00004919|Drug|irinotecan hydrochloride|Given IV
79497872|NCT00004919|Drug|amifostine trihydrate|Given IV
79497873|NCT00004919|Other|pharmacological study|Correlative studies
79815041|NCT05426837|Behavioral|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
79815042|NCT05425355|Drug|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
79986396|NCT03686540|Procedure|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
79345968|NCT05649566|Device|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
79345969|NCT02203591|Drug|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
79497874|NCT00004925|Biological|trastuzumab|
79659804|NCT06256146|Other|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
79659805|NCT06256016|Other|Neck pain massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
79815043|NCT05425355|Drug|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
79815044|NCT00705497|Procedure|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
79815045|NCT00752895|Dietary Supplement|American ginseng|Given orally
79815046|NCT00752895|Dietary Supplement|Placebo|Given orally
79986397|NCT00706498|Drug|BI 2536|
79345970|NCT02203591|Drug|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
79345971|NCT02203591|Drug|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
79345972|NCT02203591|Drug|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
79345973|NCT01642277|Drug|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
79345974|NCT04869956|Other|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
79345975|NCT04869956|Other|Dietary pattern: Standard diet|standard nutritional recommendations
79345976|NCT02230189|Biological|Segmental airway allergen challenge|
79345977|NCT02230189|Procedure|Bronchoscopy|
79345978|NCT02230189|Diagnostic Test|Methacholine challenge test|
79345979|NCT02230189|Diagnostic Test|Spirometry|
79345980|NCT02230189|Diagnostic Test|Allergen skin prick test|
79345981|NCT04196348|Procedure|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
79345982|NCT04196348|Procedure|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
79345983|NCT02304302|Drug|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
79815047|NCT00831389|Device|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
79815048|NCT04093713|Procedure|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
79345984|NCT02304302|Drug|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
79815049|NCT04093635|Device|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
79815050|NCT00831311|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
79986398|NCT01358955|Other|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
79986399|NCT01358955|Other|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
79986400|NCT04960722|Device|OIF/β-TCP|bone graft implantation
79497875|NCT00004925|Drug|pegylated liposomal doxorubicin hydrochloride|
79497876|NCT00004481|Procedure|genetic testing|
79497877|NCT00004931|Drug|leucovorin calcium|Given IV
79986401|NCT02418598|Genetic|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10^11 vg/subject.
79986402|NCT02418598|Genetic|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10^11 vg/subject.
79345985|NCT02276612|Drug|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
79497878|NCT00004931|Drug|fluorouracil|Given IV
79497879|NCT00004931|Drug|oxaliplatin|Given IV
79345986|NCT02301143|Drug|nab-Paclitaxel|
79345987|NCT02301143|Drug|Gemcitabine|
79345988|NCT02301143|Drug|Chemoradiation|
79345989|NCT02301143|Drug|Capecitabine|
79345990|NCT02301143|Procedure|Surgery|Surgical intervention
79345991|NCT02276222|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
79345992|NCT02276222|Drug|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
79345993|NCT02275364|Device|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
79345994|NCT02275364|Device|Placebo strip|Placebo strip
79345995|NCT02275364|Other|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
79345996|NCT02275052|Drug|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
79497880|NCT00004931|Other|laboratory biomarker analysis|Correlative studies
79497881|NCT00004487|Drug|chondrocyte-alginate gel suspension|
79497882|NCT00004937|Drug|acridine carboxamide|
79497883|NCT00385229|Drug|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
79345997|NCT02275052|Drug|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
79497884|NCT00004979|Drug|paclitaxel|
79497885|NCT00004979|Drug|topotecan hydrochloride|
79815051|NCT00831311|Biological|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
79345998|NCT02275052|Drug|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
79345999|NCT05649020|Drug|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
79346000|NCT04869488|Drug|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
79659806|NCT06256016|Other|Neck and thoracic massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
79659807|NCT06256003|Device|UC-A|Mobile app digital therapy
79659808|NCT06256003|Device|UC-N|Mobile app digital therapy
79815052|NCT04093479|Other|blood samples|blood samples will be taken repeatedly
79346001|NCT04869488|Drug|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
79346002|NCT04869488|Drug|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
79346003|NCT05648942|Diagnostic Test|Anemia testing|Patients will undergo a point of care test to identify possible anemia
79346004|NCT02274038|Drug|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
79370747|NCT04367584|Other|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
79497886|NCT00004493|Drug|sodium dichloroacetate|
79497887|NCT00004985|Drug|Capravirine|
79497888|NCT00004985|Drug|Nelfinavir mesylate|
79497889|NCT00004559|Behavioral|dietary polyunsaturated fatty acid|
79497890|NCT00004997|Drug|Leucovorin|
79497891|NCT00005009|Biological|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
79497892|NCT00004583|Drug|Lopinavir/Ritonavir|
79497893|NCT00004583|Drug|Nelfinavir mesylate|
79497894|NCT00004583|Drug|Lamivudine|
79497895|NCT00004583|Drug|Stavudine|
79497896|NCT00005015|Drug|Fluoxetine|
79497897|NCT00004637|Drug|Vitamin E|
79497898|NCT00005021|Biological|filgrastim|
79497899|NCT00005021|Drug|carboplatin|
79497900|NCT00005021|Drug|paclitaxel|
79497901|NCT00005021|Drug|topotecan hydrochloride|
79497902|NCT00004643|Drug|cytarabine|
79497903|NCT00005027|Drug|becatecarin|
79497904|NCT00005033|Biological|trastuzumab|
79497905|NCT00005033|Procedure|conventional surgery|
79497906|NCT00005039|Biological|recombinant fowlpox-prostate specific antigen vaccine|Given IM
79497907|NCT00005039|Biological|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
79497908|NCT00005039|Other|laboratory biomarker analysis|Correlative studies
79497909|NCT00004667|Drug|von Willebrand factor|
79346005|NCT02274038|Drug|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
79497910|NCT00004685|Drug|albuterol|
79986403|NCT04874922|Behavioral|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
79986404|NCT04874922|Behavioral|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
79346006|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
79497911|NCT00005045|Drug|carboxyamidotriazole|
79986405|NCT03686462|Device|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
79497912|NCT00005051|Drug|carboplatin|
79497913|NCT00005051|Drug|cisplatin|
79497914|NCT00005051|Drug|paclitaxel|
79497915|NCT00005051|Drug|topotecan hydrochloride|
79986406|NCT03686462|Device|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
79986407|NCT02423824|Biological|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
79986408|NCT04548570|Procedure|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
79497916|NCT00004697|Drug|choline chloride|
79497917|NCT00004727|Drug|aspirin|
79497918|NCT00004727|Drug|ticlopidine|
79497919|NCT00004733|Drug|levodopa|
79497920|NCT00004739|Drug|Antiretroviral therapy|
79497921|NCT00005057|Biological|adenovirus RSV-TK|
79497922|NCT00005057|Drug|ganciclovir|
79497923|NCT00004751|Procedure|Surgery|
79497924|NCT00004751|Procedure|Physical therapy|
79497925|NCT00004757|Drug|acyclovir|
79497926|NCT00005069|Drug|arsenic trioxide|
79497927|NCT00004763|Drug|leuprolide|
79497928|NCT00004763|Drug|Ethinyl estradiol/norethindrone|
79497929|NCT00005075|Procedure|high-intensity focused ultrasound ablation|
79497930|NCT00004787|Drug|filgrastim|
79497931|NCT00005081|Drug|O6-benzylguanine|
79497932|NCT00005081|Drug|carmustine|
79497933|NCT00005087|Biological|filgrastim|
79497934|NCT00005087|Drug|cisplatin|
79497935|NCT00005087|Drug|paclitaxel|
79497936|NCT00005087|Procedure|conventional surgery|
79497937|NCT00005087|Radiation|radiation therapy|
79497938|NCT00004799|Biological|whole-cell pertussis vaccine|
79497939|NCT00004799|Biological|diphtheria-tetanus vaccine|
79497940|NCT00004805|Behavioral|CPR instruction|
79497941|NCT00005093|Drug|gemcitabine hydrochloride|
79497942|NCT00005093|Drug|tacedinaline|
79497943|NCT00004811|Drug|itraconazole|
79497944|NCT00004817|Drug|phenytoin|
79497945|NCT00004817|Drug|valproate sodium|
79497946|NCT00005117|Drug|pravastatin|
79497947|NCT00005555|Behavioral|Exercise|
79497948|NCT02972489|Device|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
79986409|NCT02423434|Other|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
79986410|NCT01012167|Drug|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
79346007|NCT02300558|Drug|Eleclazine|Tablets administered orally
79346008|NCT02300558|Drug|Eleclazine placebo|Tablets administered orally
79497949|NCT02972489|Device|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
79497950|NCT00385385|Drug|Rifalazil|
79497951|NCT00005567|Behavioral|Parental knowledge and beliefs about infant sleep position|
79497952|NCT00385463|Drug|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
79346009|NCT04882046|Other|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
79346010|NCT04882046|Other|Data collection|collection of socio-demographic, clinical and biological data.
79497953|NCT00386165|Drug|larazotide acetate|larazotide acetate 4 mg capsules
79497954|NCT00423371|Device|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
79497955|NCT00423371|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
79497956|NCT00005579|Drug|dolastatin 10|
79497957|NCT00005585|Drug|cyclophosphamide|Given IV
79497958|NCT00005585|Drug|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
79346011|NCT02273960|Drug|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
79346012|NCT02273960|Drug|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
79346013|NCT02273960|Drug|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
79815053|NCT03980301|Diagnostic Test|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
79815054|NCT00831233|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
79497959|NCT00005585|Drug|daunorubicin hydrochloride|Given IV
79815055|NCT00831233|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
79815056|NCT00831233|Drug|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
79815057|NCT05438277|Drug|Methylprednisolone (MPA)|injection into subacromial or glenohumeral space with MPA
79815058|NCT05438277|Drug|Triamcinolone Acetonide (TA)|injection into subacromial or glenohumeral space with TA
79815059|NCT00761280|Drug|trabedersen|
79815060|NCT00761280|Drug|temozolomide|
79986411|NCT01012167|Drug|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
79346014|NCT02273960|Drug|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
79346015|NCT01646021|Drug|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
79346016|NCT01646021|Drug|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
79346017|NCT01750918|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
79497960|NCT00005585|Drug|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
79497961|NCT00005585|Drug|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
79497962|NCT00005585|Drug|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
79497963|NCT00005585|Drug|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
79497964|NCT00005585|Drug|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
79497965|NCT00005585|Drug|thioguanine|Given orally
79497966|NCT00005585|Drug|vincristine sulfate|Given IV
79497967|NCT00005591|Biological|cetuximab|
79497968|NCT00005591|Drug|gemcitabine hydrochloride|
79497969|NCT00005195|Procedure|Catheter ablation|
79497970|NCT01926444|Drug|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
79497971|NCT00005597|Drug|temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
79497972|NCT00005603|Drug|asparaginase|
79497973|NCT00005603|Drug|cyclophosphamide|
79497974|NCT00005603|Drug|cytarabine|
79815061|NCT00761280|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
79986412|NCT01012167|Other|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
79497975|NCT00005603|Drug|daunorubicin hydrochloride|
79497976|NCT00005603|Drug|dexamethasone|
79497977|NCT00005603|Drug|doxorubicin hydrochloride|
79497978|NCT00005603|Drug|mercaptopurine|
79497979|NCT00005603|Drug|methotrexate|
79497980|NCT00005603|Drug|prednisone|
79497981|NCT00005603|Drug|thioguanine|
79497982|NCT00005603|Drug|vincristine sulfate|
79497983|NCT00005609|Biological|rituximab|
79497984|NCT00005615|Biological|Interferon alfa|Interferon alfa as outlined in treatment arm.
79497985|NCT00005615|Radiation|Radiation therapy|Radiation therapy as outlined in treatment arm.
79497986|NCT00005627|Drug|carboplatin|
79497987|NCT00005627|Drug|docetaxel|
79497988|NCT00005627|Drug|estramustine phosphate sodium|
79497989|NCT00005633|Biological|OVA BiP peptide|
79497990|NCT00005633|Biological|gp209-2M antigen|
79497991|NCT00005633|Biological|recombinant 70-kD heat-shock protein|
79497992|NCT00005633|Biological|tyrosinase peptide|
79815062|NCT00761280|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
79815063|NCT00761280|Drug|carmustine|
79815064|NCT00761280|Drug|lomustine|
79815065|NCT04093089|Device|Bionode IOP Lowering System|Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
79986413|NCT01012167|Other|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
79497993|NCT00005639|Drug|Azacitidine Injection|subcutaneous injection (SC)
79659809|NCT06254924|Behavioral|QI App Users|QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
79659810|NCT06254924|Behavioral|Parents/Guardians of QI App Users|Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
79497994|NCT00005639|Drug|sodium phenylbutyrate|continuous intravenous (CIV)
79497995|NCT00005645|Drug|ILX-295501|
79497996|NCT00005663|Drug|Valacyclovir hydrochloride|
79497997|NCT00385775|Drug|AEG35156|weekly IV solution infused over 2 hrs
79497998|NCT00005675|Drug|Oral bovine type I collagen|500 mcg of CI daily for 15 months
79497999|NCT00005675|Drug|Placebo|CI placebo daily for 15 months
79498000|NCT00385853|Drug|PTK787/ZK 222584|Twice daily for each 28-day cycle
79498001|NCT00385853|Drug|Temozolomide|Daily for each 28-day cycle
79659811|NCT06254872|Behavioral|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
79659812|NCT06254365|Biological|Exogenous LEAP2 hormone|This intervention has never been examined in this type of study before.
79659813|NCT06253416|Other|Exercise|a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks
79659814|NCT06253416|Other|Control|exercise freely and without supervision with their daily routine
79659815|NCT06252818|Device|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
79659816|NCT06252636|Other|A2 Milk|Cow's milk that contains only A2 β-Casein.
79659817|NCT06252636|Other|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein.
79659818|NCT06250413|Other|FMT|Capsulated oral auto fecal microbiota transplant
79659819|NCT06250413|Other|Placebo|Capsulated hot chocolate powder
79659820|NCT06250413|Drug|Amox Clav|5 day course of Amoxicillin Clavulanic acid given to all participants
79659821|NCT06249204|Behavioral|Coaching Group|Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
79659822|NCT06248177|Dietary Supplement|Probiotic|Probiotic capsules
79659823|NCT06248177|Dietary Supplement|Placebo|Placebo capsules
79346018|NCT01750918|Drug|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
79346019|NCT01750918|Drug|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
79346020|NCT01750918|Device|5-fluorouracil|5-fluorouracil-based chemotherapy
79346021|NCT02300987|Drug|LEE011|
79346022|NCT02300987|Drug|LEE011 Placebo|
79498002|NCT00385853|Procedure|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
79815066|NCT04093089|Device|Bionode IOP Lowering System|Control: No stimulation
79498003|NCT00386321|Drug|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
79659824|NCT06244589|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method
79659825|NCT06244589|Procedure|Open-conversion cholecystectomy|Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.
79986414|NCT04522518|Device|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
79346023|NCT01750840|Device|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
79346024|NCT01750840|Device|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
79986415|NCT02426710|Device|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
79986416|NCT03424850|Radiation|HDR brachytherapy|"Dose constraints for 21 Gy:~Bladder and rectum: V70 < 1 cc~Urethra: V115 < 1 cc~V135: 0%~Dose constraints for 23 Gy:~Bladder and rectum: V65 < 1 cc~Urethra: V105 < 1 cc~V125: 0%~Dose constraints for 25 Gy:~Prostate V100 >90% (>95% preferred)~Bladder and rectum: V70 < 1 cc, Dmax <115%~Urethra: V110 < 1 cc, Dmax <120%"
79346025|NCT01750840|Device|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
79659826|NCT06244147|Dietary Supplement|KSM-66 Ashwagandha Root Extract|Participants will take KSM-66 Ashwagandha root extract 300mg twice a day for the duration of the study.
79986417|NCT05758974|Procedure|dental treatment|Extraction, pulp therapy or both
79986418|NCT02426944|Drug|NOAC|Medical arm, patients will be treated by NOAC.
79986419|NCT02426944|Device|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
79346026|NCT01606228|Drug|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
79346027|NCT01706536|Drug|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
79346028|NCT01706536|Drug|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
79659827|NCT06243263|Drug|Bupivacain|At the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.
79659828|NCT06241820|Procedure|Lumbar Sympathetic Ganglion Block|A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
79679488|NCT03458364|Device|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
79815067|NCT00916890|Drug|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
79815068|NCT00916890|Drug|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
79498004|NCT00005711|Behavioral|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
79498005|NCT00005765|Drug|nicotine|
79815069|NCT00916890|Drug|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
79346029|NCT01706536|Drug|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
79346030|NCT01706536|Drug|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
79346031|NCT01706536|Drug|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
79346032|NCT02269943|Drug|CC-486|
79498006|NCT00005765|Drug|alcohol|
79498007|NCT00005771|Device|Visual utrasound feedback|
79346033|NCT04882319|Drug|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
79346034|NCT04882319|Drug|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
79498008|NCT00005771|Procedure|Abdominal Hollowing Exercise|
79498009|NCT00005777|Procedure|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
79498010|NCT00005777|Procedure|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target <48 mm Hg)
79498011|NCT00005777|Drug|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
79498012|NCT00005777|Drug|Placebo|The infants in the placebo groups received equal volumes of saline.
79498013|NCT00005783|Drug|Recombinant-methionyl human stem cell factor|
79498014|NCT00385931|Drug|Valsartan and simvastatin|
79498015|NCT00386087|Drug|Enzastaurin Hydrochloride|
79498016|NCT00386399|Drug|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
79498017|NCT00005801|Biological|therapeutic allogeneic lymphocytes|
79498018|NCT00005801|Procedure|peripheral blood stem cell transplantation|
79498019|NCT00005801|Radiation|radiation therapy|
79498020|NCT00005807|Drug|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
79498021|NCT00005813|Biological|bispecific antibody MDX447|
79498022|NCT00005813|Biological|lymphokine-activated killer cells|
79498023|NCT00005813|Procedure|conventional surgery|
79498024|NCT00005399|Other|No interventions|No interventions
79498025|NCT04569929|Other|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
79498026|NCT00003647|Drug|allovectin-7|
79346035|NCT04882319|Drug|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
79498027|NCT00003647|Drug|allovectin-7/dacarbazine|
79498028|NCT00003647|Drug|dacarbazine|
79498029|NCT05895695|Procedure|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
79498030|NCT05895695|Procedure|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
79498031|NCT05895682|Device|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
79498032|NCT05895656|Other|7 Tesla MRI|Performing an additional 7 Tesla MRI examination as part of the initial treatment pathway.
79815070|NCT00916890|Drug|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
79815071|NCT02599701|Drug|Gabapentin|A single dose Gabapentin 300mg at bedtime.
79346036|NCT01706458|Biological|sipuleucel-T|Given IV
79346037|NCT01706458|Biological|DNA Vaccine|Given ID
79815072|NCT02599701|Drug|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
79346038|NCT02269787|Behavioral|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
79346039|NCT01605370|Drug|Nebivolol|Nebivolol 2.5 mg once daily
79346040|NCT01605370|Drug|Metoprolol succinate|Metoprolol succinate 50 mg once daily
79346041|NCT02269709|Device|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
79346042|NCT02269475|Drug|MEDI3250|MEDI3250
79346043|NCT02269475|Drug|Placebo|Placebo
79815073|NCT04093401|Other|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
79346044|NCT01605136|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
79346045|NCT01605136|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
79346046|NCT01706146|Drug|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
79346047|NCT04168450|Other|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
79498033|NCT05895630|Behavioral|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
79498034|NCT05895630|Behavioral|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
79815074|NCT04093245|Behavioral|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
79815075|NCT04093245|Behavioral|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
79815076|NCT04093245|Behavioral|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
79346048|NCT04168450|Other|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
79346049|NCT02269241|Drug|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
79346050|NCT01750684|Drug|AC105|
79346051|NCT01750684|Other|Placebo|
79346052|NCT01750294|Drug|Chlorthalidone|
79346053|NCT01749982|Other|Placebo|
79346054|NCT01749982|Drug|Choline bitartrate|
79346055|NCT01749982|Drug|Betaine|
79346056|NCT01749982|Drug|Choline bitartrate + Betaine|
79346057|NCT02269163|Biological|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
79346058|NCT02269163|Biological|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
79346059|NCT01749826|Drug|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
79498035|NCT05895591|Other|Anti-aging cosmetic care product|"frequency of application: Once a day (in the morning)~modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~duration of investigational product application: 56 days (a window of + 72 hours is allowed)~quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
79498036|NCT05895539|Other|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
79498037|NCT05895526|Procedure|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
79679489|NCT03458364|Device|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
79679490|NCT00515840|Other|Physiotherapist|Physiotherapist administered breathing retraining programme
79815077|NCT04093245|Behavioral|medical follow-up appointment|a planned follow-up appointment with their family physician
79815078|NCT04093245|Behavioral|follow-up phone call|a systematic follow-up phone call for discharged patients
79815079|NCT04093245|Other|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
79346060|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
79370748|NCT04361890|Diagnostic Test|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
79815080|NCT04093245|Other|Telemonitoring service|access to a community-based telemonitoring service
79498038|NCT05895461|Behavioral|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
79498039|NCT05895448|Drug|velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .|Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
79498040|NCT05895435|Device|radiofrequancy|"Power of device: 150 W~Duration of the session: 40 minutes~Frequency: 2 sessions per week for 8 week.~Heating temperature: According to patient tolerance."
79498041|NCT05895435|Other|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
79498042|NCT05895370|Biological|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
79498043|NCT05895370|Drug|Interleukin-2|500,000IU/m^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
79498044|NCT05895305|Combination Product|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
79498045|NCT05895240|Drug|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
79498046|NCT05895227|Procedure|Oocyte retrieval|
79498047|NCT05895214|Procedure|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
79659829|NCT06241339|Other|Mat Pilates|"Mat Pilates training will last 12 weeks, with three weekly trial sessions being held at 48-72h intervals. Each session will last approximately 60 minutes, including: 5 minutes of warm-up (light calisthenic exercises for the shoulder and pelvic girdles); 50 minutes of Mat Pilates exercises; 5 min back to calm.~Upon arriving at the training site, volunteers will rest for 10 minutes in a sitting position, after which BP measurements will be taken and HR at rest. Throughout consecutive training sessions, participants will perform Pilates method exercises with a progressively greater degree of difficulty and complexity, following the official recommendations for prescription of resistance exercise for individuals with BP elevated and post-stroke. The exercises will be performed in single sets of 10 repetitions. Groups will be advised to maintain daily activities without physical exercise during the 12-week period."
79498048|NCT05895188|Device|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
79498050|NCT05895149|Other|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
79659830|NCT06240338|Diagnostic Test|laboratory investigation and Imaging|laboratory parameters (white blood cell count,neutrophil count, lymphocyte count, hemoglobin level, platelet level, red cell distribution width (RDW) level, hematocrit (HCT), renal function, hepatic function, electrolytes, arterial blood gas, HOMA-IR) will be assessed and imaging: Abdominal ultrasonography, Abdominal CT or MRI if needed
79659831|NCT06239272|Procedure|Surgical resection|Low, Intermediate and High-risk Surgery to remove tumor (standard of care)
79659832|NCT06239272|Radiation|Proton beam radiation therapy|Low, Intermediate and High-risk Radiation therapy is considered standard of care for patients with NRSTS who have positive tumor margins. However, the dose that will be given in this study is higher than what is usually given, therefore, the dose of radiation in this study is research. Radiation will start about 3 to 6 weeks after your surgery, depending on how quickly you recover from surgery. Radiation will be given daily (Monday through Friday) for about 5 to 6 weeks.
79659833|NCT06239272|Drug|Pazopanib|Intermediate and High-risk By mouth, either by tablet or a liquid suspension, 7 doses, days 1 to 7
79346061|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
79346062|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
79498051|NCT05895149|Other|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
79346063|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
79346064|NCT02267135|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
79346065|NCT02267135|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
79498052|NCT05895123|Drug|Rosuvastatin 20 mg ,40 mg|patients will receive one tablet rosuvastatin 20-40 mg every night
79498053|NCT05895123|Drug|Atorvastatin 40mg,80mg|patients will receive one tablet Atorvastatin 20-40 mg every night
79498054|NCT05895110|Biological|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
79498055|NCT05895097|Device|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
79498056|NCT05895097|Device|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF < 40 %
79498057|NCT05895084|Behavioral|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
79498058|NCT05895071|Drug|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
79498059|NCT05895071|Drug|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
79498060|NCT05895032|Other|Exercise|12-week exercise intervention
79659834|NCT06239272|Drug|Ifosfamide|Intermediate and High-risk Ifosfamide is a structural analogue of cyclophosphamide. Into the vein (IV) over about 3 hours, 3 doses, days 1, 2, and 3
79346066|NCT02299427|Behavioral|dog safety|use of dog safety website at home for about 2 weeks
79346067|NCT02299427|Behavioral|transportation safety|use of transportation safety website at home for about 2 weeks
79346068|NCT05649371|Other|Prehabilitation|A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
79346069|NCT05649215|Other|No intervention will be applied.|This is a questionnaire study.
79346070|NCT01724866|Drug|SPI-2012|SPI-2012 SC injection.
79498061|NCT05895032|Other|Usual Care|usual care
79498062|NCT05894993|Device|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
79498063|NCT05894980|Device|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
79659835|NCT06239272|Drug|Doxorubicin|Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
79346071|NCT01724866|Drug|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
79346072|NCT01724866|Drug|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
79346073|NCT01724866|Drug|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
79346074|NCT04419935|Procedure|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
79346075|NCT02266433|Drug|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
79370749|NCT04361500|Device|Seraph 100|Seraph 100 therapy during a COVID-19 infection
79498064|NCT05894980|Device|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
79498065|NCT05894980|Device|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
79498066|NCT05894954|Dietary Supplement|Precision Medicine Approach|Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics
79498067|NCT05894954|Combination Product|Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises|"Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis"
79498068|NCT05894954|Behavioral|Standard-of-Care|Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen
79498069|NCT05894954|Behavioral|Lifestyle including diet, exercise, stress management|Combining a tailored diet, exercise and stress management program supported by coaching specialists
79659836|NCT06239272|Drug|Selinexor|"High-risk Dosage and route of administration: Selinexor tablets for oral administration should be taken at approximately the same time each day without regards to meals.~Selinexor is a selective inhibitor of nuclear export (SINE). Selinexor specifically blocks XPO1-mediated nuclear export by forming a slowly reversible covalent bond with the nuclear export protein XPO1 By mouth, either by tablet or a liquid suspension, 1 dose and day 3"
79370750|NCT00705081|Drug|ezetimibe|10 mg once daily
79986420|NCT03376321|Drug|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
79370751|NCT00705081|Drug|statin|
79498070|NCT05894915|Procedure|open surgery|Open surgery is a traditional surgery method.
79498071|NCT05894915|Procedure|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
79498072|NCT05894889|Biological|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
79498073|NCT05894863|Device|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
79498074|NCT05894850|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
79498075|NCT05894850|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
79498076|NCT05894850|Other|Manually remind the patients|Medical staff remind patients manually .
79498077|NCT05894837|Drug|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
79498078|NCT05894837|Drug|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
79498079|NCT05894824|Drug|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~Dosing Regimen~Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
79659837|NCT06237335|Drug|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
79659838|NCT06237335|Other|Placebo|Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
79346076|NCT02266433|Drug|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
79346077|NCT01748890|Device|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
79346078|NCT05648981|Other|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
79659839|NCT06234865|Other|Control Group|Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
79346079|NCT05648981|Other|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
79498080|NCT05894811|Diagnostic Test|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
79498081|NCT05894811|Diagnostic Test|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
79346080|NCT04869215|Other|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
79498082|NCT05894746|Dietary Supplement|gluten-free|see info in arm description
79498083|NCT05894746|Dietary Supplement|probiotic|see info in arm description
79498084|NCT05894746|Dietary Supplement|gluten|see info in arm description
79498085|NCT05894733|Other|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
79498086|NCT05894733|Other|control group|first and sixth month face to face interwiew
79498087|NCT05894720|Other|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
79498088|NCT05894707|Drug|SCT650C|Recombinant anti-IL-17A antibody
79498089|NCT05894694|Drug|palliative care group first-line scheme+compound kushen injection|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml, at least 4 cycles of chemotherapy.
79659840|NCT06234865|Other|Video Education Group|Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
79659841|NCT06234423|Drug|CUSP06|Antibody drug conjugate (ADC)
79659842|NCT06234293|Device|near-infrared light device|Nurses will have to find the vein for the PIVC using the near-infrared light device.
79659843|NCT06233942|Drug|BG-C9074|administered by intravenous infusion
79346081|NCT04869215|Other|Control bread|Bread baked with normal Bakers flour
79346082|NCT01747876|Drug|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
79346083|NCT02273726|Drug|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
79498090|NCT05894694|Drug|palliative care group first-line scheme|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
79498091|NCT05894668|Other|ECIRS|Endoscopic Combined Intrarenal Surgery
79659844|NCT06233942|Drug|Tislelizumab|administered by intravenous infusion
79659845|NCT06232161|Device|Red-light therapy device|Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.
79659846|NCT06232161|Device|Spectacles|Single focus spectacles, that is to say, wearing glasseses with minus power lens
79659847|NCT06231290|Other|Adult full pulpotomy procedure|The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
79659848|NCT06230614|Other|Colistin 1 MU in normal saline 1 ml|Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
79659849|NCT06230614|Other|Colistin 1 MU in normal saline 2 ml|Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
79346084|NCT02273726|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
79498092|NCT05894642|Behavioral|0|It is a case-control study, cross-sectional, so there is no intervention possible.
79498093|NCT05894629|Behavioral|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
79986421|NCT03376321|Drug|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
79986422|NCT03376321|Other|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
79346085|NCT04557358|Other|COVID-19 survey|A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
79498094|NCT05894629|Behavioral|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
79346086|NCT04557358|Other|RAPID-3|The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
79346087|NCT04557358|Other|WHOQOL-BREF|The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
79498095|NCT05894551|Other|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
79498096|NCT05894551|Other|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
79498097|NCT05894551|Other|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
79498098|NCT05894486|Drug|Lutetium[177Lu] Oxodotreotide Injection|Lutetium[177Lu] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
79498099|NCT05894447|Drug|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
79498100|NCT05894447|Drug|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
79498101|NCT05894447|Drug|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
79498102|NCT05894434|Behavioral|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
79498103|NCT05894434|Behavioral|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
79498104|NCT05894408|Other|this is no intervention|this is no intervention
79498105|NCT05894382|Device|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
79498106|NCT05894382|Device|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
79659850|NCT06227000|Behavioral|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
79815081|NCT02599896|Biological|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
79986423|NCT02418520|Device|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
79986424|NCT04437732|Device|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
79346088|NCT04557358|Other|DASS-21 instrument (depression and anxiety)|The instrument measures the presence of depression and anxiety
79346089|NCT04557358|Other|IER-R (posttraumatic stress)|The instrument measures the presence of posttraumatic stress
79346090|NCT01723228|Drug|Rasagiline|
79346091|NCT01723228|Drug|Placebo|
79498107|NCT05894343|Genetic|AAV-GAD|Bilateral infusion of AAV-GAD
79659851|NCT06227000|Behavioral|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
79346092|NCT02273180|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
79498108|NCT05894278|Other|Prescription data collection|Prescription data collection
79659852|NCT06225596|Drug|BT8009|Participants will receive BT8009 IV on days 1, 8 +/- 15 schedule of every 21-day cycle.
79659853|NCT06225596|Drug|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
79498109|NCT05894265|Other|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
79659854|NCT06225596|Drug|Gemcitabine + cisplatin Or carboplatin|Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
79659855|NCT06225596|Drug|Avelumab|After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
79346093|NCT02273180|Drug|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
79659856|NCT06225349|Dietary Supplement|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
79659857|NCT06225349|Dietary Supplement|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
79659858|NCT06225349|Dietary Supplement|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
79659859|NCT06225349|Dietary Supplement|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
79815082|NCT02599896|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
79346094|NCT02273180|Drug|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
79346095|NCT01746862|Drug|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone [r-hGH]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
79498110|NCT05894265|Other|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
79659860|NCT06224101|Behavioral|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
79498111|NCT05894265|Procedure|Saline injection|Group 3 will receive saline injection
79659861|NCT06223828|Drug|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
79659862|NCT06223048|Drug|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
79815083|NCT04094922|Behavioral|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
79346096|NCT01746862|Drug|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
79346097|NCT01745848|Drug|Roflumilast|
79498112|NCT05894252|Other|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
79498113|NCT05894226|Procedure|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
79498114|NCT05894200|Other|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
79659863|NCT06222775|Behavioral|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
79659864|NCT06222775|Behavioral|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
79815084|NCT04095000|Behavioral|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
79346098|NCT01745380|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
79498115|NCT05894161|Other|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen & chest) and legs.~A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~Walking exercise: Walking on the ground surface for 30 minutes every day."
79498116|NCT05894148|Drug|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
79498117|NCT05894148|Drug|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
79815085|NCT04095000|Behavioral|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
79815086|NCT00824369|Drug|No drug will be administered|No drug will be administered.
79815087|NCT00824291|Drug|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
79815088|NCT00824291|Genetic|Genotyping|CYP2D6 genotyping at randomization
79815089|NCT05239871|Diagnostic Test|Ultrasound|Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
79815090|NCT00804986|Drug|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
79815091|NCT00804986|Drug|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
79346099|NCT01745380|Drug|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
79346100|NCT01745146|Behavioral|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
79346101|NCT01745146|Behavioral|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
79815092|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
79346108|NCT05648474|Diagnostic Test|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
79346109|NCT05648396|Other|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
79346110|NCT05648318|Drug|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
79370752|NCT04361110|Radiation|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
79498118|NCT05894135|Drug|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
79986425|NCT03183622|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
79986426|NCT05760534|Drug|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
79986427|NCT02418364|Other|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
79986428|NCT02418364|Other|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
79346111|NCT05648318|Drug|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
79498119|NCT05894135|Drug|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
79498120|NCT05894135|Drug|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
79986429|NCT01362699|Drug|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
79986430|NCT01362699|Drug|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
79986431|NCT03686072|Procedure|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
79986432|NCT02423278|Procedure|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
79986433|NCT02423278|Procedure|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1&2 LNs) and para-aortic lymph nodes must be removed during the operation."
79498121|NCT05894135|Drug|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
79498122|NCT05894135|Drug|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
79498123|NCT05894135|Drug|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
79498124|NCT05894044|Other|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
79498125|NCT05894044|Other|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
79498126|NCT05894044|Other|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
79498127|NCT05894044|Other|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
79498128|NCT05894031|Behavioral|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
79346112|NCT02203513|Drug|LY2606368|105 mg/m^2 intravenous (IV) once every 14 days of a 28 day cycle
79346113|NCT04881890|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
79346114|NCT02299934|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
79986434|NCT02423278|Drug|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
79346115|NCT02299934|Diagnostic Test|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
79346116|NCT01703260|Drug|Roflumilast|Roflumilast dose
79346117|NCT01703260|Drug|Pioglitazone|Pioglitazone dose
79346118|NCT01703260|Drug|Placebo|Pioglitazone placebo-matching dose
79346119|NCT01703260|Drug|Placebo|Roflumilast placebo-matching dose
79346120|NCT02203357|Biological|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
79346121|NCT02299388|Drug|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
79346122|NCT02202577|Drug|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
79346123|NCT02202577|Drug|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
79346124|NCT02299076|Behavioral|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
79346125|NCT02299076|Other|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
79346126|NCT01723072|Biological|Omalizumab|Humanized monoclonal antibody against human IgE
79346127|NCT01723072|Drug|Placebo|Placebo to omalizumab
79346128|NCT01722994|Device|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
79986435|NCT01365429|Device|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
79346129|NCT01722994|Device|Chromic Gut Sterile absorbable Suture (Ethicon)|
79346130|NCT02228395|Drug|PF-04958242|Administered as specified in treatment arm
79346131|NCT02228395|Drug|Placebo|Administered as specified in treatment arm
79346132|NCT02170051|Behavioral|CBSST-CCT|
79346133|NCT02170051|Behavioral|Goal focused supportive contact|
79346134|NCT02169739|Device|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
79346135|NCT02169505|Drug|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
79346136|NCT01909791|Procedure|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
79346137|NCT01909791|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
79346138|NCT01909791|Procedure|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
79346139|NCT01909791|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
79346140|NCT02202499|Drug|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
79346141|NCT02202499|Other|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
79370753|NCT00704769|Drug|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
79659865|NCT06222775|Behavioral|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
79986436|NCT02423356|Procedure|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
79815093|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
79815094|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
79986437|NCT02950506|Device|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
79986438|NCT02950506|Other|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
79986439|NCT03183466|Procedure|arthroscopic repair|
79986440|NCT03183466|Procedure|arthroscopic debridement|
79346142|NCT02202499|Other|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
79346143|NCT02202109|Behavioral|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
79346144|NCT02202109|Behavioral|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
79346145|NCT02227849|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
79346146|NCT02227849|Drug|GLP-1 analogue|
79370754|NCT00938548|Drug|Pregabalin|Pregabalin 75 mg orally
79498129|NCT05893992|Device|Hearing aids (omnidirectional)|Device for hearing loss compensation with microphone sensitivity all around the listener.
79498130|NCT05893992|Device|Hearing aids (directional)|Device for hearing loss compensation with microphone sensitivity in front of the listener.
79498131|NCT05893992|Other|Unaided|Control condition
79498132|NCT05893966|Radiation|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
79498133|NCT05893953|Device|immediately feedback device|Sitting in a standard chair with immediate feedback device
79498134|NCT05893953|Device|Unstable chair|sitting in an unstable chair
79498135|NCT05893953|Other|Standard chair|Sitting in a standard chair
79986441|NCT05189067|Drug|Paclitaxel|i.v. 80mg/m^2
79498136|NCT05893849|Drug|Clinical probes|Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
79498137|NCT05893784|Other|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
79986442|NCT05189067|Drug|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
79986443|NCT05189067|Drug|Docetaxel|i.v. 100mg/m2
79986444|NCT03374995|Other|Best Practice|Receive standard of care
79986445|NCT03374995|Other|Quality-of-Life Assessment|Ancillary studies
79986446|NCT03374995|Device|Topical Keratin|Given topically
79986447|NCT02418208|Diagnostic Test|Performint EEG tests and BNA analysis|
79986448|NCT02828982|Device|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
79498138|NCT05893745|Other|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
79659866|NCT06222775|Behavioral|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
79659867|NCT06222775|Behavioral|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
79815095|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
79815096|NCT00752232|Other|PBS|IM injection, Day 1, month 3, 6, 9, 12
79986449|NCT02828982|Device|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
79986450|NCT01362777|Behavioral|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~15' start warming up muscles~30' muscle strengthening exercise for arms and abdominal muscles~45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~15' stretching~15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
79986451|NCT01362777|Behavioral|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~Physiological mechanisms of apneas/hypopneas~Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~Beneficials effects of CPAP and/or advanced mandibular orthosis~Description of sleep stages and physiological roles of sleep~Known effects of exercise on sleep and metabolism~Importance of good nutritional status and sleep hygiene on quality of life~How to apply theses lessons of rehabilitation in daily life"
79986452|NCT02427022|Other|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
79986453|NCT03711643|Procedure|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
79370755|NCT00938548|Drug|Vitamin Complex (placebo)|Vitamin Complex orally
79370756|NCT00932620|Drug|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
79659868|NCT06222775|Behavioral|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
79659869|NCT06222775|Behavioral|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
79659870|NCT06222775|Behavioral|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
79659871|NCT06222775|Behavioral|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
79370757|NCT00932620|Drug|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
79370758|NCT04361188|Procedure|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
79370759|NCT04361188|Procedure|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
79986454|NCT03711643|Device|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
79498139|NCT05893745|Other|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
79986455|NCT02418286|Other|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
79498140|NCT05893732|Device|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
79498141|NCT05893732|Device|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
79498142|NCT05893719|Device|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
79986456|NCT03133767|Drug|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
79986457|NCT03133767|Drug|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
79986458|NCT02422966|Drug|Paracetamol|
79498143|NCT05893693|Other|Biological|CT0594CP
79498144|NCT05893654|Drug|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
79659872|NCT06222775|Behavioral|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
79659873|NCT06222775|Behavioral|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
79659874|NCT06222775|Behavioral|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
79986459|NCT02422966|Drug|Ibuprofen|
79986460|NCT02422888|Drug|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
79986461|NCT02422888|Drug|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
79986462|NCT03633552|Drug|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
79498145|NCT05893654|Radiation|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
79679491|NCT05317611|Drug|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
79815097|NCT02600520|Drug|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
79498146|NCT05894083|Procedure|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
79986463|NCT02426632|Drug|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
79659875|NCT06221046|Other|Cream D|"Prevention~Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~Avoid rubbing/scrubbing~Reduce exposure to moisture as much as possible~Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~Continue with prevention methods, apply CREAM ARM 2 as a barrier product after every fecal incontinence event~Discontinue CREAM ARM 2 use after skin has healed~If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~Discontinue use after skin has healed~If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment"
79659876|NCT06221046|Other|Control|"Prevention~Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~Avoid rubbing/scrubbing~Reduce exposure to moisture as much as possible~Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~Continue with prevention methods, apply CREAM ARM 1 as a barrier product after every fecal incontinence event~Discontinue CREAM ARM 1 use after skin has healed~If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~Discontinue use after the skin has healed~If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment"
79815098|NCT02600520|Drug|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
79815099|NCT02600520|Drug|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
79815100|NCT02600442|Other|non interventional study|
79986464|NCT02426632|Drug|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
79986465|NCT02426632|Drug|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
79986466|NCT02426632|Drug|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
79986467|NCT02426632|Drug|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
79986468|NCT02426632|Drug|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
79659877|NCT06218368|Behavioral|Educational toolkit on MMR and polio vaccination|The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
79986469|NCT02426632|Drug|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
79659878|NCT06216509|Device|Endoscopic ultrasound pressure measurement|all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
79659879|NCT06215365|Behavioral|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
79659880|NCT06210906|Other|Assessment of gastric volume|Gastric volume is assessed using ultrasound.
79659881|NCT06210893|Other|The cricoid cartilage is located.|The cricoid cartilage is located.
79659882|NCT06210516|Device|PowerBreathe|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~Chest circumference measurements~Diaphragm movements and thickness (ultrasound)~Hand grip strength (with a Jamar hand dynamometer)~Motor Activity Log~6 Minute Walk Test (6MWT)~Canadian Occupational Performance Measure~Charlson Comorbidity Index"
79815101|NCT00760266|Drug|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
79986470|NCT02426632|Drug|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
79986471|NCT02426632|Drug|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
79815102|NCT00760266|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
79815103|NCT00753714|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
79815104|NCT00753714|Drug|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
79986472|NCT02426632|Drug|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
79986473|NCT02426632|Drug|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
79986474|NCT02426632|Drug|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
79986475|NCT03633474|Biological|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
79986476|NCT03633474|Other|PBS only|Sterile PBS only containing no bacteria
79986477|NCT05760456|Drug|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
79986478|NCT05760456|Drug|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
79986479|NCT02418130|Drug|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
79986480|NCT02418130|Drug|Placebo|
79498147|NCT05894083|Combination Product|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.
79659883|NCT06210516|Other|Conventional Physiotherapy|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~Chest circumference measurements~Diaphragm movements and thickness (ultrasound)~Hand grip strength (with a Jamar hand dynamometer)~Motor Activity Log~6 Minute Walk Test (6MWT)~Canadian Occupational Performance Measure~Charlson Comorbidity Index"
79346147|NCT01927497|Procedure|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
79346148|NCT01927497|Procedure|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
79346149|NCT02169271|Drug|Aspirin|Given PO
79346150|NCT02169271|Other|Laboratory Biomarker Analysis|Correlative studies
79346151|NCT02169271|Other|Placebo|Given PO
79346152|NCT02202031|Behavioral|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
79346153|NCT02202031|Behavioral|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
79346154|NCT01644188|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
79346155|NCT01644188|Drug|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
79498148|NCT05894083|Other|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
79498149|NCT05894083|Radiation|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
79659884|NCT06209034|Other|Optic nerve sheath measurement|ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
79659885|NCT06208215|Drug|RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
79346156|NCT01644188|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
79659886|NCT06208215|Drug|RZ358 (10 mg/kg) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
79659887|NCT06208215|Drug|RZ358 (5-10 mg/kg) + SOC|Infant participants from ≥3 months to <1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
79659888|NCT06206148|Device|Given novel electronic pain recording device|Patients in this arm will be given a custom-built pain recording device to see if the method of self-reported data collection has any effect on how many data points are collected.
79815105|NCT00753714|Drug|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
79498150|NCT05893615|Behavioral|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
79498151|NCT05893602|Other|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
79498152|NCT05893589|Other|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
79498153|NCT05893550|Dietary Supplement|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
79498154|NCT05893550|Dietary Supplement|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
79498155|NCT05893524|Diagnostic Test|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
79498156|NCT05893524|Diagnostic Test|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
79659889|NCT06206148|Other|Given Hand-written pain journal|Patients in this arm will be given a hand-written pain journal to see if the method of self-reported data collection has any effect on how many data points are collected.
79659890|NCT06206148|Other|Smartphone app|Patients in this arm will be given a research smartphone with survey app to see if the method of self-reported data collection has any effect on how many data points are collected.
79815106|NCT00759954|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
79346157|NCT01644188|Drug|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
79346158|NCT01644188|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
79659891|NCT06201325|Other|virtual reality based exercises|play VR games
79659892|NCT06201325|Other|conventional physical therapy|streching and strengthening exercises
79659893|NCT06201325|Other|home exercises program|home exercises
79679492|NCT05317611|Drug|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
79346159|NCT02201953|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79346160|NCT02201953|Drug|SOF|400 mg tablet administered orally once daily
79346161|NCT02201953|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79346162|NCT02271854|Drug|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
79346163|NCT02271854|Drug|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
79346164|NCT05296993|Dietary Supplement|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
79346165|NCT02296892|Drug|Remimazolam|For induction and maintenance of sedation
79679493|NCT05317611|Drug|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
79679494|NCT04695314|Device|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
79679495|NCT04695314|Procedure|Experimental insert|Raised shoe insert, insert used for massage
79679496|NCT04695314|Procedure|Sham insert|Flat shoe insert, insert used for massage
79815107|NCT00759954|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
79815108|NCT00804908|Drug|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
79815109|NCT00804908|Drug|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
79815110|NCT00804908|Other|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
79498157|NCT05893524|Diagnostic Test|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
79498158|NCT05893511|Procedure|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
79346166|NCT02296892|Drug|Placebo|Inactive control arm
79346167|NCT02296892|Drug|Midazolam|For induction and maintenance of sedation
79346168|NCT02270684|Device|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
79346169|NCT05647928|Other|no intervention|no intervention
79346170|NCT02168803|Drug|Evacetrapib|Administered orally
79346171|NCT02201329|Drug|Azacitidine|Azacitidine (subcutaneous)
79346172|NCT02201329|Drug|Volasertib|Volasertib escalating doses (intravenous)
79346173|NCT01927419|Drug|Nivolumab|
79346174|NCT01927419|Drug|Ipilimumab|
79346175|NCT01927419|Drug|Placebo|Matching nivolumab
79498159|NCT05893511|Drug|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
79498160|NCT05893485|Behavioral|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
79498161|NCT05893472|Combination Product|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
79679497|NCT05317572|Drug|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
79346176|NCT02168491|Drug|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
79346177|NCT02168491|Drug|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
79346178|NCT02225743|Other|Observation Of Temperature|Participants temperature will be recorded perioperatively.
79346179|NCT01721746|Biological|BMS-936558|
79346180|NCT01721746|Drug|Dacarbazine|
79346181|NCT01721746|Drug|Carboplatin|
79346182|NCT01721746|Drug|Paclitaxel|
79346183|NCT02225665|Genetic|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
79346184|NCT02225665|Genetic|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
79346185|NCT02225665|Drug|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
79346186|NCT01721200|Other|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
79346187|NCT01721200|Other|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
79346188|NCT02225587|Biological|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
79346189|NCT02225587|Biological|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
79986481|NCT02426788|Behavioral|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
79346190|NCT02225587|Biological|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
79346191|NCT02296424|Drug|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
79498162|NCT05893446|Dietary Supplement|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
79498163|NCT05892978|Other|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
79498164|NCT05892913|Drug|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
79498165|NCT05892913|Drug|Ephedrine|For sympathetic blockade (SBP<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
79498166|NCT05891522|Procedure|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
79498167|NCT05891522|Procedure|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
79679498|NCT05317572|Drug|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
79815111|NCT00808808|Biological|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
79346192|NCT02296190|Drug|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
79346193|NCT02296190|Drug|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
79346194|NCT04875026|Drug|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
79346195|NCT04875026|Device|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
79346196|NCT02296112|Drug|trametinib|Given PO
79346197|NCT02296112|Other|laboratory biomarker analysis|Correlative studies
79346198|NCT02296112|Other|pharmacological study|Correlative studies
79346199|NCT02295644|Device|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
79346200|NCT02269670|Drug|everolimus|Given PO
79346201|NCT02269670|Drug|anastrozole|Given PO
79346202|NCT02269670|Drug|letrozole|Given PO
79346203|NCT02269670|Drug|tamoxifen citrate|Given PO
79346204|NCT02269670|Drug|fulvestrant|Given IM or PO
79346205|NCT02269670|Drug|megestrol acetate|Given PO
79346206|NCT02225353|Drug|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
79346207|NCT02225353|Drug|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
79346208|NCT02225353|Drug|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
79498168|NCT05891314|Procedure|Botox Injectable Product|one group will have botox injection in the internal sphincter
79346209|NCT01641926|Biological|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
79986482|NCT03179956|Drug|Ribociclib|Treatment with ribociclib [600mg] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
79986483|NCT03391765|Drug|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
79986484|NCT03391765|Drug|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
79986485|NCT02802228|Drug|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
79346210|NCT01641926|Biological|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
79498169|NCT05891314|Procedure|Internal sphincterotomy|this group will have internal sphincterotomy
79498170|NCT05891028|Drug|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
79498171|NCT05891028|Drug|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
79498172|NCT05890716|Diagnostic Test|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
79498173|NCT05890690|Diagnostic Test|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
79498174|NCT05890690|Diagnostic Test|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
79346211|NCT02295020|Drug|Standard treatment only|Standard treatment such as NSAIDs and injections
79986486|NCT02802228|Drug|Placebo|matched placebo delivered as infusion and oral capsule
79498175|NCT05890430|Biological|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
79498176|NCT05890248|Procedure|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
79986487|NCT02426554|Dietary Supplement|DDU-supplement|DDU: Vitamin D, DHA, Uridine
79986488|NCT02426554|Dietary Supplement|Placebo supplement|
79986489|NCT03179488|Device|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
79986490|NCT03179488|Device|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
79986491|NCT03130257|Diagnostic Test|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
79986492|NCT03130257|Diagnostic Test|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
79986493|NCT03130257|Diagnostic Test|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
79986494|NCT03130257|Diagnostic Test|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
79498177|NCT05887830|Drug|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
79346212|NCT02295020|Device|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
79346213|NCT02200939|Device|Bioinductive implant|
79346214|NCT02200939|Device|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
79346215|NCT05152381|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79346216|NCT02294786|Drug|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
79346217|NCT02294786|Drug|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
79498178|NCT05887830|Other|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
79498179|NCT05885230|Procedure|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
79498180|NCT05885230|Drug|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
79498181|NCT05876000|Device|Corheart 6 Ventricular Assist System|Implantation of ventricular assist device for hemodynamic support
79498182|NCT05865028|Drug|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
79498183|NCT05861258|Drug|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
79659894|NCT06199570|Behavioral|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a 1-week pre-scan call, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a 1-week post-scan phone call, the stress management plan will be revisited for new concerns.
79815112|NCT00808808|Other|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
79815113|NCT00808808|Biological|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
79986495|NCT02801448|Drug|sulforaphane|sulforaphane-containing broccoli sprout extracts
79986496|NCT02801448|Drug|Placebo|Maltodextrine-based placebo without sulforaphane
79986497|NCT03179332|Drug|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
79346218|NCT02294786|Drug|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
79346219|NCT04880876|Drug|25mg Eluxadoline|Oral Tablets
79815114|NCT02608034|Drug|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
79815115|NCT02608034|Drug|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
79986498|NCT03179332|Drug|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
79346220|NCT04880876|Drug|100mg Eluxadoline|Oral Tablets
79346221|NCT05647694|Other|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
79498184|NCT05857800|Other|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
79498185|NCT05850598|Device|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
79986499|NCT03179332|Drug|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
79986500|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
79986501|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
79498186|NCT05850598|Device|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
79659895|NCT06199570|Behavioral|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
79346222|NCT02269124|Device|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
79346223|NCT01927341|Drug|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
79346224|NCT01927341|Drug|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
79346225|NCT02294474|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
79346226|NCT02294474|Drug|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
79659896|NCT06193083|Other|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
79346227|NCT02294474|Drug|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
79346228|NCT02168101|Drug|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
79346229|NCT02298179|Biological|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346230|NCT02298179|Biological|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346231|NCT02298179|Biological|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346232|NCT02298179|Biological|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346233|NCT02298179|Biological|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346234|NCT02298179|Biological|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346235|NCT02298179|Biological|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346236|NCT02298179|Biological|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346237|NCT02298179|Biological|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79346238|NCT02298179|Drug|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
79659897|NCT06193083|Other|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal)~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
79346239|NCT02298023|Biological|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
79346240|NCT02298023|Biological|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
79986502|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
79986503|NCT03674177|Drug|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
79986504|NCT03717259|Procedure|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
79986505|NCT03717259|Procedure|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
79986506|NCT03717259|Procedure|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
79498187|NCT05844085|Other|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
79498188|NCT05844085|Other|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
79346241|NCT02298023|Biological|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
79659898|NCT06193083|Other|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
79346242|NCT02296931|Other|Saline|Standard IV Saline Fluids
79346243|NCT02296931|Drug|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
79986507|NCT02675790|Drug|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
79815116|NCT02608034|Drug|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
79986508|NCT02675790|Drug|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
79346244|NCT02166697|Drug|candesartan cilexetil|candesartan cilexetil tablets
79986509|NCT01359189|Device|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
79986510|NCT02417896|Drug|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
79986511|NCT01365663|Drug|SPC4955|3 Weekly SC injections
79986512|NCT01365663|Drug|SPC4955|3 Weekly SC injections
79986513|NCT01365663|Drug|SPC4955|3 Weekly SC injections
79986514|NCT01365663|Drug|SPC4955|3 Weekly SC injections
79986515|NCT01365663|Drug|SPC4955|3 Weekly SC injections
79986516|NCT01365663|Drug|Saline 0.9%|3 Weekly SC injections
79986517|NCT03183544|Combination Product|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
79346245|NCT01909479|Drug|MOD-4023|Individualized once weekly dose of MOD-4023
79346246|NCT01909479|Other|Placebo|Once weekly administration of placebo
79346247|NCT04760977|Drug|Drugs administration|Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
79346248|NCT04760977|Device|Resuscitative endovascular balloon occlusion of the aorta|Resuscitative technique for exsanguinating traumas
79346249|NCT04760977|Biological|Blood transfusions|Transfuion of transported blood products for exsanguinating traumas
79346250|NCT04760977|Other|Prehospital management|Stay and play strategy vs scoop and run
79498189|NCT05844085|Dietary Supplement|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
79659899|NCT06191679|Behavioral|Decision Aid for Education and Support about Cancer Treatment (DECIDES)|DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
79659900|NCT06191679|Behavioral|Decision Aid for Education and Support about Cancer Treatment with Coach-Assisted Support (DECIDES + coach)|Live support in the form of a coach is provided to support navigation of DECIDES and promote involvement in decision-making. DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
79815117|NCT02608190|Behavioral|Working memory training|See protocol
79815118|NCT00589784|Drug|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
79815119|NCT00759876|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
79986518|NCT04380090|Drug|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
79986519|NCT04380090|Drug|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
79986520|NCT05191563|Drug|HCP1904-1|Take it once per period.
79815120|NCT04569344|Other|Laboratory test positive for SARS-CoV-2 virus|Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
79986521|NCT05191563|Drug|RLD2006|Take it once per period.
79986522|NCT05191563|Drug|RLD2001-2|Take it once per period.
79986523|NCT03711565|Device|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
79986524|NCT03711565|Device|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
79346251|NCT04760977|Device|Prehospital eFAST|Prehospital thorax/abdomen extended focused assessment sonography for trauma
79346252|NCT01955733|Drug|BI 695500|
79346253|NCT02197897|Drug|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
79498190|NCT05844085|Dietary Supplement|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
79986525|NCT02418052|Procedure|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
79498191|NCT05824195|Other|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
79498192|NCT05821530|Device|HFIT|At least 1 hour daily for 4 weeks
79498193|NCT05821530|Device|TENS|At least 1 hour daily for 4 weeks
79498194|NCT05821530|Other|Control|Users will continue to use the digital MSK program as needed
79659901|NCT06191666|Behavioral|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
79815121|NCT03981588|Other|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
79986526|NCT03685916|Other|Control|Plain rice with plain water
79346254|NCT02223793|Behavioral|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
79346255|NCT02223793|Behavioral|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
79346256|NCT02223793|Behavioral|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
79346257|NCT01926015|Biological|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
79346258|NCT01926015|Biological|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
79346259|NCT02223715|Other|CDI Pts|
79346260|NCT02196259|Drug|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
79346261|NCT02294396|Drug|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
79524848|NCT05767502|Diagnostic Test|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~Patients with an M+E score of 7 are assigned a verbal score of +2~Patients with an M+E score of 8-9 are assigned a verbal score of +4~Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~0 points if both pupils react to light,~1 point if a pupil does not react to light and has anisocoria,~2 points if both pupils do not react to light"
79659902|NCT06191666|Behavioral|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
79815122|NCT05742854|Procedure|C-sections operations|Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon
79346262|NCT02294396|Drug|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
79346263|NCT02294396|Drug|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
79346264|NCT02294396|Drug|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
79346265|NCT02294396|Drug|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
79346266|NCT01721044|Drug|Placebo|Administered orally
79815123|NCT05742854|Drug|Oxytocin|Oxytocin
79815124|NCT05742854|Drug|Carbetocin|Carbetocin
79346267|NCT01721044|Drug|Baricitinib|Administered orally
79346268|NCT01721044|Drug|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
79346269|NCT02164981|Drug|sodium nitroprusside|intravenous
79346270|NCT02164981|Other|Placebo|Placebo
79346271|NCT02195869|Drug|Ibrutinib|
79346272|NCT01908699|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
79346273|NCT01908699|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
79346274|NCT01599637|Drug|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
79346275|NCT01599637|Drug|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
79815125|NCT00823979|Drug|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
79659903|NCT06191666|Behavioral|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
79986527|NCT03685916|Other|Cumin Rice|Cumin rice with plain water
79346276|NCT02264639|Drug|Pegcetacoplan|Complement (C3) Inhibitor
79498195|NCT05818787|Behavioral|Vestibular Perceptual Learning|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
79498196|NCT05818787|Behavioral|Placebo Intervention|The placebo (or control) task will consist of oculomotor exercises that the subject will complete at home (i.e., outside of the lab). The oculomotor exercises will include saccadic eye movements performed in the horizontal and vertical planes. All movements will be completed within a limited, comfortable range of motion with the head remaining stationary. As the control intervention will be performed with the head stationary and in a seated position, no change in self-motion perception or balance is expected to result from the control (i.e., placebo) task.
79498197|NCT05784571|Other|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
79498198|NCT05784571|Other|Modified Physical Performance Test|A test of physical functioning
79498199|NCT05784571|Other|Hand grip strength|A test of hand grip strength using a hand dynamometer.
79659904|NCT06191666|Behavioral|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
79815126|NCT00823979|Drug|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
79815127|NCT00823979|Drug|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
79815128|NCT04093284|Device|The needle-free jet injector|Continuous insulin therapy for 9 days
79815129|NCT02599584|Behavioral|precritical staff|free pre critical scenario team staff
79815130|NCT04094766|Drug|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
79815131|NCT02606786|Other|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
79815132|NCT05428722|Behavioral|deep breathing exercises with a incentive spirometer|Deep breathing exercise will be explained to the patients with an incentive spirometer (IS), it will be demonstrated in practice and it will be applied from the first day of hospitalization in addition to routine treatment and care. The patient will be informed about whether they are doing it right and their questions will be answered. It will be ensured that the patients start after breakfast in the morning and make 5-10 inspirations, hold her/his breath for 3 seconds and 5-10 expirations per hour with IS until they fall asleep. The research nurse will warn the patients that they should do the exercise every hour, and the alarms of the patients' mobile phones will be set to ring every hour to be a warning. The start and end time of the exercise will be decided together with the patient, and usually the time of waking and going to bed will be taken into account.
79986528|NCT03685916|Other|Cumin Drink|Cumin drink with plain rice
79986529|NCT03685916|Other|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
79986530|NCT03685916|Other|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
79346277|NCT05648903|Other|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
79370760|NCT00003453|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79659905|NCT06191380|Behavioral|PACE-MS|A single bout of cycling.
79659906|NCT06186141|Drug|Morphine|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
79659907|NCT06186141|Drug|Oxycodone|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
79986531|NCT03685916|Other|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
79370761|NCT04367818|Procedure|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
79498200|NCT05784571|Other|6-minute walk test|Self-paced test of walking capacity.
79659908|NCT06180499|Drug|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
79659909|NCT06179472|Device|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
79986532|NCT03685916|Other|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
79498201|NCT05784571|Procedure|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
79498202|NCT05779943|Drug|Furosemide|Given IV
79498203|NCT05779943|Other|F18-rhPSMA-7.3|Given IV
79659910|NCT06172907|Behavioral|Young Adults Coping with Cancer Together Intervention|This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
79659911|NCT06172699|Device|Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device|All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
79659912|NCT06170385|Behavioral|Physical Therapy|Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
79986533|NCT03685916|Other|Tamarind Rice|Tamarind rice with plain water
79370762|NCT04367818|Procedure|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
79370763|NCT01677273|Dietary Supplement|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
79498204|NCT05779943|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79498205|NCT05779943|Procedure|Computed Tomography|Undergo PET/CT scan
79524849|NCT05767489|Combination Product|electroencephalogram (EEG) and magnetic resonance (MR)|"High-resolution 3D T1 and T2 sequences, acquired in the sagittal plane and MR reconstructed in the remaining orthogonal planes, for morphological assessment of different cortical and subcortical.~EEG tracing involving recording channels such as eye tracking (eye-tracking: electrooculogram, pupillometry, saccades, fixation times on areas predefined areas), performance measures (response times), electrocardiogram and electromyogram proper to clinical acquisition"
79524850|NCT05767476|Diagnostic Test|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~Neonatal Cranial Ultrasonography~Brain magnetic resonance imaging~Neurological assessment~Neurodevelopmental and cognitive assessment~Electroencephalogram (EEG)~Motor performance assessment"
79370764|NCT01677273|Dietary Supplement|Intact casein|30 g protein/supplement, 4 supplements/visit
79370765|NCT01677273|Dietary Supplement|Intact whey protein|30 g protein/supplement, 4 supplements/visit
79370766|NCT04355806|Drug|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
79370767|NCT04355806|Biological|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
79346278|NCT05648903|Other|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
79346279|NCT05648903|Other|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
79346280|NCT01363011|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
79346281|NCT01363011|Drug|COBI|COBI 150 mg tablet administered with food orally once daily
79346282|NCT01363011|Drug|ATV|ATV 300 mg tablet administered orally once daily
79346283|NCT01363011|Drug|DRV|DRV 800 mg tablet administered orally once daily
79346284|NCT01363011|Drug|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
79346286|NCT05648747|Other|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
79346287|NCT05648669|Drug|Elagolix|200 mg tablet
79346288|NCT05648669|Drug|Elagolix placebo|Elagolix-matched Placebo tablet
79346289|NCT02263547|Drug|teriflunomide|
79346290|NCT02263547|Drug|Colestipol|
79346291|NCT05648513|Behavioral|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
79346292|NCT01925703|Drug|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
79346293|NCT01617681|Drug|VAL489|Valsartan 3mg/kg oral solution
79346294|NCT01617681|Drug|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
79346295|NCT02263079|Drug|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
79659913|NCT06169514|Other|No intervention|No intervention
79659914|NCT06169397|Drug|XTMAB-16|XTMAB-16 infusion
79346296|NCT02263079|Drug|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
79346297|NCT02263079|Drug|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m^2) BSA.
79659915|NCT06168825|Other|Mind Over Matter (MOM)|"Each participant's involvement in the study will include:~Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~Completing 5 weekly sessions of MOM~Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits."
79370768|NCT01677351|Drug|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
79370769|NCT01677351|Drug|placebo|
79659916|NCT06165783|Other|Therapeutic Exercises and Ultrasound|describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
79659917|NCT06164132|Other|Evaluation|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
79659918|NCT06163469|Device|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
79815133|NCT00708383|Other|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
79815134|NCT00708383|Other|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
79815135|NCT02606864|Drug|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
79815136|NCT02606942|Other|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
79659919|NCT06159166|Drug|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
79346298|NCT02295995|Behavioral|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
79346299|NCT02294981|Device|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
79346300|NCT02262377|Behavioral|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
79346301|NCT02260817|Drug|11C-choline Injection|"Choline C11 Injection for PET/CT Imaging Protocol:~15 - millicuries (mCi) 11C-choline IV Injection~PET images skull base to mid thigh with 3 min per bed position~Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~Fusion of PET and CT images~Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~No IV contrast~High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~Fusion of coronal and PET images"
79346302|NCT05647967|Diagnostic Test|Ultrasound|Each patient underwent ultrasound after admission of ICU.
79346303|NCT04873193|Device|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
79346304|NCT01642589|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
79346305|NCT01642589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
79346306|NCT05647499|Behavioral|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
79346307|NCT05647421|Device|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
79346308|NCT05647421|Device|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
79346309|NCT01954251|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79346310|NCT01954251|Biological|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
79986534|NCT03685916|Other|Tamarind Drink|Tamarind drink with plain rice
79346311|NCT01644617|Drug|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
79815137|NCT05521607|Device|Picterus Jaundice Pro (JP)|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
79986535|NCT03116776|Procedure|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
79986536|NCT03116776|Drug|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
79986537|NCT02505204|Other|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
79986538|NCT02505204|Other|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
79986539|NCT01359267|Drug|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
79986540|NCT03183232|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
79986541|NCT03183232|Biological|γδ T cell|γδ T cells will be used against Lung Cancer
79986542|NCT03183232|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
79498206|NCT05779774|Behavioral|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only [comparison control] v. WayToServe training plus WayToServe Plus in-service component [intervention]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with ~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
79498207|NCT05779774|Behavioral|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only [comparison control] v. WayToServe Plus In-service Component [intervention]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
79346312|NCT01644617|Drug|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
79346313|NCT01644617|Drug|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
79498208|NCT05778903|Other|Nerve block|Suprazygomatic maxillary nerve block
79659920|NCT06149156|Behavioral|Healthy Minds Program App|The four-week intervention comprises two introductory lessons and guided meditations followed by one week of content for each pillar of well-being. Each week includes two brief lessons (5-7 minutes) with education on the scientific research behind the practices, as well as examples of how to strengthen the skills of each pillar in daily life, along with three guided meditations for which the participant can select the practice length (5-30 minutes).
79815138|NCT00823901|Drug|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
79986543|NCT01362933|Procedure|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
79986544|NCT03681626|Procedure|no tracheal suction|No tracheal suctioning during extubation
79986545|NCT03681626|Procedure|tracheal suction|tracheal suctioning during extubation
79986546|NCT05056714|Other|Questionaries|The patient will answer several questionaries
79986547|NCT01359345|Drug|gadollinum|use of on injection gadollinum Iv for imaging
79986548|NCT02417584|Device|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
79346314|NCT02294318|Behavioral|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
79986549|NCT01359423|Drug|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
79986550|NCT01359423|Drug|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
79346315|NCT02294318|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
79346316|NCT04643925|Drug|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
79659921|NCT06149156|Behavioral|Well-being Resources|List of well-being resources that comprises of online video links and books
79815139|NCT00823901|Drug|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
79346317|NCT02293499|Behavioral|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma [LTAA],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
79346318|NCT04628949|Device|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
79346319|NCT02257385|Drug|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
79498209|NCT05776797|Procedure|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
79659922|NCT06146621|Behavioral|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
79346320|NCT02257385|Drug|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
79346321|NCT02257385|Drug|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
79498210|NCT05776797|Drug|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
79524851|NCT05767450|Dietary Supplement|Probiotic Vivomixx®|The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
79659923|NCT06146621|Behavioral|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
79815140|NCT00823823|Other|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
79815141|NCT00823823|Other|Circumferential cast|Circumferential cast will be applied following closed reduction
79815142|NCT05740592|Procedure|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
79815143|NCT04540094|Drug|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
79346322|NCT02257385|Drug|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
79346323|NCT02257385|Drug|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
79346324|NCT02257385|Drug|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
79524852|NCT05767450|Dietary Supplement|Placebo|The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
79498211|NCT05768516|Other|Implementation of best practice for low back pain in primary care|"Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
79498212|NCT05765396|Device|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
79498213|NCT05752123|Biological|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
79346325|NCT02257385|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
79346326|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
79498214|NCT05746611|Biological|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
79346327|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
79346328|NCT01629667|Other|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
79346329|NCT01645280|Drug|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
79346330|NCT01645280|Drug|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
79346331|NCT01645280|Drug|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
79498215|NCT05746611|Biological|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
79498216|NCT05727098|Drug|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
79498217|NCT05727098|Drug|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
79498218|NCT05727098|Drug|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
79498219|NCT05720806|Other|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
79498220|NCT05720806|Other|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
79346332|NCT01645280|Drug|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
79659924|NCT06146621|Behavioral|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
79815144|NCT04540094|Drug|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
79346333|NCT01645280|Drug|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
79346334|NCT02256917|Biological|Human cl rhFVIII|
79346335|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
79498221|NCT05720182|Device|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~Place the probe on the target area~Identify correct landmark~Compress the compartment~Increase steadily the pressure applied by the CP probe to 80 mmHg."
79346336|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
79498222|NCT05720182|Procedure|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
79498223|NCT05720182|Other|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
79498224|NCT05698823|Device|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
79498225|NCT05694520|Other|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
79498226|NCT05692492|Drug|ZSP1601|50mg BID
79498227|NCT05692492|Drug|ZSP1601|100mg BID
79498228|NCT05692492|Drug|Placebo|Placebo
79498229|NCT05689814|Device|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
79498230|NCT05683730|Other|Intermittent caloric restriction|"Intermittente caloric restriction:~st month: restriction of 50% of the caloric intake previously determined by the dietician 1 day per week~nd month: restriction of 50% of the caloric intake 2 days per week~rd month: restriction of 60% of the caloric intake 2 days per week~th month: restriction of 75% of the caloric intake 2 days per week"
79498231|NCT05680415|Biological|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
79498232|NCT05656352|Device|Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device|Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.
79498233|NCT05656352|Diagnostic Test|Complete Blood Count|The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
79498234|NCT05649865|Diagnostic Test|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
79498235|NCT05635578|Behavioral|sleep|reiki
79498236|NCT05631990|Drug|AD-209|PO, Once daily(QD), 8weeks
79498237|NCT05631990|Drug|AD-209-1A|PO, Once daily(QD), 8weeks
79498238|NCT05631990|Drug|AD-209-1B|PO, Once daily(QD), 8weeks
79498239|NCT05631990|Drug|AD-209-1C|PO, Once daily(QD), 8weeks
79498240|NCT05631990|Drug|AD-209 placebo|PO, Once daily(QD), 8weeks
79815145|NCT02926898|Drug|ZX008 (Fenfluramine Hydrochloride)|"ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base."
79346337|NCT04188223|Biological|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
79346338|NCT04188223|Biological|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
79346339|NCT02256839|Device|CST_001|
79346340|NCT02220907|Drug|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
79346341|NCT02255981|Other|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
79498241|NCT05631990|Drug|AD-209-1 placebo|PO, Once daily(QD), 8weeks
79498242|NCT05610527|Device|ENG Implant|This is an FDA approved contraceptive device
79498243|NCT05610527|Device|LNG IUD|This is an FDA approved contraceptive device
79498244|NCT05608525|Device|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
79815146|NCT02926898|Drug|Matching Placebo|Matching Placebo
79659925|NCT06146621|Behavioral|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
79346342|NCT01601873|Device|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
79346343|NCT01601873|Device|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
79498245|NCT05608525|Behavioral|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community [22-27]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
79498246|NCT05604053|Behavioral|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
79498247|NCT05595915|Dietary Supplement|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
79498248|NCT05594732|Behavioral|Weak outdoor light|Stay and stare far on the balcony or under the tree
79498249|NCT05594732|Behavioral|Strong outdoor light|Stay and stare far in the sunlight
79659926|NCT06139458|Behavioral|Cryotherapy|Participants will receive cryotherapy on both hands and feet
79659927|NCT06139458|Behavioral|Compression|Participants will receive compression on both hands and feet
79815147|NCT02606630|Drug|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
79815148|NCT00759564|Drug|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
79815149|NCT00816023|Drug|ecallantide|infusion administered IV over the duration of the surgical procedure
79815150|NCT00816023|Drug|placebo|solution for IV infusion over the duration of the surgical>> procedure
79815151|NCT00759174|Drug|No intervention|No intervention occurs in this observational study.
79815152|NCT00815633|Drug|Alefacept|15mg intramuscular injection weekly for 12 weeks
79815153|NCT02610881|Dietary Supplement|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
79346344|NCT02194933|Drug|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
79346345|NCT05647109|Other|No intervention|No intervention
79346346|NCT04420247|Drug|Chloroquine|5 days of treatment with Chloroquine + Standard Care
79346347|NCT04420247|Drug|Hydroxychloroquine|5 days of treatment with Hydroxychloroquine + Standard Care
79346348|NCT04420247|Other|standard care|Standard Care according to Brazilian Guidelines for treating COVID-19
79346349|NCT01644890|Drug|NK105|IV, Weekly
79346350|NCT01644890|Drug|Paclitaxel|IV, Weekly
79346351|NCT04868006|Procedure|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
79659928|NCT06139354|Behavioral|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
79815154|NCT02610881|Dietary Supplement|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
79815155|NCT02610881|Behavioral|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
79815156|NCT00830765|Drug|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
79815157|NCT00830765|Drug|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
79815158|NCT04093206|Dietary Supplement|EpiCor and Vitamin C|One daily dose
79815159|NCT04093206|Dietary Supplement|Vitamin C|One daily dose
79815160|NCT00705887|Behavioral|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
79659929|NCT06130670|Other|nerve block|Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery.
79659930|NCT06127563|Other|creation of a clinical pathway to increase vaccination coverage in frail patients|creation of a clinical pathway to increase vaccination coverage for frail patients, integrating hospital and local health units through an automated algorithm
79815161|NCT00830375|Drug|Memantine|10-30mg, by mouth, daily
79659931|NCT06127251|Behavioral|PATH Intervention|"The PATH intervention guides participants in making changes in their lifestyle and PA habits to support gradual improvement of PA. The health coach provides participants with access to the PATH website and instructions on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week.~Participants will use a combination of walking, dance, and abdominal core workouts to add at least 10 minutes of MVPA to their baseline PA every two weeks. The remote coach will encourage each participant to engage in at least 2 days of aerobic training (walking or dance sessions), and one day of abdominal core workouts."
79659932|NCT06127251|Behavioral|Control Group|Study staff will have a Zoom meeting with each control group participant where they will be advised to use the Be Active Your Way handout and to self-monitor PA using Fitbit. Additionally, the group will be introduced to www.health.com, a jargon-free website that focuses on general health topics (e.g., dry eye) and the latest medical news (e.g., vaccines). Every 2 weeks control participants will meet on Zoom with study staff to review their progress in the study so as to keep the contact between the groups as similar as possible.
79659933|NCT06127251|Device|Physical activity tracker|Participants will be asked to wear a Fitbit tracker on their non-dominant hand for the entire duration of the study using a 24-hour wear protocol.
79659934|NCT06127251|Behavioral|Dietary education|The research team will examine diet quality and provide all study participants with educational content curated to promote diet quality. To minimize participants' burden, both the intervention and control arms will receive an email with a brief PDF addressing new diet components every 4 weeks
79659935|NCT06125054|Drug|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
79659936|NCT06125054|Drug|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
79815162|NCT00803270|Drug|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
79815163|NCT00803270|Procedure|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
79815164|NCT00708539|Drug|progesterone|90 mg, vaginal, once daily
79346352|NCT04868006|Procedure|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
79346353|NCT04868006|Procedure|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
79346354|NCT04865237|Biological|SARS-CoV-2 Virus|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
79346355|NCT04865237|Drug|Remdesivir|VEKLURY™
79346356|NCT01628965|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
79498250|NCT05590468|Dietary Supplement|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
79498251|NCT05590468|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient
79498252|NCT05574244|Procedure|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
79986551|NCT03179566|Behavioral|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
79986552|NCT03179566|Behavioral|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
79498253|NCT05574244|Procedure|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
79498254|NCT05572658|Biological|mRNA-1345|Sterile liquid for injection
79986553|NCT01363089|Drug|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
79498255|NCT05572658|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79498256|NCT05565560|Drug|Apremilast|Oral tablets
79498257|NCT05564325|Device|Deflectable guidewire|A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
79498258|NCT05564325|Device|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
79498259|NCT05563194|Device|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
79498260|NCT05563194|Device|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
79659937|NCT06125054|Behavioral|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated twice.
79986554|NCT01363089|Drug|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
79986555|NCT03354637|Drug|ATI-50002 high dose|Topical solution
79498261|NCT05563194|Device|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
79498262|NCT05527808|Drug|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
79498263|NCT05527808|Drug|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
79986556|NCT03354637|Drug|ATI-50002 low dose|Topical solution
79986557|NCT03354637|Drug|Placebo|Topical solution
79986558|NCT03685838|Other|Compression Stockings|Class II above knee compression stockings
79986559|NCT02422576|Other|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
79986560|NCT02422576|Other|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
79498264|NCT05527808|Drug|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
79498265|NCT05527808|Drug|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
79498266|NCT05516108|Behavioral|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
79659938|NCT06125054|Behavioral|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated twice.
79659939|NCT06123338|Drug|Pembrolizumab|Pembrolizumab will be administered on an every 3-week dosing schedule
79986561|NCT02422576|Other|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
79346357|NCT05647460|Procedure|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~Preoperative CT.~Virtual reduction of broken segments on software.~Gain occlusion.~Design surgical screw holes locating guide.~Design the custom-made plates.~Print the screw holes locating guide and the custom-made plate.~Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
79346358|NCT05647460|Procedure|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
79498267|NCT05516108|Behavioral|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
79498268|NCT05496335|Drug|AGN-151586|Intramuscular Injection
79346359|NCT05647382|Diagnostic Test|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
79346360|NCT01644734|Drug|Spiriva HandiHaler|
79498269|NCT05496335|Drug|BOTOX|Intramuscular Injection
79986562|NCT02422576|Other|Thicken Up clear: TUC|
79498270|NCT05496335|Drug|Placebo|Intramuscular Injection
79659940|NCT06123338|Drug|Trastuzumab|Trastuzumab will be administered on an every 3-week dosing schedule
79498271|NCT05480098|Drug|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
79498272|NCT05439031|Radiation|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
79498273|NCT05438511|Behavioral|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
79498274|NCT05438511|Behavioral|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
79498275|NCT05426031|Drug|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
79498276|NCT05426031|Drug|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
79659941|NCT06123039|Diagnostic Test|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
79659942|NCT06123039|Procedure|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
79986563|NCT04053023|Drug|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
79986564|NCT04053023|Drug|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
79986565|NCT01365741|Other|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
79498277|NCT05424328|Procedure|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head & neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
79986566|NCT02426320|Other|Sedation Interruption Protocol|
79986567|NCT02426320|Other|Standard Sedation Protocol|
79986568|NCT05191173|Procedure|Cardiac Surgery|No intervention, just observation is performed.
79659943|NCT06112756|Drug|Elinzanetant|Oral
79815165|NCT00708539|Drug|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
79986569|NCT02422732|Other|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
79346361|NCT02255279|Biological|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
79498278|NCT05424328|Procedure|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
79659944|NCT06112756|Other|Placebo|Oral
79815166|NCT05516537|Behavioral|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
79346362|NCT02255279|Biological|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
79659945|NCT06108947|Drug|Aspirin|Aspirin discontinuation
79346363|NCT01643798|Procedure|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
79498279|NCT05423106|Drug|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
79498280|NCT05423106|Drug|Placebo|Placebo will be administered as an oral formulation.
79986570|NCT02422732|Radiation|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
79659946|NCT06107452|Other|training strategy with adaptation of training strategies to the ANS|a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
79498281|NCT05423106|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
79498282|NCT05423106|Drug|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
79498283|NCT05423106|Drug|Entecavir (ETV)|ETV tablet will be administered orally.
79986571|NCT02422732|Genetic|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
79986572|NCT03623906|Procedure|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
79986573|NCT03623906|Procedure|Air insufflation colonoscopy|Room air insufflation colonoscopy
79986574|NCT05416788|Other|cervical manipulation|high-velocity, low-amplitude cervical manipulation
79986575|NCT05416788|Other|Sham intervention|lateral flexion and cervical rotation without manipulation
79986576|NCT01359501|Drug|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
79986577|NCT01359501|Drug|Placebo|Start to take the powder of Placebo 3g*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
79498284|NCT05423106|Drug|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
79815167|NCT05516537|Behavioral|FLEX Stretching and Toning Program|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
79815168|NCT00751998|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
79986578|NCT02422420|Behavioral|Financial Incentives|Use of financial incentives to promote health behaviors.
79986579|NCT03681548|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
79986580|NCT02417506|Other|E-OA-07 (Lanconone)|
79498285|NCT05415761|Behavioral|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
79659947|NCT06107452|Other|training strategy (standard practice)|a training strategy for subjects whose PFVP is in favour of strength or speed
79986581|NCT02417506|Drug|Ibuprofen|
79986582|NCT05188911|Drug|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
79986583|NCT05188911|Drug|Prednisone|Patients would be treated with 5mg prednisone bid.
79986584|NCT05188911|Drug|Androgen deprivation therapy|Patients would get medical or surgical castration.
79986585|NCT03676946|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
79346364|NCT01643798|Procedure|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
79346365|NCT05647031|Other|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
79346366|NCT05647226|Combination Product|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
79346367|NCT05647226|Other|Standard of care|Standard of care.
79346368|NCT02194699|Biological|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
79346369|NCT02194699|Other|Placebo|Placebo subcutaneous injection
79346370|NCT04867070|Diagnostic Test|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
79346371|NCT04866524|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
79815169|NCT00914420|Device|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
79346372|NCT04866524|Other|Physical development and General Health|Physical development and General health examination
79498286|NCT05415761|Behavioral|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
79346373|NCT04866524|Other|Developmental Red flags|Developmental Red flags Questionnaires
79498287|NCT05415761|Behavioral|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
79498288|NCT05399277|Drug|Rivaroxaban|15mg oral daily for 7 days
79498289|NCT05377944|Drug|BAT2306|150 mg/1 ml/injection (2 injections/visit)
79498290|NCT05377944|Drug|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
79659948|NCT06107179|Diagnostic Test|Multispectral Optoacoustic Tomography|In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
79659949|NCT06102304|Device|Focused Extracorpeal Shock wave|Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro [serial number: EM12681015], Italy) was used as a focused extracorporeal shock wave therapy apparatus.
79659950|NCT06102304|Device|Sham Extracorpeal shock wave|(EME S.r.l. via Degli Abeti 88/161122 Pesaro [serial number: EM12681015], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.
79815170|NCT00914420|Device|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
79815171|NCT04094532|Drug|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
79815172|NCT04094532|Drug|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
79498291|NCT05371145|Biological|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
79498292|NCT05336071|Drug|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
79498293|NCT05336071|Drug|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
79498294|NCT05333679|Device|UTRA|Collect urine on intervention participants and screen for presence of TFV.
79815173|NCT00708773|Drug|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
79986586|NCT03676946|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
79986587|NCT03676946|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
79815174|NCT05758259|Drug|combination oral and topical vitamin D|combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
79986588|NCT02426242|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
79986589|NCT03352453|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
79498295|NCT05333679|Behavioral|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
79659951|NCT06102096|Behavioral|Culturally Adapted iCBT|A culturally adapted iCBT targeting mild to moderate mental health problems among Arabic-speaking refugee and migrant youth.
79659952|NCT06100393|Device|Investigational Pre-Processing Algorithm|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
79346374|NCT05647148|Behavioral|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
79346375|NCT05369858|Drug|[14C] SKLB1028|A single 150 mg oral dose of [14C] SKLB1028 containing approximately 120 microcurie of [14C] SKLB1028
79346376|NCT02293538|Drug|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
79346377|NCT02293538|Drug|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
79346378|NCT02293538|Device|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
79986590|NCT03352453|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
79346379|NCT02194621|Drug|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
79346380|NCT02194621|Drug|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
79346381|NCT02194621|Drug|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
79659953|NCT06100393|Device|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
79346382|NCT02220205|Other|PelvicSim|
79346383|NCT02220205|Device|Manufacturer model|
79346384|NCT02266706|Drug|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
79659954|NCT06097988|Device|ABIO3419|Intra-articular injection
79659955|NCT06095505|Drug|Alisertib|Alisertib enteric-coated tablets
79659956|NCT06093126|Drug|Lemborexant 5 MG|The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
79346385|NCT02266706|Drug|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
79346386|NCT02266706|Drug|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
79346387|NCT02266706|Drug|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
79346388|NCT02266706|Drug|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
79346389|NCT02293460|Drug|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
79346390|NCT04419974|Diagnostic Test|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
79346391|NCT04419974|Diagnostic Test|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
79659957|NCT06091878|Other|Observation|Observational study, no intervention
79659958|NCT06090539|Drug|BMS-986458|Specified dose on specified days.
79659959|NCT06090539|Drug|Rituximab|Specified dose on specified days.
79659960|NCT06080100|Drug|Xenon|inhalation of xenon in a sub-narcotic dosage
79659961|NCT06080100|Other|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
79659962|NCT06079190|Drug|GSK4527226|GSK4527226 will be administered.
79659963|NCT06079190|Other|Placebo|Placebo will be administered.
79815175|NCT05758259|Drug|oral placebo and topical cholecalciferol|oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1
79815176|NCT05758259|Drug|oral placebo and basic ingredient placebo topical vitamin D|oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
79815177|NCT02607644|Device|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
79815178|NCT02607644|Device|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
79986591|NCT03623438|Behavioral|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
79986592|NCT03623438|Behavioral|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
79346392|NCT04419974|Diagnostic Test|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
79986593|NCT03128931|Device|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
79986594|NCT02417662|Radiation|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
79986595|NCT02417662|Other|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
79986596|NCT03676790|Other|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
79498296|NCT05327244|Other|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
79498297|NCT05325034|Behavioral|Early Intervention|"Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies."
79659964|NCT06076863|Other|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
79346393|NCT04419974|Diagnostic Test|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
79346394|NCT04419974|Diagnostic Test|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
79346395|NCT04419974|Diagnostic Test|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
79659965|NCT06076863|Other|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
79659966|NCT06074796|Behavioral|No intervention.|"No intervention. This is a retrospective study. Data will have been collected in routine consultations as part of the transition process for transgender patients.~Description of the collected informations : gender of destination, BMI, siblings, children, moral, previous hormone therapy, when the project was born, change of marital status desired or carried out, ALD status, psychiatric assessment, desire for future care for the transition course. Desire to preserve erectile function, parenthood desire, couple projections, type of couple, cryopreservation desired, done or not, desire of pregnancy, ultrasound count of antral follicles, initial hormone assays and tests : BMD, pelvic ultrasound? Data relating to stimulation and ovarian puncture and sperm collection."
79659967|NCT06071910|Device|ER-REBOA catheter|To achieve rapid aortic occlusion
79659968|NCT06065059|Drug|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
79659969|NCT06065059|Drug|Olaparib|PARP inhibitor
79659970|NCT06062043|Behavioral|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
79659971|NCT06061913|Behavioral|Breast Pump suction pattern|Mothers who have reached secretory activation and are pumping <350 mLs/day will be randomized to one of three breast pump suction patterns.
79659972|NCT06060340|Drug|class II furcation defects management using propolis|"A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect."
79815179|NCT02601066|Device|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
79346396|NCT04419974|Diagnostic Test|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
79498298|NCT05324878|Other|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
79498299|NCT05319873|Drug|Carboplatin|Given IV
79498300|NCT05319873|Drug|Docetaxel|Given IV
79498301|NCT05319873|Drug|Fulvestrant|Given SC
79498302|NCT05319873|Biological|Pertuzumab|Given IV
79498303|NCT05319873|Other|Quality-of-Life Assessment|Ancillary Studies
79498304|NCT05319873|Drug|Ribociclib|Given PO
79498305|NCT05319873|Biological|Trastuzumab|Given IV
79659973|NCT06059118|Drug|DFMO|Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
79498306|NCT05319873|Drug|Tucatinib|Given PO
79498307|NCT05300906|Behavioral|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
79498308|NCT05300906|Behavioral|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
79659974|NCT06059118|Drug|testosterone cypionate|On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
79815180|NCT00803738|Drug|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
79346397|NCT04419974|Diagnostic Test|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
79346398|NCT04419974|Diagnostic Test|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
79346399|NCT04419974|Diagnostic Test|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
79370770|NCT00938704|Drug|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
79498309|NCT05291884|Device|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
79659975|NCT06059118|Drug|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
79815181|NCT00803738|Drug|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
79815182|NCT00758706|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
79815183|NCT00758706|Drug|Placebo|Dosing to match AZD1236
79815184|NCT04097808|Dietary Supplement|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
79498310|NCT05288439|Diagnostic Test|Resting-state functional connectivity MRI|participants will undergo functional MRI
79498311|NCT05288439|Other|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
79815185|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
79815186|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
79498312|NCT05281458|Procedure|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
79986597|NCT03676790|Other|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
79986598|NCT03676790|Other|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
79498313|NCT05264740|Behavioral|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
79498314|NCT05264740|Behavioral|Educational materials|The control group will receive educational material only.
79659976|NCT06059118|Drug|Enzalutamide|Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
79659977|NCT06053281|Drug|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
79659978|NCT06053281|Other|Placebo|Placebo
79815187|NCT00591266|Drug|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
79815188|NCT04094376|Other|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
79346400|NCT05647070|Procedure|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, ~1 cm× ~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
79346401|NCT02266004|Device|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
79498315|NCT05260242|Other|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
79498316|NCT05249452|Other|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
79498317|NCT05218772|Other|Questionnaires|Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
79498318|NCT05201703|Drug|Fycompa|Fycompa 4 mg daily
79498319|NCT05201703|Drug|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
79815189|NCT04093128|Other|herbal tea intervention|herbal tea intervention for 7 weeks
79659979|NCT06052761|Device|Making Toys from Medical Materials|"Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top."
79815190|NCT04093050|Drug|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
79498320|NCT05200338|Drug|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
79815191|NCT04092972|Other|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
79815192|NCT04092972|Other|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
79815193|NCT05450640|Other|satisfaction survey|1 eQuestionnaire per patient completed during study
79815194|NCT02601144|Device|Deep Brain Stimulation|Deep Brain Stimulation
79815195|NCT04093908|Other|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
79346402|NCT02266004|Other|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
79498321|NCT05195125|Procedure|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
79346403|NCT04864652|Device|CHILLS Procedure|CHILLS Cryotherapy procedure
79498322|NCT05188326|Drug|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
79498323|NCT05188326|Other|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
79498324|NCT05182918|Other|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
79498325|NCT05180942|Drug|Atorvastatin Calcium 40Mg Tab|One tablet daily
79498326|NCT05165108|Device|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
79498327|NCT05164653|Drug|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
79498328|NCT05164653|Drug|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
79659980|NCT06052436|Biological|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
79659981|NCT06052436|Biological|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
79659982|NCT06051435|Other|lumbar proprioception training|"a) Sensorimotor training: Sensorimotor training and reconditioning of proprioceptive senses have recently been found to be helpful in increasing motor performance and coordination, muscle strength, sensorimotor abilities, increasing intermuscular control, and improving one's response to sensory information and muscle tone. Reconditioning of proprioceptive senses and sensorimotor training increases one's muscle adjustment ability, maximizes the sensory input in different parts of the body and aids in improving one's motor adjustment ability (Hwang et al ., 2013).~Position Exercise methods as Hollowing exercise: Participants will be asked to contract the abdominal muscles, raising the center of movement toward the navel in a quadruped position."
79346404|NCT02292719|Drug|OBV/PTV/r|Tablet
79346405|NCT02292719|Drug|Sofosbuvir|Tablet
79346406|NCT02292719|Drug|Ribavirin (RBV)|Tablet
79346407|NCT02291861|Drug|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
79986599|NCT03676790|Other|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
79346408|NCT02291861|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
79346409|NCT02291549|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
79346410|NCT02291549|Drug|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
79346411|NCT02291549|Procedure|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
79346412|NCT05651165|Device|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
79346413|NCT05651165|Device|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
79346414|NCT02264990|Drug|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
79659983|NCT06051435|Other|Hot packs|hot application in the form of hot packs on the lower abdomen and lower back for a total duration of 30 minutes, once per day, during the first two days of menstruation
79659984|NCT06051435|Other|Pelvic rocking exercise|Pelvic rocking exercise
79986600|NCT03676790|Other|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
79986601|NCT01363167|Dietary Supplement|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
79986602|NCT03710707|Drug|DNL201|Oral repeating dose
79986603|NCT03710707|Drug|Placebo|Oral repeating dose
79498329|NCT05161260|Behavioral|Yoga Breathing|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
79524853|NCT05767385|Procedure|Single Arm|"Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline."
79524854|NCT05767385|Procedure|Neonatal Neurobehavioral Scale|Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
79524855|NCT05767320|Procedure|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
79524856|NCT05767320|Procedure|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
79986604|NCT03107052|Drug|Fremanezumab|Fremanezumab
79346415|NCT02264990|Drug|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
79346416|NCT02264990|Drug|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
79346417|NCT02264990|Drug|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
79346418|NCT02264990|Drug|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
79346419|NCT05646914|Other|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
79986605|NCT01359579|Drug|varespladib methyl|Single oral 500 mg dose
79498330|NCT05161260|Behavioral|Attention Control|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
79498331|NCT05160896|Drug|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
79986606|NCT02422654|Drug|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
79498332|NCT05160896|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
79498333|NCT05160896|Drug|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
79498334|NCT05160896|Drug|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
79986607|NCT05668793|Diagnostic Test|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
79986608|NCT05188833|Device|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
79346420|NCT05646914|Other|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
79346421|NCT02291237|Drug|Eleclazine|Tablet (s) administered orally once daily
79346422|NCT02291237|Drug|Placebo|Placebo to match eleclazine administered orally once daily
79498335|NCT05145881|Dietary Supplement|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
79498336|NCT05145881|Dietary Supplement|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
79659985|NCT06050395|Behavioral|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
79498337|NCT05138939|Other|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
79346423|NCT02292446|Drug|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
79498338|NCT05138939|Other|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
79498339|NCT05138939|Other|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
79498340|NCT05129670|Device|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
79346424|NCT02290925|Drug|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
79346425|NCT02290925|Dietary Supplement|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
79346426|NCT05651087|Drug|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
79498341|NCT05129670|Device|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
79498342|NCT05128617|Drug|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
79680056|NCT03457662|Combination Product|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
79986609|NCT05188833|Drug|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
79986610|NCT02426164|Drug|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
79346427|NCT02290691|Biological|Influenza Vaccine|Influenza Vaccine
79346428|NCT02292212|Device|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
79986611|NCT02426164|Drug|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
79986612|NCT03640013|Procedure|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
79986613|NCT02417428|Dietary Supplement|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
79498343|NCT05128617|Drug|Paclitaxel|1 cycle of Paclitaxel
79498344|NCT05107375|Biological|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
79498345|NCT05107375|Biological|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
79498346|NCT05065957|Drug|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
79498347|NCT05065957|Drug|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
79498348|NCT05051241|Drug|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen.
79659986|NCT06050395|Behavioral|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
79659987|NCT06050395|Behavioral|Educational Handouts|Participants will receive educational handouts on diet.
79659988|NCT06050395|Behavioral|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
79659989|NCT06050395|Behavioral|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
79346429|NCT02291510|Drug|Met DR|metformin delayed-release tablets
79346430|NCT02291510|Drug|Met XR|metformin extended-release tablets
79346431|NCT02291510|Drug|Met IR|metformin immediate-release tablets
79346432|NCT02290223|Behavioral|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
79346433|NCT02289833|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
79498349|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
79498350|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
79498351|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
79498352|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg*2 single dose
79498353|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
79498354|NCT05031520|Procedure|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
79498355|NCT05031520|Drug|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
79498356|NCT05031520|Drug|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
79346434|NCT05646329|Behavioral|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
79498357|NCT05031520|Drug|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
79498358|NCT05019950|Drug|NIM-1324|Once daily oral tablet
79498359|NCT05019950|Drug|Placebo|Once daily oral tablet
79498360|NCT05018650|Device|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
79680057|NCT00524615|Drug|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
79498361|NCT05012813|Other|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
79498362|NCT05007431|Other|Questionnaires|Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
79986614|NCT02417428|Other|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
79986615|NCT02417428|Behavioral|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
79346435|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m^2) to determine the MTD.
79986616|NCT02417428|Other|without exercise|No exercise program will be assigned to participants.
79986617|NCT02015897|Procedure|Physical TherapyA|"Group A:~Skin care~Manual lymphatic drainage~Bandaging using Coban™2Lite~Guidance on physical activity"
79346436|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
79346437|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
79346438|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
79346439|NCT05650931|Procedure|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
79498363|NCT05003167|Device|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
79498364|NCT04989829|Drug|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
79498365|NCT04988035|Drug|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
79498366|NCT04988035|Other|Placebo|Danicopan matching placebo tablet
79498367|NCT04988035|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
79498368|NCT04987138|Device|Zenflow Spring System|The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
79498369|NCT04987138|Device|Sham Procedure|A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
79498370|NCT04986423|Drug|ZEN003694|72 mg PO QD
79680058|NCT00524654|Procedure|HVLA chiropractic manipulation|
79346440|NCT05650931|Procedure|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
79498371|NCT04986423|Drug|Enzalutamide|160 mg PO QD
79346441|NCT05650931|Procedure|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
79346442|NCT02287883|Other|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
79346443|NCT01743040|Diagnostic Test|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
79498372|NCT04939792|Drug|Vitamin D|Capsules ingested orally
79659990|NCT06050395|Behavioral|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
79346444|NCT02194465|Drug|LY2623091|Administered orally
79346445|NCT02194465|Drug|Tadalafil|Administered orally
79346446|NCT02194465|Drug|Spironolactone|Administered orally
79346447|NCT02194465|Drug|Placebo|Administered orally
79346448|NCT02287025|Drug|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
79346449|NCT02287025|Other|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
79346450|NCT02287025|Other|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
79346451|NCT01720264|Drug|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
79346452|NCT04564846|Drug|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
79346453|NCT04564846|Other|Placebo|Placebo capsule (Fish Oil)
79346454|NCT01702246|Drug|Simvastatin|40 mg, orally, once daily for 3 months
79346455|NCT01631227|Drug|Eprosartan|Eprosartan 450 mg
79346456|NCT01631227|Drug|Eprosartan Mesylate|Eprosartan mesylate 600 mg
79498373|NCT04939792|Drug|Placebo|Capsule ingested orally
79498374|NCT04939792|Drug|Vitamin D + L-cysteine|Capsule ingested orally
79498375|NCT04939792|Drug|L-cysteine|Capsule ingested orally
79498376|NCT04894903|Other|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
79659991|NCT06050395|Behavioral|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
79659992|NCT06048731|Device|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
79659993|NCT06047379|Drug|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
79659994|NCT06047379|Drug|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
79346457|NCT01631227|Drug|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
79346458|NCT01631227|Drug|Placebo Eprosartan|Placebo Eprosartan
79986618|NCT02015897|Procedure|Physical TherapyB|"Group B:~Skin care~Bandaging using Coban™2Lite~Guidance on physical activity"
79346459|NCT01719172|Device|Veriset™ Hemostatic Patch|Topical Hemostat
79346460|NCT02286947|Drug|Eteplirsen|Eteplirsen solution for IV infusion
79346461|NCT02286713|Behavioral|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
79346462|NCT02286713|Behavioral|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
79346463|NCT02286713|Behavioral|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
79346464|NCT05650385|Drug|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
79346465|NCT02285855|Drug|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
79346466|NCT02285855|Other|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
79659995|NCT06047379|Drug|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
79659996|NCT06047379|Drug|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
79659997|NCT06047379|Drug|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
79986619|NCT04249674|Diagnostic Test|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
79986620|NCT04249674|Genetic|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
79346467|NCT02285855|Radiation|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
79346468|NCT02285777|Biological|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
79346469|NCT02285777|Biological|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
79346470|NCT02285153|Drug|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
79346471|NCT02285153|Drug|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
79346472|NCT02284373|Other|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
79346473|NCT02284373|Other|Routine wound care for venous ulcers and lymphedema|wound care /dressings
79986621|NCT03745157|Drug|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
79986622|NCT02426008|Other|Growth Factors and Cytokine adding to embryo culture media|
79986623|NCT02426008|Other|No Intervention|Nothing to Add
79659998|NCT06047379|Drug|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
79659999|NCT06047379|Drug|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
79346474|NCT02284373|Device|Flexitouch pneumonic compression|pneumonic compression only
79346475|NCT01632241|Biological|Placebo plus standard therapy|Placebo plus standard therapy
79346476|NCT01632241|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
79346477|NCT01632241|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
79346478|NCT02263508|Drug|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
79346479|NCT02263508|Drug|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
79346480|NCT02263508|Drug|Placebo|Administered by intratumoral injection
79660000|NCT06047379|Drug|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
79986624|NCT04050371|Drug|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
79986625|NCT04189536|Other|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
79346481|NCT02291432|Biological|autologous muscle-derived cells (AMDC)|Cell treatment
79346482|NCT05369780|Dietary Supplement|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
79346483|NCT02290340|Drug|Placebo|Participants will receive placebo intramuscularly.
79346484|NCT02290340|Drug|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
79346485|NCT02290340|Drug|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
79986626|NCT04183764|Drug|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
79986627|NCT04447287|Drug|ASP8062|Oral
79986628|NCT04447287|Drug|Placebo ASP8062|Oral
79986629|NCT04447287|Drug|buprenorphine/naloxone|Sublingual
79986630|NCT01879319|Biological|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
79498377|NCT04864249|Device|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
79498378|NCT04864249|Other|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
79660001|NCT06047379|Drug|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
79660002|NCT06047353|Behavioral|Motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
79660003|NCT06047353|Device|Positive Airway Pressure (PAP) therapy|Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
79660004|NCT06046170|Behavioral|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.
79660005|NCT06046170|Other|Treatment as Usual|Participants will receive treatment as usual at a community mental health center, including receiving skills training.
79680059|NCT03458819|Diagnostic Test|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
79346486|NCT02290340|Drug|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
79346487|NCT05647187|Diagnostic Test|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
79346488|NCT05647187|Radiation|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
79346489|NCT02290028|Device|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
79346490|NCT01741792|Drug|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
79346491|NCT02289950|Drug|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
79346492|NCT02289950|Drug|Placebo|Placebo will be administered intravenously (IV) weekly
79346493|NCT01741012|Drug|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
79346494|NCT02288312|Drug|BIA 2-093|
79346495|NCT01740388|Drug|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
79346496|NCT01740388|Drug|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
79346497|NCT01740154|Procedure|transcranial magnetic stimulation|Undergo TMS
79346498|NCT01740154|Procedure|electromyography|Undergo EMG
79346499|NCT01740154|Other|survey administration|Ancillary studies
79346500|NCT01740154|Drug|sunitinib malate|Given PO
79346501|NCT02287922|Biological|ALX-0061|
79346502|NCT02287922|Biological|Placebo|
79986631|NCT01879319|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
79986632|NCT04165122|Biological|HDIT101|i.v. Infusion
79986633|NCT04165122|Drug|Valaciclovir|oral application of encapsulated Valaciclovir tablets
79986634|NCT04165122|Biological|HDIT101 placebo|i.v. Infusion
79986635|NCT04165122|Drug|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
79986636|NCT02417350|Other|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
79986637|NCT02417350|Other|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
79986638|NCT02422030|Drug|Lipitor Tab. 40mg|
79986639|NCT02422030|Drug|Trilipix 135mg|
79498379|NCT04850495|Drug|Cyclophosphamide|Given IV
79498380|NCT04850495|Drug|Doxorubicin Hydrochloride|Given IV
79498381|NCT04850495|Drug|Prednisone|Given PO
79498382|NCT04850495|Biological|Rituximab|Given IV
79498383|NCT04850495|Drug|Vincristine Sulfate|Given IV
79660006|NCT06045520|Behavioral|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
79660007|NCT06042855|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
79660008|NCT06042855|Drug|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
79346503|NCT02287922|Biological|Tocilizumab|
79346504|NCT02287610|Drug|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
79346505|NCT05646212|Other|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning & behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
79346506|NCT05646212|Other|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
79346507|NCT05646134|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
79346508|NCT05646134|Device|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
79346509|NCT05646056|Device|Software|Observation only
79346510|NCT04873466|Dietary Supplement|Enzyme-rich malt extract|Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
79498384|NCT04850495|Drug|Zanubrutinib|Given PO
79498385|NCT04847674|Drug|TEV-53275 Dose A|subcutaneous (sc) injection
79498386|NCT04847674|Drug|TEV-53275 Dose B|subcutaneous (sc) injection
79498387|NCT04847674|Drug|Placebo|Matching subcutaneous (sc) placebo injection
79498388|NCT04828785|Other|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
79498389|NCT04828785|Other|Food Subsidy|$40/month food subsidy
79498390|NCT04825613|Biological|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
79498391|NCT04815252|Behavioral|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
79498392|NCT04813796|Biological|mRNA-1283|Sterile liquid for injection
79498393|NCT04813796|Biological|mRNA-1273|Sterile liquid for injection
79498394|NCT04813796|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79498395|NCT04763135|Drug|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
79498396|NCT04763135|Drug|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
79498397|NCT04755816|Behavioral|Sodium intervention|The sodium dietary intervention provides uses location services to determine when a participant is at home, arrives at a grocery store or arrives at a restaurant. The user receives a tailored message to assist with making dietary choices based on sodium content.
79498398|NCT04755816|Behavioral|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
79498399|NCT04755816|Behavioral|Educational content|Standard heart failure educational information and a daily symptom survey.
79660009|NCT06041711|Procedure|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
79346511|NCT02262728|Drug|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
79346512|NCT02262728|Drug|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
79498400|NCT04750941|Drug|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
79498401|NCT04750941|Other|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
79498402|NCT04723134|Combination Product|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
79660010|NCT06041711|Procedure|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
79660011|NCT06024239|Drug|ABBV-932|Capsule; oral
79660012|NCT06024239|Drug|Placebo for ABBV-932|Capsule; oral
79660013|NCT06022510|Device|Fetoscopy Sets for Anterior and Posterior Placentas|Patients who choose to undergo fetoscopic surgery for a complicated monochorionic-diamniotic pregnancy will be offered participation in this study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
79660014|NCT06017713|Behavioral|tDCS + symptoms provocation|The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
79660015|NCT06016816|Procedure|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
79660016|NCT06016816|Procedure|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
79660017|NCT06014931|Behavioral|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
79346513|NCT02262728|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
79660018|NCT06013969|Drug|Spesolimab|Spesolimab intravenous (i.v.) infusion
79346514|NCT02262260|Drug|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
79660019|NCT06013241|Drug|Brensocatib|Film-coated tablet.
79660020|NCT06013241|Drug|Placebo|Film-coated tablet.
79498403|NCT04675450|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
79498404|NCT04675450|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
79498405|NCT04666272|Drug|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
79498406|NCT04666272|Drug|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
79498407|NCT04651998|Diagnostic Test|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
79498408|NCT04649060|Drug|Melflufen|Powder for solution for i.v. infusion
79660021|NCT06013241|Drug|Mometasone furoate nasal spray (MFNS)|Nasal spray suspension.
79660022|NCT06005558|Drug|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
79660023|NCT06005558|Drug|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
79660024|NCT06005558|Drug|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
79660025|NCT05997225|Other|opt out enrollment, tailored counseling, varenicline started prior to target quit date|Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
79660026|NCT05997225|Other|opt in enrollment, non-tailored counseling, varenicline started prior to target quit date|Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
79370771|NCT00938704|Drug|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
79370772|NCT03668379|Behavioral|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
79370773|NCT03668379|Behavioral|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
79346515|NCT02262260|Drug|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
79346516|NCT02285270|Device|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
79660027|NCT05995145|Behavioral|Active hamstring flexibility exercises with hip flexion mobilization|8 weeks x 5 times per week for 20 min. In the experimental intervention, the exercise program will be based on participant education, home-based individual exercises, and regular group meetings for check-ups by a physiotherapist according to a precise set schedule.
79660028|NCT05983939|Drug|PIPE-791|Single and multiple ascending oral doses of PIPE-791 tablets.
79346517|NCT01717768|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
79346518|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
79498409|NCT04649060|Drug|Dexamethasone|Oral tablets
79498410|NCT04649060|Drug|Daratumumab|Solution for s.c. injection
79660029|NCT05983939|Drug|Placebo|Single and multiple ascending oral doses of matching placebo tablets.
79660030|NCT05979805|Other|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
79346519|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
79346520|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
79498411|NCT04640272|Drug|RBM-007|Intravitreal injection
79498412|NCT04623008|Behavioral|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
79498413|NCT04608487|Drug|Fludarabine|Intravenous infusion
79498414|NCT04608487|Drug|Cyclophosphamide|Intravenous infusion
79498415|NCT04608487|Biological|Axicabtagene Ciloleucel|Intravenous infusion
79498416|NCT04602767|Drug|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP < 65 mmHg
79498417|NCT04602767|Drug|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP < 65 mmHg
79660031|NCT05979805|Behavioral|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
79660032|NCT05974631|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
79498418|NCT04586894|Diagnostic Test|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
79346521|NCT02260934|Drug|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
79498419|NCT04586894|Device|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
79498420|NCT04586894|Other|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
79498421|NCT04581447|Drug|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
79346522|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
79498422|NCT04581447|Other|Standard Care|Standard Care
79498423|NCT04581447|Dietary Supplement|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
79498424|NCT04580485|Drug|INCB106385|INCB106385 will be administered orally QD
79498425|NCT04580485|Drug|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
79660033|NCT05974631|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
79660034|NCT05974631|Behavioral|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
79498426|NCT04563793|Device|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
79498427|NCT04552665|Device|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R&D)
79660035|NCT05974631|Behavioral|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
79498428|NCT04520685|Drug|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
79498429|NCT04520685|Drug|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
79498430|NCT04519151|Drug|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
79660036|NCT05974267|Drug|M5717 60 mg|Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
79660037|NCT05974267|Drug|Pyronaridine|Participants will receive Pyronaridine tablets orally single dose of 720 (Participants >= 65 kg) and 540 mg (Participants >= 45 to < 65 kg) on Study Day 1 under fasting condition
79346523|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
79346524|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
79346525|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
79346526|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
79498431|NCT04519151|Drug|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
79498432|NCT04511650|Drug|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
79346527|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
79346528|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
79498433|NCT04511650|Drug|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
79346529|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
79346530|NCT02260934|Biological|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
79498434|NCT04497012|Drug|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
79498435|NCT04497012|Drug|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
79498436|NCT04484259|Drug|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
79986640|NCT04159350|Device|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
79986641|NCT04159350|Device|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
79346531|NCT04879862|Combination Product|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
79346532|NCT04879862|Combination Product|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
79346533|NCT04879862|Combination Product|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
79498437|NCT04484259|Drug|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
79498438|NCT04484259|Drug|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
79986642|NCT05668715|Other|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
79346534|NCT04879862|Combination Product|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
79346535|NCT02260388|Drug|Nortriptyline|
79346536|NCT02260388|Drug|Duloxetine|
79346537|NCT02260388|Drug|Pregabalin|
79346538|NCT02260388|Drug|Mexiletine|
79346539|NCT02260154|Drug|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
79346540|NCT02284178|Other|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
79346541|NCT02284178|Other|Usual Care|Oral suction with suction swab every 4 hours
79346542|NCT01643408|Drug|asparaginase Erwinia chrysanthemi|
79346543|NCT02283788|Drug|BIA 2-093|
79498439|NCT04463693|Drug|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
79498440|NCT04390529|Other|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
79660038|NCT05974267|Drug|Atovaquone-Proguanil|Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
79346544|NCT02283788|Drug|Moxifloxacin|
79346545|NCT02283788|Drug|Placebo|
79346546|NCT01739764|Drug|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
79346547|NCT01700530|Drug|Statin|Statins (40mg/day)for 12 weeks
79498441|NCT04348916|Biological|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
79346548|NCT01700530|Other|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
79346549|NCT01700530|Other|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
79346550|NCT01700140|Drug|SyB D-0701|Study drug patches [Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
79346551|NCT01700140|Drug|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
79346552|NCT01717456|Other|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
79498442|NCT04348916|Biological|pembrolizumab|Anti-PD-1 monoclonal antibody
79498443|NCT04310163|Other|Natural history|Parent interview and video capture
79498444|NCT04299113|Drug|Vinorelbine|Given IV
79660039|NCT05974267|Drug|M5717 200 mg|Participants will receive single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
79346553|NCT01717456|Dietary Supplement|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
79498445|NCT04299113|Drug|Mocetinostat|Given PO
79346554|NCT01717456|Drug|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
79498446|NCT04295603|Other|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
79660040|NCT05974267|Drug|M5717 660mg|Participants will receive single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
79986643|NCT04158726|Behavioral|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
79660041|NCT05970172|Drug|Roxadustat|Oral
79986644|NCT02425930|Procedure|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
79660042|NCT05967468|Behavioral|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
79660043|NCT05967468|Behavioral|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
79660044|NCT05967468|Other|Relaxation and Mentorship|Relaxation based treatment
79660045|NCT05966727|Drug|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
79660046|NCT05964647|Drug|LSD (150 µg) + ketanserin (40 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"
79660047|NCT05964647|Drug|LSD (150 µg) + olanzapine (10 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"
79660048|NCT05964647|Drug|LSD (150 µg) + lorazepam (2 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"
79986645|NCT02425930|Drug|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
79986646|NCT03685682|Biological|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
79660049|NCT05964647|Drug|LSD (150 µg) + placebo|"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
79986647|NCT01365897|Drug|Modafinil|Modafinil 200mg
79986648|NCT02422108|Drug|Denosumab|
79986649|NCT03685604|Drug|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
79986650|NCT03685604|Drug|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
79346555|NCT01717456|Behavioral|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
79346556|NCT01717456|Behavioral|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
79498447|NCT04295603|Other|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
79660050|NCT05964647|Drug|Placebo + placebo|"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
79815196|NCT02599662|Radiation|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
79986651|NCT03685526|Device|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
79986652|NCT02422342|Device|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
79986653|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
79986654|NCT01359657|Biological|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
79346557|NCT01717456|Behavioral|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
79346558|NCT01717456|Other|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
79498448|NCT04285580|Drug|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
79660051|NCT05964192|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
79986655|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
79346559|NCT01699750|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
79346560|NCT01699750|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
79346561|NCT01699750|Device|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
79346562|NCT01699750|Device|BIOTRUE®|Contact lens care system, Phase 2
79498449|NCT04285580|Drug|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
79498450|NCT04259905|Behavioral|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
79498451|NCT04259905|Behavioral|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
79346563|NCT01699750|Device|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
79346564|NCT01699750|Device|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
79346565|NCT01716754|Drug|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
79346566|NCT01716754|Drug|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
79498452|NCT04258969|Behavioral|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
79346567|NCT01716754|Drug|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
79498453|NCT04254926|Behavioral|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
79498454|NCT04245371|Drug|Lidocaine 1.8%|Topical Patch
79498455|NCT04245371|Drug|Placebo|Matching Placebo Patch
79498456|NCT04231539|Drug|Nicotine|Vape different flavor nicotine products
79986656|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
79986657|NCT01359657|Biological|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
79986658|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
79498457|NCT04231539|Device|Vaporizer Device|Take puffs from vaporizer filled with different flavors
79498458|NCT04200248|Drug|RBM-007 Injectable Solution|RBM-007 Injectable Solution
79498459|NCT04200248|Drug|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
79498460|NCT04200248|Drug|Sham|Sham intravitreal injection
79498461|NCT04189432|Biological|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
79660054|NCT05952934|Biological|0.5 mL Candin®/injection|Candin or placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
79660055|NCT05952934|Other|Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)|Placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
79986659|NCT02417116|Other|Tear supplement|Application as required to improve comfort
79986660|NCT02417116|Other|Tear supplement 2|Application as required to improve comfort
79986661|NCT02417116|Dietary Supplement|Omega 3 nutrition supplement|Taken each day
79346568|NCT01698814|Drug|AL-4943A Ophthalmic Solution|
79660056|NCT05942781|Device|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
79660057|NCT05942781|Device|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
79498462|NCT04189432|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
79986662|NCT02417116|Device|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
79986663|NCT02417116|Other|Saline|Application as required to improve comfort
79986664|NCT03685370|Procedure|LOS|placement of epidural catheters with LOS technique
79986665|NCT03685370|Procedure|X-ray placement|placement of epidural catheters with x-ray guide
79346569|NCT01698814|Drug|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
79346570|NCT01738984|Behavioral|MomZing Web Program|Online web platform that is accessed via a television connected to internet
79346571|NCT01738984|Behavioral|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
79346572|NCT01738594|Drug|carfilzomib|Given IV
79346573|NCT01738594|Drug|romidepsin|Given IV
79346574|NCT01738594|Other|laboratory biomarker analysis|Correlative studies
79346575|NCT01738438|Drug|Cabozantinib|
79498463|NCT04189419|Biological|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
79815197|NCT02599662|Radiation|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
79815198|NCT02599662|Radiation|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
79346576|NCT01716520|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
79346577|NCT01716520|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
79346578|NCT01716520|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
79346579|NCT04548310|Other|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
79815199|NCT00758394|Drug|Fluoride|Brush two times a day for 4 days.
79815200|NCT00758394|Drug|Triclosan/Fluoride|Brush two times daily for 4 days
79815201|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
79815202|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
79986666|NCT05416398|Other|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
79986667|NCT03685292|Behavioral|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
79986668|NCT03685292|Drug|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
79346580|NCT04548232|Procedure|Laparoscopic sleeve gastrectomy|bariatric surgery
79346581|NCT01698268|Procedure|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
79346582|NCT01698268|Procedure|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
79498464|NCT04189419|Other|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
79498465|NCT04188522|Diagnostic Test|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
79498466|NCT04179760|Biological|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
79498467|NCT04179760|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
79498468|NCT04178096|Other|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
79660058|NCT05941039|Device|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
79660059|NCT05941039|Device|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
79660060|NCT05938270|Drug|AZD5305|AZD5305 given orally once daily
79660061|NCT05938270|Drug|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
79660062|NCT05938270|Other|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
79815203|NCT04092738|Behavioral|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
79815204|NCT04450394|Drug|LY3209590|Administered SC
79815205|NCT04450394|Drug|Insulin Degludec|Administered SC
79815206|NCT00758160|Drug|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
79986669|NCT03685292|Device|Behavioral Division|This study is relative to minimal contact control (MCC).
79986670|NCT05416164|Radiation|Omission of radiotherapy|Omission of radiotherapy
79986671|NCT03177694|Device|Wireless bed sensor|Remote data collection
79986672|NCT01363245|Behavioral|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
79986673|NCT01363245|Behavioral|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
79815207|NCT05699564|Other|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
79815208|NCT02599740|Other|Natural fruit extract|Natural fruit extract consumed with rice
79815209|NCT02599740|Other|Assumed active|Assumed key active consumed with rice
79346583|NCT04555564|Procedure|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
79346584|NCT01697956|Drug|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
79346585|NCT01697956|Drug|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
79346586|NCT01697800|Drug|Tadalafil|
79346587|NCT01697800|Drug|Placebo|
79498469|NCT04142177|Other|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
79498470|NCT04142177|Procedure|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
79524857|NCT05767281|Behavioral|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
79524858|NCT05767268|Device|Lokomat|gait rehabilitation
79524859|NCT05767255|Drug|insulin degludec + liraglutide|The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
79660063|NCT05925985|Other|NA-Observational Registry|NA Observational Registry
79660064|NCT05925517|Other|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
79815210|NCT02599740|Other|Placebo|Rice only
79986674|NCT03685214|Drug|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
79986675|NCT03685214|Drug|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
79524860|NCT05767255|Drug|Insulin Glargine - Insulin Aspart|The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
79660065|NCT05925517|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
79346588|NCT01644500|Drug|Dulaglutide|Administered SC
79346589|NCT01644500|Drug|Glimepiride|Administered orally
79346590|NCT01644500|Drug|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
79346591|NCT01644500|Drug|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
79370774|NCT03668379|Behavioral|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
79660066|NCT05925517|Other|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
79986676|NCT01359813|Drug|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
79660067|NCT05925517|Other|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
79346592|NCT05645120|Other|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
79346593|NCT01604824|Drug|Alirocumab|SC injection in the abdomen
79346594|NCT01604824|Drug|Placebo|SC injection in the abdomen
79346595|NCT01716052|Drug|placebo|Lactulose
79346596|NCT01716052|Drug|Ibuprofen|
79346597|NCT01641692|Drug|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
79370775|NCT03668379|Behavioral|Augment w/BAT & mHealth|"Non-responders to the BAT & mHealth intervention may be re-randomized to receive an additional dose of BAT & mHealth in the form of an additional session of BAT."
79370776|NCT00938782|Device|Sedline|
79370777|NCT03666351|Drug|Amlodipine 5mg|Amlodipine 5 mg
79660068|NCT05923398|Behavioral|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
79660069|NCT05923385|Diagnostic Test|Four Square Step Test|These are standardized test which will be applied to subjects with pencil, paper and time recorder.
79660070|NCT05917990|Behavioral|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
79986677|NCT03183310|Drug|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
79986678|NCT03183310|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
79986679|NCT03183310|Drug|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
79498471|NCT04142177|Other|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
79346598|NCT01641692|Procedure|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
79498472|NCT04142177|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
79498473|NCT04142177|Procedure|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
79524861|NCT05767242|Other|Electrophysiological recording|Investigation of early neural markers using electrophysiology at 6-12-24 months
79524862|NCT05767242|Behavioral|Behavioral assessment|Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
79660071|NCT05917301|Radiation|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
79660072|NCT05915182|Combination Product|Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler|Participants with moderate to severe Chronic Obstructive Pulmonary Disease
79815211|NCT02606552|Drug|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
79815212|NCT02606552|Drug|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
79986680|NCT03685058|Device|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
79986681|NCT03685058|Other|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
79346599|NCT01641692|Drug|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
79346600|NCT04859816|Other|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
79524863|NCT05767229|Drug|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
79524864|NCT05767216|Other|Biological sampling|Blood, skin and stool samples for laboratory analysis
79524865|NCT05767203|Other|Biological samplings|Blood and/or skin samples
79346601|NCT04859816|Other|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
79346602|NCT04859816|Other|MRS|Magnetic resonance spectroscopy of liver fat content
79524866|NCT05767164|Procedure|cervical single open-door surgery|The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
79524867|NCT05767138|Behavioral|HPV Vaccine Acceptance Survey|
79524868|NCT05767125|Device|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
79524869|NCT05767125|Device|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
79660073|NCT05912647|Behavioral|MTM|Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
79815213|NCT02606552|Device|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
79498474|NCT04142177|Procedure|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
79498475|NCT04137887|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
79346603|NCT04859816|Other|Feces collection|4-day feces collection
79346604|NCT01682512|Drug|BI 695500|
79346605|NCT01682512|Drug|BI 695500|
79498476|NCT04137887|Biological|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
79498477|NCT04120402|Drug|EP-104IAR 25 mg|Single 5 mL intra-articular injection
79498478|NCT04120402|Drug|Vehicle|Single 5 mL intra-articular injection
79498479|NCT04096196|Behavioral|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
79498480|NCT04096196|Other|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
79498481|NCT04095273|Drug|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
79498482|NCT04095273|Drug|Pembrolizumab|Study drugs will be administered as scheduled
79660074|NCT05912647|Behavioral|CHW|Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one ~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive ~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
79660075|NCT05911113|Other|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
79346606|NCT01682512|Drug|Rituxan®|
79346607|NCT01682512|Drug|Rituxan®|
79346608|NCT01682512|Drug|MabThera®|
79346609|NCT02256488|Biological|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
79346610|NCT02256488|Biological|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
79346611|NCT02256488|Biological|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
79346612|NCT02256488|Biological|TIVf|Single IM administration dose of 0.5 mL of TIVf
79346613|NCT05644886|Behavioral|FP Training and Technical Support|Same as in Intervention arm description
79346614|NCT04863794|Drug|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
79346615|NCT04863716|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
79346616|NCT04863716|Procedure|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
79498483|NCT04074590|Drug|LYS006|capsule for oral use
79498484|NCT04074590|Drug|Placebo|capsule for oral use
79498485|NCT04068844|Behavioral|Exercise training|Exercise training, either whole body or isolated single leg
79498486|NCT04023487|Behavioral|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
79660076|NCT05911113|Other|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
79815214|NCT04094220|Procedure|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
79498487|NCT03997773|Behavioral|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
79498488|NCT03972969|Behavioral|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
79660077|NCT05908110|Behavioral|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
79660078|NCT05903352|Other|Stop antibiotic|Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
79346617|NCT04135352|Drug|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
79346618|NCT04135352|Biological|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
79346619|NCT04862312|Behavioral|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
79660079|NCT05903352|Drug|Continue the antimicrobial treatment|Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
79346620|NCT01715896|Biological|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
79370778|NCT03666351|Drug|Losartan|Losartan Potassium 50 mg
79660080|NCT05900908|Device|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
79660081|NCT05900908|Radiation|Stereotactic Radiation Therapy|External Beam Radiation Therapy
79660082|NCT05900648|Drug|Regorafenib|Given by PO
79660083|NCT05900648|Drug|XmAb20717|Given by (IV) vein
79660084|NCT05896839|Procedure|Biopsy|Undergo tumor biopsy
79660085|NCT05896839|Procedure|Biospecimen Collection|Undergo blood sample collection
79660086|NCT05896839|Procedure|Computed Tomography|Undergo CT scan
79660087|NCT05896839|Biological|Ipilimumab|Given IV
79986682|NCT05415930|Other|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
79498489|NCT03972969|Behavioral|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
79660088|NCT05896839|Procedure|Kidney Biopsy|Undergo kidney biopsy
79660089|NCT05896839|Procedure|Magnetic Resonance Imaging|Undergo MRI
79660090|NCT05896839|Biological|Nivolumab|Given IV
79660091|NCT05896839|Drug|Prednisone|Given PO
79660092|NCT05896839|Drug|Sirolimus|Given PO
79660093|NCT05894577|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
79660094|NCT05894577|Drug|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
79680060|NCT04689750|Diagnostic Test|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
79680061|NCT02948192|Other|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
79498490|NCT03972969|Behavioral|Health education|Provision of general information about a variety of topics
79498491|NCT03954366|Drug|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
79660095|NCT05888727|Behavioral|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
79498492|NCT03954366|Drug|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
79498493|NCT03954366|Drug|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
79498494|NCT03936569|Drug|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
79498495|NCT03936569|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
79498496|NCT03935932|Device|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
79498497|NCT03934255|Other|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
79498498|NCT03912220|Drug|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
79498499|NCT03912220|Drug|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
79498500|NCT03898167|Behavioral|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
79680062|NCT02936817|Device|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
79346621|NCT01715896|Biological|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
79346622|NCT02255552|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
79346623|NCT01714726|Drug|MEDI2070|1 iv infusion on Week 0 and Week 4
79346624|NCT01714726|Drug|placebo|1 iv infusion on Week 0 and Week 4
79346625|NCT02255474|Device|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
79498501|NCT03898167|Behavioral|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
79498502|NCT03898167|Behavioral|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
79498503|NCT03872791|Biological|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
79498504|NCT03872791|Drug|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
79498505|NCT03864042|Drug|losartan|taken orally
79498506|NCT03864042|Drug|dextromethorphan|taken orally
79498507|NCT03864042|Drug|caffeine|taken orally
79498508|NCT03864042|Drug|omeprazole|taken orally
79498509|NCT03864042|Drug|midazolam|taken orally
79346626|NCT02255474|Device|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
79346627|NCT02255474|Device|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
79498510|NCT03864042|Drug|rosuvastatin|taken orally
79498511|NCT03864042|Drug|bupropion immediate release (IR)|taken orally
79498512|NCT03864042|Drug|encorafenib|taken orally
79498513|NCT03864042|Drug|binimetinib|taken orally
79498514|NCT03864042|Drug|modafinil|taken orally
79498515|NCT03858361|Device|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
79524870|NCT05767112|Other|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
79524871|NCT05767099|Diagnostic Test|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
79524872|NCT05767060|Drug|BAT7104 injection|According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
79524873|NCT05765968|Procedure|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
79524874|NCT05765968|Procedure|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
79524875|NCT05765955|Drug|POLB 001|Investigational Medicinal Product
79524876|NCT05765955|Drug|Placebo|Matching Placebo
79498516|NCT03737604|Drug|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
79498517|NCT03737604|Drug|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
79498518|NCT03730519|Device|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
79524877|NCT05764694|Other|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
79986683|NCT05415930|Other|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
79986684|NCT05415930|Other|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
79986685|NCT05415930|Other|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
79986686|NCT03177850|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79986687|NCT03177850|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79986688|NCT03102918|Drug|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
79524878|NCT05764031|Other|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
79524879|NCT05764031|Other|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
79524880|NCT05763641|Procedure|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
79660096|NCT05888727|Behavioral|WEllness for Longevity Living with MS (WELL)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
79986689|NCT03102918|Drug|Placebo|Participants will receive placebo over a 6-week treatment period.
79986690|NCT03676712|Device|scoliosis brace|Wear at least 18 hours a day
79346628|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
79346629|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
79815215|NCT00757848|Drug|AZD9668|60 mg, oral tablet, twice daily for 28 days
79815216|NCT00757848|Drug|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
79346630|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
79986691|NCT03684902|Procedure|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
79986692|NCT03183154|Other|no intervention|no intervention
79986693|NCT03128307|Device|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
79346631|NCT05642702|Other|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
79346632|NCT05642702|Other|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
79498519|NCT03713554|Procedure|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
79498520|NCT03676504|Biological|CD19.CAR T Cells|Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose Level 3: 20×10^6 transduced cells/m^2; Dose Level 4: 5x10^7 transduced cells/m^2; Dose Level 5: 10x10^7 transduced cells/m^2; Dose Level 6: 20x10^7 transduced cells/m^2
79498521|NCT03676504|Drug|Fludarabine|3 days of fludarabine 30 mg/m^2/day
79498522|NCT03676504|Drug|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m^2/day
79660097|NCT05881759|Behavioral|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of ~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
79660098|NCT05878275|Behavioral|Parent Informational Session|Parents will receive a brochure on the importance of tummy time and limiting baby gear and watch a video on the importance of tummy time and limiting baby gear and receive support for implementing tummy time if requested.
79986694|NCT03102762|Drug|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
79986695|NCT03102762|Drug|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
79986696|NCT03684824|Drug|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
79498523|NCT03637270|Dietary Supplement|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
79498524|NCT03637270|Other|Exercise training|Including aerobic cycling training and progressive resisted exercise
79660099|NCT05874362|Other|Diagnosis of depressive episode or post traumatic stress disorder|Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
79660100|NCT05874362|Other|No diagnosis of depressive episode or post traumatic stress disorder|No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
79346633|NCT02254772|Biological|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
79346634|NCT02254772|Drug|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
79346635|NCT02254772|Radiation|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
79346636|NCT02254460|Dietary Supplement|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
79346637|NCT02254460|Other|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
79346638|NCT01682044|Biological|pegfilgrastim|Given SC
79498525|NCT03626974|Biological|Venipuncture|Venipuncture for blood collection
79498526|NCT03626974|Device|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
79498527|NCT03597594|Drug|Anti-thymocyte globulin (rabbit)|given intravenously
79498528|NCT03597594|Drug|Busulfan|given intravenously
79498529|NCT03597594|Drug|Fludarabine|given intravenously
79498530|NCT03597594|Drug|Thiotepa|given intravenous infusion
79498531|NCT03597594|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79498532|NCT03597594|Other|Donor Lymphocyte Infusion|given intravenous infusion
79498533|NCT03595657|Biological|CS1001|monoclonal antibody
79660101|NCT05873881|Drug|Colchicine 0.5 MG|Oral colchicine 0.5 mg daily
79660102|NCT05873881|Drug|Colchicine placebo|Placebo colchicine daily
79660103|NCT05873881|Drug|Thiamine Mononitrate 300 mg|Thiamine Mononitrate 300 mg daily
79346639|NCT01682044|Biological|rituximab|Given IV
79498534|NCT03591887|Biological|ABY-035|ABY-035 solution for injection
79498535|NCT03591887|Biological|Placebo|Placebo to ABY-035 solution for injection
79660104|NCT05873868|Other|Six minutes walk test|Six minutes walk test just before first intake of treatment and after 1 and 2 years
79660105|NCT05873868|Other|Kansas City questionnaire|Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
79660106|NCT05873868|Other|COMPASS31 self questionnaire|Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
79660107|NCT05873465|Drug|Sedation with Midazolam, Fentanyl, and Propofol|Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
79346640|NCT01682044|Other|flow cytometry|Correlative studies
79346641|NCT01682044|Procedure|biopsy|Correlative studies
79346642|NCT01682044|Other|immunohistochemistry staining method|Correlative studies
79346643|NCT01682044|Genetic|western blotting|Correlative studies
79346644|NCT05640986|Behavioral|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
79346645|NCT05640986|Behavioral|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
79346646|NCT05651204|Diagnostic Test|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
79346647|NCT05640596|Drug|Betamethasone|
79346648|NCT05651126|Drug|Psilocybin 5 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
79346649|NCT05651126|Drug|Psilocybin 2 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
79346650|NCT05651126|Drug|Placebo|Inactive placebo
79346651|NCT01696942|Drug|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
79346652|NCT01696942|Drug|Mesalamine|mesalamine 800 mg orally three times daily
79370779|NCT03666351|Drug|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
79498536|NCT03563690|Other|treatment1|"Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
79498537|NCT03563690|Other|treatment2|"Acupoints：Needling points are the same to the above group~operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
79524881|NCT05761691|Procedure|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
79524882|NCT05759741|Drug|MIYAIRI 588|4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
79524883|NCT05759065|Behavioral|Tele-Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.
79524884|NCT05759065|Behavioral|Tele-Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
79524885|NCT05758220|Device|MRI|Structural MRI volumetry, resting functional MRI & MR spectroscopy
79660108|NCT05873465|Procedure|Extraction of teeth|The necessary teeth will be extracted
79660109|NCT05873062|Drug|AUT00201|Single oral dose
79660110|NCT05873062|Drug|Placebo|Single oral dose
79660111|NCT05867914|Device|Inhaled Nitric Oxide (iNO)|eNOfit system delivering iNO
79346653|NCT05494814|Other|Child Care Centers Served Meals Prepared by Central Kitchen|The child care centers who are served by the central kitchen will receive meals that include locally sourced fresh fruits and vegetables to serve their staff and children.
79660112|NCT05867576|Behavioral|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
79660113|NCT05866471|Drug|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.
79498538|NCT03563690|Other|treatment3|"Acupoints：treating points are the same to the above group~Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
79815217|NCT02606396|Procedure|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
79986697|NCT03684824|Drug|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
79986698|NCT02421874|Behavioral|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
79346654|NCT05651048|Other|Control Group|Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
79346655|NCT05651048|Other|BEMER Group|BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
79498539|NCT03563690|Other|treatment4|"Acupoints：Needling points are the same to the above group~Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
79498540|NCT03563690|Other|treatment5|"points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 * 25mm single-use needle with the depth of 1-2mm."
79498541|NCT03563690|Drug|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
79498542|NCT03557684|Dietary Supplement|leucine|amino acid leucine in powder
79346656|NCT05651048|Other|Kinesiotape Group|Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
79346657|NCT05493020|Other|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
79346658|NCT05485922|Device|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
79346659|NCT05485922|Device|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
79498543|NCT03557684|Other|PO placebo|maltodextrin
79498544|NCT03557684|Biological|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
79498545|NCT03557684|Other|IV placebo|0.9% saline
79498546|NCT03557008|Biological|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
79498547|NCT03557008|Drug|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
79498548|NCT03557008|Drug|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
79498549|NCT03557008|Drug|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
79498550|NCT03556683|Device|3% Hypertonic Saline|4 mL of 3% hypertonic saline
79498551|NCT03556683|Device|7% Hypertonic Saline|4 mL of 7% hypertonic saline
79498552|NCT03543852|Behavioral|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
79498553|NCT03520881|Other|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
79498554|NCT03481413|Device|Ablation|Ablation therapy for cardiac arrhythmias
79660114|NCT05866471|Device|Transauricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will apply electrodes to two left ear targets. After electrode placement, participants will connect the electrode wire to their taVNS system and will commence self-administered vagus stimulation. The stimulation systems, which allow double-blind administration of either active or sham taVNS will require a code to initiate stimulation, which will be securely sent to participants the morning of each taVNS treatment. Once participants receive the code, they will enter it into the system to receive their randomized stimulation session (active or sham).
79660115|NCT05866471|Device|Sham taVNS|"For both the active and sham taVNS procedure, participants will apply electrodes to two left ear targets. After electrode placement, participants will connect the electrode wire to their taVNS system and will commence self-administered vagus stimulation. The stimulation systems, which allow double-blind administration of either active or sham taVNS will require a code to initiate stimulation, which will be sent to participants via HIPAA-compliant email the morning of each taVNS treatment. Once participants receive the code, they will enter it into the system to receive their randomized stimulation session (active or sham).~For sham taVNS intensity will be set at 0 mA."
79660116|NCT05866471|Behavioral|Treatment as Usual (TAU)|Participants assigned to TAU will not receive taVNS post-psilocybin dosing but will instead undergo integration sessions at 1 day and 1-week post-psilocybin dosing. This is the typical treatment approach following psilocybin administration.
79660117|NCT05865886|Drug|BI 1291583|BI 1291583
79660118|NCT05865886|Drug|Placebo|Placebo matching BI 1291583
79346660|NCT04871204|Drug|Octreotide Injection|10 mg Sandostatin LAR intramuscular injection
79346661|NCT05619770|Drug|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
79370780|NCT03666351|Drug|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
79370781|NCT03666351|Drug|current treatment|treatment is done by maintaining the current treatment
79660119|NCT05856448|Drug|GLPG3667|Capsule
79660120|NCT05856448|Drug|Placebo|Capsule
79660121|NCT05855096|Other|Google Form Questionnaire|Google form questionnaire is performed by responders.
79660122|NCT05835999|Drug|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
79660123|NCT05835999|Drug|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
79660124|NCT05835999|Drug|Placebo once per day|No therapeutic effect
79660125|NCT05835999|Drug|Placebo once per week|No therapeutic effect
79680063|NCT02936817|Radiation|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
79660126|NCT05832424|Behavioral|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
79986699|NCT02421874|Behavioral|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
79986700|NCT03681002|Behavioral|structured lifestyle program|Intensive Lifestyle counseling during one year
79986701|NCT03177538|Drug|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
79986702|NCT03177538|Drug|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
79498555|NCT03443323|Behavioral|Organizational Skills Training - School Based (OST-S)|OST-S is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-S and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
79660127|NCT05826392|Other|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
79660128|NCT05826223|Other|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
79660129|NCT05825560|Drug|OFA multimodal analgesia|Multimodal opioid free analgesia
79660130|NCT05825560|Drug|Standard multimodal analgesia|Standard remifentanil analgesia
79660131|NCT05825001|Behavioral|Smoking Cessation Intervention|Receive active EFT stimulus
79660132|NCT05825001|Behavioral|Smoking Cessation Intervention (control)|Receive control EFT stimulus
79986703|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 1
79986704|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 2
79660133|NCT05825001|Other|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
79660134|NCT05824234|Other|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
79660135|NCT05824234|Other|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
79986705|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 3
79986706|NCT01363323|Drug|Placebo|
79986707|NCT01363323|Drug|Moxifloxacin|
79346663|NCT04857710|Device|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
79498556|NCT03367637|Other|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
79498557|NCT03367637|Other|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
79498558|NCT03347617|Drug|Ferumoxytol|Given IV
79346664|NCT04857710|Device|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
79498559|NCT03347617|Other|Laboratory Biomarker Analysis|Correlative studies
79660136|NCT05821023|Other|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
79498560|NCT03347617|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
79498561|NCT03347617|Biological|Pembrolizumab|Given IV
79498562|NCT03328273|Drug|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
79498563|NCT03328273|Drug|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
79498564|NCT03136029|Dietary Supplement|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
79660137|NCT05819801|Other|Non-fasting|Instructing patients to eat before their local-only procedure
79660138|NCT05819801|Other|Fasting|Instructing patients to fast before their local-only procedure
79660139|NCT05818332|Other|Observational study|No intervention, observational only
79498565|NCT03136029|Dietary Supplement|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
79660140|NCT05816265|Drug|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
79498566|NCT03136029|Other|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
79498567|NCT03071120|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
79660141|NCT05806814|Biological|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
79660142|NCT05786924|Drug|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active KRAS or NRAS mutations
79660143|NCT05786599|Drug|methadone|"The treatment arm will take methadone 2 mg PO q8h and a placebo called placeboD PO qdaily. PlaceboD and duloxetine will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
79815218|NCT02606396|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
79815219|NCT02606396|Procedure|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
79986708|NCT03183076|Other|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
79346665|NCT04857710|Device|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
79986709|NCT03183076|Drug|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
79680064|NCT00523445|Drug|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
79680065|NCT00523445|Drug|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
79346666|NCT05465798|Drug|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
79680066|NCT02936661|Drug|Tranexamic Acid|
79986710|NCT04388553|Procedure|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
79986711|NCT05415852|Device|Laser|Laser
79986712|NCT03117244|Other|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
79986713|NCT03117244|Other|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
79986714|NCT01366287|Drug|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
79986715|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
79986716|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
79986717|NCT03177382|Radiation|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
79986718|NCT03177382|Radiation|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
79986719|NCT03177382|Procedure|TME|The TME operation will be given after the end of the neoadjuvant treatment.
79986720|NCT03177382|Drug|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
79986721|NCT05190861|Diagnostic Test|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
79346667|NCT05465798|Drug|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
79346668|NCT04860596|Behavioral|collaborative health management model|nursing education program
79346669|NCT05650424|Other|Abdominal massage training|please refer to group description
79346670|NCT05650268|Drug|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3~7 days prior to the surgery.
79346671|NCT05650268|Other|95% MCT|95% MCT supplement 3-7 day before surgery
79346672|NCT05577494|Other|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
79370782|NCT00928642|Drug|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
79498573|NCT02848235|Other|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
79498574|NCT02567877|Procedure|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
79498575|NCT02567877|Drug|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
79498576|NCT02366728|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
79498577|NCT02366728|Biological|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
79986722|NCT05190861|Diagnostic Test|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
79986723|NCT03177304|Other|Web based IPT Training|
79346673|NCT05092178|Behavioral|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
79346674|NCT05092178|Behavioral|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
79346675|NCT01640366|Device|PICO|Single-use Negative Pressure Wound Therapy System
79498578|NCT02366728|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
79679499|NCT05317572|Drug|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
79680067|NCT02936661|Drug|Placebo|
79986724|NCT05760222|Other|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
79986725|NCT03106948|Drug|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
79346676|NCT01640288|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
79346677|NCT01640288|Other|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
79346678|NCT04688996|Diagnostic Test|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
79498579|NCT02366728|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
79498580|NCT02366728|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
79660144|NCT05786599|Drug|duloxetine|"The control arm will receive duloxetine 30 mg PO qdaily, and a placebo called placeboM PO q8h. PlaceboM and methadone will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
79660145|NCT05775289|Drug|Tobemstomig|Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
79660146|NCT05775289|Drug|Pembrolizumab|Participants will receive IV pembrolizumab four 21-day cycles
79660147|NCT05775289|Drug|Paclitaxel|Participants will receive IV paclitaxel Q3W for four 21-day cycles
79986726|NCT03106948|Drug|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
79346679|NCT04835870|Drug|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
79346680|NCT04835870|Drug|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
79498581|NCT02366728|Drug|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
79498582|NCT02366728|Drug|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
79660148|NCT05775289|Drug|Pemetrexed|Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
79660149|NCT05775289|Drug|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles
79815220|NCT02601222|Drug|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
79346681|NCT04835870|Drug|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
79346682|NCT04835870|Drug|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
79346683|NCT04835870|Drug|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
79346684|NCT04835870|Drug|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
79660150|NCT05774119|Other|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
79660151|NCT05774119|Other|breakfast with water|breakfast with 250 mL of water
79679500|NCT02950805|Drug|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
79680068|NCT02948075|Drug|Quisinostat|
79498583|NCT02355002|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
79498584|NCT02333370|Drug|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
79346685|NCT01639040|Drug|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
79986727|NCT03106948|Drug|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
79346686|NCT01639040|Drug|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
79346687|NCT01639040|Other|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
79660152|NCT05771480|Biological|Durvalumab|Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)
79660153|NCT05771480|Drug|Gemcitabine monotherapy|Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
79346688|NCT04687904|Behavioral|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
79346689|NCT04687904|Behavioral|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
79498585|NCT02333370|Drug|Letrozole|25mg
79660154|NCT05771480|Drug|Gemcitabine + cisplatin|Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
79660155|NCT05771480|Drug|Gemcitabine + oxaliplatin|Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
79986728|NCT01366365|Drug|methylnaltrexone|
79986729|NCT01366365|Drug|placebo|
79986730|NCT03177148|Behavioral|Intervention by Clinicians|PCPs deliver 4 sessions of MI in person, and RDs deliver 6 sessions of MI via telephone. PCPs and RDs will receive 2 days of MI training.
79986731|NCT03177148|Behavioral|Usual Care|PCPs provide care as normal
79986732|NCT01363557|Other|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
79986733|NCT01363557|Drug|Gefitinib (IRESSA)|250 mg/day
79498586|NCT02333370|Drug|Tamoxifen|20 mg
79498587|NCT02333370|Drug|Fulvestrant|500 mg
79346690|NCT05421338|Drug|BI 456906 (C-14)|BI 456906 (C-14)
79346691|NCT05400746|Biological|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
79346692|NCT04834310|Drug|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
79346693|NCT04834310|Drug|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
79346694|NCT04834310|Other|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
79498588|NCT02333370|Drug|goserelin|
79498589|NCT02303444|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
79498590|NCT02303444|Drug|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
79498591|NCT02267564|Procedure|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
79660156|NCT05771480|Drug|Gemcitabine + carboplatin|Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
79660157|NCT05771480|Drug|Gemcitabine + cisplatin + S-1|Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)
79680069|NCT02948075|Drug|Paclitaxel|
79680070|NCT02948075|Drug|Carboplatin|
79660158|NCT05771480|Drug|Gemcitabine + S-1|Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
79660159|NCT05771480|Drug|Gemcitabine + cisplatin + albumin-bound paclitaxel|Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
79679501|NCT02950805|Drug|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
79986734|NCT02416336|Device|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
79986735|NCT01360125|Genetic|proteomic profiling|
79986736|NCT01360125|Other|flow cytometry|
79346695|NCT05397782|Device|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
79815221|NCT02601222|Drug|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
79346696|NCT05060042|Other|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
79346697|NCT05060042|Other|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
79346698|NCT05390606|Combination Product|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
79346699|NCT05372198|Drug|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
79346700|NCT05372198|Drug|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
79986737|NCT01360125|Other|laboratory biomarker analysis|
79986738|NCT02425540|Device|Pelvic MRI|
79986739|NCT01804296|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
79986740|NCT01346475|Drug|valacyclovir|1000 mg orally three times daily for 5 weeks
79679502|NCT02950727|Device|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
79815222|NCT02601222|Drug|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
79986741|NCT01346475|Drug|Valacyclovir|500 mg orally once daily for 5 weeks
79986742|NCT02416414|Device|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
79986743|NCT02416414|Device|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
79660160|NCT05770622|Other|First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)|CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is <10mg/L or >20mg/L) and, if required, recommends a new adjusted dose.
79986744|NCT05415306|Behavioral|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
79986745|NCT05415306|Behavioral|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
79346701|NCT05372198|Drug|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
79346702|NCT05359406|Combination Product|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
79660161|NCT05770089|Other|Adapted Physical Activity (APA)|A 8-weeks program of APA (2x1hour per week) via videoconferencing composed of resistance training and yoga.
79986746|NCT05415306|Behavioral|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
79986747|NCT02417038|Device|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
79986748|NCT02425384|Behavioral|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
79346703|NCT01640054|Drug|Fostamatinib|Fostamatinib 100mg once daily
79498592|NCT02267564|Procedure|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
79346704|NCT04654208|Drug|palbociclib|patients on palbociclib combination treatment
79346705|NCT05360420|Diagnostic Test|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
79498593|NCT02246920|Drug|Fluticasone propionate|50 mcg/actuation Nasal Spray
79498594|NCT02246920|Drug|Flonase®|50 mcg/actuation Nasal Spray
79498595|NCT02246920|Drug|Placebo|Inactive Nasal Spray
79498596|NCT02129244|Other|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~Assuring effective, efficient clinical care and self-management support~Promoting clinical care consistent with scientific evidence and patient preferences~Organizing data to facilitate efficient, effective care~Empowering and preparing patients to manage their health and health-care needs~Mobilizing community resources to meet the needs of patients"
79498597|NCT02086890|Device|Electro-acupuncture|
79498598|NCT02086890|Device|Laser Acupuncture|
79498599|NCT02086890|Device|Transcorneal Electrical Stimulation|
79498600|NCT02086890|Device|Sham Electro-acupuncture|
79660162|NCT05769647|Device|Virtual Reality Glasses|3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
79660163|NCT05769647|Device|Stress Ball|Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
79680071|NCT04690725|Drug|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
79498601|NCT02086890|Device|Sham laser acupuncture|
79346706|NCT04844216|Device|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
79346707|NCT04844216|Device|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
79346708|NCT05345678|Drug|Durvalumab|Dose: 1500mg Route: IV
79346709|NCT05345678|Drug|Tremelimumab|Dose: 300mg Route: IV
79346710|NCT05345288|Device|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
79815223|NCT02608736|Drug|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
79498602|NCT02086890|Device|Sham transcorneal electrical stimulation|
79498603|NCT01832402|Drug|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
79498604|NCT01832402|Drug|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
79498605|NCT01832402|Other|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
79498606|NCT01832402|Behavioral|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
79498607|NCT01832402|Behavioral|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
79498608|NCT01619488|Device|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
79498609|NCT01588392|Behavioral|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
79498610|NCT01588392|Behavioral|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
79498611|NCT01588379|Behavioral|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
79498612|NCT01588379|Behavioral|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
79346711|NCT05345288|Device|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
79498613|NCT01588379|Other|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
79498614|NCT01210625|Dietary Supplement|Nutrabiotix|Fiber supplement: 9mg or 12mg
79498615|NCT01210625|Dietary Supplement|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
79346712|NCT05335070|Drug|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
79346713|NCT05327738|Biological|Atezolizumab|Given IV
79346714|NCT05327738|Procedure|Biopsy|Undergo biopsy
79346715|NCT05327738|Drug|Cabozantinib S-malate|Given PO
79346716|NCT05327738|Radiation|Yttrium Y 90 Glass Microspheres|Given intra-arterially
79346717|NCT04419662|Drug|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
79498616|NCT01009190|Drug|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
79498617|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
79498618|NCT01009190|Drug|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
79498619|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
79498620|NCT00667628|Drug|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
79498621|NCT00667628|Drug|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
79498622|NCT00597636|Behavioral|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
79986749|NCT02425384|Behavioral|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
79986750|NCT02425384|Other|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
79346718|NCT04419662|Other|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
79346719|NCT04614740|Drug|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
79346720|NCT05353088|Other|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
79346721|NCT05353088|Other|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
79346722|NCT05351918|Other|acupuncture|Acupuncture points are punctured with needles.
79346723|NCT04589546|Drug|Nicotinamide treatment|Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
79346724|NCT04589546|Drug|placebo treatment|For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
79498623|NCT00597636|Behavioral|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
79524886|NCT05757427|Device|Wavelia #2|Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
79524887|NCT05753267|Drug|Mesalamine|Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
79524888|NCT05753267|Drug|Fenofibrate 160mg|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
79346725|NCT01600586|Device|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
79346726|NCT04411238|Other|interview|interview
79660164|NCT05768217|Behavioral|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention & Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
79986751|NCT05754060|Other|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
79986752|NCT03177226|Device|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
79986753|NCT03177226|Device|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
79986754|NCT02416960|Other|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
79986755|NCT02416960|Other|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
79986756|NCT01338636|Drug|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
79986757|NCT02416726|Device|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
79986758|NCT02416258|Drug|LP0113 aerosol spray|
79986759|NCT02416258|Drug|Aerosol spray vehicle|
79986760|NCT02416258|Drug|LEO 90100 aerosol foam|
79346727|NCT01639742|Device|New texture round breast implants|Breast implant surgery
79346728|NCT05416736|Procedure|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
79346729|NCT05416736|Procedure|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
79346730|NCT04995380|Procedure|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
79346731|NCT05291468|Radiation|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
79986761|NCT02416258|Drug|Betamethasone dipropionate aerosol spray|
79986762|NCT02416258|Drug|Calcipotriol aerosol spray|
79986763|NCT02416258|Drug|Daivobet® gel|
79986764|NCT02410720|Other|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
79986765|NCT02410720|Other|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
79986766|NCT02410720|Other|Explanation of paper and application instructions|The research fellow will explain instructions to patients
79986767|NCT02410720|Other|Picoprep solution|
79986768|NCT02416570|Drug|Clarithromycin|
79986769|NCT02416570|Drug|Placebo|
79986770|NCT02410642|Procedure|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
79986771|NCT03176914|Behavioral|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
79346732|NCT04981496|Other|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
79346733|NCT05274854|Behavioral|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
79346734|NCT05274854|Behavioral|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
79346735|NCT05347550|Other|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
79498624|NCT00003653|Drug|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79660165|NCT05768217|Behavioral|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
79346736|NCT05415098|Drug|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
79346737|NCT02164513|Drug|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
79986772|NCT03176914|Behavioral|conventional community interventions|community health programs as the sole source of health education
79498625|NCT00003653|Drug|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79346738|NCT02164513|Drug|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
79524889|NCT05751343|Drug|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
79524890|NCT05750914|Device|Broadband Light|Broadband Light treatment using standard protocol
79524891|NCT05742373|Other|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
79524892|NCT05742373|Other|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
79524893|NCT05737134|Other|MA_PESAN MOBILE APPLICATION|The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
79524894|NCT05736900|Diagnostic Test|Blood sampling|One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
79660166|NCT05766683|Drug|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
79346739|NCT02164513|Drug|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
79346740|NCT05369078|Drug|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
79524895|NCT05708417|Behavioral|Lifestyle Intervention|"The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period."
79524896|NCT05708417|Other|Placebo|No lifestyle intervention within the study, only test/datacollection
79660167|NCT05766683|Drug|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
79660168|NCT05765500|Drug|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
79815224|NCT02608736|Drug|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
79346741|NCT05369078|Drug|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
79346742|NCT04540016|Drug|[14C]HSK7653|25 mg of [14C]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
79346743|NCT04953338|Other|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
79346744|NCT04524104|Behavioral|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
79346745|NCT05232188|Procedure|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
79524897|NCT05700227|Radiation|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
79524898|NCT05683275|Other|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
79815225|NCT04015986|Dietary Supplement|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
79346746|NCT05337020|Other|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
79370783|NCT00928642|Drug|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
79498626|NCT00003653|Drug|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79524899|NCT05683275|Other|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
79524900|NCT05683275|Other|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
79660169|NCT05765500|Drug|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
79986773|NCT02416024|Device|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
79660170|NCT05764265|Drug|LTP001|LTP001 will be administered orally once daily in the morning
79660171|NCT05764239|Drug|SYNB1934v1|SYNB1934v1 IMP consists of powder for oral suspension packaged in sachets. During dose preparation, the powder will be resuspended in water or apple juice prior to administration.
79346747|NCT05230706|Other|Cephalic helmet|An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
79346748|NCT05220488|Other|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
79346749|NCT04513184|Drug|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
79346750|NCT04513184|Drug|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
79346751|NCT04756531|Drug|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
79346752|NCT04756531|Drug|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
79346753|NCT04756531|Drug|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
79346754|NCT04756531|Drug|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
79346755|NCT04756531|Drug|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
79524901|NCT05679752|Other|Facial PNF technique|Stimulation techniques used to facilitate the weak muscle groups
79524902|NCT05679752|Other|Massage therapy|frictional massage to stimulate the weak muscle groups
79346756|NCT04756531|Drug|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
79346757|NCT02218489|Drug|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
79346758|NCT02218489|Drug|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
79346759|NCT04419740|Behavioral|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
79986774|NCT00322218|Drug|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one [90Y]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m^2 immediately followed by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
79346760|NCT02192905|Behavioral|Diabetes Prevention Program Lifestyle Intervention|
79346761|NCT01713946|Drug|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
79346762|NCT01713946|Drug|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
79346763|NCT01713946|Drug|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
79346764|NCT01713946|Drug|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
79346765|NCT04916444|Device|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
79370784|NCT04361422|Drug|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
79498627|NCT00003653|Drug|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79660172|NCT05764239|Drug|Placebo|A placebo will be manufactured using an inactive powder that is color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo will be packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
79660173|NCT05762614|Other|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
79660174|NCT05741372|Drug|Rosuvastatin|Rosuvastatin
79660175|NCT05741372|Drug|Digoxin|Digoxin
79986775|NCT02410564|Behavioral|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
79986776|NCT02410564|Behavioral|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
79660176|NCT05741372|Drug|Metformin hydrochlorid|Metformin hydrochloride
79815226|NCT04015986|Dietary Supplement|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
79346766|NCT04465136|Device|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
79228256|NCT04458480|Combination Product|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
79346767|NCT05329688|Procedure|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
79498628|NCT00003653|Drug|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79660177|NCT05741372|Drug|Furosemide|Furosemide
79660178|NCT05741346|Drug|BCX9930|Taken orally at 400 mg twice daily (BID)
79986777|NCT05046730|Device|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
79986778|NCT05200494|Procedure|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
79986779|NCT03176992|Drug|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
79346768|NCT04464512|Drug|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
79660179|NCT05739682|Procedure|Local anaesthetic injection of 4% articaine with 1:100000 epinephrine|Buccal infiltration injection using a side loading aspirating syringe and a 30-gauge needle
79660180|NCT05739682|Procedure|Tooth isolation|Rubber dam application to the affected tooth
79660181|NCT05739682|Procedure|Access cavity preparation|Complete removal of caries, undermined tooth structure, and defective restoration. Access cavity preparation with complete removal of the pulp chamber roof using a sterile bur other than the ones used for caries removal.
79660182|NCT05739682|Procedure|Root canal shaping and cleaning|Working length determination using an electronic apex locator and then canal instrumentation using Hyflex CM rotary files up to size 40.04 with irrigation using 2.5% NaOCl between files.
79815227|NCT05734898|Biological|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
79986780|NCT05328336|Drug|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
79986781|NCT02410408|Device|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
79986782|NCT02410408|Other|information package|Information on PSC and RCA
79986783|NCT03176680|Procedure|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
79986784|NCT02873754|Behavioral|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
79346769|NCT04897412|Drug|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
79228257|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
79228258|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
79228259|NCT05134584|Drug|Linaclotide|290μg once daily, 4 weeks
79228260|NCT05134584|Drug|Lactulose|20mL once daily, 4 weeks
79228261|NCT05134584|Drug|Omeprazol|20mg twice daily for the first 10 days
79346770|NCT04897412|Other|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
79346771|NCT05179148|Behavioral|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
79660183|NCT05739682|Procedure|Final irrigation with antimicrobial-corticosteroid mixture|1 ml of levofloxacin will be withdrawn in a 3ml plastic syringe followed by 1 ml of fluconazole and 1 ml of dexamethasone sodium phosphate, the whole solution is then passively delivered into the canal using a 30-gauge side vented needle reaching 1 mm shorter than the working length. The solution will be left inside the canal for 5 minutes
79815228|NCT05424510|Drug|Ringer's Lactate|500 ml of Ringer's Lactate
79815229|NCT05424510|Other|IV line|Placing of an IV line before surgery
79815230|NCT02607566|Behavioral|Yoga|
79228262|NCT05134584|Drug|Itopride|50mg three times daily for the first 10 days
79228263|NCT02468960|Device|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
79498629|NCT00003653|Drug|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79498630|NCT00003653|Drug|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
79498631|NCT00003665|Biological|dendritic cell-MART-1 peptide vaccine|
79986785|NCT02873754|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
79815231|NCT02607566|Behavioral|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
79815232|NCT02607410|Drug|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
79498632|NCT00003665|Biological|gp100 antigen|
79815233|NCT02607410|Drug|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
79815234|NCT02599038|Dietary Supplement|Serine supplementation|Serine supplementation (200 mg/kg/day)
79815235|NCT05423964|Diagnostic Test|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
79815236|NCT05423964|Other|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
79815237|NCT05693090|Drug|Tipifarnib|Oral administration
79815238|NCT05693090|Drug|Osimertinib|Oral administration
79815239|NCT04092426|Other|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
79986786|NCT02873754|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
79346772|NCT05173766|Other|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
79660184|NCT05739682|Procedure|Final irrigation with cold saline|Frozen sterile saline will be brought at room temperature and monitored using a digital liquid thermometer till the temperature reaches 2.5°c. 4ml are then withdrawn in a 5ml plastic syringe and delivered inside the canal in 1 minute. The process is then repeated 5 times so that the canal receives 20 ml of 2.5°c cold saline for 5 minutes.
79986787|NCT02873754|Drug|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
79986788|NCT02873754|Drug|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
79346773|NCT02163499|Drug|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
79228264|NCT02468960|Device|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
79228265|NCT02468960|Device|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
79498633|NCT00003665|Biological|therapeutic tumor infiltrating lymphocytes|
79498634|NCT00003665|Biological|tyrosinase peptide|
79660185|NCT05739682|Procedure|Temporary restoration and patient's instructions|The canals are dried using paper points and the access cavity is sealed using a non-eugenol temporary filling.
79660186|NCT05739682|Procedure|Root canal obturation|After the 1st visit by 3 days to 1 week, the patient is scheduled for a second appointment for root canal obturation.
79660187|NCT05738967|Behavioral|Transdiagnostic cognitive behavioral therapy (CBT)|Adolescent-caregiver dyads will will participate in CBT focused on exposure therapy and behavioral activation. It will also include flexible incorporation of emotion-focused coping and adaptations for autism.
79660188|NCT05738967|Behavioral|Treatment as usual|Adolescent-caregiver dyads will participate in coordinated referrals to the community. They may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
79228266|NCT02468960|Procedure|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
79228267|NCT02468960|Other|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
79228268|NCT03792555|Drug|Paltusotine|Paltusotine, capsules, once daily by mouth
79815240|NCT05692466|Diagnostic Test|Comprehensive molecular panel test|Lab test
79498635|NCT00003671|Drug|asparaginase|
79986789|NCT02873754|Drug|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
79986790|NCT03287414|Drug|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
79986791|NCT03287414|Drug|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
79228269|NCT03792555|Drug|Placebo|Placebo, capsules, once daily by mouth
79498636|NCT00003671|Drug|cyclophosphamide|
79498637|NCT00003671|Drug|cytarabine|
79498638|NCT00003671|Drug|daunorubicin hydrochloride|
79498639|NCT00003671|Drug|dexamethasone|
79498640|NCT00003671|Drug|leucovorin calcium|
79498641|NCT00003671|Drug|mercaptopurine|
79498642|NCT00003671|Drug|methotrexate|
79498643|NCT00003671|Drug|thioguanine|
79498644|NCT00003671|Drug|vincristine sulfate|
79498645|NCT00003677|Drug|Dolastatin 10|IV bolus once every 21 days.
79986792|NCT03287414|Drug|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
79986793|NCT03174886|Drug|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
79986794|NCT03174886|Drug|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
79986795|NCT05348460|Dietary Supplement|Ketone ester drink (DeltaG®, 500 mg/kg body weight)|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
79986796|NCT05348460|Dietary Supplement|Taste-matched, isovolumic placebo drink|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
79498646|NCT00384605|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
79986797|NCT02415790|Drug|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
79660189|NCT05731713|Behavioral|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
79986798|NCT02415790|Drug|E2027 matching placebo|E2027 matching placebo capsule will be administered.
79986799|NCT03644160|Behavioral|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
79986800|NCT03669614|Drug|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
79986801|NCT03669614|Drug|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
79498647|NCT00384605|Drug|placebo|Placebo capsule once daily. Treatment for 52 weeks.
79498648|NCT00003683|Drug|doxorubicin hydrochloride|
79498649|NCT00003683|Drug|ifosfamide|
79660190|NCT05730725|Drug|BMS-986322|Specified dose on specified days
79815241|NCT05692466|Other|EORTC QLQ-30|Quality of life questionnaire
79815242|NCT02598804|Other|5 educational workshop|
79815243|NCT02598804|Other|written information booklet|
79986802|NCT02415946|Procedure|Sinus floor augmentation (lateral)|
79986803|NCT02415946|Procedure|Sinus floor augmentation (transcrestal)|
79660191|NCT05730725|Other|Placebo|Specified dose on specified days
79986804|NCT05200260|Procedure|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
79986805|NCT05200260|Procedure|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
79660192|NCT05726227|Drug|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
79660193|NCT05726227|Drug|Placebo|Placebo will be administered subcutaneously once-weekly.
79815244|NCT00917202|Drug|Methylenblue|
79815245|NCT02606240|Device|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
79346774|NCT02163187|Device|Implantation of the InterStimTM|
79346775|NCT02163187|Behavioral|MSK BFI questionnaires|
79346776|NCT02163187|Behavioral|The Low Anterior Resection Score (LARS) questionnaires|
79346777|NCT02163187|Behavioral|The EuroQOL5D questionnaires|
79346778|NCT02163187|Behavioral|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
79346779|NCT04419116|Procedure|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
79346780|NCT02191579|Biological|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
79346781|NCT02191579|Drug|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
79346782|NCT05125250|Other|Motor Control Group|will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
79660194|NCT05722353|Other|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
79660195|NCT05722002|Drug|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
79986806|NCT05200260|Drug|PARP inhibitor|For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
79346783|NCT05125250|Other|Vestibular Group|will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
79346784|NCT05324462|Drug|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
79346785|NCT04838756|Other|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
79346786|NCT04838756|Other|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
79346787|NCT01363700|Drug|DE-114 ophthalmic solution|
79346788|NCT01363700|Drug|Placebo ophthalmic solution|
79498650|NCT04329143|Procedure|open completion cholecystectomy|open excision of cystic duct remnant
79498651|NCT04329143|Procedure|lap completion cholecystectomy|lap excision of cystic duct stone
79498652|NCT00003695|Drug|chemotherapy|
79498653|NCT00003695|Procedure|surgical procedure|
79498654|NCT00003707|Drug|gemcitabine hydrochloride|
79346789|NCT01363700|Drug|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
79346790|NCT04372706|Drug|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
79346791|NCT04372706|Drug|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
79346792|NCT04178642|Drug|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
79346793|NCT04178642|Procedure|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
79346794|NCT04157894|Other|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
79660196|NCT05722002|Drug|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
79815246|NCT02600052|Other|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
79346795|NCT04157894|Other|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
79346796|NCT04157894|Other|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
79498655|NCT00003707|Drug|tipifarnib|
79498656|NCT00003713|Drug|intoplicine|
79498657|NCT00003719|Drug|irinotecan hydrochloride|
79498658|NCT00003725|Drug|valrubicin|
79498659|NCT00003725|Procedure|conventional surgery|
79498660|NCT00003731|Drug|temozolomide|
79498661|NCT00003737|Drug|becatecarin|
79498662|NCT00003743|Biological|aldesleukin|
79498663|NCT00003749|Procedure|adjuvant therapy|
79498664|NCT00003749|Procedure|conventional surgery|
79498665|NCT00003749|Radiation|brachytherapy|
79498666|NCT00003749|Radiation|radiation therapy|
79660197|NCT05722002|Drug|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
79346797|NCT04821752|Behavioral|Avoidance Education|Dietary modification and lifestyle interventions
79986807|NCT02415634|Other|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~Part 2: A rehabilitation goal setting care plan~Part 3: A patient communication forum~Part 4: Useful supports and contact information~Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
79986808|NCT02415634|Other|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
79660198|NCT05716373|Behavioral|pain|reiki
79986809|NCT03680768|Other|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
79346798|NCT04815278|Behavioral|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
79660199|NCT05714644|Other|FIT kit Screening Test|FIT kit mailed to the patient's home
79498667|NCT00003755|Drug|MKC-1|
79660200|NCT05714644|Other|Cologuard Screening Test|Cologuard test mailed to the patient's home
79660201|NCT05711082|Other|Précurseur de la dopamine|"In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.~Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house."
79660202|NCT05711082|Other|antagoniste D2|In the second condition, volunteers will receive Sulpiride 800 mg
79815247|NCT02600052|Device|treadmill|AEROBIC TRAINING
79498668|NCT00003761|Biological|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~Level 1 4.76 x 106 PFU~Level 2 4.76 x 107 PFU~Level 3 4.76 x 108 PFU"
79498669|NCT00003773|Drug|oglufanide disodium|
79815248|NCT05754476|Other|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
79815249|NCT02606318|Other|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
79986810|NCT05579106|Device|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~Temperature~Galvanic skin response~Accelerometer~Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
79986811|NCT05579106|Device|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
79346799|NCT04815278|Behavioral|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
79498670|NCT00003779|Biological|Connaught|Compare two strains of BCG
79498671|NCT00003779|Biological|Tice|Compare two strains of BCG
79498672|NCT00384917|Drug|Ketoconazole|
79498673|NCT05444153|Drug|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
79498674|NCT05444153|Drug|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
79498675|NCT00003797|Biological|trastuzumab|
79498676|NCT00003797|Drug|gemcitabine hydrochloride|
79498677|NCT00003803|Drug|cisplatin|
79498678|NCT00003803|Drug|gemcitabine hydrochloride|
79498679|NCT00003803|Radiation|radiation therapy|
79498680|NCT02972879|Procedure|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
79498681|NCT02972879|Procedure|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~LASER 904nm~P: 1.5W/cm²~30mV/cm²~Area 2 cm²~1 Joule por ponto ( in the A1 pulley)"
79228270|NCT01811862|Procedure|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
79346800|NCT04815278|Behavioral|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
79498682|NCT02972879|Procedure|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
79498683|NCT02972879|Procedure|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
79498684|NCT00003815|Biological|bleomycin sulfate|
79498685|NCT00003815|Drug|carmustine|
79498686|NCT00003815|Drug|cyclophosphamide|
79498687|NCT00003815|Drug|cytarabine|
79498688|NCT00003815|Drug|doxorubicin hydrochloride|
79498689|NCT00003815|Drug|etoposide|
79498690|NCT00003815|Drug|melphalan|
79660203|NCT05711082|Other|PLACEBO|In the third condition, volunteers will receive placebo
79660204|NCT05709379|Behavioral|Sedentary behavior|Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
79660205|NCT05704335|Other|Questionnaire administration|A trained physician will administer a structured questionnaire
79660206|NCT05704179|Other|Obstetric Quality of recovery score|Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
79660207|NCT05703490|Diagnostic Test|IADLSys system|Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
79660208|NCT05700695|Drug|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
79660209|NCT05700695|Drug|Lactulose|Oral lactulose will be given to patients in both arms
79346801|NCT04821674|Biological|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
79498691|NCT00003815|Drug|prednisolone|
79498692|NCT00003815|Drug|vincristine sulfate|
79498693|NCT00003815|Procedure|autologous bone marrow transplantation|
79498694|NCT00003815|Radiation|radiation therapy|
79498695|NCT00003821|Drug|aminopterin|
79660210|NCT05693701|Behavioral|Implementation Strategy Bundle|Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
79660211|NCT05693701|Other|Usual care notification|Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
79660212|NCT05690841|Drug|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for >= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for <16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals >=6mo and <16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for >= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for <16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals >=6mo and <16y ((CQ: Day1 600 mg, PQ age-based dosing)."
79660213|NCT05684965|Drug|XTX301|XTX301 monotherapy
79660214|NCT05681481|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
79660215|NCT05681481|Drug|Prednisone|Oral Prednisone
79346802|NCT04821674|Biological|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
79346803|NCT04791566|Drug|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
79346804|NCT04791566|Drug|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
79346805|NCT04129736|Drug|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
79498696|NCT00003827|Drug|amifostine trihydrate|
79498697|NCT00003827|Drug|cytarabine|
79498698|NCT00003827|Drug|topotecan hydrochloride|
79498699|NCT00003833|Genetic|DNA stability analysis|
79498700|NCT00003833|Genetic|gene mapping|
79346806|NCT05301218|Procedure|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
79346807|NCT04418960|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
79986812|NCT05579106|Other|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
79346808|NCT04769960|Diagnostic Test|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
79498701|NCT00003851|Biological|proteolytic enzymes|
79498702|NCT00003851|Drug|gemcitabine hydrochloride|
79498703|NCT00003851|Procedure|Gonzalez regimen|
79660216|NCT05681442|Drug|continuous pivotal βL-AB|continuous pivotal βL-AB
79660217|NCT05681442|Drug|intermittent pivotal βL-AB|intermittent pivotal βL-AB (IID = control group)
79346809|NCT04769960|Behavioral|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
79498704|NCT00003863|Genetic|comparative genomic hybridization|
79498705|NCT00003863|Genetic|cytogenetic analysis|
79498706|NCT00003863|Genetic|fluorescence in situ hybridization|
79815250|NCT02606318|Other|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
79815251|NCT00751296|Drug|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
79815252|NCT04339166|Diagnostic Test|Non-invasive chromosome screening（NICS）|NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium
79498707|NCT00003863|Genetic|gene rearrangement analysis|
79498708|NCT00003881|Biological|trastuzumab|
79498709|NCT00003881|Drug|carboplatin|
79498710|NCT00003881|Drug|paclitaxel|
79498711|NCT00003887|Biological|peripheral blood lymphocyte therapy|
79498712|NCT00003893|Drug|CMF regimen|
79498713|NCT00003893|Drug|cyclophosphamide|
79498714|NCT00003893|Drug|doxorubicin hydrochloride|
79498715|NCT00003893|Drug|epirubicin hydrochloride|
79498716|NCT00003893|Drug|fluorouracil|
79660218|NCT05681442|Drug|AG infusion most 1 dose|AG infusion most 1 dose (AMT group )
79660219|NCT05681442|Drug|AG infusion for 5 days|AG infusion for 5 days (ACT Group)
79660220|NCT05680337|Device|TENS|TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
79815253|NCT04093830|Device|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
79986813|NCT03684746|Other|No Intervention|It is an observational Study with staff
79498717|NCT00003893|Drug|methotrexate|
79679503|NCT02950727|Device|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
79346810|NCT01637402|Drug|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
79660221|NCT05679401|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
79815254|NCT04093518|Drug|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
79986814|NCT02416648|Behavioral|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
79986815|NCT03684668|Behavioral|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
79815255|NCT04093518|Drug|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
79986816|NCT03174964|Drug|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
79986817|NCT03684434|Behavioral|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
79986818|NCT03684434|Behavioral|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
79346811|NCT01637402|Drug|Prednisone|5 mg, twice daily, oral administration
79346812|NCT04419350|Procedure|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
79346813|NCT04419038|Procedure|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
79346814|NCT04419038|Procedure|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
79346815|NCT04825730|Drug|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
79346816|NCT02217475|Drug|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
79346817|NCT02217475|Drug|Placebo|Placebo administered orally once daily and taken every morning with food.
79660222|NCT05679401|Procedure|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
79986819|NCT02416804|Drug|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
79986820|NCT02416804|Drug|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
79346818|NCT05296148|Device|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
79660223|NCT05679401|Drug|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
79660224|NCT05679401|Drug|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
79660225|NCT05677451|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
79660226|NCT05677451|Drug|placebo|matching active drug
79679504|NCT02950571|Behavioral|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
79679505|NCT02950571|Behavioral|Standard Care|High level of support from an interdisciplinary team.
79346819|NCT02191267|Radiation|[F18]-T807|[F18]-T807 PET Scan to measure tau deposition in the brain.
79346820|NCT02191267|Radiation|[F18]-Florbetapir|[F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
79498718|NCT00003893|Drug|mitomycin C|
79815256|NCT02606084|Drug|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
79815257|NCT05733260|Behavioral|Exercise|10 weeks of resistance training.
79660227|NCT05674357|Behavioral|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~Cognitive Behavioral Therapy (CBT)~Acceptance Commitment Therapy (ACT)~Mindfulness-Based Cognitive Therapy (MBCT)~Mindfulness-Based Stress Reduction (MBSR)~Meaning-Centered Psychotherapy (MCP)~Cognitive Behavioral Therapy for Insomnia (CBT-I)~CBT for pain~CBT for fatigue~CBT for nausea"
79346821|NCT02191267|Device|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
79346822|NCT02191267|Genetic|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
79660228|NCT05674357|Behavioral|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
79660229|NCT05672524|Drug|Trastuzumab|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
79660230|NCT05672524|Drug|Tucatinib|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
79660231|NCT05665465|Drug|Nicotine nasal spray 0.5 mg|Participants will be administered nicotine nasal spray and provide subjective reactions
79660232|NCT05665465|Drug|Placebo|Participants will be administered placebo nasal spray and provide subjective reactions
79660233|NCT05661695|Device|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
79660234|NCT05657678|Drug|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
79660235|NCT05657678|Drug|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
79660236|NCT05653206|Procedure|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
79660237|NCT05653206|Procedure|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
79660238|NCT05640999|Radiation|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
79660239|NCT05640999|Radiation|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
79346823|NCT04418245|Diagnostic Test|Imaging by thoracic scanner|Low-dose computed tomography
79660240|NCT05640999|Other|Observation|Observation
79815258|NCT00751140|Procedure|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
79815259|NCT05732168|Diagnostic Test|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
79815260|NCT02599272|Other|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
79346824|NCT04818944|Drug|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
79346825|NCT04818944|Drug|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
79346826|NCT02189941|Drug|Deferiprone sustained-release|Deferiprone sustained-release tablets
79346827|NCT02189941|Drug|Deferiprone immediate-release|Deferiprone immediate-release tablets
79346828|NCT04194476|Diagnostic Test|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
79346829|NCT02216773|Procedure|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
79346830|NCT02216773|Procedure|Portal vein embolization (PVE)|
79498719|NCT00003893|Drug|mitoxantrone hydrochloride|
79498720|NCT00003893|Procedure|adjuvant therapy|
79498721|NCT00003893|Radiation|radiation therapy|
79498722|NCT00003899|Biological|filgrastim|
79498723|NCT00003899|Drug|cyclophosphamide|
79498724|NCT00003899|Drug|melphalan|
79498725|NCT00003899|Drug|paclitaxel|
79660241|NCT05639933|Drug|HT-001 2% Topical Gel|Topical gel, 2% active
79660242|NCT05639933|Drug|HT-001 1% Topical Gel|Topical gel, 1% active
79346831|NCT01601132|Drug|theophylline|300mg (80mg/15ml elixir)
79346832|NCT01601132|Drug|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
79346833|NCT04818398|Drug|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
79498726|NCT00003899|Drug|thiotepa|
79498727|NCT00003899|Procedure|autologous bone marrow transplantation|
79498728|NCT00003899|Procedure|peripheral blood stem cell transplantation|
79498729|NCT00003911|Radiation|stereotactic radiosurgery|
79498730|NCT00003917|Drug|topotecan hydrochloride|
79498731|NCT00003923|Drug|porfimer sodium|
79498732|NCT02973191|Drug|JCAR015|
79498733|NCT00003929|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
79498734|NCT00003929|Drug|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
79498735|NCT00003929|Drug|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
79660243|NCT05639933|Drug|HT-001 0.5% Topical Gel|Topical gel, 0.5% active
79346834|NCT04818398|Drug|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
79660244|NCT05639933|Drug|HT-001 Placebo|Topical gel, vehicle gel
79660245|NCT05637723|Other|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
79660246|NCT05637723|Other|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
79986821|NCT04933812|Behavioral|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
79346835|NCT04824482|Other|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
79346836|NCT04824482|Other|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
79346837|NCT04836962|Drug|normal saline|2cc of normal saline is administered to patient instead of dexamethasone.
79346838|NCT04836962|Drug|dexamethasone|dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
79346839|NCT05289440|Drug|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
79498736|NCT00003929|Radiation|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
79498737|NCT02210507|Other|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
79498738|NCT02210507|Other|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
79660247|NCT05635734|Drug|Azeliragon 5 mg|"Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
79660248|NCT05635734|Drug|Azeliragon 10 mg|"Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
79346840|NCT05289440|Drug|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
79498739|NCT02210507|Other|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
79498740|NCT02210663|Drug|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
79986822|NCT03684356|Procedure|socket shield technique|immediate implant placement with buccal part of the root is retained
79986823|NCT03684356|Procedure|xenograft|immediate implant placement with filling the buccal gap with xenograft
79498741|NCT04568525|Diagnostic Test|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
79498742|NCT04568837|Drug|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
79346841|NCT05289440|Drug|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
79498743|NCT04568291|Other|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
79660249|NCT05635734|Drug|Azeliragon 20 mg|"Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
79346842|NCT04709900|Diagnostic Test|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
79346843|NCT04809974|Drug|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
79346844|NCT05226884|Diagnostic Test|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
79346845|NCT05226884|Diagnostic Test|Defocus Curve|Measurement of a defocus curve
79346846|NCT03329612|Procedure|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
79498744|NCT04568291|Other|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
79498745|NCT04569617|Other|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
79498746|NCT04569617|Other|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
79660250|NCT05635643|Drug|CHS-114|CHS-114
79660251|NCT05635643|Drug|toripaliamab|toripalimab-tpzi
79660252|NCT05627167|Other|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
79660253|NCT05627167|Other|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
79660254|NCT05624450|Drug|Tozorakimab|Single IV dose of tozorakimab on Day 1.
79660255|NCT05624450|Drug|Placebo|Single IV dose of matching placebo on Day 1.
79660256|NCT05623189|Drug|HTD1801|HTD1801,1250 mg, BID
79660257|NCT05623189|Drug|Placebo|Placebo, BID
79498747|NCT04569617|Other|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
79498748|NCT04569617|Other|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
79660258|NCT05620914|Drug|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
79660259|NCT05618301|Drug|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
79660260|NCT05618301|Drug|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
79660261|NCT05618301|Procedure|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
79346847|NCT04691960|Other|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
79346848|NCT04691960|Drug|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
79370785|NCT03579615|Device|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
79660262|NCT05613816|Procedure|Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
79370786|NCT03579615|Device|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
79498749|NCT04567199|Other|Observational, retrospective|retrospective analysis of observed results, for both study groups.
79498750|NCT04569071|Device|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
79498751|NCT04568057|Device|NIR Transcranial phototherapy device|1068 nm NIR helmet
79660263|NCT05612204|Procedure|Biopsy under MRI|Biopsy under MRI
79346849|NCT04796792|Device|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
79346850|NCT05279612|Radiation|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
79660264|NCT05609916|Behavioral|Cognitive Behavioral Therapy|"During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment."
79660265|NCT05609487|Other|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
79986824|NCT02416882|Other|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
79346851|NCT03948854|Other|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
79346852|NCT03948854|Other|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
79498752|NCT04568057|Device|Placebo Transcranial Device|The placebo device looks like the active device.
79660266|NCT05609487|Device|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
79815261|NCT02599272|Other|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
79815262|NCT02599272|Other|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
79986825|NCT02416882|Other|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
79986826|NCT02416882|Other|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
79498753|NCT04568135|Other|survey|survey
79498754|NCT04567901|Other|Death|Mortality group
79498755|NCT04567901|Other|Survive|Survival group
79498756|NCT04566809|Other|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
79498757|NCT04566809|Other|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
79498758|NCT04569305|Procedure|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
79498759|NCT04569305|Procedure|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
79498760|NCT04567823|Dietary Supplement|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
79498761|NCT04568447|Device|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
79986827|NCT04792320|Dietary Supplement|Active bamboo charcoal|4g particle
79986828|NCT04792320|Dietary Supplement|probiotics|0.8g powder
79986829|NCT03176758|Drug|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
79986830|NCT03176758|Drug|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
79346853|NCT03948854|Other|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
79346854|NCT03948854|Other|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
79346855|NCT04816916|Drug|AXA1665|AXA1665 administered TID with food
79986831|NCT03176758|Device|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
79986832|NCT04203537|Drug|CA-008|Local administration during surgery
79986833|NCT04203537|Drug|Placebo|Local administration during surgery
79986834|NCT05565612|Dietary Supplement|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
79986835|NCT05565612|Dietary Supplement|Placebo|Compound based on maltodextrin and other excipients
79986836|NCT03177070|Drug|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
79346856|NCT04816916|Drug|Placebo|Matching placebo administered TID with food
79346857|NCT04809038|Other|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
79346858|NCT04809038|Other|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
79370787|NCT04367428|Biological|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
79370788|NCT04367272|Procedure|First Arthroplasty|First Knee
79370789|NCT04367272|Procedure|Second Arthroplasty|Second Knee
79986837|NCT03174808|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
79986838|NCT03680690|Procedure|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
79986839|NCT05190393|Procedure|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
79986840|NCT05190393|Procedure|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
79660267|NCT05592379|Drug|Psilocybin and Saline|"The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).~The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center."
79660268|NCT05591222|Drug|Placebo/Daxdilimab|Placebo/Daxdilimab will be administered subcutaneously as two injections for each dose.
79986841|NCT03101592|Other|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
79660269|NCT05591222|Drug|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
79498762|NCT04568915|Other|Dry Needling|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
79815263|NCT02607488|Drug|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
79986842|NCT03101592|Other|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
79986843|NCT02410174|Radiation|Stereotactic Body Radiotherapy (SBRT)|
79986844|NCT01360203|Other|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
79986845|NCT02415478|Other|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
79660270|NCT05591222|Drug|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
79660271|NCT05586321|Biological|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
79660272|NCT05585320|Drug|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
79660273|NCT05585320|Drug|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m^2 nab-Paclitaxel will be administered at a dose of 125 mg/m^2"
79815264|NCT02607488|Drug|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
79660274|NCT05585320|Drug|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m^2 Fluorouracil will be administered at 2400 mg/m^2 Irinotecan will be administered at 150 mg/m^2 Oxaliplatin will be administered at 85 mg/m^2"
79660275|NCT05585307|Drug|GS-5894|Administered orally
79986846|NCT03684200|Other|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
79986847|NCT01366599|Drug|HEC or MEC|Any HEC or MEC, including aprepitant
79986848|NCT03172000|Diagnostic Test|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
79986849|NCT03680612|Drug|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
79498763|NCT04568915|Other|Maitland Mobilization|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
79346859|NCT04809038|Other|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
79346860|NCT05652998|Biological|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
79498764|NCT04569227|Drug|EC-18|2000 mg PO daily
79498765|NCT04569227|Drug|Placebo|PO daily
79498766|NCT02210819|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
79498767|NCT02210819|Drug|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
79498768|NCT04564469|Drug|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration &( F - 15)protocol in which furosemide is administered 15 min before tracer administration
79986850|NCT03680612|Drug|cefepime 1 g or cefepime 2 g|cefepime monotherapy
79986851|NCT01360281|Other|Neuromuscular Electrical Stimulation|
79986852|NCT01360281|Other|ECR|Resisted exercises
79986853|NCT02410096|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
79986854|NCT02410096|Other|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
79986855|NCT02410096|Dietary Supplement|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
79660276|NCT05585307|Drug|B/F/TAF|Administered orally
79660277|NCT05585307|Drug|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
79660278|NCT05585307|Drug|GS-1720|Administered orally
79660279|NCT05585307|Drug|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
79660280|NCT05585307|Drug|GS-6212|Administered orally
79660281|NCT05585307|Drug|Standard of Care (Substudy 03)|Antiretroviral therapy, administered orally
79986856|NCT02410096|Dietary Supplement|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
79986857|NCT01366677|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
79346861|NCT05652998|Other|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
79346862|NCT05652998|Other|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
79498769|NCT04565639|Device|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
79660282|NCT05584410|Other|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
79498770|NCT04564235|Genetic|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
79498771|NCT04564235|Genetic|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
79498772|NCT04564001|Drug|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
79660283|NCT05584410|Other|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
79660284|NCT05584410|Other|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
79986858|NCT03684122|Biological|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
79986859|NCT05188209|Drug|MRG003|Administered intravenously
79346863|NCT05362136|Procedure|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
79346864|NCT05362136|Procedure|no perforation of the sinus floor|standard procedure for sinus floor elevation
79346865|NCT05221190|Procedure|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
79346866|NCT05221190|Procedure|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
79346867|NCT04816682|Drug|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
79346868|NCT02162719|Drug|Ipatasertib|Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
79498773|NCT04564001|Drug|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
79498774|NCT04565873|Diagnostic Test|TSH|retrospective TSH level
79498775|NCT04565561|Device|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis < 30%; B. no flow limiting dissection or TIMI grade 2-3."
79498776|NCT04565405|Other|Detergent|The tracheostomy inner cannulas will be washed with detergent.
79498777|NCT04565405|Other|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
79660285|NCT05584410|Other|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
79660286|NCT05584410|Other|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
79986860|NCT03171922|Behavioral|Internet Diet|ID group have online dietary coach every 2 weeks
79986861|NCT03171922|Behavioral|Clinic Diet|CD group have every 2 weeks visit at clinic
79986862|NCT04046939|Drug|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
79986863|NCT04046939|Drug|Placebo|placebo twice daily oral dosing for up to 12 weeks
79346869|NCT02162719|Drug|Paclitaxel|Participants received paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
79346870|NCT02162719|Drug|Placebo|Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
79346871|NCT03939728|Radiation|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
79346872|NCT05652842|Behavioral|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
79346873|NCT02161549|Device|Motus Gl CleanUp System|
79346874|NCT05652530|Drug|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
79346875|NCT02189863|Device|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
79498778|NCT04565093|Procedure|iPACK|"Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA."
79660287|NCT05584410|Other|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
79660288|NCT05584410|Behavioral|Motivational notifications|Automatic and daily reminders and / or motivational notifications
79660289|NCT05584410|Other|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
79660290|NCT05582070|Other|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
79660291|NCT05580562|Drug|ONC201|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants < 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
79660292|NCT05580562|Drug|ONC201 + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants < 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
79346876|NCT02189863|Device|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
79346877|NCT02189863|Device|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
79346878|NCT02189863|Device|Comfilcon A MF|Multifocal contact lenses worn in both eyes
79660293|NCT05580562|Other|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
79660294|NCT05567250|Behavioral|Behavioral: Telephone-based ACEs care coordination|The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
79680072|NCT02930811|Drug|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
79986864|NCT05188131|Drug|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
79346879|NCT02189863|Device|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
79370790|NCT04367194|Behavioral|Neurorehabilitation|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
79370791|NCT03778515|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
79370792|NCT04355416|Drug|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
79346880|NCT04808882|Drug|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
79498779|NCT04565093|Procedure|Periarticular local infiltration analgesia (LIA)|A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
79498780|NCT04564937|Drug|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
79815265|NCT02607488|Drug|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
79346881|NCT04808882|Drug|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
79370793|NCT04355416|Procedure|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
79498781|NCT04563689|Other|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
79498782|NCT04563689|Other|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
79498783|NCT04563221|Device|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
79498784|NCT04564859|Device|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
79498785|NCT04563767|Procedure|Infinitome|Added sequence of rs-fMRI.
79498786|NCT04563299|Drug|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
79498787|NCT04563299|Drug|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
79498788|NCT04561895|Genetic|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
79660295|NCT05558241|Device|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
79660296|NCT05557370|Biological|Human Papilloma Virus vaccine (GARDASIL 9)|Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment [time 0], 2 months [+ 6 weeks], and 6 months [+ 6 weeks] per standard guidelines) prior to renal transplantation for one cohort (Group 1) and after renal transplant in the second cohort (Group 2).
79986865|NCT05188131|Drug|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
79986866|NCT03172156|Genetic|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
79498789|NCT04561583|Device|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
79660297|NCT05554159|Behavioral|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
79660298|NCT05554159|Behavioral|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
79660299|NCT05549609|Biological|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
79660300|NCT05549609|Other|Vehicle|CryoStor CS10 cryomedium
79660301|NCT05546385|Device|Partial Rebreathing Device|Partial Rebreathing Device
79346882|NCT04808882|Drug|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
79346883|NCT02189473|Radiation|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
79346884|NCT05652452|Other|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
79346885|NCT05652452|Other|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
79370794|NCT05620810|Behavioral|neuropsychiatric symptoms|neuropsychiatric symptoms
79370795|NCT04355494|Biological|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
79660302|NCT05546385|Device|Sham breathing device|Sham breathing device
79660303|NCT05544162|Dietary Supplement|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
79986867|NCT01360359|Other|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
79986868|NCT01360359|Other|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
79498790|NCT04561583|Device|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
79498791|NCT04561505|Procedure|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
79498792|NCT04561505|Procedure|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
79498793|NCT04561817|Drug|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
79346886|NCT05164796|Device|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
79346887|NCT02188849|Other|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
79346888|NCT02188849|Drug|Creatine|Creatine powder 5 g day
79498794|NCT04561817|Drug|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
79346889|NCT05164484|Device|Transpulmonary thermodilution|Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
79346890|NCT05652374|Device|Ialuril 50ml Prefill|Bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 1 year
79660304|NCT05543642|Biological|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
79660305|NCT05543642|Biological|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
79660306|NCT05543044|Behavioral|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
79660307|NCT05542238|Behavioral|One bout of moderate-intensity sub-maximal aerobic exercise|The intervention is a 20-min acute exercise using arm ergometer
79660308|NCT05540145|Drug|SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|"Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area < 1.25m2), bid, D1-8, Q2w 50mg (body surface area >1.25m2, <1.5 m2), bid, D1-8, Q2w 60mg (body surface area >1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition."
79498795|NCT04561349|Other|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
79498796|NCT04561349|Other|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
79498797|NCT04561271|Other|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
79346891|NCT05652374|Drug|Nitrofurantoin|100mg daily (1dd100mg or 2dd50mg) for 1 year. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
79986869|NCT02409940|Biological|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
79346892|NCT01636076|Drug|QMF149|delivered via Concept1 device
79346893|NCT01636076|Drug|Salmeterol|delivered via Accuhaler®
79346894|NCT01635998|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
79346895|NCT01635920|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
79498798|NCT04561271|Other|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
79498799|NCT02211833|Drug|BI 2536|
79498800|NCT02211833|Drug|Pemetrexed|
79986870|NCT01363791|Other|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
79986871|NCT02415322|Other|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
79986872|NCT03680534|Procedure|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
79660309|NCT05536960|Other|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
79986873|NCT00704782|Drug|dimebon|
79986874|NCT03676400|Other|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
79986875|NCT03676400|Other|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
79986876|NCT01360437|Drug|Prasugrel|Prasugrel 10mg/day
79986877|NCT01360437|Drug|Ticagrelor|Ticagrelor 90mg twice a day
79346896|NCT01635920|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
79346897|NCT04793984|Device|Carragelose|inhalation 3 times a day
79346898|NCT04793984|Device|NaCl|inhalation 3 times a day
79346899|NCT03029000|Drug|Tbo-filgrastim|solution for subcutaneous injection
79346900|NCT03023150|Other|Ischemic Preconditioning|
79986878|NCT04042103|Drug|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
79986879|NCT03172078|Procedure|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
79498801|NCT04562909|Device|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
79346901|NCT03023150|Other|Sham|
79986880|NCT01363869|Dietary Supplement|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
79498802|NCT04562675|Behavioral|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
79498803|NCT04562675|Other|brochure-only|brochure-only for control group (CG)
79986881|NCT01363869|Dietary Supplement|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
79986882|NCT01363869|Dietary Supplement|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
79346902|NCT03783182|Drug|Betamethason Sodium Phosphate|Glucocorticoid
79346903|NCT03783182|Drug|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
79346904|NCT03780920|Procedure|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
79346905|NCT05651984|Device|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
79498804|NCT02211443|Biological|Recombinant full human Anti-EGFR Monoclonal Antibody|
79498805|NCT04562753|Procedure|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
79498806|NCT04562753|Procedure|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
79498807|NCT04562519|Device|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
79498808|NCT02211521|Biological|PRP|3ml of PRP
79660310|NCT05525273|Drug|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
79660311|NCT05523401|Drug|4-bromo-2,5-dimethoxyphenethylamine (10 mg)|A low dose of 10 mg 2C-B will be administered.
79660312|NCT05523401|Drug|4-bromo-2,5-dimethoxyphenethylamine (20 mg)|A medium dose of 20 mg 2C-B will be administered.
79660313|NCT05523401|Drug|4-bromo-2,5-dimethoxyphenethylamine (30 mg)|A high dose of 30 mg 2C-B will be administered.
79660314|NCT05523401|Drug|3,4-methylenedioxymethamphetamine|A moderate dose of 125 mg MDMA will be administered.
79660315|NCT05523401|Drug|Psilocybin|A moderate dose of 25 mg psilocybin will be administered.
79986883|NCT03883646|Behavioral|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
79346907|NCT03760484|Drug|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
79346908|NCT03760484|Biological|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
79346909|NCT05651750|Drug|Montelukast|receiving 2 months treatment with Montelukast once a day
79346910|NCT05651750|Drug|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
79498809|NCT02211521|Drug|Hyaluronic acid|3ml hyaluronic acid
79498810|NCT01597908|Drug|Dabrafenib|Dabrafenib 150 mg twice daily orally
79498811|NCT01597908|Drug|Vemurafenib|Vemurafenib 960 mg twice daily orally
79498812|NCT01597908|Drug|Trametinib|Trametinib 2 mg once daily orally
79498813|NCT04415970|Other|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
79660316|NCT05523401|Other|Placebo|Placebo (Mannitol)
79660317|NCT05523388|Other|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
79660318|NCT05511922|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
79986884|NCT03883646|Behavioral|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
79986885|NCT03174730|Behavioral|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
79498814|NCT04415970|Other|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
79498815|NCT01951170|Drug|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
79660319|NCT05510141|Other|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
79986886|NCT03174730|Behavioral|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
79498816|NCT01951092|Other|Text messaging|
79660320|NCT05510141|Drug|Nitrous oxide|Standard procedure
79660321|NCT05502341|Drug|Bictegravir|Tablets administered orally without regard to food
79660322|NCT05502341|Drug|Lenacapavir|Tablets administered orally without regard to food
79986887|NCT03676322|Drug|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
79986888|NCT03676322|Drug|Placebo|Participants will receive placebo matched to M5049.
79346911|NCT02917460|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
79660323|NCT05502341|Drug|BIC/LEN FDC|Tablets administered orally without regard to food
79346912|NCT05651672|Drug|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
79346913|NCT02160145|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
79346914|NCT02160145|Drug|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
79346915|NCT04807478|Drug|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
79346916|NCT01696396|Drug|Abrilumab|Administered by subcutaneous injection.
79986889|NCT02409862|Drug|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
79308242|NCT02451059|Behavioral|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
79346917|NCT01696396|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
79986890|NCT02409862|Drug|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
79986891|NCT02415010|Device|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
79986892|NCT01366989|Device|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
79986893|NCT02415088|Procedure|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
79986894|NCT02415088|Procedure|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
79986895|NCT01360671|Drug|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
79680073|NCT02930811|Drug|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
79346918|NCT02836262|Device|HIT Hip Replacement System|HIT Hip Replacement System
79346919|NCT05269784|Procedure|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
79498817|NCT04640922|Device|Gedea Pessary pHyph|Vaginal tablet
79346920|NCT05269784|Procedure|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
79346921|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
79346922|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
79346923|NCT03654638|Other|Questionnaire Administration|Ancillary studies
79346924|NCT02216071|Drug|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
79346925|NCT02216071|Drug|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
79498818|NCT04640922|Device|Placebo|Vaginal tablet
79680074|NCT02947919|Behavioral|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
79346926|NCT04418570|Behavioral|cognitive remediation|
79346927|NCT04418570|Other|attendance to an Early Intervention Service for Psychosis|
79346928|NCT01681576|Drug|Valsartan|Valsartan 320mg tablet once daily
79346929|NCT01681576|Drug|LCZ696|LCZ696 400mg tablet once daily
79346930|NCT04418726|Other|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
79498819|NCT01949532|Drug|Carfilzomib|Carfilzomib was administered by IV injection.
79498820|NCT01949142|Drug|OTO-201|Single, intratympanic injection
79498821|NCT01949142|Drug|Sham|Simulated single, intratympanic injection
79498822|NCT01948908|Drug|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
79498823|NCT01925274|Drug|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
79498824|NCT01925274|Drug|irinotecan|90 minutes IV infusion of irinotecan 180mg/m^2 on days 1 and 15 of each cycle
79986896|NCT03676244|Device|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
79986897|NCT01363947|Drug|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
79986898|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
79986899|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
79346931|NCT02819960|Drug|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
79346932|NCT02819960|Drug|Placebo|Maltodextrin
79346933|NCT04552912|Behavioral|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
79346934|NCT02188459|Drug|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
79346935|NCT04793282|Behavioral|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
79346936|NCT04759183|Other|Survey Administration|Ancillary studies
79346937|NCT04759183|Procedure|Virtual Reality Game|"Participate in VR Game Angry Birds"
79346938|NCT04759183|Procedure|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
79346939|NCT02743364|Other|Laboratory Biomarker Analysis|Correlative studies
79346940|NCT02743364|Other|Placebo Administration|Given PO
79346941|NCT02743364|Other|Quality-of-Life Assessment|Ancillary studies
79498825|NCT01925274|Drug|Cetuximab|120 minute IV infusion of cetuximab 400mg/m^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
79498826|NCT01925274|Drug|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m^2 on days 1 and 15 of each cycle
79346942|NCT02743364|Other|Questionnaire Administration|Ancillary studies
79346943|NCT02743364|Drug|Simvastatin|Given PO
79346944|NCT02214121|Drug|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
79346945|NCT02214121|Drug|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
79346946|NCT01681186|Drug|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
79346947|NCT01681186|Drug|LY2940680 Tablet (Test)|Administered orally as a tablet
79346948|NCT01681186|Drug|Lansoprazole|Administered orally as a capsule
79346949|NCT01681186|Drug|Placebo Capsule(s)|Administered orally as a capsule(s)
79346950|NCT03597464|Drug|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
79346951|NCT03597464|Drug|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
79986900|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
79986901|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
79986902|NCT05554068|Drug|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
79986903|NCT03680378|Drug|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
79986904|NCT01319331|Drug|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
79346952|NCT01695772|Drug|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
79346953|NCT01695772|Drug|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
79346954|NCT02159521|Device|EkoSonic® Endovascular System|
79346955|NCT02159521|Biological|Alteplase|Recombinant tissue plasminogen activator
79346956|NCT01636934|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
79346957|NCT01636934|Other|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
79346958|NCT01636934|Behavioral|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
79346959|NCT01712854|Drug|Budesonide|budesonide 80 mcg
79498827|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
79498828|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
79498829|NCT01972464|Drug|Progesterone|oral micronized progesterone
79498830|NCT01972464|Drug|Placebo|
79498831|NCT01948050|Device|non-invasive transcranial direct current stimulation (tDCS)|
79498832|NCT01947894|Other|Non Interventional Study|Non Interventional Study
79498833|NCT01947582|Device|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
79498834|NCT01924806|Device|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
79498835|NCT01924806|Device|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
79498836|NCT01924182|Device|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
79498837|NCT01924182|Other|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
79660324|NCT05502341|Drug|Stable Baseline Regimen|"SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~Nucleos(t)ide Reverse Transcriptase Inhibitors:~Abacavir~Emtricitabine~Lamivudine~Tenofovir alafenamide~Tenofovir disoproxil fumarate~Zidovudine~Non-Nucleosite Reverse Transcriptase Inhibitors:~Delavirdine~Efavirenz~Nevirapine~Rilpivirine~Doravirine~Integrase Inhibitors:~Bictegravir~Cabotegravir~Dolutegravir~Elvitegravir~Raltegravir~Protease Inhibitors:~Atazanavir~Darunavir~Fosamprenavir~Indinavir~Lopinavir~Nelfinavir~Saquinavir~Tipranavir~Chemokine Co-receptor 5 (CCR5) Antagonist:~Maraviroc~Fusion Inhibitors:~Enfuvirtide~gp120 Attachment Inhibitor:~Fostemsavir~Anti-CD4 Monoclonal Antibodies:~Ibalizumab-uiyk"
79660325|NCT05499013|Drug|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
79660326|NCT05499013|Drug|Placebo|sodium chloride, solution for injection
79498838|NCT01972308|Behavioral|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
79498839|NCT01972308|Behavioral|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
79346960|NCT01712854|Drug|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
79346961|NCT01693120|Device|Medtronic Phased RF Ablation System|Phased RF ablation
79346962|NCT02986594|Drug|Aspirin|
79346963|NCT02986594|Drug|Heparin|
79346964|NCT02159365|Drug|Elotuzumab|
79346965|NCT02159365|Drug|Lenalidomide|
79346966|NCT02159365|Drug|Dexamethasone|
79346967|NCT01712074|Drug|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
79346968|NCT01712074|Other|Placebo|Placebo QD
79346969|NCT02072200|Drug|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
79346970|NCT04767724|Device|Extracorporeal shock wave|Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
79370796|NCT02982460|Other|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
79370797|NCT02982460|Other|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
79346971|NCT01692730|Behavioral|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
79308243|NCT02504255|Biological|Biological samplings|Blood, urine and faecal sampling every 3 months
79346972|NCT01692730|Behavioral|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
79346973|NCT01691794|Drug|Atazanavir|
79346974|NCT01691794|Drug|Ritonavir|
79498840|NCT01946880|Drug|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
79498841|NCT01946880|Drug|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
79498842|NCT01946880|Drug|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
79498843|NCT01972152|Drug|G-Pen(TM) 1 mg|
79498844|NCT01972152|Drug|Lilly Glucagon(TM) 1 mg|
79308244|NCT02504255|Other|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
79346975|NCT01710514|Drug|FE 999913 vaginal tablet|
79346976|NCT01592344|Device|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 100-250 µsec~Pulse Rate: 50-100 Hz~Intensity: 0-30mA Time Settings~Constant Stim: On~Total Time: 6 hour"
79346977|NCT01592344|Device|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 200 µsec~Pulse Rate: 1 Hz~Intensity: 0 mA Time Settings~Constant Stim: On~Total Time: 6 hour"
79498845|NCT01972152|Drug|G-Pen(TM) 0.5 mg|
79498846|NCT01972074|Drug|Memantine|Capsule
79498847|NCT01972074|Other|Placebo|Capsule
79498848|NCT01970982|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
79498849|NCT01970982|Other|Smoking abstinence (SA)|SA for 5 days in confinement
79498850|NCT01970982|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
79660327|NCT05498181|Drug|Sacubitril-valsartan|sacubitril/valsartan
79498851|NCT01946802|Device|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
79498852|NCT01618266|Drug|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
79660328|NCT05498181|Drug|Placebo|Placebo
79660329|NCT05458141|Behavioral|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
79346978|NCT01636778|Drug|SB-497115-GR|TPO receptor agonist to increase platelet count
79346979|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
79346980|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
79346981|NCT02159053|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
79346982|NCT02158975|Drug|MLN9708|
79498853|NCT01919112|Device|tDCS|Anodal tDCS will be administered with swallowing exercises
79498854|NCT01918332|Drug|Valsartan 160mg|
79498855|NCT01918332|Drug|Rosuvastatin 20mg|
79498856|NCT01918332|Drug|Valsartan 160mg placebo|
79815266|NCT02607488|Drug|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
79498857|NCT01918332|Drug|Rosuvastatin 20mg placebo|
79498858|NCT04628832|Behavioral|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
79498859|NCT04628832|Behavioral|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
79986905|NCT04913298|Device|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
79346983|NCT02158663|Device|Repetitive Transcranial Magnetic Stimulation|TMS Device
79498860|NCT04628832|Behavioral|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
79498861|NCT01922934|Behavioral|Commercial weight loss program|vouchers for Weight Watchers
79498862|NCT01922934|Behavioral|Colorado Weigh|Group behavioral weight loss program
79346984|NCT04804982|Other|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
79346985|NCT04804124|Behavioral|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
79346986|NCT02158039|Drug|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
79346987|NCT02158039|Drug|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
79498863|NCT01922934|Dietary Supplement|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
79498864|NCT01922934|Drug|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
79498865|NCT01922934|Behavioral|Recreation center passes|1 year pass to a Denver recreation center
79498866|NCT01970592|Behavioral|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
79498867|NCT01921140|Drug|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
79498868|NCT01921140|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
79498869|NCT01921140|Other|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
79498870|NCT01921140|Other|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
79498871|NCT01920594|Drug|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
79498872|NCT01920594|Drug|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
79815267|NCT00914498|Drug|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
79346988|NCT05261282|Behavioral|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
79498873|NCT01917084|Other|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
79498874|NCT01917006|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
79498875|NCT01917006|Drug|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
79498876|NCT04625790|Device|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
79498877|NCT04625790|Other|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
79498878|NCT01916304|Drug|Levothyroxine sodium new formulation|Levothyroxine tablets
79815268|NCT02558582|Behavioral|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
79986906|NCT02406352|Device|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
79498879|NCT01916226|Drug|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
79346989|NCT03563222|Drug|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
79346990|NCT03563222|Drug|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
79346991|NCT05239364|Procedure|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
79498880|NCT01916226|Drug|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
79498881|NCT01916226|Drug|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
79498882|NCT01916226|Drug|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
79498883|NCT01969500|Behavioral|Mobile Application|
79498884|NCT01969500|Behavioral|Treatment as Usual (TAU)|
79498885|NCT05120154|Other|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
79498886|NCT05120154|Behavioral|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
79498887|NCT01915914|Drug|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
79498888|NCT01919970|Other|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
79660330|NCT05456620|Other|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
79498889|NCT01919970|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
79498890|NCT01919814|Dietary Supplement|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
79308245|NCT02504177|Drug|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
79346992|NCT04812392|Device|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
79498891|NCT01919814|Other|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
79498892|NCT01968954|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
79498893|NCT01968954|Other|Placebo|subcutaneous injection, every 2 weeks for 12 months
79498894|NCT01919190|Drug|EXPAREL|TAP with EXPAREL
79660331|NCT05456620|Other|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~Education: general information on load management, the importance of active exercise therapy and setting expectations.~No orthotic treatment.~Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
79660332|NCT05453539|Drug|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
79660333|NCT05444946|Drug|Prednisone tablet and Itraconazole|Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
79660334|NCT05444946|Drug|Oral itraconazole|Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
79660335|NCT05442047|Drug|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
79660336|NCT05442047|Drug|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
79660337|NCT05436353|Other|Turkish validity and reliability|Contact with developers and formation of steering committee Translation from English to Turkish Back translation from Turkish to English Comparison of translation Review of translated versions. Reaching consensus and development of pilot version Testing in clinical setting Revision of pilot version Testing of final version
79660338|NCT05419375|Other|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
79660339|NCT05419011|Biological|Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5|Given SC
79660340|NCT05419011|Procedure|Biopsy|Undergo biopsy
79308246|NCT02504177|Drug|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
79346993|NCT02490800|Drug|Oral daily administration of BAL101553|oral administration
79346994|NCT01635764|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79346995|NCT05609162|Procedure|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
79308247|NCT02450981|Drug|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
79308248|NCT02504021|Behavioral|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
79346996|NCT05578430|Drug|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
79346997|NCT05578430|Procedure|TACE|TACE will be performed per institutional standard of care.
79660341|NCT05419011|Procedure|Biospecimen Collection|Undergo blood sample collection
79660342|NCT05419011|Procedure|Colonoscopy|Undergo SOC colonoscopy
79660343|NCT05419011|Drug|Nogapendekin Alfa|Given nogapendekin alfa inbakicept (N-803) SC
79660344|NCT05419011|Drug|Placebo Administration|Given SC
79660345|NCT05419011|Other|Questionnaire Administration|Ancillary studies
79660346|NCT05413642|Drug|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
79660347|NCT05413642|Drug|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
79346998|NCT05578430|Procedure|Surgery|Surgery will be performed per institutional standard of care.
79346999|NCT03432260|Drug|DUR-928 30 mg|Lowest dose of 3 dose escalation arms.
79347000|NCT03432260|Drug|DUR-928 90 mg|Middle dose of 3 dose escalation arms.
79347001|NCT03432260|Drug|DUR-928 150 mg|Highest dose of 3 dose escalation arms.
79498895|NCT01919190|Drug|Placebo|Placebo
79498896|NCT01620060|Drug|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
79347002|NCT04790162|Behavioral|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
79986907|NCT02409628|Device|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
79347003|NCT03397628|Other|FIFA 11 for health|
79498897|NCT04615182|Device|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
79498898|NCT01914666|Drug|Duloxetine|Administered orally
79498899|NCT01913340|Drug|Erythropoietin|1000 U/kg/dose IV x 5 doses
79498900|NCT01913340|Drug|Normal saline|placebo: NS IV x 5 doses
79498901|NCT01864200|Biological|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
79498902|NCT01864200|Biological|Placebo|Saline placebo
79660348|NCT05407025|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
79986908|NCT03676166|Drug|Cannabis|Inhaled cannabis
79347004|NCT05474456|Other|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
79347005|NCT05474456|Other|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
79347006|NCT03342014|Device|Ultrasound|3DPD and UAD acquisitions (10 min)
79347007|NCT03342014|Biological|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
79347008|NCT05228444|Behavioral|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
79347009|NCT01634360|Drug|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
79498903|NCT01912872|Drug|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
79498904|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
79498905|NCT01912872|Drug|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
79498906|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
79660349|NCT05407025|Other|Questionnaire Administration|Complete risk factor questionnaire
79660350|NCT05406739|Other|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute [60 kcal]; 2 slices of bread [120 kcal] with 30 g strawberry jam [75 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute [120 kcal]; 4 slices of bread [240 kcal] with 60 g strawberry jam [150 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
79660351|NCT05403580|Drug|Olanzapine|Given PO
79986909|NCT02406118|Procedure|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
79986910|NCT03101514|Drug|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
79986911|NCT03101514|Drug|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
79347010|NCT04810598|Drug|Venetoclax|Oral Tablet
79347011|NCT04570280|Other|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
79347012|NCT04570280|Other|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
79498907|NCT01912872|Drug|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
79498908|NCT01912404|Drug|IDN-6556|25 mg BID for 28 days
79498909|NCT01912404|Drug|Placebo|Placebo controlled
79498910|NCT01911780|Drug|placebo|placebo matching amlodipine capsule
79498911|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
79498912|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
79498913|NCT01911780|Drug|amlodipine|capsule
79660352|NCT05403580|Drug|Placebo Administration|Given PO
79660353|NCT05403580|Other|Questionnaire Administration|Ancillary studies
79660354|NCT05402293|Diagnostic Test|Blood samples to measure lidocaine levels|Blood sampling is the only intervention Plasma samples will then be analyzed for lidocaine concentration
79986912|NCT02406040|Other|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
79986913|NCT02405884|Other|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
79986914|NCT02405728|Device|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
79347013|NCT04570280|Other|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
79347014|NCT04788758|Other|Educational Intervention|Receive G8 screening tool administration training
79347015|NCT04788758|Other|Screening Questionnaire Administration|Complete G8 screening tool
79347016|NCT04788758|Other|Referral|Receive referral
79347017|NCT04788758|Other|Questionnaire Administration|Ancillary studies
79986915|NCT02405728|Device|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
79498914|NCT01911546|Drug|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
79498915|NCT01910298|Procedure|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
79498916|NCT01910298|Procedure|Two Stage Breast Reconstruction|
79498917|NCT01909674|Device|Switch CPAP mask type|
79347018|NCT02158052|Drug|Tacrolimus|Tacrolimus starting on Day -1
79347019|NCT02158052|Drug|Equine Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
79347020|NCT02158052|Procedure|Kidney transplant from a related donor|On Day 0 the renal transplant is performed according to standard surgical techniques.
79347021|NCT02158052|Drug|Bone marrow transplant from a related donor|Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
79347022|NCT02158052|Radiation|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
79347023|NCT01635218|Drug|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
79498918|NCT05114694|Procedure|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
79370798|NCT03777735|Procedure|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
79498919|NCT05114694|Procedure|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
79498920|NCT01908816|Drug|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
79498921|NCT01908582|Drug|Evacetrapib|Administered orally
79498922|NCT01908582|Drug|Rifampin|Administered orally
79498923|NCT01908426|Drug|Cabozantinib tablets|
79498924|NCT01908426|Drug|Placebo tablets|
79498925|NCT01907100|Drug|Nintedanib|triple kinase inhibitor; 200mg starting dose
79498926|NCT01907100|Drug|Pemetrexed|backbone chemo
79660355|NCT05389189|Behavioral|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
79815269|NCT02558582|Behavioral|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
79498927|NCT01907100|Drug|Cisplatin|backbone chemo
79498928|NCT01907100|Drug|Cisplatin|backbone chemo
79347024|NCT01635218|Drug|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
79498929|NCT01907100|Drug|Pemetrexed|backbone chemo
79498930|NCT01907100|Drug|Placebo|Nintedanib matching placebo
79498931|NCT01889862|Drug|BMN165 20mg/day|BMN165 20mg/day self-administered daily
79660356|NCT05386394|Device|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
79347025|NCT01635218|Drug|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
79347026|NCT05189600|Device|Mechnical Insufflation:Exsufflation|Cough Augmentation device
79347027|NCT05351684|Drug|Dolutegravir 50 MG|already included in arm/group descriptions.
79660357|NCT05386394|Device|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
79660358|NCT05384119|Drug|TTI-101|Oral tablet
79660359|NCT05384119|Drug|Palbociclib|Oral capsule
79660360|NCT05384119|Drug|Aromatase inhibitor (AI)|Oral tablet
79660361|NCT05384119|Drug|fulvestrant|Oral tablet
79660362|NCT05384119|Drug|ribociclib|Oral tablet
79347028|NCT02049866|Drug|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
79347029|NCT05185856|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
79347030|NCT05185856|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
79347031|NCT04307186|Drug|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
79660366|NCT05379179|Drug|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
79986916|NCT04897698|Dietary Supplement|LB001|Probiotics
79347032|NCT04307186|Drug|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
79347033|NCT04297826|Behavioral|Harvest for Health|Please see previous description
79370799|NCT04355260|Procedure|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
79370800|NCT04347304|Dietary Supplement|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
79498932|NCT01889862|Drug|BMN165 40mg/day|BMN165 40mg/day self-administered daily
79498933|NCT01889862|Drug|Placebo|Non-drug placebo, self-administered daily
79498934|NCT01887912|Biological|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
79498935|NCT01887912|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
79498936|NCT04415346|Biological|HU-014 Inj|Clostridium botulinum type A
79498937|NCT01887678|Drug|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
79498938|NCT01887678|Drug|Placebo|Placebo is an injection of Saline
79660367|NCT05379179|Drug|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
79347034|NCT04274894|Drug|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
79986917|NCT02702518|Drug|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
79986918|NCT02702518|Drug|Vehicle|Drug vehicle 4 times a day for 8 weeks
79347035|NCT04786964|Drug|Cosibelimab|IV infusion
79347036|NCT04786964|Drug|Cisplatin|IV infusion
79986919|NCT04935060|Behavioral|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
79986920|NCT04935060|Behavioral|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
79986921|NCT04482946|Diagnostic Test|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
79986922|NCT03683888|Behavioral|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
79347037|NCT04786964|Drug|Carboplatin|IV infusion
79986923|NCT03683888|Behavioral|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
79986924|NCT03683732|Behavioral|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
79986925|NCT03739229|Biological|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
79347038|NCT04786964|Drug|Pemetrexed|IV infusion
79347039|NCT04786964|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
79347040|NCT04786964|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
79347041|NCT04786964|Drug|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
79347042|NCT05177120|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
79347043|NCT05177120|Other|Short form-36|Standardized questionnaire to investigate the quality of life in patients
79347044|NCT05177120|Other|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
79347045|NCT05177120|Other|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
79986926|NCT03739229|Biological|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
79986927|NCT03683654|Other|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
79986928|NCT03680300|Other|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
79498939|NCT01887600|Drug|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
79660368|NCT05378997|Drug|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
79660369|NCT05378997|Drug|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
79986929|NCT03680300|Other|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
79986930|NCT03680300|Other|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
79986931|NCT02414620|Device|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
79986932|NCT03680222|Procedure|Reversed Tracking Method|Reversed Tracking Method
79986933|NCT02414542|Device|MINIMA stem|
79347046|NCT05177120|Other|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
79660370|NCT05378997|Drug|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
79347047|NCT05177120|Diagnostic Test|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
79347048|NCT05177120|Other|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
79347049|NCT02213263|Biological|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
79347050|NCT02213263|Biological|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
79347051|NCT04781036|Drug|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 1 month.
79347052|NCT05190068|Drug|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
79660371|NCT05373537|Behavioral|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
79660372|NCT05370508|Combination Product|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS
79347053|NCT04216784|Drug|Furosemide Injection|Patient will receive furosemide intravenously
79347054|NCT04216784|Drug|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
79347055|NCT02211313|Device|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
79347056|NCT04801472|Other|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
79347057|NCT01975064|Drug|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
79347058|NCT01975064|Drug|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
79347059|NCT05051696|Drug|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
79347060|NCT04025138|Other|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~Voluntary maximum forces plantar flexors and knee extensors~Electrically evoked forces~ElectroMyoGraphic activity (EMG)~Three-Modality Evoked Potentials (TMEPs)"
79498940|NCT01887600|Drug|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
79498941|NCT01887288|Drug|Capecitabine|650 mg/m^2 PO b.i.d.
79498942|NCT01887288|Drug|Digoxin|0.25 mg once daily
79498943|NCT01887210|Behavioral|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
79660373|NCT05366166|Biological|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
79660374|NCT05366166|Drug|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
79660375|NCT05366166|Drug|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
79660376|NCT05366166|Radiation|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
79498944|NCT01887210|Behavioral|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
79660377|NCT05363462|Drug|Vancomycin 1000 MG|Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
79660378|NCT05355272|Drug|Recombinant human growth hormone|recombinant human growth hormone (rhGH)
79660379|NCT05353985|Drug|TAK-062|TAK-062 tablets.
79660380|NCT05353985|Dietary Supplement|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar|SIGE gluten bars.
79660381|NCT05353985|Drug|TAK-062 Placebo|TAK-062 placebo-matching tablets.
79660382|NCT05353985|Dietary Supplement|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar|SIGE gluten-free bars.
79498945|NCT03405714|Drug|Brivaracetam|"Pharmaceutical form: Solution for iv injection~Route of administration: intravenous use~Concentration: 10 mg/ml"
79986934|NCT03176524|Drug|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
79498946|NCT01885182|Drug|Oxycodone/Naloxone|
79498947|NCT01885182|Drug|Oxycodone|
79498948|NCT01885104|Drug|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
79498949|NCT01885104|Drug|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
79498950|NCT01885104|Drug|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
79498951|NCT04613232|Device|Wearable sensor|The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
79660383|NCT05348577|Drug|capivasertib|"320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment."
79986935|NCT03176524|Drug|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
79347061|NCT04025138|Device|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
79347062|NCT04025138|Other|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
79347063|NCT04025138|Other|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
79347064|NCT04025138|Biological|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
79347065|NCT04025138|Biological|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
79347066|NCT02210689|Drug|clindamycin phosphate vaginal cream 2%|
79347067|NCT02210689|Other|placebo|vehicle used as placebo
79347068|NCT04780178|Behavioral|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
79347069|NCT04779710|Other|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
79347070|NCT02209597|Drug|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
79370801|NCT04347304|Dietary Supplement|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
79498952|NCT04612374|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
79498953|NCT04612374|Behavioral|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
79986936|NCT03176524|Drug|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
79986937|NCT03676088|Procedure|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
79986938|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
79498954|NCT01881750|Behavioral|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
79498955|NCT01881750|Behavioral|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
79498956|NCT01906008|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
79660384|NCT05348577|Drug|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
79815270|NCT00914030|Other|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
79347071|NCT04418492|Behavioral|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
79986939|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
79986940|NCT02414464|Other|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
79986941|NCT02961582|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
79986942|NCT02961582|Other|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
79347072|NCT01469156|Drug|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
79347073|NCT04191434|Drug|Flamboyant 125/12|Flamboyant 125/12 capsule
79347074|NCT04191434|Drug|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
79660385|NCT05348577|Other|placebo|matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
79660386|NCT05348577|Drug|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
79815271|NCT02605850|Other|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
79815272|NCT02605850|Dietary Supplement|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
79815273|NCT02605850|Dietary Supplement|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
79815274|NCT05754320|Device|Tension band wire fixation|Tension band wire fixation
79347075|NCT04191434|Other|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
79347076|NCT04191434|Other|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
79347077|NCT03849716|Other|Blood sample|Blood samples obtained for biomarker analyses
79347078|NCT03849716|Other|Cheek swab|Cheek swab obtained for genetic analysis
79815275|NCT05754320|Device|Plate fixation|Tension band wire fixation
79815276|NCT00751881|Drug|Placebo|"Film-coated tablet~Oral administration"
79815277|NCT00751881|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
79498957|NCT01906008|Drug|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
79986943|NCT04039503|Drug|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
79986944|NCT04039503|Drug|Placebo|Administered SC as add-on to the pre-trial background medication.
79986945|NCT02414308|Drug|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
79986946|NCT02860728|Behavioral|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
79986947|NCT03679910|Diagnostic Test|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
79986948|NCT03679910|Diagnostic Test|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
79308249|NCT02451215|Device|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
79347079|NCT03835676|Drug|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~CMR will be performed at 6 monthly intervals for 2 years.~Peak power output at 6,12, 18 and 24 month~Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
79347080|NCT04192760|Procedure|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
79347081|NCT00909740|Drug|MEGF0444A|Intravenous escalating dose
79347082|NCT04783532|Behavioral|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
79347083|NCT04779008|Other|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
79347084|NCT02188303|Drug|LY2944876|Administered SC
79347085|NCT02188303|Drug|Placebo|Administered SC
79347086|NCT03651128|Biological|bb2121|bb2121
79347087|NCT03651128|Drug|Daratumumab|Daratumumab
79347088|NCT03651128|Drug|Pomalidomide|Pomalidomide
79347089|NCT03651128|Drug|Dexamethasone|Dexamethasone
79347090|NCT03651128|Drug|Bortezomib|Bortezomib
79347091|NCT03651128|Drug|Ixazomib|Ixazomib
79347092|NCT03651128|Drug|Lenalidomide|Lenalidomide
79347093|NCT03651128|Drug|Carfilzomib|Carfilzomib
79347094|NCT03651128|Drug|Elotuzumab|Elotuzumab
79347095|NCT00664898|Drug|bortezomib|Escalating intravenous repeating dose
79498958|NCT01906008|Behavioral|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
79986949|NCT05418114|Drug|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
79986950|NCT03683420|Behavioral|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
79347096|NCT00664898|Drug|SGN-40|Escalating intravenous repeating dose
79347097|NCT04867382|Behavioral|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
79347098|NCT04418336|Procedure|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
79347099|NCT04850300|Procedure|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
79347100|NCT04850300|Procedure|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
79347101|NCT04776980|Diagnostic Test|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
79347102|NCT02187055|Drug|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
79347103|NCT02187055|Drug|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
79498959|NCT01906008|Behavioral|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
79815278|NCT00747474|Drug|Lipotecan|Lipotecan IV day 1, 8, 15
79986951|NCT03683264|Other|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
79660387|NCT05342883|Device|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
79986952|NCT01364025|Procedure|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
79986953|NCT03225716|Drug|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
79986954|NCT03225716|Drug|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
79986955|NCT03672812|Drug|Liraglutide|liraglutide 3mg 6/6 hours
79815279|NCT04091802|Procedure|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
79986956|NCT05417880|Drug|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
79986957|NCT05417880|Drug|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
79815280|NCT02598570|Drug|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
79986958|NCT05417880|Drug|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
79986959|NCT05186883|Biological|Allogenic parathyroid cells|Allogenic parathyroid cells
79986960|NCT05186883|Other|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
79347104|NCT02187055|Biological|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
79347105|NCT00119366|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
79498960|NCT01863732|Biological|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
79498961|NCT01863732|Other|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
79498962|NCT01905540|Drug|SSP-004184AQ|Magnesium salt
79347106|NCT00119366|Drug|fludarabine phosphate|Given IV
79347107|NCT00119366|Radiation|total-body irradiation|Undergo TBI
79347108|NCT00119366|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
79347109|NCT00119366|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
79347110|NCT00119366|Drug|cyclosporine|Given IV or PO
79347111|NCT00119366|Drug|mycophenolate mofetil|Given PO
79347112|NCT00119366|Other|laboratory biomarker analysis|Correlative studies
79498963|NCT01905540|Drug|SSP-004184SS|Disodium salt
79498964|NCT01904760|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
79498965|NCT01904760|Drug|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
79986961|NCT05007652|Drug|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
79986962|NCT05007652|Drug|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
79986963|NCT03675932|Other|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
79986964|NCT01367145|Drug|OMACOR|4 capsules OMACOR 1g per day
79498966|NCT01904604|Biological|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
79498967|NCT01904604|Biological|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
79498968|NCT01904604|Biological|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
79660388|NCT05335421|Behavioral|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
79660389|NCT05333978|Device|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
79347113|NCT02246660|Drug|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
79347114|NCT02246660|Drug|Placebo|Placebo will be taken orally for 6 months.
79370802|NCT00928720|Device|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
79370803|NCT00928720|Device|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
79498969|NCT01904058|Drug|LUM001|
79498970|NCT01904058|Drug|Placebo|
79498971|NCT01904058|Drug|Ursodeoxycholic Acid|
79498972|NCT01881126|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
79498973|NCT01881126|Drug|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
79498974|NCT01881126|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
79498975|NCT01881126|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
79660390|NCT05333978|Procedure|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
79986965|NCT01367145|Drug|Placebo|4 capsules placebo per day
79986966|NCT03679754|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
79986967|NCT03679754|Drug|veledimex|"20mg/day~15 oral daily doses of veledimex"
79986968|NCT02405572|Other|infant formula|infant formulas
79986969|NCT01319409|Procedure|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
79986970|NCT01319409|Procedure|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
79986971|NCT02405806|Dietary Supplement|low carbohydrate food|low carbohydrate food
79347115|NCT04750447|Device|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
79347116|NCT03475550|Other|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
79347117|NCT02246582|Device|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen & arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
79347118|NCT02246582|Device|Guardian Mobile App|
79347119|NCT02246582|Device|640G Insulin Pump|
79660391|NCT05332366|Drug|Delgocitinib cream|Cream for topical application
79660392|NCT05332366|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
79498976|NCT03357588|Other|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
79660393|NCT05329350|Device|muscular ventricular septal defects|intervention cardiology and structural heart disease, including transseptal puncture.
79660394|NCT05329194|Drug|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab.
79660395|NCT05327803|Drug|Epetraborole|500 mg taken orally QD
79660396|NCT05327803|Drug|Placebo|Placebo taken orally QD
79660397|NCT05301140|Device|Vivistim System|VNS Paired with rehabilitation movements
79986972|NCT02405806|Dietary Supplement|standard food|standard food
79986973|NCT03632772|Drug|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
79986974|NCT03632772|Drug|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
79498977|NCT03357588|Other|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
79498978|NCT01614600|Device|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
79498979|NCT04611672|Diagnostic Test|Assessment of CA|As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
79498980|NCT04611672|Diagnostic Test|Assesment of CA only|Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
79498981|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
79498982|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
79347121|NCT02137369|Drug|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
79347122|NCT02137369|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
79660400|NCT05287451|Other|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
79660401|NCT05287451|Other|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
79347123|NCT02137369|Other|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
79347124|NCT02155309|Drug|Scopolamine|
79660402|NCT05287451|Other|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
79347125|NCT02155309|Drug|Placebo|
79347126|NCT02186821|Drug|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
79347127|NCT01710358|Drug|Adalimumab|Administered SC
79347128|NCT01710358|Drug|Baricitinib|Administered orally
79347129|NCT01710358|Drug|Methotrexate|Administered orally
79347130|NCT01710358|Drug|Adalimumab Placebo|Adalimumab placebo administered SC.
79347131|NCT01710358|Drug|Baricitinib Placebo|Baricitinib placebo administered orally.
79347132|NCT01633112|Drug|fingolimod|capsule
79347133|NCT01633112|Drug|glatiramer acetate|subcutaneous injection
79347134|NCT03455270|Drug|G1T48|oral SERD
79347135|NCT03455270|Drug|Palbociclib|CDK 4/6 Inhibitor
79986975|NCT01360749|Drug|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
79986976|NCT01360749|Drug|Placebo|Placebo dose: 2 g for 10 cm2.
79986977|NCT02960516|Device|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
79347136|NCT01691482|Drug|Albuterol/salbutamol|Albuterol/salbutamol (daily)
79347137|NCT01691482|Drug|Ipratropium|Ipratropium (daily)
79347138|NCT04776044|Drug|ATR-002|150mg tablets for oral intake
79347139|NCT04776044|Drug|Placebo|matching tablets for oral intake
79347140|NCT02246114|Device|piCO+ Smokerlyzer® monitor|
79347141|NCT02246114|Other|Text messages|
79347142|NCT01710046|Drug|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
79347143|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
79347144|NCT01710046|Drug|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
79347145|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
79347146|NCT03267758|Dietary Supplement|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
79347147|NCT03267758|Dietary Supplement|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
79347148|NCT04633616|Other|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
79370804|NCT00934024|Drug|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
79498983|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
79986978|NCT01367223|Dietary Supplement|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
79347149|NCT04633616|Other|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
79498984|NCT01880424|Drug|Placebo|matching Placebo Capsules, Oral, once daily
79498985|NCT01880424|Drug|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
79660403|NCT05286801|Biological|Atezolizumab|Given IV
79660404|NCT05286801|Procedure|Biospecimen Collection|Undergo blood sample collection
79347150|NCT02154529|Drug|Tesevatinib|
79660405|NCT05286801|Procedure|Computed Tomography|Undergo CT and/or PET-CT
79347151|NCT02154529|Drug|Trastuzumab|
79347152|NCT01954017|Biological|STP206|Live Biotherapeutic
79347153|NCT01954017|Other|Control|Sterile Water
79347154|NCT02154139|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
79347155|NCT02245568|Drug|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
79347156|NCT02154061|Drug|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
79347157|NCT02154061|Drug|Metronidazole|This is a standard antibiotic
79498986|NCT01862874|Biological|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
79498987|NCT01862874|Biological|Placebo|Formulated with AAHS adjuvant
79498988|NCT01879722|Drug|TAK-063|TAK-063 tablets
79498989|NCT01879722|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
79498990|NCT01879410|Drug|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
79660406|NCT05286801|Other|Fludeoxyglucose F-18|Given FDG
79660407|NCT05286801|Procedure|Magnetic Resonance Imaging|Undergo MRI
79986979|NCT01367223|Dietary Supplement|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
79347158|NCT02154061|Drug|Neomycin|This is a standard antibiotic.
79347159|NCT02154061|Drug|Vancomycin|This is a standard antibiotic.
79370805|NCT04360954|Diagnostic Test|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
79986980|NCT03171766|Diagnostic Test|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
79986981|NCT03171766|Diagnostic Test|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
79370806|NCT04361032|Drug|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
79498991|NCT01879410|Drug|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
79498992|NCT01879410|Drug|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
79498993|NCT01879410|Drug|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
79660408|NCT05286801|Procedure|Positron Emission Tomography|Undergo PET-CT and/or FDG-PET
79660409|NCT05286801|Biological|Tiragolumab|Given IV
79660410|NCT05286801|Procedure|X-Ray Imaging|Undergo x-rays
79660411|NCT05283304|Drug|Buprenorphine injection (BUP-Inj)|Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
79660412|NCT05283304|Other|Placebo injection|Sublingual buprenorphine induction, then Placebo injectable (300 mg)
79660413|NCT05281328|Drug|CAM2029|SC injection using a pre-filled pen
79347160|NCT01907217|Device|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
79347161|NCT01907217|Drug|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
79347162|NCT01907217|Drug|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
79347163|NCT01953783|Drug|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
79347164|NCT04416009|Device|NİCaS|whole body bioimpedence method
79347165|NCT02134015|Drug|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
79347166|NCT02134015|Drug|Erlotinib|Oral erlotinib 150 mg/day
79347167|NCT02134015|Drug|Placebo|Placebo infusion every 3 weeks
79660414|NCT05281328|Drug|Placebo|SC injection using a pre-filled pen
79347168|NCT04411485|Other|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
79347169|NCT04619979|Procedure|patients undergoing gynecological surgery under general anesthesia|patients undergoing gynecological surgery under general anesthesia
79347170|NCT01924845|Drug|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
79347171|NCT01630135|Drug|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
79347172|NCT01630135|Drug|Placebo|Placebo, intranasal, 2 weeks
79347173|NCT01691248|Drug|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
79347174|NCT01691248|Drug|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
79347175|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
79498994|NCT05114148|Device|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
79498995|NCT01903434|Drug|Evacetrapib|Administered orally
79498996|NCT01903356|Drug|Trajenta duo|Linagliptin and Metformin
79498997|NCT01862796|Behavioral|Underfeeding diet|Heart healthy diet with 35% reduced calories
79660415|NCT05278039|Behavioral|Respiratory-Swallow Phase Training|Participants will complete 6 respiratory-swallow phase training sessions that will last approximately one hour.
79660416|NCT05278039|Other|Swallow Practice|"Participants will complete 6 swallow practice sessions that will last approximately one hour."
79498998|NCT01862796|Behavioral|Weight maintaining diet|Heart healthy weight-maintaining diet
79660417|NCT05271630|Other|Autologous Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
79660418|NCT05271630|Drug|Immunomodulatory Agent|ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
79498999|NCT01878084|Other|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
79986982|NCT03171766|Diagnostic Test|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
79347176|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
79499000|NCT01878084|Other|empty extraction socket|Extraction socket will be left empty
79660419|NCT05271630|Drug|Proteasome Inhibitor|ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
79986983|NCT03171532|Procedure|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
79660420|NCT05270733|Drug|Ustekinumab|Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
79660421|NCT05270057|Drug|Etoposide|Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
79660422|NCT05270057|Drug|Doxorubicin|Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
79660423|NCT05270057|Drug|Cyclophosphamide|Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
79986984|NCT03672656|Device|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
79986985|NCT03672656|Device|conventional laser|conventional laser multiple-session treatment
79986986|NCT03675854|Drug|Cefazolin|3 weeks
79986987|NCT03672578|Other|loss-frame|loss frame label
79347177|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
79347178|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
79347179|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
79347180|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
79347181|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
79347182|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
79347183|NCT01691092|Drug|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
79499001|NCT01862640|Drug|Brexpiprazole, OPC-34712|Once-daily, tablets
79499002|NCT01862640|Drug|Placebo Oral Tablet|Once-daily, tablets
79499003|NCT01902966|Drug|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
79499004|NCT01902966|Behavioral|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
79499005|NCT01902966|Behavioral|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
79499006|NCT01902966|Behavioral|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
79660424|NCT05270057|Drug|Rituximab|Level -2 through level 7: 375 mg/m^2
79660425|NCT05270057|Drug|Vincristine|Level -2 through level 7: 0.4 mg/m^2/day
79660426|NCT05270057|Drug|Prednisone|Level -2 through level 7: 60 mg/m^2/twice daily (BID)
79660427|NCT05270057|Drug|Loncastuximab Tesirine 0.075 mg/kg by IV|Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
79660428|NCT05270057|Drug|Loncastuximab tesirine 0.12 mg/kg by IV|Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
79660429|NCT05270057|Drug|Loncastuximab tesirine 0.15 mg/kg by IV|Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
79815281|NCT04089462|Behavioral|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
79986988|NCT03672578|Other|gain-frame|gain frame label
79986989|NCT03672578|Other|text-only|text-only label
79986990|NCT03672578|Other|icon|label with icon and text
79986991|NCT03672578|Other|attribution|label with attribution
79660430|NCT05267301|Dietary Supplement|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
79660431|NCT05263648|Other|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
79660432|NCT05253833|Drug|AR882 Dose 1|Solid Oral Capsule
79986992|NCT03672578|Other|no attribution|label with no attribution
79660433|NCT05253833|Drug|AR882 Dose 2|Solid Oral Capsule
79986993|NCT03672578|Other|No label|No label
79986994|NCT02414074|Behavioral|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
79986995|NCT02414074|Behavioral|Parent Education|Everyday Parenting is a parent training curriculum.
79660434|NCT05253833|Drug|Allopurinol Tablet|Solid tablet
79660435|NCT05251259|Drug|Atuliflapon|Randomised participants will receive Atuliflapon
79347184|NCT02133001|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
79347185|NCT02133001|Drug|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
79660436|NCT05251259|Drug|Placebo|Randomised participants will receive placebo
79660437|NCT05250388|Procedure|Arthroscopic Bankart repair|Arthroscopic Bankart repair is a minimally invasive surgical procedure with the aim to reattach and tighten the detached labrum and ligaments within the shoulder joint.
79986996|NCT01367379|Procedure|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
79986997|NCT01367379|Other|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2~4 times/month)
79986998|NCT02409472|Other|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
79986999|NCT01364103|Other|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
79987000|NCT03679520|Other|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~Introduction, life-change of becoming a parent and co-parenting~Early parenthood~Breastfeeding, caring for the baby and early parenthood~and 5 Labour, birth and postnatal care"
79347186|NCT01709578|Drug|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
79347187|NCT01709578|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
79987001|NCT03679520|Other|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~(or 1 and 2) Labour, birth and postnatal care~or 3 Breastfeeding, caring for the baby and early parenthood"
79987002|NCT02413840|Behavioral|Baduanjin qigong|
79987003|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
79347188|NCT01709578|Drug|hydroxychloroquine|Dispensed according to the local practice.
79347189|NCT01709578|Drug|methotrexate|Dispensed according to the local practice.
79347190|NCT01709578|Drug|sulfasalazine|Dispensed according to the local practice.
79347191|NCT01709578|Drug|leflunomide|Dispensed according to the local practice.
79370807|NCT04361032|Drug|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
79660438|NCT05237128|Behavioral|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
79660439|NCT05237128|Behavioral|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
79660440|NCT05234944|Behavioral|Type 1 Diabetes and Life|Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
79347192|NCT02132767|Drug|Amiodarone|"Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
79347193|NCT02132767|Procedure|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
79499007|NCT01862484|Dietary Supplement|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
79499008|NCT01862484|Dietary Supplement|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
79815282|NCT04089462|Behavioral|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
79347194|NCT02132767|Drug|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
79499009|NCT01902888|Device|GORE® VIABAHN® Endoprosthesis|
79499010|NCT01862328|Drug|MLN4924|"MLN4924 (intravenously [IV]) in participants in a 21-day cycle:~MLN4924 on Days 1,3,5 of each cycle"
79499011|NCT01862328|Drug|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~Paclitaxel on Day 1 of each cycle"
79499012|NCT01862328|Drug|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
79499013|NCT01862328|Drug|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle"
79987004|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
79987005|NCT03171610|Drug|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
79347195|NCT02153905|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
79347196|NCT02153905|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
79347197|NCT02153905|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
79815283|NCT02599779|Drug|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
79987006|NCT03171610|Drug|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
79987007|NCT03675698|Other|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
79987008|NCT01364181|Drug|Udenafil|Udenafil 50mg qd po
79987009|NCT02409550|Other|CARATKids Questionnaire|
79987010|NCT02414230|Drug|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
79987011|NCT03679442|Drug|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
79347198|NCT02153905|Biological|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
79347199|NCT02153827|Other|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
79347200|NCT02153827|Other|General Shoulder exercise|general exercise consisting of active shoulder movements
79347201|NCT04752631|Drug|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
79347202|NCT02153359|Device|High Efficiency Particulate Air Cleaner|
79347203|NCT02153359|Device|Sham air cleaner|
79347204|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
79347205|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
79347206|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
79347207|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
79987012|NCT01367535|Drug|SC Methylnaltrexone (MNTX)|
79987013|NCT01367535|Drug|IV Methylnaltrexone (MNTX)|
79987014|NCT01367535|Drug|Oral Paroxetine|
79987015|NCT01367535|Drug|SC Placebo|
79987016|NCT02414776|Drug|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
79987017|NCT03174418|Procedure|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
79987018|NCT02413762|Other|No intervention|No intervention
79815284|NCT02599779|Radiation|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
79815285|NCT04093011|Procedure|Congenital Heart Disease Surgery|Patients with congenital heart disease will undergo congenital heart disease surgery.
79815286|NCT02597556|Drug|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
79815287|NCT02597556|Drug|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
79815288|NCT02599857|Device|CONCOR smartphone application|
79499014|NCT01862328|Drug|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle"
79815289|NCT04091958|Procedure|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
79660441|NCT05234164|Device|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
79660442|NCT05234164|Device|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
79660443|NCT05230992|Device|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
79815290|NCT02599623|Procedure|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
79347208|NCT02245412|Biological|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
79347209|NCT02245412|Biological|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
79347210|NCT02245412|Biological|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
79347211|NCT02244944|Drug|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
79660444|NCT05230992|Device|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
79347212|NCT01689532|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
79347213|NCT01689532|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
79347214|NCT01689532|Drug|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
79499015|NCT01862250|Drug|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~HR ≤70/min, sustained for ≥30 min after administration"
79499016|NCT01901874|Device|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
79660445|NCT05229952|Dietary Supplement|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
79815291|NCT02599623|Procedure|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
79499017|NCT01860534|Behavioral|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
79499018|NCT01901328|Drug|CB-5945|
79499019|NCT01901328|Drug|Placebo|
79499020|NCT01859988|Drug|Dupilumab|
79815292|NCT02599467|Other|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
79815293|NCT00916968|Device|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
79660446|NCT05229952|Other|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
79499021|NCT01859988|Drug|Placebo|
79499022|NCT01876446|Other|Laboratory Biomarker Analysis|Correlative studies
79499023|NCT01876446|Drug|Pegylated Irinotecan|Given IV
79499024|NCT01876446|Other|Pharmacological Study|Correlative studies
79499025|NCT01900626|Drug|epidural catheter|epidural catheter with 0.3% ropivacaine
79660447|NCT05224102|Drug|Faricimab|Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
79660448|NCT05222594|Other|Behavioral tasks during intracranial monitoring|Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
79660449|NCT05219604|Drug|DiphenhydrAMINE Injectable Solution|Intravenous infusion of diphenhydramine 50 mg.
79499026|NCT04414800|Drug|Placebo|Distilled water
79499027|NCT04414800|Drug|Ketamine|1 mg/kg intranasal ketamine
79499028|NCT04414800|Drug|Fentanyl|1μg/kg intranasal fentanyl
79499029|NCT01900314|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
79499030|NCT01899768|Drug|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
79499031|NCT01899768|Drug|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
79499032|NCT01898598|Drug|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
79499033|NCT01898598|Drug|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
79660450|NCT05218499|Drug|Brigimadlin (BI 907828)|Brigimadlin (BI 907828)
79499034|NCT01898442|Drug|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
79499035|NCT01898442|Drug|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
79499036|NCT01898442|Drug|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
79499037|NCT01898286|Drug|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
79499038|NCT01898208|Device|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
79660451|NCT05218499|Drug|Doxorubicin|doxorubicin
79660452|NCT05216835|Drug|AZD7789|Patients will receive AZD7789 (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
79499039|NCT01898208|Behavioral|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
79499040|NCT01898208|Other|Bacterial culture|This test identifies the pathogen responsible for an infection.
79347215|NCT01924689|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
79347216|NCT01591330|Drug|LY2140023 Reference form|80-mg tablet administered orally
79347217|NCT01591330|Drug|LY2140023 Test-Low|80-mg tablet administered orally
79347218|NCT01591330|Drug|LY2140023 Test-Medium|80-mg tablet administered orally
79347219|NCT01591330|Drug|LY2140023 Test-High|80-mg tablet administered orally
79347220|NCT01591096|Drug|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
79347221|NCT04867174|Behavioral|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
79347222|NCT04867174|Behavioral|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
79347223|NCT04867174|Behavioral|Race concordant|Randomized to a messenger who is race concordant with the participant
79347224|NCT04867174|Behavioral|Gender concordant|Randomized to a messenger who is gender concordant with the participant
79347225|NCT01953003|Drug|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
79347226|NCT01953003|Drug|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
79347227|NCT01952691|Device|kinesiotaping|correction method was used to align hallux.
79347228|NCT01709500|Drug|LMT (atorvastatin, simvastatin, or rosuvastatin)|
79499041|NCT01898208|Other|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
79499042|NCT01898130|Biological|bevacizumab|Given IV
79499043|NCT01898130|Procedure|quality-of-life assessment|Ancillary studies
79815294|NCT00916968|Device|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
79815295|NCT02599389|Device|Drug-coated balloons|
79347229|NCT01709500|Drug|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
79347230|NCT01709500|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
79347231|NCT01599806|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
79815296|NCT02599389|Device|Excimer Laser|
79347232|NCT01599806|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
79347233|NCT01599806|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
79347234|NCT01599806|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
79347235|NCT01599325|Drug|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
79499044|NCT01876368|Drug|LCZ696|
79499045|NCT01876368|Drug|Olmesartan|
79499046|NCT01876368|Drug|Placebo of LCZ696|
79499047|NCT01876368|Drug|Placebo of Olmesartan|
79499048|NCT01874340|Drug|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
79499049|NCT01874340|Drug|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
79347236|NCT01924299|Drug|Baricitinib|Administered orally
79347237|NCT01924299|Drug|Ketoconazole|Administered orally
79347238|NCT01924299|Drug|Fluconazole|Administered orally
79347239|NCT02182999|Device|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
79347240|NCT02182999|Drug|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
79347241|NCT02182999|Drug|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
79347242|NCT01598311|Drug|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
79347243|NCT01598311|Drug|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
79347244|NCT01598311|Drug|Placebo|Placebo size 00 opaque hard gelatin capsules.
79347245|NCT02182843|Biological|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
79499050|NCT04597242|Drug|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
79499051|NCT01897896|Drug|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
79347246|NCT02208050|Drug|Fampridine|
79499052|NCT01858194|Device|Renal sympathetic denervation|"The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
79347247|NCT02208050|Drug|Placebo|
79347248|NCT04770350|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
79499053|NCT01858194|Device|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
79499054|NCT01873950|Drug|Ranolazine|
79499055|NCT01873950|Drug|Dofetilide|
79499056|NCT01873950|Drug|Verapamil|
79499057|NCT01873950|Drug|Quinidine sulfate|
79499058|NCT01873950|Drug|Placebo|
79347249|NCT02978222|Biological|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
79347250|NCT02978222|Drug|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
79347251|NCT02181673|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
79499059|NCT01857102|Device|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
79347252|NCT02181673|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
79347253|NCT02929004|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
79347254|NCT02131129|Device|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
79499060|NCT01857102|Device|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
79499061|NCT01872078|Drug|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
79499062|NCT01872078|Drug|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
79499063|NCT04618458|Behavioral|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
79499064|NCT01896726|Drug|Baricitinib|Administered orally
79499065|NCT01896726|Drug|Microgynon|Administered orally
79499066|NCT01856790|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
79347255|NCT02131129|Device|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
79499067|NCT01856790|Drug|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
79499068|NCT01856322|Drug|Sulindac|one tablet 150mg twice daily
79499069|NCT01856322|Drug|Placebo|One tablet twice daily
79499070|NCT01856322|Other|Validate assays and shipping methods|
79499071|NCT01896102|Genetic|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
79499072|NCT01871532|Drug|Gonal-f®|
79347256|NCT02152345|Drug|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
79499073|NCT04606992|Procedure|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
79499074|NCT01855074|Drug|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
79499075|NCT01871142|Drug|Placebo|100 mL
79347257|NCT02152345|Drug|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
79499076|NCT01871142|Drug|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
79499077|NCT01871142|Drug|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
79499078|NCT04606290|Device|O2matic HOT|Automated oxygen titration with O2matic HOT
79499079|NCT04606290|Device|Oxygen concentrator|Fixed dose oxygen flow from concentrator
79499080|NCT04411056|Other|Barrier box|Placement of barrier box ( a plastic box for shielding)
79815297|NCT04019886|Other|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
79499081|NCT01895322|Drug|OPC-41061|
79499082|NCT01894776|Drug|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
79499083|NCT01894776|Drug|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
79499084|NCT01894620|Device|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
79499085|NCT01894620|Device|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
79499086|NCT01854918|Biological|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
79347258|NCT02152345|Drug|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
79347259|NCT02152345|Drug|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
79347260|NCT02152345|Drug|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
79347261|NCT02152345|Procedure|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
79347262|NCT02180659|Drug|sublingual buprenorphine tablets|
79347263|NCT02180659|Drug|Buprenorphine implant|
79347264|NCT02180659|Drug|placebo implants|
79347265|NCT02180659|Drug|sublingual placebo tablets|
79499087|NCT01854918|Drug|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
79499088|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization
79499089|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
79499090|NCT01894230|Genetic|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele
79499091|NCT01894152|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
79499092|NCT04596930|Procedure|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
79499093|NCT01854528|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79347266|NCT02130427|Diagnostic Test|CT scan|Weekly 3D/4D CT scan
79347267|NCT02207816|Procedure|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
79499094|NCT01854528|Drug|Ribavirin|Tablet
79499095|NCT01854528|Drug|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
79499096|NCT01854528|Drug|Telaprevir|Film-coated tablet
79499097|NCT01853982|Drug|Ceftolozane/Tazobactam|
79499098|NCT01853982|Drug|Piperacillin/Tazobactam|
79347268|NCT02207816|Biological|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
79347269|NCT02207816|Biological|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
79347270|NCT02207816|Biological|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
79347271|NCT02207816|Biological|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
79347272|NCT02207816|Biological|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
79347273|NCT02241512|Drug|Ibuprofen|
79347274|NCT02241512|Drug|placebo|
79499099|NCT01853280|Drug|L-methylfolate|15mg/day L-methylfolate.
79499100|NCT01853280|Drug|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
79347275|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
79815298|NCT02597400|Drug|Metformin|"Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
79347276|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
79499101|NCT01853280|Drug|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
79499102|NCT04415736|Other|No intervention, observational study|
79499103|NCT01892436|Drug|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
79499104|NCT01892436|Drug|Placebo|Placebo
79499105|NCT04415580|Other|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
79347277|NCT01709110|Drug|Teriparatide|Administered SC
79347278|NCT01709110|Drug|Risedronate|Administered orally
79347279|NCT01709110|Drug|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
79347280|NCT01709110|Drug|Calcium|Administered orally
79347281|NCT01709110|Drug|Vitamin D|Administered orally
79987019|NCT05187663|Procedure|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH & Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
79660453|NCT05213442|Diagnostic Test|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
79660454|NCT05201352|Drug|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
79987020|NCT05187663|Procedure|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
79987021|NCT03672422|Diagnostic Test|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
79347282|NCT02240108|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
79347283|NCT02240108|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
79987022|NCT03672422|Behavioral|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
79347284|NCT01590628|Drug|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
79499106|NCT04415580|Other|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
79499107|NCT01853046|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
79499108|NCT01891890|Drug|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
79499109|NCT01891890|Drug|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
79499110|NCT01891890|Drug|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
79499111|NCT01852812|Drug|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
79499112|NCT01852812|Drug|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
79499113|NCT04602624|Drug|SAGE-718|SAGE-718 oral tablets.
79660455|NCT05201352|Drug|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
79660456|NCT05189457|Drug|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
79660457|NCT05189457|Drug|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
79347285|NCT02130193|Drug|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
79347286|NCT02130193|Drug|Placebo|Subjects will receive danirixin matching placebo
79347287|NCT01590082|Drug|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
79347288|NCT01590082|Drug|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
79660458|NCT05189457|Drug|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
79347289|NCT01590082|Drug|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
79347290|NCT02285582|Other|Registry study|No intervention.
79347291|NCT01598636|Procedure|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
79347292|NCT01631474|Drug|CB-03-01|Topical cream, applied once a day
79347293|NCT01631474|Drug|Vehicle|Topical cream, applied once or twice a day
79347294|NCT01631474|Drug|CB-03-01|Topical cream, applied twice a day
79499114|NCT01869348|Behavioral|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
79499115|NCT01869192|Drug|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
79347295|NCT02203916|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
79347296|NCT02203916|Drug|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
79347297|NCT04774328|Drug|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
79347298|NCT04774328|Drug|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
79347299|NCT02179177|Drug|Apixaban|Drug is taken by mouth twice a day for 6 months
79347300|NCT02179177|Drug|Placebo|
79347301|NCT02129803|Device|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
79347302|NCT02129803|Device|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
79347303|NCT02239094|Drug|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
79347304|NCT02129647|Drug|Axitinib|
79347305|NCT02238626|Drug|Placebo (for MN-166)|
79499116|NCT01869192|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
79347306|NCT02238626|Drug|MN-166|
79347307|NCT02238626|Drug|riluzole|Patient is given 50 mg riluzole twice daily.
79347308|NCT02151643|Drug|PT20|Modified ferric oxide adipate tablets
79347309|NCT02151643|Drug|Placebo|Placebo tablets matched to each PT20 dose arm
79347310|NCT02203838|Drug|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
79347311|NCT02178709|Drug|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
79347312|NCT02238080|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
79347313|NCT02150863|Device|Ultrapulse Carbon Dioxide Laser|
79347314|NCT02150863|Device|Cellutome epidermal harvesting system|
79347315|NCT01445366|Device|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
79499117|NCT01869192|Drug|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
79499118|NCT01869192|Drug|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
79499119|NCT01869192|Radiation|Radiation Therapy|Standard dosing, fields depending on clinical findings
79499120|NCT04415190|Other|early palliative care|early palliative care
79499121|NCT04615884|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.
79347316|NCT01445366|Device|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
79347317|NCT02178553|Drug|Epidural|
79499122|NCT04615884|Other|Placebo capsules|Placebo
79499123|NCT01868646|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
79499124|NCT01868646|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
79499125|NCT01852110|Drug|MK-7622|MK-7622 capsule
79499126|NCT01852110|Drug|Placebo|Matching placebo to MK-7622 capsule
79499127|NCT01852110|Drug|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
79660459|NCT05189457|Drug|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
79347318|NCT02178553|Drug|Intercostal Bupivicaine (Exparel)|
79347319|NCT01627327|Drug|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
79347320|NCT01627327|Drug|tiotropium bromide 18mcg|inhalation powder
79347321|NCT01627249|Drug|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
79499128|NCT01851720|Drug|Low dose fentanyl PCA|
79499129|NCT01851720|Drug|Standard IV fentanyl bolus|
79499130|NCT01851330|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
79499131|NCT01851330|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79499132|NCT01868022|Drug|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
79499133|NCT01868022|Drug|paclitaxel|paclitaxel will be from commercial stock.
79499134|NCT01868022|Drug|carboplatin|carboplatin will be from commercial stock.
79499135|NCT01868022|Drug|docetaxel|docetaxel will be from commercial stock.
79499136|NCT01868022|Drug|pemetrexed|pemetrexed will be from commercial stock
79499137|NCT01868022|Drug|cisplatin|cisplatin will be from commercial stock
79499138|NCT01850004|Drug|Dasatinib|
79499139|NCT01867710|Drug|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
79660460|NCT05184335|Drug|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride.
79660461|NCT05184335|Other|Placebo|RP5063 matching Placebo
79987023|NCT03672422|Diagnostic Test|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
79347322|NCT01627249|Drug|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
79347323|NCT01627249|Drug|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
79347324|NCT01688830|Drug|Dabigatran|
79347325|NCT01688830|Drug|BI 655075|
79347326|NCT01688830|Drug|Placebo|
79347327|NCT01569022|Device|CPAP|CPAP Treatment for 12 weeks
79347328|NCT01569022|Device|MAD|MAD Treatment for 12 weeks
79499140|NCT01867710|Drug|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
79499141|NCT01867710|Drug|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
79499142|NCT01867710|Drug|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
79499143|NCT01867710|Drug|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
79499144|NCT01849848|Drug|SyB L-0501|The administration of SyB L-0501 at 90 mg/m^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
79499145|NCT01849458|Device|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
79499146|NCT04415034|Other|VAS and 5-D itch pruritus assessment|All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
79660462|NCT05177211|Drug|Fedratinib Pill|Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
79660463|NCT05171101|Other|MAVEN|The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
79347329|NCT01629823|Device|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
79347330|NCT01688050|Device|Zenith® TX2® Low Profile Endovascular Graft|Treatment of Blunt thoracic aortic injuries (BTAIs)
79347331|NCT01604278|Drug|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
79347332|NCT01604278|Drug|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
79347333|NCT01687270|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
79347334|NCT01687270|Drug|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
79347335|NCT01589770|Other|cardiac Magnetic Resonance imaging|
79347336|NCT01588990|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
79499147|NCT01832766|Drug|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
79499148|NCT01832766|Other|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
79499149|NCT01832532|Drug|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
79499150|NCT04414956|Diagnostic Test|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
79347337|NCT01588990|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
79347338|NCT01588990|Drug|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
79347339|NCT01588990|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m^2 or 50 mg total dose).
79347340|NCT01588990|Drug|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m^2 IV on Day 1 followed by 2400 mg/m^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
79347341|NCT01588990|Drug|Irinotecan|Participants will receive irinotecan 180 mg/m^2 IV on Day 1 every 2 weeks during Phase B treatment.
79347342|NCT02176525|Drug|BI 207127 NA|
79347343|NCT02176525|Drug|Placebo|
79499151|NCT04414956|Diagnostic Test|AFP|AFP will be tested using serum sample every 6 months.
79499152|NCT04414956|Diagnostic Test|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
79499153|NCT04414956|Diagnostic Test|Sonography|Sonography will be tested by experts every 6 months.
79499154|NCT04414956|Diagnostic Test|CT|Contrast-enhanced CT will be tested annually.
79499155|NCT04589910|Diagnostic Test|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
79347344|NCT02127931|Device|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
79347345|NCT02127931|Device|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
79499156|NCT04415112|Behavioral|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
79347346|NCT02126839|Drug|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
79347347|NCT02126839|Drug|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
79347348|NCT02126839|Drug|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
79347349|NCT02125279|Drug|Calcitriol|
79347350|NCT02124811|Drug|Minocycline|
79347351|NCT02148445|Other|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
79347352|NCT02148445|Other|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
79987024|NCT03672422|Diagnostic Test|Urine sample|50 ml of urine in collection container.
79987025|NCT03171376|Procedure|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
79347353|NCT02148445|Drug|Nicotine replacement therapy|
79499157|NCT04415112|Behavioral|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
79499158|NCT01848990|Drug|Commercial Hylenex® recombinant (hyaluronidase human injection)|
79499159|NCT01848990|Drug|Precommercial Hylenex recombinant (hyaluronidase human injection)|
79499160|NCT01848990|Drug|Insulin lispro|
79347354|NCT02148211|Other|Data collection|Initial and follow-up data was collected using questionnaires.
79347355|NCT02147587|Drug|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
79347356|NCT02147587|Drug|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
79347357|NCT02147353|Drug|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
79347358|NCT02147353|Drug|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
79347359|NCT02147197|Drug|Ulipristal acetate (UPA)|UPA tablet
79347360|NCT02147197|Drug|Placebo|Matching placebo tablet.
79347363|NCT02176291|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
79499161|NCT01848990|Drug|Insulin aspart|
79347364|NCT02176291|Drug|Placebo|matched placebo
79347365|NCT04769570|Procedure|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
79347366|NCT04769570|Procedure|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
79499162|NCT01848990|Drug|Insulin glulisine|
79660464|NCT05168605|Other|Home visit|Patients receiving home Visits
79660465|NCT05160051|Diagnostic Test|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
79347367|NCT04769570|Procedure|Group Control|consist of the patient group without any procedure.
79347368|NCT02175745|Drug|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
79347369|NCT02175745|Procedure|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
79347370|NCT02175745|Procedure|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
79347371|NCT02175745|Procedure|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
79499163|NCT01867086|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
79660466|NCT05159830|Drug|Cannabidiol Cap/Tab|The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Sublingual tablet contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed tablet.
79660467|NCT05159830|Drug|Placebo Cap/Tab|Placebo of similar cannabidiol galenic form
79987026|NCT03171298|Procedure|Laparoscopic Assisted Transanal Total Mesorectal Excision|"Abdominal approach with laparoscopic mobilization of the left colon~Laparoscopic isolation and transection of inferior mesenteric vessels .~Transabdominal dissection of the upper rectum and mesorectam.~Insertion of transanal platform and the creation of pneumorectum.~Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~Transanal dissection of lower and mid mesorectam~The specimen will be extracted transanally"
79987027|NCT03675542|Drug|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
79987028|NCT03171454|Procedure|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
79987029|NCT03171454|Procedure|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
79987030|NCT03679286|Device|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
79987031|NCT04482712|Drug|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
79987032|NCT04482712|Drug|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
79347372|NCT02175277|Drug|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
79347373|NCT02124265|Drug|CeraLyte 90|"This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used."
79347374|NCT02146105|Other|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
79347375|NCT02175199|Device|Lotrafilcon B contact lenses with color printing|
79347376|NCT02175199|Device|Phemfilcon A contact lenses with color printing|
79347377|NCT02175121|Drug|Placebo|Tablet, once daily for 28 days
79347378|NCT02175121|Drug|PF-06291874|Tablet, 15 mg, once daily for 28 days
79347379|NCT02175121|Drug|PF-06291874|Tablet, 35 mg, once daily for 28 days
79347380|NCT02175121|Drug|PF-06291874|Tablet, 75 mg, once daily for 28 days
79347381|NCT02175121|Drug|PF-06291874|Tablet, 150 mg, once daily for 28 days
79347382|NCT01568866|Drug|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
79347383|NCT01568866|Drug|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
79347384|NCT01568866|Drug|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
79347385|NCT01568320|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
79660468|NCT05150444|Other|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
79660469|NCT05147909|Dietary Supplement|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
79347386|NCT01567852|Drug|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
79499164|NCT01867086|Drug|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
79499165|NCT01867086|Drug|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
79987033|NCT03679208|Device|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
79347387|NCT01567852|Drug|Methohexital|Methohexital (1.5mg/kg) will be given for induction
79347388|NCT01588366|Drug|Placebo|Administered orally
79347389|NCT01588366|Drug|LY2409021|Administered orally
79347390|NCT01686958|Device|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
79347391|NCT01686568|Drug|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
79499166|NCT01831596|Device|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
79347392|NCT01686568|Drug|placebo|
79499167|NCT01848834|Biological|Pembrolizumab|IV infusion
79499168|NCT01867008|Device|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
79499169|NCT01848756|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
79499170|NCT04594434|Other|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
79499171|NCT04594434|Other|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
79499172|NCT04594434|Other|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
79499173|NCT01830972|Drug|SA-ER 500 mg|oral tablets
79499174|NCT01830972|Drug|SA-IR 500 mg|oral capsules
79987034|NCT03679208|Device|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
79347393|NCT01567462|Device|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
79347394|NCT01567462|Device|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
79347395|NCT01587898|Drug|GSK1278863|Tablet
79347396|NCT01587898|Other|Placebo|Tablet
79347397|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
79347398|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
79347399|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
79499175|NCT01848288|Device|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
79499176|NCT01848288|Device|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
79499177|NCT01848210|Drug|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
79499178|NCT01848210|Drug|Placebo|Coumarin + troxerutin placebo-matching tablets
79660470|NCT05147909|Dietary Supplement|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
79987035|NCT02409394|Drug|Hetrombopag Olamine|
79987036|NCT02409004|Drug|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
79499179|NCT01830816|Drug|Ixazomib|Ixazomib capsules
79987037|NCT02409004|Drug|Rifampin|Capsule 2x3oo mg Oral
79987038|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
79347400|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
79660471|NCT05143489|Drug|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
79987039|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
79987040|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
79987041|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
79987042|NCT03671876|Device|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
79987043|NCT04039919|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
79987044|NCT04039919|Drug|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
79347401|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
79499180|NCT01846416|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
79987045|NCT02405494|Dietary Supplement|Beverage 1|
79499181|NCT01865448|Dietary Supplement|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
79660472|NCT05143489|Drug|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
79660473|NCT05142059|Diagnostic Test|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
79347402|NCT01567306|Biological|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
79347403|NCT01587274|Drug|Naproxen|Naproxen 500mg twice/ day x 10 days
79347404|NCT01587274|Drug|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
79499182|NCT01865448|Other|Placebo|Patients in control group take daily 2 placebo capsule
79815299|NCT02597400|Drug|HMS5552|"Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
79815300|NCT00830063|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
79347405|NCT01587274|Drug|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
79347406|NCT01587118|Drug|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
79347407|NCT01905657|Biological|Pembrolizumab|IV infusion
79347408|NCT01905657|Drug|Docetaxel|IV infusion
79347409|NCT02202980|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79347410|NCT02202980|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79347411|NCT02202980|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79499183|NCT04414878|Device|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
79499184|NCT01846104|Biological|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
79499185|NCT01803282|Drug|Andecaliximab|Administered intravenous infusion
79499186|NCT01803282|Drug|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
79987046|NCT02405494|Dietary Supplement|Beverage 2|
79987047|NCT02405494|Dietary Supplement|Beverage 3|
79987048|NCT02405494|Dietary Supplement|Beverage 4|
79987049|NCT02405494|Dietary Supplement|Beverage 5|
79987050|NCT02405494|Dietary Supplement|Beverage 6|
79987051|NCT02405494|Dietary Supplement|Beverage 7|
79987052|NCT02405494|Dietary Supplement|Beverage 8|
79987053|NCT02405494|Dietary Supplement|Beverage 9|
79987054|NCT02409160|Procedure|Standard Roux-en-Y gastric bypass|
79987055|NCT05171595|Device|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
79987056|NCT05171595|Diagnostic Test|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
79499187|NCT01803282|Drug|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
79499188|NCT01803282|Drug|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
79660474|NCT05141513|Radiation|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
79660475|NCT05139979|Behavioral|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
79347412|NCT02202980|Drug|VOX|100 mg tablet administered orally once daily with food
79347413|NCT01952145|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
79347414|NCT01952145|Drug|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
79347415|NCT04416087|Other|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
79347416|NCT01923363|Drug|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
79347417|NCT01905267|Behavioral|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
79347418|NCT01923285|Device|AXIUM Neurostimulator System|
79347419|NCT01923285|Device|Control Spinal Cord Stimulation Device|
79347420|NCT01904721|Drug|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
79347421|NCT01904721|Drug|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
79347422|NCT01904721|Drug|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
79347423|NCT05122533|Diagnostic Test|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
79347424|NCT05122533|Diagnostic Test|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~tape measuring:~Spina iliaca anterior superior - medial malleolus~umbilicus - medial malleolus~greater trochanter - lateral malleolus~in standing, sitting, resupinate and side position"
79499189|NCT01803282|Drug|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
79347425|NCT01922895|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
79347426|NCT01922895|Drug|Placebo for Probiotic|Capsule manufactured without active ingredients.
79499190|NCT01803282|Drug|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
79499191|NCT01803282|Drug|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
79499192|NCT01803282|Drug|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
79499193|NCT01803282|Drug|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
79499194|NCT01803282|Drug|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
79499195|NCT01803282|Drug|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
79499196|NCT01844778|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
79499197|NCT01844778|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
79499198|NCT01844778|Drug|Colistimethate|Colistimethate was administered via nebuliser.
79660476|NCT05139979|Other|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
79660477|NCT05138965|Procedure|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
79987057|NCT03174340|Behavioral|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
79347427|NCT01922739|Drug|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
79347428|NCT01922739|Drug|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
79347429|NCT02236988|Drug|Apremilast Immediate Release|30 mg immediate release tablets
79347430|NCT02236988|Drug|Apremilast Modified Release 1|75 mg oral tablet of prototype modified release (MR) 1
79660478|NCT05138965|Procedure|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
79660479|NCT05124665|Behavioral|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
79347431|NCT02236988|Drug|Apremilast Modified Release 2|75 mg oral tablet of prototype MR 2
79347432|NCT02236988|Drug|Apremilast Modified Release 3|75 mg oral capsule of prototype MR 3
79347433|NCT02236988|Drug|Apremilast Modified Release 4|75 mg oral capsule of prototype MR 4
79347434|NCT02236988|Drug|Apremilast Modified Release 5|75 mg oral capsule of prototype MR 5
79660480|NCT05109780|Device|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
79660481|NCT05093933|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
79660482|NCT05093933|Drug|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
79987058|NCT01367613|Drug|SC Methylnaltrexone|
79987059|NCT03174106|Device|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
79987060|NCT03739151|Behavioral|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
79815301|NCT00830063|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
79347435|NCT02236988|Drug|Apremilast Modified Release 6|75 mg oral capsule of prototype MR 6
79347436|NCT02236988|Drug|Apremilast Modified Release 8|80 mg oral capsule of prototype MR 8
79347437|NCT02236988|Drug|Apremilast Modified Release 9|80 mg oral capsule of prototype MR 9
79347438|NCT02236988|Drug|Apremilast Modified Release 11|80 mg oral capsule of prototype MR 11
79499199|NCT01802580|Behavioral|Internet Survey|
79660483|NCT05091424|Drug|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab
79660484|NCT05091424|Drug|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
79987061|NCT02405182|Other|Magnetic Resonance Imaging|
79987062|NCT03745001|Drug|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
79987063|NCT03745001|Drug|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
79987064|NCT03745001|Drug|Matching placebo|Oral liquid administration daily
79347439|NCT02236988|Drug|Apremilast Modified Release 12|80 mg oral capsule of prototype MR 12
79347440|NCT02236988|Drug|Apremilast Modified Release 13|80 mg oral capsule of prototype MR 13
79347441|NCT02236988|Drug|Apremilast Modified Release 14|80 mg oral capsule of prototype MR 14
79347442|NCT02236598|Drug|K+ supplement|
79347443|NCT02236598|Drug|Placebo|
79347444|NCT01922349|Drug|BI 113608|Medium dose (Multiple dosing)
79347445|NCT01922349|Drug|Placebo|Placebo (Multiple dosing)
79347446|NCT01922349|Drug|BI 113608|Low dose (Multiple dosing)
79347447|NCT01922349|Drug|Placebo|Placebo (Single dosing)
79347448|NCT01922349|Drug|BI 113608|High dose (Single dosing)
79347449|NCT01922349|Drug|BI 113608|Medium dose (Single dosing)
79347450|NCT01922349|Drug|BI 113608|Low dose (Single dosing)
79347451|NCT01922349|Drug|BI 113608|High dose (Multiple dosing)
79347452|NCT02236520|Drug|Spironolactone|
79499200|NCT01802580|Drug|fluocinonide 0.05% ointment|
79499201|NCT01802346|Dietary Supplement|dietary intervention|Consume a low-calorie diet
79499202|NCT01802346|Procedure|nutritional support|Receive dietary advice
79499203|NCT01802346|Other|laboratory biomarker analysis|Correlative studies
79499204|NCT01611090|Drug|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
79660485|NCT05091424|Drug|Venetoclax|Participants will receive daily oral venetoclax
79660486|NCT05082142|Drug|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
79660487|NCT05080946|Drug|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
79815302|NCT00830063|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
79815303|NCT00830063|Other|placebo|placebo to match tanezumab and naproxen dosing
79815304|NCT02599233|Other|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
79815305|NCT02599233|Other|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 & 7.
79815306|NCT02599233|Other|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
79815307|NCT04092621|Drug|Amiodarone in Parenteral Dosage Form|Amiodarone IV
79815308|NCT04092621|Drug|Amiodarone Pill|Amiodarone tablet
79347453|NCT02236520|Drug|Chlorthalidone|
79347454|NCT02236520|Dietary Supplement|Diet|
79347455|NCT02236520|Drug|Placebo|
79347456|NCT04769414|Drug|Gemcitabine fluorouracil|"chemotherapy protocol given as:~Gemcitabine 1000mg/m2 IV short infusion~Leucovorin 400 mg/m2 IV short infusion~Flourouracil 400 mg/m2 direct IV shot~Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
79347457|NCT01922271|Drug|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
79347458|NCT01922271|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
79347459|NCT01922271|Drug|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
79987065|NCT01367691|Device|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
79987066|NCT02405338|Biological|WT1/PRAME vaccination|
79347460|NCT01922271|Drug|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
79347461|NCT01922271|Drug|Salbutamol|Used as resuce medication
79347462|NCT02236130|Procedure|Regional block|Single shot peripheral nerve block
79347463|NCT02236130|Procedure|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
79347464|NCT02236130|Drug|Local Anesthetic Ropivacaine|0.5% Ropivacaine
79499205|NCT01611090|Drug|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
79499206|NCT01611090|Drug|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
79499207|NCT01611090|Drug|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
79499208|NCT01844700|Drug|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
79499209|NCT01844700|Drug|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
79499210|NCT01844076|Drug|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
79499211|NCT01826604|Device|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
79499212|NCT01826604|Other|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
79499213|NCT01843842|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
79499214|NCT01843842|Drug|Placebo|Safety and Efficiency of liquid dosage form
79347465|NCT02236130|Drug|Opioids Morphine|Morphine
79347466|NCT02236130|Drug|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
79347467|NCT02233946|Behavioral|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
79347468|NCT02232698|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
79347469|NCT02232698|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
79499215|NCT01826448|Drug|PLX3397|
79499216|NCT01826448|Drug|vemurafenib|
79499217|NCT01826370|Drug|Linagliptin|tablet
79499218|NCT01826214|Drug|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
79499219|NCT04582344|Biological|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
79987067|NCT03738839|Device|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
79347470|NCT01632800|Device|High pulsed magnetic fields|Magnetic fields will escalate in strength
79347471|NCT01641809|Drug|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
79347472|NCT01641809|Drug|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
79347473|NCT01641809|Drug|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
79347474|NCT01641809|Drug|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
79347475|NCT01641809|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
79347476|NCT01641809|Drug|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
79347477|NCT01641809|Drug|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
79347478|NCT01632566|Drug|Placebo|Capsules administered orally
79499220|NCT04582344|Biological|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
79347479|NCT01632566|Drug|LY3031207|Administered orally
79347480|NCT01632566|Drug|Celecoxib|Administered orally
79347481|NCT01632566|Drug|Simvastatin|Administered orally
79499221|NCT01843062|Drug|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
79815309|NCT04092621|Procedure|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
79347482|NCT00752804|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
79347483|NCT00752804|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
79347484|NCT00752804|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
79499222|NCT01843062|Drug|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
79499223|NCT01843062|Drug|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
79660488|NCT05080946|Drug|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
79987068|NCT03738839|Procedure|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
79347485|NCT04863521|Other|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
79347486|NCT02254304|Drug|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
79987069|NCT03738839|Procedure|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
79987070|NCT01364337|Other|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
79347487|NCT04863287|Biological|2217LS|Fully Human Monoclonal Antibody
79499224|NCT01842438|Behavioral|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
79499225|NCT01799226|Other|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
79347488|NCT04863287|Other|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
79347489|NCT04420091|Dietary Supplement|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
79347490|NCT04862195|Device|Attune™|Software as a medical device
79347491|NCT04862195|Device|Cerena™|Software as a medical device
79499226|NCT01799226|Other|Triclosan|this intervention will use Colgate Total which contains triclosan
79347492|NCT04861805|Device|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
79347493|NCT05650151|Dietary Supplement|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
79815310|NCT04092621|Drug|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
79987071|NCT01364337|Other|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
79987072|NCT05166993|Device|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
79987073|NCT02405416|Procedure|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
79987074|NCT02405416|Procedure|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
79499227|NCT01825200|Biological|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
79499228|NCT01825200|Biological|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
79499229|NCT01824576|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
79499230|NCT01824498|Other|Low Fat diet|Low fat diet = 20% fat
79499231|NCT01824498|Other|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
79499232|NCT01824498|Other|High Fat Diet|High Fat Diet = 40% fat
79987075|NCT02405416|Procedure|Portal triad clamping|Portal triad are clamped in hepatectomy.
79987076|NCT01361295|Procedure|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
79347494|NCT05650151|Dietary Supplement|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
79347495|NCT02174731|Drug|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
79347496|NCT02174731|Drug|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
79499233|NCT01798134|Device|TANDEM™|
79499234|NCT01798056|Biological|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
79499235|NCT01798056|Drug|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
79660489|NCT05078229|Behavioral|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
79987077|NCT01361295|Procedure|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
79987078|NCT02405104|Drug|chlorzoxazone|ATC-code: M03BB03
79987079|NCT02405104|Drug|Placebo|Placebo
79987080|NCT02405104|Procedure|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
79987081|NCT02405104|Procedure|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
79987082|NCT01364415|Drug|Pasireotide LAR|
79987083|NCT03176368|Other|Coconut Oil|Coconut Oil
79987084|NCT03522129|Drug|CT1812|Active Study Drug
79347497|NCT01922037|Drug|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
79347498|NCT02282813|Drug|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
79347499|NCT02282813|Drug|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
79347500|NCT02282813|Drug|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
79347501|NCT02282813|Drug|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
79499236|NCT01824342|Biological|Denosumab|Administered by subcutaneous injection
79499237|NCT01841970|Device|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
79499238|NCT01823328|Drug|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
79499239|NCT01823328|Drug|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
79499240|NCT01840410|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
79499241|NCT01840410|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
79499242|NCT01797432|Drug|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
79499243|NCT01797432|Device|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
79499244|NCT01797120|Drug|Fulvestrant|"Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
79660490|NCT05078229|Behavioral|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
79660491|NCT05070429|Other|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
79987085|NCT03522129|Drug|Placebo|Non-active study drug
79987086|NCT03176446|Device|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
79987087|NCT03176446|Device|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
79815311|NCT00750438|Dietary Supplement|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
79499245|NCT01797120|Drug|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
79347502|NCT01903863|Biological|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
79499246|NCT01797120|Drug|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
79499247|NCT01796964|Drug|ESBA1008 solution|For intravitreal (IVT) injection
79987088|NCT03176446|Device|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
79987089|NCT03176446|Drug|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
79679506|NCT02942745|Behavioral|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
79815312|NCT00750438|Dietary Supplement|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
79815313|NCT00750438|Dietary Supplement|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
79815314|NCT04092699|Device|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
79815315|NCT04092465|Procedure|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
79815316|NCT00586326|Device|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
79987090|NCT03176446|Drug|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
79987091|NCT03176212|Dietary Supplement|Milk fat globule membrane|
79987092|NCT03176290|Diagnostic Test|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
79987093|NCT02408614|Other|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
79987094|NCT02408614|Other|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
79987095|NCT02408614|Other|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
79347503|NCT02123251|Behavioral|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
79499248|NCT01796964|Drug|Aflibercept|For intravitreal (IVT) injection
79499249|NCT01838694|Biological|Ala-Cpn10|
79499250|NCT01838694|Drug|Placebo|
79499251|NCT01795638|Drug|Sodium chloride|
79499252|NCT01795638|Drug|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
79499253|NCT01794780|Drug|LABA based treatment: indacaterol|LABA based treatment: indacaterol
79815317|NCT00751101|Drug|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
79987096|NCT02408614|Device|Treadmill|
79347504|NCT04746469|Behavioral|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
79347505|NCT05638529|Drug|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
79347506|NCT05638529|Drug|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
79347507|NCT01902303|Drug|Matching Placebo|Sublingual micro dosing of placebo for 7 days
79499254|NCT01794780|Drug|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
79347508|NCT01902303|Drug|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
79499255|NCT01794780|Drug|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
79499256|NCT01794780|Drug|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
79499257|NCT01794780|Drug|theophylline based treatment|theophylline based treatment
79499258|NCT01794780|Drug|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
79499259|NCT04587726|Behavioral|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~Appearance comparison~Body appreciation~Body talk~Body functionality~Appearance teasing & bullying~Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
79499260|NCT04587726|Other|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
79499261|NCT01838616|Drug|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
79347509|NCT02122783|Device|ADR™ brace resistance|
79347510|NCT02122783|Device|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
79347511|NCT04859933|Procedure|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
79347512|NCT04859933|Procedure|AV-node ablation|Right sided ablation of the AV-node
79347513|NCT01921257|Drug|Cat-PAD|
79347514|NCT01921257|Drug|Placebo|
79347515|NCT02121847|Drug|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
79347516|NCT02121847|Drug|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
79499262|NCT01838616|Drug|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
79823684|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
79987097|NCT03171142|Drug|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
79987098|NCT03171142|Drug|Air|Air 21% via nasal cannula 2 litter per minutes
79370808|NCT04747119|Other|muscle energy technique|the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
79987099|NCT04035473|Drug|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
79347517|NCT05637593|Behavioral|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
79347518|NCT05637593|Behavioral|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
79347519|NCT01921179|Behavioral|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
79347520|NCT01921179|Behavioral|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
79347521|NCT01587040|Drug|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
79347522|NCT01587040|Drug|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
79347523|NCT02144701|Dietary Supplement|Lactobacillus rhamnosus GG|Given PO
79347524|NCT02144701|Other|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
79370809|NCT04747119|Other|conventional selected physical therapy|"life style modification~Transcutaneous electrical nerve stimulation (TENS)~Flexibility stretching exercises to the hip flexors"
79499263|NCT01611792|Other|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
79660492|NCT05070429|Other|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
79660493|NCT05067790|Drug|Nusinersen|Administered as specified in the treatment arm
79660494|NCT05061420|Drug|Pembrolizumab (Keytruda®)|Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
79987100|NCT02408848|Other|Observational|This is an observational study. There is no intervention.
79987101|NCT02413528|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
79987102|NCT02413528|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
79660495|NCT05061420|Drug|SAR444245 (Thor-707)|Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
79660496|NCT05061420|Drug|Cetuximab (Erbitux®)|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
79660497|NCT05052255|Drug|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
79660498|NCT05050916|Dietary Supplement|Vitamin D|"This is a Phase II randomized, dose-ranging clinical trial including 1) a within-woman comparison of hormones pre-and post-supplementation and 2) a comparison across women on a Vitamin D and a placebo. After recruitment, there will be two phases: Phase 1 will follow all women for one menstrual cycle prior to supplementation; blood will be assayed for 25OHD. Phase 2 includes only: 1) women with less than 20 ng/ml 25OHD (deficient) OR 2) a sample of women with >20 ng/ml 25OHD (sufficient) as the placebo group. During Phase 2, deficient women will be assigned to receive a blinded dose of 50,000 IU of vitamin D supplementation per week and followed for three more menstrual cycles. Hormone levels will be compared between the pre-and post-supplementation cycles as the primary analysis. The primary aim will test: if mid-luteal progesterone, rate of estrogen rise and pre-ovulatory LH are higher in vitamin D supplemented cycles."
79823685|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
79347525|NCT05556161|Behavioral|General Practitioners and Diabetes Specialists Co-management|"Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check: Participants will receive HbA1c test once every three months.~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose and HbA1c tests, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants."
79347526|NCT01921101|Behavioral|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
79347527|NCT01921101|Other|control|participants will receive standard care for nutrition received from hospital admission to discharge
79347528|NCT01586806|Drug|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
79660499|NCT05046171|Other|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
79660500|NCT05046171|Other|Patient education|Subjects receive a written pamphlet about deprescribing.
79660501|NCT05043116|Dietary Supplement|Cholecalciferol D3|2000 IU of Vitamin D provided as oral suspension for one year
79660502|NCT05043116|Other|Oral placebo suspension|Oral suspension with no active substance tasting like the active supplement.
79347529|NCT01586806|Drug|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
79347530|NCT01586806|Drug|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
79347531|NCT02144077|Drug|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
79347532|NCT02144077|Drug|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
79347533|NCT05545553|Device|Piezosurgery|Piezosurgery used as an osteotomy device
79347534|NCT05545553|Device|Conventional burs|Conventional burs used as an osteotomy device
79660503|NCT05038839|Drug|Cabozantinib|Given PO
79347535|NCT02985892|Other|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
79347536|NCT02985892|Other|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
79347537|NCT02172625|Dietary Supplement|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
79347538|NCT02172625|Other|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
79347539|NCT05618171|Diagnostic Test|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
79347540|NCT04410016|Other|Staff Wellbeing Centres|2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
79347541|NCT05425433|Other|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
79660504|NCT05038839|Drug|Pamiparib|Given PO
79660505|NCT05037929|Drug|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
79660506|NCT05037929|Drug|Placebo|Participants will receive SC placebo Q2W.
79660507|NCT05032742|Behavioral|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
79660508|NCT05028556|Drug|Cohort 1 of Y101D|Y101D, 1mg/kg, Q2W, intravenous infusion
79660509|NCT05028556|Drug|Cohort 2 of Y101D|Y101D, 3mg/kg, Q2W, intravenous infusion
79660510|NCT05028556|Drug|Cohort 3 of Y101D|Y101D, 10mg/kg, Q2W, intravenous infusion
79660511|NCT05028556|Drug|Cohort 4 of Y101D|Y101D, 20mg/kg, Q2W, intravenous infusion
79660512|NCT05028556|Drug|Cohort 5 of Y101D|Y101D, 30mg/kg, Q2W, intravenous infusion
79660513|NCT05028153|Drug|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
79660514|NCT05028153|Other|Placebo mixture|Placebo mixture containing no active substance
79660515|NCT05026541|Behavioral|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
79823686|NCT02580578|Other|No Intervention|No intervention is administered in this study.
79660516|NCT05026541|Behavioral|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
79347542|NCT02985970|Other|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
79660517|NCT05023434|Procedure|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
79660518|NCT05012982|Device|AirBand|The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
79347543|NCT02143843|Drug|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
79660519|NCT05012982|Device|uninflated AirBand|Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
79660520|NCT05011357|Drug|Phenylephrine|Phenylephrine will be administered as an infusion
79660521|NCT05011357|Drug|Saline Control|Saline infusion
79660522|NCT05003310|Device|Active Stimulation|Stimulation will be turned ON and applied during each day of the period.
79660523|NCT05003310|Device|Sham Stimulation|Sham stimulation will be provided during the period
79987103|NCT04032977|Device|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
79987104|NCT04032977|Device|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
79987105|NCT02408926|Biological|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
79347544|NCT02121535|Drug|T80/A5 mg FDC tablet|
79347545|NCT02121535|Drug|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
79660524|NCT05003310|Drug|Baricitinib|Baricitinib (2 mg) is administered daily during the period.
79660525|NCT05003310|Drug|Background Treatment|Stable dose of standard background treatment (e.g., csDMARD therapy)
79660526|NCT04985604|Drug|Tovorafenib|Tovorafenib tablet for oral use.
79660527|NCT04985604|Drug|Pimasertib|Pimasertib capsule for oral use.
79660528|NCT04965311|Biological|Botulinum Toxin Type A|Given via endoscopic injection into intraduodenal sphincter of Oddi segment
79660529|NCT04963179|Device|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days."
79660530|NCT04959032|Drug|Lumateperone 42 mg|Lumateperone 42 mg capsules administered orally, once daily.
79987106|NCT02408926|Biological|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
79987107|NCT02408926|Biological|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
79347546|NCT02121535|Drug|H12.5 mg tablet|
79660531|NCT04959032|Drug|Placebo|Matching capsules administered orally, once daily.
79823687|NCT02618252|Device|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
79987108|NCT02408926|Biological|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
79347547|NCT02121535|Drug|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
79347548|NCT02121535|Drug|H12.5 mf tablet|A HCTZ 12.5 mg tablet
79347549|NCT02121535|Drug|T80/A5/H12.5 mg FDC tablet|
79347550|NCT05535959|Drug|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
79660532|NCT04959019|Behavioral|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
79823688|NCT02618252|Device|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
79823689|NCT02557412|Device|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
79987109|NCT04030247|Drug|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
79987110|NCT00704158|Drug|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
79987111|NCT04481698|Other|Mesoglycan|Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
79987112|NCT03738761|Drug|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
79347551|NCT01586338|Drug|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
79347552|NCT02143141|Drug|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
79347553|NCT02143141|Drug|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
79347554|NCT05500469|Device|Paul glaucoma drainage device (GDD)|Implantation of the GDD
79347555|NCT02171065|Device|sham|
79347556|NCT02171065|Device|ABSORB BVS|
79347557|NCT05036525|Device|HANBIO BarriGel|an anti-adhesive product
79347558|NCT05033561|Biological|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
79347559|NCT01566604|Drug|NVA237|Delivered via a single dose dry powder inhaler
79347560|NCT01566604|Drug|Placebo|Delivered via a single dose dry powder inhaler
79347561|NCT05497583|Other|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
79347562|NCT05497583|Other|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
79347563|NCT01684930|Drug|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
79679507|NCT02942745|Behavioral|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
79679508|NCT00515918|Dietary Supplement|iron|
79679509|NCT02950688|Biological|Seasonal LAIV|10^7.0 fluorescent focus units (FFU); administered by intranasal spray
79679510|NCT02950688|Biological|Placebo|Administered by intranasal spray
79987113|NCT03738761|Drug|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
79347564|NCT01684930|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
79347565|NCT01566214|Behavioral|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
79347566|NCT02253992|Biological|Urelumab|
79987114|NCT02413216|Behavioral|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
79347567|NCT02253992|Biological|Nivolumab|
79499264|NCT01611792|Other|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
79987115|NCT02413216|Other|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
79347568|NCT02252588|Drug|Chlorhexidine|Oral Rinse
79347569|NCT02252588|Other|Placebo|Oral Rinse
79347570|NCT05153018|Other|Blood collection|a 4-mL blood sample collected in a dry tube
79347571|NCT01585558|Drug|Ospemifene (Dose 1)|
79347572|NCT01585558|Drug|Ospemifene (Dose 2)|
79660533|NCT04959019|Behavioral|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
79347573|NCT01585558|Drug|Placebo|
79660534|NCT04958785|Drug|Magrolimab|Administered intravenously
79660535|NCT04958785|Drug|Nab-Paclitaxel|Administered intravenously
79660536|NCT04958785|Drug|Paclitaxel|Administered intravenously
79347574|NCT01565980|Behavioral|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
79347575|NCT01565980|Behavioral|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
79660537|NCT04958785|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
79347576|NCT01585246|Drug|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
79347577|NCT01585246|Drug|soybean oil soft gel|placebo (soybean oil soft gel)
79347578|NCT01585168|Drug|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
79660538|NCT04955899|Device|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
79660539|NCT04947085|Drug|Ketamine via Intravenous|Ketamine administration in sub-dissociative doses
79660540|NCT04947085|Drug|Ketamine via BAN|Ketamine administered via Breath-Actuated Nebulizer (BAN)
79660541|NCT04931654|Drug|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
79660542|NCT04921436|Procedure|cardiac surgery|prophylactic use of antibiotic-inhibitors
79679511|NCT02950688|Biological|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10^6 TCID50; administered intranasally
79987116|NCT03671642|Device|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
79347579|NCT01585168|Drug|Placebo|Identically appearing sugar pill, given orally
79347580|NCT02232074|Other|Patient navigation enhanced with legal support|
79347581|NCT02142283|Device|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
79347582|NCT02142283|Other|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
79347583|NCT02231918|Drug|MIRAPEX® - low|
79347584|NCT02231918|Drug|MIRAPEX® - medium|
79347585|NCT02231918|Drug|MIRAPEX® - high|
79347586|NCT02199314|Drug|Desflurane|
79347587|NCT02251652|Drug|Ingenol Mebutate|Ingenol mebutate 0.05% gel
79347588|NCT02251652|Procedure|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
79347589|NCT02197520|Drug|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
79347590|NCT02197520|Drug|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
79347591|NCT02197520|Drug|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
79347592|NCT04772534|Biological|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
79347593|NCT02230904|Drug|Rotigotine (Test product PR 2.3.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
79347594|NCT02230904|Drug|Rotigotine (Reference product PR 2.1.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
79347595|NCT02230670|Drug|IDN-6556|25 mg BID
79679512|NCT00516425|Biological|pegfilgrastim|
79987117|NCT03671642|Procedure|White light perfusion assessment|Traditional visual perfusion assessment in white light
79987118|NCT03671642|Procedure|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
79660543|NCT04920565|Device|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
79987119|NCT03623282|Drug|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
79987120|NCT03738605|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
79347596|NCT02230670|Drug|Placebo|
79347597|NCT02197130|Drug|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
79347598|NCT02197130|Drug|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
79660544|NCT04918316|Other|Corneal gas permeable lens|Fit in corneal gas permeable contact lens first.
79660545|NCT04914897|Drug|THOR-707|Intravenous infusion: solution for infusion
79660546|NCT04914897|Drug|Pembrolizumab|Intravenous infusion: solution for infusion
79987121|NCT04482790|Procedure|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
79347599|NCT02197130|Other|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
79347600|NCT02196506|Drug|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
79347601|NCT02196506|Drug|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
79347602|NCT02228720|Device|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
79660547|NCT04914208|Device|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
79660548|NCT04914208|Device|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
79660549|NCT04914208|Device|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
79679513|NCT00516425|Drug|cyclophosphamide|
79987122|NCT04482790|Procedure|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
79987123|NCT03738527|Drug|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
79987124|NCT03738527|Drug|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
79987125|NCT03738449|Drug|CKD-387|Test drug
79987126|NCT03738449|Drug|D484|reference drug
79987127|NCT03174262|Behavioral|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
79987128|NCT02413060|Other|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
79987129|NCT02413060|Behavioral|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
79499265|NCT01820364|Drug|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
79499266|NCT01819506|Behavioral|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
79347603|NCT02228564|Procedure|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
79347604|NCT02228564|Device|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
79347605|NCT01640951|Drug|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
79347606|NCT01640951|Drug|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
79347607|NCT01640951|Drug|Placebo|
79347608|NCT02228096|Biological|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg).
79347609|NCT01640873|Drug|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
79499267|NCT01794000|Drug|Prasugrel|Administered orally
79660550|NCT04914208|Other|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
79660551|NCT04914208|Other|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
79660552|NCT04910945|Device|VENUS AIME (RoboCor)|VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
79660553|NCT04908397|Dietary Supplement|L-carnitine|supplement provided twice a day for 2 weeks
79987130|NCT03738371|Other|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
79347610|NCT01640873|Drug|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
79660554|NCT04907526|Biological|Autologous mononuclear cells|Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
79660555|NCT04906811|Device|AuraGen 1-2-3 with AuraClens system (BK190433)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system
79660556|NCT04906811|Device|Revolve System (K120902)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System
79660557|NCT04902469|Behavioral|Pleasant Odor|Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
79347611|NCT04419623|Drug|TL-895|TL-895, administered by mouth
79347612|NCT04844801|Procedure|Risk control strategy|"Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance >30 mL/min)~Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
79347613|NCT04844801|Procedure|Rate control strategy:|"Risk-control as described above~Low dose amiodarone:~Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
79370810|NCT04360798|Other|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
79499268|NCT01794000|Drug|Placebo|Administered orally
79499269|NCT01609296|Device|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
79499270|NCT01609218|Drug|LY2140023|
79499271|NCT01609218|Drug|Aqueous activated charcoal|
79499272|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
79499273|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
79347614|NCT04844801|Procedure|Rhythm control strategy:|"Risk control as described above~High dose amiodarone:~Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses > 0.3 µg/kg/min;~NOSVA persists more than 6 hrs after initial amiodarone bolus."
79347615|NCT01683994|Drug|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
79347616|NCT01683994|Drug|Docetaxel|75mg/m^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
79347617|NCT01683994|Drug|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
79499274|NCT04580472|Drug|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
79499275|NCT04580472|Other|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
79499276|NCT01819272|Drug|Met DR|metformin delayed-release tablets
79499277|NCT01819272|Drug|Met XR|metformin extended-release tablets
79499278|NCT01819272|Drug|Placebo|placebo delayed-release tablets
79660558|NCT04902469|Behavioral|Odor Blank|Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
79499279|NCT01819194|Device|senofilcon A|
79499280|NCT01611558|Biological|Ipilimumab|
79660559|NCT04902040|Biological|Atezolizumab|Given IV
79660560|NCT04902040|Drug|Avelumab|Given IV
79660561|NCT04902040|Biological|Durvalumab|Given IV
79347618|NCT02247440|Drug|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
79347619|NCT05487989|Other|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
79347620|NCT04760054|Behavioral|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
79499281|NCT04579926|Other|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
79499282|NCT04579068|Behavioral|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
79499283|NCT04577976|Device|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
79499284|NCT01818726|Drug|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
79499285|NCT01818726|Drug|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
79499286|NCT01818726|Drug|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
79499287|NCT01818336|Drug|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
79660562|NCT04902040|Biological|Nivolumab|Given IV
79660563|NCT04902040|Biological|Pembrolizumab|Given IV
79660564|NCT04902040|Drug|Plinabulin|Given IV
79660565|NCT04902040|Radiation|Radiation Therapy|Undergo radiation therapy
79660566|NCT04892277|Biological|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
79660567|NCT04892277|Drug|Bendamustine|Given IV
79660568|NCT04892277|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79660569|NCT04892277|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79660570|NCT04892277|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79499288|NCT04592640|Other|Human amniotic mesenchymal stem cells|"Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
79499289|NCT01818258|Drug|ZDV+3TC+LPV/r|
79347621|NCT04760054|Behavioral|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
79499290|NCT01817790|Drug|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
79499291|NCT01817790|Drug|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
79499292|NCT01793688|Drug|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
79499293|NCT01793142|Drug|Viviant|Viviant (Bazedoxifene) 20mg once daily
79499294|NCT01792830|Drug|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c < 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
79347622|NCT04760054|Behavioral|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
79499295|NCT01792830|Drug|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
79815318|NCT00750204|Device|APRV|"APRV Protocol~Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
79347623|NCT05421377|Diagnostic Test|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
79347624|NCT04857203|Diagnostic Test|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
79347625|NCT01683838|Drug|Fampridine-SR|25mg bid (twice daily)
79499296|NCT01792830|Drug|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
79499297|NCT01792518|Drug|Placebo|
79499298|NCT01792518|Drug|Linagliptin 5mg|
79499299|NCT01792284|Drug|LY2605541|
79347626|NCT01683838|Drug|Placebo|Placebo
79347627|NCT05474573|Device|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
79347628|NCT05474573|Device|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
79347629|NCT01683604|Other|Observational study|
79347630|NCT05417243|Other|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
79347631|NCT04843709|Drug|MRG004A|Administrated intravenously
79347632|NCT02196038|Behavioral|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
79347633|NCT02196038|Behavioral|Attention Control|Usual care with bi-weekly contact from study staff
79347634|NCT04660643|Drug|Tirzepatide|Administered SC
79347635|NCT04660643|Other|Placebo|Administered SC
79499300|NCT01792284|Drug|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
79499301|NCT04414566|Drug|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m^2 d1,8) and cisplatin (80mg/m^2 d1) or TPF docetaxel (60mg/m^2 on day 1), cisplatin (60mg/m^2 on day 1) and fluorouracil (600mg/m^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
79499302|NCT04414566|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
79660571|NCT04892277|Procedure|Computed Tomography|Undergo CT
79660572|NCT04892277|Drug|Cyclophosphamide|Given IV
79660573|NCT04892277|Drug|Fludarabine|Given IV
79660574|NCT04892277|Procedure|Magnetic Resonance Imaging|Undergo MRI
79660575|NCT04892277|Procedure|Positron Emission Tomography|Undergo CT/PET
79660576|NCT04889924|Radiation|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
79347636|NCT04659317|Drug|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
79347637|NCT04659317|Drug|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
79660577|NCT04889924|Procedure|Lymphadenectomy|Axillary Lymph node dissection
79660578|NCT04865653|Drug|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
79660579|NCT04865653|Drug|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
79660580|NCT04865653|Drug|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
79660581|NCT04865653|Drug|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
79660582|NCT04865653|Other|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
79660583|NCT04862663|Drug|Capivasertib|Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
79660584|NCT04862663|Drug|Fulvestrant|Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
79660585|NCT04862663|Drug|Palbociclib|Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
79679514|NCT00516425|Drug|doxorubicin hydrochloride|
79679515|NCT00516425|Drug|epirubicin hydrochloride|
79679516|NCT00516425|Genetic|proteomic profiling|
79347638|NCT04855643|Device|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
79499303|NCT04414566|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m^2 every 3 weeks for 3 cycles.
79499304|NCT01837914|Procedure|Maxillary expansion|
79499305|NCT01837914|Procedure|Adenotonsillectomy|
79499306|NCT01791894|Drug|arsenic trioxide|Given IV
79499307|NCT04592016|Drug|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
79499308|NCT04592016|Drug|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
79347639|NCT04855643|Device|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
79499309|NCT04592016|Drug|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
79347640|NCT03602261|Drug|Calcifediol Oral Capsule|Capsule, weekly
79347641|NCT03602261|Drug|Placebo oral capsule|Capsule, weekly
79347642|NCT02141659|Drug|TAK-385|TAK-385 Tablets.
79347643|NCT01640249|Drug|Placebo|Capsules administered orally
79347644|NCT01640249|Drug|LY3006072|Capsules administered orally
79347645|NCT02121301|Drug|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
79499310|NCT04592016|Device|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
79499311|NCT04592016|Device|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
79660586|NCT04862663|Drug|Ribociclib|Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
79347646|NCT02121301|Drug|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
79347647|NCT02121301|Drug|Placebo (Vehicle) opthalmic solution|eyedrops
79347648|NCT05422703|Device|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
79347649|NCT05422703|Other|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
79347650|NCT05422703|Device|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
79347651|NCT05422703|Procedure|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
79347652|NCT05422703|Drug|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
79499312|NCT04592016|Procedure|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
79660587|NCT04862663|Drug|Abemaciclib|Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
79660588|NCT04849988|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
79660589|NCT04849988|Drug|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
79347653|NCT05422703|Drug|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
79347654|NCT05422703|Drug|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
79347655|NCT05422703|Dietary Supplement|Soft cold diet|For the day of surgery
79347656|NCT02227862|Drug|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
79347657|NCT02227862|Drug|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
79347658|NCT05422391|Dietary Supplement|3 day caloric restriction/metabolic reset|Participants will consume ~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
79347659|NCT02120833|Device|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
79347660|NCT02120833|Drug|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
79347661|NCT04615949|Drug|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
79347662|NCT04615949|Drug|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
79347663|NCT04591379|Drug|Influenza Vaccines|Intratumoral application of an unattenuated influenza vaccine
79347664|NCT02170207|Drug|Lansoprazole|Lansoprazole 30 mg injection
79370811|NCT04360798|Other|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
79499313|NCT04592016|Procedure|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
79499314|NCT01837680|Drug|Insulin|
79499315|NCT01836276|Drug|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
79499316|NCT01790568|Drug|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
79499317|NCT01790568|Drug|Tacrolimus|
79499318|NCT01790568|Drug|Methotrexate|
79499319|NCT01610076|Other|Code Status Video|"10 minute video about Code Status"
79660590|NCT04847206|Drug|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
79660591|NCT04847206|Drug|3,4-methylenedioxyamphetamine|A moderate dose of 93.9 mg MDA will be administered.
79499320|NCT01836198|Drug|LY2409021|
79499321|NCT01836198|Drug|Gemfibrozil|
79347665|NCT05399927|Other|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
79347666|NCT04968275|Behavioral|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
79499322|NCT01836198|Drug|Ketoconazole|
79499323|NCT01836198|Drug|Clarithromycin|
79347667|NCT04746079|Behavioral|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
79499324|NCT04590846|Behavioral|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
79499325|NCT04590846|Behavioral|General Health Course|General courses about health issues according to the curriculum of each primary school.
79499326|NCT01816074|Drug|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
79499327|NCT01816074|Behavioral|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
79347668|NCT04855097|Diagnostic Test|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
79499328|NCT01815918|Drug|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
79987131|NCT03176056|Dietary Supplement|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
79987132|NCT03176056|Dietary Supplement|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI > 24 and 30 kcal/day for underweight subjects with a BMI <18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
79347669|NCT02227784|Drug|Evacetrapib|Administered orally
79499329|NCT01815918|Drug|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
79347670|NCT02227784|Drug|Atorvastatin|Administered orally
79347671|NCT02227784|Drug|Ezetimibe|Administered orally
79499330|NCT01789476|Drug|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
79499331|NCT01789476|Drug|Placebo|Matching placebo administered using same dosing algorithm as the active arm
79499332|NCT01789320|Drug|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
79499333|NCT01815840|Drug|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
79660592|NCT04847206|Drug|lysine-3,4-methylenedioxymethamphetamine|A moderate dose of 171.7 mg lysine-MDMA will be administered.
79347672|NCT02227784|Drug|Placebo|Administered orally
79347673|NCT04419701|Procedure|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
79499334|NCT01815840|Drug|Placebo|Vismodegib placebo orally once daily
79499335|NCT01774110|Other|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
79499336|NCT01788228|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
79499337|NCT01607346|Drug|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
79660593|NCT04847206|Drug|lysine-3,4-methylenedioxyamphetamine|A moderate dose of 165.6 mg lysine-MDA will be administered.
79660594|NCT04847206|Other|Placebo|Placebo (Mannitol)
79660595|NCT04824417|Drug|Itraconazole 200 mg|Control
79660596|NCT04824417|Drug|Voriconazole 200mg|Comparator
79660597|NCT04820829|Other|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
79499338|NCT01787838|Other|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
79347674|NCT04419701|Procedure|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
79987133|NCT02915978|Drug|Fentanyl|Fentanyl delivered via sublingual spray
79347675|NCT04841213|Procedure|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
79347676|NCT01565668|Drug|AC220|oral
79347677|NCT04581551|Procedure|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
79347678|NCT04581551|Procedure|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
79660598|NCT04820829|Other|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
79347679|NCT04581551|Procedure|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
79347680|NCT04581551|Procedure|No stretch intervention|Passive mobilisation of the hemiplegic hand.
79347681|NCT04577417|Drug|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
79347682|NCT01683058|Drug|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
79499339|NCT01787760|Device|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
79499340|NCT01787760|Device|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
79499341|NCT01787760|Device|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
79499342|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
79499343|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
79499344|NCT01606800|Drug|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
79660599|NCT04820829|Other|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
79660600|NCT04814875|Drug|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
79660601|NCT04809051|Other|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
79660602|NCT04809051|Other|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
79660603|NCT04798339|Drug|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
79987134|NCT02915978|Drug|Placebo|Matching placebo delivered via sublingual spray
79347683|NCT04419545|Diagnostic Test|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
79347684|NCT04574921|Other|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
79347685|NCT04574921|Other|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
79347686|NCT05374421|Device|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
79370812|NCT03552003|Other|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
79370813|NCT00928954|Drug|gabapentin|increasing to 1200 mg/day
79499345|NCT01606800|Drug|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
79987135|NCT02412904|Drug|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
79499346|NCT04414488|Procedure|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
79347687|NCT05374421|Device|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
79347688|NCT01626859|Drug|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
79499347|NCT01772550|Device|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
79660604|NCT04798339|Drug|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
79347689|NCT01626859|Drug|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
79660605|NCT04790370|Drug|Anticoagulation with heparin|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
79679517|NCT00516425|Other|diagnostic laboratory biomarker analysis|
79347690|NCT01626859|Drug|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
79679518|NCT00516425|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
79660606|NCT04790370|Device|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
79660607|NCT04785352|Dietary Supplement|Nutrition Intervention|One egg per day for six months
79815319|NCT00750204|Device|Conventional MV|Low tidal-volume mechanical ventilation
79815320|NCT04092309|Drug|ACE inhibitor, Sacubitril-Valsartan|Search for Protective effect after chemotherapy and bone marrow transplantation
79987136|NCT02412904|Drug|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
79987137|NCT02412826|Device|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
79347691|NCT04413682|Behavioral|Structured Supervised Exercise|Structured Exercise Program under the supervision of Physical Therapist
79987138|NCT02404948|Other|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
79347692|NCT04413682|Behavioral|Structured telerehabilitation|Structured Exercise Program checked and controlled through telerehabilitation
79660608|NCT04785352|Behavioral|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
79660609|NCT04781309|Drug|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
79660610|NCT04777409|Drug|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
79815321|NCT02598414|Procedure|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
79987139|NCT03675230|Device|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
79347693|NCT02193776|Drug|PA-824|oral
79347694|NCT02193776|Drug|bedaquiline|oral
79347695|NCT02193776|Drug|moxifloxacin|oral
79815322|NCT02598414|Procedure|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
79815323|NCT02598414|Device|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
79987140|NCT03675230|Device|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
79347696|NCT02193776|Drug|pyrazinamide|oral
79660611|NCT04777409|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
79660612|NCT04773275|Device|Pulsed electric field treatment using the Aliya system|Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
79347697|NCT02193776|Drug|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
79347698|NCT05373407|Other|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
79987141|NCT02404714|Device|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
79987142|NCT03671408|Other|clinical measurements|only clinical parameters were recorded
79987143|NCT03174028|Device|laparoscopic pull-through|laparoscopic pull-through
79347699|NCT02170064|Drug|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
79370814|NCT00928954|Drug|memantine|increasing to 40 mg/day
79987144|NCT02701192|Other|Coccygectomy|Patient receiving coccygectomy surgery.
79987145|NCT02404480|Drug|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
79987146|NCT02412514|Biological|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
79987147|NCT02412514|Biological|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
79987148|NCT02412514|Biological|IPV|IPV administered at 6 weeks of age
79815324|NCT04020003|Drug|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
79347700|NCT02169830|Drug|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
79347701|NCT02169830|Drug|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
79347702|NCT02169830|Behavioral|Diet Modification|Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
79347703|NCT04545905|Diagnostic Test|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits.
79347704|NCT02169674|Biological|EngerixB, GlaxoSmithKline Vaccines|
79347705|NCT04536467|Drug|Goserelin|chemotherapy+goserelin
79347706|NCT04536467|Drug|Chemotherapy|standard chemotherapy
79347707|NCT04532489|Drug|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
79347708|NCT04946981|Dietary Supplement|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
79499348|NCT01772550|Device|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
79660613|NCT04772547|Drug|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
79660614|NCT04771377|Dietary Supplement|Protein Supplementation|protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
79499349|NCT01787292|Behavioral|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
79347709|NCT04946981|Dietary Supplement|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
79660615|NCT04768062|Drug|Viltolarsen|Received during weekly intravenous infusions
79660616|NCT04764474|Drug|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
79347710|NCT05341349|Biological|Ipilimumab|Given IV
79347711|NCT05341349|Biological|Nivolumab|Given IV
79347712|NCT05341349|Biological|Pembrolizumab|Given IV
79347713|NCT05341349|Radiation|Stereotactic Radiosurgery|Undergo SRS
79347714|NCT05341349|Procedure|Tumor Treating Fields Therapy|Undergo TTFields
79499350|NCT01787292|Behavioral|Aerobic Exercise Intervention|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
79660617|NCT04759443|Other|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
79660618|NCT04756076|Diagnostic Test|Metal level measurements|Measure multiple metal levels
79660619|NCT04745169|Behavioral|8 week home-based exercise program|Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
79660620|NCT04741997|Drug|Encorafenib Pill|Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
79660621|NCT04741997|Drug|Binimetinib Pill|Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
79660622|NCT04741997|Drug|Nivolumab|Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
79660623|NCT04739059|Biological|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
79660624|NCT04723095|Other|Follow-Up|Receive follow up
79660625|NCT04723095|Other|Medical Chart Review|Review of medical records
79660626|NCT04717414|Drug|ACE-536|Subcutaneous Injection
79660627|NCT04717414|Other|Placebo|Subcutaneous Injection
79815325|NCT03977142|Diagnostic Test|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
79987149|NCT02408458|Device|MIROMESH®|
79499351|NCT01787292|Behavioral|Self Monitoring|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
79499352|NCT04414644|Behavioral|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
79499353|NCT01814748|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
79499354|NCT01814748|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
79499355|NCT01814748|Drug|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
79660628|NCT04697589|Dietary Supplement|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
79660629|NCT04697589|Dietary Supplement|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
79347715|NCT04525547|Drug|Nintedanib|Nintedanib
79347716|NCT02169284|Drug|Erlotinib Hydrochloride|Given PO
79347717|NCT02169284|Other|Laboratory Biomarker Analysis|Correlative studies
79347718|NCT02169284|Other|Pharmacological Study|Correlative studies
79347719|NCT02169284|Other|Placebo|Given PO
79347720|NCT02169284|Other|Quality-of-Life Assessment|Ancillary studies
79347721|NCT02169284|Procedure|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
79347722|NCT02119819|Drug|LY2944876|Administered SC
79660630|NCT04697589|Dietary Supplement|Placebo|Colored maltodextrin
79987150|NCT02404558|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
79499356|NCT01814670|Biological|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
79499357|NCT01814046|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
79499358|NCT01814046|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
79499359|NCT01814046|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
79660631|NCT04678856|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79660632|NCT04678856|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79987151|NCT02404558|Drug|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
79987152|NCT02404636|Other|Interview|Brief structured interview
79347723|NCT02119819|Drug|Exenatide extended-release|Administered SC
79347724|NCT02119819|Drug|Placebo|Administered SC
79347725|NCT02119819|Drug|Metformin|Oral
79370815|NCT04355026|Drug|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
79370816|NCT04762485|Biological|Humanized CD7 CAR-T cells|Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5-10)x10^6 CD7 CAR-T cells/kg
79370817|NCT04347070|Other|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
79679519|NCT00516425|Other|pharmacological study|
79679520|NCT00516425|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
79679521|NCT00516425|Procedure|adjuvant therapy|
79679522|NCT02942706|Drug|Cetuximab|anti-EGFR monoclonal antibody
79987153|NCT04481854|Procedure|cricoid pressure|cricoid pressure during laryngoscopy
79987154|NCT04481854|Procedure|left paratracheal pressure|left paratracheal pressure during laryngoscopy
79987155|NCT02408302|Drug|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
79499360|NCT01814046|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
79499361|NCT01813890|Drug|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
79987156|NCT02404324|Other|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
79499362|NCT01813890|Drug|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
79987157|NCT03170986|Behavioral|Multisectoral agriculture and Microfinance Intervention|
79370818|NCT04762173|Device|Online self-help intervention|Access to two online, self-guided programs available on the SilverCloud Health website.
79499363|NCT01813890|Drug|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
79660633|NCT04678661|Device|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
79499364|NCT01772316|Drug|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
79499365|NCT01813422|Biological|Evolocumab|Administered by subcutaneous injection
79499366|NCT01813422|Drug|Placebo|Administered by subcutaneous injection
79499367|NCT01786668|Drug|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
79679523|NCT02942706|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
79679524|NCT02942706|Drug|FOLFIRI|Irinotecan+LV5FU2
79370819|NCT04367350|Diagnostic Test|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
79370820|NCT04367350|Diagnostic Test|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
79370821|NCT04762329|Other|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
79987158|NCT02412358|Device|toothbrush|
79987159|NCT02412280|Other|retrospecive observational|
79370822|NCT04367038|Other|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
79370823|NCT04360642|Other|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
79370824|NCT04403451|Behavioral|True North|Love Notes, Financial Stability, Jobs
79370825|NCT03549351|Other|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
79987160|NCT03173716|Procedure|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
79987161|NCT03115372|Other|Educational Intervention|Attend CRC education session
79815326|NCT04091334|Device|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
79815327|NCT04091334|Other|Standard care|Standard care and evaluation and monitoring
79987162|NCT03115372|Other|Educational Intervention|Attend healthy nutrition session
79347726|NCT04766450|Drug|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
79660634|NCT04678661|Behavioral|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
79370826|NCT04360408|Other|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
79499368|NCT01786668|Drug|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
79499369|NCT01786668|Drug|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
79499370|NCT01786668|Drug|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
79499371|NCT01786512|Drug|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
79499372|NCT01786512|Drug|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
79499373|NCT01786512|Drug|Placebo|Modified release tablets matching to omecamtiv mecarbil
79660635|NCT04663802|Behavioral|RT-targeted accountable justification|This strategy will require that the RT enter an explicit rationale in the EHR if he/she enters a tidal volume value greater than 6 cc/kg into the flowsheet, similar to the physician-targeted accountable justification strategy.
79679525|NCT00516464|Drug|Lucentis (ranibizumab)|
79987163|NCT03115372|Other|Informational Intervention|Receive CRC screening brochure
79815328|NCT00751023|Drug|Modafinil|400 mg daily for four weeks
79815329|NCT00751023|Drug|Placebo|Placebo 2 tablets daily for 4 weeks
79370827|NCT03548571|Biological|Dendritic cell immunization|Intradermal injection
79499374|NCT01786512|Drug|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
79815330|NCT04092231|Behavioral|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
79815331|NCT04091412|Drug|Butylphthalide Soft Capsules|The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
79815332|NCT04092075|Device|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
79815333|NCT04092075|Device|Control placebo with no RF|Placebo control, toothbrush with no RF
79987164|NCT03115372|Other|Survey Administration|Ancillary studies
79987165|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about CRC screening
79987166|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
79987167|NCT04481542|Diagnostic Test|MRI|check MRI quality in aorta
79987168|NCT03173872|Procedure|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
79987169|NCT02412202|Other|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
79660636|NCT04663802|Behavioral|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 cc/kg of the patient's ideal body weight (as determined by each patient's height and gender, which are entered into the EHR on admission). The physician will have the option to opt out of any of the specified LPV settings and select other values.
79660637|NCT04663802|Behavioral|physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg ideal body weight, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
79987170|NCT02408146|Procedure|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
79660638|NCT04663802|Other|Standard of Care|ICUs and clinicians will deliver standard of care to patients with no intervention
79987171|NCT02408146|Drug|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
79987172|NCT02408146|Procedure|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
79347727|NCT04852991|Procedure|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
79347728|NCT04852991|Procedure|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
79347729|NCT04765982|Diagnostic Test|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
79499375|NCT04414254|Drug|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
79499376|NCT01772160|Other|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
79499377|NCT01770912|Drug|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
79499378|NCT01770912|Drug|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
79660639|NCT04652960|Procedure|Biospecimen Collection|Undergo collection of blood samples
79660640|NCT04652960|Procedure|Computed Tomography|Undergo CT scan
79660641|NCT04652960|Drug|Duvelisib|Given PO
79660642|NCT04652960|Biological|Nivolumab|Given IV
79987173|NCT02408146|Drug|fentanyl citrate+ ondansetron hydrochloride + normal saline|
79660643|NCT04652960|Procedure|Positron Emission Tomography|Undergo PET
79987174|NCT02408146|Drug|celecoxib|
79987175|NCT02412124|Procedure|Supportive Care|Complete W2W mentoring program
79987176|NCT02412124|Other|Quality-of-Life Assessment|Complete the FACT-G
79987177|NCT02412124|Other|Questionnaire Administration|Complete the W2W Patient Survey
79347730|NCT02168816|Drug|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
79370828|NCT03548571|Drug|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
79499379|NCT01811706|Drug|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
79660644|NCT04652960|Procedure|Punch Biopsy|Undergo punch biopsies
79499380|NCT01811706|Drug|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
79660645|NCT04652518|Drug|LYT-100|oral administration
79987178|NCT04482010|Other|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~Individual interviews with a psychosocial agent;~Support groups conducted by psychosocial agents;~Culinary workshops gathering PLWHIV and healthcare professionals;~Home visits by a community worker;~Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
79987179|NCT03175900|Drug|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
79987180|NCT03175900|Drug|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
79987181|NCT03175666|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79987182|NCT03175666|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
79987183|NCT03175666|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79987184|NCT03175666|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79987185|NCT03175666|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79987186|NCT03175666|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79499381|NCT01811472|Drug|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
79499382|NCT01811472|Drug|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
79499383|NCT01811238|Drug|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
79499384|NCT01769508|Drug|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
79499385|NCT01769508|Drug|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
79660646|NCT04652518|Other|Placebo|oral administration
79987187|NCT03175666|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79987188|NCT03175666|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79987189|NCT03175666|Drug|Lovaza|omega-3-acid ethyl esters)
79987190|NCT03175666|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
79987191|NCT03175666|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
79987192|NCT03175666|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA (carcinoembryonic antigen)
79499386|NCT01769508|Drug|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
79499387|NCT01769508|Radiation|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
79499388|NCT04576260|Behavioral|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
79499389|NCT01810380|Drug|Placebo|Once daily as tablets and capsules, orally
79499390|NCT01810380|Drug|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
79499391|NCT01810380|Drug|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
79499392|NCT01769196|Drug|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
79499393|NCT01769196|Drug|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
79499394|NCT01810302|Drug|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
79499395|NCT01810302|Drug|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
79499396|NCT01783938|Biological|Nivolumab|
79499397|NCT01783938|Biological|Ipilimumab|
79499398|NCT01768572|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
79660647|NCT04648696|Drug|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
79660648|NCT04648696|Drug|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
79815334|NCT02599311|Device|transvaginal synthetic mesh|transvaginal synthetic mesh
79815335|NCT02599311|Drug|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
79347731|NCT02168816|Drug|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
79347732|NCT05315921|Drug|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
79499399|NCT01768572|Drug|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
79499400|NCT01768572|Drug|hydroxychloroquine|Dispensed according to local practice.
79987193|NCT03175666|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79987194|NCT03175666|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1)
79499401|NCT01768572|Drug|methotrexate|Dispensed according to local practice.
79660649|NCT04639388|Behavioral|neuropsychological testing, questionnaires and experimental tasks|Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
79660650|NCT04628052|Procedure|Colonoscopy|Music vs. No-Music
79987195|NCT03175666|Biological|GI-4000|RAS yeast vaccine
79987196|NCT03175666|Biological|GI-6207|CEA yeast vaccine
79987197|NCT03175666|Biological|GI-6301|Brachyury yeast vaccine
79987198|NCT03175666|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
79987199|NCT03101358|Drug|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
79347733|NCT05315921|Drug|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
79347734|NCT05315921|Drug|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
79987200|NCT02404246|Behavioral|Peer support program|
79987201|NCT02404090|Radiation|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
79987202|NCT05236218|Other|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
79987203|NCT05236218|Other|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
79347735|NCT05315921|Drug|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
79347736|NCT05315921|Drug|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
79347737|NCT05315921|Drug|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
79370829|NCT00939562|Drug|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
79499402|NCT01768572|Drug|sulfasalazine|Dispensed according to local practice.
79499403|NCT01768572|Drug|leflunomide|Dispensed according to local practice.
79499404|NCT01768572|Drug|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
79499405|NCT01768572|Drug|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
79499406|NCT01783548|Drug|BDP Nasal Aerosol|
79499407|NCT01783548|Drug|Placebo|
79660651|NCT04610866|Drug|Mitapivat|Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
79660652|NCT04609904|Drug|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
79660653|NCT04609904|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
79660654|NCT04609904|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
79660655|NCT04609904|Drug|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
79660656|NCT04609046|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
79499408|NCT01809210|Drug|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
79815336|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
79815337|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
79499409|NCT01809210|Drug|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
79499410|NCT01809210|Drug|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
79499411|NCT01809210|Drug|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
79815338|NCT00591773|Drug|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
79347738|NCT05307107|Behavioral|SHINE|Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
79347739|NCT01584232|Drug|LY2189265|
79347740|NCT01584232|Drug|Insulin glargine|
79347741|NCT01584232|Drug|Sulfonylureas (SU)|
79347742|NCT01584232|Drug|Biguanide (BG)|
79347743|NCT01639703|Drug|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
79347744|NCT04877483|Procedure|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
79660657|NCT04609046|Procedure|Computed Tomography|Undergo CT and PET/CT
79499412|NCT01809210|Drug|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
79499413|NCT01809132|Drug|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
79499414|NCT01809132|Drug|Pentoxifylline|Pentoxifylline, generic
79499415|NCT01809132|Drug|Zinc Sulfate|Zinc Sulfate, nutritional supplement
79499416|NCT01809132|Drug|Methylprednisolone|Methylprednisolone, corticosteroid
79499417|NCT01808508|Device|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
79660658|NCT04609046|Procedure|Echocardiography|Undergo ECHO
79660659|NCT04609046|Drug|Lenalidomide|Given PO
79660660|NCT04609046|Procedure|Lumbar Puncture|Undergo lumbar puncture
79660661|NCT04609046|Procedure|Magnetic Resonance Imaging|Undergo MRI
79660662|NCT04609046|Drug|Methotrexate|Given IV or PO
79660663|NCT04609046|Biological|Nivolumab|Given IV
79660664|NCT04609046|Procedure|Positron Emission Tomography|Undergo PET/CT
79660665|NCT04609046|Biological|Rituximab|Given IV
79660666|NCT04609046|Procedure|Ultrasound Imaging|Undergo testicular ultrasound
79660667|NCT04607005|Drug|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
79815339|NCT04091919|Diagnostic Test|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
79815340|NCT04091997|Diagnostic Test|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
79499418|NCT01808508|Device|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
79499419|NCT01766778|Drug|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
79499420|NCT01766778|Drug|Metformin|Metformin maximum tolerance dose
79815341|NCT00750867|Drug|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
79347745|NCT04877483|Diagnostic Test|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
79347746|NCT04877483|Diagnostic Test|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
79347747|NCT04877483|Diagnostic Test|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
79347748|NCT04877483|Diagnostic Test|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
79347749|NCT04877483|Diagnostic Test|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
79347750|NCT04877483|Diagnostic Test|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
79499421|NCT01808196|Drug|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
79499422|NCT01808118|Biological|adalimumab|40 mg every other week
79660668|NCT04607005|Drug|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
79660669|NCT04607005|Drug|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
79660670|NCT04599634|Drug|Obinutuzumab|Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
79660671|NCT04599634|Drug|Venetoclax|For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
79347751|NCT04877483|Diagnostic Test|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
79347752|NCT04877483|Diagnostic Test|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
79347753|NCT04877483|Diagnostic Test|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
79347754|NCT04877483|Diagnostic Test|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
79370830|NCT00939562|Drug|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
79499423|NCT01808118|Biological|Placebo|every other week
79499424|NCT01807650|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
79660672|NCT04599634|Drug|Magrolimab|Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
79660673|NCT04597411|Radiation|225^Ac-PSMA-617|administered intravenously under the dose escalation schedule
79815342|NCT04091841|Drug|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
79815343|NCT04091841|Other|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
79499425|NCT01807650|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
79499426|NCT01782690|Drug|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
79660674|NCT04597411|Radiation|68^Ga-PSMA-11|administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
79815344|NCT00744042|Biological|asfotase alfa|
79499427|NCT01782690|Drug|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
79499428|NCT01782378|Device|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
79499429|NCT01782378|Device|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
79499430|NCT01766310|Drug|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
79499431|NCT01766310|Drug|placebo|sugar tablet manufactured to mimic folic acid tablet
79660675|NCT04589845|Drug|Entrectinib|Adults and pediatric participants with a BSA >/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
79660676|NCT04589845|Drug|Entrectinib|Adults and pediatric participants with a BSA >/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
79660677|NCT04589845|Drug|Alectinib|Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).
79347755|NCT04877483|Diagnostic Test|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
79347756|NCT04877483|Diagnostic Test|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
79347757|NCT04877483|Diagnostic Test|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
79347758|NCT04877483|Diagnostic Test|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
79499432|NCT01765920|Drug|Ergoferon|5 ml 3 times a day
79499433|NCT01765920|Drug|Placebo|5 ml 3 times a day
79499434|NCT01782222|Drug|Rotigotine|"Rotigotine, transdermal patches:~10 cm^2 (2 mg / 24 hours); 20 cm^2 (4 mg / 24 hours); 30 cm^2 (6 mg / 24 hours); 40 cm^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
79347759|NCT02119663|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
79347760|NCT02119663|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
79347761|NCT02119663|Drug|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
79499435|NCT01782222|Other|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
79815345|NCT04091763|Drug|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
79499436|NCT04414098|Drug|INC424 / Ruxolitinib|"Ruxolitinib 5 mg orally every 12 hours during 14 days.~Total Follow-up time will be of 45 days.~The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~After discharge, monitoring of adverse events will continue during the outpatient follow-up.~Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
79660678|NCT04589845|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged >/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged <18 years on Day 1 of each 21-day cycle.
79660679|NCT04589845|Drug|Ipatasertib|For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants < 35 kg, 300 mg for participants >/= 35 and < 45 kg, 400 mg for those >/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
79660680|NCT04589845|Drug|Trastuzumab emtansine|Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
79499437|NCT01781832|Device|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
79499438|NCT01807182|Biological|Aldesleukin|Given IV
79499439|NCT01807182|Drug|Cyclophosphamide|Given IV
79660681|NCT04589845|Drug|Idasanutlin|"Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart.~Note: Cohort G has been closed for enrollment."
79660682|NCT04589845|Drug|Inavolisib|GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
79499440|NCT01807182|Drug|Fludarabine Phosphate|Given IV
79499441|NCT01807182|Other|Laboratory Biomarker Analysis|Correlative studies
79499442|NCT01807182|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
79499443|NCT04584762|Device|Automated Variable Pressure Insufflation|Acute migraine treatment
79499444|NCT01806714|Other|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
79499445|NCT01806714|Other|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
79499446|NCT01765764|Drug|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
79499447|NCT01765764|Drug|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
79499448|NCT01806168|Device|rTMS|Magstim Super Rapid-2
79499449|NCT01804842|Drug|Met DR|metformin delayed-release tablets
79499450|NCT01781286|Behavioral|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
79660683|NCT04589845|Drug|Belvarafenib|Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
79987204|NCT03173794|Other|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
79987205|NCT03171220|Biological|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
79987206|NCT03171220|Biological|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
79987207|NCT03171220|Drug|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
79987208|NCT03171220|Drug|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
79987209|NCT03171220|Biological|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
79660684|NCT04589845|Drug|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).
79660685|NCT04589845|Drug|GDC-6036|GDC-6036 will be self-administered by patients orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric patients. A treatment cycle consists of 3 weeks (21 days).
79347762|NCT04481009|Drug|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
79347763|NCT04481009|Drug|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
79347764|NCT04481009|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
79347765|NCT04481009|Drug|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
79347766|NCT05327231|Drug|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
79347767|NCT05327231|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
79347768|NCT04453085|Drug|JR-171 (lepunafusp alfa)|JR-171 IV infusion
79347769|NCT01639469|Behavioral|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
79347770|NCT01639469|Behavioral|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
79347771|NCT04855721|Drug|AUR101|Oral ROR-gamma inverse agonist
79347772|NCT04855721|Drug|Placebo|Placebo
79499451|NCT01781286|Behavioral|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
79499452|NCT01780974|Drug|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
79499453|NCT01780974|Drug|Placebo|placebo capsules
79499454|NCT01780662|Drug|Brentuximab Vedotin|Given IV
79499455|NCT01780662|Drug|Gemcitabine Hydrochloride|Given IV
79499456|NCT01780584|Drug|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
79499457|NCT01780584|Drug|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
79499458|NCT01780584|Drug|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
79499459|NCT01780506|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
79660686|NCT04589845|Drug|Camonsertib|Camonsertib will be self-administered by patients orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
79987210|NCT03170830|Diagnostic Test|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
79499460|NCT01780506|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
79815346|NCT04091763|Device|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
79347773|NCT02193074|Drug|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
79347774|NCT02193074|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
79499461|NCT01780506|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
79499462|NCT01780506|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
79499463|NCT01779648|Device|DVT-3000|
79499464|NCT01779648|Device|SCD Express|
79499465|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
79499466|NCT01762800|Drug|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
79499467|NCT01762800|Drug|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
79499468|NCT01762800|Drug|tiotropium bromide placebo|Placebo, Once daily(morning)
79660687|NCT04585191|Behavioral|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
79499469|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
79499470|NCT01597596|Biological|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
79499471|NCT01597596|Biological|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
79815347|NCT00829829|Other|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
79815348|NCT00829829|Drug|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
79499472|NCT01778556|Biological|Metreleptin|Recombinant analog of the human hormone, leptin
79499473|NCT04562376|Other|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
79499474|NCT04562376|Other|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
79499475|NCT04562298|Biological|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
79499476|NCT04562064|Device|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
79499477|NCT01761162|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
79499478|NCT01761162|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
79499479|NCT01778010|Drug|Modafinil 0 mg|Modafinil (0 mg/day)
79499480|NCT01778010|Drug|Modafinil 200 mg|Modafinil (200 mg/day)
79499481|NCT01778010|Drug|Modafinil 400 mg|Modafinil (400 mg/day)
79499482|NCT01778010|Drug|Cocaine 0 mg|Cocaine (0 mg/day)
79499483|NCT01778010|Drug|Cocaine 12 mg|Cocaine (12 mg/day)
79499484|NCT01778010|Drug|Cocaine 25 mg|Cocaine (25 mg/day)
79499485|NCT01778010|Drug|Cocaine 50 mg|Cocaine (50 mg/day)
79499486|NCT04568928|Device|OLTP/PE + FES|12 sessions OLTP/PE + FES
79660688|NCT04585191|Other|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
79499487|NCT01777854|Drug|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
79499488|NCT01777776|Drug|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
79499489|NCT01777776|Drug|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
79987211|NCT03175822|Behavioral|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements [e.g., colour and line] and principles [e.g., proportion and balance] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
79987212|NCT03173482|Other|questionnaire|asking about details of indication of cesarean section
79499490|NCT01777620|Biological|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
79660689|NCT04584502|Behavioral|Mindful Moms Yoga Mindfulness Intervention|MMORE is an 8-session yoga-mindfulness intervention protocol, offered via Zoom over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
79679526|NCT02942628|Other|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
79815349|NCT00829829|Drug|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
79987213|NCT04847934|Behavioral|distraction methods|distraction methods
79347775|NCT04852601|Other|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
79347776|NCT04418102|Dietary Supplement|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
79347777|NCT04418102|Dietary Supplement|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
79347778|NCT04765592|Device|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
79347779|NCT04764968|Drug|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
79347780|NCT02192606|Device|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
79499491|NCT01777620|Drug|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
79660690|NCT04582149|Device|EyeControl Eye-tracking Device|The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
79499492|NCT01777542|Drug|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
79660691|NCT04579666|Drug|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
79660692|NCT04579666|Other|Placebo|Sterile solution of equal volume to active arm
79347781|NCT02192606|Device|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
79347782|NCT01628107|Biological|Epoetin Hospira|Intravenous (IV) injection
79499493|NCT01777542|Drug|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
79499494|NCT01736124|Other|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
79499495|NCT01736124|Other|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
79660693|NCT04573231|Drug|18F-DCFPyL|PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
79347783|NCT04764734|Device|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
79347784|NCT04740151|Procedure|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
79347785|NCT04740151|Procedure|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
79499496|NCT01759446|Drug|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
79499497|NCT01759446|Drug|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
79499498|NCT01759446|Drug|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
79499499|NCT01759446|Drug|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
79499500|NCT01759446|Drug|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
79499501|NCT01777308|Biological|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
79499502|NCT01759368|Device|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
79499503|NCT01777152|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
79499504|NCT01777152|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
79499505|NCT01777152|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
79499506|NCT01777152|Drug|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
79499507|NCT01777152|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
79347786|NCT04745377|Diagnostic Test|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
79347787|NCT04739683|Device|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
79347788|NCT04739683|Device|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
79347789|NCT01583530|Biological|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
79499508|NCT01759290|Device|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
79499509|NCT01758900|Device|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
79499510|NCT01758900|Device|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
79499511|NCT01757184|Drug|Sebelipase Alfa|IV infusions of sebelipase alfa
79499512|NCT01757184|Drug|Placebo|IV infusions of matched placebo
79499513|NCT01775904|Drug|LY2886721 in a Capsule|Administered orally.
79499514|NCT01775904|Drug|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
79499515|NCT01775670|Device|Off-the-shelf splint|Subjects will use an off-the-shelf splint
79499516|NCT01775670|Device|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
79987214|NCT03116386|Other|run-in period|observational time i.e. baseline situation
79987215|NCT03116386|Device|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
79347790|NCT01583530|Biological|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
79347791|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
79499517|NCT01775124|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
79499518|NCT01733316|Drug|RP103|
79499519|NCT01733316|Drug|Cystagon®|
79347792|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
79499520|NCT01732926|Drug|Idelalisib|150 mg tablet administered orally twice daily
79499521|NCT01732926|Drug|Rituximab|375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
79499522|NCT01732926|Drug|Bendamustine|90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
79499523|NCT01732926|Drug|Placebo|Tablet administered orally twice daily
79499524|NCT01755858|Drug|Bendavia|
79499525|NCT01755858|Drug|Placebo|
79499526|NCT01732770|Biological|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
79499527|NCT01732770|Drug|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
79499528|NCT01732770|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
79499529|NCT01732770|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
79499530|NCT01732692|Drug|MOVIPREP|MOVIPREP solution
79499531|NCT01774968|Drug|Human Regular U-500 Insulin|
79987216|NCT03116386|Device|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
79987217|NCT05200650|Combination Product|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
79987218|NCT03116542|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
79987219|NCT03632694|Behavioral|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
79987220|NCT03632694|Behavioral|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
79987221|NCT04814550|Diagnostic Test|FFR|FFR measured by pressure wire, AccuFFRangio computed by coronary angiographic images
79987222|NCT03170674|Other|FT21039|an electronic cigarette product
79987223|NCT03170674|Other|FT21092|an electronic cigarette product
79987224|NCT03170674|Other|FT21018|an electronic cigarette product
79987225|NCT03170596|Drug|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
79499532|NCT01774344|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
79499533|NCT01774344|Drug|Placebo|Placebo tablets matching in appearance
79499534|NCT01732536|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
79987226|NCT03170596|Device|Microneedling|Microneedling is a method of percutaneous collagen induction
79987227|NCT03170752|Behavioral|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
79987228|NCT03173404|Procedure|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
79987229|NCT05194176|Device|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
79987230|NCT03173638|Procedure|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
79347793|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
79347794|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
79347795|NCT01639001|Drug|Crizotinib|250 mg two times daily [BID], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
79499535|NCT01732536|Procedure|Sham procedure|In-office bilateral sham procedure
79499536|NCT01732536|Drug|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
79499537|NCT01755702|Drug|Placebo|Placebo
79499538|NCT01755702|Drug|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
79499539|NCT01755702|Drug|ibuprofen marketed formulation|ibuprofen marketed formulation
79499540|NCT01755702|Drug|Paracetamol marketed formulation|Paracetamol marketed formulation
79987231|NCT03175354|Drug|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
79987232|NCT03175354|Drug|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
79499541|NCT01732458|Drug|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
79499542|NCT01732458|Drug|Placebo to Aprepitant|
79499543|NCT01732458|Drug|Ondansetron|Administered IV at a dose of 4 mg for participants >40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants <1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
79499544|NCT01732458|Drug|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
79499545|NCT01731990|Drug|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
79499546|NCT01731990|Drug|Placebo|Matching placebo of Canakinumab
79499547|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
79499548|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
79499549|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
79499550|NCT01708902|Drug|Metformin 500mg|Metformin 500mg BID
79987233|NCT03173326|Procedure|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
79499551|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
79499552|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
79499553|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
79987234|NCT03173326|Procedure|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
79499554|NCT01708902|Drug|Metformin 1000mg|Metformin 1000mg BID
79499555|NCT01755546|Drug|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
79499556|NCT04413864|Other|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
79987235|NCT02411968|Other|111In-Girentuximab DOTA SPECT|
79660694|NCT04546685|Other|Usual Care|Participants who are randomized to the Usual Care group (waitlist for cross-over to ER) will be instructed to continue with their normal pain care. They will receive only study surveys (baseline, 2 weeks, and 1 month). Upon completion of the 1-month study, UC participants will be invited to cross-over and receive ER. Post-class treatment appraisal/satisfaction data only will be collected.
79987236|NCT04481776|Other|Breakfast consumption|Standardised breakfast consumption across seven days
79499557|NCT04560504|Other|Control Group|Leisure activities
79499558|NCT04560504|Other|Oculomotor Training Group|Eye movement training
79499559|NCT01755234|Drug|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
79499560|NCT01755234|Drug|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
79499561|NCT01731912|Drug|Degarelix|Given SC
79499562|NCT01731912|Radiation|External Beam Radiation Therapy|Undergo standard EBRT
79499563|NCT01731912|Other|Laboratory Biomarker Analysis|Correlative studies
79679529|NCT00516542|Drug|letrozole|A daily dose of 2.5 mg will be used throughout the study.
79987237|NCT04481776|Other|Breakfast omission|No breakfast consumed across seven days
79987238|NCT03172858|Device|Intracervical balloon catheter|cervical ripening balloon
79987239|NCT03172858|Drug|Oxytocin|medication used to induce contractions
79499564|NCT01731678|Procedure|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
79499565|NCT01731600|Drug|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
79987240|NCT02403934|Device|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
79499566|NCT01730586|Drug|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
79499567|NCT04413942|Biological|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
79987241|NCT02403856|Drug|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
79987242|NCT02403856|Drug|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
79499568|NCT04413942|Other|Placebo|Formulation buffer
79499569|NCT01707030|Other|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
79499570|NCT01707030|Other|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
79660695|NCT04546685|Behavioral|Empowered Relief|The participants will attend an online Spanish Empowered Relief class. The two hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a Spanish binaural relaxation audiofile for daily use.
79660696|NCT04543539|Combination Product|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
79660697|NCT04543539|Combination Product|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
79823690|NCT02557412|Behavioral|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
79987243|NCT02403856|Procedure|Ultrasound-guided Needling and Lavage|
79987244|NCT03170284|Drug|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
79499571|NCT01755156|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
79499572|NCT01755156|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
79499573|NCT01755156|Drug|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
79499574|NCT01755156|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
79499575|NCT01755156|Drug|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
79499576|NCT01755156|Drug|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
79499577|NCT01754766|Drug|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
79987245|NCT02411734|Behavioral|Rehabilitation|Rehabilitation after hospitalization
79987246|NCT02411890|Procedure|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
79660698|NCT04528355|Drug|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
79660699|NCT04502082|Biological|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
79660700|NCT04492345|Other|Isokinetic reeducation|Conventional rehabilitation session and isokinetic during 7 weeks
79660701|NCT04492345|Other|Conventional reeducation|Conventional rehabilitation session during 7 weeks
79987247|NCT02411890|Procedure|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
79987248|NCT02411890|Procedure|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
79987249|NCT02411890|Procedure|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
79987250|NCT02407912|Drug|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
79499578|NCT01754766|Other|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
79347796|NCT01639001|Drug|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
79347797|NCT01639001|Drug|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
79347798|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 5mg QD
79347799|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD
79347800|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
79660702|NCT04478123|Drug|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
79660703|NCT04476472|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
79347801|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 25 mg QD
79347802|NCT04443959|Behavioral|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
79347803|NCT05263193|Drug|Caplacizumab|as in real world practice
79347804|NCT02167256|Drug|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
79499579|NCT01754376|Drug|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
79499580|NCT01754376|Drug|Vemurafenib|Tablets given twice daily.
79499581|NCT01605396|Drug|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, & 22-26 of 28-day cycle.
79499582|NCT01605396|Drug|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
79499583|NCT01605396|Drug|Exemestane|Exemestane 25 mg tablet administered PO QD.
79660704|NCT04466891|Drug|ZW25 (Zanidatamab)|Administered intravenously
79660705|NCT04454723|Procedure|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
79660706|NCT04454723|Procedure|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
79660707|NCT04452500|Drug|CORT108297|CORT108297- 180mg daily for 7 days
79660708|NCT04452500|Drug|Placebo|Placebo- 180mg daily for 7 days
79679530|NCT00516542|Drug|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
79679531|NCT00516542|Other|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
79347805|NCT02167256|Drug|AZD0530 125mg daily|Patients with plasma drug level <100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
79347806|NCT02167256|Drug|Placebo|50% of patients will receive placebo treatment for the duration of the study.
79347807|NCT02191046|Device|squeezable bottle|nasal irrigation twice daily for 2 weeks period
79347808|NCT02191046|Device|syringe 20 ml|nasal irrigation twice daily for 2 weeks
79347809|NCT04838795|Biological|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
79347810|NCT04851899|Dietary Supplement|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
79499584|NCT01730118|Biological|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
79499585|NCT01730040|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
79660709|NCT04448977|Drug|Ocrevus|"Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education."
79660710|NCT04432831|Drug|Faricimab|Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
79660711|NCT04432831|Other|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
79660712|NCT04428372|Drug|Mannitol|Hypertonic mannitol infusion
79660713|NCT04428372|Drug|0.9% saline|Normal saline 'placebo' arm
79660714|NCT04427384|Device|GammaTile|Surgically Targeted Radiation Therapy
79660715|NCT04419649|Drug|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
79660716|NCT04407520|Other|No patient treatment is associated with the study|No patient treatment is associated with the study.
79660717|NCT04402294|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.
79660718|NCT04365374|Device|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
79347811|NCT04851899|Dietary Supplement|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
79499586|NCT01730040|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
79499587|NCT01730040|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
79499588|NCT01730040|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
79660719|NCT04365374|Radiation|Stereotactic Radiation Therapy|External Beam Radiation Therapy
79499589|NCT01730040|Drug|Placebo|Placebo for alirocumab and ezetimibe.
79499590|NCT01706328|Drug|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
79660720|NCT04352777|Drug|Abemaciclib|50 - 150mg tablet BID as prescribed per standard of care
79347812|NCT04851899|Dietary Supplement|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
79347813|NCT04838171|Other|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
79987251|NCT02411500|Drug|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
79660721|NCT04352777|Drug|Fulvestrant|500mg as prescribed per standard of care
79987252|NCT03170128|Procedure|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
79347814|NCT02166476|Drug|Meropenem-Vaborbactam|Meropenem-vaborbactam
79660722|NCT04352777|Drug|Aromatase Inhibitors|Letrozole, anastrozole as prescribed per standard of care
79347815|NCT02166476|Drug|Piperacillin-Tazobactam|Piperacillin-tazobactam
79347816|NCT02166476|Drug|Levofloxacin|Levofloxacin
79660723|NCT04343365|Other|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
79660724|NCT04329728|Drug|AVM0703|Intravenous infusion over ~1 hours
79660725|NCT04312399|Procedure|blood take|Blood is taken to analyse degratdation products of the metabolism of amyloid
79987253|NCT03170128|Behavioral|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
79347817|NCT02166476|Drug|Saline|Saline
79347818|NCT05318261|Procedure|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
79499591|NCT01706328|Drug|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
79347819|NCT05237609|Dietary Supplement|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
79347820|NCT05237609|Other|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
79499592|NCT01706328|Drug|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
79660726|NCT04300647|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
79499593|NCT01706328|Drug|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
79660727|NCT04300647|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79499594|NCT01706328|Drug|Salbutamol as needed|Salbutamol inhalation powder
79499595|NCT01753518|Device|Subcuticular suture|subcuticular Monocryl suture closure
79499596|NCT01753518|Device|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
79499597|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
79499598|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
79660728|NCT04297683|Drug|Zilucoplan|"Drug: Zilucoplan~Administration: Subcutaneous injection~Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight"
79660729|NCT04297683|Drug|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
79660730|NCT04297683|Drug|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dose: 30 mg or 60 mg daily"
79660731|NCT04297683|Drug|Pridopidine|"Drug: Pridopidine~Administration: Oral~Dose: 45mg twice daily"
79660732|NCT04297683|Drug|SLS-005 Trehalose|"Drug: SLS-005 Trehalose~Administration: Infusion~Dose: 0.75 g/kg weekly"
79987254|NCT03170050|Device|YYD701-2|HA Filler
79987255|NCT03170050|Device|Restylane Perlane Lidocaine|HA Filler
79987256|NCT02407834|Other|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
79987257|NCT02407834|Other|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
79987258|NCT02407834|Other|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
79987259|NCT02407834|Other|S4|Immersion in Saline solution for 20 minutes, during 7 days.
79987260|NCT02407678|Genetic|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
79499599|NCT01706250|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
79660733|NCT04297683|Drug|ABBV-CLS-7262|"Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2"
79660734|NCT04297683|Drug|DNL343|"Drug: DNL343~Administration: Oral~Dose: Once per day"
79660735|NCT04291599|Drug|Ketorolac|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
79660736|NCT04291599|Drug|Opioid|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
79660737|NCT04275973|Device|Lower limb prostheses|"Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA)."
79987261|NCT02411266|Other|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
79660738|NCT04275973|Device|Orthoses for Drop-foot|Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
79987262|NCT02407522|Dietary Supplement|Black rice|They asked to keep their normal life style during intervention
79987263|NCT02407522|Other|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
79347821|NCT02224274|Drug|Clopidogrel|
79660739|NCT04275973|Device|Footwear|Different footwear will be used.
79987264|NCT02411188|Behavioral|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
79987265|NCT03169738|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79987266|NCT03169738|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
79987267|NCT03169738|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79987268|NCT03169738|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79660740|NCT04274790|Procedure|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
79660741|NCT04274660|Behavioral|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
79660742|NCT04267393|Drug|BMS-986263|Specified dose on specified days
79987269|NCT03169738|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79987270|NCT03169738|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79987271|NCT03169738|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
79987272|NCT03169738|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79347822|NCT02224274|Drug|Ticagrelor|
79347823|NCT04764110|Dietary Supplement|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
79347824|NCT04764110|Other|Placebo|Maltodextrin
79347825|NCT05219669|Drug|Nalmefene Hydrochloride|3mg nasal spray
79499600|NCT01706250|Other|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
79499601|NCT01706250|Other|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
79499602|NCT01706250|Other|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
79499603|NCT01729728|Drug|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
79499604|NCT01729026|Other|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
79660743|NCT04267393|Other|Placebo|Specified dose on specified days
79660744|NCT04264949|Other|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
79660745|NCT04264949|Other|conventional care|conventional care and the therapeutic education program
79987273|NCT03169738|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79987274|NCT03169738|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
79987275|NCT03169738|Drug|Lovaza|Omega-3-acid ethyl esters
79987276|NCT03169738|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79987277|NCT03169738|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
79987278|NCT03169738|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RαSu/IgG1 Fc complex]
79987279|NCT03169738|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
79987280|NCT03169738|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
79987281|NCT03169738|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79987282|NCT03169738|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
79987283|NCT03169738|Biological|GI-4000|Ras yeast vaccine
79987284|NCT03169738|Biological|GI-6207|CEA yeast vaccine
79987285|NCT03169738|Biological|GI-6301|Brachyury yeast vaccine
79347826|NCT04763798|Other|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
79499605|NCT01728792|Biological|TDV|TDV IM or SC injection
79987286|NCT03169738|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
79987287|NCT02407600|Drug|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
79987288|NCT02407600|Drug|Placebo|
79499606|NCT01752036|Radiation|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
79987289|NCT02403544|Radiation|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
79987290|NCT02403544|Drug|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
79499607|NCT01728324|Drug|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
79499608|NCT01728324|Drug|Ribavirin: 24-week treatment|24 weeks of active treatment
79499609|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
79499610|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
79499611|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
79660746|NCT04259229|Other|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
79660747|NCT04259229|Other|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
79660748|NCT04257045|Other|Interview|Participate in semi-structure, in-depth qualitative interviews
79660749|NCT04257045|Other|Questionnaire Administration|Complete questionnaires
79660750|NCT04257045|Other|Survey Administration|Complete survey
79679532|NCT05305170|Diagnostic Test|Levels of EETs, DHETs and HETEs|The plasmatic concentration of EETs, DHETs, and HETEs.
79987291|NCT02403544|Drug|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
79987292|NCT02411032|Behavioral|Reminder|Customer gets mailing that reminds them to take their medication.
79987293|NCT02411032|Behavioral|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
79987294|NCT02411032|Behavioral|Fresh start framing|The fresh start event will be highlighted in the mailings.
79987295|NCT02411344|Drug|Pertuzumab|"Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
79499612|NCT01728324|Drug|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
79499613|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
79499614|NCT01728324|Drug|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
79499615|NCT01728324|Drug|Faldaprevir: 16-week treatment|16 weeks of active treatment
79499616|NCT01728324|Drug|Ribavirin: 16-week treatment|16 weeks of active treatment
79499617|NCT01728324|Drug|RBV: 24-week treatment|24 weeks of active treatment
79499618|NCT01728324|Drug|BI 207127: 16-week treatment|16 weeks of active treatment
79499619|NCT01728246|Drug|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
79499620|NCT01728246|Drug|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
79499621|NCT04414020|Drug|Progesteron|intramusculer progesterone
79499622|NCT04559178|Other|Fluid challenge|fluid challenge administration when patient is in the gray zone
79499623|NCT04559022|Procedure|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
79679533|NCT05302947|Drug|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
79679534|NCT05302947|Drug|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
79987296|NCT02407444|Other|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
79347827|NCT04763798|Other|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
79499624|NCT01705236|Drug|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
79499625|NCT01705080|Device|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
79499626|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
79499627|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
79499628|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
79347828|NCT04763798|Other|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
79499629|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
79499630|NCT01751802|Drug|Ecopipam|Antagonist of the dopamine D1 receptor
79499631|NCT01751802|Drug|Placebo|Placebo for Ecopipam
79499632|NCT01704456|Behavioral|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
79499633|NCT01704456|Behavioral|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
79499634|NCT04166526|Device|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
79660751|NCT04231500|Diagnostic Test|Skin swabs|Pre-moistened skin swabs will be collected before the patient starts the conditioning regimens (before conditioning; start of HSCT = day 0, on the day of the transplantation an the repeated in week 4, 12, 24, 36 and 52 after allo-HSCT. The first swab serves as baseline reference (ideally taken at the earliest one week after a systemic antibiotic treatment). Swabs will be taken from the neck, back, right hip, buccal oral cavity and the genital mucosae. In patients who develop acute or chronic skin-GVHD additional swabs will be taken from affected skin at the time of diagnosis and then again according to the schedule of the non-lesioned skin swabs.
79679535|NCT05302947|Drug|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
79823691|NCT02557412|Other|Conventional treatment|Hygiene and diet recommendations on sleep
79987297|NCT02407444|Other|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
79823692|NCT02542202|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
79823693|NCT02487134|Device|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
79823694|NCT02487134|Device|Control|Closure of the abdomen with conventional technique
79499635|NCT04166526|Device|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
79499636|NCT01703988|Drug|Nusinersen|Single IT injection for each dose
79499637|NCT01703832|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
79499638|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
79499639|NCT01703286|Drug|Linagliptin|given once daily for 28 days
79499640|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
79499641|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
79987298|NCT03657095|Drug|Esuberaprost|Sodium tablets
79499642|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
79987299|NCT03657095|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
79987300|NCT03100344|Drug|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
79499643|NCT01703286|Drug|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
79347829|NCT04763252|Other|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
79499644|NCT04166448|Other|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
79347830|NCT05369039|Drug|Roflumilust|A selective phosphodiesterase 4 Inhibitor
79499645|NCT01703208|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
79499646|NCT01703208|Drug|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
79499647|NCT01727700|Drug|Aripiprazole|Once-daily, tablet
79499648|NCT01727700|Drug|Placebo|
79347831|NCT05369039|Drug|Prednisolone|Systemic corticosteroid
79499649|NCT01727154|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
79347832|NCT04373369|Drug|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
79347833|NCT04373369|Drug|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
79347834|NCT04310189|Procedure|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
79347835|NCT04791059|Drug|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
79347836|NCT04791059|Drug|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
79347837|NCT04791059|Drug|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
79347838|NCT05405855|Behavioral|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
79347839|NCT02189252|Drug|Epanova|
79347840|NCT02189252|Drug|Lovaza|
79347841|NCT05369117|Behavioral|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
79347842|NCT04766099|Other|Childbirth Educational Video|Educational video describing techniques for pushing
79347843|NCT05399069|Drug|VGR-R01|Gene Replacement Therapy
79347844|NCT05398913|Drug|Rimonabant|Rimonabant
79347845|NCT04256837|Device|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
79347846|NCT05396729|Device|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
79347847|NCT01583374|Drug|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
79660752|NCT04231500|Diagnostic Test|Skin punch biopsies|During the first visit, a single skin punch biopsy will be taken to state the skin condition and microbiome before allo-HSCT. Further biopsies will only be taken in case of acute or chronic cutaneous GVHD. A 4-6 mm punch biopsy will be taken from the affected skin area and a second one from a nearby unaffected part of the skin. Before the biopsy, skin disinfection will be performed to avoid contamination with surface bacteria.
79660753|NCT04231500|Diagnostic Test|additional blood sampling|an additional tube of blood (2.7ml) and an additional tube of serum (6ml) will be taken and frozen during visits 1, 2, 3 and 7 in the course of blood collection, in order to be able to carry out any later laboratory tests that may prove to be useful depending on the course of the study.
79660754|NCT04208802|Other|Use of fluoridated toothpaste|Use of fluoridated toothpaste
79347848|NCT01583374|Drug|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
79347849|NCT01583374|Drug|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
79499650|NCT01725750|Device|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
79499651|NCT01725750|Device|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
79499652|NCT01725282|Drug|quetiapine extended release (XR)|Extended release tablets
79499653|NCT01725282|Drug|Placebo|matching tablets
79499654|NCT01725126|Drug|GSK2890457|Provided as powder and capsule.
79660755|NCT04208802|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
79660756|NCT04208802|Other|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
79660757|NCT04207086|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
79660758|NCT04207086|Drug|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
79987301|NCT03100344|Drug|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
79987302|NCT02403700|Device|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
79987303|NCT02407366|Drug|Icotinib|Icotinib (125 mg ,Three times daily)
79987304|NCT02407366|Drug|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
79987305|NCT02407366|Drug|Carboplatin|Carboplatin (AUC，5) every 21 days
79347850|NCT01583296|Behavioral|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
79347851|NCT01583296|Behavioral|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
79347852|NCT04189835|Diagnostic Test|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
79347853|NCT04165577|Device|rTMS|1-Hz rTMS targeting frontal pole
79347854|NCT04165577|Device|sham rTMS|sham rTMS targeting frontal pole
79347855|NCT02222714|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
79347856|NCT02222714|Drug|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
79347857|NCT04836689|Device|nasal intermittent positive pressure ventilation (NIPPV).|"NIPPV will be administered using Leoni (Heinen&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate<100 bpm), saturation<90% and>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification."
79347858|NCT04821401|Dietary Supplement|Rejuvant|"Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA"
79347859|NCT04821401|Dietary Supplement|Placebo|Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
79347860|NCT05226143|Other|Gel Cream|Gel Cream
79347861|NCT03291743|Device|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
79499655|NCT01725126|Drug|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
79499656|NCT01725126|Drug|Placebo|Provided as powder and Capsule.
79499657|NCT01725126|Drug|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
79660759|NCT04191135|Biological|Pembrolizumab|intravenous (IV) infusion
79987306|NCT02407366|Radiation|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
79347862|NCT04145219|Biological|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
79347863|NCT04145219|Other|Placebo|For daily administration (1 tablet per day)
79347864|NCT04808921|Diagnostic Test|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
79660760|NCT04191135|Drug|Olaparib|oral tablets
79660761|NCT04191135|Drug|Carboplatin|IV infusion
79660762|NCT04191135|Drug|Gemcitabine|IV infusion
79660763|NCT04189770|Device|Accelerometer|Wear accelerometer
79660764|NCT04189770|Other|Ecological Momentary Assessment|Complete EMA questionnaire
79660765|NCT04189770|Other|Questionnaire Administration|Complete questionnaire
79987307|NCT03738137|Device|Narotrend|Narcotrend motoring
79987308|NCT03738137|Device|BIS|Bispectral index monitoring
79987309|NCT03738137|Drug|Sufentanil|sufentanil is applied.
79987310|NCT03738137|Drug|Lidocaine|Topical Anesthesia
79347865|NCT05652959|Device|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
79499658|NCT01751724|Drug|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
79499659|NCT01751724|Other|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
79499660|NCT01751646|Dietary Supplement|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
79499661|NCT01751646|Dietary Supplement|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
79499662|NCT01751568|Drug|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
79499663|NCT01751412|Radiation|Proton Radiation|
79499664|NCT04556682|Device|Rotational atherectomy|Device used for severely calcified coronary lesion preparation before stent implantation.
79499665|NCT04556682|Device|Intravascular lithotripsy|Device used for severely calcified coronary lesion preparation before stent implantation.
79347866|NCT05652881|Procedure|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
79347867|NCT04102865|Device|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
79499666|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
79499667|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
79499668|NCT01606254|Drug|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
79499669|NCT01750242|Device|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
79499670|NCT01723254|Biological|IGE-1|Intramuscular, multiple dose
79499671|NCT01723254|Biological|IGE-2|Intramuscular, multiple dose
79499672|NCT01723254|Biological|Saline|Saline (0.9% sodium chloride)
79499673|NCT01722162|Drug|Bevacizumab|
79660766|NCT04189770|Other|Survey Administration|Complete survey
79347868|NCT03132155|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
79347869|NCT03107195|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
79347870|NCT02164916|Biological|cetuximab|Given IV
79347871|NCT02164916|Drug|irinotecan hydrochloride|Given IV
79347872|NCT02164916|Drug|vemurafenib|Given PO
79499674|NCT01722162|Drug|Capecitabine|
79823695|NCT00440557|Drug|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
79499675|NCT01722162|Drug|Levocetirizine|
79987311|NCT03738137|Drug|Midazolam|midazolam is applied.
79499676|NCT01721772|Biological|BMS-936558 (Nivolumab)|
79499677|NCT01721772|Biological|Placebo matching BMS-936558 (Nivolumab)|
79499678|NCT01721772|Drug|Dacarbazine|
79499679|NCT01721772|Drug|Placebo matching Dacarbazine|
79499680|NCT01702428|Biological|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
79499681|NCT01702428|Biological|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
79499682|NCT01702428|Biological|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
79499683|NCT01702428|Biological|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
79499684|NCT01702428|Biological|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
79499685|NCT01701258|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
79499686|NCT01701258|Drug|Placebo|single-dose placebo capsule during the fMRI session only
79499687|NCT01700946|Drug|dexamethasone|given intravenously or orally
79499688|NCT01700946|Drug|vincristine sulfate|given intravenously
79499689|NCT01700946|Biological|rituximab|given intravenously
79499690|NCT01700946|Drug|clofarabine|given intravenously
79499691|NCT01700946|Drug|cyclophosphamide|given intravenously
79499692|NCT01700946|Drug|etoposide|given intravenously
79347873|NCT04091867|Drug|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
79499693|NCT01700946|Biological|aldesleukin|given subcutaneously
79499694|NCT01700946|Drug|pegaspargase|given intravenously
79347874|NCT04091867|Drug|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
79347875|NCT04091867|Radiation|Radiation Therapy|6930 cGy IMRT starting D15-D18
79347876|NCT05652101|Other|collection of medical data|"The data collected concerns:~Sex~Age~Socio-professional category of patients or parents / level of education of the parents~Family history~Neonatal patient data (pregnancy, childbirth)~Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~Genetic data if available"
79499695|NCT01700946|Drug|methotrexate|given intrathecally or intravenously
79499696|NCT01700946|Drug|mercaptopurine|given orally
79499697|NCT01700946|Drug|cytarabine|given intrathecally or intravenously
79499698|NCT01700946|Drug|mitoxantrone|given intravenously
79499699|NCT01700946|Drug|teniposide|given intravenously
79499700|NCT01700946|Drug|vinblastine|given intravenously
79499701|NCT01700946|Biological|natural killer cell infusion|undergo allogeneic natural killer cell infusion
79499702|NCT01700946|Other|laboratory biomarker analysis|correlative studies
79987312|NCT02410876|Procedure|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
79499703|NCT01700946|Drug|therapeutic hydrocortisone|given intrathecally
79347877|NCT05652101|Other|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
79499704|NCT01700946|Procedure|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
79499705|NCT01700946|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79987313|NCT02410876|Procedure|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
79987314|NCT03737279|Behavioral|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
79499706|NCT04565886|Device|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
79499707|NCT04565886|Device|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
79499708|NCT04548804|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
79499709|NCT01748994|Drug|Pioglitazone|30mg per day for four months
79499710|NCT01748994|Drug|Placebo|
79499711|NCT01721070|Drug|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
79499712|NCT01721070|Drug|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
79499713|NCT01748760|Behavioral|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
79499714|NCT01748760|Other|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
79987315|NCT03737279|Behavioral|Routine Care|"Routine care including ACOG educational pamphlets:~Day 1: Nutrition in Pregnancy~Day 2: Heart Health for Women~Day 3: Exercise after Pregnancy"
79347878|NCT05290259|Other|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
79499715|NCT01748292|Drug|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
79499716|NCT01720602|Drug|vorinostat|Given PO
79499717|NCT01720602|Drug|anastrozole|Given PO
79499718|NCT01720602|Drug|letrozole|Given PO
79987316|NCT02407210|Drug|azilsartan|
79987317|NCT02407210|Drug|Olmesartan medoxomil|
79987318|NCT03737201|Other|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
79987319|NCT03737201|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
79499719|NCT01720602|Drug|exemestane|Given PO
79499720|NCT01720602|Procedure|positron emission tomography|Correlative studies
79499721|NCT01720602|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
79499722|NCT01720602|Radiation|fludeoxyglucose F 18|Correlative studies
79499723|NCT01720602|Other|laboratory biomarker analysis|Correlative studies
79499724|NCT01746732|Drug|Ortho-Cyclen|Oral administration
79499725|NCT01746732|Drug|Evacetrapib|Oral administration
79499726|NCT01720524|Drug|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
79499727|NCT01720524|Drug|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
79987320|NCT03737201|Other|Control|without any cavity disinfectant
79660767|NCT04189146|Behavioral|Inner Engineering Intervention|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
79660768|NCT04169217|Behavioral|Prehabilitation|"A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform."
79987321|NCT02951533|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
79347879|NCT04818125|Other|Patients with breast cancer (stage I, II III or IV)|"Blood samples will be collected at different times:~at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study."
79347880|NCT05651789|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure <90 mmHg.
79347881|NCT05651789|Drug|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
79499728|NCT01720446|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
79499729|NCT01720446|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
79499730|NCT01720446|Drug|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
79499731|NCT01746108|Biological|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
79499732|NCT01717638|Biological|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
79660769|NCT04166409|Procedure|Biospecimen Collection|Correlative studies
79347882|NCT05651477|Device|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
79347883|NCT05651477|Device|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
79347884|NCT02999477|Drug|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
79347885|NCT02999477|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
79347886|NCT02999477|Procedure|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
79499733|NCT01717638|Biological|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
79499734|NCT01745094|Drug|mirabegron|oral
79499735|NCT01745094|Drug|solifenacin|oral
79499736|NCT01697748|Device|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
79660770|NCT04166409|Drug|Carboplatin|Given IV
79660771|NCT04166409|Procedure|Magnetic Resonance Imaging|Undergo MRI
79660772|NCT04166409|Other|Quality-of-Life Assessment|Ancillary studies
79660773|NCT04166409|Other|Questionnaire Administration|Ancillary studies
79660774|NCT04166409|Drug|Selumetinib Sulfate|Given PO
79660775|NCT04166409|Drug|Vincristine Sulfate|Given IV
79660776|NCT04164173|Device|EzPAP|Patient will receive 10 min EzPAP 4 times daily
79660777|NCT04164173|Device|Metaneb|Patient will receive 10 min Metaneb 4 times daily
79499737|NCT01697748|Device|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
79499738|NCT01717326|Drug|Grazoprevir|100 mg tablet orally QD
79660778|NCT04164173|Device|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
79660779|NCT04157322|Diagnostic Test|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
79660780|NCT04152772|Device|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
79987322|NCT02951533|Drug|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
79347887|NCT02222558|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
79987323|NCT03175042|Device|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
79347888|NCT02975999|Drug|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
79347889|NCT02975999|Drug|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
79347890|NCT05287529|Behavioral|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
79347891|NCT05287529|Behavioral|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
79660781|NCT04152200|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
79660782|NCT04145388|Other|online cancer risk assessment|Electronic surveys to collect family cancer history information.
79660783|NCT04145388|Other|Usual care|Family cancer history captured by provider during a clinical encounter
79660784|NCT04127578|Biological|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
79660785|NCT04127578|Drug|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
79987324|NCT03738059|Drug|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
79987325|NCT03738059|Other|normal saline 0.9%|will receive intravenous normal saline 0.9%
79987326|NCT05233462|Other|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
79347892|NCT02188784|Drug|Polysaccharide Iron Complex 150 mg|Oral Iron
79347893|NCT02188784|Drug|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
79347894|NCT02900339|Device|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
79347895|NCT02848781|Device|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
79660786|NCT04127578|Drug|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
79660787|NCT04111874|Behavioral|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
79660788|NCT04111874|Behavioral|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
79660789|NCT04109638|Device|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
79987327|NCT05233462|Other|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
79987328|NCT02700412|Drug|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
79987329|NCT03115606|Device|C-Mac D Blade|Videolaryngoscope
79987330|NCT03115606|Device|Fastrach LMA|Laryngeal mask airway
79987331|NCT02403466|Behavioral|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
79987332|NCT02403388|Other|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
79987333|NCT02407288|Device|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
79347896|NCT02848781|Procedure|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
79347897|NCT02222246|Drug|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
79347898|NCT02222246|Drug|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
79347899|NCT02222246|Drug|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
79347900|NCT02222246|Drug|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
79347901|NCT04793555|Other|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
79347902|NCT02188160|Drug|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
79347903|NCT02188160|Drug|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
79347904|NCT04190030|Behavioral|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
79347905|NCT04190030|Behavioral|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
79987334|NCT02407288|Device|Sham tDCS|
79347906|NCT03991949|Other|Experimental Infant Formula|Formula fed Ad libitum
79347907|NCT02220998|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
79347908|NCT02220998|Drug|SOF|SOF 400 mg tablet administered orally once daily
79347909|NCT02220998|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79347910|NCT02220920|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
79347911|NCT02220920|Drug|Placebo|The patients will receive Placebo orally for 16 weeks
79347912|NCT02220920|Drug|Insulin|
79347913|NCT03966053|Drug|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
79347914|NCT05204693|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
79660790|NCT04107298|Device|SUNDANCE™ Drug Coated Balloon|Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
79987335|NCT02406898|Device|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
79987336|NCT02351544|Drug|Botulinum Toxin Type A|
79987337|NCT02351544|Procedure|Surgery|
79987338|NCT02351544|Other|Daily headache diary|
79987339|NCT02351544|Other|Migraine Disability Assessment Test (MIDAS)|
79987340|NCT02351544|Other|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
79987341|NCT02351544|Other|Migraine-Specific Quality of Life Questionnaire (MSQ)|
79987342|NCT02406976|Other|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
79987343|NCT02406976|Behavioral|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
79987344|NCT02406976|Other|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
79347915|NCT05204693|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
79347916|NCT03949829|Diagnostic Test|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
79347917|NCT03946631|Diagnostic Test|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
79987345|NCT02288832|Other|-self-collected vaginal samples|
79660791|NCT04104139|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
79987346|NCT02288832|Drug|zithromax|
79987347|NCT02288832|Other|usual practices|
79987348|NCT03175588|Other|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
79987349|NCT03173014|Device|EEG|EEG monitoring
79987350|NCT02401906|Other|MRI|
79987351|NCT02401984|Other|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
79987352|NCT02403232|Procedure|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
79347918|NCT05203133|Dietary Supplement|Energy Balance|Energy balance phase to elicit weight-maintenance
79347919|NCT05203133|Dietary Supplement|Energy Deficit|Energy deficit phase to elicit weight-loss
79347920|NCT05203133|Dietary Supplement|Baseline Assessment|Free-living assessment of energy status
79347921|NCT04791293|Other|MELD-Na score|MELD-Na scores will be compared between the groups
79347922|NCT02710721|Other|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
79347923|NCT02710721|Other|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
79347924|NCT02673905|Other|Tissue Engineered Product|Implantation of tissue engineered products
79347925|NCT04790279|Drug|Amlodipine|Initiation of amlodipine 2.5 mg
79347926|NCT04790279|Drug|NIFEdipine ER|Initiation of nifedipine ER 30 mg
79347927|NCT02610023|Other|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
79347928|NCT02610023|Other|Laboratory Biomarker Analysis|Correlative studies
79347929|NCT02610023|Device|Spectroscopy|Undergo resonance Raman spectroscopy
79347930|NCT03877289|Drug|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
79499739|NCT01717326|Drug|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
79660792|NCT04104139|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79660793|NCT04104139|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79660794|NCT04089579|Biological|Cord Tissue Mesenchymal Stromal Cells|Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
79660795|NCT04089579|Other|Placebo Infusion|Placebo comparative infusion
79987353|NCT02403232|Device|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
79987354|NCT02403232|Device|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
79499740|NCT01717326|Drug|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
79499741|NCT01717326|Drug|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
79660796|NCT04086953|Diagnostic Test|6-minute walk test|This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
79660797|NCT04086953|Diagnostic Test|Walk-Time Limit Tes|Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
79660798|NCT04086953|Diagnostic Test|Incremental shuttle walk test|Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
79660799|NCT04086953|Diagnostic Test|Endurance shuttle walk test|"Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT."
79660800|NCT04086953|Diagnostic Test|Respiratory Functional Assessment|Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
79660801|NCT04083898|Biological|Isatuximab|Isatuximab will be administered on a 28-day cycle
79660802|NCT04083898|Drug|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
79660803|NCT04083898|Drug|Prednisone|Prednisone will be administered on a 28-day cycle as follows
79987355|NCT02406820|Device|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
79660804|NCT04069520|Other|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine realtime transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 12-week, pre-season training program occurring over 6 weeks."
79660805|NCT04069520|Other|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 12-week, pre-season training program occurring over 6 weeks.
79660806|NCT04067726|Drug|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
79660807|NCT04067726|Drug|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
79660808|NCT04067726|Drug|Calcium|-Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
79347931|NCT03877289|Other|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
79987356|NCT03116308|Drug|Opicapone (OPC)|50 mg OPC capsules; oral route
79987357|NCT02402998|Drug|Eltrombopag|Eltrombopag 50 mg/daily.
79987358|NCT03665441|Drug|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
79987359|NCT03665441|Drug|Gemcitabine plus Abraxane|gemcitabine, Abraxane
79987360|NCT03665441|Drug|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
79987361|NCT03169660|Drug|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
79987362|NCT02401828|Drug|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
79987363|NCT02699866|Device|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
79347932|NCT03877289|Drug|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
79987364|NCT03663569|Drug|Spiolto® Respimat®|Drug
79660809|NCT04067726|Drug|Vitamin D3|Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
79987365|NCT02401438|Other|5D ultrasound|
79987366|NCT02401438|Other|2D ultrasound|
79499742|NCT01697592|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
79660810|NCT04067726|Procedure|Core needle biopsy|Baseline and 12 months
79347933|NCT03877055|Drug|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
79499743|NCT01697592|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
79660811|NCT04067726|Procedure|Blood draw|Baseline and 12 months
79660812|NCT04054596|Behavioral|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
79660813|NCT04045795|Drug|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
79660814|NCT04045795|Drug|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
79660815|NCT04045795|Drug|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
79987367|NCT02401516|Device|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
79987368|NCT03596762|Drug|Elinzanetant (BAY3427080)|BAY3427080 capsules
79987369|NCT03596762|Drug|Placebo|Placebo capsules
79347934|NCT03877055|Drug|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
79347935|NCT04194047|Other|Transfusion|RBC transfusion (1 unit)
79347936|NCT04194047|Other|Crystalloids infusion|Infusion of 500 ml of balanced crystalloids
79987370|NCT04481386|Device|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
79660816|NCT04045795|Drug|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79660817|NCT04045795|Device|Investigational injector device|Subcutaneous administration
79660818|NCT04035486|Drug|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
79660819|NCT04035486|Drug|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
79660820|NCT04035486|Drug|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
79987371|NCT02401594|Drug|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
79660821|NCT04033978|Behavioral|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
79660822|NCT04033978|Behavioral|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
79987372|NCT02401594|Drug|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
79228271|NCT01811862|Procedure|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
79347937|NCT04792151|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
79347938|NCT05494619|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and <100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
79347939|NCT05494619|Drug|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to < 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
79660823|NCT04025905|Behavioral|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
79660824|NCT04025905|Behavioral|Informations|informations about work environment, social environment, stress management, sleep management, treatments
79660825|NCT04025398|Behavioral|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
79660826|NCT04025398|Behavioral|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
79660827|NCT04021368|Drug|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
79660828|NCT04015921|Other|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
79660829|NCT04010435|Device|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
79660830|NCT04010435|Device|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
79660831|NCT04010266|Device|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
79823696|NCT00440557|Drug|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
79987373|NCT02406508|Device|Melphalan/HDS|
79987374|NCT02406508|Drug|Sorafenib|
79987375|NCT02401360|Drug|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
79987376|NCT02401360|Drug|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
79987377|NCT02402686|Drug|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
79987378|NCT03736577|Other|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
79499744|NCT01744782|Drug|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was <1 nmol ½ cystine/mg protein.
79660832|NCT04010266|Drug|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
79660833|NCT04008368|Device|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
79660834|NCT04004442|Drug|Avelumab|Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
79660835|NCT04004442|Drug|AVB-S6-500|AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
79660836|NCT03966651|Drug|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
79347940|NCT05494619|Drug|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
79347941|NCT03826043|Diagnostic Test|Blood sample analysis|Thrombophilia, blood count and coagulation count
79347942|NCT05474495|Other|Pelvic floor muscle training|Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
79347943|NCT05474495|Other|Transverse abdominas strength training|Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
79347944|NCT01634555|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
79347945|NCT01634555|Drug|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
79347946|NCT01634555|Drug|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
79347947|NCT01634555|Drug|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
79347948|NCT05355155|Drug|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
79347949|NCT01634243|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
79499745|NCT01744392|Behavioral|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
79499746|NCT01604850|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
79499747|NCT01604850|Drug|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
79499748|NCT01604850|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
79499749|NCT01604850|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
79499750|NCT01742286|Drug|Ceritinib|"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
79499751|NCT01697358|Device|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
79815350|NCT04092036|Device|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
79347950|NCT02402309|Drug|Active topical NS2 1% dermatologic cream|
79347951|NCT02402309|Drug|Vehicle placebo 0.0% NS2 dermatologic cream|
79499752|NCT01697358|Drug|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
79499753|NCT01716234|Drug|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
79660837|NCT03952598|Device|3T MRI scanner|Research proton MRS (1H-MRS)followed by DW-MRI
79660838|NCT03932409|Drug|Pembrolizumab|"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"
79660839|NCT03932409|Radiation|Vaginal cuff brachytherapy (VCB)|Treatment should commence within 12 weeks of the surgery/hysterectomy
79660840|NCT03932409|Drug|Paclitaxel|after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
79660841|NCT03932409|Drug|Carboplatin|after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
79660842|NCT03930953|Drug|CC-99282|Specified dose on specified days
79823697|NCT00440557|Drug|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
79347952|NCT04815317|Other|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
79347953|NCT04815317|Other|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
79499754|NCT01716234|Drug|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
79499755|NCT01716234|Drug|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
79499756|NCT01716234|Drug|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
79499757|NCT01716156|Drug|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
79499758|NCT01716156|Drug|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
79499759|NCT04555512|Other|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
79660843|NCT03930953|Drug|Rituximab|Specified dose on specified days
79660844|NCT03930953|Drug|Obinutuzumab|Specified dose on specified days
79823698|NCT02528227|Other|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
79499760|NCT04555512|Other|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
79347954|NCT04815317|Other|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
79499761|NCT01739790|Drug|N-Acetylcysteine|1800 mg twice daily for 8 weeks
79499762|NCT01739790|Drug|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
79347955|NCT04815317|Other|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
79347956|NCT01542034|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79499763|NCT01696032|Drug|SGI-110|
79499764|NCT01696032|Drug|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
79660845|NCT03930953|Drug|Tafasitamab|Specified dose on specified days
79660846|NCT03930953|Drug|Valemetostat|Specified dose on specified days
79660847|NCT03905694|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
79660848|NCT03892642|Drug|Avelumab|"Induction phase:~once weekly for weeks 1-6,~once every 2 weeks at week 8, 10, and 12~Maintenance phase:~Once every week for weeks 1-3~Once every 2 weeks starting at week 5, until the next BCG treatment"
79660849|NCT03892642|Biological|BCG|"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"
79660850|NCT03872752|Behavioral|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
79347957|NCT01542034|Drug|Placebo|Phosphate buffered saline placebo for injection
79499765|NCT01696032|Drug|Carboplatin|
79499766|NCT01695954|Drug|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
79823699|NCT02528227|Other|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
79823700|NCT02528227|Other|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
79499767|NCT01695954|Drug|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
79499768|NCT01695954|Drug|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
79499769|NCT01695954|Drug|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
79499770|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
79499771|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
79660857|NCT03832062|Other|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
79347958|NCT01564732|Device|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
79347959|NCT01564732|Device|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
79347960|NCT05271929|Biological|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
79499772|NCT01694706|Drug|omeprazole|medium dose of omeprazole
79499773|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
79499774|NCT01693692|Drug|TD-9855 Group 1|
79499775|NCT01693692|Drug|TD-9855 Group 2|
79499776|NCT01693692|Drug|Placebo|
79660858|NCT03828773|Drug|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients >18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
79679536|NCT05302947|Other|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
79499777|NCT01693614|Drug|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
79499778|NCT01715298|Drug|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
79499779|NCT01715298|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
79499780|NCT01713582|Drug|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
79499781|NCT01739400|Drug|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
79499782|NCT01713348|Device|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
79499783|NCT01713348|Device|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
79499784|NCT01737996|Drug|BI 207127 + faldaprevir|fixed dose combination
79660859|NCT03828773|Drug|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
79347961|NCT05271929|Other|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~Casirivimab~Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~Imdevimab~Sotrovimab (Xevudy)~Tixagevimab / Cilgavimab (Evusheld)~Molnupiravir (MK-4482)~Nirmatrevlir / Ritonavir (Paxlovid)~Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
79660860|NCT03824639|Behavioral|Structured exercise|Exercise instruction and encouragement
79660861|NCT03824639|Behavioral|Health Education|Provision of general information about a variety of health topics
79347962|NCT01541644|Device|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
79660862|NCT03807973|Drug|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous [Zr-89]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using [Zr-89]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
79987379|NCT02402608|Dietary Supplement|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
79660863|NCT03805789|Biological|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
79660864|NCT03805789|Biological|Placebo|Albumin solution administered intravenously
79815351|NCT04091529|Device|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
79660865|NCT03781128|Drug|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
79347963|NCT05428397|Diagnostic Test|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
79347964|NCT04853056|Device|virtual reality|wearing virtual reality glasses
79660866|NCT03781128|Drug|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
79660867|NCT03761017|Biological|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
79660868|NCT03752203|Drug|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
79660869|NCT03752203|Device|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
79660870|NCT03748342|Device|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
79660871|NCT03740334|Drug|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
79660872|NCT03740334|Drug|Dexamethasone|Corticosteroids are commonly used to treat ALL.
79815352|NCT02599155|Drug|Crystalloid|normal saline administration for volume expansion in hypovolemic status
79815353|NCT02599155|Drug|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
79815354|NCT00823199|Drug|Allopurinal|300mg once daily by mouth for four weeks
79987380|NCT02402608|Dietary Supplement|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
79987381|NCT02401282|Behavioral|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
79347965|NCT04853056|Device|Cold vibration|Buzzy
79347966|NCT04814615|Drug|89Zr-daratumumab PET/CT|CD38-targeting imaging
79347967|NCT04814537|Drug|Bupivacaine Hydrochloride|Local Anesthetic Agent
79347968|NCT01582282|Dietary Supplement|placebo|fiber-free placebo
79228272|NCT05095610|Device|Flash|Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
79347969|NCT01582282|Dietary Supplement|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
79347970|NCT01582282|Dietary Supplement|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
79347971|NCT01599650|Drug|Ranibizumab|
79347972|NCT01599650|Procedure|Laser|laser photocoagulation
79347973|NCT01541254|Device|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
79347974|NCT02163902|Drug|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
79347975|NCT02163902|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
79815355|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the upper arm
79815356|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the lower abdomen
79987382|NCT02401282|Behavioral|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
79347976|NCT01630616|Drug|Odanacatib|single oral dose, tablets, 10 or 50 mg
79347977|NCT01630616|Drug|Placebo|single oral dose, tablets
79347978|NCT03774875|Drug|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
79660873|NCT03740334|Drug|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
79660874|NCT03737266|Procedure|Sonographically assisted breast surgery|Sonography
79660875|NCT03737266|Procedure|Conventional breast surgery|Conventional
79660876|NCT03732417|Other|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
79660877|NCT03720795|Behavioral|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
79660878|NCT03708341|Drug|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
79660879|NCT03708341|Drug|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
79660880|NCT03692052|Drug|AG-348|AG-348 tablet orally BID
79660881|NCT03683069|Drug|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
79660882|NCT03682848|Drug|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
79660883|NCT03670056|Drug|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
79679537|NCT02941419|Biological|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
79815357|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the thigh
79815358|NCT02611583|Device|TENS|Transcutaneous Electrical Nerve Stimulation
79815359|NCT00829439|Drug|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
79823701|NCT02528227|Other|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
79228273|NCT05633277|Procedure|Polidocanol|Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
79228274|NCT05070572|Device|Accuryn Monitoring System|Utilization of the Accuryn Monitoring System to measure intraabdominal pressure and urine output during laparoscopic inguinal hernia repair surgery.
79228275|NCT03469830|Other|SSCP|Insert
79228276|NCT03469830|Other|SPMS|Pressure therapy
79228277|NCT04490954|Device|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
79228278|NCT04490954|Device|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
79228279|NCT04458402|Radiation|Hypofractionated WPRT|Cohort 1: 41.25 Gy in 15 fx Cohort 1: 38 Gy in 10 fx
79228280|NCT03312140|Drug|Choline Chloride|
79228281|NCT03469752|Behavioral|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
79228282|NCT03303638|Behavioral|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
79228283|NCT02233179|Device|Removable cast walker|Offloading device that can be removed by patients.
79499785|NCT01713036|Drug|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) [14C] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries [mcgCi]) of [14C] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
79347979|NCT03774875|Drug|Placebo|Placebo tablets taken orally twice a day
79347980|NCT02220764|Device|Teeth abutment|
79499786|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
79499787|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
79499788|NCT01712256|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
79347981|NCT02220764|Device|Implant abutments|
79347982|NCT05264324|Procedure|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
79499789|NCT01712178|Biological|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
79660884|NCT03653091|Device|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
79679538|NCT04694768|Behavioral|Rehabilitation|Rehabilitation program
79347983|NCT04755920|Drug|SGM-101|Fluorescence-guided surgery
79347984|NCT04758806|Biological|Fecal microbial transplantation|Procured faeces procured from unrelated donor
79499790|NCT01712178|Biological|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
79347985|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
79347986|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
79499791|NCT01693068|Drug|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
79499792|NCT01693068|Drug|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
79499793|NCT01691898|Drug|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
79499794|NCT01691898|Drug|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
79499795|NCT01691898|Drug|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
79499796|NCT01691898|Drug|Rituximab|RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle.
79499797|NCT01691820|Procedure|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
79499798|NCT01691820|Procedure|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
79499799|NCT01691820|Procedure|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
79347987|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
79347988|NCT01563172|Other|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
79347989|NCT04755764|Drug|Labetalol|Beta blocker
79347990|NCT04755764|Drug|Atenolol|Beta blocker
79347991|NCT04755764|Drug|Nifedipine|Calcium channel blocker
79987383|NCT03663179|Device|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
79347992|NCT02161718|Drug|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
79499800|NCT04547400|Other|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
79499801|NCT04167930|Other|electronic medical record(EMR) Data and patient survey|"Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
79660885|NCT03653091|Device|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
79347993|NCT02161718|Drug|Placebo + olanzapine|Oral tablet, taken once daily
79347994|NCT05292989|Other|Frailty Assessment|Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer
79347995|NCT05292989|Other|Standard Care|Standard care practice
79347996|NCT03697343|Radiation|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
79347997|NCT03697343|Radiation|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
79499802|NCT01711866|Drug|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
79499803|NCT01737762|Biological|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
79499804|NCT01737762|Biological|Vehicle|
79660886|NCT03633955|Drug|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
79347998|NCT05186987|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
79347999|NCT05186987|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
79348000|NCT02219048|Drug|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
79348001|NCT02219048|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
79348002|NCT03635645|Device|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
79499805|NCT01691508|Drug|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
79660887|NCT03624712|Diagnostic Test|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
79660888|NCT03622788|Biological|Anti-Thymocyte Globulin|Given IV
79660889|NCT03622788|Drug|Cyclophosphamide|Given IV
79660890|NCT03622788|Biological|Cytokine-treated Veto Cells|Given IV
79660891|NCT03622788|Drug|Fludarabine|Given IV
79660892|NCT03622788|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
79660893|NCT03622788|Radiation|Total-Body Irradiation|Undergo TBI
79348003|NCT03635645|Device|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
79348004|NCT04786145|Procedure|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
79679539|NCT03458481|Drug|SOF|400 mg tablet administered orally once daily
79679540|NCT03458481|Drug|DAG181|Capsule administered orally once daily
79499806|NCT01691508|Drug|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
79348005|NCT04786145|Procedure|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
79348006|NCT04786145|Procedure|Placebo|No active treatment is given.
79348007|NCT04813991|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
79348008|NCT04813991|Drug|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
79348009|NCT04801901|Procedure|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
79348010|NCT04801901|Procedure|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
79348011|NCT02218736|Drug|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
79348012|NCT02218736|Drug|placebo|oral dosing of 10 mg placebo daily for 8 weeks
79348013|NCT04418687|Device|Orthoglide|Knee rehabilitation device.
79499807|NCT01691508|Drug|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
79499808|NCT01682460|Drug|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
79499809|NCT01691430|Dietary Supplement|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
79499810|NCT01691430|Dietary Supplement|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
79660894|NCT03620578|Drug|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
79679541|NCT02950103|Drug|Phosphoethanolamine|Phosphoethanolamine PO daily
79228284|NCT02233179|Device|Irremovable cast walker|Offloading device that cannot be removed by patients.
79348014|NCT04418687|Other|Physiotherapy only|Physiotherapy only.
79348015|NCT05268965|Behavioral|Experimental: group comparison|"Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~State-Trait-Anxiety Inventory (Spielberger, 1993)~Beck Depression Inventory (BDI-II, 1998)~Cognitive Emotional Regulation Questionnaire (Jermann & al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~Step 2: experience of the same scenarios in virtual reality"
79348016|NCT05266781|Procedure|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
79348017|NCT05266781|Procedure|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
79348018|NCT05037149|Drug|STP707|Investigational Product
79348019|NCT05037149|Drug|STP707|Investigational Product
79348020|NCT05037149|Drug|STP707|Investigational Product
79348021|NCT05037149|Drug|STP707|Investigational Product
79348022|NCT05037149|Drug|STP707|Investigational Product
79348023|NCT03580421|Procedure|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
79679542|NCT02942394|Device|sinus-Obliquus Stent System|
79499811|NCT04413708|Behavioral|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
79499812|NCT01709838|Drug|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
79660895|NCT03608137|Other|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
79660896|NCT03604406|Biological|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
79660897|NCT03604406|Other|Placebo Injection|Saline solution injection
79660898|NCT03604406|Biological|Varicella Zoster Vaccine|non-live vaccine to prevent herpes zoster
79660899|NCT03577028|Biological|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
79348024|NCT03580421|Procedure|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
79660900|NCT03577028|Biological|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
79660901|NCT03577028|Biological|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
79987384|NCT03663179|Device|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
79987385|NCT03662789|Drug|Iron Isomaltoside 1000|Intravenous infusion
79348025|NCT01540474|Biological|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
79348026|NCT01540474|Biological|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
79348027|NCT01540474|Biological|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
79660902|NCT03577028|Biological|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
79660903|NCT03577028|Biological|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
79660904|NCT03577028|Biological|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
79660905|NCT03574597|Drug|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
79987386|NCT03662789|Other|Placebo: NaCl 0,9%|Intravenous infusion
79987387|NCT03115996|Drug|REGN3918|Intravenous (IV) or Subcutaneous (SC)
79987388|NCT03115996|Drug|Placebo|Matching Placebo
79987389|NCT02401204|Other|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
79660906|NCT03574597|Drug|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
79815360|NCT00749775|Drug|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
79815361|NCT00705965|Behavioral|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
79815362|NCT00705965|Behavioral|Information session|One information session about living with heart disease.
79348028|NCT01540474|Other|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
79815363|NCT00705965|Other|Usual cardiological care|Usual cardiological care
79815364|NCT05758103|Dietary Supplement|Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)|Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
79348029|NCT01580488|Drug|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
79499813|NCT01682226|Device|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
79660907|NCT03567642|Drug|Osimertinib|Osimertinib 80mg daily
79660908|NCT03567642|Drug|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
79660909|NCT03567642|Drug|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
79987390|NCT03736421|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
79660910|NCT03558828|Behavioral|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
79815365|NCT02599077|Drug|Dienogest|patients assigned to this treatment receive 2 milligrams per day
79815366|NCT02599077|Drug|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
79815367|NCT00829283|Behavioral|Behavioral Weight Loss|weekly individual sessions for 6 months
79815368|NCT00829283|Behavioral|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
79815369|NCT00829283|Drug|Placebo|One pill daily
79815370|NCT00829283|Drug|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
79987391|NCT03736421|Procedure|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
79987392|NCT03736421|Diagnostic Test|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
79348030|NCT01580488|Drug|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
79348031|NCT01580488|Drug|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
79348032|NCT01580488|Drug|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
79348033|NCT01580488|Drug|Daivonex® ointment|once daily application, 3 weeks
79348034|NCT01580488|Drug|Daivonex® ointment vehicle|once daily application, 3 weeks
79348035|NCT01580020|Biological|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
79815371|NCT04091139|Behavioral|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
79815372|NCT04091139|Behavioral|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
79815373|NCT05394623|Diagnostic Test|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
79815374|NCT05758025|Procedure|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
79987393|NCT02401126|Dietary Supplement|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
79348036|NCT01580020|Drug|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
79348037|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
79499814|NCT01682226|Device|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
79499815|NCT01682226|Biological|Haploidentical donor CD34+ cells|CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
79499816|NCT04167618|Drug|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
79499817|NCT01688466|Drug|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
79499818|NCT01682148|Biological|Botulinum toxin type A|
79660911|NCT03558828|Behavioral|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
79660912|NCT03558828|Behavioral|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
79660913|NCT03558828|Behavioral|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
79348038|NCT01579474|Drug|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
79348039|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
79348040|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
79499819|NCT01681992|Biological|Priorix|Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
79499820|NCT01681992|Biological|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
79499821|NCT01681992|Biological|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
79499822|NCT01681992|Biological|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
79660914|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
79679543|NCT00516620|Behavioral|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
79679544|NCT00516620|Behavioral|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
79499823|NCT01681992|Biological|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
79499824|NCT01737840|Drug|Pantoprazole|33 patients
79815375|NCT00706199|Procedure|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
79815376|NCT00708929|Procedure|Squatting|Squatting for 6 minutes
79499825|NCT01737840|Drug|Ranitidine|33 patients
79815377|NCT00821873|Other|CR Plug|CR Plug will be placed in the harvest site
79815378|NCT00706277|Drug|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
79815379|NCT00706277|Drug|propofol|propofol 2mg
79815380|NCT00706277|Drug|remifentanil|remifentanil 0,25mcg/kg/hour
79815381|NCT00706277|Drug|fentanyl|fentanyl 100mcg
79815382|NCT00706277|Drug|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
79987394|NCT02401126|Dietary Supplement|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
79499826|NCT01687998|Drug|Evacetrapib|Administered Orally
79499827|NCT01687998|Drug|Placebo|Administered Orally
79499828|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
79499829|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
79499830|NCT01681368|Drug|Birinapant (TL32711)|47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
79499831|NCT01681212|Drug|Ipilimumab|
79499832|NCT01681212|Drug|Dacarbazine|
79499833|NCT01687296|Drug|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
79499834|NCT01687296|Drug|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
79499835|NCT01687296|Drug|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
79499836|NCT01687296|Drug|placebo tablet|placebo soluble tablet, oral ,once daily
79499837|NCT01687296|Drug|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
79499838|NCT04410432|Biological|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~1 dry tube 5 mL for isolation and freezing of serum~1 x 5 mL EDTA tube to isolate and freeze plasma~8 heparinized 6 mL tubes for flow cytometry study"
79815383|NCT00749463|Drug|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
79815384|NCT00749463|Drug|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
79815385|NCT00821327|Drug|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
79815386|NCT05412459|Drug|99mTc-DARPinG3|Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
79348041|NCT01579318|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
79348042|NCT01579318|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
79815387|NCT05412069|Device|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
79815388|NCT04038281|Other|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
79348043|NCT01562782|Other|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
79348044|NCT01579006|Drug|Tocilizumab|
79499839|NCT02071914|Drug|CT-P27|Influenza A treatment drug.
79499840|NCT02071914|Drug|Placebo|Placebo.
79815389|NCT00706667|Drug|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
79815390|NCT04090437|Procedure|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
79499841|NCT01568892|Drug|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
79499842|NCT01568892|Drug|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
79348045|NCT01578850|Drug|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
79348046|NCT01578850|Drug|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
79499843|NCT01568112|Drug|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
79499844|NCT01568112|Drug|BG00012 placebo|Placebo matching BG00012
79499845|NCT01568112|Drug|ASA|325 mg microcoated aspirin (ASA)
79499846|NCT01568112|Drug|ASA placebo|Placebo matching aspirin
79499847|NCT04116840|Drug|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
79499848|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
79499849|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
79499850|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
79499851|NCT01568034|Drug|Placebo|single-dose
79499852|NCT01568034|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
79499853|NCT01568034|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
79660915|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
79660916|NCT03558828|Behavioral|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
79815391|NCT04090593|Other|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
79823702|NCT02528227|Other|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
79499854|NCT01687218|Drug|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
79499855|NCT01687218|Drug|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
79499856|NCT01687218|Drug|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
79499857|NCT01686828|Drug|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
79499858|NCT01686828|Drug|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
79499859|NCT01686828|Drug|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
79499860|NCT01686828|Drug|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
79499861|NCT01686828|Drug|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
79499862|NCT01686438|Behavioral|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
79499863|NCT01593696|Biological|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
79499864|NCT01592760|Device|air-Q SP|air-Q SP placement for airway maintenance.
79499865|NCT01592760|Device|air-Q|air-Q placement for airway maintenance.
79499866|NCT01592760|Device|i-gel|i-gel placement for airway maintenance.
79499867|NCT03901014|Other|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
79499868|NCT03901014|Other|Very low carbohydrate diet|Ketogenic diet with <50g carbohydrate, 60-75% energy from fat, and 20% from protein
79499869|NCT01696188|Device|interscalene nerve catheter|
79499870|NCT02985762|Drug|EXPAREL|
79660917|NCT03555058|Other|Treatment escalation|Treatment escalation per TDM and physician's decision.
79660918|NCT03552978|Behavioral|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS &Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
79823703|NCT02528227|Other|Feeding Safety|Part of Health and Safety Curriculum
79815392|NCT00917085|Behavioral|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
79815393|NCT00709007|Behavioral|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
79815394|NCT00709007|Behavioral|SAT|Participants take their HIV medications by themselves.
79815395|NCT00821093|Drug|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
79815396|NCT00821093|Drug|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
79815397|NCT00821093|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
79815398|NCT00821093|Drug|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
79987395|NCT04481932|Drug|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
79823704|NCT02528227|Other|Car Seat Safety|Part of Health and Safety Curriculum
79823705|NCT02528227|Other|Bath Safety|Part of Health and Safety Curriculum
79987396|NCT03169582|Drug|Avanafil|Drug administration (Avanafil)
79660919|NCT03552978|Behavioral|VA Quitline|The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
79660920|NCT03551496|Combination Product|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
79660921|NCT03551496|Device|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
79660922|NCT03543839|Biological|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
79660923|NCT03543839|Biological|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
79660924|NCT03543839|Other|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
79660925|NCT03541889|Drug|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
79660926|NCT03534947|Drug|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
79660927|NCT03534947|Drug|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
79660928|NCT03534947|Procedure|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
79348047|NCT01539538|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
79348048|NCT01539538|Drug|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
79348049|NCT01562548|Drug|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
79348050|NCT01562548|Drug|Placebo|no active ingredient
79348051|NCT03027934|Drug|Ticagrelor|Ticagrelor, 90mg twice daily
79348052|NCT03027934|Drug|Prasugrel|Prasurgrel, 10mg once daily
79348053|NCT01562314|Drug|GWP42003|1 to 5 50 mg capsules taken BID
79348054|NCT01562314|Drug|Placebo|1 to 5 matching capsules taken BID
79348055|NCT01539226|Combination Product|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
79499871|NCT04768374|Other|Virtual Reality with Kinect|"In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents."
79228285|NCT03312062|Other|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
79499872|NCT04768374|Other|Conventional Occupational Therapy (COT)|"The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks."
79499873|NCT01603602|Biological|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
79660929|NCT03534947|Other|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
79660930|NCT03530124|Biological|PCV13|Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
79660931|NCT03530124|Biological|DTaP|ACIP Recommended vaccine
79660932|NCT03530124|Biological|HBV|ACIP Recommended vaccine
79660933|NCT03530124|Biological|IPV|ACIP Recommended vaccine
79660934|NCT03530124|Biological|Hib|ACIP Recommended vaccine
79823706|NCT02528227|Other|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
79823707|NCT02528227|Other|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
79987397|NCT03169582|Drug|Sildenafil|Drug administration (Sildenafil)
79987398|NCT02406664|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
79660935|NCT03522168|Drug|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
79499874|NCT01603602|Drug|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
79660936|NCT03522168|Drug|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
79660937|NCT03514017|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
79987399|NCT02402374|Device|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
79987400|NCT02402374|Device|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
79987401|NCT02402140|Other|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
79987402|NCT03655691|Biological|Vehicle|Vehicle Formulation
79499875|NCT01684878|Drug|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
79499876|NCT01684878|Drug|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
79499877|NCT01684878|Drug|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
79499878|NCT01684878|Drug|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
79660938|NCT03514017|Drug|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
79660939|NCT03500315|Other|HIV D+/R+|Kidney from an HIV-infected deceased donor
79660940|NCT03485209|Drug|tisotumab vedotin|Given into the vein (IV; intravenously)
79660941|NCT03485209|Drug|pembrolizumab|200mg or 400mg given by IV
79660942|NCT03485209|Drug|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
79987403|NCT03655691|Biological|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
79987404|NCT03655691|Biological|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
79499879|NCT01684878|Drug|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
79499880|NCT01684722|Dietary Supplement|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
79499881|NCT01684722|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79499882|NCT01684722|Dietary Supplement|Vitamin D placebo|Vitamin D3 placebo
79660943|NCT03485209|Drug|cisplatin|100mg/m^2 given by IV
79987405|NCT03169504|Other|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30*25 mm, 0.30*40 mm or 0.30*50 mm will be used 3 times weekly for 12 weeks.
79499883|NCT01684722|Dietary Supplement|Fish oil placebo|Fish oil placebo
79499884|NCT01592292|Drug|Rituximab|Rituximab as per physician's discretion.
79499885|NCT01592292|Drug|Adalimumab|Adalimumab as per physician's discretion.
79499886|NCT01592292|Drug|Etanercept|Etanercept as per physician's discretion.
79499887|NCT01592292|Drug|Infliximab|Infliximab as per physician's discretion.
79499888|NCT01590888|Drug|PBT2|250mg capsules administered orally once per day for 26 weeks
79660944|NCT03464097|Drug|Ozanimod|Specified dose on specified days
79348056|NCT01539226|Combination Product|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
79348057|NCT01577758|Drug|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
79348058|NCT04769674|Other|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
79348059|NCT01537432|Drug|secukinumab|secukinumab
79348060|NCT01537432|Drug|placebo|placebo comparator
79499889|NCT01590888|Drug|PBT2|100mg capsules administered orally once per day for 26 weeks
79499890|NCT01590888|Drug|Placebo|Matching capsules administered orally once per day for 26 weeks
79499891|NCT01565928|Drug|MDV3100|4 x 40 mg capsules, orally, once per day
79499892|NCT01565850|Drug|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
79499893|NCT01565850|Drug|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
79499894|NCT01565850|Drug|COBI|COBI 150 mg tablet administered orally once daily
79499895|NCT01565850|Drug|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
79499896|NCT01565850|Drug|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
79499897|NCT01565850|Drug|DRV Placebo|DRV placebo tablet administered orally once daily
79499898|NCT01565850|Drug|COBI Placebo|COBI placebo tablet administered orally once daily
79660945|NCT03464097|Other|Placebo|Specified dose on specified days
79660946|NCT03451409|Other|Tasked based functional MRI (fMRI)|2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
79499899|NCT01565850|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
79499900|NCT01565694|Drug|Solifenacin succinate|Oral suspension administered once a day via syringe.
79499901|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
79499902|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
79499903|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
79499904|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
79499905|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
79499906|NCT01590810|Drug|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
79499907|NCT01590810|Drug|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
79499908|NCT01590810|Drug|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
79499909|NCT01590810|Drug|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
79499910|NCT01590810|Drug|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
79499911|NCT01590810|Drug|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
79499912|NCT01590810|Drug|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
79660947|NCT03451409|Other|Eye Tracking Device|Camera aimed at eyes to record eye movements during tasks
79660948|NCT03435003|Drug|Aprepitant 80 mg Oral Capsule|aprepitant 80 mg orally one hour prior to scheduled surgery
79499913|NCT01590810|Drug|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
79499914|NCT01590810|Drug|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
79499915|NCT01590810|Drug|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
79499916|NCT01590810|Drug|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
79499917|NCT01590810|Drug|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
79499918|NCT01590810|Drug|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
79499919|NCT01590810|Drug|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
79499920|NCT01590810|Drug|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
79499921|NCT01590810|Drug|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
79499922|NCT01590810|Drug|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
79987406|NCT03169504|Drug|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
79499923|NCT01590810|Drug|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
79499924|NCT01590810|Drug|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
79499925|NCT01542528|Behavioral|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
79499926|NCT01565148|Drug|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
79499927|NCT01565148|Drug|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
79660949|NCT03435003|Drug|scopolamine transdermal|scopolamine transdermal patch one hour prior to scheduled surgery
79660950|NCT03435003|Procedure|Total intravenous anesthesia|Maintenance of anesthesia without the use of inhaled anesthetics.
79660951|NCT03435003|Drug|Dexamethasone|Dexamethasone 8 mg intraoperatively
79660952|NCT03435003|Drug|Ondansetron|Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
79987407|NCT03169504|Other|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
79499928|NCT01565148|Drug|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
79499929|NCT01565148|Drug|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
79499930|NCT04410354|Drug|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
79499931|NCT04410354|Drug|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
79499932|NCT04410354|Drug|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
79660953|NCT03435003|Drug|Reglan|Postoperatively scheduled Reglan
79660954|NCT03435003|Drug|Ondansetron|Postoperatively scheduled ondansetron
79660955|NCT03435003|Drug|Compazine|Postoperatively as needed compazine for breakthrough PONV
79660956|NCT03435003|Drug|Sugammadex|Reversal with sugammadex
79815399|NCT00821015|Device|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
79815400|NCT00814463|Behavioral|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
79815401|NCT00814463|Behavioral|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
79815402|NCT00814463|Procedure|MRI|MRI done every 3 months for the length of the study.
79348061|NCT04409938|Other|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
79348062|NCT04409938|Other|Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
79815403|NCT00814463|Radiation|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
79987408|NCT03169426|Drug|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
79987409|NCT03658811|Device|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
79815404|NCT00706745|Dietary Supplement|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
79348063|NCT01537120|Drug|Vildagliptin|
79348064|NCT01537120|Drug|Placebo|
79499933|NCT01564758|Drug|Linezolid|"Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
79499934|NCT01541826|Dietary Supplement|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
79499935|NCT01541826|Dietary Supplement|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
79499936|NCT01541826|Dietary Supplement|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
79499937|NCT01541748|Other|Axis|Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
79499938|NCT01589094|Drug|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
79499939|NCT01563978|Drug|fostamatinib|fostamatinib 100 mg twice daily
79499940|NCT01563978|Drug|placebo|placebo
79499941|NCT04114344|Procedure|TAPP|Trans Abdominal Pre Peritoneal approach
79499942|NCT04114344|Procedure|TEP|Total Extra Peritoneal approach
79499943|NCT01563354|Drug|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
79660957|NCT03435003|Drug|Propofol|Intravenous anesthesia will be maintained through IV propofol
79660958|NCT03435003|Drug|dexmedetomidine|maintenance of anesthesia in the intervention arm
79660959|NCT03435003|Drug|Fentanyl|intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
79815405|NCT00706745|Dietary Supplement|placebo|identical placebo capsules.
79815406|NCT05229809|Drug|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
79823708|NCT02528227|Other|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
79823709|NCT01029847|Drug|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
79499944|NCT01563354|Drug|Everolimus|10 mg tables administered orally once a day
79660960|NCT03435003|Drug|Sevoflurane|inhalational anesthesia
79660961|NCT03435003|Drug|Desflurane|inhalational anesthesia
79660962|NCT03386734|Procedure|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
79348065|NCT01537042|Drug|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
79348066|NCT01537042|Drug|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
79348067|NCT04111666|Biological|AL101|Active dose of AL101
79348068|NCT04111666|Other|Placebo|Saline solution administered as a single and multiple infusion as placebo.
79348069|NCT03897712|Device|Custom Samfilcon B Contact Lenses|Contact lens
79348070|NCT03897712|Device|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
79348071|NCT03897712|Device|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
79348072|NCT03897712|Device|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
79348073|NCT01536574|Drug|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
79348074|NCT01536418|Drug|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
79348075|NCT01536418|Drug|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
79348076|NCT04410094|Drug|Lazertinib|Lazertinib tablets will be administered orally.
79348077|NCT04410094|Drug|Itraconazole|Itraconazole capsules will be administered orally.
79823710|NCT01029847|Drug|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
79348078|NCT04410094|Drug|Rifampin|Rifampin capsules will be administered orally.
79348079|NCT01576042|Drug|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
79348080|NCT01576042|Drug|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
79499945|NCT01563354|Drug|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
79499946|NCT01588548|Drug|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
79499947|NCT01587924|Drug|GSK1278863|tablet
79660963|NCT03386734|Procedure|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
79348081|NCT01576042|Device|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
79348082|NCT01561300|Other|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
79499948|NCT01587924|Drug|rhEPO|injection
79499949|NCT03028038|Drug|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
79815407|NCT05229809|Drug|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
79660964|NCT03377088|Other|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
79815408|NCT00709163|Drug|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
79815409|NCT00709163|Drug|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
79815410|NCT00913445|Procedure|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
79348083|NCT01561300|Other|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
79348084|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
79348085|NCT01536262|Device|Respimat|Respimat inhaler
79348086|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
79348087|NCT01536262|Drug|Olodaterol|Olodaterol once daily inhalation
79499950|NCT03028038|Drug|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
79348088|NCT01536262|Device|Respimat|Respimat inhaler
79348089|NCT01536262|Device|Respimat|Respimat inhaler
79348090|NCT01560988|Drug|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
79348091|NCT01560988|Dietary Supplement|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
79348092|NCT03897556|Dietary Supplement|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
79499951|NCT03027960|Drug|Empagliflozin|10mg empagliflozin for a 2-week period
79499952|NCT03027960|Drug|Placebo Oral Capsule|10 mg placebo for a 2-week period
79660965|NCT03377088|Other|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
79660966|NCT03370276|Drug|Nivolumab|Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
79660967|NCT03370276|Drug|Cetuximab|Cetuximab intravenously (IV) at 500 mg/m^2 or 250 mg/m^2 as outlined in the treatment arms.
79815411|NCT02611505|Drug|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
79815412|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
79348093|NCT03897556|Other|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
79348094|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
79348095|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
79499953|NCT03028194|Procedure|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
79660968|NCT03367546|Procedure|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
79987410|NCT02406430|Procedure|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
79660969|NCT03365362|Drug|Long-Term Varenicline|Varenicline tablet x 24 weeks
79660970|NCT03365362|Drug|Short-Term Varenicline|varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
79660971|NCT03365362|Behavioral|Directly Observed Therapy|Varenicline doses are administered by opioid treatment program nurses
79348096|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
79499954|NCT03028194|Procedure|Placebo|No procedure after delivery of the placenta
79499955|NCT03027882|Other|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
79348097|NCT03889132|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
79348098|NCT01535560|Drug|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
79348099|NCT01535560|Drug|AL-60371 Vehicle|Inactive ingredients used as placebo
79348100|NCT04102618|Biological|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
79348101|NCT04102618|Drug|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
79348102|NCT04102618|Drug|Atezolizumab|1200 mg administered intravenously on Day 3
79499956|NCT01539642|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
79499957|NCT01539642|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
79499958|NCT01586364|Drug|Ospemifene 60Mg Oral Tablet|
79660972|NCT03365362|Behavioral|Self Administered Therapy|Varenicline doses are self-administered
79660973|NCT03329404|Device|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
79660974|NCT03329404|Device|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
79660975|NCT03327467|Biological|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling or autologous)
79499959|NCT01538628|Device|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
79815413|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
79987411|NCT03115528|Behavioral|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
79987412|NCT03732443|Diagnostic Test|FAM-CAM|Family Confusion Assessment Method
79987413|NCT03573206|Device|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
79348103|NCT04102618|Drug|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
79499960|NCT01538472|Drug|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
79815414|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
79499961|NCT01538472|Drug|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
79660976|NCT03311633|Procedure|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
79660977|NCT03283917|Biological|Daratumumab|Given IV
79660978|NCT03283917|Drug|Dexamethasone|Given IV or PO
79815415|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
79348104|NCT01575028|Drug|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
79348105|NCT01575028|Drug|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
79660979|NCT03283917|Drug|Ixazomib|Given PO
79815416|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
79815417|NCT00748215|Drug|calcium aluminosilicate anti-diarrheal|Given orally
79499962|NCT01538472|Drug|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
79499963|NCT01538472|Drug|BCNU|300 mg/m2 by vein on Day -6.
79815418|NCT00748215|Other|placebo|Given orally
79348106|NCT04783961|Procedure|Cold snare endoscopic resection|Cold snare endoscopic resection
79815419|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
79823711|NCT02452268|Drug|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
79348107|NCT04443569|Drug|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
79348108|NCT04443335|Behavioral|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
79499964|NCT01538472|Drug|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
79499965|NCT01538472|Drug|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
79499966|NCT01538472|Drug|Melphalan|140 mg/m2 by vein on Day -1.
79499967|NCT01538472|Procedure|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
79499968|NCT01538472|Drug|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
79499969|NCT01562028|Drug|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
79499970|NCT01562028|Drug|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
79660980|NCT03275064|Biological|LNA043|LNA043 intra-articular injection
79660981|NCT03275064|Other|Placebo|Placebo intra-articular injection
79660982|NCT03271762|Device|percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
79660983|NCT03271762|Procedure|cardiac surgery|mitral valve repair or mitral valve remplacement
79660984|NCT03260478|Procedure|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
79660985|NCT03252795|Procedure|uterus transplantation|transplantation of a uterus from a deceased donor
79660988|NCT03238248|Drug|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
79660989|NCT03238248|Drug|Pevonedistat Infusion|20 mg/m2
79660990|NCT03238248|Procedure|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
79815420|NCT04089384|Other|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
79815421|NCT04089384|Other|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
79815422|NCT04089540|Procedure|New intubation method|
79815423|NCT04089540|Procedure|Conventional intubation method|
79660991|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
79660992|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
79660993|NCT03228732|Drug|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
79987414|NCT03169348|Drug|sofosbuvir daclatasvir|oral tablets
79660994|NCT03228732|Drug|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
79660995|NCT03228732|Drug|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
79660996|NCT03214510|Drug|Bupivacaine|Given via thoracic epidural catheter or TAP block
79660997|NCT03214510|Drug|Fentanyl|Given via thoracic epidural catheter
79660998|NCT03214510|Drug|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
79660999|NCT03214510|Device|Implanted Medical Device|Undergo placement of thoracic epidural catheter
79661000|NCT03214510|Device|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
79661001|NCT03214510|Drug|Liposomal Bupivacaine|Given via TAP block
79661002|NCT03214510|Behavioral|Questionnaire|Ancillary studies
79661003|NCT03213652|Procedure|Biospecimen Collection|Undergo blood sample collection
79661004|NCT03213652|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
79661005|NCT03213652|Procedure|Bone Scan|Undergo a bone scan
79661006|NCT03213652|Procedure|Computed Tomography|Undergo a CT scan
79661007|NCT03213652|Drug|Ensartinib|Given PO
79661008|NCT03213652|Other|Laboratory Biomarker Analysis|Correlative studies
79661009|NCT03213652|Procedure|Magnetic Resonance Imaging|Undergo MRI
79661010|NCT03213652|Other|Pharmacological Study|Correlative studies
79661011|NCT03213652|Procedure|Positron Emission Tomography|Undergo a PET scan
79661012|NCT03213652|Procedure|Radionuclide Imaging|Undergo radionuclide imaging
79815424|NCT02598843|Other|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy"
79823712|NCT02452268|Drug|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
79987415|NCT03169348|Drug|Ledipasvir/sofosbuvir|oral tablets
79987416|NCT03172546|Genetic|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
79661013|NCT03213652|Procedure|X-Ray Imaging|Undergo an x-ray
79661014|NCT03211546|Procedure|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
79661015|NCT03211546|Procedure|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
79348109|NCT04443335|Behavioral|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
79815425|NCT02598843|Other|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced."
79661016|NCT03183102|Dietary Supplement|Flaxseed|2 months of dietary flaxseed supplementation
79815426|NCT04089228|Other|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
79815427|NCT04089228|Other|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
79348110|NCT04801355|Procedure|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
79348111|NCT04801355|Procedure|laparoscopic colon resection|Standard laparoscopic colon resection
79661017|NCT03179995|Drug|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
79661018|NCT03179995|Other|Placebo|Normal saline will be administered in the same fashion as Octreotide
79815428|NCT00917163|Device|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
79815429|NCT00917163|Device|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
79815430|NCT04090086|Drug|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
79348112|NCT01823549|Other|questionnaire administration|Ancillary studies
79348113|NCT03511157|Other|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
79815431|NCT04090086|Drug|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
79815432|NCT00749892|Drug|Erlotinib Hydrochloride|Given PO
79348114|NCT03511157|Other|Control Group|See Control group description
79348115|NCT04800965|Behavioral|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
79661019|NCT03148418|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
79661020|NCT03148418|Drug|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
79661021|NCT03138278|Other|Telephone support on demand|Dedicated phone number for help and advice for caregivers
79661022|NCT03119584|Drug|linaclotide or placebo|
79661023|NCT03112980|Device|Transcatheter aortic valve implantation|(TAVI)
79661024|NCT03112980|Procedure|Surgical aortic valve replacement|(SAVR)
79815433|NCT04088487|Behavioral|New in Town-Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
79987417|NCT03631355|Drug|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
79987418|NCT02411422|Device|Conventional endotracheal tube|Conventional endotracheal tube
79987419|NCT02411422|Device|Reinforced endotracheal tube|Reinforced endotracheal tube
79348116|NCT04800965|Behavioral|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
79348117|NCT04800965|Behavioral|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
79348118|NCT01340261|Behavioral|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
79348119|NCT04676633|Drug|STP705|Investigational Product
79348120|NCT03508895|Other|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
79348121|NCT03508895|Other|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
79661025|NCT03088605|Drug|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
79661026|NCT03088605|Drug|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
79661027|NCT03051282|Drug|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
79661028|NCT03037684|Diagnostic Test|neurophysiology|electrophysiologic measurements of peripheral nerves
79499971|NCT03028662|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
79499972|NCT04767828|Drug|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
79499973|NCT04767828|Radiation|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
79499974|NCT01585584|Drug|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
79661029|NCT02964013|Biological|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
79661030|NCT02964013|Biological|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
79661031|NCT02964013|Drug|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
79661032|NCT02964013|Drug|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
79815434|NCT04091256|Other|Single arm clinical study|Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
79815435|NCT02595645|Genetic|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
79661033|NCT02964013|Biological|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
79815436|NCT02595333|Drug|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
79499975|NCT01561560|Device|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
79815437|NCT02595333|Drug|Group S1|sufentanil was administered for analgesia in primary cesarean section
79815438|NCT02595333|Drug|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
79815439|NCT02595333|Drug|Group S2|sufentanil was administered for analgesia in repeated cesarean section
79823713|NCT03872492|Other|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~My daily survey~My evaluation~My cognition~My emotions~My voice~Data will also be collected passively."
79823714|NCT02524249|Drug|Caffeine|
79499976|NCT01561560|Device|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
79823715|NCT02524249|Drug|Placebo (dextrose)|
79823716|NCT01033981|Drug|Sunitinib|Treatment for mRCC as indication approved and physician criterium
79661034|NCT02964013|Drug|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
79661035|NCT02964013|Drug|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
79661036|NCT02959463|Other|Laboratory Biomarker Analysis|Correlative studies
79661037|NCT02959463|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
79661038|NCT02959463|Biological|Pembrolizumab|Given IV
79661039|NCT02959463|Radiation|Radiation Therapy|Undergo hemithoracic radiation therapy
79823717|NCT02430194|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
79823718|NCT02430194|Drug|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
79823719|NCT02430194|Drug|Pegylated interferon-alfa-2a|immunomodulator
79987420|NCT03169192|Drug|Zoledronic Acid|intravenous injections once every 3 months
79348122|NCT03508895|Other|Casein protein|The intervention was provided in the form of a smoothie.
79348123|NCT01313351|Device|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
79348124|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
79348125|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
79348126|NCT01574716|Drug|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
79499977|NCT01537068|Drug|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
79661040|NCT02951052|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
79228286|NCT03303482|Behavioral|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
79348127|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
79348128|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
79348129|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
79348130|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
79348131|NCT01574716|Drug|Placebo|
79348132|NCT02161562|Drug|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
79348133|NCT02161562|Drug|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
79499978|NCT01537068|Drug|Placebo|Matching placebo pills
79661041|NCT02951052|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
79661042|NCT02951052|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
79661043|NCT02951052|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
79348134|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
79348135|NCT01559116|Drug|tiotropium|low dose
79348136|NCT01559116|Drug|olodaterol|one dose only
79348137|NCT01559116|Drug|tiotropium|high dose
79348138|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
79348139|NCT01559116|Drug|Placebo|placebo matching tiotropium+olodaterol FDC
79499979|NCT01585428|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
79499980|NCT01585428|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
79499981|NCT01585428|Biological|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
79661044|NCT02951052|Drug|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~NNRTI (either the initial or second cART regimen)~Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based cART regimen)"
79661045|NCT02888600|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
79661046|NCT02888600|Behavioral|Health Education|Guided health education and stress management training
79661047|NCT02879383|Procedure|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
79661048|NCT02879383|Procedure|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
79661049|NCT02848040|Other|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
79661050|NCT02841540|Drug|H3B-8800 (RVT-2001)|H3B-8800 (RVT-2001) orally at specified doses and schedules.
79348140|NCT01559116|Device|Respimat|Respimat inhaler
79348141|NCT01574326|Drug|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
79348142|NCT01574326|Drug|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
79348143|NCT01574248|Drug|icatibant|Subcutaneous at time 0 and 6 hours
79348144|NCT01574248|Other|Placebo|Subcutaneous at time 0 and 6 hours
79348145|NCT04761094|Device|Insulin pump|Treatment with continuous subcutaneous insulin infusion
79348146|NCT01573624|Drug|FF/GSK573719|100/15.6
79348147|NCT01573624|Drug|FF/GSK573719|100/31.25
79348148|NCT01573624|Drug|FF/GSK573719|100/62.5
79348149|NCT01573624|Drug|FF/GSK573719|100/125
79348150|NCT01573624|Drug|FF/GSK573719|100/250
79348151|NCT01573624|Drug|FF|100
79348152|NCT01573624|Drug|FF/VI|100/25
79348153|NCT01557946|Drug|citalopram|citalopram 20-40 mg daily
79348154|NCT01534078|Drug|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
79348155|NCT01534078|Drug|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
79499982|NCT01585428|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
79499983|NCT01585272|Drug|ENA713|
79499984|NCT03028116|Biological|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
79499985|NCT03028116|Biological|Placebo|water for injection
79499986|NCT01560780|Drug|Prasugrel|one 10 mg tablet by mouth daily
79661051|NCT02814383|Other|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
79661052|NCT02780973|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
79661053|NCT02724878|Drug|Bevacizumab|
79661054|NCT02724878|Drug|Atezolizumab|
79661055|NCT02723331|Drug|Nab paclitaxel|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
79228287|NCT03759795|Behavioral|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
79348156|NCT03919942|Other|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
79348157|NCT03919942|Other|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
79499987|NCT01560780|Drug|Placebo|placebo similar in appearance to prasugrel
79499988|NCT01585038|Drug|Efavirenz|600mg orally every evening
79499989|NCT01585038|Drug|Rilpivirine|25mg orally once daily
79499990|NCT01560234|Drug|AZD8848|Single dose, oral inhalation (nebuliser solution)
79499991|NCT01560234|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
79499992|NCT04124328|Procedure|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
79499993|NCT04124328|Procedure|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
79661056|NCT02723331|Drug|Gemcitabine|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
79499994|NCT01559844|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
79499995|NCT01559844|Drug|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79499996|NCT01584648|Drug|Dabrafenib|Dabrafenib 150 mg twice daily
79499997|NCT01584648|Drug|Trametinib|Trametinib 2 mg once daily
79815440|NCT00749580|Drug|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA <75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
79987421|NCT05000957|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
79987422|NCT05000957|Diagnostic Test|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
79348158|NCT03919942|Other|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
79348159|NCT02185040|Drug|CC-220|0.3 mg oral capsules once every other day with or without food
79348160|NCT02185040|Drug|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
79661057|NCT02723240|Drug|NUC-3373|
79661058|NCT02717624|Drug|Acalabrutinib in combination with BR|
79815441|NCT02595177|Procedure|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
79815442|NCT02595255|Other|No intervention|No intervention
79815443|NCT02595021|Procedure|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
79815444|NCT02595021|Procedure|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
79348161|NCT02185040|Drug|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
79348162|NCT02185040|Drug|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
79348163|NCT02185040|Drug|Placebo|Matching oral placebo daily
79815445|NCT02595099|Other|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
79815446|NCT00747006|Drug|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
79348164|NCT02161406|Drug|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
79348165|NCT02161406|Drug|Placebo|125 mg of Placebo
79348166|NCT02161016|Device|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
79661059|NCT02717624|Drug|Acalabrutinib in combination with VR|
79679545|NCT00516620|Behavioral|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
79348167|NCT01573000|Biological|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
79499998|NCT01584648|Drug|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
79499999|NCT01559454|Drug|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
79500000|NCT01559454|Drug|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
79348168|NCT01572922|Device|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
79500001|NCT03028584|Behavioral|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
79500002|NCT01584024|Device|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
79661060|NCT02695225|Behavioral|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
79987423|NCT05000957|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
79500003|NCT01584024|Device|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
79500004|NCT01583166|Drug|Bupivacaine|10ml 0.5% bupivacaine
79500005|NCT01583166|Drug|Saline|10ml 0.9% sodium chloride
79500006|NCT01583166|Drug|Epinephrine|1:200,000 epinephrine
79500007|NCT01535274|Other|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 45mmHg - beach chair position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
79500008|NCT01558752|Device|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
79500009|NCT01558752|Device|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
79661061|NCT02695225|Behavioral|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
79661062|NCT02694965|Other|observational|
79987424|NCT05000957|Diagnostic Test|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
79500010|NCT01582854|Drug|Actovegin|Actovegin solution for infusion and Actovegin tablets
79500011|NCT01582854|Drug|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
79500012|NCT03884400|Procedure|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
79500013|NCT04102644|Other|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
79500014|NCT01582308|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
79987425|NCT05000957|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
79987426|NCT05000957|Diagnostic Test|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
79987427|NCT05000957|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
79987428|NCT05000957|Diagnostic Test|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
79348169|NCT01572922|Device|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
79500015|NCT01582308|Drug|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
79500016|NCT01582308|Drug|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
79500017|NCT01582308|Drug|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
79500018|NCT01582308|Drug|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
79661063|NCT02692313|Drug|Epinephrine|Dose response of epinephrine infusion
79987429|NCT05000957|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
79987430|NCT05000957|Diagnostic Test|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
79987431|NCT05000957|Diagnostic Test|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
79987432|NCT05000957|Diagnostic Test|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
79500019|NCT01558674|Drug|MK-7145|
79500020|NCT01558674|Drug|Furosemide|
79500021|NCT01558674|Drug|Torsemide|
79661064|NCT02692313|Other|Saline infusion|Placebo
79661065|NCT02664870|Procedure|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
79661066|NCT02664870|Procedure|Arthroplasty|Total hip, shoulder, or knee arthroplasty
79987433|NCT05000957|Diagnostic Test|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
79987434|NCT05000957|Diagnostic Test|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
79348170|NCT01572922|Procedure|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
79348171|NCT01572844|Device|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
79348172|NCT01572844|Drug|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
79348173|NCT01557400|Drug|Ataluren|Oral powder for suspension
79500022|NCT01558596|Procedure|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
79823720|NCT00582608|Drug|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein]
79987435|NCT05000957|Procedure|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
79500023|NCT01558596|Procedure|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
79500024|NCT01535040|Drug|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
79500025|NCT01535040|Drug|placebo|Placebo by mouth through completion of 12 weeks.
79500026|NCT04410510|Drug|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
79500027|NCT04410510|Other|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
79661067|NCT02653768|Behavioral|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
79661068|NCT02653768|Behavioral|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
79661069|NCT02638090|Drug|Vorinostat|Administered per treatment arm guidelines.
79661070|NCT02638090|Drug|Pembrolizumab|Administered per treatment arm guidelines.
79661071|NCT02606305|Drug|Mirvetuximab soravtansine|
79348174|NCT04122118|Other|Medical Chart Review|Review of medical chart
79348175|NCT04122118|Other|Educational Intervention|Receive pharmacist-led education
79348176|NCT04122118|Other|Survey Administration|Ancillary studies
79348177|NCT04121806|Other|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
79348178|NCT01533922|Drug|Placebo|placebo matching tiotropium + olodaterol FDC
79348179|NCT01533922|Drug|Tiotropium|Tiotropium 5 mcg once daily
79348180|NCT01533922|Drug|Olodaterol|Olodaterol 5 mcg once daily
79661072|NCT02606305|Drug|Bevacizumab|
79661073|NCT02606305|Drug|Carboplatin|
79815447|NCT00747006|Drug|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
79348181|NCT01533922|Drug|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
79661074|NCT02606305|Drug|Pegylated Liposomal Doxorubicin|
79815448|NCT04091100|Procedure|Electroacupuncture|An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
79661075|NCT02606305|Drug|Pembrolizumab|
79661076|NCT02597348|Procedure|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
79661077|NCT02588079|Behavioral|Internet-based cognitive behavioral therapy|
79661078|NCT02567175|Drug|Domperidone|
79661079|NCT02560805|Procedure|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
79815449|NCT04091100|Procedure|Myofascial Release|longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
79815450|NCT04091178|Dietary Supplement|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
79815451|NCT04090008|Drug|PRP gel|The PRP gel is applied on the ulcer twice per week
79815452|NCT04090008|Drug|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
79815453|NCT00917358|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
79348182|NCT01533922|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
79348183|NCT01533922|Device|Respimat|Respimat inhaler
79348184|NCT01533688|Drug|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
79348185|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
79815454|NCT02597244|Device|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
79815455|NCT00743340|Drug|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
79348186|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
79348187|NCT01532986|Other|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
79661080|NCT02560805|Behavioral|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
79661081|NCT02560805|Procedure|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
79661082|NCT02560805|Procedure|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (~0-1°C) up to the wrist for 1 minute.
79661083|NCT02560805|Drug|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
79815456|NCT00917046|Behavioral|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
79815457|NCT00917046|Behavioral|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
79500028|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
79500029|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
79823721|NCT00582608|Drug|8H9|administration of 50mg/1.73m^2 of unlabeled 8H9.
79500030|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
79500031|NCT01534962|Drug|Placebo|Oral administration, BID; for a maximum of 112 days.
79823722|NCT02579798|Device|PEEP (positive end-expiratory pressure)|
79987436|NCT05000957|Procedure|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
79987437|NCT05000957|Other|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
79987438|NCT05000957|Other|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
79987439|NCT05000957|Genetic|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
79348188|NCT01532986|Other|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
79661084|NCT02560805|Drug|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
79661085|NCT02560805|Drug|Losartan|Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
79987440|NCT04482166|Other|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
79500032|NCT04758234|Drug|LY3549492|Administered orally.
79500033|NCT04758234|Drug|Placebo|Administered orally.
79500034|NCT01582152|Drug|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
79348189|NCT01532908|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
79348190|NCT01532908|Drug|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
79348191|NCT01532908|Drug|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
79348192|NCT02160782|Drug|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
79348193|NCT02160782|Drug|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
79348194|NCT02160626|Drug|A-101 Vehicle|Placebo control
79500035|NCT01582152|Drug|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
79500036|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
79500037|NCT01581684|Drug|Placebo|Solution for oral administration
79500038|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
79500039|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
79500040|NCT01581684|Drug|BI 411034|High dose solution for oral administration
79500041|NCT01581684|Drug|BI 411034|High dose solution for oral administration
79500042|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
79500043|NCT01581684|Drug|BI 411034|High dose solution for oral administration
79500044|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
79500045|NCT01557582|Device|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
79500046|NCT01557504|Drug|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
79661086|NCT02560805|Drug|Atenolol|Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
79661087|NCT02542293|Biological|Durvalumab +Tremelimumab|
79661088|NCT02542293|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
79661089|NCT02542293|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
79661090|NCT02542293|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
79661091|NCT02542293|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
79500047|NCT01557504|Drug|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
79661092|NCT02542293|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
79661093|NCT02530463|Drug|Azacitidine|Given IV
79661094|NCT02530463|Biological|Ipilimumab|Given IV
79661095|NCT02530463|Other|Laboratory Biomarker Analysis|Correlative studies
79661096|NCT02530463|Biological|Nivolumab|Given IV
79987441|NCT04482166|Device|supraglottic airway device|supraglottic airway device
79815458|NCT00917046|Behavioral|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
79500048|NCT01557504|Drug|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
79500049|NCT01557504|Drug|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
79500050|NCT01580670|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
79348195|NCT02160626|Drug|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
79500051|NCT04748484|Device|KCC Active or inactive|Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
79348196|NCT02160626|Drug|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
79500052|NCT01534260|Drug|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
79500053|NCT01534182|Drug|Fingolimod|0.5 mg orally once a day
79500054|NCT01534182|Drug|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
79500055|NCT01534182|Drug|Glatiramer acetate (GA)|20 mg subcutaneously once a day
79661097|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
79661098|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
79987442|NCT03679052|Drug|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
79987443|NCT03679052|Drug|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
79987444|NCT03679052|Drug|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
79661099|NCT02522715|Drug|Cabazitaxel|Given IV
79661100|NCT02522715|Drug|Enzalutamide|Given PO
79661101|NCT02522715|Other|Laboratory Biomarker Analysis|Correlative studies
79661102|NCT02522715|Other|Pharmacological Study|Correlative studies
79987445|NCT03172312|Procedure|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
79987446|NCT03675074|Device|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
79661103|NCT02522715|Drug|Prednisone|Given PO
79661104|NCT02483481|Diagnostic Test|shear wave ultrasound elastography|shear wave ultrasound elastography
79661105|NCT02476916|Drug|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
79348197|NCT02160314|Device|pessary|disposable, single-use pessary
79348198|NCT02160314|Device|Absorbent pad|
79348199|NCT02160002|Procedure|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
79348200|NCT02160002|Procedure|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
79348201|NCT02218268|Drug|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
79348202|NCT02218268|Drug|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
79348203|NCT02217878|Drug|Morphine|IV bolus injection
79348204|NCT02217878|Drug|Placebo|IV bolus injection
79348205|NCT02217878|Drug|Ticagrelor|180 mg loading dose
79348206|NCT04189640|Drug|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
79348207|NCT02217566|Drug|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
79661106|NCT02447029|Drug|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
79661107|NCT02447029|Drug|standard lidocaine paracervical block|1% lidocaine paracervical injection
79661108|NCT02445781|Device|Glucose clamp|Different levels of hypoglycemia
79815459|NCT04090944|Procedure|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
79815460|NCT00749190|Drug|BI 10773|
79815461|NCT00749190|Drug|placebo|
79500056|NCT01579812|Drug|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
79661109|NCT02420977|Drug|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
79815462|NCT00749190|Drug|sitagliptin|
79815463|NCT00748566|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
79815464|NCT02597166|Drug|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
79348208|NCT02217566|Drug|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
79500057|NCT01533714|Biological|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
79500058|NCT01533246|Drug|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
79500059|NCT01533246|Other|laboratory biomarker analysis|Correlative studies
79500060|NCT01579578|Drug|AZD8931|40 mg, oral dose twice daily
79500061|NCT01579578|Drug|Placebo|Placebo, oral dose twice daily
79500062|NCT01579578|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
79500063|NCT01578486|Drug|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
79661110|NCT02413567|Device|DMR Procedure (Fractyl)|Endoscopic procedure
79500064|NCT01532934|Behavioral|motivational enhancement therapy|Four 45-minute MET sessions
79661111|NCT02386709|Device|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
79661112|NCT02328872|Device|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
79661113|NCT02328872|Device|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
79661114|NCT02312557|Drug|Enzalutamide|Given PO
79661115|NCT02312557|Other|Laboratory Biomarker Analysis|Correlative studies
79661116|NCT02312557|Biological|Pembrolizumab|Given IV
79661117|NCT02279693|Other|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
79815465|NCT03976440|Other|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
79815466|NCT04090788|Dietary Supplement|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
79815467|NCT04090788|Dietary Supplement|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
79815468|NCT02597088|Other|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
79815469|NCT00743106|Drug|Fenoldopam|Fenoldopam (0.1 ~g/kg/min)started during surgery and lasting for a total of 24 hours
79815470|NCT00743106|Drug|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
79823723|NCT03918824|Other|Data extraction from medical files|Data extraction from medical files
79348209|NCT02217566|Drug|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
79348210|NCT02217410|Biological|CFZ533|
79348211|NCT02217410|Drug|Tacrolimus (Tac)|
79348212|NCT02217410|Drug|Mycophenolate mofetil (MMF)|
79348213|NCT02217410|Drug|Corticosteroids (CS)|
79348214|NCT02217410|Biological|anti-IL2 Induction|
79348215|NCT02217332|Drug|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
79661118|NCT02279693|Other|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
79348216|NCT02184572|Biological|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
79661119|NCT02279693|Radiation|IGRT Associated With IMRT|
79661120|NCT02269527|Other|Live music|Providing 1-hour live music 5 days/ week.
79661121|NCT02206984|Drug|Tamoxifen|
79500065|NCT01532934|Other|standard care|
79500066|NCT01555164|Drug|Ranolazine|Ranolazine tablet(s) administered orally
79500067|NCT01555164|Drug|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
79500068|NCT01555164|Drug|Metformin|Metformin tablet(s) administered orally once daily
79500069|NCT01555164|Drug|Placebo to match metformin|Placebo to match metformin for the duration of the study
79500070|NCT01555164|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
79500071|NCT01555164|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
79500072|NCT03028428|Biological|Placenta Derived Mesenchymal Stem Cell|1ml 1*10^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
79500073|NCT03028428|Drug|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
79500074|NCT01578330|Drug|Fingolimod|Fingolimod 0.5mg orally once a day without food.
79500075|NCT01577160|Drug|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
79348217|NCT02184572|Biological|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
79348218|NCT02184572|Biological|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
79348219|NCT02184572|Biological|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
79348220|NCT02184572|Biological|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
79348221|NCT02181842|Drug|Pioglitazone|Pioglitazone tablets
79500076|NCT01554618|Drug|Exenatide Once Weekly|2 mg exenatide once weekly
79500077|NCT01554618|Drug|Placebo|Placebo
79500078|NCT04108728|Diagnostic Test|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
79500079|NCT01531998|Drug|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
79500080|NCT01531998|Drug|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
79661122|NCT02206984|Drug|Anastrozole|
79661123|NCT02206984|Drug|Fulvestrant|
79661124|NCT02200705|Device|Ice-Sense3TM/ ProSenseTM|
79500081|NCT01531998|Drug|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
79348222|NCT01632020|Drug|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
79500082|NCT01531998|Drug|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
79348223|NCT01632020|Drug|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
79348224|NCT02181296|Drug|ropivacaine|
79500083|NCT01531998|Behavioral|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
79661125|NCT01976182|Drug|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
79661126|NCT01976182|Drug|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
79348225|NCT04761692|Behavioral|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
79348226|NCT04761692|Behavioral|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
79348227|NCT04761692|Behavioral|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
79348228|NCT02215616|Drug|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
79348229|NCT02215616|Drug|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
79348230|NCT02213666|Device|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
79661127|NCT01940094|Drug|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
79661128|NCT01940094|Drug|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
79987447|NCT03172390|Device|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
79661129|NCT01927562|Device|Fractyl Duodenal Remodeling System|
79661130|NCT01862991|Other|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
79348231|NCT02213510|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
79348232|NCT02213510|Device|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
79348233|NCT02158442|Procedure|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
79500084|NCT01576146|Drug|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
79500085|NCT01553916|Drug|Lithium Carbonate|
79500086|NCT01553916|Radiation|Prophylactic cranial irradiation|
79661131|NCT01862991|Drug|Misoprostol|400 mcg buccal misoprostol 90 pre-op
79661132|NCT01862991|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
79661133|NCT01862991|Drug|Mifepristone|200 mcg Mifepristone orally
79661134|NCT01858896|Drug|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
79348234|NCT02158442|Drug|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
79348235|NCT02158364|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
79500087|NCT01553136|Drug|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
79661135|NCT01858896|Other|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
79500088|NCT03028506|Other|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
79500089|NCT04836468|Diagnostic Test|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
79500090|NCT01552902|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
79661136|NCT01821690|Drug|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
79661137|NCT01821690|Drug|Placebo|The placebo tablets taste and look identical to buspirone.
79661138|NCT01778296|Device|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
79348236|NCT02180672|Drug|Nasal Fluticasone|One spray per nostril, per day.
79348237|NCT02180672|Drug|Placebo|One spray per nostril, per day.
79500091|NCT01552902|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
79500092|NCT01552902|Drug|Placebo|Daily oral dosing in the AM for 6 weeks
79500093|NCT03923790|Behavioral|Educational Packet|The patient will receive an educational packet.
79661139|NCT01701674|Drug|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
79500094|NCT03923790|Behavioral|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
79500095|NCT03923790|Behavioral|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
79815471|NCT04090632|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
79815472|NCT04090554|Device|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
79661140|NCT01701674|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging [MRI] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
79815473|NCT02597322|Drug|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
79815474|NCT04090320|Device|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
79348238|NCT02213198|Behavioral|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
79661141|NCT01701674|Drug|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
79661142|NCT01701674|Drug|Cyclophosphamide as Part of Lymphodepletion|
79661143|NCT01701674|Drug|Fludarabine as Part of Lymphodepletion|
79661144|NCT01701674|Drug|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
79661145|NCT01701674|Biological|Adoptive Cell Therapy with TIL|
79661146|NCT01672255|Drug|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
79661147|NCT01672255|Drug|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
79348239|NCT02213198|Behavioral|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
79348240|NCT02157506|Drug|CXL-1427|
79348241|NCT02157506|Drug|Placebo|
79987448|NCT03678974|Behavioral|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
79348242|NCT01920711|Drug|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
79500096|NCT03923790|Behavioral|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
79500097|NCT03923790|Diagnostic Test|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is < 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
79500098|NCT04102254|Procedure|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
79987449|NCT03540914|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79348243|NCT01920711|Drug|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
79661148|NCT01588431|Drug|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
79987450|NCT03540914|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79987451|NCT02400970|Other|malignant cells|
79348244|NCT02180438|Drug|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
79500099|NCT02072928|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
79500100|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
79500101|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
79500102|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
79661149|NCT01330446|Drug|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
79661150|NCT01330446|Other|Placebo|1 by mouth every morning for a 28 day cycle.
79661151|NCT01330446|Behavioral|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
79987452|NCT03671252|Drug|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
79987453|NCT03671252|Drug|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
79987454|NCT03671252|Other|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
79661152|NCT01323374|Drug|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
79661153|NCT01323374|Drug|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
79348245|NCT02179190|Device|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
79348246|NCT02157116|Drug|cisplatin|
79348247|NCT02157116|Drug|Docetaxel|
79348248|NCT02157116|Drug|Pegfilgrastim|
79348249|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
79348250|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
79348251|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
79348252|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
79348253|NCT01920555|Drug|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
79348254|NCT02156804|Drug|Nivolumab (BMS-936558)|
79500103|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
79500104|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
79661154|NCT01323374|Drug|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
79987455|NCT03671252|Procedure|TME operation|TME operation
79987456|NCT03671252|Procedure|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
79661155|NCT01323374|Drug|Placebo|Oral, placebo TID
79661156|NCT01294020|Drug|Tacrolimus|Oral capsule
79661157|NCT01294020|Drug|Tacrolimus prolonged release|Oral capsule
79661158|NCT01277315|Drug|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
79661159|NCT01233297|Drug|Azithromycin|10 mg/kg peroral for 3 consecutive days
79661160|NCT01233297|Other|Placebo mixture|Placebo mixture containing no active substance.
79661161|NCT00960414|Behavioral|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
79661162|NCT00876772|Drug|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
79500105|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
79500106|NCT01529346|Drug|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
79500107|NCT01529346|Other|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
79500108|NCT01529346|Other|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
79661163|NCT00798226|Dietary Supplement|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
79661164|NCT00798226|Dietary Supplement|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
79987457|NCT02400892|Other|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
79987458|NCT03629249|Drug|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
79987459|NCT03629249|Drug|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
79987460|NCT03629249|Drug|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
79987461|NCT02396524|Behavioral|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
79987462|NCT03671174|Drug|Prednisone|10mg once daily orally
79661165|NCT00692939|Biological|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
79348255|NCT02156492|Drug|Evacetrapib|Administered orally.
79348256|NCT02156492|Drug|Simvastatin|Administered orally.
79348257|NCT02156492|Drug|Atorvastatin|Administered orally.
79348258|NCT04753892|Other|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
79987463|NCT03671174|Drug|Hydroxychloroquine|100mg to 200mg twice daily orally
79348259|NCT04187690|Drug|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
79348260|NCT04187690|Drug|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
79348261|NCT01920477|Biological|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
79987464|NCT03671174|Drug|Aspirin|50mg once daily orally
79987465|NCT03671174|Drug|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
79987466|NCT03172234|Other|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
79987467|NCT03172234|Drug|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
79987468|NCT03172234|Drug|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
79348262|NCT01920477|Biological|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
79348263|NCT04641195|Dietary Supplement|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
79348264|NCT04641195|Dietary Supplement|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
79348265|NCT04641195|Dietary Supplement|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
79348266|NCT04641195|Other|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
79348267|NCT02213042|Drug|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
79500109|NCT01529346|Other|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
79661166|NCT00692939|Drug|Alemtuzumab|Transplant conditioning
79661167|NCT00692939|Drug|ATG|Transplant conditioning
79987469|NCT02396836|Other|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
79661168|NCT00692939|Drug|Melphalan|Transplant conditioning
79661169|NCT00692939|Drug|Thiotepa|Transplant conditioning
79661170|NCT00692939|Drug|Rituximab|Transplant conditioning
79661171|NCT00692939|Drug|Cyclophosphamide|Mobilization
79661172|NCT00692939|Drug|G-CSF|Mobilization
79661173|NCT00692939|Drug|Mesna|Mobilization
79661174|NCT00577200|Drug|Midazolam|Midazolam
79661175|NCT00577200|Drug|Sufentanil|Sufentanil
79987470|NCT02396836|Other|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
79987471|NCT03671096|Other|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
79500110|NCT02073162|Procedure|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
79500111|NCT01529268|Drug|DR cysteamine bitartrate capsule|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
79987472|NCT03623360|Diagnostic Test|Free breathing DCE-MRI|Free breathing DCE-MRI
79987473|NCT03628781|Other|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
79987474|NCT03628781|Other|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
79987475|NCT02717078|Other|Diet Therapy|The intervention for both study groups will be a change in diet.
79987476|NCT03371251|Drug|BOS161721|SC administration
79661176|NCT00577200|Drug|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
79661177|NCT00271180|Device|Device|
79987477|NCT03371251|Drug|Placebo|SC administration
79348268|NCT02213042|Biological|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
79500112|NCT01529268|Other|DR cysteamine bitartrate placebo|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
79661178|NCT00299559|Drug|smart textiles containing menthol, camphor, cineol|application to skin
79987478|NCT03370471|Behavioral|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
79987479|NCT03370471|Behavioral|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
79987480|NCT03370471|Behavioral|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
79500113|NCT01529112|Drug|Lenvatinib|
79500114|NCT01529112|Drug|Lenvatinib matched placebo|
79500115|NCT01529112|Drug|BSC|
79500116|NCT01551420|Device|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
79661179|NCT00263081|Drug|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
79987481|NCT03370471|Behavioral|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
79987482|NCT03709849|Drug|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
79987483|NCT03709849|Drug|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
79500117|NCT01551420|Device|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
79500118|NCT01575054|Biological|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
79500119|NCT01575054|Drug|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
79661180|NCT00263081|Drug|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
79661181|NCT00293982|Behavioral|Physician knowledge of parental expectations for the visit|
79348269|NCT02213042|Drug|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
79987484|NCT05343325|Drug|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
79348270|NCT04721314|Device|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF >50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
79661182|NCT00263120|Behavioral|Pain Questionnaire|
79661183|NCT00299598|Device|alkylated polyethylenimine nanoparticles antibacterial evaluation|
79348271|NCT04721314|Device|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
79348272|NCT04418180|Drug|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
79661184|NCT00263159|Procedure|Pharmaceutical care for asthma patients|
79348273|NCT04418180|Drug|Placebo|oral distilled water
79348274|NCT02212730|Drug|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
79348275|NCT02212730|Procedure|Surgical Resection|Standard of care surgical resection of RCC tumor
79348276|NCT02212730|Drug|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
79348277|NCT02178956|Drug|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
79348278|NCT02178956|Drug|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
79500120|NCT04748328|Procedure|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
79500121|NCT01528254|Drug|Placebo of vildagliptin|
79500122|NCT01528254|Drug|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
79500123|NCT01528254|Drug|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
79661185|NCT00263198|Drug|PTK787/ZK222584|
79661186|NCT00263198|Drug|Letrozole|
79661187|NCT00294099|Biological|Aluminum hydroxide|Aluminum hydroxide adjuvant.
79661188|NCT00294099|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
79661189|NCT00263237|Drug|STA-5326|
79661190|NCT00299676|Drug|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
79661191|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
79661192|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
79661193|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
79661194|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
79661195|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
79987485|NCT05343325|Radiation|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
79348279|NCT02178956|Other|Placebo|Orally two times daily
79348280|NCT02211638|Drug|Candesartan Cilexetil|Candesartan Cilexetil tablet
79348281|NCT02178566|Drug|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
79348282|NCT02211014|Drug|acalabrutinib|
79348283|NCT01631864|Drug|LCZ696|LCZ696 was provided as 400 mg tablets.
79348284|NCT01631864|Drug|amlodipine|amlodipine was provided as 5 mg tablets.
79348285|NCT01631864|Drug|Placebo|Matching placebo to LCZ696 and amlodipine.
79348286|NCT02210780|Drug|Dupilumab|Administered via subcutaneous injection.
79348287|NCT02210780|Drug|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
79348288|NCT01557244|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
79348289|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
79348290|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
79661196|NCT00263276|Drug|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
79661197|NCT00263276|Drug|metformin|Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
79661198|NCT00299754|Drug|Misoprostol|
79661199|NCT00263315|Drug|nebulised liposomal amphotericin B|
79661200|NCT00417807|Drug|Imatinib mesilate|
79661201|NCT00263354|Drug|Oxaliplatin|
79661202|NCT00299832|Drug|Aliskiren|
79987486|NCT03709693|Device|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
79987487|NCT03709615|Behavioral|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
79987488|NCT03349645|Biological|4 mL injection of AMPION™|4 mL injection of AMPION™
79987489|NCT03678896|Behavioral|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
79987490|NCT03678896|Behavioral|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
79987491|NCT03349333|Drug|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
79987492|NCT03349333|Dietary Supplement|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
79987493|NCT03349099|Device|Cook Flexor|ureteral access sheath
79348291|NCT01557244|Drug|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
79348292|NCT01557244|Drug|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
79348293|NCT01557244|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
79348294|NCT01557244|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
79348295|NCT02177942|Other|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
79987494|NCT03349099|Device|Boston Scientific Navigator|ureteral access sheath
79348296|NCT02177942|Other|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
79661203|NCT00263393|Drug|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
79987495|NCT03707665|Diagnostic Test|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
79348297|NCT02155322|Biological|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
79348298|NCT02155322|Biological|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
79987496|NCT03348163|Drug|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
79348299|NCT02210000|Drug|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
79661204|NCT00263393|Behavioral|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
79661205|NCT00263471|Drug|7-methylxanthine|
79987497|NCT03348163|Drug|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
79987498|NCT03347695|Procedure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
79987499|NCT03347695|Procedure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
79987500|NCT02892019|Drug|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
79348300|NCT02210000|Drug|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
79348301|NCT01531894|Drug|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
79348302|NCT02209766|Drug|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
79348303|NCT02209766|Drug|Placebo|"st cohort: Dose 1(2g) D5884(n=3) in Japanese~nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
79348304|NCT02209454|Drug|Enantyum® oral solution|One dose of 25 mg DKP oral solution
79348305|NCT02209454|Drug|Keral® tablet|One dose of 25 mg DKP tablet
79348306|NCT01571596|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
79348307|NCT01557166|Drug|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
79661206|NCT00299871|Drug|LIXISENATIDE (AVE0010)|
79987501|NCT02892019|Drug|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
79815475|NCT00738699|Drug|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
79815476|NCT00738699|Drug|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
79500124|NCT01574352|Behavioral|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
79815477|NCT00738699|Drug|Paclitaxel|
79815478|NCT02596932|Other|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60mg/dL
79815479|NCT02596932|Other|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60 mg/dL
79661207|NCT00263549|Biological|House dust mite Novo Helisen Depot|
79661208|NCT00299910|Drug|Montelukast|
79815480|NCT00814307|Drug|CP-690,550|5mg CP-690,550 BID PO for 6 months
79815481|NCT00814307|Drug|CP-690,550|10 mg CP-690,550 BID PO for 6 months
79815482|NCT00814307|Drug|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
79815483|NCT00814307|Drug|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
79348308|NCT01557166|Drug|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
79348309|NCT01556932|Drug|ABH gel|Given topically
79348310|NCT01556932|Other|placebo|Given topically
79348311|NCT02985736|Drug|Topicort Topical Spray|
79348312|NCT02985658|Drug|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
79500125|NCT01574352|Behavioral|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
79661209|NCT00263627|Biological|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
79661210|NCT00263627|Other|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
79661211|NCT00294177|Device|atomic force microscopy|
79661212|NCT00294177|Device|dual polarisation interferometry|
79661213|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 1|
79661214|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 2|
79661215|NCT00425594|Drug|NuLYTELY|
79815484|NCT02597010|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
79815485|NCT02597010|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
79661216|NCT00294216|Drug|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
79661217|NCT00294255|Drug|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
79661218|NCT00263705|Drug|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
79661219|NCT00263705|Drug|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
79661220|NCT00263744|Biological|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
79661221|NCT00263744|Other|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
79348313|NCT02985658|Drug|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
79348314|NCT02985658|Drug|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
79348315|NCT02177786|Drug|Selonsertib|Tablets administered orally once daily
79348316|NCT02177786|Drug|Placebo to match selonsertib|Tablets administered orally once daily
79661222|NCT00294294|Biological|Prevenar|
79348317|NCT02153918|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
79348318|NCT02153918|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
79348319|NCT03028090|Device|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
79348320|NCT02176928|Device|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
79661223|NCT00294294|Biological|Infanrix hexa|
79661224|NCT00263783|Drug|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. [As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
79661225|NCT00300105|Drug|Tesaglitazar|
79661226|NCT00263822|Drug|erlotinib hydrochloride|
79661227|NCT00294372|Drug|BILR 355 BS|
79661228|NCT00294372|Drug|Placebo|
79661229|NCT00263861|Procedure|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
79661230|NCT00294411|Procedure|elective cesarean section|
79661231|NCT00263900|Device|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
79661232|NCT00300222|Drug|NGX-4010|
79661233|NCT00263939|Behavioral|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
79661234|NCT00300261|Behavioral|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
79661235|NCT00294450|Device|Fistula Pouching System|3 different sizes of fistula pounching system
79661236|NCT00263978|Drug|Defibrotide|
79661237|NCT00300300|Procedure|Computer-assisted surgery|no description
79348321|NCT02176928|Device|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
79815486|NCT02594943|Device|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
79348322|NCT01628510|Device|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
79348323|NCT01628510|Other|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
79500126|NCT01527006|Drug|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
79815487|NCT02594943|Device|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
79815488|NCT02596776|Procedure|Fat biopsy|up to 16 biopsy samples will be taken from each subject
79348324|NCT01571362|Drug|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
79815489|NCT02596776|Drug|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
79500127|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib <900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
79500128|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
79500129|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
79500130|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
79348325|NCT01571362|Drug|Placebo|oral placebo, divided into symmetric doses and administered twice daily
79500131|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
79500132|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
79500133|NCT01549860|Device|MIST Therapy|Non-contact low frequency ultrasound therapy
79500134|NCT01549392|Device|DECT|DECT at tumor progression and 3 months later
79500135|NCT01549392|Device|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
79500136|NCT01526148|Drug|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
79661238|NCT00264056|Device|hyperthermia|
79661239|NCT00264095|Procedure|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
79661240|NCT00293943|Procedure|Pulmonary vein ablation|
79815490|NCT02596776|Other|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
79348326|NCT01571284|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
79661241|NCT00264134|Drug|Docetaxel|
79661242|NCT00264134|Drug|Irinotecan|
79661243|NCT00264134|Drug|Carboplatin|
79348327|NCT01571284|Drug|FOLFIRI|irinotecan, 5-FU and leucovorin
79348328|NCT04825756|Behavioral|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
79348329|NCT02137772|Drug|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
79348330|NCT02137772|Drug|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
79348331|NCT04410250|Behavioral|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
79348332|NCT04418024|Drug|AG10|TTR stabilizer administered orally twice daily (BID)
79348333|NCT04418024|Drug|Placebo|Non-active control
79348334|NCT03027856|Device|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
79348335|NCT01555138|Drug|Indacaterol|Indacaterol is delivered via a SDDPI.
79348336|NCT01555138|Drug|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
79661244|NCT00300339|Drug|SL650472, Clopidogrel|
79661245|NCT00264173|Drug|Valproate sodium|
79661246|NCT00294528|Device|Nexgen LPS-flex and AGC|
79661247|NCT00264212|Drug|irbesartan and irbesartan-hydrochlorothiazide|
79661248|NCT00300378|Drug|desvenlafaxine 50 mg|
79661249|NCT00300378|Drug|desvenlafaxine 100 mg|
79661250|NCT00264251|Behavioral|Weight loss through diet and exercise|
79661251|NCT00264251|Drug|Rosiglitazone insulin sensitizing agent|
79348337|NCT02137226|Drug|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
79348338|NCT02137226|Drug|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
79348339|NCT01530334|Drug|Gefitinib 250mg|Gefitinib 250mg once daily
79348340|NCT01570192|Drug|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
79348341|NCT01570192|Drug|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
79987502|NCT03709537|Behavioral|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
79987503|NCT03710629|Other|Patients with driver genes|Patients with driver genes
79987504|NCT03710551|Other|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
79348342|NCT01570192|Drug|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
79500137|NCT01526148|Drug|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
79500138|NCT01572948|Drug|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
79500139|NCT01572948|Drug|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
79500140|NCT01525602|Drug|PLX3397|PLX3397 tablets, 200mg
79500141|NCT01525602|Drug|Paclitaxel|Paclitaxel IV
79500142|NCT04749966|Other|This is an observational study, there are no interventions|This is an observational study, there are no interventions
79500143|NCT01549002|Drug|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
79500144|NCT01549002|Drug|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
79661252|NCT00294567|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
79661253|NCT00264329|Other|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
79661254|NCT00300417|Drug|VRC-WNVDNA020-00-VP|
79661255|NCT04708925|Other|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
79661256|NCT00294606|Drug|Comparison of Effects of Phenylephrine and Norepinephrine|
79661257|NCT00300534|Device|Abbott Laboratories Determine test for syphilis|
79661258|NCT00300534|Device|Investigational syphilis immunochromatographic strip test|
79661259|NCT04708964|Drug|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
79348343|NCT01570192|Drug|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
79348344|NCT01570192|Device|tobramycin nebulization|tobramycin nebulization 600mg/day
79348345|NCT02136914|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
79348346|NCT02136914|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
79348347|NCT01530256|Biological|ALD518|160 mg IV q 4 weeks for 4 doses
79348348|NCT01530256|Biological|ALD518|320 mg IV q 4 weeks for 4 doses
79348349|NCT01530256|Biological|ALD518|640 mg IV q 4 weeks for 2 doses
79348350|NCT01554904|Device|Facial-Flex|Oral exercise device
79348351|NCT01529632|Drug|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
79348352|NCT01529632|Drug|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
79348353|NCT01529632|Drug|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
79815491|NCT02594631|Procedure|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
79815492|NCT02594631|Procedure|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
79815493|NCT02598180|Device|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
79815494|NCT02598336|Device|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
79815495|NCT02598336|Device|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
79815496|NCT02611895|Biological|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
79815497|NCT00748098|Drug|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
79348354|NCT01529632|Drug|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
79500145|NCT01548768|Drug|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
79500146|NCT01548768|Drug|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
79500147|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
79815498|NCT00748098|Drug|Placebo|Placebo
79500148|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
79500149|NCT01572792|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
79500150|NCT01572792|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
79500151|NCT01572792|Drug|Placebo|Inhaled dose-matched placebo, twice per day
79500152|NCT03028272|Other|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
79661260|NCT04708964|Drug|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
79500153|NCT03028272|Other|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
79500154|NCT01547598|Drug|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
79661261|NCT00294801|Drug|flex-a-new (food supplement)|
79661262|NCT00264368|Drug|intravenous (IV) ganciclovir|
79661263|NCT00264407|Drug|Hormone Replacement Therapy - HRT|
79815499|NCT00813995|Drug|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
79815500|NCT00813995|Drug|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
79815501|NCT02598882|Device|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
79987505|NCT03710551|Other|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
79348355|NCT01554514|Biological|rituximab|rituximab intravenously 100 mg every week for four doses
79348356|NCT01553188|Drug|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
79348357|NCT01553188|Drug|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
79348358|NCT01553188|Drug|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
79348359|NCT02175758|Drug|SOF|SOF administered orally once daily
79500155|NCT01547598|Drug|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
79500156|NCT01547598|Drug|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
79661264|NCT00300573|Drug|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
79661265|NCT00300612|Biological|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
79661266|NCT00264446|Drug|ADH300004|
79661267|NCT00300651|Behavioral|Cognitive Behavioral Therapy|
79661268|NCT00264485|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
79815502|NCT02598882|Device|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
79348360|NCT02175758|Drug|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
79348361|NCT01529008|Drug|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
79500157|NCT01547286|Biological|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is < 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
79500158|NCT01547286|Radiation|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
79500159|NCT01547286|Drug|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
79661269|NCT00294840|Device|PET-CT|
79661270|NCT00300690|Device|6 mm Uni-graft® (B-Braun)|
79661271|NCT00300690|Device|6 mm Gore-Tex® (WL Gore)|
79661272|NCT00264524|Procedure|venipuncture to withdraw patient's blood|
79661273|NCT00294879|Procedure|pressure support ventilation at 0, 5, and 10% IRT|
79815503|NCT00737529|Drug|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
79661274|NCT00264563|Behavioral|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
79815504|NCT03971526|Other|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
79815505|NCT02596542|Other|Water immersion|Different temperatures of cold water immersion will be assessed
79815506|NCT00813917|Drug|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
79815507|NCT00813917|Drug|placebo|12 weeks of placebo (double blinded) by mouth twice per day
79815508|NCT02611193|Procedure|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
79661275|NCT00264563|Behavioral|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
79661276|NCT00294918|Drug|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
79815509|NCT02611193|Procedure|Simulated manipulative treatment|Simulated Manipulative Treatment
79815510|NCT02594709|Radiation|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
79348362|NCT01529008|Drug|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
79348363|NCT01599104|Drug|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
79661277|NCT00264680|Drug|lamotrigine|
79348364|NCT01599104|Drug|Olmesartan|Olmesartan 20 mg capsule one daily
79348365|NCT01599104|Drug|Placebo|Placebo to LCZ696 or Olmesartan
79348366|NCT01569568|Other|MRI scanning|1H MRS, DTI, FMRI
79348367|NCT01569568|Behavioral|Cognitive testing|Behavioral testing
79348368|NCT05255432|Other|nil intervention|Users observation using medical device on manakin, different scenarios per group
79661278|NCT00264680|Drug|valproic acid|
79661279|NCT00300729|Drug|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
79661280|NCT00300729|Drug|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
79815511|NCT02598102|Drug|Diclofenac sodium|Diclofenac for pain relief
79815512|NCT02598102|Drug|Placebo|Placebo for comparison
79815513|NCT02598024|Behavioral|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
79348369|NCT02136680|Other|CASA Education|Basic palliative care competencies for outpatient use.
79500160|NCT01547130|Drug|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
79661281|NCT00264719|Drug|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
79661282|NCT00264719|Drug|placebo|placebo 10 mg
79823724|NCT02579330|Device|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
79987506|NCT03365791|Biological|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
79987507|NCT03365791|Biological|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
79348370|NCT01552954|Behavioral|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
79348371|NCT02175368|Device|Adhese One F Upgrade|
79348372|NCT01518244|Drug|Brinzolamide/timolol maleate fixed combination|
79500161|NCT01547130|Drug|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
79661283|NCT00264758|Device|Conventional hemodialysis|Three times per week in-center hemodialysis
79661284|NCT00264758|Device|Frequent hemodialysis|Six times per week in-center hemodialysis
79661285|NCT00264914|Drug|SR121463B|
79500162|NCT01524978|Drug|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
79500163|NCT01524978|Drug|vemurafenib|Escalating doses given orally twice a day starting on Day 2
79500164|NCT01524978|Drug|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
79500165|NCT04410120|Other|Interview|Semi-structured 45 minute interviews regarding impact of asthma attacks
79500166|NCT01524198|Drug|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
79661286|NCT00300807|Drug|XTL 6865|
79661287|NCT00264953|Drug|Adriamycin|
79661288|NCT00264953|Drug|Bleomycin|
79987508|NCT03365011|Drug|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
79500167|NCT01524198|Drug|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
79661289|NCT00264953|Drug|Vinblastine|
79661290|NCT00264953|Drug|DTIC|
79661291|NCT00264953|Drug|Etoposide|
79987509|NCT03365011|Drug|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
79987510|NCT03627767|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
79661292|NCT00264953|Drug|Procarbazine|
79987511|NCT03627767|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
79661293|NCT00264953|Drug|Prednisone|
79987512|NCT03627767|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
79348373|NCT01552408|Drug|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
79348374|NCT01552408|Procedure|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
79500168|NCT01523886|Drug|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
79500169|NCT01523886|Drug|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
79661294|NCT00264953|Drug|Vincristine|
79987513|NCT03732365|Combination Product|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
79500170|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
79500171|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
79987514|NCT03732365|Drug|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
79987515|NCT03627065|Drug|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
79500172|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
79500173|NCT01546038|Drug|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
79500174|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
79661295|NCT00264953|Radiation|radiation therapy|20 or 30Gy IF-RT
79661296|NCT00300846|Drug|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
79661297|NCT00300846|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
79987516|NCT05665985|Drug|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
79661298|NCT00294996|Drug|Myocet|
79661299|NCT02960945|Drug|CTP-543, 16 mg (2 x 8 mg tablet)|
79661300|NCT02960945|Drug|Jakafi 15Mg Tablet|
79661301|NCT00265031|Drug|Cyclophosphamide|
79661302|NCT00265031|Drug|Adriamycin|
79987517|NCT03732287|Device|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
79987518|NCT05665907|Other|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
79987519|NCT02142738|Drug|Pembrolizumab|Pembrolizumab IV solution
79987520|NCT02142738|Drug|Paclitaxel|Paclitaxel IV solution
79987521|NCT02142738|Drug|Carboplatin|Carboplatin IV solution
79987522|NCT02142738|Drug|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
79987523|NCT02142738|Drug|Cisplatin|Cisplatin IV solution
79661303|NCT00265031|Drug|Etoposide|
79661304|NCT00265031|Drug|Procarbazine|
79661305|NCT00265031|Drug|Prednisone|
79661306|NCT00265031|Drug|Vincristine|
79661307|NCT00265031|Drug|Bleomycin|
79661308|NCT00265031|Procedure|radiation therapy|
79661309|NCT00300924|Drug|Rizatriptan co-administered with Acetaminophen|
79661310|NCT00265070|Drug|Gefitinib|250 mg tablet oral daily dose
79661311|NCT00295035|Drug|CELECOXIB|
79661312|NCT00295035|Drug|CURCUMIN|
79661313|NCT00418197|Device|Total Facet Arthroplasty System® (TFAS®)|
79500175|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
79661314|NCT00295074|Procedure|neuropsychologic testing|
79661315|NCT00265226|Biological|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
79987524|NCT02142738|Drug|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
79348375|NCT01528696|Device|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
79661316|NCT00295113|Procedure|EFR|
79815514|NCT02598024|Behavioral|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
79823725|NCT02579330|Other|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
79823726|NCT03918902|Behavioral|Qestinnaires|Questionnaires
79987525|NCT03617861|Drug|Human Secretin|Injected once over one minute
79987526|NCT03617861|Drug|Placebo|Injected once over one minute
79987527|NCT03732053|Other|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
79987528|NCT03614975|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
79987529|NCT03614975|Biological|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
79348376|NCT01528696|Device|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
79348377|NCT02174276|Drug|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
79987530|NCT03613649|Drug|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
79348378|NCT02174276|Biological|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
79348379|NCT01528072|Device|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
79500176|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
79348380|NCT01527682|Drug|Latanoprost, Dorzolamide|"Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
79348381|NCT01527370|Biological|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
79500177|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
79500178|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
79661317|NCT00265265|Drug|Atomoxetine|
79348382|NCT01527292|Radiation|Stereotactic Radiation Therapy|SRT only
79500179|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
79500180|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
79661318|NCT00418275|Genetic|Recombinant Human Plasminogen Activator (HTUPA)|
79661319|NCT00265304|Drug|Ketoprofen|
79661320|NCT00295152|Behavioral|community occupational therapy in dementia|
79348383|NCT01527292|Radiation|SRT with Vertebral Augmentation Procedure|SRT with VAP
79500181|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
79500182|NCT01571232|Drug|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
79661321|NCT00295191|Procedure|high-flux membrane|high-flux dialyser
79661322|NCT00295191|Procedure|low-flux membrane|low-flux dialyser
79661323|NCT00295191|Procedure|conventional dialysate|conventional dialysate
79661324|NCT00295191|Procedure|ultrapure dialysate|ultrapure dialysate
79661325|NCT00265421|Procedure|Suture technique for perineal repair after delivery|
79661326|NCT00265460|Drug|Oliwer Twist smokeless tobacco (tobacco)|
79661327|NCT00300963|Drug|Talnetant|
79661328|NCT00265499|Procedure|Skeletonization of the internal thoracic artery|
79661329|NCT00295230|Procedure|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
79661330|NCT00301002|Drug|Alefacept|
79815515|NCT02610647|Drug|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
79815516|NCT02610647|Other|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
79500183|NCT01571232|Drug|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
79661331|NCT00265694|Drug|vinorelbine, gemcitabine and carboplatin|
79815517|NCT02610647|Other|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
79815518|NCT02610647|Other|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
79815519|NCT02595918|Procedure|Metastasectomy|Undergo metastasectomy
79815520|NCT02595918|Procedure|Nephrectomy|Undergo nephrectomy
79348384|NCT04748692|Procedure|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
79500184|NCT01544478|Biological|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
79500185|NCT02985528|Other|further diagnostic|further diagnostic procedures - mainly CHEST CT -
79500186|NCT01522950|Drug|Nebivolol|5 mg daily or 10 mg daily
79661332|NCT00301041|Other|laboratory biomarker analysis|
79815521|NCT02595918|Biological|Nivolumab|Given IV
79815522|NCT02610569|Device|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
79815523|NCT02610569|Device|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
79815524|NCT02595840|Drug|Afatinib|
79500187|NCT01522950|Drug|atenolol|25 mg daily or 50 mg daily
79500188|NCT01522950|Drug|placebo|one tablet daily
79500189|NCT01522404|Drug|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
79500190|NCT01522404|Drug|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
79500191|NCT01570686|Drug|Aliskiren|Aliskiren 300 mg once daily
79500192|NCT01522248|Biological|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
79661333|NCT00301041|Procedure|adjuvant therapy|
79661334|NCT00301041|Radiation|radiation therapy|
79500193|NCT04120584|Device|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
79500194|NCT01543776|Drug|abiraterone acetate|Given PO
79500195|NCT01518192|Drug|doxycycline|100 mg bid; 15 days
79500196|NCT01518192|Drug|cefuroxime axetil|500 mg bid; 15 days
79661335|NCT00265733|Drug|capecitabine|
79661336|NCT00265733|Drug|paclitaxel poliglumex|
79661337|NCT00301158|Behavioral|exercise intervention|
79661338|NCT00301158|Other|counseling intervention|
79661339|NCT00301158|Other|educational intervention|
79661340|NCT00301158|Procedure|complementary or alternative medicine procedure|
79661341|NCT00295269|Drug|Mythylprednisolone|
79661342|NCT00265772|Drug|MODULEN IBD (R) (specific Enteral Nutrition)|
79661343|NCT00265772|Drug|prednisolon|
79661344|NCT00301197|Behavioral|Behavioral Skills Maintenance|
79661345|NCT00301197|Behavioral|Social Facilitation Maintenance|
79661346|NCT00265811|Drug|Folfox|
79661347|NCT00265811|Drug|Cetuximab|
79815525|NCT02595840|Drug|Pemetrexed|
79815526|NCT04089774|Behavioral|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
79815527|NCT00737061|Device|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
79815528|NCT02594865|Dietary Supplement|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
79815529|NCT02594865|Dietary Supplement|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
79815530|NCT02594787|Dietary Supplement|Phosphorus|
79815531|NCT02594787|Dietary Supplement|Placebo|
79500197|NCT04099056|Device|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
79348385|NCT04748692|Procedure|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
79500198|NCT01517802|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
79348386|NCT01516216|Drug|FOLFOX + bevacizumab|
79348387|NCT01516216|Dietary Supplement|Vitamin D|
79500199|NCT01517802|Drug|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
79500200|NCT04714710|Drug|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
79661348|NCT00295308|Drug|Clonidine|clonidine up to 0.3 mg/day oral
79348388|NCT01950819|Biological|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
79348389|NCT01950819|Drug|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
79348390|NCT01950819|Drug|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
79348391|NCT01950819|Drug|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
79815532|NCT02594553|Behavioral|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
79815533|NCT02594397|Other|acupoints combination 1|
79815534|NCT02594397|Other|acupoints combination 2|
79815535|NCT02594397|Other|sham acupoints combination|
79823727|NCT03087656|Drug|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
79348392|NCT04742608|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79661349|NCT00295308|Drug|Placebo|oral capsules daily
79661350|NCT00265928|Drug|bortezomib|
79661351|NCT00265928|Drug|rituximab|
79661352|NCT00265928|Procedure|antibody therapy|
79661353|NCT00265928|Procedure|biological therapy|
79661354|NCT00265928|Procedure|enzyme inhibitor therapy|
79661355|NCT00265928|Procedure|monoclonal antibody therapy|
79661356|NCT00295347|Drug|Spironolactone|
79661357|NCT00295347|Drug|fludrocortisone|
79661358|NCT00295347|Drug|escitalopram|
79661359|NCT00265967|Drug|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
79661360|NCT00295386|Behavioral|Cognitive behavior therapy (CBT)|
79661361|NCT00295386|Drug|Zopiclone|
79348393|NCT04742608|Other|Electronic Health Record Review|Medical charts are reviewed
79987531|NCT03613649|Drug|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
79348394|NCT04767490|Procedure|Standard Duodenal Switch|
79348395|NCT04767490|Procedure|Single Anastomosis Duodenal Switch|
79500201|NCT04714710|Drug|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
79500202|NCT01520922|Biological|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
79500203|NCT01520922|Drug|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
79661362|NCT00266006|Drug|eptacog alfa (activated)|
79987532|NCT03613649|Other|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
79987533|NCT04652856|Device|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
79987534|NCT04652856|Device|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
79987535|NCT03096288|Drug|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
79500204|NCT01569438|Drug|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
79500205|NCT01569438|Drug|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
79500206|NCT01517412|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
79500207|NCT01517412|Device|Self-injector pen device (OptiClik®)|
79661363|NCT00301236|Drug|Dexmethylphenidate HCl extended-release capsules|
79661364|NCT00295425|Drug|Cyclosporine A versus mycophenolate mofetil for psoriasis|
79661365|NCT00266123|Drug|Sirolimus|
79661366|NCT00301314|Procedure|Autologous stem cell transplant|
79661367|NCT00266162|Drug|Bosentan administration|
79661368|NCT00295464|Drug|Betamethasone sodium phos (drug)|
79661369|NCT00415766|Drug|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
79823728|NCT03087656|Drug|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
79987536|NCT03096288|Other|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
79987537|NCT03731975|Procedure|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
79348396|NCT01514422|Drug|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
79348397|NCT03027700|Device|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
79348398|NCT01513330|Device|SenSura Mio|Ostomy product - 1 piece closed bag
79348399|NCT01513330|Device|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
79348400|NCT04415775|Other|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
79348401|NCT04415775|Other|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
79500208|NCT01517412|Drug|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
79500209|NCT01517178|Device|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
79661370|NCT00415766|Drug|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
79823729|NCT03870776|Drug|MAP4343|Daily oral administration of MAP4343
79500210|NCT01517178|Device|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
79987538|NCT03731975|Procedure|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
79987539|NCT05417256|Device|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
79823730|NCT03870776|Drug|Placebo|Daily oral administration of Placebo
79348402|NCT05110911|Biological|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
79348403|NCT05110911|Biological|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
79500211|NCT01489956|Biological|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
79500212|NCT01489956|Biological|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
79348404|NCT01524796|Other|No intervention. Non-interventional study|No intervention. Non-interventional study
79348405|NCT01547728|Drug|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
79348406|NCT01523392|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
79500213|NCT01489956|Biological|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
79500214|NCT03027726|Behavioral|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
79500215|NCT03027726|Other|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
79823731|NCT03918668|Behavioral|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
79348407|NCT01523392|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
79348408|NCT01512160|Drug|PF-04531083|2000 mg oral solution
79348409|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
79348410|NCT01512160|Drug|PF-04531083|1000 mg oral solution
79348411|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
79500216|NCT01516008|Drug|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
79500217|NCT01516008|Drug|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
79661371|NCT00415766|Drug|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
79348412|NCT01512160|Drug|Ibuprofen|2 x 200 mg tablets
79661372|NCT00301353|Drug|Isoflavones-enriched foods|
79661373|NCT00301392|Other|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
79661374|NCT00301392|Drug|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
79661375|NCT00415844|Drug|ELC200 (carbidopa+levodopa+entacapone)|
79348413|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
79348414|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
79348415|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
79987540|NCT05417256|Device|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
79348416|NCT01546168|Device|esophageal deviation with IDE device|esophageal deviation during AF ablation
79348417|NCT01901289|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
79348418|NCT01950741|Drug|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
79348419|NCT01950273|Drug|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
79348420|NCT01950273|Drug|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
79348421|NCT01919307|Other|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
79348422|NCT01919229|Drug|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
79348423|NCT01919229|Drug|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
79348424|NCT04626375|Drug|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
79348425|NCT04626375|Drug|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
79348426|NCT01901055|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
79348427|NCT01901055|Device|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
79500218|NCT01516008|Drug|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
79987541|NCT05665829|Procedure|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
79987542|NCT05665829|Procedure|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
79500219|NCT01489254|Drug|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
79987543|NCT03731897|Other|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
79987544|NCT03731897|Other|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
79348428|NCT01901055|Behavioral|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
79348429|NCT04615377|Behavioral|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
79987545|NCT02072148|Procedure|PET/CT|PET scan or CT scan q 4 months for 5 years
79500220|NCT01489254|Drug|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
79500221|NCT01489254|Drug|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
79500222|NCT01489020|Biological|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
79500223|NCT01489020|Biological|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
79500224|NCT03027024|Device|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
79661376|NCT00301431|Drug|DVS-233|
79661377|NCT00415883|Drug|Valsartan|
79661378|NCT00301470|Device|MR urography|undergoing both renal scintigraphy and MR within a month
79661379|NCT00266240|Drug|GK Activator (2)|Escalating doses po bid
79661380|NCT00266240|Drug|Placebo|po bid
79500225|NCT01514760|Other|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
79987546|NCT02072148|Radiation|Radiotherapy|Postoperative XRT 5000 cGy
79661381|NCT00295542|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
79661382|NCT00295542|Procedure|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
79661383|NCT00295542|Drug|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
79661384|NCT00295542|Drug|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
79661385|NCT00295542|Drug|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
79661386|NCT00295542|Drug|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
79661387|NCT00295542|Procedure|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
79661388|NCT00266318|Drug|Interferon Alfacon-1 and Ribavirin|
79661389|NCT00295581|Drug|PpPfs25/ISA51 & ScPvs25/ISA51|
79661390|NCT00266357|Drug|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
79661391|NCT00266357|Drug|Placebo / Duration of Treatment: 2 days for screening period|
79661392|NCT04719026|Other|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
79661393|NCT00301509|Drug|peginterferon and ribavirin|
79661394|NCT00266396|Behavioral|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
79661395|NCT00266396|Behavioral|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
79348430|NCT04615377|Other|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
79348431|NCT01511536|Drug|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
79348432|NCT01511536|Drug|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
79348433|NCT01511536|Drug|Prednisone 5 mg|Route of administration: oral
79348434|NCT01890759|Biological|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
79348435|NCT01900899|Procedure|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
79348436|NCT01510912|Drug|Diclofenac|35 mg bid or tid Capsules
79348437|NCT04615221|Other|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
79661396|NCT00301548|Drug|perioperative chemotherapy|
79661397|NCT00266474|Other|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
79661398|NCT00295698|Drug|Diethylcarbamazine|
79661399|NCT00266552|Drug|risperidone|
79661400|NCT00301587|Drug|Norgestimate-ethinyl estradiol, with or without folic acid|
79661401|NCT00266591|Drug|topiramate|
79661402|NCT00295737|Procedure|bronchoscopy, allergen/endotoxin instillation|
79661403|NCT04719299|Behavioral|Tell-Play-Do|Using smart phone application
79661404|NCT04719299|Behavioral|Tell-Show-Do|Using traditional behavior management technique
79661405|NCT00301626|Behavioral|smoking reduction intervention (including NRT)|
79661406|NCT00301665|Biological|Botulinum toxin type A|
79661407|NCT00295776|Drug|Lamictal in the treatment of Post-Herpetic Neuralgia|
79348438|NCT01510756|Drug|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
79500226|NCT01514682|Drug|Anti-inflammatory Combination Therapy|"salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~fluvastatin: target dose 40 mg/day, administered in a single evening dose~combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
79500227|NCT01514682|Drug|Placebo|Non-medication pills; To be taken in morning and evening intervals.
79661408|NCT00266669|Drug|Topical organogel with nitroglycerin|
79661409|NCT00417924|Behavioral|Patient education|
79661410|NCT00266747|Drug|SR58611A|
79661411|NCT00418002|Drug|AQW051|
79661412|NCT00266786|Drug|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
79987547|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
79987548|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
79348439|NCT01522456|Drug|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
79500228|NCT01514448|Drug|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
79661413|NCT00266786|Drug|Intranasal Placebo|Intranasal Placebo
79661414|NCT00295815|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
79987549|NCT01735812|Device|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
79348440|NCT01522456|Drug|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
79348441|NCT04409626|Other|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
79348442|NCT01545934|Behavioral|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
79348443|NCT03027544|Radiation|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles."
79987550|NCT05451030|Device|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
79987551|NCT03611075|Other|No Intervention|No interventions are administered in this study
79348444|NCT01521364|Drug|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
79348445|NCT01545388|Drug|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
79348446|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
79348447|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
79500229|NCT01514370|Drug|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
79500230|NCT01514370|Drug|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
79500231|NCT01514370|Drug|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
79661415|NCT00295815|Drug|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
79661416|NCT00266981|Device|APOS - exercise component|
79661417|NCT00267137|Device|Pacing Algorithms|
79661418|NCT00295971|Biological|anti-thymocyte globulin|
79661419|NCT00295971|Biological|therapeutic allogeneic lymphocytes|
79661420|NCT00295971|Drug|fludarabine phosphate|
79661421|NCT00295971|Drug|thiotepa|
79500232|NCT04705974|Procedure|Fascia iliaca block|Fascia iliaca block will be performed under ultrasound guidenance.
79500233|NCT04705974|Procedure|Femoral nerve block|Femoral nerve block will be performed under ultrasound guidenance.
79661422|NCT00295971|Procedure|allogeneic bone marrow transplantation|
79661423|NCT00295971|Procedure|allogeneic hematopoietic stem cell transplantation|
79815536|NCT00917943|Behavioral|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
79815537|NCT02594241|Drug|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
79987552|NCT05430204|Device|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
79661424|NCT00295971|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79348448|NCT01545388|Drug|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
79348449|NCT03027232|Other|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
79348450|NCT01545076|Biological|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
79348451|NCT01545076|Biological|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
79348452|NCT01545076|Biological|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
79348453|NCT01545076|Biological|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
79661425|NCT00295971|Radiation|total-body irradiation|
79661426|NCT00267176|Drug|lumiracoxib|
79661427|NCT00296010|Drug|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
79815538|NCT02594241|Drug|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
79348454|NCT01544920|Biological|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
79500234|NCT04705974|Procedure|Pericapsular nerve group block (PENG block)|Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
79500235|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
79500236|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
79500237|NCT01519674|Drug|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
79500238|NCT01519674|Drug|metformin|Subjects will continue on their pre-trial metformin treatment.
79500239|NCT01519518|Drug|unfractionated heparin|70 units/kg body weight intravenous
79661428|NCT00296010|Drug|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
79661429|NCT00296010|Drug|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
79661430|NCT00296010|Procedure|adjuvant therapy|
79661431|NCT00296010|Radiation|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
79661432|NCT00267215|Drug|Lumiracoxib|
79815539|NCT02594475|Procedure|Endoscopic retrograde cholangiopancreatography|"Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~Selective bile duct cannulation is performed using wire-guided cannulation.~In case of difficult cannulation, precut is performed using a needle-knife.~After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
79348455|NCT01544920|Drug|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight <75 kilograms [kg]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
79348456|NCT01544920|Drug|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
79815540|NCT00585975|Drug|bromfenac ophthalmic solution|sterile opthalmic solution
79500240|NCT01519518|Drug|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
79500241|NCT01519206|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
79500242|NCT01518972|Drug|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
79500243|NCT01518972|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
79500244|NCT01514136|Device|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
79661433|NCT00296049|Drug|daptomycin|
79661434|NCT00296049|Drug|vancomycin|
79661435|NCT00267254|Drug|torcetrapib/atorvastatin|
79661436|NCT00267254|Drug|simvastatin|
79815541|NCT04088253|Procedure|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
79815542|NCT00918021|Drug|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
79815543|NCT00918021|Drug|placebo|placebo
79348458|NCT01509664|Behavioral|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
79661437|NCT00301782|Biological|bleomycin sulfate|
79661438|NCT00301782|Drug|carboplatin|
79661439|NCT00301782|Drug|cisplatin|
79815544|NCT02594007|Device|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
79348459|NCT04409704|Device|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
79348460|NCT01543828|Drug|indacaterol|delivered via single-dose dry-powder inhaler
79500245|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
79500246|NCT03027570|Behavioral|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
79661440|NCT00301782|Drug|etoposide phosphate|
79661441|NCT00301782|Drug|vincristine sulfate|
79661442|NCT00267332|Drug|Modafinil|
79661443|NCT00267410|Behavioral|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
79679546|NCT00516620|Behavioral|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
79815545|NCT02594007|Device|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
79815546|NCT02594007|Device|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
79815547|NCT00585585|Drug|betahistine dihydrochloride|oral, 50-300 mg, daily
79661444|NCT04718649|Drug|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
79815548|NCT02594085|Other|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
79815549|NCT02594085|Other|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
79500247|NCT03027570|Behavioral|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
79500248|NCT03027570|Other|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
79815550|NCT02594085|Other|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
79500249|NCT04672512|Drug|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
79815551|NCT02594085|Other|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
79500250|NCT04672512|Drug|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
79500251|NCT04672512|Drug|Prednisone|Prednisone tablet for oral administration
79661445|NCT00301860|Biological|anti-thymocyte globulin|
79348461|NCT01543828|Drug|placebo|delivered via single-dose dry-powder inhaler
79500252|NCT01512264|Device|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
79500253|NCT01512108|Drug|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
79500254|NCT01512108|Drug|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
79500255|NCT01486758|Drug|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
79500256|NCT01486758|Drug|Placebo|
79500257|NCT01463982|Drug|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
79661446|NCT00301860|Biological|filgrastim|
79348462|NCT03027622|Behavioral|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
79348463|NCT01520506|Device|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
79500258|NCT01486446|Drug|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
79661447|NCT00301860|Biological|therapeutic allogeneic lymphocytes|
79661448|NCT00301860|Drug|cyclosporine|
79661449|NCT00301860|Drug|fludarabine phosphate|
79348464|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
79661450|NCT00301860|Drug|melphalan|
79661451|NCT00301860|Drug|methotrexate|
79661452|NCT00301860|Procedure|allogeneic hematopoietic stem cell transplantation|
79661453|NCT00301860|Procedure|peripheral blood stem cell transplantation|
79815552|NCT02594085|Other|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
79815553|NCT02594085|Other|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
79348465|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
79348466|NCT01543204|Drug|Etanercept|Administered by subcutaneous injection
79348467|NCT01488994|Biological|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
79348468|NCT01508650|Behavioral|Usual care|Usual care control group
79500259|NCT01486446|Drug|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
79500260|NCT03027180|Device|Noninvasive positive airway pressure with different levels|
79500261|NCT04655352|Dietary Supplement|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
79500262|NCT01485354|Device|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
79500263|NCT01510158|Drug|Lesinurad|Tablets, 200 mg once daily (qd)
79661454|NCT00267449|Device|SoftScan Optical Breast Imaging System|
79661455|NCT00301899|Biological|pertuzumab|
79661456|NCT00301899|Biological|trastuzumab|
79661457|NCT00267527|Drug|CJC 1295|
79661458|NCT00296127|Drug|Celecoxib|
79661459|NCT00267566|Behavioral|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
79815554|NCT02593929|Drug|ruxolitinib|
79815555|NCT02593851|Drug|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
79815556|NCT02593851|Drug|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
79815557|NCT02593695|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
79815558|NCT02593695|Other|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
79815559|NCT00734097|Drug|Esomeprazole 40 mg|Once a day
79815560|NCT00734097|Procedure|Physical Exam|every visit
79348469|NCT01508650|Behavioral|Rehabilitation intervention|Multi-domain rehabilitation intervention
79348470|NCT03027154|Biological|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
79348471|NCT03027154|Biological|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
79348472|NCT01488448|Drug|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
79348473|NCT01488448|Drug|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
79348474|NCT01518946|Drug|Midodrine HCl|dose at the subject's current dose level
79348475|NCT01518946|Drug|Placebo|single dose of matching placebo
79348476|NCT01488370|Device|Endotracheal intubation|Endotracheal intubation
79348477|NCT01518322|Device|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
79500264|NCT01510158|Drug|Lesinurad|Tablets, 400 mg qd
79500265|NCT01510158|Drug|Placebo|Tablets, Placebo qd
79500266|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
79500267|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
79500268|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
79500269|NCT04080882|Biological|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
79500270|NCT04080882|Other|Placebo|Treatment of platysmal bands
79500271|NCT04080882|Biological|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
79661460|NCT00296166|Procedure|Catheter ablation|
79661461|NCT00296166|Procedure|Thoracoscopic epicardial ablation|
79661462|NCT00267605|Behavioral|FHPADHD|Evidence-based psychological and behavioural distance intervention
79661463|NCT00267605|Behavioral|ADHD Standard Care|
79661464|NCT00296205|Drug|Cyclophosphamide|
79661465|NCT00296283|Behavioral|integrative behavior couples therapy|
79661466|NCT00267722|Drug|Visilizumab|
79661467|NCT00301938|Drug|7-hydroxystaurosporine|Given IV
79815561|NCT00734097|Other|Quality of Life Questionnaires|every visit
79987553|NCT05430204|Device|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~Average glucose≥130 mg/dL or~Any glucose value ≥200 mg/dL"
79500272|NCT04080882|Biological|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
79500273|NCT03027336|Dietary Supplement|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
79500274|NCT03027336|Dietary Supplement|Placebo|patients will take one tablet daily for 12 weeks.
79500275|NCT01485120|Device|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
79500276|NCT03027258|Other|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
79500277|NCT01484496|Biological|Placebo|Placebo
79500278|NCT01484496|Biological|Belimumab 200 mg SC|Belimumab 200 mg SC
79500279|NCT01484496|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
79348478|NCT01507246|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
79500280|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^8 vp/mL administered on Day 0
79815562|NCT00734097|Procedure|pregnancy test, if applicable|as needed
79348479|NCT01507246|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
79661468|NCT00301938|Drug|perifosine|Given orally
79661469|NCT00301938|Other|pharmacological study|Correlative studies
79661470|NCT00267839|Behavioral|physical exercise, wellness|
79815563|NCT05756699|Diagnostic Test|multiple reaction monitoring (MRM)-based multimarker panel|multiple reaction monitoring (MRM)-based multimarker panel test to detect hepatocellular carcinoma
79815564|NCT00819767|Drug|Aliskiren|Aliskiren was supplied in 150 mg tablets.
79348480|NCT01507090|Device|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
79348481|NCT03870022|Device|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
79348482|NCT03870022|Device|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
79348483|NCT01464346|Device|Enlite Sensor|This is the Enlite sensor (all subjects)
79348484|NCT02073448|Drug|GK530G|
79815565|NCT00819767|Drug|Valsartan|Valsartan was supplied in 160 mg capsules.
79815566|NCT00819767|Drug|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
79500281|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^9 vp/mL administered on Days 0, 28, and 56
79500282|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^10 vp/mL administered on Days 0, 28, and 56
79661471|NCT00296361|Drug|Tacrolimus|immunosuppression
79661472|NCT00296439|Behavioral|Behavior|
79815567|NCT00819767|Drug|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
79815568|NCT02593617|Other|Addiction Profile Index|
79815569|NCT02593617|Other|Alcohol Use Disorders Identification Test|
79815570|NCT02593617|Other|Barratt Impulsiveness Scale|
79815571|NCT02593617|Other|Zuckerman Sensation Seeking Scale|
79815572|NCT02593617|Other|Energy Drink Consumption Questionnaire|
79348485|NCT02073448|Drug|CD0271|
79348486|NCT02073448|Drug|CD1579|
79348487|NCT01487200|Drug|FX006 10 mg|single 3 mL IA injection
79348488|NCT01487200|Drug|FX006 40 mg|single 3 mL IA injection
79348489|NCT01487200|Drug|FX006 60 mg|single 3 mL IA injection
79348490|NCT01487200|Drug|TCA IR 40|single 1 mL IA injection
79348491|NCT01463878|Dietary Supplement|Glycerna|Diabetes specific formula
79348492|NCT01463878|Dietary Supplement|Jevity - Control Diet|Control Diet
79661473|NCT00415922|Drug|ELC200 (carbidopa+levodopa+entacapone)|
79661474|NCT00302016|Drug|AMN107|
79661475|NCT00415961|Device|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
79661476|NCT00416039|Drug|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
79661477|NCT00416039|Drug|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
79661478|NCT00296478|Drug|Endometrin|Endometrin 100mg BID x 10weeks
79661479|NCT00296478|Drug|Endometrin|Endometrin 100mg TID x 10weeks
79661480|NCT00296478|Drug|Crinone|Crinone QD x 10weeks
79679547|NCT00516620|Behavioral|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
79815573|NCT00922961|Biological|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
79815574|NCT00922961|Procedure|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
79815575|NCT00918099|Procedure|Avaulta mesh|Insertion of a mesh vs conventional repair
79815576|NCT00918099|Procedure|Anterior repair|Conventional repair
79815577|NCT05297357|Dietary Supplement|Mediterranean Diet weaning scheme|Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
79815578|NCT04088175|Other|JUUL ENDS - Virginia Tobacco 5% nicotine strength|JUUL ENDS - Virginia Tobacco 5% nicotine strength
79815579|NCT04088175|Other|JUUL ENDS - Virginia Tobacco 3% nicotine strength|JUUL ENDS - Virginia Tobacco 3% nicotine strength
79348493|NCT01486966|Drug|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
79348494|NCT01486966|Drug|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
79500283|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^11 vp/mL administered on Days 0, 28, and 56
79661481|NCT00302172|Drug|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
79661482|NCT00268151|Drug|Oxaliplatin|
79815580|NCT04088175|Other|JUUL ENDS - Menthol 5% nicotine strength|JUUL ENDS - Menthol 5% nicotine strength
79815581|NCT04088175|Other|JUUL ENDS - Menthol 3% nicotine strength|JUUL ENDS - Menthol 3% nicotine strength
79815582|NCT04088175|Other|JUUL ENDS - Mint 5% nicotine strength|JUUL ENDS - Mint 5% nicotine strength
79815583|NCT04088175|Other|JUUL ENDS - Mint 3% nicotine strength|JUUL ENDS - Mint 3% nicotine strength
79815584|NCT04088175|Other|JUUL ENDS - Mango 5% nicotine strength|JUUL ENDS - Mango 5% nicotine strength
79500284|NCT01509846|Biological|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
79500285|NCT01462344|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
79500286|NCT01462344|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
79661483|NCT00268151|Drug|Capecitabine|
79661484|NCT00418080|Drug|bicalutamide|
79500287|NCT01462344|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
79500288|NCT01462344|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
79500289|NCT01484028|Device|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
79500290|NCT01484028|Device|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
79815585|NCT04088175|Other|JUUL ENDS - Mango 3% nicotine strength|JUUL ENDS - Mango 3% nicotine strength
79815586|NCT00733005|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
79815587|NCT00733005|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
79815588|NCT00812981|Biological|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
79815589|NCT00812981|Biological|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
79815590|NCT00732615|Drug|Placebo|Placebo for subcutaneous injection
79500291|NCT01484028|Device|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
79500292|NCT01462266|Drug|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
79348495|NCT01486966|Drug|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
79348496|NCT01486966|Drug|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
79348497|NCT01486966|Drug|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
79348498|NCT04080076|Drug|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
79348499|NCT04080076|Drug|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
79661485|NCT00296556|Drug|Rivenprost (drug)|
79661486|NCT00268229|Drug|cytarabine|300 mg/m2/day
79661487|NCT00268229|Drug|daunorubicin hydrochloride|45 mg/m2/day
79661488|NCT00268229|Drug|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
79348500|NCT01900665|Drug|Solanezumab|Administered Intravenously (IV)
79500293|NCT01462266|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
79500294|NCT01462266|Biological|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
79500295|NCT01462266|Drug|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
79348501|NCT01900665|Drug|Placebo|Administered IV
79348502|NCT01900431|Drug|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
79348503|NCT01900431|Drug|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
79348504|NCT01900431|Drug|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
79348505|NCT01900431|Drug|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
79500296|NCT01508910|Biological|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
79500297|NCT01508910|Biological|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
79987554|NCT05074290|Drug|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
79348506|NCT01900431|Other|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
79348507|NCT01948791|Drug|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
79348508|NCT01899729|Drug|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
79348509|NCT01899729|Drug|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
79348510|NCT01899729|Drug|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
79348511|NCT01899729|Drug|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
79348512|NCT01899729|Drug|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
79348513|NCT01898091|Drug|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
79500298|NCT01508910|Other|Standard of care|Standard of care for refractory angina
79500299|NCT01462110|Device|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
79500300|NCT01462110|Device|W002194-0221P|5% hydroalcohol mouthrinse
79348514|NCT01898091|Drug|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
79348515|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
79348516|NCT01947855|Drug|Empagliflozin|Empagliflozin low dose
79500301|NCT04087590|Drug|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
79500302|NCT01508676|Drug|Pennsaid|
79500303|NCT01508676|Drug|Placebo (2.3% DMSO solution)|
79500304|NCT04095546|Other|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
79500305|NCT02985372|Drug|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
79500306|NCT02985372|Drug|Cytarabine|
79500307|NCT04087512|Other|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
79661489|NCT00302250|Drug|ALT-711 (alagebrium chloride)|
79348517|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
79348518|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
79348519|NCT01947855|Drug|Empagliflozin|Empagliflozin high dose tablet once daily
79348520|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
79815591|NCT00732615|Drug|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
79815592|NCT00732381|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
79661490|NCT00268307|Drug|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
79815593|NCT00732381|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
79815594|NCT04871711|Drug|Delgocitinib cream|Cream for topical application
79500308|NCT04087512|Other|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
79661491|NCT00302289|Drug|tyrosine, green tea, caffeine|
79661492|NCT00268502|Other|study of socioeconomic and demographic variables|
79815595|NCT04871711|Drug|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
79815596|NCT05756543|Behavioral|Counterfactual Inference Test|All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
79815597|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
79661493|NCT00268502|Procedure|fatigue assessment and management|
79500309|NCT02985216|Drug|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
79815598|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
79815599|NCT04037033|Behavioral|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
79500310|NCT02985216|Drug|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
79815600|NCT00732303|Drug|Pemetrexed|Pemetrexed (Alimta) 500mg/^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
79815601|NCT00732303|Radiation|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
79987555|NCT05074290|Drug|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
79661494|NCT00268502|Procedure|management of therapy complications|
79500311|NCT01482312|Device|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
79661495|NCT00268502|Procedure|psychosocial assessment and care|
79661496|NCT00268502|Procedure|quality-of-life assessment|
79661497|NCT00296595|Behavioral|Nutrition|
79661498|NCT00268541|Behavioral|Physical activity|
79661499|NCT00296634|Drug|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
79815602|NCT02593461|Device|Daifert|
79815603|NCT02593461|Other|Control Group|
79815604|NCT00813761|Device|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
79348521|NCT01888965|Drug|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
79815605|NCT00813761|Device|Proclear contact lens|control contact lens to be worn for entire length of study.
79815606|NCT00813761|Device|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
79348522|NCT01888497|Drug|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
79348523|NCT01888497|Drug|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
79348524|NCT01888497|Drug|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
79348525|NCT01888497|Drug|Placebo|Oral, prior to bedtime on the night before performance testing
79348526|NCT01505530|Drug|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
79661500|NCT00296634|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
79661501|NCT00268580|Behavioral|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
79661502|NCT00268619|Drug|Ramipril|
79661503|NCT00296673|Device|Rehabilitation device|
79815607|NCT00813761|Device|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
79815608|NCT00732069|Drug|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
79815609|NCT00732069|Drug|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
79815610|NCT00732069|Drug|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
79815611|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
79815612|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
79348527|NCT01505530|Drug|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
79348528|NCT01505530|Drug|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
79348529|NCT01485796|Biological|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
79348530|NCT01485796|Biological|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
79348531|NCT01505374|Procedure|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
79661504|NCT00268658|Device|SmartStep(tm) biofeedback device|
79661505|NCT00296712|Drug|escitalopram + bupropion|same dosing as for monotherapy arms
79661506|NCT00268697|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
79661507|NCT00268697|Drug|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
79815613|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
79815614|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
79815615|NCT02593383|Drug|Placebo|
79348532|NCT01505374|Procedure|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
79348533|NCT04613674|Drug|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
79987556|NCT03095508|Drug|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
79348534|NCT04613674|Drug|placebo+chemotherapy|placebo+chemotherapy
79348535|NCT01897233|Drug|Lumacaftor|
79348536|NCT01897233|Drug|Ivacaftor|
79500312|NCT01482312|Device|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
79500313|NCT01482312|Other|Glasses|Glasses per habitual prescription
79348537|NCT01887717|Device|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
79348538|NCT01887717|Drug|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
79348539|NCT01886781|Drug|Lactobacillus plantarum 299v|two capsules of 5 X 10 ^9 c.f.u each
79500314|NCT01461096|Biological|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
79348540|NCT01886781|Drug|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
79348541|NCT01886781|Other|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
79348542|NCT01886781|Other|Wash - out period|Wash - out period following treatment phase of eight weeks
79348543|NCT01463098|Drug|E2006 1.0 mg|E2006 1.0 mg capsule.
79348544|NCT01463098|Drug|E2006 2.5 mg|E2006 2.5 mg capsule.
79348545|NCT01463098|Drug|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
79348546|NCT01463098|Drug|E2006 10.0 mg|E2006 10.0 mg capsule.
79815616|NCT02609321|Procedure|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
79815617|NCT02609321|Procedure|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
79348547|NCT01463098|Drug|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
79348548|NCT01463098|Drug|E2006 50.0 mg|E2006 50.0 mg capsule.
79348549|NCT01463098|Drug|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
79348550|NCT01463098|Drug|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
79348551|NCT01463098|Drug|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
79348552|NCT01463098|Drug|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
79348553|NCT01463098|Drug|E2006 Matched Placebo|E2006-matched placebo capsule.
79348554|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
79348555|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
79348556|NCT01462942|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
79500315|NCT01461096|Biological|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
79500316|NCT01461096|Biological|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
79500317|NCT04077294|Other|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
79500318|NCT04077294|Other|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
79348557|NCT01462942|Drug|Placebo|Inhaled dose-matched placebo, twice per day
79348558|NCT01462942|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
79348559|NCT01462630|Drug|pazopanib hydrochloride|Given PO
79348560|NCT01462630|Other|laboratory biomarker analysis|Correlative studies
79500319|NCT01507896|Biological|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
79661508|NCT00268697|Drug|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
79661509|NCT00296751|Procedure|ECG recording|
79661510|NCT00296751|Procedure|Epidural catheter insertion|
79661511|NCT00296751|Drug|Intravenous meperidine injection|
79661512|NCT00296751|Drug|Epidural Bupivacaine and fentanyl injection|
79661513|NCT00268775|Behavioral|training and follow-up of pharmacists|
79661514|NCT00268775|Behavioral|patient-directed discontinuation letter|
79661515|NCT00302367|Drug|OROS methylphenidate hydrochloride|
79348561|NCT01462630|Procedure|positron emission tomography|Correlative studies
79348562|NCT01462630|Procedure|computed tomography|Correlative studies
79348563|NCT01462630|Radiation|fludeoxyglucose F 18|Correlative studies
79348564|NCT01504204|Drug|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
79348565|NCT01504204|Drug|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
79348566|NCT01485640|Drug|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
79348567|NCT04744207|Drug|GS-248|120 mg, capsule, once daily for 4 weeks
79348568|NCT04744207|Drug|Placebo|capsule, once daily for 4 weeks
79348569|NCT02118961|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
79348570|NCT02118961|Biological|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
79348571|NCT02140645|Drug|linagliptin|non-randomized
79348572|NCT02140411|Drug|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
79348573|NCT02139943|Drug|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
79348574|NCT02139943|Drug|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
79348575|NCT02139943|Drug|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
79348576|NCT01485172|Drug|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
79348577|NCT01485172|Drug|placebo monotherapy|placebo as monotherapy in Parkinson's disease
79348578|NCT02105701|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
79348579|NCT02105701|Drug|Ribavirin|200 mg capsule
79348580|NCT04411225|Drug|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
79348581|NCT04743349|Procedure|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
79348582|NCT01502956|Device|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
79348583|NCT01502956|Drug|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
79348584|NCT01502644|Drug|Oxycodone|Daily dosage up to 120 mg
79348585|NCT01502644|Drug|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
79348586|NCT01502644|Drug|Placebo|Placebo-matching oxycodone, placebo-matching morphine
79348587|NCT04408378|Other|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
79348588|NCT01462318|Drug|Midazolam|5 mg
79348589|NCT01462318|Other|Caffeine|200 mg
79348590|NCT01462318|Drug|S-warfarin|10 mg
79348591|NCT01462318|Other|Vitamin K|10 mg
79348592|NCT01462318|Drug|Omeprazole|40 mg
79348593|NCT01462318|Drug|Dextromethorphan|30 mg
79348594|NCT01462318|Biological|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
79348595|NCT01485094|Drug|GRT6010|Oral solution given once daily.
79348596|NCT01485094|Drug|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
79500320|NCT01507662|Behavioral|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
79987557|NCT03095508|Drug|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
79661516|NCT00302367|Drug|immediate release methylphenidate hydrochloride|
79348597|NCT01485094|Drug|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
79348598|NCT04079686|Drug|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
79500321|NCT01506960|Device|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
79348599|NCT04079686|Other|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
79500322|NCT01480674|Drug|Trastuzumab|
79500323|NCT01506882|Drug|Levetiracetam (LEV)|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: LEV 250 mg, LEV 500 mg~Frequency: Twice daily~Route of Administration: Oral use"
79500324|NCT01506726|Drug|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
79500325|NCT01506726|Drug|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
79500326|NCT01505868|Drug|Cabazitaxel|Given IV
79500327|NCT01505868|Drug|Carboplatin|Given IV
79500328|NCT01505868|Other|Laboratory Biomarker Analysis|Correlative studies
79500329|NCT01505634|Drug|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
79500330|NCT01505634|Drug|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
79500331|NCT01505634|Drug|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
79500332|NCT01505634|Drug|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
79500333|NCT01505634|Drug|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
79661517|NCT00296790|Drug|zolpidem tartrate|
79661518|NCT02961296|Other|No intervention|No intervention will be needed.
79348600|NCT01484938|Device|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
79348601|NCT01502410|Drug|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
79348602|NCT01502410|Other|pharmacological study|Optional correlative studies
79348603|NCT01502410|Other|laboratory biomarker analysis|Optional correlative studies
79348604|NCT01462162|Drug|Tocilizumab|
79661519|NCT00302406|Drug|methylphenidate hydrochloride|
79661520|NCT00302406|Drug|OROS methylphenidate hydrochloride (CONCERTA)|
79661521|NCT02961023|Other|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~1.5 to 2 hours of exercise will be performed daily, with rest intervals.~At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~Participants will be provided with a cycle ergometer, weights and a HR monitor~Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
79815618|NCT04856813|Other|Manual therapy active|massage or ischemic compression with active contraction, tha will be isometric or concentric.
79987558|NCT05416866|Procedure|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
79348605|NCT01483924|Drug|Apo805K1|Sequential parallel dose escalation.
79348606|NCT01462084|Device|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
79348607|NCT01462084|Device|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
79348608|NCT02134028|Drug|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
79348609|NCT04752488|Other|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
79348610|NCT04752488|Other|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
79348611|NCT02172950|Biological|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
79348612|NCT02151266|Behavioral|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
79815619|NCT04856813|Other|Manual therapy|massage or isquemic compression without contraction
79348613|NCT02151266|Behavioral|Exercise Only|
79348614|NCT02151266|Behavioral|Stretching and Flexibility|
79661522|NCT00302445|Drug|Efalizumab|
79815620|NCT02609243|Behavioral|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
79815621|NCT00731679|Drug|Rifaximin|
79348615|NCT02151110|Biological|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
79661523|NCT00302445|Device|Narrow Band Phototherapy|
79661524|NCT00268814|Drug|Diacetylmorphine|Diacetylmorphine (i.v.), daily
79661525|NCT00268814|Behavioral|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
79348616|NCT02151110|Biological|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
79348617|NCT02151110|Biological|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
79348618|NCT02151110|Biological|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
79348619|NCT02151110|Biological|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
79348620|NCT02151110|Biological|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
79348621|NCT02151110|Biological|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
79348622|NCT02151110|Other|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
79348623|NCT04749680|Device|PD cycler Silencia|Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
79661526|NCT00268814|Drug|Methadone|Methadone (p.o.), daily
79661527|NCT00268814|Behavioral|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
79661528|NCT00296829|Biological|Inactivated, split-virion influenza vaccine|
79661529|NCT00268853|Drug|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
79815622|NCT00731679|Drug|Placebo|
79661530|NCT00268853|Drug|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
79815623|NCT02609087|Drug|Sevoflurane|
79815624|NCT02609087|Drug|Propofol|
79815625|NCT04812119|Diagnostic Test|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, & Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
79815626|NCT04812119|Diagnostic Test|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright & Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
79348624|NCT02132312|Drug|OMS302|
79348625|NCT02132312|Drug|Phenylephrine HCl|
79815627|NCT04812119|Diagnostic Test|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright & Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
79348626|NCT02131766|Device|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
79500334|NCT04409730|Other|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
79815628|NCT04812119|Diagnostic Test|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, … & Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
79823732|NCT03014570|Behavioral|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
79348627|NCT02131766|Other|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
79348628|NCT02150954|Drug|pitocin|
79500335|NCT01460628|Drug|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
79500336|NCT01480596|Biological|Belimumab|10mg/kg IV infusion
79661531|NCT00302484|Drug|Zoledronate|
79348629|NCT04757012|Device|calinange|calinange
79348630|NCT02131532|Behavioral|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
79348631|NCT04188392|Drug|Pimavanserin|pimavanserin tablet
79348632|NCT02170688|Drug|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
79348633|NCT02170688|Other|Weight calculation|
79348634|NCT02170298|Drug|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
79661532|NCT00296868|Drug|ascorbic acid (vitamin C) versus placebo|
79661533|NCT00268931|Behavioral|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
79661534|NCT00268931|Behavioral|Social Training|This group underwent special social interactions with their parents two times each day.
79661535|NCT00296907|Behavioral|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
79815629|NCT04812119|Diagnostic Test|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes & Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
79815630|NCT04812119|Diagnostic Test|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
79987559|NCT05416866|Procedure|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
79348635|NCT02131064|Drug|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg*min/mL q3w
79661536|NCT00268970|Drug|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
79815631|NCT04812119|Diagnostic Test|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
79823733|NCT03014570|Behavioral|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
79348636|NCT02131064|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infusion q3w
79348637|NCT02131064|Drug|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
79661537|NCT00296946|Drug|ipratropium bromide (drug)|
79661538|NCT00269009|Behavioral|CHERL|
79661539|NCT00296985|Device|Fresenius Cellsaver|
79661540|NCT00269048|Drug|SB-480848|SB-480848
79661541|NCT00269048|Drug|placebo|placebo
79661542|NCT00302523|Drug|Tacrolimus|FK506,0.1mg/kg/d
79348638|NCT02131064|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
79348639|NCT02131064|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
79348640|NCT02130986|Other|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
79348641|NCT02130986|Other|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (<1 hour goal) provide clinicians the procalcitonin result.
79500337|NCT01480596|Other|Placebo|placebo IV infusion
79661543|NCT02960412|Drug|furosemide|10mg lasix given intraoperatively
79661544|NCT02960412|Drug|Normal Saline|Normal saline given intraoperatively as placebo
79500338|NCT01480284|Drug|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
79500339|NCT01480284|Drug|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
79348642|NCT02130986|Other|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended."
79815632|NCT04812119|Diagnostic Test|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
79348643|NCT02130986|Other|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
79348644|NCT02130284|Device|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
79348645|NCT04749212|Diagnostic Test|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
79348646|NCT04748822|Other|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
79500340|NCT04409028|Procedure|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
79500341|NCT01459614|Drug|Gemcitabine|IV on Days 4 and 11
79500342|NCT01459614|Drug|Taxotere|IV on Days 4 and 11
79661545|NCT04717947|Procedure|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
79348647|NCT02147288|Device|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
79500343|NCT01459614|Drug|Xeloda|orally, twice a day Days 1-14
79500344|NCT01459614|Drug|Cisplatin|IV Days 4 and 11
79500345|NCT01458522|Drug|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
79661546|NCT00269126|Drug|fluticasone propionate/salmeterol combination DISKUS|
79661547|NCT00269126|Drug|salmeterol xinafoate|
79661548|NCT00269165|Procedure|Balloon Aortic Valvuloplasty|
79661549|NCT00269165|Procedure|External Beam Radiation|
79661550|NCT00297024|Procedure|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
79661551|NCT00269204|Drug|niacin (+) laropiprant|Duration of Treatment - 24 weeks
79661552|NCT00269204|Drug|ER-niacin|Duration of Treatment - 24 weeks
79661553|NCT00297141|Drug|Capecitabine|chemotherapy oral use
79823734|NCT03869372|Device|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
79661554|NCT00297141|Drug|Oxaliplatin|chemotherapy intravenous use
79661555|NCT00269243|Drug|Quinapril|
79661556|NCT04718064|Drug|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
79661557|NCT04718064|Drug|placebo|placebo once daily, for three consecutive days,
79815633|NCT04812119|Diagnostic Test|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
79815634|NCT04812119|Diagnostic Test|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
79348648|NCT05209178|Diagnostic Test|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
79661558|NCT00297180|Drug|GW869682|
79815635|NCT04812119|Diagnostic Test|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded & Revised (GMFCS - E&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to < 4 years, 4 to < 6 years, 6 to < 12 years, and 12 to 18 years.
79815636|NCT04812119|Diagnostic Test|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
79815637|NCT04812119|Diagnostic Test|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
79348649|NCT04739150|Drug|nintedanib|nintedanib
79348650|NCT04737356|Behavioral|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
79348651|NCT04751708|Procedure|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
79348652|NCT04751708|Other|best medical management|best medical management
79348653|NCT02147132|Drug|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
79348654|NCT02147132|Drug|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
79348655|NCT02147132|Drug|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
79348656|NCT02147132|Drug|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
79661559|NCT00302601|Procedure|Scintigraphic interpretation|Not relevant
79661560|NCT00269282|Behavioral|Self-Management Training|Asthma education and self-monitoring strategies
79348657|NCT02146430|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
79348658|NCT02146430|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
79348659|NCT02146430|Drug|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
79348660|NCT02146430|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
79348661|NCT02129192|Drug|Amlodipine 5mg capsule|Amlodipine 5mg capsule
79348662|NCT02129192|Drug|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
79348663|NCT02129192|Drug|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
79661561|NCT00269282|Behavioral|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
79661562|NCT00297219|Drug|Low dialysate calcium|1.25 mmol/L dialysate calcium
79661563|NCT00297219|Drug|high dialysate calcium|1.75 mmol/L dialysate calcium
79661564|NCT00269321|Procedure|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
79661565|NCT00269321|Procedure|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
79661566|NCT00269321|Behavioral|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
79987560|NCT05416866|Procedure|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
79348664|NCT02105948|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
79661567|NCT00302640|Drug|Alinia (nitazoxanide)|
79661568|NCT00269360|Procedure|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
79661569|NCT00269360|Procedure|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
79661570|NCT00269360|Behavioral|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
79661571|NCT00297297|Other|No intervention. Applying gene profiling on needle aspirates|
79987561|NCT03632538|Diagnostic Test|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
79348665|NCT02105948|Drug|Placebo|Sterile 0.9% sodium chloride solution
79348666|NCT02128724|Drug|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
79348667|NCT02128490|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
79348668|NCT02128490|Drug|Febuxostat XR|Febuxostat over-encapsulated capsules
79661572|NCT00269438|Drug|5 ASA, enemas, suppositories, corticosteroids|
79661573|NCT00418353|Drug|Betamethasone(Celestone soluspan) and Dexamethasone|
79661574|NCT00269516|Drug|pardoprunox|fixed dose 6 mg
79661575|NCT00269516|Drug|Pardoprunox|fixed dose 12 mg
79987562|NCT05416242|Device|Traditional braces|MBT 0.022 perception traditional braces will be used without any acceleration method.
79348669|NCT02128490|Drug|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
79661576|NCT00269516|Drug|Pardoprunox|12-42mg
79661577|NCT00269516|Drug|Placebo|Placebo
79348670|NCT02128490|Drug|Colchicine|Colchicine tablets
79348671|NCT02128490|Drug|Naproxen|Naproxen tablets
79348672|NCT02128490|Drug|Lansoprazole|Lansoprazole capsules
79348673|NCT02146352|Device|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
79348674|NCT02105636|Drug|Nivolumab|
79348675|NCT02105636|Drug|Cetuximab|
79348676|NCT02105636|Drug|Methotrexate|
79348677|NCT02105636|Drug|Docetaxel|
79815638|NCT04812119|Diagnostic Test|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
79815639|NCT04812119|Diagnostic Test|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
79815640|NCT04812119|Diagnostic Test|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
79815641|NCT00731133|Drug|Disulfiram|250 mg/day
79815642|NCT03964077|Diagnostic Test|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
79348678|NCT01626872|Drug|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
79815643|NCT05756309|Device|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
79987563|NCT05416242|Device|Self-ligating braces|MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
79348679|NCT01626872|Drug|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
79348680|NCT01626872|Drug|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
79348681|NCT01626872|Drug|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
79500346|NCT01458522|Drug|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
79661578|NCT00418392|Procedure|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
79500347|NCT01505010|Procedure|Renal denervation|Renal denervation in the intervention group
79661579|NCT00418392|Procedure|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
79661580|NCT00269555|Drug|Genistein Combined Polysaccharide (GCP)|
79661581|NCT00418431|Drug|Intravitreal injection of Bevacizumab|
79661582|NCT00269594|Drug|Lamictal (lamotrigine)|
79661583|NCT00418470|Procedure|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
79661584|NCT00418470|Procedure|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
79661585|NCT00269672|Biological|13-valent Pneumococcal Conjugate Vaccine|
79661586|NCT00302757|Drug|Radioimmunotherapy|
79815644|NCT00730275|Drug|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
79987564|NCT05416242|Procedure|Self-ligating braces + piezocision|Flapless corticotomy will be applied for the upper anterior teeth.
79987565|NCT00973830|Other|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
79348682|NCT01598090|Biological|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
79500348|NCT03026946|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
79661587|NCT00302757|Procedure|allogeneic hematopoietic cell transplantation|
79348683|NCT01598090|Biological|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
79500349|NCT03026946|Drug|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
79661588|NCT00416117|Procedure|Manual Physical Therapy and Exercise|
79500350|NCT01458210|Drug|Ortho-Cyclen|Administered orally
79661589|NCT00416117|Procedure|Minimal Intervention|
79500351|NCT01458210|Biological|Dulaglutide|Administered subcutaneously
79661590|NCT00416156|Behavioral|Lifestyle modification|
79661591|NCT00302796|Drug|Bioclavid|500 + 125 mg times 3 or 6
79661592|NCT00302796|Drug|Placebo|
79987566|NCT03607487|Drug|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
79661593|NCT00425633|Drug|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
79661594|NCT00302835|Drug|non-phenacetin containing analgesics|
79661595|NCT00302874|Behavioral|Implementation of a protocol for treatment of hyperglycemia|
79661596|NCT00269750|Drug|OROS® oxybutynin or Ditropan®|
79661597|NCT00269789|Drug|Ritalin|
79661598|NCT00269789|Drug|OROS Methylphenidate HCl|
79661599|NCT00269789|Drug|Placebo|
79661600|NCT00302913|Drug|Adjustment of clopidogrel dose|
79815645|NCT00730275|Drug|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
79815646|NCT04793711|Device|EpiCeram|Barrier cream
79987567|NCT03607487|Drug|Placebo|Placebo tablet administered orally once daily.
79987568|NCT03731741|Drug|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
79987569|NCT03736187|Drug|Cephalexin|Giving cephalexin and metronidazole in one group &cephalexin alone in another group
79348684|NCT01598090|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
79348685|NCT01598090|Drug|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
79348686|NCT02105012|Drug|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
79348687|NCT02105012|Drug|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
79348688|NCT02105012|Drug|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
79348689|NCT02105012|Drug|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
79500352|NCT01478958|Dietary Supplement|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
79500353|NCT01478958|Dietary Supplement|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
79661601|NCT00269828|Drug|paclitaxel|
79661602|NCT00269828|Drug|paclitaxel poliglumex|
79661603|NCT00269867|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
79661604|NCT00269867|Drug|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
79661605|NCT00269867|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
79661606|NCT00303030|Procedure|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
79661607|NCT00303030|Procedure|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
79661608|NCT00269906|Drug|Abciximab|
79661609|NCT00269906|Drug|Placebo|
79661610|NCT02960373|Other|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
79815647|NCT02609009|Other|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
79500354|NCT01478958|Dietary Supplement|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
79500355|NCT06175442|Device|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
79815648|NCT02609009|Other|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
79987570|NCT03731663|Behavioral|Exposure to pictures of appetizing food (known as Foodporn)|- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
79987571|NCT03731663|Behavioral|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
79987572|NCT03605693|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
79661611|NCT02960373|Other|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
79348690|NCT02105012|Drug|Placebo MDI|Placebo MDI administered as 2 inhalations BID
79348691|NCT02145182|Drug|Eculizumab|Eculizumab is a complement component 5 inhibitor.
79348692|NCT02145182|Drug|Placebo|0.9% sodium chloride
79500356|NCT06175429|Diagnostic Test|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
79500357|NCT06175429|Diagnostic Test|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
79661612|NCT02960373|Other|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
79661613|NCT02960373|Other|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
79815649|NCT00730041|Device|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
79987573|NCT03736109|Genetic|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
79987574|NCT03605303|Device|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
79987575|NCT03605303|Device|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
79661614|NCT00269945|Drug|epoetin alfa|
79661615|NCT00303147|Behavioral|Expressive Writing|
79661616|NCT00269984|Drug|Epoetin alfa|
79661617|NCT00297336|Drug|Topiramate|80 patients with diagnosed with migraine
79661618|NCT00270023|Drug|epoetin alfa|
79661619|NCT00297375|Drug|tramadol HCl/acetaminophen|
79348693|NCT02145026|Drug|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
79348694|NCT02144012|Drug|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
79348695|NCT02144012|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
79348696|NCT02144012|Drug|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m^2) or 100 mg/m^2 Q3W.
79348697|NCT02103062|Drug|ABI-007|
79348698|NCT02141672|Drug|Voclosporin High Dose|
79348699|NCT02141672|Drug|Voclosporin Low Dose|
79348700|NCT02141672|Drug|Placebo|
79348701|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
79348702|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
79348703|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
79348704|NCT02141360|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
79500358|NCT06175429|Diagnostic Test|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
79500359|NCT06175429|Diagnostic Test|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
79661620|NCT02960984|Other|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
79815650|NCT00730041|Device|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
79815651|NCT04031495|Device|central vein cannulation|central vein cannulation
79661621|NCT00297414|Other|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
79661622|NCT00270062|Drug|epoetin alfa|
79815652|NCT04026893|Procedure|Uterine Transplant from Deceased Donor|The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
79815653|NCT05756231|Behavioral|SIHT-16|a pencil-paper assessment tool.
79815654|NCT04790825|Procedure|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
79661623|NCT00297453|Behavioral|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
79815655|NCT02610257|Device|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
79815656|NCT00729651|Drug|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
79815657|NCT00729651|Drug|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
79815658|NCT00729651|Dietary Supplement|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
79348705|NCT01628198|Device|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
79348706|NCT01628120|Biological|Epoetin Hospira|Subcutaneous(SC) injection
79348707|NCT01627340|Biological|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79348708|NCT02125838|Device|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
79348709|NCT02125838|Device|Endotracheal Tube|ETT
79661624|NCT00297453|Behavioral|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
79661625|NCT00297453|Behavioral|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
79661626|NCT00270101|Drug|epoetin alfa|
79661627|NCT00297531|Device|PerioWave|
79348710|NCT02125604|Drug|dimethyl fumarate|capsules administered according to the prevailing product label
79348711|NCT02124746|Drug|Momelotinib|Momelotinib tablets administered orally once daily
79348712|NCT02123966|Drug|Sirolimus|
79348713|NCT02123576|Drug|Pentoxyfylline|
79348714|NCT02123576|Drug|Placebo|
79661628|NCT00297531|Procedure|Scaling and Root Planing|
79661629|NCT00270140|Drug|epoetin alfa|
79661630|NCT00270179|Drug|epoetin alfa|
79661631|NCT00270218|Biological|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
79661632|NCT00270218|Biological|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
79500360|NCT06175403|Drug|Niacin|Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
79500361|NCT06175377|Procedure|Percutaneous coronary intervention|A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
79500362|NCT06175377|Drug|Short dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
79661633|NCT00270218|Biological|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
79661634|NCT00270218|Biological|PBS|phosphate buffered saline
79661635|NCT00297570|Drug|Pegylated Interferon and Imatinib|
79987576|NCT03735953|Diagnostic Test|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
79348715|NCT02123576|Drug|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
79348716|NCT01177397|Drug|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
79348717|NCT01160861|Drug|MEMP1972A|Repeating ascending dose
79348718|NCT01160861|Drug|placebo|Repeating ascending dose
79500363|NCT06175377|Other|Long dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.
79500364|NCT06175377|Other|Follow-up visit at 1 month|At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
79348719|NCT01158677|Procedure|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
79348720|NCT05235347|Biological|Sotrovimab|500mg IV
79500365|NCT06175377|Other|Follow-up visit at 6 months|At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
79661636|NCT00270335|Drug|Propofol|
79661637|NCT00297687|Biological|MnB rLP2086|
79661638|NCT00270374|Drug|nesiritide|
79500366|NCT06175377|Other|Follow-up visit at 12 months|At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
79500367|NCT06175351|Drug|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
79661639|NCT00297726|Behavioral|Self-Management Program|
79661640|NCT00270452|Drug|WT1 and PR1 Peptide Vaccine|
79661641|NCT00270491|Drug|Paclitaxel|
79661642|NCT00270491|Drug|Capecitabine|
79661643|NCT00270530|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
79661644|NCT00297765|Drug|Tacrolimus, Prograf®|
79661645|NCT00270569|Drug|PhyxolTM, Cisplatin|
79661646|NCT00297804|Device|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
79661647|NCT00297804|Device|Control stent|control stent
79661648|NCT00270608|Procedure|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
79661649|NCT00270608|Procedure|MRI of the spine and the right knee|a single time 45 minutes procedure
79987577|NCT03731507|Device|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
79987578|NCT03604523|Device|Dilation by Balloon|Esophageal dilation by balloon device.
79987579|NCT03604523|Device|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
79661650|NCT00270608|Procedure|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
79500368|NCT06175351|Drug|Placebo|Participants will receive IV placebo every 4 weeks.
79348721|NCT00864227|Biological|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 40 mg/m^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide: 50 mg/kg IV on Day -6~Total body irradiation: 200 centigray (cGy) on Day -1"
79348722|NCT00864227|Biological|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm^3 for three consecutive measurements, each on different days."
79348723|NCT05230511|Drug|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
79815660|NCT00729183|Drug|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
79987580|NCT03621059|Behavioral|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
79987581|NCT03731429|Drug|Lidocaine|prior to extubation
79661651|NCT00297843|Procedure|allergen challenge (grass pollen), nasal lavage|
79661652|NCT00270647|Dietary Supplement|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
79661653|NCT00270647|Dietary Supplement|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
79661654|NCT00270647|Dietary Supplement|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
79661655|NCT00270647|Dietary Supplement|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
79661656|NCT00297921|Drug|tandutinib|
79661657|NCT00297960|Drug|ziprasidone or olanzapine|
79661658|NCT00297960|Procedure|hyperinsulinaemic euglycaemic clamp|
79661659|NCT00297960|Procedure|microdialysis (skeletal muscle)|
79987582|NCT03731429|Drug|Saline Solution|Prior to extubation
79661660|NCT00270803|Drug|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
79661661|NCT00270881|Procedure|Cord blood transplantation|unrelated cord blood transplantation
79661662|NCT00270881|Radiation|TBI|Total body irradiation (TBI) 12Gy
79661663|NCT00270881|Drug|cyclophosphamide|cyclophosphamide 120mg/kg
79661664|NCT00270881|Drug|cytarabine|cytarabine 3g/m2x4
79661665|NCT00270920|Behavioral|Lactation counseling|
79661666|NCT00270959|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
79661667|NCT00270959|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
79815661|NCT00729183|Drug|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
79987583|NCT03735641|Procedure|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
79500371|NCT06175325|Procedure|Trans-radial embolisation of haemorrhoids|"Once patients have provided informed consent to participate, an assessment of symptom severity will be obtained during the initial visit using the a standardised set of 4 validated scoring systems used in research of haemorrhoidal disease. These include the French bleeding score (FBS), Goligher classification of internal haemorrhoids (GS), quality of life score (QoL) and Visual analogue score for pain (VAS). Routine blood tests will be taken. During the procedure, routine observations will be recorded on the paper CRF. The data collected on the paper CRF will be entered onto the electronic CRF.~The Transarterial fluroscopically guided superior rectal artery embolization procedure will be performed on all participants. It is a day case procedure performed under local anaesthetic."
79500372|NCT06175299|Behavioral|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
79815662|NCT00729183|Drug|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
79815663|NCT00729183|Drug|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to ~1200 mg total) for 24 months.
79815664|NCT00811733|Biological|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
79500373|NCT06175260|Diagnostic Test|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
79500374|NCT06175247|Other|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
79500375|NCT06175234|Device|Ablation Treatment|For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
79500376|NCT06175208|Behavioral|Emotional Freedom Techniques|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
79500377|NCT06175208|Behavioral|Mindfulness Meditation|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
79661668|NCT00270959|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
79661669|NCT00270959|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
79661670|NCT00298194|Drug|Z-338|
79500378|NCT06175195|Behavioral|Psychoeducational Inervention|Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
79815665|NCT00728949|Biological|IMC-A12 (cixutumumab)|10 mg/kg I.V.
79815666|NCT00728949|Drug|tamoxifen|Daily 20 mg, oral
79348724|NCT05230511|Drug|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
79348725|NCT04810715|Other|Patients with Ankylosing Spondylitis|Observational study, not applicable
79348726|NCT02102204|Drug|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
79348727|NCT02141204|Biological|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
79348728|NCT02141204|Biological|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
79500379|NCT06175169|Device|Information of Appendix (IA) model|Deep learning model
79500380|NCT06175156|Procedure|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
79661671|NCT00271037|Procedure|Colpocleisis prolapse repair surgery|
79661672|NCT00271037|Procedure|sling or other to treat or prevent stress incontinence|
79815667|NCT00728949|Drug|Anastrozole|Daily 1 mg, oral
79815668|NCT00728949|Drug|Letrozole|Daily 2.5 mg, oral
79815669|NCT00728949|Drug|Exemestane|Daily 25 mg, oral
79815670|NCT00728949|Drug|Fulvestrant|Monthly 250 mg, intramuscularly
79348729|NCT02140970|Drug|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
79500381|NCT06175156|Procedure|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
79500382|NCT06175143|Biological|GR2002 injection|TSLP monoclonal antibody
79500383|NCT06175117|Drug|compound E Jiao Jiang(cEJJ)|compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
79500384|NCT06175117|Drug|compound E Jiao Jiang(cEJJ) placebo|"compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals."
79500385|NCT06175104|Behavioral|HeartGPS|"HeartGPS includes three key components:~Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
79500386|NCT06175039|Other|Telerehabilitation exercise program|TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
79500387|NCT06175039|Other|Control program|KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
79815671|NCT00918177|Drug|AP09004|
79815672|NCT00918177|Drug|Carbidopa/Levodopa, immediate release|
79815673|NCT00728481|Drug|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
79500388|NCT06175013|Device|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
79815674|NCT00728481|Drug|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
79815675|NCT00811655|Procedure|therapeutic conventional surgery|Surgery of a single brain metastasis.
79348730|NCT02140970|Drug|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
79348731|NCT04736342|Other|PALI questionaire|Survey comprised of a series of multiple choice questions
79348732|NCT02101112|Drug|Apixaban|
79500389|NCT06175013|Device|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER 5 minutes before the Serum PURIFIANT, twice weekly
79500390|NCT06175000|Procedure|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
79500391|NCT06175000|Biological|Obinutuzumab|Given IV
79500392|NCT06175000|Other|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
79661673|NCT00306306|Device|Reprieve Endovascular Temperature Therapy System|
79661674|NCT00271076|Procedure|IVUS|
79661675|NCT00271076|Device|CAS|
79661676|NCT00271076|Procedure|CEA|
79661677|NCT00306345|Behavioral|Outreach|
79661678|NCT00271115|Behavioral|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
79661679|NCT00306423|Procedure|Other: Exercise|exercise 3 times per week for 12 weeks
79661680|NCT00271193|Behavioral|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
79661681|NCT02960256|Device|ekocardiogram test|ekocardiogram test
79661682|NCT00271232|Device|Cardiac resynchronization therapy|
79661683|NCT00418548|Drug|Etanercept|
79661684|NCT00416234|Procedure|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
79661685|NCT00416234|Procedure|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
79661686|NCT00418587|Drug|Cholecalciferol|800 IU oral daily
79661687|NCT00418587|Drug|Cholecalciferol|2000 IU oral daily
79661688|NCT00418587|Drug|Cholecalciferol|4000 IU oral daily
79815676|NCT00811655|Radiation|stereotactic radiosurgery|Pre-operative single fraction SRS
79815677|NCT03963609|Radiation|multisclice CT|assessment of the remodeling index by multisclice CT in patients with chronic stable angina
79815678|NCT02592993|Device|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
79815679|NCT04087941|Biological|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
79348733|NCT02139644|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
79661689|NCT00416273|Drug|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
79661690|NCT00416273|Drug|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
79348734|NCT02139644|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
79348735|NCT02139644|Drug|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
79348736|NCT02139644|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
79348737|NCT02139644|Drug|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
79348738|NCT02100644|Drug|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
79348739|NCT04782323|Drug|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79348740|NCT04782323|Drug|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79661691|NCT00306462|Drug|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
79661692|NCT00306462|Drug|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
79661693|NCT00416390|Dietary Supplement|lycopene|
79661694|NCT00416390|Other|laboratory biomarker analysis|
79661695|NCT00416390|Procedure|biopsy|
79661696|NCT00306501|Procedure|Swallowing Training|Swallowing Training with press of button
79987584|NCT03602339|Drug|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
79661697|NCT00416429|Biological|aldesleukin|
79661698|NCT00416429|Biological|recombinant interferon alpha-2a|
79661699|NCT00416429|Drug|medroxyprogesterone|
79661700|NCT00306540|Drug|Quetiapine Fumarate|oral flexible dose
79661701|NCT00306540|Drug|quetiapine fumarate placebo|oral 0 mg
79987585|NCT03602339|Drug|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
79500394|NCT06174974|Other|Education|The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
79500395|NCT06174935|Drug|0.01% atropine ophthalmic drop|0.01% atropine ophthalmic drop will be applied daily to the affected eye
79500396|NCT06174922|Drug|Prednisolone|Prednisolone for 4 months
79987586|NCT03735485|Other|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
79348741|NCT04782323|Drug|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79815680|NCT02593227|Biological|Low dose FRα vaccine|165ug per peptide ID injection
79348742|NCT04782323|Other|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79500397|NCT06174922|Drug|Itraconazole|SUBA-itraconazole for 4 months
79661702|NCT00271271|Drug|oxaliplatine / gemcitabine / Vinorelbine|
79815681|NCT02593227|Drug|Cyclophosphamide|IV infusion over 1 hour
79987587|NCT03735485|Other|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
79348743|NCT04782323|Drug|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79348744|NCT04782323|Drug|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79815682|NCT02593227|Biological|High dose FRα vaccine|500ug per peptide ID injection
79815683|NCT04030481|Other|inhalation anesthesia|sevoflurane was used to maintain anesthesia
79815684|NCT04030481|Other|Total intravenous anesthesia|propofol was used to maintain anesthesia
79661703|NCT00271310|Drug|hypertonic saline|
79661704|NCT00306618|Drug|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
79661705|NCT00271349|Drug|Budesonide|
79661706|NCT00306657|Procedure|Optic nerve sheath fenestration|
79815685|NCT04087863|Other|Not applicable(observational study)|Not applicable(observational study)
79987588|NCT03735485|Other|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
79987589|NCT03653429|Drug|Tranexamic Acid|administered prior to surgical incision
79987590|NCT03653429|Drug|Normal saline|administered prior to surgical incision
79661707|NCT00271388|Device|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
79661708|NCT00306696|Drug|Rosiglitazone|
79661709|NCT00306696|Drug|spironolactone|
79661710|NCT00306696|Drug|hydrochlorothiazide|
79661711|NCT00306696|Drug|frusemide|
79661712|NCT00271427|Drug|L-Selenomethionine|
79348745|NCT04782323|Drug|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79348746|NCT04782323|Drug|QII Active Comparator|Biological/Vaccine: Investigational QII Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79661713|NCT00271466|Drug|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
79661714|NCT00306735|Drug|Palonosetron|
79661715|NCT00271583|Drug|CDB-2914|
79661716|NCT00271583|Drug|levonorgestrel|
79661717|NCT00306774|Dietary Supplement|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
79661718|NCT00306774|Dietary Supplement|Placebo|Placebo capsule per day for 2 years
79815686|NCT02592915|Drug|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
79815687|NCT02592915|Other|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
79500398|NCT06174909|Drug|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
79661719|NCT00271700|Behavioral|Order Set, Education, Feedback|
79987591|NCT03601715|Other|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
79348747|NCT04239521|Other|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
79348748|NCT04168073|Other|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
79348749|NCT04168073|Other|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
79348750|NCT02074982|Drug|AIN457 300 mg|
79661720|NCT00306813|Drug|Revlimid|
79661721|NCT00271778|Procedure|mastoidotympanoplasty and tympanoplasty|
79348751|NCT02074982|Drug|ustekinumab 45/90 mg|
79500399|NCT06174909|Drug|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
79661722|NCT04718142|Device|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
79661723|NCT00306930|Device|Acetabular cup|Acetabular cup replacement
79661724|NCT00271973|Drug|Oxycodone|
79661725|NCT00306969|Drug|bexarotene|
79661726|NCT00306969|Device|photopheresis|
79815688|NCT00727311|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
79815689|NCT00727311|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
79815690|NCT04087551|Other|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
79815691|NCT02592759|Device|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
79348752|NCT02074982|Drug|placebo secukinumab|Placebo
79348753|NCT04150913|Drug|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
79348754|NCT04150913|Drug|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
79661727|NCT00272012|Drug|Insulin glulisine|
79661728|NCT00307008|Biological|Pneumovax 23™|Single dose intramuscular injection
79661729|NCT00272051|Drug|SR57746A|
79661730|NCT00307203|Drug|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
79661731|NCT00307203|Behavioral|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
79661732|NCT00307203|Drug|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
79661733|NCT00272090|Drug|Insulin glargine|
79661734|NCT00307320|Behavioral|Relaxation Training|Relaxation techniques training
79815692|NCT02592837|Device|Flexible 19G EBUS-TBNA needle|
79815693|NCT02592837|Device|21G EBUS-TBNA needle|
79815694|NCT00726999|Drug|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
79815695|NCT00726999|Drug|Placebo|
79815696|NCT00726999|Drug|Morphine|Administered as needed
79815697|NCT00585351|Drug|Ranitidine|50 mg single dose injection of Ranitidine
79815698|NCT00585351|Drug|Placebo|50 mg single dose injection of normal saline (placebo)
79815699|NCT00585351|Other|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
79987592|NCT03601715|Other|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
79500400|NCT06174896|Procedure|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
79500401|NCT06174896|Procedure|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
79500402|NCT06174896|Procedure|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
79987593|NCT03601715|Other|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
79500403|NCT06174870|Other|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
79500404|NCT06174844|Other|No intervention applied|No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
79500405|NCT06174818|Procedure|PRF|Pulsed Radiofrequency Current of the Gasserian Ganglion
79348755|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
79348756|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
79348757|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
79348758|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
79348759|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
79348760|NCT02074514|Drug|Sofosbuvir|400 mg tablet administered orally once daily
79348761|NCT02074514|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79348762|NCT04191161|Device|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
79500406|NCT06174792|Drug|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
79500407|NCT06174779|Drug|HM11260C|Test drug
79500408|NCT06174779|Drug|Placebo|Placebo drug
79500409|NCT06174766|Drug|HGP2102-1|Test drug
79500410|NCT06174766|Drug|HGP2102-2|Test drug
79500411|NCT06174766|Drug|RLD2209-1|Control drug
79500412|NCT06174766|Drug|RLD2209-2|Control drug
79500413|NCT06174753|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
79500414|NCT06174753|Diagnostic Test|CMR|CMR 3-5 days post randomization
79500415|NCT06174740|Behavioral|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
79500416|NCT06174740|Behavioral|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
79815700|NCT00585351|Other|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
79500417|NCT06174714|Behavioral|Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)|4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
79661735|NCT00272207|Drug|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
79661736|NCT00307515|Drug|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
79661737|NCT00307515|Device|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
79500418|NCT06174675|Procedure|combined bilateral infraorbital and infratrochlear nerve blocks|"Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma."
79661738|NCT00272246|Procedure|deep brain stimulation of the internal globus pallidus|
79661739|NCT00272285|Drug|Ramosetron|IV, concomitant administration with dexamethasone
79815701|NCT02592603|Device|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
79987594|NCT03735407|Device|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
79348763|NCT02099708|Drug|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
79348764|NCT02073656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79348765|NCT02073656|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79348766|NCT02242643|Biological|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
79348767|NCT02242643|Biological|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
79348768|NCT02097290|Device|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
79661740|NCT00272285|Drug|Granisetron|IV, concomitant administration with dexamethasone
79661741|NCT00307554|Biological|Pneumococcal (vaccine)|
79661742|NCT00272324|Drug|Aspirin|
79661743|NCT00272324|Drug|Folate|
79661744|NCT00307593|Drug|Infliximab|Infliximab
79661745|NCT00307593|Drug|Rituximab|Rituximab
79661746|NCT00272402|Behavioral|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
79661747|NCT00272402|Behavioral|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
79661748|NCT00307632|Drug|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
79661749|NCT00272441|Drug|inhaled corticosteroids|
79661750|NCT00272480|Drug|Zidovudine/lamivudine|
79661751|NCT00272480|Drug|Placebos|
79661752|NCT00307671|Drug|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
79661753|NCT00307671|Drug|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
79661754|NCT00307671|Drug|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
79661755|NCT00272519|Behavioral|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
79661756|NCT00307710|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
79661757|NCT00272558|Drug|Carboplatin and Vinorelbine|
79661758|NCT00272597|Drug|Risperidone|See Detailed Description.
79661759|NCT00307749|Drug|Placebo|once daily for 24 weeks
79661760|NCT00307749|Drug|MCC-257|20mg, once daily for 24 weeks
79500419|NCT06174662|Device|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
79815702|NCT02592681|Procedure|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
79815703|NCT02592681|Procedure|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
79815704|NCT02592681|Procedure|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
79815705|NCT04031651|Drug|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
79661761|NCT00307749|Drug|MCC-257|40mg, once daily for 24 weeks
79815706|NCT05757479|Procedure|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
79815707|NCT05757479|Drug|Steroid nasal spray|1 spray into each nostril once a day.
79815708|NCT05757479|Procedure|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
79815709|NCT00726609|Drug|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
79815710|NCT00726453|Device|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
79348769|NCT04061213|Diagnostic Test|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
79500420|NCT06174636|Procedure|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
79500421|NCT06174623|Device|ModulHeart Support|The ModulHeart device will be implanted in the descending abdominal aorta.
79348770|NCT02072174|Drug|Anaferon for Children|Anaferon for children: For oral use.
79348771|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
79348772|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
79348773|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
79500422|NCT06174597|Procedure|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
79500423|NCT06174584|Drug|Hypertonic saline|Hypertonic saline
79500424|NCT06174584|Other|Cow Milk|Cow Milk
79661762|NCT00307749|Drug|MCC-257|80mg, once daily for 24 weeks
79661763|NCT00307788|Procedure|acupuncture|acupuncture
79661764|NCT00272636|Procedure|Radiofrequency catheter ablation|
79500425|NCT06174545|Drug|Pigment Solution Program|adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
79500426|NCT06174454|Other|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
79661765|NCT00272636|Drug|Amiodarone and cardioversion|
79661766|NCT00281970|Drug|cisplatin|
79661767|NCT00281970|Drug|docetaxel|
79661768|NCT00281970|Procedure|adjuvant therapy|
79661769|NCT00272675|Drug|Chlorhexidine gluconate (drug) vs placebo|
79661770|NCT00307827|Drug|Visilizumab|Visilizumab administered intravenously once per day for two days
79661771|NCT00282009|Behavioral|Basic Internet|Basic Internet control intervention
79500427|NCT06174454|Other|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
79500428|NCT06174428|Device|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
79500429|NCT06174415|Device|Perceptual Learning|Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
79500430|NCT06174389|Behavioral|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
79661772|NCT00282009|Behavioral|Enhanced Internet|enhanced Internet cessation intervention
79661773|NCT00282009|Behavioral|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
79987595|NCT03731117|Drug|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
79348774|NCT02209181|Drug|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
79348775|NCT02208089|Procedure|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
79661774|NCT00272753|Drug|budesonide/formoterol Turbuhaler|
79661775|NCT00272753|Drug|formoterol Turbuhaler|
79661776|NCT00272753|Drug|salbutamol|
79661777|NCT00307866|Procedure|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
79815711|NCT00726063|Device|Nanotite dental implant|Nanotite root form titanium dental implant
79815712|NCT00726063|Device|Osseotite dental implant|Osseotite Root form titanium dental implant
79348776|NCT02208089|Procedure|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
79815713|NCT03960567|Device|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
79815714|NCT04019457|Other|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
79815715|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
79348777|NCT02242487|Drug|CVT-301|
79348778|NCT02241785|Drug|natalizumab|Administered as specified in the treatment arm
79348779|NCT02241551|Drug|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
79348780|NCT02241551|Drug|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
79348781|NCT04769687|Biological|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
79348782|NCT04769687|Biological|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
79348783|NCT04769687|Other|Placebo|Placebo
79348784|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
79661778|NCT00272831|Drug|Cilostazol|Cilostazol 100 mg twice daily
79348785|NCT02207621|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
79661779|NCT00272831|Drug|Placebo|1 tablet twice daily
79661780|NCT00417105|Procedure|hemodialysis|group 1: twice weekly, four hours
79661781|NCT00417105|Procedure|hemodialysis|group 2: twice weekly, eight hours
79661782|NCT00417105|Procedure|hemodialysis|group 3: every other day, eight hours
79661783|NCT00417105|Procedure|hemodialysis|group 4: six days a week, eight hours
79661784|NCT00416468|Drug|Aliskiren|
79815716|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
79815717|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
79815718|NCT00808028|Other|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
79815719|NCT03466346|Drug|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
79987596|NCT03735329|Device|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
79987597|NCT03735251|Other|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
79987598|NCT03735173|Procedure|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
79348786|NCT02207621|Other|Placebo|1 drop QD, AM, OU
79348787|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
79348788|NCT02240693|Drug|BI 409306|
79348789|NCT02240693|Drug|Placebo|
79348790|NCT02240693|Drug|BI 409306|
79348791|NCT02240693|Drug|Placebo|
79348792|NCT02240693|Drug|Placebo|
79348793|NCT02240693|Drug|BI 409306|
79348794|NCT02240693|Drug|BI 409306|
79348795|NCT02240693|Drug|Placebo|
79348796|NCT02240693|Drug|Placebo|
79348797|NCT02239679|Drug|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
79661785|NCT00416468|Drug|Valsartan|
79661786|NCT00307905|Drug|Traumeel S|homeopathic remedy
79661787|NCT00307905|Drug|Placebo remedy|identical size, shape and taste of treatment medication
79661788|NCT02960828|Procedure|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
79661789|NCT02960828|Drug|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
79815720|NCT03466346|Behavioral|Interpersonal Psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
79500431|NCT06174376|Device|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
79815721|NCT05754242|Drug|Ascorbic acid|1.5 gr of ascorbic acid
79815722|NCT05754242|Drug|0.9% Saline solution|100 ml of 0.9% saline solution
79661790|NCT02960828|Device|Subthreshold Laser|
79815723|NCT04030364|Behavioral|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
79987599|NCT03735173|Procedure|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
79987600|NCT05665673|Other|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
79987601|NCT03731039|Other|Observational study|Pain assessment, Anxiety assessment, Depression assessment
79987602|NCT03594227|Drug|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
79348798|NCT02239679|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
79348799|NCT02239679|Device|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
79500432|NCT06174350|Behavioral|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
79500433|NCT06174350|Other|Placebo|Intervention Description not
79815724|NCT02606006|Behavioral|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
79348800|NCT02239679|Procedure|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
79500434|NCT06174337|Behavioral|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
79661791|NCT00307944|Drug|Pantoprazole|
79661792|NCT00416507|Drug|fluorouracil|
79661793|NCT00416507|Drug|gemcitabine hydrochloride|
79661794|NCT00416507|Drug|liposomal cisplatin|
79815725|NCT02606006|Behavioral|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
79815726|NCT00809783|Biological|tanezumab|Tanezumab 10 mg
79815727|NCT00809783|Biological|tanezumab|Tanezumab 5 mg
79815728|NCT00809783|Biological|tanezumab|Tanezumab 2.5 mg
79815729|NCT05675462|Drug|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
79987603|NCT03594227|Drug|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
79987604|NCT03594227|Drug|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
79348801|NCT02072096|Drug|Glimepiride|Administered orally
79348802|NCT02072096|Drug|Metformin|Administered orally
79348803|NCT02072096|Drug|Pioglitazone|Administered orally
79348804|NCT02072096|Drug|Acarbose|Administered orally
79348805|NCT02072096|Drug|Linagliptin|Administered orally
79348806|NCT02072096|Drug|Sitagliptin|Administered orally
79348807|NCT02072096|Drug|Liraglutide|Administered subcutaneously (SC)
79348808|NCT02072096|Drug|Insulin Glargine|Administered SC
79348809|NCT02072096|Drug|Exenatide once weekly (QW)|Administered SC
79661795|NCT00416546|Drug|AEB071|
79661796|NCT00282126|Dietary Supplement|Potassium citrate|kcitrate
79661797|NCT00272870|Drug|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
79661798|NCT00272870|Genetic|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
79661799|NCT00272870|Device|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
79500435|NCT06174324|Device|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
79661800|NCT00308022|Device|High Frequency Percussive Ventilation|
79815730|NCT05675462|Drug|Tislelizumab|PD-1inhibitor
79661801|NCT00272909|Drug|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
79661802|NCT00272909|Drug|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
79661803|NCT00272909|Drug|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
79661804|NCT00282165|Drug|naratriptan|four weeks double blind experimental treatment using oral naratriptan
79815731|NCT05675462|Drug|Lenvatinib|TKI
79815732|NCT00914264|Device|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 & 12 months
79815733|NCT05754164|Behavioral|Attention Control Training|Mobile app-based attention control training is an effective training method that can help people improve their ability to control attention. It is generally recommended to undergo 4 weeks of training, with 3-4 sessions per week and one day between each session. The specific operational method of this training may vary depending on different applications, but generally, training is presented in the form of a series of tasks. These tasks may involve aspects such as focusing attention, inhibiting interference, and reacting quickly.
79815734|NCT02608658|Other|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~Obtain demographic information, as will past medical history and medications.~Perform a physical examination.~Collect samples for labs~Administer the Chronic Liver Disease Questionnaire (CLDQ)~Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~Perform a physical examination~Collect and record returned investigational product~Dispense investigational product and instruct again regarding use~Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~Perform a physical examination.~Collect samples for labs~Administer the Chronic Liver Disease Questionnaire (CLDQ)~Perform a lactulose breath test"
79661805|NCT00282165|Drug|placebo|four weeks double blind placebo treatment
79661806|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d
79661807|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
79661808|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
79348810|NCT02072096|Drug|Exenatide twice daily (BID)|Administered SC
79348811|NCT02071706|Device|PET/MRI system|Enrolled subject undergoes PET/MR scan
79661809|NCT00308100|Drug|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
79661810|NCT00308100|Drug|5% Albumin|5% albumin, administered intra- and perioperatively
79661811|NCT00273026|Drug|salmeterol xinafoate/fluticasone propionate|
79661812|NCT00282204|Behavioral|antenatal hypnosis + audio compact disc on hypnosis|
79348812|NCT05107700|Procedure|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
79348813|NCT05107700|Procedure|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
79348814|NCT01631825|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
79348815|NCT02071082|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
79348816|NCT02123108|Drug|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
79815735|NCT00809471|Drug|placebo|30 minutes orally prior to initiation of sexual activity
79815736|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
79500436|NCT06174311|Behavioral|Active Cognitive Bias Modification|The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
79500437|NCT06174298|Drug|Granulocyte Colony-Stimulating Factor (Filgrastim)|"Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
79661813|NCT00282204|Behavioral|Audio compact disc on hypnosis|
79661814|NCT00308178|Drug|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
79661815|NCT00282321|Behavioral|High Protein diet|
79815737|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
79661816|NCT00282321|Behavioral|High carbohydrate diet|
79661817|NCT00282360|Drug|Trimetazidine|
79661818|NCT00273065|Drug|Neosaxitoxin|
79661819|NCT00418626|Drug|Nilotinib|
79815738|NCT00807248|Drug|Escitalopram placebo|Once daily before bedtime for 8 weeks
79661820|NCT00418704|Drug|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
79661821|NCT00418704|Drug|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
79815739|NCT00807248|Drug|Gaboxadol placebo|Once daily before bedtime for 8 weeks
79987605|NCT03594227|Drug|Placebo|Placebo - oral administration
79987606|NCT03098550|Biological|Nivolumab|Specified dose on specified days
79661822|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
79661823|NCT00313950|Biological|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
79661824|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
79815740|NCT00807248|Drug|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
79987607|NCT03098550|Biological|Daratumumab|Specified dose on specified days
79661825|NCT00273104|Procedure|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
79815741|NCT00807248|Drug|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
79815742|NCT00807248|Drug|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
79987608|NCT05039190|Drug|HBM9161 Injection (680mg)|HBM9161 Injection
79987609|NCT05039190|Drug|Placebo|Placebo Injection
79987610|NCT03095118|Drug|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
79987611|NCT03594071|Device|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
79987612|NCT02696902|Drug|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
79987613|NCT02696902|Other|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
79815743|NCT05755061|Behavioral|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
79815744|NCT05755061|Behavioral|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
79815745|NCT05326295|Diagnostic Test|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
79815746|NCT02610491|Dietary Supplement|Hesperidin|Citrus peel extract
79500438|NCT06174298|Other|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
79661826|NCT00273104|Behavioral|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
79815747|NCT02610491|Dietary Supplement|Placebo|Cellulose
79987614|NCT05386758|Drug|Molnupiravir|Four 200 mg capsules administered orally as a single dose
79987615|NCT03169114|Drug|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
79987616|NCT03169114|Procedure|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
79661827|NCT00273221|Procedure|Glaucoma Implant Surgery|
79661828|NCT00273221|Procedure|trabeculectomy|
79661829|NCT00273221|Procedure|phacoemulsification|
79661830|NCT04708691|Other|Aerobic exercise|aerobic exercise
79661831|NCT02960178|Behavioral|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
79661832|NCT02960178|Behavioral|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
79661833|NCT00273260|Behavioral|individualised bone density feedback and education|
79661834|NCT00273299|Drug|valsartan plus hydrochlorothiazide|
79815748|NCT05720936|Procedure|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~The echo-guided approach"
79815749|NCT02610335|Other|Control group (C)|"kyphosis reeducation on Huber platform during 2 weeks,~patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~exercises on cycle ergometer or walking on treadmill : to continue at home."
79987617|NCT05011422|Device|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
79348817|NCT02123108|Drug|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) < 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
79815750|NCT02610335|Other|Test group|"spinal mobility reeducation on Huber platform during 2 weeks,~patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~exercises on cycle ergometer or walking on treadmill : to continue at home."
79500439|NCT06174285|Other|Therapeutic Intervention with Psychedelic Virtual Reality|A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
79500440|NCT06174285|Other|Therapeutic Intervention with Non-Psychedelic Virtual Reality|A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
79661835|NCT00314028|Behavioral|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
79348818|NCT02123108|Drug|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
79500441|NCT06174194|Dietary Supplement|Tulsi Gum|"The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children."
79500442|NCT06174181|Device|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
79500443|NCT06174181|Other|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
79500444|NCT06174142|Device|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
79815751|NCT02607332|Drug|Paclitaxel|
79815752|NCT03356756|Diagnostic Test|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
79348819|NCT02123108|Drug|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
79348820|NCT02121392|Device|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
79661836|NCT00314028|Other|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
79661837|NCT00418782|Drug|naproxen|
79661838|NCT00418782|Drug|CE-224535|
79661839|NCT00418782|Drug|placebo|
79661840|NCT00273338|Drug|calcitriol|
79661841|NCT00273338|Drug|docetaxel|
79661842|NCT00314067|Procedure|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
79661843|NCT00314067|Procedure|Physician training|
79661844|NCT00314067|Procedure|Practice team training|
79500445|NCT06174142|Device|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
79500446|NCT06174142|Device|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
79500447|NCT06174129|Other|Routine examinations|Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
79661845|NCT00273377|Other|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
79661846|NCT00273377|Other|Supplemental oxygen (80% vs. 30%)|
79661847|NCT00273377|Drug|Dexamethasone|4 mg
79661848|NCT00273377|Drug|Placebo|placebo
79661849|NCT00273416|Drug|PF-00592379|
79661850|NCT00273416|Drug|Sildenafil 100mg|
79661851|NCT00314184|Drug|quetiapine fumarate|
79815753|NCT05297669|Drug|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
79348821|NCT02121392|Device|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
79348822|NCT02121392|Drug|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
79348823|NCT02097056|Drug|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
79348824|NCT02121002|Drug|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
79348825|NCT02121002|Drug|Voltaren Topical Gel, 1%|Opaque, white gel
79661852|NCT00273455|Drug|bimatoprost 0.03%|
79661853|NCT00273455|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
79661854|NCT00273455|Drug|placebo|
79661855|NCT00273494|Procedure|Surgery|
79661856|NCT00308256|Behavioral|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
79661857|NCT00273533|Drug|Ramipril|
79661858|NCT00273572|Other|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
79661859|NCT00273572|Other|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
79661860|NCT00308295|Drug|Fish oil capsules|
79661861|NCT00308295|Drug|matched placebo capsules|
79661862|NCT00273611|Behavioral|Pharmacist Education about Vitamin D|
79661863|NCT00314301|Device|loaded sit-to-stand training|
79661864|NCT00273689|Drug|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
79661865|NCT00273689|Drug|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
79661866|NCT00273728|Drug|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
79661867|NCT00308334|Drug|Domperidone|10 mg po TID X 14 days
79661868|NCT00308334|Drug|Placebo- Sugar pill|placebo po TID x 14 days
79815754|NCT05297669|Drug|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
79500448|NCT06174103|Device|BiVACOR TAH System|The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
79815755|NCT05757323|Other|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
79815756|NCT05757323|Other|infant formula based on intact protein|infant formula based on intact protein
79815757|NCT00589628|Drug|infliximab|5mg/kg/dose IV at 4 week intervals
79815758|NCT00589628|Drug|infliximab|10mg/kg/dose IV at 4 week intervals
79815759|NCT05754983|Drug|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
79815760|NCT05720546|Other|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
79815761|NCT05720546|Other|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
79661869|NCT00273767|Drug|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
79661870|NCT00273767|Drug|placebo|60ml of NaCl IV slow
79661871|NCT00314379|Drug|Vitamin E 400IU/day|
79815762|NCT05720546|Other|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
79815763|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
79815764|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
79815765|NCT00914576|Drug|Placebo|2 capsules/day for 14 days
79661872|NCT00273806|Behavioral|Intervention for 4 behavioral risks by medical assistants.|
79661873|NCT00273845|Behavioral|Motivational interviewing|One session
79661874|NCT00273845|Behavioral|Strengths-Based Case Management|5 sessions
79661875|NCT00273884|Drug|Amonafide L-Malate|
79348826|NCT02121002|Drug|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
79348827|NCT02096900|Drug|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
79348828|NCT02096900|Drug|Midazolam|
79348829|NCT02120924|Drug|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
79661876|NCT00273884|Drug|Cytarabine|
79661877|NCT00308373|Drug|Metformin vs Thiazolidinedione (Pioglitazone)|
79661878|NCT00273962|Drug|ipratropium plus salbutamol UDV|
79661879|NCT00273962|Drug|salbutamol UDV|
79661880|NCT00314418|Procedure|Colonoscopy in the prone position|
79661881|NCT00274001|Drug|Nevirapine|
79815766|NCT00914576|Drug|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
79500449|NCT06174090|Other|Coronary bypass graft surgery video education|It includes information about surgical process and handling issues within the first few days of surgery.
79987618|NCT03169270|Other|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
79500450|NCT06174064|Device|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
79500451|NCT06174064|Device|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
79500452|NCT06174012|Drug|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
79500453|NCT06173999|Drug|SHR2554/CHOP|SHR2554 with CHOP
79500454|NCT06173999|Drug|SHR2554/CHOEP|SHR2554 with CHOEP
79500455|NCT06173986|Drug|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
79500456|NCT06173986|Drug|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
79500457|NCT06173986|Radiation|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
79500460|NCT06173947|Device|FibroScan® Expert 630|The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
79348830|NCT02120924|Drug|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
79348831|NCT02120924|Drug|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
79500461|NCT06173934|Drug|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
79500462|NCT06173934|Drug|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
79500463|NCT06173921|Procedure|robotic system|Implant placement will be navigated by robotic system based on a digital plan
79500464|NCT06173921|Procedure|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
79500465|NCT06173908|Procedure|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
79348832|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Oppanol
79348833|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
79348834|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
79348835|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
79348836|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Vistanex
79348837|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
79500466|NCT06173908|Procedure|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
79348838|NCT02120456|Drug|LEO 43204|
79348839|NCT02120456|Drug|Placebo|
79348840|NCT02120300|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
79500467|NCT06173882|Behavioral|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
79500468|NCT06173882|Behavioral|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
79500469|NCT06173882|Behavioral|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
79500470|NCT06173856|Other|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
79500471|NCT06173843|Other|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
79661882|NCT00308412|Biological|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
79661883|NCT00308412|Biological|Placebo|Placebo for rHPIV3cp45 vaccine
79661884|NCT00274040|Drug|Tiotropium|
79661885|NCT00274040|Drug|Ipratropium|
79661886|NCT00314457|Drug|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
79661887|NCT00308451|Drug|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
79661888|NCT00274079|Drug|SPIRIVA|
79661889|NCT00274118|Drug|telmisartan|
79661890|NCT00274118|Drug|enalapril|
79815767|NCT00914576|Drug|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
79815768|NCT00914654|Drug|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
79500472|NCT06173830|Other|radiofrequency ablation|34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
79500473|NCT06173830|Other|physical therapy|34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
79500474|NCT06173817|Device|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
79500475|NCT06173791|Device|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
79500476|NCT06173791|Device|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
79661891|NCT00419055|Procedure|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
79987619|NCT04602936|Drug|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
79661892|NCT00274157|Behavioral|Behavior|
79661893|NCT00274157|Behavioral|diet control, smoking cessation, exercize|
79815769|NCT04115618|Radiation|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
79348841|NCT02120300|Drug|SOF|400 mg tablet administered orally once daily
79348842|NCT02120300|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79348843|NCT02070380|Drug|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
79348844|NCT02070380|Drug|Dotarem|Dotarem administered at 0.1 mmol/kg
79348845|NCT02070380|Drug|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
79661894|NCT00308490|Drug|iron sucrose|
79661895|NCT00416585|Drug|isotretinoin (Roaccutane)|
79661896|NCT00274196|Procedure|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
79815770|NCT02605772|Drug|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
79815771|NCT02605772|Drug|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
79661897|NCT00274196|Procedure|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
79661898|NCT00308529|Drug|irinotecan|
79661899|NCT00308529|Drug|carboplatin|
79661900|NCT00308529|Drug|bevacizumab|
79661901|NCT00308529|Procedure|Radiation Therapy|
79661902|NCT00274235|Drug|sulfadoxine-pyrimethamine / mefloquine|
79661903|NCT00308568|Behavioral|Mailed educational brochure|
79815772|NCT02605772|Drug|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
79815773|NCT00588848|Device|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
79815774|NCT00588848|Device|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
79815775|NCT04115462|Drug|Morphine|A 20 mg tablet of morphine
79500477|NCT06173791|Device|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
79500478|NCT06173778|Drug|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
79500479|NCT06173778|Drug|Placebo|Non-active medication, self-administered
79661904|NCT00274274|Drug|insulin detemir|
79661905|NCT00274274|Drug|insulin aspart|
79661906|NCT00308607|Drug|Bevacizumab (Avastin)|
79661907|NCT00308607|Drug|dacarbazine|
79661908|NCT00308607|Drug|interferon-alfa-2a (Roferon-A)|
79815776|NCT04115462|Drug|Placebo oral tablet|Matching tablet of placebo
79661909|NCT00274313|Drug|552-02|
79661910|NCT00314613|Drug|Antipsychotic/Risperidone Consta|
79348846|NCT02069366|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive dronabinol.
79815777|NCT04115462|Drug|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
79815778|NCT04115462|Drug|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
79348847|NCT02069366|Drug|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive placebo.
79348848|NCT04732208|Diagnostic Test|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
79348849|NCT02068508|Drug|Pioglitazone|Pioglitazone Tablets
79348850|NCT02068352|Drug|OPA-15406|OPA-15406 topical ointment
79348851|NCT02068352|Drug|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
79661911|NCT00274352|Drug|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
79661912|NCT00416663|Procedure|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
79500480|NCT06173778|Drug|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke >10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
79500481|NCT06173778|Behavioral|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
79500482|NCT06173765|Other|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
79661913|NCT00314652|Drug|Buprenorphine transdermal delivery system|
79661914|NCT00274391|Drug|7% NaCl|
79661915|NCT00274391|Drug|Amiloride HCl|
79815779|NCT04115462|Drug|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
79661916|NCT00308724|Behavioral|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
79661917|NCT00308724|Behavioral|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
79661918|NCT00274430|Drug|dexamethasone 8 mg bid|
79661919|NCT00274430|Drug|tadalafil 10mg bid|
79661920|NCT00314691|Genetic|Blood samples|
79661921|NCT00274547|Drug|Tiotropium|
79679548|NCT00516620|Behavioral|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
79228288|NCT05159154|Device|Myocardial Work|Myocardial work (MW) is emerging as an alternative tool for studying LV myocardial systolic function, because it incorporates both deformation and load into its analysis. In this context, MW could be considered as an advancement of myocardial strain, allowing to investigate LV performance also in cases of changes in afterload that could lead to misleading conclusions if relying only on strain analysis. This parameter will be evaluated by using an echographer equipped with a specific software for the analysis (Ecog Vivid E95 Ultra GE®)
79228289|NCT03311984|Diagnostic Test|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
79500483|NCT06173765|Other|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
79500484|NCT06173765|Other|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
79500485|NCT06173752|Behavioral|Exposure therapy|Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
79500486|NCT06173739|Procedure|Non-surgical mechanical treatment|"Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered."
79661922|NCT00308763|Drug|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
79661923|NCT00308763|Drug|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
79661924|NCT00314730|Device|handheld Personal Digital Assistant (PDA)|
79661925|NCT00274586|Drug|Aggrenox® modified release capsules|
79661926|NCT00274586|Drug|Aggrenox® modified release capsules matching placebo|
79661927|NCT00308802|Procedure|Kidney transplantation|Participants in this study will have had a kidney transplant
79661928|NCT00274664|Device|6 hours occlusion by patching|
79815780|NCT04115462|Drug|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
79815781|NCT04115462|Drug|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
79815782|NCT04010474|Procedure|Modified Surgical APGAR Score|"Four intraoperative factors~Lowest heart rate (HR),~Lowest mean arterial pressure (MAP)~Estimated blood loss~Operation time"
79661929|NCT00274664|Device|12 hours occlusion by patching|
79661930|NCT00274703|Drug|mepolizumab|
79661931|NCT00274820|Dietary Supplement|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
79815783|NCT04026932|Other|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
79348852|NCT02207231|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
79348853|NCT02207231|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
79348854|NCT02207231|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
79815784|NCT04026932|Other|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
79500487|NCT06173726|Biological|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg~1.5g/m2, a single intravenous infusion"
79661932|NCT00274820|Drug|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
79661933|NCT00274820|Drug|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
79661934|NCT00274820|Drug|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience < grade 1 thalidomide-attributed toxicity using CTC criteria.
79661935|NCT00308841|Drug|Lidocaine (drug)|
79815785|NCT02605460|Drug|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
79661936|NCT00274859|Drug|gemcitabine hydrochloride|
79661937|NCT00274859|Drug|oxaliplatin|
79661938|NCT00314847|Device|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
79661939|NCT00274898|Drug|celecoxib|
79815786|NCT02605460|Drug|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
79815787|NCT02605460|Drug|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
79815788|NCT02605460|Procedure|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
79815789|NCT04115930|Device|Physical Activity measurement:|7 days measurement with Active style Pro HJA-350IT device
79815790|NCT00797108|Drug|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
79348855|NCT02207231|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
79228290|NCT02233257|Drug|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
79228291|NCT03311906|Drug|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
79228292|NCT03311906|Procedure|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
79661940|NCT00274898|Drug|docetaxel|
79661941|NCT00274898|Procedure|adjuvant therapy|
79661942|NCT00274898|Radiation|radiation therapy|
79815791|NCT00797108|Drug|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
79815792|NCT00797108|Drug|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
79987620|NCT04602936|Drug|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
79348856|NCT02239601|Other|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
79500488|NCT06173713|Device|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
79661943|NCT00308880|Drug|Transamin|
79823735|NCT04073654|Procedure|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
79348857|NCT02236559|Device|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
79348858|NCT02236559|Device|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%.
79348859|NCT02206685|Drug|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
79524903|NCT05677568|Device|Carillon Mitral Contour System|"The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation."
79987621|NCT02396602|Behavioral|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
79661944|NCT00277160|Drug|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
79661945|NCT00314886|Drug|Diet|
79661946|NCT00277199|Drug|Abatacept|
79661947|NCT02960100|Other|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
79661948|NCT02960100|Other|Media Intervention|Receive targeted HPV vaccine narrative-style video
79661949|NCT02960100|Other|Survey Administration|Ancillary studies
79661950|NCT00277277|Behavioral|Healthium|
79661951|NCT00308919|Drug|WST09|Treatment with WST09 Vascular Photodynamic therapy
79661952|NCT00277316|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
79661953|NCT00308958|Device|High frequency chest wall oscillator|
79823736|NCT04076228|Drug|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
79987622|NCT02694562|Device|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
79987623|NCT02874534|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
79987624|NCT02874534|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
79987625|NCT02396446|Other|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
79661954|NCT00314925|Drug|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10^7 vp/kg), IV (in the vein) over 1 hour in a single administration
79661955|NCT00277433|Other|Buccal Swab|collection of buccal swab
79661956|NCT00314964|Drug|PD-0299685|
79661957|NCT00277472|Drug|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
79661958|NCT00277472|Drug|HCTZ|25 mg taken once daily orally
79661959|NCT00277511|Drug|Levofloxacin|
79661960|NCT00315003|Drug|Telithromycin|
79661961|NCT00315003|Drug|Azithromycin|
79661962|NCT00277550|Drug|Tegaserod and Placebo|
79661963|NCT00309036|Biological|Recombinant grass pollen|
79661964|NCT00277589|Drug|Levothyroxin-Na|1 tablet 30 minutes before breakfast
79661965|NCT00277589|Drug|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
79661966|NCT00277589|Drug|Iodide|1 tablet 30 minutes before breakfast
79500489|NCT06173700|Behavioral|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
79987626|NCT05417178|Other|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
79987627|NCT03115762|Biological|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
79987628|NCT03115762|Biological|ASKB1202|
79661967|NCT00277589|Drug|Placebo|1 tablet 30 minutes before breakfast
79987629|NCT03168958|Drug|Methadone|Methadone will be provided at induction of anesthesia
79987630|NCT03168958|Drug|Saline|Saline will be administered at induction of anesthesia
79987631|NCT02396056|Other|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
79987632|NCT02396056|Other|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
79987633|NCT02396368|Drug|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
79987634|NCT02396368|Radiation|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
79228293|NCT04458246|Other|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
79228294|NCT02259465|Behavioral|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
79661968|NCT00315042|Drug|Telithromycin (HMR3647)|
79661969|NCT00315042|Drug|Penicillin|
79661970|NCT00277667|Drug|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
79661971|NCT00315081|Drug|Bromocriptin|
79823737|NCT02579252|Biological|AADvac1|
79823738|NCT02579252|Drug|Placebo|
79987635|NCT03632460|Drug|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
79228295|NCT02259465|Dietary Supplement|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
79661972|NCT00277706|Procedure|Periodontal surgery|
79661973|NCT00277706|Drug|FORTEO|parathyroid hormone; self-administration for 6 weeks
79661974|NCT00277706|Drug|Placebo|placebo; self administration for 6 weeks
79661975|NCT00277706|Dietary Supplement|Vitamin D and Calcium|PO, QD, for six weeks
79661976|NCT00309075|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
79661977|NCT00277745|Device|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
79823739|NCT02580734|Dietary Supplement|melatonin|Cross-over randomized clinical trials
79661978|NCT00419133|Biological|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
79661979|NCT00419133|Biological|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
79661980|NCT00277784|Procedure|Ultrasound examination|one ultrasound examination
79661981|NCT00309114|Procedure|bacterial interference|
79661982|NCT00277823|Drug|DVS-SR 50 mg|
79815793|NCT04112420|Diagnostic Test|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
79815794|NCT04112264|Procedure|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of <0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
79815795|NCT04112264|Procedure|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of <0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
79987636|NCT02396290|Procedure|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
79661983|NCT00277823|Drug|DVS-SR 100 mg|
79661984|NCT00277823|Drug|Placebo|
79661985|NCT00277862|Drug|Pegylated IFN- alpha 2b|
79661986|NCT00277862|Drug|Ribavirin|
79661987|NCT00309231|Procedure|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
79661988|NCT00315159|Procedure|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
79661989|NCT04719260|Behavioral|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
79661990|NCT04719260|Behavioral|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
79661991|NCT00315198|Device|Eye Patch|2 hours daily patching
79661992|NCT00315198|Procedure|Near activities|near visual activities while patching
79661993|NCT00315198|Procedure|Distance activities|distance visual activities while patching
79661994|NCT00315237|Drug|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
79815796|NCT03244826|Other|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
79815797|NCT03244826|Other|Standard Care|The usual care provided by the transplant center at DFCI.
79661995|NCT00278018|Procedure|Immunotherapy treatment for solid tumors|
79815798|NCT02607176|Drug|Heweizhixie capsule|3 #, Tid, Oral for 3 days
79500490|NCT06173674|Other|Music intervention|"The music intervention will consist of three components including:~Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
79661996|NCT00309270|Drug|Campath-1H|
79661997|NCT00278057|Drug|dialysisis with and without glucose in the dialysis|
79661998|NCT00315276|Drug|Modafinil|
79500491|NCT06173622|Behavioral|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
79661999|NCT00278096|Behavioral|occupational therapy|
79662000|NCT00309309|Drug|Rosiglitazone|
79815799|NCT04112108|Procedure|PTMC|percutaneous mitral ballooning with Inoue balloon
79815800|NCT04111718|Biological|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
79815801|NCT04111718|Behavioral|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
79815802|NCT04111640|Other|CoRe software|Computer-supported cognitive training (CT)
79815803|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
79987637|NCT02396290|Procedure|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
79815804|NCT04025996|Diagnostic Test|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~transthoracic echocardiography~computed tomography of coronary arteries~position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~pupil dilation~retinal photography~dynamic vessel analyser~IOL master"
79815805|NCT00742560|Biological|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
79987638|NCT01567956|Drug|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
79987639|NCT01567956|Drug|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
79987640|NCT03168724|Behavioral|GMT intervention|
79987641|NCT03168646|Procedure|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
79987642|NCT03168646|Procedure|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
79662001|NCT00278135|Dietary Supplement|DHA (nutritional supplement) or placebo|oral 900mg/day
79662002|NCT00315315|Procedure|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
79662003|NCT00315315|Procedure|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
79662004|NCT00315315|Procedure|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
79662005|NCT00278174|Biological|recombinant interferon alpha-1b|
79662006|NCT00309348|Other|Weekly measurement of graft flow|
79662007|NCT00416702|Drug|QAB149|
79662008|NCT00278213|Biological|alemtuzumab|
79815806|NCT00742560|Drug|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
79815807|NCT00742560|Drug|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
79815808|NCT00742560|Drug|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
79815809|NCT05637866|Other|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
79815810|NCT00796718|Radiation|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
79815811|NCT00796718|Drug|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m^2) orally twice daily for 5 weeks.
79815812|NCT00809159|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
79987643|NCT03097614|Device|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
79987644|NCT05745766|Other|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
79987645|NCT05745766|Other|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
79987646|NCT05745766|Other|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
79500492|NCT06167954|Device|EXPLORER|8 sessions of use of the device in the home and the community of the participants
79500493|NCT06167733|Device|VERTICA Active device|VERTICA device with a therapeutic RF energy level
79500494|NCT06167733|Device|VERTICA Sham device|VERTICA device with a low, non-therapeutic RF energy level
79662009|NCT00278213|Drug|cyclophosphamide|
79662010|NCT00278213|Drug|fludarabine phosphate|
79662011|NCT00278213|Drug|mitoxantrone hydrochloride|
79500495|NCT06167551|Other|mother lullaby group|mother's lullaby: the mother will be made to sing her own lullaby 5 minutes before the heel prick.
79662012|NCT00315354|Other|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
79662013|NCT00315354|Other|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
79662014|NCT00315354|Other|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
79662015|NCT00278252|Drug|etoposide|
79662016|NCT00278252|Procedure|conventional surgery|
79662017|NCT00315432|Drug|Pegylated Interferon and Ribavirin|
79815813|NCT00809159|Drug|Placebo|Placebo to AIN457
79815814|NCT02596386|Procedure|sialometry|potassium evaluation
79815815|NCT02596386|Procedure|blood test|potassium evaluation
79815816|NCT04111796|Other|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
79815817|NCT00745368|Drug|Raltegravir|400 mg tablets twice daily during duration of trial
79815818|NCT04111562|Procedure|Cranioplasty|Bone grafts
79815819|NCT04025840|Other|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
79815820|NCT04025840|Drug|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
79815821|NCT00589472|Drug|Bicalutamide|Given PO
79815822|NCT00589472|Drug|Goserelin Acetate|Given SC
79815823|NCT00589472|Other|Laboratory Biomarker Analysis|Correlative studies
79815824|NCT00589472|Drug|Leuprolide Acetate|Given IM
79815825|NCT00589472|Procedure|Therapeutic Conventional Surgery|Undergo radical prostatectomy
79815826|NCT00589472|Drug|Vorinostat|Given PO
79815827|NCT00811577|Drug|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
79662018|NCT00278330|Drug|alvocidib|Given by infusion
79662019|NCT00278330|Drug|vorinostat|Given orally
79662020|NCT00315510|Drug|Rosuvastatin|
79662021|NCT00278369|Biological|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
79662022|NCT00278369|Biological|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
79662023|NCT00315549|Drug|Telithromycin|
79662024|NCT00315549|Drug|Penicillin|
79662025|NCT00278408|Biological|filgrastim|
79815828|NCT00811577|Drug|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
79348860|NCT02206685|Drug|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
79815829|NCT02607020|Other|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
79815830|NCT02607020|Other|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
79815831|NCT02608931|Drug|Dronabinol|
79348861|NCT02206607|Drug|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
79815832|NCT02608931|Other|Placebo|placebo
79500496|NCT06167551|Other|white noise group|white noise: 5 minutes before taking heel prick blood, white noise will be started to be played on an MP3 player with white noise. The MP3 player will be placed in the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
79987647|NCT03168802|Procedure|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
79987648|NCT03168802|Procedure|Radiofrequency ablation|Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
79987649|NCT05418660|Drug|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
79987650|NCT03364309|Drug|Ixekizumab|Administered SC
79500497|NCT06167551|Other|classical music group|classical music: 5 minutes before heel prick, classical music will be started to be played from the MP3 player with white noise. The MP3 will be placed inside the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
79500498|NCT06167551|Other|Contol Group|No intervation
79987651|NCT03364309|Drug|Placebo|Administered SC
79987652|NCT03168178|Drug|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
79987653|NCT03168178|Other|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
79500499|NCT06167499|Other|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
79500500|NCT06167200|Other|No intervention, study is observational|No intervention, study is observational
79500501|NCT06167161|Device|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
79987654|NCT05166096|Drug|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
79987655|NCT05166096|Drug|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
79987656|NCT03168490|Dietary Supplement|Gluten Friendly bread|parallel study
79348862|NCT02206607|Drug|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
79348863|NCT02206607|Drug|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
79348864|NCT02206607|Drug|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
79348865|NCT02119676|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
79348866|NCT02119676|Drug|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
79348867|NCT02119676|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
79348868|NCT02206061|Behavioral|School-Based Asthma Care for Teens (SB-ACT)|
79662026|NCT00278408|Biological|rituximab|
79987657|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
79987658|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
79987659|NCT05110638|Drug|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
79987660|NCT03700788|Drug|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
79500502|NCT06167096|Other|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
79662027|NCT00278408|Drug|cyclophosphamide|
79662028|NCT00278408|Drug|doxorubicin hydrochloride|
79662029|NCT00278408|Drug|prednisone|
79662030|NCT00278408|Drug|vincristine sulfate|
79662031|NCT00278408|Radiation|radiation therapy|
79662032|NCT00315666|Drug|memantine|
79815833|NCT00744978|Drug|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
79228296|NCT02259465|Dietary Supplement|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
79228297|NCT03303326|Behavioral|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
79500503|NCT06167096|Other|Water|Water
79815834|NCT00744978|Drug|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
79987661|NCT03700788|Drug|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
79987662|NCT02395900|Dietary Supplement|Flaxseed|
79500504|NCT06166862|Other|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
79662033|NCT00278447|Behavioral|Chronic Disease Management for substance abuse|Referral to primary medical care & longitudinal, multidisciplinary care for persons with substance dependence.
79662034|NCT00278447|Behavioral|Standard care|Referral to primary medical care for persons with substance dependence.
79662035|NCT00315744|Drug|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
79987663|NCT02395900|Other|control|
79662036|NCT00315744|Drug|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
79662037|NCT00315744|Drug|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
79662038|NCT00278486|Biological|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
79662039|NCT00278603|Biological|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
79662040|NCT00309543|Drug|Fluorouracil|
79662041|NCT00309543|Drug|Leucovorin|
79987664|NCT03167398|Biological|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
79662042|NCT00278642|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
79662043|NCT00278681|Drug|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
79662044|NCT02960139|Device|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
79662045|NCT00278759|Procedure|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
79662046|NCT00278837|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
79987665|NCT03334903|Drug|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
79987666|NCT03167008|Diagnostic Test|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
79987667|NCT03167008|Diagnostic Test|blood sample|blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
79228298|NCT03469596|Diagnostic Test|MRI sequence|several MRI sequence before and after contrast product injection.
79228299|NCT03311750|Drug|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
79348869|NCT02206061|Behavioral|Directly Observed Therapy|
79348870|NCT02206061|Behavioral|Asthma Education|
79348871|NCT02095106|Device|Waterproof Cast|
79348872|NCT02095106|Device|Traditional cast|
79348873|NCT01631747|Behavioral|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
79662047|NCT00315861|Drug|pemetrexed|
79662048|NCT00315861|Drug|topotecan|
79348874|NCT01631747|Behavioral|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
79662049|NCT00279032|Drug|GW406381|
79662050|NCT00309660|Drug|Rosiglitazone|
79662051|NCT00279071|Device|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
79662052|NCT00315900|Drug|Depakote ER|depakote ER
79662053|NCT00315900|Drug|Seroquel|seroquel
79662054|NCT00279110|Behavioral|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
79662055|NCT00309699|Drug|Placebo|Daily for 3 weeks
79662056|NCT00309699|Drug|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
79662057|NCT00309699|Drug|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
79662058|NCT00279149|Procedure|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
79662059|NCT00315978|Device|Heart-to-Heart Decision Aid|
79662060|NCT00279188|Procedure|Guiding therapy by bronchial hyperrsponsiveness|
79662061|NCT00309816|Drug|sildenafil|
79662062|NCT00279266|Drug|Thiamine|
79662063|NCT00316095|Drug|telmisartan|
79815835|NCT02608775|Device|Metrodoloris Medical System|Application of a skin electrode
79662064|NCT00316095|Drug|simvastatin|
79662065|NCT00279344|Drug|Fentanyl (Matrifen)|
79348875|NCT02068118|Device|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
79500505|NCT06166862|Other|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
79500506|NCT06166654|Drug|Acetazolamide|1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
79348876|NCT01623830|Behavioral|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
79500507|NCT06166654|Drug|Metolazone 2.5 MG|2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
79500508|NCT06166654|Other|Double-placebo|This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
79500509|NCT06166420|Other|Experimental|Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
79500510|NCT06166420|Other|Active comparator|Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
79662066|NCT00418860|Drug|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
79348877|NCT04731896|Procedure|Amniotomy|artificial rupture of the amniotic sac
79348878|NCT01634165|Drug|LY2963016|Administered subcutaneously
79348879|NCT01634165|Drug|Lantus|Administered subcutaneously
79348880|NCT02235311|Drug|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
79500511|NCT06166251|Behavioral|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
79500512|NCT06166251|Behavioral|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
79500513|NCT06165328|Diagnostic Test|CT and colonoscopy|All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
79500514|NCT06165055|Diagnostic Test|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
79500515|NCT06163495|Behavioral|School-based extracurricular intervention focusing on time spent with friends and screen media use|"The intervention includes the following components:~For each participating class, children and parents will engage in two family workshops. The purpose of these events is to support the class and families in establishing and maintaining a leisure time behavior among children with less solitary screen usage and more face-to-face interaction with peers.~In the beginning of 4th grade, parents will engage in a short exercise focusing on screen media dilemmas.~Children will engage in school hour workshops focusing on the class culture related to screen media use and face-to-face interaction with peers.~Afterschool club personal will engage in a training program consisting of three workshops aimed to increase participation rate in the afterschool club.~Local stakeholders relevant to children's leisure time will engage in two workshops to develop local actions focusing on children's engagement in face-to-face interactions with peers."
79500516|NCT06163105|Procedure|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~Topical anesthesia by Tetracaine 0.5%~Clean the eyelids by gauzes with commercial available foam~Warm the eyelids by Blephasteam machine for 10 minutes~Instill Tetracaine 0.5% again~Use Mastrota paddle and Q-tip to squeeze the gland~Clean the lid margin by commercial available foam~Use Moxifloxacin 0.5% eyedrop"
79662067|NCT00316134|Procedure|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
79662068|NCT00316212|Drug|INS50589 Intravenous Infusion|
79662069|NCT00309855|Drug|Placebo|im and orally
79662070|NCT00309855|Drug|Testosterone|injections
79662071|NCT00309855|Drug|Anastrazole|orally x 21 days
79662072|NCT00309855|Drug|Dutasteride|orally x 21 days
79987668|NCT03679026|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
79500517|NCT06162871|Behavioral|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
79348881|NCT04777955|Other|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
79348882|NCT02204579|Drug|NPSP795|
79987669|NCT03168100|Drug|Elotuzumab|administered via IV infusion
79987670|NCT03168100|Drug|Lenalidomide|taken by mouth
79662073|NCT00279383|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
79662074|NCT00316251|Device|Vibration Plate Therapy|
79662075|NCT00279422|Drug|visilizumab|
79662076|NCT00279422|Drug|visilizumab|
79987671|NCT03168100|Drug|Dexamethasone|taken by mouth
79987672|NCT03168100|Drug|Bortezomib|administered as a subcutaneous injection
79987673|NCT03709381|Drug|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
79500518|NCT06162312|Other|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
79500519|NCT06161649|Behavioral|accepting the operation process of automated intelligent education software system|"Execute registration and qualification review~Automated smart education interaction"
79228300|NCT04911972|Procedure|Functional muscle transfer|Muscle transfer to restore lower limb function
79500520|NCT06155331|Drug|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
79500521|NCT06155331|Other|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
79662077|NCT00309894|Biological|sargramostim|
79662078|NCT00309894|Drug|ketoconazole|
79662079|NCT00309894|Drug|therapeutic hydrocortisone|
79662080|NCT00279461|Drug|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
79662081|NCT00279461|Drug|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
79662082|NCT00316329|Drug|Artesunate + Amodiaquine|
79662083|NCT00279539|Genetic|Vascular Endothelial Growth Factor (VEGF1)|
79662084|NCT00279578|Drug|ReFacto (Recombinant factor VIII) and Tranexamic acid|
79662085|NCT00316368|Device|Ethicon TPW32 60 cm (pacing wires x 2)|
79662086|NCT00279617|Drug|levetiracetam|open label levetricetam
79662087|NCT00309972|Drug|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
79815836|NCT02608775|Device|Aisys® care station, Acertys|Standard photoplethysmography
79987674|NCT03709381|Drug|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
79987675|NCT01353664|Drug|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
79987676|NCT04952766|Biological|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to vaccination~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
79987677|NCT02395744|Other|Paclitaxel administration using the OPC|
79662088|NCT00309972|Drug|Experimental arm (CON):|concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
79662089|NCT00310011|Drug|cisplatin|
79815837|NCT05326217|Other|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
79662090|NCT00310011|Drug|gemcitabine hydrochloride|
79662091|NCT00310011|Drug|paclitaxel|
79662092|NCT00310011|Procedure|conventional surgery|
79987678|NCT02400502|Behavioral|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
79987679|NCT02400268|Other|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
79987680|NCT02400268|Other|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
79348883|NCT02235077|Drug|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
79500522|NCT06155331|Drug|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
79987681|NCT02400424|Radiation|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
79987682|NCT03168568|Drug|Valsartan/Sacubitril or placebo|tablet (double dummy)
79500523|NCT06155331|Drug|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
79987683|NCT03168568|Drug|Valsartan or placebo|tablet (double dummy)
79987684|NCT05745610|Drug|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
79987685|NCT05745610|Drug|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
79987686|NCT02395588|Other|Guideline based care|Patient education using guideline based teaching guides
79228301|NCT03311672|Drug|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
79348884|NCT02235077|Drug|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
79348885|NCT02234141|Drug|Placebo|Tablet administered orally once daily
79348886|NCT02234141|Drug|Selonsertib|Tablets administered orally once daily
79500524|NCT06153810|Device|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
79500525|NCT06152718|Other|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
79662093|NCT00279656|Behavioral|Pharmaceutical care|
79662094|NCT00316407|Drug|lapatinib (GW572016)|1000 mg po qd
79662095|NCT00316407|Drug|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
79662096|NCT00316407|Drug|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
79662097|NCT00279695|Procedure|high frequency ultrasound examination|high frequency ultrasound examination of the eye
79662098|NCT00310089|Biological|filgrastim|
79662099|NCT00310089|Biological|pegfilgrastim|
79662100|NCT00310089|Drug|cediranib maleate|
79500526|NCT06152601|Procedure|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
79987687|NCT02395354|Device|Placing a self-expanding metallic stent|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center~Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~Clips can be placed at the distal end of the prosthesis according to the endoscopist.~Prosthesis removal time in 4 weeks."
79987688|NCT02395354|Device|A balloon dilatation|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center.~Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~It shall be deemed failure to expansion if required> 2 expansions."
79987689|NCT02400112|Drug|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
79987690|NCT02694328|Drug|ALKS 3831|Daily dosing
79348887|NCT02234063|Other|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
79348888|NCT02232893|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
79348889|NCT02232893|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
79348890|NCT02203721|Device|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
79662101|NCT00310089|Drug|cyclophosphamide|
79662102|NCT00310089|Drug|docetaxel|
79662103|NCT00310089|Drug|doxorubicin hydrochloride|
79662104|NCT00310089|Other|laboratory biomarker analysis|
79987691|NCT02694328|Drug|Olanzapine|Daily dosing
79348891|NCT02203721|Device|TECNIS Monofocal IOL, Model ZCB00|
79662105|NCT00310089|Procedure|conventional surgery|
79662106|NCT00310089|Procedure|neoadjuvant therapy|
79662107|NCT00279734|Drug|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
79662108|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
79500527|NCT06145477|Behavioral|Chicago Parent Program - individualized for families (CPPi)|CPPi is a 8-12 session individual- based parenting skills program
79500528|NCT06142526|Device|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
79987692|NCT04480996|Drug|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
79662109|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
79662110|NCT00279734|Drug|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
79662111|NCT00310128|Drug|cisplatin|
79662112|NCT00310128|Drug|cytarabine|
79662113|NCT00310128|Drug|etoposide|
79662114|NCT00310128|Drug|methylprednisolone|
79662115|NCT00310128|Drug|rituximab|
79987693|NCT02399878|Drug|Inspiratory oxygen|
79987694|NCT02395276|Device|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
79987695|NCT02395510|Drug|Vortioxetine|Vortioxetine 5-20mg
79987696|NCT05745532|Biological|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
79987697|NCT05745454|Biological|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
79500529|NCT06140667|Device|LarysealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.
79524904|NCT05668663|Diagnostic Test|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
79524905|NCT05668208|Device|E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)|ONSD measurement will be made using the E-CUBE i7 ultrasound system.
79987698|NCT02395432|Device|orotracheal intubation|
79987699|NCT02394886|Biological|ALLO-ASC-DFU|
79987700|NCT02400034|Other|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
79987701|NCT02399956|Other|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
79524906|NCT05655442|Procedure|early APM|early APM within 3 and 6 month knee pain symptoms
79662116|NCT00310128|Drug|yttrium Y 90 ibritumomab tiuxetan|
79662117|NCT00310128|Procedure|antibody therapy|
79662118|NCT00310128|Procedure|biological therapy|
79662119|NCT00310128|Procedure|chemotherapy|
79987702|NCT02399800|Procedure|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
79662120|NCT00310128|Procedure|monoclonal antibody therapy|
79662121|NCT00310128|Procedure|radiation therapy|
79662122|NCT00310128|Procedure|radioimmunotherapy|
79662123|NCT00310128|Procedure|radioisotope therapy|
79662124|NCT00279773|Drug|TKI258|
79662125|NCT00418899|Behavioral|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
79662126|NCT00416741|Behavioral|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting [plasma flucose
79662127|NCT00416780|Other|counseling intervention|
79662128|NCT00416780|Other|educational intervention|
79987703|NCT02399800|Procedure|No Celiac Block|EUS but no celiac block performed
79987704|NCT02399800|Drug|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
79987705|NCT02399566|Drug|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
79662129|NCT00416780|Procedure|psychosocial assessment and care|
79987706|NCT02399644|Behavioral|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
79662130|NCT00310167|Radiation|radiation therapy|
79662131|NCT00316563|Drug|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
79662132|NCT00316563|Other|Placebo|
79987707|NCT02399644|Other|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
79500530|NCT06140667|Device|Ambu Aura Gain|The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: >100 kg) with maximum suction catheter size of 16 Fr.
79662133|NCT00416819|Biological|filgrastim|
79662134|NCT00416819|Biological|rituximab|
79662135|NCT00416819|Drug|cytarabine|
79662136|NCT00416819|Drug|etoposide phosphate|
79987708|NCT03167164|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79987709|NCT03167164|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
79987710|NCT03167164|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79662137|NCT00416819|Drug|leucovorin calcium|
79987711|NCT03167164|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79662138|NCT00416819|Drug|methotrexate|
79987712|NCT03167164|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79987713|NCT03167164|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79987714|NCT03167164|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79500531|NCT06139718|Behavioral|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
79500532|NCT06138691|Combination Product|Ketamine Infusion plus RO DBT|The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
79500533|NCT06134544|Dietary Supplement|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
79228302|NCT03311672|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
79500534|NCT06132984|Diagnostic Test|Cardiac magnetic resonance|Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
79500535|NCT06131905|Drug|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
79500536|NCT06131905|Drug|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
79500537|NCT06128655|Other|Participation in PFCC-IR|PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is interdisciplinary patient care rounds that include one family member of the patient.
79500538|NCT06127719|Other|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
79500539|NCT06127394|Procedure|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
79662139|NCT00416819|Drug|temozolomide|
79662140|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
79662141|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
79662142|NCT00279890|Drug|Topical SR-01|
79662143|NCT00316641|Drug|Lipid-lowing Tea|
79662144|NCT00310245|Procedure|STI (structured Treatment Interruption)|
79662145|NCT00279929|Procedure|DHEA Replacement|
79662146|NCT00279968|Device|ICD|
79662147|NCT00280007|Drug|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
79662148|NCT00316680|Biological|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
79662149|NCT00280046|Drug|biphasic insulin aspart|
79348892|NCT01618695|Drug|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
79348893|NCT01618695|Drug|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
79348894|NCT01896531|Drug|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
79348895|NCT01896531|Drug|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
79348896|NCT01896531|Drug|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
79348897|NCT01896531|Drug|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
79348898|NCT01896531|Drug|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
79348899|NCT01618305|Drug|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery*.~* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
79348900|NCT01618305|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
79348901|NCT01618305|Drug|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
79662150|NCT00310284|Behavioral|Computerized delivery of cognitive-behavioral treatment of insomnia|
79662151|NCT00310284|Behavioral|Self-help manual to improve insomnia symptoms|
79662152|NCT00280085|Procedure|MR imaging|
79662153|NCT00280085|Procedure|Glucose clamp|
79348902|NCT01886313|Drug|Civamide Nasal Spray|
79348903|NCT01886313|Drug|Placebo|
79348904|NCT01896297|Drug|Pradaxa, dabigatran etexilate|75mg BID by oral
79662154|NCT00280085|Drug|Arginine|
79987715|NCT03167164|Drug|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79348905|NCT04618263|Drug|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
79348906|NCT01884675|Drug|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
79348907|NCT01884675|Drug|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
79348908|NCT01884597|Drug|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
79348909|NCT01884597|Drug|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
79500540|NCT06127394|Procedure|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
79662155|NCT00310323|Drug|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
79500541|NCT06127030|Behavioral|Brief behavioral teacher training|A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.
79500542|NCT06127030|Behavioral|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
79662156|NCT00310323|Drug|Caffeine|Administered as 4 ounces of Coca-Cola
79987716|NCT03167164|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
79348910|NCT01895361|Drug|SelG1|
79348911|NCT01895361|Drug|Placebo|
79500543|NCT06122363|Device|hysteroscopy|uterine hysteroscopy right after Novasure endometrial ablation
79987717|NCT03167164|Radiation|Stereotactic Body Radiation Therapy|radiation
79662157|NCT00310479|Device|Magnetic Resonance Spectroscopy (3Tesla)|
79662158|NCT00280280|Drug|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
79662159|NCT00316758|Drug|GK Activator (2)|Escalating doses bid
79662160|NCT00316758|Drug|Metformin|As prescribed, in patients who were in study BM18249
79987718|NCT03167164|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79987719|NCT03167164|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79987720|NCT03167164|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
79987721|NCT03167164|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
79987722|NCT03167164|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
79987723|NCT03167086|Behavioral|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
79987724|NCT03167086|Behavioral|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) [1& 2], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner [3].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk & Winter [4] for optional reading."
79987725|NCT03167086|Behavioral|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
79987726|NCT02399488|Device|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
79987727|NCT03334747|Drug|KAE609|Exploration of different doses of KAE609 to establish safety profile.
79987728|NCT03334747|Drug|Coartem|Control Arm
79228303|NCT03311672|Radiation|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
79815838|NCT05326217|Other|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
79987729|NCT02399722|Device|WICVAC|combined wound therapy
79987730|NCT02399722|Device|VAC mono therapy|mono therapy
79987731|NCT02394652|Drug|Metformin|Metformin is an antidiabetic agent given orally.
79228304|NCT03303014|Device|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
79500544|NCT06120257|Procedure|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
79987732|NCT02394652|Drug|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
79987733|NCT02394652|Drug|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
79987734|NCT02394496|Drug|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
79987735|NCT02394496|Drug|Lapatinib|1500mg (TBD) O.S. qd
79987736|NCT02394496|Drug|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
79348912|NCT01883895|Device|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
79348913|NCT01883895|Other|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
79500545|NCT06120257|Procedure|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
79500546|NCT06120257|Procedure|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
79524907|NCT05655442|Procedure|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
79524908|NCT05655429|Procedure|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
79815839|NCT02610101|Other|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
79815840|NCT02610101|Other|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
79815841|NCT02610101|Other|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
79815842|NCT04089618|Behavioral|MBLM|Complex 8 week Mind-Body program.
79987737|NCT02394496|Drug|Placebo Lapatinib|1500mg (TBD) O.S. qd
79987738|NCT03346759|Device|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
79662161|NCT00280319|Behavioral|interpersonal psychotherapy for groups|psychotherapy
79662162|NCT00280319|Behavioral|creative play therapy|consisted of play activities
79815843|NCT04034303|Genetic|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
79987739|NCT03346759|Device|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
79987740|NCT03710473|Diagnostic Test|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
79348914|NCT01883895|Other|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
79500547|NCT06117163|Behavioral|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
79348915|NCT01864005|Drug|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
79348916|NCT01864005|Drug|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
79348917|NCT01863849|Biological|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
79500548|NCT06108219|Drug|Miricorilant|Miricorilant 100 mg for oral dosing
79500549|NCT06108219|Drug|Placebo|Matching placebo for oral dosing
79500550|NCT06099457|Behavioral|SIB-Time web-application tool|Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
79500551|NCT06098339|Device|Lens A (fanfilcon A)|Daily wear for one month
79500552|NCT06098339|Device|Lens B (lotrafilcon B)|Daily wear for one month
79500553|NCT06094270|Device|EndoMind|Withdrawal time is calculated and an image report is generated using the EndoMind system.
79500554|NCT06087770|Drug|SM3321|Intravenous infusion, once a week, 28 days for a dosing cycle
79662163|NCT00280358|Drug|Fluticasone Propionate|
79662164|NCT00280358|Drug|Formoterol Fumarate|
79815844|NCT02595606|Drug|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
79987741|NCT03362671|Device|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
79987742|NCT03362671|Device|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
79987743|NCT02394418|Drug|Sevoflurane|Treatment of delirium by inhaled sevoflurane
79662165|NCT00316797|Drug|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
79348918|NCT01863771|Drug|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
79348919|NCT01863771|Other|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
79348920|NCT01894581|Dietary Supplement|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
79348921|NCT01894581|Drug|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
79348922|NCT01893411|Drug|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
79348923|NCT01893411|Drug|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
79348924|NCT01893411|Drug|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
79348925|NCT02232425|Drug|IX-01|
79348926|NCT02232425|Drug|Placebo|
79815845|NCT05755685|Drug|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
79815846|NCT00917436|Drug|Thiocolchicoside|
79662166|NCT00310518|Drug|ARQ 501|
79815847|NCT04088838|Other|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
79815848|NCT02609945|Drug|zolmitriptan|Oral Tablet and Nasal Spray
79815849|NCT02609945|Drug|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
79815850|NCT00739908|Drug|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
79500557|NCT06078904|Drug|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
79500558|NCT06078904|Drug|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
79815851|NCT00739908|Drug|Placebo|Six capsules administered three times a day for six weeks.
79815852|NCT05297435|Diagnostic Test|Questionnaires|Questionnaire study
79815853|NCT04578431|Dietary Supplement|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
79815854|NCT02596308|Biological|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
79815855|NCT02609165|Drug|rhNGF 180 µg/ml eye drops solution|eye drops
79815856|NCT02609165|Drug|vehicle eye drops|placebo
79815857|NCT05052125|Drug|Oxygen|Administering oxygen to achieve the desired peripheral oxygen saturation
79500559|NCT06078904|Drug|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
79815858|NCT00739596|Drug|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
79500560|NCT06078904|Drug|Placebo|Placebo, one pill a day, oral intake
79524909|NCT05655429|Procedure|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
79524910|NCT05647681|Drug|Douloff|topic gel
79662167|NCT00280436|Drug|GW679769|
79662168|NCT00280475|Device|Whole brain radiation therapy arm|Whole brain radiation therapy arm
79662169|NCT00280475|Device|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
79662170|NCT00316836|Procedure|mammography|
79500561|NCT06078748|Behavioral|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
79815859|NCT00739596|Drug|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
79815860|NCT05754905|Other|Magnetic resonance examination|the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
79662171|NCT00280514|Drug|cefpirome and moxifloxacin administration|
79815861|NCT04549493|Behavioral|Exposure Therapy|Exposure Therapy is used to reduce the symptoms of PTSD
79662172|NCT00280553|Drug|bupivicaine|PCA and bupivicaine infusion for up to five days
79815862|NCT00742326|Drug|Pioglitazone|45 mg/daily
79815863|NCT00742326|Drug|Placebo|one capsule daily
79815864|NCT05757089|Dietary Supplement|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
79815865|NCT05755607|Procedure|laparoscopic pancreaticoduodenectomy|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
79815866|NCT05755607|Procedure|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
79662173|NCT00280553|Other|Saline infusion|PCA and pump with saline infusion for up to five days
79815867|NCT00741936|Drug|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
79662174|NCT00310557|Drug|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
79662175|NCT00280592|Drug|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
79662176|NCT00280592|Drug|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
79815868|NCT00741936|Drug|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
79815869|NCT05754749|Drug|Iohexol 350 Mg/mL Injectable Solution|Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
79815870|NCT02608853|Other|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
79815871|NCT02597868|Drug|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
79815872|NCT02597868|Procedure|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
79815873|NCT05754671|Other|perceptual assessment of the recorded voice sample|perceptual assessment of the recorded voice samples
79815874|NCT05754671|Other|voice recording|voice recording
79815875|NCT02595294|Procedure|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
79815876|NCT02609867|Device|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
79815877|NCT00811187|Drug|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
79815878|NCT00811187|Drug|Normal Saline|5cc Normal Saline injection in each paracervical region
79500562|NCT06078748|Behavioral|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
79815879|NCT02593812|Behavioral|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
79348927|NCT01631435|Other|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
79348928|NCT01631435|Device|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
79348929|NCT02230085|Other|Administration of the questionnaire and monitoring of CPAP adherence|
79348930|NCT02202785|Drug|MLN0264|MLN0264 IV infusion
79524911|NCT05647681|Drug|paracetamol|tablets
79524912|NCT05644314|Device|The drug-eluting stent|Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
79662177|NCT00316875|Drug|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
79662178|NCT00316875|Drug|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
79662179|NCT00280631|Drug|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
79348931|NCT01882647|Drug|000-0551 Lotion|
79524913|NCT05644171|Device|RESToration Of Rehabilitative function with Epidural spinal Stimulation|Three patients with chronic motor SCI will be recruited in total for this study. The recruited patients will not be randomized nor blinded due to the nature of this study. Pre-op rehabilitation session will take place over 4 weeks. 1 month post-surgical implants, patients will undergo 24 weeks of rehabilitation. The training sessions may continue to take place after the stipulated 24 weeks as long the electrode remains implanted, and the patient is available.
79662180|NCT00316953|Drug|dasatinib|Given orally
79815880|NCT04421729|Behavioral|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
79815881|NCT04421729|Behavioral|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
79815882|NCT02596074|Drug|Omiganan (CLS001) topical gel|
79815883|NCT02596074|Drug|Vehicle topical gel|
79815884|NCT00917748|Drug|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
79815885|NCT00917748|Drug|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
79815886|NCT00917748|Drug|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
79815887|NCT02596152|Other|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
79815888|NCT02596152|Other|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
79524914|NCT05644145|Biological|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
79662181|NCT00316953|Other|pharmacological study|Correlative studies
79815889|NCT02595138|Drug|Zoledronic acid|
79815890|NCT00591149|Drug|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
79815891|NCT00591149|Drug|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
79815892|NCT00591149|Drug|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
79348932|NCT01882647|Drug|Vehicle Lotion|
79348933|NCT01882257|Device|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
79348934|NCT01882257|Device|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
79348935|NCT04415697|Diagnostic Test|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
79348936|NCT02202551|Drug|ADS-5102|
79348937|NCT02202317|Device|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
79348938|NCT02118337|Biological|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
79524915|NCT05642858|Behavioral|Digital Educational Messaging|Education via mobile phone text messages for up to 6 months.
79662182|NCT00316953|Other|laboratory biomarker analysis|Correlative studies
79662183|NCT00280670|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
79662184|NCT00419172|Drug|Deferasirox|
79662185|NCT00419172|Drug|Rifampicin|
79662186|NCT00280709|Device|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
79348939|NCT02118337|Biological|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
79662187|NCT00280787|Drug|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
79815893|NCT00735072|Drug|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
79815894|NCT00735072|Drug|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
79815895|NCT00810641|Procedure|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
79815896|NCT00810641|Procedure|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
79815897|NCT00810641|Procedure|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
79348940|NCT02118337|Biological|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
79348941|NCT02117713|Drug|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
79348942|NCT02105467|Drug|Grazoprevir 100mg / Elbasvir 50 mg FDC|
79348943|NCT02105467|Drug|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
79500563|NCT06078748|Behavioral|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
79815898|NCT05753813|Drug|Phexxi|intravaginal gel twice weekly for 4 weeks.
79815899|NCT04181723|Drug|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
79348944|NCT02202161|Drug|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
79348945|NCT02202161|Drug|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
79348946|NCT02202161|Drug|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
79662188|NCT00280787|Drug|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
79662189|NCT00280787|Drug|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
79662190|NCT00280787|Drug|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
79348947|NCT02202161|Drug|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
79348948|NCT03267563|Behavioral|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
79348949|NCT03267563|Behavioral|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
79348950|NCT03267563|Behavioral|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
79500564|NCT06078748|Behavioral|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
79662191|NCT00280787|Radiation|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
79662192|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
79662193|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
79662194|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
79662195|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
79662196|NCT00310596|Drug|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
79662197|NCT00310596|Drug|Placebo|0,9% saline at 0,6mL/kg at bolus rate
79662198|NCT00280865|Drug|Tesaglitazar|
79815900|NCT04181723|Other|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
79815901|NCT00793598|Drug|Placebo|
79815902|NCT00793598|Drug|Brincidofovir|
79348951|NCT03109847|Drug|Metformin Hydrochloride|Given Orally
79348952|NCT03109847|Other|Radioactive Iodine|Undergo radioactive iodine treatment
79348953|NCT03109847|Other|Placebo|Given orally
79348954|NCT01461928|Drug|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
79348955|NCT01461928|Drug|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
79348956|NCT03097991|Behavioral|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
79348957|NCT02892305|Procedure|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
79662199|NCT00280865|Drug|Pioglitazone|
79348958|NCT02623205|Drug|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
79500565|NCT06067659|Other|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
79524916|NCT05642416|Drug|Continuous Infusion of ropivacaine|Continuous infusion of ropivacaine
79524917|NCT05642416|Drug|Intermittent bolus of ropivacaine|Intermittent bolus of ropivacaine
79524918|NCT05636826|Drug|atherolive-drug|placebo
79524919|NCT05632263|Diagnostic Test|EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
79662200|NCT00280865|Behavioral|Dietary and Lifestyle Modification Counseling|
79662201|NCT00310635|Biological|Meningococcal C conjugate vaccine|
79662202|NCT00316992|Drug|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
79662203|NCT00317031|Drug|Acamprosate or Naltrexone|mg&d 90 days
79662204|NCT00280982|Biological|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
79662205|NCT00310674|Biological|Meningococcal C Conjugate Vaccine|
79662206|NCT00281060|Procedure|primary stenting|
79662207|NCT00317070|Drug|dimethyl sulfoxide|intravesical installation 50 ml
79815903|NCT04115072|Drug|Praziquantel 600Mg Oral Tablet x 5|Five doses of Praziquantel 40 mg/kg
79815904|NCT04115072|Drug|Praziquantel 600Mg Oral Tablet x 1|Single dose of Praziquantel 40 mg/kg
79987744|NCT02394418|Drug|Propofol|Treatment of delirium by propofol i.v. infusion
79987745|NCT02394418|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
79987746|NCT03361423|Device|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
79662208|NCT00317070|Drug|IC Cocktail|"Heparin 10,000 units~Gentamicin 80 mg~Hydrocortisone sodium succinate (Solucortef) 100 mg~Lidocaine hydrochloride 1% 10 ml~Sodium Bicarbonate 8.4% 5 ml"
79662209|NCT00317148|Drug|Placebos|Placebo capsule
79662210|NCT00317148|Drug|DHEA capsule|One capsule of DHEA
79662211|NCT00281177|Behavioral|Asthma Disparity Reduction Strategy|
79662212|NCT00310713|Biological|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
79662213|NCT00310752|Device|DermaStream(tm) application and Streaming of Saline|
79662214|NCT00281255|Drug|Allopurinol|
79662215|NCT00281255|Drug|Dobutamine|
79662216|NCT00317187|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
79662217|NCT00317187|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
79815905|NCT04025294|Device|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
79348959|NCT02623205|Drug|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
79348960|NCT01500694|Drug|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
79662218|NCT00281294|Drug|Fontolizumab|
79662219|NCT00310869|Behavioral|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
79662220|NCT00281333|Behavioral|"Karate exercises and strengthening exercises"|
79348961|NCT04188977|Other|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
79348962|NCT04188977|Other|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
79348963|NCT01500382|Drug|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
79348964|NCT01500382|Drug|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
79348965|NCT01500382|Other|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
79348966|NCT01500382|Other|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
79662221|NCT00317265|Procedure|Coronary bypass surgery|
79662222|NCT00310908|Drug|Tramadol Hcl|Active Comparator
79662223|NCT00281411|Procedure|Computed Tomography Angiography|Computed Tomography Angiography
79662224|NCT00281411|Procedure|Magnetic Resonance Angiography|Magnetic Resonance Angiography
79500566|NCT06067659|Other|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
79500567|NCT06067659|Other|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
79500568|NCT06067568|Drug|Lutikizumab Dose A|Injection; subcutaneous (SC)
79500569|NCT06067568|Drug|Lutikizumab Dose B|Injection; subcutaneous (SC)
79500570|NCT06061926|Drug|Celery Seed|Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
79500571|NCT06061926|Drug|Placebo|Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
79500572|NCT06055621|Drug|Dasatinib|Daily orally administration of DASATINIB
79500573|NCT06045962|Device|Ureteral stent|Used to open the ureter and help the kidney drain
79662225|NCT00317304|Behavioral|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
79662226|NCT00281450|Behavioral|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
79662227|NCT00281489|Device|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
79662228|NCT00281489|Behavioral|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
79662229|NCT00317343|Drug|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
79662230|NCT00416858|Drug|cisplatin|
79662231|NCT00416858|Drug|fluorouracil|
79348967|NCT01500382|Drug|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
79348968|NCT02137837|Drug|Fulvestrant|
79500574|NCT06041087|Behavioral|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
79662232|NCT00416858|Procedure|adjuvant therapy|
79500575|NCT06041087|Dietary Supplement|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
79662233|NCT00416858|Procedure|conventional surgery|
79348969|NCT02137837|Drug|Anastrozole|
79500576|NCT06041087|Dietary Supplement|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
79500577|NCT06041087|Dietary Supplement|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
79662234|NCT00416858|Procedure|neoadjuvant therapy|
79662235|NCT00416858|Radiation|radiation therapy|
79662236|NCT02960061|Drug|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
79662237|NCT02960061|Procedure|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
79348970|NCT02137837|Drug|Everolimus|
79348971|NCT02137837|Drug|Placebo - Anastrozole|
79348972|NCT02137837|Drug|Placebo - Everolimus|
79348973|NCT01483690|Drug|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
79348974|NCT01483690|Drug|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
79348975|NCT01483690|Drug|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
79348976|NCT01483690|Drug|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
79500578|NCT06041087|Dietary Supplement|Water|500ml consumed immediately after exercise and 1h after exercise.
79500579|NCT06039761|Procedure|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
79500580|NCT06035965|Other|Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19)|19 items assessing post-surgery satisfaction.
79500581|NCT06035965|Other|Quality of Life in Epilepsy Inventory (QOLIE-31)|31 items to assess different dimensions of quality of life
79500582|NCT06035965|Other|Generalized Anxiety Disorder 7 (GAD7)|7 items, rated from 0 to 3, to detect anxiety disorders.
79500583|NCT06035965|Other|Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)|to screen for depressive disorders
79662238|NCT02960061|Drug|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
79662239|NCT02960061|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
79662240|NCT00416897|Drug|chemotherapy|
79662241|NCT00416897|Drug|dexamethasone|
79662242|NCT00416897|Procedure|plasmapheresis|
79662243|NCT00317382|Device|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
79662244|NCT00310986|Behavioral|Breathing Meditation|
79662245|NCT00416975|Other|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
79662246|NCT00416975|Other|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
79987747|NCT03361423|Device|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
79815906|NCT04025294|Behavioral|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
79228305|NCT03311516|Other|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
79348977|NCT01483690|Drug|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
79348978|NCT01483690|Drug|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
79662247|NCT00416975|Procedure|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
79662248|NCT00311025|Procedure|intensive endurance, strength and balance exercises|
79662249|NCT00417014|Drug|chlorambucil|
79662250|NCT00417014|Drug|prednisolone|
79815907|NCT04005482|Other|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
79815908|NCT00796562|Drug|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
79815909|NCT00796562|Drug|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
79815910|NCT00796562|Radiation|Total body irradiation|Patients will receive TBI once a day for 4 days.
79987748|NCT02693002|Drug|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
79987749|NCT02693002|Drug|Placebo|inactive ingredient
79815911|NCT00801632|Procedure|Kidney Transplantation|Surgical transplantation of donor kidney
79815912|NCT00801632|Procedure|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
79500584|NCT06035965|Other|Evaluation of Changes in Daily Life after Epilepsy Surgery (EVOCQUE)|self-questionnaire developed by the Toulouse epileptology team in 2023 for patients who have undergone epilepsy surgery. It aims to collect the feelings of patients concerning the changes induced by surgery in their daily life according to a 7-point Likert scale.
79500585|NCT06034314|Drug|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
79815913|NCT00801632|Biological|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
79500586|NCT06018558|Genetic|OCU410|Subretinal administration of OCU410
79524920|NCT05631028|Drug|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
79348979|NCT01483690|Drug|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
79348980|NCT02104765|Drug|LY2951742|Administered subcutaneously.
79348981|NCT02104765|Drug|Placebo|Administered subcutaneously.
79987750|NCT04480606|Behavioral|Home exercise program|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
79987751|NCT05408923|Drug|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
79987752|NCT05408923|Drug|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
79348982|NCT01483144|Drug|Eflornithine|Eflornithine [250 mg tablet, three tablets (750 mg) orally once a day]
79662251|NCT00417014|Drug|procarbazine hydrochloride|
79815914|NCT00801632|Drug|cyclophosphamide|60 mg/kg infusion on days -5, -4
79815915|NCT00801632|Biological|rituximab|375 mg/m^2 infusion on days -7, -2, 5, and 12
79348983|NCT01483144|Drug|Eflornithine Placebo|Eflornithine placebo [three tablets orally once a day]
79348984|NCT01483144|Drug|Sulindac 150 MG|Sulindac [one tablet orally once a day]
79348985|NCT01483144|Drug|Sulindac placebo|Sulindac placebo [one tablet orally once a day]
79524921|NCT05631028|Drug|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
79662252|NCT00417014|Drug|vinblastine sulfate|
79662253|NCT00417014|Radiation|radiation therapy|
79662254|NCT00317421|Drug|Sildenafil citrate|
79662255|NCT00417053|Biological|filgrastim|
79662256|NCT00417053|Drug|busulfan|
79815916|NCT00801632|Drug|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
79662257|NCT00417053|Drug|carboplatin|
79662258|NCT00417053|Drug|cyclophosphamide|
79662259|NCT00417053|Drug|doxorubicin hydrochloride|
79662260|NCT00417053|Drug|etoposide phosphate|
79348986|NCT01881789|Drug|Oprozomib|Extended release (ER) tablets administered orally
79662261|NCT00417053|Drug|melphalan|
79662262|NCT00417053|Drug|vincristine sulfate|
79815917|NCT00801632|Drug|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
79662263|NCT00417053|Procedure|autologous bone marrow transplantation|
79815918|NCT00801632|Radiation|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
79662264|NCT00417053|Procedure|bone marrow ablation with stem cell support|
79662265|NCT00417053|Procedure|conventional surgery|
79815919|NCT04111484|Other|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
79815920|NCT04111484|Other|Saline|Placebo
79815921|NCT04109300|Genetic|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
79815922|NCT04109300|Other|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
79815923|NCT02604290|Device|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
79815924|NCT02604290|Device|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
79815925|NCT04111328|Drug|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
79815926|NCT04111328|Drug|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
79815927|NCT04111328|Drug|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
79815928|NCT04111328|Drug|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
79815929|NCT04111328|Drug|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
79662266|NCT00417053|Procedure|peripheral blood stem cell transplantation|
79662267|NCT00417053|Radiation|radiation therapy|
79662268|NCT00317460|Other|Physician Management|Standard physician care
79662269|NCT00317460|Behavioral|Counseling|Physician Management and Counseling
79662270|NCT00311064|Behavioral|physical activity|
79662271|NCT00281567|Drug|Tiotropium|
79662272|NCT00281567|Device|Respimat SMI|
79662273|NCT00281567|Device|HandiHaler|
79662274|NCT00317499|Other|Placebo|Placebo
79662275|NCT00317499|Drug|Etanercept|Etanercept
79662276|NCT00281606|Drug|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
79815930|NCT04111328|Drug|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
79987753|NCT05744986|Device|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
79348987|NCT01881789|Drug|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
79348988|NCT01881789|Drug|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants > 75 years of age, at the discretion of the investigator.
79348989|NCT01881789|Drug|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
79500587|NCT06005623|Device|SENS Motion + Motivational Feedback|"To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity."
79500588|NCT05988944|Other|TT+CIMT+VR|TT: Traditional Techniques CIMT: constraint-induced movement therapy VR: virtual reality
79500589|NCT05988944|Other|TT+CIMT|TT: Traditional Techniques CIMT: constraint-induced movement therapy
79500590|NCT05988944|Other|TT|TT: Traditional Techniques
79815931|NCT04111328|Drug|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
79815932|NCT04111328|Drug|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
79815933|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
79815934|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
79987754|NCT03707509|Drug|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
79987755|NCT03707509|Drug|Placebos|Maximum 6 cycles for combined therapy.
79987756|NCT03707509|Drug|Gemcitabine|Maximum 6 cycles for combined therapy.
79987757|NCT03707509|Drug|Cisplatin|Maximum 6 cycles for combined therapy.
79500591|NCT05983211|Device|Repetitive Transcranial Magnetic Stimulation|Accelerated rTMS using continuous theta burst stimulation inhibitory paradigms over bilateral M1 hand region outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600 pulses over 40 seconds. ALS patients will receive rTMS bilaterally at a regimen of cTBS for 40 seconds per treatment, for up to 8 treatment sessions per day, delivered one per hour, over 5 days.
79500592|NCT05978089|Drug|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
79500593|NCT05978089|Drug|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
79500594|NCT05963698|Device|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
79500595|NCT05958082|Behavioral|Educational video|The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
79500596|NCT05956626|Genetic|OCU410ST|Subretinal Administration of OCU410ST
79500597|NCT05955638|Device|MiSight contact lenses|Contact lens for myopia management.
79500598|NCT05955638|Device|Proclear contact lenses|Single vision contact lens as control
79500599|NCT05955300|Other|Training program|The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.
79662277|NCT00311103|Procedure|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
79815935|NCT00806819|Drug|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
79662278|NCT02960789|Other|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
79662279|NCT02960789|Other|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
79662280|NCT02960789|Device|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
79815936|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
79500600|NCT05955300|Other|Nutrition therapy|Nutrition therapy based on the New Nordic Diet
79662281|NCT02960789|Other|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
79662282|NCT02960789|Device|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
79662283|NCT00317538|Drug|infliximab, etanercept|
79815937|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
79987758|NCT03710395|Procedure|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
79815938|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
79815939|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
79815940|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
79815941|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
79815942|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
79815943|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
79815944|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
79987759|NCT03710395|Drug|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
79815945|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
79815946|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
79662284|NCT00281645|Drug|Bicifadine|
79987760|NCT02399098|Behavioral|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
79987761|NCT04889950|Device|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
79987762|NCT04889950|Device|LipiFlow|LipiFlow
79987763|NCT02394262|Radiation|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
79228306|NCT03311516|Other|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
79662285|NCT00281645|Drug|Standard of Care (pharmacological analgesic treatment)|
79662286|NCT00281723|Drug|Pro-Pe adhesive tablet|
79662287|NCT00317577|Drug|brimonidine, timolol|
79662288|NCT00417092|Procedure|Postoperative Pacing|
79662289|NCT00281762|Drug|NSAID|
79662290|NCT00317655|Drug|Glucosamine sulphate|
79662291|NCT00317655|Drug|Ginger|
79662292|NCT00317655|Drug|Ginger-Avocado-Soya|
79662293|NCT00317655|Drug|Ginger-ibuprofen|
79662294|NCT00281801|Procedure|psychosocial assessment and care|psychosocial assessment and care
79815947|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
79815948|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
79662295|NCT00281801|Procedure|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
79662296|NCT00311220|Drug|tuberculin for skin test|
79987764|NCT02394262|Other|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
79987765|NCT03093870|Drug|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
79987766|NCT03093870|Drug|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
79987767|NCT03093870|Drug|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
79987768|NCT02394184|Procedure|transcatheter aortic valve replacement|
79662297|NCT00281996|Drug|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
79662298|NCT00281996|Drug|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
79662299|NCT00311259|Drug|Melatonin (drug)|
79662300|NCT00311259|Drug|Laktose|
79662301|NCT00282035|Radiation|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
79662302|NCT00282035|Radiation|Whole breast irradiation|Whole breast irradiation
79662303|NCT00282074|Procedure|laparoscopic bilateral hernia repair|
79662304|NCT00317733|Drug|Ketoprofen in Transfersome|
79987769|NCT05744908|Other|Pentosan Polysulphate|300mg 3 times a day
79987770|NCT02394106|Drug|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
79987771|NCT02394106|Other|Placebo|Normal saline, 1000 ml, administered once
79500601|NCT05949138|Device|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
79308250|NCT03215303|Device|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
79500602|NCT05936593|Device|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
79500603|NCT05936593|Device|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
79500604|NCT05926856|Drug|Indocyanine green|Indocyanine Green 25mg kit for injection
79815949|NCT00801242|Drug|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
79815950|NCT04109534|Diagnostic Test|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc… until the FEV1 decreases 20% below the initial FEV1-value
79662305|NCT00311298|Dietary Supplement|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
79500605|NCT05926388|Other|Video-assisted training|Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
79500606|NCT05919680|Drug|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
79662306|NCT00311298|Dietary Supplement|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
79662307|NCT00282230|Drug|FK778|
79815951|NCT04109534|Diagnostic Test|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
79662308|NCT00311337|Drug|bortezomib|
79815952|NCT04109534|Diagnostic Test|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
79815953|NCT04109534|Diagnostic Test|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
79815954|NCT04108910|Diagnostic Test|Guidance UTI|
79662309|NCT00282269|Procedure|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
79662310|NCT00317811|Dietary Supplement|ascorbic acid|
79662311|NCT00317811|Drug|bortezomib|
79662312|NCT00317811|Drug|melphalan|
79662313|NCT00282386|Drug|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
79662314|NCT00282386|Drug|Placebo/ Duration of Treatment: 156 weeks|
79815955|NCT05754437|Device|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
79815956|NCT04377659|Drug|Tocilizumab|Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
79815957|NCT04024709|Procedure|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
79815958|NCT04111250|Procedure|Maxillary sinus augmentation|Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
79815959|NCT05326139|Drug|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
79815960|NCT05326139|Other|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
79815961|NCT04110782|Other|Radium223|55 kBq/ Kg
79987772|NCT01568346|Other|MRI|Breast MRI
79987773|NCT02393872|Behavioral|Feel4Diabetes-intervention|Community-based intervention.
79662315|NCT00282425|Biological|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
79662316|NCT00317850|Drug|Gabapentin (Neurontin)|
79500607|NCT05919680|Drug|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
79500608|NCT05919680|Other|Matched Placebo|Matched placebo for administration in Part A or Part B
79815962|NCT02605694|Drug|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
79815963|NCT02605694|Drug|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
79500609|NCT05917639|Device|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
79500610|NCT05917639|Device|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
79500611|NCT05917639|Device|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
79500612|NCT05912270|Behavioral|Orchestra in Class|See arm/group descriptions
79500613|NCT05909709|Drug|Alocyte low dose|"Low dose containing 0.2 - 1.0 x 10^11 particles and 3-10x10^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used."
79500614|NCT05909709|Drug|Alocyte medium dose|"Medium dose containing 0.6 - 3.0 x 10^11 particles and 9-30x10^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used."
79662317|NCT00282503|Drug|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
79662318|NCT00282503|Procedure|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
79815964|NCT02605694|Drug|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2)"
79815965|NCT02605694|Drug|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
79815966|NCT02604134|Procedure|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
79815967|NCT02604134|Drug|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
79815968|NCT02604134|Drug|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
79815969|NCT00800540|Drug|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
79815970|NCT00800540|Drug|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
79987774|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation ON|
79987775|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation OFF|
79987776|NCT02399176|Behavioral|Yoga|Subjects assume 10 physical postures for 30 seconds each
79987777|NCT02399332|Other|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
79348990|NCT02075203|Biological|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK & a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 & saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
79348991|NCT02075203|Drug|Placebo|Saline
79500615|NCT05909709|Drug|Alocyte high dose|"High dose containing 1.0 - 5.0 x 10^11 particles and 15-50x10^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used."
79662319|NCT00311415|Biological|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
79662320|NCT00317889|Procedure|Bone preparation technique: compaction|
79815971|NCT00800384|Device|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
79348992|NCT02075203|Biological|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
79348993|NCT01892163|Device|Ozurdex|Dexamethasone implant (Ozurdex)
79348994|NCT01881009|Device|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
79500616|NCT05897801|Diagnostic Test|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
79500617|NCT05896527|Drug|DC-806|DC-806 will be supplied as tablets to be administered orally.
79500618|NCT05896527|Other|Placebo|Matching placebo will be supplied as tablets to be administered orally.
79500619|NCT05896163|Drug|maplirpacept (PF-07901801)|Intravenous infusion
79500620|NCT05896163|Drug|Glofitamab|Intravenous infusion
79500621|NCT05896163|Drug|Obinutuzumab|Intravenous infusion
79500622|NCT05894603|Drug|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
79500623|NCT05894603|Drug|Molnupiravir|Molnupiravir
79662321|NCT00317889|Procedure|Bone preparation technique: broaching|
79662322|NCT00282542|Procedure|Hepatocyte Infusion|
79662323|NCT00311454|Drug|T.R.U.E.Test|
79662324|NCT00282581|Biological|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
79662325|NCT00317928|Drug|Metformin|
79815972|NCT04108832|Drug|TCM OA2|Usage: 3g twice daily
79815973|NCT04108832|Drug|PLACEBO|Usage: 3g twice daily
79815974|NCT00796328|Drug|Phenylephrine infusion|Up-down, biased coin design
79987778|NCT05744830|Other|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
79348995|NCT01881009|Device|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
79348996|NCT01500226|Drug|Rolapitant|(4 X 50 mg capsule) 200 mg PO
79348997|NCT01500226|Drug|Granisetron|2 mg PO
79348998|NCT01500226|Drug|Dexamethasone|20 mg PO
79348999|NCT01500226|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
79349000|NCT02075047|Drug|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
79349001|NCT02075047|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
79349002|NCT01859949|Drug|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
79349003|NCT01859793|Drug|sitagliptin|100 mg pill, administered once/day orally
79349004|NCT01859793|Drug|Placebo|Matching placebo in appearance given once/day orally
79349005|NCT01859715|Drug|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
79349006|NCT01859715|Drug|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
79987779|NCT05744830|Other|Complete Denture|15 patients will only receive removable complete dentures
79987780|NCT04793646|Drug|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
79987781|NCT04793646|Drug|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
79987782|NCT03106714|Diagnostic Test|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
79308251|NCT02503943|Drug|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
79349007|NCT01859715|Drug|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
79349008|NCT01890915|Other|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
79349009|NCT04616235|Drug|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
79500624|NCT05893355|Behavioral|Acupressure group|"Application to Acupressure Group~Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~The VAS Evaluating Back Pain after the application will be filled in by the participant.~The participant will be informed that the study has been completed."
79987783|NCT05232292|Biological|Ultrix Quadri|vaccination by Ultrix Quadri against flu
79987784|NCT02393638|Other|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
79987785|NCT02393638|Other|Lecture|Lecture
79308252|NCT02503943|Drug|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
79349010|NCT04616235|Other|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
79349011|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
79500625|NCT05890963|Drug|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
79500626|NCT05890963|Drug|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
79500627|NCT05890963|Drug|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
79500628|NCT05889156|Drug|NST-1024|400 mg BID
79500629|NCT05889156|Other|Placebo|matched placebo to active arm
79349012|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
79500630|NCT05884554|Drug|PF-07817883|Experimental
79500631|NCT05881005|Diagnostic Test|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
79500632|NCT05879913|Device|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
79500633|NCT05877430|Drug|CJRB-101|In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
79662326|NCT00282620|Drug|Magnesium L-lactate|
79662327|NCT00282659|Drug|magnesium L-lactate|
79662328|NCT00311493|Biological|Tick-Borne Encephalitis vaccine|
79662329|NCT00282698|Drug|Insulin infusion with a goal|
79987786|NCT03166852|Other|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
79662330|NCT00317967|Drug|Atorvastatin|80 mg pills daily
79662331|NCT00317967|Drug|Placebo|80 mg pills daily
79662332|NCT00318006|Procedure|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
79662333|NCT00318006|Procedure|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
79679549|NCT00516620|Behavioral|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
79500634|NCT05877430|Drug|Pembrolizumab injection|200 mg given by intravenous (IV) infusion once every 3 weeks
79500635|NCT05874141|Diagnostic Test|HBA1C|blood sample on EDTA
79500636|NCT05874141|Diagnostic Test|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
79500637|NCT05874141|Diagnostic Test|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
79500638|NCT05874141|Diagnostic Test|Serum creatinine and estimated glomerular filtration rate|serum sample
79500639|NCT05874141|Diagnostic Test|Complete blood count|blood sample on EDTA
79500640|NCT05874141|Diagnostic Test|Thyroid-stimulating hormone|serum sample
79500641|NCT05874141|Diagnostic Test|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
79500642|NCT05874141|Procedure|Electrocardiography (ECG)|by electrocardiogram
79500643|NCT05874141|Procedure|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
79500644|NCT05874141|Procedure|Arterial duplex ultrasound of both lower limbs|imaging
79500645|NCT05874141|Diagnostic Test|Random blood glucose|serum sample
79500646|NCT05874141|Diagnostic Test|AST, ALT, albumin|serum sample
79349013|NCT04590495|Drug|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
79500647|NCT05872295|Drug|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
79500648|NCT05865041|Drug|Farudodstat|Farudodstat tablets administered orally
79500649|NCT05865041|Drug|Placebo|Placebo tablets administered orally
79500650|NCT05859997|Biological|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
79500651|NCT05859035|Device|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
79500652|NCT05852431|Drug|Pegozafermin|Subcutaneous injection
79500653|NCT05852431|Drug|Placebo|Subcutaneous injection
79500654|NCT05846841|Behavioral|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
79500655|NCT05846841|Behavioral|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
79500656|NCT05846724|Drug|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
79500657|NCT05845554|Diagnostic Test|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
79500658|NCT05838729|Drug|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
79500659|NCT05837351|Behavioral|Exercise -Running|"At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn."
79308253|NCT02503943|Drug|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
79500660|NCT05837104|Drug|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
79500661|NCT05837104|Drug|Placebo|Placebo tablet, three times daily for four weeks.
79500662|NCT05835505|Drug|BRS201|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
79500663|NCT05835505|Drug|Placebo|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
79662334|NCT00282776|Behavioral|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
79662335|NCT00282776|Behavioral|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
79987787|NCT02399020|Behavioral|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
79987788|NCT03596736|Procedure|Elbow Hemiarthroplasty|
79308254|NCT02450825|Procedure|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
79308255|NCT02450825|Procedure|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
79987789|NCT03596736|Procedure|Total Elbow Arthroplasty|
79987790|NCT05744752|Other|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
79987791|NCT05744752|Dietary Supplement|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
79987792|NCT05744752|Dietary Supplement|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
79987793|NCT05744752|Other|Placebo|1ml NaCl 0.9% daily for 12 weeks
79987794|NCT02393404|Other|PT-FMT|Physiotherapeutic functional movement-power training
79987795|NCT02393404|Other|FMT alone|Physiotherapeutic power training
79987796|NCT02393482|Drug|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
79987797|NCT02393482|Drug|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
79987798|NCT02393482|Drug|Add back therapy 1 (tibolone)|tibolone 5 mg/die
79500664|NCT05834777|Drug|Icatibant|Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
79662336|NCT00318045|Device|Eyeglass lenses|
79662337|NCT00311571|Drug|Ethidronate|
79662338|NCT00311571|Behavioral|Physical training|
79987799|NCT02393482|Drug|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
79500665|NCT05834777|Drug|Placebo|0.9% sodium chloride will be administered as the same rate as icatibant
79500666|NCT05825404|Device|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
79308256|NCT02450825|Device|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
79500667|NCT05825404|Other|Control|Usual light.
79662339|NCT00282893|Procedure|transluminal ballooning|
79349014|NCT04590495|Drug|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
79349015|NCT01859403|Genetic|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
79349016|NCT01859403|Genetic|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
79349017|NCT01858701|Device|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
79349018|NCT01858701|Device|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
79349019|NCT01461538|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
79349020|NCT01461538|Drug|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
79349021|NCT01461538|Drug|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
79662340|NCT00282893|Other|currently existing therapies for the treatment of vasospasm|
79662341|NCT00318084|Drug|Esomeprazole|
79987800|NCT03166774|Other|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
79987801|NCT02393560|Procedure|DECT scan|
79349022|NCT02117479|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
79349023|NCT02117479|Drug|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
79349024|NCT02117479|Drug|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
79349025|NCT02229851|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
79349026|NCT02229851|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
79349027|NCT02229851|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
79349028|NCT01482910|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
79349029|NCT01482910|Drug|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
79662342|NCT00318084|Procedure|Ambulatory 24-hour esophageal pH-monitoring|
79662343|NCT00282932|Drug|Detrol LA|
79662344|NCT00318123|Drug|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
79662345|NCT00318162|Drug|low dose naltrexone|
79662346|NCT00283088|Procedure|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
79662347|NCT00283088|Drug|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
79662348|NCT00311610|Drug|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
79662349|NCT00283127|Procedure|Home sampling (urine test) for uro-genital C.trachomatis.|
79662350|NCT00318201|Drug|Erythromycin|
79662351|NCT00318201|Drug|Diltiazem|
79662352|NCT00283166|Behavioral|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
79662353|NCT00311649|Biological|Inactivated Influenza A Vaccine A/H5N1|
79662354|NCT00318240|Device|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
79987802|NCT03346057|Drug|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
79987803|NCT03346057|Drug|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
79987804|NCT03346057|Drug|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
79662355|NCT04708652|Other|No intervention|No intervention
79500668|NCT05824806|Biological|PRP Protocol A|Platelet rich plasma protocol A
79500669|NCT05824806|Biological|PRP Protocol B|Platelet rich plasma protocol B
79662356|NCT00311688|Drug|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
79662357|NCT02960750|Behavioral|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
79662358|NCT02960750|Behavioral|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
79349030|NCT04077190|Device|Adipose-derived stem cells|5cc adipose derived stem cells.
79662359|NCT00283322|Other|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
79349031|NCT04077190|Device|cortisone injection|cortisone injection
79349032|NCT01626391|Drug|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
79349033|NCT01626391|Drug|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
79349034|NCT02103439|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
79662360|NCT00318279|Device|Surgical simulator to practice vascular anastomosis|
79662361|NCT00283361|Drug|ZP120|
79662362|NCT00283361|Procedure|I.v. catherization|
79662363|NCT00283361|Procedure|6-minutes walk performance|
79662364|NCT00283361|Behavioral|Dyspnea severity assessment|
79662365|NCT00283361|Procedure|Blood sampling for laboratory tests|
79662366|NCT00283361|Procedure|ECG|
79662367|NCT00283361|Procedure|Physical examination|
79349035|NCT02103439|Drug|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
79349036|NCT02229539|Drug|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
79349037|NCT02229539|Drug|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
79349038|NCT02229539|Other|Placebo|2.5 mL placebo and 2.5 mL water administered orally
79349039|NCT01835223|Drug|Tivozanib (1mg)|Given PO
79349040|NCT01835223|Drug|Tivozanib (1.5mg)|Given PO
79349041|NCT01482598|Device|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
79349042|NCT01460446|Device|Aviva Expert blood glucose meter|
79349043|NCT01460446|Device|Aviva Nano blood glucose meter|
79500670|NCT05824806|Device|Hyaluronic acid|Hyaluronic acid
79500671|NCT05789862|Behavioral|Counseling Sessions|Virtual sessions
79500672|NCT05789862|Behavioral|Quality of Life Questionnaires|Self administered questionnaires
79500673|NCT05789225|Behavioral|Fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program is group-based with 8 participants in each group, led by a facilitator, and performed online. It comprises seven two-hour sessions held once a week, and a booster session held four weeks after the seventh session. In addition participants will receive a brochure about falls and fall risk factors.
79500674|NCT05789225|Other|Brochure|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
79500675|NCT05786365|Drug|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
79500676|NCT05773846|Drug|Ropivacaine|A long acting formulation of ropivacaine
79349044|NCT02229383|Drug|Exenatide|2 mg weekly suspension injection
79349045|NCT02229383|Drug|Exenatide matching placebo|Once weekly Placebo injection
79349046|NCT01499368|Drug|Lafutidine|Lafutidine 20mg/day
79349047|NCT01499368|Drug|Famotidine|Famotidine 40mg/day
79500677|NCT05769114|Procedure|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
79662368|NCT00311727|Biological|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
79662369|NCT00283478|Drug|Iscar Quercus|
79662370|NCT00283478|Drug|Gemcitabine|
79662371|NCT00318318|Drug|Premarin|
79662372|NCT00311805|Biological|Autologous Stem Cells (CD34+)|Intramuscular Injections
79662373|NCT00283010|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
79662374|NCT00283010|Other|Educational DVDs|
79662375|NCT00318396|Procedure|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
79662376|NCT00318396|Procedure|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
79500678|NCT05763953|Drug|Etripamil NS|"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
79500679|NCT05757609|Device|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
79500680|NCT05757609|Device|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
79500681|NCT05757362|Other|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
79500682|NCT05757063|Other|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
79987805|NCT03346057|Drug|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
79500683|NCT05757063|Other|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
79349048|NCT01499368|Drug|Omeprazole|Omeprazole 20mg/day
79349049|NCT01835145|Drug|Cabozantinib S-malate|Given PO
79500684|NCT05755035|Biological|TAK-881|Participants will receive SC infusion of TAK-881.
79500685|NCT05755035|Biological|HYQVIA|Participants will receive SC infusion of HYQVIA.
79987806|NCT03346057|Drug|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
79987807|NCT03346057|Drug|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
79349050|NCT01835145|Drug|Dacarbazine|Given IV
79500686|NCT05753176|Behavioral|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
79500687|NCT05751278|Device|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
79500688|NCT05751278|Device|Radial Jaw 4 Pulmonary Biopsy Forceps|Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
79500689|NCT05736432|Dietary Supplement|Blueberries|Experimental condition
79500690|NCT05736432|Dietary Supplement|Placebo|Placebo condition
79500691|NCT05733767|Other|Enhanced Usual Care (EUC)|Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
79987808|NCT02393326|Procedure|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
79987809|NCT02393326|Procedure|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
79308257|NCT02503631|Device|Stool Sample Collection Kit|Stool sample collection kit
79308258|NCT02178592|Drug|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
79349051|NCT01835145|Other|Laboratory Biomarker Analysis|Correlative studies
79349052|NCT01835145|Drug|Temozolomide|Given PO
79349053|NCT02229227|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
79349054|NCT02229227|Drug|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
79349055|NCT01499290|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
79349056|NCT01499290|Drug|Metronidazole|500 mg of Metronidazole
79349057|NCT01499290|Drug|Meropenem|1 gram of Meropenem
79500692|NCT05733767|Other|Nurse Practitioner Tobacco Treatment Team (NPT3)|Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
79500693|NCT05731895|Drug|BI 425809 (iclepertin)|BI 425809 (iclepertin)
79987810|NCT03523962|Drug|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used.
79349058|NCT01833897|Drug|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
79662377|NCT00283517|Drug|antipsychotics|as prescribed
79349059|NCT01833897|Drug|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
79662378|NCT00318435|Device|Stent or stent-graft deployment|
79662379|NCT00311883|Drug|hydroxychloroquine|
79662380|NCT00283556|Drug|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
79662381|NCT00283634|Drug|erlotinib and bortezomib|
79662382|NCT00318513|Drug|Bevacizumab|
79662383|NCT00283673|Behavioral|Exercise|
79662384|NCT00318552|Drug|Meropenem|
79662385|NCT00283751|Drug|insulin detemir|
79662386|NCT00283751|Drug|insulin glargine|
79662387|NCT00311922|Behavioral|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
79662388|NCT00311922|Behavioral|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
79662389|NCT00318630|Drug|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
79662390|NCT00318630|Drug|Placebo|Subjects will also receive placebo oral tablet.
79662391|NCT00283790|Drug|zolpidem tartrate|
79662392|NCT00318669|Drug|Paroxetine hydrochloride hydrate|
79662393|NCT00283829|Drug|docetaxel|chemotherapy
79662394|NCT00283829|Drug|IL2|immunotherapy
79662395|NCT00311961|Drug|Intravenous prednisolone|
79662396|NCT00311961|Drug|Oral prednisolone|
79662397|NCT00419211|Behavioral|Exercise|Tailored exercise program
79662398|NCT00283946|Drug|Zolpidem MR|Oral
79987811|NCT03523962|Drug|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the product used.
79987812|NCT02398708|Other|Questionnaires|Both groups will have questionnaires collected and compared.
79987813|NCT02398708|Other|Blood Sample|Both groups will have a blood sample collected and compared.
79662399|NCT00283946|Drug|Zolpidem|Oral
79662400|NCT00312000|Drug|capecitabine-irinotecan|"st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
79662401|NCT00312000|Drug|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
79500694|NCT05684887|Other|Digital based contact tracing|"Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~Immediate access to the contact list in Mamal Pro once validated by the health care worker.~Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~Contacts will be invited to go to the nearest testing facilities/units to get tested.~Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
79500695|NCT05676047|Behavioral|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
79500696|NCT05676047|Other|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
79500697|NCT05667493|Drug|Eplontersen|Eplontersen will be administered by SC injection.
79500698|NCT05660213|Drug|Huaier granule|Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
79500699|NCT05660213|Drug|Atezolizumab + Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
79662402|NCT00283985|Drug|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
79662403|NCT00283985|Drug|Methotrexate|3 gr/m2 at J1
79349060|NCT01833897|Drug|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
79662404|NCT00283985|Drug|Dexamethasone|40 mg/ per os at J1, J2 and J4.
79662405|NCT00283985|Drug|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
79662406|NCT00419250|Drug|lenalidomide|
79662407|NCT00419250|Drug|lenalidomide|
79662408|NCT00419250|Drug|lenalidomide|
79662409|NCT00419250|Drug|lenalidomide|
79349061|NCT01481896|Device|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
79349062|NCT02226653|Drug|Evacetrapib|Administered orally
79349063|NCT02201771|Drug|Aspirin|
79349064|NCT02201771|Drug|Ticagrelor|
79349065|NCT01460368|Drug|LY2409021|Administered orally
79349066|NCT01460368|Drug|Placebo|Administered orally
79349067|NCT01460368|Drug|Moxifloxacin|Administered orally
79349068|NCT02135705|Drug|Lomitapide|As prescribed by Physician.
79662410|NCT00419250|Drug|lenalidomide|
79662411|NCT00284024|Drug|domperidone|
79662412|NCT00284102|Procedure|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
79662413|NCT00312078|Dietary Supplement|Yogurt Supplementation|
79662414|NCT04718831|Dietary Supplement|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
79662415|NCT00318747|Drug|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
79987814|NCT02398708|Other|Stool Sample|Both groups will have a stool sample collected and compared.
79349069|NCT01460290|Drug|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
79349070|NCT01911533|Procedure|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
79349071|NCT01911533|Procedure|No extracorporeal CO2-removal|Patients are their own control group.
79349072|NCT04408456|Drug|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
79500700|NCT05660213|Drug|Camrelizumab+Apatinib|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
79500701|NCT05660213|Drug|Sintilimab+Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
79500702|NCT05658562|Drug|MT-2111|i.v. infusion
79500703|NCT05657691|Drug|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
79662416|NCT00284219|Device|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
79662417|NCT00284219|Device|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
79662418|NCT00312117|Drug|Sodium bicarbonate|
79662419|NCT00284258|Drug|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
79500704|NCT05657691|Drug|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
79500705|NCT05648110|Biological|AZD5156 (Parent study Sentinel Safety Cohort)|600 mg single dose of AZD5156 IM (300 mg of AZD1061 and 300 mg of AZD3152) on Visit 1 Day 1
79662420|NCT00284258|Drug|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
79662421|NCT00318786|Drug|biphasic insulin aspart|
79662422|NCT00284336|Drug|Caelyx|
79349073|NCT04408456|Other|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
79349074|NCT03026608|Behavioral|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
79349075|NCT02200211|Device|iPad®|Binocular therapy on iPad®
79987815|NCT02398708|Other|Clinical data|Both groups will have clinical data collected and compared.
79987816|NCT02398864|Procedure|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
79349076|NCT02200211|Other|Patching 2 hours per day, 7 days per week|
79349077|NCT01459666|Drug|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
79349078|NCT01459666|Drug|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
79500706|NCT05648110|Biological|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo IM
79500707|NCT05648110|Biological|EVUSHELD™ (Parent study Main Cohort)|600 mg single doses of EVUSHELD™ IM on Visit 1 Day 1 and on Visit 5 Day 181
79500708|NCT05648110|Biological|AZD3152 (Parent study Main Cohort)|300 mg single doses of AZD3152 IM on Visit 1 Day 1 and on Visit 5 Day 181
79500709|NCT05648110|Biological|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride IM for injection on Visit 1 Day 1 and Visit 5 Day 181
79500710|NCT05648110|Biological|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
79662423|NCT00284336|Drug|endoxan|
79662424|NCT00312156|Drug|insulin detemir|
79662425|NCT00312156|Drug|insulin NPH|
79349079|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
79500711|NCT05648110|Biological|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
79500712|NCT05648110|Biological|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
79500713|NCT05646589|Behavioral|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
79500714|NCT05646589|Behavioral|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
79500715|NCT05643794|Drug|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
79500716|NCT05643794|Other|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
79500717|NCT05628363|Device|Ethos Varian treatment system|Device that will be used to administer radiotherapy
79500718|NCT05628363|Radiation|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
79500719|NCT05628363|Drug|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
79987817|NCT03166306|Diagnostic Test|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
79987818|NCT02398630|Radiation|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
79987819|NCT02398630|Other|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
79987820|NCT02398630|Other|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
79349080|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
79987821|NCT02398630|Other|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
79349081|NCT01645475|Drug|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
79500720|NCT05626322|Drug|Maplirpacept|Intravenous infusion
79500721|NCT05626322|Drug|Tafasitamab|Intravenous infusion
79500722|NCT05626322|Drug|Lenalidomide|Oral (by mouth)
79500723|NCT05617599|Device|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
79500724|NCT05615922|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
79500725|NCT05615922|Behavioral|Word-Naming Activity|During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
79500726|NCT05608915|Other|No Cue|There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
79500727|NCT05608915|Other|Conventional Cue|Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
79500728|NCT05608915|Other|Constant Cue|The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
79500729|NCT05608915|Other|Patient hand-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
79987822|NCT03631914|Procedure|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
79987823|NCT02398552|Drug|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
79500730|NCT05608915|Other|Patient eye-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
79662426|NCT00312156|Drug|insulin aspart|
79662427|NCT00284414|Procedure|Ultrasonography or MRI|
79987824|NCT03345979|Combination Product|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
79987825|NCT03345979|Drug|Paliperidone Palmitate|Intramuscular injection
79987826|NCT04654338|Radiation|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
79349082|NCT04767113|Drug|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
79500731|NCT05608915|Other|Examiner-triggered|The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
79987827|NCT02696434|Drug|Naltrexone|daily dosing
79815975|NCT02604758|Behavioral|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
79987828|NCT02696434|Drug|Placebo|daily dosing
79308259|NCT02178592|Drug|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
79349083|NCT04767113|Drug|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
79308260|NCT03214445|Procedure|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
79349084|NCT02199509|Drug|Levetiracetam|Anticonvulsant
79500732|NCT05603650|Other|Lumineux Oral Essentials rinse|mouthrinse
79500733|NCT05603650|Other|Listerine rinse|mouthrinse
79500734|NCT05597371|Other|the use of the platform|the use of the platform
79500735|NCT05590325|Drug|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
79662428|NCT00284453|Procedure|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
79662429|NCT00318825|Drug|Nitrous oxide|
79815976|NCT02605382|Drug|Chlorhexidine gluconate|
79815977|NCT02605382|Drug|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
79500736|NCT05585918|Behavioral|SEL + Equity|For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.
79815978|NCT04114916|Dietary Supplement|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
79815979|NCT04114916|Dietary Supplement|maltodextrina|Two capsules daily at breakfast and dinner.
79815980|NCT04110860|Drug|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
79349085|NCT01458574|Drug|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
79662430|NCT04718753|Behavioral|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
79662431|NCT02959788|Other|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
79662432|NCT00284492|Procedure|Traditional chinese medicine type acupuncture|10 acupuncture sessions
79662433|NCT00284492|Behavioral|Self Care|Lifestyle advice on diet, physical activity
79662434|NCT00312234|Behavioral|Aerobic exercise|
79662435|NCT00312234|Behavioral|Qigong exercise|
79662436|NCT00284531|Drug|Daclizumab|
79662437|NCT00312273|Drug|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
79662438|NCT00312312|Biological|Specific immunotherapy|
79987829|NCT02696434|Drug|Buprenorphine|daily dosing
79987830|NCT05683093|Other|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
79987831|NCT04615416|Behavioral|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
79987832|NCT03345901|Drug|Pemafibrate|0.2 mg orally BID - twice daily
79500737|NCT05585918|Behavioral|SEL Only|For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
79987833|NCT03345901|Drug|Placebo|orally BID - twice daily
79815981|NCT04110860|Drug|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
79815982|NCT04110860|Drug|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
79815983|NCT04114760|Device|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
79987834|NCT02393092|Behavioral|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
79987835|NCT02393092|Behavioral|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
79987836|NCT02393092|Behavioral|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
79987837|NCT03166462|Other|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
79987838|NCT03166540|Other|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
79987839|NCT03166540|Other|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
79308261|NCT03214445|Procedure|Sealing margins with seal|Seal the margin of restoration with sealant without filler
79500738|NCT05583448|Device|ExploR Radial Head|Patient must have undergone primary or revision elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
79500739|NCT05580185|Device|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
79500740|NCT05578235|Procedure|stapled side-to-side anastomosis|Standard procedure for CD
79500741|NCT05578235|Procedure|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
79662439|NCT00284609|Behavioral|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
79987840|NCT02950831|Other|Accelerometry|Record of activity levels using a wrist worn accelerometer
79987841|NCT02392936|Procedure|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
79987842|NCT03709147|Drug|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
79662440|NCT00284609|Behavioral|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
79662441|NCT00318864|Behavioral|Cognitive behavioral therapy|
79662442|NCT00284648|Procedure|Surgical repair Achilles tendon rupture|
79662443|NCT00284648|Procedure|Non-surgical repair Achilles tendon rupture|
79815984|NCT04114760|Device|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
79987843|NCT03709147|Drug|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
79987844|NCT03709147|Drug|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
79662444|NCT00312351|Drug|Pegaptanib sodium|
79662445|NCT00284687|Drug|Artesunate|PO Artesunate
79662446|NCT00318942|Drug|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
79662447|NCT00318942|Drug|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
79662448|NCT00318942|Drug|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
79815985|NCT02604836|Drug|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
79987845|NCT03709147|Drug|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
79815986|NCT00588692|Device|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
79815987|NCT02604524|Device|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
79815988|NCT02604524|Other|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
79815989|NCT04114526|Other|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
79815990|NCT04110704|Procedure|Insertion of transvaginal cerclage|Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
79815991|NCT04110548|Procedure|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
79349086|NCT01458574|Drug|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
79500742|NCT05559476|Biological|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
79500743|NCT05559476|Biological|FLU HD vaccine|FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
79349087|NCT01458574|Drug|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
79349088|NCT02224703|Drug|GWP42003-P|
79349089|NCT02224703|Drug|Placebo Control|
79349090|NCT02198963|Drug|Hypochlorous acid solution 106 mg/L|test product
79349091|NCT02198963|Drug|0.1% (w/v) Sodium Lauryl Sulfate|positive control
79500744|NCT05546879|Drug|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
79500745|NCT05546879|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
79349092|NCT02198963|Drug|0.9% Physiological Saline, USP|negative control
79349093|NCT02074384|Device|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
79349094|NCT02074384|Device|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
79349095|NCT02074384|Other|Clinician|Survey of clinicians after study visits
79349096|NCT01458106|Drug|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
79349097|NCT01458106|Drug|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
79349098|NCT01457950|Drug|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
79349099|NCT01457950|Drug|placebo|double-blind phase: placebo subcutaneous injection, single dose
79500746|NCT05546879|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
79500747|NCT05546853|Drug|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
79815992|NCT04110548|Procedure|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
79987846|NCT03709147|Dietary Supplement|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
79662449|NCT00318942|Drug|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
79662450|NCT00284765|Procedure|flector|
79662451|NCT00312390|Procedure|Flicker|
79349100|NCT01457950|Drug|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
79349101|NCT01499134|Drug|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
79662452|NCT00312390|Procedure|Retinal Vessel Diameter|
79662453|NCT00312390|Procedure|Retinal Blood Flow|
79987847|NCT03709147|Drug|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
79987848|NCT02392858|Other|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
79349102|NCT01499134|Drug|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
79662454|NCT00312429|Procedure|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
79662455|NCT00284921|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
79662456|NCT00319059|Drug|systemic administration of 99mTc-HYNIC-Annexin A5|
79662457|NCT00319059|Behavioral|10 minutes of ischemic handgripping|
79662458|NCT00284999|Drug|Soothe|
79662459|NCT00284999|Drug|Refresh Tears|
79662460|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by lavage)|
79662461|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by bolus)|
79662462|NCT00312546|Drug|Enfuvirtide|90 mg subcutaneously twice daily
79815993|NCT05616104|Device|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
79987849|NCT02393170|Other|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
79987850|NCT02393170|Other|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
79349103|NCT02198651|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
79987851|NCT03709069|Dietary Supplement|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
79987852|NCT02398474|Drug|TFP block ropivacaine|
79987853|NCT02398474|Drug|ropivacaine infiltration of the iliac crest bone|
79349104|NCT02198651|Other|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
79662463|NCT00312546|Drug|Valproic acid|500 to 750 mg, taken orally twice daily
79662464|NCT00285077|Drug|SR57667B|
79662465|NCT00319137|Drug|GW274150|
79815994|NCT00915200|Dietary Supplement|N-acetylcysteine|600 mg orally twice daily for three months
79815995|NCT00915200|Dietary Supplement|silibin|480 mg orally twice daily for three months
79987854|NCT02398318|Device|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
79349105|NCT03026920|Procedure|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
79349106|NCT03026842|Drug|Decitabine|20 mg/m2/day for 5 days
79349107|NCT03026842|Drug|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
79349108|NCT03026842|Drug|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
79349109|NCT03026842|Drug|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
79500748|NCT05546853|Drug|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
79500749|NCT05546853|Drug|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
79500750|NCT05546853|Drug|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
79500751|NCT05546853|Drug|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
79662466|NCT00425009|Drug|Berberine|
79987855|NCT02398318|Device|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
79987856|NCT03710317|Drug|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
79987857|NCT03710317|Drug|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
79987858|NCT03710317|Drug|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
79987859|NCT02392780|Drug|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
79662467|NCT00425009|Drug|Metformin|
79662468|NCT00312585|Procedure|Acupuncture|
79662469|NCT00312585|Procedure|Sham comparator|
79662470|NCT00285116|Procedure|Clinical examination and radiological evaluation|
79662471|NCT00312624|Procedure|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
79662472|NCT04718402|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
79662473|NCT00319215|Drug|Ramelteon 8 mg|
79662474|NCT00319215|Drug|Zopiclone 7.5 mg|
79662475|NCT00285155|Drug|Bupropion|
79662476|NCT00285194|Drug|Allogeneic Islets of Langerhans|
79662477|NCT00285194|Drug|hOKT3γ1 (Ala-Ala)|
79662478|NCT00319293|Drug|Metformin|
79662479|NCT00285233|Biological|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
79662480|NCT00319332|Drug|Ibritumomab Tiuxetan|
79662481|NCT00319332|Drug|Iodine I 131 Tositumomab|
79662482|NCT00285350|Drug|mycophenolate mofetil|
79662483|NCT00312741|Procedure|empirical versus microbiological guided treatment|
79662484|NCT00285389|Drug|Adriblastin|
79815996|NCT00915200|Dietary Supplement|high-dose silibin|960 mg orally twice daily for three months
79987860|NCT02392780|Drug|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
79987861|NCT02392780|Drug|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
79349110|NCT01498822|Drug|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
79349111|NCT01498822|Drug|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
79349112|NCT04774211|Diagnostic Test|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
79349113|NCT01421849|Procedure|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
79349114|NCT01498120|Drug|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)~1 patch /day"
79349115|NCT01381211|Drug|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
79349116|NCT01381211|Drug|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
79815997|NCT00915200|Dietary Supplement|N-acetylcysteine placebo|excipient orally twice daily for three months
79987862|NCT03710239|Device|Dilapan-S|Synthetic osmotic dilator
79987863|NCT03710239|Device|Laminaria|Seaweed-based osmotic dilator
79349117|NCT01497262|Drug|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
79349118|NCT02224625|Drug|2% CHG Cloth solution|Investigational CHG
79349119|NCT02224625|Device|Vehicle Cloth|Excipients from CHG cloth only
79349120|NCT02224625|Drug|Active Comparator|Active comparator
79349121|NCT02224625|Other|Saline|Negative control
79349122|NCT02224625|Other|SLS|Provides a slight irritation for a positive control
79349123|NCT01195493|Other|Essential Oils solution|(Essential oils solution, Listerine®, Johnson & Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
79662485|NCT00285389|Drug|dexamethasone|
79662486|NCT00285389|Drug|Chlorambucil|
79662487|NCT00285389|Drug|rituximab|
79662488|NCT00285389|Drug|cyclophosphamide|
79662489|NCT00285389|Drug|alkeran|
79815998|NCT00915200|Dietary Supplement|silibin placebo|excipient orally twice daily for three months
79815999|NCT04108754|Other|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
79987864|NCT02393014|Procedure|Simple physical exercises|"The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
79987865|NCT04053478|Drug|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
79349124|NCT01195493|Other|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
79349125|NCT04094038|Drug|Olimel N12|A mixture of glucose, lipids, amino acids.
79349126|NCT04094038|Drug|Glucose IV|Glucose 5%
79349127|NCT00913679|Procedure|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
79349128|NCT00752453|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
79349129|NCT00752453|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
79349130|NCT00752453|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
79349131|NCT02197247|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
79662490|NCT00285389|Procedure|Total body irradiation (8Gy/4fr)|
79662491|NCT00285389|Drug|vincristine|0,4 mg/day day 1 to day 4
79662492|NCT00312780|Drug|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
79662493|NCT00285428|Drug|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
79349132|NCT02197247|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
79987866|NCT04053478|Drug|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
79349133|NCT02197247|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
79349134|NCT02197247|Procedure|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
79349135|NCT02197247|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
79349136|NCT02224157|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
79349137|NCT02224157|Drug|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
79349138|NCT02196701|Drug|Adalimumab|Administered by subcutaneous injection every other week.
79987867|NCT04053478|Drug|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
79987868|NCT04053478|Drug|Vasopressin|Vasopressin, at applicable concentrations based on literature
79987869|NCT04474392|Other|N/A (Observational Study)|Observational study, no intervention will be administered.
79987870|NCT05744518|Other|Response monitoring|Other: Response monitoring (no intervention)
79349139|NCT02196701|Drug|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
79987871|NCT02392390|Procedure|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
79987872|NCT02392390|Drug|Metvixia cream|
79349140|NCT04763291|Dietary Supplement|Juice Plus+ Fruit, Vegetable and Berry blends|Encapsulated juice powder concentrate derived from 36 dried fruits, vegetables and berries.
79987873|NCT02392546|Drug|elobixibat|
79987874|NCT02392546|Drug|placebo|
79349141|NCT04763291|Dietary Supplement|Juice Plus+ Omega blend|Encapsulated plant-based fatty acid supplement.
79349142|NCT04773119|Procedure|PVI only|Patients in this group receive PVI only
79349143|NCT04773119|Procedure|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
79349144|NCT01481116|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
79349145|NCT01481116|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
79349146|NCT01481116|Drug|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
79349147|NCT02222207|Drug|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
79349148|NCT02222207|Procedure|Sham IVT|Sham injections
79349149|NCT02222207|Drug|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
79987875|NCT02392702|Drug|C-10355|
79987876|NCT02392702|Drug|C-10358|
79987877|NCT02392702|Drug|Kalydeco|
79987878|NCT02392468|Drug|BI 409306 matching placebo|placebo
79987879|NCT02392468|Drug|BI 409306 matching placebo|placebo
79987880|NCT02392468|Drug|BI 409306|low dose
79987881|NCT02392468|Drug|BI 409306|high dose
79987882|NCT02397928|Device|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
79987883|NCT02397928|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
79987884|NCT02397928|Drug|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
79987885|NCT03593681|Device|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
79987886|NCT05744440|Drug|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10^7/kg, 5x10^7/kg) after chemotherapy with azacitidine
79349150|NCT02222207|Drug|Placebo|Placebo eye drops
79500752|NCT05541029|Behavioral|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
79662494|NCT00312819|Drug|chemotherapy +/- disulfiram|
79662495|NCT00319410|Procedure|vaginoscopic hysteroscopy|
79816000|NCT05654402|Diagnostic Test|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~Measurement of the distance between the carotid and femoral points with a tape measure (m).~Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~Before induction (awake without premedication)~During general anesthesia or loco-regional anesthesia~Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
79816001|NCT00588146|Drug|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
79816002|NCT00588146|Other|Standard care|Standard care
79816003|NCT02604602|Other|blood exam|laboratory test
79816004|NCT05653622|Procedure|Integrated boost technique (SIB) guided by PET FDOPA|intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy
79816005|NCT05613764|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms
79816006|NCT04110470|Diagnostic Test|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
79816007|NCT04110470|Diagnostic Test|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
79816008|NCT04110002|Behavioral|Injury Prevention Program|
79816009|NCT00795704|Drug|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
79349151|NCT01457014|Device|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
79500753|NCT05541029|Behavioral|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
79662496|NCT00312936|Behavioral|Mindfulness-based Stress Reduction (MBSR)|8 week program
79816010|NCT00795704|Drug|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
79816011|NCT02604368|Drug|SC411|Soft gelatin capsule
79816012|NCT02604368|Drug|Placebo|Soft gelatin capsule
79816013|NCT04108520|Other|Exercise|Exercise with respiratory training
79816014|NCT04108442|Behavioral|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
79816015|NCT04108442|Behavioral|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
79816016|NCT04108598|Other|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
79816017|NCT00444457|Biological|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
79349152|NCT01457014|Device|Continuous positive airway pressure|continuous positive airway pressure
79816018|NCT00444457|Biological|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
79349153|NCT01457014|Device|servo ventilation manual|servo ventilation titrated in manual mode
79349154|NCT02254421|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
79662497|NCT00319488|Drug|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
79662498|NCT00319488|Drug|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
79349155|NCT02254421|Drug|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
79662499|NCT00319488|Drug|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
79662500|NCT00285623|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
79662501|NCT00285662|Drug|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
79662502|NCT00319566|Drug|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
79816019|NCT05612360|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
79349156|NCT02252939|Radiation|X-Ray|X-ray as part of standard care
79349157|NCT02196077|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
79349158|NCT02196077|Drug|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
79349159|NCT02196077|Drug|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
79349160|NCT02196077|Drug|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
79662503|NCT00285701|Drug|hexaminolevulinate|
79662504|NCT00319605|Drug|Levetiracetam|
79662505|NCT00285740|Behavioral|Cognitive Behavioral Therapy (CBT) in a Group Format|
79662506|NCT00313053|Drug|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
79662507|NCT00313053|Drug|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
79816020|NCT00799058|Drug|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
79816021|NCT00799058|Drug|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
79662508|NCT00285896|Drug|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
79662509|NCT00285896|Drug|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
79349161|NCT02196077|Drug|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
79662510|NCT00319683|Drug|ADH300004|
79349162|NCT02195687|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
79662511|NCT00286052|Drug|Low Dose Naloxone|
79662512|NCT00319761|Drug|Calcitriol|
79662513|NCT00286130|Drug|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
79662514|NCT00286130|Drug|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
79662515|NCT00286130|Drug|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
79349163|NCT02195687|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
79662516|NCT00313092|Device|nCPAP treatment|treatment with positive air pressure during night
79816022|NCT00799058|Drug|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
79816023|NCT00725985|Drug|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
79816024|NCT00725985|Drug|Placebo|Placebo matched to cladribine tablets were administered.
79816025|NCT00725985|Drug|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
79349164|NCT02195531|Behavioral|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
79349165|NCT02252081|Drug|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
79349166|NCT02252081|Drug|Placebo|placebo pill(s) orally per day for 16 weeks
79662517|NCT00286208|Drug|Mifepristone, misoprostol|
79662518|NCT00319800|Drug|Gefitinib|
79349167|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
79662519|NCT00319800|Drug|Irinotecan|
79662520|NCT00286247|Genetic|INGN 201|
79662521|NCT00313131|Drug|tinidazole+fluconazole vs metronidazole+clotrimazole|
79662522|NCT00425048|Procedure|wearing gloves|
79816026|NCT04107974|Device|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
79816027|NCT04107974|Procedure|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
79816028|NCT04113824|Procedure|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
79816029|NCT04113824|Procedure|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
79816030|NCT04113980|Other|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
79816031|NCT04113980|Other|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
79816032|NCT04113980|Other|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
79662523|NCT00286286|Device|Intraperitoneal Aerosolization System, IntraMyst|
79662524|NCT00319878|Drug|Sirolimus|"Oral loading dose followed by a once daily dose:~Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
79662525|NCT00319878|Drug|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
79662526|NCT00286364|Drug|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
79662527|NCT00319917|Drug|tacrolimus|oral
79662528|NCT00319917|Drug|placebo|oral
79662529|NCT00286403|Drug|Fenoldopam Mesylate and/or MESNA|
79662530|NCT00313287|Drug|clevudine|
79662531|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
79662532|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
79662533|NCT00286481|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
79662534|NCT00425139|Behavioral|Re-Mission|
79662535|NCT00286520|Procedure|Transanal irrigation with Peristeen Anal Irrigation|
79662536|NCT00320034|Drug|R-albuterol, S-albuterol|
79662537|NCT00286559|Drug|SonoVue|
79662538|NCT00286559|Drug|Optison|
79662539|NCT02959710|Drug|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
79500754|NCT05541029|Other|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of >1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
79500755|NCT05530291|Other|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
79500756|NCT05530070|Other|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
79662540|NCT02959710|Drug|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
79349168|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
79662541|NCT02959710|Drug|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz [237 mL of Ensure® Original] at Hour 0 on Day 1)
79349169|NCT01623596|Drug|Fingolimod|
79349170|NCT01623596|Drug|Disease Modifying therapy|
79349171|NCT02219477|Drug|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
79349172|NCT02219477|Drug|dasabuvir|tablet
79349173|NCT02219477|Drug|ribavirin|tablet
79349174|NCT02119286|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
79500757|NCT05530070|Other|Standard of care|Patients will receive standard of care and baseline dietary education.
79500758|NCT05530070|Diagnostic Test|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
79500759|NCT05519878|Other|Best Practice|Undergo routine treatment and usual follow up care
79500760|NCT05519878|Device|Bright White Light Therapy|Undergo bright white therapy
79500761|NCT05519878|Behavioral|Occupational Therapy|Undergo occupational therapy
79500762|NCT05519878|Other|Questionnaire Administration|Complete questionnaires
79662542|NCT00286598|Behavioral|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
79816033|NCT04109768|Behavioral|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
79816034|NCT00793910|Drug|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
79816035|NCT00793910|Drug|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
79987887|NCT03734627|Drug|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
79662543|NCT00425178|Drug|FGF-1|
79662544|NCT00286676|Drug|Nutropin|
79987888|NCT03734627|Drug|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
79987889|NCT03734627|Drug|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
79349175|NCT02119286|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
79349176|NCT02119286|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
79349177|NCT02119286|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
79349178|NCT02250443|Drug|BYM338 (Bimagrumab)|
79349179|NCT02093390|Drug|TAK-385|TAK-385 tablets
79349180|NCT02093390|Drug|Fluconazole|Fluconazole tablets
79349181|NCT02093390|Drug|Atorvastatin|Atorvastatin tablets
79349182|NCT02194985|Drug|migalastat HCl 150 mg|Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
79349183|NCT02219087|Drug|Liposomal bupivacaine|
79662545|NCT00286676|Procedure|Oral Glucose Tolerance Test|
79662546|NCT00286676|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
79987890|NCT03734627|Drug|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
79662547|NCT00286676|Procedure|Computed Tomography (CT) Scan|
79987891|NCT03734627|Diagnostic Test|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
79987892|NCT02397850|Behavioral|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
79349184|NCT02219087|Drug|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
79816036|NCT04113902|Behavioral|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
79816037|NCT02592525|Behavioral|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
79349185|NCT02248961|Drug|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
79349186|NCT02248961|Drug|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg
79816038|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
79987893|NCT02397850|Behavioral|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
79349187|NCT02219009|Device|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
79349188|NCT02248649|Behavioral|Structured physical activity|Walking instruction and encouragement
79349189|NCT02248649|Behavioral|Health education|Provision of general information about a variety of health topics
79349190|NCT02218541|Device|abutment margin 0.5 mm subgingival|
79500763|NCT05519228|Device|ToggleLoc 2.9 mm Soft Tissue System|The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
79500764|NCT05517811|Diagnostic Test|TEG indices|Blood samples
79662548|NCT00320073|Drug|erlotinib hydrochloride|75 mg to 150mg
79662549|NCT00320073|Drug|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
79987894|NCT02397772|Drug|albendazole|Single dose of albendazole (400 mg)
79987895|NCT03592745|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
79500765|NCT05510245|Drug|PF-07081532|One PF-07081532 20 mg tablet, administered orally
79987896|NCT03592745|Device|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
79662550|NCT00320073|Drug|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
79349191|NCT02218541|Device|abutment margin 1.5 mm subgingival|
79349192|NCT02217527|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
79349193|NCT02217527|Drug|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
79349194|NCT01456936|Drug|Placebo|Triple dummy placebo for each treatment arm
79349195|NCT01456936|Drug|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
79662551|NCT00286832|Procedure|PET scan|One extra PET scan after 1 cycle of treatment.
79662552|NCT00313326|Procedure|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
79662553|NCT00286871|Drug|Neoral|
79662554|NCT00286871|Drug|Tacrolimus|
79662555|NCT00417326|Drug|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
79662556|NCT00417326|Drug|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
79662557|NCT00320229|Drug|abciximab|
79662558|NCT00313365|Procedure|Surgical Lavage (Arthrotomy)|
79662559|NCT00313365|Procedure|Arthrocentesis (Serial needle aspiration)|
79662560|NCT00417365|Device|WaterWorks Douching Device|
79662561|NCT00320268|Drug|Quetiapine fumarate|
79662562|NCT00417404|Drug|Aquasol A|IM Aquasol A 10,000IU three times weekly
79349196|NCT01456936|Drug|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
79987897|NCT02398162|Procedure|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
79349197|NCT01456936|Drug|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
79349198|NCT01456780|Drug|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
79349199|NCT01456780|Drug|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
79500766|NCT05510128|Other|Pharmacist management|"When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~Completion of the acute cystitis symptoms score (ACSS) questionnaire.~Measure the temperature.~Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made."
79500767|NCT05507164|Drug|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
79500768|NCT05500690|Dietary Supplement|Folic Acid Tablet|5 mg folic acid supplement
79500769|NCT05484804|Other|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
79662563|NCT00417404|Drug|aquasol A|10,000 IU three times weeks, by intramuscular injection
79662564|NCT00417404|Other|sham injection|sham injection
79987898|NCT02398162|Procedure|Single Blood Collection|On the enrollment day
79987899|NCT03165838|Behavioral|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
79987900|NCT03165838|Behavioral|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
79987901|NCT02398006|Other|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
79349200|NCT01456780|Drug|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
79349201|NCT01480258|Biological|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis [acellular, component], hepatitis B [recombinant DNA], polio virus [inactivated], and Haemophilus influenza type b conjugate vaccine [adsorbed]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
79500770|NCT05484804|Other|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
79500771|NCT05470023|Other|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
79500772|NCT05427253|Drug|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
79500773|NCT05427253|Drug|Placebo|Placebo for C106 solution
79662565|NCT00313404|Biological|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
79662566|NCT00417443|Drug|Clonidine|
79662567|NCT00313482|Drug|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
79662568|NCT00313482|Drug|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
79662569|NCT00313482|Drug|Prednisone|5 mg orally BID on Day 1 continuously
79349202|NCT01480258|Biological|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
79349203|NCT01480258|Biological|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
79662570|NCT00417521|Behavioral|Family-Based Treatment|
79662571|NCT00286988|Drug|Topiramate|
79662572|NCT00320307|Drug|abacavir|
79662573|NCT00287027|Drug|Risperdal Long Acting Injectable Antipsychotic Medication|
79662574|NCT00320346|Biological|Pandemic Influenza Vaccine|
79816039|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
79816040|NCT04113668|Drug|BMS-986165|Specified Dose on Specified Days
79816041|NCT04113668|Drug|diflunisal|Specified Dose on Specified Days
79500774|NCT05416814|Dietary Supplement|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
79349204|NCT01480258|Biological|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis [DTaP], Hepatitis B [HepB], Poliovirus [IPV] and Haemophilus influenzae type b [Hib] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
79349205|NCT01479868|Drug|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
79349206|NCT01479868|Drug|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
79349207|NCT01479868|Drug|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
79349208|NCT01478620|Drug|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
79662575|NCT02960906|Drug|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
79500775|NCT05414500|Drug|Mogamulizumab|Administered IV
79816042|NCT00444145|Drug|Prevacid|30 mg bid for 3 months
79816043|NCT00444145|Procedure|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
79816044|NCT04108286|Device|1-DAY ACUVUE MOIST|TEST
79816045|NCT04108286|Device|DAILIES AQUA COMFORT PLUS|CONTROL
79816046|NCT04107896|Drug|Silodosin|Cap silodosin
79816047|NCT04107896|Drug|Tamsulosin|Cap tamsulosin
79816048|NCT05582720|Behavioral|Conventional burger|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
79816049|NCT05582720|Behavioral|Vegan burger|Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
79816050|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
79816051|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
79816052|NCT04113590|Procedure|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
79500776|NCT05414500|Drug|Brentuximab vedotin|Administered IV
79500777|NCT05409924|Drug|ATR-258|Single Ascending Dose
79500778|NCT05409924|Drug|ATR-258|Multiple Ascending Dose
79500779|NCT05409924|Drug|ATR-258|Repeat Dose
79500780|NCT05406570|Procedure|Standardized ventilation|Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
79816053|NCT04106882|Drug|Ketones|Supplement administered mid-scan.
79816054|NCT04106882|Drug|Glucose|Supplement administered mid-scan.
79816055|NCT00725283|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|Intramuscular administration
79987902|NCT02398006|Other|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
79987903|NCT03592277|Drug|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
79987904|NCT03592277|Drug|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
79662576|NCT02960906|Drug|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
79987905|NCT02398084|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
79987906|NCT03730805|Behavioral|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller & Rollnick, 1991).
79987907|NCT03730805|Behavioral|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
79662577|NCT02960906|Drug|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
79662578|NCT02960906|Drug|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
79662579|NCT04717830|Drug|Gamezumab|solution for infusion
79662580|NCT00287066|Drug|Inhaled Human Insulin|
79662581|NCT00287066|Drug|Regular Human Insulin|
79662582|NCT00313521|Drug|thiotepa|
79987908|NCT03730805|Behavioral|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
79987909|NCT03167866|Behavioral|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
79987910|NCT03167866|Behavioral|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
79987911|NCT03734471|Device|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
79987912|NCT03734471|Procedure|Tube thoracostomy|Traditional chest tube placement
79987913|NCT03730727|Behavioral|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
79500781|NCT05406570|Procedure|Personalized ventilation|Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
79500782|NCT05402345|Drug|GlcNAc-GlcN|GlcNAc eye drops
79500783|NCT05402345|Other|Placebo|Placebo eye drops
79500784|NCT05402332|Drug|AVTX-801|D-Galactose medical grade supplement
79500785|NCT05385471|Biological|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
79662583|NCT00313521|Procedure|adjuvant therapy|
79662584|NCT00313521|Radiation|radiation therapy|
79662585|NCT00320463|Biological|DTPa-HBV-IPV/Hib vaccine|
79662586|NCT00419289|Behavioral|follow-up rehabilitation of participants with COPD|
79662587|NCT00287183|Drug|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
79662588|NCT00287183|Other|Placebo|Placebo
79662589|NCT00419406|Procedure|UVA1 phototherapy|
79662590|NCT00419406|Procedure|NB-UVB phototherapy|
79662591|NCT00287261|Drug|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
79662592|NCT00313599|Drug|lapatinib|
79662593|NCT00313599|Drug|paclitaxel|
79662594|NCT00287300|Drug|Sulfadoxine-Pyrimethamine|
79662595|NCT00287300|Drug|Azithromycin|
79662596|NCT00287300|Drug|Artesunate|
79662597|NCT00313755|Procedure|Narrow Band Imaging|
79662598|NCT00320502|Drug|BXT-51072|
79662599|NCT00287378|Drug|omalizumab|omalizumab as per weight and IgE
79500786|NCT05367960|Drug|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents <43 kg)
79500787|NCT05363683|Procedure|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
79662600|NCT00320580|Drug|norelgestromin/ethinyl estradiol|
79500788|NCT05363683|Procedure|Standard Care|Standard care post-operative physical therapy
79349209|NCT01455220|Drug|Tysabri ® (Natalizumab)|IV, monthly
79349210|NCT01454830|Behavioral|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
79349211|NCT01454830|Other|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
79349212|NCT01454596|Biological|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
79500789|NCT05360901|Behavioral|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
79500790|NCT05360082|Other|[11C]UCB-J|11C-labeled SV2A binding PET radioligand
79500791|NCT05360082|Other|[18F]SynVest-1|18F-labeled SV2A binding PET radioligand
79662601|NCT00287417|Device|echography|
79662602|NCT00287417|Other|blood sample|
79349213|NCT01454596|Drug|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
79349214|NCT01454596|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
79349215|NCT01454596|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
79349216|NCT04542850|Dietary Supplement|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
79349217|NCT02247479|Drug|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
79500792|NCT05346692|Other|Survey Administration|Complete Survey
79500793|NCT05346692|Other|Interview|Complete Interview
79500794|NCT05346692|Other|Text Message-Based Navigation Intervention|Complete mindfulness intervention
79662603|NCT00320619|Drug|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
79662604|NCT00320619|Drug|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
79500795|NCT05346692|Other|Interview|Complete interview
79500796|NCT05336253|Behavioral|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
79500797|NCT05336253|Behavioral|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
79662605|NCT00287456|Device|Insulin Pump|
79662606|NCT00287456|Drug|Insulin|0
79662607|NCT00287456|Procedure|Oral Glucose Tolerance Test|0
79662608|NCT00287456|Procedure|Whole body Protein Turnover|0
79662609|NCT00313833|Drug|Buprenorphine transdermal delivery system|
79662610|NCT00287495|Drug|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
79662611|NCT00320658|Biological|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
79662612|NCT00320658|Biological|CPG 7909|Adjuvant
79662613|NCT00287534|Drug|Anastrozole|oral
79662614|NCT00287534|Drug|Tamoxifen|oral
79662615|NCT00313872|Drug|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre & Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre & post hydration (if Mg <WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
79662616|NCT00313872|Drug|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
79349218|NCT02247479|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
79349219|NCT01454284|Drug|Glargine|
79349220|NCT01454284|Drug|LY2605541|
79349221|NCT01454284|Drug|Insulin Lispro|
79349222|NCT04541290|Drug|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
79349223|NCT02247401|Drug|2 DAA|ABT-450/r/ABT-267 tablets
79349224|NCT02247401|Drug|RBV|Ribavirin tablets
79349225|NCT02247011|Other|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
79349226|NCT02247011|Radiation|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
79349227|NCT02247011|Radiation|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
79349228|NCT02247011|Other|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
79349229|NCT02246777|Device|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
79662617|NCT00287573|Device|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
79662618|NCT00287573|Procedure|Brachytherapy (beta source)|Brachytherapy (beta source)
79816056|NCT00444067|Device|Spinal Sealant|Spinal Sealant System
79816057|NCT00444067|Other|Standard of Care|Standard of Care
79987914|NCT03730727|Dietary Supplement|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
79987915|NCT03115138|Other|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
79987916|NCT05665517|Device|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q&A) corpora were formed."
79987917|NCT03106402|Drug|topical bromfenac sodium hydrate|
79349230|NCT01495702|Drug|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
79349231|NCT01495702|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
79349232|NCT01495702|Drug|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
79349233|NCT01630889|Drug|Roxadustat|Oral capsule
79349234|NCT01495000|Drug|denosumab|60mg subcutaneous injection, single dose
79349235|NCT01495000|Drug|placebo|placebo subcutaneous injection, single dose
79349236|NCT01494922|Drug|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
79349237|NCT02192099|Drug|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
79662619|NCT00320697|Drug|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
79662620|NCT00320697|Drug|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
79662621|NCT00287612|Procedure|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
79662622|NCT00287612|Procedure|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
79500798|NCT05333523|Radiation|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
79816058|NCT01323283|Dietary Supplement|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
79987918|NCT03730571|Device|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
79349238|NCT01494610|Drug|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
79349239|NCT01494610|Drug|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
79349240|NCT02116777|Other|Laboratory Biomarker Analysis|Correlative studies
79662623|NCT00287651|Procedure|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
79349241|NCT02116777|Other|Pharmacological Study|Correlative studies
79349242|NCT02116777|Drug|Talazoparib|Given PO
79349243|NCT02116777|Drug|Temozolomide|Given PO
79349244|NCT01494532|Drug|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
79662624|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
79349245|NCT01494532|Drug|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
79349246|NCT02191397|Drug|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
79349247|NCT02191397|Drug|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
79349248|NCT02191397|Drug|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
79349249|NCT02191397|Drug|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
79349250|NCT01630811|Drug|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
79662625|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
79662626|NCT00322296|Drug|Bexarotene 1% gel|
79662627|NCT00320736|Drug|galantamine|
79816059|NCT01323283|Dietary Supplement|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
79816060|NCT00789854|Drug|Quetiapine XR|300 mg once daily (od)
79816061|NCT00789854|Drug|Lithium carbonate|900 mg once daily (od)
79816062|NCT00789854|Drug|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
79987919|NCT03106168|Procedure|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
79987920|NCT03734159|Drug|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
79349251|NCT01630811|Other|Placebo|Placebo will be given once daily for 7 days.
79349252|NCT03027076|Procedure|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
79349253|NCT03027076|Procedure|Collect midstream urine samples|Collect midstream urine samples
79349254|NCT02169791|Drug|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
79349255|NCT02216591|Device|Active Cognitive Training (ACT)|
79349256|NCT02216591|Device|Control (CON)|
79349257|NCT02216357|Drug|Ifetroban, Oral Capsule|
79662628|NCT00287768|Drug|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
79662629|NCT00287768|Drug|S-1|S-1 po days 1-28 every 6 weeks
79816063|NCT00725205|Biological|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms [mcg]/killogram [kg]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
79349258|NCT02216357|Drug|Placebo, Oral Capsule|
79349259|NCT01492426|Drug|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
79349260|NCT01492426|Drug|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
79816064|NCT00725205|Drug|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
79816065|NCT01323361|Procedure|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
79816066|NCT00443755|Drug|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
79816067|NCT00443755|Drug|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
79816068|NCT00443755|Drug|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
79349261|NCT01492426|Drug|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
79349262|NCT01492426|Drug|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
79349263|NCT01453348|Biological|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
79349264|NCT01453348|Biological|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 & 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
79349265|NCT01453348|Biological|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
79349266|NCT01453348|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
79349267|NCT04076410|Device|Z1 lens|CE marked device
79349268|NCT04076410|Device|Experimental Lens 1|CE marked device
79349269|NCT04076410|Device|Experimental Lens 2|CE marked device
79349270|NCT04076410|Device|Experimental Lens 3|CE marked device
79500799|NCT05333523|Radiation|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
79500800|NCT05330884|Biological|BCG vaccine|0.1ml BCg vaccine to be given intradermally
79500801|NCT05330884|Drug|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
79349271|NCT04076410|Device|Experimental Lens 4|CE marked device
79349272|NCT01453036|Procedure|23S rRNA point mutation test of Helicobacter pylori|mutation test group>> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group >> no intervention
79500802|NCT05327959|Device|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
79816069|NCT00724971|Drug|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
79816070|NCT00724971|Drug|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
79349273|NCT01453036|Procedure|UBT test & Gastroenterology with biopsy c silver stain|UBT test & Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group >> intervention
79349274|NCT01475734|Biological|albiglutide|subcutaneous injection
79349275|NCT01475734|Biological|placebo|subcutaneous injection
79349276|NCT01452412|Drug|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
79349277|NCT01452412|Drug|Placebo|To be taken on the same schedule as the active arm
79987921|NCT03734159|Drug|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
79987922|NCT02397382|Drug|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8.
79500803|NCT05307237|Device|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
79662630|NCT00320775|Drug|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
79662631|NCT00287807|Behavioral|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
79662632|NCT00320814|Drug|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
79662633|NCT00287846|Drug|imatinib mesylate|
79987923|NCT02397382|Drug|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
79662634|NCT00322413|Drug|Epoetin|
79662635|NCT00320853|Drug|Vitamin D|
79987924|NCT02397382|Drug|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
79662636|NCT00287885|Drug|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
79662637|NCT00287924|Drug|methotrexate|
79662638|NCT00287924|Procedure|adjuvant therapy|
79662639|NCT00322530|Procedure|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
79662640|NCT00287963|Drug|topotecan hydrochloride|
79662641|NCT00287963|Drug|vinorelbine tartrate|
79662642|NCT00320892|Drug|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
79987925|NCT02397382|Drug|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
79349278|NCT04409392|Other|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
79349279|NCT01491802|Drug|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
79662643|NCT00288002|Biological|trastuzumab|
79662644|NCT00288002|Drug|capecitabine|
79662645|NCT00288002|Drug|cyclophosphamide|
79349280|NCT01491802|Drug|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
79349281|NCT02168777|Drug|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
79662646|NCT00288002|Drug|docetaxel|
79662647|NCT00288002|Drug|epirubicin hydrochloride|
79662648|NCT00288002|Procedure|adjuvant therapy|
79662649|NCT00288002|Procedure|conventional surgery|
79662650|NCT00288002|Procedure|neoadjuvant therapy|
79662651|NCT00322569|Device|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
79662652|NCT00322569|Device|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
79662653|NCT00322569|Device|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
79662654|NCT00288041|Drug|carboplatin|Given IV
79987926|NCT02397382|Drug|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
79987927|NCT02397382|Drug|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
79662655|NCT00288041|Drug|paclitaxel|Given IV
79662656|NCT00288041|Drug|bortezomib|Given IV
79662657|NCT00320970|Drug|Candesartan|
79662658|NCT00322608|Drug|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
79662659|NCT00288158|Drug|Allopurinol|
79662660|NCT00288158|Drug|Probenecid|
79662661|NCT00288158|Drug|Placebo|
79662662|NCT04717752|Drug|Ovidrel|recombinant human chorionic gonadotropin for injection
79662663|NCT04717752|Drug|Troprilin|triptorelin acetate injection
79662664|NCT00288197|Drug|voriconazole|
79662665|NCT00288236|Drug|Rimonabant (SR141716)|
79662666|NCT00288236|Drug|Placebo|
79662667|NCT00322686|Drug|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
79662668|NCT00322686|Drug|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
79816071|NCT00443599|Drug|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
79816072|NCT00443599|Other|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
79816073|NCT02604056|Behavioral|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
79816074|NCT02604056|Behavioral|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
79816075|NCT04113512|Other|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
79816076|NCT02592369|Device|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
79816077|NCT04107428|Drug|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
79816078|NCT04107428|Drug|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
79816079|NCT02603978|Behavioral|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
79816080|NCT02603978|Behavioral|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
79349282|NCT02168777|Drug|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
79349283|NCT01491178|Drug|Prazaxa|Dabigatran etexilate
79349284|NCT02189837|Biological|Evolocumab|Administered by subcutaneous injection
79349285|NCT02189837|Drug|Atorvastatin|Administered by mouth
79349286|NCT02189837|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
79349287|NCT02189837|Drug|Placebo to Atorvastatin|Administered by mouth
79349288|NCT02216123|Drug|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
79349289|NCT02216123|Drug|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
79662669|NCT00321087|Drug|T2000|Dose escalation from 600 to 1000 mg
79662670|NCT00321087|Drug|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
79662671|NCT00321087|Drug|T2000|Placebo followed by dose escalation from 600 to 1000
79662672|NCT00288314|Procedure|Magnetic Resonance Imaging, Functional|Structural and functional MRI
79662673|NCT00321126|Drug|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
79662674|NCT00288353|Drug|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
79662675|NCT00288353|Drug|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
79662676|NCT00288392|Drug|Soluble beta-1,3/1,6-glucan|
79662677|NCT00322764|Drug|Uridine|
79500804|NCT05307237|Device|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
79816081|NCT02603978|Behavioral|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
79662678|NCT00288431|Drug|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
79662679|NCT00288431|Drug|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
79816082|NCT00455143|Drug|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
79500805|NCT05298358|Biological|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~Thymoglobulin 0.5 mg/kg IV day -9~Thymoglobulin 2 mg/kg IV Days -8, -7~Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~Total body irradiation (TBI) 400cGy~Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~Cy 50 mg/kg IV Days 3, 4~Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~Mesna- 10 mg/kg/ IV Day 3, 4~Patients will receive infection prophylaxis and treatment according to institutional guidelines."
79349290|NCT02216123|Drug|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
79349291|NCT02216123|Drug|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
79500806|NCT05289349|Drug|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
79662680|NCT00321165|Drug|taurolidine|
79349292|NCT02216123|Drug|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
79662681|NCT04718363|Other|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
79662682|NCT04718363|Other|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
79662683|NCT04718363|Other|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
79662684|NCT00322803|Drug|ELB139|
79662685|NCT00417560|Biological|inactivated influenza A/H5N1 vaccine|
79662686|NCT00321204|Procedure|TZD reducing the incidence of atrial arrhythmias|
79662687|NCT00417599|Behavioral|Lifestyle Intervention|lifestyle intervention .
79662688|NCT00417599|Other|control group|waiting list control group
79662689|NCT00322920|Drug|Topotecan|
79662690|NCT00322920|Drug|Cisplatin|
79662691|NCT00417638|Device|Endovascular cooling by the Celsius Control System|
79816083|NCT00455143|Drug|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
79662692|NCT00417638|Other|Standard of care|
79662693|NCT00321009|Drug|Enoxaparin|
79662694|NCT00417677|Drug|Combination of Temsirolimus and Sunitinib|
79662695|NCT00417716|Drug|Intravitreal Bevacizumab|
79662696|NCT00321243|Behavioral|Visual clues|
79662697|NCT00321282|Procedure|Atrial Fibrillation|
79662698|NCT00288470|Device|Hylaform, Hylaform Plus (hylan B gel)|
79662699|NCT00321360|Drug|Propofol|
79662700|NCT00321360|Device|Patient maintained sedation|
79500807|NCT05289349|Drug|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
79500808|NCT05278000|Other|Presence of scarcity mindset|"This observational study will examine whether~Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~Individuals with higher rates of future discounting have lower adherence to controller medication~Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
79500809|NCT05267626|Drug|AU-007|Monoclonal Antibody Targeting IL-2
79500810|NCT05267626|Drug|Aldesleukin|IL-2
79500811|NCT05263011|Other|Avocado|1 avocado as evening snack
79500812|NCT05263011|Other|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
79500813|NCT05263011|Other|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
79500814|NCT05241223|Other|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
79500815|NCT05241223|Other|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
79500816|NCT05228158|Drug|Tazemetostat|Tazemetostat oral tablets.
79662701|NCT02960594|Biological|INO-1400|
79662702|NCT02960594|Biological|INO-9012|
79662703|NCT02960594|Biological|INO-1401|
79662704|NCT00288548|Drug|Metoprolol|
79662705|NCT00321477|Drug|GW679769 oral tablets|
79816084|NCT00454987|Biological|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
79662706|NCT00288665|Device|Export catheter (Medtronic)|
79816085|NCT00454987|Biological|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
79500817|NCT05220254|Behavioral|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
79500818|NCT05220098|Drug|TAK-280|Participants will receive TAK-280 as IV infusion.
79500819|NCT05217888|Device|Sentinel|cerebral protection devices during transfemoral transcatheter aortic valve replacement
79500820|NCT05216250|Biological|BOTOX|Intramuscular injection
79500821|NCT05216250|Drug|Placebo for BOTOX|Intramuscular injection
79662707|NCT00321516|Drug|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
79662708|NCT06140277|Procedure|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
79816086|NCT00724893|Biological|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
79662709|NCT06140277|Procedure|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
79816087|NCT00724893|Drug|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
79816088|NCT00789698|Drug|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
79987928|NCT02397304|Other|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
79662710|NCT06140277|Procedure|tooth extraction only|hopeless tooth will be extracted without any intervention
79816089|NCT00789698|Drug|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
79662711|NCT06140251|Drug|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
79816090|NCT00724815|Drug|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
79816091|NCT00724815|Drug|Placebo|NP101 Placebo iontophoretic transdermal patch
79816092|NCT00454909|Biological|Meningococcal vaccine 134612|Single dose intramuscular injection.
79816093|NCT00454909|Biological|Menactra®|Single dose intramuscular injection.
79816094|NCT00798590|Drug|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
79816095|NCT00798590|Drug|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
79816096|NCT05368155|Behavioral|Brief ACT for Pelvic Pain|The Brief ACT for Pelvic Pain treatment will include three weekly, 90-minute group sessions that teach Veterans new ways to respond to difficult thoughts and emotions related to pain (Acceptance and Mindfulness Training) and encourage behavioral (re)engagement in meaningful life activities (Behavioral Change Training). The overall goal is to cultivate psychological flexibility by helping Veterans learn to respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. Workshop content is integrated with education on pelvic pain (its diagnostic criteria, etiology, and associated health outcomes) to increase alignment of the treatment with patient needs.
79500822|NCT05201456|Device|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
79500823|NCT05199584|Drug|ENV-101 (taladegib)|tablets dosed once-daily
79500824|NCT05199272|Drug|23ME-00610|23ME-00610 given by IV infusion
79500825|NCT05194293|Biological|Durvalumab|Given IV
79500826|NCT05194293|Drug|Regorafenib|Given PO
79500827|NCT05188664|Drug|LM-302|LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
79500828|NCT05188664|Drug|Toripalimab|Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
79500829|NCT05183048|Drug|[89Zr]Panitumumab Tracer|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
79500830|NCT05179187|Behavioral|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
79500831|NCT05178121|Behavioral|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
79500832|NCT05177835|Drug|ABX464|All subjects will receive ABX464 given at 25 mg QD.
79500833|NCT05174052|Drug|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
79500834|NCT05174052|Drug|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
79500835|NCT05171764|Device|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
79500836|NCT05169047|Other|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
79500837|NCT05169047|Other|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
79500838|NCT05163821|Diagnostic Test|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
79500839|NCT05163821|Diagnostic Test|ACE-III Somali Translation|Cognitive screen for dementia
79500840|NCT05162365|Biological|IBI314|Low/medium/high dose, intravenously, once, on Day 1
79500841|NCT05162365|Other|Placebo|Placebo, intravenously, once, on Day 1
79662712|NCT06140238|Drug|Parecoxib|Parecoxib administration 15 minutes before start surgical operation
79662713|NCT06140238|Drug|Normal saline|Normal saline administration 15 minutes before start surgical operation
79816097|NCT05366673|Other|massage|Perform a 10-minute back massage every day for a week
79816098|NCT01020175|Procedure|Bone marrow transplantation|Patients received bone marrow transplantation
79816099|NCT01020175|Procedure|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
79662714|NCT06140225|Behavioral|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
79816100|NCT01024933|Behavioral|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
79816101|NCT01024933|Behavioral|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
79816102|NCT00481195|Drug|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day [2 tablets]) was allowed. The dosage could not be increased after it was decreased.
79987929|NCT04869826|Device|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD_2020 universal protocol.
79987930|NCT03401112|Drug|IMR-687|Oral administration of IMR-687 once daily with or without HU.
79349293|NCT02189759|Other|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
79500842|NCT05150938|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
79500843|NCT05150938|Drug|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
79500844|NCT05150938|Drug|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
79500845|NCT05150938|Drug|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
79662715|NCT06140225|Behavioral|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
79662716|NCT06140225|Behavioral|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
79662717|NCT06140225|Behavioral|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
79662718|NCT06140225|Behavioral|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
79662719|NCT06140225|Behavioral|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
79662720|NCT06140225|Behavioral|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
79662721|NCT06140212|Behavioral|Montreal Cognitive Assessment (MoCA)|MoCA would be used to assess participants cognitive functioning.
79662722|NCT06140212|Behavioral|Chinese ICOPE screening tool (self-administration and interview versions)|The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.
79662723|NCT06140212|Behavioral|Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
79662724|NCT06140199|Procedure|Pit-picking surgery|Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
79662725|NCT06140199|Procedure|Pit-picking surgery with Sinus Laser assisted Closure|The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
79662726|NCT06140160|Procedure|Doppler ultrasound|To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
79662727|NCT06140134|Procedure|Liver Transplant|Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
79662728|NCT06140095|Drug|Evolocumab|See arm description
79349294|NCT02189759|Other|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
79349295|NCT02189759|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
79500846|NCT05146453|Procedure|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
79500847|NCT05146453|Other|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
79500848|NCT05110690|Behavioral|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
79662729|NCT06140082|Genetic|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
79662730|NCT06140069|Other|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
79662731|NCT06140056|Other|Airway pressure release ventilation|Mechanical ventilation mode
79662732|NCT06140056|Other|Volumen controlled mechanical ventilation|Mechanical ventilation mode
79349296|NCT02189759|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
79349297|NCT01490866|Drug|Axitinib|5-mg tablets PO BID
79662733|NCT06140043|Other|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
79662734|NCT06139978|Behavioral|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
79662735|NCT06139965|Other|Validity and Reliability|Assessment study
79662736|NCT06139952|Drug|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
79987931|NCT03401112|Drug|Placebo|Oral administration of placebo once daily with or without HU.
79349298|NCT01490866|Drug|Bevacizumab|5 mg/kg Days 1 and 15; IV
79349299|NCT01490866|Drug|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
79349300|NCT01490866|Drug|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
79662737|NCT06139952|Drug|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
79662738|NCT06139952|Other|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
79662739|NCT06139939|Procedure|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
79662740|NCT06139926|Drug|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (plain) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
79987932|NCT02697916|Drug|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
79987933|NCT04866316|Other|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
79349301|NCT01490866|Drug|Leucovorin|400 mg/m2 Days 1 and 15; IV
79349302|NCT01490866|Drug|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
79349303|NCT02215967|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
79349304|NCT02215967|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
79349305|NCT02215967|Biological|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10^6- 15.0x10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
79349306|NCT02168387|Device|continuous high frequency oscillator (CHFO)|
79349307|NCT02168387|Drug|Acetylcysteine|
79987934|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79500849|NCT05110690|Other|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
79500850|NCT05110001|Drug|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
79500851|NCT05110001|Drug|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
79500852|NCT05110001|Drug|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
79500853|NCT05110001|Drug|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
79500854|NCT05110001|Other|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
79500856|NCT05091632|Procedure|Electroencephalography|Undergo EEG
79662741|NCT06139913|Other|aerobic exercise|moderate intensity aerobic exercise using treadmill
79662742|NCT06139887|Behavioral|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
79662743|NCT06139887|Other|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
79662744|NCT06139848|Other|Traditional Physical Therapy|Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
79662745|NCT06139848|Other|Posterior-anterior spinal mobilization, prone press up Techniques|"Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions."
79662746|NCT06139835|Biological|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
79662747|NCT06139822|Other|Experimental Group|Hamstring stretching is the main intervention which is being used along with convention protocol for plantar fasciitis.
79987935|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79349308|NCT02168387|Drug|dornase alfa|
79349309|NCT04418219|Drug|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
79349310|NCT04418219|Biological|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
79349311|NCT04418219|Biological|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
79349312|NCT04418219|Biological|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
79349313|NCT04418219|Other|Questionnaire Administration|Ancillary studies
79349314|NCT04418219|Other|Quality of Life Assessment|Ancillary studies
79349315|NCT02188589|Device|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
79349316|NCT02167451|Drug|Maraviroc|
79349317|NCT02167139|Drug|Humira (adalimumab)|
79349318|NCT02167139|Drug|SB5 (proposed biosimilar to adalimumab)|
79349319|NCT02116621|Behavioral|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
79500857|NCT05091632|Other|Questionnaire Administration|Complete questionnaires
79816103|NCT00481195|Drug|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
79816104|NCT03604549|Drug|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
79500858|NCT05084196|Drug|Melatonin|Melatonin 5 mg capsule by mouth at bedtime
79816105|NCT03604549|Drug|Saline|Up to 10cc of saline will be infused via intrauterine catheter
79987936|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79987937|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79987938|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79987939|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79987940|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79349320|NCT02116621|Device|smartphone|
79349321|NCT02116309|Drug|Rectal Indomethacin|
79349322|NCT02116309|Drug|Epinephrine|
79349323|NCT02115607|Drug|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
79349324|NCT01490632|Drug|Placebo|Administered orally
79349325|NCT01490632|Drug|Baricitinib|Administered orally
79349326|NCT04726111|Other|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
79349327|NCT01451554|Behavioral|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
79349328|NCT01451554|Behavioral|Usual Care|self-help booklets
79349329|NCT01474486|Drug|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
79349330|NCT04075552|Behavioral|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
79500859|NCT05084196|Other|Placebo Capsule|Placebo capsule by mouth at bedtime
79500860|NCT05079347|Diagnostic Test|HIV rapid test|Using a rapid test to assess a patient's HIV status
79500861|NCT05060315|Combination Product|Remunity Pump for Remodulin|Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
79500862|NCT05035212|Biological|RSVpreF|RSV vaccine (RSVpreF)
79500863|NCT05035212|Biological|Placebo|Placebo
79500864|NCT05031234|Drug|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
79500865|NCT05031234|Drug|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
79662748|NCT06139822|Other|Control Group|Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia .
79662749|NCT06139809|Procedure|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
79662750|NCT06139796|Drug|DRV/r FDC (120/20mg)|Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
79500866|NCT05030051|Device|SkinPen Precision System|Microneedling is a relatively new, minimally invasive technique originally developed for skin rejuvenation. Controlled micro-injury to the dermis via the application of several small needles connected to a motorized device stimulates the wound healing process, resulting in the formation of new tissue and blood vessels. The SkinPen by Crown Laboratories is an FDA-cleared microneedling device proven to improve the appearance of acne scars This study evaluates the clinical performance of the SkinPen device for the treatment of signs of aging on the back of the hand. We hypothesize that the SkinPen device will produce a significant improvement in dorsal hand appearance at 3 month post treatment visit, when compared with baseline scores. The assessments will be based on the Clinician's Global Aesthetic Improvement Scale, and the Subject's Global Aesthetic Improvement Scale at the 3 month post treatment visit.
79662751|NCT06139783|Procedure|Exercise and dietary recommendations|Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
79816106|NCT01027429|Drug|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
79349331|NCT04075552|Behavioral|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
79349332|NCT04075552|Behavioral|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
79987941|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79349333|NCT01451398|Drug|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
79349334|NCT01451398|Drug|Technosphere Powder|Placebo Comparator
79349335|NCT02073565|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
79349336|NCT02073565|Device|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
79500867|NCT05029739|Device|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
79500868|NCT05015816|Diagnostic Test|Total body photography|3 monthly TBP imaging
79662752|NCT06139770|Behavioral|Family based therapy- Metacognitive therapy|Family based therapy and Metacognitive therapy
79500869|NCT05005260|Drug|Bupivacaine HCl|Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
79987942|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79500870|NCT05005260|Drug|Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj|Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
79662753|NCT06139744|Drug|DAO supplement|One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
79816107|NCT01027429|Drug|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
79816108|NCT01027429|Drug|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
79816109|NCT00454363|Other|Laboratory Biomarker Analysis|Correlative studies
79816110|NCT00454363|Drug|Pazopanib Hydrochloride|Given PO
79816111|NCT00454363|Other|Pharmacological Study|Correlative studies
79816112|NCT01020253|Drug|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
79987943|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79349337|NCT02072941|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
79500871|NCT04968587|Procedure|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
79500872|NCT04967170|Biological|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
79500873|NCT04967170|Other|Sham Procedure|Intralesional needle insertion without any injectate.
79349338|NCT02100631|Biological|PXVX0200|
79349339|NCT02100631|Biological|Placebo|
79500874|NCT04965519|Drug|RC48-ADC|2.0mg/kg IV every 2 weeks
79662754|NCT06139744|Drug|Placebo|Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
79349340|NCT01451164|Drug|OPC-34712|orally administered once daily
79349341|NCT01451164|Drug|OPC-34712|orally administered once daily
79349342|NCT01451164|Drug|OPC-34712|orally administered once daily
79349343|NCT01451164|Drug|Placebo|orally administered once daily
79500875|NCT04965298|Drug|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
79500876|NCT04965298|Other|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
79662755|NCT06139705|Other|Walking outdoor|The individuals will walk in park along a pre-designated route 20 min.
79662756|NCT06139705|Other|Walking indoor|The individuals will walk in a gym on a treadmill 20 min.
79662757|NCT06139679|Procedure|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
79662758|NCT06139666|Drug|Exparel Injectable Solution|"Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
79679550|NCT00516620|Behavioral|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
79349344|NCT02071849|Device|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
79500877|NCT04964947|Drug|Tobramycin Injection|80 milligrams of tobramycin diluted in 40 milliliters of normal saline
79679551|NCT02949752|Drug|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
79349345|NCT02071771|Device|Nelfilcon A toric contact lenses|
79349346|NCT02071771|Device|Etafilcon A toric contact lenses|
79349347|NCT02071225|Drug|bendamustine|70 milligrams per square meter (mg/m^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
79349348|NCT02071225|Drug|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
79349349|NCT01450696|Drug|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
79349350|NCT01450696|Drug|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
79349351|NCT01450696|Drug|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
79349352|NCT02070991|Drug|Macitentan|oral tablet, 10 mg once daily
79349353|NCT02070991|Drug|Placebo|matching placebo
79349354|NCT02114515|Behavioral|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
79662759|NCT06139666|Drug|Bupivacaine Injectable Solution|"Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery.~The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
79816113|NCT00454207|Drug|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
79662760|NCT06139653|Device|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
79679552|NCT05299983|Other|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
79816114|NCT01020331|Drug|Memantine|
79349355|NCT02114515|Behavioral|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
79816115|NCT01030939|Drug|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
79816116|NCT00738894|Device|Septal Occluder Device|PFO closure with study septal occluder device
79816117|NCT00738894|Drug|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
79816118|NCT00480493|Behavioral|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
79349356|NCT02114515|Behavioral|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
79349357|NCT01490086|Drug|RP5063|daily
79349358|NCT01490086|Drug|placebo|daily
79500878|NCT04964466|Biological|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
79816119|NCT01027663|Dietary Supplement|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
79816120|NCT01020409|Procedure|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
79816121|NCT00734994|Device|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
79816122|NCT00734994|Drug|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
79816123|NCT02593734|Drug|olanzapine|oral antipsychotic drug therapy
79816124|NCT02593734|Drug|risperidone|oral antipsychotic drug therapy
79816125|NCT02593734|Drug|amitryptaline|oral antidepressant drug therapy
79816126|NCT02593734|Drug|fluoxetine|oral drug therapy for depression
79816127|NCT04088526|Combination Product|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
79987944|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
79349359|NCT01490086|Drug|RP5063|daily
79349360|NCT01490086|Drug|RP5063|daily
79349361|NCT01490086|Drug|aripiprazole|daily
79349362|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
79349363|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
79349364|NCT02114203|Drug|placebo for PDE9i|oral dose, every 12 hours for 28 days
79349365|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
79816128|NCT00798434|Drug|Placebo|placebo administered orally in the morning or evening.
79662761|NCT06139653|Device|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
79816129|NCT00798434|Drug|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
79816130|NCT04106804|Drug|Abatacept 125 MG/ML|Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months
79816131|NCT00724503|Device|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 [Y-90] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
79987945|NCT02392312|Drug|ATF-Fresenius S|intravenous
79987946|NCT03115216|Procedure|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
79987947|NCT03115216|Procedure|CEIOL|Manual cataract extraction and intraocular lens placement
79349366|NCT02113579|Device|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
79349367|NCT02113579|Other|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
79349368|NCT01474018|Drug|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
79349369|NCT02100475|Drug|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
79349370|NCT02100475|Drug|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
79349371|NCT04741087|Drug|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
79349372|NCT04741087|Drug|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
79349373|NCT02113189|Other|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
79349374|NCT02113189|Other|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
79987948|NCT01310153|Procedure|prone positioning|newborn babies in prone positioning
79987949|NCT01310153|Procedure|Supine|newborn babies in supine positioning
79987950|NCT02392156|Biological|rFVIIIFc|As described in the treatment arm
79816132|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
79816133|NCT00791648|Drug|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
79662762|NCT06139640|Other|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
79662763|NCT06139627|Other|Best Practice|Receive usual care
79816134|NCT00791648|Drug|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
79816135|NCT05366595|Drug|oral zinc sulfate|Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
79816136|NCT02592213|Procedure|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
79662764|NCT06139627|Procedure|Biospecimen Collection|Undergo blood and stool sample collection
79816137|NCT04006886|Dietary Supplement|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
79816138|NCT03956511|Other|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
79816139|NCT04087239|Other|HIV|
79816140|NCT04113356|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
79662765|NCT06139627|Other|Communication Intervention|Receive GA assessment summary and assessment-based recommendations
79662766|NCT06139627|Other|Comprehensive Geriatric Assessment|Complete GA
79816141|NCT04017260|Procedure|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
79816142|NCT04017260|Procedure|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
79662767|NCT06139627|Other|Electronic Health Record Review|Ancillary studies
79662768|NCT06139627|Other|Survey Administration|Ancillary studies
79662769|NCT06139562|Behavioral|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
79662770|NCT06139562|Behavioral|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
79987951|NCT02392156|Biological|rFIXFc|As described in the treatment arm
79349375|NCT02113189|Other|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
79500879|NCT04964466|Biological|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
79662771|NCT06139549|Other|Gross motor development group session|Group session for gross motor development
79662772|NCT06139510|Other|Quantitative sensory testing|Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
79662773|NCT06139484|Device|Transcranial Magnetic Stimulation|The stimulations were performed by Magstim RAPID.
79662774|NCT06139471|Behavioral|Virtual Reality-Enhanced Gagne's Instructional Model|Virtual Reality-Enhanced Gagne's Instructional Model
79987952|NCT02392156|Drug|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
79987953|NCT02392156|Drug|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
79987954|NCT03115060|Drug|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
79500880|NCT04964466|Biological|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
79349376|NCT01440946|Drug|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
79662775|NCT06139419|Radiation|Hypofractionated radiotherapy|Participants were treated with hypofractionated radiotherapy followed by hypo-boost
79662776|NCT06139419|Drug|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
79662777|NCT06139419|Drug|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
79662778|NCT06139419|Drug|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
79987955|NCT01871220|Device|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
79987956|NCT01871220|Device|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
79987957|NCT03359473|Drug|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
79987958|NCT03359473|Drug|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
79349377|NCT01440946|Drug|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
79349378|NCT01450540|Device|REMstar Auto A-Flex|Standard CPAP
79349379|NCT01450540|Device|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
79349380|NCT02070757|Drug|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
79662779|NCT06139419|Drug|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
79662780|NCT06139393|Drug|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
79987959|NCT04831060|Procedure|Periodontal treatment|"For Cases :~Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~Non-surgical periodontal treatment~At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~Maintenance~For Controls:~Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~Plastic or pre-prosthetic surgery = gingival explant sampling~Healing control at 15 days"
79662781|NCT06139393|Drug|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
79662782|NCT06139367|Drug|TQB3454 tablets|TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
79987960|NCT03632304|Procedure|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
79500881|NCT04964466|Biological|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
79500882|NCT04938557|Device|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
79500883|NCT04938557|Device|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
79500884|NCT04937881|Drug|Tenofovir alafenamide|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
79662783|NCT06139276|Procedure|Small Needle-Knife|"The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions."
79987961|NCT02397538|Drug|Fimasartan|
79987962|NCT02397538|Drug|Amlodipine|
79987963|NCT02397538|Drug|Rosuvastatin|
79987964|NCT02397616|Other|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
79987965|NCT01429038|Biological|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
79500885|NCT04937881|Drug|Tenofovir Disoproxil Fumarate|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
79662784|NCT06139276|Other|Standard treatment|Standard treatment
79662785|NCT06139237|Other|High-protein supplement|High protein supplement 200 mL
79662786|NCT06139237|Other|Balanced supplement|Balanced supplement 200 mL
79662787|NCT06139211|Biological|JS015|JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
79662788|NCT06139211|Biological|Toripalimab|Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
79500886|NCT04911452|Device|Calmer|Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
79662789|NCT06139211|Biological|Paclitaxel|Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
79500887|NCT04875052|Device|Experimental: Whole Body Vibration|Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
79816143|NCT04017260|Procedure|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
79816144|NCT04017260|Procedure|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
79500888|NCT04875052|Device|Experimental: Local Muscle Vibration|Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
79662790|NCT06139211|Drug|Irinotecan|Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
79662791|NCT06139211|Drug|Capecitabine|Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
79816145|NCT02592135|Other|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
79816146|NCT00791492|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
79816147|NCT04017338|Drug|Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet|A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
79662792|NCT06139211|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
79500889|NCT04875052|Other|Standard ACL Rehabilitation|Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
79662793|NCT06139211|Biological|Bevacizumab|Bevacizumab will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
79662794|NCT06139211|Drug|Fluorouracil|Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
79662795|NCT06139211|Drug|Leucovorin|Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
79662796|NCT06139211|Drug|Gemcitabine|Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
79662797|NCT06139211|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
79349381|NCT02070757|Drug|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
79662798|NCT06139198|Behavioral|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
79816148|NCT04017338|Drug|Ezetimibe 10Mg Oral Tablet|A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
79816149|NCT04017338|Device|Ex Vivo Lung Perfusion|A technology that allows for the assessment and treatment of lungs prior to transplant.
79349382|NCT04417933|Device|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
79349383|NCT04417855|Diagnostic Test|G-Walk|"Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected."
79349384|NCT02100319|Drug|Azilsartan|Azilsartan tablets
79349385|NCT01625845|Drug|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
79987966|NCT02396992|Other|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
79349386|NCT01625845|Other|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
79500890|NCT04862572|Other|MRI scanning|"In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure."
79500891|NCT04861571|Dietary Supplement|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
79500892|NCT04861571|Other|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
79500893|NCT04846517|Device|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
79500894|NCT04842604|Drug|Glasdegib|25 mg or 100 mg tablet
79816150|NCT04106726|Drug|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
79816151|NCT04106726|Drug|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
79816152|NCT04106726|Drug|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
79349387|NCT01625845|Behavioral|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
79349388|NCT01473940|Biological|ipilimumab|Given IV
79349389|NCT01473940|Drug|gemcitabine hydrochloride|Given IV
79349390|NCT01473940|Other|laboratory biomarker analysis|Correlative studies
79349391|NCT04408846|Device|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
79816153|NCT03998774|Behavioral|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
79987967|NCT04418778|Behavioral|BEAR|Building Empowerment and Resilience Therapy group
79987968|NCT03589469|Drug|Loncastuximab tesirine|intravenous infusion
79349392|NCT03026374|Behavioral|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
79349393|NCT01832727|Drug|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
79349394|NCT01832727|Drug|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
79349395|NCT03026296|Behavioral|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
79349396|NCT04647058|Procedure|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
79349397|NCT04647058|Procedure|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
79349398|NCT01473394|Drug|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
79349399|NCT01473394|Drug|Vilazodone|Vilazodone was supplied as tablets.
79349400|NCT04408144|Drug|Dydrogesterone 10mg Oral Tablet|oral 10mg dydrogesterone (Duphaston) 2 times daily
79816154|NCT04106336|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
79816155|NCT02603354|Drug|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
79662799|NCT06139172|Behavioral|Functional Behavioral Training (FBT)|Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
79679553|NCT05299983|Other|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~North American Menopause Society: https://www.menopause.org/for-women~National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
79816156|NCT00723957|Drug|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m^2
79816157|NCT00723957|Drug|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m^2
79349401|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
79349402|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
79349403|NCT01449526|Device|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
79349404|NCT01449526|Device|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
79349405|NCT01440322|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
79349406|NCT01440322|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
79349407|NCT02985580|Dietary Supplement|Blueberry|
79349408|NCT02985580|Dietary Supplement|Placebo|
79349409|NCT01832493|Device|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
79349410|NCT01831791|Drug|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
79816158|NCT00723957|Drug|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
79349411|NCT01857531|Drug|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
79349412|NCT01857531|Drug|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
79349413|NCT02166047|Drug|Vesatolimod|Vesatolimod tablet administered orally
79349414|NCT02166047|Drug|Placebo|Placebo to match vesatolimod tablet administered orally
79349415|NCT01493284|Device|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
79349416|NCT02165735|Behavioral|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
79349417|NCT02165735|Other|Usual care|Usual HIV care
79349418|NCT02069899|Drug|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
79349419|NCT01831089|Drug|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
79349420|NCT02112877|Device|Veniti Vici™ Venous Stent System|
79987969|NCT03734081|Device|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
79987970|NCT03734081|Device|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
79987971|NCT03359395|Drug|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
79816159|NCT04106180|Drug|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
79987972|NCT03359395|Drug|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
79349421|NCT02098369|Behavioral|Written education material (basic)|Education material on COPD distributed to all participants.
79987973|NCT03734003|Device|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
79987974|NCT03734003|Device|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
79987975|NCT03730493|Behavioral|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
79349422|NCT02098369|Behavioral|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
79349423|NCT02098369|Behavioral|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
79349424|NCT02098369|Behavioral|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
79349425|NCT02111785|Drug|Dexamethasone|Treatment with a short course of oral dexamethasone
79349426|NCT02111785|Procedure|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
79349427|NCT02068885|Behavioral|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
79500895|NCT04842604|Drug|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
79500896|NCT04827576|Drug|Magrolimab|Administered intravenously
79500897|NCT04827576|Drug|Docetaxel|Administered intravenously, 75 mg/m^2 on Day 1 of each cycle
79816160|NCT04106180|Drug|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
79987976|NCT03730415|Procedure|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
79987977|NCT05364307|Other|Prescreener database|Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.
79816161|NCT04106180|Radiation|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
79816162|NCT02603822|Dietary Supplement|12C mannitol|12C mannitol 100 mg
79816163|NCT02603822|Drug|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
79987978|NCT03586427|Drug|AGN-241751|AGN-241751 administered orally as a single tablet
79987979|NCT03586427|Drug|Placebo|Placebo administered orally as a single tablet
79987980|NCT03733769|Procedure|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
79987981|NCT03648983|Procedure|arm circumference measurement|Undergo arm circumference measurement
79987982|NCT03648983|Device|Bioimpedance spectroscopy|bioimpedance spectroscopy
79987983|NCT05666453|Biological|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
79987984|NCT05666453|Other|No intervention|None of investigational drugs are administered to patients.
79987985|NCT02695420|Drug|25 mg Omecamtiv Mecarbil|oral tablet
79349428|NCT02068495|Drug|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
79349429|NCT02097823|Drug|Olanzapine|
79987986|NCT02695420|Drug|Placebo|oral tablet
79349430|NCT02097823|Drug|Aprepitant|
79349431|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
79349432|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
79349433|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
79349434|NCT01830855|Biological|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
79349435|NCT01830855|Biological|Saline|0.5 mL dose of sterile normal saline for injection.
79816164|NCT02603822|Dietary Supplement|13C mannitol|13C mannitol 100 mg
79987987|NCT02695420|Drug|37.5 mg Omecamtiv Mecarbil|oral tablet
79987988|NCT02695420|Drug|50 mg Omecamtiv Mecarbil|oral tablet
79987989|NCT03733613|Other|no intervention|no intervention
79349436|NCT01857063|Drug|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
79500898|NCT04817774|Biological|TX200-TR101|TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Four, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.
79662800|NCT06139172|Other|Positive Parenting Strategies-Treatment as Usual|Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
79662801|NCT06139159|Other|Outreach/navigator|"Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~Document outreach, screening, and referral activities in LHW database"
79349437|NCT01857063|Drug|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
79816165|NCT02603822|Dietary Supplement|Lactulose|lactulose 1 g
79349438|NCT01856907|Drug|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
79349439|NCT01856907|Drug|Metformin|Biguanide- insulin sensitizer
79349440|NCT01856907|Drug|Placebo pill|Will evaluate effect of lifestyle and diet only
79349441|NCT02212457|Biological|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
79662802|NCT06139159|Other|Auxiliary to care|"Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~Reviews care plan with patient and help reduce patient and system barriers impeding psychological wellbeing~Support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~Engage, activate, and empower patients to participate in the care process~Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~Assist with group sessions: affinity groups~Identify community-based resources.~Document outreach, screening, referral, and auxiliary care activities in LHW database"
79679554|NCT04694963|Procedure|Blood sample|2 ml venous blood was collected and separated into serum.
79816166|NCT04087005|Other|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
79816167|NCT02592057|Drug|SOF|SOF tablets administered orally once daily based on approved prescribing information
79816168|NCT00723801|Drug|Atenolol|Atenolol 50mg PO QD
79349442|NCT02212457|Other|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
79349443|NCT02212457|Biological|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
79500899|NCT04801160|Procedure|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
79816169|NCT00723801|Drug|Losartan|Losartan 100mg PO QD
79816170|NCT04086927|Device|Unna Boot|The unna boot is a zinc coated compression dressing
79816171|NCT00797966|Drug|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
79816172|NCT00797966|Drug|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
79816173|NCT00797966|Drug|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
79816174|NCT00723489|Biological|Live Yellow Fever Vaccine (YFV-17D)|
79816175|NCT00723489|Drug|YFV-17D Placebo|
79816176|NCT02591901|Drug|Uro vaxom|Prevention of recurrent symptomatic lower urinary tract infections
79816177|NCT02591901|Other|Placebo comparator|Placebo comparator
79349444|NCT02212457|Biological|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
79349445|NCT02097745|Drug|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
79349446|NCT02097745|Drug|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
79349447|NCT02111083|Biological|Insulin Lispro|LY275585 administered SC.
79349448|NCT01629563|Drug|PGL4001 5 mg|PGL4001 5 mg daily administration
79500900|NCT04801160|Procedure|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
79500901|NCT04789668|Drug|Bintrafusp Alfa|Given IV
79662803|NCT06139159|Other|Stepped care and task shifting|"Support counselling initiated by the psychologist~Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~Co-lead group sessions: affinity groups~Provide Mental Health First Aid to members of the community.~Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
79500902|NCT04789668|Drug|Pimasertib|Given PO
79500903|NCT04789668|Other|Quality-of-Life Assessment|Ancillary studies
79500904|NCT04785131|Other|Prune|daily consumption of 50 grams prune.
79816178|NCT05362695|Drug|IW-3300|A dose of IW-3300 administered rectally (as a low-volume [20 mL] enema).
79816179|NCT05362695|Drug|Placebo|A dose of placebo administered rectally (as a low-volume [20 mL] enema).
79816180|NCT00587990|Biological|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10^7 cells. The injections will be administered following completion of CABG surgery.
79816181|NCT00587990|Genetic|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
79816182|NCT00587990|Biological|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10^8 cells. The injections will be administered following completion of CABG surgery.
79500905|NCT04782115|Biological|intravitreal injection of RC28-E|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
79816183|NCT02603744|Biological|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
79816184|NCT00723255|Biological|bevacizumab|Given IV
79816185|NCT00723255|Drug|temsirolimus|Given IV
79816186|NCT00791258|Drug|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
79816187|NCT00791258|Drug|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
79816188|NCT00808067|Drug|dabigatran dose 1|dabigatran high dose twice daily
79816189|NCT00808067|Drug|dabigatran dose 2|dabigatran low dose twice daily
79816190|NCT00723021|Drug|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
79987990|NCT03358147|Drug|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
79500906|NCT04782115|Biological|Conbercept|KH902(Conbercept）
79679555|NCT04694963|Procedure|Data collection|"Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
79679556|NCT04694963|Procedure|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
79816191|NCT00723021|Drug|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
79816192|NCT00723021|Drug|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
79816193|NCT00723021|Drug|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
79987991|NCT03358147|Drug|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
79987992|NCT03358147|Drug|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
79987993|NCT03358147|Drug|Placebo MDI|Placebo taken as 2 inhalations BID
79500907|NCT04778514|Drug|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
79500908|NCT04778514|Drug|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
79500909|NCT04778475|Other|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
79500910|NCT04778475|Other|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
79500911|NCT04776109|Procedure|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
79500912|NCT04756401|Drug|Carfilzomib|Given IV
79500913|NCT04756401|Biological|Daratumumab|Given IV
79500914|NCT04756401|Drug|Dexamethasone|Given PO
79500915|NCT04756401|Other|Quality-of-Life Assessment|Ancillary studies
79500916|NCT04756401|Drug|Selinexor|Given PO
79500917|NCT04741776|Behavioral|Resilience Enhancement Skills Training|Family therapy
79816194|NCT00723021|Drug|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
79987994|NCT03358147|Drug|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
79987995|NCT03733457|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
79500918|NCT04741776|Behavioral|Problem-Solving Individual Therapy|Individual therapy
79500919|NCT04726293|Dietary Supplement|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
79500920|NCT04726293|Dietary Supplement|Control|control beverage 1 cup, twice a day for 4 weeks
79500921|NCT04716634|Drug|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
79500922|NCT04716634|Drug|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
79500923|NCT04708041|Biological|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
79662804|NCT06139146|Other|Muscle energy technique (MET)|"MET treatment protocol of pectoral major:~The patient's position was supine lying. Starting with the position which took the affected fibres to just short of their restriction barrier, the patient introduced a light contraction involving adduction of the arm against resistance from the therapist for 7-10 seconds. As the patient exhaled the therapist stretched across the new barrier.~MET treatment protocol of upper trapezius:~The patient moved the stabilized shoulder in a shrug motion toward the ear, and the ear toward the shoulder, with a light resistance (20% of possible strength). The contraction was sustained for 7-1 0 seconds MET treatment protocol of levator scapula The patient was in a supine position, with the hand supinated and the arm of the side to be tested extended alongside the trunk.~Strengthening of deep neck flexors: Patient was instructed to his nod head to flatten the neck's curve. 10 reps for 10 sec."
79662805|NCT06139146|Other|Core stability exercises:|"Warm up: The cat and camel stretches~Exercises:~It included Crook lying, abdominal bracing, and 10 second - 20 repetitions (reps).~Crook lying, abdominal Bracing with leg lifts holding the position for 3 second for 10 reps.~Crook lying, abdominal Bracing with bridging with 10 reps with a 10 second hold.~It included a Quadruped position with abdominal bracing for 10 s - 10 reps~Quadruped position arm lifts with abdominal bracing 10 reps on each side.~Quadruped position leg lifts with abdominal bracing 10 reps on each side.~Quadruped position alternate arm and leg lifts with abdominal bracing holding position for 3 s - 10 reps on each side.~The curl-up in hook lying, Fold arms across the torso. Lift shoulder blades off the ground. 1 to 2 seconds holds - 10 reps.~Side plank on knees; holding position for 10 s - 5 reps ."
79662806|NCT06139120|Diagnostic Test|Assessment of hypersensitivity|Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
79662807|NCT06139081|Other|Oxygen delivery mode|After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
79987996|NCT03093402|Drug|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
79349449|NCT01629563|Drug|PGL4001 10 mg|PGL4001 10mg daily administration
79349450|NCT02097277|Biological|BMS-986036|
79349451|NCT02097277|Biological|Placebo (Matching with BMS-986036)|
79679557|NCT02942550|Drug|Methylnaltrexone bromide (Relistor®).|
79679558|NCT02942550|Drug|Sodium Chloride 9mg/mL|
79987997|NCT03093402|Drug|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
79987998|NCT03585959|Device|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
79349452|NCT02212379|Drug|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
79349453|NCT02110693|Other|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
79349454|NCT02212301|Device|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
79349455|NCT02212301|Device|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
79349456|NCT02211209|Drug|Volanesorsen|
79349457|NCT02211209|Drug|Placebo|
79816195|NCT05754281|Device|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm [0.618] x 15.7 mm [0.618]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
79662808|NCT06139068|Other|Narrative Group Counseling|Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling will be applied to the intervention group once a week in 8 sessions. The application will be carried out face to face, in a calm, quiet and bright classroom where the circle seating plan will be made. 90 min. The duration of a group session is 10 minutes once. It will be completed with a break.
79662809|NCT06139068|Other|stress coping interviews|In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
79816196|NCT04087161|Other|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
79816197|NCT04309409|Drug|Nivolumab|480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
79816198|NCT04086537|Diagnostic Test|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
79987999|NCT02397070|Procedure|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
79816199|NCT02608619|Radiation|F-choline PET Scan|
79816200|NCT02608619|Device|FDG-PET|
79662810|NCT06139042|Diagnostic Test|Blood drawing|The participants had their blood drawn.
79349458|NCT02187809|Drug|Clobazam|
79662811|NCT06139016|Device|Virtual reality|Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
79662812|NCT06139003|Device|3d Printed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
79662813|NCT06139003|Device|Conventionally constructed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
79662814|NCT06138964|Drug|siSPARC + siLR4A microneedle patches|siSPARC + siLR4A microneedle patch
79662815|NCT06138964|Drug|siSPARC microneedle patch|siSPARC microneedle patch
79816201|NCT02608619|Procedure|biopsy|
79816202|NCT02591589|Other|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 > 70 mmHg or oxygen saturation greater than or equal to 92%.
79816203|NCT02591589|Other|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
79349459|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
79349460|NCT02187029|Other|Placebo|Daily dosing (tablet) for 14 days
79816204|NCT02591667|Procedure|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
79816205|NCT02591667|Drug|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
79816206|NCT02591667|Procedure|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
79662816|NCT06138938|Other|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
79662817|NCT06138912|Radiation|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
79988000|NCT02397070|Device|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
79988001|NCT02397148|Radiation|Computed Tomography|imagery with ionizing radiation
79662818|NCT06138886|Device|Pulsed electromagnetic therapy group|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
79662819|NCT06138873|Procedure|Ablation-index guided ventricular tachycardia ablation|As described in arms descriptions
79662820|NCT06138873|Procedure|Ventricular tachycardia ablation with no AI-guidance|As described in arms descriptions
79662821|NCT06138847|Diagnostic Test|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
79816207|NCT00721227|Procedure|Reduction Gastroplasty|"Subjects will undergo reduction gastroplasty by gastric plication~Subjects are followed for 12 months to evaluate outcomes and potential complications."
79988002|NCT02397148|Radiation|Cone Beam Computed Tomography|imagery with ionizing radiation
79988003|NCT03584789|Other|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
79988004|NCT03584789|Other|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
79988005|NCT03710005|Procedure|Ascent|Dehydrated Cell and Protein Concentrate injection
79988006|NCT03710005|Procedure|Standard|Standard corticosteroid injection
79988007|NCT03733379|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
79988008|NCT03733379|Drug|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
79988009|NCT03733379|Drug|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
79988010|NCT03733379|Drug|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
79988011|NCT03733379|Dietary Supplement|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
79988012|NCT03733379|Dietary Supplement|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
79988013|NCT03708991|Diagnostic Test|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
79349461|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
79349462|NCT02187029|Other|Placebo|Daily dosing (tablets) for 14 days
79349463|NCT04750655|Drug|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
79349464|NCT02162771|Biological|Rituxan|
79349465|NCT02162771|Biological|CT-P10|
79349466|NCT02162771|Drug|Cyclophosphamide|
79349467|NCT02162771|Drug|Vincristine|
79349468|NCT02162771|Drug|Prednisone|
79662822|NCT06138834|Drug|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
79988014|NCT03708991|Diagnostic Test|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
79349469|NCT02161757|Biological|Tralokinumab|Subcutaneous injection
79349470|NCT02161757|Other|Placebo|Subcutaneous injection
79988015|NCT05733676|Device|Resin infiltration|Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
79349471|NCT02160977|Procedure|total knee arthroplasty|
79349472|NCT02160899|Drug|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
79662823|NCT06138834|Drug|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
79662824|NCT06138834|Drug|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
79662825|NCT06138834|Drug|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
79662826|NCT06138834|Drug|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
79662827|NCT06138821|Device|ESG|Endoscopic sleeve gastroplasty - reduce the size of the stomach using an endoscopic plicating device
79662828|NCT06138821|Drug|GLP1-RA|Prescription for semaglutide for weight loss for 12 months.
79662829|NCT06138769|Drug|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight < 60 kg) once orally every day
79662830|NCT06138756|Device|Nerivio|Neriio is a remote electrical neuromodulation (REN) device for the treatment of migraine
79988016|NCT05733676|Device|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
79662831|NCT06138743|Drug|ARO-DM1 for Injection|single or multiple doses of ARO-DM1 by intravenous (IV) infusion
79662832|NCT06138743|Drug|Placebo|calculated volume to match active treatment by IV infusion
79988017|NCT03343639|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
79988018|NCT03343639|Drug|Matching Placebo Tablets|Placebo Tablets
79988019|NCT04479748|Drug|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
79349473|NCT02160899|Drug|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
79349474|NCT02160041|Drug|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
79349475|NCT02186873|Drug|Placebo|Participants will receive matching placebo.
79349476|NCT02186873|Drug|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
79349477|NCT02096263|Biological|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
79349478|NCT02096263|Biological|Pediarix|3 doses administered intramuscularly in the right thigh
79349479|NCT02096263|Biological|ActHIB|4 doses administered intramuscularly in the upper left thigh
79349480|NCT02096263|Biological|Pentacel|4 doses administered intramuscularly in the right thigh
79349481|NCT02096263|Biological|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
79349482|NCT02096263|Biological|Infanrix|1 dose administered intramuscularly in the right thigh
79349483|NCT02096263|Biological|Hiberix|1 dose administered intramuscularly in the left thigh
79349484|NCT02096263|Biological|Prevnar13|3 doses administered intramuscularly in the lower left thigh
79349485|NCT02096263|Biological|Rotarix|2 doses administered orally
79349486|NCT01830543|Drug|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
79349487|NCT01830543|Drug|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
79349488|NCT01830543|Drug|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
79349489|NCT01830543|Drug|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
79988020|NCT04479748|Drug|Prednisolone Acetate 1% Oph Susp|Topical steroid
79988021|NCT03647267|Device|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
79349490|NCT01830543|Drug|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
79988022|NCT03647267|Other|Observation|No intervention; sham injection only
79349491|NCT01830543|Drug|clopidogrel|One 75 mg tablet once daily for up to twelve months
79349492|NCT01830543|Drug|prasugrel|One 10 mg tablet once daily for up to twelve months
79349493|NCT01830543|Drug|ticagrelor|One 90 mg tablet twice daily for up to twelve months
79349494|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
79349495|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
79988023|NCT03707353|Biological|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10^8 pfu (intramuscularly) and MVA METRAP 2x10^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
79349496|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
79349497|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
79349498|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
79349499|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
79349500|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
79349501|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
79349502|NCT02109133|Procedure|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
79349503|NCT02109133|Procedure|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
79349504|NCT02109133|Drug|Rocuronium|
79349505|NCT02109133|Drug|Sugammadex|
79349506|NCT02109133|Drug|Atracurium|
79349507|NCT02109133|Drug|Neostigmine|
79662833|NCT06138717|Other|yoga based exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.In group 2, in addition to aerobic exercises, spinal stretching, relaxation, respiration and meditation will be performed. A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
79662834|NCT06138704|Procedure|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
79349508|NCT01623271|Drug|Gabapentin|
79988024|NCT05731180|Other|Identify pathological and not pathological lung sounds|First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
79988025|NCT03708913|Device|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
79988026|NCT03356977|Drug|Crisaborole ointment 2%|Applied BID
79988027|NCT02690974|Drug|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
79349509|NCT01856673|Behavioral|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
79349510|NCT01856673|Behavioral|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
79349511|NCT01856673|Other|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
79988028|NCT03093324|Drug|ALKS 8700|Administered as specified in the treatment arm.
79988029|NCT03093324|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
79988030|NCT03584009|Drug|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
79662835|NCT06138678|Device|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head."
79349512|NCT02095951|Drug|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
79662836|NCT06138652|Behavioral|App|Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
79349513|NCT02095873|Dietary Supplement|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
79500924|NCT04701385|Diagnostic Test|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
79816208|NCT00807599|Procedure|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
79349514|NCT02095873|Dietary Supplement|Placebo|Mannitol, 108 mg
79349515|NCT02094937|Drug|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
79816209|NCT00807599|Drug|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
79816210|NCT00721149|Device|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
79816211|NCT00788372|Drug|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
79988031|NCT03584009|Drug|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
79988032|NCT03709927|Drug|ZTI-01|6g IV fosfomycin
79349516|NCT02094937|Drug|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
79349517|NCT02094937|Drug|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
79349518|NCT02094937|Drug|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
79349519|NCT02094937|Drug|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
79500925|NCT04696263|Device|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
79500926|NCT04696263|Device|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
79500927|NCT04690738|Diagnostic Test|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
79500928|NCT04678882|Drug|Placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous (SC)
79500929|NCT04678882|Drug|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous (SC)
79500930|NCT04672304|Other|Al-Husban University Naser|filling a questionnaire
79500931|NCT04670965|Biological|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
79662837|NCT06138639|Genetic|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
79662838|NCT06138613|Drug|Tradipitant|Oral Capsule
79988033|NCT03709927|Drug|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
79988034|NCT03709927|Other|Placebo IV|IV Placebo (0.9% Normal Saline)
79662841|NCT06138574|Drug|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
79662842|NCT06138574|Drug|Remifentanil|Remifentanil
79816212|NCT04086459|Device|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
79349520|NCT02094937|Drug|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
79349521|NCT04724629|Biological|Ixekizumab|80 mg of IL-17 inhibitor
79662843|NCT06138561|Behavioral|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring > 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
79662844|NCT06138561|Behavioral|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
79662845|NCT06138561|Behavioral|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
79349522|NCT04724629|Biological|Aldesleukin|1.5 million IU (low-dose) of IL-2
79349523|NCT04724629|Drug|Colchicine|0.5 mg of indirect IL-6 inhibitor
79349524|NCT04724629|Drug|Standard of care (SOC)|Active comparator (Corticoids and antiretrovirals)
79349525|NCT04724395|Other|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
79349526|NCT04723537|Drug|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
79349527|NCT04723537|Drug|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
79349528|NCT04723537|Drug|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
79349529|NCT04723537|Drug|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
79816213|NCT00915668|Drug|JNJ-31001074|
79816214|NCT05754047|Diagnostic Test|immunohistochemistry (IHC) and in situ hybridization (ISH) Test|These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
79988035|NCT05666375|Procedure|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
79349530|NCT04183465|Other|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
79349531|NCT04183465|Other|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
79500932|NCT04670965|Biological|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
79500933|NCT04670965|Biological|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
79500934|NCT04670965|Biological|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
79500935|NCT04661020|Drug|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
79500936|NCT04642391|Drug|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
79500937|NCT04628416|Device|PICO dressing|Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites
79662846|NCT06138535|Device|digital stabilizing splint|3D Printed stabilizing splint that has been digitally designed on a modern software
79662847|NCT06138496|Drug|Cadonilimab Combined With Lenvatinib|"3.7.1 Lenvatinib Treatment Lenvatinib (8mg [body weight < 60 kg] or 12 mg [body weight ≥ 60 kg]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."
79662848|NCT06138470|Dietary Supplement|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
79662849|NCT06138470|Dietary Supplement|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
79662850|NCT06138470|Dietary Supplement|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
79662851|NCT06138470|Dietary Supplement|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
79662852|NCT06138444|Dietary Supplement|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
79662853|NCT06138444|Other|Fruit juice|Fruit juice is used as a placebo.
79662854|NCT06138431|Behavioral|CBT|Virtual CBT groups
79662855|NCT06138418|Procedure|Neurotomy|Surgical treatment of spastic foot
79662856|NCT06138405|Behavioral|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
79662857|NCT06138405|Behavioral|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
79662858|NCT06138392|Device|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
79988036|NCT03707275|Device|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
79662859|NCT06138379|Other|Experimental: 1st Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
79662860|NCT06138379|Other|Experimental: 2nd Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
79349532|NCT02093923|Drug|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary [CHO] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
79349533|NCT02093923|Drug|Placebo|Participants will receive matching placebo subcutaneously.
79349534|NCT02186561|Device|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
79349535|NCT02066467|Device|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
79349536|NCT02186171|Biological|Romosozumab|Administered by subcutaneous injection once a month.
79349537|NCT02186171|Drug|Placebo|Administered by subcutaneous injection once a month.
79349538|NCT02186015|Drug|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
79349539|NCT02066389|Drug|Placebo|Tablets for oral administration
79349540|NCT02066389|Drug|Upadacitinib|Tablets for oral administration
79349541|NCT02106403|Other|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
79349542|NCT02106403|Other|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
79349543|NCT02106403|Other|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
79349544|NCT02133131|Drug|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
79988037|NCT03707275|Other|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
79988038|NCT04167462|Drug|BMS-986165|Specified dose on Specified Days
79349545|NCT02133131|Drug|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
79349546|NCT02106325|Drug|Ketamine|IV of Ketamine (.25mg/kg)
79349547|NCT02106325|Drug|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
79500938|NCT04628416|Device|Conventional dressing|use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
79500939|NCT04613518|Drug|BMS-986165|Specified Dose on Specified Days
79500940|NCT04613518|Other|Placebo Comparator|Specified Dose on Specified Days
79500941|NCT04610372|Radiation|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
79988039|NCT04167462|Other|Placebo|Specified dose on Specified days
79349548|NCT01625689|Biological|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
79349549|NCT01625689|Biological|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
79349550|NCT02184611|Drug|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
79349551|NCT02184611|Drug|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
79349552|NCT02066311|Drug|Nelfinavir|
79988040|NCT03733223|Drug|Ateptidase|Treatment of ischemic stroke with Ateptidase
79988041|NCT03707197|Behavioral|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
79500942|NCT04610372|Radiation|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
79500943|NCT04610372|Radiation|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
79500944|NCT04610372|Radiation|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
79500945|NCT04592614|Behavioral|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
79500946|NCT04590599|Drug|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
79500947|NCT04590599|Drug|Placebo|Placebo Q3W, for a total of 4 cycles
79500948|NCT04590599|Drug|Sintilimab|Sintilimab 200mg,Q3W
79349553|NCT02184455|Biological|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
79349554|NCT02184143|Behavioral|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
79349555|NCT02184143|Other|Education|Patient education
79349556|NCT01625611|Drug|Naltrexone|Naltrexone 100 mg titrated over one week
79500949|NCT04588727|Drug|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort[s]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
79500950|NCT04588727|Drug|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
79500951|NCT04588727|Drug|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
79349557|NCT02159807|Drug|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
79349558|NCT02159807|Drug|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
79349559|NCT02066233|Device|EG Scan II (transnasal endoscopy)|
79500952|NCT04588727|Drug|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
79500953|NCT04582565|Combination Product|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
79500954|NCT04582565|Other|Standard Care|
79500955|NCT04564547|Drug|Islatravir|ISL capsule taken by mouth.
79500956|NCT04564547|Drug|Ulonivirine|Ulonivirine tablet taken by mouth.
79500957|NCT04564547|Drug|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
79500958|NCT04564547|Drug|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
79500959|NCT04564547|Drug|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
79500960|NCT04564547|Drug|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
79662861|NCT06138340|Drug|Dexmedetomidine|Participants will be sedated and maintained by dexmedetomidine during the surgery.
79349560|NCT02066233|Procedure|Standard Endoscopy|
79349561|NCT04755491|Device|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
79349562|NCT04755491|Device|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
79349563|NCT04755491|Device|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
79500961|NCT04559607|Drug|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
79500962|NCT04559607|Device|TACE|TACE if necessary
79500963|NCT04559607|Drug|Apatinib|Apatinib: 250m, po, QD
79500964|NCT04515329|Drug|Cyclosporine|Eye drops taken twice daily.
79500965|NCT04515329|Drug|Artificial tear|Preservative-free artificial tear drops 4 times a day.
79662862|NCT06138340|Drug|Propofol|Participants will be sedated and maintained by propofol during the surgery.
79662863|NCT06138327|Drug|BMN 255|Oral Capsule
79662864|NCT06138327|Drug|Placebo|Oral Capsule
79662865|NCT06138314|Other|Physical Exercise Program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
79988042|NCT05680441|Other|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
79500966|NCT04508621|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
79349564|NCT02159729|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
79349565|NCT02159729|Drug|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
79349566|NCT02159729|Drug|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
79662866|NCT06138314|Other|Neural Mobilization|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
79988043|NCT04160520|Drug|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
79349567|NCT02159729|Drug|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
79349568|NCT04749563|Drug|IGC AD1|IGC AD1 oral Solution
79349569|NCT04749563|Drug|Placebo|Placebo of IGC AD1 oral Solution
79349570|NCT02159183|Device|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
79500967|NCT04508621|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
79500968|NCT04506684|Device|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
79500969|NCT04506554|Drug|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
79500970|NCT04504669|Drug|AZD8701|FOXP3 antisense oligonucleotide
79500971|NCT04504669|Biological|Durvalumab|anti PDL-1 monoclonal antibody
79500972|NCT04498117|Biological|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
79500973|NCT04498117|Drug|Paclitaxel|175 mg/m^2, every 3 weeks
79500974|NCT04498117|Drug|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
79662867|NCT06138301|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
79816215|NCT00738582|Drug|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
79988044|NCT04160520|Drug|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
79349571|NCT02159183|Device|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
79349572|NCT02183675|Drug|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
79349573|NCT02183675|Drug|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
79349574|NCT02183675|Drug|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
79349575|NCT02183519|Drug|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
79349576|NCT02183519|Other|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
79349577|NCT02132195|Drug|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
79500975|NCT04498117|Biological|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
79349578|NCT02182973|Dietary Supplement|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
79662868|NCT06138301|Behavioral|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
79349579|NCT02182895|Drug|Saxagliptin|2.5-5 mg daily
79349580|NCT01625377|Drug|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
79349581|NCT01625377|Drug|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
79349582|NCT01625377|Drug|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
79349583|NCT01625377|Drug|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
79349584|NCT01625377|Drug|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
79349585|NCT02158949|Behavioral|mROAD|
79349586|NCT02132117|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
79349587|NCT02132117|Drug|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
79500976|NCT04498117|Drug|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
79500977|NCT04482972|Procedure|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
79662869|NCT06138262|Other|Health promotion of education pre-conception nutritional preparation|Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
79662870|NCT06138236|Drug|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
79662871|NCT06138223|Other|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
79662872|NCT06138223|Other|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO).
79662873|NCT06138210|Drug|exosomes derived from human induced pluripotent stem cell for injection|Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, protein concentration 1mg/mL).
79662874|NCT06138210|Drug|a placebo of exosomes derived from human induced pluripotent stem cell for injection|Exosomes placebo, 3.0ml
79662875|NCT06138171|Other|Psychological self-reported measures assesment (questionnaire)|The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
79349588|NCT02093689|Drug|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
79349589|NCT02093689|Drug|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
79349590|NCT02093689|Drug|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
79349591|NCT02047045|Procedure|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
79349592|NCT02047045|Drug|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
79349593|NCT02131259|Drug|Afatinib dimaleate|20mg - 50mg
79349594|NCT01856595|Drug|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
79500978|NCT04482972|Procedure|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
79500979|NCT04465448|Other|MRI|Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
79500980|NCT04459650|Procedure|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
79500981|NCT04451525|Device|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
79662876|NCT06138158|Procedure|Exercise and Education Group|Physical exercise and pain education
79662877|NCT06137105|Drug|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
79662878|NCT06136754|Drug|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
79988045|NCT04160520|Drug|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
79988046|NCT03583385|Drug|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
79228307|NCT03311438|Other|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
79662879|NCT06136572|Diagnostic Test|Rathus Assertiveness scale|Questionnaire completion
79988047|NCT03583385|Drug|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
79500982|NCT04416204|Other|glycogen loading|Subjects will consume an isocaloric diet [60% carbs, 20% protein, 20% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.
79988048|NCT03632382|Diagnostic Test|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
79988049|NCT05288335|Device|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
79988050|NCT05288335|Device|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
79228308|NCT04678206|Drug|BLU-5937|Oral administration of BLU-5937 Tablets
79500983|NCT04416204|Other|No Glycogen Loading|Subjects will consume an isocaloric diet [40% carbs, 20% protein, 40% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.
79500984|NCT04414514|Drug|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
79500985|NCT04409236|Behavioral|Quit2Heal|Use Quit2Heal app
79500986|NCT04409236|Behavioral|QuitGuide|Use QuitGuide app
79500987|NCT04409236|Other|Survey Administration|Ancillary studies
79679559|NCT02949986|Behavioral|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
79679560|NCT02942589|Other|Meal portion size|
79228309|NCT04678206|Drug|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
79349595|NCT01856595|Drug|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
79662880|NCT06136247|Diagnostic Test|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
79816216|NCT00738582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
79816217|NCT00738582|Drug|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
79816218|NCT05753657|Drug|Pioglitazone|hyperinsulinemia and hyperglycemia
79816219|NCT04106024|Drug|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
79988051|NCT05288335|Device|single vision frame glasses|single vision frame glasses
79988052|NCT04350372|Device|MitraClip Procedure|MitraClip procedure with MitraClip NT System
79988053|NCT03708835|Other|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
79500988|NCT04373642|Drug|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
79662881|NCT06136247|Diagnostic Test|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm [35,36].
79662882|NCT06135948|Drug|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
79679561|NCT02949596|Behavioral|Quality of life and quality of sexual life questionnaires|
79816220|NCT00720759|Drug|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
79816221|NCT00720759|Behavioral|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
79816222|NCT00720759|Drug|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
79816223|NCT00720759|Behavioral|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
79816224|NCT04017494|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
79816225|NCT04017494|Diagnostic Test|Blood draw for hematocrit and heart failure biomarkers|Approximately 10 ml of blood will be drawn before administration of contrast medium.
79816226|NCT04017494|Diagnostic Test|Cardiopulmonary exercise test|In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
79816227|NCT04017494|Diagnostic Test|Exhalomics|Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
79816228|NCT04017494|Diagnostic Test|Quality of life questionnaire|Questionnaire to be filled out by the Patient regarding quality of life perception
79816229|NCT03998228|Diagnostic Test|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~Radiological examination of BMD;~Calculation of the FRAX® score;~Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
79988054|NCT04792801|Radiation|PET TDM FDG-Choline|Performing an FDG TDM PET and a Choline TDM PET at two different times
79816230|NCT00918060|Drug|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
79662883|NCT06135831|Other|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
79816231|NCT00918411|Drug|Ramosetron|oral
79816232|NCT00918411|Drug|Placebo|oral
79816233|NCT00720213|Device|Respironics BiPAP autoSV2|Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
79816234|NCT00720213|Device|Respironics BiPAP autoSV3|Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
79816235|NCT00915434|Drug|JNJ-31001074|
79816236|NCT04000802|Behavioral|response to questionnary|No intervention. Observational study
79816237|NCT04086303|Other|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
79988055|NCT03708757|Other|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
79988056|NCT03708757|Other|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
79349596|NCT04589559|Behavioral|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
79349597|NCT01829295|Drug|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.
79349598|NCT01829295|Drug|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
79349599|NCT01829295|Drug|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
79349600|NCT02157935|Drug|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
79500989|NCT04370444|Device|Phallus Length Reducer|Phallus Length Reducer
79500990|NCT04370444|Other|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
79500991|NCT04359017|Drug|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
79662884|NCT06135831|Other|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
79662885|NCT06135831|Other|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
79988057|NCT03707119|Other|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
79988058|NCT02949973|Drug|voclosporin|
79662886|NCT06135831|Other|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
79679562|NCT02941302|Procedure|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
79679563|NCT00516698|Genetic|polymorphism analysis|
79816238|NCT04112966|Procedure|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
79816239|NCT04112966|Other|the health education|The health education for lymphedema prevention.
79816240|NCT04086381|Dietary Supplement|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
79816241|NCT04086381|Dietary Supplement|placebo cellulose|oral ingestion of placebo containing 20 gram cellulose daily
79816242|NCT04107350|Device|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
79988059|NCT05175937|Device|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
79988060|NCT05175937|Device|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
79349601|NCT02157935|Drug|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
79349602|NCT02157935|Other|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
79662887|NCT06135428|Other|Education Group|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
79228310|NCT03302858|Device|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
79349603|NCT02157935|Other|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
79349604|NCT04589403|Drug|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
79349605|NCT02157779|Behavioral|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
79988061|NCT04152252|Other|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
79988062|NCT04152252|Behavioral|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
79988063|NCT04384146|Radiation|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
79228311|NCT03311360|Device|drug-coated balloon|Orchid and Dahlia DCB
79349606|NCT02157779|Behavioral|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
79349607|NCT02093221|Biological|180 mg/kg Alpha1-PI|
79349608|NCT02093221|Biological|90 mg/kg Alpha1-PI|
79349609|NCT02093221|Biological|Placebo|
79228312|NCT03311360|Device|bare metal stent|any type of bare metal stent
79349610|NCT02092909|Drug|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
79500992|NCT04358705|Other|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
79500993|NCT04358705|Behavioral|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (product advertisements) are viewed (n=30) for 10 seconds per image. Following each advertisement, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image
79662888|NCT06135311|Device|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
79349611|NCT01623115|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
79349612|NCT01623115|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
79349613|NCT01623115|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
79349614|NCT02092285|Drug|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
79349615|NCT02091739|Drug|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79349616|NCT02091739|Drug|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79349617|NCT02091739|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79349618|NCT02045875|Drug|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
79349619|NCT01597635|Drug|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
79988064|NCT04384146|Behavioral|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
79988065|NCT05420922|Drug|Lenvatinib Oral Product|Lenvatinib or Sorafenib
79349620|NCT01597635|Drug|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
79816243|NCT00810407|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
79816244|NCT00720057|Drug|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
79349621|NCT01597635|Drug|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
79500994|NCT04358705|Other|Eye tracking survey|Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
79500995|NCT04358705|Behavioral|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
79662889|NCT06135311|Device|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
79816245|NCT00720057|Drug|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
79816246|NCT00790868|Drug|d-cycloserine|50mg
79988066|NCT05420922|Drug|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
79988067|NCT05420922|Procedure|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
79988068|NCT05283096|Other|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
79988069|NCT02948959|Drug|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79349622|NCT01597635|Drug|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
79988070|NCT02948959|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79349623|NCT01597635|Drug|Placebo (saline)|Administered intravenously to match intervention
79349624|NCT01828281|Device|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
79988071|NCT02948959|Drug|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
79988072|NCT02948959|Drug|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
79349625|NCT01827267|Drug|neratinib|
79988073|NCT03582215|Drug|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
79988074|NCT03582215|Drug|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
79349626|NCT01827267|Drug|temsirolimus|
79349627|NCT01855425|Radiation|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
79662890|NCT06134609|Behavioral|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
79679564|NCT00516698|Other|high performance liquid chromatography|
79679565|NCT00516698|Other|laboratory biomarker analysis|
79679566|NCT00516698|Procedure|radiomammography|
79679567|NCT02949557|Procedure|Decortication + bone grafts|
79816247|NCT00790868|Drug|placebo|50mg
79816248|NCT04105556|Other|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
79816249|NCT00719901|Drug|obatoclax mesylate|Given IV
79816250|NCT00719901|Drug|bortezomib|Given IV
79988075|NCT03582215|Drug|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
79988076|NCT03582215|Drug|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
79988077|NCT03582215|Drug|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
79988078|NCT03582215|Drug|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
79349628|NCT01854879|Device|Nucleus 6 sound processor|
79662892|NCT06133582|Behavioral|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
79988079|NCT03582215|Drug|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
79349629|NCT01827111|Drug|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
79349630|NCT01827111|Drug|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
79349631|NCT01827111|Behavioral|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
79500996|NCT04358705|Other|Aim 3 survey|"Consists of:~A screener and demographic data collection.~A tobacco product withdrawal scale~Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~The tobacco product withdrawal scale again~Measurements of nicotine dependence and flavor preferences"
79662893|NCT06133400|Other|Questionnaire|Questionnaire about socio-demographical status, health status and lifestyle habits
79662894|NCT06133400|Other|Physical measurements|Measurement of height, weight, waist circumference, blood pressure and skin pigmentation
79662895|NCT06133400|Other|Biological samples|Collect venous blood, saliva and stool samples
79662896|NCT06133244|Diagnostic Test|Imaging, blood samples, fuctional tests and physical examination|Imaging, blood samples, fuctional tests and physical examination
79662897|NCT06133166|Drug|EG017 ointment|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
79988080|NCT03582215|Drug|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
79988081|NCT03089580|Device|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
79988082|NCT03089580|Procedure|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
79349632|NCT02045095|Drug|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
79349633|NCT04183309|Other|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
79349634|NCT02181803|Drug|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
79349635|NCT02181803|Drug|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
79662898|NCT06133166|Drug|EG017 ointment placebo|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
79662899|NCT06130423|Drug|Music intervention|Music therapy carried out with Music Care
79662900|NCT06130423|Drug|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
79662901|NCT06129916|Drug|long-acting depot buprenorphine (LADB)|The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
79662902|NCT06129682|Other|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
79816251|NCT00719901|Other|laboratory biomarker analysis|Correlative studies
79816252|NCT02591277|Drug|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
79988083|NCT05420610|Other|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
79988084|NCT05420610|Other|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
79988085|NCT05420532|Other|Exergaming|A video game-based physical activity training applied using a commercial game console.
79816253|NCT02609555|Procedure|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
79349636|NCT02181803|Drug|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
79228313|NCT03311282|Device|infants bottles|"angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~flexors at the base to enhance elasticity and flexibility of the teat"
79349637|NCT01826487|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
79816254|NCT00807365|Drug|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, & 5:00 AM for 6 months.
79816255|NCT02609789|Drug|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
79349638|NCT01826487|Drug|Placebo|Placebo will be administered as per the schedule specified in the arm.
79349639|NCT02064439|Drug|BAY 59-7939|10 mg tablet once daily for 12 months
79349640|NCT02064439|Drug|BAY 59-7939|20 mg tablet once daily for 12 months
79349641|NCT02064439|Drug|ASA|100 mg tablet once daily for 12 months
79816256|NCT02609789|Drug|Placebo|0.9 percent (%) normal saline.
79816257|NCT02591355|Device|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
79816258|NCT02591355|Device|Saline solution injection|Placebo is a saline solution
79816259|NCT05753969|Device|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
79816260|NCT03781427|Device|Cardiac resynchronization therapy|Left ventricular pacing
79816261|NCT00719355|Behavioral|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
79816262|NCT00719355|Behavioral|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
79988086|NCT01568580|Drug|GreenGene|Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus
79988087|NCT04107870|Behavioral|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
79816263|NCT05753579|Behavioral|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
79816264|NCT05753579|Behavioral|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
79816265|NCT02591433|Other|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
79662906|NCT06127836|Procedure|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
79662907|NCT06127667|Behavioral|aerobic exercise|use of single bout of aerobic exercise
79816266|NCT02591433|Other|Support Group Therapy|Undergo JeffQuit group therapy
79816267|NCT02591433|Other|Quality-of-Life Assessment|Ancillary studies
79816268|NCT02609711|Drug|Candesartan cilexetil|
79816269|NCT04973657|Drug|VK0214|API in capsule
79816270|NCT04973657|Other|Placebo|API in capsule
79816271|NCT05749601|Other|Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid|Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
79816272|NCT05749601|Other|The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis|Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
79816273|NCT05749601|Other|The influence of ROS from the synovial fluid on the severity of KOA|Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
79662908|NCT06127108|Diagnostic Test|Panbio™|The Panbio™ COVID-19/Flu A&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
79662909|NCT06124313|Dietary Supplement|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
79816274|NCT04016207|Drug|Guanfacine|regular treatment
79816275|NCT00590759|Device|GORE TAG® Thoracic Endoprosthesis|implant
79988088|NCT04107870|Behavioral|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
79662910|NCT06119867|Procedure|Japanese pathological investigation|Japanese pathological investigation
79679568|NCT02942433|Behavioral|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
79816276|NCT05753423|Diagnostic Test|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
79816277|NCT04030091|Drug|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
79816278|NCT04030091|Drug|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
79816279|NCT04030013|Other|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
79816280|NCT00734604|Drug|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
79816281|NCT00734604|Drug|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
79816282|NCT00734604|Drug|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
79816283|NCT00590681|Drug|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
79816284|NCT05748509|Other|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
79816285|NCT02607917|Other|Mass Media plus clinic intervention.|
79816286|NCT02607917|Other|Media|
79816287|NCT04088682|Behavioral|Quality improvement strategies and tools|Quality improvement strategies and tools
79816288|NCT02594982|Other|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
79816289|NCT02607839|Biological|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
79662911|NCT06119867|Procedure|European pathological investigation|The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
79816290|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
79662912|NCT06119451|Behavioral|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
79816291|NCT00727272|Drug|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
79816292|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
79349642|NCT02130557|Drug|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.[1] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
79349643|NCT02130557|Drug|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
79349644|NCT01854645|Drug|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
79816293|NCT00805025|Drug|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
79816294|NCT00734214|Drug|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
79349645|NCT01854645|Drug|GP MDI|GP MDI administered as two puffs BID
79816295|NCT00734214|Drug|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
79816296|NCT03669653|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
79500997|NCT04358705|Other|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
79816297|NCT03669653|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
79662913|NCT06114680|Device|CochSyn test prototype|The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
79816298|NCT03656315|Other|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
79662914|NCT06114680|Device|Universal Smart Box (USB)|Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
79349646|NCT01854645|Drug|FF MDI|FF MDI administered as two puffs BID
79349647|NCT01854645|Drug|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
79816299|NCT05247372|Other|The effect of Iyengar yoga practice on patients with multiple sclerosis|The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
79349648|NCT01854645|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID
79349649|NCT04418089|Drug|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
79662915|NCT06114433|Other|3D printed educational model|Slide-based presention plus 3D printed educational model
79662916|NCT06114433|Other|Traditional model education|Slide-based presention plus traditional model
79816300|NCT02607995|Behavioral|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
79816301|NCT02595216|Device|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
79816302|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
79816303|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
79349650|NCT04418089|Drug|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
79349651|NCT01825941|Drug|metoclopramide|10 milligrams, administered intravenously over 15 minutes
79816304|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
79349652|NCT01825941|Drug|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
79349653|NCT01825941|Drug|placebo|
79349654|NCT02064205|Dietary Supplement|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
79349655|NCT02064205|Dietary Supplement|glucose syrup|Glucose syrup is used a control product for the polydextrose
79349656|NCT02090959|Drug|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
79500998|NCT04345250|Other|Energy restriction|A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
79662917|NCT06113679|Device|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
79349657|NCT02044159|Drug|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
79349658|NCT02044159|Other|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
79349659|NCT02090725|Drug|3-4 Diaminopyridine|
79500999|NCT04328740|Drug|TP-1454 monotherapy|Flat dose once or twice daily, alone
79501000|NCT04317716|Behavioral|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
79501001|NCT04317716|Other|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
79501002|NCT04311034|Drug|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
79501003|NCT04303676|Other|Virtual Practice Facilitation with e-Learning|"Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
79501004|NCT04303676|Other|Virtual Practice Facilitation without e-Learning|"Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
79501005|NCT04294199|Other|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
79662919|NCT06103617|Drug|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
79662920|NCT06099977|Procedure|Binaural sound|Binaural sound: Binaural sound will be applied.
79662921|NCT06099977|Procedure|Placebo|Only headphone without sound will be applied.
79662922|NCT06096025|Drug|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
79662923|NCT06094426|Biological|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
79662924|NCT06091059|Diagnostic Test|Ultrasound MRI fusion|Fused MRI images with direct ultrasound guidance
79662925|NCT06088784|Drug|ATH-399A|Orally administered drug in capsule form.
79349660|NCT02180165|Drug|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
79349661|NCT02180165|Drug|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
79349662|NCT04748705|Drug|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
79501006|NCT04277117|Behavioral|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
79501007|NCT04277117|Behavioral|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off & visual check) with the participant."
79501008|NCT04277117|Behavioral|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~Delivery: 1x per week shipment.~Engagement: Meals are shipped to the participant's home. No human engagement."
79501009|NCT04277117|Behavioral|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
79501010|NCT04273776|Drug|Suvorexant 10 mg|10 mg of suvorexant
79501011|NCT04273776|Drug|Zolpidem|5 mg of zolpidem
79662926|NCT06088784|Drug|Placebo|Orally administered drug in capsule form.
79662927|NCT06085859|Device|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
79501012|NCT04273776|Drug|Placebos|Avicel
79501013|NCT04272944|Drug|10 mg/kg Q2W|10 mg/kg MSB2311 every two weeks
79349663|NCT04748705|Drug|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
79349664|NCT02155985|Drug|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
79501014|NCT04272944|Drug|20 mg/kg Q3W|20 mg/kg MSB2311 every three weeks.
79501015|NCT04264143|Drug|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
79501016|NCT04264143|Device|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
79501017|NCT04258488|Drug|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
79662928|NCT06085859|Device|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
79662929|NCT06083480|Drug|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
79662930|NCT06083480|Drug|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
79662931|NCT06080594|Behavioral|High-intensity exercise training|Eight sessions of high-intensity knee extensor exercise are conducted on separate days over a 2-week period.
79988089|NCT05175703|Device|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
79501018|NCT04258488|Drug|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
79662932|NCT06064578|Behavioral|Project SOLVE|Project SOLVE is a ~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
79816305|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
79988090|NCT04102800|Drug|Benralizumab|subcutaneous injection
79988091|NCT03632226|Drug|18F-OGA-1|
79988092|NCT05682703|Diagnostic Test|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
79349665|NCT02155985|Drug|Placebo|Placebo for aspirin
79349666|NCT02155829|Drug|Riluzole|
79349667|NCT02155829|Drug|Placebo (for Riluzole)|
79349668|NCT02129777|Drug|Namilumab|Namilumab subcutaneous injection
79349669|NCT02129777|Drug|Placebo|Placebo subcutaneous injection
79501019|NCT04255875|Biological|Placebo|Participants will receive matching placebo
79501020|NCT04255875|Biological|PF-07209326|Participants will receive SC or IV single ascending doses
79501021|NCT04255875|Biological|PF-07209326|SCD participants will receive a multiple dose of subcutaneous PF-07209326
79501022|NCT04253548|Behavioral|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
79501023|NCT04246281|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
79662933|NCT06060626|Drug|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
79662934|NCT06060626|Drug|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
79816306|NCT00787202|Other|placebo|Administration via oral route twice daily for the duration of treatment
79501024|NCT04246281|Procedure|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
79501025|NCT04243668|Procedure|ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)|"In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire."
79349670|NCT02178995|Drug|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
79349671|NCT02128997|Device|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
79816307|NCT02609477|Drug|Istradefylline|Istradefylline 40, 80, 160 mg
79816308|NCT02609477|Drug|Phentermine 45 mg|Phentermine 45 or 90 mg
79816309|NCT02609477|Other|Placebo|Placebo
79816310|NCT05744999|Procedure|Coconut technique|We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
79349672|NCT02155283|Device|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
79349673|NCT02154581|Device|SLActive implant|
79501026|NCT04228965|Drug|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
79662935|NCT06060613|Biological|OBX-115|"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide."
79662936|NCT06059014|Drug|177Lu-PSMA-1 (radiopharmaceutical)|7.4 GBq (or 5.9 GBq in case of lower actvity) of 177Lu-PSMA-1, every 6 weeks for 4 administirations
79662937|NCT06058767|Diagnostic Test|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
79988093|NCT05664919|Drug|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
79501027|NCT04228965|Behavioral|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
79501028|NCT04228965|Behavioral|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
79501029|NCT04228367|Device|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
79662938|NCT06058767|Diagnostic Test|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
79662939|NCT06053853|Biological|Diphtheria Antitoxin|"Dosage form: Solution for injection~Dosage:~Perform sensitivity tests, and desensitization if necessary.~Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization).~The recommended DAT treatment dosage ranges (pediatric and adult) are:~Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit~Nasopharyngeal disease 40,000 - 60,000 unit~Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit~Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit"
79349674|NCT02154425|Procedure|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
79988094|NCT05175079|Device|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
79988095|NCT05175079|Other|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
79988096|NCT03323346|Drug|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
79501030|NCT04218526|Device|Vercise DBS System|Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
79349675|NCT02154425|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
79662940|NCT06051305|Behavioral|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
79662941|NCT06047509|Procedure|Focal Laser Ablation|Removal of cancerous tissue through the direct application of laser energy
79662942|NCT06044649|Behavioral|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain.
79816311|NCT02592720|Drug|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
79988097|NCT05628571|Combination Product|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
79349676|NCT02154347|Drug|KAD-1229|
79349677|NCT02154347|Drug|Placebo|
79349678|NCT02154347|Drug|Insulin|
79349679|NCT01627067|Drug|Everolimus|10 mg by mouth once daily.
79501031|NCT04197687|Biological|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
79501032|NCT04197687|Biological|Pertuzumab|permitted at physician's discretion
79501033|NCT04197687|Other|Placebo Administration|Given ID
79501034|NCT04197687|Biological|Sargramostim|Given ID
79501035|NCT04197687|Biological|Trastuzumab|therapy are at the discretion of the treating physicians
79501036|NCT04197687|Biological|Trastuzumab Emtansine|at the discretion of the treating physicians.
79501037|NCT04186494|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
79501038|NCT04186494|Device|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
79501039|NCT04186494|Combination Product|Liraglutide and CPAP|Combination of both treatments
79501040|NCT04179448|Procedure|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
79501041|NCT04179448|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
79501042|NCT04158648|Drug|Emicizumab|Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
79501043|NCT04155541|Drug|dacomitinib hydrate|The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
79662943|NCT06044649|Behavioral|Acceptance and Commitment Therapy|ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
79501044|NCT04123821|Device|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
79662944|NCT06044649|Behavioral|Emotional Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
79816312|NCT02592720|Device|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
79988098|NCT05628571|Combination Product|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
79349680|NCT01627067|Drug|Exemestane|25 mg by mouth once daily.
79349681|NCT01627067|Drug|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
79349682|NCT02178059|Drug|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
79349683|NCT02178059|Drug|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
79349684|NCT01626989|Device|BiPAP auto Advanced|Auto Servo Ventilation Device
79349685|NCT01626989|Device|BiPAP auto SV4|Auto Servo Ventilation Device
79349686|NCT04748237|Diagnostic Test|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days.
79349687|NCT02128217|Drug|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
79501045|NCT04115319|Drug|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
79501046|NCT04115319|Drug|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
79501047|NCT04110132|Procedure|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
79501048|NCT04110132|Procedure|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
79501049|NCT04107935|Behavioral|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
79501050|NCT04107935|Behavioral|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
79662945|NCT06044649|Other|Treatment as Usual|Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
79662946|NCT06040567|Other|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
79662947|NCT06040567|Other|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
79816313|NCT02592720|Device|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
79662948|NCT06037525|Device|PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
79662949|NCT06033664|Behavioral|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
79816314|NCT02608073|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
79662950|NCT06020144|Drug|TLL-018|Oral tablets administered 2pieces BID for 52 weeks.
79349688|NCT02128217|Drug|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
79816315|NCT02608073|Drug|Cisplatin|Participants will receive cisplatin, 100 mg/m^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
79816316|NCT02594904|Drug|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
79816317|NCT02605070|Drug|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
79816318|NCT04041791|Drug|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
79816319|NCT04041791|Drug|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
79816320|NCT04041791|Drug|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
79816321|NCT04041791|Drug|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
79816322|NCT04041791|Other|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
79816323|NCT04041791|Other|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
79349689|NCT02128217|Drug|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
79349690|NCT01629953|Other|Group vocational intervention|Group based manualized vocational rehabilitation
79349691|NCT01629953|Other|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
79349692|NCT02127281|Device|Prevena|Device will be applied at end of procedure over closed incision.
79349693|NCT01628549|Drug|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
79349694|NCT01628549|Drug|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
79662951|NCT06020144|Drug|Tofacitinib|Oral tablets administered 1pieces BID for 52 weeks.
79662952|NCT06006858|Biological|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
79662953|NCT06006416|Drug|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
79816324|NCT04041791|Drug|Ampicillin|Ampicillin is a penicillin-type antibiotic.
79816325|NCT05572502|Behavioral|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
79501051|NCT04105270|Drug|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
79501052|NCT04105270|Drug|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
79501053|NCT04105270|Drug|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
79501054|NCT04105270|Other|Placebo|Sixteen doses of oral placebo capsules given weekly
79501055|NCT04100200|Dietary Supplement|Mixed berries|Strawberry and red raspberry
79501056|NCT04100200|Dietary Supplement|FOS|Fructo-oligosaccharide
79501057|NCT04100200|Dietary Supplement|Control|Placebo similar in color to mixed berry supplement without any polyphenols
79501058|NCT04100200|Dietary Supplement|Combination|Mixed berry composite + FOS
79501059|NCT04099472|Behavioral|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
79501060|NCT04099472|Behavioral|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
79816326|NCT02605226|Procedure|Cryoablation therapy|Cryoablation therapy
79816327|NCT02605226|Radiation|External beam radiation therapy|External beam radiation therapy
79816328|NCT02605226|Drug|bicalutamide|bicalutamide
79349695|NCT01628549|Drug|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
79349696|NCT02127125|Drug|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
79816329|NCT02605226|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
79816330|NCT04033367|Drug|Dupilumab|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79816331|NCT04033367|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79816332|NCT00733980|Drug|GSK561679|GSK561679
79816333|NCT00733980|Other|Placebo|Placebo
79349697|NCT02127125|Drug|Synbiotic|Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
79349698|NCT02127125|Drug|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
79501061|NCT04097795|Other|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
79501062|NCT04084561|Behavioral|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (~90%).
79816334|NCT04088448|Drug|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
79816335|NCT04088448|Drug|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
79816336|NCT00806585|Drug|MK-0736|
79816337|NCT00806585|Drug|Comparator: Placebo|
79816338|NCT00806585|Drug|Comparator: HCTZ|
79501063|NCT04084561|Behavioral|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (~10%).
79501064|NCT04084561|Behavioral|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
79501065|NCT04084561|Behavioral|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
79501066|NCT04073602|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
79816339|NCT02607761|Other|Video|Video-Audio Media
79816340|NCT05740553|Device|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
79816341|NCT00480025|Biological|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
79816342|NCT00480025|Biological|Placebo Control|Intramuscular administration, 13 doses
79816343|NCT00806351|Drug|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
79816344|NCT00806351|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
79816345|NCT03589963|Behavioral|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
79349699|NCT04417751|Behavioral|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation [CS] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
79662954|NCT06002490|Drug|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
79662955|NCT06002490|Drug|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
79662956|NCT06002490|Procedure|Phlebotomy|Phlebotomy is performed aiming at a hematocrit < 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
79662957|NCT05995275|Biological|mRNA-1769|Sterile liquid for injection
79349700|NCT02090413|Drug|dimethyl fumarate|
79816346|NCT03995251|Drug|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
79349701|NCT02090413|Drug|acetylsalicylic acid|enteric-coated capsule
79349702|NCT02090413|Drug|ASA-Placebo|matched placebo
79349703|NCT04702165|Device|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
79349704|NCT02063737|Behavioral|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
79349705|NCT02063737|Behavioral|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
79662958|NCT05995275|Other|Placebo|0.9% sodium chloride injection (normal saline)
79680075|NCT04690569|Diagnostic Test|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
79816347|NCT03995251|Drug|Standard Medical Treatment|Standard Medical Treatment
79816348|NCT03995251|Other|Exercise|Exercise
79816349|NCT02606825|Other|Registry of AML patients > 60 years|
79816350|NCT01031017|Drug|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
79816351|NCT01031017|Drug|placebo|placebo
79816352|NCT03635177|Procedure|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
79816353|NCT03742531|Drug|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
79816354|NCT00733902|Biological|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
79816355|NCT00733902|Biological|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
79501067|NCT04060355|Behavioral|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
79816356|NCT00733902|Biological|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
79501068|NCT04060355|Behavioral|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
79501069|NCT04060277|Drug|Letermovir|Given as SOC
79501070|NCT04060277|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
79501071|NCT04060277|Other|Placebo Administration|Given IM
79501072|NCT04043520|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
79501073|NCT04043520|Drug|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
79680076|NCT00523523|Behavioral|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
79816357|NCT00733902|Biological|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
79816358|NCT01027741|Behavioral|Phone Referral|Participants receive phone referral to cancer control and prevention services.
79816359|NCT01027741|Behavioral|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
79349706|NCT02125877|Drug|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
79501074|NCT04043520|Drug|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
79680077|NCT00523523|Behavioral|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
79816360|NCT01027741|Behavioral|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
79816361|NCT05737355|Dietary Supplement|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
79349707|NCT02125877|Drug|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
79816362|NCT05737355|Dietary Supplement|Placebo Capsules|Maltodextrin was used as a placebo
79816363|NCT00914225|Other|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
79816364|NCT02608541|Other|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
79816365|NCT00914381|Behavioral|Behavioral therapy|
79349708|NCT01598987|Drug|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m^2/dose in combination wit Cyclosporine A or 2.0 mg/m^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
79816366|NCT02607527|Device|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
79349709|NCT02063659|Drug|Telotristat etiprate|Telotristat etiprate tablets
79501075|NCT04043520|Drug|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
79349710|NCT02063659|Drug|Placebo|Placebo-matching telotristat etiprate tablets
79349711|NCT02062879|Drug|Ketamine|Ketamine administered as patient-controlled analgesia.
79349712|NCT02062879|Drug|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
79349713|NCT02062645|Drug|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
79662959|NCT05992376|Behavioral|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
79662960|NCT05976165|Other|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
79662961|NCT05975788|Drug|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
79662962|NCT05975476|Behavioral|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
79662963|NCT05975476|Behavioral|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
79816367|NCT03540017|Drug|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
79988099|NCT05255016|Combination Product|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution [0.25%], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
79988100|NCT05255016|Other|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
79988101|NCT05610397|Device|STALIF®|STALIF® C, or M, Ti or FLX
79988102|NCT05598450|Device|rTMS and MEG for auditory hallucinations via single arm|a 4 weeks, weekly 230 minutes, 1Hz, 100%RMT-rTMS protocol
79988103|NCT03645395|Drug|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
79988104|NCT04074018|Other|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
79988105|NCT04074018|Other|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
79988106|NCT03342469|Other|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
79988107|NCT03342469|Other|Placebo|Placebo chocolate cookies
79988108|NCT05178888|Drug|MRTX849|KRAS G12C inhibitor
79988109|NCT05178888|Drug|Palbociclib|CDK 4 and 6 inhibitor
79988110|NCT03581825|Device|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
79988111|NCT03581825|Device|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
79988112|NCT03581825|Device|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
79349714|NCT04700839|Drug|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
79228314|NCT03311282|Device|Infants Bottles|"large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~flexors at the base to enhance elasticity and flexibility of the teat"
79349715|NCT04700839|Drug|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
79349716|NCT02088697|Drug|Placebo|
79349717|NCT02088697|Drug|ASC-01|
79349718|NCT01825785|Drug|Romosozumab|Administered by subcutaneous injection
79349719|NCT01825785|Drug|Placebo|Administered by subcutaneous injection
79349720|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
79501076|NCT04038294|Dietary Supplement|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
79501077|NCT04038294|Dietary Supplement|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
79501078|NCT04034056|Drug|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
79662964|NCT05971888|Behavioral|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
79662965|NCT05969795|Diagnostic Test|Transvaginal ultrasound|Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth
79816368|NCT02606747|Other||routine blood sugar control
79816369|NCT02606981|Device|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
79816370|NCT02606981|Device|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
79680078|NCT02947880|Drug|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
79816371|NCT02606435|Procedure|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
79501079|NCT04028687|Device|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
79501080|NCT04004494|Other|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
79988113|NCT03581825|Device|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
79816372|NCT02606435|Device|thrombus aspiration|thrombus aspiration with export catheter
79988114|NCT03342001|Drug|Calcitonin|calcitonin nasal spray
79988115|NCT03730025|Other|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
79988116|NCT03730025|Other|Auscultation without NeoTapAS|Auscultation without NeoTapAS
79988117|NCT03341923|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
79349721|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
79349722|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
79349723|NCT01598753|Drug|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
79349724|NCT01598753|Drug|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
79349725|NCT01598753|Behavioral|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
79501081|NCT04003311|Device|Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
79816373|NCT04015349|Diagnostic Test|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
79816374|NCT03518723|Other|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
79816375|NCT03518723|Other|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
79988118|NCT03341923|Device|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
79988119|NCT03579719|Drug|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
79228315|NCT03311282|Device|Infants Bottles|"teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~flexors at the base to enhance elasticity and flexibility of the teat"
79988120|NCT03579719|Drug|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
79501082|NCT04003311|Device|Comprehensive Anatomic Versa-Dial Titanium Humeral Head|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
79501083|NCT03981055|Device|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
79501084|NCT03981055|Device|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
79501085|NCT03981055|Other|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
79501086|NCT03943537|Drug|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
79662966|NCT05969795|Diagnostic Test|Serial serum LH, E2, P4|Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).
79662967|NCT05969795|Drug|Progesterone 100 Mg Vaginal Insert|On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
79662968|NCT05969795|Diagnostic Test|Serum P4 day of ET - Control Group|Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure
79662969|NCT05969795|Diagnostic Test|Serum P4 day of ET - Study Group|Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.
79816376|NCT05752955|Other|SMARThealth Pregnancy|"At each visit, the CHW will:~Update history and contact details~Check haemoglobin with a point of care device.~Check BP~Check iron folic acid (IFA) supply and compliance~Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
79816377|NCT00790790|Drug|Placebo|LY545694 placebo BID po for 5 weeks
79816378|NCT00790790|Drug|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
79662970|NCT05969795|Procedure|Embryo transfer|The procedure in which embryo is placed in the uterus.
79662971|NCT05969795|Diagnostic Test|Serum hCG 10 days after ET|Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of > 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)
79662972|NCT05969795|Diagnostic Test|Serum P4 10 days after ET|Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure
79680079|NCT02947880|Drug|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
79816379|NCT00790790|Drug|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
79816380|NCT02602964|Other|Deep neuromsucular block|Deep or standard neuromuscular block
79816381|NCT00914888|Drug|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
79988121|NCT03631602|Drug|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
79349726|NCT01598753|Behavioral|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
79349727|NCT02177123|Device|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
79349728|NCT01824693|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
79349729|NCT01824693|Drug|Busulfan|Given IV
79349730|NCT01824693|Drug|Cyclophosphamide|Given IV
79349731|NCT01824693|Drug|Fludarabine Phosphate|Given IV
79349732|NCT01824693|Other|Laboratory Biomarker Analysis|Correlative studies
79349733|NCT01824693|Drug|Melphalan|Given IV
79349734|NCT01824693|Drug|Mycophenolate Mofetil|Given IV or PO
79349735|NCT01824693|Other|Pharmacological Study|Correlative studies
79349736|NCT01824693|Drug|Tacrolimus|Given IV or PO
79349737|NCT02176655|Drug|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
79501087|NCT03935256|Drug|Carboplatin and Paclitaxel|Regimen I: Carboplatin AUC 6 & Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 & Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 & 7 concurrent with radiotherapy
79501088|NCT03935256|Radiation|Radiation Therapy|"An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist."
79988122|NCT03732989|Device|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
79988123|NCT03732989|Device|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
79988124|NCT03341533|Procedure|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
79988125|NCT03341533|Other|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
79501089|NCT03930914|Device|Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
79501090|NCT03928717|Behavioral|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
79501091|NCT03928717|Behavioral|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
79501092|NCT03923491|Behavioral|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
79501093|NCT03923491|Behavioral|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
79501094|NCT03923426|Other|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
79501095|NCT03896152|Drug|LNP023|approximately 2 year of Treatment with LNP023
79662973|NCT05966220|Device|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
79662974|NCT05965817|Drug|SGM-101 op top of ICG|SGM-101 op top of ICG
79662975|NCT05961189|Drug|Azithromycin|Standard of care, 5 days of drug per manufacturer's instructions.
79501096|NCT03876951|Diagnostic Test|Vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
79501097|NCT03875963|Other|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin].
79662976|NCT05957081|Drug|PMC-309 monotherapy|PMC-309 will be administered intravenously.
79662977|NCT05957081|Drug|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
79662978|NCT05957081|Drug|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~Cohort A: PMC-309 monotherapy therapy~- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
79680080|NCT04690491|Other|follicular cyclus|Days of cyclus 6-12
79680081|NCT04690491|Other|luteal cyclus|Days of cyclus 20-24
79988126|NCT03732911|Behavioral|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
79501098|NCT03863288|Procedure|Functional MRI (fMRI)|Functional MRI (fMRI) scan with affective/cognitive tasks
79501099|NCT03863288|Drug|Oxytocin Intranasal Spray 8 International Unit (8IU)|Oxytocin intranasal spray liquid administration
79501100|NCT03863288|Drug|Oxytocin intranasal spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration
79501101|NCT03863288|Drug|Oxytocin intranasal spray 48 International Unit (48IU)|Oxytocin intranasal spray liquid administration
79501102|NCT03863288|Drug|Oxytocin intranasal spray 80 International Unit (80IU)|Oxytocin intranasal spray liquid administration
79501103|NCT03863288|Drug|Placebo|Placebo intranasal spray liquid administration
79680082|NCT00523562|Other|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
79988127|NCT03631524|Device|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
79349738|NCT02176655|Drug|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
79349739|NCT02125331|Procedure|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
79349740|NCT01622569|Drug|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
79349741|NCT01824303|Drug|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
79501104|NCT03837353|Drug|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
79501105|NCT03837353|Drug|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
79501106|NCT03832010|Drug|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
79501107|NCT03832010|Drug|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
79501108|NCT03832010|Drug|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
79501109|NCT03832010|Drug|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
79501110|NCT03825835|Drug|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
79662979|NCT05953753|Behavioral|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
79662980|NCT05953064|Other|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
79662981|NCT05953064|Other|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
79501111|NCT03825835|Drug|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
79501112|NCT03812393|Drug|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
79501113|NCT03806439|Other|Radical cystectomy.|Adult patients undergoing radical cystectomy.
79662982|NCT05935436|Device|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
79988128|NCT03729791|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
79349742|NCT01824303|Other|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
79349743|NCT01853397|Device|Liposonix System (Model 2)|
79501114|NCT03806413|Other|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
79662983|NCT05935384|Diagnostic Test|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
79349744|NCT02088073|Drug|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
79662984|NCT05931302|Diagnostic Test|68Ga-FAPI-46 PET scan|"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."
79662985|NCT05923866|Drug|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
79662986|NCT05923866|Drug|Placebo|Oral administration of placebo once a daily for 24 weeks
79988129|NCT03708445|Diagnostic Test|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using antibody of aminoacyl-tRNA synthetases"
79988130|NCT02688088|Drug|Drug Cocktail|Administered orally
79988131|NCT02688088|Drug|Abemaciclib|Administered orally
79662987|NCT05921760|Drug|Ivosidenib|ivosidenib taken once daily
79662988|NCT05921760|Drug|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
79662989|NCT05921760|Drug|Nivolumab|Nivolumab taken by intravenous infusion
79662990|NCT05921760|Drug|Ipilimumab|Ipilimumab taken by intravenous infusion
79662991|NCT05916651|Behavioral|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
79988132|NCT05598216|Diagnostic Test|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
79988133|NCT03641651|Other|Rehabilitation technology|"Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~The training can take place in an outpatient or inpatient setting.~Training will be organized in individual one-to-one or group session"
79662992|NCT05916651|Behavioral|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
79349745|NCT02088073|Drug|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
79349746|NCT01823991|Drug|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
79349747|NCT01823991|Other|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
79349748|NCT01823991|Drug|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
79349749|NCT04729855|Diagnostic Test|serum HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample
79501115|NCT03794583|Drug|Inhaled treprostinil solution|Inhaled treprostinil solution per dose and schedule specified in the arm
79662993|NCT05915975|Behavioral|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
79501116|NCT03781011|Behavioral|Vegetarian diet intervention|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
79662994|NCT05915975|Behavioral|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
79662995|NCT05913401|Behavioral|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
79662996|NCT05913401|Behavioral|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
79662997|NCT05907057|Drug|Ivosidenib 500mg Oral Tablet|Provided as tablets, taken orally as two 250mg tablets once daily.
79816382|NCT00914888|Drug|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
79816383|NCT00914888|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
79816384|NCT00914888|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
79816385|NCT02603198|Drug|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
79349750|NCT02087059|Drug|Ruxolitinib|
79988134|NCT04728204|Behavioral|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
79349751|NCT04747301|Device|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
79501117|NCT03774732|Radiation|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
79662998|NCT05907057|Drug|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
79662999|NCT05903391|Device|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
79816386|NCT02603198|Drug|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
79988135|NCT03341299|Biological|LY900014|Administered SC
79988136|NCT03341299|Biological|Insulin Lispro|Administered SC
79501118|NCT03774732|Drug|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
79501119|NCT03774732|Drug|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
79501120|NCT03759366|Drug|Eculizumab|Eculizumab will be administered by IV infusion.
79501121|NCT03741374|Procedure|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
79501122|NCT03740997|Drug|Optison|Optison is administered intravenously
79501123|NCT03738904|Combination Product|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
79988137|NCT05653960|Other|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
79988138|NCT05666219|Drug|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
79988139|NCT02949271|Other|Programmed Intermittent Epidural Bolus|
79663000|NCT05903391|Device|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
79663001|NCT05895565|Drug|PMG1015|Strength: 100 mg/2 mL/vial. Dosage and Administration: Intravenous infusion of PMG1015 at 15 mg/kg, 30 mg/kg and 40 mg/kg for 30 min (±5 min), once every 4 weeks, for 3 doses.
79663002|NCT05895565|Drug|PMG1015 placebo|The placebo injection of PMG1015 contains the same excipients as PMG1015 Injection, only without the active substance. Strength: 2 mL/vial. Dosage and Administration: A single dose of placebo. Intravenous infusion for 30 min (±5 min), once every 4 weeks, for 3 doses.
79663003|NCT05886712|Other|Naloxone|Naloxone
79988140|NCT02949271|Other|Continuous Epidural Infusion|
79349752|NCT04747301|Drug|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
79349753|NCT02152163|Drug|IV Ibuprofen|
79349754|NCT02152163|Drug|placebo|
79501124|NCT03738904|Combination Product|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
79663004|NCT05886712|Other|Usual intervention|usual administered drug for overdose
79663005|NCT05884866|Drug|Dapagliflozin 10mg Tab|see arms
79663006|NCT05884866|Drug|Balcinrenone 50mg Capsule|see arms
79663007|NCT05884866|Drug|Balcinrenone 100mg Capsule|see arms
79663008|NCT05884866|Drug|Dapagliflozin matching Placebo|see arms
79663009|NCT05884866|Drug|Balcinrenone 50mg matching Placebo|see arms
79663010|NCT05884866|Drug|Balcinrenone 100mg matching Placebo|see arms
79663011|NCT05880940|Device|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
79988141|NCT02949271|Drug|Ropivacaine|
79228316|NCT03302702|Other|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
79349755|NCT02152007|Drug|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
79501125|NCT03725059|Biological|Pembrolizumab (K)|IV infusion Q3W
79501126|NCT03725059|Drug|Placebo (P)|Normal saline or dextrose IV infusion Q3W
79501127|NCT03725059|Drug|Paclitaxel (X)|IV infusion QW
79501128|NCT03725059|Drug|Doxorubicin (A)|IV infusion either in Q2W or Q3W
79501129|NCT03725059|Drug|Epirubicin (E)|IV infusion either in Q2W or Q3W
79663012|NCT05880940|Behavioral|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
79988142|NCT02949271|Drug|Fentanyl|
79501130|NCT03725059|Drug|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
79501131|NCT03725059|Drug|Endocrine therapy|Variable endocrine therapy for up 10 years
79501132|NCT03725059|Radiation|Radiation therapy|Variable radiation therapy per local standard of care
79501133|NCT03725059|Procedure|Surgery|Surgery for breast cancer
79663013|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
79349756|NCT02151851|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/ml~Route of administration: Subcutaneous injection"
79349757|NCT02151851|Drug|Methotrexate|"Active substance: Methotrexate~Pharmaceutical form: Tablet~Concentration: Maximum dose 10 mg per week~Route of administration: Oral"
79349758|NCT02151851|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Prefilled syringes~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
79349759|NCT02176421|Device|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
79349760|NCT02042443|Drug|Capecitabine|Given PO
79349761|NCT02042443|Drug|Fluorouracil|Given IV
79349762|NCT02042443|Other|Laboratory Biomarker Analysis|Correlative studies
79349763|NCT02042443|Drug|Leucovorin Calcium|Given IV
79349764|NCT02042443|Drug|Trametinib|Given PO
79349765|NCT02118896|Drug|FK506E|oral
79349766|NCT02124707|Drug|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
79349767|NCT02124707|Drug|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
79349768|NCT02124707|Drug|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
79349769|NCT02067728|Behavioral|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
79349770|NCT02067728|Behavioral|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
79349771|NCT02118428|Device|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
79349772|NCT02118428|Biological|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
79663014|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
79663015|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
79228317|NCT02234661|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
79228318|NCT04596072|Combination Product|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
79228319|NCT03311204|Device|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
79349773|NCT02067104|Drug|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
79349774|NCT02067104|Drug|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
79501134|NCT03705676|Behavioral|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
79501135|NCT03705676|Device|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
79501136|NCT03705676|Device|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
79663016|NCT05875441|Drug|Placebo|16 placebo capsules will be administered as a single dose.
79228320|NCT03311204|Other|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
79349775|NCT02092220|Device|Bionic Pancreas|
79349776|NCT02092220|Device|Insulin pump with or without CGM|
79349777|NCT02066402|Drug|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
79349778|NCT02066402|Drug|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
79349779|NCT02066402|Drug|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
79349780|NCT02066402|Drug|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
79349781|NCT02060383|Drug|Pasireotide s.c.|Administered to Cushing's disease participants.
79349782|NCT02060383|Drug|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
79349783|NCT02060383|Drug|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
79501137|NCT03695237|Drug|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
79501138|NCT03665597|Biological|Pembrolizumab Dose C|SC injection
79501139|NCT03665597|Biological|Pembrolizumab Dose A|SC injection
79501140|NCT03665597|Biological|Pembrolizumab Dose B|IV infusion
79501141|NCT03665597|Biological|Pembrolizumab Dose D|IV infusion once every 6 weeks
79349784|NCT02060383|Drug|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
79349785|NCT02060383|Drug|Pasireotide LAR|Administered to Acromegaly participants.
79501142|NCT03654573|Device|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
79501143|NCT03633708|Drug|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
79501144|NCT03631693|Procedure|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
79501145|NCT03631693|Procedure|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
79988143|NCT03732755|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
79501146|NCT03607656|Drug|Oxaliplatin|Oxaliplatin powder injection
79501147|NCT03607656|Drug|Capecitabine|Capecitabine tablet
79501148|NCT03607656|Other|TCM|TCM decoction orally taken twice a day for at least 3 months
79501149|NCT03607656|Drug|S-1|S-1 capsule
79501150|NCT03607656|Drug|Docetaxel|Docetaxel injection
79349786|NCT02060383|Drug|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
79501151|NCT03607656|Drug|5-FU|5-FU injection
79501152|NCT03603600|Device|enVista MX60E|enVista MX60E monofocal IOL
79501153|NCT03603600|Device|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
79501154|NCT03586609|Drug|Azacitidine|Given SC or IV
79501155|NCT03586609|Drug|Cladribine|Given IV
79988144|NCT03706807|Other|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
79349787|NCT02086591|Drug|Doxycycline|
79349788|NCT02065622|Drug|Adalimumab|
79349789|NCT02065622|Other|Placebo|
79349790|NCT02117648|Drug|Abemaciclib|Administered orally
79349791|NCT02117648|Drug|Clarithromycin|Administered orally
79349792|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
79501156|NCT03586609|Drug|Cytarabine|Given SC
79501157|NCT03586609|Drug|Venetoclax|Given PO
79501158|NCT03584815|Procedure|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
79501159|NCT03584815|Other|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
79501160|NCT03584373|Drug|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
79501161|NCT03584373|Drug|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
79501162|NCT03584373|Drug|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
79501163|NCT03582124|Procedure|Near-Infrared Fluorescence Imaging|Undergo imaging
79501164|NCT03582124|Drug|Panitumumab-IRDye800|Given IV
79501165|NCT03582124|Other|Pharmacokinetic Study|Correlative studies
79501166|NCT03582124|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79501167|NCT03576391|Behavioral|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
79501168|NCT03576391|Behavioral|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
79501169|NCT03576391|Behavioral|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
79501170|NCT03576391|Behavioral|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
79680083|NCT02930655|Drug|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
79501171|NCT03570333|Diagnostic Test|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
79501172|NCT03569839|Drug|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
79501173|NCT03558789|Biological|bovine lactoferrin|mouthwash
79663017|NCT05866237|Device|Patient Engagement tool|The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 and Flu vaccinations through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
79663018|NCT05863312|Procedure|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
79663019|NCT05863312|Procedure|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
79663020|NCT05863312|Other|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
79988145|NCT03706807|Other|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
79988146|NCT03640559|Drug|Seroguard|
79501174|NCT03545490|Dietary Supplement|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
79501175|NCT03527589|Device|Prostate artery embolization|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
79501176|NCT03523858|Drug|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
79501177|NCT03479567|Other|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
79501178|NCT03479567|Other|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
79501179|NCT03479567|Other|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
79501180|NCT03479567|Diagnostic Test|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
79988147|NCT03640559|Drug|Placebos|
79501181|NCT03479567|Other|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
79501182|NCT03463473|Drug|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
79501183|NCT03463473|Drug|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
79501184|NCT03463473|Drug|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
79501185|NCT03463473|Drug|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
79501186|NCT03453567|Procedure|Valve Replacement|Aortic valve replacement
79349793|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
79663021|NCT05863312|Other|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
79663022|NCT05857774|Other|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
79663023|NCT05857774|Other|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
79663024|NCT05857774|Other|Biological measurements|Skeletal troponin-I
79663025|NCT05857566|Drug|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
79663026|NCT05857358|Procedure|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
79988148|NCT03339583|Behavioral|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
79988149|NCT03339583|Drug|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
79988150|NCT03639779|Drug|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
79349794|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
79349795|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
79349796|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
79349797|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
79501187|NCT03449498|Other|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
79501188|NCT03449498|Other|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
79501189|NCT03409718|Device|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
79501190|NCT03404778|Device|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
79501191|NCT03386929|Drug|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
79816387|NCT04105790|Behavioral|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
79816388|NCT02602886|Behavioral|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
79988151|NCT03639779|Other|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
79816389|NCT04105478|Procedure|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
79988152|NCT05239195|Other|Video Laryngoscope|Laryngoscope with a camera and a video screen
79988153|NCT05239195|Other|Direct Laryngoscope|Laryngoscope without a camera or a video screen
79988154|NCT03575975|Device|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
79816390|NCT04105322|Other|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
79816391|NCT00719043|Biological|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
79988155|NCT05174923|Behavioral|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
79988156|NCT05174923|Behavioral|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
79988157|NCT05174923|Behavioral|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
79988158|NCT03636893|Drug|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
79988159|NCT03636893|Drug|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
79349798|NCT02175641|Behavioral|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
79349799|NCT02175641|Behavioral|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
79349800|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
79501192|NCT03386929|Drug|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
79501193|NCT03386929|Drug|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
79988160|NCT05174689|Diagnostic Test|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
79501194|NCT03358303|Device|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
79501195|NCT03340454|Other|Test-and-treat EHR-CHW intervention|a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
79501196|NCT03340454|Other|Usual care of EHR-only intervention|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
79501197|NCT03335839|Drug|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
79501198|NCT03335839|Other|Saline|Placebo
79501199|NCT03318640|Behavioral|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
79501200|NCT03246802|Radiation|HDR partial prostate brachytherapy|temporary radioactive implant
79988161|NCT05174689|Diagnostic Test|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
79988162|NCT05174689|Diagnostic Test|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
79816392|NCT00719043|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
79501201|NCT03245658|Drug|THC and CBD Mixture|Individually titrated doses on daily basis
79501202|NCT03241134|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
79501203|NCT03241134|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
79501204|NCT03236129|Procedure|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
79501205|NCT03236129|Procedure|Standard DLI|The patients in this arm benefit of a standard DLI.
79501206|NCT03223220|Drug|Ketamine|IV infusion
79501207|NCT03223220|Other|Normal Saline|IV infusion
79663027|NCT05857358|Drug|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~2 for the sublingual glands (0.5mL for each gland)~2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
79663028|NCT05853731|Device|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
79663029|NCT05853731|Device|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
79663030|NCT05848375|Procedure|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
79663031|NCT05848375|Drug|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
79816393|NCT00719043|Biological|Placebo|Administered as an intramuscular (IM) injection
79816394|NCT00786422|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
79816395|NCT00718887|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
79816396|NCT00718887|Drug|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
79501208|NCT03223220|Drug|Midazolam injection|Injection
79501209|NCT03194256|Behavioral|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
79663032|NCT05848375|Drug|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
79988163|NCT03729635|Procedure|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
79663033|NCT05847673|Behavioral|Online Smoking Cessation Intervention|Receive EQQUAL A intervention
79663034|NCT05847673|Behavioral|Online Smoking Cessation Intervention|Receive EQQUAL B intervention
79988164|NCT05581693|Drug|L04RD1|1 tablet of L04RD1
79988165|NCT05581693|Drug|L04TD2|1 tablet of L04TD2
79349801|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
79349802|NCT02117570|Biological|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
79349803|NCT02123459|Drug|Cephalexin|Administered orally
79349804|NCT01853475|Drug|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
79501210|NCT03148327|Drug|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
79349805|NCT01853475|Drug|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
79349806|NCT01853475|Drug|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
79349807|NCT01853475|Drug|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
79349808|NCT04411160|Drug|Vitamin C|4 gram of vitamin c slowly intravenous once daily for 4 days duration.
79349809|NCT04411160|Drug|Nitric Oxide|nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
79349810|NCT04411160|Device|ventilators|All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
79349811|NCT02151773|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
79349812|NCT02151461|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
79349813|NCT02151461|Drug|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
79349814|NCT02151461|Drug|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
79349815|NCT02151461|Drug|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
79501211|NCT03148327|Radiation|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
79501212|NCT03143322|Radiation|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
79501213|NCT03133559|Other|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
79501214|NCT03133377|Behavioral|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
79663035|NCT05847673|Other|Questionnaire Administration|Ancillary studies
79663036|NCT05847673|Other|Health Promotion and Education|Receive motivational messages and smoking cessation information via SMS text messages
79663037|NCT05834036|Drug|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
79988166|NCT05581693|Drug|L04TD2|1 tablet of L04TD2
79988167|NCT05581693|Drug|L04RD1|1 tablet of L04RD1
79988168|NCT05568121|Drug|L04RD1|1 tablet of L04RD1
79988169|NCT05568121|Drug|L04TD1|1 tablet of L04TD1
79988170|NCT05568121|Drug|L04TD1|1 tablet of L04TD1
79988171|NCT05568121|Drug|L04RD1|1 tablet of L04RD1
79988172|NCT01353586|Device|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
79988173|NCT03708289|Radiation|DXA scan|total and hip and spine dual energy x-ray absorptiometry
79988174|NCT03708289|Other|Achilles bone US|
79501215|NCT03084146|Other|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
79663038|NCT05828355|Other|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
79501216|NCT03052634|Drug|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
79663039|NCT05826912|Drug|Atorvastatin Calcium|Capsule, 80 mg/day, with no loading dose, for 28 days
79663040|NCT05826912|Drug|Minocycline Hydrochloride|Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
79663041|NCT05826912|Drug|Candesartan Cilexetil|Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
79988175|NCT03708289|Other|Medical body composition measurements|
79988176|NCT03708289|Other|Resting energy expenditure measurement|
79988177|NCT05173441|Biological|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 ~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
79988178|NCT05173441|Drug|Placebo|The initial infusion rate is 0.01 ~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
79988179|NCT05682469|Behavioral|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
79988180|NCT05682469|Behavioral|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
79988181|NCT03706651|Device|Infants hospitalized in health facilities performing Tele-expertise|
79988182|NCT05682313|Diagnostic Test|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
79988183|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 *120mg new formulation tablet as test treatment
79988184|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 *120mg current clinical formulation tablet as reference treatment
79988185|NCT05075161|Drug|Pirfenidone|From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
79349816|NCT02117414|Device|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
79349817|NCT02117414|Other|Waiting Period Visit|Waiting period time will equate to 1 hour
79349818|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
79349819|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
79349820|NCT02091986|Other|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
79349821|NCT02091752|Drug|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to <200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
79349822|NCT02117024|Drug|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
79349823|NCT02117024|Drug|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
79663042|NCT05826912|Drug|Placebo|Capsule, 2x/day for 28 days
79663043|NCT05812534|Drug|Cadonilimab|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
79663044|NCT05799274|Drug|RAD301 ([68Ga]-Trivehexin)|Whole body PET scan
79663045|NCT05799144|Biological|DNA Vaccine|Given pBI-11 IM
79663046|NCT05799144|Biological|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
79349824|NCT02117024|Drug|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~Vinorelbine~Erlotinib~Gemcitabine~Paclitaxel~Docetaxel~Pemetrexed"
79349825|NCT02091440|Device|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
79349826|NCT02064920|Drug|Placebo|Placebo for donepezil hydrochloride capsule
79501217|NCT03052634|Drug|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
79501218|NCT03052634|Drug|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
79663047|NCT05799144|Biological|Pembrolizumab|Given into vein
79816397|NCT00786188|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
79816398|NCT00786188|Drug|Sugar pill|Subjects will receive a sugar pill.
79816399|NCT00790556|Drug|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
79816400|NCT00790556|Drug|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
79988186|NCT05075161|Drug|Placebo|All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
79349827|NCT02064920|Drug|Donepezil|5 mg donepezil hydrochloride capsule.
79349828|NCT02064920|Drug|Donepezil|10 mg donepezil hydrochloride capsule.
79349829|NCT02151149|Drug|nab-paclitaxel|
79663048|NCT05799144|Procedure|Computed Tomography (CT)|Undergo a CT
79663049|NCT05799144|Procedure|Magnetic Resonance Imaging (MRI)|Undergo an MRI
79816401|NCT04112732|Dietary Supplement|Multivitamin|Multivitamin
79663050|NCT05799144|Procedure|Magnetic Resonance Imaging|Undergo blood sample collection
79663051|NCT05799144|Procedure|Biopsy|Undergo tumor biopsy
79816402|NCT04112732|Other|Placebo|Placebo
79816403|NCT00733824|Drug|AMD3100|
79816404|NCT00733824|Drug|G-CSF|
79816405|NCT00733824|Procedure|Apheresis|
79816406|NCT00718809|Drug|saracatinib|Given orally
79816407|NCT04086069|Device|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
79816408|NCT00585039|Drug|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
79349830|NCT02151149|Drug|Carboplatin|
79349831|NCT04746131|Drug|IMM0306|IMM0306 is an bi-specific antibody
79349832|NCT02150213|Procedure|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
79349833|NCT02150213|Procedure|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
79349834|NCT02150213|Procedure|Sonogram|Sonogram of the uterus (females only)
79349835|NCT02150213|Procedure|Biopsy|Uterine endometrial biopsy (females only)
79349836|NCT02150213|Drug|BGG492|No study-drug was administered in this study
79816409|NCT04085913|Drug|Lidocaine Epinephrine|Preincision injection, as is current practice
79663057|NCT05792137|Other|High saturated fat challenge meal|High saturated fat challenge meal made with palm oil
79988187|NCT05073055|Procedure|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
79663058|NCT05792137|Other|High mono unsaturated fat challenge meal|High mono unsaturated fat challenge meal made with olive oil
79663059|NCT05789446|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
79663060|NCT05787366|Other|usual care and follow-up by a nurse|follow-up by a nurse and referral to a specialist(s) according to symptoms
79663061|NCT05787366|Other|Personalized Multifactorial Intervention (IMP)|"The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~Knowledge of the disease and specific management, (led by the nurse)~Covid-19 and anxiety/depression, (psychologist)~Fatigue and adapted physical activities (video capsules)~Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential."
79663062|NCT05781542|Biological|sD-NP-GT8 DNA|0.4 mg or 1.6 mg
79663063|NCT05781542|Biological|IL-12 DNA|0.1 mg or 0.4 mg
79349837|NCT02091362|Drug|LY2409021|Administered orally
79349838|NCT02091362|Drug|Placebo|Administered orally
79663064|NCT05781542|Biological|Trimer 4571|100 mcg
79663065|NCT05781542|Biological|3M-052-AF|5 mcg
79663066|NCT05781542|Drug|Alum|500 mcg
79663067|NCT05781217|Drug|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
79988188|NCT03706573|Drug|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
79349839|NCT02091362|Drug|Metformin|Administered as background therapy.
79349840|NCT02150057|Device|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
79349841|NCT02064296|Device|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
79663068|NCT05773378|Device|Pessary Intervention|Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 12-week period.
79663069|NCT05773378|Device|Tampon Intervention|Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period.
79663070|NCT05770752|Procedure|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
79816410|NCT04085913|Drug|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
79816411|NCT04085913|Drug|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
79816412|NCT00806195|Biological|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
79501219|NCT03052634|Drug|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
79501220|NCT03023930|Other|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
79501221|NCT03023930|Other|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
79663071|NCT05768269|Other|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
79349842|NCT02064296|Device|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
79663072|NCT05767736|Drug|Diroximel Fumarate|Administered as specified in the treatment arm.
79663073|NCT05767736|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
79816413|NCT00806195|Biological|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
79663074|NCT05767736|Drug|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
79349843|NCT02063984|Behavioral|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
79349844|NCT02063984|Behavioral|Working Memory Training|25 computer-delivered sessions of neurocognitive training
79501222|NCT02969083|Procedure|RNU|Radical surgical removal by open or laparoscopic access
79501223|NCT02969083|Drug|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
79501224|NCT02969083|Drug|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
79501225|NCT02943590|Drug|Placebo|A pill taken once a day
79501226|NCT02943590|Drug|Atorvastatin|A pill taken once a day
79663077|NCT05764928|Drug|BLEX 404|BLEX 404 Oral Liquid, PO, BID
79663078|NCT05759936|Dietary Supplement|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
79663079|NCT05759936|Other|Placebo|4 week placebo supplement of 1 capsule per day
79680084|NCT02930655|Drug|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
79816414|NCT00806195|Biological|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
79816415|NCT00806195|Biological|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
79988189|NCT05518357|Biological|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
79349845|NCT02091284|Device|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
79816416|NCT00806195|Biological|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
79349846|NCT02115386|Drug|Nilotinib|supplied in 150 mg capsules to be taken orally
79349847|NCT02091206|Drug|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
79501227|NCT02925871|Behavioral|Co-designed person-centred care transitions|The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.
79501228|NCT02925871|Behavioral|Current care transitions|Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
79663080|NCT05757687|Device|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
79663081|NCT05745467|Drug|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
79663082|NCT05741788|Device|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
79680085|NCT04690803|Drug|air cooling|intervention is adding air-cooling to treatment
79680086|NCT00523757|Drug|Spironolactone|
79816417|NCT00806195|Biological|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
79816418|NCT00806195|Biological|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
79816419|NCT00806195|Biological|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
79988190|NCT05095831|Diagnostic Test|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals [kPa] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity [(m/sec)/kHz] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
79349848|NCT02091206|Drug|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
79349849|NCT02091206|Drug|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
79349850|NCT02091206|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
79501229|NCT02916472|Behavioral|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
79680087|NCT00523757|Drug|Placebo|
79680088|NCT00524693|Drug|Montelukast|4mg sachets
79680089|NCT00524693|Drug|Placebo granules|
79988191|NCT05095831|Diagnostic Test|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
79988192|NCT03638869|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
79988193|NCT03638869|Drug|Placebo|
79663083|NCT05738499|Other|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
79988194|NCT03708055|Behavioral|Exercise Intervention|Undergo weight bearing exercise program
79988195|NCT03091920|Drug|IW-1973|Oral Tablet
79988196|NCT03091920|Drug|Placebo|Oral Tablet
79988197|NCT03338569|Drug|Vitamin C|Continuous infusion of vitamin C
79988198|NCT03338569|Drug|Placebo|Placebo designed to mimic intervention
79988199|NCT03338023|Drug|LY2963016|Administered SC
79988200|NCT03338023|Drug|Lantus®|Administered SC
79988201|NCT03338023|Drug|Insulin Lispro|Administered SC
79988202|NCT03337477|Drug|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
79988203|NCT03337477|Drug|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
79988204|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
79988205|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
79988206|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
79816420|NCT02922335|Behavioral|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
79988207|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
79349851|NCT04417790|Diagnostic Test|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
79501230|NCT02916472|Behavioral|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
79663084|NCT05738499|Other|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
79663085|NCT05718843|Drug|BI 425809|BI 425809
79988208|NCT02687542|Drug|Placebo|Placebo
79988209|NCT02687542|Drug|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
79988210|NCT02687542|Drug|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
79988211|NCT02687542|Drug|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
79988212|NCT02687542|Drug|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
79663086|NCT05716048|Behavioral|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
79663087|NCT05716048|Behavioral|KF-mSMT Plus Stretching Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
79663088|NCT05712707|Drug|BXCL501 (180 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
79663089|NCT05712707|Drug|BXCL501 (240 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
79663090|NCT05712707|Other|Placebo|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
79816421|NCT02922335|Behavioral|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
79349852|NCT02090426|Other|Link2Care|
79349853|NCT02063828|Device|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
79349854|NCT02063828|Device|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
79349855|NCT02063828|Device|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
79349856|NCT02063672|Device|Lutonix DCB|
79349857|NCT02063672|Device|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
79663091|NCT05712707|Other|Lofexidine (Positive Control)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
79988213|NCT03707899|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
79988214|NCT03707899|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
79988215|NCT05054569|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
79349858|NCT02062658|Drug|Ketamine|0.5mg/kg IV
79501231|NCT02916472|Behavioral|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
79501232|NCT02914561|Drug|Filgotinib|Filgotinib tablets administered orally once daily.
79501233|NCT02914561|Other|Placebo|Placebo administered orally once daily.
79501234|NCT02840799|Drug|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
79501235|NCT02840799|Drug|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
79349859|NCT02062658|Behavioral|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
79501236|NCT02838732|Dietary Supplement|L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)|
79988216|NCT03336619|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
79988217|NCT03336619|Drug|Placebo|Placebo administered orally twice daily for five days
79988218|NCT03114904|Other|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
79988219|NCT03706339|Other|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
79988220|NCT03706339|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
79349860|NCT02115308|Drug|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
79349861|NCT02114684|Drug|moxifloxacin|[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)]
79349862|NCT02090114|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
79501237|NCT02798666|Other|High intensity exercise training|Exercise training using sprint interval exercise
79501238|NCT02798666|Other|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
79501239|NCT02773238|Procedure|Computed Tomography|Undergo FDG PET/CT
79501240|NCT02773238|Procedure|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
79501241|NCT02773238|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
79501242|NCT02773238|Other|Laboratory Biomarker Analysis|Correlative studies
79988221|NCT03706339|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
79988222|NCT03739476|Drug|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
79988223|NCT03739476|Drug|Placebo oral capsule|Compare the incidence of postoperative delirium.
79988224|NCT05000268|Other|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
79349863|NCT02090114|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
79501243|NCT02773238|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
79501244|NCT02773238|Radiation|Radiation Therapy|Undergo functional avoidance radiation therapy
79663092|NCT05707078|Procedure|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
79663093|NCT05692154|Drug|Fexofenadine|Fexofenadine oral tablet
79988225|NCT03639558|Drug|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
79663094|NCT05692154|Drug|Placebo|Fexofenadine matching placebo oral tablet
79663095|NCT05670418|Device|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
79663096|NCT05660655|Drug|Baricitinib 4 MG Oral Tablet|baricitinib 4 mg once daily
79663097|NCT05660655|Drug|Baricitinib 2 MG|baricitinib 4mg once daily in group A
79663098|NCT05657301|Drug|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
79663099|NCT05645900|Biological|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
79663100|NCT05645900|Biological|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
79663101|NCT05645900|Biological|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
79663102|NCT05638217|Combination Product|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
79663103|NCT05634863|Device|Implantable Doppler probe manufactured by COOK Medical Company.|The continuous audible Doppler signals produced by the monitoring device represent the blood flowing in the renal artery. This is an indicator of graft perfusion. Cessation of audible Doppler signals is the key that may suggest hampered blood flow due to vascular complications. In the intervention group, the monitoring device will be used as an added mechanism to monitor graft perfusion.
79663104|NCT05630053|Device|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
79663105|NCT05630053|Device|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
79663106|NCT05627661|Device|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
79663107|NCT05625945|Behavioral|Physical activity monitoring|Physical activity patterns will be measured using the activPAL3 micro monitor
79663108|NCT05624658|Combination Product|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
79663109|NCT05619731|Other|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
79816422|NCT05752877|Biological|Targeted IL-13 Rα2 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10^7 cells) for 1-2 minutes each time.
79349864|NCT02090114|Drug|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
79501245|NCT02773238|Procedure|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
79501246|NCT02773238|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
79501247|NCT02773238|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
79816423|NCT05752877|Biological|Targeted B7-H3 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10^7 cells) for 1-2 minutes each time.
79988226|NCT03639558|Drug|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
79349865|NCT02090114|Drug|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
79349866|NCT01623050|Device|SinuSys Dilation System|Sinuplasty
79501248|NCT02743858|Other|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder & the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively & at timepoints of 6,12,18, & 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer & circumferential arm measurements at a minimum of 2 years post-surgery.
79663110|NCT05609448|Procedure|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
79663111|NCT05606770|Behavioral|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
79816424|NCT05728151|Drug|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
79816425|NCT05728151|Drug|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
79816426|NCT05728151|Drug|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
79816427|NCT02919137|Other|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
79349867|NCT02089334|Drug|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
79349868|NCT04742036|Drug|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
79501249|NCT02743858|Other|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
79501250|NCT02743858|Behavioral|Quality of Life Questionnaire|
79816428|NCT00733746|Drug|erlotinib hydrochloride|oral administration
79816429|NCT00733746|Drug|gemcitabine hydrochloride|Intravenous administration
79816430|NCT00733746|Procedure|therapeutic conventional surgery|
79501251|NCT02743858|Other|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
79501252|NCT02719106|Device|Ultimaster stent|
79349869|NCT04742036|Drug|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
79501253|NCT02708615|Other|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
79501254|NCT02703506|Other|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
79501255|NCT02703506|Other|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
79501256|NCT02678091|Device|Ultrasound exam with Doppler|Ultrasound exam of the orbit
79501257|NCT02670174|Other|Traditional training|
79501258|NCT02670174|Other|Separate kinetic chain training|
79501259|NCT02670174|Other|Integrated kinetic chain training|
79501260|NCT02630628|Drug|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
79663112|NCT05606770|Behavioral|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
79663113|NCT05597098|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
79816431|NCT04028375|Other|No intervention|No intervention
79816432|NCT03422705|Device|Optimised programming|Optimised programming to avoid RV pacing when possible.
79988227|NCT03506646|Dietary Supplement|Beetroot juice|Beetroot juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
79988228|NCT01353508|Drug|LCZ696|200 mg and 400 mg tablets
79988229|NCT01353508|Drug|Valsartan|160 mg tablets
79988230|NCT05470855|Biological|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
79988231|NCT01568268|Drug|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
79501261|NCT02630628|Drug|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
79501262|NCT02619253|Drug|Pembrolizumab|
79501263|NCT02619253|Drug|Vorinostat|
79988232|NCT01568268|Drug|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
79988233|NCT03636269|Drug|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
79988234|NCT03636269|Drug|Placebo|IV placebo administered three times/week
79988235|NCT05598060|Radiation|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
79501264|NCT02598661|Drug|Imetelstat|Intravenous injection.
79501265|NCT02598661|Drug|Placebo|Matching Placebo to Imetelstat will be administered.
79501266|NCT02549820|Device|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
79501267|NCT02544815|Drug|Digoxin|Digoxin 0.25 mg pills
79501268|NCT02544815|Drug|Placebo|Placebo pills
79501269|NCT02517034|Other|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
79501270|NCT02517034|Other|Quality-of-Life Assessment|Ancillary studies
79501271|NCT02517034|Other|Questionnaire Administration|Ancillary studies
79501272|NCT02517034|Other|Survey Administration|Ancillary studies
79501273|NCT02503579|Behavioral|physical training|physical activity program, 30 minutes
79501274|NCT02481414|Biological|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
79501275|NCT02481414|Biological|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
79501276|NCT02476786|Behavioral|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
79501277|NCT02476786|Drug|Goserelin|
79501278|NCT02476786|Drug|Anastrozole|
79501279|NCT02476786|Drug|Exemestane|
79501280|NCT02476786|Drug|Fulvestrant|
79501281|NCT02476786|Drug|Tamoxifen|
79501282|NCT02476786|Other|Archived tissue collection|
79501283|NCT02400255|Drug|Crenolanib besylate|
79501284|NCT02301468|Other|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
79501285|NCT02301468|Other|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
79988236|NCT03114982|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
79349870|NCT02114606|Device|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
79501286|NCT02263729|Drug|Losartan|
79501287|NCT02263729|Drug|placebo|
79988237|NCT03114982|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
79988238|NCT04919707|Behavioral|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
79988239|NCT04919707|Procedure|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
79988240|NCT03166072|Other|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
79501288|NCT02161783|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
79501289|NCT02161783|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
79501290|NCT02161783|Radiation|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
79501291|NCT02161783|Biological|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
79501292|NCT02042300|Device|XIENCE Xpedition/Alpine/Sierra|
79988241|NCT03166072|Other|No Intervention|Participants will continue to receive treatment as usual
79988242|NCT04911361|Drug|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
79988243|NCT03166150|Other|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
79988244|NCT03166150|Other|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
79663114|NCT05595746|Procedure|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
79663115|NCT05595018|Other|End user|Participants will provide their opinions in two rounds to reach consensus
79663116|NCT05595018|Other|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
79349871|NCT04729634|Other|Mobilization|Mobilization and breathing exercises according to clinical care
79349872|NCT02113436|Drug|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
79501293|NCT02039752|Other|Treatment|
79501294|NCT01997710|Device|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
79501295|NCT01997710|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
79501296|NCT01868438|Drug|Pyronaridine-artesunate granules|
79501297|NCT01868438|Drug|Pyronaridine-artesunate tablets|
79816433|NCT03422705|Drug|Lisinopril|Uptitration of lisinopril
79816434|NCT03422705|Other|Standard care|No pacemaker adjustment or medical therapy
79816435|NCT00918216|Genetic|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
79816436|NCT00918216|Other|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
79663117|NCT05595018|Other|Supply side|Participants will provide their opinions in two rounds to reach consensus
79816437|NCT00918216|Other|medical chart review|Patients' medical charts are reviewed to obtain clinical information
79816438|NCT00918216|Procedure|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
79816439|NCT00918216|Procedure|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
79816440|NCT00918216|Procedure|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
79816441|NCT02607293|Drug|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
79816442|NCT02607293|Drug|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
79988245|NCT04906993|Drug|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
79988246|NCT04906993|Drug|platinum-based chemotherapy|Physician's choice chemotherapy
79501298|NCT01554046|Drug|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~Ages 6-12, up to 25Kg - 35mg maximum per day.~Ages 6-12, above 25Kg - 50mg maximum per day.~Ages 12-65, above 25Kg - 80mg maximum per day."
79501299|NCT01208662|Drug|Lenalidomide|oral administration
79988247|NCT03165760|Procedure|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
79988248|NCT02685202|Device|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
79988249|NCT04479592|Other|Particle counter|Particle counter to measure the aerosol generated
79988250|NCT03087786|Drug|Nicotine Bitartrate Lozenge 4mg|Test Product
79988251|NCT03087786|Drug|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
79988252|NCT03635957|Biological|Pegloticase|pegloticase administered intravenously (IV)
79988253|NCT03635957|Drug|Methotrexate (MTX)|oral MTX
79501300|NCT01208662|Drug|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
79501301|NCT01208662|Drug|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
79663118|NCT05595018|Other|Funder|Participants will provide their opinions in two rounds to reach consensus
79663119|NCT05595018|Other|Academia|Participants will provide their opinions in two rounds to reach consensus
79663120|NCT05592353|Other|Brace|Brace following hip arthroscopy
79663121|NCT05585151|Drug|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
79663122|NCT05585151|Drug|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
79816443|NCT02607293|Drug|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
79816444|NCT02607371|Other|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
79816445|NCT02607371|Other|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
79816446|NCT02607371|Other|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
79816447|NCT02607371|Other|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
79501302|NCT01208662|Procedure|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
79501303|NCT00929045|Drug|Growth Hormone Replacement|
79501304|NCT00683631|Other|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
79501305|NCT00636519|Biological|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
79501306|NCT00636519|Biological|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
79501307|NCT00540774|Device|detection of oral pathology|detection of oral pathology
79501308|NCT01457352|Drug|SPARC0921|
79663123|NCT05585125|Drug|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.~Other names:~atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate"
79663124|NCT05585125|Drug|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.~Other names:~atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate"
79663125|NCT05574192|Behavioral|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~arts-based activities.~physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
79663126|NCT05566821|Behavioral|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
79663127|NCT05563584|Behavioral|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
79501309|NCT01457352|Drug|Placebo0921|
79501310|NCT01457118|Drug|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
79501311|NCT01457118|Drug|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
79501312|NCT01457118|Drug|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
79501313|NCT01457118|Drug|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
79501314|NCT01501110|Drug|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
79501315|NCT01500720|Drug|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
79501316|NCT01500720|Drug|Topotecan|Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
79501317|NCT04408872|Diagnostic Test|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
79988254|NCT03635957|Drug|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al.2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
79663128|NCT05561855|Behavioral|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
79988255|NCT03635957|Drug|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
79988256|NCT03635957|Dietary Supplement|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
79663129|NCT05557708|Drug|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
79663130|NCT05557708|Diagnostic Test|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
79663131|NCT05556629|Other|No Intervention|This is a non-interventional study.
79349873|NCT02113436|Drug|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
79349874|NCT02087774|Behavioral|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
79349875|NCT02111564|Drug|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
79349876|NCT02111564|Drug|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from >=30 to less than (<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
79663132|NCT05546164|Other|Assessment of hand grip strength|Assessment of hand grip strength
79663133|NCT05546164|Other|Assessment of pinch strength|Assessment of pinch strength
79663134|NCT05546164|Other|Assessment of upper limb dexterity|Assessment of upper limb dexterity
79663135|NCT05545202|Other|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
79663136|NCT05541497|Drug|Varenicline Tartrate|Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
79816448|NCT02607371|Other|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
79349877|NCT02111564|Drug|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
79349878|NCT02087150|Device|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
79349879|NCT02111174|Device|Scrambler Therapy|
79349880|NCT02111174|Device|Sham Therapy|
79349881|NCT02111096|Drug|LY2409021|Administered orally
79349882|NCT02111096|Drug|Sitagliptin|Administered orally
79349883|NCT02111096|Drug|Placebo|Administered orally
79349884|NCT02111096|Drug|Metformin|Administered orally
79349885|NCT02111096|Drug|Sulfonylurea|Administered orally
79501318|NCT04408872|Diagnostic Test|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
79663137|NCT05541497|Drug|Placebo|Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
79663138|NCT05541458|Other|Food as medicine|"Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~Increase nutrition literacy.~Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
79663139|NCT05536219|Diagnostic Test|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
79816449|NCT00718419|Drug|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
79663140|NCT05527847|Behavioral|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
79663141|NCT05527847|Behavioral|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
79663142|NCT05525520|Drug|EP547|Once daily
79816450|NCT02590965|Drug|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
79349886|NCT02110706|Drug|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
79663143|NCT05525520|Drug|Placebo|Once daily
79349887|NCT02110706|Drug|Placebo|The placebo group will receive a vehicle control infusion
79816451|NCT02590965|Drug|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
79816452|NCT02591043|Procedure|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
79663144|NCT05501275|Behavioral|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
79816453|NCT03948711|Device|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
79988257|NCT05241067|Drug|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
79988258|NCT05241067|Drug|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
79988259|NCT03732599|Procedure|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
79663145|NCT05500105|Other|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
79663146|NCT05489523|Drug|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
79663147|NCT05483283|Other|Empowerment and Navigation|Empowerment and Navigation
79663148|NCT05483283|Other|SOC|SOC
79663149|NCT05459688|Drug|CIN-107|2 mg of CIN-107, once a day for 52 weeks
79816454|NCT04085757|Drug|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
79988260|NCT03732599|Procedure|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
79349888|NCT02110238|Device|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
79349889|NCT02110238|Device|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
79349890|NCT02108912|Other|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
79988261|NCT05681767|Behavioral|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
79349891|NCT02108912|Other|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
79349892|NCT02108600|Drug|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
79988262|NCT05681767|Other|Treatment as usual|Treatment as usual
79988263|NCT01310309|Device|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
79988264|NCT01353274|Drug|Micamlo|Telmisartan plus Amlodipine T40/A5
79988265|NCT05005507|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks.
79501319|NCT01500252|Device|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
79501320|NCT01500252|Device|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
79501321|NCT01476696|Drug|Prasugrel|Administered orally
79663150|NCT05458323|Device|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.
79988266|NCT05005507|Drug|PegIFN-alpha-2a|PegIFN-alpha-2a will be administered subcutaneously once weekly.
79988267|NCT05005507|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
79988268|NCT05005507|Drug|TAF|TAF film-coated tablet will be administered orally once daily.
79988269|NCT05005507|Drug|ETV|ETV film-coated tablet will be administered orally once daily.
79988270|NCT03729479|Behavioral|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
79988271|NCT03729479|Behavioral|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
79988272|NCT03729479|Behavioral|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
79988273|NCT05221255|Other|spinal magnetic stimulation|"Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
79988274|NCT04893343|Other|Antibiotic treatment|Antibiotic treatment
79349893|NCT02107898|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
79349894|NCT02107898|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
79349895|NCT02107898|Drug|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
79349896|NCT02059148|Drug|LY2835219|Administered orally.
79349897|NCT04721600|Device|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
79349898|NCT04720820|Other|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
79349899|NCT04720820|Other|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
79501322|NCT01500096|Drug|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
79663151|NCT05453656|Behavioral|exercise|physical activity promotion and engagement following kidney transplantation
79988275|NCT04893343|Other|No antibiotic treatment|No antibiotic treatment
79988276|NCT04831021|Procedure|Dialysis without physical exercise|Hemodialysis control condition
79501323|NCT01500096|Dietary Supplement|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
79663152|NCT05452590|Procedure|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
79663153|NCT05452005|Drug|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
79816455|NCT04085757|Drug|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
79816456|NCT04085679|Other|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
79816457|NCT02590887|Dietary Supplement|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
79816458|NCT00717249|Device|galyifilcon A control lens|Marketed daily wear contact lens
79816459|NCT00717249|Device|galyfilcon A with a silver additive|Investigational daily wear contact lens
79816460|NCT00727194|Drug|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
79816461|NCT00727194|Drug|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
79816462|NCT00717093|Drug|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
79816463|NCT00717093|Drug|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
79816464|NCT02592642|Behavioral|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
79988277|NCT04831021|Procedure|Dialysis with pre-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
79349900|NCT04720742|Drug|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
79349901|NCT02058992|Drug|Ramelteon|Ramelteon 8 mg tablets
79988278|NCT04831021|Procedure|Dialysis with per-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
79349902|NCT04719416|Behavioral|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
79349903|NCT02058836|Drug|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
79349904|NCT02058836|Procedure|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
79349905|NCT02107274|Drug|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
79988279|NCT02690194|Device|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
79988280|NCT02690194|Device|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
79501324|NCT04767438|Other|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
79988281|NCT05593666|Drug|LXE408|Film-coated tablets
79988282|NCT05593666|Other|Placebo|Placebo film-coated tablets
79988283|NCT05593666|Drug|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
79988284|NCT04986163|Device|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
79988285|NCT04986163|Device|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
79988286|NCT04986163|Device|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
79988287|NCT02684344|Drug|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
79988288|NCT02684344|Other|Education|Education about signs and symptoms of urinary retention
79663154|NCT05445050|Diagnostic Test|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
79349906|NCT02107274|Drug|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
79663155|NCT05439590|Behavioral|High dose CSO|Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
79663156|NCT05439590|Behavioral|Low dose CSO|Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
79663157|NCT05439590|Behavioral|Low dose OO|Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
79349907|NCT02174627|Drug|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
79349908|NCT02174627|Drug|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
79663158|NCT05439590|Behavioral|High dose OO|Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
79988289|NCT03974100|Biological|GP2411|60 mg /mL subcutaneous injection every 6 months
79988290|NCT03974100|Biological|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
79988291|NCT02689804|Drug|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
79988292|NCT02689804|Drug|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
79988293|NCT02946931|Drug|Prizbind®|Prizbind®
79988294|NCT04360369|Device|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (>23 mmHg).
79349909|NCT02173769|Drug|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
79663159|NCT05435885|Other|Pulmonary Tele-Rehabilitation|12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)
79988295|NCT04360369|Device|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
79988296|NCT04360369|Device|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
79988297|NCT03959202|Behavioral|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks & 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps & minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
79988298|NCT03959202|Other|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
79988299|NCT04752085|Diagnostic Test|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
79816465|NCT02592642|Behavioral|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
79816466|NCT02592642|Device|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
79816467|NCT02592642|Device|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine [NeuroTrac TENS from Verity Medical Ltd (U.K.)] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
79816468|NCT02592642|Device|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
79816469|NCT02592642|Device|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
79349910|NCT02173769|Drug|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
79501325|NCT01455012|Drug|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
79501326|NCT01455012|Drug|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
79663160|NCT05435885|Other|Control (Education)|Usual care with only one educational session.
79349911|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
79663161|NCT05435547|Drug|Dexamethasone|Will take Dexamethasone pre-operatively
79663162|NCT05435547|Drug|Placebo|Will take Placebo pre-operatively
79663163|NCT05432986|Device|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
79663164|NCT05424276|Drug|IkT-148009|Oral administration gelatin capsule
79349912|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
79349913|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
79663165|NCT05424276|Drug|Placebo|Oral administration gelatin capsule
79663166|NCT05415969|Other|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
79349914|NCT02149199|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
79501327|NCT01454778|Drug|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon* Popliteal: 1.8 mg/inflation of balloon* Tibial: 1.4 mg/inflation of balloon*~not to exceed 10mg total dose"
79663167|NCT05415319|Behavioral|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
79663168|NCT05414747|Device|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
79663169|NCT05414747|Device|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
79663170|NCT05413239|Behavioral|Psychoeducation to reduce diabetes distress and improve glycemic outcomes|The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting ~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
79663171|NCT05394259|Drug|Piflufolastat F18|Given by vein (IV)
79663172|NCT05388838|Biological|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
79663173|NCT05388084|Behavioral|Male peer engagement|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
79816470|NCT00716859|Drug|Timolol|Timolol 0.5% dosed twice-daily
79816471|NCT00716859|Drug|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
79816472|NCT00589121|Drug|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
79816473|NCT00589121|Radiation|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
79349915|NCT02149199|Drug|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
79501328|NCT04408404|Procedure|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
79816474|NCT00589121|Procedure|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
79816475|NCT00590135|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
79988300|NCT05597670|Other|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
79988301|NCT05597670|Other|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
79349916|NCT02149199|Drug|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
79349917|NCT02120417|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
79501329|NCT01454076|Drug|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
79501330|NCT01454076|Drug|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
79501331|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
79501332|NCT01454076|Drug|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
79501333|NCT01454076|Drug|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
79501334|NCT01454076|Drug|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
79663174|NCT05388084|Behavioral|SOC and delayed intervention|Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
79988302|NCT04353271|Drug|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
79988303|NCT04353271|Other|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
79988304|NCT01374568|Drug|sitagliptin|sitagliptin 100mg daily
79988305|NCT01374568|Other|Placebo|1 pill daily
79349918|NCT02120417|Drug|Capecitabine|Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
79349919|NCT02120417|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
79663175|NCT05380973|Other|Short fiber resin composite|resin composite reinforced with short glass fibers
79663176|NCT05380973|Other|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
79349920|NCT02148263|Device|senofilcon A|
79349921|NCT05135585|Other|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
79349922|NCT05135585|Other|Questionnaires|data collection (health data, vaccination data, etc.)
79349923|NCT02147561|Biological|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
79501335|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
79501336|NCT01453998|Biological|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
79501337|NCT01453998|Biological|Prevenar 13|Single co-administered dose, intramuscular into left thigh
79501338|NCT01453998|Biological|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
79988306|NCT03706183|Diagnostic Test|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
79988307|NCT03706183|Diagnostic Test|Hearing thresholds|The hearing levels will be determined for each group.
79501339|NCT01453374|Drug|VIVITROL 380mg|380 mg IM injection given once monthly
79501340|NCT01453296|Drug|GW642444|GW642444 25 μg; Novel dry powder inhaler
79501341|NCT01453296|Drug|Placebo|Matching placebo; Novel dry powder inhaler
79663177|NCT05380739|Behavioral|Working Memory Training|A 10-session working memory (WM) training program
79663178|NCT05379127|Other|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
79988308|NCT03706105|Behavioral|Cardiac Rehabilitation|3 x week ~1 hour of exercise + education
79988309|NCT03114826|Genetic|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
79988310|NCT01312441|Drug|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
79988311|NCT01312441|Drug|Placebo|Placebo by mouth once weekly for 6 months
79988312|NCT02682784|Drug|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
79349924|NCT02058368|Drug|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
79349925|NCT02058368|Drug|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
79349926|NCT02058368|Drug|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
79349927|NCT02058368|Drug|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
79501342|NCT01453140|Drug|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
79501343|NCT01453140|Drug|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
79501344|NCT01453140|Drug|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
79349928|NCT02107196|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
79349929|NCT02107196|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
79349930|NCT04185428|Behavioral|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
79501345|NCT01453140|Drug|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
79501346|NCT01453140|Drug|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
79501347|NCT01453140|Drug|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
79988313|NCT02682784|Drug|Placebo|
79988314|NCT03165604|Other|standard information|The participates will be given a standard information regarding the water drink before physical activity
79988315|NCT03165604|Other|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
79988316|NCT03164824|Other|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
79663179|NCT05379127|Other|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
79663180|NCT05376137|Device|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
79663181|NCT05367141|Other|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
79663182|NCT05343572|Drug|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing >83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
79663183|NCT05342675|Procedure|Rapid Rollover|Repositioning of the participant post biopsy
79663184|NCT05329337|Diagnostic Test|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
79663185|NCT05325879|Other|VAGUS-NDT|Neurodynamic test for vagus nerve
79663186|NCT05315726|Other|Dynamometer|Measurement of elbow/wrist spasticity
79816476|NCT00589667|Drug|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
79349931|NCT02058290|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
79349932|NCT02058290|Drug|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
79501348|NCT01499940|Drug|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
79501349|NCT01499160|Drug|letrozole|Drug is are to be taken orally. 2.5 mg once daily
79501350|NCT01499160|Drug|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
79663187|NCT05315726|Other|Muscle vibrations|1 session of 10 minutes
79663188|NCT05315726|Other|Muscle vibrations|3 times/week for 6 weeks
79663189|NCT05315726|Other|Placebo muscle vibration|3 times/week for 6 weeks
79501351|NCT01499160|Drug|everolimus|Drug is to be taken orally. 5 mg once daily.
79501352|NCT01498692|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
79663190|NCT05314283|Device|DV3395 C1|Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
79816477|NCT00737568|Drug|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
79816478|NCT00737568|Drug|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
79663191|NCT05313620|Drug|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
79816479|NCT00737568|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
79501353|NCT01498068|Drug|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
79501354|NCT01498068|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
79816480|NCT00737568|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
79501355|NCT01498068|Drug|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is < 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
79501356|NCT01497366|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
79349933|NCT02082158|Other|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
79501357|NCT01497366|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
79663192|NCT05313620|Drug|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
79663193|NCT05306574|Drug|Telitacicept|subcutaneous injection weekly for 52 weeks
79663194|NCT05306574|Drug|Placebo|subcutaneous injection weekly for 52 weeks
79663195|NCT05302518|Behavioral|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
79816481|NCT02607137|Behavioral|Health Education|Information on healthy living style in relation to physical activity
79816482|NCT03964584|Other|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
79816483|NCT05752799|Drug|Opioid Free Anaesthesia|"40 mg/kg magnesium sulfate in 100 ml N/S infusion~0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~0.3 mg/kg ketamine in 10 ml volume~0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value > 25 or elevation of Heart Rate and/or Blood Pressure >20%.~Placebo infusions of normal saline will be prepared to enable blinding."
79816484|NCT05752799|Drug|Opioid based anesthesia|"2 mcg/kg fentanyl in 10 ml volume~0.2 mL/kg/h remifentanil infusion~0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value > 25 or elevation of Heart Rate and/or Blood Pressure >20%.~Placebo infusions of normal saline will be prepared to enable blinding."
79349934|NCT04417322|Other|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
79349935|NCT04718480|Drug|Placebo|po placebo tablets
79349936|NCT04718480|Drug|Fluvoxamine|po fluvoxamine tablets
79349937|NCT02106884|Drug|Nab-paclitaxel|
79349938|NCT02106884|Drug|Gemcitabine|
79349939|NCT02081846|Other|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
79501358|NCT01497366|Drug|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~Dose of sofosbuvir+RBV group based on baseline weight: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg~Dose of PEG+RBV group: 800 mg"
79501359|NCT01475838|Drug|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
79501360|NCT01475838|Drug|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
79501361|NCT01475838|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
79501362|NCT01475838|Drug|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
79501363|NCT01451814|Behavioral|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
79501364|NCT01451814|Drug|Nicotine polacrilex|8 weeks of nicotine patch
79501365|NCT01451814|Behavioral|Relaxation training|Instructions in progressive muscle relaxation
79501366|NCT01451814|Behavioral|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
79501367|NCT01475370|Drug|OCV-501|"Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
79501368|NCT01496430|Drug|Placebo|
79816485|NCT02606591|Procedure|Electroencephalograph|EEG performed at beginning and end of school year.
79816486|NCT02606591|Behavioral|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
79501369|NCT01496430|Drug|Azilsartan medoxomil|
79501370|NCT01496430|Drug|Azilsartan medoxomil|
79501371|NCT04408326|Drug|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
79501372|NCT04408326|Drug|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
79501373|NCT01451424|Drug|Proellex|vaginal suppository, daily, for 12 weeks
79501374|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
79501375|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
79501376|NCT01475214|Other|Inactive placebo capsule|microcrystalline cellulose
79501377|NCT01496274|Biological|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
79501378|NCT01475136|Drug|LY2140023|
79501379|NCT01474746|Drug|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
79501380|NCT01474746|Drug|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
79501381|NCT01450800|Drug|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
79663196|NCT05302518|Behavioral|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
79816487|NCT02606591|Other|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
79816488|NCT00737100|Drug|Placebo Respimat|patient to receive placebo matching active drug once daily
79501382|NCT01450800|Drug|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
79501383|NCT03026634|Behavioral|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
79501384|NCT01474512|Drug|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
79501385|NCT01474512|Drug|Placebo|Administered SC
79501386|NCT01474434|Drug|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
79501387|NCT01474434|Drug|Placebo|matching placebo tablets
79501388|NCT02985606|Other|Caffeine powder -60|
79501389|NCT02985606|Other|Caffeine powder -30|
79501390|NCT02985606|Other|Caffeine powder 0|
79501391|NCT02985606|Other|Placebo powder -60|
79501392|NCT02985606|Other|Placebo powder -30|
79501393|NCT02985606|Other|Placebo powder 0|
79816489|NCT00737100|Drug|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
79501394|NCT01473732|Drug|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
79501395|NCT01473732|Drug|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
79663197|NCT05293288|Device|EEG-guided general anesthesia|pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
79816490|NCT00737100|Drug|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
79816491|NCT00732498|Drug|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
79816492|NCT00732498|Drug|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
79501396|NCT01473732|Drug|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
79501397|NCT01450098|Drug|LY2484595 Reference Formulation (RF)|Administered orally
79501398|NCT01450098|Drug|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
79501399|NCT01449708|Drug|TIVA NoNarc|"patients in both groups receive antiemetic prophylaxis~patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~postop management in both groups is similar in both groups"
79501400|NCT01449630|Drug|LY3031207|Administered orally
79501401|NCT01449630|Drug|Placebo|Administered orally
79663198|NCT05285917|Drug|Hydroxyurea|Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
79663199|NCT05278975|Drug|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
79663200|NCT05278494|Drug|Dextromethorphan Hydrobromide|PO
79663201|NCT05278494|Drug|Placebo|PO
79663202|NCT05275244|Device|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
79663203|NCT05273385|Device|Nanodropper|Device to apply liquid medication to eyes
79816493|NCT00732498|Drug|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
79816494|NCT00732498|Drug|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
79816495|NCT00732498|Drug|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
79816496|NCT00732498|Drug|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
79816497|NCT00732498|Drug|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from >/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
79816498|NCT00726882|Procedure|Blood sample collection only|Approximately monthly collection of blood samples.
79816499|NCT00726882|Drug|ABT-333|Previous treatment in prior ABT-333 studies.
79816500|NCT00790400|Drug|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
79816501|NCT00790400|Drug|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
79501402|NCT01449630|Drug|Celecoxib|Administered orally
79501403|NCT01493778|Drug|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
79501404|NCT01473420|Biological|Epoetin Hospira|Variable dose
79501405|NCT01473420|Biological|Epogen Amgen|Variable dose
79501406|NCT04674774|Drug|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
79501407|NCT04674774|Drug|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
79816502|NCT04087434|Device|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
79816503|NCT00918294|Device|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
79988317|NCT03164902|Device|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
79501408|NCT01492686|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
79349940|NCT02081846|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
79349941|NCT02081690|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
79349942|NCT02057666|Drug|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
79501409|NCT01492686|Drug|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
79501410|NCT01492686|Drug|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
79663204|NCT05252585|Drug|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
79663205|NCT05240001|Device|Thulium Fibre Laser|Participants will undergo treatment using the TFL
79663206|NCT05240001|Device|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
79663207|NCT05222529|Drug|Glycopyrronium bromide 25ug|25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
79663208|NCT05222529|Drug|Placebo|Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
79663209|NCT05222529|Drug|Glycopyrronium bromide 12.5ug|12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
79988318|NCT03164746|Other|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
79349943|NCT02057666|Drug|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
79501411|NCT04409496|Behavioral|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
79501412|NCT04409496|Behavioral|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
79501413|NCT04409496|Behavioral|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
79663212|NCT05194397|Dietary Supplement|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
79663213|NCT05194397|Dietary Supplement|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
79663214|NCT05194397|Other|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
79663215|NCT05169710|Drug|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
79663216|NCT05169710|Drug|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
79663217|NCT05169710|Drug|Placebo|Placebo tablet (supplied in two tablets)
79663218|NCT05151757|Other|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
79663219|NCT05130190|Device|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
79663220|NCT05117242|Biological|Acasunlimab|Acasunlimab will be administered intravenously (IV)
79663221|NCT05117242|Biological|Pembrolizumab|Pembrolizumab will be administered IV
79816504|NCT00915512|Drug|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
79816505|NCT02594670|Other|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
79816506|NCT02594670|Other|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
79663222|NCT05117229|Device|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
79349944|NCT04417400|Behavioral|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
79349945|NCT01625000|Drug|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
79349946|NCT01625000|Drug|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
79663223|NCT05114096|Drug|Celestone + placebo|"After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
79816507|NCT02594670|Other|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
79816508|NCT04106960|Other|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
79816509|NCT02594748|Behavioral|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
79349947|NCT01625000|Drug|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
79816510|NCT02594748|Behavioral|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
79349948|NCT01625000|Drug|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
79349949|NCT01625000|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
79349950|NCT02081534|Drug|AZD1722|AZD1722, oral tablet
79349951|NCT02081534|Drug|Placebo|Placebo bid, double dummy technique
79663224|NCT05114096|Drug|Celestone + Celestone|"After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone."
79663225|NCT05111509|Drug|[203Pb]VMT-α-NET|3 to 5 miliCuries of [203]Pb administered intravenously 60 minutes before the start of the scans.
79663226|NCT05111509|Device|SPECT/CT|Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
79663227|NCT05100979|Other|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
79663228|NCT05092295|Device|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
79663229|NCT05092295|Diagnostic Test|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
79816511|NCT04088214|Procedure|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
79816512|NCT00786032|Device|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
79663230|NCT05085951|Device|20 mm CRE balloon|Endoscopic balloon that is used to dilate pylorus
79349952|NCT02057198|Drug|Fidaxomicin|
79349953|NCT02057198|Drug|Metronidazole|
79349954|NCT02057198|Drug|Vancomycin|
79349955|NCT04417478|Other|Scaling and root planning|Periodontal debridement was performed in all patients.
79349956|NCT02056652|Device|Bioteque cup pessary|
79349957|NCT02056340|Drug|Atorvastatin|
79663231|NCT05085951|Diagnostic Test|OGD|OGD (No dilatation)
79816513|NCT02602652|Biological|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
79816514|NCT02593500|Drug|Budesonida Pulmictan® 200 µg|
79349958|NCT02056340|Drug|Placebo|
79349959|NCT04727060|Device|patient with knee arthroplasty|
79349960|NCT02046122|Drug|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
79349961|NCT02046122|Drug|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
79501414|NCT01449006|Drug|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
79663232|NCT05068700|Device|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
79816515|NCT02593500|Drug|Budesonide 200 µg|
79816516|NCT02594592|Other|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
79816517|NCT02594358|Drug|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
79816518|NCT00785486|Drug|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
79816519|NCT00785486|Drug|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
79816520|NCT00785486|Drug|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
79349962|NCT02046122|Biological|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
79501415|NCT01448850|Biological|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
79501416|NCT01448850|Other|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
79501417|NCT04748406|Device|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
79501418|NCT04748406|Other|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
79663233|NCT05068700|Device|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
79663234|NCT05047965|Procedure|Dixon MRI|Undergo Dixon MRI
79663235|NCT05047965|Procedure|Magnetic Resonance Imaging|Undergo standard MRI
79663236|NCT05043792|Drug|TT-00920|TT-00920 Tablets
79663237|NCT05043792|Drug|TT-00920 Placebo|TT-00920 Placebo Tablets
79816521|NCT00917904|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
79816522|NCT00917904|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
79816523|NCT00589979|Drug|Lidoderm (Lidocaine 5% Patch)|Topical Patch
79816524|NCT00589979|Drug|Placebo Patch|Topical Patch
79816525|NCT03997136|Procedure|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
79501419|NCT04748406|Other|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
79349963|NCT04704362|Behavioral|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
79349964|NCT04704362|Behavioral|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
79349965|NCT02080832|Drug|Citalopram|20 mg or 40 mg daily for 8 weeks
79501420|NCT04748406|Other|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
79501421|NCT01491672|Drug|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
79501422|NCT01447446|Drug|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
79501423|NCT01447446|Drug|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
79501424|NCT01447446|Drug|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
79349966|NCT02080832|Drug|Placebo|Placebo daily for 8 weeks
79349967|NCT02080364|Drug|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
79349968|NCT02080364|Drug|Placebo|Placebo administered orally, once daily for 18 months
79349969|NCT02079038|Device|Totalis|
79501425|NCT01447446|Drug|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
79501426|NCT01447446|Drug|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
79501427|NCT01490814|Procedure|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
79501428|NCT01490814|Procedure|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
79501429|NCT01471782|Biological|Blinatumomab|Administered by continuous intravenous infusion
79501430|NCT01490580|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
79501431|NCT01490580|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
79349970|NCT02079038|Procedure|Comparator Surgical Procedure|
79349971|NCT02045732|Biological|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
79349972|NCT02045732|Biological|Placebo|Bi-Weekly Subcutaneous Injections X 6
79349973|NCT02045732|Biological|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
79349974|NCT02045732|Biological|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
79349975|NCT02044874|Drug|APD356-lorcaserin hydrochloride|
79349976|NCT02044874|Drug|Placebo|
79349977|NCT04716920|Other|Tai Chi|Attend Tai Chi exercise classes
79349978|NCT04716920|Device|FitBit|Wear FitBit
79349979|NCT04716920|Other|Support Group Therapy|Join Tai4Chijoint group
79501432|NCT01490190|Drug|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
79501433|NCT01446042|Drug|Testosterone|Intranasal testosterone
79501434|NCT01446042|Drug|Testosterone|Intranasal testosterone
79501435|NCT01445886|Drug|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
79501436|NCT01445886|Drug|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
79816526|NCT02590653|Drug|Atorvastatin|Lipid-lowering therapy
79663238|NCT05036291|Drug|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets & Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets & Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
79663239|NCT05034601|Procedure|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
79663240|NCT05034601|Procedure|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
79816527|NCT02590497|Procedure|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
79349980|NCT04716920|Other|Questionnaire Administration|Ancillary studies
79349981|NCT04716920|Other|Quality-of-Life Assessment|Ancillary studies
79816528|NCT02590497|Drug|Gadolinium|Undergo gadolinium-enhanced MRI
79816529|NCT02590497|Other|Laboratory Biomarker Analysis|Tissue genetic analysis
79816530|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
79816531|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
79816532|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo FLAIR sequence
79816533|NCT02590497|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
79816534|NCT00797732|Device|Acupuncture|
79349982|NCT04716608|Other|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
79349983|NCT04716608|Other|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
79349984|NCT02078960|Drug|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
79349985|NCT02078102|Drug|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
79349986|NCT02078102|Drug|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
79501437|NCT01470612|Drug|CP-690,550|5 mg tablets, BID, for at least 12 months
79501438|NCT01470612|Drug|CP-690,550|10 mg tablets, BID, for at least 12 months
79501439|NCT01445730|Dietary Supplement|Fructose|3 month fructose diet 75 g/day
79816535|NCT00915746|Drug|JNJ-31001074; ketoconazole|
79816536|NCT04085055|Diagnostic Test|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
79816537|NCT05541614|Other|Emdogain® FL (flapless Emdogain®) - Enamel Matrix Derivative|Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
79349987|NCT02054702|Drug|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
79349988|NCT02054702|Drug|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
79501440|NCT01445652|Device|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
79501441|NCT01445652|Other|Spectacles|Spectacles per current prescription
79501442|NCT04073316|Drug|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
79501443|NCT04073316|Drug|Warfarin|Warfarin intake, with target INR range between 2 and 3
79501444|NCT04089852|Drug|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
79501445|NCT04089852|Drug|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
79349989|NCT02044094|Drug|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
79501446|NCT03026244|Dietary Supplement|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
79501447|NCT03026244|Dietary Supplement|Placebo product|3 periods of 3 weeks placebo product
79501448|NCT03026322|Other|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
79349990|NCT02044094|Drug|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
79349991|NCT02044094|Drug|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
79501449|NCT03026322|Other|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
79501450|NCT01470144|Drug|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
79816538|NCT05541614|Other|Emdogain® - Enamel Matrix Derivative|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal disease and in furcation defects.
79816539|NCT02608151|Other|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
79816540|NCT02608151|Other|massage without oil|
79816541|NCT02590575|Device|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
79816542|NCT00736944|Drug|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
79349992|NCT02044094|Drug|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
79349993|NCT02043938|Device|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
79349994|NCT04702646|Drug|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
79349995|NCT04702646|Procedure|Colonoscopy|colonoscopy will be performed to every patient included in the study
79816543|NCT00736944|Drug|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
79816544|NCT00736944|Drug|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
79816545|NCT00736944|Drug|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
79816546|NCT00736944|Drug|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
79816547|NCT00736944|Radiation|Radiation (Post induction)|Monday-Friday, weeks 1-7
79816548|NCT00736944|Drug|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
79816549|NCT00736944|Drug|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
79816550|NCT03195959|Other|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
79988319|NCT03164746|Other|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
79663241|NCT05019261|Other|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
79663242|NCT05017623|Drug|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
79663243|NCT05000814|Device|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
79988320|NCT05367895|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
79501451|NCT01443858|Drug|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
79501452|NCT01443858|Drug|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
79663244|NCT05000294|Drug|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
79349996|NCT02053610|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
79663245|NCT05000294|Drug|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
79663246|NCT04981860|Drug|Betadine|One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye
79349997|NCT02053610|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
79663247|NCT04981860|Drug|Avenova|One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
79663248|NCT04979910|Drug|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
79349998|NCT02053610|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
79988321|NCT03165448|Diagnostic Test|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
79988322|NCT03165448|Diagnostic Test|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
79988323|NCT03165448|Diagnostic Test|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
79349999|NCT02075606|Drug|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
79350000|NCT02043782|Device|Coloplast Test|Newly developed 1-piece convex ostomy product
79350001|NCT02043782|Device|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
79663249|NCT04979910|Drug|Placebo|matching placebo
79663250|NCT04976465|Drug|Anticoagulation|"Drug:~Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ~Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~Other Names: Asp~Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
79350002|NCT02043782|Device|Competitor soft convex|A commercially available soft convex product
79350003|NCT04701008|Drug|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
79350004|NCT02052596|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
79501453|NCT01443858|Drug|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
79350005|NCT02052596|Biological|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
79501454|NCT01443078|Drug|pemetrexed|
79501455|NCT01443078|Drug|cisplatin|
79501456|NCT01443078|Drug|Carboplatin|
79663251|NCT04976465|Drug|Without Anticoagulation|"Drug:~Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
79663252|NCT04975776|Behavioral|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
79988324|NCT03165448|Diagnostic Test|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
79988325|NCT05681533|Procedure|CT scan|coronary calcium score measurement by CT scan
79988326|NCT05466994|Other|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
79988327|NCT05466994|Other|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
79988328|NCT05354245|Dietary Supplement|Fibre supplement (potato-pectin)|Fibre supplement
79988329|NCT05354245|Dietary Supplement|Placebo|Maltodextrin
79988330|NCT05354245|Dietary Supplement|High-protein diet|High-protein diet
79988331|NCT05464888|Behavioral|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
79988332|NCT05464888|Behavioral|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
79988333|NCT05464888|Behavioral|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
79988334|NCT03165214|Device|coil|microcoils
79988335|NCT03165214|Device|hystoacryl glue|hystoacryl mixed with lipidol
79988336|NCT03705949|Drug|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
79988337|NCT03705949|Drug|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
79988338|NCT03162484|Behavioral|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
79988339|NCT04693039|Drug|Phenlarmide|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
79988340|NCT04693039|Drug|Placebo|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
79350006|NCT04681118|Biological|NurOwn (MSC-NTF cells)|Intrathecal administration
79350007|NCT02052440|Drug|Baclofen|Treatment arm: baclofen 10mg tid
79501457|NCT01443078|Drug|Gemcitabine Hydrochloride|
79501458|NCT01443078|Drug|Vinorelbine Tartrate|
79501459|NCT01443078|Drug|Docetaxel|
79501460|NCT01439880|Biological|Evolocumab|Administered by subcutaneous injection
79501461|NCT01439880|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
79501462|NCT01469364|Drug|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
79501463|NCT01469364|Procedure|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
79988341|NCT03162562|Biological|Oregovomab|Monoclonal antibody against CA 125
79988342|NCT03162562|Drug|Poly ICLC|Immune adjuvant
79988343|NCT03162718|Behavioral|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
79816551|NCT02590419|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
79816552|NCT02606669|Dietary Supplement|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
79663253|NCT04975776|Behavioral|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
79501464|NCT01439724|Device|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
79816553|NCT03943719|Diagnostic Test|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
79816554|NCT02603510|Drug|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
79663254|NCT04969380|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
79816555|NCT02603510|Drug|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
79816556|NCT04084977|Diagnostic Test|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
79816557|NCT02594436|Drug|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
79663255|NCT04964297|Device|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
79663256|NCT04945538|Other|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
79663257|NCT04937153|Biological|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
79663258|NCT04937153|Biological|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
79816558|NCT04107194|Drug|Pantoprazole 40mg|Proton pump inhibitor
79816559|NCT04107194|Drug|Amoxicillin 1000 MG|Antibiotic
79816560|NCT04107194|Drug|Clarithromycin 500mg|Antibiotic
79816561|NCT04107194|Drug|Metronidazole|Antibiotic
79816562|NCT04107194|Drug|Tetracycline 125 MG|Antibiotic
79816563|NCT04107194|Drug|Bismuth Subcitrate|Antibiotic adjuvant
79816564|NCT04107194|Drug|Rifabutin 150 MG|Antibiotic
79816565|NCT04107194|Drug|Levofloxacin 500mg|Antibiotic
79816566|NCT03180827|Procedure|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
79816567|NCT02590263|Radiation|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
79816568|NCT02590263|Drug|Temozolomide|Temozolomide will be administered per label.
79816569|NCT02590263|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
79816570|NCT02603588|Procedure|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
79816571|NCT02603588|Procedure|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
79816572|NCT00914303|Drug|AZD3241|Oral Tablet, Repeated Administration
79350008|NCT02052440|Drug|Placebo|Sugar pill by mouth three times daily
79350009|NCT02049944|Drug|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
79350010|NCT02043548|Drug|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
79663259|NCT04931147|Drug|RXC007|"RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses."
79663260|NCT04931147|Drug|RXC007 Matching Placebo|"The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study."
79816573|NCT00914303|Drug|Placebo Tablet|Oral Tablet. Repeated Administration
79816574|NCT02590185|Drug|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
79816575|NCT04104698|Diagnostic Test|Quantitative EEG|"Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~Both groups will be assessed for psychological & cognitive contributes respectively using:~A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
79816576|NCT00736476|Biological|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
79816577|NCT00736476|Biological|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
79816578|NCT02590107|Dietary Supplement|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
79816579|NCT02590107|Dietary Supplement|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
79816580|NCT02590107|Dietary Supplement|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
79350011|NCT02043548|Drug|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
79350012|NCT01622348|Drug|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
79350013|NCT01622348|Drug|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
79350014|NCT01622348|Drug|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
79350015|NCT01621880|Drug|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
79350016|NCT01621880|Drug|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
79350017|NCT01621802|Biological|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
79350018|NCT01621802|Biological|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
79350019|NCT01621802|Biological|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
79350020|NCT01621802|Biological|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
79350021|NCT02059291|Drug|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
79350022|NCT02059291|Drug|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
79350023|NCT02042924|Radiation|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
79501465|NCT01439724|Device|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
79501466|NCT01439568|Drug|LY2510924|Administered subcutaneous injection
79501467|NCT01439568|Drug|Carboplatin|Administered intravenously
79350024|NCT02042924|Device|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
79350025|NCT02041520|Drug|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
79350026|NCT02041520|Other|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
79663261|NCT04928534|Diagnostic Test|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~Cognitive function tests, including RPQ, MMSE and MoCA.~Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
79816581|NCT02590107|Other|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
79816582|NCT04104932|Procedure|Open reduction and internal fixation|Open reduction and internal fixation
79816583|NCT02606357|Drug|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
79816584|NCT04019496|Drug|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
79816585|NCT02607059|Other|Registry|
79816586|NCT04104386|Other|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
79988344|NCT03705871|Device|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
79988345|NCT03705871|Device|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
79988346|NCT03164590|Drug|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
79988347|NCT03164590|Drug|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
79350027|NCT04699994|Drug|FLOT therapy|Preoperative FLOT therapy
79350028|NCT04711226|Drug|AT-1501|AT-1501 IV infusion
79350029|NCT04699292|Procedure|Surgery|Surgery
79350030|NCT04699292|Radiation|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
79350031|NCT04699292|Radiation|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
79350032|NCT04699292|Radiation|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
79350033|NCT04699292|Radiation|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
79350034|NCT02041429|Drug|Ruxolitinib|
79350035|NCT02041429|Drug|Paclitaxel|
79350036|NCT02083783|Drug|TRI102|formulation containing active moiety (amphetamine)
79350037|NCT02083783|Other|Placebo|formulation without active moiety
79501468|NCT01439568|Drug|Etoposide|Administered intravenously
79501469|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
79501470|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
79501471|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
79501472|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
79816587|NCT00715299|Behavioral|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
79816588|NCT02602730|Behavioral|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
79816589|NCT02602730|Behavioral|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
79501473|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
79501474|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
79501475|NCT01468818|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
79350038|NCT04698109|Other|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
79350039|NCT04698109|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
79501476|NCT01468818|Drug|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
79501477|NCT01468818|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
79350040|NCT04698109|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
79501478|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
79501479|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
79501480|NCT01442376|Drug|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
79816590|NCT00918489|Drug|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
79816591|NCT04112888|Combination Product|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
79816592|NCT04112888|Procedure|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
79816593|NCT02604992|Drug|Treatment A|Dronabinol oral solution, under fed conditions
79816594|NCT02604992|Drug|Treatment B|Dronabinol oral capsule, under fed conditions
79816595|NCT02604992|Drug|Treatment C|Dronabinol oral capsule, under fasted conditions
79816596|NCT00730236|Drug|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
79816597|NCT04084899|Device|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
79988348|NCT03164590|Drug|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
79350041|NCT02083081|Behavioral|Community level intervention|Community intervention plus individual counseling
79501481|NCT01442376|Drug|Placebo to Ondansetron|
79501482|NCT01442376|Drug|Placebo to Ondansetron|
79501483|NCT01442376|Drug|Placebo to Palonosetron|
79501484|NCT01442064|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
79501485|NCT03026868|Procedure|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
79501486|NCT01441596|Drug|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
79350042|NCT02040805|Behavioral|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
79816598|NCT00915824|Other|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
79501487|NCT01441596|Drug|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
79501488|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
79501489|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
79501490|NCT01441440|Drug|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
79501491|NCT01441440|Drug|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
79501492|NCT01441440|Drug|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
79350043|NCT02040805|Behavioral|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
79501493|NCT03026400|Procedure|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
79501494|NCT03026400|Procedure|Subumbilical incision|Considered here as the ''control'' intervention.
79501495|NCT01438476|Procedure|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
79816599|NCT04084743|Other|Virtual reality intervention|Virtual reality intervention includes: Maze game software
79816600|NCT04084743|Other|Dual task intervention|The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.
79816601|NCT04084743|Other|Conventional physiotherapy|"Gait training in parallel bar~Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity"
79816602|NCT03899597|Drug|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
79816603|NCT03899597|Other|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
79816604|NCT00714285|Biological|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
79350044|NCT02059135|Biological|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
79350045|NCT02059135|Other|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
79350046|NCT02081677|Device|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
79501496|NCT01438476|Procedure|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
79501497|NCT01438476|Behavioral|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
79501498|NCT01438476|Behavioral|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
79501499|NCT03026478|Drug|Betamethasone Dipropionate|
79501500|NCT03026478|Drug|Clobetasol Propionate|
79501501|NCT01467570|Dietary Supplement|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
79501502|NCT01467570|Dietary Supplement|ESPGHAN ORS|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
79501503|NCT04066764|Drug|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
79501504|NCT04066764|Drug|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
79501505|NCT04066764|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
79663262|NCT04928209|Other|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
79663263|NCT04910776|Drug|avalglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
79663265|NCT04893265|Behavioral|Text Messaging Only|Active Comparator
79663266|NCT04893265|Behavioral|INFORMED|Experimental
79663267|NCT04889664|Drug|Ketamine|Repeated intravenous Ketamine infusions.
79663268|NCT04889664|Behavioral|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
79663269|NCT04871295|Behavioral|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
79663270|NCT04867668|Behavioral|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
79816605|NCT00714285|Biological|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
79816606|NCT02728115|Biological|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
79350047|NCT02081677|Device|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
79350048|NCT02081677|Device|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
79501506|NCT01437540|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
79501507|NCT01437540|Drug|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
79501508|NCT01440972|Other|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
79350049|NCT02081677|Device|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
79350050|NCT04720027|Diagnostic Test|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
79350051|NCT04695769|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
79350052|NCT04695769|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
79988349|NCT05119075|Other|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
79350053|NCT04417309|Behavioral|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
79501509|NCT01440972|Other|low intensity resistance training|low intensity resistance training without partial blood flow restriction
79350054|NCT04417309|Behavioral|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for 30 minutes.
79350055|NCT04694911|Behavioral|Focus Group|Participate in focus group
79501510|NCT01420536|Procedure|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
79501511|NCT01420068|Drug|SPP100|
79501512|NCT01467492|Drug|Telaprevir|Tablet
79501513|NCT01467492|Drug|Ribavirin|Tablet
79350056|NCT04694911|Other|Interview|Complete cognitive interview
79350057|NCT04694911|Other|Research or Clinical Assessment Tool|Receive OOCAT
79350058|NCT04694521|Procedure|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
79501514|NCT01467492|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
79350059|NCT04694521|Procedure|open end end to end stapler anastomosis|open end to end stapler anastomosis
79501515|NCT01466790|Drug|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
79663271|NCT04850274|Behavioral|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
79663272|NCT04850274|Behavioral|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
79663273|NCT04836195|Drug|PCLX-001|To ensure maximal safety in this first-in-human trial, the starting dose level was chosen to be 20 mg daily on a 28-day cycle.
79663274|NCT04827992|Drug|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
79663275|NCT04827992|Behavioral|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
79663276|NCT04804020|Procedure|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
79350060|NCT02038933|Drug|Nivolumab|
79350061|NCT02081599|Drug|Teneli (Teneligliptin)|
79350062|NCT02081599|Drug|Placebo|
79350063|NCT02081599|Drug|Insulin|
79501516|NCT01466790|Drug|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
79501517|NCT01466790|Drug|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
79501518|NCT01418352|Drug|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
79501519|NCT01418352|Drug|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
79501520|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
79501521|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
79501522|NCT01465464|Drug|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
79663277|NCT04804020|Procedure|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
79663278|NCT04804020|Procedure|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
79663279|NCT04781166|Behavioral|Calm program|7 online modules designed to teach cognitive behavioral skills
79816607|NCT02728115|Biological|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
79816608|NCT02590029|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
79816609|NCT02590029|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
79816610|NCT02590029|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
79816611|NCT04084665|Drug|Guselkumab|Guselkumab
79816612|NCT00776984|Drug|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
79816613|NCT00776984|Drug|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
79816614|NCT05751239|Other|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
79816615|NCT00714051|Behavioral|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
79816616|NCT00714051|Behavioral|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
79350064|NCT02038543|Drug|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
79663280|NCT04758650|Drug|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP."
79350065|NCT02038153|Other|Laboratory Biomarker Analysis|Correlative studies
79350066|NCT02038153|Drug|Lenalidomide|Given PO
79501523|NCT01465464|Drug|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
79350067|NCT02058589|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79350068|NCT02058589|Drug|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79350069|NCT02079805|Drug|Azilsartan|Azilsartan tablets
79350070|NCT02079805|Drug|Telmisartan|Telmisartan tablets
79350071|NCT02037295|Drug|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
79350072|NCT02037295|Drug|Placebo oral tablet|Placebo pills orally four times per day for 12 days
79350073|NCT02037295|Other|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
79501524|NCT03026010|Procedure|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
79501525|NCT01417104|Drug|Aliskiren|150 mg/300mg
79501526|NCT01417104|Drug|Placebo|150mg/300mg
79501527|NCT01465386|Drug|bortezomib|Given SC
79501528|NCT01465230|Drug|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
79501529|NCT04767516|Other|no intervention|no intervention
79501530|NCT04500132|Drug|EC-18|EC-18 QD
79501531|NCT04500132|Drug|Placebo EC-18|Placebo EC-18 QD
79816617|NCT00914147|Procedure|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
79816618|NCT02605499|Other|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
79350074|NCT02037295|Other|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
79350075|NCT02079649|Drug|AL-53817 Ophthalmic Solution, 0.1%|
79350076|NCT02079649|Drug|AL-78843 Ophthalmic Solution, 0.03%|
79501532|NCT01435356|Biological|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
79501533|NCT01435356|Biological|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
79501534|NCT01435122|Drug|Axitinib|Axitinib Administration as outlined in Arm description
79501535|NCT04048122|Behavioral|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
79663281|NCT04754672|Behavioral|Continuous aerobic and resistance exercise intervention|Continuous aerobic and resistance exercises intervention
79663282|NCT04754672|Behavioral|Continuous aerobic and aerobic interval exercise intervention|Continuous aerobic and aerobic interval exercise intervention
79988350|NCT05119075|Other|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
79350077|NCT02079649|Drug|Dexamethasone Ophthalmic Suspension, 0.1%|
79663283|NCT04747613|Drug|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
79663284|NCT04740671|Drug|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
79663285|NCT04740671|Drug|ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
79663286|NCT04734262|Drug|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
79350078|NCT02079649|Drug|AL-53817 Vehicle|Inactive ingredients used for masking purposes
79350079|NCT02036515|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
79350080|NCT02036515|Drug|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
79350081|NCT02036515|Drug|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
79350082|NCT02036515|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
79663287|NCT04734262|Drug|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
79663288|NCT04734262|Drug|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
79663289|NCT04733443|Device|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
79663290|NCT04733443|Device|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
79663291|NCT04704661|Drug|Ceralasertib|Given PO
79663292|NCT04704661|Biological|Trastuzumab Deruxtecan|Given IV
79663293|NCT04702308|Other|Clinical Decision Rule Alerts|The
79663294|NCT04701398|Other|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
79988351|NCT04440046|Other|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
79988352|NCT04440046|Other|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
79501536|NCT04048122|Behavioral|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
79501537|NCT01434810|Device|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
79816619|NCT04026659|Other|Multi-modal exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
79816620|NCT02606513|Other|MR Urography; CT Urography|
79816621|NCT04015557|Drug|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
79816622|NCT04015557|Drug|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
79988353|NCT04440046|Other|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
79350083|NCT02036515|Drug|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
79501538|NCT01434810|Device|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
79501539|NCT01393626|Drug|Placebo|oral tablets twice daily
79501540|NCT01393626|Drug|CP-690,550|oral tablets twice daily
79501541|NCT01393626|Drug|CP-690,550|oral tablets twice daily
79663295|NCT04701112|Device|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
79663296|NCT04698291|Procedure|Blood Donation|The blood donation will take place at the Gene & Health clinical assessment centre facilities. A trained member from Gene & Health program will be responsible for taking the blood samples.
79816623|NCT02702765|Procedure|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
79816624|NCT02702765|Procedure|Ultrasound|Ultrasound is a non-invasive procedure
79988354|NCT04440046|Other|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
79988355|NCT04440046|Other|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
79988356|NCT05309707|Device|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
79988357|NCT03387852|Drug|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
79988358|NCT03387852|Drug|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
79350084|NCT02036515|Drug|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
79350085|NCT02036515|Biological|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
79501542|NCT04059666|Other|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
79988359|NCT03387852|Drug|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
79988360|NCT03387852|Drug|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
79988361|NCT03387852|Drug|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
79988362|NCT02679274|Drug|Placebo|Intermittent intramuscular injections of saline (males and females).
79816625|NCT02702765|Drug|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
79988363|NCT02679274|Drug|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
79350086|NCT02036515|Drug|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
79501543|NCT04059666|Other|Control|Cow's milk-based Infant Formula
79501544|NCT04059276|Diagnostic Test|MRI|We will examine chronic (>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
79501545|NCT04059276|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
79350087|NCT04417075|Behavioral|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
79350088|NCT04417075|Behavioral|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
79501546|NCT01393158|Drug|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
79501547|NCT01413360|Drug|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
79501548|NCT01413204|Drug|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
79816626|NCT02702765|Procedure|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
79988364|NCT04674319|Behavioral|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
79988365|NCT05162833|Device|TheraNova Neuromodulation Device|TENS device
79988366|NCT01312285|Device|Resonator device|low level magnetic fields
79501549|NCT01413204|Drug|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
79501550|NCT01413204|Drug|Placebo|The patients will receive Placebo orally for 24 weeks.
79988367|NCT04961437|Other|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
79988368|NCT05309473|Device|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
79988369|NCT05309473|Device|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
79501553|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501554|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501555|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
79350089|NCT02078713|Behavioral|Contraceptive Decision Support Tool|"The decision support tool:~Provides an educational session about different aspects of contraception~Elicits patient preferences about different aspects of contraception~Identifies potential contraindications to certain contraceptive methods~Allows the patient to view details about and compare available contraceptive methods~Suggests methods most appropriate based on the patient's preferences~Collects questions the patient may have for her provider~Generates a printout the patient can bring to her contraceptive counseling visit"
79988370|NCT05309317|Other|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
79350090|NCT02035267|Drug|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79501556|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79350091|NCT02035267|Drug|Placebo|Phosphate buffered saline placebo for injection.
79501557|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501558|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
79501559|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501560|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501561|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
79501562|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501563|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79663297|NCT04684212|Device|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
79988371|NCT05309317|Other|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
79350092|NCT05887596|Other|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
79350093|NCT05887453|Device|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
79350094|NCT05887427|Other|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
79350095|NCT05887427|Other|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
79350096|NCT05887375|Drug|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
79501564|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
79501565|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79988372|NCT05309239|Other|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
79350097|NCT05887375|Drug|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
79816627|NCT02702765|Procedure|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
79816628|NCT02589951|Other|admission to non-psychiatric service|
79816629|NCT05534282|Behavioral|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
79816630|NCT05534282|Behavioral|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
79816631|NCT05534282|Behavioral|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
79816632|NCT02568605|Dietary Supplement|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
79816633|NCT02568605|Dietary Supplement|Placebo|Maltodextrin
79816634|NCT02568605|Behavioral|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
79816635|NCT00784784|Biological|Fluviral|One dose
79816636|NCT00784784|Drug|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
79816637|NCT00801983|Device|Alternative Keyboard|Subjects use either a typical or alternative keyboard
79816638|NCT05490368|Device|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
79350098|NCT05887375|Drug|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
79816639|NCT04114799|Procedure|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
79988373|NCT03620929|Drug|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
79988374|NCT04537741|Procedure|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
79988375|NCT04537741|Procedure|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
79988376|NCT05177497|Drug|SHR-1701|SHR-1701 administered by iv
79988377|NCT04470427|Biological|mRNA-1273|Sterile liquid for injection
79988378|NCT04470427|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79988379|NCT04969861|Drug|Bempegaldesleukin|Specified dose on specified days
79988380|NCT04969861|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
79988381|NCT04967521|Drug|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
79350099|NCT05887375|Drug|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
79350100|NCT05887362|Behavioral|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
79350101|NCT05887349|Other|Neck Stabilization Exercise|"1. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
79501566|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
79501567|NCT01412424|Drug|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
79988382|NCT04967521|Drug|Placebo|Placebo will be administered orally twice a day. Each cycle is 28 days.
79501568|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
79501569|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
79816640|NCT04114799|Procedure|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
79816641|NCT05684991|Dietary Supplement|KMS-66 Ashwagandha 300mg|One capsule is taken by mouth twice daily with water
79816642|NCT05684991|Dietary Supplement|placebo capsule|One capsule is taken by mouth twice daily with water
79816643|NCT00587288|Biological|Reslizumab|
79816644|NCT00587288|Other|Saline|
79816645|NCT00800735|Drug|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
79816646|NCT00800735|Drug|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing < 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
79816647|NCT05324163|Drug|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
79816648|NCT05324163|Drug|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
79816649|NCT05324163|Drug|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
79350102|NCT05887349|Other|Neck Stabilization Exercise + Rocabado Exercises|"2. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
79816650|NCT00730158|Drug|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
79816651|NCT00730158|Drug|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
79816652|NCT00730158|Drug|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
79816653|NCT04104074|Radiation|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
79816654|NCT04104074|Drug|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
79816655|NCT04114643|Biological|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
79501570|NCT01433172|Biological|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
79816656|NCT04114643|Biological|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
79350103|NCT05887336|Device|Walther System|Walther System providing INMEST treatment
79501571|NCT01433172|Biological|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10^6 irradiated H1944 tumor cells, 7.5 X 10^6 irradiated H2122 cells, and containing 15 X 10^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
79663298|NCT04684212|Drug|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
79663299|NCT04679012|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
79663300|NCT04679012|Drug|Rituximab|Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79663301|NCT04679012|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79663302|NCT04679012|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
79816657|NCT04114487|Other|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
79816658|NCT05750849|Procedure|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
79816659|NCT04084587|Device|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
79816660|NCT04112459|Other|prolonged mechanical ventilation|No intervention will be applied in this study
79816661|NCT00784550|Drug|Tiotropium Bromide|Long-acting muscarinic antagonist
79816662|NCT00784550|Drug|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
79816663|NCT02592564|Behavioral|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
79816664|NCT05659121|Device|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
79816665|NCT00729690|Drug|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
79816666|NCT00729690|Drug|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
79816667|NCT00729690|Drug|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
79816668|NCT04027829|Drug|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
79816669|NCT02593344|Device|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
79988383|NCT05308849|Other|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
79988384|NCT02678416|Drug|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
79988385|NCT02678416|Drug|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
79501572|NCT01433172|Biological|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
79501573|NCT01432938|Biological|dulaglutide|Administered subcutaneously
79501574|NCT01432938|Drug|Warfarin|Administered orally
79988386|NCT02678416|Drug|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
79501575|NCT03025230|Other|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
79501576|NCT03025230|Other|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
79663303|NCT04679012|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79663304|NCT04679012|Drug|Hydroxydaunomycin|Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79663305|NCT04671901|Drug|Romiplostim|Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count > 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
79663306|NCT04662281|Drug|Placebo|LX9211 matching-placebo, tablets will be administered orally.
79663307|NCT04662281|Drug|LX9211|LX9211, 200 mg, tablets will be administered orally.
79663308|NCT04659993|Behavioral|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
79816670|NCT00784238|Drug|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
79816671|NCT00917982|Other|vision therapy|
79350104|NCT05887336|Device|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
79350105|NCT05887336|Drug|Non preserved ocular lubricants|"Hyaluronic acid (HyloGel)~Hyaluronic acid and Ectoin (Hylo Dual Intense)~Hyaluronic acid and Trehalos (Theloz Duo)"
79350106|NCT05887336|Procedure|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
79663309|NCT04629716|Other|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
79816672|NCT02589873|Behavioral|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
79988387|NCT02678416|Other|Morphine (Treatment D)|Morphine administered by IV infusion
79988388|NCT03164668|Other|menthol flavored e-cigarette|menthol flavored e-cigarette
79988389|NCT03164668|Other|tobacco flavored e-cigarette|tobacco flavored e-cigarette
79988390|NCT03164512|Drug|Oral or vaporized cannabidiol|Acute drug exposure
79501577|NCT01392300|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
79663310|NCT04612790|Biological|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
79350107|NCT05887297|Behavioral|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
79663311|NCT04612790|Biological|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
79663312|NCT04602377|Drug|Pembrolizumab 25 MG/ML [Keytruda]|"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
79663313|NCT04587869|Behavioral|CBT Coping Intervention|A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
79663314|NCT04581902|Device|rTMS therapy|rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
79988391|NCT03164512|Drug|Placebo|Placebo capsule/vapor
79988392|NCT03164200|Other|High fat breakfast|High fat breakfast
79988393|NCT03164200|Other|Higher carbohydrate breakfast|Higher carbohydrate breakfast
79988394|NCT02680834|Device|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
79988395|NCT02680834|Device|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
79988396|NCT03343704|Drug|Idarucizumab|Intravenous
79988397|NCT03840642|Behavioral|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
79501578|NCT01392300|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
79501579|NCT04767204|Behavioral|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
79663315|NCT04579380|Drug|tucatinib|300 mg orally twice daily
79663316|NCT04579380|Drug|trastuzumab|Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
79816673|NCT02589873|Behavioral|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
79816674|NCT00729612|Drug|carboplatin|
79816675|NCT00729612|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
79816676|NCT00729612|Genetic|protein expression analysis|
79501580|NCT01432626|Drug|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
79988398|NCT03840642|Behavioral|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
79350108|NCT05887271|Drug|Low calorie meal replacement plan|Meal replacement diet containing ~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
79501581|NCT02985294|Other|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
79350109|NCT05887271|Diagnostic Test|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
79501582|NCT03025776|Behavioral|Reaching|sitting reaching under various task conditions (size, speed, location)
79663317|NCT04579380|Drug|fulvestrant|Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
79663318|NCT04574024|Drug|NBT-NM108 (60 g/day)|Patients will receive NBT-NM108 at 60 g/day.
79501583|NCT03025776|Behavioral|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many & which hand to use, kinematic data collected
79663319|NCT04574024|Other|NBT-NM108 (0 g/day)|Patients will receive NBT-NM108 at 0 g/day.
79501584|NCT01410474|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
79501585|NCT04037592|Device|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
79663320|NCT04573205|Drug|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
79816677|NCT00729612|Other|immunoenzyme technique|
79816678|NCT00729612|Other|immunohistochemistry staining method|
79816679|NCT00729612|Other|laboratory biomarker analysis|
79988399|NCT02680756|Drug|Ferric Maltol|
79988400|NCT02680756|Drug|Ferric Carboxy Maltose|
79988401|NCT03631836|Drug|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
79988402|NCT03631836|Drug|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
79988403|NCT03631836|Biological|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
79988404|NCT03631836|Device|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
79988405|NCT03196310|Drug|Platelet Concentrate|Platelet Rich plasma
79988406|NCT03196310|Drug|Corticosteroid injection|Kenalog
79988407|NCT03196310|Other|Normal Saline|Control Group - Placebo
79988408|NCT03162094|Drug|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
79988409|NCT03162094|Drug|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
79988410|NCT03162094|Drug|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
79816680|NCT05684913|Procedure|Zn granulate stent after FGG surgery|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
79816681|NCT05684913|Procedure|Hemostatic agent suturing|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
79501586|NCT04037592|Device|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
79501587|NCT04037592|Device|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
79663321|NCT04573140|Biological|Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)|The Phase I, Stratum 1 dose-escalation study will be performed in up to 28 adult participants using a Bayesian optimal interval (BOIN) design with an initial embedded accelerated titration design (ATD) to efficiently identify the maximally tolerated dose (MTD). For the initial ATD, patients will be enrolled and treated in cohorts of size 1 starting at dose level -4 to dose level -1, and will expand to a cohort size of 3 after the first DLT is observed or at dose level 0. There are 8 dose levels to potentially be assessed including the possibility of 4 dose levels for the ATD and 4 for the BOIN.
79663322|NCT04572295|Drug|E7090|E7090 oral tablet.
79816682|NCT04102202|Drug|BOL-DP-o-05|BOL-DP-o-05
79501588|NCT01391130|Drug|LY2510924|Administered subcutaneously
79816683|NCT04102202|Drug|Placebo|Placebo
79816684|NCT02589795|Biological|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
79816685|NCT02589795|Biological|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
79816686|NCT02589795|Device|Trigrid Delivery System - Intramuscular|Electroporation
79501589|NCT01391130|Drug|Sunitinib|Administered orally
79988411|NCT03670862|Other|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
79501590|NCT04046094|Drug|Ascorbic Acid|Ascorbic Acid Intravenous
79501591|NCT01410240|Procedure|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
79663323|NCT04572295|Drug|Fulvestrant|Fulvestrant intramuscular injection.
79663324|NCT04572295|Drug|Exemestane|Exemestane oral tablet.
79663325|NCT04571970|Genetic|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
79663326|NCT04569747|Combination Product|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
79663327|NCT04569747|Drug|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
79816687|NCT02589795|Device|Trigrid Delivery System - Intradermal|Electroporation
79816688|NCT02602418|Other|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
79816689|NCT02602418|Other|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
79816690|NCT05325801|Biological|BMCA and GPRC5D dual target CAR-T cells(OriC321)|Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
79816691|NCT00585546|Drug|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
79816692|NCT00768248|Drug|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
79816693|NCT00768248|Drug|normal saline (placebo)|the basal rate will be set at 7 mL/h
79816694|NCT02589717|Drug|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
79816695|NCT04099550|Device|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
79816696|NCT04099550|Other|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
79816697|NCT02602028|Drug|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
79816698|NCT05684757|Behavioral|Dietary Advice|Dietary Advice
79350110|NCT05887271|Diagnostic Test|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
79350111|NCT05887271|Diagnostic Test|Blood test|Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
79350112|NCT05887271|Diagnostic Test|Electrocardiogram|An ECG will be obtained to assess for baseline rhythm.
79350113|NCT05887271|Diagnostic Test|Accelerometery|Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
79350114|NCT05887271|Diagnostic Test|6 minute walk test (6MWT)|Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
79663328|NCT04569123|Device|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
79663329|NCT04569123|Device|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
79988412|NCT03674918|Diagnostic Test|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
79988413|NCT03086460|Drug|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
79988414|NCT03086460|Drug|Formoterol Inhalation Solution|Active Control
79501592|NCT01410240|Drug|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
79663330|NCT04568616|Drug|Letrozole 2.5mg|Aromatase Inhibitor
79988415|NCT03086460|Drug|Placebo pMDI|Matched Placebo
79988416|NCT02674490|Device|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
79663331|NCT04568434|Drug|Olezarsen|Olezarsen will be administered by SC injection.
79988417|NCT02674490|Behavioral|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
79350115|NCT05887271|Diagnostic Test|Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Skeletal muscle strength will be measured using a cybex dynamometer.
79501593|NCT01409928|Device|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
79501594|NCT04037124|Procedure|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
79501595|NCT01431534|Drug|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m^2, 28 mg/m^2, or 33 mg/m^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
79663332|NCT04568434|Drug|Placebo|Olezarsen-matching placebo will be administered by SC injection.
79663333|NCT04567238|Behavioral|Mobile contingency management|Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
79663334|NCT04554160|Device|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
79663335|NCT04554160|Device|A smartwatch|A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
79663336|NCT04544189|Drug|Alpelisib|300mg (oral) once daily, in a 28-day cycle
79663337|NCT04544189|Drug|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
79663338|NCT04544189|Drug|Placebo|300 mg by mouth once daily, in a 28-day cycle
79501596|NCT01409382|Behavioral|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
79501597|NCT01408914|Drug|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
79501598|NCT04044846|Behavioral|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
79501599|NCT04044222|Biological|Sintilimab|IV
79501600|NCT04044222|Drug|Carboplatin|IV
79501601|NCT04044222|Drug|Etoposide|IV
79501602|NCT04044222|Drug|Ifosfamide|IV
79501603|NCT04044222|Drug|Placebo|IV
79501604|NCT04044222|Drug|Carboplatin|IV
79350116|NCT05887271|Other|Assessment of quality of life and heart failure symptoms|Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
79350117|NCT05887271|Other|Assessment of sarcopenia|Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
79501605|NCT04044222|Drug|Etoposide|IV
79501606|NCT04044222|Drug|Ifosfamide|IV
79501607|NCT01431144|Procedure|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
79501608|NCT01431144|Procedure|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
79501609|NCT01430754|Drug|tasimelteon|20 mg tasimelteon capsules, daily
79501610|NCT01430754|Drug|Placebo|Placebo capsules, daily
79663339|NCT04543409|Biological|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
79663340|NCT04543409|Biological|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
79663341|NCT04518813|Device|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
79663342|NCT04497727|Other|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
79663343|NCT04495088|Drug|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
79501611|NCT01390428|Drug|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
79501612|NCT01430130|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
79501613|NCT04052256|Diagnostic Test|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
79501614|NCT01407354|Device|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
79501615|NCT01407354|Other|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
79501616|NCT01407276|Drug|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
79501617|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
79501618|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
79501619|NCT01390272|Behavioral|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
79501620|NCT01390272|Behavioral|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
79816699|NCT05486390|Behavioral|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~Goal setting and action plan~After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
79816700|NCT04103684|Drug|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
79350118|NCT05887271|Other|Assessment of frailty|Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
79350119|NCT05887271|Other|Qualitative interview|Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
79501621|NCT01429584|Drug|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
79501622|NCT01429584|Drug|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
79501623|NCT01406652|Procedure|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
79501624|NCT01406574|Drug|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
79501625|NCT01406574|Drug|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
79501626|NCT01405950|Drug|Zanaflex Capsules|0.025 mg/kg
79501627|NCT01405950|Drug|Zanaflex Capsules|0.05 mg/kg
79501628|NCT01405950|Drug|Zanaflex Capsules|0.075 mg/kg
79501629|NCT01405950|Drug|Zanaflex Capsules|0.1 mg/kg
79501630|NCT01405560|Drug|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
79501631|NCT01405560|Biological|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
79501632|NCT01405560|Drug|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
79501633|NCT01428882|Drug|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
79501634|NCT01428882|Drug|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
79501635|NCT01428258|Other|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
79501636|NCT01428258|Other|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
79663344|NCT04495088|Drug|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
79501637|NCT01389882|Procedure|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
79663345|NCT04495088|Drug|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
79663346|NCT04495088|Drug|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
79988418|NCT02674490|Device|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
79988419|NCT03162250|Drug|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
79988420|NCT03162250|Drug|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
79501638|NCT01442688|Drug|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
79501639|NCT01442688|Drug|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
79501640|NCT01466166|Biological|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
79501641|NCT03814200|Drug|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
79663347|NCT04495088|Drug|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
79663348|NCT04495088|Drug|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
79501642|NCT03814200|Drug|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
79501643|NCT03814200|Drug|Rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
79501644|NCT01426854|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
79663349|NCT04495088|Drug|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
79663350|NCT04486989|Behavioral|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
79663351|NCT04486989|Other|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
79663352|NCT04474184|Procedure|Biospecimen Collection|Receive vaginal kit for biospecimen collection
79988421|NCT03162250|Drug|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
79501645|NCT01426854|Other|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
79663353|NCT04474184|Behavioral|Focus Group|Attend focus group
79663354|NCT04474184|Other|Survey Administration|Ancillary studies
79663355|NCT04448366|Behavioral|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
79663356|NCT04438317|Procedure|Pleural drainage procedure with Seldinger procedure|Pleural drainage using Seldinger technique.
79663357|NCT04438317|Procedure|Pleural drainage procedure with surgical-like technique|Pleural drainage using Surgical-like technique.
79663358|NCT04434937|Drug|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
79663359|NCT04421560|Drug|Ibrutinib|Capsule, taken by mouth daily
79988422|NCT03670706|Behavioral|Exercise|Package of care
79988423|NCT03670706|Other|analgesic optimisation|optimisation
79988424|NCT03114280|Drug|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
79663360|NCT04421560|Drug|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
79663361|NCT04421560|Drug|Rituximab|Given as infusion into a vein (intravenous, IV)
79663362|NCT04405167|Drug|Tasquinimod|Tasquinimod will be supplied as oral capsules.
79663363|NCT04405167|Drug|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
79988425|NCT03114280|Other|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
79988426|NCT03678818|Other|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
79988427|NCT03678740|Other|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
79988428|NCT03163654|Procedure|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
79350120|NCT05887271|Diagnostic Test|Skeletal muscle magnetic resonance spectroscopy|Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.
79816701|NCT04103684|Drug|Dexamethasone|0.6mg per kg perday for 5 days
79816702|NCT04084275|Behavioral|breastfeeding education|
79816703|NCT04084275|Behavioral|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
79816704|NCT04084275|Behavioral|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
79816705|NCT04084275|Behavioral|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
79350121|NCT05887258|Drug|Opioid free anesthesia|Administer a combination of drugs in substitution for morphine
79816706|NCT04084275|Behavioral|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
79816707|NCT04084275|Behavioral|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
79816708|NCT02602184|Drug|AR/101|
79350122|NCT05887232|Procedure|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
79350123|NCT05887232|Procedure|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
79350124|NCT05887219|Drug|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
79816709|NCT02602184|Drug|Placebo|
79816710|NCT00775268|Procedure|Biopsy|Biopsy taken
79816711|NCT00775268|Diagnostic Test|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
79816712|NCT00775268|Other|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
79816713|NCT00775268|Procedure|computed tomography|Undergo scans
79988429|NCT03163654|Procedure|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
79350125|NCT05887219|Drug|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
79350126|NCT05887206|Other|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
79350127|NCT05887193|Device|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
79350128|NCT05887193|Device|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
79663364|NCT04395365|Drug|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
79663365|NCT04395365|Drug|Placebo oral tablet|Placebo
79663366|NCT04391114|Procedure|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
79988430|NCT03678662|Other|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
79501646|NCT04050774|Device|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
79501647|NCT01426386|Drug|FE 999049|
79501648|NCT01426386|Drug|Gonal - F|
79501649|NCT01404234|Drug|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
79501650|NCT01403610|Drug|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
79663367|NCT04391114|Procedure|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
79816714|NCT00775268|Procedure|fine-needle aspiration|sample collected
79350129|NCT05887193|Device|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
79350130|NCT05887193|Device|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
79350131|NCT05887180|Other|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
79350132|NCT05887154|Device|Microwave ablation|microwave ablation
79350133|NCT05887115|Behavioral|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
79350134|NCT05887089|Other|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
79816715|NCT00775190|Drug|ortho tricyclen|brand name oral contraceptive
79816716|NCT00775190|Drug|Trinessa|generic oral contraceptive
79816717|NCT00479557|Biological|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
79501651|NCT01403610|Drug|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
79663368|NCT04389853|Procedure|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
79816718|NCT00479557|Biological|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
79816719|NCT00479557|Biological|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
79816720|NCT00479557|Drug|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
79816721|NCT00774800|Drug|Humalog|
79816722|NCT00774800|Drug|Humulin-R|
79816723|NCT00774800|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
79816724|NCT00774800|Other|Liquid meal|
79816725|NCT00439309|Device|Gelfoam/Thrombin|Gelfoam/Thrombin
79350135|NCT05887063|Other|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
79816726|NCT00439309|Device|VascuSeal|VascuSeal
79350136|NCT05887024|Device|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
79350137|NCT05887024|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
79350138|NCT05887024|Procedure|McKenzie Back exercises|Graduated Progressive back exercise program.
79350139|NCT05887024|Device|electric heating pads|electrical conducting heat pack.
79350140|NCT05886998|Drug|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
79350141|NCT05886998|Other|Normal Saline|0.9% sodium chloride solution (normal saline)
79816727|NCT00479167|Drug|Bortezomib and Tositumomab I-131|
79816728|NCT00725712|Drug|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
79816729|NCT02594046|Other|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
79816730|NCT05251701|Device|Personal KinetiGraph® (PKG®) System|The PKG® System includes a wrist-worn device that records and measures movement patterns in conditions such as Parkinson's disease.
79816731|NCT00729378|Other|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
79816732|NCT05246787|Behavioral|breastfeeding|nonphamacological methods
79816733|NCT05246787|Combination Product|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
79816734|NCT05246787|Device|shotblocker|it is a small plastic tool
79501652|NCT01403610|Drug|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
79501653|NCT01403064|Biological|ALD518|IV
79501654|NCT01403064|Drug|0.9% saline|IV Infusion
79501655|NCT01402986|Other|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
79501656|NCT01402986|Biological|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
79816735|NCT00478933|Device|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
79816736|NCT00478933|Procedure|Blood sampling|Blood sampling
79816737|NCT03967860|Diagnostic Test|CT scan|Post surgical standard CT Scan as predictor of complication
79350142|NCT05886959|Other|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
79350143|NCT05886959|Other|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
79350144|NCT05886959|Other|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
79350145|NCT05886959|Other|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
79501657|NCT01402986|Other|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
79501658|NCT01402986|Biological|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
79501659|NCT01402908|Drug|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
79501660|NCT01402908|Other|Placebo|Lactose lyophilized powder
79501661|NCT01389258|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
79501662|NCT01389102|Drug|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
79816738|NCT04084353|Other|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
79816739|NCT04087824|Device|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
79816740|NCT00725322|Drug|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
79816741|NCT00725322|Drug|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
79816742|NCT04084197|Drug|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
79816743|NCT04084197|Drug|HIP1801|Tamsulosin 0.4mg
79816744|NCT02593890|Device|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
79816745|NCT02589483|Procedure|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
79988431|NCT03678662|Other|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
79988432|NCT03678662|Other|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
79988433|NCT03163810|Device|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
79988434|NCT03163810|Device|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
79988435|NCT01312363|Drug|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
79988436|NCT03163888|Procedure|Navigation TKR|Traditional over Conventional TKR
79988437|NCT03674762|Device|Microgrooved dental implants|Dental Implant placement
79350146|NCT05886959|Other|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
79350147|NCT05886959|Other|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
79988438|NCT03678584|Other|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
79988439|NCT02600234|Device|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
79988440|NCT02600234|Other|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
79988441|NCT02677714|Radiation|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
79988442|NCT03670550|Device|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
79988443|NCT03161678|Drug|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
79988444|NCT03161678|Drug|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
79988445|NCT03114670|Biological|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
79988446|NCT03670472|Other|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
79988447|NCT03674684|Other|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
79501663|NCT01389102|Drug|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
79988448|NCT05596656|Diagnostic Test|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
79988449|NCT03678272|Procedure|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
79816746|NCT02589483|Device|Hemopatch|The rectal anastomosis reinforced with Hemopatch
79988450|NCT03678272|Procedure|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
79988451|NCT03678272|Procedure|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
79988452|NCT03678272|Procedure|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
79988453|NCT03632070|Behavioral|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
79988454|NCT03674606|Drug|Low dose aspirin|One 75 mg aspirin dose taken daily
79988455|NCT03670394|Diagnostic Test|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
79350148|NCT05886959|Other|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
79350149|NCT05886959|Other|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
79988456|NCT02677324|Drug|ABT199|Oral BCL-2 antagonist
79988457|NCT03670238|Device|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
79501664|NCT01389102|Drug|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
79501665|NCT01389102|Drug|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
79501666|NCT01389102|Drug|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
79501667|NCT01389102|Drug|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
79350150|NCT05886946|Other|ABG|ABG
79350151|NCT05886933|Drug|Fexuprazan Hydrochloride|Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
79350152|NCT05886829|Combination Product|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
79350153|NCT05886829|Combination Product|Placebo|Placebo nasal spray
79350154|NCT05886803|Other|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
79501668|NCT01402284|Drug|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
79816747|NCT00725010|Drug|Temozolomide|Temozolomide will be administered orally at 75 mg/m^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m^2 to 200 mg/m^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
79816748|NCT00725010|Radiation|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
79816749|NCT02589561|Device|Remote fitting|remote fitting of hearing aids
79816750|NCT02589561|Device|Face to face fitting|face to face fitting of hearing aids
79816751|NCT05684601|Device|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
79501669|NCT01402284|Drug|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
79663369|NCT04389853|Procedure|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
79816752|NCT05216055|Combination Product|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
79816753|NCT05216055|Drug|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
79816754|NCT02592408|Drug|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
79816755|NCT02592408|Drug|SDPQ|single dose primaquine on day 2
79816756|NCT02592408|Drug|14DPQ|14 day primaquine starting on day 2
79816757|NCT02592408|Drug|14DPQ on Day 42|14 day primaquine starting on day 42
79816758|NCT03939195|Other|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
79816759|NCT00767000|Drug|MK-0941|MK-0941 tablets three times daily
79816760|NCT00767000|Drug|Comparator: Placebo|Matching placebo to MK-0941 three times daily
79816761|NCT00767000|Biological|Lantus|Lantus injection once daily
79816762|NCT00767000|Drug|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
79816763|NCT05194449|Other|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
79350155|NCT05886790|Biological|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
79501670|NCT01402284|Drug|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
79501671|NCT01402284|Drug|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
79501672|NCT01402284|Drug|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
79816764|NCT05194449|Other|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
79816765|NCT00724932|Drug|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
79816766|NCT00724932|Drug|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
79816767|NCT00724932|Drug|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
79816768|NCT00724932|Drug|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
79816769|NCT00766532|Drug|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
79816770|NCT02602340|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
79816771|NCT02589093|Device|Stimulation|
79350156|NCT05886790|Biological|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
79350157|NCT05886790|Biological|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
79350158|NCT05886751|Other|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
79501673|NCT01388790|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
79501674|NCT01388790|Drug|Cisplatin|Cisplatin 60 mg/m^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
79501675|NCT01388790|Drug|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
79501676|NCT01388478|Drug|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
79501677|NCT01424670|Drug|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
79501678|NCT01424670|Drug|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
79816772|NCT04083807|Biological|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
79816773|NCT04083807|Procedure|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
79501679|NCT01424514|Drug|SB-705498|12mg intra nasal
79501680|NCT01424514|Drug|Placebo|Placebo intra nasal
79816774|NCT02601794|Behavioral|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
79663370|NCT04386941|Procedure|Xpeeda Fibre Laser Vaporesection of the Prostate|"Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue."
79816775|NCT05188989|Drug|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
79816776|NCT05188989|Drug|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
79816777|NCT05188989|Drug|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
79816778|NCT05188989|Drug|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
79350159|NCT05886751|Other|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
79350160|NCT05886751|Other|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
79816779|NCT00774566|Procedure|PV-Isolation RF|Radiofrequency
79988458|NCT03670238|Device|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
79816780|NCT00774566|Procedure|PV-Isolation Cryo|Cryo-Balloon
79816781|NCT02589249|Dietary Supplement|AyuFlex|Active product
79816782|NCT02589249|Dietary Supplement|Placebo|Placebo
79816783|NCT02589327|Other|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
79816784|NCT04103918|Device|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
79350161|NCT05886751|Other|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
79350162|NCT05886751|Other|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
79350163|NCT05886751|Other|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
79350164|NCT05886751|Other|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
79350165|NCT05886751|Other|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
79350166|NCT05886738|Other|Fasting|Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
79816785|NCT05183685|Procedure|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
79816786|NCT05183685|Procedure|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
79816787|NCT04022018|Radiation|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
79350167|NCT05886725|Other|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
79350168|NCT05886699|Other|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
79501681|NCT01400958|Drug|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
79501682|NCT01400958|Drug|Placebo|Placebo x 42 days; THEN, No More Placebo
79501683|NCT01388166|Procedure|Education|Education
79501684|NCT01400412|Drug|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
79501685|NCT01400412|Drug|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
79501686|NCT01400412|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
79350169|NCT05886699|Other|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
79350170|NCT05886660|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
79350171|NCT05886660|Drug|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
79350172|NCT05886660|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
79350173|NCT05886660|Drug|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
79350174|NCT05886647|Other|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
79350175|NCT05886647|Other|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
79350176|NCT05886608|Device|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
79350177|NCT05886569|Device|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
79350178|NCT05886543|Behavioral|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
79501687|NCT01400412|Drug|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
79501688|NCT01400412|Drug|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
79501689|NCT01400412|Drug|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
79501690|NCT01400412|Drug|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
79501691|NCT01422876|Drug|high dose FDC|once daily
79501692|NCT01422876|Drug|BI 10773 high dose|once daily
79501693|NCT01422876|Drug|high dose FDC placebo|once daily
79501694|NCT01422876|Drug|low dose FDC placebo|once daily
79501695|NCT01422876|Drug|high dose FDC placebo|once daily
79501696|NCT01422876|Drug|high dose FDC placebo|once daily
79501697|NCT01422876|Drug|low dose FDC placebo|once daily
79501698|NCT01422876|Drug|low dose FDC placebo|once daily
79501699|NCT01422876|Drug|high dose BI 10773 placebo|once daily
79501700|NCT01422876|Drug|low dose FDC|once daily
79501701|NCT01422876|Drug|high dose FDC placebo|once daily
79501702|NCT01422876|Drug|BI 10773 low dose|low dose once daily
79501703|NCT01422876|Drug|high dose BI 10773 placebo|once daily
79501704|NCT01422876|Drug|high dose BI 10773 placebo|once daily
79501705|NCT01422876|Drug|linagliptin|once daily
79501706|NCT01422876|Drug|low dose FDC placebo|once daily
79501707|NCT01422876|Drug|linagliptin placebo|once daily
79501708|NCT01422876|Drug|BI 10773 low dose placebo|once daily
79501709|NCT01422876|Drug|linagliptin placebo|once daily
79350179|NCT05886543|Behavioral|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
79816788|NCT04022018|Radiation|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
79816789|NCT04084041|Device|Simeox|Airway clearance device
79816790|NCT04084041|Other|CCPT|Conventional chest physiotherapy
79501710|NCT01422876|Drug|low dose BI 10773 placebo|once daily
79501711|NCT01422876|Drug|linagliptin placebo|once daily
79501712|NCT01422876|Drug|high dose BI 10773 placebo|once daily
79501713|NCT01422876|Drug|BI 10773 low dose placebo|once daily
79501714|NCT01422876|Drug|low dose BI 10773 placebo|once daily
79816791|NCT00916214|Other|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
79816792|NCT00766376|Device|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
79816793|NCT05163483|Drug|Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
79816794|NCT00587054|Drug|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
79350180|NCT05886530|Other|No intervention|Observational data collection only.
79501715|NCT01422876|Drug|linagliptin placebo|once daily
79501716|NCT01422720|Drug|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
79501717|NCT01387932|Device|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
79501718|NCT01387932|Procedure|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
79501719|NCT04413786|Drug|oxytocin treatment|intranasal administration of oxytocin (24IU)
79501720|NCT04413786|Drug|placebo treatment|intranasal administration of placebo (24IU)
79501721|NCT01422408|Drug|Fluocinonide Cream|Given topically
79501722|NCT01422408|Procedure|Management of Therapy Complications|Receive fluocinonide cream
79501723|NCT01422408|Other|Questionnaire Administration|Ancillary studies
79501724|NCT01399788|Drug|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
79501725|NCT01399788|Drug|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
79501726|NCT01387542|Drug|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
79501727|NCT01387230|Drug|GSK573719|62.5 mcg
79501728|NCT01387230|Drug|GSK573719|125mcg
79501729|NCT01387230|Other|Placebo|Placebo
79501730|NCT01387074|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
79501731|NCT01386606|Drug|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
79816795|NCT04083729|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
79350181|NCT05886517|Device|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
79988459|NCT03674450|Behavioral|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
79501732|NCT01386606|Drug|Testosterone|"topical gel~1X a day 6 weeks"
79501733|NCT01385748|Drug|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
79350182|NCT05886465|Drug|Atezolizumab|1200 mg, iv.drip, Q3W
79350183|NCT05886465|Drug|Bevacizumab|15mg/kg, iv.drip, Q3W
79350184|NCT05886465|Procedure|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
79350185|NCT05886439|Drug|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
79350186|NCT05886439|Drug|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
79350187|NCT05886439|Drug|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
79816796|NCT00766142|Biological|cetuximab|
79350188|NCT05886426|Diagnostic Test|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
79501734|NCT01385748|Drug|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
79501735|NCT01385748|Drug|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
79501736|NCT01397448|Drug|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
79501737|NCT01397448|Drug|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
79501738|NCT01397448|Drug|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
79501739|NCT01385202|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
79501740|NCT05365932|Device|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
79501741|NCT01384734|Drug|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
79501742|NCT01384734|Drug|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
79501743|NCT01384734|Drug|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
79816797|NCT00766142|Drug|fluorouracil|
79816798|NCT00766142|Drug|leucovorin calcium|
79816799|NCT00766142|Drug|oxaliplatin|
79816800|NCT00766142|Procedure|adjuvant therapy|
79816801|NCT00766142|Procedure|therapeutic conventional surgery|
79988460|NCT03114748|Other|EEG|
79988461|NCT03114748|Other|DBS switched OFF and ON|
79988462|NCT02461784|Procedure|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
79988463|NCT03161782|Other|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
79350189|NCT05886413|Other|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application we will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
79501744|NCT01384734|Drug|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
79501745|NCT01384734|Drug|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
79501746|NCT01384734|Drug|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
79501747|NCT01384734|Drug|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
79501748|NCT01384734|Drug|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
79350190|NCT05886361|Other|No intervention involved|No intervention involved
79501749|NCT01396512|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
79501750|NCT01396512|Biological|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
79501751|NCT01396434|Biological|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
79501752|NCT01383954|Drug|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
79501753|NCT05365464|Drug|Progesterone Pill|Orally active progesterone
79501754|NCT05365464|Drug|hCG|Given by subcutaneous injection
79816802|NCT05152563|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
79816803|NCT05152563|Other|Placebo|Placebo
79988464|NCT03161782|Other|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
79988465|NCT03161782|Other|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
79501755|NCT01383486|Drug|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
79501756|NCT01383486|Drug|Advil|Commercially available Advil; oral caplet upon incidence of pain
79501757|NCT04407780|Other|No interventions are planned|Non applicable
79501758|NCT04766736|Procedure|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
79501759|NCT01383174|Behavioral|Peer Support Program|"Work with a trained counselor who is a breast cancer survivor~Meet 8 times in-person over the 8 week program with the counselor~Counselor helps participant develop a personalized support program to help her improve her quality of life~Receives information on breast cancer, its treatments, and stress management"
79823740|NCT05673434|Biological|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)<71> and <85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
79350191|NCT05886322|Diagnostic Test|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
79988466|NCT03161782|Other|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
79988467|NCT03670082|Drug|Lu AF35700|20 mg Lu AF35700 single oral dose
79663371|NCT04386941|Procedure|Greenlight XPS Vaporization of the Prostate|The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
79988468|NCT03670082|Drug|Lu AF35700 iv|100 μg [14C]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
79988469|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
79988470|NCT02443220|Device|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
79988471|NCT02443220|Device|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
79988472|NCT03163966|Drug|CR6086|oral CR6086 capsules
79350192|NCT05886322|Diagnostic Test|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
79350193|NCT05886322|Diagnostic Test|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
79501760|NCT01396278|Drug|Placebo|Placebo matching fluticasone propionate HFA MDI
79501761|NCT01396278|Drug|Fluticasone propionate|Fluticasone propionate HFA MDI
79350194|NCT05886257|Drug|Candonilimab|10mg/kg, iv.drip, every 3 week
79988473|NCT03163966|Drug|Methotrexate|oral Methotrexate tablets
79988474|NCT03163966|Drug|Placebo|oral CR6086 Placebo capsules
79350195|NCT05886257|Drug|Bevacizumab|15mg/kg, iv.drip, every 3 week
79350196|NCT05886231|Other|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
79350197|NCT05886218|Device|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
79350198|NCT05886205|Drug|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
79350199|NCT05886192|Drug|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
79350200|NCT05886192|Drug|Norepinephrine|norepinephrine
79350201|NCT05886179|Other|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
79501762|NCT01396278|Drug|BI 54903|BI 54903 via Respimat inhaler
79501763|NCT05365152|Dietary Supplement|Meal Replacement|Meal Replacement
79501764|NCT05365074|Drug|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
79501765|NCT01383096|Drug|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
79501766|NCT01383096|Drug|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
79663372|NCT04381338|Other|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
79663373|NCT04375800|Drug|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
79663374|NCT04375800|Drug|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
79988475|NCT03678116|Drug|Sugar Pill (placebo)|Taken orally in capsule form
79988476|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
79988477|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine)|Taken orally in capsule form
79988478|NCT03163498|Other|No intervantion. It´s a Cross-Sectional Study|No intervential
79988479|NCT03768648|Other|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
79988480|NCT03768648|Other|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
79988481|NCT03768648|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
79988482|NCT03768648|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
79988483|NCT03768648|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
79988484|NCT03678038|Drug|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
79350202|NCT05886166|Other|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
79350203|NCT05886153|Device|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
79501767|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
79501768|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
79501769|NCT04040244|Other|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
79501770|NCT04040244|Other|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
79988485|NCT03678038|Drug|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
79988486|NCT03163420|Drug|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
79988487|NCT03163420|Other|Placebo|Fructose
79988488|NCT04744272|Device|myAsthma|myAsthma is an online digital self-management application to support asthma patients by offering education, inhaler technique, pulmonary rehabilitation, symptoms and medication usage tracking remotely.
79988489|NCT03677960|Drug|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
79350204|NCT05886127|Device|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
79501771|NCT01383018|Device|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
79501772|NCT01382940|Drug|rituximab|1000 mg in 250 mL intravenous infusion
79501773|NCT01382940|Drug|methotrexate|10 to 25 mg/week (oral or parenteral)
79988490|NCT04440436|Drug|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
79988491|NCT01568814|Drug|Low volume PEG|low volume polyethylene glycol 2 liter one time
79988492|NCT01568814|Drug|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
79988493|NCT05405686|Drug|Lutropin alfa|addition of recombinant luteinizing hormone
79988494|NCT05405686|Drug|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
79988495|NCT05405686|Diagnostic Test|Endometrial biopsy|pipelle de cornier biopsy
79501774|NCT01382940|Drug|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
79501775|NCT01382940|Drug|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
79501776|NCT01382940|Drug|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
79988496|NCT04711122|Drug|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
79988497|NCT05272696|Drug|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
79988498|NCT05272696|Procedure|surgery|Patients with PR but the maximum diameter of tumor > 3cm or SD or PD can receive surgery directly.
79988499|NCT05272696|Radiation|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
79350205|NCT05886101|Behavioral|Health Education|Health education will be provided to the intervention group on health literacy, self care, productivity improvement
79663375|NCT04340947|Other|Very low nicotine cigarettes|Participants will be randomized to smoke menthol and non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory
79350206|NCT05886088|Drug|LID104|Experimental
79350207|NCT05886088|Drug|Dapagliflozin|Active comparator
79350208|NCT05886088|Drug|Linagliptin|Active comparator
79350209|NCT05886075|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
79350210|NCT05886010|Device|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79350211|NCT05886010|Device|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79350212|NCT05886010|Device|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79350213|NCT05886010|Device|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79501777|NCT01381926|Drug|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
79501778|NCT01381926|Drug|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
79501779|NCT01395888|Drug|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
79823741|NCT04073576|Device|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
79501780|NCT01395888|Drug|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
79501781|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
79501782|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
79501783|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
79501784|NCT01381692|Drug|Bortezomib|Given IV or SC
79501785|NCT01381692|Drug|Dexamethasone|Given PO
79501786|NCT01381692|Other|Laboratory Biomarker Analysis|Correlative studies
79501787|NCT01381692|Other|Quality-of-Life Assessment|Ancillary studies
79501788|NCT01381692|Biological|Rituximab|Given IV
79501789|NCT01381692|Drug|Temsirolimus|Given IV
79501790|NCT01395030|Diagnostic Test|Computed Tomography|Undergo FCH PET/CT
79501791|NCT01395030|Drug|18F-fluoromethylcholine|Undergo FCH PET/CT
79663376|NCT04338763|Drug|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
79663377|NCT04338763|Drug|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
79350214|NCT05886010|Device|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79988500|NCT05272696|Drug|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
79350215|NCT05885984|Behavioral|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
79501792|NCT01395030|Diagnostic Test|Positron Emission Tomography|Undergo FCH PET/CT
79501793|NCT01381068|Device|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
79501794|NCT01394952|Drug|Dulaglutide|Administered subcutaneously
79501795|NCT01394952|Drug|Placebo|Administered subcutaneously
79501796|NCT01394718|Drug|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
79501797|NCT01394718|Other|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
79501798|NCT01394250|Device|Buzzy|Cold, Vibrational Device
79501799|NCT01394250|Drug|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
79501800|NCT01380990|Genetic|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101*) are infused intravenously
79501801|NCT01380990|Other|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
79501802|NCT01380990|Drug|Busulfan|Busulfan is used for non-myeloablative conditioning
79501803|NCT01380990|Drug|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
79501804|NCT01380834|Drug|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
79501805|NCT01380834|Drug|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
79988501|NCT05563116|Diagnostic Test|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
79501806|NCT04407702|Other|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
79501807|NCT04407702|Procedure|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
79663378|NCT04328532|Device|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
79823742|NCT04073576|Device|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
79988502|NCT03520946|Drug|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
79988503|NCT03520946|Drug|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
79501808|NCT04407702|Radiation|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
79988504|NCT03677726|Behavioral|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
79501809|NCT04766658|Other|Gargle Phonation|Subjects will gargle water while making sound
79988505|NCT03677726|Other|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
79988506|NCT05547906|Drug|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
79816804|NCT00916526|Procedure|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~Apply nose clip and subject should be directed to breathe through the mouth~Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~Insert 5 mg capsule into inhalation device, and proceed as above~Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
79501810|NCT04766658|Other|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
79501811|NCT05360940|Diagnostic Test|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
79663379|NCT04318886|Behavioral|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
79663380|NCT04306120|Other|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
79816805|NCT03983486|Other|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
79816806|NCT00724854|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
79816807|NCT00724854|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
79988507|NCT03674060|Drug|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
79501812|NCT04407468|Procedure|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
79501813|NCT04009746|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
79663381|NCT04301401|Other|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
79350216|NCT05885984|Other|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
79501814|NCT05368740|Device|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention [2].
79501815|NCT05361330|Drug|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
79501816|NCT05361330|Drug|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
79501817|NCT05364060|Other|Questionnaires|Different questionnaires detailed in the objectives part
79501818|NCT00214968|Drug|Modafinil|maximum dosage 400 mg/day (4 tablets)
79501819|NCT00210522|Drug|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
79501820|NCT00214422|Radiation|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
79501821|NCT03592212|Drug|Salbutamol|Measurement of bronchodilator response (BDR)
79501822|NCT03024450|Drug|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
79501823|NCT03997422|Procedure|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
79663382|NCT04301401|Other|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
79663383|NCT04301401|Other|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
79663384|NCT04279067|Device|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
79988508|NCT03674060|Drug|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
79988509|NCT03163186|Procedure|Transarterial embolization|Transarterial hepatic embolization of liver cancer
79988510|NCT02049632|Procedure|Omission of axillary clearance|
79988511|NCT03163576|Drug|Niacin|tablets
79988512|NCT03163576|Drug|Phosphate Binder|tablets
79350217|NCT05885919|Drug|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
79350218|NCT05885919|Drug|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
79350219|NCT05885906|Drug|Aloevera|Mouthwash
79350220|NCT05885906|Drug|Thyme honey|Mouthwash
79350221|NCT05885906|Drug|Saline|Mouthwash
79350222|NCT05885854|Drug|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
79350223|NCT05885841|Drug|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
79350224|NCT05885802|Other|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
79988513|NCT01971008|Device|Elastic abdominal binder|
79988514|NCT01971008|Device|Placebo binder|
79501824|NCT04263090|Drug|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
79501825|NCT04263090|Drug|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
79663385|NCT04279067|Behavioral|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
79988515|NCT04058912|Genetic|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
79988516|NCT02781870|Procedure|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
79988517|NCT02781870|Procedure|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
79988518|NCT03673982|Behavioral|iCASK|Materials and support to aid transitions
79988519|NCT04759846|Drug|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
79350225|NCT05885776|Drug|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
79501826|NCT03832764|Device|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
79988520|NCT04759846|Drug|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
79988521|NCT04759846|Drug|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
79988522|NCT01810718|Drug|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or <200mg/die The MTD will be used for phase II
79350226|NCT05885750|Behavioral|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
79350227|NCT05885750|Behavioral|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
79350228|NCT05885750|Behavioral|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
79988523|NCT01383798|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
79663386|NCT04279067|Behavioral|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
79988524|NCT01383798|Dietary Supplement|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
79988525|NCT01644578|Procedure|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
79988526|NCT01374178|Drug|LY2963016|Administered subcutaneously
79501829|NCT05630508|Behavioral|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
79501830|NCT05630508|Other|Sham|Receiving standard care, LIVEN educational material and access to the application
79501831|NCT05368818|Other|Secukinumab|Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
79501832|NCT05630274|Drug|Selpercatinib|Administered orally
79501833|NCT05630274|Drug|Moxifloxacin|Administered orally
79501834|NCT05630274|Drug|Placebo|Administered orally.
79988527|NCT01374178|Drug|Lantus|Administered subcutaneously
79988528|NCT03673592|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
79501835|NCT04407624|Other|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
79501836|NCT04407624|Other|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
79501837|NCT05632692|Other|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
79988529|NCT03161314|Procedure|Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program|(Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
79988530|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
79988531|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
79350229|NCT05885711|Other|self-management|self-managing a pessary: removing, cleaning and inserting
79350230|NCT05885659|Other|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
79501838|NCT03594162|Drug|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10^5 or 5 x 10^5
79501839|NCT03594162|Drug|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
79988532|NCT03161392|Diagnostic Test|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
79988533|NCT03161392|Diagnostic Test|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
79988534|NCT03161470|Other|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
79988535|NCT03161470|Other|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
79501840|NCT03594162|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
79501841|NCT03594162|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
79501842|NCT04407312|Drug|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
79501843|NCT04407312|Drug|placebo|Placebo, tablet, 200mg, once daily, 30 days.
79501844|NCT04407312|Drug|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
79501845|NCT04407312|Drug|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
79501846|NCT03993444|Behavioral|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
79501847|NCT03993444|Behavioral|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
79501848|NCT04326738|Drug|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
79501849|NCT04326738|Drug|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
79663387|NCT04271046|Behavioral|STAR-C-VTF|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
79988536|NCT03161470|Other|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
79988537|NCT03161548|Drug|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
79988538|NCT03161548|Procedure|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
79501850|NCT03597126|Device|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1&2)
79501851|NCT03597126|Device|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1&2)
79501852|NCT04347486|Drug|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
79501853|NCT04347486|Drug|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
79501854|NCT04347486|Drug|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
79501855|NCT04347486|Drug|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
79501856|NCT03025152|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
79501857|NCT03025152|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
79501858|NCT05632458|Device|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
79501859|NCT05632224|Drug|Aprepitant|The drug is given 1 hour before the start of the surgery
79501860|NCT05632224|Drug|Granisetron|The drug is given 10 minutes before the patients's extubation
79501861|NCT05632146|Procedure|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
79501862|NCT05632146|Procedure|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
79501863|NCT03024840|Drug|Sevoflurane|Sevoflurane: 1%~2%
79501864|NCT03024840|Drug|Propofol|Propofol: 9-15 mg/kg/h
79663388|NCT04271046|Behavioral|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
79663389|NCT04270045|Device|Non-invasive forced airway oscillometry|This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
79350231|NCT05885659|Behavioral|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
79350232|NCT05885659|Behavioral|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
79501865|NCT05366088|Behavioral|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
79663390|NCT04268771|Biological|Experimental: Arm A: DRL_RI|Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
79663391|NCT04268771|Biological|Arm B: Rituxan®/Mabthera®|Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
79823743|NCT02924870|Other|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
79228321|NCT04490876|Procedure|3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method|After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
79228322|NCT02811939|Drug|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
79988539|NCT03161548|Radiation|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
79988540|NCT03025542|Drug|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
79988541|NCT03025542|Other|Placebo|Subjects will receive injections of Placebo.
79350233|NCT05885633|Procedure|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
79350234|NCT05885620|Device|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
79350235|NCT05885568|Biological|blood sampling|Blood sampling from healthy volunteers
79350236|NCT05885568|Other|drone transportation|drone transportation
79350237|NCT05885568|Other|car transportation|car transportation
79350238|NCT05885451|Drug|AMG 592|Administered as SC injection
79350239|NCT05885451|Other|Placebo|Administered as SC injection
79501866|NCT05366088|Behavioral|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
79501867|NCT03595644|Radiation|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
79663392|NCT04260243|Other|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
79350240|NCT05885425|Behavioral|Telemedicine correction of medical treatment|On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
79663393|NCT04260243|Other|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
79663394|NCT04253145|Drug|PM 01183|Lyophilisate for solution for infusion
79663395|NCT04253145|Drug|Atezolizumab|Concentrate for solution for infusion
79663396|NCT04251741|Diagnostic Test|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
79663397|NCT04251741|Other|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
79823744|NCT02924870|Other|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
79823745|NCT00427999|Drug|imatinib mesylate|
79988542|NCT03114436|Other|Observational Data Collection|All aspects of deceased donor care in the ICU.
79988543|NCT03673514|Procedure|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
79350241|NCT05885425|Behavioral|Education for proper lifestyle|Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
79350242|NCT05885399|Drug|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
79350243|NCT05884346|Other|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
79350244|NCT05884307|Other|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
79501868|NCT03595644|Drug|TKI|Received EGFR-TKI treatment
79501869|NCT05631678|Drug|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
79501870|NCT05631678|Drug|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
79823746|NCT00427999|Drug|Treosulfane|
79823747|NCT00427999|Drug|etoricoxib|
79823748|NCT00427999|Drug|pioglitazone|
79988544|NCT03161236|Other|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
79988545|NCT03161236|Other|non exercise program|continue usual lifestyle
79501871|NCT05631600|Biological|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
79663398|NCT04246606|Diagnostic Test|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~<10%: low risk~[10-20%]: intermediate risk~>20%: high risk"
79663399|NCT04244188|Other|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
79663400|NCT04239339|Drug|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
79663401|NCT04239339|Drug|Placebo|Placebo daily for approximately 3 weeks.
79663402|NCT04238715|Drug|E7090|E7090 tablets orally.
79988546|NCT03673436|Procedure|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
79663403|NCT04225832|Behavioral|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
79816808|NCT04023734|Behavioral|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
79816809|NCT04023734|Behavioral|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
79816810|NCT04023734|Behavioral|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
79988547|NCT03114514|Biological|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
79663404|NCT04222920|Other|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
79816811|NCT04023734|Behavioral|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
79663405|NCT04222920|Other|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
79663406|NCT04222920|Drug|Adalimumab|Adalimumab
79663407|NCT04208230|Device|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
79663408|NCT04198506|Other|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.
79663409|NCT04198506|Other|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
79663410|NCT04196972|Other|Communication Intervention|Receive ECHO telementoring intervention
79663411|NCT04196972|Other|Questionnaire Administration|Ancillary studies
79663412|NCT04196972|Other|Waiting List|Placed on wait-list
79663413|NCT04194827|Diagnostic Test|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
79663414|NCT04194827|Diagnostic Test|Disease activity|Dose reduction based on adalimumab diseas activity
79663415|NCT04194827|Drug|Adalimumab|Adalimumab
79823749|NCT00427999|Drug|dexamethasone|
79823750|NCT01032967|Procedure|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
79663416|NCT04177914|Procedure|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
79816812|NCT04023734|Behavioral|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
79816813|NCT00919347|Other|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa < 0.1 bpm2.~Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa < 0.5 bpm2 or 0.1 < RFa < 0.5 bpm2.~Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
79816814|NCT04083651|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
79663417|NCT04177914|Device|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
79816815|NCT04083651|Drug|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
79501872|NCT05631522|Other|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
79816816|NCT00728988|Drug|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
79988548|NCT03673358|Behavioral|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
79988549|NCT03114358|Other|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
79816817|NCT00728988|Drug|Atorvastatin|40mg daily after PCI for 30 days.
79816818|NCT05130957|Other|Massage Application with clove oil|The experimental group is given a massage with clove oil,
79816819|NCT05130957|Other|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
79816820|NCT04087746|Drug|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
79350247|NCT05884060|Other|No intervention|No interventions
79350248|NCT05881993|Drug|CBP-4888|siRNA therapeutic
79816821|NCT04087746|Drug|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
79816822|NCT00728754|Device|Dental implant Osseotite Prevail|Root form titanium dental implant
79350249|NCT05881993|Other|Placebo|Normal Saline
79350250|NCT05876260|Behavioral|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
79350251|NCT05876260|Behavioral|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
79350252|NCT05876260|Behavioral|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
79228323|NCT02811939|Drug|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
79663418|NCT04177849|Procedure|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
79501873|NCT05631444|Biological|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
79501874|NCT03599778|Drug|Apatinib|XELOX + apatinib's MTD
79501875|NCT03990012|Procedure|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
79816823|NCT00728754|Device|Dental implant Osseotite|root form titanium dental implant
79816824|NCT04083417|Drug|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
79816825|NCT04083417|Other|No antibiotic treatment|No prescription of antibiotics
79816826|NCT00728130|Procedure|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
79350253|NCT05875870|Behavioral|Daylight exposure combine walking|"Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~Weekly exercise consultation via communication software (LINE App).~Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
79816827|NCT02588937|Drug|EntecaBell ODT. 0.5mg|
79816828|NCT02588937|Drug|Baraclude Tab. 0.5mg|
79816829|NCT03938025|Procedure|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
79350254|NCT05875870|Behavioral|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
79350255|NCT05868772|Device|Active Sentry Handpiece|With low IOP settings
79816830|NCT04083105|Drug|Nitrous Oxide|Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
79816831|NCT04083105|Drug|Midazolam|Intranasal midazolam will be given after nitrous oxide administration.
79501876|NCT03990012|Procedure|3D Scanning|Subjects will undergo 3D scanning of the breasts.
79501877|NCT03980418|Procedure|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
79501878|NCT03979404|Device|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
79501879|NCT03599700|Diagnostic Test|myeloproliferative neoplasms|BLOOD SAMPLING
79501880|NCT04008264|Drug|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
79501881|NCT05631288|Genetic|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
79350256|NCT05868772|Device|Ozil Handpiece|With high IOP settings.
79501882|NCT03595410|Other|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
79501883|NCT03595254|Behavioral|Thrive|Computerized Cognitive Behavior Therapy program
79663419|NCT04177849|Procedure|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
79501884|NCT05631210|Other|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
79501885|NCT03599466|Drug|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
79501886|NCT03599466|Drug|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
79350257|NCT05867719|Other|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
79501887|NCT03599388|Behavioral|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
79816832|NCT00735696|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
79501888|NCT03599310|Behavioral|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
79501889|NCT03599310|Behavioral|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
79501890|NCT03987672|Dietary Supplement|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
79501891|NCT03986970|Drug|Tenofovir|Pre-exposure prophylaxis
79663420|NCT04173442|Drug|dupilumab|Dupilumab cohort
79816833|NCT00735696|Drug|Paclitaxel|200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
79350258|NCT05863741|Device|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
79350259|NCT05863741|Device|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
79350260|NCT05861232|Behavioral|Behavioral|fear and anxiety during inhalation therapy
79501892|NCT03594942|Diagnostic Test|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
79501893|NCT03594864|Procedure|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
79663421|NCT04152603|Behavioral|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
79988550|NCT03669692|Behavioral|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
79663422|NCT04149288|Dietary Supplement|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
79663423|NCT04149288|Dietary Supplement|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
79350261|NCT05860257|Behavioral|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
79501894|NCT03594786|Device|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
79663424|NCT04144972|Device|Medtronic Summit RC+S|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
79663425|NCT04126135|Drug|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
79501895|NCT03599232|Other|Formative objective structured clinical examination (OSCE)|
79663426|NCT04126135|Drug|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
79501896|NCT03978546|Diagnostic Test|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
79501897|NCT03978546|Diagnostic Test|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
79501898|NCT03978546|Diagnostic Test|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
79501899|NCT03594396|Drug|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
79663427|NCT04116541|Drug|HDM201|HDM201 120mg, Every 3 weeks, Per os
79663428|NCT04116541|Drug|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
79663429|NCT04116541|Drug|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
79663430|NCT04116541|Drug|Alectinib|Alectinib, 600mg twice daily, Per os
79663431|NCT04116541|Drug|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
79663432|NCT04116541|Drug|Trametinib|Trametinib 2 mg/day, continuous, Per os
79663433|NCT04116541|Drug|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
79663434|NCT04116541|Drug|Avapritinib|300 mg/day,continuous, Per os
79663435|NCT04086823|Drug|RZL-012|Subcutaneous injection to the submental fat area
79228324|NCT02811939|Drug|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
79501900|NCT03594396|Drug|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
79663436|NCT04086823|Drug|Placebo|Placebo
79663437|NCT04085744|Drug|Lidocaine 10% Spray|lidocaine will be apply on the cuff
79663438|NCT04085744|Drug|Mometasone nasal spray|mometasone spray will be applied on the cuff
79663439|NCT04060693|Device|P0.5|Investigational Medical Device collecting spectral raman data from tissue.
79663440|NCT04053582|Behavioral|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
79816834|NCT00735696|Drug|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
79816835|NCT02593968|Drug|Recombinant Human Interferon a-2b Gel|
79350262|NCT05858151|Behavioral|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
79350263|NCT05855122|Drug|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
79350264|NCT05824858|Drug|LY3537982|Administered orally.
79350265|NCT05804201|Procedure|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
79350266|NCT05794984|Other|Focus group discussions and survey questionnaire|Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
79350267|NCT05794477|Biological|Adebrelimab|Specified dose on specified days
79350268|NCT05794477|Biological|SHR-1802|Specified dose on specified days
79350269|NCT05794477|Drug|Carboplatin/Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
79501901|NCT03599076|Other|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
79501902|NCT03598764|Procedure|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
79350270|NCT05794477|Drug|Paclitaxel/Nab-Paclitaxel/Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
79501903|NCT03598764|Procedure|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
79501904|NCT03594240|Drug|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
79501905|NCT03594240|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
79501906|NCT03594006|Behavioral|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
79501907|NCT03593850|Behavioral|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
79501908|NCT03593850|Behavioral|Silence Group|Audio file that contained no sounds.
79501909|NCT03024762|Procedure|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
79816836|NCT02593968|Drug|Placebo|
79228325|NCT02811939|Drug|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
79501916|NCT05633004|Device|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
79501917|NCT04747782|Other|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
79501918|NCT03593694|Behavioral|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
79501919|NCT03593694|Behavioral|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
79823751|NCT01032967|Radiation|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
79350271|NCT05789381|Procedure|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
79350272|NCT05778396|Procedure|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
79350273|NCT05778396|Procedure|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
79350274|NCT05762133|Behavioral|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of PND with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
79350275|NCT05752825|Radiation|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
79501920|NCT03593694|Behavioral|TECH DMBAT Other|Technology delivered diabetes education
79501921|NCT03593616|Procedure|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
79663441|NCT04053582|Behavioral|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
79663442|NCT04030143|Drug|Aripiprazole|Administered as an intramuscular (IM) depot injection.
79663443|NCT04030143|Drug|Aripiprazole|Administered as an IM depot injection.
79663444|NCT04025814|Device|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
79663445|NCT04025814|Behavioral|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
79663446|NCT04005547|Behavioral|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication *Bring your Trusted Adult* Session 6 - Let's Talk About Growing Up
79663447|NCT04003428|Device|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
79663448|NCT03994874|Drug|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
79663449|NCT03993873|Drug|elzovantinib (TPX-0022)|Oral elzovantinib (TPX-0022) capsules
79988551|NCT03669692|Behavioral|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
79501922|NCT05632848|Drug|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
79350276|NCT05752825|Radiation|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
79501923|NCT03598374|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
79663450|NCT03973489|Behavioral|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
79663451|NCT03973489|Drug|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
79988552|NCT03051464|Procedure|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
79350277|NCT05752825|Diagnostic Test|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
79350278|NCT05752825|Diagnostic Test|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
79350279|NCT05752825|Diagnostic Test|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of >13,5 seconds is associated with an increased risk of falls.
79501924|NCT03598374|Dietary Supplement|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
79501925|NCT03598374|Behavioral|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
79663452|NCT03973489|Drug|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
79663453|NCT03966612|Other|Questionnaires|"Questionnaires about:~Socio-professional situation~Lifestyle~Health~NME 1~specific breast cancer survey~Imaging"
79663454|NCT03961919|Drug|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
79663455|NCT03961919|Drug|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
79663456|NCT03961919|Drug|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
79501926|NCT03593460|Drug|Synthetic PreImplantation Factor|peptide
79501927|NCT03024294|Other|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
79501928|NCT04407078|Drug|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
79501929|NCT04407078|Drug|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
79501930|NCT04003116|Drug|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
79663457|NCT03961919|Procedure|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
79663458|NCT03955068|Other|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
79663459|NCT03950635|Dietary Supplement|Dietary Intervention|Consume whole-foods, fiber-rich diet
79663460|NCT03950635|Dietary Supplement|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
79663461|NCT03950635|Other|Questionnaire Administration|Ancillary studies
79988553|NCT03051464|Radiation|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
79988554|NCT03051464|Radiation|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
79988555|NCT03161002|Genetic|detection of genotype|detection of genotype by next generation sequencing
79501931|NCT00218634|Behavioral|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
79501932|NCT00218634|Behavioral|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
79501933|NCT00217620|Drug|sorafenib|800 mg per day, daily until progression
79501934|NCT00217464|Drug|fulvestrant|intramuscularly
79501935|NCT00214500|Drug|migalastat HCl|
79501936|NCT04002726|Other|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
79501937|NCT03597984|Radiation|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
79501938|NCT03597906|Procedure|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
79501939|NCT03597906|Procedure|manifest refraction|using for ablation the exact manifest refraction
79501940|NCT03597906|Procedure|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
79501941|NCT03597906|Procedure|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
79501942|NCT03597516|Drug|RP-G28|powder for reconstitution for oral administration
79988556|NCT03669848|Other|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
79501943|NCT03597516|Drug|Placebos|powder for reconstitution for oral administration
79501944|NCT03597282|Biological|NEO-PV-01|Personal Cancer Vaccine
79663462|NCT03947385|Drug|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
79663463|NCT03947385|Drug|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
79988557|NCT05746312|Behavioral|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
79988558|NCT03673280|Procedure|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
79501945|NCT03597282|Biological|Nivolumab|monoclonal antibody against PD-1
79501946|NCT03597282|Other|Adjuvant|immune adjuvant
79501947|NCT03597282|Biological|APX005M|monoclonal agonist antibody against CD40
79501948|NCT03597282|Biological|ipilimumab|monoclonal antibody against CTLA4
79501949|NCT03597204|Diagnostic Test|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
79501950|NCT03593304|Drug|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
79501951|NCT03593304|Drug|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
79663464|NCT03947385|Drug|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
79816837|NCT02591862|Drug|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
79816838|NCT02588547|Drug|Granisetron|IV granisetron 1 mg before spinal anethesia
79501952|NCT03593304|Drug|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
79501953|NCT03593304|Drug|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
79501954|NCT00211536|Drug|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
79501955|NCT00211536|Device|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
79501956|NCT00211536|Drug|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
79501957|NCT04001088|Dietary Supplement|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
79501958|NCT04001088|Other|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
79663465|NCT03942328|Biological|Atezolizumab|Given IV
79663466|NCT03942328|Biological|Bevacizumab|Given IV
79663467|NCT03942328|Radiation|External Beam Radiation Therapy|Undergo high-dose EBRT
79663468|NCT03942328|Procedure|Pheresis|Undergo apheresis
79663469|NCT03942328|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
79663470|NCT03942328|Biological|Therapeutic Autologous Dendritic Cells|Given IT
79988559|NCT04612062|Drug|CEE321|CEE321 administered to all subjects
79350280|NCT05752825|Diagnostic Test|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
79350281|NCT05752825|Diagnostic Test|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
79350282|NCT05752825|Diagnostic Test|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
79988560|NCT03167788|Device|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
79350283|NCT05745701|Drug|PF-07081532|Oral Tablet
79350284|NCT05745701|Device|Cyclosporine|Oral Solution
79350285|NCT05745701|Drug|Itraconazole|Oral Capsule
79350286|NCT05742594|Drug|Lazertinib|Lazertinib will be administered orally.
79350287|NCT05742334|Procedure|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
79663471|NCT03934931|Other|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
79663472|NCT03934931|Other|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
79663473|NCT03934931|Other|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
79663474|NCT03934931|Other|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
79816839|NCT02588547|Drug|Granisetron|IV granisetron 0.7 mg before spinal anethesia
79816840|NCT02588547|Drug|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
79663475|NCT03934931|Other|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
79816841|NCT00478231|Drug|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
79988561|NCT03167788|Other|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood & Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
79350288|NCT05742334|Device|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
79816842|NCT04083261|Other|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
79988562|NCT03673202|Diagnostic Test|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
79663476|NCT03934931|Other|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
79988563|NCT01383642|Other|No intervention, observational study|
79988564|NCT03167944|Device|Low thermal electrosurgery system|PEAK Plasmablade
79988565|NCT03167944|Device|Conventional Electrocautery|Conventional Electrocautery
79988566|NCT03036254|Device|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
79988567|NCT03036254|Device|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
79988568|NCT03631212|Behavioral|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
79663477|NCT03929718|Drug|Spironolactone|receive spironolactone treatment after CTI ablation
79988569|NCT03162874|Drug|Placebo oral capsule|BID
79988570|NCT03162874|Drug|PXT002331 - dose 1|Oral
79988571|NCT03162874|Drug|PXT002331 - dose 2|Oral
79988572|NCT03672890|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening & evaluation, and stroke education in patients admitted with stroke.
79988573|NCT05420220|Biological|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
79988574|NCT05420220|Combination Product|Axitinib|5mg bid po
79228326|NCT02468882|Dietary Supplement|Watercress|100g of watercress daily during radiation therapy
79350289|NCT05741086|Drug|Evolocumab|evolocumab (140 mg every 2 weeks)
79350290|NCT05741086|Drug|Atorvastatin|Atorvastatin 20-40mg
79350291|NCT05731388|Diagnostic Test|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
79350292|NCT05722262|Drug|K-001|K-877-ER and CSG452 combination tablet
79350293|NCT05722262|Drug|K-877-ER|K-877-ER tablet
79350294|NCT05722262|Drug|CSG452|CSG452 tablet
79350295|NCT05711446|Other|Double Voiding|Participant will be instructed to void twice.
79663478|NCT03929718|Drug|No Spironolactone|no spironolactone treatment
79663479|NCT03927144|Drug|AMG334|Subcutaneous Injection
79663480|NCT03927144|Drug|Oral Prophylactic|SOC Oral Tablet/Capsule
79663481|NCT03919708|Device|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
79663482|NCT03918642|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
79663483|NCT03918642|Behavioral|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
79988575|NCT03022370|Behavioral|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
79663484|NCT03904251|Drug|Gemtuzumab Ozogamicin|Given IV
79988576|NCT03631758|Other|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
79663485|NCT03904251|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79663486|NCT03901339|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
79663487|NCT03901339|Drug|Eribulin|Administered intravenously per NCCN guidelines
79988577|NCT03631758|Behavioral|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
79663488|NCT03901339|Drug|Capecitabine|Administered orally per NCCN guidelines
79663489|NCT03901339|Drug|Gemcitabine|Administered intravenously per NCCN guidelines
79988578|NCT03631758|Other|Sham information|Educational information not specific to mammography or cancer screening
79988579|NCT02642562|Drug|Ferric Derisomaltose|
79988580|NCT03623204|Other|Dyspnea evaluation|
79988581|NCT04601610|Drug|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
79988582|NCT04601610|Drug|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
79988583|NCT02490306|Device|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
79988584|NCT03668912|Behavioral|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
79988585|NCT01382004|Drug|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
79988586|NCT01382004|Drug|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
79988587|NCT03669224|Other|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
79228327|NCT05157984|Procedure|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
79663490|NCT03901339|Drug|Vinorelbine|Administered intravenously per NCCN guidelines
79663491|NCT03900923|Drug|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
79663492|NCT03896750|Drug|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
79663493|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
79501959|NCT03976128|Behavioral|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
79501960|NCT03976128|Behavioral|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
79501961|NCT03596970|Drug|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
79988588|NCT03669224|Other|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
79501962|NCT03596970|Drug|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
79988589|NCT03669224|Other|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
79228328|NCT01329549|Drug|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
79501963|NCT03596892|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
79501964|NCT03596892|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
79501965|NCT03596892|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79501966|NCT03596814|Other|No Interventional study|Retrospective data
79501967|NCT04199286|Procedure|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
79501968|NCT04198896|Other|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
79501969|NCT03592836|Drug|Loop Diuretics|intravenous administration of diuretics
79501970|NCT03596502|Drug|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
79663494|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every week
79501971|NCT03596502|Drug|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
79501972|NCT03592680|Dietary Supplement|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
79988590|NCT04584528|Other|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~Genotype~Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
79350296|NCT05711446|Other|Regular Voiding|Participant will void as usual
79501973|NCT03592680|Other|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
79663495|NCT03885713|Biological|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
79663496|NCT03874858|Drug|Nilotinib|Nilotinib oral 300 mg QD hard capsules
79228329|NCT01329549|Drug|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
79350297|NCT05710887|Drug|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
79501974|NCT04198194|Diagnostic Test|Predictors of events|Apple Heart & Movement Study in Apple Research app
79501975|NCT03592524|Behavioral|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
79501976|NCT04198038|Behavioral|Songwriting with licensed music therapist|Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
79501977|NCT03596346|Other|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
79501978|NCT03596346|Other|Control product without added RI|2 snack bars daily containing 0 g of RI.
79663497|NCT03874858|Drug|Nilotinib|Nilotinib oral 300 mg BID hard capsules
79663498|NCT03874858|Drug|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
79663499|NCT03869892|Drug|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
79350298|NCT05710887|Drug|Placebo|Administration of the placebo (oxygen-air mixture [FiO2 ≈0.3]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
79988591|NCT03669458|Device|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
79988592|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
79988593|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
79988594|NCT03668834|Procedure|Dermabrasion with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
79988595|NCT03668834|Procedure|Dermaroller with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit.~Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
79988596|NCT03668834|Procedure|Liquid nitrogen induced blister with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~The site to be grafted is outlined with a surgical marking pen.~To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~The patient is asked to visit 24 hours later.~The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
79350299|NCT05699044|Diagnostic Test|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
79350300|NCT05693272|Biological|COVAC-1|Intramuscular vaccine against SARS-CoV-2
79350301|NCT05693272|Biological|Saline Placebo|Intramuscular injection of saline placebo
79350302|NCT05657041|Drug|Clopidogrel|Body weight adjusted clopidogrel dosing
79350303|NCT05653362|Device|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
79350304|NCT05653362|Device|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
79350305|NCT05635097|Behavioral|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
79501979|NCT03596190|Diagnostic Test|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
79501980|NCT03592446|Device|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
79988597|NCT04546620|Drug|R-CHOP|Arm A patients will receive R-CHOP alone.
79350306|NCT05632484|Biological|Cord blood sampling|Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing
79350307|NCT05632484|Biological|Cord blood sampling|Collection of 50 to 100 mL of cord blood from the cord blood collection bag
79350308|NCT05632484|Biological|Cord sampling|Collection of 20 centimeters (cm) of umbilical cord
79350309|NCT05622461|Behavioral|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
79350310|NCT05621889|Procedure|virtual group speech therapy intervention guided by a patient partner|virtual group speech therapy intervention guided by a patient partner
79350311|NCT05607420|Biological|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
79350312|NCT05607420|Biological|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
79350313|NCT05607316|Drug|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily at bedtime for the remainder of the study."
79501981|NCT03592446|Device|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
79988598|NCT04546620|Drug|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
79350314|NCT05607238|Procedure|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
79350315|NCT05607238|Procedure|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
79350316|NCT05605587|Drug|Leflunomide 20 mg|once daily for 6 months
79501982|NCT03596112|Other|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
79501983|NCT03596112|Other|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
79501984|NCT04197570|Drug|Opioid Anesthetics|see arm/group description
79988599|NCT04058210|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
79501985|NCT04197570|Drug|Non Opioid Analgesics|see arm/group description
79501986|NCT04197882|Biological|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
79988600|NCT04058210|Drug|IVA|150-mg tablet for oral administration.
79663500|NCT03869892|Drug|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
79988601|NCT03021668|Device|Prevena Peel & Place Dressing|Prevena Peel & Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
79988602|NCT03021668|Other|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
79988603|NCT03668756|Procedure|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
79988604|NCT03669380|Other||
79988605|NCT03669068|Procedure|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~Patients undergoing elective gastrointestinal endoscopy."
79350317|NCT05596682|Device|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
79350318|NCT05585515|Behavioral|Sleep deprivation|Total sleep deficit of consecutive 8 hours
79350319|NCT05585515|Behavioral|Sleep restriction|Total sleep deficit of cumulative 8 hours
79988606|NCT03668678|Other|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
79988607|NCT03668990|Other|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
79988608|NCT03668210|Procedure|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
79988609|NCT03623126|Other|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
79988610|NCT03020888|Device|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
79988611|NCT03668522|Other|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
79988612|NCT03668132|Other|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
79988613|NCT02250300|Drug|MLN9708 (2.3 mg)|2.3 mg
79988614|NCT02250300|Drug|MLN9708 (4.0 mg)|4.0 mg
79988615|NCT02250300|Drug|MLN9708 (3.0 mg)|3.0 mg
79988616|NCT04403490|Behavioral|HABIT-ILE|2 weeks HABIT-ILE
79988617|NCT04403490|Behavioral|Conventional intervention|2 weeks usual intervention (waitlist group)
79988618|NCT03020966|Drug|Acetaminophen|Oral acetaminophen, intravenous placebo
79988619|NCT03020966|Drug|Acetaminophen|Intravenous acetaminophen, oral placebo
79350320|NCT05584163|Device|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
79501987|NCT03591978|Diagnostic Test|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
79501988|NCT04197024|Device|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
79663501|NCT03869892|Biological|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
79663502|NCT03869892|Biological|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
79663503|NCT03859973|Drug|BI 425809|Tablet
79663504|NCT03859973|Drug|Placebo|Tablet
79350321|NCT05582993|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF administered by intravenous injection.
79501989|NCT04197024|Device|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
79501990|NCT03024060|Drug|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
79663505|NCT03814876|Behavioral|Group session psycho-education|Active comparator - control group
79663506|NCT03814876|Behavioral|FITS|Manualized family intervention
79988620|NCT01381770|Biological|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
79350322|NCT05582993|Biological|ADVATE|ADVATE administered by intravenous injection.
79350323|NCT05582642|Device|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
79350324|NCT05582369|Behavioral|Affective Rewards Messages|Messages about the affective rewards of exercise
79350325|NCT05581758|Drug|AMG 510|Oral Tablet
79350326|NCT05554146|Other|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
79350327|NCT05554146|Other|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
79350328|NCT05554146|Other|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
79350329|NCT05554146|Other|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
79350330|NCT05553301|Biological|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
79350331|NCT05553301|Biological|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
79350332|NCT05553301|Biological|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
79350333|NCT05553301|Biological|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
79501991|NCT03024060|Drug|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
79501992|NCT03024060|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
79501993|NCT03024060|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
79663507|NCT03784677|Drug|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
79663508|NCT03761394|Device|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
79663509|NCT03761394|Device|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
79663510|NCT03761394|Device|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
79663511|NCT03724318|Procedure|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
79663512|NCT03721952|Behavioral|Facilitator-Based Intervention|Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
79350334|NCT05541315|Drug|JNJ-88260237|JNJ-88260237 will be administered orally.
79350335|NCT05541315|Drug|Placebo|Matching placebo will be administered orally.
79350336|NCT05538741|Drug|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for >80 years old
79350337|NCT05538741|Drug|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
79501994|NCT03024138|Radiation|Repeat CT scan|
79501995|NCT03024216|Drug|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
79501996|NCT03024216|Drug|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
79988621|NCT01383564|Procedure|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
79350338|NCT05536323|Drug|Remimazolam bolus|Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, <40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, >80 years
79350339|NCT05536323|Drug|Remimazolam continuous|Remimazolam 12 mg/kg/hr
79350340|NCT05535738|Drug|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
79350341|NCT05535738|Other|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
79350342|NCT05535738|Drug|Dupilumab|300mg
79350343|NCT05535738|Drug|Adalimumab|40mg
79350344|NCT05535738|Drug|Ustekinumab|45mg
79350345|NCT05535738|Drug|Guselkumab|100mg
79350346|NCT05535738|Drug|Canakinumab|150mg
79350347|NCT05535738|Drug|Sarilumab|200mg
79501997|NCT03596034|Other|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
79501998|NCT03595956|Other|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
79501999|NCT03981744|Drug|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
79502000|NCT03981744|Drug|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
79502001|NCT03981744|Drug|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
79663513|NCT03718065|Drug|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
79663514|NCT03718065|Drug|Placebo|Placebo comparator.
79663515|NCT03714711|Procedure|total hip arthroplasty|Total hip replacement
79816843|NCT05095233|Behavioral|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
79663516|NCT03714711|Procedure|total knee arthroplasty|Total knee replacement
79988622|NCT01383564|Procedure|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
79663517|NCT03701230|Other|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
79988623|NCT03020576|Device|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
79988624|NCT03020576|Other|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
79988625|NCT00892866|Other|Cytology Specimen Collection Procedure|Correlative studies
79988626|NCT00892866|Other|Laboratory Biomarker Analysis|Correlative studies
79988627|NCT03667976|Behavioral|SATHI|see above
79350348|NCT05535738|Drug|Triamcinolone Acetonide|0.1% ointment
79350349|NCT05535738|Drug|Betamethasone Valerate|0.1% ointment
79350350|NCT05535738|Drug|Fluticasone Propionate|0.005% ointment
79350351|NCT05535738|Device|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (<2mm length) will be used to collect interstitial fluid
79502002|NCT03981744|Drug|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
79663518|NCT03700567|Other|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
79663519|NCT03699020|Behavioral|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
79663520|NCT03699020|Other|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
79663521|NCT03689335|Procedure|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
79663522|NCT03689335|Device|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
79663523|NCT03684811|Drug|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
79663524|NCT03684811|Drug|Azacitidine|Azacitidine will be administered per the site's standard of care.
79663525|NCT03684811|Biological|Nivolumab|Nivolumab will be administered per the site's standard of care.
79663526|NCT03684811|Drug|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
79663527|NCT03672773|Drug|Talazoparib|Given PO
79988628|NCT04051268|Biological|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
79988629|NCT04051268|Biological|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
79988630|NCT04051268|Biological|Vi Polysaccharide Vaccine|1 dose of Active Comparator
79350352|NCT05535738|Device|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
79350353|NCT05535738|Procedure|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
79816844|NCT05095233|Device|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
79988631|NCT05420298|Other|cervical mobilization|All participants will receive only single session of cervical mobilization
79988632|NCT05420298|Other|cervical manipulation|All participants will receive only single session of cervical manipulation
79988633|NCT03017612|Device|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
79350354|NCT05518110|Drug|Trametinib|2mg of Trametinib (orally) daily.
79228330|NCT01329549|Drug|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
79663528|NCT03672773|Drug|Temozolomide|Given PO
79816845|NCT02588703|Behavioral|Cognitive Behavioral Therapy|Coping Skills Treatment
79228331|NCT03302546|Procedure|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
79988634|NCT03635099|Drug|Placebo (fasted)|Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
79502003|NCT03591900|Device|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
79350355|NCT05518110|Drug|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
79502004|NCT03591744|Drug|Bortezomib|Given SC
79816846|NCT02588703|Behavioral|Usual Care|Existing DUI program group counseling
79988635|NCT03635099|Drug|BI 25 mg (fasted)|25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
79816847|NCT02588625|Drug|BMS-986020|
79350356|NCT05451589|Behavioral|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
79988636|NCT03635099|Drug|BI 50 mg (fasted)|50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
79988637|NCT03635099|Drug|BI 100 mg (fasted)|100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
79988638|NCT03635099|Drug|BI 200 mg (fasted)|200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
79988639|NCT03635099|Drug|Placebo (fed)|4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
79988640|NCT03635099|Drug|BI 400 mg once daily (fed)|4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
79988641|NCT03635099|Drug|BI 200 mg twice daily, 400 mg total (fed)|2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
79988642|NCT03667898|Procedure|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
79350357|NCT05451589|Behavioral|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
79502005|NCT03591744|Biological|Daratumumab|Given IV
79988643|NCT03667898|Procedure|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
79988644|NCT03668444|Behavioral|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
79988645|NCT03668444|Behavioral|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
79502006|NCT03591744|Drug|Dexamethasone|Given IV and PO
79502007|NCT03591744|Drug|Lenalidomide|Given PO
79502008|NCT03591744|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79502009|NCT03595800|Procedure|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
79502010|NCT03023670|Procedure|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
79502011|NCT03023670|Procedure|cardiopulmonary bypass|Low rate (4\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
79502012|NCT03023592|Drug|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
79502013|NCT03591666|Drug|Anlotinib|Anlotinib p.o. qd
79663529|NCT03665337|Behavioral|mTranS-C|MOBILE HEALTH
79663530|NCT03665337|Behavioral|Control|MOBILE HEALTH
79663531|NCT03661723|Drug|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
79663532|NCT03661723|Drug|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
79663533|NCT03661723|Radiation|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
79663534|NCT03635801|Device|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
79663535|NCT03634124|Biological|Blood test|Additional blood test of 4,5 ml of venous blood
79988646|NCT03668366|Drug|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
79816848|NCT02588625|Other|Placebo|
79988647|NCT03668288|Other|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
79350358|NCT05429164|Other|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
79502014|NCT04196946|Drug|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
79502015|NCT04196946|Drug|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
79816849|NCT02588469|Other|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
79816850|NCT02588469|Other|Control group|Standard obesity care with physical activity program
79816851|NCT00474175|Drug|Placebo gel|single dose (less than 1g) of a matching placebo gel
79988648|NCT04595786|Drug|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
79350359|NCT05429164|Other|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
79350360|NCT05429164|Other|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
79502016|NCT04199208|Other|Prehabilitation and Immunonutrition|See study synopsis
79502017|NCT04199208|Other|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
79988649|NCT04595786|Drug|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
79663536|NCT03634124|Other|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
79502018|NCT03591588|Other|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
79663537|NCT03629340|Drug|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
79816852|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
79816853|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
79350363|NCT05345717|Drug|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
79350364|NCT05332613|Behavioral|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
79350365|NCT05332613|Behavioral|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
79350366|NCT05332613|Behavioral|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
79350367|NCT05332054|Biological|Allogeneic CAR-T therapy|N/A this is an observational study
79350368|NCT05327127|Drug|K-877-ER|K-877-ER tablet
79350369|NCT05327127|Drug|CSG452|CSG452 tablet
79350370|NCT05327127|Drug|Placebo|Placebo tablet
79350371|NCT05319717|Dietary Supplement|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
79350372|NCT05319717|Dietary Supplement|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
79663538|NCT03629340|Drug|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
79350373|NCT05276362|Device|Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
79350374|NCT05276362|Device|Actiwatch|The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
79350375|NCT05245968|Drug|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
79350376|NCT05245968|Drug|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
79350377|NCT05245968|Drug|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
79502019|NCT04194918|Behavioral|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
79502020|NCT04194918|Other|Text Message|Receive text messages
79502021|NCT04194918|Other|Handout|Receive handouts via email
79502022|NCT04194918|Other|Questionnaire Administration|Ancillary studies
79502023|NCT04194918|Other|Quality-of-Life Assessment|Ancillary studies
79502024|NCT04194918|Other|Survey Administration|Ancillary studies
79663539|NCT03598595|Drug|Docetaxel|Given IV
79663540|NCT03598595|Drug|Gemcitabine|Given IV
79663541|NCT03598595|Drug|Hydroxychloroquine|Given PO
79663542|NCT03569956|Other|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
79816854|NCT00919425|Other|biologic sample preservation procedure|
79816855|NCT03002389|Drug|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
79816856|NCT03002389|Drug|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
79816857|NCT02979379|Other|Pain|
79988650|NCT04584164|Device|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
79663543|NCT03568994|Drug|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
79663544|NCT03568994|Drug|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
79816858|NCT04082949|Biological|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
79988651|NCT02108652|Drug|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
79988652|NCT01383408|Other|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
79988653|NCT05419752|Drug|bioceramic sealer|bioceramic based obturating sealer
79988654|NCT05419752|Drug|MTA|MTA based obturating sealer
79988655|NCT05419752|Drug|resin sealer|resin based obturating sealer
79988656|NCT03634085|Drug|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
79988657|NCT05419596|Procedure|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
79988658|NCT04373148|Other|There is no intervention|There is no intervention
79988659|NCT01381614|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
79228332|NCT03302546|Procedure|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
79228333|NCT02234739|Drug|Voriconazole|2-week long intravenous instillation of voriconazole
79228334|NCT04442516|Other|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
79350378|NCT05232682|Dietary Supplement|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
79502025|NCT04747938|Device|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
79663545|NCT03568994|Drug|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
79663546|NCT03568994|Drug|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
79663547|NCT03568994|Drug|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
79350379|NCT05225337|Other|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
79350380|NCT05225337|Other|Daily calorie restriction|25% energy restriction every day Diet counseling provided
79350381|NCT05220514|Drug|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
79502026|NCT04747938|Behavioral|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
79502027|NCT03023904|Biological|Nivolumab|Given IV
79502028|NCT03023904|Other|Laboratory Biomarker Analysis|Correlative studies
79502029|NCT03966768|Device|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
79663548|NCT03566043|Genetic|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
79663549|NCT03502018|Drug|Bupivacaine liposome|A long-acting liposomal bupivacaine
79663550|NCT03502018|Drug|Saline|Saline injection used as control
79663551|NCT03499236|Device|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
79502030|NCT03966768|Device|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
79502031|NCT04406922|Procedure|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
79502032|NCT03591198|Behavioral|Qigong Training|Eight-Section Brocades
79502033|NCT03591198|Behavioral|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
79663552|NCT03499236|Other|Control|Right heart catheterization, invasive echocardiography.
79663553|NCT03484299|Procedure|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
79663554|NCT03484299|Drug|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
79663555|NCT03484299|Drug|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
79663556|NCT03471624|Drug|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
79663557|NCT03445689|Other|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
79350382|NCT05220514|Drug|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
79350383|NCT05194969|Device|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
79502034|NCT04196400|Drug|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
79502035|NCT04021758|Behavioral|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
79502036|NCT04196322|Other|observational study|observational study
79502037|NCT04196088|Device|Ultivision Artificial Intelligence Software|Screening Colonoscopy
79502038|NCT04196088|Device|No Artificial Intelligence Software enhancement|Screening Colonoscopy
79663558|NCT03445689|Other|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
79988660|NCT03729323|Behavioral|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
79502039|NCT04196166|Other|preoperative blood tests|
79502040|NCT03591042|Diagnostic Test|cervical length screening|transvaginal ultrasound cervical length
79502041|NCT04195932|Other|Exercise training|
79502042|NCT03590886|Other|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
79502043|NCT03972774|Diagnostic Test|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
79988661|NCT03729323|Behavioral|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
79350384|NCT05194969|Device|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
79350385|NCT05185440|Behavioral|GIFTSS Training|training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
79502044|NCT03972774|Other|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
79502045|NCT03023436|Procedure|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
79502046|NCT03023436|Procedure|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
79663559|NCT03445689|Other|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
79988662|NCT01381536|Drug|GSK1550188 1mg/kg or 10mg/kg|IV one shot
79988663|NCT02676778|Drug|E7777|
79988664|NCT03160924|Other|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
79350386|NCT05185440|Behavioral|Learning Collaborative|learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
79350387|NCT05185440|Behavioral|Provider Scripts|scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
79350388|NCT05178082|Behavioral|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
79502047|NCT03023436|Drug|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
79663560|NCT03445689|Other|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
79663561|NCT03445689|Other|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
79663562|NCT03445689|Other|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
79663563|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
79350389|NCT05178082|Behavioral|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
79502048|NCT03023436|Drug|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
79502049|NCT04020042|Other|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
79502050|NCT04020042|Other|Landmark palpation|Epidural landmarks will be determined with palpation
79663564|NCT03441048|Drug|Cladribine|Cladribine 5mg/m^2/day IV over two hours on days 2-6.
79663565|NCT03441048|Drug|Cytarabine|Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.
79663566|NCT03441048|Drug|Mitoxantrone|Mitoxantrone 10mg/m^2/day IV on days 2-4.
79816859|NCT04082949|Other|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
79502051|NCT04026594|Other|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
79502052|NCT04026594|Other|Relaxation group|control group
79350390|NCT05168826|Device|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
79350391|NCT05166239|Procedure|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
79350392|NCT05166239|Drug|Lenvatinib 1|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily after HAIC.
79350393|NCT05166239|Drug|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
79502053|NCT04025424|Genetic|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
79663567|NCT03441048|Drug|G-CSF|G-CSF at a dose of 300 µg on days 1-6.
79663568|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
79663569|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
79816860|NCT03574129|Behavioral|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
79816861|NCT01020643|Drug|controlled administration of propofol|comparison of propofol sedation
79988665|NCT01381458|Drug|FSC|fluticasone propionate / salmeterol xinofoate combination
79228335|NCT02736474|Drug|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
79350394|NCT05166239|Drug|Lenvatinib 2|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily.
79502054|NCT04023396|Drug|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
79502055|NCT04195464|Other|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
79502056|NCT04195464|Other|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
79502057|NCT04195386|Procedure|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
79502058|NCT04195386|Procedure|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
79502059|NCT04195152|Other|Observational|No intervention
79228336|NCT02736474|Drug|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
79350395|NCT05166239|Drug|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
79502060|NCT04195074|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
79663570|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
79663571|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
79663572|NCT03441048|Biological|Lintuzumab-Ac-225 (Recommended Phase 2 Dose)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
79816862|NCT03537391|Diagnostic Test|Whole body contrast enhanced computer tomography|Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
79350396|NCT05145296|Combination Product|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
79823752|NCT02579018|Behavioral|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
79823753|NCT04825652|Drug|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
79823754|NCT04825652|Drug|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
79350397|NCT05133180|Drug|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
79350398|NCT05133180|Other|Vehicle|Vehicle will be instilled with the same scheme of the test product
79502061|NCT04195074|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
79502062|NCT04195074|Drug|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
79502063|NCT04194762|Other|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
79502064|NCT03971838|Behavioral|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
79502065|NCT04029792|Combination Product|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
79502066|NCT04029792|Combination Product|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
79502067|NCT04029948|Procedure|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
79502068|NCT04029948|Procedure|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
79502069|NCT03590262|Drug|Metformin|take the metformin 500mg twice or three times a day
79663573|NCT03429907|Behavioral|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
79663574|NCT03429907|Behavioral|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
79663575|NCT03414983|Biological|Nivolumab|Specified dose on specified days
79350399|NCT05122767|Drug|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
79663576|NCT03414983|Drug|Oxaliplatin|Specified dose on specified days
79350400|NCT05122767|Drug|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, >=30kg (P 900mg, H 900mg)
79663577|NCT03414983|Drug|Leucovorin|Specified dose on specified days
79988666|NCT01381458|Drug|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
79350401|NCT05105958|Drug|Tideglusib|1000 mg/day per os
79228337|NCT02736474|Drug|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
79228338|NCT02736474|Drug|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
79350402|NCT05095922|Drug|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
79502070|NCT04029636|Other|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
79502071|NCT04029402|Other|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
79502072|NCT04029558|Dietary Supplement|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
79502073|NCT04029558|Dietary Supplement|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
79502074|NCT04194684|Drug|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
79663578|NCT03414983|Drug|Fluorouracil|Specified dose on specified days
79663579|NCT03414983|Drug|Bevacizumab|Specified dose on specified days
79663580|NCT03411499|Procedure|Early surgery|Surgery within 72 hours from endocarditis diagnosis
79663581|NCT03411499|Procedure|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
79663582|NCT03398161|Other|Quality-of-Life Assessment|Ancillary studies
79663583|NCT03398161|Other|Questionnaire Administration|Ancillary studies
79663584|NCT03398161|Radiation|Radiation Therapy|Undergo ultra low dose radiation therapy
79823755|NCT03847220|Diagnostic Test|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
79823756|NCT00661713|Biological|rMenB+OMV NZ|
79823757|NCT00661713|Biological|Placebo|
79823758|NCT02578472|Drug|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
79663585|NCT03396575|Biological|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
79350403|NCT05095922|Drug|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
79350404|NCT05095922|Drug|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
79663586|NCT03396575|Biological|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
79663587|NCT03396575|Drug|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
79816863|NCT03537391|Diagnostic Test|99mTC-HMDP planar bone scintigraphy (BS)|Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
79823759|NCT02578472|Drug|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
79823760|NCT02578472|Drug|Placebo|Matching Placebo will be administered orally.
79350405|NCT05062980|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
79350406|NCT05062980|Drug|pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
79823761|NCT00786123|Dietary Supplement|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
79350407|NCT05062980|Drug|docetaxel|Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
79502075|NCT03590106|Behavioral|Peer Recovery Support Program|See above
79823762|NCT00786123|Dietary Supplement|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
79823763|NCT04047225|Device|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
79663588|NCT03396575|Drug|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
79663589|NCT03396575|Drug|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
79988667|NCT05419440|Procedure|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp & blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding & complete drainage of pus & removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema & inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes & air leak test , in all cases we put large drain at pelvis
79350408|NCT05062980|Drug|ramucirumab|Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
79350409|NCT05062980|Drug|Investigator's Treatment of Choice|Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
79350410|NCT05046574|Other|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
79663590|NCT03396575|Biological|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
79663591|NCT03395847|Biological|Pembrolizumab|Given IV
79350411|NCT05044598|Other|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
79663592|NCT03340675|Drug|Ifetroban|Weight based, once daily oral ifetroban
79663593|NCT03340675|Drug|Placebo|Matching oral placebo
79663596|NCT03335670|Drug|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
79823764|NCT00782925|Other|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
79350412|NCT05030961|Behavioral|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
79350413|NCT05030961|Behavioral|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
79350414|NCT05014360|Drug|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
79663597|NCT03304613|Behavioral|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
79663598|NCT03304613|Behavioral|Promoting Resilience through Innovative Self-Management|Already noted.
79663599|NCT03301805|Drug|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~28 days a cycle."
79663600|NCT03298659|Diagnostic Test|iFR|Treatment guided by instantaneous wave-free ratio
79663601|NCT03298659|Diagnostic Test|CMR|Treatment guided by stress perfusion CMR
79663602|NCT03296774|Behavioral|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
79663603|NCT03296774|Behavioral|Usual Care|
79663604|NCT03288974|Drug|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
79663605|NCT03275610|Genetic|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
79663606|NCT03272477|Drug|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
79663607|NCT03272477|Drug|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
79988668|NCT05746156|Diagnostic Test|lymphatic mapping|"Peritumoral injection of [99mTc]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
79350415|NCT04954300|Other|no intervention|No intervention
79350416|NCT04944147|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA)
79350417|NCT04944147|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants
79350418|NCT04944147|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions
79663608|NCT03272477|Drug|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
79823765|NCT00782925|Other|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
79823766|NCT00782925|Other|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
79823767|NCT04073888|Procedure|Semen collection|Semen collection for seminogram and spermocytogram
79988669|NCT05179486|Procedure|Biospecimen Collection|Undergo collection of tissue, and blood
79988670|NCT05179486|Other|Questionnaire Administration|Complete questionnaire
79988671|NCT05419206|Diagnostic Test|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
79988672|NCT05746000|Behavioral|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
79350419|NCT04944147|Behavioral|Progressive muscle relaxation (PMR)|Standardized instructed PMR training, 9 sessions
79988673|NCT05746000|Behavioral|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
79988674|NCT03162406|Dietary Supplement|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
79988675|NCT03162406|Dietary Supplement|Placebo|Oral supplementation once per week for 6 months
79823768|NCT04072796|Behavioral|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
79988676|NCT02946385|Biological|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
79350420|NCT04939558|Device|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
79502076|NCT04194294|Drug|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
79823769|NCT03835975|Biological|13vPnC|Pneumococcal conjugate vaccine
79823770|NCT03835975|Biological|PPSV23|Pneumococcal polysaccharide vaccine
79823771|NCT03835975|Biological|20vPnC|Pneumococcal conjugate vaccine
79823772|NCT04072718|Radiation|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
79988677|NCT02946385|Biological|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
79988678|NCT05177341|Other|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
79988679|NCT05308771|Device|VPC syringe|Use of the visual pressure control syringe for epidural space detection
79988680|NCT05676190|Combination Product|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
79988681|NCT05676190|Combination Product|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
79988682|NCT05676190|Combination Product|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
79988683|NCT05676190|Combination Product|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
79663609|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
79663610|NCT03272477|Drug|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
79663611|NCT03272477|Drug|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
79663612|NCT03272477|Drug|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
79816864|NCT03537391|Diagnostic Test|99mTc-HMDP single photon emission computer tomography/computer tomography|SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index ~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
79350421|NCT04921449|Other|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
79350422|NCT04921449|Other|Usual Care|Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.
79350423|NCT04907253|Drug|Quercetin|500 mg twice daily
79350424|NCT04907253|Drug|Placebo|twice daily
79350425|NCT04898400|Procedure|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
79663613|NCT03272477|Drug|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
79663614|NCT03272477|Drug|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
79350426|NCT04875715|Other|Almond Oil|Almond oil
79350427|NCT04875715|Drug|Hydroquinone Topical|Hydroquinone 2% cream
79350428|NCT04874584|Behavioral|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
79663615|NCT03272477|Drug|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
79663616|NCT03272477|Drug|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
79663617|NCT03272477|Drug|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
79663618|NCT03272477|Drug|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
79663619|NCT03272477|Drug|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
79663620|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
79663621|NCT03272477|Drug|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
79663622|NCT03272477|Drug|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
79663623|NCT03272477|Drug|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
79663624|NCT03272477|Diagnostic Test|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
79663625|NCT03272477|Procedure|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
79663626|NCT03270631|Other|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
79663627|NCT03270631|Other|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
79663628|NCT03270631|Other|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
79663629|NCT03270631|Other|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
79816865|NCT03537391|Diagnostic Test|Whole-body magnetic resonance imaging|Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
79350429|NCT04874584|Behavioral|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
79663630|NCT03265314|Behavioral|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
79663631|NCT03265314|Behavioral|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
79663632|NCT03261674|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
79663633|NCT03261674|Behavioral|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
79663634|NCT03255070|Drug|ARX788|An antibody drug conjugate
79663635|NCT03253848|Other|Best Practice|Discussion between doctors and APL expert
79663636|NCT03253848|Other|Laboratory Biomarker Analysis|Correlative studies
79816866|NCT03537391|Diagnostic Test|Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography|18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is < 6 mm.
79816867|NCT05683665|Device|scintigraphy DaTSCAN|DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
79350430|NCT04861597|Behavioral|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
79350431|NCT04861597|Behavioral|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
79350432|NCT04847050|Biological|mRNA-1273|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered IM on Day 1 and 29 for vaccine naive cohorts or on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study
79350433|NCT04836429|Drug|Porfimer Sodium|Given IV
79502077|NCT04194294|Other|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
79502078|NCT04029324|Procedure|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
79663637|NCT03253848|Procedure|Supportive Care|Receive simplified guidelines and support
79663638|NCT03229356|Other|Best Practices Advisory (BPA)|"BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
79350434|NCT04836429|Procedure|Video-Assisted Thoracic Surgery|Undergo VATS
79502079|NCT04029324|Procedure|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
79502080|NCT04029324|Procedure|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
79502081|NCT04029324|Procedure|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
79502082|NCT04029090|Drug|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
79502083|NCT04029090|Drug|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
79502084|NCT04029090|Drug|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
79502085|NCT04193982|Drug|Saroglitazar|Patient receives Saraglitazar 4mg once daily
79350435|NCT04836429|Drug|Photodynamic Therapy|Undergo photodynamic therapy
79502086|NCT04193982|Drug|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
79502087|NCT04193982|Drug|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
79502088|NCT04193982|Behavioral|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
79502089|NCT04028778|Drug|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
79502090|NCT04028778|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
79663639|NCT03229356|Other|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
79663640|NCT03176953|Drug|topiramate|active medication
79816868|NCT03529591|Device|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
79663641|NCT03176953|Behavioral|prolonged exposure|psychotherapy
79502091|NCT04028778|Other|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
79663642|NCT03176953|Drug|placebo|non-active medication
79663643|NCT03128775|Behavioral|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
79502092|NCT04028856|Drug|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
79502093|NCT03594474|Other|Intravenous lipid emulsion|using higher dose of IV lipids after birth
79502094|NCT04028544|Drug|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
79502095|NCT04028544|Drug|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
79350436|NCT04836429|Device|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
79350437|NCT04832152|Other|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
79350438|NCT04828954|Other|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
79350439|NCT04828954|Other|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
79350440|NCT04822467|Device|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
79350441|NCT04822467|Device|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
79988684|NCT04917211|Procedure|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
79988685|NCT02694718|Drug|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m^2 bid orally on Days 1-14, and at a dose of 825mg/m^2 bid on Days 22-35 and 43-56.
79663644|NCT03128775|Behavioral|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
79816869|NCT03529591|Procedure|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
79502096|NCT04406220|Other|Small clog size|Participants will be randomized to run in small clogs
79816870|NCT01027975|Procedure|laparoscopic Nissen/laparoscopic Thal|
79816871|NCT02588391|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
79816872|NCT02588391|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
79816873|NCT02588391|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
79502097|NCT04406220|Other|Large clog size|Participants will be randomized to run in large clogs
79502098|NCT04193592|Drug|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
79502099|NCT03964272|Device|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
79502100|NCT03963102|Drug|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
79502101|NCT03599856|Other|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
79350442|NCT04817566|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
79502102|NCT04193358|Dietary Supplement|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
79663645|NCT03128775|Behavioral|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
79663646|NCT03110978|Biological|Nivolumab|Given IV
79663647|NCT03110978|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
79663648|NCT03091075|Drug|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
79663649|NCT03091075|Drug|Placebo|Placebo group will receive placebo for 12 weeks postoperative
79663650|NCT03080974|Drug|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
79663651|NCT03080974|Procedure|Irreversible Electroporation|Non-thermal ablation of tumor
79816874|NCT02588313|Dietary Supplement|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
79816875|NCT02968537|Behavioral|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
79988686|NCT02694718|Drug|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m^2/d intravenously on Day 1 and 50mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
79350443|NCT04817566|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
79350444|NCT04817566|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
79350445|NCT04777266|Behavioral|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy [37], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence [38]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
79663652|NCT03059563|Drug|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
79663653|NCT03059563|Other|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
79502103|NCT04193358|Other|PLACEBO|Sugar pills
79502104|NCT04193748|Drug|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
79663654|NCT03040973|Drug|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
79663655|NCT03040973|Drug|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
79663656|NCT03040973|Drug|Gefitinib|tablets for oral use; 250mg; once a day
79663657|NCT03040973|Drug|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
79502105|NCT04028154|Procedure|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
79988687|NCT04378153|Other|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy in Study A during 6-week study period.
79988688|NCT04378153|Other|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy in Study A during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
79663666|NCT03004287|Drug|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
79350446|NCT04769713|Procedure|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
79350447|NCT04769713|Drug|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
79350448|NCT04769713|Drug|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
79350449|NCT04756674|Other|No intervetion will be used|No intervention will be used
79350450|NCT04728581|Drug|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
79350451|NCT04728581|Drug|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
79350452|NCT04728581|Drug|Placebo|a gelatinous capsule without an active ingredient
79350453|NCT04720703|Behavioral|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
79502106|NCT04028154|Procedure|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
79663667|NCT03004287|Drug|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
79663668|NCT03004287|Drug|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
79663669|NCT03004287|Drug|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
79663670|NCT03004287|Drug|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
79663671|NCT03004287|Drug|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
79663672|NCT03004287|Drug|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
79663673|NCT03004287|Drug|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
79663674|NCT03004287|Drug|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
79663675|NCT03004287|Procedure|ASCT|day 0 of Transplant(s)
79663676|NCT03004287|Drug|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
79663677|NCT03004287|Drug|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
79663678|NCT02986659|Drug|Metformin|
79663679|NCT02986659|Drug|Placebo|
79663680|NCT02933489|Diagnostic Test|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
79663681|NCT02933489|Diagnostic Test|Digital Tomosynthesis Mammography|Undergo DBT
79663682|NCT02933489|Other|Quality-of-Life Assessment|Ancillary studies
79988689|NCT04378153|Other|Discontinuation of dornase alfa (dnase)|Discontinuation of current dornase alfa (dnase) therapy in Study B during 6-week study period.
79350454|NCT04720703|Behavioral|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
79502107|NCT04028076|Behavioral|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
79663683|NCT02933489|Other|Questionnaire Administration|Ancillary studies
79663684|NCT02837978|Drug|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
79663685|NCT02837978|Drug|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
79350455|NCT04677543|Drug|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
79350456|NCT04677543|Drug|Azithromycin|Oral tablet
79350457|NCT04677543|Drug|Ethambutol|Oral tablet
79350458|NCT04677543|Drug|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
79350459|NCT04671511|Procedure|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
79350460|NCT04671511|Diagnostic Test|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
79350461|NCT04662840|Procedure|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
79350462|NCT04662840|Procedure|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
79350463|NCT04662840|Procedure|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
79350464|NCT04633317|Device|A pneumatic nebulizer|Inhaled colistimethate sodium generated by a pneumatic nebulizer
79350465|NCT04633317|Device|A vibrating mesh nebulizer|Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
79350466|NCT04630951|Other|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
79350467|NCT04630951|Other|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
79663686|NCT02833402|Device|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
79663687|NCT02802423|Drug|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
79988690|NCT04378153|Other|Continuation of dornase alfa (dnase)|Continuation of current dornase alfa (dnase) therapy in Study B during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily).
79350468|NCT04580459|Behavioral|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
79350469|NCT04580459|Behavioral|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
79350470|NCT04546568|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
79502108|NCT04027764|Drug|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \8
79663688|NCT02777346|Device|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
79663689|NCT02777346|Device|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
79663690|NCT02743806|Drug|Vedolizumab|Vedolizumab IV infusion
79663691|NCT02694666|Other|Controlled whole-body vibration training|The intervention is an 8-week program
79350471|NCT04546568|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
79350472|NCT04544293|Drug|Molgramostim|Molgramostim 300 µg nebulizer solution
79350473|NCT04544293|Drug|Placebo|Matching placebo
79350474|NCT04513548|Drug|Ligelizumab|One injection every four weeks
79350475|NCT04513548|Drug|Placebo|One injection every four weeks
79350476|NCT04495998|Diagnostic Test|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
79350477|NCT04485494|Diagnostic Test|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
79502109|NCT04027842|Device|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
79502110|NCT04192890|Device|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
79502111|NCT03592602|Procedure|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
79502112|NCT04027530|Drug|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
79663692|NCT02693652|Biological|CVI-HBV-002|"Investigational product: CVI-HBV-002~Dose: 20ug or 40ug~Frequency: 3 or 6 times~Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~Administration route: Intramuscular injection"
79663693|NCT02692170|Biological|CVI-HBV-001|Investigational Product
79663694|NCT02692170|Biological|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
79663695|NCT02674100|Other|Registry|
79663696|NCT02668653|Drug|Chemotherapy|
79663697|NCT02668653|Drug|Quizartinib|
79663698|NCT02668653|Drug|Placebo|
79663699|NCT02661997|Behavioral|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
79350478|NCT04484948|Other|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"Participants will perform the SHAQ.~BHT and 6MWT will be performed in the randomized way for each participant.~For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~6MWT will be performed according to the ATS guidelines.~Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
79502113|NCT03023358|Drug|chidamide|30mg po twice a week
79502114|NCT03023358|Drug|cyclophosphamide|750mg/m2 iv on day 1
79502115|NCT03023358|Drug|liposomal doxorubicin|30mg/m2 iv on day 1
79502116|NCT03023358|Drug|vincristine|1.4mg/m2 iv on day 1
79502117|NCT03023358|Drug|prednisone|100mg/d po on day 1-5
79988691|NCT03106090|Other|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
79988692|NCT03105778|Diagnostic Test|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
79350481|NCT04469231|Device|Anterior Cervical Discectomy & Fusion|ACDF
79350482|NCT04448951|Other|transcriptomics|transcriptomics
79350483|NCT04448951|Other|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
79350484|NCT04448951|Other|cytokines|peripheral blood cytokine analysis
79350485|NCT04448080|Device|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
79502118|NCT03023280|Procedure|Radiofrequency ablation|
79350486|NCT04421040|Device|Biotronic 3 implant of device|The Biotronic 3 device will be implanted by the research team physician.
79350487|NCT04421040|Device|Biotonic 3 explant of device|The Biotronic 3 device will be removed from the patient by the research team physician.
79350488|NCT04413201|Drug|Afatinib|Afatinib followed by osimertinib or ICT
79663700|NCT02661997|Behavioral|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
79663701|NCT02652052|Other|Standard of Care - Observation Only|Control Arm - Observation only
79350489|NCT04413201|Drug|Osimertinib|Osimertinib followed by ICT
79350490|NCT04411251|Behavioral|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
79663702|NCT02652052|Drug|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
79988693|NCT03161080|Device|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
79228339|NCT04490798|Procedure|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
79350491|NCT04411251|Behavioral|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
79350492|NCT04373460|Biological|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
79502119|NCT04192812|Drug|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
79502120|NCT04192812|Drug|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
79350493|NCT04373460|Biological|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
79502121|NCT04192578|Device|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
79502122|NCT04407000|Drug|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
79502123|NCT04407000|Drug|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
79502124|NCT04192422|Other|no intervention|This is a cohort study no intervention
79502125|NCT04192656|Device|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
79502126|NCT04192656|Drug|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
79502127|NCT04192656|Drug|Ginaton|ginnaton is ginkgo biloba extract
79502128|NCT04191954|Drug|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
79502129|NCT04191954|Drug|receive artificial tears drop|receive artificial tears drop with the same frequency
79502130|NCT04192032|Other|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
79502131|NCT04192032|Other|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
79502132|NCT04192032|Other|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
79502133|NCT04192032|Other|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
79502134|NCT04192032|Other|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
79663703|NCT02652052|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
79663704|NCT02649972|Drug|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
79502135|NCT04027062|Behavioral|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
79502136|NCT04026828|Genetic|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
79663705|NCT02615119|Drug|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
79663706|NCT02615119|Drug|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
79816876|NCT02968537|Behavioral|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
79502137|NCT04191408|Procedure|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
79816877|NCT02968537|Behavioral|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
79663707|NCT02558010|Drug|Methadone|Perioperative IV methadone to be given
79988694|NCT03161080|Device|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
79988695|NCT03161080|Device|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
79988696|NCT04923139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
79988697|NCT04891627|Diagnostic Test|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
79350494|NCT04302272|Device|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
79350495|NCT04298658|Diagnostic Test|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
79502138|NCT04191564|Procedure|low perfusion state|reduce SAP below 100 mmHg
79663708|NCT02558010|Other|Normal Saline|control arm
79663709|NCT02558010|Drug|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
79663710|NCT02550548|Drug|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
79663711|NCT02550548|Drug|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
79988698|NCT04365829|Device|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
79663712|NCT02550548|Drug|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
79663713|NCT02545673|Behavioral|Enhanced linkage to care|
79663714|NCT02545673|Behavioral|Standard-of-care plus|
79663715|NCT02534233|Device|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
79663716|NCT02530502|Other|Laboratory Biomarker Analysis|Correlative studies
79663717|NCT02530502|Biological|Pembrolizumab|Given IV
79502139|NCT04191564|Procedure|normal perfusion state|maintain SAP above 100 mmHg
79663718|NCT02530502|Radiation|Radiation Therapy|Undergo focal RT
79663719|NCT02530502|Drug|Temozolomide|Given PO
79663720|NCT02494700|Radiation|External Beam Radiation Therapy|Undergo orbital EBRT
79663721|NCT02494700|Drug|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
79663722|NCT02460783|Other|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
79663723|NCT02460783|Other|Healthy Living Diet|Counseling and educational material on diet portion, consistency
79663724|NCT02437318|Drug|Fulvestrant|
79663725|NCT02437318|Drug|Alpelisib|
79502140|NCT04195620|Other|High self-disclosure|"The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?"
79663726|NCT02437318|Drug|Alpelisib placebo|
79663727|NCT02305238|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
79663728|NCT02234934|Biological|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10^6 cells per kg of body weight transduced ex vivo with 1 x 10^8 IG/mL of lentiviral vector to achieve > 0.3 integrated copies per cell."
79663729|NCT02176148|Drug|fluocinonide 0.05% cream|
79663730|NCT02175004|Drug|Inotersen|Inotersen SC
79663731|NCT02143050|Drug|Dabrafenib|
79663732|NCT02143050|Drug|Trametinib|
79663733|NCT02143050|Drug|Metformin|
79663734|NCT01957956|Other|Laboratory Biomarker Analysis|Correlative studies
79663735|NCT01957956|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
79663736|NCT01957956|Drug|Temozolomide|Given PO
79663737|NCT01863550|Drug|Bortezomib|Given SC or IV
79663738|NCT01863550|Drug|Carfilzomib|Given IV
79663739|NCT01863550|Drug|Dexamethasone|Given PO
79350496|NCT04298658|Diagnostic Test|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
79663740|NCT01863550|Other|Laboratory Biomarker Analysis|Optional correlative studies
79663741|NCT01863550|Drug|Lenalidomide|Given PO
79663742|NCT01863550|Other|Quality-of-Life Assessment|Ancillary studies
79502141|NCT04195620|Other|Low self-disclosure|"The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?"
79502142|NCT04191018|Diagnostic Test|Liver elastography|Liver stiffness measurement
79502143|NCT04191018|Diagnostic Test|Splenic elastography|Splenic stiffness measurement
79502144|NCT04191018|Diagnostic Test|Gastrointestinal endoscopy|Gastrointestinal endoscopy
79502145|NCT03023982|Drug|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
79502146|NCT03023982|Device|Ultrasound|All blocks will be done under ultrasound
79502147|NCT03023982|Procedure|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
79502148|NCT03023982|Drug|Opioids|standard pain control with opioids
79502149|NCT03023982|Drug|NSAID|standard pain control with NSAIDs
79502150|NCT04191252|Diagnostic Test|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
79502151|NCT03951870|Behavioral|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
79502152|NCT03951870|Biological|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
79663743|NCT01686334|Biological|DC vaccine|Autologous WT1 mRNA-electroporated DCs
79350497|NCT04298658|Other|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
79663744|NCT01620203|Other|No intervention/treatment is given|
79350498|NCT04298658|Diagnostic Test|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
79350499|NCT04298658|Diagnostic Test|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
79350500|NCT04280081|Drug|Selpercatinib|Administered orally
79502153|NCT04026360|Other|no intervention|
79502154|NCT04192110|Drug|Diuretic initiation or augmentation|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
79502155|NCT04025736|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
79502156|NCT04025736|Drug|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
79502157|NCT04766112|Other|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
79663745|NCT01465490|Behavioral|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
79663746|NCT01334983|Behavioral|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
79663747|NCT00866957|Procedure|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
79663748|NCT00105378|Behavioral|Dutch EASYcare Study Geriatric Intermediate Care Programme|
79663749|NCT00091637|Drug|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
79663750|NCT00091637|Drug|Placebo infusion|bolus infusion over a 10 minute period once
79663751|NCT00288743|Drug|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
79663752|NCT00321633|Drug|carboplatin|
79816878|NCT02968537|Behavioral|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
79663753|NCT00321633|Drug|docetaxel|
79816879|NCT02968537|Behavioral|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
79988699|NCT04692688|Drug|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
79663754|NCT02960633|Device|Corail with collar.|
79988700|NCT04692688|Drug|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
79350501|NCT04213014|Behavioral|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents [Zoom option if needed]; 2nd and 3rd meetings delivered virtually for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior week.
79350502|NCT04210583|Device|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
79663755|NCT02960633|Device|Corail without collar.|
79663756|NCT00288782|Drug|Mirtazapine|
79988701|NCT05681221|Other|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
79988702|NCT05681221|Other|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
79988703|NCT04303507|Drug|Chloroquine or Hydroxychloroquine|A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
79988704|NCT04303507|Drug|Placebo|Placebo
79502158|NCT04766112|Other|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
79502159|NCT04190940|Behavioral|Behavioral Assessment|"Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment."
79502160|NCT04195230|Behavioral|Multi-tasking Training|Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
79502161|NCT04199598|Drug|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
79502162|NCT04199598|Drug|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
79502163|NCT04199598|Drug|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
79502164|NCT04199598|Drug|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
79663757|NCT01059825|Drug|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
79663758|NCT01059825|Drug|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
79663759|NCT01059825|Drug|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
79663760|NCT01059825|Drug|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
79663761|NCT01059825|Drug|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
79663762|NCT01059825|Drug|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
79663763|NCT01059825|Drug|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
79988705|NCT04296643|Device|Medical Mask|Medical Mask (known also as Surgical Mask)
79988706|NCT04296643|Device|N95 respirator|N95 respirator
79988707|NCT03202537|Drug|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
79663764|NCT00288899|Other|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
79663765|NCT00288899|Other|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
79663766|NCT00321750|Drug|1% pimecrolimus cream|
79663767|NCT00321867|Procedure|Graft augmented posterior repair|Posterior repair with graft
79502165|NCT04190784|Other|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
79663768|NCT00321867|Procedure|Control|Native tissue repair
79663769|NCT00288977|Procedure|Islet Infusion|
79816880|NCT02968537|Behavioral|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
79816881|NCT05045391|Diagnostic Test|Aspergillus IgG detection|Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
79350503|NCT04200690|Other|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
79502166|NCT04190784|Other|Placebo stretching|The therapist maintains the same manual contact without stretching force.
79502167|NCT03023748|Drug|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
79350504|NCT04200690|Other|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
79502168|NCT04190316|Other|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
79502169|NCT04190160|Drug|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
79663770|NCT00321945|Procedure|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
79663771|NCT00323076|Drug|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
79663772|NCT00323154|Drug|Nalbuphine|
79663773|NCT00289055|Device|stent|Cordis SMART™ Nitinol Stent
79663774|NCT00289055|Device|angioplasty|balloon angioplasty
79663775|NCT00323232|Device|2 Versus 4 Hole DHS|See Detailed Description.
79663776|NCT00289172|Biological|Live attenuated human rotavirus vaccine|
79663777|NCT00323349|Procedure|Oral Glucose Tolerance Testing|
79663778|NCT00323349|Behavioral|Education tailored to learning style preferences|
79663779|NCT00289250|Drug|Sulfadoxine-pyrimethamine|
79663780|NCT00289250|Drug|Sulfadoxine-pyrimethamine plus artesunate|
79663781|NCT00289367|Drug|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
79663782|NCT00289367|Drug|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
79663783|NCT00323505|Drug|Pegylated Interferon|
79816882|NCT01031329|Procedure|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
79502170|NCT04190004|Drug|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
79663784|NCT00323505|Drug|Interferon-alpha2a|
79663785|NCT00289406|Drug|S-amlodipine gentisate|
79816883|NCT05034939|Device|FLEX Vessel Prep System|"The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions."
79988708|NCT02944513|Device|Quell|
79350505|NCT04193904|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
79502171|NCT04190004|Drug|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
79502172|NCT03961620|Device|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
79502173|NCT04406298|Procedure|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
79502174|NCT04406298|Procedure|Large Volume Paracentesis|Large Volume Paracentesis > 5litres
79502175|NCT04025892|Behavioral|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
79502176|NCT04406376|Drug|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
79502177|NCT04025268|Behavioral|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
79663786|NCT00289406|Drug|Amlodipine besylate|
79663787|NCT00323544|Drug|zidovudine and lamivudine (Combivir®)|
79663788|NCT00323544|Drug|emtricitabine and tenofovir DF|
79350506|NCT04193904|Radiation|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
79350507|NCT04159805|Drug|TAK-079|TAK-079 subcutaneous injection
79350508|NCT04159805|Drug|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
79663789|NCT00289445|Drug|Mitomycin C|
79350509|NCT04139902|Drug|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
79663790|NCT00289445|Drug|5-FU|
79663791|NCT00289445|Drug|Folinic acid|
79663792|NCT00323583|Drug|paclitaxel|
79663793|NCT00323583|Drug|oxaliplatin|
79663794|NCT00323583|Drug|leucovorin|
79663795|NCT00323583|Drug|5-fluorouracil|
79663796|NCT00323583|Drug|glutathione|
79663797|NCT00323583|Drug|calcium and magnesium|
79663798|NCT00323583|Procedure|Chemotherapy|
79663799|NCT00323583|Procedure|Chemoprotection|
79663800|NCT00323583|Procedure|Complementary and alternative therapy|
79663801|NCT00289484|Drug|Omega-3 Polyunsaturated Fatty Acids|
79988709|NCT03638557|Other|Nutritious Lunch|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
79663802|NCT00323661|Device|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
79663803|NCT00323661|Device|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
79816884|NCT05034939|Device|Angioplasty|The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
79988710|NCT04289935|Procedure|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
79816885|NCT05030649|Device|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
79816886|NCT05030649|Device|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
79988711|NCT04235413|Behavioral|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
79988712|NCT04762537|Other|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
79988713|NCT04762537|Other|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
79988714|NCT04755673|Other|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
79988715|NCT03620851|Other|effect of age|effect of age on the efficiency of enhanced recovery program
79350510|NCT04139902|Drug|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
79988716|NCT04920643|Procedure|Ultrafiltration|Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
79988717|NCT03631134|Drug|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
79350511|NCT04136509|Procedure|sinus floor elevation|sinus floor elevation with the lateral technique
79502178|NCT04025268|Behavioral|Standard of Care|Standard of prenatal care
79663804|NCT00289562|Drug|forodesine hydrochloride (BCX-1777)|
79663805|NCT00289601|Drug|eptifibatide|
79663806|NCT00323778|Drug|Hyalgan|
79988718|NCT01381380|Procedure|Manual therapy|Manual therapy, once a week for 8 weeks
79663807|NCT00289679|Device|Hip prosthesis revision|
79663808|NCT00323817|Drug|Z-338|
79663809|NCT00289796|Biological|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
79663810|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
79663811|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
79663812|NCT00323895|Device|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
79663813|NCT00289835|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
79663814|NCT00303225|Drug|Vaccine: SIGA-246|
79663815|NCT00323934|Drug|MGCD0103|Oral dosage 2 times weekly.
79663816|NCT00290030|Drug|Alfuzosin|
79663817|NCT00303264|Drug|dexloxiglumide|
79663818|NCT00303264|Drug|Nexium (esomeprazole)|
79663819|NCT00290069|Drug|Tacrolimus|
79663820|NCT00290069|Drug|Rapamycin|
79663821|NCT04718259|Drug|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
79663822|NCT04718259|Drug|midazolam|midazolam
79663823|NCT00290108|Drug|Propofol|
79663824|NCT00323973|Drug|Bisoprolol|10 mg qd
79663825|NCT00290225|Behavioral|Breath Water Sound Course and Traumatic Incident Reduction|
79502179|NCT04025346|Other|Capsimax|1 capsule to be taken before breakfast.
79502180|NCT04025346|Other|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
79502181|NCT04025034|Procedure|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
79663826|NCT00324012|Drug|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
79663827|NCT00290264|Drug|Budesonide/formoterol|
79663828|NCT00303342|Behavioral|mind body treatment|regulation of attention, respiration and posture
79988719|NCT04909645|Diagnostic Test|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)*80/CO.
79663829|NCT00303342|Behavioral|desensitization|mentation on insomnia behaviors and cognitive activity
79988720|NCT04011618|Drug|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
79988721|NCT04011618|Drug|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
79663830|NCT00290303|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
79988722|NCT04163809|Device|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
79988723|NCT04153279|Biological|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
79988724|NCT04725318|Other|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
79350512|NCT04136509|Procedure|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
79350513|NCT04136509|Device|dental implant placement|During reentry after bone biopsy dental implants were placed.
79350514|NCT04136509|Diagnostic Test|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
79663831|NCT00324051|Drug|olanzapine therapy|
79350515|NCT04136366|Drug|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
79350516|NCT04136366|Other|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
79663832|NCT00303381|Drug|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
79350517|NCT04103450|Drug|Vibegron|oral administration
79663833|NCT00303381|Drug|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
79663834|NCT00303381|Drug|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
79663835|NCT00290420|Drug|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
79350518|NCT04098835|Behavioral|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
79350519|NCT04049591|Drug|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
79816887|NCT04082715|Drug|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
79988725|NCT04138615|Drug|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
79988726|NCT04138615|Other|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
79988727|NCT01383330|Drug|megace|800mg
79502182|NCT04025112|Device|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
79988728|NCT01383330|Drug|DW-ES(A)|625mg
79502183|NCT04025112|Other|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
79502184|NCT04024722|Procedure|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
79988729|NCT01383330|Drug|DW-ES(B)|625mg
79502185|NCT04024800|Biological|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in > 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1)."
79350520|NCT04049591|Drug|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
79502186|NCT04024800|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
79502187|NCT04195854|Device|P4HB product|Retrospective use of P4HB in various anatomies
79502188|NCT04199520|Combination Product|surgery combined with systemic therapy|surgery combined with systemic therapy
79502189|NCT04199520|Other|systemic therapy|systemic therapy
79502190|NCT04406610|Biological|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
79663836|NCT00324090|Behavioral|High and low glycemic index|
79663837|NCT00303420|Drug|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
79663838|NCT00303420|Drug|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
79988730|NCT03018938|Drug|Insulin Analog Mid Mixture|Administered SC
79988731|NCT03018938|Drug|Basal Insulin Analog|Administered SC
79350521|NCT04024293|Device|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
79350522|NCT03993171|Drug|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
79350523|NCT03910907|Drug|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
79988732|NCT03631368|Drug|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
79502191|NCT04024176|Other|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
79502192|NCT04024332|Drug|ACT-541468|ACT-541468 25 mg; administered orally
79502193|NCT04023864|Dietary Supplement|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
79502194|NCT04023864|Dietary Supplement|Placebo|Placebo for 12 week
79502195|NCT03022890|Behavioral|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
79502196|NCT03022890|Behavioral|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
79502197|NCT04021056|Other|No intervention|
79502198|NCT04023786|Procedure|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
79502199|NCT04023630|Drug|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
79502200|NCT04023630|Drug|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
79502201|NCT04023630|Drug|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
79988733|NCT02943577|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
79988734|NCT02943577|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
79988735|NCT03174535|Drug|Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.|The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
79988736|NCT04776499|Drug|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
79988737|NCT03668054|Drug|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
79502202|NCT04199754|Drug|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
79502203|NCT04199754|Radiation|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
79502204|NCT04199754|Radiation|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
79502205|NCT04199754|Drug|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
79502206|NCT04023474|Procedure|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
79502207|NCT04023006|Device|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
79502208|NCT04022928|Other|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
79502209|NCT04147104|Device|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
79663839|NCT00324129|Drug|MGCD0103|MGCD0103 given orally three times per week.
79663840|NCT00290576|Dietary Supplement|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
79663841|NCT00303537|Drug|metformin|
79663842|NCT00290849|Drug|Bivalirudin|
79663843|NCT00290927|Drug|insulin glulisine|
79663844|NCT00303576|Drug|dapivirine (TMC120) vaginal gel|
79663845|NCT00290966|Drug|XRP6976|
79663846|NCT00324285|Drug|Amylase resistant starch added ORS|
79663847|NCT00291005|Drug|ARD6562, Docetaxel|
79663848|NCT00303615|Drug|Fluoxymesterone 10 mg|
79350524|NCT03909139|Biological|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
79350525|NCT03901456|Behavioral|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
79816888|NCT04082715|Drug|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
79350526|NCT03901456|Behavioral|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
79350527|NCT03866148|Device|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
79350528|NCT03811847|Drug|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
79350529|NCT03811847|Other|Placebo|Placebo comparator MPH Matched Placebo Tablet
79350530|NCT03795454|Behavioral|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
79350531|NCT03743844|Behavioral|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
79350532|NCT03732794|Device|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
79350533|NCT03725410|Device|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
79663849|NCT00303615|Drug|Anastrozole 1 mg|
79502210|NCT04147104|Device|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
79663850|NCT00291044|Other|testing for HSV 1 and 2 IgG type specific antibosy|
79663851|NCT00324324|Drug|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
79663852|NCT00324324|Drug|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
79663853|NCT00303654|Procedure|biopsy|
79663854|NCT00303654|Procedure|therapeutic conventional surgery|
79663855|NCT00291122|Drug|celecoxib 400 mg BID|
79663856|NCT00324363|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
79663857|NCT00324363|Drug|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
79663858|NCT00303732|Drug|RAD001 (everolimus)|
79816889|NCT04082715|Drug|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
79350534|NCT03725410|Device|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
79816890|NCT00443209|Drug|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
79816891|NCT00443209|Drug|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
79816892|NCT00443209|Drug|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
79350535|NCT03709472|Behavioral|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
79502211|NCT04147182|Drug|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
79816893|NCT00443209|Drug|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
79816894|NCT00443209|Drug|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
79816895|NCT00443209|Drug|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
79663859|NCT00303732|Drug|PTK787 (vatalanib)|
79663860|NCT00291239|Behavioral|partial sleep deprivation|
79663861|NCT00291356|Drug|GSK189075 oral tablets|
79663862|NCT00291356|Drug|GW869682 oral tablets|
79663863|NCT00291395|Drug|PGI2|
79663864|NCT00303771|Drug|fluorouracil|
79663865|NCT00303771|Drug|irinotecan hydrochloride|
79663866|NCT00303771|Drug|leucovorin calcium|
79663867|NCT00291473|Drug|CHP-HER2, CHP-NY-ESO-1|
79663868|NCT00324441|Device|Iratherm® 1000|
79816896|NCT02588235|Drug|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
79816897|NCT02588235|Drug|Atorvastatin|atorvastatin (20 mg/day）
79816898|NCT01020955|Drug|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
79816899|NCT01020955|Drug|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
79350536|NCT03709472|Behavioral|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
79350537|NCT03675477|Drug|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
79350538|NCT03675477|Drug|Placebo|Placebo Oral Tablet
79502212|NCT04146792|Behavioral|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
79502213|NCT04146792|Behavioral|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
79502214|NCT04146948|Other|no intervention|no intervention in this study
79663869|NCT00291512|Behavioral|Theory-based counseling program|
79663870|NCT00303810|Drug|carboplatin|
79663871|NCT00303810|Drug|cisplatin|
79663872|NCT00303810|Drug|cyclophosphamide|
79663873|NCT00303810|Drug|etoposide phosphate|
79663874|NCT00303810|Drug|high-dose chemotherapy|
79663875|NCT00303810|Drug|lomustine|
79663876|NCT00303810|Drug|methotrexate|
79663877|NCT00303810|Drug|thiotepa|
79663878|NCT00303810|Drug|vincristine sulfate|
79663879|NCT00303810|Radiation|radiation therapy|
79663880|NCT00291590|Behavioral|DHEP|
79663881|NCT00324480|Drug|alvocidib|Given IV
79663882|NCT00324480|Drug|vorinostat|Given orally
79663883|NCT00324480|Other|pharmacological study|Correlative studies
79663884|NCT00291629|Drug|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
79663885|NCT00291629|Procedure|collection of mobilized peripheral blood stem cells|
79663886|NCT00291629|Procedure|Intracoronary infusion of mobilized cells|
79502215|NCT04022304|Biological|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
79816900|NCT01028209|Drug|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]PBR06, followed by PET imaging.
79350539|NCT03674736|Dietary Supplement|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
79350540|NCT03647358|Device|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
79350541|NCT03647358|Drug|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose.
79350542|NCT03596606|Procedure|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~Soft tissue techniques.~Articulatory techniques applied at cervical level~Osteopathic manipulation techniques applied at the affected jaw/s.~Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
79502216|NCT04022304|Biological|Humulin® N|Humulin® N (human insulin [recombinant deoxyribonucleic acid origin] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
79502217|NCT04022382|Device|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
79663887|NCT00303888|Drug|docetaxel|Given IV
79502218|NCT04021446|Other|Exercise|personalized exercise prescription
79988738|NCT03667742|Diagnostic Test|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
79350543|NCT03596606|Procedure|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
79350544|NCT03590054|Drug|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
79502219|NCT04022460|Diagnostic Test|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
79502220|NCT04022460|Diagnostic Test|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
79502221|NCT04022460|Other|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
79663888|NCT00303888|Drug|idronoxil|Given orally
79663889|NCT00303888|Other|placebo|Given orally
79663890|NCT00291707|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
79663891|NCT00291707|Drug|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if >6000 cGy to be delivered)
79663892|NCT00291707|Procedure|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
79663893|NCT00324519|Device|Foley bulb|
79663894|NCT00324519|Drug|misoprostol|
79663895|NCT00291746|Drug|Esomeprazole|
79663896|NCT00291746|Procedure|Bravo technique|
79663897|NCT00303927|Drug|capecitabine|
79663898|NCT00419484|Drug|pioglitazone|
79663899|NCT00291785|Drug|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 & 29 of each 42-day cycle
79663900|NCT00291785|Drug|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
79816901|NCT05015985|Other|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
79816902|NCT05015985|Other|control group|music relaxation using a music playlist supply (control group)
79350545|NCT03590054|Biological|Pembrolizumab|Given IV on day 1 of every 21 day cycle
79663901|NCT00291785|Drug|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
79502222|NCT03930654|Behavioral|iPrEP|"iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
79502223|NCT03930654|Behavioral|Usual Care|"Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
79816903|NCT04082793|Combination Product|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
79816904|NCT04082793|Combination Product|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
79816905|NCT00439231|Drug|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
79350546|NCT03581123|Behavioral|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
79350547|NCT03581123|Other|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
79350548|NCT03581123|Combination Product|SMT + SSM|Combination Treatment
79663902|NCT00304005|Drug|laromustine|
79663903|NCT00291824|Behavioral|Cardiovascular risk factors and willingness to change|
79816906|NCT01021189|Drug|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
79350549|NCT03581123|Drug|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
79663904|NCT00324558|Drug|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
79663905|NCT00291863|Drug|Simvastatin|
79663906|NCT00304200|Drug|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
79663907|NCT00291902|Drug|SB-681323|
79663908|NCT00291941|Biological|Henogen HBV vaccine|20µg, Month 0, 2 and 6
79663909|NCT00291941|Biological|FENDRIX|20 µg,Months 0, 1, 2 and 6
79663910|NCT00291980|Biological|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
79663911|NCT00291980|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
79663912|NCT00324597|Drug|gemcitabine hydrochloride|
79663913|NCT00324597|Drug|motesanib diphosphate|
79663914|NCT00324597|Other|pharmacological study|
79816907|NCT01021189|Drug|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
79816908|NCT04993755|Drug|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
79663915|NCT00292019|Procedure|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
79816909|NCT04993755|Drug|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
79663916|NCT00324714|Drug|risedronate sodium|
79663917|NCT00324714|Other|diagnostic laboratory biomarker analysis|
79663918|NCT00292058|Device|Videoconference equipment (telepsychiatry)|
79663919|NCT00304317|Drug|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
79663920|NCT00304317|Other|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
79816910|NCT01031485|Dietary Supplement|Milk peptides and plant sterols|
79988739|NCT03623048|Other|chlorhexidine|antibacterial and anti-inflammatory mouthwash
79350550|NCT03568097|Drug|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
79350551|NCT03546582|Drug|Pembrolizumab|Anti-PD-1 targeted immunotherapy
79350552|NCT03546582|Radiation|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
79350553|NCT03536585|Device|Vulvovaginal treatment|"Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
79663921|NCT00292097|Procedure|Early tracheostomy|early conversion - less than or equal to 72 hours
79663922|NCT00292097|Procedure|Late tracheostomy|Late conversion (10-14 days)
79663923|NCT00324792|Drug|intensive insulin therapy|
79663924|NCT00292175|Procedure|Narrow Band Imaging|
79663925|NCT00292175|Procedure|colonoscopy|
79663926|NCT00292214|Drug|Paracetamol (acetaminophen)|
79663927|NCT00324831|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
79663928|NCT00324831|Drug|cyclophosphamide|
79663929|NCT00324831|Drug|doxorubicin hydrochloride|
79663930|NCT00324831|Drug|prednisone|
79663931|NCT00324831|Drug|rituximab|
79663932|NCT00324831|Drug|sargramostim|
79663933|NCT00324831|Drug|vincristine|
79663934|NCT00324831|Procedure|Intervention/procedure|
79663935|NCT00324831|Procedure|antibody therapy|
79663936|NCT00324831|Procedure|biological therapy|
79663937|NCT00324831|Procedure|chemotherapy|
79663938|NCT00324831|Procedure|colony-stimulating factor therapy|
79663939|NCT00324831|Procedure|cytokine therapy|
79663940|NCT00324831|Procedure|monoclonal antibody therapy|
79663941|NCT00324831|Procedure|non-specific immune-modulator therapy|
79816911|NCT01031485|Other|Placebo|
79816912|NCT00437983|Dietary Supplement|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
79816913|NCT00437983|Dietary Supplement|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
79816914|NCT00783692|Drug|vedolizumab|Vedolizumab for intravenous infusion
79988740|NCT03623048|Other|saline|anti-inflammatory cleansing mouthwash
79988741|NCT03623048|Other|Propolis extract|antibacterial mouthwash
79988742|NCT03623048|Other|pomegranate extract|antibacterial mouthwash
79663942|NCT00324831|Procedure|therapeutic procedure|
79816915|NCT00783692|Other|Placebo|Placebo intravenous infusion
79816916|NCT04992273|Drug|casirivimab+imdevimab|Single dose administered based on weight
79502224|NCT04020900|Other|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
79663943|NCT00324831|Procedure|tumor cell derivative vaccine|
79663944|NCT00324831|Procedure|vaccine therapy|
79663945|NCT00292253|Device|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
79663946|NCT00292253|Device|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
79663947|NCT00292331|Procedure|cyanoacrylate injection to treat gastric variceal hemorrhage|
79663948|NCT00304434|Drug|Oseltamivir|
79816917|NCT02588157|Device|Macintosh|Direct laryngoscopy
79816918|NCT02588157|Device|Glidescope|Glidescope videolaryngoscope
79502225|NCT04020666|Drug|Urinary Kallidinogenase|
79502226|NCT04405986|Procedure|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
79502227|NCT04405986|Procedure|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
79502228|NCT04021992|Drug|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
79502229|NCT04022070|Other|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
79663949|NCT00304434|Drug|Probenecid|
79663950|NCT00292409|Drug|Aripiprazole|
79816919|NCT02588157|Device|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
79816920|NCT01031173|Biological|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
79988743|NCT01312597|Other|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
79663951|NCT00324909|Drug|Hyperbaric Oxygen Therapy|
79663952|NCT00304473|Drug|Quetiapine fumarate|
79663953|NCT00292448|Drug|Ba 679 BR Respimat|
79663954|NCT00292448|Drug|Tiotropium (Spiriva) inhalation capsule 18 ug|
79663955|NCT00324948|Drug|Topical alprostadil (PGE-1)|
79663956|NCT00304551|Drug|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
79663957|NCT00304551|Drug|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
79663958|NCT00304551|Drug|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
79663959|NCT00325026|Drug|Misoprostol|
79663960|NCT00325026|Device|Foley bulb|
79816921|NCT04082871|Other|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.[19] This system was explained in detail and applied successfully in many previous studies.[10, 14, 20] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
79816922|NCT04959903|Biological|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at [Day 4-Day 10] after T cell depleted allogeneic HSCT
79350554|NCT03536585|Device|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
79502230|NCT03593148|Other|Lifestyle|Lifestyle treatment
79663961|NCT00304590|Drug|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
79663962|NCT00292487|Drug|Iopamidol 370 mgI/mL|
79663963|NCT00325104|Procedure|Parathyroid hormone testing|
79663964|NCT00325104|Procedure|Serum calcium testing|
79663965|NCT00292526|Drug|Enalapril|enalapril orally administered
79663966|NCT00418509|Drug|Mometasone furoate|
79663967|NCT00418509|Drug|Formoterol fumarate|
79663968|NCT00292721|Drug|Celecoxib|celecoxib: loading and maintenance for 6 months
79663969|NCT00292760|Drug|Alemtuzumab|
79663970|NCT00292760|Drug|Methyprednisolone|
79663971|NCT00325182|Drug|Levetiracetam|
79663972|NCT00325182|Other|Historical controls|
79663973|NCT00292799|Drug|Orlistat Vs Metformin|
79663974|NCT00304629|Drug|galantamine|
79663975|NCT00292838|Drug|fluticasone 25, 50, 100, 200 mcg|
79663976|NCT00304668|Drug|dapivirine (TMC120) vaginal gel|
79663977|NCT04718324|Other|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
79816923|NCT00783224|Drug|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
79988744|NCT03016598|Drug|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
79663978|NCT04718324|Other|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
79816924|NCT00783224|Drug|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
79816925|NCT00783224|Drug|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
79816926|NCT00783224|Drug|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
79988745|NCT03016598|Drug|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
79663979|NCT00292877|Drug|SB-240563 (Mepolizumab)|
79663980|NCT00292916|Behavioral|whole body vibration|
79663981|NCT00292916|Behavioral|resistance exercise|
79663982|NCT00292916|Behavioral|"wellness"|
79663983|NCT00325221|Device|HM on|Home Monitoring activated after implantation
79663984|NCT00325221|Device|HM Off|Home Monitoring activated 9 months after implantation
79663985|NCT00292955|Drug|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
79663986|NCT00325260|Biological|Influvac; subunit influenza vaccine|
79663987|NCT00292994|Behavioral|Exercise|
79663988|NCT00292994|Behavioral|Weight Loss|
79663989|NCT00293072|Drug|Rituximab|
79663990|NCT00293111|Drug|SDX-101 (R-Etodolac)|
79816927|NCT04102124|Drug|SHR3680|Tablet. Specifications of 80mg
79816928|NCT04102124|Drug|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
79816929|NCT04102124|Drug|SHR3680(Placebo)|Tablet. Specifications of 80mg
79816930|NCT04102124|Drug|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
79816931|NCT04015479|Dietary Supplement|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
79816932|NCT04015479|Behavioral|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
79816933|NCT04082559|Other|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
79816934|NCT04082559|Other|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
79816935|NCT04082559|Other|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
79350555|NCT03511352|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
79816936|NCT04082559|Other|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
79816937|NCT04082559|Other|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
79816938|NCT04082559|Other|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
79502231|NCT03022734|Drug|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
79502232|NCT03022734|Radiation|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
79663991|NCT00304785|Drug|latanoprost 0.005%|
79663992|NCT00304785|Drug|Fotil|
79816939|NCT04082559|Other|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
79816940|NCT04082325|Drug|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
79816941|NCT04082325|Drug|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
79816942|NCT04082325|Drug|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
79816943|NCT04082325|Drug|Placebo|Placebo to Lu AF88434 oral solution, single dose
79816944|NCT00782834|Drug|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
79350556|NCT03511352|Behavioral|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
79350557|NCT03382860|Diagnostic Test|Fundus videos|Recordings of fundus videos
79350558|NCT03381326|Procedure|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
79663993|NCT00304785|Drug|placebo|
79663994|NCT00293150|Drug|Eplerenone|
79663995|NCT00325299|Drug|Magnesium|
79663996|NCT02960334|Device|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
79663997|NCT00293228|Drug|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
79663998|NCT00293228|Drug|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
79663999|NCT00325338|Biological|Ragweed MATAMPL|
79664000|NCT00293345|Drug|gemcitabine hydrochloride|
79664001|NCT00293345|Drug|triapine|
79664002|NCT00293501|Drug|tinzaparin sodium|
79664003|NCT00325377|Procedure|MME Procedure|
79816945|NCT02587845|Drug|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
79350559|NCT03354377|Behavioral|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
79664004|NCT00293618|Device|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
79664005|NCT00293618|Other|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
79664006|NCT00293618|Other|Feedback|Feedback about the physician's personal performance on prevention of PONV
79816946|NCT02587845|Drug|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
79816947|NCT04103528|Other|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
79816948|NCT04103528|Other|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
79816949|NCT05683431|Behavioral|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short & rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
79816950|NCT04103840|Other|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
79816951|NCT02601404|Device|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
79988746|NCT03667664|Behavioral|Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy|"Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people."
79988747|NCT04052737|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
79350560|NCT03354377|Behavioral|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
79988748|NCT04052737|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
79350561|NCT03354377|Behavioral|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
79350562|NCT03338374|Device|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
79350563|NCT03251495|Drug|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
79664007|NCT00325455|Drug|MK0859|
79664008|NCT00293657|Drug|Lornoxicam 8 mg|
79664009|NCT00293657|Drug|Lornoxicam 16 mg|
79664010|NCT00293657|Drug|Placebo|
79350564|NCT03239132|Behavioral|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
79664011|NCT00325494|Drug|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
79664012|NCT00293696|Drug|bicalutamide (Casodex), goserelin (Zoladex)|
79664013|NCT00304863|Drug|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
79664014|NCT00293735|Drug|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
79664015|NCT00293735|Drug|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
79664016|NCT00293852|Procedure|Outpatient clinic follow-up|
79664017|NCT00304980|Drug|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
79664018|NCT00293891|Drug|Tacrolimus Cream|
79816952|NCT04099394|Behavioral|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
79816953|NCT04099394|Behavioral|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
79816954|NCT00584805|Biological|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is < 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
79816955|NCT00765674|Drug|Aliskiren|150 and 300 mg tablets
79816956|NCT00765674|Drug|Amlodipine|5 and 10 mg capsules
79816957|NCT00765674|Drug|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
79350565|NCT03239132|Behavioral|Meditation educational materials|Meditation educational materials
79664019|NCT00325533|Behavioral|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
79816958|NCT00765674|Drug|Placebo|tablet
79350566|NCT03234478|Other|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
79816959|NCT00765674|Drug|Placebo|capsules
79350567|NCT03226249|Procedure|Computed Tomography|Undergo FDG-PET/CT
79502233|NCT04406532|Behavioral|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
79664020|NCT00325533|Other|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
79664021|NCT00293930|Drug|Tacrolimus|
79350568|NCT03226249|Drug|Dacarbazine|Given IV
79664022|NCT00305019|Drug|clevudine|
79664023|NCT00293969|Drug|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
79816960|NCT00765362|Device|Encore Mobile-Bearing Knee|Used for primary total knee replacement
79988749|NCT03017846|Drug|Cantharidin|Application of topical cantharidin
79988750|NCT04691869|Device|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
79988751|NCT04613791|Biological|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
79350569|NCT03226249|Drug|Doxorubicin Hydrochloride|Given IV
79350570|NCT03226249|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
79350571|NCT03226249|Other|Laboratory Biomarker Analysis|Correlative studies
79350572|NCT03226249|Biological|Pembrolizumab|Given IV
79350573|NCT03226249|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
79350574|NCT03226249|Drug|Vinblastine Sulfate|Given IV
79350575|NCT03184155|Drug|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
79350576|NCT03184155|Drug|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
79350577|NCT03172624|Drug|Nivolumab|nivolumab 3 mg/kg every 2 weeks
79664024|NCT00325611|Behavioral|Multidisciplinary palliative care team met with patient|
79664025|NCT00294008|Drug|Risperdal Consta|flexible dosage for 24 months
79664026|NCT00305097|Dietary Supplement|Decaffeinated coffee|5 cups per day for 8 weeks
79664027|NCT00305097|Dietary Supplement|Caffeinated coffee|5 cups per day for 8 weeks
79664028|NCT00305097|Dietary Supplement|No coffee|
79664029|NCT00294086|Drug|valsartan 160 mg|
79664030|NCT00294086|Drug|valsartan 160 mg BID|
79664031|NCT00325689|Drug|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
79816961|NCT04231929|Device|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved."
79816962|NCT00586898|Drug|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
79816963|NCT00586898|Drug|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
79816964|NCT00586898|Drug|Bicalutamide|A pure nonsteroidal antiandrogen
79816965|NCT00586898|Drug|Testosterone transdermal gel|an androgenic anabolic steroid
79816966|NCT00586898|Drug|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
79816967|NCT02587455|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
79664032|NCT00325689|Drug|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
79988752|NCT03667118|Dietary Supplement|Food Supplement|A powder blend of 16 common allergenic proteins ([oat, milk, egg, sesame, wheat] [almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut] [cod, shrimp, salmon]) combined with 400 IU of Vitamin D3
79664033|NCT00294125|Drug|Flavocoxid|Daily flavocoxid for 12 weeks
79664034|NCT00294125|Drug|Placebo|Daily placebo for 12 weeks
79664035|NCT00294164|Drug|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
79816968|NCT02587455|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
79350578|NCT03172624|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
79664036|NCT00294164|Drug|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
79816969|NCT04099238|Drug|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
79816970|NCT04099082|Other|samples|blood sample nasal swab
79816971|NCT00919659|Dietary Supplement|parenteral nutrition|25kcal/kg bw with parenteral nutrition
79816972|NCT04099316|Device|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
79816973|NCT04099316|Device|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
79816974|NCT04098926|Radiation|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
79988753|NCT02857855|Procedure|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
79988754|NCT02857855|Procedure|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
79988755|NCT03666728|Drug|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
79988756|NCT03666728|Drug|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
79988757|NCT03666871|Biological|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
79502234|NCT04406532|Behavioral|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
79502235|NCT04021836|Other|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
79502236|NCT04020588|Drug|Celecoxib 200mg|Will be administered for 6 weeks
79664037|NCT00325728|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
79664038|NCT00325728|Drug|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
79988758|NCT03666871|Biological|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
79988759|NCT03014180|Device|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
79988760|NCT03638401|Procedure|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
79350579|NCT03100331|Other|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
79350580|NCT03063944|Drug|STAT Inhibitor OPB-111077|Given PO
79350581|NCT03063944|Drug|Decitabine|Given IV
79350582|NCT03063944|Drug|Venetoclax|Given PO
79350583|NCT03063944|Other|Laboratory Biomarker Analysis|Correlative studies
79502237|NCT04020588|Drug|Placebo oral capsule|Will be administered for 6 weeks
79664039|NCT00417794|Drug|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
79664040|NCT00417794|Drug|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
79664041|NCT00417833|Drug|Intravitreal Bevacizumab|
79664042|NCT00305214|Procedure|T Wave Alternans Test|
79664043|NCT00417872|Drug|Nitazoxanide|
79664044|NCT00417872|Drug|Metronidazole|
79816975|NCT04098926|Radiation|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
79988761|NCT04747873|Behavioral|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
79664045|NCT00294203|Drug|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
79816976|NCT04101812|Drug|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
79988762|NCT04747873|Behavioral|Stepped Care|Stepped care procedure (see arm/group descriptions).
79664046|NCT00294203|Other|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
79664047|NCT00305292|Drug|Modafinil-Alcohol Interactions|
79350584|NCT03062631|Drug|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
79502238|NCT04020588|Drug|Minocycline 100mg|Will be administered for 6 weeks
79350585|NCT03013309|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
79350586|NCT03013309|Other|Treatment as usual|Treatment as usual
79350587|NCT02971046|Other|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
79502239|NCT04146402|Drug|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
79502240|NCT04146402|Drug|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
79502241|NCT04146168|Diagnostic Test|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
79502242|NCT04146480|Diagnostic Test|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
79664048|NCT00294242|Procedure|membrane sweeping|
79664049|NCT00305331|Drug|Domperidone (drug)|
79816977|NCT04101812|Drug|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
79816978|NCT04923867|Device|Suturable DuraGen™|Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
79988763|NCT03667040|Behavioral|JOOL app|Participants will use the JOOL app for 30 days
79502243|NCT03021798|Other|No Drug and no aspecific intervention|No intervention
79988764|NCT03666650|Drug|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
79988765|NCT03011840|Other|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
79988766|NCT03666572|Other|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
79988767|NCT03666572|Other|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
79502244|NCT03021876|Drug|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
79502245|NCT03021876|Other|usual intake|baseliner
79988768|NCT03666572|Other|Placebo (Lactose)|Placebo (Lactose)
79988769|NCT03667508|Procedure|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
79988770|NCT03667508|Procedure|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
79988771|NCT02942485|Drug|Metronidazole|P/r suppositories
79988772|NCT02942485|Drug|Tinidazole|P/o tablets
79988773|NCT03666494|Drug|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
79988774|NCT03666494|Drug|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
79988775|NCT03666494|Drug|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
79988776|NCT03622970|Device|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
79988777|NCT03622970|Behavioral|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
79988778|NCT03666884|Drug|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
79350588|NCT02901860|Other|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
79502246|NCT03948438|Procedure|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
79988779|NCT03666884|Biological|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
79502247|NCT04020354|Behavioral|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
79988780|NCT04057664|Behavioral|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
79988781|NCT02942407|Drug|apixaban|oral anticoagulant
79988782|NCT02942407|Drug|warfarin|oral anticoagulant
79350589|NCT02849548|Drug|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
79350590|NCT02849548|Other|placebo|Pill with inactive ingredients
79502248|NCT04020354|Behavioral|Usual Care|Usual customary care
79502249|NCT03907410|Other|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
79502250|NCT03907410|Other|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
79664050|NCT00294281|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
79350591|NCT02791685|Behavioral|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
79664051|NCT00325767|Drug|nebulized albuterol (2.5 mg/3ml/dose)|
79664052|NCT00325767|Drug|nebulized levalbuterol (1.25 mg/3ml/dose)|
79664053|NCT00325767|Drug|nebulized placebo (3ml/dose)|
79664054|NCT00294359|Drug|Mitomycin C; Capecitabine; Bevacizumab|
79664055|NCT00294437|Drug|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
79664056|NCT00305370|Drug|Aripiprazole|
79664057|NCT00325806|Drug|Ramipril|
79816979|NCT02587533|Other|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
79664058|NCT00294476|Drug|IVIG|
79350592|NCT02791685|Behavioral|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
79350593|NCT02791685|Behavioral|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
79664059|NCT00294476|Procedure|Biological Therapy|
79350594|NCT02780310|Drug|Lenvatinib|
79350595|NCT02772367|Procedure|skin punch biopsy|
79350596|NCT02763072|Device|Enlighten Laser|
79350597|NCT02763072|Device|Excel V Laser|
79350598|NCT02758431|Drug|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
79350599|NCT02758431|Drug|Placebo Gel|Placebo gel packet applied daily for 28 days.
79664060|NCT00305409|Drug|Synbiotic (Synergy I / B.longum)|
79664061|NCT00294593|Drug|folinic acid|
79350600|NCT02758431|Drug|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
79350601|NCT02758431|Drug|Testosterone Gel|Testosterone Gel applied daily for 28 days
79350602|NCT02758431|Drug|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
79350603|NCT02756000|Procedure|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
79664062|NCT00325845|Procedure|Synvisc viscosupplementation|
79664063|NCT00294710|Drug|Aliskiren|
79664064|NCT00294749|Drug|Ciprofloxacine|
79664065|NCT00325923|Behavioral|Decision aid|
79664066|NCT00294788|Biological|Fluvax|
79664067|NCT00294788|Drug|PCC® (Lactobacillus fermentum VRI 003)|
79664068|NCT00325962|Drug|6R-BH4 (sapropterin dihydrochloride)|
79664069|NCT00294866|Drug|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
79664070|NCT00305487|Drug|Ciclesonide nasal spray|
79664071|NCT00294905|Behavioral|Implementation of a combined smoking cessation strategy|
79664072|NCT00305526|Device|Contak Renewal (CRT-D)|
79664073|NCT00294944|Drug|Idazoxan|
79664074|NCT00326040|Device|Glaucoma Surgery|
79664075|NCT02960477|Other|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
79664076|NCT02960477|Other|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
79664077|NCT00326079|Device|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
79664078|NCT00326157|Drug|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
79664079|NCT00295100|Drug|Tamoxifen|
79664080|NCT00326235|Drug|Buspirone|
79664081|NCT00295178|Drug|Daptomycin|
79664082|NCT00295178|Drug|Vancomycin|
79816980|NCT02587533|Other|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
79816981|NCT02587533|Other|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
79816982|NCT02587533|Other|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
79988783|NCT03666806|Biological|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
79988784|NCT03638089|Behavioral|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
79988785|NCT02921035|Drug|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
79988786|NCT03009344|Drug|Tazemetostat|Tazemetostat tablets.
79502251|NCT04145544|Device|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~Cut the ArtiFascia® to the required shape under aseptic conditions~Apply ArtiFascia® to the damaged area~Suture the ArtiFascia® in place~Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
79816983|NCT04916847|Other|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
79988787|NCT03322423|Device|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
79988788|NCT03322423|Device|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
79350604|NCT02756000|Procedure|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
79502252|NCT04145544|Device|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
79350605|NCT02601365|Drug|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
79350606|NCT02601365|Drug|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
79350607|NCT02601365|Drug|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
79350608|NCT02583893|Drug|Sirolimus|Given PO
79816984|NCT04912245|Behavioral|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
79816985|NCT04870905|Drug|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
79664083|NCT00305799|Procedure|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
79816986|NCT02587689|Biological|anti-MUC1 CAR T Cells|
79816987|NCT04082403|Procedure|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
79816988|NCT04082403|Procedure|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
79816989|NCT04862325|Other|Multimodal Prehabilitation|"High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy"
79664084|NCT00295217|Device|ExAblate 2000|
79664085|NCT00305838|Drug|tamoxifen citrate|
79816990|NCT00919737|Drug|NPC-08|Polifeprosan 20 with Carmustine 3.85%
79816991|NCT03936231|Other|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
79350609|NCT02583893|Drug|Mitoxantrone|Given IV
79350610|NCT02583893|Drug|Etoposide|Given IV
79816992|NCT02587611|Other|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
79816993|NCT02587611|Other|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
79816994|NCT04848051|Behavioral|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
79816995|NCT04848051|Behavioral|CRC Reminder & Short message|Participants randomized to the CRC Reminder & short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
79816996|NCT04848051|Behavioral|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
79988789|NCT03322423|Device|Spherical Contact Lens 2|BioTrue ONEDay Spherical
79350611|NCT02583893|Drug|Cytarabine|Given IV
79350612|NCT02538315|Drug|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by [18F]FDOPA PET/CT imaging
79350613|NCT02411448|Drug|Ramucirumab|Administered IV.
79350614|NCT02411448|Drug|Placebo|Administered IV.
79350615|NCT02411448|Drug|Erlotinib|Administered orally.
79350616|NCT02411448|Drug|Gefitinib|Administered orally.
79350617|NCT02411448|Drug|Osimertinib|Administered orally.
79502253|NCT04146558|Drug|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
79664086|NCT00305838|Other|diagnostic laboratory biomarker analysis|
79664087|NCT00295256|Behavioral|nurse case manager|
79664088|NCT00295295|Device|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
79664089|NCT00295295|Other|Standing|Standing 10 min/day
79664090|NCT00326274|Drug|Helioblock® SX Cream|
79664091|NCT00305916|Procedure|Multislice spiral computed tomography coronary angiography|
79664092|NCT00305916|Procedure|conventional coronary angiography|
79664093|NCT00295334|Drug|alcohol|
79664094|NCT00295373|Drug|Rosuvastatin|
79664095|NCT00295373|Behavioral|Exercise Training|
79664096|NCT00305955|Device|Spectacles|optimal spectacle correction
79664097|NCT00295412|Drug|quetiapine (drug)|
79664098|NCT00295529|Behavioral|Multifaceted educational intervention|Educational materials available at end of study
79664099|NCT00326352|Drug|Sedation with propofol and remifentanil|
79664100|NCT00419601|Drug|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
79664101|NCT00419601|Drug|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
79816997|NCT04848051|Behavioral|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
79988790|NCT03007472|Device|CI532|Cochlear implant
79988791|NCT03007472|Device|Nucleus 7|Sound processor
79502254|NCT04146558|Other|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
79988792|NCT03321721|Procedure|Suture for wound repair|Repair of wound with suture
79988793|NCT03321721|Device|Suture for wound repair|Repair of wound with suture
79502255|NCT03619044|Other|2 FES-PET Imaging will be performed:|"before treatment initiation~before treatment cycle 3 initiation"
79988794|NCT04621981|Drug|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
79502256|NCT04146246|Diagnostic Test|G6PD assay|A test for G6PD deficiency.
79502257|NCT04020120|Other|questionnaires|answer questionnaires
79988795|NCT04621981|Drug|Normal Saline|This group was treated with normal saline.
79502258|NCT04145856|Dietary Supplement|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
79502259|NCT04145856|Combination Product|I31 probiotic combined to Alverine/Simethicone|"I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
79502260|NCT04145856|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
79502261|NCT04146090|Other|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
79502262|NCT04146090|Other|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
79502263|NCT04140786|Drug|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
79502264|NCT04144998|Diagnostic Test|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
79816998|NCT04847661|Drug|Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases|Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
79816999|NCT00919815|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
79817000|NCT00919815|Drug|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
79817001|NCT02587377|Other|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
79988796|NCT03015116|Other|Stretching|Daily foot and ankle stretching protocol
79988797|NCT03015116|Other|Cryotherapy|Daily cryotherapy in conjunction with stretching
79988798|NCT03015116|Device|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
79988799|NCT03015116|Device|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
79988800|NCT03667430|Dietary Supplement|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
79988801|NCT03667430|Dietary Supplement|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
79988802|NCT03667352|Procedure|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
79988803|NCT03667352|Procedure|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
79502265|NCT04147650|Drug|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
79502266|NCT04147650|Drug|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
79502267|NCT04147650|Drug|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
79502268|NCT04147650|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
79664102|NCT00306033|Drug|Intravenous ImmuneGlobulin|
79664103|NCT00306072|Drug|nutritional herbal extract from Salacia oblonga|
79664104|NCT00295607|Drug|Tacrolimus|immunosuppression
79664105|NCT00295607|Drug|steroids, monoclonal anti-IL2R antibody|immunosuppression
79664106|NCT00326391|Drug|methylphenidate hydrochloride extended-release tablets|
79664107|NCT00306111|Drug|pegfilgrastim|Single dose (6mg) one day after chemotherapy
79664108|NCT00295685|Drug|Antacids|
79350618|NCT02368041|Device|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
79350619|NCT02350465|Behavioral|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
79350620|NCT02350465|Behavioral|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
79350621|NCT02321514|Device|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
79350622|NCT02266134|Behavioral|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
79502269|NCT04023942|Behavioral|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
79502270|NCT04022226|Drug|Ketamine|Induction agent that suppresses infra-slow waves
79228340|NCT02234895|Device|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
79502271|NCT04022226|Drug|Methohexital|Induction agent that does not suppress infra-slow waves
79502272|NCT04029012|Drug|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
79502273|NCT04025658|Drug|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
79502274|NCT03605706|Drug|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
79502275|NCT03605706|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
79664109|NCT00306150|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
79664110|NCT00306150|Drug|Placebo|Placebo is used according to the description of Arm 1
79664111|NCT00295724|Drug|Bicifadine|
79664112|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
79988804|NCT03667352|Drug|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
79988805|NCT03666338|Other|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
79988806|NCT03665948|Other|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
79988807|NCT03665948|Other|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
79988808|NCT03667274|Procedure|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
79988809|NCT03665870|Behavioral|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
79350623|NCT02266134|Behavioral|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
79350624|NCT02197845|Behavioral|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
79988810|NCT03006458|Device|comfilcon A|toric contact lens
79350625|NCT02197845|Behavioral|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
79350626|NCT02107144|Drug|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
79350627|NCT01943643|Procedure|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
79502276|NCT03605706|Drug|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
79502277|NCT03924180|Dietary Supplement|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
79502278|NCT05581680|Other|dental impressions|dental impressions
79502279|NCT05581680|Other|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
79502280|NCT05581680|Other|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
79502281|NCT05581680|Other|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
79502282|NCT04023240|Drug|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
79502283|NCT04023240|Procedure|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
79502284|NCT04023240|Procedure|Positron Emission Tomography (PET) scan|PET images will be acquired.
79502285|NCT05586438|Drug|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
79817002|NCT00796991|Drug|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
79988811|NCT03006458|Device|omafilcon B|toric contact lens
79664113|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
79664114|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
79664115|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
79988812|NCT04056104|Diagnostic Test|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
79988813|NCT03320941|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
79988814|NCT03320941|Drug|Placebo|Placebo will be supplied as tablets to be taken daily orally.
79988815|NCT03005288|Drug|BYM338 10 mg/kg|intravenous infusion every four weeks
79988816|NCT03005288|Other|Placebo|intravenous infusion every four weeks
79988817|NCT04055246|Dietary Supplement|Inulin|9 grams of food grade inulin added to custom made fiber bars.
79664116|NCT00295763|Drug|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
79664117|NCT00326430|Behavioral|Cognitive Therapy, Interpersonal Therapy|
79664118|NCT00417911|Drug|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
79664119|NCT00326469|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
79664120|NCT00417950|Drug|Acarbose|
79664121|NCT00306267|Drug|epoetin alfa|
79817003|NCT00796991|Drug|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
79817004|NCT00796991|Drug|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
79817005|NCT00796991|Drug|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
79988818|NCT04055246|Dietary Supplement|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
79988819|NCT03665792|Device|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
79988820|NCT03533816|Drug|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
79988821|NCT03533816|Drug|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
79988822|NCT03666260|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
79988823|NCT03666260|Procedure|femoral block|femoral block with echography
79502286|NCT05581524|Device|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
79502287|NCT04765878|Device|RespirAq Humidification|Humidifier
79502288|NCT04024566|Device|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
79502289|NCT05581446|Diagnostic Test|Visual Analogue Scale|pain type severity determination and quality of life assessment
79502290|NCT03921294|Drug|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
79664122|NCT04718597|Procedure|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
79817006|NCT05682183|Behavioral|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
79817007|NCT05682183|Other|Treatment as usual|Care management from assigned care manager
79817008|NCT04082247|Behavioral|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
79817009|NCT04112225|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
79817010|NCT04787211|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
79817011|NCT04787211|Drug|Placebo|Placebo given by intravenous administration
79817012|NCT04112147|Drug|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
79817013|NCT04112147|Drug|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
79817014|NCT04112147|Drug|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
79502291|NCT04145232|Biological|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
79664123|NCT04718597|Procedure|Open inguinal hernia repair|Classical approach (open repair)
79664124|NCT00326508|Drug|Daclizumab|
79664125|NCT00295802|Device|Integrated Imaging High Intensity Focused Ultrasound|
79664126|NCT00295802|Device|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
79664127|NCT00326586|Drug|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
79664128|NCT00295841|Drug|clofarabine|
79664129|NCT00295841|Drug|cytarabine|
79664130|NCT00326664|Drug|Cediranib Maleate|Given orally
79664131|NCT00295919|Drug|fenretinide lipid matrix|
79664132|NCT00295919|Drug|ketoconazole|
79664133|NCT00295919|Other|laboratory biomarker analysis|
79664134|NCT00295919|Other|pharmacological study|
79664135|NCT04930809|Drug|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
79817015|NCT04081857|Drug|HGP1810|HGP1810: Vildagliptin/Metformin
79817016|NCT04081857|Drug|HCP1704|HCP1704: Vildagliptin/Metformin
79817017|NCT02604953|Diagnostic Test|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
79817018|NCT02604953|Diagnostic Test|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
79988824|NCT03665714|Other|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
79817019|NCT04773171|Other|Computer-assisted Cognitive Remediation|Drill practice and bridging activities
79817020|NCT04773171|Other|Conventional training programmes|Existing conventional activities in the settings
79817021|NCT02605109|Other|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
79817022|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
79817023|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
79817024|NCT04114331|Other|Manual therapy and exercise|Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
79988825|NCT03665714|Other|Enteral Nutrition Emulsion(TPF-T)|TPF-T
79664136|NCT00295958|Biological|LMB-2 immunotoxin|
79988826|NCT03003494|Drug|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
79988827|NCT03559699|Drug|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
79664137|NCT00295958|Biological|MART-1 antigen|
79664138|NCT00295958|Biological|gp100 antigen|
79664139|NCT00295958|Biological|incomplete Freund's adjuvant|
79664140|NCT00295997|Biological|anti-thymocyte globulin|
79664141|NCT00295997|Biological|filgrastim|
79664142|NCT00295997|Biological|graft-versus-tumor induction therapy|
79664143|NCT00295997|Biological|therapeutic allogeneic lymphocytes|
79664144|NCT00295997|Drug|busulfan|
79664145|NCT00295997|Drug|cyclophosphamide|
79664146|NCT00295997|Drug|fludarabine phosphate|
79664147|NCT00295997|Drug|methotrexate|
79664148|NCT00295997|Drug|mycophenolate mofetil|
79664149|NCT00295997|Drug|tacrolimus|
79664150|NCT00295997|Procedure|allogeneic bone marrow transplantation|
79664151|NCT00295997|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79664152|NCT00295997|Procedure|peripheral blood stem cell transplantation|
79988828|NCT04324645|Other|Noona Software|Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
79664153|NCT00296114|Procedure|Serum and DNA Samples|To collect serum and DNA samples from subjects
79817025|NCT02586987|Drug|Selumetinib|Selumetinib oral
79817026|NCT02586987|Drug|MEDI4736|MEDI4736 IV
79988829|NCT02449681|Drug|TH-4000 (Tarloxotinib)|
79502292|NCT04144764|Other|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
79664154|NCT00296153|Drug|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
79664155|NCT00326703|Procedure|Hypobaric hypoxia|
79664156|NCT00418067|Device|Endeavor|Zotarolimus-eluting stent
79664157|NCT00418067|Device|Cypher|Sirolimus-eluting stent
79988830|NCT02573233|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
79664158|NCT00418067|Device|Taxus Liberte|Paclitaxel-eluting stent
79664159|NCT04869969|Procedure|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
79664160|NCT04869969|Procedure|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
79817027|NCT02586987|Drug|Tremelimumab|Tremelimumab, IV
79817028|NCT04114253|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79988831|NCT02573233|Drug|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
79988832|NCT02573233|Drug|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
79988833|NCT02573233|Drug|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
79988834|NCT02573233|Drug|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
79502293|NCT04144764|Other|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
79502294|NCT04029246|Behavioral|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
79502295|NCT04029246|Behavioral|Incentive|Offer of a shopping voucher if patient attends for appointment
79502296|NCT04144920|Behavioral|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
79664161|NCT00296270|Behavioral|Memory for truth|
79664162|NCT00296309|Drug|Tacrolimus|Immunosuppression
79502297|NCT04144920|Behavioral|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
79664163|NCT00296348|Drug|tacrolimus|immunosuppression
79664164|NCT00296348|Drug|mycophenolate mofetil|oral
79502298|NCT04144920|Behavioral|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
79502299|NCT04027452|Behavioral|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
79502300|NCT04027452|Behavioral|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
79664165|NCT00296348|Drug|daclizumab|oral
79664166|NCT00296348|Drug|steroids|oral
79664167|NCT04835376|Device|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
79664168|NCT00296387|Drug|Rosuvastatin|
79664169|NCT00296387|Drug|Atorvastatin|
79664170|NCT00326742|Behavioral|Trier Social Stress Test|
79664171|NCT00296426|Procedure|New technology - PAML|
79664172|NCT00326820|Drug|ibandronate sodium|
79664173|NCT00326820|Drug|zoledronic acid|
79988835|NCT03867487|Drug|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
79988836|NCT03867487|Drug|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
79664174|NCT00326820|Drug|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
79664175|NCT00296465|Drug|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
79664176|NCT00296465|Drug|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
79502301|NCT04144452|Other|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
79502302|NCT04144452|Other|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
79988837|NCT01381224|Other|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
79988838|NCT04127539|Behavioral|Strong & Steady exercise program|The community-based group exercise program S&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
79988839|NCT01381146|Behavioral|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
79502303|NCT03947190|Biological|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
79502304|NCT03947190|Biological|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
79502305|NCT03947190|Biological|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
79502306|NCT04144374|Drug|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
79664177|NCT00296465|Drug|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
79664178|NCT00296465|Drug|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
79988840|NCT01381146|Behavioral|TAU|have access to other jail programs and services
79988841|NCT01569048|Drug|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
79664179|NCT00326859|Drug|remifentanil|
79664180|NCT00326976|Drug|FX06|400 mg as intravenous injection in two divided boluses
79664181|NCT00326976|Procedure|Percutaneous coronary intervention|
79988842|NCT01569048|Drug|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
79988843|NCT03941574|Drug|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
79988844|NCT01384344|Other|observational|Observation during a physical exercise
79350628|NCT01860170|Drug|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
79502307|NCT04144374|Procedure|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
79988845|NCT03935880|Device|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
79502308|NCT04026282|Procedure|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
79988846|NCT03935880|Procedure|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
79502309|NCT04026282|Procedure|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
79664182|NCT00296582|Behavioral|Gastric Motor Function Measurement|
79664183|NCT00296621|Drug|L-Glutamine|L-Glutamine
79664184|NCT00296621|Drug|placebo|placebo
79664185|NCT04717011|Diagnostic Test|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
79988847|NCT05304234|Diagnostic Test|Ultrasound or abbreviated MRI|Abdominal ultrasound or abbreviated MRI
79988848|NCT04008420|Other|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
79988849|NCT01380912|Drug|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
79988850|NCT03315793|Drug|Duloxetine Hydrochloride|Administered orally
79988851|NCT03315793|Drug|Placebo|Administered orally
79988852|NCT01569204|Drug|Etoposide|
79988853|NCT01569204|Drug|Cyclophosphamide|
79350629|NCT01860170|Drug|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
79664186|NCT04762407|Drug|HGP1910|Take it once per period.
79664187|NCT04762407|Drug|HGP1909|Take it once per period.
79664188|NCT04762407|Drug|HCP1903|Take it once per period.
79664189|NCT00296699|Drug|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
79664190|NCT00296738|Device|SPECT/CT|GE INFINIA HAWKEYE
79988854|NCT01569204|Drug|Doxorubicin|
79988855|NCT01569204|Drug|Prednisone|
79988856|NCT01569204|Drug|Procarbazine|
79988857|NCT01569204|Drug|Dexamethasone|
79988858|NCT01569204|Drug|Dacarbazine|
79988859|NCT01569204|Drug|Brentuximab Vedotin|
79817029|NCT02586753|Other|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
79817030|NCT02586753|Other|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
79502310|NCT04144296|Diagnostic Test|Study procedure|"Measurement of the flow rate of supplemental oxygen~Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~Taking of an ABG sample (ABG1) from the arterial line~Taking of capillary blood gas analysis from the earlobe and from the finger tip~Taking of an a second ABG (ABG2) from the arterial line"
79817031|NCT00920049|Behavioral|Persuasion|
79817032|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
79817033|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
79817034|NCT00584727|Device|senofilcon A toric contact lens|contact lens
79817035|NCT00584727|Device|alphafilcon A toric|contact lens
79988860|NCT02676466|Dietary Supplement|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
79664191|NCT04581486|Other|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
79664192|NCT04581486|Other|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
79988861|NCT02676466|Drug|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
79988862|NCT02676466|Other|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
79988863|NCT02676466|Other|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
79988864|NCT03350269|Other|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
79988865|NCT01383252|Procedure|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
79350630|NCT01860170|Drug|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
79350631|NCT01847274|Drug|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
79350632|NCT01847274|Drug|placebo|
79350633|NCT01802788|Device|St Jude Medical Portico replacement aortic valve|
79664193|NCT00296777|Drug|Escitalopram|8 weeks: up to 40 mg/day
79817036|NCT00584727|Device|etafilcon A sphere|contact lens
79817037|NCT04081935|Device|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
79817038|NCT00799409|Drug|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
79350634|NCT01802788|Procedure|Transcatheter Aortic Valve Implant|
79350635|NCT01611168|Other|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
79502311|NCT04144218|Drug|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
79502312|NCT04144218|Drug|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
79502313|NCT05580900|Other|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
79664194|NCT00296777|Drug|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
79664195|NCT00296777|Drug|Imipramine|"8 weeks: up to 300mg/day~*if patient does not have contraindication."
79664196|NCT00327054|Drug|Nigella sativa seed|
79817039|NCT00799409|Drug|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
79817040|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
79817041|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
79817042|NCT00782210|Drug|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
79502314|NCT05580900|Other|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
79502315|NCT04021602|Behavioral|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
79664197|NCT00296855|Drug|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
79664198|NCT00296894|Drug|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
79664199|NCT00296894|Drug|Placebo|Placebo
79350636|NCT01603316|Behavioral|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
79350637|NCT01603316|Behavioral|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
79664200|NCT00296933|Drug|Escitalopram|
79664201|NCT00296933|Drug|Bupropion XL|
79664202|NCT00296972|Drug|peg interferon plus ribavirin|
79817043|NCT04111679|Other|Music|Participant selected music, applied using noise cancelling headphones
79817044|NCT05678153|Diagnostic Test|Nordic Orofacial Test-Screen (NOT-S)|screening tool to detect orofacial dysfunction
79817045|NCT00920127|Dietary Supplement|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
79817046|NCT01558115|Drug|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
79817047|NCT01558115|Other|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
79988866|NCT01383252|Procedure|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
79664203|NCT00297011|Drug|valacyclovir+clobetasol gel|
79664204|NCT00327093|Drug|cetuximab|indication : second intention treatment
79502316|NCT04021602|Behavioral|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
79988867|NCT01380756|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
79664205|NCT00327093|Drug|bevacizumab|Indication: first intention treatment
79350638|NCT01560819|Drug|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
79350639|NCT01497184|Procedure|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
79350640|NCT01497184|Genetic|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
79664206|NCT00297050|Drug|Peramivir|
79350641|NCT01425528|Drug|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
79664207|NCT04708587|Drug|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
79350642|NCT01300832|Procedure|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
79350643|NCT01150487|Procedure|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
79502317|NCT04021602|Behavioral|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
79664208|NCT04708587|Drug|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
79817048|NCT01294007|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
79817049|NCT01294007|Procedure|Autograft bone|Iliac Crest and Local Autograft Bone
79988868|NCT01380756|Drug|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
79988869|NCT04439890|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
79664209|NCT00297128|Drug|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
79350644|NCT00866554|Drug|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
79350645|NCT00866554|Drug|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
79502318|NCT05580822|Drug|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
79664210|NCT00297128|Drug|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
79664211|NCT00327132|Drug|Omeprazole, Amoxicillin, Clarithromycin|
79664212|NCT00297206|Drug|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
79664213|NCT04478019|Drug|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
79664214|NCT00297245|Drug|cognitive function|
79664215|NCT00327210|Behavioral|Blood Glucose Awareness Training|
79664216|NCT00297284|Drug|Modafinil|
79350646|NCT00645931|Behavioral|protein and calorie controlled diet and self-hypnotic relaxation|daily
79350647|NCT00452023|Drug|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
79350648|NCT00442104|Drug|Ganaxolone|
79350649|NCT00441896|Drug|Ganaxolone|
79350650|NCT00441896|Other|Placebo|
79664217|NCT04392531|Drug|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
79988870|NCT04439890|Drug|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
79988871|NCT04439890|Drug|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
79664218|NCT04392531|Drug|Standard treatment|Standard of care according to hospital protocol
79664219|NCT00297323|Drug|Topiramate|75 patients over the age of 2 years old with epilepsy.
79664220|NCT00327249|Drug|imexon|
79664221|NCT00327288|Drug|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
79350651|NCT00202800|Drug|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
79350652|NCT00194714|Biological|HER-2/neu Peptide Vaccine|Given ID
79350653|NCT00194714|Other|Laboratory Biomarker Analysis|Correlative studies
79664222|NCT00327288|Drug|docetaxel|IV once every 21 days for duration of study
79664223|NCT04344600|Drug|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
79988872|NCT04439890|Drug|Placebo|Placebo
79988873|NCT03695497|Procedure|Direct anterior approach|total hip arthroplasty with DAA
79350654|NCT02034877|Biological|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
79350655|NCT02034877|Procedure|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
79350656|NCT02034799|Biological|Bioseal Fibrin Sealant|
79350657|NCT02034799|Other|Standard of Care (SoC)|
79350658|NCT02057575|Drug|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
79350659|NCT02057575|Drug|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
79502319|NCT05580822|Drug|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
79502320|NCT04026126|Behavioral|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
79502321|NCT05580354|Drug|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
79664224|NCT04344600|Other|Saline|Saline subcutaneous injection
79664225|NCT04333134|Drug|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
79664226|NCT00327327|Drug|imexon|30-60 minutes IV, days 1,8,15 every 28 days
79664227|NCT00327327|Drug|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
79664228|NCT00327366|Procedure|Light therapy|
79664229|NCT04303104|Other|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
79664230|NCT04303104|Other|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
79664231|NCT00297362|Drug|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
79988874|NCT03695497|Procedure|Direct Lateral Approach|total hip arthroplasty with DLA
79988875|NCT02324725|Drug|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
79350660|NCT02057575|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
79502322|NCT04144062|Other|CAD/CAM crowns|CAD/CAM crowns
79664232|NCT00297440|Behavioral|Cognitive-behavioral treatment|
79664233|NCT00297440|Behavioral|Exercise|
79664234|NCT00327483|Behavioral|Internet based education software|
79350661|NCT02057575|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
79350662|NCT02077465|Drug|Andecaliximab|400 mg andecaliximab administered intravenously
79350663|NCT02077465|Drug|Placebo to match Andecaliximab|Placebo to match andecaliximab administered intravenously
79350664|NCT02034565|Drug|Apixaban|
79502323|NCT04143906|Drug|Vinorelbine|injection
79502324|NCT04143906|Drug|Gemcitabine|injection
79350665|NCT02075515|Biological|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
79350666|NCT02034409|Device|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
79502325|NCT04143906|Drug|Carboplatin|injection
79350667|NCT02034409|Device|Sham Comparator|20 minutes daily for 48 weeks
79350668|NCT04682587|Drug|Axitinib|Inlyta, axitinib
79350669|NCT04682587|Drug|Avelumab|Avelumab, Bavencio
79350670|NCT04682587|Drug|Pembrolizumab|Pembrolizumab, Keytruda
79502326|NCT04143750|Drug|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi [14C]Vicagrel, in fasting within 5 minutes
79502327|NCT03022110|Device|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
79502328|NCT02708004|Drug|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
79502329|NCT02708004|Other|Placebo|Matching active drug
79502330|NCT03021720|Procedure|Arterial access|Location of arterial puncture
79502331|NCT02708706|Drug|hyaluronic acid (hyruan)|2cc hyaluronic acid
79502332|NCT02708706|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
79664235|NCT05459220|Drug|SHR0410 Injection|SHR0410 Injection（Low Dose）
79664236|NCT05459220|Drug|SHR0410 Injection|SHR0410 Injection（High Dose）
79988876|NCT03633695|Device|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
79988877|NCT03633695|Device|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
79502333|NCT04143672|Device|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
79502334|NCT04143672|Diagnostic Test|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
79664237|NCT05459220|Drug|Placebo|Placebo for SHR0410 Injection.
79664238|NCT00297518|Device|PerioWave|
79664239|NCT00297518|Procedure|Scaling and Root Planing|
79664240|NCT04231773|Drug|Nitric Oxide|40 parts per million dosage
79664241|NCT04231773|Drug|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
79664242|NCT00297635|Device|GlucoDYNAMIX™ intervention system|
79350671|NCT04417543|Drug|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
79350672|NCT04417543|Drug|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
79350673|NCT02021318|Drug|Roxadustat|Oral tablet.
79350674|NCT02021318|Drug|Darbepoetin alfa|Subcutaneous or intravenous injection.
79350675|NCT02041286|Device|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
79350676|NCT02020616|Drug|LY3053102|Administered SC
79350677|NCT02020616|Drug|Exenatide ER|Administered SC
79350678|NCT02020616|Drug|Placebo|Administered SC
79350679|NCT02020616|Drug|Metformin|Administered orally (PO)
79502335|NCT04143828|Behavioral|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
79502336|NCT05587608|Procedure|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
79502337|NCT02703714|Drug|Pembrolizumab|200 mg given intravenously (IV)
79664243|NCT00297635|Device|GlucoMON™ telemetry device|
79664244|NCT04224012|Other|Exercise and respiratory therapy|Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
79664245|NCT00297674|Drug|Intravenous Clarithromycin|
79664246|NCT00297713|Drug|ALTU-238|
79228341|NCT02234895|Device|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
79350680|NCT02048072|Drug|Gilenya|Autonomic testing during first dose administration of Gilenya.
79350681|NCT02047604|Drug|SAN-300 0.5 mg/kg QW|
79350682|NCT02047604|Drug|SAN-300 1.0 mg/kg QW|
79350683|NCT02047604|Drug|SAN-300 2.0 mg/kg QOW|
79350684|NCT02047604|Drug|SAN-300 4.0 mg/kg QOW|
79350685|NCT02047604|Drug|SAN-300 4.0 mg/kg QW|
79350686|NCT02047604|Drug|Placebo|
79502338|NCT02703714|Drug|Sargramostim|250 µg given subcutaneously (SC)
79664247|NCT04207593|Drug|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2>90% or pO2 >60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
79664248|NCT00297752|Drug|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
79988878|NCT01380678|Drug|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
79988879|NCT01380678|Drug|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
79502339|NCT03919578|Biological|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
79664249|NCT00297752|Drug|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
79664250|NCT00297791|Procedure|surgery|randomized to open or laparoscopic technique
79664251|NCT05459142|Drug|Medical Abortion|Medical Abortion
79664252|NCT00297869|Procedure|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
79664253|NCT05459103|Other|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
79502340|NCT03919578|Biological|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
79350687|NCT01622660|Drug|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
79350688|NCT01622660|Drug|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
79502341|NCT03945864|Device|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
79502342|NCT03945864|Device|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
79502343|NCT04143048|Other|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
79502344|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
79664254|NCT05459103|Other|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
79664255|NCT00297947|Drug|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
79664256|NCT00297947|Drug|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
79664257|NCT05459025|Behavioral|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
79664258|NCT05459025|Behavioral|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
79664259|NCT04718714|Drug|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
79664260|NCT04718714|Drug|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
79664261|NCT04718714|Drug|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
79664262|NCT04009239|Behavioral|Time Restricted Feeding|Consuming energy during a short interval during the day
79664263|NCT00297986|Device|Helmet|Evaluation of different interfaces for NPPV
79664264|NCT05458635|Procedure|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
79664265|NCT00298025|Drug|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
79664266|NCT00298025|Drug|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
79502345|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
79502346|NCT03904446|Drug|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
79664267|NCT00298025|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
79664268|NCT00298025|Drug|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
79664269|NCT00298025|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
79664270|NCT03923439|Device|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
79664271|NCT03917745|Behavioral|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
79664272|NCT00298142|Procedure|Usual Care provided by a medical doctor (GP or Neurologist)|
79502347|NCT03904446|Drug|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
79664273|NCT00298142|Procedure|Usual care plus Physio-/ Manual Therapy|
79664274|NCT00298181|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
79502348|NCT04143984|Drug|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
79502349|NCT04143984|Radiation|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
79502350|NCT04143984|Drug|Camrelizumab|An anti-PD-1 antibody.
79502351|NCT05583318|Other|Data collection|Data from hematological malignancy registries
79664275|NCT05458518|Procedure|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
79664276|NCT00298220|Behavioral|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
79664277|NCT00298220|Behavioral|Dissemination guideline and patient information letters|
79664278|NCT00298220|Behavioral|Tailored educational training|for GP(T)s
79664279|NCT00298220|Behavioral|Tailored outreach based facilitator support|in the practices of the GPTs
79664280|NCT00298220|Behavioral|Facilitation of co-operation with local addiction services|
79502352|NCT05583318|Other|Questionnaires|"9 questionnaires were sent out:~QLQ-C30 and SF-12 Quality of Life Questionnaire.~Oral quality of life questionnaire QLQ-OH15~Sexuality questionnaire SHQ-C22~Anxiety and depression questionnaire HADS,~Rosenberg Self-Esteem Questionnaire~RNLI Reintegration to Normal Life Questionnaire~Social Support Questionnaire SSQ6,~Socio-economic status questionnaire EPICES,~Complementary questionnaire collecting data on socio-professional status."
79502353|NCT05582772|Other|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
79502354|NCT05582772|Other|RSM intervention|Telephone-based, symptom management of patients with cancer
79502355|NCT05582772|Other|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
79502356|NCT03902652|Procedure|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
79502357|NCT03902652|Procedure|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
79502358|NCT03916692|Dietary Supplement|Carbohydrate drink|Meal replacement drink containing 200 kcal
79502359|NCT03916692|Dietary Supplement|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
79502360|NCT03916692|Dietary Supplement|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
79664281|NCT00298220|Behavioral|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
79664282|NCT00298220|Behavioral|Reminder-card for GP's desk|
79664283|NCT00298220|Behavioral|Personal feedback to patients|Patients receive advise based on their premeasurement answers
79988880|NCT02213809|Behavioral|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
79350689|NCT04697498|Procedure|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
79350690|NCT04697498|Procedure|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
79350691|NCT04680182|Procedure|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
79350692|NCT02019602|Procedure|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
79664284|NCT05458089|Diagnostic Test|18F-FDG|18F-FDG intravenous injection
79664285|NCT00298259|Procedure|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
79664286|NCT03826641|Drug|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
79664287|NCT03826641|Drug|HCP1801|Dapagliflozin/Metformin 10/1000mg
79664288|NCT00298298|Biological|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
79817050|NCT02606123|Drug|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
79350693|NCT02019602|Procedure|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
79817051|NCT04111913|Drug|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
79350694|NCT02019602|Procedure|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
79502361|NCT04142970|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
79502362|NCT04765332|Other|DLQI and PSO-TARGET QoL grid|At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
79502363|NCT03022344|Radiation|Cardiac CT|
79502364|NCT04142346|Behavioral|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
79502365|NCT04142112|Device|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
79502366|NCT04142112|Device|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
79502367|NCT04143282|Drug|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
79502368|NCT04143282|Drug|Chemotherapy|standard chemotherapy
79502369|NCT04142190|Drug|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
79664289|NCT03754140|Drug|Polidocanol Injection|Sclerotic agent
79817052|NCT04081467|Other|Bed rest|10-day of complete bed rest
79988881|NCT02213809|Behavioral|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
79502370|NCT04142190|Drug|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
79502371|NCT05582148|Device|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
79502372|NCT04149678|Drug|Ozanimod|Ozanimod
79502373|NCT04149678|Drug|Cyclosporine|Cyclosporine
79502374|NCT05581992|Drug|AMG 510|Oral Tablet
79502375|NCT05581992|Drug|Omeprazole|Capsule
79502376|NCT03021174|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
79502377|NCT03021174|Behavioral|Nutrition Education Control|12 weeks of implementing eating tips
79664290|NCT00298337|Drug|Mixture of probiotic bacteria and prebiotic oligosaccharide|
79817053|NCT02605265|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
79817054|NCT02605265|Drug|Capecitabine|
79817055|NCT02605265|Drug|Irinotecan|
79817056|NCT02605265|Drug|Oxaliplatin|
79817057|NCT04682769|Other|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
79228342|NCT04442672|Procedure|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
79228343|NCT04442672|Procedure|sham|surrounding the cuff but not inflate it.
79664291|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
79664292|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
79664293|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
79664294|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
79664295|NCT03528486|Behavioral|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
79664296|NCT00298415|Drug|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
79502378|NCT03020940|Drug|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
79664297|NCT00298415|Drug|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
79664298|NCT00298454|Drug|Furosemide|
79664299|NCT04708392|Device|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
79502379|NCT03020628|Biological|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
79664300|NCT03517956|Drug|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
79664301|NCT03517956|Drug|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
79664302|NCT00298493|Procedure|Sedation management strategy|
79664303|NCT00298532|Procedure|Advanced Life Support|
79664304|NCT03505476|Device|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
79664305|NCT03505476|Other|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
79664306|NCT03505476|Other|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
79664307|NCT00298571|Drug|.5% bupivacaine with epinephrine|
79988882|NCT03314233|Procedure|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
79664308|NCT00419679|Procedure|x-ray diffraction of human hair|
79664309|NCT00298649|Behavioral|Lay Health Advisor|
79664310|NCT00298688|Drug|Gefitinib|
79664311|NCT00298727|Behavioral|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
79664312|NCT00298727|Behavioral|ePBL|Online Problem-Based Course
79664313|NCT05457894|Biological|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
79664314|NCT05457894|Biological|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
79664315|NCT03448653|Other|Colonoscopy with NBI|Colonoscopy with NBI
79817058|NCT02604875|Other|observation|blood sampling during 24 hours
79988883|NCT02675998|Drug|Tenapanor|
79988884|NCT02675998|Drug|Placebo|
79664316|NCT03439839|Drug|iptacopan|iptacopan bid orally administered
79664317|NCT03439839|Combination Product|Standard of Care|Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
79664318|NCT05457777|Behavioral|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
79664319|NCT00298883|Drug|Myfortic|Myfortic 360mg PO BID for six weeks
79664320|NCT00298922|Drug|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
79664321|NCT00298922|Drug|Placebo|tablet orally thrice weekly for 24 weeks
79664322|NCT05457738|Other|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
79817059|NCT04081623|Device|Raydiant Oximetry Sensing System|The investigational device is used to record fetal pulse signals.
79988885|NCT01384188|Drug|ONO-5334|150 mg for 5 days administered in the morning or in the evening
79988886|NCT01384188|Drug|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
79988887|NCT04588519|Device|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
79664323|NCT05457738|Other|No E-REVA® app|No use smartphone
79664324|NCT00298961|Device|Videoconference equipment FALCON/IP|
79664325|NCT00299039|Drug|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
79664326|NCT00299039|Drug|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
79817060|NCT04101500|Drug|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
79817061|NCT04101500|Drug|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
79817062|NCT04101500|Drug|Placebo Tablets|Applied only to the control group.
79228344|NCT02233491|Behavioral|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
79228345|NCT02233491|Other|Control|No additional support other than lifestyle advice by clinician
79228346|NCT05157750|Other|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
79502380|NCT03020628|Biological|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
79502381|NCT05581914|Other|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
79502382|NCT05581914|Other|Care as Usual|The care as usual the adolescents receives
79664327|NCT05457621|Other|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
79664328|NCT00299117|Behavioral|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
79817064|NCT04103060|Drug|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
79817065|NCT04103060|Drug|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
79664329|NCT00299234|Drug|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
79664330|NCT00299273|Behavioral|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
79817066|NCT02586441|Device|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
79817067|NCT02586441|Drug|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
79817068|NCT02586441|Drug|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
79502383|NCT05580198|Diagnostic Test|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
79817069|NCT02586363|Drug|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
79817070|NCT02586363|Drug|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
79502384|NCT04141956|Other|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
79502385|NCT03645408|Drug|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
79817071|NCT02586363|Drug|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
79817072|NCT00920205|Drug|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
79817073|NCT00764660|Drug|SCH 900435|tablets
79817074|NCT00764660|Drug|Placebo|tablets
79817075|NCT02586285|Drug|S-Adenosyl Methionine|500mg-1000mg,iv,qd
79817076|NCT00584415|Device|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
79817077|NCT05326022|Device|Microcurrent therapy|Microcurrent therapy
79817078|NCT05326022|Device|Low Level Laser Therapy|Laser therapy
79817079|NCT05326022|Other|Medical therapy|Medical therapy
79817080|NCT02586129|Drug|YH14755|20/1500mg, QD
79817081|NCT02586129|Drug|Metformin|1500mg, QD
79817082|NCT02586129|Drug|Rosuvastatin|20mg, QD
79817083|NCT00916604|Drug|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
79350695|NCT02019602|Biological|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection~Concentration: 200 mg/ml~Route of Administration: Subcutaneous Use"
79350696|NCT01994876|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
79350697|NCT01994876|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
79817084|NCT00916604|Drug|Placebo|Placebo oral suspension, 8 days treatment
79817085|NCT04081077|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
79817086|NCT04081077|Drug|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
79502386|NCT03645408|Other|Sham injection|Subjects received a sham injection with no study drug.
79502387|NCT04141722|Behavioral|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
79502388|NCT04141722|Behavioral|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
79502389|NCT04141410|Drug|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
79502390|NCT04141410|Device|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
79502391|NCT04141488|Other|experimantal group|Control Group
79817087|NCT04081077|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
79502392|NCT04141254|Other|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
79502393|NCT04141254|Other|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
79817088|NCT04081077|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
79817089|NCT04081077|Drug|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
79817090|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
79817091|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
79817092|NCT02586051|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
79817093|NCT02586051|Drug|Intravenous Immunoglobulin|High dose (2 grams per kilogram [g/kg]) IVIG (maximum 140 grams).
79817094|NCT02601326|Procedure|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
79350698|NCT04696718|Dietary Supplement|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
79350699|NCT02040428|Biological|EVARREST™ Fibrin Sealant Patch|
79350700|NCT02040428|Biological|Topical hemostat|
79350701|NCT02018822|Device|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
79350702|NCT02018822|Device|TPH3|light-cured resin composite for teeth
79502394|NCT03914976|Procedure|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
79502395|NCT04149756|Other|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
79502396|NCT04141098|Device|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
79502397|NCT05586204|Behavioral|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
79817095|NCT02601326|Procedure|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
79817096|NCT04101734|Device|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
79988888|NCT05666063|Diagnostic Test|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
79988889|NCT01380600|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10^6 pfu/kg, 1x10^7 pfu/kg, 3x10^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
79988890|NCT03264118|Procedure|Scaling and root planing|Furcation treatment by scaling and root planing
79988891|NCT03264118|Drug|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
79228347|NCT02234973|Behavioral|Quality Improvement|Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
79350703|NCT02018822|Device|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
79350704|NCT02055157|Drug|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
79350705|NCT02022007|Drug|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
79350706|NCT02022007|Drug|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
79350707|NCT02022007|Drug|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
79502398|NCT05586204|Behavioral|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
79664331|NCT05457543|Diagnostic Test|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
79817097|NCT04101734|Device|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
79350708|NCT04716595|Drug|K-877 ER 0.2 mg/day morning administration (once daily)|K-877 ER 0.2 mg tablet
79350709|NCT04716595|Drug|K-877 ER 0.2 mg/day evening administration (once daily)|K-877 ER 0.2 mg tablet
79350710|NCT04689919|Drug|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
79350711|NCT04689685|Other|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
79664332|NCT00299351|Drug|Depsipeptide|
79664333|NCT00299390|Drug|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
79664334|NCT00299429|Procedure|Stenting and minimally invasive bypass surgery|
79664335|NCT00299429|Procedure|PCI with DES|PCI with DES
79664336|NCT00299468|Behavioral|Patient Activation Measure Intervention Package|
79664337|NCT00299585|Procedure|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
79817098|NCT02601638|Other|Demographics and Health History Questionnaire|
79817099|NCT02601638|Other|Pre-Class Laryngectomy Survey|
79817100|NCT02601638|Behavioral|Counseling session with speech pathologist|
79988892|NCT03539406|Biological|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
79988893|NCT03539406|Drug|Chemotherapy|Cyclofosfamide/fludarabine treatment
79988894|NCT03064048|Dietary Supplement|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
79988895|NCT03064048|Dietary Supplement|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
79988896|NCT05231434|Other|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
79988897|NCT05231434|Other|aerobic activity|aerobic activity
79988898|NCT03113812|Drug|ABvac40|
79988899|NCT03113812|Drug|Placebo|
79988900|NCT04605874|Other|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
79988901|NCT02674204|Drug|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
79502399|NCT05586204|Behavioral|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
79502400|NCT05586204|Behavioral|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
79502401|NCT04149834|Procedure|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
79817101|NCT02601638|Behavioral|Total Laryngectomy Preoperative Education Class|
79817102|NCT02601638|Other|Day of Hospital Discharge Laryngectomy Survey|
79988902|NCT02674204|Drug|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
79988903|NCT05675644|Drug|Drospirenone-only pill|Single dose based on adaptive dose-finding design
79988904|NCT03113890|Genetic|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
79988905|NCT03113890|Genetic|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
79502402|NCT04149834|Procedure|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
79664338|NCT02808585|Drug|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
79664339|NCT02808585|Drug|Placebo Injection|Four weekly subcutaneous injections of placebo.
79664340|NCT02751762|Other|Observation Only|No Intervention
79664341|NCT00299780|Drug|Stem cell mobilization|
79664342|NCT05457348|Procedure|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
79664343|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
79664344|NCT00299819|Biological|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
79664345|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
79664346|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
79664347|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
79988906|NCT03113890|Other|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
79988907|NCT02579044|Drug|Everolimus and lonafarnib|
79988908|NCT03160690|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
79988909|NCT04461106|Other|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women
79817103|NCT02601638|Other|Day of Discharge Practicum|
79988910|NCT02941627|Device|Neuro Zti|Cochlear implant
79988911|NCT02941627|Device|Neuro One|Sound processor
79502403|NCT04140474|Device|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
79988912|NCT03525379|Drug|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
79988913|NCT03525379|Drug|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
79988914|NCT03476551|Drug|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
79988915|NCT03521934|Drug|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
79988916|NCT03521934|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79988917|NCT03434353|Drug|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
79988918|NCT03434353|Drug|TAF|Administered orally once daily with food
79988919|NCT03374137|Biological|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
79502404|NCT04149444|Drug|Trifluridine/Tipiracil|Oral medication
79502405|NCT03020706|Drug|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
79502406|NCT04149366|Device|Retainer|Orthodontic retainer
79502407|NCT04148976|Dietary Supplement|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
79502408|NCT04148976|Dietary Supplement|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
79817104|NCT02601638|Other|Laryngectomy Education Study Exit Survey|
79988920|NCT03415776|Procedure|Hemodialysis|Renal replacement therapy
79988921|NCT02914184|Biological|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
79988922|NCT02914184|Biological|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
79988923|NCT01380522|Drug|Metronidazole|Capsules, single-dose, fed
79817105|NCT00763958|Drug|Placebo|Placebo to match buprenorphine administered for 3 months
79988924|NCT01380522|Drug|Flagyl|Capsules, single-dose, fed
79988925|NCT03611712|Drug|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
79988926|NCT03633227|Drug|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
79988927|NCT03633227|Drug|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
79988928|NCT03665324|Other|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
79502409|NCT05583084|Other|Investigation|
79502410|NCT04140630|Other|No intervention|No intervention; 1 week observational study
79502411|NCT04149132|Device|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
79664348|NCT04716660|Other|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
79817106|NCT00763958|Drug|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
79817107|NCT02601482|Behavioral|CON|
79817108|NCT02601482|Behavioral|IW-60|
79817109|NCT02601482|Behavioral|IW-45|
79817110|NCT04101578|Drug|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
79817111|NCT00763256|Drug|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
79817112|NCT00763256|Drug|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
79350712|NCT04681963|Other|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
79350713|NCT04680949|Drug|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
79664349|NCT00299858|Drug|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
79817113|NCT02585973|Drug|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
79817114|NCT02585973|Drug|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
79350714|NCT04680949|Drug|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
79817115|NCT02585973|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
79350715|NCT02031679|Drug|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
79350716|NCT02031679|Drug|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
79350717|NCT04689139|Diagnostic Test|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
79350718|NCT02053753|Drug|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
79350719|NCT02053753|Drug|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
79350720|NCT02019979|Drug|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
79350721|NCT02019979|Behavioral|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
79817116|NCT00920283|Device|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
79228348|NCT04320732|Behavioral|Observation of behavior and COVID-19 infection will be conducted.|No intervention, only prospective observation of behavior will be conducted by a questionnaire.
79350722|NCT04687501|Device|Virtual Reality|Virtual reality in gynaecological surgery in the pre- and postoperative setting
79350723|NCT02019667|Drug|SGS-742|
79350724|NCT02019667|Drug|Placebo|
79350725|NCT02030821|Drug|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
79350726|NCT02030821|Drug|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
79502412|NCT04149132|Diagnostic Test|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
79664350|NCT00299897|Drug|SP01A|
79664351|NCT05455944|Drug|Pregabalin 150mg|Two capsules of pregabalin is administered orally to patients
79350727|NCT02052739|Drug|SAGE-547|Solution for injection for IV infusion
79350728|NCT02019277|Drug|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
79350729|NCT02019277|Drug|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
79350730|NCT02019277|Drug|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
79350731|NCT02019277|Drug|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
79502413|NCT03908892|Drug|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
79502414|NCT03908892|Drug|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
79502415|NCT04140318|Drug|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
79664352|NCT05455944|Drug|Placebo|Two identical placebo capsules is administered orally to patients
79664353|NCT00299936|Drug|Ribavirin, PEG-Intron|
79664354|NCT00300014|Procedure|Intravitreal triamcinolone injection|
79664355|NCT00300014|Procedure|Air-fluid exchange|
79664356|NCT00300092|Drug|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
79817117|NCT00920283|Device|Driver Cobalt Alloy Coronary Stent|
79817118|NCT04081311|Device|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
79817119|NCT04080921|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
79817120|NCT00762788|Device|senofilcon A|1 week extended wear contact lens
79817121|NCT00762788|Device|lotrafilcon A|1 week extended wear contact lens
79817122|NCT00762788|Device|lotrafilcon B|1 week extended wear contact lens
79817123|NCT00762788|Device|balafilcon A|1 week extended wear contact lens
79350732|NCT02019277|Drug|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
79350733|NCT04712773|Device|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
79350734|NCT04712773|Device|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
79350735|NCT02030119|Behavioral|Financial Incentives|
79502416|NCT04140318|Drug|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
79502417|NCT03021408|Other|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
79502418|NCT03021408|Other|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
79664357|NCT00300131|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
79664358|NCT01785459|Drug|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
79350736|NCT02030119|Behavioral|Daily feedback|
79350737|NCT04686331|Diagnostic Test|Biomarkers for pneumonia|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis"
79350738|NCT01823835|Drug|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
79502419|NCT03021408|Other|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
79502420|NCT04140006|Drug|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
79502421|NCT04140006|Drug|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
79502422|NCT04140006|Drug|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
79502423|NCT04140006|Drug|Control|Flapped surgery for insertion of dental implant without topical application of any gel
79664359|NCT01785459|Drug|Standard Care|10 mg Intravenous injection of Prochlorperazine
79664360|NCT04716894|Drug|BI 474121|BI 474121 oral solution
79664361|NCT04716894|Drug|Itraconazole|Itraconazole oral solution
79502424|NCT04140084|Device|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
79817124|NCT00762788|Device|comfilcon A|1 week extended wear contact lens
79502425|NCT04140240|Behavioral|intervention group|Parallel Assignment a experimental design with pre test and post test
79502426|NCT04146324|Drug|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
79502427|NCT03588936|Drug|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
79502428|NCT03588936|Drug|Tocilizumab|Participants will receive 2 doses of tocilizumab
79502429|NCT03588936|Drug|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
79502430|NCT03588858|Other|structured interview questionnaires|"Module (1): Socio-demographic characteristics~Module (2) :Occupational history~Module (3): Presence of work related injuries and diseases by history and observation.~Module (4): Food frequency questionnaires (FFQ) during the past week.~Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
79664362|NCT00300287|Drug|Vildagliptin|
79664363|NCT00300326|Procedure|Computer assist|same implant using a computer-assisted surgical technique.
79664364|NCT05451732|Procedure|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
79664365|NCT00300404|Drug|daraprim|
79664366|NCT00300404|Drug|pyrimethamine|
79664367|NCT00300404|Drug|folinic acid|
79664368|NCT01539447|Drug|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
79817125|NCT00762788|Device|etafilcon A|1 week extended wear contact lens
79502431|NCT03588624|Device|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
79502432|NCT03585582|Other|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
79988929|NCT03665246|Behavioral|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
79988930|NCT03297372|Device|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
79502433|NCT03020862|Dietary Supplement|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
79988931|NCT05042232|Other|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
79350739|NCT01823835|Drug|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
79350740|NCT01823835|Drug|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
79350741|NCT01823679|Drug|Capecitabine|Given orally
79350742|NCT04414293|Radiation|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
79350743|NCT01823289|Drug|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
79664369|NCT01539447|Drug|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
79664370|NCT00300443|Drug|bimatoprost|
79664371|NCT00300521|Genetic|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
79664372|NCT00300560|Drug|Colistin|
79817126|NCT04080609|Drug|Dorzagliatin|GKA currently under clinical development
79988932|NCT05042232|Other|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
79988933|NCT02913326|Drug|Dabigatran etexilate|
79817127|NCT04080687|Device|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
79502434|NCT03586128|Drug|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
79817128|NCT00583947|Drug|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
79350744|NCT01822899|Drug|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
79988934|NCT02913326|Drug|Warfarin|
79988935|NCT01384110|Dietary Supplement|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
79988936|NCT03666182|Other|No Intervention|No Intervention
79988937|NCT01384032|Dietary Supplement|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
79350745|NCT01822899|Drug|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
79350746|NCT01822899|Drug|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
79502435|NCT03586128|Drug|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
79350747|NCT01822899|Drug|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
79350748|NCT01822821|Drug|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
79350749|NCT01822821|Drug|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
79664373|NCT00300638|Procedure|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
79664374|NCT00300638|Behavioral|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
79664375|NCT00327522|Biological|pneumococcal vaccine|
79817129|NCT00583947|Drug|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
79817130|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
79350750|NCT01822665|Drug|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
79350751|NCT01822665|Drug|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
79350752|NCT01822665|Other|Placebo|Placebo tablets
79350753|NCT02173301|Drug|XP23829 400 mg QD|active dose 1
79817131|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
79350754|NCT02173301|Drug|XP 23829 800 mg QD|active dose 2
79350755|NCT02173301|Drug|XP23829 400 mg BID|active dose 3
79350756|NCT02173301|Drug|Placebo|control
79502436|NCT03582462|Drug|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
79502437|NCT03582462|Drug|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
79817132|NCT00762476|Drug|3804-250A|"topical product~apply 2 pumps~apply at least every 4 hours or after hand washing"
79817133|NCT00762476|Drug|3804-291|"topical~apply 2 pumps~apply at least every 4 hours or after hand washing"
79817134|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
79817135|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
79988938|NCT01384032|Dietary Supplement|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
79817136|NCT00762164|Drug|Vytorin|Vytorin 10/80 split into 4
79988939|NCT01384032|Dietary Supplement|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
79988940|NCT03665558|Device|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
79350757|NCT01822587|Drug|Propranolol, 40 mg|
79350758|NCT01822587|Drug|Propranolol, 80 mg|
79664376|NCT04718051|Drug|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
79350759|NCT01822587|Drug|Placebo|
79350760|NCT04588077|Biological|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
79350761|NCT04588077|Biological|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
79350762|NCT04595331|Device|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
79502438|NCT03580278|Biological|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
79664377|NCT04718051|Drug|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
79664378|NCT00327561|Procedure|Intensive periodontal therapy|
79664379|NCT00327561|Procedure|Community based periodontal therapy|
79664380|NCT00300716|Drug|Memantine|
79664381|NCT04717167|Other|Dry Needling|
79664382|NCT04717167|Other|Sham Needling|
79664383|NCT00300794|Drug|Ketamine|
79664384|NCT05373303|Biological|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
79817137|NCT00762164|Drug|Simvastatin|Simvastatin 20 milligrams
79817138|NCT02585817|Device|Remote CIED Management|Information Technology
79817139|NCT00762086|Device|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
79817140|NCT00762086|Other|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
79988941|NCT01382862|Other|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
79988942|NCT03630978|Procedure|Liver resection|Major or minor, open or laparoscopic liver resection
79350763|NCT04587999|Other|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
79350764|NCT04587999|Other|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
79350765|NCT01822353|Dietary Supplement|Dietary supplement|Milk, egg or nut oral immunotherapy
79350766|NCT01821963|Drug|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
79350767|NCT01821963|Drug|Ribavirin|Starting dose: 1,000 mg by mouth daily.
79350768|NCT01821963|Drug|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
79350769|NCT01821729|Drug|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
79988943|NCT03665480|Drug|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
79817141|NCT04098614|Behavioral|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
79817142|NCT00761774|Drug|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
79988944|NCT03725891|Drug|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
79350770|NCT01821729|Drug|Losartan|Taken orally every day during Phase I for all 8 cycles
79350771|NCT01821729|Radiation|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
79350772|NCT01820637|Device|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
79350773|NCT02172911|Biological|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
79350774|NCT02172911|Device|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
79350775|NCT02120027|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
79817143|NCT00583791|Device|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
79817144|NCT04080375|Drug|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
79817145|NCT04080375|Drug|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
79817146|NCT00781274|Drug|MP-424|750 mg every 8 hours for 12 weeks
79988945|NCT03725891|Drug|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
79350776|NCT02120027|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
79350777|NCT01850823|Drug|placebo|
79350778|NCT01850823|Drug|Mometasone Nasal Spray|
79350779|NCT01850823|Drug|Mometasone nasal spray|
79350780|NCT01820559|Drug|Placebo|Tablets
79350781|NCT01820559|Drug|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
79350782|NCT01820559|Drug|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
79350783|NCT01818765|Procedure|Trans-ventricular-septal placement of LV pacing lead|
79350784|NCT01818765|Other|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
79350785|NCT01818765|Other|Acute response assessment|Cardiac output monitoring
79988946|NCT03725891|Drug|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
79502439|NCT03589950|Drug|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
79817147|NCT00781274|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
79350786|NCT01850589|Other|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~Chantix (varenicline) GlaxoSmithKline,~Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
79988947|NCT01383876|Behavioral|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
79350787|NCT01818531|Drug|Adductor canal block|
79817148|NCT00781274|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
79817149|NCT02585739|Genetic|blood sample|
79817150|NCT02585583|Radiation|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
79350788|NCT01818531|Drug|Lumbar plexus block|
79817151|NCT04103294|Dietary Supplement|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
79350789|NCT02171429|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
79350790|NCT02171429|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
79350791|NCT02171429|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
79350792|NCT02171429|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
79350793|NCT01818297|Device|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
79350794|NCT01818141|Drug|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
79350795|NCT01818141|Drug|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
79350796|NCT01849497|Biological|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
79350797|NCT01849497|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
79350798|NCT02147093|Device|Test (multi-focal)|contact lens was to be worn a daily wear.
79502440|NCT03589950|Drug|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
79502441|NCT03589872|Diagnostic Test|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
79817152|NCT04103294|Dietary Supplement|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
79817153|NCT02585505|Procedure|stem cells|stem cell will be injected
79988948|NCT01383876|Behavioral|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
79502442|NCT03589716|Other|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
79502443|NCT03589716|Other|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
79664385|NCT05373303|Biological|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
79817154|NCT03995576|Other|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
79350799|NCT02147093|Device|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
79817155|NCT04080765|Behavioral|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
79350800|NCT04170465|Drug|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
79350801|NCT04170465|Drug|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
79350802|NCT02119325|Dietary Supplement|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
79350803|NCT02119325|Dietary Supplement|0% fibre|Placebo is an energy matched powdered beverage
79350804|NCT01816893|Other|Hypoglycemic hyperinsulinemic clamp|
79350805|NCT01816893|Other|Euglycemic hyperinsulinemic clamp|
79502444|NCT03589716|Other|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
79502445|NCT03589716|Other|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
79502446|NCT03589716|Other|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
79502447|NCT03589638|Device|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
79664386|NCT00300833|Drug|Tirofiban|pci
79664387|NCT00327600|Drug|imexon|
79664388|NCT00327600|Drug|DTIC|
79988949|NCT03751163|Drug|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
79350806|NCT01848483|Behavioral|AIDS EPC Package plus MI|"Motivational Interviewing: In MI session #1, the nurse will set the agenda & ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 & 4, the nurse will also introduce advance care planning.~EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic & conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation & coordination of care."
79350807|NCT01848483|Other|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
79502448|NCT03589638|Device|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
79664389|NCT00300872|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
79817156|NCT04080765|Behavioral|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
79502449|NCT03589638|Device|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
79817157|NCT04103372|Other|Surveillance 6 monthly|6 monthly surveillance
79817158|NCT04103372|Other|Radiotherapy and surveillance|as per local policy
79817159|NCT04103372|Other|surveillance 3 montly|3 monthly surveillance
79502450|NCT03022500|Drug|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
79664390|NCT00300872|Device|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
79664391|NCT00300911|Drug|Rosiglitazone(drug), cardiac adverse effects|
79664392|NCT00327678|Drug|Rituximab|
79664393|NCT00327678|Drug|Imatinib Mesylate|
79664394|NCT00300950|Biological|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
79664395|NCT00300950|Drug|Gemcitabine|Chemotherapy
79664396|NCT05372601|Dietary Supplement|Relax+|Prebiotics, daily administered
79817160|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
79817161|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
79817162|NCT02585427|Dietary Supplement|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
79817163|NCT02585193|Behavioral|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
79817164|NCT02585271|Device|Transanal decompression tube|22 Fr transanal decompression tube
79817165|NCT02585271|Device|Stent|self-expandable colorectal nitinol alloys stent
79817166|NCT05520177|Drug|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
79817167|NCT05520177|Drug|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
79817168|NCT00780416|Drug|MP-424|750 mg every 8 hours for 12 weeks
79817169|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
79988950|NCT03751163|Drug|Hydroquinone 4% Cream|Hydroquinone 4% Cream
79664397|NCT05372601|Dietary Supplement|Maltodextrin|Placebo, daily administered
79988951|NCT03751163|Other|Sunscreen|Sunscreen SPF 30
79350808|NCT05133479|Behavioral|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
79350809|NCT01610271|Device|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
79350810|NCT02170727|Drug|DCV/ASV/BMS-791325|
79350811|NCT01847313|Drug|Liraglutide|Daily administration of liraglutide for 6 months
79350812|NCT02144285|Drug|LY3113593|Administered IV
79350813|NCT02144285|Drug|LY3113593|Administered SC
79502451|NCT04148742|Drug|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
79502452|NCT03589560|Drug|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
79817170|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
79817171|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
79817172|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
79988952|NCT03751163|Device|Placebo|Encapsulated placebo
79350814|NCT02144285|Drug|Placebo|Administered IV
79817173|NCT02585037|Other|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
79988953|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intramuscularly
79988954|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intradermal
79502453|NCT03589560|Drug|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
79502454|NCT04148898|Drug|Osimertinib|Treatment of LM With osimertinb
79350815|NCT02144285|Drug|Placebo|Administered SC
79350816|NCT02117687|Drug|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
79350817|NCT02117687|Drug|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
79502455|NCT04148898|Drug|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
79817174|NCT02585037|Other|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
79988955|NCT01380444|Procedure|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
79988956|NCT01380444|Procedure|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
79350818|NCT04742153|Drug|MRG002|Administrated intravenously
79502456|NCT04148820|Drug|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
79502457|NCT03588312|Procedure|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
79502458|NCT03589404|Device|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
79664398|NCT00300989|Device|Inion OTPS Biodegradable Fixation System|
79664399|NCT00327756|Drug|Coenzyme Q10|
79664400|NCT00301106|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
79664401|NCT00301145|Behavioral|smoking cessation intervention|
79664402|NCT00301145|Drug|varenicline|
79664403|NCT00301145|Other|counseling intervention|
79664404|NCT00301145|Other|internet-based intervention|
79988957|NCT03639545|Drug|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
79988958|NCT03639545|Drug|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
79817175|NCT02585037|Other|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
79988959|NCT03639545|Drug|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
79350819|NCT02105987|Drug|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
79350820|NCT02105987|Drug|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
79664405|NCT05366946|Other|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
79988960|NCT03639545|Drug|Placebos|The patients receive for 12 weeks.
79350821|NCT04185623|Procedure|denudation time lag|The time between ovum pickup and denudation of oocyte
79988961|NCT03181386|Drug|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
79988962|NCT03181386|Drug|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
79988963|NCT03181386|Drug|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
79350822|NCT02141633|Procedure|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
79350823|NCT02141633|Procedure|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
79817176|NCT02584881|Other|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
79350824|NCT02141633|Drug|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
79664406|NCT00301223|Drug|Pregabalin|
79664407|NCT00301301|Drug|Gemcitabine|
79664408|NCT00301301|Drug|Cisplatinum|
79664409|NCT00301301|Drug|Rituximab|
79664410|NCT05320302|Drug|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
79664411|NCT00301340|Drug|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
79817177|NCT04098692|Drug|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
79817178|NCT04098692|Drug|[14C]-Derazantinib solution for infusion|100 μg [14C]-derazantinib intravenous administration
79502459|NCT04148586|Other|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
79502460|NCT03589248|Diagnostic Test|GIF score|assessment by GIF score
79664412|NCT04717206|Other|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
79664413|NCT04717206|Other|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
79664414|NCT00301496|Device|Coban 2 Layer Compression System|
79664415|NCT00301535|Drug|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
79988964|NCT02912468|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79664416|NCT00301574|Drug|galantamine|
79350825|NCT02141633|Drug|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
79350826|NCT01846611|Drug|Trabectedin|1.1 mg/m^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
79350827|NCT01846611|Drug|DOXIL|30 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
79350828|NCT01846611|Drug|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
79350829|NCT01846611|Drug|DOXIL|50 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
79350830|NCT02141399|Drug|ALKS 5461|Sublingual tablet, taken daily
79350831|NCT04586673|Biological|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10^9 vp
79350832|NCT04586673|Biological|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10^10 vp
79350833|NCT04586673|Biological|MVA.tHIVconsv3 (M3)|MVA.tHIVconsv3 1 x 10^8 pfu
79350834|NCT04586673|Biological|MVA.tHIVconsv4 (M4)|MVA.tHIVconsv4 09. x 10^8 pfu
79350835|NCT01846299|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
79664417|NCT00327834|Drug|atomoxetine|
79664418|NCT00301613|Drug|Mycophenolate mofetil|MMF,1.0g/d
79664419|NCT00327873|Other|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
79664420|NCT00327873|Other|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
79817179|NCT04098692|Drug|[14C]-Derazantinib capsule|300 mg [14C]-derazantinib oral administration (3x100 mg capsules)
79664421|NCT00301652|Drug|mycophenolate mofetil|MMF,1.0g/d
79817180|NCT04098536|Behavioral|Diesel exhaust|Exposure to diesel exhaust fumes
79988965|NCT02912468|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79988966|NCT02912468|Drug|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
79664422|NCT00327912|Procedure|Laparoscopic Biliopancreatic diversion with Duodenal switch|
79664423|NCT00327912|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
79664424|NCT00301691|Behavioral|behavioral dietary intervention|
79664425|NCT00301691|Other|educational intervention|
79817181|NCT02584803|Radiation|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~Patient Acceptability of procedure~Patient Comfort:~Ease of exam for the examiner"
79988967|NCT03725813|Other|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
79988968|NCT04835298|Other|Dyspnea|questionnaires
79988969|NCT03639467|Drug|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
79988970|NCT03729167|Procedure|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
79350836|NCT01846299|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
79988971|NCT01382706|Drug|docetaxel|Given IV
79350837|NCT01628393|Drug|Ozanimod|Oral capsule taken once a day
79350838|NCT01628393|Drug|Placebo|Oral capsule taken once a day
79350839|NCT01846221|Drug|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
79350840|NCT01846221|Drug|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
79350841|NCT01815099|Device|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
79350842|NCT01845831|Drug|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
79664426|NCT00301691|Other|preventative dietary intervention|
79817182|NCT04079985|Other|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
79350843|NCT01845831|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
79664427|NCT05252871|Device|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
79664428|NCT00301730|Biological|aldesleukin|
79664429|NCT00301730|Biological|therapeutic tumor infiltrating lymphocytes|
79664430|NCT00301730|Biological|trastuzumab|
79664431|NCT00301730|Drug|paclitaxel|
79664432|NCT00301730|Procedure|conventional surgery|
79664433|NCT00301769|Drug|SJG-136|Given IV
79664434|NCT00301847|Drug|sorafenib tosylate|
79664435|NCT00327990|Drug|Ibandronate|
79664436|NCT00327990|Drug|Alendronate|
79664437|NCT00301886|Drug|ibandronate|
79664438|NCT00301886|Drug|zoledronate|
79664439|NCT00301886|Procedure|quality-of-life assessment|
79664440|NCT00301925|Biological|pegfilgrastim|
79664441|NCT00301925|Drug|capecitabine|
79664442|NCT00301925|Drug|cyclophosphamide|
79664443|NCT00301925|Drug|epirubicin hydrochloride|
79664444|NCT00301925|Drug|fluorouracil|
79664445|NCT00301925|Drug|methotrexate|
79664446|NCT00301925|Procedure|adjuvant therapy|
79664447|NCT00302120|Procedure|Contrast-enhanced MR mammography|
79664448|NCT00328029|Drug|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
79350844|NCT01845831|Drug|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
79350845|NCT01845831|Drug|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
79350846|NCT01845831|Drug|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
79350847|NCT01845831|Drug|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
79350848|NCT01627691|Device|Lotus Valve System|"bioprosthetic bovine pericardial aortic valve~delivery system"
79350849|NCT01844895|Drug|Abatacept|
79502461|NCT03589248|Diagnostic Test|US score|assessment by ultrasonography score
79664449|NCT00328029|Procedure|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
79350850|NCT02116361|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
79350851|NCT02116361|Drug|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
79350852|NCT02140775|Behavioral|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
79350853|NCT01844817|Drug|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
79350854|NCT01844817|Drug|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
79350855|NCT04594239|Device|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
79502462|NCT03588156|Drug|Benapenem|Dose-escalation For 11 level dose groups A1 ~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
79664450|NCT00328029|Procedure|pharmacokinetics, done during the treatment|"12 blood collections :~after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~3 hours after 2nd taken of Busulfan~3 hours after 3rd taken of Busulfan~3 hours after 4th taken of Busulfan~3 hours after 5th taken of Busulfan~3 hours after 6th taken of Busulfan."
79350856|NCT04594239|Device|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
79502463|NCT03588156|Drug|Placebo|Placebo
79502464|NCT03588000|Other|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
79502465|NCT03941808|Drug|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
79502466|NCT03941808|Drug|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
79664451|NCT00302198|Behavioral|ALS Registry|
79664452|NCT00302237|Device|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
79664453|NCT05234775|Drug|lerodalcibep|300 mg of each drug given SC as single dose
79664454|NCT05231889|Device|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
79664455|NCT05231889|Device|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
79664456|NCT00302276|Drug|Metobes-compound|
79664457|NCT00302315|Device|transcutaneous electrical nerve stimulation|
79664458|NCT00302354|Drug|OROS methylphenidate HCl|
79350857|NCT04594239|Device|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
79502467|NCT03587610|Biological|Remedial vaccination|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
79664459|NCT00302354|Drug|SODAS methylphenidate HCl|
79664460|NCT00302393|Drug|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
79664461|NCT00302393|Drug|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
79988972|NCT01382706|Drug|lapatinib ditosylate|Given PO
79988973|NCT01382706|Other|immunohistochemistry staining method|Correlative studies
79350858|NCT04594239|Device|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
79350859|NCT01814553|Drug|afatinib|Daily treatment starting 40 mg per day
79350860|NCT01814553|Drug|loperamide|Follow cohort assignment and diarrhea management guidelines
79350861|NCT02116205|Biological|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
79350862|NCT02116205|Biological|Placebo|0.9% sodium chloride
79350863|NCT02116205|Device|TriGrid Delivery System (TDS)|The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
79350864|NCT01844583|Drug|Alisertib|Alisertib tablets
79350865|NCT01844583|Drug|Esomeprazole|Esomeprazole capsules
79350866|NCT01844583|Drug|Rifampin|Rifampin capsules
79350867|NCT02115815|Biological|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
79502468|NCT03589092|Genetic|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
79664462|NCT00328107|Biological|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
79664463|NCT00302432|Behavioral|Behavior therapy, cigarette holders, Flowers Menthol|
79664464|NCT00328146|Other|Observation of sternal reentry|Observation of sternal reentry
79664465|NCT00302471|Drug|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
79988974|NCT01382706|Genetic|fluorescence in situ hybridization|Correlative studies
79988975|NCT01382706|Other|laboratory biomarker analysis|Correlative studies
79988976|NCT03725735|Behavioral|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
79988977|NCT03665402|Drug|Isoniazid|One of the first line anti-tubercolosis drug
79350868|NCT02115815|Biological|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
79988978|NCT03665090|Behavioral|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
79988979|NCT01380288|Drug|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
79502469|NCT03941496|Drug|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~5 mg/m^2~15 mg/m^2~30 mg/m^2~50 mg/m^2~75 mg/m^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~an increase in TNF and IFN-γ signaling pathways~an increase in ex vivo mycobacterial growth inhibition assay"
79664466|NCT00302471|Drug|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
79350869|NCT02115815|Biological|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
79350870|NCT02115815|Biological|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
79350871|NCT02115815|Biological|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
79502470|NCT03895476|Diagnostic Test|palatal wound will not cover|after harvesting the graft from the palate the wound will be left uncovered with secondary healing intention
79502471|NCT03895476|Diagnostic Test|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
79664467|NCT00302471|Drug|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
79664468|NCT00302471|Drug|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
79350872|NCT02115815|Biological|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
79664469|NCT00302510|Procedure|immunoadsorption|immunoadsorption
79664470|NCT00419913|Dietary Supplement|Dehydroepiandrosterone|DHEA 25 mg tid
79664471|NCT00302549|Drug|FK506|FK506,0.1mg/kg/d
79664472|NCT04716855|Other|Quality of life and daily living activities assessment tests|
79988980|NCT03665012|Other|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
79988981|NCT03110484|Drug|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
79988982|NCT03110484|Drug|Erlotinib|Erlotinib 100mg once daily
79988983|NCT03110328|Drug|MK3475|anti-PD1 immunotherapy
79988984|NCT04438499|Device|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
79988985|NCT01562015|Drug|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
79988986|NCT03751085|Device|AW frame|AW stereotactic frame for intracranial lesion biopsy
79350873|NCT02115815|Biological|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
79350874|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
79350875|NCT02115113|Drug|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
79988987|NCT03729089|Other|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
79502472|NCT03895476|Diagnostic Test|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
79350876|NCT02114879|Behavioral|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
79502473|NCT03895476|Diagnostic Test|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
79350877|NCT02114879|Behavioral|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
79502474|NCT04406064|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
79502475|NCT04405752|Device|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
79988988|NCT00002874|Drug|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
79988989|NCT00002874|Radiation|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
79350878|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
79350879|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
79350880|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
79350881|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
79502476|NCT04405752|Device|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
79502477|NCT03894150|Drug|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
79502478|NCT05702892|Diagnostic Test|ELISA|ELISA(enzyme-linked immunosorbent assay)
79502479|NCT03255564|Other|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
79502480|NCT04765410|Diagnostic Test|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
79502481|NCT04765254|Other|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
79502482|NCT03581058|Drug|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
79502483|NCT03580980|Drug|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
79502484|NCT03580980|Procedure|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
79502485|NCT03580980|Drug|Morphine|patient controlled analgesia by morphine
79502486|NCT04405440|Behavioral|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
79664473|NCT00419991|Drug|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
79988990|NCT00002874|Drug|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
79988991|NCT03001076|Drug|Bempedoic acid|bempedoic acid 180 mg tablet
79502487|NCT02985060|Device|Arctic Sun|"Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~Recovery phase:Rewarming velocity: 0.05~0.1℃ (within 30 hours)"
79502488|NCT02985060|Other|Standard treatment|"All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
79502489|NCT02985060|Drug|Saline|
79502490|NCT03587454|Diagnostic Test|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
79664474|NCT04718090|Procedure|PENG Block|Pericapsular nerve group block in shoulder surgery.
79664475|NCT04716816|Procedure|Stripping massage|Stripping massage for rhomboid myofascial trigger points
79502491|NCT03587376|Drug|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
79664476|NCT00302627|Drug|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
79988992|NCT03001076|Drug|Ezetimibe|ezetimibe 10 mg tablet
79988993|NCT03001076|Other|Placebo|matching placebo tablet
79988994|NCT03555305|Drug|Insulin Glargine|Administered SC
79988995|NCT03555305|Drug|Lantus|Administered SC
79988996|NCT01310387|Behavioral|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
79502492|NCT03587298|Procedure|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
79502493|NCT04148196|Other|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
79664477|NCT00302627|Drug|vitamin D|baseline, 6,12 months
79988997|NCT03725579|Drug|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
79350882|NCT02138825|Drug|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
79350883|NCT02138825|Drug|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
79502494|NCT03587220|Drug|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
79502495|NCT03587220|Radiation|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
79664478|NCT00302627|Drug|Calcium Carbonate|baseline, 6,12 months
79664479|NCT05129943|Device|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
79988998|NCT03725579|Drug|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
79664480|NCT05129943|Device|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
79664481|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
79664482|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
79988999|NCT03728855|Behavioral|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
79989000|NCT03018834|Drug|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
79989001|NCT03018834|Drug|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
79989002|NCT03553823|Procedure|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
79350884|NCT02138747|Drug|Mirabegron|Oral
79350885|NCT02138747|Drug|Tolterodine ER|Oral
79350886|NCT02105285|Drug|OPC-1085EL ophthalmic solution|
79350887|NCT02105285|Drug|Carteolol long-acting ophthalmic solution|
79350888|NCT02104895|Radiation|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
79664483|NCT05070741|Behavioral|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged ~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted ~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
79664484|NCT00328302|Drug|Candesartan|
79664485|NCT00328302|Drug|Placebo|
79817183|NCT04080141|Diagnostic Test|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
79817184|NCT04080141|Procedure|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
79817185|NCT00920517|Biological|rDEN2/4delta30(ME) vaccine|10^3 PFU dose
79817186|NCT00920517|Biological|Placebo|placebo for rDEN2/4delta30(ME) vaccine
79817187|NCT02584569|Drug|TAK-915|TAK-915 oral suspension
79817188|NCT00761462|Drug|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
79350889|NCT02104895|Radiation|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
79664486|NCT00418340|Drug|probiotic (bacterial/dietary supplement)|
79817189|NCT00761462|Drug|Non-quinolone antibiotic|Common used dose and route
79350890|NCT01621490|Biological|Nivolumab|
79350891|NCT01621490|Drug|Ipilimumab|
79350892|NCT02018887|Drug|LY2969822|Capsules administered orally
79350893|NCT02018887|Drug|Placebo|Capsules administered orally
79817190|NCT04101032|Behavioral|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
79817191|NCT00761306|Drug|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
79989003|NCT05422716|Device|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
79989004|NCT03728777|Dietary Supplement|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
79350894|NCT02030041|Drug|Vitamin D|Vitamin D will be given to achieve normal serum levels
79350895|NCT02030041|Drug|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
79350896|NCT02030041|Drug|Placebo|Placebo will be provided to the study participants
79350897|NCT01994720|Drug|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
79817192|NCT02584491|Behavioral|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
79817193|NCT04079595|Device|Head immobilization mask|Immobilization
79989005|NCT05422404|Procedure|Anti-Reflux Mucosectomy|ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.
79989006|NCT05422404|Procedure|Anti-reflux mucosal ablation|ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
79664487|NCT00418418|Procedure|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
79350898|NCT01994720|Drug|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
79350899|NCT01814007|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79350900|NCT01844115|Drug|Placebo|
79350901|NCT01844115|Drug|Vilazodone|Viibryd
79502496|NCT03587220|Other|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
79502497|NCT03587220|Drug|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
79502498|NCT04148274|Other|No intervention|There is no intervention for this study.
79502499|NCT04148040|Procedure|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
79502500|NCT03586908|Drug|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2~D6: PHP-201 0.5% topical eye drop OU TID
79502501|NCT03580746|Procedure|Taping and posteromedial release|
79664488|NCT00418418|Procedure|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
79664489|NCT00418418|Biological|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
79989007|NCT03000686|Biological|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
79502502|NCT03580746|Procedure|Ponseti|
79502503|NCT04147572|Drug|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
79502504|NCT04147572|Drug|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
79502505|NCT04147572|Drug|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
79502506|NCT04147572|Device|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
79502507|NCT04147572|Device|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
79989008|NCT03000686|Other|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
79502508|NCT05702580|Procedure|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
79502509|NCT03580590|Drug|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
79502510|NCT03580590|Drug|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
79502511|NCT03580590|Drug|Placebo Oral Tablet|Placebo Oral Tablet
79502512|NCT03934944|Device|Phone application|Weekly foot alerts and educational video
79502513|NCT03934944|Other|Usual care|Usual routine of diabetic foot education
79502514|NCT03192462|Biological|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
79502515|NCT03586752|Other|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
79664490|NCT00418418|Biological|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
79664491|NCT00328380|Drug|Rifaximin|
79664492|NCT00418496|Drug|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
79664493|NCT00418496|Drug|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
79664494|NCT05024721|Drug|HIP2101|Test drug
79664495|NCT05024721|Drug|RLD2101|Reference drug
79502516|NCT03586752|Other|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
79502517|NCT03891576|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
79817194|NCT00772538|Drug|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
79350902|NCT02018042|Drug|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
79350903|NCT04667390|Other|total knee arthroplasty|total knee arthroplasty
79350904|NCT01813305|Drug|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
79350905|NCT01813305|Drug|CSTC1 Matched vehicle|
79350906|NCT01993940|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
79350907|NCT01993940|Drug|Placebo|Placebo tablet taken orally once a day
79502518|NCT03586674|Drug|Lipanthyl|Tablet
79502519|NCT03586674|Drug|Ursogal|suspension
79664496|NCT05024721|Drug|HPP2101|Placebo drug
79664497|NCT05024721|Drug|HPP2102|Placebo drug
79817195|NCT00772538|Drug|placebo|Matching placebo
79817196|NCT04079517|Drug|Tamoxifen|A registered SERM drug, Tamoxifen.
79817197|NCT02584413|Device|Magnetic resonance imaging|-Standard of care
79350908|NCT01843803|Other|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
79502520|NCT05702346|Behavioral|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
79502521|NCT03156348|Other|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
79228349|NCT03302390|Procedure|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than <3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
79502522|NCT03580200|Other|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
79502523|NCT03580122|Drug|Arginine Aspartate|Asparten
79502524|NCT03346668|Drug|Topical gabapentin|topical gabapentin 6% solution
79502525|NCT03156426|Other|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
79502526|NCT03585738|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
79502527|NCT03585738|Dietary Supplement|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
79664498|NCT00302705|Drug|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
79664499|NCT00302705|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
79664500|NCT00302705|Procedure|Missing one dose|Patients skip the dose the second day of monitoring
79350909|NCT01843803|Other|attention control|Patients will view a brief healthy living video on an iPad
79350910|NCT02017171|Drug|Allopurinol|
79350911|NCT02017171|Drug|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
79350912|NCT04686097|Procedure|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
79350913|NCT04686097|Procedure|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
79350914|NCT02029417|Drug|cytarabine|Given SC
79350915|NCT02029417|Drug|omacetaxine mepesuccinate|Given SC
79350916|NCT02029417|Drug|decitabine|Given IV
79664501|NCT00328419|Device|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
79664502|NCT00328419|Device|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
79664503|NCT00302783|Behavioral|Multi-Source Feedback: including self-assessment & coaching|
79817198|NCT02584413|Drug|Gadolinium contrast|-Standard of care
79817199|NCT00761150|Drug|ABT-712|ABT-712 extended-release tablet
79817200|NCT00761150|Drug|Placebo|Placebo tablet
79817201|NCT00760994|Behavioral|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert & Forsyth, 2005; Hayes, Strosahl, & Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, & Barlow, 2004).
79502528|NCT03583164|Drug|F901318|30mg tablets with a maximum daily dose of 300mg with dose adjustments according to plasma levels of F901318 and concomitant treatment with CYP inducers or inhibitors
79664504|NCT05015712|Behavioral|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
79989009|NCT02646228|Other|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
79989010|NCT04701138|Dietary Supplement|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
79664505|NCT00302822|Drug|enfuvirtide|from week 0 to 24
79350917|NCT02029417|Other|laboratory biomarker analysis|Correlative studies
79502529|NCT03589326|Drug|Ponatinib|Ponatinib Tablets.
79502530|NCT03589326|Drug|Imatinib|Imatinib Tablets.
79664506|NCT00302822|Drug|emtricitabine/tenofovir|1 pill/day
79664507|NCT00302822|Drug|lopinavir or efavirenz|investigator choice
79350918|NCT02016716|Drug|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
79350919|NCT02016716|Drug|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
79350920|NCT02016716|Drug|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
79350921|NCT02016716|Drug|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
79502531|NCT03589326|Drug|Vincristine|Vincristine IV injection.
79502532|NCT03589326|Drug|Dexamethasone|Dexamethasone Tablets.
79502533|NCT03589326|Drug|Cytarabine|Cytarabine IV infusion.
79502534|NCT03589326|Drug|Methotrexate|Methotrexate IV infusion.
79502535|NCT03589326|Drug|Prednisone|Prednisone Tablets.
79502536|NCT05684640|Drug|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
79502537|NCT05684640|Drug|Placebo|Tablets, Oral, 0mg, BID
79664508|NCT00328458|Drug|EPO906 (epothilone B)|
79664509|NCT00302861|Biological|MyVax|
79664510|NCT04716582|Behavioral|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
79502538|NCT03585192|Other|Skin Group|"If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
79664511|NCT04716582|Behavioral|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
79664512|NCT04716582|Behavioral|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
79664513|NCT00302900|Behavioral|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
79664514|NCT00302900|Behavioral|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
79664515|NCT00302900|Behavioral|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
79664516|NCT04716621|Other|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
79664517|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
79664518|NCT00302978|Behavioral|Behavior therapy|
79350922|NCT02050321|Drug|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
79664519|NCT00303017|Dietary Supplement|flavocoxid|flavonoid mixture
79350923|NCT02050321|Drug|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
79664520|NCT00303017|Drug|Naproxen|non-steroidal anti-inflammatory drug
79664521|NCT00303056|Drug|HOE140 Icatibant|
79664522|NCT00328497|Drug|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
79817202|NCT00760994|Behavioral|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
79817203|NCT00760994|Other|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
79350924|NCT02017015|Drug|nab-paclitaxel|nab-paclitaxel at 125 mg/m^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
79350925|NCT02017015|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
79350926|NCT02016625|Drug|Faldaprevir|
79350927|NCT02016625|Drug|Faldaprevir|
79350928|NCT02016625|Drug|Cyclosporine|
79350929|NCT02016625|Drug|Tacrolimus|
79350930|NCT02016482|Biological|Adalimumab|
79664523|NCT00303134|Drug|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
79664524|NCT00303173|Behavioral|Guided Imagery|
79664525|NCT00328536|Drug|Omacor|
79350931|NCT02016482|Other|Placebo|
79350932|NCT02028871|Drug|Intranasal Insulin|
79817204|NCT00583557|Drug|belimumab|IV 10mg/kg Q28 days
79350933|NCT02028871|Drug|Placebo|
79350934|NCT02028715|Drug|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
79350935|NCT02028715|Drug|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
79350936|NCT02016170|Drug|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
79350937|NCT02016170|Drug|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
79350938|NCT02016170|Drug|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
79350939|NCT02015546|Drug|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
79350940|NCT02027701|Biological|IgPro20|
79350941|NCT02038790|Drug|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
79350942|NCT02038790|Drug|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
79350943|NCT04693286|Biological|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
79350944|NCT04693286|Other|Placebo|Placebo contains no active ingradients, only sucrose in buffer
79350945|NCT02027623|Behavioral|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
79350946|NCT02027623|Behavioral|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
79350947|NCT04684381|Drug|L-glutamine|Pharmacokinetic study
79817205|NCT00586820|Drug|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
79502539|NCT03585192|Other|Warmer Group|"Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
79502540|NCT03585426|Drug|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
79817206|NCT00586820|Drug|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
79817207|NCT04578093|Behavioral|LARC peer-based curriculum|Peer-based educational videos and supplemental activities
79817208|NCT00760838|Drug|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
79989011|NCT01382550|Drug|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
79989012|NCT05421936|Drug|Osimertinib|Treatment as the first EGFR-TKI
79817209|NCT00760838|Drug|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
79989013|NCT01380132|Procedure|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
79989014|NCT02493660|Device|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
79989015|NCT02493660|Procedure|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
79989016|NCT01382472|Drug|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
79989017|NCT01382472|Drug|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
79502541|NCT03585036|Drug|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
79817210|NCT00920595|Drug|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
79989018|NCT05421468|Other|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
79350948|NCT02015221|Device|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
79989019|NCT03552029|Drug|Quizartinib|20 or 30 mg tablets for oral administration
79989020|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
79989021|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
79502542|NCT03585036|Drug|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
79502543|NCT03585036|Drug|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
79989022|NCT03725423|Drug|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
79817211|NCT00586664|Drug|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
79350949|NCT02015221|Device|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
79350950|NCT04678843|Behavioral|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
79817212|NCT00586664|Drug|placebo comparator|sterile ophthalmic solution
79817213|NCT00586664|Drug|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
79989023|NCT06171646|Behavioral|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
79989024|NCT06171620|Device|Virtual reality headset|Distraction therapy using a virtual reality headset. Participants will access a digitally created environment such as a forest or sub sea exploration with relaxing auditory cues.
79989025|NCT06171620|Other|Standard of care|Elective procedure performed as planned according to current standard of care in the hospital.
79989026|NCT06171607|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
79989027|NCT06171607|Drug|Perflutren Lipid Microspheres|Given IV
79989028|NCT06171607|Drug|Sulfur Hexafluoride Lipid Microspheres|Given IV
79989029|NCT06171594|Combination Product|Chlorhexidine mouthwash|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of Chlorhexidine (CHX) mouthwash on healthy control and people with dental erosion (PwDE). This study aims to explore mouthwash's effect on oral microbiome recovery in WMS and salivary pellicle and its impact on blood pressure and arterial stiffness in healthy controls PwDE
79989030|NCT06171568|Other|Tests and questionnaires|"1 year after discharge from neurosurgery department, included patients will answer to the:~Modified Rankin Scale;~Instrumental Activities of Daily Living (IADL) questionnaire;~Montreal Cognitive Assessment (MoCA);~Frontal assessment battery (BREF);~Rivermead questionnaire;~Short Form (36) Health Survey (SF-36)~Community Integration Questionnaire - Revised (CIQ-R)~Posttraumatic stress disorder CheckList (PCL-5)"
79989031|NCT06171555|Device|CTM|decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act.
79989032|NCT06171555|Drug|Celestone|standard of care
79350951|NCT02027311|Drug|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
79350952|NCT02027311|Drug|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
79350953|NCT02027311|Drug|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
79350954|NCT02047903|Drug|Afatinib|50, 40, 30 or 20 mg
79350955|NCT02015065|Drug|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
79350956|NCT02026141|Drug|Dexmedetomidine|
79350957|NCT02026141|Drug|Normal Saline Placebo|
79350958|NCT02026063|Drug|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
79350959|NCT02025907|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
79350960|NCT02025907|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
79350961|NCT02025907|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily.
79350962|NCT01813071|Biological|WRSS1|
79817214|NCT02584335|Drug|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
79350963|NCT02025751|Drug|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
79350964|NCT02025751|Drug|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
79350965|NCT02025205|Device|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
79502544|NCT03584880|Device|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
79502545|NCT03584880|Device|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
79502546|NCT03155568|Procedure|sciatic nerve block|sciatic nerve block at popliteal fossa
79817215|NCT02584335|Drug|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
79817216|NCT00437281|Drug|Placebo|Placebo
79350966|NCT01812837|Device|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
79350967|NCT01812837|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
79817217|NCT00437281|Drug|Pregabalin|Orally-administered pregabalin
79502547|NCT03155568|Procedure|ankle block|block of major nerves supplying the foot at the level of the ankle
79817218|NCT02584023|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
79350968|NCT01812837|Radiation|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
79350969|NCT02024971|Drug|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
79350970|NCT01843023|Drug|Extended Release Naltrexone|naltrexone for extended release injectable suspension
79350971|NCT01843023|Behavioral|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
79502548|NCT03155568|Drug|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
79350972|NCT01843023|Drug|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
79817219|NCT02602106|Behavioral|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
79817220|NCT04556487|Other|evaluation|we will evaluate the home environment of the children asking by parents
79817221|NCT04102904|Other|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
79817222|NCT02584179|Device|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
79817223|NCT04102982|Drug|Camrelizumab|Patients will be treated with camrelizumab alone.
79817224|NCT04102982|Other|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
79817225|NCT04548609|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
79664526|NCT00303212|Other|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
79664527|NCT00328575|Radiation|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
79989033|NCT06171542|Device|CTM Injection|All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
79989034|NCT06171529|Device|CTM|CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
79350973|NCT01812759|Drug|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
79350974|NCT01812759|Drug|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
79989035|NCT06171529|Other|Placebo|placebo/Saline control injection
79350975|NCT01812759|Other|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
79350976|NCT01812057|Drug|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
79350977|NCT01812057|Drug|Placebo|Sodium Chloride 0.9% -5 ml
79350978|NCT01842633|Drug|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
79350979|NCT01842633|Drug|Ibuprofen|Caplets containing 200 mg of ibuprofen
79350980|NCT01842633|Other|Placebo|Matching placebo caplets
79350981|NCT01810263|Dietary Supplement|high protein supplement|Dietary Supplement: high protein supplement
79664528|NCT00303290|Drug|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
79664529|NCT00303290|Drug|Ara-C (cytosine arabinoside)|10 mg under the skin daily
79664530|NCT00328692|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
79664531|NCT00328692|Drug|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
79817226|NCT04544007|Drug|Poly ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
79817227|NCT05468073|Drug|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
79817228|NCT05468073|Drug|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
79989036|NCT06171516|Behavioral|iCBT|All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.
79817229|NCT04526847|Behavioral|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide ~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means ~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, & Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to ~75% of the normal energy requirements. They will receive a diet plan that recommended ~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
79817230|NCT04526847|Behavioral|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume ~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
79817231|NCT00920673|Procedure|MRI|MRI during 35 to 65 minutes
79350982|NCT01841697|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
79817232|NCT04520061|Behavioral|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
79817233|NCT02584101|Behavioral|ACT|ACT therapy administered in 3 sessions over a 4 week period
79817234|NCT02584101|Behavioral|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
79817235|NCT02583945|Procedure|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
79817236|NCT05442255|Other|Toxicological analysis|Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
79502549|NCT03584802|Other|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
79664532|NCT04718246|Other|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~Penetration of cortical bone will be achieved with no. 6 round burs.~The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
79817237|NCT05674773|Procedure|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
79817238|NCT04079205|Device|Wearable Device(exoRehab)|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
79817239|NCT04079205|Behavioral|Home rehabilitation program|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
79817240|NCT04079283|Diagnostic Test|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
79817241|NCT04079283|Diagnostic Test|Semantic|Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
79817242|NCT04079283|Diagnostic Test|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
79817243|NCT05674695|Drug|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
79817244|NCT04079049|Procedure|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
79817245|NCT04079049|Drug|Control|Oncological treatment in control group
79817246|NCT04078971|Other|Western diet|Subjects in this intervention will follow a normal western diet
79350983|NCT01841697|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
79664533|NCT00419718|Drug|inhaled human insulin|
79664534|NCT00303407|Drug|nadroparin|
79664535|NCT00328731|Procedure|Procedure|
79817247|NCT04078971|Other|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
79989037|NCT06171451|Diagnostic Test|PET with 11C-Fe-CIT|Use of the PET11C-Fe_CIT method for the early diagnosis of Parkinson's and in the differential diagnosis between Parkinson's and parkinsonism.
79350984|NCT01841697|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
79350985|NCT01841697|Drug|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
79350986|NCT01841697|Drug|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
79350987|NCT01841697|Drug|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
79502550|NCT03584802|Other|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
79664536|NCT00303524|Drug|Goserelin acetate|Injection 3.6 mg monthly
79817248|NCT02596269|Drug|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
79817249|NCT02596269|Drug|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
79817250|NCT00741039|Biological|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients >65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
79989038|NCT06171438|Diagnostic Test|Urine Biomarkers|Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
79664537|NCT00303524|Drug|Goserelin acetate|injection 10.8 mg every 3 months
79664538|NCT00419796|Drug|Lumiracoxib|
79989039|NCT06171438|Diagnostic Test|Gene expression profiling of donor kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
79664539|NCT00303563|Drug|P38 Inhibitor (4)|50mg po qd
79989040|NCT06171438|Diagnostic Test|Gene expression profiling of recipient kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
79989041|NCT06171412|Behavioral|Glu-COACH|peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens
79989042|NCT06171412|Behavioral|Enhanced standard-of-care (ESOC)|This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.
79989043|NCT06171347|Other|Oral cold spray (tap water)|Oral cold spray (tap water)
79664540|NCT00303563|Drug|P38 Inhibitor (4)|150mg po qd
79664541|NCT00303563|Drug|P38 Inhibitor (4)|300mg po qd
79664542|NCT00303563|Drug|Placebo|po qd
79664543|NCT00419835|Drug|enalapril|
79664544|NCT00419835|Drug|losartan|
79664545|NCT00328809|Drug|spironolactone|spironolactone administered to ESRD patients at low dose
79664546|NCT00303641|Device|Medtronic Resting Heart Bypass System|
79664547|NCT00420030|Drug|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
79664548|NCT00303758|Drug|cisplatin|
79664549|NCT00303758|Drug|fluorouracil|
79664550|NCT00303758|Drug|gemcitabine hydrochloride|
79664551|NCT00303758|Drug|leucovorin calcium|
79664552|NCT00332280|Drug|AMT2003|
79664553|NCT00303797|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
79664554|NCT00303797|Drug|sorafenib tosylate|
79664555|NCT00420069|Device|MRTX device|device for ventilation
79664556|NCT00303836|Drug|cyclophosphamide|Given IV
79502551|NCT03584568|Behavioral|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
79664557|NCT00303836|Drug|fludarabine phosphate|Given IV
79664558|NCT00303836|Biological|therapeutic autologous lymphocytes|Given IV
79664559|NCT00303836|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
79664560|NCT00303836|Biological|gp100 antigen|Given SC
79664561|NCT00303836|Biological|MART-1 antigen|Given SC
79664562|NCT00303836|Biological|incomplete Freund's adjuvant|Given SC
79664563|NCT00303836|Biological|filgrastim|Given SC
79817251|NCT00741039|Biological|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
79817252|NCT02595801|Other|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
79817253|NCT04019769|Drug|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
79817254|NCT02583555|Behavioral|Interview followed by frequent telephone support|Interview followed by telephone support
79817255|NCT02583321|Device|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
79989044|NCT06171334|Device|Remote ischemic conditioning|The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
79350988|NCT01841073|Dietary Supplement|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
79664564|NCT00303836|Biological|aldesleukin|Given IV
79989045|NCT06171321|Drug|S-1(Intravenous combined with oral)|Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
79350989|NCT01841073|Dietary Supplement|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
79350990|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
79350991|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
79350992|NCT01841073|Dietary Supplement|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
79502552|NCT03584568|Other|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
79502553|NCT03020238|Procedure|BiClamp group|electric energy
79502554|NCT03020238|Procedure|water jet group|water jet energy
79664565|NCT00303875|Behavioral|behavioral dietary and exercise intervention|
79664566|NCT00420186|Drug|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
79664567|NCT00420225|Device|Low-weight prolypropylene mesh|
79664568|NCT00303992|Biological|trastuzumab|
79664569|NCT00303992|Drug|irinotecan hydrochloride|
79664570|NCT00304226|Drug|valsartan|
79664571|NCT00304226|Drug|amlodipine|
79664572|NCT00420264|Device|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
79664573|NCT00304304|Behavioral|Asthma education|Research assistant worked with CCC staff on asthma prevention
79664574|NCT00332319|Drug|GW679769|
79664575|NCT00304382|Biological|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
79664576|NCT00304382|Biological|Pneumovax|0.5 ml IM one time
79502555|NCT04405128|Diagnostic Test|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called 'Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
79502556|NCT04405128|Diagnostic Test|Brain MRI|Brain MRI for investigation of brain tIssue motion in the presence of acute acquired brain injury.
79664577|NCT00328848|Behavioral|Behavioral|Group Treatment(patient education, self management support, caregiver support)
79502557|NCT03584412|Behavioral|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
79664578|NCT00328848|Behavioral|behavioral|patient education, self management support, caregiver support
79664579|NCT00304421|Drug|rabeprazole|
79664580|NCT00304421|Drug|pantoprazole|
79664581|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
79664582|NCT00332397|Device|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
79664583|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
79664584|NCT00304460|Biological|aldesleukin|
79664585|NCT00304499|Drug|Oxybutynin|
79664586|NCT00328887|Genetic|CD40 Gene Transfer|gene transfer, intratumoral administration
79664587|NCT00304538|Drug|very low dose (VLD) glucagon|
79664588|NCT00420498|Drug|Atomoxetine (Strattera™)|
79664589|NCT00304577|Procedure|Bilateral recession|
79664590|NCT00304577|Procedure|Unilateral recession and resection|
79664591|NCT00328965|Drug|Lacidipine|Lacidipine 2, 4, 6mg
79817256|NCT02583321|Device|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
79989046|NCT06171308|Device|Traditional Chinese moxibustion apparatus|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
79502558|NCT03584412|Other|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
79502559|NCT03155646|Drug|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
79664592|NCT00304616|Drug|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
79989047|NCT06171295|Diagnostic Test|Blood draw|The blood draws in specified time points
79989048|NCT06171282|Drug|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
79664593|NCT00332436|Drug|brimonidine/timolol fixed combination|
79664594|NCT00304655|Drug|Aripiprazole|
79350993|NCT01841073|Dietary Supplement|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
79350994|NCT01809327|Drug|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
79350995|NCT01809327|Drug|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
79664595|NCT00329004|Drug|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
79664596|NCT00304733|Device|cast vs. shoe|
79350996|NCT01809327|Drug|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
79350997|NCT03272139|Drug|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
79350998|NCT03272139|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
79350999|NCT01808313|Drug|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
79664597|NCT00332514|Behavioral|telephone call by a pharmacist|
79664598|NCT00332553|Drug|Raloxifene|
79664599|NCT00332553|Drug|medroxyprogesterone acetate|
79664600|NCT00332553|Drug|estrogen|
79817257|NCT04454229|Other|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
79989049|NCT06171243|Drug|Lidocaine topical|"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~10 grams will be applied every 12 hours for a period of 48 hours."
79351000|NCT01840605|Drug|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
79989050|NCT06171230|Other|Eye Movement Desensitization and Reprocessing|Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.
79502560|NCT03155646|Drug|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
79502561|NCT03155646|Drug|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
79502562|NCT03584178|Device|Budesonide via MAD device|Delivery through Mucosal Atomization Device
79989051|NCT06171230|Other|Attention control phase|Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
79989052|NCT06171217|Drug|Hydroxyurea|Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
79989053|NCT06171217|Drug|Hydroxyurea|Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
79989054|NCT06171204|Procedure|Injection of SVF in fat pad of the knee|Knee fat pad injection with SVF at orthopaedics/physical medicine outpatient clinic
79989055|NCT06171139|Other|Counseling Tool|Non-therapeutic educational intervention
79664601|NCT00332553|Drug|17 beta estradiol|
79664602|NCT00329121|Drug|PEP005|
79664603|NCT00332631|Drug|N-acetylcysteine|
79989056|NCT06171139|Other|Questionnaires|Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
79989057|NCT06171126|Dietary Supplement|Faeces|Faeces from donor selected based on European guidelines, compared to own faeces (placebo)
79664604|NCT00332631|Drug|Placebo|
79664605|NCT00304772|Drug|Fluconazole|400mg/day
79989058|NCT06171100|Drug|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
79989059|NCT06171087|Drug|Domperidon|oral
79989060|NCT06171087|Drug|Placebo|oral tablet
79989061|NCT06171074|Biological|CM310|CM310 injection
79989062|NCT06171061|Drug|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
79989063|NCT06171061|Other|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
79989064|NCT06171048|Biological|CM310|CM310 injection
79351001|NCT01840605|Drug|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
79351002|NCT04593381|Radiation|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
79351003|NCT02023879|Drug|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
79502563|NCT03584178|Device|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
79502564|NCT04405206|Drug|Oxaliplatin|OXA 130mg/m2
79502565|NCT04405206|Drug|Capecitabine|Cape 1000mg/m2
79502566|NCT04405206|Radiation|intensity modulated radiotherapy|IMRT 50.4Gy/22f
79502567|NCT04405206|Procedure|DRE-Endoscopy-MRI-CEA|examination process in follow up
79502568|NCT04405206|Procedure|Nonoperative Management|Watch and Wait
79502569|NCT04405206|Procedure|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
79502570|NCT04405206|Procedure|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
79502571|NCT04405206|Behavioral|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
79502572|NCT03101046|Drug|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
79502573|NCT03101046|Drug|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
79502574|NCT03152448|Behavioral|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
79664606|NCT00304772|Drug|Micafungin|150mg/day
79664607|NCT00332670|Procedure|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
79664608|NCT00332670|Procedure|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
79664609|NCT00304811|Drug|Vancomycin|
79664610|NCT00304811|Drug|Vancomycin plus Gentamicin|
79664611|NCT00304811|Drug|Vancomycin plus Rifampin|
79664612|NCT00304811|Drug|Vancomycin plus Gentamicin plus Rifampin|
79664613|NCT00332787|Drug|Fluoxetine|
79664614|NCT00304850|Behavioral|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
79989065|NCT06171009|Behavioral|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
79502575|NCT03159936|Biological|Tofacitinib citrate|10 mg daily by mouth
79989066|NCT06171009|Behavioral|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
79989067|NCT06170996|Behavioral|Internet-Assisted behavioral parent training (IA-BPT)|Internet-Assisted behavioral parent training in group format, 8 sessions over 2 months, delivered by systematically trained and supervised psychologists.
79502576|NCT03027414|Drug|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
79502577|NCT03027414|Device|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
79502578|NCT03156816|Drug|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
79989068|NCT06170983|Drug|Azithromycin|500 mg once daily for 3 days
79989069|NCT06170983|Diagnostic Test|Biopsy|Skin punch biopsy
79989070|NCT06170983|Other|Skin inflammation model|LPS- or imiquimod induced skin inflammation
79664615|NCT00304850|Drug|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
79989071|NCT06170970|Drug|Solriamfetol|solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)
79502579|NCT03156816|Drug|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
79502580|NCT03583944|Drug|Eribulin Mesylate|Eribulin mesylate IV infusion.
79502581|NCT02841696|Device|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
79502582|NCT04764786|Other|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
79502583|NCT04764786|Other|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
79664616|NCT00329199|Behavioral|Attachment-Based Family Therapy|
79989072|NCT06170970|Drug|Placebo|Four weeks of oral placebo
79989073|NCT06170957|Other|Modified pacifier|"In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times."
79989074|NCT06170931|Procedure|posterior cruciate ligament-retaining prostheses|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
79989075|NCT06170931|Procedure|posterior cruciate ligament-substituting prostheses|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
79989076|NCT06170918|Drug|Remimazolam|remimazolam is given intravenously
79502584|NCT03159546|Device|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
79502585|NCT03159858|Device|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
79502586|NCT03583632|Other|visual acuity testing|testing of visual ycuity by ETDRS charts
79664617|NCT00329277|Procedure|perimetry|
79664618|NCT00329316|Drug|Crinone Gel 8%|
79664619|NCT00305045|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
79664620|NCT00332826|Drug|Technosphere Insulin|
79664621|NCT00305201|Drug|pravastatin|
79664622|NCT00332865|Behavioral|Swallowing Exercises|Daily exercises
79664623|NCT00305240|Procedure|T Wave Alternans Test|
79664624|NCT00329355|Drug|sumatriptan succinate/naproxen sodium|
79502587|NCT03583632|Device|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
79664625|NCT00305279|Other|Dietary|Dietary
79351004|NCT02023879|Drug|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
79351005|NCT02023879|Drug|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
79351006|NCT02023879|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
79502588|NCT03583476|Drug|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
79502589|NCT03583398|Procedure|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
79502590|NCT03583320|Diagnostic Test|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
79664626|NCT00305279|Other|Dietary|Dietary
79664627|NCT00305279|Other|Dietary|Dietary
79817258|NCT04454229|Other|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
79817259|NCT02583087|Procedure|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
79664628|NCT00332904|Drug|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
79989077|NCT06170892|Other|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
79664629|NCT00332904|Drug|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
79351007|NCT04417153|Behavioral|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
79351008|NCT02014441|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
79664630|NCT00329394|Drug|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
79664631|NCT00305396|Drug|Sirolimus|
79664632|NCT00332943|Procedure|MR colonography with fecal tagging|
79664633|NCT00305435|Drug|Romiplostim (AMG-531)|Romiplostim (AMG-531)
79664634|NCT00329472|Drug|gemcitabine, cisplatin|
79664635|NCT02960399|Biological|Zostavax®|Zostavax® immunization
79664636|NCT00332982|Behavioral|Focused knowledge translation strategies|
79664637|NCT00305474|Drug|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
79664638|NCT00329511|Drug|methyldopa vs. clonidine|Comparison of compliance
79664639|NCT00329511|Drug|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
79351009|NCT02013817|Drug|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
79351010|NCT02013817|Drug|fludarabine|Every 4 weeks, 6 cycles
79351011|NCT02013817|Drug|cyclophosphamide|Every 4 weeks, 3 cycles
79351012|NCT01994863|Device|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
79351013|NCT01994863|Device|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
79351014|NCT02023099|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
79351015|NCT02023099|Drug|Placebo|Tablet
79351016|NCT02013037|Drug|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
79351017|NCT01967719|Other|mTHS 2.2|Single use of mTHS 2.2
79351018|NCT01967719|Other|mCC|Single use of subject's own mCC
79351019|NCT01967719|Other|NNS|Single administration of 1 mg of nicotine
79351020|NCT04416607|Drug|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
79502591|NCT03583242|Drug|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
79502592|NCT03583242|Drug|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
79502593|NCT03078426|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
79502594|NCT03078426|Other|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
79989078|NCT06170866|Behavioral|Socially supported physical activity|Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
79351021|NCT04416607|Drug|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
79351022|NCT01967173|Drug|Flovent Diskus® 100 mcg|Flovent is an ICS
79351023|NCT01967173|Drug|Flovent Diskus® 250 mcg|Flovent is an ICS
79351024|NCT01967173|Drug|Flovent Diskus® 500 mcg|Flovent is an ICS
79502595|NCT03159312|Behavioral|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
79502596|NCT05701410|Diagnostic Test|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
79664640|NCT00305513|Procedure|The phasic alerting treatment|
79664641|NCT00333021|Drug|Fondaparinux sodium|
79351025|NCT01967173|Drug|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
79664642|NCT00333021|Drug|GSK576428|
79664643|NCT00305552|Drug|THALIDOMIDE|THALIDOMIDE
79664644|NCT00329589|Drug|Velcade (bortezomib)|
79989079|NCT06170853|Other|Exercise with augmented reality glasses|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
79989080|NCT06170827|Drug|AIO-001|AIO-001 Solution for SC injection.
79351026|NCT01967173|Drug|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
79351027|NCT01994629|Biological|MenACWY-CRM|MenACWY-CRM
79351028|NCT01994629|Biological|MenACWY-TT|MenACWY-TT
79351029|NCT01994395|Device|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
79989081|NCT06170814|Other|Exercise|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
79502597|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
79502598|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
79502599|NCT05703126|Diagnostic Test|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
79664645|NCT00305591|Drug|l-ornithine l-aspartate|
79502600|NCT05703126|Diagnostic Test|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
79502601|NCT05703126|Diagnostic Test|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
79502602|NCT05703126|Diagnostic Test|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
79502603|NCT05703126|Diagnostic Test|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
79502604|NCT05703126|Diagnostic Test|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
79502605|NCT05703126|Diagnostic Test|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
79502606|NCT05703126|Diagnostic Test|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
79502607|NCT05703126|Diagnostic Test|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
79664646|NCT00333060|Drug|OT-551 ophthalmic solution|
79664647|NCT00305630|Drug|Periocular injection of triamcinolone acetonide 40mg|
79664648|NCT00329628|Drug|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
79664649|NCT00329628|Drug|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
79664650|NCT00305669|Biological|sargramostim|
79664651|NCT00305669|Other|immunohistochemistry staining method|
79664652|NCT00305669|Other|immunological diagnostic method|
79664653|NCT00305669|Other|laboratory biomarker analysis|
79664654|NCT00305669|Procedure|conventional surgery|
79664655|NCT00305669|Procedure|neoadjuvant therapy|
79664656|NCT00333099|Dietary Supplement|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
79664657|NCT00333099|Other|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
79664658|NCT00305708|Biological|anti-thymocyte globulin|
79664659|NCT00305708|Drug|busulfan|
79502608|NCT05703126|Diagnostic Test|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
79502609|NCT05703126|Diagnostic Test|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
79502610|NCT05703126|Diagnostic Test|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
79502611|NCT05703126|Diagnostic Test|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
79502612|NCT05703126|Diagnostic Test|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
79502613|NCT05703126|Diagnostic Test|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
79502614|NCT03155334|Other|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~individual reading of the text;~individual questionnaire for a quantitative and qualitative evaluation;~a brief semi-structured interview to each participant;~a text revision to address any problems identified from participant feedback."
79502615|NCT03582696|Behavioral|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
79502616|NCT03159390|Other|phenylacetate salt of ornithine|
79502617|NCT03159156|Behavioral|Applied Tension|Described above.
79502618|NCT03159156|Behavioral|Respiration Control|Described above.
79502619|NCT03159156|Behavioral|Applied Tension/Respiration Control|Described above.
79502620|NCT03582306|Behavioral|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
79502621|NCT03582306|Behavioral|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
79502622|NCT05629182|Other|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
79502623|NCT03582228|Behavioral|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
79502624|NCT03159234|Radiation|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
79502625|NCT03159234|Radiation|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
79502626|NCT03159234|Radiation|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
79502627|NCT03020316|Behavioral|Peer Mentor|A volunteer with a similar disease as the subject
79502628|NCT03020316|Behavioral|Transcendental Meditation|A meditation technique
79502629|NCT03158844|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
79664660|NCT00305708|Drug|fludarabine phosphate|
79502630|NCT05628246|Other|Telemedicine|Telemedicine
79351030|NCT01994395|Other|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
79502631|NCT05628246|Other|In-person|In-person
79502632|NCT05701332|Biological|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
79502633|NCT03582072|Behavioral|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.*
79502634|NCT03581994|Diagnostic Test|DDI Test Report|Test results of simulated patients
79351031|NCT01992536|Biological|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
79351032|NCT01992536|Biological|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
79351033|NCT01992536|Biological|Placebo|Saline solution for injection (0.5mL)
79502635|NCT03581916|Drug|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
79502636|NCT03154866|Dietary Supplement|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
79351034|NCT01993927|Drug|Voglibose|Voglibose Tablets / Voglibose OD Tablets
79351035|NCT02015390|Procedure|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
79351036|NCT02015390|Procedure|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
79351037|NCT02012959|Drug|Tolvaptan|
79502637|NCT03154866|Dietary Supplement|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
79502638|NCT03581838|Behavioral|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
79664661|NCT00305708|Procedure|allogeneic bone marrow transplantation|
79664662|NCT00305708|Procedure|peripheral blood stem cell transplantation|
79664663|NCT00305708|Procedure|umbilical cord blood transplantation|
79664664|NCT00305708|Radiation|radiation therapy|
79664665|NCT04716543|Diagnostic Test|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
79664666|NCT00305747|Drug|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
79664667|NCT00333255|Drug|Nepafenac Ophthalmic Suspension, 0.1%|
79664668|NCT00305786|Drug|gemcitabine hydrochloride|
79664669|NCT00305786|Drug|oxaliplatin|
79351038|NCT01990742|Behavioral|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
79502639|NCT03581682|Other|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
79502640|NCT03157986|Other|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
79502641|NCT03157986|Other|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
79502642|NCT03158142|Drug|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
79502643|NCT05701176|Diagnostic Test|[18F]F-AraG PET scan|[18F]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
79502644|NCT03154944|Device|Ostomy device 1|This device consists of a known adhesive and a new top film
79502645|NCT03154944|Device|Ostomy device 2|This device consists of a new adhesive and a known top film
79664670|NCT00329667|Device|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
79664671|NCT00305825|Biological|bevacizumab|
79664672|NCT00305825|Drug|letrozole|
79664673|NCT00333294|Drug|Gefitinib|
79351039|NCT02012491|Drug|Misoprostol|
79351040|NCT02012491|Drug|Mifepristone|
79351041|NCT01990664|Device|senofilcon A|
79351042|NCT01990664|Device|senofilcon A for Astigmatism|
79351043|NCT04416139|Biological|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
79351044|NCT02038010|Drug|PI3K inhibitor BYL719|Given PO
79351045|NCT02038010|Biological|ado-trastuzumab emtansine|Given IV
79351046|NCT02038010|Other|pharmacological study|Correlative studies
79351047|NCT02038010|Other|laboratory biomarker analysis|Optional correlative studies
79351048|NCT04416698|Behavioral|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
79351049|NCT04416698|Behavioral|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
79351050|NCT04178798|Drug|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
79502646|NCT03154944|Device|Ostomy device 3|This device consists of a known adhesive and a new top film
79664674|NCT00333294|Procedure|Radiation therapy|
79664675|NCT00333294|Drug|Cisplatin|
79664676|NCT00333294|Drug|Vinorelbine|
79664677|NCT00305903|Drug|Rivastigmine, memantine|
79664678|NCT00329706|Procedure|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
79664679|NCT00329823|Drug|Etanercept sc 50mg per week for 12 weeks|
79664680|NCT00306020|Drug|topical morphine|
79351051|NCT01989572|Other|Laboratory Biomarker Analysis|Correlative studies
79351052|NCT01989572|Other|Placebo|Given GM-CSF placebo SC
79351053|NCT01989572|Other|Placebo|Given peptide placebo SC
79664681|NCT00329862|Procedure|Laparoscopic Truncal Vagotomy|
79664682|NCT00306137|Drug|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~Stratum 1: complete primary pneumonectomy~Stratum II: decortication or completion pneumonectomy~Stratum III: esophagectomy by transhiatal approach~Stratum IV: esophagectomy by transthoracic approach"
79664683|NCT00306137|Drug|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
79664684|NCT00329940|Drug|Letrozole|
79351054|NCT01989572|Biological|Sargramostim|Given SC
79502647|NCT03028740|Drug|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
79502648|NCT03028740|Drug|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
79502649|NCT03157596|Other|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD & methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
79502650|NCT03154632|Device|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
79351055|NCT01989572|Biological|Tyrosinase Peptide|Given SC
79351056|NCT04416776|Drug|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
79502651|NCT03154632|Device|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
79351057|NCT02036294|Other|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
79502652|NCT03027648|Procedure|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
79502653|NCT05252520|Drug|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
79502654|NCT03886584|Other|Monitoring source test|Internal- and external-monitoring correct responses and inversions
79502655|NCT01670448|Procedure|PECBLOCK under echoguidance|Performance of block under echography
79502656|NCT01670682|Procedure|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
79664685|NCT00306176|Drug|Rosiglitazone|
79351058|NCT02036294|Other|Usual Care|Standard Healthcare Services
79351059|NCT02035748|Drug|Ocriplasmin|0.5 mg/0.2 mL solution for injection
79351060|NCT02014376|Drug|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
79351061|NCT02014376|Drug|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
79351062|NCT02014376|Drug|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
79351063|NCT02035202|Behavioral|CBT2go|CBT administered using mobile intervention.
79664686|NCT00333333|Procedure|Cord blood|Cord blood will be obtained at the time of delivery.
79664687|NCT00329979|Behavioral|vascular access site|Randomized vascular access site
79664688|NCT00333372|Drug|Z-338|
79664689|NCT00330018|Drug|Valganciclovir|Valganciclovir
79664690|NCT00330018|Drug|Acyclovir|Acyclovir
79664691|NCT00333450|Biological|Pneumococcal vaccine|
79664692|NCT00306254|Drug|PD 0348292|
79664693|NCT00306254|Drug|Enoxaparin|
79664694|NCT00333489|Drug|valsartan|
79664695|NCT00333528|Drug|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
79664696|NCT00333528|Drug|Placebo: Normal saline|Intramuscular administration
79664697|NCT03275753|Other|Visual Function Tests|All subjects will undergo a battery of visual function tests
79664698|NCT00330096|Drug|Hesperidin|
79351064|NCT02035202|Device|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
79351065|NCT01988402|Drug|allopurinol|
79664699|NCT00330096|Other|Placebo|
79664700|NCT03275714|Device|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
79664701|NCT00330135|Drug|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
79664702|NCT00330135|Drug|placebo injection|placebo injection - 1 injection
79664703|NCT03275558|Drug|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
79664704|NCT03275558|Drug|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
79351066|NCT01988402|Drug|Placebo (sugar pill)|
79351067|NCT01988090|Drug|800 IU Vitamin D Supplement|Standard Dose
79989082|NCT06170801|Behavioral|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
79351068|NCT01988090|Drug|50,000 IU Vitamin D supplement|High Dose
79351069|NCT01988012|Biological|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
79351070|NCT02011945|Drug|Dasatinib|
79817260|NCT04436055|Other|No Intervention will be used|Since this is an observational study, there are no interventions.
79351071|NCT02011945|Drug|Nivolumab|
79664705|NCT03275558|Drug|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
79817261|NCT02583165|Biological|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
79817262|NCT00772382|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
79351072|NCT04666909|Diagnostic Test|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP > 135 mm Hg or DBP > 85 mmHg (based on the average of 3 BP readings); or average SBP > 130 mm Hg or DBP > 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
79351073|NCT02013830|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
79351074|NCT02013830|Drug|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
79351075|NCT02010775|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
79351076|NCT02010775|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
79351077|NCT01993615|Procedure|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
79351078|NCT01993615|Procedure|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
79351079|NCT01619059|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
79351080|NCT01619059|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
79351081|NCT01619059|Drug|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
79664706|NCT00330213|Behavioral|red wine and cognac consumption|
79664707|NCT03275519|Other|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
79664708|NCT03275519|Other|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
79664709|NCT00333567|Drug|Lumiracoxib|
79817263|NCT02582931|Device|MRI-guided SBRT|
79817264|NCT02582931|Behavioral|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
79817265|NCT02582931|Behavioral|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
79817266|NCT04102748|Procedure|I-incision, M-flap and conventional implant exposure techniques|Implant uncovering in the second stage using 3 different exposure techniques
79502657|NCT01670682|Procedure|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
79502658|NCT01670682|Device|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
79817267|NCT04078659|Drug|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
79664710|NCT02956694|Behavioral|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
79664711|NCT00330252|Drug|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
79817268|NCT04078659|Drug|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
79351082|NCT01619059|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
79664712|NCT00330252|Drug|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
79351083|NCT04691804|Drug|Fuzuloparib , Abiraterone acetate and Prednisone|"Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~Prednisone tablets (strength: 5 mg) 5mg, Bid po"
79351084|NCT04691804|Drug|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~Prednisone tablets (strength: 5 mg)5mg, Bid po"
79351085|NCT04416997|Procedure|Blood and serum samples|The blood and serum samples will taken from RA patients
79351086|NCT04176757|Drug|ZN-c5|ZN-c5 study drug to be administered orally daily
79351087|NCT02013206|Drug|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
79664713|NCT00333645|Drug|Caspofungin|
79664714|NCT04698473|Other|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
79351088|NCT04690634|Procedure|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
79351089|NCT04416854|Procedure|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
79351090|NCT04416854|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
79817269|NCT04078659|Drug|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
79351091|NCT04416854|Drug|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
79351092|NCT01807923|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
79817270|NCT04078659|Drug|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
79351093|NCT01807923|Drug|Ivacaftor|Film-coated tablet
79351094|NCT01807923|Drug|Placebo|Matching placebo tablet
79351095|NCT01966003|Drug|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
79351096|NCT01966003|Drug|Paclitaxel|Administered 200 mg/m² IV Q3W
79351097|NCT01966003|Drug|ABP 215|Administered 15 mg/kg Q3W by IV infusion
79351098|NCT01966003|Drug|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
79351099|NCT01839279|Drug|Tizanidine|
79351100|NCT01839279|Drug|Placebo|
79351101|NCT01839279|Drug|Moxifloxacin|
79351102|NCT01807299|Dietary Supplement|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
79351103|NCT01807299|Other|Physical Training|
79502659|NCT01670994|Biological|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
79502660|NCT03157752|Behavioral|Quality of life questionnaire|Quality of life questionnaire
79502661|NCT03157908|Device|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
79502662|NCT03028896|Procedure|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
79817271|NCT04078659|Drug|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
79817272|NCT04078659|Drug|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
79351104|NCT01965535|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
79351105|NCT01965535|Drug|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing < 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
79351106|NCT01965535|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
79351107|NCT01965535|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
79502663|NCT03157440|Diagnostic Test|Ring oxymetry|a new type oxymetry wear on index finger like a ring
79502664|NCT03157050|Other|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
79502665|NCT03156972|Procedure|Replacment of mitral valve|Mitral valve replacment by prothsis
79502666|NCT01671072|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
79502667|NCT01671072|Drug|Normal Saline|Sodium chloride 0.9%, 3.5ml
79817273|NCT04078659|Procedure|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
79989083|NCT06170801|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
79351108|NCT04659577|Behavioral|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
79502668|NCT01671150|Drug|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
79502669|NCT03156738|Drug|MT-2990|Subjects will receive a single IV dose of MT-2990
79502670|NCT03156738|Drug|Placebo|Subjects will receive a single IV dose of placebo
79351109|NCT01964755|Drug|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
79351110|NCT01964755|Drug|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
79351111|NCT01964755|Drug|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
79502671|NCT01671228|Other|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
79502672|NCT01671228|Other|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
79502673|NCT01671228|Other|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
79664715|NCT04698473|Other|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
79664716|NCT00330291|Drug|Xyrem|
79664717|NCT04698707|Other|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
79664718|NCT04698707|Other|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
79664719|NCT00451100|Drug|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
79817274|NCT02583243|Behavioral|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
79664720|NCT00451100|Drug|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
79989084|NCT06170775|Other|Pulp therapy|Pulp capping material
79989085|NCT06170775|Drug|Sodiumhexametaphosphate|Sodiumhexametaphosphate
79989086|NCT06170775|Other|MTA|MTA
79989087|NCT06170762|Other|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
79989088|NCT06170762|Drug|Sodiumhexametaphosphate|Sodiumhexametaphosphate
79664721|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 100 and 150
79664722|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
79989089|NCT06170762|Other|MTA|MTA
79989090|NCT06170723|Drug|BMS-986368|Specified dose on specified days
79989091|NCT06170723|Drug|Itraconazole|Specified dose on specified days
79989092|NCT06170723|Drug|Famotidine|Specified dose on specified days
79989093|NCT06170710|Drug|Anti-PD-1 monoclonal antibody|"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"
79989094|NCT06170710|Other|Postoperative CCRT|Postoperative chemoradiotherapy
79989095|NCT06170658|Device|Test Lenses|Daily disposable, silicone hydrogel investigational lenses for one week
79989096|NCT06170658|Device|Control Lenses|Daily disposable, hydrogel commercially available lenses for one week
79351112|NCT01964755|Biological|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
79351113|NCT01964755|Drug|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
79351114|NCT01964755|Drug|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
79502674|NCT01671384|Drug|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
79989097|NCT06170593|Drug|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
79989098|NCT06170580|Diagnostic Test|Conventional duplex|Conventional carotid duplex measurement
79989099|NCT06170580|Diagnostic Test|Ultrasound-based flow imaging using plane wave imaging|Ultrasound-based flow imaging using plane wave imaging
79664723|NCT00420537|Drug|Mycophenolate mofetil|mycophenolate with low doses
79664724|NCT00420537|Drug|Everolimus|
79664725|NCT00451139|Drug|artemether/lumefantrine|
79664726|NCT00451139|Drug|quinine|
79989100|NCT06170580|Diagnostic Test|Ultrasound-based flow imaging using cascaded wave imaging|Ultrasound-based flow imaging using cascaded wave imaging
79989101|NCT06170541|Device|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
79989102|NCT06170541|Device|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
79664727|NCT00451139|Drug|atovaquone/proguanil|
79989103|NCT06170528|Device|AURA_ALZ|AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
79989104|NCT06170515|Diagnostic Test|CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)|BGM Test
79989105|NCT06170515|Diagnostic Test|Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)|HbA1c Test
79351115|NCT01964521|Device|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
79351116|NCT04416295|Device|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
79351117|NCT01991743|Drug|Group 2.5|Administration of bupivacaine 2.5 mg.
79664728|NCT00333684|Device|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
79664729|NCT00451256|Drug|AVI-5126|
79664730|NCT00330330|Drug|ISIS 113715|
79664731|NCT00330408|Behavioral|GP training|
79664732|NCT00451295|Drug|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
79664733|NCT00451295|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
79351118|NCT01991743|Drug|Group 5|Administration of 5 mg bupivacaine
79351119|NCT01991743|Drug|Group 7.5|Administration of 7.5 mg bupivacaine
79351120|NCT01991743|Drug|Group 10|Administration of 10mg bupivacaine.
79351121|NCT01991197|Drug|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
79351122|NCT01991197|Drug|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
79351123|NCT01991197|Drug|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
79351124|NCT01991197|Drug|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
79351125|NCT01990573|Drug|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
79351126|NCT01990573|Drug|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
79351127|NCT01990573|Other|control no methadone|The control group will not receive methadone.
79351128|NCT01990495|Other|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
79351129|NCT01990495|Other|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
79664734|NCT00330486|Drug|Acamprosate|
79502675|NCT01671384|Drug|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
79664735|NCT00451373|Device|CVVH and SLED|
79664736|NCT00451373|Drug|Vancomycin|
79989106|NCT06170502|Device|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
79664737|NCT00451373|Drug|Daptomycin|
79664738|NCT00451373|Device|FX60, AV600 (dialyzer)|
79817275|NCT02583243|Drug|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
79817276|NCT02583009|Drug|PAC-14028 cream 0.1%|Topical application
79817277|NCT02583009|Drug|PAC-14028 cream 0.3%|Topical application
79351130|NCT01990339|Drug|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
79351131|NCT02007577|Drug|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
79351132|NCT02007577|Drug|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
79351133|NCT01990261|Drug|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
79989107|NCT06170424|Procedure|spray skin|The patients who used the autologous skin cell suspension combined with skin grafting.
79351134|NCT04658095|Device|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
79989108|NCT06170424|Procedure|Control group|The patients who used skin grafting.
79989109|NCT06170411|Device|Elexir (program1)|The Elexir is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as Trigeminal Nerve Stimulation. The Elexir will deliver trigeminal nerve stimulation.
79351135|NCT04658095|Device|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
79351136|NCT04658095|Device|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
79351137|NCT01963117|Radiation|Combined hyperthermia and radiation therapy|
79351138|NCT02006719|Biological|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
79351139|NCT02006719|Other|Placebo|Placebo injection
79351140|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
79351141|NCT01962493|Other|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
79351142|NCT01962493|Drug|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
79351143|NCT01989169|Drug|Midazolam|
79351144|NCT01989169|Drug|SSP-004184SS|
79664739|NCT00333723|Drug|Rosiglitazone|
79351145|NCT01988779|Drug|oral levofloxacin|
79351146|NCT01988779|Drug|nebulized levofloxacin|
79351147|NCT01988233|Behavioral|BAILAMOS© Dance Program|
79664740|NCT00451412|Drug|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
79664741|NCT00451412|Drug|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
79664742|NCT04717245|Drug|Promestriene Vaginal|Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
79664743|NCT04717245|Other|Fractional CO2 LASER|"LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1"
79817278|NCT02583009|Drug|PAC-14028 cream 1.0%|Topical application
79817279|NCT02583009|Drug|PAC-14028 cream vehicle|Topical application
79817280|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
79817281|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
79664744|NCT04717245|Other|Microablative Fractional radiofrequency|"Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third."
79989110|NCT06170411|Device|sham device|The sham device will deliver sham trigeminal nerve stimulation.
79989111|NCT06170359|Procedure|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score >4.
79351148|NCT01988233|Behavioral|Health Education Control Group|
79351149|NCT01987765|Drug|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
79351150|NCT01987609|Drug|Hylenex|
79502676|NCT03154164|Device|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
79502677|NCT01671540|Device|intrapulmonary percussive ventilation|
79502678|NCT01671540|Other|standard treatment|breathing control exercises
79502679|NCT01671774|Drug|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
79664745|NCT00451490|Drug|Agomelatine|
79664746|NCT00451490|Drug|Fluoxentine|
79989112|NCT06170333|Drug|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
79989113|NCT06170307|Diagnostic Test|two-dimensional speckle tracking echocardiography|The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
79351151|NCT01987609|Drug|Normal Saline|
79351152|NCT04657159|Other|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
79351153|NCT04174651|Behavioral|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
79502680|NCT01671774|Drug|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
79502681|NCT01671774|Drug|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
79502682|NCT01671774|Drug|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
79664747|NCT00330525|Drug|sibutramine|
79664748|NCT03275441|Diagnostic Test|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
79664749|NCT00333918|Drug|bromfenac ophthalmic solution|
79664750|NCT00333918|Drug|placebo comparator|
79664751|NCT04716738|Diagnostic Test|Blood analyses and coprological|We will take a blood and stool sample
79664752|NCT00451568|Drug|Metformin|500 mg 2 tablets 2 times a day
79664753|NCT00451568|Drug|Desorelle|1 tablet/day in 21 days
79664754|NCT04716465|Other|Dysautonomia|Indicators of dysautonomia
79664755|NCT00330603|Procedure|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
79664756|NCT00451646|Drug|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
79664757|NCT00451724|Drug|Intranasal ketamine|
79664758|NCT00451763|Drug|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
79351154|NCT04174651|Behavioral|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
79502683|NCT01671852|Drug|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
79502684|NCT01671852|Drug|Placebo|
79502685|NCT01672086|Device|Stelkast Surpass Acetabular System implant|
79502686|NCT03153930|Behavioral|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
79502687|NCT03153930|Behavioral|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
79664759|NCT04716348|Procedure|muscle energy technique|muscle energy technique for suboccipital muscles
79664760|NCT00330720|Device|Emergency Response System (Device)|
79664761|NCT00451841|Device|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
79664762|NCT00330798|Drug|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
79351155|NCT02013674|Biological|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
79351156|NCT01987232|Drug|Carfilzomib|Administered by intravenous infusion.
79664763|NCT00330798|Other|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
79664764|NCT00451880|Drug|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
79664765|NCT00451880|Drug|famotidine|single dose, supplied as 20-mg or 40-mg tablets
79664766|NCT00451997|Drug|Gleevec|600 mg (capsules) by mouth once daily
79664767|NCT00451997|Drug|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
79351157|NCT01987232|Drug|Carboplatin|Administered by intravenous infusion.
79664768|NCT00330993|Drug|mifepristone, misoprostol|
79664769|NCT00331032|Drug|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
79664770|NCT00331032|Drug|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
79664771|NCT00452075|Drug|erlotinib|150mg daily
79351158|NCT01987232|Drug|Etoposide|Administered by intravenous infusion.
79351159|NCT04676204|Drug|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
79351160|NCT04676204|Drug|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
79664772|NCT00331071|Drug|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
79664773|NCT00331071|Drug|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
79664774|NCT00452153|Procedure|Characterization Legionnella|"Characterisation Legionnella by polymerase chain reaction (PCR)~Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
79664775|NCT00331110|Device|Laterally-Wedged Insole with Ankle Strapping|
79664776|NCT00331110|Device|Laterally-Weged Insole|
79351161|NCT04676204|Drug|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
79351162|NCT04676204|Drug|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
79502688|NCT05547750|Drug|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
79664777|NCT02956889|Drug|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
79989114|NCT06170294|Drug|TCR-MAGE-A4 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~MAGE-A4-directed T cell receptor-engineered T Cells"
79351163|NCT04676204|Drug|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
79351164|NCT04676204|Drug|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
79351165|NCT01986920|Drug|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
79351166|NCT01986920|Drug|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
79351167|NCT01986920|Drug|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
79351168|NCT01986920|Drug|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
79351169|NCT02010632|Drug|Generic clopidogrel product Apolets®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
79351170|NCT02010632|Drug|Original clopidogrel product Plavix®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
79351171|NCT01986140|Device|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
79351172|NCT01986140|Other|Control No treatment|No treatment to prevent hair loss
79351173|NCT01986062|Drug|AR11|
79351174|NCT01986062|Drug|Placebo|
79502689|NCT05547750|Drug|Placebo|Similar-looking placebo tablets
79664778|NCT02956889|Radiation|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
79664779|NCT00333996|Drug|Dexamethasone|
79351175|NCT01985360|Procedure|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
79664780|NCT00452192|Drug|Telmisartan|telmisartan 80 mg daily over 2 weeks
79817282|NCT00798707|Drug|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
79817283|NCT02582853|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
79817284|NCT02582853|Procedure|Blood Sample|Blood sample
79817285|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
79989115|NCT06170268|Other|Routine Care Documentation|Routine Care Documentation
79351176|NCT01985360|Procedure|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
79351177|NCT01985360|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
79351178|NCT01985360|Behavioral|Lifestyle|Diet, physical activity, smoking cessation
79351179|NCT01985360|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
79351180|NCT02032706|Device|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
79502690|NCT04370106|Other|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
79664781|NCT00334035|Drug|Quetiapine|
79664782|NCT03275363|Diagnostic Test|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black & white), verbal fluency, digit forward and backward span."
79817286|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
79817287|NCT00760214|Drug|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
79989116|NCT06170255|Behavioral|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
79989117|NCT06170242|Drug|EDP-323 Dose Regimen 1|EDP-323 capsule
79989118|NCT06170242|Drug|EDP-323 Dose Regimen 2|EDP-323 capsule
79817288|NCT04078425|Drug|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
79817289|NCT04098380|Procedure|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
79351181|NCT02032238|Device|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
79351182|NCT04689074|Other|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
79351183|NCT04689074|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
79351184|NCT04689074|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
79351185|NCT04688450|Device|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
79351186|NCT01985126|Drug|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
79502691|NCT04317612|Other|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
79502692|NCT04317612|Other|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
79664783|NCT03275363|Diagnostic Test|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
79664784|NCT03275363|Biological|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
79817290|NCT04098380|Procedure|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
79817291|NCT02582541|Procedure|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
79989119|NCT06170242|Drug|Placebo|Placebo capsule
79664785|NCT03275363|Diagnostic Test|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
79664786|NCT03275363|Diagnostic Test|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
79664787|NCT00334152|Drug|casopitant|
79664788|NCT03275324|Device|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
79989120|NCT06170203|Other|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
79351187|NCT01985126|Drug|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
79351188|NCT01985126|Drug|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
79351189|NCT01985126|Drug|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
79351190|NCT01985126|Drug|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
79351191|NCT01985126|Drug|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
79351192|NCT01984892|Drug|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
79502693|NCT04244682|Device|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
79502694|NCT04200768|Other|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
79664789|NCT00334191|Drug|Sodium Bicarbonate|
79664790|NCT00334191|Drug|Placebo|
79664791|NCT04698512|Device|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
79502695|NCT04404816|Drug|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
79502696|NCT04077372|Behavioral|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
79502697|NCT04077372|Behavioral|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
79351193|NCT04416620|Other|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
79664792|NCT04698668|Device|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
79664793|NCT00334269|Behavioral|Health messaging at weekly home visits by health counsellor|
79664794|NCT00334269|Behavioral|Weekly home delivery of bottled spring water|
79664795|NCT00334269|Behavioral|Weekly afterschool physical activity program for 5-18y.o.|
79989121|NCT06170177|Procedure|Radical Cystectomy|A radical cystectomy is an operation to remove the whole bladder
79989122|NCT06170164|Diagnostic Test|Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.
79351194|NCT01807221|Drug|Finerenone (BAY94-8862)|
79351195|NCT01807221|Drug|Placebo|
79351196|NCT01807221|Drug|Inspra (eplerenone)|
79351197|NCT01838499|Biological|MEDI8968|SC injection at baseline, Week 4 and Week 8
79351198|NCT01838499|Biological|Saline|SC injection at baseline, Week 4 and Week 8
79351199|NCT01807065|Biological|sipuleucel-T|Given IV
79351200|NCT01807065|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
79502698|NCT04348968|Device|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
79502699|NCT01672398|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
79502700|NCT01672476|Drug|Placebo|Placebo
79502701|NCT01672476|Drug|Valsartan|Valsartan 80mg
79502702|NCT01672476|Drug|Fimasartan|Fimasartan 30mg
79664796|NCT00334269|Behavioral|Cooking classes and grocery store tours with dietician|
79664797|NCT00334269|Behavioral|Pedometers to track/increase weekly physical activity|
79664798|NCT04698551|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
79664799|NCT00334308|Procedure|Barley protein bread or control (casein) bread|
79664800|NCT00334347|Drug|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
79502703|NCT01672554|Drug|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
79664801|NCT00334347|Drug|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
79351201|NCT01807065|Other|laboratory biomarker analysis|Correlative studies
79664802|NCT00334386|Drug|Torasemide Prolonged Release (loop diuretic)|
79664803|NCT00334386|Drug|Torasemide Immediate Release (loop diuretic)|
79664804|NCT00452231|Drug|D-cycloserine|
79664805|NCT00452231|Behavioral|Cognitive-Behavioral Therapy|
79989123|NCT06170151|Diagnostic Test|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
79351202|NCT04583709|Device|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
79664806|NCT00334425|Drug|MENOPUR; GONAL-F|
79664807|NCT03275207|Drug|saline|an equal volume of saline
79664808|NCT03275207|Drug|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
79664809|NCT00334464|Drug|Standard of care or genotyping dosing of warfarin dosing|
79664810|NCT03275012|Drug|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and >15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
79664811|NCT03275012|Drug|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
79664812|NCT00334503|Drug|Miglitol|
79351203|NCT02031458|Drug|Atezolizumab|1200 mg IV every 3 weeks
79351204|NCT02009696|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
79502704|NCT03153696|Behavioral|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
79664813|NCT04698395|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy for children with cerebral palsy
79664814|NCT04698395|Behavioral|Regular care|customary or usual care given to any infant/toddler with cerebral palsy
79664815|NCT00334581|Drug|Irbesartan|Administration throughout the study period
79989124|NCT06170138|Other|Test product 1 - Test product 2 - Comparator product|"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."
79351205|NCT02009696|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
79502705|NCT03153540|Device|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
79664816|NCT00334581|Drug|Irbesartan|Administration throughout the study period
79817292|NCT02582541|Procedure|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
79817293|NCT00638391|Drug|Anastrozole|
79351206|NCT01806597|Biological|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
79502706|NCT03153540|Device|Sham iTBS|Sham intervention
79502707|NCT05033808|Drug|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
79502708|NCT05033808|Drug|Placebo|NaCl is given once over 15 Minutes via a central line
79502709|NCT05027256|Device|Entia Liberty|Home Monitoring solution
79664817|NCT00452270|Drug|Xylometazoline|
79664818|NCT00334620|Procedure|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
79664819|NCT00334659|Drug|apricitabine|
79664820|NCT00452465|Behavioral|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
79664821|NCT00452504|Drug|SRA-444|
79989125|NCT06170112|Other|Spinal Orthosis Application|Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
79989126|NCT06170099|Radiation|low level laser therapy|irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
79989127|NCT06170099|Device|bonny supported distal jet|distal jet distalizing appliance is supported on two paramedian screw
79351207|NCT01806597|Biological|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
79351208|NCT01806597|Biological|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
79351209|NCT02031302|Device|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
79351210|NCT01610037|Drug|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
79351211|NCT01610037|Drug|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
79351212|NCT01610037|Drug|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
79989128|NCT06170034|Behavioral|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
79351213|NCT04687514|Drug|Dulaglutide|Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
79664822|NCT00452582|Drug|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
79664823|NCT00452582|Other|Usual care|Physical therapy, occupational therapy, speech therapy
79351214|NCT04687514|Drug|Placebo|Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
79351215|NCT01806051|Drug|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
79351216|NCT01837797|Drug|Placebo|Once daily, tablets, orally
79351217|NCT01837797|Drug|Brexpiprazole 1 mg|once daily dose, tablets, orally
79351218|NCT01837797|Drug|Brexpiprazole 3 mg|once daily dose, tablets, orally
79351219|NCT01984424|Drug|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
79351220|NCT01984424|Drug|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
79351221|NCT01984424|Other|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
79351222|NCT01984424|Drug|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
79351223|NCT01984424|Other|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
79351224|NCT01984424|Drug|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
79351225|NCT01837719|Drug|Atazanavir|300-mg capsule
79817294|NCT02583867|Behavioral|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
79351226|NCT01837719|Drug|Cobicistat|150-mg tablet
79664824|NCT00452621|Procedure|blood draw|
79664825|NCT00334698|Drug|Cetirizine|
79664826|NCT00334698|Drug|Pseudoephedrine|
79664827|NCT00334698|Drug|Cetirizine with Pseudoephedrine|
79664828|NCT00334776|Biological|MART-1 antigen|
79817295|NCT02583633|Drug|Transdermal nitroglycerin|
79351227|NCT01837719|Drug|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
79664829|NCT00334776|Biological|gp100:209-217(210M) peptide vaccine|
79664830|NCT00334776|Biological|therapeutic autologous dendritic cells|
79664831|NCT00334776|Biological|tyrosinase peptide|
79664832|NCT00452660|Drug|Exjade|
79989129|NCT06170034|Other|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
79664833|NCT00452738|Behavioral|Therapy dog|
79817296|NCT02583633|Drug|nifedipine|
79989130|NCT06170008|Device|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
79351228|NCT01984268|Drug|ACTHAR|
79351229|NCT04675580|Behavioral|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
79351230|NCT04675190|Procedure|Major abdominal Surgery|Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
79351231|NCT04674800|Biological|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
79351232|NCT02031146|Procedure|Lumbar puncture|
79351233|NCT02009384|Drug|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
79351234|NCT01805037|Drug|brentuximab vedotin|Given IV
79351235|NCT01805037|Biological|rituximab|Given IV
79351236|NCT01805037|Other|laboratory biomarker analysis|Correlative studies
79664834|NCT00452738|Behavioral|Costumed character|
79664835|NCT00452738|Behavioral|Parents-only|
79664836|NCT00334854|Drug|doxorubicin hydrochloride|
79664837|NCT00334854|Drug|ifosfamide|
79664838|NCT00334854|Procedure|adjuvant therapy|
79664839|NCT00334854|Procedure|conventional surgery|
79664840|NCT00334854|Procedure|neoadjuvant therapy|
79664841|NCT00334854|Radiation|radiation therapy|
79664842|NCT03274973|Drug|Zomacton|Injection
79664843|NCT00334932|Drug|bortezomib|
79664844|NCT00334932|Drug|melphalan|
79664845|NCT00334932|Drug|pegylated liposomal doxorubicin hydrochloride|
79664846|NCT00452777|Drug|BVT.115959|
79664847|NCT00452777|Drug|Placebo|
79664848|NCT00334971|Procedure|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
79664849|NCT00452816|Behavioral|Workplace Solutions Consulting approach|"Consulting process includes:~baseline measure of best practices~gap analysis and recommendations reporting~delivery of solution set toolkits for each practice chosen for implementation"
79664850|NCT00452816|Behavioral|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
79664851|NCT00335010|Drug|Nitroglycerin|
79664852|NCT00452855|Procedure|Sevoflurane-remifentanil anaesthesia|
79664853|NCT00335088|Drug|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
79664854|NCT00452894|Drug|varenicline tartrate|
79664855|NCT00335166|Drug|Pardaprunox|12-42 mg
79664856|NCT00335166|Drug|pramipexole|1.5-4.5 mg
79664857|NCT00335166|Drug|Placebo Comparator|Placebo
79664858|NCT00452972|Drug|Spinal Anesthesia|
79664859|NCT00335205|Drug|ropinirole|
79664860|NCT00453011|Device|posterior chamber intraocular lens|
79817297|NCT04447833|Drug|Mesenchymal Stromal Stem Cells - KI-MSC-PL-205|Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
79664861|NCT00453011|Device|anterior chamber intraocular lens|
79817298|NCT02582385|Other|in-situ cytokine expression|
79817299|NCT04186689|Other|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
79502710|NCT01672632|Other|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
79351237|NCT01803711|Drug|Desvenlafaxine|
79502711|NCT04026984|Drug|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
79664862|NCT03274934|Behavioral|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
79664863|NCT03274934|Behavioral|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
79817300|NCT00638469|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
79817301|NCT00638469|Other|No treatment|no UV exposure
79351238|NCT01803711|Dietary Supplement|Omega 3 Fatty acids|
79351239|NCT01803711|Drug|Placebo (for Omega 3 fatty acid supplement)|
79989131|NCT06170008|Device|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
79351240|NCT01836549|Drug|imetelstat sodium|Given IV
79351241|NCT01836471|Drug|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
79351242|NCT01836471|Drug|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
79351243|NCT01836471|Drug|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
79502712|NCT04026984|Drug|Placebo|Matching Placebo tablets
79502713|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
79502714|NCT03153618|Other|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
79502715|NCT04275882|Diagnostic Test|Electrocardiogram|There will be no new intervention performed for the patients.
79502716|NCT04404348|Behavioral|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
79502717|NCT04404348|Behavioral|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
79664864|NCT03274934|Behavioral|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
79664865|NCT00335361|Device|Intra Vas Device (IVD)|
79664866|NCT00453050|Drug|imiquimod|
79664867|NCT00453050|Drug|indocyanine green solution|
79817302|NCT02689011|Procedure|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
79502718|NCT01672944|Other|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
79817303|NCT02689011|Procedure|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
79817304|NCT02582307|Drug|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
79817305|NCT02582307|Drug|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
79502719|NCT01672944|Other|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
79502720|NCT03152994|Other|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
79351244|NCT01836471|Drug|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
79351245|NCT02030600|Drug|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
79351246|NCT02030600|Drug|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
79502721|NCT02653248|Radiation|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
79502722|NCT04764240|Procedure|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
79502723|NCT03024528|Behavioral|CPOT assessment|Polish version of Critical care pain observation tool validation.
79664868|NCT00453050|Other|flow cytometry|
79817306|NCT02689245|Drug|Tenofovir|
79817307|NCT02689245|Drug|Fecal Microbiota Transplantation (FMT)|
79817308|NCT04187001|Other|Content Validity|Use Delphi technique for achieve consensus
79817309|NCT04187001|Other|Cultural adaptation|Adapt the content to the target population
79351247|NCT01802775|Drug|edoxaban|
79351248|NCT01802775|Drug|Clopidogrel|75mg tablet
79351249|NCT01802775|Drug|Aspirin|
79502724|NCT03153072|Biological|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
79502725|NCT03609372|Behavioral|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
79502726|NCT05394948|Dietary Supplement|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
79664869|NCT00453050|Other|immunologic technique|
79664870|NCT00453050|Other|laboratory biomarker analysis|
79664871|NCT00335400|Drug|Anesthetic Dilating Gel|
79664872|NCT00453089|Drug|VG101|
79664873|NCT00420576|Drug|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
79664874|NCT00420615|Drug|Patupilone and Omeprazole|
79664875|NCT00420615|Drug|Patupilone + Midalzolam|
79351250|NCT04591041|Device|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
79351251|NCT04591041|Other|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
79664876|NCT00453167|Drug|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
79664877|NCT00453167|Drug|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
79664878|NCT00420654|Drug|Growth Hormone|1.25 mg, 6 months
79817310|NCT00802841|Drug|nilotinib|Supplied as 200 mg tablets
79817311|NCT00802841|Drug|imatinib|Supplied as 100 mg and 400 mg tablets
79502727|NCT05394948|Dietary Supplement|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
79664879|NCT00420654|Drug|Placebo|Equivalent to 1.25 mg, 6 months
79989132|NCT06170008|Device|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
79502728|NCT03504228|Device|Roadsaver|Dual layer micromesh Roadsaver carotid stent
79664880|NCT00420654|Other|Healthy controls|Healthy controls
79664881|NCT00420693|Drug|sevoflurane|
79664882|NCT00420810|Drug|MK0928 / Duration of Treatment : 8 Weeks|
79351252|NCT01802385|Drug|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
79351253|NCT01773993|Drug|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
79351254|NCT01802073|Drug|Oral Vancomycin|
79351255|NCT01607073|Drug|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
79351256|NCT01773291|Other|acupuncture|acupuncture on GV26 and 12 Well points
79351257|NCT01773291|Other|laser acupuncture|laser acupuncture on GV26 and 12 Well points
79351258|NCT01773291|Other|control|sham laser acupuncture
79351259|NCT01801917|Drug|Placebo|Matching placebo tablet for oral administration
79664883|NCT00453323|Drug|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
79664884|NCT00453323|Drug|Capecitabine|capecitabine 900mg/m2 bid po on day 1~14, 1 weeks rest, until disease progression
79664885|NCT00335439|Drug|ketorolac tromethamine 0.5% (Acular®)|
79664886|NCT00453401|Drug|NB-001|
79664887|NCT00453440|Procedure|Cheek swab & blood test|Cheek swab & blood test
79664888|NCT04698083|Diagnostic Test|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
79664889|NCT00335595|Drug|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
79664890|NCT00335595|Drug|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
79351260|NCT01801917|Drug|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
79989133|NCT06169956|Drug|Neoadjuvant nivolumab in combination with platinum-based chemotherapy|Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
79989134|NCT06169930|Other|This was an observational study without any intervention|This was an observational study without any intervention
79351261|NCT04170075|Behavioral|Whole Body Vibration|Undergo WBV
79664891|NCT00453518|Device|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
79664892|NCT00453557|Drug|rhGH|
79664893|NCT00335673|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
79664894|NCT00335712|Drug|ONO-5129|
79664895|NCT00453635|Drug|Docetaxel|Docetaxel at the dose of 75mg/m^2 IV on day 1 every 3 weeks for 6 consecutive cycles
79664896|NCT00453635|Drug|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
79664897|NCT00453635|Drug|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
79664898|NCT00453635|Drug|Vinorelbine|Vinorelbine at the dose of 60mg/m^2 per os,weekly
79989135|NCT06169917|Behavioral|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
79351262|NCT02008916|Drug|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
79351263|NCT02008916|Drug|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
79351264|NCT01772823|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
79351265|NCT01772823|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
79351266|NCT01772823|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
79351267|NCT04177082|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
79664899|NCT00335751|Procedure|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
79664900|NCT04698278|Device|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
79664901|NCT00335790|Procedure|Hyperbaric Therapy|
79664902|NCT00335868|Drug|danusertib|
79664903|NCT00335868|Other|laboratory biomarker analysis|
79664904|NCT00335868|Other|pharmacological study|
79664905|NCT04698200|Other|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
79664906|NCT00335907|Procedure|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
79664907|NCT00335946|Device|HANS non-needle acupuncture|
79664908|NCT00335946|Procedure|Stimulation of two acupuncture points bi-lateral|
79664909|NCT00335985|Drug|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
79351268|NCT02029976|Behavioral|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
79351269|NCT02029976|Behavioral|Mailed monthly newsletters|Newsletters
79351270|NCT01983254|Behavioral|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
79351271|NCT01983254|Other|education program|web-based, ICU-specific education program
79351272|NCT01771809|Drug|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
79351273|NCT01771809|Drug|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
79351274|NCT01771731|Drug|Cannabis|
79351275|NCT01982942|Drug|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
79351276|NCT01982942|Drug|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
79351277|NCT01769469|Drug|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
79351278|NCT02008526|Behavioral|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
79351279|NCT02008526|Behavioral|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
79351280|NCT04581915|Drug|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
79351281|NCT04581915|Other|Placebo|Placebo capsule
79351282|NCT01769391|Drug|Necitumumab|Administered IV
79351283|NCT01769391|Drug|Paclitaxel|Administered IV
79664910|NCT00335985|Drug|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
79989136|NCT06169917|Behavioral|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
79351284|NCT01769391|Drug|Carboplatin|Administered IV
79351285|NCT01800903|Device|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
79351286|NCT01800903|Device|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
79351287|NCT01800903|Device|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
79351288|NCT04413747|Behavioral|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
79351289|NCT04413747|Behavioral|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
79351290|NCT04413747|Behavioral|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
79351291|NCT01767987|Drug|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
79351292|NCT01767987|Drug|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
79664911|NCT00336102|Other|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
79502729|NCT04843332|Behavioral|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
79502730|NCT01673412|Other|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
79502731|NCT03153306|Drug|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
79502732|NCT03152916|Device|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
79351293|NCT01800201|Behavioral|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
79502733|NCT01673724|Drug|pramipexole|pramipexole
79502734|NCT01673724|Drug|Bromocriptine|bromocriptine
79664912|NCT00336102|Procedure|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
79351294|NCT01767909|Drug|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
79351295|NCT01767909|Drug|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
79351296|NCT02029274|Drug|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
79502735|NCT04765098|Drug|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
79502736|NCT04765098|Drug|Etoposide|etoposide 50mg/m2 daily
79502737|NCT01673880|Drug|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
79502738|NCT01673958|Other|Exercise|Comparison between stair descending and stair ascending training
79502739|NCT01674036|Drug|Genz-682452|Capsules for oral administration.
79502740|NCT01674036|Drug|Placebo|Placebo to Genz-682452
79502741|NCT04348578|Other|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
79502742|NCT03378102|Biological|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
79502743|NCT01775046|Device|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
79664913|NCT00336102|Procedure|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
79502744|NCT03032328|Dietary Supplement|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
79502745|NCT03025464|Device|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
79351297|NCT02029274|Drug|Placebo|Matching placebo to BAF312 as tablets for oral administration.
79351298|NCT02008370|Drug|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
79502746|NCT02998164|Behavioral|augmentative and alternative communication technology|
79664914|NCT00453791|Drug|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
79989137|NCT06169917|Other|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
79351299|NCT01981616|Drug|Vedolizumab|Vedolizumab for intravenous infusion
79351300|NCT01981616|Drug|Placebo|Placebo intravenous infusion
79351301|NCT01981616|Biological|Hepatitis B vaccine|
79351302|NCT01981616|Biological|Oral cholera vaccine|
79351303|NCT02104817|Drug|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
79351304|NCT02104817|Drug|corn oil control|corn oil control arm
79351305|NCT01962103|Drug|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
79502747|NCT02998164|Behavioral|Usual Care|No change to the therapy care received
79502748|NCT02980692|Drug|SUNPG1623 I|injection
79502749|NCT02980692|Drug|SUNPG1623 II|injection
79502750|NCT02980692|Drug|SUNPG1623 III|injection
79502751|NCT02980692|Drug|SUNPG1623 IV|injection
79502752|NCT02980692|Drug|PLACEBO|injection
79502753|NCT04747392|Biological|SAL001|administrated once by subcutaneous injection
79502754|NCT04747392|Biological|FORSTEO|administrated once by subcutaneous injection
79502755|NCT03728712|Diagnostic Test|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
79502756|NCT01674192|Drug|prucalopride|single dose of 2 mg prucalopride
79502757|NCT01674270|Drug|Degarelix|
79664915|NCT00453791|Drug|Placebo|Placebo MDI will be given to the subjects.
79664916|NCT00336141|Drug|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
79664917|NCT00453830|Procedure|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
79351306|NCT01962103|Drug|nab-paclitaxel|IV infusion
79351307|NCT01961323|Drug|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
79351308|NCT04186403|Drug|Brexpiprazole|Administered as tablets.
79351309|NCT01960855|Drug|ABT-494|ABT-494 capsule administered orally twice daily (BID).
79351310|NCT01960855|Drug|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
79502758|NCT01674270|Drug|Casodex|
79502759|NCT01674270|Drug|LHRH Agonist|
79502760|NCT01674348|Drug|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
79502761|NCT01674348|Drug|Placebo|Placebo
79502762|NCT01674504|Drug|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
79502763|NCT02431104|Device|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
79502764|NCT02326116|Other|Trachael Preparation Education|
79502765|NCT01674582|Other|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
79502766|NCT05353062|Procedure|Hemostatic therapy|Bipolar hemostatic forceps
79502767|NCT05353062|Procedure|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
79502768|NCT03152370|Drug|E7046|oral administration
79502769|NCT03152370|Radiation|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
79502770|NCT03152370|Radiation|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
79502771|NCT03152370|Drug|capecitabine|chemotherapy
79502772|NCT03152370|Drug|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
79664918|NCT00336180|Behavioral|HealthWise South Africa curriculum|18 classroom lessons
79502773|NCT02187120|Drug|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
79502774|NCT02187120|Drug|Placebo|
79502775|NCT02335710|Device|Journey II BCS TKA|
79502776|NCT01674738|Drug|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
79502777|NCT01674738|Drug|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
79502778|NCT01674738|Drug|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
79989138|NCT06169904|Drug|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
79502779|NCT01674972|Other|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
79502780|NCT01675206|Dietary Supplement|Vitamin K2 supplementation|
79502781|NCT01537458|Procedure|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
79502782|NCT03150576|Drug|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
79502783|NCT03150576|Drug|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
79502784|NCT04747080|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
79502785|NCT04747080|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
79502786|NCT01675284|Biological|AT-301|Inactivated H5N1 Influenza Virion Vaccine
79502787|NCT01675362|Drug|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
79502788|NCT01675362|Drug|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
79502789|NCT01675362|Drug|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
79502790|NCT01675362|Drug|Placebo|They will receive placebo
79502791|NCT01675518|Drug|ASP7991|oral
79502792|NCT01675518|Drug|Placebo|oral
79664919|NCT02273648|Device|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
79664920|NCT00336219|Drug|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
79664921|NCT04698239|Device|LASER MILESMAN 445 NM|Laser application
79664922|NCT00453869|Other|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
79664923|NCT00336297|Procedure|Woman Abuse Screening Tool|
79664924|NCT00336297|Procedure|Partner Violence Screen|
79664925|NCT00336297|Procedure|Computerized screening|
79351311|NCT02007434|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79351312|NCT02007434|Drug|Placebo|Phosphate buffered saline placebo for injection
79351313|NCT02007434|Other|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
79351314|NCT02007434|Drug|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
79989139|NCT06169891|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
79989140|NCT06169891|Other|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
79989141|NCT06169891|Drug|Compound Betamethasone Injection|1 mL i.m. once on Day 1
79351315|NCT02007434|Drug|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
79502793|NCT03158532|Drug|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
79664926|NCT00336297|Procedure|Face to face screening|
79664927|NCT00336297|Procedure|Written screening on forms|
79502794|NCT03158532|Drug|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
79664928|NCT00453908|Drug|Alfuzosin|
79664929|NCT00336336|Drug|n-3 PUFA|1 g die per os
79664930|NCT00336336|Drug|Rosuvastatin|10 mg die per os
79817312|NCT00772148|Drug|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
79989142|NCT06169891|Other|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
79351316|NCT02007434|Drug|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
79351317|NCT02007434|Other|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
79351318|NCT01987453|Drug|LDV/SOF|Tablet(s) administered orally once daily
79351319|NCT01987453|Drug|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
79351320|NCT02006641|Drug|Placebo|Once daily, matching placebo capsules, orally
79351321|NCT02006641|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
79502795|NCT03158532|Drug|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
79502796|NCT03158532|Drug|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
79664931|NCT00336336|Drug|Placebo|1 gram c. per os
79664932|NCT00336336|Drug|Placebo|10 mg c. per os
79664933|NCT00336375|Drug|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
79664934|NCT00336414|Drug|cyclophosphamide-prednisone-azathioprine|
79664935|NCT00336453|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
79664936|NCT00336453|Biological|Influenza Vaccination|0.25mL dose for intramuscular injection
79664937|NCT00336531|Drug|itraconazole|2.5 mg/kg twice daily for the first two days --> once daily
79502797|NCT04404738|Procedure|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
79351322|NCT04416919|Other|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
79351323|NCT04652167|Diagnostic Test|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
79351324|NCT04652167|Diagnostic Test|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
79351325|NCT04652167|Diagnostic Test|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
79351326|NCT01959919|Device|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
79351327|NCT04176601|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
79351328|NCT01986985|Device|PET/MRI system|Compared to PET CT
79502798|NCT04404738|Procedure|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
79502799|NCT03879876|Drug|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
79502800|NCT01675986|Drug|hydroxyzine|75 mg
79502801|NCT01675986|Drug|Pregabalin|150 mg
79502802|NCT01675986|Drug|Lactose|4 g
79502803|NCT03155490|Behavioral|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
79351329|NCT01986907|Drug|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
79664938|NCT00453947|Device|CPAP and Non Invasive Ventilation|
79664939|NCT00454064|Behavioral|cognitive-behavioral treatment|
79664940|NCT00322062|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
79664941|NCT00322062|Drug|Sodium Phosphate Solution|1 x 45ml solution, BID
79664942|NCT00454103|Drug|123I-Iodometomidate|
79664943|NCT00336648|Drug|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
79664944|NCT00336648|Drug|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
79664945|NCT00336648|Procedure|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
79351330|NCT01959841|Drug|ASP2151|200 mg once daily or 400 mg once daily
79351331|NCT01959841|Drug|valaciclovir|1000 mg three times daily
79351332|NCT02005627|Drug|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
79351333|NCT02005627|Drug|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
79351334|NCT02104583|Drug|Eleclazine|Eleclazine tablets administered orally
79351335|NCT02104583|Drug|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
79351336|NCT02073929|Drug|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
79351337|NCT02073929|Drug|placebo|Placebo s.c. daily for 26 weeks
79351338|NCT02113007|Drug|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
79351339|NCT02104505|Drug|Gamma Tocopherol 700 mg capsules,|2 capsules daily
79351340|NCT02104505|Drug|Placebo|Safflower oil capsules
79351341|NCT02111993|Device|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
79351342|NCT02111993|Device|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
79351343|NCT01959607|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
79351344|NCT01959607|Other|CC|Single use of subject's own cigarette (CC)
79351345|NCT01959607|Other|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
79351346|NCT04186325|Procedure|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
79351347|NCT02111603|Drug|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
79351348|NCT04725851|Procedure|High concentration Oxygen therapy|FiO2 >80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
79989143|NCT06169878|Device|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
79351349|NCT04725851|Procedure|Control: Room Air or Low concentration Oxygen|FiO2 <30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
79351350|NCT02102399|Behavioral|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
79351351|NCT02102399|Behavioral|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
79664946|NCT03274817|Drug|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
79664947|NCT03274817|Drug|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
79502804|NCT03150186|Other|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
79351352|NCT02111369|Drug|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
79502805|NCT03150186|Other|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
79502806|NCT03150186|Other|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
79502807|NCT03875664|Drug|Liposomal bupivacaine|Extended-release local anesthetic
79502808|NCT03875664|Drug|Placebo - injection|Injectable normal saline solution
79664948|NCT03274817|Drug|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
79664949|NCT00322140|Drug|CDDO|
79664950|NCT00230087|Procedure|blood donation|phlebotomy until iron depleted
79664951|NCT00230204|Procedure|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
79989144|NCT06169865|Other|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
79502809|NCT01676064|Drug|ringer lactate solution|
79502810|NCT01676064|Other|restrictive fluid regime|
79664952|NCT00230321|Drug|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
79664953|NCT02959632|Behavioral|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
79351353|NCT02111369|Procedure|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
79664954|NCT00230399|Drug|Celecoxib|
79664955|NCT00230399|Drug|Capecitabine|
79664956|NCT00230399|Drug|Irinotecan|
79664957|NCT00336765|Drug|XL647|Tablets supplied in 50-mg strength administered orally daily
79664958|NCT00230438|Procedure|External Beam Radiotherapy|
79817313|NCT00772148|Drug|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
79351354|NCT02111213|Behavioral|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
79351355|NCT02111213|Behavioral|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
79351356|NCT04736303|Device|BIS|The implementation of BIS monitoring
79351357|NCT02110901|Drug|PRT-201|
79351358|NCT02110901|Drug|Placebo|
79351359|NCT02070965|Drug|DFD01 Spray|
79351360|NCT02070965|Drug|Comp01 Lotion|
79351361|NCT02109107|Device|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
79502811|NCT01670136|Drug|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
79502812|NCT01670214|Procedure|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
79502813|NCT04747002|Drug|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
79502814|NCT03873480|Procedure|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
79502815|NCT03872310|Device|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
79502816|NCT04404426|Dietary Supplement|L-citrulline|Administration of citrulline enterally for 7 days.
79502817|NCT04404426|Other|Placebo|Administration of placebo (water) enterally for 7 days
79502818|NCT04764084|Drug|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
79502819|NCT04764084|Drug|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
79502820|NCT03860922|Device|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
79502821|NCT02984904|Other|survey|survey
79502822|NCT03871530|Other|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
79664959|NCT00336843|Drug|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
79351362|NCT02100839|Drug|AEM-28|Solution for injection
79664960|NCT00230477|Drug|Hepsera|
79664961|NCT00230477|Drug|Hepsera and lamivudine|
79664962|NCT00230516|Drug|Nexium|
79989145|NCT06169839|Behavioral|Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),
79817314|NCT02582229|Device|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
79351363|NCT02100839|Drug|Normal Saline|0.9% saline for injection
79351364|NCT02069093|Drug|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
79351365|NCT02069093|Drug|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
79502823|NCT03871530|Other|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
79502824|NCT03871530|Other|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
79664963|NCT00230516|Drug|Prevacid|
79664964|NCT00336882|Drug|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
79664965|NCT00336882|Drug|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
79664966|NCT00306332|Procedure|T-cell and B-cell depletion|
79664967|NCT00336921|Drug|Alfuzosin|Once daily
79351366|NCT02069093|Drug|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
79351367|NCT02109029|Drug|Insulin Peglispro|Administered IV
79351368|NCT02109029|Drug|Human Insulin|Administered IV
79664968|NCT00336921|Drug|Placebo|Once daily
79664969|NCT00306371|Device|1450nm diode laser|
79664970|NCT00336960|Drug|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
79502825|NCT03871530|Other|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
79351369|NCT02069015|Behavioral|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
79351370|NCT04734977|Device|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
79351371|NCT04734977|Device|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
79502826|NCT03871530|Other|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
79817315|NCT02689089|Drug|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
79502827|NCT03871530|Other|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
79502828|NCT03871530|Other|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
79502829|NCT03871530|Other|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
79502830|NCT03871530|Other|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
79502831|NCT03871530|Other|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
79502832|NCT03871530|Other|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
79502833|NCT03871530|Other|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
79502834|NCT03871530|Other|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
79502835|NCT03871530|Other|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
79664971|NCT00336960|Drug|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
79664972|NCT00336960|Procedure|conventional surgery|4-10 weeks after completion of chemoradiotherapy
79989146|NCT06169839|Behavioral|Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
79351372|NCT04734977|Other|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
79502836|NCT02984826|Other|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
79502837|NCT02984826|Other|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
79664973|NCT00336960|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
79664974|NCT00336960|Procedure|tumor biopsy|at baseline and then at the time of surgical resection
79664975|NCT00336960|Other|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
79664976|NCT00306410|Drug|colecalciferol|
79989147|NCT06169839|Behavioral|Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
79351373|NCT01598129|Genetic|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
79664977|NCT00340080|Drug|Abacavir|
79664978|NCT00418535|Drug|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
79664979|NCT00337038|Drug|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
79664980|NCT02960243|Device|Deep Brain Stimulation|"DBS System Medtronic~DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~These settings will be used to evaluate effects of voice tremor as well"
79664981|NCT00418613|Drug|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
79664982|NCT00418613|Drug|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
79664983|NCT04715841|Other|gait assessment|gait assessment were done using 3DMA system
79664984|NCT02960711|Drug|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
79664985|NCT02960711|Drug|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
79502838|NCT03870048|Device|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
79664986|NCT00306449|Behavioral|Small group seminar-based educational intervention|
79351374|NCT02068547|Biological|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
79351375|NCT02068547|Biological|Bone Marrow Aspirate|
79664987|NCT00306566|Biological|CYT004-MelQbG10|
79664988|NCT00337116|Drug|iso sorbide dinitrate iv bolus or s/l|
79664989|NCT00306605|Behavioral|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
79817316|NCT00638547|Drug|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
79817317|NCT02605889|Other|Laser acupuncture|Laser acupuncture
79817318|NCT00759902|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
79817319|NCT00759902|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
79817320|NCT04077957|Drug|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
79351376|NCT02108951|Drug|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
79351377|NCT02107859|Drug|Ataluren|Ataluren will be administered per dose and schedule specified in the arm.
79351378|NCT02007278|Drug|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
79351379|NCT02007278|Drug|glimepiride|
79351380|NCT02007278|Drug|Metformin|
79351381|NCT02107313|Drug|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
79351382|NCT02107313|Drug|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
79351383|NCT02028338|Combination Product|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
79351384|NCT02028338|Combination Product|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
79351385|NCT05089487|Procedure|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
79351386|NCT01625897|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
79351387|NCT01625897|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
79351388|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
79502839|NCT03866538|Drug|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
79664990|NCT00340314|Procedure|Circumferential Pulmonary Vein Ablation|
79664991|NCT00340314|Drug|Antiarrhythmic Drug Therapy|
79664992|NCT00306644|Drug|Rosiglitazone|study drug
79664993|NCT00337233|Procedure|yoga therapy|10 week yoga class
79664994|NCT00306683|Drug|DIAZOXIDE|
79664995|NCT00306722|Drug|AQUAVAN® (fospropofol disodium) Injection|
79664996|NCT00337389|Drug|5- Fluorouracil (5-FU)|
79664997|NCT00337389|Drug|bevacizumab (Avastin)|
79664998|NCT00337389|Drug|Leucovorin|
79664999|NCT00337389|Drug|CoFactor (ANX-510)|
79665000|NCT00306761|Device|Dynamic Wheelchair Seating System|
79665001|NCT00306800|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
79665002|NCT00340431|Drug|MSP1(42)-FVO & MSP1(42)-3D7|
79665003|NCT00306839|Procedure|standardized Lichtenstein technique|
79665004|NCT00340470|Behavioral|Driver Education|
79665005|NCT00306878|Drug|Abatacept|
79665006|NCT04715724|Other|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
79665007|NCT00306956|Behavioral|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
79817321|NCT04077957|Drug|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
79989148|NCT06169826|Drug|l-Histidine|In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.
79989149|NCT06169826|Other|Control|Control
79989150|NCT06169813|Other|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
79989151|NCT06169813|Other|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
79989152|NCT06169813|Behavioral|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
79351389|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
79351390|NCT02106923|Drug|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
79502840|NCT03861624|Procedure|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
79502841|NCT03861624|Procedure|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
79502842|NCT01677390|Drug|SGN-75|1-2 mg/kg IV every 21 days
79989153|NCT06169527|Drug|Dupilumab|Dupilumab cohort
79989154|NCT06169462|Procedure|PENG block|Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
79989155|NCT06169462|Procedure|PENG block+ SIFCB|Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
79989156|NCT06168812|Drug|Glipizide|The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
79351391|NCT02106923|Drug|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
79351392|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
79351393|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
79989157|NCT06165757|Behavioral|noise stimulation|Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.
79989158|NCT06164626|Procedure|Extraction|extraction: in all groups, extraction will be performed
79989159|NCT06164626|Radiation|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
79351394|NCT02006732|Drug|olodaterol|fixed dose combination
79502843|NCT01677390|Drug|everolimus|10 mg PO daily
79502844|NCT03661086|Device|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
79665008|NCT02960165|Behavioral|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
79989160|NCT06164626|Biological|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
79989161|NCT06164210|Behavioral|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
79989162|NCT06164197|Device|Lokomat|Robot Assisted Gait Training
79989163|NCT06164197|Device|Thera Trainer Balo|Virtual Reality Based Balance Training Device
79989164|NCT06164197|Other|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
79989165|NCT06162585|Biological|Gene Therapy product-MCO-010|Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients
79989166|NCT06161207|Procedure|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection|Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
79989167|NCT06161025|Drug|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
79989168|NCT06161025|Drug|Gemcitabine|Gemcitabine will be administered as an IV infusion
79989169|NCT06161025|Drug|Paclitaxel|Paclitaxel will be administered as an IV infusion
79989170|NCT06161025|Drug|Topotecan|Topotecan will be administered as an IV infusion
79989171|NCT06161025|Drug|PLD|PLD will be administered as an IV infusion
79989172|NCT06160999|Behavioral|Religious conferences|The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
79989173|NCT06160999|Behavioral|Vaccine-in-a-van|For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
79989174|NCT06160414|Drug|Metformin|Participants will receive Metformin orally, after fasting.
79989175|NCT06160414|Drug|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
79989176|NCT06160414|Drug|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
79989177|NCT06159894|Other|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
79989178|NCT06159894|Other|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
79989179|NCT06159868|Other|Structured physiotherapy and rehabilitation|Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.
79989180|NCT06159868|Other|Standard care|Standard ward based care provided by usual care teams
79665009|NCT02960165|Behavioral|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
79351395|NCT02006732|Drug|tiotropium|fixed dose combination
79351396|NCT02006732|Drug|placebo|
79665010|NCT00337506|Drug|Dexamethasone|
79665011|NCT00337506|Drug|velcade|
79502845|NCT03750864|Behavioral|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance & Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
79502846|NCT03749070|Dietary Supplement|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
79989181|NCT06159569|Device|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
79989182|NCT06159556|Other|Peanut intake|Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
79989183|NCT06159426|Other|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
79502847|NCT03748602|Procedure|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
79502848|NCT01345656|Drug|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
79351397|NCT02098733|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
79351398|NCT02028182|Biological|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm^2, 0.20 mg/cm^2 and 0.40 mg/cm^2) and negative control
79502849|NCT01345656|Drug|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
79502850|NCT01345656|Drug|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
79817322|NCT04077957|Drug|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
79817323|NCT04077957|Drug|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
79351399|NCT04684472|Biological|Modified anti-CD19 CAR T cells|intravenous infusion
79351400|NCT02098109|Drug|XM02 Filgrastim|
79351401|NCT02098109|Drug|Filgrastim|
79351402|NCT02098109|Procedure|Apheresis|
79351403|NCT02098109|Drug|Plerixafor|
79351404|NCT02098109|Procedure|Stem Cell Transplant|
79351405|NCT02097719|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
79351406|NCT02097719|Drug|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
79502851|NCT01345656|Drug|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
79817324|NCT04077957|Drug|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
79351407|NCT02097719|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
79502852|NCT01345656|Drug|Placebo|Placebo tablets for duration of 4 weeks
79502853|NCT01345656|Drug|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
79502854|NCT03744624|Procedure|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
79502855|NCT03744624|Device|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
79502856|NCT03743064|Drug|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
79351408|NCT02097719|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
79351409|NCT01449370|Drug|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
79351410|NCT02067533|Procedure|soft tissue repair in flexion position|
79351411|NCT02067533|Procedure|soft tissue repair in extension position|
79351412|NCT02066129|Drug|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
79351413|NCT02066129|Drug|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
79502857|NCT03743064|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
79502858|NCT01196832|Procedure|blood sample|blood sample for fibrocytes analysis
79502859|NCT01196832|Procedure|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
79502860|NCT03737916|Other|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
79665012|NCT00307073|Device|Implantable Pulse Generator|
79665013|NCT04717856|Other|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
79665014|NCT04715607|Diagnostic Test|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
79502861|NCT03737916|Other|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
79665015|NCT00307229|Biological|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
79665016|NCT00337584|Procedure|Pre-surgical screening|
79665017|NCT00307307|Drug|Niacin/simvastatin compared to simvastatin alone at 2 doses|
79665018|NCT00337623|Drug|Prednisolone|
79665019|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
79502862|NCT04763460|Device|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
79502863|NCT04763616|Drug|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
79502864|NCT04763616|Drug|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
79502865|NCT04747158|Biological|Convalescent plasma|COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
79502866|NCT03652974|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
79665020|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
79665021|NCT00307424|Device|AutoCPAP|
79665022|NCT00307424|Device|FixCPAP|
79665023|NCT00307463|Procedure|strict volume control policy|strict volume control by UF and dietary salt restriction
79665024|NCT00307463|Procedure|antihypertensive drugs administration|continue antihypertensive medications
79665025|NCT00421005|Drug|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
79665026|NCT00337740|Procedure|endoscopic variceal banding|
79665027|NCT00337740|Drug|propranolol|
79665028|NCT00307502|Drug|Nevirapine|tablets 200 mg, 400 mg/day
79665029|NCT00307502|Drug|Efavirenz|tablets 600 mg, 600 mg/day
79665030|NCT00307502|Drug|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
79665031|NCT00307502|Drug|Nelfinavir|tablets 250 mg, 2500 mg/day
79665032|NCT00307502|Drug|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
79665033|NCT00307502|Drug|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
79665034|NCT00307502|Drug|Atazanavir|capsules 200 mg, 400 mg/day
79665035|NCT00307502|Drug|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
79665036|NCT00307502|Drug|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
79665037|NCT00307502|Drug|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
79665038|NCT00307502|Drug|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
79817325|NCT04077957|Drug|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
79351414|NCT02066051|Device|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
79351415|NCT02066051|Procedure|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
79351416|NCT01980992|Drug|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
79351417|NCT04085068|Other|cranioscaral treatment|dural release
79351418|NCT02065895|Device|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
79665039|NCT00307541|Biological|Pneumococcal (vaccine)|
79665040|NCT00307580|Drug|Cathflo Activase (Alteplase)|
79665041|NCT00307619|Drug|topiramate|
79665042|NCT00340938|Procedure|Blood testing|
79351419|NCT02065895|Device|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
79665043|NCT00307658|Drug|Intravenous immunoglobulins (human immunoglobulins G)|
79665044|NCT00337974|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
79665045|NCT00337974|Other|Educational DVDs|
79665046|NCT00307697|Procedure|receipt of copy of psychiatic assessment letter|
79665047|NCT00337545|Drug|RAD001|
79665048|NCT00307775|Drug|oestradiol|
79665049|NCT04715919|Diagnostic Test|Chest Computed Tomography|Evaluation of Lung Structure
79665050|NCT04715919|Diagnostic Test|Pulmonary Function Tests|Respiratory Capacity
79665051|NCT04715919|Other|Six Minutes Walk Test|Exercise Capacity
79665052|NCT04715919|Other|Quality of Life|Physical disability assessment tool
79665053|NCT00307814|Drug|Epoetin Alfa|
79665054|NCT00341055|Drug|Epoetin alfa|
79665055|NCT00307853|Drug|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
79665056|NCT00307853|Other|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
79665057|NCT00307853|Other|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
79665058|NCT00338052|Drug|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
79665059|NCT00307892|Drug|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
79665060|NCT00307892|Drug|Placebo|placebo remedy
79665061|NCT00338091|Drug|Benazepril|
79665062|NCT00338091|Drug|Losartan|
79665063|NCT00307970|Drug|HFA FP MDI|
79351420|NCT02065895|Device|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
79665064|NCT00307970|Device|conventional chamber/mask; anti-static chamber/mask|
79351421|NCT04723511|Other|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants the treatment sequence. This will be a session of Kendall exercises as described below. This will followed be performing GPR techniques of Anterior Chain stretch in the supine frog like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Staring from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session a forth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take a bout 90 minutes."
79351422|NCT04723511|Other|Kendall exercises|"exercises that correct upper crossed syndrome:~Treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be 15 times repeated for 3 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be 15 times repeated for 3 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times."
79665065|NCT00308009|Procedure|Vaginal Repair for prolapse, TVT procedure|"TVT at the time of Vaginal Repair~TVT 3 months after Vaginal Repair"
79665066|NCT00308009|Procedure|TVT and Prolapse surgery|"TVT at the time of Prolapse surgery~TVT 3 months after Prolapse Surgery"
79665067|NCT00308048|Drug|Pegylated Interferon alfa 2b and ribavirin|
79665068|NCT00338130|Drug|AZD6244|Oral liquid or Capsule
79665069|NCT00338130|Drug|Temozolomide|oral
79665070|NCT00308126|Drug|Hydroxyethyl Starch 130/0.4 (Voluven)|
79817326|NCT04114019|Diagnostic Test|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
79665071|NCT00308165|Procedure|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
79665072|NCT00308165|Drug|Topotecan|chemotherapeutic drug for the treatment of brain tumors
79665073|NCT00338208|Behavioral|Training in the Use of Low Vision Devices|
79665074|NCT00418652|Device|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
79665075|NCT00418652|Device|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
79665076|NCT00418652|Device|TMS over the vertex|10Hz TMS for over vertex.
79665077|NCT00418769|Drug|Nilotinib|
79665078|NCT00308204|Drug|Raptiva|injection
79817327|NCT04102670|Device|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
79817328|NCT04102670|Device|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
79817329|NCT04102670|Device|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
79817330|NCT04102670|Device|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
79817331|NCT04102670|Other|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
79817332|NCT04114097|Drug|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
79817333|NCT04114097|Drug|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
79817334|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
79665079|NCT00425334|Drug|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
79665080|NCT00425334|Drug|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
79665081|NCT00308243|Drug|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
79665082|NCT00338247|Drug|lapatinib + capecitabine|Experimental
79665083|NCT00308321|Drug|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
79665084|NCT00308321|Drug|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
79817335|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
79502867|NCT03652974|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
79502868|NCT03652974|Drug|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
79351423|NCT04723355|Device|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
79351424|NCT04723355|Device|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
79502869|NCT03652974|Drug|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
79351425|NCT04417985|Device|18F-FDG PET/CT, MRI|
79351426|NCT02106455|Drug|Sodium risedronate|Sodium risedronate tablets
79351427|NCT02006654|Drug|Placebo|Once daily, matching placebo capsules, orally
79351428|NCT02006654|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
79502870|NCT03650244|Device|REMEEX implantation|Device implantation
79502871|NCT03649152|Drug|Propagermanium|Immediate release capsule
79502872|NCT03649152|Drug|Placebo|Placebo capsule
79502873|NCT02082288|Other|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) >35 (0) 30-35 (1) <30 (2) No of retrived oocyte <5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos <2 (0) 2-4 (1) >4 (2) No of good quality embryos <3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)"
79502874|NCT03646188|Drug|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
79502875|NCT03646188|Drug|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
79502876|NCT03646188|Drug|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
79665085|NCT00308360|Drug|Risperidone, divalproex|
79665086|NCT00308399|Drug|Itopride|
79351429|NCT01980056|Drug|Vosaroxin|Dose level 1: Vosaroxin 50 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
79502877|NCT03646188|Drug|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
79502878|NCT03646188|Drug|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
79502879|NCT03849456|Drug|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
79502880|NCT03645720|Device|Plastic cannula|puncture using plastic cannula
79502881|NCT03645096|Drug|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
79351430|NCT02027558|Behavioral|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
79502882|NCT03645096|Drug|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
79502883|NCT03645096|Drug|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
79502884|NCT03734172|Diagnostic Test|Sample collection|Specimen collection
79502885|NCT03732300|Other|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
79502886|NCT04762524|Other|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
79665087|NCT04715802|Procedure|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
79351431|NCT02027558|Behavioral|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
79502887|NCT03642678|Dietary Supplement|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
79502888|NCT03642210|Combination Product|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
79502889|NCT03844386|Biological|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
79502890|NCT03844386|Biological|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
79502891|NCT03844386|Other|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
79665088|NCT04715802|Procedure|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
79665089|NCT04715802|Procedure|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
79665090|NCT00341250|Drug|AMA1-C1/Alhydrogel Malaria Vaccine|
79502892|NCT02082678|Drug|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
79502893|NCT02082678|Drug|Placebo|Inactive ingredient matching the active medication in appearance
79502894|NCT03836430|Behavioral|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
79502895|NCT04403958|Procedure|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
79502896|NCT04403958|Procedure|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
79502897|NCT04763850|Other|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
79502898|NCT03624114|Procedure|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
79502899|NCT01677468|Procedure|Intermediate embolization|TACE with substasis using gelfoam
79989184|NCT06157788|Diagnostic Test|functional Magnetic Resonance Imaging and clinical assessment|"fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~General Linear Model Analysis of Task-Related Activation~TICA Analysis of Functional Connectivity~White Matter TBSS of DTI Data~Voxel-based morphometry analysis of T1 images"
79502900|NCT01677468|Procedure|Complete embolization|TACE with complete embolization using gelfoam
79502901|NCT00003816|Biological|anti-thymocyte globulin|Given IV
79502902|NCT00003816|Drug|busulfan|Given IV
79351432|NCT02027402|Procedure|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
79502903|NCT00003816|Drug|carboplatin|Given IV
79502904|NCT00003816|Drug|cyclophosphamide|Given IV
79502905|NCT00003816|Drug|etoposide|Given IV
79502906|NCT00003816|Drug|fludarabine phosphate|Given IV
79989185|NCT06155383|Drug|Capecitabine|1000 mg/m2, Bid orally, D1-14, every 3 weeks
79502907|NCT00003816|Drug|melphalan|Given IV
79351433|NCT01448824|Drug|LY2484595|Administered orally
79502908|NCT00003816|Drug|thiotepa|Given IV
79502909|NCT00003816|Radiation|total-body irradiation|Given twice daily for 3 days
79502910|NCT03618654|Drug|Metformin|Given PO
79502911|NCT03618654|Biological|Durvalumab|Given IV
79502912|NCT03617874|Other|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
79665091|NCT00308438|Drug|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
79351434|NCT01448824|Drug|Placebo|Administered orally
79351435|NCT01448824|Drug|Ketoconazole|Administered orally
79351436|NCT02005562|Drug|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (*) height (h)/ liter(L).
79351437|NCT02005562|Drug|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
79351438|NCT02005562|Drug|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
79502913|NCT03617874|Other|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
79502914|NCT03614910|Device|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
79502915|NCT03718104|Other|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
79502916|NCT03718104|Other|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
79502917|NCT03718104|Genetic|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
79502918|NCT03718104|Other|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
79502919|NCT03714750|Procedure|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
79502920|NCT03714750|Procedure|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
79502921|NCT01677078|Device|Neuronavigation system|Neuronavigation
79502922|NCT01677078|Device|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
79502923|NCT04763070|Drug|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
79502924|NCT04763694|Device|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
79665092|NCT00338325|Behavioral|Reading program|Reading of children's story/picture books preoperatively
79665093|NCT00308477|Drug|dexamethasone|
79665094|NCT00308594|Drug|Dexamethasone|
79817336|NCT00796757|Drug|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
79502925|NCT04762914|Other|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
79502926|NCT03828318|Other|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
79817337|NCT00796757|Drug|interferon alfa-2a|3 MIU sc t.i.w.
79989186|NCT06155383|Drug|oxaliplatin|130 mg/m2, intravenous infusion, D1, every 3 weeks
79502927|NCT03609060|Drug|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
79502928|NCT03706794|Behavioral|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
79665095|NCT00341328|Biological|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
79665096|NCT00338364|Behavioral|PAT|Coping and Distraction Intervention
79817338|NCT00759356|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
79351439|NCT02005562|Drug|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
79817339|NCT00759356|Drug|KADIAN|2 x 100 mg, single-dose capsule
79989187|NCT06155383|Drug|Disitamab Vedotin|2.5 mg/kg, intravenous infusion, D1, every 2 weeks
79989188|NCT06155383|Drug|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
79989189|NCT06154772|Other|Color Therapy|Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.
79989190|NCT06153212|Procedure|Membrane placement with bone grafting|The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
79989191|NCT06153069|Drug|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol ≤50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
79989192|NCT06153069|Drug|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol ≤50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
79351440|NCT02005562|Drug|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
79351441|NCT01448044|Drug|BMS-790052 (NS5A Replication Complex Inhibitor)|
79351442|NCT01448044|Drug|Placebo matching BMS-790052|
79351443|NCT01448044|Drug|Pegylated-interferon alfa 2a|
79351444|NCT01448044|Drug|Ribavirin|
79502929|NCT03706794|Behavioral|Headache Education|Non-tailored education provided via a smartphone application.
79502930|NCT03705234|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
79665097|NCT00308789|Procedure|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
79665098|NCT00308789|Procedure|CPAP|Continuous positive airway pressure
79351445|NCT02025530|Other|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
79351446|NCT01472380|Drug|efavirenz|600 mg
79351447|NCT01472380|Drug|fenofibric acid 105 mg|fenofibric acid 105 mg
79502931|NCT03705234|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
79502932|NCT03704766|Diagnostic Test|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79665099|NCT00308867|Procedure|Photodynamic Therapy|
79989193|NCT06152263|Other|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
79989194|NCT06149403|Genetic|Experimental: OTL-203|Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene
79989195|NCT06149403|Genetic|Active Comparator: Allo-HSCT|Active Comparator: Allogeneic hematopoietic stem cell transplantation
79989196|NCT06147583|Other|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
79351448|NCT01978262|Biological|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
79351449|NCT01447576|Drug|ADT|Once daily dosing during the duration of the study.
79351450|NCT01447576|Drug|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
79351451|NCT04084834|Other|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
79351452|NCT01447420|Drug|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
79351453|NCT01447420|Drug|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
79502933|NCT03704766|Diagnostic Test|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79502934|NCT03704766|Diagnostic Test|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
79665100|NCT00308867|Procedure|Cryosurgery|
79665101|NCT00341445|Behavioral|Effect of Cockroach Allergen|
79665102|NCT00308906|Drug|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
79989197|NCT06123351|Device|Denneroll cervical traction orthodontic|traction for 3 to 15 minutes once daily
79989198|NCT06123351|Other|stretching and strengthening exercises|strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
79989199|NCT06123351|Device|Vacuum-formed soft occlusal splint|2 mm thick elastic rubber sheets
79989200|NCT06113458|Behavioral|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
79989201|NCT06113458|Behavioral|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
79989202|NCT06113458|Behavioral|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
79989203|NCT06113458|Behavioral|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
79502935|NCT03704766|Diagnostic Test|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79665103|NCT00338403|Procedure|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
79665104|NCT00308945|Drug|travoprost 0.004% (drug)|local drop application
79665105|NCT00308945|Drug|latanoprost 0.005% (drug)|local drop application
79665106|NCT00338442|Drug|VariZIG™|Biological / Vaccine
79989204|NCT06109571|Device|Connections App|The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
79989205|NCT06107751|Other|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
79989206|NCT06107751|Other|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
79989207|NCT06105918|Procedure|Biospecimen Collection|Undergo blood sample collection
79989208|NCT06105918|Procedure|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
79989209|NCT06105918|Radiation|External Beam Radiation Therapy|Undergo EBRT
79502936|NCT03704766|Diagnostic Test|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79351454|NCT01446874|Drug|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
79351455|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
79351456|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
79502937|NCT03704766|Diagnostic Test|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79502938|NCT03704766|Diagnostic Test|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79351457|NCT01439074|Device|Mepilex Ag|Dressing
79665107|NCT00338481|Drug|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
79665108|NCT00338481|Drug|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
79351458|NCT01439074|Drug|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
79351459|NCT01438996|Biological|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
79502939|NCT03704766|Diagnostic Test|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
79502940|NCT03704766|Diagnostic Test|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
79502941|NCT03704766|Diagnostic Test|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
79665109|NCT00309062|Biological|Recombinant birch pollen|
79989210|NCT06105918|Other|Flotufolastat F-18|Given IV
79989211|NCT06105918|Drug|Lutetium Lu 177 PSMA-10.1|Given IV
79989212|NCT06105918|Procedure|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
79989213|NCT06105918|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
79989214|NCT06100588|Other|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
79989215|NCT06100588|Other|Manual therapy|Manual therapy comprises stretching of muscles, mobilizations, traction and translation of vertebrae, Sustained Natural Apophyseal Glides (SNAG), dynamic soft tissue mobilization, Muscle Energy Techniques (MET) and home-exercises.
79665110|NCT00309101|Drug|tacrolimus|Oral
79989216|NCT06100237|Drug|Teclistamab|Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
79989217|NCT06100237|Drug|Talquetamab|Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
79351460|NCT01438840|Drug|Avatrombopag|
79351461|NCT01438840|Drug|Placebo|
79989218|NCT06100237|Drug|Daratumumab SC|Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
79989219|NCT06099769|Drug|Enzalutamide|mouth once daily (160 mg/day)
79989220|NCT06099769|Drug|Mifepristone|mouth once daily 300-mg tablet
79989221|NCT06099769|Drug|TPC|"The treating physician must select from one of the following regimens:~Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~Carboplatin AUC 6 IV Day 1 in a 21-day cycle~Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
79989222|NCT06090448|Device|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
79989223|NCT06079593|Procedure|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
79989224|NCT06079593|Procedure|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
79989225|NCT06073314|Diagnostic Test|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
79502942|NCT03704766|Diagnostic Test|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
79502943|NCT03704766|Diagnostic Test|Synovial PCR for Kingella kingae|In participants < 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
79502944|NCT03704766|Diagnostic Test|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
79502945|NCT03704766|Diagnostic Test|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
79665111|NCT00309218|Drug|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
79989226|NCT06073314|Diagnostic Test|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
79351462|NCT01438840|Drug|Standard of care|"Permitted ITP concomitant background therapies are as follows:~Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport [P-gp] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
79502946|NCT03704766|Diagnostic Test|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
79502947|NCT03704766|Diagnostic Test|Serum D-dimer|A blood test performed at the hospital.
79502948|NCT03704766|Diagnostic Test|Serum Procalcitonin|A blood test performed at the hospital.
79502949|NCT03704766|Diagnostic Test|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
79665112|NCT00309296|Behavioral|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
79665113|NCT00338637|Device|APOS shoe kit|
79989227|NCT06072196|Drug|Novel hormonal therapy|As provided in real-world setting
79351463|NCT01471054|Drug|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
79351464|NCT01471054|Drug|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
79351465|NCT01978184|Drug|gemcitabine|
79351466|NCT01978184|Drug|abraxane|
79351467|NCT01978184|Drug|hydroxychloroquine|
79351468|NCT01445548|Drug|Sirolimus|
79502950|NCT03704766|Diagnostic Test|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
79502951|NCT03826992|Drug|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
79665114|NCT00309335|Drug|Phentolamine Mesylate (NV-101)|
79665115|NCT00341640|Procedure|Blood testing|
79351469|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
79351470|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
79351471|NCT04408768|Other|standard protocol for stroke patients|Standard protocol for stroke patients
79665116|NCT00309374|Drug|LPS 2ng/kg intravenous bolus|
79351472|NCT02005484|Drug|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
79351473|NCT02024750|Behavioral|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
79351474|NCT01597973|Drug|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
79351475|NCT01597973|Drug|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
79351476|NCT04671680|Device|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
79351477|NCT02023268|Device|T2762|1 drop in each eye 3 to 6 times daily during 84 days
79351478|NCT02023268|Device|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
79351479|NCT02047253|Drug|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
79351480|NCT02047253|Drug|Dexamethasone|Administered prior to administration of Study drug
79351481|NCT02047253|Drug|Acyclovir|Administered orally twice daily
79665117|NCT00309374|Drug|Simvastatin 80mg; administered daily p.o. over 5 days|
79351482|NCT04707131|Drug|LEM-S401|siRNA encapsulated in DegradaBALL®
79351483|NCT04707131|Drug|Placebo|Placebo
79351484|NCT02096705|Drug|Dapagliflozin|Tablet
79665118|NCT00309374|Drug|Rosuvastatin 40mg; administered daily p.o. over 5 days|
79665119|NCT00309413|Drug|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
79665120|NCT00309413|Drug|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
79989228|NCT06067451|Behavioral|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
79502952|NCT03826992|Drug|Venetoclax|"Venetoclax Dose:~Dose Level 0 - weight based daily dosing for 21 days~Dose Level -1 - weight based daily dosing for 14 days~Dose Level -2- weight based daily dosing for 10 days~Dose Level -3- weight based daily dosing for 7 days"
79502953|NCT00004092|Biological|filgrastim|Given IV or subcutaneously
79989229|NCT06061302|Other|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
79989230|NCT06061302|Other|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
79989231|NCT06055556|Procedure|Partial Heart Transplantation|"Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue."
79989232|NCT06055556|Other|Freshly procured valve|Fresh donor graft semilunar heart valve.
79989233|NCT06050668|Dietary Supplement|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
79502954|NCT00004092|Drug|carboplatin|Given IV
79989234|NCT06047041|Behavioral|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~Asks teachers and students to report on 7 areas of student social-emotional functioning~Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~Individualized technical assistance for schools to support EIS implementation."
79351485|NCT02096705|Drug|Dapagliflozin Placebo|Tablet
79351486|NCT04705571|Device|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
79351487|NCT02096471|Drug|PD-0325901|
79351488|NCT02096003|Drug|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
79351489|NCT02096003|Drug|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
79502955|NCT00004092|Drug|cyclophosphamide|Given IV
79502956|NCT00004092|Drug|doxorubicin hydrochloride|Given IV
79502957|NCT00004092|Drug|paclitaxel|Given IV
79502958|NCT00004092|Drug|thiotepa|Given IV
79989235|NCT06047041|Behavioral|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~Collaboration with colleagues in schools that are also implementing the EIS.~Opportunities to consult with university faculty and content experts in school mental health.~Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
79989236|NCT06041828|Device|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
79989237|NCT06041828|Other|Standard oral hygiene|Standard oral hygiene instructions
79502959|NCT00004092|Procedure|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
79502960|NCT00004146|Radiation|radiation therapy|Undergo radiotherapy
79351490|NCT02062385|Biological|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
79351491|NCT02062385|Biological|Placebo to V260|Placebo control
79351492|NCT02062385|Biological|OPV|Oral poliovirus vaccine administered according to the standard of care
79351493|NCT02062385|Biological|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
79351494|NCT02062151|Other|Acupuncture|Acupuncture
79351495|NCT02060903|Drug|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
79351496|NCT02060903|Drug|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
79351497|NCT02095691|Device|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
79351498|NCT02095535|Drug|Chlorhexidine gluconate|antiseptic
79502961|NCT00004146|Drug|carboxyamidotriazole|Given orally
79502962|NCT00004146|Other|pharmacological study|Correlative studies
79351499|NCT04703699|Device|Myval Transcatheter Heart Valve System|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
79351500|NCT02095223|Device|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
79351501|NCT02095223|Behavioral|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
79351502|NCT02095145|Other|Laboratory Biomarker Analysis|Correlative studies
79351503|NCT02095145|Other|Pharmacological Study|Correlative studies
79351504|NCT02095145|Other|Placebo|Given PO
79351505|NCT02095145|Drug|Pomegranate-Extract Pill|Given PO
79502963|NCT00004500|Drug|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
79351506|NCT04722029|Biological|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
79351507|NCT02059187|Drug|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
79351508|NCT02059187|Drug|Lantus™|Lantus™ (insulin glargine [rDNA origin]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
79502964|NCT00004500|Other|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
79989238|NCT06040268|Drug|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
79989239|NCT06040268|Drug|Placebo|HFA134a inhaler
79502965|NCT03606330|Diagnostic Test|Cardiac imaging tests|"2D transthoracic echocardiography~128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~Shear stress evaluation via computational fluid dynamics.~Intracoronary imaging techniques: IVUS and OCT."
79502966|NCT03606330|Diagnostic Test|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
79502967|NCT03605628|Other|measuring tape|measurement of change in abdominal wall length [cm] during neuromuscular block with a measuring tape.
79502968|NCT03605628|Other|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
79502969|NCT03605628|Other|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~extremely poor conditions~poor conditions~acceptable conditions~good conditions~optimal conditions"
79989240|NCT06027320|Behavioral|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
79989241|NCT06027320|Behavioral|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
79989242|NCT06023732|Behavioral|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
79989243|NCT06021353|Device|UV fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
79351509|NCT02059187|Drug|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
79351510|NCT02043899|Drug|[124I]meta-Iodobenzylguanidine|Single intravenous administration of [124I]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq [124I]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
79351511|NCT04719611|Dietary Supplement|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
79351512|NCT02043509|Behavioral|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
79351513|NCT04719377|Device|catheter placement|catheter placement
79351514|NCT02058563|Biological|Priorix®|1 dose administered as a subcutaneous (SC) injection.
79351515|NCT02058563|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
79502970|NCT03701724|Device|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
79502971|NCT03701724|Device|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
79989244|NCT06021353|Device|IR fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
79989245|NCT06021353|Procedure|LASIK|Laser-assisted in situ keratomileusis (LASIK) surgery
79989246|NCT06011317|Drug|EDG-7500|EDG-7500 is administered orally once daily
79989247|NCT06011317|Drug|Placebo|Placebo is administered orally once daily
79989248|NCT06008054|Drug|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
79989249|NCT06008054|Drug|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
79351516|NCT01622231|Drug|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
79665121|NCT04715880|Procedure|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
79989250|NCT06006169|Drug|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
79989251|NCT06006169|Drug|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
79989252|NCT06005857|Other|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
79351517|NCT04417439|Other|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
79351518|NCT02042183|Drug|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
79351519|NCT02042183|Drug|Placebo|0 mcg soft capsules of placebo for oral administration
79351520|NCT01977482|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
79351521|NCT01977482|Drug|Placebo|Matching placebo tablet for GSK1278863
79351522|NCT01977482|Drug|rhEPO|rhEPO will be procured from local market
79351523|NCT02058095|Drug|Tadalafil|"Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
79989253|NCT06005857|Other|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
79989254|NCT05999565|Other|Motor Imagery Exercises|"Lateralization Training: Individuals with cervical discogenic pain will receive lateralization training using a mobile application called Recognize Neck from the Neuro Orthopaedic Institute in Adelaide, Australia.~Kinesthetic Imagery: During this training, individuals will be asked to actively perform exercises and feel the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to imagine the positions of their bodies, the surface they are on, and the desired postures.~Visual Imagery: Individuals will be asked to actively perform exercises and visualize the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to mentally visualize their body positions, the surface they are on, and the exercises.~Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises in front of a mirror."
79502972|NCT03701724|Device|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
79989255|NCT05999565|Other|Motor Control Exercises|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
79989256|NCT05991700|Drug|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
79989257|NCT05991700|Drug|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
79989258|NCT05977270|Device|Lifebloom One|LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
79989259|NCT05971160|Behavioral|Financial education videos|Brief videos providing structured information on managing one's money
79989260|NCT05971160|Other|Microgrant|$150 stipend
79502973|NCT00745992|Other|Blood drawn (lab data)|"Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
79502974|NCT03825198|Procedure|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
79502975|NCT03825198|Drug|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
79502976|NCT03825198|Procedure|spine fusion|fusion of lumbar vertebral body on 1 or two levels
79351524|NCT02058095|Drug|Placebo|"Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
79351525|NCT04718207|Device|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
79502977|NCT03825198|Drug|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
79351526|NCT04663022|Other|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
79351527|NCT02023112|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
79502978|NCT03825198|Drug|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
79502979|NCT03825198|Drug|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
79351528|NCT02023112|Drug|Ribavirin|Capsule
79351529|NCT01977092|Behavioral|Motivational interviewing case management|
79351530|NCT01977092|Behavioral|Resource referrals|
79502980|NCT03825198|Drug|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
79351531|NCT01976624|Drug|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
79502981|NCT03825198|Drug|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
79665122|NCT04715880|Procedure|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
79989261|NCT05971160|Behavioral|Peer mentoring|One-on-one structured mentoring sessions with a trained peer
79989262|NCT05969860|Procedure|Clinical Encounter|Receive treatment in clinic
79989263|NCT05969860|Other|Home Health Encounter|Receive at-home treatment
79989264|NCT05969860|Other|Quality-of-Life Assessment|Ancillary studies
79989265|NCT05969860|Other|Questionnaire Administration|Ancillary studies
79817340|NCT04101266|Other|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
79502982|NCT03825198|Drug|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
79351532|NCT02041091|Drug|Tabalumab Auto-Injector|Administered SC
79351533|NCT02041091|Drug|Tabalumab Prefilled Syringe|Administered SC
79351534|NCT04717973|Diagnostic Test|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
79502983|NCT03825198|Drug|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
79502984|NCT03825198|Drug|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
79665123|NCT00309491|Drug|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
79351535|NCT02057549|Drug|Haloperidol|Intravenous dose of haloperidol 5 mg.
79351536|NCT02057549|Drug|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
79351537|NCT02057393|Drug|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
79351538|NCT02057393|Drug|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
79502985|NCT03825198|Drug|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
79502986|NCT03825198|Drug|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
79502987|NCT03596658|Drug|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
79665124|NCT00309491|Drug|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~1st therapy week:125mg/-/125mg Aminoglutethimide daily~2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
79665125|NCT02960048|Device|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
79502988|NCT03690648|Other|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
79502989|NCT03690648|Genetic|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
79665126|NCT02960048|Device|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
79665127|NCT00309530|Drug|5-fluorouracil, levamisol, interferon|
79817341|NCT04101266|Other|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
79665128|NCT00309569|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2
79817342|NCT04113941|Drug|Neuronox|intradetrusor injection
79817343|NCT04113941|Drug|Placebo|intradetrusor injection
79351539|NCT02057393|Drug|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
79351540|NCT04698161|Other|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
79351541|NCT04698161|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
79665129|NCT00309569|Drug|Methotrexate|Methotrexate 40mg/m2
79665130|NCT00309569|Drug|Fluorouracil|Fluorouracil 600mg/m2
79665131|NCT00309569|Drug|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
79665132|NCT00309569|Other|Surgery|Surgery
79351542|NCT04698161|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
79351543|NCT02040779|Drug|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
79351544|NCT02040779|Drug|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
79502990|NCT03690648|Genetic|Blood collection|Collection of 20 ml of blood with kit of blood collection
79665133|NCT00338715|Device|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
79665134|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
79665135|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
79665136|NCT00309686|Drug|Paliperidone ER|
79665137|NCT00309725|Drug|galantamine|
79665138|NCT00309764|Behavioral|Telemedicine|
79665139|NCT00338754|Drug|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
79817344|NCT04102592|Other|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
79817345|NCT04102592|Other|Untreated Lesu (baby wrap)|Matching untreated lesu
79817346|NCT04113473|Other|Yoga Therapy|"An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes."
79817347|NCT00721734|Drug|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
79817348|NCT04113551|Drug|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
79817349|NCT04113551|Drug|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
79817350|NCT04113551|Drug|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
79817351|NCT04113551|Drug|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
79989266|NCT05968859|Behavioral|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
79989267|NCT05968859|Behavioral|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
79989268|NCT05967780|Other|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper & lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
79351545|NCT02040779|Drug|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
79351546|NCT02056301|Drug|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
79351547|NCT02056301|Drug|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
79351548|NCT01967732|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
79351549|NCT01967732|Other|CC|Single use of subject's own conventional cigarette (CC)
79502991|NCT01677156|Diagnostic Test|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
79502992|NCT03689166|Dietary Supplement|Probiotic|Reduce preterm birth with this dietary supplement
79817352|NCT02592954|Drug|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
79351550|NCT01967732|Other|NNS|Single administration of 1 mg of nicotine
79351551|NCT01967576|Drug|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
79351552|NCT02039687|Drug|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
79351553|NCT02039687|Other|Placebo|Formulation buffer
79351554|NCT02003534|Drug|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
79351555|NCT02055365|Biological|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
79351556|NCT05127473|Drug|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
79351557|NCT05127473|Drug|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
79351558|NCT05127473|Drug|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
79502993|NCT03689166|Other|Placebo|Placebo
79502994|NCT03684408|Device|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
79502995|NCT03684408|Device|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
79502996|NCT03684408|Device|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
79817353|NCT02592954|Drug|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
79351559|NCT02039375|Other|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
79351560|NCT02054897|Drug|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
79351561|NCT02054897|Drug|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
79817354|NCT02605343|Other|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
79817355|NCT00544427|Device|Optical coherence tomography|Optical coherence tomography imaging
79351562|NCT04713605|Device|Critical closing pressure detection|Observational study that determines the critical closing pressure (CrCP) of the brain by comparison of the cerebral blood flow velocity (measured by TCD) and invasive blood pressure measurement (IABP)
79351563|NCT01976312|Other|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
79351564|NCT01976312|Drug|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
79351565|NCT02039219|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
79351566|NCT02039219|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
79351567|NCT02053493|Drug|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
79502997|NCT03681366|Device|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
79351568|NCT02053493|Drug|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
79351569|NCT02003144|Biological|eculizumab|
79351570|NCT04661540|Drug|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
79351571|NCT04661540|Drug|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
79502998|NCT03591354|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology & Dexcom G6 CGM for 3 months.
79502999|NCT03591354|Device|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
79351572|NCT02001194|Behavioral|Individual Incentives|
79351573|NCT02001194|Behavioral|Team Incentives|
79351574|NCT02001194|Behavioral|Individual plus Team Incentives|
79351575|NCT02038907|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
79665140|NCT00309803|Device|FiberNet Embolic Protection Device|
79665141|NCT00338793|Drug|prednisolone|
79665142|NCT00418847|Drug|miglustat|Target dose of 320 mg/m^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
79665143|NCT00309881|Biological|rituximab|
79665144|NCT00309881|Drug|cyclophosphamide|
79665145|NCT00309881|Drug|doxorubicin hydrochloride|
79665146|NCT00309881|Drug|prednisone|
79665147|NCT00309881|Drug|vincristine sulfate|
79665148|NCT00309920|Biological|darbepoetin alfa|
79351576|NCT02038907|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
79351577|NCT02038829|Drug|Placebo|Placebo
79503000|NCT03582852|Procedure|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
79351578|NCT02038829|Drug|SUN101 3 mcg|SUN-101 3 mcg bid
79351579|NCT02038829|Drug|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
79351580|NCT02038829|Drug|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
79351581|NCT02038829|Drug|SUN-101 50 mcg|SUN-101 50 mcg bid
79351582|NCT02038829|Drug|Aclidinium|Aclidinium 400 mcg bid
79351583|NCT04693247|Device|EQ103|Refraction device
79503001|NCT00006156|Other|Control|No injection of FSH
79503002|NCT00006156|Drug|Drug: FSH|FSH Stimulation Test
79503003|NCT03677778|Procedure|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
79503004|NCT03677778|Other|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
79503005|NCT03810534|Behavioral|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
79503006|NCT05347836|Diagnostic Test|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
79503007|NCT05347758|Drug|HRS-7535|Drug: HRS-7535
79503008|NCT05347758|Drug|Placebo|Drug: Placebo
79503009|NCT05347680|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
79503010|NCT05347680|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
79503011|NCT03580434|Device|V-STRUT|Minimally invasive implantation of V-STRUT
79503012|NCT03580356|Biological|Ligelizumab|Liquid in vial
79503013|NCT03580356|Biological|Omalizumab|Lyophilized powder for solution in vial
79503014|NCT03580356|Other|Placebo|Liquid in vial
79665149|NCT00309920|Drug|cyclophosphamide|
79665150|NCT00309920|Drug|docetaxel|
79351584|NCT02038049|Drug|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
79351585|NCT02038049|Drug|Placebo|Placebo to VAY736
79351586|NCT02052011|Drug|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
79351587|NCT02052011|Drug|Placebo|
79351588|NCT02036645|Biological|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
79351589|NCT02036645|Biological|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
79351590|NCT02036645|Biological|IV Placebo|Placebo for IV injection
79503015|NCT06125938|Procedure|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
79503016|NCT06125938|Procedure|Autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
79665151|NCT00309920|Drug|doxorubicin hydrochloride|
79665152|NCT00309920|Drug|epirubicin hydrochloride|
79665153|NCT00309920|Drug|fluorouracil|
79665154|NCT00309998|Biological|bevacizumab|
79817356|NCT00914615|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
79817357|NCT00798317|Drug|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
79503017|NCT06125899|Behavioral|emhGAP-Age|"Adapted emhGAP-IG;~Adapted Problem-Solving Therapy (PST-PC)~Support/supervision of lay providers~Links to social support resources."
79817358|NCT00798317|Drug|Placebo|Intravitreal injection placebo.
79989269|NCT05967780|Other|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|"The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital."
79503018|NCT06125886|Diagnostic Test|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
79989270|NCT05967780|Other|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
79503019|NCT06125873|Drug|Metformin|Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
79503020|NCT06125860|Dietary Supplement|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
79503021|NCT06125860|Dietary Supplement|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
79503022|NCT06125860|Dietary Supplement|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
79503023|NCT06125847|Genetic|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
79989271|NCT05967416|Biological|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
79503024|NCT06125834|Drug|Trastuzumab Emtansine (T-DM1)|Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
79503025|NCT06125821|Other|questionnaire|questionnaire
79817359|NCT04113629|Device|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
79989272|NCT05967416|Radiation|External-beam radiotherapy (XRT)|Radiotherapy given by external beam
79503026|NCT06125808|Drug|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
79989273|NCT05966649|Other|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
79503027|NCT06125808|Drug|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
79503028|NCT06125782|Drug|Omega 3 fatty acid|Omega 3 fatty acid 1 gm softgel capsule- 1 for children at or below 25 kg and two for above 25 kg.
79503029|NCT06125782|Drug|Placebo of Omega-3 fatty acid softgel capsule|Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
79503030|NCT06125756|Drug|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10^12 vg/kg.
79503031|NCT06125756|Drug|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10^12 vg/kg.
79503032|NCT06125756|Drug|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10^13 vg/kg.
79817360|NCT00779402|Other|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
79817361|NCT00779402|Biological|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
79817362|NCT00771914|Drug|Aspirin|Aspirin 81mg tablet
79817363|NCT00771914|Drug|Lovaza|Lovaza 4 grams
79817364|NCT00771914|Drug|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
79989274|NCT05966649|Other|Placebo|Matching placebo
79817365|NCT00771914|Other|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
79817366|NCT04078893|Other|telephone recruitment|using telephone to recruit inactive donors on two different methods
79989275|NCT05950113|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
79351591|NCT02036645|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
79351592|NCT02051933|Drug|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
79503033|NCT06125717|Biological|H1 influenza antigen|Either 7.5 μg or 15 μg of the H1 influenza antigen
79503034|NCT06125652|Drug|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
79503035|NCT06125639|Behavioral|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
79665155|NCT00309998|Drug|vinorelbine tartrate|
79817367|NCT04347759|Other|Symptom Care at Home-Heart Failure|When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad. Based on symptom severity, intervention group will receive automated coaching messages. There will be a toll-free number for participants to call and a password to log into the system which will be stored on a secure and HIPPA-compliant sever. Calls can be personalized to allow the voice to greet the patient by name.
79989276|NCT05950113|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
79351593|NCT02051933|Drug|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
79665156|NCT00338832|Behavioral|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
79817368|NCT00779324|Drug|Amantadine Hydrochloride|100 mg every morning and noon
79989277|NCT05950113|Procedure|Computed Tomography|Undergo PET/CT
79989278|NCT05950113|Drug|Cyclophosphamide|Receive IV
79503036|NCT06125600|Other|Clustering of people living with obesity using behavioural questionnaires|In a cross-sectional analysis using the online Aviitam® platform, a cluster analysis was carried out in overweight/obese adults. The following questionnaires were studied: Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Epworth Sleepiness Scale, Morin's Insomnia Scale, Intuitive Eating Scale-2 (IES-2), Binge Eating Scale (BES), Ricci/Gagnon Physical Activity questionnaire and EQ-5D Quality-of-Life questionnaire.
79665157|NCT00338832|Behavioral|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
79817369|NCT00779324|Drug|Placebo|one placebo tablet every morning and 12 Noon
79989279|NCT05950113|Procedure|Echocardiography|Undergo ECHO
79503037|NCT06125587|Drug|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
79503038|NCT06125587|Drug|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
79989280|NCT05950113|Drug|Fludarabine|Receive IV
79989281|NCT05950113|Other|Fludeoxyglucose F-18|Receive IV
79989282|NCT05950113|Other|Immunotherapy|Receive CART-BCMA/CS1 cells IV
79989283|NCT05950113|Procedure|Leukapheresis|Undergo leukapheresis
79989284|NCT05950113|Procedure|Magnetic Resonance Imaging|Undergo MRI
79989285|NCT05950113|Procedure|Positron Emission Tomography|Undergo PET/CT
79503039|NCT06125561|Other|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
79665158|NCT00338871|Procedure|home exercise|
79665159|NCT00310115|Behavioral|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
79817370|NCT04078347|Procedure|Paravertebral block at T4 and T5 level|Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
79817371|NCT00779246|Other|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
79817372|NCT00779246|Drug|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
79817373|NCT00779246|Other|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
79817374|NCT04078113|Other|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
79817375|NCT04097990|Other|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
79989286|NCT05946837|Drug|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
79989287|NCT05946837|Device|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
79989288|NCT05946837|Device|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
79989289|NCT05946590|Procedure|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
79989290|NCT05944419|Device|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
79989291|NCT05940129|Behavioral|Women and Child, Safety, Health and Empowerment (WC-SHE)|The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
79989292|NCT05934890|Biological|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
79503040|NCT06125496|Other|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
79989293|NCT05934890|Biological|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
79989294|NCT05934084|Behavioral|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
79989295|NCT05924841|Drug|BL-B01D1|Administration by intravenous infusion
79989296|NCT05924841|Drug|SI-B003|Administration by intravenous infusion
79989297|NCT05920720|Behavioral|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
79351594|NCT02050373|Radiation|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
79351595|NCT04711811|Biological|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
79351596|NCT02049437|Drug|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
79503041|NCT06125470|Behavioral|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
79503042|NCT06125470|Behavioral|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing & Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
79503043|NCT06125470|Behavioral|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
79665160|NCT00310115|Behavioral|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
79989298|NCT05911932|Other|Biosample collection.|Blood draw.
79989299|NCT05888792|Other|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
79351597|NCT02049437|Drug|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
79351598|NCT02035553|Drug|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
79351599|NCT02035553|Drug|Placebo|Placebo, two tablets, once daily by mouth
79351600|NCT04711733|Other|Interview|The qualitative interview aims to identify the supportive care needs of patients and parents as well as their expectations with regard to a long-term follow-up.
79351601|NCT04711733|Other|Self-report questionnaire|"To assess the quality of life, anxiety/depression of former patients and relatives:~For child and adolescent patients (less than 15 years old at inclusion):~Pediatric Quality of Life Inventory Cancer module~Screen for Child Anxiety Related Emotional Disorders Revised~Children's Depression Inventory~For patients over 15 years of age at the time of inclusion and parents:~36-Item Short Form Health Survey~Hospital Anxiety and Depression Scale~To describe and evaluate the offer and use of the network of health professionals who are aware of post-treatment issues: number of consultations, speciality and location of the professionals requested following the long-term follow-up consultation, time between referral and first consultation, evaluation of the geographical accessibility of care around the patient's home."
79351602|NCT04711733|Other|Medical consultation|"To assess adherence to long-term follow-up medical consultation:~- number of patients summoned/ number of consultations carried out ; reason for refusal of long-term follow-up medical consultation To assess medical complications through clinical data collection"
79351603|NCT01445080|Other|Laboratory Biomarker Analysis|Correlative studies
79351604|NCT01445080|Other|Pharmacological Study|Correlative studies
79351605|NCT01445080|Drug|Sorafenib Tosylate|Given orally
79665161|NCT00310115|Behavioral|Counseling Intervention|2 in-person counseling sessions
79989300|NCT05883826|Behavioral|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
79665162|NCT00310154|Drug|docetaxel|
79989301|NCT05882110|Procedure|Cultured autologous epidermal cell membrane|The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
79989302|NCT05870150|Biological|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10^3 CFU, 1-5x10^4 CFU, 1-5x10^5 CFU, 1-5x10^6 CFU)
79989303|NCT05866419|Device|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
79989304|NCT05860296|Drug|SLC-391|SLC-391 is an AXL inhibitor
79989305|NCT05860296|Biological|Pembrolizumab|Immunotherapy
79351606|NCT02035475|Device|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
79351607|NCT04692779|Other|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
79503044|NCT06125470|Behavioral|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
79503045|NCT06125470|Behavioral|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
79665163|NCT00310154|Drug|gefitinib|
79665164|NCT00310154|Other|laboratory biomarker analysis|
79665165|NCT00310154|Radiation|radiation therapy|
79665166|NCT00338910|Drug|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
79665167|NCT00310232|Drug|Epoetin Alfa|
79665168|NCT00418730|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
79665169|NCT00310271|Biological|pPJV7630 with pPJV2012 administered by PMED|
79665170|NCT00310349|Biological|23 valent pneumococcal polysaccharide vaccine|
79665171|NCT00342108|Behavioral|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
79665172|NCT00310505|Drug|Amphotericin B deoxycholate given as daily administration|
79989306|NCT05859009|Procedure|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
79665173|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
79989307|NCT05859009|Drug|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
79989308|NCT05849129|Drug|Ascorbic acid|High dose ascorbic acid delivered intravenously
79989309|NCT05849129|Other|Normal Saline|0.9% NaCl solution
79351608|NCT04181177|Other|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
79351609|NCT04748536|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
79351610|NCT04748536|Drug|Placebo|Matching placebo for IRL201104
79503046|NCT06125470|Behavioral|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
79351611|NCT01438294|Other|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
79665174|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
79665175|NCT00339066|Drug|Sertraline|
79665176|NCT00310583|Drug|Pregabalin|
79989310|NCT05849012|Other|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
79503047|NCT06125418|Procedure|customized healing abutment|patients will undergoes one-stage implant placement with customized healing abutments with different macrogeometry and emergence angle made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
79665177|NCT00310622|Device|HyperQ Signal recording|
79989311|NCT05849012|Other|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
79989312|NCT05846659|Drug|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
79989313|NCT05846659|Drug|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
79351612|NCT01438294|Other|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
79351613|NCT04709471|Drug|Nicotine|Participants will reduce their nicotine intake
79351614|NCT04709471|Device|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
79351615|NCT04709471|Behavioral|Reduction|Participants will reduce the number of Juul pods that they use
79503048|NCT06125418|Procedure|standard healing abutment|patients will undergoes one-stage implant placement with standard titanium healing abutment made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
79503049|NCT06125405|Drug|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
79503050|NCT06125392|Diagnostic Test|Coronary physiology assessment|Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
79503051|NCT06125366|Drug|BAY1747846|Single dose; IV injection.
79503052|NCT06125366|Drug|Matching placebo|Single dose; IV injection.
79503053|NCT06125353|Dietary Supplement|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
79503054|NCT06125327|Drug|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
79503055|NCT06125327|Drug|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
79989314|NCT05846659|Radiation|PULSAR|1st day of Cycles 1, 2 and 3.
79989315|NCT05828342|Procedure|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
79989316|NCT05819268|Behavioral|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
79351616|NCT04690985|Behavioral|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
79351617|NCT04690985|Other|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
79503056|NCT06125301|Device|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
79503057|NCT06125197|Biological|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
79503058|NCT06125197|Biological|Pembrolizumab|Pembrolizumab, a monoclonal antibody binding PD-1
79503059|NCT06125184|Drug|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
79503060|NCT06125171|Drug|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m^2, 500mg, qd, q4w BSA<1.2m^2, 250mg, qd, q4w"
79665178|NCT00310661|Drug|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
79665179|NCT00310661|Other|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
79665180|NCT00421044|Drug|Patupilone/EPO906|
79665181|NCT00310700|Biological|Meningococcal C conjugate vaccine|
79989317|NCT05819268|Behavioral|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
79989318|NCT05816590|Other|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
79665182|NCT04715256|Behavioral|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
79665183|NCT04715256|Genetic|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
79665184|NCT04715256|Diagnostic Test|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
79665185|NCT00425217|Drug|Rituximab|
79665186|NCT00310778|Drug|high sodium diet|high sodium diet
79351618|NCT02033759|Device|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
79351619|NCT02033759|Other|Anxiety Questionnaire|21 item questionnaire
79351620|NCT02033759|Other|Traditional Circumferential Measurements|
79351621|NCT01959529|Drug|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
79351622|NCT01959529|Drug|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
79665187|NCT00310778|Drug|low sodium diet|low sodium diet
79665188|NCT00310778|Drug|ramipril 10 mg|ramipril 10 mg
79665189|NCT00310778|Drug|valsartan 160 mg|valsartan 160 mg
79665190|NCT00310778|Drug|candesartan 8 mg|candesartan 8 mg
79665191|NCT00310778|Drug|atenolol 50 mg|atenolol 50 mg
79665192|NCT00421083|Drug|tadalafil|
79665193|NCT00310895|Drug|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
79665194|NCT00425256|Drug|Bremelanotide|
79665195|NCT00310934|Drug|methadone|
79665196|NCT00310934|Drug|buprenorphine / methadone sequence|
79665197|NCT00310934|Behavioral|Relapse prevention|
79665198|NCT00310934|Behavioral|Contingency management|
79665199|NCT00421122|Drug|budesonide/formoterol (Symbicort)|inhalation therapy
79665200|NCT00421122|Drug|budesonide (Pulmicort)|inhalation
79665201|NCT00421122|Drug|terbutaline sulfate (Bricasol)|inhalation therapy
79351623|NCT02033369|Drug|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
79503061|NCT06125158|Procedure|Conventional ankle training|The program included ankle elastic band resistance training and balance training, in which the elastic band resistance training required subjects to complete resistance training in ankle plantarflexion, dorsiflexion, inversion and eversion directions with the help of elastic bands; and the balance training required subjects to complete the movements of standing with eyes open, standing with eyes closed, and throwing and catching the ball on flat ground and BOSU ball.
79503062|NCT06125158|Procedure|Hip strength training|Hip strength training required subjects to complete resistance training in hip abduction and posterior extension, anterior step-up and lateral step-up exercises with the help of elastic bands.
79665202|NCT00310973|Behavioral|Social Network Intervention|
79989319|NCT05814536|Drug|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
79989320|NCT05812911|Procedure|Standard oxygen|"Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
79351624|NCT02032901|Drug|Daclatasvir|
79351625|NCT02032901|Drug|Sofosbuvir|
79351626|NCT04681469|Drug|Niraparib|"For all patient's population:~Niraparib 200 mg/day: day -49 to day -21;~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~Niraparib 200 mg/day: day -21 to day -7~Dostarlimab 500 mg iv: day -7~Radiological assessment (day -1, ± 3 days),~Surgery (original margin) at day 0 (±3 days)~Standard postoperative (chemo)radiotherapy according to pathologic report;~Maintenance Niraparib, 200 mg/day for 6 months~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
79503063|NCT06125158|Procedure|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the gluteus mediums and gluteus maximus muscles of the affected side was carried out using the TB6807 low-frequency therapeutic instrument (with prescription for neuromuscular electrical stimulation) manufactured by China Tangbang Science and Technology Company.
79351627|NCT04416971|Procedure|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
79351628|NCT04690127|Other|Plyometric Exercise|Plyometric training consisting of ten different exercises [vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
79817376|NCT04186533|Behavioral|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
79989321|NCT05812911|Procedure|HFNO|"The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
79351629|NCT04689659|Biological|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
79351630|NCT02020967|Other|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
79817377|NCT04186533|Behavioral|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
79817378|NCT02581761|Drug|CYTOTEC|synthetic prostaglandin E1
79817379|NCT02581761|Other|Placebo|no active material
79989322|NCT05812911|Procedure|NIV|"Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
79989323|NCT05803785|Drug|BBC1501|BBC1501 solution for Intravitreal injection
79503064|NCT06125106|Drug|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
79503065|NCT06125093|Behavioral|Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)|"The IY-ASLD® program is a weekly group-based intervention for parents of children presenting neurodevelopmental problems (ASD symptoms, communication or language difficulties). The group is formed by 6-10 parents, and it is led by a group leader and a co-therapist, trained in the model.~The intervention is manualized. It includes video modelling and emphasizes the importance of practice-based learning through role-playing. The IY-ASLD® program takes into consideration the different developmental levels of each child and pairs parents according to this variable in role-play and other one-to-one discussions. Weekly home tasks will be assigned to parents, and families will be phoned each week to encourage home-based practice.~The intervention will be conducted online. Even though the IY-ASLD® original intervention comprises 14 sessions, the online format requires 22 weekly sessions.~Fidelity to the intervention will be assessed in accordance with the regulations of the program."
79665203|NCT00425295|Behavioral|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
79665204|NCT00311012|Drug|Aliskiren|
79665205|NCT00421161|Drug|olive oil and omega 3 in a combined cream|
79817380|NCT04101344|Other|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
79817381|NCT00771758|Drug|oxycodone IR|maximum daily dose 450 mg
79817382|NCT00771758|Drug|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
79989324|NCT05798104|Behavioral|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
79989325|NCT05790837|Behavioral|"Computer prompt Stand up for your Health®"|"The intervention group consists on the implementation of a desktop application Stand up for your Health® computer prompt following the model proposed by the Guide to Physical Activity at Work (34). This app works by showing reminders and asking users to pause their work activity and take an active break. Pauses can be customized and programmed according to the user's preference, allowing control of the time of each pause, between pauses, and the possibility of delaying or interrupting the pause. In this study, the Stand up for your Health® app will be scheduled to appear every 60 minutes on the workers' computers and each break will last for 2 minutes. During this resting period, the worker will see a notice or reminder on their screen with a countdown clock. The application allows you to postpone or interrupt directions."
79351631|NCT01986829|Device|Microwave ablation|"Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
79351632|NCT01986829|Device|Cryoablation|"Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
79665206|NCT00311051|Drug|ramatroban|
79665207|NCT00311051|Drug|montelukast|
79817383|NCT00771758|Drug|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
79503066|NCT06125080|Drug|Utidelone|Utidelone (30 mg/m2, days 1-5, every 3 weeks)
79817384|NCT05293821|Diagnostic Test|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
79989326|NCT05776927|Drug|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
79989327|NCT05776927|Drug|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
79989328|NCT05776927|Drug|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
79989329|NCT05776927|Drug|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
79351633|NCT01986829|Device|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
79351634|NCT01986829|Other|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
79503067|NCT06125080|Drug|Tirelizumab|Tirelizumab（200mg, day1, every 3 weeks）
79503068|NCT06125080|Drug|Bevacizumab|Bevacizumab(7.5mg/kg, day1, every 3 weeks)
79503069|NCT06125041|Drug|Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy|Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy*(20-30)f), brain (3Gy*10f)/ bone (3Gy*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
79503070|NCT06125028|Drug|[68Ga]Ga-PentixaFor|[68Ga]Ga-PTF i.v. injection
79817385|NCT02581371|Drug|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
79989330|NCT05776927|Drug|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
79989331|NCT05776927|Drug|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
79989332|NCT05776927|Device|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
79989333|NCT05776927|Device|Girohaler|Girohaler for Comparator and Placebo delivery.
79989334|NCT05759039|Procedure|Medial patellofemoral ligament reconstruction|Medial patellofemoral ligament reconstruction
79351635|NCT01986829|Other|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
79351636|NCT01986751|Drug|Clonidine|
79351637|NCT01986751|Drug|ropivacaine|
79351638|NCT02004847|Device|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
79351639|NCT01438060|Drug|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
79351640|NCT01438060|Drug|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
79503071|NCT06125028|Drug|[18F]Fluorodeoxyglucose|[18F]FDG i.v. injection.
79665208|NCT00311129|Drug|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
79665209|NCT00311129|Drug|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
79989335|NCT05746247|Behavioral|Testing centralized referral mechanisms for PCPs|"For patients with a Penn PCP, we are testing the two different centralized referral mechanisms to increase the number of referrals to preventive cardiology (active choice vs default/opt out referrals)~For active choice: A non-interruptive In Basket alert will be delivered to PCPs that have patients that have been screened as positive with the FIND FH tool and recommends a referral to a lipid specialist. PCPs will have the choice of either accepting the referral or declining the referral. If they do not take action on the In Basket alert, the referral will stay in their In Basket.~For default/opt out: A non-interruptive In Basket alert will be delivered to PCPs that have patients that have been screened as positive with the FIND FH tool and recommends a referral to a lipid specialist. Not interacting with the BPA or accepting the BPA will indicate that the referral to a lipid specialist should be placed."
79351641|NCT01469182|Biological|SCH 39641|Rapidly dissolving tablet sublingually once daily
79351642|NCT01469182|Drug|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
79351643|NCT01444378|Device|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
79351644|NCT02020889|Biological|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
79351645|NCT02020889|Drug|Placebo|Placebo will be available as 0.9% sodium chloride
79351646|NCT01444300|Drug|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
79351647|NCT01444300|Drug|Placebo|placebo pill, bid for 12 weeks
79351648|NCT04681001|Device|nasal spray|application of nasal spray into nostrils and mouth
79503072|NCT06125015|Diagnostic Test|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
79351649|NCT01443364|Biological|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
79351650|NCT02020577|Drug|Cetuximab( erbitux®)|once per week
79351651|NCT02020577|Drug|Afatinib|once per day
79351652|NCT02020031|Drug|Vancomycin|
79503073|NCT06125002|Drug|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
79503074|NCT06125002|Drug|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
79503075|NCT06124989|Diagnostic Test|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
79503076|NCT06124976|Drug|ST-02|ST-02 drug instillation into the upper urinary tract (renal pelvis)
79503077|NCT06124963|Drug|WX390|WX390 tablet, 0.9 mg once a day
79503078|NCT06124963|Drug|Toripalimab|240 mg, Day 1, every 3 weeks
79817386|NCT02581371|Other|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
79817387|NCT02688465|Drug|Apomorphine|
79989336|NCT05746247|Behavioral|Testing out patient outreach methods|Testing health care system mediated outreach vs Family Heart Foundation mediated outreach to see which type of outreach might be most effective at getting patients to schedule an appointment with a lipid specialist
79989337|NCT05741944|Other|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
79989338|NCT05741944|Other|standard care|All patients in control condition receive usual care.
79989339|NCT05729659|Dietary Supplement|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
79989340|NCT05729659|Dietary Supplement|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
79989341|NCT05720507|Behavioral|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
79351653|NCT04179305|Behavioral|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
79351654|NCT04179305|Behavioral|Usual Care Arm|Oncologists will provide care in non-specific manner.
79351655|NCT02019719|Drug|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
79351656|NCT02019719|Drug|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
79351657|NCT02030405|Drug|Ixazomib|Given orally (PO)
79351658|NCT01975376|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
79351659|NCT01975376|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
79503079|NCT06124911|Other|Leg Press Resistance Training (3x5)|Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
79351660|NCT01443130|Drug|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
79351661|NCT01443130|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
79665210|NCT00311285|Device|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
79351662|NCT04065256|Other|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
79503080|NCT06124911|Other|Leg Press Resistance Training (5x5)|Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
79665211|NCT04715412|Other|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
79665212|NCT00311441|Biological|Tick-Borne Encephalitis vaccine|
79351663|NCT04065256|Other|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
79351664|NCT01436500|Drug|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
79665213|NCT00342381|Drug|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
79351665|NCT01436500|Drug|Placebo|Sterile water with 5% Dextrose
79351666|NCT01958827|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
79351667|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
79351668|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
79351669|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
79351670|NCT01620086|Device|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
79665214|NCT00342381|Drug|Placebo|Single dose placebo treatment
79665215|NCT00311480|Biological|Influenza vaccine surface antigen adjuvanted with MF59|
79665216|NCT00311519|Drug|Hylenex|
79665217|NCT00311558|Biological|recombinant interferon alfa-2b|SSG x 5 week
79665218|NCT00311558|Drug|sodium stibogluconate|SSG & IFN
79665219|NCT00311558|Drug|SSG & interferon|1 arm study with SSG & interferon
79351671|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
79665220|NCT00418925|Drug|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
79351672|NCT04670653|Drug|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
79351673|NCT04670653|Drug|MOMETASONE FUROATE|Mometasone furoate nasal spray
79351674|NCT01436110|Drug|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
79351675|NCT01436110|Drug|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
79351676|NCT01436110|Drug|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
79351677|NCT01619852|Drug|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
79351678|NCT01619852|Drug|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
79351679|NCT04069936|Biological|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
79665221|NCT00311597|Procedure|Radiosurgery|single fractionated radiation therapy
79665222|NCT00339417|Drug|Albendazole|
79351680|NCT04069936|Biological|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
79351681|NCT04069936|Drug|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
79351682|NCT02000882|Drug|BKM120|
79351683|NCT02000882|Drug|capecitabine|
79351684|NCT02000882|Drug|Trastuzumab|
79665223|NCT00339417|Drug|Ivermectin|
79665224|NCT00311636|Drug|cyclophosphamide|
79665225|NCT00311636|Drug|docetaxel|
79665226|NCT00311636|Drug|doxorubicin hydrochloride|
79665227|NCT00311636|Drug|epirubicin hydrochloride|
79665228|NCT00311636|Drug|fluorouracil|
79665229|NCT00311636|Drug|methotrexate|
79665230|NCT00311636|Drug|paclitaxel|
79665231|NCT00311636|Drug|triptorelin|
79665232|NCT00311636|Procedure|adjuvant therapy|
79665233|NCT00311675|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
79665234|NCT00311714|Drug|CS-8958 formulated as dry powder|
79665235|NCT00311714|Other|Placebo|
79503081|NCT06124885|Diagnostic Test|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
79665236|NCT00339456|Drug|HAART|
79351685|NCT01965938|Device|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
79503082|NCT06124872|Other|Survey questionnaire|Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported
79665237|NCT00311753|Drug|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
79665238|NCT00311753|Drug|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
79665239|NCT00311792|Behavioral|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
79665240|NCT00311792|Behavioral|Traditional clinical education|
79351686|NCT01965938|Device|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
79351687|NCT01965860|Other|additional curriculum (E-learning + simulation)|
79351688|NCT01965860|Other|additional E-learning|
79665241|NCT00311831|Behavioral|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
79665242|NCT00311831|Behavioral|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
79351689|NCT04415827|Diagnostic Test|bicycle ergometry test with spiroergometry|"The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)"
79665243|NCT00311870|Drug|nisoldipine|
79665244|NCT00311870|Drug|lisinopril|
79665245|NCT00311948|Behavioral|Telephone counseling + interactive website = more abstinence|
79665246|NCT00311948|Behavioral|Behavioral: interactive website|
79665247|NCT00311987|Drug|3,5-Diiodothyropropionic acid (DITPA) therapy|
79665248|NCT00342849|Drug|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
79665249|NCT00342849|Drug|Placebo|
79665250|NCT00312026|Drug|efalizumab|
79665251|NCT00312065|Device|Application of reflective heat shield to thermistor probe|
79665252|NCT00312104|Drug|insulin detemir|
79665253|NCT00312104|Drug|insulin glargine|
79665254|NCT00312104|Drug|insulin aspart|
79665255|NCT00339690|Other|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
79665256|NCT00312143|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
79665257|NCT00343005|Biological|AMA1-C1|
79665258|NCT00343005|Drug|AMA1-C1/alhydrogel Malaria Vaccine|
79665259|NCT00312182|Drug|Nelfinavir|
79665260|NCT00312260|Drug|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
79665261|NCT00312260|Drug|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
79665262|NCT00343122|Procedure|echocardiography for intrapulmonary vasodilatation|
79351691|NCT04666129|Drug|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
79665263|NCT00312299|Device|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
79665264|NCT00312299|Device|Round edge PMMA IOL|Round edge PMMA IOL
79351692|NCT04666129|Drug|Abiraterone|Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.
79351693|NCT04666129|Drug|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
79351694|NCT04666129|Drug|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
79503083|NCT06124872|Other|Key informant interview|Semi-structured interview with selected key informants
79665265|NCT00312299|Device|Acrysof IOL|Acrysof IOL
79665266|NCT00312299|Device|square Edge PMMA IOL|Square edge PMMA intra ocular lens
79665267|NCT00312299|Device|Square Edge PMMA IOL|Square Edge PMMA IOL lens
79665268|NCT00312416|Drug|Clonidin|
79351695|NCT04666129|Drug|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
79351696|NCT04666129|Drug|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
79665269|NCT00312416|Drug|Brimonidine|
79351697|NCT04666051|Biological|Application of fibrin glue sealant|
79503084|NCT06124859|Other|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
79503085|NCT06124846|Behavioral|CB-Abst|incentivized, biochemically verified abstinence via contingency management
79351698|NCT01965704|Drug|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
79503086|NCT06124846|Behavioral|CB-Mon|monitoring with no required abstinence
79503087|NCT06124820|Device|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
79503088|NCT06124820|Device|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
79503089|NCT06124781|Procedure|Blood sample|A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
79665270|NCT00339768|Drug|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
79665271|NCT00312455|Drug|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
79665272|NCT00312455|Drug|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
79665273|NCT00312455|Drug|Placebo|5 capsules/day
79665274|NCT00343161|Drug|esomeprazole|
79989342|NCT05717192|Device|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
79503090|NCT06124781|Procedure|Skin biopsies|2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.
79503091|NCT06124781|Procedure|ROAT test|ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
79351699|NCT01965704|Drug|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
79351700|NCT02003365|Drug|FX006 10 mg|Extended-release formulation
79351701|NCT02003365|Drug|FX006 40 mg|Extended-release formulation
79665275|NCT00343161|Drug|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
79665276|NCT00312533|Drug|Hylan F- 20|
79351702|NCT02003365|Drug|TCA IR 40 mg|Immediate-release formulation
79351703|NCT01975220|Drug|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
79351704|NCT01975220|Drug|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
79665277|NCT00312611|Device|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
79665278|NCT00312650|Drug|liposomal doxorubicin and gemcitabine|
79665279|NCT00343200|Drug|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
79503092|NCT06124768|Procedure|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is >50% stenosis of the diameter of the iliac vein.
79665280|NCT00343200|Drug|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
79351705|NCT01975220|Drug|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
79351706|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
79665281|NCT00312767|Drug|Fabrazyme (agalsidase beta)|
79665282|NCT00312806|Drug|Pantoprazole|Pantoprazole 40 mg o.d.
79665283|NCT00347685|Drug|tramadol ER|
79665284|NCT00312962|Behavioral|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
79665285|NCT00312962|Behavioral|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
79665286|NCT00343239|Drug|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
79351707|NCT01975220|Drug|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
79351708|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
79989343|NCT05714345|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
79351709|NCT04665583|Other|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
79351710|NCT01958437|Device|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
79351711|NCT01974752|Drug|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
79351712|NCT01974752|Drug|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
79351713|NCT01974752|Drug|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
79665287|NCT00343239|Drug|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
79665288|NCT00343239|Drug|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
79665289|NCT00313001|Drug|biphasic insulin aspart|
79665290|NCT00313001|Drug|exenatide|
79665291|NCT00343278|Drug|Valaciclovir Hydrochloride|
79665292|NCT00313040|Behavioral|Brief Consultation with Health Counselor, workbook|
79665293|NCT00313040|Behavioral|Usual Care wait list|
79665294|NCT00343317|Drug|Intrapartum Cefoxitin (2g) vs. placebo|
79665295|NCT00313079|Drug|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
79665296|NCT00313079|Drug|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
79665297|NCT00343356|Drug|Trement|
79665298|NCT00347724|Drug|Tramadol HCl ER|
79665299|NCT00313157|Drug|Metoprolol|
79665300|NCT00313157|Drug|Diltiazem|
79665301|NCT00313157|Drug|Verapamil|
79665302|NCT00313157|Drug|Carvedilol|
79665303|NCT00343395|Drug|AVANDAMET|2/500 mg
79665304|NCT00347763|Procedure|10% permethrin in water applied as low volume spray|
79989344|NCT05714345|Drug|Fludarabine|Chemotherapy for lymphodepletion
79989345|NCT05714345|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
79351714|NCT01999946|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
79351715|NCT01958281|Drug|SOF|Tablet(s) administered orally once daily
79351716|NCT01958281|Drug|RBV|200 mg tablet administered orally once daily
79351717|NCT01958281|Drug|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
79351718|NCT04665115|Drug|Ibrutinib|Given PO
79351719|NCT04665115|Other|Quality-of-Life Assessment|Ancillary studies
79351720|NCT01958125|Device|gammaCore|Vagal stimulation
79351721|NCT02002975|Drug|Pioglitazone|Pioglitazone tablets
79351722|NCT02001181|Drug|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
79351723|NCT02001181|Drug|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
79351724|NCT04644679|Diagnostic Test|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
79351725|NCT04644679|Diagnostic Test|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
79351726|NCT04176055|Drug|Haloperidol|haloperidol intervention
79817388|NCT04186611|Other|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
79351727|NCT01999465|Device|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (300 us)~Ch1 Ramp+ (2 seconds)~On Time 1 (10 seconds)~Ch1 Ramp - (2 seconds)"
79351728|NCT01999465|Device|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (48 us)~Ch1 Ramp+ (0 seconds)~On Time 1 (0 seconds)~Ch1 Ramp - (0 seconds)"
79351729|NCT01982773|Behavioral|Virtual Hope Box Smartphone App|Smartphone app
79351730|NCT01982773|Behavioral|Enhanced Treatment as Usual|Printed materials
79351731|NCT01974206|Biological|ASP0113|intramuscular injection
79351732|NCT01974206|Drug|Placebo|intramuscular injection
79351733|NCT04416464|Other|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
79351734|NCT04659278|Dietary Supplement|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
79351735|NCT04659278|Dietary Supplement|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
79351736|NCT04659278|Other|Placebo|Total CBD = CBD + (CBD-A * 0.877). Total THC = THCA-A * 0.877 + Delta 9 THC, ND = <LOQ, T-Caryophyllene = Trans-Caryophyllene, <LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
79351737|NCT04659278|Dietary Supplement|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
79351738|NCT01999868|Biological|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh <= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab."
79351739|NCT01999868|Biological|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
79351740|NCT01999868|Drug|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
79351741|NCT01999868|Drug|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
79351742|NCT01957579|Drug|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
79351743|NCT03511963|Drug|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
79503093|NCT06124768|Procedure|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is >50% stenosis of the diameter of the iliac vein.
79817389|NCT02688543|Procedure|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
79817390|NCT02688543|Radiation|radiofrequency ablation|
79817391|NCT02688543|Device|ultrasound|
79817392|NCT00758498|Drug|armodafinil|50 mg/day orally, once daily in the morning for 3 days
79817393|NCT00758498|Drug|armodafinil|150 mg/day orally, once daily in the morning for 3 days
79351744|NCT03511963|Drug|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
79351745|NCT01999322|Drug|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
79351746|NCT01999322|Drug|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
79351747|NCT01996982|Device|CCS Device|Core Cooling System Device
79351748|NCT01965158|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
79503094|NCT06124755|Device|Viabahn endoprosthesis group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
79503095|NCT06124755|Device|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
79989346|NCT05714345|Genetic|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
79351749|NCT01965158|Drug|Placebo|Placebo tablet taken orally once a day
79503096|NCT06124742|Device|clear aligners|taste perception will be evaluated before and after using clear aligners.
79817394|NCT00758498|Drug|placebo|placebo tablets, once daily in the morning for 3 days
79989347|NCT05700552|Behavioral|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
79817395|NCT00798161|Drug|BI 1356|BI 1356 high dose tablet, once daily
79989348|NCT05687071|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 52 weeks
79351750|NCT01964924|Drug|Akt Inhibitor GSK2141795|Given PO
79989349|NCT05683340|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
79228350|NCT03726957|Behavioral|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
79351751|NCT01964924|Other|Laboratory Biomarker Analysis|Correlative studies
79351752|NCT01964924|Drug|Trametinib|Given PO
79351753|NCT01964378|Drug|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
79351754|NCT01964378|Drug|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
79503097|NCT06124729|Drug|Bevacizumab Combined With PD-1 Monoclonal Antibody|Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS colorectal cancer with liver metastases
79503098|NCT06124690|Device|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
79503099|NCT06124664|Diagnostic Test|Radionuclide venography|With the patient in an upright position, 370 MBq of 99mTc pertechnetate is injected into one of the dorsal veins of the foot after applying a tourniquet in the area of the ankle joint. Then, with the help of a gamma camera detector, the movement of the radiopharmaceutical is monitored in the following segments: tibial (muscular-venous pump of the lower leg), popliteal, femoral and iliocaval. To study the evacuation function of the muscular-venous pump (MVP) of the leg, using an analytical computer program, areas of interest are identified in the tendon, muscle parts of the veins of the leg and the popliteal vein. The time of evacuation of the radiopharmaceutical from the MVP of the leg is estimated - the average transport time of the isotope.
79817396|NCT00798161|Drug|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
79817397|NCT00798161|Drug|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
79817398|NCT00798161|Drug|Metformin|Metformin 500 mg tablet, twice daily
79817399|NCT00798161|Drug|metformin|metformin 1000 mg tablet, twice daily
79817400|NCT00798161|Drug|matching placebo|matching placebo
79989350|NCT05683340|Drug|Placebo|placebo, tablet, once daily, for 12 weeks
79989351|NCT05676931|Drug|Domvanalimab|Administered as specified in the treatment arm
79989352|NCT05676931|Drug|Quemliclustat|Administered as specified in the treatment arm
79989353|NCT05676931|Drug|Zimberelimab|Administered as specified in the treatment arm
79989354|NCT05676931|Drug|Docetaxel|Administered as specified in the treatment arm
79989355|NCT05676931|Drug|Platinum-Based Doublet|Administered as specified in the treatment arm
79989356|NCT05663034|Behavioral|Mindfulness-based treatment for insomnia (MBTI)|A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
79351755|NCT01442038|Drug|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
79351756|NCT01442038|Drug|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
79503100|NCT06124664|Diagnostic Test|single-photon emission computed tomography|"SPECT of the pelvic veins with in vivo-labelled red blood cells (RBCs). For radionuclide assessment of the state of the pelvic veins, 2 ml of Perfotech solution is injected into the cubital vein for subsequent labeling of red blood cells in vivo. In 20 minutes. 370 MBq of 99mTc-pertechnetate is injected into one of the veins of the dorsum of the foot and radionuclide venoscintigraphy is performed according to the method presented above. 20 minutes after the administration of the radiopharmaceutical and the venography, SPECT of the pelvic veins is performed. Tomography of the distribution of labeled erythrocytes in the pelvic veins is carried out in a circular orbit with the gamma camera detector rotated 360°. The analysis of the obtained information is carried out using the standard ECT Protocol software package, which allows obtaining sections in 3 projections (sagittal, transversal and coronal) with a slice step of 8 mm."
79989357|NCT05663034|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I)|Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
79989358|NCT05662943|Drug|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
79989359|NCT05659381|Drug|Cisplatin|Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
79351757|NCT01998919|Drug|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
79351758|NCT01998919|Drug|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
79351759|NCT01998919|Drug|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
79351760|NCT01998919|Drug|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
79351761|NCT01998919|Drug|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
79351762|NCT01964300|Biological|peginterferon alfa-2b|Given subcutaneously (SC)
79351763|NCT01964300|Other|laboratory biomarker analysis|Correlative studies
79989360|NCT05659381|Other|No treatment|No treatment with Cisplatin
79351764|NCT01964222|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
79351765|NCT04416230|Behavioral|massage|The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
79351766|NCT04416230|Behavioral|quiet time|During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
79351767|NCT04416074|Behavioral|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
79351768|NCT04416074|Other|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
79351769|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets
79351770|NCT01467700|Drug|Placebo|Ramelteon placebo-matching tablets
79351771|NCT01972724|Drug|Pioglitazone|Pioglitazone tablets
79351772|NCT01972724|Drug|Metformin|Metformin as prescribed in clinical practice
79351773|NCT01972724|Drug|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
79351774|NCT01441960|Drug|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
79351775|NCT01441960|Drug|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
79989361|NCT05641662|Other|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
79989362|NCT05620979|Behavioral|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
79351776|NCT04508062|Procedure|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
79351777|NCT04508062|Procedure|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
79665305|NCT00313235|Biological|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
79351778|NCT04062838|Drug|Dextrose 50|As above
79351779|NCT04408534|Other|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
79351780|NCT01955707|Drug|natalizumab|Administered as described in the treatment arm
79351781|NCT01955707|Drug|Placebo|Matched placebo
79351782|NCT01435798|Drug|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
79351783|NCT01972568|Drug|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
79351784|NCT01972568|Drug|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
79351785|NCT01972568|Drug|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
79665306|NCT00347802|Drug|Bimatoprost 0.03%, Travoprost 0.004%|
79351786|NCT01955161|Drug|Placebo|Once daily, matching placebo capsules, orally
79351787|NCT01955161|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
79351788|NCT01441414|Biological|PF-04856884|15 mg/kg/week intravenously [IV] until toxicity or disease progression
79351789|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
79989363|NCT05616767|Other|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
79989364|NCT05614648|Drug|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
79351790|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
79351791|NCT01971554|Drug|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
79503101|NCT06124651|Procedure|Total knee replacement with cruciate retaining femoral component|To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
79503102|NCT06124651|Procedure|Total knee replacement with cruciate substituting femoral component|"To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different."
79665307|NCT00313274|Drug|Clevudine|
79665308|NCT00343434|Behavioral|behavioral dietary intervention|
79989365|NCT05614648|Device|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
79989366|NCT05613413|Drug|Cabozantinib 40 MG|Cabozantinib is taken my mouth
79351792|NCT01971554|Drug|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
79351793|NCT04411459|Other|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
79351794|NCT04664335|Other|questionnaire|if no Reply to questionnaire, telephone interview
79351795|NCT01955083|Device|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
79351796|NCT01955083|Device|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
79351797|NCT01955005|Behavioral|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
79351798|NCT01955005|Other|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
79665309|NCT00343434|Behavioral|exercise intervention|
79665310|NCT00343434|Dietary Supplement|soy isoflavones|
79665311|NCT00343434|Dietary Supplement|soy protein isolate|
79665312|NCT00343434|Other|counseling intervention|
79665313|NCT00343434|Other|educational intervention|
79665314|NCT00343434|Procedure|psychosocial assessment and care|
79665315|NCT00343434|Procedure|quality-of-life assessment|
79665316|NCT00419042|Drug|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
79989367|NCT05613413|Drug|Pembrolizumab 200mg|Pembrolizumab is given intravenously
79989368|NCT05613413|Drug|Pembrolizumab 400mg|Pembrolizumab is given intravenously
79989369|NCT05610839|Behavioral|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods & Twohig, 2008).
79351799|NCT01954927|Drug|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
79989370|NCT05608824|Device|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
79989371|NCT05606731|Behavioral|Family-Based Childhood Obesity Intervention|The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
79351800|NCT01954927|Drug|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
79665317|NCT00419042|Drug|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
79989372|NCT05606289|Behavioral|Crisis Intervention Team (CIT) training|Standard 40-hour CIT training given in one week.
79989373|NCT05598905|Drug|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
79503103|NCT06124612|Diagnostic Test|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
79665318|NCT00347841|Drug|Bimatoprost 0.03%, Latanoprost|
79665319|NCT00425126|Drug|Epoetin Alfa|
79665320|NCT00343551|Drug|Aliskiren|
79665321|NCT04715334|Device|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
79665322|NCT00347997|Device|217z Laser|LASIK correction of myopia and myopic astigmatism
79665323|NCT00343590|Device|Whole Body Vibration machine|
79665324|NCT00343629|Drug|sulindac|
79665325|NCT00343629|Other|pharmacological study|
79665326|NCT00343668|Drug|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
79665327|NCT00348036|Behavioral|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
79989374|NCT05598905|Drug|Oxycodone 10mg|one 10mg tablet
79989375|NCT05598905|Drug|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
79989376|NCT05595187|Device|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
79503104|NCT06124599|Other|Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other
79665328|NCT00348036|Other|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
79665329|NCT00343707|Drug|vestipitant|
79989377|NCT05588674|Dietary Supplement|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
79989378|NCT05588674|Other|Placebo Capsule|8.5 week supplementation period. One capsule daily.
79989379|NCT05584553|Device|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
79989380|NCT05584553|Device|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
79351801|NCT01954771|Behavioral|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
79351802|NCT01954771|Other|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
79351803|NCT01997281|Dietary Supplement|dietary fiber-enriched cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~one serving of steamed egg is added for dinner and breakfast"
79503105|NCT06124599|Other|Identification of symptoms of menstrual in control patient in the last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
79503106|NCT06124573|Drug|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
79503107|NCT06124560|Drug|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
79503108|NCT06124547|Drug|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
79665330|NCT00343707|Drug|paroxetine|
79989381|NCT05581810|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.
79989382|NCT05581810|Behavioral|Cognitive Rehabilitation|Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
79989383|NCT05579587|Device|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
79989384|NCT05577364|Drug|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
79989385|NCT05577364|Drug|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
79989386|NCT05564663|Behavioral|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
79228351|NCT05124834|Diagnostic Test|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
79228352|NCT05124834|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
79351804|NCT01997281|Other|conventional cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
79665331|NCT00313391|Drug|Risperdal Consta|
79665332|NCT00348075|Device|Neurovision|
79665333|NCT00348114|Procedure|Transplantation of cultivated limbal epithelium|
79665334|NCT00343902|Drug|Crataegus Special Extract WS 1442|
79665335|NCT00348153|Drug|Adalimumab|
79665336|NCT00313508|Biological|Autologous Dendritic Cells (DC)|Given intranodally
79817401|NCT02688231|Other|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
79228353|NCT03712371|Drug|Chitosan|The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
79817402|NCT02688231|Other|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
79351805|NCT04663087|Device|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
79351806|NCT04663087|Other|Standard of Care|As currently provided by EMS services
79351807|NCT01953913|Drug|Afatinib|Patient will receive afatinib once daily
79351808|NCT01971476|Drug|volasertib|intravenous administration on day 1of a treatment course
79665337|NCT00313508|Drug|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
79665338|NCT00313508|Biological|Autologous Lymphocyte Infusion (ALI)|Infusion
79665339|NCT00343941|Drug|Tucaresol tablets 25 mg|
79665340|NCT00313547|Drug|Quinapril 40 mg|
79665341|NCT00313547|Drug|Quinapril 10 mg and amlodipine 5 mg|
79665342|NCT00348192|Drug|SB-742457|
79817403|NCT02581683|Drug|Magnesium Sulfate|Given via adductor canal block
79817404|NCT02581683|Drug|Ropivacaine|Given via adductor canal block
79817405|NCT02581683|Other|Sham|Sham adductor canal block
79817406|NCT02688075|Other|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
79817407|NCT04076709|Procedure|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
79817408|NCT04111523|Drug|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
79817409|NCT00638781|Drug|Desmoteplase|Desmoteplase 62.5 µg/kg BW
79989387|NCT05564663|Behavioral|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
79989388|NCT05548452|Drug|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
79228354|NCT02467088|Other|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
79228355|NCT02235129|Other|breath-holding|
79228356|NCT05727956|Procedure|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
79228357|NCT03469518|Dietary Supplement|β-Cx plus PS plus GOS|
79228358|NCT03469518|Dietary Supplement|β-Cx plus PS|
79351809|NCT01996904|Procedure|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
79351810|NCT01996904|Procedure|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
79351811|NCT01970540|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
79665343|NCT00348192|Drug|donepezil|
79665344|NCT00313625|Drug|busulfan|
79665345|NCT00313625|Drug|melphalan|
79665346|NCT00313625|Drug|methotrexate|
79665347|NCT00313625|Drug|tacrolimus|
79665348|NCT00313625|Procedure|allogeneic hematopoietic stem cell transplantation|
79665349|NCT00313625|Procedure|peripheral blood stem cell transplantation|
79817410|NCT00638781|Drug|Desmoteplase|Desmoteplase 90 µg/kg BW
79817411|NCT00638781|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW
79665350|NCT00343980|Drug|rosiglitazone|Tablets, 4 mg once or twice a day.
79665351|NCT00343980|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
79665352|NCT00343980|Drug|glimepiride|Tablets, 4 mg/day.
79665353|NCT00313859|Drug|simvastatin|
79665354|NCT00348231|Drug|dual-action insulin analog|
79665355|NCT00313898|Drug|sildenafil (viagra)|
79665356|NCT00313937|Drug|Insulin glargine|
79665357|NCT00348270|Device|Tecnis Z9000 intraocular lens|
79665358|NCT00348270|Device|MA60 intraocular lens|
79665359|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
79817412|NCT00638781|Drug|Placebo|Placebo
79989389|NCT05548452|Drug|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
79989390|NCT05548426|Drug|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
79989391|NCT05548426|Drug|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
79351812|NCT01970540|Drug|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
79351813|NCT01963676|Device|tDCS|
79989392|NCT05546281|Other|No intervention|No intervention
79228359|NCT03302078|Drug|BI 1015550|Fed state
79351814|NCT01963676|Device|Sham stimulation|
79351815|NCT01996826|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
79351816|NCT01996826|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
79351817|NCT01996748|Drug|DF277|Two administrations daily for 7 days
79351818|NCT01996748|Drug|Placebo|Two administrations daily for 7 days
79351819|NCT01621178|Drug|Dulaglutide|Administered SC
79989393|NCT05534529|Drug|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
79351820|NCT01621178|Drug|Insulin glargine|Administered SC
79351821|NCT01621178|Drug|Insulin lispro|Administered SC
79351822|NCT01962974|Biological|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
79351823|NCT01962896|Drug|Erlotinib|
79351824|NCT01962896|Drug|Sirolimus|
79351825|NCT01970462|Drug|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
79665360|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
79665361|NCT00344097|Procedure|Soy protein|
79665362|NCT00314054|Drug|HCV-796|HCV-796 1000mg single dose
79665363|NCT00348387|Biological|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
79665364|NCT00348387|Biological|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
79665365|NCT00314171|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
79351826|NCT01970462|Drug|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
79665366|NCT00314171|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
79665367|NCT00348426|Drug|Botulinum AntiToxin|
79351827|NCT01958671|Drug|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
79989394|NCT05525676|Behavioral|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
79989395|NCT05525676|Behavioral|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 & 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
79989396|NCT05521815|Other|Coma arousal therapy|early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
79989397|NCT05521815|Other|Selected physiotherapy program|selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
79989398|NCT05514197|Drug|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
79989399|NCT05514197|Drug|Control Rx|Intravenous loading 100ml normal saline
79351828|NCT01958671|Drug|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
79989400|NCT05513313|Biological|JYNNEOS|smallpox vaccine
79989401|NCT05511909|Drug|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
79351829|NCT01958671|Drug|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
79989402|NCT05511909|Drug|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
79351830|NCT01958671|Drug|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
79351831|NCT01958671|Drug|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
79503109|NCT06124495|Drug|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
79665368|NCT00348426|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
79989403|NCT05511909|Drug|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
79989404|NCT05496075|Drug|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
79989405|NCT05496075|Drug|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
79351832|NCT01958671|Drug|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
79351833|NCT01995266|Drug|Asunaprevir|
79351834|NCT01995266|Drug|Daclatasvir|
79503110|NCT06124469|Diagnostic Test|US-guided fine needle aspiration (FNA)|This study enrolled consecutive patients in follow-up for DTC history who underwent US-guided fine needle aspiration (FNA) of the LNs for suspicious metastatic cervical
79665369|NCT00348426|Procedure|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
79665370|NCT00314210|Drug|Quetiapine SR|
79665371|NCT00344214|Behavioral|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
79817413|NCT04115423|Drug|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
79351835|NCT01969058|Drug|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
79351836|NCT01968980|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
79351837|NCT01968980|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
79665372|NCT00344214|Behavioral|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
79989406|NCT05494905|Other|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
79989407|NCT05494905|Other|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
79989408|NCT05493735|Drug|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
79989409|NCT05493735|Drug|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
79989410|NCT05486585|Other|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
79989411|NCT05480722|Other|Dietary Intervention|Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity
79989412|NCT05480722|Other|Hypertonic Saline|Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
79989413|NCT05480124|Device|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
79351838|NCT01961882|Drug|OCV-501|
79351839|NCT01961882|Drug|Placebo|
79351840|NCT04174118|Drug|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
79503111|NCT06124430|Other|ECOX box|For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
79665373|NCT00314288|Drug|Sarizotan HCl|
79665374|NCT00348465|Procedure|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
79665375|NCT00344253|Drug|Interferon beta|
79665376|NCT00344253|Drug|Methotrexate|
79228360|NCT03302078|Drug|BI 1015550|Fasted state
79228361|NCT04378920|Drug|LEAF-4L6715|LEAF-4L6715
79228362|NCT03473028|Procedure|transabdominal ultrasound guided embryo transfer|400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer
79351841|NCT04174118|Drug|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
79351842|NCT01968434|Device|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
79351843|NCT01968434|Drug|carbocisteine cough syrup|Mucolytic
79351844|NCT04659902|Dietary Supplement|Protein form|Protein form and absence or presence of calcium manipulated
79351845|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
79351846|NCT01946438|Biological|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
79665377|NCT00314405|Drug|Methylene blue (1%)|
79665378|NCT00314405|Drug|Rhenium sulfure|
79351847|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
79665379|NCT00314405|Procedure|Surgical procedure|
79989414|NCT05480124|Device|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
79989415|NCT05477901|Other|Supplemental cash transfer|Supplemental cash transfer ($40/month)
79989416|NCT05474027|Other|Avoidance of Deliberate Hypotensive Anesthesia|The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
79989417|NCT05474027|Drug|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
79989418|NCT05469815|Behavioral|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
79989419|NCT05465239|Device|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
79989420|NCT05462288|Device|Entia Liberty|Home monitoring blood analyser
79351848|NCT01946438|Biological|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
79665380|NCT00314405|Procedure|Anatomo-pathologic procedure|
79989421|NCT05447858|Other|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
79351849|NCT01946282|Other|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
79503112|NCT06124417|Drug|Sertraline|The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
79665381|NCT04715295|Drug|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
79989422|NCT05447858|Other|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
79665382|NCT04715295|Drug|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
79665383|NCT04715295|Combination Product|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
79665384|NCT00314483|Drug|Mesenchymal Stem Cell Infusion|
79665385|NCT00348504|Drug|levosimendan|
79665386|NCT00348504|Drug|dobutamine|
79665387|NCT00348543|Procedure|laser treatment|
79665388|NCT00314561|Drug|Pioglitazone, Rosiglitazone|
79665389|NCT00344409|Drug|darbepoetin alfa|
79665390|NCT00314600|Device|above and below elbow cast|
79665391|NCT00348582|Drug|Ketorolac, Nepafenac|
79665392|NCT00314639|Drug|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
79665393|NCT00348621|Procedure|Visual impairment intervention program|enhanced access to eye care services
79665394|NCT00314678|Drug|Topotecan|
79665395|NCT00314678|Drug|Cisplatin|
79665396|NCT00314678|Drug|Paclitaxel|
79665397|NCT00314717|Behavioral|Control diet|
79665398|NCT00314717|Behavioral|Low GI diet|
79665399|NCT00344526|Drug|Melphalan|
79665400|NCT00344526|Drug|Dexamethasone|
79503113|NCT06124365|Other|Shock wave therapy and core stability exercises|20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.
79351850|NCT01946282|Other|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
79351851|NCT01946282|Other|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
79351852|NCT01945580|Procedure|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
79351853|NCT01945034|Drug|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
79665401|NCT00344526|Procedure|Autologous stem cell transplantation|
79351854|NCT01945034|Drug|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
79351855|NCT01945034|Drug|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
79351856|NCT01945034|Drug|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
79351857|NCT04655768|Device|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
79351858|NCT04638062|Other|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
79665402|NCT00344565|Drug|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
79665403|NCT00344565|Behavioral|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
79665404|NCT00314834|Drug|Intradialytic parenteral nutrition|
79228363|NCT03473028|Procedure|transvaginal ultrasound guided embryo transfer|400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
79228364|NCT03712137|Device|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
79503114|NCT06124365|Other|core stability exercises only|20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
79665405|NCT00348699|Drug|AFP464|Given IV
79665406|NCT00348699|Other|pharmacological study|Correlative studies
79665407|NCT00348699|Other|laboratory biomarker analysis|Correlative studies
79989423|NCT05445284|Behavioral|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
79989424|NCT05445284|Other|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
79351859|NCT04638062|Other|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
79665408|NCT00314873|Drug|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
79989425|NCT05444517|Procedure|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
79989426|NCT05444517|Procedure|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
79989427|NCT05443178|Drug|Nivaquine ® (Chloroquine)|dose escalation and extension trial
79989428|NCT05442671|Behavioral|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
79989429|NCT05432466|Drug|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
79989430|NCT05432466|Drug|Placebo BID|placebo for ACER-002
79351860|NCT04636970|Other|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
79351861|NCT01618214|Drug|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
79351862|NCT01917968|Device|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
79351863|NCT01917968|Procedure|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
79989431|NCT05424289|Device|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
79503115|NCT06124352|Diagnostic Test|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
79503116|NCT06124352|Diagnostic Test|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
79503117|NCT06124352|Diagnostic Test|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 [24, 25].
79989432|NCT05403749|Biological|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
79989433|NCT05403749|Drug|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
79989434|NCT05403749|Biological|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
79989435|NCT05400122|Drug|Vactosertib|Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 [ALK5]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
79989436|NCT05400122|Drug|Fludarabine Phosphate|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
79989437|NCT05400122|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
79989438|NCT05400122|Drug|IL-2|"Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth"
79351864|NCT01917656|Drug|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
79989439|NCT05400122|Drug|Natural Killer Cells|Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer [14, 19-23]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
79503118|NCT06124339|Behavioral|Physical Activity|There will be three sessions a week over the course of 16 weeks.
79351865|NCT01917656|Drug|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
79351866|NCT01917656|Drug|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
79351867|NCT01944722|Device|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
79351868|NCT01944722|Procedure|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
79503119|NCT06124339|Behavioral|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
79989440|NCT05398250|Behavioral|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
79351869|NCT04415918|Drug|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
79351870|NCT01917344|Other|MRI|
79503120|NCT06124339|Behavioral|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
79503121|NCT06124326|Dietary Supplement|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
79503122|NCT06124300|Dietary Supplement|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
79503123|NCT06124274|Behavioral|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with [13 Carbon(13C)]-leucine.
79503124|NCT06124222|Procedure|Prosthetic oral rehabilitation|Prosthetic rehabilitation with fixed and/or removable prosthesis.
79351871|NCT02017535|Drug|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
79351872|NCT02017535|Behavioral|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
79351873|NCT01944098|Drug|Lidocaine|
79351874|NCT01944098|Drug|Placebo|
79351875|NCT02017223|Device|Knowme Device Wear|
79351876|NCT01944020|Device|CPAP|use of CPAP each night for 2 months
79351877|NCT01943552|Drug|placebo|normal saline
79351878|NCT01943552|Drug|ipratropium bromide|ipratropium bromide
79351879|NCT01915940|Drug|Bimatoprost|Bimatoprost ocular insert
79351880|NCT01915940|Drug|Timolol 0.5%|Timolol 0.5% solution
79351881|NCT01915940|Drug|Placebo Eye Drops|Placebo topical eye drops
79351882|NCT01915940|Device|Placebo Ocular Insert|Ocular insert without any active drug
79351883|NCT01914926|Drug|Metoprolol|
79989441|NCT05398250|Behavioral|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~A brief risk assessment and mood check~Review and, if needed, revision of SPI-A~Support related to outpatient mental health treatment initiation"
79665409|NCT00348738|Drug|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, <15g/dl is reached or until the end of the radiation therapy.
79989442|NCT05395104|Drug|Midazolam|Syrup for oral administration
79351884|NCT01914926|Drug|Diltiazem|
79989443|NCT05395104|Drug|Cefiderocol|Liquid for intravenous infusion
79989444|NCT05389462|Drug|ADCT-601|Intravenous (IV) infusion
79351885|NCT02016755|Biological|HGF Plasmid|Intramuscular injection in the affected limb.
79665410|NCT00314912|Drug|Tramiprosate (3APS)|
79989445|NCT05389462|Drug|Gemcitabine|Intravenous (IV) infusion
79989446|NCT05380713|Drug|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
79989447|NCT05380713|Drug|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
79989448|NCT05380713|Drug|Durvalumab|tremelimumab-durvalumab in adjuvant setting
79989449|NCT05365776|Behavioral|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
79989450|NCT05365776|Behavioral|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
79989451|NCT05365776|Other|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through text message support.
79989452|NCT05359445|Biological|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
79989453|NCT05359445|Biological|IMA401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
79989454|NCT05351788|Drug|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
79989455|NCT05351788|Drug|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
79989456|NCT05351788|Drug|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
79989457|NCT05351788|Drug|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
79989458|NCT05350319|Radiation|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
79989459|NCT05350254|Other|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
79989460|NCT05350254|Other|Standard chiropractic care|Standard care based on clinician's judgement
79351886|NCT05119166|Dietary Supplement|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
79351887|NCT05119166|Biological|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
79351888|NCT05119166|Dietary Supplement|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
79503126|NCT06124170|Procedure|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
79503127|NCT06124170|Procedure|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
79503128|NCT06124170|Procedure|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
79817414|NCT04115423|Drug|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
79351889|NCT01942148|Drug|Aripiprazole|
79351890|NCT02030015|Drug|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
79351891|NCT02030015|Other|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
79817415|NCT04113005|Drug|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
79817416|NCT00588341|Drug|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
79989461|NCT05327491|Drug|Sotorasib|Oral Tablet
79989462|NCT05322239|Device|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the ~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
79989463|NCT05322239|Device|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
79989464|NCT05321199|Drug|Tranexamic acid|Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
79989465|NCT05320029|Device|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
79351892|NCT02029235|Drug|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
79351893|NCT02029235|Drug|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
79351894|NCT01617434|Drug|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
79351895|NCT01617434|Drug|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
79503129|NCT06124157|Procedure|Biospecimen Collection|Undergo blood and CSF sample collection
79503130|NCT06124157|Biological|Blinatumomab|Receive IV
79503131|NCT06124157|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79503132|NCT06124157|Drug|Calaspargase Pegol|Receive IV
79665411|NCT00344604|Behavioral|Role of psychosocial and quality of life parameters prior to and following LASIK.|
79665412|NCT00314990|Drug|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
79665413|NCT00344643|Device|Silicone Hydrogel Soft Contact Lenses|
79817417|NCT00914693|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
79817418|NCT00915083|Drug|Amrubicin|40mg/m^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
79989466|NCT05320029|Device|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
79989467|NCT05307263|Procedure|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
79351896|NCT01940354|Device|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
79351897|NCT01940354|Device|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
79351898|NCT01940120|Device|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
79503133|NCT06124157|Drug|Cyclophosphamide|Receive IV
79665414|NCT00315029|Behavioral|evidence based decision aid|evidence based decision aid
79503134|NCT06124157|Drug|Cytarabine|Receive IV
79503135|NCT06124157|Drug|Dasatinib|Receive PO or NG
79503136|NCT06124157|Drug|Daunorubicin|Receive IV
79503137|NCT06124157|Drug|Doxorubicin|Receive IV
79503138|NCT06124157|Procedure|Echocardiography|Undergo ECHO
79503139|NCT06124157|Drug|Leucovorin|Receive PO or IV
79503140|NCT06124157|Drug|Mercaptopurine|Receive PO
79665415|NCT00315029|Behavioral|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
79665416|NCT00348777|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
79665417|NCT00348777|Drug|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
79665418|NCT00315107|Drug|Alesse|
79989468|NCT05307263|Procedure|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
79351899|NCT01911260|Dietary Supplement|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
79351900|NCT01911260|Other|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
79351901|NCT02015819|Biological|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
79351902|NCT02015819|Drug|flucytosine|Given orally
79351903|NCT02015819|Drug|leucovorin calcium|Given orally
79351904|NCT02015819|Other|pharmacological study|Correlative studies
79351905|NCT02015819|Other|laboratory biomarker analysis|Correlative studies
79351906|NCT01939496|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
79351907|NCT01939496|Drug|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
79351908|NCT01939028|Procedure|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
79817419|NCT00802529|Drug|Methylprednisolone|2 transtympanic injections at interval of two weeks.
79817420|NCT00802529|Drug|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
79989469|NCT05301920|Device|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
79351909|NCT01939028|Procedure|sentinel lymph node biopsy|Undergo SLN biopsy
79817421|NCT02605811|Drug|temozolomide|
79351910|NCT01939028|Drug|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
79351911|NCT01939028|Drug|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
79351912|NCT01939028|Procedure|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
79351913|NCT01939028|Procedure|lymphadenectomy|Undergo para-aortic lymphadenectomy
79351914|NCT01938716|Drug|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
79351915|NCT01937390|Drug|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
79351916|NCT01937390|Drug|Indacterol 300 µg|inhalation powder
79989470|NCT05300282|Drug|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
79817422|NCT02605811|Radiation|prophylaxis cranial radiotherapy|2
79817423|NCT00758264|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
79817424|NCT00758264|Biological|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
79817425|NCT04027517|Drug|JTZ-951|"Oral tablet~Dose adjustments as maintenance dose is allowed according to the result of Hb level."
79817426|NCT04027517|Drug|Darbepoetin Alfa|"Intravenous administration~Dose adjustments as maintenance dose is allowed according to the result of Hb level."
79817427|NCT02601092|Procedure|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
79817428|NCT02601092|Procedure|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
79503141|NCT06124157|Drug|Methotrexate|Receive IT or IV
79351917|NCT01937390|Drug|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
79351918|NCT01937390|Drug|Indacterol 150 µg|inhalation powder
79817429|NCT02605655|Drug|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
79817430|NCT02605655|Other|Placebo|Instant noodles without drug
79351919|NCT04651712|Diagnostic Test|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
79351920|NCT04685681|Behavioral|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
79351921|NCT04685681|Other|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
79351922|NCT04685057|Dietary Supplement|Placebo|Intervention with a daily dose of placebo for 6 months
79351923|NCT04685057|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic for 6 months
79503142|NCT06124157|Procedure|Multigated Acquisition Scan|Undergo MUGA
79503143|NCT06124157|Drug|Pegaspargase|Receive IV
79503144|NCT06124157|Drug|Prednisolone|Receive PO
79503145|NCT06124157|Drug|Prednisone|Receive PO
79503146|NCT06124157|Radiation|Radiation Therapy|Undergo radiation therapy
79503147|NCT06124157|Drug|Thioguanine|Receive PO
79503148|NCT06124157|Drug|Vincristine|Receive IV
79503149|NCT06124092|Other|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
79503150|NCT06124079|Other|OPY interactive messaging service|3 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The three versions differ in the motivational techniques interspersed throughout the OPY experience.
79817431|NCT00588731|Drug|Cannabidiol|Active Cannabidiol daily over 6 weeks
79817432|NCT00588731|Drug|Placebo|Placebo
79817433|NCT04111367|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
79817434|NCT04111367|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
79817435|NCT05629949|Drug|QL1701|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
79817436|NCT05629949|Drug|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
79503151|NCT06124079|Other|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
79351924|NCT04685057|Dietary Supplement|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
79351925|NCT02028767|Drug|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
79351926|NCT02028767|Drug|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
79351927|NCT02028767|Drug|Metformin 500 mg|Metformin 500 mg tablet
79665419|NCT04715490|Other|The Multimedia Symptom Management Program Intervention|"The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period."
79351928|NCT02028767|Drug|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
79351929|NCT01959932|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
79665420|NCT04715490|Other|Control group|The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
79665421|NCT02960126|Drug|Aspirin|
79665422|NCT02960126|Drug|Clopidogrel|
79665423|NCT00348855|Other|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
79665424|NCT00348855|Behavioral|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
79665425|NCT00348855|Behavioral|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
79665426|NCT00348855|Behavioral|Stop Smoking|Minimal intervention
79989471|NCT05300282|Combination Product|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
79351930|NCT01959932|Other|Smoking abstinence (SA)|SA for 5 days in confinement
79351931|NCT01959932|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
79351932|NCT04416893|Diagnostic Test|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
79351933|NCT04416893|Diagnostic Test|Sars-Cov2 serology|A microsample of blood will be taken for serology
79351934|NCT04651244|Diagnostic Test|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
79351935|NCT04651244|Diagnostic Test|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
79351936|NCT04651244|Diagnostic Test|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
79351937|NCT02028065|Drug|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
79351938|NCT02028065|Drug|Placebo|Placebo administered as a single IV bolus over 10 seconds
79351939|NCT04683965|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
79503152|NCT06124027|Device|Monitoring tcPCO2 and mitoPO2|Monitoring tcPCO2 using SenTec and mitoPO2 using COMET
79503153|NCT06123975|Other|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
79351940|NCT04683965|Drug|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1~5,d8~12
79351941|NCT04683965|Drug|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
79351942|NCT02015195|Other|Acetic Acid (5%)|
79351943|NCT02015195|Other|Sodium Bicarbonate Slurry (50%)|
79351944|NCT02015195|Other|Papain Slurry (70%)|
79351945|NCT02015195|Other|Ammonia (10%)|
79351946|NCT02015195|Drug|Lidocaine (4%)|
79351947|NCT02015195|Other|Isopropyl Alcohol (70%)|
79351948|NCT02015195|Other|Hot Tap Water (40 degrees Celsius)|
79351949|NCT02015195|Other|No treatment|
79351950|NCT02015039|Drug|BoNT Injections|
79351951|NCT02015039|Procedure|Occupational Therapy|
79665427|NCT00348855|Behavioral|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
79665428|NCT00348855|Other|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
79665429|NCT00315185|Drug|Cetuximab|
79665430|NCT00344721|Dietary Supplement|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
79665431|NCT00344721|Dietary Supplement|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
79817437|NCT05629949|Drug|Docetaxel|The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
79989472|NCT05299892|Device|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
79503154|NCT06123962|Procedure|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
79503155|NCT06123923|Other|no intervention|no intervention, just retrospective observation
79503156|NCT06123910|Dietary Supplement|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
79503157|NCT06123910|Other|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
79665432|NCT00315224|Behavioral|heart-rate controlled 12 week exercise program|
79665433|NCT00344760|Drug|Enfuvirtide|subcutaneously twice a day
79503158|NCT06123884|Drug|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
79665434|NCT00344760|Drug|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
79665435|NCT00348894|Drug|[S,S]-Reboxetine|[S,S]-reboxetine
79665436|NCT00348894|Drug|Any|Any standard of care treatment for DPN
79665437|NCT00315536|Drug|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
79817438|NCT04111445|Drug|ADG116|IV infusion at Day 1 of each cycle
79817439|NCT04112771|Drug|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
79817440|NCT04112771|Other|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
79989473|NCT05298410|Other|Limitless|Participants will be instructed to take Limitless for 30 days.
79989474|NCT05295433|Drug|mRNA-3705|A sterile liquid for injection
79989475|NCT05281276|Drug|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
79989476|NCT05281276|Drug|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
79665438|NCT00348972|Drug|Lantus® (insulin glargine)|
79665439|NCT00315575|Procedure|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
79665440|NCT00315692|Device|Biomarker Assay (CA125 and HE4)|
79665441|NCT00315770|Procedure|weight loss diets for young adults|
79665442|NCT00344838|Device|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
79817441|NCT02605577|Procedure|new systemic nutrition management protocol|a new established systemic nutrition management protocol
79228365|NCT03712137|Other|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
79351952|NCT02025725|Drug|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
79351953|NCT02025725|Drug|Placebo Nasal Spray|nasal spray formulation with vehicle only
79351954|NCT02025179|Drug|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
79351955|NCT02025179|Device|Vibration|Vibration 10 min/day for 12 months
79503159|NCT06123884|Drug|Cisplatin|the usage and dosage should be determined by the investigator
79351956|NCT02013791|Drug|Vehicle|Vehicle of cyclosporine administered as per protocol
79665443|NCT00349050|Device|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
79665444|NCT00349050|Procedure|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
79665445|NCT00349089|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
79665446|NCT00349089|Drug|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
79665447|NCT00349089|Drug|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
79665448|NCT00349128|Drug|fenofibrate and metformin combination (drug)|
79665449|NCT00349167|Drug|PR-104|
79665450|NCT00349167|Other|laboratory biomarker analysis|
79665451|NCT00349167|Other|pharmacological study|
79665452|NCT00315848|Drug|Buprenorphine transdermal delivery system|
79665453|NCT00349206|Drug|sorafenib tosylate|Given orally
79665454|NCT00349206|Drug|temsirolimus|Given IV
79665455|NCT00315887|Drug|Buprenorphine transdermal delivery system|
79351957|NCT02013791|Other|Sham|Sham administered to non-study eye as per protocol on Day 1
79665456|NCT00421395|Biological|90Y-hLL2|weekly dosing for either 2 or 3 weeks
79228366|NCT03472950|Drug|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
79228367|NCT03472950|Drug|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
79351958|NCT02013791|Drug|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
79351959|NCT02024867|Drug|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
79351960|NCT01953601|Drug|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
79351961|NCT01953601|Drug|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
79351962|NCT01953601|Other|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
79503160|NCT06123884|Drug|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
79503161|NCT06123884|Drug|carboplatin|the usage and dosage should be determined by the investigator
79665457|NCT00315926|Drug|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
79665458|NCT00315926|Drug|Placebo|a mixture of ethanol and physiological saline
79665459|NCT00421434|Drug|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
79665460|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
79351963|NCT01952665|Device|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
79351964|NCT01952665|Device|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
79351965|NCT01952041|Behavioral|Device: Smartphone|
79351966|NCT01952041|Behavioral|Treatment as usual|
79351967|NCT04416529|Behavioral|Tele-MBCT|Please see arm/group description.
79351968|NCT04668235|Drug|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
79351969|NCT04668235|Drug|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
79351970|NCT01951573|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
79503162|NCT06123884|Drug|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
79665461|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
79665462|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
79351971|NCT01951573|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
79351972|NCT02023697|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
79351973|NCT01951417|Drug|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
79351974|NCT01951417|Other|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
79351975|NCT01951417|Other|Foam Wash|Foam Wash (twice daily)
79351976|NCT01951261|Procedure|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
79351977|NCT02023151|Drug|Omalizumab|
79503163|NCT06123819|Device|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
79503164|NCT06123702|Behavioral|Fear extinction|Extinction of conditioned fear response
79503165|NCT06123702|Drug|Cannabidiol Cap/Tab|6 100-mg capsules
79503166|NCT06123702|Drug|Placebo|6 placebo capsules
79503167|NCT06123676|Device|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
79503168|NCT06123650|Device|Repetitve transcranial magnetic stimulation|"The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days."
79503169|NCT06123650|Device|Sham transcranial magnetic stimulation|Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.
79503170|NCT06123637|Behavioral|Analgesia nociception index-guided anesthesia|Maintaining the blood pressure based on analgesia nociception index of >50 value
79665463|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
79503171|NCT06123637|Behavioral|Standard anesthesia|Maintaining the blood pressure based on anesthesiologist's decision
79503172|NCT06123624|Drug|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
79503173|NCT06123624|Drug|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
79503174|NCT06123585|Other|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
79503175|NCT06123585|Other|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
79665464|NCT00315965|Drug|Nitric oxide, Carbon monoxide, Helium|
79665465|NCT00349245|Drug|Remifentanil|
79665466|NCT00349245|Drug|Dexmedetomidine|
79665467|NCT00316043|Behavioral|Written information for parents|
79665468|NCT00316043|Behavioral|Distance learning package for General Practitioners|
79665469|NCT00316043|Behavioral|Distance learning package for practice assistants|
79665470|NCT06165796|Device|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
79665471|NCT06165770|Procedure|laparoscopy|Conservative or surgery treatment for cornual pregnancies
79665472|NCT06165731|Behavioral|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
79665473|NCT06165731|Behavioral|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
79351978|NCT04643743|Device|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
79351979|NCT01979185|Drug|Simvastatin|
79351980|NCT01979185|Drug|SSP-004184SS|
79351981|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
79351982|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
79665474|NCT06165692|Biological|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
79665475|NCT06165679|Drug|Prilocaine|The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl
79351983|NCT01946191|Behavioral|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
79351984|NCT01946191|Behavioral|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
79351985|NCT01946191|Behavioral|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
79351986|NCT01937312|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
79351987|NCT01937312|Drug|Vehicle|Inactive ingredients used as a placebo comparator
79351988|NCT01937312|Drug|Prostaglandin analogue|
79351989|NCT04622384|Other|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
79351990|NCT04632836|Other|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
79351991|NCT01935128|Drug|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
79351992|NCT01934972|Other|CR + DCS (D-cycloserine)|CR + DCS
79351993|NCT01934972|Other|CR + placebo|CR + placebo
79503176|NCT06123364|Drug|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
79351994|NCT01959230|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
79503177|NCT06123364|Device|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
79503178|NCT06123364|Device|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
79503179|NCT06122948|Drug|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
79503180|NCT06122948|Drug|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
79503181|NCT06122142|Device|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
79665476|NCT06165679|Drug|Bupivacaine|The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
79351995|NCT01959230|Drug|Vehicle|Ophthalmic solution to be applied as directed.
79351996|NCT01959230|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
79351997|NCT01959230|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
79351998|NCT01909778|Drug|BI 201335|single oral doses
79351999|NCT01977937|Drug|Gabapentin 250mg/5mL NDC:59762-5025-01|
79352000|NCT01977937|Drug|Simple Syrup|
79352001|NCT02015663|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
79352002|NCT01978093|Biological|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
79817442|NCT05629481|Procedure|Fractional carbon dioxide laser treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
79352003|NCT01978093|Biological|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
79352004|NCT01978093|Biological|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
79352005|NCT01978093|Biological|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
79503182|NCT06122142|Device|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
79503183|NCT06122142|Device|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
79503184|NCT06122129|Procedure|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
79503185|NCT06122129|Procedure|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
79503186|NCT06121713|Dietary Supplement|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
79503187|NCT06121713|Dietary Supplement|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
79503188|NCT06121713|Dietary Supplement|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
79503189|NCT06121466|Drug|Abdominal wall injections with lidocaine 2%|Injections will be administered for patient who are identified as having abdominal wall pain.
79503190|NCT06121193|Behavioral|PREVENT tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
79665477|NCT06165666|Other|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
79665478|NCT06165666|Other|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
79503191|NCT06121193|Behavioral|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
79665479|NCT06165588|Other|Tour de France|Participating in the Tour de France as cyclist
79665480|NCT06165523|Other|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
79665481|NCT06165523|Other|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
79665482|NCT06165523|Other|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
79503192|NCT06121167|Diagnostic Test|urinary partial oxygen pressure|arterial blood gas
79503193|NCT06120751|Biological|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
79503194|NCT06120751|Biological|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
79503195|NCT06120712|Biological|GC101 TIL|"Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."
79503196|NCT06120101|Behavioral|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
79503197|NCT06119893|Drug|submucosal 8 mg (2 mL) dexamethasone application|The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
79665483|NCT06165510|Device|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
79503198|NCT06119893|Drug|submucosal 2 mL 0.9% isotonic sodium chloride application|The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
79503199|NCT06118619|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
79665484|NCT06165510|Procedure|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
79352006|NCT01978093|Biological|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
79503200|NCT06118463|Diagnostic Test|Detection of serum AUNIP expression|The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
79352007|NCT01978093|Biological|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
79352008|NCT01951105|Drug|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
79503201|NCT06118164|Behavioral|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
79503202|NCT06118164|Behavioral|pursing- lip breathing|pursing- lip breathing
79503203|NCT06118164|Behavioral|aerobic walking exercise|aerobic walking exercise
79665485|NCT06165497|Behavioral|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
79665486|NCT06165497|Other|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
79665487|NCT06165445|Device|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
79665488|NCT06165445|Device|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
79665489|NCT06165432|Drug|Topical Benzocaine|Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
79665490|NCT06165432|Other|Topical ice|For the other half of the palate topical ice would be used before greater palatine nerve block
79665491|NCT06165406|Procedure|Distal radial access|Distal radial access for coronary procedures
79665492|NCT06165393|Dietary Supplement|Slow-release CHO-AA|Slow-release CHO-AA, alginate encapsulated
79352009|NCT01951105|Drug|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
79503204|NCT06116942|Device|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
79665493|NCT06165393|Dietary Supplement|Slow-release CHO|Slow-release CHO, alginate encapsulated
79665494|NCT06165393|Dietary Supplement|CHO|Carbohydrate-only, control
79665495|NCT06165315|Behavioral|Parenting program|Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
79665496|NCT06165302|Behavioral|Exercise Intervention|12 weeks of prescribed exercise intervention.
79665497|NCT06165289|Other|PRP Injection|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
79665498|NCT06165276|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
79665499|NCT06165276|Biological|Meningococcal Group C-CRM197 Conjugate Vaccine|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
79665500|NCT06165237|Drug|BR6001-1|One tablet administered alone, Once a day
79665501|NCT06165237|Drug|BR6001-2|One tablet administered alone, Once a day
79665502|NCT06165211|Other|Nature sound listening|The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
79665503|NCT06165211|Other|Routine care|Patients will watch the program they want on the bedside TV during hemodialysis.
79817443|NCT05629481|Procedure|Fractional carbon dioxide laser sham treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
79352010|NCT01951105|Drug|Placebo|Take two placebo capsules three times a day for 12 weeks.
79665504|NCT06165198|Device|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
79665505|NCT06165185|Other|Water|Please see the associated arm description
79817444|NCT04109573|Procedure|high resolution anal manometry|functional studies before and after anal laser ablation
79817445|NCT04112615|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
79989477|NCT05280938|Behavioral|MAAP|Women randomized to the MAAP intervention will complete an 8 week (2hr/wk) hybrid adapted Kabat-Zinn's MBSR.(Kabat-Zinn, 1990) MAAP intervention includes activities related to spirituality, self-empowerment, interdependence, and story-telling, which are salient to AAW.(Watson-Singleton et al., 2019) Women will receive practice links and a program work book (5th grade level) containing objectives and weekly MAAP activities/. Individual weekly home practice is expected. Type and minutes of home practice will be recorded in weekly logs. Program attendance, type, amount of practice, and changes in mindfulness (Five Facet Mindfulness Questionnaire) will be included in data analysis.
79989478|NCT05280938|Behavioral|Educational Program|"The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects."
79352011|NCT01958918|Drug|Ranibizumab|0.5 mg intravitreal injection
79352012|NCT01958918|Drug|Aflibercept|2 mg intravitreal injection
79665506|NCT06165185|Other|Coffee|Please see the associated arm description
79665507|NCT06165185|Other|Control|Please see the associated arm description
79665508|NCT06165172|Device|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
79352013|NCT01945489|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
79989479|NCT05280769|Other|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
79352014|NCT01945489|Drug|Normal saline|Normal saline (placebo) injected into the detrusor.
79352015|NCT04173559|Behavioral|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
79352016|NCT01934894|Drug|cabazitaxel|
79352017|NCT01934894|Drug|lapatinib|
79503205|NCT06116942|Device|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
79352018|NCT01950169|Drug|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
79503206|NCT06114667|Device|Ventilatory support via nasal high flow|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
79665509|NCT06165159|Other|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
79665510|NCT06165146|Drug|Repaglinide|Administered orally.
79665511|NCT06165146|Drug|Pirtobrutinib|Administered orally.
79665512|NCT06165133|Other|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
79665513|NCT06165133|Other|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
79352019|NCT01950169|Other|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
79352020|NCT01950169|Dietary Supplement|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
79352021|NCT01934504|Procedure|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
79352022|NCT01950013|Behavioral|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
79352023|NCT01950013|Behavioral|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
79503207|NCT06114667|Device|Ventilatory support via NIV|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
79817446|NCT05642273|Device|oXiris membrane|oXiris membrane for 24h
79817447|NCT05642273|Diagnostic Test|Blood tests|Blood tests just after randomization (H0) and at H24, H48 and 7 days
79989480|NCT05280769|Other|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
79989481|NCT05280769|Other|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
79989482|NCT05280769|Other|Smokeless tobacco|Participant's typical brand of smokeless tobacco
79989483|NCT05279040|Drug|Trikafta|Elexacaftor/Tezacaftor/Ivacaftor combination therapy
79989484|NCT05278234|Behavioral|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
79989485|NCT05269628|Drug|Cannabidiol (CBD)|Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.
79503210|NCT06112249|Behavioral|SAFE Employment Training|The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
79503211|NCT06110143|Other|Periodontal treatment|Periodontal treatment
79503212|NCT06108323|Behavioral|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
79989486|NCT05269628|Drug|Tetrahydrocannabinol (THC)|The drug dose will be 2.5 mg b.i.d. during the first 7 days of active treatment, and 5 mg b.i.d. for the following treatment.
79503213|NCT06108323|Behavioral|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
79352024|NCT04632524|Drug|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
79817448|NCT05628233|Drug|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
79352025|NCT01949155|Drug|OTO-201|Single, intratympanic injection
79503214|NCT06105957|Behavioral|Core|The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals. Weekly tips and discussion board postings invite participants to apply skills introduced in the modules and prompt interaction and social support within the closed group which starts the program simultaneously.
79503215|NCT06105957|Behavioral|Facilitated Weekly Group Sessions|Participants will receive 24 facilitated online video-conference-based weekly group sessions. These groups will be 60 minutes long and will be facilitated by a trained professional, who reinforces the information and behavioral strategies introduced in the weekly modules, elicits the experiences of participants in applying behavioral skills to establish new diet and exercise habits, and guides problem solving. Group cohesion to offer social support is promoted.
79503216|NCT06105957|Behavioral|Counselor Crafted Feedback|Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
79665514|NCT06165120|Procedure|Bracka's repair using preputial graft|"Staged repair:~Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate &/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion."
79817449|NCT04109261|Drug|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
79817450|NCT04109339|Drug|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
79352026|NCT01949155|Drug|Sham|Simulated single, intratympanic injection
79352027|NCT01909466|Drug|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
79817451|NCT05628077|Other|No intervention|No intervention
79989487|NCT05269628|Drug|Placebo CBD|Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
79989488|NCT05269628|Drug|Placebo THC|Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
79352028|NCT01977625|Drug|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
79352029|NCT01977625|Other|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
79352030|NCT01944631|Device|Placebo|Nasal spray saline
79352031|NCT01944631|Device|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
79352032|NCT01948063|Drug|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
79503217|NCT06105957|Behavioral|Individual Coaching Calls|Participants will receive 3 online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss. The first call will emphasize amplifying motivation and promoting early treatment engagement by establishing rapport, exploring personal reasons for weight loss and lifestyle change, and reinforcing and expanding change talk, and it will occur prior to starting the core program. Subsequent calls will use a motivational interviewing-informed approach to problem solve barriers to self-monitoring, particularly dietary self-monitoring because of the strong role it plays in promoting better weight loss and will occur during the first half of the program, reflecting the critical role of early engagement in the treatment program on long term weight loss success. Coaching calls will be of approximately 30 min duration and will follow a semi-structured interview format.
79817452|NCT04109495|Other|Smart phone application(NOOM)|The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.
79352033|NCT01948063|Dietary Supplement|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
79679569|NCT02942433|Behavioral|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
79989489|NCT05261490|Drug|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
79352034|NCT01995071|Drug|ABT-493|Tablet
79352035|NCT01995071|Drug|ABT-530|Tablet
79352036|NCT01995071|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79352037|NCT01995071|Drug|Ribavirin (RBV)|Tablet
79352038|NCT01994837|Drug|ABT-199|Tablet
79989490|NCT05261490|Drug|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
79503218|NCT06105957|Behavioral|Pre-Scripted Feedback|Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring within each of the following domains: dietary monitoring, physical activity monitoring, and self-weighing, as well as on weekly module completion. Feedback is automatically generated based on decision algorithms and will be sent from program staff.
79817453|NCT04109495|Other|Non-user|The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
79503219|NCT06104280|Other|Post-Illumination Pupillary Response (PIPR)|The PIPR is measured in six, 80-s test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response
79665515|NCT06165120|Procedure|STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap|"Staged repair:~Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate &/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion."
79665516|NCT06165107|Other|No intervention|No intervention
79665517|NCT06165042|Other|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
79989491|NCT05254795|Other|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
79503220|NCT06104280|Other|Polysomnography|Measure electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory channels (effort and nasal pressure), and oxygen saturation.
79503221|NCT06104280|Other|Multiple Sleep Latency Test|Assist in the diagnosis of disorders of hypersomnolence,63 it is also used in research to quantify daytime sleepiness and serves as a more objective measure of daytime sleepiness than self-report questionnaires
79665518|NCT06165042|Other|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
79503222|NCT06104280|Behavioral|Ecological Momentary Assessments|Morning after overnight Visit 2, participants will complete ecological momentary assessments (EMAs) over a 10-day assessment period. Using EMA through the InsightTM mHealth platform to capture momentary craving, withdrawal and mood states across 10 days among persons who smoke and nonsmokers prior to an overnight procedures. Participants will complete morning and evening sleep diaries via the EMA InsightTM mHealth platform self-reported sleep and wake information, fatigue, naps, opioid craving and withdrawal.
79665519|NCT06165016|Device|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
79817454|NCT04109417|Procedure|osteotomy filled with PRP-gel and covered with PRP-biomembrane|
79817455|NCT04109417|Procedure|osteotomy site following the surgical intervention was left empty|
79817456|NCT00757172|Biological|panitumumab|
79817457|NCT00757172|Drug|cisplatin|
79817458|NCT00757172|Drug|docetaxel|
79989492|NCT05241210|Device|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
79989493|NCT05237882|Other|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
79989494|NCT05231668|Drug|SAR439459|Powder for solution for infusion; IV infusion
79352039|NCT02010593|Drug|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
79352040|NCT02010593|Drug|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
79352041|NCT01994291|Drug|Ranibizumab|"Intravitreal Injection supplied as:~10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~Adminstered once a month for 12 weeks"
79989495|NCT05231668|Drug|Placebo|Solution for infusion; IV infusion
79989496|NCT05225623|Behavioral|BWLT|This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
79352042|NCT01994291|Drug|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
79817459|NCT00757172|Procedure|neoadjuvant therapy|
79352043|NCT01994291|Drug|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
79352044|NCT01994291|Drug|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
79352045|NCT02094677|Device|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
79352046|NCT02094677|Device|etafilcon A|Participants were randomized to wear etafilcon A control lens.
79352047|NCT02094677|Device|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
79352048|NCT04667195|Other|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~Demographics,~comorbidity,~symptoms,~objective findings,~triage at admission,~blood test results,~urine test results"
79352049|NCT04674371|Other|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
79352050|NCT01993823|Drug|G238|Five drops into the ear canal twice daily for 14 days
79352051|NCT01993823|Drug|Clotrimazole|Five drops into the ear canal twice daily for 14 days
79679570|NCT02942433|Behavioral|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
79817460|NCT00757172|Procedure|therapeutic conventional surgery|
79817461|NCT00757172|Radiation|radiation therapy|
79989497|NCT05225623|Behavioral|Waitlist Control for BWLT|This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
79989498|NCT05214105|Other|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
79989499|NCT05212272|Procedure|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
79679571|NCT02942316|Device|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~after induction, before opioid administration~after opioid administration, steady state~surgical incision~end of procedure"
79679572|NCT04694612|Drug|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
79679573|NCT04694612|Drug|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
79665520|NCT06165016|Device|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
79679574|NCT04694612|Drug|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
79817462|NCT04097678|Other|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
79679575|NCT02942238|Procedure|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
79989500|NCT05212272|Diagnostic Test|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
79352052|NCT04673123|Other|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
79989501|NCT05212272|Behavioral|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
79817463|NCT00797225|Drug|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
79989502|NCT05212272|Procedure|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
79989503|NCT05209347|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
79989504|NCT05183737|Dietary Supplement|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
79352053|NCT04673123|Other|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
79817464|NCT00797225|Drug|Elagolix|Elagolix tablets administered orally
79817465|NCT00797225|Drug|Placebo to Elagolix|Placebo tablet administered orally
79989505|NCT05180799|Biological|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
79989506|NCT05180799|Biological|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
79989507|NCT05180799|Biological|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
79989508|NCT05178784|Device|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
79817466|NCT00797225|Drug|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
79817467|NCT04258605|Device|ASHCOM Shoulder System|Reverse Shoulder Arthroplasty
79817468|NCT05277285|Drug|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
79817469|NCT04069143|Diagnostic Test|18F-BMS-986327|Imaging Agent
79989509|NCT05176210|Drug|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient
79989510|NCT05176210|Drug|Placebo|Placebo
79817470|NCT04033731|Behavioral|Attention Network Task|The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
79989511|NCT05172180|Drug|Reamberin|the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
79352054|NCT01993667|Drug|Low Dose Acetazolamide|Administration of low dose acetazolamide
79352055|NCT01993667|Drug|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
79352056|NCT01992107|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
79817471|NCT04110665|Drug|Tramadol|Tramadol 100 mg tablet
79817472|NCT04110665|Drug|Nefopam 20 MG/ML|120 mg for 24 hours
79817473|NCT04110665|Drug|Morphine Sulfate|Tablet 10mg
79817474|NCT04110665|Drug|Oxycodone 20mg|release
79817475|NCT04077333|Procedure|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
79352057|NCT01992107|Biological|TIV1c|Licensed Influenza Vaccine
79817476|NCT00778700|Other|Placebo Cream|Cream with no active drug
79817477|NCT00778700|Drug|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
79989512|NCT05172180|Drug|Ringer's solution|Ringer's solution at an average daily dose of 8.1 ml/kg/day
79503223|NCT06104280|Device|Actigraphy|7-day actigraphy period will be used to determine the habitual sleep start and wake times. The CamNTech MotionWatch8 (Cambridge, UK) is a solid-state piezo-electric accelerometer that collects data on activity (i.e., arm motion) and ambient light.Actigraphy data are downloaded from the MotionWatch8 into the software (MotionWare) for analysis, management, and exportation. Bed and wake times will be entered by the subjects via a REDCap link and this information coupled with the sleep diary reports will be entered to determine sleep intervals. Algorithms in the Motion Watch 8 software will determine sleep start, sleep end, total sleep time (duration), sleep quality, sleep efficiency, wake after sleep onset, and sleep fragmentation
79665521|NCT06165003|Other|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
79665522|NCT06164990|Other|PEKK framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
79665523|NCT06164977|Procedure|Percutaneous coronary intervention.|Revascularization of chronic total coronary occlusion.
79665524|NCT06164964|Diagnostic Test|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
79665525|NCT06164938|Diagnostic Test|Diagnostic accuracy|The aim is to obtain a regional measure of brain glucose metabolism in each normal subject because this is a functional measure of brain activity.
79503224|NCT06104280|Other|DLMO|Participants will be given an evening meal and then be accompanied to the UAB Highlands Hospital Sleep Unit by 5:30pm. The sleep unit allows for strict control of light exposure (< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels.Participants will be allowed to sleep in darkness until 8:00am, at which time they will be provided transportation.We will also bank frozen samples taken prior to the light exposure for later calculation of the Dim Light Melatonin Onset (DLMO), a circadian phase estimate.
79817478|NCT04077489|Procedure|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
79817479|NCT00793403|Other|As per routinary clinical care|As per routine clinical care
79817480|NCT02687763|Biological|ProQuad|"2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~to participate in the three (3) antibody titer blood draws."
79352058|NCT01992107|Biological|TIV2c|Novartis Investigational Vaccine
79352059|NCT04673045|Device|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
79665526|NCT06164912|Other|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
79665527|NCT06164912|Other|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
79665528|NCT06164886|Other|Waiting list|patient on the waiting list for scheduled surgical admissions
79352060|NCT04673045|Device|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
79665529|NCT06164873|Drug|IBI362|Once-weekly injections of gradually increased doses of IBI362
79665530|NCT06164873|Drug|Placebo|Once-weekly injections of volume-matched placebo
79665531|NCT06164860|Other|Meditteranean Diet|The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
79665532|NCT06164860|Other|Ketogenic Diet|The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
79989513|NCT05167201|Device|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
79352061|NCT01934192|Drug|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
79665533|NCT06164834|Drug|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
79665534|NCT06164834|Drug|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
79665535|NCT06164834|Drug|Esomeprazole 20mg|Esomeprazole 20 mg tablet
79665536|NCT06164808|Device|HeartWatch|The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
79352062|NCT01934192|Drug|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
79817481|NCT03995030|Diagnostic Test|massively paralleled sequencing|Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.
79352063|NCT01934192|Drug|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
79352064|NCT01934192|Drug|Placebo IV|Placebo will be administered IV every 6 hours
79665537|NCT06164756|Other|Cognitive Behavior Therapy (CBT)|Participants will receive 10 weeks of CBT
79665538|NCT06164756|Other|Treatment As Usual (TAU)|Participants will receive standard of care treatment
79665539|NCT06164730|Drug|VERVE-102|Intravenous (IV) infusion
79665540|NCT06164717|Behavioral|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
79665541|NCT06164717|Behavioral|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
79679576|NCT02942238|Procedure|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
79665542|NCT06164717|Other|DBS stimulation ON/OFF|"Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF."
79817482|NCT04110899|Other|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
79817483|NCT04100876|Genetic|Global DNA methylation will be quantified in the DNA samples by colorimetry|Global DNA methylation will be quantified in the DNA samples by colorimetry
79817484|NCT02581293|Procedure|Group 1: Only visceral peritoneum will be closed|
79352065|NCT01933880|Drug|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
79352066|NCT01933880|Other|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
79665543|NCT06164691|Device|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
79665544|NCT06164691|Device|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
79665545|NCT06164691|Other|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
79665546|NCT06164665|Drug|Pioglitazone 15mg|Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
79665547|NCT06164665|Other|Placebo|100% microcrystalline cellulos
79352067|NCT04647578|Device|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
79352068|NCT04620980|Diagnostic Test|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
79352069|NCT02008877|Drug|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
79352070|NCT02008877|Drug|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
79665548|NCT06164652|Device|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
79665549|NCT06164639|Behavioral|aspiration|Based on whether the patient meets the diagnosis of aspiration pneumonia.
79665550|NCT06164639|Diagnostic Test|bronchial alveolar fluid|Performing bronchoscopy.
79817485|NCT02581293|Procedure|Group 2 : Only parietal peritoneum will be closed|
79817486|NCT02581293|Procedure|Group 3 : Both of them will be closed|
79817487|NCT02581293|Procedure|Group 4: None of them will be closed|
79817488|NCT04109105|Other|NHS-PEG coated collagen patch|Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
79817489|NCT02687997|Other|poligraphy|Sleep study
79817490|NCT04109183|Drug|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
79989514|NCT05165498|Procedure|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
79989515|NCT05156112|Device|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
79989516|NCT05154487|Drug|Alpelisib Pill|Kinase inhibitor
79352071|NCT01933334|Drug|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
79352072|NCT01908140|Drug|Aclidinium Bromide / Formoterol Fumarate|
79989517|NCT05154487|Drug|Fulvestrant injection|estrogen receptor agonist
79352073|NCT01908140|Drug|Salmeterol / Fluticasone|
79665551|NCT06164600|Dietary Supplement|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum [65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M]
79665552|NCT06164600|Drug|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
79665553|NCT06164574|Other|Survival analysis|Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
79817491|NCT04055883|Drug|DA-1229|All participants are administered one tablet per day for 96 weeks
79989518|NCT05140122|Drug|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
79989519|NCT05140122|Other|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
79989520|NCT05099822|Drug|CC-97489|Specified dose on specified days
79989521|NCT05099822|Other|Placebo|Specified dose on specified days
79989522|NCT05086393|Drug|Duloxetine|Patients will be randomized to receive Duloxetine or a placebo.
79989523|NCT05086393|Drug|Placebos|Patients will be randomized to receive Duloxetine or a placebo.
79989524|NCT05079568|Device|Oculus Go VR headset|Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
79989525|NCT05079568|Device|Sham Oculus Go VR headset|Virtual reality program with two-dimensional nature video
79989526|NCT05077033|Drug|phIL12 GET|intratumoral phIL12 gene electrotransfer
79989527|NCT05072080|Biological|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%
79989528|NCT05072080|Biological|Placebo|Placebo is comprised of formulation buffer
79989529|NCT05068791|Drug|Psilocybin|0.36 mg/kg will be administered orally to participants
79989530|NCT05068791|Drug|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
79989531|NCT05063929|Other|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
79989532|NCT05063929|Other|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
79989533|NCT05059639|Other|Almond|Consume 2 ounces of almond daily for 8 weeks
79989534|NCT05059639|Other|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
79665554|NCT06164535|Drug|Control group|35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
79665555|NCT06164535|Drug|DPP-4 inhibitor group|35 T2DM patients will be given DPP-4 I once or twice daily
79665556|NCT06164535|Drug|DPP-4 inhibitor + metformin group|35 T2DM patients will be given DPP-4 I + metformin once or twice daily
79665557|NCT06164509|Drug|Alphintern® , tablet, Amoun, Egypt|Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
79665558|NCT06164483|Diagnostic Test|Auditory test|"The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~Speech Perception test~In case of tinnitus: tinnitus questionnaire and acuphenometry~DPOAEs~ABR"
79665559|NCT06164483|Other|CSF sampling|Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
79665560|NCT06164418|Procedure|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
79665561|NCT06164405|Device|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
79989535|NCT05047523|Drug|ALXN1840|Administered as an oral tablet.
79989536|NCT05047523|Drug|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
79989537|NCT05042362|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
79989538|NCT05042362|Drug|Placebo|Matching placebo orally once daily
79989539|NCT05006196|Diagnostic Test|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
79989540|NCT05003986|Drug|Sparsentan|Population 1: 800 mg Sparsentan
79989541|NCT05003986|Drug|Sparsentan|Population 2: 400 mg Sparsentan
79989542|NCT04983940|Drug|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
79352074|NCT02008565|Drug|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
79352075|NCT02008565|Drug|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
79352076|NCT02008565|Behavioral|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
79352077|NCT02008565|Behavioral|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
79665562|NCT06164392|Drug|Indocyanine green|Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
79665563|NCT06164379|Drug|Finerenone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
79665564|NCT06164379|Drug|Spironolactone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
79989543|NCT04981730|Behavioral|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
79665565|NCT06164366|Device|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
79989544|NCT04980248|Biological|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
79989545|NCT04979806|Drug|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
79665566|NCT06164366|Device|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
79989546|NCT04979806|Drug|Meropenem|1 g IV q8h
79989547|NCT04967807|Diagnostic Test|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
79989548|NCT04967807|Diagnostic Test|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
79989549|NCT04966910|Behavioral|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
79989550|NCT04966910|Behavioral|Treatment as usual|Regular check-ins, resource/referral provision
79989551|NCT04958122|Drug|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
79989552|NCT04958122|Drug|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
79989553|NCT04951492|Drug|Olaparib|Given PO
79989554|NCT04948112|Device|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
79989555|NCT04948112|Device|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
79989556|NCT04927975|Drug|Upadacitinib|Oral tablets
79989557|NCT04927975|Drug|Placebo|Oral tablets
79989558|NCT04927247|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
79989559|NCT04927247|Drug|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
79989560|NCT04926831|Drug|capmatinib|150 mg and 200 mg tablets for oral administration
79989561|NCT04922463|Device|PLASOMA|Treatment with cold plasma device
79989562|NCT04915846|Drug|ApoTamox 10mg|All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
79665567|NCT06164353|Biological|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
79665568|NCT06164327|Drug|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m^2 or 22.5mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
79352078|NCT01907906|Device|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
79665569|NCT06164327|Drug|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
79665570|NCT06164327|Drug|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
79665571|NCT06164327|Drug|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
79665572|NCT06164327|Drug|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
79665573|NCT06164327|Drug|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
79665574|NCT06164327|Drug|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
79989563|NCT04915846|Drug|Placebo|placebo comparator
79989564|NCT04900038|Drug|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
79989565|NCT04900038|Drug|Dolutegravir|DTG was available as 50 mg tablets administered orally.
79989566|NCT04900038|Drug|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
79352079|NCT01907828|Device|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
79352080|NCT01907828|Device|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
79352081|NCT01907516|Device|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
79352082|NCT01907516|Behavioral|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
79352083|NCT01931462|Device|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
79352084|NCT01931150|Drug|Topical Dapsone 5% Gel|
79352085|NCT01931150|Other|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
79352086|NCT01931150|Drug|oral antibiotics|
79352087|NCT01930214|Device|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
79503225|NCT06104280|Other|Melatonin Suppression Test|The sleep unit allows for strict control of light exposure (< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels. Participants will be asked to refrain from caffeine consumption 12 hours before reporting to the sleep unit and will provide 2-3 ml of saliva every 30 minutes starting at 6:00pm and ending after the light exposure. For melatonin suppression, 2-hours light exposure will begin 2 hours before the calculated mid-sleep time. Collection saliva samples 1-h, 30-min, and immediately before the light exposure and every 30 min throughout exposure. Samples will be centrifuged and frozen/stored at -20ºC until assay and remaining samples stored at -80ºC. Melatonin levels will be assayed via the Buhlmann Direct Saliva Melatonin. Melatonin suppression will be calculated as the percent decrease from the sample taken immediately prior to the light exposure
79817492|NCT04244565|Behavioral|Self-directed model of clinical learning for nurses|the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources & decide whether learning method can be used, and engaging in self-reflection & evaluation.
79352088|NCT01958294|Device|MICHI Neuroprotection System|
79989567|NCT04900038|Drug|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
79989568|NCT04880642|Drug|C21|C21
79989569|NCT04880642|Drug|Placebo|Placebo
79989570|NCT04880434|Drug|Fludarabine|Administered intravenously
79989571|NCT04880434|Drug|Cyclophosphamide|Administered intravenously
79989572|NCT04880434|Biological|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
79989573|NCT04877535|Device|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
79989574|NCT04873856|Dietary Supplement|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
79989575|NCT04865588|Procedure|rotational atherectomy|angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
79989576|NCT04865588|Device|cutting balloon|a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
79989577|NCT04865588|Device|plain old balloon|current standard treatment of stent placement
79989578|NCT04850599|Drug|Carfilzomib|Given IV
79989579|NCT04850599|Biological|Isatuximab|Given IV
79352089|NCT01906346|Drug|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
79352090|NCT01906346|Drug|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
79352091|NCT01958060|Drug|BI 1034020|intravenous part
79352092|NCT01958060|Drug|Placebo to BI 1034020|intravenous part
79352093|NCT04618874|Diagnostic Test|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
79352094|NCT04645004|Drug|Aspirin 81Mg Non-enteric coated Tab|one tab daily
79352095|NCT01929980|Drug|Bortezomib|
79352096|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing <50 kg.
79352097|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
79352098|NCT01929044|Drug|654-II (anisodamine)|10mg injection
79352099|NCT01929044|Drug|Buscopan® (hyoscine butylbromide)|20mg injection
79352100|NCT01903460|Drug|LUM001|
79352101|NCT01903460|Drug|Placebo|
79352102|NCT01957202|Drug|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
79989580|NCT04850599|Drug|Pomalidomide|Given PO
79989581|NCT04847739|Procedure|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
79503226|NCT06095154|Radiation|New-mode reduce-volume target IMRT|The CTVp was defined as a subclinical disease consisting of 10 mm margin surrounding GTVnx (not including all nasopharyngeal mucosa)
79989582|NCT04847739|Drug|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
79989583|NCT04831580|Device|da Vinci|Minimally invasive robotic-assisted surgical device
79989584|NCT04831580|Other|open surgery|open radical hysterectomy
79989585|NCT04826640|Other|Observational|Observational
79989586|NCT04826003|Drug|RO7122290|RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
79989587|NCT04826003|Drug|Cibisatamab|Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
79352103|NCT01957202|Drug|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
79352104|NCT01957202|Drug|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
79352105|NCT01957202|Drug|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
79352106|NCT01616654|Drug|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
79352107|NCT01616654|Drug|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
79989588|NCT04826003|Drug|Obinutuzumab|"Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab"
79352108|NCT01616654|Drug|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
79352109|NCT01616654|Drug|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
79352110|NCT01616654|Drug|Vehicle cream|Vehicle cream applied once daily
79352111|NCT01902290|Biological|Placebo|Placebo administered subcutaneously
79352112|NCT01902290|Biological|Brodalumab|Brodalumab administered subcutaneously
79503227|NCT06094218|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
79503228|NCT06094218|Behavioral|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
79503229|NCT06093321|Device|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
79503230|NCT06093321|Device|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
79503231|NCT06087276|Drug|60 mg ulixacaltamide|Once daily oral treatment with titration
79352113|NCT01467466|Drug|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
79352114|NCT01467466|Drug|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
79665575|NCT06164288|Drug|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~Dose Level 1: 1×106 cells/kg;~Dose Level 2: 2×106 cells/kg;~Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
79665576|NCT06164249|Other|strength training|Strength training, three times a week, during nine weeks.
79665577|NCT06164223|Device|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
79665578|NCT06164158|Other|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
79665579|NCT06164158|Other|No procedural videos|No procedural videos
79989589|NCT04824638|Biological|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
79352115|NCT01467466|Drug|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
79352116|NCT01467466|Drug|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
79989590|NCT04824638|Biological|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
79352117|NCT01441180|Drug|GS7977|drug intervention
79352118|NCT01441180|Drug|RBV|drug intervention
79352119|NCT01441102|Drug|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
79665580|NCT06164106|Behavioral|Virtual Crisis Response Planning|Individuals complete a chat-based experimental collaborative suicide intervention virtually.
79665581|NCT06164106|Behavioral|In-Person Crisis Response Planning|Individuals complete a collaborative suicide intervention in-person.
79665582|NCT06164106|Behavioral|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
79352120|NCT04061980|Drug|Binimetinib|Given PO
79352121|NCT04061980|Drug|Encorafenib|Given PO
79352122|NCT04061980|Biological|Nivolumab|Given IV
79503232|NCT06087276|Drug|Placebo|Once daily oral treatment
79503233|NCT06086340|Drug|Palbociclib|Palbociclib with an aromatase inhibitor therapy
79665583|NCT06164093|Other|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial [NCT03655808])
79665584|NCT06164093|Other|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
79665585|NCT06164080|Other|participants receiving Corticosteroid|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
79665586|NCT06164067|Other|abortus within 24 hours or 24-48 hours|second trimester medical termination
79989591|NCT04820023|Drug|BBT-176|BBT-176 given orally alone
79989592|NCT04817891|Device|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
79989593|NCT04809805|Drug|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
79989594|NCT04803604|Behavioral|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
79989595|NCT04784052|Drug|JSP191|Participants will receive a single IV dose at start of conditioning
79989596|NCT04784052|Device|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
79503234|NCT06086340|Drug|Aromatase Inhibitor|Aromatase Inhibitor Therapy
79503235|NCT06085326|Other|Smart Checklist|The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
79352123|NCT01467076|Drug|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
79503236|NCT06082518|Device|Monoplace Hyperbaric Chamber (Class III medical device).|"40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada."
79989597|NCT04784052|Biological|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
79989598|NCT04784052|Biological|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
79989599|NCT04784052|Drug|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
79989600|NCT04784052|Drug|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
79989601|NCT04784052|Drug|Rituximab|1 dose of rituximab will be given at the end of conditioning
79352124|NCT01467076|Drug|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
79352125|NCT01466062|Drug|Palivizumab|
79352126|NCT04504864|Drug|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
79352127|NCT04504864|Drug|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
79352128|NCT04060342|Drug|GB1275|Oral
79665587|NCT06164054|Device|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
79665588|NCT06164054|Behavioral|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
79679577|NCT02950064|Drug|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
79679578|NCT02941224|Device|SELUTION DCB (sirolimus coated balloon)|
79679579|NCT02949791|Procedure|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
79352129|NCT04060342|Drug|nab-paclitaxel and gemcitabine|IV infusion
79352130|NCT04060342|Drug|pembrolizumab|IV infusion
79503237|NCT06075979|Other|Lumbar disc herniation|Patients undergoing surgery for lumbar disc herniation
79503238|NCT06075979|Other|Lumbar spinal stenosis|Patients undergoing surgery for lumbar spinal stenosis
79503239|NCT06075966|Other|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
79503240|NCT06075966|Other|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
79989602|NCT04781153|Procedure|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
79679580|NCT02949791|Other|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
79989603|NCT04777201|Drug|Faricimab|Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
79989604|NCT04777201|Other|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
79352131|NCT01435018|Drug|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade >= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade >= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
79503241|NCT06067438|Drug|Amiodarone Hydrochloride|Given IV and via feeding tube
79503242|NCT06067438|Other|Saline|Given IV
79503243|NCT06065501|Behavioral|PACE intervention|"The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance."
79503244|NCT06065501|Behavioral|Usual care|Nurses provide routine education and consultation
79503245|NCT06057974|Other|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
79503246|NCT06057753|Behavioral|MyStroke|Personalized video-based stroke education platform
79679581|NCT02949791|Other|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
79989605|NCT04770259|Other|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
79228368|NCT02467244|Drug|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
79503247|NCT06050954|Drug|Pembrolizumab (200mg)|200mg Pembrolizumab every six weeks via IV infusion.
79503248|NCT06050954|Drug|Pembrolizumab (400mg)|400mg Pembrolizumab every six weeks via IV infusion.
79679582|NCT02941107|Drug|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P[8] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
79679583|NCT02941107|Drug|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
79352132|NCT01435018|Drug|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
79352133|NCT01435018|Drug|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m^2 body surface area (BSA) every 3 weeks.
79352134|NCT01435018|Drug|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing"
79352135|NCT01419184|Drug|Daptomycin|
79503249|NCT06050954|Diagnostic Test|Monitoring|active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
79503250|NCT06050369|Device|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
79503251|NCT06050369|Device|MRI|Get the anatomical shape of the brain.
79503252|NCT06048185|Biological|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
79503253|NCT06031428|Behavioral|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
79503254|NCT06031428|Behavioral|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
79503255|NCT06027723|Drug|Nicotine|Nicotine delivered through a vape
79989606|NCT04760405|Other|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
79352136|NCT01419184|Drug|Vancomycin|
79352137|NCT01417234|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
79352138|NCT01417156|Drug|Nintedanib|150 mg bid
79352139|NCT01417156|Drug|Pirfenidoneone|Existing treatment
79352140|NCT01417078|Drug|Diazepam|single-dose; dosage in mg, based on patient body weight
79352141|NCT01954394|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
79352142|NCT01954394|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
79352143|NCT01464424|Drug|Travoprost 0.004% ophthalmic solution|
79352144|NCT01464424|Drug|Bimatoprost 0.01% ophthalmic solution|
79665589|NCT06164041|Behavioral|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
79665590|NCT06164015|Diagnostic Test|3D Ultrasound scan with power Doppler angiography|The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
79665591|NCT06164002|Other|change in restoration material and margin design.|comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
79352145|NCT01902134|Drug|Placebo|Placebo single oral dose (first 8 hours)
79989607|NCT04754139|Other|WeChat mobile mini-application|Sexual health education and the role of PrEP
79503256|NCT06027723|Other|Placebo|Placebo nicotine-free vaping liquid delivered through a vape
79665592|NCT06163989|Drug|TheaLoz Duo Eyedrop|TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
79352146|NCT01902134|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
79503257|NCT06024512|Device|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
79665593|NCT06163989|Drug|Saline Eyedrop|Saline 0.9% eyedrop is used as a control eyedrop and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
79679584|NCT02949713|Behavioral|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
79989608|NCT04753749|Drug|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
79989609|NCT04753749|Drug|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
79352147|NCT01902134|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
79352148|NCT01902134|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
79352149|NCT01902134|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
79352150|NCT01902134|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
79352151|NCT01902134|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
79352152|NCT05110586|Other|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
79989610|NCT04749888|Behavioral|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
79989611|NCT04749524|Diagnostic Test|Measurement of Otoacoustic Emissions with and without suppression noise|Otoacoustic emissions will be recorded using an ear probe with and without a suppression noise.
79989612|NCT04715048|Drug|PrabotulinumtoxinA|Glabellar line correction
79989613|NCT04715048|Drug|Onabotulinum toxin A|Glabellar line correction
79989614|NCT04701151|Drug|Bacillus Calmette Guerin|The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
79989615|NCT04685590|Drug|Dasatinib + Quercetin|D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
79989616|NCT04685590|Other|Placebo Capsules|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
79989617|NCT04675710|Procedure|Conventional Surgery|Undergo surgery
79989618|NCT04675710|Drug|Dabrafenib|Given PO
79989619|NCT04675710|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79503258|NCT06019338|Other|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
79665594|NCT06163963|Diagnostic Test|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer|This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
79989620|NCT04675710|Biological|Pembrolizumab|Given IV
79989621|NCT04675710|Other|Quality-of-Life Assessment|Ancillary studies
79989622|NCT04675710|Drug|Trametinib|Given PO
79503259|NCT06014086|Drug|PH-762|PH-762 is a potent RNAi molecule targeting PD-1.
79503260|NCT06013579|Behavioral|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
79665595|NCT06163950|Other|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
79989623|NCT04648202|Drug|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
79989624|NCT04647253|Device|AGENT DCB|Drug coated PTCA balloon catheter
79989625|NCT04647253|Device|PTCA balloon catheter|PTCA balloon catheter
79665596|NCT06163937|Other|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79503261|NCT06013579|Behavioral|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
79228369|NCT03706521|Drug|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
79503262|NCT06013579|Behavioral|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
79503263|NCT06013579|Behavioral|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
79503264|NCT06004492|Behavioral|blended learning program|8 hours of workshops and four months of practical learning on technology platforms
79228370|NCT03301688|Biological|Toripalimab|To compare the different drug batch number with different process
79352153|NCT01954082|Drug|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
79352154|NCT01954082|Drug|Placebo|% glucose(dextrose)
79352155|NCT01417000|Biological|GVAX Pancreas|
79352156|NCT01417000|Biological|CRS-207|
79503265|NCT06002347|Behavioral|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
79665597|NCT06163937|Other|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79665598|NCT06163937|Other|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79665599|NCT06163911|Device|ECG|Routine care 12-lead electrocardiogram
79352157|NCT01417000|Drug|Cyclophosphamide|
79352158|NCT01416142|Device|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
79352159|NCT01416142|Device|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
79352160|NCT01415986|Drug|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
79352161|NCT01415986|Device|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
79352162|NCT01415908|Device|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
79665600|NCT06163911|Device|Echocardiography|Routine care echocardiography
79665601|NCT06163898|Drug|Alnuctamab|Specified dose on specified days
79665602|NCT06163898|Drug|Mezigdomide|Specified dose on specified days
79665603|NCT06163898|Drug|Dexamethasone|Specified dose on specified days
79665604|NCT06163885|Other|Stoma care education with flipped classroom|Flipped classroom model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
79665605|NCT06163885|Other|Stoma care education with peer-supported education model|Peer-supported education model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
79665606|NCT06163872|Behavioral|survey study|survey study
79679585|NCT00518219|Drug|TW|TW,120mg/d
79679586|NCT00516854|Drug|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
79503266|NCT06001112|Other|cheek acupuncture|Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
79817493|NCT04036695|Device|Reveal LINQ insertable cardiac monitoring system|A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
79989626|NCT04644172|Behavioral|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
79665607|NCT06163833|Drug|Mesenchymal stromal cell low dosage-80*10^6 cells|"MSCs have to be administered at the dosage of 80*10^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
79665608|NCT06163833|Drug|Mesenchymal stromal cell low dosage-160*10^6 cells|"MSCs have to be administered at the dosage of 160*10^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
79228371|NCT02259543|Other|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
79352163|NCT01415908|Other|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
79352164|NCT01415518|Drug|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
79352165|NCT01415518|Drug|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
79352166|NCT01415518|Drug|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
79352167|NCT04058392|Biological|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
79817494|NCT00638859|Drug|Telithromycin (HMR3647)|
79503267|NCT06001112|Drug|Etoricoxib|etoricoxib 120mg
79503268|NCT05994235|Drug|Mosunetuzumab|"Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks."
79665609|NCT06163833|Other|Placebo-storage solution|Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
79665610|NCT06163807|Drug|Antiasthmatic|real-life
79665611|NCT06163781|Device|Blood culture prediction tool|Machine learning based predicition tool
79989627|NCT04644172|Behavioral|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
79989628|NCT04644172|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
79989629|NCT04644172|Other|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
79989630|NCT04634240|Procedure|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
79352168|NCT04057846|Device|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
79352169|NCT04767412|Device|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
79352170|NCT01393600|Drug|NBI-98854|12.5 mg powder in bottle once daily for 14 days
79352171|NCT01393600|Drug|NBI-98854|50 mg powder in bottle once daily for 14 days
79352172|NCT01393600|Drug|Placebo|Solution containing no active substance
79352173|NCT01432756|Behavioral|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
79665612|NCT06163768|Procedure|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
79665613|NCT06163755|Drug|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
79679587|NCT04694729|Other|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
79989631|NCT04631484|Drug|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
79989632|NCT04631484|Drug|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
79989633|NCT04630418|Other|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
79989634|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
79665614|NCT06163716|Behavioral|Multidomain intervention (MD-Int) group|The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
79817495|NCT00793325|Drug|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
79817496|NCT02537847|Drug|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
79352174|NCT04767178|Drug|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
79989635|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
79352175|NCT04767178|Drug|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
79352176|NCT01432600|Drug|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
79665615|NCT06163677|Biological|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
79665616|NCT06163664|Behavioral|Use of chatGPT for 1 week|Use of chatGPT for 1 week
79352177|NCT01432600|Drug|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
79665617|NCT06163638|Behavioral|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive function, psychosocial well-being, quality of the family relationship and expectations regarding aging and motor competence due to the intervention, 2 arms were created to test the effets.
79665618|NCT06163625|Device|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
79665619|NCT06163625|Behavioral|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
79817497|NCT02537847|Drug|Ertapenem|Control group will be given ertapenem only for 10 days.
79817498|NCT04076553|Behavioral|CBT|Participants will complete 12 sessions of CBT
79817499|NCT04076553|Behavioral|ICT|"Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12"
79989636|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
79989637|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
79352178|NCT01432600|Drug|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
79352179|NCT01432444|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
79352180|NCT01432366|Other|SC anti-TNF|Subcutaneous (SC) anti-TNF
79665620|NCT06163625|Behavioral|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
79665621|NCT06163625|Biological|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
79503269|NCT05994235|Drug|Tazemetostat Pill|Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
79665622|NCT06163612|Behavioral|Clinical Interview|A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
79665623|NCT06163612|Behavioral|Clinical Questionnaires|A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
79352181|NCT01415440|Drug|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
79352182|NCT01415440|Drug|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
79679588|NCT04694729|Other|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
79503270|NCT05991427|Biological|Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
79503271|NCT05991427|Biological|Zoster Vaccine Recombinant, Adjuvanted (Shingrix)|2 doses of Shingrix vaccine on Day 0 and Month 4
79679589|NCT05318742|Procedure|laser|Endolaser photocoagulation during PPV
79352183|NCT04049890|Other|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
79352184|NCT04049890|Other|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
79352185|NCT04049890|Other|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
79352186|NCT02076412|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
79503272|NCT05991427|Biological|ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
79503273|NCT05991427|Biological|Shingrix|2 doses of Shingrix vaccine on Day 0 and Month 4
79503274|NCT05991427|Biological|IH ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
79503275|NCT05991427|Biological|IH saline|2 doses of saline on Day 0 and Month 4
79352187|NCT02076412|Drug|Placebo|Placebo tablet PO bid (morning and evening)
79352188|NCT04048252|Other|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
79503276|NCT05991232|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
79503277|NCT05990569|Other|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
79503278|NCT05990192|Drug|Niraparib oral capsule|Niraparib used following SBRT treatment until disease progression
79503279|NCT05990192|Radiation|SBRT|SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
79503280|NCT05987020|Other|Aromatherapy|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil."
79503281|NCT05982158|Behavioral|Avatar therapy|Seven 50-minute therapy sessions conducted by videoconferencing.
79989638|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
79989639|NCT04578535|Drug|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
79352189|NCT04048252|Other|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
79352190|NCT01932788|Drug|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
79503282|NCT05982158|Behavioral|Cognitive behavioural therapy (CBT)|Seven 50-minute therapy sessions conducted by videoconferencing.
79503283|NCT05979688|Behavioral|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
79989640|NCT04577573|Device|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
79989641|NCT04577573|Device|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
79989642|NCT04574362|Drug|Rimegepant|One 75mg orally disintegrating tablet
79503284|NCT05977049|Behavioral|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
79503285|NCT05972512|Other|Placebo|Mode of usage: Two times a day Route of administration: Oral
79989643|NCT04574362|Drug|Placebo|Matching placebo
79989644|NCT04566887|Drug|Acalabrutinib|Administered as 100mg tablets.
79989645|NCT04566887|Drug|R-CHOP chemotherapy|R-CHOP chemotherapy
79989646|NCT04564027|Drug|Ceralasertib|Tablets will be administered orally
79989647|NCT04562896|Device|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
79989648|NCT04562688|Other|CICADAS and then PEERS|Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. After 16 weeks, participants will then crossover to PEERS, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians.
79352191|NCT01932788|Drug|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
79352192|NCT01414738|Radiation|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
79352193|NCT01414114|Drug|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
79352194|NCT01393444|Device|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
79352195|NCT01431976|Drug|Lamictal|No comparison
79352196|NCT01413958|Drug|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
79352197|NCT01413958|Drug|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
79503286|NCT05972512|Dietary Supplement|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
79503287|NCT05972512|Dietary Supplement|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
79679590|NCT02949869|Other|Spinal Sonography|As described previously
79679591|NCT02940990|Radiation|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
79679592|NCT02940990|Drug|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
79679593|NCT00518297|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
79665624|NCT06163612|Other|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
79665625|NCT06163612|Behavioral|Behavioural Games|The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
79665626|NCT06163586|Other|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
79352198|NCT01413958|Drug|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
79352199|NCT02985502|Other|pancreatogenic diabetes|pancreatogenic diabetes
79665627|NCT06163573|Biological|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
79665628|NCT06163573|Biological|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
79665629|NCT06163560|Device|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
79665630|NCT06163560|Device|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
79989649|NCT04562688|Other|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
79352200|NCT01413178|Drug|Busulfan|Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
79352201|NCT01413178|Drug|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
79352202|NCT01413178|Other|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
79352203|NCT01413178|Drug|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
79352204|NCT01413178|Drug|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
79665631|NCT06163547|Radiation|MMA embolization|Middle meningeal artery embolization
79665632|NCT06163391|Drug|SOT201|intravenous infusion
79665633|NCT06163209|Diagnostic Test|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~Sagittal plane, along the most prominent part of nasal dorsum.~Transverse plane, level of nasion.~Transverse plane, level of intercanthal line.~Transverse plane, level of rhinion.~Along inferior border of the right nasal bone.~Along inferior border of the left nasal bone.~Along medial part of the right orbital rim below frontomaxillary suture.~Along medial part of the right orbital rim below frontomaxillary suture.~Along the line connecting right frontomaxillary suture and the tip of the nose.~Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
79665634|NCT06163209|Diagnostic Test|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~Bony part of the nasal septum~Left nasal bone - part proximal to the intercanthal line~Right nasal bone - part proximal to the intercanthal line~Left nasal bone - part distal to the intercanthal line~Right nasal bone - part distal to the intercanthal line~Frontal process of the left maxilla~Frontal process of the right maxilla"
79665635|NCT06158867|Device|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
79679594|NCT00518297|Drug|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
79503288|NCT05970796|Behavioral|Pelvic floor muscle training|"The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia."
79665636|NCT06158412|Drug|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~The last ATRA dose will be given in the evening on the day of carfilzomib administration.~Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~Pomalidomide 4mg orally daily, d1-21;~Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; >75 years: 20 mg/day."
79989650|NCT04562688|Other|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
79665637|NCT06158399|Drug|Azacitidine in combination with R-CHOP|"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"
79352205|NCT01413178|Procedure|Stem cell transplant|Stem cell infusion on Day 0.
79679595|NCT00518297|Drug|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
79817500|NCT04077645|Behavioral|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
79352206|NCT01799889|Drug|Entospletinib MM|Entospletinib MM tablet administered orally
79989651|NCT04551521|Drug|Vemurafenib|960 mg twice daily during run-in Phase, followed by 720 mg twice daily
79989652|NCT04551521|Drug|Cobimetinib|60 mg once daily
79989653|NCT04551521|Drug|Atezolizumab|840 mg every 2 weeks
79352207|NCT01799889|Drug|Entospletinib SDD|Entospletinib SDD tablet administered orally
79352208|NCT01412944|Drug|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
79352209|NCT01412944|Drug|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
79503289|NCT05970718|Drug|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
79352210|NCT03025906|Drug|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
79352211|NCT03025906|Drug|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
79503290|NCT05970718|Drug|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
79352212|NCT04055272|Behavioral|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
79817501|NCT04077645|Behavioral|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
79817502|NCT04077645|Behavioral|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
79352213|NCT04053712|Drug|Glucagon|GlucaGen(R), Novo Nordisk, DK
79817503|NCT02687841|Drug|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
79989654|NCT04551521|Drug|Trastuzumab|8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
79989655|NCT04551521|Drug|Pertuzumab|840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
79989656|NCT04551521|Drug|Alectinib|600 mg twice daily
79352214|NCT04053712|Device|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
79352215|NCT01798485|Drug|Docetaxel|Docetaxel, 75 mg/m^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
79503291|NCT05949957|Behavioral|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
79352216|NCT01798485|Drug|Ganetespib|Ganetespib, 150 mg/m^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
79503292|NCT05949957|Behavioral|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
79503293|NCT05949957|Behavioral|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
79665638|NCT06158386|Drug|Chidamide combined with Linperlisib|Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
79665639|NCT06158165|Device|Mostcare (Vytech, Vygon, Padua, Italy)|Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
79989657|NCT04551521|Drug|Ipatasertib|400 mg once daily
79503294|NCT05949710|Behavioral|aerobic exercise(AE)|The participants in Groups A and C will receive AE three times per week, and those in Group D will receive AE five times per week (the same supervised AE protocol three times a week with additional home-based AE training with an instructional video two times a week). The exercise movements in the instructional video will be identical to those of the supervised exercise to enable the participants to easily perform the exercise at home. The participants in the two control groups (Groups B and E) will maintain their original lifestyle without any exercise intervention during the 16 weeks.
79503295|NCT05944302|Behavioral|EMDR group|Eye Movement Desensitization and Reprocessing
79352217|NCT01767597|Other|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
79352218|NCT01767597|Other|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
79665642|NCT06156475|Procedure|Proprioception exercises|Patients trained for proprioception exercises.
79989658|NCT04551521|Drug|Atezolizumab|1200 mg every 3 weeks
79989659|NCT04551521|Drug|Atezolizumab|1200 mg in the first cycle, followed by 840 mg every 3 weeks
79665643|NCT06156475|Procedure|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
79665644|NCT06156475|Procedure|Wand Exercise|Patients were educated with wand exercises.
79665645|NCT06156423|Other|Motor control exercise|Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
79665646|NCT06156423|Other|Standard exercise|The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
79665647|NCT06156280|Drug|TQH2929 injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
79665648|NCT06156280|Drug|Placebo injection|Placebo comparator
79665649|NCT06155695|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
79665650|NCT06155695|Behavioral|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
79665651|NCT06153888|Procedure|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
79665652|NCT06153394|Drug|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
79665653|NCT06153394|Drug|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
79665654|NCT06153225|Dietary Supplement|Protein products|In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
79352219|NCT01767519|Biological|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
79665655|NCT06152835|Other|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
79503298|NCT05933174|Other|Prompt-sheet|Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
79665659|NCT06151119|Diagnostic Test|68Ga FAPI PET/CT|68Ga FAPI PET/CT
79989660|NCT04551521|Drug|Atezolizumab|1,200 mg every 3 weeks
79352220|NCT01767519|Drug|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
79352221|NCT01767519|Drug|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
79352222|NCT01767519|Drug|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
79352223|NCT01797783|Device|Nelfilcon A multifocal contact lens with comfort additive|
79352224|NCT01797783|Device|Nelfilcon A multifocal contact lens|
79352225|NCT01766817|Drug|BMS-986020|
79352226|NCT01766817|Drug|Placebo matching with BMS-986020|
79352227|NCT01797705|Device|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
79352228|NCT01797081|Biological|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
79352229|NCT01797081|Biological|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
79352230|NCT01797081|Other|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
79503299|NCT05933174|Other|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
79665660|NCT06151106|Drug|Chidamide combined with Duvillisib|Specified dose on specified days
79665661|NCT06151080|Drug|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
79665662|NCT06150859|Drug|Ayahausca-Assisted psychotherapy|"Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions."
79989661|NCT04551521|Drug|Inavolisib|9 mg once daily
79989662|NCT04545762|Drug|Fludarabine|Given intravenously (IV)
79989663|NCT04545762|Drug|Cyclophosphamide|Given intravenously (IV)
79989664|NCT04545762|Biological|anti-CD19 CAR-T cells|Single infusion
79989665|NCT04536584|Other|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
79503300|NCT05921565|Behavioral|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
79503301|NCT05913791|Dietary Supplement|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
79503302|NCT05913791|Other|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
79817504|NCT02687841|Drug|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
79817505|NCT04076475|Device|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
79817506|NCT05121441|Drug|ARD-101|Twice daily, oral administration
79503303|NCT05908695|Drug|GV-971|Administered PO
79503304|NCT05908695|Drug|Placebo|Administered PO
79503305|NCT05895266|Drug|ABBV-903|Oral Tablet
79503306|NCT05895266|Drug|Midazolam|Oral Liquid
79503307|NCT05894421|Drug|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
79817507|NCT05121441|Drug|Placebo|Twice daily, oral administration
79352231|NCT01794117|Drug|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
79352232|NCT01766037|Device|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
79823773|NCT03838562|Other|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
79817508|NCT04011267|Other|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
79665663|NCT06150859|Behavioral|Constructivist Psychotherapy|Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions
79665664|NCT06150859|Other|No treatment|No treatment during the control period
79817509|NCT00778622|Drug|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
79817510|NCT00915980|Procedure|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
79817511|NCT00777920|Drug|Ambrisentan|Tablet administered orally once daily
79817512|NCT04236141|Drug|Polatuzumab Vedotin|Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
79817513|NCT04236141|Drug|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
79352233|NCT01766037|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
79352234|NCT04413903|Procedure|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
79665665|NCT06150755|Procedure|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
79665666|NCT06150755|Procedure|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
79817514|NCT04236141|Drug|Rituximab|Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
79817515|NCT04236141|Drug|Placebo|Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
79817516|NCT02601248|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
79352235|NCT01765569|Drug|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
79352236|NCT01765569|Drug|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
79352237|NCT04414605|Drug|Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)|Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
79352238|NCT04414605|Drug|Secukinumab Auto-Injector [Cosentyx]|Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
79352239|NCT01609257|Biological|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
79352240|NCT01609257|Biological|Saline Comparator|2 doses IM 28 days apart
79352241|NCT04569357|Drug|Prospecta|Oral administration.
79665669|NCT06150248|Other|Education Intervention|"This intervention is based on the Social Cognitive Theory (SCT) and The Health Belief Model (HBM) to improve knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
79352242|NCT04569357|Drug|Placebo|Oral administration.
79352243|NCT01609023|Drug|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
79352244|NCT01765179|Drug|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
79352245|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
79352246|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
79665670|NCT06150248|Other|No intervention|They will have their regular curriculums and normal physical activity routine.
79665671|NCT06149741|Procedure|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
79665672|NCT06147284|Behavioral|Preventive interventions|Parallel randomized controlled trial
79665673|NCT06146465|Other|speciality|Not
79665674|NCT06144502|Behavioral|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
79665675|NCT06142409|Dietary Supplement|Enzyme containing lozenge|Lozenge containing multiple enzyme combination
79665676|NCT06132789|Biological|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
79817517|NCT04097522|Other|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
79352247|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
79665677|NCT06125925|Procedure|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
79665678|NCT06125925|Drug|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
79665679|NCT06124677|Drug|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
79665680|NCT06120647|Dietary Supplement|Essential amino acids (EAA)|intake of 240 mg EAA per kg lean body mass after a resistance exercise session
79817518|NCT04233099|Procedure|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
79817519|NCT04097444|Biological|Bevacizumab|Given IV
79817520|NCT04097444|Drug|5-fluorouracil|Given IV
79817521|NCT04097444|Drug|Leucovorin calcium|Given IV
79817522|NCT04097444|Drug|Irinotecan hydrochloride|Given IV
79817523|NCT04097444|Drug|Oxaliplatin|Given IV
79817524|NCT04097444|Drug|Capecitabine|Given PO
79817525|NCT04097288|Drug|Citalopram 40mg|Single dose
79817526|NCT04097288|Drug|Reboxetine 8 mg|Single dose
79352248|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
79352249|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
79352250|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
79352251|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
79352252|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
79352253|NCT01793883|Drug|40 mg Laninamivir Octanoate|
79352254|NCT01793883|Drug|80 mg Laninamivir Octanoate|
79817527|NCT04097288|Drug|Placebo oral tablet|Single dose
79817528|NCT04097288|Drug|Placebo oral tablet|Single dose
79817529|NCT03994094|Other|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
79817530|NCT04076007|Dietary Supplement|Beetroot juice|
79352255|NCT01793883|Drug|Placebo|
79817531|NCT04076007|Dietary Supplement|Nitrate depleted beetroot juice|
79817532|NCT04005105|Behavioral|Intensive management|Management based on premorbid MAP and MPP
79352256|NCT01792635|Drug|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
79352257|NCT01792635|Drug|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
79352258|NCT01953692|Biological|Pembrolizumab|IV infusion
79352259|NCT01953692|Drug|Lenalidomide 20 mg|oral capsule
79352260|NCT01953692|Drug|Lenalidomide 25 mg|oral capsule
79817533|NCT03995901|Biological|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
79817534|NCT04076085|Other|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
79817535|NCT02581059|Drug|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
79352261|NCT01791153|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
79503308|NCT05894070|Other|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~Standardized, phonetically balanced text~Sustained, modulated production of five vowels~Picture description~Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~Health barometer~Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erythro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
79503309|NCT05889845|Drug|Candin, Intradermal Solution|Injection at the base of the selected wart
79503310|NCT05889845|Drug|Placebo|Injection at the base of the selected wart
79352262|NCT01791153|Drug|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
79503311|NCT05883319|Other|manuel therapy|approaches will be applied for 3 days / week for 6 weeks.
79665681|NCT06118892|Device|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
79665682|NCT06110091|Behavioral|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
79665683|NCT06110091|Behavioral|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
79817536|NCT02581059|Dietary Supplement|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
79352263|NCT01791153|Drug|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
79352264|NCT01791153|Drug|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
79352265|NCT01791153|Drug|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
79665684|NCT06105684|Drug|Capecitabine Pill|Will be given once per day by mouth
79817537|NCT05247957|Biological|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
79352266|NCT01791153|Drug|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
79989666|NCT04536584|Other|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
79352267|NCT01926782|Drug|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
79352268|NCT01926782|Drug|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
79352269|NCT01926782|Drug|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
79352270|NCT01926626|Drug|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
79352271|NCT01926626|Drug|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
79503312|NCT05883319|Other|exercises|approaches will be applied for 3 days / week for 6 weeks.
79503313|NCT05880485|Radiation|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
79352272|NCT01953224|Behavioral|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
79352273|NCT01953224|Device|Smartphone|
79503314|NCT05876390|Procedure|Breast surgery|Breast surgery
79503315|NCT05876390|Drug|analgesia|Multimodal analgesia
79665685|NCT06099678|Behavioral|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
79665686|NCT06099678|Behavioral|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
79503316|NCT05866757|Other|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
79503317|NCT05865158|Other|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
79503318|NCT05861284|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
79503319|NCT05854745|Behavioral|HBB Virtual Training|HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
79503320|NCT05854745|Behavioral|HBB In-person Training|HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
79503321|NCT05849181|Device|Moona Device|Moona Device pillow pad
79503322|NCT05849181|Device|Inactive Moona Device|Inactive Moona Device pillow pad
79503323|NCT05845021|Combination Product|Surgeon-Initiated Bone Health Referral Pathway|Described in arm description
79665687|NCT06096246|Procedure|Pulmonary vein isolation|The catheter ablation (with a CE [Conformité Européenne] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
79665688|NCT06096246|Procedure|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
79989667|NCT04526782|Drug|Encorafenib 75 MG|450 mg (6 × 75 mg capsule) per day
79989668|NCT04526782|Drug|Binimetinib 15 MG|45 mg (3 × 15 mg tablet) twice daily
79989669|NCT04522973|Other|Beverage with ethanol and E-cigarette liquid with ethanol|Beverage with ethanol and E-cigarette liquid with ethanol
79989670|NCT04522973|Other|Beverage with ethanol and E-cigarette liquid without ethanol|Beverage with ethanol and E-cigarette liquid without ethanol
79665689|NCT06096246|Device|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
79665690|NCT06096246|Procedure|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
79665691|NCT06082310|Other|Exercise|Two HIIT modalities
79665692|NCT06081309|Device|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
79665693|NCT06075823|Device|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
79665694|NCT06075823|Other|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
79665695|NCT06073938|Drug|NHWD-870|The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
79665696|NCT06059443|Behavioral|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
79665697|NCT06058949|Behavioral|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
79665698|NCT06058949|Behavioral|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
79352274|NCT01900730|Drug|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
79352275|NCT01900730|Drug|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
79352276|NCT01900730|Behavioral|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
79352277|NCT01900730|Behavioral|Pill Diary|Patient given a pill diary to record the time each dose taken.
79352278|NCT01900730|Behavioral|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
79352279|NCT01952834|Dietary Supplement|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
79503324|NCT05836779|Drug|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
79665699|NCT06050616|Other|MRI scans|"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."
79665700|NCT06050616|Other|Psychological measures|"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."
79665701|NCT06050616|Other|Life experiences|Self-report questionnaires on experiences of bullying and trauma.
79665702|NCT06050616|Biological|Blood and urine samples|Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
79503325|NCT05834309|Other|Physical exercise|The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
79665703|NCT06050616|Other|Mental health symptoms|"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."
79665704|NCT06050278|Other|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
79817538|NCT02581605|Device|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
79817539|NCT00796445|Drug|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
79817540|NCT00796445|Drug|Placebo|IM solution, a course of 13 injections administered over 27 months
79989671|NCT04522973|Other|Beverage without ethanol and E-cigarette liquid with ethanol|Beverage without ethanol and E-cigarette liquid with ethanol
79352280|NCT01952834|Drug|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
79352281|NCT04643912|Diagnostic Test|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
79817541|NCT04075773|Behavioral|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
79817542|NCT04108871|Procedure|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
79817543|NCT03799263|Procedure|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
79352282|NCT01952054|Drug|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
79503326|NCT05819827|Other|Blood and Tissue|"Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy."
79665705|NCT06050252|Procedure|Biopsy|Undergo tissue biopsy
79989672|NCT04522973|Other|Beverage without ethanol and E-cigarette liquid without ethanol|Beverage without ethanol and E-cigarette liquid without ethanol
79503327|NCT05816473|Other|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
79665706|NCT06050252|Procedure|Biospecimen Collection|Undergo blood sample collection
79989673|NCT04521608|Behavioral|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
79989674|NCT04484077|Biological|hCT-MSC|2x10^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
79352283|NCT01925768|Drug|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
79665707|NCT06050252|Drug|Cisplatin|Given IV
79665708|NCT06050252|Procedure|Computed Tomography|Undergo CT scan
79665709|NCT06050252|Biological|Durvalumab|Given IV
79665710|NCT06050252|Drug|Gemcitabine|Given IV
79665711|NCT06050252|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79352284|NCT01925768|Drug|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
79352285|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
79352286|NCT01431274|Drug|tiotropium|low dose
79352287|NCT01431274|Drug|olodaterol|one dose only
79352288|NCT01431274|Drug|tiotropium|high dose
79352289|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
79989675|NCT04470908|Drug|Zanubrutinib|Single oral dose of 320 mg
79665712|NCT06050252|Procedure|Resection|Undergo surgical resection
79665713|NCT06047366|Drug|Sodium bicarbonate|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
79665714|NCT06047366|Drug|Lidocaine w/ epi|Septodont's standard formulation of 2% lidocaine with epinephrine
79665715|NCT06047366|Drug|Articaine w/ epi|Septodont's standard formulation of 4% articaine with epinephrine
79817544|NCT03999047|Diagnostic Test|PRISMA score|Screening for frailty using PRISMA-7
79989676|NCT04470908|Drug|Rifabutin|Oral dose of 300 mg once daily
79989677|NCT04458038|Other|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
79989678|NCT04451044|Device|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
79989679|NCT04451044|Procedure|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
79989680|NCT04439292|Drug|Dabrafenib Mesylate|Given PO
79352290|NCT01431274|Device|Respimat|Respimat inhaler
79503328|NCT05811364|Device|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
79503329|NCT05811364|Device|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
79503330|NCT05806138|Drug|Vericiguat|A starting dose of vericiguat 2.5 mg will be administered in-clinic at the Day 1 visit. Titration visits will occur on Days 14 and 28, with dose escalation to 5 mg and 10 mg.
79817545|NCT02580513|Behavioral|Circadian Misalignment|
79817546|NCT03939819|Device|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
79989681|NCT04439292|Drug|Trametinib Dimethyl Sulfoxide|Given PO
79989682|NCT04439188|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
79989683|NCT04439149|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
79989684|NCT04419766|Other|IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying|The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
79989685|NCT04417530|Drug|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
79989686|NCT04417530|Device|Suprachoroidal Microinjector|Suprachoroidal Injection Device
79989687|NCT04417530|Device|PDT Laser|Laser Administration
79352291|NCT01991795|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
79352292|NCT01991795|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
79352293|NCT02076100|Drug|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
79665716|NCT06047366|Drug|Mepivacaine plain|Septodont's standard formulation of 3% mepivacaine
79665717|NCT06041672|Behavioral|Warm Water Hand Baths|"Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
79665718|NCT06041646|Drug|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
79665719|NCT06036134|Behavioral|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
79665720|NCT06036134|Behavioral|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
79989688|NCT04416633|Drug|Durvalumab|500-mg/120-mg IV
79989689|NCT04413266|Dietary Supplement|Curcumin supplementation|The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
79989690|NCT04399876|Combination Product|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
79352294|NCT01411852|Drug|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
79352295|NCT01411852|Drug|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
79352296|NCT01411774|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
79665721|NCT06036134|Behavioral|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
79989691|NCT04399837|Drug|Spesolimab|Solution for injection
79989692|NCT04399837|Drug|Placebo|Solution for injection
79989693|NCT04391803|Device|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
79989694|NCT04388930|Other|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
79352297|NCT01411774|Drug|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
79352298|NCT01411774|Drug|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
79352299|NCT01411228|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
79352300|NCT01410604|Drug|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
79352301|NCT01410604|Drug|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
79817547|NCT03939819|Device|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
79989695|NCT04388930|Other|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
79989696|NCT04388930|Other|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
79989697|NCT04388930|Other|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
79989698|NCT04388930|Other|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
79989699|NCT04388930|Other|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
79989700|NCT04374630|Drug|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
79989701|NCT04374630|Drug|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
79989702|NCT04368013|Procedure|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
79989703|NCT04365413|Device|MSOT Device|The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
79352302|NCT01991483|Drug|LY2928057|Administered intravenously
79817548|NCT04219449|Diagnostic Test|PT|measuring PT drawn on citrated blood sample
79352303|NCT01991483|Drug|Placebo|Administered intravenously
79352304|NCT01410448|Drug|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
79352305|NCT01410448|Drug|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
79352306|NCT01410448|Drug|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
79503331|NCT05806138|Other|Optimal medical therapy|All subjects will be followed by a cardiologist throughout the study period and will receive optimal medical therapy for cardiomyopathy/heart failure following the ACCF/AHA and ESC Guidelines for the Management of Heart Failure recommendations, applied individually at the discretion of the treating investigator and in line with individual tolerability. This includes medications such as ßblockers, angiotensin converting enzyme inhibitors(ACEI), angiotensin receptor/neprilysin inhibitor (ARNI), angiotensin receptor blockers (ARB), and mineralocorticoid antagonists
79352307|NCT01410448|Drug|Steroids|Steroids were administered according to local clinical practice.
79503332|NCT05789368|Dietary Supplement|Placebo sachet|consume 1 sachet per day
79503333|NCT05789368|Dietary Supplement|VeCollal sachet|consume 1 sachet per day
79503334|NCT05789368|Dietary Supplement|Collagen sachet|consume 1 sachet per day
79503335|NCT05788692|Device|electric tootbrush|Participants will brush twice per day with an electric toothbrush
79817549|NCT04219449|Diagnostic Test|Protein C|measuring protein C drawn on citrated blood sample
79989704|NCT04365413|Procedure|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
79989705|NCT04364269|Drug|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
79989706|NCT04364269|Drug|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
79817550|NCT04219449|Diagnostic Test|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
79989707|NCT04364269|Drug|Placebo|Participants will receive hard capsules of Placebo, twice a day.
79817551|NCT04209855|Drug|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
79352308|NCT01943851|Drug|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
79817552|NCT04209855|Drug|Paclitaxel|Paclitaxel is a taxane that can stabilize microtubules to inhibit cell division. It was approved for treatment of recurrent epithelial ovarian cancer.
79989708|NCT04358874|Other|Medication reconciliation|Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
79989709|NCT04358874|Other|Blood Pressure Management|Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (>160/100)
79352309|NCT01430104|Drug|Teriparatide|Administered subcutaneously during the Treatment Period
79352310|NCT01430104|Drug|Aspara-CA 600 mg|Administered orally throughout the study
79352311|NCT01430104|Drug|Alfarol 1.0 µg|Administered orally throughout the study
79352312|NCT01990859|Biological|Ipilimumab|
79352313|NCT02093897|Biological|rVIII-SingleChain|
79352314|NCT01990313|Device|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
79352315|NCT01947517|Device|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
79989710|NCT04337970|Drug|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
79989711|NCT04337970|Drug|Axitinib|5 mg PO BID
79503336|NCT05788692|Device|manual toothbrush|Participants will brush twice per day with a manual toothbrush
79503337|NCT05788692|Device|toothbrushing assisting application|Participants will brush twice per day with toothbrushing assisting application
79817553|NCT04209855|Drug|Topotecan|Topotecan induces irreversible DNA damage. It inhibits topoisomerase 1, leading to both single and double strand DNA break that eventually promote apoptosis. Topotecan was approved for treatment of epithelial ovarian cancer after failure of initial or subsequent chemotherapy.
79352316|NCT01947517|Device|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
79352317|NCT02006927|Device|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
79352318|NCT01947283|Behavioral|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
79503338|NCT05786768|Drug|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
79817554|NCT04209855|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin is a standard chemotherapy regimen used for treating platinum-resistant ovarian cancer. The active component doxorubicin is an anthracycline that intercalates DNA, leading to inhibition of replication and subsequently, the inhibition of proper cell division.
79989712|NCT04318080|Drug|Tislelizumab|200 mg intravenously (IV) every 3 weeks (Q3W)
79503339|NCT05786768|Drug|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
79503340|NCT05777343|Other|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
79352319|NCT01947283|Behavioral|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
79352320|NCT02006693|Device|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
79352321|NCT02006693|Procedure|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
79503341|NCT05777343|Other|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
79503342|NCT05777343|Other|Cognitive training|Online sessions of cognitive training.
79503343|NCT05765084|Biological|Dendritic cell vaccination|WT1/DC vaccines (8-10 x 10^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
79503344|NCT05765084|Drug|Atezolizumab|Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
79503345|NCT05765084|Drug|Platinum/pemetrexed based chemotherapy|On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
79503346|NCT05763056|Procedure|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
79665723|NCT06029842|Other|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
79352322|NCT01976845|Drug|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
79352323|NCT01976845|Drug|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
79352324|NCT01976845|Drug|Saline|Saline 2 ml IV, in the pre-op area as a premedication
79352325|NCT01989689|Drug|Etanercept|Etanercept 50mg twice weekly
79352326|NCT01989689|Drug|Placebo|
79665724|NCT06028282|Radiation|SPECT|SPECT of thyroid traced with I-131
79665725|NCT06024174|Drug|BMS-986466|Specified dose on specified days
79665726|NCT06024174|Drug|Adagrasib|Specified dose on specified days
79352327|NCT01943539|Device|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
79352328|NCT04416373|Diagnostic Test|RT PCR SARS-CoV-2|Positive SARS-CoV-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samples
79352329|NCT04638595|Other|Observation|This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
79352330|NCT01942993|Drug|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
79352331|NCT01989455|Drug|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
79352332|NCT01989455|Drug|Placebo|Placebo: normal saline solution.
79665727|NCT06024174|Drug|Cetuximab|Specified dose on specified days
79503347|NCT05763056|Procedure|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
79503348|NCT05763056|Device|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
79503349|NCT05754125|Dietary Supplement|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
79989713|NCT04316962|Other|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~Individual goal-setting~Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~Peer support."
79665728|NCT06014723|Procedure|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
79665729|NCT06004830|Drug|Spironolactone|All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
79665730|NCT06004180|Drug|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
79665731|NCT05984810|Procedure|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
79665732|NCT05980806|Drug|Selinexor 60 mg|Participants will receive selinexor 60 mg oral tablets QW.
79665733|NCT05980806|Drug|Selinexor 40 mg|Participants will receive selinexor 40 mg oral tablets QW.
79989714|NCT04309721|Drug|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
79352333|NCT01942837|Drug|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
79352334|NCT01987895|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
79352335|NCT01987895|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
79665734|NCT05980806|Drug|Ruxolitinib|Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
79989715|NCT04309721|Drug|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
79989716|NCT04299945|Dietary Supplement|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
79352336|NCT01987895|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
79352337|NCT01987895|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
79352338|NCT02005445|Device|CPAP|Continuous positive airway pressure
79352339|NCT02005445|Behavioral|HLSE|Healthy living and sleep education
79352340|NCT01618669|Drug|Regadenoson|Administered as an intravenous (IV) bolus
79352341|NCT01618669|Procedure|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
79352342|NCT01390948|Drug|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
79665735|NCT05980806|Drug|Pacritinib|Participants will receive pacritinib 200 mg twice daily.
79665736|NCT05980806|Drug|Momelotinib|Participants will receive momelotinib 200 mg once daily.
79665737|NCT05979051|Drug|SHR-1703|SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
79665738|NCT05979051|Drug|SHR-1703 Placebo|SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
79989717|NCT04299945|Dietary Supplement|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
79817555|NCT04075929|Other|Training effects on aerobic output|The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
79817556|NCT00756938|Drug|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
79989718|NCT04299048|Drug|PF-06946860|subcutaneous injection
79989719|NCT04254549|Drug|Rifaximin|550 mg by mouth three times daily for 14 days
79989720|NCT04254549|Drug|Placebo|By mouth three times daily for 14 days
79989721|NCT04227288|Drug|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
79989722|NCT04210206|Other|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
79989723|NCT04182204|Drug|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
79989724|NCT04182204|Drug|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
79989725|NCT04182204|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
79989726|NCT04182204|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
79989727|NCT04179981|Device|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
79989728|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
79989729|NCT04172532|Procedure|Biopsy|Undergo tissue collection
79352343|NCT01390948|Radiation|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
79665739|NCT05972772|Drug|Doxycyclin|100-mg film-coated tablets; Pfizer
79665740|NCT05972772|Drug|Azithromycin|250-mg capsules; Pfizer
79665741|NCT05972122|Drug|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
79665742|NCT05965570|Drug|Brensocatib|Oral tablets.
79989730|NCT04172532|Procedure|Biospecimen Collection|Undergo blood sample collection
79989731|NCT04172532|Procedure|Computed Tomography|Undergo CT
79989732|NCT04172532|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79989733|NCT04172532|Procedure|Magnetic Resonance Imaging|Undergo MRI
79989734|NCT04172532|Drug|Peposertib|Given PO
79989735|NCT04172532|Other|Placebo Administration|Given PO
79665743|NCT05965570|Drug|Clarithromycin|Oral tablets.
79665744|NCT05959421|Biological|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
79989736|NCT04156919|Behavioral|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
79503350|NCT05754125|Dietary Supplement|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
79817557|NCT04076865|Drug|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
79352344|NCT01390948|Drug|Temozolomide (TMZ)|75 milligrams per square meter (mg/m^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m^2/day) x 12 cycles, 1st cycle 150 mg/m^2/days 1-5, escalated to 200 mg/m^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
79352345|NCT02005211|Drug|AZD3293|Oral solution
79352346|NCT02005211|Drug|Placebo|Oral solution
79352347|NCT03842722|Device|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
79503351|NCT05754125|Dietary Supplement|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
79503352|NCT05750667|Behavioral|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
79503353|NCT05747274|Device|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
79503354|NCT05745350|Drug|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
79503355|NCT05735366|Drug|SAIL66|SAIL66 as a IV infusion
79352348|NCT01429792|Drug|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
79665745|NCT05959421|Biological|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
79665746|NCT05950191|Other|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
79665747|NCT05950191|Other|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
79352349|NCT01429792|Drug|ribavirin [Copegus]|standard treatment, orally daily
79352350|NCT04034446|Biological|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
79665748|NCT05950191|Behavioral|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
79352351|NCT01409434|Drug|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
79352352|NCT01925612|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
79352353|NCT01925612|Drug|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
79352354|NCT01925612|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
79352355|NCT01925612|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
79352356|NCT01925612|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
79352357|NCT01925612|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
79503356|NCT05735366|Drug|Tocilizumab|Tocilizumab as a IV infusion
79503357|NCT05735340|Behavioral|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
79503358|NCT05735340|Behavioral|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
79503359|NCT05734508|Biological|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
79352358|NCT01925612|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
79352359|NCT02093663|Drug|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
79665749|NCT05949918|Behavioral|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
79352360|NCT02093663|Drug|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
79352361|NCT01408888|Biological|LY2189265|Administered subcutaneously
79352362|NCT01408888|Drug|Sitagliptin|Administered orally
79352363|NCT01918033|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
79503360|NCT05731193|Other|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
79503361|NCT05717387|Behavioral|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
79665750|NCT05949892|Behavioral|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
79665751|NCT05949086|Behavioral|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
79665752|NCT05943756|Behavioral|Signature Strengths|The treatment group will complete 6 web-based sessions of Signature Strengths(1 sessions per week for 6 weeks), designed to teach lessons focused on the Aware-Explore-Apply interventional framework. Sessions are approximately 60 minutes long.
79665753|NCT05943756|Behavioral|TBI Education Course|The control group will complete 6 web-based sessions of a TBI Education Course(1 sessions per week for 6 weeks), designed to teach lessons based on the TBI Model Systems Knowledge Translation Center's fact sheets. Sessions are approximately 60 minutes long.
79503362|NCT05717387|Behavioral|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
79352364|NCT01918033|Drug|Placebo|Matching placebo to desloratadine 5 mg tablets
79352365|NCT01408732|Drug|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
79352366|NCT01408732|Other|Standard Treatment|Normal standard of care followed by Drug interevention
79665754|NCT05937373|Device|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
79665755|NCT05937373|Other|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
79665756|NCT05936229|Biological|Interferon Beta-1A|Given IV
79665757|NCT05936229|Procedure|X-Ray Imaging|Undergo x-ray
79665758|NCT05936229|Procedure|Echocardiography|Undergo ECHO
79665759|NCT05936229|Procedure|Multigated Acquisition Scan|Undergo MUGA
79503363|NCT05717075|Behavioral|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
79503364|NCT05711134|Behavioral|Audit and Feedback on Individual Practice Patterns|Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
79503365|NCT05706376|Behavioral|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
79665760|NCT05936229|Procedure|Computed Tomography|Undergo CT
79989737|NCT04156919|Other|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
79352367|NCT04626037|Behavioral|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
79503366|NCT05706376|Behavioral|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
79503367|NCT05701150|Other|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
79503368|NCT05701150|Other|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
79503369|NCT05700448|Biological|Sugemalimab|IV infusion
79503370|NCT05700448|Drug|Placebo|IV infusion
79665761|NCT05936229|Procedure|Positron Emission Tomography|Undergo PET/CT
79665762|NCT05936229|Procedure|Lumbar Puncture|Undergo LP
79665763|NCT05936229|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79665764|NCT05936229|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79665765|NCT05936229|Procedure|Biospecimen Collection|Undergo blood and CSF sample collection
79665766|NCT05936229|Procedure|Biopsy|Undergo tissue biopsy
79665767|NCT05935748|Drug|NKT2152|Oral HIF2a inhibitor
79665768|NCT05935748|Drug|palbociclib|a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
79665769|NCT05935748|Other|sasanlimab|an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
79989738|NCT04134091|Drug|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
79665770|NCT05930613|Drug|Certolizumab (CIMZIA® ; TNF-α antagonist)|400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
79817558|NCT00796367|Drug|VI-0521|7.5 mg phentermine and 46 mg topiramate
79817559|NCT00796367|Drug|Placebo|placebo
79352368|NCT01390402|Drug|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
79352369|NCT01390402|Drug|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
79352370|NCT01390402|Procedure|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
79352371|NCT01390402|Drug|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
79665771|NCT05930613|Drug|Placebo (NaCl 0.9 % solution)|NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
79665772|NCT05925348|Diagnostic Test|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
79665773|NCT05917574|Other|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
79817560|NCT00796367|Drug|VI-0521|15 mg phentermine and 92 mg topiramate
79503371|NCT05700448|Drug|Pegaspargase|Intramuscular injection
79503372|NCT05700448|Drug|Gemcitabine|IV infusion
79665774|NCT05912426|Behavioral|Reduced-sodium potassium-enriched salt|Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
79665775|NCT05910008|Procedure|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
79817561|NCT02580825|Behavioral|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
79665776|NCT05910008|Procedure|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
79817562|NCT02580825|Behavioral|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
79989739|NCT04134091|Drug|LPCN 1144 Formulation B|Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
79989740|NCT04134091|Drug|Placebo|Oral matching placebo capsule administered as BID
79352372|NCT01390402|Drug|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
79352373|NCT01390402|Procedure|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
79352374|NCT01390402|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
79503373|NCT05700448|Drug|Oxaliplatin|IV infusion
79665777|NCT05909878|Device|Virtual Reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
79817563|NCT00770588|Drug|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
79817564|NCT00770588|Drug|Placebo|To match Gefitinib
79989741|NCT04115644|Drug|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
79989742|NCT04115644|Drug|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
79352375|NCT01390402|Drug|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
79989743|NCT04115644|Drug|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
79989744|NCT04113382|Drug|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
79989745|NCT04113382|Drug|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol [PEG] 3350).
79989746|NCT04108026|Drug|Durvalumab|1500 mg IV every 4 weeks
79989747|NCT04099823|Other|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
79989748|NCT04099823|Diagnostic Test|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
79352376|NCT01390402|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
79352377|NCT01976299|Device|AVERT|
79352378|NCT01428076|Drug|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
79817565|NCT02604719|Drug|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
79817566|NCT03788343|Dietary Supplement|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
79665778|NCT05909878|Other|Standard Protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. Specifically at the hospital (HSJ), standard care also includes access to a television mounted near the MRI playing videos.The research nurse will be able to complete any information should they find it incomplete or substandard.
79817567|NCT03788343|Drug|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
79817568|NCT02604797|Drug|Nalbuphine|patient-controlled intravenous analgesia
79503374|NCT05700084|Drug|Utidelone Capsule (Part 1)|"At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively."
79665779|NCT05908149|Device|Insole Splint|Insole splint used in 'Pes equinus' in patients with hemiplegia
79352379|NCT01900652|Drug|Emibetuzumab|Administered IV
79352380|NCT01900652|Drug|Erlotinib|Administered Orally
79352381|NCT02093351|Drug|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
79352382|NCT02093351|Drug|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
79352383|NCT02093351|Drug|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
79665780|NCT05905133|Drug|CBP-201|subcutaneous injection
79817569|NCT02604797|Drug|Sufentanil|patient-controlled intravenous analgesia
79817570|NCT02604797|Drug|flurbiprofen axetil|patient-controlled intravenous analgesia
79352384|NCT02093351|Drug|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
79352385|NCT02093351|Procedure|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
79352386|NCT02078284|Biological|CPP|One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
79352387|NCT02078284|Biological|LSP|
79352388|NCT02092961|Drug|Fostamatinib|Fostamatinib 100mg twice daily.
79665781|NCT05903807|Drug|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
79665782|NCT05901415|Procedure|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
79665783|NCT05901415|Procedure|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
79665784|NCT05899387|Procedure|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
79817571|NCT02604797|Drug|ramosetron|patient-controlled intravenous analgesia
79817572|NCT04107233|Behavioral|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
79817573|NCT00777608|Drug|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
79817574|NCT00777608|Drug|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
79817575|NCT00777608|Drug|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
79817576|NCT00777608|Drug|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
79817577|NCT03905031|Device|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD>0.2 is abnormal and suggestive of intracranial hematoma.
79817578|NCT02580903|Radiation|Radiology|Only a small subsample will require CT and right heart catherisation
79817579|NCT00792935|Drug|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
79817580|NCT00792935|Drug|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
79817581|NCT00792935|Drug|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin [(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)], the participant should remain on the same metformin dose throughout the study.
79503375|NCT05700084|Drug|Drug A Utidelone Capsule (Part 2: Group A-B)|"Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
79665785|NCT05899387|Procedure|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
79665786|NCT05899387|Procedure|Blood sampling|Blood sampling at defined time points according to protocol
79665787|NCT05890105|Drug|PF-07853578|PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
79352389|NCT02092961|Drug|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
79352390|NCT02092961|Drug|Placebo of Fostamatinib|Placebo bid for 6 weeks.
79352391|NCT02092961|Drug|Placebo of Adalimumab|Placebo injection once every two weeks.
79352392|NCT01898078|Drug|Alisertib|Alisertib ECT
79352393|NCT01987817|Biological|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
79352394|NCT01987817|Biological|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
79665788|NCT05890105|Drug|Placebo|Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
79665789|NCT05879679|Behavioral|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
79665790|NCT05879146|Drug|Nirogacestat|Given by PO
79665791|NCT05878236|Diagnostic Test|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
79817582|NCT03904563|Drug|Bevacizumab|Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
79817583|NCT03904563|Radiation|chest radiation|split-course chest radiation
79817584|NCT03904563|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
79665792|NCT05878106|Dietary Supplement|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
79665793|NCT05878106|Other|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
79665794|NCT05877014|Other|questionnaires|EQ-5D-5L and SF-12
79817585|NCT00770510|Drug|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
79989749|NCT04099823|Diagnostic Test|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
79989750|NCT04078568|Drug|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
79989751|NCT04078568|Drug|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
79352395|NCT01940497|Drug|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
79665795|NCT05877014|Other|scanner|CT scan at M9 and then at M12 if the humerus is not consolidated at M6
79989752|NCT04078568|Drug|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
79228372|NCT05727722|Biological|a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy|"A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10^9, moving to the 3+3 design phase at the dose of 0.5x10^9. According to the semi-logarithmic incremental (10^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored."
79352396|NCT01940497|Drug|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
79352397|NCT01940497|Drug|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
79352398|NCT01940497|Drug|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
79352399|NCT01924364|Device|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
79989753|NCT04064723|Device|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
79665796|NCT05873816|Device|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
79665797|NCT05873816|Device|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
79503376|NCT05700084|Drug|Drug A Utidelone Capsule (Part 2: Group B-A)|"Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
79503377|NCT05700084|Drug|Drug B Utidelone Injection (Part 2: Group A-B)|"Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle."
79228373|NCT03723369|Device|accupuncture|accupuncture
79503378|NCT05700084|Drug|Drug B Utidelone Injection (Part 2: Group B-A)|"Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle."
79503379|NCT05692596|Other|Data collection|Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
79503380|NCT05691231|Device|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
79989754|NCT04064528|Dietary Supplement|Amino Acids|10 g bolus of essential amino acids
79352400|NCT01924364|Procedure|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
79352401|NCT01987505|Drug|Rituximab|1400 mg will be injected subcutaneously (SC).
79352402|NCT01923896|Behavioral|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
79352403|NCT01923896|Drug|d-cycloserine (DCS)|
79352404|NCT01923896|Drug|Placebo|lactose powder
79352405|NCT02004353|Device|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
79352406|NCT01938625|Drug|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
79352407|NCT01938625|Drug|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
79352408|NCT01938625|Drug|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
79352409|NCT01938625|Drug|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
79352410|NCT01938625|Drug|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
79503381|NCT05689151|Drug|Abrocitinib|Study Drug for Observational Data Collection
79503382|NCT05688540|Other|e book|e book
79503383|NCT05688540|Other|traditional education booklet|traditional education booklet
79989755|NCT04057456|Other|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
79989756|NCT04057456|Other|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
79503384|NCT05681000|Drug|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
79817586|NCT00770510|Drug|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
79817587|NCT00770510|Drug|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
79817588|NCT00770510|Drug|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
79817589|NCT00770510|Drug|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
79817590|NCT02580747|Biological|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
79352412|NCT01975675|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
79352413|NCT01975675|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
79352414|NCT01975285|Drug|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
79503385|NCT05679154|Behavioral|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
79503386|NCT05679154|Behavioral|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
79352415|NCT01975285|Drug|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
79665798|NCT05861778|Drug|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
79665799|NCT05850988|Other|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
79665800|NCT05850988|Other|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
79665801|NCT05849779|Drug|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
79989757|NCT04057456|Drug|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
79352416|NCT01974895|Biological|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
79352417|NCT01974895|Biological|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
79503387|NCT05668585|Drug|CFT1946|Specified oral dose on specified day
79503388|NCT05668585|Drug|Trametinib|Specified oral dose on specified day
79503389|NCT05666102|Behavioral|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
79503390|NCT05662865|Drug|SGLT2 inhibitor|SGTL2i (15 mg) once daily
79503391|NCT05662865|Other|Controlled, Adaptive Study Diet|An adaptive study diet combined with SGLT2i, which consists of four sequential, 7-day long phases in which dietary carbohydrates are gradually reduced (50% carbs, 30% carbs, 20% carbs, and 10% carbs) based on safety and tolerability to achieve moderate ketosis. All diet phases are isocaloric. All meals are provided on an inpatient unit.
79503392|NCT05630365|Diagnostic Test|Panbio™|The Panbio™ COVID-19/Flu A&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
79352418|NCT01974817|Biological|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
79352419|NCT04415749|Biological|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
79352420|NCT04415749|Other|Placebo|Normal saline
79352421|NCT04624399|Drug|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
79503393|NCT05629533|Device|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
79503394|NCT05622071|Drug|Tislelizumab|Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
79352422|NCT01915849|Drug|LIK066|LIK066 15 mg, 50 mg and 150 mg
79352423|NCT01915849|Drug|Placebo|
79989758|NCT04057456|Other|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
79352424|NCT01915771|Drug|lomitapide|20 mg dose
79352425|NCT01938391|Device|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
79352426|NCT01915303|Drug|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
79352427|NCT01987427|Drug|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
79352428|NCT01987427|Drug|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
79989759|NCT04030442|Drug|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
79665802|NCT05849779|Drug|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
79989760|NCT04030442|Other|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
79989761|NCT04026386|Behavioral|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
79989762|NCT04010539|Drug|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
79352429|NCT01987427|Drug|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
79352430|NCT01937299|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
79352431|NCT01937299|Drug|Vehicle|Inactive ingredients used as a placebo comparator
79352432|NCT01937299|Drug|Travoprost 0.004% ophthalmic solution|
79503395|NCT05618054|Behavioral|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
79503396|NCT05613036|Drug|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
79503397|NCT05613036|Drug|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
79503398|NCT05613036|Drug|BI 907828|BI 907828
79503399|NCT05606575|Device|Nelli|Nelli is a non-EEG physiological signal-based seizure detection and quantification device that is indicated for use as an adjunct to seizure monitoring during periods of rest. The device utilizes automated analysis of audio and video (media) data collected via the personal recording unit (PRU) hardware accessory to identify epileptic and non-epileptic seizure events with a positive motor component.
79503400|NCT05606146|Device|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
79503401|NCT05601219|Drug|ADA-011|ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
79665803|NCT05848440|Drug|AZD9550|Participants will be administered AZD9550 subcutaneously.
79665804|NCT05848440|Drug|AZD9550|Participants will be administered AZD9550 intravenously.
79665805|NCT05848440|Drug|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
79989763|NCT04010539|Drug|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
79989764|NCT04010539|Drug|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
79352433|NCT02003963|Behavioral|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
79352434|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
79503402|NCT05601219|Drug|PD(L)-1 inhibitor|PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
79503403|NCT05591352|Dietary Supplement|Chenopodium formosanum extracts sachet|consume 1 sachet per day
79503404|NCT05591352|Dietary Supplement|Placebo sachet|consume 1 sachet per day
79503405|NCT05589883|Behavioral|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
79817591|NCT04077177|Behavioral|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
79817592|NCT04077255|Drug|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
79817593|NCT00770432|Drug|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
79817594|NCT00770432|Other|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
79665806|NCT05847634|Device|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
79817595|NCT00792701|Drug|cisplatin|Given IV
79817596|NCT00792701|Drug|gemcitabine hydrochloride|Given IV
79817597|NCT03772353|Drug|Dalpiciclib|Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
79665807|NCT05847569|Biological|Belantamab Mafodotin|Given IV
79817598|NCT03772353|Drug|Pyrotinib|Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)
79503406|NCT05584696|Other|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
79817599|NCT03772353|Drug|Letrozole|Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).
79817600|NCT03772353|Drug|Fulvestrant|Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
79817601|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine Cohort A|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
79817602|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
79817603|NCT05559983|Other|Placebo Cohort A|Sterile 0.9% sodium chloride
79817604|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine Cohort B|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
79817605|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
79352435|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
79817606|NCT05559983|Other|Placebo Cohort B|Sterile 0.9% sodium chloride
79352436|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
79352437|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
79352438|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
79352439|NCT01790295|Drug|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
79503407|NCT05584696|Other|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
79665808|NCT05847569|Procedure|Biospecimen Collection|Undergo collection of blood samples
79665809|NCT05847569|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
79665810|NCT05847569|Procedure|Bone Marrow Biopsy|Undergo biopsy
79665811|NCT05847569|Procedure|Computed Tomography|Undergo CT scan
79665812|NCT05847569|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79665813|NCT05847569|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79817607|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine Cohort C|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
79817608|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
79817609|NCT05559983|Other|Placebo Cohort C|Sterile 0.9% sodium chloride
79817610|NCT03765567|Drug|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
79817611|NCT02580669|Other|Neuropsychological assessment|A neuropsychological assessment is done
79817612|NCT02580669|Other|Neurologic consultation|A neurologic consultation is done
79817613|NCT02580669|Other|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
79817614|NCT00777296|Drug|ARIKACE™|Study start date is before Jan 18, 2017.
79817615|NCT00777296|Drug|Placebo|Study start date is before Jan 18, 2017.
79503408|NCT05584618|Other|Education|education
79817616|NCT05186805|Drug|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
79665814|NCT05844566|Device|Decision Support System (DSS)|"This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion."
79665815|NCT05829044|Device|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
79665816|NCT05829044|Device|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
79665817|NCT05826002|Behavioral|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
79817617|NCT04106609|Other|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
79817618|NCT04106609|Other|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
79817619|NCT02603549|Other|Pituitary panel will be drawn pre-op and post-op for all patients.|
79817620|NCT05084547|Other|No intervention|No intervention
79817621|NCT04097132|Device|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
79817622|NCT04076163|Other|serious game|a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
79817623|NCT00756470|Drug|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
79817624|NCT00756470|Drug|Paclitaxel|80 mg/m^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
79817625|NCT00756470|Drug|5-Fluorouracil (5-FU)|500 mg/m^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
79817626|NCT00756470|Drug|Epirubicin|75 mg/m^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
79817627|NCT00756470|Drug|Cyclophosphamide|500 mg/m^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
79817628|NCT00792623|Biological|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
79817629|NCT03862599|Device|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
79817630|NCT03862599|Other|Standard care|Cialis and vacuum pump
79817631|NCT04096898|Device|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
79503409|NCT05582681|Diagnostic Test|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
79503410|NCT05582681|Other|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
79503411|NCT05582681|Drug|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
79503412|NCT05566054|Drug|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
79817632|NCT04106921|Other|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
79817633|NCT05052567|Drug|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
79989765|NCT03999333|Device|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
79989766|NCT03977194|Drug|Carboplatin|AUC 6 every 4 weeks
79989767|NCT03977194|Drug|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
79989768|NCT03977194|Drug|Atezolizumab|1200 mg every 3 weeks
79989769|NCT03962959|Device|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
79989770|NCT03942887|Drug|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
79989771|NCT03942887|Drug|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
79989772|NCT03942887|Drug|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
79989773|NCT03942887|Drug|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
79503413|NCT05566054|Drug|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
79665818|NCT05809414|Device|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
79817634|NCT00756314|Behavioral|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
79989774|NCT03924830|Procedure|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
79352440|NCT01597557|Drug|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
79352441|NCT01597557|Other|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
79352442|NCT01914757|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
79352443|NCT01914757|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
79352444|NCT02003573|Drug|decitabine iv|decitabine iv fixed dose
79228374|NCT03301610|Other|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
79352445|NCT02003573|Drug|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
79352446|NCT01914679|Device|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
79352447|NCT01789281|Drug|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
79503414|NCT05566054|Drug|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
79989775|NCT03924830|Procedure|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
79503415|NCT05560932|Behavioral|IMB-motivational interviewing (MI) techniques (IMB-MI)|The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
79989776|NCT03924830|Procedure|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
79989777|NCT03900689|Other|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
79989778|NCT03900689|Other|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
79989779|NCT03866460|Diagnostic Test|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
79989780|NCT03831503|Biological|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
79989781|NCT03831503|Device|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
79989782|NCT03831503|Device|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
79352448|NCT01789281|Drug|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
79352449|NCT01923740|Device|XIENCE V EECSS|Subjects receiving XIENCE V
79989783|NCT03800017|Biological|Hyperoxia|Participants breathe 60% oxygen during exercise
79352450|NCT01923740|Device|Absorb BVS System|Subjects receiving Absorb BVS System
79352451|NCT01789203|Drug|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
79352452|NCT01789203|Drug|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
79352453|NCT01789047|Drug|Topiramate|Topiramate as adjunct to amantadine
79665819|NCT05809414|Drug|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
79665820|NCT05795517|Drug|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
79352454|NCT01789047|Drug|Placebo|Placebo control
79503416|NCT05557760|Behavioral|Cognitive Control Training (CCT)|"The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control."
79352455|NCT01789047|Drug|Amantadine|Existing treatment for all participants
79503417|NCT05557760|Behavioral|Cognitive Control Training (CCT) + Booster Sessions|The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
79352456|NCT01788423|Device|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
79352457|NCT01617187|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
79665821|NCT05795517|Drug|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
79503418|NCT05552001|Drug|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
79665822|NCT05795517|Drug|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
79665823|NCT05795517|Drug|Placebo|placebo ，QD，oral，Day1 to week 12
79665824|NCT05795517|Drug|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
79352458|NCT01617187|Drug|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
79665825|NCT05789784|Other|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
79665826|NCT05789784|Other|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
79665827|NCT05774756|Drug|Setmelanotide|Solution for daily subcutaneous injection
79352459|NCT01617187|Drug|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
79665828|NCT05774756|Drug|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
79665829|NCT05761613|Device|CeraShield Endotracheal Tube|An endotracheal tube coated with with an antimicrobial hydrophilic coating containing ceragenins (CSAs)
79352460|NCT01617187|Drug|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
79352461|NCT01759407|Drug|Ropivicaine|
79352462|NCT01759407|Drug|Epinephrine|
79352463|NCT01787331|Drug|Itraconazole|Given PO
79352464|NCT01787331|Other|Laboratory Biomarker Analysis|Correlative studies
79352465|NCT01787331|Other|Pharmacological Study|Correlative studies
79352466|NCT01757847|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
79665830|NCT05761613|Device|Endotracheal tube with subglottic secretion drainage|An endotracheal tube with subglottic secretion drainage
79665831|NCT05758376|Behavioral|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
79665832|NCT05755165|Behavioral|Depression|~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
79665833|NCT05755165|Behavioral|Depression, adjusted|~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
79665834|NCT05755165|Behavioral|Control|~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
79817635|NCT04108793|Other|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
79817636|NCT00727506|Drug|BIBW 2992|BIBW 2992 once daily
79817637|NCT00727506|Drug|TMZ|TMZ 21/28
79352467|NCT01757847|Behavioral|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
79352468|NCT01787097|Drug|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
79352469|NCT01787097|Drug|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
79352470|NCT01787097|Drug|Formoterol 24ug|Turbuhaler
79665835|NCT05739942|Drug|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
79665836|NCT05739942|Drug|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of [68Ga]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
79665837|NCT05739942|Other|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
79665838|NCT05734196|Drug|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
79665839|NCT05725408|Behavioral|Dialectical behavior therapy-informed group eating intervention protocol (telehealth)|A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
79817638|NCT00727506|Drug|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
79989784|NCT03785405|Drug|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules [12.5 mg (4 granules), 31.25 mg (10 granules), in capsules] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
79989785|NCT03774641|Drug|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
79352471|NCT01787097|Drug|BUD total dose 800ug|Turbuhaler
79352472|NCT04414371|Other|Yoga|Yoga Namaskar and Nadi Shuddhi
79352473|NCT01757691|Drug|Fingolimod 0.5mg/daily|
79352474|NCT01757691|Drug|Placebo|
79352475|NCT01786707|Biological|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
79352476|NCT01786707|Other|Hyperbaric oxygen therapy|
79352477|NCT01786707|Drug|Insulin|Insulin dose as per clinical management
79352478|NCT01786707|Drug|Metformin|Metformin dose as tolerated
79352479|NCT01786629|Drug|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
79503419|NCT05540288|Drug|Nalmefene|"Week 1: 18 mg/d~Week 2:~In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~In the presence of grade 3 ARs, 18 mg/d~In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
79665840|NCT05725408|Behavioral|Dialectical behavior therapy-informed group eating intervention protocol (in-person)|A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
79665841|NCT05723510|Drug|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
79352480|NCT01786629|Drug|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
79352481|NCT01786551|Drug|Eplerenone|50 mg daily for 14 days
79352482|NCT01973569|Drug|denosumab|denosumab administered subcutaneously
79352483|NCT01973569|Drug|placebo|placebo administered subcutaneously to match denosumab
79665842|NCT05723510|Drug|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
79352484|NCT01973491|Drug|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
79352485|NCT01951586|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
79352486|NCT01951586|Drug|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
79352487|NCT01951586|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
79352488|NCT01951586|Drug|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
79352489|NCT01951586|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
79352490|NCT04643678|Drug|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
79352491|NCT04643678|Other|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
79352492|NCT04641728|Drug|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
79352493|NCT04641728|Drug|Olaparib|olaparib 300 mg twice daily (BID)
79665843|NCT05723510|Drug|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
79665844|NCT05723510|Drug|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
79665845|NCT05717400|Drug|Bevacizumab|Given by vein (IV)
79665846|NCT05717400|Drug|Atezolizumab|Given by vein (IV)
79665847|NCT05717400|Drug|Sofosbuvir|Given by PO
79665848|NCT05717400|Drug|Velpatasvir|Given by PO
79665849|NCT05717400|Drug|Voxilaprevir|Given by PO
79665850|NCT05717400|Drug|Ribavirin|Given by PO
79352494|NCT01785849|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
79352495|NCT01785849|Drug|Placebo|Administered intravenously (IV) three times per week.
79352496|NCT01756833|Drug|Doxycycline|100 mg po bid
79352497|NCT01756833|Drug|Placebo|capsule identical to the doxycycline capsule
79352498|NCT01617967|Drug|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks [Q3W]: Day 0 and Day 21) and an alternative premedication regimen.
79503420|NCT05540288|Drug|Placebo|"Week 1: 1 tablet/d~Week 2:~In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~In the presence of grade 3 ARs, 1 tablet/d~In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
79503421|NCT05537285|Device|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
79817639|NCT04108715|Procedure|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
79817640|NCT04108715|Procedure|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
79665851|NCT05709782|Procedure|Spine Radiosurgery|scan
79665852|NCT05709782|Device|Magnetic Resonance imaging|scan
79352499|NCT01785615|Drug|Atorvastatin|80mg
79352500|NCT01785615|Other|Placebo|80mg
79352501|NCT01756053|Drug|ABT-089|Selective neuronal nicotinic receptor agonist.
79665853|NCT05709782|Radiation|MR-LINAC|scan
79665854|NCT05709210|Other|Recording of smartphone usage data|Recording of smartphone usage data
79665855|NCT05704920|Other|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
79665856|NCT05704920|Other|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
79352502|NCT01756053|Drug|Placebo|Matched placebo capsules supplied by study drug supplier.
79352503|NCT04576299|Other|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
79352504|NCT01785069|Device|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
79352505|NCT01784523|Drug|Hydroxychloroquine|
79352506|NCT01784211|Drug|LY2605541|
79352507|NCT01784211|Drug|Insulin Glargine|
79503422|NCT05537285|Device|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
79503423|NCT05537285|Device|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
79665857|NCT05704647|Drug|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
79665858|NCT05704647|Drug|Nivolumab|Given by IV (vein)
79665859|NCT05704647|Drug|Relatlimab|Given by IV (vein)
79665860|NCT05696977|Drug|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
79352508|NCT01783821|Drug|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
79352509|NCT01783821|Drug|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
79352510|NCT01783821|Drug|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
79352511|NCT01783743|Other|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
79352512|NCT01608321|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
79352513|NCT01608321|Device|Sham device|Placebo Device that simulates active rTMS treatment
79352514|NCT01608087|Drug|BI 695502|BI 695502 single i.v. infusion
79352515|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
79503424|NCT05536440|Drug|PF-07261271|IV or SC
79503425|NCT05536440|Drug|Placebo|IV or SC
79503426|NCT05522972|Behavioral|Video Game Vision Training|A new approach for improving amblyopic vision using video games
79503427|NCT05522972|Behavioral|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
79503428|NCT05522972|Behavioral|Occlusion Therapy|Conventional treatment for amblyopia
79503429|NCT05518539|Device|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
79817641|NCT03862131|Device|MyoStrain®|MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
79352516|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
79352517|NCT01912963|Drug|Pertuzumab|
79503430|NCT05512806|Drug|AZD5462|Participants will receive AZD5462 orally.
79352518|NCT01912963|Drug|Trastuzumab|
79352519|NCT01912963|Drug|eribulin|
79352520|NCT01912807|Drug|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
79352521|NCT01912807|Drug|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
79352522|NCT01782885|Procedure|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
79352523|NCT01782885|Drug|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
79352524|NCT01912729|Behavioral|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
79503431|NCT05503927|Other|No Intervention|This is a non-interventional study, therefore no intervention is used.
79503432|NCT05494034|Device|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
79503433|NCT05483075|Behavioral|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
79503434|NCT05482542|Other|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
79503435|NCT05482542|Drug|Cyclophosphamide/ATG|Cyclophosphamide/ATG
79989786|NCT03773523|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
79989787|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
79352525|NCT01912729|Behavioral|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
79352526|NCT01754493|Drug|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
79352527|NCT01972789|Drug|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
79352528|NCT01934335|Drug|Vandetanib|
79352529|NCT01934335|Other|Placebo|
79503436|NCT05482542|Drug|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
79503437|NCT05471518|Other|No intervention|No intervention
79665861|NCT05695040|Behavioral|"dietary workshop proteins"|"The workshop will have 2 objectives:~Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
79665862|NCT05689892|Other|Decision Coach Sessions|"Participants in the intervention group and their families will be referred to the DC to meet independently and discuss recommended treatment pathways.~Multiple sessions may be necessary until a final decision is reached. All SDM consults will be done virtually using a secure videoconferencing platform. The Ottawa Family Decision Guide will be used to facilitate the discussion. A DA will be provided to the study participants in the form of information cards containing information about different treatment options in pediatric IBD. This includes administration schedule, side effects, risk of cancer, among others. The DA has been developed and provided by the Cincinnati Children's Hospital Medical Center and adapted to the Canadian setting with electronic version by this research group with approval from the authors."
79665863|NCT05689684|Dietary Supplement|AG+XOS+AXOS|4-month parallel randomized controlled study
79665864|NCT05689684|Dietary Supplement|Placebo Maltodextrin|4-month parallel randomized controlled study
79665865|NCT05686408|Drug|TNX-601 ER|Patients will take 1 pill orally once daily for 6 weeks.
79352530|NCT01912339|Device|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
79665866|NCT05686408|Drug|Placebo|Patients will take 1 pill orally once daily for 6 weeks.
79665867|NCT05678218|Procedure|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
79665868|NCT05676294|Drug|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
79817642|NCT00789815|Device|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3~12 mg/kg/hour) to maintain BIS around 65~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
79989788|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
79989789|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
79665869|NCT05676294|Drug|Placebo|oral matched placebo one hour prior to ambulatory surgery
79352531|NCT01912339|Procedure|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
79989790|NCT03699241|Biological|Placebo|Tris-NaCl Diluent
79989791|NCT03673462|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
79989792|NCT03673462|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
79989793|NCT03673462|Biological|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
79989794|NCT03673462|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79352532|NCT01911793|Device|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
79352533|NCT04632511|Device|MetaSAMP|Rectal Sampler
79352534|NCT01933789|Behavioral|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
79352535|NCT01910389|Drug|Tadalafil|
79665870|NCT05665088|Drug|BXCL501|Sublingual Film
79989795|NCT03673462|Biological|Rotavirus Vaccine|Pharmaceutical form: Oral solution Route of administration: Oral
79989796|NCT03673462|Biological|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79989797|NCT03673462|Biological|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
79989798|NCT03673462|Biological|Varicella Virus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
79989799|NCT03611725|Procedure|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
79989800|NCT03611725|Procedure|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
79989801|NCT03590327|Device|Transcranial Magnetic Stimulation|rTMS
79352536|NCT01910389|Drug|Placebo for tadalafil|
79665871|NCT05665088|Drug|Matching Placebo|Sublingual Placebo Film
79665872|NCT05665049|Behavioral|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
79989802|NCT03583684|Behavioral|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
79665873|NCT05662241|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
79665874|NCT05662241|Other|Placebo|Placebo
79352537|NCT01970995|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
79989803|NCT03574207|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
79989804|NCT03570229|Other|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
79352538|NCT01970995|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
79352539|NCT01970995|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
79352540|NCT01970527|Biological|Ipilimumab|Given IV
79352541|NCT01970527|Other|Laboratory Biomarker Analysis|Correlative studies
79352542|NCT01970527|Other|Pharmacological Study|Correlative studies
79352543|NCT01970527|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79352544|NCT01931995|Device|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
79352545|NCT01931995|Procedure|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
79352546|NCT01408576|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
79352547|NCT01408576|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
79665875|NCT05661669|Drug|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
79665876|NCT05661669|Drug|Saline|The placebo will be a 0.9% saline solution administered over 40 minutes.
79352548|NCT01427920|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
79352549|NCT01427608|Drug|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
79665877|NCT05657275|Diagnostic Test|CRP dosage|multimodal algorithm
79352550|NCT01427608|Drug|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
79352551|NCT01408030|Drug|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
79352552|NCT01408030|Drug|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
79352553|NCT01408030|Drug|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
79665878|NCT05657275|Diagnostic Test|multiplex PCR|multimodal algorithm
79665879|NCT05657275|Diagnostic Test|chest scan without injection|multimodal algorithm
79665880|NCT05655494|Behavioral|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
79665881|NCT05655494|Behavioral|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
79352554|NCT01408030|Drug|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
79352555|NCT04407832|Device|heat probe or hemoclip|for hemostasis
79352556|NCT04407832|Device|heat probe or hemoclip|for hemostasis
79352557|NCT02985424|Other|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
79665882|NCT05650970|Other|routine therapy|Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients
79665883|NCT05650970|Other|radial nerve mobilization exercise|Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
79665884|NCT05649072|Behavioral|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
79665885|NCT05649072|Behavioral|Screening Form|Participant will be answering demographic details
79665886|NCT05641896|Drug|[18F]FAPI-74 PET/CT|[18F]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
79665887|NCT05641844|Device|RD2 Ver.02|Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
79665888|NCT05641844|Other|Saline|Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
79665889|NCT05636722|Behavioral|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
79817643|NCT00789815|Drug|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S* 2~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S* 2~3 or if intolerance of procedure. Alfentanil as study arm.~*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
79352558|NCT01897532|Drug|Placebo|placebo matching tablets
79352559|NCT01897532|Drug|Linagliptin|
79352560|NCT01923428|Drug|AZD1722|
79352561|NCT01923428|Drug|Placebo|
79352562|NCT04627376|Other|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
79352563|NCT01896128|Drug|Armodafinil|
79352564|NCT01896128|Drug|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
79352565|NCT01949870|Drug|Cisplatin|day1 and day8 at each cycle
79352566|NCT01949870|Drug|Gemcitabine|day1 and day8 at each cycle
79352567|NCT01949870|Drug|Selumetinib|25mg/day, 50mg/day and 75mg/day
79352568|NCT01949480|Procedure|Thoracotomy|
79352569|NCT01949480|Procedure|Video-Assisted Thoracoscopic Surgery (VATS)|
79352570|NCT01949090|Biological|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
79352571|NCT01949090|Biological|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
79352572|NCT01948076|Device|resident with GE vscan|resident with GE vscan
79352573|NCT01922258|Drug|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
79989805|NCT03547739|Behavioral|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
79665890|NCT05629845|Procedure|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
79352574|NCT01406938|Drug|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
79352575|NCT01406938|Drug|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
79503438|NCT05470777|Combination Product|"CD22/CD19 CAR T and auto-HSCT sandwich strategy"|The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5*10^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Standard BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
79352576|NCT01405924|Drug|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
79352577|NCT01405924|Drug|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
79503439|NCT05458960|Behavioral|Social needs navigator program|4 months of assistance tailored to the needs of the participant
79503440|NCT05458960|Behavioral|Enhanced usual care|Referral to United Way 2-1-1
79503441|NCT05456295|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
79503442|NCT05453617|Behavioral|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
79503443|NCT05453617|Behavioral|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
79665891|NCT05629845|Procedure|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
79665892|NCT05626582|Procedure|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
79665893|NCT05626582|Procedure|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
79665894|NCT05625776|Procedure|pain delivery with capsaicin and heat|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful
79352578|NCT01405924|Drug|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
79352579|NCT01405924|Drug|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
79352580|NCT01426438|Drug|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
79665895|NCT05625776|Procedure|distractor delivery with sensory TENS|Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
79665896|NCT05624944|Drug|TS-142 5 mg|Single-dose of 5 mg of TS-142
79817644|NCT02592174|Other|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
79352581|NCT01426438|Drug|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
79503444|NCT05448209|Behavioral|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
79503445|NCT05432778|Drug|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
79503446|NCT05429736|Behavioral|Motor Skill Training (MST)|During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
79503447|NCT05429736|Device|Transcutaneous Spinal Stimulation (TSS)|TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
79503448|NCT05421832|Device|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
79503449|NCT05421780|Dietary Supplement|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
79503450|NCT05421780|Dietary Supplement|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
79503451|NCT05421780|Dietary Supplement|control biscuits|Consumption of plain biscuits as breakfast.
79503452|NCT05417126|Biological|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
79503453|NCT05394051|Behavioral|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
79503454|NCT05391828|Device|Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design|TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.
79503455|NCT05391828|Device|Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design|TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
79503456|NCT05390736|Behavioral|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
79665899|NCT05610891|Drug|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
79817645|NCT02592174|Other|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
79817646|NCT02592174|Radiation|cerebral images sub-study|Standard magnetic resonance imaging
79352582|NCT01426438|Drug|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
79352583|NCT04407910|Combination Product|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
79352584|NCT04407910|Combination Product|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
79352585|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
79352586|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
79503457|NCT05390736|Behavioral|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
79503458|NCT05390736|Behavioral|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
79665900|NCT05609994|Drug|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
79817647|NCT04019730|Other|diet|low carbohydrate diet (< 10 EN% carbs) vs high carbohydrate diet (>50 EN% carbs)
79352587|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
79352588|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
79352589|NCT01425814|Drug|Reference|Dry powder inhalation (capsule),single dose
79352590|NCT01425814|Drug|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
79352591|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
79352592|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
79352593|NCT01782495|Drug|ribavirin|tablet
79352594|NCT01922102|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
79352595|NCT01922102|Drug|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
79352596|NCT01922102|Drug|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
79352597|NCT01405768|Drug|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
79352598|NCT01405768|Drug|Non-buffered lidocaine|
79352599|NCT01913353|Biological|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
79352600|NCT01913353|Biological|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
79352601|NCT01754259|Drug|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
79503459|NCT05390736|Behavioral|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
79503460|NCT05390736|Behavioral|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
79817648|NCT05042583|Procedure|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
79503461|NCT05390736|Behavioral|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
79665901|NCT05605691|Device|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
79665902|NCT05591924|Procedure|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
79352602|NCT01754259|Drug|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
79817649|NCT00721578|Drug|voriconazole|Patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
79352603|NCT04618406|Device|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
79352604|NCT04618406|Other|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
79817650|NCT00789737|Drug|Welchol|Welchol 625mg tablets
79817651|NCT00789737|Drug|Placebo|placebo
79817652|NCT03854721|Drug|VAX014|Solution for intravesical infusion, 3.33x10^10 rBMCs per vial
79817653|NCT02592252|Behavioral|Participatory gender training|10 sessions of participatory gender training
79352605|NCT01405456|Drug|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
79352606|NCT01405456|Other|placebo and lifestyle|placebo pill daily and lifestyle counseling
79352607|NCT04031794|Device|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
79352608|NCT01404988|Behavioral|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
79352609|NCT01404988|Behavioral|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
79503462|NCT05390736|Behavioral|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
79817654|NCT02592252|Other|Microfinance|Microfinance loan
79352610|NCT01404988|Other|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
79352611|NCT04043026|Drug|Statin|Any statin therapy
79352612|NCT01389232|Device|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
79352613|NCT01404208|Drug|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
79989806|NCT03547739|Behavioral|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
79989807|NCT03522831|Drug|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
79989808|NCT03522831|Drug|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
79989809|NCT03517787|Other|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
79989810|NCT03517787|Other|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
79503463|NCT05390736|Behavioral|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
79503464|NCT05380856|Device|Turning ON the neuromodulator|IPG on
79503465|NCT05380856|Device|Turning OFF the neuromodulator|IPG OFF
79503466|NCT05369052|Drug|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
79503467|NCT05369052|Drug|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
79503468|NCT05359822|Other|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
79665903|NCT05591924|Procedure|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
79817655|NCT04019574|Drug|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
79228375|NCT03301610|Other|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
79352614|NCT01404208|Drug|Placebo|Sugar pill
79817656|NCT04019574|Drug|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
79817657|NCT04019574|Drug|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
79352615|NCT01617668|Drug|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
79352616|NCT01617668|Drug|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
79503469|NCT05354115|Diagnostic Test|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
79817658|NCT04019574|Other|Placebo|IV Placebo as a bolus injection
79352617|NCT01425268|Device|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
79503470|NCT05353751|Behavioral|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
79665904|NCT05591924|Procedure|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
79817659|NCT02593266|Behavioral|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~Module 1: Depression and family~Module 2: Psychoeducation about depression~Module 3:The child's perspective on their parent's depression~Module 4: Skills development~Module 5: Preparation for the family session~Module 6: Family session~Module 7: Revision and future planning~Follow-up"
79817660|NCT04106687|Procedure|Ultrasound Guided Caudal Block|Postoperative pain procedure
79989811|NCT03517787|Other|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
79989812|NCT03517787|Other|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
79352618|NCT01425268|Procedure|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
79352619|NCT01425190|Drug|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
79352620|NCT01388530|Device|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
79665905|NCT05591924|Procedure|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
79665906|NCT05591196|Device|Non-invasive Electrical Spinal Cord Stimulation|Electrical stimulation of the spinal cord using surface electrodes
79665907|NCT05591196|Other|Activity Based Rehabilitation|Exercise therapy targeting paralyzed hand and arm
79817661|NCT04106687|Procedure|Sacral Erector Spinae Block|Postoperative pain procedure
79817662|NCT05374122|Diagnostic Test|DSOC with AI biopsy guidance|Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.
79352621|NCT01895270|Drug|Isradipine|Isradipine extended release formulation
79352622|NCT01895270|Drug|Placebo|Placebo will consist of microcrystalline cellulose.
79503471|NCT05353452|Behavioral|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
79503472|NCT05353452|Behavioral|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
79503473|NCT05353283|Behavioral|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
79817663|NCT05374122|Diagnostic Test|DSOC biopsy without AI guidance|"Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.~Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies."
79989813|NCT03513783|Other|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~A clinical exam is performed by the Physical Medicine & Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
79989814|NCT03464292|Drug|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
79503474|NCT05353283|Device|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
79503475|NCT05352009|Other|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
79817664|NCT02581449|Dietary Supplement|omega-3|dietary supplement
79352623|NCT01424722|Device|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
79352624|NCT01424644|Biological|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
79503476|NCT05352009|Other|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
79503477|NCT05344209|Biological|UV1|UV1 vaccine
79503478|NCT05344209|Drug|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
79503479|NCT05344209|Drug|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
79665908|NCT05590260|Drug|IV iron infusion|single-dose IV iron infusion
79665909|NCT05590260|Drug|Oral iron tablets|60 mg of elemental iron
79665910|NCT05589480|Other|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
79665911|NCT05567315|Drug|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
79503480|NCT05335148|Drug|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
79503481|NCT05327764|Other|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
79989815|NCT03464292|Other|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
79989816|NCT03452137|Drug|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
79352625|NCT01424644|Biological|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
79352626|NCT01920854|Drug|soluble ferric pyrophosphate|
79352627|NCT01920854|Drug|Placebo|
79352628|NCT01403194|Device|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
79352629|NCT01403116|Drug|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
79352630|NCT01403116|Drug|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
79352631|NCT01402570|Dietary Supplement|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
79503482|NCT05327764|Other|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
79817665|NCT02581449|Other|empty soft gelatin capsules|empty softgels of matched size, shape and color
79989817|NCT03452137|Drug|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
79989818|NCT03434717|Other|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
79503486|NCT05309577|Behavioral|Behavioral Self-Monitoring + Motivational Interviewing|Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
79503487|NCT05299931|Drug|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
79989819|NCT03434717|Other|Care as usual|Patients will get care as usual
79989820|NCT03432364|Genetic|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
79503488|NCT05295628|Device|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
79989821|NCT03421353|Drug|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
79352632|NCT03025204|Biological|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
79352633|NCT03025204|Procedure|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
79352634|NCT01753401|Drug|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
79503489|NCT05295628|Device|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
79503490|NCT05280067|Device|ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
79503491|NCT05277740|Device|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
79503492|NCT05260892|Device|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
79503493|NCT05258435|Device|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
79503494|NCT05246566|Other|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
79503495|NCT05244304|Drug|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
79352635|NCT01753401|Drug|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
79352636|NCT01753401|Drug|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
79352637|NCT01618916|Drug|LY3015014|Administered SC
79503496|NCT05244304|Drug|Placebo|Not active drug
79503497|NCT05235321|Device|Standard GAT|Standard Goldmann Applanation Tonometry (GAT): this is the standard method for IOP measurement in clinical practice
79503498|NCT05235321|Device|Fixed force GAT|An investigational device similar to standard GAT
79989822|NCT03421353|Drug|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
79989823|NCT03421353|Drug|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
79989824|NCT03421353|Drug|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
79503499|NCT05235321|Device|Upright applanating prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device
79503500|NCT05235321|Device|Supine Applanating Prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device performed in the supine position
79503501|NCT05216809|Behavioral|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain >7,000 steps/day.
79352638|NCT01618916|Other|Placebo|Administered SC
79989825|NCT03421353|Drug|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
79989826|NCT03421353|Drug|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
79352639|NCT01753323|Drug|KAF156|KAF156 was supplied as tablets for oral use.
79352640|NCT04566939|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
79352641|NCT04566939|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
79352642|NCT04566939|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
79352643|NCT04566939|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79352644|NCT04566939|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79352645|NCT04566939|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
79352646|NCT04566939|Procedure|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79352647|NCT04566939|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
79352648|NCT04566939|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
79352649|NCT01894568|Drug|Insulin Peglispro|Administered SC using a prefilled pen.
79352650|NCT01894568|Drug|Insulin Glargine|Administered SC using a prefilled pen
79352651|NCT01894568|Drug|Oral Antihyperglycemic Medications (OAMs)|Administered orally
79503502|NCT05216809|Behavioral|Step-Reduction|Participants will be required to reduce their daily step-counts to <2,000 steps/day. Further, they will be required to refrain from structured physical activity.
79503503|NCT05216432|Drug|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
79503504|NCT05216432|Drug|Fulvestrant|500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
79503505|NCT05216432|Drug|Palbociclib 125mg|125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
79989827|NCT03421353|Drug|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
79989828|NCT03408665|Radiation|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
79989829|NCT03406624|Procedure|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
79989830|NCT03348969|Drug|Mitomycin c|Neoadjuvant Mitomycin C
79352652|NCT01618838|Radiation|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
79352653|NCT01920152|Biological|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
79503506|NCT05216432|Drug|Ribociclib 400mg|400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
79817666|NCT04110977|Device|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
79503507|NCT05216432|Drug|Ribociclib 600mg|600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
79503508|NCT05215275|Behavioral|exercise|"the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds."
79503509|NCT05200559|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
79352654|NCT01920152|Device|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
79352655|NCT01752933|Drug|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
79352656|NCT01752855|Biological|New formulation adalimumab|New formulation adalimumab 40 mg every other week
79352657|NCT01402492|Drug|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
79352658|NCT01402492|Drug|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
79352659|NCT01402102|Dietary Supplement|Aged garlic powder|Aged garlic powder(6.0g/day)
79503510|NCT05200559|Drug|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
79665912|NCT05567315|Device|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
79665913|NCT05566561|Drug|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
79665914|NCT05557279|Drug|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
79665915|NCT05541484|Drug|SGLT2 inhibitor|See above.
79817667|NCT04086498|Other|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
79817668|NCT04086498|Other|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
79817669|NCT04086498|Other|KD|The group received a plan for a low carbohydrate ketogenic diet
79503511|NCT05194722|Behavioral|Wysa mobile app|"Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available."
79503512|NCT05185622|Drug|Vamorolone|Oral administration of vamorolone for 12 weeks.
79503513|NCT05178732|Dietary Supplement|Bolus ingestion of protein|Different phases of the menstrual cycle
79352660|NCT01402102|Dietary Supplement|Placebo powder|Placebo powder(6.0g/day)
79352661|NCT04029220|Behavioral|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
79352662|NCT01423084|Biological|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
79503514|NCT05178732|Dietary Supplement|a blend of protein and polyphenol|a blend of protein and polyphenol
79352663|NCT04042168|Diagnostic Test|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
79352664|NCT04026334|Device|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
79503515|NCT05173987|Biological|pembrolizumab|Intravenous (IV) infusion
79503516|NCT05173987|Drug|carboplatin|IV infusion
79817670|NCT00792467|Drug|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
79352665|NCT01894256|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
79352666|NCT01780935|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
79503517|NCT05173987|Drug|paclitaxel|IV infusion
79503518|NCT05173987|Drug|docetaxel|IV infusion
79503519|NCT05173987|Drug|cisplatin|IV infusion
79503520|NCT05171179|Procedure|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
79503521|NCT05171179|Device|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
79503522|NCT05171179|Drug|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
79503523|NCT05171179|Drug|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.
79503524|NCT05171179|Drug|Lidocaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arm 1.
79503525|NCT05161754|Procedure|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
79503526|NCT05160922|Drug|crizotinib|crizotinib oral treatment
79665916|NCT05541484|Device|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
79817671|NCT00585468|Drug|Myfortic|Myfortic 720 mg orally twice daily
79817672|NCT03962946|Other|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
79817673|NCT03962946|Other|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
79352667|NCT01894100|Device|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
79817674|NCT02604641|Dietary Supplement|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
79503527|NCT05149443|Behavioral|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
79817675|NCT02604641|Dietary Supplement|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
79817676|NCT02604641|Dietary Supplement|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
79817677|NCT04087356|Genetic|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
79817678|NCT05600387|Drug|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
79989831|NCT03343184|Procedure|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
79989832|NCT03343184|Procedure|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
79989833|NCT03343184|Procedure|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
79352668|NCT02334982|Drug|TAK-137|TAK-137 tablets
79352669|NCT02334982|Drug|Placebo|TAK-137 placebo-matching tablets
79665917|NCT05540340|Other|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
79665918|NCT05538351|Device|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
79665919|NCT05527886|Other|AAROM|AAROM with knee to wall exercise, 3x30 reps
79817679|NCT04087044|Device|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"Oculo-Motility and Positional Testing,~Caloric Testing"
79665920|NCT05527886|Other|Slow Load|Single leg heel raise, 3x10 reps
79665921|NCT05527886|Other|Plyometric|Double leg 5 inch wall hops, 3x10 sec
79665922|NCT05521464|Other|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
79817680|NCT00724152|Behavioral|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
79817681|NCT00724152|Behavioral|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
79989834|NCT03343184|Procedure|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
79989835|NCT03307785|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
79352670|NCT03025516|Device|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
79503528|NCT05149443|Behavioral|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
79503529|NCT05139615|Drug|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
79989836|NCT03307785|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
79503530|NCT05139615|Drug|APD418|Participants will receive a single dose of APD418 as an IV infusion.
79503531|NCT05139615|Drug|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
79503532|NCT05115292|Biological|BJ-005|dosed with intravenous infusion
79817682|NCT02591940|Procedure|Surgery or Treatment by Heart Catheter|
79352671|NCT03025516|Device|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
79352672|NCT01422850|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
79352673|NCT01422538|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
79503533|NCT05111223|Device|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
79817683|NCT00721110|Drug|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
79817684|NCT00721110|Drug|Placebo|Placebo boluses and infusions will be substituted
79817685|NCT00721110|Drug|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
79352674|NCT01422538|Drug|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
79817686|NCT00721110|Drug|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
79817687|NCT02580279|Drug|EGCG|
79817688|NCT02580279|Drug|placebo|
79503534|NCT05111223|Device|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
79817689|NCT02592096|Drug|0.1% Pazufloxacin Mesilate Ear Drops|
79817690|NCT02592096|Drug|0.3% Pazufloxacin Mesilate Ear Drops|
79503535|NCT05111223|Device|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
79817691|NCT02592096|Drug|0.5% Pazufloxacin Mesilate Ear Drops|
79352675|NCT01422538|Other|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
79817692|NCT02592096|Drug|Pazufloxacin mesilate injection|
79665923|NCT05521464|Other|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
79989837|NCT03307785|Drug|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.
79989838|NCT03307785|Drug|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
79989839|NCT03307785|Drug|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
79989840|NCT03307785|Drug|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
79817693|NCT00791999|Drug|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
79817694|NCT00791999|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
79817695|NCT00791999|Drug|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
79352676|NCT04025866|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
79352677|NCT04025866|Other|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
79352678|NCT01422382|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
79352679|NCT01422382|Drug|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
79503536|NCT05105399|Procedure|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
79503537|NCT05100004|Device|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
79503538|NCT05100004|Device|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
79665924|NCT05517850|Behavioral|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
79989841|NCT03307785|Drug|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
79989842|NCT03292484|Biological|AR101|AR101
79989843|NCT03267381|Other|Blood draw (before surgery)|Blood will be drawn before surgery
79503539|NCT05074381|Other|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
79503540|NCT05074381|Other|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
79665925|NCT05517850|Behavioral|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
79665926|NCT05511961|Behavioral|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
79817696|NCT00791999|Drug|Placebo of CDP870|given every 2 weeks until Week22 (SC)
79352680|NCT04025788|Device|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
79503541|NCT05066672|Drug|NV-5138|NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
79817697|NCT04085484|Dietary Supplement|More concentrated parenteral nutrition solution|This study is a single-center retrospective observational study comparing two cohorts of very low birth weight (VLBW, birth weight < 1500 grams) infants who received parenteral nutrition (PN) either before or after a concentrated PN regime was implemented into clinical use. Both PN regimes were based on standardized PN solutions.
79352681|NCT01401322|Drug|Lenalidomide|50 mg; po
79503542|NCT05066672|Drug|matched placebo|matched placebo oral capsules
79503543|NCT05064865|Dietary Supplement|Freeze-dried table grape powder|Consumption of 46g/day freeze-dried table grape powder
79989844|NCT03267381|Other|Blood draw (every 3 months)|Blood will be drawn every 3 months
79352682|NCT01387594|Procedure|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
79503544|NCT05064865|Dietary Supplement|Placebo of the table grape powder|Consumption of 46g/day placebo version of the freeze-dried table grape powder
79352683|NCT01387594|Drug|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
79352684|NCT01401010|Drug|Doripenem|500 mg every 8 hours
79352685|NCT01401010|Drug|doripenem|1000 mg every 8 hours
79352686|NCT01400932|Drug|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
79352687|NCT01400932|Drug|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
79503545|NCT05044351|Device|Fluobeam LX|See arm description
79503546|NCT05044351|Other|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
79503547|NCT05041621|Device|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
79503548|NCT05041127|Biological|Cetuximab|Given IV
79503549|NCT05041127|Other|Questionnaire Administration|Ancillary studies
79503550|NCT05028101|Procedure|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
79503551|NCT05028101|Behavioral|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
79503552|NCT05020912|Drug|ALA|At first visit, ALA applied to one BCC lesion
79503553|NCT05020912|Procedure|PDT|PDT with blue light (for 30 min (~20 mJ/cm2))
79503554|NCT05008172|Procedure|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
79665927|NCT05509036|Other|No interventions|No interventions
79352688|NCT01400698|Drug|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
79352689|NCT01400698|Drug|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
79665928|NCT05506631|Procedure|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
79665929|NCT05506631|Procedure|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
79665930|NCT05483608|Other|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
79665931|NCT05483608|Other|Recumbent cycling|Exercise using a recumbent cycle ergometer
79352690|NCT01400698|Other|Observation only|Subjects were only observed.
79352691|NCT01890746|Drug|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose was adjusted to 60mg /m2.
79503555|NCT04987346|Other|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
79503556|NCT04987346|Other|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
79503557|NCT04963738|Drug|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
79665932|NCT05483491|Drug|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
79665933|NCT05483491|Drug|Aldesleukin 720,000 IU/kg IV every eight hours|Aldesleukin 720,000 IU/kg IV every eight hours after KK-LC-1 TCR-T cell infusion for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
79665934|NCT05482425|Other|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
79665935|NCT05479123|Drug|Propranolol three times a day|"Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
79665936|NCT05479123|Drug|Propranolol twice a day|"Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
79665937|NCT05479123|Drug|Timolol|Patients with a small (<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
79665938|NCT05476549|Dietary Supplement|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
79665939|NCT05476549|Dietary Supplement|Placebo|Placebo supplement containing carrier material only
79665940|NCT05474404|Diagnostic Test|Cervical smear test|collection of cervical cells using spatula
79352692|NCT01890746|Drug|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
79665941|NCT05471557|Procedure|pain delivery|Experimental pain paradigm delivered that is short-term and painful but not harmful.
79665942|NCT05471557|Procedure|distractor delivery|Distractor stimulus delivered that is short-term and attention-demanding but not painful.
79665943|NCT05461820|Drug|Methimazole|Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
79817698|NCT04033263|Other|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79503558|NCT04959396|Device|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
79503559|NCT04951050|Device|Rapamycin target eluting stent|Rapamycin target eluting stent
79503560|NCT04944836|Drug|Clomiphene Citrate|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
79503561|NCT04944836|Procedure|Rotator Cuff Repair|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
79503562|NCT04923477|Other|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external & internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
79503563|NCT04918615|Procedure|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
79503564|NCT04890171|Procedure|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
79352693|NCT01890746|Drug|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were <100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were <100 Gi/L.
79503565|NCT04890171|Procedure|Surgery|Gastrectomy with lymph node dissection by a surgeon
79352694|NCT01890746|Drug|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were <100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were <100 Gi/L.
79665944|NCT05459324|Device|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
79665945|NCT05454969|Behavioral|One-4-ALL Initiative|We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
79665946|NCT05454969|Behavioral|Control|Patients will receive standard of care.
79665947|NCT05450198|Biological|MK-6194|MK-6194 administered subcutaneously (SC)
79665948|NCT05450198|Biological|Placebo|Placebo comparator to MK-6194 administered SC
79665949|NCT05449756|Other|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
79817699|NCT04033263|Other|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79352695|NCT04614350|Biological|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
79352696|NCT04614350|Biological|AlloDerm|AlloDerm tissue matrix
79352697|NCT01422304|Drug|Sugammadex|Sugammadex 4 mg/kg intravenously
79352698|NCT01422304|Drug|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
79352699|NCT01422304|Drug|Placebo to neostigmine|Normal saline (NaCl 0.9%)
79352700|NCT01422304|Drug|Placebo to sugammadex|Normal saline (NaCl 0.9%)
79352701|NCT01387516|Behavioral|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
79503568|NCT04866914|Behavioral|Acceptance and Commitment Therapy for Insomnia|ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
79503569|NCT04866914|Behavioral|Cognitive Behavioral Therapy for Insomnia|Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
79503570|NCT04865419|Drug|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
79817700|NCT04033263|Other|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79817701|NCT04033263|Other|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79503571|NCT04865419|Drug|Voriconazole|Voriconazole film-coated tablet will be administered orally.
79817702|NCT04033263|Other|Mouth rinse 5|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79817703|NCT04033263|Other|Mouth rinse 6|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79817704|NCT04033263|Other|Mouth rinse 7|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79817705|NCT04033263|Other|Mouth rinse 8|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79989845|NCT03267381|Other|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
79352702|NCT01387516|Behavioral|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
79503572|NCT04861818|Behavioral|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
79503573|NCT04837586|Other|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
79817706|NCT04033263|Other|Mouth rinse 9|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
79989846|NCT03267134|Device|Hydrus Microstent|Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
79989847|NCT03267134|Procedure|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
79503574|NCT04837586|Device|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
79503575|NCT04837586|Device|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
79503576|NCT04834414|Biological|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
79665950|NCT05445947|Behavioral|The EASEL (Enhancing And Supporting Early Development to Better Children's Lives) Approach|"The EASEL Approach consists of a set of educator-led practices that can be incorporated into the daily classroom environment for children three to six years of age. The overall purpose of this approach is to enhance early childhood educators' teaching practices that would promote children's SEB+EF development.~Nine EASEL practices were selected for inclusion in the EASEL Approach. These are a) core fundamental practices that are evidence-based, b) practices that expert stakeholders identified as ones for which local early childhood educators may need additional training, c) practices that are not already covered in pre-service training to avoid replication for educators, d) a combination of practices that educators may already be implementing and can enhance, and new practices, and e) a balance of antecedent and consequential practices (i.e., practices that can be implemented before and after a target behavior)."
79665951|NCT05429255|Behavioral|Aerobic Exercise|Bicycle training
79817707|NCT04075227|Drug|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
79817708|NCT04075227|Drug|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
79989848|NCT03260881|Drug|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
79989849|NCT03260881|Drug|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
79503577|NCT04834414|Biological|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
79665952|NCT05429255|Behavioral|Exergame Training|Nintendo Wii
79817709|NCT03499821|Device|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
79989850|NCT03244124|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
79665953|NCT05425992|Other|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
79352703|NCT01387516|Behavioral|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
79352704|NCT01387516|Behavioral|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
79503578|NCT04827966|Other|Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
79503579|NCT04827966|Other|Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
79665954|NCT05425862|Drug|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
79817710|NCT00585078|Drug|Capecitabine|
79817711|NCT00585078|Drug|Oxaliplatin|
79817712|NCT00720876|Biological|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
79817713|NCT00720876|Drug|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
79817714|NCT00723840|Other|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
79352705|NCT03812146|Behavioral|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
79503580|NCT04827966|Other|MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
79817715|NCT03956316|Device|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
79503581|NCT04827966|Other|Zap® 1.23% APF gel - Acidulated phosphate fluoride|1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
79817716|NCT00789581|Drug|Doxorubicin|Doxorubicin 60 mg/m2
79503582|NCT04827966|Other|Listerine fluoride mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
79817717|NCT00789581|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2
79817718|NCT00789581|Drug|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
79817719|NCT00789581|Drug|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
79817720|NCT04075071|Behavioral|Teacher-Child Interaction Training - Universal|Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
79817721|NCT00717756|Drug|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
79989851|NCT03244124|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
79352706|NCT03812146|Behavioral|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
79352707|NCT01421134|Drug|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
79503583|NCT04818359|Behavioral|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
79503584|NCT04796974|Device|Cention|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
79503585|NCT04796194|Combination Product|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
79503586|NCT04790799|Other|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
79503587|NCT04780776|Device|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
79503588|NCT04780776|Device|Sham comparator|5+16 weeks of visible light exposure
79503589|NCT04772300|Combination Product|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
79503590|NCT04772300|Device|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
79817722|NCT00915629|Dietary Supplement|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
79817723|NCT04111289|Drug|-Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
79352708|NCT01421134|Drug|Placebo|Placebo
79352709|NCT01894022|Drug|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
79503591|NCT04766710|Other|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
79817724|NCT04108637|Procedure|penicillin allergy assessment pathway|"Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction"
79817725|NCT05674539|Drug|Fludarabine and Busulfan|Fludarabine with total dose of 150 mg/m^2 in combination with Busulfan with total dose of 6.4 mg/kg
79817726|NCT05674539|Drug|Fludarabine and Melphalan|Fludarabine with total dose of 150 mg/m^2 in combination with Melphalan with total dose of 140 mg/m^2
79817727|NCT04108559|Procedure|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
79817728|NCT04108559|Procedure|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
79817729|NCT04108559|Other|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
79817730|NCT00717522|Drug|Pomalidomide|
79817731|NCT04128189|Biological|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
79817732|NCT05014659|Dietary Supplement|Creatine monohydrate|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
79817733|NCT05014659|Dietary Supplement|Placebo|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
79817734|NCT00791921|Drug|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
79352710|NCT01615328|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
79352711|NCT01615328|Device|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
79352712|NCT01387282|Drug|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
79352713|NCT01387282|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
79352714|NCT01386970|Drug|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
79503592|NCT04766710|Other|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
79503593|NCT04763031|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
79503594|NCT04756570|Other|Control|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
79503595|NCT04756570|Other|Robotic Group 1|Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
79503596|NCT04756570|Other|Robotic Group 2|Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
79503597|NCT04752137|Drug|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
79665955|NCT05425862|Drug|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
79817735|NCT00791921|Drug|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
79817736|NCT04111055|Device|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
79352715|NCT01890434|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
79352716|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
79352717|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
79665956|NCT05415774|Device|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
79665957|NCT05415774|Device|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
79817737|NCT02580123|Behavioral|Intervention taught by trained educators|
79817738|NCT04106843|Drug|Lutetium Lu 177 Dotatate|Given IV
79817739|NCT04106453|Procedure|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
79817740|NCT04106453|Procedure|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
79989852|NCT03244124|Other|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
79352718|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
79352719|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
79503598|NCT04752137|Device|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
79503599|NCT04741256|Behavioral|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
79352720|NCT01385566|Biological|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
79352721|NCT01385566|Biological|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
79352722|NCT05365984|Diagnostic Test|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
79352723|NCT05365984|Other|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
79352724|NCT01780545|Drug|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
79503600|NCT04739865|Drug|Psilocybin|Open label
79503601|NCT04722341|Behavioral|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
79503602|NCT04722341|Behavioral|Control|More than equal to a 12-hour daily eating period
79503603|NCT04705467|Device|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
79503604|NCT04680715|Radiation|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
79665958|NCT05415774|Device|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
79665959|NCT05415774|Device|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
79665960|NCT05415774|Device|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
79665961|NCT05415774|Device|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
79817741|NCT03475953|Drug|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
79817742|NCT03475953|Drug|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
79352725|NCT01780545|Drug|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
79352726|NCT01780389|Drug|Open-label flexibly dosed milnacipran|
79352727|NCT04573569|Behavioral|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
79352728|NCT01778985|Drug|Premarin|
79352729|NCT01778985|Other|Placebo|
79665962|NCT05413681|Diagnostic Test|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
79665963|NCT05413681|Diagnostic Test|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
79665964|NCT05413668|Drug|RVP-001|Intravenous administration of RVP-001
79665965|NCT05413668|Drug|Placebo|Intravenous administration of saline placebo
79665966|NCT05413551|Drug|Low-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
79665967|NCT05413551|Drug|Standard dose of isoniazid|15 mg/kg oral tablet (up to 900 mg)
79989853|NCT03244124|Other|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
79665968|NCT05413551|Drug|High-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
79817743|NCT03475953|Drug|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
79817744|NCT03475953|Drug|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
79817745|NCT03475953|Drug|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
79989854|NCT03235804|Dietary Supplement|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
79989855|NCT03217188|Radiation|conventionally fractionated full dose re-irradiation|re-irradiation [60-70 Gy (RBE) in 2 Gy (RBE) fractions
79352730|NCT01778751|Behavioral|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
79352731|NCT01865084|Drug|Tadalafil|Administered orally
79352732|NCT01865084|Drug|Placebo|
79352733|NCT01778127|Behavioral|Activity Monitor|Measurement of physical activity.
79665969|NCT05413278|Behavioral|Behavioral|Patient education, information and empowerment
79352734|NCT01778127|Behavioral|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
79352735|NCT01778127|Behavioral|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
79352736|NCT01892540|Diagnostic Test|positron emission tomography/computed tomography|Undergo PET/CT
79352737|NCT01892540|Diagnostic Test|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
79503605|NCT04656028|Genetic|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database <0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
79503606|NCT04656028|Behavioral|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~Increasing motivation for a healthy lifestyle;~Increasing adherence to treatment;~Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
79503607|NCT04656028|Diagnostic Test|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
79503608|NCT04656028|Other|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
79665970|NCT05409664|Behavioral|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
79989856|NCT03217188|Radiation|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break [+/- 2 weeks], repeated up to 4 cycles)."
79352738|NCT01892540|Device|Position Device|
79352739|NCT01385098|Dietary Supplement|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
79352740|NCT01398514|Drug|Escitalopram|Escitalopram 10mg/day or matched pill placebo
79352741|NCT01398358|Behavioral|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
79503609|NCT04656028|Other|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
79665971|NCT05409664|Behavioral|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
79989857|NCT03199040|Drug|Durvalumab|-Human monoclonal antibody
79989858|NCT03199040|Biological|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
79989859|NCT03199040|Device|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
79503610|NCT04656028|Other|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
79503611|NCT04656028|Other|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
79503612|NCT04656028|Other|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
79665972|NCT05408169|Behavioral|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within [X] weeks (by [DD.MM.YYYY]) or as soon as possible."
79817746|NCT04106375|Behavioral|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
79817747|NCT04108325|Drug|YY-20394|Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
79352742|NCT01398358|Behavioral|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
79989860|NCT03199040|Procedure|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
79989861|NCT03198702|Drug|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
79665973|NCT05408169|Behavioral|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
79352743|NCT03025282|Drug|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
79665974|NCT05407818|Drug|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
79989862|NCT03198702|Other|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
79989863|NCT03198650|Drug|Acalabrutinib|Acalabrutinib
79352744|NCT03025282|Drug|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
79352745|NCT03025282|Drug|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
79352746|NCT03025282|Drug|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
79352747|NCT03025282|Drug|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
79352748|NCT03025282|Drug|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
79352749|NCT01778049|Drug|BI 10773|Empagliflozin active
79352750|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
79352751|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
79352752|NCT01778049|Drug|BI 10773|Empagliflozin active
79352753|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
79352754|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
79665977|NCT05401071|Other|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
79665978|NCT05401071|Combination Product|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, >71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, >71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, >71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, >71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, >50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
79665979|NCT05401071|Other|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
79665980|NCT05401071|Other|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
79989864|NCT03198650|Drug|Obinutuzumab|Obinutuzumab
79352755|NCT01778049|Drug|BI 10773|Empagliflozin active
79352756|NCT01778049|Drug|BI 10773|Empagliflozin active
79352757|NCT01778049|Drug|BI 10773|Empagliflozin active
79352758|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
79352759|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
79352760|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
79352761|NCT01778049|Drug|BI 10773|Empagliflozin active
79352762|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
79352763|NCT01777581|Drug|Milnacipran|
79352764|NCT01777581|Drug|Placebo|
79352765|NCT01864148|Drug|BIIB033|
79352766|NCT01864148|Other|Placebo|
79352767|NCT01864148|Drug|Avonex|
79352768|NCT01751139|Procedure|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
79503613|NCT04638465|Procedure|Transoral robotic surgery|Transoral resection with neck dissection
79989865|NCT03192956|Other|No active intervention|No active intervention is performed
79989866|NCT03159897|Drug|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
79989867|NCT03159897|Drug|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
79503614|NCT04638465|Drug|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
79665981|NCT05398302|Procedure|Image Guided Biopsy|Undergo image-guided biopsy
79989868|NCT03159897|Drug|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
79989869|NCT03159897|Drug|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
79352769|NCT01751139|Other|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
79989870|NCT03113981|Device|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
79352770|NCT04415138|Device|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
79352771|NCT01890122|Drug|Alogliptin|Alogliptin tablets
79352772|NCT01890122|Drug|Metformin HCl|Metformin HCl capsules
79352773|NCT01890122|Drug|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
79352774|NCT01890122|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets
79352775|NCT01890122|Drug|Metformin Placebo|Metformin placebo-matching capsules
79352776|NCT01890122|Drug|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
79352777|NCT01397890|Drug|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
79352778|NCT01397890|Drug|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
79352779|NCT01777269|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
79352780|NCT01777269|Drug|Placebo|Take one capsule daily
79352781|NCT04616456|Drug|[F-18]PBR06|PET radiopharmaceutical
79665982|NCT05394337|Drug|Atezolizumab|Given by vein (IV)
79989871|NCT03102866|Other|Best Practice|Receive usual care
79989872|NCT03102866|Behavioral|Exercise Intervention|Undergo aerobic and strength training exercise
79989873|NCT03102866|Other|Quality-of-Life Assessment|Ancillary studies
79352782|NCT04616456|Drug|Verdiperstat|verdiperstat targets microglial inflammation in the brain
79352783|NCT05365360|Device|LaserCap SD|LaserCap SD
79352784|NCT05365360|Device|Sham LaserCap|Sham LaserCap
79352785|NCT05365360|Device|LaserCap HD+|LaserCap HD+
79352786|NCT04016272|Device|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
79352787|NCT04016272|Device|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
79352788|NCT04371250|Other|Survey and Questionnaire|Resilience and Loneliness questionnaires
79352789|NCT01751061|Behavioral|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
79352790|NCT01751061|Other|Usual care|usual ICU care
79352791|NCT01777191|Drug|Ixekizumab Auto-Injector|Administered SC by auto-injector
79503615|NCT04638465|Drug|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
79503616|NCT04638465|Radiation|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
79503617|NCT04638465|Radiation|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
79503618|NCT04630522|Drug|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
79665983|NCT05394337|Drug|Tiragolumab|Given by vein (IV)
79665985|NCT05388955|Other|None, transplantation recipients|None, observational
79989874|NCT03102866|Other|Questionnaire Administration|Ancillary studies
79989875|NCT03096886|Behavioral|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
79989876|NCT03079999|Drug|Aspirin|Twice daily aspirin
79989877|NCT03079999|Drug|Placebo|Twice daily placebo
79989878|NCT03078010|Drug|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
79989879|NCT03078010|Drug|cefepime|(2 gm IV q 8 hrs)
79989880|NCT03072238|Drug|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
79989881|NCT03072238|Drug|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
79989882|NCT03072238|Drug|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
79989883|NCT03072238|Drug|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
79989884|NCT03017755|Other|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
79503619|NCT04630522|Drug|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
79503620|NCT04630522|Drug|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
79665986|NCT05375162|Behavioral|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
79817748|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
79989885|NCT02977403|Behavioral|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
79989886|NCT02977403|Behavioral|Booster Attention Retraining|All subjects can opt to undergo attention bias training after the randomized phase of the study is complete
79989887|NCT02970318|Drug|Acalabrutinib (ACP-196)|Acalabrutinib monotherapy
79989888|NCT02970318|Drug|Rituximab|Rituximab in combination with idelalisib or bendamustine
79989889|NCT02970318|Drug|Idelalisib|Idelalisib in combination with rituximab
79352792|NCT01777191|Drug|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
79352793|NCT01896050|Drug|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
79352794|NCT01896050|Drug|Tamoxifen|Patients were treated with tamoxifen for up to one year
79352795|NCT01775787|Drug|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco & Menthol Flavor for 7-10 days or Tobacco & Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
79352796|NCT01775553|Drug|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
79503621|NCT04630522|Dietary Supplement|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
79503622|NCT04623996|Drug|TP-0184|Oral dose
79503623|NCT04615013|Drug|Capecitabine|Not applicable to this study
79989890|NCT02970318|Drug|Bendamustine|Bendamustine in combination with rituximab
79989891|NCT02949726|Drug|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
79989892|NCT02949726|Device|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
79503624|NCT04615013|Drug|Carboplatin|Not applicable to this study
79503625|NCT04615013|Drug|Docetaxel|Not applicable to this study
79503626|NCT04615013|Drug|Fluorouracil|Not applicable to this study
79503627|NCT04615013|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
79503628|NCT04615013|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79503629|NCT04615013|Drug|Leucovorin|Not applicable to this study
79352797|NCT01775475|Drug|cyclophosphamide|Given IV
79352798|NCT01775475|Drug|doxorubicin hydrochloride|Given IV
79352799|NCT01775475|Drug|vincristine sulfate|Given IV
79352800|NCT01775475|Drug|prednisone|Given PO
79352801|NCT01775475|Drug|lomustine|Given PO
79352802|NCT01775475|Drug|etoposide|Given PO
79352803|NCT01775475|Drug|cyclophosphamide|Given PO
79503630|NCT04615013|Drug|Oxaliplatin|Not applicable to this study
79503631|NCT04615013|Drug|Paclitaxel|Not applicable to this study
79665987|NCT05375162|Behavioral|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
79817749|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
79817750|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
79352804|NCT01775475|Drug|procarbazine hydrochloride|Given PO
79352805|NCT01775475|Other|laboratory biomarker analysis|Correlative studies
79352806|NCT01774929|Drug|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
79352807|NCT01888874|Drug|GLPG0634|GLPG0634 capsules.
79352808|NCT01888874|Drug|Placebo|Placebo capsules.
79352809|NCT01749735|Device|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
79352810|NCT01749735|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
79352811|NCT01749735|Device|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
79352812|NCT01749033|Other|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
79503632|NCT04597190|Drug|Selective serotonin reuptake inhibitor|Prescribers and patients choose among three selective serotonin reuptake inhibitors (SSRI), sertraline, paroxetine, or fluoxetine based on patient's treatment history (i.e., failed SSRI trials due to side-effects or lack of efficacy) and preference. If a patient experiences problematic side effects after taking their choice of SSRI, the provider may switch them to another of the SSRI options during the first 8 weeks of follow-up. Patients on any antidepressant (including SSRIs) at enrollment will be cross-tapered over four weeks to either fluoxetine, sertraline or paroxetine (i.e., the old drug will be tapered down while the new drug is tapering up).
79503633|NCT04597190|Drug|Serotonin-norepinephrine reuptake inhibitor|Prescribers will prescribe venlafaxine.
79352813|NCT01749033|Other|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
79352814|NCT01749033|Other|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
79352815|NCT01774305|Drug|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
79352816|NCT01774305|Drug|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
79989893|NCT02948686|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
79989894|NCT02948686|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
79352817|NCT01737021|Other|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
79352818|NCT01397422|Drug|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
79352819|NCT01888640|Device|TENS|"TENS Parameters: Active TENS and Placebo TENS~TENS Frequency - 2-125 Hz~TENS Pulse Width - 200 µs~TENS Intensity - Maximal tolerable intensity~Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~Administration - Daily~TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
79352820|NCT01736475|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
79352821|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
79352822|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
79352823|NCT01736475|Biological|PEGylated Recombinant Factor VIII|On-demand treatment
79665988|NCT05375162|Behavioral|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
79665989|NCT05375162|Behavioral|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
79817751|NCT00791765|Biological|Etanercept|Etanercept for subcutaneous injection.
79817752|NCT00791765|Biological|Placebo|Placebo for subcutaneous injection.
79352824|NCT01863758|Biological|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
79352825|NCT01863680|Drug|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent [%] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
79352826|NCT01863680|Drug|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
79352827|NCT01863680|Drug|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
79352828|NCT01863680|Drug|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
79352829|NCT01747629|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
79352830|NCT01747629|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
79352831|NCT04170920|Device|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
79352832|NCT01863368|Other|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
79352833|NCT01863368|Other|Systane® ULTRA lubricant eyedrops|
79352834|NCT01863368|Other|OPTIVE® lubricating eyedrops|
79817753|NCT03646227|Other|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
79817754|NCT00789191|Drug|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
79352835|NCT01886690|Drug|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
79352836|NCT01886690|Drug|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
79352837|NCT01886378|Drug|UX007|
79352838|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
79352839|NCT04616378|Other|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
79352840|NCT04616378|Other|Phase 3 No Prosthesis|No prosthetic device is attached.
79352841|NCT04616378|Other|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
79352842|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
79352843|NCT01885208|Drug|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
79352844|NCT01885208|Drug|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
79352845|NCT01859702|Drug|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
79352846|NCT04599686|Drug|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
79352847|NCT04599686|Radiation|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
79352848|NCT01835132|Device|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
79352849|NCT01747551|Drug|Oxaliplatin|
79352850|NCT01747551|Drug|Leucovorin|
79352851|NCT01747551|Drug|Fluorouracil|
79352852|NCT01747551|Drug|Ziv-aflibercept|
79352853|NCT01736397|Drug|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
79352854|NCT01736397|Drug|Placebo|
79817755|NCT00789191|Drug|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
79352855|NCT01859390|Drug|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
79352856|NCT01859390|Dietary Supplement|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
79352857|NCT01858766|Drug|SOF|400 mg tablet administered orally once daily
79352858|NCT01858766|Drug|VEL|Tablet administered orally once daily
79352859|NCT01858766|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79352860|NCT01734993|Drug|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
79352861|NCT01745367|Drug|Tivozanib Hydrochloride|
79352862|NCT01745367|Drug|paclitaxel|
79352863|NCT01745367|Drug|Placebo|
79352864|NCT01733121|Drug|NBI-98854|25 mg capsule
79352865|NCT01733121|Drug|NBI-98854|50 mg capsule
79352866|NCT01733121|Drug|Placebo|
79352867|NCT01744977|Behavioral|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
79817756|NCT00789191|Drug|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
79352868|NCT01383928|Drug|Ixazomib|Ixazomib capsules
79503634|NCT04597190|Behavioral|Written Exposure Therapy|Written Exposure Therapy will be delivered during six 30 minute sessions. The first session includes psychoeducation about symptoms of PTSD, provides a treatment rationale for approaching the trauma memory, and discusses the use of writing as a means of doing so. In sessions 2-6, patients will write about the memory of their worst traumatic event for 20 minutes, with a focus on details of the event and thoughts and feelings that occurred during the event. Patients are directed to write about the same trauma memory during each session. The session ends with the therapist instructing the patient to allow themselves to experience any trauma-related memories, images, thoughts, and feelings in the interval between sessions. The therapist reads the narrative between sessions to make sure instructions were followed. Feedback about the narrative is provided to the patient at the beginning of sessions 3-6. This feedback is used to prompt the patient for writing in the current session.
79503635|NCT04582578|Device|CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
79352869|NCT01383928|Drug|Lenalidomide|Lenalidomide capsules
79352870|NCT01383928|Drug|Dexamethasone|Dexamethasone Tablets
79817757|NCT00789191|Drug|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
79352871|NCT04023604|Other|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
79352872|NCT04023604|Other|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
79352873|NCT05365048|Other|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
79352874|NCT05365048|Other|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
79352875|NCT05367388|Drug|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
79352876|NCT05367388|Drug|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
79352877|NCT01382602|Biological|AMDC-USR|AMDC-USR Treatment
79352878|NCT01382602|Biological|Placebo|Placebo treatment
79352879|NCT05893420|Device|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
79352880|NCT05893420|Other|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
79352881|NCT05893368|Other|Sharing all key aspects associated with the quality of life in a single digital environment|"A digital platform called DNMLAB (DNMLAB) offers the possibility of sharing all key aspects associated with the quality of life in a single digital environment by activating:~a digital narrative diary in which the patient has the opportunity to share with the multidisciplinary team her needs, critical issues~report Patient-Reported Outcome Measures (PROMs) aimed at detecting health-related quality of life (i.e. QLQ-C30-B23 EORTC).~digital narrative diary focused on three main areas of health-related behavior-nutrition, physical activity, and sleep habits-aimed at personalizing and reshaping lifestyle, daily behaviors and, if required, the care pathway.~The patient will be guided by narrative prompts, but at the same time will always be free to share all aspects related to her lifestyle that she deems useful, in addition to those detected, to benefit from a personalized care approach."
79352882|NCT05893316|Diagnostic Test|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
79352883|NCT05893303|Other|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
79352884|NCT05893303|Other|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
79352885|NCT05893290|Other|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
79352886|NCT05893290|Other|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
79352887|NCT05893212|Behavioral|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
79503636|NCT04577170|Diagnostic Test|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
79817758|NCT04967235|Other|Conventional Exercise-based Cardiac Rehabilitation Session|"This session will be composed of:~I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of treadmill aerobic exercise at an intensity of 60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus; IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position."
79817759|NCT04967235|Other|Dance-based Cardiac Rehabilitation Session|I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of dance therapy. The intensity of the choreography will be set at the same range as the conventional exercise-based session. (60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus); IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position.
79352888|NCT05893212|Behavioral|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
79352889|NCT05893199|Device|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
79503637|NCT04576130|Device|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
79503638|NCT04575961|Drug|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
79679596|NCT04691583|Other|Fast diet|"Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."
79817760|NCT02603315|Other|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
79817761|NCT03923595|Other|Adherence intervention research|dedicated management
79817762|NCT00789035|Drug|BI 10773|
79352890|NCT05893199|Other|Usual care|usual follow-up in primary care both arms
79352891|NCT05892900|Device|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
79817763|NCT00789035|Drug|placebo|
79503639|NCT04575363|Other|Blood sample|Blood sample
79503640|NCT04550728|Combination Product|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
79503641|NCT04550728|Combination Product|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
79503642|NCT04549519|Other|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
79503643|NCT04545840|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
79679597|NCT00518414|Other|Marketed infant formula with DHA and ARA|
79679598|NCT00518414|Other|Milk-based infant formula with DHA and ARA|
79817764|NCT00789035|Drug|metformin|
79817765|NCT02579577|Other|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
79817766|NCT02579577|Other|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
79817767|NCT02579577|Other|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
79503644|NCT04537364|Diagnostic Test|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity >1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
79679599|NCT00518414|Other|Milk-based formula with DHA, ARA, prebiotics|
79817768|NCT05016843|Behavioral|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
79817769|NCT05016843|Behavioral|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
79817770|NCT05016843|Other|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
79817771|NCT05016843|Other|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
79817772|NCT05016843|Other|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
79817773|NCT05016843|Other|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
79817774|NCT05016843|Other|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
79989895|NCT02948686|Other|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
79503645|NCT04535271|Drug|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
79503646|NCT04533997|Drug|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide > 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
79679600|NCT02277015|Device|Miller Laryngoscope|Direct Laryngoscopy
79679601|NCT02277015|Device|The Berci-Kaplan DCI|Videolaryngoscope-1
79679602|NCT02277015|Device|The AirTraq|Videolaryngoscope-2
79679603|NCT02277015|Device|GlideScope GVL|Videolaryngoscope-3
79679604|NCT02277015|Device|The Pentax AWS|Videolaryngoscope-4
79989896|NCT02948686|Other|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
79989897|NCT02904577|Other|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
79989898|NCT02879409|Drug|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
79989899|NCT02879409|Drug|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
79989900|NCT02879409|Drug|Sitagliptin|Oral: 100 mg once daily
79352892|NCT05892900|Device|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
79352893|NCT05892848|Diagnostic Test|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
79352894|NCT05892822|Other|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
79352895|NCT05892809|Other|use an incubator cover|Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
79989901|NCT02879409|Drug|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
79989902|NCT02879409|Drug|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
79989903|NCT02879409|Drug|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
79989904|NCT02879409|Drug|human insulin|insulin dosage and administration according to physician
79989905|NCT02840149|Drug|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
79352896|NCT05892783|Other|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
79352897|NCT05892731|Other|with depression|age-related hearing loss with depression
79503647|NCT04533997|Drug|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide > 160 mg"
79503648|NCT04511052|Dietary Supplement|Probiotic|Daily intake of 10 x 10^9 CFU of a proprietary strain for a total duration of 10 weeks
79503649|NCT04511052|Other|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
79503650|NCT04511052|Dietary Supplement|Carotenoid supplement|1 capsule daily containing ~20 mg of total carotenoids for a total duration of 10 weeks
79503651|NCT04506814|Device|Endocardial PVI|Catheter based PVI
79503652|NCT04506814|Device|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
79352898|NCT05892731|Other|without depression|age-related hearing loss without depression
79352899|NCT05892705|Drug|Dexmedetomidine Injection [Precedex]|intrathecal injection of 5 mcg dexmedetomidine
79503653|NCT04500275|Drug|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
79503654|NCT04500275|Other|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
79352900|NCT05892692|Behavioral|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
79503655|NCT04495543|Behavioral|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
79352901|NCT05892627|Dietary Supplement|PoZibio|PoZibio (50 x 10^9 CFUs/ CAPSULE)
79503656|NCT04486742|Behavioral|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
79503657|NCT04473833|Procedure|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
79503658|NCT04472195|Other|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
79503659|NCT04446832|Other|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
79665990|NCT05375162|Behavioral|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
79352902|NCT05892627|Dietary Supplement|Placebo|Placebo
79665991|NCT05372887|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
79665992|NCT05372887|Drug|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
79665993|NCT05371964|Drug|Imetelstat|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
79665994|NCT05371964|Drug|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) as the standard of care per local prescribing guidelines.
79665995|NCT05365581|Drug|ASP2138|intravenous
79817775|NCT04108013|Drug|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
79817776|NCT04108013|Drug|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
79817777|NCT04105985|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
79817778|NCT04105985|Drug|Articaine Injection|Local anesthetic
79817779|NCT04074213|Drug|Clozapine|Clozapine treatment
79352903|NCT05892601|Other|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
79503660|NCT04442893|Behavioral|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
79817780|NCT04110587|Biological|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
79352904|NCT05892575|Behavioral|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
79817781|NCT04110587|Procedure|Temporomandibular Joint Arthroscopy|Lysis and Lavage
79817782|NCT04110587|Drug|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
79817783|NCT04110587|Drug|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
79817784|NCT04110587|Drug|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
79817785|NCT04110587|Drug|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
79817786|NCT04110587|Other|Exercise program|Home exercise program
79817787|NCT03625869|Device|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
79817788|NCT03386253|Device|active tDCS|two 13 minute tDCS sessions separated by 20 minutes in between
79817789|NCT03386253|Device|sham tDCS|sham tDCS session given for same length of time as active
79817790|NCT02633163|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
79503661|NCT04442893|Other|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
79503662|NCT04439331|Drug|Defactinib Hydrochloride|Given PO
79503663|NCT04439279|Drug|Trametinib Dimethyl Sulfoxide|Given PO
79352905|NCT05892562|Other|No intervention|As this study is purely observational, no intervention is involved.
79503664|NCT04428788|Drug|CC-94676|Specified dose on specified days
79503665|NCT04428788|Drug|CC1083611|Specified dose on specified days
79503666|NCT04428788|Drug|CC1083610|Specified dose on specified days
79503667|NCT04409847|Diagnostic Test|ABPM|24 hour ambulatory blood pressure monitoring
79503668|NCT04409847|Diagnostic Test|ECG|Electrocardiogram
79503669|NCT04409847|Diagnostic Test|FMD|Flow mediated dilatation
79352906|NCT05892536|Procedure|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
79503670|NCT04409847|Diagnostic Test|PWV|Pulse wave velocity
79503671|NCT04409847|Diagnostic Test|Rarefaction|nailbed capillaroscopy
79503672|NCT04409652|Procedure|Head on bed|During emergence, head is kept on bed without pillow.
79503673|NCT04409652|Procedure|Head on pillow|During emergence, head is kept on pillow.
79503674|NCT04400981|Procedure|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
79352907|NCT05892484|Device|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
79352908|NCT05892484|Diagnostic Test|X-RAY|Routine X-RAY
79352909|NCT05892471|Drug|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
79503675|NCT04400981|Other|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
79817791|NCT02633163|Drug|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution.
79352910|NCT05892471|Drug|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
79503676|NCT04369573|Combination Product|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
79503677|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
79817792|NCT02633163|Drug|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
79817793|NCT04074915|Other|Placebo mouth rinse|Normal saline
79817794|NCT04074915|Drug|Chlorhexidine mouth rinse|Chlorhexidine gluconate
79817795|NCT04074915|Drug|Test group|Chamomile mouth rinse
79817796|NCT05673525|Device|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
79817797|NCT02579733|Drug|Azathioprine|
79817798|NCT02579733|Drug|Placebo|
79352911|NCT05892445|Behavioral|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
79352912|NCT05892367|Other|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
79352913|NCT05892354|Dietary Supplement|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
79352914|NCT05892354|Dietary Supplement|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
79352915|NCT05892328|Other|Watermelon Flesh Dose 1|1 cup watermelon flesh, ~152g, 7 days/week over a 4-week period
79503678|NCT04365868|Drug|belapectin|intravenous
79503679|NCT04365868|Drug|Placebo|intravenous
79503680|NCT04343859|Drug|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
79503681|NCT04340895|Other|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
79503682|NCT04340895|Other|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
79352916|NCT05892328|Other|Watermelon Flesh Dose 2|2 cups watermelon flesh, ~304 g, 7 days/week over a 4-week period
79665996|NCT05358158|Procedure|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
79352917|NCT05892328|Other|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
79503683|NCT04335487|Behavioral|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
79503684|NCT04335487|Behavioral|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
79503685|NCT04329676|Procedure|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
79665997|NCT05358158|Procedure|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
79665998|NCT05358158|Procedure|Standard chest drain placement|Chest drain is left in pleura.
79665999|NCT05351879|Biological|GAD-alum (Diamyd) 40 μg/mL|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
79666000|NCT05348603|Other|Traditional Letter|Patients receive a traditional letter.
79666001|NCT05348603|Other|Direct to Patient Message|Patients receive a direct to patient message via the portal.
79666002|NCT05348603|Other|Chatbot|Patients are contacted by a chatbot via the portal.
79666003|NCT05348603|Other|Banner|Patients are exposed to a banner ad via the portal.
79817799|NCT03326193|Drug|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (>=) 77 kg and Baseline platelet count of >=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (<) 77 kg and/or Baseline platelet count of <150,000/μL will take 200 mg (2X100 mg) at each dose administration.
79352918|NCT05892315|Procedure|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
79352919|NCT05892315|Procedure|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
79352920|NCT05892289|Procedure|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
79352921|NCT05892263|Other|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
79352922|NCT05892224|Procedure|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
79352923|NCT05892198|Procedure|surgery|surgery with primary closure, Rhomboid flap , or Rotational flap
79352924|NCT05892185|Device|GELA|GELA glaucoma implant
79503686|NCT04328116|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use)
79503687|NCT04308941|Diagnostic Test|Intraocular pressure|The intraocular pressure will be measured using one of three devices
79666004|NCT05340790|Drug|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
79666005|NCT05340790|Drug|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
79666006|NCT05323630|Device|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
79817800|NCT03326193|Biological|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
79352925|NCT05892185|Device|XEN|XEN gel stent implant
79352926|NCT05892146|Drug|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
79352927|NCT05892146|Drug|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
79352928|NCT05892120|Behavioral|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
79352929|NCT05892107|Procedure|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
79352930|NCT05892107|Procedure|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
79503688|NCT04294966|Drug|Dextrose|Administering dextrose to healthy volunteers for our placebo group
79503689|NCT04294966|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
79503690|NCT04294966|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
79503691|NCT04294576|Drug|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
79666007|NCT05323474|Other|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
79666008|NCT05323474|Other|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
79352931|NCT05892107|Procedure|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
79666009|NCT05321563|Behavioral|iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)|iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
79817801|NCT02517099|Drug|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
79817802|NCT02517099|Drug|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
79503692|NCT04294576|Drug|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
79503693|NCT04277546|Drug|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
79503694|NCT04277546|Drug|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
79503695|NCT04274361|Drug|Ketamine|Ketamine infusion
79503696|NCT04274361|Drug|Placebo|Placebo infusion
79503697|NCT04245215|Drug|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
79503698|NCT04218825|Drug|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
79666010|NCT05317936|Drug|Pirtobrutinib|Given by PO
79352932|NCT05892068|Drug|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
79503699|NCT04214990|Drug|Aspirin 100mg|Daily aspirin 100 mg for 5 years
79503700|NCT04214990|Drug|Placebo oral tablet|Daily placebo for 5 years
79503701|NCT04211740|Drug|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
79503702|NCT04211740|Drug|Placebo|Placebo is supplied as granules and take orally once a week.
79666011|NCT05317936|Drug|Venetoclax|GIven by PO
79817803|NCT02517099|Drug|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
79817804|NCT04073199|Procedure|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
79817805|NCT04073199|Procedure|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
79817806|NCT02473263|Drug|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
79817807|NCT02473263|Drug|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
79503703|NCT04198727|Other|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
79503704|NCT04198727|Drug|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
79503705|NCT04166864|Device|Transcranial magnetic Stimulation|Transcranial magnetic stimulation delivered at the Subject's SCC-determined frequency. Each Subject will receive 40 pulses every 26 seconds, over 75 trains.
79666012|NCT05315544|Device|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
79666013|NCT05291546|Drug|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
79666014|NCT05291546|Drug|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
79666015|NCT05291546|Other|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
79666016|NCT05285813|Drug|Vibecotamab|Given by vein (IV)
79666017|NCT05285813|Drug|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
79817808|NCT02473263|Drug|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
79352933|NCT05892055|Other|Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
79352934|NCT05892042|Drug|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
79352935|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
79352936|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
79352937|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
79503709|NCT04142632|Procedure|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
79503710|NCT04128072|Drug|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
79503711|NCT04128072|Radiation|Total Skin Electron Beam Therapy (TSEB)|"After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~Mogamulizumab is stopped during TSEB administration."
79503712|NCT04128072|Drug|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
79503713|NCT04123548|Biological|StrataGraft skin tissue|StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm^2 of treatment area using no more than 20 tissues.
79503714|NCT04101396|Dietary Supplement|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
79503715|NCT04097548|Behavioral|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
79503716|NCT04095364|Procedure|Biopsy|Undergo tumor biopsy
79352938|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
79352939|NCT05892003|Other|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
79503717|NCT04095364|Procedure|Biospecimen Collection|Undergo blood sample collection
79503718|NCT04095364|Drug|Carboplatin|Given IV
79666018|NCT05285813|Drug|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
79666019|NCT05285813|Drug|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
79666020|NCT05281809|Drug|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
79666021|NCT05280613|Behavioral|Family Check-Up|See arm/group description
79666022|NCT05280613|Behavioral|Treatment as Usual|See arm/group description
79503719|NCT04095364|Procedure|Imaging Technique|Undergo medical imaging
79352940|NCT05892003|Other|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
79352941|NCT05892003|Other|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
79503720|NCT04095364|Drug|Letrozole|Given PO
79503721|NCT04095364|Drug|Paclitaxel|Given IV
79503722|NCT04066374|Device|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
79503723|NCT04063826|Device|PET MRI|All participants will have a liver scan
79503724|NCT04061720|Behavioral|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
79503725|NCT04061720|Behavioral|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
79503726|NCT04040842|Diagnostic Test|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
79503727|NCT04022733|Drug|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
79503728|NCT04022733|Drug|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
79666023|NCT05271552|Drug|BXCL501|Sublingual Film
79666024|NCT05271552|Drug|Matching Placebo|Sublingual Placebo Film
79352942|NCT05891964|Drug|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
79666025|NCT05268224|Diagnostic Test|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
79666026|NCT05267951|Device|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
79352943|NCT05891938|Other|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
79666027|NCT05267951|Device|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
79352944|NCT05891925|Other|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~older adult id,~date, hour and time that the older adult listened to each poem,~poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
79817809|NCT02473263|Drug|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
79817810|NCT03249831|Drug|Cyclophosphamide|Orally daily
79352945|NCT05891912|Other|Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)|"The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~1 session per week: 15min small TABLET and 15min LIGHTS game.~1 session per week: 15min TABLE TABLET and 15min game of VINTAGE."
79352946|NCT05891769|Drug|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
79352947|NCT05891704|Procedure|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
79352948|NCT05891704|Procedure|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
79352949|NCT05891691|Behavioral|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
79352950|NCT05891665|Procedure|Corticotomy|A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
79666028|NCT05267951|Other|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
79679605|NCT02942199|Other|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
79679606|NCT00518453|Biological|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
79679607|NCT05318664|Other|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
79817811|NCT03249831|Drug|Pentostatin|Intravenous
79817812|NCT03249831|Drug|Rabbit anti-thymocyte globulin|Intravenous
79666029|NCT05249088|Other|Protocolised reduction of non-resuscitation fluids|"Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~Parenteral nutrition is administered according to local protocol~Intravenous medications are concentrated according to a predefined protocol~Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
79666030|NCT05249088|Other|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~Medications are concentrated according to local protocol"
79817813|NCT03249831|Drug|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
79817814|NCT03249831|Drug|Mycophenolate mofetil|IV or oral
79352951|NCT05891665|Procedure|Traditional traction of the impacted canine without corticotomy|In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
79503729|NCT03976154|Other|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
79503730|NCT03969420|Drug|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
79503731|NCT03969420|Drug|Alvocidib (flavopiridol)|Administered intravenously
79817815|NCT03249831|Biological|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
79817816|NCT03222609|Drug|Ruxolitinib|Tablet; Oral
79817817|NCT03222609|Drug|Navitoclax|Tablet; Oral
79817818|NCT02578485|Device|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
79817819|NCT02578485|Device|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
79817820|NCT02578485|Device|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
79817821|NCT02578485|Device|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
79503734|NCT03921242|Drug|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
79352952|NCT05891652|Procedure|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
79989906|NCT02754037|Radiation|Fluorodeoxyglucose (FDG) positron emission tomography (PET)|This imaging method uses radiotracers for functional analysis of liver inflammation. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
79352953|NCT05891561|Drug|Pertuzumab|4 cycles of taxane, pertuzumab, trastuzumab
79352954|NCT05891535|Procedure|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
79352955|NCT05891535|Procedure|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
79352956|NCT05891457|Combination Product|Nutritional Intervention|"Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
79352957|NCT05891444|Device|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
79352958|NCT05891444|Device|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
79503735|NCT03921242|Drug|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
79503736|NCT03921242|Drug|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
79503737|NCT03921242|Drug|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
79503738|NCT03921242|Drug|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
79503739|NCT03914443|Biological|Nivolumab|240 mg or 360 mg
79503740|NCT03914443|Drug|5-FU|750 or 800 mg^2
79503741|NCT03914443|Drug|CDDP|70 or 80 mg/m^2
79503742|NCT03914443|Drug|DTX|70 mg/m^2
79817822|NCT02578485|Device|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
79503744|NCT03875573|Drug|Durvalumab|an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
79503745|NCT03875573|Radiation|Stereotactic Body Radiotherapy|Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
79503746|NCT03875573|Drug|Oleclumab|an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
79503747|NCT03873844|Behavioral|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
79679608|NCT02942121|Other|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
79817823|NCT04074369|Diagnostic Test|CRISPR-based Test|CRISPR-based Test performed on sputum or BALF in TB suspects.
79679609|NCT02941185|Drug|Devit-3 Oral Drop|
79679610|NCT00518492|Procedure|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
79352959|NCT05890378|Other|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
79666031|NCT05245097|Device|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
79352960|NCT05890066|Procedure|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
79352961|NCT05889949|Drug|Sorafenib|oral sorafenib
79666032|NCT05235009|Diagnostic Test|Combined free GAGome MCED test|The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
79817824|NCT00437203|Drug|PF-00477736|"Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
79817825|NCT00437203|Drug|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
79817826|NCT04072653|Procedure|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
79817827|NCT00753272|Biological|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
79817828|NCT00753272|Biological|Fluarix TM|IM administration, two times one annual dose
79817829|NCT02419287|Drug|crizotinib|
79817830|NCT00437125|Drug|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
79817831|NCT03173001|Diagnostic Test|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
79817832|NCT02578407|Other|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
79817833|NCT03511027|Device|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
79817834|NCT03511027|Other|SME only|At discharge, participants will be provided with self-medication education.
79817835|NCT02578329|Behavioral|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
79352962|NCT05889949|Drug|Lenvatinib|oral lenvatinib
79352963|NCT05889858|Other|Data collection|Data collection
79352964|NCT05888987|Biological|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
79503748|NCT03873844|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
79503749|NCT03867617|Other|Regulatory T cells|Single infusion of expanded regulatory T cells.
79503750|NCT03867617|Drug|Tocilizumab|Treatment during first month post-transplant.
79503751|NCT03867617|Other|Bone marrow|Infusion of donor bone marrow cells.
79666033|NCT05228964|Device|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
79817836|NCT02578329|Behavioral|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
79817837|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
79352965|NCT05887804|Biological|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
79352966|NCT05887804|Biological|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
79352967|NCT05887804|Drug|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
79503752|NCT03867617|Procedure|Kidney transplant|Living donor kidney transplantation.
79503753|NCT03867617|Other|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
79503754|NCT03863119|Drug|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
79666034|NCT05224362|Device|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
79503755|NCT03861767|Drug|Metformin ER|tablet
79503756|NCT03861767|Drug|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
79503757|NCT03842696|Drug|Vorinostat|"HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
79503758|NCT03842696|Procedure|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
79666035|NCT05222750|Other|Pre-COVID-19|Pre-COVID-19
79817838|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
79817839|NCT02578173|Device|AVERT PLUS|
79817840|NCT01028365|Other|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
79817841|NCT04698135|Other|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
79817842|NCT04698135|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
79817843|NCT04698135|Other|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
79503759|NCT03842696|Drug|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
79989907|NCT02754037|Other|Magnetic resonance imaging (MRI)|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
79228376|NCT02235207|Behavioral|Neuromuscular exercise|"Fustra20 Neck & Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~improve movement control in different posture and movements of the neck and back~improve flexibility with active functional movements~improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
79352968|NCT05880303|Procedure|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
79503760|NCT03842696|Drug|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
79666036|NCT05222750|Other|COVID-19|COVID-19
79666037|NCT05222750|Other|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
79666038|NCT05215769|Behavioral|Health Education|Participate in a video intervention
79817844|NCT01028443|Drug|Sandimmune|
79817845|NCT01028443|Drug|Artelose|
79817846|NCT04096976|Other|logistic regression|To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
79817847|NCT03116997|Drug|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
79817848|NCT03116997|Drug|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
79989908|NCT02754037|Radiation|PET Explorer|Similar to the regular PET-Scan, this imaging method uses radiotracers to scan multiple organs of the body. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
79989909|NCT02713438|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
79352969|NCT05879952|Behavioral|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
79352970|NCT05879952|Behavioral|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
79666039|NCT05215769|Other|Questionnaire Administration|Complete questionnaires
79666040|NCT05215678|Other|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
79666041|NCT05215678|Other|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
79666042|NCT05211336|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
79666043|NCT05211336|Drug|Prednisone|Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
79666044|NCT05211336|Drug|Lenalidomide|Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
79817849|NCT02600780|Drug|Febuxostat|Comparison of two anti-hyperuricemic molecules
79817850|NCT02600780|Drug|Allopurinol|Comparison of two anti-hyperuricemic molecules
79817851|NCT00582309|Procedure|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
79666045|NCT05211336|Drug|Venetoclax|Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
79666046|NCT05211336|Drug|Ibrutinib|Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
79666047|NCT05209594|Behavioral|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
79989910|NCT02713438|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
79352971|NCT05875103|Diagnostic Test|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~naming tests : BNT 34 (Colombo & Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~vocabulary test (Mill Hill - Deltour, 1993),~repetition tests (Gremots - Bézy et al., 2016),~articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~semantic matching task adapted from the PPT (Howard & Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
79666048|NCT05209594|Behavioral|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
79666049|NCT05201183|Combination Product|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
79666050|NCT05183841|Drug|Bronchodilator (Ipratropium and Fenoterol)|8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
79666051|NCT05183841|Other|Placebo|8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
79228377|NCT05727566|Other|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
79228378|NCT03301454|Drug|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
79228379|NCT02467790|Drug|PEX168|PEX 168: 200µg,Subcutaneous,one time.
79503761|NCT03842696|Drug|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
79352972|NCT05874999|Other|Supramaximal High-Intensity Interval Training at 60% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle."
79352973|NCT05874999|Other|Moderate-Intensity Continuous Training|"MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle.~Duration MICT: 20 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
79352974|NCT05874999|Other|Supramaximal High-Intensity Interval Training at 80% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
79352975|NCT05873608|Other|Educational video|Testing an educational video
79352976|NCT05873608|Other|Interview|Participate in interview
79503762|NCT03842696|Drug|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
79666052|NCT05174221|Drug|Mezagitamab|TAK-079 subcutaneous injection.
79666053|NCT05168033|Other|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
79666054|NCT05168033|Other|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
79666055|NCT05166577|Drug|Nanatinostat|Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week
79666056|NCT05166577|Drug|Nanatinostat|Nanatinostat at the confirmed RP2D
79666057|NCT05166577|Drug|Valganciclovir|Valganciclovir starting at 900 mg orally daily
79817852|NCT00582309|Procedure|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving >80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
79352977|NCT05873608|Other|Observation|Undergo observation
79352978|NCT05873075|Other|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
79352979|NCT05867446|Behavioral|pecha kucha|pecha kucha training
79352980|NCT05842265|Other|Self acupressure|patients will do self acupressure
79352981|NCT05838209|Drug|test|Ozone oil used as an adjunctive of scaling and root planing and control,
79352982|NCT05838209|Drug|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
79352983|NCT05834972|Device|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
79503763|NCT03758625|Biological|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
79503764|NCT03758625|Biological|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
79503765|NCT03758625|Biological|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
79503766|NCT03758625|Biological|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
79503767|NCT03758625|Biological|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
79666058|NCT05166577|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
79666059|NCT05163873|Procedure|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
79817853|NCT00582309|Procedure|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
79817854|NCT00443053|Drug|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
79817855|NCT01977183|Dietary Supplement|MSPrebiotic|Potato Resistant Starch
79503768|NCT03758625|Biological|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
79666060|NCT05162404|Behavioral|Video Education Program|"The following topics are addressed in each module of the videos:~Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
79817856|NCT01977183|Dietary Supplement|Placebo|Placebo - Corn Starch
79817857|NCT00720798|Drug|Tocilizumab|For participants weighing > 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
79817858|NCT00720798|Drug|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
79817859|NCT00720798|Drug|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
79817860|NCT00720798|Drug|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
79817861|NCT01816971|Drug|dexamethasone|Given IV or PO
79352984|NCT05820737|Dietary Supplement|EF2001|One capsule to be consumed once a day
79352985|NCT05820737|Dietary Supplement|beLP1|One capsule to be consumed once a day
79503769|NCT03756298|Drug|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
79503770|NCT03756298|Drug|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
79503771|NCT03723252|Drug|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd
79666061|NCT05159934|Drug|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
79666062|NCT05159934|Drug|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
79817862|NCT01816971|Drug|carfilzomib|Given IV
79228380|NCT02235363|Procedure|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
79352986|NCT05820737|Dietary Supplement|Placebo|One capsule to be consumed once a day
79352987|NCT05809505|Diagnostic Test|360-degree Turn Test|The 360-degree turn test is a measure of dynamic balance. The person tested turns in a complete circle (360 degrees) while the time to complete and/or the number of steps to complete the turn is recorded.
79352988|NCT05809505|Other|Expanded Disability Status Scale|The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
79503772|NCT03723252|Drug|Placebo|Participants will receive placebo po qd
79666063|NCT05159518|Drug|PRT2527|PRT2527 will be administered by intravenous infusion
79666064|NCT05139316|Genetic|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
79666065|NCT05139316|Other|Placebo|Normal Saline infusion
79666066|NCT05139316|Drug|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
79666067|NCT05139316|Drug|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
79666068|NCT05127226|Drug|ION582|ION582 will be administered by IT injection.
79989911|NCT02713438|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
79352989|NCT05809505|Other|Perceived Exertion|The Borg Rating of Perceived Exertion (RPE) is a way of measuring physical activity intensity level. Perceived exertion is how hard you feel like your body is working. It is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. Although this is a subjective measure, your exertion rating based on a 6 to 20 rating scale, may provide a fairly good estimate of your actual heart rate during physical activity.
79352990|NCT05808725|Drug|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
79352991|NCT05808725|Drug|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
79352992|NCT05803798|Device|IPL+LLLT|preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
79503773|NCT03716349|Diagnostic Test|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
79503774|NCT03716349|Other|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
79352993|NCT05792540|Drug|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
79503775|NCT03716349|Drug|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
79503776|NCT03716349|Device|rubber dam|The area will be isolated with rubber dam isolation
79503777|NCT03716349|Other|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
79503778|NCT03716349|Procedure|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
79503779|NCT03716349|Procedure|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
79817863|NCT01816971|Drug|lenalidomide|Given PO
79503780|NCT03716349|Procedure|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
79817864|NCT01816971|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
79503781|NCT03716349|Other|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
79503782|NCT03716349|Procedure|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
79503783|NCT03716349|Procedure|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
79503784|NCT03716349|Other|Consent|The consent form will be signed, copy will be provided to the patient
79503785|NCT03716349|Other|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
79817865|NCT01816971|Other|laboratory biomarker analysis|Correlative studies
79352994|NCT05792540|Drug|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
79352995|NCT05792540|Drug|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
79503786|NCT03716349|Radiation|xray|When necessary a radiograph (xray) will be obtained
79503787|NCT03716349|Other|Release of medical information signed|The release of medical information form will be signed
79503788|NCT03716349|Other|Oral Exam|An Oral Exam will be completed
79503789|NCT03716349|Other|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
79503790|NCT03716349|Other|Clinical Assessment|A clinical assessment will be completed by the evaluators
79503791|NCT03716349|Device|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
79817866|NCT03995095|Other|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
79989912|NCT02713438|Behavioral|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
79989913|NCT02700620|Behavioral|Internet-delivered CBT|Guided internet treatment
79989914|NCT02664753|Drug|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~< à 60kg : 2g/day > 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
79989915|NCT02664753|Drug|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
79989916|NCT02621398|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
79989917|NCT02621398|Drug|Carboplatin|Given IV
79817867|NCT03995329|Other|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
79817868|NCT03489187|Device|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
79989918|NCT02621398|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
79989919|NCT02621398|Other|Laboratory Biomarker Analysis|Correlative studies
79989920|NCT02621398|Drug|Paclitaxel|Given IV
79989921|NCT02621398|Biological|Pembrolizumab|Given IV
79989922|NCT02609750|Other|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
79989923|NCT02609750|Other|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
79352996|NCT05788198|Other|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~empowering and engaging people and communities;~strengthening governance and accountability;~reorienting the model of care;~coordinating services within and across sectors;~creating an enabling environment."
79666069|NCT05121376|Genetic|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
79666070|NCT05121376|Genetic|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
79503792|NCT03716349|Device|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
79352997|NCT05780307|Drug|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
79352998|NCT05773573|Device|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
79352999|NCT05773573|Device|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
79353000|NCT05756010|Device|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
79353001|NCT05742412|Device|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
79666071|NCT05121376|Genetic|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
79353002|NCT05742412|Device|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
79353003|NCT05740033|Procedure|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
79817869|NCT04936893|Behavioral|Mindfulness Practice|10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks
79817870|NCT04936893|Behavioral|Cognitive training|10-15 mins of cognitive games using Lumosity, for 3 weeks
79503793|NCT03710343|Drug|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
79503794|NCT03691935|Drug|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
79503795|NCT03691935|Drug|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
79503796|NCT03686345|Drug|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
79666072|NCT05121376|Genetic|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
79666073|NCT05121376|Genetic|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
79817871|NCT01021267|Drug|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
79666074|NCT05121376|Genetic|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
79817872|NCT04072965|Other|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
79817873|NCT04072731|Other|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
79666075|NCT05121376|Genetic|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
79666076|NCT05120427|Dietary Supplement|Lipid based nutrient Supplements (LNS):|LNS are 20 g/~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
79666077|NCT05120427|Device|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
79817874|NCT03478267|Diagnostic Test|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
79817875|NCT04086420|Behavioral|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
79817876|NCT04086420|Behavioral|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
79817877|NCT00756002|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
79353004|NCT05740033|Procedure|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
79353005|NCT05729412|Other|Mentioned|If prescription is properly filled for specific details than it is compliance
79503797|NCT03677141|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
79503798|NCT03677141|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
79503799|NCT03677141|Drug|Rituxumab|Participants will receive rituxumab via IV.
79666078|NCT05108233|Other|Survey Administration|Complete survey
79666079|NCT05081076|Device|Glazing|The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain & Glaze Kit, following the manufacturer's instructions.
79666080|NCT05081076|Device|Polishing|The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
79666081|NCT05081050|Other|Only Follow-up|No intervention is planned.
79353006|NCT05701826|Drug|HRS3797|HRS3797 for injection, low dose
79989924|NCT02525029|Drug|Pregnyl®|"Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
79503800|NCT03677141|Drug|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
79989925|NCT02455479|Biological|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
79666082|NCT05078957|Other|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
79666083|NCT05078957|Other|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
79989926|NCT02455479|Biological|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
79989927|NCT02427620|Drug|Cyclophosphamide|Given IV
79989928|NCT02427620|Drug|Cytarabine|Given IV
79503801|NCT03677141|Drug|Doxorubicin|Participants will receive doxorubicin via IV.
79503802|NCT03677141|Drug|Vincristine|Participants will receive vincristine via IV.
79503803|NCT03677141|Drug|Prednisone|Participants will receive oral prednisone.
79503804|NCT03677141|Drug|Tocilizumab|Participants will receive tocilizumab via IV.
79503805|NCT03636074|Procedure|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
79666084|NCT05078957|Other|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
79666085|NCT05075382|Procedure|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
79817878|NCT00756002|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
79989929|NCT02427620|Drug|Dexamethasone|Given PO or IV
79989930|NCT02427620|Drug|Doxorubicin|Given IV
79989931|NCT02427620|Drug|Doxorubicin Hydrochloride|Given IV
79989932|NCT02427620|Drug|Ibrutinib|Given PO
79989933|NCT02427620|Other|Laboratory Biomarker Analysis|Correlative studies
79989934|NCT02427620|Drug|Methotrexate|Given IV
79817879|NCT04017403|Drug|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
79817880|NCT04017403|Drug|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
79817881|NCT00717366|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
79817882|NCT02939989|Drug|Sofosbuvir|Tablet for oral administration
79817883|NCT02939989|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
79817884|NCT02939989|Drug|Ribavirin|Tablet for oral administration
79666086|NCT05063981|Drug|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
79666087|NCT05057182|Biological|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
79817885|NCT04096742|Drug|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
79817886|NCT04096742|Other|Vehicle|Lotion not containing active ingredient (tretinoin)
79989935|NCT02427620|Biological|Rituximab|Given IV
79666088|NCT05057169|Biological|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
79666089|NCT05057169|Biological|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
79817887|NCT04085640|Other|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
79817888|NCT04085640|Other|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
79989936|NCT02427620|Drug|Vincristine|Given IV
79989937|NCT02427620|Drug|Vincristine Sulfate|Given IV
79989938|NCT02408549|Drug|Lacosamide Tablet|"Active substance: Lacosamide~Pharmaceutical form: Tablet~Concentration: 50 mg and 100 mg~Route of Administration: Oral administration"
79989939|NCT02408549|Drug|Lacosamide Oral Solution|"Active substance: Lacosamide~Pharmaceutical form: Oral solution~Concentration: 10 mg/ml~Route of Administration: Oral administration"
79989940|NCT02378558|Device|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
79353007|NCT05701826|Drug|HRS3797|HRS3797 for injection, medium dose
79989941|NCT02265601|Other|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
79666090|NCT05050942|Drug|CAM2029|CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
79666091|NCT05050942|Drug|Octreotide LAR|Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
79989942|NCT02265601|Other|standard care|paper/pencil living will form
79353008|NCT05701826|Drug|HRS3797|HRS3797 for injection, high dose
79353009|NCT05700214|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine
79666092|NCT05050942|Drug|Lanreotide ATG|Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
79989943|NCT02242942|Drug|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
79989944|NCT02242942|Drug|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
79989945|NCT02242942|Drug|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
79989946|NCT01837277|Drug|Dolutegravir 50 mg|Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
79353010|NCT05700214|Drug|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
79666093|NCT05050617|Diagnostic Test|Point-of-care echocardiography|Subjects will undergo point-of-care echocardiography at the time of presentation/enrollment to assess for evidence of right sided heart dilation/strain.
79353011|NCT05693779|Behavioral|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
79353012|NCT05676918|Behavioral|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
79353013|NCT05676918|Behavioral|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
79666094|NCT05030909|Behavioral|transdiagnostic group treatment|The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
79666095|NCT05004675|Biological|lerodalcibep|300 mg
79666096|NCT05004675|Drug|Inclisiran|284 mg
79666097|NCT05002218|Behavioral|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day.
79666098|NCT05002218|Behavioral|Balance Training|Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
79353014|NCT05623657|Other|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
79989947|NCT01837277|Drug|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
79353015|NCT05623657|Other|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
79353016|NCT05622383|Other|aromatherapy|aromatherapy,
79353017|NCT05622383|Other|music concert|music concert
79353018|NCT05622383|Other|aromatherapy and music concert,|aromatherapy and music concert,
79353019|NCT05600686|Drug|Cyclophosphamide|Given IV
79353020|NCT05600686|Drug|Doxorubicin|Given IV
79666099|NCT04998578|Device|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
79666100|NCT04996758|Drug|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
79666101|NCT04986657|Device|ChromoSeq|Novel, streamlined whole genome sequencing approach
79989948|NCT01827605|Other|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
79353021|NCT05600686|Drug|Etoposide|Given IV
79989949|NCT01827605|Drug|BEAM|"BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc"
79989950|NCT01778647|Dietary Supplement|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
79989951|NCT01778647|Drug|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
79353022|NCT05600686|Biological|Loncastuximab Tesirine|Given IV
79353023|NCT05600686|Drug|Prednisone|Given PO
79353024|NCT05600686|Biological|Rituximab|Given IV
79503806|NCT03617679|Drug|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
79666102|NCT04977414|Behavioral|Making Data Count Training intervention|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
79353025|NCT05600686|Drug|Vincristine|Given IV
79353026|NCT05581082|Other|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
79353027|NCT05564338|Drug|Sitravatinib|Administered orally
79503807|NCT03617679|Drug|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
79503808|NCT03616821|Drug|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
79353028|NCT05564338|Drug|Tislelizumab|Administered intravenously
79353029|NCT05564338|Drug|sitravatinib-matching placebo|administered orally
79353030|NCT05564338|Drug|tislelizumab-matching placebo|administered intravenously
79353031|NCT05550818|Other|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
79353032|NCT05550818|Other|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
79353033|NCT05536284|Drug|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
79353034|NCT05534386|Behavioral|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
79503809|NCT03616821|Drug|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
79989952|NCT01658878|Biological|Nivolumab|
79666103|NCT04974567|Other|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
79666104|NCT04969874|Other|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
79666105|NCT04965246|Behavioral|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
79666106|NCT04965246|Other|Usual Care|Participants in the usual care group will receive no intervention
79666107|NCT04959331|Drug|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
79666108|NCT04959331|Drug|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
79666109|NCT04959331|Drug|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
79989953|NCT01658878|Drug|Sorafenib|
79353035|NCT05534386|Behavioral|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
79353036|NCT05534386|Behavioral|First stage control intervention|A set of skill-based pamphlets will be given.
79353037|NCT05534386|Behavioral|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
79353038|NCT05527756|Other|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
79353039|NCT05527756|Other|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
79353040|NCT05514210|Behavioral|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
79503810|NCT03602092|Other|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
79666110|NCT04959331|Drug|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
79989954|NCT01658878|Drug|Ipilimumab|
79989955|NCT01658878|Drug|Cabozantinib|
79989956|NCT01628406|Procedure|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
79989957|NCT01624285|Drug|sorafenib tosylate|Given PO
79989958|NCT01624285|Other|placebo|Given PO
79989959|NCT01624285|Other|laboratory biomarker analysis|Correlative studies
79989960|NCT01523002|Drug|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
79353041|NCT05503446|Other|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
79503811|NCT03593915|Combination Product|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
79503812|NCT03572634|Drug|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
79503813|NCT03572634|Combination Product|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
79503814|NCT03541850|Drug|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
79503815|NCT03541850|Other|Quality-of-Life Assessment|Ancillary studies
79503816|NCT03541850|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79353042|NCT05497921|Device|handLITE LED device|handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
79353043|NCT05445674|Combination Product|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
79353044|NCT05445674|Other|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
79817889|NCT02600858|Behavioral|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
79817890|NCT03994315|Other|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
79817891|NCT03994315|Other|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
79353045|NCT05441137|Behavioral|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
79353046|NCT05441137|Behavioral|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
79666111|NCT04948775|Other|Cervical stabilization exercises|A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
79666112|NCT04916951|Drug|Amoxicillin|oral one-time dose of amoxicillin
79989961|NCT01523002|Drug|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
79989962|NCT01491269|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
79503817|NCT03535272|Drug|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
79503818|NCT03535272|Drug|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
79503819|NCT03517137|Drug|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
79503820|NCT03517137|Drug|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
79503821|NCT03517137|Drug|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
79666113|NCT04916951|Drug|Cephalexin|oral one-time dose of cephalexin
79666114|NCT04912076|Drug|BM41|Subcutaneous injection of increasing doses of BM41
79989963|NCT01471106|Drug|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
79989964|NCT01431807|Drug|SYR-472|oral, for up to 52 weeks.
79666115|NCT04912076|Other|Placebo|Subcutaneous injections of placebo containing aluminium hydroxide.
79666116|NCT04912076|Drug|ALK Alutard SQ Betula verrucosa|Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
79817892|NCT02590926|Procedure|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
79817893|NCT04100642|Drug|Hemay808|topical apply
79817894|NCT04100642|Drug|Placebo|topical apply
79817895|NCT01031719|Biological|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
79817896|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
79817897|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
79989965|NCT01402258|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
79817898|NCT00723606|Drug|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
79989966|NCT00493792|Device|Stryker X3 crosslink|Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
79989967|NCT00489307|Drug|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
79353047|NCT05440123|Other|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
79353048|NCT05437393|Device|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
79353049|NCT05435612|Device|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
79503822|NCT03517137|Drug|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
79503823|NCT03517137|Drug|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
79503824|NCT03517137|Drug|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
79503825|NCT03517137|Radiation|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
79503826|NCT03511534|Behavioral|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
79989968|NCT00489307|Drug|Placebo|Placebo PO twice daily x 14 days
79503827|NCT03511534|Other|Pharmacotherapy|Pharmacotherapy by a psychiatrist
79989969|NCT00349310|Drug|Pramipexole|
79989970|NCT00267917|Device|Berodual Respimat|
79989971|NCT00267917|Device|Berodual HFA-MDI|
79989972|NCT00171002|Drug|valsartan/amlodipine|
79989973|NCT00154323|Drug|Oxcarbazepine|
79989974|NCT03521141|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
79503828|NCT03500081|Device|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
79666117|NCT04898413|Behavioral|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
79817899|NCT00723606|Drug|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
79989975|NCT03521141|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
79989976|NCT03521141|Genetic|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
79817900|NCT01028521|Drug|CM3.1-AC100|Solution for sc injection, single ascending doses
79817901|NCT01028521|Drug|Placebo|Solution for sc injection
79353050|NCT05429099|Procedure|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
79817902|NCT01021501|Drug|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
79817903|NCT01028599|Other|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
79503831|NCT03456336|Other|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
79989977|NCT03521141|Genetic|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
79989978|NCT03521141|Behavioral|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
79503832|NCT03456336|Other|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
79503833|NCT03452007|Device|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of [5-6-5]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
79503834|NCT03442309|Device|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
79503835|NCT03442309|Device|Fluoride Varnishes|Fluoride varnish (FV)
79503836|NCT03442309|Device|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
79503837|NCT03396809|Device|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
79666118|NCT04898413|Behavioral|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
79666119|NCT04897269|Procedure|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
79666120|NCT04891419|Device|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
79817904|NCT04009057|Other|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
79353051|NCT05429099|Procedure|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
79353052|NCT05424198|Procedure|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
79353053|NCT05409391|Device|Insulin Titration System|A noval insulin titration system, which is based on deep learning
79503838|NCT03384836|Other|Laboratory Biomarker Analysis|Correlative studies
79503839|NCT03384836|Biological|Pembrolizumab|Given IV
79503840|NCT03384836|Drug|Propranolol Hydrochloride|Given PO
79503841|NCT03336333|Drug|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
79503842|NCT03336333|Drug|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m^2/day on the first 2 days of each cycle for 6 cycles.
79503843|NCT03336333|Drug|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m^2 on day 0 of cycle 1, and at a dose of 500 mg/m^2 on day 1 of cycles 2 to 6
79503844|NCT03336333|Drug|Venetoclax|400 mg tablets administered orally once daily.
79503845|NCT03329521|Other|Multicomponent intervention|Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
79666121|NCT04881565|Other|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
79666122|NCT04865289|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
79817905|NCT04005001|Other|HindSight|HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.
79817906|NCT04005001|Other|InSight|Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
79817907|NCT01021579|Drug|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
79817908|NCT01021579|Drug|Metfomin plus Simvastatin|
79503846|NCT03298737|Behavioral|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
79503847|NCT03283449|Drug|18F-AV-1451|
79503848|NCT03283449|Device|PET|PET scanner for brain imaging
79503849|NCT03250767|Device|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
79503850|NCT03240874|Behavioral|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
79666123|NCT04865289|Biological|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
79666124|NCT04865289|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
79666125|NCT04865289|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
79666126|NCT04852302|Behavioral|CALM Therapy|The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
79666127|NCT04848506|Drug|CK-3773274 (5 - 20 mg)|CK-3773274 tablets administered orally
79666128|NCT04832724|Genetic|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
79666129|NCT04832087|Drug|Teduglutide|Standard of care Teduglutide dosing
79817909|NCT01031875|Drug|pazopanib hydrochloride|
79353054|NCT05395819|Procedure|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
79353055|NCT05395819|Procedure|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
79353056|NCT05395364|Behavioral|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
79353057|NCT05383911|Behavioral|Shared Decision Making Intervention|We are currently developing a shared decision making intervention for AYAs with SCD to provide decision supports for disease-modifying therapies. As the intervention is currently in development, additional details will be provided once development and usability testing phases have been completed.
79353058|NCT05381454|Drug|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
79353059|NCT05368428|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
79666130|NCT04828018|Other|Coffee Morning|Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
79666131|NCT04828018|Other|Recruitment Leaflets|Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
79817910|NCT01031875|Radiation|fludeoxyglucose F 18|
79817911|NCT01021657|Procedure|trabeculectomies, non penetrating deep sclerectomies|
79503851|NCT03240874|Behavioral|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
79666132|NCT04828018|Other|Consent Form completion|All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
79666133|NCT04828018|Other|Participant Information Sheet|All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
79666134|NCT04828018|Other|New In-Pensioner Resident Information Pack|New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
79353060|NCT05367063|Drug|Canagliflozin 100mg or Sitagliptin 100mg|70 eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
79353061|NCT05364242|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
79353062|NCT05360771|Device|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
79353063|NCT05360771|Device|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
79353064|NCT05358548|Drug|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
79353065|NCT05358548|Drug|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
79817912|NCT01021735|Drug|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
79817913|NCT01021735|Drug|Rituximab|1g x2 by IV infusion repeated every 5 months or more
79817914|NCT03378271|Device|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
79353066|NCT05358548|Drug|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
79353067|NCT05358548|Drug|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
79353068|NCT05358548|Drug|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
79989979|NCT03728621|Behavioral|Normocaloric and balanced diet, physical activity|Promotion of normocaloric & balanced diet and physical activity
79503852|NCT03240874|Behavioral|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
79503853|NCT03240068|Drug|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
79989980|NCT03722147|Biological|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
79666135|NCT04828018|Other|Key Staff Interviews|Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
79989981|NCT03722069|Other|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
79989982|NCT03722069|Other|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
79989983|NCT03725267|Drug|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
79989984|NCT03725267|Drug|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
79666136|NCT04828018|Other|In-Pensioner Resident Interviews|In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
79989985|NCT02997176|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
79989986|NCT03000452|Drug|DARATUMUMAB|DARATUMUMAB
79989987|NCT03000452|Drug|DURVALUMAB|DURVALUMAB
79353069|NCT05348564|Behavioral|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
79353070|NCT05346250|Behavioral|Non-exercise control|12 month lifestyle education
79817915|NCT00442351|Drug|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
79989988|NCT03664856|Other|interview|The patient will be asked to answer the questions that the interviewer will ask him.
79989989|NCT03664388|Drug|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
79989990|NCT03664310|Other|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
79353071|NCT05346250|Behavioral|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
79353072|NCT05346250|Behavioral|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
79353073|NCT05343364|Drug|Vonoprazan|Oral Tablet
79353074|NCT05342038|Device|T-02|Stent retriever
79353075|NCT05329415|Diagnostic Test|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
79989991|NCT03664310|Other|Control|Physical health control
79989992|NCT04056416|Device|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
79989993|NCT03663686|Drug|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
79989994|NCT01373164|Drug|Galunisertib|Administered orally
79989995|NCT01373164|Drug|Gemcitabine|Administered intravenously
79989996|NCT01373164|Drug|Placebo|Administered orally
79989997|NCT04349332|Device|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate <30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
79989998|NCT02999984|Genetic|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
79503854|NCT03240068|Drug|Saline|Normal saline will be used as the placebo comparator.
79353076|NCT05308238|Behavioral|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
79503855|NCT03229057|Drug|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
79503856|NCT03229057|Drug|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
79503857|NCT03229057|Drug|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
79503858|NCT03136445|Drug|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
79503859|NCT03136445|Drug|Placebo|IV (saline) or oral placebo tablets
79503860|NCT03121469|Device|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
79503861|NCT03089554|Drug|Therapeutic Intervention|Therapeutic Intervention
79503862|NCT03083665|Drug|Placebo|"Pharmaceutical form: Film-coated tablets~Route of administration: Oral use"
79666137|NCT04828018|Other|ICECAP-A Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
79666138|NCT04828018|Other|WHOQOL-BREF Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
79817916|NCT00442351|Other|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
79817917|NCT00436501|Drug|docetaxel|25 mg/m^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
79989999|NCT02999984|Drug|busulfan|Busulfan is used for non-myeloablative conditioning
79353077|NCT05308238|Behavioral|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
79503863|NCT03083665|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 25 mg tablets and 50 mg tablets~Route of administration: Oral use"
79503864|NCT03070184|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
79503865|NCT03070184|Dietary Supplement|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
79503866|NCT03070184|Other|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
79503867|NCT03070184|Drug|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
79503868|NCT03059030|Device|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
79503869|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
79503870|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
79503871|NCT03033342|Drug|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
79503872|NCT03033342|Drug|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
79990000|NCT02999984|Drug|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
79503873|NCT03033342|Drug|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
79503874|NCT03033342|Drug|Oral single doses of placebo|Single doses of placebo to match MRX-4
79503875|NCT03033342|Drug|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
79503876|NCT03033342|Drug|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
79990001|NCT03664154|Behavioral|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
79990002|NCT03664700|Device|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
79990003|NCT03550313|Biological|Multivalent|Pneumococcal conjugate vaccine
79353078|NCT05299671|Behavioral|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
79503877|NCT02958670|Other|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
79503878|NCT02957968|Drug|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
79503879|NCT02957968|Drug|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
79503880|NCT02957968|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
79503881|NCT02957968|Drug|Carboplatin|carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
79503882|NCT02957968|Drug|Decitabine|Given IV
79353079|NCT05288972|Device|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
79353080|NCT05288972|Device|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
79503883|NCT02957968|Drug|Pembrolizumab|Given IV
79503884|NCT02889653|Drug|Any oral antithrombotics (antiplatelets or anticoagulants)|
79503885|NCT02819518|Biological|Pembrolizumab|IV infusion
79503886|NCT02819518|Drug|Nab-paclitaxel|IV infusion
79503887|NCT02819518|Drug|Paclitaxel|IV infusion
79503888|NCT02819518|Drug|Gemcitabine|IV infusion
79503889|NCT02819518|Drug|Carboplatin|IV infusion
79503890|NCT02819518|Drug|Normale Saline Solution|IV infusion
79503891|NCT02786277|Other|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
79503892|NCT02759133|Device|Metal wire|Localization technique for breast surgery using metal wire
79503893|NCT02759133|Device|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
79503894|NCT02718066|Drug|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
79666139|NCT04820283|Behavioral|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
79666140|NCT04820283|Behavioral|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
79503895|NCT02661022|Drug|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
79503896|NCT02661022|Drug|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
79666141|NCT04818060|Other|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
79990004|NCT03550313|Biological|Prevnar 13|Pneumococcal conjugate vaccine
79990005|NCT03312907|Drug|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
79990006|NCT03312907|Drug|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
79990007|NCT03312907|Drug|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
79353081|NCT05281666|Device|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
79666142|NCT04818060|Diagnostic Test|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
79666143|NCT04818060|Diagnostic Test|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
79990008|NCT03312907|Drug|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
79990009|NCT03312907|Drug|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to <= 5 mg/day will administered through Week 104.
79990010|NCT03312907|Drug|Steroid Taper|Steroid taper will include prednisone doses equivalent to =< 5 mg/day in all Arms through Week 104.
79990011|NCT02999672|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
79503897|NCT02616796|Behavioral|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
79503898|NCT02599363|Drug|Ribociclib (LEE011)|
79817918|NCT00436501|Biological|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
79817919|NCT00436501|Other|laboratory biomarker analysis|Correlative studies
79503899|NCT02599363|Drug|Paclitaxel|
79817920|NCT00436501|Other|pharmacological study|Correlative studies
79990012|NCT03664076|Diagnostic Test|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
79990013|NCT03664622|Drug|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
79503900|NCT02578797|Drug|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
79817921|NCT00755846|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
79503901|NCT02505750|Radiation|3D conformal EBRT|External Beam Radiation Therapy
79353082|NCT05281666|Device|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
79503902|NCT02505750|Device|Contact X-ray brachytherapy 50 kV|
79503903|NCT02505750|Drug|Capecitabine|
79503904|NCT02503709|Drug|CDK Inhibitor AT7519|Given IV
79503905|NCT02503709|Other|Laboratory Biomarker Analysis|Correlative studies
79503906|NCT02503709|Drug|Onalespib|Given IV
79503907|NCT02503709|Other|Pharmacological Study|Correlative studies
79503908|NCT02475681|Drug|Acalabrutinib|
79666144|NCT04806893|Drug|lerodalcibep|300 mg subcutaneous injection every month (Q4W)
79666145|NCT04806893|Other|Placebo|matching subcutaneous injection every month (Q4W)
79503909|NCT02475681|Drug|Obinutuzumab|
79503910|NCT02475681|Drug|Chlorambucil|
79353083|NCT05276739|Behavioral|Bright Light|6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
79353084|NCT05276739|Behavioral|Time-restricted eating|6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.
79353085|NCT05276739|Behavioral|Dim light|dim light (<3 lux) throughout the 16-hour wake episode
79353086|NCT05276739|Behavioral|12-h meal window|12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
79503911|NCT02464046|Drug|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
79503912|NCT02464046|Drug|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
79503913|NCT02413736|Drug|Imatinib|Imatinib 400 mg/day
79666146|NCT04799912|Procedure|Elective labor induction|Elective labor induction at 39 weeks of gestation
79817922|NCT00755846|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
79353087|NCT05275803|Dietary Supplement|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
79353088|NCT05275803|Dietary Supplement|Control|The participant does not use probiotics after non-surgical periodontal treatment.
79503914|NCT02407119|Drug|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
79503915|NCT02407119|Drug|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
79503916|NCT02369406|Drug|Nevirapine|
79503917|NCT02369406|Drug|Kaletra|
79503918|NCT02369406|Drug|Lamivudine|
79503919|NCT02369406|Drug|Zidovudine|
79503920|NCT02251665|Other|No intervention|a single-center prospective observational study
79666147|NCT04797247|Drug|lerodalcibep|PCSK9 inhibitor
79666148|NCT04797104|Drug|lerodalcibep|300 mg Q4W
79817923|NCT00755846|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
79817924|NCT00755846|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
79817925|NCT00755846|Drug|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
79817926|NCT00755846|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
79817927|NCT03850093|Drug|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
79353089|NCT05274477|Drug|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
79817928|NCT03850093|Drug|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
79817929|NCT03850093|Drug|placebo|patients received oral placebo 2 hrs preoperative
79353090|NCT05274477|Drug|Placebo|no active component
79353091|NCT05274282|Other|Animation Therapy|Stop-motion movie shooting process designed for improving attention skill and regulating hyperactive and impulsive behaviours.
79353092|NCT05268016|Drug|ME3183|ME3183 capsule
79353093|NCT05268016|Drug|Placebo|Placebo capsule
79353094|NCT05262556|Drug|NP-101 (TQ Formula)|Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
79817930|NCT00442117|Drug|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
79503921|NCT02232126|Other|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
79353095|NCT05262556|Drug|Nivolumab (3mg/kg)|Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
79353096|NCT05262556|Drug|Ipilimumab (1mg/kg)|Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
79353097|NCT05261503|Other|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
79353098|NCT05261503|Other|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
79990014|NCT03664622|Drug|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
79353099|NCT05244070|Drug|BMS-986403|Specified dose on specified days
79990015|NCT05276869|Other|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create [10].
79990016|NCT01911676|Drug|PF-03463275|
79503922|NCT02127073|Drug|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
79503923|NCT02112214|Drug|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
79503924|NCT02112214|Other|Placebo|Placebo for bismuth-based quadruple therapy
79503925|NCT02095808|Procedure|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
79817931|NCT00442117|Drug|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
79990017|NCT01911676|Drug|Placebo|
79990018|NCT03663998|Biological|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
79353100|NCT05244070|Drug|Fludarabine|Specified dose on specified days
79353101|NCT05244070|Drug|Cyclophosphamide|Specified dose on specified days
79353102|NCT05236777|Drug|Natalizumab|Administered as specified in the treatment arm.
79353103|NCT05231473|Other|Nurse Enhanced Recovery After Surgery participation|Bellvitge University Hospital will include the NEC participation along Enhanced Recovery After Surgery program.
79353104|NCT05222607|Drug|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
79353105|NCT05201833|Behavioral|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
79353106|NCT05201833|Behavioral|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
79353107|NCT05201833|Procedure|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
79353108|NCT05201833|Procedure|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
79353109|NCT05177354|Device|Inceptiv|Implantable Neurostimulator with Neuro Sense
79817932|NCT04096508|Behavioral|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
79817933|NCT04096352|Behavioral|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
79990019|NCT03663998|Biological|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
79353113|NCT05156164|Device|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
79353114|NCT05156164|Device|Control Group|KT application on the deltoid but without support function
79503926|NCT02078544|Other|Integrated Molecular Analysis|
79503927|NCT02074267|Drug|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
79503928|NCT02074267|Drug|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
79503929|NCT01905813|Drug|INCB040093|Escalating doses starting at 100 mg every day (QD)
79990020|NCT01793233|Other|Laboratory Biomarker Analysis|Correlative studies
79990021|NCT01793233|Other|Questionnaire Administration|Ancillary studies
79990022|NCT03113734|Other|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
79817934|NCT04096352|Behavioral|Indirect Method|Information on voice function and voice hygiene.
79817935|NCT02600702|Other|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
79817936|NCT02600702|Other|Physical modalities|
79990023|NCT04051658|Device|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
79990024|NCT05276713|Drug|Tucidinostat|Tucidinostat in combination with endocrine drugs
79353115|NCT05155761|Device|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
79817937|NCT01796145|Other|Fibroscan|
79990025|NCT05276635|Behavioral|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
79990026|NCT05276635|Behavioral|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
79990027|NCT04056182|Drug|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
79990028|NCT03573323|Drug|Ixekizumab|Administered SC
79990029|NCT03573323|Drug|Guselkumab|Administered SC
79990030|NCT03573323|Drug|Placebo|Administered SC
79353116|NCT05145426|Device|Low Intensity Focused Ultrasound|Application of LIFU
79353118|NCT05129891|Drug|Semaglutide D|Tablet given orally
79353119|NCT05129891|Drug|Semaglutide G|Tablet given orally
79353120|NCT05129891|Drug|Semaglutide H|Tablet given orally
79353121|NCT05129891|Drug|Semaglutide I|Tablet given orally
79353122|NCT05129891|Drug|NNC0385-0434 B|Tablet given orally
79990031|NCT01895842|Drug|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
79990032|NCT04058054|Device|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
79990033|NCT04058054|Device|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
79353123|NCT05129891|Drug|NNC0385-0434 C|Tablet given orally
79353124|NCT05129891|Drug|NNC0385-0434 D|Tablet given orally
79353125|NCT05129891|Drug|NNC0385-0434 E|Tablet given orally
79503930|NCT01905813|Drug|INCB040093|INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
79990034|NCT04058054|Device|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
79990035|NCT04058054|Drug|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
79503931|NCT01905813|Drug|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
79990036|NCT04058054|Drug|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
79503932|NCT01901562|Device|Ductoscopic papillectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
79817938|NCT04095962|Other|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine [18] and the WHO [19].
79817939|NCT03070119|Drug|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
79817940|NCT04095884|Procedure|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
79353126|NCT05120466|Behavioral|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
79353127|NCT05120466|Behavioral|Usual health education curriculum|The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
79353128|NCT05096117|Drug|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
79353129|NCT05096117|Drug|Placebo|1 x per day for 6 weeks
79353130|NCT05083130|Behavioral|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
79353131|NCT05072093|Behavioral|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
79353132|NCT05072093|Drug|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
79353133|NCT05072093|Drug|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
79503933|NCT01678027|Drug|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
79503934|NCT01678027|Drug|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
79503935|NCT01658670|Behavioral|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
79503936|NCT01658670|Behavioral|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
79503937|NCT01121588|Drug|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
79503938|NCT00930319|Other|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
79503939|NCT00819247|Drug|Degarelix|Given as a subcutaneous injection.
79503940|NCT00739986|Drug|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
79503941|NCT00739986|Drug|Semapimod|Semapimod 60 mg IV x 3 days
79503942|NCT00739986|Drug|Placebo|placebo IV x 3 days
79503943|NCT00716976|Drug|sodium thiosulfate|Given IV
79503944|NCT00716976|Procedure|examination|Patients undergo audiological assessments periodically
79503945|NCT00634634|Drug|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
79503946|NCT00634634|Drug|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
79503947|NCT00509353|Drug|irinotecan hydrochloride|
79503948|NCT00509353|Drug|vincristine sulfate|
79503949|NCT00509353|Radiation|iobenguane I 131|
79353134|NCT05072093|Drug|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
79503950|NCT00271934|Biological|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
79817941|NCT02578017|Behavioral|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
79353135|NCT05065840|Behavioral|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
79503951|NCT00049595|Biological|bleomycin sulfate|
79503952|NCT00049595|Biological|filgrastim|
79503953|NCT00049595|Biological|pegfilgrastim|
79503954|NCT00049595|Drug|ABVD regimen|
79503955|NCT00049595|Drug|BEACOPP regimen|
79503956|NCT00049595|Drug|cyclophosphamide|
79503957|NCT00049595|Drug|dacarbazine|
79503958|NCT00049595|Drug|doxorubicin hydrochloride|
79503959|NCT00049595|Drug|etoposide|
79503960|NCT00049595|Drug|prednisone|
79503961|NCT00049595|Drug|procarbazine hydrochloride|
79503962|NCT00049595|Drug|vinblastine sulfate|
79503963|NCT00049595|Drug|vincristine sulfate|
79990037|NCT03306043|Drug|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
79817942|NCT03917355|Behavioral|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
79353136|NCT05057273|Drug|BT-11|Oral once daily tablet
79353137|NCT05057273|Drug|Active comparator|Biologic
79503964|NCT03578796|Diagnostic Test|ECAS-N|assessing ALS-specific cognitive impairment
79666149|NCT04783402|Other|e-OTCAT program|"The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions."
79666150|NCT04783402|Other|Educational handbook and standard care|At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
79666151|NCT04783155|Device|POWERBreathe Plus®|Commercially available pressure-threshold device
79666152|NCT04783155|Other|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
79990038|NCT01728220|Combination Product|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
79990039|NCT01728220|Combination Product|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
79990040|NCT04057430|Device|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
79990041|NCT04057430|Device|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
79990042|NCT04498286|Diagnostic Test|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
79666153|NCT04782752|Radiation|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
79666154|NCT04780568|Drug|Osimertinib|Given PO
79990043|NCT01313533|Drug|Polyarginine|Vein soak treated with polyarginine
79990044|NCT01313533|Drug|Vein soak treated with Lactated Ringers Solution|Vein soak
79353138|NCT05049733|Drug|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
79353139|NCT05049733|Drug|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
79353140|NCT05049733|Drug|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
79990045|NCT03663842|Other|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
79990046|NCT03725189|Device|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
79990047|NCT04479904|Drug|Famitinib|po
79990048|NCT03725111|Device|venous compression|venous compression
79353141|NCT05049733|Drug|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
79353142|NCT05047718|Biological|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
79353143|NCT05047718|Biological|COVID-19 vaccine Pfizer (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
79353144|NCT05047718|Biological|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
79503965|NCT03578796|Diagnostic Test|MoCA|assessing cognitive impairment
79503966|NCT03578796|Diagnostic Test|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
79503967|NCT03578796|Other|Questionnaire|Questions related to work situation and car driving
79990049|NCT01069172|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
79817943|NCT03014817|Procedure|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
79817944|NCT03014817|Procedure|Electrocautery|Dissection with electrocautery
79990050|NCT01069172|Procedure|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
79990051|NCT03724955|Drug|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
79353145|NCT05047718|Biological|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
79353146|NCT05027633|Drug|Pembrolizumab|given by IV
79353147|NCT05027633|Drug|Docetaxel|given by IV
79353148|NCT05027633|Drug|Cisplatin|given by IV
79503968|NCT03668106|Procedure|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
79666155|NCT04780568|Drug|Tegavivint|Given IV
79817945|NCT00752726|Drug|Orlistat|Weight loss treatment
79817946|NCT00752726|Drug|Placebo|Inactive
79990052|NCT03724955|Other|Placebo|The placebo group will receive placebo oral daily for 6 months
79990053|NCT04220008|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
79353149|NCT05027633|Drug|Carboplatin|given by IV
79666156|NCT04773873|Device|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
79817947|NCT03012243|Procedure|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
79817948|NCT03012243|Procedure|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
79990054|NCT04220008|Drug|Busulfan|Given IV
79990055|NCT04220008|Drug|Clofarabine|Given IV
79353150|NCT04993183|Behavioral|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
79817949|NCT03918525|Other|Sindhi families|It is an observational study and no intervention is involved
79817950|NCT04093544|Device|Deep brain stimulation|Steered stimulation using directional leads
79990056|NCT04220008|Drug|Cyclophosphamide|Given IV
79990057|NCT04220008|Drug|Gemcitabine|Given IV
79353151|NCT04983108|Other|No Intervention|No intervention. This is an observational Study
79503969|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
79503970|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
79503971|NCT03575052|Drug|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
79503972|NCT03575052|Drug|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
79990058|NCT04220008|Drug|Mycophenolate Mofetil|Given IV
79990059|NCT04220008|Biological|Rituximab|Given IV
79990060|NCT04220008|Drug|Tacrolimus|Given IV
79990061|NCT04220008|Drug|Vorinostat|Given PO
79990062|NCT03721991|Dietary Supplement|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
79990063|NCT03721991|Dietary Supplement|placebo|matching placebo
79990064|NCT02911688|Drug|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
79503973|NCT03574896|Other|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
79990065|NCT02911688|Drug|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
79990066|NCT05580250|Drug|LY3526318|Administered orally.
79503974|NCT04762056|Other|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
79353152|NCT04975893|Biological|mRNA-1647|No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
79353153|NCT04975893|Other|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
79353154|NCT04966559|Drug|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
79353155|NCT04966559|Drug|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
79503975|NCT04761900|Diagnostic Test|the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases|
79503976|NCT03804528|Behavioral|Aerobic Exercise|Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session.
79503977|NCT03556020|Drug|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
79503978|NCT03570918|Biological|MGD014|HIV-1 x CD3 bispecific DART molecule
79503979|NCT05347524|Other|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
79503980|NCT01677546|Device|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
79990067|NCT05580250|Drug|Placebo|Administered orally.
79503981|NCT01677546|Device|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
79990068|NCT05580250|Drug|Iohexol|Administered intravenously (IV).
79503982|NCT04403724|Drug|Bupivacaine-fentanyl-Morphine.|2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
79990069|NCT05580250|Drug|Simvastatin|Administered orally.
79990070|NCT05580250|Drug|Metformin|Administered orally.
79990071|NCT03663374|Drug|Odelepan|Tablets, 125 mg
79353156|NCT04954820|Drug|Lutathera|2 additional infusions of Lutathera®
79353157|NCT04936529|Dietary Supplement|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
79353158|NCT04936529|Drug|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
79353159|NCT04936529|Biological|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
79353160|NCT04920253|Device|Study Device Debridement|debritom+ water jet debridement
79353161|NCT04920253|Device|SOC Debridement|Sharp Scalpel
79503983|NCT04403646|Dietary Supplement|ARBOX|dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
79990072|NCT03663374|Drug|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
79990073|NCT03431948|Drug|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
79990074|NCT03431948|Drug|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
79990075|NCT03431948|Drug|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
79990076|NCT03431948|Radiation|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
79990077|NCT02670928|Behavioral|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
79990078|NCT03662516|Drug|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
79990079|NCT03662516|Drug|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
79990080|NCT04978168|Behavioral|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
79990081|NCT04978168|Behavioral|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 12 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
79990082|NCT04978168|Behavioral|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
79503984|NCT04403646|Other|PLACEBO|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
79817951|NCT02600000|Radiation|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
79817952|NCT02600000|Device|Cardiopulmonary test|Assessment of maximal functional capacity
79990083|NCT04057508|Other|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
79817953|NCT02600000|Device|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
79817954|NCT02600000|Device|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
79990084|NCT04887077|Device|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
79990085|NCT04887077|Behavioral|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
79990086|NCT03663062|Diagnostic Test|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
79990087|NCT03728543|Drug|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
79990088|NCT03728465|Biological|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
79503985|NCT04403568|Drug|Ursolic Acid|Ursolic Acid 150mg
79503986|NCT04403568|Drug|Curcumin|Curcumin 600mg
79503987|NCT03552822|Other|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
79503988|NCT03551028|Device|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
79503989|NCT03547986|Diagnostic Test|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
79503990|NCT03547986|Diagnostic Test|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
79503991|NCT03546738|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
79503992|NCT03546738|Procedure|Sham spinal cord stimulation|No spinal cord stimulation is provided
79503993|NCT03546738|Device|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
79503994|NCT03564756|Dietary Supplement|Vitamin C|1000mg Vitamin C per day
79503995|NCT03561246|Other|Incline treadmill walking|Those with a Pp 0.47 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
79503996|NCT03561246|Other|Decline treadmill walking|Those with a Pp 0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
79503997|NCT03462966|Drug|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
79817955|NCT04072263|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
79817956|NCT04072263|Drug|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
79990089|NCT03728465|Biological|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
79990090|NCT03728387|Other|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
79503998|NCT03462654|Behavioral|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
79503999|NCT03462654|Behavioral|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
79504000|NCT01678872|Drug|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
79666157|NCT04773873|Device|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
79990091|NCT03662984|Drug|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
79990092|NCT03662984|Drug|Placebo Oral Tablet|To compare ciprofibrate
79353162|NCT04907643|Device|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
79504001|NCT03535818|Procedure|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
79504002|NCT03794700|Other|Hospice Decision Aids|Paper and video hospice decision aid
79990093|NCT03724799|Device|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
79990094|NCT03728231|Other|Complete blood count|taking blood sample from venous blood
79990095|NCT03724721|Procedure|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
79990096|NCT03305809|Drug|LY3154207|Administered orally.
79666158|NCT04773873|Device|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
79817957|NCT04072263|Drug|Carboplatin|chemotherapy i.v.
79817958|NCT04072263|Drug|Paclitaxel|Chemotherapy i.v.
79817959|NCT00755222|Biological|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
79990097|NCT03305809|Drug|Placebo|Administered orally.
79990098|NCT02994056|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79990099|NCT02994056|Drug|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
79990100|NCT03728153|Drug|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
79353163|NCT04898621|Dietary Supplement|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
79353164|NCT04898621|Dietary Supplement|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
79353165|NCT04860752|Device|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
79353166|NCT04851613|Drug|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
79353167|NCT04835168|Drug|BT-11 low|Oral
79353168|NCT04835168|Drug|BT-11 high|Oral
79353169|NCT04835168|Drug|Placebo|Oral
79504003|NCT04403412|Procedure|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
79504004|NCT04403412|Procedure|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
79504005|NCT04403412|Procedure|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
79504006|NCT03458676|Procedure|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
79504007|NCT03458676|Procedure|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
79504008|NCT03458598|Procedure|Rectus sheath block|Rectus sheath block under ultrasound
79504009|NCT03458598|Procedure|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
79504010|NCT03458598|Drug|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
79817960|NCT00755222|Biological|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
79817961|NCT02956239|Procedure|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
79817962|NCT02956239|Procedure|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
79353170|NCT04801420|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
79353171|NCT04801420|Biological|Placebo|PBS (Phosphate Buffered Saline)
79353172|NCT04783272|Diagnostic Test|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
79353173|NCT04746794|Behavioral|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
79504011|NCT03458598|Procedure|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
79504012|NCT01672242|Device|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
79666159|NCT04771156|Drug|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
79666160|NCT04771156|Drug|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
79666161|NCT04767854|Behavioral|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
79817963|NCT02956239|Procedure|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
79666162|NCT04767854|Other|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
79666163|NCT04767854|Other|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
79666164|NCT04754906|Other|Sequence 1|perform arm movements towards a target
79666165|NCT04754906|Other|Sequence 2|judge the verticality of an object
79817964|NCT00441727|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
79817965|NCT00441727|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
79817966|NCT00441727|Drug|Placebo|Placebo once daily
79817967|NCT04095728|Dietary Supplement|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
79817968|NCT04095728|Other|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
79817969|NCT02955225|Device|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
79817970|NCT02955225|Device|Passive shoe insole|A deactivated insole measures shoe pressure only.
79817971|NCT04074057|Other|Conventional Cardiac Rehab Classes|conventional weekly CR programme lasting 8-12 sessions.
79353174|NCT04726462|Other|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
79504013|NCT01672242|Device|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
79504014|NCT03791736|Procedure|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
79666166|NCT04754906|Other|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
79666167|NCT04739943|Device|Mobile Monitoring Device|App for self monitoring device for respiratory symptoms
79817972|NCT04074057|Device|Heart Track|"Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness."
79990101|NCT04934488|Behavioral|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
79990102|NCT04056806|Drug|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
79353175|NCT04726462|Other|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
79666168|NCT04738162|Drug|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
79353176|NCT04723264|Behavioral|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
79504015|NCT01672008|Drug|NOX-100|
79504016|NCT01676376|Device|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
79504017|NCT01676376|Other|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
79504018|NCT01679964|Drug|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
79504019|NCT02404818|Procedure|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
79666169|NCT04717934|Device|GAL1906|hyaluronic acid dermal filler gel
79666170|NCT04666636|Drug|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
79817973|NCT04072185|Other|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
79817974|NCT05673447|Biological|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 6×10^8, 1×10^9, 1.5×10^9 Anti-CD19 CAR NK cells will infused in each group using the 3 + 3 dose-escalation strategy."
79817975|NCT00770120|Drug|everolimus|
79817976|NCT03996655|Drug|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
79817977|NCT03996655|Drug|Neostigmine|Reversal of neuromuscular blockers
79817978|NCT01032031|Dietary Supplement|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
79817979|NCT01032031|Dietary Supplement|Placebo capsule|One capsule daily for 3 months
79817980|NCT01032109|Drug|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
79990103|NCT03724643|Other|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
79990104|NCT04056884|Behavioral|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
79353177|NCT04706676|Behavioral|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
79353178|NCT04706676|Behavioral|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
79504020|NCT02404818|Procedure|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
79504021|NCT05346822|Procedure|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
79504022|NCT03524898|Drug|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
79504023|NCT03524898|Drug|gemcitabine|1000 mg/m2
79504024|NCT03524820|Drug|Cetuximab|Administration of drug
79504025|NCT03524508|Drug|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
79504026|NCT03524508|Drug|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
79504027|NCT03521856|Behavioral|shoulder exercise|Exercises performed 3 times a week for 12 weeks
79504028|NCT03521856|Behavioral|education|
79504029|NCT03457818|Drug|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
79504030|NCT03457818|Other|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
79504031|NCT01676844|Drug|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
79504032|NCT01676844|Drug|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
79504033|NCT04403334|Drug|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
79817981|NCT04100330|Biological|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
79817982|NCT04100330|Drug|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
79817983|NCT04100252|Other|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
79990105|NCT04057118|Drug|SKI-O-703|Oral administration, twice per day
79990106|NCT04057118|Drug|Placebo|Oral administration, twice per day
79817984|NCT00436345|Drug|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
79817985|NCT00436345|Drug|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
79990107|NCT03548051|Procedure|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
79504034|NCT04403334|Drug|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
79666171|NCT04666636|Drug|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
79666173|NCT04636775|Diagnostic Test|Microbiome|Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
79666174|NCT04629339|Drug|INCB086550|INCB086550 will be administered orally twice a day.
79666175|NCT04618913|Drug|Apixaban|Anticoagulant
79666176|NCT04618913|Drug|Rivaroxaban|Anticoagulant
79666177|NCT04618913|Drug|Edoxaban|Edoxaban
79666178|NCT04618913|Drug|Dabigatran|Dabigatran
79666179|NCT04618913|Drug|VKA|Vitamin K antagonist
79666180|NCT04618913|Drug|LMWH|Low Molecular Weight Heparin
79504035|NCT03779646|Drug|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate <75bpm and systolic blood pressure <90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
79504036|NCT03500016|Other|High intensity interval training|See under arm description.
79504037|NCT03499080|Behavioral|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
79504038|NCT03499080|Behavioral|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
79666181|NCT04618770|Device|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
79666182|NCT04612738|Behavioral|Hello (serious game)|Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with >100 patients/caregivers from diverse backgrounds.
79666183|NCT04612738|Behavioral|The Conversation Project (CP) Starter Kit|"The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program."
79353179|NCT04706676|Behavioral|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
79353180|NCT04699968|Drug|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
79666184|NCT04612738|Other|Table Topics (general conversation game)|Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
79666185|NCT04608552|Behavioral|OMT Exercises|Oral and oropharyngeal exercises
79666186|NCT04608552|Behavioral|Nasal Breathing Exercises|Nasal breathing exercises each week
79666187|NCT04608552|Other|Use of Nasal Lavage|Use of nasal lavage with application of 10ml of saline in each nostril two times per day
79666189|NCT04599296|Device|Hip brace|Hip brace
79666190|NCT04588792|Drug|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
79666191|NCT04588792|Drug|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
79666192|NCT04576377|Biological|FluBlok|Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.
79666193|NCT04576377|Other|Placebo|0.5mL saline placebo.
79666194|NCT04568603|Drug|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
79353181|NCT04699968|Drug|SHR-1701|SHR -1701, Intravenous
79353182|NCT04667455|Diagnostic Test|Biomarker analysis at enrolment|Controls will be compared to cases using biomarker analyses and non-invasive cardiac imaging techniques to improve risk stratification of cases
79353183|NCT04667455|Diagnostic Test|Biomarker analyses throughout the study|Controls will be compared to cases using biomarker analyses and non-invasive cardiac imaging techniques to improve risk stratification of cases
79353184|NCT04629521|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
79504039|NCT03499080|Behavioral|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
79504040|NCT05346744|Other|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
79353185|NCT04628026|Drug|Venetoclax|Induction cycle 1: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-12 (after a 1/2/3 day ramp-up phase) (as determined during run-in phase) Induction cycle 2: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, patients not in CR/CRi: days 1-12 (after a 1/2/3 day ramp-up phase) or patients in CR/CRi: days 1-14 (without ramp-up) (as determined during run-in phase) Consolidation phase: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-14 (as determined during run-in phase)
79504041|NCT00089778|Drug|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
79666195|NCT04561544|Behavioral|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
79666196|NCT04554940|Biological|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
79666197|NCT04554147|Behavioral|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
79666198|NCT04553549|Device|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
79666199|NCT04552873|Drug|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
79666200|NCT04552873|Other|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
79817986|NCT00916448|Drug|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
79817987|NCT00916448|Drug|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
79823774|NCT03838562|Other|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
79353186|NCT04628026|Drug|Placebo|Induction cycle 1: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-12 (after a 1/2/3 day ramp-up phase) (as determined during run-in phase) Induction cycle 2: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, patients not in CR/CRi: days 1-12 (after a 1/2/3 day ramp-up phase) or patients in CR/CRi: days 1-14 (without ramp-up) (as determined during run-in phase) Consolidation phase: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-14 (as determined during run-in phase)
79370831|NCT04355104|Behavioral|Education|"A one hour educational session per week for 4 weeks. In a total of 4 sessions of education, the content based on LBP Clinical Practice Guidelines which recommended that education and counseling strategies for patients with low back pain.~Education session will be through video lecturing as a motivated tool of education for all subject who are in experimental group, this video will repeated the same in every educational session and will be sent for all participants.~The neuroscience education will be by the therapist using interactive slide show and hand-drawing images.~In addition to the education video, slide show, we will specify the education for every patient to give him all that he need, questions and details, mention his case on real spine to explore it and to determine the expected goal from what he need and what we have."
79504042|NCT00089778|Drug|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
79990108|NCT03548051|Drug|Saline|250 ml of saline delivered by retention enema
79353187|NCT04628026|Combination Product|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients >60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients >60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are >60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients >60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
79353188|NCT04628026|Other|Autologous stem cell transplantation|Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
79370832|NCT04355104|Behavioral|Standard physical therapy|Two session physical therapy per week for 4 weeks. The physical therapy will be based on patients case.
79370833|NCT04359940|Diagnostic Test|Cardiac MRI|For clinical surveillance
79370834|NCT04359862|Drug|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
79504043|NCT00089778|Other|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
79504044|NCT00089544|Drug|Dacarbazine|Given IV
79504045|NCT00089544|Drug|Doxorubicin Hydrochloride|Given IV
79504046|NCT00089544|Biological|Filgrastim|Given subcutaneously
79504047|NCT00089544|Drug|Ifosfamide|Given IV
79817988|NCT04095650|Behavioral|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
79504048|NCT00089544|Other|Laboratory Biomarker Analysis|Correlative studies
79504049|NCT00089544|Radiation|Radiation Therapy|Undergo radiotherapy
79504050|NCT00089544|Drug|Thalidomide|Given orally
79504051|NCT00089544|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79504052|NCT00089076|Biological|ipilimumab|Given IV
79666201|NCT04544709|Drug|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
79666202|NCT04535921|Other|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
79666203|NCT04532515|Device|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
79666204|NCT04532515|Device|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
79666205|NCT04528732|Behavioral|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
79990109|NCT03728075|Device|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
79504053|NCT00089076|Other|laboratory biomarker analysis|Correlative studies
79504054|NCT03774654|Genetic|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose Level 1: 1 x 10^7/m2. Dose Level 2: 3 x 10^7/m2. Dose Level 3: 1 x 10^8/m2."
79504055|NCT00088374|Drug|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
79370835|NCT04359862|Drug|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
79990110|NCT03305731|Behavioral|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
79990111|NCT03305575|Drug|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
79370836|NCT04354948|Behavioral|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
79666206|NCT04528732|Behavioral|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
79370837|NCT04354948|Behavioral|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
79504056|NCT00088374|Drug|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
79666207|NCT04523207|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
79817989|NCT02601716|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
79990112|NCT03305575|Drug|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
79990113|NCT04916782|Other|Quality of life Questionnaire|Quality of life questionnaire
79504057|NCT00088374|Drug|[15-O] H2O|[15-0] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
79504058|NCT00088374|Drug|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
79504059|NCT03773250|Behavioral|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
79666208|NCT04523207|Drug|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
79666209|NCT04523207|Drug|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
79990114|NCT02993822|Drug|Orvepitant Maleate|Tablet, once daily, oral
79990115|NCT02993822|Drug|Placebo|Tablet, once daily, oral
79990116|NCT04846972|Behavioral|FASTRACS intervention|"Intervention (4 steps) :~Penultimate to last chemotherapy : patient will receive tools of the intervention~1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
79990117|NCT02391844|Drug|Oxycodone|Oxycodone with Acetaminophen Extended Release
79990118|NCT03663296|Other|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
79353189|NCT04628026|Other|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
79353190|NCT04614454|Device|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
79353191|NCT04614454|Device|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
79353192|NCT04605861|Drug|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
79353193|NCT04605861|Drug|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
79504060|NCT03493620|Procedure|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
79666210|NCT04505540|Other|Bridge Clinic|Specialized addiction bridge clinic
79817990|NCT02601716|Biological|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
79353194|NCT04575220|Other|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
79504061|NCT03493620|Procedure|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
79504062|NCT03772548|Diagnostic Test|MRI|We will examine acute (<4 weeks post SCI) to chronic (>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
79504063|NCT03772548|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
79504064|NCT00087594|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
79666211|NCT04497870|Drug|Peppermint oil|Administration of peppermint oil at one of two daily doses.
79666212|NCT04482582|Radiation|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
79666213|NCT04482582|Other|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
79666214|NCT04467437|Other|Gait Training|Training that targets rehabilitation of walking function
79990119|NCT03285854|Diagnostic Test|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
79353195|NCT04569266|Other|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
79504065|NCT00087594|Drug|ribavirin|1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
79990120|NCT03663140|Diagnostic Test|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
79990121|NCT02391922|Behavioral|First aid course|
79504066|NCT03770286|Device|5% Fluoride Varnish|Topical varnish
79504067|NCT03770286|Device|38% Silver diamine fluoride|Topical varnish
79990122|NCT02391922|Behavioral|First aid instructions by mobile phone|
79990123|NCT04056728|Biological|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic acid])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
79990124|NCT04056338|Other|No intervention|No intervention.
79990125|NCT02391766|Behavioral|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
79990126|NCT02391766|Behavioral|usual care|
79990127|NCT04056260|Procedure|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
79990128|NCT05675020|Behavioral|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
79990129|NCT05674864|Drug|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
79504068|NCT03770286|Device|Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
79504069|NCT03492528|Biological|blood samples|blood samples
79504070|NCT03769350|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
79990130|NCT02391688|Drug|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
79504071|NCT05347056|Diagnostic Test|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
79504072|NCT05347056|Diagnostic Test|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
79504073|NCT05347056|Diagnostic Test|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
79504074|NCT05347056|Diagnostic Test|Radiograph|spinal radiograph AP/Lateral
79504075|NCT05347056|Behavioral|SRS 22|SRS-22 Patient Questionnaire
79504076|NCT00087516|Drug|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
79990131|NCT02391688|Drug|Bupropion|
79990132|NCT02391688|Drug|Fexofenadine|
79990133|NCT04117360|Other|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
79504077|NCT00087516|Drug|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
79504078|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
79666215|NCT04467437|Device|Transcutaneous Spinal Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training
79990134|NCT02391454|Device|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
79353196|NCT04569266|Other|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
79990135|NCT02391454|Other|Usual care|
79990136|NCT01068860|Drug|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
79990137|NCT01068860|Drug|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
79353197|NCT04564443|Other|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
79353198|NCT04564443|Other|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
79504079|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
79666216|NCT04458272|Drug|DS-1001b|250 mg, twice daily, continuous oral administration
79666217|NCT04455815|Drug|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
79666218|NCT04454437|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
79504080|NCT00087516|Drug|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
79504081|NCT03768960|Drug|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
79504082|NCT00087126|Drug|topotecan hydrochloride|
79504083|NCT03767946|Diagnostic Test|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
79504084|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
79666219|NCT04420975|Procedure|Definitive Surgical Resection|Undergo definitive surgical resection
79666220|NCT04420975|Biological|Nanoplexed Poly I:C BO-112|Given intratumorally
79666221|NCT04420975|Biological|Nivolumab|Given IV
79666222|NCT04420975|Radiation|Radiation Therapy|Undergo radiation therapy
79666223|NCT04415268|Behavioral|Exercise|Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
79353199|NCT04564443|Other|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
79504085|NCT03490734|Dietary Supplement|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
79504086|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
79666224|NCT04415268|Behavioral|Unsupervised exercise|Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
79817991|NCT02601716|Biological|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
79817992|NCT01032187|Drug|Meglumine antimoniate|20mg/kg/day IV for 20 days
79817993|NCT01032187|Drug|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
79990138|NCT03661736|Other|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
79353200|NCT04564443|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
79353201|NCT04564443|Other|Fibracol Wound Dressing|Application of a collagen alginate dressing
79353202|NCT04560140|Behavioral|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
79353203|NCT04553822|Other|Assisted autogenous drainage group (DAA)|DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.
79353204|NCT04553822|Other|Group prolonged slow expiration (ELPr)|Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
79353205|NCT04553822|Other|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
79353206|NCT04549532|Behavioral|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
79504087|NCT03490734|Dietary Supplement|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
79817994|NCT01028755|Drug|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
79504088|NCT03490734|Other|Water|Three mL administered per associated logo presentation only during MRI procedure.
79504089|NCT04763382|Other|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
79504090|NCT04763382|Other|Control gruop|Pre-test, post-test and urinalysis
79504091|NCT03489564|Behavioral|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
79504092|NCT03489564|Behavioral|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
79666225|NCT04415268|Drug|CFTR Modulators|"Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES"
79817995|NCT00769184|Drug|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
79817996|NCT00769184|Other|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
79817997|NCT00769184|Drug|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
79817998|NCT01028833|Other|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
79817999|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
79818000|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
79818001|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
79818002|NCT00468559|Drug|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
79818003|NCT00468559|Drug|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
79818004|NCT00468559|Drug|Double Blind Placebo|Double Blind Placebo
79818005|NCT00754442|Drug|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
79818006|NCT02600390|Biological|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
79818007|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
79818008|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
79353207|NCT04549532|Behavioral|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
79353208|NCT04528511|Device|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
79353209|NCT04506606|Procedure|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
79353210|NCT04469764|Drug|Abemaciclib|Given PO
79353211|NCT04469764|Drug|Anastrozole|Given PO
79353212|NCT04469764|Drug|Letrozole|Given PO
79666226|NCT04404192|Drug|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
79666227|NCT04404192|Drug|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
79666228|NCT04402073|Drug|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
79666229|NCT04402073|Drug|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
79353213|NCT04457895|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
79504093|NCT04763304|Other|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
79353214|NCT04457895|Other|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
79504094|NCT04763304|Other|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
79504095|NCT00086346|Drug|Sirolimus (Rapamune)|
79504096|NCT00086346|Drug|Cyclosporine or Tacrolimus|
79504097|NCT00085566|Drug|everolimus|
79818009|NCT00754052|Drug|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
79818010|NCT04095182|Drug|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)
79353215|NCT04457310|Drug|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
79353216|NCT04457310|Drug|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
79353217|NCT04457310|Drug|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
79353218|NCT04457310|Drug|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
79353219|NCT04457310|Other|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
79353220|NCT04432922|Other|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
79504098|NCT00085566|Drug|gefitinib|
79504099|NCT00085098|Biological|filgrastim|Given by infusion or injection
79504100|NCT00085098|Drug|carboplatin|Given IV over 1 hour
79504101|NCT00085098|Drug|cisplatin|Given IV over 6 hours
79666230|NCT04402073|Drug|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
79666231|NCT04402073|Drug|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
79666232|NCT04402073|Radiation|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
79666233|NCT04400500|Diagnostic Test|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
79666234|NCT04384770|Radiation|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
79818011|NCT04095182|Drug|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
79353221|NCT04416737|Other|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
79353222|NCT04414202|Procedure|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
79353223|NCT04414202|Radiation|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
79353224|NCT04381468|Drug|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
79504102|NCT00085098|Drug|cyclophosphamide|Given IV over 1 hour
79504103|NCT00085098|Drug|etoposide|Given IV over 2 hours
79504104|NCT00085098|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week
79504105|NCT00084864|Dietary Supplement|calcitriol|Given orally
79504106|NCT00084864|Drug|dexamethasone|Given orally
79666235|NCT04384770|Radiation|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
79666236|NCT04384770|Other|Questionnaire Administration|Ancillary studies
79353225|NCT04381468|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
79353226|NCT04376333|Behavioral|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
79504107|NCT00084864|Other|clinical observation|No intervention before surgery
79990139|NCT03662594|Other|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
79990140|NCT04056572|Drug|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
79504108|NCT03487302|Other|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
79990141|NCT04056650|Drug|L-theanine|up to 250 mg
79990142|NCT04056650|Dietary Supplement|Caffeine supplement|50-400mg
79353227|NCT04376333|Behavioral|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
79353228|NCT04376333|Other|Standard Conservative Care|Standard conservative dental care for orofacial pain
79504109|NCT03487302|Other|Neuropsychological test battery|"Mini Mental State Examination (MMSE), Measso et al. (1993);~Frontal Assessment Battery (FAB), Appollonio et al. (2005);~Symbol Digit Test, Amodio et al. (2002);~Digit Cancellation Test, Della Sala et al. (1992);~Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~Digit Span, Orsini et al (1987);~Corsi block-tapping test, Orsini et al. (1987);~Babcock story recall test, Carlesimo et al. (2002);~Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~Semantic verbal fluency, Novelli (1986);~Imitating gestures, De Renzi et al. (1980);~Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
79818012|NCT04095182|Drug|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5~11)
79818013|NCT04095182|Drug|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
79818014|NCT04095182|Drug|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)
79818015|NCT04095182|Drug|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
79990143|NCT04056650|Device|N1 app|N1 App on mobile device
79353229|NCT04364607|Drug|Neostigmine|Participants will receive 0.5 mg IM neostigmine
79353230|NCT04364607|Drug|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
79353231|NCT04348383|Drug|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
79353232|NCT04348383|Drug|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
79353233|NCT04332926|Other|Tobacco product administration and assessment|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
79818016|NCT00916916|Other|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
79990144|NCT03662438|Other|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
79353234|NCT04316286|Procedure|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
79353235|NCT04316286|Other|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
79353236|NCT04301622|Device|Primary Knee implants|Primary knee arthroplasty
79504110|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
79504111|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
79504112|NCT01677702|Dietary Supplement|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
79504113|NCT01677780|Drug|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m^2) to 1800 mg/m^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
79504114|NCT05346978|Dietary Supplement|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
79504115|NCT05346978|Dietary Supplement|Placebo|collagen colored with green pigment used in the food industry
79504116|NCT03485196|Other|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
79504117|NCT01473108|Drug|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
79990145|NCT03662438|Device|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device [Philips SimplyGo Mini] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
79990146|NCT03661658|Procedure|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
79353237|NCT04299828|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
79504118|NCT01473108|Drug|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
79504119|NCT01473108|Drug|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
79504120|NCT01473108|Drug|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
79818017|NCT04093232|Drug|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
79990147|NCT03661658|Procedure|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
79990148|NCT03661580|Behavioral|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
79990149|NCT03661580|Behavioral|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
79353238|NCT04294472|Drug|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
79353239|NCT04294472|Other|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
79353240|NCT04285476|Diagnostic Test|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
79353241|NCT04283409|Other|Graded activity|Exercise therapy using principles of cognitive behavioral therapy and education
79353242|NCT04283409|Other|Motor Control Exercises|Exercise therapy using principles of motor control and motor learning and education
79504121|NCT00084318|Biological|cetuximab|400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
79504122|NCT00084318|Drug|cisplatin|30 mg/m^2 intravenously infused over over 60 minutes in weeks 2 through 7.
79504123|NCT00084318|Drug|docetaxel|15 mg/m^2 intravenously infused over 30 minutes in weeks 2 through 7.
79504124|NCT00084318|Radiation|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
79504125|NCT00084084|Drug|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
79504126|NCT00083616|Biological|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
79504127|NCT04402710|Behavioral|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
79504128|NCT04402710|Behavioral|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
79504129|NCT00083226|Drug|doxorubicin|Given IV
79504130|NCT00083226|Drug|bortezomib|Given IV
79504131|NCT05346510|Procedure|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
79504132|NCT00082758|Biological|hu14.18-Interleukin-2 fusion protein|Given IV
79504133|NCT01678014|Procedure|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
79504134|NCT01678014|Procedure|Capsulotomy|
79353243|NCT04261361|Behavioral|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
79353244|NCT04261361|Behavioral|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
79353245|NCT04261361|Behavioral|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
79353246|NCT04233918|Drug|Evinacumab|Part A: Single IV dose Part B & C: IV dose Q4W
79353247|NCT04230564|Drug|azacitidine|Patients taking azacitidine
79353248|NCT04230564|Drug|venetoclax|patients taking venetoclax
79353249|NCT04230564|Drug|glasdegib|patients taking glasdegib
79353250|NCT04230421|Device|The Monsenso system with feedback|See description under intervention
79353251|NCT04230421|Device|The Monsenso system without feedback|See description under intervention
79353252|NCT04230421|Device|CAG Bipola and mood monitoring only|See description under intervention
79353253|NCT04210089|Device|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~Unna boot from MPJs to just below the knee,~Sterile Kerlix from MPJs to just below the knee~Sterile 4 inch Kling wrap from the MPJs to just below the knee,~Four inch coban from MPJs to just below the knee, and~Ace wraps from MPJs to just below the knee"
79353254|NCT04210089|Device|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
79504135|NCT04403178|Diagnostic Test|Radiographic examination with a Migration of > 40 %|Radiographic examination
79818018|NCT04093154|Device|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
79353255|NCT04190862|Drug|E-CEL UVEC|Injection of E-CEL UVEC
79353256|NCT04187040|Procedure|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~Covering all surfaces of the hands (based on own judgement)~Rotational rubbing of fingertips in the palm of the alternate hand~Rotational rubbing of both thumbs"
79353257|NCT04187040|Procedure|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~Rubbing hands palm to palm~Palm to palm with fingers interlaced~Right palm over left dorsum with interlaced fingers and vice versa~Back of fingers to opposing palms with fingers interlocked~Rotational rubbing of left thumb clasped in right palm and vice versa~Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
79353258|NCT04182022|Behavioral|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
79353259|NCT04182022|Behavioral|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
79353260|NCT04170660|Diagnostic Test|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
79353261|NCT04162678|Procedure|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
79353262|NCT04162678|Other|Laboratory Biomarker Analysis|Correlative studies
79353263|NCT04162678|Procedure|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
79353264|NCT04162678|Other|Medical Chart Review|Review of medical chart
79353265|NCT04161781|Drug|18F-BMS-986229 Injection|Single injection prior to scan
79353266|NCT04161781|Drug|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
79353267|NCT04161781|Diagnostic Test|PET/CT Scan|Whole-body PET/CT (80 mA)
79504136|NCT03424512|Behavioral|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
79818019|NCT02599844|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
79818020|NCT02599844|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
79818021|NCT02599844|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
79818022|NCT02599844|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
79818023|NCT02599844|Drug|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
79353268|NCT04143269|Device|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
79818024|NCT02600312|Device|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
79818025|NCT04099784|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
79818026|NCT04099784|Other|Physical development and General Health|Physical development and General health examination
79818027|NCT04099784|Other|Developmental Red flags|Developmental Red flags Questionnaires
79818028|NCT00747812|Device|Precision|Implantable Neurostimulator
79818029|NCT04092920|Device|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
79818030|NCT02927067|Drug|Maribavir|Participants will receive 400 mg of maribavir BID orally.
79818031|NCT02927067|Drug|Valganciclovir|Participants will receive valganciclovir tablets orally.
79353269|NCT04143269|Device|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
79353270|NCT04104529|Other|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
79353271|NCT04104529|Other|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
79353272|NCT04085536|Procedure|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
79504137|NCT03424200|Behavioral|Routine care|Participants will receive routine care
79504138|NCT03424200|Other|Coaching plus routine care|Participants will receive coaching plus routine care
79818032|NCT02927067|Other|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
79818033|NCT02600468|Drug|Orencia|
79353273|NCT04085172|Drug|Guanfacine hydrochloride (TAK-503)|In both Part A and Part B of the study participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 52 weeks.
79353274|NCT04085172|Drug|Atomoxetine hydrochloride|Participants in Part A of the study will receive Atomoxetine hydrochloride oral capsule once daily for 52 weeks.
79353275|NCT04085172|Other|Placebo|In Part A participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks.
79353276|NCT04081545|Drug|Opioid Anesthetics|see arm/group description
79353277|NCT04081545|Drug|Non Opioid Analgesics|see arm/group description
79504139|NCT03438318|Drug|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
79666237|NCT04347330|Drug|Intensive BP Control|Participants in the Intensive group have a goal of home SBP <120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
79818034|NCT04094636|Behavioral|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
79353278|NCT04076527|Drug|UDCA|Routine data is collected for UDCA therapy.
79353279|NCT04076527|Drug|Ocaliva|Routine data is collected for OCA therapy.
79353280|NCT04064697|Drug|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
79353281|NCT04063215|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
79504140|NCT03438318|Drug|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
79504141|NCT03438318|Radiation|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
79504142|NCT03087942|Drug|QAW039|450 mg
79504143|NCT03087942|Drug|QAW39A|450 mg
79504144|NCT03087942|Drug|QAW39A2107|450 mg
79504145|NCT03087942|Drug|QAW39A2107|450 mg
79504146|NCT01678092|Biological|omalizumab|
79504147|NCT04402320|Drug|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
79504148|NCT04402320|Device|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
79504149|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
79818035|NCT04094636|Behavioral|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
79818036|NCT04094402|Other|None. It is an observational study|None. It is an observational study
79818037|NCT02577939|Behavioral|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
79818038|NCT04094480|Device|polymeric non absorbable clips|a method to secure appendicular stump
79504150|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
79504151|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
79504152|NCT03436056|Drug|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
79504153|NCT03088176|Drug|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
79990150|NCT03661502|Device|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
79353282|NCT04060251|Device|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
79353283|NCT04060251|Other|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
79504154|NCT03088176|Drug|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
79504155|NCT03088176|Drug|Dabrafenib|150mg PO qday
79504156|NCT03088176|Drug|Trametinib|2mg PO qday
79353284|NCT04048876|Drug|CC-90001|oral
79504157|NCT00087984|Biological|MB-002|Dendritic Cell Immunotherapy
79990151|NCT03661502|Device|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
79353285|NCT04048876|Drug|Placebo|oral
79353286|NCT04036279|Procedure|Total Hip Arthroplasty|
79353287|NCT04001751|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
79504158|NCT01678404|Drug|131I-rituximab|
79504159|NCT03087864|Drug|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
79504160|NCT03087864|Drug|Carboplatin|Chemotherapy
79504161|NCT03087864|Drug|Paclitaxel|Chemotherapy
79504162|NCT03087864|Radiation|Radiotherapy 23 x 1.8 Gy|Radiotherapy
79504163|NCT03087630|Behavioral|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
79504164|NCT03087630|Behavioral|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
79504165|NCT03087630|Behavioral|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
79504166|NCT03087630|Behavioral|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
79504167|NCT01678482|Device|light based device for treatment of acne|
79818039|NCT04094480|Other|endoloops|a method to secure appendicular stump
79990152|NCT02989610|Device|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
79818040|NCT04073901|Other|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
79353288|NCT03976011|Device|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
79504168|NCT01678716|Behavioral|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
79353289|NCT03975959|Other|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
79353290|NCT03967990|Other|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
79353291|NCT03967990|Other|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
79353292|NCT03967990|Other|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
79353293|NCT03944785|Drug|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
79504169|NCT01678716|Dietary Supplement|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
79504170|NCT01678716|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
79504171|NCT00081510|Drug|Lonafarnib|
79504172|NCT00081510|Drug|Placebo|
79504173|NCT00081510|Drug|anastrozole|
79353294|NCT03921424|Biological|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
79353295|NCT03921424|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
79353296|NCT03921424|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
79353297|NCT03915912|Behavioral|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
79353298|NCT03896230|Drug|Ketamine Injectable Product|Three different doses of ketamine will be administered.
79504174|NCT00088452|Drug|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
79818041|NCT02598596|Biological|Pegloticase|Pegloticase, IV
79818042|NCT02598596|Drug|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
79818043|NCT01751685|Behavioral|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
79818044|NCT01751685|Other|Control|monthly educational lectures on various topics
79353299|NCT03878316|Drug|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
79504175|NCT00088452|Drug|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
79504176|NCT00088452|Drug|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
79504177|NCT03417570|Procedure|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
79504178|NCT03417570|Device|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
79504179|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
79353302|NCT03860571|Drug|Placebo|Oral tablet
79353303|NCT03860571|Drug|BT-11|Oral tablet
79353304|NCT03854929|Drug|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
79353305|NCT03854929|Drug|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
79353306|NCT03852628|Drug|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
79353307|NCT03852628|Drug|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
79504180|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
79504181|NCT03087474|Other|Non-Interventional|Non-Interventional
79353308|NCT03847142|Other|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
79353309|NCT03847142|Other|Outpatient primary care|Usual care delivered through the outpatient primary care setting
79353310|NCT03833531|Behavioral|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
79353311|NCT03833531|Behavioral|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
79353312|NCT03826524|Drug|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
79353313|NCT03811769|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
79353314|NCT03811769|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
79353315|NCT03741426|Drug|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
79353316|NCT03741426|Drug|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
79353317|NCT03741426|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
79504182|NCT01679106|Other|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
79504183|NCT01679106|Other|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
79666238|NCT04347330|Drug|Standard BP Control|Participants in the Standard group has a goal of home SBP <135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
79504184|NCT04403100|Drug|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
79504185|NCT04403100|Drug|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
79504186|NCT04403100|Drug|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
79504187|NCT04403100|Drug|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
79818045|NCT00586508|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
79353318|NCT03707158|Behavioral|Therapist-led Face-to-Face Cognitive-Behavioral Therapy|Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
79818046|NCT00586508|Drug|bevacizumab|10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
79818047|NCT00586508|Drug|Enzyme-inducing antiepileptic drugs (EIAED)|Administered orally
79818048|NCT00586508|Drug|Non-enzyme inducing antiepileptic drugs (NEIAED)|Administered orally
79504188|NCT03087318|Behavioral|Physical activity|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~during 3 months."
79504189|NCT03086538|Drug|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
79504190|NCT03086538|Drug|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
79504191|NCT04761276|Device|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
79504192|NCT03473730|Procedure|Biopsy|Undergo biopsy
79504193|NCT03473730|Biological|Daratumumab|Given IV
79504194|NCT03473730|Other|Laboratory Biomarker Analysis|Correlative studies
79504195|NCT03473730|Procedure|Metastasectomy|Undergo metastasectomy
79504196|NCT03473730|Procedure|Nephrectomy|Undergo nephrectomy
79666239|NCT04322136|Procedure|Pleurodesis via Video-assisted thoracoscopic surgery|Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
79818049|NCT00581919|Drug|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
79818050|NCT04094168|Drug|DEL NIDO CARDIOPLEGIA|"Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq."
79818051|NCT04094168|Drug|COLD BLOOD BASED CARDIOPLEGIA|Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
79818052|NCT00723528|Drug|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
79818053|NCT00723528|Drug|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
79818054|NCT00723528|Drug|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
79990153|NCT02989610|Device|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
79990154|NCT01372774|Radiation|stereotactic radiosurgery|Undergo RT
79990155|NCT01372774|Radiation|whole-brain radiation therapy|Undergo radiotherapy (RT)
79504197|NCT01679262|Device|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
79353319|NCT03707158|Behavioral|Digital Cognitive-Behavioral Therapy|Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
79504198|NCT02984748|Device|Cochlear implant|
79504199|NCT03081858|Drug|TSD-001|Administered via intravesical instillation.
79504200|NCT03082560|Diagnostic Test|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
79504201|NCT01679340|Drug|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
79504202|NCT01679340|Drug|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
79504203|NCT01679340|Drug|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
79504204|NCT03087084|Device|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
79504205|NCT03089814|Procedure|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
79504206|NCT03089970|Diagnostic Test|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
79353320|NCT03691480|Procedure|simple exsufflation|simple exsufflation
79353321|NCT03691480|Procedure|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
79666240|NCT04322136|Device|Indwelling pleural catheter (with talc pleurodesis if suitable)|Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
79666241|NCT04312126|Device|MRI system|MRI system - GE Discovery MR750 3T
79504207|NCT03087006|Other|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
79504208|NCT03087006|Other|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
79504209|NCT01679574|Drug|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
79504210|NCT01679574|Drug|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
79504211|NCT01679574|Drug|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
79504212|NCT01679652|Drug|Nebivolol|Tablet i blinded in capsula
79504213|NCT01679652|Drug|placebo|
79504214|NCT03086928|Other|lava ultimate|resin nano ceramic material
79504215|NCT03086928|Other|E.max cad|Lithium disilicate glass ceramic
79504216|NCT04761744|Drug|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
79504217|NCT01679886|Radiation|Rubidium PET|Rubidium PET
79504218|NCT04402476|Device|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
79353322|NCT03636282|Behavioral|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
79504219|NCT03089736|Behavioral|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
79990156|NCT04055402|Other|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
79990157|NCT04055402|Other|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
79990158|NCT04055480|Device|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
79990159|NCT04055480|Device|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
79990160|NCT03660800|Drug|CTAP101 Capsules|Calcifediol Extended-Release Capsules
79353323|NCT03623633|Drug|denosumab|denosumab 60 milligrams subcutaneously every 6 months
79990161|NCT03158090|Procedure|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
79504220|NCT03089736|Behavioral|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
79504221|NCT03089736|Other|Treatment as usual (TAU)|pharmacological treatment + advices
79504222|NCT03432000|Other|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
79353324|NCT03623633|Drug|alendronate|alendronate 70 milligrams weekly
79666242|NCT04312126|Device|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
79666243|NCT04290897|Drug|Anhydrous Enol-oxaloacetate|Given PO
79666244|NCT04290897|Other|Questionnaire Administration|Ancillary studies
79990162|NCT03158090|Drug|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
79990163|NCT03158090|Radiation|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
79990164|NCT02670538|Drug|Cariprazine|Cariprazine capsule one per day orally.
79990165|NCT02670538|Drug|Placebo|Matching placebo capsule one per day orally.
79990166|NCT03131414|Other|Diet|Dietary intake
79990167|NCT03131414|Other|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
79504223|NCT03089502|Other|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
79504224|NCT03089658|Drug|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
79504225|NCT03089190|Dietary Supplement|DC7-2|Effects on appetite
79823775|NCT04038086|Diagnostic Test|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
79990168|NCT03114592|Other|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
79353325|NCT03623633|Drug|raloxifene|raloxifene 60 milligrams daily
79353326|NCT03623347|Other|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
79353327|NCT03602976|Drug|Ursodeoxycholic Acid|weight-based dosing
79353328|NCT03601247|Device|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
79353329|NCT03595072|Other|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
79504226|NCT03089190|Dietary Supplement|DC7-2 + potato protein isolate|Effects on appetite
79504227|NCT03089190|Dietary Supplement|Potato protein isolate|Effects on appetite
79990169|NCT03547583|Drug|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
79990170|NCT03547583|Drug|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
79990171|NCT02391298|Behavioral|Mindfulness Meditation|
79353330|NCT03582579|Behavioral|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
79353331|NCT03582579|Behavioral|Training on a computer screen|Action Video Game Based Training on a computer screen
79353332|NCT03581227|Other|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
79353333|NCT03554174|Drug|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
79353334|NCT03554174|Drug|Placebo|microcrystalline cellulose capsule
79353335|NCT03554174|Drug|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
79353336|NCT03540680|Other|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
79666245|NCT04276779|Other|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
79666246|NCT04276779|Other|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
79818055|NCT00723528|Drug|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
79990172|NCT02391532|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
79353337|NCT03508440|Procedure|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
79353338|NCT03508440|Drug|Prednisone|Oral Steroid
79353339|NCT03445845|Drug|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
79353340|NCT03445845|Drug|TNF blocker|"TNF blocker (originator or biosimilar) :~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow."
79353341|NCT03445845|Biological|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
79353342|NCT03422861|Drug|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
79353343|NCT03422861|Drug|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
79504228|NCT03089190|Dietary Supplement|Placebo|Inactive whey protein, not expected to affect appetite.
79990173|NCT02391532|Dietary Supplement|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
79990174|NCT03114202|Other|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
79990175|NCT03114202|Other|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
79990176|NCT02391610|Other|No intervention|
79990177|NCT03727763|Drug|Vemurafenib|960mg po bid
79990178|NCT03727763|Drug|Cetuximab|500mg/m2 iv gtt (14 days per course)
79353344|NCT03421496|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
79353345|NCT03421496|Drug|Placebo|Matching oral solution
79353346|NCT03421496|Drug|Vigabatrin|Powder suspension
79353347|NCT03321786|Other|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
79353348|NCT03306992|Behavioral|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
79353349|NCT03278106|Other|Laboratory Biomarker Analysis|Correlative studies
79353350|NCT03278106|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
79353351|NCT03255252|Drug|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
79353352|NCT03255252|Combination Product|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
79353353|NCT03254420|Device|Calypso beacon implant|Calypso beacon implant before radiotherapy
79353354|NCT03254420|Radiation|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
79353355|NCT03240523|Drug|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
79990179|NCT02391220|Other|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
79353356|NCT03230747|Device|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
79353357|NCT03214198|Drug|Vonoprazan|Vonoprazan tablets
79353358|NCT03192215|Drug|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
79353359|NCT03192215|Drug|Aspirin|Aspirin 81 mg by mouth once daily.
79353360|NCT03027804|Procedure|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
79353361|NCT02914639|Drug|SF0166 Topical Ophthalmic Solution|
79353362|NCT02865018|Drug|cetirizine|
79353363|NCT02852538|Behavioral|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
79353364|NCT02795143|Drug|Isotretinoin|
79353365|NCT02795143|Other|Placebo|
79353366|NCT02790736|Drug|propranolol|active treatment
79353367|NCT02790736|Drug|Placebo|inactive pill
79990180|NCT02391220|Other|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
79353368|NCT02736981|Behavioral|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
79353369|NCT02736981|Behavioral|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
79353370|NCT02736981|Behavioral|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
79353371|NCT02704208|Behavioral|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
79353372|NCT02704208|Behavioral|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
79353373|NCT02664337|Other|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
79353374|NCT02664337|Other|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
79504229|NCT03089424|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
79504230|NCT03089424|Device|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
79504231|NCT03089346|Diagnostic Test|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
79353375|NCT02663739|Device|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
79353376|NCT02663362|Other|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
79504232|NCT03089346|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
79504233|NCT03081234|Drug|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
79504234|NCT03081234|Drug|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
79504235|NCT03081234|Drug|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
79666247|NCT04276779|Behavioral|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
79823776|NCT04038086|Other|circadian rhythm|Blood and CSF will be collected five times throughout the day.
79990181|NCT03724565|Procedure|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
79990182|NCT02670382|Dietary Supplement|EPA|10 week supplementation
79990183|NCT02670382|Dietary Supplement|DHA|10 week supplementation
79990184|NCT02670382|Dietary Supplement|sunflower oil|4-week lead-in
79990185|NCT01310621|Drug|Bovine surfactant|"Dose of diluted surfactant : 20ml/kg~Type :Bovine surfactant~Phospholipid concentration: 5 mg/ml~Number of lavages to be given: 2 (10ml/kg each)"
79990186|NCT02991482|Drug|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
79990187|NCT02991482|Drug|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
79990188|NCT02991482|Drug|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
79353377|NCT02516670|Dietary Supplement|Ascorbic Acid|Given IV
79353378|NCT02516670|Drug|Docetaxel|Given IV
79353379|NCT02516670|Other|Laboratory Biomarker Analysis|Correlative studies
79504236|NCT03417492|Drug|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
79504237|NCT03080922|Biological|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
79504238|NCT04402164|Device|Herbst appliance|telescopic appliance for mandibular advancement
79666248|NCT04276779|Behavioral|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
79990189|NCT03660644|Behavioral|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
79990190|NCT02674750|Drug|CUDC-907|
79666249|NCT04236167|Device|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
79666250|NCT04234971|Drug|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
79818056|NCT00723528|Drug|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
79818057|NCT00723528|Drug|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
79823777|NCT04038086|Drug|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
79990191|NCT03998566|Device|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
79990192|NCT02389192|Drug|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
79990193|NCT05672758|Behavioral|Sprint training|One-year cycle including specific sprint-oriented athletic training
79990194|NCT05672758|Behavioral|Endurance training|One-year cycle including specific endurance-oriented athletic training
79990195|NCT05672758|Behavioral|Recreational Training|One year of nonspecific recreational training
79353380|NCT02516670|Other|Pharmacological Study|Correlative studies
79353381|NCT02516670|Other|Placebo|Given IV
79353382|NCT02516670|Other|Quality-of-Life Assessment|Ancillary studies
79353383|NCT02345629|Procedure|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
79504239|NCT03080532|Other|dietary habits|
79353384|NCT02345629|Behavioral|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
79504240|NCT03080766|Drug|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
79504241|NCT03080688|Device|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
79353385|NCT02345629|Procedure|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
79666251|NCT04234971|Drug|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
79666252|NCT04220411|Drug|AR100DP1|topical ointment
79666253|NCT04209543|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily
79818058|NCT00723528|Drug|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
79818059|NCT00751790|Drug|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
79818060|NCT04092998|Procedure|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
79818061|NCT04086810|Drug|DCCR|Once daily oral administration
79818062|NCT02598674|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
79818063|NCT02598674|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
79818064|NCT02598674|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
79353386|NCT02345629|Procedure|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
79818065|NCT02598674|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
79504242|NCT03080298|Drug|BP101|
79504243|NCT03080298|Drug|Placebo|
79504244|NCT04401618|Other|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
79666254|NCT04209543|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily
79504245|NCT03080376|Other|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
79504246|NCT03080376|Other|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
79504247|NCT03080376|Other|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
79504248|NCT03080844|Behavioral|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
79504249|NCT03080844|Behavioral|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
79504250|NCT03392064|Biological|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
79666255|NCT04209543|Drug|Progesterone oral tablet|Progesterone oral tablet will be administered orally once daily
79353387|NCT02315898|Drug|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
79353388|NCT02285842|Device|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
79353389|NCT02280525|Drug|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
79818066|NCT02598674|Drug|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
79990196|NCT02391376|Other|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
79353390|NCT02280525|Drug|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
79818067|NCT04020536|Drug|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
79818068|NCT00917228|Device|recordings with device equipped|
79818069|NCT00917228|Device|Control|Recording without device equipped
79353391|NCT02280525|Drug|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
79353392|NCT02280525|Drug|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
79353393|NCT02280525|Procedure|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
79504251|NCT03080064|Behavioral|Health Coach Intervention|Please see arm description.
79504252|NCT04761354|Procedure|Unilateral adrenalectomy|
79504253|NCT03089112|Drug|HGP1607|Take it once per period
79818070|NCT02598518|Behavioral|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
79818071|NCT02598518|Behavioral|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
79504254|NCT03089112|Drug|HGP1501|Take it once per period
79818072|NCT00916760|Biological|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
79818073|NCT00916760|Biological|Placebo|Subcutaneous monthly treatment
79818074|NCT02600078|Device|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
79990197|NCT02391376|Other|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
79990198|NCT02391376|Other|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
79990199|NCT02391142|Drug|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
79353394|NCT02280525|Drug|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
79353395|NCT02157883|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
79353396|NCT02157883|Drug|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
79353397|NCT02157883|Drug|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
79353398|NCT02149667|Device|total hip arthroplasty implant|
79504255|NCT03089112|Drug|HGP1607+HGP1501|Take it once per period
79504256|NCT03083886|Other|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
79504257|NCT03083886|Other|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
79504258|NCT03083886|Other|Usual PCP led care|Primary care provider will direct patients' care pathway.
79818075|NCT02600078|Other|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
79666256|NCT04194489|Other|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
79818076|NCT02600078|Other|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
79818077|NCT02600078|Other|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
79990200|NCT02388334|Other|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~identify the specific support needs of the caregivers~study the links between the quality of care as perceived by the professionals, patients and caregivers~identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
79990201|NCT02391064|Behavioral|Cognitive evaluation|"Questionnaires for assessment of confounding factors~Cognitive evaluation~Walking tests and 9 Hole Peg Test"
79353399|NCT02133898|Other|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
79666257|NCT04194450|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
79666258|NCT04194450|Dietary Supplement|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
79666259|NCT04190303|Other|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
79666260|NCT04188834|Device|Customized version of DAVID device|A customized version of the DAVID device will be used to expose patients to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
79666261|NCT04188834|Device|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
79666262|NCT04158739|Drug|Cytarabine|Given IT
79666263|NCT04158739|Biological|Flotetuzumab|Given IV
79818078|NCT00723450|Drug|lamictal|Flexible Dosing
79818079|NCT02599610|Other|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
79818080|NCT02599610|Device|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
79818081|NCT02599532|Drug|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
79990202|NCT02391064|Behavioral|Expanded Disability Status Scale (EDSS) score|- EDSS score
79990203|NCT02390986|Drug|LON002|Extension study to provide continuing access to LON002 medication.
79990204|NCT02987972|Biological|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
79353400|NCT02071290|Device|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
79353401|NCT02066181|Other|Laboratory Biomarker Analysis|Optional correlative studies
79353402|NCT02066181|Other|Placebo Administration|Given PO
79353403|NCT02066181|Other|Quality-of-Life Assessment|Optional ancillary studies
79818082|NCT02598752|Other|Symptom-limited cardiopulmonary exercise test (CPET)|
79990205|NCT02987972|Biological|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
79353404|NCT02066181|Drug|Sorafenib Tosylate|Given PO
79353405|NCT01970865|Drug|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
79353406|NCT01970865|Drug|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
79990206|NCT02987972|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
79990207|NCT04479202|Drug|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
79666264|NCT04147325|Drug|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
79666265|NCT04142697|Behavioral|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
79666266|NCT04136275|Biological|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
79666267|NCT04123093|Device|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
79818083|NCT02598752|Other|Resting assessment of cardiac function by echocardiography|
79818084|NCT02598752|Other|Post-exercise assessment of cardiac function by echocardiography|
79353407|NCT01928576|Drug|Azacitidine|
79353408|NCT01928576|Drug|Entinostat|
79504259|NCT04279626|Procedure|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
79504260|NCT03088956|Other|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
79504261|NCT03088722|Other|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
79818085|NCT02598752|Other|Pulmonary function|
79818086|NCT02598752|Behavioral|Patient-reported outcomes questionnaire|
79818087|NCT00751400|Drug|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
79818088|NCT04086342|Drug|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
79818089|NCT04086342|Drug|Placebo|Placebo is a vehicle oil that will match CHI-902.
79504262|NCT03088644|Drug|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
79504263|NCT03088644|Drug|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
79990208|NCT04479202|Drug|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
79504264|NCT03088254|Drug|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
79504265|NCT03088254|Drug|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
79504266|NCT03088254|Drug|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
79504267|NCT03088488|Diagnostic Test|fasting venous blood samples|
79353409|NCT01928576|Drug|Nivolumab|
79504268|NCT05685420|Drug|Herombopag|Thrombopoietin receptor agonist
79666268|NCT04123093|Device|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
79990209|NCT02388256|Device|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
79666269|NCT04119440|Biological|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
79666270|NCT04119440|Biological|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
79353410|NCT01880060|Behavioral|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
79666271|NCT04119440|Other|Placebo|Administrations of placebo via the intramuscular route
79666272|NCT04091347|Behavioral|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
79666273|NCT04082767|Drug|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
79666274|NCT04082767|Drug|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
79666275|NCT04077320|Behavioral|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
79990210|NCT02388256|Other|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
79990211|NCT02388100|Procedure|Capillary HbA1c collection|
79504269|NCT04279080|Other|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
79504270|NCT05689086|Other|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
79504271|NCT03086772|Behavioral|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
79504272|NCT03086772|Behavioral|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
79504273|NCT05689008|Biological|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1*10^6 cells/kg suspended in 100 ml albumin solution.
79504274|NCT05688930|Other|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
79353411|NCT01880060|Behavioral|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
79504275|NCT05688930|Other|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
79504276|NCT05684484|Drug|Roflumilast 500 Ug ORAL TABLET [Daliresp]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
79504277|NCT05684484|Drug|corticosteroids +immune suppressive +amino salicylic acid|conventional treatment
79504278|NCT03391908|Diagnostic Test|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
79504279|NCT03086382|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
79353412|NCT01869114|Drug|Sirolimus|Given PO
79504280|NCT03086382|Drug|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
79504281|NCT04401696|Device|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
79504282|NCT04401696|Other|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
79666276|NCT04077320|Behavioral|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
79666277|NCT04071990|Behavioral|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
79666278|NCT04071990|Behavioral|CBGT|CBGT for OCD patients, without involvement of family members
79666279|NCT04068831|Drug|Talazoparib|1 mg talazoparib daily
79353413|NCT01869114|Drug|Azacitidine|Given IV
79353414|NCT01843751|Drug|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
79353415|NCT01815983|Other|Videolaryngoscopy review.|Review of video recordings.
79353416|NCT01756248|Drug|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
79353417|NCT01744652|Drug|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
79504283|NCT05680428|Other|early feeding|oral feeding within 12hours after stoma reversal
79504284|NCT05680428|Procedure|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
79666280|NCT04068831|Drug|Avelumab|800 mg avelumab every 2 weeks
79666281|NCT04012138|Drug|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
79818090|NCT05341362|Procedure|LiDCOrapid|According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
79818091|NCT04093778|Other|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
79818092|NCT00585312|Drug|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
79990212|NCT01372618|Drug|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
79353418|NCT01744652|Drug|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
79353419|NCT01711541|Drug|Carboplatin|Given IV
79504285|NCT03086304|Device|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
79504286|NCT03086304|Device|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
79666282|NCT04012138|Drug|Insulin Aspart|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
79666283|NCT04011410|Drug|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
79666284|NCT03992469|Drug|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
79666285|NCT03992469|Drug|Placebo|Placebo capsules made of cornstarch
79990213|NCT03304873|Drug|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
79990214|NCT03304873|Drug|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
79990215|NCT02669758|Drug|ALKS 3831|Tablets were administered for daily dosing
79990216|NCT02987660|Procedure|Topography Guided LASIK|Corneal surgery for refractive error correction
79353420|NCT01711541|Drug|Cisplatin|Given IV
79353421|NCT01711541|Drug|Fluorouracil|Given IV
79353422|NCT01711541|Drug|Hydroxyurea|Given PO
79353423|NCT01711541|Other|Laboratory Biomarker Analysis|Correlative studies
79353424|NCT01711541|Drug|Paclitaxel|Given IV
79353425|NCT01711541|Other|Placebo Administration|Given PO
79353426|NCT01711541|Radiation|Radiation Therapy|Undergo radiation therapy
79353427|NCT01711541|Drug|Veliparib|Given PO
79353428|NCT01584102|Behavioral|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
79353429|NCT01584102|Behavioral|group fitness classes only|15 weeks biweekly group fitness
79353430|NCT01370512|Drug|Droxidopa|100 mg tablets by mouth three times a day
79353431|NCT01370512|Drug|Pyridostigmine|60 mg tablets by mouth three times a day
79504287|NCT03415308|Other|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
79504288|NCT03415308|Other|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
79504289|NCT03415308|Other|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
79666286|NCT03989999|Procedure|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.~If TCD is normal (FVd>25 cm/sec and PI <1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
79666287|NCT03989947|Drug|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
79353432|NCT01370512|Other|Placebo|Looks exactly like the study drug but contains no active ingredients
79353433|NCT00944632|Drug|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
79353434|NCT00944632|Drug|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
79353435|NCT00717795|Behavioral|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
79353436|NCT00717795|Behavioral|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
79353437|NCT00584883|Drug|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
79353438|NCT00215813|Drug|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
79666288|NCT03988569|Other|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
79353439|NCT00179465|Drug|Tiagabine|Up to 36 mg daily
79353440|NCT00179465|Drug|Placebo|Placebo
79504290|NCT04279002|Other|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
79504291|NCT03414996|Other|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
79504292|NCT03086226|Drug|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
79353441|NCT00134030|Drug|Cisplatin|Given IV
79353442|NCT00134030|Drug|Doxorubicin Hydrochloride|Given IV
79353443|NCT00134030|Drug|Etoposide|Given IV
79353444|NCT00134030|Drug|Ifosfamide|Given IV
79353445|NCT00134030|Drug|Methotrexate|Given IV
79353446|NCT00134030|Biological|Peginterferon Alfa-2b|Given subcutaneously
79353447|NCT00134030|Other|Quality-of-Life Assessment|Ancillary studies
79353448|NCT00134030|Other|Questionnaire Administration|Ancillary studies
79353449|NCT00134030|Procedure|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
79353450|NCT01382446|Drug|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
79666289|NCT03977571|Procedure|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
79666290|NCT03977571|Other|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
79353451|NCT01382446|Other|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
79666291|NCT03972891|Other|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~no therapeutic intervention during the break~no language-specific specific exercises~language-specific strategies in everyday life can be applied, e.g. modeling techniques"
79666292|NCT03969082|Behavioral|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
79666293|NCT03964051|Drug|Omalizumab Injection|Omalizumab 300 mg for subcutaneous injection
79666294|NCT03951467|Other|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
79666295|NCT03945032|Other|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
79666296|NCT03912194|Behavioral|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
79666297|NCT03912194|Behavioral|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
79666298|NCT03912194|Behavioral|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
79353452|NCT01382212|Drug|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
79504293|NCT03086226|Drug|Itraconazole|This will be the active comparator
79504294|NCT03085992|Drug|FOLFOXIRI plus Bevacizumab|"BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
79504295|NCT03085992|Other|Chemoradiotherapy plus Bevacizumab|"FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
79504296|NCT03362424|Biological|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
79504297|NCT03362424|Procedure|Rotator cuff repair|Rotator cuff repair
79504298|NCT03086070|Drug|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
79504299|NCT03086070|Drug|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
79504300|NCT05688306|Drug|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
79353453|NCT01381900|Drug|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
79353454|NCT01381900|Drug|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
79666299|NCT03910452|Drug|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
79818093|NCT00585312|Drug|Placebo|Masked, placebo comparator
79990217|NCT02987660|Procedure|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
79990218|NCT02987660|Device|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
79504301|NCT03086148|Drug|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
79818094|NCT00753506|Dietary Supplement|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
79990219|NCT02987660|Device|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
79504302|NCT03086148|Drug|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
79504303|NCT03359538|Drug|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
79504304|NCT03359538|Drug|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
79524724|NCT03830034|Drug|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins & milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline & then 4, 8 & 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
79818095|NCT00753506|Dietary Supplement|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
79990220|NCT04528069|Device|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
79990221|NCT04528069|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
79990222|NCT03661268|Other|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
79353455|NCT01381900|Drug|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
79353456|NCT01381900|Drug|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
79353457|NCT01381900|Drug|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
79353458|NCT01744665|Drug|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
79353459|NCT03025126|Other|Multimedial Rehabilitation|
79818096|NCT03980912|Diagnostic Test|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
79504305|NCT04272138|Behavioral|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
79818097|NCT05406440|Drug|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
79818098|NCT05406440|Drug|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
79353460|NCT03025126|Other|Usual care program|Usual care at home program according to healthcare professional's advice
79353461|NCT04560933|Procedure|Blood sample collection|Blood sample collection
79524725|NCT03837132|Behavioral|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
79818099|NCT00720096|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
79818100|NCT00720096|Drug|Topotecan|"Topotecan (daily x 5 days of a 21 day cycle)~Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
79818101|NCT04086108|Dietary Supplement|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
79818102|NCT04086108|Dietary Supplement|GABA supplement|1 gram of GABA dissolved in water.
79818103|NCT04086108|Dietary Supplement|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
79818104|NCT02577783|Drug|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
79353462|NCT01744197|Drug|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
79353463|NCT05369416|Other|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
79353464|NCT05369416|Other|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of > 4200 mg/Day) for two weeks.
79353465|NCT04565301|Drug|Dexamethasone|adductor canal block
79353466|NCT04565301|Drug|neostigmine|adductor canal block
79353467|NCT04565301|Other|NaCl solutions|adductor canal block
79353468|NCT01732107|Drug|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
79524726|NCT03831360|Behavioral|Yoga|Hatha yoga for depressed adolescents
79524727|NCT03831360|Behavioral|Group CBT|Group cognitive behavioral therapy for depressed adolescents
79666300|NCT03910452|Drug|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
79666301|NCT03910452|Drug|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
79353469|NCT01743027|Drug|AL-4943A ophthalmic solution|
79353470|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
79666302|NCT03910452|Drug|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
79666303|NCT03910452|Radiation|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
79353471|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.1%|
79353472|NCT01743027|Drug|AL-4943A ophthalmic solution vehicle|
79353473|NCT01380730|Biological|Evolocumab|Administered by subcutaneous injection
79353474|NCT01380730|Other|Placebo to Evolocumab|Administered by subcutaneous injection
79353475|NCT05364034|Other|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
79353476|NCT04010968|Drug|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~if BM MRD at M9 < 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
79353477|NCT04010968|Drug|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
79504306|NCT04272138|Behavioral|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
79504307|NCT05345808|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
79666304|NCT03910452|Biological|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
79666305|NCT03905330|Drug|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
79990223|NCT03660566|Procedure|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
79990224|NCT03660566|Procedure|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
79353478|NCT01395784|Drug|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
79990225|NCT04526509|Drug|GSK3901961|GSK3901961 as an IV infusion.
79990226|NCT04526509|Drug|GSK3845097|GSK3845097 as an IV infusion.
79990227|NCT04526509|Drug|GSK4427296|GSK4427296 as an IV infusion.
79990228|NCT04526509|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
79353479|NCT01380184|Drug|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
79353480|NCT01395394|Drug|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
79524728|NCT03838068|Biological|Biodentine|Biodentine is considered a calcium silicate cement
79524729|NCT03838068|Biological|mineral trioxide aggregate|calcium based silicate cement
79524730|NCT03838068|Procedure|cervical pulpotomy|coronal pulp tissue was removed till the orifice
79524731|NCT03838068|Drug|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
79524732|NCT03836508|Device|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
79353481|NCT01395394|Other|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
79353482|NCT05362552|Other|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
79353483|NCT00002826|Drug|paclitaxel|
79353484|NCT00002826|Drug|valspodar|
79353485|NCT01395316|Drug|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
79353486|NCT04331938|Drug|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
79353487|NCT05362084|Procedure|lumbar medial branch block|lumbar medial branch block
79353488|NCT01742091|Drug|LY2541546 - SC|Administered SC
79353489|NCT01742091|Drug|LY2541546 - IV|Administered IV
79353490|NCT01742091|Drug|Placebo - SC|Administered SC
79504308|NCT04401228|Other|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact < one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
79504309|NCT02336958|Drug|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
79504310|NCT02336958|Drug|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
79504311|NCT02336958|Drug|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
79353491|NCT01742091|Drug|Placebo - IV|Administered IV
79353492|NCT01731951|Drug|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
79353493|NCT04560777|Other|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
79353494|NCT01731171|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
79353495|NCT01731171|Dietary Supplement|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
79504312|NCT02336958|Drug|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
79666306|NCT03905330|Other|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
79353496|NCT01741701|Drug|Oxaloacetate (OAA)|
79353497|NCT01741701|Drug|Placebo|
79353498|NCT01741545|Biological|Pegylated-Interferon-lambda|
79353499|NCT01741545|Drug|Ribavirin|
79353500|NCT01741545|Drug|Daclatasvir|
79353501|NCT01884350|Drug|Apixaban|
79353502|NCT01614795|Biological|Cixutumumab|Given IV
79353503|NCT01614795|Other|Laboratory Biomarker Analysis|Correlative studies
79353504|NCT01614795|Drug|Temsirolimus|Given IV
79353505|NCT01834586|Drug|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
79353506|NCT01614249|Dietary Supplement|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
79504313|NCT03409926|Dietary Supplement|Acacia Gum|dietary supplement will be added to the participant's usual diet
79504314|NCT04760886|Other|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
79504315|NCT03085602|Behavioral|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
79990229|NCT04526509|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
79504316|NCT03085602|Behavioral|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
79666307|NCT03871816|Other|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
79353507|NCT01614249|Dietary Supplement|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
79818105|NCT02577783|Drug|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
79504317|NCT04401306|Other|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
79990230|NCT03660410|Other|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
79990231|NCT03660410|Other|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
79990232|NCT03303469|Drug|FMISO|FMISO PET/CT imaging at baseline
79990233|NCT03303469|Drug|FMISO|FMISO PET/CT post TACE
79990234|NCT03303469|Drug|FMISO|FMISO PET/CT post SBRT
79990235|NCT02990000|Behavioral|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
79353508|NCT01597778|Biological|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
79666308|NCT03839758|Procedure|TSA standard|Glenoid preparation will be done with 2D CT-Scan
79666309|NCT03839758|Procedure|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
79666310|NCT03839758|Procedure|TSA Blueprint|Glenoid preparation will be done with Blueprint software
79666311|NCT03839758|Procedure|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
79666312|NCT03835520|Drug|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
79666313|NCT03835520|Drug|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
79666314|NCT03824769|Behavioral|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
79818106|NCT04089410|Device|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
79818107|NCT04089410|Device|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
79990236|NCT04521127|Other|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
79504318|NCT04401306|Other|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
79353509|NCT01597778|Biological|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
79353510|NCT01614093|Drug|Oxytocin|Single dose intranasal oxytocin (24 IU)
79353511|NCT01614093|Drug|Placebo|Placebo- Sugar pill
79353512|NCT01834274|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
79353513|NCT01834274|Drug|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
79353514|NCT01834274|Drug|Sitagliptin|Sitagliptin tablets
79353515|NCT01834274|Drug|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
79353516|NCT01834274|Drug|Metformin|Metformin tablets
79353517|NCT01739595|Drug|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
79353518|NCT01739595|Drug|Placebo|Oral capsule taken one time daily for 3 months
79353519|NCT01833494|Drug|PA21|
79353520|NCT01738971|Other|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
79353521|NCT01738971|Other|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
79353522|NCT01738581|Device|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
79353523|NCT01738581|Behavioral|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
79504319|NCT03356496|Device|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
79504320|NCT03085446|Behavioral|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
79666315|NCT03824769|Behavioral|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
79666316|NCT03821233|Drug|ZW49|"Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~Expansion: MTD or RD identified in the dose-escalation part of the study"
79353524|NCT01738581|Behavioral|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
79353525|NCT01738503|Drug|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
79353526|NCT01738503|Drug|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
79504321|NCT03085446|Behavioral|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
79504322|NCT03085368|Drug|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
79353527|NCT01738191|Drug|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
79353528|NCT01738191|Drug|Placebo|
79353529|NCT01737879|Drug|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
79353530|NCT01737879|Drug|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
79353531|NCT01879683|Drug|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
79353532|NCT04415307|Other|Acupuncture|Acupuncture over acupoints.
79353533|NCT04415307|Other|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
79353534|NCT04415307|Other|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
79353535|NCT04415307|Other|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
79353536|NCT01605825|Drug|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
79353537|NCT01605825|Drug|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
79353538|NCT04558905|Other|Face-to-face medical visits|Face-to-face medical visits
79353539|NCT04558905|Other|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
79504323|NCT03085290|Other|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
79504324|NCT03085290|Other|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
79666317|NCT03793478|Drug|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
79666318|NCT03793478|Drug|Fludarabine|30 mg/m^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
79666319|NCT03793478|Drug|Cytarabine|"2000 mg/m^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
79504325|NCT05687760|Biological|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
79504326|NCT05687760|Drug|Calcium hydroxide|calcium hydroxide
79504327|NCT03409380|Dietary Supplement|Arginine Drink|10 g of arginine in a formulated drink
79504328|NCT03409380|Dietary Supplement|Plain Drink|formulated drink
79504329|NCT03085134|Other|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
79504330|NCT03085134|Other|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
79504331|NCT03084978|Procedure|General Anesthesia|General anesthesia by standard endotracheal intubation.
79504332|NCT03084978|Procedure|Conscious Sedation|Conscious sedation
79666320|NCT03793478|Drug|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
79353540|NCT04558749|Other|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
79353541|NCT04558749|Other|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
79353542|NCT01727505|Device|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
79353543|NCT01727505|Device|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
79504333|NCT03084744|Behavioral|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
79504334|NCT03084744|Behavioral|Active monitoring|Active tele-monitoring by clinical psychologists.
79504335|NCT03084588|Drug|methadone|Patients will be given methadone at induction of anesthesia
79504336|NCT03084588|Procedure|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
79504337|NCT03408366|Procedure|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
79504338|NCT03408366|Other|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
79504339|NCT03408366|Other|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
79504340|NCT03084276|Other|High-fat meal|High-fat meal
79504341|NCT03084276|Other|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
79504342|NCT03084432|Diagnostic Test|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
79504343|NCT05345652|Procedure|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
79666321|NCT03793478|Drug|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
79504344|NCT05345574|Drug|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
79504345|NCT05345574|Drug|remifentanil infusion|remifentanil as anaesthetic adjuvant
79504346|NCT03084198|Procedure|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
79504347|NCT03084198|Procedure|Standard care for ALF|A standard of care for subjects with acute liver failure.
79504348|NCT05598606|Drug|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
79504349|NCT05598606|Drug|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
79504350|NCT03350880|Other|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
79504351|NCT05597358|Radiation|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
79818108|NCT04089410|Other|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
79818109|NCT04089410|Other|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
79823778|NCT03177577|Device|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
79823779|NCT03177577|Device|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
79353544|NCT04564677|Device|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
79353545|NCT04564053|Drug|LNA043|Single intra-articular injection on Day 1
79353546|NCT04564053|Drug|Placebo|Single intra-articular injection on Day 1
79353547|NCT01726803|Other|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
79353548|NCT01726803|Other|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
79353549|NCT01726335|Drug|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
79353550|NCT01877421|Drug|2 mg KSL-W|
79353551|NCT01877421|Drug|4 mg KSL-W|
79353552|NCT01877421|Drug|6 mg KSL-W|
79353553|NCT01877421|Drug|10 mg KSL-W|
79353554|NCT01877421|Drug|20 mg KSL-W|
79504352|NCT05597358|Radiation|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
79504353|NCT03084120|Other|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
79504354|NCT03084120|Other|Retrieval of umbilical cord blood.|-During childbirth
79504355|NCT03084120|Other|Retrieval of placenta.|-During childbirth
79823780|NCT04072640|Drug|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
79823781|NCT04072640|Drug|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
79353555|NCT01877421|Drug|30 mg KSL-W|
79353556|NCT01877421|Drug|50 mg KSL-W|
79823782|NCT04072640|Drug|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
79990237|NCT04521127|Other|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 * 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
79990238|NCT03660254|Behavioral|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
79990239|NCT03660176|Drug|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
79990240|NCT03660176|Other|routine management|the colonic irrigations
79990241|NCT04056026|Biological|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
79990242|NCT03661190|Other|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
79353557|NCT01877421|Drug|75 mg KSL-W|
79353558|NCT01877421|Drug|100 mg KSL-W|
79990243|NCT03661190|Other|Card Pairs|A basic picture-matching task.
79990244|NCT03660020|Drug|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
79990245|NCT03660020|Drug|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
79990246|NCT03659942|Other|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
79990247|NCT03659864|Other|diesel exhaust particulate|aerosolised diesel exhaust particulate
79353559|NCT01877421|Other|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
79353560|NCT01726023|Drug|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
79353561|NCT01726023|Drug|metronidazole|Metronidazole 500mg/100ml solution for infusion
79353562|NCT01726023|Drug|Meropenem|Meropenem powder for solution for infusion 1000mg
79353563|NCT01877265|Drug|LY2605541|
79353564|NCT01877187|Drug|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
79353565|NCT04609761|Drug|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
79353566|NCT01858532|Drug|Atrasentan|Film-coated tablet
79504356|NCT03084120|Other|Collection of newborn's and mother's lock of hair.|-During childbirth
79823783|NCT01566487|Drug|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
79823784|NCT04819646|Dietary Supplement|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
79823785|NCT04819646|Dietary Supplement|Dietary Supplement|Dietary Supplement capsules
79990248|NCT03659864|Other|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
79353567|NCT01858532|Drug|Placebo|Film-coated tablet
79353568|NCT01883492|Device|Femoral Stem|JMDN classification/Class III device
79353569|NCT01883492|Device|Acetabular Cup|JMDN classification: Class III device
79353570|NCT01883492|Device|Acetabular Liner|JMDN classification: Class III device
79353571|NCT01832480|Drug|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
79353572|NCT01832480|Drug|MTZ 2 g|MTZ 2 g
79823786|NCT04073264|Procedure|monofilament|In the intervention group,monofilament absorbable suture,will be used.
79666322|NCT03757299|Diagnostic Test|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
79666323|NCT03745287|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
79353573|NCT04613960|Drug|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
79666324|NCT03736213|Behavioral|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
79990249|NCT03659864|Other|small graphene oxide|aerosolised 'small' graphene oxide
79990250|NCT03659864|Other|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
79666325|NCT03736213|Behavioral|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
79353574|NCT04613960|Drug|normal saline|Placebo treatment
79823787|NCT04019210|Procedure|MODIFIED TRABECULECTOMY|Rectangular scleral flap
79823788|NCT02576288|Drug|Sitagliptin|anti-inflammatory properties
79823789|NCT02576288|Drug|Placebo|No anti-inflammatory properties
79823790|NCT00427921|Biological|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
79990251|NCT03659864|Other|filtered air|control: filtered air
79990252|NCT04055714|Device|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
79990253|NCT03661034|Device|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
79990254|NCT03659786|Other|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
79990255|NCT03659708|Procedure|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
79990256|NCT03659708|Procedure|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
79504357|NCT03084120|Other|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
79504358|NCT03084120|Other|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
79504359|NCT03084042|Device|fMRI|
79504360|NCT04400916|Drug|Tranexamic acid|A single drop administered topically
79990257|NCT03659630|Behavioral|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
79990258|NCT03659630|Behavioral|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
79353575|NCT04598984|Diagnostic Test|serum adipokines|Level of serum adipokines will be measured with flow cytometry
79353576|NCT04598282|Device|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
79504361|NCT04400916|Other|Balanced Salt Solution|A single drop administered topically
79504362|NCT03406104|Genetic|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
79504363|NCT03406104|Other|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
79504364|NCT04761042|Other|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
79504365|NCT04761042|Other|WAYA-Holiday|"An attention control group (information in Detailed description)"
79504366|NCT04400526|Behavioral|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
79990259|NCT03659552|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
79990260|NCT03659474|Other|compression|compression by Game Ready
79990261|NCT03659474|Other|ice pack|cryotherapy for ice pack
79990262|NCT03659474|Other|immersion|immersion therapy
79990263|NCT03659396|Other|individualized Tai Chi|individualized Tai Chi training exercise
79823791|NCT04794374|Other|Telerehabilitation|Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
79823792|NCT00432991|Drug|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
79823793|NCT00432991|Drug|Saline Placebo|0.5 mL, IM (in the muscle), one time
79990264|NCT03659396|Other|Entire Tai Chi|the classical Yang style Tai Chi program
79990265|NCT03659396|Other|home-based program|Home-based exercise
79990266|NCT03662048|Behavioral|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
79990267|NCT04055870|Procedure|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
79353577|NCT04598282|Other|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
79353578|NCT01858376|Dietary Supplement|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
79353579|NCT01831856|Drug|1g of F373280|Oral administration, one capsule each evening with dinner.
79353580|NCT01831856|Drug|Placebo|Oral administration, one capsule each evening with dinner.
79353581|NCT01831544|Device|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
79353582|NCT01857206|Biological|Mammalian cell based flu vaccine|
79353583|NCT01857206|Biological|Egg based flu vaccine|
79353584|NCT01882088|Drug|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
79504367|NCT04400526|Behavioral|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
79504368|NCT04400526|Behavioral|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
79504369|NCT05686746|Drug|Baricitinib 4 MG|4 mg oral daily
79504370|NCT05686746|Drug|Baricitinib 2 MG|2 mg oral daily
79504371|NCT05686746|Drug|MMF|1000 mg oral daily
79504372|NCT03083574|Device|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
79353585|NCT01881776|Procedure|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
79990268|NCT03660956|Behavioral|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
79353586|NCT01708161|Drug|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
79990269|NCT03660956|Behavioral|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
79990270|NCT03659318|Procedure|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
79990271|NCT03659318|Procedure|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
79353587|NCT01708161|Drug|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
79353588|NCT04557033|Other|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
79353589|NCT01707693|Behavioral|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing & follow-up
79353590|NCT01707693|Behavioral|Information / Attention Comparison|Physical Activity information given & follow-up, no behavioral counseling
79353591|NCT01722669|Drug|isoquercetin or quercetin|Single dose PK/PD study
79353592|NCT01707147|Drug|Trajenta tablet|Linagliptin
79666326|NCT03725332|Behavioral|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance abuse counselors, perinatal nurse educators, and/or Peer Health Specialists. Consultations will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
79823794|NCT00432835|Device|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
79353593|NCT01876251|Drug|PF-03084014|Tablet, 10 mg, twice a day
79353594|NCT01876251|Drug|PF-03084014|Tablet, 50 mg, twice a day
79353595|NCT01876251|Drug|PF-03084014|Tablet, 100 mg, twice a day
79353596|NCT01876251|Drug|Docetaxel|Solution for IV infusion 75 mg/m^2, every 3 weeks
79353597|NCT01876251|Drug|Docetaxel|Solution for IV infusion 100 mg/m^2, every 3 weeks
79353598|NCT01875471|Device|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
79353599|NCT01875471|Device|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
79353600|NCT01875237|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
79353601|NCT01875237|Drug|Melphalan|140 mg/m2 by vein on Day -2.
79353602|NCT01875237|Drug|Alemtuzumab|50 mg by vein on Day -1.
79504373|NCT03832452|Drug|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
79504374|NCT03832452|Other|Placebo|hard capsules for oral administration
79353603|NCT01875237|Procedure|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
79353604|NCT01875237|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
79990272|NCT03661892|Drug|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
79504375|NCT03832452|Drug|Moxifloxacin|400 mg; film-coated tablets for oral administration
79990273|NCT03658850|Drug|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
79504376|NCT03832452|Drug|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
79504377|NCT03832452|Drug|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
79504378|NCT03343860|Procedure|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
79504379|NCT03343860|Procedure|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
79504380|NCT03343860|Procedure|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
79823795|NCT00580970|Drug|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
79990274|NCT03658850|Drug|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
79990275|NCT03659162|Drug|Azole Antifungal|oral gel & injections
79353605|NCT01875237|Drug|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
79353606|NCT01875237|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
79353607|NCT01875237|Procedure|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
79353608|NCT01875237|Drug|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade > 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
79353609|NCT01875237|Drug|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
79666327|NCT03725332|Behavioral|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator and community-based peer support specialist. Small group care meetings will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1)Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
79666328|NCT03706365|Drug|Abemaciclib|Administered orally.
79666329|NCT03706365|Drug|Abiraterone Acetate|Administered orally.
79666330|NCT03706365|Drug|Prednisone|Administered orally.
79666331|NCT03706365|Drug|Placebo|Administered orally.
79666332|NCT03693521|Device|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
79504381|NCT03343860|Procedure|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
79504382|NCT03343860|Procedure|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
79823796|NCT01030081|Drug|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
79823797|NCT01030081|Drug|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
79823798|NCT00665925|Drug|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
79353610|NCT01875237|Behavioral|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
79353611|NCT01874535|Drug|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
79353612|NCT01722045|Drug|Intravitreal Aflibercept Injection (IAI)|
79353613|NCT01721109|Drug|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
79353614|NCT01874145|Drug|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
79823799|NCT00665925|Drug|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
79353615|NCT01874145|Drug|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
79353616|NCT04415385|Drug|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
79353617|NCT04415385|Drug|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
79353618|NCT01720797|Device|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
79504383|NCT03343860|Procedure|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
79666333|NCT03693521|Other|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
79353619|NCT01720797|Drug|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
79353620|NCT01720797|Other|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
79353621|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
79353622|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
79353623|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
79666334|NCT03684564|Drug|Rivaroxaban|Oral tablet 15 mg twice daily for 24 months
79666335|NCT03684564|Drug|Warfarin|Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
79666336|NCT03672825|Drug|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
79504384|NCT03343860|Procedure|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
79990276|NCT03659084|Drug|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
79990277|NCT01068626|Drug|Rosuvastatin|10 mg once daily
79353624|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
79353625|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
79353626|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
79353627|NCT01881620|Device|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
79353628|NCT01830920|Drug|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
79353629|NCT01830920|Drug|Placebo|A normal saline solution identical in appearance to the active drug solution
79504385|NCT03343860|Procedure|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
79504386|NCT03343860|Procedure|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
79353630|NCT01881230|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
79353631|NCT01881230|Drug|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
79504387|NCT03343860|Procedure|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
79504388|NCT03083496|Drug|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
79504389|NCT03083496|Drug|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
79504390|NCT03083418|Device|control group|No EDP treatment
79666337|NCT03643939|Device|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
79666338|NCT03643939|Device|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
79666339|NCT03609853|Drug|Placebo|Placebo vapor (distilled water)
79666340|NCT03609853|Drug|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
79353632|NCT01881230|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
79353633|NCT01856582|Biological|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
79823800|NCT00665925|Drug|Placebo|Placebo, orally, either once a day, or twice a day
79353634|NCT01829360|Behavioral|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
79823801|NCT02578004|Other|biochemical and molecular analysis|
79990278|NCT01068626|Drug|Placebo for rosuvastatin|once daily
79990279|NCT03060668|Other|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
79990280|NCT03060668|Other|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
79990281|NCT02921750|Device|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
79990282|NCT02921750|Device|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
79990283|NCT03659006|Biological|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
79990284|NCT03657836|Dietary Supplement|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
79990285|NCT03657836|Drug|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
79990286|NCT03622502|Drug|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
79990287|NCT03622502|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
79990288|NCT03622502|Drug|Normal saline|Normal saline was infused over 10 min before end of the surgery
79990289|NCT03658460|Other|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
79504391|NCT03083418|Device|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
79504392|NCT05548920|Other|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
79990290|NCT03658382|Other|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
79353635|NCT01856114|Drug|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
79504393|NCT05548920|Other|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
79504394|NCT03083340|Behavioral|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
79504395|NCT04279938|Drug|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
79818110|NCT04089410|Other|Autonomic Balance, Orthostatic and Hypoxic tolerance|"Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
79823802|NCT02578160|Procedure|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
79990291|NCT04401566|Other|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
79990292|NCT04401566|Other|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
79353636|NCT01856114|Other|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
79504396|NCT04279938|Drug|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
79504397|NCT04279938|Drug|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
79504398|NCT03083262|Other|no intervention|None, there is no intervention
79504399|NCT05686434|Drug|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
79504400|NCT03083106|Device|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
79990293|NCT04401566|Other|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
79990294|NCT04397354|Drug|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
79353637|NCT01856114|Behavioral|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
79353638|NCT01855958|Procedure|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
79353639|NCT01855958|Procedure|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
79504401|NCT03338244|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
79504402|NCT03338244|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
79990295|NCT04397354|Drug|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
79818111|NCT04089410|Other|Psychological Testing|"Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
79353640|NCT01855412|Other|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
79353641|NCT01614470|Drug|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
79353642|NCT01614470|Drug|Placebo|oral use, administered twice a day (q12h)
79353643|NCT01880528|Drug|lisinopril|Given PO
79353644|NCT01880528|Drug|placebo|Given PO
79504403|NCT03083028|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
79990296|NCT04397354|Drug|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
79353645|NCT01854944|Drug|Brexpiprazole 1mg to 4mg|
79353646|NCT01829048|Drug|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
79353647|NCT01829048|Drug|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
79353648|NCT01829048|Drug|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
79504404|NCT03083028|Procedure|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
79504405|NCT03082950|Diagnostic Test|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
79504406|NCT03082794|Dietary Supplement|NCD|Negative Calorie Diet
79504407|NCT03082794|Dietary Supplement|LCD|Low Calorie Diet
79504408|NCT05685888|Other|Medication history|The study was retrospective and did not involve the application of interventions
79823803|NCT02578784|Device|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
79990297|NCT02970344|Behavioral|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
79990298|NCT03658226|Behavioral|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
79353649|NCT01829048|Drug|Placebo|Placebo Q12h
79353650|NCT01854710|Drug|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
79353651|NCT01854710|Drug|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
79353652|NCT01854710|Drug|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
79353653|NCT01854710|Drug|Oral placebo|Oral capsule identical in appearance to moxifloxacin
79353654|NCT01828034|Drug|Gemcitabine|
79353655|NCT01828034|Drug|Cisplatin|
79504409|NCT03400410|Behavioral|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
79353656|NCT01828034|Drug|MEK162|
79353657|NCT01853696|Drug|loteprednol etabonate|
79353658|NCT01853696|Drug|prednisolone acetate 1%|
79353659|NCT01871805|Drug|Alectinib|Participants will receive alectinib as described in the arm descriptions.
79353660|NCT01719861|Drug|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
79504410|NCT04348188|Behavioral|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
79504411|NCT03082404|Other|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
79353661|NCT01853618|Drug|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
79353662|NCT01853618|Procedure|RFA|Performed on Day 36
79353663|NCT01853618|Procedure|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
79353664|NCT01853618|Procedure|Cryoablation|Performed on Day 36
79353665|NCT01853462|Other|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
79666341|NCT03608579|Drug|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
79823804|NCT02578784|Device|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
79353666|NCT01853462|Other|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
79990299|NCT04387916|Drug|KC1036|Part 1: Dose-escalation phase , KC1036 10mg~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
79353667|NCT01719783|Biological|LAIV H5N2|2 doses provided intranasally
79353668|NCT01719783|Other|Placebo|2 doses of placebo provided intranasally
79353669|NCT04415619|Procedure|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
79353670|NCT01853384|Biological|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
79990300|NCT03657758|Drug|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
79353671|NCT01853384|Other|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
79353672|NCT01878890|Drug|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
79353673|NCT01878890|Drug|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
79353674|NCT01878890|Drug|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
79353675|NCT01878890|Drug|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
79353676|NCT04415606|Device|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
79353677|NCT01827332|Drug|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
79353678|NCT01827332|Drug|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
79353679|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
79353680|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
79353681|NCT01719003|Drug|Empagliflozin low dose qd|Empagliflozin low dose once daily
79504412|NCT03334344|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
79353682|NCT01719003|Drug|Empagliflozin high dose qd|Empagliflozin high dose once daily
79353683|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
79353684|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
79353685|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
79353686|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
79353687|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
79353688|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
79353689|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
79353690|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
79353691|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
79353692|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
79524733|NCT03836508|Device|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
79990301|NCT03657758|Drug|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
79990302|NCT02920970|Device|narafilcon A|contact lens
79990303|NCT02920970|Device|stenfilcon A|contact lens
79990304|NCT03658148|Procedure|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
79990305|NCT01068158|Drug|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
79990306|NCT01068158|Drug|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
79990307|NCT03303079|Drug|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
79504413|NCT04348344|Behavioral|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
79504414|NCT05505864|Behavioral|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
79504415|NCT03832218|Diagnostic Test|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~Test : Wechsler Intelligence Scale for Children (WISC-V)~Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~Global Assessment of Functioning Scale~Scale : Brief Psychiatric Rating Scale (BPRS)~Test : Children Depression Inventory (CDI)~Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~Scale : Conners' scale (parents and teachers)"
79504416|NCT05454228|Behavioral|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
79504417|NCT03082092|Drug|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
79504418|NCT03082092|Drug|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
79504419|NCT04401852|Drug|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
79353693|NCT01853228|Drug|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
79353694|NCT01853228|Drug|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
79353695|NCT01853228|Drug|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
79353696|NCT01705587|Drug|teriparatide|20 microgram once-daily subcutaneous injection
79353697|NCT01718535|Device|Spartan FRX CYP2C19 Test System|
79353698|NCT01705509|Drug|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
79353699|NCT04551183|Other|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
79504420|NCT04401852|Drug|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
79818112|NCT04089410|Other|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
79504421|NCT04761510|Behavioral|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
79353700|NCT04551183|Device|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
79353701|NCT01853072|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
79504422|NCT03081936|Dietary Supplement|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
79504423|NCT03081936|Dietary Supplement|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
79504424|NCT03081936|Dietary Supplement|Oral consumption of breast milk|Daily oral consumption of breast milk
79504425|NCT03318120|Behavioral|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
79504426|NCT03398538|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
79504427|NCT03398538|Other|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
79353702|NCT01853072|Other|Nepafenac vehicle|Inactive ingredients used as placebo comparator
79353703|NCT01853072|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
79353704|NCT01877720|Device|noninvasive respiratory support with NAVA mode and PSV|
79353705|NCT01870869|Device|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
79353706|NCT01877408|Procedure|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
79679611|NCT02942043|Drug|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
79679612|NCT00516971|Drug|Esomeprazole 20mg once daily|
79990308|NCT03303079|Drug|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
79353707|NCT01877408|Device|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
79353708|NCT01717287|Drug|Raltegravir Film-coated Tablet|
79504428|NCT03398538|Other|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
79504429|NCT03398538|Other|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
79504430|NCT03081780|Biological|FATE-NK100|"Preparative regimen:~Fludarabine 25 mg/m2 x 5 days start Day -6~Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
79504431|NCT04278612|Other|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
79504432|NCT05430282|Other|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
79504433|NCT05430282|Other|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
79504434|NCT03082482|Behavioral|Self-help materials|Self-help smoking cessation materials
79990309|NCT03303079|Drug|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
79990310|NCT01067846|Drug|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
79353709|NCT01717287|Drug|Raltegravir Chewable Tablet|
79353710|NCT01717287|Drug|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
79353711|NCT01827254|Other|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
79353712|NCT01824602|Drug|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
79353713|NCT01824602|Drug|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
79353714|NCT01824602|Drug|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
79679613|NCT02942082|Other|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
79679614|NCT02942082|Other|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
79990311|NCT01067846|Drug|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
79990312|NCT01067846|Behavioral|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
79353715|NCT01824602|Drug|Placebo|Placebo sugar pills
79353716|NCT01704651|Drug|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
79353717|NCT01704651|Drug|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
79353718|NCT01876706|Device|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
79353719|NCT01876082|Drug|PAZOPANIB treatment|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
79990313|NCT03657680|Other|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
79990314|NCT03658070|Drug|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
79818113|NCT03953040|Diagnostic Test|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
79353720|NCT01876082|Drug|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
79818114|NCT04092608|Procedure|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable < 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
79353721|NCT01704495|Drug|AZD5069|AZD5069 oral capsules self-administered twice daily.
79353722|NCT01704495|Drug|Placebo|Placebo oral capsules self-administered twice daily.
79353723|NCT01716663|Device|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
79353724|NCT01716585|Drug|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79353725|NCT01716585|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
79818115|NCT04092608|Procedure|LOW CVP (restrictive group)|Goal = CVP < 7mmHg and only 2 ml/kg/h max during surgery.
79818116|NCT00723294|Procedure|cryosurgery|
79353726|NCT01716585|Drug|Placebo for ABT-450/r/ABT-267|Tablet
79353727|NCT01716585|Drug|Placebo for ABT-333|Tablet
79353728|NCT01716585|Drug|Placebo for ribavirin|Capsule
79504435|NCT03082482|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke <10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
79818117|NCT00723294|Procedure|therapeutic conventional surgery|
79818118|NCT04072029|Procedure|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
79818119|NCT04092140|Device|ultrasound|easy new non invasive tool
79818120|NCT04092296|Other|resin infiltration|using infiltrant resin intervene proximal caries
79818121|NCT04092296|Other|remineralization|using fluoride to remineralize proximal caries
79818122|NCT04092296|Other|sham|replace resin with water
79504436|NCT03082482|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
79504437|NCT03082482|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
79504438|NCT03082170|Device|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
79504439|NCT03082170|Diagnostic Test|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
79504440|NCT03082170|Behavioral|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
79823805|NCT00426751|Drug|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
79353729|NCT01852292|Drug|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
79353730|NCT01852292|Drug|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
79353731|NCT01852292|Drug|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m^2.
79353732|NCT01715805|Drug|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
79504441|NCT05096598|Drug|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
79504442|NCT05096598|Drug|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
79504443|NCT03308916|Diagnostic Test|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
79504444|NCT03308916|Diagnostic Test|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
79504445|NCT03308916|Diagnostic Test|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
79353733|NCT01715805|Drug|Placebo|Dose-matched placebo capsule once per day
79504446|NCT03308916|Diagnostic Test|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
79679615|NCT00517088|Drug|IPAQ|
79353734|NCT01715805|Drug|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
79353735|NCT01852214|Drug|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
79353736|NCT01852214|Drug|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
79353737|NCT01393990|Drug|LY2228820|Administered orally
79504447|NCT03308916|Diagnostic Test|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
79504448|NCT03308916|Diagnostic Test|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
79504449|NCT03308916|Diagnostic Test|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
79504450|NCT03081702|Drug|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
79504451|NCT03081702|Drug|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
79504452|NCT05345964|Drug|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
79504453|NCT05345964|Drug|Placebo|Subjects will take Placebo orally(once daily) on Day 1
79353738|NCT01393990|Drug|Midazolam|
79353739|NCT01393990|Drug|Tamoxifen|
79353740|NCT05366374|Other|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
79353741|NCT00210184|Drug|Irinotecan associated to fluorouracil and leucovorin|
79353742|NCT00210106|Device|Ablathermy|
79353743|NCT05368480|Other|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
79504454|NCT05345964|Drug|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
79504455|NCT05345964|Drug|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
79666342|NCT03587272|Drug|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on Days -5 to -3) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
79353744|NCT00210964|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
79353745|NCT00210964|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
79504456|NCT05345964|Drug|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
79504457|NCT05345964|Drug|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
79504458|NCT04399824|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
79504459|NCT04399824|Other|Quality-of-Life Assessment|Ancillary studies
79679616|NCT02939664|Device|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
79353746|NCT00210652|Drug|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
79353747|NCT05369104|Biological|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
79353748|NCT05365126|Behavioral|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
79504460|NCT04399824|Other|Questionnaire Administration|Ancillary studies
79504461|NCT04399824|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79504462|NCT04279782|Other|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
79504463|NCT05397210|Device|Infinity-Lock Button System|Infinity-Lock Button System
79504464|NCT05393076|Drug|Linerixibat|Linerixibat dose and administration as per study intervention.
79504465|NCT05385510|Biological|R21/Matrix-M™|Adjuvanted malaria vaccine
79504466|NCT05381220|Other|early mobilization|Received early activities provided by the Institute 24 hours after stroke
79353749|NCT05362162|Procedure|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
79353750|NCT02985268|Device|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
79353751|NCT02985268|Drug|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
79353752|NCT02985268|Device|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
79353753|NCT05630560|Other|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
79353754|NCT04022122|Procedure|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
79353755|NCT03593434|Drug|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
79353756|NCT04019314|Procedure|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
79353757|NCT04019314|Procedure|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
79504467|NCT05378958|Other|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
79504468|NCT04347876|Diagnostic Test|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
79353758|NCT05366608|Diagnostic Test|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
79504469|NCT05059704|Other|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
79679617|NCT02939664|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
79679618|NCT00518570|Drug|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
79353759|NCT03995992|Behavioral|sport|10 days of sport (diving or multisport), once training per day
79353760|NCT03995056|Behavioral|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
79353761|NCT03792958|Drug|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
79353762|NCT05632588|Other|Observational study|Observational surveillance study
79353763|NCT04407208|Biological|Convalescent plasma|The minimum titer of specific antibody is 1/80
79353764|NCT03025360|Drug|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
79990315|NCT03657914|Procedure|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
79990316|NCT03657524|Other|echocardiography|Speckle tracking echocardiography
79504470|NCT05059704|Other|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
79353765|NCT04766554|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
79990317|NCT03311659|Biological|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
79504471|NCT05006352|Drug|DNL343|Oral repeating dose
79504472|NCT05006352|Drug|Placebo|Oral repeating dose
79504473|NCT05418192|Other|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
79990318|NCT03874234|Drug|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
79990319|NCT03874234|Drug|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
79990320|NCT03657446|Drug|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
79990321|NCT03657446|Drug|Placebo|Matching placebo infusion
79990322|NCT03657446|Drug|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
79504474|NCT05418192|Other|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
79504475|NCT04399434|Other|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
79504476|NCT04760574|Diagnostic Test|Testosterone|Serum total testosterone and free testosterone level
79990323|NCT05276323|Drug|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
79353766|NCT05632510|Diagnostic Test|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
79353767|NCT03025048|Behavioral|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
79990324|NCT05276323|Drug|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
79504477|NCT03237390|Drug|Gemcitabine Hydrochloride|Given IV
79504478|NCT03237390|Other|Laboratory Biomarker Analysis|Correlative studies
79504479|NCT03237390|Other|Pharmacological Study|Correlative studies
79504480|NCT03237390|Drug|Ribociclib|Given PO
79504481|NCT05328804|Drug|rhTPO|subcutaneous injection
79990325|NCT02727452|Other|Skin-to-skin contact|
79504482|NCT05328804|Drug|Herombopag|Orally by mouth
79504483|NCT05348850|Device|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
79990326|NCT05276245|Behavioral|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
79990327|NCT05275777|Drug|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
79990328|NCT05275777|Drug|Doxorubicin|Administered as an intravenous infusion.
79990329|NCT05275777|Drug|Cyclophosphamide|Administered as an intravenous infusion.
79990330|NCT05275777|Drug|Paclitaxel|Administered as an intravenous infusion.
79990331|NCT02985398|Biological|ALD403 (Eptinezumab)|
79353768|NCT03599050|Behavioral|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
79353769|NCT03593512|Procedure|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
79504484|NCT05340348|Other|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
79504485|NCT03293238|Procedure|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
79504486|NCT03293238|Procedure|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
79504487|NCT03293238|Procedure|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
79353770|NCT03595462|Other|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be ~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be ~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
79504488|NCT03293238|Procedure|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
79504489|NCT03292068|Combination Product|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
79818123|NCT02577705|Behavioral|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
79818124|NCT02577705|Behavioral|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
79666343|NCT03580629|Behavioral|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
79666344|NCT03579446|Drug|Hydrocodone|Given by PO
79818125|NCT02577705|Behavioral|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
79818126|NCT00918450|Drug|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
79990332|NCT05275621|Device|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
79666345|NCT03579446|Drug|Hydromorphone|Given by PO
79666346|NCT03579446|Drug|Levorphanol|Given PO
79666347|NCT03579446|Drug|Morphine|Given by PO
79353771|NCT03595462|Other|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
79504490|NCT03292068|Dietary Supplement|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
79666348|NCT03579446|Drug|Oxycodone|Given by PO
79666349|NCT03579446|Drug|Oxymorphone|Given by PO
79666350|NCT03579446|Other|Questionnaire Administration|Ancillary studies
79666351|NCT03538301|Drug|ND-L02-s0201 (Low Dose)|Intravenous administration every 2 weeks
79666352|NCT03538301|Drug|ND-L02-s0201 (High Dose)|Intravenous administration every 2 weeks
79666353|NCT03538301|Other|Other: Placebo|Saline
79666354|NCT03537508|Biological|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
79666355|NCT03537508|Biological|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
79666356|NCT03537508|Biological|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, and 6 months of age, Intramuscular
79353772|NCT03990532|Radiation|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
79504491|NCT03292068|Other|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
79504492|NCT04400136|Drug|Lansoprazole oral tablets 30 mg|Post operative prescription
79504493|NCT04941066|Behavioral|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
79504494|NCT04941066|Behavioral|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
79504495|NCT04938336|Behavioral|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
79504496|NCT04932252|Drug|A4368 or placebo tablet|orally administered
79504497|NCT04278300|Biological|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
79504498|NCT04278300|Biological|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
79504499|NCT02984436|Procedure|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
79666357|NCT03537508|Biological|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
79353773|NCT03990532|Radiation|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
79504500|NCT02984436|Behavioral|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
79818127|NCT04092374|Procedure|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
79504501|NCT05266014|Drug|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
79666358|NCT03537508|Biological|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
79666359|NCT03537508|Biological|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
79666360|NCT03537508|Biological|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
79353774|NCT03990064|Other|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
79504502|NCT03693144|Other|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
79504503|NCT03693144|Other|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
79504504|NCT03693144|Other|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
79504505|NCT04902768|Other|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
79504506|NCT02984670|Behavioral|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
79666361|NCT03537508|Biological|Varicella vaccine|Varicella vaccine at 12 months of age
79666362|NCT03537508|Biological|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
79818128|NCT02591628|Behavioral|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
79818129|NCT04090112|Drug|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
79504507|NCT02984670|Behavioral|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
79504508|NCT02984670|Behavioral|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
79818130|NCT04090112|Drug|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
79504509|NCT04592406|Other|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR<30mL/min/1.73m2 patients.
79818131|NCT02590770|Behavioral|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
79818132|NCT02590770|Other|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
79818133|NCT04091906|Device|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
79818134|NCT03951948|Other|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
79818135|NCT04071717|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
79818136|NCT04071717|Behavioral|Sham NIRS neurofeedback|Sham NIRS neurofeedback
79818137|NCT00747344|Drug|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
79818138|NCT00747344|Drug|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
79353775|NCT05632042|Behavioral|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
79353776|NCT03595306|Dietary Supplement|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
79666363|NCT03509558|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
79818139|NCT00747344|Drug|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
79818140|NCT00747344|Drug|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
79818141|NCT00580983|Radiation|IMRT|
79818142|NCT00580983|Drug|Paclitaxel|
79353777|NCT03595306|Dietary Supplement|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
79818143|NCT00580983|Drug|Carboplatin|
79818144|NCT00580983|Drug|Cisplatin|
79353778|NCT03595306|Dietary Supplement|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
79666364|NCT03509558|Other|Physical Therapy|physical therapy to improve walking and standing functions
79666365|NCT03496675|Behavioral|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
79666366|NCT03496675|Behavioral|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
79666367|NCT03496675|Other|Standard care|May include pharmacological and non-pharmacological interventions as locally available
79666368|NCT03485157|Biological|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
79666369|NCT03485157|Drug|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
79666370|NCT03424018|Drug|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
79818145|NCT00580983|Drug|5-Fluorouracil|
79818146|NCT02576223|Drug|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
79818147|NCT02576223|Drug|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
79818148|NCT04089878|Procedure|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
79818149|NCT04089878|Other|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
79818150|NCT00917618|Other|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
79818151|NCT00917618|Other|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
79666371|NCT03405155|Biological|Nivolumab|Given IV
79666372|NCT03383692|Drug|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
79818152|NCT02309931|Procedure|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
79818153|NCT02309931|Procedure|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
79818154|NCT04071873|Diagnostic Test|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
79990333|NCT05275621|Procedure|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
79990334|NCT04460144|Diagnostic Test|Mass spectrometry|Proteomic analysis
79353779|NCT05631652|Device|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
79353780|NCT03594916|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
79504510|NCT02984592|Behavioral|physical exercise|regular exercise programs in the previous 6 months.
79353781|NCT03594916|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
79353782|NCT03989362|Drug|Vopratelimab|Specified dose on specified days
79353783|NCT03989362|Drug|Ipilimumab|Specified dose on specified days
79504511|NCT04746144|Procedure|Total knee arthroplasty|
79666373|NCT03383692|Drug|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
79666374|NCT03383692|Drug|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
79504512|NCT04857840|Drug|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
79504513|NCT04582968|Other|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
79524734|NCT03832530|Behavioral|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
79524735|NCT03832296|Behavioral|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
79666375|NCT03342196|Drug|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
79818155|NCT04071873|Behavioral|HIV testing education|Participants will be provided with education on community based HIV resources.
79818156|NCT02577627|Device|PrediCare|
79818157|NCT02599376|Device|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
79823806|NCT00426751|Drug|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
79504514|NCT04563468|Procedure|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of ~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at ~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
79504515|NCT04563468|Procedure|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
79504516|NCT03261570|Drug|Pyridostigmine|60mg by mouth
79504517|NCT03261570|Drug|Digoxin|0.5 (500mcg) by mouth
79818158|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
79504518|NCT03261570|Drug|Placebo|Lactulose 50mg by mouth
79818159|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
79818160|NCT02577393|Drug|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
79818161|NCT02599298|Device|Continuous Positive Airway Therapy|
79504519|NCT05292612|Behavioral|iCBT(C&W) for SAD|iCBT(C&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
79666376|NCT03342196|Drug|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
79353784|NCT04009096|Biological|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10^10 vp ChAd63 PvDBP and one dose of 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
79353785|NCT03594838|Other|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
79353786|NCT05631106|Behavioral|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
79353787|NCT05631106|Behavioral|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
79353788|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
79504520|NCT03227562|Drug|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
79504521|NCT04277364|Dietary Supplement|phosphatidic acid supplementation|The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
79504522|NCT04277364|Other|Placebo (corn starch supplementation)|Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
79504523|NCT04277364|Other|Strength training|All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
79504524|NCT05276778|Diagnostic Test|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
79818162|NCT02599298|Behavioral|Sleep-Study Guided Multidisciplinary Therapy|
79818163|NCT02241291|Procedure|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
79818164|NCT00753896|Drug|exenatide|subcutaneous injection, 2.0mcg, once weekly
79353789|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
79353790|NCT04407130|Drug|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
79353791|NCT04407130|Drug|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
79353792|NCT04407130|Drug|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
79353793|NCT03599440|Other|Pressure line extensions|"Two types of extension lines are connected:~Perfusor® line 150cm (polyethylene)~conventional arterial extension line"
79353794|NCT03599284|Drug|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
79353795|NCT03599284|Drug|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
79353796|NCT03599284|Drug|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
79353797|NCT03599284|Drug|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
79353798|NCT04407052|Drug|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
79353799|NCT04407052|Drug|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
79504525|NCT04557228|Dietary Supplement|Placebo|4 weeks of placebo supplements
79504526|NCT04557228|Dietary Supplement|Phosphatidylserine|4 weeks of 900mg phosphatidylserine supplements
79504527|NCT04278378|Dietary Supplement|Riboflavin|1.6 mg riboflavin / day for 24 weeks
79504528|NCT04278378|Dietary Supplement|Folic acid|0.4 mg folic acid / day for 24 weeks
79504529|NCT04278378|Dietary Supplement|Placebo|
79666377|NCT03342196|Drug|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
79666378|NCT03330132|Biological|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
79666379|NCT03330132|Biological|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
79666380|NCT03330132|Biological|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
79666381|NCT03330132|Biological|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
79666382|NCT03309007|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
79818165|NCT02597114|Drug|AGT-181|intravenous infusion over 3-4 hours
79823807|NCT02576366|Drug|Voriconazole|
79353800|NCT03024814|Drug|Acetaminophen|"The first group will receive acetaminophen as the following~Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
79353801|NCT03024814|Drug|Dextrose 5|"The second group will receive placebo (D5W) as the following~Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
79353802|NCT03024502|Drug|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
79353803|NCT03024502|Drug|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
79353804|NCT03024502|Drug|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
79353805|NCT03024580|Drug|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
79353806|NCT03024580|Drug|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
79353807|NCT03024580|Drug|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
79353808|NCT03024580|Drug|Exemestane 25 MG|Exemestane 25 mg PO daily
79353809|NCT03024580|Drug|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
79823808|NCT02576366|Drug|Rifampin|
79823809|NCT01030159|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
79353810|NCT03024580|Drug|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
79353811|NCT03599128|Other|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
79353812|NCT03599128|Other|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
79353813|NCT03599128|Other|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
79353814|NCT03599128|Other|Placebo|Reconstituted in water and given to subjects
79353815|NCT03594682|Other|Intervention/treatment|"experimentalgroup initial dose：~250mg qod~250mg qd/500mg qd by turn~500mg qd control group： 750mg qd"
79353816|NCT01851590|Device|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
79353817|NCT01851590|Drug|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
79353818|NCT01851590|Drug|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
79353819|NCT03598972|Other|intervention|elementary analysis
79353820|NCT03598816|Drug|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
79504530|NCT04399512|Procedure|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
79504531|NCT04399278|Diagnostic Test|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~T0: baseline.~T1: At the end of the first EEO (15 sec or 30 sec)~T2: 1 minute after completion of the first EEO. Return to baseline.~T3: At the end of the second EEO (15 sec or 30 sec)~T4: 1 minute after completion of the second EEO. Return to baseline.~T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
79504532|NCT04797468|Drug|HLX23|administered IV.
79504533|NCT04785924|Drug|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
79504534|NCT04765176|Device|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
79504535|NCT04514562|Device|NeVa Stent Retrievers|mechanical neurothrombectomy
79504536|NCT04509180|Procedure|Catheter ablation|Endovascular approach
79504537|NCT04509180|Procedure|Convergent procedure|Surgical and endovascular approach
79504538|NCT04509024|Behavioral|Incidental training|Nonspeech perceptual building block categories are established, which may be used to scaffold language learning.
79504539|NCT04509024|Behavioral|Explicit training|Traditional explicit language training, which involves establishing sound to meaning.
79504540|NCT04348110|Dietary Supplement|Placebo tablets|consume 2 tablets per day for 8 weeks
79504541|NCT04348110|Dietary Supplement|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
79524736|NCT03832296|Behavioral|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
79504542|NCT04506294|Behavioral|eScreen system|The eScreen system is composed of a child screening component and a parent information component. The child screening component is delivered via a game-like interface and includes assessment of current pain, PTSS, and functional recovery. Children are asked to play the game at least 3x/week. The parent information component consists of text / email messages sent to parents at least weekly that summarize child ratings and include a link to an online dashboard with additional personalized information for parents.
79504543|NCT05251818|Other|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
79504544|NCT05251818|Other|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
79666383|NCT03309007|Drug|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
79353821|NCT03598816|Drug|Tremelimumab|-Tremelimumab will be administered first
79666384|NCT03261544|Procedure|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
79504545|NCT04398810|Procedure|robotic single port cholecystectomy|"Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~Residual gas aspiration~Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~Warming of the washing solution in the abdominal cavity"
79504546|NCT02084628|Drug|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
79504547|NCT04760418|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
79990335|NCT03310723|Device|Face Mask preoxygenation|Standard face mask preoxygenation.
79666385|NCT03206671|Drug|Rituximab window|Rituximab window (375 mg/m²)
79666386|NCT03206671|Drug|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
79990336|NCT03310723|Device|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
79666387|NCT03206671|Drug|Cyclophosphamide|see detailed protocol description
79990337|NCT02760290|Procedure|Extraperitoneal cesarean section|
79666388|NCT03206671|Drug|Cytarabine|see detailed protocol description
79990338|NCT02760290|Procedure|Intraperitoneal cesarean section|
79990339|NCT05672212|Device|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
79990340|NCT05672212|Device|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
79353822|NCT03598816|Device|TDS-IM v1.0 System|-Integrated electroporation device
79666389|NCT03206671|Drug|Dexamethasone|see detailed protocol description
79666390|NCT03206671|Drug|Doxorubicin hydrochloride|see detailed protocol description
79666391|NCT03206671|Drug|Vindesine Sulfate|see detailed protocol description
79666392|NCT03206671|Drug|Etoposide|see detailed protocol description
79666393|NCT03206671|Drug|Ifosfamide|see detailed protocol description
79666394|NCT03206671|Drug|Methotrexate|see detailed protocol description
79823810|NCT01030237|Other|FID 114657|1 drop both eyes four times a day for 6 weeks
79823811|NCT01030237|Other|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
79823812|NCT04046679|Drug|Bleomycin|Skin bleomycin infusion through tattoo machine
79823813|NCT04046679|Other|Saline Solution|Saline solution infusion through tattoo machine
79990341|NCT05672212|Drug|Sufentanil|Sufentanil
79353823|NCT03598816|Biological|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
79353824|NCT03598816|Procedure|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
79504548|NCT04277520|Procedure|Root canal therapy|Different types of instrumentation motions during root canal therapy
79666395|NCT03206671|Drug|Prednisolone|see detailed protocol description
79666396|NCT03206671|Drug|Vincristine|see detailed protocol description
79990342|NCT05275309|Other|Exploration of optimal PEEP in supine and prone position|"General anesthesia is done in routine manner~A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~One hour after prone position, optimal PEEP is determined again."
79990343|NCT02388022|Device|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
79990344|NCT02725892|Other|NIS observational stud|NIS observational study : Epidemiologic registry
79504549|NCT04399902|Device|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
79504550|NCT04277754|Other|Observational|To Observe and describe motor and visual development
79504551|NCT04451772|Drug|Elsubrutinib|Oral; Capsule
79504552|NCT04451772|Drug|Placebo for Elsubrutinib|Oral; Capsule
79504553|NCT04451772|Drug|Upadacitinib|Oral; Tablet
79504554|NCT04451772|Drug|Placebo for Upadacitinib|Oral; Tablet
79504555|NCT03831984|Drug|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
79990345|NCT05275153|Other|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
79504556|NCT03831984|Drug|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
79823814|NCT01323439|Device|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
79990346|NCT02390674|Drug|Ciclosporin|Comparison between ciclosporin and placebo
79353825|NCT05633758|Drug|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
79504557|NCT02084706|Procedure|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
79504558|NCT02084706|Drug|2% Lidocaine|
79504559|NCT02084706|Drug|Triamcinolone (20 g)|
79504560|NCT02084706|Procedure|J-tip lidocaine administration|
79504561|NCT02084706|Procedure|Triamcinolone (20 g) Injection over the A1 pulley.|
79504562|NCT04686084|Device|Dual-energy computed tomography scan|Diagnostic CT scan
79504563|NCT04433988|Drug|Pentoxifylline|Pentoxifylline 400 mg SR tablet
79823815|NCT00786279|Other|ethanol|15 gm ethanol daily for 6 months
79823816|NCT00786279|Other|Ethanol-free beverage|0 grams ethanol daily for 6 months.
79990347|NCT02390674|Drug|Saline|
79990348|NCT03657290|Drug|vadadustat|Vadadustat Tablets
79990349|NCT02390830|Other|Falls Prevention|
79504564|NCT04433988|Drug|Placebo|Placebo tablet
79504565|NCT04425408|Device|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
79504566|NCT04685538|Drug|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~1st Drop instillation, then wait for 5 minutes~Eye Disinfection, then wait for 2 minutes~2nd Drop instillation, then wait for 1 minute~3rdDrop instillation, then wait for 1 minute~Start of Surgery."
79504567|NCT04685538|Drug|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~1st Drop instillation, then wait for 5 minutes~Eye Disinfection, then wait for 2 minutes~2nd Drop instillation, then wait for 1 minute~3rdDrop instillation, then wait for 1 minute~Start of Surgery."
79504568|NCT03255798|Device|G2 and G3|Two iStent inject devices and one iStent supra device
79504569|NCT04746222|Biological|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
79504570|NCT04746222|Other|Placebo|Single dose of 30 oral placebo capsules
79504571|NCT04746768|Combination Product|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
79504572|NCT04344678|Drug|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
79504573|NCT04344678|Drug|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
79504574|NCT03212118|Behavioral|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
79666397|NCT03184792|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
79666398|NCT03184792|Other|Physical therapy|Physical therapy to improve arm and hand functions
79666399|NCT03178617|Other|Educational Intervention|Attend standard of care LIP
79666400|NCT03178617|Other|Educational Intervention|Attend HIP
79666401|NCT03178617|Other|Quality-of-Life Assessment|Ancillary studies
79666402|NCT03178617|Other|Questionnaire Administration|Ancillary studies
79666403|NCT03161431|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
79666404|NCT03161431|Biological|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
79666405|NCT03129126|Drug|LP-10|Intravesical tacrolimus
79818166|NCT04852107|Other|Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation|"Lead Implantation which will be conducted in 2 steps:~Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm."
79353826|NCT05633758|Drug|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
79353827|NCT03598738|Drug|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
79353828|NCT03594292|Device|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
79818167|NCT00743444|Drug|AZD3355|65 mg capsules, oral, 3 single doses
79818168|NCT00743444|Drug|Placebo|capsules, oral, 3 single doses
79353829|NCT03594292|Procedure|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
79666406|NCT03098563|Drug|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
79823817|NCT01030315|Drug|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
79823818|NCT00791193|Drug|Paliperidone ER|
79823819|NCT00791271|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
79990350|NCT02390830|Other|Reduction of limitations at body function and activity levels|
79353830|NCT03594214|Diagnostic Test|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
79353831|NCT04004182|Dietary Supplement|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
79353832|NCT04003948|Drug|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
79504575|NCT03212118|Behavioral|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
79504576|NCT03212118|Behavioral|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
79666407|NCT03066960|Procedure|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
79666408|NCT03066960|Procedure|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
79666409|NCT03048019|Drug|Tirofiban|Patients will receive Tirofiban during the PCI procedure
79666410|NCT03048019|Drug|Cangrelor|Patients will receive Cangrelor during the PCI procedure
79666411|NCT03036007|Other|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
79666412|NCT03036007|Other|Exercises with Internet support|Neck-specific exercise with Internet support
79666413|NCT03035604|Other|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
79666414|NCT03030079|Device|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
79666415|NCT03019133|Device|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
79666416|NCT03019133|Device|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
79990351|NCT03622346|Procedure|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
79990352|NCT02613728|Behavioral|Accelerated Recovery Plan|
79353833|NCT05633368|Other|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~Patient Health Questionnaire (PHQ-9)~Clinical Global Impression (CGI)~Scaling question regarding depressive symptomatology"
79353834|NCT03598582|Drug|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
79353835|NCT03593980|Dietary Supplement|Cranberry juice|400ml cranberry juice
79353836|NCT03976882|Drug|Hetrombopag|Hetrombopag
79353837|NCT03976882|Drug|Placebo|Placebo
79353838|NCT03024736|Other|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
79504577|NCT04056312|Behavioral|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
79504578|NCT04056312|Behavioral|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
79504579|NCT03249558|Drug|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
79666417|NCT03006705|Drug|Nivolumab|Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
79666418|NCT03006705|Drug|Tegafur-gimeracil-oteracil potassium|Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
79818169|NCT02598284|Other|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
79823820|NCT00791271|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
79990353|NCT02613728|Behavioral|Early Discharge|
79990354|NCT02613728|Other|Telemedicine|
79353839|NCT04747990|Procedure|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
79666419|NCT03006705|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
79666420|NCT03006705|Drug|Capecitabine|Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
79666421|NCT03006705|Drug|Placebo|Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
79666422|NCT02998645|Drug|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
79823821|NCT02555163|Device|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
79990355|NCT02613728|Behavioral|Standard Enhanced Care|
79990356|NCT02390596|Drug|Anakinra|The dose of Anakinra will be 2mg/kg (patients <10kg and/or <8 months: 4mg/kg). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra 4mg/kg (patients <10kg and/or <8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients <10kg and/or <8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
79990357|NCT02663674|Drug|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
79990358|NCT02663674|Other|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
79990359|NCT02908880|Device|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
79353840|NCT03598504|Device|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
79353841|NCT02985346|Biological|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
79353842|NCT02979730|Other|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
79353843|NCT02979730|Other|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
79353844|NCT01852058|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
79353845|NCT05633134|Procedure|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
79353846|NCT05633134|Procedure|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
79990360|NCT03657212|Drug|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
79353847|NCT03593668|Drug|Metformin|"2-week dose adjustment period（0-2weeks）[before meals] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
79353848|NCT03593668|Drug|Benaglutide|"2-week dose adjustment period（0-2weeks） [before meals] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
79353849|NCT05632900|Procedure|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
79504580|NCT03249558|Drug|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
79990361|NCT03310411|Drug|Lasmiditan|Administered orally
79990362|NCT03310411|Drug|Sumatriptan|Administered orally
79990363|NCT03310411|Drug|Placebo for Lasmiditan|Administered orally
79353850|NCT03598348|Drug|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
79353851|NCT03598348|Drug|Apatinib|Apatinib 250mg po Qd
79353852|NCT03598192|Procedure|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
79353853|NCT03598192|Procedure|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
79353854|NCT03598192|Drug|Ropivacaine|Ropivacaine has been treated the both group
79353855|NCT03598192|Drug|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
79990364|NCT03310411|Drug|Placebo for Sumatriptan|Administered orally
79990365|NCT03301831|Behavioral|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
79823822|NCT02555163|Device|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
79990366|NCT02909504|Drug|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
79990367|NCT02505230|Behavioral|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
79990368|NCT02390440|Drug|EXPAREL|
79353856|NCT03597958|Genetic|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
79504581|NCT03249558|Drug|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
79666423|NCT02998645|Drug|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~12-24 months: dose was maintained"
79666424|NCT02953899|Behavioral|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
79666425|NCT02953899|Behavioral|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
79823823|NCT00786357|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
79990369|NCT03677830|Drug|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
79353857|NCT04003246|Radiation|Thoracic RT and Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV], first dose within 3 days of RT initiation
79353858|NCT04003246|Drug|Consolidative Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV] up to one year
79504582|NCT03246828|Other|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
79504583|NCT04746300|Procedure|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
79504584|NCT04746300|Procedure|Blood sample|Blood samples will be taken for additional translational research
79504585|NCT02476812|Behavioral|Positive Piggy Bank|Already noted.
79666426|NCT02917720|Other|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
79823824|NCT00786357|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
79823825|NCT00791349|Drug|Immediate release (IR) Paliperidone|
79666427|NCT02917720|Drug|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
79990370|NCT03677830|Drug|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
79990371|NCT02387866|Drug|AG-221|
79990372|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
79990373|NCT02199691|Biological|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
79990374|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
79990375|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
79990376|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
79990377|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
79353859|NCT00218296|Drug|Usual Care Group|Nicotine replacement therapy
79353860|NCT00218296|Other|Reduction Group|Subject selects preferred method for reduction.
79353861|NCT00217672|Biological|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
79353862|NCT00217672|Drug|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
79353863|NCT03593122|Device|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
79990378|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
79353864|NCT03597880|Other|obese patients|underwent bariatric surgery
79353865|NCT03592966|Dietary Supplement|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
79353866|NCT03592966|Dietary Supplement|Placebo|Freeze-dried placebo powder
79353867|NCT03597802|Other|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
79353868|NCT03597802|Other|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
79353869|NCT03597724|Other|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
79353870|NCT00216736|Drug|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
79353871|NCT00216736|Drug|placebo|Single dose oral placebo at ED discharge
79353872|NCT03592810|Other|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
79353873|NCT01850030|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
79353874|NCT01850030|Drug|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
79353875|NCT01850030|Drug|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
79353876|NCT01850030|Drug|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
79353877|NCT00215644|Drug|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
79504586|NCT04316442|Biological|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
79504587|NCT02090712|Procedure|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
79504588|NCT03206190|Other|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
79504589|NCT03206190|Behavioral|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
79504590|NCT03206190|Diagnostic Test|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
79504591|NCT03206190|Diagnostic Test|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
79666428|NCT02805855|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
79353878|NCT00215644|Drug|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
79353879|NCT00215644|Drug|Cisplatin|Participants will receive cisplatin 60 mg/m^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
79353880|NCT00215644|Drug|Capecitabine|Participants will receive capecitabine 1250 mg/m^2 daily in a 21-day cycles up to a maximum of 8 cycles.
79353881|NCT03597490|Combination Product|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
79353882|NCT04747756|Other|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
79353883|NCT03597412|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
79353884|NCT03597412|Drug|Monorova|Rosuvastatin 20mg
79353885|NCT03592732|Other|Blood sample|Blood sample
79353886|NCT01870401|Device|Lutonix DCB|
79353887|NCT01870401|Device|Uncoated PTA Catheter|
79504592|NCT03206190|Diagnostic Test|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
79504593|NCT03206190|Diagnostic Test|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
79504594|NCT03206190|Diagnostic Test|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
79504595|NCT04277052|Device|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
79666429|NCT02724228|Drug|BMN 111|BMN 111 will be administered subcutaneously daily.
79818170|NCT02598284|Other|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
79666430|NCT02719327|Drug|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
79666431|NCT02719327|Other|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
79666432|NCT02711709|Other|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~muscle weakness~fatigue~low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
79353888|NCT03597334|Behavioral|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
79353889|NCT04414839|Device|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
79504596|NCT03204396|Drug|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
79504597|NCT03204396|Drug|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) once weekly for 12 weeks
79666433|NCT02711709|Other|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
79818171|NCT05673369|Drug|CKD-387|1 Tablet
79818172|NCT05673369|Drug|D484|1 Tablet
79990379|NCT05671978|Procedure|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
79353890|NCT04414839|Device|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
79504598|NCT04398498|Diagnostic Test|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
79666434|NCT02711709|Other|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
79666435|NCT02711709|Other|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
79666436|NCT02710734|Drug|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
79666437|NCT02710734|Drug|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
79666438|NCT02710734|Drug|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
79666439|NCT02710734|Drug|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
79818173|NCT00743366|Drug|Marijuana|0,6.2% THC
79818174|NCT00743366|Drug|Quetiapine|200 mg/day
79818175|NCT00743366|Drug|Placebo oral capsule|
79818176|NCT01760655|Drug|Fludarabine phosphate|Given IV
79818177|NCT01760655|Drug|Busulfan|Given IV
79353891|NCT00213148|Drug|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
79504599|NCT03631680|Procedure|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
79990380|NCT05671978|Procedure|neutral position|The patient was then placed in the netural position
79990381|NCT02390128|Other|observational only|
79990382|NCT03113578|Device|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
79990383|NCT03105856|Biological|CERVARIX|- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
79504600|NCT03174132|Device|Restylane Perlane Lidocaine|Intradermal injection
79990384|NCT03105856|Biological|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp & Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
79990385|NCT03299881|Device|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
79990386|NCT03299881|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
79990387|NCT02389972|Drug|Dasatinib|
79990388|NCT03105934|Procedure|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
79990389|NCT03299101|Other|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
79990390|NCT02663128|Drug|Lanabecestat|Administered orally
79990391|NCT02389582|Drug|Dabigatran|Use for 5 days
79353892|NCT00213148|Drug|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
79353893|NCT00213148|Drug|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
79504601|NCT03174132|Device|Restylane Perlane|Intradermal injection
79504602|NCT04271904|Other|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
79504605|NCT04233528|Diagnostic Test|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
79504606|NCT01680510|Dietary Supplement|Alga Dunaliella Bardawil|
79504607|NCT01680510|Other|Placebo (starch)|
79504608|NCT04398186|Diagnostic Test|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
79504609|NCT03818802|Dietary Supplement|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
79504610|NCT03818802|Dietary Supplement|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
79504611|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
79504612|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
79504613|NCT04398108|Drug|Margetuximab Margetuximab-IV|Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
79504614|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
79504615|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
79504616|NCT01625286|Drug|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
79504617|NCT01625286|Drug|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
79990392|NCT02389582|Drug|Enoxaparin|Use for 5 days
79504618|NCT04277130|Behavioral|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I & II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
79666440|NCT02710734|Radiation|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
79666441|NCT02710734|Procedure|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
79666442|NCT02710734|Drug|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
79666443|NCT02710734|Drug|Mitomycin C|Intravenous on day 1 with radiation treatment
79990393|NCT03298867|Biological|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
79990394|NCT03298867|Other|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
79353894|NCT00213148|Drug|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
79353895|NCT00213148|Drug|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
79353896|NCT01704261|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
79353897|NCT01704261|Drug|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
79353898|NCT01704261|Drug|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
79353899|NCT01704261|Drug|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
79353900|NCT01715571|Device|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
79666444|NCT02669225|Other|[18F]florbetaben|PET radiotracer to image Amyloid beta (AB) load in human brain.
79353901|NCT00212758|Drug|Nutropin AQ|Nutropin AQ
79666445|NCT02580994|Drug|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
79666446|NCT02580994|Drug|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
79666447|NCT02546661|Drug|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
79666448|NCT02546661|Drug|MEDI4736|MEDI4736
79990395|NCT02906930|Drug|semaglutide|Oral administration once daily.
79353902|NCT04549545|Device|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
79666449|NCT02546661|Drug|Olaparib|MEDI4736 (durvalumab) + Olaparib
79666450|NCT02546661|Drug|AZD1775|MEDI4736 (durvalumab) + AZD1775
79666451|NCT02546661|Drug|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
79666452|NCT02546661|Drug|AZD9150|MEDI4736 (durvalumab) + AZD9150
79990396|NCT02906930|Drug|placebo|Oral administration once daily.
79666453|NCT02546661|Drug|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
79666454|NCT02543567|Biological|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
79353903|NCT04549545|Device|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
79504619|NCT03801174|Behavioral|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
79353904|NCT03592420|Behavioral|Interdisciplinary multicomponent interventions|
79504620|NCT03801174|Behavioral|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
79504621|NCT03796962|Drug|XEN1101|Oral dose
79504622|NCT05158062|Biological|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
79504623|NCT05158062|Drug|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
79990397|NCT02389426|Device|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
79990398|NCT02389426|Device|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
79990399|NCT02389426|Device|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
79504624|NCT05158062|Biological|bevacizumab|bevacizumab 15 mg/kg Q3W
79504625|NCT05158062|Drug|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
79504626|NCT05158062|Drug|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
79990400|NCT02389426|Device|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
79818178|NCT01760655|Radiation|Total-Body Irradiation|Undergo TBI
79818179|NCT01760655|Biological|Therapeutic Allogeneic Lymphocytes|Undergo DLI
79990401|NCT05274841|Other|Support of relatives|Screening of the support needs of relatives
79990402|NCT02389660|Behavioral|Blended Cognitive Behavioural Therapy (CBT)|
79990403|NCT02389660|Behavioral|Treatment as usual|
79990404|NCT04580407|Biological|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
79990405|NCT02389504|Other|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
79353905|NCT03592420|Behavioral|Usual care|standard care
79353906|NCT01824290|Drug|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
79353907|NCT01824290|Drug|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
79504627|NCT05158062|Drug|docetaxel|docetaxel 60 ~ 70 mg/m2 Q3W during treatment period
79504628|NCT01076868|Drug|Primaquine|Primaquine x 14 days
79504629|NCT03193866|Drug|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
79524737|NCT05447208|Drug|Growth Hormone|Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
79524738|NCT05447208|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
79524739|NCT05444556|Drug|Imlunestrant|Administered orally.
79524740|NCT05444556|Drug|Repaglinide|Administered orally.
79524741|NCT05444556|Drug|Omeprazole|Administered orally.
79524742|NCT05444556|Drug|Dextromethorphan|Administered orally.
79524743|NCT05444556|Drug|Quinidine|Administered orally.
79524744|NCT05444556|Drug|Rosuvastatin|Administered orally.
79990406|NCT02389504|Other|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
79990407|NCT05256589|Diagnostic Test|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
79504630|NCT05151432|Device|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
79666455|NCT02543567|Biological|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
79353908|NCT01824290|Drug|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
79666456|NCT02543567|Biological|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
79666457|NCT02543567|Biological|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
79818180|NCT01760655|Drug|Cyclophosphamide|Given IV
79818181|NCT01760655|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
79818182|NCT01760655|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
79818183|NCT01760655|Drug|Tacrolimus|Given IV
79818184|NCT01760655|Drug|Mycophenolate Mofetil|Given IV
79818185|NCT01760655|Other|Laboratory Biomarker Analysis|Correlative studies
79823826|NCT00440401|Drug|fibrinogen (human) + thrombin (human)|
79353909|NCT03596944|Drug|Statin|Prescribed with statins for primary prevention
79353910|NCT03592342|Drug|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
79353911|NCT01715415|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79353912|NCT01715415|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
79353913|NCT01715415|Drug|Placebo for ABT-450/r/ABT-267|Tablet
79353914|NCT01715415|Drug|Placebo for ABT-333|Tablet
79353915|NCT01715415|Drug|Placebo for ribavirin|Capsule
79353916|NCT00211510|Device|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
79504631|NCT05151432|Device|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
79504632|NCT05151432|Other|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
79524745|NCT05444556|Drug|Digoxin|Administered orally.
79524746|NCT05444400|Other|Strengthening|Strengthening
79524747|NCT05444400|Other|Conventional protocol|Conventional protocol
79524748|NCT05443542|Device|Virtual Reality|Game to be played is a commercially available VR game
79524749|NCT05443542|Other|Control intervention|Sodoku, crossword puzzles
79524750|NCT05442294|Behavioral|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
79524751|NCT05441904|Drug|PXL770|A single dose of 500 and 750 mg was administered to each subject.
79524752|NCT05441436|Procedure|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
79666458|NCT02543567|Biological|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
79666459|NCT02543567|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
79666460|NCT02530489|Drug|Atezolizumab|Given IV
79504633|NCT05151432|Device|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US & Electromagnetic field.
79353917|NCT00211510|Device|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
79353918|NCT01869777|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
79504634|NCT04199052|Behavioral|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
79504635|NCT04195776|Drug|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
79818186|NCT00721968|Device|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
79353919|NCT04199260|Device|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
79353920|NCT03596710|Procedure|Image Guided Biopsy|Undergo image guided biopsy
79353921|NCT01714947|Drug|[^14C]-alisertib|[^14C]-alisertib oral solution
79353922|NCT01714947|Drug|alisertib|Alisertib enteric coated tablets
79504636|NCT03708588|Drug|Ticagrelor|Chewed
79666461|NCT02530489|Drug|Nab-paclitaxel|Given IV
79679619|NCT02939586|Procedure|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
79353923|NCT03596632|Drug|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C]-fenebrutinib
79353924|NCT03596554|Other|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
79353925|NCT04198636|Drug|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
79353926|NCT04198636|Drug|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
79353927|NCT04414995|Drug|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
79353928|NCT04414995|Drug|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
79504637|NCT03708588|Drug|Ticagrelor|Integral
79524753|NCT05441436|Procedure|Solid organ transplantation|Solid organ transplantation
79524754|NCT05441358|Procedure|Open Heart Surgery|Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
79524755|NCT05441202|Device|transdermal therapy|transdermal therapy with Chinese medicine
79524756|NCT05440578|Drug|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
79818187|NCT00721968|Procedure|cataract surgery alone|Cataract surgery alone
79818188|NCT00743288|Drug|Melphalan|Same as above
79818189|NCT00743288|Drug|Panobinostat|
79818190|NCT04073511|Drug|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
79353929|NCT04414995|Drug|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
79353930|NCT03591718|Drug|BI 456906|Solution for injection
79353931|NCT03591718|Drug|Placebo|solution for injection
79353932|NCT01869699|Drug|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
79353933|NCT01869699|Drug|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
79990408|NCT02387320|Other|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
79990409|NCT05255497|Device|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
79990410|NCT02389348|Drug|DSM265|Single oral doses of DSM265
79990411|NCT02389348|Drug|OZ439|Single oral doses of OZ439
79990412|NCT05255341|Procedure|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
79353934|NCT04198480|Drug|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
79990413|NCT03656978|Behavioral|dynamic|Use the according methods in dynamic arm descriptions.
79353935|NCT01714635|Device|Tecnis Multifocal Intraocular Lens|
79990414|NCT03656978|Behavioral|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
79990415|NCT02383108|Drug|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
79353936|NCT01714635|Device|Monofocal Intraocular Lens|
79353937|NCT03596398|Genetic|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
79353938|NCT01713933|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
79353939|NCT03759106|Other|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
79990416|NCT02383108|Drug|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
79990417|NCT02383186|Procedure|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
79990418|NCT02383186|Procedure|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
79353940|NCT03759106|Other|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
79353941|NCT01868997|Drug|teprotumumab|
79353942|NCT01868997|Drug|normal saline|
79353943|NCT01875848|Drug|buprenorphine/naloxone|partial opioid agonist
79353944|NCT01875848|Drug|opioid dose escalation|up to 25% increase in patient's current opioid dose
79353945|NCT04588142|Dietary Supplement|Probiotic|Non-elite athletes receive probiotic for 6 weeks
79353946|NCT04588142|Dietary Supplement|Placebo|Non-elite athletes receive placebo for 6 weeks
79353947|NCT04198402|Biological|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
79353948|NCT04198168|Drug|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
79823827|NCT00440401|Drug|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
79990419|NCT03656822|Diagnostic Test|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
79990420|NCT03656822|Diagnostic Test|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
79666462|NCT02519985|Device|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
79666463|NCT02431780|Device|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
79990421|NCT03656822|Diagnostic Test|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
79990422|NCT03656822|Diagnostic Test|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
79990423|NCT03656822|Diagnostic Test|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
79990424|NCT03656822|Diagnostic Test|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
79990425|NCT02387242|Drug|Rifampicin|Single oral dose of rifampicin
79990426|NCT03656588|Drug|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
79990427|NCT03656588|Drug|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
79504640|NCT03667404|Dietary Supplement|Resistant maltodextrin|Resistant maltodextrin powder
79504641|NCT03667404|Dietary Supplement|maltodextrin|maltodextrin powder
79504642|NCT04276662|Drug|DS-3201b|1 dose of 50 mg DS-3201b
79504643|NCT04130802|Drug|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
79504644|NCT04130802|Drug|Placebo|Vehicle eye drops
79504645|NCT04276350|Procedure|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
79666464|NCT02363205|Behavioral|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
79818191|NCT04073511|Drug|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
79990428|NCT02387086|Drug|Thalidomide|
79504646|NCT04276350|Procedure|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
79990429|NCT02387086|Drug|placebo|
79990430|NCT02387086|Drug|Gefitinib|
79990431|NCT02387086|Drug|Aspirin|
79990432|NCT02383030|Drug|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
79504647|NCT03613740|Drug|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
79504648|NCT03613740|Drug|Placebo|Intervention will be administered 30 minutes before breakfast.
79666465|NCT02253238|Behavioral|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
79666466|NCT02253238|Behavioral|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
79990433|NCT02382952|Device|Differential Dissector|
79990434|NCT02382952|Other|Standard Dissection Method|
79990435|NCT02386930|Behavioral|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
79990436|NCT02389114|Other|Soy Protein|Soy protein is commonly consumed in Asian diet.
79990437|NCT02389114|Other|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
79666467|NCT02253238|Other|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
79353949|NCT03973294|Device|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
79504649|NCT03166098|Diagnostic Test|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
79504650|NCT03087162|Drug|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
79353950|NCT03591172|Drug|Propolis|Using propolis as a final irrigation in revascularization
79353951|NCT03591172|Drug|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
79353952|NCT03591172|Drug|saline|Using saline as a final irrigation in revasculariztion
79504651|NCT03165942|Other|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
79504652|NCT03165942|Other|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
79504653|NCT03165942|Drug|Ethanol|
79504654|NCT03163992|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
79504655|NCT04397328|Drug|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
79504656|NCT04397328|Drug|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
79666468|NCT02253238|Behavioral|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
79666469|NCT02253238|Behavioral|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
79666470|NCT02239341|Other|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
79666471|NCT02239341|Other|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
79666472|NCT02227719|Device|CTI|CTI is the titanium mesh
79666473|NCT02227719|Device|Collagen membrane|
79353953|NCT04197622|Drug|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
79666474|NCT02223377|Drug|Morphine|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
79990438|NCT02386852|Drug|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
79990439|NCT02386852|Drug|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
79353954|NCT03592654|Behavioral|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
79353955|NCT03596008|Dietary Supplement|Active drink|The freeze-dried strawberry powder (25 g) in active drink
79353956|NCT03596008|Dietary Supplement|Placebo drink|Placebo drink
79666475|NCT02223377|Drug|Hydromorphone|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
79666476|NCT02146508|Procedure|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
79353957|NCT03595930|Drug|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
79666477|NCT02146508|Device|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
79666478|NCT02139020|Other|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
79666479|NCT02136160|Behavioral|attitude change, behavioral change|
79666480|NCT02136160|Behavioral|prevention program|
79818192|NCT04073511|Drug|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
79823828|NCT00783003|Drug|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
79823829|NCT00783003|Drug|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
79353958|NCT03595852|Drug|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
79353959|NCT03595852|Drug|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
79353960|NCT03591016|Other|Recording number of IV attempts|Recording number of IV attempts in the operating room
79353961|NCT03595696|Other|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
79666481|NCT02094261|Drug|AZD9291|Once daily tablet 80 mg
79666482|NCT02077192|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
79504657|NCT04100538|Behavioral|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
79504658|NCT03163602|Drug|Control group|Access flap and debridement
79666483|NCT02074553|Drug|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
79666484|NCT02074553|Drug|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
79666485|NCT02074553|Drug|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
79666486|NCT02074553|Drug|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
79666487|NCT01751360|Drug|SYR-472|
79666488|NCT01697527|Biological|aldesleukin|Given SC
79666489|NCT01697527|Drug|fludarabine phosphate|Given IV
79666490|NCT01697527|Drug|cyclophosphamide|Given IV
79666491|NCT01697527|Other|laboratory biomarker analysis|Correlative studies
79823830|NCT00783003|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
79823831|NCT00783003|Drug|Placebo|Matching placebo.
79504659|NCT03163602|Device|Test group|Regenerative treatment
79504660|NCT03084354|Other|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
79504661|NCT04398576|Behavioral|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
79504662|NCT04398576|Behavioral|Community actions|There will be embedded community-based actions within a local strategy.
79504663|NCT03081468|Device|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
79504664|NCT03081468|Device|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
79504665|NCT03392376|Drug|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
79504666|NCT03392376|Other|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
79504667|NCT05243628|Biological|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
79504668|NCT05243628|Biological|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79504669|NCT05243628|Device|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
79504670|NCT05249478|Procedure|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
79504671|NCT04083222|Drug|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
79504672|NCT04083222|Drug|ISIS 757456|ISIS 757456 administered as SC injection.
79504673|NCT05249946|Other|FoodStep - a sustainable health-promoting model for food services and early childhood education and care|The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
79504674|NCT04276506|Other|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
79666492|NCT01697527|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
79666493|NCT01697527|Biological|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
79666494|NCT01697527|Radiation|fludeoxyglucose F 18|Undergo PET scan using [18F] FDG tracer
79666495|NCT01697527|Procedure|positron emission tomography|Undergo fludeoxyglucose F18 PET
79666496|NCT01664598|Drug|Tocilizumab|8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
79666497|NCT01653678|Dietary Supplement|Vitamin D-3 (cholecalciferol), 2000 IU|
79504675|NCT04276506|Other|information group|A visual information booklet which is prepared by the researchers will be used
79504676|NCT03148080|Procedure|Cognitive Assessment|Complete CogState
79666498|NCT01653678|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
79666499|NCT01653678|Dietary Supplement|Vitamin D placebo|
79666500|NCT01653678|Drug|Fish oil placebo|
79666501|NCT01632007|Drug|SYR-472|
79666502|NCT01632007|Drug|Alogliptin 25 mg|
79666503|NCT01632007|Drug|Placebo|
79504677|NCT03148080|Other|Questionnaire Administration|Complete Self-Report Questionnaire
79504678|NCT05246124|Other|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
79504679|NCT05244252|Drug|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
79504680|NCT05244252|Drug|Bupivacaine|bupivacaine
79504681|NCT05249790|Drug|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
79504682|NCT05249790|Drug|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
79504683|NCT03370224|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
79504684|NCT03370224|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
79666504|NCT01524926|Drug|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
79666505|NCT01402271|Drug|carboplatin|
79666506|NCT01402271|Drug|paclitaxel|
79504685|NCT03304314|Diagnostic Test|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
79504686|NCT03286842|Drug|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
79504687|NCT05243784|Behavioral|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
79666507|NCT01402271|Drug|pazopanib hydrochloride|
79666508|NCT01402271|Other|laboratory biomarker analysis|
79504689|NCT05245188|Other|Chocolate milk shakes - Product 1|11.3 glucose
79504690|NCT05245188|Other|Chocolate milk shakes - Product 2|8.84 glucose
79504691|NCT05245188|Other|Chocolate milk shakes - Product 3|4.24 glucose
79504692|NCT05245188|Other|Chocolate milk shakes - Product 4|4.36 glucose
79504693|NCT05240274|Drug|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
79666509|NCT01402271|Other|pharmacological study|
79504694|NCT05240274|Drug|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
79666510|NCT01387295|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
79666511|NCT01288378|Drug|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
79666512|NCT01280682|Drug|rituximab|anti-CD20 monoclonal antibody 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
79666513|NCT01209936|Device|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
79679620|NCT02939586|Procedure|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
79504695|NCT05240196|Other|music|playing binaural or non-binaural music
79504696|NCT05240586|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
79504697|NCT05240586|Procedure|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
79679621|NCT00517127|Drug|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
79504698|NCT05240586|Procedure|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
79504699|NCT05244018|Drug|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
79504700|NCT05244018|Drug|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
79504701|NCT04396314|Behavioral|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
79504702|NCT04396314|Behavioral|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
79504703|NCT04276818|Procedure|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
79504704|NCT04276818|Procedure|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
79504705|NCT04396392|Behavioral|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
79504706|NCT02395224|Other|cancer treatment and follow-up according to current regional and national guidelines|
79504707|NCT02391402|Behavioral|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
79504708|NCT02391402|Behavioral|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
79504709|NCT04397640|Diagnostic Test|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
79666514|NCT01129505|Behavioral|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
79504710|NCT02398500|Biological|LMG324|IVT injection
79504711|NCT02398500|Biological|Ranibizumab 0.5 mg|IVT injection
79504712|NCT02398500|Biological|Sham|Fake injection used for masking purposes
79504713|NCT03042858|Other|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
79666515|NCT01072825|Other|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
79504714|NCT03042858|Other|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
79504715|NCT03039660|Behavioral|RefreshMD|Online Sleep Improvement Course
79504716|NCT03039660|Behavioral|Bond Between Us|Online Educational Course
79504717|NCT03037476|Behavioral|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
79504718|NCT03037476|Behavioral|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
79990440|NCT02386852|Drug|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
79990441|NCT02388802|Procedure|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
79353962|NCT04197466|Other|Pelvic Floor Exercise Group|The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
79353963|NCT04197466|Other|Kinesio tape|Kinesio tape application will be performed by ligament technique to the sacral region.
79353964|NCT04197466|Other|Electrical stimulation|External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
79353965|NCT04197388|Device|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
79353966|NCT03590860|Drug|LY3322207|Administered by SC injection
79353967|NCT03590860|Drug|Placebo|Administered by SC injection
79353968|NCT04197154|Behavioral|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
79353969|NCT04197154|Behavioral|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
79353970|NCT04197154|Behavioral|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
79504719|NCT04276896|Biological|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
79666516|NCT01072825|Biological|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
79666517|NCT01072825|Other|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
79679622|NCT00517127|Drug|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
79990442|NCT02388802|Procedure|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
79990443|NCT02388802|Procedure|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
79990444|NCT02388802|Drug|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
79353971|NCT04197154|Behavioral|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
79353972|NCT04197154|Behavioral|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
79353973|NCT04191382|Drug|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
79353974|NCT04191382|Drug|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
79353975|NCT01703091|Drug|Ramucirumab|Administered IV
79353976|NCT01703091|Drug|Placebo|Administered IV
79353977|NCT01703091|Drug|Docetaxel|Administered IV
79504720|NCT02984514|Radiation|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
79504721|NCT04276428|Drug|LY3209590|Administered SC.
79990445|NCT02388802|Procedure|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
79990446|NCT02388802|Procedure|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
79990447|NCT02386696|Other|Ultrasound|Lung ultrasound examination on healthy volunteers
79990448|NCT05358964|Behavioral|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
79818193|NCT02591394|Behavioral|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
79990449|NCT02382874|Biological|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
79990450|NCT02382718|Biological|FAST fish mCyp c 1|Subcutaneous immunotherapy
79504722|NCT04276428|Drug|Insulin Degludec|Administered SC.
79504723|NCT05248932|Drug|Norepinephrine bolus|5 microgram bolus therapy
79353978|NCT03023644|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
79353979|NCT01712685|Drug|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
79353980|NCT01712685|Procedure|PET/CT|
79353981|NCT04195516|Other|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
79353982|NCT03590782|Other|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
79504724|NCT05248932|Device|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
79504725|NCT05248932|Drug|Norepinephrine infusion|2.5 microgram/min infusion
79504726|NCT05246826|Other|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
79504727|NCT05246826|Other|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
79504728|NCT05247528|Drug|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
79504729|NCT05247528|Drug|Placebo|Placebo Comparator
79504730|NCT03140514|Drug|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
79504731|NCT02395614|Drug|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
79666518|NCT01072825|Other|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
79666519|NCT01072825|Other|Bone evaluation|PQCT scanner, BMD assessment
79666520|NCT01050218|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
79666521|NCT00679029|Drug|doxorubicin hydrochloride|Given IV
79666522|NCT00679029|Drug|cyclophosphamide|Given IV
79666523|NCT00679029|Biological|bevacizumab|Given IV
79666524|NCT00679029|Drug|paclitaxel|Given IV
79990451|NCT02382718|Biological|Placebo|Subcutaneous immunotherapy
79990452|NCT02382484|Device|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
79990453|NCT02382562|Behavioral|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
79990454|NCT02386306|Drug|GC021109|
79990455|NCT02386306|Other|Placebo|
79666525|NCT00679029|Drug|gemcitabine hydrochloride|Given IV
79353983|NCT05103267|Device|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
79353984|NCT03023800|Procedure|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
79666526|NCT00679029|Other|laboratory biomarker analysis|Correlative studies
79666527|NCT00679029|Biological|pegfilgrastim|Given subcutaneously
79666528|NCT00548730|Procedure|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
79353985|NCT03023800|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
79666529|NCT00519116|Drug|Rapamune® (Sirolimus)|
79353986|NCT03590548|Diagnostic Test|gausher disease|lab investigation and radio logical
79666530|NCT00519116|Drug|Tacrolimus|
79666531|NCT00519116|Drug|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
79666532|NCT00518375|Drug|Rapamune® (Sirolimus)|
79666533|NCT00518375|Drug|Neoral® (Cyclosporine)|
79666534|NCT00518375|Drug|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
79353987|NCT04196998|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
79353988|NCT04196998|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
79353989|NCT04196998|Drug|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
79353990|NCT04197232|Other|clinical evaluation|- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
79353991|NCT04196452|Drug|Ipilimumab|Specified dose on specified days
79353992|NCT03590392|Biological|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
79353993|NCT01867671|Biological|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
79353994|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
79353995|NCT01867671|Biological|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
79353996|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
79353997|NCT03992950|Other|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
79353998|NCT04028206|Dietary Supplement|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
79353999|NCT04028206|Device|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
79354000|NCT04028206|Behavioral|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
79990456|NCT02382172|Behavioral|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
79354001|NCT04601649|Behavioral|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
79354002|NCT03590236|Other|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
79504732|NCT02395614|Drug|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
79504733|NCT04396938|Drug|Lamotrigine|Active Drug Capsule
79504734|NCT04396938|Drug|Placebos|Placebo Capsule
79504735|NCT00639678|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
79504736|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
79504737|NCT00639678|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
79504738|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
79504739|NCT02914158|Drug|Goserelin|
79504740|NCT02914158|Drug|Tamoxifen|
79504741|NCT02914158|Drug|Aromatase Inhibitors|
79504742|NCT02914158|Drug|Leuprolide|
79504743|NCT02765802|Drug|Peginterferon Lambda-1A|
79679623|NCT05174130|Device|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
79990457|NCT02382172|Other|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
79990458|NCT02983604|Drug|GS-5829|Tablet(s) administered orally once daily
79990459|NCT02983604|Drug|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
79354003|NCT03590236|Other|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
79354004|NCT01702311|Drug|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
79354005|NCT04196608|Drug|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
79354006|NCT04196608|Drug|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
79354007|NCT04022200|Device|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
79354008|NCT04196296|Behavioral|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
79354009|NCT04196296|Behavioral|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
79354010|NCT04552743|Drug|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
79354011|NCT04552743|Drug|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
79354012|NCT03590158|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
79504744|NCT05241132|Drug|Tislelizumab plus chemotherapy|"Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
79504745|NCT03132792|Genetic|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
79990460|NCT02983604|Drug|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
79354013|NCT03590080|Drug|Methylprednisolone|
79504746|NCT05241054|Drug|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
79504747|NCT05241054|Drug|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
79504748|NCT05241054|Drug|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
79504749|NCT05241054|Drug|Fentanyl|fentanyl 1 microgram.kg
79504750|NCT05241054|Drug|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
79504751|NCT05241054|Procedure|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
79354014|NCT03593278|Drug|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
79354015|NCT04028362|Drug|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
79354016|NCT03023410|Procedure|VERASENSE|Sensor-Assisted Revision TKA
79354017|NCT03594058|Drug|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
79504752|NCT05241054|Drug|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
79504753|NCT05241054|Drug|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
79504754|NCT05241054|Other|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
79818194|NCT02591394|Behavioral|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
79818195|NCT04089254|Behavioral|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
79990461|NCT02386618|Procedure|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN < 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
79990462|NCT03656432|Drug|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
79990463|NCT02386462|Drug|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
79990464|NCT02386462|Drug|Propofol|
79990465|NCT03656276|Behavioral|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
79504755|NCT05241054|Drug|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
79818196|NCT04089254|Behavioral|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
79818197|NCT02579187|Procedure|tooth extraction|The study tooth will be removed
79818198|NCT02579187|Radiation|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
79818199|NCT02579187|Drug|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
79354018|NCT03594058|Drug|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
79354019|NCT03594058|Drug|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
79354020|NCT01712061|Drug|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
79354021|NCT01712061|Drug|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
79354022|NCT03591094|Drug|PTI-428|Active
79354023|NCT03591094|Drug|Placebo|Placebo
79354024|NCT04195672|Device|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
79504756|NCT04760106|Diagnostic Test|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
79504757|NCT05240820|Procedure|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
79990466|NCT02382328|Drug|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
79990467|NCT02382328|Drug|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
79354025|NCT03592186|Behavioral|Parenting Wisely+|Parenting Wisely+ experimental intervention
79354026|NCT03592186|Behavioral|Treatment as Usual|Treatment as Usual
79354027|NCT03598114|Behavioral|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
79354028|NCT03599674|Behavioral|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
79354029|NCT04195360|Other|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
79354030|NCT04195282|Other|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
79504758|NCT03182400|Behavioral|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
79666535|NCT00338689|Dietary Supplement|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
79666536|NCT00195429|Drug|Tacrolimus|
79354031|NCT04195282|Other|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
79354032|NCT04029766|Drug|HSK3486|
79354033|NCT04193644|Behavioral|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
79666537|NCT00195429|Drug|Sirolimus|
79666538|NCT00195429|Drug|prednisone|
79666539|NCT00349284|Drug|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
79666540|NCT00316160|Drug|Bupropion Hydrochloride Extended-release|
79818200|NCT02579187|Other|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
79990468|NCT03656198|Biological|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
79990469|NCT03656198|Drug|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
79354034|NCT04193644|Behavioral|Walking training|Walking training with moderate intensity
79354035|NCT04195048|Other|Risk factors|Risk factors: modifiable and unmodifiable risk factors
79354036|NCT04195126|Device|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
79354037|NCT04190290|Other|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
79354038|NCT04190290|Diagnostic Test|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
79504759|NCT03182400|Behavioral|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
79504760|NCT00638508|Drug|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
79504761|NCT00638508|Drug|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
79666541|NCT00316160|Drug|Extended-release Venlafaxine|
79666542|NCT00349323|Behavioral|Community directed treatment|
79666543|NCT02959931|Other|High Potassium Meal|Breakfast meal that provides ~2400 mg of dietary potassium. Meals are isocaloric.
79666544|NCT02959931|Other|Low Potassium Meal|Breakfast meal that provides ~540 mg of potassium. Meals are isocaloric.
79666545|NCT00349362|Drug|Testosterone|Sustanon- 200mg intramuscular testosterone
79666546|NCT00349362|Drug|0.9% saline|Saline intramuscular injection every two weeks
79666547|NCT00316238|Drug|olanzapine-RAIM|
79354039|NCT04194736|Other|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
79818201|NCT02579187|Drug|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
79354040|NCT04197544|Procedure|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
79354041|NCT04194892|Biological|Pegilodecakin|Administered SQ
79354042|NCT04028752|Biological|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
79354043|NCT04197778|Drug|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
79354044|NCT04194658|Drug|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
79666548|NCT00316238|Drug|placebo|
79666549|NCT00349401|Drug|ketorolac|
79666550|NCT00349401|Drug|morphine|
79990470|NCT02382250|Behavioral|Survey|Survey will be given to all participants
79354045|NCT04194502|Diagnostic Test|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
79666551|NCT00316316|Behavioral|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
79990471|NCT02388490|Drug|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
79666552|NCT00316316|Behavioral|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
79666553|NCT00349440|Drug|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
79818202|NCT02579187|Drug|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
79818203|NCT02579187|Procedure|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
79818204|NCT02579187|Drug|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
79354046|NCT04194580|Behavioral|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
79354047|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
79354048|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
79354049|NCT04028518|Drug|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
79354050|NCT03023956|Procedure|Locking plates were used for proximal humeral fractures.|
79354051|NCT04028440|Biological|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
79666554|NCT00316394|Device|Preventive Care Checklist Form|
79666555|NCT00349479|Behavioral|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
79666556|NCT00316433|Drug|Irinotecan (CPT-11)|
79666557|NCT00316433|Drug|Oxaliplatin (Eloxatin)|
79666558|NCT00349518|Drug|Dasatinib|
79666559|NCT00316472|Drug|Niacinamide|
79666560|NCT00316511|Drug|Aroplatin|
79666561|NCT00349557|Drug|bevacizumab, bicalutamide and goserelin|
79666562|NCT00349557|Procedure|intensity modulated radiation therapy (IMRT)|
79666563|NCT00316550|Drug|AV608|
79666564|NCT00349596|Drug|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
79666565|NCT00316628|Biological|influenza vaccine|
79666566|NCT00349635|Drug|Metformin and Metformin + Fenofibrate|
79666567|NCT00316745|Drug|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
79354052|NCT04748068|Device|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
79354053|NCT04748068|Device|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
79354054|NCT04190914|Other|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
79354055|NCT01711983|Device|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
79354056|NCT04747678|Drug|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
79354057|NCT04028128|Dietary Supplement|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
79354058|NCT04028128|Dietary Supplement|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
79354059|NCT04027660|Device|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~Administration of Articain 1:200.000~No flap procedure~Place a Zirconia Implant on the alveolar post extraction socket~Place xenograft biomaterial in the jumping gap~Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~Final Impression with a IOS~Placement of the Final Crown~3 month post crown post op~3 IOS will be made for volumetric evaluation :~before tooth extraction~3 month of Osseointegration for final impression~3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
79354060|NCT04194112|Diagnostic Test|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
79354061|NCT04191928|Drug|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
79666568|NCT00316745|Drug|TS-1|S-1 Day1~14, everyday P.O.(Day 15~28 rest)
79818205|NCT02579187|Drug|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
79354062|NCT04193332|Device|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
79354063|NCT04193800|Other|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
79354064|NCT02080312|Drug|Magnevist (gadopentetate dimeglumine)|
79504762|NCT05240430|Drug|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
79504763|NCT00637806|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
79666569|NCT00316745|Drug|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
79666570|NCT00316745|Drug|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
79666571|NCT00316745|Drug|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.
79666572|NCT00349674|Drug|Azathioprine: 2 mg/kg/day|
79666573|NCT00349674|Drug|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
79666574|NCT00316784|Drug|IDEA-033 (and rescue medication)|
79666575|NCT00344916|Drug|Ng-monomethyl-L-arginine (drug)|
79666576|NCT00316823|Genetic|gene expression analysis|
79354065|NCT04027582|Other|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
79354066|NCT04199884|Behavioral|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
79354067|NCT04199884|Behavioral|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
79354068|NCT04199806|Other|Questionnaire review|Review data from questionnaires received about MMS experience.
79354069|NCT04027504|Dietary Supplement|Fitabisc|Biscuits containing antioxidants
79990472|NCT02386540|Behavioral|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
79354070|NCT04027738|Other|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
79354071|NCT04199494|Other|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
79666577|NCT00316823|Genetic|polymerase chain reaction|
79354072|NCT04193488|Behavioral|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
79504764|NCT00637806|Drug|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
79504765|NCT00637806|Drug|Placebo|Placebo oral suspension, 5 mL once daily
79504766|NCT04396782|Other|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
79666578|NCT00316823|Genetic|reverse transcriptase-polymerase chain reaction|
79666579|NCT00316823|Other|diagnostic laboratory biomarker analysis|
79666580|NCT00316823|Other|immunohistochemistry staining method|
79666581|NCT00316823|Procedure|needle biopsy|
79666582|NCT00344955|Drug|HMG-CoA reductase inhibition (atorvastatin)|
79666583|NCT00316901|Procedure|computed tomography|
79666584|NCT00316901|Procedure|positron emission tomography|
79666585|NCT00316901|Radiation|fludeoxyglucose F 18|
79666586|NCT00316940|Drug|bortezomib|
79666587|NCT00316940|Radiation|samarium Sm 153 lexidronam pentasodium|
79666588|NCT00344994|Drug|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
79666589|NCT00349791|Drug|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
79666590|NCT00349791|Drug|Placebo patch|placebo patch replaced twice a week for two years
79666591|NCT00316979|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
79354073|NCT04193488|Behavioral|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
79354074|NCT04193488|Behavioral|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
79354075|NCT03023098|Device|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
79354076|NCT03023098|Device|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
79354077|NCT03962686|Drug|statin Oral Tablet plus PCSK9i|Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
79354078|NCT04193020|Other|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
79679624|NCT00518648|Other|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
79679625|NCT00518648|Other|Usual care|Usual care
79679626|NCT03458208|Drug|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
79679627|NCT03458208|Drug|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
79818206|NCT02579187|Procedure|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
79990473|NCT02377414|Drug|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
79990474|NCT02377414|Drug|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
79990475|NCT02377336|Drug|GS-6615|GS-6615 tablets administered orally
79990476|NCT02377336|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
79990477|NCT02381938|Behavioral|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
79990478|NCT02381938|Other|Healthy Finances|6-month intervention to educate and improve financial health
79990479|NCT02662582|Drug|Reldesemtiv|Oral tablet
79354079|NCT04199338|Other|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
79990480|NCT02662582|Drug|Placebo|Oral tablet
79990481|NCT02382094|Drug|Bicalutamide|
79354080|NCT04192864|Procedure|Lingually based triangular flap|"A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar."
79354081|NCT04192864|Procedure|Buccally based triangular flap|The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
79354082|NCT04027270|Other|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
79354083|NCT04027192|Drug|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
79354084|NCT04027192|Drug|BAY2328065 tablet|50 mg tablet, orally
79679628|NCT03458208|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
79504767|NCT04396782|Other|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
79990482|NCT04439500|Behavioral|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
79504768|NCT00637728|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
79504769|NCT00637728|Drug|Placebo|Placebo oral suspension, 5 mL once daily
79354085|NCT04027192|Drug|Placebo LSF|Matching Placebo LSF, orally
79504770|NCT01922466|Procedure|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~1st week - SC 0.2cc/day, 2 days/week~2nd week - SC 0.4cc/day, 2 days/week~3nd week - SC 0.8cc/day, 2 days/week"
79504771|NCT01922466|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
79504772|NCT00637572|Drug|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
79504773|NCT00637572|Drug|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
79666592|NCT00317018|Behavioral|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
79666593|NCT00345072|Device|Web-based decision aid system|
79666594|NCT00317057|Procedure|Patient education and disease management|
79666595|NCT00317096|Procedure|FCM|Active comparator: Chemotherapy
79504774|NCT00637416|Drug|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
79504775|NCT00637416|Other|Placebo|placebo taken by mouth daily for 3 months
79504776|NCT03154320|Other|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
79666596|NCT00317096|Procedure|R-FCM|experimental: Chemotherapy with additional rituximab
79666597|NCT00317096|Drug|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
79354086|NCT04027192|Drug|Placebo tablet|Matching Placebo tablet, orally
79354087|NCT04027192|Drug|Midazolam|1 mg per day, orally
79354088|NCT04406506|Device|nasogastric|• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube
79354089|NCT04406506|Device|nasojejunal|"The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~Patients were placed in right lateral position"
79504777|NCT03154320|Other|Standard treatment|Standard treatment
79504778|NCT00636792|Drug|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
79504779|NCT00636792|Drug|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
79504780|NCT00636792|Drug|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
79666598|NCT00317096|Other|observation only|no Intervention after completion of FCM or R-FCM
79818207|NCT02579187|Other|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
79666599|NCT00349947|Behavioral|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
79679629|NCT03458208|Drug|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
79679630|NCT00517166|Device|CAT (Combat Arms Tourniquet)|device
79679631|NCT02939625|Device|muscle training|
79818208|NCT02579187|Procedure|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 & 4 weeks post extraction
79818209|NCT02579187|Procedure|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
79354090|NCT04406506|Drug|(erythromycin 250 mg IV bolus)|prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
79354091|NCT04193098|Biological|CTL|CTL injection
79354092|NCT04193098|Biological|Toripalimab|Toripalimab injection
79354093|NCT04192942|Other|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
79354094|NCT04021186|Other|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
79504781|NCT03558984|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
79504782|NCT03558984|Other|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
79354095|NCT04026724|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
79354096|NCT04026802|Other|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
79354097|NCT04026802|Other|Standard of Care|Does not include early implementation of physical therapy
79354098|NCT04020796|Dietary Supplement|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
79354099|NCT03832348|Device|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
79354100|NCT04026100|Biological|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).
79354101|NCT04192552|Other|PAUSE Perioperative DOAC Management|"Apixaban & Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl <50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
79504783|NCT03108924|Drug|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
79666600|NCT00317135|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
79679632|NCT02939625|Device|Continue Positive Airway Pressure|
79354102|NCT04192552|Other|ASRA Perioperative DOAC Management|"Apixaban & Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl >80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~*Low-dose heparin bridging can be used if at high A-TE risk"
79354103|NCT04020640|Other|no intervention|Measure human intake using stable isotope technique
79354104|NCT04192162|Other|Mud therapy application|Aplication the mud pack therapy from 20 minutes
79354105|NCT04192162|Other|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
79354106|NCT04192162|Other|Hygienic water|Exercise in hygienic water
79354107|NCT03022942|Other|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
79504784|NCT04506918|Other|IVR survey|Participants will receive an IVR survey
79504785|NCT04506918|Other|SMS survey|Participants will receive a SMS survey
79504786|NCT04499508|Device|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
79354108|NCT03022942|Other|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
79504787|NCT01922778|Procedure|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
79354109|NCT04191694|Other|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
79354110|NCT04191694|Drug|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
79504788|NCT00636636|Drug|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
79504789|NCT00636636|Drug|Placebo|Once daily; 300 mg and 600 mg tablets
79504790|NCT05244954|Drug|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
79504791|NCT05244954|Drug|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
79354111|NCT04191850|Procedure|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
79354112|NCT04191772|Other|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
79354113|NCT04026022|Drug|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
79354114|NCT04026022|Drug|Placebo|Placebo plaster in the ER or PACU
79354115|NCT04020406|Biological|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
79354116|NCT04020328|Drug|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR<50ml/min
79354117|NCT04020094|Combination Product|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
79354118|NCT04025476|Drug|Steroids|IV and oral steroids
79504792|NCT00635778|Drug|dalotuzumab|Administered as an IV infusion over one to two hours
79504793|NCT04396470|Device|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
79504794|NCT01929252|Drug|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
79990483|NCT04439500|Behavioral|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
79504795|NCT01929252|Drug|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
79504796|NCT04275960|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
79679633|NCT02939625|Device|bilevel positive airway pressure|
79679634|NCT00517205|Procedure|Non-contrast helical computerized tomogram (NCHCT)|
79818210|NCT02579187|Radiation|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
79504797|NCT04276038|Device|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
79504798|NCT04275804|Device|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm)
79666601|NCT00317135|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
79354119|NCT04025320|Other|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
79504799|NCT04275804|Other|Conventional Dressing|Alternate Day Dressing
79504800|NCT00634920|Drug|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
79504801|NCT00634920|Drug|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
79504802|NCT00634920|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
79504803|NCT00634920|Drug|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
79504804|NCT00634920|Drug|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
79666602|NCT00345111|Procedure|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
79666603|NCT00317174|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
79666604|NCT00349986|Drug|Insuline glargine|
79666605|NCT00317213|Drug|LIBERTAL- a phospholipid mixture|
79666606|NCT00345150|Drug|Ng-monomethyl-L-arginine (drug)|
79666607|NCT00317252|Drug|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
79666608|NCT04714788|Device|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
79504805|NCT01923012|Drug|Vitamin K2 (Menaquinone)|
79666609|NCT04714788|Other|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
79666610|NCT00317291|Procedure|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
79504806|NCT01923090|Drug|Finasteride|Finasteride 5mg once daily for 3 weeks
79666611|NCT00317291|Other|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
79504807|NCT01923090|Drug|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
79504808|NCT01929330|Drug|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
79504809|NCT01929330|Drug|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
79666612|NCT00345189|Drug|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
79666613|NCT00317330|Drug|Isoniazid|
79666614|NCT00317330|Drug|Pyrazinamide|
79666615|NCT00317330|Drug|Rifampin|
79666616|NCT00350064|Behavioral|Exercise Training|16 weeks of aerobic exercise training at two different intensities
79666617|NCT00317408|Biological|anti-thymocyte globulin|
79666618|NCT00317408|Drug|busulfan|
79666619|NCT00317408|Drug|carboplatin|
79354120|NCT04025320|Other|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
79354121|NCT01874288|Drug|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
79354122|NCT02080468|Drug|lomitapide|20 mg
79354123|NCT02080468|Drug|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
79354124|NCT04020016|Drug|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
79354125|NCT04020016|Drug|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
79354126|NCT02985112|Device|FFR and IVUS-NIRS|
79666620|NCT00317408|Drug|carmustine|
79666621|NCT00317408|Drug|cyclosporine|
79666622|NCT00317408|Drug|cytarabine|
79666623|NCT00317408|Drug|dexamethasone|
79354127|NCT04025164|Radiation|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
79354128|NCT04025164|Radiation|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
79666624|NCT00317408|Drug|etoposide phosphate|
79354129|NCT04191226|Diagnostic Test|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
79354130|NCT04021966|Procedure|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
79354131|NCT01874054|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
79354132|NCT01874054|Drug|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
79504810|NCT01929564|Other|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
79504811|NCT01929564|Other|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
79504812|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
79504813|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
79666625|NCT00317408|Drug|idarubicin|
79666626|NCT00317408|Drug|ifosfamide|
79666627|NCT00317408|Drug|leucovorin calcium|
79666628|NCT00317408|Drug|lomustine|
79504814|NCT04396548|Drug|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
79666629|NCT00317408|Drug|melphalan|
79666630|NCT00317408|Drug|methotrexate|
79666631|NCT00317408|Drug|mitoxantrone hydrochloride|
79354133|NCT01873742|Other|STIC feedback system|This condition includes the use of the STIC feedback system.
79354134|NCT04766242|Other|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
79354135|NCT04766242|Other|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
79354136|NCT01873586|Procedure|Posterolateral Fusion|
79354137|NCT04029610|Procedure|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
79354138|NCT04029610|Drug|lidocaine and adrenalin|lidocaine and adrenalin
79354139|NCT04029610|Drug|lidocaine and arterial blockage|lidocaine and arterial blockage
79354140|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
79666632|NCT00317408|Drug|prednisolone|
79666633|NCT00317408|Drug|thiotepa|
79666634|NCT00317408|Drug|vinblastine sulfate|
79666635|NCT00317408|Drug|vindesine|
79666636|NCT00317408|Procedure|allogeneic hematopoietic stem cell transplantation|
79666637|NCT00317408|Procedure|autologous hematopoietic stem cell transplantation|
79666638|NCT00317408|Procedure|peripheral blood stem cell transplantation|
79354141|NCT04026880|Drug|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
79354142|NCT04026880|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
79354143|NCT04190992|Other|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
79354144|NCT04190992|Other|Usual care|A pamphlet introduce the introduction of types of surgery
79354145|NCT04191070|Device|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
79666639|NCT00317408|Radiation|total-body irradiation|
79666640|NCT00345267|Device|Integrated Care Pathway|
79666641|NCT00317447|Drug|Oral Prednisone|
79666642|NCT00350103|Drug|SPM 929|
79666643|NCT00317525|Device|Spectacle Lenses|
79666644|NCT02959554|Drug|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
79354146|NCT04191070|Device|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
79504815|NCT04396548|Drug|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
79354147|NCT04190602|Device|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
79354148|NCT04024384|Drug|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
79354149|NCT04023916|Drug|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
79354150|NCT04023838|Procedure|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
79354151|NCT04023760|Drug|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
79354152|NCT03022786|Other|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
79504816|NCT01923246|Behavioral|Single WEB intervention|Brief WEB intervention recieved once
79504817|NCT01923246|Behavioral|Repeated WEB intervention|WEB intervention recieved twice.
79504818|NCT01923246|Behavioral|Single IVR intervention|IVR intervention recieved once
79504819|NCT01923246|Behavioral|Repeated IVR intervention|IVR intervention recieved twice
79504820|NCT01923324|Behavioral|Physician telephone consultation|Pain physician support for family physician treating patient
79504821|NCT01923324|Behavioral|Usual family physician care|Usual family physician care without telephone consultation with pain physician
79666645|NCT02959554|Drug|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
79666646|NCT02959554|Drug|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
79504822|NCT04395456|Drug|AMY-101|C3 complement inhibitor
79504823|NCT04395456|Other|WFI 5% glucose|Placebo
79666647|NCT00345306|Drug|Comparison between two different progesterone administration|
79666648|NCT00317681|Drug|Tacrolimus ointment|
79666649|NCT00350181|Drug|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
79666650|NCT00350181|Drug|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
79990484|NCT02386150|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
79504824|NCT01929720|Behavioral|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
79666651|NCT00350181|Drug|BCNU|15 mg/kg, IV
79666652|NCT00350181|Drug|VP-16|60 mg/kg, IV
79990485|NCT02908100|Drug|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
79990486|NCT02908100|Drug|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
79990487|NCT02377180|Procedure|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
79354153|NCT03022786|Other|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
79354154|NCT03022786|Other|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
79354155|NCT04020952|Other|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
79354156|NCT04020952|Other|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
79354157|NCT04020952|Other|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
79504825|NCT01929798|Device|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
79504826|NCT01929954|Biological|Gintuit|One time placement of Gintuit over socket graft.
79504827|NCT01929954|Device|Bio-Gide|One time placement of Bio-Gide over socket graft.
79504828|NCT04395690|Procedure|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
79666653|NCT00350181|Drug|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
79504829|NCT00633984|Behavioral|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
79354158|NCT04020718|Behavioral|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
79354159|NCT04020718|Drug|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
79504830|NCT00633984|Drug|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
79504831|NCT00633984|Drug|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
79504832|NCT04395612|Drug|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
79666654|NCT00350181|Drug|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
79666655|NCT00350181|Drug|BU|BU 1 mg/kg every 6hr x 4 doses, IV
79504833|NCT04395612|Drug|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
79666656|NCT00317759|Biological|therapeutic autologous lymphocytes|
79666657|NCT00317759|Drug|fludarabine phosphate|
79666658|NCT00317798|Biological|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
79666659|NCT00317798|Drug|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
79666660|NCT00345462|Biological|Trivalent virosomal influenza vaccine|
79818211|NCT02579187|Other|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
79818212|NCT04092062|Device|ToothWave|RF-utilizing powered toothbrush for teeth whitening
79354160|NCT04020718|Behavioral|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
79354161|NCT04027348|Drug|Dexamethasone|Given IV
79354162|NCT04027348|Drug|Metoclopramide|Given IV
79354163|NCT04027348|Drug|Octreotide|Given IV
79504834|NCT01923558|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
79504835|NCT01920048|Procedure|Percutaneous Coronary Intervention|
79504836|NCT01920048|Drug|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
79504837|NCT01920048|Device|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
79666661|NCT00345501|Drug|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
79818213|NCT04092062|Device|powered toothbrush|regular powered toothbrush with no RF
79818214|NCT02590692|Biological|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
79818215|NCT04019912|Other|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
79354164|NCT04195204|Drug|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
79504838|NCT01926990|Device|perfusion computed tomography|Undergo perfusion CT
79504839|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
79504840|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
79504841|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
79666662|NCT00345501|Drug|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
79666663|NCT00317837|Procedure|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
79666664|NCT00317837|Procedure|bipolar hemiarthroplasty|bipolar hemiarthroplasty
79666665|NCT00345657|Drug|Niacin Extended Release/Lovastatin|
79666666|NCT00317876|Drug|cyclophosphamide|
79666667|NCT00317876|Drug|cyclosporine|
79666668|NCT00317876|Drug|methotrexate|
79666669|NCT00317876|Procedure|allogeneic bone marrow transplantation|
79354165|NCT04195204|Drug|Placebos|Investigators administrated intravenously saline solution as a placebo
79354166|NCT04406350|Procedure|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
79354167|NCT04023136|Procedure|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
79354168|NCT04023214|Diagnostic Test|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
79354169|NCT04023292|Drug|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
79354170|NCT04023292|Drug|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
79354171|NCT03948958|Other|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
79354172|NCT03948958|Other|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
79354173|NCT03948958|Other|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
79354174|NCT03948958|Other|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
79666670|NCT00317876|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79354175|NCT03948958|Other|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
79354176|NCT04198090|Behavioral|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
79666671|NCT00317915|Drug|Irbesartan treatment|
79666672|NCT00317954|Drug|Spironolactone|
79354177|NCT02703688|Behavioral|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
79354178|NCT02703688|Other|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
79354179|NCT04190758|Other|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
79354180|NCT04023448|Procedure|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
79354181|NCT04022902|Other|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
79354182|NCT02704312|Radiation|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
79354183|NCT02080546|Procedure|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
79354184|NCT02080546|Procedure|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
79354185|NCT02080546|Device|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
79354186|NCT04022824|Other|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
79354187|NCT04022824|Other|Non-OSA|Patients without OSA (apnea hypopnea index <15) based on sleep study
79354188|NCT03023254|Other|Hydrotherapy|3-week Avène hydrotherapy
79666673|NCT00317993|Drug|ezetimibe|
79818216|NCT04019912|Other|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
79818217|NCT02579109|Other|memory test|
79818218|NCT02598440|Drug|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
79666674|NCT00317993|Drug|simvastatin|
79666675|NCT00317993|Drug|ezetimibe plus simvastatin|
79666676|NCT00350415|Drug|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
79666677|NCT00318032|Drug|multi-factorial intervention|
79818219|NCT02598440|Drug|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
79818220|NCT02575989|Other|1: control group|Classic - current management of trauma patients by French medical teams
79504842|NCT01921218|Drug|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
79504843|NCT01921218|Drug|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
79504844|NCT01921218|Drug|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
79504845|NCT01921218|Drug|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
79504846|NCT01920438|Procedure|Percutaneous Endoscopic Gastrostomy|PEG
79504847|NCT01920438|Procedure|Radiologically-guided insertion of Gastrostomy|RIG
79504848|NCT00633750|Drug|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
79504849|NCT00633750|Genetic|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
79504850|NCT00633750|Genetic|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
79504851|NCT00633750|Other|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
79504852|NCT00633750|Other|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
79504853|NCT00633750|Other|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
79504854|NCT00633750|Other|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
79504855|NCT00633750|Other|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
79504856|NCT00633750|Procedure|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
79504857|NCT01922856|Biological|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
79354189|NCT03022240|Drug|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
79354190|NCT03022240|Drug|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
79504858|NCT01922856|Other|No Intervention|Controls only receive challenge
79354191|NCT03022240|Drug|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
79354192|NCT03022240|Drug|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
79354193|NCT02701738|Dietary Supplement|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
79354194|NCT04022434|Dietary Supplement|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
79354195|NCT04022434|Dietary Supplement|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
79504859|NCT00633360|Drug|Drospirenone and ethinyl estradiol|Once daily by mouth
79504860|NCT00633360|Drug|Placebo|Once daily by mouth
79504861|NCT00988260|Drug|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
79504862|NCT00988260|Drug|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
79504863|NCT00988260|Drug|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
79504864|NCT00633126|Drug|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
79524757|NCT05446662|Other|music therapy|Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.
79990488|NCT02377180|Procedure|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
79354196|NCT04196374|Genetic|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
79990489|NCT02377180|Procedure|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
79990490|NCT02377024|Dietary Supplement|TF 600mg|
79990491|NCT02377024|Dietary Supplement|TF 1200mg|
79354197|NCT04196686|Device|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
79354198|NCT04196686|Other|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
79524758|NCT05446662|Other|aromatherapy|Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.
79990492|NCT02377024|Dietary Supplement|placebo|
79990493|NCT02377102|Procedure|Physical Therapy|12 weeks of supervised physical therapy.
79990494|NCT02386228|Genetic|collection of CSF and blood|collection of CSF and blood
79990495|NCT03656120|Drug|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
79990496|NCT03656120|Drug|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
79990497|NCT03656120|Drug|placebo control group|Participants only take placebos for 12 weeks during the research.
79666678|NCT00318071|Device|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
79666679|NCT00345696|Drug|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
79666680|NCT00345696|Drug|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
79818221|NCT02575989|Other|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
79818222|NCT04091594|Device|Flexible orthotic|Participants will receive the SIAFO to wear
79818223|NCT04091594|Device|Standard orthotic|Participants will received the standard AFO to wear
79818224|NCT00750308|Drug|Ramipril|Ramipril 10 mg per day for three weeks
79990498|NCT04341298|Other|11-point pain scale|Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
79354199|NCT03957850|Behavioral|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny & Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
79354200|NCT03957850|Behavioral|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
79504865|NCT00989664|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
79504866|NCT01923870|Drug|Androxal 25 mg|
79504867|NCT00632736|Drug|Ropinirole XL (formerly CR)|
79818225|NCT00750308|Drug|Tadalafil|tadalafil 10 mg every other day for three weeks
79818226|NCT00750308|Drug|placebo|placebo matching ramipril
79990499|NCT04341298|Other|Headache diary|Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
79504868|NCT01923948|Drug|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
79504869|NCT01923948|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
79504870|NCT00989196|Biological|Human-cl rhFVIII|50 IU/kg for PK dose
79504871|NCT00989196|Biological|Kogenate FS|50 IU/kg for PK dose
79504872|NCT04288362|Other|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
79504873|NCT04288362|Other|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
79354201|NCT04192318|Behavioral|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
79504874|NCT03100110|Device|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
79504875|NCT00632502|Drug|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
79504876|NCT00632502|Drug|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
79504877|NCT00632502|Drug|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
79504878|NCT00632424|Drug|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
79666681|NCT00345696|Drug|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
79818227|NCT00750308|Drug|placebo|placebo matching tadalafil
79504879|NCT00631488|Drug|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
79504880|NCT00631488|Drug|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
79504881|NCT00631488|Drug|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
79990500|NCT04341298|Device|Avulux®|Avulux® device
79354202|NCT04192318|Other|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
79354203|NCT04192318|Other|Treatment as usual|Treat and release
79354204|NCT02704390|Drug|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
79354205|NCT04147390|Drug|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
79504882|NCT00631488|Drug|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
79504883|NCT00631488|Drug|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
79504884|NCT00631488|Drug|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
79504885|NCT01924104|Drug|Low molecular weight heparin|2500 mIU/day, subcutaneously
79504886|NCT01924104|Drug|Low dose aspirin|75 mg/day, orally
79990501|NCT04341298|Device|Sham Avulux®|Sham Avulux®
79354206|NCT04147390|Drug|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
79354207|NCT02706964|Device|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
79354208|NCT02706964|Device|Magnetic resonance imaging|A brain MRI will be performed.
79354209|NCT02706964|Device|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
79354210|NCT02708758|Behavioral|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
79354211|NCT02708680|Drug|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
79354212|NCT02708680|Drug|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
79354213|NCT02708680|Drug|Placebo|A pill containing no active drug ingredient
79504887|NCT01924104|Drug|Heparin & aspirin|Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)
79504888|NCT01924104|Other|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
79504889|NCT00988884|Biological|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
79504890|NCT00988884|Biological|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
79504891|NCT00988884|Biological|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
79504892|NCT00988884|Biological|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
79504893|NCT00988884|Biological|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
79990502|NCT02166242|Drug|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
79504894|NCT00631020|Behavioral|CBME|6 weeks of once a week one-on-one CBME
79504895|NCT00631020|Drug|Optional NRT|NicoDerm CQ nicotine transdermal patch
79818228|NCT02577237|Behavioral|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
79818229|NCT02577237|Behavioral|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
79504896|NCT00987402|Other|Plain soap and water (PSW)|Presence or absence of infection
79818230|NCT02577237|Other|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
79990503|NCT03656042|Drug|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~Non-treatment"
79666682|NCT00318110|Procedure|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
79818231|NCT02577237|Other|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
79990504|NCT02381860|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
79990505|NCT02381860|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
79990506|NCT03655964|Drug|Olmesartan|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
79504897|NCT00987402|Other|Alcohol-based hand rub (ABHR)|Presence or absence of infection
79504898|NCT00630864|Drug|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
79666683|NCT04708236|Drug|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
79666684|NCT04708236|Drug|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
79666685|NCT04708236|Drug|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
79818232|NCT02579031|Device|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
79818233|NCT02579031|Device|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
79818234|NCT06240234|Device|Capnodynamic method|All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
79990507|NCT03655964|Drug|Nebivolol|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
79990508|NCT03655964|Other|No antihypertensive treatment|Patients will be left without treatment
79990509|NCT02385994|Device|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
79990510|NCT02381236|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
79354214|NCT03931642|Drug|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
79354215|NCT03931642|Drug|Blinatumomab|Blinatumomab by continuous vein infusion
79354216|NCT04147312|Drug|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
79354217|NCT04147312|Drug|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
79354218|NCT03931564|Procedure|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
79990511|NCT02982590|Drug|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
79354219|NCT03931564|Procedure|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
79990512|NCT02982590|Drug|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
79990513|NCT02381548|Drug|Adavosertib|Given PO
79354220|NCT04146766|Combination Product|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
79504899|NCT01924338|Device|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
79504900|NCT01924338|Device|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
79504901|NCT01924338|Procedure|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
79504902|NCT01924416|Behavioral|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
79504903|NCT01924416|Behavioral|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
79666686|NCT04708236|Other|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
79990514|NCT02381548|Drug|Belinostat|Given IV
79990515|NCT02381548|Other|Laboratory Biomarker Analysis|Correlative studies
79990516|NCT02381548|Other|Pharmacological Study|Correlative studies
79990517|NCT02381314|Biological|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
79504904|NCT00630786|Drug|Panitumumab|Administered by intravenous infusion
79504905|NCT00630786|Drug|Conatumumab|Administered by intravenous infusion
79504906|NCT00630396|Drug|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
79990518|NCT02345408|Drug|CCX872-B|Tablets (oral administration)
79990519|NCT02386072|Drug|mirabegron|oral
79990520|NCT02386072|Drug|antimuscarinic medication|oral
79504907|NCT00636480|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
79504908|NCT00636480|Drug|ChloraPrep One Step|Administer topically
79504909|NCT00636480|Drug|Sterile saline|0.9% NaCl solution
79666687|NCT00318188|Procedure|standardized reeducation and readaptation program|
79666688|NCT00350454|Device|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
79666689|NCT00350454|Device|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
79990521|NCT03655730|Other|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
79990522|NCT03655730|Other|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
79990523|NCT03656900|Device|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
79990524|NCT03656900|Device|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
79666690|NCT00350454|Device|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
79504910|NCT01924572|Procedure|cord clamping at 2 minutes|
79666691|NCT00318227|Procedure|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
79354221|NCT04021342|Dietary Supplement|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
79354222|NCT04021342|Dietary Supplement|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
79354223|NCT04021888|Other|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
79354224|NCT04021420|Device|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~an implantable ultrasound transducer,~a needle connection device,~an external radiofrequency generator, and~an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
79354225|NCT04021420|Drug|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
79354226|NCT04144582|Drug|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
79354227|NCT01611974|Drug|Maribavir|Tablet for oral administration
79354228|NCT04147078|Biological|DC vaccine subcutaneous administration|subcutaneous administration
79354229|NCT04146688|Other|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
79354230|NCT01848938|Behavioral|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
79504911|NCT01924572|Procedure|cord clamping at 5 minutes|
79504912|NCT01924572|Procedure|cord milking|
79504913|NCT01924728|Device|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
79504914|NCT01924728|Device|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
79504915|NCT00985686|Other|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
79504916|NCT00635934|Device|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
79666692|NCT00318266|Device|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
79504917|NCT00630552|Other|Placebo|Inactive dummy of AMG 655.
79504918|NCT00630552|Drug|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
79504919|NCT00630552|Drug|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
79504920|NCT01924962|Device|revascularisation|revascularisation of chronic occluded coronary artery
79666693|NCT00345735|Drug|Fentanyl|
79666694|NCT00345774|Drug|PRX-08066|
79666695|NCT00318344|Drug|Atuna Racemosa|
79666696|NCT02959749|Drug|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
79354231|NCT04146454|Other|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
79504921|NCT03098394|Device|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
79504922|NCT03098394|Device|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
79504923|NCT01920126|Drug|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
79504924|NCT01920126|Drug|Saline|
79504925|NCT00984594|Other|Primary injury site|Autograft will be placed in the primary defect site.
79504926|NCT00984594|Other|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
79504927|NCT01925118|Biological|Irradiated donor lymphocyte infusion|
79504928|NCT01925352|Drug|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
79504929|NCT01925430|Device|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
79504930|NCT01925430|Device|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
79504931|NCT01920204|Drug|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
79504932|NCT00984204|Device|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
79504933|NCT04508010|Other|IVR|Participants will receive an IVR survey
79504934|NCT04508010|Other|CATI|Participants will receive a CATI survey
79504935|NCT00983892|Behavioral|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
79504936|NCT02984202|Device|auditory midbrain implant (AMI)|
79504937|NCT04275258|Other|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
79504938|NCT01925664|Behavioral|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
79504939|NCT01925742|Other|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
79504940|NCT01925742|Other|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
79504941|NCT01925742|Other|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
79504942|NCT01925742|Other|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
79504943|NCT01925742|Other|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
79818235|NCT06240221|Device|Elevation Spine Saber-C System|Device: Elevation Spine Saber-C System Elevation Spine Saber-C System will be fixated between C2 through T1 according to surgeon standard of care at clinical practices through the United States.
79354232|NCT04149418|Other|Yogurt|Low-fat flavored yogurt
79504944|NCT01925820|Drug|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
79504945|NCT01925898|Drug|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
79354233|NCT04149418|Other|Control food|Low-fat flavored soy pudding
79354234|NCT01871870|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
79504946|NCT01925898|Drug|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
79666697|NCT02959749|Drug|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
79990525|NCT03656900|Radiation|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
79990526|NCT03656900|Other|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
79990527|NCT03656900|Other|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
79990528|NCT03655496|Device|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
79990529|NCT04439422|Behavioral|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
79990530|NCT04439422|Other|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
79990531|NCT02381470|Drug|Faropenem|Faropenem 600mg
79990532|NCT02381470|Drug|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
79990533|NCT02381470|Drug|Cefadroxil|Cefadroxil 1g
79990534|NCT02381470|Drug|Rifampicin|Rifampicin 10mg/kg
79354235|NCT02080780|Drug|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
79354236|NCT02080780|Drug|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 & Day 8 to the perianal area (~2.5 cm [1 inch]; ~8.5 mg)
79990535|NCT02381158|Drug|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
79990536|NCT04241536|Procedure|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
79990537|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
79990538|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
79990539|NCT02385838|Behavioral|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
79990540|NCT02385838|Behavioral|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
79990541|NCT02385838|Behavioral|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
79990542|NCT02385838|Behavioral|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
79354237|NCT01871558|Drug|Vildagliptin|50 mg b.i.d
79354238|NCT01871558|Drug|Metformin|metformin is to be kept unchanged
79354239|NCT01871558|Drug|sulfonylurea (SU)|
79354240|NCT01871558|Drug|Basal Insulin|
79354241|NCT01711359|Drug|Baricitinib|Administered orally
79354242|NCT01711359|Drug|Methotrexate|Administered orally
79354243|NCT01711359|Drug|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
79504947|NCT00983580|Drug|Aspirin|Given PO
79504948|NCT00983580|Drug|Eflornithine|Given PO
79504949|NCT00983580|Other|Laboratory Biomarker Analysis|Correlative study
79504950|NCT00983580|Other|Placebo|Given PO
79504951|NCT00983580|Other|Telephone-Based Intervention|Ancillary studies
79504952|NCT01920672|Behavioral|Timed Planned Activity|
79504953|NCT01920672|Behavioral|Home Safety and Education Program|
79504954|NCT00982878|Drug|Maraviroc|150mg twice daily
79990543|NCT02381080|Drug|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
79504955|NCT00982488|Drug|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
79354244|NCT01711359|Drug|MTX Placebo|MTX placebo administered orally once weekly.
79354245|NCT01711359|Drug|Folic Acid|Administered orally every day
79354246|NCT04149496|Combination Product|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
79354247|NCT04140136|Dietary Supplement|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
79354248|NCT04140136|Dietary Supplement|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
79504956|NCT00982488|Drug|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
79504957|NCT00982410|Behavioral|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
79504958|NCT00982410|Behavioral|educational supportive group|A control condition providing social support and education about pain and/or drug use.
79504959|NCT00982020|Drug|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
79504960|NCT00982020|Behavioral|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
79504961|NCT00982020|Behavioral|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
79504962|NCT01926054|Drug|Acthar gel|
79504963|NCT01926132|Drug|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
79504964|NCT01926132|Drug|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
79504965|NCT02984358|Other|Animal protein based diet|
79504966|NCT02984358|Other|Low-nucleotide mycoprotein based diet|
79504967|NCT02984358|Other|High-nucleotide mycoprotein based diet|
79504968|NCT01920906|Procedure|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
79504969|NCT01926210|Other|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
79504970|NCT01926210|Other|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
79666698|NCT00318383|Biological|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
79990544|NCT02381080|Drug|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
79354249|NCT04146532|Drug|Aspirin 500 MG|Single 500mg aspirin capsule.
79504971|NCT01926288|Drug|Entecavir maleate tablets|
79504972|NCT01926288|Drug|blank Baraclude tablets|
79504973|NCT01926288|Drug|Blank maleate entecavir tablets|
79504974|NCT01926288|Drug|Baraclude tablets|
79504975|NCT01926366|Drug|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
79504976|NCT01926366|Drug|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
79504977|NCT00981084|Drug|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
79504978|NCT00980148|Drug|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
79666699|NCT00318383|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
79990545|NCT02381080|Drug|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
79990546|NCT04724824|Device|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
79504979|NCT00980148|Drug|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
79504980|NCT03064854|Drug|PDR001|Powder for solution for infusion
79354250|NCT04146532|Drug|Placebo|Single 500mg placebo capsule.
79354251|NCT03929224|Drug|Medicinal honey|Treat healing surgical site with medicinal honey
79354252|NCT03929224|Drug|Bacitracin|Treat healing surgical site with bacitracin
79354253|NCT04146610|Drug|an antibody drug conjugate|Multiple dose grouping
79354254|NCT02985034|Procedure|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
79504981|NCT03064854|Drug|Cisplatin|Intravenous infusion
79504982|NCT03064854|Drug|Gemcitabine|Intravenous infusion
79504983|NCT03064854|Drug|Pemetrexed|Intravenous infusion
79504984|NCT03064854|Drug|Carboplatin|Intravenous infusion
79504985|NCT03064854|Drug|Paclitaxel|Intravenous infusion
79504986|NCT03064854|Drug|Canakinumab|Subcutaneous injection
79504987|NCT01921530|Procedure|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
79666700|NCT00350571|Behavioral|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
79504988|NCT01921530|Procedure|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
79504989|NCT01926678|Other|Swedish massage therapy|
79504990|NCT01926678|Other|Light touch therapy|
79504991|NCT01926756|Procedure|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
79504992|NCT01926756|Procedure|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
79504993|NCT01926834|Drug|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
79504994|NCT01926834|Drug|placebo|normal saline, 500ml,i.v.,qd, for 7 days
79504995|NCT01921608|Device|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
79504996|NCT01926912|Drug|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
79504997|NCT04395378|Device|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
79504998|NCT03385512|Behavioral|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
79666701|NCT00350571|Behavioral|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
79666702|NCT00350571|Behavioral|standard care follow up|routine counselor phone calls and letters
79666703|NCT00318422|Drug|liraglutide|
79666704|NCT00318422|Drug|rosiglitazone|
79504999|NCT03385512|Behavioral|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
79666705|NCT00318422|Drug|glimepiride|
79666706|NCT00345813|Dietary Supplement|soy isoflavones|Given orally
79666707|NCT00345813|Dietary Supplement|soy protein isolate|Given orally
79505000|NCT03385512|Behavioral|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
79354255|NCT03925870|Drug|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
79354256|NCT04146376|Other|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
79354257|NCT04146376|Drug|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are <100% in the third trimester of pregnancy
79354258|NCT04146376|Drug|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
79505001|NCT01921764|Behavioral|Workplace physical exercise|
79505002|NCT01921764|Behavioral|Home physical exercise|
79505003|NCT00983814|Drug|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
79505004|NCT00983814|Drug|Placebo|Placebo matched oral capsules taken TID from Baseline to end of Week 8
79505005|NCT01921842|Behavioral|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
79505006|NCT03088332|Procedure|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
79505007|NCT01921920|Drug|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
79666708|NCT00345813|Other|placebo|Given orally
79666709|NCT00350610|Other|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
79666710|NCT00350610|Behavioral|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
79666711|NCT00318500|Drug|ERB-041|
79666712|NCT00345852|Procedure|Fetoscopic Selective Laser Photocoagulation|
79666713|NCT00318539|Drug|Quetiapine|
79666714|NCT00345891|Behavioral|Coping-focused counseling telephone calls|
79666715|NCT00350649|Behavioral|Standard CBT|Manualized delivery of CBT by trained clinicians
79666716|NCT00350649|Behavioral|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
79666717|NCT00350649|Behavioral|CM/abstinence|Contingency Management
79666718|NCT00350649|Behavioral|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
79666719|NCT00318617|Drug|GW510516X|
79505008|NCT04275414|Drug|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
79666720|NCT00350688|Radiation|Helical tomotherapy IMRT|Helical tomotherapy IMRT
79354259|NCT04146376|Other|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
79505009|NCT04395924|Diagnostic Test|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~Sample of amniotic fluid~2 samples of blood cord after the birth of the new born~2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
79505010|NCT04395144|Procedure|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
79666721|NCT00419198|Procedure|Postconditioning|Postconditioning during angioplasty
79666722|NCT00419198|Procedure|standard angioplasty|standard angioplasty without postconditioning
79354260|NCT01710657|Drug|Lacosamide 50 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 50 mg~Route of Administration: Oral use"
79354261|NCT01710657|Drug|Lacosamide 100 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 100 mg~Route of Administration: Oral use"
79666723|NCT00346008|Genetic|mutation analysis|
79666724|NCT00346008|Other|high performance liquid chromatography|
79666725|NCT00346008|Other|laboratory biomarker analysis|
79990547|NCT04724824|Device|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
79505011|NCT04395144|Procedure|Standard care|Patients will not receive any special instructions with regards to proning.
79505012|NCT04395768|Dietary Supplement|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
79505013|NCT04395768|Drug|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
79505014|NCT04395768|Drug|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
79505015|NCT04395768|Dietary Supplement|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
79505016|NCT04395768|Dietary Supplement|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
79505017|NCT04395768|Dietary Supplement|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
79990548|NCT02385760|Drug|CTX-4430|
79990549|NCT02385760|Drug|Placebo|
79990550|NCT04694248|Drug|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
79990551|NCT04694248|Drug|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
79990552|NCT02376478|Drug|TNF-alpha inhibitors|therapy for at least 6 months
79990553|NCT02376478|Drug|Alternative/no medication|therapy for at least 6 months or no therapy
79505018|NCT04396158|Radiation|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
79505019|NCT01927224|Drug|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
79990554|NCT02376478|Other|Alternative/no medication|phototherapy for at least 6 months
79990555|NCT02376478|Drug|Purine/folic acid analogues|therapy for at least 6 months
79990556|NCT02385448|Drug|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
79990557|NCT02385448|Drug|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
79990558|NCT02376634|Behavioral|Hypnosis|Patients will be taught self-hypnosis.
79990559|NCT02376400|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29 or 57.
79990560|NCT02376400|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29 or 57.
79990561|NCT02376400|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
79990562|NCT03106012|Procedure|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
79990563|NCT03106012|Procedure|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
79990564|NCT02385370|Drug|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
79990565|NCT02385370|Drug|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
79666726|NCT00346008|Other|questionnaire administration|
79666727|NCT00419237|Drug|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
79505020|NCT01927224|Drug|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
79505021|NCT01927224|Drug|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
79666728|NCT00350766|Procedure|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
79990566|NCT02385058|Drug|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
79505022|NCT03831750|Other|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
79505023|NCT01921998|Procedure|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
79505024|NCT01927458|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
79666729|NCT00318695|Dietary Supplement|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
79666730|NCT00318695|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
79990567|NCT02385058|Drug|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
79990568|NCT02385058|Drug|Placebo|Placebo tablet orally once starting on Day 21.
79990569|NCT02376088|Drug|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
79990570|NCT03310021|Biological|Andexanet alfa|fXa inhibitor antidote
79990571|NCT03310021|Drug|Apixaban|factor Xa inhibitor
79990572|NCT03310021|Drug|Rivaroxaban|factor Xa inhibitor
79990573|NCT03310021|Drug|Edoxaban|factor Xa inhibitor
79354262|NCT01710657|Drug|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
79505025|NCT04396080|Procedure|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
79505026|NCT01927536|Device|White LED Flashlight|white light setting
79505027|NCT01927536|Device|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
79524759|NCT05446662|Other|Progressive Relaxation Exercises|Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.
79524760|NCT05446662|Other|Hand massage|Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.
79990574|NCT03310021|Drug|Placebo|Placebo
79990575|NCT04630717|Other|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
79666731|NCT00346047|Drug|Placebo|Corresponding placebo is applied for 12weeks
79666732|NCT00346047|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
79666733|NCT00421200|Drug|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
79990576|NCT04630717|Other|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
79990577|NCT03333109|Biological|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
79990578|NCT03333109|Other|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
79990579|NCT02940223|Drug|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
79354263|NCT04142710|Device|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
79354264|NCT04765930|Other|Q-switched nd:YAG laser toning|Q-switched nd:YAG laser toning for melasma.
79354265|NCT05582044|Other|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
79354266|NCT05582044|Other|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
79354267|NCT05582044|Other|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
79354268|NCT03906682|Behavioral|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
79505028|NCT01927614|Radiation|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~Prospectively gated calcium scoring.~Stress-myocardial CT perfusion.~Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
79505029|NCT01927692|Other|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
79505030|NCT01927692|Other|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
79505031|NCT01922154|Drug|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
79505032|NCT01922154|Procedure|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
79505033|NCT04554576|Behavioral|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
79505034|NCT04554576|Behavioral|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
79990580|NCT02940223|Behavioral|Exercise Intervention|Complete resistance exercises and undergo walking program
79990581|NCT02940223|Behavioral|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
79505035|NCT04554576|Behavioral|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
79666734|NCT00421200|Drug|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
79666735|NCT00350805|Procedure|EEG|One 20 minutes session
79666736|NCT00318773|Drug|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
79666737|NCT00318851|Device|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
79505036|NCT03060642|Device|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
79505037|NCT03060642|Device|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
79666738|NCT00350883|Behavioral|Cognitive Therapy|Goal-oriented talk therapy
79666739|NCT00350883|Other|Treatment as Usual|Keep getting usual care
79666740|NCT00318890|Drug|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
79666741|NCT00318890|Drug|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
79524761|NCT05448690|Procedure|Two different approaches|Please refer to Groups
79524762|NCT05445570|Diagnostic Test|Non-Interventional|This is an observational, non interventional study
79524763|NCT01689402|Device|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
79666742|NCT00318890|Procedure|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
79666743|NCT00318890|Drug|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
79666744|NCT00346086|Drug|AIC (Amb a 1 Immunostimulatory Conjugate)|
79666745|NCT00318968|Drug|Esomeprazole|
79666746|NCT00350922|Behavioral|Psychoeducation|
79666747|NCT00319007|Drug|Sulindac (drug)|
79666748|NCT00319007|Drug|VSL#3 (probiotic)|
79505038|NCT01927848|Dietary Supplement|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
79505039|NCT01927848|Dietary Supplement|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
79666749|NCT00319007|Drug|Inulin (probiotic)|
79666750|NCT00350961|Drug|Gemcitabine|
79666751|NCT00350961|Drug|Oxaliplatin|
79666752|NCT00350961|Drug|Capecitabine|
79666753|NCT00319085|Procedure|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
79666754|NCT00346242|Drug|Zoledronic Acid|
79354269|NCT03906682|Behavioral|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
79666755|NCT00421473|Drug|Atovaquone / Proguanil|
79666756|NCT00319163|Drug|levonorgestrel/ethinyl estradiol|
79354270|NCT03021772|Drug|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
79354271|NCT03021772|Drug|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
79354272|NCT04149886|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
79354273|NCT04149886|Device|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
79354274|NCT05584774|Procedure|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
79354275|NCT05581654|Procedure|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
79354276|NCT05581576|Drug|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
79505040|NCT01927926|Dietary Supplement|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
79505041|NCT01927926|Dietary Supplement|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
79505042|NCT01922310|Behavioral|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
79505043|NCT04552470|Drug|Placebo|3 matching placebo tablets taken twice a day (BID)
79666757|NCT00346281|Device|32P BioSilicon|
79666758|NCT00319202|Drug|Candesartan|32 mg/d for 6 months
79666759|NCT00319202|Drug|Placebo|Placebo administration for 6 months
79666760|NCT00319241|Behavioral|Parenting Intervention|
79666761|NCT00421512|Drug|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
79666762|NCT00319280|Procedure|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
79666763|NCT00351078|Drug|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
79666764|NCT00319319|Drug|Mecamylamine hydrochloride (Inversine)|
79354277|NCT04149262|Drug|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
79354278|NCT04149262|Drug|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
79354279|NCT04149262|Device|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
79354280|NCT03647800|Biological|APVO436|APVO436
79666765|NCT00346359|Biological|anti-thymocyte globulin|
79666766|NCT00346359|Drug|busulfan|
79666767|NCT00346359|Drug|fludarabine phosphate|
79666768|NCT00346359|Drug|methotrexate|
79666769|NCT00346359|Drug|tacrolimus|
79666770|NCT00346359|Procedure|allogeneic hematopoietic stem cell transplantation|
79666771|NCT00346359|Procedure|peripheral blood stem cell transplantation|
79505044|NCT04552470|Drug|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
79505045|NCT04550130|Device|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
79505046|NCT04556916|Diagnostic Test|Blood sample|"Per patient 49 ml of peripheral blood sample :~21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
79505047|NCT03423342|Dietary Supplement|nicotinamide riboside|nicotinamide riboside capsule
79505048|NCT03423342|Drug|Placebo|matching placebo capsule
79505049|NCT01928160|Drug|pemetrexed disodium|Given IV
79505050|NCT01928160|Drug|carboplatin|Given IV
79505051|NCT01928160|Drug|cisplatin|Given IV
79505052|NCT01928160|Drug|erlotinib hydrochloride|Given PO
79666772|NCT00319358|Dietary Supplement|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
79666773|NCT00319358|Dietary Supplement|Placebo|placebo
79666774|NCT00319397|Behavioral|Exercise-Training Program|
79818236|NCT06240208|Behavioral|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
79818237|NCT06240195|Other|data collection|Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
79354281|NCT04145908|Procedure|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
79505053|NCT01928160|Other|laboratory biomarker analysis|Correlative studies
79666775|NCT00346437|Genetic|Ad5FGF-4 vs. Placebo|Intracoronary infusion
79666776|NCT00319475|Procedure|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
79818238|NCT06240182|Procedure|conventional surgery|Surgery performed using conventional rotary burs
79818239|NCT06240182|Procedure|piezoelectric device|surgery performed using piezoelectric device.
79818240|NCT06240169|Procedure|DPC with MTA in AGEI|DPC using MTA in 18-40 years
79818241|NCT06240169|Procedure|DPC with BD in AGEI|DPC using BD in 18-40 years
79818242|NCT06240169|Procedure|DPC with MTA in AGEII|DPC using MTA in 41-60Years
79818243|NCT06240169|Procedure|DPC with BD in AGEII|DPC using BD in 41-60Years
79818244|NCT06240156|Other|3D arch pad design Insole group|3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.
79818245|NCT06240156|Other|flat Insole group|General Insole without any special features
79818246|NCT06240143|Drug|Ipilimumab|intradermal
79818247|NCT06240143|Drug|Nivolumab|intradermal
79818248|NCT06240143|Drug|Nivolumab|intravenous
79354282|NCT05581420|Drug|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
79354283|NCT05581420|Drug|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
79505054|NCT04274946|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
79505055|NCT01928238|Device|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
79818249|NCT06240130|Procedure|sodium hypochlorite lavage|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl
79818250|NCT06240130|Procedure|Chlorhexidine lavage|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine
79666777|NCT00351117|Drug|St. John's Wort|SJW in capsule form 300 mg PO TID
79666778|NCT00351117|Drug|Lactose|lactose in gelatin capsule that same as St. John's wort
79666779|NCT00319514|Drug|Docetaxel|
79666780|NCT00346515|Device|FiberNet Emboli Protection System|
79666781|NCT00319670|Drug|MiraLax|
79666782|NCT00351195|Drug|Etoposide|
79666783|NCT00351195|Drug|Oxaliplatin|
79666784|NCT00351195|Drug|Capecitabine|
79505056|NCT01928238|Device|Noninvasive pressure support ventilation (NPSV)|
79505057|NCT01928316|Drug|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
79505058|NCT01928316|Drug|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
79505059|NCT04346472|Other|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
79354284|NCT05581342|Diagnostic Test|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
79354285|NCT05581264|Behavioral|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
79354286|NCT03022474|Behavioral|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
79354287|NCT03021070|Other|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
79354288|NCT04149340|Drug|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
79354289|NCT03021226|Behavioral|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
79818251|NCT06240117|Procedure|Intraoperative cellular salvage|When the patient is randomized to this intervention the cell salvage machine will be set up for intraoperative use. The surgical team will collect blood from the surgical field into the cell salvage machine, which will process the blood for reinfusion. The volume of blood available for reinfusion is determined by the amount of blood lost which can be collected into the cell salvage system. The blood collected into the salvage system will be collected and processed per standard operating room procedure. At least 100mL of blood collected in the system are necessary for processing. If >100mLs are collected, they will be processed and reinfused. The need for additional blood products and medications will be determined by the anesthesiology team based on the patient's hemodynamic status and will proceed per standard of care.
79354290|NCT03021226|Behavioral|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
79505060|NCT04551846|Dietary Supplement|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
79505061|NCT04551846|Dietary Supplement|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
79666785|NCT00319709|Drug|SR58611A|
79990582|NCT02940223|Other|Laboratory Biomarker Analysis|Correlative studies
79990583|NCT02940223|Other|Placebo|Given PO
79354291|NCT03021226|Behavioral|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
79354292|NCT02984956|Device|pleth variability index|
79354293|NCT04148794|Behavioral|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
79354294|NCT05580952|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
79354295|NCT03904498|Drug|Tolcapone|Tolcapone 100 mg tablets
79354296|NCT03904498|Drug|Placebo|Placebo tablets
79505062|NCT04550520|Diagnostic Test|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
79666786|NCT00346593|Device|Silicone hydrogel contact lens|
79666787|NCT00351234|Drug|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
79666788|NCT00319787|Drug|Iressa|
79666789|NCT00319826|Other|No intervention|This is an observational study with no intervention
79666790|NCT00319865|Drug|Velcade|
79666791|NCT00319865|Drug|Thalidomide|
79666792|NCT00319865|Drug|Adriamycin|
79666793|NCT00319865|Drug|Dexamethasone|
79666794|NCT00319943|Procedure|Computer-based training for Mild Cognitive Impairment (MCI)|
79666795|NCT00320021|Drug|Pyridorin (pyridoxamine dihydrochloride)|
79354297|NCT04405960|Drug|Alfacalcidol 1 MCG Oral Capsule|The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
79354298|NCT04405960|Drug|Sugar pill|The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
79354299|NCT04405804|Drug|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight < 40 kg 2.5 mg/day in patients between 3-18 years with weight > 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight < 40 kg 15 mg/day in patients between 3-18 years, weight > 40 kg"
79505063|NCT04550520|Diagnostic Test|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
79505064|NCT04759482|Diagnostic Test|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
79505065|NCT01928628|Drug|Lercanidipine 10mg|
79505066|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg|
79666796|NCT02959593|Device|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
79818252|NCT06240104|Diagnostic Test|cardiac output index monitor|During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
79666797|NCT00320060|Drug|Pyridorin (pyridoxamine dihydrochloride)|
79505067|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg|
79505068|NCT01928628|Drug|Lercanidipin 10mg Placebo|
79505069|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg Placebo|
79505070|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg Placebo|
79666798|NCT00320099|Drug|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
79666799|NCT00320099|Drug|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
79666800|NCT00320099|Drug|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
79666801|NCT00320099|Drug|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
79505071|NCT01928706|Other|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
79666802|NCT00346671|Other|Rest|30 min supine rest
79666803|NCT00346671|Other|Sham|30 min session with Sham practitioner
79666804|NCT00346671|Other|Reiki|30 min session with Reiki practitioner
79666805|NCT00320138|Procedure|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
79666806|NCT00351312|Device|special socks|
79666807|NCT00320294|Drug|irinotecan|
79990584|NCT02940223|Behavioral|Quality-of-Life Assessment|Ancillary studies
79666808|NCT00320294|Drug|cisplatin|
79666809|NCT00351390|Other|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
79666810|NCT00351390|Other|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP <1000 pg/mL
79990585|NCT02940223|Other|Questionnaire Administration|Ancillary studies
79354300|NCT04145206|Behavioral|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
79354301|NCT04145128|Drug|AG881|AG-881 tablets.
79354302|NCT03945604|Drug|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
79354303|NCT05580484|Procedure|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
79354304|NCT03944356|Drug|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
79354305|NCT04148716|Procedure|additional biopsies|additional biopsies during a fibroscopy planned in the care
79666811|NCT00320333|Procedure|pulmonary rehabilitation programme|
79666812|NCT00346749|Drug|Salmeterol|
79666813|NCT00346749|Drug|Fluticasone Propionate/Salmeterol Combination Product|
79666814|NCT00320450|Drug|SB-681323|
79666815|NCT00346788|Procedure|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
79354306|NCT03582436|Procedure|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
79354307|NCT01701063|Drug|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
79354308|NCT01701063|Drug|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
79666816|NCT00419276|Procedure|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
79354309|NCT01701063|Drug|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
79354310|NCT04406116|Device|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
79354311|NCT04145050|Other|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
79354312|NCT03941314|Device|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
79354313|NCT03941314|Device|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
79354314|NCT04144816|Other|Not applicable (no intervention)|Not applicable (no intervention)
79354315|NCT04144660|Device|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
79666817|NCT00351429|Device|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
79666818|NCT00351507|Drug|Vildagliptin|
79990586|NCT01312831|Other|Vitamin B12 (cyanocobalamin)|
79354316|NCT01700985|Drug|122-0551|Applied twice daily for two weeks
79354317|NCT01700985|Drug|Vehicle|Applied twice daily for two weeks
79354318|NCT04148404|Procedure|Normothermic group|"Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
79818253|NCT06240091|Device|DISC-MA|DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.
79818254|NCT06240039|Other|Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon|"The experimental days consist of four study days:~Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes."
79990587|NCT01312987|Dietary Supplement|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
79990588|NCT04431193|Drug|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
79990589|NCT03295201|Other|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
79990590|NCT03295201|Other|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
79990591|NCT03293485|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
79354319|NCT04144426|Behavioral|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
79354320|NCT04144426|Behavioral|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
79354321|NCT03920722|Drug|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
79354322|NCT03920722|Drug|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
79354323|NCT05580094|Other|general anesthesia only.|induction of general anesthesia by propofol and maintenance sevoflurane.
79354324|NCT05580094|Other|general anesthesia plus supraclavicular block.|induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
79818255|NCT06240026|Device|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
79990592|NCT03309943|Drug|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
79354325|NCT05586100|Drug|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing <50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
79354326|NCT05587270|Other|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
79666819|NCT00320567|Drug|norgestimate/ethinyl estradiol|
79818256|NCT06240026|Device|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.5cm and 1cm rounds, attached to a digitimer.
79818257|NCT06240013|Other|Foam Rolling|Participants will take a long sitting position on a solid and flat surface, positioning their arms back and transferring their body weight to their palms. The foam roller to be applied to the dominant side will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa, applying pressure for 2 minutes.
79990593|NCT03309943|Drug|Placebo|Participants will take one dose of Placebo on two separate occasions.
79354327|NCT05587270|Radiation|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
79354328|NCT04148248|Other|No intervention|There is no intervention for this study
79354329|NCT05585008|Device|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
79354330|NCT05584852|Other||no intervention
79354331|NCT05585086|Other|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
79666820|NCT00346827|Drug|Apomorphine Nasal Powder|
79666821|NCT00346866|Drug|anecortave acetate|
79818258|NCT06240013|Other|Proprioceptive Neuromuscular Facilitation Stretching|A PNF stretching protocol will be implemented with each participant assuming a tall sitting position on a solid, flat surface with their knees extended as much as possible. At this moment, the participant will be asked to perform maximum isometric hamstring muscle contraction for 5 seconds, followed by 5 seconds of relaxation and 20 seconds of stretching.
79990594|NCT01313065|Drug|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
79666822|NCT00320723|Drug|bupropion, transdermal nicotine patch|
79666823|NCT00351546|Drug|Vildagliptin|
79666824|NCT00320762|Device|OculusGen Biodegradable Collagen Matrix Implant|
79666825|NCT00346944|Procedure|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
79823832|NCT01034215|Behavioral|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
79990595|NCT01732627|Biological|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
79990596|NCT01732627|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
79990597|NCT03307837|Drug|CA-008|Local administration during surgery
79990598|NCT03307837|Drug|Placebo|Local administration during surgery
79990599|NCT05065255|Device|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
79990600|NCT04296799|Drug|SMP-100|SAD/MAD
79990601|NCT04296799|Drug|Placebo|Placebo
79990602|NCT03637933|Procedure|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
79666826|NCT00351585|Drug|Vildagliptin|
79990603|NCT03331315|Drug|Celecoxib|
79666827|NCT00320879|Drug|irbesartan|
79990604|NCT03331315|Drug|Ketorolac|
79990605|NCT03329989|Biological|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
79354332|NCT03904030|Other|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
79354333|NCT03902938|Biological|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
79354334|NCT03902938|Other|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
79354335|NCT05583136|Device|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
79354336|NCT05583136|Device|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
79354337|NCT05583136|Device|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
79505072|NCT01928706|Other|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
79505073|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
79505074|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
79666828|NCT00346983|Drug|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
79354338|NCT01710501|Drug|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
79354339|NCT01710501|Biological|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
79354340|NCT01710501|Drug|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
79354341|NCT01710501|Drug|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
79505075|NCT03084900|Other|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
79505076|NCT01929096|Drug|Compound Edaravone Injection|
79505077|NCT01929096|Drug|Edaravone Injection|
79666829|NCT00346983|Drug|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
79990606|NCT03287869|Drug|Brexpiprazole|Brexpiprazole tablets
79354342|NCT05583058|Other|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
79990607|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
79990608|NCT02661490|Drug|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
79990609|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
79666830|NCT00347061|Drug|afuzosin|
79666831|NCT00320957|Device|OculusGen Biodegradable Collagen Matrix Implant|
79666832|NCT00347100|Drug|Insulin Glargine|Throughout study period
79666833|NCT00347100|Drug|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
79666834|NCT00347100|Drug|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
79666835|NCT00347100|Drug|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
79666836|NCT00347100|Drug|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
79666837|NCT00347100|Drug|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
79666838|NCT00347139|Drug|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
79990610|NCT03287791|Drug|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
79990611|NCT03287791|Drug|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
79354343|NCT04144270|Other|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
79354344|NCT04144114|Dietary Supplement|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
79354345|NCT04144114|Dietary Supplement|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
79354346|NCT04144114|Dietary Supplement|Placebo|Placebo
79505078|NCT05600790|Behavioral|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
79505079|NCT03059004|Behavioral|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
79505080|NCT03059004|Behavioral|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
79505081|NCT03059004|Behavioral|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
79505082|NCT03059004|Behavioral|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
79354347|NCT01700829|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
79354348|NCT01700829|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
79354349|NCT04143880|Drug|Progesterone|intramuscular injection intranasal administration
79354350|NCT04143880|Other|saline|intramuscular injection intranasal administration
79354351|NCT04144192|Drug|Lidocaine patch 1.8%|
79354352|NCT04144192|Drug|Lidocaine 5% patch|
79354353|NCT04144192|Drug|Lidocaine 2% Injectable Solution|
79354354|NCT01710345|Drug|Sufentanil NanoTab 20 mcg|
79354355|NCT01710345|Drug|Sufentanil NanoTab 30 mcg|
79354356|NCT01710345|Drug|Placebo NanoTab|
79354357|NCT04143568|Other|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
79354358|NCT03022006|Drug|elbasvir, grazoprevir|
79354359|NCT04148092|Drug|ripretinib|orally administered solid dosage form
79354360|NCT04143334|Diagnostic Test|Conventional survey|
79505083|NCT04554888|Drug|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
79505084|NCT04554888|Drug|Papain|Papain will be applied by 1 SPT prick thought the skin
79505085|NCT04554888|Drug|Histamine|Histamine will be applied by 1 SPT prick thought the skin
79666839|NCT00347139|Drug|Salmeterol 50mcg|Salmeterol 50mcg
79354361|NCT05582824|Other|Blood and urine test|Daily blood and urine samples
79505086|NCT04554888|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
79505087|NCT04553016|Biological|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
79666840|NCT00321035|Device|OculusGen Biodegradable Collagen Matrix Implant|
79666841|NCT00347178|Procedure|Laser Peripheral Iridotomy|
79354362|NCT02335216|Device|Implantation with the commercially available Axium neurostimulator|
79666842|NCT00321074|Drug|TACROLIMUS|Immunosuppression
79666843|NCT00321113|Drug|tacrolimus|immunosuppression
79354363|NCT04148326|Other|No Intervention|There is no intervention for this study.
79666844|NCT00321113|Drug|mycophenolate mofetil|oral
79666845|NCT00321113|Drug|steroids|oral
79666846|NCT00347256|Drug|cisplatin|
79354364|NCT04147936|Dietary Supplement|AXA1665|Dietary supplement: AXA1665
79354365|NCT04147936|Dietary Supplement|Placebo|Placebo
79354366|NCT04148014|Behavioral|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
79354367|NCT04143022|Device|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
79505088|NCT04553016|Biological|Placebo|IM administration of 0.9% sterile sodium chloride solution
79505089|NCT03374592|Radiation|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
79505090|NCT03374592|Radiation|Conventional Radiotherapy|Conventional radiotherapy technique
79505091|NCT04553406|Drug|SPR720|Capsules for oral administration
79505092|NCT04553406|Drug|Placebo|Capsules for oral administration
79666847|NCT00347256|Procedure|targeted radiation therapy|
79666848|NCT00347256|Procedure|tumor resection|
79666849|NCT00321152|Other|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
79666850|NCT00347295|Drug|Brotizolam|
79666851|NCT00347295|Drug|Estazolam|
79666852|NCT00321191|Drug|No nitrous oxide|
79666853|NCT00321191|Drug|Administration of N2O|
79666854|NCT00351624|Behavioral|DHA|
79666855|NCT00351624|Behavioral|placebo|
79666856|NCT00321230|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
79990612|NCT03287791|Drug|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
79990613|NCT03287791|Other|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
79354368|NCT04143256|Other|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
79505093|NCT04553406|Drug|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
79505094|NCT04395300|Other|Web Based Survey|On line survey distributed electronically
79505095|NCT04124796|Other|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
79505096|NCT04124718|Genetic|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
79505097|NCT04394052|Diagnostic Test|MR imaging|Medical imaging
79666857|NCT00351663|Drug|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine 40mg x1/day"
79823833|NCT01034215|Behavioral|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
79354369|NCT04143256|Other|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
79354370|NCT04143256|Other|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
79354371|NCT04143256|Other|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
79354372|NCT04143256|Other|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
79354373|NCT04143256|Other|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
79354374|NCT04143256|Other|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
79505098|NCT05601960|Other|anti-acne dermocosmetic|Topical application once daily for 2 months
79666858|NCT00321347|Drug|Lidocaine|
79666859|NCT00351702|Drug|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
79666860|NCT00351780|Device|FFR measurement, side branch angioplasty|
79354375|NCT04143256|Other|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
79505099|NCT05605002|Drug|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
79505100|NCT05605002|Procedure|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
79666861|NCT00321425|Procedure|brachial plexus block|
79666862|NCT00321425|Procedure|ultrasound guidance|
79823834|NCT00791427|Drug|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
79354376|NCT04143256|Other|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
79354377|NCT04143256|Other|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
79354378|NCT04143412|Drug|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
79666863|NCT00321425|Procedure|electrical nerve stimulation|
79666864|NCT00351858|Drug|ertumaxomab|
79505101|NCT05605002|Procedure|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
79666865|NCT00351897|Device|pulsed dye (585nm) laser therapy|
79666866|NCT00321542|Other|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
79666867|NCT00351975|Drug|Belinostat|Given IV
79666868|NCT00351975|Drug|Azacitidine|Given SC
79354379|NCT05582278|Drug|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
79505102|NCT05604846|Dietary Supplement|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
79666869|NCT00351975|Other|Laboratory Biomarker Analysis|Correlative studies
79354380|NCT05582278|Drug|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
79354381|NCT05582278|Drug|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight <60 kg
79354382|NCT05582278|Drug|tislelizumab|tislelizumab 200 mg, every 3 weeks.
79666870|NCT00321581|Drug|Cediranib, AZD2171, RECENTIN|
79666871|NCT00321659|Behavioral|Aerobic|3x/week of walking and cycling
79666872|NCT00321659|Behavioral|Strength training|3x/week of resistance training activities
79666873|NCT00321659|Behavioral|Combination|3x/week of aerobic and strength training activities
79666874|NCT00321659|Behavioral|FSHC|Biweekly group education group meetings
79666875|NCT00352092|Drug|calcineurin inhibitor|
79666876|NCT00352092|Drug|sirolimus|
79666877|NCT00352092|Drug|mycophenolate mofetil|
79666878|NCT00322010|Procedure|early PT OT|"Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~Sessions began with active assisted and active range of motion exercises in the supine position.~If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~The session progresses to transfer training, and finally pre-gait exercises and ambulation.~Progression of activities is dependent on patient tolerance and stability.~Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
79666879|NCT00352131|Drug|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
79666880|NCT00322127|Drug|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
79354383|NCT05582122|Biological|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
79666881|NCT00352170|Dietary Supplement|calcium supplementation|calcium carbonate 1500 mg/day
79666882|NCT00352170|Dietary Supplement|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
79354384|NCT04147702|Other|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
79354385|NCT01710033|Drug|Placebo|Placebo tables twice daily (BID) for 28 days
79354386|NCT01710033|Drug|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
79354387|NCT01710033|Drug|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
79354388|NCT01710033|Drug|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
79354389|NCT04148170|Procedure|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
79505103|NCT04124484|Drug|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
79505104|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
79505105|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
79505106|NCT04124484|Drug|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
79505107|NCT04124016|Dietary Supplement|Inulin|Powder of inulin fractions dissolved into 250 ml of water
79505108|NCT04124016|Dietary Supplement|green tea extract|Powder of green tea extract dissolved into 200 ml of water
79505109|NCT04124016|Dietary Supplement|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
79505110|NCT04124016|Dietary Supplement|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
79505111|NCT04124094|Drug|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
79505112|NCT04124094|Drug|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
79505113|NCT04124094|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
79505114|NCT05604612|Procedure|Corticision|Incisions in the cortical plate of maxillary bone
79505115|NCT05604378|Procedure|Gastrectomy|All patients in our study underwent gastrectomy.
79666883|NCT00352170|Dietary Supplement|Placebo|calcium and vitamin D3 placebo
79666884|NCT00322166|Other|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
79666885|NCT00322166|Other|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
79666886|NCT00322166|Other|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
79354390|NCT01822496|Radiation|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
79354391|NCT01822496|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
79354392|NCT01822496|Drug|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
79354393|NCT01822496|Drug|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
79354394|NCT01822496|Drug|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
79354395|NCT01822496|Drug|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
79505116|NCT04123782|Device|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
79505117|NCT04123782|Device|Placebo F-ESW Treatment|Very low concentration of F-ESW.
79505118|NCT03831438|Drug|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
79505119|NCT04123392|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
79505120|NCT04123392|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
79505121|NCT04123392|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79505122|NCT04393038|Drug|ABX464|ABX464 50mg QD for 28 days + Standard of Care
79505123|NCT04393038|Drug|Placebo|Placebo 50mg QD for 28 days + Standard of Care
79505124|NCT03030924|Device|Solace|Noninvasive physiologic monitor
79505125|NCT05601258|Other|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
79505126|NCT05607966|Device|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
79505127|NCT04760262|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
79505128|NCT04760262|Drug|Propofol|BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
79505129|NCT04127292|Behavioral|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
79505130|NCT04123002|Other|Miswak chewing sticks|Chewing stick are routinely used by this population
79505131|NCT04123236|Other|Age 0-18|Patients under 18 years of age
79505132|NCT04123236|Other|Age 18-26|Patients over18 years of age
79505133|NCT04123236|Other|Girls|Girls
79505134|NCT04123236|Other|Boys|Boys
79505135|NCT03047928|Drug|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
79505136|NCT03047928|Biological|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
79505137|NCT04122846|Behavioral|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
79505138|NCT05607810|Genetic|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
79505139|NCT05607654|Device|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
79505140|NCT05607654|Device|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79505141|NCT04127682|Other|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
79666887|NCT02959580|Drug|Hydrocortisone Butyrate|topical use
79666888|NCT02959580|Procedure|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
79505142|NCT04122144|Behavioral|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL & Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
79505143|NCT04122066|Drug|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
79505144|NCT03228264|Device|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
79505145|NCT03228264|Device|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
79354396|NCT01822496|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
79505146|NCT05607264|Other|Kinsiotaping|Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
79505147|NCT05607264|Other|Motion-controlled VR games|Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
79505148|NCT05607264|Other|Conventional treatment|patients received conventional treatment for chronic shoulder impingement syndrome only.
79505149|NCT04122300|Drug|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
79505150|NCT04122300|Drug|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
79505151|NCT04121910|Drug|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
79505152|NCT04121910|Drug|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
79505153|NCT04274478|Device|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
79666889|NCT00352248|Procedure|Tongue Acupuncture (Procedure)|
79666890|NCT00322205|Drug|zyban|
79666891|NCT00352287|Drug|Recombinant human growth hormone; pioglitazone|
79354397|NCT03936088|Device|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
79666892|NCT00322244|Procedure|Massage Therapy|
79666893|NCT00352326|Device|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
79666894|NCT00322283|Drug|Oglemilast|Oglemilast, 15mg once per day, oral administration
79666895|NCT00322283|Drug|Placebo|Dose-marched placebo, once per day, oral administration
79666896|NCT00352404|Device|Endomicroscope|
79666897|NCT00322322|Drug|L-Carnitine|L-Carnitine
79666898|NCT00352443|Drug|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
79666899|NCT00352443|Drug|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
79666900|NCT00322361|Biological|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
79666901|NCT00322361|Biological|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
79666902|NCT00352482|Drug|Sildenafil (50 mg)|
79666903|NCT00322400|Drug|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
79354398|NCT03936088|Device|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
79505154|NCT03830736|Combination Product|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
79505155|NCT03830736|Combination Product|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
79666904|NCT00322400|Drug|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
79505156|NCT03830736|Combination Product|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
79505157|NCT03830736|Combination Product|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
79505158|NCT03830736|Combination Product|Control product|Glucose based beverage without added test components is used as control product
79505159|NCT04393818|Behavioral|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep disorders), work environment, and social support.
79505160|NCT04393896|Behavioral|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
79505161|NCT04129788|Drug|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
79505162|NCT04129788|Drug|Placebo oral tablet|three doses taken, one per day on three consecutive days
79505163|NCT03831126|Drug|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
79505164|NCT05607186|Radiation|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
79505165|NCT04073784|Drug|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
79505166|NCT05606796|Drug|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
79505167|NCT04121208|Drug|JNJ-40346527|Active study drug
79505168|NCT04121208|Other|Placebo|Non-active study drug
79990614|NCT03287791|Other|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
79354399|NCT01867047|Drug|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
79354400|NCT01867047|Drug|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
79505169|NCT04393740|Diagnostic Test|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
79505170|NCT03831204|Device|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
79505171|NCT03831204|Diagnostic Test|prognostic scores|Effect and GWTGHF were calculated for every patient
79505172|NCT05606640|Diagnostic Test|Biopsychological pain assessment|At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
79505173|NCT04129710|Drug|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
79505174|NCT04129710|Drug|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
79505175|NCT04129710|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
79505176|NCT04129710|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
79505177|NCT04129710|Drug|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
79505178|NCT04129710|Drug|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
79505179|NCT03200808|Drug|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
79505180|NCT05603598|Drug|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
79505181|NCT02983656|Biological|live attenuated varicella vaccine|
79505182|NCT04121130|Device|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
79505183|NCT04121130|Device|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
79354401|NCT03588988|Drug|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
79354402|NCT03588988|Drug|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
79354403|NCT05581888|Device|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
79505184|NCT04129476|Behavioral|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
79354404|NCT04414137|Other|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
79354405|NCT05580172|Drug|RH324|polymolecular
79505185|NCT04128852|Device|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
79666905|NCT00322400|Drug|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
79354406|NCT05586178|Behavioral|Reminder that facilitates action|Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
79505186|NCT04129008|Drug|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
79354407|NCT05586178|Behavioral|Consistency framing|The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
79505187|NCT04129008|Drug|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
79505188|NCT04121052|Drug|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
79666906|NCT00352521|Drug|bevacizumab|
79666907|NCT00352521|Drug|irinotecan|
79666908|NCT00352521|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79823835|NCT00786513|Other|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
79505189|NCT04120896|Behavioral|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
79666909|NCT00322478|Behavioral|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
79354408|NCT05586178|Behavioral|Information provision about the uniqueness of the bivalent booster|The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
79354409|NCT05586178|Behavioral|Information provision about bivalent booster eligibility|The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
79505190|NCT04120896|Behavioral|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
79666910|NCT00322478|Behavioral|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
79354410|NCT05586178|Behavioral|Information provision about the severity of COVID-19 symptoms|The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
79354411|NCT01821560|Drug|Baclofen|
79354412|NCT01821560|Drug|placebo|
79666911|NCT00322478|Behavioral|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
79666912|NCT00352599|Drug|Lovastatin|
79666913|NCT00352599|Drug|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
79354413|NCT01871402|Drug|000-0551 Lotion|
79666914|NCT00352599|Drug|placebo pill|
79354414|NCT01871402|Drug|Vehicle Lotion|
79354415|NCT03588832|Diagnostic Test|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
79354416|NCT04607174|Other|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
79505191|NCT04128930|Device|PAP titration at home|Fixed CPAP or APAP titration at home
79505192|NCT05603130|Other|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
79505193|NCT04128462|Drug|MNK-6105|L-Ornithine Phenylacetate for IV infusion
79505194|NCT04128462|Drug|Placebo|Matching placebo for IV infusion
79505195|NCT04128462|Drug|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
79666915|NCT00352638|Other|counseling intervention|
79666916|NCT00352638|Other|educational intervention|
79666917|NCT00352638|Other|study of socioeconomic and demographic variables|
79666918|NCT00322595|Drug|Quetiapine fumarate|
79666919|NCT00322595|Drug|Paroxetine|
79666920|NCT00352677|Drug|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
79666921|NCT00352716|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
79666922|NCT00331149|Drug|Ropinirole prolonged release|
79990615|NCT03287791|Other|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
79823836|NCT00786513|Other|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
79990616|NCT03287791|Other|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
79990617|NCT02381002|Other|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
79354417|NCT05580328|Drug|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
79354418|NCT04415450|Behavioral|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
79354419|NCT03901300|Behavioral|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
79354420|NCT03901300|Behavioral|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
79354421|NCT03588676|Other|Melatonin|5mg Melatonin
79505196|NCT04394520|Other|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
79354422|NCT03588676|Other|Placebo|5mg Placebo capsule
79354423|NCT03467542|Device|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
79505197|NCT04394520|Other|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
79505198|NCT04394520|Other|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
79823837|NCT00791505|Drug|ciprofloxacin|1500 mg a day for 10 days
79505199|NCT04394520|Other|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
79823838|NCT00791505|Drug|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
79823839|NCT02598960|Drug|BMS-986156|
79823840|NCT02598960|Drug|Nivolumab|
79990618|NCT03287635|Drug|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
79990619|NCT02380924|Drug|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
79990620|NCT02380924|Drug|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
79990621|NCT04051918|Behavioral|Piano Training|Cognitive training via music learning
79990622|NCT03694405|Biological|MenACWY-CRM|Booster vaccination with MenACWY-CRM
79990623|NCT03694405|Biological|MenACWY-DT|Booster vaccination with MenACWY-DT
79990624|NCT03694405|Biological|MenACWY-TT|Booster vaccination with MenACWY-TT
79505200|NCT04128618|Device|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
79505201|NCT03309306|Other|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
79354424|NCT01846442|Drug|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
79505202|NCT03309306|Behavioral|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
79505203|NCT04120662|Procedure|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
79505204|NCT04120662|Device|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
79666923|NCT00331149|Drug|ropinirole immediate release|
79666924|NCT00331188|Drug|Sanvar® (vapreotide)|
79666925|NCT00352833|Drug|catumaxomab|
79666926|NCT00322673|Drug|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
79666927|NCT00331305|Behavioral|Supervised Exercise|
79666928|NCT00331305|Behavioral|Home-Based Exercise|
79666929|NCT00331305|Drug|Sertraline (Zoloft)|
79666930|NCT00331305|Drug|Placebo Pill|
79666931|NCT00322751|Drug|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
79354425|NCT01846442|Drug|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
79990625|NCT03287089|Drug|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
79505205|NCT04120506|Drug|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
79505206|NCT04120350|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
79666932|NCT00352950|Drug|AMG 954/Panitumumab|
79666933|NCT00322907|Drug|Cotrifazid vs mefloquine or quinine+SP|
79666934|NCT00352989|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
79990626|NCT03287089|Drug|Placebo Oral Tablet|Matching placebo
79990627|NCT02380768|Device|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
79354426|NCT01846442|Drug|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
79354427|NCT01846442|Drug|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
79354428|NCT03586570|Drug|Aprocitentan 25mg|Oral tablets in strength of 25 mg
79354429|NCT03586570|Drug|Placebo|Oral tablets matching aprocitentan tablets
79354430|NCT03588598|Drug|SHC014748M|a selective PI3Kδ inhibitor
79354431|NCT03588364|Other|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
79666935|NCT00322946|Biological|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
79666936|NCT00322946|Biological|Placebo|Placebo for rDEN4delta30-4995
79666937|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
79666938|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
79823841|NCT00426361|Biological|Boostrix ® Polio|One dose of vaccine administered intramuscularly
79354432|NCT03588208|Other|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
79354433|NCT03588208|Other|Educational Program|Structured education program were performed during one hour class once a week for five weeks
79354434|NCT01709721|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
79354435|NCT01709721|Device|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
79354436|NCT03588520|Diagnostic Test|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
79354437|NCT03588052|Procedure|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
79505207|NCT04120350|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
79505208|NCT04120350|Drug|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
79505209|NCT04394598|Drug|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
79505210|NCT04394598|Radiation|Pelvic Radiation|50Gy/25Fx
79666939|NCT00322985|Drug|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
79666940|NCT00353028|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
79505211|NCT04394598|Drug|Capecitabine|625mg/m2 bid Monday-Friday per week
79666941|NCT00353028|Drug|Placebo|Placebo
79666942|NCT00323024|Drug|NX1011|
79666943|NCT00331539|Device|Cochlear Implant|
79666944|NCT00323102|Drug|Multihance|
79666945|NCT00331578|Device|Excel drug-eluting coronary artery stent|
79666946|NCT00353067|Drug|veliflapon (DG-031)|
79990628|NCT02380768|Device|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
79666947|NCT00323219|Drug|Cefazolin and Moxifloxacin|See Detailed Description.
79823842|NCT00426361|Biological|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
79505212|NCT04394598|Drug|Irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
79505213|NCT04394598|Other|Placebo|3g tid per day for 5weeks
79666948|NCT00353106|Behavioral|Interview|30-minute interviews of participating patients and their caregiver(s).
79666949|NCT00353106|Behavioral|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
79666950|NCT00331656|Device|Non-invasive positive pressure mask ventilators|
79666951|NCT00331656|Device|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
79823843|NCT00665847|Drug|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
79666952|NCT00323375|Drug|AQ-13|A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
79666953|NCT00323375|Drug|Chloroquine (CQ) Treatment|A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
79818259|NCT06240000|Procedure|Radiofrequency ablation|Firstly, the posterior superior iliac spine was showed in the transverse plane, and it was gradually moved proximally until gluteus maximus muscle disappears and gluteus medius arises. Medial branch of the SCN is seen between iliac crest and thoracolumbar fascia as an ovoid structure. Radiofrequency device was utilized with 22-gauge 10-cm, 5 mm RF cannulas for all procedures. Cannula was placed thorough the SCN area and Sensory fiber stimulation was started between 0.3 and 0.5 V. The patient was asked for feedback on symptoms such as numbness, paresthesia or pain. If the patient did not report any sensory symptoms within the specified sensory stimulation range, the cannula was repositioned. Motor stimulation was given up to 1.5 V and it was checked whether there was any contraction or not. If there is no contraction detected, the SCN was ablated at 42° degrees centigrade for 240 seconds.
79354438|NCT03588052|Procedure|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
79354439|NCT01866657|Drug|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
79505214|NCT04120272|Procedure|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
79505215|NCT04394832|Behavioral|Brief cognitive intervention|See the information provided in the experimental arm description.
79505216|NCT04127916|Drug|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
79505217|NCT04127760|Radiation|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
79505218|NCT03302130|Behavioral|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
79505219|NCT03302130|Device|Arterial spin labeling MRI|Single PLD PCASL
79505220|NCT03302130|Device|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
79505221|NCT04127370|Procedure|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
79505222|NCT02984046|Drug|Protein CC16|
79505223|NCT04127526|Other|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
79505224|NCT05602428|Drug|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
79505225|NCT05602428|Drug|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
79505226|NCT05602428|Drug|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
79505227|NCT02983890|Drug|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
79666954|NCT00331695|Drug|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
79666955|NCT00323531|Procedure|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
79666956|NCT00323531|Procedure|VATS decortication|thoracoscopic decortication
79666957|NCT00323570|Drug|activated recombinant human factor VII|
79666958|NCT00353145|Drug|Gemcitabine (Gemox)|1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 repeated every 14 days (one cycle).
79666959|NCT00353145|Drug|Oxaliplatin|100 mg/m^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
79666960|NCT00353145|Behavioral|Questionnaire|Quality of Life Surveys
79666961|NCT00323648|Drug|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
79666962|NCT00353184|Drug|Montelukast 5-mg orally added to standard therapy|
79990629|NCT02384980|Device|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
79666963|NCT00323687|Drug|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
79666964|NCT02959515|Procedure|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
79990630|NCT02385136|Drug|Temozolomide|
79666965|NCT02959515|Procedure|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
79990631|NCT02380534|Procedure|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
79505228|NCT02983890|Drug|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
79505229|NCT03022968|Drug|[18F]T807 PET|Imaging with [18F]T807 PET
79505230|NCT04129944|Drug|UBX0101|Investigational drug intra-articular injection
79505231|NCT04129944|Other|Placebo|Placebo intra-articular injection
79666966|NCT00353223|Behavioral|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
79818260|NCT06239974|Drug|Vericiguat|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
79990632|NCT02375932|Behavioral|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
79990633|NCT02375932|Behavioral|Usual Care Control|Patients continue to receive usual care from their primary care provider
79990634|NCT03113188|Drug|CBP501|CBP501, CDDP plus Nivolumab
79990635|NCT02376322|Radiation|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
79505232|NCT05602350|Behavioral|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
79666967|NCT00353223|Behavioral|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
79666968|NCT00323804|Biological|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
79666969|NCT00323804|Drug|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
79354440|NCT01866657|Other|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
79505233|NCT05602350|Behavioral|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
79354441|NCT01866657|Other|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
79505234|NCT04124172|Device|Real rTMS (Magstim)|See arm description
79505235|NCT04124172|Device|Sham rTMS|See arm description
79505236|NCT04393194|Drug|Vaginal Cream with Applicator [Dose Form]|Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
79505237|NCT04126980|Behavioral|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
79505238|NCT04127058|Drug|Iloperidone|Oral Tablet
79505239|NCT05600010|Other|Microplastics|Detection of microplastics as a yes/no value
79505240|NCT03012360|Drug|ceftriaxone|2 g iv every 24h
79505241|NCT03012360|Drug|ciprofloxacin|400 mg iv every 8h
79354442|NCT01866657|Other|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
79505242|NCT03012360|Drug|imipenem|1 g iv every 8h
79666970|NCT00323804|Drug|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
79354443|NCT01866657|Drug|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
79354444|NCT01866657|Biological|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
79505243|NCT03012360|Drug|linezolid|600 mg iv every 12h
79505244|NCT03012360|Drug|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
79505245|NCT04121598|Other|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
79505246|NCT05609838|Other|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
79505247|NCT04392882|Behavioral|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
79505248|NCT04126668|Drug|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
79505249|NCT04126434|Device|mask|facemask
79666971|NCT00353340|Drug|n acetylcysteine|
79666972|NCT00353340|Drug|sodium bicarbonate|
79505250|NCT04126512|Other|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
79505251|NCT02979678|Other|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
79505252|NCT04126122|Diagnostic Test|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
79505253|NCT04758936|Drug|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
79666973|NCT00353340|Drug|sodium chloride|
79666974|NCT00323843|Drug|Isoproterenol|
79666975|NCT00331812|Procedure|Mitochondrial functions and oxidative stress|
79354445|NCT01866657|Drug|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
79354446|NCT03587350|Device|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
79666976|NCT00331851|Drug|liraglutide|
79666977|NCT00331851|Drug|insulin glargine|
79666978|NCT00331851|Drug|metformin|
79666979|NCT00331851|Drug|glimepiride|
79666980|NCT00323999|Procedure|Hysteroscopic resection of fibroids, polyps and endometrium.|
79666981|NCT00331890|Drug|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
79666982|NCT00331890|Drug|Placebo|As active drug
79818261|NCT06239974|Diagnostic Test|Stress Cardiac Magnetic Resonance|All patients will have stress CMR examinations at recruitment and at the end of trial.
79818262|NCT06239961|Behavioral|Social Connection|6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.
79354447|NCT03581344|Diagnostic Test|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
79354448|NCT03020836|Behavioral|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
79354449|NCT03020836|Behavioral|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
79354450|NCT01700205|Other|Type of Formula|infant formula
79354451|NCT03589690|Dietary Supplement|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
79354452|NCT03589690|Dietary Supplement|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
79354453|NCT03589534|Diagnostic Test|home pregnancy test|Each participant will use 4 different home pregnancy tests
79505254|NCT04758936|Drug|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
79505255|NCT03830814|Procedure|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
79505256|NCT04126044|Drug|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
79354454|NCT03589456|Other|No intervention|There are no interventions associated with this registry as it is purely observational.
79354455|NCT01700049|Drug|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
79354456|NCT03587194|Drug|Otezla|Otezla 30mg BID
79354457|NCT01699815|Drug|Acetaminophen|
79354458|NCT03586960|Device|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
79354459|NCT03589222|Drug|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
79354460|NCT03589222|Drug|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
79354461|NCT03589222|Drug|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
79354462|NCT03589222|Drug|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
79354463|NCT01866423|Drug|orteronel|Given PO
79505257|NCT04126044|Drug|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
79505258|NCT03822390|Device|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
79354464|NCT01866423|Other|laboratory biomarker analysis|Correlative studies
79354465|NCT01846208|Drug|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
79354466|NCT01846208|Drug|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
79505259|NCT03822858|Drug|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
79505260|NCT03829878|Drug|CP101|Orally administered donor derived full spectrum microbiota
79505261|NCT03829878|Drug|Placebo|Placebo for CP101
79818263|NCT06239961|Behavioral|Nutritional Coaching|4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.
79818264|NCT06239961|Behavioral|Physical Activity Coaching|4 weekly physical activity coaching sessions with a 1 hour duration for each call.
79666983|NCT01059773|Drug|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
79666984|NCT01059773|Drug|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
79354467|NCT04166799|Device|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
79354468|NCT03586804|Other|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
79354469|NCT03589066|Drug|LY03003|28 mg intramuscular suspension
79354470|NCT01845974|Device|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
79505262|NCT03829800|Dietary Supplement|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
79505263|NCT03829800|Dietary Supplement|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
79666985|NCT00353379|Drug|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
79818265|NCT06239948|Other|With Music|each subject was placed in a TMS laboratory with music for 20 minutes
79818266|NCT06239948|Other|Without Music|each subject was placed in a TMS laboratory without music for 20 minutes
79818267|NCT06239909|Other|24-h pad-weight test|The patients will be asked to perform the 24-h pad-weight test
79818268|NCT06239909|Other|Patient Global Impression - Improvement Questionnaire|The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
79666986|NCT00353379|Drug|Placebo|Participants will take placebo for 6 weeks.
79354471|NCT01845974|Device|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
79354472|NCT03020368|Biological|Leeches|
79354473|NCT03020368|Drug|Diclofenac|
79666987|NCT00324077|Drug|Dasatinib in combination with imatinib|
79354474|NCT03020290|Device|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
79354475|NCT03442582|Biological|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
79666988|NCT00331929|Device|Minato A 500 AS spirometer|Spirometry at rest
79666989|NCT00324194|Drug|MGCD0103|MGCD0103 oral dose given 2 times per week.
79666990|NCT00324311|Drug|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
79666991|NCT00353613|Behavioral|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
79666992|NCT00324389|Drug|Interferon alpha|
79354476|NCT03581422|Drug|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
79354477|NCT03581266|Other|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
79354478|NCT05702944|Drug|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
79505264|NCT03829800|Dietary Supplement|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
79505265|NCT03829800|Dietary Supplement|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
79505266|NCT04125810|Biological|Probiotic|Probiotic
79505267|NCT04125810|Other|Placebo|Placebo
79666993|NCT00332007|Drug|Tonabersat|two tablets once daily
79666994|NCT00332007|Drug|Placebo|two tablets once daily
79354479|NCT05702866|Diagnostic Test|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
79818269|NCT06239883|Other|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
79354480|NCT03581110|Diagnostic Test|computed tomography|noncontrast-enhanced chest computed tomography
79354481|NCT04765618|Procedure|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
79354482|NCT03586180|Behavioral|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
79354483|NCT03580876|Drug|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
79354484|NCT03580876|Drug|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
79354485|NCT03580798|Procedure|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
79818270|NCT06239870|Drug|Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy|Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
79990636|NCT02375776|Other|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
79354486|NCT03580798|Procedure|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
79354487|NCT03586024|Drug|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
79505268|NCT04758858|Other|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
79505269|NCT04758858|Device|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
79505270|NCT04758858|Other|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
79505271|NCT04758858|Other|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
79666995|NCT00353691|Drug|glimepiride|
79666996|NCT00353691|Drug|metformin|
79354488|NCT05702632|Device|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
79666997|NCT00324428|Procedure|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
79666998|NCT00332046|Drug|GW679769|
79666999|NCT00324467|Drug|Cyclophosphamide|"Dose: 750 mg/m^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
79505272|NCT04758858|Other|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
79505273|NCT04758858|Other|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
79354489|NCT05702632|Device|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
79505274|NCT04758858|Other|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
79505275|NCT04758858|Other|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
79667000|NCT00324467|Drug|Doxorubicin|"Dose: 50 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
79818271|NCT06239857|Procedure|Epidural pulsed radiofrequency|The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
79505276|NCT04758858|Other|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
79505277|NCT04758858|Device|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
79354490|NCT05702632|Procedure|traditional physical therapy program|Facilitation of balance and gait training
79505278|NCT04758858|Other|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
79667001|NCT00324467|Drug|Vincristine|"Dose: 1.4 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
79818272|NCT06239844|Other|Experimental: Nav-Team|Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
79818273|NCT06239831|Device|ExSpiron and ActivPAL Monitors|ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
79818274|NCT06239818|Device|Photobiomodulation therapy (PBMt)|Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
79505279|NCT04758858|Other|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
79667002|NCT00324467|Drug|Prednisone|"Dose: 45 mg/m^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
79667003|NCT00324467|Drug|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
79667004|NCT00324467|Drug|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
79667005|NCT00324467|Drug|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
79990637|NCT02376244|Other|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
79990638|NCT02376244|Other|Standard care|Standard care cardiac rehabilitation according to current guidelines
79505280|NCT04758858|Other|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
79505281|NCT04758858|Other|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
79505282|NCT04758858|Other|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
79505283|NCT04758858|Other|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
79505284|NCT04758858|Other|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
79505285|NCT04758858|Other|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
79505286|NCT04125888|Drug|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
79667006|NCT00324467|Drug|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
79667007|NCT00324467|Drug|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
79667008|NCT00324467|Drug|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
79667009|NCT00324467|Drug|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
79823844|NCT00665847|Drug|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir [LPV], darunavir [DRV], atazanavir [ATV] or saquinavir [SQV]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N[t]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
79823845|NCT01030393|Drug|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
79354491|NCT03354520|Behavioral|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
79354492|NCT03354520|Behavioral|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
79354493|NCT03354520|Behavioral|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
79354494|NCT03580642|Device|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
79505287|NCT04759092|Device|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
79667010|NCT00324467|Drug|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
79667011|NCT00324467|Drug|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
79354495|NCT03585868|Other|Placebo|Beverage with no flavonoids
79505288|NCT02975310|Procedure|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
79505289|NCT02975310|Procedure|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
79354496|NCT03585868|Other|Flavonoids|Flavonoids-enriched cacao beverage
79354497|NCT03585868|Dietary Supplement|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
79354498|NCT03585634|Behavioral|Dads in Gear Program|
79354499|NCT03163264|Behavioral|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
79354500|NCT03163264|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
79354501|NCT03886324|Combination Product|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
79505290|NCT02975310|Other|General Anesthesia|ESS will be performed under general anesthesia in the operating room
79505291|NCT02975310|Other|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
79505292|NCT04394208|Drug|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
79505293|NCT04394208|Drug|Placebo|Placebo comparator
79505294|NCT05608980|Drug|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
79505295|NCT05608980|Drug|Placebo|once daily eyelid wipes for 2 weeks
79505296|NCT03829566|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
79505297|NCT03829566|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
79505298|NCT03829566|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
79505299|NCT03829566|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
79667012|NCT00324467|Drug|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
79667013|NCT00324467|Drug|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
79667014|NCT00324467|Drug|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
79667015|NCT00324467|Drug|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
79505300|NCT03829566|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
79505301|NCT03829566|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
79505302|NCT03829566|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
79505303|NCT03829566|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
79505304|NCT03933306|Drug|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
79505305|NCT03933306|Drug|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
79505306|NCT03933306|Other|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
79505307|NCT03933306|Other|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure > 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
79505308|NCT04125576|Diagnostic Test|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
79505309|NCT04125654|Device|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
79505310|NCT04394442|Drug|Hydroxychloroquine|400mg BD first day then 200 mg BD for 5 days
79505311|NCT04125264|Device|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
79667016|NCT00324467|Drug|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
79667017|NCT00324467|Other|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
79823846|NCT00783081|Drug|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
79505312|NCT02972424|Drug|Teriparatide Prefilled Syringe|TPTD 20 mcg
79505313|NCT02972424|Drug|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
79505314|NCT04393428|Other|[TIMP-2]*[IGFBP-7]|[TIMP-2]*[IGFBP-7] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
79505315|NCT05608590|Drug|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
79505316|NCT04393584|Drug|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
79505317|NCT04393584|Drug|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
79505318|NCT04393584|Drug|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
79505319|NCT04393584|Drug|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
79505320|NCT04393584|Drug|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
79505321|NCT02316366|Device|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
79505322|NCT03828864|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
79505323|NCT03828864|Device|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
79505324|NCT02315352|Drug|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
79505325|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
79505326|NCT02315352|Drug|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
79505327|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
79505328|NCT02315352|Drug|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
79667018|NCT00332085|Drug|Chromium Picolinate|
79667019|NCT00324506|Drug|Mycophenolate Mofetil (CellCept)|
79667020|NCT00332124|Drug|Choline|900 mg every day until birth of infant
79667021|NCT00332124|Dietary Supplement|Placebo|Corn oil every day in place of choline
79667022|NCT00419432|Other|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
79823847|NCT00783081|Drug|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
79823848|NCT00783081|Drug|Placebo|Placebo BID for 26 weeks.
79823849|NCT00426127|Drug|Docetaxel|
79823850|NCT00426127|Drug|Liposomal Doxorubicin|
79505329|NCT04125108|Other|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
79505330|NCT05608356|Biological|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
79667023|NCT00419432|Other|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
79505331|NCT05608356|Drug|Sham Injection|Sham injection as a placebo injection
79505332|NCT03828474|Drug|Acetazolamide Pill|Acetazolamide pill
79505333|NCT04394364|Device|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
79667024|NCT04714554|Drug|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
79667025|NCT04714554|Drug|Relugolix|Relugolix 120-mg tablets; oral administration.
79667026|NCT04714554|Drug|Erythromycin|Erythromycin 500-mg tablets; oral administration.
79505334|NCT05608122|Other|Obervation|This study is an observational study without any intervention
79505335|NCT05608122|Other|Obervation|This study is an observational study without any intervention
79505336|NCT04120818|Procedure|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
79667027|NCT00419471|Drug|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
79505337|NCT04120818|Procedure|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
79505338|NCT03822156|Other|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
79667028|NCT00419471|Drug|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
79667029|NCT00419510|Behavioral|Culturally Tailored Genetic Counseling|
79667030|NCT00353769|Procedure|Hair Apposition Technique|
79667031|NCT00324545|Behavioral|Medium-intensity Minimally-directive Counseling|
79667032|NCT00426348|Drug|Valsartan|Valsartan (80-160mg/day)
79667033|NCT00426348|Drug|Probucol|Probucol (750mg/day)
79505339|NCT03822234|Procedure|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
79667034|NCT00426348|Drug|Placebo|Placebo
79667035|NCT00324584|Device|Telemonitoring of glucose values using GlucoNet device|
79667036|NCT00353808|Drug|[S,S]-Reboxetine|
79667037|NCT00324623|Biological|Melan-A VLP vaccine, IMP321 adjuvant|
79667038|NCT00324623|Biological|adoptive immunotherapy|
79667039|NCT00324623|Biological|therapeutic autologous lymphocytes|
79667040|NCT00324623|Drug|cyclophosphamide|
79667041|NCT00324623|Drug|fludarabine phosphate|
79667042|NCT00353847|Device|Acupuncture|
79667043|NCT00324662|Device|Implantable cardioverter-defibrillator|
79667044|NCT00426426|Behavioral|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
79667045|NCT00426426|Behavioral|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
79667046|NCT00426426|Behavioral|Waiting list|
79667047|NCT00324779|Biological|rituximab|
79667048|NCT00353886|Procedure|TONI-3|
79667049|NCT00353886|Procedure|WRAT-3|
79667050|NCT00353886|Procedure|Connor's Rating Scales PRS & TRS|
79667051|NCT00353886|Procedure|Peabody Picture Vocabulary Test|
79667052|NCT00353886|Procedure|Children's Memory Scale|
79667053|NCT00353886|Procedure|WISC-3|
79667054|NCT00353886|Procedure|Behavioral Assessment System for Children PRS & TRS|
79667055|NCT00324818|Drug|metronidazole and azithromycin|
79823851|NCT00426127|Drug|Enoxaparin|
79823852|NCT02578212|Other|Placebo|
79823853|NCT02578056|Device|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
79505340|NCT03827928|Behavioral|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
79505341|NCT04392414|Biological|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
79505342|NCT04392414|Biological|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
79505343|NCT03828084|Drug|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
79505344|NCT03827772|Other|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
79505345|NCT03827772|Other|Standard of care treatment|Nutritional supplementation, supportive management.
79505346|NCT03822000|Other|Survival|Elderly patients with fall-induced femoral fracture who were survived.
79667056|NCT00324974|Drug|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
79505347|NCT03822000|Other|Death|Elderly patients with fall-induced femoral fracture who were dead.
79505348|NCT02315430|Drug|Cabozantinib S-malate|Given PO
79505349|NCT02315430|Other|Laboratory Biomarker Analysis|Optional correlative studies
79505350|NCT04274244|Drug|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~Single internal modified mattress suture (5/0 Vicryl, Ethicon).~Sutures will be removed after two weeks."
79505351|NCT04274244|Drug|Enamel Matrix Proteins (Active comparator group)|"Regenerative periodontal therapy + Enamel matrix proteins:~The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~Single internal modified mattress suture (5/0 Vicryl, Ethicon).~Sutures will be removed after two weeks."
79667057|NCT00324974|Drug|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
79667058|NCT00325013|Drug|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
79667059|NCT00353964|Drug|rEV131|
79667060|NCT00353964|Drug|Prenisolone sodium phosphate 1.0%|
79818275|NCT06239818|Other|Standard of Care|The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
79823854|NCT02578056|Procedure|Genital prolapse surgery|Surgical correction of genital prolapse
79505352|NCT04274322|Other|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
79505353|NCT04273698|Behavioral|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
79505354|NCT04274166|Drug|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
79505355|NCT04274088|Procedure|Cataract surgery|Phacoemulsification surgery
79505356|NCT02983968|Other|Description of the cirrhosis management|
79505357|NCT02983734|Drug|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
79505358|NCT02983734|Drug|Placebos|Sugar pill
79667061|NCT00353964|Drug|rEV131 vehicle|
79990639|NCT03286543|Device|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
79228381|NCT03469440|Other|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
79354502|NCT01865487|Biological|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
79354503|NCT01865487|Biological|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
79354504|NCT03585556|Drug|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
79354505|NCT03585556|Biological|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
79354506|NCT03585556|Drug|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
79354507|NCT05702398|Drug|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
79354508|NCT05702398|Drug|Nicotinamide|500 mg NAM twice a day for 6 months
79354509|NCT05702398|Other|Other: Placebo|Identical placebo pills twice a day
79354510|NCT01699503|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
79354511|NCT01709409|Drug|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
79354512|NCT01709409|Drug|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
79990640|NCT02380846|Other|White rice|Control - white rice
79990641|NCT02380846|Other|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
79354513|NCT01698879|Drug|Mylotarg|"Cohort 1 version 1.0. GO: 6mg/m^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m^2, SC, days 0 to 7. GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
79354514|NCT02335294|Drug|TRV130|Rescue: Ibuprofen, oxycodone
79505359|NCT03821454|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
79823855|NCT00783159|Procedure|Power Training|Power training, Vitamin D substitution
79354515|NCT02335294|Drug|Morphine|Rescue: Ibuprofen, oxycodone
79354516|NCT02335294|Drug|Placebo|Rescue: Ibuprofen, oxycodone
79354517|NCT01698801|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
79354518|NCT01698801|Drug|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
79354519|NCT03580252|Other|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
79823856|NCT00783159|Procedure|Strength Training|Strength training, Vitamin D substitution
79823857|NCT00783159|Other|Control|Vitamin D substitution, Lifestyle consultation
79990642|NCT02380846|Other|Rice with fish|Treatment 2 - steamed white rice with steamed fish
79990643|NCT02380846|Other|Rice with egg white|Treatment 3 - steamed white rice with egg white
79990644|NCT02380846|Other|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
79990645|NCT02380222|Other|Interview|Single interview lasting approximately one hour
79354520|NCT04548297|Other|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
79354521|NCT03585166|Procedure|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
79354522|NCT03585166|Procedure|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
79354523|NCT05702242|Procedure|IUD removal with no visible strings|Removal with either alligator forceps or MVA
79354524|NCT05702242|Device|Alligator forceps|IUD removal with alligator forceps
79354525|NCT05702242|Device|Manual Vacuum Aspirator|IUD removal with MVA
79354526|NCT01682811|Drug|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
79505360|NCT03821454|Drug|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
79505361|NCT03827148|Other|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
79990646|NCT03306433|Device|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
79990647|NCT02380144|Other|Fresh orange fruit and pasteurized fruit juice|
79990648|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
79505362|NCT04392492|Device|MANTA vascular closure device|Femoral access site closure using the MANTA closure device
79505363|NCT04392570|Diagnostic Test|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
79354527|NCT01682811|Drug|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
79354528|NCT01682811|Drug|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
79354529|NCT01682811|Drug|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
79354530|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
79505364|NCT03827304|Device|Virtual Reality Distraction from Burn Pain|Patients wore a VR headset while undergoing a burns dressing change
79505365|NCT03820674|Other|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
79505366|NCT03820674|Other|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
79505367|NCT03820518|Drug|Calcitriol|
79990649|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
79990650|NCT02384902|Other|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
79990651|NCT02940691|Drug|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
79505368|NCT03820440|Diagnostic Test|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
79505369|NCT03820440|Diagnostic Test|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
79505370|NCT01453764|Procedure|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
79505371|NCT03820206|Drug|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
79505372|NCT03820206|Procedure|Cesarean section|Lower segement transverse cesarean section
79823858|NCT02555709|Drug|VTP-43742|VTP-43742 administered as an oral capsule once daily
79823859|NCT02555709|Drug|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
79990652|NCT02379910|Drug|AM1030-CREAM or placebo|
79990653|NCT04949269|Drug|Deucravacitinib|Specified dose on specified days
79990654|NCT04949269|Drug|Famotidine|Specified dose on specified days
79990655|NCT02380066|Drug|Anyu Peibo|Placebo
79990656|NCT04938271|Device|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
79990657|NCT02379754|Drug|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
79990658|NCT02375620|Biological|PEG-somatropin|
79354531|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
79505373|NCT02955654|Behavioral|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
79823860|NCT02555709|Drug|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
79990659|NCT04911673|Behavioral|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
79990660|NCT04911673|Dietary Supplement|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
79505374|NCT02955654|Drug|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
79990661|NCT02384824|Procedure|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
79990662|NCT01313377|Drug|gemcitabine hydrochloride|
79990663|NCT01313377|Drug|oxaliplatin|
79990664|NCT01313377|Other|clinical observation|
79990665|NCT01313377|Procedure|adjuvant therapy|
79990666|NCT01313377|Procedure|quality-of-life assessment|
79990667|NCT02384746|Drug|Fulvestrant|500 mg intramuscular every 28 days
79990668|NCT02384746|Drug|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
79990669|NCT02375464|Drug|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
79505375|NCT02955654|Behavioral|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
79667062|NCT00354003|Behavioral|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
79667063|NCT00325169|Drug|Tiotropium + SERETIDE 50/500|
79990670|NCT02375386|Procedure|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
79990671|NCT02375386|Procedure|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
79990672|NCT02375386|Procedure|fMRI|Both groups will receive an fMRI.
79990673|NCT02375386|Behavioral|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
79990674|NCT02375386|Other|Questionnaires|Both groups will receive Questionnaires
79990675|NCT02375386|Behavioral|Physical Impairment|Both groups will receive testing on physical impairment.
79990676|NCT03113344|Drug|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
79505376|NCT01453842|Dietary Supplement|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
79505377|NCT01453842|Dietary Supplement|Olive oil|Carrot and olive oil and 1½ g of paracetamol
79505378|NCT01453842|Dietary Supplement|Carrot|Carrot and 1½ g of paracetamol
79505379|NCT03826836|Behavioral|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
79667064|NCT00426504|Procedure|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
79667065|NCT00325208|Device|partial-vacuum milk bottle|
79667066|NCT00325208|Device|anti-vacuum milk bottle|
79667067|NCT00426543|Drug|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
79505380|NCT04392648|Drug|TAK-573|TAK-573 intravenous infusion.
79505381|NCT04392648|Drug|Pomalidomide|Pomalidomide capsules orally.
79505382|NCT04392648|Drug|Bortezomib|Bortezomib injection subcutaneously.
79505383|NCT04392648|Drug|Cyclophosphamide|Cyclophosphamide tablets orally.
79505384|NCT04392648|Drug|Dexamethasone|Dexamethasone tablets orally.
79667068|NCT00426543|Drug|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
79667069|NCT00325247|Drug|ZINC|
79505385|NCT03826602|Drug|Tucatinib|150mg administered orally twice daily
79505386|NCT03826602|Drug|Metformin|850mg administered orally
79667070|NCT00325286|Drug|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
79990677|NCT03112954|Drug|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
79990678|NCT03112954|Drug|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
79990679|NCT03113266|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
79354532|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
79667071|NCT00354042|Drug|GW597901X|
79667072|NCT00325325|Drug|everolimus and tacrolimus|
79667073|NCT00325481|Drug|FluMist|
79667074|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
79667075|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
79990680|NCT02375230|Procedure|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
79990681|NCT02375230|Procedure|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
79505387|NCT03826602|Drug|Iohexol|1500 mg administered intravenously (IV)
79505388|NCT03820128|Other|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
79505389|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
79505390|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
79505391|NCT03821220|Behavioral|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
79505392|NCT03821220|Behavioral|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
79505393|NCT03821220|Behavioral|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
79505394|NCT03820908|Drug|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
79667076|NCT00354081|Drug|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
79667077|NCT00354081|Drug|placebo|placebo, in a capsule, taken orally once a day
79667078|NCT00325559|Procedure|Normoinsulinemic eu- or hyperglycemic clamp|
79667079|NCT04705311|Other|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
79667080|NCT04705311|Behavioral|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
79990682|NCT02384590|Behavioral|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
79354533|NCT03585088|Device|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score <=60.
79354534|NCT03321760|Radiation|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
79354535|NCT03580096|Other|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
79354536|NCT03580096|Other|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
79354537|NCT03580018|Drug|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
79505395|NCT02953548|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
79667081|NCT00325637|Drug|cilnidipine|Cilnidipine 10~20mg, qd, po for 4 weeks.
79667082|NCT04714593|Biological|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
79667083|NCT00426582|Drug|Patupilone|
79667084|NCT04717583|Procedure|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
79667085|NCT00354198|Drug|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
79990683|NCT02384278|Behavioral|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
79354538|NCT03580018|Procedure|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
79990684|NCT02379598|Dietary Supplement|Aminoacid based formula|Formula based on aminoacid
79990685|NCT02379598|Dietary Supplement|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
79990686|NCT02379676|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
79990687|NCT02379676|Drug|Clopidogrel|Clopidogrel 75mg once daily for 30 days
79990688|NCT02379364|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
79354539|NCT03584854|Drug|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
79354540|NCT03584854|Drug|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
79354541|NCT04765540|Behavioral|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors & hand-shaped sign posts pointing to the station"
79354542|NCT04765540|Behavioral|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board & general encouragement"
79505396|NCT02953002|Device|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
79818276|NCT06239805|Device|QMR|"A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off."
79818277|NCT06239753|Behavioral|Dynamic Neuromuscular Stabilization|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
79667086|NCT00354198|Drug|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
79818278|NCT06239753|Behavioral|Standard Prenatal Education Program Implementation|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
79818279|NCT06239740|Procedure|Electroacupuncture group|The acupuncture needle was placed on the scalp at a Chinese traditional acupuncture point. Subsequently, a small electrode was attached to the needle. A minor amount of electricity runs through the electrode, producing a slight vibration or soft hum during the treatment.
79354543|NCT04765540|Behavioral|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
79354544|NCT03586336|Device|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
79505397|NCT02952456|Other|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
79505398|NCT02952222|Drug|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
79505399|NCT02952222|Drug|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
79354545|NCT03586336|Device|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
79354546|NCT03584698|Drug|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
79667087|NCT00325676|Drug|Pantoprazole|
79667088|NCT00325715|Drug|AGN 201904|
79667089|NCT00325715|Drug|esomeprazole|
79667090|NCT00354237|Other|Conventional antidiabetic treatment|No intensive treatment
79667091|NCT00354237|Other|Intensive insulin treatment|Intensive insulin treatment
79667092|NCT00325793|Drug|Nicardipine|
79667093|NCT00426621|Drug|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
79667094|NCT00426621|Drug|Placebo|4 grams per knee, 4 times per day, for 12 weeks
79667095|NCT00325832|Device|BpTRU|
79667096|NCT00325832|Device|Conventional mercury sphygmomanometry|
79354547|NCT03584698|Drug|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
79354548|NCT03588130|Drug|EscharEx (5% EX-02 formulation)|Active arm
79354549|NCT03588130|Drug|Gel Vehicle|Control arm
79354550|NCT03588130|Drug|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
79354551|NCT05702008|Other|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1&ipp=All&lang=1&level=2&sublinkid=502&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
79354552|NCT03584620|Other|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
79354553|NCT03584620|Other|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
79354554|NCT05703178|Behavioral|Online Pain Coping Skills Training|The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
79354555|NCT05703178|Other|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
79354556|NCT03584308|Dietary Supplement|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
79505400|NCT02952222|Drug|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
79505401|NCT03826446|Procedure|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
79990689|NCT02379130|Behavioral|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
79354557|NCT03584308|Dietary Supplement|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
79354558|NCT03584308|Dietary Supplement|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
79505402|NCT03826056|Behavioral|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
79354559|NCT03584308|Dietary Supplement|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
79354560|NCT01682031|Dietary Supplement|selenomethionine|Given PO
79354561|NCT01682031|Other|placebo|Given PO
79354562|NCT01682031|Drug|cisplatin|Given IV
79354563|NCT01682031|Radiation|radiation therapy|Undergo radiotherapy
79354564|NCT01682031|Procedure|quality-of-life assessment|Ancillary studies
79354565|NCT03584230|Behavioral|Assigned to positive group|See arm description
79354566|NCT03584230|Behavioral|Assigned to negative group|See arm description
79354567|NCT03020134|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
79354568|NCT03020134|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
79354569|NCT03020134|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
79354570|NCT03020134|Drug|Placebo|Placebo
79354571|NCT03020056|Drug|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
79354572|NCT03020056|Procedure|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
79354573|NCT05701774|Drug|DCCR|Once daily oral administration
79354574|NCT03584074|Drug|Pregabalin 75mg|Orally taken twice daily for 8 weeks
79354575|NCT03584074|Drug|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
79354576|NCT03584386|Device|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
79354577|NCT03583996|Combination Product|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
79505403|NCT03826056|Behavioral|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
79505404|NCT03821688|Procedure|SAS-JB|single anastomosis sleeve jejunal bypass
79505405|NCT03821688|Procedure|OAGB|one anastomosis gastric bypass
79505406|NCT03821688|Procedure|LSG|laproscopic sleeve gastrectomy
79505407|NCT03826368|Dietary Supplement|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
79505408|NCT03825354|Behavioral|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
79818280|NCT06239740|Procedure|Sham acupuncture|participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
79818281|NCT06239727|Drug|PD-1 blocking antibody|"IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1."
79818282|NCT06239727|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
79354578|NCT03583918|Device|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
79354579|NCT03583762|Diagnostic Test|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
79354580|NCT03583762|Diagnostic Test|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
79354581|NCT03583294|Other|MRI pelvic|Pelvic MRI
79354582|NCT05701696|Diagnostic Test|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
79354583|NCT05701696|Diagnostic Test|Widespread pain index|Total the number of painful body areas
79354584|NCT05701696|Diagnostic Test|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
79354585|NCT05701696|Other|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
79354586|NCT05701696|Diagnostic Test|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
79354587|NCT05701696|Diagnostic Test|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
79354588|NCT03153826|Other|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
79354589|NCT03158818|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
79505409|NCT04391478|Drug|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
79505410|NCT04391478|Drug|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
79505411|NCT03828006|Dietary Supplement|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
79505412|NCT03828006|Other|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
79505413|NCT03823014|Device|Elator|Measurement for device, use of device
79505414|NCT04346706|Device|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
79505415|NCT04346706|Device|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
79505416|NCT03825900|Device|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
79354590|NCT03156556|Behavioral|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
79354591|NCT04405336|Drug|tab block|injection of tab block to women who are doing cs
79354592|NCT04405336|Drug|PCA|giving women PCA
79505417|NCT03826134|Drug|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
79667097|NCT04717778|Dietary Supplement|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
79667098|NCT04714242|Drug|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
79818283|NCT06239727|Drug|Cisplatin (80 mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
79354593|NCT04405336|Drug|women who will not receive tab block or PCA|no tab block or PCA will be given
79354594|NCT03583138|Drug|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
79354595|NCT03153514|Biological|Obinutuzumab|"Obinutuzumab i.v.~[Day 0 = day of stem cell transplant]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
79354596|NCT03583060|Behavioral|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
79667099|NCT00353535|Procedure|Total Lymphoid irradiation|
79667100|NCT00325871|Procedure|concurrent chemoradiation|
79667101|NCT00354276|Drug|cytarabine|
79667102|NCT00354276|Drug|laromustine|
79667103|NCT00325910|Drug|Metformin|
79667104|NCT00354315|Behavioral|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
79818284|NCT06239727|Radiation|Reduced-dose Intensity-modulated radiotherapy|"Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F."
79818285|NCT06239727|Radiation|Conventional-dose Intensity-modulated radiotherapy|"Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F."
79818286|NCT06239727|Drug|Cisplatin (100 mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
79818287|NCT06239727|Drug|Capecitabine|Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
79818288|NCT06239714|Drug|SGB-3403|SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
79667105|NCT00325949|Drug|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
79818289|NCT06239714|Other|Atorvastatin|The dosage of atorvastatin was determined by the investigator
79667106|NCT00325949|Drug|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
79667107|NCT00325949|Drug|placebo|2 tablets BID
79505418|NCT03825978|Behavioral|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
79354597|NCT03020524|Biological|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
79354598|NCT03020602|Other|Laboratory Biomarker Analysis|Correlative studies
79505419|NCT03826212|Dietary Supplement|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
79505420|NCT03826212|Dietary Supplement|Placebo|Placebo 1,600 mg/day for 12 weeks.
79667108|NCT04714476|Device|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
79354599|NCT03020602|Other|Pharmacological Study|Correlative studies
79505421|NCT03078348|Other|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
79667109|NCT00326027|Drug|Pantoprazole|Efficacy of Pantoprazole
79667110|NCT01059318|Drug|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
79667111|NCT00326066|Device|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
79667112|NCT00326066|Procedure|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
79667113|NCT04714515|Drug|Montelukast|An FDA approved medicine to treat asthmatic patients
79818290|NCT06239714|Other|Placebo|Normal saline 0.9%
79823861|NCT04047069|Behavioral|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
79823862|NCT04047069|Behavioral|Awareness Training|"Exp.~General information about HD~Approaches to Coping with HD Symptoms~Self care skills (eg hygiene)"
79354600|NCT03020602|Drug|Ubidecarenone Injectable Nanosuspension|Given IV
79354601|NCT03582982|Behavioral|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
79354602|NCT03153670|Other|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
79354603|NCT03582904|Procedure|tDCS|real or sham tDCS delivered to primary motor cortex
79505422|NCT03078348|Behavioral|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
79667114|NCT04714515|Drug|Hydroxychloroquine|An FDA approved antiarthritis drug
79667115|NCT04714515|Drug|Ivermectin|An FDA approved anti-parasitic medicine
79667116|NCT00326105|Drug|Quetiapine fumarate|
79667117|NCT00354354|Drug|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
79667118|NCT00326144|Drug|Quetiapine fumarate|
79667119|NCT01058655|Drug|Everolimus|
79667120|NCT01058655|Drug|Tivozanib|
79667121|NCT00326222|Behavioral|Lifestyle counseling|Self-management group education
79505423|NCT03078348|Behavioral|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
79505424|NCT03829956|Device|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
79505425|NCT04391868|Drug|Viagra Tablet|50 mg tablet on Day 1 of each period
79505426|NCT04391868|Drug|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
79354604|NCT01567527|Drug|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
79505427|NCT04391868|Drug|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
79505428|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
79505429|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
79505430|NCT03823794|Other|No intervention|Observational analysis of usual care only
79505431|NCT03821532|Other|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
79505432|NCT03821766|Device|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
79505433|NCT01454310|Device|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
79667122|NCT00326261|Procedure|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
79667123|NCT00326261|Procedure|Ultrasound|
79354605|NCT01567527|Drug|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
79505434|NCT01454310|Device|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
79667124|NCT00326300|Drug|methylphenidate hydrochloride extended-release tablets|
79505435|NCT03827382|Behavioral|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
79505436|NCT03829332|Biological|Pembrolizumab|IV infusion
79505437|NCT03829332|Drug|Lenvatinib|oral capsule
79505438|NCT03829332|Drug|Placebo for lenvatinib|oral capsule
79505439|NCT03825666|Other|ProvideXtra® Fresenius Kabi|Improving wellbeeing
79505440|NCT01454388|Other|breakfast|
79667125|NCT00426777|Drug|risedronate|risedronate 35mg tablet, weekly for 12 months
79667126|NCT00426777|Drug|risedronate|35mg weekly
79667127|NCT00426777|Drug|Control|risedronate-matched placebo weekly
79667128|NCT00326339|Drug|R788|R788 50 mg, 100 mg, or 150 mg PO bid
79667129|NCT00326339|Drug|Placebo|Placebo PO bid
79667130|NCT01058421|Procedure|intensive physical therapy|four week course of daily intensive physical therapy
79667131|NCT01058421|Procedure|control group|four weeks of routine physical therapy
79667132|NCT00419549|Drug|Glyceryl - trinitrate|Transdermal Patch once only
79667133|NCT00419549|Drug|Valdecoxib|Single parenteral administration
79667134|NCT00354471|Procedure|Uterine Artery Embolization|
79667135|NCT00326378|Drug|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
79667136|NCT00326378|Drug|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
79667137|NCT00326573|Behavioral|Motivational Interviewing|
79667138|NCT04717232|Other|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
79823863|NCT00425503|Drug|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
79354606|NCT03582670|Behavioral|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
79354607|NCT03582670|Behavioral|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
79354608|NCT03582670|Behavioral|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
79505441|NCT01454466|Procedure|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
79505442|NCT01454544|Biological|AIT Tablet|1 tablet per day in 12 months
79505443|NCT03824730|Device|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
79505444|NCT03824886|Other|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
79505445|NCT02983188|Drug|Berberine|Berberine tablets, 0.3g every time, two times daily
79667139|NCT04717232|Other|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
79667140|NCT00326768|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
79667141|NCT00326768|Drug|Telmisartan 40 mg|
79667142|NCT00326768|Drug|Telmisartan 80 mg/HCTZ 12.5 mg|
79667143|NCT00326807|Drug|Naltrexone|
79667144|NCT01058304|Other|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
79505446|NCT02983188|Drug|Placebos|Placebo tablets, 0.3g every time, two times daily
79990690|NCT02379130|Behavioral|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
79990691|NCT02379286|Other|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
79990692|NCT04439812|Other|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
79505447|NCT02983188|Drug|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
79505448|NCT01450176|Drug|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
79505449|NCT01450176|Drug|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
79505450|NCT01450254|Device|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
79505451|NCT01450254|Other|Control|No intervention will be prescribed to the control group during participation in the study.
79990693|NCT02375308|Behavioral|HDT|20 sessions, individual psychotherapy
79505452|NCT01454622|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
79505453|NCT01454622|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
79505454|NCT01450332|Device|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
79505455|NCT01450410|Drug|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
79354609|NCT03159988|Drug|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
79354610|NCT03159988|Behavioral|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
79354611|NCT03582592|Behavioral|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
79354612|NCT03582358|Other|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
79667145|NCT01058304|Other|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
79667146|NCT00327002|Drug|LY518674|
79990694|NCT02375308|Behavioral|ACDT|20 sessions, individual psychotherapy
79990695|NCT02375074|Behavioral|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
79990696|NCT02375074|Behavioral|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
79990697|NCT02375152|Procedure|Anterior Capsulotomy|
79505456|NCT01450410|Drug|Placebo|Placebo treatment will last for 12 weeks.
79505457|NCT02950818|Behavioral|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
79354613|NCT03159598|Device|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
79505458|NCT03824418|Procedure|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
79667147|NCT01058265|Other|Integrative|Integrative Medicine medical evaluation.
79990698|NCT03113032|Other|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
79354614|NCT03159598|Device|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
79354615|NCT03159598|Other|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
79354616|NCT01818752|Drug|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
79505459|NCT04391712|Device|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
79667148|NCT01058265|Other|Standard|Standard general medical evaluation.
79667149|NCT00354510|Drug|GW842470X cream|
79823864|NCT00786669|Drug|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
79354617|NCT01818752|Drug|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
79823865|NCT00786669|Drug|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
79354618|NCT01818752|Drug|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
79354619|NCT01818752|Drug|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
79354621|NCT03582202|Procedure|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
79354622|NCT03582202|Procedure|Standard care|Nutritional handling by nurse
79505460|NCT04391712|Other|Regular Inpatient Medical Care|Regular inpatient medical care
79505461|NCT04391634|Other|volume guarantee|volume guarantee assist-control mechanical ventilation
79505462|NCT04391634|Other|pressure-controlled|pressure-controlled assist-control mechanical ventilation
79505463|NCT01450488|Drug|masitinib|masitinib 3 mg/kg/day
79505464|NCT01450488|Drug|masitinib|masitinib 6 mg/kg/day
79505465|NCT01450566|Drug|Lidocaine|Use of lidocaine
79667150|NCT04717037|Biological|Olive Oil Massage|olive oil massage application.
79667151|NCT00354549|Drug|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
79667152|NCT00354549|Drug|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
79667153|NCT01057251|Drug|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
79667154|NCT01057251|Drug|Placebo|5 mg or 20 mg once daily, oral administration
79667155|NCT04708353|Drug|placebo capsule (vitamin c)|the patient will receive one placebo capsule (vitamin c) once one hour before the operation
79667156|NCT04708353|Drug|Group pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
79667157|NCT04708353|Drug|Group pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
79667158|NCT04708574|Behavioral|Lifestyle intervention|
79667159|NCT04708574|Other|Placebo - Control|
79990699|NCT03113032|Other|Normal pre-surgical care|Routine pre-surgical care
79990700|NCT03105544|Other|simulation-based training|As described under group descriptions
79990701|NCT03105622|Behavioral|TV and music|Watching TV or listening to music while running on a treadmill
79990702|NCT02378896|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
79990703|NCT02378896|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
79990704|NCT02378818|Behavioral|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
79354623|NCT03159520|Behavioral|Advice sheet|Advice on management of post orthodontic pain
79505466|NCT01450566|Drug|Saline|Saline
79505467|NCT03824262|Device|HICO-VARIOTHERM 550|Warming during perioperative period.
79667160|NCT00425646|Biological|bevacizumab|
79354624|NCT03159832|Drug|SHR3824|All subjects were given SHR3824 20mg only one time.
79354625|NCT03582046|Device|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
79505468|NCT03824262|Device|Mistral-Air Plus forced air warming device|Warming during perioperative period.
79667161|NCT00425646|Drug|imatinib mesylate|
79667162|NCT00327080|Procedure|MRI|
79667163|NCT00327080|Drug|L-NMMA|
79667164|NCT00327080|Drug|Acetylcholine|
79667165|NCT00426816|Drug|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
79667166|NCT00426816|Drug|Placebo|Placebo to match SB-649868
79667167|NCT00327119|Drug|ABX-EGF (panitumumab)|
79667168|NCT00426894|Procedure|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
79667169|NCT00327158|Procedure|Transesophageal transducer|One time use of reamer during surgery
79667170|NCT00327158|Procedure|echocardiography|takes photos of right atrium during the reaming processes
79990705|NCT02374684|Drug|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
79990706|NCT02374684|Drug|Placebo|Placebo to match with experimental groups
79505469|NCT03043014|Drug|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
79505470|NCT01450644|Other|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
79505471|NCT02983344|Drug|Ropivacaine|Fascia iliaca compartment block using ropivacaine
79505472|NCT02983344|Drug|Fentanyl|Intravenous fentanyl
79667171|NCT00426933|Drug|Daptomycin|
79667172|NCT00426933|Drug|Vancomycin|
79505473|NCT02983344|Device|Ultrasound|Ultrasound-guided fascia iliaca compartment block
79505474|NCT01450878|Drug|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
79667173|NCT00327197|Drug|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
79667174|NCT00327197|Procedure|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
79667175|NCT00425724|Drug|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
79667176|NCT00426972|Drug|estradiol (Zesteem)|
79823866|NCT00786669|Drug|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
79823867|NCT00786669|Drug|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
79990707|NCT02374528|Procedure|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
79505475|NCT02914314|Drug|perampanel|oral suspension.
79505476|NCT01451034|Procedure|WHYX cancer group|WHYX cancer diagnosed by pathologic report
79505477|NCT03824340|Drug|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
79505478|NCT03824028|Device|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
79505479|NCT03823872|Other|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
79505480|NCT03823872|Other|Normal feeding|Normal feeding= consume food per normal schedule
79667177|NCT00327275|Behavioral|strength training|
79667178|NCT00327314|Procedure|Transplantation|
79667179|NCT00327314|Procedure|Hematopoietic cell transplantation|
79505481|NCT01455246|Drug|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
79667180|NCT00425763|Drug|AQAS|AQAS dosed by body weight, on days 0, 1, 2
79990708|NCT02374528|Procedure|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
79354626|NCT03582046|Device|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
79505482|NCT01455246|Drug|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
79505483|NCT01455324|Device|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
79505484|NCT01451112|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
79505485|NCT02910648|Behavioral|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
79990709|NCT02378740|Drug|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
79990710|NCT02378740|Drug|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
79990711|NCT02383732|Behavioral|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention & Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
79505486|NCT01455480|Drug|RPh201, botanical drug product|topical
79354627|NCT05701462|Diagnostic Test|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
79505487|NCT03823950|Drug|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
79505488|NCT02914782|Other|Observational Study|
79505489|NCT01451190|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
79667181|NCT00327353|Drug|formoterol (TURBOHALER)|
79667182|NCT00327353|Drug|Salmeterol (DISKUS)|
79667183|NCT00425841|Drug|gemcitabine hydrochloride|
79667184|NCT00425841|Drug|oxaliplatin|
79667185|NCT00425841|Procedure|adjuvant therapy|
79667186|NCT00425841|Procedure|neoadjuvant therapy|
79667187|NCT00425841|Radiation|hypofractionated radiation therapy|
79667188|NCT00425841|Radiation|stereotactic radiosurgery|
79667189|NCT00327431|Genetic|Cheek swab samples for DNA|
79667190|NCT00427050|Drug|PEP005|
79505490|NCT01451268|Drug|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
79667191|NCT05459168|Other|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
79823868|NCT00786669|Drug|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
79228382|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
79228383|NCT02801331|Device|Stochastic Vibrotactile Stimulation (SVS)|Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle vibrations and sounds during mattress stimulations.
79354628|NCT04405492|Device|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
79505491|NCT01451268|Drug|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
79505492|NCT01451346|Dietary Supplement|B. Infantis 35624|One sachet daily for 12 weeks
79505493|NCT03823638|Dietary Supplement|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
79505494|NCT01455558|Drug|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
79505495|NCT02884908|Drug|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
79505496|NCT02884908|Other|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
79505497|NCT01451580|Drug|Lipo-Dox|
79667192|NCT05459168|Other|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
79667193|NCT05459168|Device|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
79667194|NCT05458895|Other|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79667195|NCT05458895|Other|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79667196|NCT05458895|Other|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79505498|NCT01451658|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
79505499|NCT01455792|Procedure|Biopsies using image fusion|MRI and soft image fusion guided biopsy
79667197|NCT05458895|Other|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79667198|NCT05458895|Other|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79505500|NCT01455792|Procedure|Gold standard biopsy|Gold standard TRUS biopsy
79667199|NCT05458895|Other|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79505501|NCT01451892|Other|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
79667200|NCT05458895|Other|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79505502|NCT01451892|Other|patient education|overweight individuals participating in a patient education program
79505503|NCT04392258|Diagnostic Test|TSH determination|Determination of serum concentration of thyrotropin (TSH)
79505504|NCT04392258|Diagnostic Test|FT4 determination|Determination of serum free thyroxine (FT4) concentration
79667201|NCT05458895|Other|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
79667202|NCT00427089|Drug|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
79667203|NCT00427089|Drug|Sodium Phosphate solution (NaP)|45 ml solution; BID
79667204|NCT05458661|Device|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps >6mm diameter and corneal pachymetry maps >6mm.
79667205|NCT00427128|Drug|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
79667206|NCT00427128|Drug|placebo|Week 13-36.
79505505|NCT04392258|Diagnostic Test|FT3 determination|Determination of serum free triiodothyronine (FT3) concentration
79505506|NCT04392258|Diagnostic Test|SPINA-GT|Calculation of thyroid's secretory capacity (SPINA-GT)
79505507|NCT04392258|Diagnostic Test|SPINA-GD|Calculation of total deiodinase activity (SPINA-GD)
79818291|NCT06239701|Behavioral|LPA+Fitbit Intervention|"In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences."
79505508|NCT01455948|Device|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
79505509|NCT01455948|Procedure|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
79505510|NCT02851056|Biological|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered."
79505511|NCT02851056|Procedure|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
79505512|NCT02851056|Biological|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
79505513|NCT02851056|Drug|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
79505514|NCT02937948|Other|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
79505515|NCT02937948|Radiation|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
79524764|NCT01689480|Other|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
79667207|NCT05458466|Other|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
79667208|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
79823869|NCT01030471|Behavioral|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
79354629|NCT04405492|Device|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
79354630|NCT04405492|Device|Capillary and salivary sampling|Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
79354631|NCT05701384|Drug|Lazertinib|160mg po qd
79505516|NCT02936466|Behavioral|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~At least one connection per week during 4 weeks~Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
79505517|NCT02935374|Drug|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
79505518|NCT02935374|Drug|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
79505519|NCT02935374|Drug|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
79354632|NCT04142554|Drug|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
79354633|NCT01362608|Drug|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
79667209|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
79667210|NCT00427167|Drug|AMA1-C1/Alhydrogel + CPG 7909|
79990712|NCT02383732|Behavioral|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
79354634|NCT01362608|Drug|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
79354635|NCT03581968|Device|Artificial Pancreas|"The system is composed of 3 main components:~Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
79505520|NCT01452204|Other|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
79505521|NCT01452438|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
79505522|NCT01452594|Drug|Diphenylcyclopropenone|Topical administration
79505523|NCT01452594|Drug|Placebo|Placebo
79505524|NCT01452750|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
79505525|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
79667211|NCT00427206|Drug|acetaminophen (4g/day)|
79505526|NCT01452750|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
79505527|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
79667212|NCT00427206|Drug|placebo|
79667213|NCT00425997|Drug|Valsartan/HCTZ|
79667214|NCT00425997|Drug|amlodipine|
79667215|NCT00425997|Drug|HCTZ|
79667216|NCT05458388|Procedure|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
79667217|NCT05458388|Procedure|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
79667218|NCT00427245|Drug|cyclophosphamide|
79667219|NCT00427245|Drug|goserelin acetate|
79667220|NCT00427245|Procedure|adjuvant therapy|
79667221|NCT00427245|Procedure|fertility assessment and management|
79505528|NCT01452750|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
79505529|NCT01452750|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
79823870|NCT00786747|Behavioral|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
79505530|NCT04273308|Device|whole-body vibration training|The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
79505531|NCT01452828|Drug|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
79505532|NCT01452828|Drug|TR-701 FA|Two separate infusions of 200 mg
79505533|NCT01452828|Drug|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
79505534|NCT01452906|Drug|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
79505535|NCT01452906|Drug|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
79354636|NCT03159286|Behavioral|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
79505536|NCT01452906|Drug|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
79823871|NCT00786747|Behavioral|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
79823872|NCT00791739|Drug|trazodone, pregabalin|"phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
79354637|NCT03159286|Behavioral|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
79228384|NCT03234738|Drug|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
79354638|NCT03159286|Behavioral|Control|Participants view social networking site profiles with no alcohol content.
79354639|NCT03581890|Other|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~age- and sex-adjusted available income the year before surgery~Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~Urbanicity (in four officially, predefined categories)."
79354640|NCT03159364|Biological|pathogen-specific CTLs|Patients will receive approximately 1x10^5~1x10^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
79354641|NCT01871090|Device|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
79354642|NCT03158974|Drug|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
79354643|NCT04142008|Device|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
79354644|NCT05703022|Other|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
79354645|NCT03159052|Drug|SHR3824|Once daily, 52 weeks
79354646|NCT03159052|Drug|Placebo|Once daily, 24 weeks
79354647|NCT03158584|Drug|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
79354648|NCT03265366|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
79228385|NCT03234738|Drug|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
79354649|NCT03265366|Device|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
79354650|NCT03158506|Drug|HMS5552|[14C]-labelled HMS5552
79505537|NCT01453218|Drug|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
79505538|NCT02837250|Behavioral|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
79505539|NCT02837250|Behavioral|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
79524765|NCT01689558|Drug|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
79524766|NCT01689870|Drug|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
79505540|NCT02795598|Procedure|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
79354651|NCT03156712|Dietary Supplement|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
79354652|NCT03158662|Other|Survey|Survey Study
79354653|NCT04765228|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
79354654|NCT04765228|Drug|Anlotinib|Anlotinib
79667222|NCT00427245|Procedure|neoadjuvant therapy|
79354655|NCT04141540|Genetic|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
79354656|NCT04141384|Device|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
79354657|NCT04140994|Device|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
79354658|NCT03158350|Other|Instructed Brushing Method|Stationary Bristle Technique
79354659|NCT03158428|Other|CSD170202AA|A moist snuff product
79667223|NCT05458349|Device|acellular dermis|
79823873|NCT00425269|Behavioral|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
79823874|NCT02555475|Other|community based hepatitis C care and treatment|
79524767|NCT01689870|Drug|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
79823875|NCT00791895|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme
79667224|NCT00426036|Drug|Licarbazepine|
79354660|NCT03158428|Other|CSD170202AB|A moist snuff product
79524768|NCT01689948|Behavioral|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
79667225|NCT05458154|Other|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
79667226|NCT00427323|Procedure|light exposure|
79524769|NCT01689012|Behavioral|Facial Exercise|
79524770|NCT05768828|Diagnostic Test|Nociceptive Blink Reflex|Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
79354661|NCT04140916|Device|Midline catheter|Peripherally inserted short intravenous catheter
79354662|NCT04140916|Device|PICC-line catheter|Peripherally inserted long intravenous catheter
79524771|NCT05768750|Other|Rehabilitation|X
79524772|NCT05768724|Behavioral|intervention diet|"The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked."
79354663|NCT04140760|Other|Symprove|A liquid probiotic
79354664|NCT04140760|Other|Symprove placebo product|An inert placebo
79354665|NCT01818596|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
79354666|NCT03156400|Other|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
79354667|NCT03158194|Behavioral|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
79354668|NCT03156634|Other|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
79505541|NCT02795598|Procedure|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
79228386|NCT03301142|Procedure|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
79354669|NCT03156634|Other|WebMD|WebMD is an internet based health information source.
79354670|NCT04415216|Device|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
79505542|NCT03849378|Dietary Supplement|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
79505543|NCT03849378|Dietary Supplement|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
79505544|NCT02730780|Dietary Supplement|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
79505545|NCT02730780|Dietary Supplement|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
79505546|NCT03823092|Diagnostic Test|polarization sensitivity|test of polarization vision as described in Study Description
79505547|NCT03823248|Drug|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
79505548|NCT03823248|Drug|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
79505549|NCT03823248|Drug|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
79990713|NCT02383732|Behavioral|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
79505550|NCT03823248|Drug|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
79505551|NCT03823248|Drug|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
79505552|NCT03823248|Drug|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
79505553|NCT03822936|Drug|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
79505554|NCT03822936|Radiation|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
79505555|NCT03822624|Dietary Supplement|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
79505556|NCT03822624|Other|Placebo|Placebo comparator with maltodextrin as a carrier.
79505557|NCT03822546|Other|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
79990714|NCT01411267|Drug|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
79505558|NCT03822546|Other|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
79505559|NCT03822546|Other|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
79667227|NCT05458115|Procedure|Liver resection|Patient underwent hepatic R0 resection within a week
79667228|NCT00426075|Device|Elastic stockings|
79667229|NCT05458076|Drug|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
79823876|NCT01807728|Other|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
79823877|NCT01807728|Other|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
79354671|NCT04405882|Procedure|topographic guided trans epithelial excimer laser|In this retrospective study 8 eyes affected by cornea ectasia of 8 patients (mean age 31.50±14.73 years) underwent simultaneous CCR and CXL. Preoperative and 6 month postoperative uncorrected distance visual acuity (UDVC) and distance corrected visual acuity (DCVA) were measured using the Efficacy and Safety index. Objective and subjective quality of vision were respectively evaluated through preoperative and 6 month postoperative corneal morphological irregularity index (CMI), National Eye Institute Visual Function NEI-VFQ25 and NEI-VFQ39 questionnaires.
79354672|NCT03157570|Behavioral|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
79354673|NCT03157726|Procedure|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
79354674|NCT03157726|Procedure|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
79505560|NCT03822546|Other|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
79667230|NCT05458076|Drug|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
79990715|NCT01411267|Drug|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~20 mg for patients age <1 yr~30 mg for patients age 1-1.99 years of age~50 mg for patients age 2-2.99 years of age~70 mg for patients >3 years of age"
79354675|NCT03156322|Drug|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
79354676|NCT03156322|Drug|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
79354677|NCT03156322|Drug|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
79354678|NCT05682664|Other|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
79354679|NCT05682664|Other|Usual care|Routine outpatient clinical visits every 3 months.
79354680|NCT04140682|Device|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
79354681|NCT04140682|Device|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
79354682|NCT03156088|Device|"Sacral Neuromodulator InterStim"|
79505561|NCT03822546|Other|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
79667231|NCT05458076|Drug|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
79354683|NCT03021382|Other|data collection, non-intervention|
79354684|NCT03156166|Procedure|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
79354685|NCT04140058|Drug|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
79990716|NCT01411267|Drug|Etoposide|150 mg/m2/day IV on days 1 through 5.
79667232|NCT00427362|Drug|Adalimumab|
79667233|NCT05458037|Procedure|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
79667234|NCT00426114|Drug|Administration of an IV glucose-injection|
79667235|NCT00426192|Drug|i.v. mannitol|
79990717|NCT01411267|Drug|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~6 mg for patients age < 1yr~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
79990718|NCT02378584|Other|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
79990719|NCT03113110|Drug|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
79990720|NCT02661880|Behavioral|preferred music|listening to preferred music choices
79990721|NCT03306277|Biological|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
79990722|NCT02383888|Drug|BI 425809|
79354686|NCT04140058|Drug|Normal saline|Placebo of 10 mL normal saline was administered.
79354687|NCT03157648|Other|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
79505562|NCT03822546|Other|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
79505563|NCT04391088|Other|vaccine coverage assessment|vaccine coverage assessment
79667236|NCT00426192|Procedure|hemofiltration|
79354688|NCT02899078|Drug|Ibrutinib|Given PO
79354689|NCT02899078|Drug|Nivolumab|Given IV
79354690|NCT01670344|Procedure|Treatment with investigational method (virtual implant positioning system)|
79505564|NCT04273152|Diagnostic Test|advanced glycation endproducts reader|advanced glycation endproducts reader
79667237|NCT05457920|Behavioral|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
79667238|NCT05457920|Behavioral|pulse therapy|pulse therapy
79667239|NCT00427401|Drug|PF-00915275|
79667240|NCT00425919|Drug|PPM-204|
79667241|NCT01056822|Drug|1|Continue with same dose of MMF as patient was taking before randomisation
79354691|NCT01670344|Procedure|Treatment with surgical standard of care|
79354692|NCT04747444|Other|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
79354693|NCT04764760|Device|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
79354694|NCT01670734|Drug|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
79354695|NCT03155776|Diagnostic Test|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
79354696|NCT03155464|Procedure|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
79354697|NCT03155464|Drug|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
79667242|NCT01056822|Drug|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
79354698|NCT01670890|Drug|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
79354699|NCT01670890|Drug|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
79667243|NCT05457764|Device|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
79667244|NCT05457530|Drug|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
79667245|NCT05457530|Combination Product|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
79354700|NCT01676428|Radiation|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions <5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
79354701|NCT04577794|Drug|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
79354702|NCT04577794|Drug|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
79354703|NCT04551196|Drug|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
79354704|NCT04551196|Drug|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
79354705|NCT03155152|Other|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
79505565|NCT01453452|Behavioral|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
79505566|NCT01453452|Behavioral|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
79505567|NCT01453452|Other|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
79667246|NCT05457530|Drug|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
79990723|NCT02383888|Drug|BI 425809|
79990724|NCT02383888|Drug|Placebo|
79505568|NCT01453452|Procedure|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
79505569|NCT02910024|Device|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
79505570|NCT02910024|Device|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
79505571|NCT01453686|Drug|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
79667247|NCT04705194|Procedure|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
79505572|NCT01453686|Drug|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
79505573|NCT02983266|Device|InTENsity MicroCombo|An electrotherapy device.
79505574|NCT01459926|Drug|TD-1211|once daily
79505575|NCT01459926|Drug|TD-1211|Once daily
79667248|NCT04705194|Procedure|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
79354706|NCT03155152|Other|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
79354707|NCT01671124|Other|Soline capsule|
79354708|NCT03155230|Other|no intervention|no intervention
79354709|NCT04764838|Other|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~Bending sideways in Mountain Stance~Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
79505576|NCT01459926|Drug|TD-1211|Once daily
79505577|NCT01459926|Drug|Placebo|Once daily
79990725|NCT02383888|Drug|BI 425809|
79990726|NCT04664569|Other|observational study|observational study
79990727|NCT02378194|Drug|Placebo|24 weeks, once daily oral administration
79990728|NCT02378194|Drug|HD-003 (800mg/day)|24 weeks, once daily oral administration
79667249|NCT05457452|Device|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
79667250|NCT04705857|Combination Product|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
79990729|NCT02378194|Drug|HD-003 (1600mg/day)|24 weeks, once daily oral administration
79990730|NCT00579709|Biological|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained <4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, & mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
79990731|NCT02374294|Device|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
79228387|NCT03301142|Procedure|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
79354710|NCT04457674|Behavioral|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
79354711|NCT04457674|Behavioral|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
79354712|NCT01923298|Drug|Estradiol|
79354713|NCT03155386|Other|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~The intensity of lesion enhancement~The presence and type of artefacts on the recombined images.~The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
79679635|NCT00517283|Drug|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
79354714|NCT01671436|Behavioral|Central Meditation and Imagery Therapy|
79354715|NCT05629156|Other|No intervention implemented. Observational study only|Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.
79354716|NCT01671514|Dietary Supplement|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
79354717|NCT01671514|Other|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
79354718|NCT05196022|Other|Cochlear implant|G2 will receive a cochlear implant during the study
79505578|NCT01456182|Drug|AFX-2|Dose level 1
79990732|NCT02374216|Procedure|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
79505579|NCT01456182|Drug|AFX-2|Dose level 2
79505580|NCT01456182|Drug|AFX-2|Dose level 3
79505581|NCT01456182|Drug|AFX-2|Dose level 4
79505582|NCT01456182|Drug|AFX-2|Dose level 5
79505583|NCT01455870|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
79505584|NCT01455870|Drug|sitagliptin|oral sitagliptin 100 mg/day
79505585|NCT01456260|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
79505586|NCT01456260|Drug|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
79505587|NCT01456260|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
79667251|NCT04705506|Drug|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
79228388|NCT04457388|Other|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
79505588|NCT01456260|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
79505589|NCT01456260|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
79667252|NCT05457374|Procedure|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
79667253|NCT05457374|Procedure|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
79667254|NCT04704960|Other|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
79667255|NCT05457335|Procedure|undergoing PGT|Preimplantation genetic testing for aneuploidy
79667256|NCT00432393|Drug|levodopa-carbidopa|
79505590|NCT01456260|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
79505591|NCT01452516|Device|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
79505592|NCT01452516|Device|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
79667257|NCT05455385|Other|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
79667258|NCT05455385|Other|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
79667259|NCT05455385|Other|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
79990733|NCT02383498|Other|GI-6301 Placebo|GI-6301 Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of GI-6301 placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
79990734|NCT02383498|Biological|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
79505593|NCT01890408|Drug|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
79505594|NCT01890564|Other|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
79505595|NCT01890564|Other|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
79990735|NCT02383498|Radiation|Radiotherapy|Standard of care
79505596|NCT01890564|Other|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
79354719|NCT01671592|Biological|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
79667260|NCT04705077|Drug|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
79818292|NCT06239701|Behavioral|Fitbit Only|"In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls."
79818293|NCT06239688|Behavioral|essentiALZ|essentiALZ is a web-based training that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
79354720|NCT04402606|Other|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
79354721|NCT01671670|Other|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
79354722|NCT01671670|Other|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
79354723|NCT03154840|Drug|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
79505597|NCT01456338|Behavioral|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
79667261|NCT05453045|Drug|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
79667262|NCT04705272|Other|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
79667263|NCT05451251|Device|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine demyelinating lesion
79354724|NCT04404790|Drug|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
79667264|NCT00432432|Drug|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
79228389|NCT03302000|Other|Early Visual Stimulation|Early visual stimulation
79228390|NCT03302000|Other|standard care|standard care
79354725|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
79667265|NCT02957487|Device|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
79818294|NCT06239688|Behavioral|Project ECHO|ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
79990736|NCT02383498|Device|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
79990737|NCT02378350|Device|Hemodialysis treatment (no specific device is defined)|
79354726|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
79354727|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
79354728|NCT04404790|Drug|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
79354729|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
79354730|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
79354731|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
79354732|NCT03154762|Device|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
79505598|NCT01456338|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
79505599|NCT01890798|Drug|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
79505600|NCT01890876|Other|Walking uphill|ascending about 500 m
79505601|NCT01890876|Other|Walking downhill|descending about 500 m
79354733|NCT03154762|Device|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
79354734|NCT03154918|Drug|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
79354735|NCT01671904|Drug|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter [mg/m^2]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
79354736|NCT01671904|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
79354737|NCT01671904|Drug|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m^2) on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.
79354738|NCT01671904|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
79354739|NCT03154684|Other|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~Inspection of the environment at the patient's home~Care and autonomy support~Social life support~Secondary prevention strategies:~Home exercise program (3x/weeks)~Protein enriched food preparation (20g whey protein/day)~Support to take vitamin D supplementation (2000 IU/day)~Recommendation and support to eat calcium rich foods~Motivation to be physically active"
79354740|NCT03154684|Other|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
79354741|NCT03732118|Device|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
79354742|NCT01672138|Procedure|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
79354743|NCT01672138|Procedure|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
79354744|NCT01672138|Procedure|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
79354745|NCT03154450|Device|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
79354746|NCT03154450|Device|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
79354747|NCT04027894|Drug|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
79354748|NCT04027894|Drug|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
79354749|NCT01672216|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
79354750|NCT01672216|Device|EMG-biofeedback alone|
79354751|NCT03154216|Behavioral|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
79354752|NCT03154216|Other|Drink|Beverage to be consumed after exercise
79354753|NCT03985150|Other|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
79354754|NCT03985150|Radiation|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
79354755|NCT03977272|Drug|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
79354756|NCT03977272|Drug|Chemotherapy|modified-FOLFIRINOX
79354757|NCT03154528|Diagnostic Test|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males & 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
79354758|NCT03947398|Device|BLIMP balloon|Using BLIMP balloon to cross lesion
79354759|NCT03947398|Device|Low profile balloon|using low profile balloon to cross lesion
79354760|NCT01672372|Dietary Supplement|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
79354761|NCT01672372|Dietary Supplement|Placebo Max Stress B|
79354762|NCT03154372|Other|Expert supervised practice with validated metrics|
79354763|NCT03154372|Other|self guided practice with validated metrics|
79354764|NCT01676506|Drug|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
79354765|NCT01676506|Procedure|Ranibizumab Injection|
79505602|NCT04844658|Dietary Supplement|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
79354766|NCT03154294|Drug|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
79354767|NCT03154294|Drug|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
79354768|NCT03154294|Drug|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
79228391|NCT05727410|Drug|nivolumab, docetaxel, cisplatin Group|Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
79505603|NCT04844658|Dietary Supplement|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
79990738|NCT02378350|Drug|Peritoneal Dialysis treatment (no specific drug is defined)|
79505604|NCT04844658|Drug|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
79667266|NCT05421494|Behavioral|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
79990739|NCT02383654|Procedure|Autologous Adipose-Tissue Derived Stem Cells|"Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
79990740|NCT02378116|Procedure|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
79354769|NCT03154606|Other|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
79354770|NCT03154606|Other|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
79354771|NCT03154606|Other|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
79354772|NCT03154606|Other|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
79354773|NCT03154606|Other|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
79354774|NCT03154606|Other|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
79354775|NCT03154606|Other|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
79505605|NCT04841538|Drug|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
79505606|NCT02450292|Procedure|Bioabsorbable screw fixation|
79505607|NCT04849650|Drug|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
79505608|NCT04849650|Drug|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
79505609|NCT05587140|Device|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
79505610|NCT05587140|Device|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
79990741|NCT02377960|Behavioral|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
79990742|NCT02377960|Behavioral|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
79990743|NCT02377960|Behavioral|Usual care|Usual care
79990744|NCT02377804|Other|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
79505611|NCT05587140|Device|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
79354776|NCT03154606|Other|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
79990745|NCT02377804|Other|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
79990746|NCT02377804|Device|stainless steel needles (0.3mm x 50mm)|
79505612|NCT01456728|Dietary Supplement|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
79505613|NCT01456728|Dietary Supplement|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
79505614|NCT01891110|Procedure|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
79505615|NCT01891110|Procedure|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
79505616|NCT01891110|Procedure|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
79505617|NCT01891266|Procedure|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
79667267|NCT05421494|Behavioral|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
79667268|NCT02957526|Behavioral|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
79990747|NCT02373748|Device|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
79667269|NCT02957526|Behavioral|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
79667270|NCT02957448|Drug|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
79667271|NCT02957448|Drug|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
79990748|NCT02373904|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
79990749|NCT02372032|Procedure|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
79228392|NCT03653715|Device|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
79228393|NCT03653715|Device|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
79505618|NCT01891266|Procedure|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
79505619|NCT01891500|Drug|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
79505620|NCT01891500|Drug|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
79505621|NCT01891500|Drug|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
79505622|NCT02862132|Drug|Vedolizumab|
79505623|NCT02859402|Drug|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
79990750|NCT02372032|Procedure|ozone therapy|percutaneous intradiscal ozone injection
79505624|NCT02859402|Drug|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
79505625|NCT02857374|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
79667272|NCT00432471|Procedure|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
79354777|NCT03154606|Other|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
79354778|NCT03154606|Other|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
79354779|NCT03154606|Other|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
79354780|NCT03154606|Other|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
79354781|NCT01672450|Drug|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
79354782|NCT01672528|Other|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
79354783|NCT01672528|Other|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
79354784|NCT03154060|Device|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
79354785|NCT01854268|Drug|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
79354786|NCT01672606|Drug|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
79354787|NCT01594281|Drug|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
79505626|NCT02857374|Drug|Fluorescein Sodium Injection|Given IV
79354788|NCT01594281|Procedure|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
79354789|NCT05025124|Device|Entia Liberty|Home monitoring system
79505627|NCT02857374|Other|Laboratory Biomarker Analysis|Correlative studies
79505628|NCT02857374|Procedure|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
79505629|NCT04273074|Radiation|sonographic assessment|preoperative sonographic assessment to airway
79505630|NCT04843722|Biological|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
79505631|NCT04844268|Biological|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
79505632|NCT04844268|Biological|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
79667273|NCT04704765|Other|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
79667274|NCT00427596|Drug|Solabegron|
79667275|NCT00432510|Drug|C1 esterase inhibitor [human] (C1INH-nf)|
79667276|NCT05354258|Drug|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
79667277|NCT05354258|Drug|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
79667278|NCT05354258|Drug|Amodiaquine|SMC partner drug
79667279|NCT05354258|Drug|Sulfadoxine pyrimethamine|SMC partner drug
79505633|NCT04844268|Biological|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
79667280|NCT05338580|Drug|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
79667281|NCT00427674|Drug|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
79667282|NCT05306366|Drug|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
79667283|NCT01588899|Device|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
79667284|NCT02273466|Drug|Desipramine tablet|
79667285|NCT02273466|Drug|Crobenetine infusion|
79667286|NCT02273466|Drug|Placebo infusion|
79818295|NCT06239662|Behavioral|Therapeutic Group|The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
79818296|NCT06239662|Behavioral|Usual care|The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
79818297|NCT06239649|Procedure|Genicular nerve Radiofrequency Ablation block|Genicular nerve Radiofrequency Ablation block
79667287|NCT05245643|Device|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
79818298|NCT06239636|Biological|UP421|Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
79818299|NCT06239623|Drug|JSI-1187|Use ERK inhibitor JSI-1187 to treat solid tumor
79818300|NCT06239610|Device|electromagnetic placement device|Daily use of an EMPD to verify FT position
79818301|NCT06239597|Behavioral|occupation-based lifestyle intervention|9 week lifestyle course
79990751|NCT03130959|Biological|Nivolumab|Specified dose on specified days
79990752|NCT03130959|Biological|Ipilimumab|Specified dose on specified days
79354790|NCT04764526|Other|Protein-enriched ice cream|Offering two protein-enriched ice creams
79354791|NCT05565820|Other|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
79667288|NCT00427713|Drug|capecitabine|
79667289|NCT00427713|Drug|oxaliplatin|
79667290|NCT00427713|Procedure|adjuvant therapy|
79818302|NCT06239597|Other|Other courses|Other courses in the same university, during the same academic years.
79818303|NCT06239584|Procedure|Biopsies performed via bronchoscopy|An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
79818304|NCT06239558|Other|Qualitative exploration|Semi-structured Interviews and focus group
79818305|NCT06239545|Behavioral|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
79818306|NCT06239532|Drug|HAIC+TAE|Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
79354792|NCT05565820|Drug|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
79354793|NCT03153904|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
79505634|NCT04844268|Biological|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
79505635|NCT04842552|Drug|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
79667291|NCT00427713|Procedure|standard follow-up care|
79667292|NCT02273505|Drug|Asasantin (ER)|
79667293|NCT02273505|Drug|Persantin|
79990753|NCT02371954|Behavioral|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
79990754|NCT02371954|Other|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
79990755|NCT02373670|Behavioral|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
79505636|NCT04842552|Drug|Placebo|Placebo
79667294|NCT02273505|Drug|Acetyl salicylic acid (ASA)|
79667295|NCT05210621|Drug|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
79505637|NCT01891656|Behavioral|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller & Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
79354794|NCT03153904|Other|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
79354795|NCT01566981|Procedure|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
79667296|NCT00427752|Procedure|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
79667297|NCT00427830|Biological|MVA85A|
79990756|NCT02373670|Behavioral|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
79990757|NCT01367769|Other|No intervention|There will be no intervention in this study.
79228394|NCT03653715|Device|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
79354796|NCT01672684|Procedure|support group therapy|Complete at-home group video calling support sessions
79354797|NCT01672684|Other|educational intervention|Receive an educational workbook journal
79354798|NCT01870778|Drug|RLX030|1 mg/mL solution in 6 mL vials
79354799|NCT01870778|Drug|Placebo|Matching placebo solution to serelaxin
79354800|NCT05496322|Device|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
79354801|NCT05496322|Device|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
79354802|NCT04964050|Drug|Capozide|Capozide will be administered as per the treatment sequence.
79354803|NCT04964050|Drug|ACE-Hemmer-Ratiopharm|ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
79354804|NCT03541330|Other|semi-directive interview|semi-structured interview conducted by a clinical psychologist
79354805|NCT03526900|Drug|Atezolizumab|"Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
79354806|NCT03427294|Other|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
79354807|NCT03420742|Drug|Midazolam|Midazolam syrup.
79505638|NCT01891656|Behavioral|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere & Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman & Massey, 2008). As discussed by Hester & Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
79667298|NCT05174156|Drug|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
79667299|NCT00432549|Drug|Almotriptan|
79667300|NCT00432549|Drug|Topiramate|
79667301|NCT00427947|Drug|ropivacaine/placebo|Continuous sciatic nerve bloc
79667302|NCT00432588|Drug|misoprostol|
79667303|NCT00432588|Drug|dinoprostone|
79667304|NCT00427986|Drug|Galactose, intravenous|
79667305|NCT00428025|Drug|diclofenac|100 mg diclofenac rectal suppository
79667306|NCT00428025|Drug|placebo|similar shape and size suppository
79667307|NCT00428064|Drug|Sirolimus|
79667308|NCT00428064|Drug|cyclosporine|
79667309|NCT05011253|Other|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
79667310|NCT00432627|Drug|Deferasirox|one dose of 20 mg/kg/day
79505639|NCT04390932|Other|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
79505640|NCT04390932|Other|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
79505641|NCT04390932|Other|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
79505642|NCT01456884|Behavioral|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
79505643|NCT01456884|Behavioral|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
79505644|NCT02813928|Genetic|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
79505645|NCT01891812|Drug|Nitrous oxide 50%|
79818307|NCT06239532|Drug|Tislelizumab|Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
79505646|NCT01457274|Other|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (<60) than those in the light sedation group (BIS 70-80)."
79505647|NCT01892046|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
79667311|NCT00419705|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
79667312|NCT00432705|Procedure|Checking stability of ankle|Flexing and walking
79667313|NCT00419783|Drug|bilastine|20 mg tablets.
79354808|NCT03420742|Drug|Brigatinib|Brigatinib tablets.
79354809|NCT01672840|Dietary Supplement|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
79354810|NCT01672840|Dietary Supplement|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
79354811|NCT02370706|Drug|PIM447|pan-pim inhibitor
79354812|NCT02370706|Drug|Ruxolitinib|JAK1/JAK2 inhibitor
79354813|NCT02370706|Drug|LEE011|CDK4/6 inhibitor
79354814|NCT01818284|Drug|Filgrastim|5 µg/kg in the morning daily for 4 days.
79505648|NCT04389996|Other|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
79505649|NCT01892124|Behavioral|Motivational Interviewing/Cognitive Behavioral-based Therapy|
79505650|NCT01892202|Other|Cohort|
79505651|NCT01892358|Behavioral|SKIN Intervention|
79505652|NCT01892358|Other|Treatment as Usual|
79667314|NCT00419783|Drug|Bilastine|100 mg (5 tablets of 20 mg)
79667315|NCT00419783|Drug|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
79667316|NCT00419783|Drug|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
79667317|NCT00419783|Drug|Placebo|Placebo tablets
79667318|NCT04704492|Drug|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
79818308|NCT06239532|Drug|Surufatinib|Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
79818309|NCT06239519|Behavioral|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
79505653|NCT04840836|Behavioral|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
79505654|NCT04272684|Other|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
79505655|NCT01457664|Drug|Placebo|Placebo to RO4995819 once daily for 14 days
79505656|NCT01457664|Drug|RO4995819|RO4995819 doses once daily for 14 days
79667319|NCT00419822|Procedure|Acupuncture|6 Acupuncture visits
79990758|NCT02373592|Behavioral|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
79990759|NCT02373592|Device|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
79505657|NCT04390464|Drug|Ravulizumab|Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
79667320|NCT00419822|Procedure|Sham Acupuncture|6 Acupuncture visits with sham procedure
79667321|NCT00419822|Other|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
79990760|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
79990761|NCT01370031|Drug|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
79990762|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
79990763|NCT01370031|Drug|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
79990764|NCT02373514|Drug|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
79990765|NCT02373514|Drug|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
79990766|NCT01364493|Drug|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
79990767|NCT02371798|Drug|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
79990768|NCT02373358|Behavioral|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
79990769|NCT01367925|Device|Stryker Triathlon® CS Tibial Insert|
79990770|NCT01367925|Device|Stryker Triathlon® PS Tibial Insert|
79990771|NCT01370187|Drug|Montelukast|Montelukast 4mg daily for 2 months
79354815|NCT01818284|Drug|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
79990772|NCT04483960|Drug|Nafamostat Mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
79990773|NCT04483960|Drug|Enoxaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h."
79990774|NCT04483960|Drug|Dalteparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h."
79505658|NCT04390464|Drug|Baricitinib|Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
79354816|NCT01818284|Procedure|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
79354817|NCT02081014|Drug|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
79354818|NCT01673074|Drug|(PDT) Photodynamic therapy|photosensitizer
79505659|NCT04390464|Other|Standard of care|Regular standard of care for COVID-19 patients
79505660|NCT04390542|Behavioral|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
79505661|NCT04845750|Device|Rodeo Micro Mapping Catheter|The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
79505662|NCT04844424|Drug|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
79505663|NCT01892670|Other|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
79818310|NCT06239506|Other|no intervention|no intervention
79818311|NCT06239493|Diagnostic Test|IVUS Guided|Those already undergoing an IVUS guided percutaneous vascular intervention
79354819|NCT01673152|Dietary Supplement|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
79354820|NCT01673152|Dietary Supplement|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
79354821|NCT05405842|Device|Transauricular Vagal Nerve Stimulation|TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
79354822|NCT01673230|Procedure|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
79354823|NCT03153358|Drug|Icotinib|icotinib 125 milligram three times a day
79990775|NCT04483960|Drug|Tinzaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia)."
79505664|NCT01892748|Drug|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
79818312|NCT06239480|Drug|QTORIN 3.9% Rapamycin Anhydrous Gel|QTORIN 3.9% Rapamycin Anhydrous Gel Topical
79818313|NCT06239480|Drug|Placebo|Placebo Topical Gel
79818314|NCT06239467|Drug|OKI-219|Oral twice daily
79354824|NCT03153358|Radiation|SBRT|given radiation for the primary lesion
79354825|NCT03025594|Drug|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
79354826|NCT03025594|Drug|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
79354827|NCT04404946|Other|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
79354828|NCT04404946|Other|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
79354829|NCT04404946|Other|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
79354830|NCT01673542|Drug|Lidocaine-Prilocaine 5%|
79354831|NCT01673542|Drug|DEXERYL|
79354832|NCT04804540|Drug|Vedolizumab IV|Vedolizumab IV infusion
79505665|NCT01892748|Drug|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
79505666|NCT01892826|Drug|hCG|5000IU
79505667|NCT01892904|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
79354833|NCT03713710|Behavioral|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
79505668|NCT01892982|Behavioral|Problem Solving Education tailored to NICU|
79818315|NCT06239467|Drug|Fulvestrant|Intramuscular injection
79818316|NCT06239467|Drug|Trastuzumab|Intravenous (IV)
79990776|NCT04483960|Biological|Hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
79990777|NCT01370343|Drug|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
79354834|NCT03713710|Behavioral|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
79990778|NCT01370343|Drug|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
79354835|NCT02634268|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
79354836|NCT01610492|Drug|belimumab|10mg/kg administered intravenously
79354837|NCT01673776|Device|PulsioFlex® Monitoring|"goal directed therapy according to PulsioFlex® Monitoring- measurements~femoral catheter~extended perioperative monitoring~nutritional supplementation, (if necessary)"
79354838|NCT01817582|Drug|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
79990779|NCT01368003|Drug|STA9090|200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
79990780|NCT01368003|Drug|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
79354839|NCT01817582|Drug|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
79354840|NCT01817582|Drug|Soothe® Lubricant Eye Drops|
79990781|NCT01364571|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
79354841|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
79354842|NCT01594125|Drug|Nintedanib low dose|twice daily oral dosing
79354843|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
79354844|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
79354845|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
79354846|NCT04792684|Diagnostic Test|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
79354847|NCT01673932|Biological|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
79354848|NCT01673932|Procedure|surgery|
79354849|NCT02986113|Behavioral|MAPS tailored multimedia patient activation program|
79354850|NCT02986113|Behavioral|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
79354851|NCT02986113|Behavioral|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
79354852|NCT02986113|Behavioral|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
79354853|NCT04404868|Other|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
79354854|NCT04604288|Biological|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
79354855|NCT04775134|Diagnostic Test|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
79354856|NCT01870076|Behavioral|Healing Touch|
79354857|NCT01870076|Behavioral|Healing Touch, Sham|
79354858|NCT01870076|Behavioral|Control, Presence|
79505669|NCT01893060|Drug|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
79505670|NCT01893060|Drug|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
79505671|NCT01893060|Drug|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
79505672|NCT01893060|Other|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
79505673|NCT01457742|Device|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
79505674|NCT01457742|Device|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
79505675|NCT02314650|Other|acupoint stimulation|stimulation was given at acupoints
79505676|NCT02314650|Other|non-acupoint stimulation|stimulation was given at non-acupoints
79505677|NCT02314650|Other|electrodes attached|electrode were attached to skin
79505678|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
79990782|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79228395|NCT03653715|Device|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
79354859|NCT01592721|Biological|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
79354860|NCT02125396|Other|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
79354861|NCT02125396|Other|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
79354862|NCT01613378|Other|No intervention|No intervention administered in this study
79505679|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
79505680|NCT01457820|Drug|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
79505681|NCT01457898|Device|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
79505682|NCT04758156|Drug|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
79354863|NCT01592409|Drug|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
79354864|NCT01592409|Drug|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
79354865|NCT02081638|Drug|Aspirin|Daily Asprin daily
79354866|NCT02081638|Drug|Atorvastatin|Daily Atorvastatin Daily
79354867|NCT04603508|Drug|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
79354868|NCT04603508|Drug|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
79354869|NCT04603508|Drug|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
79354870|NCT04603508|Other|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
79505683|NCT04758156|Drug|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
79505684|NCT05020782|Drug|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
79505685|NCT05029986|Behavioral|Socialization phase|Control condition: does not involve speech-related exercises
79505686|NCT05029986|Behavioral|Speech breathing intervention|Experimental condition: involves speech-related exercises
79505687|NCT01893294|Drug|gemcitabine hydrochloride|Given IT
79354871|NCT04603508|Other|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
79354872|NCT04603508|Other|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
79354873|NCT01674166|Drug|prucalopride|single dose 0.03 mg/kg prucalopride open label
79354874|NCT02235688|Drug|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
79505688|NCT01893294|Drug|fluorouracil|Given IV
79505689|NCT01893294|Radiation|radiation therapy|Undergo radiation therapy
79505690|NCT01893294|Other|laboratory biomarker analysis|Correlative studies
79505691|NCT01458054|Drug|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
79354875|NCT02235688|Drug|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
79354876|NCT02235688|Drug|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
79354877|NCT02235688|Drug|gemcitabine|
79505692|NCT01458054|Drug|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
79667322|NCT04703517|Diagnostic Test|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
79667323|NCT04959305|Drug|HCP1803-3|Take it once daily for 8 weeks orally.
79667324|NCT04959305|Drug|RLD2003|Take it once daily for 8 weeks orally.
79667325|NCT04959305|Drug|RLD2004|Take it once daily for 8 weeks orally.
79667326|NCT04959305|Drug|RLD2005|Take it once daily for 8 weeks orally.
79667327|NCT04959305|Drug|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
79667328|NCT04959305|Drug|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
79818317|NCT06239454|Device|interleaving stimulation|ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
79505693|NCT05028270|Procedure|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
79505694|NCT01458444|Device|Non invasive ventilation (VNI)|BIPAP® vision
79505695|NCT01458444|Device|Non invasive ventilation|OPTIFLOW system
79818318|NCT06239454|Device|empirical stimulation|Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60~90µs pulse width, 130~185Hz frequency and varied voltage) during the follow-up.
79818319|NCT06239441|Drug|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
79818320|NCT06239428|Behavioral|i-TREAT|A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
79228396|NCT02467010|Drug|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
79354878|NCT01676584|Drug|RO6811135|single ascending doses sc
79354879|NCT01676584|Drug|placebo|single doses sc
79354880|NCT03152578|Other|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
79354881|NCT03152578|Other|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
79354882|NCT03152578|Other|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
79354883|NCT01065532|Device|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
79354884|NCT01065532|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
79354885|NCT01674244|Behavioral|Integrative Exercise|
79818321|NCT06239428|Other|Waitlist|A 12-week waitlist with access to online mindfulness material.
79818322|NCT06239389|Drug|Thalidomide 100mg|Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.
79818323|NCT06239389|Drug|Hydroxyurea|Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
79818324|NCT06239350|Behavioral|Counseling|Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
79818325|NCT06239350|Behavioral|Contingency management|Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
79990783|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
79354886|NCT01674244|Behavioral|Monitor Only Waitlist|
79354887|NCT03152734|Procedure|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
79354888|NCT01697319|Drug|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
79354889|NCT03152812|Procedure|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
79990784|NCT01364571|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
79990785|NCT01364571|Procedure|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79990786|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
79990787|NCT01364571|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
79990788|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79990789|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
79990790|NCT01364571|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
79354890|NCT01674322|Drug|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
79990791|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79354891|NCT04746898|Other|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
79354892|NCT04746898|Other|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
79354893|NCT04746898|Other|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
79354894|NCT03152344|Procedure|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds).
79354895|NCT03152500|Device|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
79505696|NCT05029518|Drug|SMP-100|In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
79505697|NCT02784756|Device|Quantiferon-CMV assay|
79505698|NCT01893450|Drug|Methimazole|
79505699|NCT01893450|Drug|Bromocriptine|
79990792|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
79990793|NCT02371720|Behavioral|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
79990794|NCT04223583|Drug|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
79354896|NCT03152500|Device|Acrysof SN60WF IOL|IOL in the bag
79354897|NCT03885310|Device|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
79354898|NCT04764916|Drug|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
79505700|NCT01893450|Drug|Pentoxifylline|
79505701|NCT05027100|Drug|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
79505702|NCT02374944|Procedure|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
79667329|NCT04704687|Other|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
79354899|NCT04764916|Drug|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
79505703|NCT02887794|Other|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
79818326|NCT06239350|Behavioral|Text-based support|All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
79990795|NCT02373436|Other|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
79354900|NCT01674790|Behavioral|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
79354901|NCT01674790|Behavioral|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
79354902|NCT01674790|Behavioral|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
79354903|NCT01674790|Behavioral|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
79354904|NCT01674868|Drug|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
79354905|NCT01674868|Drug|placebo|subjects will take one pill po daily for 90 days.
79354906|NCT01674946|Other|saline|intraduodenal perfusion
79354907|NCT01674946|Other|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
79354908|NCT01674946|Other|oleanolic acid|intraduodenal perfusion
79505704|NCT05020938|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
79667330|NCT00428103|Procedure|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
79667331|NCT04906109|Drug|Vemlidy Tab|1T
79990796|NCT02373436|Other|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
79354909|NCT01674946|Dietary Supplement|oleic acid|intraduodenal perfusion
79505705|NCT05027568|Drug|Single ascending doses of IOA-289|Single dose, oral administration of liquid-filled capsules, with a starting dose of 30 mg
79505706|NCT05027568|Drug|Placebo single doses|Single dose, oral administration of liquid-filled capsules, matching placebo
79505707|NCT02775162|Device|Normothermic Machine Perfusion (NMP)|
79505708|NCT02775162|Other|Standard of Care (Ice)|
79354910|NCT01675024|Drug|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
79354911|NCT01675024|Drug|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
79354912|NCT02081950|Biological|Enoxaparin sodium|comparison of 2 different administration of drug
79354913|NCT03878212|Other|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
79354914|NCT03878212|Other|mHealth application|a mHealth device
79505709|NCT01458600|Drug|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
79505710|NCT01458600|Drug|Methimazole|T Methimazole 5 mg 3x2 for 18 months
79667332|NCT04906109|Drug|DA-2803 Tab|1T
79667333|NCT04871438|Device|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
79667334|NCT04823897|Drug|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
79667335|NCT00428181|Behavioral|Brief alcohol intervention|Brief alcohol intervention
79505711|NCT01458600|Drug|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
79505712|NCT01458600|Drug|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
79505713|NCT01458600|Drug|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
79505714|NCT01893528|Drug|REGN2009|
79505715|NCT01893528|Other|placebo|
79354915|NCT04404322|Other|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
79505716|NCT02771028|Behavioral|Emotional Freedom Techniques|
79505717|NCT02764788|Other|Specific auriculotherapy|Specific auriculotherapy with needles
79505718|NCT02764788|Other|non-specific auriculotherapy|non-specific auriculotherapy with needles
79354916|NCT04404322|Other|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
79990797|NCT03634761|Behavioral|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
79354917|NCT01675180|Other|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
79354918|NCT01675180|Other|Control|No intervention
79354919|NCT03152422|Diagnostic Test|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
79354920|NCT03155932|Drug|APD334|APD334 active treatment for 24 weeks.
79354921|NCT01675258|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
79505719|NCT02764788|Other|seed auriculotherapy|non-specific auriculotherapy with seeds
79505720|NCT04272528|Other|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
79505721|NCT04272528|Other|conventional care|Nurses carry out the routine care procedures.
79505722|NCT02839278|Biological|Blood sample|
79505723|NCT02832570|Drug|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
79505724|NCT02832570|Drug|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
79354922|NCT01675414|Other|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
79354923|NCT01675570|Drug|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
79505725|NCT02832492|Behavioral|pupil near response|
79505726|NCT02763150|Behavioral|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
79505727|NCT02763150|Other|Health Promotion|The health promotion group will receive education on healthy eating and activity
79505728|NCT02761746|Behavioral|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
79505729|NCT02759484|Behavioral|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
79667336|NCT00428181|Behavioral|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
79990798|NCT03634761|Behavioral|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
79990799|NCT02371564|Device|High flow humidified oxygen|
79990800|NCT02371564|Device|Standard flow humidified oxygen|
79990801|NCT02371486|Procedure|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
79990802|NCT02371486|Procedure|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
79505730|NCT02759484|Behavioral|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
79505731|NCT02757300|Device|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
79505732|NCT02757300|Device|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
79505733|NCT02509260|Device|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
79505734|NCT02509260|Other|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
79505735|NCT01458834|Behavioral|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
79505736|NCT01458834|Behavioral|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
79505737|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
79505738|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
79505739|NCT01458912|Drug|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
79505740|NCT01458912|Drug|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
79505741|NCT02747862|Other|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP [i.e. identifiable APC mutation], and/or a compatible family history or personal adenoma burden of > 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
79505742|NCT02743728|Device|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
79667337|NCT04703478|Other|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
79818327|NCT06239337|Diagnostic Test|Xpert MTB/RIF Ultra in stools and urine|All children with presumptive TB had at least 1 sample collected of respiratory or extrapulmonary specimen (considered as gold standard) and 1 sample of stools and 1 sample of urine. All of them were analyzed with Xpert MTB/RIF Ultra.
79818328|NCT06239324|Drug|Latanoprost|Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
79818329|NCT06239311|Drug|Methotrexate|Solution for injection in prefilled pen
79818330|NCT06239311|Drug|Placebo|Solution for injection in prefilled pen
79818331|NCT06239298|Drug|ZG005 Powder for Injection|intravenous infusion(IV), once every 3 weeks
79505743|NCT02743728|Device|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
79505744|NCT02743728|Behavioral|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
79505745|NCT02743338|Behavioral|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
79505746|NCT02743338|Behavioral|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
79667338|NCT00432822|Drug|tetrahydrobiopterin (BH4)|
79667339|NCT00432861|Drug|PANCRECARB® (pancrelipase)|Capsules
79667340|NCT00432861|Drug|Placebo|Capsules
79667341|NCT00432900|Radiation|[(11)C]PBR28|PET Ligand
79679636|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
79667342|NCT04627805|Behavioral|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research & Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
79818332|NCT06239298|Drug|Donafenib Tosilate Tablets|The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
79818333|NCT06239285|Device|Brief Violence Intervention VR (BVI-VR)|BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
79354924|NCT01675570|Drug|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
79354925|NCT01675648|Drug|Lofexidine|
79667343|NCT00428337|Biological|EP-1233|DNA-HIV-recombinant vaccine
79990803|NCT02371486|Procedure|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
79667344|NCT00428337|Biological|MVA-mBN32|HIV-recombinant viral vaccine
79667345|NCT04703400|Other|anonymous survey|anonymous survey with 25 mandatory questions
79990804|NCT02371486|Procedure|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
79818334|NCT06239285|Other|Treatment as Usual (TAU)|group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
79818335|NCT06239259|Other|Questionare As described in Secondary Outcomes|All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
79354926|NCT01675648|Drug|Diazepam|
79354927|NCT01675648|Drug|Placebo for Lofexidine|
79990805|NCT04961697|Behavioral|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
79990806|NCT02377648|Device|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.
79667346|NCT00428376|Device|Building Blocks|
79667347|NCT04575233|Procedure|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
79354928|NCT01675648|Drug|Placebo for Diazepam|
79354929|NCT01566435|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
79354930|NCT01566435|Drug|Cisplatin|
79354931|NCT01566435|Drug|Fluorouracil|
79354932|NCT01566435|Radiation|Intensity modulated radiation therapy|
79354933|NCT01566435|Drug|Cetuximab|
79354934|NCT01566435|Procedure|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
79354935|NCT03868228|Procedure|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
79354936|NCT01675726|Other|questionary on quality of life|
79354937|NCT01675804|Other|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
79505747|NCT02743338|Behavioral|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
79505748|NCT02742324|Drug|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
79679637|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
79354938|NCT01675804|Drug|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
79354939|NCT01675804|Other|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
79354940|NCT01696929|Drug|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
79354941|NCT04649008|Diagnostic Test|3T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 3 Tesla.
79354942|NCT04649008|Diagnostic Test|Intracranial electroencephalography recordings|Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
79354943|NCT04649008|Diagnostic Test|7T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 7 Tesla.
79354944|NCT03865654|Other|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
79354945|NCT01696773|Other|Tangerine tomato juice|Post-prandial feeding study
79354946|NCT01696773|Other|Red tomato juice|Post-prandial feeding study
79818336|NCT06239246|Other|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
79990807|NCT01368159|Device|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
79990808|NCT02371408|Drug|ravidasvir hydrochloride|200 mg
79990809|NCT02371408|Drug|sofosbuvir|400 mg
79990810|NCT02371408|Drug|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
79679638|NCT02940912|Drug|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
79990811|NCT01364805|Drug|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
79679639|NCT02940912|Drug|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
79679640|NCT00518726|Biological|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
79505749|NCT02742324|Drug|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
79505750|NCT01459146|Drug|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
79505751|NCT01459146|Drug|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
79505752|NCT01459146|Drug|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
79990812|NCT01364805|Drug|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
79354947|NCT03158740|Behavioral|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
79354948|NCT03158740|Behavioral|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
79354949|NCT01696695|Drug|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
79354950|NCT01696695|Drug|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
79354951|NCT01676038|Procedure|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
79354952|NCT01676038|Procedure|Conventional Total Knee Arthroplasty|Conventional technique.
79354953|NCT05261386|Drug|CBT-008|Cyclodextrin
79370838|NCT03540927|Behavioral|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
79505753|NCT05028894|Other|No intervention|No intervention
79505754|NCT05024136|Device|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
79505755|NCT05024136|Device|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
79679641|NCT02941029|Other|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
79990813|NCT04399018|Other|Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection.~Blood sample will be stained according to the manufacturers' recommendations with a lyophilized cocktail (LyotubeTM ready-to-use, BD Bioscience).~At least 10,000 neutrophils will be acquired on a 3-laser, 8-color BD FACSCanto-II TM flow cytometer (BD Biosciences, San José, CA).~Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
79505756|NCT05026398|Drug|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
79505757|NCT05026398|Other|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
79990814|NCT01370889|Drug|resveratrol|Given PO
79505758|NCT01895244|Drug|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
79990815|NCT01370889|Other|laboratory biomarker analysis|Correlative studies
79505759|NCT02724930|Behavioral|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
79505760|NCT05586750|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
79505761|NCT05586750|Drug|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
79505762|NCT01893606|Drug|N-acetyl-D-glucosamine|
79505763|NCT01893606|Drug|placebo|
79679642|NCT03459053|Behavioral|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
79679643|NCT02940795|Other|Coke|Patients were given a 20 ounce bottle of Coke Cola.
79679644|NCT02940795|Other|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
79679645|NCT00517322|Drug|ramipril|ramipril 2.5- 5 mg once daily
79990816|NCT01364883|Biological|Vaccination Schedule One|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
79354954|NCT04617340|Other|Multifaceted clinical pharmacy intervention|"Assessing patient and caregiver preferences~Medication reconciliation on admission~Performing a comprehensive medication review before discharge~Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge."
79818337|NCT06239233|Procedure|Laparoscopic cholecystectomy|"The surgeon makes small incisions in the abdominal wall, usually around the navel.~Trocars (hollow tubes) are inserted through these incisions to provide access for the laparoscope and specialized instruments.~A laparoscope, a thin tube with a light and camera, is inserted through one of the trocars. It allows the surgical team to visualize the abdominal cavity on a monitor.~The surgeon carefully identifies the gallbladder and the cystic duct, which connects the gallbladder to the common bile duct.~The cystic duct and artery are clipped and cut to disconnect the gallbladder from the biliary system. This step ensures the safe removal of the gallbladder.~The surgeon gently detaches the gallbladder from the liver bed and removes it through one of the small incisions.~Any bleeding vessels are sealed, and the small incisions are closed with stitches or surgical glue."
79354955|NCT03862066|Other|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
79990817|NCT01364883|Biological|Vaccination Schedule Two|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
79505764|NCT02085720|Device|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
79667348|NCT04575233|Procedure|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
79354956|NCT03862066|Other|Tissue collection|Left over tissue will be collected at the time of surgery
79354957|NCT03861988|Drug|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
79354958|NCT03861988|Drug|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
79354959|NCT01670266|Drug|ONO-9054|
79354960|NCT01670266|Drug|Placebo|
79354961|NCT03755440|Drug|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
79354962|NCT01676194|Other|Intra-arterial administration of DC BeadsR|
79354963|NCT03860974|Drug|Serratus Plane block (single injection)|A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
79667349|NCT04575233|Drug|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
79990818|NCT01364883|Biological|Vaccination Schedule Three|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
79354964|NCT03860974|Drug|Paravertebral block (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
79354965|NCT01565889|Drug|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
79354966|NCT01565889|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
79505765|NCT02716974|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
79505766|NCT02716974|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
79505767|NCT02716974|Drug|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
79667350|NCT04565951|Behavioral|PsychArmor S.A.V.E.|The intervention is called PsychArmor S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
79679646|NCT00517322|Drug|irbesartan|irbesartan 150-300 mg once daily
79354967|NCT01565889|Drug|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
79354968|NCT01565889|Drug|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
79354969|NCT01565889|Drug|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
79354970|NCT01565889|Drug|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
79354971|NCT01565889|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
79354972|NCT01565889|Drug|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
79354973|NCT01565889|Drug|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
79354974|NCT01565889|Drug|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
79354975|NCT01565889|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79505768|NCT02716974|Procedure|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
79505769|NCT02716974|Radiation|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
79505770|NCT01890096|Radiation|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
79505771|NCT01890096|Radiation|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
79505772|NCT01459380|Biological|Bevacizumab|Given IV
79505773|NCT01459380|Drug|Carboplatin|Given IV
79505774|NCT01459380|Other|Laboratory Biomarker Analysis|Correlative studies
79505775|NCT01459380|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79505776|NCT01459380|Drug|Veliparib|Given PO
79505777|NCT04346004|Drug|Normal saline|"Participants in Control group are administered IV 100cc normal saline & IM normal saline (1cc) 1 day before surgery."
79505778|NCT04346004|Drug|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) & IM Vitamin B12 (1mg) 1 day before surgery."
79505779|NCT02680314|Drug|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
79505780|NCT05586672|Device|EEG-HR|Passation EEG-HR
79505781|NCT05586672|Diagnostic Test|ADI-R|Passation of ADI-R scale
79818338|NCT06239220|Biological|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
79505782|NCT05586672|Diagnostic Test|ADOS-2|Passation of ADOS-2 scale
79505783|NCT05586672|Diagnostic Test|IDE|Passation of IDE scale
79354976|NCT01696071|Drug|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
79354977|NCT01696071|Drug|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
79354978|NCT03855280|Drug|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
79354979|NCT01591863|Drug|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
79354980|NCT03851302|Other|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
79354981|NCT03851302|Other|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
79354982|NCT03851302|Other|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
79354983|NCT03850756|Diagnostic Test|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
79354984|NCT03850756|Diagnostic Test|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
79354985|NCT03850756|Diagnostic Test|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
79354986|NCT01591785|Drug|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
79354987|NCT01591785|Drug|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
79370839|NCT03540927|Other|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
79505784|NCT05586672|Diagnostic Test|MSEL|Passation of MSEL scale
79505785|NCT05586672|Diagnostic Test|Dunn|Passation of Dunn scale
79505786|NCT02707692|Biological|Fluarix|Intramuscular injection with Fluarix® .
79505787|NCT02707692|Biological|Pneumovax|Intramuscular injection with Pneumovax.
79505788|NCT02707692|Other|Placebo|Intramuscular injection with sterile saline (placebo).
79505789|NCT02706678|Drug|Tacrolimus sustained-release capsule|Oral
79505790|NCT02703948|Device|Restylane Silk with Lidocaine|
79679647|NCT02939430|Drug|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
79818339|NCT06239220|Drug|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
79818340|NCT06239220|Biological|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
79818341|NCT06239194|Drug|MDX2001|MDX2001 intravenous infusion
79990819|NCT01364883|Biological|Vaccination Schedule Four|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
79990820|NCT01364883|Biological|Vaccination Schedule Five|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
79990821|NCT01364883|Biological|Vaccination Schedule Six|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
79990822|NCT01364883|Biological|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
79990823|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
79990824|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
79990825|NCT01368237|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
79990826|NCT01368315|Drug|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
79990827|NCT01368315|Drug|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
79990828|NCT01368315|Drug|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
79990829|NCT01368315|Drug|No intervention|No intervention to one out of four test fields marked on the patient's back.
79354988|NCT04773639|Behavioral|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
79354989|NCT04773639|Behavioral|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
79354990|NCT03658798|Procedure|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
79990830|NCT02371096|Drug|MabThera (rituximab)|
79990831|NCT02371096|Drug|RGB-03|
79990832|NCT04420455|Drug|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
79505791|NCT02697006|Device|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
79505792|NCT02666742|Drug|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
79505793|NCT02666742|Drug|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
79505794|NCT04390776|Drug|PF-06651600|PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
79505795|NCT01893762|Biological|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
79505796|NCT01893762|Biological|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
79667351|NCT04565951|Behavioral|sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
79667352|NCT00428415|Drug|Tesofensine|
79667353|NCT00428454|Device|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
79667354|NCT00432978|Drug|Bosentan administration|
79667355|NCT00433056|Other|STI|CD4 guided treatment interruption
79667356|NCT00433056|Drug|stable HAART|continuous therapy
79667357|NCT04460612|Device|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
79667358|NCT04460612|Other|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
79354991|NCT03654040|Biological|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
79354992|NCT03654040|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
79505797|NCT01893684|Behavioral|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
79505798|NCT01893684|Behavioral|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
79505799|NCT01893684|Behavioral|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
79667359|NCT00428532|Drug|Licorice root extract or Pomegranate juice|
79354993|NCT03654040|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
79667360|NCT04401332|Other|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
79667361|NCT01051791|Drug|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
79505800|NCT02684292|Biological|pembrolizumab|IV infusion
79990833|NCT01368393|Procedure|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
79990834|NCT01368393|Procedure|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
79990835|NCT02372968|Other|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
79990836|NCT03124407|Drug|Capsaicin Topical Solution|Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
79667362|NCT04346537|Device|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
79667363|NCT01056510|Drug|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
79667364|NCT01056510|Drug|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
79667365|NCT01056510|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
79667366|NCT01051323|Drug|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
79667367|NCT04321811|Other|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
79679648|NCT02939430|Drug|Intravenous neostigmine and atropine|
79505801|NCT02684292|Biological|brentuximab vedotin|IV infusion
79505802|NCT04391010|Other|Surgical masks|Surgical masks will be applied in health care providers
79505803|NCT04391010|Other|Filtering respirators|Filtering respirators will be applied in health care providers
79667368|NCT01056276|Drug|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
79667369|NCT01056276|Drug|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
79667370|NCT01056276|Drug|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
79667371|NCT01055886|Drug|nicotine patch|Nicotine patch, 7-21 mg.
79990837|NCT03124407|Other|Drug product vehicle|This is the vehicle for the active treatment drug product, but without capsaicin
79990838|NCT02371018|Dietary Supplement|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
79990839|NCT01370967|Other|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
79354994|NCT03654040|Drug|mesna|"Mesna is administered:~Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~In conjunction with the cyclophosphamide, per institutional practice with CTX."
79667372|NCT01055886|Drug|placebo patch|placebo patch used from weeks 4-6
79667373|NCT00433095|Drug|Navelbine|
79818342|NCT06239181|Behavioral|Breathing Exercises|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.
79990840|NCT01370967|Other|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
79990841|NCT01370967|Other|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
79990842|NCT02370940|Other|High phytate intake|
79990843|NCT02370940|Other|Low phytate intake|
79990844|NCT01368471|Device|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
79990845|NCT01368471|Device|Control BMS or DES|Control BMS or DES
79505804|NCT02983032|Behavioral|BBTI|3 group sessions over 4 weeks
79505805|NCT01459692|Other|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
79505806|NCT04390074|Other|COVID-19 and Intensive Care|No intervention, observational.
79505807|NCT02649426|Device|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
79505808|NCT02649426|Device|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
79990846|NCT02365246|Device|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
79505809|NCT01459770|Other|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
79667374|NCT00433095|Drug|Herceptin|
79667375|NCT00433095|Drug|Navelbine (oraly)|
79667376|NCT01055613|Device|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
79990847|NCT01364961|Dietary Supplement|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
79990848|NCT02370862|Drug|Neostigmine and Glycopyrrolate|
79990849|NCT01371045|Other|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
79667377|NCT01055613|Device|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
79667378|NCT00433134|Behavioral|Adherence|
79667379|NCT04301804|Drug|SHR6390|a selective small-molecule CDK4/6 inhibitor
79667380|NCT01055457|Device|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
79667381|NCT01055457|Device|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
79370840|NCT04354714|Drug|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
79370841|NCT04354714|Procedure|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
79370842|NCT04366960|Drug|Enoxaparin|Subcutaneous enoxaparin
79370843|NCT03539445|Drug|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
79667382|NCT04148144|Other|No intervention included|No intervention included
79667383|NCT00428571|Procedure|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
79667384|NCT00428571|Procedure|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
79354995|NCT03654040|Drug|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
79354996|NCT01695993|Device|Acupressure bands|Bilateral acupressure wrist bands
79354997|NCT01695993|Other|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
79354998|NCT01695993|Behavioral|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
79354999|NCT01695993|Other|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
79355000|NCT01695993|Behavioral|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
79505810|NCT01459770|Other|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
79505811|NCT02377206|Other|ADAS-Cog evaluation|[18F]DPA-714 PET imaging
79505812|NCT01894074|Behavioral|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
79505813|NCT01894074|Behavioral|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
79505814|NCT01459848|Behavioral|block play|30 minutes of block play
79505815|NCT01459848|Behavioral|baby dvd|30 minutes of dvd viewing
79505816|NCT04390854|Biological|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
79505817|NCT04390854|Biological|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge** at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
79505818|NCT02630316|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
79818343|NCT06239181|Other|no intervention/routine procedure|Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
79505819|NCT02630316|Drug|Placebo|Placebo administered four times daily
79505820|NCT02875704|Other|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
79505823|NCT02354820|Other|Evidence Based Constipation Reminders|
79505824|NCT02624544|Drug|esomeprazole|esomex 40 mg twice daily
79818344|NCT06239168|Dietary Supplement|Citrus extract|As described in experimental arm
79355001|NCT01565343|Drug|florbetapir F 18|IV injection, 370MBq (10mCi)
79355002|NCT03740932|Diagnostic Test|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
79355003|NCT00003460|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
79505825|NCT02624544|Drug|desonide|topical corticosteroid desonid 0,1% b.i.d
79505826|NCT02620410|Device|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
79505827|NCT01893840|Device|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
79505828|NCT02613936|Device|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
79667385|NCT00428571|Procedure|Intensive Medical Management|lifestyle, diet, medication optimization
79355004|NCT03646786|Device|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
79355005|NCT03646630|Procedure|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
79355006|NCT03646630|Procedure|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
79355007|NCT03842956|Procedure|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
79355008|NCT04763122|Other|not applicable as it is a retrospective study|It is a retrospective study
79370844|NCT03539445|Drug|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
79370845|NCT04360876|Drug|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
79370846|NCT04360876|Drug|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
79505829|NCT02613936|Behavioral|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
79667386|NCT04100291|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
79505830|NCT02603328|Drug|Atorvastatin|40-80 mg OD
79505831|NCT02603328|Other|Placebo|inactive
79505832|NCT02335788|Device|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
79505833|NCT02327286|Behavioral|Promote and support healthy behaviors|"Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
79505834|NCT01451970|Other|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
79667387|NCT04100291|Other|Placebo|Placebo by daily enema with placebo mixture
79667388|NCT04703283|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
79667389|NCT04046120|Other|Heel-free bandage|The bandage is made by leaving the heel uncovered.
79667390|NCT04716647|Other|Ayurveda|Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
79667391|NCT04703049|Other|Blood Viscosity Testing|we calculated WBV using the formula [(0.12 × hematocrit) + (0.17 × (total protein - 2.07)]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
79667392|NCT00428649|Dietary Supplement|20 µg selenium|20 µg selenium as selenomethionine
79667393|NCT00428649|Dietary Supplement|40 µg selenium|40 µg selenium as selenomethionine
79505835|NCT02598258|Other|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
79355009|NCT03836872|Device|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
79355010|NCT03836326|Other|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
79355011|NCT03836326|Other|Control|Routine care provided by health professionals in the NICU
79355012|NCT04762420|Other|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
79505836|NCT01450722|Procedure|bypass surgery, stent placement|bypass surgery, stent placement
79505837|NCT01450722|Procedure|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
79505838|NCT01456104|Biological|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
79505839|NCT01451736|Drug|paliperidone palmitate|long-acting injectable
79505840|NCT01451736|Drug|risperidone|oral
79667394|NCT00428649|Dietary Supplement|60 µg selenium|60 µg selenium as selenomethionine
79355013|NCT04747132|Other|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
79355014|NCT03642106|Behavioral|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
79370847|NCT04403529|Drug|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
79505841|NCT02310594|Other|cytology specimen collection procedure|Undergo blood sample collection
79505842|NCT02310594|Other|laboratory biomarker analysis|Correlative studies
79505843|NCT02868918|Drug|biodentine|tricalcium silicate cement used to replace the carious dentin
79505844|NCT02868918|Drug|glass ionomer cement|high viscosity glass ionomer used as a base material
79505845|NCT02868918|Device|DigoraH optium|digital Xray for follow up
79505846|NCT02586870|Device|Intravascular Ultrasound|
79667395|NCT00428649|Dietary Supplement|80 µg selenium|80 µg selenium as selenomethionine
79667396|NCT00428649|Dietary Supplement|100 µg selenium|100 µg selenium as selenomethionine
79667397|NCT00428649|Dietary Supplement|120 µg selenium|120 µg selenium as selenomethionine
79667398|NCT00428649|Dietary Supplement|placebo|placebo
79667399|NCT03790709|Drug|High dose ANAVEX2-73|Oral capsule
79505847|NCT02378766|Behavioral|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
79667400|NCT03790709|Drug|Mid dose ANAVEX2-73|Oral capsule
79990850|NCT02365324|Behavioral|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
79505848|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
79667401|NCT03790709|Drug|Placebo oral capsule|Oral capsule
79990851|NCT02365324|Behavioral|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
79667402|NCT00419900|Procedure|diagnosis of breast cancer by x-ray diffraction of hair|
79990852|NCT04945083|Other|Experimental Nutritional Pudding|High Calorie, High Protein pudding
79990853|NCT02370628|Procedure|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~Step 1: facet block~Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
79505849|NCT04757844|Device|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
79505850|NCT04758078|Other|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
79505851|NCT04758078|Other|Placebo|Nebulized 0.9% saline will be given four times per day
79505852|NCT01450956|Drug|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
79505853|NCT01450956|Other|Control|Patients will receive only oxygen and air through oxygenator
79505854|NCT02300922|Drug|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
79505855|NCT02300922|Drug|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
79505856|NCT02300922|Drug|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
79505857|NCT02297724|Other|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
79505858|NCT01453530|Drug|Sugammadex|A single dose of sugammadex 2 mg/kg iv
79505859|NCT01453530|Drug|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
79505860|NCT01453530|Other|Placebo|Placebo
79667403|NCT00433173|Procedure|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
79667404|NCT00433173|Drug|testosterone|transdermal 7.5 g/per day for 3 months
79667405|NCT00433173|Drug|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
79228397|NCT02467010|Drug|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
79355015|NCT03834142|Device|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
79355016|NCT03737032|Device|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
79355017|NCT03737032|Device|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
79355018|NCT03737032|Device|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
79355019|NCT03833440|Drug|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
79355020|NCT03833440|Drug|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
79505861|NCT02983422|Drug|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
79505862|NCT02983422|Drug|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
79505863|NCT02983422|Drug|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
79667406|NCT00433173|Drug|goserelin acetate implant|single depot injection 10.8 mg 3 months
79505864|NCT02295540|Radiation|hypofractionated radiation therapy|Undergo hypofractionated IMRT
79505865|NCT02295540|Radiation|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
79505866|NCT02295540|Procedure|therapeutic conventional surgery|Undergo surgery
79505867|NCT02295540|Other|laboratory biomarker analysis|Correlative studies
79505868|NCT05585892|Other|Elaboration and individual mailed feedback|see above
79667407|NCT00433173|Procedure|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
79505869|NCT05585814|Drug|Capecitabine|Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3weeks for 3 cycles
79505870|NCT05585814|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 3cycles
79505871|NCT05585814|Drug|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 3 cycles
79505872|NCT05585814|Drug|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
79505873|NCT05585736|Drug|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
79505874|NCT01989780|Drug|Paclitaxel|
79505875|NCT01989780|Drug|Bevacizumab|
79505876|NCT01989780|Drug|Letrozole|
79505877|NCT01989780|Drug|Anastrozole|
79505878|NCT01989780|Drug|Exemestane|
79667408|NCT00433173|Procedure|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
79667409|NCT00433173|Procedure|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
79505879|NCT01989780|Drug|Fulvestrant|
79667410|NCT00433173|Procedure|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
79667411|NCT00433173|Procedure|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
79505880|NCT01989780|Drug|Goserelin|
79505881|NCT01989780|Drug|leuprorelin|
79505882|NCT02265588|Behavioral|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
79505883|NCT02549898|Drug|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
79505884|NCT02549898|Drug|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
79505885|NCT02549898|Other|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
79505886|NCT02549898|Other|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
79505887|NCT02545608|Device|Restylane Vital|
79505888|NCT01894464|Behavioral|Teacher led intervention|
79505889|NCT01981044|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
79505890|NCT04756986|Drug|malic acid|1% malic acid spray
79505891|NCT02513784|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
79505892|NCT02510742|Device|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
79505893|NCT02510742|Device|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
79667412|NCT00433173|Procedure|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
79667413|NCT01055028|Drug|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
79667414|NCT01055028|Drug|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
79667415|NCT00433212|Device|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
79667416|NCT00433212|Device|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
79667417|NCT03611816|Biological|Blood taken|Collection of clinical data
79667418|NCT03611816|Genetic|Blood taken|Collection of DNA
79667419|NCT03611816|Genetic|Blood taken|Collection of plasma
79667420|NCT00428727|Drug|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
79667421|NCT00428727|Drug|placebo patch|daily application during 90 days
79679649|NCT00517400|Device|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
79990854|NCT02370628|Procedure|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
79990855|NCT02929407|Drug|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
79990856|NCT02929407|Drug|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
79990857|NCT02373280|Drug|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
79505894|NCT02283996|Other|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
79667422|NCT03440957|Other|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
79667423|NCT00433368|Drug|L-Ornithine L-Aspartate|
79505895|NCT02283996|Drug|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
79505896|NCT02369484|Drug|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
79505897|NCT04390152|Drug|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
79505898|NCT04390152|Drug|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
79505899|NCT04390230|Procedure|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
79505900|NCT02238834|Drug|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
79505901|NCT02238834|Drug|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
79505902|NCT02238834|Drug|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
79505903|NCT02238834|Drug|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
79505904|NCT02498730|Behavioral|Interval Training|High Intensity Interval Training at 100% VO2Max
79667424|NCT00428766|Drug|MORAb-003|
79990858|NCT02373280|Drug|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)]
79990859|NCT02373280|Drug|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].
79990860|NCT02373280|Drug|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
79505905|NCT02498730|Behavioral|Continuous Training|Continuous Stimulous at 60% VO2Max
79667425|NCT04716569|Drug|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
79667426|NCT00428805|Behavioral|classroom curriculum|"classroom curriculum for 3 & 4 year old children includes activities to increase intake of fruits, vegetables, & whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
79679650|NCT02940717|Other|Vita suprinity|New glass ceramic material
79679651|NCT02940717|Other|Emax CAD|standard etchable glass ceramic used for laminate venneers
79505906|NCT02498730|Behavioral|Control|Only Dependent Variables Measures
79505907|NCT02496936|Other|SFA|High saturated fatty acid/SFA oil source
79355021|NCT03833440|Drug|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
79355022|NCT03833440|Drug|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
79355023|NCT03833440|Drug|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
79355024|NCT03833440|Drug|Savolitinib|"600 mg QD~1 cycle = 28 days"
79355025|NCT01677442|Procedure|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
79355026|NCT01677442|Procedure|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
79355027|NCT01695135|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
79355028|NCT01695135|Drug|Placebo|Placebo (4 tablets) taken orally once daily
79355029|NCT01695135|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
79355030|NCT01610414|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
79505908|NCT02496936|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
79505909|NCT02496936|Other|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
79505910|NCT02496936|Other|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
79505911|NCT02496936|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
79505912|NCT02496780|Drug|novolog insulin|3x daily rapid-acting insulin
79505913|NCT02496780|Drug|levemir insulin|basal insulin once a day
79505914|NCT02496780|Drug|placebo|once or 3x daily
79505915|NCT01953588|Drug|fulvestrant|Fulvestrant 500 mg IM
79505916|NCT01953588|Drug|anastrozole|Anastrozole 1 mg oral tablet
79505917|NCT01953510|Biological|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
79505918|NCT01953510|Biological|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
79990861|NCT01368549|Other|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
79990862|NCT02370550|Drug|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
79990863|NCT02370550|Drug|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
79990864|NCT02370550|Drug|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
79355031|NCT01610414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
79355032|NCT03832114|Drug|LNP023|Increasing doses of LNP023 up to 200 mg.
79505919|NCT02475252|Procedure|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
79505920|NCT02177058|Other|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
79505921|NCT02177058|Other|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
79505922|NCT02174016|Dietary Supplement|Ketogenic diet|
79505923|NCT02456532|Drug|placebo|
79505924|NCT02456532|Drug|Zolpidem CR|
79505925|NCT02456532|Drug|Eszopiclone|
79505926|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
79505927|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
79355033|NCT01564407|Drug|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
79355034|NCT03830944|Diagnostic Test|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
79355035|NCT03830944|Diagnostic Test|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
79355036|NCT03830944|Diagnostic Test|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
79355037|NCT03830944|Diagnostic Test|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
79505928|NCT05578950|Drug|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
79505929|NCT05578950|Drug|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
79505930|NCT05586126|Drug|Sevoflurane|sevoflurane inhalation
79505931|NCT01893996|Drug|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
79505932|NCT01893996|Drug|Placebo|
79667427|NCT00428805|Behavioral|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
79355038|NCT03749902|Drug|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
79667428|NCT00428805|Behavioral|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
79355039|NCT03749902|Drug|Oxytocin|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
79355040|NCT01590771|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
79355041|NCT01590771|Drug|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
79355042|NCT01590771|Drug|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
79355043|NCT01590771|Drug|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
79355044|NCT01590771|Drug|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
79355045|NCT03735940|Other|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
79355046|NCT03830242|Diagnostic Test|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
79667429|NCT00428805|Behavioral|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
79667430|NCT00428805|Behavioral|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
79679652|NCT00518765|Drug|Aliskiren|
79990865|NCT02370550|Drug|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
79990866|NCT02365168|Other|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
79990867|NCT02365168|Other|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
79355047|NCT03830242|Diagnostic Test|B-ultrasonography|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
79505933|NCT02442180|Drug|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
79505934|NCT02442180|Drug|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
79505935|NCT02442180|Drug|placebo|equivalent to G-CSF doses
79505936|NCT01924260|Drug|alisertib|Given PO
79505937|NCT01924260|Drug|gemcitabine|Given IV
79505938|NCT02439762|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
79679653|NCT00518765|Drug|Aliskiren plus placebo|
79679654|NCT00518765|Drug|Aliskiren|
79990868|NCT02365168|Other|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
79355048|NCT04764058|Drug|Tienam 500|Imipenem and cilastatin sodium
79355049|NCT04764058|Device|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
79505939|NCT02439762|Behavioral|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
79505940|NCT02983110|Procedure|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
79667431|NCT00428805|Behavioral|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
79355050|NCT04763824|Behavioral|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
79355051|NCT03638674|Other|DXA + CT|Two dual-energy X-ray scans + CT scan
79355052|NCT03636724|Behavioral|E-intervention|The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
79355053|NCT01563237|Device|MIDI Arrow|Implantation of MIDI Arrow
79355054|NCT03735316|Drug|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
79355055|NCT03735316|Procedure|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
79505941|NCT02983110|Procedure|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
79505942|NCT02983110|Procedure|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
79505943|NCT02432742|Device|Restylane Perlane|Intradermal injection
79505944|NCT02432742|Device|Restylane|Intradermal injection
79667432|NCT00428805|Behavioral|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
79355056|NCT03735316|Drug|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
79355057|NCT01694433|Drug|Calcipotriene|1g daily BID
79355058|NCT01694433|Drug|Placebo|1g daily BID
79355059|NCT01694121|Behavioral|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
79505945|NCT02430558|Biological|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
79505946|NCT05585970|Diagnostic Test|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
79505947|NCT02086500|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
79505948|NCT02086500|Other|Saline control|Saline Control
79505949|NCT04757064|Other|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
79505950|NCT01894386|Drug|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
79355060|NCT01694121|Behavioral|Comparison|general health intervention for men, not inclusive of HIV or relationship health
79355061|NCT03729388|Other|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
79355062|NCT01676662|Device|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
79505951|NCT01894386|Drug|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
79505952|NCT01894386|Drug|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
79667433|NCT03190577|Genetic|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
79667434|NCT03114059|Diagnostic Test|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
79667435|NCT04703127|Drug|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
79355063|NCT01676662|Device|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
79505953|NCT01894386|Drug|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
79505954|NCT02104986|Drug|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
79505955|NCT02104986|Drug|Vepeside-ifosfamide-Cisplatin|
79505956|NCT04757454|Diagnostic Test|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
79505957|NCT01894932|Behavioral|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams & Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
79818345|NCT06239168|Dietary Supplement|Maltodextrin|As described in comparator arm
79990869|NCT02365168|Other|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
79355064|NCT01693185|Drug|Remifentanil|continuous infusion 0.4 mcg/kg/min
79355065|NCT01693185|Drug|Midazolam|bolus injection
79990870|NCT02365402|Drug|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
79355066|NCT01693185|Drug|Meperidine|bolus injection for 30 sec 1.0 mg/kg
79667436|NCT04703127|Drug|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
79355067|NCT01693185|Drug|placebo (for remifentanil)|normal saline mimic diluted remifentanil
79355068|NCT01693185|Drug|placebo (for midazolam)|normal saline mimic to midazolam injection
79355069|NCT01693185|Drug|placebo (for meperidine)|normal saline mimic meperidine injection
79355070|NCT03630640|Drug|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
79355071|NCT03629470|Other|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
79355072|NCT03629470|Other|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
79667437|NCT00428883|Drug|N-acetylcysteine (NAC)|
79818346|NCT06239155|Drug|AST-3424|liquid formulation for Intravenous infusion
79818347|NCT06239129|Drug|Initiation of specific medications|multiple therapies studied within this database
79818348|NCT06239129|Procedure|Undertaking of specific procedures|multiple procedures/surgeries studied within this database
79355073|NCT03629080|Biological|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
79355074|NCT03629080|Biological|placebo|Saline will be used for placebo.
79355075|NCT03628534|Device|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
79355076|NCT03820882|Device|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
79355077|NCT03820882|Device|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
79355078|NCT03815500|Behavioral|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
79355079|NCT03625726|Biological|Thrombin generation assay (in vitro)|One blood sample.
79818349|NCT06239129|Diagnostic Test|Abnormalities in specific laboratory tests|multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database
79818350|NCT06239103|Device|Pulsed electromagnetic field therapy|Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
79990871|NCT02370472|Other|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
79355080|NCT03625024|Behavioral|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
79355081|NCT04403854|Diagnostic Test|MRI|If possible with spectroscopy
79355082|NCT04403854|Procedure|Spinal Tap|together with CSF pressure estimate
79355083|NCT03814954|Drug|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
79355084|NCT03814954|Drug|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
79355085|NCT03813160|Drug|Lenabasum 20 mg|oral capsule
79355086|NCT03813160|Drug|Lenabasum 5 mg|oral capsule
79355087|NCT03813160|Drug|Placebo|oral capsule
79355088|NCT03812848|Other|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
79355089|NCT03619252|Biological|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
79355090|NCT03619252|Drug|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
79818351|NCT06239103|Device|Sham treatment|Sham treatment, using the same PEMF device
79355091|NCT03717142|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
79355092|NCT03807856|Drug|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
79355093|NCT03807856|Other|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
79355094|NCT03807154|Behavioral|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
79355095|NCT03807154|Behavioral|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
79355096|NCT03716284|Procedure|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
79355097|NCT03806530|Drug|Gabapentin|100 mg capsule
79355098|NCT03806530|Drug|Ropinirole|0.50 mg capsule
79355099|NCT03806530|Drug|Placebo Gabapentin|Placebo capsule
79355100|NCT03806530|Drug|Placebo Ropinirole|Placebo capsule
79818352|NCT06239090|Device|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
79818353|NCT06239090|Behavioral|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
79818354|NCT06239077|Other|Non Invasive Prenatal Test via blood sample|Maternal - blood draw, Paternal - blood draw/Saliva sample
79505958|NCT01894932|Behavioral|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
79505959|NCT04757532|Drug|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
79505960|NCT04757532|Drug|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
79667438|NCT03082391|Device|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
79355101|NCT03608020|Drug|BMX-001|Manganese butoxyethyl pyridyl porphyrin
79355102|NCT03608020|Radiation|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
79355103|NCT00003820|Drug|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
79667439|NCT03082391|Device|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
79667440|NCT04702971|Drug|Flunarizine|The flunarizine will be given per clinical routine
79667441|NCT04702971|Other|healthy control|no intervention for healthy control
79667442|NCT02841644|Procedure|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
79355104|NCT01693029|Drug|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
79355105|NCT01693029|Drug|US-licensed epoetin alfa|Solution for subcutaneous injection.
79355106|NCT01589445|Drug|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
79505961|NCT04757532|Drug|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
79505962|NCT04757532|Drug|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
79505963|NCT04757532|Drug|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
79505964|NCT01890954|Device|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
79667443|NCT02841644|Other|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
79667444|NCT00433407|Biological|trastuzumab|
79667445|NCT00433485|Drug|sirolimus|
79667446|NCT00433485|Genetic|comparative genomic hybridization|
79667447|NCT00433485|Genetic|gene expression analysis|
79355107|NCT01589445|Drug|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
79355108|NCT01588509|Drug|Romosozumab|Administered by subcutaneous injection
79355109|NCT01588353|Drug|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
79667448|NCT00433485|Genetic|microarray analysis|
79667449|NCT00433485|Genetic|protein expression analysis|
79667450|NCT00433485|Genetic|proteomic profiling|
79667451|NCT00433485|Other|laboratory biomarker analysis|
79667452|NCT00433485|Other|mass spectrometry|
79667453|NCT00433485|Procedure|biopsy|
79679655|NCT00518765|Drug|Aliskiren plus placebo|
79679656|NCT02939469|Other|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
79679657|NCT00517478|Procedure|Blood Sample|
79679658|NCT02939391|Drug|KW-6356|Oral administration
79355110|NCT01588197|Behavioral|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
79355111|NCT01588197|Behavioral|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
79355112|NCT01588197|Behavioral|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
79355113|NCT01561989|Dietary Supplement|cholecalciferol|Given PO
79355114|NCT01561989|Other|questionnaire administration|Ancillary studies
79355115|NCT01561989|Biological|trivalent influenza vaccine|Given IM
79355116|NCT00004054|Drug|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
79355117|NCT00004054|Drug|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
79505965|NCT02065830|Device|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
79355118|NCT00004054|Drug|etoposide|50 mg/m^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
79355119|NCT00004054|Drug|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
79505966|NCT02064114|Procedure|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
79505967|NCT02064114|Procedure|control group|Followed for a period of 3,6 and 12 months after the procedure.
79667454|NCT02676791|Drug|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
79667455|NCT00429000|Device|thermospot|
79667456|NCT01600079|Biological|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
79667457|NCT00429039|Drug|L-leucyl-L-leucine methyl ester (LLME)|
79355120|NCT00004054|Drug|paclitaxel|135 mg/m^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
79355121|NCT00004054|Drug|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
79355122|NCT00004054|Radiation|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
79505968|NCT04756830|Biological|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
79667458|NCT01370486|Drug|melatonin|melatonin cp 2 mg 1x/d for 1 month
79667459|NCT01370486|Drug|placebo|placebo cp 1x/d for 1 month
79667460|NCT00429078|Genetic|2nd Generation Designer T Cells|
79667461|NCT00433524|Procedure|computed tomography|
79667462|NCT00429117|Behavioral|Survey|Internet survey lasting 30 to 40 minutes.
79667463|NCT00491309|Behavioral|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
79667464|NCT00429156|Device|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
79667465|NCT00429156|Device|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
79667466|NCT00327548|Behavioral|guided imagery|
79667467|NCT00433602|Other|clinical observation|
79667468|NCT00433602|Procedure|management of therapy complications|
79667469|NCT00433602|Procedure|ultrasound imaging|
79667470|NCT00327587|Drug|Valsartan + amlodipine|
79667471|NCT00327587|Drug|Valsartan + HCTZ|
79667472|NCT00327587|Drug|Amlodipine + HCTZ|
79667473|NCT00327587|Drug|Valsartan + amlodipine + HCTZ|
79667474|NCT00429195|Behavioral|Dietary Fatty Acid Modification|
79505969|NCT02063022|Drug|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
79990872|NCT02364934|Drug|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
79505970|NCT02063022|Drug|Intensified chemotherapy|"Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
79505971|NCT02059668|Biological|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
79355123|NCT00004054|Drug|warfarin|To keep international normalized ratio (INR) > 1.5 and < 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
79355124|NCT01587885|Drug|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
79355125|NCT01587885|Drug|Omeprazole 20 mg|Tablets, orally
79355126|NCT01587651|Drug|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
79355127|NCT01587651|Drug|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
79355128|NCT01587651|Drug|Ticagrelor Maintenance Dose|one 90mg film coated tablet
79355129|NCT03800992|Other|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
79505972|NCT01895010|Device|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
79355130|NCT04763434|Drug|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
79505973|NCT01895010|Drug|tropisetron|only tropisetron 6mg before TACE
79505974|NCT02039388|Procedure|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
79505975|NCT04389528|Other|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
79505976|NCT05413356|Drug|Ruxolitinib|Oral ruxolitinib twice daily
79667475|NCT00327665|Biological|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
79355131|NCT04763668|Other|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
79667476|NCT00327665|Biological|Pneumo 23™|Single-dose intramuscular injection.
79667477|NCT00327665|Biological|Placebo|1 intramuscular injection.
79355132|NCT04763668|Other|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
79355133|NCT04747210|Behavioral|contextual one-on-one coaching|Training workshop and coaching one-on-one
79355134|NCT04747210|Behavioral|Trainig workshop|Ten-hour training workshop.
79667478|NCT00327665|Biological|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
79667479|NCT00433641|Drug|sibutramine|placebo
79355135|NCT04762966|Drug|Metformin|Level of Metformin blood concentration
79355136|NCT03602560|Drug|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
79355137|NCT03602560|Drug|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
79667480|NCT00433641|Drug|sibutramine|oral 15 mg sibutramine once per day
79505977|NCT00613860|Device|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
79505978|NCT00603330|Biological|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
79667481|NCT00433641|Drug|sibutramine|oral sibutramine 10 mg once per day
79355138|NCT03602560|Drug|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
79667482|NCT00327704|Drug|albumin|albumin 20% 100 ml/8 hours for 3 days
79667483|NCT00327704|Drug|saline|saline 100 ml/8hours for 3 days
79667484|NCT01050816|Procedure|Chondron(autologous chondrocyte) Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
79355139|NCT03597256|Device|Restylane Defyne|Intradermal injection
79355140|NCT03596788|Dietary Supplement|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
79355141|NCT03596788|Dietary Supplement|Placebo Beverage|The placebo beverage will contain aspartame.
79355142|NCT01691859|Drug|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
79505979|NCT01896336|Drug|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
79505980|NCT04293666|Dietary Supplement|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
79505981|NCT04293666|Dietary Supplement|placebo|Maltodextrin, same calorie as kefir, 200ml/day
79505982|NCT00556218|Behavioral|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
79505983|NCT00556218|Behavioral|No Meditation|No meditation; usual care.
79505984|NCT00532740|Radiation|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
79505985|NCT00530010|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
79505986|NCT00508794|Behavioral|Yoga Group|3 sessions of yoga each week for 6 weeks.
79505987|NCT00508794|Behavioral|Stretching Control Group|3 sessions of stretching each week for 6 weeks
79667485|NCT00327821|Behavioral|calorie controlled diet|
79355143|NCT00779116|Drug|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
79667486|NCT00429234|Drug|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
79667487|NCT00429234|Drug|Gemcitabine|Starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
79667488|NCT00327938|Device|Measuring of skin conductance|
79667489|NCT00327938|Procedure|Tetanic stimuli|
79667490|NCT00433680|Behavioral|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
79667491|NCT00433719|Drug|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
79667492|NCT00328055|Behavioral|AD-Easy (Advance Directive-Easy)|
79818357|NCT06238999|Device|Restoration of non-carious cervical lesions|Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
79818358|NCT06238986|Other|Non-Interventional Study|Non-interventional study
79505988|NCT00508794|Behavioral|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
79505989|NCT00508794|Other|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
79667493|NCT00328055|Behavioral|AD-Standard (Advance Directive-Standard)|
79355144|NCT00779116|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
79355145|NCT03794284|Diagnostic Test|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
79505990|NCT04253652|Other|Fasted breath samples|Will be completed pre and post iron therapy
79667494|NCT04704297|Drug|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
79667495|NCT04704297|Drug|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
79679659|NCT02939391|Drug|KW-6356|Oral administration
79679660|NCT02939391|Drug|Placebo|Oral administration
79818361|NCT06238934|Biological|Bone marrow aspirate matrix|Bone marrow aspirate * Hyaluronic acid
79818362|NCT06238934|Biological|Bone marrow aspirate|Bone marrow aspirate
79505991|NCT04253652|Other|IBS-SSS|Will be completed pre and post iron therapy
79505992|NCT04253652|Other|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
79505993|NCT04253652|Other|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
79505994|NCT02087748|Drug|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
79505995|NCT02087748|Drug|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
79505996|NCT04755738|Combination Product|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
79505997|NCT04755270|Device|VR Glasses|techniques of hypnofertility and VR glasses
79505998|NCT04755504|Diagnostic Test|EEG behind the ear|2 additional electrodes behind each ear will record EEG
79505999|NCT01490502|Drug|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
79506000|NCT02317692|Behavioral|Parent training|
79818363|NCT06238934|Device|Hyaluronic acid|Hyaluronic acid
79370848|NCT04403529|Drug|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
79370849|NCT04354324|Drug|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
79370850|NCT04403373|Behavioral|Waitlist control|waitlist control
79370851|NCT04403373|Behavioral|Moderate-intensity walking exercise|walking exercise
79370852|NCT04403373|Behavioral|Vigorous-intensity walking exercise|walking exercise
79818364|NCT06238908|Drug|NGGT003|Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)
79818365|NCT06238895|Drug|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
79355146|NCT02073435|Behavioral|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~Bowel preparation (e.g. Colace or Golytely)~Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc)~I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
79355147|NCT01676740|Drug|Iron Supplement,|Pills to be swallowed
79355148|NCT01676740|Drug|Placebo|Daily administration of active drug or placebo
79355149|NCT01691781|Drug|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
79355150|NCT04111731|Procedure|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
79506001|NCT01435746|Behavioral|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
79506002|NCT01428024|Device|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
79355151|NCT04111731|Procedure|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
79355152|NCT04111731|Procedure|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
79355153|NCT04111731|Procedure|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
79355154|NCT01561755|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
79506003|NCT01428024|Device|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
79506004|NCT01895790|Device|Pancreatic Duct Stent Placement|
79667496|NCT04704297|Drug|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
79667497|NCT04704414|Device|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
79667498|NCT00328211|Dietary Supplement|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
79667499|NCT00328211|Dietary Supplement|Sphingomyelin|1000mg/day for 19 days
79667500|NCT00328211|Other|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
79506005|NCT01412970|Other|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
79355155|NCT01561755|Drug|Placebo|Placebo - 2gr/kg over 2 days of saline
79355156|NCT03789214|Drug|Placebo oral capsule|Placebo Sleep Medication
79506006|NCT01935414|Device|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
79506007|NCT01935414|Device|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
79506008|NCT01896414|Dietary Supplement|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
79355157|NCT03789214|Drug|Low Dose Suvorexant|Low Dose Suvorexant
79355158|NCT03789214|Drug|High Dose Suvorexant|High Dose Suvorexant
79355159|NCT01585155|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
79355160|NCT04124367|Drug|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
79506009|NCT01896414|Dietary Supplement|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
79506010|NCT01412190|Device|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
79506011|NCT01412190|Other|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
79506012|NCT01895868|Other|Simulation-based ultrasound training|
79506013|NCT02318550|Other|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~Normal operating mode~SAR ≤ 2.0 W/kg per patient."
79506014|NCT02319174|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
79355161|NCT04124367|Device|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
79355162|NCT04124367|Drug|Placebo|100 ml once daily 0.9% saline
79355163|NCT04124367|Device|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
79506015|NCT01393314|Device|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
79506016|NCT01341444|Device|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
79506017|NCT01341444|Other|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
79355164|NCT01560507|Drug|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
79355165|NCT01560507|Drug|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
79355166|NCT01560507|Drug|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
79506018|NCT01331148|Drug|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
79506019|NCT01331148|Other|Placebo|placebo with daily calcium/Vitamin D soft chews
79506020|NCT01311492|Behavioral|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
79506021|NCT01311492|Behavioral|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
79679661|NCT00518804|Behavioral|Functional Behavioural Skills Group and Parent Training|
79679662|NCT02940873|Behavioral|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
79355167|NCT03785470|Other|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
79506022|NCT04969302|Diagnostic Test|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
79506023|NCT01862718|Procedure|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
79506024|NCT01862718|Procedure|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
79506025|NCT01286922|Other|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
79370853|NCT04354636|Drug|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
79370854|NCT04354636|Other|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
79506026|NCT01855464|Procedure|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
79506027|NCT01855464|Procedure|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
79506028|NCT00273624|Drug|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
79506029|NCT00273624|Drug|Placebo|placebo
79506030|NCT00224796|Device|V.A.C. ® System|
79370855|NCT04354090|Drug|JY09|Subcutaneous injection
79370856|NCT04359550|Biological|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
79370857|NCT04359550|Other|placebo|placebo
79370858|NCT04354480|Biological|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
79990873|NCT02364934|Drug|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
79370859|NCT04354480|Other|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
79506031|NCT01253070|Procedure|Biopsy|Undergo biopsy
79506032|NCT01253070|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
79506033|NCT01253070|Drug|Cytarabine|Given IV
79667501|NCT04704180|Behavioral|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
79667502|NCT00433758|Device|GlucoTrack|GT
79370860|NCT03567525|Procedure|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
79370861|NCT03567525|Procedure|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
79506034|NCT01253070|Drug|Daunorubicin Hydrochloride|Given IV
79506035|NCT01253070|Other|Laboratory Biomarker Analysis|Correlative studies
79506036|NCT01253070|Other|Quality-of-Life Assessment|Ancillary studies
79667503|NCT00419978|Procedure|Colectomy|
79667504|NCT01054560|Device|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
79506037|NCT01253070|Other|Questionnaire Administration|Ancillary studies
79667505|NCT01054560|Device|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
79667506|NCT00328250|Behavioral|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
79370862|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
79667507|NCT00328289|Device|transcutaneous muscle stimulation, treadmill|
79667508|NCT00433797|Dietary Supplement|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
79667509|NCT00328367|Drug|aripiprazole|aripiprazole augmentation of clozapine
79667510|NCT00328367|Drug|placebo|placebo
79667511|NCT04703088|Drug|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
79370863|NCT02084511|Drug|BI 1026706|BI 1026706
79370864|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
79506038|NCT01253070|Drug|Sorafenib Tosylate|Given PO
79506039|NCT01252914|Device|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
79506040|NCT01840956|Biological|HAVG|HAVG is implanted into patients' arm.
79506041|NCT02087514|Procedure|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
79506042|NCT02087514|Other|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~1 week~2 weeks~3 weeks~4 weeks~5 weeks~6 weeks"
79506043|NCT01212822|Biological|bevacizumab|Given IV
79506044|NCT01212822|Drug|oxaliplatin|Given IV
79506045|NCT01212822|Drug|leucovorin calcium|Given IV
79506046|NCT01212822|Drug|fluorouracil|Given IV
79506047|NCT01212822|Procedure|therapeutic conventional surgery|Undergo surgical resection
79667512|NCT04703088|Drug|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
79355168|NCT03591328|Diagnostic Test|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
79355169|NCT03694600|Diagnostic Test|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
79355170|NCT03690700|Other|BFRE|BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
79355173|NCT03684538|Other|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
79355174|NCT03684538|Other|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
79355175|NCT03684538|Other|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
79506048|NCT01212822|Other|laboratory biomarker analysis|Correlative studies
79667513|NCT00328445|Behavioral|Positive Action|See publications
79667514|NCT00433875|Drug|AMG 714|
79667515|NCT00328484|Behavioral|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
79355176|NCT03684538|Other|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
79355177|NCT03682978|Drug|Arbaclofen|Arbaclofen tablet.
79355178|NCT03682978|Drug|Placebo|Placebo tablet.
79370865|NCT02084511|Drug|Celecoxib|Celecoxib capsule
79370866|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
79506049|NCT00163566|Drug|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
79506050|NCT04389606|Other|Study Formula (SF)|New infant formula for term infants fed ad lib
79506051|NCT04389606|Other|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
79506052|NCT04705662|Diagnostic Test|Lactulose breath test|Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
79506053|NCT04705662|Other|Stool sample|Participants will provide a stool sample pre and post iron supplementation
79506054|NCT04705662|Other|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis
79506055|NCT04705662|Other|Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire|Participants will complete the questionnaire pre and post iron supplementation
79506056|NCT04705662|Dietary Supplement|Ferrous Sulphate|Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
79506057|NCT04687020|Drug|Viltolarsen|Received during weekly intravenous infusions
79506058|NCT04784286|Other|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
79355179|NCT03676192|Drug|CT-16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
79355180|NCT03676192|Drug|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
79355181|NCT01584843|Drug|GSK1358820|IM injection of Botulinum Toxin Type A
79355182|NCT03580408|Drug|Nivolumab|240 mg
79355183|NCT03580408|Drug|Vinblastin|6mg/m²
79355184|NCT01560429|Procedure|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
79355185|NCT01560429|Procedure|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
79355186|NCT03895593|Other|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
79355187|NCT01582971|Other|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
79355188|NCT04762732|Device|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
79355189|NCT04762732|Device|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
79355190|NCT03766750|Drug|LIMA association|1 coated tablet, oral, once a day.
79355191|NCT03766750|Drug|Tradjenta|1 coated tablet, oral, once a day.
79355192|NCT03766750|Drug|Forxiga|1 coated tablet, oral, once a day.
79355193|NCT03576586|Behavioral|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
79355194|NCT03576586|Behavioral|Attention placebo control|Brief cognitive task plus usual care in the maternity department
79667516|NCT00328484|Behavioral|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
79667517|NCT00429312|Biological|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
79355195|NCT04762810|Drug|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
79355196|NCT04762810|Drug|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
79355197|NCT03674242|Drug|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
79355198|NCT03674242|Drug|Gemcitabine|IV infusion 1000 mg/m2
79355199|NCT03674242|Drug|Carboplatin|IV infusion AUC2
79370867|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
79370868|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
79667518|NCT00328640|Drug|Optimal treatment|
79667519|NCT00328679|Device|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
79667520|NCT00328718|Drug|montelukast (5mg QD)|
79990874|NCT02364856|Device|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
79506059|NCT04784286|Other|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
79355200|NCT04762654|Other|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
79355201|NCT04762108|Other|Standard of care|Patients will be given standard of care as per their clinical needs
79355202|NCT04761952|Drug|azathioprine|daily orally
79355203|NCT04761952|Drug|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
79355204|NCT04761952|Drug|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E&DHA-E; per capsule one at a time, Three times a day.
79355205|NCT03760432|Procedure|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
79355206|NCT03673072|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
79355207|NCT03673072|Drug|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
79355208|NCT03673072|Procedure|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
79355209|NCT03673072|Drug|Adjuvant chemotherapy|Can be selected by Investigator's Choice
79370869|NCT00942448|Other|Placebo s.c.|1 single injection at day of dental surgical extraction
79506060|NCT05391984|Other|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
79506061|NCT05391984|Other|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
79667521|NCT00328718|Drug|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
79667522|NCT00328757|Behavioral|Regular diet as the first postoperative meal|
79506062|NCT04783818|Radiation|Adjuvant Radiotherapy|PMRT
79667523|NCT01054443|Drug|Placebo|Tablet
79667524|NCT01054443|Drug|Lusutrombopag|Tablet
79667525|NCT00328796|Procedure|acupuncture in 6 specific points|
79990875|NCT02372656|Drug|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
79667526|NCT00328796|Drug|lidocaine 10mg/ml|
79667527|NCT01580319|Other|physical exercise|150 minutes per week
79667528|NCT00420134|Procedure|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
79667529|NCT00429390|Behavioral|Ramadan Fasting|
79667530|NCT00420173|Procedure|Laboratory analysis|blood withdrawal
79667531|NCT00429468|Drug|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
79667532|NCT00420251|Drug|Genotropin|
79667533|NCT04702698|Drug|Peposertib|Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
79667534|NCT04702698|Drug|Peposertib|Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
79506063|NCT04783116|Dietary Supplement|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
79506064|NCT04783116|Dietary Supplement|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
79506065|NCT04782960|Drug|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
79506066|NCT04782960|Drug|Placebo|0.9 saline
79506067|NCT01075230|Procedure|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
79506068|NCT04480242|Drug|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
79355210|NCT01677208|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
79355211|NCT01677208|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
79355212|NCT01677208|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
79355213|NCT01690299|Drug|Apremilast|Apremilast 30 mg tablet orally BID
79355214|NCT01690299|Drug|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
79667535|NCT00328835|Procedure|Brief Elevation of IOP|
79667536|NCT00328874|Drug|Coenzyme Q10|
79667537|NCT00429546|Behavioral|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
79355215|NCT01690299|Drug|Placebo tablet|Placebo tablets BID
79355216|NCT01690299|Drug|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
79355217|NCT03570814|Drug|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
79355218|NCT03570814|Drug|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
79667538|NCT00429546|Other|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
79667539|NCT00328913|Drug|5-hydroxytryptophan (food supplement)|
79667540|NCT00433953|Drug|Mycophenolate Mofetil (CellCept)|
79667541|NCT00433953|Behavioral|Dietary Monitoring|
79667542|NCT00433953|Behavioral|Drug Diary|
79667543|NCT00433953|Procedure|Blood Sampling|
79355219|NCT03570814|Drug|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
79355220|NCT03570814|Drug|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
79506069|NCT04480242|Drug|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
79506070|NCT04480242|Drug|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
79506071|NCT04480242|Drug|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
79506072|NCT04480242|Behavioral|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
79667544|NCT02957643|Drug|Iron|oral treatment
79667545|NCT00328991|Device|duct tape occlusion therapy|
79667546|NCT02957604|Drug|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
79667547|NCT00329069|Drug|atorvastatin (drug)|
79667548|NCT00429624|Procedure|Chiropractic manipulation|
79667549|NCT00429624|Drug|acetaminophen|
79667550|NCT00329147|Drug|desvenlafaxine SR|
79667551|NCT00329147|Drug|desipramine|
79667552|NCT00329147|Drug|paroxetine|
79667553|NCT04702503|Drug|WP1220|Topical administration 2x daily for 84 consecutive days
79355221|NCT00723736|Drug|Desloratadine|2.5 ml (1.25 mg) once daily
79355222|NCT00305344|Procedure|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
79355223|NCT00305344|Biological|Cord blood|Develop Cord blood vaccine
79355224|NCT03569566|Other|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
79355225|NCT01690143|Drug|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
79355226|NCT01690143|Drug|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
79355227|NCT05347498|Drug|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
79355228|NCT05347498|Drug|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
79506073|NCT01026012|Drug|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
79506074|NCT02088216|Drug|N-acetylcysteine|600mg po twice a day for 12 months
79667554|NCT00329186|Drug|desvenlafaxine SR|
79667555|NCT00329186|Drug|venlafaxine ER|
79667556|NCT00434031|Drug|docetaxel|
79667557|NCT00434031|Drug|cyclophosphamide|
79667558|NCT00434031|Drug|trastuzumab|
79667559|NCT00434031|Drug|liposomal doxorubicin|
79818366|NCT06238882|Combination Product|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
79355229|NCT05347420|Diagnostic Test|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
79355230|NCT03669250|Drug|CVN058|3-way crossover
79355231|NCT03669250|Drug|Placebos|Placebo
79355232|NCT03553732|Other|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
79506075|NCT02088216|Other|On-demand treatment|receive as-needed therapy
79506076|NCT04782648|Procedure|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
79506077|NCT04782882|Behavioral|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
79506078|NCT01014936|Drug|MSC2156119J|
79667560|NCT00329225|Drug|rosiglitazone|
79667561|NCT01050543|Drug|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
79990876|NCT02372656|Drug|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
79990877|NCT02372656|Drug|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
79667562|NCT01050543|Drug|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
79667563|NCT00329264|Drug|Quetiapine fumarate|
79667564|NCT00329342|Behavioral|Occupational ergonomic training|Adequate postural habits in activities of daily living
79506079|NCT01896180|Drug|ALZ-1101|ALZ-1101 Ophthalmic Solution
79506080|NCT01896180|Drug|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
79990878|NCT03123939|Biological|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
79990879|NCT01368627|Device|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
79990880|NCT02358681|Drug|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
79355233|NCT03668938|Other|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
79355234|NCT03668938|Other|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
79355235|NCT03567850|Behavioral|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
79506081|NCT00981162|Drug|sorafenib tosylate|Given PO
79506082|NCT00981162|Drug|everolimus|Given PO
79506083|NCT00981162|Other|laboratory biomarker analysis|Correlative study
79506084|NCT00981162|Other|pharmacogenomic studies|Correlative study
79667565|NCT04703946|Other|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~Association or not of the AG with sex.~Association or not of the AG with gestational age.~Association or not of the AG with other minor and major malformations."
79667566|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
79667567|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
79990881|NCT02358681|Drug|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
79506085|NCT00981162|Other|pharmacological study|Correlative study
79506086|NCT00960102|Device|cochlear implant|Multichannel Nucleus cochlear implant
79506087|NCT00960102|Device|hearing aid|Phonak hearing aid
79506088|NCT04755894|Drug|HDDO-1756|single dose
79506089|NCT04755894|Drug|HDDO-17561/HDDO-17562|single dose
79506090|NCT04782024|Dietary Supplement|7-Keto 50mg|
79506091|NCT04782024|Dietary Supplement|7-Keto 25mg|
79506092|NCT04782024|Dietary Supplement|Placebo|
79506093|NCT04389762|Dietary Supplement|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
79506094|NCT04346160|Diagnostic Test|Schirmer Test I|Collection of tear fluid
79506095|NCT04755348|Other|Product A|A 4mg nicotine pouch product
79506096|NCT04755348|Other|Product B|A 4mg nicotine pouch product
79506097|NCT04755348|Other|Product C|A 2mg nicotine lozenge product
79506098|NCT04755348|Other|Product D|A 2mg nicotine lozenge product
79506099|NCT04755348|Other|Product E|A 2mg nicotine lozenge product
79506100|NCT04755348|Other|Product F|A 2mg nicotine lozenge product
79667568|NCT00429780|Biological|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
79667569|NCT00329459|Drug|sumatriptan succinate/naproxen sodium|
79667570|NCT00329459|Drug|placebo|placebo to match
79506101|NCT04755036|Other|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
79355236|NCT03668626|Other|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
79355237|NCT01677364|Drug|Oxytocin|Arm - Induction of labour
79355238|NCT03566524|Dietary Supplement|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
79506102|NCT04754958|Device|Immersion in virtual reality using Nordic Neurolab(™) Visual System|In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
79667571|NCT00329498|Drug|L-Ascorbic Acid|
79990882|NCT02358681|Drug|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
79355239|NCT03566524|Dietary Supplement|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
79355240|NCT03563248|Drug|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
79355241|NCT03563248|Drug|Losartan|Losartan is a drug that is used to lower blood pressure
79355242|NCT03563248|Drug|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
79355243|NCT03563248|Radiation|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
79667572|NCT00434187|Drug|ERB-041|
79355244|NCT03563248|Procedure|Surgery|definitive surgical resection
79355245|NCT03663400|Diagnostic Test|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
79355246|NCT04403776|Drug|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
79667573|NCT00329537|Drug|Sargramostim (Leukine)|Self-subcutaneous injection
79667574|NCT00329537|Drug|Placebo|Self-subcutaneous injection
79667575|NCT00429897|Drug|Bendroflumethiazide 2.5mg - 5mg|
79667576|NCT00429897|Drug|Amiloride 20-40mg|
79667577|NCT00429897|Drug|Spironolactone 50-100mg|
79667578|NCT00429897|Drug|Frusemide 20-40mg|
79667579|NCT00429897|Drug|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
79667580|NCT00329576|Biological|Hepatitis B vaccine|
79667581|NCT00429936|Drug|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
79667582|NCT00429975|Drug|levofloxacin|
79667583|NCT00429975|Drug|ceftriaxone|
79990883|NCT02358681|Drug|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
79506103|NCT00909012|Dietary Supplement|high oleic sunflower oil|placebo, which does not provide DHA
79506104|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
79506105|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
79506106|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
79506107|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
79506108|NCT00875004|Biological|epoetin beta|
79506109|NCT00875004|Drug|systemic chemotherapy|
79506110|NCT00875004|Procedure|quality-of-life assessment|
79667584|NCT00329615|Drug|Insulatard, flexpen|
79667585|NCT00430014|Drug|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
79667586|NCT00329654|Procedure|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
79667587|NCT00430053|Genetic|gene rearrangement analysis|
79667588|NCT00430053|Genetic|polymerase chain reaction|
79667589|NCT00430053|Genetic|proteomic profiling|
79667590|NCT00430053|Other|flow cytometry|
79667591|NCT00430053|Other|immunohistochemistry staining method|
79667592|NCT00430053|Procedure|biopsy|
79679663|NCT02940873|Behavioral|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
79990884|NCT03123861|Drug|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
79506111|NCT04781790|Other|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
79506112|NCT05320692|Drug|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
79506113|NCT05320692|Procedure|TACE|TACE Alone.
79506114|NCT01895166|Procedure|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
79355247|NCT04403776|Drug|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
79667593|NCT01056393|Drug|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
79990885|NCT03123861|Drug|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
79355248|NCT03559348|Drug|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
79667594|NCT01056393|Drug|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
79990886|NCT01368705|Dietary Supplement|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
79990887|NCT01368705|Dietary Supplement|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
79506115|NCT01895166|Procedure|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
79506116|NCT04781556|Other|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
79506117|NCT01763580|Drug|Tacrolimus|Oral
79506118|NCT01763580|Drug|Prednisolone|Oral
79506119|NCT04754724|Diagnostic Test|GIMate|Use of GIMate to detect lactose malabsorption
79990888|NCT01368705|Dietary Supplement|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
79506120|NCT04754724|Diagnostic Test|H2 Check|Use of H2 Check to detect lactose malabsorption
79506121|NCT04781010|Device|MRI|MRI pattern in children with Leukodystrophy
79506122|NCT00857922|Other|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
79506123|NCT00826098|Biological|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
79506124|NCT01753830|Device|Durolane|4.5 mL
79506125|NCT01753830|Device|PBS|4.5 mL
79506126|NCT03990948|Other|Blood sampling|Blood sample collection
79506127|NCT01745250|Device|Emervel Lips|Lip treatment of both upper and lower lip
79506128|NCT01745250|Device|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
79506129|NCT00760812|Behavioral|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
79506130|NCT00760812|Behavioral|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
79667595|NCT04716491|Device|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
79506131|NCT01740492|Drug|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
79506132|NCT01740492|Drug|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
79667596|NCT01055106|Drug|GW05|vaginal gel once daily regimen A
79818370|NCT06238856|Drug|SLIT™ Amikacin|Amikacin administered via the Pari LC STAR™ nebulizer.
79818371|NCT06238856|Drug|Placebo|Nebulized saline.
79818372|NCT06238843|Drug|irinotecan|Subjects in the contral arm will receive irinotecan 125mg/m2 IV D1, D8, Q3W in 3-weeks cycles or 150mg/m2 IV D1, Q2W in 2-week cycles
79818373|NCT06238843|Drug|IBI343|IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles
79818374|NCT06238843|Drug|paclitaxel|Subjects in the contral arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles.
79818375|NCT06238817|Drug|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
79818376|NCT06238817|Drug|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
79355249|NCT01679938|Behavioral|primary obesity prevention|"Training of child care providers.~Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
79506133|NCT01740492|Other|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
79506134|NCT04780386|Drug|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
79506135|NCT04780386|Drug|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
79506136|NCT04780308|Procedure|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
79506137|NCT04780854|Drug|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
79506138|NCT04780854|Drug|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
79355250|NCT03541018|Procedure|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
79506139|NCT04780152|Device|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
79667597|NCT01055106|Drug|GW05|vaginal gel once daily regimen B
79355251|NCT04762030|Drug|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
79355252|NCT04761874|Other|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
79355253|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
79355254|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
79355255|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
79355256|NCT01559259|Drug|Ibuprofen|Two caplets of ibuprofen 200 mg
79355257|NCT01559259|Drug|Placebo|Two caplets of placebo
79355258|NCT01679548|Procedure|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
79355259|NCT01679548|Procedure|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
79506140|NCT04780152|Device|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
79667598|NCT01055106|Drug|GW05|vaginal gel once daily regimen C
79667599|NCT01055106|Drug|Metronidazole|vaginal gel 0.75% once daily for 5 days
79667600|NCT00329693|Drug|Norprolac|Placebo
79667601|NCT00329693|Drug|Norprolac|Quinagolide
79667602|NCT00329693|Drug|Norprolac|Quinagolide
79667603|NCT00329693|Drug|Norprolac|Quinagolide
79355260|NCT03538912|Other|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
79667604|NCT00430131|Procedure|Cognitive Orientation to Occupational Performance|
79667605|NCT00430131|Procedure|Contemporary Treatment Approach|
79667606|NCT00329810|Drug|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
79667607|NCT00329888|Procedure|Endoscopic papillary balloon dilatation|
79667608|NCT00329888|Procedure|Endoscopic sphincterotomy|
79667609|NCT00430170|Drug|Dipyridamole|Dipyridamole 2x200mg 7day per os
79667610|NCT00430170|Drug|caffeine|caffeine 4mg/kg iv
79667611|NCT00329927|Biological|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
79667612|NCT00329966|Biological|Surface Antigen, Inactivated, Influenza (form.2006-07)|
79667613|NCT00434265|Behavioral|Physical training|
79667614|NCT00330005|Behavioral|Group Psychotherapy|
79667615|NCT04716530|Other|No intervention is associated with the study.|No intervention is associated with the study.
79667616|NCT00330044|Drug|Premetrexed (Alimta)|
79667617|NCT00330044|Drug|Carboplatin|
79667618|NCT00430326|Drug|Avotermin|
79667619|NCT00330083|Biological|ALK Ragweed Tablet|
79667620|NCT00430365|Drug|lenalidomide|oral drug
79355261|NCT03538912|Other|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
79355262|NCT03537118|Procedure|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
79818377|NCT06238804|Procedure|KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches|A3.1, A3.2, A3.3
79506141|NCT04780152|Drug|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
79506142|NCT01737528|Procedure|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
79506143|NCT04779840|Other|anemia assessment|evaluation of anemia status
79506144|NCT01735656|Device|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
79506145|NCT00644280|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
79667621|NCT00430365|Drug|placebo|oral placebo
79355263|NCT03088306|Drug|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
79667622|NCT00330122|Procedure|fore locked plate|
79355264|NCT03088306|Drug|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
79818378|NCT06238791|Other|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.
79355265|NCT03088306|Drug|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
79355266|NCT03088306|Drug|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
79506146|NCT00641316|Procedure|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
79506147|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
79506148|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
79506149|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
79506150|NCT04779762|Other|Crohn's disease exclusion diet (CDED)|Dietary therapy for Crohn's disease
79506151|NCT04779762|Drug|Ustekinumab Injection [Stelara]|Drug for Crohn's disease
79667623|NCT00330122|Procedure|external radiocarpal fixer|
79667624|NCT00330239|Drug|Paroxetine CR|
79667625|NCT01051557|Other|Laboratory Biomarker Analysis|Correlative studies
79667626|NCT01051557|Drug|Perifosine|Given PO
79667627|NCT01051557|Drug|Temsirolimus|Given IV
79667628|NCT01051557|Procedure|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
79667629|NCT00330278|Drug|Cefazolin|
79667630|NCT00430404|Other|Collaborative care (Intervention)|Structured shared care with treatment protocol & support
79667631|NCT00330317|Drug|letrozole|2.5mg letrozole once-daily
79667632|NCT03270384|Device|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
79667633|NCT00330356|Behavioral|Low Salt Diet versus High salt diet|
79667634|NCT00430443|Drug|Liposomal Annamycin|3-day IV infusion
79818379|NCT06238752|Drug|Apatinib Combined With Tislelizumab and Chemotherapy|apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
79818380|NCT06238739|Other|Control - Standard Strategies for hypothermia prevention|Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
79818381|NCT06238739|Other|Fluid warming before infusion and infiltration|Passive Measures: Patients underwent one-hour preoperative warming with hot air warming blankets at 38°C (100.4°F), operating room (OR) temperature was maintained at a minimum of 21°C (69.8°F), aseptic/antiseptic solutions along with infiltration fluid were all warmed to 38°C (100.4°F), and surgical fields were kept as dry as possible.
79990889|NCT04116645|Other|genital and rectal swab|6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
79818382|NCT06238739|Device|Thermal convection blanket by water flow (Blanketrol)|Blanketrol: Patients underwent continuous intra-operative temperature protection, using a thermal convection blanket by water flow (Blanketrol®) at 40°C (104°F).
79818383|NCT06238739|Device|Conductive fabric electric warming device (HotDog)|HotDog: Patients underwent permanent intra-operative thermal protection measures with conductive fabric electric warming device (HotDog®) at 40°C (104°F).
79990890|NCT01368783|Drug|atazanavir|400 mg/day for 2 days
79355267|NCT03088306|Drug|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
79355268|NCT03088306|Drug|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
79355269|NCT03088306|Drug|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
79355270|NCT03088306|Drug|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
79355271|NCT01672762|Drug|ipragliflozin|oral
79355272|NCT03088384|Drug|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
79355273|NCT01677598|Drug|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
79355274|NCT01676350|Procedure|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
79355275|NCT01677754|Drug|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
79506152|NCT04779996|Diagnostic Test|Laboratory Samples|"After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
79506153|NCT04778202|Diagnostic Test|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
79667635|NCT00330395|Drug|caspofungin acetate|Duration of Treatment 28 Days
79667636|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
79667637|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
79667638|NCT00434382|Drug|Sevoflurane|
79667639|NCT00434382|Drug|Isoflurane|
79667640|NCT00434382|Drug|Desflurane|
79667641|NCT00434382|Drug|Propofol|
79667642|NCT00434382|Drug|Fentanyl|
79667643|NCT00434382|Drug|Sufentanil|
79667644|NCT00434382|Drug|Alfentanil|
79667645|NCT00434382|Drug|Remifentanil|
79667646|NCT00434382|Device|Midlatency auditory evoked potentials|
79667647|NCT00430560|Behavioral|cognitive rehabilitation|computer training
79667648|NCT00430560|Procedure|work therapy|opportunity to work in carefully supervised hospital job
79667649|NCT00430560|Behavioral|work therapy|work therapy
79667650|NCT01054170|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
79667651|NCT01054170|Drug|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
79667652|NCT00330629|Behavioral|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
79667653|NCT00330629|Behavioral|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
79355276|NCT01677754|Drug|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
79355277|NCT01677754|Drug|Donepezil|Stable dose as background medication
79355278|NCT01677754|Drug|Memantine|Stable dose as background medication in combination with AChEIs
79506154|NCT04777968|Drug|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
79667654|NCT00330707|Drug|Bacillus Calmette Guerin and interferon alpha|
79667655|NCT00434460|Behavioral|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
79667656|NCT00330746|Drug|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
79667657|NCT00330746|Drug|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
79667658|NCT00330746|Drug|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
79667659|NCT00330746|Drug|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
79355279|NCT01677754|Drug|Rivastigmine|Stable dose as background medication
79355280|NCT01677754|Drug|Galantamine|Stable dose as background medication
79355281|NCT03419572|Other|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
79355282|NCT01670032|Drug|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
79355283|NCT01670032|Drug|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
79355284|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
79506155|NCT04779606|Drug|Ocular gel|3 drops instilled in the right eye
79355285|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
79355286|NCT03088228|Diagnostic Test|gingival crevicular fluid collection|
79506156|NCT05295654|Other|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
79506157|NCT01722708|Drug|Clindamycin|Oral clindamycin 300 Milligrams*2/Day for a week
79667660|NCT01053741|Biological|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
79667661|NCT01053741|Biological|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
79667662|NCT04702230|Diagnostic Test|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
79667663|NCT00330785|Drug|Amlodipine/Atorvastatin|
79667664|NCT00330824|Drug|antibiotic/steroid combination|1gtt, 4x/d, 15 days
79667665|NCT00330824|Drug|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
79667666|NCT00434538|Device|BST-DermOn|
79506158|NCT01722708|Drug|Metronidazole|Oral metronidazole 500 Milligrams*2/Day for a week
79506159|NCT04779450|Other|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
79506160|NCT04779450|Other|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
79506161|NCT04777890|Other|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
79990891|NCT01368783|Drug|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
79506162|NCT04777890|Other|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
79506163|NCT04777890|Other|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
79506164|NCT04778124|Procedure|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
79667667|NCT00330902|Drug|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
79818384|NCT06238713|Procedure|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
79818385|NCT06238713|Procedure|Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
79990892|NCT01368783|Drug|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
79990893|NCT01368783|Drug|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
79355287|NCT01670500|Drug|Cisplatin|administered intravenously every 3 weeks for 4 doses
79355288|NCT01670500|Drug|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
79355289|NCT01670500|Drug|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
79355290|NCT01678612|Other|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
79355291|NCT03525574|Drug|VX-445|Fixed-dose combination (FDC) tablets (VX-445/TEZ/IVA)
79355292|NCT03525574|Drug|TEZ|FDC tablets (VX-445/TEZ/IVA)
79667668|NCT00330902|Drug|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
79667669|NCT00434616|Procedure|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
79667670|NCT00434616|Biological|saline injection|saline injections
79667671|NCT00430794|Drug|Spironolactone|
79818386|NCT06238700|Dietary Supplement|pregnenolone|Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
79355293|NCT03525574|Drug|IVA|FDC tablets (VX-445/TEZ/IVA)
79355294|NCT03525574|Drug|IVA|IVA tablet
79355295|NCT03418402|Device|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
79667672|NCT00330980|Drug|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
79667673|NCT00330980|Drug|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
79818387|NCT06238700|Other|placebo|Placebo pills are identical-appearing capsules containing cellulose
79818388|NCT06238687|Biological|STRO-002|STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
79990894|NCT01509339|Drug|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
79990895|NCT01371279|Device|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
79990896|NCT03123471|Drug|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
79990897|NCT03123471|Other|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
79990898|NCT02661178|Drug|emodepside (BAY 44-4400)|
79990899|NCT02661178|Drug|placebo|
79990900|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)
79506165|NCT04778124|Procedure|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
79506166|NCT04777812|Diagnostic Test|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
79506167|NCT02316678|Other|No intervention|There is no intervention
79667674|NCT00330980|Drug|Placebo|Participants will receive placebo for 6 months.
79667675|NCT00430833|Drug|candesartan|
79667676|NCT00434655|Procedure|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
79990901|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])
79355296|NCT03418402|Device|Standard insufflator|Standard insufflator
79355297|NCT03087682|Diagnostic Test|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
79506168|NCT03726528|Diagnostic Test|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
79506169|NCT04777578|Other|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
79506170|NCT04754568|Other|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
79355298|NCT03087526|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
79506171|NCT04754568|Other|Role-playing instructional design|60 minute traditional role-playing with standardized patient
79506172|NCT01896492|Drug|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
79506173|NCT04754490|Diagnostic Test|Speech Recognition|Speech Recognition
79506174|NCT01711632|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
79667677|NCT00331058|Procedure|Bronchoscopsy|Healthy and Asthmatic Volunteers
79667678|NCT00331058|Procedure|Prednisolone|Asthmatic Volunteers
79355299|NCT02405260|Drug|TTP399 400 mg|once daily
79667679|NCT00430872|Behavioral|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
79667680|NCT00331097|Drug|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
79667681|NCT00331097|Drug|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
79667682|NCT00331097|Drug|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
79667683|NCT00331097|Drug|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
79667684|NCT00434694|Procedure|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
79667685|NCT00331175|Drug|Peptide YY3-36|
79990902|NCT02370316|Behavioral|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
79990903|NCT02370316|Behavioral|Clinical Structured Treatment|structured case management and symptom-targeted medication
79990904|NCT02372500|Dietary Supplement|Chewing gum|Sugar free chewing gum
79667686|NCT00430911|Drug|Radiotherapy|
79667687|NCT00331214|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
79667688|NCT00331214|Drug|placebo patch|placebo patch replaced every 3-4 days for 6 months
79355300|NCT02405260|Drug|TTP399 800 mg|once daily
79355301|NCT02405260|Drug|Sitagliptin 100 mg|once daily
79355302|NCT02405260|Drug|Placebo|once daily
79355303|NCT03519646|Drug|Eliglustat|"This is a 3-year study and the enrollment time of this study is 24 months.~The participants have to receive the investigational agent, Cerdelga~The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~No need for fasting before use, but can't take with grapefruit juice.~Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
79355304|NCT02984722|Drug|Metformin|
79355305|NCT02402530|Drug|Placebo|Matching placebo administered as intravenous infusion.
79355306|NCT02402530|Drug|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
79818389|NCT06238674|Other|indirect calorimetry and nitrogen balance|"nutrition therapy with energy guided by indirect calorimetry measurements and total protein guided by nitrogen balance with the maximum of 1.3 g/kg/d~, repeated indirect calorimetry if renal replacement therapy was initiated and follow up of urea nitrogen balance after 7 days of intervention to guarantee positive nitrogen balance"
79506175|NCT04756206|Drug|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
79355307|NCT03087370|Other|No intervention|No intervention
79355308|NCT03087292|Other|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
79355309|NCT02401750|Drug|Oxycodone Naltrexone (a)|
79506176|NCT04756206|Drug|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
79506177|NCT04777500|Device|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
79506178|NCT04777188|Procedure|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
79667689|NCT04702074|Drug|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
79355310|NCT02401750|Drug|Oxycodone Naltrexone (b)|
79355311|NCT02401750|Drug|Placebo|Matches both experimental drugs
79355312|NCT02400736|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
79355313|NCT02400736|Other|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
79355314|NCT03086980|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
79818390|NCT06238674|Other|Indirect calorimetry (Standard care nutrition arm)|indirect calorimetry measurements using the Q-NRG+ device will be conducted and urea nitrogen balance were measured . In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry and urea nitrogen balance measurements
79818391|NCT06238661|Diagnostic Test|Urology visit with Risk Calculator and MRI|Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
79355315|NCT03086980|Other|Treatment as Usual|Usual Care will be provided.
79355316|NCT03086668|Procedure|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
79355317|NCT03086668|Procedure|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
79355318|NCT01689519|Drug|Placebo|Placebo supplied as tablets
79355319|NCT01689519|Drug|Vemurafenib|Vemurafenib supplied as tablets
79355320|NCT01689519|Drug|Cobimetinib|Cobimetinib supplied as tablets
79990905|NCT03840447|Behavioral|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
79990906|NCT02372812|Drug|dexamethasone|12 mg of dexamethasone
79355321|NCT01689363|Drug|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
79355322|NCT01689363|Drug|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
79355323|NCT01689363|Drug|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
79667690|NCT04702074|Drug|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
79667691|NCT00434733|Biological|Pandemic influenza vaccine|
79355324|NCT04410471|Diagnostic Test|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
79506179|NCT04745598|Behavioral|Control group: Dental Model|- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
79506180|NCT04745598|Behavioral|Computer-assisted teaching format group|- Patients receive a Powerpoint presentation containing:
79667692|NCT00434772|Drug|glucagon|
79818392|NCT06238648|Procedure|Biopsy|Undergo biopsy
79990907|NCT02372812|Drug|Placebo|
79990908|NCT02365012|Drug|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
79990909|NCT01369017|Drug|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
79990910|NCT01369017|Drug|Placebo|Injection of NS
79990911|NCT01371357|Drug|TEST 1|2.4 g/day of guanidinoacetic acid
79990912|NCT01371357|Drug|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
79990913|NCT01371357|Drug|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
79990914|NCT01371357|Drug|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
79355325|NCT02072421|Procedure|PCI|
79355326|NCT01558635|Device|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
79355327|NCT01558635|Procedure|Mitral Valve surgery|Classic mitral valve surgery was performed
79506181|NCT04745598|Behavioral|Plaque-disclosing group|- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
79506182|NCT04745598|Behavioral|Intra-oral camera group|- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
79506183|NCT04779060|Drug|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
79506184|NCT04779060|Drug|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
79355328|NCT01558635|Device|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
79506185|NCT04779060|Drug|saline|normal saline will be mixed with bupivacaine intrathecally
79506186|NCT04778826|Procedure|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
79667693|NCT04703907|Other|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
79667694|NCT00331253|Procedure|Indocyanine Green-Mediated Photothrombosis|
79667695|NCT00431028|Device|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
79667696|NCT00431106|Drug|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
79228398|NCT02467010|Drug|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
79506187|NCT04777110|Drug|Esketamine|The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
79506188|NCT04777110|Other|Saline|The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
79506189|NCT04776876|Biological|Retifanlimab|Given IV
79506190|NCT04776876|Drug|Telotristat Ethyl|Given PO
79228399|NCT02232555|Drug|Duloxetine|
79228400|NCT02232555|Drug|Placebo|
79355329|NCT01558635|Procedure|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
79355330|NCT00089986|Drug|Intravenous GR270773- Phospholipid Emulsion|
79355331|NCT00089986|Other|Placebo|
79355332|NCT03507946|Device|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
79667697|NCT00431106|Drug|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
79667698|NCT00431106|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
79667699|NCT00331370|Behavioral|GP training and Health Education|
79667700|NCT00431145|Drug|Niacin|
79506191|NCT04776642|Other|Biobank for Left atrial appendage tissue|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
79506192|NCT04776642|Other|Biobank for Blood|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
79667701|NCT00431145|Drug|Niacin+Statin|
79667702|NCT00331487|Drug|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
79667703|NCT00331487|Drug|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
79667704|NCT00431223|Behavioral|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
79667705|NCT00331526|Biological|aldesleukin|
79667706|NCT00331526|Biological|therapeutic autologous lymphocytes|
79667707|NCT00331526|Procedure|adjuvant therapy|
79667708|NCT00331526|Procedure|conventional surgery|
79667709|NCT00435084|Drug|APO866|
79506193|NCT04776642|Other|Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
79506194|NCT01982058|Other|communication intervention|
79506195|NCT01982058|Other|counseling intervention|
79506196|NCT01982058|Other|nutrition intervention|
79667710|NCT00331565|Procedure|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
79667711|NCT00431262|Drug|antabuse (disulfiram)|
79667712|NCT00331604|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
79667713|NCT00331604|Drug|insulin detemir|Injection s.c., 50% of daily dose.
79667714|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
79667715|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
79667716|NCT00435123|Dietary Supplement|Nutritional Supplement ProStat 64 twice a day|
79667717|NCT00435123|Dietary Supplement|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
79667718|NCT04716764|Other|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
79667719|NCT00331643|Drug|ixabepilone|Given IV
79667720|NCT00331721|Drug|Enecadin|Dose escalating
79667721|NCT00331721|Drug|Placebo|Placebo comparator
79667722|NCT00431340|Drug|PXD101|
79667723|NCT00431379|Drug|Tenecteplase|
79667724|NCT00331838|Drug|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
79818393|NCT06238648|Procedure|Biospecimen Collection|Undergo collection of blood samples
79355333|NCT03504124|Other|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
79506197|NCT01982058|Other|questionnaire administration|
79506198|NCT04753944|Dietary Supplement|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
79506199|NCT04753944|Dietary Supplement|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
79506200|NCT01895400|Drug|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
79667725|NCT00331838|Drug|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
79667726|NCT00331838|Drug|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
79355334|NCT03455686|Other|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
79355335|NCT03086824|Device|magnetic resonance-guided focused ultrasound|
79355336|NCT03455140|Drug|PEG- BCT-100|PEGylated recombinant human arginase 1
79355337|NCT03086512|Device|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
79355338|NCT03086512|Device|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
79506201|NCT01895400|Drug|Placebo|Take placebo drug 1T bid po medication for 8 weeks
79506202|NCT04753866|Device|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
79506203|NCT05605626|Other|the better retaining of skills|identify which teaching program has the better retaining of skills
79506204|NCT04753554|Device|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
79506205|NCT04753554|Other|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
79667727|NCT00331838|Drug|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
79667728|NCT03277365|Other|Receive genetic risk information|Risk scores are provided by ResearchKit app.
79667729|NCT00331877|Procedure|family conference with bereavement information leaflet|
79667730|NCT00431418|Drug|Sildenafil|Sildenafil oral solution
79667731|NCT00431418|Drug|Placebo|Placebo solution
79667732|NCT00331916|Drug|quinolone|
79667733|NCT00420368|Dietary Supplement|No food supplement|
79667734|NCT00420368|Dietary Supplement|Food supplement: fortified spread|
79667735|NCT00420368|Dietary Supplement|Food supplement: maize-soy flour|
79667736|NCT00420446|Behavioral|Adjusted diet|
79667737|NCT00331955|Drug|doxorubicin hydrochloride|Given IV
79667738|NCT00331955|Drug|vorinostat|Given orally
79355339|NCT03452878|Behavioral|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
79355340|NCT03501082|Other|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
79355341|NCT03501082|Other|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
79667739|NCT00331955|Other|pharmacological study|Correlative studies
79667740|NCT00331955|Other|laboratory biomarker analysis|Correlative studies
79667741|NCT00331994|Drug|Bacillus clausii|3 bacillus clausii vials/day for one month
79667742|NCT00331994|Drug|Metronidazole|3 Metronidazole tablets/day for one week
79667743|NCT00435240|Behavioral|Paleolithic diet|
79667744|NCT00332033|Drug|Pirfenidone|
79667745|NCT00435279|Drug|Eszopiclone|Eszopiclone 3 mg
79667746|NCT00435279|Drug|Placebo|Placebo
79355342|NCT03501082|Other|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
79355343|NCT03501082|Other|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
79355344|NCT05346640|Device|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
79355345|NCT03086278|Drug|AST-008|AST-008 is a toll-like receptor 9 agonist.
79355346|NCT03086434|Other|Culturally Tailored Intervention|School-based substance use prevention
79355347|NCT03086434|Other|Standard Substance Abuse Education|Class room program
79355348|NCT03497806|Biological|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
79355349|NCT01689207|Drug|Avibactam (AVI)|PART A: AVI IV infusion
79355350|NCT01689207|Drug|Aztreonam (ATM)|PART A: ATM IV infusion
79506206|NCT05272098|Other|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
79506207|NCT05272098|Other|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
79506208|NCT04753476|Biological|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
79506209|NCT04753476|Drug|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
79524773|NCT05768724|Behavioral|control diet|"Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked"
79524774|NCT05768698|Diagnostic Test|Software algorithm|Validation of a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization
79355351|NCT01689207|Drug|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
79355352|NCT01689207|Drug|Placebo|PART A, PART B, PART C: matching placebo IV infusions
79355353|NCT00089284|Drug|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
79355354|NCT00089284|Drug|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
79355355|NCT00089284|Drug|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
79355356|NCT03497104|Other|Surplus blood tests|Surplus blood donation
79355357|NCT01688973|Drug|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
79355358|NCT01688973|Other|Laboratory Biomarker Analysis|Correlative studies
79355359|NCT01688973|Drug|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
79355360|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 72 weeks
79355361|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 48 weeks
79355362|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
79355363|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
79355364|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
79355365|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
79355366|NCT03492658|Drug|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
79506210|NCT05605392|Other|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
79506211|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
79506212|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
79506213|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
79506214|NCT05605314|Other|Cyclosporine|eye drop
79506215|NCT04775940|Procedure|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
79506216|NCT04775940|Procedure|Occlusive collagen membrane|Occlusive collagen membrane
79506217|NCT02089464|Device|NBS-guided rTMS|
79667747|NCT00435279|Drug|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
79667748|NCT00332072|Drug|bimatoprost/timolol fixed combination|
79667749|NCT00431613|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
79667750|NCT00431613|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
79818394|NCT06238648|Procedure|Computed Tomography|Undergo PET/CT and/or CT
79355367|NCT03492658|Drug|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
79506218|NCT02089464|Device|Sham rTMS|
79667751|NCT00431613|Drug|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
79667752|NCT00431613|Radiation|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
79667753|NCT00431613|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
79667754|NCT00435318|Procedure|Iontophoresis|
79667755|NCT00332228|Drug|depot naltrexone|long-acting depot parenteral formulation of naltrexone
79667756|NCT00332228|Behavioral|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
79667757|NCT00332228|Drug|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
79667758|NCT00431691|Drug|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
79667759|NCT00431691|Drug|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
79667760|NCT00431691|Drug|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
79667761|NCT00431691|Drug|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
79667762|NCT00332267|Procedure|Endotoxin infusion, Normobaric hypoxia|
79667763|NCT00435357|Device|mobile-bearing TKA|
79667764|NCT00435357|Device|fixed- bearing TKA|
79667765|NCT00332306|Drug|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients <60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
79667766|NCT00332306|Drug|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients < 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
79667767|NCT00431730|Procedure|flicker light stimulation|
79667768|NCT00332345|Drug|brimonidine/timolol fixed combination|
79506219|NCT02089464|Procedure|Task oriented rehabilitation|
79667769|NCT00435396|Biological|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
79667770|NCT00332384|Drug|brimonidine/timolol fixed combination|
79667771|NCT00435435|Drug|Disulfiram|
79667772|NCT00435435|Drug|Acamprosate|
79667773|NCT00435435|Drug|Naltexone|
79667774|NCT00420485|Drug|gimatecan|
79667775|NCT00435474|Procedure|Wound treatment|wound treatment (silver product, alginate and foam dressing)
79667776|NCT00435474|Procedure|wound treatment|wound treatment (honey product, alginate and foam dressing)
79667777|NCT00435474|Other|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
79667778|NCT00435474|Other|relaxation therapy|relaxation therapy
79818395|NCT06238648|Biological|Epcoritamab|Given SC
79818396|NCT06238648|Procedure|Magnetic Resonance Imaging|Undergo MRI
79818397|NCT06238648|Other|Patient Observation|Undergo observation
79818398|NCT06238648|Procedure|Positron Emission Tomography|Undergo PET/CT
79506220|NCT04775862|Drug|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
79506221|NCT05605158|Drug|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
79506222|NCT05605158|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
79506223|NCT04754880|Diagnostic Test|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
79667779|NCT00332540|Drug|bimatoprost/timolol fixed combination|
79990915|NCT01369173|Other|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
79990916|NCT01369251|Behavioral|Hygiene|
79355368|NCT05347108|Procedure|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
79355369|NCT03086122|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
79355370|NCT03085966|Biological|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
79355371|NCT03085654|Drug|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
79506224|NCT05598762|Genetic|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
79506225|NCT01053234|Dietary Supplement|Standardised meals|
79506226|NCT02090088|Drug|Not applicable- observational study|
79667780|NCT00332618|Device|OXYGENATED GLYCEROL TRIESTERS|
79667781|NCT04704102|Behavioral|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
79667782|NCT04704102|Behavioral|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
79667783|NCT04704102|Behavioral|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
79990917|NCT01369251|Procedure|Usual alcohol care|
79990918|NCT02660944|Drug|RSLV-132|RNase-Fc fusion protein
79990919|NCT02660944|Drug|Placebo|Saline placebo
79990920|NCT01365351|Other|Growth hormone|Drug given by prescription
79990921|NCT02370082|Device|Localization of breast lesion|localization of breast lesion for removal
79355372|NCT03085654|Drug|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
79355373|NCT03085732|Drug|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
79355374|NCT00087568|Drug|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
79355375|NCT00087568|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
79355376|NCT04402762|Drug|Ovine Enoxaparin|The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
79506227|NCT03433170|Procedure|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
79506228|NCT03433170|Procedure|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
79506229|NCT04775238|Other|Silver nanoparticles|AgNPs (19±5 nm)
79506230|NCT04775238|Other|Copper nanoparticles|CuNPs (150-350 nm)
79506231|NCT05595798|Diagnostic Test|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
79506232|NCT01896882|Other|Sodium restriction|
79506233|NCT05580042|Drug|AC-1101|For each patient, once daily (QD)
79667784|NCT00332735|Drug|spinal administration of articaine|
79667785|NCT00332735|Drug|spinal administration of bupivacaine|
79667786|NCT00435552|Procedure|Ease-It Spray|
79667787|NCT00332774|Drug|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
79667788|NCT00332774|Drug|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
79667789|NCT00332774|Other|Nepafenac ophthalmic suspension vehicle|
79818399|NCT06238635|Drug|Dostarlimab|Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
79818400|NCT06238635|Drug|Cobolimab|Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
79818401|NCT06238622|Drug|BI 1015550|BI 1015550
79818402|NCT06238596|Procedure|rehabilitation|The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
79355377|NCT04402762|Drug|Enoxaparin Prefilled Syringe [Lovenox]|The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
79355378|NCT03487900|Diagnostic Test|Colonoscopy|Colonoscopy for CD patients in clinical remission
79355379|NCT00085540|Drug|depsipeptide|Given IV
79506234|NCT04775160|Device|SmartSafe|"The SmartSafe Ecological Momentary Intervention is contained in the MEmind smartphone application and consists of a Safety plan, an Enhanced contact via app (app-EC) intervention, and a mental toolbox. The Safety plan is a set of personalized coping strategies that the patient can use in a suicidal crisis. Our safety plan was adapted to a digital environment, including the possibility to activate pre-recorded messages, lead to websites with health resources, or put the patient in contact with the emergency services. The Enhanced contact via app (app-EC) intervention is inspired by the SIAM project and consists in messages that will be sent via the MEmind app inquiring patients about their mental well-being and informing them of the means to request preferential or urgent care. The mental toolbox contains videos relaxation techniques videos and behavioral activation and mentalization exercises."
79506235|NCT03288480|Drug|PT-112|This is a single arm study
79818403|NCT06238583|Drug|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
79990922|NCT03625245|Other|Control Yogurt|125 g/day
79990923|NCT03625245|Other|Yogurt Variety 1|125 g/day
79990924|NCT03625245|Other|Yogurt Variety 2|125 g/day
79355380|NCT01677676|Biological|FP-01.1|IM injection
79355381|NCT01677676|Biological|FP-01.1-Adjuvant|IM injection
79355382|NCT02984488|Procedure|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
79355383|NCT02984488|Procedure|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
79355384|NCT01688739|Drug|Erenumab|Administered by subcutaneous injection or intravenous injection
79355385|NCT01688739|Drug|Placebo|Administered by subcutaneous injection or intravenous injection
79355386|NCT03085264|Behavioral|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
79506236|NCT01895478|Behavioral|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
79506237|NCT03095742|Diagnostic Test|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
79667790|NCT00431769|Drug|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
79667791|NCT00332813|Behavioral|HIV Risk Behavior Intervention|
79667792|NCT00435630|Other|LapSim training|complete curriculum training on LapSim surgical simulator
79355387|NCT00084838|Biological|filgrastim|
79990925|NCT04894071|Drug|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
79355388|NCT00084838|Drug|cisplatin|
79355389|NCT00084838|Drug|cyclophosphamide|
79355390|NCT00084838|Drug|cytarabine|
79355391|NCT00084838|Drug|dexrazoxane hydrochloride|
79355392|NCT00084838|Drug|doxorubicin hydrochloride|
79355393|NCT00084838|Drug|etoposide|
79355394|NCT00084838|Drug|leucovorin calcium|
79506238|NCT03095742|Diagnostic Test|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
79506239|NCT03094026|Behavioral|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
79667793|NCT00332852|Drug|Letrozole|2.5 mg/day - oraly
79667794|NCT00435669|Drug|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
79667795|NCT00435669|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
79667796|NCT00332891|Drug|SR58611A|
79355395|NCT00084838|Drug|methotrexate|
79355396|NCT00084838|Drug|temozolomide|
79355397|NCT00084838|Drug|therapeutic hydrocortisone|
79355398|NCT00084838|Drug|vincristine sulfate|
79355399|NCT00084838|Radiation|radiation therapy|
79355400|NCT00084838|Drug|Dactinomycin|
79355401|NCT01558089|Drug|etanercept|according to SmPC and clinical practice
79355402|NCT01558089|Drug|methotrexate|according to SmPC and clinical practice
79355403|NCT01581021|Device|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
79355404|NCT01581021|Device|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
79355405|NCT03085342|Diagnostic Test|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
79355406|NCT04410003|Biological|Fecal microbial transplant|Fecal microbial transplant
79355407|NCT00084682|Drug|romidepsin|Given IV
79355408|NCT01556997|Drug|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
79355409|NCT01556997|Drug|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
79355410|NCT01556997|Drug|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
79355411|NCT00082888|Other|Laboratory Biomarker Analysis|Correlative studies
79506240|NCT03094026|Behavioral|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
79506241|NCT04774770|Behavioral|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
79506242|NCT01614990|Drug|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
79506243|NCT01614990|Drug|Placebo|placebo (Powerade®) daily for 7 days.
79506244|NCT05433558|Other|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
79667797|NCT00435708|Behavioral|5 portions fruit and vegetables/day|Participants consume > = 5 portions fruit and veg per day
79667798|NCT00332930|Biological|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
79667799|NCT00332930|Biological|HIV gag-pol antigens and interferon-gamma (IFN-y)|
79667800|NCT00431808|Biological|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
79667801|NCT00431808|Biological|AMA1|50 micrograms of AMA1
79667802|NCT00332969|Drug|Octreotide|
79667803|NCT00333008|Drug|Doxil|
79506245|NCT04774614|Procedure|anterior laminate veneers|VITA ENAMIC multiColor
79355412|NCT00082888|Drug|Tipifarnib|Given PO
79506246|NCT05074134|Drug|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi [14C]-TNP-2092 administered over 60 minutes (± 10 minutes).
79506247|NCT05421546|Dietary Supplement|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
79506248|NCT05390970|Procedure|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
79506249|NCT04773756|Drug|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
79506250|NCT03012984|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
79355413|NCT03482986|Behavioral|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
79506251|NCT03012984|Drug|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
79506252|NCT01574118|Behavioral|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
79355414|NCT04403152|Other|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
79506253|NCT01574118|Behavioral|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
79506254|NCT01574118|Behavioral|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
79667804|NCT00333008|Drug|Cyclophosphamide|
79667805|NCT00333008|Drug|Vincristine|
79667806|NCT00333008|Drug|Prednisone|
79990926|NCT04894071|Drug|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
79990927|NCT02372422|Other|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
79990928|NCT02372422|Other|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
79355415|NCT04403152|Other|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
79355416|NCT03085186|Drug|Crizotinib|
79990929|NCT03550287|Dietary Supplement|Experimental product|10 g/day
79990930|NCT03550287|Dietary Supplement|Placebo product|10 g/day
79355417|NCT03084874|Behavioral|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
79355418|NCT03084952|Drug|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
79506255|NCT01574118|Behavioral|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
79506256|NCT01574118|Behavioral|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
79506257|NCT01574118|Behavioral|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
79506258|NCT01574118|Behavioral|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
79667807|NCT00333008|Drug|Rituximab|
79667808|NCT00333008|Drug|Pegfilgrastim|
79667809|NCT00435747|Drug|PARECOXIB SODIUM|
79990931|NCT02372266|Other|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
79355419|NCT03084952|Drug|Glucantime|Leishmaniasis standard drug in Brazil
79506259|NCT01574118|Behavioral|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
79355420|NCT00082810|Drug|fulvestrant|Given intramuscularly
79355421|NCT00082810|Drug|tipifarnib|Given IV
79355422|NCT04402918|Diagnostic Test|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
79355423|NCT03085108|Other|No Intervention|No Intervention
79355424|NCT01678066|Device|Bilateral cardiac output|
79355425|NCT03445000|Drug|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
79355426|NCT03085030|Drug|Antioxidant Formula|Antioxidant tablet will be taken by the patients
79355427|NCT03085030|Drug|Placebo|The placebo will be taken by the patients
79355428|NCT03444064|Biological|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
79355429|NCT03443128|Drug|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
79506260|NCT04773990|Device|Biodex Balance System|Subjects will receive several unique training modules using biodex
79506261|NCT04773990|Other|specific physical therapy exercise program|Subjects will receive recommended PT program
79506262|NCT05051202|Other|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
79506263|NCT05051202|Other|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
79506264|NCT05290974|Other|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
79506265|NCT05290974|Other|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
79506266|NCT02866344|Procedure|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
79990932|NCT02372266|Other|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
79506267|NCT02866344|Procedure|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
79506268|NCT04773132|Other|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
79506269|NCT01565382|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
79506270|NCT04773444|Behavioral|Eccentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
79506271|NCT04773444|Behavioral|Concentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
79506272|NCT01895556|Other|Information|
79667810|NCT00333047|Drug|Letrozole|
79667811|NCT00431886|Procedure|64 multi-detector computed tomography|
79667812|NCT00333086|Drug|Letrozole|
79667813|NCT00333125|Drug|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
79667814|NCT00333125|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
79667815|NCT00333125|Other|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
79667816|NCT00333164|Drug|Asprin, Cilostazol|
79667817|NCT00333203|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
79818404|NCT06238570|Device|Gavi, Merck® (automated vitrification instrument)|"This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.~The oocytes will be stored in closed cassettes in liquid nitrogen"
79355430|NCT03437746|Drug|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
79506273|NCT01895556|Other|Control|
79506274|NCT02744430|Drug|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
79506275|NCT02744430|Other|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
79355431|NCT03437746|Biological|Blood samples|Blood samples (D0, D1, D2, D3, D4)
79506276|NCT05208138|Device|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
79990933|NCT03293667|Other|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
79990934|NCT01372449|Drug|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but <60 kg, and 6 mg for subjects weighing ≥ 20 kg but < 40kg.
79990935|NCT01372449|Drug|Placebo|
79990936|NCT02369926|Procedure|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
79990937|NCT02369926|Procedure|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
79355432|NCT03084562|Other|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
79506277|NCT05204706|Other|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
79506278|NCT04772976|Other|Observational study, not applicable|Observational study, not applicable
79506279|NCT00054756|Drug|TRH (Thyrotropin Releasing Hormone)|
79355433|NCT03479710|Biological|FMT infusion|Fecal microbiota transplantation via OGD
79355434|NCT01577745|Biological|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
79667818|NCT00333203|Other|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
79667819|NCT01052493|Drug|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
79667820|NCT01052493|Drug|Placebo|0.9% saline
79667821|NCT00333242|Drug|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
79667822|NCT04703634|Procedure|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
79667823|NCT00333281|Drug|tadalafil|
79506280|NCT04772430|Radiation|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
79355435|NCT01678378|Behavioral|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
79355436|NCT03084250|Drug|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
79506281|NCT04772508|Procedure|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
79506282|NCT04772508|Biological|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
79506283|NCT04772508|Drug|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
79506284|NCT01896960|Drug|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
79667824|NCT00435864|Procedure|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
79355437|NCT03084250|Drug|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
79355438|NCT01688037|Drug|NBI-98854|25 mg capsule
79355439|NCT01688037|Drug|NBI-98854|50 mg capsule
79990938|NCT04688541|Device|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
79355440|NCT01688037|Drug|Placebo|
79355441|NCT03084484|Dietary Supplement|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
79506285|NCT02091102|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
79506286|NCT00055692|Biological|bevacizumab|Given orally
79506287|NCT05043012|Device|flexible AIR coil|mpMRI scan
79506288|NCT05043012|Device|endorectal coi|mpMRI scan
79355442|NCT03084484|Procedure|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
79355443|NCT03084406|Other|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
79667825|NCT00333320|Procedure|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
79667826|NCT00333320|Procedure|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
79818405|NCT06238570|Device|Vitrolife system|The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
79990939|NCT04688541|Device|Foley catheter|Foley catheter
79990940|NCT02364622|Device|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
79990941|NCT02364622|Device|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
79355444|NCT03084328|Dietary Supplement|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
79355445|NCT03707314|Procedure|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
79506289|NCT04772352|Drug|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
79667827|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
79818406|NCT06238544|Drug|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
79990942|NCT02364622|Device|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
79506290|NCT04772352|Behavioral|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
79355446|NCT01678534|Drug|Allogenic mesenchymal stem cells from adipose tissue|
79355447|NCT01678534|Drug|Placebo|
79355448|NCT01678690|Drug|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
79355449|NCT01679080|Drug|Zoledronic acid|antiresorptive and calcium and vitamin D
79355450|NCT01679080|Drug|Teriparatide|anabolic and calcium and vitamin D
79355451|NCT01679080|Other|No active treatment|Calcium and vitamin D
79355452|NCT01679158|Device|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
79355453|NCT03083782|Drug|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
79506291|NCT00056472|Drug|Olanzapine|10-20mg/day
79506292|NCT00056472|Drug|Sertraline|150-200mg/day
79667828|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
79667829|NCT00333398|Biological|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
79355454|NCT03083782|Drug|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
79355455|NCT03083782|Drug|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
79355456|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
79355457|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
79355458|NCT03083860|Device|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
79355459|NCT03402334|Behavioral|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
79506293|NCT00056472|Other|placebo|tablet that ressembles sertraline but contains no medication
79506294|NCT00056550|Biological|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
79506295|NCT04752930|Diagnostic Test|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score <20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
79667830|NCT00333476|Drug|MSI-1256F (Squalamine Lactate)|
79667831|NCT00435981|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
79667832|NCT01052103|Drug|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
79667833|NCT01052103|Drug|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
79355460|NCT03087994|Behavioral|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
79506296|NCT04752930|Diagnostic Test|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score <20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
79990943|NCT04666389|Drug|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
79355461|NCT03087994|Behavioral|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
79355462|NCT03083392|Procedure|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
79355463|NCT03083392|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
79355464|NCT03471442|Procedure|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
79355465|NCT03471442|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
79355466|NCT03471442|Drug|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
79355467|NCT03471442|Drug|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
79355468|NCT03471442|Drug|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
79667834|NCT01052103|Drug|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
79667835|NCT00333515|Drug|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
79667836|NCT00333515|Drug|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
79667837|NCT00333554|Dietary Supplement|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
79667838|NCT00333554|Dietary Supplement|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
79667839|NCT00436020|Device|TMS|Transcranial Magnetic Stimulation
79667840|NCT00436020|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
79990944|NCT02364544|Behavioral|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
79355469|NCT01679392|Drug|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
79355470|NCT01679470|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
79667841|NCT00333593|Device|Large pore dialyser|
79990945|NCT02364544|Behavioral|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
79990946|NCT02364544|Behavioral|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
79355471|NCT04279912|Device|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
79355472|NCT03083158|Drug|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
79355473|NCT04277416|Device|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
79355474|NCT03083236|Other|Standard PBI|Standard Parent Based Intervention (PBI)
79355475|NCT03083236|Other|Enhanced|Enhanced Parent Based Intervention (EPBI)
79355476|NCT03082924|Device|Control group|Neither cycle training nor inspiratory muscle training.
79355477|NCT03082924|Device|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
79355478|NCT03082924|Device|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
79506297|NCT04271826|Procedure|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
79506298|NCT04771884|Drug|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
79667842|NCT00333593|Device|Standard dialyser|
79667843|NCT00432081|Drug|indomethacin|
79506299|NCT02538744|Drug|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
79506300|NCT02538744|Drug|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 [placebo], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
79355479|NCT03082924|Device|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
79506301|NCT02538744|Drug|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
79506302|NCT02538744|Drug|Placebo|
79355480|NCT01679704|Dietary Supplement|Food products|
79506303|NCT00060528|Drug|Recombinant Fowlpox-GM-CSF|
79667844|NCT00333632|Drug|Dexmedetomidine|
79355481|NCT04273360|Other|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
79355482|NCT04273360|Other|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
79355483|NCT03083080|Procedure|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
79355484|NCT03083080|Drug|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
79355485|NCT03083080|Drug|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
79370870|NCT02982148|Device|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
79506304|NCT00060528|Drug|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
79506305|NCT00060528|Drug|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
79506306|NCT00060528|Drug|Recombinant Human GM-CSF|
79506307|NCT02255838|Device|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
79667845|NCT00333632|Drug|Propofol|
79667846|NCT00333632|Drug|Midazolam|
79667847|NCT00333632|Drug|Fentanyl|
79667848|NCT00333632|Drug|Isoflurane|
79667849|NCT00436059|Drug|bortezomib|
79667850|NCT00420524|Drug|Patupilone/EPO906|
79370871|NCT02982148|Device|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
79370872|NCT04697758|Drug|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
79370873|NCT04697758|Drug|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
79506308|NCT02255838|Device|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
79667851|NCT00432120|Drug|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
79667852|NCT00436098|Behavioral|Motorpedagogic exercise|physical training
79667853|NCT00432198|Drug|Zolpidem (Myslee®)|Oral
79667854|NCT00432198|Drug|placebo|Oral
79667855|NCT01051986|Procedure|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
79667856|NCT01051986|Procedure|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
79667857|NCT00420563|Drug|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
79667858|NCT00420563|Drug|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
79667859|NCT00432315|Drug|Docetaxel + CDDP|"3 cycles chemotherapy : docetaxel + CDDP~Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~3 cycles adjuvant chemotherapy docetaxel"
79667860|NCT00432315|Drug|docetaxel + CDDP|"3 cycles chemotherapy: docetaxel + CDDP~Radiochemotherapy~3 cycles adjuvant chemotherapy docetaxel"
79667861|NCT00333671|Drug|Glycerol|
79667862|NCT00333749|Biological|Drinking or rinsing the mouth 2-3 times for 1 day|
79667863|NCT00333749|Biological|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
79667864|NCT00432354|Drug|atorvastatin|
79667865|NCT00333827|Drug|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
79355486|NCT03080038|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
79667866|NCT00333827|Procedure|cell|stem cell
79818407|NCT06238518|Procedure|Intravascular Lithotripsy|The size of the IVL balloon catheter is selected in a 1:1 ratio to the distal reference vessel diameter. The balloon catheter is then inflated to 4 atm, and 10 impulses are delivered. Subsequently, the balloon is inflated to 8 atm and then deflated to re-establish blood flow. Up to 100 impulses can be delivered, and the balloon can be repositioned within the lesion. In cases involving multiple lesions with different reference vessel diameters, various sizes of IVL balloons may be employed. If the IVL balloon catheter is unable to pass through the lesion, pre-dilatation can be performed using a smaller diameter noncompliant balloon or rotational atherectomy.
79355487|NCT04761562|Drug|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
79506309|NCT04696224|Drug|Tranexamic acid|The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
79355488|NCT04761562|Procedure|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
79506310|NCT04696224|Other|Saline solution|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
79506311|NCT04690452|Behavioral|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
79667867|NCT03278184|Device|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
79667868|NCT03278184|Device|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
79818408|NCT06238518|Procedure|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
79818409|NCT06238505|Other|Virtual|application will be made with virtual reality device
79818410|NCT06238505|Other|biodex|application will be made with biodex device
79818411|NCT06238492|Behavioral|game-like computerized activities|Experimental
79355489|NCT05346328|Drug|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
79506312|NCT04689438|Diagnostic Test|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
79506313|NCT04688580|Drug|XW10172|Various formulations
79506314|NCT04753008|Drug|Dopamine administration|Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
79355490|NCT03082690|Drug|DuoGel|1% IQP-0528 in gel formulation
79355491|NCT04403230|Procedure|Retreatment of teeth prepared without finish line|Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
79355492|NCT03082300|Drug|naquotinib|Oral
79506315|NCT04771494|Other|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP > 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP < 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
79506316|NCT04771104|Dietary Supplement|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
79506317|NCT00060606|Procedure|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
79506318|NCT00060606|Procedure|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
79506319|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
79506320|NCT00063570|Drug|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
79506321|NCT00063570|Drug|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
79506322|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
79990947|NCT02364544|Behavioral|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
79990948|NCT02364544|Other|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
79990949|NCT01369407|Other|No Intervention|Not an interventional study
79355493|NCT03082768|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two [18F]MNI-968 injections and PET scans.
79355494|NCT03082456|Diagnostic Test|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
79355495|NCT03082456|Diagnostic Test|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
79355496|NCT03082456|Diagnostic Test|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
79355497|NCT04761172|Procedure|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
79370874|NCT04697758|Drug|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
79506323|NCT04770714|Diagnostic Test|Breast MRI|Standard of Care Breast MRI
79506324|NCT04770714|Diagnostic Test|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
79506325|NCT01897038|Drug|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
79818412|NCT06238492|Behavioral|Placebo|game-like computerized activities
79370875|NCT03562455|Other|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
79355498|NCT01679860|Procedure|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
79355499|NCT01679860|Drug|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
79355500|NCT05346952|Drug|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
79506326|NCT01897038|Drug|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
79506327|NCT04770792|Other|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
79355501|NCT03089788|Other|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
79506328|NCT04770792|Other|Mineral trioxide aggregate.|Mineral trioxide aggregate.
79506329|NCT00064038|Drug|dexamethasone|Given orally
79506330|NCT00064038|Drug|lenalidomide|Given orally
79355502|NCT03089788|Other|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
79506331|NCT00064038|Other|placebo|Given orally
79506332|NCT04770558|Other|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
79355503|NCT03089632|Other|Gluten-free diet|One-month gluten-free diet
79990950|NCT02372110|Drug|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
79355504|NCT03081442|Drug|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
79370876|NCT03562455|Behavioral|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
79506333|NCT01960530|Drug|Hydrocortisone granules|Multi-particulate granules
79506334|NCT01960530|Drug|Hydrocortisone Tablet|Standard hydrocortisone tablets
79506335|NCT01960530|Drug|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
79506336|NCT01960530|Other|Dexamethasone|Challenge agent
79506337|NCT01897350|Other|Cardiac magnetic resonance imaging|
79506338|NCT01737060|Device|Reverse total shoulder arthroplasty|
79506339|NCT04389372|Behavioral|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
79506340|NCT04770168|Behavioral|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
79506341|NCT04769934|Device|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
79990951|NCT02372110|Drug|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
79990952|NCT02372188|Other|water|Control
79990953|NCT02372188|Dietary Supplement|caffeine|
79990954|NCT02372188|Dietary Supplement|caffein + homoeriodictyol sodium salt|
79990955|NCT02372188|Dietary Supplement|homoeriodictyol sodium salt|
79506342|NCT01897428|Drug|Test-Bepotastine salicylate 9.64 mg|
79506343|NCT01897428|Drug|Reference-bepotastine besilate 10 mg|
79506344|NCT05606562|Procedure|Dental care|Participants will be offered free dental care
79506345|NCT00067236|Drug|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
79506346|NCT00067236|Drug|Placebo tablet|placebo tablet, twice a day for 90 days
79506347|NCT04753398|Device|Blood Pressure Monitor, medication dispenser, telemonitoring technology|The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
79506348|NCT00007644|Procedure|Radical prostatectomy|Surgical removal of the prostate
79506349|NCT00068718|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
79506350|NCT00024102|Drug|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 & 8 and 5-FU 600 mg/sq m IV push d 1 & 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
79506351|NCT00024102|Drug|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
79506352|NCT05606250|Other|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
79506353|NCT05606016|Behavioral|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
79355505|NCT03081442|Device|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
79355506|NCT04402450|Procedure|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
79506354|NCT05606016|Behavioral|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
79506355|NCT05606016|Behavioral|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
79506356|NCT00074802|Drug|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
79506357|NCT00074802|Behavioral|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
79506358|NCT05605938|Drug|Tenoten for children|Oral administration
79506359|NCT05605938|Drug|Placebo|Oral administration
79506360|NCT00156390|Device|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
79506361|NCT00156390|Other|LV lead placement as per standard of care (without echo guidance)|
79506362|NCT00029172|Other|case management|
79506363|NCT04592562|Device|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
79990956|NCT02369692|Device|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
79667869|NCT03278184|Device|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
79667870|NCT00333905|Procedure|Ischemic exercise training|
79667871|NCT00436137|Behavioral|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
79355507|NCT04402450|Procedure|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
79355508|NCT03089710|Other|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
79355509|NCT03080818|Dietary Supplement|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
79355510|NCT03080818|Other|Placebo|2 placebo capsules per day for 90 days
79667872|NCT04716374|Other|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content [(former tumor cell content (TCC%)] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
79667873|NCT00438009|Drug|Coxsackievirus A21|Two doses of drug, separated by 48 hours
79667874|NCT00333944|Drug|Pralidoxime(drug)|
79667875|NCT04702347|Diagnostic Test|Urine biomarker|Bladder urine samples (> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
79667876|NCT00334022|Drug|enfuvirtide|1ml BID
79667877|NCT04701528|Drug|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
79667878|NCT04701528|Drug|Tacrolimus|Comparator
79667879|NCT00334100|Behavioral|Exercise|Treadmill exercise
79818413|NCT06238479|Drug|LY4101174|Intravenous
79818414|NCT06238466|Drug|AZD1705|Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.
79990957|NCT04652505|Other|Questionnaire Administration|Complete questionnaires
79990958|NCT01371435|Drug|Paroxetine|
79990959|NCT03634449|Device|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
79990960|NCT03634449|Device|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
79990961|NCT01319643|Drug|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
79990962|NCT02975336|Drug|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
79990963|NCT02975336|Drug|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
79990964|NCT02975336|Drug|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
79355511|NCT03080662|Device|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
79355512|NCT03080662|Device|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
79355513|NCT03431194|Drug|midodrine|oral midodrine tablets 5 mg
79355514|NCT03431194|Drug|Placebo|
79355515|NCT03080740|Drug|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
79990965|NCT02975336|Drug|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
79355516|NCT03080740|Drug|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
79355517|NCT03084094|Device|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
79506364|NCT00030264|Drug|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
79506365|NCT00030264|Drug|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
79506366|NCT01897116|Drug|Hydroxychloroquine (HCQ)|
79506367|NCT01897116|Drug|Vemurafenib (VEM)|
79506368|NCT00036738|Drug|Cyclosporine|Given IV or PO
79506369|NCT00036738|Drug|Dasatinib|Given PO
79506370|NCT00036738|Drug|Fludarabine Phosphate|Given IV
79506371|NCT00036738|Drug|Imatinib Mesylate|Given PO
79506372|NCT00036738|Drug|Mycophenolate Mofetil|Given PO
79506373|NCT00036738|Drug|Nilotinib|Given PO
79355518|NCT03464500|Dietary Supplement|Mitopure 500mg|Mitopure containing softgels
79355519|NCT03464500|Dietary Supplement|Mitopure 1000mg|Mitopure containing softgels
79355520|NCT03464500|Dietary Supplement|Placebo|Placebo containing softgels
79355521|NCT03399994|Device|device implantation during coronary angioplasty|device implantation during coronary angioplasty
79355522|NCT04279990|Other|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
79355523|NCT03080584|Other|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
79355524|NCT03089242|Other|observation of microRNA expression|no intervention
79506374|NCT00036738|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
79506375|NCT00036738|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
79506376|NCT00036738|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
79506377|NCT00036738|Radiation|Total-Body Irradiation|Undergo TBI
79506378|NCT00038610|Drug|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
79506379|NCT00038610|Drug|Cyclophosphamide|300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.
79506380|NCT00038610|Drug|Doxorubicin|50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
79506381|NCT00038610|Drug|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
79990966|NCT02975336|Drug|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
79990967|NCT01371513|Other|continuous screening|practice patterns for screening prostate cancer
79990968|NCT02364154|Other|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
79990969|NCT02364154|Other|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
79990970|NCT02369614|Other|Active Comparator: 1 Hz rTMS|1 Hz rTMS
79990971|NCT02369614|Other|Active Comparator: 10 Hz rTMS|10 Hz rTMS
79355525|NCT03089164|Diagnostic Test|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
79355526|NCT04402372|Device|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
79990972|NCT02369614|Other|Sham Comparator:|Sham rTMS
79990973|NCT03124563|Behavioral|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
79990974|NCT03124563|Behavioral|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
79990975|NCT02364232|Behavioral|bilateral training with and without mirror feedback|
79990976|NCT02359396|Drug|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
79355527|NCT03081832|Drug|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
79355528|NCT03081832|Other|Control|Not treated.
79506382|NCT00038610|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
79355529|NCT03081754|Radiation|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
79355530|NCT03081520|Behavioral|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
79355531|NCT03081520|Behavioral|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
79355532|NCT03081520|Behavioral|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
79370877|NCT04359082|Dietary Supplement|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
79506383|NCT00038610|Drug|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
79818415|NCT06238466|Other|Placebo|Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.
79990977|NCT01369719|Drug|osveral|receive 20 mg/kg daily orally
79990978|NCT01369719|Drug|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
79990979|NCT04479046|Other|PMMA crowns|New type of pediatric crowns
79990980|NCT01369797|Other|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
79990981|NCT02369380|Device|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
79990982|NCT02038816|Drug|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for < 14ml/kg/mo pRBCs (~ <4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
79990983|NCT02038816|Drug|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
79990984|NCT04809831|Other|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
79990985|NCT04809831|Other|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
79990986|NCT02359162|Drug|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
79506384|NCT00038610|Drug|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
79667880|NCT04701294|Device|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
79667881|NCT04701294|Device|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
79990987|NCT02359162|Drug|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
79990988|NCT02359162|Drug|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
79990989|NCT02359162|Drug|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
79990990|NCT02359162|Drug|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
79990991|NCT02359162|Drug|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
79990992|NCT02359162|Drug|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
79990993|NCT02359162|Drug|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
79355533|NCT03080506|Device|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
79355534|NCT03394456|Other|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
79355535|NCT03394456|Other|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
79355536|NCT03080350|Drug|Fentanyl sublingual|Fentanyl sublingual
79355537|NCT03080350|Drug|Fentanyl ev|Fentanyl ev
79355538|NCT03080350|Drug|Placebo sublingual|Placebo sublingual
79355539|NCT03080350|Drug|Placebo ev|Placebo - NaCL 0,9% ev
79355540|NCT03080428|Diagnostic Test|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
79506385|NCT00038610|Drug|Mesna|600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
79506386|NCT00038610|Drug|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
79667882|NCT00334139|Drug|Zoledronic Acid|every 4 weeks for 4 months
79667883|NCT00334178|Drug|Laxymig ER (drug)|
79667884|NCT03279978|Drug|BI 730357|BI 730357 film-coated tablet
79990994|NCT02359162|Radiation|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
79990995|NCT03634605|Procedure|Chemical pleurodesis|
79990996|NCT03634605|Drug|Tetracycline Topical Ointment|
79355541|NCT03080194|Drug|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
79355542|NCT03080194|Drug|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
79355543|NCT03080116|Drug|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
79506387|NCT00156936|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
79667885|NCT03279978|Drug|Placebo|Placebo
79667886|NCT03279978|Drug|Midazolam|Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
79667887|NCT00334217|Behavioral|Cognitive Remediation|PSS Cogrehab
79990997|NCT03634605|Drug|Normal saline|
79990998|NCT03634605|Drug|Lidocaine 2% Injectable Solution|
79990999|NCT05653804|Procedure|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
79991000|NCT02363764|Procedure|Nasal swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
79991001|NCT02363764|Procedure|Cough swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
79991002|NCT02363764|Procedure|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~- Expectorating CF patients"
79991003|NCT02363764|Procedure|Induced sputum|"Will be obtained by the physiotherapist in:~Non-expectorating CF patients~Bronchoscopy CF patients"
79991004|NCT02363764|Procedure|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients"
79991005|NCT02363764|Other|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
79991006|NCT03655418|Other|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
79991007|NCT02363842|Device|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
79991008|NCT02363842|Other|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
79991009|NCT02369302|Drug|DWC20141|Tablet
79667888|NCT00438048|Procedure|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
79667889|NCT00438048|Drug|Artificial Saliva|5ml 3 times daily
79667890|NCT00334256|Drug|Tenofovir (TDF)|
79355544|NCT03080116|Drug|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
79355545|NCT03080116|Other|Placebo|4 tablets, per OS
79355546|NCT03081598|Drug|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
79355547|NCT03081598|Other|Placebo|Placebo soft gelatine capsule
79355548|NCT04401670|Other|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt [Hologic, Inc., Bedford, MA, USA] and a visual inspection by acetic acid (VIA) by a nurse.
79355549|NCT04401670|Behavioral|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler [Preventive Oncology International, Cleveland, OH, USA]."
79355550|NCT03088774|Other|Information material|Online web-application developed together with patients with low back pain
79355551|NCT03089008|Other|Eccentric exercises|
79355552|NCT03089008|Other|Stretching exercises|
79667891|NCT00334256|Drug|Emtricitabine (FTC)|
79667892|NCT00438087|Drug|methylprednisolone|methylprednisolone administrated intra and post operatively
79991010|NCT02369302|Drug|DWC20142|Tablet
79991011|NCT02369302|Drug|DWC20141, DWC20142|Tablet
79991012|NCT03079869|Drug|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
79991013|NCT03653936|Device|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
79991014|NCT02363920|Device|HOF|the addition of high oxygen flow to patients breathing spontaneously
79506388|NCT00156936|Drug|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
79506389|NCT00076050|Dietary Supplement|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
79667893|NCT00334334|Biological|Pneumococcal (vaccine)|
79506390|NCT00076050|Dietary Supplement|Placebo|Placebo soy isoflavones
79818416|NCT06238440|Other|Splint and taping methods|"In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape"
79991015|NCT02363920|Device|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
79355553|NCT03081286|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
79355554|NCT03081286|Procedure|Fat graft|The harvested lipoaspirate is injected at the site of pain.
79355555|NCT03081286|Procedure|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
79355556|NCT04279678|Procedure|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
79506391|NCT00046566|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
79667894|NCT00438126|Behavioral|A lifestyle educational program|
79667895|NCT00334373|Procedure|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
79667896|NCT03279939|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
79818417|NCT06238414|Other|Early psychotherapeutic intervention|The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
79818418|NCT06238401|Drug|ACR246 for injection|80 mg/vial
79818419|NCT06238388|Drug|HSK21542 Injection|A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
79991016|NCT03654794|Biological|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
79991017|NCT03654170|Drug|BI 425809 mixed with [C-14] BI425809|Oral Solution
79991018|NCT03000153|Other|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
79370878|NCT04359082|Other|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
79370879|NCT04359316|Drug|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
79370880|NCT04359316|Drug|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
79506392|NCT00046566|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
79506393|NCT00046566|Behavioral|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
79506394|NCT00077922|Drug|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
79506395|NCT01897974|Other|Survey|Families complete survey to measure medication compliance.
79667897|NCT03279939|Device|Color Fundus Photography|Non-contact white light photography.
79667898|NCT03279939|Device|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
79506396|NCT00161382|Behavioral|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
79506397|NCT00161382|Behavioral|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
79506398|NCT00079326|Biological|trastuzumab|Given IV
79506399|NCT00079326|Drug|ixabepilone|Given IV
79506400|NCT00079326|Other|laboratory biomarker analysis|Correlative studies
79667899|NCT03279939|Device|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
79667900|NCT00334412|Drug|Ambisome|
79355557|NCT04402528|Behavioral|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
79355558|NCT01610336|Drug|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
79355559|NCT01610336|Drug|Gefitinib|Gefitinib 250 mg taken once daily
79506401|NCT02187354|Drug|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment & no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) & 28μg/day for the escalated dose after dose step should not be exceeded.
79667901|NCT00334412|Drug|caspofungin|
79667902|NCT00438165|Behavioral|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
79667903|NCT04701879|Other|Spine decompression with core stability exercises|"50 minutes per session~Decompression with core stability on alternate days for 8 visits."
79667904|NCT04701879|Other|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
79667905|NCT00334490|Drug|Sildenafil|12.5 mg Sildenafil once with optional second dose
79667906|NCT00334490|Drug|Sildenafil|12.5 mg orally once with optional second dose
79667907|NCT00334490|Drug|Placebo|Oral Placebo in 5 mls distilled water
79667908|NCT00436176|Behavioral|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
79355560|NCT03086200|Behavioral|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
79355561|NCT05689138|Other|Oral and Fecal Sample Collection|No interventions
79667909|NCT00334529|Drug|Oseltamivir|
79667910|NCT04716218|Procedure|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
79667911|NCT03271281|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
79667912|NCT03271281|Device|PET/CT|Following injection of 68Ga-NODAGA-E[c(RGDyK)]2 the patients will be subjected to whole body PET/CT
79667913|NCT00334568|Drug|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
79667914|NCT00334568|Drug|Placebo|Placebo
79506402|NCT02187354|Other|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
79355562|NCT05685550|Drug|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd*14d,every 21 days until disease progression or adverse reactions that were tolerated.
79506403|NCT01898052|Drug|single anaesthetic drug|inject periarticular tissue of the knee after implantation
79506404|NCT01898052|Drug|multimodal drug injection|inject periarticular tissue of the knee
79506405|NCT00051168|Drug|Travatan|Travoprost (0.004%) 1 drop each eye once daily
79506406|NCT00083382|Drug|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
79506407|NCT00083382|Drug|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
79506408|NCT00083382|Drug|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
79506409|NCT04506840|Other|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
79506410|NCT00167388|Other|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
79667915|NCT03272451|Procedure|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
79991019|NCT02369146|Drug|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
79355563|NCT05689060|Other|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
79355564|NCT05689060|Other|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
79355565|NCT03088696|Other|stimulation|activation of the acupuncture point
79355566|NCT03088696|Other|no stimulation|no activation of the acupuncture point
79355567|NCT01613222|Device|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
79667916|NCT03272451|Procedure|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
79818420|NCT06238349|Drug|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
79991020|NCT02363452|Drug|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
79991021|NCT02939313|Device|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
79355568|NCT03088462|Other|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
79355569|NCT03088462|Behavioral|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
79667917|NCT02273544|Drug|Asasantin ER (new formulation - low)|
79667918|NCT02273544|Drug|Asasantin ER (new formulation - medium)|
79991022|NCT02939313|Device|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
79991023|NCT02939313|Device|sham|sham stimulation
79991024|NCT02363608|Other|standard post surgery care|
79355570|NCT03088462|Behavioral|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
79355571|NCT05345860|Other|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~BRCA positive patients: standard adjuvant chemotherapy + olaparib~BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
79355572|NCT05345860|Other|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
79355573|NCT05345860|Other|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
79355574|NCT05345860|Other|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
79355575|NCT05345860|Other|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
79355576|NCT05345860|Other|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
79355577|NCT03323866|Drug|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
79355578|NCT03323866|Drug|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
79355579|NCT05688670|Procedure|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
79355580|NCT05688670|Procedure|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
79355581|NCT05688670|Drug|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
79506411|NCT00167544|Drug|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
79506412|NCT00167544|Drug|Placebo|Saline
79506413|NCT00167934|Drug|Valproate|Depakote ER 500 mg to 3000 mg taken every night
79506414|NCT00167934|Drug|Placebo|Placebo given at same frequency as Valproate
79667919|NCT02273544|Drug|Asasantin ER (new formulation - high)|
79991025|NCT02363608|Behavioral|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
79506415|NCT00168324|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
79506416|NCT00168324|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
79506417|NCT00168324|Other|Sham Injection|Sham injection on Day 0.
79506418|NCT00084552|Radiation|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
79506419|NCT02091882|Drug|Placebo|Oral placebo-embedded IEM tablet.
79506420|NCT02091882|Combination Product|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
79506421|NCT00085254|Drug|cilengitide|Given IV
79506422|NCT00085254|Drug|temozolomide|Given orally
79991026|NCT02363608|Behavioral|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
79506423|NCT00085254|Radiation|radiation therapy|Undergo radiotherapy
79506424|NCT00085254|Other|laboratory biomarker analysis|Correlative studies
79667920|NCT02273544|Drug|Asasantin ER - commercial formulation|
79667921|NCT00334607|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
79667922|NCT00436293|Drug|Docetaxel|75 mg/m²
79667923|NCT00436293|Drug|Cisplatin|75 mg/m²
79667924|NCT00334646|Drug|Oral GW679769|150mg oral, once daily on days 1-3
79667925|NCT00334646|Drug|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
79667926|NCT04701606|Drug|Artecom® (pyronaridine-artesunate)|"* Participant body weight (Artecom® dose)~≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~≥ 45kg and < 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
79991027|NCT03634137|Drug|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
79991028|NCT03634137|Drug|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
79991029|NCT02358772|Other|thrombolysis in a pre-hospital setting (STEMO concept)|
79355582|NCT05684848|Device|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
79991030|NCT02358694|Dietary Supplement|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
79355583|NCT05684848|Device|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
79355584|NCT03322618|Biological|blood samples|7 tubes of 6 ml (42 ml of blood )
79355585|NCT03390244|Device|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
79355586|NCT04761484|Procedure|Vascular access on admission|PIVC insertion
79370881|NCT03762135|Other|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
79506425|NCT00085254|Other|pharmacological study|Correlative studies
79506426|NCT01897272|Behavioral|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
79506427|NCT00253890|Drug|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
79506428|NCT00253890|Drug|Placebo|1-3 at bedtime
79506429|NCT00254592|Drug|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
79506430|NCT00254592|Drug|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
79506431|NCT00254592|Drug|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
79506432|NCT00254592|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
79506433|NCT00254592|Drug|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
79506434|NCT00254592|Drug|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
79506435|NCT00254592|Drug|Bevacizumab|10mg/kg q 2 wks
79506436|NCT00255684|Biological|graft-versus-tumor induction therapy|
79506437|NCT00255684|Drug|cyclophosphamide|
79506438|NCT00255684|Drug|cyclosporine|
79506439|NCT00255684|Drug|fludarabine phosphate|
79506440|NCT00255684|Drug|mycophenolate mofetil|
79506441|NCT00255684|Procedure|umbilical cord blood transplantation|
79506442|NCT00255684|Radiation|radiation therapy|
79506443|NCT00256776|Drug|Velcade (Bortezomib)|
79506444|NCT00256776|Drug|Thalidomide|
79506445|NCT00256776|Drug|Dexamethasone|
79506446|NCT00257322|Drug|GM-CSF|250ug/m^2 SQ QD with a cap of 500mcg SQ QD
79506447|NCT00258180|Biological|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
79506448|NCT00258180|Drug|cyclophosphamide|Administered IV over 1 hour on days 1-4
79506449|NCT00258882|Biological|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
79506450|NCT01899222|Device|Handheld fundus photography|diagnostic imaging with two types of retina camera
79506451|NCT00176202|Drug|Divalproex Sodium|Divalproex sodium is a mood stabilizer
79506452|NCT00176202|Drug|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
79506453|NCT00176592|Drug|Betaseron|Betaseron 250 micrograms injected SQ every other day
79506454|NCT00176592|Drug|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
79506455|NCT00176826|Procedure|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
79506456|NCT00176826|Drug|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
79506457|NCT00176904|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
79667927|NCT04701606|Drug|Placebo|"* Participant body weight (Placebo dose)~≥ 65kg (Placebo 4 tablets)~≥ 45kg and < 65kg (Placebo 3 tablets)"
79667928|NCT00334685|Drug|[S,S]-Reboxetine + Pregabalin|[S,S]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
79355587|NCT03320668|Other|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
79506458|NCT00176904|Drug|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
79506459|NCT00179478|Drug|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
79506460|NCT02134782|Behavioral|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
79506461|NCT02134782|Other|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
79991031|NCT02358694|Other|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
79667929|NCT00334685|Drug|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
79355588|NCT03366298|Combination Product|Epipen 0.3mg|Epipen 0.3mg auto-injector
79355589|NCT03366298|Combination Product|Emerade 300mcg|Emerade 300mcg auto-injector
79667930|NCT00436371|Drug|Amisulpride|Oral tablets
79506462|NCT00182754|Drug|octreotide acetate|Given subcutaneously
79667931|NCT00334724|Procedure|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
79667932|NCT00334724|Procedure|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
79991032|NCT04473807|Drug|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
79991033|NCT02323659|Drug|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
79355590|NCT03366298|Combination Product|Emerade 500mcg|Emerade 500mcg auto-injector
79370882|NCT03762135|Other|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
79370883|NCT00939796|Device|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
79506463|NCT00182754|Other|placebo|Given subcutaneously
79506464|NCT00183456|Behavioral|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
79506465|NCT00183456|Behavioral|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
79667933|NCT00436410|Biological|colloidal gold-bound tumor necrosis factor|
79667934|NCT00436410|Other|electron microscopy|
79667935|NCT00436410|Other|pharmacological study|
79667936|NCT00436410|Procedure|conventional surgery|
79667937|NCT00334763|Biological|bevacizumab|
79667938|NCT00334763|Drug|carboplatin|
79667939|NCT00334763|Drug|chemoprotection|
79667940|NCT00334763|Drug|paclitaxel|
79667941|NCT00334763|Radiation|radiation therapy|
79667942|NCT00436449|Drug|Avotermin|
79667943|NCT04716062|Procedure|Open or Laparoscopic-assisted Colorectal surgery|Colorectal surgery
79506466|NCT00184548|Drug|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
79506467|NCT00184548|Drug|placebo|placebo
79667944|NCT00436722|Drug|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
79667945|NCT00334880|Drug|NRP104|
79667946|NCT00436761|Biological|anti-thymocyte globulin|
79667947|NCT00436761|Biological|graft-versus-tumor induction therapy|
79991034|NCT02323659|Drug|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
79228010|NCT04184037|Behavioral|Mindfulness meditation delivered via a mobile app|"This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided."
79506468|NCT00085410|Drug|bortezomib|Given IV
79355591|NCT03320512|Behavioral|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
79355592|NCT03320512|Behavioral|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
79355593|NCT03320512|Behavioral|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
79370884|NCT00939874|Drug|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
79506469|NCT00186498|Drug|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
79506470|NCT00186498|Drug|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
79506471|NCT00265200|Drug|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
79506472|NCT00087672|Drug|CC-5013|10 mg orally (2 capsules) daily
79506473|NCT00265512|Behavioral|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
79506474|NCT00265512|Behavioral|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
79506475|NCT00265980|Drug|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
79506476|NCT00265980|Drug|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
79506477|NCT00187200|Device|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
79667948|NCT00436761|Biological|sargramostim|
79667949|NCT00436761|Drug|busulfan|
79667950|NCT00436761|Drug|cyclosporine|
79667951|NCT00436761|Drug|melphalan|
79667952|NCT00436761|Drug|methylprednisolone|
79667953|NCT00436761|Other|flow cytometry|
79667954|NCT00436761|Other|immunologic technique|
79667955|NCT00436761|Other|laboratory biomarker analysis|
79667956|NCT00436761|Procedure|allogeneic hematopoietic stem cell transplantation|
79667957|NCT00436761|Procedure|umbilical cord blood transplantation|
79667958|NCT00436800|Drug|Gemcitabine|1000mg/m² over 10mg/m²/min
79355594|NCT05683522|Other|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
79355595|NCT05683522|Other|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
79355596|NCT05683522|Other|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
79355597|NCT05688514|Device|Innovalve MR system|Innovalve MR system
79355598|NCT03315598|Procedure|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
79355599|NCT05688358|Diagnostic Test|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
79355600|NCT04401124|Other|no intervention|no intervention
79991035|NCT01372527|Other|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
79355601|NCT03364270|Drug|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with [F-18] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
79355602|NCT03364114|Device|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
79355603|NCT03364114|Device|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
79355604|NCT04401514|Device|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
79355605|NCT03082066|Other|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
79355606|NCT04279288|Device|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
79355607|NCT01612676|Drug|FE 202158|
79355608|NCT05424172|Behavioral|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
79355609|NCT05424172|Behavioral|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
79355610|NCT05424172|Behavioral|Stage-II, Groups 1a/2a: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
79355611|NCT05424172|Behavioral|Stage-II, Groups 1b/2b: E-Coaching 4x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
79355612|NCT01869764|Drug|omega-3 fatty acid|Given PO
79355613|NCT01869764|Other|placebo|Given PO
79355614|NCT01869764|Other|laboratory biomarker analysis|Correlative studies
79991036|NCT02358460|Device|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
79991037|NCT02368834|Behavioral|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
79991038|NCT03634059|Drug|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
79355615|NCT05396248|Behavioral|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
79355616|NCT05396248|Behavioral|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
79355617|NCT01842620|Drug|Metformin|Oral antidiabetic agent
79355618|NCT04400266|Drug|B+MEL|Buspirone and Melatonin
79355619|NCT04746742|Procedure|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
79355620|NCT04746742|Procedure|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
79355621|NCT04348162|Other|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
79355622|NCT05658172|Diagnostic Test|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
79370885|NCT04359160|Device|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
79370886|NCT04359160|Other|Questionnaire|Paper questionnaire follow-up, with questions and score
79370887|NCT03557385|Drug|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~Rate of 4 mL/sec, volume of 10 cc (left coronary system)~Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
79506478|NCT00187200|Device|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
79506479|NCT00088218|Drug|Clofarabine|1-hour IV infusion 30 mg/m^2 daily times 5 days (Days 1-5)
79506480|NCT00088218|Drug|Ara-C|20 mg/m^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
79228011|NCT02229279|Device|Teleconsulting|
79506481|NCT00189228|Drug|Xolair|Patients are administered Xolair
79506482|NCT00091260|Drug|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
79506483|NCT00091260|Drug|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
79667959|NCT00436800|Drug|Oxaliplatin|100 mg/m² over 2 hours.
79991039|NCT02358382|Drug|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
79506484|NCT00193128|Drug|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
79667960|NCT00334997|Procedure|endoscopic surgery|
79355623|NCT05658172|Diagnostic Test|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
79355624|NCT05658172|Diagnostic Test|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
79355625|NCT05658172|Other|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
79506485|NCT00193128|Drug|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
79506486|NCT00193128|Drug|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
79506487|NCT00193128|Radiation|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
79506488|NCT00193596|Drug|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
79506489|NCT00193596|Drug|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
79506490|NCT00193596|Drug|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
79506491|NCT00193596|Drug|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
79667961|NCT00334997|Procedure|laser surgery|
79667962|NCT00334997|Radiation|radiation therapy|
79667963|NCT00436839|Drug|Docetaxel|75mg/m² intravenously (day 1) every 21 days
79667964|NCT00436839|Drug|Mitoxantrone|12mg/m² intravenously every 21 days
79667965|NCT00436839|Drug|Prednisone|10mg orally given daily
79667966|NCT00335036|Device|ICD lead implant|Randomization of ICD lead type at implant
79667967|NCT00335036|Device|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
79667968|NCT00436878|Behavioral|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
79667969|NCT00335075|Drug|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
79667970|NCT00335075|Drug|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
79667971|NCT00436995|Drug|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
79667972|NCT00437190|Device|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
79667973|NCT00437190|Device|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
79506492|NCT00193596|Drug|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
79506493|NCT01899378|Dietary Supplement|Lactobacillus reuteri DSM 17938|10^8 CFU
79506494|NCT01899378|Dietary Supplement|Bifidobacterium longum infantis|10^9 CFU
79355626|NCT05687656|Device|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
79355627|NCT04746664|Behavioral|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
79355628|NCT03359356|Drug|Dupilumab|A total of 24 doses
79355629|NCT03359356|Drug|Placebo|A total of 24 doses
79355630|NCT05687422|Procedure|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
79355631|NCT05687422|Procedure|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
79355632|NCT04760704|Biological|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
79355633|NCT01931839|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
79355634|NCT01931839|Drug|Ivacaftor|Film-coated tablet, oral use
79355635|NCT01842308|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
79355636|NCT01842308|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
79355637|NCT01842308|Drug|Carfilzomib|Given IV
79355638|NCT01842308|Other|Laboratory Biomarker Analysis|Correlative studies
79355639|NCT01842308|Drug|Melphalan|Given IV
79506495|NCT01899534|Other|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
79355640|NCT01931059|Drug|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
79355641|NCT01931059|Other|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
79355642|NCT01841762|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
79355643|NCT03301636|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
79355644|NCT03301636|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
79355645|NCT03301636|Drug|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
79355646|NCT01841060|Procedure|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
79355647|NCT04414592|Other|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
79355648|NCT04602494|Drug|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
79355649|NCT04602494|Drug|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
79370888|NCT03557385|Drug|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
79506496|NCT00091962|Behavioral|Psychoeducation; Treatment recommendations|Counseling program
79506497|NCT00091962|Drug|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
79506498|NCT00091962|Other|Usual Care|Physicians' Usual care
79506499|NCT00194532|Drug|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
79506500|NCT00194532|Drug|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
79667974|NCT04716179|Diagnostic Test|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
79991040|NCT03633981|Other|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~right and left pupillometry (3 times)~BIS values~right and left NIRS values~right and left transcranial Doppler~neurological clinical examination"
79355650|NCT03379402|Other|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
79355651|NCT04587050|Diagnostic Test|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
79355652|NCT04587050|Diagnostic Test|Cervical cytology|Cervical cytology
79355653|NCT04587050|Diagnostic Test|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
79355654|NCT04414904|Other|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
79355655|NCT05627518|Drug|Linaprazan glurate|100 mg
79355656|NCT01814696|Device|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
79355657|NCT01970371|Drug|plazomicin|
79667975|NCT04716179|Diagnostic Test|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
79991041|NCT03633981|Other|neurological assessment when a neurological event occurs|"next neurological event:~seizures~pupillary asymmetry~myoclonias~brain stem reflex abnormalities~osteotendinous reflex abnormalities"
79667976|NCT04716179|Diagnostic Test|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
79991042|NCT03633981|Other|mortality assessment|to 28 days
79991043|NCT02358304|Drug|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
79991044|NCT02358304|Drug|Placebo|
79991045|NCT02363218|Radiation|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
79991046|NCT01319955|Biological|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
79991047|NCT02363530|Device|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
79991048|NCT02363530|Device|BSS|Balanced Salt Solution including normal saline and glucose
79991049|NCT02363140|Other|Will undergo a single MRI assessment with intravenous dye|
79991050|NCT02363140|Other|pre and post surgery MRI scan|
79991051|NCT02362906|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
79355658|NCT01970371|Drug|colistin|
79355659|NCT01970371|Drug|meropenem|
79355660|NCT01970371|Drug|tigecycline|
79355661|NCT01970371|Drug|antibiotic of Investigator's choice|
79355662|NCT03300466|Device|GP0045|Hyaluronic acid gel
79506501|NCT00194610|Drug|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
79506502|NCT00194610|Other|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
79506503|NCT00093756|Radiation|3-dimensional conformal radiation therapy|
79506504|NCT00093756|Drug|bortezomib|Given IV
79355663|NCT03300466|Device|Comparator|Hyaluronic acid gel
79370889|NCT03557385|Device|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
79370890|NCT03557385|Device|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
79370891|NCT03528213|Drug|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
79506505|NCT00093756|Drug|paclitaxel|Given IV
79506506|NCT00093756|Drug|carboplatin|Given IV
79667977|NCT04716179|Other|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
79667978|NCT00437229|Drug|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
79667979|NCT00437229|Drug|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
79667980|NCT00437229|Drug|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
79667981|NCT00335192|Drug|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
79818421|NCT06238349|Other|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
79818422|NCT06238349|Other|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
79818423|NCT06238349|Other|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
79991052|NCT02362906|Drug|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
79355664|NCT01868594|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
79991053|NCT02362906|Drug|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
79991054|NCT02362906|Drug|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
79506507|NCT04389138|Other|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
79506508|NCT04145154|Other|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
79667982|NCT00335192|Drug|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
79667983|NCT00335192|Drug|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
79991055|NCT02362906|Drug|second generation cephalosporin|
79991056|NCT02362906|Drug|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
79991057|NCT02362906|Drug|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
79991058|NCT02368912|Drug|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
79991059|NCT02368912|Drug|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
79228012|NCT02229357|Biological|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
79355665|NCT01868594|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
79355666|NCT03300232|Behavioral|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
79355667|NCT05686876|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
79228013|NCT02224521|Drug|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
79667984|NCT00437307|Drug|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
79667985|NCT00335231|Drug|gatifloxacin ophthalmic (ZYMAR)|
79991060|NCT02368912|Drug|ASP1707 single dose fasted|Oral, healthy young male
79991061|NCT02368912|Drug|ASP1707 single dose fed|Oral, healthy young male
79991062|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
79991063|NCT02368912|Drug|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
79667986|NCT00437346|Procedure|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
79355668|NCT01616953|Biological|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
79355669|NCT01616953|Procedure|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
79667987|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
79667988|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
79991064|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
79355670|NCT05619718|Behavioral|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
79355671|NCT05619718|Other|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
79355672|NCT03293524|Genetic|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
79506509|NCT04118556|Biological|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
79991065|NCT02368912|Drug|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
79991066|NCT02368912|Drug|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
79991067|NCT02368912|Drug|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
79991068|NCT03160144|Procedure|open lung approach|
79667989|NCT00335270|Drug|fos-amprenavir calcium, ritonavir|
79667990|NCT00335270|Drug|abacavir/lamivudine as Epzicom|
79667991|NCT00437385|Drug|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
79991069|NCT04059796|Device|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
79991070|NCT04059796|Device|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
79991071|NCT02362984|Drug|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
79991072|NCT02362984|Drug|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
79991073|NCT02362750|Other|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
79991074|NCT02362750|Other|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
79818424|NCT06238336|Drug|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
79355673|NCT03293524|Drug|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
79506510|NCT04118556|Drug|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
79506511|NCT00267696|Drug|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
79506512|NCT00267696|Drug|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
79506513|NCT00267696|Drug|Carboplatin|
79506514|NCT00267774|Device|Fractional flow reserve|
79506515|NCT00267774|Procedure|Angio-guided PCI|
79506516|NCT00195624|Biological|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
79667992|NCT00437385|Procedure|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
79667993|NCT00437385|Behavioral|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
79818425|NCT06238323|Behavioral|LAFIYA|LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
79818426|NCT06238310|Diagnostic Test|Comparison of two external marker substance for measuring glomerular filtration rate|Two external marker substance compares for measuring GFR.
79355674|NCT01867658|Device|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
79355675|NCT05613946|Drug|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
79355676|NCT05613946|Drug|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
79506517|NCT00195624|Drug|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
79506518|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
79506519|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
79506520|NCT00195702|Drug|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
79506521|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
79228014|NCT02224521|Drug|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
79228015|NCT02224521|Drug|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
79228016|NCT02224521|Drug|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
79506522|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
79667994|NCT00335309|Procedure|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
79667995|NCT00335309|Drug|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
79355677|NCT05613946|Drug|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
79667996|NCT00437424|Drug|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
79667997|NCT00335348|Drug|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
79667998|NCT00335348|Drug|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
79355678|NCT04401046|Other|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
79667999|NCT00435903|Device|Palm Pilot|
79668000|NCT00334919|Behavioral|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
79668001|NCT00437463|Drug|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
79668002|NCT00420602|Dietary Supplement|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
79668003|NCT00437502|Biological|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
79991075|NCT02362750|Other|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
79355679|NCT03375892|Other|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
79355680|NCT03375892|Other|Free breathing during radiation|The patient will be instructed to breathe freely.
79355681|NCT01867580|Device|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
79818427|NCT06238284|Other|no intervention|Since it is a retrospective study, no intervention is needed.
79991076|NCT02362750|Other|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
79355682|NCT01867580|Device|V.A.C.Ulta without instillation|NPWT only
79355683|NCT05686720|Drug|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10^6 cells, then increased to 5.0×10^7 and 2.0×10^8 cells. The infusion is given every 2 weeks.
79355684|NCT04414982|Behavioral|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
79355685|NCT04414982|Behavioral|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
79506523|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
79506524|NCT00196716|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
79506525|NCT00197184|Biological|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
79506526|NCT00197184|Biological|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
79506527|NCT00198042|Procedure|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
79506528|NCT00201240|Biological|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10*6/kg and CD3+ < 1 x 10*5/kg
79506529|NCT00098670|Biological|alemtuzumab|Given SC
79506530|NCT00098670|Biological|rituximab|Given IV
79506531|NCT00098670|Drug|fludarabine phosphate|Given IV
79506532|NCT04098588|Behavioral|BEAST|See Arm Description
79668004|NCT00437502|Biological|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
79668005|NCT00420680|Drug|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
79668006|NCT00420680|Drug|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
79228017|NCT02224521|Drug|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
79228018|NCT02224521|Drug|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
79228019|NCT01944800|Drug|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
79355686|NCT04400734|Other|No intervention, observational study|no intervention
79355687|NCT05604742|Drug|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
79355688|NCT03290326|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
79370892|NCT03528213|Drug|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
79370893|NCT03528213|Drug|Normal saline|normal saline at physician discretion
79370894|NCT05620030|Other|Univentricular Heart|Prevention of complications when discovered
79370895|NCT03758001|Drug|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
79370896|NCT03758001|Drug|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
79506533|NCT04098588|Behavioral|Descriptive Feedback|See Arm Description
79506534|NCT00100230|Drug|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
79506535|NCT00201864|Drug|Exemestane|25 mg orally per day
79506536|NCT00201864|Drug|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
79506537|NCT00202722|Drug|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
79506538|NCT00100698|Drug|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
79668007|NCT00420680|Drug|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
79668008|NCT04701567|Diagnostic Test|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
79668009|NCT00420719|Device|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
79370897|NCT03758001|Drug|Sintilimab|200mg iv infusion day 1 of every 21 days
79506539|NCT00100698|Drug|placebo|placebo subcutaneously once a day, 18 months
79506540|NCT00103116|Biological|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
79506541|NCT00205374|Drug|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
79506542|NCT00205374|Drug|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
79506543|NCT00103194|Drug|lapatinib ditosylate|Given PO
79506544|NCT00103194|Other|laboratory biomarker analysis|Correlative studies
79506545|NCT00277446|Drug|Soy isoflavones|
79506546|NCT00278538|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
79506547|NCT00208026|Drug|Pimecrolimus 1% Cream|Open label single arm
79668010|NCT00437541|Device|Insulation retrofitted into house|
79506548|NCT00208494|Device|Total Hip Replacement|Total hip replacement
79506549|NCT00208494|Device|Total hip replacement|Total hip replacement
79506550|NCT00106392|Drug|Tacrolimus|oral
79506551|NCT00106392|Drug|Placebo|oral
79506552|NCT00211692|Drug|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
79668011|NCT00420758|Dietary Supplement|Food supplement: fortified spread|Provision of fortified spread
79668012|NCT00420758|Dietary Supplement|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
79668013|NCT00437580|Drug|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
79668014|NCT00420797|Drug|10% Phenylephrine hydrochloride gel|
79668015|NCT00437619|Drug|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
79668016|NCT00420836|Drug|Tobramycin|
79668017|NCT00437697|Drug|dalteparin|
79668018|NCT00335426|Procedure|Spinal manipulative therapy|
79668019|NCT00437736|Drug|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
79228020|NCT01944800|Drug|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/> 75 years or < 60 kg
79228021|NCT03617367|Biological|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
79228022|NCT02470676|Device|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
79228023|NCT02470676|Drug|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
79355689|NCT05300776|Diagnostic Test|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion<1%, columnar epithelial cell proportion <5% .~Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils > 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
79355690|NCT03351556|Behavioral|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
79355691|NCT03351556|Behavioral|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
79355692|NCT03350386|Drug|FYU-981|Single administration
79355693|NCT03350386|Drug|Oxaprozin|Repeated administration
79370898|NCT05346861|Drug|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
79506553|NCT00211692|Drug|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
79506554|NCT01899690|Drug|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
79506555|NCT04378140|Other|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
79506556|NCT01897584|Other|inverse IE|in only one group changes of I:E ratio would be applied
79506557|NCT01899846|Drug|Hydroxyprogesterone caproate 250 mg/ml|
79506558|NCT00214890|Drug|Tenofovir|300 mg once daily
79506559|NCT00214890|Drug|Abacavir|600 mg once daily
79506560|NCT00216060|Drug|Risedronate|Daily oral risedronate combined with androgen deprivation
79506561|NCT00216060|Drug|Placebo|Daily oral placebo combined with androgen deprivation
79506562|NCT00106938|Device|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
79506563|NCT00106938|Procedure|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
79506564|NCT02100072|Device|Nd:YAG 1440 nm laser|
79506565|NCT00110136|Drug|St. John's Wort|St. John's Wort 300mg tablet three times per day
79506566|NCT00282282|Drug|tacrolimus|Given orally just prior to and following stem cell transplant
79506567|NCT00282282|Drug|sirolimus|Given orally just prior to and following stem cell transplant
79506568|NCT00282282|Drug|fludarabine|Given once daily over 30 minutes for 4 days
79506569|NCT00282282|Drug|busulfex|Given intravenously over 3 hours for 4 days
79506570|NCT00282672|Device|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
79506571|NCT00282672|Device|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
79506572|NCT00282828|Drug|Sertraline|
79506573|NCT00282828|Drug|Venlafaxine|
79506574|NCT00282828|Drug|Placebo|
79506575|NCT00282828|Drug|Clonazepam|
79506576|NCT00112242|Biological|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
79506577|NCT00112242|Biological|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
79668020|NCT00335465|Drug|Insulin glargine|once a daily, sc injection, 100IU/ml
79668021|NCT00335543|Drug|cisplatin|
79668022|NCT00335543|Drug|gemcitabine hydrochloride|
79668023|NCT00335543|Procedure|adjuvant therapy|
79668024|NCT00335543|Procedure|conventional surgery|
79668025|NCT00335543|Procedure|neoadjuvant therapy|
79668026|NCT00335543|Radiation|radiation therapy|
79668027|NCT00437814|Drug|Ketamine, effect on intracranial pressure|
79818428|NCT06238271|Device|Acriva BB UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
79506578|NCT00112242|Biological|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
79506579|NCT00112242|Biological|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
79506580|NCT00112242|Biological|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
79506581|NCT00284154|Drug|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
79506582|NCT01899924|Behavioral|Event Related Potentials recording|
79668028|NCT00335582|Drug|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
79668029|NCT00437853|Drug|Anastrozole|
79668030|NCT00335621|Drug|Inhaled Tiotropium|
79668031|NCT00437892|Drug|atorvastatin|tablets, 40 mg day, 3 months
79668032|NCT00437892|Drug|atorvastatin|tablets, 40 mg once daily
79668033|NCT00437892|Behavioral|diet|daily
79668034|NCT00437892|Behavioral|diet|daily diet
79370899|NCT05346861|Drug|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
79668035|NCT00335660|Drug|AV608|
79668036|NCT00437970|Drug|Pioglitazone|15mg of Pioglitazone taken orally twice a day
79668037|NCT00437970|Drug|Metformin|500 mg of Metformin taken orally twice a day
79668038|NCT00335699|Drug|Rosuvastatin|
79668039|NCT03279003|Device|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
79668040|NCT04716140|Procedure|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion > grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
79668041|NCT00335855|Device|Auto-injector for IM/SC vaccine administration|
79668042|NCT00335894|Drug|hMG-IBSA|
79668043|NCT00335933|Drug|Gabapentin extended-release tablets|
79668044|NCT00336011|Device|Magnetic resonance imaging|
79668045|NCT03270111|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
79370900|NCT04358614|Drug|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
79370901|NCT01670409|Radiation|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
79370902|NCT01670409|Drug|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
79370903|NCT05619562|Diagnostic Test|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
79370904|NCT04761705|Drug|JV-GL1|Experimental Treatment
79370905|NCT04761705|Drug|Latanoprost 0.005% Ophthalmic Solution|Active Control
79370906|NCT04358692|Device|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
79370907|NCT04403217|Other|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
79370908|NCT04358926|Device|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
79370909|NCT04358770|Drug|Clocortolone Pivalate|Cream, 0.1%
79370910|NCT04402983|Other|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
79370911|NCT04564300|Procedure|Training|Both groups will perform a standardized training protocol
79370912|NCT04525144|Drug|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
79506583|NCT00223236|Drug|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
79668046|NCT03270111|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
79355694|NCT04761016|Other|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
79355695|NCT04761016|Other|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
79355696|NCT04279444|Dietary Supplement|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
79506584|NCT00223236|Drug|Placebo|Placebo matching active medication in all other aspects.
79506585|NCT00223704|Drug|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
79506586|NCT00223704|Drug|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
79506587|NCT00223704|Drug|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
79506588|NCT00224952|Other|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
79506589|NCT00225420|Drug|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
79506590|NCT00225420|Drug|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
79506591|NCT00225420|Radiation|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
79668047|NCT03270111|Behavioral|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
79668048|NCT03270111|Behavioral|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
79668049|NCT00336089|Behavioral|exercise intervention|
79668050|NCT00336089|Other|educational intervention|
79668051|NCT00336089|Procedure|complementary or alternative medicine procedure|
79668052|NCT00336089|Procedure|fatigue assessment and management|
79668053|NCT00336089|Procedure|management of therapy complications|
79668054|NCT00336089|Procedure|pain therapy|
79668055|NCT00336089|Procedure|quality-of-life assessment|
79668056|NCT00336167|Drug|bezafibrate (drug)|
79668057|NCT00336206|Drug|Alemtuzumab|
79668058|NCT00347334|Behavioral|infant home positioning|
79991077|NCT02362750|Other|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
79991078|NCT02362750|Other|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
79355697|NCT03371056|Biological|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
79355698|NCT05345548|Diagnostic Test|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
79355699|NCT03283462|Dietary Supplement|Mitopure|Mitopure (Urolithin A) containing softgels
79355700|NCT03283462|Dietary Supplement|Placebo|Placebo containing softgels
79668059|NCT00336245|Device|Copper T Intrauterine Contraceptive Device|
79668060|NCT00336245|Drug|Hormonal Contraception|
79668061|NCT00336362|Drug|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
79668062|NCT00347373|Drug|Tonalin Conjugated linoleic acid (dietary supplement)|
79991079|NCT02362750|Other|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
79991080|NCT02368678|Procedure|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
79355701|NCT04400968|Procedure|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen [FT2], uterus [FT5], sympathetic [HI4], kidney [CS6], heart [CI4], endocrine [IT2] and thalamus [PC2].
79506592|NCT00225498|Drug|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
79991081|NCT02368678|Procedure|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
79370913|NCT05619484|Device|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
79370914|NCT05618470|Drug|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
79506593|NCT00225732|Other|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
79506594|NCT00225732|Drug|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
79506595|NCT02096718|Drug|Afatinib healthy|
79506596|NCT02096718|Drug|Afatinib severe renally impaired|
79506597|NCT02096718|Drug|Afatinib moderate renally impaired|
79506598|NCT00113022|Drug|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
79668063|NCT00336401|Drug|Sevoflurane or Propofol|
79668064|NCT00336518|Drug|peginterferon alfa-2a|
79668065|NCT00336518|Drug|ribavirin|
79668066|NCT00336557|Procedure|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
79355702|NCT04400968|Procedure|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
79355703|NCT04400968|Procedure|Auricular therapy Placebo group|Sham auricular therapy
79355704|NCT04400968|Procedure|kinesio tape Placebo group|Sham kinesio tape
79355705|NCT05686330|Device|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
79355706|NCT03368716|Behavioral|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
79506599|NCT00113022|Drug|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
79668067|NCT00336596|Procedure|transcranial ultrasound in patients treated with iv t-PA|
79668068|NCT03277872|Device|Laryngoscopy with GlideScope (GVL) Blade|"st Laryngoscopy with GVL Blade~nd Laryngoscopy with MAC Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
79668069|NCT03277872|Device|Laryngoscopy with MacIntosh (MAC) Blade|"st Laryngoscopy with MAC Blade~nd Laryngoscopy with GVL Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
79668070|NCT00336635|Biological|cell-culture derived smallpox vaccine|
79506600|NCT02097732|Drug|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
79506601|NCT02097732|Procedure|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
79506602|NCT04752306|Other|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
79506603|NCT02028468|Procedure|hemiarthroplasty|
79506604|NCT00113334|Drug|ABT-510|100 mg subcutaneously twice daily
79506605|NCT00286182|Drug|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
79506606|NCT00286182|Drug|Placebo|Placebo
79668071|NCT00347490|Drug|Enoxaparine|
79668072|NCT00336674|Biological|Intranasal insulin|440IU Insulin
79668073|NCT00336674|Other|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
79668074|NCT00444483|Behavioral|Structured diabetes teaching and treatment program|
79506607|NCT00286728|Behavioral|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
79506608|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
79506609|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
79506610|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
79506611|NCT00226590|Drug|Gemcitabine|Induction Chemotherapy.
79506612|NCT00226590|Drug|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
79506613|NCT00226590|Drug|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
79506614|NCT00226590|Procedure|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
79506615|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10* gms topically each day
79506616|NCT00114114|Drug|Goserelin acetate|3.6 gms sc every 4 weeks
79506617|NCT00227760|Drug|Cediranib Maleate|Given PO
79506618|NCT00227760|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
79506619|NCT00227760|Other|Laboratory Biomarker Analysis|Correlative studies
79506620|NCT00227760|Other|Pharmacological Study|Correlative studies
79506621|NCT00227994|Drug|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
79506622|NCT00227994|Drug|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
79668075|NCT00336752|Procedure|non operative treatment|non operative treatment -casting for 6 weeks
79668076|NCT00336752|Procedure|operative treatment of ankle fractures|operative treatment of ankle fractures
79668077|NCT00444522|Drug|Alprazolam thermal aerosol|
79668078|NCT00336791|Drug|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m^2 IV on day 1 and day 4 of 21 day cycle."
79506623|NCT04250454|Behavioral|CONTRACT|"The intervention will consist of four elements:~Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~Home Activity Plan (HAP)~Home-based Feedback training~Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
79668079|NCT00336791|Drug|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m^2 IV on day 1 of 21 day cycle."
79506624|NCT00114504|Drug|simvastatin|simvastatin 5-10 mg/day
79506625|NCT04247802|Other|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
79668080|NCT00336791|Drug|Doxorubicin|FAC Chemotherapy: 50 mg/m^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
79355707|NCT05686174|Dietary Supplement|MBS217|Soybean Fermented Extract (MBS217)
79668081|NCT00336791|Drug|Paclitaxel|80 mg/m^2 by vein (IVPB) over 1 hour every week for 12 weeks
79668082|NCT00336791|Drug|Epirubicin|FEC: 100 mg/m^2 IV on day 1 of 21 day cycle.
79506626|NCT04247802|Other|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
79506627|NCT00118248|Drug|tanespimycin|Given IV
79355708|NCT05686174|Dietary Supplement|Placebo|Without active ingredient
79355709|NCT05685940|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
79355710|NCT05685940|Procedure|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
79506628|NCT04245384|Other|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
79506629|NCT04245384|Other|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
79668083|NCT00347529|Biological|pPML7789 with and without pPJV2012 administered by PMED|
79355711|NCT05567458|Drug|Luspatercept|Specified dose on specified days
79355712|NCT05567458|Drug|Placebo|Specified dose on specified days
79355713|NCT03344692|Drug|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
79506630|NCT00230022|Behavioral|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
79355714|NCT03344692|Other|Placebo|prefilled pen containing 1 ml of solution without Praluent
79506631|NCT01898676|Drug|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
79668084|NCT00336830|Behavioral|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
79668085|NCT00336830|Behavioral|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
79668086|NCT00444561|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC administration
79668087|NCT00347568|Device|TX-plore|PI has terminated at institution and there is no one available to report.
79668088|NCT00336908|Drug|a combination of MCT, LCT , and Fish Oil|
79355715|NCT03343132|Behavioral|Standard locomotor therapy|Typical clinical therapy.
79355716|NCT04278820|Drug|TQA3526|Tablet(s) administered orally once daily
79355717|NCT04278820|Drug|Placebo to match TQA3526|Tablet(s) administered orally once daily
79355718|NCT05305924|Other|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
79355719|NCT05305924|Other|No Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
79506632|NCT01898676|Drug|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
79506633|NCT04243902|Device|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
79506634|NCT00230802|Drug|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
79506635|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
79506636|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
79506637|NCT00288366|Drug|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
79506638|NCT00288366|Drug|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
79506639|NCT00288600|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin
79355720|NCT05685862|Device|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
79818429|NCT06238258|Behavioral|SPECTROM Training|Training regarding treatment of behavioral challenges in adults with intellectual disability
79355721|NCT05298436|Other|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
79355722|NCT05556148|Drug|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
79355723|NCT05555524|Other|Baby oil|"Before each application~Hand hygiene will be done~Skin care will be done to the affected area and the area is thoroughly dried.~Participants will wear a hospital gown and seated comfortably on their bed.~Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~Message will be applied for three times a week before each hemodialysis session for 12 weeks"
79355724|NCT05555524|Other|Placebo|"Before each application~Hand hygiene will be done~Skin care will be done to the affected area and the area is thoroughly dried.~Participants will wear a hospital gown and seated comfortably on their bed.~Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~Message will be applied for three times a week before each hemodialysis session for 12 weeks"
79355725|NCT03342586|Diagnostic Test|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
79355726|NCT03342586|Other|Auditory Attention and Executive Functions Test|"Trail Making Test (Parts A & B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
79355727|NCT03342586|Other|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
79355728|NCT03342586|Other|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
79506640|NCT00288600|Drug|Normal saline solution|Normal saline solution 10 ml/Kg
79506641|NCT00290472|Drug|temsirolimus|
79506642|NCT04752852|Drug|Dexamethasone|8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
79506643|NCT04752852|Drug|Placebo|2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
79506644|NCT00291876|Biological|Havrix™|2 doses at 12 months interval
79818430|NCT06238232|Diagnostic Test|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq [0.05mCi]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
79818431|NCT06238219|Drug|Neuromuscular Blocking Agent|Administration of any neuromuscular blocking agent for surgery under general anesthesia
79355729|NCT03342586|Other|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
79355730|NCT03340246|Procedure|Delayed sclerotherapy|See arm descriptions
79668089|NCT00444639|Drug|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
79355731|NCT03340246|Procedure|Immediate phlebectomy|See arm description
79506645|NCT01899144|Drug|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
79668090|NCT00336947|Drug|tegafur-gimeracil-oteracil potassium|
79818432|NCT06238206|Other|Focus group discussion|The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
79818433|NCT06238180|Device|VIOSync-SPI|The intervention in this study involves an AI-driven clinical decision-support system, VIOSync Sepsis Prediction Index (SPI), designed for the early prediction of sepsis in patients undergoing abdominal surgery. VIOSync integrates data from PPG-based wearable wireless devices that monitor vital signs, electronic health records, and laboratory tests. The AI model analyzes this multimodal data to proactively identify signs of sepsis providing an early warning score, the SPI, to clinicians. The distinguishing feature of this intervention is its use of real-time data and advanced AI analytics to enhance early sepsis detection, aiming to improve patient outcomes in postoperative care.
79506646|NCT01899144|Drug|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
79668091|NCT00336947|Drug|tegafur-uracil|
79355732|NCT04279132|Behavioral|POSTOPERATIVE COGNITIVE DYSFUNCTION|NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
79355733|NCT05552248|Device|LumbarBelt SOFT 300|15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks.
79355734|NCT05552248|Other|Control group LumbarBelt SOFT 300|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks.
79355735|NCT05552248|Device|LumbarBelt MID 500|15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks.
79355736|NCT05552248|Other|Control group LumbarBelt MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks.
79668092|NCT00336947|Procedure|adjuvant therapy|
79668093|NCT00347607|Behavioral|community surveillance and re-treatment|
79668094|NCT00444717|Drug|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
79818434|NCT06238167|Drug|Tislelizumab|Tislelizumab, 200mg Q3W, max 16 cycles.
79818435|NCT06238167|Drug|S-1 therapy|S1 d1-14 bid (< 1.25m^2 40mg, 1.25m^2-1.5m^2 50mg, ≥ 1.5m^2 60mg), followed by 7 days off (Q3W, max 16 cycles).
79818436|NCT06238167|Drug|low dose SOX therapy|Oxaliplatin: 78mg/m^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
79818437|NCT06238154|Drug|Flurbiprofen|The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
79355737|NCT04400422|Dietary Supplement|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
79355738|NCT04278430|Device|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
79506647|NCT01899144|Drug|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
79506648|NCT00234078|Drug|0.5% OPC-12759|
79506649|NCT00234078|Drug|1% OPC-12759|
79991082|NCT02358226|Behavioral|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
79506650|NCT00234078|Drug|2% OPC-12759|
79506651|NCT00234078|Drug|placebo|
79668095|NCT00347646|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
79668096|NCT00337064|Procedure|Radiation Therapy|
79668097|NCT00421278|Drug|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
79668098|NCT00421317|Drug|Imatinib|800 mg/day until disease progression or toxicity
79668099|NCT00337259|Drug|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
79668100|NCT04699734|Diagnostic Test|Xylocaine 1%|Nerve block
79668101|NCT04699734|Diagnostic Test|NaCl 9mg/ml|Nerve block
79668102|NCT00337298|Drug|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
79668103|NCT00337298|Drug|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
79668104|NCT04699851|Behavioral|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
79506652|NCT00118404|Behavioral|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
79506653|NCT00118404|Drug|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
79506654|NCT00118404|Other|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
79506655|NCT00118404|Behavioral|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
79506656|NCT00121836|Drug|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
79506657|NCT00121836|Drug|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
79355739|NCT04278430|Device|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
79355740|NCT05537974|Procedure|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
79355741|NCT05093374|Drug|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
79355742|NCT05093374|Drug|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
79355743|NCT05249374|Drug|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
79355744|NCT05249374|Drug|Human serum albumin|10 g/bottle (20%, 50 mL)
79355745|NCT05247580|Other|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
79506658|NCT01898910|Procedure|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
79506659|NCT01898910|Procedure|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
79506660|NCT01898910|Drug|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
79506661|NCT00237666|Drug|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
79506662|NCT00296322|Drug|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
79506663|NCT00297102|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
79506664|NCT00297102|Drug|Placebo|once daily
79506665|NCT00123162|Drug|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
79506666|NCT00123162|Drug|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
79506667|NCT01897818|Device|communication system P300 Speller|
79506668|NCT04751838|Other|no intervention|no intervention
79668105|NCT04699851|Behavioral|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
79506669|NCT00123630|Drug|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
79506670|NCT00123630|Drug|Placebo|Placebo given IV once every 2-4 weeks based on weight
79506671|NCT00124176|Drug|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
79506672|NCT00124176|Drug|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
79506673|NCT00240162|Drug|PTK787/ZK 222584|
79668106|NCT00337337|Behavioral|Multiple grain|
79355746|NCT04278742|Other|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
79355747|NCT03338218|Drug|Volulyte 6%|Solution for infusion
79355748|NCT03338218|Drug|Ionolyte|Solution for infusion
79355749|NCT04400032|Biological|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
79355750|NCT05262088|Other|video recording of general movements|"Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS)."
79355751|NCT05226910|Device|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
79355752|NCT05226910|Device|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
79355753|NCT05524948|Other|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
79355754|NCT05524948|Other|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
79668107|NCT00337337|Behavioral|Ordinary Asian- rice|
79668108|NCT00337376|Drug|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
79668109|NCT00337376|Drug|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
79355755|NCT01839656|Drug|nusinersen|Administered by intrathecal (IT) injection
79355756|NCT03335332|Behavioral|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
79355757|NCT03335332|Behavioral|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
79668110|NCT00337415|Drug|MK0354|
79668111|NCT03275688|Diagnostic Test|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
79668112|NCT00337493|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
79668113|NCT00337493|Drug|mycophenolate mofetil [CellCept]|1g po bid
79668114|NCT00337493|Drug|Cyclosporine or tacrolimus|Reduced
79668115|NCT00337493|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
79668116|NCT00444756|Procedure|J-tip jet injection of 1% buffered lidocaine|
79668117|NCT03275649|Other|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
79355758|NCT05047900|Diagnostic Test|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
79355759|NCT01839188|Biological|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Hepatitis B [HB; Recombinant DNA], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
79355760|NCT01839188|Biological|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
79355761|NCT01839188|Biological|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
79355762|NCT01839188|Biological|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
79355763|NCT01839188|Biological|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine [PCV; 13-valent, adsorbed]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
79355764|NCT05223088|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
79355765|NCT05223088|Drug|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
79355766|NCT05223088|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
79355767|NCT05223088|Drug|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
79355768|NCT01838876|Drug|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
79506674|NCT00299988|Drug|Intravenous Immunoglobulin|
79506675|NCT00299988|Other|Placebo|
79506676|NCT04226352|Drug|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
79818438|NCT06238141|Other|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
79818439|NCT06238141|Other|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
79355769|NCT01838876|Drug|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
79355770|NCT03279250|Drug|Abiraterone Acetate|Given PO
79355771|NCT03279250|Drug|Apalutamide|Given PO
79355772|NCT03279250|Biological|Gonadotropin-releasing Hormone Analog|Given IM
79506677|NCT00300456|Drug|ABT-335|135 mg, daily, 12 weeks
79506678|NCT00300456|Drug|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
79506679|NCT00300456|Drug|Placebo|Daily, 12 weeks, see Arm Description for placebo information
79506680|NCT00125034|Biological|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
79506681|NCT00125034|Drug|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
79506682|NCT02100930|Biological|Anti-GD2 3F8 Monoclonal Antibody|
79506683|NCT02100930|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
79506684|NCT02100930|Drug|oral isotretinoin|
79506685|NCT00241176|Drug|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS & CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
79355773|NCT03279250|Drug|Prednisone|Given PO
79355774|NCT03279250|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
79355775|NCT01838642|Drug|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
79355776|NCT05007418|Biological|STI-1492|Anti-CD38 A2 KOKI DAR T cells
79355777|NCT05240170|Device|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
79355778|NCT05240170|Device|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (>800 HU or ≤800 HU), matched cases will be selected for comparison.
79506686|NCT00125658|Other|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
79355779|NCT01611194|Drug|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
79355780|NCT01611194|Drug|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
79355781|NCT05181046|Device|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
79355782|NCT05181046|Other|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
79355783|NCT01813058|Drug|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~placebo i.e. saline 0.9% (intravenous injection)~intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
79355784|NCT01813058|Drug|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~TXA as previously described."
79355785|NCT05163262|Other|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
79355786|NCT01867424|Drug|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
79355787|NCT04986514|Other|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
79355788|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
79355789|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
79355790|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
79506687|NCT00125658|Other|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
79818440|NCT06238128|Behavioral|Opioid Rapid Resonse System (ORRS) training|ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.
79355791|NCT04601168|Device|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
79355792|NCT01811732|Drug|Delafloxacin|Delafloxacin
79355793|NCT01811732|Drug|Vancomycin|Vancomycin
79355794|NCT01811732|Drug|Aztreonam|Aztreonam
79355795|NCT01811732|Drug|Placebo|Placebo
79355796|NCT05146648|Device|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
79355797|NCT04400344|Other|No intervention|No intervention
79355798|NCT04399720|Procedure|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
79355799|NCT01836458|Drug|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
79355800|NCT05139004|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
79355801|NCT05139004|Biological|Basiliximab|Given IV
79355802|NCT05139004|Drug|Fludarabine Phosphate|Given IV
79355803|NCT05139004|Drug|Indium In 111-DOTA-Basiliximab|Given IV
79355804|NCT05139004|Drug|Melphalan|Given IV
79355805|NCT05139004|Biological|Palifermin|Given IV
79991083|NCT02358226|Behavioral|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
79818441|NCT06238128|Behavioral|Non-active opioid overdose response training|"Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
79506688|NCT02102100|Drug|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
79818442|NCT06238102|Other|pure tone audiometry|measuring hearing impairment to select patients with hearing loss to evaluate who can this hearing impairment affects their quality of life
79818443|NCT06238076|Device|Universal surgical device FIBUMAND|This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
79991084|NCT02368600|Behavioral|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
79506689|NCT02102100|Drug|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
79679664|NCT00517517|Biological|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
79818444|NCT06238063|Behavioral|Nurse-led Advance Care Planning (ACP) Intervention|An ACP discussion between the participating resident, family members, and the trained nurse will be incorporated into the annual review. The proposed ACP intervention will be divided into three parts (three weekly sessions, 1.5 hours each): 1) preparatory, 2) discussion, and 3) follow-up sessions.
79818445|NCT06238050|Procedure|introduction of oxygen therapy or not|During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
79991085|NCT03085914|Drug|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
79355806|NCT05139004|Radiation|Total Lymphoid Irradiation|Undergo TMLI
79355807|NCT05139004|Radiation|Total Marrow Irradiation|Undergo TMLI
79355808|NCT05139004|Biological|Yttrium Y 90 Basiliximab|Given IV
79818446|NCT06237985|Procedure|ProTaper Gold file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the ProTaper Gold rotary file system up to F2 for mesial canals.
79355809|NCT04073992|Behavioral|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
79355810|NCT01811186|Drug|Oxycodone/naloxone|Oxycodone/naloxone titration
79355811|NCT04414436|Behavioral|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
79355812|NCT03240328|Biological|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
79506690|NCT02094534|Biological|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
79506691|NCT02094534|Other|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
79679665|NCT02939352|Device|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
79679666|NCT02939352|Device|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
79679667|NCT00517673|Drug|GSK945237|
79818447|NCT06237985|Procedure|OneShape file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the OneShape rotary file system up to 25/.06 for mesial canals.
79818448|NCT06237985|Procedure|TruNatomy file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the TruNatomy rotary file system up to 26/.04 for mesial canals.
79818449|NCT06237959|Dietary Supplement|Keranat™|300 mg/capsule(proso millet and wheat extract 600 mg/day)
79818450|NCT06237959|Dietary Supplement|placebo|300 mg/capsule(600 mg/day as placebo)
79991086|NCT03085914|Drug|Pembrolizumab|Pembrolizumab
79991087|NCT03085914|Drug|Oxaliplatin|Oxaliplatin
79991088|NCT03085914|Drug|Leucovorin|Leucovorin
79991089|NCT03085914|Drug|5-Fluorouracil|5-Fluorouracil
79991090|NCT03085914|Drug|Gemcitabine|Gemcitabine
79991091|NCT03085914|Drug|nab-Paclitaxel|nab-Paclitaxel
79668118|NCT04715789|Behavioral|graded exposure and activity|"Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
79668119|NCT00444834|Drug|Carvedilol|50 mg
79355813|NCT04746196|Other|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
79506692|NCT00242502|Drug|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
79355814|NCT01866098|Drug|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
79506693|NCT00242502|Drug|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
79506694|NCT04389060|Dietary Supplement|Grape seed extract|Two capsule grape seed extract (total 600 mg)
79506695|NCT01899066|Drug|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
79506696|NCT01899066|Drug|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
79506697|NCT01890720|Device|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
79355815|NCT01866098|Drug|Placebo|
79355816|NCT04919356|Genetic|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
79668120|NCT00337688|Device|isometric joystick|isometric joystick
79668121|NCT04698486|Other|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
79355817|NCT04399798|Drug|Baricitinib|4 mg/day for 7 days
79355818|NCT04897360|Behavioral|Increased breathing|hyperventilation to lower ETCO2
79355819|NCT04897360|Other|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
79355820|NCT04889326|Other|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
79668122|NCT00337766|Drug|Desmopressin (DDAVP)|
79668123|NCT00337766|Drug|Placebo|
79668124|NCT00444873|Drug|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
79355821|NCT04885972|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
79355822|NCT04885972|Drug|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
79355823|NCT04885972|Drug|Placebo|Vehicle solution
79506698|NCT01890720|Other|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
79506699|NCT00244140|Drug|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
79506700|NCT00244140|Drug|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
79668125|NCT00337805|Other|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
79991092|NCT03085914|Drug|Carboplatin|Carboplatin
79991093|NCT03085914|Drug|Paclitaxel|Paclitaxel
79355824|NCT03985540|Behavioral|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
79355825|NCT03985540|Behavioral|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
79355826|NCT03985540|Behavioral|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
79355827|NCT03985540|Behavioral|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
79355828|NCT04347772|Dietary Supplement|Oral Nutrition Support|Intensive Nutrition Intervention
79355829|NCT03263026|Drug|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
79506701|NCT00126750|Behavioral|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
79506702|NCT00127062|Other|Oxford street|2 h walk around Oxford street
79991094|NCT03085914|Drug|Pemetrexed|Pemetrexed
79991095|NCT03085914|Drug|Cyclophosphamide|Cyclophosphamide
79355830|NCT03263026|Other|R-CHOP + placebo|R-CHOP + placebo
79355831|NCT04858360|Drug|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
79991096|NCT03085914|Drug|Carboplatin|Carboplatin
79991097|NCT03085914|Drug|Cisplatin|Cisplatin
79228024|NCT02229669|Procedure|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
79355832|NCT04858360|Drug|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
79506703|NCT00127062|Other|Hyde park|2 h walk around Hyde park
79506704|NCT00127218|Drug|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
79668126|NCT01580397|Drug|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
79355833|NCT04858360|Other|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
79355834|NCT04858360|Other|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
79355835|NCT04858360|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
79355836|NCT01865552|Biological|SB4|SC administration
79355837|NCT01865552|Biological|EU sourced Enbrel|SC administration
79355838|NCT01865552|Biological|US sourced Enbrel|SC administration
79506705|NCT00127218|Drug|niacin|long-acting niacin daily for 18 months
79991098|NCT03085914|Drug|5-Fluorouracil|5-FU
79991099|NCT03085914|Drug|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
79991100|NCT02357680|Other|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
79991101|NCT01736956|Procedure|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
79991102|NCT01081288|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
79991103|NCT02467608|Drug|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
79506706|NCT00127218|Drug|Placebo|matching placebo pill daily for 18 months
79668127|NCT04715594|Device|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
79679668|NCT00517673|Drug|Sugar Pill|Placebo
79506707|NCT00127530|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
79506708|NCT00127530|Drug|Placebo|sugar pill, twice a day (b.i.d.)
79506709|NCT04346238|Other|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
79506710|NCT00250926|Drug|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
79991104|NCT02467608|Drug|HRZE|the same as experimental group,without the excipient of HUEXC030 only
79355839|NCT03205072|Device|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
79355840|NCT01809314|Drug|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
79355841|NCT02984332|Other|Lower limb immobilisation (leg brace)|
79668128|NCT04715594|Device|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
79991105|NCT02368288|Drug|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
79991106|NCT01380054|Behavioral|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
79991107|NCT01063114|Radiation|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
79991108|NCT02450136|Drug|pazopanib|
79991109|NCT05421312|Drug|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
79991110|NCT05421312|Drug|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
79991111|NCT05421312|Drug|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
79991112|NCT02368054|Drug|Bupivacaine|Infiltration anesthesia
79991113|NCT02368054|Drug|Adrenaline|Infiltration anesthesia
79991114|NCT01569282|Procedure|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
79991115|NCT01569282|Procedure|Stent strategy|Biliary and/or enteral stents on demand
79991116|NCT02357602|Drug|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
79991117|NCT01379196|Drug|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
79355842|NCT01803464|Device|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
79355843|NCT01803464|Drug|Botox|Children who are candidates to receive Botox as part of their standard of care.
79355844|NCT01808690|Drug|Metformin|
79355845|NCT01808690|Drug|Placebo|
79355846|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 1|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
79355847|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 2|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
79355848|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 3|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
79355849|NCT04583618|Biological|Pneumococcal 13 - valent conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
79506711|NCT00250926|Drug|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
79506712|NCT00250926|Drug|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
79506713|NCT00251238|Drug|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
79506714|NCT00251862|Behavioral|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
79506715|NCT00251862|Behavioral|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
79506716|NCT00251862|Behavioral|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
79506717|NCT00303966|Drug|sorafenib tosylate|Given orally
79506718|NCT00304512|Drug|migalastat HCl|
79506719|NCT00304746|Drug|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
79506720|NCT00304746|Drug|Placebo|Placebo
79506721|NCT05267730|Behavioral|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
79668129|NCT00444990|Device|Magnetic Flex Pad|
79668130|NCT00337883|Drug|Erlotinib HCl (OSI-774)|
79668131|NCT00451113|Drug|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
79668132|NCT00337922|Drug|Lamivudine / Abacavir Sulfate|
79506722|NCT05267418|Device|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
79506723|NCT00134004|Drug|cyclophosphamide|
79506724|NCT00134004|Drug|fludarabine phosphate|
79506725|NCT00134004|Drug|mycophenolate mofetil|
79506726|NCT00134004|Drug|tacrolimus|
79506727|NCT00134004|Procedure|allogeneic bone marrow transplantation|
79506728|NCT00134004|Radiation|radiation therapy|
79506729|NCT00135798|Drug|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued."
79668133|NCT04699578|Diagnostic Test|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
79668134|NCT00337961|Procedure|Optic Nerve Sheath Fenestration|
79991118|NCT03112720|Device|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
79991119|NCT03112720|Drug|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
79991120|NCT01382316|Behavioral|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
79355850|NCT04583618|Biological|Pneumococcal Vaccine Polyvalent|Pharmaceutical form:Solution for injection Route of administration: intramuscular
79355851|NCT04413734|Drug|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
79355852|NCT04413734|Drug|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
79506730|NCT00136812|Behavioral|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
79506731|NCT00137280|Behavioral|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
79506732|NCT01790334|Other|Ultrasonography|
79668135|NCT00451230|Drug|cocaine|
79668136|NCT00451230|Drug|hydrocortisone|
79668137|NCT00338000|Drug|Epoetin alfa|
79668138|NCT00451269|Device|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
79668139|NCT00338078|Device|nocturnal oxygen treatment from oxygen concentrators|
79668140|NCT00338117|Drug|Galantamine hydrobromide|
79355853|NCT03229798|Drug|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
79355854|NCT03229798|Combination Product|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
79355855|NCT04808908|Biological|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
79355856|NCT03927742|Behavioral|Shade + app with messaging|Shade wearable device and application with UV messaging activated
79355857|NCT03927742|Behavioral|Shape + app without messaging|Shade wearable device and application without UV messaging activated
79506733|NCT00138294|Biological|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
79355858|NCT04805944|Drug|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
79355859|NCT04805944|Drug|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
79668141|NCT02956707|Other|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
79668142|NCT00338195|Behavioral|Individualized caffeine cessation instructions|Intervention is described in the protocol
79355860|NCT04805944|Drug|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
79668143|NCT00451308|Procedure|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
79668144|NCT00451308|Procedure|Induction of labor with foley balloon with 30cc|30cc of saline in foley
79355861|NCT04805944|Drug|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
79355862|NCT04805944|Drug|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
79668145|NCT00451347|Device|Quadriceps strength training|
79668146|NCT00451347|Device|Taping|
79818451|NCT06237933|Behavioral|Enhanced intervention via social networking site (SNS)|We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks
79991121|NCT01382316|Behavioral|Usual care|Group format, six weekly education sessions about alcohol and drugs
79991122|NCT01382238|Drug|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
79355863|NCT03906292|Drug|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
79355864|NCT03906292|Drug|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
79355865|NCT03906292|Drug|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
79355866|NCT03906292|Drug|Asciminib|Asciminib 80 mg QD Monotherapy
79355867|NCT04399642|Procedure|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
79355868|NCT04399564|Device|temporary hemodialysis catheters|Vascular access using temporary vs.long-term hemodialysis catheters
79355869|NCT04399564|Device|long-term hemodialysis catheters|long-term hemodialysis catheters
79355870|NCT03672526|Device|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
79355871|NCT03229174|Drug|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
79355872|NCT03229174|Drug|Placebo|Placebo (sugar pill)
79668147|NCT00451347|Device|Home exercise|
79668148|NCT00338273|Drug|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
79668149|NCT00338273|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
79668150|NCT03277833|Dietary Supplement|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
79668151|NCT03277833|Dietary Supplement|Placebo|Placebo, parallel design
79668152|NCT00338312|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
79668153|NCT00338312|Drug|Placebo patch|placebo patch changed twice a week for one year
79668154|NCT00451386|Drug|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
79668155|NCT00451386|Drug|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
79355873|NCT03227926|Drug|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
79355874|NCT03227926|Diagnostic Test|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
79506734|NCT02103114|Drug|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level*%) X body weight)/1.4~expressed as a % normal level based on functional ATIII assay"
79668156|NCT00420875|Device|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
79668157|NCT02956824|Other|Standard care|Current care
79818452|NCT06237933|Behavioral|Standard intervention|In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
79355875|NCT03227770|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
79818453|NCT06237920|Drug|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
79355876|NCT03227770|Device|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
79355877|NCT04562194|Device|NeVa Stent Retriever|mechanical neurothrombectomy
79355878|NCT04398472|Behavioral|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
79355879|NCT01363297|Drug|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2."
79370915|NCT05618470|Drug|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
79506735|NCT02103114|Other|Placebo|Normal saline placebo
79506736|NCT00140244|Drug|r-metHuLeptin|
79668158|NCT00338351|Biological|Pneumococcal (vaccine)|
79668159|NCT00451425|Behavioral|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
79818454|NCT06237920|Drug|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
79818455|NCT06237907|Other|Patients underwent lymphedema surgery|Patients who have developed lymphedema and undergone lymphedema surgery.
79668160|NCT00338390|Drug|Abacavir|Change tenofovir to abacavir
79668161|NCT00338390|Drug|Didanosine|Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
79991123|NCT01382238|Drug|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
79228025|NCT02229669|Procedure|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
79370916|NCT04358536|Device|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
79506737|NCT00140244|Drug|Placebo|
79506738|NCT02103270|Drug|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
79506739|NCT02103270|Drug|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
79506740|NCT02103270|Drug|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
79506741|NCT01790412|Behavioral|Exercise group|Combined two land aerobic sessions and one aquatic activities session
79818456|NCT06237907|Other|Patients underwent surgery without LVA|For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
79506742|NCT01790022|Drug|Methylprednisolone|
79506743|NCT00140556|Radiation|Chemoradiotherapy|External beam radiation daily (M-F)
79818457|NCT06237894|Other|Multisensory Stimulation|Multisensory Stimulation
79818458|NCT06237868|Device|rTMS Active|The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.
79818459|NCT06237868|Device|rTMS Sham|The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
79355880|NCT04758598|Device|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
79668162|NCT00338390|Drug|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
79818460|NCT06237855|Other|Self-drain removal|Subjects will be trained to self-remove drain at home following ventral hernia repair.
79228026|NCT01933724|Drug|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
79355881|NCT04758598|Device|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
79355882|NCT04757116|Device|iTind|The iTind is implemented for 5-7 days
79355883|NCT04757116|Procedure|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
79506744|NCT00140556|Drug|Cisplatin|Cisplatin week 1 and 5 of radiation
79668163|NCT00338429|Behavioral|FHP Sleep Program|Cognitive-Behavioral Intervention
79668164|NCT00338468|Drug|epoetin alfa|
79228027|NCT01933724|Drug|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
79228028|NCT02229747|Drug|Meloxicam|
79228029|NCT02229747|Drug|Diclofenac|
79228030|NCT02229747|Drug|Nimesulide|
79228031|NCT02232789|Drug|Mephedrone|Single oral dose mephedrone
79355884|NCT04756804|Drug|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
79506745|NCT00140556|Drug|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
79506746|NCT00140556|Drug|Erlotinib|Erlotinib daily during radiation
79506747|NCT05215392|Behavioral|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
79506748|NCT00142116|Drug|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
79506749|NCT00142116|Drug|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
79668165|NCT00338507|Drug|Erdosteine|
79668166|NCT00445185|Biological|Henogen HB vaccine|Month 12, 24 and 36
79668167|NCT00445185|Biological|Fendrix vaccine|Month 12, 24 and 36
79668168|NCT00338546|Drug|Cocaine hydrochloride|
79668169|NCT00338546|Drug|Dexmedetomidine|
79228032|NCT02232789|Drug|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
79228033|NCT02232789|Drug|Placebo|Single oal dose placebo
79228034|NCT03030222|Drug|Empagliflozin 10 mg Tab|Empagliflozin 10 mg Tab
79228035|NCT03030222|Drug|Placebo Oral Tablet|Empagliflozin matching placebo
79228036|NCT04089735|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
79228037|NCT04089735|Drug|APP13007, 0.1%|APP13007 eye drop, 0.1%
79668170|NCT00338546|Procedure|Microneurography|
79668171|NCT00338546|Procedure|Laser doppler velocimetry|
79668172|NCT00338585|Drug|alfimeprase|
79668173|NCT00451503|Device|Middle Ear Implant|surgery
79668174|NCT00338624|Drug|oxybutynin chloride extended release|
79668175|NCT00338663|Device|knee immobilization splint|
79668176|NCT00445419|Biological|PEV2A PEV2B|
79668177|NCT00451581|Procedure|Endoscopic papillary balloon dilation-5 minutes|
79668178|NCT00451581|Procedure|Endoscopic papillary balloon dilation-1 minute|
79668179|NCT00338780|Drug|Lamivudine/ Placebo 100mg daily|
79818461|NCT06237829|Behavioral|Single bump acuity|Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, ~100% success rate control, will be constructed
79991124|NCT03112564|Other|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
79991125|NCT03112564|Drug|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
79355885|NCT04756804|Drug|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
79355886|NCT03199924|Drug|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
79355887|NCT03199924|Drug|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
79355888|NCT03199924|Drug|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
79506750|NCT05201430|Drug|FOLFOXIRI|irinotecan* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
79668180|NCT00451620|Drug|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
79668181|NCT00451620|Drug|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
79668182|NCT00338858|Other|walking and balance performance evaluation|
79668183|NCT00338858|Procedure|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
79668184|NCT00451737|Device|Isokinetic test|
79228038|NCT04089735|Drug|APP13007 Placebo, 0.05%|APP13007 placebo eyedrop, 0.05%
79228039|NCT04089735|Drug|APP13007 Placebo, 0.1%|APP13007 placebo eyedrop, 0.1%
79355889|NCT01908907|Dietary Supplement|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
79355890|NCT01908907|Dietary Supplement|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
79355891|NCT04398940|Drug|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
79355892|NCT04632199|Drug|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
79355893|NCT04632199|Drug|111In-IPN01087 High dose|Administered once via slow intravenous injection.
79506751|NCT05201430|Drug|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
79506752|NCT05188560|Other|Action observation therapy|Subject is asked to observe videos with motor contents
79228040|NCT02892708|Procedure|Surgery|partial or complete resection followed by radiotherapy
79228041|NCT02892708|Radiation|radiotherapy|radiotherapy after a brain biopsy
79506753|NCT05188560|Other|motor imagery|mental simulation of a motor task
79668185|NCT00338897|Drug|SR123781A|
79668186|NCT00445497|Drug|amoxicillin-clavulanate potassium|
79668187|NCT00445497|Drug|ciprofloxacin|
79668188|NCT00445497|Procedure|psychosocial assessment and care|
79668189|NCT00445497|Procedure|quality-of-life assessment|
79668190|NCT00451776|Drug|etomidate|patients who received etomidate
79668191|NCT00451776|Drug|propofol|patients who received propofol
79668192|NCT00338936|Drug|Valsartan + Hydrochlorothiazide|
79668193|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
79506754|NCT00142506|Drug|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
79506755|NCT00142506|Drug|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
79355894|NCT03826498|Biological|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
79506756|NCT05266794|Drug|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
79506757|NCT05266794|Drug|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
79506758|NCT00142818|Drug|Naltrexone|150 mg daily for males; 100 mg daily for females
79506759|NCT00142818|Drug|Modafinil|400 mg daily
79506760|NCT00142818|Drug|Placebo|400 mg and/or 100-150 mg placebo pills
79506761|NCT05266716|Behavioral|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
79355895|NCT03826498|Other|Standard therapy|The standard therapy can include drugs, special psychology training etc.
79355896|NCT04746430|Drug|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
79355897|NCT04277650|Other|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
79355898|NCT03832270|Behavioral|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
79355899|NCT03832270|Behavioral|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
79355900|NCT03258892|Other|Educational Intervention|Receive STG
79355901|NCT03258892|Other|Quality-of-Life Assessment|Ancillary studies
79355902|NCT03258892|Other|Survey Administration|Ancillary studies
79370917|NCT04358146|Other|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
79370918|NCT04358146|Other|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
79355903|NCT04277494|Other|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
79355904|NCT04277572|Procedure|Aortic valve replacement|Aortic valve surgery
79991126|NCT01379976|Drug|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
79991127|NCT01379976|Drug|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
79355905|NCT04430842|Drug|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
79355906|NCT04686838|Behavioral|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
79355907|NCT04686838|Behavioral|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
79355908|NCT04677010|Other|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
79355909|NCT04277806|Behavioral|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
79506762|NCT00147030|Procedure|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
79506763|NCT05266560|Drug|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-[(1R)-1-cyclopropylethyl]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
79228042|NCT02523222|Dietary Supplement|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
79355910|NCT04666402|Other|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
79506764|NCT05266560|Drug|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
79506765|NCT00147966|Drug|rituximab|treatment with rituximab
79506766|NCT04528212|Drug|Glimepiride Tablets|Glimepiride (4 mg) per Day
79506767|NCT04528212|Drug|glimepiride plus fenofibrate|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
79506768|NCT04528212|Drug|glimepiride plus curcumin|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
79668194|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
79668195|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
79668196|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
79506769|NCT05265936|Procedure|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
79506770|NCT05265936|Procedure|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
79506771|NCT05265858|Procedure|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
79506772|NCT00148668|Drug|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
79506773|NCT00148668|Drug|Navelbine|Weekly injections given starting week 3 and ending week 14
79506774|NCT00148668|Drug|Taxotere|Given every three weeks starting week 3 and ending on week 14
79506775|NCT00148668|Drug|Carboplatin|Given every three weeks starting week 3 and ending on week 14
79506776|NCT05265780|Procedure|kinesiotape|an elastic adhesive tape
79506777|NCT05265780|Procedure|sham taping|a sham taping without the tension
79506778|NCT00149838|Procedure|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
79506779|NCT00149838|Drug|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
79506780|NCT00149838|Procedure|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
79506781|NCT01790646|Other|intubation|intubation using Glidescope videolaryngoscope
79506782|NCT04410822|Other|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
79355911|NCT04666402|Diagnostic Test|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
79506783|NCT00324870|Drug|vorinostat|Given orally
79506784|NCT00324870|Drug|bevacizumab|Given IV
79506785|NCT00151320|Drug|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
79355912|NCT04666402|Diagnostic Test|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
79370919|NCT05620498|Drug|tislelizumab+lenvatinib+GMOX|tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
79370920|NCT05620498|Drug|tislelizumab+GEMOX|tislelizumab+GEMOX
79506786|NCT00326196|Device|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
79506787|NCT00326196|Procedure|Coronary artery bypass graft (CABG)|coronary bypass
79506788|NCT04332198|Other|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
79506789|NCT00328770|Drug|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
79506790|NCT05105568|Behavioral|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
79506791|NCT04281654|Other|Active Social Conversation|Active Social Conversation
79991128|NCT01379898|Drug|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
79991129|NCT01379898|Drug|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
79668197|NCT00338975|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
79668198|NCT00338975|Behavioral|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
79991130|NCT02368366|Behavioral|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
79991131|NCT02368366|Behavioral|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
79991132|NCT02368366|Behavioral|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
79991133|NCT02367898|Other|Lumosity Cognitive Training|adaptive online cognitive training
79991134|NCT02367898|Other|Crossword Puzzles|timed online crossword puzzles
79991135|NCT04479280|Device|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
79355913|NCT03771430|Behavioral|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~60-min session by AktivA trained PT)~Signs/symptoms, risk factors, weight control, treatment~Importance of physical activity~Appropriate activity & training modalities~Exercise and CBT Support~60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~Warm-up session~Strengthening exercises~Functional exercises~Stretching~Monitoring of CBT progress~Review of CBT lessons learned~Integration of CBT skills~Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~Pain causes & prevention~Pain management~Health promotion & stress reduction at home & work~Adapting for leisure & work~Controlling flare-ups~Maintaining & improving results"
79355914|NCT03771430|Procedure|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
79506792|NCT04952376|Behavioral|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
79506793|NCT04952376|Behavioral|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
79506794|NCT04952376|Behavioral|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
79506795|NCT04177680|Drug|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
79991136|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
79991137|NCT03160066|Dietary Supplement|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
79991138|NCT03160066|Dietary Supplement|Placebo|Placebo
79991139|NCT02367742|Behavioral|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
79506796|NCT04177680|Drug|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
79991140|NCT02367742|Behavioral|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
79991141|NCT04334356|Behavioral|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
79506797|NCT01790724|Behavioral|Walking exercise|
79818462|NCT06237829|Behavioral|Optimal spacing between bumps|Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
79818463|NCT06237829|Behavioral|Improving signal from a single bump with designer materials|"Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps)."
79506798|NCT00330876|Drug|Pitavastatin|
79668199|NCT00338975|Behavioral|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
79818466|NCT06237556|Other|Placebo|Patients in the control group will receive placebo.
79818467|NCT06237556|Drug|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
79506799|NCT01792206|Drug|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
79818468|NCT06237452|Biological|VE303|VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.
79506800|NCT01792206|Drug|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
79506801|NCT00333606|Behavioral|Acupuncture|Body acupuncture of 1 specific point per trial session
79506802|NCT04947852|Device|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
79506803|NCT04947852|Device|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
79506804|NCT00334074|Drug|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
79668200|NCT00338975|Behavioral|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
79818469|NCT06237452|Biological|Placebo|Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.
79991142|NCT02362516|Drug|BI 425809|
79991143|NCT02367664|Biological|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
79991144|NCT02367664|Biological|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
79668201|NCT00339014|Drug|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
79668202|NCT00339014|Other|Placebo|Identical placebo
79668203|NCT00451854|Procedure|Random, no advanced notice drug and alcohol testing|
79668204|NCT04715828|Other|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
79668205|NCT04715828|Other|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
79668206|NCT04715828|Other|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
79668207|NCT04715828|Other|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
79668208|NCT00445614|Behavioral|Effects of trout on CVD risk markers and plasma proteome|
79668209|NCT00339053|Drug|Immunonutrition ( Impact)|
79668210|NCT00339092|Behavioral|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
79668211|NCT00339092|Behavioral|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
79668212|NCT00445731|Behavioral|exercise intervention|
79668213|NCT00445731|Procedure|management of therapy complications|
79668214|NCT00445731|Procedure|observation|
79818470|NCT06237426|Drug|Methylone|"A course of methylone treatment includes weekly oral methylone administrations for up to 4 weeks.~Participants may be eligible to receive up to two courses of methylone treatment in this study. After a course of methylone treatment is complete, participants will return to observational study visits."
79818471|NCT06237283|Behavioral|Early shower|Start shower after drain removal
79818472|NCT06237166|Behavioral|mylovia|Participants will receive access to the digital health intervention mylovia in addition to TAU.
79818473|NCT06236724|Drug|Asciminib|Given by PO
79991145|NCT02367664|Biological|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
79991146|NCT05421000|Procedure|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
79506805|NCT00335478|Drug|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.
79506806|NCT01790802|Device|2RT nanosecond laser|active laser therapy
79506807|NCT01790880|Behavioral|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
79506808|NCT01790880|Behavioral|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
79506809|NCT02103816|Device|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
79506810|NCT04870164|Drug|Ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
79506811|NCT04870164|Drug|Placebo|One administration at day 1 by infusion.
79668215|NCT00420914|Procedure|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
79668216|NCT00420953|Drug|Cordarone|
79668217|NCT00425204|Drug|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
79668218|NCT00425243|Drug|zolpidem-MR (SL800750)|
79668219|NCT00451893|Procedure|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
79668220|NCT00451893|Procedure|Lichtenstein operation with a light-weight mesh|Johnson&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
79668221|NCT00425282|Drug|RWJ-333369|
79668222|NCT00339131|Drug|Ultratrace iobenguane I 131|
79506812|NCT01791036|Procedure|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
79506813|NCT01791036|Procedure|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
79506814|NCT04345926|Drug|Propofol|Stepped propofol concentration after 20 min of LOS
79506815|NCT04345926|Device|Electroencephalogram recording|Acquisition of EEG activity
79506816|NCT03974646|Behavioral|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
79506817|NCT00337350|Drug|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
79506818|NCT00337350|Drug|placebo|matched placebo for rosiglitazone 4mg/day
79506819|NCT00338598|Drug|Glycine|Glycine, 0.8 gr per kg given in two daily doses
79668223|NCT00339170|Behavioral|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
79668224|NCT00339170|Behavioral|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
79668225|NCT00451932|Drug|FK778|
79668226|NCT00451971|Drug|LEFLUNOMIDE|
79506820|NCT00338598|Drug|placebo|
79506821|NCT00338988|Drug|Capecitabine|1500 mg/m^2 PO twice daily x 14 days.
79506822|NCT00338988|Drug|Oxaliplatin|130 mg/m^2 IV over 2 hours on day 1 of cycle.
79668227|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
79668228|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
79668229|NCT00445926|Device|deep TMS H-coil|
79668230|NCT00339365|Behavioral|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
79668231|NCT00339365|Behavioral|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
79506823|NCT00343044|Drug|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
79506824|NCT00343044|Drug|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
79506825|NCT04724304|Diagnostic Test|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
79506826|NCT04724304|Diagnostic Test|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
79506827|NCT00344370|Drug|Pitavastatin|Pitavastatin 4 mg QD
79506828|NCT00344370|Drug|Atorvastatin|Atorvastatin 40 mg
79506829|NCT00344682|Drug|memantine|memantine 5mg - 20mg PO daily
79506830|NCT00344682|Drug|Placebo|5mg - 20mg PO daily over 8 weeks
79668232|NCT00452049|Procedure|parathyroidectomy|parathyroidectomy
79668233|NCT00452088|Biological|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
79506831|NCT00345384|Drug|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
79991147|NCT05421000|Procedure|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
79668234|NCT00452088|Biological|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
79355915|NCT03197662|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
79355916|NCT03197662|Drug|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
79355917|NCT04391062|Drug|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
79355918|NCT04391062|Device|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
79355919|NCT04384276|Other|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
79668235|NCT00452088|Biological|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
79991148|NCT04275934|Behavioral|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
79355920|NCT04384276|Other|Retrospective Control|No interventions will be administered to the historical control group.
79355921|NCT03247582|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
79355922|NCT01808612|Drug|Fluoxetine|
79506832|NCT00345384|Other|Placebo (Normal Saline)|
79668236|NCT00452166|Drug|rosiglitazone|
79991149|NCT02367274|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
79991150|NCT01379820|Device|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
79991151|NCT02357212|Procedure|coronary angiography|invasive procedure performed to determine coronary anatomy
79355923|NCT01808612|Drug|Placebo|
79355924|NCT01908829|Drug|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
79355925|NCT01908829|Drug|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
79355926|NCT01908829|Drug|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
79355927|NCT01908829|Drug|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
79355928|NCT01908829|Drug|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
79668237|NCT00446004|Drug|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
79668238|NCT00446004|Drug|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
79668239|NCT00446082|Drug|Pasireotide|
79668240|NCT03275376|Drug|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
79668241|NCT03275376|Drug|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
79991152|NCT02357212|Procedure|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
79991153|NCT01382160|Biological|adalimumab|40 mg every two weeks, by subcutaneous way
79506833|NCT01791114|Other|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
79506834|NCT01791114|Other|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
79668242|NCT03275337|Device|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
79991154|NCT00735748|Drug|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
79991155|NCT00735748|Drug|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
79991156|NCT03630900|Other|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
79668243|NCT03275259|Device|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
79668244|NCT00339872|Drug|IMA-638|
79355929|NCT01908829|Drug|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
79355930|NCT01908829|Drug|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
79355931|NCT01908829|Drug|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
79355932|NCT04277338|Drug|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
79355933|NCT01773122|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
79668245|NCT03275220|Diagnostic Test|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
79991157|NCT02367196|Drug|CC-90002|
79991158|NCT02367196|Drug|Rituximab|
79991159|NCT05418504|Drug|Dental anesthesia|Dental anesthesia, used to do any dental procedure
79991160|NCT02362126|Device|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
79991161|NCT05406414|Behavioral|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~Assessment and introduction to the sleep diary~Review of sleep diary - agreements on behavior changes and goals.~Information on normal sleep, sleep problems and circadian rhythm~Cognitive techniques~Introduction to relaxation training~Follow-up on goals and plan for prevention relapse of sleep problems"
79991162|NCT05406414|Behavioral|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
79991163|NCT01377792|Drug|Hypertonic saline|comparison of different dosages of drug
79991164|NCT02356978|Device|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
79991165|NCT02356978|Device|DRAP|
79991166|NCT03408886|Drug|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
79668246|NCT04698447|Dietary Supplement|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
79991167|NCT03408886|Drug|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
79228043|NCT02232867|Behavioral|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
79228044|NCT05224596|Diagnostic Test|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
79506835|NCT01791114|Other|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
79506836|NCT01791114|Other|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
79991168|NCT03408886|Biological|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
79228045|NCT02232945|Drug|placebo of oseltamivir phosphate|
79228046|NCT02232945|Drug|oseltamivir phosphate|
79228047|NCT02232945|Drug|Banlangen (Radix Isatidis) granules|
79506837|NCT01791114|Other|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
79991169|NCT02357056|Other|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
79991170|NCT02357056|Other|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
79506838|NCT01791114|Other|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
79506839|NCT01791114|Other|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
79506840|NCT04271592|Drug|ABI-H3733 Liquid Oral Dosage Form|ABI-H3733 liquid oral dosage form
79991171|NCT02357056|Other|Virtual Reality|daVinci Surgical Skills simulation
79355934|NCT01773122|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
79668247|NCT04698447|Dietary Supplement|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
79668248|NCT04698447|Dietary Supplement|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
79668249|NCT00340106|Behavioral|Counseling|
79668250|NCT00446238|Behavioral|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
79668251|NCT00446238|Behavioral|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
79355935|NCT01773122|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
79991172|NCT02367508|Behavioral|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
79355936|NCT01773122|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
79355937|NCT01808534|Drug|palifosfamide|Given IV
79355938|NCT01808222|Drug|FACBC|Participants will receive a bolus of anti-[18F]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
79355939|NCT04343482|Device|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
79355940|NCT01772576|Device|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
79355941|NCT03192358|Diagnostic Test|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
79370921|NCT01670565|Drug|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
79668252|NCT00340184|Drug|paclitaxel, carboplatin|
79668253|NCT00446277|Procedure|cataract surgery|
79506841|NCT04271592|Drug|ABI-H3733 Solid Oral Dosage Form|ABI-H3733 solid oral dosage form
79506842|NCT04271592|Drug|Placebo to ABI-H3733 Liquid Oral Dosage Form|Placebo to ABI-H3733 liquid oral dosage form
79506843|NCT04271592|Drug|Placebo to ABI-H3733 Solid Oral Dosage Form|Placebo to ABI-H3733 solid oral dosage form
79991173|NCT02362204|Behavioral|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
79991174|NCT03078582|Drug|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
79991175|NCT02361892|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
79991176|NCT04013334|Drug|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
79355942|NCT03192358|Other|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
79355943|NCT03218800|Combination Product|Ertapenem|"Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance < 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
79506844|NCT04271514|Drug|RPT193|Antagonist of the CCR4 chemokine receptor
79506845|NCT04271514|Drug|Placebo|Matching placebo
79506846|NCT01791192|Drug|FTY720|Fingolimod
79506847|NCT01791192|Drug|Oral Corticosteroid|Oral Corticosteroid
79506848|NCT01793766|Device|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
79668254|NCT04698408|Other|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
79991177|NCT04013334|Drug|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
79991178|NCT03285412|Drug|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
79991179|NCT03285412|Other|Endocrine therapy|Hormone therapy
79228048|NCT02232945|Drug|placebo of Banlangen(Radix Isatidis) granules|
79506849|NCT01793766|Device|Sham modulation|
79506850|NCT04019418|Dietary Supplement|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
79506851|NCT04019418|Other|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
79506852|NCT04019418|Other|Rest|30 minutes laying on a bed
79506853|NCT04019418|Other|Water|A drink containing 300ml of water
79506854|NCT00347022|Drug|Xenetix|300 mg of iodine/ml
79506855|NCT00347022|Drug|Visipaque|270 mg of iodine/ml
79991180|NCT03077724|Drug|Fish oil|Fish oil supplementation
79991181|NCT03077724|Drug|Placebos|Olive Oil capsules
79991182|NCT02361814|Procedure|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
79991183|NCT01379742|Device|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
79991184|NCT01379742|Device|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
79991185|NCT02361658|Other|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
79355944|NCT01802216|Procedure|Scaling and root planing|non-surgical periodontal disease treatment
79991186|NCT02361658|Other|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
79506856|NCT04714866|Behavioral|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
79506857|NCT00350142|Radiation|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
79506858|NCT00350142|Drug|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
79506859|NCT00350142|Other|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
79506860|NCT00350142|Radiation|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
79506861|NCT00350220|Other|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
79506862|NCT00350220|Other|Low Hb transfusion group|RBCs will not be transfused unless the Hb < 9.0 g/dl
79506863|NCT01791348|Other|d2 test of attention|
79506864|NCT03962400|Procedure|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
79355945|NCT01802216|Drug|Minocycline|antibiotic microspheres
79506865|NCT03962400|Procedure|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
79506866|NCT04588272|Device|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
79506867|NCT03860610|Diagnostic Test|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
79506868|NCT03860610|Diagnostic Test|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
79506869|NCT03860610|Diagnostic Test|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
79506870|NCT03860610|Diagnostic Test|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
79991187|NCT02361658|Other|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
79355946|NCT04760158|Other|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
79506871|NCT03860610|Diagnostic Test|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
79668255|NCT04698408|Other|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids <10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
79668256|NCT00446316|Drug|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
79668257|NCT00446316|Drug|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
79668258|NCT00446394|Behavioral|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
79355947|NCT03621904|Drug|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
79355948|NCT01808144|Drug|lesinurad|Tablets, 400 mg once daily (QD)
79355949|NCT01808144|Drug|lesinurad|Tablets, 200 mg QD
79355950|NCT01808144|Drug|febuxostat|Tabletsm 80 mg QD
79355951|NCT01801982|Other|non-interventional|non-interventional
79355952|NCT02085070|Drug|MK-3475|IV MK-3475
79355953|NCT01808066|Device|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
79506872|NCT03860610|Diagnostic Test|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
79506873|NCT03860610|Diagnostic Test|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
79506874|NCT01791426|Device|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
79506875|NCT01791426|Device|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
79506876|NCT03821844|Behavioral|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
79506877|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
79506878|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
79506879|NCT00351000|Drug|Ziprasidone|
79668259|NCT00446394|Behavioral|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
79355954|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
79355955|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
79355956|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
79355957|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
79355958|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
79355959|NCT01801436|Drug|Bortezomib|Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
79355960|NCT01771250|Biological|Insulin Peglispro|Daily doses administered SC.
79355961|NCT01771250|Biological|Insulin Glargine|Daily doses administered SC.
79355962|NCT01770860|Device|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
79506880|NCT00351936|Drug|Aripiprazole|
79506881|NCT00351936|Drug|placebo|
79668260|NCT03275181|Diagnostic Test|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
79668261|NCT03275181|Diagnostic Test|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
79668262|NCT03275181|Diagnostic Test|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
79668263|NCT00446433|Drug|CC-5013|
79668264|NCT00340574|Drug|AMA1-C1/Alhydrogel + CpG 7909|
79668265|NCT00340613|Drug|glargine insulin|
79668266|NCT03275025|Drug|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
79668267|NCT03275025|Drug|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
79668268|NCT03275025|Drug|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
79355963|NCT01770860|Device|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
79355964|NCT01770860|Device|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
79355965|NCT01770860|Device|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
79506882|NCT00352794|Drug|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
79991188|NCT02356744|Other|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
79506883|NCT00352794|Drug|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
79668269|NCT03275025|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
79668270|NCT00340691|Drug|Doxycycline|
79668271|NCT00452244|Drug|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
79355966|NCT03568708|Drug|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
79991189|NCT02356510|Procedure|Primary PCI|
79355967|NCT04305106|Drug|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
79355968|NCT04305106|Other|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
79355969|NCT04305106|Other|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
79355970|NCT01603875|Biological|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
79355971|NCT01770392|Drug|Nintedanib|single dose administration
79355972|NCT01770392|Drug|Rifampicin|single dose once daily for 7 days
79355973|NCT01770392|Drug|Nintedanib|single dose administration
79506884|NCT04421118|Other|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
79668272|NCT00452244|Drug|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
79506885|NCT00353418|Drug|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
79506886|NCT00353418|Drug|Ribavirin|800 mg orally daily for 48 weeks
79506887|NCT00353418|Drug|Ribavirin|1000 mg or 1200 mg (based on patient weight of < 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
79668273|NCT00446472|Drug|Regranex®|Regranex gel will be used for a total of 16 weeks
79668274|NCT00446472|Drug|Hydrogel|Placebo hydrogel will be applied for 16 weeks
79355974|NCT02020564|Behavioral|Speed of Processing Training|
79355975|NCT02020564|Behavioral|Placebo Control|
79355976|NCT01603641|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
79506888|NCT00353652|Drug|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg
79506889|NCT00353652|Drug|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg.
79506890|NCT00353652|Drug|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
79668275|NCT04715711|Other|Forearm coolng|forearm immersion will be performed for active cooling assessment
79668276|NCT04715711|Other|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
79991190|NCT02366884|Drug|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
79991191|NCT02366884|Drug|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
79991192|NCT02366884|Drug|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
79991193|NCT02356276|Procedure|D2 lymphadenectomy|
79991194|NCT02356276|Procedure|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
79506891|NCT00353652|Drug|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
79506892|NCT00353652|Drug|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
79668277|NCT04715711|Other|mist-fan|a mist-fan will be placed in front of the participant for active cooling
79668278|NCT04715711|Other|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
79506893|NCT01792362|Other|Weight loss diet|Control the patients diet to make them loosing weight
79506894|NCT03740880|Other|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
79991195|NCT02356276|Drug|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40 mg/m^2 bid, po, day 1-14 (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
79991196|NCT02361502|Drug|mirabegron|
79991197|NCT02361502|Drug|placebo|
79506895|NCT02982798|Drug|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
79506896|NCT02982798|Drug|JLP-1310|administration of JLP-1310
79991198|NCT02356354|Procedure|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
79991199|NCT02366962|Biological|ASP7374|subcutaneous
79228049|NCT01876784|Drug|Vandetanib (SAR390530)|"Pharmaceutical form: tablet~Route of administration: oral"
79355977|NCT02018692|Dietary Supplement|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
79355978|NCT02018692|Dietary Supplement|Placebo:Starch|Starch powder
79506897|NCT03709914|Drug|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
79506898|NCT03709914|Drug|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
79355979|NCT03492112|Device|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
79355980|NCT03492112|Drug|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
79991200|NCT02356120|Other|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
79991201|NCT02367118|Drug|Prednisone|
79991202|NCT02367118|Drug|Placebo|
79991203|NCT02361268|Behavioral|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
79991204|NCT02361268|Behavioral|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
79991205|NCT02355808|Behavioral|Tailored Leaflet|
79991206|NCT02355808|Behavioral|GP visit|
79991207|NCT02355730|Procedure|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
79991208|NCT00979212|Drug|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
79991209|NCT00979212|Drug|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
79991210|NCT00979212|Drug|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
79228050|NCT01876784|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79355981|NCT03492112|Drug|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
79355982|NCT04397380|Device|Thermography|Measure Temperature using Thermal Camera
79355983|NCT04397380|Device|Tympanic Temperature|Measure Temperature using Tympanic Temperature
79506899|NCT03921840|Behavioral|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps & minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
79506900|NCT03921840|Other|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
79506901|NCT01794078|Drug|Aminophylline 400 mg|Xanthine derivative
79506902|NCT01794078|Drug|Ambrisentan 5 mg|Endothelin receptor antagonist
79506903|NCT01794078|Other|Placebo|
79991211|NCT00979212|Procedure|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
79991212|NCT02356042|Other|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
79991213|NCT02355964|Behavioral|Exercise|Aerobe exercise 3 times a week in 8 weeks
79228051|NCT02546622|Biological|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
79228052|NCT02546622|Biological|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
79355984|NCT01556763|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
79355985|NCT01556763|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
79355986|NCT01556763|Drug|Placebo|Matching placebo was administered as one capsule per day for 21 days.
79506904|NCT03436680|Other|Best Practice|Receive standard of care
79506905|NCT03436680|Behavioral|Neurofeedback|Complete neurofeedback training sessions
79506906|NCT03436680|Other|Quality-of-Life Assessment|Ancillary studies
79818474|NCT06236659|Dietary Supplement|Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
79818475|NCT06236659|Dietary Supplement|Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
79991214|NCT02355964|Behavioral|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
79506907|NCT03436680|Other|Questionnaire Administration|Ancillary studies
79668279|NCT00446589|Drug|ibandronate|iv 1mg ibandronate monthly for one year
79668280|NCT00446589|Drug|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
79668281|NCT00446628|Behavioral|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
79668282|NCT00452322|Drug|Testosterone Substitution by Testosterone Undecanoate i.m.|
79228053|NCT02229903|Device|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
79506908|NCT01791504|Device|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
79506909|NCT00354978|Drug|5-Fluorouracil|"400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection."
79506910|NCT00354978|Drug|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
79506911|NCT00354978|Drug|Leucovorin|400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
79668283|NCT00452478|Drug|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
79668284|NCT00452517|Procedure|Percutaneous Coronary Intervention|
79668285|NCT00452556|Drug|Docetaxel|Weekly
79668286|NCT00452556|Drug|Leuprolide Acetate (Eligard®)|2.5 years
79668287|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
79668288|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
79668289|NCT00446667|Drug|mannitol|400mg BD for 2 days
79506912|NCT00354978|Drug|Irinotecan|180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.
79506913|NCT01794156|Behavioral|Cognitive behavior therapy|
79991215|NCT02355652|Device|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
79506914|NCT01794156|Behavioral|Mindfulness-based stress reduction|
79506915|NCT01794156|Behavioral|Inference-based therapy|
79506916|NCT04194060|Combination Product|Enhanced Recovery after Surgery group|"Tracheal intubation and with General anesthesia~Short acting anesthetic agents,avoid opioid agents~Omental patch repair with placement of sub hepatic drain~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Post operative nausea and vomiting prophylaxis.~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~Avoid opiod analgesics."
79506917|NCT04194060|Combination Product|Conventional|"Tracheal intubation~Short acting anesthetic agents, avoid opiod anesthesia agents.~Omental patch repair along with sub hepatic drain placement.~Post operative nausea and vomiting prophylaxis.~Ambulation-as per patients' own request.~Initiation of oral feed- after passage of 1st flatus.~Nasogastric tube removal-output <300ml/day with resolution of ileus.~Removal of urinary catheter- when patient sits on bed side/ambulate.~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~Patient will receive opiod analgesics."
79506918|NCT00355914|Procedure|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
79506919|NCT01792596|Other|Pasta with protein|Pasta with Protein
79506920|NCT01792596|Other|Pasta with Fiber|Pasta with Fiber
79506921|NCT01792596|Other|Pasta|Pasta
79506922|NCT00356304|Behavioral|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
79506923|NCT00356304|Behavioral|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
79506924|NCT03138096|Biological|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
79506925|NCT03138096|Other|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
79668290|NCT03277755|Drug|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
79991216|NCT02355652|Device|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
79506926|NCT02855892|Other|Placebo|
79506927|NCT02855892|Drug|GV1001|
79228054|NCT02229903|Device|Sham Treatment|29 treatments over 6 weeks.
79506928|NCT02816580|Other|Blood collection|
79506929|NCT02713854|Procedure|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
79506930|NCT04182516|Drug|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
79506931|NCT00357162|Drug|belinostat|Given IV
79506932|NCT04011072|Radiation|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
79506933|NCT00358332|Biological|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
79506934|NCT00358332|Biological|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
79506935|NCT01792908|Device|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
79506936|NCT02442414|Drug|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
79506937|NCT01773486|Drug|Hesperidin|Citrus polyphenol, hesperidin
79506938|NCT01773486|Drug|Placebo|Placebo matching hesperidin
79506939|NCT03984240|Drug|Midazolam|Participant will be sedated by midazolam.
79506940|NCT03984240|Drug|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
79506941|NCT00359736|Drug|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
79355987|NCT01556763|Drug|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
79506942|NCT00360126|Drug|lamotrigine|
79506943|NCT00360360|Drug|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
79355988|NCT04397146|Dietary Supplement|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
79506944|NCT00360360|Drug|carboplatin|Carboplatin AUC 6.0 IV Day 1
79355989|NCT01576575|Drug|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
79355990|NCT01576575|Drug|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
79355991|NCT01576575|Drug|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
79506945|NCT00360360|Drug|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
79506946|NCT00360360|Drug|erlotinib|Erlotinib 150 mg by mouth daily
79506947|NCT01552590|Drug|Tolvaptan|
79355992|NCT01576575|Drug|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
79355993|NCT05051566|Drug|LY3502970|Administered orally.
79355994|NCT05051566|Drug|Esomeprazole|Administered orally.
79355995|NCT01555983|Drug|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
79355996|NCT01576341|Drug|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
79355997|NCT03451630|Behavioral|High-Touch|Intensive, in-person support.
79355998|NCT03451630|Behavioral|High-Tech|Remote care management and self-directed digital tools.
79355999|NCT03451630|Behavioral|Usual Care/Optimal Discharge Planning|Transition to other Health Plan disease management programs.
79356000|NCT04247464|Procedure|Fasting|Food intake restriction
79356001|NCT04241224|Device|Atherectomy|Endovascular treatment of peripheral arterial disease
79506948|NCT01552590|Drug|Placebo|
79506949|NCT01496664|Procedure|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
79506950|NCT01105884|Procedure|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
79506951|NCT01105884|Procedure|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
79506952|NCT01105884|Procedure|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
79506953|NCT01105884|Procedure|Hydrogel|All the subjects in this group will be treated with Hydrogel
79506954|NCT01105884|Procedure|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
79506955|NCT00549978|Drug|Cilostazol|cilostazol, then cilostazol/probucol
79506956|NCT00549978|Drug|Probucol|Probucol probucol/ cilostazol
79506957|NCT03983226|Procedure|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
79506958|NCT03983226|Drug|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
79506959|NCT03983226|Drug|Niraparib|Niraparib maintenance therapy
79506960|NCT04346082|Behavioral|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
79506961|NCT00360672|Drug|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
79506962|NCT00360828|Drug|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride [CPT-11; CAMPTOSAR] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
79356002|NCT03411070|Device|Implanted Medical Device|Undergo SCOUT reflector placement
79356003|NCT03411070|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79668291|NCT03277755|Drug|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
79668292|NCT03277755|Drug|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
79356004|NCT03331978|Behavioral|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
79991217|NCT03630744|Other|Fluid therapy|"Analyze the type of fluid administered:~crystalloids:~Saline serum 0.9% ....... ml~Ringer Lactate ........ ml~Isofundin ® ........ ml~Plasmalyte® ... ... ml~Glucose Serum 5% ....... ml~Glucose serum 10% ........ ml~Glucosaline serum ........ ml~colloids:~Hydroxyethyl starch 130 / 0.4 ... ... ml~Hydroxyethyl alimdon 130 / 0.42 ... .... ml~Gelatins ... ....... ml~Albumin 5% .......... ml~Albumin 20% .......... ml.~Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~Analyze the form of administration:~Standard~Standard with dosimeters~on pump"
79991218|NCT03160534|Other|preoperative exercise|Each intervention session contains a stretching part and aerobic training
79356005|NCT04398004|Drug|Clarithromycin|Treatment with 500 mg Clarithromycin orally twice daily for seven days
79356006|NCT01687413|Radiation|Intensity-modulated radiation therapy (IMRT)|
79356007|NCT01687413|Drug|Cisplatin|
79356008|NCT04181320|Device|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
79356009|NCT01555671|Drug|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
79506963|NCT00360828|Drug|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
79506964|NCT00361140|Drug|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
79668293|NCT03277677|Drug|Normal saline|for resuscitation in sepsis patients
79668294|NCT03277677|Drug|Ringer's Acetate|for resuscitation in sepsis patients
79668295|NCT00452595|Drug|DVS-233 SR (desvenlafaxine sustained release )|
79991219|NCT01379586|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
79668296|NCT02956980|Biological|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
79668297|NCT00341354|Behavioral|Prolonged Mechanical Ventilation|
79668298|NCT01580436|Procedure|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
79668299|NCT02956668|Other|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
79668300|NCT02956668|Other|Blindsight Training alone|The patient undergo visual rehabilitation
79356010|NCT01555671|Drug|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
79356011|NCT03255616|Other|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
79668301|NCT00341432|Behavioral|Nicotine Replacement Therapy|
79668302|NCT00452634|Drug|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
79991220|NCT01379586|Drug|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
79991221|NCT02038738|Drug|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
79991222|NCT02361424|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
79991223|NCT02361424|Drug|placebo|
79356012|NCT03255616|Other|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
79356013|NCT03226756|Drug|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
79356014|NCT01801358|Drug|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
79991224|NCT05347368|Other|Control group (conventional therapy)|Physical therapy will be performed using physical agent modality that include hot pack (15 min), and therapeutic exercises (5 repetition per set, 2 sets each session) therapeutic exercises include spinal extension exercise, prone hip extension exercise, posterior pelvic tilt, cat-camel exercise
79668303|NCT00452634|Drug|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
79668304|NCT00452634|Drug|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
79356015|NCT01801358|Drug|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
79991225|NCT05347368|Other|Primal Reflex release Technique|The SI/Lumbar release Iliopsoas release Piriformis release Hamstring release Gastrocnemius release
79991226|NCT02366416|Behavioral|Exercise training|Physical activity
79991227|NCT01377558|Other|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
79356016|NCT01807598|Drug|Brentuximab vedotin|
79356017|NCT01801280|Drug|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
79356018|NCT01801280|Drug|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
79356019|NCT01801280|Drug|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
79356020|NCT01769456|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
79356021|NCT01769456|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
79506965|NCT00361140|Drug|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
79506966|NCT01794468|Other|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
79506967|NCT00361374|Dietary Supplement|eicosapentaenoic acid|1 gram/day
79506968|NCT00361374|Dietary Supplement|docosahexaenoic acid|1 gram/day
79668305|NCT03277599|Drug|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
79356022|NCT01769378|Drug|Placebo|Administered SQ
79668306|NCT03277599|Drug|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
79668307|NCT03277599|Drug|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
79668308|NCT00341471|Procedure|Risk Behavior Prevention Intervention Program|
79668309|NCT00452712|Procedure|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
79668310|NCT00452751|Procedure|laparoscopy-assisted distal gastrectomy|
79668311|NCT00452751|Procedure|open distal gastrectomy|
79668312|NCT00452829|Drug|Folic Acid and inositol|Folic Acid and inositol
79356023|NCT01769378|Drug|Dulaglutide|Administered SQ
79356024|NCT01769378|Drug|Glimepiride|Administered PO
79506969|NCT00361374|Drug|Placebo|980 milligram/day
79506970|NCT00362466|Drug|Dasatinib|Tablets, Oral, Once daily, 5-7 years
79506971|NCT00362466|Drug|Imatinib|Tablets, Oral, Once daily, 5-7 years
79506972|NCT00305682|Biological|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
79668313|NCT00452829|Drug|Folic acid and placebo|Folic acid and placebo
79668314|NCT03277560|Other|No Intervention as it is an observational study|No Intervention as it is an observational study
79991228|NCT01377558|Other|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
79506973|NCT00305682|Drug|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
79506974|NCT00305682|Drug|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
79668315|NCT03277443|Procedure|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
79356025|NCT01807520|Biological|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
79506975|NCT00305682|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
79356026|NCT01807520|Biological|Placebo|Placebo was provided in pre-filled 1 mL syringes.
79356027|NCT01806896|Drug|PF-02545920|"Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Treatment for 28 days."
79356028|NCT01806896|Drug|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
79356029|NCT01806896|Drug|PF-02545920|"5mg dose~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
79506976|NCT00305682|Procedure|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
79506977|NCT00305682|Radiation|total body irradiation|Administered Day -1, 200 cGy
79506978|NCT00305682|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
79506979|NCT00305760|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
79506980|NCT00305760|Biological|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
79506981|NCT00305760|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
79506982|NCT00309738|Drug|pitavastatin|
79506983|NCT00309738|Drug|simvastatin|
79506984|NCT00310050|Drug|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
79506985|NCT00310050|Device|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
79506986|NCT00363168|Drug|Ranibizumab|0.3 mg/0.05 ml dose
79228055|NCT05218746|Procedure|Serratus anterior plane block|High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.
79506987|NCT00363168|Drug|Ranibizumab|0.5 mg/0.05 ml dose
79506988|NCT03723798|Drug|SA001 Low dose|3 tablets b.i.d for 12 weeks
79506989|NCT03723798|Drug|SA001 Mid dose|3 tablets b.i.d for 12 weeks
79818479|NCT06236490|Diagnostic Test|Blood Oxygen Level Test|The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.
79818480|NCT06236490|Diagnostic Test|Wingate Anaerobic Test|WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.
79506990|NCT03723798|Drug|SA001 High dose|3 tablets b.i.d for 12 weeks
79506991|NCT03723798|Drug|Placebo|3 tablets b.i.d for 12 weeks
79506992|NCT01794546|Behavioral|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
79506993|NCT00365274|Drug|Cyclophosphamide|Given IV 750 mg/m^2 day 1
79506994|NCT00365274|Drug|Doxorubicin hydrochloride|Given 50 mg/m^2 IV day 1
79506995|NCT00365274|Drug|vincristine sulfate|Given 1.4 mg/m^2 IV
79506996|NCT00365274|Drug|prednisone|100 mg orally daily days 1 - 5
79506997|NCT00365274|Drug|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
79506998|NCT00310362|Behavioral|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
79506999|NCT00311376|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
79507000|NCT00311376|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
79507001|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
79507002|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
79507003|NCT03238170|Device|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
79356030|NCT01806896|Drug|Placebo|"Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
79356031|NCT01768676|Drug|avanafil|100 mg
79356032|NCT01768676|Drug|Placebo|
79356033|NCT01555125|Drug|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
79356034|NCT01555125|Drug|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
79356035|NCT01555125|Drug|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
79356036|NCT01768286|Drug|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
79356037|NCT01768286|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79356038|NCT01800968|Drug|Liraglutide|Active Drug
79818481|NCT06236490|Diagnostic Test|Cardiopulmonary Exercise Test|CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth < 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
79356039|NCT01800968|Drug|Placebo|Placebo
79356040|NCT01799720|Dietary Supplement|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
79356041|NCT01799720|Dietary Supplement|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
79356042|NCT01799720|Drug|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
79356043|NCT01687257|Drug|SOF|SOF 400 mg tablet administered orally once daily
79356044|NCT01687257|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79356045|NCT01806740|Drug|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
79356046|NCT01687101|Drug|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
79356047|NCT01968967|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
79356048|NCT01968967|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
79356049|NCT01554579|Drug|Gefapixant|BID
79356050|NCT01554579|Drug|Sugar Pill|Placebo
79356051|NCT01806662|Drug|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
79356052|NCT01806662|Other|Placebo|Injection of placebo
79370922|NCT01670565|Drug|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at <2,000 mg/day for <3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
79370923|NCT01670565|Other|Placebo Infusion|Infusion of normal saline
79507004|NCT02104830|Biological|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
79507005|NCT02104830|Biological|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
79356053|NCT01930123|Drug|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
79356054|NCT01930123|Other|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
79356055|NCT01930045|Drug|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
79356056|NCT01930045|Drug|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
79356057|NCT04631263|Device|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
79356058|NCT01929343|Drug|lidocaine following cue-induced craving|as described in Arm Description
79356059|NCT01929343|Drug|lidocaine following neutral stimulus|as described in Arm Description
79668316|NCT03277443|Procedure|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
79668317|NCT03277443|Device|2D cephalometric radiograph|2D cephalometric radiograph
79356060|NCT01929343|Drug|saline|as described in Arm Description
79356061|NCT01968811|Device|Avance Foam dressing kit|
79356062|NCT01806584|Biological|SRM003|One time implant (3 SRM003 pieces) on surgery day.
79668318|NCT03277443|Device|3D computerized tomography|3D computerized tomography
79668319|NCT00452907|Drug|Artesunate|oad, per os, 3 days of treatment
79668320|NCT00452907|Drug|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
79668321|NCT00452907|Drug|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
79356063|NCT01806584|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
79356064|NCT01798706|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
79356065|NCT01798706|Drug|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
79370924|NCT03088215|Device|shock-waves|Application of shock-waves (radial and focused)
79507006|NCT02104830|Biological|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
79507007|NCT02104830|Biological|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
79507008|NCT02104830|Biological|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
79507009|NCT00311766|Drug|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
79507010|NCT00311766|Drug|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
79668322|NCT00446784|Drug|CE-224,535|
79668323|NCT00446784|Drug|Methotrexate|
79668324|NCT00452985|Drug|Docetaxel|60-75 mg/m²
79668325|NCT00452985|Drug|Carboplatin|AUC 5
79668326|NCT00453024|Procedure|Pericardial graft & tissue glue|
79668327|NCT00453024|Procedure|scleral flap & sutures|
79668328|NCT03277404|Procedure|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
79668329|NCT03277404|Procedure|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
79668330|NCT03277326|Procedure|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
79668331|NCT03277326|Procedure|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
79668332|NCT03277326|Procedure|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
79668333|NCT03277287|Radiation|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
79668334|NCT03277209|Drug|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
79991229|NCT01377558|Other|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
79991230|NCT05331612|Behavioral|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
79991231|NCT02361190|Drug|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
79356066|NCT01798706|Drug|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
79356068|NCT04397926|Drug|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
79356069|NCT01767194|Biological|Dinutuximab|Given IV
79356070|NCT01767194|Drug|Irinotecan Hydrochloride|Given IV
79356071|NCT01767194|Other|Laboratory Biomarker Analysis|Optional correlative studies
79356072|NCT01767194|Biological|Sargramostim|Given SC or IV
79356073|NCT01767194|Drug|Temozolomide|Given PO
79356074|NCT01767194|Drug|Temsirolimus|Given IV
79356075|NCT04398784|Dietary Supplement|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
79356076|NCT04398784|Dietary Supplement|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
79228056|NCT05218746|Procedure|Erector spinae block|A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
79356077|NCT01575873|Drug|Denosumab|Administered by subcutaneous injection once every 6 months
79356078|NCT01575873|Drug|Placebo for risendronate|Administered orally once a day
79356079|NCT01575873|Drug|Risendronate|Administered orally once a day
79356080|NCT01575873|Drug|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
79356081|NCT03216928|Diagnostic Test|Blood test|
79991232|NCT02361190|Drug|Placebo|Administration of 1ml aqueous saline spray
79991233|NCT02361112|Drug|pyrotinib combined with capecitabine|
79991234|NCT03080454|Device|sham Doublestim|PathMaker MyoRegulator device
79991235|NCT03080454|Device|anodal Doublestim|PathMaker MyoRegulator device
79991236|NCT05327712|Behavioral|Control group|No outreach during the intervention period beyond an initial eligibility notice.
79991237|NCT05327712|Behavioral|Email only|Email reminders in addition to an initial eligibility notice.
79991238|NCT05327712|Behavioral|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
79991239|NCT05327712|Behavioral|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
79991240|NCT02943304|Other|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
79356082|NCT04276636|Drug|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
79356083|NCT04397224|Diagnostic Test|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
79356084|NCT03028545|Behavioral|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
79356085|NCT00002644|Drug|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
79356086|NCT00002644|Other|Placebo|Placebo 20Mg Tab
79356087|NCT01575561|Drug|Lurasidone|Lurasidone 20-80 mg taken orally once daily
79356088|NCT03574480|Behavioral|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
79356089|NCT03574480|Behavioral|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
79356090|NCT03089086|Biological|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to <3 months apart in adolescents.
79507011|NCT00313560|Drug|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
79507012|NCT01791738|Procedure|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
79356091|NCT04112758|Other|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
79356092|NCT04087876|Drug|derazantinib|derazantinib will be administered orally
79507013|NCT00314106|Biological|Melanoma Reactive TIL|
79507014|NCT00314106|Drug|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
79507015|NCT00314106|Biological|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
79507016|NCT00314106|Drug|Fludarabine|25 mg/m^2/day intravenous x 5 days
79507017|NCT00314106|Radiation|1200 total body irradiation (TBI)|1200 cGY total body radiation
79507018|NCT00315120|Procedure|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
79507019|NCT00315120|Procedure|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
79507020|NCT00315120|Procedure|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
79507021|NCT00315120|Procedure|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
79507022|NCT00315588|Drug|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
79507023|NCT01793064|Behavioral|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
79991241|NCT02360956|Drug|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
79356095|NCT04746352|Procedure|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
79370925|NCT01675479|Device|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
79370926|NCT01678755|Drug|ABT-126|ABT-126 Low Dose
79370927|NCT01678755|Drug|ABT-126|ABT-126 High Dose
79370928|NCT01678755|Drug|Placebo|Placebo
79507024|NCT01793064|Behavioral|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
79507025|NCT00367380|Other|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
79507026|NCT00367380|Other|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
79507027|NCT00367380|Other|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
79507028|NCT00368316|Biological|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
79668335|NCT00342134|Procedure|Stem Cell Transplanataion|
79668336|NCT00453141|Drug|dosing of Betamethasone|
79991242|NCT02360956|Drug|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
79356096|NCT04746352|Procedure|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
79356097|NCT03164122|Drug|injection of microfat and plasma rich platelet PRP|intra-articular injections
79356098|NCT03164122|Device|MRI|MRI 3T
79356099|NCT04397770|Drug|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
79356100|NCT04397770|Drug|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
79356101|NCT04397770|Drug|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
79507029|NCT00368940|Behavioral|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
79507030|NCT00368940|Behavioral|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
79507031|NCT00369564|Drug|glutamic acid|Given orally 3 times daily
79507032|NCT00369564|Other|placebo|Given orally 3 times daily
79507033|NCT00315822|Other|80% oxygen|Supplemental oxygen will be administered during surgery
79507034|NCT00315822|Other|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
79668337|NCT03277092|Device|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
79668338|NCT03277092|Procedure|Usual care|The blood drawing is performed traditionally
79991243|NCT05461716|Device|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
79991244|NCT02367976|Drug|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
79356102|NCT03082846|Radiation|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
79356103|NCT03082846|Drug|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
79356104|NCT03213418|Behavioral|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
79356105|NCT05249764|Other|Supervised Home Based Exercise Training|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
79370929|NCT04358380|Other|Liver injury|LFTs elevation or liver decompensation
79356106|NCT05249764|Other|Unsupervised stretching and breathing exercises|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
79507035|NCT01794624|Behavioral|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
79507036|NCT01794624|Behavioral|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
79507037|NCT00316524|Biological|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
79507038|NCT00316524|Biological|Placebo|Tris-Buffer
79507039|NCT02994498|Drug|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
79991245|NCT05461638|Procedure|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
79991246|NCT05461638|Procedure|Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
79991247|NCT02360800|Procedure|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
79356107|NCT04276324|Other|Resistance training|Ten weeks of resistance training
79356108|NCT04276324|Other|Testing sessions|Testing sessions
79356109|NCT05240482|Procedure|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
79507040|NCT00317226|Drug|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
79507041|NCT05288010|Combination Product|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
79507042|NCT01793298|Drug|ASM-024|Ascending doses of ASM-024
79507043|NCT02973126|Procedure|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
79507044|NCT05287854|Device|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
79507045|NCT05287776|Device|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
79507046|NCT05287698|Other|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
79507047|NCT01794858|Other|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
79507048|NCT00318708|Drug|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
79507049|NCT00318708|Drug|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
79507050|NCT00318708|Drug|placebo clarithromycin|placebo clarithromycin twice daily
79356110|NCT04746118|Behavioral|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
79507051|NCT00319644|Device|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
79507052|NCT02422446|Drug|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
79507053|NCT05287386|Drug|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
79991248|NCT02360800|Procedure|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
79507054|NCT02056704|Device|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
79507055|NCT05287152|Device|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
79507056|NCT05286840|Diagnostic Test|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
79668339|NCT00453219|Procedure|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
79668340|NCT00453219|Procedure|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
79991249|NCT02360878|Device|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
79991250|NCT03501966|Drug|Acetazolamide|Medical therapy including diet
79991251|NCT03501966|Procedure|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
79991252|NCT03501966|Procedure|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
79991253|NCT02361034|Drug|GRC 27864|
79668341|NCT00453219|Genetic|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
79991254|NCT02361034|Drug|Placebo|
79991255|NCT02355184|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
79507057|NCT05286606|Behavioral|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
79507058|NCT04271670|Other|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
79668342|NCT00453219|Procedure|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
79668343|NCT00453219|Procedure|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
79818482|NCT06235879|Other|Control Group (Interscalene brachial plexus block)|"Patients will receive ultrasound guided interscalene brachial plexus block after induction of general anesthesia.~Scanning with SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) will be started just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle.~the transducer will be moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles at the level of the sixth cervical vertebra deep to the sternocleidomastoid muscle.~The needle will be then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction.~After negative aspiration and assurance that high resistance to injection is absent, 0.25% bupivacaine hydrochloride will be injected in a 5-ml increment below the lower root, between the 3 roots, and above the upper root.(Total amount is 15 ml of 0.25% bupivacaine hydrochloride)."
79818483|NCT06235879|Procedure|Pericapsular nerve group (PENG) block|"Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia.~Using SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) ,A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head.~After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle can't be advanced further.~The needle tip will be placed between the deltoid muscle and subscapularis tendon, after a careful aspiration, 15 ml of 0.25% bupivacaine hydrochloride will be injected."
79356111|NCT04746118|Behavioral|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
79507059|NCT04271670|Other|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
79507060|NCT04271670|Other|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
79507061|NCT04750746|Other|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
79507062|NCT04750746|Other|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
79668344|NCT00421031|Drug|DVS-233 SR|
79668345|NCT03277053|Device|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
79668346|NCT03277053|Other|Control.|Patient receive an ipad with no application.
79668347|NCT00421070|Procedure|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
79668348|NCT03274908|Other|regular medical treatment|regular medical treatment
79668349|NCT00421109|Drug|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
79668350|NCT00421109|Drug|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
79507063|NCT04750668|Other|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
79507064|NCT04750590|Procedure|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
79507065|NCT04750590|Procedure|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
79507066|NCT04750200|Procedure|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
79818484|NCT06235801|Drug|Gilteritinib|Given by PO
79356112|NCT04746118|Other|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
79356113|NCT02783716|Procedure|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
79356114|NCT02783716|Diagnostic Test|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
79356115|NCT05241886|Other|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
79356116|NCT03145168|Other|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
79356117|NCT03145168|Other|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
79356118|NCT05249140|Device|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
79507067|NCT00321594|Drug|belinostat|Given IV
79507068|NCT04751214|Procedure|APPENDICECTOMY|
79668351|NCT00421109|Drug|Placebo|Encapsulated tablet. Once daily for 28 days
79818485|NCT06235801|Drug|Momelotinib|Given by PO
79818486|NCT06234774|Procedure|Robot-assisted laparoscopic surgery|
79818487|NCT06234774|Procedure|Conventional (non-robotic) laparoscopic surgery|
79818488|NCT06234397|Drug|BH3120|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of BH3120 in solid tumors
79991256|NCT05326854|Other|supportive care|After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
79991257|NCT02355262|Other|Informational Intervention|Receive CATCH-UP intervention
79507069|NCT04751136|Drug|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
79507070|NCT04750980|Other|food allergy|food allergy
79668352|NCT00446823|Device|XCell cellulose wound dressing|
79668353|NCT00446823|Device|Impregnated gauze dressing|
79668354|NCT02273583|Drug|continuous oral cyclophosphamide and methotrexate|
79668355|NCT00446862|Drug|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
79668356|NCT00453258|Other|Eye Examination|Subjects receiving eye examination
79668357|NCT00342368|Procedure|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
79668358|NCT00446901|Dietary Supplement|Selenium|Selenized yeast, 300 ug/day
79668359|NCT00453297|Drug|MF101|
79668360|NCT00453375|Drug|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
79668361|NCT00453375|Drug|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
79668362|NCT00446940|Drug|rosuvastatin|
79668363|NCT00446940|Drug|atorvastatin|
79818489|NCT06234072|Drug|Astragalus + Gemcitabine|Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
79356119|NCT05241808|Behavioral|Girls Can...Move!|Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
79356120|NCT01609790|Biological|Bevacizumab|Given IV
79356121|NCT01609790|Other|Laboratory Biomarker Analysis|Correlative studies
79356122|NCT01609790|Other|Pharmacological Study|Correlative studies
79356123|NCT01609790|Other|Placebo Administration|Given IV
79356124|NCT01609790|Biological|Trebananib|Given IV
79356125|NCT01767116|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79356126|NCT01767116|Drug|Ribavirin|Capsule
79356127|NCT01767116|Drug|Placebo for ribavirin|Capsule
79356128|NCT01574703|Drug|placebo|All dosing to have taken place per study A3051123
79356129|NCT01574703|Drug|varenicline tartrate|All dosing to have taken place per study A3051123
79356130|NCT01574703|Drug|bupropion hydrochloride|All dosing to have taken place per study A3051123
79356131|NCT01574703|Drug|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
79507071|NCT04750980|Other|respiratory allergy|respiratory allergy
79507072|NCT04750980|Other|healthy controls|healthy controls
79991258|NCT02355496|Other|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
79991259|NCT03477630|Biological|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
79356132|NCT03028623|Procedure|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
79356133|NCT03028623|Procedure|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
79356134|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
79356135|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
79356136|NCT01686633|Drug|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
79356137|NCT04413669|Procedure|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
79356138|NCT01685697|Procedure|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
79356139|NCT01685697|Procedure|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
79356140|NCT03028233|Behavioral|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
79507073|NCT00390234|Drug|ziv-aflibercept|Given IV
79507074|NCT00391716|Drug|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
79507075|NCT00391716|Behavioral|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
79507076|NCT00391716|Drug|placebo|lactose capsule compounded to mimic gabapentin capsules
79507077|NCT00391716|Drug|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
79668364|NCT00453414|Drug|Iloprost Inhalation Solution (Ventavis)|
79668365|NCT00342836|Procedure|Akt levels|
79668366|NCT00446979|Drug|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
79668367|NCT00446979|Drug|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
79668368|NCT00453453|Drug|Nesiritide|Nesiritide given orally in the emergency department
79668369|NCT00447018|Drug|20% mannitol|
79507078|NCT00392496|Drug|sunitinib malate|Given orally
79668370|NCT00447018|Drug|7.45% hypertonic saline solution|
79668371|NCT05649033|Other|data collection|Work-related stress evaluation
79668372|NCT00343070|Drug|Oral administration of escitalopram during 8 weeks|
79668373|NCT00453492|Drug|risedronate sodium|
79991260|NCT03477630|Drug|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
79991261|NCT01379040|Other|Cystic Fibrosis patients|
79991262|NCT02981342|Drug|Abemaciclib|Administered orally
79507079|NCT01958190|Drug|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
79507080|NCT01958190|Drug|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
79507081|NCT01571778|Behavioral|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
79507082|NCT04388982|Biological|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
79356141|NCT03028233|Behavioral|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
79818490|NCT06234072|Drug|Gemcitabine alone|Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
79356142|NCT02395120|Behavioral|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
79356143|NCT02395120|Behavioral|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
79356144|NCT02395120|Behavioral|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
79356145|NCT02395120|Behavioral|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
79356146|NCT02395120|Behavioral|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
79991263|NCT02981342|Drug|LY3023414|Administered orally
79356147|NCT01685229|Device|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
79356148|NCT01685229|Drug|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
79356149|NCT03141424|Drug|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
79356150|NCT03028389|Procedure|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
79356151|NCT03614494|Drug|Piroxicam 40 mg|Additional co-treatment
79356152|NCT03614494|Drug|Levonorgestrel 1.5mg|Standard treatment
79507083|NCT04388982|Biological|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
79507084|NCT04388982|Biological|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
79668374|NCT00447096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
79668375|NCT00343148|Drug|AVI-4126 Injection (RESTEN-NG®)|
79668376|NCT00343187|Drug|ACZONE (dapsone) Gel, 5%|
79668377|NCT00343187|Drug|Vehicle Control|
79668378|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
79668379|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
79668380|NCT00453570|Biological|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
79668381|NCT00343226|Drug|Basiliximab|
79991264|NCT02981342|Drug|Gemcitabine|Administered IV
79991265|NCT02981342|Drug|Capecitabine|Administered orally
79991266|NCT02794246|Biological|CART-19 cells|
79507085|NCT05286216|Behavioral|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
79507086|NCT00638898|Drug|busulfan|Given IV
79356153|NCT03028155|Drug|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
79507087|NCT00638898|Drug|melphalan|Given IV
79507088|NCT00638898|Drug|topotecan hydrochloride|Given IV
79356154|NCT03028155|Drug|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
79668382|NCT00447174|Behavioral|Dyadic treatment for parental bereavement|
79818491|NCT06234020|Other|To see the frequency of vertebrospinal anomalies in patients presenting with Anorectal Malformation|The patients presenting with anorectal malformation go through x-ray. We will get the reporting of x-ray done to see the vertebral anomalies and the patients presenting with fecal/urinary incontinence will go through MRI for spinal anomalies.
79991267|NCT02355106|Device|PolarStart System|Atrial flutter Ablation
79356155|NCT01551693|Drug|STA-9090|
79356156|NCT01922518|Procedure|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
79507089|NCT00638898|Other|laboratory biomarker analysis|Correlative studies
79356157|NCT01922518|Procedure|Apex pacing|Put RV lead around the apex
79356158|NCT04276402|Procedure|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
79507090|NCT00638898|Biological|filgrastim|Given IV or subcutaneously
79507091|NCT00638898|Procedure|autologous hematopoietic stem cell transplantation|Undergo transplantation
79507092|NCT00638898|Other|pharmacological study|Correlative studies
79507093|NCT00638898|Procedure|autologous bone marrow transplantation|Undergo transplantation
79507094|NCT01793454|Other|Fraction of inspired oxygen 40%|
79668383|NCT00343265|Drug|Vaginal progesterone gel|Vaginal gel once daily
79668384|NCT00343265|Drug|Placebo gel|once daily
79668385|NCT00453609|Drug|long-lasting injectable naltrexone|
79668386|NCT00343304|Device|Robot|
79668387|NCT00343304|Device|Ergometer|
79668388|NCT00447213|Drug|Insulin glargine|Patient specific, injected, daily, 24 weeks
79668389|NCT00447213|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
79668390|NCT00447213|Drug|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
79668391|NCT00343343|Device|NovoFine® needle 6 mm|
79668392|NCT00343343|Device|NovoFine® needle 4 mm|
79668393|NCT00453648|Other|White-fleshed sweet potatoes|
79668394|NCT00453648|Other|Orange-fleshed sweet potatoes (boiled)|
79668395|NCT00453648|Other|Orange-fleshed sweet potatoes (fried)|
79356159|NCT01574157|Drug|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
79356160|NCT01574157|Drug|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
79356161|NCT04276246|Device|dental implants and retentive implant components|retentive components (Group A Test), which are connected to the implants to retain the RPD
79507095|NCT01793454|Other|Fraction of inspired oxygen 80%|
79507096|NCT00393978|Drug|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
79507097|NCT00393978|Drug|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
79507098|NCT00396006|Biological|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
79668396|NCT00453648|Other|WFSP and capsule of retinyl palmitate|
79668397|NCT00343421|Biological|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
79507099|NCT00397020|Drug|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
79818492|NCT06233773|Procedure|Kinesio Taping|Kinesio Taping
79507100|NCT00397020|Drug|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
79356162|NCT04276246|Device|dental implants and supportive implant components|supportive components (Group B Control), which are connected to the implants to support the RPD
79356163|NCT05247892|Procedure|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
79356164|NCT05247892|Procedure|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
79356165|NCT05245708|Drug|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
79356166|NCT05245708|Drug|intranasal placebo|Each subject will be assigned to intranasal placebo.
79356167|NCT01574079|Other|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
79356168|NCT01574079|Other|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
79356169|NCT05249686|Other|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
79356170|NCT05249686|Other|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
79356171|NCT01922596|Drug|Ropivacaine|
79507101|NCT00371436|Procedure|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
79818493|NCT06233773|Procedure|Manual Lymph Drainage|Manual Lymph Drainage Group
79818494|NCT06233773|Other|Control Group|Control Group
79356172|NCT01922596|Drug|Placebo|
79356173|NCT01573767|Drug|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
79507102|NCT00371436|Procedure|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
79507103|NCT00397878|Drug|saracatinib|Given orally
79507104|NCT00397878|Other|laboratory biomarker analysis|Correlative studies
79507105|NCT00400686|Biological|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
79668398|NCT00343421|Biological|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
79668399|NCT00343499|Drug|valsartan|
79668400|NCT00453687|Drug|GSK233705|investigational drug
79668401|NCT00447291|Drug|Supplement: Omega-3 Fish Oil|
79668402|NCT00447291|Behavioral|Multi-Disciplinary Nutrition & Exercise program|
79668403|NCT04715360|Combination Product|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
79668404|NCT04715360|Drug|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
79668405|NCT00447369|Drug|Pregabalin|
79668406|NCT00447369|Drug|sodium valproate|
79668407|NCT00343616|Procedure|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
79668408|NCT00343616|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
79818495|NCT06232863|Drug|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
79818496|NCT06232798|Other|a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter|This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
79818497|NCT06232798|Other|catheter ablation|catheter ablation
79991268|NCT02360722|Other|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
79356174|NCT01573767|Drug|Placebo|Placebo inhalation powder during treatment period
79507106|NCT05215938|Diagnostic Test|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
79818498|NCT06232772|Diagnostic Test|α- Synuclein Ultrafine Fluorescence Detection Method|This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.
79507107|NCT00373386|Drug|growth hormone|Growth Hormone treatment
79507108|NCT05154552|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
79507109|NCT05154552|Other|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
79507110|NCT01796574|Dietary Supplement|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
79507111|NCT01795404|Behavioral|Inquiry Based Stress Reduction (IBSR)|
79507112|NCT04271124|Other|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
79507113|NCT00373698|Behavioral|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
79818499|NCT06231758|Drug|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
79818500|NCT06231758|Drug|Metformin|Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
79356175|NCT01573767|Drug|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
79356176|NCT04397068|Procedure|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
79818501|NCT06231745|Drug|Methotrexate|Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
79991269|NCT02360722|Other|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
79356177|NCT04396678|Behavioral|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
79668409|NCT00343616|Procedure|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
79668410|NCT00343616|Procedure|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
79668411|NCT00453726|Procedure|Non invasive mechanical ventilation|
79668412|NCT00343655|Drug|Atorvastatin|
79356178|NCT03133546|Drug|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
79356179|NCT03133546|Drug|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
79668413|NCT00453765|Drug|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
79668414|NCT00453765|Drug|placebo|placebo
79668415|NCT00343733|Drug|OraVescent Fentanyl|
79507114|NCT00374088|Drug|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
79507115|NCT00374088|Drug|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
79507116|NCT00401622|Behavioral|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
79507117|NCT00401622|Behavioral|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
79356180|NCT01551303|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
79507118|NCT04270890|Device|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
79991270|NCT02360644|Dietary Supplement|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
79356181|NCT01551303|Drug|Placebo|Matched nasal spray placebo
79507119|NCT00374244|Drug|Pimozide|half of the subjects are randomized to the active drug group
79356182|NCT01550757|Behavioral|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
79507120|NCT00374244|Drug|placebo|half of the subjects are randomized to placebo group
79668416|NCT00447408|Behavioral|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
79991271|NCT02354716|Device|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions & function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- & post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, & what characteristics determine & predict refractory & recurrent strictures.
79991272|NCT02366026|Biological|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
79991273|NCT02354794|Dietary Supplement|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
79991274|NCT02354794|Dietary Supplement|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
79991275|NCT03159910|Behavioral|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
79991276|NCT03159910|Behavioral|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
79991277|NCT03159442|Drug|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
79507121|NCT04270812|Behavioral|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
79668417|NCT00447408|Behavioral|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
79356183|NCT01685073|Drug|Zolpidem extended-release|nightly administration of zolpidem extended-release
79356184|NCT01685073|Behavioral|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
79507122|NCT00377832|Drug|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
79507123|NCT00401778|Drug|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
79668418|NCT00343811|Drug|Modafinil|
79668419|NCT00453804|Drug|injectable naltrexone|
79668420|NCT00453804|Drug|oral naltrexone|
79668421|NCT00343850|Drug|Asacol (mesalamine)|
79668422|NCT00447486|Drug|GW842166|
79668423|NCT00343928|Other|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
79668424|NCT00453843|Device|rehabilitation robotics|sequence of intervention
79668425|NCT00453843|Procedure|Movement therapy|sequence of intervention
79668426|NCT00447525|Biological|REVAXIS®|
79668427|NCT00447525|Biological|DT-Polio®|
79991278|NCT03159442|Drug|Placebo|Powder for inhalation administered via single dose DPI
79356185|NCT01922674|Procedure|Standard open tension-free inguinal hernia repair with mesh|
79507124|NCT00402714|Procedure|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
79507125|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
79507126|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
79507127|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
79356186|NCT01922908|Biological|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
79356187|NCT01922908|Biological|Placebo Comparator|Normal saline
79507128|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
79668428|NCT00344006|Drug|chlorproguanil-dapsone-artesunate|
79668429|NCT00344006|Drug|artemether-lumefantrine|
79668430|NCT02273661|Drug|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
79668431|NCT02273661|Drug|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
79668432|NCT00447642|Drug|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
79668433|NCT00447642|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
79668434|NCT00344123|Drug|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
79668435|NCT00344123|Drug|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
79668436|NCT00453882|Device|flostat (TM) System|
79668437|NCT00344201|Device|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
79668438|NCT00453960|Dietary Supplement|Genivis|54 mg/day daily for 6 months
79668439|NCT00453960|Drug|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
79668440|NCT00453960|Other|placebo|tablets daily for 6 months
79668441|NCT00344240|Behavioral|Functional circuit training with lifestyle behavior|
79668442|NCT00447681|Drug|ILV-094|
79668443|NCT00454038|Device|HYPRO SORB F|resorbable, double layered, collagen membrane
79668444|NCT04715282|Procedure|Epley maneuver|Epley maneuver
79356188|NCT05240950|Drug|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10^6/kg, 3×10^6/kg, and 6×10^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
79507129|NCT00405288|Drug|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
79507130|NCT00458406|Device|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
79668445|NCT00454077|Procedure|radioiodine therapy after rhTSH|
79818502|NCT06231745|Drug|Paroxetine|Paroxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive compulsive disorder (OCD), panic attacks, anxiety or post-traumatic stress disorder (PTSD).
79818503|NCT06231420|Other|Encourage using pedometer|Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator
79818504|NCT06231420|Device|pedometer|pedometer
79818505|NCT06230211|Other|Music Therapy|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
79356189|NCT05241574|Radiation|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
79356190|NCT05241574|Drug|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
79356191|NCT01923142|Biological|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
79356192|NCT01923142|Biological|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
79356193|NCT05241184|Diagnostic Test|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
79356194|NCT05241028|Drug|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
79356195|NCT01572909|Drug|Bendavia (MTP-131)|0.05 mg/kg/hr
79356196|NCT01572909|Drug|Placebo|Identically appearing placebo
79507131|NCT00458406|Device|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
79356197|NCT01572675|Drug|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
79356198|NCT01572675|Drug|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
79356199|NCT05929937|Drug|Opioids|Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
79507132|NCT00381810|Drug|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
79507133|NCT00381810|Drug|Methylprednisolone|
79507134|NCT00381810|Drug|Acetaminophen|
79507135|NCT00381810|Drug|Diphenhydramine|
79507136|NCT00458952|Drug|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
79507137|NCT00459732|Dietary Supplement|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
79507138|NCT00459732|Dietary Supplement|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
79507139|NCT00459810|Drug|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
79668446|NCT00447720|Behavioral|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
79818506|NCT06230211|Other|Maternal Voice|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
79818507|NCT06229353|Biological|Gardasil 9|Prevent HPV-associated diseases and cancers
79356200|NCT05929937|Other|No opioids|Standard of care, patients will not receive a prescription for opioids.
79507140|NCT00459810|Drug|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
79991279|NCT02360332|Behavioral|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
79991280|NCT03160300|Device|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
79818508|NCT06229054|Drug|Dexmedetomidine|Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
79818509|NCT06229054|Drug|Bupivacaine Hydrochloride|local anesthesic which works through blocking sodium channels
79991281|NCT03160300|Device|Music|Relaxing music without a binaural beat component
79991282|NCT02360566|Behavioral|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
79356201|NCT05929924|Dietary Supplement|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
79356202|NCT05929872|Other|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
79507141|NCT00405522|Drug|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
79991283|NCT03428100|Drug|Baricitinib|Administered orally.
79991284|NCT03428100|Drug|Placebo|Administered orally.
79991285|NCT03428100|Drug|Topical corticosteroid|Administered as standard-of-care.
79356203|NCT05929872|Other|Sham non-invasive brain stimulation|SHAM tDCS
79507142|NCT00405522|Drug|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
79507143|NCT00381966|Device|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
79356204|NCT05929794|Drug|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
79507144|NCT00461292|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
79507145|NCT00461292|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
79507146|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
79507147|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
79507148|NCT00382590|Drug|5-Azacytidine|75 mg/m^2 daily for 7 days (days 1-7) via subcutaneous injection.
79507149|NCT00382590|Drug|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
79507150|NCT00382590|Drug|Valproic Acid (VPA)|50 mg/m^2 orally daily days 1-7.
79356205|NCT05929794|Drug|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
79507151|NCT00382824|Dietary Supplement|Coenzyme Q10|active drug
79507152|NCT00382824|Other|Placebo|Placebo
79507153|NCT00462072|Drug|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
79991286|NCT02365948|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/mL~Route of Administration: Subcutaneous injection"
79507154|NCT00462228|Drug|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
79668447|NCT00344474|Behavioral|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
79668448|NCT00447759|Drug|Celecoxib|200-400mg daily in divided doses
79668449|NCT00447759|Drug|Diclofenac|prescribed medication taken orally
79991287|NCT02365948|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringes~Concentration: 0.9 % Saline~Route of Administration: Subcutaneous injection"
79991288|NCT02360410|Behavioral|Check Yourself App with Feedback|
79668450|NCT00344513|Drug|Beta-blockers including Carvedilol|
79668451|NCT00344513|Drug|ACE inhibitors|
79991289|NCT02360176|Procedure|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
79991290|NCT02360176|Procedure|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
79668452|NCT00454155|Drug|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
79668453|NCT00344552|Drug|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
79668454|NCT00447798|Behavioral|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building & strengths based case management
79668455|NCT00447837|Drug|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
79668456|NCT00344591|Behavioral|Structured Ecosystems Therapy (SET)|
79991291|NCT02354950|Drug|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
79991292|NCT02980874|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
79507155|NCT00462228|Drug|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
79818510|NCT06227767|Other|spinal stabilization exercise|The exercise program will be implemented in the hospital under the supervision of a physiotherapist for 6 weeks, and the next 6 weeks will be followed as a home program. The first group will be given an exercise program 2 days a week, the second group will be given an exercise program 4 days a week. The exercise program is planned to be 40 minutes and the first 5 minutes of the program will be warm-up and the last 5 minutes will be cool-down exercises.
79991293|NCT02980874|Drug|suprachoroidal sham|suprachoroidal sham procedure
79818511|NCT06227702|Other|Fluid management according to Venous Excess Ultrasound (VExUS) Score|Management of furosemide intravenous infusion according to VeXus results
79991294|NCT02980874|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
79356206|NCT05929794|Diagnostic Test|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
79356207|NCT05929794|Diagnostic Test|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
79356208|NCT05929794|Diagnostic Test|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
79507156|NCT00408564|Biological|cetuximab|
79507157|NCT00408564|Drug|capecitabine|
79507158|NCT00408564|Drug|oxaliplatin|
79507159|NCT00408564|Procedure|conventional surgery|
79507160|NCT00408564|Radiation|radiation therapy|
79507161|NCT00408564|Drug|Gemcitabine|
79668457|NCT00344591|Behavioral|Individually tailored intervention|
79668458|NCT00447915|Drug|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
79668459|NCT00447915|Drug|RIS placebo|0 mg(p.o.)/day for 36 months
79991295|NCT02354872|Drug|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
79668460|NCT00447915|Drug|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
79668461|NCT00447915|Drug|ibandronic acid placebo|0mg(i.v.)/month for 35 months
79668462|NCT00447915|Drug|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
79668463|NCT00447915|Dietary Supplement|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
79668464|NCT00344630|Device|TAXUS Stent and Cypher Stent|
79668465|NCT00344669|Drug|Albendazole 400 mg, given 6 monthly|
79991296|NCT02354872|Behavioral|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
79991297|NCT02354872|Behavioral|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
79507162|NCT02110758|Other|Pilot of Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track & coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track & coordinate care, and measure and improve performance.
79991298|NCT02354872|Behavioral|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
79668466|NCT03274791|Diagnostic Test|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
79991299|NCT02354872|Other|No Treatment|No Treatment
79991300|NCT02354638|Behavioral|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
79668467|NCT03274791|Diagnostic Test|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
79507163|NCT02111772|Biological|Rhinovirus|
79668468|NCT03274791|Diagnostic Test|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
79507164|NCT00383448|Drug|Clofarabine|days -7 through -3: 40 mg/m^2 intravenously over 2 hours
79507165|NCT00383448|Procedure|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
79507166|NCT00383448|Drug|Melphalan|day -2: 140 mg/m^2 intravenously over 30 minutes
79507167|NCT00383448|Biological|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
79507168|NCT00383448|Drug|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
79507169|NCT00383448|Drug|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR<25 mL/minute corrected)
79818512|NCT06226961|Device|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
79991301|NCT02354638|Drug|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
79991302|NCT02354404|Biological|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
79991303|NCT02354404|Biological|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
79356209|NCT05929794|Other|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
79356210|NCT05929755|Drug|Depo-Medrol|steroid
79356211|NCT05929755|Drug|Gel-Flow NT|hemostatic agent
79356212|NCT05929690|Other|Self-acupuncture|Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
79356213|NCT05929638|Behavioral|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
79356214|NCT05929625|Device|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
79668469|NCT00344708|Procedure|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
79356215|NCT05929625|Device|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
79356216|NCT05929586|Other|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
79356217|NCT05929560|Other|Conventional impression|Palatal impressions obtained using an irreversible hydrocolloid impression material
79668470|NCT03274713|Device|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
79818513|NCT06226753|Procedure|Type of anaesthesia used|Spinal anaesthesia will be used for closure of loop ileostomy
79991304|NCT02354404|Biological|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
79356218|NCT05929560|Other|Digital impression|after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
79991305|NCT01066052|Drug|r-hGH|Subcutaneous administration.
79356219|NCT05929521|Other|C-PrEP+|Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
79668471|NCT03274713|Device|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
79668472|NCT00344747|Behavioral|dietary, behavioral, physical activity|
79991306|NCT02360254|Drug|Insulin degludec|Once daily injection of insulin degludec
79356220|NCT05929508|Other|Ischemic Preconditioning|A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
79356221|NCT05929456|Drug|Cetuximab-IRDye800|patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
79356222|NCT05929443|Other|END-IT intervention for nursing homes|Complex intervention, as described in the arm/group descriptions
79991307|NCT02360020|Device|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
79356223|NCT05929417|Other|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
79356224|NCT05929365|Procedure|colonoscopy|determine the mutation profile of resected colorectal neoplasia
79356225|NCT05929339|Drug|Oxytocin|Intravenous oxytocin
79991308|NCT03112642|Procedure|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered.
79356226|NCT05929326|Diagnostic Test|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
79991309|NCT03112642|Device|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
79991310|NCT01377324|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with ~200MBq 18F-FES
79356227|NCT05929313|Device|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
79356228|NCT05929313|Device|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
79356229|NCT05929248|Drug|Telitacicept|160mg once a week for 48 weeks
79356230|NCT05929248|Drug|conventional therapy|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
79356231|NCT05929248|Drug|Placebo|Used once a week in combination with standard treatment
79356232|NCT05929209|Diagnostic Test|Assessment of disease biomarkers|Assessment of serum, histological and radiological biomarkers
79668473|NCT00344786|Drug|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
79668474|NCT03274674|Other|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
79991311|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1mg, tid
79991312|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
79991313|NCT01569516|Drug|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
79991314|NCT01569516|Drug|Placebo|0mg, tid
79991315|NCT02359942|Drug|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
79356234|NCT05929144|Other|MRI sequences testing|Testing different MRI sequences in order to optimize them
79356235|NCT05929118|Other|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
79356236|NCT05929118|Other|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
79356237|NCT05929105|Procedure|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
79991316|NCT02359708|Procedure|Surgical hand disinfection.|Bacterial recolonization
79356238|NCT05929105|Other|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
79356239|NCT05929053|Other|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
79356240|NCT05929040|Behavioral|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
79356241|NCT05929014|Device|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
79356242|NCT05929014|Device|Cathodal-Transcranial direct current stimulation (cathodal-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal electrode will be attached over the left primary motor area while the anodal will be applied over the right supraorbital.
79356243|NCT05929014|Device|Sham bilateral-tDCS|Sham bilateral-tDCS
79356244|NCT05929014|Device|Sham cathodal-tDCS|Sham cathodal-tDCS
79356245|NCT05928988|Drug|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
79356246|NCT05928975|Other|MT+ PNE with MI|"The manual therapy treatment approach entailed the management of symptoms based on the clinical judgment of the attending physiotherapist. The physiotherapist selectively employed techniques such as spinal mobilization/manipulation, soft tissue massage, supervised exercises and muscle and neural mobilization, while excluding the utilization of electrophysical modalities. The participants will receive 10 Manual Therapy sessions of 30 minutes within a period of 4 weeks.~The pain neuroscience education program is based on previous clinical studies and available educational materials and is enhanced by motivational interviewing techniques. The program consisted of 4 individualized educational sessions, each lasting 30 minutes. All key aspects of pain neurophysiology were explained and discussed. At the end of the first session, participants will be provided with informational handouts to support the educational process."
79356247|NCT05928975|Other|MT|"Participants in this group will be given the same MT program as MT + PNE with MI group without the application of PNE."
79356248|NCT05928975|Other|Control|The participants in the control group will be provided with written instructions for performing general exercises at home. These exercises will consist of gentle stretching exercises specifically targeting the low back muscles, as well as relief positions and breathing relaxation exercises.
79668475|NCT04715165|Drug|USG-STAP with bupivacaine and dexmedetomidine|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
79668476|NCT04715165|Drug|IP bupivacaine and dexmedetomidine|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
79668477|NCT00454233|Drug|YM543|Oral
79668478|NCT00454233|Drug|Metformin|Oral
79818514|NCT06225752|Drug|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
79991317|NCT05461248|Procedure|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
79991318|NCT05461248|Procedure|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
79668479|NCT00454233|Drug|Placebo|oral
79668480|NCT04715477|Behavioral|Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
79668481|NCT00448032|Drug|PPM-204|
79991319|NCT02359630|Device|EasyTube|Insertion for ventilation
79991320|NCT02359630|Device|Endotracheal tube|Insertion for ventilation
79507170|NCT00383448|Device|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
79507171|NCT00383448|Drug|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
79507172|NCT00383760|Drug|eribulin mesylate|Given IV
79507173|NCT00384774|Drug|Lasmiditan|Administered as intravenous infusion
79356249|NCT05928949|Other|pilates exercises|Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
79356250|NCT05928936|Drug|Sodium Bicarbonate|Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
79356251|NCT05928936|Behavioral|Exercise Training|"Exercise training consists of progressive, interval-based Spin exercise on stationary bicycles three times per week for 12 weeks, led by a certified exercise physiologist. The duration of each session begins at 20 minutes and is increased by 1 to 2 minutes as tolerated to a goal of 45 minutes per session. Exercise intensity begins at low levels (50% of maximal heart rate reserve (HRR)) and increases by 5% every week to a goal of 75% maximal HRR. Each session includes a 5-min warm up, then an interval-based, work-out phase that includes steady up-tempo cadences, sprints, and climbs, followed by a 5-minute cool down."
79507174|NCT00384774|Drug|Placebo|Administered as intravenous infusion
79507175|NCT00410280|Biological|IMA-638 is a biologic|
79507176|NCT00410826|Drug|erlotinib hydrochloride|Given orally
79507177|NCT00410826|Drug|cisplatin|Given IV
79507178|NCT00410826|Radiation|3-dimensional conformal radiation therapy|35 fractions
79507179|NCT00410826|Radiation|intensity-modulated radiation therapy|35 fractions
79507180|NCT00410826|Procedure|quality-of-life assessment|Ancillary studies
79507181|NCT00464646|Drug|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
79507182|NCT00464646|Drug|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
79507183|NCT00464646|Drug|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
79507184|NCT00464646|Drug|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
79507185|NCT00464646|Drug|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
79507186|NCT00385008|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
79507187|NCT00385008|Drug|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
79507188|NCT00466206|Device|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
79507189|NCT00466206|Device|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
79668482|NCT04714931|Diagnostic Test|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
79668483|NCT00454272|Drug|Teicoplanin|
79668484|NCT00454272|Drug|Vancomycin|
79668485|NCT00448071|Drug|MTR107|
79679669|NCT02940756|Drug|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
79991321|NCT02354560|Drug|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
79991322|NCT01378884|Drug|Domperidone|Patient to receive treatment with Domperidone
79507190|NCT00466206|Procedure|3MP (Magnetic Mini-Mover Procedure)|"Subject has EKG performed to measure baseline cardiac activity.~Magnimplant is implanted.~After one week, Magnatract is fitted.~Chest x-ray and 2nd EKG performed 30 days post-implantation.~Patient and parents complete QoL questionnaire 30d post-implantation.~Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~CT scan and third EKG performed after explanation.~Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
79356252|NCT05928936|Drug|Placebo|Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
79507191|NCT00410904|Drug|cediranib maleate|
79507192|NCT00410904|Drug|pemetrexed disodium|
79507193|NCT00385788|Drug|Gemcitabine|800 mg/m^2 IV over 30 minutes on Day -7 (1 day)
79507194|NCT00385788|Drug|Fludarabine|33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)
79507195|NCT00385788|Drug|Melphalan|70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
79507196|NCT00385788|Drug|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
79507197|NCT00385788|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
79507198|NCT00385788|Drug|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
79668486|NCT00344825|Drug|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
79991323|NCT05457504|Behavioral|Remote blood pressure monitoring|Participants assigned to this arm will participate in the experimental intervention
79818515|NCT06225752|Drug|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
79356253|NCT05928819|Procedure|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
79356254|NCT05928793|Behavioral|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
79356255|NCT05928780|Drug|A1:SG with SHR3680|SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
79818516|NCT06224192|Combination Product|Rocatinlimab Prefilled Syringe|Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.
79356256|NCT05928780|Drug|A2:SG|SG 10mg/kg d1, 8
79356257|NCT05928780|Drug|B1:SG with SHR1210|SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
79991324|NCT05457504|Behavioral|Usual Care|Participants assigned to this arm will participate in a placebo intervention
79991325|NCT02354326|Radiation|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
79356258|NCT05928780|Drug|B2:SG|SG 10mg/kg， d1, 8
79356259|NCT05928780|Drug|C1:SG with SHR3162|SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
79507199|NCT00385788|Drug|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
79507200|NCT00385788|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
79507201|NCT00411684|Drug|CDB-2914|
79507202|NCT00386256|Device|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
79507203|NCT00386256|Other|Telephone counseling|
79356260|NCT05928780|Drug|C2:SG|SG 10mg/kg d1, 8
79356261|NCT05928780|Drug|D1:SG with VEGFRI|SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
79356262|NCT05928780|Drug|D2:SG|SG 10mg/kg d1, 8
79507204|NCT00412074|Drug|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
79507205|NCT00412074|Drug|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
79507206|NCT00412074|Drug|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
79818517|NCT06223022|Behavioral|Proactive nurse-led telephone follow-up|An intervention nurse call the patients regularly with predetermined intervals and give support
79356263|NCT05928754|Diagnostic Test|care strategy|"Uveitis patients:~Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
79507207|NCT00412464|Drug|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
79507208|NCT00466752|Drug|sorafenib tosylate|Given PO
79507209|NCT00466752|Genetic|microarray analysis|Correlative studies
79507210|NCT00466752|Other|immunohistochemistry staining method|Correlative studies
79507211|NCT00466752|Genetic|gene expression analysis|Correlative studies
79507212|NCT00466752|Procedure|needle biopsy|Correlative studies
79507213|NCT00466752|Procedure|therapeutic conventional surgery|Undergo prostatectomy
79507214|NCT00466752|Other|laboratory biomarker analysis|Correlative studies
79991326|NCT02354326|Radiation|computed tomography|Undergo CT without VNC
79507215|NCT00466752|Genetic|western blotting|Correlative studies
79356266|NCT05928715|Other|Finger feeding|The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
79668487|NCT00448110|Drug|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
79668488|NCT00448110|Drug|Intravenous Ketorolac|Intravenous Ketorolac
79991327|NCT02039050|Drug|Tiotropium|
79991328|NCT02039050|Drug|Aclidinium|
79991329|NCT05764200|Dietary Supplement|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
79991330|NCT05764200|Dietary Supplement|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
79356267|NCT05928702|Procedure|temperature-elevating armbath|Hydrotherapeutic Approach
79356268|NCT05928637|Drug|D745, D759, D150|QD, PO for 5 days
79507216|NCT00466752|Genetic|RNA analysis|Correlative studies
79507217|NCT02115750|Drug|Etanercept|Head-to-head comparison
79507218|NCT02115750|Drug|CHS-0214|
79507219|NCT02115828|Drug|Vismodegib|
79507220|NCT02115984|Drug|Panagen|
79507221|NCT02115984|Drug|Placebo|
79507222|NCT02115984|Procedure|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
79507223|NCT00413166|Drug|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
79507224|NCT00413166|Drug|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
79507225|NCT00413166|Drug|Idarubicin|"12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
79507226|NCT00413166|Drug|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
79507227|NCT00386880|Other|Sounds|
79507228|NCT00413400|Drug|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
79668489|NCT00448110|Drug|placebo|placebo
79668490|NCT00344864|Device|LADARWave|
79668491|NCT00454311|Procedure|Biopsy of Day 3 Embryo|
79668492|NCT00454311|Procedure|· day embryo biopsy|
79356269|NCT05928533|Other|clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex|the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
79356270|NCT05928507|Diagnostic Test|Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections|"The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.~Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information."
79356271|NCT05928481|Other|Simulation-based postpartum bleeding management training|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
79356272|NCT05928468|Biological|LYB002V14|Participants receiving one or two boost doses of LYB002V14 after a three-dose primary series of inactivated COVID-19 vaccine.
79507229|NCT00413400|Drug|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
79507230|NCT00413478|Drug|5-Azacytidine|Starting dose level: 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
79356273|NCT05928468|Biological|LYB002V14A|Participants receiving one or two boost doses of LYB002V14A after a three-dose primary series of inactivated COVID-19 vaccine.
79818518|NCT06219369|Procedure|Group T|"SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique."
79356274|NCT05928468|Biological|LYB002CA|Participants at 18-59 years old receiving two boost doses of LYB002CA after a three-dose primary series of inactivated COVID-19 vaccine.
79356275|NCT05928455|Biological|LYB001|Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.
79356276|NCT05928455|Biological|CoronaVac|Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
79668493|NCT00448149|Drug|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
79668494|NCT00448149|Drug|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
79818519|NCT06216665|Other|Continuous Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test
79356277|NCT05928442|Device|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
79356278|NCT05928442|Behavioral|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
79356279|NCT05928442|Device|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
79507231|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
79668495|NCT00344942|Drug|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
79668496|NCT00344942|Drug|placebo|a double spray into each nostril once daily
79668497|NCT00454350|Drug|Hectorol (doxercalciferol injection)|
79668498|NCT00454350|Drug|Zemplar (Paricalcitol injection)|
79668499|NCT00448188|Procedure|central venous catheter application|
79668500|NCT00454389|Device|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
79668501|NCT00454389|Drug|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
79507232|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
79507233|NCT00467298|Behavioral|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
79507234|NCT00467298|Behavioral|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
79356280|NCT05928429|Device|Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA|Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
79356281|NCT05928364|Procedure|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
79356282|NCT05928338|Behavioral|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
79356283|NCT05928286|Drug|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
79356284|NCT05928273|Device|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
79356285|NCT05928247|Behavioral|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), we also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), we will recommend using a chained schedule FCT (chained-FCT).
79356286|NCT05928247|Behavioral|Non-Contingent Reinforcement (NCR)|During NCR, we will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
79356287|NCT05928247|Behavioral|Competing Items and Response Blocking|We will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. We will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. We will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
79507235|NCT00467298|Behavioral|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
79507236|NCT00467844|Drug|GTx-024|1 mg GTx 024
79507237|NCT00467844|Drug|GTx-024|3 mg GTx-024
79507238|NCT00467844|Drug|Placebo|Matching Placebo
79507239|NCT00387036|Drug|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
79507240|NCT00387036|Drug|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
79507241|NCT04388592|Other|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
79818520|NCT06216665|Other|Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test
79818521|NCT06213259|Drug|KD6005|Biological: KD6005, SQ
79818522|NCT06213259|Drug|Placebo|Placebo, SQ
79991331|NCT02354248|Procedure|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
79991332|NCT02354170|Drug|Mifepristone|
79991333|NCT02354170|Drug|Placebo|
79991334|NCT05348382|Procedure|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
79356288|NCT05928247|Behavioral|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
79356289|NCT05928208|Diagnostic Test|no intervention|no intervention
79356290|NCT05928169|Drug|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
79356291|NCT05928156|Other|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
79356292|NCT05928156|Other|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
79356293|NCT05928143|Procedure|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
79356294|NCT05928143|Procedure|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
79507242|NCT00470106|Behavioral|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
79507243|NCT00470106|Behavioral|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
79507244|NCT00470106|Behavioral|hybrid intervention|A combination of the two groups listed above.
79818523|NCT06212492|Drug|NMBAs|Early and systematic use of NMBAs
79818524|NCT06212492|Other|Prone positioning|Early and systematic use of prone positioning
79818525|NCT06206525|Other|Initial insulin dosing using the calculator|Participants will receive initial insulin doses by the calculator on hospital admission.
79991335|NCT05348382|Procedure|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
79991336|NCT03112876|Other|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
79356295|NCT05928130|Other|plyometric training protocol|"The plyometric training program will last for 4 weeks, with three sessions per week. The plyometric exercises will be performed immediately after a warm-up. The program will incorporate bilateral, unilateral, acyclic, cyclic, horizontal, vertical, lateral, and diagonal movements involving both slow and fast movements.~Each session will include 4-5 plyometric exercises, with 2-10 sets per exercise and 1-10 repetitions per set. The training volume will progressively increase from the 1st to the 2nd week and then the intensity will increase while the volume decreases from the 3rd to the 4th week in both intervention groups. However, the final volume will vary by 50% between the groups."
79507245|NCT00470106|Behavioral|skills training|Skills training in how to identify symptoms of illness and medication side effects.
79507246|NCT00387660|Drug|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
79507247|NCT00387660|Drug|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
79507248|NCT00472056|Drug|Carmustine|300 mg/m^2 IV for 1 Day
79507249|NCT00472056|Drug|Etoposide|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
79991337|NCT03077646|Behavioral|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
79507250|NCT00472056|Drug|Cytarabine|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
79507251|NCT00472056|Drug|Melphalan|140 mg/m^2 IV x 1 Day
79507252|NCT00472056|Drug|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.
79507253|NCT00415506|Drug|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
79507254|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
79507255|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
79507256|NCT01795092|Other|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
79507257|NCT00475878|Drug|escitalopram|10mg escitalopram/day for 3 months
79507258|NCT00475878|Drug|placebo|placebo capsule/day for 3 months
79507259|NCT01795170|Dietary Supplement|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) [23,24], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
79668502|NCT00344981|Drug|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
79679670|NCT02940756|Drug|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
79991338|NCT03077646|Behavioral|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
79991339|NCT03077646|Behavioral|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
79991340|NCT02359240|Procedure|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
79818526|NCT06205875|Procedure|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
79818527|NCT06205875|Procedure|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
79991341|NCT02359240|Procedure|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
79991342|NCT02352610|Procedure|LRTI|
79356296|NCT05928065|Other|Collection of datas|Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
79356297|NCT05928052|Device|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
79991343|NCT02352610|Device|Biotenodesis Screw|
79991344|NCT02927964|Drug|Ibrutinib|Given PO
79356298|NCT05928000|Drug|Bulevirtide|BulevIrtide treatment in patients with chronic hepatitis D
79356299|NCT05927974|Diagnostic Test|Passive testing|Passive testing includes baseline recordings or behavioral tasks without stimulation. Examples include language tasks, cognitive, and motor tasks. Passive testing typically takes 30-60 minutes and does not require presence of an epileptologist as the tasks are of minimal or no risk.
79356300|NCT05927974|Diagnostic Test|Active testing|"Active testing includes any study activity in which stimulation occurs. The most frequent paradigm consists of delivering small amounts of electrical stimulation through the implanted grid/strip/depth electrodes. This will be either continuous stimulation or patterned stimulation such as intermittent theta-burst . Stimulation will range between 1-8 mAmp. The duration of these pulses will last between 2-5 seconds.~Subjects may be asked to rest quietly or to perform behavioral tasks during stimulation. Since there is a risk of evoking seizure activity with active testing, presence of an epileptologist is required. Active testing will only occur once the PI/staff has communicated with the epileptologist regarding safety, feasibility, and timing of active testing. Active testing will typically take 60-90 minutes and is only performed once patients are back on their anti-seizure medications."
79991345|NCT02927964|Radiation|Radiation Therapy|Undergo radiation therapy
79356301|NCT05927961|Diagnostic Test|histopathology|There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.
79507260|NCT01795170|Drug|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
79991346|NCT02927964|Drug|TLR9 Agonist SD-101|Given IT
79507261|NCT01796886|Other|pupillometry data|
79507262|NCT00477204|Drug|Simvastatin|simvastatin 20 mg daily
79507263|NCT00477204|Drug|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
79507264|NCT00528450|Drug|arsenic trioxide|
79507265|NCT00528450|Drug|idarubicin|
79507266|NCT00528450|Drug|tretinoin|
79507267|NCT00478218|Drug|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
79507268|NCT00478218|Drug|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 & 22
79507269|NCT00478218|Drug|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
79507270|NCT00479154|Drug|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
79507271|NCT04270656|Procedure|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
79507272|NCT04270656|Procedure|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
79356302|NCT05927948|Device|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
79356303|NCT05927233|Drug|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
79356304|NCT05927233|Drug|Saline|30 ml Normal saline
79356305|NCT05926232|Drug|Repotrectinib|Repotrectinib
79356306|NCT05925725|Drug|• harpagozid • boswellin = LOXACON|Exercise therapy
79507273|NCT00422448|Genetic|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
79507274|NCT00424554|Drug|temozolomide|"Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
79507275|NCT02117310|Drug|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
79507276|NCT00425802|Biological|anti-thymocyte globulin|
79507277|NCT00425802|Biological|filgrastim|
79668503|NCT00344981|Drug|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
79668504|NCT00448266|Drug|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
79668505|NCT00448266|Drug|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
79668506|NCT00454428|Procedure|pulsatile intra-aortic balloon pump|
79668507|NCT00345020|Procedure|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
79668508|NCT00454545|Drug|Atorvastatin|
79668509|NCT00345059|Drug|docetaxel|
79668510|NCT00345059|Drug|vinorelbine|
79668511|NCT00345059|Drug|gemcitabine|
79668512|NCT00345059|Drug|capecitabine|
79668513|NCT03274635|Behavioral|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
79668514|NCT00345098|Drug|SR58611A|
79668515|NCT00448305|Drug|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
79668516|NCT00448305|Drug|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
79668517|NCT00448305|Drug|Paclitaxel|Paclitaxel 90 mg/m² weekly
79668518|NCT00345137|Drug|Ng-monomethyl-L-arginine (drug)|
79668519|NCT00448383|Biological|adalimumab|40mg every other week
79668520|NCT00345215|Behavioral|High Sodium Diet|250-350 mmol
79991347|NCT03147586|Drug|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
79991348|NCT03147586|Drug|placebo|placebo
79991349|NCT01377246|Drug|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
79507278|NCT00425802|Biological|graft-versus-tumor induction therapy|
79507279|NCT00425802|Biological|rituximab|
79507280|NCT00425802|Drug|cyclophosphamide|
79507281|NCT00425802|Drug|cyclosporine|
79507282|NCT00425802|Drug|fludarabine phosphate|
79507283|NCT00425802|Drug|mycophenolate mofetil|
79507284|NCT00425802|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79507285|NCT00425802|Radiation|total-body irradiation|
79668521|NCT00345215|Behavioral|Low Sodium Diet|25-35 mmol
79668522|NCT00448461|Drug|heparin|comparison between heparin and bivalirudin
79668523|NCT00448461|Drug|bivalirudin|comparison between heparin and bivalirudin
79668524|NCT00345410|Drug|AVE1625 B|
79991350|NCT01377246|Other|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
79668525|NCT00454623|Behavioral|drawing serum adiponectin level|
79668526|NCT00345449|Behavioral|Decision Aid|
79668527|NCT00454662|Drug|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
79668528|NCT00454662|Drug|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
79668529|NCT00345527|Behavioral|Emotion and Behaviour Regulation Treatment (EBRT)|
79356307|NCT05925595|Device|Medical Device Iniettabile Ginocchio|Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
79356308|NCT05925231|Diagnostic Test|Box and Block Test|3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
79668530|NCT00345527|Behavioral|Cognitive Behavioural Therapy|
79668531|NCT00345566|Procedure|Nutrition composition|
79668532|NCT00345644|Drug|risedronate|risedronate sodium 35 mg tablets (once a week dose)
79668533|NCT00345644|Drug|risedronate placebo|placebo for risedronate tablets (once a week dose)
79668534|NCT00345722|Procedure|strawberry dietary intervention|
79668535|NCT00454701|Drug|Alefacept exposure|Observational
79668536|NCT00345761|Drug|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
79668537|NCT00345761|Drug|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
79668538|NCT00345761|Drug|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
79668539|NCT00345800|Drug|Sodium Oxybate (Xyrem)|"Active Substance: Sodium Oxybate~Pharmaceutical form: Oral Solution~Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~Route of administration: Oral"
79668540|NCT00454740|Drug|solifenacin succinate|Oral
79668541|NCT00345917|Device|Retinal transplantation instrument|
79668542|NCT00345917|Device|Fetal tissue.|
79668543|NCT03276897|Other|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
79668544|NCT00345956|Biological|Human rotavirus liquid vaccine|
79668545|NCT03276858|Drug|CRN00808|Investigational drug
79668546|NCT03276858|Drug|Placebo Oral Solution|Placebo
79668547|NCT03276858|Drug|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
79668548|NCT03276858|Drug|Placebo oral capsule|Placebo
79356309|NCT05924906|Drug|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
79356310|NCT05922917|Device|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
79356311|NCT05921786|Device|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
79356312|NCT05921786|Device|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
79356313|NCT05906862|Drug|AMT-253|Administered intravenously
79356314|NCT05904548|Device|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
79507286|NCT00530634|Drug|cisplatin|
79507287|NCT00530634|Drug|gemcitabine hydrochloride|
79507288|NCT00530634|Genetic|gene expression analysis|
79507289|NCT00530634|Genetic|reverse transcriptase-polymerase chain reaction|
79507290|NCT00530634|Other|immunohistochemistry staining method|
79507291|NCT00530634|Procedure|adjuvant therapy|
79507292|NCT00530634|Procedure|conventional surgery|
79507293|NCT00530634|Radiation|radiation therapy|
79507294|NCT02113410|Behavioral|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
79668549|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
79668550|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
79507295|NCT02113410|Behavioral|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
79507296|NCT00531882|Drug|Pioglitazone|30 mg once a day
79507297|NCT00531882|Drug|Simvastatin|40 mg once a day
79507298|NCT00531882|Drug|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
79507299|NCT00428298|Drug|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
79507300|NCT00428298|Drug|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
79668551|NCT00454896|Drug|VESIcare®|Oral
79668552|NCT00454896|Drug|placebo|Oral
79668553|NCT00421226|Drug|ACZ885|
79668554|NCT03276624|Procedure|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
79507301|NCT00486018|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
79507302|NCT00486018|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
79668555|NCT00346112|Procedure|psycho-educational|
79668556|NCT00346190|Drug|Alendronate|
79668557|NCT00454974|Device|Wearable artificial kidney|
79507303|NCT00486018|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
79507304|NCT00486642|Drug|Bicalutamide|Given PO
79668558|NCT00346229|Biological|filgrastim|
79668559|NCT00346229|Biological|pegfilgrastim|
79668560|NCT00346229|Drug|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
79668561|NCT00346229|Procedure|hyperthermia treatment|
79668562|NCT00455052|Drug|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
79507305|NCT00486642|Other|Laboratory Biomarker Analysis|Correlative studies
79507306|NCT00486642|Drug|Pazopanib Hydrochloride|Given PO
79507307|NCT00486642|Other|Pharmacological Study|Correlative studies
79991351|NCT02353936|Drug|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH & Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
79991352|NCT02353858|Other|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
79991353|NCT02353858|Radiation|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
79668563|NCT00346385|Drug|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
79668564|NCT00448578|Drug|Quetiapine Fumarate|
79668565|NCT00448578|Drug|Lithium|
79991354|NCT02353858|Drug|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
79991355|NCT02578758|Behavioral|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
79356315|NCT05904132|Device|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
79356316|NCT05890131|Other|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
79356317|NCT05880537|Other|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
79356318|NCT05873218|Drug|Ephedrine|The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.
79356319|NCT05873218|Drug|Normal Saline Placebo|Placebo will be administered at matching rate.
79668566|NCT00346424|Drug|Alfimeprase|
79668567|NCT03276507|Diagnostic Test|Pulmonary function studies|
79668568|NCT03276507|Diagnostic Test|Echocardiogram|
79668569|NCT03276507|Diagnostic Test|Electrocardiogram|
79668570|NCT03276507|Diagnostic Test|Chest radiography|
79668571|NCT03276507|Diagnostic Test|Blood test|
79668572|NCT03276507|Behavioral|Quality of life questionnaire|
79668573|NCT00346463|Drug|Allopurinol|
79668574|NCT00455091|Drug|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/> 105 copies/mL and ALT > 2.0 x UNL
79668575|NCT00346502|Drug|20% betulinic acid ointment|
79668576|NCT00346502|Drug|BA|20% Betulinic Acid Ointment
79668577|NCT04699344|Diagnostic Test|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
79668578|NCT00346580|Drug|Nelfinavir|
79668579|NCT00346619|Drug|Nelfinavir|
79668580|NCT00346658|Drug|magnesium|
79668581|NCT02273700|Drug|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
79668582|NCT02273778|Procedure|MRI Scan|
79668583|NCT02273778|Procedure|PET-CT Scan|
79668584|NCT02273778|Other|No intervention|
79668585|NCT00346736|Procedure|Acupuncture (Procedure)|
79668586|NCT00448656|Procedure|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
79668587|NCT02959658|Drug|Dimethyl fumarate|
79668588|NCT02959658|Drug|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
79507308|NCT04388514|Procedure|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
79507309|NCT00428922|Drug|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
79668589|NCT04698213|Drug|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
79668590|NCT04698213|Drug|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
79668591|NCT00346814|Drug|intravitreal injection|
79668592|NCT02273817|Drug|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
79668593|NCT00346853|Drug|4-Methylpyrazole|15 mg/kg dose
79668594|NCT00346853|Other|saline|
79668595|NCT00448695|Procedure|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
79356320|NCT05858034|Other|Customized activity plan|Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.
79356321|NCT05858034|Other|Customized nutrition plan|Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
79356322|NCT05853380|Device|Informed Vital Core App|All subjects assigned to a single arm, pulse rate measurement will be collected, calculated, and displayed on the web based application. A conventional ECG device will also be used to collect and display the heart rate at the same time. If additional consent is obtained subjects may provide blood pressure and SpO2 measurements for the web based application.
79356323|NCT05848622|Behavioral|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
79356324|NCT05848622|Behavioral|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
79356325|NCT05842291|Device|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
79356326|NCT05842291|Device|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
79507310|NCT00428922|Drug|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
79356327|NCT05842291|Device|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
79507311|NCT00428922|Drug|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
79507312|NCT00533442|Drug|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
79507313|NCT00533442|Drug|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
79507314|NCT00533442|Drug|Tacrolimus|Part of standard maintenance.
79507315|NCT00533442|Drug|Steroids|Part of standard maintenance
79507316|NCT00533910|Drug|Rifaximin|550mg BID rifaximin for 8 weeks
79507317|NCT00533910|Drug|placebo|same as the experimental arm
79507318|NCT01954524|Drug|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
79668596|NCT00346892|Biological|Rotavirus (vaccine)|
79668597|NCT00346931|Procedure|Phacoemulsification, implantation of intraocular lens|
79668598|NCT00346931|Procedure|Phacoemulsification, Implantation of IOL, trabeculotomy|
79668599|NCT00346970|Drug|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
79668600|NCT00346970|Drug|Placebo|Placebo tablets
79668601|NCT00455130|Drug|Inhaled mannitol|
79818528|NCT06205875|Drug|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
79818529|NCT06205225|Behavioral|Text4HF|Behavioral text messages about heart failure self-care
79818530|NCT06205225|Behavioral|MyApps|consumer mobile health apps and devices for heart failure self-care
79356328|NCT05841355|Other|Educate|Education sessions
79356329|NCT05841355|Other|Empower|Empowerment sessions
79356330|NCT05839158|Other|HFMT cell suspension|Perform FUE autologous hair transplantation on the patient according to the guidelines and standard procedures. During the procedure, a hollow punch is used to individually punch out follicular units from the donor area. The epidermis, some dermis tissue, sebaceous glands, and surrounding tissue of the follicular units are separated and removed before the remaining follicular tissue is implanted into the recipient area. The separated tissue is trimmed with surgical scissors to create a cell suspension. After completion of the procedure, the HFMT cell suspension is evenly applied to the treatment group surface. Double vaseline gauze is used to cover all donor areas and is then wrapped with sterile dry gauze with moderate pressure.
79507319|NCT00535002|Drug|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
79507320|NCT00535002|Drug|Placebo|
79507321|NCT02117934|Biological|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
79507322|NCT02117934|Biological|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
79668602|NCT00347048|Drug|tacrolimus|oral
79668603|NCT00347048|Drug|Placebo|oral
79668604|NCT00448773|Behavioral|Online education|
79668605|NCT00455169|Biological|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
79668606|NCT00347087|Drug|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
79668607|NCT00347165|Drug|bevacizumab intravitreal injection|
79668608|NCT00455208|Drug|Cura-100|
79668609|NCT00455247|Drug|Glutamine|
79818531|NCT06205225|Behavioral|MyApps & Text4HF|Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
79356331|NCT05839158|Other|Mupirocin ointment|the Minoxidil ointment is evenly applied to the control group surface.
79818532|NCT06192316|Behavioral|3x3 between-subjects experimental exposure|"Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, Tobacco Free, Synthetic Nicotine) between-subjects design. We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions. Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to. Within each condition, pack images will vary by 4 brands and 4 flavors per brand. While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking."
79668610|NCT00347204|Drug|ketorolac (Acular LS)|
79668611|NCT00347204|Drug|Nepafenac (Nevanac)|
79818533|NCT06190288|Other|Transitional care model|A newly developed care model to support frail older adults during their transition from hospital to home.
79818534|NCT06189365|Device|Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
79356332|NCT05827549|Drug|Blincyto|Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
79818535|NCT06182085|Drug|PRI-002|Oral administration
79356333|NCT05783297|Behavioral|Treatment Text (TXTXT)|This study will test a tailored, personalized SMS text message reminder intervention to improve adherence to ART among non-adherent youth and young adults with HIV. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the 6-month intervention period. Participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
79356334|NCT05783297|Behavioral|Standard of Care|Standard of care ART adherence support includes adherence counseling during visits scheduled at least twice annually and appointment reminders.
79507323|NCT00429702|Drug|Decadron®|Given IV
79507324|NCT00429702|Drug|Benadryl®|Given IV
79507325|NCT00429702|Drug|Ativan®|Given IV
79507326|NCT00429702|Drug|ondansetron hydrochloride|Given IV
79507327|NCT00535392|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if <50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
79668612|NCT00347243|Procedure|phacoemulsification (cataract surgery)|
79668613|NCT00448851|Biological|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
79668614|NCT00455286|Drug|Methotrexate|
79668615|NCT00455286|Drug|Methylprednisolone|
79668616|NCT00455286|Drug|Temozolomide|
79668617|NCT00455364|Drug|Voriconazole|
79668618|NCT00347321|Procedure|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
79668619|NCT00448929|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
79668620|NCT00347399|Drug|bevacizumab intravitreal injection|
79668621|NCT00347399|Procedure|verteporfin photodynamic therapy|
79668622|NCT00455442|Drug|Mifepristone|
79818536|NCT06182085|Drug|Placebo|Oral administration
79818537|NCT06181162|Other|Social and/or physical environmental interventions|To be determined in the co-creation groups on the four sites (Denmark, the Netherlands, Nigeria, South Africa)
79818538|NCT06173960|Device|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
79991356|NCT02578758|Behavioral|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
79507328|NCT00535782|Drug|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
79818539|NCT06173531|Drug|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
79991357|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
79991358|NCT02353702|Procedure|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
79991359|NCT02353702|Drug|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
79991360|NCT02353702|Device|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
79356335|NCT05777772|Behavioral|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
79356336|NCT05768763|Behavioral|Community-enhanced reach activities|We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care working closely with community health system, leveraging existing mobile outreaches in the community.
79356337|NCT05768763|Behavioral|Person-centered care delivery|Structured approach to provide patient-centered biomedical options for prevention. Tailored services for youth, pregnant women, and persons without viral suppression, mobile populations, with heavy alcohol use, or severe hypertension.
79507329|NCT00535782|Drug|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
79507330|NCT00535782|Drug|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
79507331|NCT00431184|Drug|Pentazocine|see arms description
79991361|NCT02353702|Drug|Infusion of placebo during 48 hours|
79991362|NCT02353702|Drug|NaCl|
79507332|NCT00431184|Drug|Lorazepam|see arms description
79507333|NCT00535938|Other|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
79507334|NCT00537576|Biological|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
79991363|NCT02532660|Drug|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
79991364|NCT02532660|Drug|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
79991365|NCT02532660|Drug|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
79991366|NCT02532660|Drug|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
79356338|NCT05768763|Other|Data-enhancement to improve precision of interventions|Both community-enhanced reach and person-centered delivery will be strengthened through the strategic collection and use of data. Analysis will be conducted to enhance the effectiveness of ongoing outreach activities by identifying high yield venues and locations and local regions and persons who would benefit form more frequent or intensive outreach or services due to, eg, elevated risk of HIV infection, unsuppressed viral load, and uncontrolled HTN.
79356339|NCT05768763|Behavioral|Standard of Care|Standard of Care in Uganda and Kenya
79507335|NCT00537576|Biological|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
79507336|NCT00537576|Biological|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
79507337|NCT00537576|Other|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
79668623|NCT00347477|Drug|HyperHAES vs. RA-solution/NaCl|
79668624|NCT00347516|Procedure|IOL calculation formula|
79668625|NCT00449085|Procedure|Electrophysiology|
79668626|NCT00449085|Device|CARTO™ XP EP Navigation System V9|
79668627|NCT00347555|Biological|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
79991367|NCT01377168|Drug|oral naltrexone|
79991368|NCT01377168|Drug|Placebo pill|
79991369|NCT02892149|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79507338|NCT00537576|Other|Medium dose Placebo|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
79507339|NCT00537576|Other|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
79991370|NCT02892149|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
79507340|NCT01795794|Drug|omeprazole|
79507341|NCT01795950|Drug|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
79507342|NCT01796028|Drug|METFORMIN|
79507343|NCT01796028|Drug|Placebo|
79507344|NCT01796028|Drug|TAXOTERE®|
79507345|NCT00491244|Drug|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
79991371|NCT02353624|Behavioral|Cycling|Cycling distance of 2880 km in 14 days
79356340|NCT05761288|Behavioral|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
79356341|NCT05741710|Drug|Methylone|Methylone capsules, given orally, once a week for 4 weeks
79356342|NCT05741710|Drug|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
79356343|NCT05739994|Other|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
79507346|NCT00491244|Drug|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
79507347|NCT00492336|Drug|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
79507348|NCT00492336|Drug|Placebo|Placebo 1 tablet each day
79818540|NCT06173531|Drug|Placebo|Placebo given TID, identical in appearance respective to carbetocin treatment
79818541|NCT06171490|Other|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
79818542|NCT06171490|Other|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
79356344|NCT05739994|Other|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
79356345|NCT05721326|Other|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
79507349|NCT00538434|Biological|Reslizumab|
79507350|NCT00538434|Other|Saline|
79507351|NCT00538512|Biological|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
79507352|NCT00538512|Biological|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
79507353|NCT00538512|Other|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
79507354|NCT00538824|Drug|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
79668628|NCT00347555|Drug|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
79668629|NCT00347555|Biological|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
79668630|NCT00455598|Drug|ISIS 113715|doses of 100 and 200 mg per week
79668631|NCT00347594|Device|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
79668632|NCT00347594|Device|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
79668633|NCT00347672|Biological|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
79356346|NCT05668000|Other|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
79356347|NCT05668000|Other|Mobile application|The mobile application provide only self-management interventions.
79356348|NCT05632562|Drug|O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI|High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
79356349|NCT05562830|Biological|Zilovertamab vedotin|Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
79356350|NCT05553444|Behavioral|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
79356351|NCT05542121|Device|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
79356352|NCT05542121|Other|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
79356353|NCT05541406|Behavioral|Proud & Empowered|Proud & Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
79356354|NCT05523830|Other|No Intervention|No intervention
79356355|NCT05514184|Dietary Supplement|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with >2/3% of the protein from plant-proteins.
79356356|NCT05511181|Device|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
79668634|NCT02956863|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
79818543|NCT06171490|Other|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
79818544|NCT06171490|Other|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
79818545|NCT06170619|Device|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
79818546|NCT06170372|Drug|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
79356357|NCT05511181|Device|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
79668635|NCT02956863|Procedure|Exercises|Exercise for stretching and strength for neck muscles
79668636|NCT00347711|Drug|Intravitreal injection|
79668637|NCT00455637|Biological|Botulinum toxin type A|
79668638|NCT00347750|Drug|Lopinavir pharmacokinetic/pharmacodynamic analysis|
79818547|NCT06170372|Drug|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
79818548|NCT06169319|Biological|EN3835|Biologic: Intrafascial injection
79818549|NCT06169319|Other|Placebo|Intrafascial injection
79668639|NCT00455676|Procedure|Chevron osteotomy versus Scarf osteotomy|
79668640|NCT00347789|Procedure|Glaucoma surgery- Bleb revision|
79668641|NCT03276312|Device|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
79356358|NCT05449977|Diagnostic Test|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
79356359|NCT05449626|Diagnostic Test|Assessment|The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
79356360|NCT05441280|Drug|pimavanserin|pimavanserin 34mg PO at bedtime
79356361|NCT05441280|Other|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
79356362|NCT05434338|Diagnostic Test|HPV detection test|Samples taken from the squamocolumnar junction using swabs (UTM Copan)
79356363|NCT05425264|Other|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
79356364|NCT05413161|Biological|ADL-018|150 mg/mL, Solution for injection in PFS
79356365|NCT05413161|Biological|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
79356366|NCT05413161|Biological|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
79668642|NCT00347828|Drug|Moxifloxacin ophthalmic solution 0.5%|
79668643|NCT00347828|Drug|Gatifloxacin ophthalmic solution 0.3%|
79991372|NCT02352532|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
79991373|NCT02352532|Other|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
79356367|NCT05411562|Diagnostic Test|SARS-CoV-2 genomic sequencing|SARS-CoV-2 viral genomic sequencing and phylogenetic analyses
79356368|NCT05410730|Drug|SHR-1501|SHR-1501 single agent dose escalation will consist of 3 dose groups: 200 μ g、400 μ g and 600 μ g, and in combination of BCG. The administration method is intravesical instillation.
79356369|NCT05386719|Other|Prescreening|Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status & questions about cardiovascular disease.
79356370|NCT05386719|Other|Screening and Enrollment|Consent
79356371|NCT05386719|Behavioral|Baseline|Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
79356372|NCT05386719|Behavioral|Interpret BMI|Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
79356373|NCT05386719|Other|Interpret HbA1c|"HbA1c results categorized as follows:~HbA1c <5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication"
79668644|NCT00449124|Drug|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
79818550|NCT06163729|Drug|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
79991374|NCT02348476|Other|No Intervention|No study drug is administered in this study.
79991375|NCT05046912|Behavioral|Yoga|8 weeks of online weekly yoga or chair yoga class
79991376|NCT05046912|Behavioral|Mindfulness|8 weeks of online weekly mindfulness class
79356374|NCT05386719|Other|Interpret lipid panel and assess other risk factors|"Based on above categories:~HbA1c <5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol >200, family history of Coronary Artery Disease/Heart Attack in first degree family <55 year old male or <65 year old female, systolic blood pressure >130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%"
79356375|NCT05386719|Behavioral|Assess 10 year risk of cardiovascular event|If risk factors are present - refer to Cardiovascular Disease Prevention Program
79668645|NCT00449124|Biological|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10^6 PFU, TG4040 10^7 PFU and TG4040 10^8 PFU.
79668646|NCT00347867|Drug|Viagra administration in IUGR/PET pregnancies|
79668647|NCT00347906|Procedure|laser treatment|
79668648|NCT00449202|Drug|oleoyl-estrone (MP 101)|
79668649|NCT00347945|Procedure|Pencil Push-ups|
79668650|NCT00347945|Procedure|Office-based Vision Therapy|
79668651|NCT00347945|Procedure|Placebo Office-based Vision Therapy|
79668652|NCT00455715|Drug|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
79356376|NCT05386719|Behavioral|Recommendations|Provide individual patient handout based on all above interventions
79356377|NCT05386719|Behavioral|Follow-Up|6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
79668653|NCT00455754|Drug|Esomeprazole|
79991377|NCT02348398|Drug|Pazopanib|600 mg by mouth daily in a 28 day cycle.
79356378|NCT05386693|Procedure|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
79356379|NCT05378750|Other|Diuretic algorithm|Implementing diuretic algorithm
79991378|NCT02348398|Drug|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
79991379|NCT02348398|Behavioral|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
79356380|NCT05353647|Biological|Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a|A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
79991380|NCT02352688|Procedure|Enhanced Colorectal Geriatric Care|
79356381|NCT05343169|Behavioral|Overdose Education and Naloxone Distribution|"Education on OD risk behaviors and methods for responding to an OD, including naloxone use.~Duration and dose: Single 20-minute training at time of enrollment, provided to all participants in both arms"
79356382|NCT05343169|Behavioral|Advanced Education in Safer Substance Use, Treatment, and Self-Care|Education about misinformation about OAT, self-care, SEP services, HIV/HCV treatment Duration/dose: 9 mos., monthly ~2 hr. group sessions + ongoing access to video archive of recorded trainings.
79356383|NCT05343169|Behavioral|Social Service and Health Navigation|Help navigate access and barriers to healthcare, motivation and health goals Duration/dose: 9 mos., monthly face-to-face sessions to set goals and schedule appts, phone calls between sessions > 1x/wk.
79356384|NCT05343169|Behavioral|Peer Social Support|Support with social (re)integration, isolation, relationship building Duration/dose: 9 mos., monthly face-to-face events and phone calls/texts between sessions > 1x/wk.
79668654|NCT00347984|Other|Systane Lubricant eye drops|
79356385|NCT05339932|Other|Manual Wheelchair Skills Training|The intervention involves manual wheelchair skills training.
79356386|NCT05336396|Other|BMI|Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
79356387|NCT05281497|Behavioral|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
79991381|NCT03147352|Device|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
79356388|NCT05281497|Behavioral|Social media|We built a LINE group to inspire the intervention group.
79356389|NCT05281497|Other|exercise including an 18-minutes calisthenics|exercise including an 18-minutes calisthenics
79356390|NCT05228314|Biological|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
79356391|NCT05228314|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
79991382|NCT02352454|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
79991383|NCT01378806|Behavioral|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
79668655|NCT00348023|Drug|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
79668656|NCT00348062|Drug|Bimatoprost|
79668657|NCT00449241|Device|Acupuncture|
79668658|NCT00348101|Drug|Combined therapy with enoximone and esmolol|
79668659|NCT00455832|Procedure|peginterferon alpha and ribavirin|sperm collection
79991384|NCT03147274|Behavioral|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
79991385|NCT05278338|Drug|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
79991386|NCT05278338|Drug|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
79668660|NCT00348179|Procedure|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
79668661|NCT00455871|Drug|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
79668662|NCT00455871|Drug|Lucentis|Lucentis intravitreal injection
79668663|NCT00348218|Device|NeuroVision|
79668664|NCT00449280|Drug|Sorafenib|400mg BID (200 mg twice daily)
79668665|NCT00449280|Drug|Rapamycin|30mg once weekly
79668666|NCT00449280|Drug|Rapamycin|3mg once daily
79668667|NCT00348257|Device|Hair removal by laser/IPL device|
79668668|NCT00455910|Drug|Thalidomide|
79668669|NCT00348296|Drug|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
79991387|NCT05278338|Drug|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
79991388|NCT03721757|Biological|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
79818551|NCT06163014|Behavioral|My Symptoms eHealth programme|"My Symptoms supports patients' self-efficacy and behavioural changes. The programme is activated by the patient after prescription by the GP. The patient is free to choose relevant tasks corresponding to wishes, needs/requirements and own perspectives.~Summary of content:~Symptom explanations and facts about frequent symptoms including brief animated explanations~Physical energy (sleep, diet and activity)~Working with resources and strain in everyday life~Values and choices (meaning and existential issues)~Thoughts~Feelings (emotion regulation)~Self-care (attention incl. mindfulness and audio exercises)~Preparation for a follow-up visit with the GP and relapse prevention. The above modules connect to four general tools: symptom registration, 'don't break the chain', goal setting staircase and notebook.~After 6 weeks: Voluntary GP follow-up consultation. After 8 weeks: End-of-treatment."
79507355|NCT00538824|Drug|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
79507356|NCT00538824|Drug|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of < 40cc/min*"
79507357|NCT00539526|Drug|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
79668670|NCT00449319|Procedure|Identification of appropriate therapies according to risks factors|
79356392|NCT05228314|Other|Squalene based adjuvant|Squalene based adjuvant
79356393|NCT05228314|Other|CpG/alum adjuvant|CpG/alum adjuvant
79668671|NCT00449319|Drug|Daunorubicine|
79668672|NCT00449319|Procedure|Transplant|
79818552|NCT06160622|Drug|Leritrelvir|Oral
79991389|NCT03721757|Biological|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
79356394|NCT05227521|Behavioral|Adapted H-GRASP feedback program|Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
79991390|NCT02352376|Other|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
79991391|NCT02352376|Other|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
79356395|NCT05184985|Device|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
79356396|NCT05184985|Device|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
79668673|NCT00348335|Drug|Cyclosporine 0.05%|
79668674|NCT00348335|Drug|Ocular lubricant|
79668675|NCT00449358|Procedure|apply methyl-ALA cream|
79668676|NCT00348413|Drug|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
79668677|NCT00348452|Drug|tramadol HCl ER; celecoxib|
79668678|NCT00449397|Drug|Quetiapine Fumarate|
79668679|NCT00348491|Drug|Lumiracoxib|
79668680|NCT03274323|Device|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
79668681|NCT03274323|Procedure|Trabeculectomy|Standard trabeculectomy
79668682|NCT00348530|Drug|Verapamil|
79668683|NCT00449436|Drug|TRIZIVIR|TRIZIVIR
79818553|NCT06158802|Other|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
79818554|NCT06153758|Drug|Formulation A|Danuglipron IR PF-06882961-82 40 mg Oval White to Off-White Tablet
79818555|NCT06153758|Drug|Formulation B|Danuglipron MR, Danuglipron 80 mgA (500 mgW) Oval MR Tablet (Long Release)
79818556|NCT06153758|Drug|Formulation C|Danuglipron MR, Danuglipron 80 mgA (1000 mgW) Oval MR Tablet (Long Release)
79818557|NCT06153758|Drug|Formulation D|Danuglipron MR Danuglipron 80 mgA (500 mgW) Oval MR Tablet (Short Release)
79507358|NCT00539526|Drug|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
79507359|NCT00539526|Drug|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
79507360|NCT00496860|Biological|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
79507361|NCT01796106|Device|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
79507362|NCT01796106|Device|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
79507363|NCT03371004|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
79507364|NCT00541242|Drug|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
79507365|NCT00541242|Drug|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
79818558|NCT06151405|Other|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~A variety of vegetables and fruits~Grains, at least half of which are whole grains~Fat-free or low-fat dairy~A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
79818559|NCT06151405|Other|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
79818560|NCT06151405|Other|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
79356397|NCT05167760|Drug|Apraclonidine|1-2 drops per eye every 8 hours for 2 weeks
79668684|NCT00449436|Drug|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
79356398|NCT05135195|Other|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
79668685|NCT00449436|Drug|Boosted Protease Inhibitor|Boosted Protease Inhibitor
79507366|NCT00438204|Biological|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
79507367|NCT00438204|Drug|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
79507368|NCT00438204|Drug|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
79507369|NCT00438750|Other|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
79507370|NCT00438750|Other|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
79507371|NCT00439296|Drug|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
79668686|NCT00348569|Device|64 Channel VCT|
79668687|NCT03274284|Combination Product|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
79668688|NCT00348608|Drug|iodixanol|
79668689|NCT03274245|Behavioral|Intervention Package|"Community Level:~Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~Transect Walk: village walk to identify and mark feces in community;~Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~Wall painting: village map noting households that use latrines always.~Sub-Community level:~Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~Household Level:~Household visits: to those with latrines to motivate use;~Latrine repairs: for households with non-functional latrines to make functional."
79991392|NCT03727607|Drug|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
79991393|NCT05157516|Procedure|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
79991394|NCT05157516|Procedure|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
79991395|NCT02348242|Device|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
79356399|NCT05135195|Other|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
79356400|NCT05134480|Procedure|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
79507372|NCT00439296|Drug|Dexamethasone|"In Treatment Course 1 only:~10 mg/m2/day divided BID.~Take dexamethasone by mouth days 1-14."
79668690|NCT03274245|Other|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
79668691|NCT00348647|Behavioral|physical training program to prevent injuries|
79668692|NCT00456027|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
79991396|NCT02348242|Device|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
79991397|NCT02348242|Device|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
79356401|NCT05127590|Drug|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
79507373|NCT00439296|Drug|PEG-asparaginase|"In Treatment Course 1:~2500 IU's/m2/day.~Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~2500 IU's/m2/day.~Intramuscular injection (IM) on day 15."
79507374|NCT00439296|Drug|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
79507375|NCT00439296|Drug|Cytarabine|"Given Intrathecally on day 1 of course 1 at the dose defined by age below.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age~Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
79507376|NCT00439296|Drug|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
79507377|NCT00439296|Drug|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
79991398|NCT04187092|Other|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
79507378|NCT00439296|Drug|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
79668693|NCT00448734|Drug|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
79991399|NCT04187092|Other|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
79991400|NCT05084976|Behavioral|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
79991401|NCT02352142|Other|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
79991402|NCT02352142|Behavioral|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
79507379|NCT00542490|Radiation|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
79507380|NCT03117660|Drug|Vitamin A|vitamin A daily X3-4 weeks
79668694|NCT00448734|Drug|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
79818561|NCT06151366|Other|non interventional|non interventional
79818562|NCT06151197|Biological|EN3835|Biologic: EN3835 injection
79991403|NCT02896127|Drug|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
79507381|NCT00439374|Drug|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
79991404|NCT02896127|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
79991405|NCT02351986|Procedure|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
79991406|NCT02351986|Other|ice pack|
79507382|NCT00439374|Other|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
79507383|NCT00439608|Drug|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
79668695|NCT00348725|Drug|fenofibrate and metformin fixed combination (drug)|
79668696|NCT00456066|Device|Export Aspiration System|Patients scheduled for emergency angioplasty
79507384|NCT01797042|Behavioral|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
79507385|NCT00500448|Device|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
79668697|NCT00348764|Drug|lauromacrogol|
79818563|NCT06151197|Other|Placebo|Placebo injection
79818564|NCT06150183|Biological|BNT314|Intravenous infusion
79818565|NCT06150183|Biological|Pembrolizumab|Intravenous infusion
79818566|NCT06147713|Device|Vibrotactile foot device (Smart shoe)|A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
79818567|NCT06145282|Drug|Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
79356402|NCT05116891|Drug|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
79356403|NCT05116891|Drug|mFOLFOX|mFOLFOX/CAN04
79356404|NCT05116891|Drug|DTX|DTX/CAN04
79356405|NCT05116891|Drug|G/C|G/C/CAN04
79356406|NCT05100342|Diagnostic Test|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
79668698|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
79668699|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
79356407|NCT05095038|Dietary Supplement|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
79356408|NCT05095038|Dietary Supplement|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
79507386|NCT04750122|Drug|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
79507387|NCT04749576|Dietary Supplement|saffron supplement for IBD|anti inflammatory effect
79507388|NCT00441558|Drug|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
79507389|NCT01797276|Drug|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
79507390|NCT00443352|Drug|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
79668700|NCT00456105|Behavioral|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
79818568|NCT06143059|Drug|Ethanol|Sterile, 95% ethanol will be administered through IV infusion
79507391|NCT00445302|Drug|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
79818569|NCT06143059|Drug|Saline|Saline is administered as the placebo
79507392|NCT00502944|Behavioral|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
79507393|NCT00502944|Behavioral|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
79507394|NCT00504504|Drug|Rituximab|375 mg/m^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
79507395|NCT00504504|Drug|Adriamycin|25 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
79507396|NCT00504504|Drug|Bleomycin|10 U/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
79507397|NCT00504504|Drug|Vinblastine|6 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
79507398|NCT00504504|Drug|Dacarbazine (DTIC)|375 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
79507399|NCT00504660|Drug|Capecitabine|Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
79507400|NCT00504660|Drug|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
79507401|NCT00504660|Drug|Temozolomide|Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
79668701|NCT03276156|Drug|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
79507402|NCT00504660|Drug|Lomustine|Arms 2,3 = 100 mg/m^2 PO on Day 4.
79507403|NCT00504660|Drug|6-Thioguanine|Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
79507404|NCT00505362|Procedure|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
79507405|NCT00505518|Drug|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
79507406|NCT00505518|Behavioral|Collaborative psychiatric and primary medical care|Regular care visits from health workers
79668702|NCT00348842|Procedure|Newcastle Virus|
79668703|NCT00456144|Drug|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
79668704|NCT00456183|Biological|MVA 85A|
79668705|NCT00348920|Procedure|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
79507407|NCT00544674|Drug|PR104|administered at a dose of 1100 mg/m^2 by intravenous infusion over 1 hour and repeated every three weeks
79507408|NCT00544674|Other|F-18-fluoromisonidazole|administered intravenously prior to PET scan
79507409|NCT00544908|Drug|dasatinib|
79507410|NCT00544908|Other|immunoenzyme technique|
79507411|NCT00544908|Other|immunohistochemistry staining method|
79507412|NCT00544908|Other|laboratory biomarker analysis|
79507413|NCT00544908|Procedure|quality-of-life assessment|
79507414|NCT00447330|Drug|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
79507415|NCT04388280|Diagnostic Test|Echocardiography|Functional assessment of coronary artery disease
79507416|NCT04388280|Diagnostic Test|CT angiography|Anatomical assessment of coronary artery disease
79507417|NCT02115048|Drug|Letrozole|
79507418|NCT02115048|Drug|Afatinib|
79507419|NCT00546156|Drug|Doxorubicin|Standard chemotherapy regimen
79668706|NCT00348959|Behavioral|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
79668707|NCT00449514|Drug|tamoxifen|
79668708|NCT00449514|Drug|clomiphene citrate|
79668709|NCT00348998|Biological|bevacizumab|
79668710|NCT00348998|Drug|bicalutamide|
79668711|NCT00348998|Drug|goserelin acetate|
79668712|NCT00348998|Radiation|radiation therapy|
79668713|NCT00456222|Behavioral|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
79668714|NCT00349037|Biological|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
79668715|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
79668716|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
79668717|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
79818570|NCT06140355|Behavioral|Qigong|a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up
79507420|NCT00546156|Drug|Cyclophosphamide|Standard chemotherapy regimen
79507421|NCT00546156|Drug|Paclitaxel|Standard chemotherapy regimen
79507422|NCT00546156|Drug|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
79507423|NCT00449046|Drug|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
79507424|NCT00508716|Behavioral|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
79356409|NCT05069038|Drug|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
79356410|NCT05065983|Biological|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
79356411|NCT05013099|Biological|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
79356412|NCT04983030|Biological|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
79507425|NCT00509496|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days.
79668718|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
79356413|NCT04983030|Biological|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
79356414|NCT04983030|Biological|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
79356415|NCT04983030|Biological|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
79356416|NCT04983030|Biological|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
79356417|NCT04981613|Drug|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
79356418|NCT04973566|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
79356419|NCT04973566|Drug|Etanercept|Etanercept will be administered subcutaneously.
79356420|NCT04973566|Drug|Hydroxychloroquine|HCQ will be administered orally.
79356421|NCT04947579|Drug|CC-99677|Oral
79356422|NCT04947579|Other|Placebo|Oral
79507426|NCT00509496|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenous
79507427|NCT00509496|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
79818571|NCT06140355|Behavioral|Daily 2 min pain management survey|Completing one short survey (2 min) daily through your phone or computer (you will get a survey link through email or text), with a 6-month follow-up.
79356423|NCT04932447|Behavioral|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
79668719|NCT00449592|Drug|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
79668720|NCT00449592|Drug|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
79668721|NCT00349076|Drug|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
79668722|NCT00349076|Drug|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
79356424|NCT04928014|Other|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
79356425|NCT04906148|Other|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
79507428|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
79507429|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
79507430|NCT00547638|Device|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
79507431|NCT00547638|Device|cyanoacrylate|Topical Skin Adhesive
79507432|NCT00510744|Drug|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
79507433|NCT00548418|Drug|Topotecan|
79507434|NCT00548418|Drug|Cisplatin|
79507435|NCT00548418|Drug|Bevacizumab|
79507436|NCT00511914|Biological|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
79507437|NCT00511992|Drug|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
79668723|NCT00349115|Drug|Thalidomide|
79356426|NCT04906148|Other|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
79356427|NCT04863092|Behavioral|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
79668724|NCT00456339|Drug|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
79356428|NCT04856189|Biological|Pembrolizumab|Given IV
79356429|NCT04856189|Drug|Selinexor|Given PO
79356430|NCT04855929|Drug|ANV419|ANV419 administered by intravenous (IV) infusion
79356431|NCT04855929|Drug|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
79356432|NCT04848558|Drug|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
79356433|NCT04848558|Other|Placebo|Participants will receive IV infusion or SC injection of placebo.
79356434|NCT04846686|Biological|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
79356435|NCT04845620|Drug|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
79507438|NCT00511992|Drug|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
79507439|NCT00511992|Drug|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
79507440|NCT00451698|Drug|acyanotic erythropoietin|Single dose IV push
79507441|NCT00451698|Drug|acyanotic placebo|Single dose IV push
79507442|NCT01796262|Dietary Supplement|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
79507443|NCT01796262|Dietary Supplement|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
79507444|NCT01796340|Behavioral|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
79356436|NCT04845620|Drug|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
79356437|NCT04844411|Drug|JNJ-67835989|JNJ-67835989 will be administered orally.
79356438|NCT04844411|Drug|Placebo|Matching placebo will be administered orally.
79507445|NCT01796340|Behavioral|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
79507446|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
79507447|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
79507448|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
79507449|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
79507450|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
79507451|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
79507452|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
79507453|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
79507454|NCT01797354|Behavioral|Cognitive-behavioral therapy and hypnosis group|
79507455|NCT01797354|Behavioral|Support group|
79507456|NCT00549042|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
79507457|NCT00549042|Drug|Placebo|Placebo
79507458|NCT00452868|Drug|Donepezil|Donepezil 5 milligrams a day for 6 weeks
79507459|NCT00453336|Drug|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
79507460|NCT00453336|Procedure|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
79668725|NCT00349193|Drug|laquinimod 0.3|laquinimod 0.3mg
79668726|NCT00349193|Drug|laquinimod 0.6|laquinimod 0.6mg
79668727|NCT00349193|Other|Placebo|Blinded Placebo
79507461|NCT00549822|Drug|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
79507462|NCT00550290|Drug|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
79507463|NCT00550290|Drug|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
79507464|NCT03255408|Drug|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
79507465|NCT03255408|Drug|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
79507466|NCT03255408|Drug|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
79507467|NCT03255408|Drug|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
79507468|NCT01797198|Drug|ASP3652|Oral
79356439|NCT04843527|Device|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
79356440|NCT04843527|Device|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
79668728|NCT00449709|Drug|GSK221149|
79356441|NCT04816201|Other|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
79356442|NCT04811235|Device|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
79668729|NCT00421421|Drug|Dutasteride|
79356443|NCT04797650|Drug|CTP-543 matching placebo|Administered as tablets.
79356444|NCT04797650|Drug|CTP-543|Administered as tablets.
79356445|NCT04760496|Drug|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
79356446|NCT04760496|Drug|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
79356447|NCT04736472|Device|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
79356448|NCT04734145|Diagnostic Test|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
79507469|NCT01797198|Drug|Gemfibrozil|Oral
79507470|NCT01797198|Drug|Repaglinide|Oral
79507471|NCT00550368|Biological|Biological intervention: Enteropathogenic E. coli|5x10^8 or 1x10^9 organisms of EPEC were administered to all participants.
79507472|NCT00551070|Other|Laboratory Biomarker Analysis|Correlative studies
79507473|NCT00551070|Other|Pharmacological Study|Correlative studies
79668730|NCT03274206|Biological|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
79507474|NCT00551070|Drug|Selumetinib|Given PO
79507475|NCT00551070|Drug|Selumetinib Sulfate|Given PO
79668731|NCT03274206|Drug|Placebo|BLS-ILB-E710c-placebo
79507476|NCT00552786|Drug|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
79507477|NCT00552786|Drug|glucose|1 gm glucose capsule
79507478|NCT01797744|Other|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
79507479|NCT00517530|Drug|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
79507480|NCT00518154|Drug|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
79507481|NCT00553098|Biological|Alemtuzumab|Given IV
79507482|NCT00553098|Procedure|Allogeneic Bone Marrow Transplantation|Undergo HCT
79507483|NCT00553098|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
79507484|NCT00553098|Drug|Cyclosporine|Given PO or IV
79507485|NCT00553098|Drug|Fludarabine Phosphate|Given IV
79507486|NCT00553098|Other|Laboratory Biomarker Analysis|Correlative study
79507487|NCT00553098|Drug|Mycophenolate Mofetil|Given PO or IV
79507488|NCT00553098|Radiation|Total-Body Irradiation|Undergo low dose TBI
79507489|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
79507490|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
79507491|NCT00554970|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
79507492|NCT00554970|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
79668732|NCT00421460|Drug|Testosterone Undecanoate,1000mg|duration for 4 injections
79668733|NCT00349232|Behavioral|lifestyle intervention (diet and physical activity)|
79668734|NCT00449826|Procedure|Computed Tomographic Angiography|CT scan
79668735|NCT00349271|Procedure|Stem cell|Stem cell
79668736|NCT00349271|Drug|Filgrastime (G-CSF)|Filgrastime (G-CSF)
79668737|NCT00349271|Drug|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
79668738|NCT00456417|Drug|123-I MNI-187 Injection and Imaging Procedures|
79356449|NCT04722822|Behavioral|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Providers within intervention practices will receive training which includes both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
79507493|NCT00554970|Drug|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
79507494|NCT00554970|Drug|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
79507495|NCT00520884|Drug|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
79507496|NCT00520884|Drug|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
79356450|NCT04722822|Behavioral|(Control) Recommending HPV vaccine for patients 11-12 years of age|Providers within control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
79356451|NCT04705597|Drug|BGE-175|Drug
79507497|NCT00520884|Other|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
79668739|NCT03274167|Drug|Gabapentin 300mg|
79356452|NCT04705597|Other|Placebo|Placebo
79356453|NCT04704830|Biological|R21/Matrix-M|Adjuvanted malaria vaccine
79507498|NCT00520884|Other|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
79507499|NCT00521352|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
79507500|NCT00521352|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
79668740|NCT03274167|Drug|Placebo oral capsule|
79668741|NCT00349427|Drug|Rosiglitazone 4 mg|
79356454|NCT04704830|Biological|Rabies vaccine|Placebo Comparator
79356455|NCT04682431|Drug|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
79507501|NCT00523302|Device|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
79507502|NCT00523302|Device|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
79668742|NCT00449943|Procedure|Computed Tomographic Angiography|CT scan
79356456|NCT04682431|Drug|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
79507503|NCT00524472|Other|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
79507504|NCT00524472|Other|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
79507505|NCT00524940|Biological|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
79507506|NCT00525174|Device|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
79507507|NCT00525174|Device|Patching|2 hours daily patching of the sound eye
79507508|NCT00525174|Procedure|Near activities|one hour near visual activities
79668743|NCT00449943|Procedure|Myocardial Perfusion Imaging Scan|SPECT
79668744|NCT00349505|Procedure|hyper thermic chemo + surgery|
79668745|NCT00349583|Drug|Topical Cyclosporine, Tears|
79668746|NCT00449982|Drug|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
79668747|NCT00349661|Drug|impact on VASP test|
79668748|NCT00456651|Device|CPAP (Continuous Positive Airway Pressure)|
79668749|NCT00349700|Procedure|Compression: 2 weeks four layer bandages, then stockings|
79668750|NCT00349700|Procedure|debridement|
79668751|NCT00349700|Procedure|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
79668752|NCT00450021|Drug|[(11)C] MePPEP|
79668753|NCT00349739|Drug|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
79356457|NCT04682431|Drug|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
79356458|NCT04682431|Drug|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
79356459|NCT04682431|Drug|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
79356460|NCT04682431|Drug|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
79668754|NCT00456690|Other|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
79356461|NCT04682431|Drug|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
79668755|NCT00349817|Behavioral|web-based learning, didactic lecture and role-play|
79668756|NCT00450060|Device|lumbar puncture with Quincke-design needles|
79668757|NCT00450060|Device|lumbar puncture with Sprotte-design needles|
79356462|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
79356463|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
79356464|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
79356465|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
79356466|NCT04682431|Drug|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
79668758|NCT00349856|Device|Biofinity|Soft contact lens
79668759|NCT00456729|Drug|Metronidazole|
79668760|NCT00456729|Procedure|Blood tests|
79668761|NCT00349895|Device|Coronary stent implantation|Percutaneous Coronary Intervention
79668762|NCT00349934|Biological|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
79668763|NCT00450099|Drug|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
79668764|NCT00450138|Drug|ZD6474 (vandetanib)|once daily oral dose
79818572|NCT06138977|Device|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
79356467|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
79356468|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
79356469|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
79356470|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
79356471|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
79668765|NCT00450138|Drug|Cisplatin|intravenous infusion
79668766|NCT00450138|Radiation|Radiation|radiation of head and neck
79668767|NCT00350051|Drug|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
79668768|NCT00350090|Drug|Epoetin Alfa|
79507509|NCT04384848|Other|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
79507510|NCT04166916|Other|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
79991407|NCT03153592|Procedure|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
79991408|NCT03153592|Procedure|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
79991409|NCT03724097|Other|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
79991410|NCT03724097|Other|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
79991411|NCT03724097|Drug|target drug with the score above 0,1|target drug with the score above 0,1
79991412|NCT03724097|Drug|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
79991413|NCT03724097|Drug|non-target drug|non-target drug
79356472|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
79356473|NCT04649073|Biological|OPC-415|OPC-415 (up to 1×10^7cells/kg) On 2 days
79356474|NCT04582201|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
79356475|NCT04563507|Radiation|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
79356476|NCT04563507|Drug|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
79356477|NCT04563507|Drug|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
79356478|NCT04542603|Drug|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with [11C]PiB and One PET with [18F]DPA-714 before chemotherapy treatment begins. One more PET with [18F]DPA-714 after completion of 3-6 cycles of chemotherapy.
79356479|NCT04534114|Drug|Fesomersen sodium (BAY2976217)|Study intervention will be injected subcutaneously.
79356480|NCT04534114|Drug|Placebo|Matching placebo to BAY2976217 will be injected subcutaneously.
79356481|NCT04517344|Other|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
79356482|NCT04515641|Drug|Islatravir|Two ISL 30 mg capsules taken by mouth.
79507511|NCT04166916|Other|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
79507512|NCT00555048|Biological|alemtuzumab|
79507513|NCT00555048|Drug|busulfan|
79507514|NCT00555048|Drug|cyclophosphamide|
79507515|NCT00555048|Drug|methotrexate|
79507516|NCT00555048|Drug|tacrolimus|
79507517|NCT00555048|Procedure|allogeneic hematopoietic stem cell transplantation|
79507518|NCT00555048|Procedure|peripheral blood stem cell transplantation|
79507519|NCT00525798|Drug|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
79991414|NCT03724097|Drug|palliative care|palliative care
79356483|NCT04490200|Device|VESTA respirator|The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
79356484|NCT04490200|Device|Conventional N95 respirator|The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
79356485|NCT04474366|Drug|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
79356486|NCT04474366|Other|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
79356487|NCT04465643|Drug|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
79356488|NCT04465643|Drug|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
79356489|NCT04450706|Other|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
79507520|NCT00525798|Drug|SMC021 Placebo|SMC021 - Placebo, once daily
79507521|NCT00555360|Behavioral|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
79507522|NCT00555360|Behavioral|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
79507523|NCT00525876|Drug|Cyclophosphamide|"Matched Donors:~750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
79507524|NCT00525876|Drug|Fludarabine|"30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
79668769|NCT04699110|Drug|Adrenaline|Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
79668770|NCT04699110|Drug|Adenosine|Control group will receive adenosine (100 to 400 mcg)
79668771|NCT04698759|Other|No Intervention|no Intervention
79356490|NCT04450706|Other|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
79356491|NCT04430439|Behavioral|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
79356492|NCT04430439|Behavioral|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
79356493|NCT04422431|Drug|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
79356494|NCT04416451|Drug|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
79356495|NCT04416451|Drug|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~Week 1: 100 mg~Week 2: 200 mg~Week 3: 400 mg~Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
79356496|NCT04406649|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
79356497|NCT04362644|Drug|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue [F-18]FDG and the translocator protein (TSPO) ligand [F-18]DPA-714 in two separate imaging sessions.
79356498|NCT04316390|Dietary Supplement|Control|study drink (two weeks)
79356499|NCT04316390|Dietary Supplement|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
79668772|NCT00350168|Drug|valsartan + amlodipine|
79356500|NCT04316390|Dietary Supplement|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
79356501|NCT04316390|Dietary Supplement|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
79356502|NCT04308369|Biological|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
79356503|NCT04232228|Other|No intervention|No intervention was used in this study.
79356504|NCT04171817|Drug|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
79356505|NCT04152863|Biological|Gebasaxturev IV|Administered as an IV infusion of 1 X 10^9 TCID50
79356506|NCT04152863|Biological|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10^8 TCID50
79356507|NCT04152863|Drug|Pembrolizumab|Administered as an IV infusion of 200 mg
79356508|NCT04129554|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
79356509|NCT04129554|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
79356510|NCT04129554|Drug|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
79668773|NCT03274089|Device|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~Collects patient information using patient-specific identification~Prompts the user for answers to screening questions for acute conditions~Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~Triages patients based on responses to screening questions, physiological parameters and blood test results~Provides recommendations to the patient on the care plan, self management and lifestyle choices"
79668774|NCT00350246|Procedure|Laser Refractive Surgery|
79668775|NCT00456924|Drug|VA2914|
79668776|NCT00350285|Behavioral|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
79668777|NCT00350285|Behavioral|Marijuana education|Information about health and behavioral effects of marijuana use.
79679671|NCT02940756|Drug|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
79356511|NCT04129554|Drug|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
79668778|NCT00105534|Drug|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
79507525|NCT00525876|Drug|Rituximab|"Matched Donors:~375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
79668779|NCT00105534|Other|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
79356512|NCT04129554|Drug|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
79668780|NCT00350441|Drug|Sildenafil Citrate|
79668781|NCT00350480|Drug|Provera|
79668782|NCT00350480|Drug|Combination Birth Control pills|
79668783|NCT00350597|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
79356513|NCT04129554|Drug|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
79356514|NCT04129554|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
79356515|NCT04115488|Biological|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
79668784|NCT00457080|Device|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
79668785|NCT00350753|Drug|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
79668786|NCT00457119|Drug|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
79668787|NCT00350831|Drug|XL820|
79668788|NCT00350909|Behavioral|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
79668789|NCT00350948|Drug|Telcyta|Day 1 of 28 day Cycle.
79668790|NCT00350948|Drug|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
79668791|NCT00450567|Procedure|computed tomography|
79356516|NCT04109729|Drug|Nivolumab|"Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total"
79356517|NCT04080752|Drug|JNJ-61393215|JNJ-61393215 will be administrated orally.
79356518|NCT04080752|Drug|Placebo|Matching placebo will be administered orally.
79356519|NCT04078581|Other|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
79356520|NCT04062344|Other|Swab|Rectal swab before and after the drug provocation testing
79356521|NCT04049513|Biological|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
79356522|NCT04049513|Drug|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m^2 IV on days -5 to -3, inclusive
79356523|NCT04002180|Drug|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
79356524|NCT03999879|Diagnostic Test|Measure of OxPhos upregulation|OxPhos upregulation [i.e., lower phosphocreatine (PCr)-to-ATP ratio levels] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
79507526|NCT00525876|Drug|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
79507527|NCT00525876|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells.
79668792|NCT00450567|Procedure|positron emission tomography|
79356525|NCT03999879|Diagnostic Test|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
79356526|NCT03992872|Biological|Chikungunya|Virus Like Particle
79356527|NCT03968419|Drug|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
79356528|NCT03968419|Drug|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
79356529|NCT03924986|Drug|Tislelizumab|200 mg administered intravenously (IV)
79356530|NCT03924986|Drug|Placebo|Placebo to match Tislelizumab
79356531|NCT03924986|Drug|Gemcitabin|1 g/m2, administered as an IV infusion within 30 minutes
79356532|NCT03924986|Drug|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
79507528|NCT00555750|Drug|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
79668793|NCT00450567|Radiation|fludeoxyglucose F 18|
79356533|NCT03915379|Drug|JNJ-67571244|JNJ-67571244 will be administered.
79356534|NCT03911492|Procedure|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
79356535|NCT03866902|Behavioral|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
79668794|NCT00457158|Device|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
79668795|NCT00350987|Behavioral|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
79668796|NCT00421499|Drug|dark chocolate|
79507529|NCT00555750|Drug|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
79507530|NCT00526188|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
79668797|NCT00421538|Drug|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
79668798|NCT00421538|Drug|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
79668799|NCT03276039|Diagnostic Test|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
79668800|NCT04714697|Drug|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
79991415|NCT03157414|Drug|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
79356536|NCT03866902|Other|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
79356537|NCT03866577|Biological|Biological: M254|M254 administered as intravenous infusion
79356538|NCT03866577|Drug|Placebo|Placebo administered as intravenous infusion
79356539|NCT03866577|Biological|Intravenous immunoglobulin (IVIg)|IVIg administered as intravenous infusion
79991416|NCT03157414|Other|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
79356540|NCT03859193|Behavioral|Nutritional Video|A 10 - 15 minute video
79356541|NCT03835702|Other|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
79991417|NCT03157024|Device|Ring Sham (RS)|
79991418|NCT03157024|Device|Real Needle (RN)|
79991419|NCT03157024|Device|Kim Sham (KS)|
79991420|NCT03546647|Device|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
79991421|NCT03546647|Device|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
79356542|NCT03824041|Dietary Supplement|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
79356543|NCT03824041|Dietary Supplement|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
79356544|NCT03824041|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
79356545|NCT03784846|Behavioral|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
79356546|NCT03784846|Behavioral|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
79991422|NCT03156478|Behavioral|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
79991423|NCT03156478|Behavioral|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
79991424|NCT03727529|Other|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
79991425|NCT03727529|Other|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
79991426|NCT01310543|Behavioral|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
79991427|NCT02348164|Other|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
79991428|NCT02348164|Other|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
79991429|NCT03147196|Drug|Bicalutamide|Given PO
79991430|NCT03147196|Other|Laboratory Biomarker Analysis|Correlative studies
79991431|NCT03147196|Other|Questionnaire Administration|Ancillary studies
79991432|NCT03147196|Drug|Raloxifene Hydrochloride|Given PO
79991433|NCT03153436|Biological|Myoinositol|
79991434|NCT03077412|Drug|Filgotinib|Tablet(s) administered orally once daily
79991435|NCT03077412|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
79991436|NCT03544229|Drug|TAK-906 Maleate|TAK-906 maleate capsules.
79991437|NCT03544229|Drug|Placebo|TAK-906 maleate placebo-matching capsules.
79991438|NCT03147118|Diagnostic Test|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
79991439|NCT02353312|Drug|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
79991440|NCT02351908|Drug|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
79668801|NCT03275961|Behavioral|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
79668802|NCT00351026|Drug|Methadone|short-term methadone maintenance
79507531|NCT00556140|Drug|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
79507532|NCT00527124|Drug|cediranib maleate|Given orally
79507533|NCT00527124|Drug|docetaxel|Given IV
79668803|NCT00351065|Drug|SK3530|
79668804|NCT00457314|Behavioral|Exercise|Regular exercise training
79668805|NCT04714658|Other|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~st group collective workshop : allow the patient to better understand autoimmune~nd workshop : fatigue and techniques that enable its best management.~rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
79668806|NCT00457353|Drug|Bacillus Clausii|For 5 days
79991441|NCT02351908|Drug|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
79507534|NCT00527124|Drug|prednisone|Given orally
79356547|NCT03756350|Device|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
79356548|NCT03731104|Device|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=[SpO2-rScO2]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
79507535|NCT00527124|Other|laboratory biomarker analysis|Correlative studies
79668807|NCT00457353|Other|Oral rehydration therapy|For 5 days
79668808|NCT00351104|Drug|Ketoprofen Topical Patch 20%|
79668809|NCT03275922|Drug|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
79668810|NCT03275922|Drug|ZNS|Zolmitriptan Nasal Spray
79991442|NCT02351908|Drug|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
79991443|NCT01371240|Drug|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
79668811|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
79668812|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
79668813|NCT00457431|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
79507536|NCT00527592|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
79507537|NCT00527592|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
79356549|NCT03731104|Device|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
79356550|NCT03731104|Device|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = [π x d2 x VTI x HR] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
79356551|NCT03703635|Device|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter [Sinomed Inc., Tianjin, China]) is navigated by the microwire to the lesion of the target artery.
79356552|NCT03703635|Drug|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
79356553|NCT03684512|Behavioral|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
79668814|NCT00351221|Drug|rhIGF-1/rhIGFBP-3|
79668815|NCT00457470|Drug|AG-014699|
79668816|NCT00351260|Procedure|Coronary Angioplasty|
79356554|NCT03684512|Behavioral|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
79356555|NCT03684512|Behavioral|Facebook Group|Facebook group for parents to provide additional support and education
79356556|NCT03672760|Device|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
79668817|NCT04698642|Drug|CBL-514|Both sides of the abdominal region will receive CBL-514.
79356557|NCT03672760|Device|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
79507538|NCT02121912|Device|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
79507539|NCT02121912|Device|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
79507540|NCT00556452|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~1st dose level: 20 mg/m2/day x 5 days~2nd dose level: 30 mg/m2/day x 5 days~3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
79507541|NCT00556452|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
79668818|NCT00450606|Procedure|Balneotherapy and hydrotherapy|
79507542|NCT00556452|Radiation|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
79507543|NCT03158376|Drug|Gabapentin|
79507544|NCT03158376|Drug|Placebo|
79507545|NCT01797510|Behavioral|Web Based Health Coaching|
79668819|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
79668820|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
79668821|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
79668822|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
79507546|NCT02126748|Other|inhalation 4ml hypertonic saline 3% 3x/day|
79507547|NCT02126748|Device|Intrapulmonary Percussive Ventilation|
79507548|NCT02126748|Procedure|Assisted Autogenic Drainage|
79507549|NCT05622630|Procedure|Four-cell bath|Four-cell bath:Treatment with direct current
79356558|NCT03672760|Device|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
79991444|NCT02353390|Other|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
79356559|NCT03666559|Drug|Azacitidine|Chemotherapy
79356560|NCT03662022|Drug|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
79356561|NCT03653741|Drug|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
79356562|NCT03649971|Drug|Guselkumab|Guselkumab SC will be administered every 4 weeks.
79356563|NCT03649971|Drug|Placebo|Placebo SC will be administered every 4 weeks.
79356564|NCT03648996|Other|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
79356565|NCT03648996|Drug|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
79356566|NCT03648996|Drug|Placebo|6 months of placebo treatment
79507550|NCT05622630|Procedure|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
79507551|NCT01797900|Drug|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
79507552|NCT01797900|Drug|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
79356567|NCT03648996|Other|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
79356568|NCT03627403|Drug|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. . Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
79356569|NCT03586050|Device|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
79356570|NCT03585465|Drug|Vinblastine|"Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
79356571|NCT03585465|Drug|Cyclophosphamide|"Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
79507553|NCT01797900|Radiation|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
79668823|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
79668824|NCT00351494|Procedure|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
79507554|NCT03746808|Behavioral|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
79668825|NCT00351494|Procedure|embolization|Intervention is described in the case report form for each patient
79668826|NCT00450645|Drug|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
79668827|NCT04714307|Diagnostic Test|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
79668828|NCT04714307|Diagnostic Test|Cognitive Testing|"Cross-sectional Cognitive evaluation with~CCAS Scale~Trail-Making Test parts A and B~Stroop Color-Word Test"
79818573|NCT06138730|Behavioral|Appa Complete|Weekly mentorship meetings & guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
79991445|NCT02352064|Procedure|PET (18-FDG)|Every patient will have a PET
79991446|NCT03078816|Device|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991447|NCT03078816|Device|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991448|NCT03078816|Device|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991449|NCT03078816|Device|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991450|NCT03078816|Device|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79356572|NCT03585465|Drug|Capecitabine|"Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
79356573|NCT03585465|Drug|Nivolumab|"Arm A, B or C (First stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle~Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle"
79356574|NCT03523351|Radiation|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
79356575|NCT03523351|Drug|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
79356576|NCT03523312|Radiation|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
79356577|NCT03523312|Drug|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
79668829|NCT04714307|Diagnostic Test|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
79668830|NCT04714307|Diagnostic Test|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
79668831|NCT04714307|Diagnostic Test|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
79668832|NCT04714307|Diagnostic Test|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
79668833|NCT00457548|Behavioral|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
79668834|NCT00351572|Procedure|Cell Search Assay|
79356578|NCT03513614|Procedure|Tailored axillary surgery - both Arms|Axillary lymph node dissection - Arm A
79507555|NCT04747704|Behavioral|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
79507556|NCT05622552|Device|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
79668835|NCT00450684|Device|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
79668836|NCT00450684|Device|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
79668837|NCT00351689|Behavioral|dietary supplement|
79668838|NCT04714268|Procedure|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
79668839|NCT00457782|Drug|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
79668840|NCT00351182|Drug|Telithromycin|
79668841|NCT00351182|Drug|Doxycycline|
79668842|NCT00457860|Drug|Immunotoxin therapy|
79668843|NCT00457860|Drug|CAT-8015 immunotoxin|
79668844|NCT00457860|Procedure|Biological therapy|
79668845|NCT00351806|Drug|Erigeron breviscapus injection|
79668846|NCT00351806|Drug|hua tuo zai zao wan (a herbal medicine pill)|
79668847|NCT00351806|Drug|Compound stroke herbal medicine (8 herbal)|
79668848|NCT00457899|Drug|Quetiapine IR (Immediate Release)|oral
79668849|NCT00457938|Other|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
79668850|NCT00457938|Other|Diet|10 % versus 35 % fat in diet
79668851|NCT00351845|Behavioral|Low carbohydrate diet (behavior)|
79668852|NCT00458016|Drug|MB07803|Daily oral administration
79668853|NCT00458016|Drug|Placebo|Daily oral administration
79668854|NCT00351884|Drug|Vildagliptin AM|
79668855|NCT00351884|Drug|vildagliptin pm|
79668856|NCT00351884|Drug|placebo|
79668857|NCT00458055|Drug|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
79668858|NCT00351923|Biological|MeMuRu-OKA (study vaccine)|
79356579|NCT03513614|Radiation|Radiotherapy - Arm A|Regional nodal irradiation excluding the dissected axilla - Arm A
79356580|NCT03513614|Radiation|Radiotherapy - Arm B|Regional nodal irradiation including the full axilla - Arm B
79356581|NCT03507725|Behavioral|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
79356582|NCT03507725|Procedure|Prostate Biopsy|Prostate needle biopsy under local anesthesia
79668859|NCT00450762|Drug|gemcitabine|
79668860|NCT00450762|Drug|carboplatin|
79668861|NCT00351962|Procedure|Fractionated Stereotactic Radiotherapy|
79668862|NCT03275883|Procedure|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
79668863|NCT04698798|Procedure|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
79668864|NCT00352157|Behavioral|Revival Soy Dietary Supplement|
79668865|NCT00450840|Drug|Simvastatin|
79356583|NCT03507725|Behavioral|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
79356584|NCT03503331|Drug|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with [C-11]PiB-PET/MRI. [C-11]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
79356585|NCT03483961|Biological|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
79507557|NCT05622552|Device|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
79507558|NCT03572790|Drug|Prucalopride|1mg prucalopride capsule, once daily for seven days
79507559|NCT03572790|Other|Placebo|Lactose placebo capsule, once daily for seven days
79507560|NCT05622474|Drug|Induction chemotherapy plus Concurrent chemotherapy|"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."
79507561|NCT05622474|Drug|Concurrent chemotherapy|Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
79507562|NCT05622474|Radiation|IMRT|Radical radiation: Intensity-modulated radiotherapy
79507563|NCT03428802|Other|Laboratory Biomarker Analysis|Correlative studies
79991451|NCT03078816|Device|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79356586|NCT03483961|Biological|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
79356587|NCT03483961|Biological|Placebo|Placebo is vaccine diluent alone
79356588|NCT03481296|Behavioral|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
79356589|NCT03481296|Behavioral|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
79356590|NCT03477513|Radiation|Radation Therapy|Personalized Radiation Therapy
79356591|NCT03459807|Drug|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
79356592|NCT03459807|Procedure|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
79356593|NCT03449238|Drug|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
79356594|NCT03441477|Device|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
79507564|NCT03428802|Biological|Pembrolizumab|Given IV
79507565|NCT03379194|Behavioral|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
79507566|NCT02319486|Drug|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
79991452|NCT03078816|Device|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991453|NCT03078816|Device|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991454|NCT03078816|Device|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
79991455|NCT02039128|Dietary Supplement|Krill oil or Fish oil|
79356595|NCT03441477|Device|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
79991456|NCT02039128|Dietary Supplement|Placebo|
79507567|NCT02319486|Drug|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
79507568|NCT03271554|Drug|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
79507569|NCT03093636|Device|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
79356596|NCT03441477|Device|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
79356597|NCT03439293|Drug|Ixazomib|Ixazomib capsule.
79356598|NCT03439293|Drug|Daratumumab|Daratumumab IV infusion.
79356599|NCT03439293|Drug|Dexamethasone|Dexamethasone tablets.
79356600|NCT03433742|Other|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
79356601|NCT03423979|Device|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
79356602|NCT03423979|Drug|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
79356603|NCT03420430|Biological|GL-ONC1|
79356604|NCT03298178|Procedure|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
79356605|NCT03298178|Procedure|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
79356606|NCT03239210|Drug|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
79356607|NCT03239210|Drug|Placebo|placebo equivalent
79356608|NCT03227224|Drug|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
79356609|NCT03227224|Drug|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
79356610|NCT03196466|Biological|Valproic acid|titration
79356611|NCT03196466|Biological|carbamazepine|titration
79356612|NCT03196466|Biological|phenobarbital|titration
79356613|NCT03196466|Biological|phenytoin|titration
79356614|NCT03196466|Biological|levetiracetam|titration
79356615|NCT03196466|Biological|lamotrigine|titration
79356616|NCT03196466|Biological|topiramate|titration
79356617|NCT03196466|Biological|oxcarbazepine|titration
79356618|NCT03196466|Biological|stiripentol|titration
79356619|NCT03196466|Biological|clobazam|titration
79356620|NCT03196466|Biological|brivaracétam|titration
79356621|NCT03196466|Biological|felbamate|titration
79356622|NCT03196466|Biological|lacosamide|titration
79356623|NCT03196466|Biological|rufinamide|titration
79356624|NCT03196466|Biological|gabapentine|titration
79356625|NCT03196466|Biological|pregabaline|titration
79356626|NCT03196466|Biological|sultiame|titration
79356627|NCT03196466|Biological|tiagabine|titration
79356628|NCT03196466|Biological|vigabatrine|titration
79356629|NCT03196466|Biological|mesuximide|titration
79356630|NCT03196466|Biological|primidone|titration
79356631|NCT03196466|Biological|perampanel|titration
79356632|NCT03196466|Biological|ethosuximide|titration
79507570|NCT03093636|Other|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
79507571|NCT05622162|Drug|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
79356633|NCT03196466|Biological|zonisamide|titration
79356634|NCT03196466|Biological|cannabidiol|titration
79356635|NCT03196466|Other|genetic polymorphisms|genetic polymorphisms
79356636|NCT03184870|Drug|BMS-813160|Specified dose on specified days
79356637|NCT03184870|Biological|Nivolumab|Specified dose on specified days
79356638|NCT03184870|Drug|Nab-paclitaxel|Specified dose on specified days
79356639|NCT03184870|Drug|Gemcitabine|Specified dose on specified days
79507572|NCT05622162|Drug|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
79507573|NCT00546390|Device|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
79668866|NCT00352196|Drug|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
79668867|NCT00352196|Other|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
79356640|NCT03184870|Drug|5-fluorouracil (5-FU)|Specified dose on specified days
79356641|NCT03184870|Drug|Leucovorin|Specified dose on specified days
79507574|NCT00860652|Radiation|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
79507575|NCT00860652|Radiation|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
79507576|NCT04039074|Behavioral|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
79507577|NCT04039074|Behavioral|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
79668868|NCT00450879|Drug|Pazopanib Hydrochloride|Given PO
79668869|NCT00450879|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
79356642|NCT03184870|Drug|Irinotecan|Specified dose on specified days
79356643|NCT03122522|Drug|ipilimumab|ipilimumab 3mg/kg
79356644|NCT03122522|Drug|nivolumab|nivolumab 1mg/kg
79356645|NCT03108846|Drug|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
79356646|NCT03108846|Drug|Placebo|Masked placebo
79356647|NCT03086343|Drug|Abatacept|IV infusion
79356648|NCT03086343|Drug|Placebo for abatacept|IV infusion
79356649|NCT03086343|Drug|Upadacitinib|15 mg extended release tablet
79356650|NCT03086343|Drug|Placebo for upadacitinib|Film-coated tablet
79356651|NCT03074734|Other|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
79356652|NCT02904226|Drug|JTX-2011|Specified dose on specified days
79356653|NCT02904226|Drug|Nivolumab|Specified dose on specified days
79356654|NCT02904226|Drug|Ipilimumab|Specified dose on specified days
79356655|NCT02904226|Drug|Pembrolizumab|Specified dose on specified days
79356656|NCT02862431|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
79668870|NCT00450879|Other|Pharmacological Study|Correlative studies
79668871|NCT00450879|Other|Laboratory Biomarker Analysis|Correlative studies
79668872|NCT00352235|Drug|KRN7000|
79668873|NCT00352313|Drug|ATN-161|Given IV
79668874|NCT00352313|Drug|carboplatin|Given IV
79668875|NCT00352352|Procedure|Tongue Acupuncture (Procedure)|
79668876|NCT00450957|Dietary Supplement|lycopene|Given orally
79668877|NCT00450957|Other|pharmacological study|Correlative studies
79356657|NCT02862431|Drug|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
79356658|NCT02788045|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
79356659|NCT02788045|Biological|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5mL injection administered intramuscularly.
79356660|NCT02788045|Biological|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
79356661|NCT02788045|Drug|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
79356662|NCT02775695|Drug|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
79356663|NCT02679040|Procedure|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
79356664|NCT02679040|Drug|Chemotherapy|Chemotherapy treatment
79507578|NCT04039074|Behavioral|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
79507579|NCT05622084|Device|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
79668878|NCT00352391|Other|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
79668879|NCT03275844|Procedure|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
79668880|NCT00352430|Drug|Nitric Oxide/INP Pulse Delivery|
79356665|NCT02679040|Radiation|Radiation therapy|Radiation therapy
79507580|NCT00556842|Device|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
79507581|NCT00556842|Device|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
79668881|NCT00352430|Drug|Nitric Oxide/INO Pulse Delivery|
79668882|NCT00450996|Drug|Topical Steroids|
79356666|NCT02643498|Radiation|Stereotactic Body Radiotherapy (SBRT)|
79356667|NCT02610075|Drug|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
79356668|NCT02599454|Drug|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
79356669|NCT02599454|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
79356670|NCT02559856|Drug|Apixaban|
79356671|NCT02559856|Drug|Rivaroxaban|
79356672|NCT02505919|Device|AQUABEAM System|The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
79356673|NCT02505919|Procedure|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
79356674|NCT02482311|Drug|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
79668883|NCT00352469|Drug|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
79668884|NCT00451074|Drug|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
79668885|NCT00352508|Behavioral|Dietary advice|
79668886|NCT00465621|Drug|Xalatan|
79668887|NCT00465660|Behavioral|Progressive resistance training|
79668888|NCT00465699|Drug|Topical B12 0.07%|
79668889|NCT00352625|Drug|Ketoprofen Topical Patch 20%|
79668890|NCT00465777|Behavioral|Guideline adherence and financial incentive|
79356675|NCT02344680|Drug|Anti-HIV Agents|
79356676|NCT02338609|Drug|Everolimus|Blood sample and Tanner Stage assessment
79356677|NCT02338609|Drug|Envirolimus drug class as prescribed by Physician|At the discretion of the investigator, patients may be treated with commercially available everolimus, as per local product information/ standard of care.
79356678|NCT02315703|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
79356679|NCT02315703|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
79356680|NCT02315703|Biological|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
79356681|NCT02315703|Biological|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
79356682|NCT02315703|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
79356683|NCT02188108|Other|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
79356684|NCT02132858|Other|cytology specimen collection procedure|Correlative studies
79356685|NCT02132858|Other|laboratory biomarker analysis|Correlative studies
79356686|NCT02049359|Other|Texting|Bidirectional texting once weekly for 12 weeks
79356687|NCT01839695|Device|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
79507582|NCT00558012|Drug|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
79507583|NCT00558012|Dietary Supplement|Vitamin D 800 IU/daily|Daily divided dose
79668891|NCT00352703|Drug|Kepivance (Palifermin)|
79991457|NCT03723941|Drug|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
79679672|NCT02949245|Procedure|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
79679673|NCT02939547|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
79991458|NCT03723941|Other|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
79356688|NCT01836783|Other|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
79356689|NCT01836783|Other|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
79356690|NCT01698905|Drug|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
79507584|NCT00558012|Dietary Supplement|Calcium 1200 mg/daily|supplement plus diet
79507585|NCT00558246|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
79507586|NCT00558246|Device|Suture|Topical Suturing
79507587|NCT00558792|Drug|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
79507588|NCT00558792|Drug|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
79507589|NCT00558792|Drug|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
79991459|NCT03153046|Dietary Supplement|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
79356691|NCT01608074|Procedure|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
79356692|NCT01608074|Other|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
79356693|NCT01466686|Radiation|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
79356694|NCT01466686|Drug|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
79356695|NCT01093196|Drug|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period [different doses according to the age of patients (65-75 or >75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
79356696|NCT01093196|Drug|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period [day 21 to 28]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
79507590|NCT03884634|Device|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
79507591|NCT00561600|Device|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
79507592|NCT00561600|Device|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
79507593|NCT00561834|Drug|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
79668892|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
79991460|NCT03153046|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
79507594|NCT04388202|Drug|Sertraline|FDA approved antidepressant
79507595|NCT04388202|Drug|Escitalopram|FDA approved antidepressant
79507596|NCT02128074|Drug|KRX-0502|1g tablets of KRX-0502
79507597|NCT02128230|Device|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
79356697|NCT01093196|Drug|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
79356698|NCT01091831|Drug|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
79818574|NCT06138730|Behavioral|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
79818575|NCT06134336|Other|Interview|No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.
79356699|NCT01091831|Drug|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
79991461|NCT03155698|Combination Product|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
79991462|NCT03155698|Radiation|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
79356700|NCT01091831|Drug|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
79356701|NCT01091831|Drug|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
79356702|NCT00481546|Genetic|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
79507598|NCT02128230|Drug|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, & 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
79668893|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
79991463|NCT03723863|Behavioral|Occupational Therapy|Receive in-person occupational therapist-led work consultation
79668894|NCT00352742|Drug|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
79668895|NCT00465933|Drug|AIDA|
79991464|NCT03155308|Device|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
79991465|NCT03721679|Biological|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
79668896|NCT00352820|Behavioral|Interview|Recorded face-to-face session.
79356703|NCT00093834|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
79356704|NCT00093834|Drug|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
79356705|NCT00093834|Drug|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
79507599|NCT02128230|Drug|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 & -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 & -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
79818576|NCT06132659|Other|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
79668897|NCT00352820|Behavioral|Questionnaire|Written survey lasting approximately 30 minutes.
79668898|NCT00352859|Drug|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
79356706|NCT01550289|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
79356707|NCT01550289|Biological|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
79356708|NCT04277026|Behavioral|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
79668899|NCT00352859|Drug|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
79668900|NCT00352898|Biological|MeMuRu-OKA (study vac)|
79668901|NCT00352898|Biological|MMR, Varicella vacc (control)|
79668902|NCT00105183|Biological|Placebo|placebo infusion, single
79668903|NCT00105183|Biological|EZ-2053|single IV infusion, 9 mg/kg
79668904|NCT00105183|Biological|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
79668905|NCT00466089|Drug|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
79668906|NCT04714346|Other|no interventions|there is no intervention
79356709|NCT04108143|Device|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
79507600|NCT02128230|Drug|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
79507601|NCT02128230|Drug|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 & -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 & -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
79507602|NCT02128230|Drug|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
79507603|NCT02128230|Drug|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, & 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, & 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
79507604|NCT03416244|Drug|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
79507605|NCT03416244|Drug|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
79507606|NCT05560776|Procedure|Endobronchial ultrasound|Two or three passes per lymph node
79507607|NCT05560620|Behavioral|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
79507608|NCT05560620|Other|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
79507609|NCT05560620|Other|No Caffeine|De-caffeinated coffee
79507610|NCT04388124|Drug|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
79507611|NCT04388124|Drug|Placebo|Placebo
79507612|NCT05560152|Drug|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
79507613|NCT02130258|Device|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
79507614|NCT02130258|Procedure|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
79507615|NCT03172416|Drug|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
79668907|NCT00466128|Drug|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
79668908|NCT00466245|Drug|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
79668909|NCT00466245|Drug|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
79668910|NCT00353015|Drug|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
79668911|NCT00353015|Drug|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
79668912|NCT00466284|Drug|Tarceva (erlotinib)|
79668913|NCT00353054|Drug|Caltrate® 600 + D|
79668914|NCT00353054|Behavioral|Weight loss intervention|
79668915|NCT00466362|Behavioral|The Evje Model|
79668916|NCT00353093|Procedure|Ultrasonography of the deep vein system of the legs|
79668917|NCT00466401|Drug|Simvastatin|
79668918|NCT00466401|Drug|Ezetimibe|
79668919|NCT00353249|Behavioral|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
79668920|NCT00466479|Drug|brimonidine|
79668921|NCT00466479|Procedure|laser trabeculoplasty|
79668922|NCT03272256|Drug|IM156|Sequential 3+3 design.
79668923|NCT00353288|Biological|MeMuRu-OKA (study vacc)|
79668924|NCT00353288|Biological|MMR, Varicella vacc (control)|
79668925|NCT03272100|Procedure|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
79668926|NCT00353327|Procedure|Plasma infusion|
79356710|NCT04107519|Behavioral|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
79356711|NCT01968031|Drug|Istradefylline 40 mg|Istradefylline 40 mg and placebo
79356712|NCT01968031|Drug|Istradefylline 20 mg|Istradefylline 20 mg and placebo
79356713|NCT01968031|Drug|Placebo|Placebo
79356714|NCT01684215|Drug|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
79356715|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
79356716|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
79356717|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
79356718|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
79356719|NCT01908205|Drug|Intranasal Oxytocin|
79356720|NCT01908205|Drug|Placebo|
79356721|NCT01549041|Drug|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
79356722|NCT01549041|Drug|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
79668927|NCT00353405|Behavioral|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
79668928|NCT00353405|Behavioral|Mass media|Mass media provides messages that support sexual health skills.
79668929|NCT00353405|Behavioral|Control|Control group received no social skills training and no media mass media messages.
79668930|NCT00466518|Drug|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
79991466|NCT04674228|Other|Electronic Health Record Review|Review of medical records
79991467|NCT03639948|Drug|Carboplatin|Intravenous solution
79991468|NCT03639948|Drug|Docetaxel|Intravenous solution
79991469|NCT03639948|Drug|Pembrolizumab|Intravenous solution
79991470|NCT03639948|Drug|Pegfilgrastim|Injectable product
79668931|NCT00458094|Behavioral|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
79668932|NCT00458094|Behavioral|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
79818577|NCT06132659|Other|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
79818578|NCT06132581|Device|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
79818579|NCT06132581|Device|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
79356723|NCT01907815|Drug|Akt Inhibitor GSK2141795|Given PO
79356724|NCT01907815|Other|Laboratory Biomarker Analysis|Correlative studies
79356725|NCT01907815|Drug|Trametinib|Given PO
79507616|NCT03172416|Drug|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
79507617|NCT03033420|Device|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
79356726|NCT01548573|Drug|Dexamethasone|Given PO
79356727|NCT01548573|Procedure|Tandem autologous stem cell transplant|
79356728|NCT01548573|Drug|Cisplatin|Given IV
79356729|NCT01548573|Drug|Doxorubicin|Given IV
79356730|NCT01548573|Drug|Cyclophosphamide|Given IV or PO
79356731|NCT01548573|Drug|Etoposide|Given IV
79356732|NCT01548573|Drug|Bortezomib|Given IV
79356733|NCT01548573|Drug|Thalidomide|Given PO
79356734|NCT01548573|Drug|Melphalan|Given IV
79356735|NCT01907737|Other|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
79356736|NCT01907737|Other|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
79507618|NCT01798212|Procedure|endoscopic full thickness plication|
79356737|NCT01907737|Other|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
79507619|NCT05560074|Device|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
79507620|NCT05560074|Other|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
79507621|NCT05559996|Device|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
79356738|NCT01907737|Other|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
79356739|NCT01570491|Other|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
79668933|NCT04714580|Other|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
79668934|NCT00353561|Drug|Boric|Gelatin capsules filled with 600 mg of boric acid
79668935|NCT00353561|Drug|Fluconazole|150 mg oral fluconazole gives once in 14 days
79507622|NCT05559840|Device|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
79507623|NCT05559840|Device|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
79507624|NCT02812212|Device|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
79991471|NCT03146728|Other|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
79991472|NCT02347852|Drug|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
79356740|NCT01570491|Other|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
79356741|NCT04118517|Other|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing >50% of the protein.
79356742|NCT04117425|Biological|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
79507625|NCT02812212|Device|diuretic renography|diuretic renography to measure the cortical transit time.
79507626|NCT02601378|Drug|LXS196|LXS196 as a single agent
79507627|NCT02601378|Drug|LXS196 and HDM201|LXS196 in combination with HDM201
79668936|NCT00466596|Drug|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
79668937|NCT00458172|Behavioral|Assessment of beliefs and attitudes|
79668938|NCT00466635|Drug|GT267-004 (tolevamer potassium sodium)|
79668939|NCT00353678|Drug|YM150|
79668940|NCT00458250|Procedure|Haploidentical hematopoietic stem cell transplantation|
79668941|NCT00458250|Drug|Busulfan|
79668942|NCT00458250|Drug|Cyclophosphamide|
79668943|NCT00458250|Drug|CAMPATH-1H|
79991473|NCT02347696|Behavioral|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
79991474|NCT02347696|Behavioral|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
79991475|NCT02347696|Behavioral|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1."
79991476|NCT02347696|Behavioral|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~Progression: increase of 1-2.5 kg*week-1~Training of all muscle groups in the same session"
79991477|NCT02347696|Behavioral|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
79668944|NCT00458250|Drug|Cyclosporin A|
79668945|NCT00458250|Drug|Methotrexate|
79668946|NCT02959736|Behavioral|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
79668947|NCT00466674|Drug|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
79668948|NCT00353717|Drug|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
79668949|NCT00466713|Drug|Rosiglitazone therapy|
79668950|NCT00353756|Drug|C326, IL-6 Inhibitory Avimer protein|
79668951|NCT00466791|Drug|Methylphenidate Transdermal System|Placebo
79668952|NCT00353912|Drug|valsartan + amlodipine|
79668953|NCT00458289|Drug|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
79668954|NCT00466830|Other|questionnaire administration|
79668955|NCT00466830|Procedure|management of therapy complications|
79507628|NCT02434848|Drug|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
79507629|NCT02434848|Drug|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
79507630|NCT05559450|Drug|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
79507631|NCT05559450|Other|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
79507632|NCT01669200|Other|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
79507633|NCT01669200|Other|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
79507634|NCT05559294|Behavioral|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
79507635|NCT05559294|Behavioral|Education and care as Usual (ECAU)|Active control
79507636|NCT05559138|Other|no intervention|no intervention
79507637|NCT00564954|Drug|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
79668956|NCT00466830|Procedure|psychosocial assessment and care|
79668957|NCT00466830|Procedure|quality-of-life assessment|
79668958|NCT00353990|Drug|Insulin Aspart|
79507638|NCT00564954|Drug|Placebo|orally once a day for 7 days
79668959|NCT00458328|Drug|Z-338|
79818580|NCT06132581|Device|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
79991478|NCT02347696|Behavioral|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
79991479|NCT04879914|Dietary Supplement|Butyrate|3 cps/die 300 mg/cps
79991480|NCT04879914|Dietary Supplement|Placebo|3 cps/die 300 mg/cps
79991481|NCT02353234|Other|Bread|In each arm subjects consume bread
79991482|NCT01569360|Device|Corset|the patients are assigned the use of a custome made corset during daytime
79356743|NCT01929109|Drug|LY2409021|Administered orally
79356744|NCT01518153|Drug|Fludarabine|40 mg/m^2 by vein on Day -6 to -3.
79356745|NCT01518153|Drug|Melphalan|140 mg/m^2 by vein on Day -2.
79356746|NCT01518153|Drug|Alemtuzumab|50 mg by vein on Day -1.
79668960|NCT00354068|Drug|imatinib mesylate|
79991483|NCT03510455|Drug|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
79356747|NCT01518153|Procedure|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
79507639|NCT00565110|Behavioral|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
79507640|NCT00565266|Drug|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
79507641|NCT00565266|Drug|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
79668961|NCT00354068|Drug|temozolomide|
79668962|NCT00354068|Other|pharmacological study|
79668963|NCT00466869|Drug|Betahistine|
79668964|NCT00354146|Drug|tipifarnib (R115777)|
79668965|NCT00458367|Drug|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
79668966|NCT00466908|Device|Pentacam and IOL Master|Pentacam and IOL Master
79668967|NCT00354185|Drug|tanespimycin|Given IV
79668968|NCT00354185|Drug|belinostat|Given IV
79668969|NCT00354185|Other|laboratory biomarker analysis|Correlative studies
79668970|NCT00354185|Other|pharmacological study|Correlative studies
79668971|NCT00458445|Drug|SPD465|
79668972|NCT00458445|Other|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
79991484|NCT02353156|Other|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
79356748|NCT01518153|Drug|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
79356749|NCT01518153|Drug|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
79507642|NCT00565266|Drug|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
79507643|NCT05609526|Other|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
79991485|NCT02353156|Other|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
79507644|NCT05609526|Other|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
79356750|NCT01518153|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
79356751|NCT01518153|Procedure|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64.
79356752|NCT01518153|Procedure|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64.
79356753|NCT01906489|Drug|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79356754|NCT01906489|Drug|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79356755|NCT04620343|Procedure|A: Breathing advice with bio-feedback|Information and breathing advice with biofeedback will serve as an active comparator in this study, and time allowed for IBA and biofeedback in this study will be max 30 min. The teaching will be provided by the attending physician and the test leader. The session will follow a strict checklist. After the laryngoscope has been secured in correct position the patient will be shown his/her larynx on the screen, providing the patient with basic knowledge on laryngeal anatomy and function in a calm atmosphere before the CLE-test. After, the patients will be trained to make any symptoms abate, and a good breathing posture and how to optimally use their breathing muscles.
79356756|NCT04620343|Procedure|B: Breathing advice with bio-feedback, Inspiratory muscle training (IMT)|Breathing advise and IMT. The inspiratory muscle training (IMT) will build on the information the patients have obtained during the IBA and biofeedback session. The IMT will focus on training endurance and coordination of the PCA muscle, aiming to reduce fatigue of the abducting capacity of the larynx and to enhance coordination and create a sense of laryngeal control. When performing the IMT sessions, it is of utmost importance that a functional diaphragmatic breathing pattern has been established, and that this breathing pattern is maintained throughout all the IMT sessions. Once the patient has demonstrated that he/she is able to perform breathing according to these principles, the IMT session will follow a detailed protocol while wearing a flexible laryngoscope and settings and techniques are adjusted to ensure max open larynx. The patient will perform IMT training at home as instructed and have video meetings one and three weeks after initial training to observe progress.
79507645|NCT05609526|Other|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
79507646|NCT02124018|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
79507647|NCT02124018|Device|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
79507648|NCT04346316|Drug|SHR0302|Oral tablets taken once daily (QD)
79507649|NCT00567840|Drug|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
79507650|NCT00568386|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
79507651|NCT00568386|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
79507652|NCT01798290|Behavioral|narrative medicine: reading workshop|
79507653|NCT01798290|Behavioral|critical reading|
79507654|NCT03830970|Dietary Supplement|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
79507655|NCT03830970|Dietary Supplement|White Rice|Minute Rice Long Grain White Rice
79507656|NCT01797978|Drug|Intravenous methylene blue administration|Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
79507657|NCT01797978|Drug|Placebo|
79507658|NCT05363202|Drug|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
79507659|NCT05363202|Drug|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
79507660|NCT05363202|Drug|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
79507661|NCT05439174|Other|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
79668973|NCT00354263|Biological|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
79356757|NCT04620343|Procedure|C: Breathing advice with bio-feedback, Speech Therapy|The training period with the speech therapist takes three days, divided into 6 sessions. The training is continued at home, implementing the techniques during physical activity and at rest. The aim of the speech therapy is to help the patients to develop a strategy on how to control his/her larynx during exercise, and to be able to continue exercising without experiencing dramatic EILO incidents. They will be informed that the best approach is to start practicing while performing low to moderate intensity exercise, and then gradually increase the intensity as they become more confident. It will be emphasized that the new breathing technique they are about to adopt will need to be repeated until it becomes adapted as a part of their automated breathing pattern. Patients will be followed up with video meetings one and three weeks after initial training to observe progress.
79356758|NCT04620343|Procedure|D: Breathing advice with bio-feedback, IMT and Speech Therapy|All treatments as described above.
79356759|NCT04620343|Procedure|A: If CLE-test unchanged, additional IMT and Speech Therapy|All treatments as described above.
79356760|NCT04620343|Procedure|Surgery 1: Supraglottoplasty - full procedure under general anesthesia|Endoscopic supraglottoplasty with carbon dioxide laser and cold steel microlaryngeal instruments. The patient is intubated with an armored laser-tube which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot is utilized. Releasing incisions are made at the anterior border of both AEFs. The depth of the incisions are limited to the cranial border of the ventricular folds. The cuneiform tubercles including their surrounding mucosa are removed in a circular pattern before the two incisions are adjoined, thus creating a drop shaped excision. Care is taken to avoid scarring. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. In case of perioperative edema of the laryngeal mucosa, corticosteroids are administrated to prevent laryngeal edema post-operatively.
79356761|NCT04620343|Procedure|Surgery 2: Supraglottoplasty - mini-invasive procedure under general anesthesia|"Endoscopic supraglottoplasty with carbon dioxide laser. The patients are intubated with an armored laser-tube, which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope (Benjamin/Lindholm) is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot are utilized. Four punctures will be made along the lateral borders of both aryepiglottic folds bilateral, thus creating a row of small punctures parallel to the rim of the aryepiglottic folds. The punctions should not be deeper than the incision in the full procedure (above); i.e. less than 5 millimeter, and care must be taken to avoid heat affecting the nervus recurrens posteriorly. Care is taken to avoid scarring and collateral thermal injury. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. No antibiotic prophylaxis is administered."
79668974|NCT00354263|Biological|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
79668975|NCT00466986|Drug|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
79668976|NCT00354302|Dietary Supplement|calcium carbonate|
79668977|NCT00354302|Dietary Supplement|calcium citrate|
79668978|NCT00354302|Dietary Supplement|cholecalciferol|
79668979|NCT00354302|Drug|alendronate sodium|
79668980|NCT00354302|Drug|calcium gluconate|
79668981|NCT00354302|Drug|risedronate sodium|
79668982|NCT00354302|Other|laboratory biomarker analysis|
79668983|NCT00354302|Procedure|dual x-ray absorptometry|
79507662|NCT05394012|Biological|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
79507663|NCT05394012|Biological|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
79507664|NCT02129478|Drug|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
79356762|NCT01517373|Drug|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
79668984|NCT04714229|Biological|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
79356763|NCT01517373|Drug|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
79668985|NCT04714229|Biological|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
79356764|NCT01517373|Drug|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
79356765|NCT01517373|Drug|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
79356766|NCT01517373|Drug|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
79507665|NCT02129556|Drug|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
79507666|NCT05362500|Drug|Glycolic Acid 70%|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing
79507667|NCT05362500|Drug|Tranexamic acid injection|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
79507668|NCT05161806|Drug|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
79507669|NCT05161806|Device|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
79668986|NCT00458523|Biological|alemtuzumab|
79668987|NCT00458523|Genetic|fluorescence in situ hybridization|
79668988|NCT00458523|Genetic|mutation analysis|
79356767|NCT01517295|Drug|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
79356768|NCT01541865|Device|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
79356769|NCT01541397|Drug|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
79356770|NCT04104321|Drug|Aramchol|Aramchol 300 mg BID
79356771|NCT04104321|Drug|Placebo|Placebo BID
79668989|NCT00458523|Other|flow cytometry|
79668990|NCT00467064|Behavioral|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
79668991|NCT00467064|Other|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
79668992|NCT00354380|Drug|Methylene blue|
79668993|NCT00354380|Drug|Artesunate|
79668994|NCT00354380|Drug|Amodiaquine|
79356772|NCT04104165|Device|Foley Catheter|Foley catheter used for treatment of urinary retention
79356773|NCT04103775|Behavioral|Cognitive Remediation|See Cognitive Remediation Arm description.
79356774|NCT04103775|Behavioral|Active Control|See Active Control Arm description.
79356775|NCT01548417|Drug|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
79356776|NCT01548417|Drug|Sugar Pill|600 mg/day, oral pill, 7 days
79356777|NCT01546857|Drug|Placebo|Normal Saline
79356778|NCT01546857|Drug|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
79356779|NCT04767867|Other|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
79507670|NCT05362188|Drug|Nicotinamide Topical|"Patients with discoid lupus erythematosus (face & scalp) will be given topical nicotinamide in two concentrations (2&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream & gel)."
79507671|NCT01798368|Device|PBASE system 2.0|
79507672|NCT05353374|Drug|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
79507673|NCT05353374|Drug|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
79507674|NCT05292300|Dietary Supplement|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
79507675|NCT05292300|Behavioral|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
79668995|NCT00354419|Radiation|total-body irradiation|Undergo radiotherapy
79668996|NCT00354419|Drug|cyclophosphamide|Given IV
79668997|NCT00354419|Biological|anti-thymocyte globulin|Given IV
79668998|NCT00354419|Drug|cyclosporine|Given IV
79668999|NCT00354419|Procedure|umbilical cord blood transplantation|Undergo transplantation
79669000|NCT00354419|Drug|mycophenolate mofetil|Given IV or orally
79669001|NCT00354419|Procedure|bone marrow aspiration|Correlative study
79669002|NCT00354419|Genetic|DNA analysis|Correlative study
79669003|NCT00354419|Biological|filgrastim|Given IV or SC
79356780|NCT01540851|Behavioral|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
79356781|NCT01540851|Other|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
79356782|NCT01516749|Drug|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
79356783|NCT01516437|Procedure|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
79356784|NCT01516437|Procedure|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
79356785|NCT01516437|Procedure|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
79356786|NCT01515423|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
79356787|NCT01515423|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
79507676|NCT05214222|Drug|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~Anlotinib: once a day, 1 capsule each time (10mg for body weight <60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
79507677|NCT05214222|Drug|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
79507678|NCT05195268|Procedure|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
79507679|NCT05108064|Diagnostic Test|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
79507680|NCT05198232|Behavioral|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
79669004|NCT00458679|Biological|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10^7) of IL-2 secreting B-cells together with (2 x 10^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
79356788|NCT01515423|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
79356789|NCT01515423|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
79356790|NCT01515423|Drug|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
79669005|NCT00354458|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
79669006|NCT00354458|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
79356791|NCT01515423|Drug|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
79507681|NCT05198232|Behavioral|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
79669007|NCT00458718|Drug|rimonabant (SR141716)|
79669008|NCT00354497|Other|physiologic testing|
79669009|NCT00354497|Other|study of socioeconomic and demographic variables|
79669010|NCT00354497|Procedure|evaluation of cancer risk factors|
79669011|NCT00354497|Procedure|mutation carrier screening|
79356792|NCT01515423|Drug|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
79356793|NCT01515423|Drug|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
79356794|NCT01515423|Drug|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
79507682|NCT05175690|Diagnostic Test|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
79507683|NCT05048550|Device|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
79356795|NCT00637156|Device|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
79507684|NCT04932018|Behavioral|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
79356796|NCT00637156|Device|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
79356797|NCT00637000|Drug|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
79356798|NCT00637000|Drug|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
79356799|NCT00637000|Drug|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
79507685|NCT04932018|Behavioral|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
79669012|NCT00354497|Procedure|study of high risk factors|
79669013|NCT00467181|Drug|Fenoldopam|
79669014|NCT00354536|Drug|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
79669015|NCT00354536|Biological|placebo injection|placebo injection
79669016|NCT00467220|Behavioral|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
79669017|NCT00425711|Drug|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
79669018|NCT00467337|Procedure|Medial-Wedge Insole intervention|
79356800|NCT01515189|Biological|Ipilimumab|
79356801|NCT04767399|Behavioral|protaper next|rotary systems used on patients need root canal treatment
79356802|NCT01546623|Drug|TAP-144-SR(6M)|
79356803|NCT01546623|Drug|TAP-144-SR(3M)|
79356804|NCT01546155|Radiation|PET imaging|Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer
79669019|NCT00425789|Procedure|Treatment with Hyperbaric oxygen|
79669020|NCT00425867|Behavioral|PAR1 polymoprhisms and placental invasion|
79507686|NCT02829528|Behavioral|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
79507687|NCT04747236|Drug|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
79507688|NCT04747236|Drug|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
79507689|NCT04747236|Drug|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
79507690|NCT04747236|Drug|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
79507691|NCT04747236|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
79356805|NCT00636610|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
79507692|NCT04742946|Other|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
79356806|NCT00636610|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
79356807|NCT00636610|Drug|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
79356808|NCT00636610|Drug|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
79507693|NCT01797666|Drug|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
79507694|NCT05017194|Drug|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
79507695|NCT04993248|Other|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
79507696|NCT04850820|Dietary Supplement|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
79507697|NCT04850820|Dietary Supplement|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
79507698|NCT04850820|Dietary Supplement|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
79507699|NCT04778748|Diagnostic Test|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
79507700|NCT04520100|Behavioral|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
79507701|NCT04520100|Behavioral|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
79507702|NCT04501380|Drug|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
79507703|NCT04465734|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
79507704|NCT04465734|Drug|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
79669021|NCT03274011|Drug|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
79669022|NCT00425906|Drug|nicotine|
79669023|NCT00425906|Other|Placebo|
79669024|NCT00425906|Procedure|Quality of life|
79507705|NCT04465734|Drug|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
79507706|NCT04388358|Drug|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
79507707|NCT04417296|Diagnostic Test|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
79356809|NCT00636610|Drug|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then fluorouracil 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
79669025|NCT00425984|Procedure|Adult male circumcision|
79669026|NCT00467376|Drug|Insulin Glulisine|3 times a day before each meal
79356810|NCT01923220|Drug|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
79356811|NCT01923220|Other|Aloe Vera Jel|To be applied topically once daily
79669027|NCT00467376|Drug|Lispro|3 times a day before each meal
79669028|NCT00467376|Drug|Insulin Glargine|once daily
79669029|NCT00426023|Drug|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
79669030|NCT00426023|Drug|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
79669031|NCT00467415|Behavioral|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
79669032|NCT00467415|Behavioral|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
79669033|NCT00467454|Drug|Naltrexone|daily
79991486|NCT03630432|Behavioral|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
79669034|NCT00467454|Drug|Placebo|daily
79669035|NCT00426101|Drug|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
79669036|NCT00426101|Drug|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
79669037|NCT00426101|Drug|Cyclosporin|"WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR."
79356812|NCT00635050|Drug|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
79356813|NCT05240404|Drug|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
79356814|NCT05240404|Procedure|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
79356815|NCT01923376|Drug|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
79356816|NCT01923376|Drug|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
79991487|NCT03630432|Other|Usual Care|Usual Care
79991488|NCT02353000|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
79991489|NCT02353000|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
79507708|NCT04954872|Behavioral|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
79507709|NCT04954872|Behavioral|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
79507710|NCT02132520|Device|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
79507711|NCT02132520|Behavioral|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
79356817|NCT05245786|Biological|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
79507712|NCT04020198|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
79507713|NCT03885336|Other|No Interventions|There are no interventions in this study. Participants are observed.
79991490|NCT02351596|Other|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
79356818|NCT05245786|Procedure|Imaging Technique|Undergo imaging
79669038|NCT00426101|Procedure|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: <1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg. Prednisolone: <1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg."
79356819|NCT00634504|Drug|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
79356820|NCT00634504|Drug|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
79356821|NCT03101254|Drug|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
79356822|NCT03101254|Drug|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
79356823|NCT03101254|Drug|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
79356824|NCT04396054|Device|Lag Screws|Method of internal fixation
79356825|NCT04396054|Device|double Y-shaped plates|Method of internal fixation
79356826|NCT00634114|Drug|Esomeprazole|10mg once daily oral administration
79356827|NCT00634114|Drug|Esomeprazole|20mg once daily oral administration
79356828|NCT00634114|Drug|Omeprazole|10mg once daily oral administration
79356829|NCT00634036|Drug|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
79356830|NCT00634036|Drug|placebo|matching placebo (inert tablet)
79356831|NCT05241496|Diagnostic Test|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
79507714|NCT03869814|Other|Blood Draw|Blood Draw
79669039|NCT00426101|Procedure|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
79669040|NCT00426140|Drug|Patupilone|
79669041|NCT00467493|Drug|Anastrozole|
79669042|NCT00426179|Drug|Imatinib|
79356832|NCT01545375|Biological|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
79507715|NCT03856632|Drug|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
79507716|NCT03856632|Other|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
79991491|NCT02351596|Other|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
79356833|NCT01545375|Biological|Placebo|4 doses administered intramuscularly
79356834|NCT01545375|Biological|Prevnar 13®|4 doses administered intramuscularly
79356835|NCT01545375|Biological|PedvaxHIB®|4 doses administered intramuscularly
79356836|NCT04396912|Procedure|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
79507717|NCT03856632|Drug|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
79507718|NCT03856632|Procedure|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
79507719|NCT03821142|Device|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
79818581|NCT06129344|Other|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
79818582|NCT06129344|Other|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
79818583|NCT06129149|Behavioral|Trauma-Informed Care-adapted and Checklist-guided ACP intervention|The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
79818584|NCT06127979|Procedure|core needle biopsy|Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
79507720|NCT04256460|Behavioral|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
79818585|NCT06127979|Other|blood draw|blood draw
79818586|NCT06126224|Drug|KarXT|KarXT 20/2 mg (total daily dose [TDD] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)
79818587|NCT06126224|Drug|Placebo|Placebo Capsules
79818588|NCT06124924|Drug|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
79356837|NCT01539837|Drug|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
79356838|NCT01539837|Drug|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
79356839|NCT01539837|Drug|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
79356840|NCT01539759|Device|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
79356841|NCT04410081|Drug|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
79507721|NCT03725046|Other|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
79507722|NCT01798602|Drug|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
79507723|NCT01798602|Drug|Placebo|Identical placebo for rosuvastatin
79507724|NCT03722082|Behavioral|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
79818589|NCT06123286|Dietary Supplement|Tart Cherry|1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
79356842|NCT03153124|Other|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
79818590|NCT06123286|Dietary Supplement|Omega 3 FA (Fish Oil)|2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) [650 mg EPA and 450 mg DHA per capsule] daily for 12 weeks
79356843|NCT01923610|Biological|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
79356844|NCT01923766|Drug|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
79356845|NCT03831724|Device|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
79507725|NCT03722082|Behavioral|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
79507726|NCT00604890|Drug|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
79507727|NCT00604890|Drug|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
79507728|NCT00604890|Other|Placebo|Topical treatment placebo applied to the lesion
79507729|NCT03694704|Device|FineHearing strategy|Cochlear implant with FineHearing strategy
79507730|NCT02783430|Drug|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
79818591|NCT06122194|Drug|Drug: PF-07817883|PF-07817883 tablet
79818592|NCT06120283|Drug|BGB-43395|Planned doses administered orally.
79818593|NCT06120283|Drug|Fulvestrant|Standard dose administered via intramuscular injection.
79818594|NCT06120283|Drug|Letrozole|Standard dose administered orally as a tablet.
79818595|NCT06119035|Other|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
79818596|NCT06118281|Drug|Ziltivekimab|Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
79818597|NCT06118281|Drug|Placebo|Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
79680090|NCT02931201|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
79991492|NCT03630510|Other|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
79818598|NCT06116149|Behavioral|In-person health coach delivery of the GLB|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
79818599|NCT06116149|Behavioral|Technology-assisted health coach delivery of the GLB|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
79356846|NCT01923844|Drug|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
79818602|NCT06112730|Other|Standard pulmonnary rehabilitation|Undergo routine pulmonary rehabilitation without dietary intervention
79356847|NCT00633022|Drug|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
79818603|NCT06112730|Other|Nutritional supplementation intervention|Receive personalized dietary guidelines based on indirect calorimetry assessment
79991493|NCT03509675|Drug|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
79356848|NCT00633022|Drug|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
79507731|NCT02783430|Drug|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
79507732|NCT02783430|Drug|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
79991494|NCT03509675|Drug|Placebos|Placebo
79991495|NCT01376934|Procedure|procedure hysteroscopy|office hysteroscopy with gas or saline solution
79991496|NCT02351752|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)
79991497|NCT02353078|Drug|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
79356849|NCT01923922|Radiation|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
79356850|NCT01929304|Other|Survey|
79356851|NCT01924000|Drug|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
79356852|NCT01924000|Drug|Placebo|
79356853|NCT01924078|Drug|Capecitabine|metronomic use: capecitabine 500mg/tid
79356854|NCT01924078|Drug|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
79356855|NCT01929616|Drug|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
79356856|NCT01929694|Dietary Supplement|Berocca Boost|
79356857|NCT01929694|Dietary Supplement|Placebo|
79356858|NCT01924156|Biological|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
79356859|NCT01929850|Procedure|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
79356860|NCT01929850|Behavioral|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
79356861|NCT00630994|Drug|Dacogen|
79356862|NCT00630838|Drug|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
79356863|NCT00630838|Drug|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
79356864|NCT03126136|Device|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
79356865|NCT01924234|Drug|Morphine|
79356866|NCT01924234|Drug|Remifentanil|
79356867|NCT01924312|Behavioral|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
79356868|NCT00630058|Drug|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
79356869|NCT00630058|Drug|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
79356870|NCT01925794|Device|COBRA PzF|
79356871|NCT01927198|Drug|Placebo|
79356872|NCT01927198|Drug|RDEA3170 5 mg|
79356873|NCT01927198|Drug|RDEA3170 10 mg|
79356874|NCT01927198|Drug|RDEA3170 12.5 mg|
79356875|NCT01924468|Drug|Oral methylphenidate and Oral haloperidol|
79356876|NCT03536416|Behavioral|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
79356877|NCT01924546|Other|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
79356878|NCT01923064|Drug|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
79356879|NCT01923064|Drug|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
79356880|NCT01924624|Drug|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
79356881|NCT01924702|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
79356882|NCT01924702|Device|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
79356883|NCT01929382|Drug|interferon gamma 1b|Standard therapy vs dose titration
79356884|NCT01924780|Device|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
79356885|NCT01924780|Device|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
79356886|NCT01924780|Device|NEMOS Device sham stimulation 10 minutes|
79356887|NCT00981448|Dietary Supplement|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
79507733|NCT03656328|Dietary Supplement|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
79669043|NCT00458874|Behavioral|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
79507734|NCT03656328|Dietary Supplement|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
79356888|NCT01926184|Behavioral|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
79356889|NCT01926184|Behavioral|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
79356890|NCT01924858|Drug|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of [18F]-GSK2647544 and a PET scan.
79356891|NCT01924858|Drug|[18F]GSK2647544 IV bolus|[18F]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
79356892|NCT04395820|Diagnostic Test|Lung function test|MBW
79356893|NCT04395820|Diagnostic Test|Imaging|MP-MRI
79356894|NCT04395742|Other|Data collection|Only data collection
79356895|NCT00989950|Drug|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
79356896|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
79507735|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
79507736|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
79356897|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
79669044|NCT00426218|Drug|ACZ885|
79669045|NCT00458913|Drug|bortezomib|
79669046|NCT00458913|Drug|cisplatin|
79356898|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
79356899|NCT01924936|Behavioral|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
79356900|NCT04276012|Other|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
79356901|NCT01925092|Drug|mifepristone|tablets
79356902|NCT03121378|Other|Blood sample 1|Blood taken before prosthesis implantation
79356903|NCT03121378|Other|Blood sample 2|Blood taken after prosthesis implantation
79356904|NCT01920256|Other|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
79356905|NCT01920256|Other|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
79356906|NCT04347850|Other|blood sample|Collection
79507737|NCT03642366|Other|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
79507738|NCT05246436|Procedure|warming saline media|use warm saline as a distention media in office hysteroscopy
79507739|NCT05246436|Procedure|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
79507740|NCT05246358|Device|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
79507741|NCT00604968|Drug|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
79507742|NCT00605202|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
79507743|NCT00605202|Dietary Supplement|Licorice|Licorice candy 32 grams a day for 14 days.
79356907|NCT01925248|Dietary Supplement|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
79680091|NCT00524732|Biological|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
79356908|NCT01925248|Dietary Supplement|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
79356909|NCT01905943|Drug|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m^2 in previously untreated participants, and bendamustine 50 mg/m^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
79356910|NCT01905943|Drug|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
79507744|NCT00605358|Behavioral|Open Door intervention|"Open Door intervention subjects will:~receive an evaluation~receive a referral to a local mental health provider~identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
79507745|NCT05245578|Drug|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
79507746|NCT05245578|Drug|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
79507747|NCT00605826|Device|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
79507748|NCT00605826|Device|Sham Injection|Sham injection at the start of the blinded phase.
79507749|NCT05216562|Drug|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
79507750|NCT05216562|Drug|Placebo Intravenous Injection|Intravenous injection of Placebo
79507751|NCT05216562|Drug|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
79507752|NCT03381300|Procedure|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
79507753|NCT02132598|Drug|cabozantinib|
79507754|NCT00605904|Drug|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
79507755|NCT00605904|Drug|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
79507756|NCT00605904|Drug|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
79991498|NCT02353078|Procedure|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
79669047|NCT00458991|Drug|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
79669048|NCT01059617|Biological|GSK Biologicals' FluLaval®|Intramuscular injection
79991499|NCT02353078|Device|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
79991500|NCT03509207|Drug|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
79356911|NCT01905943|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m^2 p.o. QD Day 1-3 in fit participants only.
79669049|NCT01059617|Biological|Placebo (saline)|Intramuscular injection
79669050|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
79669051|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
79991501|NCT03727295|Drug|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
79228401|NCT02235441|Other|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
79356912|NCT01905943|Drug|Fludarabine|Fludarabine 25 mg/m^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m^2 per os (p.o.) QD Day 1-3 in fit participants only.
79356913|NCT01905943|Drug|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
79356914|NCT01905553|Drug|SSP-004184SS|Disodium salt
79356915|NCT04629625|Biological|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
79356916|NCT04629625|Biological|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
79356917|NCT04629625|Biological|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
79356918|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
79356919|NCT01929031|Drug|ibuprofen|tablet.
79356920|NCT01929031|Drug|ibuprofen|tablet
79356921|NCT01929031|Drug|caffeine|tablet
79356922|NCT01929031|Drug|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
79356923|NCT01929031|Drug|placebo|tablet
79669052|NCT03271944|Device|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
79991502|NCT03145792|Behavioral|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
79356924|NCT01929031|Drug|placebo|tablet
79356925|NCT01929031|Drug|caffeine|tablet
79356926|NCT01929031|Drug|ibuprofen|tablet
79356927|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
79356928|NCT00989092|Biological|darbepoetin alfa|Administered subcutaneously.
79356929|NCT00988858|Drug|LY2603618|150 milligram per square meter (mg/m^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
79356930|NCT00988858|Drug|Pemetrexed|500 mg/m^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
79356931|NCT01920334|Drug|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
79507757|NCT00605904|Drug|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
79507758|NCT01798914|Drug|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
79507759|NCT00607620|Behavioral|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
79356932|NCT01920334|Drug|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
79356933|NCT04395352|Device|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
79356934|NCT01920490|Device|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
79356935|NCT01920490|Device|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
79356936|NCT04275622|Behavioral|Lifestyle including optimal exercise and diet modification.|The intervention group will receive diet education and be given exercise suggestion.
79356937|NCT01920646|Other|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
79507760|NCT05175768|Other|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
79507761|NCT05175768|Other|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
79507762|NCT05175768|Other|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
79507763|NCT05097846|Drug|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
79356938|NCT00986986|Drug|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
79356939|NCT01925482|Drug|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
79669053|NCT03273933|Device|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
79356940|NCT01925482|Drug|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
79356941|NCT01925482|Drug|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
79356942|NCT01925482|Drug|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
79356943|NCT01925482|Drug|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
79356944|NCT01925482|Drug|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
79669054|NCT03273933|Device|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
79818604|NCT06110598|Drug|Capecitabine|Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
79228402|NCT02235519|Drug|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
79228403|NCT02235519|Drug|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
79356945|NCT04275466|Procedure|necrotic cavity lavage|"At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is >100 mL.~Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is >38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
79356946|NCT01904773|Drug|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
79669055|NCT00459030|Other|educational intervention via internet|additional cancer screening information via password protected internet site
79356947|NCT01928719|Drug|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
79356948|NCT01928719|Drug|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
79669056|NCT00459030|Other|educational intervention mailed|
79991503|NCT03145792|Behavioral|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
79991504|NCT03727217|Diagnostic Test|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
79991505|NCT04438798|Other|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
79356949|NCT00986674|Biological|cixutumumab|Given IV
79356950|NCT00986674|Drug|carboplatin|Given IV
79356951|NCT00986674|Drug|paclitaxel|Given IV
79356952|NCT00986674|Biological|cetuximab|Given IV
79356953|NCT00986440|Drug|CS-7017|CS-7017
79356954|NCT00986440|Drug|Placebo|Placebo
79356955|NCT01904383|Drug|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
79356956|NCT01920880|Other|Quantitative Sensory Testing analysis|
79356957|NCT01904149|Drug|Placebo|Placebo single oral dose (first 8 hours)
79356958|NCT01904149|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
79356959|NCT01904149|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
79356960|NCT01904149|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
79669057|NCT00459030|Other|No additional educational intervention|
79669058|NCT04705337|Drug|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
79669059|NCT04705337|Other|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
79991506|NCT04438798|Other|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
79669060|NCT00459069|Biological|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
79669061|NCT00426257|Procedure|Secondary debulking|Secondary debulking
79669062|NCT00426257|Procedure|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
79669063|NCT00467571|Drug|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
79356961|NCT01904149|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
79669064|NCT00467688|Device|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
79356962|NCT01904149|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
79356963|NCT01904149|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
79356964|NCT00986362|Drug|Ocriplasmin|175µg ocriplasmin intravitreal injection
79356965|NCT00986362|Drug|Placebo|Placebo intravitreal injection
79356966|NCT01925560|Other|Agave Inulin|3x3 Latin square with 3 periods
79818605|NCT06109701|Procedure|Debridement with ultrasonic device and scaling with plastic curettes|Supragingival and subgingival debridement
79991507|NCT01378650|Drug|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
79991508|NCT01378650|Drug|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
79991509|NCT03721601|Device|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
79356967|NCT01925560|Other|Placebo|control- 0 (zero) grams/day inulin
79356968|NCT01890421|Drug|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
79356969|NCT01925638|Drug|BAY86-9766|
79356970|NCT01925638|Drug|Ketoconazole|
79356971|NCT01925716|Other|Corn oil|corn oil 56 g/day for 21 days
79356972|NCT01925716|Other|Olive oil|olive oil 56 g /day for 21 days
79356973|NCT03092284|Biological|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC_ASC
79356974|NCT03092284|Biological|Placebo|Saline
79669065|NCT00426296|Drug|atazanavir (Reyataz)|
79669066|NCT00426296|Drug|ritonavir (Norvir)|
79669067|NCT03271905|Drug|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
79356975|NCT00985738|Drug|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
79356976|NCT00985738|Other|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
79356977|NCT01928485|Other|active surveillance|Undergo active surveillance
79356978|NCT01928485|Drug|Sunphenon|Given PO
79356979|NCT01928485|Other|laboratory biomarker analysis|Correlative studies
79356980|NCT01928485|Other|Questionnaire Administration|Ancillary studies
79356981|NCT00985504|Drug|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
79356982|NCT00985504|Drug|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
79356983|NCT01921036|Procedure|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
79356984|NCT01921036|Procedure|combined exercise|Moderate endurance and resistance exercise once a week over six months
79356985|NCT01921192|Drug|Folic Acid, vit B6 and B12|
79356986|NCT01921192|Drug|Placebo|
79356987|NCT04275388|Drug|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
79669068|NCT03271905|Device|Mesh nebulization|Nebulization with Mesh device.
79669069|NCT00426374|Procedure|echocardiography and blood test|
79680092|NCT02930772|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z46-100)"
79818606|NCT06109701|Procedure|Debridement with erythritol based air-polishing powde|Supragingival and subgingival debridement
79818607|NCT06108284|Device|Intervention Arm (Biphasic cuirass ventilation)|Patients in this arm will be placed on Biphasic cuirass ventilation
79991510|NCT03721601|Device|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
79991511|NCT02351830|Other|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
79991512|NCT02351830|Procedure|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
79991513|NCT04530162|Procedure|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
79991514|NCT03721523|Diagnostic Test|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
79507764|NCT05097846|Drug|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
79356988|NCT04275388|Drug|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
79669070|NCT00459225|Drug|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
79669071|NCT00426413|Drug|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
79669072|NCT00459264|Drug|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
79818608|NCT06105073|Procedure|Pulmonary Rehabilitation Program|Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Speciality Hospital from the Medical Center La Raza IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires.
79356989|NCT01921426|Drug|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
79818609|NCT06101069|Procedure|MRF in conjunction with IVIM MRI without contrast|MRF in conjunction with IVIM MRI scan, without contrast.
79991515|NCT03721523|Diagnostic Test|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
79356990|NCT03458962|Genetic|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
79356991|NCT01926106|Device|nIPPV|one of the twins was randomly allocated to nIPPV
79356992|NCT01926106|Device|nCPAP|another of the twins was allocated to nCPAP
79669073|NCT00459264|Drug|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
79991516|NCT04796922|Drug|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
79991517|NCT04796922|Drug|rituximab|rituximab will be administered intravenously on select days as per protocol.
79669074|NCT00426452|Drug|Vatalinib|
79669075|NCT00467727|Other|Phase Contrast Mammography|Standard and magnification views
79669076|NCT00426491|Drug|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
79669077|NCT03273777|Procedure|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
79991518|NCT04796922|Drug|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
79669078|NCT00426530|Drug|everolimus (RAD001)|
79669079|NCT00459420|Drug|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
79669080|NCT00459420|Drug|placebo|placebo
79669081|NCT00467766|Behavioral|Psychosocial information, counseling, and support|
79669082|NCT00467766|Drug|Donepezil (Aricept)|
79356993|NCT01921504|Device|Acupuncture|"Acupuncture treatment~Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
79507765|NCT05097846|Drug|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
79507766|NCT05097846|Drug|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
79507767|NCT04388046|Device|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
79507768|NCT00608634|Drug|perillyl alcohol|Applied as topical cream
79507769|NCT00608634|Other|placebo|Applied as topical cream
79669083|NCT00459459|Procedure|Fine needle aspiration of the thyroid|
79507770|NCT03088566|Procedure|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
79507771|NCT03088566|Procedure|Conventional foot screening|The foot screening is performed with clinical conventional methods.
79669084|NCT00467805|Procedure|Light therapy|
79669085|NCT00467883|Drug|Liposomal Amphotericin B|high dosage
79669086|NCT00426608|Drug|metyrapone|Metyrapone will be available as 250 mg dose capsule.
79669087|NCT00426608|Drug|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
79669088|NCT00426608|Drug|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
79669089|NCT00426608|Drug|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
79356994|NCT01921582|Drug|Methylphenidate|"Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
79356995|NCT01921582|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~Phase 2 aims to reduce food intake and restructure eating-related cognitions;~Phase 3 focuses upon relapse prevention"
79991519|NCT03721445|Device|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
79356996|NCT02984098|Drug|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
79356997|NCT03398902|Behavioral|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
79356998|NCT03398902|Other|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
79356999|NCT00985426|Biological|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
79357000|NCT00985426|Biological|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
79507772|NCT02897700|Drug|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
79507773|NCT02897700|Drug|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
79507774|NCT02897700|Drug|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
79507775|NCT02889666|Drug|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79507776|NCT02889666|Drug|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79669090|NCT00467922|Drug|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
79669091|NCT00467922|Drug|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
79669092|NCT00426647|Drug|Buprenorphine|
79669093|NCT00426647|Drug|Tramadol|
79669094|NCT00468078|Procedure|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
79669095|NCT00468078|Drug|F-18 FPCIT|5mCi, intravenous injection
79669096|NCT00468156|Behavioral|written materials only|related to fruit/vegetable servings/day
79669097|NCT00468156|Behavioral|written materials|related to fruit/vegetable servings/day
79991520|NCT04305678|Drug|Mepolizumab|Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
79991521|NCT03723785|Drug|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
79357001|NCT00985426|Other|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
79357002|NCT00985192|Drug|everolimus|
79357003|NCT00985192|Other|laboratory biomarker analysis|
79357004|NCT03392662|Device|Hemopatch|Patients received product at the discretion of their surgeon.
79669098|NCT00468156|Behavioral|telephone support|related to fruit/vegetable servings/day
79669099|NCT00426725|Device|EasyLabour|According to the trial protocol
79669100|NCT01059344|Drug|Mesalamin|4.8g/day, 800 mg tablets
79669101|NCT00459615|Drug|Artesunate for Injection|
79357005|NCT03390010|Drug|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
79357006|NCT03390010|Drug|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
79507777|NCT02889666|Drug|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79507778|NCT02889666|Drug|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79669102|NCT00468351|Procedure|Intravitreal Injection of 1,5 mg of bevacizumab|
79669103|NCT00468351|Procedure|Intravitreal injection of 4 mg of Triamcinolone acetonide|
79507779|NCT02889666|Drug|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79507780|NCT02889666|Drug|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79357007|NCT00985114|Device|EndoBarrier|EndoBarrier implant
79507781|NCT02889666|Drug|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
79507782|NCT02889666|Drug|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
79507783|NCT04955340|Drug|[14C]-resminostat|1 single dose of 400 mg [14C]-resminostat
79669104|NCT00459654|Drug|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
79669105|NCT00459654|Drug|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
79669106|NCT00468429|Drug|Subconjunctival Bevacizumab|
79669107|NCT00468468|Behavioral|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
79669108|NCT00468507|Dietary Supplement|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
79669109|NCT00426803|Drug|activated recombinant human factor VII|
79669110|NCT00459771|Drug|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
79991522|NCT05255614|Device|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device & software at Swedan
79357008|NCT00985114|Behavioral|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
79357009|NCT00984568|Biological|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
79357010|NCT00984568|Drug|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
79357011|NCT00984568|Drug|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
79357012|NCT00984568|Drug|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
79669111|NCT00459771|Drug|Placebo|Placebo, 32 mg, oral QD
79669112|NCT01058369|Drug|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
79669113|NCT00459849|Procedure|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
79669114|NCT03271788|Other|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
79669115|NCT01057433|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
79669116|NCT01057433|Drug|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
79669117|NCT00459888|Device|PolarCath Peripheral Dilatation System (Boston Scientific)|
79669118|NCT01057394|Device|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
79669119|NCT01057394|Device|RF PVI Ablation|Radiofrequency ablation
79669120|NCT00459927|Device|Floseal tonsillectomy|
79507784|NCT04815330|Other|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
79357013|NCT02984176|Drug|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
79357014|NCT02984176|Drug|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
79357015|NCT03075280|Procedure|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
79357016|NCT01921738|Drug|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
79357017|NCT01921738|Drug|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
79357018|NCT01921738|Drug|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
79357019|NCT01921738|Drug|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
79507785|NCT04815330|Other|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
79357020|NCT01921816|Device|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
79507786|NCT02740374|Device|ROTEM|ROTEM coagulation assessment and guided transfusion management.
79669121|NCT00459927|Device|Coblation tonsillectomy|
79669122|NCT00459966|Procedure|Preoperative rehabilitation|
79357021|NCT04395976|Other|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
79357022|NCT03092050|Behavioral|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
79357023|NCT03092050|Behavioral|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
79507787|NCT02740374|Other|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
79669123|NCT01058642|Drug|ADL5747|
79669124|NCT01058642|Drug|Placebo|
79357024|NCT01926418|Behavioral|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
79357025|NCT00984256|Drug|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
79357026|NCT00984256|Other|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
79357027|NCT00984022|Device|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
79357028|NCT00984022|Device|Type of dressing - Aquacel|Aquacel dressing
79357029|NCT01926574|Behavioral|long rehabilitation program|
79507788|NCT00609804|Drug|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
79507789|NCT00609804|Drug|Erlotinib|Erlotinib 150 mg once daily by mouth
79507790|NCT00610116|Device|Electronic Repositioning|Change of pacing vectors for CRT pacing
79507791|NCT00610428|Drug|Staccato Placebo|Inhaled Staccato Placebo
79507792|NCT00610428|Drug|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
79669125|NCT01058642|Drug|Pregabalin|
79669126|NCT00426881|Behavioral|Exercise Training|Twice weekly resistance training for 52 weeks.
79669127|NCT00426881|Behavioral|Exercise training|Once weekly resistance training for 52 weeks.
79669128|NCT00426881|Behavioral|Exercise training|Twice weekly resistance training for 52 weeks.
79669129|NCT03271437|Behavioral|PC-based Flash|Progressive counting with Flash technique
79669130|NCT03271437|Behavioral|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
79669131|NCT00426920|Drug|Insulin|
79669132|NCT03271710|Device|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
79669133|NCT00426959|Device|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
79507793|NCT00610428|Drug|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
79507794|NCT00610740|Drug|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
79818610|NCT06097871|Dietary Supplement|Skin Nutraceutical Supplement|The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
79357030|NCT01926574|Behavioral|short rehabilitation program|
79507795|NCT00610740|Procedure|therapeutic conventional surgery|hysterectomy
79357031|NCT01926574|Behavioral|Acceptance and commitment therapy (ACT)|
79357032|NCT01922128|Drug|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
79357033|NCT01890265|Drug|Pamrevlumab|Solution for infusion
79357034|NCT01890265|Drug|Placebo|Solution for infusion
79357035|NCT01890265|Drug|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
79357036|NCT01890265|Drug|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
79357037|NCT01926652|Drug|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
79357038|NCT03073954|Other|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
79357039|NCT03073954|Behavioral|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
79357040|NCT01926730|Other|Restriction diet|Selected food items will be limited in the participants diet
79507796|NCT02444676|Other|Stratification and outcomes|No necessary
79507797|NCT04470180|Behavioral|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
79507798|NCT04470180|Behavioral|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
79507799|NCT00611442|Drug|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
79507800|NCT00611442|Drug|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
79507801|NCT02136420|Drug|Promethazine|Subject receives promethazine
79507802|NCT02136420|Behavioral|Hyper gravity training|Subject receives hypergravity training before testing
79507803|NCT02136420|Drug|Placebo|Placebo
79507804|NCT02136420|Behavioral|No hypergravity training|Subjects do not receive normal Earth gravity
79507805|NCT02136498|Drug|Varenicline|Standard 12 week course of varenicline, provided in both arms
79507806|NCT02136498|Behavioral|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
79507807|NCT02136498|Behavioral|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
79507808|NCT00612222|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
79669134|NCT00468624|Drug|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
79669135|NCT00468624|Procedure|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
79669136|NCT00468624|Procedure|blood sampling before and after pegvisomant/placebo|
79669137|NCT00468624|Procedure|arginine stimulation test after each limb|
79669138|NCT00426998|Drug|Verteporfin|
79669139|NCT00426998|Drug|Bevacizumab|
79507809|NCT00612222|Biological|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
79507810|NCT00612222|Biological|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
79357041|NCT03070444|Device|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
79507811|NCT00612222|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
79507812|NCT00612222|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
79507813|NCT01931436|Drug|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
79357042|NCT03070444|Device|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
79357043|NCT03070444|Device|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
79357044|NCT03070444|Procedure|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
79357045|NCT03070444|Other|Questionnaire|A questionnaire is completed at the follow-up visits.
79357046|NCT01928329|Drug|Exenatide (Bydureon®)|
79357047|NCT01928329|Drug|Placebo|
79357048|NCT01922206|Behavioral|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
79357049|NCT01922284|Biological|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
79507814|NCT01842360|Biological|Placebo|The subjects will receive daily dose of placebo during 12 months
79507815|NCT01842360|Biological|MV130|The subjects will receive daily dose of MV130 during 12 months
79507816|NCT00612768|Biological|TRUE Test allergens Fragrance Mix and Thimerosol|"Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
79507817|NCT01711242|Drug|Capecitabine|
79507818|NCT01711242|Drug|Oxaliplatin|
79818611|NCT06097871|Other|Placebo pill|A placebo pill containing non-active ingredients
79818612|NCT06091943|Drug|Tislelizumab IV|Planned doses will be administered intravenously.
79357050|NCT01922284|Biological|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
79357051|NCT01922284|Biological|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
79357052|NCT01922284|Biological|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
79507819|NCT01711242|Radiation|Radiotherapy|
79507820|NCT04405908|Biological|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
79818613|NCT06091943|Drug|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
79818614|NCT06091943|Drug|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
79357053|NCT01890109|Biological|Erenumab|Administered via subcutaneous injection.
79357054|NCT01890109|Drug|Placebo|Administered via subcutaneous injection
79357055|NCT03108976|Other|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
79507821|NCT04405908|Biological|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
79507822|NCT04405908|Biological|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
79507823|NCT04405908|Biological|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
79357056|NCT03108976|Other|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
79357057|NCT03108976|Other|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
79357058|NCT03069976|Drug|Metronidazole|Flagyl x 14 days.
79507824|NCT04333368|Biological|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
79507825|NCT04333368|Other|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
79507826|NCT04331496|Other|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
79818615|NCT06087926|Device|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes."
79357059|NCT00982930|Drug|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
79357060|NCT03069664|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
79357061|NCT03069664|Device|Covered Self-expandable Metal Stent|Pancreatic duct stent
79507827|NCT04331496|Other|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
79818616|NCT06087315|Other|Multi-faceted oxygen systems strengthening interventions (different for each country)|The specific approaches are different in each country but broadly include efforts to: (1) strengthening policies, strategies, and governance of medical oxygen production, distribution, maintenance, and use; (2) building capacity of healthcare workers and technicians to use and maintain oxygen well, and (3) strengthening oxygen-related data acquisition and use for forecasting, budgeting, and monitoring.
79818617|NCT06075706|Biological|MC0518|MC0518 will be intravenously infused immediately after thawing.
79507828|NCT04304274|Procedure|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
79507829|NCT04304274|Procedure|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
79818618|NCT06075706|Biological|BAT|BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
79818619|NCT06069713|Behavioral|CBD advertisements|Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
79507830|NCT04304274|Drug|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
79818620|NCT06063577|Device|Stratafix suture|Stratafix symmetric suture
79818621|NCT06063577|Device|Standard of care suture|Standard of care suture
79357062|NCT05602168|Other|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate and buccal swab
79357063|NCT00981682|Drug|SER120|once a day treatment of nocturia
79357064|NCT01903993|Drug|Docetaxel|Participants received starting dose of 75 mg/m^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
79818622|NCT06062654|Other|Hospital-assisted Rehabilitation|Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
79818623|NCT06062654|Other|Home-based Rehabilitation|Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
79818624|NCT06059612|Procedure|injection|steroid injection into superior cluneal nerve
79818625|NCT06057493|Other|Retinal Imaging with Optina4C Camera|"The study consists of 2 visits and 8 Imaging sessions:~The participant will go through four (8) imaging sessions in two visits with the Optina-4CTM cameras to get pictures of your retina. These imaging sessions will be done by three qualified operators who have been trained on the study device by Optina Diagnostics."
79357065|NCT01903993|Drug|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram [mg/kg]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
79669140|NCT00427076|Drug|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
79669141|NCT00427076|Drug|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
79669142|NCT00427115|Behavioral|Multimodal exercise and psychosocial program|
79357066|NCT00981292|Dietary Supplement|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
79669143|NCT00427232|Drug|BQ-123 and BQ-788|
79669144|NCT00468702|Device|CoaguChek S|
79669145|NCT00427271|Drug|aspirin|
79669146|NCT00460083|Drug|Elidel(R) (pimecrolimus 1%)|
79669147|NCT00460083|Device|EpiCeram(R) -ceramide based barrier repair cream|
79669148|NCT00427310|Drug|fluorouracil|
79669149|NCT00427310|Other|Observation|
79669150|NCT00427310|Drug|sodium heparin|
79669151|NCT00468741|Behavioral|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
79669152|NCT00468741|Behavioral|CHESS|informational services of CHESS available to subject
79669153|NCT00468741|Behavioral|CHESS|CHESS informational services and social support available to subject
79669154|NCT00427388|Drug|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
79818628|NCT06051695|Biological|A2B694|Autologous logic-gated Tmod CAR T cells
79818629|NCT06051695|Diagnostic Test|xT CDx with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
79669155|NCT00427388|Other|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
79669156|NCT01056653|Behavioral|Standard Dose|Two intevention home visits
79669157|NCT01056653|Behavioral|High Dose|Four intervention home visits
79669158|NCT01056653|Behavioral|Comparison Group|One home visit, information only
79991523|NCT05255614|Device|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
79991524|NCT05255458|Biological|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
79357067|NCT00981292|Dietary Supplement|Placebo|Pharmaceutical grade silica was utilized as placebo
79357068|NCT03065140|Other|Training or detraining|A period of detraining or a supervised exercise program.
79357069|NCT01927042|Behavioral|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
79357070|NCT01927042|Behavioral|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
79357071|NCT01927510|Behavioral|Early mobilisation|
79357072|NCT00980044|Drug|Tramadol|Oral Medication
79357073|NCT00980044|Drug|Placebo|Oral Medication
79669159|NCT01056536|Behavioral|Structured intervention for the prevention of sexually transmitted infections (STI).|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
79669160|NCT01056536|Device|Free condoms|Subjects will be proposed free condoms at the end of the pre-travel consultation.
79669161|NCT00427427|Drug|Trastuzumab|
79669162|NCT04704947|Drug|nonselective beta blocker|nonselective beta blocker
79669163|NCT04704947|Drug|cardio-selective beta blocker group|cardio-selective beta blocker group
79669164|NCT04704947|Drug|alendronate sodium|alendronate sodium
79991525|NCT05255458|Drug|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
79991526|NCT04441320|Device|Coated metal ureteral stent(CMUS)|Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
79669165|NCT04705142|Drug|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
79669166|NCT04705064|Diagnostic Test|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
79669167|NCT00460161|Procedure|acupuncture|2 treatments/week for 4 weeks
79669168|NCT00460161|Other|placebo/sham acupuncture|2 treatments/week for 4 weeks
79991527|NCT04441320|Device|Double-J stent(DJS)|Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
79991528|NCT04478656|Biological|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
79357074|NCT05601934|Other|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
79357075|NCT01927588|Drug|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
79357076|NCT01927588|Drug|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
79357077|NCT05601466|Drug|QN-023a|NK cell therapy
79357078|NCT05601466|Drug|Cyclophosphamid|Lympho-conditioning Agent
79357079|NCT05601466|Drug|Fludarabine|Lympho-conditioning Agent
79357080|NCT05601466|Drug|Cytarabine|Lympho-conditioning Agent
79357081|NCT01903837|Drug|Samidorphan (Low Dose)|Tablets taken once daily
79357082|NCT01903837|Drug|Samidorphan (Medium Dose)|Tablets taken once daily
79669169|NCT00427466|Drug|Pemetrexed|
79507831|NCT04290780|Other|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
79507832|NCT04253496|Other|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
79507833|NCT01285362|Drug|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
79507834|NCT01285362|Drug|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
79357083|NCT01903837|Drug|Samidorphan (High Dose)|Tablets taken once daily
79357084|NCT01903837|Drug|Placebo|Tablets taken once daily
79357085|NCT01903837|Drug|Olanzapine|Tablets taken once daily
79357086|NCT01927666|Dietary Supplement|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
79357087|NCT00982696|Biological|Opioid Growth Factor|250ug per kilogram weekly IV infusions
79357088|NCT00982150|Drug|Talampanel|50mg capsules tid
79357089|NCT02984254|Device|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
79507835|NCT00612924|Device|Anaconda Stent Graft System|Endovascular device
79507836|NCT00612924|Device|Anaconda ONE-LOK Stent Graft System|Endovascular device
79507837|NCT02132832|Drug|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
79507838|NCT02132832|Drug|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
79507839|NCT00614406|Drug|Celebrex|One 400mg tablet daily.
79357090|NCT02984254|Device|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
79357091|NCT02984254|Device|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
79357092|NCT02984254|Device|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
79669170|NCT00468897|Drug|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
79669171|NCT00427505|Drug|Deferasirox|
79669172|NCT00427544|Drug|PRA-027|
79669173|NCT00460200|Genetic|polymorphism analysis|
79669174|NCT00460200|Other|laboratory biomarker analysis|
79357093|NCT02984254|Device|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
79357094|NCT02984254|Device|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
79357095|NCT02984254|Device|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
79507840|NCT00614406|Drug|Placebo|One tablet daily.
79507841|NCT02132910|Other|RESTORE Intervention|
79507842|NCT02133066|Procedure|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
79507843|NCT02133066|Device|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
79507844|NCT02133066|Procedure|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
79669175|NCT00460200|Other|physiologic testing|
79669176|NCT00460200|Other|questionnaire administration|
79991529|NCT03149926|Other|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
79507845|NCT00614484|Radiation|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
79507846|NCT00614484|Drug|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
79507847|NCT00614484|Drug|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
79669177|NCT00460200|Procedure|conventional surgery|
79669178|NCT00460200|Procedure|fatigue assessment and management|
79669179|NCT00460200|Procedure|psychosocial assessment and care|
79507848|NCT04159974|Drug|Durvalumab 50 MG/ML|IV Infusion
79507849|NCT04159974|Drug|Tremelimumab|IV Infusion, Combination with Durvalumab
79669180|NCT00427583|Drug|imatinib mesylate|
79669181|NCT00468936|Drug|Myfortic|enteric coated Cellcept pills in applicable dose for patient
79669182|NCT00427622|Other|physiologic testing|
79669183|NCT00469053|Drug|Buprenorphine|
79818630|NCT06049654|Device|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
79818631|NCT06049654|Device|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
79991530|NCT03543137|Drug|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
79357096|NCT01903525|Drug|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
79507850|NCT04142502|Drug|Propofol|Propofol as a sedation drug
79507851|NCT04142502|Drug|Dexmedetomidin|Dexmedetomidine as a sedation drug
79507852|NCT00615420|Dietary Supplement|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
79507853|NCT00615420|Dietary Supplement|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
79507854|NCT00568854|Biological|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
79507855|NCT00569010|Drug|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days
79507856|NCT00569010|Drug|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age<65 years) or 3 days (age>=65 years)"
79507857|NCT00616122|Drug|cyclophosphamide|
79507858|NCT00616122|Drug|methotrexate|
79507859|NCT00616122|Drug|sunitinib malate|
79669184|NCT00427739|Procedure|Cardiac CT|64 slice spiral computerized tomography
79669185|NCT00460278|Drug|XL418|
79818632|NCT06046586|Behavioral|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
79818633|NCT06046586|Behavioral|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
79507860|NCT00616122|Other|laboratory biomarker analysis|
79507861|NCT00616200|Other|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
79507862|NCT00617058|Drug|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
79507863|NCT00617058|Behavioral|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
79507864|NCT00618540|Biological|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
79669186|NCT00460356|Other|Laboratory Biomarker Analysis|Correlative studies
79669187|NCT00460356|Procedure|Lymphadenectomy|Undergo lymphadenectomy
79669188|NCT00428012|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
79669189|NCT00428012|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
79669190|NCT00469131|Drug|tacrolimus + steroid|
79669191|NCT00469131|Drug|tacrolimus + mycophenolate mofetil|
79669192|NCT00428051|Other|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
79669193|NCT00460395|Procedure|Surgery|
79669194|NCT00460395|Procedure|Stereotactic radiosurgery|
79669195|NCT02956356|Dietary Supplement|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
79669196|NCT02956356|Dietary Supplement|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
79818634|NCT06046586|Behavioral|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
79818635|NCT06046586|Behavioral|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
79818636|NCT06046573|Behavioral|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
79357097|NCT01903525|Drug|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
79357098|NCT00981526|Drug|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
79357099|NCT00981526|Drug|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
79357100|NCT00981526|Drug|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
79357101|NCT00981526|Drug|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
79507865|NCT00618540|Drug|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age <12 months)
79507866|NCT00618540|Drug|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age <12 months)
79507867|NCT00618540|Procedure|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
79669197|NCT02956356|Dietary Supplement|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
79669198|NCT02956356|Dietary Supplement|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
79669199|NCT00428129|Drug|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
79669200|NCT03271515|Biological|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
79669201|NCT00428168|Drug|Betahistine|Betahistine 24mg BID
79507868|NCT00570960|Drug|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
79669202|NCT00428285|Procedure|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
79669203|NCT00428363|Device|Cataract surgery with implantation of an intraocular lens|
79669204|NCT00428402|Behavioral|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
79507869|NCT00570960|Biological|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
79507870|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
79507871|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
79507872|NCT00571428|Drug|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
79507873|NCT00571974|Device|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
79507874|NCT00571974|Drug|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
79507875|NCT00571974|Procedure|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
79507876|NCT00621348|Drug|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
79507877|NCT00621348|Drug|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
79507878|NCT00621348|Drug|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
79507879|NCT00574236|Drug|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
79507880|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
79357102|NCT05601310|Device|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
79357103|NCT01927900|Dietary Supplement|HMO|
79357104|NCT01927900|Dietary Supplement|Glucose|
79357105|NCT04274920|Other|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
79357106|NCT04274920|Other|Light cured calcium hydroxide|Light cured calcium hydroxide
79357107|NCT04274842|Other|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
79357108|NCT04274608|Drug|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
79357109|NCT04274608|Behavioral|Weight Management Program|12 week weight management program
79357110|NCT05601076|Procedure|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
79357111|NCT05601076|Procedure|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
79357112|NCT05600998|Drug|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
79507881|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
79507882|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
79507883|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
79357113|NCT05607940|Procedure|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
79357114|NCT05607940|Procedure|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
79507884|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
79357115|NCT04394728|Drug|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
79507885|NCT00574704|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
79507886|NCT00574704|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
79507887|NCT00574704|Drug|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
79507888|NCT00574704|Drug|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
79507889|NCT01168219|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
79507890|NCT01168219|Biological|Anti-Thymocyte Globulin|Given IV
79507891|NCT01168219|Drug|Azacitidine|Given SC or IV
79507892|NCT01168219|Drug|Busulfan|Given IV
79507893|NCT01168219|Drug|Fludarabine Phosphate|Given IV
79507894|NCT01168219|Other|Laboratory Biomarker Analysis|Correlative studies
79507895|NCT01168219|Drug|Methotrexate|Given IV
79507896|NCT01168219|Other|Pharmacological Study|Correlative studies
79507897|NCT01168219|Drug|Tacrolimus|Given PO or IV
79507898|NCT01115803|Drug|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
79669205|NCT00469170|Device|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
79507899|NCT01115803|Drug|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
79507900|NCT01115803|Drug|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
79507901|NCT01115569|Drug|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
79507902|NCT01107886|Drug|Saxagliptin|5 mg or 2.5 mg once daily
79669206|NCT00469248|Device|Intra-aortic balloon pump counterpulsation|
79669207|NCT00428480|Behavioral|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
79669208|NCT00428480|Behavioral|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
79357116|NCT03831412|Behavioral|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
79818637|NCT06046573|Behavioral|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
79357117|NCT03831412|Behavioral|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
79357118|NCT05607706|Behavioral|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
79357119|NCT05607628|Combination Product|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
79507903|NCT01107886|Drug|Placebo|
79669209|NCT00460473|Drug|Dexmedetomidine|
79669210|NCT00460473|Drug|Placebo|
79669211|NCT00428519|Drug|Placebo|Placebo for 14 days
79669212|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
79818638|NCT06046573|Behavioral|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
79818639|NCT06046573|Behavioral|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
79818640|NCT06045845|Dietary Supplement|Beet Juice|70 milliliter (70mL) standard Beet Juice (Beet It Sport Shot) consumed 2.5 hours before exercise test
79818641|NCT06045845|Dietary Supplement|Placebo|70mL placebo Beet Juice (Beet It Sport Shot with nitrate removed) consumed 2.5 hours before exercise test
79507904|NCT01107457|Biological|Ixekizumab|Administered subcutaneously
79507905|NCT01107457|Drug|Placebo|Administered subcutaneously
79228404|NCT03300908|Behavioral|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
79507906|NCT05767008|Other|Sunscreen -R43|Long wear metal oxide particles
79507907|NCT05766969|Drug|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
79507908|NCT05766969|Drug|Placebo|An inactive compound.
79507909|NCT05766865|Procedure|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
79507910|NCT05766865|Procedure|Conservative treatment|Standard treatment for intracerebral hemorrhage
79669213|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
79669214|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
79669215|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
79669216|NCT00460512|Drug|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
79669217|NCT01056380|Drug|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
79669218|NCT01056380|Drug|Placebo|Tablet, twice daily with food for 5 days
79669219|NCT00460590|Biological|MVA 85A|ID vaccine
79357120|NCT05607628|Combination Product|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
79357121|NCT04759378|Diagnostic Test|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
79357122|NCT01927861|Drug|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
79357123|NCT05606536|Drug|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
79357124|NCT05600218|Drug|No intervention - Observational study|Real life drug evaluation
79357125|NCT05602948|Behavioral|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump & fun and the Move & learn interventions have a set of strategies underpinning implementation (see Move & Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
79357126|NCT05602948|Behavioral|'Move & Learn' intervention|"The physical activities in Move & Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump & fun and the Move & learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
79507911|NCT05766826|Other|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
79507912|NCT05766826|Other|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
79507913|NCT05766696|Procedure|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
79507914|NCT05766696|Procedure|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
79507915|NCT05766644|Other|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q&A session. Topics are on general disease information, nutrition, and exercise.
79507916|NCT05766618|Procedure|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~Space closure will be done on a 17x25 stainless steel wire~Both molars will be indirectly anchored to the miniscrew~Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~The First injection will be 3 weeks before extraction~By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~follow up every month and injection will be repeated month after month with an observational period of 5 months."
79507917|NCT05766605|Drug|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
79669220|NCT01055834|Drug|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
79357127|NCT03831178|Dietary Supplement|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
79669221|NCT01055834|Drug|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
79357128|NCT03831178|Drug|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
79357129|NCT03353272|Behavioral|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
79357130|NCT05602870|Diagnostic Test|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
79669222|NCT00469326|Drug|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
79669223|NCT01055639|Behavioral|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
79357131|NCT01927627|Drug|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
79357132|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
79357133|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with sarcoma.
79507918|NCT05766605|Drug|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
79507919|NCT05766605|Drug|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
79507920|NCT05766605|Drug|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
79228405|NCT03300908|Behavioral|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
79228406|NCT05376501|Dietary Supplement|Astaxanthin|8 mg Astaxanthin per capsule, taken once a day with meal
79507921|NCT05766605|Drug|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
79357134|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
79357135|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with breast cancer.
79507922|NCT05766605|Drug|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
79357136|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with esophagus cancer.
79357137|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with lung cancer.
79357138|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
79357139|NCT04394104|Other|Survey|No intervention is being administered.
79357140|NCT01889251|Drug|Ocriplasmin|
79357141|NCT01889251|Drug|Sham injection|
79357142|NCT05602714|Other|Collection Data|
79507923|NCT05766527|Biological|KM602|Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
79507924|NCT05766436|Drug|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
79507925|NCT05766436|Drug|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
79669224|NCT01055639|Behavioral|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
79669225|NCT00460629|Procedure|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
79228407|NCT05376501|Other|Placebo|Modified food starch
79357143|NCT05602558|Biological|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
79357144|NCT05602558|Biological|Placebo|Aluminium hydroxide adjuvant
79357145|NCT04394338|Other|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
79357146|NCT01616563|Behavioral|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
79357147|NCT01616563|Behavioral|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
79357148|NCT05602324|Dietary Supplement|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
79357149|NCT05600608|Dietary Supplement|Oral Stimulant Drink|please see description of the drink in the arm/ group section
79507926|NCT05766436|Drug|Placebo|placebo ODF and 0.9% normal saline nebulizer
79669226|NCT00460668|Behavioral|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
79669227|NCT04704713|Drug|Afamelanotide|
79669228|NCT04704713|Drug|Placebo|
79669229|NCT00469365|Behavioral|pharmacist contact with the patient via telephone|
79357150|NCT01616173|Drug|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
79507927|NCT05766397|Drug|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
79818645|NCT06042699|Dietary Supplement|Oral ferrous sulfate|Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
79818646|NCT06042699|Dietary Supplement|Oral placebo tablet|Oral placebo tablet provided as placebo comparator.
79507928|NCT05766384|Drug|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
79357151|NCT01616173|Drug|Dexamethasone|8mg/2mL
79818647|NCT06042491|Behavioral|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions >= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
79818648|NCT06039878|Behavioral|Bonding-Evoked Oxytocin|Mother participates in bonding activity with infant at ages 1, 3, and 6 months
79507929|NCT05766319|Device|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~Measurement of peripheral oxygen saturation (%)~Automatic recording of heart rate (beats/min)~Automatic recording of activity (step count) (numbers/day)"
79228408|NCT02466932|Device|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
79228409|NCT05727254|Behavioral|Agility training|Multi-component (strength, balance, cognition) exercise training.
79357152|NCT01616173|Drug|Saline|2mL
79357153|NCT05609734|Other|no intervention, only observational retrospective study|no intervention, only observational retrospective study
79507930|NCT05766319|Device|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
79507931|NCT05766319|Device|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
79507932|NCT05766293|Device|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
79507933|NCT05766293|Other|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
79507934|NCT05766228|Other|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
79357154|NCT05609500|Behavioral|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
79507935|NCT05766176|Diagnostic Test|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
79507936|NCT05766137|Procedure|Alveolar ridge preservation|Socket preservation
79507937|NCT05766098|Genetic|Genotyping|Characterization of genetic profile of tumor tissues
79507938|NCT05766085|Diagnostic Test|Dexamethasone suppression test|Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
79507939|NCT05766072|Other|EMOTION Kids coping with anxiety and depression (Kendall et. al, 2013) (Mestrende barn in Norwegian) Martinsen et al, 2014|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
79507940|NCT05766059|Device|Transcranial Magnetic Stimulation|The standard PAS protocol will be compared with the mirrorPAS protocol.
79507941|NCT05766033|Other|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
79357155|NCT03044314|Drug|Illoprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
79507942|NCT05765994|Diagnostic Test|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
79507943|NCT05765981|Drug|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
79507944|NCT05765916|Behavioral|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
79507945|NCT05765877|Drug|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
79507946|NCT05765825|Drug|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
79507947|NCT05765825|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
79507948|NCT05765825|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
79507949|NCT05765825|Drug|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
79507950|NCT05765825|Radiation|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.Following the induction phase, participants will continue maintenance therapy with serplulimab thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 30 Gy in 10 fractions in the fifth and sixth cycle
79507951|NCT05765799|Other|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
79507952|NCT05765773|Biological|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
79507953|NCT05765747|Drug|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
79228410|NCT05727254|Behavioral|Exercise recommendations|Participants are being given the standard recommendations how much exercise and what type older adults should do.
79357156|NCT03040102|Other|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
79357157|NCT03040102|Other|Standard of Care|Standard of Care practice is used
79357158|NCT05608720|Behavioral|Information Booklet|Information Booklet prior to the dental visit
79357159|NCT05608642|Other|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
79507954|NCT05765747|Drug|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
79669230|NCT00469365|Behavioral|Pharmacist contact with the patient's physician via fax|
79669231|NCT00469365|Behavioral|Usual care|
79669232|NCT02957513|Behavioral|Text Messaging (TM)|As specified in the arm description above
79669233|NCT02957513|Behavioral|Health Coaching (HC)|As specified in the arm description above
79669234|NCT02957513|Behavioral|Enhanced Usual Care (EC)|As specified in the arm description above
79669235|NCT00460707|Drug|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
79228411|NCT05727254|Behavioral|Exercise diary|Participants are instructed to write down their physical activity and exercises.
79228412|NCT02235675|Device|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
79669236|NCT00460707|Drug|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
79228413|NCT02235753|Behavioral|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
79507955|NCT05765708|Other|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
79507956|NCT05765708|Diagnostic Test|Action Observation|Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
79507957|NCT05765695|Procedure|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
79357160|NCT05608642|Other|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
79507958|NCT05765656|Behavioral|GP - pharmacist collaboration and pharmacist motivational interviewing|"Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
79507959|NCT05765643|Other|Nurse parental support in symptom management using a mobile health App|Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
79507960|NCT05765630|Biological|BLOOD SAMPLES|BLOOD SAMPLES
79507961|NCT05765617|Drug|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
79507962|NCT05765617|Other|Placebo|Placebo give 2x1 per day for five day
79507963|NCT05765591|Other|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
79357161|NCT05608642|Other|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
79507964|NCT05765565|Device|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
79507965|NCT05765565|Device|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
79357162|NCT05608564|Procedure|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
79357163|NCT05608564|Procedure|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
79507966|NCT05765552|Other|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
79507967|NCT05765552|Other|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
79507968|NCT05765539|Device|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~One examination with the US machine by the midwife focused on 4 targets ;~One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
79669237|NCT00460707|Drug|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
79669238|NCT00460707|Drug|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
79669239|NCT00460707|Drug|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
79669240|NCT00428636|Procedure|ileostomy|
79669241|NCT00469404|Drug|Buprenorphine|
79357164|NCT03036904|Drug|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
79669242|NCT01055132|Device|Etafilcon A toric contact lens|contact lens to correct astigmatism
79669243|NCT01055132|Device|Nelfilcon A toric contact lens|contact lens to correct astigmatism
79507969|NCT05765474|Behavioral|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
79507970|NCT05765474|Behavioral|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
79507971|NCT05765422|Other|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
79507972|NCT05765409|Other|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
79507973|NCT05765409|Other|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
79507974|NCT05765357|Drug|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
79507975|NCT05765357|Drug|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
79507976|NCT05765331|Device|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
79507977|NCT05765292|Dietary Supplement|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
79507978|NCT05765292|Dietary Supplement|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
79507979|NCT05765279|Drug|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
79507980|NCT05765279|Drug|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
79357165|NCT03036904|Drug|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
79357166|NCT03036904|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79357167|NCT03036904|Drug|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79507981|NCT05765279|Drug|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
79507982|NCT05765279|Drug|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
79507983|NCT05765240|Drug|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
79507984|NCT05765240|Procedure|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
79507985|NCT05765188|Other|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
79507986|NCT05765162|Behavioral|Patient reported ourcomes|Full screening for the perioperative periode
79507987|NCT05765149|Other|No intervention|This is an observational study, no intervention will be implemented.
79507988|NCT05765110|Other|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
79507989|NCT05765110|Other|DBS OFF state|Turning off the stimulation during experiment
79669244|NCT00460785|Drug|Opioid|
79669245|NCT01054976|Drug|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
79669246|NCT00469443|Drug|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
79991531|NCT03543137|Drug|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
79507990|NCT05765110|Other|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
79507991|NCT05765110|Other|DBS ON state|Experiment will be performed with stimulation (ON condition)
79507992|NCT05765097|Device|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
79507993|NCT05764980|Behavioral|visual function evaluation|visual function evaluation
79507994|NCT05764902|Behavioral|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
79507995|NCT05764850|Genetic|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
79507996|NCT05764837|Other|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
79507997|NCT05764811|Drug|Canagliflozin 100mg|100 mg daily for a month
79507998|NCT05764798|Drug|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
79507999|NCT05764798|Drug|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
79991532|NCT04478188|Other|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
79991533|NCT03723629|Other|No intercention|No intercention
79357168|NCT03036904|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79508000|NCT05764746|Drug|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
79818649|NCT06039878|Behavioral|Distress Relieving Effects of Sucrose|Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
79357169|NCT03036904|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
79357170|NCT03036904|Drug|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
79357171|NCT05608486|Device|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
79357172|NCT02983942|Dietary Supplement|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
79357173|NCT02983942|Dietary Supplement|Routine diet|Routine diet is given without blood ketone requirement
79357174|NCT05608096|Device|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
79508001|NCT05764746|Drug|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
79508002|NCT05764746|Drug|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
79508003|NCT05764668|Drug|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
79508004|NCT05764668|Drug|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
79508005|NCT05763602|Drug|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
79508006|NCT05762367|Diagnostic Test|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
79508007|NCT05762315|Behavioral|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
79508008|NCT05762172|Other|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
79357175|NCT05604898|Drug|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
79508009|NCT05761145|Diagnostic Test|Blood sample collection|Blood sample collection
79508010|NCT05759676|Device|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
79991534|NCT02347462|Device|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
79818650|NCT06039878|Behavioral|Hedonic Response to Sucrose|Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
79991535|NCT02347462|Other|Standard care|Standard care according to the hospital severe asthma protocol
79991536|NCT02895347|Behavioral|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
79991537|NCT05763966|Other|No intervention|Observational study where participants are followed over time
79991538|NCT02347306|Other|Telephone interview|
79991539|NCT02343484|Drug|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
79991540|NCT02343484|Drug|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
79991541|NCT03630276|Diagnostic Test|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
79508011|NCT05759637|Diagnostic Test|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
79508012|NCT05759117|Procedure|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
79508013|NCT05757622|Drug|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
79508014|NCT05757622|Drug|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
79508015|NCT05746650|Procedure|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
79508016|NCT05746650|Drug|Growth hormone (somatropin)|Daily injection of growth hormone
79508017|NCT05746650|Other|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
79669247|NCT00469443|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
79669248|NCT00469443|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
79669249|NCT00469443|Drug|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
79991542|NCT03539549|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
79669250|NCT00469443|Drug|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
79669251|NCT00469443|Drug|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
79669252|NCT00469443|Drug|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
79669253|NCT00460863|Procedure|using cool versus warm dialysate during hemodialysis|
79669254|NCT00428870|Procedure|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
79991543|NCT04173000|Other|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
79669255|NCT00469482|Other|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
79508018|NCT05745649|Other|Resistance exercises|Resistance exercises
79818651|NCT06039878|Behavioral|Typical versus Challenging Feeding-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
79508019|NCT05745649|Other|Ankle weights|Ankle weights
79669256|NCT00469482|Other|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
79669257|NCT00428909|Drug|Imatinib/Acetaminophen|
79669258|NCT00469521|Drug|Refresh Tears, 9582X|
79669259|NCT00429065|Drug|Rituximab|
79508020|NCT05731726|Drug|Serplilumab|"Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w"
79357176|NCT05604898|Other|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
79357177|NCT05604898|Drug|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
79357178|NCT05604898|Other|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
79357179|NCT01544595|Drug|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
79357180|NCT01544595|Drug|Placebo|Placebo
79357181|NCT05600842|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
79357182|NCT04759534|Biological|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
79508021|NCT05731726|Drug|Capecitabine|Given PO
79508022|NCT05731726|Drug|Oxaliplatin|Given IV
79508023|NCT05731726|Drug|Celecoxib|celebrex
79818652|NCT06039878|Behavioral|Caloric Compensation-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
79508024|NCT05715931|Drug|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
79818653|NCT06039878|Behavioral|Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)|When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
79818654|NCT06037668|Device|BVR-100|Experimental self-guided VR intervention for the treatment of SAD
79508025|NCT05715931|Drug|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
79508026|NCT05715931|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
79508027|NCT05714774|Device|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
79357183|NCT05606224|Behavioral|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
79357184|NCT04392700|Drug|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
79357185|NCT04392700|Drug|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
79357186|NCT01539525|Behavioral|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
79357187|NCT01539525|Other|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
79357188|NCT02960620|Device|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
79357189|NCT03827902|Device|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
79357190|NCT03828058|Drug|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
79357191|NCT03828058|Drug|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
79357192|NCT03827590|Drug|Test|three times a day for five days
79357193|NCT03827590|Drug|Active Comparator Control 1|three times a day for five days
79357194|NCT03827590|Drug|Active Comparator Control 2|three times a day for five days
79357195|NCT03827590|Drug|Placebo|three times a day for five days
79357196|NCT03827668|Drug|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
79357197|NCT03827668|Drug|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
79357198|NCT03827668|Drug|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
79357199|NCT02958280|Behavioral|Fit&Sober App|Fit&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
79357200|NCT02958280|Behavioral|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
79818655|NCT06037668|Device|BES-100|Active at-home VR intervention comparator
79818656|NCT06037317|Drug|SY-3505|LTK tyrosine kinase inhibitor
79508028|NCT05708183|Dietary Supplement|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
79508029|NCT05708183|Dietary Supplement|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
79508030|NCT05699317|Other|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
79508031|NCT05698992|Other|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
79508032|NCT05698914|Behavioral|Telehealth mindfulness-based intervention (MBI)|The telehealth MBI is adapted from Mindfulness-based cognitive therapy for chronic pain and consists of eight, weekly 75-minute individual sessions (90 minutes allotted for the first session) with a mindfulness interventionist delivering the intervention over telehealth (online with audio and video camera) in addition to the patient receiving their usual postsurgical care. Participants will begin the intervention after completing the 2-week postoperative assessment and within 4 weeks after surgery. Participants will be asked to practice skills between sessions approximately 20-40 minutes per day.
79508033|NCT05698914|Behavioral|Telehealth Education|Participants will receive a written educational booklet at the time of randomization (within 2-4 weeks after surgery) and 8, weekly telehealth sessions lasting 30 minutes in addition to usual postsurgical care. The educational materials are reviewed individually with the participant during weekly telehealth sessions (online with audio and video camera) by a physical therapist.
79508034|NCT05695378|Drug|KM-819|Subjects will receive KM-819 400 mg orally daily.
79508035|NCT05695378|Drug|Placebo|Subjects will receive Placebo orally daily.
79680093|NCT04693481|Other|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
79680094|NCT02930382|Other|Baroreflex assessment|
79991544|NCT04173000|Other|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
79991545|NCT04478032|Device|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
79991546|NCT04158024|Other|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
79991547|NCT02039206|Device|Deep TMS|1Hz Stimulation
79991548|NCT03506477|Drug|Enstilar® foam|for 4 weeks
79991549|NCT03506477|Drug|Vehicle foam|for 4 weeks
79991550|NCT03149692|Other|Penile allograft transplantation|Proof of concept of surgical procedure
79991551|NCT02351206|Radiation|x-ray, MRI|
79357201|NCT01513551|Biological|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
79357202|NCT01513551|Biological|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
79508036|NCT05686200|Behavioral|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
79508037|NCT05648838|Device|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
79508038|NCT05645744|Biological|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
79508039|NCT05645744|Biological|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
79508040|NCT05640089|Other|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
79508041|NCT05635669|Device|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
79508042|NCT05635669|Device|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
79508043|NCT05635669|Device|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
79991552|NCT03629964|Device|Wiersma Head Stabilizer|Experimental device attached to treatment table.
79991553|NCT03629964|Device|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
79508044|NCT05633680|Diagnostic Test|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
79991554|NCT03726983|Other|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
79508045|NCT05594823|Other|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
79991555|NCT02343328|Biological|Fecal Microbiota Transplant|
79991556|NCT02343328|Biological|Placebo|
79357203|NCT01513551|Biological|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
79508046|NCT05594823|Other|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
79508047|NCT05590741|Behavioral|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
79508048|NCT05589272|Other|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
79357204|NCT03827122|Drug|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
79508049|NCT05589272|Other|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
79508050|NCT05587491|Device|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
79669260|NCT02956941|Behavioral|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
79669261|NCT00429221|Behavioral|Tailored Medication Messages for Parents|
79669262|NCT00460902|Device|Transcranial Magnetic Stimulation (TMS)|
79669263|NCT04704206|Other|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
79991557|NCT04428606|Dietary Supplement|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
79357205|NCT02956642|Device|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
79357206|NCT02956642|Device|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
79357207|NCT03827356|Device|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
79508051|NCT05586022|Procedure|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
79508052|NCT05582915|Diagnostic Test|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
79508053|NCT05581797|Other|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
79508054|NCT05577741|Behavioral|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
79508055|NCT05577741|Behavioral|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
79508056|NCT05577741|Other|Standard treatment|Standard of care treatment
79669264|NCT06189729|Behavioral|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
79680095|NCT02947724|Drug|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
79991558|NCT04428606|Dietary Supplement|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
79357208|NCT03827200|Drug|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
79357209|NCT02983630|Other|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
79508057|NCT05573503|Other|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
79508058|NCT05572580|Other|questionnaire|the patients are asked to fill in a questionnaire
79508059|NCT05565196|Behavioral|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
79508060|NCT05556226|Drug|ABBV-154 Dose Formulation A|Subcutaneous Injection
79508061|NCT05556226|Drug|ABBV-154 Dose Formulation B|Subcutaneous Injection
79508062|NCT05542758|Other|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
79508063|NCT05534815|Behavioral|Employment-based abstinence reinforcement|Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
79508064|NCT05520073|Dietary Supplement|Lactobacillus plantarum|Lactobacillus product 1 pack daily
79508065|NCT05520073|Dietary Supplement|Vitamin C|Vitamin C tablet 1 pack daily
79669265|NCT06189729|Behavioral|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
79669266|NCT06189703|Device|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
79669267|NCT06189690|Device|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
79357210|NCT03827278|Drug|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
79669268|NCT06189677|Other|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
79669269|NCT06189664|Diagnostic Test|Frozen section|Frozen section analysis
79818657|NCT06036602|Biological|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
79818658|NCT06036602|Other|Placebo|0.9% NaCl solution for injection.
79818659|NCT06035120|Device|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
79818660|NCT06035068|Drug|Indocyanine green|Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
79818661|NCT06029127|Drug|BGB-A445|Administered intravenously at protocol defined dose
79818662|NCT06029127|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) administered intravenously
79669270|NCT06189651|Device|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
79818663|NCT06029127|Drug|Tislelizumab|Administered intravenously at protocol defined dose
79818664|NCT06029127|Drug|Sitravatinib|Administered orally at protocol defined dose
79818665|NCT06029127|Drug|Ramucirumab|10 mg/kg administered intravenously
79357211|NCT03826732|Behavioral|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
79357212|NCT01513473|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
79357213|NCT01513473|Drug|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
79357214|NCT01513473|Drug|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
79357215|NCT04346368|Biological|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).
79357216|NCT04346368|Biological|Placebo|Placebo
79357217|NCT03826810|Radiation|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
79669271|NCT06189651|Procedure|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
79818666|NCT06029127|Drug|Selected Interventions|Administered at protocol defined dose
79508066|NCT05512260|Device|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
79357218|NCT03826810|Procedure|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
79357219|NCT03826654|Dietary Supplement|fortified oil|35 g fortified sunflower oil
79357220|NCT03826654|Dietary Supplement|Placebo|plain oil
79508067|NCT05510544|Drug|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
79508068|NCT05510492|Other|EDUCATION|THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,
79357221|NCT03109990|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
79357222|NCT03109990|Drug|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
79357223|NCT03826420|Behavioral|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
79818667|NCT06029127|Drug|BGB-15025|Administered orally at protocol defined dose
79357224|NCT03826420|Behavioral|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
79357225|NCT03826420|Behavioral|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
79357226|NCT03825562|Behavioral|acceptance and commitment therapy, ACT|
79357227|NCT01513317|Drug|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
79357228|NCT01513317|Drug|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
79357229|NCT01513317|Drug|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
79357230|NCT03825484|Drug|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
79357231|NCT02983474|Procedure|cholecystectomy|"Laparoscopic surgery~Reverse Trendelenburg position~Skin incision and trocar insertion~CO2 gas insufflation~Intra-abdominal inspection and gallbladder exposure~Gallbladder traction~Calot triangle exposure~Cystic artery and cystic duct isolation~Gallbladder bed dissection~Bleeding control~Gallbladder extraction~Trocar removal and wound closure~Open surgery~Supine position~Skin incision~Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
79357232|NCT04105179|Device|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
79357233|NCT04105179|Device|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
79357234|NCT03066310|Diagnostic Test|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
79357235|NCT03825640|Behavioral|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
79357236|NCT04274452|Biological|efgartigimod|Intravenous infusion of efgartigimod
79508069|NCT05510492|Other|APPLIED EDUCATION|"the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then"
79508070|NCT05509699|Drug|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
79680096|NCT02936583|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
79680097|NCT02936544|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code:Z09-054)
79508071|NCT05509699|Drug|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
79508072|NCT05506618|Diagnostic Test|Nasal Swab|Collection of one more nasal swabs
79508073|NCT05506618|Diagnostic Test|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
79508074|NCT05505903|Diagnostic Test|Temerature measurement|Temerature measurement on admission to WBN or NICU
79508075|NCT05500365|Procedure|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
79357237|NCT04274452|Other|Placebo|Intravenous infusion of placebo
79508076|NCT05495126|Diagnostic Test|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 & Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
79508077|NCT05495126|Diagnostic Test|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
79508078|NCT05488119|Behavioral|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
79357238|NCT03825328|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
79508079|NCT05460715|Device|Quadra P anteverted|"Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~Assessment of functional recovery by gait analysis study~Collect the rate of complications throughout the course of the study"
79508080|NCT05444803|Other|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
79508081|NCT05444803|Other|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
79508082|NCT05443399|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
79508083|NCT05443399|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
79357239|NCT03825328|Drug|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
79357240|NCT03825328|Drug|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
79357241|NCT03825328|Drug|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
79357242|NCT03057184|Behavioral|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
79508084|NCT05443399|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
79508085|NCT05426200|Behavioral|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
79680098|NCT02936427|Drug|Dexamethasone|perineural infiltration of dexamethasone
79680099|NCT00523913|Drug|rosiglitazone|
79680100|NCT02930499|Device|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
79680101|NCT02930499|Device|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
79357243|NCT03825016|Drug|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
79357244|NCT03825016|Drug|Diclofenac Sodium|Oral Diclofenac Sodium
79357245|NCT04392466|Other|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
79357246|NCT03043924|Drug|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
79357247|NCT03043924|Drug|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
79508086|NCT05410366|Other|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
79508087|NCT05407376|Other|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
79508088|NCT05396170|Procedure|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
79508089|NCT05378386|Device|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
79508090|NCT05338125|Procedure|Micro-electrode measurement|Electrophysiological measurement with single-unit micro-electrode
79508091|NCT05335772|Behavioral|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
79508092|NCT05335772|Behavioral|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
79508093|NCT05321342|Behavioral|BCCU|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, & Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator [developed at UCF; Dieker, Hynes, Hughes, & Smith, 2008], and self-monitoring) and utilizing motivational interviewing (Miller & Rollnick, 2012) to empower teacher practice change.
79508094|NCT05315310|Device|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
79508095|NCT05294718|Procedure|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
79669272|NCT06189638|Drug|Antimicrobial Peptide PL-5 Topical Spray and Placebo|Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
79669273|NCT06189612|Other|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
79991559|NCT04428606|Dietary Supplement|Placebo|Placebo
79669274|NCT06189612|Other|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
79669275|NCT06189612|Other|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
79669276|NCT06189586|Drug|aerosol inhalation of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
79669277|NCT06189586|Drug|intravenous injection of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
79669278|NCT06189573|Procedure|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
79680102|NCT02947763|Drug|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
79991560|NCT02343016|Device|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
79991561|NCT02343094|Drug|PBA 7,5g/d|Treatment for 14 days with PBA
79357248|NCT03824548|Other|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
79357249|NCT03824314|Drug|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
79508096|NCT05294718|Procedure|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
79357250|NCT03824314|Drug|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
79357251|NCT03824392|Biological|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
79508097|NCT05269953|Device|Active stimulation|Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
79508098|NCT05269953|Device|Sham stimulation|Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
79508099|NCT05256641|Drug|Acalabrutinib|Given PO
79508100|NCT05249543|Behavioral|Unified protocol|Transdiagnostic cognitive-behavioral therapy
79508101|NCT05249543|Behavioral|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
79508102|NCT05228652|Other|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
79669279|NCT06189573|Procedure|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
79669280|NCT06189547|Other|different prior cancer history type|different types of prior cancer history
79508103|NCT05226130|Device|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
79818669|NCT06022614|Drug|Use Bupivacaine 0.25% Injectable Solution|Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.
79357252|NCT03824392|Biological|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
79508104|NCT05226130|Device|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
79508105|NCT05219916|Procedure|Blood collection.|"One additional 80 mL blood collection will be collected from HIV patients during a scheduled blood collection as part of their regular follow-up.~Samples will be transported within 3-5 hours by a carrier approved for the transportation of infectious biological samples from the Croix Rousse hospital to the P3 laboratory of the Ecole Normale Supérieure, Lyon for analysis."
79508106|NCT05219318|Drug|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response after 12 months of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
79508107|NCT05219318|Other|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
79508108|NCT05214534|Other|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
79669281|NCT06189534|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
79669282|NCT06189521|Other|Extracorporeal shock wave group|In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).
79669283|NCT06189521|Other|ultrasound group|In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
79818670|NCT06022614|Drug|Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine|Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine
79991562|NCT02343094|Drug|PBA 15g/d|Treatment for 14 days with PBA
79991563|NCT03073980|Drug|IV Acetaminophen|IV Acetaminophen for pain control during procedure
79991564|NCT03073980|Drug|PO Acetaminophen|PO Acetaminophen for pain control during procedure
79991565|NCT03073980|Other|Placebo IV Acetaminophen|Placebo IV Acetaminophen
79508109|NCT05187533|Other|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
79991566|NCT03073980|Other|Placebo PO Acetaminophen|Placebo PO Acetaminophen
79991567|NCT02347384|Device|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
79357253|NCT03824392|Biological|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
79357254|NCT02976922|Dietary Supplement|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
79508110|NCT05177588|Drug|Metformin Hydrochloride|Metformin 2000 mg/day
79508111|NCT05174078|Other|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
79669284|NCT06189521|Other|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
79991568|NCT02347384|Device|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
79991569|NCT03146416|Drug|Evinacumab|SC or IV administration of Evinacumab
79991570|NCT03146416|Drug|Placebo|Matching placebo
79991571|NCT03146572|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
79357258|NCT03824002|Drug|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
79357259|NCT03824002|Drug|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
79357260|NCT03824002|Drug|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
79357261|NCT03824002|Drug|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
79357262|NCT03824002|Drug|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
79508112|NCT05174078|Other|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
79508113|NCT05171660|Drug|Sintilimab Injection|Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
79680103|NCT02947841|Other|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
79680104|NCT02947841|Other|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
79991572|NCT03146572|Other|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
79991573|NCT03149458|Other|dance|dance program
79991574|NCT03149458|Other|control|upper limb rehabilitation
79991575|NCT03930186|Drug|Apremilast|Tablets for oral administration
79991576|NCT03930186|Drug|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
79991577|NCT02351362|Behavioral|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
79991578|NCT02351440|Drug|duloxetine|patients will be randomized to receive either duloxetine or placebo
79818671|NCT06021275|Other|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
79508114|NCT05171660|Drug|Control Test|XELOX + Bevacizumab
79680105|NCT02930421|Other|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
79818672|NCT06021275|Other|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
79357263|NCT03823846|Drug|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
79818673|NCT06018038|Diagnostic Test|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
79357264|NCT03823846|Drug|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
79357265|NCT03823846|Drug|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
79508115|NCT05156034|Drug|SRK-001|Participants will receive IV doses of SRK-001.
79680106|NCT00523952|Drug|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
79680107|NCT02936349|Other|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
79508116|NCT05156034|Drug|Placebo|Participants will receive IV doses of placebo.
79669285|NCT06189495|Drug|GenSci048|1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
79669286|NCT06189495|Drug|GenSci048 placebo|"1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
79357266|NCT03823846|Drug|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
79357267|NCT03823846|Other|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
79357268|NCT03823846|Drug|normal analgesia pump administration|Dose of analgesia pump was added if needed.
79508117|NCT05133258|Other|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
79508118|NCT05059873|Drug|Prednisone|Oral prednisone 40mg/day for five consecutive days
79669287|NCT06189456|Device|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
79680108|NCT00524069|Biological|bevacizumab|
79818674|NCT06015048|Drug|SHR-A1811 combined with Pyrotinib.|SHR-A1811 combined with Pyrotinib
79818675|NCT06015048|Drug|SHR-A1811 combined with other antitumor therapies|SHR-A1811 combined with other antitumor therapies
79818676|NCT06010628|Drug|Tenecteplase|intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
79818677|NCT06010303|Drug|LBL-007|LBL-007 will be administered at a standard dose intravenously.
79818678|NCT06010303|Drug|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
79818679|NCT06010303|Drug|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
79357269|NCT03823846|Drug|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
79357270|NCT02908750|Drug|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
79357271|NCT02908750|Drug|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
79357272|NCT03823612|Drug|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
79508119|NCT05059873|Drug|Placebo|Oral placebo of 40mg/day for five consecutive days
79818680|NCT06004141|Behavioral|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
79818681|NCT06001125|Drug|Methotrexate|Methotrexate 20 mg PO weekly
79818682|NCT06000410|Biological|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
79508120|NCT05055024|Drug|Mazindol|Drug: NLS-2
79508121|NCT05051644|Behavioral|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
79357273|NCT03823612|Drug|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
79357274|NCT03823924|Procedure|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
79357275|NCT04273906|Procedure|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
79357276|NCT04273906|Procedure|Placebo technique|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
79357277|NCT02834104|Device|RMI|
79669288|NCT06189456|Device|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
79669289|NCT06189443|Other|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
79669290|NCT06189430|Other|Yoga|Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation. The yoga intervention we recommend was created within the framework of the asanas that the elderly can do in the literature and by taking the expert opinion of a sports physician.
79669291|NCT06189430|Other|Standard exercise|It is a type of exercise similar in intensity to vinyasa yoga. (50-70% MHR: maximum pulse rate)
79680109|NCT00524069|Drug|capecitabine|
79991579|NCT02351440|Drug|placebo|placebo
79357278|NCT02834104|Other|myocardial biopsy|
79357279|NCT02834104|Biological|blood sample|
79508122|NCT05051644|Behavioral|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
79680110|NCT00524069|Drug|gemcitabine hydrochloride|
79680111|NCT00524069|Other|flow cytometry|
79680112|NCT00524069|Other|laboratory biomarker analysis|
79680113|NCT00524069|Procedure|adjuvant therapy|
79680114|NCT00524069|Procedure|computed tomography|
79818683|NCT06000410|Drug|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
79991580|NCT03504917|Drug|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
79991581|NCT03504917|Drug|Placebo|Participants will receive matching placebo.
79991582|NCT02343172|Drug|HDM201|
79991583|NCT02343172|Drug|LEE011|
79991584|NCT03899688|Procedure|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
79357280|NCT03823222|Dietary Supplement|Duckweed protein|20 grams isolated protein
79357281|NCT03823222|Dietary Supplement|Whey protein|20 grams isolated protein
79357282|NCT03823066|Device|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
79357283|NCT02810704|Drug|Enteric Coated Aspirin|
79357284|NCT02810704|Drug|Warfarin|
79357285|NCT02810704|Drug|Rivaroxaban|
79357286|NCT04392076|Procedure|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
79357287|NCT02790424|Device|Imaging devices|technological adjustment tests
79357288|NCT02738398|Radiation|FDG PET/CT|
79357289|NCT03822988|Other|no intervention, only complete a survey|we will ask patients to answer to a survey
79508123|NCT05045664|Radiation|Standard|12 x 2 Gy involved site radiotherapy plus Rituximab
79508124|NCT05045664|Radiation|Experimental|2 x2 Gy involved site radiotherapy plus Obinutuzumab
79508125|NCT05045664|Drug|Standard|Rituximab with 12 x 2 Gy involved site radiotherapy
79508126|NCT05045664|Drug|Experimental|Obinutuzumab with 2 x2 Gy involved site radiotherapy
79508127|NCT05037552|Procedure|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
79357290|NCT03822754|Biological|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
79508128|NCT05037552|Procedure|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
79508129|NCT05012631|Drug|Losartan|Losartan dosing for participants <16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
79508130|NCT04990479|Biological|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
79508131|NCT04990479|Biological|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
79508132|NCT04985227|Other|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
79508133|NCT04966091|Other|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
79508134|NCT04954196|Drug|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~The frozen embryo transfer will be performed 6 days after progesterone initiation.~The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
79680115|NCT00524069|Procedure|neoadjuvant therapy|
79680116|NCT02936193|Procedure|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
79357291|NCT03822754|Biological|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
79357292|NCT03822676|Device|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
79357293|NCT02926222|Drug|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
79357294|NCT02926222|Drug|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
79680117|NCT02936193|Procedure|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
79680118|NCT00524810|Drug|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
79680119|NCT00524810|Drug|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
79680120|NCT00524849|Biological|Zoledronic acid|Zometa 1 mg weekly (intravenous)
79991585|NCT02351128|Drug|Lanreotide|
79508135|NCT04954196|Drug|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~The frozen embryo transfer will be performed 6 days after progesterone initiation.~The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
79357295|NCT01453816|Procedure|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
79818684|NCT06000098|Other|Restrictive fluid therapy|"0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down)."
79357296|NCT04273282|Drug|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
79357297|NCT04273282|Drug|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
79357298|NCT04391530|Behavioral|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
79508136|NCT04944290|Drug|Brinzolamide/brimonidine ophthalmic suspension|Test product
79508137|NCT04944290|Drug|Simbrinza 0.2%/1% Ophthalmic Suspension|Reference product
79508138|NCT04937166|Biological|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
79669292|NCT06189417|Behavioral|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
79669293|NCT06189404|Drug|Tigulixostat|300 mg oral dose
79357299|NCT01453972|Behavioral|Long distanse moderate training|Moderate exercise
79818685|NCT05991960|Device|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
79818686|NCT05988970|Other|Blood samples will be collected at two times before the treatment initiation:|"at 4:00 a.m.~at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable)."
79818687|NCT05987917|Device|BTL-785-2|Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
79357300|NCT01453972|Behavioral|Long interval training|High-intensity exercise, long duration
79357301|NCT01453972|Behavioral|Short interval training|High intensity exercise, short duration
79357302|NCT01454206|Behavioral|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
79357303|NCT01454440|Drug|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure) vs placebo.
79357304|NCT01454518|Procedure|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
79357305|NCT01454518|Procedure|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
79357306|NCT01454674|Other|2, 5 & 10 Vegetable doses|2,5 & 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers & tomatoes consumed for 3 week intervals
79357307|NCT01454986|Drug|ALXN1007|Single dose, IV
79357308|NCT01454986|Other|Placebo|Single dose, IV
79357309|NCT02983084|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
79508139|NCT04937166|Drug|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
79669294|NCT06189404|Drug|Theophylline|400 mg oral dose
79357310|NCT01455142|Drug|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
79357311|NCT01455298|Other|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
79357312|NCT01455376|Drug|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
79357313|NCT01455532|Drug|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
79357314|NCT01455532|Drug|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
79357315|NCT01455532|Drug|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
79357316|NCT01455532|Drug|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
79357317|NCT01455532|Drug|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
79357318|NCT01455688|Drug|early HAART|Initiation of HAART within 5 days of ICU admission
79357319|NCT01455688|Drug|Late HAART|Initiation of HAART after ICU discharge
79357320|NCT01455844|Drug|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
79357321|NCT01455844|Other|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
79357322|NCT01455844|Drug|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
79357323|NCT01455922|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
79357324|NCT01455922|Drug|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
79357325|NCT01456156|Radiation|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
79357326|NCT04391140|Other|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
79357327|NCT01456234|Drug|Oseltamivir|Oseltamivir 75 mg BID
79357328|NCT01456312|Drug|Peginterferon alfa-2a|Duration and combination
79357329|NCT01456312|Drug|Entecavir|combination
79357330|NCT05587114|Diagnostic Test|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
79357331|NCT01456468|Drug|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
79357332|NCT01456546|Drug|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
79357333|NCT01456546|Drug|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
79357334|NCT01456624|Drug|Megace|800mg
79357335|NCT01456624|Drug|DW-ES(B)|625mg
79357336|NCT01456702|Procedure|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
79357337|NCT01456858|Other|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
79357338|NCT01456858|Other|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
79357339|NCT01457092|Device|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
79357340|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
79357341|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
79508140|NCT04937166|Drug|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
79508141|NCT04922840|Behavioral|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
79357342|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
79508142|NCT04921488|Device|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
79669295|NCT06189352|Other|Positive feeding of the preterm infant|Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
79669296|NCT06189339|Diagnostic Test|non-cancerous cyst|For patients who have a pancreatic cyst bigger than 2cm found during a radiology exam, they will undergo an Endoscopic ultrasound exam to check the cyst and fluid will be collected for testing, including glucose, CEA (carcinoembryonic antigen), and amylase. A biopsy will be done if possible. We will analyze how well the glucose level in the fluid can tell us if the cyst is cancerous or not, using CEA level, EUS findings, and amylase level as the standard. This is an observational study, and patients will receive standard medical treatment.
79669297|NCT06189339|Diagnostic Test|cancerous cyst.|For patients who have a pancreatic cyst bigger than 2cm found during a radiology exam, they will undergo an Endoscopic ultrasound exam to check the cyst and fluid will be collected for testing, including glucose, CEA (carcinoembryonic antigen), and amylase. A biopsy will be done if possible. We will analyze how well the glucose level in the fluid can tell us if the cyst is cancerous or not, using CEA level, EUS findings, and amylase level as the standard. This is an observational study, and patients will receive standard medical treatment.
79991586|NCT01378182|Genetic|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
79991587|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
79669298|NCT06189326|Procedure|non-penetrating deep sclerectomy|Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
79680121|NCT00524849|Drug|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
79680122|NCT02936154|Drug|PF-06650833|
79991588|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
79991589|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
79357343|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
79357344|NCT01457404|Behavioral|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
79357345|NCT01457404|Behavioral|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
79357346|NCT01457482|Other|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
79357347|NCT01457482|Other|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
79357348|NCT01457560|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
79357349|NCT01457560|Biological|OPV|One dose administered orally
79357350|NCT04758442|Other|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
79669299|NCT06189326|Procedure|primary combined trabeculotomy-trabeculectomy|Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
79669300|NCT06189300|Other|Education and counseling intervention|In addition to standard training, training and consultancy will be provided to individuals with stoma intermittently within a month.
79818688|NCT05987917|Other|No Treatment|The subject who will serve as control will not be treated with the study device.
79818689|NCT05983250|Drug|TNX-103|levosimendan 1 mg
79357351|NCT01457638|Procedure|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
79357352|NCT01457638|Procedure|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
79357353|NCT01457716|Drug|Budesonide|Single inhalation
79357354|NCT01457716|Drug|Formoterol|Single inhalation
79357355|NCT01457716|Device|Easyhaler|Inhaler device
79357356|NCT01457716|Device|Turbohaler Forte|Inhaler device
79669301|NCT06189274|Other|Anatomy-Based Electrode Array Selection|Use of pre-operative imaging to select the appropriate length electrode vs standard of care
79818690|NCT05983250|Drug|Placebo|Placebo
79818691|NCT05983068|Drug|dupilumab|solution for injection; by subcutaneous (SC) injection
79357357|NCT01457872|Behavioral|Strength-based case management|Strength-based case management
79357358|NCT01457872|Behavioral|Control condition - referral only|Referral only
79357359|NCT04391218|Other|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
79669302|NCT06189274|Other|Standard of Care Electrode Array Selection|Use of standard of care electrode which is the FLEX 28 electrode
79818692|NCT05981365|Drug|Voxelotor|Drug drug interaction
79818693|NCT05981365|Drug|Bupropion|Drug drug interaction
79818694|NCT05981365|Drug|Repaglinide|Drug drug interaction
79818695|NCT05981365|Drug|Flurbiprofen|Drug drug interaction
79818696|NCT05981365|Drug|Omeprazole|Drug drug interaction
79508143|NCT04920032|Drug|TAS-102|Given PO
79508144|NCT04920032|Drug|Irinotecan|Given IV
79508145|NCT04920032|Combination Product|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
79508146|NCT04920032|Diagnostic Test|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
79508147|NCT04908176|Drug|Avapritinib|avapritinib tablets
79508148|NCT04908176|Drug|midazolam|midazolam syrup
79680123|NCT02936154|Drug|placebo|
79680124|NCT00524888|Procedure|suturing laceration|suturing simple lacerations of the hand
79680125|NCT00524888|Procedure|bioadhesive|using bioadhesive on simple lacerations of the hand
79680126|NCT02936115|Other|TruSkin®|
79680127|NCT02936115|Other|Wound Cover|
79680128|NCT00524927|Drug|Methoxyflurane|
79818697|NCT05981365|Drug|Midazolam|Drug drug interaction
79818698|NCT05981365|Drug|Metformin|Drug drug interaction
79818699|NCT05981365|Drug|Furosemide|Drug drug interaction
79818700|NCT05981365|Drug|Rosuvastatin|Drug drug interaction
79818701|NCT05980949|Drug|KarXT|KarXT 20/2 mg TID (total daily dose [TDD] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
79991590|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
79991591|NCT02342938|Procedure|MEG or fMRI And INtracranial EEG|
79991592|NCT02342938|Procedure|fMRI|
79508149|NCT04906525|Behavioral|Resistance training|Participants will undergo 6 weeks of supervised resistance training
79508150|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
79508151|NCT04882540|Drug|brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 100 mg tablets~Route of administration: Oral use"
79508152|NCT04881721|Procedure|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
79508153|NCT04859829|Other|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
79508154|NCT04859829|Other|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
79669303|NCT06189261|Other|Holistic needs assessment based on the use of patient-reported outcome measures|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
79669304|NCT06189248|Behavioral|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
79818702|NCT05978037|Biological|RH5.1 and/or RH5.2-VLP with Matrix-M|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."
79508155|NCT04851158|Device|Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
79669305|NCT06189235|Other|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
79680129|NCT00524927|Drug|Normal Saline|
79357360|NCT04391296|Procedure|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
79357361|NCT04346602|Other|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
79357362|NCT01458028|Drug|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
79357363|NCT01458028|Drug|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
79357364|NCT01458262|Other|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
79508156|NCT04851158|Device|Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
79508157|NCT04808076|Procedure|Shunt surgery|Shunt operation
79508158|NCT04801680|Device|Mpact 3D metal cup|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
79508159|NCT04801654|Diagnostic Test|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
79679674|NCT02949167|Behavioral|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
79818703|NCT05972941|Behavioral|Health communications|Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.
79818704|NCT05966844|Behavioral|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
79357365|NCT01458496|Behavioral|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
79508160|NCT04784260|Other|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
79508161|NCT04778267|Drug|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
79508162|NCT04778267|Drug|Dexamethasone phosphate|used as additive to bupivacaine
79508163|NCT04744454|Drug|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
79991593|NCT01569672|Behavioral|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
79357366|NCT01458652|Drug|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
79508164|NCT04735471|Genetic|ADI-001|Anti-CD20 CAR-T
79508165|NCT04735471|Drug|Fludarabine|Chemotherapy for Lymphodepletion
79508166|NCT04735471|Drug|Cyclophosphamide|Chemotherapy for Lymphodepletion
79679675|NCT02941068|Drug|fluconazole and caspofungin|
79679676|NCT00517712|Drug|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
79818705|NCT05966662|Device|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
79818706|NCT05960578|Drug|Apalutamide|Given PO
79818707|NCT05960578|Procedure|Biopsy|Undergo tumor biopsy
79818708|NCT05960578|Procedure|Biospecimen Collection|Undergo collection of blood samples
79818709|NCT05960578|Procedure|Computed Tomography|Undergo CT scan
79991594|NCT01569672|Behavioral|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
79991595|NCT02342860|Other|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~Software: operations and maintenance (O&M) training for teachers, hygiene training, and basic hygiene package."
79991596|NCT03146260|Procedure|Conventional TESE|usual procedure for sperm extraction
79991597|NCT03146260|Procedure|Microdissection TESE|Procedure of extraction is performed under the operating microscope
79991598|NCT03536663|Device|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
79357367|NCT01458886|Drug|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
79357368|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
79357369|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
79357370|NCT01458886|Drug|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
79357371|NCT02880982|Dietary Supplement|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
79357372|NCT02880982|Other|Placebo|Weekly oral placebo softgel capsule
79508167|NCT04718181|Drug|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
79508168|NCT04718181|Drug|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
79679677|NCT00518843|Behavioral|FBT-BN|Mobilizing parents to curtail binge eating and purging
79991599|NCT03770052|Drug|duvie|take the intervention drug once daily according to the randomized groups
79991600|NCT02351050|Device|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
79991601|NCT02351050|Other|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
79991602|NCT02350894|Behavioral|Graded and behavevial theraphy|Graded and behavevial theraphy
79991603|NCT03565211|Drug|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
79991604|NCT02346994|Dietary Supplement|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
79357373|NCT01458964|Drug|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
79679678|NCT00518843|Behavioral|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
79680130|NCT02936310|Behavioral|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
79818710|NCT05960578|Drug|Golimumab|Given SC
79818711|NCT05960578|Procedure|Magnetic Resonance Imaging|Undergo MRI
79818712|NCT05960578|Procedure|PSMA PET Scan|Undergo PSMA PET
79818713|NCT05957367|Drug|DCC-3116|Oral Tablet Formulation
79818714|NCT05957367|Drug|Ripretinib|Oral Tablet Formulation
79991605|NCT02346994|Dietary Supplement|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
79991606|NCT02346760|Drug|UB-621|100 mg/ml, subcutaneous injection
79508169|NCT04696497|Diagnostic Test|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~Shoulder Side muscular compartment~Anterior Arm muscular compartment~Anterior thigh muscular compartment~Antero-lateral leg muscular compartment"
79679679|NCT00517907|Drug|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
79357374|NCT01459120|Other|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
79357375|NCT01459120|Other|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
79357376|NCT01459198|Biological|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10^5 or 10^6 plaque-forming units (PFU), depending on study arm.
79357377|NCT01459198|Biological|Placebo vaccine|Given intranasally once at a baseline study visit
79357378|NCT01459276|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
79508170|NCT04696497|Diagnostic Test|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
79679680|NCT02939274|Drug|Verteporfin|
79679681|NCT02939274|Device|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
79679682|NCT00518921|Drug|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
79991607|NCT02342626|Behavioral|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
79508171|NCT04696497|Diagnostic Test|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
79508172|NCT04661384|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
79508173|NCT04656301|Drug|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
79508174|NCT04651153|Drug|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
79228414|NCT02235753|Behavioral|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
79357379|NCT01459276|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
79357380|NCT02490904|Drug|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
79357381|NCT02490904|Drug|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
79357382|NCT01459432|Other|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
79357383|NCT04390984|Drug|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
79357384|NCT02878408|Genetic|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
79357385|NCT01459900|Procedure|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
79357386|NCT01459900|Procedure|Renal angiography|Renal angiography by femoral access.
79357387|NCT01459978|Other|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
79357388|NCT02874898|Behavioral|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
79357389|NCT02873806|Procedure|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
79357390|NCT02873806|Drug|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
79357391|NCT02873806|Device|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
79357392|NCT02873806|Drug|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
79357393|NCT02873806|Drug|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~Week 1: 1 drop four (4) times per day in the study eye~Week 2: 1 drop three (3) times per day in the study eye~Week 3: 1 drop two (2) times per day in the study eye~Week 4: 1 drop one (1) time per day in the study eye"
79357394|NCT01890382|Dietary Supplement|Whey protein|30 g in total; twice a day (morning and evening)
79357395|NCT01890382|Dietary Supplement|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
79508175|NCT04651153|Other|Placebo|Subjects will receive Placebo at pre-specified time-points.
79508176|NCT04644692|Other|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
79508177|NCT04598711|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
79508178|NCT04598711|Behavioral|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
79508179|NCT04598711|Behavioral|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
79508180|NCT04598711|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
79679683|NCT00518921|Drug|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
79679684|NCT00518921|Drug|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
79679685|NCT00518921|Drug|Placebo|Placebo, double dummy
79357396|NCT01890382|Dietary Supplement|leucine supplementation|7.5 g/d in total; three times per day
79357397|NCT01890382|Dietary Supplement|soy protein|30 g in total; twice a day
79357398|NCT01890382|Dietary Supplement|creatine|6.0 g in total; twice a day
79508181|NCT04598711|Behavioral|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
79508182|NCT04597047|Diagnostic Test|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
79679686|NCT02940678|Other|No intervention|
79508183|NCT04597047|Diagnostic Test|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
79508184|NCT04587518|Behavioral|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons [long and short-term consequences] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
79818715|NCT05957367|Drug|Cetuximab|Solution for Injection
79818716|NCT05957367|Drug|Encorafenib|Oral capsule formulation
79818717|NCT05956756|Behavioral|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
79818718|NCT05955846|Procedure|cataract surgery|Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
79818719|NCT05955846|Device|implantation of device IOL FG-80030.1|implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
79357399|NCT01890382|Dietary Supplement|placebo|
79357400|NCT01890616|Device|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
79357401|NCT01890772|Drug|Telaprevir|
79357402|NCT01890772|Drug|Peginterferon alfa-2a|
79357403|NCT01890772|Drug|Ribavirin|
79357404|NCT01890772|Dietary Supplement|Vitamin D|
79357405|NCT01890850|Other|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
79357406|NCT02816788|Behavioral|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
79357407|NCT01891006|Device|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
79357408|NCT01891006|Other|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
79357409|NCT04272112|Combination Product|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
79508185|NCT04573504|Drug|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
79508186|NCT04573504|Drug|Placebo|Placebo
79508187|NCT04560972|Drug|Atezolizumab|Given IV
79508188|NCT04560972|Drug|Carboplatin|Given IV
79508189|NCT04560972|Drug|Etoposide|Given IV
79508190|NCT04560972|Drug|Protein Phosphatase 2A Inhibitor LB-100|Given IV
79508191|NCT04545385|Drug|TEV-48574|subcutaneous infusion
79508192|NCT04545385|Drug|Placebo|Matching Placebo
79508193|NCT04542421|Diagnostic Test|Lung ultrasound use in patients hospitalized with COVID|Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
79508194|NCT04532814|Other|Exercise|Cycling 60% VO2 max
79508195|NCT04521335|Drug|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
79818720|NCT05952947|Biological|HRYZ-T101 Injection|On day 1, the TCR-T cells will be administered intravenously.
79991608|NCT03723395|Drug|tucatinib|300mg dose, orally administered
79508196|NCT04521335|Drug|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
79508197|NCT04515615|Drug|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
79508198|NCT04515615|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
79508199|NCT04515615|Drug|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
79679687|NCT00516659|Biological|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
79679688|NCT00516659|Biological|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
79679689|NCT00518960|Drug|ProAlgaZyme|
79679690|NCT02940600|Device|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
79818721|NCT05952947|Drug|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
79818722|NCT05952037|Drug|BGB-11417|Administered orally as a tablet.
79357410|NCT04272112|Combination Product|BruxZir, Glidewell|Type: high translucent zirconia
79357411|NCT04272112|Combination Product|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
79357412|NCT04272346|Behavioral|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
79357413|NCT04272346|Behavioral|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
79357414|NCT04272346|Behavioral|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
79357415|NCT01891084|Drug|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
79357416|NCT01891084|Drug|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
79357417|NCT01891084|Drug|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
79357418|NCT01891474|Device|U-health care|voice inception technique based U-healthcare service
79357419|NCT01891708|Other|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
79357420|NCT01891786|Behavioral|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
79357421|NCT01891786|Behavioral|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
79357422|NCT01891942|Procedure|twitch by magstim|
79357423|NCT01892098|Dietary Supplement|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
79508200|NCT04508582|Diagnostic Test|Cardiovascular magnetic resonance|Imaging of the heart with CMR, without use of contrast agents.
79508201|NCT04508582|Diagnostic Test|Echocardiography|Imaging of the heart with ultrasound.
79991609|NCT03723395|Drug|itraconazole|200mg dose
79508202|NCT04508582|Diagnostic Test|Blood test|Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
79508203|NCT04502563|Other|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
79508204|NCT04502563|Other|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
79508205|NCT04462458|Device|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
79508206|NCT04454645|Behavioral|mABC|Intervention targets parenting sensitivity and nurturance.
79508207|NCT04454645|Behavioral|mDEF|Intervention targets parenting enhancing infant cognitive development
79508208|NCT04438161|Behavioral|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
79669306|NCT06189222|Device|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li & Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
79669307|NCT06189209|Drug|Tenalisib|Tenalisib will be administered 800mg BID, orally
79357424|NCT01892098|Dietary Supplement|Placebo|Cellulose pill given as placebo
79818724|NCT05939414|Drug|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
79508209|NCT04431661|Procedure|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
79818725|NCT05936151|Drug|LY3437943|Administered SC
79818726|NCT05936151|Drug|Placebo|Administered SC
79991610|NCT03723395|Drug|rifampin|600mg dose
79991611|NCT03723395|Drug|gemfibrozil|600mg tablets
79357425|NCT01892176|Dietary Supplement|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
79357426|NCT01892254|Drug|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
79679691|NCT02940600|Procedure|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
79991612|NCT03723395|Drug|repaglinide|1mg dose
79357427|NCT01892254|Drug|Placebo|Placebo (to metformin)
79357428|NCT01892332|Drug|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
79508210|NCT04431661|Procedure|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
79508211|NCT04431661|Procedure|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
79679692|NCT02949401|Behavioral|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
79357429|NCT01892488|Drug|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
79508212|NCT04419675|Other|Observational Cohort, usual care = physical therapy|usual care = physical therapy
79508213|NCT04406584|Procedure|Injection into olfactory cleft|Already stated above.
79991613|NCT03723395|Drug|tolbutamide|500mg dose
79991614|NCT03723395|Drug|midazolam|2mg dose
79991615|NCT03723395|Drug|digoxin|0.5 mg dose
79669308|NCT06189196|Device|BLOW BOTTLE|Blow Bottle PEP' is the cost-effective device comparative to other PEP devices. Treatment (CPT) along with BBPEP twice a day. Therapist made a cost-effective BBPEP which generates 10 cm of H2O PEP and it was given for 10 breaths, 3 sets with 5 second hold.
79357430|NCT01892488|Drug|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
79357431|NCT04390204|Other|intervenions|"Motor control exercises~A supervised home self-rehabilitation program"
79508214|NCT04399772|Behavioral|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
79669309|NCT06189196|Other|ACBT|Active cycle of breathing technique (ACBT) is an alternative airway clearance technique. A typical ACBT cycle consists of breathing control, three to four thoracic expansion exercises, and a forced expiratory technique (huffing). ACBT has been shown to improve short-term secretion clearance in patients with chronic lung disease. It is also flexible, tolerated, and accepted well by patients. Although ACBT is widely used in patients with respiratory conditions characterized by chronic sputum production.
79357432|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
79357433|NCT01892644|Other|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
79669310|NCT06189157|Biological|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
79357434|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
79357435|NCT01892878|Procedure|VerteLoc|Single Arm
79357436|NCT01892956|Other|Nutritional intervention|"2 dietary interventions~personalized diet based on algorithm predictions of glucose response to foods~Mediterranean-style diet"
79991616|NCT01377948|Behavioral|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
79357437|NCT01893034|Procedure|Arthroscopic treatment of femoroacetabular impingement|
79357438|NCT01893034|Other|Physiotherapy and activity modification|
79357439|NCT02804230|Device|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
79357440|NCT01901653|Drug|Rovalpituzumab tesirine (SC16LD6.5)|
79357441|NCT01925989|Biological|LY2605541|Administered SQ
79991617|NCT02350738|Other|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
79357442|NCT01925989|Biological|Insulin Glargine|Administered SQ
79991618|NCT02350738|Other|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
79228415|NCT04269447|Diagnostic Test|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
79228416|NCT00702650|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
79228417|NCT04203147|Behavioral|Supportive Therapy (Control)|Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
79357443|NCT01901419|Drug|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
79357444|NCT02798536|Drug|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
79357445|NCT02798536|Drug|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
79357446|NCT01901341|Drug|CB-5945|
79357447|NCT01901341|Drug|Placebo|
79357448|NCT04758286|Procedure|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
79357449|NCT04757896|Procedure|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
79357450|NCT04757896|Procedure|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
79357451|NCT01615939|Drug|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
79357452|NCT01615939|Drug|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
79357453|NCT02789878|Drug|Goserelin|Androgen Deprivation Therapy
79669311|NCT06189144|Other|Emollient cream treatment|Rilastil Difesa Sterile cream
79669312|NCT06189144|Other|no treatment|no treatment
79357454|NCT02789878|Drug|Prednisone|Corticosteroid
79991619|NCT02350738|Other|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
79991620|NCT04459728|Behavioral|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
79357455|NCT02789878|Drug|Abiraterone|CYP17 inhibitor
79357456|NCT02789878|Drug|Apalutamide|Androgen-receptor antagonist
79357457|NCT01901185|Drug|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
79357458|NCT01893424|Drug|Sativex buccal spray|buccal spray
79357459|NCT01893424|Drug|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
79357460|NCT02788708|Drug|Lenvatinib Mesylate|Given PO
79357461|NCT02788708|Drug|Paclitaxel|Given IV
79357462|NCT02788708|Other|Pharmacological Study|Correlative studies
79357463|NCT01888003|Drug|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
79357464|NCT01888003|Drug|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
79669313|NCT06189131|Device|Ventriject|Ventriject is a non-exercise method for estimating V02Max
79357465|NCT01888003|Other|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb < 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
79357466|NCT02783560|Behavioral|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
79991621|NCT04459728|Behavioral|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
79991622|NCT04459728|Behavioral|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
79508215|NCT04399772|Behavioral|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
79669314|NCT06189118|Behavioral|Online Mindfulness Based Cognitive Therapy or Health Education Program|12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
79669315|NCT06189105|Other|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
79669316|NCT06189105|Other|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
79669317|NCT06189092|Drug|Bleomycin|Using electroporation to infuse bleomycin in the lesion
79669318|NCT06189040|Drug|BNT162b2 30µg|intramuscular administration of 30µg
79669319|NCT06189040|Drug|BNT162b2 20µg|intramuscular administration of 20µg
79669320|NCT06189040|Drug|BNT162b2 6µg|intradermal administration of 6µg
79669321|NCT06189040|Drug|mRNA-1273 100µg|intramuscular administration of 100µg
79357467|NCT02783560|Behavioral|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
79357468|NCT01893502|Behavioral|Telephone counselling from Quitline|
79669322|NCT06189040|Drug|mRNA-1273 50µg|intramuscular administration of 50µg
79669323|NCT06189040|Drug|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10^8 infectious units
79991623|NCT04459728|Behavioral|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
79228418|NCT04203147|Behavioral|Home DM-BAT|Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
79357469|NCT02775214|Device|Video Laryngoscopy|
79669324|NCT06189027|Drug|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
79508216|NCT04293341|Behavioral|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
79508217|NCT04293341|Behavioral|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
79669325|NCT06189027|Behavioral|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
79669326|NCT06189001|Drug|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
79669327|NCT06189001|Other|Placebo (saline)|Intravenous saline during experimental days
79669328|NCT06188975|Drug|DRUG: ABBV-CLS-484|
79991624|NCT04459728|Behavioral|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
79991625|NCT04459728|Behavioral|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
79991626|NCT04459728|Behavioral|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
79669329|NCT06188962|Behavioral|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
79991627|NCT02350972|Biological|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
79991628|NCT02342470|Drug|Placebo|Drug : Placebo
79669330|NCT06188936|Device|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
79669331|NCT06188936|Other|Survey|Surveys will be completed on a hard copy or electronically.
79991629|NCT02342470|Drug|PMK-S005 1|Drug : PMK-S005 1 (50mg)
79991630|NCT02342470|Drug|PMK-S005 2|Drug : PMK-S005 2 (100mg)
79357470|NCT02773732|Drug|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
79357471|NCT02773732|Drug|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
79357472|NCT02773732|Drug|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
79357473|NCT02773732|Drug|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
79357474|NCT04390126|Other|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
79991631|NCT02342470|Drug|PMK-S005 3|Drug : PMK-S005 3 (150mg)
79991632|NCT04436952|Device|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
79991633|NCT04436952|Device|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
79357475|NCT04390126|Other|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
79357476|NCT02769520|Drug|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
79991634|NCT04436952|Behavioral|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
79508218|NCT04293341|Behavioral|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
79508219|NCT04293341|Behavioral|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
79508220|NCT04288921|Diagnostic Test|Swab|Swab samples for diagnostic test
79508221|NCT04263194|Device|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
79508222|NCT04263194|Device|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
79508223|NCT04247126|Drug|SY-5609|An oral CDK7 Inhibitor
79508224|NCT04247126|Drug|Fulvestrant|Estrogen receptor antagonist
79508225|NCT04247126|Drug|Gemcitabine|Nucleoside metabolic inhibitor
79508226|NCT04247126|Drug|Nab-paclitaxel|Taxane-type chemotherapy
79508227|NCT04241250|Device|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
79508228|NCT04241250|Device|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
79508229|NCT04182425|Other|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
79508230|NCT04168489|Device|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
79508231|NCT04168489|Device|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
79508232|NCT04152954|Device|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
79508233|NCT04151706|Drug|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
79508234|NCT04151706|Drug|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
79508235|NCT04151706|Drug|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
79508236|NCT04151706|Radiation|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
79508237|NCT04151706|Drug|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
79508238|NCT04151706|Drug|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
79508239|NCT04147468|Other|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
79508240|NCT04147468|Other|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
79669332|NCT06188923|Drug|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
79669333|NCT06188923|Drug|Placebo|Same as active comparator, except placebo dispensed
79669334|NCT06188910|Other|Neurofeedback|Conducting neurofeedback sessions guided by a researcher
79669335|NCT06188910|Other|Health education|Health education on mobile phone addiction
79679693|NCT03458091|Device|THRIVE|Oxygenation during apnea using transversal humidified oxygen
79818727|NCT05935644|Behavioral|ORCHID|The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.
79508241|NCT04125186|Diagnostic Test|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
79508242|NCT04125186|Diagnostic Test|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
79508243|NCT04125186|Diagnostic Test|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
79508244|NCT04125186|Other|No other intervention|No other intervention
79508245|NCT04119453|Drug|Rivoceranib|Film-coated tablets
79508246|NCT04114734|Behavioral|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
79508247|NCT04097353|Behavioral|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
79508248|NCT04097353|Behavioral|Surviving Strong for Kids (SS4K)|Enhanced usual care
79508249|NCT04093986|Other|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
79508250|NCT04093986|Other|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
79508251|NCT04065438|Device|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
79508252|NCT04006119|Biological|Ad-RTS-hIL-12|"intratumoral injection of Ad-RTS-hIL-12~2.0 x 10^11 viral particles (vp) per injection"
79508253|NCT04006119|Drug|Veledimex|20mg/day 15 oral daily doses of veledimex
79991635|NCT03531905|Drug|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
79508254|NCT04006119|Drug|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
79991636|NCT03531905|Drug|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
79818728|NCT05929651|Biological|MenACYW conjugate vaccine|Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
79818729|NCT05928806|Drug|Botensilimab|Botensilimab 75mg IV
79818730|NCT05928806|Drug|Balstilimab|Balstilimab 450mg IV
79508255|NCT04004793|Behavioral|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500~750 kcal/day) for 3 months, with <35% as fat, >15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
79508256|NCT04004793|Drug|Dapagliflozin 10 MG Oral Tablet|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
79991637|NCT03531905|Drug|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
79508257|NCT04004793|Drug|Placebo Oral Tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
79508258|NCT04002011|Drug|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of [2.0-3.0]. Other anticoagulants will be not administrated.
79508259|NCT04002011|Drug|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
79508260|NCT04002011|Drug|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
79508261|NCT04002011|Drug|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
79508262|NCT04002011|Drug|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
79669336|NCT06188897|Other|Self-stretching of the masticatory musculature|"If the subject belonged to the Treatment group, he was instructed to self-stretch the masticatory muscle.~This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting."
79669337|NCT06188897|Other|Control group intervention|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
79991638|NCT03531905|Drug|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
79669338|NCT06188871|Drug|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
79669339|NCT06188845|Other|Kinesio taping|Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
79679694|NCT03458091|Device|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
79818731|NCT05928806|Drug|Ipilimumab|Ipilimumab 1mg/kg IV
79818732|NCT05928806|Drug|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
79991639|NCT02350426|Other|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
79991640|NCT02350426|Other|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
79991641|NCT02350426|Other|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
79991642|NCT02346682|Drug|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
79508263|NCT03968991|Diagnostic Test|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
79508264|NCT03968107|Other|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
79991643|NCT04385706|Behavioral|Applied Coaching Model|The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
79991644|NCT03131934|Biological|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
79508265|NCT03934437|Behavioral|mLTCR|mHealth-enhanced Linkage to Care and Retention
79991645|NCT03131934|Biological|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
79508266|NCT03934437|Behavioral|LTCR|Linkage and Retention Services (Standard-of-Care)
79508267|NCT03903692|Device|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
79508268|NCT03903692|Device|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
79508269|NCT03886610|Other|Healthy controls|individuals without spinal cord injury
79508270|NCT03886610|Other|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
79508271|NCT03886610|Other|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
79508272|NCT03878849|Drug|2X-121|Every patient will receive daily oral administrations of 3 x 200 mg 2X-121 hard gelatin capsules in a 28-day cycle.
79508273|NCT03878849|Device|2X-121 DRP®|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
79508274|NCT03789591|Drug|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
79508275|NCT03783026|Drug|Apremilast|Tablets for oral administration
79508276|NCT03775460|Drug|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
79991646|NCT03131934|Procedure|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
79991647|NCT03531827|Drug|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
79991648|NCT03531827|Drug|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
79991649|NCT05764512|Other|Endorphin massage|"With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours."
79991650|NCT04105816|Device|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
79508277|NCT03775460|Drug|Placebo|Participants in the control arm will receive placebo along side prednisolone
79508278|NCT03775460|Drug|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
79508279|NCT03735797|Diagnostic Test|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
79508280|NCT03635112|Drug|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
79508281|NCT03635112|Drug|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
79508282|NCT03591731|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
79508283|NCT03591731|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
79508284|NCT03588728|Other|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
79508285|NCT03588728|Behavioral|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
79508286|NCT03547947|Device|Medacta Shoulder System|Total Shoulder Arthroplasty
79669340|NCT06188819|Procedure|Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium|In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
79357477|NCT02764528|Behavioral|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
79357478|NCT02764528|Behavioral|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
79357479|NCT02764528|Behavioral|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
79991651|NCT04105816|Diagnostic Test|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
79991652|NCT02346448|Procedure|endoscopic sphincterotomy|sphincterotomy during ERCP
79357480|NCT02735512|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
79991653|NCT02346448|Procedure|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
79357481|NCT02735512|Other|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
79508287|NCT03535584|Behavioral|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
79508288|NCT03534726|Device|7 T CMR|7 tesla MRI device
79508289|NCT03513081|Behavioral|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
79508290|NCT03500354|Dietary Supplement|Nutrient drink|High calorie drink with therapeutic supplements
79508291|NCT03455582|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
79508292|NCT03455582|Other|Ecological evaluation|Virtual reality task and Actual reality
79508293|NCT03455582|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
79679695|NCT04694144|Device|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
79991654|NCT02346448|Procedure|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
79991655|NCT03057678|Other|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
79679696|NCT00517946|Drug|pseudoephedrine hydrochloride|
79991656|NCT01377870|Biological|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
79679697|NCT00517946|Drug|cetirizine hydrochloride|
79818733|NCT05922501|Drug|Isatuximab|An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
79669341|NCT06188806|Other|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
79669342|NCT06188806|Other|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
79669343|NCT06188780|Diagnostic Test|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
79669344|NCT06188767|Drug|Testosterone Undecanoate|Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
79669345|NCT06188754|Behavioral|Time restricted eating|Limiting food intake to 10 hours per day
79669346|NCT06188754|Behavioral|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
79508294|NCT03455582|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
79357482|NCT02735122|Drug|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
79508295|NCT03455582|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
79508296|NCT03448926|Other|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
79357483|NCT02735122|Drug|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
79508297|NCT03439033|Drug|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
79508298|NCT03439033|Drug|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
79508299|NCT03439033|Drug|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
79508300|NCT03405558|Other|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
79508301|NCT03405311|Device|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
79508302|NCT03405311|Other|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
79508303|NCT03400982|Diagnostic Test|Bone densitometry measurement|Bone densitometry and measurement of body composition
79357484|NCT02735122|Drug|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
79357485|NCT02735122|Drug|Placebo Tablet|2 placebo tablets
79357486|NCT02735122|Drug|Placebo Caplet|2 placebo caplets
79357487|NCT02735122|Drug|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
79357488|NCT02726542|Drug|somatropin|Norditropin (growth hormone) given by injection using a pen-device
79357489|NCT02722798|Drug|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
79357490|NCT02720848|Device|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
79357491|NCT02720848|Device|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
79508304|NCT03380962|Drug|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
79508305|NCT03380377|Drug|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
79508306|NCT03330886|Drug|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
79357492|NCT02718118|Device|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
79357493|NCT02718118|Device|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
79357494|NCT01893580|Behavioral|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
79357495|NCT01893580|Behavioral|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
79508307|NCT03282799|Drug|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
79508308|NCT03263546|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
79508309|NCT03263546|Behavioral|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
79508310|NCT03192020|Procedure|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
79508311|NCT03192020|Drug|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
79508312|NCT03192020|Procedure|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
79508313|NCT02987543|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
79991657|NCT01377870|Biological|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
79508314|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
79508315|NCT02987543|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
79508316|NCT02987543|Drug|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
79508317|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg tablets) once daily
79508318|NCT02983045|Drug|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
79508319|NCT02983045|Drug|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
79508320|NCT02983045|Drug|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
79508321|NCT02983045|Drug|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
79508322|NCT02944136|Behavioral|enhanced usual care|usual care from health providers
79508323|NCT02944136|Behavioral|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
79508324|NCT02923440|Biological|blood sample|
79508325|NCT02894398|Drug|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
79508326|NCT02894398|Drug|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
79508327|NCT02894398|Drug|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
79508328|NCT02894398|Drug|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
79508329|NCT02894398|Drug|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
79508330|NCT02871752|Behavioral|Health promotion|mindfulness-based stress reduction
79508331|NCT02869399|Dietary Supplement|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~eat mostly food of plant origin~eat lean meat, limit intake of red meat and avoid processed meat~increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
79508332|NCT02855034|Other|Blood samples|Blood samples for dosage: copeptin and protein S100B
79508333|NCT02708810|Device|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
79508334|NCT02708810|Radiation|80 Gy Radiation|
79508335|NCT02678689|Biological|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
79508336|NCT02678689|Device|Intraventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
79508337|NCT02678052|Drug|Vedolizumab|Vedolizumab exposure
79508338|NCT02678052|Biological|Other Biological Agent|Other Biological Agent exposure
79508339|NCT02564263|Biological|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
79508340|NCT02564263|Drug|paclitaxel|80-100 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
79357496|NCT01893580|Behavioral|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
79508341|NCT02564263|Drug|docetaxel|75 mg/m^2 administered as IV infusion on Day 1 of every 21-day cycle
79508342|NCT02564263|Drug|irinotecan|180 mg/m^2 administered as IV infusion on Day 1 of every 14-day cycle
79669347|NCT06188702|Drug|S095035|S095035 will be taken orally once daily in 28-day cycle.
79669348|NCT06188689|Diagnostic Test|Pacing|"Ventricular 10 beat burst at 500ms (120bpm)~Ventricular 10 beat burst at 400ms (150bpm)~Atrial 10 beat burst at 500ms (120bpm)~Atrial 10 beat burst at 400ms (150bpm)."
79669349|NCT06188676|Drug|Cyclophosphamide|Ciclofosfamida
79669350|NCT06188676|Drug|Doxorubicin Hydrochloride|Adriamycin
79669351|NCT06188676|Drug|Etoposide Phosphate|Etopophos
79991658|NCT03146026|Behavioral|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
79357497|NCT01893580|Behavioral|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
79357498|NCT02718040|Device|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
79669352|NCT06188676|Drug|Prednisolone|Prednisolonum
79991659|NCT02342392|Drug|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
79991660|NCT02342236|Device|cemented or cementless type of hip prothesis|
79357499|NCT01893658|Drug|Omalizumab|administration of a single dose together with the standard treatment
79669353|NCT06188676|Drug|Rituximab|Chimeric Anti-CD20 Antibody
79357500|NCT01893658|Drug|Prednisone|standard treatment
79669354|NCT06188676|Drug|Vincristine Sulfate|Oncovin
79508343|NCT02540018|Device|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
79508344|NCT02540018|Device|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
79508345|NCT02522247|Procedure|UPP|surgery with cold steel in general anesthesia
79669355|NCT06188676|Drug|Filgrastim|G-CSF
79991661|NCT02342158|Procedure|biopsy or surgical sampling|
79991662|NCT02342158|Other|blood sampling|
79991663|NCT02342080|Other|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
79991664|NCT02342080|Device|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
79991665|NCT05764434|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
79669356|NCT06188676|Drug|Pegfilgrastim|PEG-filgrastim
79669357|NCT06188676|Drug|Nivolumab 40 mg in 4 ml Injection|Opdivo
79818734|NCT05922501|Drug|Belantamab mafodotin|An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
79508346|NCT02513056|Other|MRI|MRI
79508347|NCT02423265|Drug|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
79508348|NCT02423265|Drug|Placebo|Matching placebo: up-titration after 1 week
79508349|NCT02416050|Procedure|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
79357501|NCT02692768|Other|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
79357502|NCT02692768|Other|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
79508350|NCT02379819|Device|Nucleus Hybrid L24 Implant|
79508351|NCT02368886|Drug|Clobetasol Propionate|Given topically
79508352|NCT02368886|Other|Pharmacological Study|Correlative studies
79508353|NCT02368886|Other|Quality-of-Life Assessment|Ancillary studies
79508354|NCT02368886|Drug|Regorafenib|Given PO
79508355|NCT02332369|Device|Capsular Tension Ring|
79508356|NCT02301286|Drug|Acetylsalicylic acid|
79508357|NCT02301286|Drug|Placebo Acetylsalicylic acid|
79508358|NCT02262221|Other|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
79508359|NCT02227238|Drug|DTG|DTG is supplied as 50 mg tablets
79508360|NCT02227238|Drug|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
79508361|NCT02227238|Drug|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
79508362|NCT02225925|Radiation|Brachytherapy|
79508363|NCT02216305|Procedure|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
79508364|NCT02216305|Procedure|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
79508365|NCT02126969|Radiation|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
79508366|NCT02126969|Drug|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
79508367|NCT02121743|Device|strattice|use of a strattice
79508368|NCT02121743|Procedure|No strattice|no use of a strattice
79508369|NCT02099188|Drug|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
79508370|NCT02099188|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
79508371|NCT02099188|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
79508372|NCT02099188|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
79508373|NCT02099188|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
79508374|NCT02099188|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
79508375|NCT02099188|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
79818735|NCT05922501|Drug|Pomalidomide|An immunomodulatory agent, capsule taken orally.
79508376|NCT02099188|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
79508377|NCT02099188|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
79508378|NCT02099188|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
79508379|NCT02099175|Drug|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
79508380|NCT02099175|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
79991666|NCT05462964|Behavioral|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
79991667|NCT05462964|Behavioral|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
79991668|NCT02342002|Drug|Mifepristone|Mifepristone for treatment of missed abortion
79991669|NCT02342002|Drug|Misoprostol|Misoprostol for treatment of missed abortion
79991670|NCT04478110|Behavioral|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
79508381|NCT02099175|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
79357503|NCT02692768|Other|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
79680131|NCT00524966|Procedure|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
79818736|NCT05922501|Drug|Dexamethasone|A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
79818737|NCT05921942|Drug|Metformin|500 mg twice daily or 1000 mg once daily
79357504|NCT02688556|Drug|cyclosporine|
79357505|NCT02688556|Drug|vehicle of OTX-101|
79357506|NCT01925209|Drug|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
79357507|NCT01925209|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
79357508|NCT02684032|Drug|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
79357509|NCT02684032|Drug|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
79357510|NCT02684032|Drug|Letrozole|Letrozole at 2.5 mg daily
79357511|NCT02684032|Drug|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
79508382|NCT02099175|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
79508383|NCT02099175|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
79508384|NCT02099175|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
79508385|NCT02099175|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
79508386|NCT02099175|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
79669358|NCT06188650|Drug|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
79669359|NCT06188637|Drug|Ozanimod Oral Capsule|open label ozanimod
79357512|NCT01614925|Device|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
79357513|NCT01614925|Procedure|Periodontal surgery|Periodontal surgery alone
79669360|NCT06188611|Drug|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
79669361|NCT06188546|Drug|Propofol|trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
79669363|NCT06188507|Drug|GSK4347859|GSK4347859 will be administered
79669364|NCT06188507|Drug|Placebo|Placebo will be administered
79357514|NCT02388178|Drug|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
79357515|NCT02388178|Drug|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
79508387|NCT02099175|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
79508388|NCT02099175|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
79508389|NCT01840150|Procedure|breath test|Undergo NA-NOSE breath test
79508390|NCT01840150|Other|laboratory biomarker analysis|Correlative studies
79669365|NCT06188468|Diagnostic Test|18F-FDG PET/CT, 68Ga-THP-Trop2 VHH PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-THP-Trop2 VHH, and undergoes PET/CT imaging within the specified time.
79669366|NCT06188455|Drug|Fluzoparib Capsules|Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
79669367|NCT06188455|Drug|Apatinib Mesylate Tablets|Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
79669368|NCT06188442|Drug|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
79669369|NCT06188442|Drug|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
79669370|NCT06188429|Diagnostic Test|DSM-5|Using DSM-5 for diagnostic testing of the children in the study group.
79669371|NCT06188403|Procedure|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
79669372|NCT06188390|Procedure|Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid|Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist
79669373|NCT06188390|Procedure|Ultrasound guided median nerve hydrodissection injection with Dextrose water|Dextrose water was injected under ultrasound guidance around median nerve at the wrist
79508391|NCT01754610|Behavioral|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
79508392|NCT01716026|Drug|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
79508393|NCT01715285|Drug|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
79508394|NCT01715285|Drug|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
79508395|NCT01715285|Other|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
79508396|NCT01715285|Drug|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
79508397|NCT01715285|Drug|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
79508398|NCT01705184|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
79508399|NCT01705184|Drug|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
79508400|NCT01705184|Drug|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
79508401|NCT01285817|Drug|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
79508402|NCT01285479|Drug|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
79991671|NCT04478110|Behavioral|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
79991672|NCT02341768|Device|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
79508403|NCT01250496|Drug|Aminophylline|75 mg of intravenous aminophylline
79508404|NCT01250496|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
79508405|NCT01134757|Biological|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
79508406|NCT01105975|Drug|LY2484595|Administered daily by mouth for 12 weeks
79508407|NCT01105975|Drug|Atorvastatin|Administered daily by mouth for 12 weeks
79508408|NCT01105975|Drug|Simvastatin|Administered daily by mouth for 12 weeks
79991673|NCT02341846|Other|Qualitative interviews|
79508409|NCT01105975|Drug|Rosuvastatin|Administered daily by mouth for 12 weeks
79508410|NCT01105975|Drug|Placebo for LY2484595|Administered daily by mouth for 12 weeks
79508411|NCT01105975|Drug|Placebo for Statins|Administered daily by mouth for 12 weeks
79508412|NCT00831623|Radiation|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
79508413|NCT00831623|Radiation|Proton|As above
79508414|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin)|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
79508415|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
79680132|NCT02935920|Behavioral|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
79680133|NCT02276846|Device|Paclitaxel-Eluting Balloon|
79680134|NCT02935725|Drug|Low dose AUT00206 800mg|
79680135|NCT02935725|Drug|High dose AUT00206 2000 mg|
79508416|NCT00639639|Biological|tetanus toxoid|Given by injection
79357516|NCT02388178|Drug|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
79508417|NCT00639639|Biological|therapeutic autologous dendritic cells|Given intradermally
79508418|NCT00639639|Biological|therapeutic autologous lymphocytes|Given IV
79669376|NCT06188351|Device|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
79669377|NCT06188351|Device|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
79669378|NCT06188338|Combination Product|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
79669379|NCT06188338|Combination Product|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
79669380|NCT06188325|Drug|Eliglustat|Pharmaceutical form:Capsule-Route of administration:Oral
79669381|NCT06188299|Other|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
79669382|NCT06188221|Drug|Lidocaine|The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
79669383|NCT06188221|Drug|Corticoids|The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
79669384|NCT06188208|Drug|VVD-130850|Oral tablets
79669385|NCT06188208|Drug|Pembrolizumab|IV infusion
79669386|NCT06188195|Drug|Dexamethasone|ACS intervention were used in the experimental group
79357517|NCT02384668|Dietary Supplement|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
79357518|NCT02384668|Dietary Supplement|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
79357519|NCT02377258|Other|Non Interventional|
79508419|NCT00591695|Procedure|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
79508420|NCT00591695|Procedure|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
79508421|NCT00280202|Procedure|Biopsy of the major carinal area|Biopsy performed intraoperatively
79508422|NCT00280202|Procedure|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
79508423|NCT00280202|Procedure|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
79669387|NCT06188169|Procedure|Increasing the inspiratory pressure if atelectasis detected by US|The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
79669388|NCT06188156|Procedure|Anethesia|To assess the effectiveness of thoracic epidural blockage versus ultrasonic guided PECS II block versus ultrasound guided serratus anterior plane block for postoperative pain management in modified radical mastectomy.
79669389|NCT06188143|Combination Product|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
79680136|NCT02935725|Drug|Placebo|
79357520|NCT01898923|Drug|ON101 Cream|
79508424|NCT00280202|Procedure|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
79508425|NCT00280202|Procedure|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
79508426|NCT00280202|Procedure|Analysis of lymph nodes|Tissues banked for future analysis
79508427|NCT00079417|Drug|Carboplatin|Given IV
79508428|NCT00079417|Procedure|Cryosurgery|
79508429|NCT00079417|Procedure|Infrared Laser Therapy|
79508430|NCT00079417|Radiation|Iodine I-125|Undergo radioactive therapy
79508431|NCT00079417|Radiation|Radiation Therapy|Undergo radioactive therapy
79508432|NCT00079417|Radiation|Ruthenium Ru-106|Undergo radioactive therapy
79357521|NCT01898923|Other|Aquacel® Hydrofiber® dressing|
79357522|NCT04251442|Device|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
79357523|NCT04551586|Drug|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
79357524|NCT04551586|Drug|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
79508433|NCT00079417|Drug|Vincristine Sulfate|Given IV
79508434|NCT04387968|Diagnostic Test|Covid-19 presto test|Use an auto-test in 15 minutes get the results about covid-19 anticorps
79508435|NCT04387890|Diagnostic Test|Serologic SARS-CoV-2 screening|Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
79669390|NCT06188130|Other|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
79669391|NCT06188130|Other|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
79669392|NCT06188130|Other|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
79669393|NCT06188130|Other|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
79669394|NCT06188104|Drug|Trichloroacetic acid|Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
79669395|NCT06188091|Behavioral|Exercise|Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
79669396|NCT06188052|Drug|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
79669397|NCT06188000|Dietary Supplement|Extra Virgin Olive Oil|The patients was given extra virgin olive oil, an unrefined (not processed with chemicals or heat) for of olive oil
79669398|NCT06188000|Dietary Supplement|Olive Oil|The patients was given olive oil.
79669399|NCT06188000|Dietary Supplement|Placebo|The patients was given empty capsule
79357525|NCT01924429|Drug|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
79357526|NCT04553848|Behavioral|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
79508436|NCT04387578|Device|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
79508437|NCT04387266|Radiation|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
79508438|NCT04386876|Drug|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
79508439|NCT04386876|Drug|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH & Co.-Germany)
79669400|NCT06187987|Device|Mechanical thrombectomy|Aspirational mechanical thrombectomy
79669401|NCT06187987|Drug|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
79357527|NCT04553848|Behavioral|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
79357528|NCT04553848|Behavioral|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~Biomechanical Constraints~Stability Limits~Anticipatory Postural Adjustments~Reactive Postural Response~Sensory Orientation~Stability in Gait"
79357529|NCT01898299|Device|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
79357530|NCT01898299|Device|Sham tDCS|Sham (inactive) tDCS treatment
79357531|NCT04550650|Other|Training groupe|Using virtual training
79357532|NCT04550650|Other|PNF|PNF technique was used
79508440|NCT04387032|Other|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
79508441|NCT04387032|Other|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
79508442|NCT04386486|Other|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
79357533|NCT04550650|Other|Spinning grp|They only worked with spinning bikes.
79357534|NCT04550650|Other|Balance|Balance development was done
79508443|NCT04386486|Other|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
79508444|NCT04386642|Drug|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
79508445|NCT04386642|Drug|Placebo|normal saline solution in a clear 50-ml syringe
79508446|NCT04386408|Combination Product|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
79508447|NCT04386408|Combination Product|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
79669402|NCT06187974|Other|observation|observation
79357535|NCT01886287|Drug|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
79357536|NCT04559386|Other|Survey|Questionnaire
79357537|NCT04395118|Behavioral|Mailed Outreach|The investigators will randomize elevated LFT patients (~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
79357538|NCT04628065|Behavioral|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
79508448|NCT04386564|Diagnostic Test|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
79669403|NCT06187961|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
79669404|NCT06187961|Drug|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
79669405|NCT06187948|Other|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
79669406|NCT06187922|Drug|Pregabalin 75mg|Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
79669407|NCT06187922|Procedure|adductor canal block|Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
79669408|NCT06187909|Procedure|PECS II BLOCK|The linear probe will be placed transversely between the clavicle medially and above . After identifying the pectoralis major and minor muscles , the probe will be angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. The block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered. Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs will be detected. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 20 ml bupivacaine.
79991674|NCT05230966|Device|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
79508449|NCT04385628|Behavioral|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
79508450|NCT04385784|Other|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
79357539|NCT04393870|Other|Foccusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
79508451|NCT04385784|Other|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
79357540|NCT02707588|Drug|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
79357541|NCT02707588|Drug|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
79357542|NCT02707588|Radiation|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
79669409|NCT06187909|Procedure|MTP BLOCK|The block will be performed with the patient in a sitting position ,High frequency linear probe will be placed in a vertical orientation 3 cm lateral to the midline at T2 level in parasagittal plane. We will identify the midpoint between the transverse process and parietal pleura, and the distance from this point to the skin will be measured which will be the measured depth of insertion and will be marked in the block needle. The block needle will be inserted out of plane to the probe and advanced till the marked depth till the point is confirmed, 10 ml of 0.25% bupivacaine will be injected. Similar two injections will be made at T4, T6 levels sonographic identification and level determination by counting from the second rib.
79669410|NCT06187896|Drug|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
79669411|NCT06187896|Drug|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
79669412|NCT06187870|Other|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
79669413|NCT06187857|Behavioral|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
79669414|NCT06187844|Procedure|Inguinal exploration|Inguinal exploration will be done for all the included patients.
79508452|NCT04385550|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
79508453|NCT04385550|Drug|AK105 injection|AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
79991675|NCT02350582|Device|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
79669415|NCT06187844|Procedure|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
79991676|NCT02350504|Behavioral|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
79508454|NCT04385550|Drug|Paclitaxel injection|Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
79508455|NCT04385550|Drug|Docetaxel injection|Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
79680137|NCT02935725|Drug|Ketamine|
79680138|NCT02935725|Other|Saline|
79357543|NCT05602480|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
79357544|NCT05602480|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
79357545|NCT05604586|Dietary Supplement|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
79357546|NCT05604586|Dietary Supplement|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
79357547|NCT05604430|Device|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
79357548|NCT05604352|Device|DiaSole|Diabetic ulcer offloading insole
79357549|NCT05604118|Drug|Aspirin|1 week of aspirin supplementation prior to sampling
79357550|NCT03030274|Device|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
79357551|NCT04759222|Diagnostic Test|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
79357552|NCT04760080|Other|pre-treatment data|"We will evaluate in all patients pre-treatment data :~Melanoma staging at treatment initiation~Melanoma characteristics at initial diagnosis~Number and location of metastasis~Performans status~Demographic information"
79357553|NCT04760080|Other|during study treatment|"We will evaluate in all patients during study treatment :~Rate of adverse events~Type of adverse events~Radiological response to treatment by CTscans that are routinely performed every three months."
79357554|NCT01885195|Drug|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
79357555|NCT03337594|Drug|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
79357556|NCT03337594|Drug|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
79357557|NCT03337594|Procedure|Surgery|Cardiac surgery
79357558|NCT04393792|Drug|Povidone-Iodine|0.23% three times daily (tds) for 3 days
79357559|NCT04393792|Drug|Normal saline|0.9% three times daily (tds) for 3 days
79357560|NCT04129762|Other|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
79680139|NCT04693442|Other|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling & scar assessment questionnaires
79680140|NCT02935764|Drug|Irinotecan|180 mg/m2 iv gtt, d1
79680141|NCT02935764|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
79357561|NCT04129762|Other|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
79357562|NCT04129684|Other|Probiotics|subgingival delivery and lozenges
79357563|NCT01896895|Drug|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
79357564|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
79357565|NCT01896895|Drug|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
79357566|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
79357567|NCT03026764|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
79357568|NCT03026764|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
79357569|NCT04129606|Diagnostic Test|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
79508456|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
79357570|NCT04129372|Behavioral|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
79357571|NCT02315872|Drug|ACTH|ACTH injections twice weekly for 28 weeks.
79357572|NCT02315872|Drug|Placebo|Placebo injections twice weekly for 28 weeks.
79357573|NCT04128826|Other|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM & FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
79357574|NCT04128982|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
79357575|NCT04128202|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
79508457|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
79357576|NCT04128202|Behavioral|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
79357577|NCT04128592|Device|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
79508458|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
79508459|NCT04384926|Procedure|Elective Cancer Surgery|Planned, curative cancer surgery
79508460|NCT04384614|Diagnostic Test|Test PCR|Viral load (COVID+) testing by PCR
79508461|NCT04384614|Genetic|TDR|IDR and blood sampling for testing DNA Cheque
79357578|NCT04128280|Procedure|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
79357579|NCT04128280|Procedure|TUIB|a surgery: transurethral incision of bladder neck
79357580|NCT04127812|Behavioral|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
79508462|NCT04384614|Other|Clinical Examination|COVID 19 symptoms and Physical Examination
79669416|NCT06187818|Drug|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group [experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period]
79669417|NCT06187779|Other|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
79669418|NCT06187766|Diagnostic Test|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
79669419|NCT06187753|Diagnostic Test|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
79991677|NCT03149536|Diagnostic Test|Pharmacogenetic test|To develop a pharmacogenetic prediction test
79357581|NCT04127890|Dietary Supplement|ELO Water|oxygen-enriched water
79357582|NCT04127890|Dietary Supplement|Placebo drinking water|bottled drinking water
79357583|NCT04128046|Procedure|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
79508463|NCT04384536|Procedure|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
79508464|NCT04384380|Drug|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
79508465|NCT04384458|Drug|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
79508466|NCT04384458|Drug|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
79669420|NCT06187727|Drug|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
79669421|NCT06187714|Procedure|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
79669422|NCT06187688|Other|Questionnaire|Patients to complete a questionnaire on measurement of pain intensity.
79669423|NCT06187675|Behavioral|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
79991678|NCT02341690|Other|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
79680142|NCT02935764|Drug|Leucovorin|400mg/m2 iv gtt,d1
79818738|NCT05920967|Drug|Dexamethasone Palmitate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
79991679|NCT02341690|Other|control|Standard care at the promotion centre in the municipality
79991680|NCT03657264|Drug|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
79991681|NCT03657264|Drug|Moxifloxacin 400mg|One tablet per os
79991682|NCT03657264|Drug|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
79991683|NCT03657264|Drug|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
79991684|NCT02345824|Drug|Ribociclib|CDK4/6 INHIBITOR
79991685|NCT02345902|Drug|Haloperidol|haloperidol 1.25 mg P.O q.d
79991686|NCT02345902|Other|Placebo|placebo 1.25 mg P.O q.d
79991687|NCT02345902|Other|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
79991688|NCT05462808|Drug|High viscosity glass ionomer cement|High viscosity glass ionomer cement
79991689|NCT05462808|Device|Stainless steel crown|Stainless steel crown
79357584|NCT04128046|Procedure|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
79357585|NCT04128124|Other|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
79357586|NCT04393714|Procedure|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
79991690|NCT03149614|Other|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
79357587|NCT04127500|Drug|dexmedetomidine|dexmedetomidine
79991691|NCT03149614|Other|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
79991692|NCT02350270|Other|gait and cognitive testing|
79508467|NCT04383990|Other|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
79508468|NCT04384224|Other|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
79357588|NCT04127344|Behavioral|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
79357589|NCT03017326|Drug|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
79357590|NCT03017326|Drug|Doxorubicin|Arms C, D and E used in combination
79991693|NCT04477954|Combination Product|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
79991694|NCT02345980|Drug|Sildenafil|
79357591|NCT03017326|Drug|Carboplatin|Arms C and D used in combination
79508469|NCT04383834|Device|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
79508470|NCT04383678|Device|Extracorporeal membrane oxygenation|Veno-venous or veno-arterial extracorporeal oxygenation
79508471|NCT04383600|Procedure|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
79991695|NCT02345980|Drug|Placebo|
79991696|NCT02346058|Drug|Esarin Gel|
79991697|NCT02345746|Drug|Oxaliplatin|infusion over 12 hours via HAI
79357592|NCT03017326|Drug|5Fluorouracil|Arm C used alone
79357593|NCT03017326|Drug|Vincristine|Arms C and D used in combination
79357594|NCT03017326|Drug|Etoposide|Arm D used in combination
79357595|NCT03017326|Drug|Irinotecan|Arm D used in combination
79357596|NCT03017326|Drug|Gemcitabine|Arm F used in combination
79357597|NCT03017326|Drug|Oxaliplatin|Arm F used in combination
79357598|NCT03017326|Drug|Sorafenib|Arm used in combination
79357599|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
79357600|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
79357601|NCT04126954|Other|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
79357602|NCT04126876|Drug|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
79508472|NCT04383366|Device|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
79508473|NCT04383366|Device|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
79508474|NCT04383366|Device|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
79669424|NCT06187662|Behavioral|Checklist|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs. Meaning, if a clinician in Arm A is faced with a scenario in which it is customary or usual care to consider a blood culture, the clinician will be asked to first review this checklist. The checklist is not a binding or absolute process - the clinician should use both the checklist and typical clinical judgment to decide if the blood culture test is needed or not. The checklist is based on prototypes used in the completed parent study, BrighT STAR and the earlier preliminary studies at Johns Hopkins.
79991698|NCT02345746|Drug|Folinic Acid|as a 2-hour infusion via HAI on day 2
79991699|NCT02345746|Drug|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
79991700|NCT03629808|Procedure|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
79991701|NCT03629808|Procedure|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
79357603|NCT04126876|Drug|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
79357604|NCT04126564|Behavioral|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations & yoga.
79357605|NCT04126564|Behavioral|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
79357606|NCT04126330|Dietary Supplement|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
79357607|NCT04126330|Dietary Supplement|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
79991702|NCT02341612|Other|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
79508475|NCT04383054|Behavioral|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
79508476|NCT04383054|Behavioral|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
79508477|NCT04382742|Behavioral|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
79508478|NCT04382040|Drug|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
79508479|NCT04382040|Drug|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
79508480|NCT04381884|Drug|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
79508481|NCT04381962|Drug|Azithromycin Capsule|Azithromycin 500 mg OD PO 14 days
79508482|NCT04382430|Procedure|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
79508483|NCT04382430|Procedure|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
79991703|NCT02341612|Other|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
79991704|NCT02341612|Other|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
79991705|NCT02341612|Other|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
79991706|NCT02341612|Other|passive recovery|The control group was exposed to treatment after the EIMD protocol.
79991707|NCT02341378|Biological|TissueGene-C(Low dose)|TissueGene-C at 6.0x10^6 cells
79991708|NCT02341378|Biological|TissueGene-C(High dose)|TissueGene-C at 1.8x10^7 cells
79991709|NCT03794778|Drug|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
79991710|NCT03794778|Drug|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
79991711|NCT03794778|Drug|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
79991712|NCT03530345|Drug|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
79991713|NCT03530345|Drug|Placebo|Glass vials with matching placebo.
79991714|NCT02350114|Procedure|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
79357608|NCT04126720|Dietary Supplement|topical corticosteroids and vitamin E suplements|
79357609|NCT04126720|Drug|Topical corticosteroid and placebo capsules|
79508484|NCT04381572|Behavioral|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
79508485|NCT04381026|Dietary Supplement|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
79508486|NCT04381026|Dietary Supplement|Placebo|Filler agent
79508487|NCT04381104|Drug|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
79508488|NCT04380870|Dietary Supplement|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
79669425|NCT06187662|Behavioral|Targeted Messaging|This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.
79991715|NCT03790332|Drug|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
79991716|NCT02350192|Behavioral|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
79991717|NCT02341300|Device|Cast Iron Pot|Cast iron pot
79991718|NCT02341300|Device|Alumnium Pot|Aluminum Skillet
79991719|NCT02341222|Device|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
79991720|NCT02341222|Device|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
79991721|NCT03723317|Procedure|Liver transplantation|First deceased-donor liver transplantation
79357610|NCT04126252|Drug|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
79357611|NCT04126252|Behavioral|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
79357612|NCT04126252|Combination Product|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
79669426|NCT06187649|Procedure|breast reconstruction|breast expander/implant insertion for breast reconstruction following mastectomy
79669427|NCT06187623|Other|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
79357613|NCT04126252|Other|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
79991722|NCT05462418|Procedure|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
79991723|NCT05462418|Procedure|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
79991724|NCT03721211|Drug|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
79991725|NCT03721211|Device|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
79991726|NCT03426072|Other|modified IHI breakthrough series|"There are five main elements to the intervention:~Establishment of the team and set up~Establishing baseline performance and knowledge~Ongoing developmental support~Learning sessions (3)~Action periods (3)~The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
79991727|NCT02341066|Device|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
79991728|NCT03726827|Other|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
79991729|NCT05764356|Genetic|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
79991730|NCT05764356|Other|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
79991731|NCT05764356|Other|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
79357614|NCT04125940|Dietary Supplement|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
79357615|NCT04125940|Dietary Supplement|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
79357616|NCT04125940|Other|Placebo|12oz water + food coloring
79991732|NCT02345668|Behavioral|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
79991733|NCT02345668|Drug|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
79357617|NCT04125628|Behavioral|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
79357618|NCT04125628|Behavioral|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
79357619|NCT04393480|Other|Robotic therapy|ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
79357620|NCT04393480|Other|Conventional therapy|Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
79508489|NCT04380558|Other|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
79508490|NCT04380402|Drug|Atorvastatin|Atorvastatin 40 mg tablet
79508491|NCT04380246|Other|Qualitative Interview|There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
79508492|NCT04380012|Drug|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
79508493|NCT04380012|Drug|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
79508494|NCT04380168|Procedure|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
79991734|NCT02345668|Behavioral|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
79991735|NCT03500159|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
79991736|NCT03500159|Drug|Placebo|Appearance and weight matched tablets without the active product ingredient
79991737|NCT02345278|Drug|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
79357621|NCT04393402|Procedure|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
79357622|NCT03007732|Drug|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
79357623|NCT03007732|Drug|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
79357624|NCT03007732|Drug|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
79357625|NCT03007732|Drug|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
79508495|NCT04379934|Dietary Supplement|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
79508496|NCT04379856|Drug|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
79508497|NCT04379388|Behavioral|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
79669428|NCT06187623|Other|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
79669429|NCT06187610|Behavioral|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
79669430|NCT06187584|Drug|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
79669431|NCT06187584|Drug|Acetaminophen|15mg/kg PO q6 hours
79228419|NCT03300596|Behavioral|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
79357626|NCT03007732|Drug|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
79669432|NCT06187584|Drug|Ibuprofen|10mg/kg PO q6 hours
79357627|NCT03007732|Radiation|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
79357628|NCT03007420|Drug|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
79357629|NCT03007420|Drug|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
79669433|NCT06187571|Other|CT+MWM|The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
79669434|NCT06187571|Other|CT|Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
79357630|NCT04125706|Drug|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
79991738|NCT02345278|Other|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
79357631|NCT04125706|Drug|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
79357632|NCT04125394|Device|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
79357633|NCT04125004|Device|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
79357634|NCT04125082|Drug|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
79357635|NCT04125160|Device|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
79357636|NCT04125160|Diagnostic Test|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
79357637|NCT04393246|Drug|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
79357638|NCT04393246|Drug|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
79357639|NCT04393246|Drug|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
79357640|NCT04393246|Other|Standard of care|Regular standard of care for COVID-19 patients
79357641|NCT01923181|Drug|semaglutide|Once-daily oral administration as tablets.
79357642|NCT01923181|Drug|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
79357643|NCT01923181|Drug|oral placebo|Once-daily oral administration as tablets.
79508498|NCT04379310|Drug|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
79508499|NCT04378998|Other|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
79508500|NCT04378686|Other|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
79508501|NCT04378608|Drug|OBV/PTV/r) ± ribavirin (RBV)|
79508502|NCT04378218|Behavioral|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
79508503|NCT04377906|Behavioral|Modification Lifesyle|high protein-fiber and exercise
79508504|NCT04377828|Device|Pigment laser|one to two session of pigment laser (532 nm)
79508505|NCT04377750|Drug|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
79508506|NCT04377516|Other|pelvic floor muscle training|pelvic floor muscle training
79508507|NCT04377516|Other|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
79508508|NCT04377516|Other|education of pelvic girdle|education of pelvic girdle
79508509|NCT04377282|Other|Food-1|Cooked buckwheat
79508510|NCT04377282|Other|Food-2|Cooked couscous
79508511|NCT04377282|Other|Food-3|Water
79508512|NCT04376970|Drug|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
79508513|NCT04376970|Drug|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
79508514|NCT04377048|Drug|Nivolumab|"as described in NGS Arm"
79508515|NCT04377048|Drug|Gemcitabine|"as described in NGS Arm"
79508516|NCT04377048|Drug|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
79508517|NCT04376892|Other|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
79508518|NCT04376814|Drug|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
79508519|NCT04376814|Drug|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
79508520|NCT04376814|Drug|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
79508521|NCT04376034|Biological|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
79508522|NCT04376034|Biological|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
79508523|NCT04376034|Other|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
79508524|NCT04376190|Radiation|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
79357644|NCT04124224|Other|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
79991739|NCT03785340|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
79357645|NCT04124302|Drug|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
79357646|NCT04124302|Drug|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
79669435|NCT06187558|Procedure|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
79669436|NCT06187545|Device|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
79669437|NCT06187545|Device|Usual care|Deep sedation without minimum viable prototype
79991740|NCT03785340|Drug|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
79357647|NCT04124302|Drug|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
79357648|NCT04123990|Diagnostic Test|Iron status testing|Iron status testing
79357649|NCT04124068|Other|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
79357650|NCT04124068|Device|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
79357651|NCT04124068|Device|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
79357652|NCT04124068|Device|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
79357653|NCT04411069|Drug|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
79357654|NCT04123912|Behavioral|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
79357655|NCT04123912|Behavioral|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
79991741|NCT02345590|Drug|Eplerenone|25mg of eplerenone
79357656|NCT04124146|Radiation|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
79357657|NCT01896271|Drug|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
79991742|NCT03499067|Device|Test lens|Contact lens
79991743|NCT03499067|Device|Control lens|Contact lens
79357658|NCT01896271|Radiation|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
79508525|NCT04375566|Other|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
79991744|NCT02345200|Procedure|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
79991745|NCT02345200|Procedure|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
79991746|NCT05462184|Behavioral|Cognitive-Behavioral Therapy (CBT)|
79991747|NCT05462184|Behavioral|Acceptance and Commitment Therapy (ACT)|
79508526|NCT04375488|Other|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
79991748|NCT03146182|Behavioral|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
79991749|NCT03146182|Behavioral|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
79991750|NCT03723083|Drug|CC-2001|CC-2001 will be administered orally
79991751|NCT03562481|Drug|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
79991752|NCT03562481|Drug|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
79991753|NCT02349880|Behavioral|shared decision making training|
79357659|NCT04123600|Device|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
79508527|NCT04375488|Other|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
79508528|NCT04375098|Biological|COVID-19 convalescent plasma|COVID-19 convalescent plasma
79357660|NCT01884571|Drug|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
79357661|NCT01884571|Drug|Methylprednisolone|125 mg, IV (in the vein) on day 1.
79508529|NCT04375176|Diagnostic Test|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
79991754|NCT04029298|Behavioral|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
79991755|NCT03760224|Other|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
79357662|NCT01884571|Drug|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
79357663|NCT01884571|Drug|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
79357664|NCT01884571|Drug|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
79357665|NCT04123678|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
79357666|NCT04123522|Procedure|anterior approach|anterior approach
79357667|NCT04123522|Procedure|posterior appraoch|posteiror appraoch
79357668|NCT01884337|Drug|Apixaban|
79357669|NCT02996890|Biological|MV-ZIKA|MV-Zika vaccine
79357670|NCT02996890|Other|Placebo|physiological saline
79357671|NCT04123288|Drug|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
79357672|NCT04123288|Drug|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
79357673|NCT04392934|Procedure|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
79357674|NCT04123210|Dietary Supplement|Vitamin A supplement|
79357675|NCT04123210|Dietary Supplement|Placebo|
79357676|NCT02994550|Drug|FSH/LH|
79357677|NCT04123132|Other|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
79357678|NCT01922089|Drug|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
79357679|NCT04122664|Device|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
79357680|NCT04122664|Device|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
79357681|NCT04122430|Other|Review of Health Information|
79357682|NCT04122586|Drug|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
79357683|NCT04122820|Diagnostic Test|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
79991756|NCT03760224|Other|SMS group|SMS group for 8 weeks
79991757|NCT03726593|Drug|Artesunate and Pyronaridine|Standard weight based dosing
79991758|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
79991759|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
79991760|NCT03971266|Device|Activity Monitor|Wear a Fitbit
79991761|NCT03971266|Other|Media Intervention|Complete smartphone based PRO diary
79991762|NCT03145948|Drug|ABBV-553|It is administered orally.
79991763|NCT03145948|Drug|Placebo|It is administered orally.
79991764|NCT03197064|Drug|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
79991765|NCT02345044|Drug|CS-3150|
79991766|NCT02345044|Drug|placebo|
79991767|NCT02345044|Drug|eplerenone|
79991768|NCT03529409|Behavioral|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
79508530|NCT04375254|Other|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
79669438|NCT06187519|Device|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
79991769|NCT02350036|Other|ultrasound monitoring|Uterine artery Doppler assessment
79508531|NCT04375020|Drug|GABA|GABA nutritional supplement 750mg per day for 6 months
79508532|NCT04374942|Drug|Hydroxychloroquine|Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
79508533|NCT04374942|Drug|Placebo oral tablet|Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
79508534|NCT04374786|Device|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
79508535|NCT04374864|Drug|Trelagliptin|Anti diabetic
79357684|NCT04121884|Behavioral|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
79357685|NCT01884025|Behavioral|Get Moving and Get Well|Walking Class
79357686|NCT01884025|Behavioral|Health and Humor Class|Class about the role of humor in health
79508536|NCT04374396|Procedure|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
79669439|NCT06187506|Drug|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
79669440|NCT06187506|Drug|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
79991770|NCT03722771|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
79991771|NCT03722771|Other|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
79991772|NCT03722771|Other|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
79357687|NCT04121494|Biological|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
79991773|NCT03722771|Diagnostic Test|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
79508537|NCT04374396|Radiation|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
79991774|NCT03722771|Diagnostic Test|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
79991775|NCT03722771|Diagnostic Test|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
79357688|NCT04121494|Biological|ChadOx1 85A - IM|Intramuscular administration
79357689|NCT04121416|Drug|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
79357690|NCT04121416|Drug|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
79357691|NCT02983864|Behavioral|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
79357692|NCT02983864|Behavioral|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
79357693|NCT02983864|Behavioral|Relaxation|A one session intervention focused on increasing relaxation skills
79357694|NCT02983864|Behavioral|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
79508538|NCT04374318|Drug|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
79508539|NCT04374552|Drug|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate &Azithromycin
79508540|NCT04374552|Drug|Placebo|Drug - placebo
79508541|NCT04374162|Procedure|PEEP|different PEEP set on the anesthetic machine
79508542|NCT04373850|Behavioral|Home Visit|Physical exam, medication dose titration
79991776|NCT03722771|Diagnostic Test|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
79991777|NCT02349802|Drug|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
79991778|NCT02349802|Drug|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
79991779|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
79991780|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
79991781|NCT03498287|Device|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
79357695|NCT04121338|Procedure|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
79508543|NCT04374006|Drug|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
79508544|NCT04374006|Drug|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
79508545|NCT04374006|Other|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
79991782|NCT03498287|Device|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
79991783|NCT02349724|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
79991784|NCT02939820|Drug|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
79991785|NCT03721055|Radiation|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
79991786|NCT05254522|Other|not aplicable since it is a Registry|not aplicable since it is a registry
79991787|NCT02349958|Device|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
79357696|NCT04121338|Drug|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
79357697|NCT01896193|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79357698|NCT01896193|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79357699|NCT04121104|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
79357700|NCT04121104|Other|SCS is switched on|Spinal cord stimulator is on
79357701|NCT04120792|Behavioral|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
79357702|NCT04120792|Behavioral|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
79357703|NCT04120792|Behavioral|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
79357704|NCT04120792|Behavioral|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
79669441|NCT06187493|Drug|lisinopril, enalapril|"Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
79357705|NCT04393012|Other|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
79991788|NCT02349958|Device|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
79991789|NCT02349958|Device|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
79357706|NCT04121026|Other|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~history of contact~suggestive TB symptoms~tachycardia~chest radiography~abdominal ultrasound~Xpert MTB/RIF Ultra. A score of >100 is highly predictive of TB. In children with a score >100, anti-TB treatment will be initiated immediately. In children with a score of <100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
79357707|NCT01922011|Drug|Daptomycin|IV daptomycin Infusion A in 12 to <18 years old (7 mg/kg); in 7 to < 12 year olds (9 mg/kg); in 24 months to <7 year olds (12 mg/kg); in 12 to <24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
79357708|NCT01922011|Drug|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
79357709|NCT01922011|Drug|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
79508546|NCT04373772|Other|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
79508547|NCT04373538|Behavioral|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
79991790|NCT02349958|Device|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
79991791|NCT04872426|Other|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
79991792|NCT02039284|Device|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
79991793|NCT02039284|Device|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
79357710|NCT04120090|Drug|low dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 10 mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 5mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 2.5mg twice daily.
79357711|NCT04120090|Drug|high dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 20mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 10mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 5mg twice daily
79357712|NCT01883635|Behavioral|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
79357713|NCT01883635|Behavioral|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
79357714|NCT02983786|Drug|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
79508548|NCT04373304|Other|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
79508549|NCT04373070|Combination Product|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 [2017], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
79669442|NCT06187493|Drug|dapagliflozin, empagliflozin|"Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
79508550|NCT04372836|Procedure|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
79357715|NCT04127968|Drug|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
79357716|NCT04127968|Drug|Oil|Children in control group will receive equal volume of oil.
79357717|NCT01921387|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
79357718|NCT01921387|Drug|Carmustine|Given IV
79357719|NCT01921387|Drug|Cytarabine|Given IV
79357720|NCT01921387|Drug|Etoposide|Given IV
79508551|NCT04372290|Other|Product A|Usual brand (UB) filtered, combustible cigarette
79508552|NCT04372290|Other|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
79508553|NCT04372290|Other|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
79508554|NCT04372290|Other|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
79508555|NCT04372290|Other|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
79508556|NCT04372212|Device|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
79508557|NCT04372134|Device|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
79357721|NCT01921387|Other|Laboratory Biomarker Analysis|Correlative studies
79357722|NCT01921387|Drug|Melphalan|Given IV
79508558|NCT04371978|Drug|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
79508559|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
79357723|NCT01921387|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
79357724|NCT01921387|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
79357725|NCT04129996|Drug|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
79508560|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
79508561|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
79508562|NCT04371822|Drug|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
79508563|NCT04371822|Other|placebo|No Intervention
79508564|NCT04370886|Behavioral|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
79508565|NCT04370964|Other|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
79508566|NCT04370964|Other|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
79669443|NCT06187480|Procedure|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
79669444|NCT06187467|Other|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
79669445|NCT06187454|Device|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
79508567|NCT04370808|Other|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
79357726|NCT03179644|Other|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
79357727|NCT04129216|Drug|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
79669446|NCT06187454|Device|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
79669447|NCT06187441|Drug|Daratumumab Injection|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
79357728|NCT04129216|Drug|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
79669448|NCT06187441|Drug|Dexamethasone|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
79357729|NCT04129216|Drug|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
79508568|NCT04370262|Drug|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
79508569|NCT04370262|Drug|SOC + Placebo|Standard of Care treatment plus IV placebo
79669449|NCT06187441|Drug|Lenalidomide capsule|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
79357730|NCT04129216|Diagnostic Test|Blueprint|studies the genomics of the tumor and tumor behavior
79357731|NCT04129216|Diagnostic Test|Mammaprint|studies the genomics of the tumor
79357732|NCT04122274|Behavioral|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
79508570|NCT04370340|Device|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
79508571|NCT04369872|Procedure|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
79508572|NCT04369716|Other|Whole oranges|Navel oranges (227 g total)
79508573|NCT04369716|Other|Whole Apples|Red Delicious apple with skin (230 g)
79357733|NCT04122274|Behavioral|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
79357734|NCT04122274|Behavioral|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
79508574|NCT04369716|Other|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) [40% pomace by weight]
79508575|NCT04369716|Other|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) [45% pomace by weight]
79508576|NCT04369716|Other|Orange juice|Orange Juice (250 g)
79508577|NCT04369716|Other|Apple juice|Apple Juice (235 g)
79508578|NCT04369404|Behavioral|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
79508579|NCT04369404|Behavioral|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
79357735|NCT04120558|Other|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
79508580|NCT04369404|Behavioral|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
79508581|NCT04369248|Other|hepassocin|hepassocin levels in polycystic ovary syndrome
79508582|NCT04369092|Other|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
79508583|NCT04369170|Device|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
79508584|NCT04369170|Device|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
79669450|NCT06187415|Behavioral|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
79669451|NCT06187389|Other|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
79669452|NCT06187376|Drug|Chinese Herbal Medicine (CHM) supplement|Dropper of tincture by mouth for 12 weeks.
79669453|NCT06187376|Drug|Placebo|Matching placebo tincture.
79669454|NCT06187363|Procedure|TIP Procedure|Tubularized incised plate procedre
79669455|NCT06187363|Procedure|Other proceudres|other procedures than TIP procedure
79669456|NCT06187350|Device|AI cancer detection system|The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score > 7 will be double-reviewed as normal.
79669457|NCT06187337|Device|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
79669458|NCT06187324|Diagnostic Test|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
79508585|NCT04368624|Other|Skin Tape|Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.
79508586|NCT04368624|Diagnostic Test|Blood Draw|Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
79508587|NCT04368546|Drug|Sunitinib|
79508588|NCT04368312|Other|No intervention|No intervention, just of questionnaire including validated tests
79508589|NCT04368000|Behavioral|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
79508590|NCT04368000|Behavioral|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
79508591|NCT04367532|Other|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
79508592|NCT04367532|Other|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
79508593|NCT04367376|Other|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
79508594|NCT04367376|Other|manual therapy|manual therapy
79991794|NCT02039284|Device|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
79991795|NCT02039284|Device|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
79991796|NCT04806594|Device|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
79508595|NCT04367376|Other|instrumental manual therapy|instrumental manual therapy
79669459|NCT06187272|Behavioral|Listening to music|Students listened to background music during a practical examination of 60 bpm.
79669460|NCT06187246|Behavioral|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
79508596|NCT04367454|Other|Use of Personal Protective Equipment|As described in the arm descriptions
79508597|NCT04366986|Other|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
79508598|NCT04366986|Other|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
79508599|NCT04366674|Procedure|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
79508600|NCT04366596|Device|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
79508601|NCT04366596|Device|Angioplasty with plain old balloon|Angioplasty with plain old balloon
79508602|NCT04366284|Other|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
79508603|NCT04366284|Other|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
79508604|NCT04366284|Other|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
79508605|NCT04366128|Drug|CAPA indution immunotherapy|"Camelirumab 200mg Intravenous injection on day 1.~Apatinib 250mg taken orally once daily.~Pegaspargase 2000U/m2 Intramuscular injection on day 1."
79508606|NCT04365972|Behavioral|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
79508607|NCT04365894|Other|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
79508608|NCT04365816|Other|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
79669461|NCT06187246|Other|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
79669462|NCT06187233|Other|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
79508609|NCT04365738|Other|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
79357736|NCT04120558|Other|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
79508610|NCT04365582|Drug|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
79508611|NCT04365582|Drug|Hydroxychloroquine|200 mg x 3/day for 10 days
79508612|NCT04365582|Drug|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
79508613|NCT04365270|Drug|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
79508614|NCT04365270|Drug|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
79508615|NCT04365270|Drug|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
79508616|NCT04365270|Drug|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), >99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
79508617|NCT04365504|Diagnostic Test|Dual energy X ray absorbtiometry|The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
79669463|NCT06187220|Device|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions >=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
79508618|NCT04365192|Device|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
79991797|NCT02344888|Drug|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
79508619|NCT04365192|Device|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
79991798|NCT02344888|Drug|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
79669466|NCT06187142|Behavioral|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
79669467|NCT06187142|Behavioral|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
79991799|NCT02349334|Device|Percutaneous Tibial Nerve Stimulation|
79669468|NCT06187142|Behavioral|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
79669469|NCT06187142|Behavioral|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
79508620|NCT04365426|Device|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
79991800|NCT03497429|Drug|Niraparib|Niraparib capsule
79991801|NCT02762604|Behavioral|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
79991802|NCT02762604|Behavioral|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
79508621|NCT04365426|Procedure|Thermal (cold) stimulus|Water cold bath
79508622|NCT04365426|Other|Oral contraceptive (OC)|Oral contraceptive (OC)
79991803|NCT03146104|Drug|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
79508623|NCT04365426|Other|No oral contraceptive (No OC)|No oral contraceptive (No OC)
79508624|NCT04367220|Diagnostic Test|Diagnostic testing performed as per routine care|
79508625|NCT04364724|Other|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
79508626|NCT04365036|Drug|Toripalimab|toripalimab 240mg, d1, intravenous drip
79508627|NCT04365036|Drug|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
79508628|NCT04365036|Drug|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
79508629|NCT04365036|Drug|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
79991804|NCT03146104|Drug|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
79991805|NCT04752150|Other|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
79508630|NCT04365036|Radiation|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25~26 days
79818739|NCT05920967|Drug|Dexamethasone Sodium Phosphate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
79818740|NCT05919589|Other|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
79991806|NCT05254444|Behavioral|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
79991807|NCT05254444|Behavioral|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
79991808|NCT04682340|Diagnostic Test|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
79669470|NCT06187142|Behavioral|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
79508631|NCT04364490|Device|Copernicus noVF|Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
79508632|NCT04364490|Device|Copernicis VF-Plus|Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
79508633|NCT04364490|Other|Control group|Usual care
79508634|NCT04364022|Drug|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
79508635|NCT04363710|Other|Low Calorie Diet|800-1000 Kcal/day
79669471|NCT06187142|Behavioral|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
79991809|NCT05254366|Drug|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
79991810|NCT05254132|Procedure|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
79508636|NCT04363866|Drug|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
79508637|NCT04363866|Drug|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
79669472|NCT06187142|Behavioral|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
79991811|NCT03497039|Drug|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
79508638|NCT04363788|Procedure|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
79508639|NCT04363554|Other|Fluid intake|The participants will intake fluid
79508640|NCT04363554|Other|Thirsting|The participants will thirst
79508641|NCT04363476|Other|SHRED Osteoarthritis program|Combined exercise and education intervention
79508642|NCT04363086|Behavioral|iFightDepression online self-help tool|Computerized cognitive behavior therapy
79508643|NCT04363086|Behavioral|Treatment as Usual|TAU
79508644|NCT04363086|Behavioral|phone call|phone call
79508645|NCT04363398|Other|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
79508646|NCT04363398|Other|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
79508647|NCT04362384|Drug|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
79508648|NCT04362384|Drug|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
79508649|NCT04361916|Other|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
79508650|NCT04361760|Device|single-puls TMS|Medical Device (MD): MagPro X100
79669473|NCT06187116|Other|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
79669474|NCT06187116|Other|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
79669475|NCT06187103|Device|HyperSight Imaging|Patients undergo 2 HyperSight CBCT acquisitions in addition to the standard imaging for treatment guidance. The HyperSight CBCT images will be acquired at the start of treatment, and approximately halfway through treatment. If the patient is sent for mid-treatment re-planning, a third HyperSight CBCT will be acquired on the same day as their re-simulation.
79669476|NCT06187090|Dietary Supplement|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
79669477|NCT06187051|Device|FEVAR|Relining the EVAR with FEVAR
79669478|NCT06187051|Device|Explantation|open surgery to explant the previous EVAR
79508651|NCT04361760|Device|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
79508652|NCT04361526|Device|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
79508653|NCT04361604|Biological|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
79508654|NCT04361604|Other|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
79508655|NCT04361604|Other|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
79508656|NCT04361448|Other|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
79669479|NCT06187012|Other|Hypertensive pregnancy|Participants will attend one visit lasting approximately 3-4 hours on a single day or split over multiple visits to complete all measures. Participants will first be asked to provide written informed consent for the study. Participants' anthropometric measures (waist-to-hip ratio, height and weight, hip and waist circumference and left arm circumference and resting blood pressures will then be taken. After this, the participants will undergo cardiopulmonary exercise testing, followed by magnetic resonance imaging, echocardiography, retinal imaging and vascular imaging of the ear. The study visit will conclude with participants being provided with a wrist-worn physical activity monitor to wear for 7-9 days following the visit. These monitors will provide objective measures of physical activity while people go about their normal activities.
79669480|NCT06186986|Drug|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
79818741|NCT05915728|Drug|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
79818742|NCT05915728|Drug|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
79508657|NCT04361292|Procedure|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
79508658|NCT04361370|Drug|Olaparib-Pembrolizumab-Bevacizumab|"Olaparib 300mg (twice daily [BID])~Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
79669481|NCT06186973|Other|Monitoring with Neobeat heart rate meter|"At the designated time for cord clamping as per clinical indication, a 10 cm segment of the umbilical cord will be double-clamped and 5 ml of preferably arterial blood will be obtained.~In infants brought to the resuscitation table, six ECG electrodes will be placed on the skin and cardiac output will be measured with a hemodynamic monitor (PhysioFlow®) for at least 10 min, or until the end of resuscitation/stabilization."
79508659|NCT04361136|Drug|Delgocitinib cream|Cream for topical application
79508660|NCT04361136|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
79669482|NCT06186973|Other|Maternal arterial blood gases|Arterial blood gases will be drawn from a radial artery line and analyzed at the end of a contraction at pre-specified time points during labor.
79818743|NCT05915728|Drug|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
79818744|NCT05915728|Drug|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
79818745|NCT05915026|Drug|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
79818746|NCT05913973|Drug|Pvs230D1-EPA/Matrix-M|Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
79357737|NCT04393168|Combination Product|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
79357738|NCT02983708|Biological|Peripheral blood mononuclear cells (mPBMC)|
79669483|NCT06186973|Other|Amniotic fluid lactate|Amniotic fluid will be collected (2mL) and analyzed at pre-specified time points after rupture of the membranes.
79669484|NCT06186960|Device|Tandem Virtual Reality|Hospice patients and their primary caregiver will each wear virtual reality headsets and will experience a customized and synchronized 5-15min virtual reality experience.
79669485|NCT06186947|Other|No intervention|Participants are not subjected to any specific intervention.
79669486|NCT06186921|Drug|Dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
79669487|NCT06186908|Diagnostic Test|Saliva obtaining|Full-mouth clinical periodontal measurements recorded and saliva obtained.
79818747|NCT05910528|Drug|RVT-3101|Induction and maintenance treatment
79818748|NCT05909904|Drug|Tislelizumab|Administered intravenously
79818749|NCT05909904|Drug|BGB-A425|Administered intravenously
79818750|NCT05909904|Drug|LBL-007|Administered intravenously
79818751|NCT05909644|Drug|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
79818752|NCT05909644|Drug|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
79818753|NCT05909397|Drug|ARV-471 (PF-07850327)|Pharmaceutical form: Tablets. Route of Administration: Oral
79818754|NCT05909397|Combination Product|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
79818755|NCT05909397|Drug|Letrozole|Pharmaceutical form: Capsules. Route of Administration: Orally
79357739|NCT02983708|Drug|G-CSF|
79357740|NCT02983708|Drug|Placebo|
79508661|NCT04360902|Other|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
79357741|NCT02979496|Dietary Supplement|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
79357742|NCT02979496|Dietary Supplement|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
79818756|NCT05909397|Combination Product|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
79991812|NCT03497039|Other|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
79991813|NCT02340910|Procedure|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
79991814|NCT02340910|Procedure|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
79357743|NCT02979496|Dietary Supplement|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
79508662|NCT04360668|Other|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
79669488|NCT06186895|Drug|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
79818757|NCT05903105|Other|Questionnaires|Patients fill in a questionnaire
79357744|NCT02979496|Dietary Supplement|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
79669489|NCT06186895|Drug|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
79357745|NCT03824080|Drug|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
79357746|NCT01895335|Drug|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
79669490|NCT06186882|Behavioral|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
79669491|NCT06186869|Behavioral|Aerobic Exercise and diet intervention|subjects randomized and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform moderate-intensity aerobic exercises
79818758|NCT05901922|Behavioral|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
79818759|NCT05901519|Drug|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
79818760|NCT05895552|Drug|RTA 901|RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
79818761|NCT05895552|Drug|Placebo|Matching placebo capsules will be administered once daily during a fasted state.
79818762|NCT05891600|Device|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
79818763|NCT05887167|Biological|autologous hematopoietic stem cells added to planned CAR T|Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
79818764|NCT05883124|Drug|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
79818765|NCT05883124|Drug|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
79669492|NCT06186869|Behavioral|Hiit and diet intervention|subjects randomised and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform high-intensity interval exercises in the gym
79818766|NCT05879926|Drug|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
79818767|NCT05879926|Drug|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
79357747|NCT03829696|Drug|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
79357748|NCT03829696|Drug|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
79818769|NCT05864703|Procedure|Adjustment|Instrument-assisted, high velocity, low amplitude adjustment
79357749|NCT03829696|Drug|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
79357750|NCT03829696|Diagnostic Test|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
79357751|NCT03829774|Device|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
79508663|NCT04360668|Other|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
79508664|NCT04360668|Other|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
79818770|NCT05864703|Procedure|Sham|Instrument-assisted light touch to neck
79818771|NCT05861323|Behavioral|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
79818772|NCT05856331|Drug|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
79818773|NCT05856331|Drug|Zemaira|Alpha1-Proteinase Inhibitor (Human)
79508665|NCT04360512|Procedure|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
79508666|NCT04359966|Drug|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
79508667|NCT04359966|Drug|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
79669493|NCT06186869|Behavioral|Diet|subjects randomised and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet
79357752|NCT03829774|Drug|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
79357753|NCT02974738|Drug|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
79357754|NCT02972398|Drug|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
79357755|NCT02972398|Drug|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
79357756|NCT02971072|Procedure|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
79357757|NCT02971072|Other|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
79357758|NCT04392778|Biological|MSC Treatment|"Protocol length: 1 week~Doses:~Application: 3 million cells/kg IV-------------------------------------------------0 day~Application: 3 million cells/kg IV ------------------------------------------------3rd day~Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
79508668|NCT04359966|Drug|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
79508669|NCT04359966|Drug|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
79508670|NCT04360122|Drug|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
79508671|NCT04360122|Drug|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
79508672|NCT04360122|Drug|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
79508673|NCT04360356|Combination Product|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
79508674|NCT04360356|Other|Standard Care|Oxygen via Ventilators
79508675|NCT04359576|Diagnostic Test|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
79669494|NCT06186843|Behavioral|Plant-based diet|A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
79357759|NCT04392778|Biological|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
79357760|NCT01617655|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
79508676|NCT04359810|Biological|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
79508677|NCT04359810|Biological|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
79508678|NCT04359264|Other|Cash transfer|Cash transfer of $1000
79508679|NCT04359342|Dietary Supplement|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
79508680|NCT04359342|Dietary Supplement|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
79508681|NCT04359342|Dietary Supplement|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
79669495|NCT06186830|Other|Validity and reliability analyses|Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
79508682|NCT04359342|Dietary Supplement|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
79508683|NCT04358952|Diagnostic Test|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
79357761|NCT01617655|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
79508684|NCT04358796|Device|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
79508685|NCT04358796|Device|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
79508686|NCT04358718|Procedure|general anesthesia|Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
79357762|NCT01617655|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
79357763|NCT04758910|Device|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
79669496|NCT06186817|Procedure|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
79669497|NCT06186817|Procedure|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
79357764|NCT04758910|Device|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
79818774|NCT05849207|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
79818775|NCT05848700|Drug|SEP-363856|SEP-363856 Tablet
79508687|NCT04358718|Procedure|general anesthesia combined with epidural analgesia|Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
79508688|NCT04358562|Drug|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
79508689|NCT04358562|Drug|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
79508690|NCT04358094|Other|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
79508691|NCT04358094|Other|Standard script|Standard script during peripherical veinous catheter set up
79357767|NCT03828916|Other|NuShield|SOC surgery with the addition of NuShield
79357768|NCT02965768|Drug|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
79357769|NCT01895101|Drug|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
79669498|NCT06186817|Behavioral|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
79669499|NCT06186817|Procedure|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
79669500|NCT06186804|Drug|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
79669501|NCT06186752|Behavioral|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
79357770|NCT01895101|Drug|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
79357771|NCT03828682|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet [Envarsus]
79357772|NCT03828682|Drug|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
79357773|NCT03828682|Drug|Mycophenolic Acid Oral Product|mycophenolic acid tablets
79357774|NCT03828682|Drug|Tacrolimus|Twice daily tacrolimus
79818776|NCT05848700|Drug|Placebo|Placebo Tablet
79357775|NCT03828682|Drug|Methylprednisolone|Methylprednisolone taper
79357776|NCT03828682|Drug|Prednisone|Prednisone taper
79357777|NCT03828682|Drug|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
79508692|NCT04358484|Behavioral|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
79508693|NCT04358172|Other|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
79669502|NCT06186739|Behavioral|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
79357778|NCT03483649|Drug|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
79357779|NCT03483649|Drug|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
79357780|NCT03483649|Drug|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
79357781|NCT03483649|Drug|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
79669503|NCT06186739|Behavioral|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
79669504|NCT06186713|Other|This was an observational study, and no Intervention was given to the patients.|This was an observational study, and no Intervention was given to the patients.
79357782|NCT03822208|Biological|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
79357783|NCT03822208|Other|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
79357784|NCT03822520|Drug|Celecoxib|Celecoxib 400mg capsule
79357785|NCT03822520|Drug|Moxifloxacin|Moxifloxacin 400mg tablet
79357786|NCT03822520|Other|Water|Pure water 150ml
79357787|NCT03822364|Drug|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
79357788|NCT03822364|Drug|active comparator|commercially available apomorphine injector
79357789|NCT03822364|Drug|009-0|Inhaled placebo via Staccato device
79357790|NCT03822364|Drug|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
79357791|NCT03822364|Drug|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
79357792|NCT03822364|Drug|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
79357793|NCT03822364|Drug|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
79357794|NCT03822130|Drug|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
79357795|NCT03822130|Drug|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
79357796|NCT03822130|Drug|Systemic Chemotherapy|Systemic Chemotherapy
79357797|NCT03822130|Drug|Oral Chemotherapy|Oral Chemotherapy
79228420|NCT03300596|Behavioral|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
79508694|NCT04357860|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
79508695|NCT04357860|Drug|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
79508696|NCT04357860|Drug|Best available treatment|Best available treatment up to 14 days
79508697|NCT04358016|Drug|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
79669505|NCT06186700|Drug|Pentoxifylline|Pentoxiphylline tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
79669506|NCT06186700|Drug|Placebo|Placebo tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
79669507|NCT06186674|Diagnostic Test|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
79991815|NCT04871087|Device|Green Light|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
79508698|NCT04358016|Drug|Somatostatin|Somatostatin
79357798|NCT04274062|Procedure|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
79357799|NCT03821974|Procedure|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
79508699|NCT04357548|Device|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
79508700|NCT04358250|Procedure|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
79508701|NCT04358250|Procedure|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
79508702|NCT04357626|Other|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
79669508|NCT06186674|Diagnostic Test|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
79669509|NCT06186674|Diagnostic Test|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
79508703|NCT04357704|Other|S0N0|(no ITD)
79508704|NCT04357704|Other|S0N500|(ITD +500µs on noise)
79508705|NCT04357704|Other|S-500N500|(ITD -500µs on signal and +500 µs on noise)
79508706|NCT04357704|Other|S0N1000|(ITD + 1000 µs on noise)
79669510|NCT06186661|Other|neurophysiological exercise|The content of the treatment program consisted of neurophysiological exercises based on Bobath.
79669511|NCT06186661|Other|cognitive rehabilitation|Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
79669512|NCT06186648|Drug|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
79669513|NCT06186635|Other|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
79669514|NCT06186635|Other|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
79669515|NCT06186609|Drug|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
79669516|NCT06186596|Device|Triamcinolone delivered via injection assistance device|0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
79991816|NCT02349490|Device|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
79991817|NCT03720899|Drug|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
79508707|NCT04357704|Other|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
79669517|NCT06186583|Drug|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
79669518|NCT06186570|Behavioral|Online-Based Self-Help Intervention|See the description above.
79508708|NCT04357938|Device|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
79508709|NCT04357470|Other|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
79991818|NCT03720899|Drug|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
79991819|NCT02340754|Behavioral|Mindfulness-based Stress Reduction|
79669519|NCT06186557|Other|No intervention|No intervention
79818778|NCT05840159|Drug|Doxycycline|Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
79991820|NCT02340754|Behavioral|MS Education Control|
79508710|NCT04357392|Drug|Prednisone|Prednisone 10mg, TID * 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
79508711|NCT04357002|Drug|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
79508712|NCT04357002|Drug|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
79818779|NCT05840159|Other|Placebo|Placebo
79991821|NCT03145870|Other|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
79991822|NCT03145636|Device|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
79508713|NCT04357002|Drug|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
79991823|NCT03145636|Other|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
79991824|NCT03145636|Other|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
79991825|NCT03145480|Drug|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
79357800|NCT03821974|Procedure|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
79508714|NCT04357080|Procedure|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
79508715|NCT04356846|Drug|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
79508716|NCT04356378|Other|Data record|Data record
79991826|NCT03145480|Drug|Ibrutinib|560mg po daily
79991827|NCT03145480|Other|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
79991828|NCT03726515|Biological|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
79991829|NCT03726515|Biological|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
79991830|NCT02349568|Procedure|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
79991831|NCT02349568|Procedure|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
79508717|NCT04356222|Drug|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
79508718|NCT04356222|Drug|methotrexate|Intrathecal chemotherapy specified dose on specified days
79508719|NCT04356144|Diagnostic Test|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
79508720|NCT04356144|Diagnostic Test|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
79508721|NCT04356300|Biological|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
79357801|NCT03821662|Behavioral|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
79357802|NCT01894477|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
79357803|NCT01894477|Drug|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
79991832|NCT03071094|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4
79991833|NCT03071094|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
79508722|NCT04356456|Dietary Supplement|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
79991834|NCT02340364|Behavioral|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
79991835|NCT02340364|Behavioral|Self-care Education|208 patients randomized to self-care education alone.
79991836|NCT05761392|Other|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
79991837|NCT04478968|Other|presence of AVF|Functioning AVF may have cardiotoxic potential
79991838|NCT02525406|Other|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
79669520|NCT06186531|Dietary Supplement|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
79669521|NCT06186531|Drug|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
79991839|NCT04595292|Other|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
79991840|NCT03145402|Biological|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
79991841|NCT03145402|Biological|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
79669522|NCT06186518|Other|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
79991842|NCT04438876|Other|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
79991843|NCT04438876|Other|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
79991844|NCT04477798|Diagnostic Test|PCT-DIA/MS|PCT-DIA/MS will be validated to classify FNA biopsy specimens
79991845|NCT03148990|Biological|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
79357804|NCT01894477|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
79991846|NCT03148990|Biological|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
79991847|NCT02340598|Other|cold vest|The lowering of body temperature increases basal metabolic rate
79991848|NCT03559517|Biological|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
79991849|NCT03559517|Other|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
79991850|NCT02340442|Other|Obstetrical care parameters|
79991851|NCT02340442|Other|DVA measurements|
79991852|NCT02340442|Other|Fundus photographs|
79991853|NCT04477642|Drug|Abatacept|10mg/kg intravenously administered on Day 1
79991854|NCT03149146|Other|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
79357805|NCT01894477|Radiation|Total-Body Irradiation|Undergo TBI
79357806|NCT01894477|Drug|Treosulfan|Intravenously administered Treosulfan
79357807|NCT01894477|Other|Laboratory Biomarker Analysis|Correlative Studies
79357808|NCT03821428|Procedure|Acupuncture|Needling of P6 and CV24 points
79357809|NCT03821428|Procedure|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
79508723|NCT04355988|Procedure|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
79991855|NCT03149146|Other|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
79508724|NCT04356066|Diagnostic Test|serum cxcl10 by ELISA|serum sample
79508725|NCT04355754|Device|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
79508726|NCT04355910|Behavioral|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
79357810|NCT03821350|Other|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
79508727|NCT04355676|Drug|Selinexor|20 mg selinexor oral tablet.
79508728|NCT04355598|Drug|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
79508729|NCT04355598|Drug|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
79508730|NCT04355598|Drug|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
79508731|NCT04355286|Drug|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
79508732|NCT04355520|Drug|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
79508733|NCT04355520|Drug|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
79508734|NCT04355442|Procedure|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
79508735|NCT04355208|Other|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
79508736|NCT04355052|Drug|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
79508737|NCT04355052|Drug|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
79508738|NCT04354974|Behavioral|Evaluation|Evaluation of a cognitive remediation program for mood disorders
79508739|NCT04354662|Drug|Toripalimab|240mg d1
79508740|NCT04354662|Drug|Docetaxel|50mg/m2, d1;
79508741|NCT04354662|Drug|Fluorouracil|2600 mg/m², d1
79508742|NCT04354662|Drug|Leucovorin|200 mg/m², d1
79508743|NCT04354662|Drug|Oxaliplatin|85 mg/m², d1
79508744|NCT04354350|Drug|Ramipril|Ramipril dispensing claim is used as the reference
79508745|NCT04354350|Drug|Telmisartan|Telmisartan dispensing claim is used as the exposure
79508746|NCT04354740|Procedure|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
79508747|NCT04354194|Procedure|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
79508748|NCT04354194|Procedure|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
79508749|NCT04354116|Device|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
79357811|NCT03820648|Device|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
79991856|NCT02344732|Drug|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
79991857|NCT02344732|Drug|Homatropine 2% eye drops thrice daily|
79991858|NCT02344732|Drug|Oxygen gas|
79228421|NCT01337115|Procedure|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
79357812|NCT03820648|Device|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
79357813|NCT03821194|Other|Gua sha|Scrape the skin around the knee joint
79357814|NCT03821194|Other|hot pack|hot pack
79508750|NCT04354116|Device|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
79357815|NCT03820570|Procedure|hernia repair|inguinal hernia repair
79508751|NCT04353882|Other|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
79508752|NCT04353570|Other|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
79357816|NCT03820414|Biological|CRV 101|(Different formulations)
79357817|NCT03820414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
79357818|NCT03820336|Dietary Supplement|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
79357819|NCT03820336|Dietary Supplement|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
79508753|NCT04353336|Drug|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
79508754|NCT04353726|Other|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
79669523|NCT06186518|Other|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
79669524|NCT06186505|Device|AirGlove|AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
79669525|NCT06186492|Drug|WVE-006|RNA editing oligonucleotide
79669526|NCT06186479|Drug|Aconite pain oil|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
79357820|NCT04391998|Drug|Iron Supplement|oral tablet twice daily after meals
79357821|NCT04391998|Drug|Metronidazole Oral|500 mg oral twice daily
79508755|NCT04353180|Drug|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
79508756|NCT04353180|Drug|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
79991859|NCT03720743|Other|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
79991860|NCT02344654|Drug|Indocyanine green|
79991861|NCT02344654|Device|Near-infrared illumination|To see the fluorescence from indocyanine green
79991862|NCT02344654|Drug|Urografin|
79991863|NCT02344654|Radiation|X-ray|
79508757|NCT04353180|Drug|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
79508758|NCT04353180|Drug|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
79508759|NCT04353180|Drug|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
79508760|NCT04352868|Device|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
79357822|NCT04391998|Drug|Albendazole|200 mg oral single dose
79357823|NCT03828604|Behavioral|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
79508761|NCT04352868|Device|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
79508762|NCT04352946|Drug|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
79357824|NCT03828604|Behavioral|Placebo Trier Social Stress Task|Active control version of the TSST
79357825|NCT03824782|Device|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
79357826|NCT03822598|Behavioral|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
79508763|NCT04352946|Drug|Placebo oral tablet|Placebo tablets 400mg daily
79508764|NCT04352712|Other|blood sampling|blood sampling
79508765|NCT04352634|Other|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
79991864|NCT03720665|Combination Product|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)]
79991865|NCT05253742|Other|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
79508766|NCT04352322|Dietary Supplement|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
79508767|NCT04352322|Dietary Supplement|Placebo|oral solution with no active ingredients
79508768|NCT04352478|Diagnostic Test|Histopathological result|Incidental gallbladder cancer and other pathology
79357827|NCT03792880|Behavioral|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
79508769|NCT04351932|Biological|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
79508770|NCT04351932|Biological|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
79508771|NCT04351932|Biological|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
79508772|NCT04352088|Procedure|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
79508773|NCT04351542|Dietary Supplement|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
79508774|NCT04351542|Other|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
79508775|NCT04351464|Other|physical therapy and reflexology|
79508776|NCT04351308|Drug|MAPI chemotherapy|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²)"
79508777|NCT04351308|Drug|Apatinib Mesylate|anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
79818780|NCT05837377|Other|Control- standard medication education|"Common Procedure:~- Student Information and Consent Form will be obtained from the students.~For the control group~Theoretical training in drug administration skills is provided.~Skill training: Skill training on intramuscular and subcutaneous injection and intravenous medication administration using task trainers in the simulation laboratory.~After the skill evaluation phase, a safe drug administration scenario will be applied."
79818781|NCT05837377|Other|Experiment- cognitive load theory based on medication education|"For the experiment group~Theoretical training will be provided based on the results of both the knowledge test and the self-efficacy test, and will be designed according to the principles of cognitive load theory.~Skills training: includes the necessary skill applications for students with task trainers and a virtual simulation designed according to the cognitive load theory for these skills.~After the skill evaluation phase, a safe drug administration scenario will be applied."
79818782|NCT05834244|Drug|Azacitidine|Given by IV (vein)
79818783|NCT05834244|Drug|Venetoclax|Given by PO
79818784|NCT05834244|Drug|NK Cells|Given by IV (vein)
79508778|NCT04351308|Drug|Camrelizumab|anti-PD-1 antibody 200mg ivgtt. Q2W
79508779|NCT04351152|Biological|Lenzilumab|Administered as an intravenous (IV) infusion
79508780|NCT04351152|Drug|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
79508781|NCT04351074|Procedure|LIFT|ligation of the intersphincteric fistula track
79508782|NCT04351074|Procedure|fistulectomy|excision of the fistulous track with its internal and external orifices
79508783|NCT04350918|Device|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
79508784|NCT04350918|Device|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
79508785|NCT04350996|Other|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
79508786|NCT04350528|Drug|Chlorpromazine or Pentobarbital|Sedation
79508787|NCT04350684|Drug|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
79818785|NCT05827510|Device|BTL-585F|BTL-585F device with BTL-585-4 applicator
79818786|NCT05822609|Drug|Semaglutide|1.0 mg
79508788|NCT04350684|Drug|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
79508789|NCT04350684|Drug|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
79508790|NCT04350684|Drug|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
79508791|NCT04350684|Drug|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
79508792|NCT04350450|Drug|Hydroxychloroquine|400 mg tablet
79818787|NCT05822609|Other|Placebo|Placebo
79818788|NCT05817422|Biological|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
79818789|NCT05817422|Other|Placebo|0.9% NaCl solution for injection.
79991866|NCT05253664|Behavioral|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
79991867|NCT03722537|Procedure|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
79508793|NCT04350216|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
79508794|NCT04349592|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
79508795|NCT04349592|Drug|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
79508796|NCT04349592|Other|Placebo Tablet|Oral, one tablet three times a day for 7 days
79508797|NCT04349592|Other|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
79669527|NCT06186479|Drug|Placebo|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
79818790|NCT05814159|Drug|Anakinra|sub cutaneous daily injection
79818791|NCT05814159|Drug|Placebo|sub cutaneous daily injection
79818792|NCT05801029|Drug|Osimertinib|Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
79818793|NCT05801029|Drug|Amivantamab|Amivantamab will be administered as an IV infusion at 1050 mg (< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (from Day 1 every week for 4 weeks and then every 2 weeks) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg [body weight < 80 kg] or 1050 mg [body weight ≥ 80 kg] on day 2.
79357828|NCT03792880|Behavioral|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
79357829|NCT03774160|Behavioral|Generacion Actual|See description in arm description.
79508798|NCT04349748|Behavioral|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
79508799|NCT04349748|Behavioral|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
79818794|NCT05793567|Diagnostic Test|Coronary angiogram with coronary reactivity testing (CRT)|CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
79818795|NCT05784233|Behavioral|Relevance (Likelihood Salient Item is Target)|The proportion of trials, when the salient visual item is present in the array, where the salient item is the search target.
79818796|NCT05780866|Other|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
79508800|NCT04349202|Diagnostic Test|EUROIMMUN assay|Serology testing to detect SARS-CoV-2 antibodies
79508801|NCT04348812|Behavioral|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
79508802|NCT04348812|Other|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
79508803|NCT04348890|Drug|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
79508804|NCT04347642|Procedure|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
79508805|NCT04347642|Procedure|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
79508806|NCT04347252|Drug|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
79508807|NCT04346940|Other|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
79357830|NCT03822286|Other|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
79357831|NCT03822286|Other|Support group|A counseling master mix 8~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40~60 minutes each time.
79357832|NCT03822286|Other|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
79357833|NCT03820180|Drug|Test Product|2 inhalations of Test and Reference product in each study period
79357834|NCT03820180|Drug|Reference Product|2 inhalations of Test and Reference product in each study period
79508808|NCT04346940|Other|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
79508809|NCT04347096|Behavioral|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
79508810|NCT04347096|Behavioral|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
79508811|NCT04346862|Drug|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
79508812|NCT04346862|Drug|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
79508813|NCT04347174|Drug|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
79669528|NCT06186466|Other|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G*Power software to assess the significance and impact of various factors on the propensity for violence.
79818797|NCT05780814|Behavioral|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
79818798|NCT05780814|Behavioral|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
79991868|NCT03722537|Procedure|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
79991869|NCT04029844|Device|Colibri TAVI System|Implantation of Colibri heart valve
79991870|NCT03726281|Drug|Nivolumab|Nivolumab 240 mg, IV
79357835|NCT01894243|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
79357836|NCT03822832|Drug|BI 655130|Solution for infusion
79508814|NCT04347174|Drug|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
79818799|NCT05764915|Drug|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
79357837|NCT03822832|Drug|Placebo|Solution for infusion
79357838|NCT04758364|Other|measurement of gait speed|Cross sectional, cohort
79508815|NCT04346784|Behavioral|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
79508816|NCT04346784|Behavioral|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
79508817|NCT04346784|Behavioral|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
79508818|NCT04346784|Behavioral|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
79508819|NCT04346550|Other|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS > 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS<3, no fever and tolerating oral intake
79508820|NCT04345848|Drug|Enoxaparin|Two different doses of anticoagulation
79669529|NCT06186440|Drug|Cisplatin Plus Temozolomide|Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
79508821|NCT04345770|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
79508822|NCT04345770|Drug|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
79669530|NCT06186440|Drug|Temozolomide|Temozolomide
79669531|NCT06186388|Diagnostic Test|TEMPO iMOvifa|Screening test with 28 testing points
79669532|NCT06186375|Other|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
79669533|NCT06186349|Genetic|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
79508823|NCT04345770|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
79508824|NCT04345692|Drug|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
79991871|NCT03148834|Procedure|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
79991872|NCT03148912|Diagnostic Test|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
79991873|NCT03726203|Device|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
79991874|NCT03726203|Device|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
79991875|NCT05233306|Device|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
79991876|NCT03720353|Drug|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
79508825|NCT04345380|Other|Implantation of an Alcon Acrysof SN60WF intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
79508826|NCT04345380|Other|Implantation of an AMO Tecnis ZCB00 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
79508827|NCT04345380|Other|Implantation of an Envista MX60 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
79508828|NCT04345458|Drug|prefilled liquid etanercept(Yisaipu)|
79508829|NCT04345458|Drug|lyophilized etanercept powder(Yisaipu)|
79508830|NCT04345614|Drug|Auxora|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
79508831|NCT04345614|Drug|Placebo|Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
79508832|NCT04344912|Other|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
79991877|NCT03720353|Drug|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
79991878|NCT03720353|Drug|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
79991879|NCT02344264|Drug|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
79991880|NCT02344264|Drug|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
79357839|NCT04613713|Other|Somatocognitive physiotherapy|"The main intervention areas include:~education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~techniques to cope with emotions and thoughts related to bodily experiences and to PVD~structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
79357840|NCT04613713|Other|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
79357841|NCT03762694|Device|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
79357842|NCT01450150|Device|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
79357843|NCT01450150|Device|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
79357844|NCT01450228|Drug|KI1001|Prolonged release melatonin 2mg
79357845|NCT01450228|Drug|Placebo KI1001|Placebo KI1001 tablets
79357846|NCT01450384|Drug|sorafenib tosylate|Given PO
79357847|NCT01450384|Drug|pemetrexed disodium|Given IV
79357848|NCT01450384|Other|laboratory biomarker analysis|Correlative studies
79357849|NCT01450384|Procedure|biopsy|Optional correlative studies
79357850|NCT01450462|Dietary Supplement|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
79357851|NCT01450462|Dietary Supplement|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
79357852|NCT02643238|Device|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
79357853|NCT01450774|Drug|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
79508833|NCT04344990|Procedure|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
79508834|NCT04344990|Procedure|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
79991881|NCT03148678|Behavioral|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
79991882|NCT03148678|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
79991883|NCT03148678|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
79991884|NCT03148678|Behavioral|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
79991885|NCT03112252|Other|no specifications. Depending on the patients|patients with allergic rhinitis
79991886|NCT02344030|Device|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
79991887|NCT02344030|Device|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
79991888|NCT03145246|Procedure|regeneration treated teeth loss|number of regeneration treated teeth loss
79991889|NCT03145246|Procedure|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
79991890|NCT02343874|Other|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
79991891|NCT02340208|Drug|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
79991892|NCT02340052|Drug|Pain treatment|Registration af actual analgesic treatment and outcomes
79991893|NCT02340130|Biological|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
79991894|NCT02340130|Biological|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
79357854|NCT01450774|Drug|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
79357855|NCT01450852|Behavioral|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
79357856|NCT01450930|Drug|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
79357857|NCT01450930|Drug|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
79357858|NCT01451008|Device|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
79357859|NCT01451086|Biological|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
79357860|NCT01451086|Biological|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
79357861|NCT01451242|Other|no intervention is made|no intervention is made
79357862|NCT01451710|Drug|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
79508835|NCT04344990|Procedure|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
79508836|NCT04344834|Diagnostic Test|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
79508837|NCT04344756|Drug|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
79357863|NCT01451788|Device|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
79357864|NCT01451866|Other|resistance training|hypertrophic resistance training
79357865|NCT01451866|Other|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
79357866|NCT01451944|Behavioral|education|home asthma case management and education
79357867|NCT01452022|Device|Inductigraft|Synthetic bone graft
79508838|NCT04344288|Drug|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
79508839|NCT04344288|Other|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
79508840|NCT04344522|Procedure|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
79991895|NCT03112330|Device|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
79991896|NCT03112330|Device|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
79991897|NCT03112486|Procedure|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
79991898|NCT02339662|Drug|Gabapentin|muscles pain treatment
79508841|NCT04344522|Procedure|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
79508842|NCT04344522|Procedure|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
79669534|NCT06186336|Other|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
79669535|NCT06186323|Behavioral|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
79669536|NCT06186323|Behavioral|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales | Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills"
79508843|NCT04344522|Procedure|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
79508844|NCT04344210|Behavioral|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
79508845|NCT04343742|Drug|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
79669537|NCT06186323|Behavioral|Test Of Sensory Functions In Infants (TSFI)|his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
79991899|NCT02339662|Drug|Amitriptyline|muscles pain treatment
79357868|NCT01452100|Drug|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
79357869|NCT01452100|Other|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
79991900|NCT02343796|Other|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
79357870|NCT01452334|Biological|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
79357871|NCT01452490|Device|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
79357872|NCT01452568|Drug|Aspirin|150mg/daily for three months, starting day after surgery
79357873|NCT01452568|Drug|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
79991901|NCT02343796|Device|everStick|GC, Belgium
79991902|NCT02343718|Drug|Vinblastine|
79991903|NCT02343718|Drug|Temsirolimus|
79991904|NCT02343562|Dietary Supplement|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
79991905|NCT02343562|Dietary Supplement|Placebo|Multivitamin off-the-counter.
79991906|NCT03148522|Drug|Escitalopram|receive escitalopram
79357874|NCT01452646|Other|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
79508846|NCT04343508|Other|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
79508847|NCT04343196|Radiation|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
79508848|NCT04343118|Procedure|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
79669538|NCT06186310|Other|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
79669539|NCT06186310|Other|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
79357875|NCT01452724|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
79357876|NCT01452724|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
79357877|NCT01452724|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
79508849|NCT04342728|Dietary Supplement|Ascorbic Acid|Readily available marketed open label ascorbic acid
79669540|NCT06186297|Dietary Supplement|Cranberry extract|polyphenol PAC-1
79991907|NCT03148522|Drug|Duloxetine|receive duloxetine
79991908|NCT03148522|Drug|Mirtazapine|receive mirtazapine
79991909|NCT02339896|Biological|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
79508850|NCT04342728|Dietary Supplement|Zinc Gluconate|Readily available marketed open label zinc gluconate
79669541|NCT06186232|Procedure|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
79818800|NCT05763667|Drug|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
79508851|NCT04342728|Dietary Supplement|Ascorbic Acid and Zinc Gluconate|Readily available marketed open label ascorbic acid and zinc gluconate
79508852|NCT04342728|Other|Standard of Care|Readily available prescribed medications/ supplements- None study supplements
79669542|NCT06186219|Drug|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) < 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
79508853|NCT04342650|Drug|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
79508854|NCT04342650|Drug|Placebo oral tablet|150mg placebo tablets
79357878|NCT01452724|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
79357879|NCT01452880|Drug|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
79508855|NCT04342416|Behavioral|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
79991910|NCT03148444|Drug|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
79991911|NCT03148132|Drug|Bevacizumab Injection|0.5mg/0.02 mL
79991912|NCT03148132|Drug|Ranibizumab Ophthalmic|0.25mg/0.025 mL
79991913|NCT02339350|Drug|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
79357880|NCT01452880|Drug|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
79357881|NCT01513239|Biological|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
79508856|NCT04342104|Other|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~lymphopenia~thrombocytopenia~CRP~ferritin~LDH~troponin I~NT-ProBNP~Liver enzymes~D-dimers~radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
79669543|NCT06186167|Procedure|Chest Wall Fat Tissue Collection|As part of routine cardiac device implantation, chest wall fat tissue is collected for histopathological analysis. This tissue, which is typically discarded, will be used to identify amyloid deposits in high-risk cardiac patients. No additional surgical intervention is performed beyond the standard procedure for device implantation.
79669544|NCT06185894|Procedure|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures & tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
79669545|NCT06185894|Procedure|Conventional conservative surgery|Conventional conservative surgery
79508857|NCT04342104|Other|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
79508858|NCT04341714|Other|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
79669546|NCT06185647|Other|No intervention. Observational retrospective study|No intervention.
79669547|NCT06185439|Behavioral|Prenatal Pilates Assisted Childbirth Preparation Training|Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
79991914|NCT02339350|Drug|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
79357882|NCT01513239|Biological|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
79357883|NCT01513239|Biological|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
79357884|NCT01513239|Drug|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
79357885|NCT01453114|Behavioral|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
79508859|NCT04341402|Drug|Antifungal Nail Gel Study|Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
79991915|NCT02339428|Drug|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
79357886|NCT01453192|Drug|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
79991916|NCT02339428|Drug|Placebo|Inactive pill manufactured to mimic diclofenac tablet
79991917|NCT02337322|Drug|Dolutegravir|
79991918|NCT02337322|Drug|Darunavir/r|
79991919|NCT02337166|Device|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
79991920|NCT02337166|Procedure|Periodontal flap surgery|
79991921|NCT03148288|Dietary Supplement|Vitamin D|VItamin D
79991922|NCT03148288|Dietary Supplement|placebo|placebo
79991923|NCT02339272|Other|non interventional|
79508860|NCT04341636|Radiation|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
79357887|NCT01453270|Device|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
79357888|NCT01453270|Other|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
79357889|NCT01453426|Drug|BG00012 Dose 1|
79508861|NCT04341480|Drug|Chemotherapy|Routine chemotherapy for individual tumor type.
79357890|NCT01453426|Drug|BG00012 Dose 2|
79508862|NCT04341168|Other|this study is non- interventional|this study is non- interventional
79508863|NCT04341324|Other|It is an observational study.|
79508864|NCT04340544|Drug|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
79357891|NCT01544127|Behavioral|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
79508865|NCT04340544|Drug|Placebo|Placebo capsules
79508866|NCT04340622|Device|supra-luminous LED|810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
79669548|NCT06185426|Drug|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
79508867|NCT04340622|Device|Sham|Light-emitting diode covered with aluminium foil
79669549|NCT06185179|Drug|Metformin|Metformin will be distributed in 500mg pills.
79991924|NCT02348944|Other|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
79991925|NCT02039362|Drug|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
79991926|NCT04948138|Dietary Supplement|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
79991927|NCT02348866|Other|method of laundering and donning scrubs|
79357892|NCT01544127|Behavioral|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
79508868|NCT04340934|Device|REZUM system|Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
79508869|NCT04340778|Drug|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
79508870|NCT04340778|Drug|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
79508871|NCT04340778|Drug|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
79508872|NCT04340466|Other|No intervention|No intervention
79508873|NCT04340388|Drug|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
79508874|NCT04340388|Drug|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
79818801|NCT05763667|Drug|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
79508875|NCT04340310|Diagnostic Test|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
79669550|NCT06185179|Other|Placebo|Placebo will be distributed in pill form
79669551|NCT06185140|Other|cardiac rehabilitation program|Cardiac rehabilitation program
79818802|NCT05762757|Other|Colposcopy educational material|-Will consist of a handout featuring education and information regarding colposcopies.
79818803|NCT05759377|Device|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
79991928|NCT02339194|Procedure|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
79991929|NCT02339116|Drug|fluoruracil|
79991930|NCT02339116|Drug|Oxaliplatin|
79991931|NCT02339116|Drug|Irinotecan|
79508876|NCT04340232|Drug|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
79991932|NCT02339116|Drug|Bevacizumab|
79991933|NCT02349100|Device|Nellix Endoprosthesis|Implantation of Nellix
79991934|NCT02348710|Behavioral|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
79991935|NCT02348710|Behavioral|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
79991936|NCT03964402|Drug|intervention treatment|intervention treatment (any)
79669552|NCT06185140|Other|TELEA platform|TELEA platform
79669553|NCT06185010|Other|One Resistance Training Set (Single Session)|The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
79508877|NCT04339842|Other|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
79669554|NCT06185010|Other|Three Resistance Training Sets (Single Session)|The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
79669555|NCT06185010|Other|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
79818804|NCT05758545|Device|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The System is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purposes of blinding is sensor detecting whether the device is lying on the skin.
79357893|NCT01544127|Other|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
79357894|NCT01453504|Drug|DHAP|Dexamethasone, Cytarabine, Cisplatin
79357895|NCT01453504|Drug|Everolimus|
79357896|NCT01453582|Drug|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
79508878|NCT04339686|Diagnostic Test|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
79669556|NCT06185010|Other|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
79669557|NCT06185010|Other|Control (8 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
79669558|NCT06184672|Other|dry needling|"the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes"
79818805|NCT05758545|Device|Sham device|The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
79357897|NCT01453582|Drug|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
79357898|NCT01512693|Drug|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
79228422|NCT01337115|Procedure|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
79228423|NCT03761784|Drug|S6G5T-3|Once a day topical cream
79228424|NCT03761784|Drug|S6G5T-8|Once a day topical cream
79357899|NCT02588482|Device|high-density electroencephalography|Auditory stimulations during electroencephalography recording
79357900|NCT02588482|Device|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
79357901|NCT01453738|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
79357902|NCT01453738|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
79357903|NCT01454908|Device|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
79669559|NCT06184542|Biological|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
79669560|NCT06184542|Biological|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
79669561|NCT06184542|Biological|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
79818806|NCT05758077|Device|Selective Cytopheretic Device|"The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation."
79357904|NCT04272892|Behavioral|Digital cognitive behavioural therapy for insomnia|6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
79357905|NCT04272892|Behavioral|Sleep hygiene information|A leaflet detailing advice to improve sleep through changes in sleep hygiene
79669562|NCT06184542|Biological|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
79669563|NCT06184542|Biological|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
79669564|NCT06184542|Biological|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
79669565|NCT06184542|Biological|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
79669566|NCT06184451|Other|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
79508879|NCT04338672|Other|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
79508880|NCT04338906|Drug|Camostat Mesilate|400 mg tid, d1-d7
79508881|NCT04338906|Drug|Placebo|Instead of Camostat Mesilate, tid, d1-d7
79508882|NCT04338906|Drug|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
79508883|NCT04338282|Drug|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
79508884|NCT04338438|Drug|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
79818807|NCT05758077|Other|Standard of Care|Standard of care CKRT for the subject's condition, as appropriate
79818808|NCT05755906|Drug|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
79669567|NCT06184451|Device|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
79818809|NCT05755906|Drug|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
79818810|NCT05747924|Drug|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
79818811|NCT05747924|Drug|Placebo|Placebo will be administered via intravenous (IV) infusion
79818812|NCT05743504|Drug|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
79818813|NCT05736731|Biological|A2B530|Autologous logic-gated Tmod CAR T-cells
79818814|NCT05736731|Diagnostic Test|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
79818815|NCT05735730|Other|Blood draw|The study intervention consists of a blood draw for genetic analysis.
79508885|NCT04338126|Drug|Tranexamic acid|previously described
79508886|NCT04338126|Drug|Placebo oral tablet|previously described
79508887|NCT04337736|Other|Physical exercise|
79508888|NCT04337658|Drug|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
79228425|NCT04100187|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
79508889|NCT04337658|Drug|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
79508890|NCT04337658|Drug|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
79508891|NCT04337658|Drug|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
79508892|NCT04337502|Diagnostic Test|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
79508893|NCT04337424|Diagnostic Test|Sampling salivary|Collection of 1 to 2 ml of saliva
79818821|NCT05728853|Radiation|Assessment of body composition|Assessment of body composition using BIA and DXA
79508894|NCT04337190|Biological|blood sampling|blood sampling at the day of admission, day 3 and day 7
79508895|NCT04337268|Drug|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
79508896|NCT04337268|Drug|saline 0.9%|Intravenous infusion for 60 min.
79818822|NCT05724693|Drug|Bemnifosbuvir (BEM)|Day 1: A single dose of BEM will be administered
79991937|NCT02338804|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
79991938|NCT02338804|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
79991939|NCT02338726|Other|Gynecological examination|Comparison of questionnaires and gynecological examination
79991940|NCT04824274|Drug|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
79991941|NCT04824274|Drug|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
79991942|NCT04824274|Procedure|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
79508897|NCT04337112|Drug|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
79508898|NCT04336566|Dietary Supplement|Melatonin|Melatonin 5mg
79508899|NCT04336566|Dietary Supplement|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
79991943|NCT04824274|Procedure|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
79991944|NCT03112018|Behavioral|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
79508900|NCT04336254|Biological|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
79508901|NCT04336254|Other|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
79508902|NCT04336488|Drug|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
79508903|NCT04336488|Drug|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
79508904|NCT04336176|Device|PulseFlow DF boot|Offloading boot
79508905|NCT04336176|Device|Usual standard of care|Usual standard of care (offloading device)
79508906|NCT04336176|Device|Sham|Sham shoe (closest to barefoot or baseline pressures)
79508907|NCT04335864|Procedure|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
79508908|NCT04335864|Procedure|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
79508909|NCT04335786|Drug|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
79508910|NCT04335786|Drug|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
79818823|NCT05724329|Drug|Tislelizumab + Dasatinib + Quercetin (neoadjuvant)|Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
79818824|NCT05724329|Procedure|surgery|Standard of care
79818825|NCT05724329|Drug|Tislelizumab + Dasatinib + Quercetin (adjuvant)|Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
79818826|NCT05723926|Device|Vine Filter|The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
79818827|NCT05720104|Device|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
79508911|NCT04335630|Diagnostic Test|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
79508912|NCT04335474|Procedure|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
79669568|NCT06184451|Device|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
79818828|NCT05720104|Other|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
79818829|NCT05718258|Drug|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
79991945|NCT03112018|Behavioral|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
79991946|NCT03112018|Behavioral|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
79818830|NCT05717686|Drug|AHB-137 injection|AHB-137 will be administered
79818831|NCT05717686|Drug|Placebo|Placebo will be administered
79818832|NCT05712018|Drug|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
79818833|NCT05712018|Drug|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
79991947|NCT03112018|Behavioral|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
79991948|NCT03112018|Behavioral|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
79991949|NCT03112096|Drug|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
79370930|NCT04358302|Behavioral|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
79508913|NCT04335474|Procedure|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
79508914|NCT04335318|Device|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
79669569|NCT06184295|Device|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
79669570|NCT06184282|Drug|MEBO|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
79669571|NCT06184282|Drug|Lidocaine|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
79991950|NCT03111862|Diagnostic Test|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
79991951|NCT02509494|Biological|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
79991952|NCT02509494|Biological|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
79991953|NCT02509494|Biological|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
79991954|NCT02509494|Biological|Placebo|0.9% saline for injection.
79669572|NCT06184217|Other|Experimental group (MSPE programme group).|Experimental group. MSPE Programme. This group will receive a face-to-face mindfulness MSPE programme for 6 weeks, once a week for 1h 50min-2 hours. In addition to doing mindfulness activities at home. Each session contains the following exercises: (1) intention meditation, sultana exercise, diaphragmatic breathing and sitting meditation with a focus on breath, body and sound; (2) diaphragmatic breathing, Body Scan; (3) sitting meditation, dynamics of emotions, Mindful Yoga on the floor; (4) letting go of attachments, mindful Yoga on the floor walking meditation; (5) sports meditation, sitting meditation with a focus on breath, body and sound; (6) intention meditation, body scan analysis and review of sports meditation.
79991955|NCT02348554|Behavioral|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
79991956|NCT02348554|Behavioral|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
79991957|NCT02348788|Drug|Artemether-lumefantrine + Primaquine|
79991958|NCT02348788|Drug|Chloroquine + Primaquine|
79991959|NCT03147976|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
79991960|NCT05763108|Diagnostic Test|genetic test|COL1A1 or COL5A1 genetic test
79357906|NCT04273204|Diagnostic Test|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
79357907|NCT01458340|Drug|TD-9855|Once daily
79357908|NCT01458340|Drug|TD-9855|Once daily
79991961|NCT05763108|Other|Beighton joint laxity test|Based on Beighton scale.
79357909|NCT01458340|Drug|Placebo|Once daily
79357910|NCT04847752|Procedure|carotid artery stenting|common treatments for carotid artery stenosis
79357911|NCT04847752|Procedure|carotid endarterectomy|common treatments for carotid artery stenosis
79357912|NCT04847752|Drug|Aspirin|the dosage and duration
79818834|NCT05712018|Drug|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
79818835|NCT05710133|Other|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
79357913|NCT04847752|Drug|Clopidogrel|the dosage and duration
79357914|NCT04847752|Drug|Anticoagulant|the dosage and duration
79357915|NCT04847752|Drug|Statin|the dosage and duration
79669573|NCT06184217|Other|Control group (relaxation group).|These instructions included a combination of tension-relaxation of specific muscles and simple breathing techniques. They were recommended to do this on a daily basis, with a minimum of 4 sessions per week.
79357916|NCT04847752|Drug|PCSK9 inhibitor|the dosage and duration
79357917|NCT04844554|Other|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
79357918|NCT04844554|Other|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
79818836|NCT05710133|Other|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
79508915|NCT04334694|Device|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
79669574|NCT06184204|Drug|Trombix® (Rivaroxaban)|20mg or 15 mg as per the doctor's prescription
79669575|NCT06184152|Diagnostic Test|CEUS vs aMRI|Comparison between CEUS and aMRI
79818837|NCT05705401|Radiation|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
79818838|NCT05705401|Drug|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
79991962|NCT04811482|Behavioral|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
79991963|NCT02337010|Device|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
79991964|NCT02337010|Device|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
79991965|NCT02337010|Drug|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
79357919|NCT04846270|Device|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
79357920|NCT04845568|Behavioral|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
79357921|NCT04844008|Dietary Supplement|Nanobubble drink|Commercially available sports drink
79357922|NCT02868190|Device|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
79357923|NCT02864914|Drug|Empagliflozin|drug
79357924|NCT02864914|Drug|DPP-4 inhibitors|drug
79508916|NCT04334928|Drug|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
79508917|NCT04334928|Drug|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
79508918|NCT04334928|Drug|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
79508919|NCT04334928|Drug|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
79669576|NCT06184113|Procedure|Aortic valve replacement surgery|Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
79669577|NCT06184113|Diagnostic Test|Computed tomography|All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
79818839|NCT05698732|Device|Coroflex® ISAR NEO coronary stent system|Patients in whom treatment with Coroflex® ISAR NEO coronary stent system has been attempted
79669578|NCT06184113|Diagnostic Test|Echocardiography|All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.
79669579|NCT06184061|Combination Product|Herbal Supplement|Herbal supplement will be the mixture of strawberry, black mulberry, blueberry, raspberry, ginseng, ashwagandha, honey, water
79818840|NCT05691400|Drug|Palbociclib 125Mg Tab|125 mg single dose
79818841|NCT05691400|Drug|Ribociclib 200Mg Oral Tablet|200 mg single dose
79818842|NCT05691400|Drug|Abemaciclib 150 MG Oral Tablet|150 mg single dose
79818843|NCT05686070|Drug|Asundexian (BAY2433334)|Once daily, oral
79818844|NCT05686070|Drug|Placebo|Placebo to asundexian, once daily, oral
79818845|NCT05683002|Dietary Supplement|Aronia supplementation|As described in experimental arm
79818846|NCT05683002|Dietary Supplement|Cellulose supplementation|As described in placebo comparator arm
79357925|NCT04272814|Other|Compression therapy|Compression application
79508920|NCT04334850|Procedure|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
79508921|NCT04334850|Other|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
79508922|NCT04334616|Device|Video Laryngocope|VDL used for VDL arm
79508923|NCT04334616|Device|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
79508924|NCT04334226|Other|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
79669580|NCT06183619|Procedure|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
79669581|NCT06183619|Procedure|Pulmonary vein isolation|Pulmonary vein isolation only
79357926|NCT04272814|Diagnostic Test|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
79357927|NCT04272580|Drug|Control group|No preload was given before spinal anesthesia.
79357928|NCT04272580|Drug|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
79357929|NCT04272580|Drug|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
79669582|NCT06183177|Other|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
79669583|NCT06183177|Other|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
79669584|NCT06183138|Genetic|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
79669585|NCT06182306|Procedure|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
79669586|NCT06182267|Drug|L Arginine|toothpaste
79669587|NCT06182267|Drug|Sodium Fluoride|toothpaste
79669588|NCT06181825|Behavioral|COMET-BA (Common Elements Toolbox- Behavioral Activation)|COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
79669589|NCT06180824|Drug|Gelafundin|"Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment."
79818847|NCT05682651|Procedure|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
79991966|NCT02337010|Drug|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
79818848|NCT05677854|Other|Health literacy based motivaonal interview|Motivational interviewing technique was used based on health literacy.
79818849|NCT05677854|Other|Health literacy based health education|Health education based on health literacy was used.
79669591|NCT06180330|Other|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
79818850|NCT05676944|Device|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
79357930|NCT04272580|Drug|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
79357931|NCT04390438|Procedure|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
79357932|NCT04390438|Procedure|Dry needling|Needle emplacement without electrical current nor substance
79357933|NCT04843852|Drug|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
79357934|NCT04390516|Device|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
79357935|NCT02849470|Procedure|Intradermal Injection in hair loss|Comparative Injection of Control (PRP & Acel) in hair loss; 2) Intradermal Injection in hair loss
79357936|NCT02849470|Procedure|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
79357937|NCT02849470|Procedure|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
79357938|NCT02849470|Procedure|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
79669592|NCT06180161|Behavioral|multidomain intervention|"Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community."
79669593|NCT06179082|Combination Product|Botox then threads|patients in which Botox injection then threads insertion were used
79818851|NCT05674786|Device|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
79818852|NCT05672355|Procedure|Biospecimen Collection|Undergo blood sample collection
79818853|NCT05672355|Biological|mRNA COVID-19 Vaccine|Given IM
79818854|NCT05672355|Biological|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
79818855|NCT05670795|Drug|Recombinant Follicle Stimulating Hormone|clinical pregnancy rates
79669594|NCT06179082|Procedure|threads only|patients in which threads insertion only was used
79991967|NCT02338570|Drug|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
79669595|NCT06179030|Diagnostic Test|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
79991968|NCT02348320|Biological|Personalized polyepitope DNA vaccine|
79357939|NCT02849470|Procedure|MatriStem Matrix (ACell) - Current Standard of Care|
79669596|NCT06179030|Drug|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
79669597|NCT06178367|Drug|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
79991969|NCT02337088|Procedure|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
79357940|NCT02849470|Procedure|HD-PRP (High Density Platelet Rich Plasma)|
79357941|NCT02849470|Procedure|Emulsified AD-tSVF|
79357942|NCT02849470|Procedure|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
79357943|NCT02846974|Device|Pulse oximeter|A pulse oximeter will be used for calibration
79357944|NCT05025358|Drug|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
79357945|NCT05026528|Other|Digital diabetes self management education and support system|Digital diabetes self management and support system
79669598|NCT06178367|Drug|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
79669599|NCT06178367|Drug|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
79669600|NCT06175962|Behavioral|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
79669601|NCT06174402|Drug|Fenofibrate|Fenofibrate 200 mg/day
79669602|NCT06174402|Drug|Placebo|1 tablet/ day
79508925|NCT04334382|Drug|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
79508926|NCT04334382|Drug|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
79669603|NCT06174402|Drug|UDCA|UDCA 13-15mg/kg/day
79669604|NCT06171945|Behavioral|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
79991970|NCT02337088|Procedure|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
79991971|NCT05114902|Diagnostic Test|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
79818856|NCT05670795|Drug|Recombinant Follicle Stimulating Hormone and Clomiphene Citrate|clinical pregnancy rates
79991972|NCT02338414|Drug|Romiplostim|Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10^9/L -> Subcutaneous Romiplostim (biweekly injection)
79669605|NCT06171945|Behavioral|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
79357946|NCT05024188|Drug|Antibiotics|Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day.
79357947|NCT05024188|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
79357948|NCT05024188|Other|Cellules Pills|7 days of cellules placebo pills.
79357949|NCT05024188|Other|Agarose Capsules|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
79669606|NCT06171945|Behavioral|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
79818857|NCT05668819|Device|TH-001|TH001 is a software program intended to treat adults with prediabetes.
79508927|NCT04333758|Device|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
79357950|NCT05023876|Other|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
79357951|NCT05023876|Other|Respiratory Exercise|Respiratory Exercise
79357952|NCT04390594|Drug|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
79357953|NCT02843386|Drug|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
79357954|NCT02843386|Other|Intensive surveillance|"Intensive surveillance~Total duration: 3 years.~liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
79357955|NCT05022082|Other|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
79508928|NCT04333992|Drug|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
79357956|NCT05024422|Drug|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
79357957|NCT05024422|Drug|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
79357958|NCT04272502|Drug|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
79357959|NCT04758130|Other|Zamplo Digital Health Platform|This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
79357960|NCT01890070|Dietary Supplement|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
79357961|NCT01890070|Dietary Supplement|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
79357962|NCT01890070|Dietary Supplement|Red wine|Italian Organic Red Wine
79508929|NCT04333992|Drug|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
79669607|NCT06171854|Drug|Cabozantinib|cabozantinib in patients with refractory mCRC
79669608|NCT06168539|Other|Emboless|Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.
79669609|NCT06168539|Other|Standard|Standard dialysis set is used as comparative
79669610|NCT06168383|Drug|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
79991973|NCT02336776|Other|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
79991974|NCT02336854|Drug|Tacrobell tab. 2mg|
79991975|NCT02336854|Drug|Prograf cap. 2mg|
79508930|NCT04333836|Device|Removable Clear Aligners|"Plaster dental models will be poured from the rubber base impression.~Digital dental models will be created through scanning of plaster dental models.~Planning of the aligners will be done on 3 shape clear aligner studio®.~Aligners will be fabricated on 3d printed models using vacuum formers.~Anchorage reinforcement for posterior segments by using buccal miniscrews.~Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~Patient will receive the following aligner after 2 weeks.~Follow up visits every 2 weeks until complete canine retraction."
79508931|NCT04332978|Drug|Fluticasone Propionate|
79991976|NCT02338024|Behavioral|Modified Antiretroviral Treatment Access Study intervention|
79357963|NCT01890070|Dietary Supplement|Olive Oil|Italian Organic Olive Oil
79357964|NCT01890070|Dietary Supplement|Wild mixed greens|Italian organic wild mixed greens
79357965|NCT01890070|Dietary Supplement|Chestnut|Italian Organic Chestnut
79991977|NCT02338180|Other|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
79357966|NCT01890070|Other|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
79357967|NCT02819596|Drug|Savolitinib|
79357968|NCT02819596|Drug|MEDI4736|
79357969|NCT02819596|Drug|Tremelimumab|
79357970|NCT02818894|Drug|Lidocaine|Spinal anesthesia administered prior to participant's THA
79357971|NCT02818894|Drug|Bupivacaine|Spinal anesthesia administered prior to participant's THA
79357972|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
79357973|NCT01893736|Other|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
79669611|NCT06168383|Drug|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
79991978|NCT02338180|Other|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
79991979|NCT02039440|Other|Blood draw|One-time blood draw
79991980|NCT02332330|Device|VEST|
79991981|NCT02338102|Other|Saline mixture|premeasured salt packets mixed with distilled water
79991982|NCT02332174|Drug|rufinamide|comparison of different doses, sex and medication conditions
79370931|NCT01670799|Drug|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
79370932|NCT02404935|Drug|Cetuximab|
79508932|NCT04332900|Device|Elastic hip strap|The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.
79991983|NCT02338258|Device|Anti-rotational plate|
79991984|NCT02338258|Device|Exchanged Intramedullary nailing|
79991985|NCT02332252|Device|Scalpel|Skin incision performed with a scalpel during cesarean section.
79669612|NCT06168383|Drug|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
79991986|NCT02332252|Device|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
79669613|NCT06168019|Other|Exposures|COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
79669614|NCT06166485|Other|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
79508933|NCT04332900|Device|Insole|Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
79508934|NCT04333212|Device|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
79508935|NCT04332666|Drug|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
79508936|NCT04332666|Drug|Placebos|infusion of NaCl 0.9% without diluted peptide in it
79508937|NCT04332822|Drug|R-pola-mini-CHP|"Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
79508938|NCT04332822|Drug|R-mini-CHOP|"Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
79508939|NCT04332510|Other|Intact formula|600 ml of infant formula with intact protein
79357974|NCT01893736|Other|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
79669615|NCT06166225|Behavioral|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
79669616|NCT06166225|Behavioral|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
79669617|NCT06166225|Behavioral|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
79228426|NCT03300440|Dietary Supplement|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
79357975|NCT02672644|Device|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
79357976|NCT02672644|Device|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
79357977|NCT05586646|Dietary Supplement|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
79669618|NCT06165900|Drug|adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
79991987|NCT02332252|Procedure|Skin incision|
79370933|NCT02404935|Drug|FOLFIRI and cetuximab|
79370934|NCT00943150|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
79370935|NCT00943150|Procedure|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
79508940|NCT04332510|Other|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
79508941|NCT04332510|Other|High protein formula|600 ml of infant formula with high protein level
79508942|NCT04332510|Other|Human breast milk|600 ml of breast milk, safe for human consumption
79508943|NCT04332276|Drug|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
79991988|NCT03493451|Drug|Tislelizumab|Administered intravenously
79357978|NCT05586568|Drug|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
79508944|NCT04332276|Drug|optimized oral treatment|The patient will received his usual dopaminergic treatment.
79669619|NCT06165900|Drug|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
79669620|NCT06165575|Device|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
79508945|NCT04332354|Other|routine care. No intervention|no intervention
79508946|NCT04332042|Drug|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
79357979|NCT05586568|Drug|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
79357980|NCT05586568|Drug|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
79357981|NCT01893814|Dietary Supplement|Probiotics|
79991989|NCT02332096|Device|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
79357982|NCT01893814|Dietary Supplement|Control|
79357983|NCT02660320|Device|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
79357984|NCT02660320|Device|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
79508947|NCT04332120|Procedure|tubal sterilization|
79508948|NCT04341870|Drug|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
79669621|NCT06165575|Device|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
79669622|NCT06165471|Behavioral|Online and offline blended teaching|The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.
79669623|NCT06165471|Behavioral|Traditional teaching|The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
79669624|NCT06163287|Dietary Supplement|Supplement|Dietary supplement containing molecular hydrogen
79669625|NCT06163287|Dietary Supplement|Placebo|Inert substance
79991990|NCT03726125|Drug|LY3374849 - SC|Administered SC
79991991|NCT03726125|Drug|Insulin Degludec - SC|Administered SC
79991992|NCT03726125|Drug|LY3374849 - IV|Administered IV
79357985|NCT02655406|Other|Class 2 compression stockings|
79357986|NCT02624908|Drug|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
79508949|NCT04341870|Drug|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
79991993|NCT03726125|Drug|Insulin Degludec - IV|Administered IV
79508950|NCT04341870|Drug|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
79508951|NCT04331808|Drug|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
79508952|NCT04331184|Procedure|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
79669626|NCT06161805|Drug|Esketamine hydrochloride|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. [1].
79669627|NCT06161805|Drug|Placebo|8 hour infusion with saline (NaCl 0.9%)
79669628|NCT06160895|Drug|TQ-A3334 tablets|TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
79669629|NCT06160895|Drug|TQ-A3334 placebo tablets|TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
79669630|NCT06157177|Drug|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
79508953|NCT04330872|Drug|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
79508954|NCT04330872|Drug|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
79991994|NCT02337868|Biological|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
79991995|NCT02337868|Other|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
79508955|NCT04331028|Device|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
79669631|NCT06156644|Device|PFA|Ablation to treat trail fibrillation
79357987|NCT02624908|Drug|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
79357988|NCT02616406|Device|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
79508956|NCT04330794|Other|NMFACT|caries index
79508957|NCT04330794|Other|DMF index|caries index chart to collect data about decayed missed filled teeth
79669632|NCT06154278|Drug|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
79669633|NCT06153264|Other|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
79991996|NCT02336620|Drug|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
79991997|NCT02336620|Drug|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
79669634|NCT06153264|Other|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
79669635|NCT06152328|Other|Virtual reality applications based on mirror therapy|Mirror therapy-based games will be played for 30 minutes every day for eight weeks, three days a week, for the VR group.
79991998|NCT03725969|Dietary Supplement|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
79669636|NCT06152328|Other|Conventional treatment|Bobath therapy, walking exercises, upper extremity active exercises, and proprioceptive neuromuscular facilitation techniques will be applied three days a week for eight weeks.
79669637|NCT06152328|Other|Mirror therapy|In conventional mirror therapy, the unaffected extremities of the individuals will be positioned outside the mirror, while the affected extremities will be placed inside the mirror so that the patient cannot see them. In this way, the image of the intact hand will be transferred to the affected side and activities will be performed three days a week for eight weeks.
79669638|NCT06152328|Other|Placebo virtual reality|For 8 weeks, watching the uninteractive virtual environment for 10 minutes
79991999|NCT03725969|Dietary Supplement|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
79992000|NCT02336308|Drug|Ketamine|
79228427|NCT03300440|Dietary Supplement|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
79357989|NCT02597374|Device|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
79357990|NCT05586412|Device|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
79357991|NCT02587000|Drug|Ulipristal acetate|
79357992|NCT02587000|Drug|Placebo|
79508958|NCT04331106|Diagnostic Test|Online Questionnaire|Online Questionnaire via SoSci Survey
79992001|NCT02336308|Drug|Placebo, Normal Saline|
79992002|NCT02332018|Radiation|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
79992003|NCT02336386|Drug|CDD|Chemotherapy
79508959|NCT04330404|Behavioral|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
79508960|NCT04330404|Behavioral|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
79357993|NCT04757818|Other|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
79357994|NCT04757818|Other|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
79508961|NCT04330326|Drug|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
79508962|NCT04330326|Drug|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
79508963|NCT04329936|Behavioral|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
79508964|NCT04329858|Procedure|silver modified glass ionomer|occlusal cavity filled with silver modified
79508965|NCT04329858|Procedure|zinc modified|occlusal cavity filled with zinc modified
79508966|NCT04329858|Procedure|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
79508967|NCT04329468|Device|DS-MCE|"The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel."
79508968|NCT01628250|Procedure|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
79992004|NCT02336386|Drug|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
79357995|NCT04758052|Other|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
79508969|NCT01628250|Procedure|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
79508970|NCT01620996|Behavioral|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
79669639|NCT06151717|Other|Non-Interventional Study|Non-interventional study
79992005|NCT02337712|Radiation|q.d. RT|65 Gy in 26 fractions
79992006|NCT02337712|Radiation|b.i.d.RT|45 Gy in 30 fractions
79992007|NCT02337712|Drug|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
79992008|NCT02337556|Other|Peptamen Bariatric|Commercially available enteral diet
79992009|NCT02337556|Other|Replete|Commercially available enteral diet
79992010|NCT04564534|Other|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
79992011|NCT04490902|Procedure|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
79992012|NCT04490902|Procedure|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
79228428|NCT02236065|Procedure|Umbilical cord blood therapy|
79357996|NCT02563678|Drug|Hyperbaric Oxygen|Hyperbaric oxygen therapy
79357997|NCT02563678|Other|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
79357998|NCT02563678|Other|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
79357999|NCT02562430|Drug|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
79358000|NCT02562430|Drug|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
79669640|NCT06150144|Drug|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
79669641|NCT06150144|Other|SURGERY|Total excision of the lesion
79669642|NCT06148337|Dietary Supplement|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
79358001|NCT02556424|Drug|Dexamethasone|Intravitreal implant at D0
79358002|NCT02556424|Drug|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
79669643|NCT06148337|Dietary Supplement|Placebo|psyllium husk fiber powder
79669644|NCT06147336|Device|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
79669645|NCT06146088|Biological|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
79669646|NCT06144762|Biological|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
79992013|NCT02337400|Behavioral|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
79358003|NCT02549638|Genetic|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
79358004|NCT02543944|Drug|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
79992014|NCT02337400|Behavioral|15 minute counseling interview|
79992015|NCT02899858|Other|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
79992016|NCT02899858|Other|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
79508971|NCT01620996|Behavioral|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
79669647|NCT06144385|Biological|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
79669648|NCT06144099|Biological|fresh frozen plasma|transfusion of fresh frozen plasma
79669649|NCT06144099|Biological|prothrombin complex concentrate|prothrombin complex concentrate administration
79669650|NCT06143436|Diagnostic Test|Constitution in Chinese Medicine Questionnaire|Using questionnaire to collect data from new lung cancer patients.
79669651|NCT06143020|Procedure|Erector spinae plane block|In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
79669652|NCT06141460|Drug|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
79669653|NCT06140966|Drug|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
79669654|NCT06140966|Drug|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
79669655|NCT06140966|Drug|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
79669656|NCT06140966|Drug|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
79508972|NCT01620996|Behavioral|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
79508973|NCT00704106|Drug|Entecavir|0.5 or 1 mg dose qd
79669657|NCT06140966|Drug|Cisplatin|Given by vein: days 1-4 of each Induction cycle
79669658|NCT06140966|Drug|epirubicin|Given by vein: days 1-4 of each Induction cycle
79669659|NCT06140966|Drug|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
79669660|NCT06140966|Drug|Etoposide|Given by vein: days 1-4 of each Induction cycle
79669661|NCT06140966|Drug|Melphalan|Given by vein: day -1 of Transplant
79669662|NCT06140966|Procedure|ASCT|day 0 of Transplant
79669663|NCT06140966|Drug|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
79669664|NCT06139107|Drug|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
79669665|NCT06139107|Drug|Letrozole|Letrozole 2.5mg daily
79669666|NCT06136832|Behavioral|Pneumococcal Vaccine Education|Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
79358005|NCT02543944|Drug|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
79358006|NCT02543944|Drug|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
79358007|NCT02543944|Drug|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
79508974|NCT05620992|Device|Echocardiography|Echocardiography 3 and 6 months post operative
79358008|NCT02543944|Drug|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
79358009|NCT02543944|Drug|Placebo|Microcrystalline cellulose
79358010|NCT02531308|Drug|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
79508975|NCT05620680|Biological|CD7 CAR-T cells|patient was subjected to 0.5-2×10^6 cells/kg of CD7 CAR- T
79508976|NCT05620602|Other|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
79508977|NCT05620602|Other|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
79669667|NCT06136455|Drug|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
79669668|NCT06136455|Drug|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
79669669|NCT06136455|Other|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
79669670|NCT06136455|Drug|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
79358011|NCT02531308|Drug|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
79358012|NCT02531308|Drug|Cyclophosphamide|Interferes with DNA replication
79358013|NCT02531308|Drug|Doxorubicin|anthracycline antitumor antibiotic
79358014|NCT02531308|Drug|Vincristine|Inhibits cell mitosis causing cell death.
79358015|NCT02531308|Drug|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
79358016|NCT02531308|Drug|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
79358017|NCT02523976|Drug|Dasatinib|Second-generation tyrosine kinase inhibitor
79358018|NCT02523976|Drug|prednisone|
79358019|NCT02523976|Drug|cyclophosphamide|
79358020|NCT02523976|Drug|daunorubicin|
79358021|NCT02523976|Drug|vincristine|
79358022|NCT02523976|Drug|cytarabine|
79358023|NCT02523976|Drug|mercaptopurine|
79358024|NCT02523976|Drug|methotrexate|
79358025|NCT02523976|Drug|dexamethasone|
79358026|NCT02523976|Drug|mitoxantrone|
79358027|NCT02523976|Drug|etoposide|
79358028|NCT02523976|Procedure|allogeneic hematopoietic stem cell transplantation|
79358029|NCT02523976|Procedure|autologous hematopoietic stem cell transplantation|
79358030|NCT02507986|Device|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
79358031|NCT02507986|Device|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
79508978|NCT05620602|Other|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
79669671|NCT06134804|Biological|ExPEC9V|ExPEC9V will be administered as an IM injection.
79669672|NCT06134804|Biological|Placebo|Placebo will be administered as an IM injection.
79508979|NCT05620602|Other|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
79508980|NCT05620446|Procedure|endoscopy|the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
79508981|NCT05620056|Drug|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
79508982|NCT05619978|Other|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
79508983|NCT05619978|Other|T315I|Patients with chronic myeloid leukemia with T315I mutation
79508984|NCT05619666|Procedure|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
79508985|NCT05614752|Drug|Fexuprazan|Fexuclue Tablet 40mg
79508986|NCT05578638|Combination Product|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
79508987|NCT05578638|Combination Product|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
79508988|NCT05578638|Combination Product|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
79669673|NCT06134804|Biological|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
79669674|NCT06133699|Procedure|Orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye.|Study participants will undergo orchofuniculectomy through an inguinal or laparoscopic approach. After completion of the orchofuniculectomy, indocyanine green (ICG) dye with or without methylene blue dye will be injected into the spermatic cord stump. Next step is detection with a gamma detector the sentinel lymph nodes and follow removing of one or more (up to 4) lymph nodes during laparoscopy. These lymph nodes will be sent for histological examination.
79669675|NCT06133699|Diagnostic Test|Radiopharmaceutical administration (Technetium/methylene blue)|24 hours before surgery, a radiotracer (RP) will be injected into the spermatic cord followed by SPECT to identify the regional sentinel lymph node(s).
79508989|NCT05345106|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
79669676|NCT06132126|Drug|LY3938577|Administered SC.
79669677|NCT06132126|Drug|Placebo|Administered SC.
79669678|NCT06132126|Drug|Insulin degludec|Administered SC.
79992017|NCT02899858|Procedure|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
79992018|NCT02899858|Other|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
79992019|NCT02899858|Other|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
79992020|NCT02899858|Other|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
79228429|NCT02236065|Biological|Filgrastim|
79370936|NCT03511131|Behavioral|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
79508990|NCT05285826|Biological|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
79508991|NCT05285826|Other|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
79508992|NCT05281536|Other|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
79508993|NCT05278884|Behavioral|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
79508994|NCT05278884|Behavioral|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
79508995|NCT05136690|Drug|Nicotine patch|Nicotine 21 mg transdermal nicotine patch.
79508996|NCT05136690|Drug|MK-4334|MK-4334 250 mg capsule taken by mouth.
79508997|NCT05136690|Drug|Placebo patch|Placebo patch.
79508998|NCT05136690|Drug|Placebo capsule|Placebo capsule taken by mouth.
79669679|NCT06131866|Other|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
79669680|NCT06131788|Behavioral|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
79669681|NCT06129890|Device|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
79370937|NCT03511131|Behavioral|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
79508999|NCT05135754|Device|Heylo|Test of the supporting product (test product) for a 12 weeks period. No measurement will be conducted. All endpoints are captured via surveys send to the subjects every 14 days.
79509000|NCT05035680|Biological|Unadjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection
79509001|NCT05035680|Biological|SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)|Single 0.8 mL IM injection
79509002|NCT05035680|Biological|MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
79509003|NCT04902066|Other|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
79509004|NCT04902066|Other|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
79509005|NCT04578678|Other|Steering|Fine tuning of the STN-DBS settings
79509006|NCT04505358|Drug|PU-AD|active vs placebo
79509007|NCT04505358|Drug|Placebo|active vs placebo
79669682|NCT06129890|Device|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
79370938|NCT03511131|Behavioral|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
79370939|NCT03511131|Behavioral|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
79509008|NCT04133142|Procedure|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
79509009|NCT03956082|Device|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
79669683|NCT06129175|Biological|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
79669684|NCT06129175|Other|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
79669685|NCT06129058|Device|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
79669686|NCT06129058|Device|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
79358032|NCT05586256|Radiation|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
79358033|NCT02505958|Other|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
79509010|NCT03956082|Device|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
79509011|NCT03538314|Drug|UV1|UV1 (300 microgram)
79509012|NCT03538314|Drug|GM-CSF|GM-CSF (37,5 or 75 microgram)
79509013|NCT03233802|Behavioral|Individualized Assess & Treatment (IATP)|See previous description
79509014|NCT03233802|Behavioral|Packaged Cognitive-Behavioral (PCBT)|See previous description
79509015|NCT03233802|Behavioral|Case Management (CaseM)|See previous description
79509016|NCT03063450|Drug|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
79992021|NCT03492281|Drug|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
79669687|NCT06128304|Other|Core Implementation strategies|"Core Implementation Strategies~Ongoing consultation~Educational meetings~Strengthen referral system~Prepare patients to be active participants"
79669688|NCT06128304|Other|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement"
79228430|NCT02467556|Drug|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
79669689|NCT06128239|Behavioral|Caring Contacts|Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.
79669690|NCT06127823|Behavioral|Dietary treatment|Dietary counselling
79992022|NCT03492281|Drug|Vibegron placebo|placebo to match vibegron (experimental drug)
79992023|NCT03492281|Drug|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
79358034|NCT02505958|Other|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
79358035|NCT01893892|Dietary Supplement|levocarnitine|Given PO
79358036|NCT01893892|Other|placebo|Given PO
79358037|NCT01893892|Other|questionnaire administration|Ancillary studies
79358038|NCT04757974|Drug|Fostemsavir 600 mg|Fostemsavir tablets will be administered via oral route.
79509017|NCT03063450|Other|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
79509018|NCT02882646|Device|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
79509019|NCT02788344|Other|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
79509020|NCT01436292|Drug|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS."
79509021|NCT01326000|Drug|FOLFIRI|standard iv chemotherapy
79509022|NCT01326000|Drug|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
79669692|NCT06126562|Drug|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
79669693|NCT06119165|Behavioral|Environmental nudges|Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
79992024|NCT03492281|Drug|Tolterodine placebo|placebo to match tolterodine (active comparator)
79992025|NCT02331784|Behavioral|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
79358039|NCT04757974|Drug|Fostemsavir 200 mg|Fostemsavir tablets will be administered via oral route.
79358040|NCT04757506|Drug|Naltrexone|opioid receptor antagonist
79992026|NCT02331784|Behavioral|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
79992027|NCT02327494|Drug|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
79992028|NCT02336152|Device|Anaesthesia, Teles Pro, Body suit|
79358041|NCT04757506|Drug|Placebo|
79669694|NCT06118411|Drug|Upadacitinib|Oral Tablets
79509023|NCT01326000|Drug|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
79509024|NCT00807456|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
79509025|NCT03035214|Drug|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
79509026|NCT03035370|Biological|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
79509027|NCT03035370|Biological|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
79509028|NCT03035370|Biological|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
79509029|NCT03035370|Biological|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
79509030|NCT03035058|Drug|Vedolizumab|Vedolizumab intravenous infusion
79358042|NCT02484820|Device|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
79669695|NCT06118411|Drug|Placebo|Oral Tablets
79992029|NCT02331862|Drug|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
79992030|NCT02327182|Drug|MT-4666|
79992031|NCT02327026|Procedure|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
79669696|NCT06117969|Drug|Tibolone|1.25mg po qd
79669697|NCT06117969|Drug|Xiangshao granules|4g po tid
79669698|NCT06117969|Drug|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
79992032|NCT02327026|Procedure|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
79992033|NCT02327104|Behavioral|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
79992034|NCT02327104|Other|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
79992035|NCT03070782|Drug|ISIS 681257|ISIS 681257 solution for SC injection.
79992036|NCT03070782|Drug|Placebo|Sterile normal saline (0.9% NaCl)
79992037|NCT02335840|Other|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
79992038|NCT02335840|Other|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
79358043|NCT02477644|Drug|Olaparib|Tablets, per os, 300 mg twice daily;
79358044|NCT02477644|Drug|Placebo|Tablets, per os, 300 mg twice daily.
79370940|NCT03509025|Drug|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
79509031|NCT03035058|Drug|Placebo|Placebo
79509032|NCT03034824|Procedure|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
79509033|NCT03034824|Procedure|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
79509034|NCT03034824|Procedure|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
79669699|NCT06116708|Device|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
79669700|NCT06116708|Device|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
79370941|NCT04320940|Drug|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
79669701|NCT06113887|Other|psychoeducation based on acceptance and commitment therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
79992039|NCT02335840|Other|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
79669702|NCT06113341|Drug|IDegLira|Pre-filled pen injection.
79509035|NCT03034746|Other|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
79992040|NCT02335840|Other|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
79509036|NCT03034746|Other|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
79509037|NCT03034980|Other|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
79509038|NCT03034590|Other|questionnaire|
79509039|NCT03034434|Device|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
79509040|NCT03034668|Dietary Supplement|CS16-003 Full dose|350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
79509041|NCT03034668|Dietary Supplement|CS16-003 Half dose|175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
79509042|NCT03034668|Dietary Supplement|Placebo|Maltodextrin: 350 mg
79992041|NCT03756688|Device|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
79509043|NCT03034278|Other|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
79509044|NCT03033966|Device|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
79509045|NCT03033810|Device|Fractional flow reserve and instantaneous wave-free ratio|"To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~The development of software for the automatic detection of the lowest point of microvascular resistance."
79509046|NCT03033654|Other|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
79669703|NCT06111040|Other|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
79992042|NCT03756688|Device|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
79992043|NCT03525119|Biological|TDV|TDV SC injection
79992044|NCT03525119|Biological|HAV Vaccine|HAV Vaccine IM injection.
79669704|NCT06110793|Drug|Lenvatinib|20mg orally PO daily
79669705|NCT06110793|Drug|Pembrolizuma|400mg IV Q6W
79669706|NCT06110793|Drug|Fulvestrant|500mg IM Q4W
79669707|NCT06108479|Drug|DF6215|Immunotherapy (cytokine) targeting effector cells.
79992045|NCT03525119|Biological|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
79992046|NCT03525119|Biological|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
79370942|NCT03422523|Drug|Atezolizumab|Intravenous drip
79669708|NCT06101628|Other|Gel nail application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
79992047|NCT04423614|Other|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
79992048|NCT04423614|Other|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
79992049|NCT05230654|Drug|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
79992050|NCT05230654|Drug|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO.
79992051|NCT05761314|Diagnostic Test|Molecular characterization of solid tumor in RASopathies|NGS analysis on tumor sample
79370943|NCT03422523|Drug|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
79370944|NCT03422523|Drug|Gemcitabine 1000 mg|intravenous drip
79370945|NCT03422523|Drug|Oxaliplatin 100 MG|intravenous drip
79370946|NCT03032536|Drug|AL-3778|AL-3778 tablets or capsules
79370947|NCT03032536|Drug|Entecavir|Entecavir once daily for 14 days
79358045|NCT02472028|Other|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
79509047|NCT03033732|Drug|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
79509048|NCT03033732|Drug|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
79509049|NCT03033498|Drug|ABBV-951|ABBV-951 administered by subcutaneous infusion.
79992052|NCT02039518|Drug|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
79992053|NCT02039518|Other|observation group|observation group
79358046|NCT02472028|Other|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
79358047|NCT02466334|Drug|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
79992054|NCT02228304|Drug|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
79992055|NCT02228304|Drug|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
79992056|NCT03722381|Drug|Amlodipine Besylate|Pharmacokinetics
79992057|NCT04352608|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
79509050|NCT03033888|Behavioral|Health-Literacy Focused Education Session|
79509051|NCT03033264|Drug|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
79509052|NCT03033264|Device|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
79509053|NCT03033030|Diagnostic Test|Ultrasound|Ultrasound examination
79509054|NCT03032874|Procedure|Colonoscopy|They all had screening colonoscopy
79509055|NCT03032952|Other|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
79509056|NCT03032796|Behavioral|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
79992058|NCT04352608|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
79992059|NCT04352608|Biological|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
79509057|NCT03032796|Behavioral|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
79992060|NCT04352608|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
79992061|NCT04352608|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
79358048|NCT02466334|Drug|Placebo|40 ml of normal saline over 20 mins
79358049|NCT02460874|Drug|Glyburide|1.25mg, twice a day
79358050|NCT02460874|Other|Placebo|1.25mg, twice a day
79509058|NCT03032796|Behavioral|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
79669709|NCT06101212|Other|survey|After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.
79358051|NCT02451436|Behavioral|Sleep and Media Use Intervention|
79358052|NCT02451436|Behavioral|Study Skills Control Group|
79992062|NCT04352608|Biological|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
79358053|NCT02443324|Drug|Ramucirumab|Administered IV
79358054|NCT02443324|Drug|Pembrolizumab|Administered IV
79358055|NCT01893970|Behavioral|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
79358056|NCT01893970|Behavioral|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
79358057|NCT01894048|Drug|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
79358058|NCT02427178|Biological|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
79358059|NCT02420314|Drug|Paclitaxel|"Administered intravenously (IV)~Prescribed at 200 mg/m2 (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
79509059|NCT03032796|Behavioral|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
79669710|NCT06101173|Biological|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
79669711|NCT06101173|Biological|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
79669712|NCT06101173|Biological|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
79358060|NCT02420314|Drug|Carboplatin|"Administered intravenously (IV)~Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
79358061|NCT02420314|Drug|Ascorbic Acid|"Administered intravenously (IV)~75g per infusion~Two infusions per week~1 cycle is 3 weeks~given up to 4 cycles~may be given while chemotherapy if delayed due to low counts"
79358062|NCT02418832|Procedure|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
79358063|NCT02404012|Dietary Supplement|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
79358064|NCT01539291|Drug|Idelalisib|Idelalisib tablet(s) administered orally twice daily
79358065|NCT04746040|Drug|Test|2 inhalations of Test and Reference product in each study period
79358066|NCT04746040|Drug|Reference|2 inhalations of Test and Reference product in each study period
79669713|NCT06101173|Biological|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
79669714|NCT06101173|Biological|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
79669715|NCT06101173|Biological|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
79358067|NCT02400814|Drug|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
79358068|NCT02400814|Radiation|Stereotactic Body Radiation Therapy|Undergo SAR
79358069|NCT02398240|Drug|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
79358070|NCT02398240|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
79358071|NCT02398240|Drug|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
79509060|NCT03032562|Diagnostic Test|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
79509061|NCT03032718|Behavioral|Whole-body vibration training|Whole-body vibration exercise
79509062|NCT03032094|Procedure|connective tissue graft|palatal connective tissue graft to attain root coverage
79509063|NCT03031860|Other|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
79509064|NCT03031704|Procedure|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
79509065|NCT03031548|Device|Point-of-care ultrasound exam|No intervention
79509066|NCT03031548|Radiation|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
79669716|NCT06100653|Drug|BCG for therapeutic use|The 10 patients were infused with BCG 120mg dissolved in 40 ~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.
79992063|NCT04352608|Biological|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
79358072|NCT02398240|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
79358073|NCT02022280|Drug|Lansoprazole|
79358074|NCT02022280|Drug|Placebo|Vitamin pill
79509067|NCT03031314|Device|barbed suture|
79509068|NCT03031314|Device|standard suture|
79669717|NCT06098612|Drug|C11-SY08|a PET imaging agent
79509069|NCT03031158|Behavioral|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
79669718|NCT06097676|Drug|Placebo|Placebo
79358075|NCT02372734|Other|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
79358076|NCT02364310|Device|Baroreceptor stimulation with Barostim Neo TM|
79358077|NCT01538199|Device|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
79509070|NCT03031158|Behavioral|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
79669719|NCT06097676|Drug|Alprazolam 2 mg|Oral dose of alprazolam 2 mg
79669720|NCT06097676|Drug|Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg|Oral dose of GE-IR 200 mg
79669721|NCT06097676|Drug|Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg|Oral dose of GE-IR 450 mg
79669722|NCT06097676|Drug|Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg|Oral dose of GE-IR 700 mg
79992064|NCT04352608|Biological|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
79992065|NCT04352608|Biological|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
79992066|NCT04352608|Biological|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
79509071|NCT03031470|Drug|Reparixin|Reparixin 168 hrs continuous infusion
79509072|NCT03031470|Other|Standard care procedures|Standard procedures for administration of Immunosuppressive and support post transplant therapies
79992067|NCT04352608|Biological|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
79509073|NCT03031080|Device|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
79992068|NCT04352608|Biological|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
79509074|NCT03031002|Behavioral|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
79358078|NCT01538199|Device|Sham device|The sham device does not emit near-infrared radiation.
79358079|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
79358080|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
79669725|NCT06089239|Other|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
79669726|NCT06089239|Other|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
79669727|NCT06088030|Drug|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
79358081|NCT01511055|Drug|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
79358082|NCT02344186|Drug|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
79669728|NCT06085339|Behavioral|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
79669729|NCT06084195|Biological|Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis~blood sample : 3 EDTA tubes~ex vivo MRI data"
79669730|NCT06080906|Biological|IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
79669731|NCT06080906|Biological|IRV on a 0-, 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
79669732|NCT06080906|Biological|Placebo on Day 0, 28|Two doses of placebo at the vaccination schedule of Day 0, 28
79992069|NCT03722303|Other|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
79992070|NCT03722303|Drug|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
79358083|NCT04757428|Procedure|Endocrown|Endocrown
79358084|NCT01537887|Drug|LY2484595|Administered orally once daily for 10 days.
79358085|NCT01537887|Drug|Placebo|Administered orally once daily for 10 days.
79509075|NCT03030768|Drug|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
79509076|NCT03030768|Behavioral|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
79509077|NCT03030846|Other|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
79509078|NCT03030846|Other|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
79669733|NCT06080906|Biological|Placebo on Day 0, 28, 56|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
79669735|NCT06074627|Dietary Supplement|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
79358086|NCT01537887|Drug|Moxifloxacin|Single dose administered orally.
79992071|NCT05203146|Device|PIMPmyHospital (mHealth tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
79358087|NCT04757350|Other|Observational research, not applicable|Observational research, not applicable
79358088|NCT02305264|Drug|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
79358089|NCT05585944|Diagnostic Test|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
79509079|NCT03030690|Other|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
79509080|NCT03030690|Other|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
79509081|NCT03030690|Other|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
79669736|NCT06074627|Dietary Supplement|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
79992072|NCT05203146|Other|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
79358090|NCT01489527|Biological|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
79358091|NCT01489527|Other|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
79358092|NCT02315170|Device|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
79358093|NCT02315170|Device|standard lid speculum|standard wire lid speculum
79358094|NCT01487577|Drug|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
79358095|NCT02290366|Radiation|Focal prostate brachytherapy with Cesium-131|
79358096|NCT01928056|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
79358097|NCT05585866|Drug|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
79509082|NCT03030456|Device|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
79509083|NCT03031392|Diagnostic Test|Sensitivity test|Routine clinical and radiographic examination
79509084|NCT03031236|Behavioral|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
79509085|NCT03030144|Other|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
79358098|NCT01992952|Drug|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
79358099|NCT01992952|Drug|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
79358100|NCT01992952|Drug|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
79509086|NCT03030300|Drug|Novolin 30R;Pioglitazone;Metformin|"Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
79669737|NCT06074627|Dietary Supplement|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
79818858|NCT05668143|Behavioral|Virtual reality|The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
79358101|NCT01928134|Dietary Supplement|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
79818859|NCT05661604|Other|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be up to 12 months.
79818860|NCT05660486|Other|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
79358102|NCT01928134|Dietary Supplement|Vit K2+CaCO3|
79669738|NCT06074627|Dietary Supplement|Energy Active Study Product 1.3 Usage|Participants will use their Radicle Energy Active Study Product 1.3 as directed for a period of 6 weeks.
79669739|NCT06072794|Drug|VL-PX10|VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
79669740|NCT06068959|Device|Photobiomodulation using LED|Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles
79669741|NCT06068959|Device|Placebo|Photobiomodulation Placebo
79669742|NCT06065527|Behavioral|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
79669743|NCT06065527|Behavioral|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
79358103|NCT01894438|Behavioral|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
79669744|NCT06064890|Procedure|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
79669745|NCT06064890|Genetic|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
79669746|NCT06057571|Drug|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
79669747|NCT06056245|Procedure|Preoperative step|"Explanation of the surgery and use of the IV-PCA pump.~Signed informed consent."
79818861|NCT05660486|Other|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
79818862|NCT05658003|Drug|[177Lu]Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
79358104|NCT01894438|Behavioral|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
79358105|NCT01928212|Device|Optical coherence tomography|
79818863|NCT05658003|Drug|ARDT|administered orally on a continuous basis, as per package insert and guidelines
79358106|NCT01894594|Drug|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
79358107|NCT01928368|Drug|AMG 282|Single dose either subcutaneously or intravenously on day 1.
79992073|NCT02326792|Other|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
79509087|NCT03029442|Drug|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
79358108|NCT01928368|Drug|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
79358109|NCT01970254|Other|Hepatitis B Screening|Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
79358110|NCT01970254|Other|Survey Administration|Ancillary studies
79992074|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
79669748|NCT06056245|Drug|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
79992075|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
79992076|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
79992077|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
79992078|NCT03558503|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
79992079|NCT04351984|Device|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
79992080|NCT05761236|Other|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
79992081|NCT02331706|Drug|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
79992082|NCT02326870|Device|AutoLap|
79992083|NCT03489863|Drug|Prasugrel|Maintenance dose will be maintained for 10±3 days.
79992084|NCT03489863|Drug|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
79358111|NCT04756882|Drug|AbobotulinumtoxinA 500 UNT|"Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes"
79358112|NCT04756492|Drug|sandimmun|follow up for treatment response
79370948|NCT03032536|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
79992085|NCT03144934|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
79509088|NCT03029442|Other|Placebo (normal saline)|Identical Denosumab volume of normal saline
79509089|NCT03029286|Behavioral|Usual Care Arm|Health information provided by the American Cancer Society Website
79509090|NCT03029286|Behavioral|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
79509091|NCT03027492|Other|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
79509092|NCT03025620|Dietary Supplement|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
79509093|NCT03025620|Dietary Supplement|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
79992086|NCT03144934|Drug|Placebo|This is the placebo of GX-I7 described above.
79992087|NCT05763030|Behavioral|Adapted Sleep Well, Bee Well|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
79509094|NCT03024372|Device|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
79509095|NCT03024372|Device|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
79509096|NCT03023514|Dietary Supplement|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
79669749|NCT06056245|Drug|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
79992088|NCT05665205|Other|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
79992089|NCT05665205|Other|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
79992090|NCT04344444|Drug|Hydroxychloroquine|tablets provided as described in Arm B
79358113|NCT02271256|Device|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
79992091|NCT04344444|Drug|Azithromycin|tablets provided as described in Arm C
79992092|NCT03489551|Drug|Haldol|
79992093|NCT03144544|Procedure|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
79509097|NCT03023514|Drug|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
79509098|NCT03022812|Other|Neck-specific exercise|Neck-specific exercise
79992094|NCT05762952|Drug|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
79992095|NCT05762952|Drug|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
79509099|NCT03022266|Behavioral|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
79509100|NCT03021252|Device|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
79509101|NCT03021252|Device|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
79509102|NCT03020784|Drug|Placebo|Placebo
79509103|NCT03020784|Drug|PF-06818883|Treatment
79509104|NCT03019926|Biological|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
79509105|NCT03019848|Dietary Supplement|Curcumin|
79509106|NCT03019848|Other|Placebo|
79669750|NCT06054256|Behavioral|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
79992096|NCT03722225|Other|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
79358114|NCT01894126|Behavioral|Two-way SMS Dialogue|
79358115|NCT01894126|Behavioral|One-way SMS Messaging|
79358116|NCT02267512|Drug|ATG-F|Intravenous (IV)
79509107|NCT03019770|Behavioral|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
79509108|NCT03019614|Drug|Hydrocortisone|Generic hydrocortisone
79509109|NCT03019614|Drug|Chronocort|Modified formulation of hydrocortisone
79358117|NCT01928602|Behavioral|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, & adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
79358118|NCT01928602|Behavioral|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
79358119|NCT01536951|Drug|LY3009104|administered orally
79358120|NCT01536951|Drug|Placebo|Administered orally
79358121|NCT01536951|Drug|moxifloxacin|Administered orally
79358122|NCT02259322|Behavioral|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
79509110|NCT03019380|Device|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
79358123|NCT02259322|Behavioral|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
79358124|NCT02259322|Behavioral|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
79509111|NCT03019302|Device|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
79509112|NCT03019224|Procedure|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
79669751|NCT06054256|Behavioral|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
79818864|NCT05658003|Drug|[68Ga]Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
79818865|NCT05658003|Other|Best supportive care|Best supportive/best standard of care as defined by the local investigator
79358125|NCT01536795|Drug|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
79358126|NCT01536795|Drug|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
79358127|NCT04767633|Drug|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
79358128|NCT01894750|Behavioral|group-based skill building self-care program|
79358129|NCT01894828|Dietary Supplement|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
79358130|NCT05585554|Radiation|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
79358131|NCT05583760|Procedure|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
79358132|NCT05583760|Procedure|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
79358133|NCT01928914|Drug|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
79358134|NCT01928914|Drug|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
79358135|NCT01928914|Drug|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
79358136|NCT01928914|Drug|moxifloxacin|moxifloxacine given on Day 3 only
79358137|NCT01928914|Drug|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
79992097|NCT05202834|Device|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
79358138|NCT01928914|Drug|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
79992098|NCT02331550|Procedure|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
79358139|NCT02249104|Drug|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
79509113|NCT03019224|Procedure|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
79669752|NCT06054256|Other|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
79992099|NCT02331550|Procedure|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
79992100|NCT02335684|Other|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
79992101|NCT02335684|Other|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
79358140|NCT02249104|Other|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
79358141|NCT01928992|Device|3D|subjects that underwent 3D mammography
79358142|NCT01928992|Device|2D|those subjects that underwent 2D mammography
79669754|NCT06052176|Drug|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
79818866|NCT05647811|Drug|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
79358143|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
79358144|NCT01929538|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
79358145|NCT01929538|Device|covered self-expanding biliary metal stent, 12mm in diameter|
79358146|NCT01929538|Device|covered self-expanding biliary metal stent, 10mm in diameter|
79358147|NCT04389736|Behavioral|Sitting|Participants sat in a chair with back, arms and legs supported.
79358148|NCT04389736|Behavioral|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
79669759|NCT06046274|Biological|Pembrolizumab|Pembrolizumab intravenous (IV) infusion
79669760|NCT06046274|Biological|Acasunlimab|Acasunlimab IV infusion
79818867|NCT05646563|Drug|NM8074|NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
79509114|NCT03019224|Procedure|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
79509115|NCT03019224|Procedure|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
79358149|NCT04389736|Behavioral|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
79669761|NCT06041204|Drug|Letrozole 2.5mg|Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
79669762|NCT06041204|Drug|Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet|Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
79669763|NCT06041048|Drug|Modafinil|Single dose (200 mg) of medication versus placebo given to healthy control subjects
79818868|NCT05646563|Drug|Soliris|Complement C5 blocker administered intravenously
79358150|NCT04395040|Other|Semi-structured interview|Semi-structured interview
79358151|NCT01929070|Drug|HCP1007|
79358152|NCT01929070|Drug|Omarco and Crestor|
79358153|NCT01536561|Biological|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
79358154|NCT02243020|Device|Vagus Nerve Stimulation (VNS)|
79358155|NCT01929148|Procedure|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
79358156|NCT01929148|Procedure|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
79358157|NCT02236312|Drug|Botulinum Toxin Type A|
79509116|NCT03019224|Procedure|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
79509117|NCT03019224|Drug|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
79818869|NCT05646524|Drug|NM8074|NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
79818870|NCT05645822|Other|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
79818871|NCT05641259|Drug|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
79818872|NCT05641259|Drug|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
79358158|NCT02236312|Drug|Placebo|
79358159|NCT01916278|Device|Emervel Lips Lidocaine|
79358160|NCT01916278|Device|Juvéderma Volbella with Lidocaine|
79358161|NCT03084640|Drug|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
79358162|NCT03084640|Drug|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
79818873|NCT05633810|Drug|Aspirin|40 mg non-enteric-coated tablet taken twice daily.
79509118|NCT03019224|Procedure|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
79992102|NCT05198388|Diagnostic Test|βeta endorphins, interleukin 6 and interleukin 38|"- Collection of peripheral blood samples in gel tube.~- Creparation of samples in centrifuge to obtain serum.~- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
79669764|NCT06032013|Other|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~Medical assessment~Physical training and counselling on physical activity~Identification and control of risk factors~Nutritional assessment and counselling~Psychological assessment and intervention~Education and information"
79358163|NCT03084640|Drug|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
79358164|NCT01536405|Biological|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
79509119|NCT03019146|Other|HIIT|
79358165|NCT01536405|Biological|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
79358166|NCT01892410|Other|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
79509120|NCT03019146|Other|HOLD|
79358167|NCT04409691|Drug|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
79358168|NCT04409691|Drug|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
79358169|NCT01887808|Other|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
79358170|NCT04096989|Other|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
79509121|NCT03019146|Other|HUG|
79509122|NCT03018990|Other|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
79509123|NCT03018600|Behavioral|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
79509124|NCT03018522|Other|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
79669765|NCT06030141|Other|sesame oil application|sesame oil application
79358171|NCT04096989|Other|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
79509125|NCT03018756|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
79509126|NCT03018756|Drug|Placebo|0.9% saline solution will be inhaled via nebulizer
79509127|NCT03018444|Drug|Atorvastatin|Atorvastatin tablet
79509128|NCT03018444|Other|Placebo|Placebo tablet
79509129|NCT03018210|Procedure|Surgical repair of the rotator cuff|
79509130|NCT03018054|Drug|E6007|once daily administration
79509131|NCT03018054|Drug|Placebo|once daily administration
79509132|NCT03017664|Other|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
79509133|NCT03017664|Other|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
79509134|NCT03017196|Other|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
79669766|NCT06030141|Other|nigella sativa oil application|nigella sativa oil application
79992103|NCT03557801|Behavioral|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
79992104|NCT03557801|Behavioral|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
79992105|NCT03557801|Other|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
79509135|NCT03017430|Drug|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
79509136|NCT03017430|Drug|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
79509137|NCT03017430|Drug|Doxylamin|
79669767|NCT06025292|Other|Lean Pork vs Plant Based|Participants will eat pre prepared study meals for three days that have either protein sourced from lean pork or plant sources.
79992106|NCT05762874|Drug|Ruxolitinib|JAK inhibitor
79992107|NCT04210180|Drug|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
79818874|NCT05633810|Drug|Aspirin Placebo|non-enteric-coated tablet taken twice daily.
79509138|NCT03017430|Drug|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
79509139|NCT03017352|Drug|Exenatide|
79509140|NCT03017352|Drug|Placebos|
79509141|NCT03016884|Biological|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
79509142|NCT03016962|Device|cap-assisted colonoscopy|cap-assisted colonoscopy
79509143|NCT03016962|Device|Standard colonoscopy|Standard colonoscopy
79669768|NCT06020274|Behavioral|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
79992108|NCT04210180|Other|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
79992109|NCT03523871|Drug|Mavyret|Patients will be on 8 weeks of Mavyret
79992110|NCT04017390|Drug|Theraworx Foam|Apply Theraworx Foam alone
79992111|NCT04017390|Drug|Placebo Foam|Apply placebo foam alone
79992112|NCT04017390|Other|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
79509144|NCT03017274|Other|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
79509145|NCT03016572|Behavioral|Standard of Care|Follow-Up Calls, Questionnaires
79509146|NCT03016572|Behavioral|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
79509147|NCT03016572|Behavioral|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
79509148|NCT03016728|Behavioral|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
79509149|NCT03016806|Radiation|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
79509150|NCT03016806|Radiation|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
79509151|NCT03016806|Drug|Cyclophosphamide|50 mg/kg or 60 mg/kg
79509152|NCT03016806|Drug|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
79509153|NCT03016806|Procedure|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
79509154|NCT03016806|Drug|Busulfan|0.8 mg/kg x 16 doses
79509155|NCT03016806|Drug|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
79509156|NCT03016806|Drug|Melphalan|140 mg/m2
79669771|NCT06019975|Diagnostic Test|FDG-PET|Brain FDG-PET
79669772|NCT06018844|Other|NUDGE|NUDGE is a brief mHealth text messaging intervention designed to promote activity in adolescents by allowing them to set, monitor, and receive feedback on daily PA goals through text message.
79669773|NCT06016348|Procedure|Endovascular treatment|This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
79358172|NCT02219776|Drug|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
79358173|NCT02219776|Other|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
79358174|NCT04756960|Drug|CHF6001|4 inhalations of CHF6001 800µg/20mg NEXThaler® DPI (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5kBq)) of [14C]-labelled CHF6001
79358175|NCT01487265|Drug|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
79358176|NCT01516606|Drug|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
79358177|NCT04389970|Behavioral|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
79358178|NCT01485627|Behavioral|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
79509157|NCT03016650|Drug|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
79818875|NCT05633810|Drug|Colchicine|0.5 mg tablet taken once daily
79992113|NCT04017390|Other|Placebo Foam and night time splint|Apply placebo foam and night time splint
79992114|NCT03523715|Dietary Supplement|Prunes|12 oz of prunes daily
79992115|NCT03523715|Drug|Docusate Sodium|Oral docusate sodium twice daily
79992116|NCT03980730|Drug|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
79992117|NCT03980730|Drug|Placebo|Matching placebo capsule administered orally, once daily
79992118|NCT03523091|Drug|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
79992119|NCT02512510|Drug|TD-4208|
79992120|NCT02512510|Drug|Placebo|
79992121|NCT00753090|Device|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
79358179|NCT02209636|Drug|Lanthanum carbonate|Non-calcium containing phosphorus binder
79358180|NCT02209636|Drug|placebo|Table identical to lanthanum carbonate but with no active ingredient
79358181|NCT02209636|Drug|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
79509158|NCT03016650|Drug|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
79509159|NCT03016494|Drug|Co-administration of DWC20155 and DWC20156|
79509160|NCT03016494|Drug|DWJ1386 Tab.|
79509161|NCT03016260|Biological|Infliximab|Anti-TNF alpha originator
79509162|NCT03016260|Biological|Adalimumab|Anti-TNF alpha originator
79509163|NCT03016260|Biological|Etanercept|Anti-TNF alpha originator
79509164|NCT03016260|Biological|Golimumab|Anti-TNF alpha originator
79818876|NCT05633810|Drug|Colchicine Placebo|tablet taken once daily.
79992122|NCT00753090|Device|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
79992123|NCT03438383|Device|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
79509165|NCT03016260|Biological|Certolizumab Pegol|Anti-TNF alpha originator
79509166|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
79509167|NCT03016260|Biological|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
79358182|NCT02209636|Drug|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
79669774|NCT06015789|Other|Questionnaire|Administration of questionnaires for the evaluation of self-care
79509168|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
79669775|NCT06014008|Other|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
79992124|NCT03438383|Device|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
79669776|NCT06012084|Behavioral|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
79669777|NCT06011876|Other|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
79818877|NCT05628324|Behavioral|practice muscle activation patterns|practice upper limb muscle activation patterns using EMG-controlled games
79358183|NCT02209636|Procedure|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
79358184|NCT02209636|Procedure|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
79358185|NCT02209636|Procedure|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
79358186|NCT01515904|Behavioral|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
79509169|NCT03016182|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
79509170|NCT03016182|Procedure|Control|Control group witnout remote ischemic preconditioning
79509171|NCT03016026|Procedure|ERAS|Undergo an ERAS program
79509172|NCT03015870|Behavioral|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
79509173|NCT03015870|Behavioral|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
79509174|NCT03015714|Other|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
79669778|NCT06011876|Other|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
79669779|NCT06011876|Other|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
79669780|NCT06009614|Dietary Supplement|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
79669781|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
79669782|NCT06009614|Dietary Supplement|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
79818878|NCT05628324|Behavioral|task practice|practice functional upper limb tasks
79358187|NCT01508325|Drug|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
79669783|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
79509175|NCT03015714|Other|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
79509176|NCT03015948|Drug|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
79992125|NCT04477408|Other|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
79509177|NCT03015948|Drug|Placebo|a single dose of placebo (n=2) for each dose cohort .
79818879|NCT05626491|Device|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
79818880|NCT05626491|Device|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
79358188|NCT01508325|Drug|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
79358189|NCT01514344|Drug|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
79358190|NCT01514344|Biological|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
79509178|NCT03015480|Behavioral|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
79509179|NCT03015636|Behavioral|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
79509180|NCT03015636|Other|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
79509181|NCT03015246|Drug|Extended release morphine|Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
79509182|NCT03015246|Drug|Buprenorphine/Naloxone low dose|Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
79509183|NCT03015246|Drug|Buprenorphine/Naloxone moderate dose|Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
79509184|NCT03015246|Drug|Buprenorphine/Naloxone high dose|Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
79509185|NCT03015246|Drug|Active stressor|Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
79509186|NCT03015246|Drug|Placebo stressor|Lactose
79509187|NCT03014856|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
79509188|NCT03015168|Radiation|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
79669784|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
79669785|NCT06009614|Dietary Supplement|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
79358191|NCT01508169|Device|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
79669786|NCT06009614|Dietary Supplement|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
79669787|NCT06005480|Drug|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
79669788|NCT06003218|Drug|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
79669789|NCT06003218|Drug|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
79669790|NCT06003218|Drug|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
79992126|NCT05762016|Procedure|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
79992127|NCT03105310|Drug|Pegylated interferon alfa|Pegylated interferon alfa
79992128|NCT03105310|Drug|Ezetimibe|Ezetimibe
79509189|NCT03015012|Genetic|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
79509190|NCT03015012|Other|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
79509191|NCT03014544|Device|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
79509192|NCT03014544|Device|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
79509193|NCT03014778|Drug|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
79509194|NCT03014778|Drug|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
79509195|NCT03014466|Behavioral|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
79509196|NCT03014466|Behavioral|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
79509197|NCT03014310|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
79509198|NCT03014310|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
79509199|NCT03014310|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
79509200|NCT03014154|Other|Training|
79358192|NCT01536171|Other|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
79669791|NCT06002607|Other|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
79669792|NCT06002607|Other|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
79669793|NCT05999305|Other|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
79358193|NCT01536093|Other|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
79358194|NCT01536093|Other|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
79358195|NCT02191930|Drug|B-CAP|
79358196|NCT02191930|Drug|Brentuximab Vedotin|
79358197|NCT01536015|Drug|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
79669794|NCT05999305|Other|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
79818881|NCT05618314|Drug|AT-527|single dose AT-527
79992129|NCT05179434|Procedure|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
79358198|NCT01536015|Drug|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
79358199|NCT04725825|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
79509201|NCT03014232|Procedure|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
79509202|NCT03014232|Procedure|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
79358200|NCT04725825|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
79509203|NCT03014388|Other|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
79358201|NCT03028077|Dietary Supplement|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
79358202|NCT03028077|Dietary Supplement|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
79509204|NCT03014388|Other|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
79509205|NCT03014076|Drug|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
79509206|NCT03014076|Drug|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
79509207|NCT03013842|Device|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
79358203|NCT03028077|Dietary Supplement|Placebo|Placebo 1 g/day
79358204|NCT01863940|Device|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
79358205|NCT01484691|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
79358206|NCT01464034|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
79358207|NCT01464034|Drug|Pomalidomide|PO daily on Days 1-21, every 28 Days
79358208|NCT01464034|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
79509208|NCT03013686|Procedure|Interval appendectomy|Laparoscopic appendectomy
79509209|NCT03013686|Procedure|Follow-up with MRI|Abdominal MRI
79509210|NCT03013764|Behavioral|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
79992130|NCT05179434|Procedure|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
79509211|NCT03013764|Behavioral|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
79509212|NCT03013530|Procedure|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
79509213|NCT03013296|Other|GIP-A|GIP-A
79669795|NCT05992350|Other|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
79669796|NCT05987956|Drug|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
79669797|NCT05987956|Drug|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
79358209|NCT01860898|Other|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
79509214|NCT03013296|Other|Placebo|Placebo
79509215|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
79509216|NCT03013296|Other|GIP-A + Exendin[9-39]|GIP-A + Exendin[9-39]
79509217|NCT03013452|Device|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
79509218|NCT03013452|Behavioral|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
79509219|NCT03013608|Procedure|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
79509220|NCT03013140|Drug|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV<5%"
79509221|NCT03013140|Procedure|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
79509222|NCT03012906|Other|the prevalence of ischemic events|
79509223|NCT03012516|Behavioral|PAP-treatment by physiotherapist|
79509224|NCT03012516|Behavioral|Ordinary PAP-treatment at the health care center|
79669798|NCT05985434|Procedure|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
79669799|NCT05981235|Biological|AZD6422 CLDN18.2 CAR-T product|AZD6422 CAR-T product infusion after pre-conditioning
79669800|NCT05981118|Drug|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
79992131|NCT02326714|Other|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
79992132|NCT02326714|Other|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
79509225|NCT03012750|Drug|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
79669801|NCT05981118|Drug|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
79669802|NCT05973448|Other|Novel Lighting Condition|Horizontal and vertical lights over a doorway visible from the bed
79669803|NCT05973448|Other|Control Lighting Condition|Standard night light plugged into wall socket
79669804|NCT05968456|Other|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
79818882|NCT05618314|Drug|AT-527|Single dose of AT-527 pre- and post-dialysis
79358210|NCT01458730|Drug|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
79358211|NCT01535235|Drug|Lisinopril|Lisinopril 20mg QD x 24 weeks
79358212|NCT01535235|Drug|Placebo|Placebo QD x24wks
79358213|NCT02985723|Device|AT LISA tri toric 939MP|
79818883|NCT05618314|Drug|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
79358214|NCT04748211|Procedure|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
79358215|NCT04748211|Procedure|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
79509226|NCT03012204|Device|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
79509227|NCT03012204|Device|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
79509228|NCT03012204|Device|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
79992133|NCT03144466|Combination Product|Pembrolizumab|antiPD1 monoclonal antibody
79992134|NCT03144310|Other|lung ultrasound|lung ultrasound and blood gas
79358216|NCT04095429|Behavioral|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
79358217|NCT04095429|Behavioral|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
79669806|NCT05961410|Drug|Eltrombopag olamine|Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
79669807|NCT05956769|Drug|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
79669808|NCT05956769|Diagnostic Test|thromboelastography|thromboelastography (TEG6)
79669809|NCT05956769|Drug|Placebo|Normal saline injection
79669810|NCT05956665|Behavioral|Shed-MEDS deprescribing intervention|See single arm description
79509229|NCT03012204|Device|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
79509230|NCT03012438|Device|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
79669811|NCT05945212|Device|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
79669812|NCT05945212|Device|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
79669813|NCT05945212|Other|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
79669814|NCT05945212|Other|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
79669815|NCT05945212|Other|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
79818884|NCT05610982|Behavioral|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
79509231|NCT03012048|Device|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
79669816|NCT05945212|Other|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
79669817|NCT05945212|Other|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
79669818|NCT05945212|Other|Barthel index|The Barthel index measure autonomy in daily life.
79669819|NCT05945212|Other|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
79818885|NCT05609370|Drug|LBL-007|Low dose intravenously (IV) once every 3 weeks.
79818886|NCT05609370|Drug|LBL-007|Medium dose IV once every 3 weeks
79358218|NCT02168686|Genetic|ADVM-043|Gene transfer vector administration
79358219|NCT04756336|Drug|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
79358220|NCT01456390|Device|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
79358221|NCT02317744|Drug|Naltrexone and bupropion combination|
79358222|NCT02317744|Other|Pill Placebo|
79358223|NCT05577442|Drug|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
79358224|NCT01895764|Drug|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
79358225|NCT01895764|Drug|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
79509232|NCT03012048|Device|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
79509233|NCT03012048|Device|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
79509234|NCT03012126|Behavioral|Healthy Weight Clinic|
79358226|NCT04756102|Other|Observation of their fetomaternal outcome|observe the fetal outcome and maternal outcome
79358227|NCT01895140|Device|Renal denervation device|
79358228|NCT01894360|Drug|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
79358229|NCT01483599|Drug|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
79358230|NCT01483599|Drug|CNTO 1959 (15 mg)|SC injections
79358231|NCT01483599|Drug|CNTO 1959 (50 mg)|SC injections
79358232|NCT01483599|Drug|CNTO 1959 (100 mg)|SC injections
79358233|NCT01483599|Drug|CNTO 1959 (200 mg)|SC injections
79358234|NCT01483599|Drug|Adalimumab|SC injections
79358235|NCT01483599|Drug|Placebo|SC injections
79358236|NCT01407562|Drug|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
79818887|NCT05609370|Drug|LBL-007|High dose IV once every 2 or 3 weeks
79509235|NCT03012126|Behavioral|Healthy Weight and Your Child|
79509236|NCT03011970|Drug|Oxytocin|
79509237|NCT03011970|Drug|Placebo|
79509238|NCT03011736|Other|Laboratory Biomarker Analysis|Correlative studies
79358237|NCT01407562|Drug|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
79509239|NCT03011736|Procedure|Parathyroidectomy|Undergo parathyroidectomy
79509240|NCT03011658|Procedure|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
79509241|NCT03011502|Other|Biological samples collection of blood and feces|
79669820|NCT05945212|Other|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
79669821|NCT05945212|Other|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
79669822|NCT05945212|Other|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
79669823|NCT05945212|Other|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
79669824|NCT05943977|Drug|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
79669825|NCT05943977|Drug|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
79818888|NCT05609370|Drug|Tislelizumab|Low dose IV once every 3 weeks
79818889|NCT05609370|Drug|Tislelizumab|High dose IV once every 4 weeks
79358238|NCT01407562|Drug|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
79358239|NCT01406548|Drug|BPS804 20mg/Kg|
79818890|NCT05609370|Drug|Bevacizumab biosimilar|7.5 mg/kg IV every 3 weeks
79818891|NCT05609370|Drug|Bevacizumab biosimilar|5 mg/kg IV once every 2 weeks
79358240|NCT01406548|Drug|Placebo to 20mg/Kg BPS804|
79358241|NCT01798810|Procedure|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
79358242|NCT01393522|Drug|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
79358243|NCT01393522|Drug|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
79358244|NCT02086786|Drug|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
79358245|NCT02120482|Device|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
79358246|NCT02318992|Biological|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
79358247|NCT04389814|Diagnostic Test|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
79358248|NCT01776736|Device|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
79358249|NCT02108158|Drug|Azzalure|
79358250|NCT01774630|Drug|Nilotinib|300 mg/twice a day
79358251|NCT01895920|Other|Blood sample|
79358252|NCT01895218|Drug|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
79358253|NCT01895218|Other|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
79358254|NCT01895998|Drug|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
79358255|NCT02086708|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
79358256|NCT02065882|Biological|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
79358257|NCT01507545|Drug|MORAb-004|MORAb-004 8mg per kg IV once a week
79358258|NCT01507545|Drug|Placebo|Placebo - normal saline IV once a week
79358259|NCT01507545|Other|Best supportive care|Best supportive care to improve quality of life
79358260|NCT04409535|Other|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
79358261|NCT01482819|Device|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
79358262|NCT01482819|Device|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
79509242|NCT03011424|Device|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
79509243|NCT03011580|Dietary Supplement|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
79509244|NCT03011580|Dietary Supplement|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
79509245|NCT03011190|Behavioral|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
79358263|NCT01482819|Device|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
79358264|NCT01482819|Device|polymacon|contact lenses worn bilaterally for 8-12 hours
79358265|NCT01482819|Other|spectacles|habitual spectacles owned by subject, non-specific manufacturer
79358266|NCT01534533|Dietary Supplement|Placebo|one gelatine capsule containing starch per day, for 12 months
79358267|NCT01534533|Dietary Supplement|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
79358268|NCT01534533|Dietary Supplement|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
79509246|NCT03010878|Other|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
79509247|NCT03010878|Other|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
79818892|NCT05609370|Drug|Capecitabine|850 milligrams per square meter (mg/m^2) twice daily orally for 2 weeks, followed by a one-week treatment break every 3 weeks
79358269|NCT01534533|Dietary Supplement|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
79358270|NCT02986035|Other|ECA cream|
79358271|NCT02061358|Drug|UV-4B 3 mg|Oral solution, single dose
79358272|NCT02061358|Drug|UV-4B 10 mg|Oral solution, single dose
79358273|NCT02061358|Drug|UV-4B 30 mg|Oral solution, single dose
79358274|NCT02061358|Drug|UV-4B 90 mg|Oral solution, single dose
79358275|NCT02061358|Drug|UV-4B 180 mg|Oral solution, single dose
79358276|NCT02061358|Drug|UV-4B 360 mg|Oral solution, single dose
79358277|NCT02061358|Drug|UV-4B 720 mg|Oral solution, single dose
79818893|NCT05609370|Drug|5-Fluorouracil|1600 to 2400 mg/m^2 IV every 2 weeks
79818894|NCT05606952|Device|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
79818895|NCT05606406|Other|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
79509248|NCT03011112|Procedure|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
79992135|NCT05173350|Other|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
79992136|NCT05173350|Other|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
79992137|NCT03105466|Procedure|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
79992138|NCT03105466|Device|Acellular Porcine Cornea|
79992139|NCT03105466|Drug|Tacrolimus eye drops|
79992140|NCT03105466|Drug|Tobradex eyedrops|
79509249|NCT03010722|Drug|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
79992141|NCT02335528|Behavioral|SimCoach|
79992142|NCT03478787|Drug|risankizumab|Subcutaneous (SC) injection
79992143|NCT03478787|Drug|secukinumab|Subcutaneous (SC) injection
79509250|NCT03010644|Other|n/a - observational study|n/a - observational study
79509251|NCT03010098|Device|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
79669826|NCT05943977|Device|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
79669828|NCT05931601|Drug|Noradrenaline|See arm description
79669829|NCT05930093|Dietary Supplement|Placebo|Placebo matching LivPhcD cap.
79669830|NCT05930093|Dietary Supplement|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
79669831|NCT05930093|Dietary Supplement|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
79669832|NCT05930093|Dietary Supplement|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
79818896|NCT05605093|Drug|Shionogi Protease Inhibitor (S-217622)|S-217622 is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
79818897|NCT05605093|Drug|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
79992144|NCT03105154|Other|Prevena Dressing|Prevena dressing is applied on one groin
79992145|NCT03105154|Other|Conventional Dressing|Conventional dressing is applied on the contralateral groin
79992146|NCT03105076|Other|Decision aids|Shared decision making with decision aids
79509252|NCT03010098|Device|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
79358278|NCT02061358|Drug|UV-4B 1000 mg|Oral solution, single dose
79818898|NCT05597943|Behavioral|Malama App|The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
79818899|NCT05597540|Drug|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
79358279|NCT02061358|Drug|Placebo|Oral solution, single dose
79358280|NCT01758796|Procedure|Non-operative treatment|Below-the-knee cast for six weeks.
79358281|NCT01758796|Procedure|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
79358282|NCT01746160|Drug|C1 Implant|Patients treated with dental implants.
79358283|NCT01895296|Drug|Pasireotide|somatostatin analogue pasireotide
79358284|NCT01895296|Drug|Placebo|placebo s.c.
79358285|NCT04272190|Other|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
79358286|NCT04389502|Device|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
79358287|NCT04389502|Other|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
79358288|NCT01895374|Procedure|laser treatments|
79358289|NCT01895374|Other|amniotic membrane application|
79358290|NCT01895374|Device|hydrocolloid application|
79358291|NCT01299532|Device|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
79358292|NCT01276600|Drug|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
79358293|NCT04756180|Drug|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
79358294|NCT04745806|Device|ActiGraft|Whole blood clot (WBC) gel
79358295|NCT04755868|Drug|Talazoparib|The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
79358296|NCT04755868|Drug|Placebo|The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
79358297|NCT05567926|Dietary Supplement|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
79358298|NCT05567926|Dietary Supplement|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
79358299|NCT05560204|Device|Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)|"Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses high amplitude pulsed electrical fields to ablate tissues through the mechanism of irreversible electroporation~Percutaneous LAA Occlusion (LAAO) has been emerged as an alternative to oral anticoagulants for stroke prophylaxis in patients who refused or contraindicated to OAC"
79509253|NCT03010332|Biological|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
79669833|NCT05929885|Drug|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1*6 and UGT1A1*28 genotype status."
79358300|NCT01896076|Other|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
79358301|NCT01252888|Device|iStents|Implantation of two iStents through a small temporal clear corneal incision
79358302|NCT01642342|Other|laboratory biomarker analysis|Correlative studies
79358303|NCT01642342|Other|pharmacological study|Correlative studies
79358304|NCT01642342|Biological|recombinant albumin fusion protein sEphB4-HSA|Given IV
79358305|NCT04755556|Other|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
79358306|NCT04755556|Other|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
79358307|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
79509254|NCT03010020|Behavioral|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
79509255|NCT03010020|Behavioral|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
79509256|NCT03009864|Drug|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
79669834|NCT05929378|Procedure|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
79669837|NCT05918978|Drug|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
79358308|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
79509257|NCT03009864|Drug|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
79509258|NCT03009708|Other|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
79509259|NCT03009630|Procedure|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
79669838|NCT05918029|Drug|Potassium citrate|Oral potassium citrate
79669839|NCT05918029|Drug|Placebo|Placebo capsule identical to active ingredient
79669840|NCT05917548|Device|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
79669841|NCT05917548|Behavioral|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
79669844|NCT05908656|Procedure|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
79818900|NCT05597540|Drug|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
79509260|NCT03009630|Device|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
79509261|NCT03009474|Drug|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
79669845|NCT05908383|Drug|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
79669846|NCT05908383|Other|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
79669847|NCT05901909|Behavioral|Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients|Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
79992147|NCT02331628|Device|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.~Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~The energy flux density (EFD) will be 'high level'~All participants will be supplied with headphones to reduce the noise level emitted by the machine."
79992148|NCT02887482|Biological|GLS-5700|GLS 5700 at 2 mg DNA/dose
79992149|NCT02887482|Biological|Placebo|
79509262|NCT03009474|Drug|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
79509263|NCT03009552|Procedure|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
79509264|NCT03009318|Other|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
79509265|NCT03009084|Behavioral|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
79509266|NCT03008694|Device|PET/CT|pet/ct is used as radiotherapy simulation
79509267|NCT03008928|Behavioral|Alcooquizz|
79818901|NCT05590728|Drug|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
79818902|NCT05588479|Dietary Supplement|Pomegranate extract|One capsule of pomegranate extract (500 mg) will be taken daily at any time of the day for a period of 12 weeks.
79509268|NCT03009006|Drug|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
79669851|NCT05896592|Diagnostic Test|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
79669852|NCT05896592|Diagnostic Test|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
79669853|NCT05896592|Procedure|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
79669854|NCT05896592|Procedure|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
79818903|NCT05588479|Dietary Supplement|Control|One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
79818904|NCT05575063|Device|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
79509269|NCT03009006|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
79509270|NCT03008850|Drug|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
79509271|NCT03008850|Drug|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
79509272|NCT03008538|Other|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
79669855|NCT05896592|Procedure|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
79818905|NCT05575063|Device|Control Healon EndoCoat|Ophthalmic Viscoelastic device
79818906|NCT05566639|Biological|mRNA-1010|Sterile liquid for injection
79818907|NCT05566639|Biological|Licensed quadrivalent inactivated seasonal influenza vaccine|Sterile suspension for injection.
79669856|NCT05896592|Diagnostic Test|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
79992150|NCT03488927|Behavioral|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
79992151|NCT02335372|Procedure|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
79992152|NCT02335372|Drug|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
79992153|NCT02335372|Drug|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
79992154|NCT02335372|Procedure|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
79992155|NCT01569750|Drug|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
79992156|NCT01569750|Drug|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
79992157|NCT01569750|Drug|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
79669857|NCT05896592|Diagnostic Test|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
79992158|NCT01569750|Drug|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
79992159|NCT01569750|Drug|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
79358309|NCT01220752|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
79358310|NCT01615510|Drug|Tapentadol immediate release|100 mg, single administration
79358311|NCT01615510|Drug|placebo|placebo, single administration
79358312|NCT00530062|Drug|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
79358313|NCT00530062|Drug|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
79358314|NCT01209364|Device|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
79669858|NCT05896592|Diagnostic Test|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
79669859|NCT05896592|Diagnostic Test|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
79669860|NCT05893940|Procedure|Low Intensity Vibration Therapy|Undergo LIMS vibration therapy
79669861|NCT05893940|Procedure|Dual X-ray Absorptiometry|Undergo DEXA scan
79669862|NCT05893940|Procedure|Biospecimen Collection|Undergo blood sample collection
79669863|NCT05893758|Device|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
79669864|NCT05889793|Drug|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
79669865|NCT05889793|Drug|Placebo|Participant takes a placebo for 10 consecutive days.
79669866|NCT05872282|Device|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
79358315|NCT05080192|Drug|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
79358316|NCT05080192|Drug|Placebo|Matching placebo (once/day) for 10 days
79358317|NCT00474370|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
79358318|NCT00474370|Drug|Placebo|One tablet of placebo once daily.
79358319|NCT00472966|Drug|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
79358320|NCT01896154|Dietary Supplement|NPS|Comparison of multiple dietary non-digestible polysaccharides
79358321|NCT01573780|Drug|Smac mimetic TL32711|Given IV
79358322|NCT01573780|Drug|gemcitabine hydrochloride|Given IV
79358323|NCT01573780|Other|laboratory biomarker analysis|Correlative studies
79358324|NCT01573780|Other|pharmacological study|Correlative studies
79358325|NCT01573780|Procedure|biopsy|Optional correlative studies
79358326|NCT01186276|Dietary Supplement|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
79358327|NCT01186276|Dietary Supplement|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
79358328|NCT01141426|Behavioral|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
79358329|NCT01141426|Behavioral|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
79358330|NCT01895530|Dietary Supplement|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
79358331|NCT01547260|Drug|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
79358332|NCT01547260|Drug|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
79358333|NCT02317042|Device|Juno|Juno device set to ST mode with participant's current therapy settings.
79992160|NCT02335138|Behavioral|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
79358334|NCT02317042|Device|Juno|Juno device set to AutoEPAP iVAPS mode.
79358335|NCT02317042|Device|Juno|Juno device set to Fixed EPAP iVAPS mode.
79358336|NCT01896388|Drug|Ifenprodil Tartrate|
79358337|NCT01896388|Drug|Placebo|
79358338|NCT01125436|Dietary Supplement|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
79358339|NCT01125436|Dietary Supplement|Cholecalciferol|Weekly placebo plus 800 calcium alone
79509273|NCT03008538|Other|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
79818908|NCT05563948|Drug|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
79818909|NCT05560529|Behavioral|DBT|Applying DBT modules in group format over 20 weeks
79818910|NCT05560529|Drug|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
79818911|NCT05560529|Diagnostic Test|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
79818912|NCT05559580|Drug|Avenciguat (BI 685509)|Avenciguat (BI 685509)
79818913|NCT05559580|Drug|Placebo|Placebo
79992161|NCT02335138|Behavioral|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
79992162|NCT02326558|Procedure|laparoscopic microwave ablation-assisted enucleation|
79358340|NCT01113658|Device|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
79669867|NCT05868629|Other|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
79669868|NCT05868122|Drug|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
79669869|NCT05868122|Drug|Placebo|Placebo will be administered orally.
79669870|NCT05864560|Device|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
79669871|NCT05859477|Drug|Nivolumab|360 mg, i.v., every 3 weeks
79818916|NCT05541861|Biological|BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
79818917|NCT05541861|Biological|BNT162b4 5 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
79818918|NCT05541861|Biological|BNT162b4 10 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
79818919|NCT05541861|Biological|BNT162b4 15 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
79818920|NCT05541861|Biological|BNT162b4 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
79818921|NCT05541861|Biological|BNT162b2 Monovalent (OMI XBB.1.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
79818922|NCT05539963|Drug|STIMULAN VG|Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.
79818923|NCT05539963|Drug|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements.
79818924|NCT05534646|Drug|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
79818925|NCT05534646|Drug|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
79818926|NCT05530980|Behavioral|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. Each weekly session will be led by a trained facilitator and will include a brief educational component, participant updates on progress, group discussions about overcoming barriers, supervised competitive physical activities, and goal setting for the upcoming week. Educational content will be reinforced and social support will be provided during warmup and cool down walks. Participants will be asked to set behavioral goals toward increasing physical activity and improving dietary habits and will be provided resources to self-monitor their activity, dietary intake, and weight.
79818927|NCT05526573|Device|Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)|Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB
79818928|NCT05525858|Drug|Alectinib|ALK fusion or mutations, Mutations or amplification in any of the following: RET
79992163|NCT02326558|Procedure|conventional laparoscopic partial nephrectomy|
79992164|NCT02331316|Other|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
79992165|NCT02331004|Other|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
79669872|NCT05859477|Drug|Capecitabine|capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
79669873|NCT05859477|Drug|Oxaliplatin|130 mg/m², i.v., day 1, every 3 weeks
79818929|NCT05525858|Drug|Atezolizumab|"MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)"
79818930|NCT05525858|Drug|Erlotinib|"EGFR Exon 19 deletions in the region E746_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I"
79669874|NCT05857397|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
79669875|NCT05855200|Biological|Dostarlimab|Dostarlimab will be administered.
79669876|NCT05855200|Drug|CAPEOX|CAPEOX will be administered.
79669877|NCT05855200|Drug|FOLFOX|FOLFOX will be administered.
79669878|NCT05851924|Drug|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 46 hours (±60 minutes) on days 1 and 15 of every 4-week cycle"
79669879|NCT05851924|Combination Product|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
79669880|NCT05851183|Drug|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
79358341|NCT04755478|Procedure|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
79358342|NCT04755478|Procedure|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
79818931|NCT05525858|Drug|Trastuzumab + Pertuzumab|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board"
79358343|NCT04755400|Other|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
79358344|NCT04755400|Dietary Supplement|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
79358345|NCT04755400|Dietary Supplement|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
79358346|NCT04777942|Procedure|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
79358347|NCT04777942|Procedure|Surgery alone|hepatic resection remove the liver tumors
79358348|NCT00436540|Drug|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
79358349|NCT00436540|Drug|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
79818932|NCT05525858|Drug|Trastuzumab emtansine|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775_G776insSVMA, A775_G776insYVMA (i.e.,Y772_A775dup,M774_A775insAYVME 770delinsEAYVM), G776_V777 > AVCV, G776_V777 > AVGCV, G776_V777 > VCV, G776_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777_G778insC, V777L, V777M, G778_Y779insGSP, P780_Y781insGSP (i.e.,G778_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board"
79818933|NCT05525858|Drug|Vemurafenib|BRAF_V600E/D/K/R mutations
79818934|NCT05525858|Drug|Bevacizumab + Erlotinib|FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
79818935|NCT05525858|Drug|Entrectinib|ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
79818936|NCT05525858|Drug|Pralsetinib|RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
79818937|NCT05511363|Drug|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
79818938|NCT05511363|Drug|Placebo|Placebo Capsules
79818939|NCT05508867|Biological|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
79992166|NCT02331004|Other|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
79992167|NCT02326480|Other|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
79358350|NCT00425230|Drug|Duloxetine|
79358351|NCT04778098|Other|Received SMS reminder|telenursing
79818940|NCT05508867|Drug|bendamustine|IV infusion
79818941|NCT05508867|Drug|gemcitabine|IV infusion
79358352|NCT03793738|Procedure|Anterior component separation|
79358353|NCT03793738|Procedure|Posterior component separation|
79818942|NCT05503030|Drug|Nintedanib|Nintedanib
79818943|NCT05502783|Drug|fostamatinib|Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin < 10 g/dL, platelets < 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
79358354|NCT03783052|Device|SmartPill in fasted state|SmartPill administration in fasted state
79358355|NCT03783052|Device|SmartPill in fed state|SmartPill administration in fed state
79358356|NCT03783052|Other|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
79358357|NCT03783052|Other|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
79992168|NCT02331160|Behavioral|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
79992169|NCT02334904|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
79358358|NCT04778254|Other|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
79358359|NCT04778254|Other|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
79818944|NCT05475886|Drug|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
79818945|NCT05468697|Drug|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
79818946|NCT05468697|Drug|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
79358360|NCT04778254|Other|conventional obturator|clasp retained obturator for management of hemi maxillectomy
79992170|NCT02334904|Drug|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
79509274|NCT03008304|Drug|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
79509275|NCT03008226|Device|Implementation of 9 mm intrabronchial valves|
79509276|NCT03008148|Radiation|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
79509277|NCT03008148|Drug|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
79509278|NCT03008148|Drug|Siroquine|"Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
79509279|NCT03007992|Drug|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
79509280|NCT03007836|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
79509281|NCT03007446|Drug|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
79358361|NCT01066858|Drug|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
79509282|NCT03007446|Drug|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
79509283|NCT03007446|Drug|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
79509284|NCT03007368|Other|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79358362|NCT04777552|Other|diazepam (or equivalence if other benzodiazepine)|
79358363|NCT04777318|Other|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
79370949|NCT03032770|Device|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
79509285|NCT03007368|Other|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
79509286|NCT03007368|Other|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79509287|NCT03007368|Other|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79509288|NCT03007368|Other|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79509289|NCT03007368|Other|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79509290|NCT03007368|Other|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79509291|NCT03007368|Other|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
79509292|NCT03007602|Other|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
79509293|NCT03007680|Other|Core muscle activation|
79509294|NCT03007524|Drug|High dose Rosuvastatin|20mg/d qN, at least 6 months
79509295|NCT03007524|Drug|Low dose Rosuvastatin|10mg/d qN, at least 6 months
79509296|NCT03007290|Other|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
79509297|NCT03007134|Other|Retrospective Chart Review|No intervention.
79509298|NCT03007212|Procedure|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
79509299|NCT03006900|Other|Pilates|Pilates
79509300|NCT03006900|Other|Massage|Massage
79509301|NCT03006978|Device|TearCare|
79509302|NCT03006978|Device|Warm Compress|
79509303|NCT03007056|Other|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
79509304|NCT03006822|Other|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
79818947|NCT05461521|Other|Family members of patients admitted to the ICU|"At inclusion:~Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~Venous blood sampling at 350 relatives~Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU."
79818948|NCT05461521|Other|Health care professionals|All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
79358364|NCT04777318|Other|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
79509305|NCT03006822|Other|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
79509306|NCT03006822|Other|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
79509307|NCT03006744|Behavioral|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
79509308|NCT03006744|Behavioral|Reading enjoyment training|Training on how to make reading enjoyable for children.
79509309|NCT03006588|Procedure|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
79509310|NCT03006510|Other|Hypoglycemia prediction alert|"In real time, for a patient with a glucose <90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is >35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
79669881|NCT05851183|Behavioral|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
79669882|NCT05850546|Drug|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
79669883|NCT05850546|Drug|Corticosteroid|guideline-recommended corticosteroid therapy
79669884|NCT05845008|Drug|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
79669885|NCT05844995|Drug|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
79669886|NCT05844267|Behavioral|Experimental led booster breaks|Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
79818949|NCT05461521|Other|Patients|Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
79818952|NCT05446740|Biological|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
79992171|NCT02331238|Behavioral|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
79818953|NCT05446740|Biological|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
79818954|NCT05446740|Biological|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
79358365|NCT04777318|Other|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
79358366|NCT01506609|Drug|Placebo|
79509311|NCT03005886|Procedure|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
79669887|NCT05844267|Behavioral|Experimental unled computer-prompts|"Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary."
79669888|NCT05841290|Procedure|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
79669889|NCT05841290|Procedure|Supplemental local anesthesia|if needed
79358367|NCT01506609|Drug|Veliparib|
79358368|NCT01506609|Drug|Carboplatin|
79358369|NCT01506609|Drug|Temozolomide|
79358370|NCT01506609|Drug|Paclitaxel|
79358371|NCT04777162|Drug|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
79358372|NCT04777162|Drug|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
79358373|NCT02087956|Behavioral|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
79358374|NCT02087956|Behavioral|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
79358375|NCT03027219|Drug|Alprostadil|Vasodilator for anastomosis-site of free flap
79358376|NCT04776772|Dietary Supplement|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
79370950|NCT03032614|Drug|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
79669890|NCT05841290|Procedure|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
79669891|NCT05841290|Procedure|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
79669892|NCT05841290|Procedure|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
79509312|NCT03005886|Procedure|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
79509313|NCT03005886|Procedure|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
79509314|NCT03006120|Procedure|Retroperitoneal hematoma due to cardiac catheterization|
79358377|NCT04776772|Dietary Supplement|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
79669893|NCT05841290|Procedure|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
79669894|NCT05841290|Procedure|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
79818955|NCT05446740|Biological|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
79358378|NCT01506453|Drug|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
79358379|NCT01506453|Drug|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
79358380|NCT00218686|Behavioral|psychoeducational|psychoeducational
79358381|NCT00218686|Behavioral|control|VTC
79669895|NCT05841290|Procedure|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
79669896|NCT05841290|Procedure|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
79669897|NCT05841290|Procedure|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
79669898|NCT05841290|Procedure|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
79669899|NCT05841290|Procedure|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
79358382|NCT04389580|Drug|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
79370951|NCT03032614|Drug|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
79509315|NCT03006042|Drug|Bupivacaine|
79509316|NCT03005496|Drug|Zinc|included in intervention arm
79509317|NCT03005496|Drug|Nifedipine|included in intervention and control arm
79509318|NCT03005496|Drug|Beta Carotene|included in intervention arm
79509319|NCT03005496|Drug|Vitamin D3|included in intervention arm
79509320|NCT03005496|Drug|Dexamethasone|included in intervention and control arm
79509321|NCT03005808|Drug|Ropivacaine|Surgery for appendicitis
79509322|NCT03005730|Other|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
79509323|NCT03005730|Other|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
79358383|NCT04389580|Drug|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
79358384|NCT01482429|Other|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
79358385|NCT03856437|Behavioral|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
79370952|NCT03032614|Drug|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
79509324|NCT03005652|Behavioral|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
79509325|NCT03005652|Behavioral|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
79509326|NCT03005574|Behavioral|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
79509327|NCT03005574|Behavioral|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
79509328|NCT03005262|Drug|MLN8237|
79509329|NCT03005340|Drug|Treatment B|Bazedoxifene 20 mg
79509330|NCT03005340|Drug|Treatment C|Cholecalciferol granule 10 mg
79509331|NCT03005340|Drug|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
79509332|NCT03005184|Drug|Valsartan 80 mg bid|oral medication during run-in and washout period
79509333|NCT03005184|Drug|Enalapril 10 mg bid|oral medication
79669900|NCT05841290|Procedure|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
79669901|NCT05841290|Procedure|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
79669902|NCT05841290|Procedure|Master cone check|Master cone check Clinically and confirmatory radiograph
79509334|NCT03005184|Drug|Sacubitril-Valsartan 200 mg bid|oral medication
79509335|NCT03005184|Drug|Icatibant|intravenous medication
79818956|NCT05446740|Biological|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
79509336|NCT03005184|Drug|Placebo|intravenous medication
79509337|NCT03004794|Other|medical records review|
79509338|NCT03004560|Procedure|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
79509339|NCT03004560|Procedure|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
79669903|NCT05841290|Drug|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
79669904|NCT05841290|Diagnostic Test|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
79669905|NCT05841290|Procedure|Obturation|done by lateral condensation technique
79669906|NCT05841290|Diagnostic Test|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
79669907|NCT05841277|Drug|LY3819469|Administered SC.
79509340|NCT03004716|Other|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
79509341|NCT03004092|Procedure|blood sample|Twice weekly blood sample, and at every outpatient visit
79509342|NCT03004170|Behavioral|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
79509343|NCT03004170|Behavioral|Telephone-Administered Coping Effectiveness Training|
79509344|NCT03004014|Other|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
79509345|NCT03003858|Device|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
79509346|NCT03003702|Device|Nonin|
79509347|NCT03003936|Behavioral|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
79509348|NCT03003624|Device|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
79509349|NCT03003624|Device|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
79669908|NCT05837923|Dietary Supplement|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
79669909|NCT05837923|Dietary Supplement|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
79509350|NCT03003624|Device|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
79509351|NCT03003234|Procedure|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
79509352|NCT03003234|Device|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
79509353|NCT03003234|Dietary Supplement|Nutri drink|Liquid meal of 200 ml.
79509354|NCT03003156|Procedure|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
79509355|NCT03003156|Procedure|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
79669910|NCT05837923|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
79669911|NCT05837923|Dietary Supplement|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
79669912|NCT05837923|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
79669913|NCT05837923|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
79669914|NCT05837923|Dietary Supplement|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
79669915|NCT05837923|Dietary Supplement|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
79669916|NCT05837923|Dietary Supplement|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
79669917|NCT05837910|Dietary Supplement|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
79509356|NCT03002844|Drug|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
79509357|NCT03002844|Drug|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
79509358|NCT03002844|Drug|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
79358386|NCT04409067|Diagnostic Test|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
79509359|NCT03002922|Drug|BAY987517|Sunscreen formula Y65-158
79509360|NCT03003078|Device|OncoSil™|The implantation of OncoSil™
79818957|NCT05446740|Biological|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
79358387|NCT00199108|Drug|Depocyt|
79358388|NCT00199108|Drug|Dexamethasone|
79358389|NCT04776538|Biological|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
79358390|NCT04776538|Biological|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
79358391|NCT01504971|Other|symptom questionaire|GerdQ questionaire
79358392|NCT01504971|Procedure|pH monitoring|24-hour pH monitoring
79358393|NCT01504971|Procedure|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
79358394|NCT01504971|Drug|rabeprazole|10mg, bid, p.o.
79669918|NCT05837910|Dietary Supplement|Calm Active Study Product 1.2 Usage|Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
79669919|NCT05837910|Dietary Supplement|Calm Active Study Product 1.3 Usage|Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
79669920|NCT05837910|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
79669921|NCT05837910|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
79669922|NCT05837910|Dietary Supplement|Calm Active Study Product 2.1 Usage|Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
79669923|NCT05837910|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
79669924|NCT05837910|Dietary Supplement|Calm Active Study Product 3.1 Usage|Participants will use their Radicle Calm Active Study Product 3.1 as directed for a period of 6 weeks.
79669925|NCT05837910|Dietary Supplement|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
79669926|NCT05837910|Dietary Supplement|Calm Active Study Product 4.1 Usage|Participants will use their Radicle Calm Active Study Product 4.1 as directed for a period of 6 weeks.
79818958|NCT05446740|Biological|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
79818959|NCT05446740|Biological|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
79818960|NCT05446740|Biological|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
79509361|NCT03002688|Other|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
79509362|NCT03002766|Procedure|Breast conservative surgery|
79509363|NCT03002532|Radiation|whole brain radiotherapy|
79509364|NCT03002220|Drug|radium-223|Radium-223 at a dose of 55 kBq
79509365|NCT03002298|Behavioral|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
79669927|NCT05837481|Behavioral|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
79818961|NCT05446740|Biological|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
79358395|NCT04776616|Device|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
79358396|NCT04776616|Device|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
79358397|NCT01479777|Device|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
79358398|NCT03027063|Behavioral|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
79509366|NCT03002298|Behavioral|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
79509367|NCT03002298|Behavioral|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
79509368|NCT03002298|Behavioral|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
79509369|NCT03002376|Drug|REGN2810|REGN2810 treatment
79509370|NCT03002064|Drug|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
79509371|NCT03002064|Drug|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
79509372|NCT03002064|Drug|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
79992172|NCT03717077|Procedure|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
79509373|NCT03001908|Other|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
79509374|NCT03001908|Other|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
79509375|NCT03002142|Device|Hearing aids|Phonak Audéo B-R (Target V 5.0)
79669928|NCT05830968|Device|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is ~6 months, depending on subject recruitment rate.
79992173|NCT02326090|Drug|cis-UCA ophthalmic solution 1.0%|
79992174|NCT02326090|Drug|cis-UCA ophthalmic solution 2.5%|
79509376|NCT03002142|Device|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
79669929|NCT05830058|Procedure|Biospecimen Collection|Undergo blood collection
79509377|NCT03001752|Device|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
79509378|NCT03001752|Device|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
79669930|NCT05830058|Procedure|Computed Tomography|Undergo CT or PET/CT
79669931|NCT05830058|Procedure|Positron Emission Tomography|Undergo PET
79669932|NCT05830058|Other|Questionnaire Administration|Ancillary studies
79669933|NCT05830058|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79669934|NCT05829343|Procedure|Laparoscopic Left colectomy|Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
79669935|NCT05829343|Procedure|Robotic left colectomy|Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
79669936|NCT05826847|Procedure|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
79669937|NCT05826847|Procedure|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
79669938|NCT05826847|Procedure|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
79509379|NCT03001752|Device|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
79509380|NCT03001596|Procedure|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
79509381|NCT03001596|Procedure|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
79509382|NCT03001596|Procedure|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
79509383|NCT03001440|Other|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
79509384|NCT03001284|Other|NO intervention|
79509385|NCT03001050|Device|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
79509386|NCT03000972|Procedure|Cement augmentation|
79509387|NCT03000972|Procedure|PFN-A Nail|
79509388|NCT03001206|Device|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
79509389|NCT03001128|Drug|Antiretroviral treatment pause|Antiretroviral treatment pause
79509390|NCT03000894|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
79669939|NCT05825963|Dietary Supplement|Psyllium|The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
79669940|NCT05825469|Behavioral|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
79669941|NCT05823480|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
79669942|NCT05823480|Drug|Azacitidine|Given IV
79992175|NCT02326090|Drug|Placebo ophthalmic solution|
79992176|NCT01311011|Procedure|SCT|SCT
79358399|NCT03027063|Behavioral|Usual Care|Participants will receive the ACC/AHA exercise guidelines
79370953|NCT04182490|Biological|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
79370954|NCT04182490|Drug|Placebo|Identical appearing placebo
79370955|NCT03032458|Drug|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
79370956|NCT03032458|Drug|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
79509391|NCT03000660|Drug|Venetoclax|Venetoclax at one of four escalating doses
79509392|NCT03000660|Drug|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
79509393|NCT03000582|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
79509394|NCT03000582|Dietary Supplement|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
79509395|NCT03000582|Dietary Supplement|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
79509396|NCT03000582|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
79509397|NCT03000816|Radiation|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
79669943|NCT05823480|Procedure|Biospecimen Collection|Undergo blood sample collection
79669944|NCT05823480|Procedure|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
79669945|NCT05823480|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
79669946|NCT05823480|Procedure|Echocardiography|Undergo ECHO
79669947|NCT05823480|Biological|Magrolimab|Given IV
79669948|NCT05823480|Procedure|Multigated Acquisition Scan|Undergo MUGA
79669949|NCT05823480|Other|Questionnaire Administration|Ancillary studies
79669950|NCT05823012|Drug|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
79818962|NCT05446740|Combination Product|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
79992177|NCT02326246|Other|multi-parametic MRI|
79818963|NCT05446740|Combination Product|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
79358400|NCT04776304|Behavioral|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
79358401|NCT04753918|Drug|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
79509398|NCT03000504|Device|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
79509399|NCT03000270|Device|Impella unloading prior to PPCI|Impella unloading prior to PPCI
79358402|NCT04753918|Drug|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
79509400|NCT03000114|Procedure|Percutaneous Needle Aponeurotomy|
79509401|NCT03000114|Drug|XIAFLEX|
79509402|NCT03000036|Drug|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
79509403|NCT03000036|Device|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
79818964|NCT05442216|Drug|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
79818965|NCT05442216|Drug|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
79509404|NCT03000036|Drug|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
79509405|NCT02999802|Behavioral|Exercise|Progressive resistance exercise training
79509406|NCT02999412|Procedure|Comprehensive medication review|"A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature [4]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
79669951|NCT05819372|Procedure|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~After application this point of fixation on the patient~Finite element analysis will be done again to verify the previous results"
79669954|NCT05817084|Procedure|medial opening wedge high tibial osteotomy|medial opening wedge valgus high tibial osteotomy
79818966|NCT05442216|Drug|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
79358403|NCT04753918|Procedure|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
79358404|NCT04753918|Device|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
79358405|NCT04161664|Drug|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
79358406|NCT00936832|Drug|FOLFIRI regimen|
79358407|NCT00936832|Drug|fluorouracil|
79358408|NCT00936832|Drug|irinotecan hydrochloride|
79669955|NCT05817084|Procedure|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
79818967|NCT05439382|Procedure|Gingival recession regenerative surgery|Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
79358409|NCT00936832|Drug|leucovorin calcium|
79992178|NCT03437447|Drug|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
79992179|NCT03437447|Drug|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
79992180|NCT02459080|Drug|TD-4208|
79358410|NCT00936832|Drug|sunitinib malate|
79358411|NCT00936832|Other|laboratory biomarker analysis|
79358412|NCT00936832|Other|pharmacogenomic studies|
79358413|NCT00936832|Other|pharmacological study|
79358414|NCT04753606|Drug|Obicetrapib|tablets
79358415|NCT04755946|Drug|Roflumilast|adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
79358416|NCT04755946|Drug|Placebo|Placebo
79358417|NCT01896466|Device|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
79358418|NCT01896466|Behavioral|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
79509407|NCT02999412|Procedure|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
79509408|NCT02999412|Procedure|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
79509409|NCT02998944|Other||not any intervention for this study
79509410|NCT02998008|Behavioral|high intensity interval training|
79509411|NCT02996292|Device|Traditional brackets|Treating of crowding using traditional brackets
79992181|NCT02459080|Drug|Placebo|
79358419|NCT01479621|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
79358420|NCT01479621|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
79358421|NCT01479621|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
79509412|NCT02996292|Device|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
79509413|NCT02996292|Device|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
79669956|NCT05816850|Diagnostic Test|EZH2 mutations/CNAs by droplet digital PCR (ddPCR)|Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
79992182|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged > 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
79358422|NCT01479621|Drug|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
79358423|NCT00918892|Genetic|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
79370957|NCT03032458|Drug|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
79358424|NCT00918892|Other|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
79358425|NCT00918892|Other|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
79358426|NCT04776226|Drug|Citalopram|Antidepressant use in patients with depression
79669957|NCT05816850|Diagnostic Test|EZH2-derived gene expression signature by RNA-Seq|Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
79358427|NCT02319304|Drug|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
79358428|NCT02319304|Radiation|Low dose fractionated radiation therapy (LDFRT)|see arm description
79358429|NCT00910312|Device|Ice-Sense|Ice-Sense Cryoprobe
79358430|NCT00899782|Other|cytology specimen collection procedure|correlative studies
79358431|NCT00885664|Drug|Truvada (tenofovir/emtricitabine)|Tenofovir/emtricitabine fixed dose combination once daily
79509414|NCT02995824|Other|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) [lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)] [Group 1] versus other ART regimens including boosted PI or NNRTIs [Group 2] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
79669958|NCT05816057|Biological|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
79358432|NCT00885664|Drug|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
79358433|NCT04775992|Other|gabapentoids|Preemptive analgesia
79358434|NCT04775758|Behavioral|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
79358435|NCT04775758|Behavioral|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
79358436|NCT04775602|Drug|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
79818968|NCT05436535|Biological|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI >7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
79358437|NCT04784104|Drug|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
79358438|NCT04784104|Drug|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
79358439|NCT04784104|Drug|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
79358440|NCT04784104|Procedure|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
79358441|NCT04784104|Procedure|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
79509415|NCT02995356|Other|Collecting cervical liquid and sera samples|
79370958|NCT02245438|Drug|Tipranavir low dose|
79370959|NCT02245438|Drug|Tipranavir high dose|
79370960|NCT02245438|Drug|Ritonavir low dose|
79370961|NCT02245438|Drug|Ritonavir high dose|
79358442|NCT00880594|Drug|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
79358443|NCT04783870|Drug|Dapagliflozin|Dapagliflozin 10 mg PO QD
79358444|NCT04783870|Drug|Placebo|Placebo
79358445|NCT01896310|Device|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
79358446|NCT04783636|Drug|leuprorelin acetate 3.75mg|PT105, PT105R
79358447|NCT04784026|Other|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
79358448|NCT04784026|Other|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
79358449|NCT04784026|Other|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
79358450|NCT00820846|Biological|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
79358451|NCT00820846|Biological|Placebo|1 mL of sodium chloride for injection
79358452|NCT00820846|Biological|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
79358453|NCT03371368|Procedure|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
79358454|NCT03371368|Procedure|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
79358455|NCT03371368|Behavioral|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
79358456|NCT03364348|Drug|Utomilumab|Given IV
79992183|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~Fit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~Unfit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
79358457|NCT03364348|Drug|Trastuzumab|Given IV
79358458|NCT03364348|Drug|Ado-Trastuzumab Emtansine|Given IV
79358459|NCT04775290|Behavioral|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
79358460|NCT04782622|Drug|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
79358461|NCT04775212|Drug|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
79358462|NCT04775212|Drug|Sevoflurane|Sevoflurane
79358463|NCT03355066|Drug|SM08502|SM08502 tablets to be administered orally.
79358464|NCT04774900|Procedure|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
79358465|NCT04774900|Procedure|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
79358466|NCT04774900|Procedure|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
79358467|NCT04774900|Procedure|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
79358468|NCT04774900|Procedure|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
79358469|NCT04774978|Device|TTE|Transthoracic echocardiography
79358470|NCT04774822|Procedure|Color Fundus Photography|Stereoscopic Fundus photography
79358471|NCT04774822|Drug|Mydriatics Agent|Eye dilating agent
79358472|NCT04774822|Procedure|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
79358473|NCT04782934|Device|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
79358474|NCT04782388|Drug|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
79509416|NCT02989974|Behavioral|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
79509417|NCT02989740|Procedure|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
79358475|NCT04782388|Other|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
79818969|NCT05436535|Drug|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
79358476|NCT04782076|Drug|Dabigatran|Administered orally.
79358477|NCT04782076|Drug|Selpercatinib|Administered orally.
79358478|NCT04782310|Drug|Pregabalin|Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
79358479|NCT04782310|Drug|Duloxetine|Duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
79358480|NCT04781764|Procedure|surgery|surgery
79358481|NCT04774432|Other|GM-CSF group|GM-CSF added to CAPA and maturation medium
79818970|NCT05436535|Drug|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI >7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
79818971|NCT05436535|Drug|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI >7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
79818972|NCT05436535|Drug|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
79358482|NCT04774432|Other|Control group|GM-CSF will not be added to CAPA and maturation medium
79358483|NCT04774588|Other|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
79358484|NCT04774510|Other|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
79358485|NCT04774042|Dietary Supplement|Infloran probiotic|Infloran
79358486|NCT04774042|Dietary Supplement|HAC probiotic|HAc probiotic
79358487|NCT04774042|Dietary Supplement|Infloran placebo|Infloran placebo
79358488|NCT04774042|Dietary Supplement|HAC placebo|HAC placebo
79358489|NCT03300544|Drug|Capecitabine|Given PO
79358490|NCT03300544|Drug|Fluorouracil|Given IV
79358491|NCT03300544|Drug|Leucovorin|Given IV
79358492|NCT03300544|Drug|Oxaliplatin|Given IV
79358493|NCT03300544|Radiation|Radiation Therapy|Undergo chemoradiation
79358494|NCT03300544|Biological|Talimogene Laherparepvec|Given intralesionally
79370962|NCT02245438|Drug|Norethindrone-Ethinyl Estradiol|
79509418|NCT02989896|Device|perfusion index|
79509419|NCT02989350|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
79358495|NCT03249844|Drug|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
79358496|NCT04755166|Procedure|Lateral ridge augmentation|
79509420|NCT02989350|Dietary Supplement|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
79509421|NCT02989428|Procedure|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
79358497|NCT04755010|Device|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
79509422|NCT02989116|Behavioral|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
79358498|NCT04781608|Behavioral|English: In It Together (IIT)|Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
79358499|NCT00637624|Drug|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
79358500|NCT00637624|Drug|Placebo|Placebo once every 3 weeks intravenous saline fluid
79509423|NCT02989116|Behavioral|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
79509424|NCT02989116|Behavioral|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
79509425|NCT02989116|Behavioral|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
79509426|NCT02989116|Genetic|Saliva collection|Collection of a saliva sample for genotyping
79992184|NCT03720041|Drug|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Placebo: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
79358501|NCT04754620|Other|real time online video visit|Participants have received an online visit by a smartphone application
79509427|NCT02989116|Procedure|Brain Magnetic Resonance Imaging|Structural and functional MRI
79358502|NCT04773964|Drug|MET642|MET642 active treatment
79509428|NCT02989116|Behavioral|Cognitive testing|Battery of cognitive and academic tasks on executive functions
79509429|NCT02989272|Drug|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
79509430|NCT02989272|Other|saline group|saline group (30 patients) who will receive pretreatment by saline solution
79358503|NCT04773964|Drug|Placebo|Placebo comparator
79509431|NCT02989038|Other|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
79509432|NCT02989038|Other|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
79509433|NCT02989038|Other|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
79509434|NCT02988804|Device|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
79509435|NCT02988804|Device|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
79358504|NCT01479465|Biological|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
79358505|NCT01479465|Drug|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
79358506|NCT01479465|Drug|Leucovorin|l-Leucovorin 200 mg/m^2 or dl-leucovorin 400 mg/m^2 administered via intravenous infusion over 2 hours
79358507|NCT01479465|Drug|Irinotecan|Irinotecan 180 mg/m^2 administered via intravenous infusion over 90 minutes
79358508|NCT01479465|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 administered via intravenous bolus and 2400 mg/m^2 via intravenous infusion over 46 hours
79358509|NCT04773574|Device|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~st trimester : gestational age 8-12 weeks~nd trimester : gestational age 24-28 weeks~rd trimester : gestational age 34-38 weeks"
79358510|NCT04773496|Diagnostic Test|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
79509436|NCT02988726|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
79509437|NCT02988648|Radiation|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
79509438|NCT02988570|Behavioral|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
79509439|NCT02988492|Device|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
79669959|NCT05807594|Behavioral|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
79818973|NCT05436535|Drug|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
79358511|NCT04773886|Drug|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
79358512|NCT04773886|Drug|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
79358513|NCT04773886|Biological|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~Acellular platelet plasma- top most layer~Platelet rich fibrin -middle layer~Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
79358514|NCT04781686|Drug|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
79358515|NCT04781686|Drug|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
79358516|NCT04781686|Drug|S1|S1 (BSA<1.25 40mg, BSA >=1.25-<1.5 50mg, BSA >=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
79358517|NCT04781686|Drug|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
79358518|NCT04781920|Other|datas collection|data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
79358519|NCT05605132|Other|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~head relocation~gaze stability~eye follow~saccadic eye movement~head and eye coordination"
79358520|NCT05605132|Other|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
79358521|NCT05605132|Other|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
79358522|NCT04780906|Other|Wrist taping|Wrist taping as used as standard in CrossFit practice
79358523|NCT03996460|Drug|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
79358524|NCT03996460|Drug|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
79358525|NCT03996460|Drug|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
79509440|NCT02988024|Drug|LY03005|LY03005
79509441|NCT02988024|Drug|Pristiq|
79509442|NCT02988102|Other|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
79509443|NCT02988258|Genetic|CMV-TCR transduced donor-derived T cells|Dose escalation
79509444|NCT02988180|Other|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
79669960|NCT05807594|Behavioral|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
79669961|NCT05806346|Drug|TXA administration|Tranexamic acid intravenous administration
79669962|NCT05806346|Drug|Placebo administration|Placebo (normal saline) intravenous administration
79669963|NCT05803850|Drug|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
79669964|NCT05801614|Other|Low carb diet|Low calori diet
79669965|NCT05797519|Device|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
79669966|NCT05796687|Behavioral|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
79992185|NCT03720041|Drug|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Ixazomib: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
79358526|NCT04780594|Procedure|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
79358527|NCT04780750|Drug|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
79358528|NCT04780672|Drug|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
79509445|NCT02988180|Other|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
79669967|NCT05792696|Behavioral|PPI guided strategies|For targeted MAP or lower, if PPI<1, more fluid therapy. if PPI>3, vasoconstriction therapy. For MAP<65mmHg and 1<=PPI<3, test bolus of 250 ml crystalloid fluid.
79669968|NCT05792696|Behavioral|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
79669969|NCT05784246|Drug|Mirikizumab IV|Administered IV
79669970|NCT05784246|Drug|Mirikizumab SC|Administered SC
79669971|NCT05784181|Device|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
79669972|NCT05782361|Drug|Tepotinib|Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
79228431|NCT02467556|Behavioral|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
79228432|NCT02467556|Other|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
79669973|NCT05782361|Drug|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
79228433|NCT02262585|Drug|BIBR 277 tablet|
79228434|NCT02262585|Drug|BIBR 277 capsule|
79228435|NCT03309254|Other|High Glycemic Index|High Glycemic Index Food
79228436|NCT03309254|Other|Low Glycemic Index|Low Glycemic Index Food
79228437|NCT03195894|Device|TripleA|
79228438|NCT02262663|Drug|Vilaprisan (BAY1002670)|
79509446|NCT02987790|Other|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are <35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak> 100mg / L), with a limit of seven days, if there is clinical improvement.
79509447|NCT02987712|Other|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
79509448|NCT02987556|Device|Continuous Glucose Monitoring|Collection of glucose data
79509449|NCT02987556|Device|External Insulin Pump|insulin delivery
79509450|NCT02987556|Other|telemdecine|Remote follow up by care health providers team
79509451|NCT02987556|Device|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
79509452|NCT02987400|Drug|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
79509453|NCT02987400|Drug|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
79509454|NCT02987244|Drug|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
79509455|NCT02987244|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
79509456|NCT02987244|Drug|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
79509457|NCT02987244|Drug|Vindesine|vindesine (4mg)was administered intravenously on d1;
79669974|NCT05773040|Drug|JV-213|Given by (IV) vein
79669975|NCT05773040|Procedure|Leukapheresis|Given by IV (vein)
79669976|NCT05772065|Behavioral|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
79669977|NCT05772065|Behavioral|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
79669978|NCT05770921|Device|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
79669979|NCT05768711|Drug|Venetoclax|Combination of Azacitidine and Venetoclax
79818974|NCT05429268|Drug|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
79509458|NCT02987244|Drug|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
79509459|NCT02987244|Drug|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
79509460|NCT02987166|Radiation|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
79509461|NCT02987166|Drug|Pembrolizumab|200 mg
79509462|NCT02987088|Drug|Sodium Nitrite|
79509463|NCT02987322|Dietary Supplement|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
79509464|NCT02986932|Device|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
79509465|NCT02987010|Drug|IDH305|Isocitrate Dehydrogenase 1 inhibitor
79509466|NCT02986776|Behavioral|Inpatient Care|21 days of inpatient substance misuse treatment
79509467|NCT02986776|Behavioral|Outpatient Care|21 days of outpatient substance misuse treatment
79509468|NCT02986542|Procedure|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
79509469|NCT02986152|Behavioral|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
79669984|NCT05760924|Device|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
79818975|NCT05429268|Drug|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
79818976|NCT05425784|Device|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
79818977|NCT05425784|Other|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
79818978|NCT05421416|Drug|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
79358529|NCT04780672|Drug|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
79818979|NCT05421416|Drug|Placebo|Placebo sugar pill
79358530|NCT04780984|Drug|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
79358531|NCT04780984|Drug|Placebo|Placebo comparator
79509470|NCT02986464|Device|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
79509471|NCT02986464|Other|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
79509472|NCT02986308|Other|No intervention|
79509473|NCT02982642|Drug|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
79509474|NCT02982642|Drug|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
79509475|NCT02982486|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
79818980|NCT05415137|Drug|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
79358532|NCT04773340|Behavioral|Dialectical Behavior Therapy|Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
79358533|NCT02090374|Other|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
79358534|NCT02090374|Other|Poly I:C|Single dose: 500ug
79358535|NCT02090374|Other|R848|High dose: 10ug Low dose: 1-2ug
79509476|NCT02982486|Drug|Nivolumab|Ninolumab 240 mg IV every 2 weeks
79992186|NCT02326168|Drug|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
79358536|NCT02090374|Other|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
79358537|NCT02090374|Other|Vitamin D|4000U orally
79358538|NCT02090374|Other|Tuberculin|Tuberculin PPD
79509477|NCT02982408|Dietary Supplement|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to ~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
79818981|NCT05415137|Drug|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
79509478|NCT02982408|Behavioral|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
79818982|NCT05415137|Drug|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
79358539|NCT04772716|Procedure|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
79358540|NCT04772794|Other|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
79358541|NCT04773028|Other|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
79358542|NCT04772872|Other|Assessment by Brazelton neonatal behavior for group A,Band C|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
79358543|NCT02222740|Drug|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
79358544|NCT02222740|Drug|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
79358545|NCT04752982|Behavioral|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
79358546|NCT04752982|Behavioral|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
79818983|NCT05414097|Other|Semi-structured focus group discussions - Women|Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
79818984|NCT05414097|Other|semi-structured focus groups discussions - Men|Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
79818985|NCT05414097|Other|In-depth key stakeholders interviews|In-depth interviews to contextualise findings from women and men focus group discussions.
79992187|NCT02334826|Procedure|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
79228439|NCT03309176|Drug|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
79358547|NCT04780360|Procedure|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
79358548|NCT04780360|Procedure|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
79358549|NCT04780438|Drug|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
79358550|NCT04780438|Drug|Placebo|Patients rendomized in this arm will receive placebo.
79358551|NCT04780126|Other|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
79669985|NCT05760924|Device|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
79818986|NCT05414097|Other|Discrete Choice Experiment - Women|Discrete Choice Experiment to determine preferences to different cancer screening models.
79818987|NCT05414097|Other|Development and User Pre-testing Workshops|Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 &2.
79992188|NCT02334826|Procedure|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
79358552|NCT04779892|Drug|Infliximab|100mg/vial
79358553|NCT02844868|Device|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
79992189|NCT03487445|Drug|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
79992190|NCT03487445|Drug|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
79992191|NCT02109172|Drug|TD-4208|
79992192|NCT02109172|Drug|Placebo|
79992193|NCT02326012|Behavioral|Emotion Regulation Individual Therapy for Adolescents|
79358554|NCT02844868|Device|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
79358555|NCT04389268|Diagnostic Test|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
79358556|NCT04771702|Device|Edmon|Exhaled air will be analyzed for propofol
79358557|NCT04771546|Device|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
79358558|NCT04389424|Drug|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
79358559|NCT04389424|Drug|Exemestane|Use of exemestane for breast cancer recurrence prevention
79358560|NCT04389424|Drug|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
79358561|NCT04389424|Diagnostic Test|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
79358562|NCT04389424|Diagnostic Test|Recurrence|Breast cancer recurrence under endocrine therapy
79358563|NCT04389346|Procedure|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
79358564|NCT04389346|Procedure|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
79358565|NCT04771390|Drug|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
79509479|NCT02982408|Behavioral|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
79509480|NCT02982252|Behavioral|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
79509481|NCT02982330|Behavioral|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing <10% carbohydrate, ~75% fat, and 15% protein. Matched for calories to the active comparator arm.
79509482|NCT02982330|Behavioral|Guidelines Breakfast|A low fat breakfast containing ~55% carbohydrate, <30% fat, and 15% protein. Matched for calories to the experimental arm.
79818988|NCT05413811|Drug|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
79358566|NCT04771390|Drug|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
79358567|NCT04771390|Drug|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
79358568|NCT04771390|Drug|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
79358569|NCT04771468|Device|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
79358570|NCT04771468|Device|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
79818989|NCT05413811|Drug|Placebo|Intravaginal topical placebo cream
79358571|NCT04779502|Other|oregawash|mouthwash containing oregano essential oil
79358572|NCT04779502|Other|corsodyl|0.2% chlorhexidine mouthwash
79358573|NCT04779502|Other|placebo|distilled water
79358574|NCT05480956|Behavioral|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
79358575|NCT05480956|Behavioral|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
79509483|NCT02981784|Drug|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
79818990|NCT05413798|Other|Urine HPV testing|Human papillomavirus (HPV) testing in urine sample.
79818991|NCT05413798|Other|Self-collected cervicovaginal specimen|Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
79818992|NCT05413798|Other|Provider-collected cervical samples|Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
79818993|NCT05406921|Behavioral|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
79818994|NCT05405582|Combination Product|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
79818995|NCT05405582|Other|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
79818996|NCT05396898|Drug|LCP-tacrolimus|Prophylaxis of transplant rejection in liver and kidney allograft recipients
79509484|NCT02981784|Procedure|allogeneic stem cell transplantation|
79509485|NCT02981862|Other|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
79509486|NCT02981706|Procedure|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
79509487|NCT02981706|Procedure|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
79509488|NCT02981394|Procedure|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
79509489|NCT02981316|Biological|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
79509490|NCT02981238|Dietary Supplement|Phytostandard® Eschscholtzia / Valerian|
79509491|NCT02981160|Other|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
79509492|NCT02980926|Drug|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
79669986|NCT05760924|Device|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
79669987|NCT05759338|Device|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
79669988|NCT05758168|Procedure|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
79818997|NCT05396898|Drug|twice-daily tacrolimus|Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
79992194|NCT02334592|Radiation|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
79358576|NCT05480956|Behavioral|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
79358577|NCT05411380|Drug|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
79358578|NCT05411380|Drug|Capecitabine|500mg orally three times a day (continuously)
79509493|NCT02980926|Drug|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
79509494|NCT02980614|Device|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
79509495|NCT02980458|Drug|Deferiprone 500Mg Tablet|
79509496|NCT02980458|Drug|Deferiprone 500 MG Oral Tablet [Ferriprox]|
79818998|NCT05388435|Drug|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
79818999|NCT05388292|Other|Emergency triage decision support system|Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
79819000|NCT05384587|Drug|asciminib|Supplied in 40 mg tablets for oral use to be taken daily. Dose may be increased at 6 and 12 months based on molecular response with BCR-ABL1 Polymerase Chain Reaction testing.
79669989|NCT05756621|Drug|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight < 50 kg), followed by gradual reduction according to clinical evolution."
79669990|NCT05756621|Drug|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
79669991|NCT05755347|Other|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
79509497|NCT02980380|Other|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
79669992|NCT05755347|Other|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
79358579|NCT05411380|Drug|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
79509498|NCT02980302|Procedure|Cutaneous biopsy|Under local anesthesia
79509499|NCT02980146|Other|Non interventional study|
79509500|NCT02979912|Biological|Platelet Lysate|Eye drops of Platelet Lysate
79509501|NCT02979990|Other|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
79669993|NCT05755347|Other|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
79669994|NCT05755347|Other|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
79669995|NCT05755347|Other|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
79358580|NCT04779580|Procedure|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
79358581|NCT04779580|Procedure|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
79358582|NCT04771312|Behavioral|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
79669997|NCT05738083|Diagnostic Test|machine learning models|Area under the curve (ROC), accuracy, precise, sensitivity, specificity indicators to show the prediction performance of machine learning models
79669998|NCT05734729|Device|EFFIDRAIN|. Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.
79509502|NCT02979990|Other|Control Video|The control group will have access to a video about the IVF process
79669999|NCT05734729|Device|Manual drainage system|drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
79670000|NCT05728333|Drug|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
79670001|NCT05728333|Drug|Alteplase|Intravenous alteplase before endovascular thrombectomy.
79509503|NCT02979756|Procedure|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
79509504|NCT02979288|Drug|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
79509505|NCT02979288|Other|NO Intervention|NO Intervention
79670002|NCT05727072|Drug|LY3848575|Administered IV.
79509506|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
79358583|NCT04771312|Behavioral|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
79509507|NCT02979210|Other|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
79509508|NCT02978976|Drug|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
79509509|NCT02978976|Drug|saline|saline placebo injection in the same regimen.
79358584|NCT04770688|Drug|Osimertinib|Osimertinib, 80mg, QD, p.o.
79509510|NCT02979132|Drug|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
79509511|NCT02979132|Drug|Ferinject(R)|Single-dose Ferinject(R) administration
79509512|NCT02979132|Dietary Supplement|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
79358585|NCT04770688|Drug|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
79358586|NCT05390476|Drug|Capecitabine|500mg orally three times a day (continuously)
79509513|NCT02978664|Procedure|Air insufflation|Air insufflation during colonoscopy including insertion phase
79509514|NCT02978664|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
79509515|NCT02978664|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
79670003|NCT05727072|Drug|LY3848575|Administered SC.
79670004|NCT05727072|Drug|Placebo|Administered IV.
79670005|NCT05727072|Drug|Placebo|Administered SC.
79670006|NCT05726591|Device|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
79358587|NCT05390476|Drug|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
79358588|NCT04770298|Other|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
79509516|NCT02978820|Other|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
79358589|NCT05379088|Behavioral|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
79358590|NCT01503021|Drug|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
79509517|NCT02978820|Other|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
79509518|NCT02978742|Behavioral|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
79358591|NCT01503021|Other|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
79358592|NCT04779034|Other|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
79509519|NCT02978742|Behavioral|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
79509520|NCT02978586|Device|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline [Ga-68]PSMA PET/MR. If participants test positive for [Ga-68]PSMA tumor uptake, they will under up to 2 additional scans
79509521|NCT02978274|Drug|MMF|MMF withdrawal by engraftment post haplo-SCT
79228440|NCT03309176|Other|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
79358593|NCT04778956|Drug|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
79358594|NCT04778956|Procedure|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
79358595|NCT04778800|Drug|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
79370963|NCT04761939|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0"
79509522|NCT02978274|Drug|MMF|MMF withdrawal by 2 month post haplo-SCT
79509523|NCT02978430|Device|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
79670008|NCT05723562|Biological|Dostarlimab|Dostarlimab will be administered.
79358596|NCT04778800|Drug|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
79509524|NCT02978430|Other|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
79509525|NCT02978352|Other|learning|
79509526|NCT02977962|Behavioral|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
79509527|NCT02977962|Other|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
79509528|NCT02978040|Drug|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
79670009|NCT05720520|Other|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
79670010|NCT05719363|Device|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
79670011|NCT05719285|Drug|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
79358597|NCT04778800|Drug|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
79819001|NCT05380453|Biological|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
79819002|NCT05380453|Drug|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
79819003|NCT05375825|Procedure|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
79358598|NCT01531725|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
79358599|NCT05324332|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
79358600|NCT05324332|Drug|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
79509529|NCT02978040|Drug|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old) .
79509530|NCT02978040|Drug|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
79509531|NCT02977416|Other|anti-TNFα|
79509532|NCT02977728|Other|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
79670012|NCT05719285|Drug|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
79670014|NCT05712720|Drug|Experimental: Group 1|RZ402 50 mg oral tablet, once daily for 3 months
79670015|NCT05712720|Drug|Experimental: Group 2|RZ402 200mg oral tablet, once daily for 3 months
79670016|NCT05712720|Drug|Experimental: Group 3|RZ402 400mg oral tablet, once daily for 3 months
79819004|NCT05375825|Drug|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
79358601|NCT04778878|Device|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
79358602|NCT04769908|Drug|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
79819005|NCT05375825|Diagnostic Test|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
79819006|NCT05373719|Other|No intervention; observational|No intervention; observational
79358603|NCT04769908|Drug|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
79358604|NCT04769908|Drug|Sintilimab|Sintilimab, IV, 200mg, q3w
79358605|NCT01478373|Drug|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
79358606|NCT04778488|Device|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
79509533|NCT02987634|Other|PeriActive|mouthwash
79509534|NCT02977650|Procedure|Endoscopic ultrasonography-guided fine needle aspiration|
79509535|NCT02977338|Other|Retrospective review|
79509536|NCT02977104|Other|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
79670017|NCT05712720|Other|Placebo: Group 4|Placebo, once daily for 3 months
79509537|NCT02977182|Other|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
79358607|NCT01502709|Device|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
79509538|NCT02977260|Other|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
79509539|NCT02977260|Other|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
79509540|NCT02977260|Other|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
79358608|NCT01502709|Device|placebo|Matching placebo device
79670018|NCT05708144|Diagnostic Test|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
79670019|NCT05698407|Drug|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
79670020|NCT05698407|Drug|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
79358609|NCT03843268|Device|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
79358610|NCT03843268|Device|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
79358611|NCT02931058|Other|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
79358612|NCT02931058|Other|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
79358613|NCT02931058|Other|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
79509541|NCT02977260|Other|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
79509542|NCT02976870|Radiation|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
79509543|NCT02977026|Behavioral|CYD|
79358614|NCT01477749|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
79509544|NCT02977026|Behavioral|AHC|
79509545|NCT02976558|Behavioral|Clown theatrical Performance|
79509546|NCT02976558|Procedure|Acupuncture|Acupuncture according to Traditional Chinese Medicine
79509547|NCT02976558|Behavioral|Music Therapy TaKeTiNa|
79670021|NCT05697939|Diagnostic Test|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
79358615|NCT05606458|Behavioral|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
79819007|NCT05373381|Dietary Supplement|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition [Healthtrac].
79358616|NCT05297734|Other|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
79358617|NCT05297734|Behavioral|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
79358618|NCT04094259|Behavioral|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
79358619|NCT00054028|Drug|suramin|Given IV
79358620|NCT00054028|Drug|paclitaxel|Given IV
79509548|NCT02976324|Device|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
79509549|NCT02976402|Radiation|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
79509550|NCT02976168|Other|12° head down tilt|supine head down tilt
79670022|NCT05694013|Device|Roche DPM Module|Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
79358621|NCT00054028|Other|pharmacological study|Correlative studies
79358622|NCT04753060|Procedure|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
79370964|NCT03032146|Procedure|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
79370965|NCT03087669|Device|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
79509551|NCT02976246|Dietary Supplement|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
79670023|NCT05694013|Drug|Atezolizumab SC|Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
79509552|NCT02976246|Other|Placebo|One tablet of placebo given once daily.
79509553|NCT02976480|Procedure|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
79509554|NCT02976480|Procedure|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
79992195|NCT05076916|Behavioral|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
79358623|NCT05274334|Other|Assessment of de novo lipogenesis non-invasively in exhaled breath|"Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~Participants execute several exhalation sets over time.~Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~Participants execute several exhalation sets over time.~After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
79509555|NCT02975856|Dietary Supplement|Table Red Wine|
79509556|NCT02975856|Dietary Supplement|Young Port Red Wine|
79509557|NCT02976012|Drug|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
79670024|NCT05694013|Other|Local SOC support|Participants will receive local SOC support
79228441|NCT05727020|Diagnostic Test|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
79358624|NCT00058240|Drug|alvocidib|Given IV
79370966|NCT03087669|Drug|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
79370967|NCT00939952|Drug|ertapenem|500 mg IV once
79509558|NCT02976012|Procedure|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
79509559|NCT02975778|Device|Pain Monitor™|Pain measured by Pain Monitor™
79670025|NCT05691790|Behavioral|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview ~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
79819013|NCT05369273|Other|intra-articular injection|intra-articular injection
79228442|NCT05727020|Diagnostic Test|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
79358625|NCT05606068|Device|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
79358626|NCT05605990|Device|Innovative tourniquet (Acusense Nonpneumatic tourniquet)|To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
79358627|NCT01502631|Drug|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
79509560|NCT02975388|Drug|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
79509561|NCT02975466|Device|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
79509562|NCT02975466|Device|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
79509563|NCT02975466|Device|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
79509564|NCT02975622|Procedure|Central venous catheterization|Ultrasound guided central venous catheterization
79819014|NCT05369273|Radiation|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
79819015|NCT05369273|Other|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
79819016|NCT05369273|Other|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
79509565|NCT02975544|Behavioral|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
79509566|NCT02975076|Drug|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
79358628|NCT01502631|Drug|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
79819017|NCT05358301|Dietary Supplement|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
79509567|NCT02975076|Drug|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
79509568|NCT02975076|Drug|Aspirin|
79509569|NCT02975076|Drug|Clopidogrel|
79509570|NCT02975076|Drug|placebo of clopidogrel|
79819018|NCT05358301|Dietary Supplement|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
79358629|NCT03027999|Other|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP > 2.7"
79228443|NCT02602353|Drug|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
79358630|NCT03027921|Other|elastography|
79358631|NCT05262946|Behavioral|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
79509571|NCT02975232|Behavioral|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
79509572|NCT02975232|Behavioral|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
79509573|NCT02975154|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
79509574|NCT02974920|Drug|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
79358632|NCT05262946|Behavioral|foot care education|Recommendations for preventing foot ulcers
79358633|NCT05262946|Combination Product|usual care|drugs and diet usual care
79358634|NCT03026907|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
79358635|NCT03026907|Drug|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
79358636|NCT00060424|Drug|Cyclosporine|Given PO
79358637|NCT00060424|Drug|Fludarabine Phosphate|Given IV
79358638|NCT00060424|Procedure|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
79358639|NCT00060424|Other|Laboratory Biomarker Analysis|Correlative studies
79358640|NCT00060424|Drug|Mycophenolate Mofetil|Given PO
79358641|NCT00060424|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
79509575|NCT02974920|Drug|Aspirin|Aspirin 100 mg once daily for 180 days
79509576|NCT02974764|Other|No intervention/exposures|
79509577|NCT02974530|Other|Neurological evaluation|
79509578|NCT02974530|Other|Laryngological evaluation|
79509579|NCT02974530|Other|MRI evaluation|
79509580|NCT02974530|Other|Breathing investigation|
79509581|NCT02974530|Other|MRI and articulatory investigation|
79509582|NCT02974530|Other|Postural investigation|
79509583|NCT02974530|Other|Voice and soundscape investigation|
79509584|NCT02974374|Drug|PF-06835919|Single or repeated, escalating dose
79509585|NCT02974374|Other|Placebo|Single or repeated, escalating dose
79509586|NCT02974062|Other|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
79670026|NCT05691790|Behavioral|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
79358642|NCT00060424|Radiation|Total-Body Irradiation|Undergo TBI
79358643|NCT03026751|Procedure|Bone Marrow Aspirate|Bone marrow aspirate
79358644|NCT05253040|Other|KEEP Intervention|Educational intervention
79819019|NCT05358210|Behavioral|Blueberry Consumption|Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
79819020|NCT05358210|Behavioral|Dried Date Consumption|Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
79358645|NCT05253040|Other|control|booklet from Parkinson's UK
79358646|NCT05215522|Device|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
79819021|NCT05357963|Procedure|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
79819022|NCT05351580|Device|DiSCERN|Smart watch Monitoring
79509587|NCT02973906|Other|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
79509588|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
79509589|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
79509590|NCT02973672|Drug|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
79819023|NCT05351554|Drug|Namilumab|Namilumab administered subcutaneously
79819024|NCT05351554|Drug|Placebo|Placebo administered subcutaneously to match namilumab dosing
79819025|NCT05351554|Drug|Open label Namilumab|Namilumab administered subcutaneously
79819026|NCT05351554|Drug|Prednisone|Prednisone or equivalent
79358647|NCT00062764|Drug|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
79358648|NCT00063232|Drug|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
79358649|NCT00063622|Drug|Pioglitazone|30 mg daily
79358650|NCT00063622|Dietary Supplement|Vitamin E|800 IU daily
79358651|NCT00063622|Drug|Matching placebo|Daily
79370968|NCT02401815|Drug|PLX9486|PLX9486 will be administered per dose and schedule specified in the arm.
79509591|NCT02973360|Drug|Docosahexaenoic Acid|Oral Capsule
79509592|NCT02973360|Drug|Placebo|Oral Capsule
79509593|NCT02973282|Other|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
79992196|NCT02331082|Other|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
79670027|NCT05690087|Drug|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
79670028|NCT05690087|Drug|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
79819027|NCT05350774|Drug|IV normal saline|IV normal saline 250ml for 5 days
79819028|NCT05350774|Drug|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
79358652|NCT05185726|Behavioral|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
79358653|NCT05185726|Behavioral|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
79509594|NCT02973204|Drug|Sorafenib|
79509595|NCT02973204|Procedure|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
79509596|NCT02973204|Drug|Everolimus|
79509597|NCT02973204|Drug|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
79509598|NCT02972970|Device|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
79509599|NCT02972736|Radiation|Radiation dose expressed as DAP|
79509600|NCT02972814|Device|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
79819029|NCT05350202|Drug|Empagliflozin|Empagliflozin
79819030|NCT05346809|Drug|Isatuximab|Isatuximab in IV form 10 mg/kg doses
79819031|NCT05346809|Other|Standard Procedures|Standard procedures (standard of care) for transplant
79509601|NCT02972814|Device|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
79509602|NCT02972814|Device|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
79509603|NCT02959476|Drug|Ropivacaine|Anesthetic
79509604|NCT02959476|Drug|Placebos|Inactive comparator
79509605|NCT02959398|Device|Standard mammography|Standard mammography
79509606|NCT02959398|Device|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
79509607|NCT02959008|Device|measure TOI and BP|Both groups measure TOI and BP.
79509608|NCT02958930|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
79819032|NCT05341726|Behavioral|BREATHE Intervention|BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
79358654|NCT05185726|Behavioral|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
79509609|NCT02958852|Drug|Letrozole|
79509610|NCT02958852|Drug|Letrozole and atorvastatin|
79819033|NCT05341726|Behavioral|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
79819034|NCT05332951|Other|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
79819035|NCT05327023|Procedure|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
79509611|NCT02958852|Drug|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
79509612|NCT02958774|Radiation|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
79509613|NCT02676804|Other|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own."
79509614|NCT02641782|Drug|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
79509615|NCT02641782|Drug|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
79509616|NCT02641782|Drug|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
79509617|NCT02641782|Drug|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
79509618|NCT02641782|Drug|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
79509619|NCT02641314|Drug|metronomic therapy|"Propranolol 0.5 mg/kgxd p.o. day 1,~mg/kgxd p.o. day 2,~mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
79819036|NCT05327023|Drug|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
79819037|NCT05327023|Drug|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
79819038|NCT05327023|Drug|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
79358655|NCT00153166|Drug|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
79358656|NCT00153166|Drug|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
79358657|NCT00153166|Drug|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
79358658|NCT00153166|Drug|placebo/placebo|placebo orally three times daily
79358659|NCT00156910|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
79358660|NCT00156910|Other|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
79358661|NCT01475721|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
79358662|NCT01475721|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
79358663|NCT01475721|Drug|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
79358664|NCT01475721|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
79670029|NCT05681143|Other|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
79358665|NCT01475721|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
79358666|NCT01475721|Drug|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
79509620|NCT01711710|Device|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
79509621|NCT04769622|Procedure|Non-surgical periodontal treatment|all included patients will be subjected to non-surgical periodontal therapy
79358667|NCT00065806|Drug|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
79358668|NCT00065806|Drug|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
79358669|NCT02091466|Device|pre-warming|warming patients 30 minutes prior to anesthesia
79358670|NCT01530087|Device|CASTLE barrier|Prototype barrier to be used in place of current two piece device
79358671|NCT00068770|Radiation|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
79358672|NCT00068770|Drug|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
79509622|NCT04769622|Other|Questionnaires|"All patients will be asked to complete a set of questionnaires regarding:~adherence to Mediterranean Diet;~sleep quality;~physical activity;~perceived stress."
79509623|NCT04769778|Drug|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
79670030|NCT05681143|Other|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
79509624|NCT04769076|Combination Product|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
79509625|NCT04769232|Device|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
79509626|NCT04768998|Other|Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
79670031|NCT05677256|Biological|nOPV2|Vaccination
79358673|NCT01475487|Procedure|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
79358674|NCT04102527|Other|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~Digestive Functional Score of Neurological Patients~Bowel Function Index~Severity score for constipation~Bristol Scale~Constipation assessment scale~Estimate scale of risk of constipation"
79358675|NCT01475331|Drug|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
79358676|NCT01475331|Drug|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
79358677|NCT01475331|Drug|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
79358678|NCT01500213|Drug|Rolapitant|200 mg PO
79358679|NCT01500213|Drug|Granisetron|10 mcg/kg IV
79358680|NCT01500213|Drug|Dexamethasone|20 mg PO and 8 mg PO
79670032|NCT05676112|Drug|nintedanib|nintedanib
79670033|NCT05676112|Drug|pirfenidone|pirfenidone
79670034|NCT05674396|Radiation|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
79670035|NCT05674396|Radiation|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
79670036|NCT05674188|Behavioral|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
79819039|NCT05327023|Drug|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
79358681|NCT01500213|Drug|Placebo|(4 X 0 mg capsules) o mg PO
79358682|NCT00069160|Drug|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
79358683|NCT00069160|Drug|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
79358684|NCT00069160|Other|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
79358685|NCT00071890|Drug|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
79358686|NCT00071890|Drug|HAART|HAART from week 0 to week 24
79358687|NCT00071890|Drug|Treatment interruption|HAART is interrupted from week 24 in both arms
79358688|NCT01475253|Drug|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
79509627|NCT04768842|Drug|LY3209590|Administered SC.
79509628|NCT04768764|Procedure|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
79509629|NCT04768764|Procedure|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
79670037|NCT05672368|Device|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
79358689|NCT01475253|Other|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
79358690|NCT01475253|Procedure|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
79358691|NCT00072514|Drug|gemcitabine hydrochloride|Given IV
79358692|NCT00072514|Drug|carboplatin|Given IV
79509630|NCT04768764|Drug|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
79509631|NCT04768764|Procedure|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
79670038|NCT05672342|Drug|Cannabidiol|Given PO
79819040|NCT05327023|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
79819041|NCT05319353|Drug|Maribavir|Participants will receive maribavir.
79819042|NCT05315570|Other|BD4QoL platform|The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
79358693|NCT00072514|Drug|dexamethasone|Given PO
79358694|NCT00072514|Biological|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
79358695|NCT00074308|Drug|imatinib mesylate|Given orally
79358696|NCT00074308|Biological|bevacizumab|Given IV
79358697|NCT00074308|Other|pharmacological study|Correlative studies
79670039|NCT05672342|Drug|Delta-8-Tetrahydrocannabinol|Given PO
79670040|NCT05672342|Drug|Placebo Administration|Given PO
79358698|NCT00074308|Other|laboratory biomarker analysis|Correlative studies
79670041|NCT05672342|Other|Questionnaire Administration|Ancillary studies
79670042|NCT05668650|Drug|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
79670043|NCT05668650|Drug|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
79670044|NCT05657808|Dietary Supplement|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
79670045|NCT05657808|Dietary Supplement|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
79819043|NCT05306028|Drug|Metformin or insulin treatment|"For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose > 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose."
79358699|NCT00159250|Drug|AVI-4658 (PMO)|morpholino antisense oligonucleotide
79358700|NCT00165958|Procedure|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
79358701|NCT00165958|Procedure|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
79358702|NCT01898026|Dietary Supplement|Bread|Samples of white bread, with or without the addition of PGX fibre blend
79358703|NCT01898026|Dietary Supplement|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
79509632|NCT04768530|Procedure|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
79509633|NCT04768530|Drug|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
79509634|NCT04768140|Procedure|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
79670046|NCT05657808|Dietary Supplement|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
79670047|NCT05657808|Dietary Supplement|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
79670048|NCT05657808|Dietary Supplement|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
79670049|NCT05657808|Dietary Supplement|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
79670050|NCT05657808|Dietary Supplement|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
79509635|NCT04768140|Procedure|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
79358704|NCT01898026|Dietary Supplement|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
79509636|NCT04749654|Other|The Salivary pH measured|The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
79509637|NCT04749654|Other|The saliva flow rate was measured|The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
79509638|NCT04749654|Other|Streptococcus mutans and Lactobacillus counts in saliva were measured|The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
79509639|NCT04749498|Other|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
79509640|NCT04749498|Other|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
79509641|NCT04749498|Other|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
79819044|NCT05305040|Biological|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
79358705|NCT01898026|Dietary Supplement|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
79358706|NCT00166036|Drug|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
79358707|NCT00166036|Drug|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
79358708|NCT01500135|Drug|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
79358709|NCT01500135|Drug|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
79370969|NCT02401815|Drug|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
79509642|NCT04749498|Other|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
79509643|NCT04749342|Other|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
79509644|NCT04749420|Other|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
79509645|NCT04748562|Drug|Progesterone|Taking prontogest vaginally
79509646|NCT04745286|Drug|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
79670051|NCT05657808|Dietary Supplement|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
79670052|NCT05657808|Dietary Supplement|Placebo Control Form 4|Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
79509647|NCT04745286|Drug|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
79358710|NCT00167206|Procedure|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
79358711|NCT00167206|Procedure|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
79509648|NCT04745364|Behavioral|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
79509649|NCT04745442|Drug|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
79509650|NCT04745442|Drug|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
79509651|NCT04744740|Device|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
79509652|NCT04745052|Other|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
79509653|NCT04744896|Device|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
79509654|NCT04744896|Device|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
79509655|NCT04744506|Device|Tissue Marker Clip|Tissue Marker Clip Placed in Metastatic Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
79509656|NCT04744038|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
79509657|NCT04743882|Other||
79509658|NCT04743648|Behavioral|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
79819045|NCT05305040|Biological|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
79819046|NCT05304520|Drug|Natalizumab|Administered as specified in the treatment arm.
79358712|NCT00167206|Procedure|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
79358713|NCT00167206|Drug|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
79358714|NCT01475097|Drug|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
79358715|NCT01475097|Drug|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
79358716|NCT04779190|Device|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
79509659|NCT04743414|Drug|CTP-543|Itraconazole in solution dosage form
79509660|NCT04743336|Other|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
79509661|NCT04743180|Device|LUMINOR© Paclitaxel eluting balloon|Patients will be treated with the Luminor paclitaxel eluting balloon
79509662|NCT04743258|Procedure|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling & alignment.
79509663|NCT04743258|Procedure|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
79670053|NCT05657808|Dietary Supplement|Rest Study Active Product 4.1 Usage|Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
79670054|NCT05657808|Dietary Supplement|Rest Study Active Product 4.2 Usage|Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
79670055|NCT05657808|Dietary Supplement|Rest Study Active Product 4.3 Usage|Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
79358717|NCT04779190|Device|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
79509664|NCT04742790|Diagnostic Test|Scalp electroencephalography (EEG)|Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
79509665|NCT04742790|Diagnostic Test|Laser-evoked potentials (LEPs)|Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
79670056|NCT05657743|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
79819047|NCT05293860|Other|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
79358718|NCT04779190|Other|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
79358719|NCT01529385|Device|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
79509666|NCT04742790|Diagnostic Test|Cognitive auditory-evoked potentials (P300)|Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero & Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
79670057|NCT05656599|Drug|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
79670058|NCT05652725|Dietary Supplement|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
79670059|NCT05652725|Dietary Supplement|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
79670060|NCT05652725|Dietary Supplement|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
79819048|NCT05293860|Other|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
79819049|NCT05291182|Drug|SY-4835|WEE1 inhibitor
79819050|NCT05286554|Drug|gonadotropin releasing hormone-agonist|subcutaneous injection
79358720|NCT01529385|Device|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
79358721|NCT01474551|Drug|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
79670061|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
79819051|NCT05286554|Drug|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
79819052|NCT05280548|Drug|Venglustat (GZ402671)|Tablet; Oral
79358722|NCT02094586|Biological|PXVX0200 Lot A|Lot P700-1CA03
79358723|NCT02094586|Biological|PXVX0200 Lot B|Lot P700-3CA03
79358724|NCT02094586|Biological|PXVX0200 Lot C|Lot P700-6BA03
79358725|NCT02094586|Biological|Placebo|Placebo
79358726|NCT02985645|Procedure|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
79358727|NCT02985645|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
79358728|NCT01500057|Device|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
79358729|NCT01500057|Device|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
79358730|NCT02094664|Device|Heated and humidified oxygen|
79358731|NCT01499667|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
79358732|NCT01499667|Drug|Placebo|Matching placebo in capsules for oral administration once daily.
79358733|NCT00168298|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
79358734|NCT00168298|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
79358735|NCT00168298|Other|Sham Injection|Sham injection on Day 0.
79358736|NCT01474317|Device|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
79358737|NCT00075088|Device|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
79358738|NCT00075088|Other|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
79358739|NCT00076258|Behavioral|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
79358740|NCT00076258|Behavioral|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
79358741|NCT00078286|Drug|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
79358742|NCT00078286|Drug|Placebo|Dosage ranging from 50 mg to 200 mg once a day
79358743|NCT00078754|Drug|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
79358744|NCT00078754|Drug|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
79358745|NCT00078754|Drug|Placebo|Placebo capsules by mouth, up to 8 capsules daily
79358746|NCT00080470|Device|bion|battery powered microstimulator
79670062|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
79670063|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
79358747|NCT00081328|Drug|Metformin|capsule, 1000 mg bid
79358748|NCT00081328|Drug|Rosiglitazone|capsule, 4 mg bid
79358749|NCT00081328|Behavioral|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
79358750|NCT00082342|Device|Phoressor II (IOMED)|sham stimulation
79358751|NCT00082342|Device|Phoressor II (IOMED)|real tDCS stimulation
79358752|NCT01499355|Biological|BIIB023|
79358753|NCT01499355|Biological|Placebo|
79358754|NCT01499355|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
79358755|NCT01499355|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
79358756|NCT00083122|Drug|cisplatin|Given IV
79358757|NCT00083122|Drug|alvocidib|Given IV
79358758|NCT00083122|Drug|cisplatin/flavopiridol|Given IV
79358759|NCT01474239|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
79358760|NCT01474239|Drug|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
79370970|NCT02401815|Drug|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
79670064|NCT05652725|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
79819053|NCT05280548|Drug|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
79819054|NCT05280548|Drug|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
79819055|NCT05280548|Drug|Migalastat|Hard capsules; Oral
79819056|NCT05278416|Device|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
79358761|NCT03026829|Device|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
79358762|NCT01473381|Drug|Vilazodone|Vilazodone was supplied as film-coated tablets.
79358763|NCT01473381|Drug|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
79358764|NCT01473381|Drug|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
79509667|NCT04742790|Diagnostic Test|Cervical somatosensory-evoked potentials|Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
79509668|NCT04742790|Diagnostic Test|Pupillometry|Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter [variation coefficient of pupillary dilation, VCPD, Charier et al. 2017]), light-evoked speed of pupil constriction [maximum pupil constriction velocity, PCV, Connely et al., 2014]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
79819057|NCT05277896|Drug|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
79819058|NCT05277896|Drug|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
79819059|NCT05273255|Biological|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
79819060|NCT05272423|Diagnostic Test|FoundationOne® Liquid CDx|The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
79358765|NCT01473381|Drug|Citalopram|Citalopram was supplied as encapsulated tablets.
79358766|NCT00168454|Biological|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
79358767|NCT00168454|Drug|Placebo|Placebo (normal saline) injected into detrusor on Day 1
79358768|NCT00175006|Other|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
79358769|NCT04737772|Behavioral|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
79670065|NCT05652725|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
79670066|NCT05652725|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
79358770|NCT04737772|Behavioral|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
79358771|NCT01499277|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
79358772|NCT01499277|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
79358773|NCT01499277|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
79358774|NCT00176800|Drug|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
79358775|NCT00176800|Procedure|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
79358776|NCT00176800|Procedure|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
79358777|NCT00176878|Procedure|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
79358778|NCT00176878|Drug|Fludarabine monophosphate|fludarabine 175 mg/m^2 (total) on Days -6 through -3.
79358779|NCT00176878|Procedure|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
79358780|NCT00176878|Drug|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
79358781|NCT00176878|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
79358782|NCT01898182|Other|Kinetin, N6-furfuryladenine, 0.1%|
79358783|NCT02338336|Drug|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
79358784|NCT02338336|Drug|Placebo|Matching placebo liquid for topic administration.
79358785|NCT04672174|Diagnostic Test|Questionnaire: DemTect|Questionnaire is handed out to subjects
79358786|NCT01499199|Drug|Dolutegravir|50mg Once Daily
79358787|NCT01499043|Drug|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
79358788|NCT00087022|Biological|girentuximab|Given IV
79358789|NCT00087022|Other|placebo|Given IV
79358790|NCT00179998|Drug|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
79358791|NCT00179998|Drug|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
79509669|NCT04742790|Diagnostic Test|Saccadic Peak Velocity|The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
79358792|NCT00181168|Drug|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
79509670|NCT04742790|Diagnostic Test|Adaptive tracking test|The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.
79509671|NCT04742790|Diagnostic Test|Body Sway Test|Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
79670067|NCT05652725|Dietary Supplement|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
79358793|NCT02151526|Drug|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
79819061|NCT05261425|Device|Monocryl buried|Participants randomized to this group will receive the Monocryl (suture) buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
79819062|NCT05261425|Device|Nylon (FDA Approved) not buried|Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
79819063|NCT05255536|Procedure|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
79819064|NCT05255536|Procedure|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
79358794|NCT00089752|Device|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
79358795|NCT00089752|Device|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
79819065|NCT05254327|Drug|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
79819066|NCT05252702|Device|Aveir DR Leadless Pacemaker System|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
79819067|NCT05251727|Drug|thrombomodulin alfa|Weight based dose of reconstituted treatment
79670068|NCT05652725|Dietary Supplement|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
79670069|NCT05652725|Dietary Supplement|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
79670070|NCT05652725|Dietary Supplement|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
79670071|NCT05642078|Biological|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
79819068|NCT05251727|Drug|Placebo|Weight based dose of reconstituted treatment
79819069|NCT05250063|Drug|LUM-201|Administered orally once daily
79358796|NCT00090844|Drug|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
79358797|NCT01897012|Drug|Alisertib|Given PO
79358798|NCT01897012|Other|Laboratory Biomarker Analysis|Correlative studies
79358799|NCT01897012|Drug|Romidepsin|Given IV
79358800|NCT01498887|Drug|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
79358801|NCT01498653|Drug|GW685698/GW642444|ICS/LABA
79358802|NCT01498653|Drug|CCI18781|ICS
79358803|NCT01498575|Behavioral|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
79358804|NCT01498185|Drug|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
79509672|NCT04742790|Diagnostic Test|N-back working memory test|"Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B … C … B)."
79509673|NCT04742790|Other|Patient-reported outcomes|Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
79509674|NCT04742478|Procedure|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
79670072|NCT05642078|Biological|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
79670073|NCT05642078|Biological|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
79670074|NCT05641246|Drug|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
79358805|NCT01498185|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
79358806|NCT01528605|Dietary Supplement|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
79358807|NCT01528605|Dietary Supplement|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
79509675|NCT04742244|Dietary Supplement|Lvemon verbena extract|Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
79509676|NCT04742244|Dietary Supplement|maltodextrin|Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
79509677|NCT04741854|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
79509678|NCT04741152|Procedure|Pancreatic resection|Different pancreatic resections
79670075|NCT05641246|Drug|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
79819070|NCT05249530|Other|Chiropractic spinal adjustment|Chiropractic spinal adjustment
79819071|NCT05249530|Other|Non-force simulation|Non-force simulation
79819072|NCT05245409|Other|Chiropractic adjustment using an activator|Chiropractic adjustment using an activator
79819073|NCT05242029|Drug|Placebo|Participants will receive placebo in a clinical setting.
79819074|NCT05242029|Drug|Psilocybin|Participants will receive 40mg psilocybin in a clinical setting.
79819075|NCT05232864|Drug|Secukinumab|STUDY DRUG
79358808|NCT01528605|Dietary Supplement|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
79358809|NCT01528605|Dietary Supplement|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
79358810|NCT01528605|Dietary Supplement|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
79509679|NCT04740840|Drug|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
79670076|NCT05640193|Biological|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
79358811|NCT01528605|Dietary Supplement|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
79358812|NCT01528215|Device|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
79358813|NCT01528215|Device|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
79358814|NCT01527357|Biological|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
79358815|NCT01527357|Biological|Gelatin sponge|Absorbable gelatin sponge for topical administration.
79358816|NCT00093964|Drug|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
79358817|NCT00093964|Drug|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
79358818|NCT01526889|Drug|LFG316|LFG316 administered intravitreally (IVT)
79358819|NCT01526889|Drug|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
79358820|NCT00181714|Drug|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
79358821|NCT04643626|Device|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
79358822|NCT01472835|Drug|Midazolam|Used for anxiolysis
79358823|NCT01472835|Drug|Fentanyl|Used for analgesia and as a sedative
79358824|NCT00185692|Procedure|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
79358825|NCT00185692|Drug|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
79509680|NCT04740840|Drug|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
79670077|NCT05639569|Device|Ankura™ TAA Stent Graft Systems|All patients will be implanted with Ankura™ TAA Stent Graft Systems in accordance with the instructions for use (IFU).
79358826|NCT00185692|Drug|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
79358827|NCT00185692|Drug|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
79358828|NCT00185692|Drug|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
79358829|NCT00185692|Drug|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
79670079|NCT05633407|Drug|Efgartigimod|Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
79670080|NCT05633407|Drug|Placebo|"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
79358830|NCT00185692|Drug|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
79358831|NCT00185692|Drug|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
79358832|NCT00185692|Drug|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
79509681|NCT04740762|Behavioral|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
79670081|NCT05632718|Other|Exercise|Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
79670082|NCT05626569|Drug|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
79670083|NCT05624372|Diagnostic Test|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
79670084|NCT05620888|Behavioral|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
79358833|NCT01526733|Drug|Sham Injection|
79670085|NCT05620888|Behavioral|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
79670086|NCT05619926|Drug|STSP-0601 for Injection|Intravenous Injection
79358834|NCT01526733|Drug|Recombinant human hyaluronidase PH20|
79358835|NCT01526733|Drug|Insulin aspart|
79358836|NCT01526733|Drug|Insulin lispro|
79358837|NCT00094900|Drug|IL-1 Trap|
79358838|NCT00096460|Drug|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
79358839|NCT00096460|Drug|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
79370971|NCT00947752|Drug|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
79370972|NCT00947752|Drug|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
79509682|NCT04740528|Diagnostic Test|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
79509683|NCT04740450|Device|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm _ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
79509684|NCT04740450|Device|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
79228444|NCT02602353|Drug|Placebo Patch|One Placebo Patch applied daily for 3 days
79228445|NCT02602353|Drug|No Treatment|No Treatment for 3 days
79228446|NCT03472794|Other|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
79228447|NCT02467634|Biological|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
79358840|NCT00096460|Radiation|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of < 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days."
79358841|NCT00096460|Drug|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
79819076|NCT05232838|Device|eShunt Implant|The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
79670087|NCT05618145|Other|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
79670088|NCT05609565|Drug|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
79670089|NCT05609565|Drug|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
79670090|NCT05608902|Other|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
79670091|NCT05607108|Drug|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
79670092|NCT05605730|Other|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
79670093|NCT05605730|Other|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
79670094|NCT05605730|Other|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
79670095|NCT05601492|Drug|Otezla - Standard Care|The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
79992197|NCT02331082|Other|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
79358842|NCT00096460|Procedure|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
79670096|NCT05601492|Behavioral|Reminder Text Intervention with apremilast|Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
79670097|NCT05601492|Behavioral|Extended Consultation for apremilast|Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
79819077|NCT05229588|Drug|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
79358843|NCT00096460|Procedure|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
79670098|NCT05598320|Drug|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
79670099|NCT05598320|Drug|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
79358844|NCT00096460|Drug|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
79670100|NCT05596747|Drug|LY3209590|Administered SC.
79358845|NCT00096460|Drug|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
79670101|NCT05596747|Drug|Insulin Glargine|Administered SC.
79819078|NCT05228171|Behavioral|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
79819079|NCT05225103|Behavioral|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
79819080|NCT05220865|Procedure|Hall Technique|"Only food scraps or debris will be removed from the caries cavity.~The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~The child will be asked to bite firmly until the crown is pushed down over the tooth.~If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~The child will continue to bite on a cotton roll until the cement hardens~Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
79819081|NCT05220865|Procedure|Modified Hall Technique|"Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~The child will be asked to bite firmly until the crown is pushed down over the tooth.~If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~The child will continue to bite on a cotton roll until the cement hardens~Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
79819082|NCT05219825|Behavioral|Breathwork workshop|Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
79819083|NCT05215509|Behavioral|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
79670102|NCT05596162|Other|Blood Flow Restriction Therapy|Exercise with Blood Flow Restriction
79819084|NCT05215509|Behavioral|No exercise|Control group, therefore no supervised exercise regime
79992198|NCT02331082|Device|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
79228448|NCT04983498|Drug|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
79228449|NCT04983498|Drug|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
79358846|NCT00006178|Drug|Sirolimus|
79358847|NCT00006178|Drug|Thymoglobulin|
79358848|NCT00097708|Drug|experimental anti-anxiety drug|
79358849|NCT00098956|Drug|topotecan hydrochloride|Given IV
79358850|NCT00098956|Drug|7-hydroxystaurosporine|Given IV
79358851|NCT01472757|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
79358852|NCT01472757|Drug|Placebo|Placebo delivered via a new dry powder inhaler
79358853|NCT02197156|Drug|10 mg HC-ER|Single dose
79670103|NCT05596162|Other|Standard Physical Therapy|Exercise without Blood Flow Restriction
79670104|NCT05582434|Drug|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
79670105|NCT05582434|Drug|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
79992199|NCT02331082|Device|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
79992200|NCT02331082|Behavioral|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
79670106|NCT05582434|Drug|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
79992201|NCT02331082|Other|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
79992202|NCT03144154|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
79992203|NCT02334670|Drug|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
79992204|NCT02330848|Dietary Supplement|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
79358854|NCT02197156|Drug|20 mg HC-ER|Single dose
79358855|NCT02197156|Drug|30 mg HC-ER|Single dose
79358856|NCT02197156|Drug|40 mg HC-ER|Single dose
79670107|NCT05580237|Procedure|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
79358857|NCT02197156|Drug|10 mg HC / 325 mg APAP|Single dose
79358858|NCT02197156|Drug|Matching Placebo|Single dose
79358859|NCT00187720|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
79358860|NCT01472289|Other|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
79358861|NCT00006244|Drug|melphalan|Given IV
79358862|NCT00006244|Biological|recombinant interferon alfa|Given SC
79358863|NCT00006244|Biological|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
79358864|NCT00006244|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
79358865|NCT00187876|Procedure|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
79509685|NCT04740216|Behavioral|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
79509686|NCT04740216|Behavioral|exercise therapy|the control group performed 20-minute stretching exercises each time.
79509687|NCT04740138|Behavioral|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
79509688|NCT04740684|Other|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
79509689|NCT04739904|Other|Normoxia|48 hours experimental protocol conducted at sea level
79509690|NCT04739904|Other|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
79509691|NCT04739904|Other|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
79670110|NCT05571644|Drug|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
79509692|NCT04739748|Diagnostic Test|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
79670111|NCT05571644|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
79358866|NCT00187876|Procedure|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
79509693|NCT04739202|Drug|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
79670112|NCT05571644|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
79992205|NCT02330848|Dietary Supplement|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
79509694|NCT04739202|Drug|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
79509695|NCT04739514|Other|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
79358867|NCT01525875|Drug|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
79358868|NCT01525875|Drug|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
79509696|NCT04739046|Drug|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
79509697|NCT04738656|Dietary Supplement|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
79358869|NCT01898260|Device|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
79509698|NCT04738266|Diagnostic Test|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
79509699|NCT04738500|Procedure|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
79509700|NCT04738500|Procedure|PCA|PCA will be applied after surgery
79509701|NCT04738032|Other|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
79358870|NCT01898260|Device|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
79358871|NCT04409379|Diagnostic Test|Relative telomere length|Relative telomere length in peripheral blood cell
79358872|NCT04409613|Other|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
79358873|NCT01525641|Drug|Mirapex LA|Pramipexole Hydrochloride Hydrate
79358874|NCT03026985|Other|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
79358875|NCT00006400|Drug|Hydroxyurea|Participants will receive hydroxyurea.
79358876|NCT00006400|Drug|Placebo|Participants will receive placebo.
79358877|NCT01496469|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
79509702|NCT04738188|Procedure|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
79509703|NCT04738188|Procedure|cTACE|Transcatheter arterial chemoembolization
79509704|NCT04738188|Device|Drug-eluting Beads|Drug-eluting beads
79509705|NCT04738188|Drug|Epirubicin|Chemotherapy drug for intra-arterial infusion
79509706|NCT04737798|Other|oil pulling with coconut oil|using oil pulling therapy with coconut oil
79509707|NCT04737798|Other|oil pulling with sesame oil|using oil pulling therapy with sesame oil
79509708|NCT04737486|Drug|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
79509709|NCT04737486|Other|Placebo|D-PBS
79358878|NCT01496469|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
79358879|NCT00189436|Drug|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
79358880|NCT00189436|Drug|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
79358881|NCT04091607|Other|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
79358882|NCT01471353|Drug|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
79509710|NCT04737564|Behavioral|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
79358883|NCT01525407|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
79358884|NCT01525407|Drug|Atorvastatin Calcium|Given PO
79358885|NCT01525407|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
79358886|NCT01471197|Biological|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
79670118|NCT05563961|Drug|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
79819085|NCT05214313|Behavioral|Music Therapy|"The standardised music therapy protocol of 45 minutes will include at each session :~10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~Active phase: (25 min)~5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM."
79358887|NCT01471197|Biological|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
79358888|NCT04408989|Drug|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
79358889|NCT04408989|Drug|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
79358890|NCT04408989|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
79358891|NCT00011986|Drug|Paclitaxel|Given IV
79670119|NCT05563961|Drug|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
79819086|NCT05208762|Drug|SGN-PDL1V|Given into the vein (IV; intravenously)
79358892|NCT00011986|Drug|Carboplatin|Given IV
79358893|NCT00011986|Drug|Gemcitabine Hydrochloride|Given IV
79358894|NCT00011986|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|
79228450|NCT04983498|Other|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
79228451|NCT04983498|Other|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
79358895|NCT00011986|Drug|Topotecan Hydrochloride|Given IV
79358896|NCT00011986|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79358897|NCT01898416|Drug|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
79358898|NCT01524783|Drug|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
79358899|NCT01524783|Drug|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
79358900|NCT01524783|Other|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
79358901|NCT01494987|Drug|Ranolazine|Ranolazine tablet(s) administered orally
79358902|NCT01494987|Drug|Placebo|Placebo to match ranolazine for the duration of the study
79358903|NCT01494987|Drug|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
79358904|NCT01494987|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
79358905|NCT01494987|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
79358906|NCT04409769|Other|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
79358907|NCT01524627|Drug|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
79358908|NCT01524627|Drug|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
79358909|NCT01469637|Drug|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
79358910|NCT01469637|Drug|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
79358911|NCT04748367|Device|Virtual Reality Headset|Virtual Reality Headset running SILVER software
79509711|NCT04737564|Behavioral|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
79670120|NCT05558501|Other|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2)= 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
79670121|NCT05558501|Other|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
79670122|NCT05552794|Diagnostic Test|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
79819087|NCT05208762|Drug|pembrolizumab|200 mg once every 3 weeks given into the vein (IV; intravenously)
79819088|NCT05208047|Drug|CGT9486 plus sunitinib|Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.
79670123|NCT05545137|Drug|Pivmecillinam hydrochloride tablets|400mg tablet
79819089|NCT05208047|Drug|CGT9486|Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.
79819090|NCT05208047|Drug|Sunitinib|Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.
79819091|NCT05208047|Drug|Sunitinib|Participants will receive sunitinib orally until study stopping rules are met.
79819092|NCT05204550|Drug|unfractionated heparin|intranasal
79819093|NCT05204550|Drug|0.9%sodium chloride|intranasal
79819094|NCT05189145|Drug|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
79819095|NCT05189145|Other|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen & LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
79819096|NCT05189145|Diagnostic Test|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
79819097|NCT05189145|Drug|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
79819098|NCT05189145|Other|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone & Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels < 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels >10ng, continued on 400 mg prontogest suppositories twice daily
79819099|NCT05189145|Drug|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
79819100|NCT05183906|Diagnostic Test|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
79819101|NCT05180136|Dietary Supplement|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
79819102|NCT05180136|Dietary Supplement|Control group|Placebo 1,000 mg/day for 8 weeks
79819103|NCT05179122|Procedure|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
79358912|NCT00012298|Biological|rituximab|Given IV
79358913|NCT00012298|Biological|yttrium Y 90 ibritumomab tiuxetan|Given IV
79358914|NCT00012298|Biological|indium In 111 ibritumomab tiuxetan|Given IV
79358915|NCT00012298|Biological|oprelvekin|Given subcutaneously
79358916|NCT00012298|Biological|filgrastim|Given subcutaneously
79819104|NCT05179057|Drug|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
79819105|NCT05179057|Drug|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
79819106|NCT05174169|Device|Signatera test|Central ctDNA testing for all patients
79819107|NCT05174169|Drug|mFOLFOX6 3-6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
79509712|NCT04737564|Behavioral|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
79670124|NCT05545137|Drug|Fosfomycin Tromethamine Granules|3g/pack
79670125|NCT05543915|Device|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
79670126|NCT05539027|Drug|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
79670127|NCT05539027|Drug|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
79670130|NCT05537246|Procedure|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
79509713|NCT04737408|Drug|Rosuvastatin 40mg|Rosuvastatin 40 mg
79670131|NCT05535972|Drug|FF/UMEC/VI|FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
79509714|NCT04737174|Drug|ES-481|28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
79509715|NCT04736784|Other|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
79509716|NCT04736784|Other|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
79670134|NCT05531097|Drug|HSK31679|Single or multiple oral doses of HSK31679
79670135|NCT05531097|Drug|Placebo|Matching placebo
79670136|NCT05522075|Behavioral|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
79670137|NCT05522075|Behavioral|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
79819108|NCT05174169|Drug|CAPOX 3 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
79819109|NCT05174169|Drug|mFOLFIRINOX|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
79228452|NCT04831424|Behavioral|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
79670146|NCT05511246|Drug|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
79358917|NCT00193258|Drug|Bevacizumab|10mg/kg IV infusion every 2 weeks
79509717|NCT04736238|Procedure|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
79358918|NCT00193258|Drug|Erlotinib|150 mg po daily
79358919|NCT00193258|Drug|Imatinib|400-600mg daily
79358920|NCT00029536|Biological|Progesterone Lozenges|200mg Progesterone Lozenges
79509718|NCT04736238|Procedure|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
79509719|NCT04736160|Other|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
79509720|NCT04735848|Dietary Supplement|Iron-supplement application|The participants will take the corresponding amount of iron-supplement supervised at 8am.
79509721|NCT04735380|Device|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
79509722|NCT04735302|Other|Radiographic Feature|Radiographic rewiev
79509723|NCT04734912|Other|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
79509724|NCT04735146|Other|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
79509725|NCT04734522|Device|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
79509726|NCT04734756|Device|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
79819110|NCT05174169|Drug|mFOLFOX6 6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
79819111|NCT05174169|Drug|CAPOX 6 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
79819112|NCT05166889|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
79358921|NCT00029536|Other|Matched Placebo Lozenges|Matched Placebo Lozenges
79819113|NCT05166889|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
79228453|NCT02621736|Other|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
79358922|NCT00193492|Drug|Bevacizumab|
79358923|NCT00193492|Drug|Rituximab|
79358924|NCT00194116|Drug|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
79358925|NCT00194116|Drug|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
79358926|NCT02096458|Drug|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
79358927|NCT02096692|Device|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
79358928|NCT02096692|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
79992206|NCT02334202|Behavioral|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
79358929|NCT00194896|Drug|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
79509727|NCT04734834|Dietary Supplement|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
79509728|NCT04734600|Device|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
79358930|NCT00194896|Drug|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
79358931|NCT00197392|Device|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
79358932|NCT00197392|Device|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
79358933|NCT04348474|Drug|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
79358934|NCT04348474|Drug|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
79358935|NCT04318834|Other|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
79358936|NCT04290286|Other|i2TransHealth|i2TransHealth: online intervention for TGD people
79358937|NCT00107536|Drug|lapatinib ditosylate|
79358938|NCT00107536|Other|laboratory biomarker analysis|Correlative studies
79358939|NCT04389190|Other|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
79358940|NCT00108550|Drug|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
79358941|NCT00108550|Drug|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
79670147|NCT05511246|Procedure|Catheter ablation|Endocardial catheter ablation of VT substrate
79670148|NCT05498948|Dietary Supplement|Probiotic mixture|orally take .
79670149|NCT05498935|Other|CPB time|Cardiopulmonary bypass time
79670150|NCT05495815|Drug|6 months of SAT|6 months of oral suppressive antibiotic therapy
79670151|NCT05495815|Drug|12 months of SAT|12 months of oral suppressive antibiotic therapy
79670152|NCT05495815|Drug|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
79509729|NCT04734600|Other|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
79358942|NCT00109876|Procedure|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
79358943|NCT02093962|Drug|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
79358944|NCT02093962|Drug|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
79670153|NCT05492175|Other|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
79358945|NCT02094118|Biological|Point-of-care washed red blood cell transfusion.|
79358946|NCT02094118|Biological|Standard of care red blood cell transfusion.|
79358947|NCT01897636|Procedure|EUS-guided fine-needle injection of DCs vaccinations|
79358948|NCT00200902|Drug|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
79358949|NCT00200902|Other|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
79509730|NCT05314842|Drug|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
79819114|NCT05166889|Drug|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
79509731|NCT05314842|Drug|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
79509732|NCT05314530|Behavioral|ReTA-model|Validating the rehabilitation model ReTA
79819115|NCT05159193|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1, q3w
79819116|NCT05159193|Drug|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m^2, i.v., d1, q3w
79819117|NCT05159193|Drug|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
79819118|NCT05159193|Drug|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
79819119|NCT05159193|Drug|docetaxel (T)|docetaxel (T) 90~100 mg/m^2, i.v., d1, q3w
79509733|NCT05314140|Diagnostic Test|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
79509734|NCT05313984|Device|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
79509735|NCT05313906|Drug|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
79992207|NCT02334202|Other|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
79670154|NCT05492175|Other|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
79509736|NCT05313828|Drug|Acyclovir|acyclovir 4 times /day
79992208|NCT02334280|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
79992209|NCT02974868|Drug|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
79992210|NCT02974868|Drug|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
79509737|NCT05313828|Drug|Tobramycin|tobramycin 4 times /day
79992211|NCT02974868|Drug|Placebo|Placebo
79992212|NCT03144076|Other|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
79992213|NCT05076526|Biological|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~Sorbitol: 40mg/mL~Molecular weight of 2MDa, sterilized in moist heat"
79509738|NCT05313828|Drug|Fluorometholone|Fluorometholone 4 times/ day
79992214|NCT05076526|Biological|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~3g of inert cell-selector gel~0.6mL of anticoagulant (sodium citrate 4%)"
79509739|NCT05313828|Drug|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
79509740|NCT05313750|Drug|anti-infective therapy sitafloxacin|anti-infective therapy
79509741|NCT05313750|Drug|anti-infective therapy levofloxacin|anti-infective therapy
79509742|NCT05313126|Other|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
79509743|NCT05290350|Other|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
79819120|NCT05159193|Drug|docetaxel (T)|docetaxel (T) 75 mg/m^2, i.v., d1, q3w
79509744|NCT05248464|Other|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
79509745|NCT05248464|Other|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
79509746|NCT05213910|Dietary Supplement|Lactichoc|dosage form: mix of 8 strains containing 1.2x10^11 CFU frequency, and duration: 2 capsules/day during 10 days
79819121|NCT05159193|Drug|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
79819122|NCT05159193|Drug|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
79992215|NCT03111784|Other|Fish consumption and lipid profiles|
79992216|NCT02330614|Other|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
79992217|NCT02330614|Other|Nothing - control group|Only NEO-FFI test , data used as control
79992218|NCT02330692|Other|No intervention|
79992219|NCT03653858|Device|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
79509747|NCT05213910|Other|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
79509748|NCT05201196|Other|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination & pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
79509749|NCT05201196|Other|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
79358950|NCT00200902|Behavioral|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
79509750|NCT05158530|Other|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
79509751|NCT05158530|Other|Pulmonary Exercises|"4 weeks protocol~Deep breathing Exercises* 10 Reps 3 sets~Postural drainage (10 minutes * 2 sets /day)~Incentive spirometry* 10 Reps 3 sets~Bed activities (Active ankle and hand pumping exercise * 10 Reps 3 sets)"
79670155|NCT05492175|Other|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
79509752|NCT05138952|Behavioral|Mindfulness Meditation|"30-day mediation program comprising:~Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
79509753|NCT04662684|Drug|Rivaroxaban 10 MG|No intervention
79509754|NCT04661202|Other|combined resistance and aerobic exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1~3 sets of 8~12 submaximal contraction of PFM by holding 6~10 seconds with 12~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1~3 seconds 3~6 seconds of rest between each contraction."
79509755|NCT04634682|Dietary Supplement|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
79509756|NCT04531410|Dietary Supplement|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
79509757|NCT04531410|Dietary Supplement|oleic acid supplementation|Oils given at morning meal with extra enzymes
79358951|NCT00201448|Biological|Hepatitis A Vaccine|Single dose give IM
79509758|NCT04497246|Other|Questionnaire|Data collection by means of various questionnaires
79509759|NCT04442256|Drug|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
79670156|NCT05490771|Procedure|Biopsy|Undergo tumor biopsy
79670157|NCT05490771|Procedure|Computed Tomography|Undergo CT
79670158|NCT05490771|Drug|Copanlisib Hydrochloride|Given IV
79358952|NCT00201448|Biological|Towne CMV Vaccine|Single dose given subcutaneously
79358953|NCT00201760|Drug|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
79358954|NCT00201760|Drug|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
79358955|NCT00201760|Drug|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
79670159|NCT05490771|Procedure|Magnetic Resonance Imaging|Undergo MRI
79670160|NCT05486169|Procedure|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
79670161|NCT05486065|Drug|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
79670162|NCT05486065|Drug|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
79670163|NCT05483595|Drug|Chinese herbal medicine FYTF-919|Oral liquid 10ml
79670164|NCT05480514|Device|TEST LENS|etafilcon A with cosmetic pattern
79670165|NCT05480514|Device|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
79509760|NCT04175106|Other|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
79509761|NCT04175106|Other|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
79509762|NCT04175106|Other|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
79992220|NCT05076136|Other|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
79509763|NCT04175106|Other|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
79509764|NCT04081428|Radiation|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
79509765|NCT04044144|Dietary Supplement|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
79509766|NCT04713930|Drug|JNJ-61393215|JNJ-61393215 will be administered orally.
79509767|NCT04713930|Drug|Placebo|Placebo will be administered orally.
79509768|NCT04713696|Other|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
79509769|NCT04713696|Other|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
79509770|NCT04713384|Device|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
79509771|NCT04712682|Other|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
79670166|NCT05468242|Drug|Neoadjuvant chemo-immunotherapy|The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab [200 mg, once every 3 weeks (Q3W)].
79670167|NCT05468242|Drug|Bevacizumab|The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
79992221|NCT05076136|Other|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
79992222|NCT03654482|Device|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
79992223|NCT02330536|Device|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
79992224|NCT03653780|Device|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
79358956|NCT00201838|Drug|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
79509772|NCT04712916|Behavioral|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
79509773|NCT04708002|Other|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
79509774|NCT04708080|Procedure|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
79509775|NCT04707924|Device|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
79509776|NCT04707456|Other|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
79992225|NCT05076058|Dietary Supplement|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
79358957|NCT00201838|Drug|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
79358958|NCT00040846|Biological|alemtuzumab|Given IV
79358959|NCT00040846|Drug|fludarabine phosphate|Given IV
79358960|NCT00040846|Radiation|total-body irradiation|Undergo TBI
79358961|NCT00040846|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
79509777|NCT04707612|Other|No intervention.|No intervention.
79509778|NCT04707378|Device|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
79509779|NCT04706988|Other|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
79509780|NCT04706832|Device|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
79358962|NCT00040846|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
79819123|NCT05159193|Drug|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
79992226|NCT05076058|Other|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
79358963|NCT00040846|Drug|mycophenolate mofetil|Given PO
79358964|NCT00040846|Drug|cyclosporine|Given IV or PO
79358965|NCT00041938|Drug|aspirin|325 mg per day
79358966|NCT00041938|Drug|Warfarin|INR 2.5-3.0; target INR 2.75
79358967|NCT00202930|Drug|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
79358968|NCT00044044|Drug|Lurasidone 20 mg|Lurasidone 20mg/day tablets
79358969|NCT00044044|Drug|Lurasidone 40mg|Lurasidone 40mg/day tablets
79358970|NCT00044044|Drug|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
79358971|NCT00044044|Drug|Haloperidol 10mg|Haloperidol 10mg/day tablets
79358972|NCT00044044|Drug|Placebo|Matching Placebo to Lurasdione and Haloperidol
79358973|NCT00112918|Biological|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
79358974|NCT00112918|Drug|Capecitabine|Film-coated tablets
79358975|NCT00112918|Drug|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
79358976|NCT00112918|Drug|Leucovorin calcium|Administered as a 200 mg/m^2 infusion over 2 hours.
79358977|NCT00112918|Drug|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
79358978|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
79358979|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
79358980|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
79358981|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
79509781|NCT04706286|Drug|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
79509782|NCT04706286|Drug|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
79509783|NCT04706052|Other|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
79358982|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
79358983|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
79358984|NCT00205504|Drug|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
79358985|NCT00205660|Other|Stayers|Participants remain on their current antipsychotic.
79358986|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
79509784|NCT05139966|Drug|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
79509785|NCT05138718|Diagnostic Test|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
79509786|NCT05138640|Other|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
79509787|NCT05138562|Drug|Placebo Comparator: Placebo|4 x placebo capsules, QD
79509788|NCT05138562|Drug|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
79509789|NCT05138562|Drug|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
79509790|NCT05138562|Drug|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
79670168|NCT05468242|Radiation|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose to the thoracic lesions.
79228454|NCT01337973|Behavioral|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
79228455|NCT01337973|Behavioral|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
79228456|NCT01337973|Behavioral|E-TAU|Enhanced Treatment as Usual
79228457|NCT03300362|Drug|Seasonal influenza vaccine|Seasonal influenza vaccine
79228458|NCT03300362|Drug|MVA-NP+M1|Trial vaccine
79228459|NCT03300362|Drug|Sodium chloride|Saline placebo
79358987|NCT00113230|Drug|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
79358988|NCT00113230|Drug|Capecitabine|900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
79358989|NCT00113230|Radiation|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
79358990|NCT00049036|Biological|rituximab|Given IV
79358991|NCT00049036|Drug|etoposide|Given IV
79358992|NCT00049036|Drug|doxorubicin hydrochloride|Given IV
79358993|NCT00049036|Drug|vincristine sulfate|Given IV
79358994|NCT00049036|Drug|prednisone|Given orally
79358995|NCT00049036|Drug|cyclophosphamide|Given IV
79358996|NCT00049036|Other|laboratory biomarker analysis|Correlative studies
79358997|NCT00212446|Device|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
79358998|NCT00049504|Drug|cyclophosphamide|Given IV
79358999|NCT00049504|Drug|fludarabine phosphate|Given IV
79359000|NCT00049504|Drug|tacrolimus|Given IV or orally
79359001|NCT00049504|Drug|mycophenolate mofetil|Given orally
79359002|NCT00049504|Genetic|polymerase chain reaction|Correlative studies
79359003|NCT00049504|Genetic|fluorescence in situ hybridization|Correlative studies
79359004|NCT00049504|Genetic|polymorphism analysis|Correlative studies
79359005|NCT00049504|Genetic|gene expression analysis|Correlative studies
79359006|NCT00049504|Radiation|total-body irradiation|Undergo total-body irradiation
79359007|NCT00049504|Procedure|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
79509791|NCT00575016|Biological|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
79509792|NCT00575016|Biological|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
79509793|NCT00575016|Biological|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
79509794|NCT00575016|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
79509795|NCT00577512|Drug|DTPACE|"Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~Thalidomide 200 mg by mouth (PO) Days 1-7~Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~Adriamycin 15 mg/m2 Days 1-4~Cyclophosphamide 600 mg/m2 Days 1-4~Etoposide 60 mg/m2 Days 1-4"
79509796|NCT00577590|Drug|Metformin|Metformin is taken alone
79359008|NCT00049504|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
79509797|NCT00577590|Drug|Rosiglitazone|Rosiglitizone is taken with Metformin
79509798|NCT00577590|Drug|Lovaza|Lovaza is taken with Metformin
79670169|NCT05468242|Drug|Tislelizumab|Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
79819124|NCT05158387|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
79359009|NCT00050986|Drug|Temozolomide|Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
79359010|NCT00050986|Drug|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
79359011|NCT00214786|Biological|Islet cell transplantation|Allogenic islet transplantation
79359012|NCT00118144|Drug|bortezomib|Given IV
79359013|NCT00118378|Drug|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
79359014|NCT00118378|Drug|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
79359015|NCT00217438|Drug|melphalan|Given IV
79359016|NCT00217438|Drug|amifostine trihydrate|Given IV
79359017|NCT00217438|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
79359018|NCT00217438|Genetic|fluorescence in situ hybridization|Correlative study
79670170|NCT05467800|Drug|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
79670171|NCT05455541|Diagnostic Test|AI augmented POCUS examination|Internists will perform POCUS studies as they consider appropriate for patient management. Interpretation of the POCUS exams will be aided by machine learning based analysis of the videos.
79670172|NCT05454709|Drug|Dasiglucagon|Use of dasiglucagon in the AP system.
79670173|NCT05454709|Drug|GlucaGen|Use of GlucaGen in the AP system.
79670174|NCT05454189|Device|Reduced IPD Flush Schedule|IPD flush every 12 weeks
79359019|NCT00217438|Procedure|bone marrow ablation with stem cell support|Undergo transplant
79509799|NCT00578214|Drug|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
79509800|NCT00578214|Other|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
79509801|NCT00578214|Drug|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
79992227|NCT03143998|Drug|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
79992228|NCT05075902|Behavioral|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
79992229|NCT05075668|Device|CPAP face mask|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
79992230|NCT05075668|Device|High flow nasal cannula (HFNC)|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
79359020|NCT04480450|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
79359021|NCT00217594|Drug|Alemtuzumab (Campath)|
79359022|NCT00118534|Behavioral|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
79359023|NCT00118534|Behavioral|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
79359024|NCT00052078|Drug|Sertraline (SRT)|Participants were treated with sertraline.
79359025|NCT00052078|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
79359026|NCT00052078|Drug|Placebo|Participants were treated with a placebo pill.
79359027|NCT05820646|Other|Boswellia Sacra|"Boswellia Sacra used as an intracanal medicament for 3 days~Boswellia Sacra used as an intracanal medicament for 7 days"
79359028|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)|Assess early and late genito-urinary (GU) toxicities induced assessed via the International Prostate Symptom Score (I-PSS) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
79509802|NCT00578214|Drug|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
79509803|NCT00580398|Behavioral|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
79509804|NCT00580398|Drug|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
79509805|NCT00581256|Radiation|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
79670175|NCT05454189|Device|Standard IPD Flush Schedule|IPD flush every 4 weeks
79819125|NCT05158387|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
79819126|NCT05158387|Drug|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
79992231|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
79359029|NCT05820633|Radiation|"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite (EPIC-26):"|Assess early and late genito-urinary (GU) and gastro-intestinal (GI) toxicities induced and quality of life assessed via expanded prostate cancer index composite (EPIC-26) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
79359030|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)|Assess early and late sexual health in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
79992232|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
79359031|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)|Assess early and late toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
79509806|NCT00581256|Radiation|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
79509807|NCT00582660|Drug|Celecoxib|400 mg twice a day for 7 days prior to surgery
79509808|NCT00582660|Drug|Placebo|one tablet of placebo will be given for 7 days prior to surgery
79509809|NCT00582894|Drug|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
79509810|NCT00583050|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
79509811|NCT00583908|Device|senofilcon A|toric contact lens
79509812|NCT00583908|Device|balafilcon A toric|toric contact lens
79509813|NCT00583908|Device|lotrafilcon B toric|toric contact lens
79509814|NCT00583908|Device|omafilcon A|toric contact lens
79509815|NCT00584220|Device|senofilcon A toric|contact lens
79509816|NCT00584220|Device|alphafilcon A toric|contact lens
79509817|NCT00584922|Procedure|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
79819127|NCT05156710|Drug|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
79819128|NCT05156710|Drug|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
79819129|NCT05156710|Drug|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
79819130|NCT05156710|Drug|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
79992233|NCT02334046|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
79992234|NCT03486899|Drug|BMS-986036|Specified dose on specified days.
79992235|NCT03486899|Other|Placebo|Specified dose on specified days.
79359032|NCT05820633|Radiation|Report and compare the biochemical disease free survival (bDFS)|Assess the 5 and 10 years biochemical disease-free survival (bDFS) in the UHF group and compare them for non-inferiority to those of the control group.
79359033|NCT05820633|Radiation|Report and compare the disease free survival (DFS)|Assess the 5 and 10 years disease-free survival (DFS) in the UHF group and compare them for non-inferiority to those of the control group.
79359034|NCT05820633|Radiation|Report and compare the metastase free survival (MFS)|Assess the 5 and 10 years metastasis-free survival (MFS) in the UHF group and compare them for non-inferiority to those of the control group.
79509818|NCT00585780|Drug|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
79359035|NCT05820633|Radiation|Report and compare the overall survival (OS)|Assess the 5 and 10 years overall survival (OS) in the UHF group and compare them for non-inferiority to those of the control group.
79359036|NCT05820607|Biological|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
79359037|NCT05820542|Other|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
79359038|NCT05820542|Other|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
79359039|NCT05820529|Procedure|adenotonsillectomy|removal of adenoid,tonsil in one session
79359040|NCT05820529|Procedure|adenoidectomy|removal of adenoid
79359041|NCT05820529|Procedure|tonsillectomy|removal of tonsil
79359042|NCT05820516|Device|TricValve implantation|TricValve implantation
79359043|NCT05820438|Device|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
79359044|NCT05820412|Other|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
79359045|NCT05820399|Dietary Supplement|Organic Guayusa Extract|Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
79359046|NCT05820399|Dietary Supplement|Placebo|Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
79359047|NCT05820386|Procedure|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
79359048|NCT05820386|Procedure|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
79509819|NCT00585780|Drug|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
79509820|NCT00586170|Device|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
79359049|NCT05820373|Behavioral|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
79509821|NCT00586170|Device|Placebo Device|10 hours of treatment per day for up to 24 weeks
79509822|NCT00586170|Procedure|Surgery|Open Reduction and Internal Fixation of the nonunion site
79819131|NCT05156710|Drug|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
79819132|NCT05156710|Drug|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
79359050|NCT05820373|Behavioral|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
79670176|NCT05454176|Device|Libre 2|"The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level <=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use."
79670177|NCT05454176|Device|Device for SMBG and Libre Pro|"A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group."
79670178|NCT05447650|Device|i-Lumen(TM) AMD|Transpalpebral microcrurrent stimulation
79670179|NCT05447650|Device|i-Lumen(TM) AMD Sham|Transpalpebral sham stimulation
79670181|NCT05438719|Device|MOTUS Total Joint Replacement|The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
79670182|NCT05431088|Drug|GBT021601|Tablets which contain GBT021601 drug substance
79359051|NCT05820373|Behavioral|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
79359052|NCT05820282|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
79359053|NCT05820282|Other|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
79509823|NCT00586482|Drug|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
79509824|NCT00586482|Drug|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
79509825|NCT00586482|Behavioral|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
79670183|NCT05430477|Device|Electrical impedance imaging using Non-Significant Risk device (EII probe)|novel small field-of-view Non-Significant Risk device (EII probe)
79819133|NCT05156710|Drug|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
79819134|NCT05151640|Drug|Nintedanib|Nintedanib
79819135|NCT05145413|Drug|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
79359054|NCT05820269|Behavioral|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
79359055|NCT05820165|Radiation|high-resolution 3D-T1|Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
79359056|NCT05820165|Radiation|diffusion tensor imaging (DTI)|Subjects undergo a DTI imaging to obtain images of white matter lesions
79359057|NCT05820165|Radiation|resting-state functional magnetic resonance imaging (rs-fMRI)|Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity
79359058|NCT05820165|Radiation|arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)|Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions
79509826|NCT03708354|Drug|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
79509827|NCT03708354|Drug|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
79670184|NCT05429892|Behavioral|Smoking cessation counseling and food delivery|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
79992236|NCT02918552|Drug|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
79819136|NCT05145413|Drug|Placebo|Placebo Capsules
79819137|NCT05142189|Biological|BNT116|intravenous injection
79819138|NCT05142189|Biological|Cemiplimab|intravenous infusion
79359059|NCT05820165|Radiation|susceptibility-weighted images (SWIs)|Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
79819139|NCT05142189|Drug|Docetaxel|intravenous infusion
79819140|NCT05142189|Drug|Carboplatin|intravenous infusion
79992237|NCT02918552|Drug|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
79509828|NCT03297684|Drug|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
79509829|NCT01685424|Drug|Etoricoxib|As per routine clinical practice in the United Kingdom
79509830|NCT01327638|Drug|etoricoxib|Patients with SpA/AS who took etoricoxib
79509831|NCT01327638|Drug|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
79509832|NCT01327638|Drug|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
79509833|NCT00393354|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
79509834|NCT00393354|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
79509835|NCT00166530|Drug|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
79359060|NCT05820113|Device|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
79359061|NCT05820074|Diagnostic Test|Neural Activity Recording|Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
79509836|NCT00166530|Drug|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
79509837|NCT00166530|Drug|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
79359062|NCT05820074|Diagnostic Test|Movement Parameter Recording|Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
79359063|NCT05820074|Other|Neuromodulation|Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
79359064|NCT05820061|Diagnostic Test|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
79509838|NCT00588900|Drug|cediranib maleate|
79819141|NCT05142189|Drug|Paclitaxel|intravenous infusion
79992238|NCT02330458|Procedure|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall >3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
79992239|NCT05068882|Dietary Supplement|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
79359065|NCT05820048|Drug|Lansoprazole 15 mg|"Short-term treatment of active duodenal ulcer~Short-term treatment of active benign gastric ulcers~Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~Maintain duodenal ulcer after treatmentLaw~Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~Short-term treatment of gastroesophageal reflux disease~Short-term treatment of erosive reflux esophagitis~Post-treatment maintenance therapy for erosive reflux esophagitis~Pathological hyperdivision, including Zolinger Ellison syndrome"
79359066|NCT05819996|Behavioral|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
79359067|NCT05819983|Drug|Ivermectin Tablets|Ivermectin 200µg/kg BW
79359068|NCT05819983|Drug|Permethrin Cream|Permethrin cream 5%
79359069|NCT05819970|Drug|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament
79819142|NCT05123664|Other|Capsule|1 cap daily at same time of the day with or without food for 4 weeks
79992240|NCT05068882|Dietary Supplement|High-protein nutrition|Oral nutrition with high-protein content
79359070|NCT05819970|Drug|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament
79359071|NCT05819905|Diagnostic Test|PET/CT|Pre treatment staging 18F-FDG PET/CT
79359072|NCT05819736|Other|Monitoring|Monitoring
79359073|NCT05819723|Other|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
79509839|NCT00588900|Drug|irinotecan hydrochloride|
79509840|NCT00589056|Drug|cisplatin|
79509841|NCT00589056|Drug|etoposide|
79509842|NCT00589056|Drug|nelfinavir mesylate|
79509843|NCT00589056|Genetic|protein expression analysis|
79509844|NCT00589056|Other|immunohistochemistry staining method|
79509845|NCT00589056|Other|laboratory biomarker analysis|
79509846|NCT00589056|Procedure|biopsy|
79509847|NCT00589056|Radiation|radiation therapy|
79509848|NCT00590226|Drug|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
79509849|NCT00590226|Drug|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
79509850|NCT00590460|Biological|CAMPATH-1H|Given intravenous on days -8, -7, and -6
79509851|NCT00590460|Biological|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
79819143|NCT05114746|Radiation|177Lu-PSMA-617|administered intravenously at a dose of 7.4 GBq (+/- 10%). A 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
79992241|NCT05068882|Dietary Supplement|Standard nutrition|Oral nutrition with standard ingredients
79670185|NCT05429892|Behavioral|Smoking cessation counseling|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials."
79992242|NCT02330380|Drug|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
79359074|NCT05819645|Behavioral|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
79359075|NCT05819632|Other|curcumin gel 2%|curcumin gel 2%
79359076|NCT05819606|Other|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
79359077|NCT05819567|Device|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
79359078|NCT05819554|Procedure|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
79359079|NCT05819489|Diagnostic Test|Dynamic Vision Testing|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
79509852|NCT00590460|Drug|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
79509853|NCT00590460|Procedure|Stem cell infusion|Stem cells are infused on day 0
79509854|NCT00590772|Drug|montelukast|10 mg po each day (compared to placebo for 2 weeks)
79509855|NCT00590772|Drug|placebo|placebo for 2 weeks
79509856|NCT00591942|Device|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
79670186|NCT05429892|Behavioral|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
79992243|NCT02330380|Drug|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
79670187|NCT05427162|Drug|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
79992244|NCT02330380|Drug|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
79992245|NCT02330380|Drug|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
79359080|NCT05819437|Other|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
79359081|NCT05819411|Behavioral|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
79359082|NCT05819411|Behavioral|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
79509857|NCT00592176|Drug|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
79670189|NCT05419856|Drug|4P-004|single intraarticular administration in the knee joint
79359083|NCT05819333|Other|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
79359084|NCT05819333|Other|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
79359085|NCT05819307|Device|OCT/FLIM|OCT/FLIM imaging of the retina
79670190|NCT05419856|Drug|Placebo|single intraarticular administration in the knee joint
79359086|NCT05819281|Dietary Supplement|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
79359087|NCT05819281|Dietary Supplement|PLACEBO|Maltodextrin
79509858|NCT00592488|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
79509859|NCT00593346|Radiation|brachytherapy|brachytherapy (radioactive implants)
79670191|NCT05417165|Biological|Pneumococcal 20-valent Conjugate Vaccine|Given IM
79670192|NCT05417165|Biological|Pneumococcal Polyvalent Vaccine|Given IM
79670193|NCT05416333|Drug|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
79670194|NCT05416333|Other|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
79670195|NCT05411497|Biological|Autologous MUC1-activated T-cells|Given IV
79359088|NCT05819229|Drug|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
79359089|NCT05819216|Device|Treadmill|Gait training on treadmill training
79359090|NCT05819177|Other|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
79359091|NCT05819164|Device|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
79359092|NCT05819164|Device|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
79670196|NCT05411497|Drug|Cyclophosphamide|Given IV
79670197|NCT05407805|Other|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
79670198|NCT05403996|Behavioral|Activa-Mente|Active break program
79992246|NCT02330380|Drug|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
79359093|NCT05819164|Device|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
79359094|NCT05819151|Diagnostic Test|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
79359095|NCT05819086|Behavioral|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
79359096|NCT05819086|Behavioral|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
79992247|NCT02330380|Other|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
79992248|NCT02330380|Other|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
79359097|NCT05819060|Drug|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
79370973|NCT03032692|Device|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
79370974|NCT03032692|Other|Exercise with biofeedback|
79370975|NCT03032692|Other|exercise without biofeedback|
79992249|NCT02038348|Device|PET with 18F-FDOPA|
79992250|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
79992251|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
79992252|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
79819144|NCT05114746|Radiation|68Ga-PSMA-11|68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi).
79819145|NCT05114746|Other|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
79670199|NCT05403879|Procedure|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
79670200|NCT05400070|Drug|Neoadjuvant therapy 1|Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
79670201|NCT05390177|Behavioral|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
79670202|NCT05388058|Drug|Cannabidiol|Applied topically
79670203|NCT05388058|Drug|Placebo Administration|Applied topically
79670204|NCT05388058|Other|Quality-of-Life Assessment|Ancillary studies
79992253|NCT02333890|Drug|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
79992254|NCT02333890|Drug|Placebo|
79992255|NCT03719963|Device|Cochlear implant|Cochlear implant for hearing process by surgical intervention
79992256|NCT03143686|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
79992257|NCT03485495|Drug|Divaza|Oral administration.
79992258|NCT03485495|Drug|Placebo|Oral administration.
79992259|NCT03652532|Behavioral|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
79370976|NCT03457155|Other|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~At intensive care admission time~24h after admission time~In case of FA occurrence~In case of sinusal rhythm recovery (in patients with new onset FA)"
79370977|NCT03087747|Procedure|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
79670205|NCT05388058|Other|Questionnaire Administration|Ancillary studies
79670206|NCT05379920|Behavioral|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
79670207|NCT05379920|Behavioral|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
79370978|NCT03032224|Procedure|Resection of the esophagus and the gastroesophageal junction|
79370979|NCT03456687|Drug|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
79370980|NCT03497013|Device|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
79370981|NCT03497013|Device|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
79370982|NCT03495375|Dietary Supplement|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
79370983|NCT03495375|Other|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
79370984|NCT00948298|Drug|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
79370985|NCT00948298|Drug|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
79370986|NCT05346783|Drug|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
79370987|NCT05346783|Other|Placebo (vehicle)|1 drop 6 times a day
79370988|NCT05346783|Drug|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
79819146|NCT05113368|Drug|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) [3 weeks on/1 week off] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
79819147|NCT05113368|Drug|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
79819148|NCT05110742|Drug|Fludarabine Phosphate|Given by IV
79819149|NCT05110742|Drug|Cyclophosphamide|Given by IV
79819150|NCT05110742|Drug|CAR.5/IL15-transduced CB-NK cells|Given by IV
79509860|NCT00595530|Drug|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~Patients begin the ketamine infusion at 0.05 mg/kg/hr.~4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~patient's pain has not improved to an acceptable level~side effects remain acceptable~4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
79819151|NCT05109728|Drug|[177Lu]Lu-DOTA-TATE|"Group 1: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
79819152|NCT05109728|Drug|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
79819153|NCT05109728|Other|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
79819154|NCT05109728|Other|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
79819155|NCT05100862|Drug|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day or 320 mg once a day) continuously in repeated 28-day cycles.
79509861|NCT00596622|Drug|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
79359098|NCT05819034|Other|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
79359099|NCT05819034|Other|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
79359100|NCT05818995|Drug|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: <standard dose, standard dose, >standard dose Frequency of administration: once a day, twice a day, three times a day.
79359101|NCT05818982|Drug|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
79509862|NCT00597246|Drug|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
79359102|NCT05818982|Drug|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
79509863|NCT00597246|Other|PET Scan|GE Advance PET scanner for sequential body imaging
79509864|NCT00597402|Drug|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
79509865|NCT00597402|Drug|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
79509866|NCT00597402|Radiation|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
79509867|NCT00597402|Drug|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
79509868|NCT00597558|Drug|Egg white protein|Egg white protein powder
79670208|NCT05379101|Diagnostic Test|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
79670209|NCT05379101|Diagnostic Test|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
79819156|NCT05100862|Drug|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
79670210|NCT05379101|Diagnostic Test|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
79819157|NCT05100862|Drug|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
79819158|NCT05100862|Drug|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
79819159|NCT05098054|Drug|Soticlestat|Soticlestat tablets.
79819160|NCT05096299|Device|OCS Heart|Transplanted with OCS preserved heart.
79819161|NCT05090371|Drug|Ofatumumab|3 loading doses followed by administration every 4 weeks as per label
79819162|NCT05090371|Drug|Disease modifying treatment (DMT)|Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
79819163|NCT05088863|Other|flaxseed|40g of flaxseed per day
79992260|NCT03652532|Behavioral|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
79370989|NCT00948610|Drug|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
79992261|NCT02330302|Drug|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
79509869|NCT00598806|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
79509870|NCT00598806|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
79509871|NCT00598806|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
79509872|NCT00601146|Procedure|chest computed tomography scan|Once a year for three years
79509873|NCT00601926|Biological|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
79819164|NCT05084638|Drug|Ofatumumab|20mg subcutaneous injection
79359103|NCT05818969|Behavioral|Hypnosis Therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
79819165|NCT05082454|Device|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
79992262|NCT02330302|Drug|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
79359104|NCT05818917|Drug|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
79359105|NCT05818813|Device|Renal denervation|Renal denervation (ReCor Medical)
79819166|NCT05063331|Procedure|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
79819167|NCT05063331|Procedure|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
79509874|NCT00603018|Drug|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
79509875|NCT00603408|Drug|Cisplatin|
79509876|NCT00603408|Radiation|Radiation Therapy|
79509877|NCT00603408|Procedure|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
79509878|NCT00603564|Procedure|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
79509879|NCT00603720|Drug|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
79359106|NCT05818748|Device|virtual reality|virtual reality distraction
79819168|NCT05056675|Procedure|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
79359107|NCT05818670|Drug|Tamsulosin|long term follow up
79509880|NCT00603720|Drug|L-Arginine|aids in nitric oxide production
79509881|NCT00603720|Drug|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
79509882|NCT00622518|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
79509883|NCT00625404|Drug|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
79670211|NCT05370911|Drug|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
79670212|NCT05370287|Other|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
79670213|NCT05370287|Device|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
79670214|NCT05370105|Other|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
79670215|NCT05367999|Diagnostic Test|initial Paroxysmal Event Profile|The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
79670216|NCT05356403|Drug|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
79992263|NCT02330224|Other|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~Telephone based follow-up for all patients by nurses"
79992264|NCT03653624|Other|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
79359108|NCT05818670|Drug|Tadalafil|long term follow up
79359109|NCT05818657|Biological|levels of CKD markers, Oral health status, apical periodontitis|To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
79359110|NCT05818657|Biological|systemic inflammatory marker, Oral health status, apical periodontitis|estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
79370990|NCT02245750|Device|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
79509884|NCT00625404|Other|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
79509885|NCT00626340|Drug|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
79509886|NCT00626340|Drug|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
79509887|NCT00626340|Drug|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
79509888|NCT00626340|Drug|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
79509889|NCT00626574|Drug|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
79670217|NCT05356403|Drug|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
79359111|NCT05818605|Behavioral|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
79359112|NCT05818592|Other|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
79359113|NCT05818579|Other|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
79359114|NCT05817552|Diagnostic Test|Geomagic Control X|3D Surface matching and compare
79359115|NCT05816681|Drug|DWJ1230|Daewoong Pharmaceutical
79509890|NCT00626574|Drug|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
79509891|NCT00626808|Drug|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
79509892|NCT00626886|Drug|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
79509893|NCT00626886|Drug|placebo collagen sponge|collagen
79509894|NCT00627978|Drug|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
79509895|NCT00628134|Drug|calfactant|single inhaled dose by nebulizer
79509896|NCT00628134|Drug|isotonic saline|single inhaled dose by nebulizer
79509897|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
79670218|NCT05355415|Device|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
79509898|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
79509899|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for patients in this group
79509900|NCT00632970|Drug|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
79359116|NCT05816681|Drug|DWB2001|Daewoong Bio
79359117|NCT05816512|Drug|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
79370991|NCT03032302|Dietary Supplement|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
79370992|NCT03032302|Dietary Supplement|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
79509901|NCT00632970|Drug|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
79509902|NCT00632970|Drug|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
79509903|NCT00635232|Drug|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
79509904|NCT00635232|Drug|placebo|placebo capsules once daily for 12 weeks
79509905|NCT00635232|Drug|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
79509906|NCT00635232|Drug|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
79509907|NCT00635232|Drug|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
79509908|NCT00637494|Drug|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
79509909|NCT00637494|Drug|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
79509910|NCT00638274|Procedure|Air|3 mls used for identifying epidural space
79670219|NCT05351385|Procedure|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
79670220|NCT05351385|Procedure|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
79670221|NCT05351385|Procedure|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
79670222|NCT05351385|Procedure|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
79670223|NCT05351385|Procedure|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
79670224|NCT05351385|Procedure|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
79509911|NCT00638274|Procedure|Saline|3 mls of saline used to identify epidural space
79359118|NCT05816512|Drug|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
79509912|NCT00638820|Procedure|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
79509913|NCT00638820|Drug|Campath, Busulfan, Clofarabine|"12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~11 Campath-1H 0.3 mg/kg intravenously over 2 hours~10 Campath-1H 0.3 mg/kg intravenously over 2 hours~9 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~8 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~7 Rest~6 Clofarabine 40 mg/m2 intravenously over 2 hours~5 Clofarabine 40 mg/m2 intravenously over 2 hours~4 Clofarabine 40 mg/m2 intravenously over 2 hours~3 Clofarabine 40 mg/m2 intravenously over 2 hours~2 Clofarabine 40 mg/m2 intravenously over 2 hours"
79359119|NCT05816499|Drug|Cadonilimab|Given IV, 10mg/kg Q3W
79509914|NCT00638820|Procedure|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
79670225|NCT05344339|Procedure|Distal gastrectomy|Reconstruction after Distal Gastrectomy
79670226|NCT05342623|Drug|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
79992265|NCT03143530|Procedure|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
79992266|NCT03143530|Drug|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
79509915|NCT00641862|Dietary Supplement|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
79509916|NCT00641862|Other|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
79670227|NCT05342623|Drug|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
79819169|NCT05056675|Procedure|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
79509917|NCT00643578|Drug|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
79509918|NCT00643578|Drug|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
79819170|NCT05042284|Drug|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
79992267|NCT03143530|Drug|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
79992268|NCT01065818|Drug|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
79670228|NCT05336565|Other|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
79359120|NCT05816499|Drug|Anlotinib|oral，6mg/8mg/10mg qd 2W/3W
79359121|NCT05816499|Drug|Docetaxel|Given IV, 60-75mg/m2 Q3W
79359122|NCT05816486|Diagnostic Test|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
79359123|NCT05816434|Behavioral|Sleep extension|>1 hour additional time in bed per night for 1 week.
79819171|NCT05039307|Behavioral|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
79359124|NCT05816291|Dietary Supplement|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
79359125|NCT05816239|Procedure|Dual Energy CT|Patient will receive Dual Energy CT
79670229|NCT05335733|Diagnostic Test|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
79819172|NCT05038254|Other|Best Practice|Receive standard of care telemedicine
79819173|NCT05038254|Procedure|Patient Monitoring|Undergo remote monitoring
79509919|NCT00643578|Device|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
79509920|NCT00644592|Drug|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
79509921|NCT00644592|Drug|Fenofibrate|160 mg/day orally for 4 weeks
79509922|NCT00645450|Drug|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
79509923|NCT00645450|Drug|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
79509924|NCT00645762|Device|RS-Series Rhinosinusitis Treatment System|Single arm
79509925|NCT00645762|Device|FinESS Balloon|
79509926|NCT00647400|Biological|adalimumab|Adalimumab 40 mg every other week, subcutaneous
79509927|NCT00647400|Biological|adalimumab|Adalimumab 80 mg every other week, subcutaneous
79509928|NCT00652080|Drug|API 31510|Topical Cream; 3% active; AM & PM application
79509929|NCT00652314|Device|Thrombi-Gel|Applicaton of Hemostatic product during surgery
79670230|NCT05328622|Behavioral|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
79819174|NCT05038254|Other|Questionnaire Administration|Ancillary studies
79359126|NCT05816213|Device|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: ~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
79359127|NCT05816200|Device|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
79509930|NCT00654030|Drug|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
79509931|NCT00654654|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm biopsies~Two injection treatments of facial wrinkles and creases~Conduct of study assessments"
79509932|NCT00656448|Drug|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
79509933|NCT00659802|Drug|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
79509934|NCT00659802|Drug|Placebo|Matching dose of Placebo
79509935|NCT00659802|Drug|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
79819175|NCT05035498|Drug|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
79819176|NCT05035498|Drug|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
79819177|NCT05035485|Drug|Phenylephrine|A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
79819178|NCT05035485|Drug|Norepinephrine|A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
79509936|NCT00660504|Drug|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
79509937|NCT00660504|Drug|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
79359128|NCT05816200|Device|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
79359129|NCT05816161|Diagnostic Test|Integrated Neuromuscular Inhibition Technique|Exercises
79359130|NCT05816161|Diagnostic Test|Myofascial Release|Exercises
79359131|NCT05816109|Diagnostic Test|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
79359132|NCT05816109|Diagnostic Test|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
79359133|NCT05816096|Combination Product|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
79359134|NCT05816096|Combination Product|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
79359135|NCT05815966|Behavioral|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
79359136|NCT05815953|Device|Polarstem|Stem used in total hip replacement. Manufacturer: Smith & Nephew Orthopaedics AG, Baar, Switzerland.
79359137|NCT05815953|Device|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
79359138|NCT05815940|Behavioral|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
79359139|NCT05815914|Other|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
79509938|NCT00661674|Drug|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
79359140|NCT05815914|Other|control group|Routine nutritional and dietary recommendations will be given.
79359141|NCT05815901|Drug|Epaminurad 6 mg|Epaminurad 6 mg tablet
79359142|NCT05815901|Drug|Epaminurad 9 mg|Epaminurad 9 mg tablet
79359143|NCT05815901|Drug|Febuxostat 40 mg|Febuxostat 40 mg tablet
79359144|NCT05815901|Drug|Febuxostat 80 mg|Febuxostat 80 mg tablet
79359145|NCT05815901|Drug|Epaminurad 6 mg placebo|Placebo tablet
79359146|NCT05815901|Drug|Epaminurad 9 mg placebo|Placebo tablet
79359147|NCT05815901|Drug|Febuxostat 40 mg placebo|Placebo tablet
79359148|NCT05815901|Drug|Febuxostat 80 mg placebo|Placebo tablet
79359149|NCT05815862|Drug|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
79819179|NCT05034146|Drug|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
79359150|NCT05815849|Dietary Supplement|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
79359151|NCT05815823|Other|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
79670233|NCT05318937|Drug|SAGE-718|Softgel capsules
79670234|NCT05318937|Drug|SAGE-718-matching placebo|Softgel capsules
79670236|NCT05316155|Drug|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
79819180|NCT05034146|Device|PET/CT|68Ga-FAPI PET/CT scan were performed 20~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
79819181|NCT05032040|Biological|vudalimab|Monoclonal bispecific antibody
79670237|NCT05315973|Device|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
79670238|NCT05313334|Behavioral|GAMBIT Task|The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
79819182|NCT05019963|Behavioral|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
79819183|NCT05019963|Other|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
79819184|NCT05016245|Combination Product|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
79359152|NCT05815823|Other|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
79359155|NCT05815784|Drug|Atropine|0.05% atropine. One drop per eye per day for 2 years.
79359156|NCT05815784|Device|MiSight contact lenses|Daily wear for 2 years.
79359157|NCT05815771|Procedure|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
79359158|NCT05815771|Procedure|Bone Marrow stem cells aspirate|stem cells
79359159|NCT05815732|Other|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
79359160|NCT05815719|Drug|Corifollitropin Alfa|150 micrograms per dose
79359161|NCT05815719|Drug|Follitropin Alfa|Variable dose.
79359162|NCT05815719|Drug|Follitropin Alfa Biosimilar|Variable dose.
79670239|NCT05306288|Other|Blood Sample Collection|Subjects enrolled in DELFI-L201 will have blood specimens collected (~30 mL) at enrollment or up to 30 days from enrollment.
79819185|NCT05016245|Procedure|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
79359163|NCT05815719|Drug|Urinary Human follicle stimulating hormone|Variable dose.
79359164|NCT05815706|Device|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
79359165|NCT05815667|Behavioral|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
79670241|NCT05295940|Drug|LY3841136|Administered SC.
79819186|NCT04987359|Behavioral|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
79819187|NCT04981119|Other|Apheresis|Apheresis procedure performed for collection of PBMCs.
79819188|NCT04981119|Diagnostic Test|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
79359166|NCT05815654|Device|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
79359167|NCT05815641|Dietary Supplement|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
79359168|NCT05815615|Device|Plasmapheresis|Plasma donation at different frequencies
79359169|NCT05815589|Other|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
79359170|NCT05815576|Behavioral|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
79359171|NCT05815550|Drug|PPI|Use of PPI defined as PPI mentioned in the safety report
79359172|NCT05815524|Other|Physical activity training|training on treadmill
79359173|NCT05815511|Dietary Supplement|Probiotic mixture|Oral capsule consumption once a day for 12 weeks
79359174|NCT05815511|Dietary Supplement|Placebo|Oral capsule consumption once a day for 12 weeks
79359175|NCT05815472|Device|Fitbit charge|Internet of Things Technologies Device
79359176|NCT05815407|Other|No intervention|No intervention
79359177|NCT05815394|Drug|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
79359178|NCT05815381|Other|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
79359179|NCT05815355|Dietary Supplement|exclusive enteral nutrition treatment group|
79359180|NCT05815329|Other|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
79670242|NCT05295940|Drug|Placebo|Administered SC.
79670243|NCT05294302|Behavioral|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
79359181|NCT05815316|Drug|18F-PSMA-1007|(3S, 10S, 14S)-1-[4-[[(2S)-4-carboxy-3-[(2S)-4-carboxy-2-(6-[18F]fluoropyridin-3- amido)butanamido]butanamido]methyl]phenyl]-3- [(naphtalen-2-yl)methyl]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
79359182|NCT05815303|Drug|Cadonilimab|10mg/kg iv on day 1, every 21 day
79359183|NCT05815303|Drug|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
79509939|NCT00661674|Drug|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
79509940|NCT00661674|Other|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
79509941|NCT00662298|Drug|prednisolone|40mg of prednisolone once a day for 14 days
79670244|NCT05294302|Behavioral|Coping Space|Coping Space is a psychosocial informational website for PCCC.
79819189|NCT04981119|Diagnostic Test|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
79359184|NCT05815303|Drug|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
79359185|NCT05815290|Drug|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
79509942|NCT00666666|Drug|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
79509943|NCT00666666|Drug|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
79509944|NCT00666666|Other|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
79509945|NCT00666978|Behavioral|smoking cessation intervention|
79509946|NCT00666978|Drug|bupropion hydrochloride|
79509947|NCT00666978|Genetic|gene expression analysis|
79359186|NCT05815134|Biological|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
79359187|NCT05815121|Other|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
79509948|NCT00666978|Genetic|polymerase chain reaction|
79670245|NCT05293639|Device|Pulse Field Ablation|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
79670246|NCT05280093|Device|AtriCure ISOLATOR Synergy Surgical Ablation System|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
79670247|NCT05279118|Dietary Supplement|Ketogenic diet|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
79670248|NCT05279118|Drug|ACTH|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
79819190|NCT04978467|Device|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
79359188|NCT05815121|Other|Control|with stickers only on the points, and the points should not be massaged.
79359189|NCT05815108|Other|NO INTERVENTION|NO INTERVENTION
79509949|NCT00666978|Other|counseling intervention|
79509950|NCT00666978|Other|educational intervention|
79509951|NCT00666978|Procedure|psychosocial assessment and care|
79509952|NCT00668382|Biological|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
79509953|NCT00669552|Procedure|Percutaneous coronary intervention|PCI previously electively scheduled.
79509954|NCT00670956|Drug|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
79509955|NCT00670956|Drug|Placebo|PLACEBO: IM x 2 doses 24 hours apart
79509956|NCT00671502|Drug|Carisoprodol SR|700 mg twice daily
79509957|NCT00671502|Drug|Carisoprodol SR|500 mg twice daily
79509958|NCT00671502|Drug|Placebo|Placebo tablet
79819191|NCT04974645|Device|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
79359190|NCT05815082|Procedure|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
79359191|NCT05815082|Drug|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
79359192|NCT05815056|Device|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
79670249|NCT05272852|Device|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
79670250|NCT05272618|Diagnostic Test|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
79670251|NCT05271513|Device|non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )|repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation
79670252|NCT05271513|Device|non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation|sham trans-spinal magnetic stimulation
79670253|NCT05268679|Other|Biospecimen Collection|A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up
79670254|NCT05268679|Other|Questionnaire|Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire
79670255|NCT05268679|Other|Electronic Health Record Review|For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
79359193|NCT05815056|Drug|drug intervention|using sufentanyl 5mg intravenously during the surgery
79359194|NCT05815043|Behavioral|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
79359195|NCT05815043|Dietary Supplement|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
79359196|NCT05814978|Other|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
79359197|NCT05814965|Procedure|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
79670257|NCT05263804|Other|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
79819192|NCT04974645|Other|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
79819193|NCT04973930|Behavioral|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
79819194|NCT04973930|Drug|Venlafaxine HCl ER|FDA-approved antidepressant medications
79819195|NCT04973436|Behavioral|Dialectical Behavioral Therapy Skills Training|LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
79509959|NCT00671970|Drug|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs & 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
79670258|NCT05263804|Other|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
79819196|NCT04970654|Drug|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
79819197|NCT04970654|Drug|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
79819198|NCT04961177|Other|EITC & ACEs Training|We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.
79359198|NCT05814965|Procedure|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
79359199|NCT05814965|Diagnostic Test|assessment of inflammatory marker|assessment of inflammatory markers
79509960|NCT00672204|Biological|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
79359200|NCT05814965|Diagnostic Test|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
79509961|NCT00672204|Drug|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
79509962|NCT00672204|Drug|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
79509963|NCT00672204|Drug|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
79509964|NCT00672438|Drug|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
79509965|NCT00672438|Other|Saline placebo infusion|Intravenous infusion of normal saline
79509966|NCT00672594|Drug|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
79509967|NCT00673764|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
79670259|NCT05257759|Other|Usual care|Standard management offered in the intensive care unit
79670260|NCT05257759|Other|Electrostimulation|The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
79359201|NCT05814952|Genetic|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
79359202|NCT05814926|Drug|GP681|GP681, tablet, oral
79509968|NCT00673764|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
79992269|NCT02333968|Behavioral|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
79992270|NCT03483623|Other|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
79992271|NCT03483623|Other|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
79359203|NCT05814874|Dietary Supplement|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
79359204|NCT05814874|Dietary Supplement|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
79509969|NCT00674466|Drug|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
79509970|NCT00674466|Drug|Placebo|twice-a-week
79509971|NCT00674622|Drug|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
79509972|NCT00674622|Procedure|Placebo|Saline/lidocaine
79359205|NCT05814874|Other|Placebo|Placebo pill
79509973|NCT00675558|Procedure|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) & fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
79509974|NCT00675558|Procedure|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
79359206|NCT05814861|Diagnostic Test|culture and PCR|"Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR)."
79359207|NCT05814770|Drug|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP < 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
79370993|NCT04053166|Device|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
79509975|NCT00675792|Drug|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
79509976|NCT00675792|Drug|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
79359208|NCT05814770|Drug|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP < 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
79359209|NCT05814731|Drug|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
79359210|NCT05814731|Drug|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
79359211|NCT05814718|Drug|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
79359212|NCT05814718|Drug|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
79359215|NCT05814601|Drug|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
79359216|NCT05814562|Behavioral|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
79359217|NCT05812391|Procedure|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
79359218|NCT05812391|Procedure|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
79359219|NCT05812235|Procedure|esophagectomy|esophagectomy
79359220|NCT05812105|Other|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
79359221|NCT05812014|Biological|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
79359222|NCT05812014|Drug|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
79509977|NCT00675792|Drug|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
79992272|NCT03483623|Other|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
79359223|NCT05812001|Behavioral|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
79509978|NCT00676182|Other|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
79509979|NCT00676572|Other|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
79359224|NCT05812001|Behavioral|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
79359225|NCT05810974|Dietary Supplement|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
79359226|NCT05810974|Dietary Supplement|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
79359227|NCT05810974|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
79359228|NCT05810545|Other|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
79359229|NCT05810519|Behavioral|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
79359230|NCT05810519|Behavioral|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
79359231|NCT05808426|Device|Bonus Winner Mahjong|Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
79359232|NCT05807451|Procedure|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
79359233|NCT05804643|Procedure|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
79359234|NCT05804136|Device|Duramesh|Laparotomy closure with Duramesh
79359235|NCT05804136|Device|Polydioxanone suture|Laparotomy closure with standard PDS
79359236|NCT05803759|Dietary Supplement|Allicor|Each capsule contains 150 mg dried garlic powder
79359237|NCT05803759|Drug|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
79670261|NCT05257759|Other|Evaluation of the neuromuscular system|"Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition."
79670262|NCT05253053|Drug|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
79670263|NCT05253053|Drug|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
79670264|NCT05253053|Drug|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
79819199|NCT04961177|Other|EITC Outreach & Screening|"Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each)."
79359238|NCT05801861|Device|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
79992273|NCT03483623|Other|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
79359239|NCT05801861|Device|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
79992274|NCT02329990|Dietary Supplement|phosphorus|phosphorus supplement
79359240|NCT05801861|Device|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79992275|NCT03653468|Behavioral|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
79992276|NCT03143608|Device|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
79670265|NCT05252312|Behavioral|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
79992277|NCT03652844|Procedure|AAM|Subcutaneous injection procedure
79992278|NCT03653312|Device|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
79992279|NCT03143764|Behavioral|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
79992280|NCT03622034|Other|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
79992281|NCT02333734|Other|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces ~ 90% of the maximum heart rate. The time spent per session is expected to last ~ 25 minutes.
79992282|NCT02318277|Drug|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
79992283|NCT02318277|Drug|INCB024360|INCB024360: Oral daily dosing
79992284|NCT03653234|Device|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
79992285|NCT02333656|Other|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
79992286|NCT03143452|Drug|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
79992287|NCT03143452|Drug|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
79359241|NCT05801861|Device|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79359243|NCT05795257|Procedure|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
79370994|NCT04053166|Other|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
79509980|NCT00676806|Biological|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.
79509981|NCT00676806|Biological|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
79359244|NCT05786378|Biological|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
79359245|NCT05786378|Drug|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
79509982|NCT00677898|Behavioral|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
79509983|NCT00677898|Behavioral|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
79509984|NCT00678444|Other|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
79359246|NCT05786378|Procedure|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
79359247|NCT05785845|Radiation|Computed tomography-guided stereotactic adaptive radiotherapy|Fractions will be delivered on consecutive business days.
79359248|NCT05785845|Device|ETHOS|ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
79359249|NCT05782738|Procedure|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
79509985|NCT00678834|Dietary Supplement|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
79509986|NCT00678834|Dietary Supplement|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
79509987|NCT00678834|Dietary Supplement|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
79670266|NCT05248516|Dietary Supplement|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
79992288|NCT03693742|Diagnostic Test|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
79359250|NCT05781880|Other|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
79509988|NCT00679380|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
79509989|NCT00679380|Drug|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
79992289|NCT03693742|Other|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
79359251|NCT05779241|Drug|LYN-005|Risperidone long-acting oral capsule
79359252|NCT05779241|Drug|Risperidone|Risperidone immediate release (IR) oral tablets
79359253|NCT05778344|Behavioral|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
79359254|NCT05772572|Other|Questionnaires|"Questionnaires are completed only once and assess:~recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~psychiatric questionnaires for parents and patients on anxiety and depression~behavior questionnaires for the parents and the patient: assessment of attachment~questionnaires for the parents and the patient concerning the family context, the quality of life"
79359255|NCT05770596|Drug|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
79359256|NCT05770596|Other|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
79359257|NCT05768100|Dietary Supplement|1,3-Butanediol|1,3-Butanediol
79509990|NCT00679380|Drug|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
79509991|NCT00679380|Drug|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
79509992|NCT00679380|Drug|Placebo|Placebo
79509993|NCT00680706|Drug|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
79509994|NCT00680706|Drug|Placebo|D5W (50 ml)
79509995|NCT00682734|Drug|metoclopramide|metoclopramide 20 mg
79509996|NCT00682734|Drug|metoclopramide|metoclopramide 40 mg
79670267|NCT05248516|Dietary Supplement|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~children with a WHZ<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~children with a WHZ>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
79670268|NCT05248516|Dietary Supplement|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
79992290|NCT03693742|Other|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
79359258|NCT05768100|Dietary Supplement|Placebo|Isovolumic placebo
79359259|NCT05766358|Behavioral|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
79359260|NCT05766358|Drug|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
79359261|NCT05762926|Other|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
79509997|NCT00682734|Drug|metoclopramide|metoclopramide 10 mg
79509998|NCT00682734|Drug|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
79670269|NCT05236673|Drug|JARDIANCE®|JARDIANCE® film-coated tablets 10mg
79509999|NCT00683046|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
79992291|NCT01063868|Drug|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
79992292|NCT01063868|Drug|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
79992293|NCT04054934|Behavioral|Reversed Circadian Rhythm|Revered day/ night sleep cycle
79510000|NCT00683046|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
79670271|NCT05230589|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79992294|NCT04054934|Behavioral|Normal Circadian Rhythm|Normal day/ night sleep cycle
79992295|NCT02333266|Other|Candidemia|
79359262|NCT05751317|Diagnostic Test|Culture|"Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium.~Pink colonies will be inoculated on bile esculin agar medium.~Enterococci produce blackening of the agar"
79359263|NCT05751317|Diagnostic Test|Staining:|The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
79359264|NCT05751317|Diagnostic Test|Biochemical reactions:|"Catalase test.~Salt tolerance test"
79359265|NCT05751317|Diagnostic Test|VITEK|Automated identification of Enterococci will be done with VITEK2 system.
79510001|NCT00683046|Drug|Stem cells|Stem cell infusion on day 0.
79510002|NCT00683046|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
79992296|NCT02692443|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
79992297|NCT02692443|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
79670272|NCT05227027|Behavioral|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
79670273|NCT05227027|Behavioral|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
79992298|NCT02974088|Device|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
79359266|NCT05751317|Diagnostic Test|Antibiotic sensitivity test|Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
79359267|NCT05751317|Diagnostic Test|nanoparticles effect|The effect of nanoparticles on Enterococci antimicrobial resistance pattern
79359268|NCT05751317|Diagnostic Test|The biofilm formation activity|The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
79670274|NCT05221294|Drug|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
79670277|NCT05214716|Diagnostic Test|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
79359269|NCT05751317|Diagnostic Test|molecular diagnosis|Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
79992299|NCT02974088|Device|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
79992300|NCT02329912|Device|SmartPill|Application of the SmartPill at the end of surgery
79359270|NCT05750082|Device|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
79359271|NCT05748470|Other|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
79359272|NCT05748470|Other|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
79819200|NCT04961177|Other|Assistance with EITC|"We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey."
79359273|NCT05746182|Diagnostic Test|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
79359274|NCT05745909|Procedure|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
79359275|NCT05745909|Procedure|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
79359276|NCT05742113|Device|Masimo Radical-7|perfusion index measuring device
79359277|NCT05740228|Device|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
79510003|NCT00683826|Dietary Supplement|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
79510004|NCT00683826|Other|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
79670278|NCT05192447|Behavioral|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
79670279|NCT05185089|Drug|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
79670280|NCT05185089|Drug|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
79819201|NCT04959175|Drug|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
79819202|NCT04959175|Procedure|Allogeneic HSCT|Stem cell transplant
79819203|NCT04959175|Drug|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
79359278|NCT05740228|Device|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
79992301|NCT01372683|Other|Dietary Intervention|Comparison of oat based breakfast cereals
79510005|NCT00683826|Dietary Supplement|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
79510006|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
79510007|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
79670281|NCT05184504|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
79510008|NCT00685932|Device|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
79992302|NCT02333500|Other|olfactory workshop|olfactory workshop
79510009|NCT00687102|Drug|tamoxifen|oral tamoxifen plus placebo daily for 5 years
79670282|NCT05184361|Behavioral|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
79670283|NCT05184361|Behavioral|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
79359279|NCT05740228|Device|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
79359280|NCT05737667|Behavioral|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
79510010|NCT00687102|Drug|raloxifene|oral raloxifene plus placebo daily for 5 years
79510011|NCT00688662|Procedure|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
79510012|NCT00688662|Procedure|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
79510013|NCT00690924|Drug|calcitriol|Oral
79510014|NCT00690924|Other|laboratory biomarker analysis|Correlative Study
79992303|NCT02333500|Other|other workshop|other workshop: discussion group, dance and body Expression
79992304|NCT02333500|Other|No intervention|control group
79992305|NCT05193435|Other|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
79992306|NCT05193435|Other|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
79992307|NCT05060536|Procedure|Removal of infrapatellar fat pad|"There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty."
79992308|NCT05060536|Procedure|No removal of infrapatellar fat pad|Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
79992309|NCT04210869|Dietary Supplement|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
79992310|NCT04993924|Drug|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
79992311|NCT02330068|Drug|citalopram|Cases
79510015|NCT00690924|Other|pharmacological study|Correlative Study
79510016|NCT00691002|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
79670284|NCT05181735|Drug|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
79670285|NCT05181735|Drug|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
79670286|NCT05175131|Drug|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
79992312|NCT04904458|Other|"Experimental group (enfacement illusion)"|Virtual reality enfacement illusion exposure
79359281|NCT05737004|Diagnostic Test|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
79359282|NCT05733013|Other|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
79992313|NCT04904458|Other|Control Group (Pleasant virtual environment exposure)|Pleasant virtual environment exposure
79359283|NCT05723107|Drug|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
79359284|NCT05723107|Device|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
79370995|NCT04053166|Biological|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
79510017|NCT00691002|Drug|LEO 80190 Vehicle|
79510018|NCT00691002|Drug|Hydrocortisone|
79670287|NCT05175131|Drug|Mebeverine|Duspatalin®, coated tablets 135 mg
79670288|NCT05175131|Drug|Simethicone|Espumisan® capsules 40 mg
79670289|NCT05172843|Procedure|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
79670290|NCT05172843|Behavioral|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
79819204|NCT04959175|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
79510019|NCT00691002|Drug|Calcipotriol|
79510020|NCT00693498|Biological|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
79510021|NCT00693498|Biological|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
79670291|NCT05172557|Behavioral|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
79670292|NCT05172557|Behavioral|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
79992314|NCT05193357|Device|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
79992315|NCT02494869|Behavioral|Nonlinear Aerobic Training|
79992316|NCT02494869|Other|Height, Weight, BMI measure|
79992317|NCT02494869|Other|Blood draw|
79359285|NCT05723029|Other|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
79359286|NCT05723029|Other|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
79510022|NCT00693654|Drug|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
79510023|NCT00693654|Drug|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
79670294|NCT05166798|Behavioral|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
79670295|NCT05162976|Biological|Nivolumab|Given IV
79670296|NCT05162976|Drug|Oral Azacitidine|Given PO
79670297|NCT05157919|Behavioral|ICU-Care|The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
79670298|NCT05156671|Biological|Adrecizumab (HAM 8101)|Drip infusion over 60 minutes.
79670299|NCT05156671|Drug|Placebo|Drip infusion over 60 minutes
79992318|NCT02494869|Other|Cardiopulmonary exercise test|
79992319|NCT02385045|Device|i-scan|i-scan function is located on the head of the Pentax endoscopes
79510024|NCT00695292|Drug|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
79510025|NCT00695292|Drug|Carboplatin|carboplatin AUC=4 on Day 1
79510026|NCT00695292|Drug|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
79510027|NCT00696618|Drug|Fleet Enema|hyper-osmolar preparation
79510028|NCT00696618|Drug|tap water enema|hypo-osmolar preparation
79510029|NCT00696618|Drug|Normosol-R enema|iso-osmolar preparation
79510030|NCT00700440|Drug|C225 (cetuximab)|one week before and then weekly during radiotherapy
79510031|NCT00701376|Other|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
79510032|NCT00702780|Drug|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
79670300|NCT05155163|Behavioral|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
79670301|NCT05153161|Device|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
79992320|NCT02385045|Device|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
79359287|NCT05720377|Device|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
79359288|NCT05720299|Drug|Treatment with Akkermansia muciniphila|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
79359289|NCT05720299|Other|Treatment with placebo|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
79359290|NCT05719701|Drug|ICP-490|The initial dose of ICP-490 is 0.1 mg, five dose groups are planned for the dose exploration (0.1 mg to 1.5 mg).
79510033|NCT00702780|Drug|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
79992321|NCT02330146|Drug|RCT-01|
79359291|NCT05716984|Drug|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
79992322|NCT02330146|Drug|Placebo|
79359292|NCT05716984|Drug|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
79359293|NCT05715177|Other|Cura Kinesio-taping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
79510034|NCT00704028|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
79510035|NCT00704028|Drug|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
79510036|NCT00704262|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
79510037|NCT00706446|Drug|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
79670302|NCT05147571|Device|Responsive stimulation|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
79670303|NCT05147571|Device|Sham stimulation|For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
79992323|NCT02329444|Procedure|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
79992324|NCT02329444|Procedure|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
79359294|NCT05715177|Other|Placebo kinesio-taping|Placebo kinesiotaping
79510038|NCT00706446|Drug|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
79510039|NCT00706446|Drug|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
79992325|NCT01990521|Procedure|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
79510040|NCT00706446|Drug|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
79359295|NCT05715034|Behavioral|Compassionate Care|Single-session web-based program
79359296|NCT05715034|Behavioral|Relaxing with Nature|Single-session web-based program
79359297|NCT05713448|Other|No intervention|No intervention
79359298|NCT05713305|Procedure|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
79359299|NCT05713305|Procedure|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
79359300|NCT05701163|Other|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
79510041|NCT00706446|Drug|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
79510042|NCT00706836|Drug|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
79510043|NCT00706836|Drug|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
79510044|NCT00706836|Drug|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
79510045|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
79510046|NCT00708942|Drug|Placebo|Placebo suppository, for 3-7 hours application
79510047|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
79510048|NCT00708942|Drug|Placebo|Placebo ointment for 5 hours application
79510049|NCT00709878|Procedure|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
79510050|NCT00710814|Drug|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
79510051|NCT00710814|Other|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
79510052|NCT00711828|Drug|Bortezomib|Given IV
79510053|NCT00711828|Biological|Rituximab|Given IV
79510054|NCT00711828|Drug|Cyclophosphamide|Given PO
79510055|NCT00711828|Drug|Dexamethasone|Given PO
79510056|NCT00711828|Other|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
79819205|NCT04959175|Drug|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is > 1,000/mm3 over the course of three days or > 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
79359301|NCT05689879|Drug|STOP arm|TNF-alpha antagonists withdrawal
79359302|NCT05688904|Drug|Imipramine|Topical 4% Imipramine
79359303|NCT05688904|Other|Vehicle|Vehicle
79359304|NCT05687357|Drug|Tislelizumab|IV infusion
79359305|NCT05687357|Drug|S-1|Oral tablets
79359306|NCT05687357|Drug|Oxaliplatin|IV infusion
79359307|NCT05687357|Drug|Nab paclitaxel|IV infusion
79359308|NCT05687357|Radiation|Radiation|TOMO/VMAT
79359309|NCT05683457|Biological|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
79359310|NCT05683457|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79670304|NCT05142202|Radiation|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
79670305|NCT05141227|Procedure|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates & screws
79819206|NCT04959175|Drug|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
79819207|NCT04959175|Drug|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
79819208|NCT04959175|Procedure|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
79359311|NCT05682144|Biological|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
79819209|NCT04946968|Drug|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
79359312|NCT05675943|Biological|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
79359313|NCT05673330|Other|Spinal Mobilizations|"Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
79359314|NCT05673330|Other|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
79359315|NCT05662800|Diagnostic Test|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
79359316|NCT05657769|Device|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
79359317|NCT05657769|Device|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
79359318|NCT05656924|Device|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
79359319|NCT05653934|Behavioral|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
79359320|NCT05653934|Procedure|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
79359321|NCT05653934|Behavioral|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
79510057|NCT00711828|Other|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
79510058|NCT00712296|Drug|ASHMI 4|4 capsules orally twice a day
79510059|NCT00712296|Drug|ASHMI 12|12 capsules orally twice a day
79510060|NCT00712296|Drug|Placebo|Placebo 6 capsules twice a day
79670306|NCT05141227|Procedure|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov & minimal fixation of the articular surface using cannulated screws through mini open approaches
79670307|NCT05139875|Drug|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
79670308|NCT05139875|Drug|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
79819210|NCT04945460|Drug|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
79359322|NCT05653570|Diagnostic Test|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
79510061|NCT00712530|Biological|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
79510062|NCT00712530|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
79510063|NCT00715104|Biological|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
79510064|NCT00715104|Biological|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
79510065|NCT00715650|Behavioral|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
79510066|NCT00715650|Behavioral|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
79510067|NCT00715728|Device|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
79510068|NCT00715728|Device|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
79510069|NCT00715884|Device|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
79510070|NCT00715884|Device|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
79670309|NCT05139810|Drug|Donidalorsen|Donidalorsen will be administered by SC injection.
79670310|NCT05139810|Drug|Placebo|Donidalorsen-matching placebo will be administered by SC injection.
79670311|NCT05133336|Drug|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment until the optimal dose (1 or 2 mg) is selected at interim analysis, after which these subjects will receive Saroglitazar Magnesium Optimal Dose (1 or 2 mg) up to Week 52. If the selection of optimal dose is inconclusive at the interim analysis, all subjects in this arm will continue to receive Saroglitazar Magnesium 1 mg as per the initial treatment assignment for the entire treatment period up to Week 52.
79359323|NCT05653570|Diagnostic Test|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
79359324|NCT05648539|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
79359325|NCT05646654|Procedure|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
79359326|NCT05646654|Procedure|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
79359327|NCT05645159|Other|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
79359328|NCT05643482|Device|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
79359329|NCT05643482|Other|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
79359330|NCT05636280|Other|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
79359331|NCT05636280|Other|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
79359332|NCT05633693|Behavioral|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
79359333|NCT05633693|Behavioral|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
79359334|NCT05633446|Biological|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
79359335|NCT05633446|Other|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
79359336|NCT05633446|Biological|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
79359337|NCT05633446|Other|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
79359338|NCT05618938|Other|Rocabado's approach|"Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~Rest position of the tongue~Control of TMJ rotation~Rhythmic stabilization technique~Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks"
79359339|NCT05618938|Other|Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~Tongue position at rest~Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~Nasal-diaphragmatic breathing~Tongue up and wiggle~Strengthening~Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks"
79359340|NCT05616065|Other|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
79819211|NCT04945460|Drug|Placebo|Administered by subcutaneous injection
79359341|NCT05616065|Other|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
79370996|NCT04053166|Other|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
79510071|NCT00715962|Behavioral|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
79510072|NCT00715962|Other|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
79359342|NCT05612139|Device|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
79510073|NCT00715962|Other|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
79510074|NCT00716586|Drug|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
79510075|NCT00716742|Drug|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
79510076|NCT00716820|Drug|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
79510077|NCT00717054|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
79359343|NCT05604222|Drug|Mirabegron 50 MG|Medication to treat overactive bladder
79359344|NCT05604222|Behavioral|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
79359345|NCT05654610|Device|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
79359346|NCT05589350|Other|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
79359347|NCT05586152|Drug|INV-102|INV-102 Ophthalmic Solution
79359348|NCT05586152|Drug|Vehicle|Vehicle Ophthalmic Solution
79510078|NCT00717054|Drug|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
79510079|NCT00717288|Drug|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
79510080|NCT00717288|Drug|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
79510081|NCT00717288|Drug|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
79510082|NCT00717912|Other|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
79510083|NCT00717912|Other|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
79819212|NCT04945460|Drug|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
79510084|NCT00717912|Other|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
79510085|NCT00718302|Device|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
79510086|NCT00718302|Device|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
79510087|NCT00719160|Drug|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
79510088|NCT00719160|Drug|Placebo|Placebo 20 mg twice a day for 9 days
79510089|NCT00720330|Drug|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
79510090|NCT00720330|Drug|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
79510091|NCT00720330|Other|placebo|placebo
79510092|NCT00721188|Drug|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
79510093|NCT00721500|Device|etafilcon A|contact lens
79510094|NCT00721500|Device|narafilcon A|contact lens
79359349|NCT05565222|Drug|Piperacillin/tazobactam or temocillin|"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"
79359350|NCT05565222|Drug|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure)
79359351|NCT05562427|Behavioral|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
79359352|NCT05552820|Device|Verum Electroacupuncture|Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
79359353|NCT05552820|Device|Sham Electroacupuncture|Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
79359354|NCT05547932|Procedure|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
79359355|NCT05546502|Biological|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
79359356|NCT05546502|Biological|Active Comparator|Covovax
79359357|NCT05537233|Drug|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
79359358|NCT05537233|Drug|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
79510095|NCT00722124|Drug|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
79510096|NCT00722124|Drug|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
79510097|NCT00722124|Other|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
79510098|NCT00722436|Drug|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
79510099|NCT00722436|Drug|saline|Placebo
79819213|NCT04943562|Diagnostic Test|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
79819214|NCT04943380|Diagnostic Test|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
79670312|NCT05133336|Drug|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm will receive Saroglitazar Magnesium 2 mg treatment until the optimal dose (1 or 2 mg) is selected at interim analysis, after which these subjects will receive Saroglitazar Magnesium Optimal Dose (1 or 2 mg) up to Week 52. If the selection of optimal dose is inconclusive at the interim analysis, all subjects in this arm will continue to receive Saroglitazar Magnesium 2 mg as per the initial treatment assignment for the entire treatment period up to Week 52.
79992326|NCT01990521|Device|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
79359359|NCT05532865|Other|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
79510100|NCT00724308|Other|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
79510101|NCT00724308|Other|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
79510102|NCT00724464|Biological|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
79670313|NCT05133336|Drug|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
79992327|NCT02333344|Drug|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
79359360|NCT05532865|Other|Stool samples|A stool sample for collection of digestive microbiota at inclusion
79359361|NCT05532865|Other|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
79359362|NCT05532865|Other|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
79359363|NCT05524623|Other|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
79370997|NCT04053166|Other|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
79670314|NCT05132790|Drug|SHR-1316 at a dose 20mg/kg q3w|Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
79670315|NCT05132790|Drug|SHR6390 at a dose of 150mg orally, daily|SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
79992328|NCT01312857|Drug|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
79359364|NCT05506345|Behavioral|Creative Drama Workshop|"The host introduces the theme and stressor scene of this workshop~Nursing students group discussion~Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events"
79359365|NCT05497635|Drug|STSA-1002 Injection|Intravenous injection
79359366|NCT05497635|Drug|Placebo|Intravenous injection
79359368|NCT05482789|Drug|Exenatide|10 microgram injected sub-cutaneously once
79359369|NCT05476211|Device|BTL-785F|Radiofrequency
79359370|NCT05474950|Drug|minocycline|minocycline capsule (100mg) per day orally
79359371|NCT05465096|Procedure|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
79359372|NCT05462509|Device|bCPAP with blenders|The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
79359373|NCT05461404|Other|Topical Emollient Therapy|Application of high-linoleate (>60% linoleic acid) SSO to the epidermis.
79359374|NCT05458557|Diagnostic Test|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
79359375|NCT05457413|Procedure|Sleeve gastrectomy|Bariatric surgery
79670316|NCT05132790|Radiation|SBRT|radiation therapy for breast cance before surgery.
79819215|NCT04942366|Other|High intensity interval training|HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).
79359376|NCT05452213|Drug|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
79359377|NCT05447689|Behavioral|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
79359378|NCT05445076|Biological|anti-TRBV9 monoclonal antibody, low dose|infusion
79359379|NCT05445076|Biological|anti-TRBV9 monoclonal antibody, high dose|infusion
79359380|NCT05445076|Other|placebo|infusion
79359381|NCT05436912|Drug|Selpercatinib|Administered orally.
79359382|NCT05413928|Behavioral|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
79359383|NCT05413928|Behavioral|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
79359384|NCT05413928|Behavioral|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
79359385|NCT05413928|Other|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
79359386|NCT05413837|Diagnostic Test|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
79670317|NCT05124210|Biological|Sotrovimab|Sotrovimab will be administered.
79359387|NCT05413837|Diagnostic Test|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
79819216|NCT04942366|Other|Strength training|Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
79819217|NCT04931498|Other|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
79359388|NCT05408520|Procedure|Targeted Muscle Reinnervation|When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
79359389|NCT05406219|Drug|BAY2395840|Immediate release (IR) tablet, oral administration
79370998|NCT05430958|Drug|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
79992329|NCT01312857|Drug|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
79992330|NCT02974010|Drug|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
79992331|NCT02974010|Drug|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
79359390|NCT05393973|Other|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
79992332|NCT02974010|Drug|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
79359391|NCT05393973|Other|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
79992333|NCT02974010|Drug|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
79359392|NCT05389722|Drug|CC-92480|Specified dose on specified days
79359393|NCT05389722|Drug|Rifampin|Specified dose on specified days
79359394|NCT05389722|Drug|Itraconazole|Specified dose on specified days
79510103|NCT00724464|Drug|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
79992334|NCT05193201|Drug|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
79992335|NCT02030938|Device|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
79992336|NCT03122535|Device|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
79819218|NCT04931498|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
79819219|NCT04931498|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
79992337|NCT03122535|Device|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
79992338|NCT04835818|Diagnostic Test|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
79359395|NCT05389722|Drug|Digoxin|Specified dose on specified days
79359396|NCT05389722|Drug|Rosuvastatin|Specified dose on specified days
79359397|NCT05373680|Drug|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
79510104|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
79510105|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
79819220|NCT04931498|Procedure|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~Flow cytometry to quantify cell surface expression of key erythroid markers~Proteomic analysis of isolated erythrocytes using mass spectrometry"
79359398|NCT05373680|Drug|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
79359399|NCT05373680|Other|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
79359400|NCT05372718|Drug|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
79359401|NCT05372718|Procedure|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
79992339|NCT01061606|Drug|temsirolimus|Given IV
79992340|NCT02329678|Procedure|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
79992341|NCT04118361|Diagnostic Test|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
79992342|NCT04118361|Diagnostic Test|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
79992343|NCT02333578|Procedure|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
79359402|NCT05364970|Combination Product|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
79359403|NCT05364970|Combination Product|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
79359404|NCT05362682|Other|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
79510106|NCT00727740|Drug|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
79670318|NCT05118932|Behavioral|Mindful Movement Intervention|"There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants."
79819221|NCT04931498|Procedure|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~Flow cytometry to quantify cell surface expression of key markers~Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~Immunoglobulin isotype titre analysis in plasma~Isolation of monocytes for subsequent use in phagocytosis assays"
79359405|NCT05361122|Dietary Supplement|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at <20 weeks gestation).
79359406|NCT05361122|Dietary Supplement|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
79359407|NCT05359640|Other|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
79370999|NCT05430958|Drug|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
79371000|NCT05430958|Device|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
79510107|NCT00727740|Drug|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
79359408|NCT05353348|Drug|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
79359409|NCT05353348|Drug|Iron sucrose|Within 1 week of admission, 3 consecutive combination regimens of 200mg of iron sucrose and saline combined with subcutaneous saline infusions at 8am daily
79510108|NCT00728910|Drug|Atorvastatin|10 mg QD for 4 weeks
79359410|NCT05338281|Device|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
79359411|NCT05334836|Diagnostic Test|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
79510109|NCT00728910|Drug|ABT335|135 mg QD added to atorvastatin for 8 weeks
79359412|NCT05331820|Other|weekly mobile reminder|a weekly reminder will be sent to participants in the intervention group via mobile internet applications
79510110|NCT00728910|Drug|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
79510111|NCT00729846|Drug|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
79510112|NCT00729846|Device|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence [600mW/cm2].
79510113|NCT00729846|Device|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2].
79359413|NCT05326256|Other|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
79359414|NCT05326256|Other|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
79819222|NCT04908189|Drug|Deucravacitinib|Specified dose on specified days
79819223|NCT04908189|Other|Placebo|Specified dose on specified days
79359415|NCT05320419|Other|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
79510114|NCT00729924|Drug|Raltegravir|400mg orally every 12 hours for 7 days
79510115|NCT00731094|Behavioral|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
79510116|NCT00731640|Device|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
79510117|NCT00731874|Drug|Tacrolimus|Dosed to achieve target trough concentrations.
79510118|NCT00732030|Device|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
79510119|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
79510120|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
79510121|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
79510122|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
79510123|NCT00733278|Device|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
79670321|NCT05112627|Procedure|Biospecimen Collection|Undergo blood collection
79819224|NCT04908189|Drug|Apremilast|Specified dose on specified days
79359416|NCT05320419|Other|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
79359417|NCT05314543|Other|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
79510124|NCT00733356|Drug|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
79510125|NCT00733512|Device|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
79510126|NCT00735306|Drug|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
79510127|NCT00735306|Drug|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
79510128|NCT00735306|Radiation|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
79819225|NCT04878016|Biological|ZKAB001|Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，
79819226|NCT04878016|Drug|Placebo|Patients will receive placebo administered by IV infusion every 21days.
79819227|NCT04878016|Drug|Carboplatin|Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
79819228|NCT04878016|Drug|Etoposide|"Etoposide (100 mg/m^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy."
79819229|NCT04877470|Other|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
79359418|NCT05313022|Biological|ZR-202-CoV|Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine
79359419|NCT05313022|Other|Placebo|Normal saline solution
79510129|NCT00735462|Drug|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
79510130|NCT00735462|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
79510131|NCT00735462|Drug|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
79510132|NCT00735618|Other|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
79510133|NCT00736242|Biological|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
79510134|NCT00736242|Drug|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
79359420|NCT05294263|Drug|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
79359421|NCT05294263|Drug|Placebo|Matching, inactive medication
79819230|NCT04875975|Drug|Rozanolixizumab|"Pharmaceutical form: Solution for infusion~Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period."
79510135|NCT00736632|Drug|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
79359422|NCT05294068|Other|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
79359423|NCT05294068|Other|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
79359424|NCT05294068|Other|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
79510136|NCT00736632|Drug|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
79359425|NCT05292625|Biological|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
79510137|NCT00737178|Device|CuT380A|Comparison of different timing of IUD insertion
79510138|NCT00738426|Device|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
79510139|NCT00738426|Device|Sham device|non-therapeutic light energy output
79359426|NCT05292625|Biological|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
79510140|NCT00739752|Behavioral|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
79510141|NCT00739752|Behavioral|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
79510142|NCT00739752|Behavioral|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
79819231|NCT04875975|Drug|Placebo|"Pharmaceutical form: Solution for infusion~Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period."
79371001|NCT05428930|Drug|CKDB-501B|Intramuscular injection CKDB-501B
79510143|NCT00739752|Behavioral|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
79510144|NCT00739752|Behavioral|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
79510145|NCT00739752|Behavioral|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
79510146|NCT00740376|Device|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
79510147|NCT00740376|Device|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
79510148|NCT00741156|Drug|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
79819232|NCT04859621|Drug|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
79670322|NCT05104723|Drug|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
79819233|NCT04859621|Drug|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
79819234|NCT04859621|Drug|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
79819235|NCT04859621|Other|standard antibiotic therapy|standard antibiotic therapy
79670323|NCT05102370|Drug|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
79359427|NCT05292625|Other|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
79359428|NCT05285579|Biological|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
79359429|NCT05285579|Other|Tumour samples|reuse of tumour tissue collect in usual patient care
79819236|NCT04859608|Drug|Spacing of Eculizumab infusions|Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is > 150 mg/L). Spacing of infusion can be decided every 3 months.
79510149|NCT00741390|Device|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
79510150|NCT00741390|Device|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
79510151|NCT00741390|Device|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
79670324|NCT05092035|Diagnostic Test|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
79819237|NCT04857034|Drug|Deucravacitinib|Specified dose on specified days
79819238|NCT04857034|Drug|Placebo|Specified dose on specified days
79992344|NCT02329522|Device|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
79992345|NCT02329522|Device|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
79308418|NCT03208751|Behavioral|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
79359430|NCT05281757|Device|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
79359431|NCT05280886|Procedure|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
79359432|NCT05271981|Other|Retrospective data collection|Data collection from the medical file of the patients
79359433|NCT05271981|Other|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
79359434|NCT05271916|Drug|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
79819239|NCT04852887|Other|Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|"Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator."
79819240|NCT04852887|Drug|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
79819241|NCT04840615|Biological|LMB-100|LMB-100 administered into lesion on days 1 and 4 during cycle 1.
79819242|NCT04840615|Drug|ipilimumab|Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
79819243|NCT04840615|Drug|Diphenhydramine|Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
79819244|NCT04840615|Drug|Famotidine|Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
79670327|NCT05090475|Behavioral|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
79670328|NCT05089695|Device|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
79819245|NCT04840615|Drug|Acetaminophen|Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
79359435|NCT05271916|Drug|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
79670329|NCT05089604|Drug|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
79670330|NCT05089604|Drug|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
79670331|NCT05088681|Other|Rehabilitation program|The exercise intervention will consist of an individualized prescription of resistance training, balance training and cardiovascular exercises delivered for 20 session, one-hour, two/three times per week.
79510152|NCT00741390|Device|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
79510153|NCT00741390|Device|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
79819246|NCT04840615|Drug|Dexamethasone|Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
79819247|NCT04840615|Procedure|Biopsy|As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, & 4 Day 1, and Cycle 4 Day 21 (±7 days).
79359436|NCT05271656|Device|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
79819248|NCT04840615|Diagnostic Test|FDG-PET|At screening, at the end of cycles 2 & 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
79359437|NCT05261594|Dietary Supplement|Caffeine|Caffeine capsule 150 mg, oral intake
79992346|NCT02333422|Other|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
79992347|NCT04729192|Other|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
79510154|NCT00741468|Drug|Proellex|2, 25 mg Proellex capsules administered daily
79510155|NCT00741468|Drug|CYP1A2 probe|Caffeine (200 mg)
79510156|NCT00741468|Drug|CYP2C9 probe|Tolbutamide (250 mg)
79510157|NCT00741468|Drug|CYP2C19 probe|Omeprazole (20 mg)
79510158|NCT00741468|Drug|CYP2D6 probe|Dextromethorphan (30 mg)
79510159|NCT00741468|Drug|CYP3A4 probe|Midazolam (2mg)
79819249|NCT04840615|Diagnostic Test|CT CAP|At screening, at the end of cycles 2 & 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
79510160|NCT00741858|Procedure|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
79510161|NCT00741858|Procedure|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
79819250|NCT04840615|Diagnostic Test|MRI|At screening, at the end of cycles 2 & 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
79992348|NCT02329756|Drug|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
79359438|NCT05261594|Drug|Placebo|Placebo capsule, oral intake
79359439|NCT05254431|Behavioral|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
79359440|NCT05247567|Biological|serum punction|A blood sample inclusion and at the end of study visit
79359441|NCT05247567|Biological|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
79359442|NCT05245617|Device|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
79371002|NCT05428930|Drug|Botox®50U|Intramuscular injection Botox®50U
79371003|NCT03031834|Drug|Quinapril|
79510162|NCT00742170|Device|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
79359443|NCT05238103|Combination Product|Corrie Virtual Cardiac Rehabilitation Program|The Corrie Virtual Cardiac Rehabilitation Program is multi dimensional intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
79510163|NCT00742872|Drug|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
79670332|NCT05087498|Biological|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
79670333|NCT05087498|Biological|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
79819251|NCT04840615|Diagnostic Test|ECG|At screening, Cycle 1 Day 1, Cycles 2, 3, & 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
79819252|NCT04840615|Diagnostic Test|Echocardiogram|At screening.
79819253|NCT04830215|Drug|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
79819254|NCT04829136|Dietary Supplement|Kate Farms 1.0|Given enteral nutrition via nasoenteric feeding
79510164|NCT00742872|Drug|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
79510165|NCT00743574|Dietary Supplement|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
79510166|NCT00743574|Drug|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
79510167|NCT00743574|Dietary Supplement|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
79510168|NCT00743574|Dietary Supplement|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
79510169|NCT00743730|Other|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
79510170|NCT00743730|Other|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
79359444|NCT05236179|Other|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
79670334|NCT05081609|Drug|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
79670335|NCT05081609|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
79670336|NCT05081609|Drug|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
79670337|NCT05081609|Drug|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
79670338|NCT05081609|Procedure|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
79670339|NCT05081011|Device|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
79670340|NCT05081011|Device|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
79670341|NCT05072964|Device|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
79670342|NCT05069545|Drug|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
79670343|NCT05069545|Drug|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
79819255|NCT04829136|Dietary Supplement|Standard of Care Nutritional Support|Given standard of care, which may be parenteral nutrition
79819256|NCT04829136|Other|Survey Administration|Ancillary studies
79819257|NCT04825912|Behavioral|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
79510171|NCT00743730|Other|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
79359445|NCT05235815|Procedure|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
79359446|NCT05234515|Diagnostic Test|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
79510172|NCT00745290|Drug|Bupivacaine HCl|200 mg bupivacaine HCl
79510173|NCT00745290|Drug|SKY0402|600 mg SKY0402 (study drug).
79510174|NCT00748410|Drug|SB-656933|7 days repeat dose
79510175|NCT00748956|Drug|Low dose NPY|50nmol, administered intranasally
79510176|NCT00748956|Drug|High dose NPY|100nmol administered intranasally
79510177|NCT00748956|Drug|Placebo|placebo comparator (0nmol)) administered intranasally
79510178|NCT00749268|Device|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
79510179|NCT00749268|Device|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
79510180|NCT00750282|Drug|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
79670344|NCT05068960|Drug|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
79670345|NCT05068960|Drug|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
79670346|NCT05067972|Drug|PF-07260437|B7-H4 x CD3 bi-specific mAb
79670347|NCT05067972|Diagnostic Test|B7-H4 IHC|B7-H4 expression
79670348|NCT05064553|Device|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
79510181|NCT00750360|Biological|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
79510182|NCT00751530|Drug|raltegravir|New combination ART incorporating raltegravir with other ARVs.
79359447|NCT05234515|Other|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
79510183|NCT00753636|Drug|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
79510184|NCT00753948|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
79510185|NCT00754494|Drug|erlotinib hydrochloride|Given PO
79510186|NCT00754494|Other|placebo|Given PO
79510187|NCT00754494|Other|laboratory biomarker analysis|Correlative studies
79510188|NCT00755040|Drug|cyclosporine ophthalmic emulsion|Given as eye drops
79510189|NCT00755040|Other|placebo|Given as eye drops
79359448|NCT05234437|Drug|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
79359449|NCT05220748|Combination Product|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
79510190|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
79510191|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
79510192|NCT00756600|Drug|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
79670349|NCT05064553|Device|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
79510193|NCT00756600|Drug|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
79510194|NCT00756678|Drug|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
79510195|NCT00756678|Drug|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
79510196|NCT00758550|Device|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
79670350|NCT05064553|Diagnostic Test|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
79359450|NCT05220748|Biological|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
79359451|NCT05217420|Behavioral|Moving Well|Experimental arm
79359452|NCT05217420|Behavioral|Staying Well|Active comparator arm
79359453|NCT05209230|Procedure|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
79510197|NCT00758550|Device|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
79510198|NCT00758784|Drug|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
79510199|NCT00758862|Drug|2% TD1414 Cream|Application 3 times daily for 7 days
79510200|NCT00759330|Drug|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
79510201|NCT00759330|Drug|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
79510202|NCT00759330|Drug|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
79670351|NCT05056402|Biological|3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 1 and 6 month.
79670352|NCT05056402|Biological|2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Two doses administered intramuscularly at 0 and 6 month.
79510203|NCT00759330|Drug|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
79510204|NCT00759408|Drug|BQ-123|6-120 µg/min
79510205|NCT00759642|Drug|lapatinib|lapatinib 1500 mg PO daily
79510206|NCT00759798|Drug|Fludarabine|25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
79510207|NCT00759798|Drug|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
79510208|NCT00759798|Drug|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
79510209|NCT00760578|Drug|Placebo|Once daily, oral
79359454|NCT05209230|Other|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
79670353|NCT05054140|Drug|IMU-838|IMU-838 tablets
79359455|NCT05199610|Drug|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
79510210|NCT00760578|Drug|Pioglitazone|Once daily, oral
79510211|NCT00760578|Drug|MSDC-0160 90 mg|Once daily, oral
79510212|NCT00760578|Drug|MSDC-0160 220 mg|Once daily, oral
79510213|NCT00761202|Drug|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
79670354|NCT05054140|Drug|Placebo matching IMU-838|Placebo matching IMU-838 tablets
79510214|NCT00761202|Drug|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
79510215|NCT00761592|Biological|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
79510216|NCT00761592|Biological|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
79510217|NCT00762216|Device|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
79510218|NCT00762450|Drug|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
79510219|NCT00762450|Drug|fluoride|Rinse 3 times daily with assigned toothpaste slurry
79510220|NCT00762450|Drug|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
79510221|NCT00762528|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
79510222|NCT00762528|Drug|Sodium monofluorophosphate toothpaste|Twice daily usage
79510223|NCT00765570|Radiation|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
79510224|NCT00765570|Radiation|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
79510225|NCT00765570|Radiation|Standard radiation|15 Standard radiation treatments
79510226|NCT00765570|Radiation|Standard radiation|standard radiation treatment
79510227|NCT00765648|Drug|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
79510228|NCT00765648|Drug|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
79510229|NCT00766116|Drug|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
79510230|NCT00766116|Drug|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
79670355|NCT05053399|Device|Model Series ZXT|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
79359456|NCT05194332|Device|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
79359457|NCT05193786|Procedure|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
79371004|NCT02982382|Other|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
79371005|NCT02982382|Other|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
79371006|NCT02982382|Other|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
79510231|NCT00767364|Biological|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
79670356|NCT05051059|Other|Functional outcome|3D-motion analysis and strength assessment
79359458|NCT05187364|Behavioral|COPE|The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
79359459|NCT05180357|Other|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
79359460|NCT05180253|Diagnostic Test|Esophageal studies|Healthy subjects will undergo esophageal and blood testing.
79670357|NCT05051059|Other|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
79359461|NCT05166694|Other|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
79670358|NCT05048394|Device|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
79819261|NCT04819841|Genetic|nula-cel Drug Product|nula-cel is administered via IV infusion following a myeloablative conditioning regimen
79359462|NCT05166694|Other|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
79819262|NCT04807777|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
79359463|NCT05166694|Other|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
79359464|NCT05164744|Diagnostic Test|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
79510232|NCT00769314|Drug|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
79510233|NCT00769314|Drug|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
79510234|NCT00769392|Drug|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
79510235|NCT00769392|Drug|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
79510236|NCT00769392|Drug|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
79510237|NCT00769392|Drug|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
79510238|NCT00770874|Drug|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
79670359|NCT05048394|Device|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
79670360|NCT05047094|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79670361|NCT05047094|Drug|Pembrolizumab|200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
79359465|NCT05164744|Diagnostic Test|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
79510239|NCT00770874|Drug|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
79510240|NCT00771264|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
79359466|NCT05164744|Diagnostic Test|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
79359467|NCT05164744|Diagnostic Test|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
79359468|NCT05158907|Other|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
79510241|NCT00772590|Drug|Raltegravir|Tablets, 400mg, twice daily
79510242|NCT00772590|Drug|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
79510243|NCT00772590|Other|raltegravir placebo|One tablet, twice daily
79510244|NCT00772590|Other|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
79510245|NCT00772590|Drug|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
79670362|NCT05043584|Device|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
79670363|NCT05041062|Drug|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
79670364|NCT05041062|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
79359469|NCT05157477|Behavioral|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
79359470|NCT05152485|Drug|BIIB104 Reference Formulation|Administered as specified in the treatment arm
79359471|NCT05152485|Drug|BIIB104 Test Formulation|Administered as specified in the treatment arm
79510246|NCT00773370|Behavioral|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
79819263|NCT04802720|Other|Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)|"The sessions are outlined as follow:~psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~coping effectiveness training (Session 2);~identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~challenging and restructuring unhelpful cognitions (Session 4);~behavioral activation within the limitations of the caregiving context (Session 5);~problem-solving (Session 6);~communication strategies and assertiveness training (Session 7);~consolidating gains, maintenance, and relapse prevention (Session 8)."
79819264|NCT04802720|Other|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|"The sessions are outlined as follow:~psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~attention regulation skills training (Sessions 1-2);~training in metacognitive skills (Sessions 3-4);~exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~consolidating gains, taking larger proactive steps, and relapse prevention (Session 8)."
79819265|NCT04798274|Device|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
79992349|NCT02329756|Drug|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
79992350|NCT04567342|Other|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
79992351|NCT04567342|Other|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
79992352|NCT04567342|Other|No personal contact attempt|No personal contact attempts will be made.
79359472|NCT05149950|Behavioral|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
79359473|NCT05144035|Drug|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
79359474|NCT05141565|Other|No intervention|No intervention
79359475|NCT05137925|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
79670365|NCT05040126|Drug|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
79992353|NCT04567342|Other|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
79359476|NCT05137925|Behavioral|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
79670366|NCT05040126|Drug|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
79670367|NCT05040126|Drug|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
79992354|NCT03985072|Drug|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
79992355|NCT02329288|Drug|Triamcinolone Acetonide|
79992356|NCT02329288|Drug|placebo|
79359477|NCT05137119|Drug|Cefazolin|Cefazolin
79359478|NCT05137119|Drug|Penicillin|benzylpenicillin
79359479|NCT05137119|Drug|Clindamycin|Clindamycin
79359480|NCT05137119|Drug|Vancomycin|Vancomycin or Daptomycin
79359481|NCT05137119|Other|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
79359482|NCT05128006|Other|New patient teledermatology visit|new patient teledermatology visits
79359483|NCT05127109|Combination Product|Nutrition Ecosystem pathway|"parenteral nutrition initiated within 72 hours of operative intervention~Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~Philips Lumify L12-4 broadband linear array transducer ultrasound~expedited delivery of oral nutrition supplements and~a team-based approach on proper documentation of nutrition delivery and intake"
79359484|NCT05127109|Other|Comparator|retrospective cohort of 300 historical matched control subjects
79359485|NCT05085808|Drug|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
79359486|NCT05085808|Drug|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
79359487|NCT05085808|Drug|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
79359488|NCT05084625|Other|Digitized support|Access to information about the disease, treatment, side effects and self-care
79359489|NCT05079750|Biological|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
79359490|NCT05078944|Device|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
79359491|NCT05078944|Device|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
79510247|NCT00773370|Behavioral|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
79359492|NCT05078944|Drug|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
79359493|NCT05076019|Drug|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
79819266|NCT04796337|Biological|Sotatercept|Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.
79819267|NCT04794101|Biological|Genetic: AAV5-hRKp.RPGR Intermediate Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
79819268|NCT04794101|Biological|Genetic: AAV5-hRKp.RPGR Low Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
79819269|NCT04787198|Drug|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
79359494|NCT05076019|Drug|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
79371007|NCT00944554|Drug|Varenicline|Varenicline given twice a day or five weeks.
79371008|NCT00944554|Drug|Placebo|Placebo given twice a day or five weeks.
79510248|NCT00773604|Device|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
79510249|NCT00775944|Behavioral|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
79510250|NCT00775944|Behavioral|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
79510251|NCT00775944|Drug|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
79992357|NCT01861353|Other|Cranberry-lingonberry juice|
79359495|NCT05073913|Diagnostic Test|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
79359496|NCT05069922|Other|Fresh Frozen Plasma|Fresh Frozen Plasma
79359497|NCT05065333|Other|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models [Ref 1, 2]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
79359498|NCT05065333|Other|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
79359499|NCT05063097|Other|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol [THC]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
79359500|NCT05063097|Other|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
79359501|NCT05063097|Other|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of > 3 parts per million (ppm) signifying active smoking.
79359502|NCT05062239|Drug|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
79359503|NCT05062239|Drug|No-intervention.|Continuance of prior statin therapy
79510252|NCT00780234|Procedure|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
79510253|NCT00780234|Procedure|quantitative high resolution CT scan|High resolution CT scan of the chest
79510254|NCT00780234|Drug|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
79510255|NCT00781950|Dietary Supplement|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
79510256|NCT00781950|Dietary Supplement|Placebo|Wheat and Mixed Dietary Oils
79819270|NCT04787198|Drug|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
79819271|NCT04786171|Diagnostic Test|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
79510257|NCT00784524|Biological|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
79510258|NCT00784524|Biological|aldesleukin|Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.
79992358|NCT01861353|Other|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
79359504|NCT05061277|Drug|Recifercept|A lyophilized powder for solution for injection
79359505|NCT05056740|Biological|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
79359506|NCT05036005|Drug|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
79359507|NCT05036005|Drug|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
79510259|NCT00785772|Drug|Gabapentin|100-200mg once a day
79510260|NCT00785772|Drug|Gabapentin|200-500mg once a day
79510261|NCT00785772|Drug|Gabapentin|400-1000mg (200-500 mg twice a day)
79510262|NCT00787332|Drug|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
79510263|NCT00787722|Procedure|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
79510264|NCT00787722|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
79510265|NCT00787722|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
79510266|NCT00787722|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
79510267|NCT00787722|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
79510268|NCT00787722|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
79819272|NCT04783935|Drug|Mavenclad®|No intervention will be administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568_0022 (NCT03364036) will be enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
79819273|NCT04779827|Behavioral|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
79359508|NCT05036005|Drug|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
79359509|NCT05035823|Device|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
79359510|NCT05033769|Drug|Eribulin Injection [Halaven]|on days 1 and 8 q21d
79359511|NCT05033769|Drug|Paclitaxel injection|on days 1, 8, and 15 q21d
79510269|NCT00787722|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
79510270|NCT00788892|Drug|CPX-351|
79510271|NCT00788892|Drug|Cytarabine|
79510272|NCT00788892|Drug|Daunorubicin|
79510273|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
79510274|NCT00789672|Device|patching|2 hours daily patching
79510275|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
79510276|NCT00789750|Drug|Colesevelam|Colesevelam 625 mg tablets
79510277|NCT00789750|Drug|Placebo|Placebo tablets appearing to be colesevelam
79510278|NCT00789750|Drug|Pioglitazone|30 mg or 45 mg pioglitazone therapy
79510279|NCT00790062|Drug|Oxytocin|See arms
79510280|NCT00793572|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
79510281|NCT00793572|Drug|Bortezomib|Given SC
79510282|NCT00793572|Drug|Cyclosporine|Given IV
79359512|NCT05030142|Procedure|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
79510283|NCT00793572|Drug|Cyclosporine|Given PO
79819274|NCT04779827|Behavioral|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
79992359|NCT02329054|Drug|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
79992360|NCT03122457|Drug|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
79992361|NCT02328976|Other|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
79359513|NCT05030142|Drug|Best medical treatment alone|Best medical treatment alone (usual care)
79359514|NCT05019846|Drug|Triptorelin Embonate|single administration before SRT starting
79359515|NCT05019846|Drug|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
79359516|NCT05014971|Behavioral|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
79359517|NCT05014256|Behavioral|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
79359518|NCT05011578|Radiation|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
79359519|NCT05004233|Biological|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
79359520|NCT05004233|Biological|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
79359521|NCT05004025|Device|Novocure Optune|Novacure Optune with Opdivo and Yervoy
79359522|NCT05004025|Drug|Opdivo|Novacure Optune with Opdivo and Yervoy
79359523|NCT05004025|Drug|Yervoy|Novacure Optune with Opdivo and Yervoy
79992362|NCT02333032|Other|Inclined treadmill training|
79992363|NCT04407988|Drug|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
79992364|NCT05192967|Behavioral|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
79992365|NCT05192967|Behavioral|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
79992366|NCT02329132|Drug|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
79992367|NCT03634371|Drug|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
79992368|NCT03634371|Drug|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
79359524|NCT04998240|Biological|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
79510284|NCT00793572|Drug|Fludarabine Phosphate|Given IV
79510285|NCT00793572|Other|Laboratory Biomarker Analysis|Correlative studies
79510286|NCT00793572|Drug|Melphalan|Given IV
79510287|NCT00793572|Drug|Mycophenolate Mofetil|Given PO
79510288|NCT00793572|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
79992369|NCT04342078|Dietary Supplement|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is < 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if > 50-80 nmol/l, and no additional supplement if > 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
79992370|NCT05192811|Dietary Supplement|Lactobacillus paracasei K56|probiotic K56 capsule, 1capsule/day (10^9cfu) ,for 60days
79510289|NCT00793572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
79510290|NCT00793572|Procedure|Syngeneic Bone Marrow Transplantation|Undergo transplantation
79510291|NCT00793572|Radiation|Total-Body Irradiation|Undergo radiotherapy
79510292|NCT00793650|Drug|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
79510293|NCT00793650|Drug|Melphalan|"All patients received melphalan (100 mg/m^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m^2."
79510294|NCT00793650|Procedure|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
79510295|NCT00794508|Biological|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
79510296|NCT00795210|Drug|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
79510297|NCT00795210|Drug|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
79992371|NCT05192811|Dietary Supplement|placebo|placebo capsule(maltodextrin) , 1capsule/day ,for 60days
79992372|NCT03143296|Other|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
79992373|NCT02332954|Drug|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
79992374|NCT01372059|Other|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
79819275|NCT04776629|Drug|Orticumab|A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
79359525|NCT04998240|Biological|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
79359526|NCT04998240|Biological|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
79371009|NCT03031990|Behavioral|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
79510298|NCT00795288|Drug|Simvastatin, 80 mg/day for 21 days|Active treatment group
79510299|NCT00795288|Drug|placebo|Control group
79510300|NCT00795366|Drug|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
79510301|NCT00795366|Drug|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
79510302|NCT00796302|Drug|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
79510303|NCT00796302|Drug|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
79819276|NCT04776629|Drug|Placebo|Placebo for orticumab, containing all components of formulation except the active ingredient
79819277|NCT04775953|Drug|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
79819278|NCT04775953|Drug|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
79510304|NCT00796302|Behavioral|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
79992375|NCT01372059|Other|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
79992376|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
79992377|NCT00230607|Drug|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
79992378|NCT02328664|Procedure|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
79359527|NCT04997824|Procedure|Artificial Intelligence-based atrial fibrillation catheter ablation|"Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~AI-guided prediction for poor responder of AFCA in the outpatient clinic~Sharing information on the AI prediction with the patient and family member~AFCA after consent to the procedure~Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~Monitoring esophageal temperature~Evaluation of Procedure and ablation time, and complication afer procedure~Post-procedure rhythm follow-up is carried out according to the study design above."
79992379|NCT02332642|Other|Immuno-monitoring|
79992380|NCT03111160|Procedure|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
79992381|NCT03111160|Procedure|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
79510305|NCT00796302|Drug|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
79510306|NCT00796926|Drug|Systane Ultra eyedrops|Four times a day
79510307|NCT00796926|Drug|Refresh eye drops|Four times a day
79670368|NCT05039645|Behavioral|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of >2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
79670370|NCT05038800|Biological|MK-0482|IV infusion
79819279|NCT04775953|Drug|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
79670371|NCT05037422|Procedure|STARR surgery|"This intervention is carried out under general anesthesia or spinal anesthesia. It consists of the circular resection of the surplus of rectal mucosa. Rectal resection and suturing is performed using automatic mechanical forceps introduced through the anus."
79819280|NCT04775953|Drug|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
79992382|NCT03953859|Genetic|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
79992383|NCT05365191|Procedure|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
79992384|NCT02328820|Other|Percutaneous coronary intervention (PCI)|For lesions with both FFR<=0.8 and CFR<2.0
79992385|NCT02328820|Other|Optimal medical therapy (OMT)|For lesions with FFR>0.8 or CFR>=2.0 or both
79359528|NCT04997824|Procedure|Medical Therapy|"Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~Decision for AFCA based on clinical guidelines and the experience of the attending physician~AFCA after consent to the procedure~Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~Monitoring esophageal temperature~Evaluation of Procedure and ablation time, and complication afer procedure"
79359529|NCT04997200|Behavioral|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
79359530|NCT04995341|Device|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
79359531|NCT04995341|Device|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
79359532|NCT04992611|Behavioral|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
79670372|NCT05036343|Device|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
79992386|NCT01372761|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
79992387|NCT01372761|Drug|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
79992388|NCT03866512|Behavioral|Forearm immobilization|Two days of forearm immobilization
79992389|NCT03634527|Behavioral|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
79819281|NCT04775953|Drug|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
79992390|NCT03634527|Behavioral|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
79992391|NCT03778606|Dietary Supplement|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
79819282|NCT04775953|Drug|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
79992392|NCT03873675|Diagnostic Test|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
79510308|NCT00798018|Drug|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
79510309|NCT00798018|Drug|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
79510310|NCT00798018|Drug|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
79510311|NCT00798018|Drug|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
79510312|NCT00798486|Device|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
79510313|NCT00798720|Drug|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
79510314|NCT00798720|Drug|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
79510315|NCT00799578|Drug|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
79819283|NCT04773353|Drug|Follitropin Delta (FE 999049)|FE 999049 will be administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 will have their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (<15 pmol/L) the daily FE 999049 dose will be 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose will be on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose will be fixed throughout the stimulation period and maximum allowed daily dose will be 12 μg. Participants could be treated for a maximum of 20 days.
79819284|NCT04773353|Drug|Follitropin Alfa (GONAL-F)|GONAL-F will be administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F will be 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose will be 450 IU. Participants could be treated for a maximum of 20 days.
79992393|NCT03111706|Procedure|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
79819285|NCT04767217|Drug|artemether-lumefantrine (ALN)|Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
79819286|NCT04767217|Drug|dihydroartemisinin-piperaquine (DHA-PPQ)|dihydroartemisinin-piperaquine (DHA-PPQ)
79359533|NCT04992611|Behavioral|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
79359534|NCT04991506|Drug|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
79359535|NCT04991506|Drug|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
79510316|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
79510317|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
79819287|NCT04765384|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
79819288|NCT04763421|Device|ENSEAL X1 Curved Jaw|ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
79819289|NCT04763109|Other|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
79819290|NCT04746729|Other|No intervention|No intervention
79819291|NCT04741607|Device|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
79819292|NCT04741607|Procedure|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
79819293|NCT04741607|Procedure|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
79359536|NCT04990544|Biological|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
79359537|NCT04990544|Biological|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
79359538|NCT04990544|Biological|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
79359539|NCT04990544|Biological|Placebo|Normal saline solution
79359540|NCT04990427|Drug|CLBS201|1 x 10^6 to 300 x 10^6 autologous CD34+ cells
79510318|NCT00799812|Drug|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
79510319|NCT00799812|Other|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
79359541|NCT04987502|Other|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
79359542|NCT04987502|Behavioral|Standard treatment|counselling, relaxation techniques, sound enrichment
79819294|NCT04732221|Drug|MK-5475|MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
79819295|NCT04732221|Drug|Placebo to MK-5475|Placebo administered as dry powder inhalation
79819296|NCT04731233|Biological|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
79359543|NCT04984759|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
79359544|NCT04984759|Drug|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
79510320|NCT00799812|Other|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
79819297|NCT04731233|Drug|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
79819298|NCT04724746|Behavioral|Written Exposure and Cognitive Behavioral Therapy|Intervention involves writing details about a recent sexual assault and coping skills for substance use.
79819299|NCT04722432|Device|Outside the Scope (OTS), Detachable Catheter System|Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
79819300|NCT04718675|Drug|KB-0742|Oral capsules
79819301|NCT04718415|Drug|sintilimab, paclitaxel, carboplatin|Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
79819302|NCT04718415|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
79819303|NCT04717466|Biological|Secukinumab|300mg subcutaneous injection
79819304|NCT04713215|Other|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
79992394|NCT03863769|Other|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
79359545|NCT04982068|Biological|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
79359546|NCT04982068|Biological|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
79359547|NCT04982068|Biological|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
79359548|NCT04982068|Other|Placebo|Normal saline solution
79359549|NCT04978480|Other|no intervention|There is no intervention. We are only collecting standard of care data.
79510321|NCT00801138|Drug|saline|2 ml 0.9% saline (placebo)
79359550|NCT04971044|Behavioral|COACH|Multi-Level Behavioral Intervention
79510322|NCT00801138|Drug|Dexamethasone|dexamethasone 8 mg (2 ml)
79510323|NCT00801138|Drug|ropivacaine|30 ml 0.5% ropivacaine
79510324|NCT00801138|Drug|Bupivacaine|30 ml 0.5% bupivacaine
79510325|NCT00801684|Drug|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
79510326|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
79992395|NCT03111472|Other|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
79510327|NCT00801684|Drug|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
79510328|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
79992396|NCT02328898|Device|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
79992397|NCT02328898|Device|Resolute Integrity stent|
79992398|NCT02332408|Radiation|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
79992399|NCT02332408|Radiation|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
79992400|NCT03775785|Dietary Supplement|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
79992401|NCT05174715|Other|BIA|nutritional status was evaluated using BIA
79992402|NCT02328742|Biological|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
79992403|NCT02328742|Other|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
79510329|NCT00801684|Drug|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
79510330|NCT00803010|Drug|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
79992404|NCT02328742|Biological|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
79359551|NCT04971044|Behavioral|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
79359552|NCT04967729|Device|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
79359553|NCT04956159|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
79510331|NCT00803010|Drug|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
79819305|NCT04712721|Drug|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
79819306|NCT04711460|Behavioral|Younger participants|Younger Participants 19-29 years received TAU + Tx over 5 weeks
79819307|NCT04711460|Behavioral|Older participants|older participants 30-54 years received TAU + Tx over 5 weeks
79359554|NCT04956159|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
79819308|NCT04711460|Behavioral|TAU|Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only
79359555|NCT04955990|Drug|PAH Therapies|PAH therapies will be administered in a routine clinical setting and data will be collected from participants who newly initiate any PAH therapy(ies), or have already been receiving macitentan 10 mg for at least 3 months prior to the index date. Participants will receive PAH therapies such as Macitentan, Ambrisentan, Bosentan, Tadalafil, Sildenafil, Riociguat, Selexipag, Epoprostenol, Iloprost, Treprostinil, and Beraprost.
79359556|NCT04952324|Other|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
79359557|NCT04951726|Drug|Neostigmine|cholinesterase inhibitor
79359558|NCT04948892|Other|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
79359559|NCT04937478|Other|Observation|Only observational study, no intervention.
79359560|NCT04936919|Device|BroadBand Light|Treatment arm will receive Broadband light treatment
79510332|NCT00803010|Drug|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
79510333|NCT00803400|Drug|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
79510334|NCT00803400|Drug|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
79510335|NCT00804648|Drug|Timolol Maleate in Sorbate|0.5%
79510336|NCT00804648|Drug|Timolol hemihydrate|0.5%
79510337|NCT00804648|Drug|Timolol maleate gel forming solution|0.5%
79670376|NCT05020743|Other|No intervention|Not applicable for a Natural History Study
79670377|NCT05016011|Biological|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
79670378|NCT05016011|Procedure|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
79670379|NCT05013970|Other|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
79670380|NCT05013970|Other|Radiographic imaging|MRI of the knee
79819309|NCT04711460|Behavioral|TAU + MIndfulness practice|Participants received TAU + mindfulness training
79819310|NCT04710615|Device|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
79359561|NCT04931212|Procedure|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
79510338|NCT00805038|Behavioral|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
79510339|NCT00805038|Behavioral|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
79510340|NCT00806598|Drug|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~MDS patients <55 years receive 3.5 mg/kg/day for 5 days~MDS patients >55 years receive 2.5 mg/kg/day for 5 days"
79510341|NCT00806598|Drug|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
79992405|NCT02328742|Biological|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
79510342|NCT00806598|Drug|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
79510343|NCT00806598|Drug|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
79510344|NCT00806676|Drug|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
79510345|NCT00807768|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
79510346|NCT00807768|Drug|Carboplatin|Given IV
79510347|NCT00807768|Radiation|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
79510348|NCT00807768|Radiation|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
79510349|NCT00807768|Other|Laboratory Biomarker Analysis|Correlative studies
79510350|NCT00807768|Drug|Paclitaxel|Given IV
79510351|NCT00807768|Other|Quality-of-Life Assessment|Ancillary studies
79510352|NCT00807768|Other|Questionnaire Administration|Ancillary studies
79510353|NCT00808470|Drug|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
79670381|NCT05012657|Device|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
79670382|NCT05009511|Behavioral|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
79359562|NCT04926792|Device|Leadless Pacemaker|Leadless pacemaker implantation
79359563|NCT04926571|Drug|Dexamethasone Oral|New users of Dexamethasone
79359564|NCT04924127|Diagnostic Test|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
79359565|NCT04919135|Biological|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
79359566|NCT04919135|Drug|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
79670383|NCT05003804|Biological|STMC-103H|STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
79670384|NCT05003804|Biological|Placebo|Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
79670385|NCT05003271|Other|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
79359567|NCT04918823|Drug|Restasis|Subject will use one drop of Restasis in the lens before insertion
79359568|NCT04909073|Drug|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
79359569|NCT04894656|Diagnostic Test|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
79359570|NCT04893772|Dietary Supplement|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
79359571|NCT04887519|Other|No Intervention|This is a non-interventional study.
79359572|NCT04885166|Other|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
79359573|NCT04885166|Behavioral|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
79359574|NCT04884607|Other|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
79359575|NCT04876651|Other|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
79359576|NCT04869683|Other|description of MDS pzatient cohort|description of MDS patient cohort
79819311|NCT04710264|Other|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
79359577|NCT04869514|Procedure|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
79359578|NCT04863599|Other|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
79359579|NCT04861766|Device|STYLAGE® L|Injection in both NLFs
79359580|NCT04861766|Device|Active Comparator|Injection in both NLFs
79359581|NCT04857996|Drug|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
79359582|NCT04857996|Other|Sham|Sham procedure
79359583|NCT04857814|Device|ADAMM- RSM Device|All participants will wear the ADAMM- RSM device for a 6 month period
79359584|NCT04842747|Drug|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
79359585|NCT04839458|Device|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
79359586|NCT04810481|Device|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
79510354|NCT00808470|Other|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
79359587|NCT04806724|Behavioral|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
79359588|NCT04806724|Behavioral|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
79359589|NCT04800913|Diagnostic Test|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
79359590|NCT04800913|Diagnostic Test|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
79359591|NCT04785651|Drug|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
79359592|NCT04785651|Procedure|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
79359593|NCT04781114|Drug|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
79510355|NCT00810498|Device|Trilogy|Exposure for one hour on the Trilogy ventilator
79510356|NCT00810498|Device|Standard of Care|Exposure to participants current ventilator
79510357|NCT00810576|Drug|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
79510358|NCT00810576|Drug|Bortezomib|Dose of 1.3 mg/m^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
79510359|NCT00810888|Drug|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
79510360|NCT00810888|Drug|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
79510361|NCT00811434|Drug|Lactulose|1.5cc/kg/day po for three months
79510362|NCT00811434|Drug|placebo|1.5 ml sugar water/kg day for three months
79819312|NCT04705168|Diagnostic Test|Nevisense electrical impedance spectroscopy|Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) > 5 mm in diameter
79819313|NCT04704544|Other|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
79819314|NCT04695977|Drug|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
79359594|NCT04781114|Drug|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
79359595|NCT04780204|Drug|Treatment|Tenofovir Alafenamide 25 mg oral once daily
79359596|NCT04770480|Behavioral|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
79359597|NCT04770480|Behavioral|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
79510363|NCT00812604|Drug|Ping On Ointment|Ping On Ointment
79510364|NCT00812604|Drug|Vaseline|Placebo
79510365|NCT00812838|Drug|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
79510366|NCT00812838|Other|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
79510367|NCT00812838|Drug|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
79510368|NCT00812916|Procedure|RF ablation, using specialized CFAE software|RF ablation
79359598|NCT04762719|Drug|PET/CT Scan with 11C-ER176|Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
79359599|NCT04762719|Diagnostic Test|Core biopsy of gastric muscle|The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
79359600|NCT04755231|Device|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
79359601|NCT04755231|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
79992406|NCT05296239|Other|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
79992407|NCT05256459|Other|Long term follow-up|No extra intervention.
79992408|NCT02328586|Other|Group Acupuncture|
79359602|NCT04753853|Procedure|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
79359603|NCT04748588|Drug|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
79359604|NCT04735510|Drug|cyclosporine ophthalmic emulsion 0.05%|All subjects will receive restasis
79359605|NCT04734015|Behavioral|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
79359606|NCT04696523|Drug|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
79510369|NCT00814788|Drug|Bicalutamide|50 mg oral tablet daily
79510370|NCT00814788|Drug|Everolimus|10 mg oral capsule daily
79510371|NCT00815490|Device|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
79992409|NCT03604107|Genetic|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
79510372|NCT00816348|Drug|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
79992410|NCT02332486|Drug|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
79359607|NCT04696523|Drug|air/oxygen|Control group will be treated with air/oxygen
79359608|NCT04664400|Behavioral|Symbolic conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
79359609|NCT04664400|Behavioral|Conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
79359610|NCT04664400|Behavioral|Instructions|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
79359611|NCT04664400|Behavioral|Counterfactual|Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
79359612|NCT04657770|Device|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
79359613|NCT04655222|Drug|Interferon Beta Therapy|Administered as specified in the treatment arm.
79359614|NCT04652440|Drug|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
79510373|NCT00817596|Device|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
79510374|NCT00820872|Biological|trastuzumab|
79510375|NCT00820872|Drug|carboplatin|
79510376|NCT00820872|Drug|docetaxel|
79510377|NCT00820872|Drug|lapatinib ditosylate|
79510378|NCT00821184|Drug|Vesicare (solifenacin)|5mg po qd
79819315|NCT04695977|Drug|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
79992411|NCT05173857|Device|Advance PTX|PTA in Dysfunctional Haemodialysis Access
79992412|NCT05173857|Device|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
79992413|NCT05173857|Drug|Paclitaxel (PTX)|Paclitaxel (PTX)
79359615|NCT04652440|Procedure|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
79359616|NCT04650867|Device|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
79992414|NCT03111238|Drug|REX-001|REX-001 is administered through an intra-arterial catheter.
79510379|NCT00821184|Behavioral|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
79510380|NCT05237154|Other|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
79510381|NCT05237154|Other|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
79510382|NCT05236686|Procedure|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
79510383|NCT05235594|Device|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
79510384|NCT05215860|Behavioral|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
79510385|NCT05215860|Other|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
79510386|NCT05206812|Drug|durvalumab|"durvalumab 1500 mg QD*~Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
79510387|NCT05131152|Drug|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
79510388|NCT05131152|Device|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
79670386|NCT04992312|Drug|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
79992415|NCT03111238|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
79992416|NCT01372137|Drug|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
79992417|NCT01372137|Other|Glucose 5%|Placebo
79992418|NCT03620097|Dietary Supplement|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
79992419|NCT03620097|Other|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
79992420|NCT05078086|Other|No intervention|No intervention
79992421|NCT05078008|Procedure|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
79992422|NCT05078008|Procedure|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
79992423|NCT03417999|Drug|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
79359617|NCT04643951|Behavioral|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
79819316|NCT04694339|Other|Survey|Survey
79819317|NCT04692532|Other|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
79819318|NCT04692532|Other|Calorie restriction|25% energy restriction every day
79359618|NCT04614389|Other|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
79359619|NCT04614389|Other|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
79359620|NCT04614389|Device|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
79359621|NCT04612725|Biological|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
79359622|NCT04612725|Biological|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
79359623|NCT04612192|Device|Active luminette|receive an active blue-enriched light-glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
79992424|NCT02328430|Device|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
79359624|NCT04612192|Device|Placebo luminette|receive a dim red-light placebo light (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
79359625|NCT04607967|Device|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
79359626|NCT04605159|Biological|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
79510389|NCT05110872|Behavioral|Cigarette flavor restricted and e-cigarette flavor restricted|"Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
79359627|NCT04605159|Drug|Placebo|One dose of lyophilized sucrose reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
79819319|NCT04682145|Drug|Turoctocog alfa pegol|Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
79359628|NCT04604067|Drug|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
79359629|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine
79359630|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20 g BID x 12 weeks
79359631|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30 g BID x 12 weeks
79819320|NCT04676386|Diagnostic Test|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
79819321|NCT04676061|Drug|Norethindrone acetate (NTA)|norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
79819322|NCT04676061|Drug|Placebo|Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
79819323|NCT04658186|Drug|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
79819324|NCT04658186|Drug|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
79510390|NCT05110872|Behavioral|Cigarette flavor restricted and e-cigarette flavor unrestricted|"Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
79819325|NCT04656678|Device|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
79992425|NCT03142516|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
79992426|NCT03142516|Drug|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
79992427|NCT03142516|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
79510391|NCT05110872|Behavioral|Cigarette flavor unrestricted and e-cigarette flavor restricted|"Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
79510392|NCT05110872|Behavioral|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
79510393|NCT04982718|Diagnostic Test|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
79510394|NCT04982718|Diagnostic Test|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
79510395|NCT04956276|Drug|ALXN1830|Administered as an SC infusion.
79359632|NCT04603443|Dietary Supplement|Protein Control|Protein placebo control - all amino acids except for BCAA, 30 g BID x 12 weeks
79510396|NCT04956276|Drug|Placebo|Administered as an SC infusion.
79992428|NCT03142516|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
79992429|NCT03482453|Drug|TAK-788|TAK-788 capsules.
79510397|NCT04905342|Drug|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
79510398|NCT04905342|Drug|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
79510399|NCT04900116|Drug|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
79670387|NCT04989218|Drug|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
79670388|NCT04987281|Procedure|Computed Tomography|Undergo CT
79992430|NCT03482453|Drug|Placebo|TAK-788 placebo-matching capsules.
79992431|NCT03482453|Drug|TAK-788|TAK-788 DiC.
79359633|NCT04594109|Behavioral|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
79359634|NCT04594109|Behavioral|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
79510400|NCT04900116|Drug|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
79510401|NCT04900116|Drug|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
79510402|NCT04900116|Drug|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
79510403|NCT04690530|Procedure|mechanical ventilation|mechanical vantilation will be performed
79992432|NCT05077930|Biological|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
79992433|NCT05077930|Drug|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
79992434|NCT05077696|Other|Drawing a tube of blood (serum)|dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
79992435|NCT05077618|Other|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
79992436|NCT03480425|Diagnostic Test|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
79992437|NCT03719729|Drug|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
79992438|NCT05077462|Drug|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
79992439|NCT05077462|Drug|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
79992440|NCT03719651|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
79510404|NCT04690530|Drug|Sedation|sedation wil be performed
79510405|NCT04640298|Device|Cingal|CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
79510406|NCT04603248|Drug|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
79670389|NCT04987281|Drug|Indocyanine Green Solution|Given via injection
79670390|NCT04987281|Device|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
79992441|NCT03719651|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
79992442|NCT03719651|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
79992443|NCT03719651|Behavioral|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
79992444|NCT02328508|Device|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
79992445|NCT03714113|Diagnostic Test|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
79992446|NCT03111004|Other|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
79992447|NCT03472547|Drug|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
79992448|NCT00799396|Drug|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
79992449|NCT00799396|Drug|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
79670391|NCT04982653|Other|Quality-of-Life Assessment|Ancillary studies
79359635|NCT04593069|Behavioral|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
79992450|NCT05077306|Other|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
79510407|NCT04340700|Drug|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
79510408|NCT04213248|Drug|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
79992451|NCT03143062|Diagnostic Test|NEWS|NEWS
79510409|NCT03878394|Other|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
79510410|NCT03878394|Other|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
79510411|NCT03763656|Drug|Hydroxyurea|Oral Hydroxyurea
79510412|NCT03419676|Device|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
79510413|NCT03166722|Other|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
79510414|NCT03166722|Device|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
79510415|NCT02682888|Behavioral|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
79510416|NCT02682888|Drug|Oxytocin|intranasal administration of oxytocin
79510417|NCT02682888|Drug|Placebo|intranasal administration of placebo
79510418|NCT02641236|Drug|Vancomycin-polymyxin B|
79670392|NCT04982653|Procedure|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
79670393|NCT04982653|Procedure|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
79992452|NCT03469349|Drug|Actovegin|Actovegin intravenous infusion and tablets.
79670394|NCT04977154|Other|Primary prevention|The primary prevention that the trainers put in place for the hockey players
79670395|NCT04973345|Drug|Terbutaline|management of asthma symptoms
79670396|NCT04967417|Drug|Pemetrexed, Carboplatin, Pembrolizumab|"Pemetrexed 500mg/m2~Carboplatin AUC 5.0~Pembrolizumab 200mg"
79992453|NCT03469349|Drug|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
79992454|NCT03639233|Behavioral|YESS!|Web based self-management education
79992455|NCT03467945|Drug|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
79992456|NCT03467945|Drug|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
79992457|NCT03467945|Drug|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
79359636|NCT04586712|Drug|High dose CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 1000mg/30mL (high).
79359637|NCT04586712|Drug|Low Dose CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD oil at concentrations of 500mg/30mL (low)
79359638|NCT04586712|Drug|Vehicle Control Group|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
79359639|NCT04585711|Drug|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
79359640|NCT04566484|Drug|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
79359641|NCT04566484|Drug|Normal Saline|Normal saline is the placebo
79359642|NCT04551495|Drug|Entrectinib|Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
79359643|NCT04551495|Drug|Letrozole|Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
79359644|NCT04551495|Drug|Goserelin|Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
79359645|NCT04548778|Diagnostic Test|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
79359646|NCT04536779|Other|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
79359647|NCT04533659|Behavioral|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
79359648|NCT04533659|Behavioral|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
79359649|NCT04523558|Device|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
79359650|NCT04520087|Procedure|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
79359651|NCT04515316|Device|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
79359652|NCT04515316|Device|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
79359653|NCT04513132|Device|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
79359654|NCT04513132|Device|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
79359655|NCT04508478|Behavioral|Aerobic training|Aerobic training
79359656|NCT04508478|Behavioral|Resistance training|Resistance training
79819326|NCT04646226|Device|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
79992458|NCT03719261|Drug|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
79359657|NCT04508478|Behavioral|Control physical exercise|Control physical exercise
79359658|NCT04501718|Drug|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
79819327|NCT04646226|Procedure|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
79819328|NCT04640259|Other|Online Survey|Epidemiological Survey (approx 200 questions)
79359659|NCT04501705|Drug|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
79359660|NCT04496453|Other|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
79359661|NCT04483791|Combination Product|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
79359662|NCT04463394|Drug|Vasopressin|Vasopressin administered intravenously
79670397|NCT04967417|Drug|Paclitaxel, Carboplatin, Pembrolizumab|"Paclitaxel 200mg/m2~Caboplatin AUC 6.0~Pembrolizumab 200mg"
79670398|NCT04963725|Drug|Ustekinumab|No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
79670399|NCT04963192|Device|Connected actimeter to measure physical activity in OSA patients|Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
79670400|NCT04963192|Device|Connected BORA Band to measure physical activity in COPD patients only|Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
79510419|NCT02402088|Behavioral|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
79670401|NCT04963192|Other|IPAQ to evaluated physical activity|Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
79359663|NCT04459104|Other|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
79359664|NCT04459104|Other|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
79510420|NCT02402088|Behavioral|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
79670402|NCT04963192|Device|Connected scale to measure weight|Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
79670403|NCT04963192|Device|Connected tensiometer to measure arterial pressure|Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
79819329|NCT04636307|Other|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
79359665|NCT04454905|Drug|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
79510421|NCT02402088|Behavioral|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
79510422|NCT00284700|Drug|Iron|
79670404|NCT04963192|Device|Connected BORA Band to measure oxygen saturation in COPD patients only|Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
79670405|NCT04963192|Device|Connected BORA Band to measure heart rate in COPD patients only|Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
79670406|NCT04963192|Device|Connected BORA Band to measure respiratory rate in COPD patients only|Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
79670407|NCT04963192|Other|EXASCORE to evaluated COPD severity|COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
79819330|NCT04636229|Biological|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
79819331|NCT04636229|Drug|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
79819332|NCT04633278|Drug|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
79819333|NCT04633278|Drug|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
79819334|NCT04633252|Drug|ADT|For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
79359666|NCT04454905|Drug|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
79359667|NCT04448106|Biological|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
79359668|NCT04440163|Biological|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
79359669|NCT04440163|Biological|Saline|Placebo
79359670|NCT04440163|Biological|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
79510423|NCT00142272|Drug|Ciprofloxacin|
79670408|NCT04963192|Other|Epworth scale to evaluate sleepiness|Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
79670409|NCT04963192|Other|Pichot scale to evaluate fatigue|Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
79670410|NCT04963192|Other|Usability questionnaire|Subjective assessment of each device by means of usability questionnaire at M6
79670411|NCT04963192|Other|SF36 questionnaire|Quality of life evaluated by the SF36 questionnaire at inclusion and M6
79670412|NCT04955301|Behavioral|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
79359671|NCT04440163|Biological|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
79819335|NCT04633252|Drug|Prednisone|For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
79510424|NCT00821886|Drug|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
79819336|NCT04633252|Drug|M7824|M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
79359672|NCT04436601|Drug|Polyethylene Glycols|Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.
79819337|NCT04633252|Drug|Docetaxel|Docetaxel 75mg/m^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
79992459|NCT03719261|Drug|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
79992460|NCT00069238|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
79992461|NCT00069238|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
79359673|NCT04436601|Drug|Lactulose|Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
79359674|NCT04428801|Biological|autologous adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
79510425|NCT00821886|Drug|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
79510426|NCT00821886|Drug|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
79359675|NCT04417036|Drug|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
79359676|NCT04417036|Other|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
79510427|NCT00821964|Drug|imiquimod|Given topically
79992462|NCT03435497|Behavioral|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
79510428|NCT00821964|Drug|Abraxane|Given IV
79819338|NCT04633252|Drug|M9241|M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
79992463|NCT03143140|Other|PAFA|percutaneous ablation of tumor feeding artery
79992464|NCT03143140|Other|tumor ablation|ablation of tumor area directly
79510429|NCT00821964|Other|laboratory biomarker analysis|Correlative studies
79510430|NCT00821964|Genetic|RNA analysis|Correlative studies
79510431|NCT00821964|Other|immunoenzyme technique|Correlative studies
79510432|NCT00822354|Drug|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
79670415|NCT04939662|Drug|Olaparib+Bevacizumab to SCLC patients|"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
79819339|NCT04624854|Drug|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
79819340|NCT04624854|Drug|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
79819341|NCT04609878|Drug|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
79819342|NCT04609878|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
79819343|NCT04609878|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
79992465|NCT03639155|Drug|vadadustat reference tablets|oral tablet
79992466|NCT03639155|Drug|vadadustat test tablets|oral tablet
79819344|NCT04609878|Drug|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
79819345|NCT04599218|Other|Prostate Biopsy|Standard of care
79819346|NCT04599218|Other|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
79819347|NCT04599218|Device|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
79992467|NCT03145324|Other|Collection of vaccine histories|
79992468|NCT02328274|Procedure|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
79992469|NCT05080348|Procedure|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
79510433|NCT00822510|Behavioral|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
79510434|NCT00822510|Behavioral|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
79510435|NCT00822588|Device|Sangvia® System|Sangvia® Intra- and Post-op System
79510436|NCT00824070|Drug|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
79510437|NCT00824070|Drug|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
79992470|NCT05080348|Procedure|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
79992471|NCT02328196|Behavioral|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
79992472|NCT03073200|Drug|Ixekizumab|Administered SC
79359677|NCT04417036|Drug|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
79992473|NCT03073200|Drug|Placebo|Administered SC
79992474|NCT03073200|Drug|Etanercept|Administered SC
79992475|NCT03142126|Device|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
79992476|NCT05080114|Procedure|Modified Bakay technique (MT)|The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
79992477|NCT05080114|Procedure|Standard technique (ST)|"The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally."
79359678|NCT04416243|Behavioral|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
79359679|NCT04402151|Drug|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
79359680|NCT04402151|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
79359681|NCT04373785|Radiation|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
79510438|NCT00824070|Drug|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
79992478|NCT05079958|Behavioral|cognitive-behavioral education|four-week cognitive-behavioral education course
79992479|NCT05079958|Behavioral|12-week brisk walking|12-week brisk walking
79992480|NCT02328352|Procedure|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
79992481|NCT02328352|Procedure|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
79992482|NCT02328352|Procedure|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
79992483|NCT02328352|Procedure|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
79992484|NCT03290781|Drug|Ontamalimab|Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).
79992485|NCT03290781|Other|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
79992486|NCT01569984|Radiation|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
79510439|NCT00824460|Drug|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
79510440|NCT00824460|Drug|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
79510441|NCT00824460|Drug|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
79510442|NCT00824460|Drug|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
79510443|NCT00824460|Drug|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
79510444|NCT00824460|Drug|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
79510445|NCT00824538|Drug|sunitinib malate|
79510446|NCT00824538|Other|flow cytometry|
79359682|NCT04373785|Drug|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
79359683|NCT04373785|Drug|NG101m|Oral NG101m capsule continuously twice daily.
79359684|NCT04367571|Other|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
79510447|NCT00824538|Other|immunohistochemistry staining method|
79510448|NCT00824538|Other|laboratory biomarker analysis|
79510449|NCT00825318|Procedure|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
79510450|NCT00825786|Drug|Ropivacaine|ropivacaine (15 ml).
79992487|NCT02328118|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
79992488|NCT02328118|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
79992489|NCT03466073|Drug|Recombinant Human Plasma Gelsolin|Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
79371010|NCT03031990|Behavioral|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
79992490|NCT03466073|Other|Normal Saline Placebo|Normal saline in volume equivalent to drug
79992491|NCT02602314|Drug|Imatinib|
79992492|NCT02602314|Drug|Nilotinib|
79992493|NCT03412019|Other|Music|Selections of Mozart piano sonatas
79992494|NCT05079880|Drug|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
79510451|NCT00825786|Drug|Mepivacaine|One syringe will contain mepivacaine (15 ml)
79510452|NCT00826800|Drug|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
79510453|NCT00830076|Drug|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
79510454|NCT00830076|Drug|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
79992495|NCT05079880|Drug|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
79510455|NCT00830076|Drug|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
79510456|NCT00830076|Drug|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
79510457|NCT00830232|Device|closed-cell stent (Xact stent)|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
79510458|NCT00830232|Device|Open-cell stent (Acculink carotid)|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
79510459|NCT00830310|Behavioral|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
79992496|NCT05021146|Other|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
79992497|NCT05021146|Other|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
79510460|NCT00830310|Behavioral|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
79510461|NCT00830310|Behavioral|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
79510462|NCT00830310|Behavioral|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
79992498|NCT05021146|Other|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
79510463|NCT00830388|Drug|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
79510464|NCT00831480|Drug|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
79510465|NCT00832338|Drug|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
79510466|NCT00832338|Drug|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
79510467|NCT00834210|Drug|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
79992499|NCT03714035|Other|no intervention|no intervention
79992500|NCT05018338|Device|Brain shift monitoring|For use to monitor brain shift during craniotomy
79992501|NCT03716765|Dietary Supplement|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
79992502|NCT03716687|Device|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
79992503|NCT05017324|Device|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
79992504|NCT01311323|Procedure|PCI|Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
79992505|NCT01311323|Procedure|CABG|Coronary Artery Bypass Graft
79510468|NCT00834210|Drug|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
79510469|NCT00834288|Drug|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
79992506|NCT05079646|Other|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
79510470|NCT00834288|Drug|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
79510471|NCT00834678|Drug|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
79510472|NCT00834678|Drug|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
79510473|NCT00834678|Drug|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
79510474|NCT00835224|Drug|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
79510475|NCT00835224|Drug|Midodrine|To treat low blood pressure.
79510476|NCT00835224|Drug|Placebo|A pill with an inactive substance that looks like the study drug.
79510477|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
79510478|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
79510479|NCT00837252|Drug|Finasteride|Participants received 5mg of oral finasteride daily for three months.
79510480|NCT00839982|Drug|clofarabine|Given PO
79510481|NCT00839982|Drug|cytarabine|Given SC
79510482|NCT00842946|Behavioral|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
79510483|NCT00842946|Behavioral|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
79510484|NCT00843180|Other|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
79510485|NCT00845130|Biological|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
79510486|NCT00848016|Drug|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
79510487|NCT00848172|Drug|Octanoic Acid|4mg/kg
79510488|NCT00848172|Drug|Placebo|identical capsules
79510489|NCT00849810|Drug|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
79510490|NCT00849810|Drug|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
79510491|NCT00856050|Drug|letrozole|Taken orally once a day continuously
79510492|NCT00857532|Drug|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
79510493|NCT00858390|Dietary Supplement|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
79510494|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
79992507|NCT03070002|Biological|Denosumab|Given SC
79992508|NCT03070002|Other|Laboratory Biomarker Analysis|Correlative studies
79510495|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
79510496|NCT00858858|Drug|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
79992509|NCT02327728|Procedure|Botulinum toxin A injection (5 sites: 12.5U)|
79992510|NCT02327728|Procedure|Botulinum toxin A injection (4 sites: 10U)|
79992511|NCT02327728|Drug|Botulinum toxin A 12.5U|
79992512|NCT02327728|Drug|Botulinum toxin A 10U|
79992513|NCT03142672|Procedure|pulpotomy|vital endodontic procedure
79992514|NCT03142672|Procedure|tooth filling|tooth filling
79992515|NCT02918318|Drug|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
79992516|NCT02918318|Drug|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
79992517|NCT02918318|Drug|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
79670416|NCT04935203|Behavioral|Priming intervention|The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take ~2 min.
79819348|NCT04591210|Drug|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
79819349|NCT04591210|Drug|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
79819350|NCT04587856|Other|bone marrow withdrawal|bone marrow samples evaluation
79359685|NCT04367571|Other|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
79359686|NCT04366310|Device|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
79359687|NCT04366310|Procedure|rewarming|warming fingertip skin temperature using an instant hot pack
79371011|NCT03031990|Behavioral|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
79819351|NCT04585269|Behavioral|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
79819352|NCT04576507|Drug|Cannabis|Investigates two strengths of cannabis.
79371012|NCT03031756|Device|glycine powder air-polishing (Air-Flows)Perio Powder|
79371013|NCT03031756|Device|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
79371014|NCT00944710|Drug|Atropine|Weekend atropine 1%
79819353|NCT04573920|Drug|Atrasentan|Film-coated tablet
79819354|NCT04573075|Procedure|Ghost ileostomy|a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
79819355|NCT04573075|Procedure|loop ileostomy|a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
79819356|NCT04573075|Procedure|no outlet|no further intervention is used after colorectal resection and forming of a primary anastomosis
79819357|NCT04568707|Other|blood sample|blood sample for serum (serology, biomarkers) and DNA
79992518|NCT02918318|Drug|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
79992519|NCT03713957|Drug|GRF6021|GRF6021 for IV infusion
79992520|NCT03713957|Other|Placebo|Placebo for IV infusion
79992521|NCT01374321|Drug|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
79992522|NCT01374321|Drug|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
79992523|NCT04960150|Device|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
79992524|NCT04960150|Device|Plesterin|Plesterin
79992525|NCT02327806|Device|pulsed electromagnetic field therapy|
79992526|NCT04926454|Drug|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
79992527|NCT03196167|Drug|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
79371015|NCT00944710|Device|Plano lens|plano lens over the sound eye
79371016|NCT00944710|Drug|Atropine|Weekend atropine 1%
79371017|NCT00945100|Device|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
79359688|NCT04359563|Behavioral|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
79359689|NCT04357574|Other|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
79992528|NCT03196167|Other|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
79992529|NCT03652376|Drug|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
79992530|NCT04875988|Procedure|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
79992531|NCT04875988|Procedure|Traditional|ultrasound will not be used in the traditional IV placement group
79992532|NCT03411863|Device|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
79992533|NCT03411863|Device|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
79992534|NCT04262726|Behavioral|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
79992535|NCT04262726|Behavioral|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
79510497|NCT00859950|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
79992536|NCT03719027|Diagnostic Test|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
79510498|NCT00862446|Drug|Omegaven|1 gram/kg/day daily until on feeds
79359690|NCT04317755|Behavioral|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
79510499|NCT00864084|Other|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
79510500|NCT00864708|Device|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
79510501|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
79510502|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
79992537|NCT04256876|Device|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
79992538|NCT04256876|Device|TTNS Sham|See section 'arms'
79371018|NCT00945100|Device|Eye Patch|2 hours patching daily
79510503|NCT00868140|Drug|pioglitazone|pioglitazone 45 mg
79510504|NCT00868140|Drug|Placebo|placebo daily
79510505|NCT00868218|Biological|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
79510506|NCT00868374|Drug|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
79510507|NCT00868374|Drug|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
79510508|NCT00868452|Drug|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
79510509|NCT00868452|Drug|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
79510510|NCT00869622|Drug|Risedronate|35 mgs/week + calcium and vit d
79510511|NCT00869622|Drug|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
79510512|NCT00871260|Drug|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
79510513|NCT00874614|Radiation|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
79510514|NCT00875550|Drug|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
79510515|NCT00875550|Drug|Midazolam|Rescue medication for sedation according to UMSS scores
79670417|NCT04928807|Combination Product|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 * 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
79510516|NCT00875550|Drug|Fentanyl|Rescue medication for pain based on UMSS scores
79510517|NCT00875550|Drug|Morphine|Rescue medication for pain based on UMSS scores.
79510518|NCT00878436|Drug|Panobinostat|
79510519|NCT00878436|Drug|Bicalutamide|
79670418|NCT04922164|Behavioral|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
79510520|NCT00878826|Drug|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
79510521|NCT00879060|Drug|Spironolactone|spironolactone 50mg daily
79510522|NCT00879060|Drug|Placebo|inactive placebo pill daily
79510523|NCT00880230|Device|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
79510524|NCT00880464|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
79510525|NCT00882102|Drug|Decitabine|Decitabine 20 mg/m^2 IV over 1-1/2 hours daily for 5 days.
79510526|NCT00882102|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m^2 IV on day 5.
79510527|NCT00884052|Drug|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
79510528|NCT00884052|Drug|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
79510529|NCT00884754|Device|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
79510530|NCT00884910|Device|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
79510531|NCT00885768|Procedure|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
79670419|NCT04921969|Drug|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
79670420|NCT04921969|Drug|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
79510532|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
79510533|NCT00886236|Drug|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
79670421|NCT04920578|Drug|JNJ-69095897|JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
79670422|NCT04920578|Other|Placebo|Matching placebo will be administered orally in Parts 1 and 3.
79371019|NCT05384236|Other|kinesiology taping|To apply kinesiology taping in plantar fascia
79371020|NCT05384236|Other|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
79670423|NCT04919642|Drug|TT-00420|TT-00420 tablet, administered orally once daily
79670426|NCT04912830|Procedure|Tension-free vaginal tape|female incontinence surgery with polypropylene tape applied
79819361|NCT04549103|Other|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
79819362|NCT04542135|Drug|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
79819363|NCT04542135|Drug|Placebo|placebo pills twice daily
79819366|NCT04538378|Drug|Olaparib|Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
79819367|NCT04538378|Drug|Durvalumab|Durvalumab will be administered IV into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
79992539|NCT04808284|Device|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
79510534|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
79510535|NCT00886626|Drug|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
79510536|NCT00886704|Dietary Supplement|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
79670427|NCT04912375|Behavioral|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
79670428|NCT04910607|Other|Questionnaire|"Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal"
79670429|NCT04910607|Other|Interview|Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
79819368|NCT04519710|Biological|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
79819369|NCT04505839|Drug|STP1002|Oral capsule, QD
79819370|NCT04499781|Behavioral|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
79819371|NCT04499781|Behavioral|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
79819372|NCT04498429|Other|Integrated Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
79510537|NCT00886704|Dietary Supplement|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
79670430|NCT04899362|Device|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
79359691|NCT04315545|Diagnostic Test|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
79359692|NCT04312997|Drug|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
79359693|NCT04312997|Drug|Placebo|Sterile saline for inhalation
79510538|NCT00887562|Drug|Idebenone|900 mg/day for 1 month
79510539|NCT00887562|Drug|Idebenone|2250 mg/day for 1 month
79510540|NCT00887562|Other|Placebo|Placebo - No idebenone
79670431|NCT04899362|Procedure|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
79670432|NCT04899362|Device|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
79670433|NCT04894344|Behavioral|Education group|Is taught to choose low-sodium foods
79670434|NCT04892264|Biological|Belantamab Mafodotin|Given IV
79670435|NCT04892264|Biological|Daratumumab|Given IV
79670436|NCT04892264|Drug|Dexamethasone|Given PO
79670437|NCT04892264|Drug|Lenalidomide|Given PO
79670438|NCT04892264|Other|Quality-of-Life Assessment|Ancillary studies
79510541|NCT00887640|Drug|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
79670439|NCT04890613|Drug|CX-5461|150 mg sterile lyophilized powder containing 1% sucrose
79359694|NCT04309552|Drug|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
79371021|NCT03031600|Diagnostic Test|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
79510542|NCT00887640|Drug|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
79510543|NCT00889200|Drug|eszopiclone|6 weeks standard oral therapy
79510544|NCT00889512|Drug|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
79510545|NCT00889512|Drug|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
79510546|NCT00889824|Device|balance prosthesis|vibrotactile stimulation
79992540|NCT04808284|Device|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
79510547|NCT00890682|Drug|SKY0402|Local infiltration of 8cc SKY0402
79510548|NCT00890682|Drug|Placebo|Local infiltration of 8cc Placebo
79992541|NCT04808284|Device|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
79992542|NCT05197803|Device|Hearing aid model|Amplification
79992543|NCT04054700|Device|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
79992544|NCT04054700|Device|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
79359695|NCT04309552|Drug|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
79359696|NCT04309461|Behavioral|Stress Management Control|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
79359697|NCT04309461|Behavioral|Adapted MBC2 Program|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
79510549|NCT00890916|Device|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
79510550|NCT00892710|Drug|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
79510551|NCT00892710|Drug|Bevacizumab|15 mg/kg IV every 21 days
79359698|NCT04304508|Drug|BAY2433334|Tablet, taken orally once a day.
79510552|NCT00892710|Drug|Carboplatin|AUC=5 IV every 21 days
79510553|NCT00894504|Drug|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
79359699|NCT04304508|Other|BAY2433334 matching placebo|Tablet, taken orally once a day.
79359700|NCT04292145|Behavioral|Relaxation Application|The use of an application for relaxation.
79510554|NCT00894504|Drug|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
79510555|NCT00894504|Drug|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
79510556|NCT00894738|Procedure|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
79510557|NCT00895752|Drug|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
79510558|NCT00895830|Drug|APD405|IV
79510559|NCT00895830|Drug|Placebo|IV
79510560|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
79819373|NCT04498429|Other|Verbal Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
79992545|NCT05387044|Radiation|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
79992546|NCT03142828|Drug|Chlorhexidine|Healing abutment with Clorhexidine
79359701|NCT04292145|Behavioral|Relaxation Only|The individual's personal method to relax.
79359702|NCT04291560|Behavioral|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
79359703|NCT04291300|Drug|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
79359704|NCT04288856|Drug|BIIB078|Administered as specified in the treatment arm.
79992547|NCT03142828|Other|Placebo|Healing abutment without any antiseptic
79359705|NCT04275180|Drug|Argatroban|Argatroban plus standard medical treatment
79510561|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
79510562|NCT00896298|Drug|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
79510563|NCT00896298|Drug|Placebo|Sugar pill
79510564|NCT00898560|Drug|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
79510565|NCT00898560|Drug|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
79510566|NCT00899574|Drug|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
79510567|NCT00900666|Drug|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
79510568|NCT00900666|Drug|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
79510569|NCT00900822|Device|Straumann Bone Ceramic|Granules applied once during surgery
79510570|NCT00900822|Device|BioOss|Granules that are applied once during surgery
79992548|NCT01372839|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
79359706|NCT04271332|Drug|Arbaclofen|Arbaclofen tablet
79359707|NCT04271332|Drug|Placebo oral tablet|Manufactured to match Arbaclofen in size, shape, color and taste
79510571|NCT00902226|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
79510572|NCT00903162|Drug|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
79992549|NCT01372839|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
79359708|NCT04268875|Device|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
79359709|NCT04267978|Drug|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
79359710|NCT04250233|Device|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
79359711|NCT04230252|Drug|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
79359712|NCT04206332|Drug|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
79359713|NCT04206332|Other|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
79359714|NCT04189263|Other|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day)
79359715|NCT04189263|Drug|standard of care aromatase inhibitors|standard of care aromatase inhibitors
79359716|NCT04174157|Other|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
79359717|NCT04174157|Drug|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
79510573|NCT00903162|Drug|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
79510574|NCT00903162|Drug|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
79359718|NCT04170426|Biological|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
79510575|NCT00904488|Drug|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
79992550|NCT01065350|Drug|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
79510576|NCT00904488|Drug|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
79510577|NCT00905580|Drug|Pregabalin|Pregabalin 150 mg orally
79510578|NCT00905580|Drug|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
79510579|NCT00908388|Device|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
79510580|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
79510581|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
79510582|NCT00909324|Drug|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
79510583|NCT00909324|Drug|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
79510584|NCT00911586|Drug|Testosterone undecanoate|
79510585|NCT00911742|Drug|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
79510586|NCT00911742|Drug|Zytram|1 Zytram 200 mg tablet as a single dose
79510587|NCT00911898|Drug|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
79510588|NCT00912990|Drug|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
79510589|NCT00912990|Drug|Normal saline|One Intravenous dose
79359719|NCT04159194|Other|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (~55% CHO) and the type and amount of ingested food will be recorded.
79359720|NCT04159194|Other|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
79359721|NCT04157192|Other|Real acupuncture|The patient will be treated for migraine with real acupuncture.
79359722|NCT04157192|Other|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
79359723|NCT04155398|Procedure|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
79510590|NCT00913068|Procedure|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
79992551|NCT01065350|Drug|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
79992552|NCT03434249|Dietary Supplement|Bifidobacterium, BB-12® (Bifidolactis Infant)|
79992553|NCT03434249|Dietary Supplement|Bifidolactis Infant Placebo|
79359724|NCT04152343|Device|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions >2cm
79359725|NCT04152239|Procedure|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
79359726|NCT04121650|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
79510591|NCT00913068|Procedure|standard post op pain control|opiates
79510592|NCT00914862|Drug|Ramelteon|Ramelteon tablets, orally for one day only.
79359727|NCT04117178|Drug|Donepezil|Adjustment of treatment with donepezil according to serum level.
79359728|NCT04117178|Drug|Memantine|Adjustment of treatment with memantine according to serum level.
79510593|NCT00915798|Behavioral|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
79510594|NCT00915798|Behavioral|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
79510595|NCT00915954|Diagnostic Test|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
79510596|NCT00915954|Diagnostic Test|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
79510597|NCT00915954|Diagnostic Test|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
79510598|NCT00916032|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
79670447|NCT04870606|Drug|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
79670448|NCT04870606|Drug|Placebo|Placebo+Standard of care determined by PI and local regulatory
79670449|NCT04864054|Biological|ECT204 T cells|ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
79510599|NCT00919932|Behavioral|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
79670450|NCT04862923|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
79670451|NCT04861337|Drug|Remimazolam|Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.
79819374|NCT04441905|Other|Placebo|One time 60-minute IV infusion of lyophilized placebo for SAR440894
79819375|NCT04441905|Biological|SAR440894|One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
79819376|NCT04428554|Radiation|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
79819377|NCT04419519|Drug|Venetoclax monotherapy|Venetoclax monotherapy
79819378|NCT04419519|Drug|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
79819379|NCT04418167|Drug|JSI-1187|JSI-1187 capsules for oral administration
79819380|NCT04418167|Drug|Dabrafenib|Dabrafenib capsules for oral administration
79819381|NCT04416932|Procedure|Ultasound|Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
79819382|NCT04390113|Biological|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
79819383|NCT04390113|Biological|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
79819384|NCT04381650|Drug|TAK-981|TAK-981 IV infusion.
79819385|NCT04381650|Drug|Pembrolizumab|Pembrolizumab IV infusion.
79992554|NCT03142906|Diagnostic Test|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
79510600|NCT00919932|Device|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
79510601|NCT00922194|Drug|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
79670452|NCT04861337|Drug|Placebo|Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
79819386|NCT04380545|Drug|Fluorouracil|Given IV
79819387|NCT04380545|Biological|Nivolumab|Given IV
79819388|NCT04380545|Biological|Recombinant Interferon Alpha 2b-like Protein|Given SC
79819389|NCT04372108|Drug|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
79819390|NCT04372108|Drug|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
79819391|NCT04362839|Biological|Ipilimumab|Given IV
79819392|NCT04362839|Biological|Nivolumab|Given IV
79819393|NCT04362839|Drug|Regorafenib|Given PO
79819394|NCT04361942|Biological|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.
79819395|NCT04361942|Other|Placebo|Intravenous injection of 100 ml physiological saline solution containing no cells
79819396|NCT04358237|Drug|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
79819397|NCT04358237|Drug|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
79819398|NCT04357873|Drug|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
79819399|NCT04353778|Drug|Pyridostigmine|Eight weeks of low-dose pyridostigmine
79819400|NCT04353778|Drug|Placebos|matching placebo x 8 weeks
79819401|NCT04353778|Procedure|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
79819402|NCT04352166|Drug|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
79819403|NCT04352166|Drug|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
79819404|NCT04327934|Drug|GnRH antagonist|GnRH antagonist up to 16 days.
79992555|NCT03033693|Other|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
79359729|NCT04117178|Diagnostic Test|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
79992556|NCT03033693|Other|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
79510602|NCT00923598|Drug|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
79510603|NCT00923910|Drug|WT1 Peptide-Pulsed Dendritic Cells|
79359730|NCT04115826|Procedure|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
79510604|NCT00923910|Drug|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
79670453|NCT04857463|Other|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
79670454|NCT04857463|Other|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
79670455|NCT04856891|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
79670456|NCT04856891|Other|Placebo|Placebo
79670457|NCT04853810|Other|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
79819405|NCT04327934|Drug|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
79819406|NCT04317417|Behavioral|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
79819407|NCT04299373|Drug|Alcohol: Oral administration|Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
79819408|NCT04299373|Drug|Alcohol: Intravenous administration|Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
79992557|NCT05079490|Behavioral|motor intervention|gross motor skill intervention combined with fitness training
79992558|NCT02914977|Drug|Daunorubicin|"Agent: Daunorubicin~Dose: 6.75 mg/m2/day~Route: IV~Schedule: Days 1-5~Duration: One cycle"
79992559|NCT03718715|Drug|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
79992560|NCT05053347|Dietary Supplement|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 5d/day(ALA 2.5g/d). The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
79992561|NCT05053347|Dietary Supplement|Corn oil capsule|The participants were asked to take corn oil capsule 5d/day. The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
79992562|NCT05079022|Drug|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
79670458|NCT04851145|Diagnostic Test|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
79359731|NCT04115826|Procedure|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
79359732|NCT04109820|Dietary Supplement|MitoQ|Oral; 20mg once a day for 14 days
79359733|NCT04094961|Drug|Ixazomib|Oral, administered four times per cycle
79359734|NCT04094961|Drug|Pomalidomide|Oral, administered 14 times per cycle
79359735|NCT04094961|Drug|Dexamethasone|Oral, fixed dose administered 8 times per cycle
79359736|NCT04070040|Drug|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
79359737|NCT04054817|Device|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
79359738|NCT04053946|Device|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
79359739|NCT04046406|Device|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
79992563|NCT05078788|Procedure|Laser uretherotomy|Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
79992564|NCT05078788|Procedure|Laser uretherotomy with triamcinolone|After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
79359740|NCT04056013|Device|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
79670459|NCT04850781|Behavioral|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
79992565|NCT02032654|Drug|Flucloxacillin|
79992566|NCT02032654|Drug|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
79992567|NCT04737694|Dietary Supplement|Ketone ester|Oral ketone ester + glucose supplement
79992568|NCT04737694|Dietary Supplement|Glucose|Glucose supplement
79992569|NCT04734886|Dietary Supplement|L. reuteri DSM 17938 + vitamin D|1 * 10^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
79992570|NCT04734886|Dietary Supplement|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
79992571|NCT03142282|Drug|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
79359741|NCT04044248|Device|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
79359742|NCT04040413|Procedure|bariatric surgery|All bariatric procedures
79992572|NCT03142282|Radiation|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
79992573|NCT03114969|Device|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
79992574|NCT03114969|Device|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
79992575|NCT03114969|Device|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
79992576|NCT03114969|Device|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
79992577|NCT03114969|Device|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
79992578|NCT03114969|Device|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
79510605|NCT00923910|Drug|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
79992579|NCT03114969|Device|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
79992580|NCT05078710|Drug|Telitacicept|160mg once a week for 24 weeks
79992581|NCT05078632|Other|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
79992582|NCT03144778|Biological|Durvalumab|Given IV
79992583|NCT03144778|Biological|Tremelimumab|Given IV
79992584|NCT02046096|Device|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
79670460|NCT04850781|Behavioral|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
79819409|NCT04298203|Drug|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
79992585|NCT02046096|Device|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
79992586|NCT03142360|Drug|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
79992587|NCT05124678|Drug|Isoniazid Tablets|High dose of isoniazid
79992588|NCT04668820|Diagnostic Test|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
79510606|NCT00923910|Drug|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
79510607|NCT00923910|Drug|WT1 Peptides|dendritic cell vaccine
79510608|NCT00923910|Drug|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
79510609|NCT00923910|Drug|Diphenhydramine|Pre-medication
79510610|NCT00923910|Drug|Acetaminophen|Pre-medication
79510611|NCT00924066|Drug|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m^2 for a total of 30mg/m^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
79510612|NCT00924612|Drug|Oral testosterone undecanoate (containing 300 mg T)|
79992589|NCT03463577|Other|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
79992590|NCT04667884|Dietary Supplement|Prebiotics or Probiotics|All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
79359743|NCT04039633|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
79359744|NCT04039633|Procedure|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
79359745|NCT04033614|Device|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
79359746|NCT04030676|Procedure|Biopsies|Two more biopsies in inflammatory zone will be collected.
79359747|NCT04030676|Biological|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
79359748|NCT04014205|Drug|Orelabrutinib (ICP-022)|ICP-022 The drug product is a white, round, uncoated tablet
79359749|NCT04010422|Diagnostic Test|no intervention|no intervention
79359750|NCT04010409|Other|no intervention|no intervention
79359751|NCT04005651|Device|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
79359752|NCT04005651|Device|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
79359753|NCT04005651|Device|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
79359754|NCT03991936|Drug|Placebos|Normal saline intralesional injection
79510613|NCT00925782|Drug|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
79670461|NCT04844775|Biological|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
79359755|NCT03991936|Drug|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
79359756|NCT03991936|Drug|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
79510614|NCT00925782|Drug|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
79510615|NCT00925938|Drug|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
79510616|NCT00925938|Drug|placebo|placebo
79359757|NCT03991936|Drug|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
79359758|NCT03991936|Drug|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
79359759|NCT03979599|Procedure|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
79359760|NCT03979599|Drug|magnesium sulphate& levobupivacaine|magnesium sulphate& levobupivacaine
79359761|NCT03979599|Drug|Levobupivacaine|levobupivacaine
79359762|NCT03974230|Other|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
79359763|NCT03974230|Biological|blood sample|Blood sample will be performed (genetic analyses).
79359764|NCT03974230|Other|slit lamp examination|Slit lamp examination will be performed.
79359765|NCT03969693|Radiation|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
79510617|NCT00926952|Drug|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
79510618|NCT00926952|Device|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
79359766|NCT03956784|Device|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~Normal situation~Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
79359767|NCT03956784|Other|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~Immediate complications and warning signs:~Tachycardia> 120 bpm~Dyspnea~Rectorragies and / or melena~Vomiting with or without presence of blood~Major abdominal pain (visual analogue scale> 6/10)~Fever> 38~Management to deal with complications: call the service and / or the surgeon~Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
79359768|NCT03948698|Other|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
79359769|NCT03946514|Drug|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
79359770|NCT03946514|Drug|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
79359771|NCT03945279|Drug|BIIB100|Administered as specified in the treatment arm.
79359772|NCT03945279|Drug|Placebo|Administered as specified in the treatment arm.
79510619|NCT00927264|Behavioral|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits & 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
79670462|NCT04844775|Biological|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"Drep-HIV-PT1 1mg (see above)~Drep-HIV-PT1 1mg (see above)"
79510620|NCT00927264|Behavioral|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
79670463|NCT04844775|Biological|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
79819410|NCT04298203|Dietary Supplement|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
79819411|NCT04298203|Other|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
79819412|NCT04298086|Other|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
79359773|NCT03935958|Dietary Supplement|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
79359774|NCT03935958|Other|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
79359775|NCT03935295|Drug|AbobotulinumtoxinA|Paraspinal abobotulinumtoxinA injections (compared to placebo)
79510621|NCT00927576|Behavioral|Digit span testing|Testing of short-term verbal memory with digit span
79510622|NCT00927576|Behavioral|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
79510623|NCT00927576|Behavioral|Finger tapping|Testing motor speed with a finger tapping test.
79510624|NCT00927576|Behavioral|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
79819413|NCT04298086|Other|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
79819414|NCT04298086|Other|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
79670464|NCT04844203|Diagnostic Test|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
79992591|NCT05761002|Biological|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
79359776|NCT03935295|Drug|Placebos|Placebo prepared by Ipsen for use as control
79819415|NCT04298086|Other|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
79992592|NCT03424824|Drug|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
79992593|NCT03424824|Drug|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
79359777|NCT03935295|Device|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
79359778|NCT03927651|Drug|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
79359779|NCT03919214|Other|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg.
79670465|NCT04842591|Diagnostic Test|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
79819416|NCT04298086|Other|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
79819417|NCT04288427|Drug|Finasteride|Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
79819418|NCT04287946|Device|Ablation|Ablation of a single-side of the greater splanchnic nerve
79819419|NCT04285242|Other|Observational assessments|Clinical assessments
79819420|NCT04277637|Drug|BGB-11417|Film-coated tablets administered once daily at a dose as specified in the treatment arm
79819421|NCT04277637|Drug|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
79819422|NCT04277637|Drug|obinutuzumab|Given as an intravenous infusion administered per label.
79819423|NCT04276441|Device|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
79992594|NCT03424824|Drug|Placebo|Tablet, once daily oral administration
79992595|NCT03424824|Drug|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
79670470|NCT04823858|Procedure|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
79670471|NCT04822272|Device|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
79670472|NCT04821154|Device|Persona Revision Knee System|Patients in this cohort will have been previously implanted with the Persona Revision Knee system in the described configuration per standard of care. The Persona Revision knee system is a total knee system that is widely available for use in the United States and is designed for use in primary and revision knee surgical interventions.
79359780|NCT03915444|Drug|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
79359782|NCT03894631|Procedure|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
79359783|NCT03894631|Procedure|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
79359784|NCT03892785|Drug|Prednisone treatment|tapering prednisone regimen
79359785|NCT03892785|Drug|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
79359786|NCT03892785|Drug|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~W0: 7.5 mg/week~W1: 0.2 mg/Kg/week~W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
79359787|NCT03892785|Other|Questionnaires|HAQ, SF-36, FACIT-fatigue
79359788|NCT03892785|Biological|Blood samples|Additionnal blood samples for immunomonitoring
79359789|NCT03888287|Device|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
79359790|NCT03888287|Other|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
79670477|NCT04814992|Behavioral|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
79670478|NCT04811560|Drug|JNJ-75276617|JNJ-75276617 is administered orally.
79670479|NCT04800315|Drug|CC-93538|Specified dosages on specified days
79670480|NCT04800315|Other|Placebo|Specified dosages on specified days
79510625|NCT00927576|Behavioral|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
79510626|NCT00927576|Behavioral|Verbal fluency|Evaluating how many words are produced in 90s.
79819424|NCT04276441|Device|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
79819425|NCT04271475|Drug|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
79359791|NCT03880058|Drug|SLI-F06|Active treatment
79359792|NCT03880058|Drug|Formulation buffer|Placebo treatment
79359793|NCT03876795|Biological|Bone Marrow Concentrate|Bone Marrow Concentrate injection
79359794|NCT03869034|Combination Product|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
79510627|NCT00927576|Behavioral|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
79510628|NCT00927576|Behavioral|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
79510629|NCT00927576|Behavioral|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
79510630|NCT00927576|Behavioral|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
79819426|NCT04271475|Drug|Placebo|Participant will receive matching placebo tablets orally od.
79819427|NCT04260867|Other|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
79510631|NCT00927888|Drug|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
79510632|NCT00927888|Drug|Placebo|placebo is identical in appearance in comparison to active drug.
79510633|NCT00928200|Drug|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
79510634|NCT00928200|Drug|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
79510635|NCT00928200|Drug|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
79510636|NCT00928200|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
79510637|NCT00928200|Drug|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
79670481|NCT04799054|Drug|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT injection
79819428|NCT04260867|Other|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
79819429|NCT04260256|Drug|[18F]F-AraG|[18F]F AraG injection and PET Scan Two tumor biopsies of single lesion
79670482|NCT04799054|Drug|Pembrolizumab|Pembrolizumab will be administered IV
79819430|NCT04243941|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
79819431|NCT04238455|Procedure|Sham serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
79819432|NCT04238455|Procedure|Serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
79359795|NCT03869034|Drug|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
79359796|NCT03861975|Other|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
79359797|NCT03861351|Device|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
79359798|NCT03858608|Dietary Supplement|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
79359799|NCT03858608|Other|Usual asthma care|Usual asthma management
79359800|NCT03849638|Other|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~5 minutes of heating at a comfortable speed for the patient~Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
79510638|NCT00928200|Drug|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
79670483|NCT04789252|Biological|Bioinformatics analysis of single cell transcriptomics data|"Sample collection: Myeloid cell purification + Single cell sequencing~Primary analysis: QC sequencing data + Reads alignment + UMI quantification~Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~Validation: FACS analysis + immunohistochemistry"
79670484|NCT04776486|Drug|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
79670485|NCT04776005|Other|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
79992596|NCT04661956|Procedure|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
79992597|NCT05060172|Device|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
79819433|NCT04218812|Diagnostic Test|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
79510639|NCT00928200|Drug|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
79670487|NCT04769362|Drug|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
79819434|NCT04218812|Diagnostic Test|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~Automated detection of EDs~Source imaging of each spike cluster and seizure onset epoch."
79992598|NCT04983927|Device|cASPECTS|Clinical decision support system for scoring ASPECTS score
79992599|NCT01477008|Device|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
79992600|NCT01477008|Procedure|Marrow Stimulation|Microfracture or Subchondral Drilling
79992601|NCT01374399|Behavioral|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
79359801|NCT03842475|Procedure|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
79359802|NCT03841097|Drug|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
79510640|NCT00928200|Drug|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
79510641|NCT00929838|Behavioral|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
79510642|NCT00929838|Behavioral|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
79670488|NCT04769219|Other|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
79670489|NCT04768114|Behavioral|Genetically-Informed RiskProfile|"Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~This is a fully remote trial, with intervention delivered via video conferencing."
79670490|NCT04768114|Other|Brief Cessation Advice|"Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~This is a fully remote trial, with brief cessation advice delivered via video conferencing."
79670491|NCT04767672|Dietary Supplement|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
79359803|NCT03841097|Drug|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
79670492|NCT04767672|Dietary Supplement|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
79359804|NCT03831776|Drug|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (> 300 mg/d > 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
79359805|NCT03831776|Drug|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
79510643|NCT00929838|Behavioral|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
79510644|NCT00929838|Behavioral|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
79510645|NCT00931164|Drug|Sodium Oxybate|dosage is by weight
79510646|NCT00931242|Drug|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
79510647|NCT00932022|Drug|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
79510648|NCT00932022|Other|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
79819437|NCT04214392|Biological|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
79359806|NCT03831425|Dietary Supplement|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
79359807|NCT03831425|Other|Placebo|6 week trial of either treatment with Placebo
79359808|NCT03804944|Radiation|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
79359809|NCT03804944|Drug|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
79992602|NCT04598386|Other|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers >2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
79359810|NCT03804944|Biological|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
79359811|NCT03790111|Drug|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
79359812|NCT03780543|Drug|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
79359813|NCT03772314|Drug|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
79359814|NCT03772314|Drug|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
79359815|NCT03760575|Drug|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
79359816|NCT03760575|Procedure|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
79359817|NCT03760575|Drug|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
79359818|NCT03760575|Drug|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
79359819|NCT03750981|Behavioral|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
79359820|NCT03747393|Behavioral|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
79359821|NCT03747393|Behavioral|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
79359822|NCT03745820|Drug|BIIB104|Administered as specified in the treatment arm
79359823|NCT03745820|Other|Placebo|Administered as specified in the treatment arm
79359824|NCT03720522|Procedure|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
79359825|NCT03720522|Procedure|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
79359826|NCT03720522|Procedure|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
79359827|NCT03720522|Procedure|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
79359828|NCT03706664|Other|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
79359829|NCT03704922|Biological|Transfusion|Red cell units for transfusion
79359830|NCT03699631|Drug|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
79992603|NCT04598386|Other|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
79992604|NCT02861820|Device|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
79992605|NCT03122145|Drug|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
79992606|NCT03122145|Device|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
79510649|NCT00934596|Procedure|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV & Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
79510650|NCT00934596|Drug|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
79510651|NCT00935064|Drug|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
79819438|NCT04214392|Biological|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
79359831|NCT03699631|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
79359832|NCT03699631|Drug|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
79359833|NCT03686150|Dietary Supplement|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
79510652|NCT00935064|Other|Placebo|Placebo orally one tablet once a day for 6 weeks.
79510653|NCT00935766|Drug|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
79992607|NCT05081830|Behavioral|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
79510654|NCT00935766|Drug|Placebo|
79510655|NCT00937794|Behavioral|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
79359834|NCT03680781|Device|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
79359835|NCT03678233|Drug|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
79510656|NCT00937794|Other|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
79510657|NCT00939120|Drug|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
79359836|NCT03663218|Radiation|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
79359837|NCT03657771|Other|DED|DED: Diet eliminating dairy
79510658|NCT00939120|Drug|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
79510659|NCT00939120|Drug|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
79359838|NCT03657771|Other|FREE|FREE: Diet eliminating dairy and food additives
79359839|NCT03650478|Device|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
79510660|NCT00939198|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
79510661|NCT00939900|Drug|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
79510662|NCT00940290|Other|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
79510663|NCT00940446|Device|Insorb staples|absorbable staples required for wound closure
79510664|NCT00940446|Device|metal staples (Ethicon metal stapler)|wound closure with metal staples
79510665|NCT00943098|Drug|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
79670493|NCT04763200|Device|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI <20 kg/m2 or body weight <60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
79510666|NCT00943098|Drug|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
79510667|NCT00943488|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
79670494|NCT04763200|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
79670495|NCT04753138|Device|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
79992608|NCT05081830|Behavioral|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
79992609|NCT05150535|Radiation|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
79670496|NCT04753138|Device|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
79670497|NCT04742959|Drug|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
79670498|NCT04742959|Combination Product|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
79510668|NCT00943800|Drug|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
79992610|NCT05150535|Radiation|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
79992611|NCT03140800|Device|intrauterine device|a method of contraception inserted in the uterus
79992612|NCT02327650|Procedure|The examinations for bones in joints of OA and RA patients|
79992613|NCT03144856|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
79992614|NCT05080894|Device|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
79992615|NCT04949022|Device|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
79992616|NCT05762562|Other|Telerehabilitation with open source platforms|"Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program."
79992617|NCT04457752|Biological|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
79992618|NCT02327338|Device|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
79510669|NCT00943800|Procedure|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
79510670|NCT00943800|Procedure|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
79510671|NCT00943800|Drug|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
79670499|NCT04742673|Drug|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
79670500|NCT04742673|Drug|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
79992619|NCT02327338|Drug|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
79992620|NCT05080816|Dietary Supplement|Parenteral nutrition (PN)|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
79359840|NCT03650478|Device|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
79359841|NCT03632616|Other|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, and 6 months post-intervention.
79359842|NCT03617718|Drug|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
79359843|NCT03606642|Drug|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
79359844|NCT03606642|Device|The Synergy® stent|IVUS guided stent
79359845|NCT03604172|Behavioral|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
79510672|NCT00943800|Drug|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
79510673|NCT00943878|Biological|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
79819439|NCT04208217|Behavioral|Modeling to Learn (MTL)|Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
79819440|NCT04208217|Behavioral|Usual quality improvement (QI)|Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
79992621|NCT05080816|Dietary Supplement|Enteral nutrition|Oral nutrition drink. 2 * 200 ml on the night before operation. 1* 200 ml on the morning of operation day.
79992622|NCT05080816|Other|Control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
79992623|NCT02327416|Drug|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
79992624|NCT02327416|Drug|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
79992625|NCT02327416|Drug|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
79992626|NCT05080582|Behavioral|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
79992627|NCT05080582|Behavioral|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
79992628|NCT03114657|Drug|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
79992629|NCT03114657|Drug|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
79992630|NCT05071456|Other|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
79992631|NCT02926950|Drug|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
79819441|NCT04203069|Device|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
79819442|NCT04203069|Device|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
79819443|NCT04185064|Device|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
79819444|NCT04185064|Other|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
79359846|NCT03604172|Behavioral|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
79510674|NCT00943878|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
79510675|NCT00943878|Drug|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
79510676|NCT00945282|Drug|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
79819445|NCT04183790|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
79992632|NCT02926950|Drug|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
79992633|NCT02926950|Drug|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
79992634|NCT03410693|Drug|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
79359847|NCT03591263|Other|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
79359848|NCT03572322|Other|Focus Group|Focus Group
79359849|NCT03572322|Other|Interviews|Interviews
79359850|NCT03561012|Behavioral|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
79359851|NCT03561012|Other|Control Condition|Standard of care
79359852|NCT03527043|Drug|Escitalopram|10mg by mouth daily for 6 weeks
79359853|NCT03527043|Other|Placebo|matched placebo control by mouth for 6 weeks
79510677|NCT00945282|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
79992635|NCT03410693|Drug|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
79992636|NCT01064414|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
79510678|NCT00945282|Drug|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
79819446|NCT04183790|Drug|IVA|Mono tablet for oral administration.
79819447|NCT04181762|Drug|secukinumab|STUDY DRUG
79819448|NCT04176562|Device|RTI Spine products|"Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~Bone graft substitute - is intended to aid in fusion."
79819449|NCT04176016|Drug|OTSA101-DTPA-111In|single IV injection, 185MBq/body
79992637|NCT01064414|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
79992638|NCT04254172|Device|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
79510679|NCT00945282|Drug|Placebo|Placebo is a capsule with no drug in it.
79510680|NCT00945282|Drug|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
79510681|NCT00945594|Device|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
79510682|NCT00945750|Drug|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
79992639|NCT04944849|Diagnostic Test|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
79992640|NCT03433703|Drug|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW <60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
79359854|NCT03503032|Procedure|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery [applied to both arms]
79359855|NCT03503032|Procedure|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium [Fenestrated arm]
79359856|NCT03496207|Drug|Placebo|Placebo
79359857|NCT03496207|Drug|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
79510683|NCT00945750|Drug|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
79510684|NCT00947310|Device|Standard ICD programming|Standard ICD programming
79819450|NCT04176016|Drug|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
79992641|NCT03652766|Behavioral|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
79992642|NCT05202600|Procedure|Appendectomy|Surgical removal of the vermiform appendix.
79992643|NCT04904601|Dietary Supplement|Kale supplement|Kale (blanched freeze-dried Kale) group1
79992644|NCT04904601|Dietary Supplement|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
79992645|NCT03653078|Device|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
79992646|NCT03713723|Device|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
79992647|NCT05202444|Procedure|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
79992648|NCT01374633|Drug|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
79359858|NCT03496207|Other|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
79359859|NCT03494868|Dietary Supplement|Carbohydrate Drink|2 - 12 oz drinks
79359860|NCT03481985|Other|Fenestration status|The exposure variable will be status of the Fontan fenestration
79359861|NCT03458221|Drug|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
79359862|NCT03458221|Drug|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
79510685|NCT00947310|Device|High rate cutoff|Programming of a high rate cutoff
79992649|NCT03652922|Drug|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
79992650|NCT03713567|Behavioral|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
79510686|NCT00947310|Device|Long delay|Programming of a prolonged delay
79992651|NCT01178814|Drug|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
79992652|NCT04053920|Behavioral|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
79510687|NCT00948090|Drug|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
79510688|NCT00948792|Procedure|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
79510689|NCT00948792|Procedure|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
79992653|NCT04053920|Behavioral|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
79992654|NCT03713489|Procedure|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
79992655|NCT04053686|Behavioral|Breaks|3-min breaks every half hour at work
79992656|NCT05202288|Biological|Ervebo|Administration of r-VSV-ZEBOV vaccine
79992657|NCT05202288|Drug|Inmazeb|Administration of Inmazeb
79359863|NCT03458221|Drug|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
79510690|NCT00950352|Drug|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
79510691|NCT00950352|Drug|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
79359864|NCT03458221|Drug|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
79359865|NCT03451487|Drug|Panadol®|Acetaminophen 500mg Tablet
79359866|NCT03451487|Drug|SafeTynadol®|Acetaminophen 500mg Tablet
79359867|NCT03444870|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
79359868|NCT03444870|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
79359869|NCT03429322|Behavioral|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
79359870|NCT03429322|Other|Usual Care|Participants will receive and provide usual and customary care in their communities.
79359871|NCT03410030|Drug|Ascorbic Acid|combination therapy
79359872|NCT03410030|Drug|Paclitaxel protein-bound|combination therapy
79359873|NCT03410030|Drug|Cisplatin|combination therapy
79359874|NCT03410030|Drug|Gemcitabine|combination therapy
79359875|NCT03406221|Behavioral|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
79359876|NCT03406221|Other|Control Condition|Standard of care
79510692|NCT00953862|Drug|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
79819451|NCT04164199|Drug|Tislelizumab|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
79992658|NCT03652298|Other|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
79992659|NCT03652298|Other|support and attention (usual care)|support and attention (usual care)
79992660|NCT03463031|Drug|GSP 301 NS|1 spray in each nostril twice daily for 14 days
79992661|NCT03463031|Drug|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
79359877|NCT03400553|Diagnostic Test|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
79359878|NCT03397017|Other|Transfusion|
79359879|NCT03382301|Drug|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
79359880|NCT03382301|Drug|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
79359881|NCT03379870|Device|Electric Acoustic Speech Processor: EAS fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
79359882|NCT03379870|Device|Electric Acoustic Speech Processor: Electric only fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
79359883|NCT03290391|Other|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
79359884|NCT03290391|Drug|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
79359885|NCT03290391|Behavioral|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
79510693|NCT00955032|Device|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
79670501|NCT04740372|Other|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
79992662|NCT04054388|Behavioral|LINE re-education|
79359886|NCT03280030|Drug|Midostaurin|Midostaurin 50 mg [two 25 mg capsules] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
79359887|NCT03280030|Drug|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
79359888|NCT03260842|Diagnostic Test|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
79359889|NCT03235219|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
79359890|NCT03235219|Drug|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
79510694|NCT00955032|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
79510695|NCT00955266|Drug|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
79510696|NCT00955266|Drug|Placebo|Normal saline, 50cc delivered over 5 minutes
79510697|NCT00957684|Drug|eslicarbazepine acetate|once-daily oral tablet
79992663|NCT05202132|Diagnostic Test|Questionnaire|A 3 item validated questionnaire assessing masticatory function
79992664|NCT05202132|Diagnostic Test|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
79670502|NCT04739852|Other|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
79670503|NCT04732052|Device|Transcranial Direct Current Stimulation|non-invasive brain stimulator
79359891|NCT03224624|Other|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
79359892|NCT03194867|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79359893|NCT03194867|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79510698|NCT00957684|Drug|placebo|once daily placebo comparator
79670504|NCT04730271|Device|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
79670505|NCT04718844|Drug|SLN124|SLN124 for subcutaneous (s.c.) injection
79670506|NCT04718844|Drug|Placebo|Sodium chloride for s.c. injection
79992665|NCT03652688|Behavioral|Three 0's|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
79510699|NCT00958308|Other|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
79510700|NCT00958308|Other|Placebo|Placebo is devoid of microorganisms.
79510701|NCT00959166|Other|PET scan|PET brain scan
79510702|NCT00961662|Drug|D-Tagatose|powder to be dissolved in water prior to dosage.
79510703|NCT00962598|Drug|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
79670507|NCT04706715|Other|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
79992666|NCT03652688|Behavioral|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
79670508|NCT04706715|Drug|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
79670509|NCT04706598|Drug|Camrelizumab|Solution for Infusion (Intravesical)
79670510|NCT04700722|Diagnostic Test|Skin Biopsy|Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
79992667|NCT05762484|Procedure|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
79992668|NCT05762484|Drug|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
79670515|NCT04670874|Other|Quality-of-Life Assessment|Complete quality of life questionnaire
79670516|NCT04670874|Other|Questionnaire Administration|Complete quality of life questionnaire
79819452|NCT04164199|Drug|Pamiparib|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
79819453|NCT04164199|Drug|Pemetrexed 500 mg/m² IV|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
79992669|NCT03462641|Drug|Flumazenil|1mg in 10cc normal saline
79992670|NCT03462641|Drug|Placebo|10 cc normal saline
79992671|NCT04150796|Procedure|Ventral Hernia Repair|Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
79992672|NCT05206968|Radiation|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
79992673|NCT04858074|Drug|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
79992674|NCT04856202|Behavioral|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
79992675|NCT02974634|Other|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
79992676|NCT04814316|Diagnostic Test|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
79992677|NCT04113122|Diagnostic Test|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
79359894|NCT03143647|Other|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
79359895|NCT03143504|Diagnostic Test|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
79819454|NCT04164199|Drug|Capecitabine 1000 mg/m² PO BID|Day 1 to Day 15 of each 21 day cycle, to be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
79510704|NCT00962598|Dietary Supplement|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
79359896|NCT03138720|Drug|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
79510705|NCT00962754|Procedure|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
79670517|NCT04669288|Drug|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
79670518|NCT04669288|Drug|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
79670519|NCT04666987|Drug|Insulin degludec and liraglutide (IDegLira)|Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
79670520|NCT04666454|Drug|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
79359897|NCT03131726|Drug|Simvastatin 40mg|see arm description
79359898|NCT03112590|Biological|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
79359899|NCT03112590|Drug|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m^2/week, for 12 weeks.
79359900|NCT03112590|Drug|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
79359901|NCT03112590|Other|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
79359902|NCT03112590|Procedure|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
79359903|NCT03085394|Drug|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
79359904|NCT03085394|Drug|Placebo|Preoperative intravenous administration of 10 ml saline
79359905|NCT03065621|Drug|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
79359906|NCT03060629|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
79359907|NCT03060629|Biological|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
79359908|NCT03060629|Biological|Placebo|Participants will receive matching placebo.
79359909|NCT03060434|Drug|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
79359910|NCT03060434|Drug|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
79359911|NCT03617354|Procedure|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
79359912|NCT03021486|Drug|Chlorpromazine|Given IV
79510706|NCT00964548|Drug|Dantrolene|1.25 mg/kg IV once over 60 min
79359913|NCT03021486|Drug|Haloperidol|Given IV
79359914|NCT03021486|Other|Quality-of-Life Assessment|Ancillary studies
79510707|NCT00964548|Drug|Dantrolene|2.5 mg/kg IV once over 60 min
79510708|NCT00905268|Drug|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
79510709|NCT00905268|Drug|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
79510710|NCT00965250|Drug|IMC-12|20 mg/kg intravenously once every three weeks
79359915|NCT03021486|Other|Questionnaire Administration|Ancillary studies
79359916|NCT02999789|Device|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
79359917|NCT02999789|Device|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
79359918|NCT02970331|Drug|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
79359919|NCT02945631|Radiation|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
79359920|NCT02945631|Radiation|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
79359921|NCT02935556|Other|no intervention|database and epigenetic study
79670521|NCT04666454|Drug|Dipyridamole 200 mg|200 mg b.i.d
79670522|NCT04666454|Drug|Apixaban 5 mg Oral Tablet|5mg b.i.d
79670523|NCT04666454|Other|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
79359922|NCT02923115|Drug|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
79359923|NCT02923115|Drug|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
79510711|NCT00966186|Procedure|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
79510712|NCT00967044|Drug|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
79992678|NCT04113122|Diagnostic Test|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
79670526|NCT04648254|Drug|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
79670527|NCT04633005|Drug|Polypill|Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.
79359924|NCT02923115|Drug|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
79359925|NCT02910583|Drug|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
79359926|NCT02910583|Drug|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
79359927|NCT02910583|Drug|Placebo|placebo capsules to match ibrutinib administered orally once daily
79670528|NCT04633005|Drug|Control Rx|Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
79819455|NCT04164199|Drug|Temozolomide 120, 80, 40 or 20 mg PO Once Daily (QD)|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
79819456|NCT04164199|Drug|Sitravatinib|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
79819457|NCT04164199|Drug|Ociperlimab|Participants will receive tislelizumab followed by the administration of ociperlimab on Day 1 of each 21-day cycle (ie, once every 3 weeks)
79359928|NCT02896348|Device|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
79359929|NCT02896348|Other|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
79359930|NCT02866461|Other|No treatment|Observation
79359931|NCT02863172|Behavioral|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
79359932|NCT02863172|Procedure|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
79359933|NCT02821299|Other|Laryngeal transplantation|Laryngeal transplantation
79359934|NCT02820857|Drug|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
79359935|NCT02820857|Drug|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
79359936|NCT02797457|Procedure|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
79359937|NCT02797457|Procedure|Prosthetic forehands|Prosthetic forehands
79359938|NCT02797314|Other|Bone biopsies|Bone biopsies
79359939|NCT02790710|Drug|Propanolol|Active treatment
79359940|NCT02790710|Drug|Placebo|
79359941|NCT02762318|Other|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
79510713|NCT00967044|Drug|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
79510714|NCT00968838|Procedure|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients >50 years of age are randomized to receive either radiated or non radiated transfusions."
79670529|NCT04627103|Device|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
79992679|NCT04804332|Procedure|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
79670530|NCT04622527|Other|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
79670531|NCT04616534|Procedure|Biopsy|Undergo biopsy (dose expansion cohort only)
79670532|NCT04616534|Procedure|Biospecimen Collection|Undergo collection of blood samples
79670533|NCT04616534|Procedure|Diagnostic Imaging|Undergo medical imaging scans
79670534|NCT04616534|Drug|Elimusertib|Given PO
79670535|NCT04616534|Drug|Gemcitabine|Given IV
79819458|NCT04164199|Drug|BAT1706|Participants will receive tislelizumab followed by the administration of BAT1706 on Day 1 of each 21-day cycle (ie, once every 3 weeks). If applicable, ociperlimab will be administered after completion of the BAT1706 infusion
79819459|NCT04164199|Drug|Fruquintinib|Fruquintinib will be self-administered orally once daily for 21 days, followed by 7 days off in 28-day cycles with or without food.
79819460|NCT04161287|Procedure|transcatheter arterial chemoembolization|The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
79359942|NCT02680015|Behavioral|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
79359943|NCT02650843|Other|DAT SPECT imaging|
79510715|NCT00970320|Other|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
79670536|NCT04612244|Device|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
79670537|NCT04612244|Device|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
79819461|NCT04146207|Drug|SHR0302|SHR0302 po QD
79819462|NCT04146207|Drug|Prednisone|Prednisone 1mg/kg/d po
79819463|NCT04119687|Biological|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
79992680|NCT04804332|Other|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
79992681|NCT04737876|Biological|BX002-A|bacteriophage cocktail
79992682|NCT04737876|Other|Placebo|Placebo
79359944|NCT02648477|Drug|Anastrozole|Given PO
79359945|NCT02648477|Drug|Doxorubicin Hydrochloride|Given IV
79359946|NCT02648477|Drug|Exemestane|Given PO
79359947|NCT02648477|Other|Laboratory Biomarker Analysis|Correlative studies
79359948|NCT02648477|Drug|Letrozole|Given PO
79359949|NCT02648477|Biological|Pembrolizumab|Given IV
79359950|NCT02613377|Other|Blood transfusion|
79359951|NCT02604732|Procedure|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
79510716|NCT00973752|Drug|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
79510717|NCT00973752|Drug|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
79510718|NCT00973752|Drug|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
79359952|NCT02604732|Procedure|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
79510719|NCT00973752|Drug|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
79510720|NCT00973752|Drug|Cytarabine|Intrathecally during Induction and CNS therapy
79510721|NCT00973752|Drug|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
79819464|NCT04114877|Behavioral|Attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. AR is the most commonly used CBM intervention in the study of addiction-related attentional bias. The idea behind AR is to reduce attentional bias and therefore minimize exposure to drug cues, because attention to such stimuli may provoke craving and undermine cessation attempts.
79819465|NCT04114877|Behavioral|Visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues. In the typical VP task, a pair of pictures or words (e.g. one smoking-related and one neutral) is briefly presented simultaneously side by side on a computer screen. After the pictures disappear, a probe stimulus (e.g. a small dot) is presented in the location that had been occupied by one of the pictures (or words), and participants are required to press a key as quickly as possible in response to the probe. Attentional bias for drug-related cues is detected by a faster response to a probe that replaces a drug-related stimulus (vs. a neutral stimulus), since attention will have been preferentially allocated to that area of visual display. The traditional VP task only assesses attentional bias, and does not modify it in any way.
79359953|NCT02603640|Device|MRI scanning|
79992683|NCT04128956|Drug|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
79819466|NCT04114851|Device|NoL|NoL active
79992684|NCT05206578|Drug|AGT2, AGZ|Tablet, q.d.
79992685|NCT05206578|Drug|AGT2|Tablet, q.d.
79992686|NCT05206578|Drug|AGT4, AGZ|Tablet, q.d.
79992687|NCT05206578|Drug|AGT4|Tablet, q.d.
79992688|NCT03651908|Procedure|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
79992689|NCT05206032|Other|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
79359954|NCT02498847|Behavioral|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~What is Osteoarthritis?~Information about treatments~Exercise~Sleep hygiene~Relaxation~Pleasant Activity Scheduling~Goal setting~Problem Solving~Pacing~Communication"
79359955|NCT02487394|Procedure|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
79359956|NCT02481648|Other|Exercise|
79359957|NCT02444429|Drug|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
79359958|NCT02444429|Other|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
79359959|NCT02444429|Other|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
79359960|NCT02318342|Drug|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
79992690|NCT05201274|Behavioral|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
79359961|NCT02296216|Device|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
79359962|NCT02258165|Device|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
79359963|NCT02154516|Device|ODH Hip System|
79359964|NCT02134184|Biological|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
79359965|NCT02029846|Drug|Standard Treatment|traditional drugs only
79359966|NCT02029846|Drug|Incretin-Based Treatment|incretin-based drugs
79359967|NCT06018649|Combination Product|Balneotherapy plus complex|The three groups of study (SAB, LAB, LIB) will get same balneotherapy intervention with the difference in duration and mode (outpatient/inpatient). Balneotherapy plus complex procedures: swimming pool with light exercises- 20 min (29-31°C), rest 15 min, wrapping/bath with peloids (peat mud, sapropel)- 20 min (38-40°C), rest 20 min, mineral water bath- 20 min (36-38°C), salt therapy- 25 min (humidity 35%, temperature about 22°).
79359968|NCT06018649|Combination Product|Combined nature resources treatment|"The participants of CNT group will be given combined treatment: nature therapy procedure (45 min) and balneotherapy plus complex intervention procedures.~The nature therapy procedure was created by researchers by combining the principles of nature therapy, mindfulness, wild nature therapy, kinesiology selecting actions suitable for the season. A procedure instructions with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest)."
79510722|NCT00973752|Drug|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
79510723|NCT00973752|Drug|Clofarabine|Intravenously during Consolidation 1 Therapy
79670538|NCT04601753|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79510724|NCT00973752|Drug|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
79510725|NCT00974142|Drug|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
79510726|NCT00974142|Drug|Placebo|Fifteen patients will receive will receive placebo.
79510727|NCT00974376|Drug|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
79510728|NCT00974376|Drug|Placebo|1200mg/day of placebo for 12 weeks
79670539|NCT04589754|Drug|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
79992691|NCT05201274|Behavioral|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
79359969|NCT06018649|Other|Nature therapy procedure|The participants of NT group will be given nature therapy procedure (45 min) created by researchers by combining the principles of nature therapy, kinesiology, mindfulness, wild nature therapy, selecting actions suitable for the season. A procedure instruction with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest).
79359970|NCT06018623|Other|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
79359971|NCT06018610|Other|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
79359972|NCT06018610|Other|Control|Conventional rehabilitation will be applied to the control group.
79359973|NCT06018597|Drug|Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL|No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
79359974|NCT06018584|Other|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
79359975|NCT06018532|Device|PRESAGE CARE|PRESAGE Care informations from the application will be processed by the PRESAGE Care algorithm in real time, and may generate alerts indicating an increased risk of hospitalization or emergency department visits within 7 to 14 days. These alerts will be transmitted to a Care Manager platform, who will analyse the situation, initiate the healthcare intervention and coordinate its implementation. In practice, a care manager (coordinating nurse) will process the alert and carry out an initial assessment of the beneficiary's situation, using the information feedback platform, then by telephone, contacting the older adults beneficiary and the relative. The care manager may or may not implement preventive measures. If necessary, the patient may be offered an outpatient medical consultation, a home visit, a consultation with his or her GP and/or social or paramedical interventions.
79359976|NCT06018519|Other|Clinical endpoints|"Number of epileptic seizures~Change in antiepileptic treatment (increase or decrease)~Visual analogical scale on a target symptom defined with the parents,~CGI,~Actimetry data over 24 hours,~Podometry data over 24 hours,~6 minutes' walk test,~Clinical examination~Feasibility of performing an MRI without any anesthesia on a mock scanner"
79359977|NCT06018519|Other|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
79359978|NCT06018519|Other|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
79359979|NCT06018519|Other|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
79510729|NCT00974376|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
79359980|NCT06018519|Other|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
79359981|NCT06018519|Other|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
79359982|NCT06018519|Other|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
79359983|NCT06018519|Other|3T MRI|37- Structural, metabolic and functional data
79359984|NCT06018519|Other|Cardiac assessments|"38- ECG~39- Ultrasound"
79359985|NCT06018519|Other|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
79359986|NCT06018506|Drug|BR108 injection|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
79359987|NCT06018454|Other|Handout on PGT-A|Educational handout on PGT-A
79359988|NCT06018454|Other|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
79510730|NCT00976248|Drug|RAD001|Taken orally once a day
79510731|NCT00976404|Biological|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
79510732|NCT00976404|Drug|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
79359989|NCT06018363|Biological|Allogenic B7H3 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10^7 cells) , dose 2 (3 × 10^7 cells), dose 3 (1× 10^8 cells); Phase 2 : dose of RP2D.
79359990|NCT06018285|Behavioral|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
79359991|NCT06018259|Procedure|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
79359992|NCT06018246|Dietary Supplement|Malnutrition five-step treatment model + conventional nutritional intervention|"Before operation：Same as arm description.~After operation:Same as control group.~Out-of-hospital: Same as before operation.~Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
79510733|NCT00976404|Drug|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
79510734|NCT00977184|Procedure|50 HZ Repetitive TMS|
79510735|NCT00977184|Procedure|Sham rTMS|
79510736|NCT00977808|Device|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
79510737|NCT00977808|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
79510738|NCT00981474|Drug|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
79510739|NCT00981474|Device|Control group|Institutional standard of care.
79510740|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
79510741|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
79510742|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
79670540|NCT04589754|Drug|Adriamycin-based chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
79992692|NCT03629496|Other|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
79992693|NCT05762406|Device|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
79992694|NCT05761704|Drug|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
79992695|NCT05761704|Drug|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
79992696|NCT05205798|Behavioral|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
79992697|NCT05205798|Behavioral|Washout period|No interventional food consumption for 1 week
79992698|NCT05205798|Behavioral|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
79992699|NCT01060670|Device|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
79992700|NCT01060670|Other|Conventional Wound Therapy|Conventional Wound Therapy
79992701|NCT05205642|Device|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
79992702|NCT05205642|Device|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
79992703|NCT05205642|Diagnostic Test|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R&D company, and for measurement 1 cc of serum will be needed.
79992704|NCT03652142|Other|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
79992705|NCT03652142|Drug|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
79992706|NCT01176578|Other|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
79371022|NCT03031600|Diagnostic Test|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
79819467|NCT04111835|Diagnostic Test|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
79819468|NCT04101331|Drug|AFM13|weekly intravenous infusions of 200mg
79819469|NCT04091048|Device|Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)|Aortic valve replacement
79819470|NCT04090060|Behavioral|Practice Self-/Companion Exams|300 men and 50 couples will be randomized and encouraged to practice anal exams at home before Visit 2. Practice results will be elicited by staff. They will return for Visit 2 (six months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam at home, they will record the results. At the clinic, they will have a Digital Anal Rectal Exam (DARE) by a clinician who will give the subject his results.
79819471|NCT04090060|Behavioral|Control Arm|300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (six months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam at home, and record the results. At the clinic, they will receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
79992707|NCT02971670|Biological|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
79992708|NCT04629378|Drug|Meropenem Injection|Meropenem IV 6 grams
79992709|NCT04629378|Drug|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
79992710|NCT04629378|Drug|Pyrazinamide|Pyrazinamide 20-30mg/kg
79819472|NCT04079218|Drug|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
79992711|NCT04629378|Drug|Bedaquiline|Bedaquiline 400mg
79992712|NCT04629378|Drug|Rifafour|Rifafour (HRZE) Standard dose
79371023|NCT00949078|Drug|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
79670541|NCT04585789|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
79992713|NCT04615806|Drug|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
79992714|NCT03651674|Device|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
79992715|NCT03651674|Drug|Drug treatment|Patients only have antipsychotic drugs
79992716|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
79992717|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
79992718|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
79992719|NCT01569906|Radiation|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
79371024|NCT00945256|Other|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
79992720|NCT03651440|Other|PNF|PNF
79670542|NCT04585789|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
79670543|NCT04585789|Drug|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
79670544|NCT04585789|Drug|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
79670545|NCT04585789|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
79670546|NCT04585789|Drug|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
79819473|NCT04074343|Drug|TAS-102|Given PO
79819474|NCT04074343|Drug|Irinotecan|Given IV
79819475|NCT04051502|Drug|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
79992721|NCT03651440|Other|lumbar stabilization training|lumbar stabilization training
79992722|NCT03651440|Other|Physical Therapy|Physical Therapy
79992723|NCT03651440|Other|Control|Control group
79510743|NCT00981630|Biological|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
79992724|NCT02971202|Drug|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
79992725|NCT02971202|Drug|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
79992726|NCT05761548|Diagnostic Test|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
79670547|NCT04585763|Device|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
79670548|NCT04581512|Drug|EP0042|EP0042 Oral 20 mg 50 mg capsules
79510744|NCT00983346|Drug|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
79992727|NCT00702494|Biological|TB-403|Multiple IV
79992728|NCT02926638|Drug|Erlotinib Hydrochloride|Given PO
79371025|NCT00945256|Drug|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
79670549|NCT04581473|Drug|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
79992729|NCT02926638|Other|Laboratory Biomarker Analysis|Correlative studies
79510745|NCT00985140|Radiation|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
79510746|NCT00986856|Drug|Fucidin® cream|
79670550|NCT04581473|Drug|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
79371026|NCT00945256|Dietary Supplement|Amino Acid Drink|7.5 gram Amino Acid drink
79371027|NCT00940576|Dietary Supplement|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
79371028|NCT00940576|Other|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
79371029|NCT05354752|Drug|VC005 tablets|VC005 groups repeat administration for 7 days
79371030|NCT05354752|Drug|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
79670551|NCT04572165|Drug|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79819476|NCT04051502|Drug|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~Dorsal side of the IP ligament~Ventral side of the IP ligament~Dorsal side of the utero-ovarian ligament~Ventral side of the utero-ovarian ligament"
79992730|NCT02926638|Biological|Rilotumumab|Given IV
79992731|NCT00641420|Procedure|Fractionated Laser Resurfacing|
79510747|NCT00987480|Drug|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
79510748|NCT00987480|Device|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
79992732|NCT03651596|Behavioral|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
79992733|NCT03651596|Behavioral|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
79992734|NCT03650582|Drug|Glucagon|Intranasal glucagon
79992735|NCT03650582|Drug|Placebo|Intranasal placebo
79510749|NCT00987558|Drug|Eslicarbazepine acetate|
79510750|NCT00987558|Drug|Simvastatin|
79371031|NCT03854032|Biological|Nivolumab|Given IV
79371032|NCT03854032|Biological|IDO1 Inhibitor BMS-986205|Given PO
79371033|NCT03854032|Procedure|Therapeutic Conventional Surgery|Undergo Surgery
79510751|NCT00987948|Drug|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
79510752|NCT00989586|Biological|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
79371034|NCT03854032|Other|Questionnaire Administration|Ancillary studies
79670552|NCT04572165|Drug|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79670553|NCT04572165|Drug|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79670554|NCT04567602|Drug|PAH medication|There will be no specific interventions.
79992736|NCT02903030|Drug|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
79992737|NCT02903030|Drug|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
79992738|NCT03650504|Procedure|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
79371035|NCT02982226|Other|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
79371036|NCT02982226|Other|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
79371037|NCT03031288|Device|A|standard bottle
79670556|NCT04563871|Drug|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
79992739|NCT03650504|Procedure|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
79992740|NCT03650426|Procedure|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
79992741|NCT03650426|Procedure|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
79992742|NCT02969408|Drug|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
79510753|NCT00989586|Biological|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
79510754|NCT00989586|Procedure|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
79510755|NCT00989586|Procedure|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
79359993|NCT06018246|Other|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
79670557|NCT04563325|Drug|Oral co-amoxiclav or oral dicloxacillin only|High dose oral treatment followed by standard dose oral treatment
79992743|NCT03462563|Device|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
79992744|NCT03462563|Device|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
79992745|NCT03716453|Procedure|Standard protocol|Give narcotic according to vital signs
79371038|NCT03031288|Device|B|vented base bottle
79670558|NCT04563325|Drug|IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin|IV treatment followed by standard dose oral treatment
79992746|NCT03716453|Procedure|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score > 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score < 50 indicates inadequate narcotic and narcotic should be given."
79670559|NCT04559815|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79670560|NCT04547192|Other|Improving initial care of the injured|Improvement in Care Processes
79819477|NCT04051502|Drug|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
79992747|NCT05180214|Drug|Bupivacain|analgesic
79992748|NCT05180214|Drug|Ketorolac|analgesia
79992749|NCT01060124|Drug|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
79992750|NCT03461003|Other|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
79371039|NCT03031522|Radiation|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
79371040|NCT03031444|Drug|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
79992751|NCT03461003|Other|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
79992752|NCT03461003|Drug|Amlodipine|Calcium-channel blocker; antihypertensive
79992753|NCT03461003|Drug|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
79992754|NCT03461003|Drug|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
79992755|NCT03461003|Drug|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
79359994|NCT06018207|Drug|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 4mg; (3) If not succeed, the second subject takes 8mg; (4) Until seven sequence reversal inflection points."
79992756|NCT05177172|Other|High beta glucans|higher dose betaglucans
79359995|NCT06018181|Drug|Shuxuetong Injection|According to clinical real treatment records
79359996|NCT06018090|Other|The presence and rate of MES measured by TCD monitoring|TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
79359997|NCT06018077|Behavioral|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
79359998|NCT06018025|Drug|CGRP antibody|treatment with CGRP antibody for 4 months
79359999|NCT06017986|Other|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
79360000|NCT06017986|Other|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
79510756|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
79510757|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
79992757|NCT05177172|Other|Low beta glucans|lower dose beta glucans
79360001|NCT06017986|Other|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
79360002|NCT06017986|Other|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
79360003|NCT06017986|Other|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
79360004|NCT06017986|Other|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
79360005|NCT06017921|Drug|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
79360006|NCT06017921|Drug|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
79360007|NCT06017830|Device|Physical treatment agents|Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
79371041|NCT03031444|Drug|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
79992758|NCT05177172|Other|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
79992759|NCT05177172|Other|Polar lipids|low dose polar lipids
79992760|NCT05177172|Other|Control|No beta glucans or polar lipids
79992761|NCT03650348|Drug|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
79992762|NCT05761470|Drug|Camrelizumab|"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."
79992763|NCT05761470|Drug|Fluzoparib|Fluzoparib
79992764|NCT05761470|Drug|Nab-paclitaxel|Nab-paclitaxel
79819478|NCT04051502|Drug|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
79992765|NCT01372293|Drug|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
79992766|NCT05205096|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
79992767|NCT05759598|Other|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
79992768|NCT05759598|Other|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
79992769|NCT02904902|Drug|adalimumab|Subcutaneous Injection
79992770|NCT03650270|Drug|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
79360008|NCT06017778|Device|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
79360009|NCT06017778|Other|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
79360010|NCT06017752|Behavioral|STAC Teacher Module|"The STAC Teacher Module is a 30-minute presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies teachers can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
79360011|NCT06017726|Other|treatment of insulin resistance with appropriate modality according to each patient|insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
79360012|NCT06017700|Behavioral|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
79360013|NCT06017700|Behavioral|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
79510758|NCT00989586|Procedure|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
79510759|NCT00989586|Biological|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
79819479|NCT04047602|Radiation|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
79819480|NCT04035850|Drug|Vortioxetine Tablets|Strength 5-20 mg
79819481|NCT04031560|Behavioral|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
79992771|NCT03621722|Other|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
79992772|NCT04425720|Device|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX* and a pulse oximeter.
79992773|NCT04425720|Other|Standard of Care|This group will be treated based on standard of care at our institution.
79992774|NCT03649568|Other|Pork|1 oz lean pork
79992775|NCT03649568|Other|Egg|1 large whole egg
79992776|NCT03649568|Other|Black beans|0.5 cups cooked black beans
79992777|NCT03649568|Other|Almonds|1 oz almonds
79510760|NCT00990288|Drug|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
79510761|NCT00991458|Drug|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
79510762|NCT00991458|Drug|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
79510763|NCT00991458|Drug|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
79510764|NCT00993798|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
79510765|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
79510766|NCT00993798|Drug|Bupivacaine HCl Treatment 1c|20.0 ml
79510767|NCT00993798|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
79670561|NCT04543903|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79670562|NCT04540692|Drug|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
79819482|NCT04029480|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
79819483|NCT04029480|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
79360014|NCT06017674|Procedure|Intra-articular Pulsed Radiofrequency|A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
79360015|NCT06017674|Drug|Steroid Injection|8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
79360016|NCT06017661|Dietary Supplement|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
79510768|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
79360017|NCT06017661|Dietary Supplement|Nutridrink Skin Repair|2 times a day
79819484|NCT04029480|Drug|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
79819485|NCT04029480|Drug|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
79819486|NCT04029480|Biological|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
79819487|NCT04029480|Drug|Metformin|Participants will receive stable dose of background metformin.
79360018|NCT06017648|Device|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
79510769|NCT00993798|Drug|Bupivacaine HCl Treatment 2c|20.0 ml
79510770|NCT00995904|Drug|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
79510771|NCT00995904|Drug|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
79510772|NCT00995904|Drug|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
79670563|NCT04540692|Drug|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
79670564|NCT04537039|Diagnostic Test|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
79360019|NCT06017648|Device|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
79360020|NCT06017635|Other|Exposure factors|"General information Name, gender, age, weight (kg), major diseases~Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge."
79360021|NCT06017609|Drug|JTT-861 Capsules|Active drug capsules containing JTT-861
79510773|NCT00996372|Drug|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
79510774|NCT00996372|Drug|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
79510775|NCT00997620|Drug|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
79670565|NCT04532372|Other|Best Practice|Receive standard of care drugs
79670566|NCT04532372|Drug|Leflunomide|Given PO
79670567|NCT04532372|Drug|Placebo Administration|Given PO
79819488|NCT04029181|Other|Anti-CD8 PET imaging agent|An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
79819489|NCT04019444|Biological|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
79819490|NCT04019444|Other|Placebo|0.9% Sodium Chloride, USP injection.
79510776|NCT00997620|Drug|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
79670568|NCT04532307|Behavioral|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
79819491|NCT04019444|Biological|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
79360022|NCT06017609|Drug|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
79360023|NCT06017596|Device|PEEK framework|All-on-4 implants with PEEK framework of fixed detachable prosthesis
79360024|NCT06017492|Behavioral|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
79360025|NCT06017466|Diagnostic Test|Visual Vertigo Analogue Scale (VVAS)|The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
79360026|NCT06017375|Other|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
79360027|NCT06017349|Device|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
79371042|NCT05320042|Device|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
79510777|NCT00997932|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
79670569|NCT04532307|Behavioral|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
79819492|NCT03997240|Procedure|Chiropractic Applied Clinical Neuroscience|Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
79819493|NCT03989336|Drug|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
79819494|NCT03989336|Drug|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
79819495|NCT03989336|Drug|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve [AUC] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
79992778|NCT03629574|Procedure|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
79819496|NCT03989336|Drug|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
79992779|NCT05204628|Drug|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
79992780|NCT05204628|Drug|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
79360028|NCT06017349|Device|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
79360029|NCT06017349|Device|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
79360030|NCT06017310|Diagnostic Test|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
79360031|NCT06017271|Diagnostic Test|CTPA (computed tomography pulmonary angiography)|The CTPA diagnosis suggest or did not suggest pulmonary embolism.
79371043|NCT05320042|Device|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
79371044|NCT02982304|Device|Deep Brain Stimulation|Deep Brain Stimulation Electrode
79819497|NCT03974113|Drug|Fitusiran|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
79992781|NCT05285072|Radiation|PET-CT scan|PET-CT scan using 68Ga-DFO
79992782|NCT05204394|Drug|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
79510778|NCT00998010|Drug|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
79510779|NCT00999102|Drug|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
79670570|NCT04532307|Behavioral|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
79670571|NCT04532307|Behavioral|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
79670572|NCT04514510|Drug|Isoquercetin|"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."
79670573|NCT04514510|Drug|Placebo|"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."
79670574|NCT04514497|Procedure|Biopsy|Undergo tumor biopsy
79670575|NCT04514497|Procedure|Biospecimen Collection|Undergo collection of blood samples
79670576|NCT04514497|Procedure|Computed Tomography|Undergo CT
79670577|NCT04514497|Drug|Elimusertib|Given PO
79670578|NCT04514497|Drug|Irinotecan Hydrochloride|Given IV
79670579|NCT04514497|Procedure|Magnetic Resonance Imaging|Undergo MRI
79992783|NCT05204394|Other|Standard of Care|Any oral 1st line approved HIV treatment regimen
79992784|NCT03650972|Other|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
79992785|NCT05065398|Drug|HLX208|450mg bid, take orally
79992786|NCT02904512|Device|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
79510780|NCT00999102|Drug|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
79510781|NCT01000662|Radiation|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
79670580|NCT04514497|Drug|Topotecan Hydrochloride|Given IV
79670581|NCT04509752|Other|Survey|An online survey will be sent to each clinic to answer the survey questions.
79670582|NCT04507854|Other|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
79670583|NCT04505956|Device|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
79670584|NCT04505956|Device|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
79670585|NCT04502576|Device|Noninvasive respiratory support|"In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit"
79670586|NCT04496219|Device|Acupuncture Therapy|Undergo acupuncture therapy
79510782|NCT01000662|Radiation|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
79510783|NCT01000818|Drug|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
79510784|NCT01000818|Drug|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
79670587|NCT04496219|Biological|BCG Solution|Given by intravesical injection
79670588|NCT04496219|Other|Best Practice|Receive standard of care symptom management
79670589|NCT04496219|Other|Quality-of-Life Assessment|Ancillary studies
79360032|NCT06017232|Other|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
79360033|NCT06017167|Drug|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
79510785|NCT01000818|Drug|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
79510786|NCT01001052|Drug|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
79510787|NCT01001442|Drug|BT062|intravenous administration
79510788|NCT01002456|Other|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
79510789|NCT01002456|Other|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
79510790|NCT01003080|Device|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
79510791|NCT01003080|Other|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
79510792|NCT01003938|Drug|Topotecan|
79670590|NCT04496219|Other|Questionnaire Administration|Ancillary studies
79670591|NCT04494412|Drug|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
79670592|NCT04482556|Device|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
79670593|NCT04482556|Device|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
79670594|NCT04464993|Behavioral|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
79819498|NCT03962335|Behavioral|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
79819499|NCT03962335|Behavioral|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
79360034|NCT06017167|Drug|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
79371045|NCT02980198|Biological|IFN-Kinoid|IM administration
79371046|NCT02980198|Other|Placebo|IM administration
79510793|NCT01003938|Drug|Erlotinib|
79510794|NCT01004718|Radiation|Fludeoxyglucose F18|Undergo FDG PET/CT scans
79510795|NCT01004718|Procedure|Computed Tomography|Undergo FDG PET/CT scans
79510796|NCT01004718|Procedure|Positron emission tomography|Undergo FDG PET/CT scans
79819500|NCT03962335|Behavioral|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
79819501|NCT03942653|Drug|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
79819502|NCT03942653|Drug|Pembrolizumab|Pembrolizumab, IV, Q3W
79992787|NCT02904512|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
79819503|NCT03924661|Device|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
79360035|NCT06017154|Other|Motor-Cognitive Training Program|The training will incorporate cognitive tasks which focus on reaction time, processing speed, working memory, cognitive flexibility, and inhibitory control using visual stimuli on a screen or through sensors which illuminate using LED lights. These cognitive tasks will be performed while also executing physical performance tasks that challenge static and dynamic postural stability, lateral movement, agility, and other movement patterns. The training session will last approximately 30 minutes and participants will complete up to 5 exercises
79992788|NCT05065008|Other|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
79992789|NCT05065008|Other|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
79360036|NCT06017141|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
79360037|NCT06017141|Other|Electronic Health Record Review|Ancillary studies
79360038|NCT06017141|Drug|Fentanyl Citrate|Given via injection
79360039|NCT06017141|Drug|Propofol|Given IV
79360040|NCT06017141|Other|Questionnaire Administration|Ancillary studies
79360041|NCT06017141|Drug|Sevoflurane|Given via inhalation
79360042|NCT06017141|Procedure|Surgical Procedure|Undergo SOC surgery
79360043|NCT06017076|Other|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
79360044|NCT06017076|Device|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
79360045|NCT06017063|Other|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
79819504|NCT03918447|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
79360048|NCT06017037|Drug|Citalopram 20mg|Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
79360049|NCT06017037|Drug|Placebo|Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
79360050|NCT06017024|Device|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
79819505|NCT03918447|Drug|Placebo oral capsule|Capsule containing an inert placebo
79360051|NCT06016985|Dietary Supplement|caffeine gum|This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
79360052|NCT06016933|Drug|spirulina gel|Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
79360053|NCT06016933|Procedure|SRP of all teeth|Patients received oral hygiene instructions and SRP of all teeth.
79360054|NCT06016894|Procedure|coronally advanced flap|coronally advanced flap operation
79360055|NCT06016894|Other|Nanocrystalline hydroxyapatite loaded in PRF|Nanocrystalline hydroxyapatite loaded in PRF
79819506|NCT03911973|Drug|Gedatolisib|Gedatolisib, 150-180MG IV
79819507|NCT03911973|Drug|Talazoparib|.75-1.00mg
79992790|NCT03713333|Diagnostic Test|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~Handheld imaging - focused echocardiographic examination (Butterfly IQ)~Smartphone iECG for cardiac rhythm assessments (Alivecor)~Blood Pressure (CloudDX)~Oxygen Saturation (CloudDX)~Weight (CloudDX)~Point-of-Care Genetic Testing (Phosphorous)"
79992791|NCT05031624|Drug|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
79360056|NCT06016894|Other|Nanocrystalline tricalcium phosphate loaded in PRF|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF
79360057|NCT06016868|Procedure|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
79371047|NCT02980198|Other|ISA 51|adjuvant
79992792|NCT05031624|Drug|Normal saline|Single subcutaneous dose of normal saline
79992793|NCT03650738|Drug|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
79819508|NCT03898986|Biological|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
79992794|NCT04053530|Other|restorative materials|glass ionomer and bulk fill flowable composite
79360058|NCT06016868|Procedure|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
79360059|NCT06016855|Procedure|Tumor Debulking|Undergo surgical debulking
79360060|NCT06016855|Drug|Lutetium Lu 177 Dotatate|Given by IV
79360061|NCT06016855|Procedure|Computed Tomography|Undergo Computed Tomography
79360062|NCT06016855|Procedure|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
79360063|NCT06016855|Drug|Copper Cu 64 Dotatate|Given by IV
79360064|NCT06016855|Procedure|Positron Emission Tomography|Undergo Positron Emission Tomography
79360065|NCT06016803|Device|Cicatryl (RL3010A - DP0378)|Tested product is applied twice a day. The maximum duration of application is 7 days.
79360066|NCT06016699|Other|blood draws|Blood draws to collect PBMCs at baseline (week 0), during (chemo)radiation treatment (end of week 3 and/or before delivery of cycle 4 of cisplatin) and after conclusion of (chemo)radiation (week 9, week 12, week 20, week 34 and week 60, respectively 1 week, 5 weeks, 3 months, 6 months and 12 months after completion of (chemo)radiation) in order to compare immunological function upon treatment with either protons or photons
79360067|NCT06016660|Other|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
79670595|NCT04464993|Behavioral|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
79360068|NCT06016647|Other|Musculoskeletal-specific WSIB programs of care|Clinicians within this network provide care under a standardized framework that limits confounding from different interventions and the researchers will not manipulate treatment decisions.
79371048|NCT05258734|Other|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
79371049|NCT05258734|Other|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
79670596|NCT04464993|Behavioral|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
79819509|NCT03898986|Biological|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
79992795|NCT02904200|Device|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
79992796|NCT02904200|Device|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
79992797|NCT03432533|Drug|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
79360069|NCT06015581|Behavioral|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
79360070|NCT06015581|Behavioral|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
79360071|NCT06014918|Device|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
79360072|NCT06014372|Drug|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
79360073|NCT06014372|Drug|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
79360074|NCT06013254|Dietary Supplement|sour liquid|applying lemon juice
79360075|NCT06012227|Dietary Supplement|kent'erbas cheese study|"Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming"
79360076|NCT06011330|Drug|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
79360077|NCT06011213|Behavioral|Information notification based on the health warning system for heat waves and cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the intervention group will be alerted to the early warning information through the Wechat Mini Programme.
79360078|NCT06011213|Device|The electrocardiography(ECG) and blood pressure monitoring|The electrocardiography (ECG) and blood pressure indicators will be monitored every day during the study period in the intervention group and monitoring group, respectively.
79360079|NCT06011018|Other|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
79992798|NCT03432533|Device|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
79992799|NCT03621800|Other|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
79360080|NCT06011018|Other|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
79360081|NCT06011018|Other|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (mozart's clarinex concerto in A major K622), with Alpha (8Hz) binaural beat stimulation
79992800|NCT05285462|Behavioral|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
79992801|NCT05285462|Behavioral|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
79992802|NCT03649334|Drug|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
79510797|NCT01005576|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
79510798|NCT01005810|Drug|N-Acetylcysteine|1200 mg twice daily for 8 weeks
79510799|NCT01005810|Drug|placebo|2 capsules twice daily for 8 weeks
79360082|NCT06010589|Drug|DWJ1558|DWJ1558
79360083|NCT06010589|Drug|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
79360084|NCT06007391|Drug|Nicotinamide|nicotinamide 3g per day
79360085|NCT06006403|Biological|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
79510800|NCT01005810|Behavioral|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
79510801|NCT01005888|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
79510802|NCT01005888|Drug|Placebo (saline)|
79360086|NCT06002945|Other|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
79360087|NCT05997563|Drug|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
79360088|NCT05995548|Other|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
79510803|NCT01007136|Device|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
79360089|NCT05990452|Drug|9MW2921|All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
79371050|NCT02980432|Other|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
79371051|NCT03031132|Behavioral|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
79371052|NCT03031132|Behavioral|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
79510804|NCT01007136|Device|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
79510805|NCT01007526|Other|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
79819510|NCT03892824|Device|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
79992803|NCT03649334|Drug|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
79819511|NCT03879434|Device|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
79819512|NCT03857477|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
79819513|NCT03857477|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
79819514|NCT03857477|Procedure|MRI Scan|MRI scan will be offered to men identified within the top 10% genetic risk score profile.
79819515|NCT03857477|Procedure|Prostate biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
79819516|NCT03856060|Other|Questionnaire Administration|Complete questionnaires
79819517|NCT03856060|Other|Video|Watch videos of doctor and patient interaction in different settings
79819518|NCT03834519|Biological|Pembrolizumab|IV infusion
79371053|NCT03031132|Behavioral|Breakfast Skipping|Participants will skip breakfast each morning.
79371054|NCT03031054|Procedure|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
79819519|NCT03834519|Drug|Olaparib|Oral tablets
79819520|NCT03834519|Drug|Abiraterone acetate|Oral tablets
79819521|NCT03834519|Drug|Prednisone|Oral tablets
79819522|NCT03834519|Drug|Enzalutamide|Oral tablets or oral capsules
79819523|NCT03834519|Drug|Prednisolone|Oral tablets
79819524|NCT03833934|Diagnostic Test|Plasma Next Generation Sequencing (NGS)|Liquid biospys
79819525|NCT03817931|Drug|Anticholinergic|Tablet taken once daily.
79819526|NCT03817931|Drug|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
79819527|NCT03817931|Diagnostic Test|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
79819528|NCT03817931|Diagnostic Test|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
79819529|NCT03810807|Drug|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
79819530|NCT03810807|Drug|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
79819531|NCT03809962|Device|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
79819532|NCT03809286|Device|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
79819533|NCT03809286|Behavioral|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
79819534|NCT03809286|Device|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
79992804|NCT02901548|Drug|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
79510806|NCT01007994|Drug|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril < 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine < 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol <40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg"
79510807|NCT01008462|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
79510808|NCT01008462|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
79510809|NCT01008462|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
79510810|NCT01008462|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
79510811|NCT01008462|Drug|Carmustine|Given IV
79510812|NCT01008462|Drug|Cyclophosphamide|Given IV
79510813|NCT01008462|Drug|Cytarabine|Given IV
79371055|NCT03031054|Procedure|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
79510814|NCT01008462|Drug|Etoposide|Given IV
79670597|NCT04464993|Behavioral|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a >5 min continuous bout of exercise (as defined by Fitbit minutes >4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
79371056|NCT03031366|Other|3d roadmap guidance|TIPS was established using 3d roadmap
79819535|NCT03808662|Radiation|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x [1 + d/(α/β)] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
79819536|NCT03808662|Drug|Standard of care|Standard of care per physician discretion
79510815|NCT01008462|Drug|Fludarabine Phosphate|Given IV
79510816|NCT01008462|Other|Laboratory Biomarker Analysis|Correlative study
79510817|NCT01008462|Drug|Melphalan|Given IV
79510818|NCT01008462|Drug|Mycophenolate Mofetil|Given PO
79510819|NCT01008462|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
79510820|NCT01008462|Drug|Tacrolimus|Given IV or PO
79510821|NCT01008462|Radiation|Total-Body Irradiation|Undergo TBI
79371057|NCT03031366|Other|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
79371058|NCT00945334|Drug|Neomycin|500 mg po bid for 14 days
79510822|NCT01010568|Drug|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
79510823|NCT01011816|Biological|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
79510824|NCT01011816|Drug|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
79371059|NCT00945334|Drug|Placebo|placebo for 14 days tid
79371060|NCT00945334|Drug|Rifaximin|550 mg po tid
79371061|NCT00087789|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10^10 vg, CERE-110 1.0 x 10^11 vg, CERE-110 2.0 x 10^11 vg
79510825|NCT01011894|Drug|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
79510826|NCT01012362|Drug|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
79510827|NCT01012362|Drug|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
79670600|NCT04443907|Biological|OTQ923|Single intravenous infusion of OTQ923 cell suspension
79670601|NCT04443907|Biological|OTQ923|Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
79510828|NCT01012674|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
79371062|NCT03578224|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
79510829|NCT01012674|Other|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
79670602|NCT04439123|Drug|Capivasertib|Given PO
79670603|NCT04434729|Device|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
79819537|NCT03808337|Radiation|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
79819538|NCT03808337|Drug|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
79819539|NCT03808077|Drug|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
79819540|NCT03808077|Drug|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
79819541|NCT03798678|Drug|Carfilzomib|Given IV
79819542|NCT03798678|Drug|Dexamethasone|Given PO
79992805|NCT02901548|Procedure|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
79510830|NCT01013844|Behavioral|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter > or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
79510831|NCT00986544|Procedure|no drain|drain positioned on the skin
79670604|NCT04429542|Drug|BCA101|EGFR/TGFβ fusion monoclonal antibody
79670605|NCT04429542|Drug|Pembrolizumab|anti-PD-1
79670606|NCT04418154|Drug|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
79819543|NCT03798678|Drug|Telaglenastat Hydrochloride|Given PO
79992806|NCT03649256|Diagnostic Test|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
79992807|NCT04053374|Other|Blood sampling|Blood sampling +/- CSF sampling
79992808|NCT03650660|Other|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
79371063|NCT03578224|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
79371064|NCT03578224|Procedure|Fine-Needle Aspiration|Undergo FNA
79371065|NCT03578224|Drug|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
79371066|NCT03559114|Drug|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
79371067|NCT03559114|Drug|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
79371068|NCT03492021|Other|Diet Intervention_AP-CPT|Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
79510832|NCT00986544|Procedure|drain positioned|drain positioned in the subhepatic space
79510833|NCT00986544|Procedure|drain not positioned|Drain positioned in the abdominal wall
79992809|NCT02903966|Drug|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
79992810|NCT02903966|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
79992811|NCT03457727|Drug|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
79992812|NCT03457727|Drug|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
79992813|NCT03647618|Other|Ultrasound|Ultrasound-guided regional anaesthesia
79360090|NCT05980572|Drug|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
79992814|NCT03431441|Device|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
79360091|NCT05980572|Device|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
79360092|NCT05980572|Drug|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
79371069|NCT03492021|Other|Diet Intervention_PP-PPT|Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
79510834|NCT01014390|Device|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
79510835|NCT01015170|Drug|bupropion HCl|150mg BID for up to 8 weeks + counseling
79510836|NCT01015326|Other|Questionnaire|Administered questionnaire
79992815|NCT03648554|Drug|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
79670607|NCT04418154|Drug|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
79510837|NCT01015326|Other|Questionnaire|Administered questionnaire
79670608|NCT04418154|Drug|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
79670609|NCT04418154|Drug|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
79992816|NCT03648554|Other|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
79992817|NCT03457103|Device|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
79992818|NCT03457103|Device|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
79992819|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
79992820|NCT03648320|Other|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
79992821|NCT05284994|Drug|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
79510838|NCT01016106|Genetic|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
79510839|NCT01016652|Device|etafilcon A multifocal contact lens|low-add multifocal contact lens
79510840|NCT01016652|Device|etafilcon A Contact Lens|standard sphere contact lens
79510841|NCT01017042|Drug|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
79510842|NCT01018056|Drug|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
79670610|NCT04404985|Procedure|Surgical AVF|"Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure."
79670611|NCT04404985|Procedure|Endo-vascular AVF|Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
79992822|NCT03649100|Procedure|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
79992823|NCT03649022|Device|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
79992824|NCT04053296|Other|Observational study|We follow up the results of patients.
79992825|NCT03648944|Other|Accelerated Rehabillitation|
79992826|NCT03648944|Other|Non-Accelerated Rehabillitation|
79992827|NCT03455543|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
79360093|NCT05980182|Behavioral|mHealth Application|Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
79360094|NCT05978570|Other|A personally tailored exercise program|A personally tailored exercise program will be offered to the participants after Physical Therapy assessment, before the surgery.
79992828|NCT03455543|Device|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
79360095|NCT05975515|Procedure|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
79510843|NCT01018056|Drug|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
79360096|NCT05967585|Device|Behavioral: Quitting Program (TIQ)|"Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support."
79510844|NCT01018056|Drug|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
79670614|NCT04389294|Diagnostic Test|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
79670615|NCT04388163|Drug|Gentian Violet|Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
79819544|NCT03795818|Behavioral|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
79819545|NCT03788811|Device|ERG assessment (RSPA)|Processing and analysis of retinal signals
79360097|NCT05964673|Device|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
79510845|NCT01018134|Drug|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
79360098|NCT05964153|Diagnostic Test|Liquid Biopsy|Analysis of the circulating free DNA in blood patients affected by gliomas
79360099|NCT05961046|Device|Vivity IOL|Vivity IOL
79360100|NCT05954988|Drug|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
79510846|NCT01018134|Drug|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
79510847|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
79510848|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
79510849|NCT01018134|Drug|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
79670616|NCT04384341|Radiation|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
79670617|NCT04384341|Biological|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
79670618|NCT04381117|Drug|Previously Treated with EN3835|No treatment to be administered - Observational only
79819546|NCT03773367|Drug|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
79819547|NCT03773367|Drug|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
79819548|NCT03773367|Drug|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
79819549|NCT03749447|Drug|Bardoxolone methyl|Bardoxolone methyl capsules
79819550|NCT03745924|Drug|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
79510850|NCT01018134|Drug|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
79510851|NCT01019928|Drug|AZD1386|95 mg, oral solution, single dose
79510852|NCT01019928|Drug|Placebo to AZD1386|Placebo, oral solution, single dose
79510853|NCT01020006|Drug|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated."
79510854|NCT01020006|Drug|Gemcitabine|
79670619|NCT04367116|Procedure|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
79360101|NCT05954988|Drug|Placebo|Matching placebo
79360102|NCT05946161|Behavioral|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
79360103|NCT05936645|Procedure|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
79510855|NCT05395962|Drug|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
79510856|NCT05395962|Drug|Bleomycin|treatment with bleomycin in association with electroporation
79510857|NCT05395728|Other|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
79510858|NCT05395728|Other|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
79510859|NCT05395572|Device|Kinesio® Tape|In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
79510860|NCT05394480|Diagnostic Test|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
79510861|NCT05394090|Diagnostic Test|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
79510862|NCT05391048|Drug|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
79670620|NCT04361825|Drug|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects > 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
79670621|NCT04345913|Procedure|Biopsy|Undergo biopsy
79670622|NCT04345913|Procedure|Biospecimen Collection|Undergo blood sample collection
79670623|NCT04345913|Procedure|Computed Tomography|Undergo CT scan
79510863|NCT05391048|Drug|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
79510864|NCT05387538|Procedure|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
79670624|NCT04345913|Drug|Copanlisib Hydrochloride|Given IV
79670625|NCT04345913|Drug|Eribulin Mesylate|Given IV
79670626|NCT04345913|Procedure|Magnetic Resonance Imaging|Undergo MRI
79670627|NCT04345601|Biological|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.
79670628|NCT04345601|Other|Supportive Care|Patients will receive supportive care per their treating physician
79670629|NCT04344470|Device|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
79992829|NCT03648242|Behavioral|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~One-click addition of elevated BMI to problem list~Reminder to utilize Suggested PowerPlan~One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~Links to existing, evidence-based childhood obesity screening and management guidelines"
79992830|NCT03068754|Drug|Acthar|Repository corticotropin for subcutaneous injection
79670630|NCT04344470|Device|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
79670631|NCT04341246|Device|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
79670632|NCT04337554|Device|Exoskeleton footwear|Assistive footwear
79670633|NCT04330313|Procedure|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
79670634|NCT04330313|Procedure|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
79992831|NCT03068754|Drug|Placebo|Matching placebo for subcutaneous injection
79992832|NCT02965820|Device|Opti-Free® PureMoist® contact lens solution|
79670635|NCT04330313|Procedure|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
79670636|NCT04330313|Procedure|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
79670639|NCT04322708|Other|Placebo|Placebo
79670640|NCT04322708|Drug|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
79670641|NCT04322604|Drug|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
79670642|NCT04322604|Other|Placebo|Placebo
79819551|NCT03736889|Drug|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
79819552|NCT03736226|Device|SYNERGYTM Stent System|no intervention design in the study
79819553|NCT03734315|Device|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
79510865|NCT05387538|Procedure|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
79992833|NCT02965820|Device|Habitual Multi-Purpose Contact Lens Solution|
79510866|NCT05017584|Drug|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
79510867|NCT05010096|Drug|Copanlisib|Given IV
79510868|NCT05010096|Drug|Elimusertib|Given PO
79510869|NCT04403880|Other|Sample collection|"Optional nasal specimen(s)~Blood collection"
79510870|NCT04147416|Drug|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
79510871|NCT04147416|Drug|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
79670643|NCT04317807|Drug|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
79670644|NCT04317807|Other|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
79360104|NCT05936645|Procedure|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
79360105|NCT05936606|Drug|Clopidogrel monotherapy|Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
79360106|NCT05936606|Drug|Tailored anti-platelet therapy|In the tailored therapy arm, non-HPR (PRU<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
79992834|NCT02965820|Device|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
79992835|NCT03713099|Device|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
79360107|NCT05936086|Drug|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
79360108|NCT05936086|Drug|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
79360109|NCT05936086|Drug|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
79510872|NCT04129866|Behavioral|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
79510873|NCT04129866|Behavioral|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
79510874|NCT03984318|Procedure|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
79992836|NCT03716375|Drug|Intrapleural Medications|urokinase
79819554|NCT03726268|Drug|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients."
79819555|NCT03726268|Drug|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
79819556|NCT03726268|Drug|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
79819557|NCT03726268|Drug|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
79992837|NCT04021472|Behavioral|Text message|Two months of daily text messages to support meeting a health goal
79992838|NCT05203848|Procedure|Community Dance Intervention|The main dance instructor for the CDP is Yarra Ileto, who is the Artistic Director for NUS Dance Synergy. Yarra was trained at LASALLE College of the Arts, graduating with a First Class BA (Hons) Dance in 2008. Also, she has experience with crafting and conducting Community Dance Programs (CDP) for Seniors. Yarra will be developing the dance lesson plan and also training selected students from NUS Dance Synergy to guide the seniors during the dance sessions. Older adults will learn and practice the basic steps together for the first few weeks. Then, the student dance instructors will start teaching the dance formation. During each session, participants will need to warm up first to prevent injuries before practicing dance steps. Small group practicing is reserved for older adults to interact with each other. All the participants will do relaxation exercises before ending the session to cool down their bodies and release muscle tensions.
79510875|NCT03899532|Device|Remote Ischemic Conditioning|Standard manual blood pressure cuff
79510876|NCT03899532|Other|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
79510877|NCT03786042|Behavioral|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
79510878|NCT03786042|Other|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
79510879|NCT03767010|Other|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
79510880|NCT03767010|Other|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
79670646|NCT04284839|Drug|DOAC|Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
79670647|NCT04284839|Drug|VKA|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
79510881|NCT03660072|Other|Non-Interventional|Non-Interventional
79510882|NCT03554850|Device|Trevo® Retriever|Stent retriever procedure
79510883|NCT03178890|Device|OHMG|Device will be implanted in all enrolled patients.
79670648|NCT04283461|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
79992839|NCT05203848|Other|Control group|Control group
79992840|NCT03648164|Other|CHAT-CS Survey|Students will complete a computer-based survey
79819558|NCT03726268|Drug|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
79819559|NCT03719430|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
79819560|NCT03719430|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
79819561|NCT03695601|Other|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
79819562|NCT03693170|Drug|encorafenib|300 mg administered orally once daily (QD)
79819563|NCT03693170|Drug|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
79992841|NCT03430895|Drug|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
79670649|NCT04278560|Device|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
79992842|NCT03648086|Other|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
79992843|NCT03712709|Diagnostic Test|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
79992844|NCT04312386|Other|OPTIMAT|Baseline menue, not optimized
79360110|NCT05936086|Drug|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
79510884|NCT03125148|Device|Enteral stenting|Enteral stent for malignant duodenal obstruction
79360111|NCT05932511|Drug|30% ascorbic acid in DMSO|see above
79360112|NCT05927792|Device|repeated transcranial magnetic stimulation (continuous theta-burst stimulation)|Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
79510885|NCT03029364|Behavioral|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
79510886|NCT02406222|Drug|Pomalidomide|Chemotherapy
79670650|NCT04278560|Device|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
79670651|NCT04278560|Behavioral|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
79510887|NCT02406222|Drug|Dexamethasone|Chemotherapy
79510888|NCT02406222|Drug|Cyclophosphamide|Chemotherapy
79510889|NCT02247726|Drug|Saline Placebo (0.5mL injection)|
79510890|NCT02247726|Drug|RSV F vaccine (0.5mL injection)|
79510891|NCT00475488|Procedure|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
79510892|NCT00458796|Drug|zoledronic acid|
79510893|NCT00458796|Procedure|quality-of-life assessment|
79670652|NCT04272294|Device|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
79992845|NCT03718481|Other|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training [1]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
79992846|NCT03452189|Drug|Vancomycin|Oral vancomycin 250mg capsules
79360113|NCT05927792|Device|sham repeated transcranial magnetic stimulation|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
79360114|NCT05925101|Behavioral|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
79510894|NCT01021956|Drug|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
79510895|NCT01022190|Drug|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
79670653|NCT04272073|Other|High-Protein Mediterranean Diet|As in arm/group descriptions
79670654|NCT04272073|Other|Resistance Exercise|As in arm/group descriptions
79670655|NCT04272073|Other|Standard Dietary Advice|As in arm/group descriptions
79992847|NCT03452189|Other|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
79992848|NCT04306380|Other|no intervention, database study|data collection from EMR for database
79360115|NCT05925101|Behavioral|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
79510896|NCT01024296|Device|Port Close|Device for applying loop suture to close surgical site
79510897|NCT01024686|Biological|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
79670656|NCT04272073|Other|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
79670657|NCT04263922|Drug|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
79670658|NCT04263922|Drug|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
79670659|NCT04261556|Device|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously."
79670660|NCT04261556|Device|Sham tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously."
79992849|NCT03451721|Device|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
79992850|NCT00603954|Drug|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
79510898|NCT01024686|Biological|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
79510899|NCT01024686|Biological|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
79510900|NCT01025076|Device|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
79510901|NCT01026402|Drug|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
79510902|NCT01027806|Drug|Montelukast|1 pill per day for 4 months
79510903|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
79510904|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
79510905|NCT01029912|Device|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
79360116|NCT05925101|Behavioral|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
79360117|NCT05925101|Behavioral|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
79992851|NCT00603954|Drug|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
79992852|NCT03712631|Procedure|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
79992853|NCT03712553|Behavioral|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
79992854|NCT03712553|Behavioral|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
79992855|NCT03712553|Behavioral|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
79360118|NCT05925101|Behavioral|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
79992856|NCT03712553|Behavioral|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
79510906|NCT01032330|Device|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
79510907|NCT01032954|Drug|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~Crow's feet wrinkles - 70 units~Glabella - 50 units~Forehead - 40 units~Mid face:~Lower eyelid - 5 units~Nasal wrinkles - 20 units~Malar wrinkles - 10 units~Lower face:~Peri-oral wrinkles - 15 units~Asymmetric smile or gummy smile - 5 units~Cellulitic chin - 20 units~Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
79510908|NCT01033422|Drug|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
79819564|NCT03693170|Drug|Cetuximab|"Standard of care for the 28 first weeks(*) and then every 2 weeks (**) :~(*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (**) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
79510909|NCT01033422|Drug|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
79819565|NCT03690336|Drug|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
79819566|NCT03681561|Drug|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~Dose Levels:~(starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
79819567|NCT03681561|Drug|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
79819568|NCT03669822|Other|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
79819569|NCT03666377|Other|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
79819570|NCT03664206|Diagnostic Test|MRS, conventional TMS and treshold tracking TMS|"Using~two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
79819571|NCT03663933|Drug|Immunosuppression Only Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
79819572|NCT03663933|Drug|Reduced Intensity Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
79371070|NCT05198908|Other|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
79510910|NCT05593848|Procedure|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
79510911|NCT05593848|Procedure|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
79819573|NCT03663933|Drug|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25
79510912|NCT05593380|Device|Non-invasive intracranial pressure monitoring|Treatment based on readings from Bioelectrical impedance analysis monitor（intracranial pressure and perturbation index (PI)）.
79510913|NCT05593380|Other|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
79510914|NCT05593380|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
79510915|NCT05593224|Device|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
79510916|NCT05593068|Procedure|MRI|Pancreatic MRI
79510917|NCT05592834|Behavioral|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
79510918|NCT05592834|Behavioral|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
79510919|NCT05592834|Other|Control|This group will receive neither the PD nor the PFT interventions but care as usual
79510920|NCT05525988|Procedure|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
79510921|NCT05517564|Drug|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
79510922|NCT05517564|Other|Placebo|Placebo-to-match GM-60106 capsules
79670662|NCT04251377|Device|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
79819574|NCT03663933|Procedure|Allogeneic HSC|Stem cell transplant
79992857|NCT04271748|Other|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
79992858|NCT03427619|Drug|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
79360119|NCT05925101|Behavioral|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
79360120|NCT05925101|Behavioral|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
79510923|NCT05489328|Other|Candidate-1|Biological
79510924|NCT05489328|Other|Candidate-2|Biological
79670663|NCT04248920|Behavioral|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
79670664|NCT04232280|Biological|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
79670665|NCT04232280|Other|Placebo|0.9% sodium chloride (normal saline) injection
79670666|NCT04226313|Diagnostic Test|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
79670667|NCT04226313|Diagnostic Test|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
79670668|NCT04224740|Drug|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
79670669|NCT04224740|Drug|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
79670670|NCT04213079|Device|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
79670671|NCT04213079|Device|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
79670673|NCT04209595|Drug|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
79360121|NCT05925101|Behavioral|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
79510925|NCT05489328|Other|Candidate-3|Biological
79510926|NCT05489328|Other|Candidate-4|Biological
79510927|NCT05489328|Other|Candidate-5|Biological
79510928|NCT05489328|Other|Candidate-6|Biological
79510929|NCT05489328|Other|Candidate Control|Biological
79510930|NCT05489328|Biological|13vPnC|13-valent pneumococcal conjugate vaccine
79510931|NCT05489328|Biological|PCV15|15-valent pneumococcal conjugate vaccine
79510932|NCT05412498|Behavioral|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
79510933|NCT05412498|Behavioral|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
79819575|NCT03658785|Biological|TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
79510934|NCT05402826|Dietary Supplement|Oral zinc + vitamin E|In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
79510935|NCT05402826|Dietary Supplement|Placebo|Patients in the placebo group will receive placebo pills before and after surgery.
79992859|NCT03407729|Other|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
79992860|NCT03407729|Other|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
79992861|NCT03712475|Drug|Pregabalin|pharmacokinetic study under fasting conditions
79992862|NCT02435433|Drug|Ramucirumab|Administered IV
79992863|NCT02435433|Drug|Placebo|Administered IV
79992864|NCT01372371|Biological|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
79992865|NCT01372371|Biological|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
79992866|NCT01372371|Biological|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
79992867|NCT05167383|Device|VRH (Virtual Reality Hypnosis)|Hypnosis is delivered as a standardized therapeutic intervention through virtual reality, using a digital sedation software (AQUA ®, Onfomfort SA).
79360122|NCT05924919|Procedure|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
79819576|NCT03658785|Drug|Aldesleukin|IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
79992868|NCT05167383|Behavioral|Standard care|The standard treatment (ST) for labor pain as used in our hospital contains massage, aquatherapy and postural exercises. This is always available for any woman in labor.
79992869|NCT01374711|Drug|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
79992870|NCT01374711|Drug|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
79992871|NCT01374711|Other|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
79992872|NCT05167071|Drug|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
79992873|NCT05167071|Drug|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
79992874|NCT03120351|Drug|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
79992875|NCT03120351|Drug|Placebo patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
79992876|NCT05165355|Drug|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
79992877|NCT01374789|Drug|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
79992878|NCT01374789|Drug|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
79992879|NCT05164809|Device|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
79992880|NCT05101083|Device|New Receiver-in-Canal Device|Successor of previous device generation
79992881|NCT05101083|Device|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
79510936|NCT05376930|Drug|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
79992882|NCT02354703|Drug|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
79992883|NCT02354703|Drug|Placebo|Placebo + BBCET counseling
79992884|NCT00740181|Drug|chemotherapy|
79992885|NCT00384111|Drug|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
79992886|NCT00384111|Drug|R-CVP|Standard R-CVP
79992887|NCT05008887|Drug|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
79992888|NCT05008887|Drug|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
79992889|NCT05008887|Device|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
79992890|NCT01376115|Drug|Nelarabine|
79360123|NCT05924919|Procedure|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
79510937|NCT05246202|Behavioral|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
79510938|NCT05246202|Behavioral|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
79670674|NCT04209595|Drug|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
79670675|NCT04209595|Drug|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
79992891|NCT01376193|Drug|Naratriptan|Collection of safety data
79992892|NCT01373073|Other|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
79992893|NCT01373073|Other|Control human milk fortifier|Control human milk fortifier to be added to human milk
79360124|NCT05919238|Combination Product|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
79360125|NCT05911204|Other|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
79360126|NCT05896709|Other|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
79510939|NCT05244798|Drug|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
79510940|NCT05244798|Radiation|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
79510941|NCT05244798|Drug|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
79510942|NCT05193708|Device|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
79510943|NCT05193708|Device|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
79510944|NCT05179668|Drug|Dapagliflozin 10 MG|administered orally once daily
79510945|NCT05179668|Drug|Placebo|administered orally once daily
79510946|NCT05088564|Procedure|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
79510947|NCT05088564|Procedure|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
79670676|NCT04208529|Biological|CTX001|CTX001 infusion.
79670677|NCT04208477|Procedure|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
79670678|NCT04202640|Procedure|Mechanical Stimulation|The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.
79992894|NCT04944771|Drug|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
79992895|NCT04944771|Drug|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
79992896|NCT01374945|Device|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
79510948|NCT05048628|Other|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
79510949|NCT04910724|Other|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
79510950|NCT04799418|Device|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
79510951|NCT04627038|Drug|LY3556050|LY3556050 Given orally
79510952|NCT04627038|Drug|Placebo|Placebo Given orally
79670679|NCT04202640|Procedure|Massages|"Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~One part muscle exercise~One part skin work (drainage)"
79670681|NCT04200443|Drug|Cabozantinib|Given PO
79819577|NCT03658785|Drug|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
79360127|NCT05888974|Diagnostic Test|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
79360128|NCT05882903|Drug|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
79360129|NCT05882903|Device|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
79360130|NCT05875116|Behavioral|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
79670682|NCT04200443|Other|Quality-of-Life Assessment|Ancillary studies
79670683|NCT04200443|Other|Questionnaire Administration|Ancillary studies
79670684|NCT04200443|Drug|Temozolomide|Given PO
79670685|NCT04199221|Behavioral|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
79819578|NCT03658785|Drug|Fludarabine|Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
79819579|NCT03655262|Behavioral|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
79510953|NCT04460430|Drug|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
79510954|NCT04316910|Drug|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
79510955|NCT04241796|Device|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
79510956|NCT04104594|Diagnostic Test|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
79510957|NCT04104594|Other|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
79670686|NCT04199221|Behavioral|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
79992897|NCT05197413|Dietary Supplement|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
79510958|NCT04104594|Other|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
79510959|NCT04104594|Other|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
79510960|NCT04104594|Biological|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
79510961|NCT03952416|Behavioral|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
79819580|NCT03645564|Other|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
79360131|NCT05875116|Behavioral|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
79360132|NCT05875116|Behavioral|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
79510962|NCT03446664|Device|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
79510963|NCT03149562|Drug|plasma transfusions|These critical ill neonates with plasma transfusions
79510964|NCT03149562|Drug|non-plasma transfusions|These critical ill neonates without plasma transfusions
79670687|NCT04190446|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79670688|NCT04190446|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
79670689|NCT04190446|Other|Quality-of-Life Assessment|Ancillary studies
79670690|NCT04190446|Other|Questionnaire Administration|Ancillary studies
79670691|NCT04190446|Procedure|Computed Tomography|Undergo CT scan
79670692|NCT04190446|Procedure|Magnetic Resonance Imaging|Undergo MRI
79670693|NCT04190446|Procedure|Biospecimen Collection|Undergo blood sample collection
79670694|NCT04182672|Drug|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
79670695|NCT04175431|Procedure|Positron Emission Tomography|Undergo fluciclovine PET/CT
79670696|NCT04175431|Procedure|Lymphadenectomy|Undergo lymphadenectomy
79670697|NCT04175431|Radiation|Radiation Therapy|Undergo radiation therapy
79670698|NCT04175431|Drug|Abiraterone Acetate|Given PO
79670699|NCT04175431|Drug|Prednisone|Given PO
79670700|NCT04175431|Procedure|Computed Tomography|Undergo fluciclovine PET/CT
79670701|NCT04175431|Drug|Abiraterone|Given PO
79360133|NCT05873712|Procedure|Biospecimen Collection|Undergo collection of blood samples
79360134|NCT05873712|Procedure|Bone Marrow Biopsy|Undergo BM biopsy
79360135|NCT05873712|Procedure|Computed Tomography|Undergo CT and/or PET/CT
79360136|NCT05873712|Drug|Cyclophosphamide|Given IV
79360137|NCT05873712|Drug|Fludarabine|Given IV
79360138|NCT05873712|Procedure|Leukapheresis|Given IV
79360139|NCT05873712|Biological|Lisocabtagene Maraleucel|Given IV
79360140|NCT05873712|Procedure|Lymph Node Biopsy|Undergo lymph node biopsy
79670702|NCT04175431|Procedure|PSMA PET Scan|Undergo PSMA PET scan
79670703|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
79670704|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via non-rebreather
79670705|NCT04171037|Other|Questionnaire Administration|Ancillary studies
79670706|NCT04171037|Device|Optiflow THRIVE|Oxygen Administration
79510965|NCT01842672|Drug|Clofarabine|Dose Escalation of Clofarabine
79670708|NCT04124315|Other|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
79670709|NCT04124315|Other|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
79670710|NCT04117295|Device|Carmat Total Artificial Heart|Heart replacement therapy
79670711|NCT04115163|Drug|Gemcitabine|Given IV
79819581|NCT03639025|Device|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
79360141|NCT05873712|Procedure|Positron Emission Tomography|Undergo PET/CT
79360142|NCT05873712|Drug|Zanubrutinib|Given PO
79371071|NCT05198908|Other|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
79670712|NCT04115163|Drug|Nab-paclitaxel|Given IV
79670713|NCT04113759|Behavioral|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain <2/10 on VAS and RPE <5 on 0-10 scale. (Heerey et al), and no break down in form."
79371072|NCT03087435|Device|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
79510966|NCT01842672|Drug|Mitoxantrone|
79510967|NCT01531374|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
79510968|NCT01240902|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
79510969|NCT01240902|Device|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
79510970|NCT01034592|Drug|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
79510971|NCT01037790|Drug|PD-0332991|Given orally, 125 mg QD on a 21-day
79670714|NCT04113759|Behavioral|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
79992898|NCT01375023|Radiation|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
79992899|NCT01375023|Biological|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
79360143|NCT05872737|Behavioral|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.
79360144|NCT05872737|Behavioral|General Parenting Education and Advice|Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
79510972|NCT01038336|Behavioral|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
79510973|NCT01038336|Behavioral|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
79510974|NCT01040052|Biological|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
79510975|NCT01040208|Drug|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
79819582|NCT03623321|Drug|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
79510976|NCT01040208|Drug|flibanserin 100 mg qhs|100mg qhs
79510977|NCT01040208|Drug|placebo 2 tablets qhs|50 mg placebo
79510978|NCT01043094|Drug|Pitavastatin 4mg|Pitavastatin 4mg single dose
79510979|NCT01043562|Diagnostic Test|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
79510980|NCT01043562|Other|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole >4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a >10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
79510981|NCT01043640|Drug|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
79510982|NCT01043640|Drug|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
79510983|NCT01043640|Drug|Busulfan|Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
79510984|NCT01043640|Procedure|Allogeneic stem cell transplantation|Administered > 24 hours after last dose of busulfan.
79360145|NCT05872451|Drug|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
79360146|NCT05872451|Diagnostic Test|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
79360147|NCT05868278|Other|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
79360148|NCT05862987|Dietary Supplement|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
79510985|NCT01043640|Drug|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~If body weight is ≤ 40 kg dosing will be 3 times daily~If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
79360149|NCT05862987|Dietary Supplement|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
79360150|NCT05862623|Drug|AER-01|AER-01 solution for inhalation delivered via nebulizer
79360151|NCT05862623|Drug|Placebo|Placebo for solution for inhalation delivered via nebulizer
79360152|NCT05861921|Other|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
79360153|NCT05858437|Dietary Supplement|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
79360154|NCT05858437|Other|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
79510986|NCT01043640|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
79510987|NCT01044030|Drug|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
79510988|NCT01044030|Drug|Placebo|7.5 mL by mouth three times daily
79510989|NCT01044966|Drug|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
79510990|NCT01045122|Drug|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
79510991|NCT01045122|Drug|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
79510992|NCT01049802|Device|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
79819583|NCT03615742|Other|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
79819584|NCT03615742|Drug|Budesonide|1.6mg of budesonide from a Turbuhaler.
79510993|NCT01050582|Drug|Risperidone|As per local prescribing practices
79510994|NCT01050582|Drug|Other atypical antipsychotic drugs|As per local prescribing practices
79992900|NCT05197101|Procedure|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
79992901|NCT05039775|Device|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
79510995|NCT01050660|Other|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
79510996|NCT01050660|Other|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
79360155|NCT05854953|Device|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
79360156|NCT05854953|Device|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
79360157|NCT05854953|Device|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
79819585|NCT03615742|Other|Filtered Air|Exposure to HEPA filtered air, as a control.
79360158|NCT05854953|Device|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
79360159|NCT05854953|Device|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
79360160|NCT05854498|Drug|Liposomal irinotecan|60mg/m2 IV on days 1 and 15
79360161|NCT05854498|Drug|TAS102|35mg/m2 PO BID on days 1-5 and 15-19
79360162|NCT05854498|Drug|Bevacizumab|5mg/kg IV on days 1 and 15
79510997|NCT01051440|Drug|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
79510998|NCT01051440|Drug|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
79510999|NCT01051518|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
79511000|NCT01051596|Drug|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
79511001|NCT01051596|Drug|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
79511002|NCT01053000|Drug|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
79992902|NCT05039775|Behavioral|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
79992903|NCT05197023|Drug|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
79511003|NCT05822453|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
79992904|NCT03633669|Diagnostic Test|Fecal calprotectin|Testing every 3 months
79511004|NCT05822453|Drug|S1|S1 (60 mg/day if body surface area < 1.25 m2, 80 mg/day if body surface area = 1.25~1.50 m2) will be administered by PO on Day 1 ~ 14 of each 21-day cycle
79992905|NCT03633669|Other|Routine care|As per treating gastroenterologist
79360163|NCT05853211|Combination Product|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
79360164|NCT05844852|Device|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
79360165|NCT05841472|Drug|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
79511005|NCT05822453|Drug|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
79819586|NCT03615742|Other|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
79992906|NCT01375101|Drug|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
79992907|NCT01375101|Drug|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
79360166|NCT05831449|Drug|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
79360167|NCT05831449|Drug|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
79360168|NCT05831449|Drug|Placebo|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
79360169|NCT05825014|Other|No intervention|No intervention
79360170|NCT05822011|Procedure|Rhomboid intercostal subserratus plane block|Fascial plane block
79360171|NCT05822011|Procedure|Erector spinae plane block|Fascial plane block
79992908|NCT05196711|Drug|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
79992909|NCT05196711|Drug|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
79992910|NCT04878003|Drug|KRT-232|KRT-232, administration by mouth
79992911|NCT04878003|Drug|TL-895|TL-895, administration by mouth
79992912|NCT03633591|Drug|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
79992913|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
79511006|NCT05822401|Behavioral|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
79992914|NCT03633591|Drug|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
79992915|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
79992916|NCT01376271|Drug|Paroxetine|
79992917|NCT05196555|Procedure|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
79992918|NCT04885881|Procedure|Ozone therapy|Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
79992919|NCT04885881|Procedure|Lidocaine injection group|Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
79360172|NCT05822011|Procedure|Thoraccic Epidural analgesia|Neuroaxial block
79511007|NCT05822401|Behavioral|Usual care (control)|Will continue their work as usual
79819587|NCT03598998|Biological|Pembrolizumab|Given IV
79992920|NCT01375179|Drug|KRP203|
79992921|NCT01375179|Drug|Placebo matching KRP203|
79992922|NCT05196321|Other|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
79360173|NCT05821725|Device|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
79360174|NCT05821725|Device|Control|Hemostatic sponge
79360175|NCT05819450|Procedure|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
79511008|NCT01028820|Drug|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
79511009|NCT05822349|Behavioral|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
79819588|NCT03598998|Drug|Pralatrexate|Given IV
79360176|NCT05818358|Dietary Supplement|black beans|¾ cup of cooked black beans
79360177|NCT05818358|Dietary Supplement|wheat berries|¾ cup of cooked whole wheat grain
79360178|NCT05818358|Dietary Supplement|white rice|¾ cup of cooked white rice
79360179|NCT05818124|Drug|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
79360180|NCT05818124|Drug|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
79511010|NCT05822336|Other|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
79511011|NCT05822323|Other|BTX-A|Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
79819589|NCT03595371|Drug|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
79819590|NCT03580044|Combination Product|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
79992923|NCT01373307|Behavioral|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
79992924|NCT04820205|Drug|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
79992925|NCT04820205|Drug|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
79992926|NCT01375257|Drug|Oral treatment with antibiotics for endocarditis|
79992927|NCT01375257|Drug|Guideline treatment with parenteral antibiotics|
79992928|NCT01375335|Drug|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
79992929|NCT05195307|Other|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
79360181|NCT05818124|Drug|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
79360182|NCT05818124|Drug|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
79360183|NCT05818124|Biological|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
79360184|NCT05818046|Diagnostic Test|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
79360185|NCT05818046|Procedure|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
79360186|NCT05813743|Diagnostic Test|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
79511012|NCT05822323|Procedure|free gingival graft|The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
79670719|NCT04102189|Drug|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
79670720|NCT04102189|Other|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
79670721|NCT04090268|Other|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
79670722|NCT04087317|Drug|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
79670723|NCT04087317|Drug|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
79670724|NCT04087317|Drug|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
79670725|NCT04087317|Drug|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
79670726|NCT04087317|Drug|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
79670727|NCT04079361|Diagnostic Test|Blood samples|Bood samples during prenatal and postnatal visits
79670728|NCT04077723|Drug|RO7227166|RO7227166 will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
79670729|NCT04077723|Drug|Obinutuzumab|A fixed dose of obinutuzumab will be administered seven days prior to first does of RO7227166 and glofitamab and then Q3W in combination with RO7227166 in Part I
79670730|NCT04077723|Drug|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with RO7227166 in Part II and Part III
79511013|NCT05822310|Procedure|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
79511014|NCT05822310|Procedure|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
79992930|NCT05194527|Other|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
79511015|NCT05822310|Procedure|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
79819591|NCT03580044|Drug|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
79819592|NCT03579030|Drug|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
79819593|NCT03579030|Drug|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
79992931|NCT01375413|Behavioral|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
79819594|NCT03574571|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
79992932|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
79511016|NCT05822284|Diagnostic Test|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
79511017|NCT05822271|Procedure|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
79511018|NCT05822232|Device|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
79511019|NCT05822232|Device|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
79511020|NCT05822232|Device|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
79992933|NCT01373463|Drug|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
79992934|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
79992935|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
79511021|NCT05822206|Behavioral|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
79819595|NCT03574571|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
79819596|NCT03574571|Drug|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
79819597|NCT03555578|Drug|Leuprorelin Acetate|Leuprorelin Acetate Injection Kit
79992936|NCT01373463|Drug|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
79992937|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
79992938|NCT01373463|Procedure|Lobectomy|Surgery
79819598|NCT03525002|Drug|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
79819599|NCT03525002|Other|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
79992939|NCT01373463|Procedure|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
79511022|NCT05822206|Behavioral|Life Steps and Sexual Decision-Making|
79819600|NCT03520491|Drug|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
79819601|NCT03520491|Drug|Ipilimumab|Ipilimumab 3 mg/kg
79819602|NCT03520491|Procedure|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
79992940|NCT04573647|Drug|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
79992941|NCT05194371|Radiation|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
79992942|NCT05194215|Device|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
79992943|NCT03113409|Drug|Buprenorphine|Buprenorphine will be administered daily
79511023|NCT05822193|Other|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
79992944|NCT03113409|Drug|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
79511024|NCT05822180|Drug|NANOS1 , argent colloïdal ,|orally, during 5 day
79511025|NCT05822167|Other|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
79992945|NCT03113409|Drug|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
79992946|NCT05193747|Other|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
79511026|NCT05822167|Other|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
79511027|NCT05822167|Other|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
79670731|NCT04077723|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
79992947|NCT05193513|Device|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
79992948|NCT03634293|Drug|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
79992949|NCT03634293|Drug|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
79819603|NCT03520400|Behavioral|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
79819604|NCT03474965|Drug|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
79819605|NCT03474107|Drug|Enfortumab Vedotin|Intravenous infusion
79992950|NCT01373541|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
79670733|NCT04071925|Procedure|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
79819606|NCT03474107|Drug|Docetaxel|Intravenous infusion
79670734|NCT04061226|Device|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
79670735|NCT04054167|Drug|Low Dose Radiation Therapy|Undergo ultra low dose radiation
79819607|NCT03474107|Drug|Vinflunine|Intravenous infusion
79819608|NCT03474107|Drug|Paclitaxel|Intravenous infusion
79819609|NCT03446157|Drug|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
79819610|NCT03446157|Drug|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
79819611|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
79302626|NCT05714189|Other|Low FODMAP diet|The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
79360187|NCT05810467|Other|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA <10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, >50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
79360188|NCT05810233|Dietary Supplement|Ascorbic acid 1000mg|Health supplement
79360189|NCT05810233|Other|Placebo|Glucose chewable tablet without any ascorbic acid
79511028|NCT05822167|Other|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
79511029|NCT05822167|Other|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
79511030|NCT05822167|Other|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
79511031|NCT05822167|Other|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
79511032|NCT05822167|Other|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
79670736|NCT04042376|Drug|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg*3 capsules taken together at one time).
79819612|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
79819613|NCT03434678|Procedure|Open Pancreaticoduodenectomy|Whipple' Procedure
79819614|NCT03422328|Drug|macitentan|macitentan 10 mg, film-coated tablet, oral use
79992951|NCT01373541|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
79670737|NCT04040634|Drug|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP <120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
79992952|NCT03633747|Drug|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
79992953|NCT01376739|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
79511033|NCT05822167|Other|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
79992954|NCT05190783|Drug|Formocresol|mixture of formalin, cresol and glycerine used for fixation of pulp tissues
79992955|NCT05190783|Drug|MTA|material used for pulp regeneration, direct and indirect pulp capping
79992956|NCT05190783|Drug|TheraCal|light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
79992957|NCT05190783|Procedure|pulpotomy|removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
79992958|NCT05190783|Procedure|partial pulpotomy|complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
79511034|NCT05822037|Biological|CT0594CP|Cell injection
79670738|NCT04040634|Drug|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
79670739|NCT04038515|Drug|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
79670740|NCT04038515|Drug|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
79992959|NCT01375647|Biological|IPV|Administered per protocol
79992960|NCT01375647|Biological|Rotarix|Administered per protocol
79670741|NCT04038515|Drug|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
79670742|NCT04038515|Drug|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
79511035|NCT05822024|Behavioral|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
79670743|NCT04038515|Other|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
79992961|NCT01373619|Drug|Ivabradine|ivabradine titrated to 7.5 mg BID
79992962|NCT01376817|Drug|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
79992963|NCT01376817|Drug|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
79992964|NCT01375803|Dietary Supplement|Novel dietary fiber|oral consumption in beverage
79992965|NCT01375803|Dietary Supplement|Novel dietary fiber|Oral consumption in beverage
79992966|NCT01375803|Other|Placebo|Oral consumption in beverage
79992967|NCT01373697|Drug|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
79992968|NCT01373697|Drug|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
79511036|NCT05821946|Other|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
79360190|NCT05805891|Drug|bortezomib|bortezomib 2mg/week subcutaneous injection
79360191|NCT05805358|Drug|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
79360192|NCT05805124|Diagnostic Test|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~renal function tests~hematologic tests~coagulation tests~hepatic function tests~ECG~cardiac function tests~pulmonary function tests~endocrine function tests"
79360193|NCT06133790|Genetic|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
79511037|NCT05821920|Device|MUST MINI system|cervical posterior fixation system
79360194|NCT06133764|Procedure|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
79360195|NCT06133764|Procedure|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
79360196|NCT06133764|Procedure|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
79670744|NCT04038515|Other|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
79670745|NCT04038515|Other|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
79992969|NCT01375881|Drug|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
79360197|NCT06133764|Procedure|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
79360198|NCT06133764|Procedure|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
79360199|NCT06133751|Drug|black chokeberry (Aronia melanocarpa)|Black chokeberry capsules standardized for anthocyanin compounds
79360200|NCT06133751|Drug|Placebo|Chokeberry fiber placebo capsules
79992970|NCT03427073|Drug|ALM201|Drug: ALM201 administered subcutaneously
79511038|NCT05821894|Other|Observational study|
79511039|NCT05821881|Other|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
79360201|NCT06133738|Other|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
79511040|NCT05821803|Other|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
79511041|NCT05821803|Other|Foot Core Exercises|4 weeks including
79511042|NCT05821790|Other|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
79511043|NCT05821751|Dietary Supplement|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
79511044|NCT05821751|Drug|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
79670746|NCT04038515|Other|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
79511045|NCT05821751|Drug|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
79511046|NCT05821712|Drug|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
79511047|NCT05821712|Drug|0.057% sodium fluoride Mouthwash|mouthwash
79511048|NCT05821673|Procedure|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
79511049|NCT05821673|Procedure|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
79511050|NCT05821647|Other|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
79511051|NCT05821621|Other|no intervention|observational study : there is no intervention
79511052|NCT05821452|Drug|Camrelizumab|200mgQ3w
79992971|NCT05760885|Behavioral|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
79511053|NCT05821452|Drug|Paclitaxel|175mg/m2，D1，Q3w
79511054|NCT05821452|Drug|Cisplatin|75mg/m2，D1，Q3w
79511055|NCT05821452|Radiation|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
79511056|NCT05821400|Other|observational study|observational study
79511057|NCT05821361|Drug|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
79992972|NCT05760885|Behavioral|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
79992973|NCT03716219|Other|Exercise Training|Physical activity in children and adults with asthma.
79992974|NCT04690023|Procedure|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
79992975|NCT04690023|Procedure|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
79360202|NCT06133738|Other|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
79360203|NCT06133738|Other|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
79360204|NCT06133725|Procedure|erector spinae plane block|The experimental group received ultrasound-guided erector spinae plane block, and bilateral erector spinae plane block was performed at T7 segment with 20ml 0.375% ropivacaine on each side.While the control group received ultrasound-guided transversus abdominis plane block combined with rectus sheath block, which will be performed under the costal margin with 10ml 0.375% ropivacaine for bilateral transversus abdominis plane block and 10ml 0.375% ropivacaine for bilateral rectus sheath block.
79371073|NCT05153590|Drug|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
79511058|NCT05821348|Diagnostic Test|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
79511059|NCT05821270|Other|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
79511060|NCT05821257|Other|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
79670747|NCT04038515|Other|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
79670748|NCT04035278|Biological|Dengusiil|Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
79670749|NCT04035278|Biological|Placebo|Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
79670750|NCT04034927|Procedure|Biospecimen Collection|Undergo blood sample collection
79670751|NCT04034927|Procedure|Computed Tomography|Undergo CT
79670752|NCT04034927|Procedure|Magnetic Resonance Imaging|Undergo MRI
79670753|NCT04034927|Drug|Olaparib|Given PO
79670754|NCT04034927|Biological|Tremelimumab|Given IV
79670755|NCT04033926|Drug|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
79670756|NCT04033926|Drug|Placebo|Subcutaneous injection for 16 weeks
79992976|NCT04690023|Drug|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
79992977|NCT04690023|Drug|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
79992978|NCT03066804|Drug|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
79360205|NCT06133686|Drug|Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)|Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
79360206|NCT06133686|Drug|Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)|Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
79819615|NCT03421561|Device|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
79511061|NCT05821257|Other|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
79992979|NCT03066804|Drug|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
79360207|NCT06133660|Procedure|pars plana vitrectomy|pars plana vitrectomy and Silicone oil removal to distinguish subjects
79819616|NCT03421561|Device|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
79992980|NCT03066804|Drug|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
79360208|NCT06133634|Dietary Supplement|Fisetin|Fisetin dietary supplement
79360209|NCT06133634|Other|Placebo|Placebo capsules identical in appearance to fisetin capsules
79360210|NCT06133608|Other|MOBILIZATION TRAINING|"Things to consider in the hospital in the early period after surgery: The first day in the hospital after surgery, the importance of the abduction pillow and early mobilization,~Exercises performed in bed in the early period after surgery: Exercises such as ankle pump, ankle rotation, bed-supported knee bending, hip contraction, opening exercise, thigh exercise, straight leg raise,~Early standing up: Activities such as sitting in bed or on a chair, standing up with the help of a walker, walking,~Exercises performed while standing: Exercises such as lifting the knee, opening the leg to the side,~Daily living activities: It will provide information on regulating ADLs such as bathing, dressing, using the toilet, getting into and driving the car, going up and down stairs, eating, sleeping, doing housework, sexual life, and information about the safety precautions that should be taken at home."
79511062|NCT05821192|Drug|Rituximab|375mg/m2 by IV infusion once every 3 weeks
79511063|NCT05821192|Drug|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
79511064|NCT05821192|Drug|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
79511065|NCT05821192|Drug|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
79992981|NCT03066804|Drug|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
79992982|NCT03066804|Drug|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
79992983|NCT03066804|Drug|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
79992984|NCT03633357|Drug|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
79992985|NCT03633357|Drug|Placebo|Participants will take two placebo tablets daily, for seven days.
79511066|NCT05821192|Drug|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
79511067|NCT05821166|Device|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
79511068|NCT05821153|Drug|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
79511069|NCT05821140|Procedure|dental treatment for global oral rehabilitation|dental treatment can include conservative, orthodontic, prosthetic or surgical procedures
79511070|NCT05821140|Other|oral health check up|regular preventive follow-up visit (every 6 months)
79511071|NCT05821114|Other|Head elevation_H|High flow_Head-elevation
79511072|NCT05821114|Other|Supine_H|High flow_Supine
79511073|NCT05821114|Other|Head elevation_L|Low flow_head elevation
79511074|NCT05821114|Other|Supine_L|Low flow_supine
79819617|NCT03420508|Drug|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
79819618|NCT03420508|Diagnostic Test|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
79511075|NCT05821062|Other|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
79511076|NCT05821062|Other|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
79670757|NCT04025606|Drug|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
79360211|NCT06133595|Behavioral|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
79360212|NCT06133569|Behavioral|ReDirection|Self help program based on principles for cognitive behavioral therapy
79511077|NCT05821062|Other|standard ASA therapy|ASA 100 mg daily
79511078|NCT05821036|Behavioral|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
79511079|NCT05821010|Combination Product|LFMT-capsules|Lyophilized fecal microbiota transplantation capsules
79360213|NCT06133556|Drug|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9~-8d, Cladribine 5 mg/m2 -9~-5d, Bu3.2mg/kg -5~-3d； Cy 30mg/kg -2~-1 d
79511080|NCT05820984|Other|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
79511081|NCT05820984|Other|Usual practice|Peer review as it is usual practice at the journal
79670758|NCT04025606|Drug|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
79670759|NCT04025580|Biological|Flucelvax|Seasonal influenza vaccine
79819619|NCT03412058|Procedure|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
79360214|NCT06133556|Drug|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
79371074|NCT03490864|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
79511082|NCT05820958|Other|Shantali massage|"The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~face and chest; 4 types of movements 10reps each;~upper extremity; 4 types of movements, 10 reps each (left and right separately);~abdomen; 2 types of movements, 10 reps each;~lower extremity; 3 types of movements, 10 reps each (left and right separately);~back; 2 types of movements, 10 reps each;~final integration; 3 types of movements, 10 reps each."
79670760|NCT04025580|Biological|Fluvirin|Seasonal influenza vaccine
79670761|NCT04025580|Biological|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
79819620|NCT03412058|Procedure|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
79670762|NCT04021277|Drug|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
79670763|NCT04021277|Drug|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
79670764|NCT04021277|Device|Ultrasound|Ultrasound activation and enhancement
79670765|NCT04020913|Drug|Somatropin injection|"Boys with short stature will be studied for measures of:~skeletal muscle strength, power, and endurance~muscle agility~lean body mass accrual~bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
79670766|NCT03999827|Other|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
79819621|NCT03412058|Procedure|Biopsy|To be performed at disease progression if medically feasible
79360215|NCT06133543|Procedure|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
79360216|NCT06133530|Dietary Supplement|Human milk oligosaccharides|Prebiotic
79360217|NCT06133530|Dietary Supplement|Maltose|Control
79360218|NCT06133517|Drug|Sacituzumab govitecan|Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
79360219|NCT06133517|Drug|Zimberelimab|ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
79670767|NCT03998020|Other|scale of severity|assessment of the severity of the sleep disorders by scale
79511083|NCT05820945|Other|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
79511084|NCT05820919|Behavioral|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
79360220|NCT06133517|Drug|Domvanalimab|DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
79360221|NCT06133491|Biological|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
79670768|NCT03998020|Genetic|blood sample|Genetical study, serum and sample
79670769|NCT03996837|Other|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
79670770|NCT03993327|Biological|Iodine I 124 Monoclonal Antibody M5A|Given IV
79670771|NCT03993327|Procedure|Positron Emission Tomography|Undergo PET scan
79670772|NCT03982368|Drug|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
79670773|NCT03982368|Drug|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
79670774|NCT03982368|Other|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
79670775|NCT03969446|Drug|Decitabine|Given IV
79360222|NCT06133426|Device|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
79360223|NCT06133413|Device|Body Comp Pro connected scale (Withings manufacturer)|Use once a week
79511085|NCT05820919|Other|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
79511086|NCT05820880|Drug|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
79511087|NCT05820880|Drug|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
79511088|NCT05820867|Procedure|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
79670776|NCT03969446|Biological|Pembrolizumab|Given IV
79670777|NCT03969446|Drug|Venetoclax|Given PO
79670778|NCT03968068|Procedure|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
79670779|NCT03968068|Procedure|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
79670780|NCT03960840|Biological|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
79992986|NCT02954237|Device|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
79992987|NCT03629262|Drug|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
79360224|NCT06133413|Other|Alert generation by remote plateform|Alert will be generated from weight regain > 5% of baseline weight
79360225|NCT06133387|Device|ELS System|The intended endoluminal resection procedures of the ELS System are partial thickness local excision procedures (resection of a lesion without removing a large colon segment or the entire colon).
79992988|NCT03629262|Drug|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
79992989|NCT04224090|Diagnostic Test|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
79992990|NCT05208372|Diagnostic Test|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
79992991|NCT05208372|Diagnostic Test|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
79819622|NCT03410875|Drug|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
79360226|NCT06133361|Biological|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
79360227|NCT06133361|Procedure|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
79360228|NCT06133335|Other|Periodontal examination|"Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells."
79992992|NCT05213988|Dietary Supplement|Intermittent Fasting|Intermittent fasting meal pattern
79360230|NCT06133296|Other|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
79511089|NCT05820867|Procedure|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
79992993|NCT05213988|Drug|Fibrates|Bezafibrate 400 mg/day
79992994|NCT05213988|Dietary Supplement|Low-Carbohydrate/High-Protein diet|Low-calorie, low-carbohydrate, high-protein diet
79992995|NCT05207904|Drug|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
79992996|NCT05207826|Diagnostic Test|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
79992997|NCT04150692|Biological|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
79992998|NCT04150692|Procedure|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
79992999|NCT04150692|Procedure|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
79993000|NCT05715450|Procedure|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
79993001|NCT05213754|Procedure|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
79360231|NCT06133296|Other|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
79360232|NCT06133270|Drug|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
79360233|NCT06133270|Drug|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
79511090|NCT05820789|Other|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
79670781|NCT03960840|Drug|Ibrutinib|Tablets or capsules for oral daily use
79670782|NCT03960372|Behavioral|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
79670783|NCT03954574|Diagnostic Test|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
79360234|NCT06133257|Procedure|Goal-Directed Fluid Therapy guided by Inferior Vena Cava Collapsibility Index|Measuring Inferior vena cava(IVC) diameter using ultrasound then calculation Inferior vena cava(IVC) collapsibility index and administer fluid accordingly.
79360235|NCT06133257|Procedure|standard fluid management|standard fluid management
79360236|NCT06133231|Dietary Supplement|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-3 capsules of EMP+ two to three times per day for eight weeks.
79360237|NCT06133218|Other|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
79670784|NCT03944304|Drug|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
79993002|NCT05207514|Drug|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
79993003|NCT05207514|Drug|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
79360238|NCT06133205|Other|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
79993004|NCT05207514|Drug|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
79993005|NCT05207514|Drug|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
79993006|NCT04250337|Biological|Lebrikizumab|Subcutaneous injection
79993007|NCT04250337|Other|Placebo|Subcutaneous injection
79993008|NCT04250337|Other|Topical Corticosteroid|Topical Corticosteroid
79360239|NCT06133192|Drug|Uvadex|Uvadex use for ECP
79993009|NCT04011540|Behavioral|Digital data|Receiving digital data prior to a scheduled mental health session
79360240|NCT06133192|Drug|Steroids|steroids 2 mg/kg/d
79360241|NCT06133153|Device|THIODERM ELATE|Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
79511091|NCT05820776|Other|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
79511092|NCT05820750|Device|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
79511093|NCT05820750|Procedure|pulpectomy with metapex|root canal treatment using standard technique
79511094|NCT05818774|Procedure|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
79511095|NCT05818774|Procedure|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
79511096|NCT05818189|Device|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
79993010|NCT04687059|Biological|PQ Grass|Suspension for injection
79302627|NCT05714189|Other|Endometriosis diet|The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
79360242|NCT06133153|Device|Juvéderm Ultra 3|BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
79360243|NCT06133127|Other|Frailty assessment|Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
79360244|NCT06133101|Drug|Standard Soy Milk|Consumption of commercially available soy milk
79360245|NCT06133101|Drug|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
79993011|NCT04687059|Drug|Placebo Option 1|Suspension for injection
79993012|NCT04687059|Drug|Placebo Option 2|Solution for injection
79993013|NCT05760729|Diagnostic Test|Cognitive testing|Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
79993014|NCT01373775|Other|Patient charts reviewing|Reviewing chart and identifying risk factors
79993015|NCT03118947|Drug|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
79993016|NCT03983733|Other|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
79993017|NCT03953079|Drug|Drug: GB-102|Intravitreal injection of GB-102
79993018|NCT03953079|Drug|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
79993019|NCT04572399|Device|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
79670785|NCT03934684|Drug|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib will be administered as a 30-minute infusion.~Dexamethasone will be taken by mouth or intravenously."
79993020|NCT03885999|Device|Fecobionics|Fecobionics is a new device for studying defecation
79993021|NCT03879525|Other|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
79670786|NCT03934684|Drug|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib will be administered as a 10 minute infusion.~Lenalidomide will be taken orally.~Dexamethasone will be taken by mouth or intravenously."
79993022|NCT03879525|Other|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
79993023|NCT03108027|Drug|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
79993024|NCT03108027|Drug|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
79993025|NCT03108027|Drug|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
79993026|NCT03812601|Procedure|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
79993027|NCT03794427|Other|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
79993028|NCT03794427|Other|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
79993029|NCT03794427|Other|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
79993030|NCT03794427|Other|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
79993031|NCT03606291|Radiation|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
79360246|NCT06133088|Drug|dalpiciclib; fluvestrant; compound gossypol acetate tablets|"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."
79360247|NCT06133049|Drug|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
79511097|NCT05818189|Device|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
79511098|NCT05817162|Drug|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
79993032|NCT03427827|Drug|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
79993033|NCT03633513|Diagnostic Test|LBT-3627|Immunomodulatory agent
79993034|NCT03633513|Diagnostic Test|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
79360248|NCT06133049|Drug|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
79360249|NCT06133049|Drug|No DMTs|Women with MS not exposed to any DMTs during pregnancy
79670787|NCT03932201|Drug|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
79670788|NCT03927768|Diagnostic Test|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
79670789|NCT03927768|Diagnostic Test|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
79670790|NCT03912207|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
79993035|NCT03410901|Biological|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
79993036|NCT03410901|Other|Laboratory Biomarker Analysis|Correlative studies
79993037|NCT03410901|Radiation|Radiation Therapy|Undergo radiation therapy
79511099|NCT05817162|Procedure|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
79511100|NCT05817162|Drug|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
79511101|NCT05817162|Drug|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
79670791|NCT03912207|Other|Saline placebo|Saline is a routinely used placebo.
79670792|NCT03899402|Drug|Insulin|Standard of care insulin for pump or injection and serves as a control
79670793|NCT03899402|Drug|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
79371075|NCT03490864|Dietary Supplement|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
79670794|NCT03899402|Drug|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
79670795|NCT03899402|Drug|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
79670796|NCT03885531|Device|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
79670797|NCT03880019|Procedure|Computed Tomography|Undergo CT
79670798|NCT03880019|Procedure|Core Biopsy|Undergo tumor biopsy
79670799|NCT03880019|Procedure|Magnetic Resonance Imaging|Undergo MRI
79819623|NCT03410875|Drug|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
79371076|NCT03490864|Other|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
79371077|NCT03490864|Other|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
79511102|NCT05816421|Behavioral|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
79511103|NCT05816421|Behavioral|Non-Affinity KEEP|Non-Affinity KEEP
79511104|NCT05815628|Diagnostic Test|DISQVER|NGS based infection diagnosis
79511105|NCT05814809|Drug|JP-1366 20mg tablet|T : JP-1366 20mg tablet
79511106|NCT05814809|Drug|JP-1366 20mg capsule|R : JP-1366 20mg capsule
79511107|NCT05812690|Other|This is a non intervention - observation only study|This is non intervention study
79511108|NCT05810402|Biological|Liquid Biopsy|"30mL blood sample:~1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
79511109|NCT05809180|Drug|Rituximab|Rituximab 375mg/m2 ivgtt d1;
79670800|NCT03880019|Drug|Olaparib|Given PO
79670801|NCT03880019|Drug|Temozolomide|Given PO
79670802|NCT03864419|Biological|Rituximab and Hyaluronidase Human|Given SC
79670803|NCT03864419|Drug|Cyclophosphamide|Given IV
79670804|NCT03864419|Drug|Vincristine|Given IV
79670805|NCT03864419|Drug|Methotrexate|Given IV
79670806|NCT03864419|Drug|Doxorubicin|Given IV
79670807|NCT03864419|Drug|Doxorubicin Hydrochloride|Given IV
79670808|NCT03864419|Drug|Prednisone|Given PO
79670809|NCT03864419|Drug|Etoposide|Given IV
79670810|NCT03864419|Biological|Rituximab|Given IV
79670811|NCT03850795|Drug|HC-1119|oral once daily 80 mg
79670812|NCT03850795|Drug|Enzalutamide|oral once daily 160 mg
79670813|NCT03847844|Biological|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
79670814|NCT03847844|Other|Placebo|Normal saline
79670816|NCT03829111|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
79670817|NCT03829111|Biological|Ipilimumab|Given IV
79670818|NCT03829111|Biological|Nivolumab|Given IV
79819624|NCT03401853|Other|Laboratory Biomarker Analysis|Correlative studies
79819625|NCT03401853|Biological|Pembrolizumab|Given IV
79819626|NCT03401853|Biological|Rituximab|Given IV
79819627|NCT03401853|Biological|Obinutuzumab|Given IV
79993038|NCT03410901|Drug|TLR9 Agonist SD-101|Given intratumorally
79360250|NCT06133023|Procedure|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
79360251|NCT06133023|Procedure|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
79360252|NCT06132997|Procedure|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
79511110|NCT05809180|Drug|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
79511111|NCT05809180|Drug|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
79511112|NCT05809180|Drug|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
79511113|NCT05809180|Drug|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
79511114|NCT05807854|Procedure|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
79819628|NCT03384641|Drug|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
79360253|NCT06132997|Procedure|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
79360254|NCT06132971|Behavioral|New Beginnings Program|
79360255|NCT06132945|Drug|Cabozantinib|Cabozantinib (40 mg PO daily)
79360256|NCT06132945|Device|Nivolumab|Nivolumab (240 mg IV Day 1 and Day 15)
79360257|NCT06132945|Radiation|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
79511115|NCT05807854|Device|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
79993039|NCT01373853|Procedure|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
79819629|NCT03376581|Procedure|Platelet rich plasma|Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
79993040|NCT01373853|Procedure|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
79993041|NCT03357939|Drug|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
79511116|NCT05802238|Drug|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
79511117|NCT05802238|Other|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
79993042|NCT03357939|Drug|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
79993043|NCT05759403|Diagnostic Test|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
79993044|NCT03713073|Device|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
79511118|NCT05802173|Drug|TDM-105795, 0.0025%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
79511119|NCT05802173|Drug|TDM-105795, 0.02%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
79511120|NCT05802173|Drug|TDM-105795 topical vehicle solution|The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
79511121|NCT05799807|Procedure|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
79511122|NCT05799807|Procedure|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
79511123|NCT05796570|Drug|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
79511124|NCT05796570|Drug|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
79511126|NCT05768295|Device|Axiom BL X3|collecting data on the use of Axiom BL X3 and patient satisfaction
79511127|NCT05755945|Other|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
79511128|NCT05751837|Biological|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
79511129|NCT05749848|Drug|[¹⁴C]-LY3372689|Administered orally.
79511130|NCT05728970|Diagnostic Test|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
79511131|NCT05728970|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 & Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
79819630|NCT03362177|Biological|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
79360258|NCT06132932|Drug|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
79371078|NCT03030898|Diagnostic Test|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
79511132|NCT05714098|Behavioral|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
79511133|NCT05699031|Device|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
79819631|NCT03362177|Other|Placebo|Placebo Comparator
79819632|NCT03345173|Drug|CI-581-a|Two infusions in the context of naltrexone induction protocol.
79371079|NCT00089973|Drug|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m^2).
79371080|NCT03030820|Procedure|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
79993045|NCT03713073|Device|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
79993046|NCT05760495|Other|blood sampling|Blood sampling for evaluation of oxidative stress markers
79993047|NCT03633435|Procedure|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
79993048|NCT03107715|Behavioral|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
79360259|NCT06132906|Procedure|Orthognathic surgery (lefort1)|"All patients will be treated under general anesthesia.~The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~External reference marking~Incision and subperiosteal dissection~Maxillary osteotomy~Pterygomaxillary disjunction,~Septal, vomerine, and lateral nasal osteotomies~Down fracture~Mobilization of the maxilla~Application of stent in one group and the locating guide in the other group.~Maxillary fixation~Occlusal evaluation~Wound debridement and closure"
79993049|NCT03107715|Behavioral|Positive Messaging|iPad based behavioral intervention facilitated by researcher
79993050|NCT03567057|Drug|ADS-5102, 274 mg|Oral capsules
79360260|NCT06132815|Device|Laser troughing|Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
79993051|NCT03508557|Behavioral|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
79511134|NCT05699031|Other|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
79511135|NCT05689853|Drug|AK119|AK119 is an anti-CD73 monoclonal antibody.
79511136|NCT05689853|Drug|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
79511137|NCT05686083|Dietary Supplement|C6 ketone di-ester|C6 ketone di-ester
79511138|NCT05686083|Dietary Supplement|Novel ketone di-ester|Novel ketone di-ester
79819633|NCT03345173|Drug|CI-581-b|Two infusions in the context of naltrexone induction protocol.
79993052|NCT03316833|Device|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score <33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
79993053|NCT05760417|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
79993054|NCT04388787|Device|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
79993055|NCT03477357|Device|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
79993056|NCT03057600|Drug|Paclitaxel|standard weekly paclitaxel in 28-day cycles
79993057|NCT03057600|Drug|CB-839|CB-839 administered as oral tablets twice daily (BID)
79993058|NCT04382937|Drug|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
79993059|NCT04382937|Drug|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
79993060|NCT04355169|Drug|Naldemedine|Oral tablet
79993061|NCT04355169|Drug|Placebo|Oral tablet
79993062|NCT05206890|Drug|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
79993063|NCT05212974|Other|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
79308419|NCT03208517|Other|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
79511139|NCT05668286|Drug|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
79819634|NCT03333343|Drug|EGF816|Study Drug
79819635|NCT03333343|Drug|trametinib|Study Drug
79819636|NCT03333343|Drug|ribociclib|Study Drug
79819637|NCT03333343|Drug|LXH254|Study Drug
79819638|NCT03333343|Drug|INC280|Study Drug
79360261|NCT06132815|Other|Retraction cord and astringent|Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
79360262|NCT06132815|Other|Cordless retraction paste with astringent|The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
79511140|NCT06024083|Behavioral|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
79511141|NCT06024057|Drug|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
79511142|NCT06024031|Drug|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
79511143|NCT06024018|Device|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
79511144|NCT06024018|Behavioral|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
79511145|NCT06024005|Drug|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
79308420|NCT04857801|Drug|Teduglutide|effect of teduglutide on intestinal rehabilitation
79308422|NCT03343457|Behavioral|Cognitive therapy|
79308423|NCT03208439|Device|lower-limb cycling system|patients will receive 30-minute cycling exercise
79511146|NCT06024005|Device|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
79511147|NCT06023979|Other|Full weight bearing|Full weight bearing monitored with a bio-feedback insole
79511148|NCT06023979|Other|Partial weight bearing|Partial weight bearing monitored with a bio-feedback insole
79819639|NCT03333343|Drug|gefitinib|Study Drug
79360263|NCT06132815|Other|Cordless retraction paste without astringent|The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
79360264|NCT06132802|Procedure|Patients who received treatment involving ARS and arthrocentesis only|A 5mm acrylic anterior repositioning splint (ARS) with maxillary coverage was crafted from alginate impressions. After arthrocentesis, the ARS was worn incrementally over six months, starting at two hours and reaching 14 hours daily. In the second week, wear time was continuous, increasing to 24 hours daily (excluding meals) until the sixth month. The ramp was removed in the seventh week. Follow-ups involved grinding the splint by 1mm every four weeks. Arthrocentesis included anesthesia, betadine prep, and using two 18-gauge needles to inject Ringer's lactate solution (100-200 cc) for joint lavage, freeing the disc by moving the lower jaw in various orientations.
79360265|NCT06132802|Procedure|Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|"A 5mm acrylic anterior repositioning splint (ARS) was crafted from alginate impressions, secured with Adam's clasps on upper first molars. After arthrocentesis, patients wore the splint incrementally over six months, starting at two hours and reaching 24 hours daily (excluding meals). The ramp was removed in the seventh week, and follow-ups included grinding the splint by 1mm every four weeks until it reached 3mm, guided by articulating paper.~Arthrocentesis involved administering anesthesia, prepping the area with betadine, and using two 18-gauge needles to inject 2-3 ml of Ringer's lactate solution for joint lavage. The lower jaw was moved to free the disc and release fibrous tissue. I-PRF preparation included centrifuging collected blood for 3 minutes at 700 rpm, and the resulting I-PRF was injected into the superior joint space of the lavaged joints."
79360266|NCT06132776|Device|HiToP 191 PNP|High tone therapy
79360267|NCT06132776|Device|Placebo device|Placebo therapy
79360268|NCT06132750|Other|No intervention|No intervention
79360269|NCT06132711|Other|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
79360270|NCT06132646|Other|Proprioceptive exercises|Specific proprioceptive exercises for the wrist that the patient has to do currently with standard rehabilitation.
79511149|NCT06023940|Dietary Supplement|High fiber|A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
79511150|NCT06023914|Other|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
79511151|NCT06023914|Other|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
79511152|NCT06023901|Diagnostic Test|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
79670819|NCT03828227|Drug|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks [q2w]),~Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~Bevacizumab: 5 mg/kg IV (day 1, q2w),~FA: 400 mg/m² IV/2h (day 1, q2w),~5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~No 5-FU bolus"
79670820|NCT03828227|Drug|Capecitabine plus bevacizumab|"Bevacizumab: 7.5 mg/kg intravenous infusion [IV] (day 1; q3w),~Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
79819640|NCT03306927|Dietary Supplement|Whole yellow pea chili|Chili containing whole yellow peas
79819641|NCT03306927|Dietary Supplement|Split yellow pea chili|Chili containing split yellow peas
79360271|NCT06132633|Device|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
79511153|NCT06023888|Other|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
79511154|NCT06023888|Other|Mapping strategy|PVI+ non-PV trigger
79511155|NCT06023875|Drug|Cadonilimab|Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
79819642|NCT03306927|Dietary Supplement|Rice chili|Chili containing long grain white rice
79819643|NCT03306862|Dietary Supplement|Whole yellow pea soup|Soup containing whole yellow peas
79819644|NCT03306862|Dietary Supplement|Split yellow pea soup|Soup containing split yellow peas
79360272|NCT06132620|Drug|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
79360273|NCT06132620|Drug|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
79360274|NCT06132607|Device|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
79360275|NCT06132594|Procedure|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
79360276|NCT06132594|Procedure|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
79511156|NCT06023875|Drug|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
79511157|NCT06023875|Drug|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
79511158|NCT06023849|Device|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
79511159|NCT06023810|Behavioral|Watson's human care theory-based motivational interviewing method|The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
79511160|NCT06023797|Drug|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
79511161|NCT06023784|Procedure|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
79511162|NCT06023784|Procedure|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
79511163|NCT06023771|Procedure|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
79511164|NCT06023758|Drug|KN026|KN026：30 mg/kg Q3W
79511165|NCT06023758|Drug|KN046|KN046：5 mg/kg Q3W
79511166|NCT06023758|Drug|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
79511167|NCT06023745|Genetic|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
79670827|NCT03818035|Drug|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
79670828|NCT03818035|Drug|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
79670829|NCT03809793|Other|Exercise Program|12-week walking based intervention (3 sessions per week)
79670830|NCT03809793|Diagnostic Test|DXA|Participants will undergo an assessment of body composition (DXA)
79670831|NCT03809793|Diagnostic Test|MRI|used to measure fat stored in the liver
79819645|NCT03306862|Dietary Supplement|Potato soup|Soup containing potatoes
79511168|NCT06023693|Behavioral|i-Sleep & BioClock|Module 1 Psychoeducation about normal sleep and insomnia, Psychoeducation on the biological clock: the circadian rhythm, chronotypes, zeitgebers, importance of light behaviour Basic sleep hygiene: information about behaviours that are known to promote or impede sleep e.g. performing physical exercise or the use of caffeine Module 2 Sleep restriction and stimulus control: patients are taught to use the bedroom only to sleep and to restrict the time in bed to the average amount of night-time sleep Module 3 Worrying and relaxation: audio files with progressive muscle relaxation exercises are offered and techniques to stop worrying (e.g. thought blocking, evaluation and worry time) Module 4 Erroneous cognitions about sleep: the basics of cognitive behavioural therapy are explained and the most common erroneous ideas about insomnia are discussed Module 5 Summary and plan for the future
79511169|NCT06023693|Behavioral|Online Psychoeducation|Online psychoeducation about sleep and the biological clock, basic sleep hygiene
79511170|NCT06023381|Other|Sliding sign|"All women had Transabdominal Ultra-sonography using SAMSUNG WS80 elite ultrasound machine during the preoperative examination, using the real-time Transabdominal pelvic features (the relative motion between the maternal abdominal and uterine wall).~The patient was asked to breathe deeply, accentuating her respiratory movements and the sonographer recorded a video clip in a mid-sagittal plane lateral to umbilicus focus on the infra-umbilical space, to determine whether the structure glided freely in relation to adjacent structures. To be considered as sliding, the structures had to glide easily, one against the other (positive sliding sign); no motion of the structure in question signaled a negative sliding sign."
79511171|NCT05814042|Drug|Next Generation ORS (oral rehydration solution) (including placebo|Nutrition used to stop diarrhea
79511172|NCT05814042|Drug|Current standard control ORS (oral rehydration solution)|current standard control ORS in diarrheic patients with cholera
79511173|NCT05557877|Procedure|Biospecimen Collection|Undergo collection of blood
79670832|NCT03809793|Diagnostic Test|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
79670833|NCT03809793|Diagnostic Test|VO2 Max|Assessment of maximum aerobic capacity.
79993064|NCT03371823|Other|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
79993065|NCT03371823|Drug|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
79993066|NCT03879642|Behavioral|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
79993067|NCT05212896|Drug|BC006|BC006 monoclonal antibody injection
79993068|NCT03619980|Other|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
79993069|NCT03125967|Other|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
79993070|NCT03125967|Other|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
79993071|NCT04308603|Diagnostic Test|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
79993072|NCT05212506|Biological|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
79993073|NCT03012789|Procedure|Surgery|Surgical excision
79511174|NCT05557877|Drug|Low-Dose Aspirin|Given PO
79511175|NCT05557877|Other|Questionnaire Administration|Ancillary studies
79670834|NCT03809793|Diagnostic Test|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
79670835|NCT03809793|Procedure|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
79511176|NCT05557877|Procedure|Ultrasound-Guided Biopsy|Undergo ultrasound-guided breast biopsy
79360277|NCT06132555|Other|Online questionnaire survey|"The investigators have made an electronic questionnaire through the questionnaire star, and send the link or two-dimensional code of the electronic questionnaire to the subjects through WeChat or SMS to remind them to fill in the answer on the mobile phone or computer.~The questionnaire consisted of four parts: (1) basic information of the interviewees, (2) drug abuse of the interviewees, (3) drug treatment interventions received by the interviewees, and (4) problems encountered by the interviewees when they return to society."
79360278|NCT06132555|Other|In-depth personal interview|The in-depth personal interview was conducted in a semi-structured way. The outline of the interview was formulated from seven aspects: drug use history, drug abstinence history, relapse situation, living conditions, physical and mental health status, return to society status, and active drug abstinence willingness of the drug abstinence personnel. The aim was to understand the needs of drug addicts in terms of family relationship, peer relationship, history of drug use, history of drug withdrawal, employment, economy, social support network, psychology, and assistance.
79670836|NCT03809793|Drug|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
79993074|NCT02966301|Drug|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
79511181|NCT05365061|Other|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
79511182|NCT05365061|Other|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
79511183|NCT05365061|Other|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
79511184|NCT05297396|Other|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
79511185|NCT05092516|Device|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
79511186|NCT05092516|Device|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
79511187|NCT05023291|Diagnostic Test|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
79511188|NCT04831125|Other|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
79511189|NCT04609735|Other|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
79511190|NCT04609735|Other|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
79511191|NCT04609709|Other|Thrust Manipulation, Electric Dry Needling and Exercise|Thrust Manipulation, Electric Dry Needling
79511192|NCT04609709|Other|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
79511193|NCT04035408|Other|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
79511194|NCT03968614|Other|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
79511195|NCT03968614|Other|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
79511196|NCT03695471|Biological|Pembrolizumab|Given IV
79670837|NCT03804892|Diagnostic Test|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
79670838|NCT03804892|Diagnostic Test|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
79670839|NCT03804892|Diagnostic Test|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
79670840|NCT03804892|Other|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
79670841|NCT03804892|Other|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
79511197|NCT03167710|Other|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
79511198|NCT03167710|Other|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
79511199|NCT03085043|Procedure|Bone Scan|Undergo bone scan
79511200|NCT03085043|Procedure|Computed Tomography|Undergo CT of the abdomen and pelvis
79511201|NCT03085043|Procedure|Magnetic Resonance Imaging|Undergo pelvic MRI
79670842|NCT03798093|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
79993075|NCT03262623|Other|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
79360279|NCT06132555|Other|Colloquia|"The colloquia were carried out in the form of group interviews, 1-2 people from each different institution were selected to participate, and the number of people in each colloquium was controlled to be between 6 and 12.~The colloquia mainly focused on: ① The status quo of the implementation of the local drug drug treatment policy, ② the status quo of the compulsory isolation drug treatment work, ③ the status quo of the work of social workers for drug drug treatment, ④ the status quo of the work of community health centers, ⑤ the operation of various mechanisms in the work of various units, and ⑥ what content in the drug control work needs assistance from other departments and what external resources are needed."
79360280|NCT06132542|Biological|stem cell therapy|The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture.
79360281|NCT06132529|Diagnostic Test|Brain Magnetic Resonance Imaging (MRI) Scan|Imaging of the brain
79360282|NCT06132529|Other|Speech Sample|Recorded reading aloud of pre-written words and sentences
79511202|NCT03085043|Procedure|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
79511203|NCT02464696|Drug|Methylprednisolone|IPS cohort only
79511204|NCT02464696|Procedure|Oxygen Therapy|Receive high flow oxygen therapy
79511205|NCT02464696|Device|Positive Air Pressure Device|Undergo NIPPV
79670843|NCT03798093|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
79670844|NCT03794921|Other|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
79670845|NCT03783871|Device|Microwave ablation|Subjects will be treated with microwave ablation.
79819646|NCT03306706|Dietary Supplement|Whole pea muffins|2 muffins containing whole peas
79819647|NCT03306706|Dietary Supplement|Split pea muffins|2 muffins containing split peas
79993076|NCT03262623|Other|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
79511210|NCT02135874|Drug|Clofarabine|Given IV
79511211|NCT02135874|Drug|Cytarabine|Given IV
79511212|NCT02135874|Drug|Dexamethasone|Given IV
79511213|NCT02135874|Drug|Idarubicin|Given IV
79511214|NCT02135874|Biological|Rituximab|Given IV
79511215|NCT02135874|Drug|Sorafenib|Given PO
79511216|NCT02135874|Drug|Sorafenib Tosylate|Given PO
79511217|NCT02135874|Drug|Vincristine|Given IV
79993077|NCT05759169|Other|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
79511218|NCT02135874|Drug|Vincristine Sulfate|Given IV
79511219|NCT02114138|Procedure|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
79511220|NCT02114138|Diagnostic Test|urine collection|urine collection will be performed on both the control group and hospitalized participants
79511221|NCT01738139|Drug|Imatinib Mesylate|Given PO
79360283|NCT06132529|Other|Electronic Daily Headache Diary|Headache diary to provide information about headaches experience that day.
79511222|NCT01738139|Biological|Ipilimumab|Given IV
79819648|NCT03306706|Dietary Supplement|Wheat muffins|2 muffins containing wheat
79360284|NCT06132516|Other|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
79360285|NCT06132516|Other|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
79360286|NCT06132490|Device|Conventional Insufflator with 12 mmHg intra-abdominal pressure|In this group conventional insufflators, which have been in clinical practice for a long time, will be used under low intra-abdominal pressure throughout the surgery.
79511223|NCT01719718|Procedure|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
79511224|NCT01719718|Procedure|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
79511225|NCT00791635|Other|Quality-of-Life Assessment|Ancillary studies
79511226|NCT00791635|Other|Questionnaire Administration|Complete questionnaires
79511227|NCT00501826|Drug|Cyclophosphamide|Given IV
79511228|NCT00501826|Drug|Cytarabine|Given IV
79511229|NCT00501826|Drug|Dexamethasone|Given IV or PO
79511230|NCT00501826|Drug|Doxorubicin Hydrochloride|Given IV
79511231|NCT00501826|Drug|Mercaptopurine|Given PO
79511232|NCT00501826|Drug|Methotrexate|Given IV and PO
79511233|NCT00501826|Drug|Nelarabine|Given IV
79511234|NCT00501826|Drug|Pegaspargase|Given IV
79511235|NCT00501826|Drug|Prednisone|Given PO
79511236|NCT00501826|Drug|Venetoclax|Given PO
79511237|NCT00501826|Drug|Vincristine Sulfate|Given IV
79511238|NCT00492817|Procedure|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
79511239|NCT00323674|Device|Polysoft Mesh|Polysoft Mesh is used.
79511240|NCT00323674|Device|Light Weight Mesh|Light Weight Mesh is used.
79511241|NCT05646628|Behavioral|Qualitative Interviews|Semi-structured Qualitative Interviews
79511242|NCT05645471|Behavioral|Together After Cancer|This is an online couples intervention for Latina breast cancer survivors and their intimate partners.
79819649|NCT03299231|Device|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
79819650|NCT03299231|Device|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
79819651|NCT03298893|Drug|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
79819652|NCT03298893|Drug|Cisplatin|40 mg/m2, once a week during radiotherapy
79511243|NCT05636059|Other|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
79511244|NCT05636059|Other|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
79993078|NCT03107091|Drug|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
79511245|NCT05636059|Other|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
79511246|NCT05622500|Procedure|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
79511247|NCT05622500|Combination Product|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
79511248|NCT05620472|Drug|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of [99mTc]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
79511249|NCT05618951|Other|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~Latissimus pull down~Prone V- raise~Modified Prone Cobra"
79511250|NCT05588583|Device|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~a soft silicone wound contact layer (Safetac)~a flexible absorbent pad of compressed polyurethane foam~an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
79511251|NCT05581823|Drug|Tavapadon|Oral tablets
79511252|NCT05581823|Drug|Carbamazepine|Extended-release oral tablets
79511253|NCT05553951|Behavioral|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
79511254|NCT05553951|Behavioral|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
79993079|NCT03849768|Drug|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79993080|NCT03849768|Drug|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79993081|NCT03189693|Other|PVB|nerve stimulator-guided PVB will be performed at two levels
79993082|NCT03189693|Other|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
79993083|NCT03189693|Other|GA|All patients will receive general anesthesia.
79819653|NCT03298893|Radiation|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
79511255|NCT05540704|Behavioral|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
79511256|NCT05540704|Other|Usual Care|Usual care for problems in Type 1 diabetes management
79511257|NCT05526976|Other|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus & Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
79819654|NCT03283540|Procedure|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
79819655|NCT03283540|Procedure|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
79993084|NCT03189693|Other|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
79993085|NCT03065400|Drug|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
79993086|NCT05200065|Procedure|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
79993087|NCT05200065|Procedure|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
79993088|NCT05212350|Procedure|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
79993089|NCT05212350|Procedure|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
79511258|NCT05498116|Drug|Montelukast|10mg daily
79511259|NCT05498116|Other|Placebo|1 capsule daily
79993090|NCT04165863|Procedure|total knee replacement surgery|total knee replacement surgery
79993091|NCT05199675|Behavioral|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
79993092|NCT05109156|Other|This is an observational study|This is an observational study
79993093|NCT05059314|Other|Brisk walking (moderate physical activity)|"Warm up and cool down~Brisk walk (30 mintues each session per week 5 days)~Week 1 to 6"
79993094|NCT05734716|Drug|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
79993095|NCT05734716|Drug|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
79993096|NCT05734716|Drug|Sterile Sodium Chloride|sham treatment with sterile saline
79360287|NCT06132490|Device|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
79360288|NCT06132490|Device|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
79511260|NCT05489978|Behavioral|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~Para-social contact~Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~Participatory learning techniques~Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
79511261|NCT05483686|Behavioral|Shine|This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.
79993097|NCT05044884|Other|Otago Exercise training|"Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~Back of thigh stretch, calf stretch, (hold for 8 seconds).~Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~Pulmonary rehabilitation program~Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~Stretch exercise for major respiratory muscles."
79993098|NCT05044884|Other|Circuit training|"Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~Sit on floor and stand up with assistance and then without assistance.~Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~Pulmonary rehabilitation program~Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~Stretch exercise for major respiratory muscles"
79511262|NCT05483686|Behavioral|Control|A playlist of CDC-developed videos designed to provide information on HIV for transgender women
79511263|NCT05450484|Drug|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
79511264|NCT05430373|Biological|GT101|Autologous tumor infiltrating lymphocyte injection
79511265|NCT05412446|Drug|ADAPT6-SPECT|Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
79511266|NCT05408377|Other|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
79819656|NCT03264079|Drug|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
79511267|NCT05408377|Other|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
79511268|NCT05404412|Procedure|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
79511269|NCT05398484|Drug|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
79511270|NCT05398484|Drug|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
79511271|NCT05398484|Behavioral|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
79511272|NCT05389982|Other|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
79670846|NCT03758742|Behavioral|High-Fruit Diet|Participants will consume a diet rich in whole fruit. During Phase I (Weeks 1-4; supervised controlled feeding), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In Phase II (Week 5-12; supervised controlled feeding), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable during Phases I and II. In the Follow-Up Phase (Months 4-12; free-living), participants will be instructed to continue consuming at least one-third of their diet as whole fruit and to make healthy food choices.
79670848|NCT03750227|Procedure|Conventional Surgery|Undergo surgery
79670849|NCT03750227|Other|Quality-of-Life Assessment|Ancillary studies
79670850|NCT03750227|Other|Questionnaire Administration|Ancillary studies
79993099|NCT05211258|Device|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
79993100|NCT05733000|Procedure|Biospecimen Collection|Undergo blood sample collection
79371081|NCT03030742|Other|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~Satisfaction with pain control 2-4 weeks postpartum~Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~Patient characteristics associated with high opioid use~Methods of storage and disposal of unused opioids"
79371082|NCT04402203|Drug|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
79511273|NCT05389982|Other|Standard Care|Office based pathway
79670851|NCT03750227|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
79670852|NCT03749057|Drug|Rivaroxaban|Rivaroxaban 15-20 mg daily
79670853|NCT03748641|Drug|Niraparib|Participants will receive niraparib 200 mg capsules once daily.
79670854|NCT03748641|Drug|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
79670855|NCT03748641|Drug|Prednisone|Participants will receive prednisone 10 mg tablets daily.
79670856|NCT03748641|Drug|Placebo|Participants will receive matching placebo once daily.
79670857|NCT03748641|Drug|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
79670858|NCT03744104|Biological|Quadrivalent influenza vaccine|0.5 mL, intramuscular, one dose
79670859|NCT03744104|Biological|Trivalent influenza vaccine A|0.5 mL, intramuscular, one dose
79670860|NCT03744104|Biological|Trivalent influenza vaccine B|0.5 mL, intramuscular, one dose
79670861|NCT03737994|Drug|Alectinib|Given PO
79670862|NCT03737994|Drug|Brigatinib|Given PO
79819657|NCT03264079|Drug|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
79308424|NCT04857879|Other|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
79308425|NCT03208361|Drug|Penicillin V|
79308426|NCT03208361|Drug|Amoxicillin|
79308427|NCT04847115|Procedure|Operative|Intramedullary screw fixation
79670863|NCT03737994|Drug|Carboplatin|Given IV
79670864|NCT03737994|Drug|Ceritinib|Given PO
79670865|NCT03737994|Drug|Cisplatin|Given IV
79670866|NCT03737994|Drug|Crizotinib|Given PO
79670867|NCT03737994|Drug|Ensartinib|Given PO
79670868|NCT03737994|Drug|Lorlatinib|Given PO
79670869|NCT03737994|Drug|Pemetrexed|Given IV
79819658|NCT03261453|Device|Active Elipse Device|Intervention Device
79819659|NCT03261453|Device|Elipse Sham Device|Control Device
79511274|NCT05388786|Behavioral|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
79819660|NCT03255031|Other|1. Ketogenic Diet (KD) / Standard American (SA) Meals and Shakes|1. Ketogenic Diet (KD) / Standard American (SA) Meals and Shakes: Participants will be randomized to a meal plan of either a ketogenic diet (KD) or standard American (SA) diet at the time they sign the consent (day 1 or 2 of admission). For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) or KD meal depending on treatment randomization. Compliance tests are done twice a week with a blood test measuring ketone levels. To ensure that the diet is double blind in both the outpatient and inpatient phases, solid snacks are always ketogenic and shakes are either KD or SA.
79993101|NCT05733000|Procedure|Computed Tomography|Undergo CT
79371083|NCT04402203|Drug|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
79371084|NCT03030976|Drug|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
79511275|NCT05387733|Drug|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
79670870|NCT03736304|Device|AKI alert|An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
79670871|NCT03736304|Other|Usual care|Patients will receive standard clinical care by the doctor in charge.
79670872|NCT03729999|Device|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
79670873|NCT03706482|Biological|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
79819661|NCT03238326|Drug|Brexpiprazole|Once daily, oral tablets
79819662|NCT03232073|Drug|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
79819663|NCT03196934|Drug|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
79993102|NCT05733000|Drug|Devimistat|Receive IV
79993103|NCT05733000|Drug|Fluorouracil|Receive IV
79993104|NCT05733000|Drug|Gemcitabine Hydrochloride|Receive IV
79993105|NCT05733000|Drug|Hydroxychloroquine|Receive PO
79670876|NCT03685175|Drug|Formal study using hyperpolarized 13C-pyruvate injection|Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)
79670877|NCT03685175|Drug|Feasible study using hyperpolarized 13C-pyruvate injection|Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
79993106|NCT05733000|Procedure|Magnetic Resonance Imaging|Undergo MRI
79993107|NCT05210946|Drug|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
79993108|NCT05210868|Drug|CM355|"Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
79993109|NCT03417180|Drug|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
79511276|NCT05387733|Drug|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
79993110|NCT03417180|Device|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
79360289|NCT06132464|Behavioral|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
79360290|NCT06132451|Other|Postponement of antihypertensive treatment|Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
79360291|NCT06132438|Drug|PEP-CMV vaccine|The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
79511277|NCT05386615|Device|Body System - Functional|MR-Guided Focused Ultrasound
79511278|NCT05374655|Other|Preoperative blood glucose control|Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
79511279|NCT05372757|Procedure|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
79511280|NCT05366699|Procedure|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
79511281|NCT05366699|Procedure|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
79511282|NCT05336084|Behavioral|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
79670878|NCT03674112|Drug|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
79670879|NCT03674112|Drug|Pertuzumab IV|Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
79670880|NCT03674112|Drug|Trastuzumab IV|Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
79670881|NCT03673501|Drug|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
79670882|NCT03673501|Drug|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
79993111|NCT03085095|Drug|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
79993112|NCT03085095|Drug|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
79993113|NCT04097301|Drug|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
79993114|NCT05199363|Other|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
79993115|NCT05199363|Other|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
79511283|NCT05334979|Other|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
79511284|NCT05327296|Drug|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
79511285|NCT05327296|Drug|Propofol|Intravenous infusion of propofol
79511286|NCT05317026|Procedure|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
79511287|NCT05317026|Procedure|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
79511288|NCT05292755|Drug|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
79511289|NCT05292755|Drug|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
79511290|NCT05289752|Procedure|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
79511291|NCT05289752|Device|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
79819664|NCT03118492|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
79819665|NCT03118492|Drug|Cyclophosphamide|Given IV
79819666|NCT03118492|Drug|Fludarabine|Given IV
79819667|NCT03118492|Biological|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
79819668|NCT03118492|Other|Laboratory Biomarker Analysis|Correlative studies
79819669|NCT03118492|Drug|Melphalan|Given IV
79819670|NCT03118492|Drug|Mycophenolate Mofetil|Given PO
79819671|NCT03118492|Drug|Tacrolimus|Given IV or PO
79360292|NCT06132425|Behavioral|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
79360293|NCT06132425|Behavioral|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
79371085|NCT03030976|Drug|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
79360294|NCT06132412|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
79360295|NCT06132412|Other|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
79360296|NCT06132399|Device|VIRTUAL REALITY GLASSES|The RESET virtual reality software will be integrated into the PICO virtual reality glasses (Pico Interactive, San Francisco, US) by DYNAMICS. Virtual reality consists of simulated interactions with environments and events that are presented to the individual through technology. The virtual environments may mirror real world situations or represent controlled environments away from the real world.
79360297|NCT06132386|Other|biopsy|colorectal biopsy for tissue acquisition
79511292|NCT05283395|Drug|Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%|Enrolled subjects will be instructed to self-instill 1 drop of Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% in each eye daily in the evening
79511293|NCT05277532|Behavioral|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
79511294|NCT05270863|Drug|BRIMOCHOL™ PF|A single drop in each eye at a visit.
79511295|NCT05270863|Drug|Carbachol PF|A single drop in each eye at a visit.
79511296|NCT05270863|Drug|Brimonidine tartrate|A single drop in each eye at a visit.
79819672|NCT03118492|Radiation|Total-Body Irradiation|Undergo TBI
79819673|NCT03113760|Drug|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
79360298|NCT06132373|Behavioral|Peer delivered problem solving therapy|PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
79511297|NCT05269511|Drug|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
79511298|NCT05264857|Behavioral|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
79511299|NCT05251298|Other|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
79511300|NCT05237219|Procedure|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
79511301|NCT05237219|Procedure|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
79511302|NCT05237141|Drug|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
79511303|NCT05232409|Biological|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
79670883|NCT03668340|Drug|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
79993116|NCT05199363|Other|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
79993117|NCT05760105|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
79670886|NCT03654547|Drug|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
79670887|NCT03650764|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
79670888|NCT03650764|Drug|Pembrolizumab|Pembrolizumab is commercially available
79670889|NCT03650764|Other|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
79670890|NCT03650764|Other|FACT H&N|-Screening, start of cycle 2, start of cycle 5
79360299|NCT06132321|Behavioral|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
79360300|NCT06132308|Procedure|PENG Block with 0.25% bupivacaine|Peng block was performed.
79360301|NCT06132295|Other|Nursing care|"Consistent Schedule for the Replacement of Positioning Line Pens~Tailored Educational Content~Hypoallergenic Adhesive Patches~Enriched Treatment Care Platform~Participants with BMI > 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI < 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
79360302|NCT06132217|Drug|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
79670891|NCT03650764|Procedure|Peripheral blood|-Baseline
79670892|NCT03644485|Drug|Tacrolimus immediate-release formulation|oral
79670893|NCT03644485|Drug|Tacrolimus prolonged-release formulation|oral
79511304|NCT05232409|Combination Product|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
79511305|NCT05226078|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
79670894|NCT03644485|Drug|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
79670895|NCT03644485|Drug|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
79670896|NCT03644485|Drug|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
79511306|NCT05218369|Drug|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
79670898|NCT03641092|Behavioral|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
79670899|NCT03641092|Behavioral|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site [when recruited families will be ineligible for CenteringParenting groups that will start in control sites]. They will receive anticipatory guidance and handouts that are standard for the clinic.
79670900|NCT03631940|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
79670901|NCT03631940|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
79670902|NCT03625986|Other|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine."
79819674|NCT03113760|Other|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
79308428|NCT04847115|Other|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
79360303|NCT06132217|Drug|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
79360304|NCT06132204|Drug|HRS-7535 Tablets|HRS-7535 Tablets
79360305|NCT06132191|Drug|Cemiplimab|
79360306|NCT06132152|Procedure|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
79360307|NCT06132152|Procedure|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
79360308|NCT06132100|Device|digitalized incentive spirometry|digitalized incentive spirometry
79360309|NCT06132100|Device|traditional incentive spirometry|traditional incentive spirometry
79360310|NCT06132061|Other|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
79360311|NCT06132061|Other|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
79371086|NCT03454425|Device|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
79819675|NCT03103932|Other|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
79360312|NCT06132061|Other|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
79360313|NCT06132061|Other|Waiting treatment.|Waiting treatment.
79360314|NCT06132048|Device|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
79360315|NCT06132035|Drug|CG-P5 peptide|Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye [self-administered] using the single use tear-off disposable packaging
79360316|NCT06132035|Drug|Placebo|Patient will instill daily 1 package of Placebo eye drops in the study eye [self-administered] using the single use tear-off disposable packaging
79360317|NCT06132035|Drug|Aflibercept Injection [Eylea]|Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
79511307|NCT05213741|Device|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
79511308|NCT05163795|Procedure|Lateral locking plate|Plating of the distal femur fracture with lateral locking plate.
79511309|NCT05137301|Device|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
79511310|NCT05137015|Other|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~Balance~Core stability~Hamstring eccentrics~Glute activation~Plyometrics~Running~Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
79511311|NCT05130398|Biological|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
79511312|NCT05130398|Dietary Supplement|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
79511313|NCT05130398|Diagnostic Test|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
79511314|NCT05130398|Combination Product|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
79511315|NCT05130398|Biological|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
79819676|NCT03077451|Other|Laboratory Biomarker Analysis|Correlative studies
79511316|NCT05130398|Other|Placebo|About 30 children do not receive diet, nor active pathogen detection
79511317|NCT05124691|Combination Product|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
79511318|NCT05124691|Drug|Albendazole|Albendazole 400mg single dose
79993118|NCT02811783|Drug|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
79993119|NCT02811783|Drug|Placebo Lotion|Topical TID for 2 weeks
79993120|NCT03632811|Other|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
79993121|NCT02746029|Other|Clinical examination|
79360318|NCT06132009|Procedure|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
79360319|NCT06131996|Other|Volar supported splint|participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
79360320|NCT06131996|Other|elastic splint|participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
79371087|NCT03454425|Device|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
79819677|NCT03077451|Drug|Nelfinavir Mesylate|Given PO
79360321|NCT06131931|Other|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
79511319|NCT05107336|Drug|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
79511320|NCT05107336|Drug|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection [0.9% saline solution]), once per month.
79511321|NCT05097274|Other|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
79511322|NCT05097274|Other|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
79511323|NCT05097274|Other|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
79819678|NCT03070301|Drug|LEE011|LEE011 200 mg daily
79819679|NCT03070301|Drug|everolimus|everolimus 5 mg daily or 2.5mg daily
79819680|NCT03047005|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
79511324|NCT05036785|Other|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
79511325|NCT05014087|Drug|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
79819681|NCT03047005|Other|Placebo|Placebo
79511326|NCT05012878|Behavioral|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
79993122|NCT05198973|Behavioral|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
79670903|NCT03625986|Other|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
79670904|NCT03621943|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
79670905|NCT03621943|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
79360322|NCT06131931|Other|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
79360323|NCT06131515|Device|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
79360324|NCT06130215|Other|Simple meal management|"Regular meal: Total Carbs per Day x 0.6 / 3~Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5"
79670906|NCT03598270|Drug|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
79670907|NCT03598270|Drug|Carboplatin|Intravenous. Day 1
79360325|NCT06130215|Other|Precise meal management|precise carbohydrate counting for each meal
79360326|NCT06130020|Behavioral|Expressive Writing: Self|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
79511327|NCT05012878|Behavioral|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
79670908|NCT03598270|Drug|Paclitaxel|175 mg/m². Intravenous. Day 1
79670909|NCT03598270|Drug|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
79670910|NCT03598270|Drug|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
79670911|NCT03598270|Drug|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
79670912|NCT03598270|Drug|Atezolizumab|1200 mg. Intravenous. Day 1
79670913|NCT03596671|Device|RENOVA iStim™ System|Tibial implantable neuromodulation device
79670914|NCT03593317|Drug|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
79670915|NCT03593317|Drug|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
79670916|NCT03582176|Drug|Lactose Placebo|One capsule by mouth twice per day
79308429|NCT02501915|Device|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
79511328|NCT05012878|Behavioral|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
79670917|NCT03582176|Drug|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
79670918|NCT03582176|Drug|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
79670919|NCT03581214|Other|No oxygen|No facemask, room air only
79670920|NCT03581214|Other|Oxygen|10Liters/minute oxygen by facemask
79670921|NCT03578367|Drug|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
79511329|NCT05012878|Behavioral|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
79511330|NCT05007093|Drug|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
79511331|NCT05005793|Drug|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
79511332|NCT05005793|Drug|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
79360327|NCT06130020|Behavioral|Expressive Writing: Other|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.
79360328|NCT06130020|Behavioral|Factual Writing|This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
79511333|NCT04982640|Behavioral|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
79511334|NCT04982640|Behavioral|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
79511335|NCT04982640|Behavioral|Nutrition Counseling|One, 30-minute session with registered dietitian
79511336|NCT04970134|Other|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
79511337|NCT04970134|Other|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
79511338|NCT04970134|Other|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
79511339|NCT04966351|Behavioral|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
79511340|NCT04966351|Behavioral|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
79511341|NCT04955678|Drug|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
79511342|NCT04955678|Drug|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
79511343|NCT05175547|Drug|Clevidipine|Blood pressure management with Clevidipine
79511344|NCT04948866|Behavioral|ADRD-PC Program|Included in arm/group descriptions
79511345|NCT04924166|Drug|Placebo|Inactive dose of capsules that appear identical to active dose
79511346|NCT04924166|Drug|Hydrocortisone|Hydrocortisone 180 mg in capsule form
79511347|NCT04921787|Other|Low Intensity|Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.
79511348|NCT04921787|Other|High Intensity|Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.
79511349|NCT04919681|Other|Stretch exercises|The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
79670922|NCT03578367|Drug|Imatinib|Imatinib 400 mg taken orally once daily
79360329|NCT06129747|Radiation|Radiation Therapy|"Weeks 1, 2 and 3~Weeks 1, 2 and 3 will include 5 days of treatment.~One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
79360330|NCT06129526|Dietary Supplement|EPAVasc|EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol
79360331|NCT06129526|Dietary Supplement|Corn Oil|Corn Oil
79360332|NCT06129448|Diagnostic Test|transthoracic echocardiography|All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
79360333|NCT06129188|Drug|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
79360334|NCT06129188|Drug|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
79360335|NCT06128447|Drug|ZP5-9676 600 mg dose|oral, chewable tablet formulation of flubendazole
79360336|NCT06128447|Drug|Placebo|Matching placebo
79360337|NCT06128330|Drug|Tranexamic acid bolus 20 mg/kg|Bolus of tranexamic acid in the standard dose group
79360338|NCT06128330|Drug|Tranexamic acid bolus 10 mg/kg|Bolus of tranexamic acid in the low dose group
79360339|NCT06128330|Drug|Tranexamic acid bolus 1 mg/kg|Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
79360340|NCT06128330|Drug|Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group|Tranexamic acid continuous infusion during the procedure
79360341|NCT06127862|Other|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
79360342|NCT06127862|Other|No training was given|No training was given
79360343|NCT06126757|Device|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
79360344|NCT06126757|Other|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
79360345|NCT06126549|Behavioral|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
79360346|NCT06126549|Behavioral|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
79511350|NCT04908371|Procedure|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
79670923|NCT03578367|Drug|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
79670924|NCT03578367|Drug|Asciminib single agent|Asciminib 80 mg taken orally once daily
79670926|NCT03571763|Other|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
79670927|NCT03568058|Drug|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
79360347|NCT06126549|Behavioral|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
79360348|NCT06126393|Diagnostic Test|next generation sequencing AND Immunohistochemical examination|First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
79360349|NCT06125067|Procedure|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
79819682|NCT03038750|Other|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
79360350|NCT06125067|Procedure|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
79360351|NCT06125067|Procedure|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
79360352|NCT06124625|Procedure|Rehabilitation combined to a digital maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
79360353|NCT06124625|Procedure|Rehabilitation without maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.
79360354|NCT06124287|Diagnostic Test|MR Enterography (MRE)|MRI scan
79360355|NCT06124131|Behavioral|Financial incentive for colorectal cancer screening|$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
79360356|NCT06124131|Behavioral|Financial incentive for flu shot|$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
79360357|NCT06124131|Behavioral|Financial incentive for COVID-19 shot|$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
79511351|NCT04908371|Procedure|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
79819683|NCT03038750|Other|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
79819684|NCT03038750|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
79308430|NCT03041961|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
79993123|NCT05410353|Behavioral|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing < 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
79360358|NCT06124001|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
79993124|NCT05410353|Behavioral|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
79993125|NCT05198661|Biological|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
79993126|NCT02364843|Dietary Supplement|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
79360359|NCT06124001|Drug|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
79511352|NCT04893551|Biological|Tilvestamab|Tilvestamab will be administered as IV infusion.
79993127|NCT03633123|Drug|D_PLEX|D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
79993128|NCT03633123|Other|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
79511353|NCT04893512|Drug|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
79993129|NCT02276547|Device|Mitral valve replacement|Transcatheter mitral valve replacement
79993130|NCT05296083|Dietary Supplement|G3P-01|G3P-01 is a food-grade pectic product derived from squash.
79993131|NCT01917903|Behavioral|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
79308431|NCT03041961|Dietary Supplement|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
79360363|NCT06116656|Diagnostic Test|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
79511354|NCT04863313|Dietary Supplement|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
79511355|NCT04863313|Dietary Supplement|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
79511356|NCT04838379|Drug|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block & tap block was performed
79511357|NCT04830878|Drug|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
79670928|NCT03568058|Drug|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
79993132|NCT01917903|Behavioral|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
79360364|NCT06115577|Diagnostic Test|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
79360365|NCT06114147|Device|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
79360366|NCT06114147|Device|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
79360367|NCT06114147|Device|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
79360368|NCT06111898|Other|No Intervention|No intervention
79360369|NCT06107634|Procedure|Gastropexy|"In the intervention group, the following three additional attachment points between the stomach and surrounding anatomical structures will be completed with non-absorbable suture material:~The left lateral part of the fundus flap is adapted to the diaphragm at its flat tendinous part of the diaphragm lateral to the hiatus, with a 2-3 cm long continuous non-absorbable suture (left postero-lateral gastropexy).~The anterior stomach wall is attached to the abdominal wall with a 2-3 cm long continuous non-absorbable suture (anterior gastropexy).~The posterior fundus is adapted to the right crus with a 2-3 cm long non-absorbable suture (right-posterior gastropexy)."
79360370|NCT06105567|Behavioral|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
79993133|NCT02966834|Drug|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
79993134|NCT02966834|Drug|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
79993135|NCT03106077|Biological|Mirvetuximab Soravtansine|Given IV
79360371|NCT06099964|Behavioral|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
79360372|NCT06099964|Behavioral|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
79360373|NCT06099509|Other|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
79360374|NCT06096428|Device|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
79360375|NCT06096428|Device|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
79360376|NCT06095349|Other|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
79360377|NCT06094855|Other|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
79360378|NCT06094322|Other|MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction
79308432|NCT03041961|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
79360379|NCT06094049|Other|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
79670929|NCT03556839|Drug|Atezolizumab|Intravenous Infusion
79670930|NCT03556839|Drug|Bevacizumab|Intravenous Infusion
79670931|NCT03556839|Drug|Cisplatin/Carboplatin|Intravenous Infusion
79670932|NCT03556839|Drug|Paclitaxel|Intravenous Infusion
79670933|NCT03534700|Procedure|parasacral flap reconstruction|parasacral flap reconstruction
79360380|NCT06094049|Other|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
79360381|NCT06089668|Other|Observational Study|None, this is a non-interventional trial
79360382|NCT06081335|Device|EdgeEndo x7 continuous rotation files|endodontic files operating in continuous rotation
79360383|NCT06081335|Device|EdgeOne Fire reciprocating files|endodontic files operating in reciprocating motion
79360384|NCT06075615|Drug|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
79360385|NCT06073626|Behavioral|Relational agent (RA) / Chatbot|Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.
79360386|NCT06073626|Behavioral|Enhanced Usual Care (EUC)|Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
79308433|NCT03343379|Other|Core stability tests|A test battery comprised of field tests to evaluate core stability
79308434|NCT04857567|Behavioral|TSC program (Three Self-Commitment program)|"Self-Competence program~- A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~Self-Care program~- A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent"
79360387|NCT06072378|Behavioral|Value-manipulation|During the decision-making task, different choices are assigned different values probabilistically.
79360388|NCT06055946|Device|robotic assisted radical prostatectomy|Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
79360389|NCT06052592|Other|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
79360391|NCT06045611|Dietary Supplement|Isolated Pea Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
79670934|NCT03534700|Procedure|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
79308435|NCT02501837|Drug|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
79360392|NCT06045611|Dietary Supplement|Isolated Whey Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
79360393|NCT06045611|Dietary Supplement|Isolated Faba Bean Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
79360394|NCT06045611|Dietary Supplement|Placebo|Participants will consume the placebo in an opaque mug wearing a nose clip.
79670936|NCT03517969|Drug|Berzosertib|Given IV
79670937|NCT03517969|Drug|Carboplatin|Given IV
79670938|NCT03517969|Drug|Docetaxel|Given IV
79670939|NCT03517969|Other|Laboratory Biomarker Analysis|Correlative studies
79511358|NCT04815889|Behavioral|PRIMUS parent training Group|"The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~Support in the child's everyday environment home / preschool~Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~Web courses"
79670940|NCT03517722|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
79360395|NCT06039774|Drug|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
79360396|NCT06039774|Drug|Placebo|Placebo
79360397|NCT06037980|Drug|Gemcitabine|◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
79360398|NCT06037980|Drug|Nab paclitaxel|◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
79360399|NCT06037980|Drug|Cisplatin|◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
79360400|NCT06037980|Procedure|Curative Surgery|Curative surgery on primary tumor
79360401|NCT06037980|Drug|Capecitabine|1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
79360402|NCT06026371|Drug|Fecal Microbiota Transplantation Capsule|Given PO
79360403|NCT06026371|Drug|Placebo|Given PO
79360404|NCT06023602|Drug|Generic cetrorelix acetate|Generic cetrorelix acetate (0.25 mg SC)
79511365|NCT04800107|Biological|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
79511366|NCT04800107|Biological|Placebo capsule|Placebo capsule
79670941|NCT03517722|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
79360405|NCT06023602|Drug|Reference cetrorelix acetate|reference cetrorelix acetate (0.25 mg SC)
79360406|NCT06014385|Drug|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
79360407|NCT06014385|Radiation|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of [11C]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
79670942|NCT03517722|Drug|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
79819685|NCT03038750|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
79511367|NCT04796051|Device|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
79511368|NCT04796051|Other|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
79511369|NCT04786782|Diagnostic Test|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
79511370|NCT04786782|Diagnostic Test|LSM and PLT count|Patients whose LSM >15kPa, or PLT count < 150*10^9 should be screened with upper GI endoscopy
79670943|NCT03507491|Drug|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
79670944|NCT03507491|Drug|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
79360408|NCT06014112|Device|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
79670945|NCT03503370|Drug|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
79670946|NCT03503370|Drug|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
79360409|NCT06013813|Procedure|Radial Artery approach on percutaneous coronary intervention (PCI)|"Randomized patients with a right patent radial artery.~The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~Technique and devices (introducer and compression devices) are the same in both approaches."
79360410|NCT06007781|Biological|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
79360411|NCT06007781|Biological|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
79360412|NCT06007482|Drug|ES009|ES009 is administered via intravenous infusion, once every 21 days.
79360413|NCT06006702|Drug|TYRA-300-B01|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
79360414|NCT06006286|Drug|Atezolizumab|Given by IV (vein)
79360415|NCT06006286|Drug|Bevacizumab|Given by IV (vein)
79360416|NCT06006286|Drug|ADI-PEG 20|Given by Injection (inj)
79360417|NCT06004973|Device|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
79360418|NCT06004115|Drug|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
79360419|NCT06004115|Other|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
79819686|NCT03038750|Other|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
79819687|NCT03038750|Other|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
79819688|NCT03038750|Other|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
79819689|NCT03038750|Other|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
79819690|NCT03038750|Other|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
79670947|NCT03484884|Diagnostic Test|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
79360420|NCT06003751|Drug|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
79511371|NCT04786574|Drug|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
79670948|NCT03474718|Biological|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
79670949|NCT03474718|Biological|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
79819691|NCT03038750|Other|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
79819692|NCT03038750|Other|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
79360421|NCT06003751|Drug|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
79360422|NCT06003751|Drug|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
79360423|NCT05999695|Other|self-management|"The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts."
79670950|NCT03465696|Behavioral|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
79670951|NCT03465696|Behavioral|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
79670955|NCT03441282|Drug|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
79670956|NCT03439462|Drug|nab-sirolimus|nab-sirolimus combined with mFOLFOX6 + bevacizumab
79360424|NCT05999695|Other|regular care|"gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text."
79670957|NCT03432936|Device|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
79360425|NCT05999032|Behavioral|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
79360426|NCT05999032|Behavioral|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
79819693|NCT03038750|Other|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
79819694|NCT03038750|Other|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
79819695|NCT03038750|Other|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
79819696|NCT03038750|Other|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
79819697|NCT03038750|Other|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
79819698|NCT03038750|Other|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
79819699|NCT03038750|Other|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
79360427|NCT05999032|Behavioral|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
79511372|NCT04769986|Behavioral|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
79670958|NCT03427099|Behavioral|Rehabilitation with a biopsychosocial focus|Rehabilitation with a biopsychosocial focus
79670959|NCT03427099|Behavioral|Control group|usual care
79670960|NCT03414502|Drug|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.
79670961|NCT03414502|Drug|Abatacept|Starting dose which may be adjusted as needed at the discretion of the investigator
79670962|NCT03414502|Drug|Adalimumab|Starting dose which may be adjusted as needed at the discretion of the investigator
79670963|NCT03414502|Drug|Azathioprine|Starting dose which may be adjusted as needed at the discretion of the investigator
79670964|NCT03414502|Drug|Baricitinib|Starting dose which may be adjusted as needed at the discretion of the investigator
79670965|NCT03414502|Drug|Certolizumab|Starting dose which may be adjusted as needed at the discretion of the investigator
79819700|NCT03038750|Other|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
79819701|NCT03038750|Other|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
79819702|NCT03030378|Procedure|Biopsy|Undergo a tumor biopsy
79819703|NCT03030378|Procedure|Biospecimen Collection|Undergo collection of blood
79819704|NCT03030378|Procedure|Computed Tomography|Undergo a CT scan
79819705|NCT03030378|Biological|Edodekin alfa|Given SC
79819706|NCT03030378|Procedure|Magnetic Resonance Imaging|Undergo a MRI
79819707|NCT03030378|Biological|Pembrolizumab|Given IV
79819708|NCT03030378|Procedure|Positron Emission Tomography|Undergo a PET scan
79819709|NCT03019185|Drug|Placebo Oral Capsule|Capsule containing an inert placebo
79819710|NCT03019185|Drug|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
79819711|NCT02991365|Other|nasal insulin|
79819712|NCT02991365|Other|placebo spray|
79819713|NCT02974621|Biological|Bevacizumab|Given IV
79819714|NCT02974621|Drug|Cediranib|Given PO
79819715|NCT02974621|Drug|Cediranib Maleate|Given PO
79819716|NCT02974621|Drug|Olaparib|Given PO
79511373|NCT04769986|Behavioral|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
79511374|NCT04761159|Drug|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
79511375|NCT04723641|Other|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
79511376|NCT04716296|Drug|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
79511377|NCT04716296|Drug|Saline|Saline will be given for the second stage of the DBS surgery.
79670966|NCT03414502|Drug|Etanercept|Starting dose which may be adjusted as needed at the discretion of the investigator
79670967|NCT03414502|Drug|Golimumab|Starting dose which may be adjusted as needed at the discretion of the investigator
79993136|NCT04052984|Procedure|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
79670968|NCT03414502|Drug|Hydroxychloroquine|Starting dose which may be adjusted as needed at the discretion of the investigator
79993137|NCT03648866|Other|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
79360428|NCT05999032|Behavioral|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
79360429|NCT05992662|Behavioral|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~Reminder of weekly practices~Recording changes in mindful eating in participant experience diaries during the follow-up"
79993138|NCT03648788|Other|NA (Observation study)|NA (Observation study)
79993139|NCT03647540|Procedure|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
79360430|NCT05988138|Behavioral|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
79360431|NCT05988138|Behavioral|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
79511378|NCT04704141|Drug|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
79511379|NCT04682041|Dietary Supplement|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
79511380|NCT04682041|Other|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
79511381|NCT04652661|Drug|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
79670969|NCT03414502|Drug|Infliximab|Starting dose which may be adjusted as needed at the discretion of the investigator
79670970|NCT03414502|Drug|Leflunomide|Starting dose which may be adjusted as needed at the discretion of the investigator
79670971|NCT03414502|Drug|Minocycline|Starting dose which may be adjusted as needed at the discretion of the investigator
79670972|NCT03414502|Drug|Rituximab|Starting dose which may be adjusted as needed at the discretion of the investigator
79670973|NCT03414502|Drug|Sarilumab|Starting dose which may be adjusted as needed at the discretion of the investigator
79670974|NCT03414502|Drug|Sulfasalazine|Starting dose which may be adjusted as needed at the discretion of the investigator
79819717|NCT02963025|Procedure|PEEP level|
79511382|NCT04652661|Drug|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
79511383|NCT04650451|Biological|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
79993140|NCT03647540|Procedure|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
79360432|NCT05984706|Other|Focus groups and Delphi Questionnaire|1. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
79360433|NCT05983575|Device|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
79670975|NCT03414502|Drug|Tofacitinib|Starting dose which may be adjusted as needed at the discretion of the investigator
79670976|NCT03410615|Radiation|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
79670977|NCT03410615|Drug|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
79993141|NCT04009382|Other|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
79993142|NCT04009382|Other|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
79993143|NCT03648008|Drug|Hydromorphone|0.002 mg*kg-1 bolus with 0.002 mg*kg-1 background infusion for group BH 0.002 mg*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
79993144|NCT03648008|Drug|Morphine|0.015 mg*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
79360434|NCT05983575|Device|Placebo|Placebo
79360435|NCT05978661|Drug|FKC288|Administration of FKC288 Four dose groups of 0.1×10^6 CAR-T/kg, 0.3×10^6 CAR-T/kg, 1.0×10^6 CAR-T/kg, and 3.0×10^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
79511384|NCT04637165|Other|This is a non-interventional study|This is a non-interventional study
79511385|NCT04623931|Other|Quality-of-Life Assessment|Ancillary studies
79511386|NCT04623931|Other|Questionnaire Administration|Ancillary studies
79511387|NCT04623931|Radiation|Radiation Therapy|Undergo radiation therapy
79511388|NCT04623931|Drug|Temozolomide|Given PO
79511389|NCT04611542|Behavioral|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
79511390|NCT04607330|Other|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
79670978|NCT03410615|Drug|Durvalumab|Given in concurrent and adjuvant phase
79670979|NCT03410615|Drug|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
79670980|NCT03409263|Other|Observational study|Not applicable (observational registry study)
79670981|NCT03389230|Biological|HER2(EQ)BBζ/CD19t+ T cells|Given via catheter
79670982|NCT03389230|Other|Laboratory Biomarker Analysis|Correlative studies
79670983|NCT03389230|Procedure|Leukapheresis|Undergo leukapheresis
79670984|NCT03384914|Biological|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
79670985|NCT03384914|Biological|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
79670986|NCT03375762|Other|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
79819718|NCT02963025|Procedure|Use of recruitment maneuvers|
79819719|NCT02961881|Drug|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
79993145|NCT03647930|Device|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
79511391|NCT04600323|Drug|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
79511392|NCT04600323|Drug|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
79511393|NCT04590781|Biological|XmAb18087|Monoclonal bispecific antibody
79511394|NCT04590781|Drug|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
79511395|NCT04573751|Drug|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
79511396|NCT04573751|Drug|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
79670987|NCT03375762|Other|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
79670988|NCT03375320|Drug|Cabozantinib S-malate|Given PO
79670989|NCT03375320|Procedure|Computed Tomography|Undergo CT
79670990|NCT03375320|Procedure|Magnetic Resonance Imaging|Undergo MRI
79670991|NCT03375320|Other|Placebo Administration|Given PO
79993146|NCT03105297|Device|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
79993147|NCT03105297|Other|No strip|
79360436|NCT05976724|Other|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
79360437|NCT05976724|Other|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
79360438|NCT05968690|Drug|Propranolol|Propranolol will be administered to patients in all cohorts.
79360439|NCT05968690|Drug|Naltrexone|Naltrexone will be administered to patients in cohorts 2, 3, and 4.
79511397|NCT04573751|Drug|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
79511398|NCT04573751|Drug|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
79511399|NCT04545437|Other|Admission to ICU|Exposure is admission to an Intensive Care Unit
79511400|NCT04539704|Device|magnet and sham|In same subject some areas will have magnet and others will have sham
79511401|NCT04536701|Behavioral|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
79511402|NCT04526834|Drug|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
79511403|NCT04522622|Drug|Teriparatide|20 micrograms
79670992|NCT03375320|Other|Quality-of-Life Assessment|Ancillary studies
79670993|NCT03375320|Procedure|X-Ray Imaging|Undergo x-ray
79670994|NCT03374982|Device|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
79670995|NCT03371498|Drug|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
79670996|NCT03371498|Drug|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
79670997|NCT03368729|Drug|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
79993148|NCT03647384|Drug|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
79511404|NCT04522622|Diagnostic Test|DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT|All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 18 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 18 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
79993149|NCT03647384|Drug|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
79360440|NCT05966168|Device|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
79360441|NCT05963048|Drug|Rituximab|IV infusion 1000 mg
79360442|NCT05963048|Drug|IL6 inhibitor|6 mg/kg I V infusion monthly
79360443|NCT05959356|Drug|Cetuximab + Envafolimab + mFOLFOXIRI|Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
79360444|NCT05959356|Drug|Cetuximab + mFOLFOX6/FOLFIRI|Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
79360445|NCT05948059|Drug|SHR-2106 injection or placebo|starting dose from 50 mg
79511405|NCT04522622|Procedure|Bone biopsy|All participants are invited to undergo a bone biopsy after 18 months, but it is not a must to have the procedure done to participate in the study.
79511406|NCT04522622|Diagnostic Test|Cardiac tests|All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
79993150|NCT05284916|Behavioral|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
79993151|NCT05702541|Device|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
79993152|NCT05702541|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
79360446|NCT05948059|Drug|SHR-2106 injection or placebo|starting dose from 300 mg
79511407|NCT04522622|Other|Blood and urine samples and physical examination|All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
79511408|NCT04511962|Other|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
79670998|NCT03368729|Drug|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
79360447|NCT05935800|Behavioral|COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC|This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
79511409|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
79993153|NCT05702541|Device|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
79993154|NCT05198037|Device|Bihemispheric tDCS|The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
79511410|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
79360448|NCT05935579|Drug|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
79511411|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
79360449|NCT05935579|Drug|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of <60 kg, taken once daily.
79511412|NCT04432207|Drug|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
79511413|NCT04432207|Drug|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
79511414|NCT04425447|Drug|Tumescent local anesthesia|"Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue."
79511415|NCT04425447|Drug|Thoracic paravertebral block|The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.
79511416|NCT04425447|Drug|Thoracic interfascial plane block|"Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A"
79511417|NCT04338581|Biological|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
79511418|NCT04338581|Biological|Placebo|Placebo for AMG 714
79511419|NCT04338581|Procedure|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
79511420|NCT04323787|Other|observational|No Intervention
79511421|NCT04323449|Device|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
79670999|NCT03366636|Behavioral|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~1. Thinking about the future~2. Present actions to achieve future success~3. Safeguarding one's future~4. Creating a Healthy Life Plan~5. Navigating service systems"
79671000|NCT03325101|Procedure|Cryosurgery|Undergo cryosurgery
79671001|NCT03325101|Biological|Pembrolizumab|Given IV
79671002|NCT03325101|Procedure|Pheresis|Undergo apheresis
79671003|NCT03325101|Biological|Therapeutic Autologous Dendritic Cells|Given IT
79671004|NCT03310918|Other|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
79671005|NCT03310918|Other|Standard Leukemia care|Standard care per the hospital guideline
79360450|NCT05935579|Drug|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
79511422|NCT04298541|Drug|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
79511423|NCT04298541|Drug|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
79511424|NCT04272736|Dietary Supplement|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
79511425|NCT04261673|Procedure|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
79511426|NCT04261673|Procedure|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
79511427|NCT04248868|Device|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
79511428|NCT04248868|Drug|r-tPA|Pulse spray and infusion
79511429|NCT04246138|Procedure|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
79511430|NCT04217993|Drug|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
79511431|NCT04211831|Drug|URO-902|intradetrusor injection
79511432|NCT04211831|Drug|Placebo|intradetrusor injection
79511433|NCT04205656|Biological|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
79511434|NCT04205656|Biological|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
79511435|NCT04205656|Other|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
79511436|NCT04169074|Drug|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
79511437|NCT04148105|Drug|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
79511438|NCT04148105|Other|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
79511439|NCT04139122|Drug|SJP-0132|SJP-0132 is administered as an eye drop
79511440|NCT04139122|Drug|Placebo|Placebo is administered as an eye drop
79511441|NCT04121676|Drug|AGEN2373|An Anti-CD137 Monoclonal Antibody
79511442|NCT04121676|Drug|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
79511443|NCT04067518|Biological|SHP674|SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m^2: 2500 IU/m^2 every 14 days if BSA <0.6 m^2: 82.5 IU/kg every 14 days
79671006|NCT03302494|Device|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
79671007|NCT03302494|Device|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
79671008|NCT03287544|Other|Combined rehabilitation|Linguistic training as well as communication training.
79671009|NCT03287544|Other|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
79511444|NCT04033419|Drug|Memantine|"memantine dose~Week 1: 5 mg dose once daily~Week 2: 5 mg dose twice daily~Week 3: 5 mg each morning/10 mg each evening~Week 4 through the end of Chemotherapy: 10 mg dose twice daily~Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
79671010|NCT03260569|Drug|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
79511445|NCT04026607|Dietary Supplement|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
79511446|NCT04019197|Drug|Semaglutide Injectable Product|semaglutide subcutaneous injection
79819720|NCT02952144|Device|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
79819721|NCT02932410|Drug|Macitentan|Dispersible tablet; Oral use
79511447|NCT04019197|Drug|Placebo|placebo injection
79511448|NCT04014283|Dietary Supplement|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
79511449|NCT04014283|Other|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
79511450|NCT04014283|Other|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
79511451|NCT03958006|Device|Cochlear implant|Tumor resection with cochlear implant
79511452|NCT03912233|Drug|VX-121|Tablets for oral administration.
79671011|NCT03260569|Drug|Placebo|Nitrogen plus oxygen
79671012|NCT03258593|Drug|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
79671013|NCT03258593|Drug|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
79671014|NCT03258593|Drug|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
79671015|NCT03258593|Drug|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
79819722|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
79511453|NCT03912233|Drug|TEZ|TEZ tablet for oral administration.
79511454|NCT03912233|Drug|VX-561|Tablets for oral administration.
79511455|NCT03912233|Drug|TEZ/IVA|Fixed-dose combination tablets for oral administration.
79511456|NCT03912233|Drug|IVA|Tablets for oral administration.
79511457|NCT03912233|Drug|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
79511458|NCT03879668|Device|eIPOS|Electronic version of IPOS
79819723|NCT02891382|Behavioral|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
79819724|NCT02891382|Behavioral|Goal setting|Goals for weight loss and change in levels of HbA1c
79671016|NCT03258593|Procedure|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
79671017|NCT03258593|Procedure|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
79671018|NCT03258593|Procedure|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
79671019|NCT03258593|Diagnostic Test|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
79671020|NCT03258593|Diagnostic Test|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
79671021|NCT03258593|Diagnostic Test|CT|Computed tomography (CT) at screening and every 12 months while on study.
79511459|NCT03842865|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
79993155|NCT05225025|Behavioral|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
79360451|NCT05924334|Other|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
79360452|NCT05924334|Other|placebo|placebo
79360453|NCT05922085|Other|Ultrasound|performed within 3 hours prior to extubation
79360454|NCT05922085|Other|nasofibroscopie|performed within 24 to 36 hours after extubation
79360455|NCT05915299|Device|OCS Heart|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
79360456|NCT05910697|Other|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
79671022|NCT03258593|Diagnostic Test|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
79671023|NCT03250663|Behavioral|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
79671024|NCT03250663|Drug|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
79671025|NCT03241615|Other|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
79671026|NCT03223090|Behavioral|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
79819725|NCT02891382|Behavioral|Companion Support|Patient has a companion/team support partner to support achieving goals.
79360457|NCT05906251|Genetic|SRP-6004|Single IV infusion of SRP-6004
79360458|NCT05901285|Drug|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
79360459|NCT05899868|Device|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
79511460|NCT03834870|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
79511461|NCT03781817|Drug|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
79819726|NCT02891382|Behavioral|Individual Reward|The cash reward is given to the patient with diabetes.
79819727|NCT02891382|Behavioral|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
79819728|NCT02885974|Drug|Celecoxib|Celecoxib (100 mg daily)
79819729|NCT02885974|Drug|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
79993156|NCT05225025|Other|Standard of Care|Usual hospital care with no behavioral intervention
79993157|NCT05054751|Drug|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side."
79819730|NCT02885974|Drug|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
79360460|NCT05890079|Other|Subcostal transversus abdominis plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
79360461|NCT05890079|Other|External oblique intercostal plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
79360462|NCT05889039|Device|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
79360463|NCT05889039|Procedure|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
79360464|NCT05889039|Procedure|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
79819731|NCT02866149|Biological|Blood sampling|Up to 5 blood samplings can be performed at different time points
79360465|NCT05885113|Behavioral|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
79511462|NCT03781817|Drug|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
79511463|NCT03729648|Behavioral|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
79511464|NCT03689868|Behavioral|Virtual Reality|Virtual Reality headset with calming scenery
79511465|NCT03636451|Drug|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
79993158|NCT05054751|Drug|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side."
79511466|NCT03636451|Drug|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
79511467|NCT03576989|Dietary Supplement|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
79819732|NCT02866149|Procedure|Tumor sampling|One tumor sampling can be performed, if applicable
79819733|NCT02866149|Other|Stool sampling|Up to 5 blood samplings can be performed at different time points
79819734|NCT02860039|Biological|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
79819735|NCT02860039|Biological|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
79819736|NCT02860039|Other|Laboratory Biomarker Analysis|Correlative studies
79511468|NCT03576989|Other|placebo|placebo contains mineral oil
79511469|NCT03546062|Other|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
79360466|NCT05873374|Biological|50 μg Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2
79360467|NCT05873374|Other|Placebo|Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
79819737|NCT02807636|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
79360468|NCT05868096|Other|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
79360469|NCT05868096|Other|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
79360470|NCT05866406|Behavioral|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
79511470|NCT03539952|Drug|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
79511471|NCT03539952|Drug|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
79511472|NCT03539952|Drug|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
79671027|NCT03223090|Behavioral|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
79819738|NCT02807636|Drug|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
79360471|NCT05866406|Behavioral|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
79511473|NCT03539952|Drug|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-<W108)
79511474|NCT03479697|Device|HIRREM|Technology
79671028|NCT03212742|Drug|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
79671029|NCT03212742|Drug|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
79511475|NCT03479697|Other|Continued Current Care|Continue their current clinical care.
79511476|NCT03355365|Biological|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
79511477|NCT03355365|Other|Intrathecal saline injection|Placebo
79511478|NCT03332550|Procedure|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
79511479|NCT03332550|Procedure|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
79511480|NCT03278691|Drug|Saline|1 ml saline IV Q6H
79511481|NCT03278691|Drug|Ketorolac|15 mg (15 mg/ml) IV Q6H
79511482|NCT03253991|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
79511483|NCT03044158|Device|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
79819739|NCT02807636|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
79360472|NCT05866406|Behavioral|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
79360473|NCT05864859|Other|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
79360474|NCT05863130|Drug|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
79360475|NCT05863130|Drug|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
79511484|NCT03044158|Behavioral|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
79511485|NCT03044158|Other|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
79511486|NCT02948569|Drug|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
79511487|NCT02929108|Behavioral|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
79511488|NCT02929108|Behavioral|ACCESS|"Intervention will have two components.~Participants will be enrolled in a Secret Facebook group for social support and education~Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
79511489|NCT02880631|Device|BAROSTIM NEO™ System|
79511490|NCT02880618|Device|Barostim Neo™ System|
79511491|NCT02876042|Device|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
79511492|NCT02726763|Device|Transcranial Direct Current Stimulation (tDCS)|
79511493|NCT02726763|Behavioral|Questionnaires|
79511494|NCT02705846|Other|Observation of treatment outcomes via Questionnaire|
79511495|NCT02661295|Drug|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
79511496|NCT02657265|Device|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
79511497|NCT02657265|Device|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
79511498|NCT02653716|Behavioral|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
79511499|NCT02653716|Behavioral|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
79360476|NCT05861245|Radiation|5-fraction hipofractionated protontheray|"The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction."
79511500|NCT02621489|Drug|Bydureon|2 mg Once Weekly
79511501|NCT02621489|Drug|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
79511502|NCT02621489|Drug|Metformin|Metformin 1g BID
79511503|NCT02596880|Drug|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
79360477|NCT05839470|Drug|cadonilimab|Cadonilimab (6mg/kg, iv, Q2W, Day1)
79360478|NCT05839470|Drug|irinotecan|irinotecan* 165 mg/m² iv continue for 1.5 hours, D1
79511504|NCT02596880|Drug|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
79511505|NCT02596880|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
79511506|NCT02553525|Procedure|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
79360479|NCT05839470|Drug|Oxaliplatin|oxaliplatin 85 mg/m² iv continue for 2 hours,
79360480|NCT05839470|Drug|leucovorin or levoleucovorin|leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours
79360481|NCT05839470|Drug|5-FU|5-FU 2400 mg/m² cont. inf. 46h
79360482|NCT05836103|Behavioral|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
79360483|NCT05825729|Diagnostic Test|Dry suction technique (A)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~- Dry suction puncture: Once the lesion is located and punctured, the stylet will be completely removed, and a 10 mL syringe with a vacuum of 10 mL will be attached. In each pass, the needle will be advanced and retracted 20-30 times according to the standard technique. The suction will then be closed, and the needle will be removed. The fanning technique will be performed whenever possible."
79360484|NCT05825729|Diagnostic Test|Slow-pull technique (B)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms."
79511507|NCT02553525|Procedure|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
79671030|NCT03212742|Radiation|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
79671031|NCT03201458|Drug|Atezolizumab|Given IV
79671032|NCT03201458|Procedure|Biopsy|Undergo tumor biopsy
79671033|NCT03201458|Procedure|Biospecimen Collection|Undergo collection of blood samples
79671034|NCT03201458|Drug|Cobimetinib|Given PO
79671035|NCT03201458|Procedure|Computed Tomography|Undergo CT
79671036|NCT03201458|Procedure|Magnetic Resonance Imaging|Undergo MRI
79671037|NCT03193814|Drug|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
79993159|NCT04791735|Procedure|Laparoscopy|"Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~Use of laparoscopic specific devices:~Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~Use of a laparoscopic camera system with 0° or 30°~Use of a dedicated laparoscopic ultrasound probe.~Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
79993160|NCT04791735|Procedure|Laparotomy|"Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
79360485|NCT05825729|Diagnostic Test|Wet suction technique (C)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~- Wet suction technique: Prior to puncture, the stylet should be removed and the needle should be flushed with 1-2 ml of physiological saline and a 10 ml vacuum syringe with 3-5 ml of saline should be attached. In each pass, the needle should be moved forward and backward 20-30 times. Aspiration should be opened as the needle advances and closed as it is withdrawn. Afterwards, the aspiration should be closed and the needle should be removed. The fanning technique should be performed whenever possible."
79993161|NCT00604617|Procedure|Interferon-Gamma Release Assay|IGRAs
79993162|NCT00604617|Drug|RT-23|TST - tuberculin skin test
79360486|NCT05824741|Behavioral|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
79360487|NCT05822531|Behavioral|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
79360488|NCT05814653|Behavioral|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
79511508|NCT02522520|Behavioral|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
79511509|NCT02522520|Behavioral|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
79511510|NCT02522520|Device|Omron Walking Style pro. 20|
79511511|NCT02474368|Radiation|Intensity Modulated Radiation Therapy (IMRT)|
79511512|NCT02474368|Drug|Cisplatin|
79993163|NCT05573295|Other|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
79511513|NCT02474368|Radiation|Stereotactic Body Radiotherapy (SBRT)|
79511514|NCT02412748|Behavioral|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
79511515|NCT02412748|Behavioral|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
79511516|NCT02305095|Drug|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
79511517|NCT02272946|Drug|Canakinumab|150mg Canakinumab received subcutaneously
79511518|NCT02272946|Drug|Placebo|150mg Placebo received subcutaneously
79511519|NCT02115698|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
79511520|NCT02115698|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
79511521|NCT02115698|Dietary Supplement|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
79511522|NCT02115698|Dietary Supplement|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
79993164|NCT05573295|Other|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
79511523|NCT02115698|Dietary Supplement|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
79511524|NCT02040714|Procedure|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
79511525|NCT02040714|Procedure|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
79511526|NCT02040714|Procedure|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
79511527|NCT02040714|Procedure|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
79511528|NCT01995344|Drug|Cyclophosphamide|
79511529|NCT01995344|Drug|Fludarabine|
79671038|NCT03191916|Device|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
79671039|NCT03191916|Device|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
79671040|NCT03178149|Drug|ASP7317|subretinal injection
79671041|NCT03178149|Drug|tacrolimus|oral
79993165|NCT05573295|Other|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
79993166|NCT05007249|Procedure|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
79993167|NCT03426995|Drug|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
79993168|NCT03426995|Drug|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
79993169|NCT03426995|Biological|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
79511530|NCT01995344|Genetic|Tumour Infiltrating Lymphocytes|
79511531|NCT01995344|Drug|Interleukin-2|
79511532|NCT01923662|Device|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
79511533|NCT01845688|Drug|Losartan Tablets & QingReMoShen Granule|
79511534|NCT01845688|Drug|Losartan Tablets & Placebo Granule|
79511535|NCT01844726|Drug|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
79511536|NCT01844726|Drug|Placebo|Single injection of placebo (saline)
79511537|NCT01679132|Device|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
79511538|NCT01591291|Drug|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
79511539|NCT01591291|Drug|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
79671042|NCT03178149|Drug|trimethoprim-sulfamethoxazole|oral
79671043|NCT03178149|Drug|Acyclovir|oral
79671044|NCT03178149|Drug|Nystatin|oral
79511540|NCT01093300|Device|Paclitaxel-eluting balloon catheter|
79511541|NCT01093300|Device|Everolimus-eluting stent|
79511542|NCT00852124|Biological|VSL#3|VSL#3 2 times daily
79511543|NCT00852124|Biological|VSL#3 or placebo|1 packet 2 x daily of placebo
79511544|NCT01053078|Drug|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
79511545|NCT01053078|Other|Placebo|1 month treatment; placebo tablet once daily for 28 days
79511546|NCT01053156|Drug|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
79511547|NCT01053156|Drug|Placebo|Placebo will be given daily for 3 months.
79511548|NCT01053312|Drug|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).
79511549|NCT01054404|Drug|Furosemide|Furosemide 0.3 mg/kg
79671046|NCT03164785|Drug|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
79511550|NCT01054404|Drug|Placebo|Placebo (up to 5mL)
79993170|NCT03426995|Biological|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
79511551|NCT01055184|Biological|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
79511552|NCT01056198|Drug|Santyl|2 mm Santyl applied once daily.
79671047|NCT03153553|Other|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
79511553|NCT01056198|Procedure|Control|Daily gauze and optional sharp debridement
79511554|NCT01058070|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
79511555|NCT01060020|Drug|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
79511556|NCT01060098|Drug|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
79511557|NCT01061034|Drug|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
79511558|NCT01064076|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
79671048|NCT03153553|Other|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
79360489|NCT05814653|Behavioral|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
79360490|NCT05810753|Behavioral|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
79511559|NCT01065480|Behavioral|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
79511560|NCT01065480|Behavioral|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
79511561|NCT01065558|Drug|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
79511562|NCT01065714|Drug|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
79511563|NCT01065714|Drug|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
79511564|NCT01066026|Procedure|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
79671053|NCT03136887|Device|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
79671054|NCT03135652|Radiation|adjuvant SBRT|adjuvant SBRT of liver lesions
79671055|NCT03135652|Drug|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
79993171|NCT03426995|Other|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
79360491|NCT05810181|Other|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
79360492|NCT05793684|Drug|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
79360493|NCT05793684|Drug|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
79360494|NCT05793684|Drug|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
79360495|NCT05790967|Other|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
79360496|NCT05790408|Device|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
79360497|NCT05790408|Device|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
79360498|NCT05779917|Biological|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
79360499|NCT05774301|Behavioral|simulation-based training|the training will include a theoretical & practical parts
79360500|NCT05767749|Drug|lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
79360501|NCT05767749|Drug|Ropivacaine 0.5% Injectable Solution|0.5 ml Ropivacaine 0.5% Injectable Solution
79360502|NCT05767749|Drug|Bupivacaine 0.5% Injectable Solution|0.5ml bupivacaine 0.5%
79511565|NCT01066026|Drug|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
79511566|NCT01072032|Device|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
79511567|NCT01072188|Device|Arginine/Calcium Carbonate|One time treatment
79511568|NCT01072188|Device|Nupro - Fluoride Free|Brush twice daily
79671056|NCT03130244|Device|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
79671057|NCT03130244|Drug|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
79671058|NCT03125928|Drug|Atezolizumab|Monoclonal antibody
79671059|NCT03125928|Drug|Paclitaxel|Chemotherapy
79671060|NCT03125928|Drug|Trastuzumab|Monoclonal antibody
79671061|NCT03125928|Drug|Pertuzumab|Monoclonal antibody
79511569|NCT01072656|Device|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
79511570|NCT01076244|Procedure|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
79511571|NCT01083654|Behavioral|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
79671062|NCT03113487|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
79671063|NCT03113487|Biological|Pembrolizumab|Given IV
79360503|NCT05766774|Other|Low-added sugar, high-fat diet|Consist of <5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
79360504|NCT05766774|Other|High-added sugar, high-fat CF diet|Consist of ≥13% kcal from added sugars and the glycemic index will be >60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
79360505|NCT05759728|Biological|CNA3103: 5 x 10^7 cells|CNA3103: 5 x 10^7 cells - intravenous infusion
79671064|NCT03109197|Other|Biospecimin Collection|
79671069|NCT03103971|Biological|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
79671070|NCT03103971|Drug|Cyclophosphamide|Given IV
79671071|NCT03103971|Drug|Fludarabine|Given IV
79511572|NCT01083654|Behavioral|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
79671072|NCT03103971|Other|Laboratory Biomarker Analysis|Correlative studies
79993172|NCT05200533|Other|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
79993173|NCT05200533|Other|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
79360506|NCT05759728|Biological|CNA3103: 1.5 x 10^8 cells|CNA3103: 1.5 x 10^8 cells - intravenous infusion
79360507|NCT05759728|Biological|CNA3103: 4.5 x 10^8 cells|CNA3103: 4.5 x 10^8 cells - intravenous infusion
79993174|NCT05560815|Procedure|Any surgical procedure|Might differ for substudies.
79993175|NCT05200299|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
79360508|NCT05759728|Biological|CNA3103: 1.5 x 10^9 cells|CNA3103: 1.5 x 10^9 cells - intravenous infusion
79360509|NCT05759728|Biological|CNA3103: 2.5 x 10^7 cells|CNA3103: 2.5 x 10^7 cells - intravenous infusion
79360510|NCT05754359|Behavioral|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
79360511|NCT05752500|Behavioral|Cognitive Behavioral Intervention for Physical Activity|Interventionist will use cognitive and behavioral techniques to help the participant increase facilitators and decrease barriers to physical activity, particularly barriers such as lack of motivation, depression, and chronic pain. Meetings will occur every other week for 4 months.
79360512|NCT05752500|Behavioral|Social Support for Physical Activity|This component will leverage the social functionality of the Fitbit app, promoting social support and friendly competition via a moderated Facebook group.
79360513|NCT05752500|Behavioral|Physical Activity Coaching|The PA coach will meet with the participant to set goals for physical activity (steps) and encourage self-monitoring. Meetings will occur every other week for 4 months.
79360514|NCT05752500|Behavioral|Brief Advice and Self-Monitoring|Participants will receive a single session with brief advice about increasing physical activity, and instructions on how to use their study-provided FitBit.
79360515|NCT05752292|Behavioral|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
79671073|NCT03103971|Procedure|Leukapheresis|Undergo leukapheresis
79360516|NCT05752292|Behavioral|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
79360517|NCT05752292|Behavioral|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
79360518|NCT05752292|Behavioral|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
79360519|NCT05752292|Behavioral|Action planning (AP)|Interactive prompts to problem solve challenges
79360520|NCT05736016|Device|medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)|All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
79511573|NCT01083732|Drug|dabigatran etexilate|Experimental dose chosen based on age and weight
79511574|NCT01084278|Drug|Colchicine|Colchicine tablets
79511575|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
79511576|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
79671074|NCT03103971|Other|Pharmacological Study|Correlative studies
79993176|NCT05200299|Drug|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
79993177|NCT03940989|Other|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
79993178|NCT04867499|Other|No intervention|Descriptive study. No intervention.
79993179|NCT03424265|Dietary Supplement|EAA mixture|Dietary supplement intervention for 12-weeks
79993180|NCT03424265|Dietary Supplement|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
79511577|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
79511578|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
79511579|NCT01085760|Drug|Vancomycin|Comparison of different drug doses
79511580|NCT01086228|Device|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
79511581|NCT01086852|Biological|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
79511582|NCT01088646|Device|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
79511583|NCT01090752|Drug|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
79511584|NCT01090752|Drug|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
79511585|NCT01093014|Behavioral|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
79671075|NCT03090165|Drug|ribociclib|400mg PO
79671076|NCT03090165|Drug|ribociclib|600mg PO
79360521|NCT05732142|Other|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
79511586|NCT01093014|Behavioral|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
79511587|NCT01093014|Behavioral|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
79511588|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
79511589|NCT01093794|Drug|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
79511590|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
79671077|NCT03090165|Drug|Bicalutamide|150mg PO
79993181|NCT05181423|Other|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
79993182|NCT04934319|Behavioral|Balance and Proprioceptive Training|"Step-by-step training (5 levels)~30 minute per training~3 times per week~Four weeks"
79993183|NCT03322566|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
79993184|NCT03322566|Drug|Epacadostat|Epacadostat administered orally twice daily.
79511591|NCT01093794|Drug|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
79511592|NCT01094106|Drug|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
79671078|NCT03073382|Other|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
79671079|NCT03049033|Other|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
79360522|NCT05725837|Drug|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
79360523|NCT05719935|Device|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
79671080|NCT03049033|Other|Occupational Therapy|Occupational Therapy uses traditional motor training.
79511593|NCT01094106|Drug|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
79511594|NCT01094574|Drug|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
79671081|NCT03049033|Other|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
79671082|NCT03033225|Procedure|Endoscopic Ultrasound|Undergo EUS-guided PDT
79511595|NCT01094574|Drug|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
79511596|NCT01094574|Drug|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
79671083|NCT03033225|Procedure|Fluorescence Imaging|Undergo fluorescence imaging
79671084|NCT03033225|Drug|Photodynamic Therapy|Undergo EUS-guided PDT
79819740|NCT02807636|Other|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
79819741|NCT02807636|Drug|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
79993185|NCT03322566|Drug|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
79993186|NCT03322566|Drug|Placebo|Matching placebo administered orally twice daily.
79360524|NCT05716516|Drug|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
79360525|NCT05711667|Procedure|Biospecimen Collection|Undergo collection of blood samples
79360526|NCT05711667|Drug|Letermovir|Given PO or IV
79360527|NCT05703061|Behavioral|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
79360528|NCT05702424|Drug|IGM-7354|IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
79360529|NCT05695885|Behavioral|STEPS|behavioral counseling
79511597|NCT01095510|Biological|CINRYZE|
79511598|NCT01096290|Drug|lubiprostone|24mcg BID, capsule, oral 30days
79993187|NCT03822975|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is >225 seconds.
79360530|NCT05695885|Behavioral|Services as usual (SAU)|behavioral counseling normally provided
79511599|NCT01096290|Drug|Matched placebo|Twice daily for 30days, oral
79511600|NCT01096680|Drug|SPD489 20 mg|Single oral dose of 20 mg
79511601|NCT01096680|Drug|SPD489 50 mg|Single oral dose of 50 mg
79511602|NCT01096680|Drug|SPD489 70 mg|Single oral dose of 70 mg
79511603|NCT01096680|Drug|Armodafinil|Single oral dose of 250 mg
79511604|NCT01096680|Drug|Placebo|Single oral dose
79511605|NCT01096992|Drug|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
79511606|NCT01096992|Drug|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
79511607|NCT01096992|Drug|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
79511608|NCT01097304|Drug|Ursodiol|Given PO
79671085|NCT03033225|Other|Quality-of-Life Assessment|Ancillary studies
79671086|NCT03033225|Other|Questionnaire Administration|Ancillary studies
79671087|NCT03033225|Drug|Verteporfin|Given IV
79671088|NCT03030118|Drug|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
79671089|NCT03030118|Drug|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
79671090|NCT03011567|Drug|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
79671091|NCT03011567|Drug|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
79671092|NCT03006302|Drug|Epacadostat|50, 100, 300, or 600 mg taken by mouth twice a day, every day of each cycle
79671093|NCT03006302|Drug|Pembrolizumab|200 mg IV on Day 1 of each cycle
79671094|NCT03006302|Biological|CRS-207|1x10^9 CFU given IV on Day 2 of Cycles 3-6 (Arm A) or Day 2 of Cycles 1-6 (Arm B)
79671095|NCT03006302|Drug|CY|200 mg/m^2 given IV on Day 1 of Cycles 1-2 (Arm A only)
79671096|NCT03006302|Biological|GVAX|5x10^8 cells given as 6 intradermal injections on Day 2 of Cycles 1-2 (Arm A only)
79671097|NCT02997293|Other|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
79671098|NCT02988609|Device|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
79511609|NCT01097304|Other|Laboratory Biomarker Analysis|Correlative studies
79993188|NCT03822975|Drug|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is >225 seconds.
79511610|NCT01097460|Drug|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
79993189|NCT05543733|Behavioral|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
79993190|NCT05732532|Drug|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
79360531|NCT05687292|Device|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
79360532|NCT05686499|Other|Didactic Lectures and demonstrations|"Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
79360533|NCT05678439|Dietary Supplement|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
79360534|NCT05678439|Other|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
79511611|NCT01098006|Other|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
79511612|NCT01098318|Dietary Supplement|Herbal extract|340-1,360 mg daily
79511613|NCT01098318|Drug|Sertraline|50-200 mg daily
79511614|NCT01098318|Other|Lactose monohydrate|1-4 capsules daily
79511615|NCT01100112|Drug|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
79511616|NCT01100268|Drug|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
79511617|NCT01101750|Biological|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
79511618|NCT01102218|Drug|Erythropoietin|Standard of Care
79511619|NCT01102218|Drug|Erythropoietin|Standard of Care
79511620|NCT01102218|Drug|Pentoxifylline|400 mg qd po for 6 months
79671099|NCT02962973|Device|CARMAT TAH|
79671100|NCT02962973|Procedure|Surgical intervention|
79671101|NCT02932553|Device|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
79671102|NCT02924129|Device|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
79993191|NCT05732532|Drug|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
79993192|NCT05732532|Drug|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
79993193|NCT05732532|Drug|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
79993194|NCT05732532|Procedure|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
79993195|NCT05178225|Dietary Supplement|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
79511621|NCT01102764|Behavioral|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
79511622|NCT01102764|Behavioral|In Person|PE therapy delivered in person at the VAMC
79993196|NCT05178225|Other|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
79360535|NCT05667207|Diagnostic Test|Point-of-care microscopy and dipstick guided management|"GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices."
79360536|NCT05658484|Drug|Dimethyl fumarate|Administered as specified in the treatment arm.
79993197|NCT05178225|Diagnostic Test|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
79993198|NCT05210244|Dietary Supplement|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
79360537|NCT05658198|Behavioral|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
79360538|NCT05653882|Biological|AB248|Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug
79360539|NCT05653882|Biological|Pembrolizumab|Intravenous infusion of pembrolizumab
79511623|NCT01103934|Drug|Vitamin D3|4000 IU once daily
79511624|NCT01103934|Drug|Placebo|Placebo taken once daily
79511625|NCT01103934|Drug|Fluticasone Propionate|200 mcg daily, intranasal
79511626|NCT01104090|Device|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
79993199|NCT05210244|Dietary Supplement|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
79993200|NCT02969018|Drug|PF-06700841|
79993201|NCT02969018|Other|Placebo|
79993202|NCT04624620|Behavioral|Teaching Kitchen Collaborative Curriculum|This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
79993203|NCT03255096|Drug|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
79993204|NCT03255096|Drug|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
79511627|NCT01104090|Device|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
79511628|NCT01104402|Device|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
79511629|NCT01105650|Drug|Fludarabine|Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).
79511630|NCT01105650|Drug|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
79993205|NCT03255096|Drug|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
79993206|NCT01319721|Procedure|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
79360540|NCT05650476|Drug|Talazoparib|capsules
79511631|NCT01105650|Drug|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
79360541|NCT05613985|Other|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) [If, during the study, PEDIS is < 2, the ulcer will be covered with nonadherent paraffin gauze].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
79360542|NCT05613985|Device|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
79993207|NCT01319721|Procedure|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
79360543|NCT05613517|Other|Eye examination|"orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~ocular biometry~corneal topography~monocular photographs in photopic condition"
79360544|NCT05609110|Device|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
79360545|NCT05609110|Device|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
79993208|NCT01319721|Procedure|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
79360546|NCT05598723|Drug|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
79511632|NCT01105650|Biological|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10^7 cells/kg will be given.
79511633|NCT01105650|Drug|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m^2 3 times per week for 6 doses).
79511634|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
79993209|NCT05284682|Diagnostic Test|Right hearted catheterization|Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
79819742|NCT02738788|Other|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
79819743|NCT02732834|Behavioral|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
79819744|NCT02732834|Behavioral|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
79819745|NCT02732834|Behavioral|Audio recordings of clinical consultations|
79819746|NCT02732834|Behavioral|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
79819747|NCT02732834|Behavioral|2-hour empathic communication skills training|2-hour empathic communication skills training
79819748|NCT02732834|Behavioral|Standardized Patient Assessments|pre-training SPA, post-training SPA
79819749|NCT02732834|Behavioral|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
79819750|NCT02732834|Behavioral|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
79360547|NCT05598723|Drug|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
79819751|NCT02666963|Drug|RTA 901 Capsules, 10 or 40 mg|
79360548|NCT05595382|Behavioral|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
79819752|NCT02666963|Drug|Placebo|
79819753|NCT02657486|Drug|BGJ398|
79360549|NCT05595382|Behavioral|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
79360550|NCT05592158|Procedure|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
79360551|NCT05591859|Device|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
79511635|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
79511636|NCT01105650|Drug|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m^2 3 times per week for 6 doses).
79511637|NCT01106040|Drug|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
79511638|NCT01110252|Drug|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
79511639|NCT01110252|Procedure|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
79511640|NCT01110252|Genetic|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
79819754|NCT02654587|Biological|OSE2101|
79819755|NCT02654587|Drug|Docetaxel|
79819756|NCT02654587|Drug|Pemetrexed|
79819757|NCT02650648|Drug|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight<70kg) or 1500mg/m^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
79819758|NCT02650648|Biological|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
79819759|NCT02650648|Biological|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over ~30-90 minutes
79819760|NCT02650648|Drug|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10^5 U/m^2/day.
79819761|NCT02552823|Other|Group1|
79819762|NCT02552823|Other|Group2|
79819763|NCT02520778|Drug|Navitoclax|Given PO
79819764|NCT02520778|Drug|Osimertinib|Given PO
79511641|NCT01110876|Drug|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
79511642|NCT01110876|Drug|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
79671106|NCT02891824|Drug|atezolizumab + avastin + platinum-based chemotherapy|"atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
79671107|NCT02891824|Drug|placebo + avastin + platinum-based chemotherapy|"placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
79819765|NCT02478502|Drug|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
79360552|NCT05589194|Behavioral|Nursing Practices Based on Kolcaba's Comfort Theory|Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
79671108|NCT02824263|Other|CPAP withdrawal|CPAP is discontinued for 3 nights.
79671109|NCT02814838|Drug|Ladarixin|Ladarixin oral capsule
79819766|NCT02473146|Drug|Gemtuzumab ozogamicin (GO)|
79511643|NCT01110876|Drug|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
79511644|NCT01112358|Drug|r-FSH|r-FSH will be administered as specified in the arm description.
79511645|NCT01112358|Drug|r-hLH|r-hLH will be administered as specified in the arm description.
79511646|NCT01112358|Drug|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
79511647|NCT01112358|Drug|r-hCG|r-hCG will be administered as specified in the arm description.
79511648|NCT01112358|Drug|Progesterone|Progesterone will be administered as specified in the arm description.
79511649|NCT01112670|Drug|Sitagliptin|sitagliptin 100 mg x 1 dose
79511650|NCT01112670|Drug|atorvastatin|atorvastatin 40 mg x 5 doses
79511651|NCT01114620|Biological|Arepanrix™|Intramuscular administration, one dose
79511652|NCT01115556|Drug|Ranibizumab|2.0 mg
79511653|NCT01115556|Drug|Ranibizumab|0.5 mg
79511654|NCT01116024|Device|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
79511655|NCT01116102|Drug|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
79671110|NCT02814838|Drug|Placebo|Placebo oral capsule
79671111|NCT02783690|Radiation|Hypofractionation|40 Gy (RBE) in 15 daily fractions
79671112|NCT02737046|Drug|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
79671113|NCT02737046|Drug|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
79819767|NCT02371135|Genetic|colonic biopsies|
79819768|NCT02371135|Genetic|questionnaires|
79819769|NCT02367989|Dietary Supplement|0g barley β-glucan no fibre|Food containing no barley β-glucan and no additional fibre
79511656|NCT01118988|Behavioral|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
79819770|NCT02367989|Dietary Supplement|2g barley β-glucan|Food containing low amounts of barley β-glucan
79819771|NCT02367989|Dietary Supplement|4g barley β-glucan|Food containing medium amounts of barley β-glucan
79360553|NCT05577403|Behavioral|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd & 4th week of intervention."
79993210|NCT05210010|Device|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
79993211|NCT03015324|Drug|Hydroxychloroquine|Hydroxychloroquine
79511657|NCT01119222|Drug|Gabapentin|Capsule, single 1200mg dose
79511658|NCT01119222|Drug|Diphenhydramine|Tablet, single 50mg dose
79511659|NCT01119222|Drug|Morphine|IV, single 10mg dose
79993212|NCT05754450|Drug|AVTX-803|L-fucose crystalline powder
79360554|NCT05577000|Biological|Manufactured Anti-BCMA CAR-T cells|Given IV
79360555|NCT05577000|Drug|Fludarabine|Given IV
79511660|NCT01119222|Drug|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
79671114|NCT02737046|Drug|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
79671115|NCT02737046|Drug|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
79671117|NCT02713607|Drug|Doxycycline|Given doxycycline to acne subjects
79819772|NCT02367989|Dietary Supplement|6g barley β-glucan|Food containing high amounts of barley β-glucan
79671119|NCT02698254|Biological|Bevacizumab|
79819773|NCT02367989|Dietary Supplement|0g barley β-glucan with fibre|Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
79360556|NCT05577000|Drug|Cyclophosphamide|Given IV
79511661|NCT01119456|Biological|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
79671120|NCT02698254|Other|Quality-of-Life Assessment|Ancillary studies
79671121|NCT02698254|Radiation|Radiation Therapy|Undergo radiation therapy with conventional fractionation
79671122|NCT02688894|Other|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
79671123|NCT02669173|Drug|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
79671124|NCT02669173|Drug|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
79360557|NCT05572554|Other|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
79511662|NCT01119456|Biological|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
79511663|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
79671125|NCT02661464|Biological|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
79671126|NCT02661464|Biological|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
79671127|NCT02647203|Drug|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
79671128|NCT02647021|Behavioral|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
79993213|NCT04605744|Behavioral|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
79993214|NCT05174871|Behavioral|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
79993215|NCT05174871|Behavioral|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
79671129|NCT02647021|Behavioral|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
79993216|NCT05193474|Behavioral|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
79993217|NCT02985138|Procedure|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
79993218|NCT02985138|Procedure|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
79993219|NCT02985138|Device|Pedicle screw and cage|Pedicle screw and cage
79993220|NCT05139849|Drug|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
79993221|NCT05139849|Drug|Sodium chloride|Sodium chloride 9 mg/ml
79993222|NCT02905032|Behavioral|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
79993223|NCT05504187|Drug|KP104|KP104 will be administered.
79993224|NCT05191368|Other|No intervention|No intervention
79993225|NCT02799186|Procedure|blood sample for genetic analysis|
79360558|NCT05571228|Behavioral|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
79360559|NCT05566704|Device|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
79511664|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
79511665|NCT01119456|Biological|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
79511666|NCT01119456|Biological|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
79511667|NCT01119456|Biological|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
79511668|NCT01119456|Biological|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
79671130|NCT02618408|Drug|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
79993226|NCT02767518|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
79993227|NCT03351075|Other|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~Start immediately after surgery, sessions are individual and take 30 minutes~Intensive phase (4 months): 1-2x/week~Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
79360560|NCT05561595|Behavioral|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
79360561|NCT05561595|Behavioral|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
79360562|NCT05553327|Behavioral|Multimodal prehabilitation|"Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~Mental health: mindfulness group sessions led by psychologists will be held."
79360563|NCT05543629|Biological|BMS-986442|Specified dose on specified days
79360564|NCT05543629|Biological|Nivolumab|Specified dose on specified days
79819774|NCT02348749|Radiation|18F-MFBG (meta-fluoro benzylguanidine)|About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
79993228|NCT03351075|Other|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
79360565|NCT05543629|Drug|Docetaxel|Specified dose on specified days
79360566|NCT05543629|Drug|Carboplatin|Specified dose on specified days
79360567|NCT05543629|Drug|Pemexetred|Specified dose on specified days
79360568|NCT05543629|Drug|Paclitaxel|Specified dose on specified days
79360569|NCT05531786|Drug|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
79360570|NCT05517265|Drug|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
79360571|NCT05517265|Drug|Calquence|acalabrutinib according to Calquence® SmPC.
79360572|NCT05515978|Drug|Metformin|In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.
79360573|NCT05515978|Behavioral|Lifestyle Modification|"Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss"
79360574|NCT05508399|Other|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~Blood cell samples;~Paraffin sample of residual tumor tissue of biopsy;~Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
79360575|NCT05499520|Other|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
79360576|NCT05499143|Other|Online questionnaire|Online questionnaire impact for DCD - Belgian version
79511669|NCT01120236|Drug|Bicalutamide|Given PO
79511670|NCT01120236|Biological|Cixutumumab|Given IV
79511671|NCT01120236|Drug|Goserelin Acetate|Given SC
79511672|NCT01120236|Other|Laboratory Biomarker Analysis|Correlative studies
79511673|NCT01120236|Drug|Leuprolide Acetate|Given IM
79511674|NCT01120236|Other|Pharmacological Study|Correlative studies
79360577|NCT05487170|Drug|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
79360578|NCT05480761|Biological|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
79511675|NCT01120704|Drug|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
79524775|NCT05768685|Behavioral|Affective touch paradigm|Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm. After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness. As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch inclose relationships.
79360579|NCT05469165|Drug|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
79360580|NCT05469165|Other|Placebo|Placebo administration for 3months
79360581|NCT05466578|Drug|abrocitinib|
79360582|NCT05459831|Device|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
79360583|NCT05458102|Drug|Vesatolimod|Administered orally
79360584|NCT05458102|Drug|Cobicistat|Administered orally
79360585|NCT05458102|Drug|Voriconazole|Administered orally
79360586|NCT05458102|Drug|Rifabutin|Administered orally
79360587|NCT05449067|Procedure|Group A and Group B|Group A: Participants receive APD for 12 weeks then switch to CAPD for another 12 weeks; Group B: Participants receive CAPD for 12 weeks and switch to APD for another 12 weeks.
79360588|NCT05440643|Biological|Peanut SLIT-tablet|Peanut extract
79360589|NCT05439980|Other|Knowledge questionnaire|Completion of a questionnaire at baseline
79360590|NCT05439980|Other|Focus groups|structured interviews
79360591|NCT05439421|Behavioral|Package/Advertisement With Claim|Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
79360592|NCT05439421|Behavioral|Package/Advertisement Without Claim|Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
79360593|NCT05431413|Drug|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
79360594|NCT05431413|Drug|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
79360595|NCT05431413|Drug|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
79360596|NCT05417334|Device|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
79360597|NCT05413590|Other|Questionnaires completion|Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
79360598|NCT05413590|Other|Isometric forces|Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
79360599|NCT05413590|Other|Energy cost|Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
79360600|NCT05408884|Other|Social Support|"Social support phone buddy program."
79360601|NCT05408884|Other|Basic income|$750 per month for 12 months
79360602|NCT05400330|Biological|LX1001|Gene therapy
79360603|NCT05395507|Drug|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
79360604|NCT05395507|Drug|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
79360605|NCT05391711|Behavioral|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~Culturally Smart Relationships Training (live, virtual)~JEDI enhanced monthly supervision from case managers~Monthly emails with activity suggestions for mentors and youth"
79524776|NCT05768672|Behavioral|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
79819775|NCT02348749|Device|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
79360606|NCT05388032|Behavioral|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to <2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
79360607|NCT05374785|Drug|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
79360608|NCT05374785|Other|Placebo|Tablets without CPL409116 as an active substance
79360609|NCT05366712|Device|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
79360610|NCT05337566|Drug|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
79360611|NCT05337566|Drug|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
79819776|NCT02348749|Other|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
79819777|NCT02316002|Drug|Pembrolizumab|
79993229|NCT03351075|Other|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
79511676|NCT01120704|Drug|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
79511677|NCT01120704|Behavioral|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 & 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
79671131|NCT02618408|Drug|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
79819778|NCT02311374|Other|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
79819779|NCT02311374|Other|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
79819780|NCT02295306|Device|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
79511678|NCT01120704|Behavioral|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
79511679|NCT01120704|Behavioral|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
79671132|NCT02618408|Drug|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
79671133|NCT02611453|Other|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
79819781|NCT02288247|Drug|Enzalutamide|Oral
79819782|NCT02288247|Drug|Docetaxel|intravenous infusion
79819783|NCT02288247|Drug|Prednisolone|Oral
79819784|NCT02288247|Drug|Placebo|Oral
79819785|NCT02283177|Drug|crenolanib|
79360612|NCT05333874|Drug|Neoadjuvant chemotherapy administered before surgical extraction of a tumor|SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
79360613|NCT05333874|Other|Observational|In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting). No investigational drugs will be used. Samples of ctDNA will be collected at time points described in the study arm.
79360614|NCT05332626|Dietary Supplement|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
79360615|NCT05332626|Dietary Supplement|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
79511680|NCT01120704|Behavioral|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 & 23."
79511681|NCT01121250|Behavioral|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
79511682|NCT01121250|Behavioral|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
79511683|NCT01122030|Drug|Naldemedine|Tablets or solution for oral administration
79511684|NCT01122030|Drug|Placebo|Tablets or solution for oral administration
79511685|NCT01122108|Drug|Cholestyramine|Cholestyramine 12 grams, one time dose
79511686|NCT01122108|Drug|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
79511687|NCT01123512|Device|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
79511688|NCT01124370|Device|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
79511689|NCT05307042|Diagnostic Test|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
79360616|NCT05324293|Drug|HMI-115|Once Every 2 weeks, subcutaneously injection
79360617|NCT05321862|Drug|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic [68Ga]Ga-PentixaFor
79360618|NCT05320666|Behavioral|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC…MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
79360619|NCT05308108|Procedure|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
79360620|NCT05304195|Diagnostic Test|Glucocerebrosidase|Blood sample (10ml) for GCase activity
79819786|NCT02283177|Drug|cytarabine|
79819787|NCT02283177|Drug|daunorubicin|
79819788|NCT02283177|Drug|idarubicin|
79993230|NCT03315741|Drug|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
79360621|NCT05304195|Genetic|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
79360622|NCT05279417|Drug|ATI-450 50mg oral tablet BID|Oral, small molecule MK2 inhibitor
79360623|NCT05279417|Drug|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
79360624|NCT05279417|Drug|Methotrexate|15 mg to 25 mg weekly
79360625|NCT05279417|Drug|ATI-450 20mg oral tablet BID|Oral, small molecule MK2 inhibitor
79360626|NCT05270694|Behavioral|Public Health Intervention Package|"The intervention package consists of two components:~At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
79511690|NCT05306730|Device|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
79360627|NCT05267652|Other|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
79360628|NCT05267652|Other|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
79360629|NCT05251389|Other|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
79360630|NCT05233436|Drug|PF-07265028|PF-07265028 will be administered orally
79360631|NCT05233436|Biological|Sasanlimab|Administered subcutaneously
79360632|NCT05224258|Device|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
79360633|NCT05215158|Drug|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
79511691|NCT05306184|Procedure|Electroconvulsive therapy (ECT)|ECT
79511692|NCT05291442|Other|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
79511693|NCT05289960|Other|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
79819789|NCT02259231|Drug|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
79360634|NCT05206981|Device|IlluminOss Device|Patients may enroll in the registry if they have been implanted (retrospective) or will be implanted (prospective) with the IlluminOss device.
79360635|NCT05197569|Other|thyme oil|Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
79360636|NCT05196841|Behavioral|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
79360637|NCT05195437|Other|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
79819790|NCT02259231|Drug|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
79819791|NCT02259231|Drug|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
79511694|NCT05288478|Combination Product|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
79819792|NCT02259231|Drug|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
79360638|NCT05180838|Device|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
79360639|NCT05178927|Device|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram & set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
79360640|NCT05168813|Biological|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
79819793|NCT02259231|Drug|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
79360641|NCT05168813|Biological|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
79511695|NCT05115942|Drug|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 52 weeks.
79511696|NCT05115942|Drug|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 52 weeks.
79511697|NCT04974138|Drug|Amlodipine besylate tablets|The amlodipine used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
79671134|NCT02609776|Drug|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
79671135|NCT02609776|Drug|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
79819794|NCT02218593|Device|WREX orthosis|Upper extremity exoskleton used to assist movement
79819795|NCT02153619|Behavioral|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
79819796|NCT02153619|Behavioral|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
79819797|NCT02153619|Behavioral|questionnaires assessments|
79819798|NCT02112188|Behavioral|In-depth Patient Interviews|
79360642|NCT05168813|Biological|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
79360643|NCT05166265|Device|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
79360644|NCT05165225|Drug|Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment|Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m^2 d1 iv Q3W for 4 cycles
79511698|NCT04974138|Drug|Amlodipine besylate and folic acid tablets|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
79511699|NCT04973982|Drug|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
79511700|NCT04973982|Drug|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
79511701|NCT04973514|Procedure|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
79671136|NCT02609776|Drug|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
79671137|NCT02609776|Drug|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
79819799|NCT02112188|Behavioral|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
79819800|NCT02112188|Behavioral|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
79819801|NCT02105766|Drug|Alemtuzumab|Immunosuppressant
79819802|NCT02105766|Drug|Sirolimus|Immunosuppressant
79511702|NCT04733664|Device|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
79819803|NCT02105766|Drug|Cyclophosphamide|Immunosuppressant
79671138|NCT02609776|Drug|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
79819804|NCT02105766|Drug|Pentostatin|Immunosuppressant
79819805|NCT02105766|Procedure|Radiotherapy|Immunosuppressant and myelosuppressant
79819806|NCT02062827|Biological|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
79819807|NCT02029729|Drug|omaveloxolone|
79819808|NCT02029716|Drug|RTA 408 Lotion 0.5%, 1%, 3%|
79360645|NCT05145400|Drug|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.
79360646|NCT05145400|Drug|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR > 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR < 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
79360647|NCT05145400|Drug|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
79360648|NCT05143177|Drug|Evogliptin|DA-1229 5mg, 1 tab
79360649|NCT05143177|Drug|Evogliptin|DA-1229 10 mg, 1 tab
79360650|NCT05143177|Drug|Placebo|DA-1229 Placebo, 1 tab
79360651|NCT05142709|Drug|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
79360652|NCT05124977|Drug|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
79511703|NCT04503720|Device|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
79511704|NCT04503720|Device|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
79511705|NCT04487964|Dietary Supplement|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
79511706|NCT04342182|Biological|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
79671143|NCT02568267|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
79671144|NCT02502786|Biological|humanized anti-GD2 antibody|
79671145|NCT02502786|Drug|GM-CSF|
79671146|NCT02499172|Biological|Shanchol|
79819809|NCT02029716|Drug|Lotion vehicle/placebo|
79819810|NCT02028559|Device|Propulse 1|Move kidney stones with Propulse 1 device.
79819811|NCT02022462|Behavioral|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
79819812|NCT01906853|Biological|BCG|
79511707|NCT04237974|Device|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
79511708|NCT04142892|Drug|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
79511709|NCT04125498|Other|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
79360653|NCT05124977|Drug|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
79360654|NCT05114941|Device|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
79360655|NCT05114941|Drug|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
79360656|NCT05111093|Device|ARC-IM Investigational System implantation|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
79360657|NCT05108805|Procedure|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, HR, RR, SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
79511710|NCT04125498|Other|Placebo treatment|Similar to OMT without pressure
79511711|NCT04125498|Other|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
79511712|NCT04017702|Device|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
79671148|NCT02478099|Drug|MPDL3280A|Anti-PD-L1 antibody
79671149|NCT02455687|Drug|Hi-dose iv MgSO4|
79671150|NCT02455687|Drug|Nebulized budesonide|
79671151|NCT02455687|Drug|Std-dose iv MgSO4|
79671152|NCT02455687|Drug|Nebulized normal saline|
79360658|NCT05108805|Procedure|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
79360659|NCT05108805|Procedure|Out-Patient Clinic Visit|Physical exam and review of all available data
79360660|NCT05108805|Procedure|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
79511713|NCT03829098|Other|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
79511714|NCT03795168|Device|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
79671153|NCT02446964|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
79671154|NCT02446964|Drug|Cyclophosphamide|Given IV
79671155|NCT02446964|Drug|Fludarabine Phosphate|Given IV
79671156|NCT02446964|Other|Laboratory Biomarker Analysis|Correlative studies
79671157|NCT02446964|Drug|Mycophenolate Mofetil|Given PO or IV
79360661|NCT05094791|Device|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
79511715|NCT03795168|Device|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
79511716|NCT03792360|Drug|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
79671158|NCT02446964|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
79671159|NCT02446964|Drug|Tacrolimus|Given IV and PO
79360662|NCT05094791|Device|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
79819813|NCT01825278|Device|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
79819814|NCT01821131|Other|muffin|
79360663|NCT05094791|Device|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
79360664|NCT05076370|Drug|CBD Day 1|CBD 400mg
79511717|NCT03749928|Device|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
79511718|NCT03749928|Device|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
79671160|NCT02446964|Radiation|Total Marrow Irradiation|Undergo TMLI
79671161|NCT02446600|Procedure|Biospecimen Collection|Undergo blood sample collection
79671162|NCT02446600|Drug|Carboplatin|Given IV
79671163|NCT02446600|Drug|Cediranib Maleate|Given PO
79671164|NCT02446600|Procedure|Computed Tomography|Undergo CT
79671165|NCT02446600|Procedure|Echocardiography|Undergo ECHO
79671166|NCT02446600|Drug|Gemcitabine|Given IV
79671167|NCT02446600|Drug|Gemcitabine Hydrochloride|Given IV
79671168|NCT02446600|Other|Laboratory Biomarker Analysis|Correlative studies
79671169|NCT02446600|Procedure|Magnetic Resonance Imaging|Undergo MRI
79671170|NCT02446600|Procedure|Multigated Acquisition Scan|Undergo MUGA
79671171|NCT02446600|Drug|Olaparib|Given PO
79360665|NCT05076370|Drug|CBD Day 2|CBD 800mg
79360666|NCT05076370|Drug|CBD Day 3|CBD 1200mg
79360667|NCT05073159|Biological|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
79360668|NCT05062707|Procedure|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
79360669|NCT05062291|Device|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
79360670|NCT05061238|Device|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
79360671|NCT05057312|Behavioral|Experimental arm 1|Video narrative persuasion
79360672|NCT05057312|Behavioral|Experimental arm 2|Written narrative Persuasion
79360673|NCT05057312|Other|Experimental arm 3|Enhanced Access to HPV vaccines
79671172|NCT02446600|Drug|Paclitaxel|Given IV
79671173|NCT02446600|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79671174|NCT02446600|Other|Pharmacological Study|Correlative studies
79671175|NCT02446600|Other|Quality-of-Life Assessment|Ancillary studies
79671176|NCT02395367|Procedure|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
79360674|NCT05057312|Other|Experimental arm 4|Video narrative persuasion; Enhanced Access to HPV vaccines
79360675|NCT05057312|Other|Experimental arm 5|Written narrative Persuasion; Enhanced access to HPV vaccines
79511719|NCT03697356|Drug|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~Rituximab 375 mg/m2 intravenous on day 1~Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~Lenalidomide 15mg p.o on day 1-21~Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
79511720|NCT03616782|Drug|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
79511721|NCT03336372|Drug|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
79671177|NCT02395367|Radiation|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
79671178|NCT02395367|Drug|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
79679698|NCT00517985|Drug|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
79511722|NCT03099798|Other|Questionnaires|"All patients will complete a number of questionnaires at different time points.~SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~1 week, 1 month, 3, 6 and 12 months after treatment"
79511723|NCT03099798|Diagnostic Test|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
79511724|NCT02410512|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
79511725|NCT02410512|Drug|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
79511726|NCT02364492|Drug|MAG-TN3 + AS15|
79511727|NCT00849888|Biological|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg & serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant & thymus biopsy. Followed by immune evaluations.
79360676|NCT05056168|Other|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
79511728|NCT00849888|Other|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg & serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy & skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
79511729|NCT00255138|Drug|Atomoxetine|
79511730|NCT01125774|Drug|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
79511731|NCT01125774|Drug|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
79511732|NCT01128192|Drug|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
79511733|NCT01128270|Drug|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
79511734|NCT01128270|Drug|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
79511735|NCT01128270|Drug|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
79511736|NCT01128270|Drug|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
79511737|NCT01128426|Other|No Intervention|No Intervention
79360677|NCT05043207|Diagnostic Test|uAud|Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure
79360678|NCT05043207|Diagnostic Test|Traditional audiometry|Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
79511738|NCT01128972|Drug|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
79511739|NCT01128972|Drug|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
79511740|NCT01128972|Drug|Sterile water|Sterile water rinse
79511741|NCT01129206|Drug|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
79511742|NCT01129206|Drug|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
79511743|NCT01129206|Radiation|fludeoxyglucose F 18|Correlative studies
79511744|NCT01129206|Procedure|positron emission tomography|Correlative studies
79511745|NCT01129440|Device|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
79511746|NCT01129440|Device|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
79511747|NCT01130844|Drug|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
79511748|NCT01130844|Drug|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
79511749|NCT01130844|Drug|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
79511750|NCT01134198|Drug|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
79511751|NCT01134198|Drug|placebo|placebo
79511752|NCT01134276|Procedure|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
79511753|NCT01134900|Other|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
79360679|NCT05025449|Diagnostic Test|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
79360680|NCT05025449|Drug|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. Contrast may be redosed if images are inadequate or incomplete. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by AAST criteria.
79511754|NCT01135368|Drug|Lansoprazole|Lansoprazole capsules
79511755|NCT01136226|Drug|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
79511756|NCT01137006|Biological|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
79511757|NCT01137006|Biological|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
79511758|NCT01137006|Biological|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
79511759|NCT01137006|Biological|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
79360681|NCT05012371|Drug|Cabozantinib|Given PO
79511760|NCT01137006|Biological|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
79511761|NCT01137006|Biological|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
79511762|NCT01137006|Biological|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
79511763|NCT01137396|Drug|Modafinil|Modafinil 400mg PO QDaily following up-titration for ~8weeks
79511764|NCT01137396|Behavioral|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
79511765|NCT01138098|Biological|Engerix™-B|Intramuscular, single dose
79511766|NCT01139190|Drug|PL3100|Oral administration
79360682|NCT05012371|Drug|Everolimus|Given PO
79360683|NCT05012371|Drug|Lenvatinib|Given PO
79360684|NCT05012371|Other|Questionnaire Administration|Ancillary studies
79511767|NCT01139190|Drug|Naproxen|Oral administration
79511768|NCT01139814|Device|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
79511769|NCT01140360|Drug|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
79511770|NCT01141374|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
79671181|NCT02351063|Drug|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
79671182|NCT02346396|Device|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
79671183|NCT02323880|Other|Pharmacological Study|Correlative studies
79671184|NCT02323880|Drug|Selinexor|Given PO
79819815|NCT01775085|Behavioral|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts & Sources of Meaning; 2) Identity, Cancer Survivorship, & Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present & Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity & Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, & Humor; and 8) Transitions: Reflections & Hopes for the Future.
79819816|NCT01775085|Behavioral|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
79819817|NCT01767675|Procedure|Secondary Cytoreductive Surgery|
79819818|NCT01767675|Drug|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
79819819|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|5 cycles
79819820|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|6 cycles
79819821|NCT01696513|Procedure|Suction|
79819822|NCT01696513|Procedure|Subcision|
79819823|NCT01689116|Drug|Bardoxolone Methyl 20mg|Oral
79819824|NCT01689116|Drug|Bardoxolone Methyl 80mg|Oral
79819825|NCT01689116|Drug|Bardoxolone Methyl Placebo|Oral
79511771|NCT01141374|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
79511772|NCT01141608|Other|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
79511773|NCT01141608|Other|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
79511774|NCT01142310|Drug|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
79511775|NCT01142310|Drug|Placebo|
79511776|NCT01143636|Device|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
79511777|NCT01143792|Behavioral|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
79511778|NCT01143792|Behavioral|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
79360685|NCT05011279|Other|Move Together app/Garmin Activity Tracker|"The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~Garmin activity tracker in this study is for participants to track their steps and sedentary time."
79360686|NCT05004935|Dietary Supplement|beetroot juice|single intake of beetroot juice containing 800mg nitrates
79511779|NCT01143792|Behavioral|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
79511780|NCT01143870|Other|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
79671188|NCT02298959|Procedure|Biopsy|Undergo tumor biopsy
79819826|NCT01689116|Drug|Moxifloxacin 400mg|Oral
79819827|NCT01689116|Drug|Moxifloxacin Placebo|Oral
79360687|NCT05004935|Other|nitrate|single intake of 800mg nitrates
79360688|NCT05002816|Drug|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
79511781|NCT01144026|Biological|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
79360689|NCT05002816|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion. There will be 2 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be teste
79511782|NCT01144026|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
79511783|NCT01144338|Drug|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
79511784|NCT01144338|Drug|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
79511785|NCT01146600|Drug|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
79511786|NCT01146600|Drug|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
79511787|NCT01146834|Drug|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
79511788|NCT01146834|Drug|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
79819828|NCT01688076|Procedure|Botulinum Toxin A|Forehead will be injected with Botox.
79819829|NCT01655186|Drug|Bardoxolone Methyl|
79819830|NCT01655186|Drug|Placebo|
79819831|NCT01598363|Drug|Digoxin|Oral, Day 1 and Day 10
79819832|NCT01598363|Drug|Rosuvastatin|Oral, Day 1 and Day 10
79819833|NCT01576887|Drug|Bardoxolone Methyl 20 mg|Oral, once daily
79819834|NCT01576887|Drug|Placebo|Oral, once daily
79511789|NCT01146834|Drug|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
79671189|NCT02298959|Procedure|Biospecimen Collection|Undergo blood sample collection
79671190|NCT02298959|Procedure|Computed Tomography|Undergo CT scan
79671191|NCT02298959|Procedure|Magnetic Resonance Elastography|Undergo MRI
79671192|NCT02298959|Biological|Pembrolizumab|Given IV
79993231|NCT05307393|Behavioral|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
79993232|NCT03632967|Device|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
79360690|NCT04999358|Behavioral|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
79993233|NCT05077449|Drug|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
79993234|NCT05077449|Drug|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
79511790|NCT01146834|Drug|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
79360691|NCT04999358|Behavioral|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
79360692|NCT04999332|Drug|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
79511791|NCT01147302|Biological|Placebo|
79511792|NCT01147302|Biological|C1 Esterase Inhibitor (Human)|
79511793|NCT01147380|Biological|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
79511794|NCT01149876|Other|Nu Skin Product|Thin layer of Nu Skin product applied to face.
79511795|NCT01149876|Other|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
79511796|NCT01149876|Drug|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
79511797|NCT01149876|Other|CeraVe moisturizer|Thin layer of CeraVe applied to face.
79511798|NCT01150500|Device|MDT-4107 Zotarolimus-Eluting Coronary Stent|
79993235|NCT03632733|Drug|Tetracycline|Tetracycline cream
79993236|NCT03632733|Drug|Clotrimazole|Clotrimazole cream
79993237|NCT03632733|Drug|Tetracycline and Clotrimazole|Combination cream
79671193|NCT02298959|Biological|Ziv-Aflibercept|Given IV
79993238|NCT03632733|Other|Placebo|Placebo cream without active drug ingredients
79671194|NCT02270814|Drug|nab-paclitaxel|
79671195|NCT02270814|Drug|Cisplatin|
79671196|NCT02270814|Drug|Carboplatin|
79671197|NCT02270814|Biological|Cetuximab|
79671198|NCT02228681|Drug|Everolimus|10mg daily by mouth
79671199|NCT02228681|Drug|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
79671200|NCT02228681|Drug|Letrozole|2.5mg once a day by mouth
79671201|NCT02228681|Drug|Medroxyprogesterone Acetate|200 mg daily by mouth
79671202|NCT02213107|Drug|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~Enzalutamide by mouth daily and dutasteride by mouth daily or~Enzalutamide by mouth daily and finasteride by mouth daily"
79360693|NCT04993885|Drug|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10^9/L and 200×10^9/L. If the platelet count does not reach to 30×10^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
79360694|NCT04987814|Other|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
79360695|NCT04987814|Other|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
79360696|NCT04987814|Other|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
79360697|NCT04987476|Biological|analyzes in singles cells|genome expression analyzes in single cells
79511799|NCT01151046|Drug|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
79511800|NCT01151046|Drug|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
79511801|NCT01151046|Drug|Exemestane|Exemestane (25 mg) administered orally once per day
79993239|NCT03259425|Drug|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
79360698|NCT04982952|Behavioral|Contingency Management - Increasing|Increasing incentive payment for abstinent participant
79360699|NCT04982952|Behavioral|Fixed payments|Fixed payments for attending study visits
79360700|NCT04978506|Drug|BI 1569912|BI 1569912
79360701|NCT04978506|Drug|Placebo|Placebo
79360702|NCT04964726|Behavioral|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
79360703|NCT04949048|Device|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
79360704|NCT04948476|Other|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~Cool dialysate (35.0◦C)~Dialysate sodium of 145mmol/L~Dialysate calcium of 1.5mmol/L~Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~Most recent pre-dialysis potassium <6mmo/L and bicarbonate >12mmol/L~Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis <1L/session~If available, timed urine collection with result for mean creatinine and/or urea clearance >12mL/min"
79360705|NCT04948476|Other|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
79360706|NCT04944992|Drug|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
79360707|NCT04944992|Drug|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
79360708|NCT04914507|Device|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
79360709|NCT04900506|Procedure|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
79360710|NCT04893824|Device|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
79360711|NCT04874194|Drug|Omacetaxine Mepesuccinate|Given SC
79360712|NCT04874194|Drug|Venetoclax|Given PO
79360713|NCT04862455|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
79511802|NCT01151436|Device|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
79511803|NCT01152294|Behavioral|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
79511804|NCT01153620|Drug|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
79511805|NCT01153620|Other|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
79360714|NCT04862455|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
79511806|NCT01154322|Device|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
79511807|NCT01154634|Drug|AZD2516, 5 mg|Capsule, oral
79511808|NCT01154634|Drug|AZD2516, 16 mg|Capsule, oral
79511809|NCT01154634|Drug|AZD2516, 40 mg|Capsule, oral
79511810|NCT01154634|Drug|Placebo|Capsule, oral
79511811|NCT01155180|Drug|Leptin|Hormone - daily self injections for 6 months
79511812|NCT01155180|Drug|Placebo|Placebo
79671206|NCT02115282|Procedure|Biospecimen Collection|Undergo collection of blood and archived tissue samples
79819836|NCT01563562|Drug|Bardoxolone Methyl|Oral, Single dose
79819837|NCT01551446|Drug|Bardoxolone Methyl|Oral, once daily
79360715|NCT04862455|Biological|Pembrolizumab|Given IV
79671207|NCT02115282|Procedure|Computed Tomography|Undergo CT
79671208|NCT02115282|Drug|Entinostat|Given PO
79671209|NCT02115282|Drug|Exemestane|Given PO
79819838|NCT01549769|Drug|Bardoxolone Methyl|Oral, once daily
79360716|NCT04862455|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79360717|NCT04857788|Other|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
79360718|NCT04851678|Other|None - observational study|None - observational study
79819839|NCT01515787|Drug|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m^2 IV over 2 hours on day 1, leucovorin 400 mg/m^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m^2 bolus over 5-15 minutes then 2400 mg/m^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
79819840|NCT01515787|Other|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
79819841|NCT01515787|Procedure|surgery|low anterior resection with total mesorectal excision
79360719|NCT04843566|Procedure|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
79360720|NCT04843566|Procedure|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
79360721|NCT04843566|Drug|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
79360722|NCT04842773|Diagnostic Test|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
79511813|NCT01155336|Drug|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
79511814|NCT01155336|Drug|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
79511815|NCT01161420|Device|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
79671210|NCT02115282|Drug|Goserelin|Given PO
79671211|NCT02115282|Drug|Goserelin Acetate|Given SC
79671212|NCT02115282|Procedure|Magnetic Resonance Imaging|Undergo MRI
79671213|NCT02115282|Other|Placebo Administration|Given PO
79671214|NCT02115282|Other|Quality-of-Life Assessment|Ancillary studies
79671215|NCT02111941|Other|Laboratory Biomarker Analysis|Correlative studies
79671216|NCT02111941|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
79819842|NCT01515787|Procedure|magnetic resonance imaging or endorectal ultrasound|
79819843|NCT01503866|Drug|bardoxolone methyl|oral, single dose
79819844|NCT01467427|Drug|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
79819845|NCT01461161|Drug|bardoxolone methyl|oral, single dose
79671217|NCT01998971|Drug|Daratumumab|Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
79671218|NCT01998971|Drug|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
79819846|NCT01440244|Procedure|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
79819847|NCT01351675|Drug|Placebo|Oral, once daily
79819848|NCT01351675|Drug|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
79360723|NCT04837209|Drug|Niraparib|Capsule, taken by mouth
79511816|NCT01163214|Drug|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
79511817|NCT01163214|Drug|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
79511818|NCT01163604|Drug|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
79511819|NCT01163604|Drug|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
79511820|NCT01163760|Device|etafilcon A|daily disposable contact lens
79511821|NCT01163760|Device|ocufilcon D|daily disposable contact lens
79671219|NCT01998971|Drug|Pomalidomide|Administered orally in accordance with product labeling and local standards.
79671220|NCT01998971|Drug|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
79360724|NCT04837209|Drug|Dostarlimab|Intravenous infusion
79360725|NCT04837209|Radiation|Radiation therapy|Radio Therapy
79360726|NCT04837092|Drug|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
79360727|NCT04836897|Device|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
79360728|NCT04820530|Drug|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
79511822|NCT01167504|Other|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
79671221|NCT01998971|Drug|Melphalan|Administered orally in accordance with product labeling and local standards.
79671222|NCT01998971|Drug|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
79671223|NCT01998971|Drug|Thalidomide|Administered orally in accordance with product labeling and local standards.
79671224|NCT01998971|Drug|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
79819849|NCT01192464|Drug|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
79819850|NCT01143558|Device|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
79819853|NCT01087294|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant
79993240|NCT03259425|Drug|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
79360729|NCT04813627|Procedure|Regular blood sample collection for ctDNA assessment|Blood samples for in vitro testing of ctDNA status will be drawn at study visits every three months
79360730|NCT04812795|Other|Culturally tailored anti-smoking messages|Anti-smoking messages that are culturally tailored for sexual minority women.
79360731|NCT04812795|Other|Non-culturally tailored interventions|Anti-smoking messages that are not culturally tailored for sexual minority women.
79360732|NCT04807907|Behavioral|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
79671225|NCT01998971|Drug|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
79671226|NCT01998971|Drug|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
79671227|NCT01998971|Drug|Lenalidomide|Administered orally in accordance with product labeling and local standards.
79993241|NCT03259269|Other|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
79360733|NCT04797767|Drug|Cladribine|Given IV
79360734|NCT04797767|Drug|Cytarabine|Given IV
79360735|NCT04797767|Drug|Mitoxantrone|Given IV
79360736|NCT04797767|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
79360737|NCT04797767|Drug|Venetoclax|Given PO
79360738|NCT04770207|Drug|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
79360739|NCT04759105|Drug|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
79360740|NCT04759105|Other|Sham Procedure|anaesthesia, no disc injection, no placebo injection
79360741|NCT04752163|Drug|DS-1594b|Given DS-1594b PO
79360742|NCT04752163|Drug|Azacitidine|Given IV or SC
79360743|NCT04752163|Drug|Cyclophosphamide|Given IV
79360744|NCT04752163|Drug|Cytarabine|Given IT
79360745|NCT04752163|Drug|Dexamethasone|Given PO or IV
79360746|NCT04752163|Biological|Filgrastim|Given SC
79360747|NCT04752163|Drug|Leucovorin|Given IV or PO
79360748|NCT04752163|Drug|Mesna|Given IV
79360749|NCT04752163|Drug|Methotrexate|Given IT
79360750|NCT04752163|Drug|Posaconazole|Given PO
79360751|NCT04752163|Drug|Prednisone|Given PO
79360752|NCT04752163|Biological|Rituximab|Given IV
79360753|NCT04752163|Drug|Venetoclax|Given PO
79360754|NCT04752163|Drug|Vincristine|Given IV
79360755|NCT04752163|Drug|Voriconazole|Given PO
79360756|NCT04751331|Biological|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
79360757|NCT04751331|Biological|Saline|0.9% saline administered as an intravenous bolus
79671228|NCT01998971|Drug|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
79671229|NCT01991977|Procedure|Diffusion Weighted Imaging|Undergo DTI
79671230|NCT01991977|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
79671231|NCT01991977|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79671232|NCT01991977|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
79993242|NCT04923555|Behavioral|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
79993243|NCT04923555|Behavioral|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
79360758|NCT04749030|Other|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (~50 grams of original donor faeces).
79360759|NCT04749030|Other|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
79360760|NCT04744428|Behavioral|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
79360761|NCT04744428|Behavioral|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
79360762|NCT04738877|Diagnostic Test|Body fat measurement|Body fat measurement using skinfolds
79360763|NCT04738877|Diagnostic Test|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
79360764|NCT04738877|Diagnostic Test|Echocardiography|Transthoracic echocardiography
79360765|NCT04738877|Diagnostic Test|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
79360766|NCT04732598|Drug|Paclitaxel + bevacizumab therapy|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~[Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV"
79360767|NCT04732598|Drug|Paclitaxel + bevacizumab + atezolizumab|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~[Atezolizumab] 840 mg/body, day 1,15, IV [Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV"
79360768|NCT04726683|Procedure|Dry needling and placebo injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.
79360769|NCT04726683|Procedure|Injection and placebo dry needling|Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin
79360770|NCT04726683|Procedure|Dry needling and injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.
79511823|NCT01168674|Drug|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
79511824|NCT01168674|Drug|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
79511825|NCT01168908|Drug|Sildenafil|20mg tablet three times daily
79671233|NCT01991977|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET
79511826|NCT01168986|Other|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
79511827|NCT01168986|Other|Exercise|Participants perform an exercise to strengthen the deep neck flexors
79511828|NCT01169064|Device|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
79671234|NCT01991977|Other|Quality-of-Life Assessment|Ancillary studies
79671235|NCT01991977|Drug|Temozolomide|Receive temozolomide
79671236|NCT01989585|Procedure|Biopsy|Undergo biopsy
79671237|NCT01989585|Procedure|Biospecimen Collection|Undergo collection of blood samples
79671238|NCT01989585|Procedure|Computed Tomography|Undergo CT
79671239|NCT01989585|Drug|Dabrafenib|Given PO
79671240|NCT01989585|Other|Laboratory Biomarker Analysis|Correlative studies
79819854|NCT01087294|Biological|Anti-CD19-chimeric-antigen-receptor-transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
79671241|NCT01989585|Procedure|Magnetic Resonance Imaging|Undergo MRI
79671242|NCT01989585|Biological|Navitoclax|Given PO
79511829|NCT01169064|Device|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
79511830|NCT01170390|Drug|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
79511831|NCT01170390|Drug|Portia|30 mcg EE/0.15 mg LNG cyclically
79511832|NCT01170390|Drug|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
79511833|NCT01170546|Other|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
79511834|NCT01170546|Other|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
79511835|NCT01170546|Other|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
79511836|NCT01134510|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
79819855|NCT01087294|Procedure|Leukapheresis|Donors will undergo leukapheresis
79511837|NCT01134510|Drug|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
79511838|NCT01171794|Drug|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
79511839|NCT01171794|Drug|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
79671243|NCT01989585|Other|Pharmacological Study|Correlative studies
79671244|NCT01989585|Drug|Trametinib|Given PO
79671245|NCT01941277|Behavioral|Current Recommendations Exercise Group|
79671246|NCT01941277|Behavioral|Intensive Exercise Group|
79511840|NCT01172184|Procedure|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
79511841|NCT01175148|Drug|Atorvastatin calcium (Lipitor)|40 mg PO daily
79671247|NCT01938261|Drug|paracetamol|
79671248|NCT01938261|Drug|0.45 % saline solution|Placebo
79671249|NCT01934582|Drug|UT-15C SR|
79671250|NCT01934582|Drug|treprostinil diethanolamine|Open label study drug.
79671251|NCT01894854|Procedure|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
79671252|NCT01854554|Radiation|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
79671253|NCT01854554|Radiation|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
79819856|NCT01053936|Drug|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
79819857|NCT01044069|Biological|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed & frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, & transduced with the 19-28z chimeric receptor & expanded. All relapsed (either MRD+ or morphologic) & refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo & highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
79819858|NCT00974415|Procedure|CO2|CO2 treatment delivered to randomized flank at each study visit
79819859|NCT00974415|Procedure|Sham|Sham treatment to other flank at each study visit
79819860|NCT00967785|Drug|Mozobil (TM)|
79819861|NCT00897702|Other|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
79819862|NCT00897702|Other|immunoenzyme technique|
79819863|NCT00897702|Procedure|biopsy|
79819864|NCT00897702|Procedure|histopathologic examination|
79511842|NCT01175226|Drug|BTA798|BTA798 twice daily
79511843|NCT01175226|Drug|Placebo|Placebo twice daily
79511844|NCT01175850|Device|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
79511845|NCT01175850|Device|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
79511846|NCT01177098|Drug|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
79511847|NCT01177098|Drug|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
79511848|NCT01177956|Biological|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
79511849|NCT01177956|Drug|Cisplatin|Subjects will receive 75 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
79511850|NCT01177956|Drug|5-Fluorouracil|Subjects will receive 750 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
79511851|NCT01178268|Device|XIENCE V EECSS|Patients who will receive this stent.
79671254|NCT01854554|Behavioral|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
79671255|NCT01854554|Behavioral|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
79671256|NCT01817959|Drug|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
79671257|NCT01817959|Drug|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
79671258|NCT01792687|Drug|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
79993244|NCT04923555|Behavioral|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
79671259|NCT01792687|Drug|Abiraterone acetate|1,000 mg, oral, daily
79671260|NCT01792687|Drug|Prednisone|5 mg, oral, daily
79511852|NCT01178268|Device|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
79511853|NCT01179984|Device|Bard® LifeStent® Vascular Stent System|Stent Implantation
79511854|NCT01181076|Dietary Supplement|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
79671261|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 5 Gy x 5 (over 1-2 weeks)*
79671262|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 6.6 Gy x 5 (over 1-2 weeks)*
79671263|NCT01755195|Drug|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
79671264|NCT01697384|Drug|histrelin acetate|52 week implant
79679699|NCT04690920|Drug|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
79993245|NCT03101241|Drug|CX-8998|T-type calcium channel blocker
79993246|NCT03101241|Drug|Placebo|Placebo comparator
79993247|NCT03061188|Other|Laboratory Biomarker Analysis|Correlative studies
79360771|NCT04726683|Procedure|Placebo dry needling and placebo injection|Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
79360772|NCT04709978|Diagnostic Test|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
79360773|NCT04709978|Diagnostic Test|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
79360774|NCT04709978|Diagnostic Test|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
79360775|NCT04709978|Diagnostic Test|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
79360776|NCT04709978|Diagnostic Test|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
79360777|NCT04709978|Diagnostic Test|Lung Ultrasound|To image the lungs (ED participants only)
79360778|NCT04709978|Diagnostic Test|Respiratory Function Tests|To measure respiratory pressures.
79819865|NCT00823654|Other|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
79360779|NCT04694456|Other|cytokines dosage|Mesure of cytokines concentration in serum
79360780|NCT04694456|Procedure|test of walk|patient must walk during 6 minutes on a flat surface
79360781|NCT04694456|Procedure|Manual muscular test|test performed to evaluate the patient muscular weakness
79360782|NCT04694456|Procedure|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
79993248|NCT03061188|Biological|Nivolumab|Given IV
79993249|NCT03061188|Other|Pharmacological Study|Correlative studies
79360783|NCT04657432|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
79993250|NCT03061188|Drug|Veliparib|Given PO
79993251|NCT03449147|Drug|Placebo|Placebo tablet administered orally BID
79360786|NCT04617444|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360787|NCT04617444|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360788|NCT04603352|Other|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
79360789|NCT04581629|Drug|Encaleret|Tablets administered orally
79671265|NCT01637987|Procedure|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
79679700|NCT00519038|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
79679701|NCT00519038|Other|Usual Care|Usual care is the current practice actually performed in the hospital
79993252|NCT03449147|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
79993253|NCT03449147|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
79993254|NCT03628638|Other|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
79511855|NCT01182480|Behavioral|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
79511856|NCT01183650|Drug|Tadalafil|5 mg, administered orally, daily for 10 days
79993255|NCT04031040|Device|Genio(TM) system therapy|Hypoglossal nerve stimulation system
79993256|NCT05588453|Biological|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
79993257|NCT05588453|Drug|Temozolomide|Given PO
79511857|NCT01183728|Other|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
79511858|NCT01184898|Drug|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
79671266|NCT01637987|Procedure|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
79671267|NCT01637987|Procedure|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein & surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
79671268|NCT01604512|Diagnostic Test|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
79819866|NCT00823654|Other|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
79819867|NCT00811889|Other|Placebo|Placebo
79819868|NCT00811889|Drug|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
79819869|NCT00702533|Device|Pentagastrin Injection BP|
79819870|NCT00702533|Drug|Pentagastrin|
79360790|NCT04568382|Other|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
79360791|NCT04568382|Other|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
79360792|NCT04551391|Other|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
79819871|NCT00669188|Other|Information absent|Information
79360793|NCT04540406|Drug|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
79819872|NCT00669188|Other|Information|Information
79819873|NCT00664027|Drug|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
79360794|NCT04540406|Other|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
79360795|NCT04539808|Drug|Capecitabine|Given PO
79360796|NCT04539808|Drug|Fluorouracil|Given IV
79360797|NCT04539808|Drug|Irinotecan Hydrochloride|Given IV
79360798|NCT04539808|Drug|Leucovorin Calcium|Given IV
79360799|NCT04539808|Drug|Losartan Potassium|Given PO
79360800|NCT04539808|Drug|Oxaliplatin|Given IV
79360801|NCT04539808|Radiation|Radiation Therapy|Undergo short-course or long-course RT
79360802|NCT04539808|Procedure|Resection|Undergo surgical resection
79511859|NCT01184898|Drug|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
79511860|NCT01184898|Drug|Etoposide|100 mg/m2/day IV
79511861|NCT01184898|Drug|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
79671269|NCT01541709|Drug|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
79819874|NCT00597805|Behavioral|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
79360803|NCT04539808|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
79360804|NCT04539808|Procedure|Biospecimen Collection|Undergo blood sample collection
79360805|NCT04538716|Procedure|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
79360806|NCT04530487|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
79360807|NCT04530487|Drug|Cyclosporine|Given IV and PO
79360808|NCT04530487|Drug|Etoposide|Given IV
79360809|NCT04530487|Drug|Fludarabine Phosphate|Given IV
79360810|NCT04530487|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
79360811|NCT04530487|Drug|Melphalan|Given IV
79360812|NCT04530487|Drug|Mycophenolate Mofetil|Given IV or PO
79671270|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
79671271|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
79671272|NCT01450020|Other|educational intervention|Receive ACS material
79671273|NCT01450020|Other|questionnaire administration|Ancillary studies
79671274|NCT01450020|Other|counseling intervention|Undergo PN session
79671275|NCT01450020|Other|survey administration|Ancillary studies
79819875|NCT00565708|Other|placebo|Placebo Comparator
79360813|NCT04530487|Drug|Tacrolimus|Given IV and PO
79360814|NCT04530487|Drug|Thiotepa|Given IV
79360815|NCT04528680|Device|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
79360816|NCT04528680|Drug|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
79360817|NCT04528680|Drug|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
79360818|NCT04523324|Biological|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
79360819|NCT04523324|Biological|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
79360820|NCT04513808|Drug|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
79360821|NCT04513808|Drug|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
79360822|NCT04494113|Procedure|Biopsy|Undergo biopsy
79360823|NCT04494113|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
79360824|NCT04494113|Procedure|Resection|Undergo surgical resection
79360825|NCT04494113|Drug|Triapine|Given IV
79360826|NCT04484935|Drug|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight < 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
79360827|NCT04478734|Drug|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
79360828|NCT04478734|Drug|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
79511862|NCT01188876|Drug|carboplatin|Given intravenously on Day 1 of each 28-day cycle
79511863|NCT01188876|Drug|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
79511864|NCT01188876|Drug|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
79511865|NCT01188876|Drug|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
79671276|NCT01450020|Procedure|quality-of-life assessment|Ancillary studies
79671277|NCT01394263|Drug|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
79671278|NCT01394263|Drug|Zoladex goserelin implant|goserelin implant injection.
79671279|NCT01347567|Other|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
79671280|NCT01263769|Drug|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
79819876|NCT00565708|Drug|Acetylsalicylic acid|Adjuvant Therapy
79819877|NCT00550849|Drug|RTA 402|5 mg oral capsules
79819878|NCT00550849|Drug|RTA 402|25 mg oral capsules
79819879|NCT00550849|Drug|RTA 402|50 mg oral capsules
79511866|NCT01189110|Device|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
79671281|NCT01154764|Drug|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
79671282|NCT01154764|Drug|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
79993258|NCT01311401|Other|NONE intervention|NONE intervention
79993259|NCT03716141|Other|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
79360829|NCT04478292|Drug|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight < 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
79360830|NCT04478292|Procedure|Primary surgery resection|Resection of the primary tumor up-front
79360831|NCT04478292|Drug|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
79360832|NCT04478292|Drug|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
79360833|NCT04478292|Procedure|Biopsy|Tumors are deemed unresectable at diagnosis.
79360834|NCT04478292|Procedure|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
79360835|NCT04478292|Procedure|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
79360836|NCT04478292|Drug|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
79360837|NCT04478292|Drug|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
79511867|NCT01192542|Device|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
79511868|NCT01192542|Device|enfilcon A lens|Marketed silicone hydrogel contact lens
79511869|NCT01193010|Procedure|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
79671283|NCT01153035|Device|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
79671284|NCT01035983|Drug|Frovatriptan 2.5 mg|
79671285|NCT01013025|Procedure|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
79671286|NCT01004978|Drug|Cisplatin|Undergo TACE
79671287|NCT01004978|Procedure|Computed Tomography|Undergo CT scan
79671288|NCT01004978|Drug|Doxorubicin Hydrochloride|Undergo TACE
79671289|NCT01004978|Drug|Doxorubicin-Eluting Beads|Undergo TACE
79671290|NCT01004978|Other|Laboratory Biomarker Analysis|Correlative studies
79671291|NCT01004978|Procedure|Magnetic Resonance Imaging|Undergo MRI
79671292|NCT01004978|Drug|Mitomycin|Undergo TACE
79671293|NCT01004978|Other|Pharmacological Study|Correlative studies
79671294|NCT01004978|Other|Placebo Administration|Given PO
79671295|NCT01004978|Drug|Sorafenib Tosylate|Given PO
79671296|NCT00937001|Procedure|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
79819880|NCT00538343|Drug|berubicin hydrochloride (RTA 744)|
79819881|NCT00535314|Drug|RTA 402 Dose1|
79819882|NCT00535314|Drug|RTA 402 Dose2|
79819883|NCT00529438|Drug|Bardoxolone methyl|
79993260|NCT03716141|Other|Conventional Saline dressing|saline dressing of diabetic wounds will be done
79993261|NCT02366520|Device|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
79993262|NCT05186454|Drug|Morphine Sulfate|analgesia
79993263|NCT05186454|Drug|Bupivacaine|Analgesia
79993264|NCT05186454|Drug|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
79993265|NCT05177640|Drug|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
79993266|NCT02113878|Drug|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
79993267|NCT02113878|Drug|Cisplatin|Cisplatin is a chemotherapy drug
79671297|NCT00904540|Drug|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (<6 weeks) LBP, subacute (6 weeks to <3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
79819884|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
79993268|NCT02113878|Radiation|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
79993269|NCT05162898|Drug|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
79993270|NCT05162898|Drug|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight <60kg) orally, once a day
79993271|NCT05162898|Device|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
79993272|NCT03628872|Procedure|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
79993273|NCT03628872|Device|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
79993274|NCT03628872|Device|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
79360838|NCT04478292|Drug|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
79360839|NCT04478292|Drug|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
79360840|NCT04466033|Device|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
79360841|NCT04464174|Drug|Ipatasertib|Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
79360842|NCT04464174|Drug|Capecitabine|Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
79360843|NCT04464174|Drug|Eribulin|Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
79360844|NCT04464174|Drug|Carboplatin|Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
79360845|NCT04464174|Drug|Gemcitabine|Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
79360846|NCT04459117|Drug|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
79360847|NCT04459117|Drug|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
79360848|NCT04428112|Behavioral|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
79360849|NCT04428112|Behavioral|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
79671298|NCT00904202|Drug|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
79819885|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
79819886|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
79993275|NCT05113290|Drug|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10^12 vp) if the sum of the maximum lesion diameters was > 10 cm, 2 vials (1.0 × 10^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
79993276|NCT05113290|Drug|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
79993277|NCT03628794|Device|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
79671299|NCT00904202|Drug|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
79360850|NCT04408690|Procedure|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
79360851|NCT04408690|Other|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
79360852|NCT04408690|Procedure|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
79360853|NCT04407754|Dietary Supplement|Inositol supplement|Inositol supplements given to inositol arm
79819887|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
79819888|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
79993278|NCT03461952|Drug|Nivolumab|240mg
79993279|NCT03461952|Drug|Ipilimumab|1mg/kg
79360854|NCT04407754|Dietary Supplement|Placebo supplement|Placebo supplement given to placebo arm
79360855|NCT04407364|Device|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
79360856|NCT04387305|Drug|Tranexamic acid injection|Active drug is provided to participants as described based on the TXA arm they are randomized to.
79360857|NCT04377217|Other|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
79360858|NCT04374305|Drug|Brigatinib|Oral daily per predetermined dosage per protocol.
79360859|NCT04374305|Drug|Neratinib|Oral daily per predetermined dosage per protocol.
79360860|NCT04351958|Behavioral|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
79360861|NCT04351555|Drug|Osimertinib|Oral
79360862|NCT04351555|Drug|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
79360863|NCT04351555|Drug|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
79360864|NCT04351555|Drug|Placebo|Oral
79360865|NCT04351555|Drug|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
79679702|NCT04691895|Other|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
79819889|NCT00529113|Drug|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
79993280|NCT03423173|Biological|TAK-003|TDV subcutaneous injection
79993281|NCT03423173|Biological|Placebo|TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
79511870|NCT01193010|Procedure|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
79511871|NCT01193868|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
79511872|NCT01193868|Other|laboratory biomarker analysis|Correlative studies
79511873|NCT01193868|Other|pharmacological study|Correlative studies
79511874|NCT01195116|Drug|Dexmedetomidine|1 mcg/kg/hour
79511875|NCT01195116|Drug|Normal Saline|1mcg/kg/hr
79360866|NCT04317742|Device|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
79511876|NCT01196442|Other|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
79671300|NCT00904202|Drug|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
79671301|NCT00904202|Drug|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
79360867|NCT04317742|Device|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
79511877|NCT01196442|Other|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
79511878|NCT01197612|Drug|pulmicort|applied to nasal packing after surgery
79511879|NCT01198158|Biological|Bevacizumab|Given IV
79511880|NCT01198158|Drug|Everolimus|Given PO
79511881|NCT01198158|Other|Laboratory Biomarker Analysis|Correlative studies
79511882|NCT01198158|Other|Pharmacological Study|Correlative studies
79819890|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
79360868|NCT04299906|Device|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
79360869|NCT04297254|Drug|Lenvatinib|Lenvatinib capsules.
79511883|NCT01199952|Behavioral|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
79511884|NCT01200030|Behavioral|electrical stimulation with exercises|electrical stimulation with exercises
79511885|NCT01200030|Behavioral|placebo stimulation with exercises|placebo stimulation with exercises
79511886|NCT01200498|Drug|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
79511887|NCT01203774|Drug|Glargine insulin|20-180 units per day
79511888|NCT01205568|Device|Transcatheter Cutting Balloon therapy|
79511889|NCT01205568|Procedure|High Pressure Balloon Angioplasty|
79511890|NCT01205646|Drug|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
79671302|NCT00904202|Drug|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
79671303|NCT00904202|Drug|Gabapentin 1800 mg/day + Lidoderm patch|
79671304|NCT00904020|Drug|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
79671305|NCT00719966|Drug|anastrozole|Patients receive aromatase inhibition therapy.
79302628|NCT04998513|Drug|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight < 70 kilograms, 20 mg if bodyweight > 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
79360870|NCT04262882|Behavioral|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
79360871|NCT04262882|Behavioral|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
79360872|NCT04244981|Drug|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
79993282|NCT03348228|Dietary Supplement|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
79993283|NCT05062746|Other|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
79360873|NCT04244981|Drug|Fresh Frozen Plasma|When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
79671306|NCT00719966|Drug|exemestane|Patients receive aromatase inhibition therapy.
79993284|NCT05062746|Other|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
79993285|NCT03192540|Other|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
79993286|NCT03619824|Drug|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
79993287|NCT03619824|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
79360874|NCT04244773|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79511891|NCT01205646|Device|PET Scan|2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
79511892|NCT01206660|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
79511893|NCT01206660|Drug|placebo|Placebo administered to affected area twice a day for 28 days
79511894|NCT01206738|Behavioral|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
79511895|NCT01206738|Behavioral|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
79671307|NCT00719966|Drug|letrozole|Patients receive aromatase inhibition therapy.
79671308|NCT00719966|Procedure|assessment of therapy complications|Endothelial function is measured
79671309|NCT00671008|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79671310|NCT00671008|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79819891|NCT00529113|Drug|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
79819892|NCT00529113|Drug|Placebo|Placebo capsules x 28 days
79993288|NCT03619824|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
79993289|NCT03619824|Radiation|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
79993290|NCT01759836|Drug|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
79993291|NCT03447821|Drug|400 mg Rifamycin SV dosage|
79993292|NCT03447821|Drug|800 mg Rifamycin SV dosage|
79993293|NCT03447821|Drug|1200 mg Rifamycin SV dosage|
79511896|NCT01206738|Behavioral|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
79511897|NCT01207752|Drug|Systane Balance|Artificial tear emulsion drop
79993294|NCT03079284|Other|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
79819893|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
79308262|NCT02503397|Device|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
79360875|NCT04244773|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360876|NCT04201184|Behavioral|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
79360877|NCT04201184|Behavioral|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
79819894|NCT00527410|Drug|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
79993295|NCT05630339|Dietary Supplement|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
79993296|NCT05630339|Dietary Supplement|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
79993297|NCT05630339|Dietary Supplement|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
79993298|NCT03447353|Drug|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
79360878|NCT04198922|Drug|Acalabrutinib|Given PO
79511898|NCT01207752|Drug|Optive Lubricant Eye Drops|Artificial tear eye drop
79511899|NCT01207908|Drug|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
79671311|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
79671312|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
79819895|NCT00526812|Drug|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
79819896|NCT00526812|Drug|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
79360879|NCT04198922|Other|Questionnaire Administration|Ancillary studies
79511900|NCT01208220|Device|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
79511901|NCT01208220|Biological|Collagenase Ointment|Apply TIW
79511902|NCT01208922|Drug|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
79511903|NCT01208922|Drug|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
79511904|NCT01209702|Biological|tocilizumab|Administered intravenously (iv) every 4 weeks
79511905|NCT01209702|Drug|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
79511906|NCT01210170|Drug|placebo|placebo inhalation before albuterol.
79511907|NCT01210170|Drug|mometasone 400 mcg|mometasone inhalation before albuterol.
79511908|NCT01210170|Drug|mometasone 200 mcg|200ug mometasone before albuterol.
79511909|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
79511910|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
79671313|NCT00644033|Drug|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
79671314|NCT00643604|Drug|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
79671317|NCT00585559|Drug|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
79671318|NCT00585559|Drug|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
79671319|NCT00585559|Drug|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
79360880|NCT04189991|Device|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
79360881|NCT04182373|Drug|Antithrombin gamma|Intravenous infusion, once a day, 7 days
79511911|NCT01210560|Drug|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
79360882|NCT04182373|Drug|physiological saline|Intravenous infusion, once a day, 7 days
79360883|NCT04180085|Drug|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
79671320|NCT00585559|Drug|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
79671321|NCT00585559|Drug|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
79671322|NCT00486356|Drug|capecitabine|
79671323|NCT00486356|Drug|carboplatin|
79671324|NCT00486356|Drug|epirubicin hydrochloride|
79671325|NCT00486356|Genetic|microarray analysis|
79993299|NCT03447353|Drug|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
79993300|NCT03447353|Drug|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
79993301|NCT03055884|Device|tDCS|active tDCS versus sham tDCS
79360884|NCT04179175|Drug|secukinumab|secukinumab 300mg every 2 or every 4 weeks
79993302|NCT03055884|Behavioral|Verbal paired-associate learning task|with or without repeated retrieval practice
79993303|NCT03718169|Behavioral|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
79993304|NCT03446885|Drug|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
79993305|NCT03446885|Drug|Placebo|Placebo capsule administered orally
79360885|NCT04175977|Behavioral|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
79360886|NCT04175977|Behavioral|Usual Care|Usual care as provided by the hospice agency
79360887|NCT04168060|Procedure|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
79360888|NCT04168060|Procedure|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
79360889|NCT04168060|Procedure|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
79511912|NCT01210560|Drug|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
79511913|NCT01210560|Drug|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
79511914|NCT01210716|Device|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
79671326|NCT00486356|Genetic|polymorphism analysis|
79671327|NCT00486356|Other|pharmacological study|
79671328|NCT00475514|Drug|Frovatriptan 2.5mg QD|
79671329|NCT00475514|Drug|Frovatriptan 2.5 mg BID|
79671330|NCT00475514|Drug|placebo|
79671331|NCT00471601|Behavioral|counseling intervention|
79671332|NCT00471601|Behavioral|questionnaire administration|
79671333|NCT00471601|Behavioral|psychosocial assessment and care|
79671334|NCT00471601|Behavioral|quality-of-life assessment|
79671335|NCT00447382|Drug|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
79671336|NCT00447382|Drug|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
79671337|NCT00447382|Drug|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
79671338|NCT00439946|Drug|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
79671339|NCT00439946|Device|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
79671340|NCT00383877|Drug|insulin detemir|
79671341|NCT00383877|Drug|insulin NPH|
79671342|NCT00325403|Drug|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
79671343|NCT00325403|Other|Placebo|Placebo oral tablet twice daily
79671344|NCT00278785|Behavioral|Brief Motivational Interview|10-20 minute brief motivational interview
79671345|NCT00226421|Drug|Oxymorphone Extended Release|
79671346|NCT00226395|Drug|Oxymorphone immediate release|
79511915|NCT01211106|Behavioral|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
79511916|NCT01211106|Behavioral|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
79671347|NCT00225797|Drug|Oxymorphone Extended Release|
79671348|NCT00147199|Drug|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
79671349|NCT00147199|Drug|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
79993306|NCT03712319|Behavioral|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
79360890|NCT04161235|Device|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
79360891|NCT04140305|Drug|RPC-1063|Oral capsule
79360892|NCT04135859|Behavioral|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
79360893|NCT04135859|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
79360894|NCT04133948|Drug|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
79360895|NCT04133948|Drug|Nivolumab|2 courses nivolumab 240 mg q3weeks
79360896|NCT04133948|Drug|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
79511917|NCT01211340|Behavioral|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
79671350|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
79679703|NCT00518024|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
79679704|NCT02939508|Other|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
79511918|NCT01211730|Drug|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
79819897|NCT00500994|Device|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
79819898|NCT00750152|Drug|NAFT-500|topical cream application up to 4 weeks
79360897|NCT04126642|Behavioral|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
79360898|NCT04126642|Behavioral|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
79360899|NCT04107948|Other|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
79360900|NCT04107948|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
79360901|NCT04103892|Drug|CLE-100|1 tablet of CLE-100 administered once daily
79360902|NCT04103892|Drug|placebo|1 tablet of placebo administered once daily
79360903|NCT04082936|Drug|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
79671351|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
79671352|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
79819899|NCT00750152|Drug|Placebo|placebo cream applied for up to 4 weeks
79679705|NCT02939508|Other|Non-colon originated: Neostigmin, Colonoscopy decompression|
79360904|NCT04070183|Behavioral|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
79511919|NCT01212900|Drug|Statins, HMG CoA|Statin therapy
79511920|NCT01215240|Device|Peritoneal dialysis|Prophylactic peritoneal dialysis
79511921|NCT01215318|Device|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
79679706|NCT00518102|Drug|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
79819900|NCT02597192|Other|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
79360905|NCT04070183|Behavioral|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
79360906|NCT04068610|Drug|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
79360907|NCT04068610|Drug|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
79360908|NCT04068610|Drug|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
79360909|NCT04068610|Drug|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
79819901|NCT02597192|Other|oral hygiene products without Bacillus|products without Bacillus
79819902|NCT05392790|Other|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
79819903|NCT05392790|Drug|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
79819904|NCT05392790|Other|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
79819905|NCT04071483|Procedure|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
79360910|NCT04057833|Drug|E-CEL UVEC|Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
79360911|NCT04057040|Drug|PTG-300|Active
79360912|NCT04057040|Drug|Placebo|Placebo
79360913|NCT04005690|Drug|Cobimetinib|Given PO
79360914|NCT04005690|Drug|Olaparib|Given PO
79360915|NCT04005690|Drug|Onvansertib|Given PO
79360916|NCT04005690|Drug|Temuterkib|Given PO
79360917|NCT03997370|Procedure|Biospecimen Collection|Undergo collection of blood samples
79360918|NCT03997370|Drug|Carboplatin|Given IV
79360919|NCT03997370|Drug|Iohexol|Given IV
79360920|NCT03981926|Other|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
79360921|NCT03961971|Drug|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
79360922|NCT03938298|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
79511922|NCT01215786|Drug|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
79511923|NCT01215786|Drug|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
79511924|NCT01215786|Drug|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
79511925|NCT01216410|Drug|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
79993307|NCT03712319|Behavioral|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
79360923|NCT03938298|Other|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
79360924|NCT03921827|Device|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
79360925|NCT03919968|Behavioral|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
79360926|NCT03919968|Behavioral|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
79511926|NCT01216410|Drug|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
79511927|NCT01216410|Drug|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
79308263|NCT03213743|Drug|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
79511928|NCT01218048|Drug|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
79511929|NCT01218048|Procedure|Surgery|Surgery for tumor
79511930|NCT01218048|Radiation|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
79511931|NCT01218048|Drug|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
79360927|NCT03882372|Device|Nasal high flow|See arm description.
79360928|NCT03879135|Biological|rVWF|Recombinant von Willebrand factor
79679707|NCT00518102|Other|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
79679708|NCT02939235|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
79679709|NCT02939235|Drug|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
79679710|NCT00518141|Drug|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
79679711|NCT02938962|Drug|Tranexamic Acid|
79679712|NCT00519701|Drug|hydroxyurea|
79511932|NCT01218672|Device|Photoselective Vaporization of the Prostate|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator."
79511933|NCT01218672|Device|Transurethral Resection of the Prostate|Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
79511934|NCT01218984|Drug|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
79511935|NCT01218984|Drug|Medisorb naltrexone 150 mg|Single administration via IM injection.
79511936|NCT01218984|Drug|Medisorb naltrexone 300 mg|Single administration via IM injection.
79511937|NCT01218984|Drug|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
79993308|NCT00710970|Drug|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
79308264|NCT03212495|Drug|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
79308265|NCT03212495|Drug|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
79360929|NCT03879135|Biological|rFVIII|Recombinant Factor VIII
79360930|NCT03874936|Drug|Dexamethasone 24mg Solution for Injection|Administrated i.v.
79360931|NCT03874936|Drug|Saline Solution for Injection|administrated i.v.
79360932|NCT03870854|Procedure|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
79360933|NCT03860844|Drug|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
79511938|NCT01218984|Drug|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
79360934|NCT03860844|Drug|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
79511939|NCT01220466|Device|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
79511940|NCT01222260|Drug|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
79511941|NCT01222260|Drug|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
79511942|NCT01222494|Behavioral|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
79993309|NCT03716063|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
79360935|NCT03860844|Drug|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79360936|NCT03860844|Drug|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79360937|NCT03860844|Drug|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79360938|NCT03860844|Drug|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
79511943|NCT01222494|Behavioral|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
79360939|NCT03860844|Drug|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79993310|NCT04957524|Device|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
79993311|NCT03718013|Device|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
79993312|NCT03718013|Device|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
79993313|NCT02868528|Genetic|chromosome screening with NGS technology|
79993314|NCT04945746|Procedure|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
79360940|NCT03860844|Drug|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79993315|NCT05209542|Procedure|Hysterosalpingo-Foam Ultrasonography|"Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
79993316|NCT05209542|Procedure|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
79993317|NCT03421379|Drug|Glucagon Nasal Powder|Administered intranasally
79993318|NCT03421379|Drug|Glucagon Hydrochloride Solution|Administered IM
79511944|NCT01222572|Radiation|Stereotactic boost|
79511945|NCT01222572|Radiation|Conventional RT|
79511946|NCT01222572|Drug|Etoposide|
79671353|NCT00135668|Drug|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
79671354|NCT00066703|Drug|exemestane|
79993319|NCT03712241|Drug|K-285|Topical
79993320|NCT03712241|Drug|Indomethacin|Capsule
79671355|NCT00066703|Drug|tamoxifen|
79671356|NCT00066703|Drug|triptorelin|
79671357|NCT00066690|Drug|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
79993321|NCT01311479|Procedure|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
79360941|NCT03860844|Drug|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79360942|NCT03860844|Drug|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79671358|NCT00066690|Other|Laboratory Biomarker Analysis|Correlative studies
79671359|NCT00066690|Procedure|Oophorectomy|Undergo bilateral surgical oophorectomy
79360943|NCT03860844|Drug|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79360944|NCT03860844|Drug|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
79360945|NCT03860844|Drug|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79360946|NCT03860844|Drug|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
79360947|NCT03860844|Drug|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
79360948|NCT03860844|Drug|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
79360949|NCT03860844|Drug|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
79360950|NCT03860844|Drug|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
79511947|NCT01222572|Drug|Cisplatin|
79511948|NCT01222884|Drug|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
79511949|NCT01222884|Drug|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
79360951|NCT03856814|Device|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
79511950|NCT01223352|Drug|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
79360952|NCT03853304|Other|+ Folic acid|Salt fortified with folic acid
79671360|NCT00066690|Other|Quality-of-Life Assessment|Ancillary studies
79671361|NCT00066690|Radiation|Radiation Therapy|Undergo ovarian irradiation
79511951|NCT01224210|Drug|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
79671362|NCT00066690|Drug|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
79671363|NCT00066690|Drug|Triptorelin|3.75 mg by im injection q28 days for 5 years
79511952|NCT01224444|Other|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
79671364|NCT00469560|Drug|Deferasirox|
79671365|NCT04704167|Other|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
79671366|NCT00469599|Drug|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
79671367|NCT00469599|Drug|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
79671368|NCT00429260|Drug|Saredutant|
79671369|NCT00460980|Behavioral|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
79671370|NCT00429338|Procedure|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
79360953|NCT03853304|Other|+ Vitamin B12|Salt fortified with vitamin B12
79360954|NCT03853304|Other|DFS|Salt fortified with iron and iodine
79360955|NCT03841149|Other|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
79360956|NCT03808272|Device|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
79360957|NCT03787264|Drug|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
79360958|NCT03787264|Biological|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
79360959|NCT03787264|Biological|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
79360960|NCT03787264|Biological|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
79360961|NCT03786523|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
79360962|NCT03786523|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
79511953|NCT01224678|Dietary Supplement|vitamin D|Given orally
79511954|NCT01224678|Other|placebo|Given orally
79511955|NCT01225068|Drug|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
79671371|NCT00429338|Procedure|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
79671372|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
79671373|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
79671374|NCT00429377|Drug|tacrolimus|
79671375|NCT00469716|Drug|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
79671376|NCT00429455|Behavioral|Survey|3-Part Questionnaire
79671377|NCT00461019|Procedure|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
79819906|NCT05404802|Device|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
79360963|NCT03777631|Procedure|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
79360964|NCT03745612|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
79360965|NCT03745612|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
79360966|NCT03739372|Other|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
79360967|NCT03736512|Device|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
79360968|NCT03732950|Biological|Pembrolizumab|Given IV
79360969|NCT03721068|Biological|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10^6, 1.0 x 10^6, 1.5 x 10^6
79671378|NCT00429533|Drug|Dapsone|
79671379|NCT00461058|Drug|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
79360970|NCT03721068|Drug|Cyclophosphamide|500 mg/m^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
79360971|NCT03721068|Drug|Fludarabine|30 mg/m^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
79360972|NCT03710109|Other|EEG|non-invasive, non-interventional sensor
79671380|NCT00461058|Drug|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
79671381|NCT00429611|Procedure|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
79819907|NCT05404802|Device|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
79511956|NCT01225068|Drug|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
79671382|NCT00461136|Drug|Aliskiren|
79679713|NCT02939040|Behavioral|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
79679714|NCT02939157|Other|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
79819908|NCT01387113|Other|Computed tomography perfusion imaging|As per standard of care at CPMC
79819909|NCT02597036|Drug|LY3127804|Administered IV
79819910|NCT02597036|Drug|Ramucirumab|Administered IV
79819911|NCT02597036|Drug|Paclitaxel|Administered IV
79819912|NCT04073355|Behavioral|Physical Activity|Smartphone-delivered physical activity intervention
79993322|NCT05208996|Drug|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
79993323|NCT02739750|Other|No intervention|There is no intervention for this study. It is a MRS.
79511957|NCT01225926|Device|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
79511958|NCT01225926|Device|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
79511959|NCT01226706|Drug|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
79511960|NCT01226706|Drug|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
79511961|NCT01231230|Drug|fluticasone|220- mcg once
79511962|NCT01231230|Drug|placebo inhalation|placebo inhalation once
79511963|NCT01231230|Drug|Salmeterol|50 mcg salmeterol once
79511964|NCT01231230|Drug|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
79511965|NCT01232946|Drug|liraglutide|1.8mg subcutaneous qd for 3 months
79511966|NCT01232946|Drug|insulin detemir|5units subcutaneous bid titrated to fasting glucose of <130mg/dL for 3 months
79671383|NCT02957708|Other|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
79671384|NCT02957708|Other|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
79671385|NCT00469794|Procedure|stress test|
79671386|NCT00429650|Behavioral|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
79360975|NCT03691493|Drug|Anastrozole|Given PO
79671387|NCT00429650|Behavioral|diet|Use a prescribed diet to maintain weight loss
79671388|NCT00429650|Behavioral|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
79511967|NCT01232946|Drug|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose <130mg/dL for 3 months.
79671389|NCT00461214|Other|Participation in laparoscopic training curriculum|General Surgery Training Outcome
79360976|NCT03691493|Drug|Exemestane|Given PO
79360977|NCT03691493|Drug|Fulvestrant|Given IM
79360978|NCT03691493|Drug|Letrozole|Given PO
79360979|NCT03691493|Drug|Palbociclib|Given PO
79360980|NCT03691493|Radiation|Radiation Therapy|Undergo radiation therapy
79671390|NCT00429689|Procedure|Saliva sample|
79671391|NCT00469872|Procedure|Context-focused compared to child-focused interventions|
79671392|NCT00429728|Drug|GW876008|
79679715|NCT00519155|Drug|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
79679716|NCT00519155|Procedure|Open flap debridement|Open flap debridement alone
79679717|NCT02939196|Procedure|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
79360981|NCT03691493|Drug|Tamoxifen|Given PO
79360982|NCT03634007|Biological|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
79360983|NCT03632421|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360984|NCT03632421|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79511968|NCT01233726|Dietary Supplement|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
79511969|NCT01233726|Dietary Supplement|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
79511970|NCT01233726|Dietary Supplement|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
79511971|NCT01235910|Drug|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
79511972|NCT01236300|Device|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
79511973|NCT01236378|Drug|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
79511974|NCT01236768|Drug|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
79511975|NCT01236768|Drug|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
79511976|NCT01237080|Device|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
79511977|NCT01237080|Device|Fastrach|The Fastrach is an intubation laryngeal mask.
79511978|NCT01238640|Drug|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
79511979|NCT01238640|Drug|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
79511980|NCT01238640|Drug|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
79511981|NCT01240122|Device|Biotrue MPS|Multi-purpose contact lens care solution
79511982|NCT01240122|Device|Investigational MPS|Multi-purpose contact lens care solution
79679718|NCT02939196|Procedure|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
79511983|NCT01241916|Device|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
79511984|NCT01241916|Device|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
79511985|NCT01243320|Drug|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
79511986|NCT01243320|Drug|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
79993324|NCT02675946|Drug|CGX1321|
79511987|NCT01245270|Dietary Supplement|Bilberry capsule first, then control cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
79671393|NCT03271476|Behavioral|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
79993325|NCT02675946|Drug|Pembrolizumab|
79993326|NCT02675946|Drug|encorafenib|
79511988|NCT01245270|Dietary Supplement|Control capsule first then bilberry cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
79511989|NCT01245972|Procedure|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
79511990|NCT01246050|Other|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
79511991|NCT01246050|Other|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
79511992|NCT01247064|Drug|Nebulized 3% saline|4 mL of nebulized 3% saline once
79511993|NCT01247064|Drug|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
79511994|NCT01247220|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
79511995|NCT01247220|Procedure|Peripheral Laser|Angiography-directed peripheral laser
79993327|NCT02675946|Drug|cetuximab|
79993328|NCT02900378|Drug|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
79993329|NCT02900378|Drug|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
79993330|NCT02900378|Drug|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
79993331|NCT02900378|Drug|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
79993332|NCT03058692|Biological|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
79993333|NCT03058692|Other|Placebo|Placebo is saline injection
79993334|NCT03058692|Biological|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
79993335|NCT03647228|Drug|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
79511996|NCT01247298|Combination Product|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
79511997|NCT01249872|Drug|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
79511998|NCT01249872|Drug|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
79511999|NCT01249872|Drug|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
79512000|NCT01249872|Drug|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
79512001|NCT01249872|Drug|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
79360985|NCT03623464|Other|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
79819913|NCT04071639|Drug|Haloperidol 2Mg Tab|Haloperidol take 0.5mg~2mg three time a day.
79819914|NCT04071639|Drug|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
79819915|NCT04071639|Drug|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
79360986|NCT03623464|Other|Standard of care|Post-operative standard of care information
79360987|NCT03621592|Device|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
79360988|NCT03621592|Device|Acticoat®|Silver impregnated contact layer dressing
79360989|NCT03612544|Other|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79671394|NCT03273738|Diagnostic Test|folate level measurement|the level of folate measured in plasma with homocysteine
79671395|NCT03273738|Diagnostic Test|B12|B12 measurement in blood
79671396|NCT04704245|Drug|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
79671397|NCT04704245|Drug|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
79679719|NCT00519740|Other|inhalative specific bronchial provocation with grass-pollen|
79679720|NCT04691076|Drug|Propofol|Propofol is administered by target-controlled infusion
79679721|NCT04691076|Drug|Esketamine|Esketamine is intravenously administrated
79679722|NCT04691076|Drug|Fentanyl|Fentanyl is intravenously administrated
79819916|NCT04071639|Drug|Idebenone|Idebebone take 30mg three times a day.
79819917|NCT04071639|Drug|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
79819918|NCT04089176|Drug|Carbetocin|carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
79819919|NCT04089176|Drug|oxytocin|oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
79819920|NCT02577081|Other|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
79819921|NCT03971786|Behavioral|Quality of life|Assessment of quality of life through measuring scales
79512002|NCT01249872|Drug|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
79512003|NCT01250184|Other|Physical therapy|Twelve sessions (3 per week)
79512004|NCT01250184|Drug|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
79512005|NCT01250184|Other|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
79512006|NCT01250730|Drug|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
79512007|NCT01250730|Drug|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
79512008|NCT01250730|Drug|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
79819922|NCT02596724|Other|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
79993336|NCT03647228|Drug|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
79360990|NCT03612544|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360991|NCT03612453|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
79512009|NCT01251042|Device|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
79512010|NCT01251588|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
79512011|NCT01251588|Procedure|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
79512012|NCT01251978|Drug|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
79512013|NCT01251978|Drug|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
79512014|NCT01253148|Device|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
79512015|NCT01253460|Drug|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
79993337|NCT04052594|Drug|LY3475766 - IV|Administered IV
79993338|NCT04052594|Drug|LY3475766 - SC|Administered SC
79993339|NCT04052594|Drug|Placebo - IV|Administered IV
79993340|NCT04052594|Drug|Placebo - SC|Administered SC
79512016|NCT01253460|Drug|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
79512017|NCT01253460|Drug|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
79671398|NCT04704245|Procedure|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
79671399|NCT03271671|Other|NAVA during Non invasive ventilation|NIV during respiratory failure
79671400|NCT03271671|Other|PSV during Non invasive ventilation|PSV during respiratory failure
79671401|NCT04703933|Other|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
79512018|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
79512019|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
79512020|NCT01254552|Drug|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
79512021|NCT01254552|Drug|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
79512022|NCT01256034|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
79671402|NCT03271632|Biological|CAR T cells|Infusion of multi-CAR T cells
79671403|NCT00429806|Drug|DHEA|DHEA
79671404|NCT00429806|Drug|Placebo|Placebo
79819923|NCT02596646|Procedure|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
79819924|NCT02596646|Procedure|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
79819925|NCT04818255|Behavioral|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
79993341|NCT03621566|Other|No intervention|Routine care (registry)
79512023|NCT01244724|Drug|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
79671405|NCT03273660|Device|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
79671406|NCT00429845|Behavioral|Nutritional|
79819926|NCT00749996|Device|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
79993342|NCT04052750|Behavioral|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
79993343|NCT04379154|Device|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
79512024|NCT01256424|Drug|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
79512025|NCT01256424|Drug|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
79671407|NCT03271593|Other|No intervention|No intervention
79671408|NCT00469950|Behavioral|exercise training|Exercise training in groups
79671409|NCT00429962|Drug|intravitreal ranibizumab|intraocular injection
79671410|NCT00429962|Drug|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
79671411|NCT03273504|Other|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
79671412|NCT03273504|Other|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
79671413|NCT00430001|Drug|docetaxel|
79671414|NCT00430001|Drug|vinorelbine|
79671415|NCT00430001|Drug|trastuzumab|
79671416|NCT00461370|Drug|SRX251|
79671417|NCT04703894|Dietary Supplement|AYMES 'CARDIFF'|AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
79993344|NCT04052438|Diagnostic Test|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
79512026|NCT01256424|Drug|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
79512027|NCT01256424|Drug|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
79512028|NCT01257750|Drug|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
79819927|NCT00749996|Procedure|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
79993345|NCT03647150|Drug|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
79512029|NCT01258374|Drug|Raltegravir|Raltegravir, 400 mg bid
79512030|NCT01258374|Drug|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
79512031|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
79512032|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
79512033|NCT01262118|Drug|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
79512034|NCT01263132|Drug|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
79512035|NCT01263132|Drug|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
79512036|NCT01264614|Behavioral|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
79512037|NCT01267422|Drug|rAAV2-ND4|injection
79512038|NCT01267656|Device|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
79512039|NCT01267656|Device|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
79512040|NCT01269372|Device|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
79512041|NCT01269372|Device|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
79512042|NCT01270542|Drug|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
79512043|NCT01270542|Other|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
79512044|NCT01271244|Drug|Escitalopram|10-20mg daily for 12 weeks
79512045|NCT01271868|Biological|IB1001|
79512046|NCT01271946|Device|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
79512047|NCT01272882|Device|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
79512048|NCT01272960|Device|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
79512049|NCT01272960|Device|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
79512050|NCT01273896|Drug|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
79512051|NCT01274520|Device|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
79512052|NCT01275300|Drug|Aspirin|
79512053|NCT01275300|Drug|Placebo|
79512054|NCT01275300|Drug|Niacin|
79512055|NCT01276314|Drug|anti- TNF-a|25mg BIW, SC
79512056|NCT01276314|Drug|Prednisolone|1-1.5 mg / kg / day
79671418|NCT00461448|Dietary Supplement|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
79671419|NCT00430079|Drug|etanidazole|Given IV
79512057|NCT01276860|Device|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
79512058|NCT01280058|Drug|Carboplatin|Given IV
79512059|NCT01280058|Other|Laboratory Biomarker Analysis|Correlative studies
79512060|NCT01280058|Drug|Paclitaxel|Given IV
79512061|NCT01280058|Biological|Wild-type Reovirus|Given IV
79512062|NCT01280604|Drug|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
79512063|NCT01282242|Drug|IV rt-PA|open-label
79512064|NCT01283022|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
79671420|NCT00430079|Procedure|conventional surgery|Undergo surgery
79671421|NCT00430079|Other|pharmacological study|Correlative studies
79671422|NCT00430079|Other|laboratory biomarker analysis|Correlative studies
79671423|NCT00469989|Procedure|Infection with hookworm larvae|
79671424|NCT00430118|Drug|asparaginase|
79671425|NCT00430118|Drug|cyclophosphamide|
79671426|NCT00430118|Drug|cytarabine|
79671427|NCT00430118|Drug|daunorubicin hydrochloride|
79360992|NCT03612453|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
79360993|NCT03612375|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360994|NCT03612375|Other|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360995|NCT03612336|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360996|NCT03612336|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360997|NCT03603353|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
79512065|NCT01285050|Drug|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
79512066|NCT01285050|Drug|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
79671428|NCT00430118|Drug|dexamethasone|
79671429|NCT00430118|Drug|doxorubicin hydrochloride|
79671430|NCT00430118|Drug|etoposide|
79671431|NCT00430118|Drug|ifosfamide|
79993346|NCT03647150|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
79671432|NCT00430118|Drug|mercaptopurine|
79671433|NCT00430118|Drug|methotrexate|
79671434|NCT00430118|Drug|prednisone|
79671435|NCT00430118|Drug|thioguanine|
79671436|NCT00430118|Drug|vincristine sulfate|
79671437|NCT00430118|Drug|vindesine|
79671438|NCT00430118|Radiation|radiation therapy|
79671439|NCT00461487|Behavioral|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
79512067|NCT01285050|Drug|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
79512068|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
79512069|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
79671440|NCT00461487|Behavioral|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
79671441|NCT00461526|Drug|crofelemer|125 mg crofelemer vs. placebo
79671442|NCT00430157|Drug|GSK256066|
79993347|NCT03647150|Behavioral|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
79993348|NCT04373226|Behavioral|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
79360998|NCT03603353|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79360999|NCT03603340|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79512070|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
79512071|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
79512072|NCT01286454|Drug|fesoterodine|single dose of tablet
79512073|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
79512074|NCT01287078|Drug|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
79512075|NCT01290978|Drug|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
79512076|NCT01290978|Drug|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
79512077|NCT01291056|Other|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
79512078|NCT01291056|Drug|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
79512079|NCT01292304|Drug|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
79512080|NCT01292538|Device|Erchonia GLS|532 nm green diode low level laser light device
79512081|NCT01292538|Device|Placebo laser|Sham light output with no therapeutic benefit
79512082|NCT01293396|Drug|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
79512083|NCT01293396|Drug|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
79512084|NCT01293396|Drug|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
79671443|NCT00461565|Drug|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
79671444|NCT00461565|Drug|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
79671445|NCT00461565|Drug|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
79671446|NCT00461565|Drug|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
79671447|NCT00430196|Drug|BOTOX®|
79671448|NCT00430196|Drug|Zanaflex®|
79671449|NCT00470028|Device|Transcranial Magnetic Stimulation|
79671450|NCT00430235|Drug|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
79671451|NCT00470145|Drug|SB-568859|
79819928|NCT02577159|Drug|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
79993349|NCT04708158|Biological|Novaferon|a novel recombinant antiviral protein drug
79361000|NCT03603340|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79361001|NCT03587064|Device|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
79361002|NCT03587064|Device|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
79361003|NCT03575351|Drug|Standard of Care|Standard of Care
79361004|NCT03575351|Genetic|JCAR017|JCAR017
79361005|NCT03529422|Drug|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
79671452|NCT04697979|Other|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
79671453|NCT00430391|Other|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
79671454|NCT00430391|Other|Routine Control|Participants are assigned to the routine, standard consent.
79671455|NCT00470340|Drug|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
79993350|NCT04708158|Biological|Placebo|Saline
79993351|NCT02964338|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
79361006|NCT03529422|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
79671456|NCT00430430|Procedure|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
79671457|NCT00430430|Procedure|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
79671458|NCT00430469|Drug|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
79671459|NCT00461643|Drug|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
79671460|NCT00430547|Drug|Carbimazole, radio-active iodine (I131)|
79819929|NCT00916994|Device|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
79819930|NCT00749684|Biological|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
79819931|NCT02575755|Drug|Azithromycin plus piperaquine phosphate|
79819932|NCT02575755|Drug|Sulfadoxine-pyrimethamine|
79819933|NCT02576769|Other|No intervention|
79819934|NCT04071561|Other|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
79819935|NCT04071561|Other|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
79993352|NCT02964338|Drug|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
79993353|NCT03056352|Drug|Metoclopramide|Intravenous medication drip
79512085|NCT01294098|Drug|Marcaine|0.75 cc/kg of 1/4% Marcaine
79512086|NCT01295112|Drug|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
79512087|NCT01295112|Drug|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
79512088|NCT01296360|Biological|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
79512089|NCT01296360|Biological|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
79671461|NCT00430586|Drug|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
79671462|NCT00430586|Drug|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
79361009|NCT03493685|Drug|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
79361010|NCT03493685|Drug|Irbesartan|target dose of 300 mg daily
79671463|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
79671464|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
79671465|NCT01053962|Drug|SP-304 0.3 mg|SP-304 0.3 mg
79993354|NCT03056352|Drug|Diphenhydramine|Intravenous medication drip
79361011|NCT03486197|Other|Laboratory Biomarker Analysis|Correlative studies
79361012|NCT03486197|Biological|Pembrolizumab|Given IV
79671466|NCT01053962|Drug|SP-304 1.0 mg|SP-304 1.0 mg
79993355|NCT04360980|Drug|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
79361013|NCT03486197|Radiation|Radiation Therapy|Undergo neutron radiation therapy
79361014|NCT03459846|Drug|Durvalumab|Durvalumab 1500 mg IV q4w
79361015|NCT03459846|Drug|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
79361016|NCT03459846|Drug|Placebo|Matching placebo for oral tablet BID
79361017|NCT03439683|Other|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
79512090|NCT01298544|Procedure|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
79512091|NCT01299090|Device|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
79512092|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
79512093|NCT01301742|Drug|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
79512094|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
79512095|NCT01303224|Drug|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
79512096|NCT01303224|Drug|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
79512097|NCT01303224|Drug|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
79512098|NCT01303224|Drug|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
79512099|NCT01304082|Drug|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
79512100|NCT01304082|Drug|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
79512101|NCT01304082|Drug|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
79512102|NCT01304238|Drug|lepirudin|lepirudin
79512103|NCT01304238|Drug|danaparoid|danaparoid
79512104|NCT01304238|Drug|argatroban|argatroban
79512105|NCT01304238|Drug|fondaparinux|fondaparinux
79512106|NCT01305252|Drug|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
79512107|NCT01305252|Drug|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
79512108|NCT01307748|Other|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
79671467|NCT01053962|Drug|SP-304 3.0 mg|SP-304 3.0 mg
79671468|NCT01053962|Drug|SP-304 9.0 mg|SP-304 9.0 mg
79671469|NCT01053962|Drug|Placebo|Placebo
79671470|NCT00461799|Drug|orlistat|
79671471|NCT00430664|Procedure|Pleurodesis with either talc or iodopovidone|
79993356|NCT03645278|Drug|SHR0532|Ascending dose oral adminstration
79993357|NCT03645278|Drug|Placebo|Ascending dose oral administration
79993358|NCT03647072|Drug|CHOP|CHOP only
79671472|NCT00461838|Procedure|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
79361018|NCT03417583|Other|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
79361019|NCT03370406|Drug|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
79361020|NCT03370406|Drug|Imiquimod 5% cream|Topical application of 5% cream over a 3 week period.
79671473|NCT00461838|Other|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
79512109|NCT01308060|Drug|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
79361021|NCT03362294|Drug|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
79671474|NCT00430703|Behavioral|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
79361022|NCT03362294|Drug|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
79671475|NCT00470379|Drug|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
79993359|NCT03647072|Drug|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
79361023|NCT03362060|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
79361024|NCT03362060|Biological|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
79361025|NCT03354741|Other|laser therapy|stimulation of the acupuncture point P6 by laser therapy
79512110|NCT01308060|Other|Placebo|
79512111|NCT01308294|Biological|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
79361026|NCT03325985|Behavioral|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
79361027|NCT03325985|Behavioral|Facilitated,outpatient specialty palliative care|In-person palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
79819936|NCT04073277|Device|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
79671476|NCT00430742|Drug|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
79819937|NCT04073277|Device|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
79819938|NCT04073121|Device|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
79671477|NCT00430742|Drug|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
79671478|NCT00430820|Procedure|per intervention|per intervention
79819939|NCT00746798|Biological|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
79671479|NCT00470457|Biological|Allergen specific immunotherapy|
79671480|NCT00430859|Drug|Alkaline Phosphatase|Intravenous over a period of 24 hours
79671481|NCT00430859|Drug|Placebo|Saline over a period of 24h
79671482|NCT03271320|Other|appearance scales|appearance scales : AVS; ASWAP; DAS 59
79819940|NCT00746798|Biological|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
79819941|NCT00746798|Biological|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
79819942|NCT00746798|Biological|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
79819943|NCT00716274|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
79819944|NCT00716274|Drug|Placebo|oral, daily, for 16 weeks
79993360|NCT03647072|Drug|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
79993361|NCT05284136|Dietary Supplement|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
79993362|NCT05284136|Drug|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
79361028|NCT03298984|Drug|Alvocidib|IV bolus followed by IV infusion
79361029|NCT03298984|Drug|Cytarabine|continuous infusion
79361030|NCT03298984|Drug|Daunorubicin|IV bolus
79361031|NCT03270358|Procedure|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
79361032|NCT03270358|Procedure|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
79361033|NCT03248492|Drug|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
79361034|NCT03232164|Drug|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
79671483|NCT03271164|Device|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
79671484|NCT03271164|Other|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
79671485|NCT00430898|Drug|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
79671486|NCT00470613|Genetic|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
79671487|NCT00461916|Drug|Half-Dose Depot Triptorelin|
79671488|NCT00461916|Drug|Reduced-Dose Daily Buserelin|
79671489|NCT00430976|Behavioral|Minds in Motion|
79671490|NCT03273465|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
79679723|NCT00519935|Behavioral|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
79819945|NCT00746564|Device|SJM Confirm|All patients in this study will receive the SJM Confirm device.
79819946|NCT02598908|Diagnostic Test|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
79819947|NCT01298193|Drug|Aprepitant|Efficacy phase (second cycle)
79819948|NCT04090970|Device|Briagen|Natural complex carbohydrate wound dressing for skin wounds
79819949|NCT02590536|Drug|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
79819950|NCT02590536|Drug|placebo|
79819951|NCT02576691|Device|percutaneous coronary intervention|
79512112|NCT01308294|Biological|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
79361035|NCT03225560|Other|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
79512113|NCT01308294|Biological|"2 vaccine injections in distinct limbs"|
79671491|NCT02957409|Drug|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
79361036|NCT03224468|Drug|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
79671492|NCT01053221|Drug|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
79671493|NCT01053221|Drug|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
79671494|NCT02956551|Biological|DC vaccine|subcutaneous administration
79671495|NCT00431054|Drug|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
79361037|NCT03219528|Drug|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
79361038|NCT03219528|Other|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
79671496|NCT00431054|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour every 4 weeks
79671497|NCT00470652|Device|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
79361039|NCT03216252|Biological|samples|Blood samples, oral smear and urine
79361040|NCT03172195|Procedure|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
79361041|NCT03172195|Biological|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
79361042|NCT03172195|Biological|blood sample|Blood sample will be collected in more.
79361043|NCT03163511|Combination Product|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
79361044|NCT03162016|Procedure|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
79361045|NCT03160430|Drug|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
79361046|NCT03160430|Drug|Placebos|matching placebo capsule
79361047|NCT03149003|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
79512114|NCT01308840|Drug|Panitumumab|Day 1 and 15 = 6 mg/kg IV
79671498|NCT00431171|Drug|Lithium carbonate|
79671499|NCT02956395|Other|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
79671500|NCT00431210|Biological|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
79361048|NCT03149003|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
79361049|NCT03148275|Other|Questionnaire Administration|Ancillary studies
79361050|NCT03148275|Drug|Trametinib|Given PO
79361051|NCT03103750|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
79361052|NCT03103750|Drug|PHNO|Used as a tracer for in vivo imaging.
79361053|NCT03103750|Dietary Supplement|calcitriol|three 0.5 mcg capsules
79361054|NCT03103750|Drug|Placebo oral capsule|three 0.5 mcg capsules
79361055|NCT03103750|Procedure|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
79361056|NCT03103750|Drug|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
79361057|NCT03103581|Drug|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
79512115|NCT01308840|Drug|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
79512116|NCT01308840|Drug|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
79671501|NCT00470691|Procedure|plaster cast|complete circular plaster cast
79671502|NCT00470691|Procedure|dorsal splint|dorsal plaster splint
79671503|NCT00431249|Drug|Cilostazol|
79671504|NCT00470769|Procedure|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
79993363|NCT03646916|Drug|Dexamethasone|Gluco-corticosteroid
79361058|NCT03093974|Drug|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
79361059|NCT03093974|Other|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
79361060|NCT03089606|Diagnostic Test|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
79361061|NCT03089606|Diagnostic Test|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
79361062|NCT03089606|Drug|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
79361063|NCT03089606|Diagnostic Test|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
79361064|NCT03084510|Device|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~a bioprosthetic bovine pericardial aortic valve, and~a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
79361067|NCT03029949|Behavioral|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
79993364|NCT03646916|Other|No dexamethasone|Nothing
79993365|NCT04305756|Drug|Enoxaparin|Low molecular weight heparin
79512117|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
79361068|NCT03029949|Behavioral|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
79361069|NCT03029949|Other|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
79361070|NCT03023332|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
79671505|NCT00470808|Drug|POMx|
79671506|NCT00461955|Procedure|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
79993366|NCT02898662|Drug|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
79993367|NCT02898662|Drug|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
79993368|NCT04437810|Biological|Albumin|- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
79993369|NCT04437810|Other|Standard Medical Treatment|standard medical therapy
79993370|NCT04368156|Device|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
79361071|NCT03023332|Behavioral|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
79361072|NCT03023332|Behavioral|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
79361073|NCT03023085|Drug|BLI4700|BLI4700 bowel preparation
79361074|NCT02993731|Drug|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
79361075|NCT02993731|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
79361076|NCT02993731|Drug|Gemcitabine|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
79361077|NCT02991703|Device|pOpmètre®|the pOpmètre® uses saturation sensors,
79361078|NCT02991703|Device|Sphygmocor|the Sphygmocor uses applanation tonometry
79361079|NCT02991573|Device|Prime & Bond Universal|Prime & Bond Universal
79512118|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
79512119|NCT01310400|Biological|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
79512120|NCT01311102|Drug|Lidocaine|1.33 cc 2% liquid lidocaine
79512121|NCT01311102|Drug|Normal Saline|1.33cc normal saline
79512122|NCT01312038|Drug|Simethicone|single 125 mg chewable tablet
79512123|NCT01312038|Drug|Placebo|chewable calcium tablet
79993371|NCT04354272|Other|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
79993372|NCT03645980|Drug|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
79993373|NCT03645980|Drug|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
79361080|NCT02991573|Device|Ceram X|
79512124|NCT01312272|Drug|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
79512125|NCT01312272|Drug|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
79512126|NCT01312818|Drug|Bortezomib|1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
79512127|NCT01312818|Drug|Vorinostat|180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
79361081|NCT02991573|Device|Prime & Bond XP|Control
79361082|NCT02991573|Procedure|technique 1|
79361083|NCT02991573|Procedure|technique 2|
79361084|NCT02977052|Drug|Ipilimumab|
79361085|NCT02977052|Drug|Nivolumab|
79361086|NCT02977052|Procedure|Surgery|Surgery will be done at 6 weeks
79361087|NCT02977052|Procedure|Blood for PBMCs|Blood will be taken for translational research on PBMCs
79361088|NCT02977052|Procedure|Biopsies|Biopsies will be taken during screening and at relapse.
79361089|NCT02945722|Drug|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
79361090|NCT02945722|Other|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
79361091|NCT02945579|Radiation|External Beam Radiation Therapy|Undergo EBRT
79361092|NCT02945579|Other|Laboratory Biomarker Analysis|Correlative studies
79361093|NCT02945579|Other|Quality-of-Life Assessment|Ancillary studies
79361094|NCT02945579|Other|Questionnaire Administration|Ancillary studies
79361095|NCT02945579|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
79361096|NCT02934529|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
79361097|NCT02934529|Drug|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
79361098|NCT02934529|Drug|5-FU|5-FU 400 mg/m² bolus day 1, q d15
79361099|NCT02934529|Drug|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
79361100|NCT02934529|Drug|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
79512128|NCT01312818|Drug|Dexamethasone|6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
79993374|NCT03645980|Drug|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
79361101|NCT02934529|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
79993375|NCT04315038|Procedure|spinal anesthesia|Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
79361102|NCT02934529|Drug|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
79361103|NCT02934529|Drug|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
79361104|NCT02934529|Drug|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
79361105|NCT02934529|Drug|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
79361106|NCT02934399|Other|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
79361107|NCT02922816|Biological|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
79361108|NCT02922816|Procedure|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
79361109|NCT02922816|Procedure|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
79361110|NCT02922816|Other|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
79512129|NCT01312818|Drug|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
79512130|NCT01312818|Drug|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16."
79361111|NCT02914951|Behavioral|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
79512131|NCT01313520|Drug|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
79512132|NCT01313520|Drug|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
79512133|NCT01313910|Dietary Supplement|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
79512134|NCT01315002|Drug|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
79512135|NCT01315002|Drug|Placebo patch|Placebo patch
79512136|NCT01315158|Drug|Propofol Alone|"Recommended Propofol doses before considering crossover:~Induction: 2-2.5 mg/kg~Maintenance: 0.1-0.2 mg/kg/min"
79512137|NCT01315158|Drug|Propofol+Benzo/Opioids|"Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
79512138|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
79512139|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
79671507|NCT00470886|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
79671508|NCT00431483|Behavioral|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
79671509|NCT00461994|Behavioral|diet|
79361112|NCT02914951|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
79671510|NCT00461994|Behavioral|exercise|
79671511|NCT00461994|Behavioral|diet and exercise|
79671512|NCT00431522|Drug|Valproic acid, sodium salt|
79671513|NCT00462111|Drug|Indometacin|
79819952|NCT03944928|Other|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
79361113|NCT02903368|Drug|Apalutamide|
79819953|NCT00719862|Drug|Placebo nasal spray|Placebo
79361114|NCT02903368|Drug|Leuprolide|
79361115|NCT02903368|Drug|Prednisone|
79361116|NCT02903368|Drug|Abiraterone Acetate|
79361117|NCT02855554|Other|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
79819954|NCT00719862|Drug|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
79819955|NCT02578953|Drug|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
79361118|NCT02841839|Drug|Stannous Fluoride|
79361119|NCT02826161|Drug|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
79512140|NCT01317030|Other|Non-Contact Lens Wear|No intervention
79512141|NCT01318278|Drug|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
79671514|NCT00431561|Drug|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
79671515|NCT00431561|Drug|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
79671516|NCT00431561|Drug|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
79671517|NCT00431561|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
79512142|NCT01318278|Drug|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
79512143|NCT01318356|Behavioral|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
79512144|NCT01318356|Drug|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
79512145|NCT01318356|Drug|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
79512146|NCT01322022|Behavioral|ParentTraining|5 sessions of individual parent training
79512147|NCT01322022|Other|Parent Education|Parent Education to control for time and attention
79512148|NCT01324128|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
79512149|NCT01324128|Drug|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
79512150|NCT01324128|Drug|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
79512151|NCT01324518|Drug|ORM-12741|60mg twice a day
79512152|NCT01324518|Drug|ORM-12741|200mg twice a day
79512153|NCT01324518|Drug|Placebo for ORM-12741|Placebo twice a day
79512154|NCT01326780|Drug|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
79512155|NCT01326780|Drug|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
79671518|NCT00431561|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
79671519|NCT00462150|Behavioral|home-based emotional disclosure|
79361120|NCT02826161|Drug|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
79361121|NCT02799901|Biological|Nivolumab|Injection of nivolumab
79361122|NCT02799901|Radiation|hypofractionned radiotherapy|radiation
79361123|NCT02796885|Other|no intervention - observational study|
79361124|NCT02766543|Device|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
79361125|NCT02753127|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
79361126|NCT02753127|Drug|Fluorouracil|
79361127|NCT02753127|Drug|Leucovorin|
79361128|NCT02753127|Drug|Irinotecan|
79361129|NCT02753127|Drug|Bevacizumab|
79361130|NCT02752685|Drug|Pembrolizumab|
79361131|NCT02752685|Drug|Nab-Paclitaxel|
79512156|NCT01326780|Drug|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
79512157|NCT01326780|Other|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
79512158|NCT01328184|Drug|levonorgestrel|multiple doses
79512159|NCT01328184|Drug|levonorgestrel|multiple doses
79512160|NCT01328184|Drug|Ethinylestradiol|multiple doses
79512161|NCT01328184|Drug|Microgynon + BI 10773|multiple doses BI 10773
79512162|NCT01328184|Drug|Ethinylestradiol|multiple doses
79512163|NCT01328964|Drug|Fluticasone propionate|fluticasone propionate 44 mcg
79512164|NCT01328964|Drug|Budesonide|budesonide
79512165|NCT01328964|Drug|Montelukast|montelukast
79512166|NCT01329198|Device|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
79512167|NCT01330134|Drug|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
79993376|NCT03645200|Drug|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
79512168|NCT01330134|Drug|lidocaine|1% lidocaine subcutaneous injection alone
79671520|NCT00462150|Behavioral|time management control condition|
79361132|NCT02746796|Drug|ONO-4538|
79361133|NCT02746796|Drug|Oxaliplatin|
79819956|NCT02578953|Drug|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
79819957|NCT04073589|Biological|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
79671521|NCT00462189|Drug|Immunotoxin therapy|
79819958|NCT02578719|Drug|bupivacaine|marcaine %0.5 20 ml flacon
79993377|NCT03645902|Diagnostic Test|Magnetic resonance imaging|
79361134|NCT02746796|Drug|Tegafur- Gimeracil-Oteracil potassium|
79512169|NCT01330290|Drug|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
79512170|NCT01331304|Drug|Lithium|600-900mg per day over 6 months
79361135|NCT02746796|Drug|Capecitabine|
79361136|NCT02746796|Drug|Placebo|
79512171|NCT01331304|Drug|Quetiapine|100-800mg a day over 6 months
79512172|NCT01331694|Drug|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
79512173|NCT01331694|Drug|tiotropium|patients initiating treatment with tiotropium
79512174|NCT01331694|Drug|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
79512175|NCT01333098|Drug|Mifepristone|300mg per day, by mouth, for 21-28 days
79671522|NCT00462189|Drug|CAT-8015 Immunotoxin|
79671523|NCT00462189|Procedure|Biological therapy|
79671524|NCT00431600|Other|100% Oxygen|100% Oxygen- breathing over 30 minutes
79671525|NCT00431639|Behavioral|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
79679724|NCT04690842|Diagnostic Test|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
79679725|NCT02949323|Other|urinary stone|patients of group one have urinary stones
79993378|NCT04844567|Device|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
79512176|NCT01333488|Device|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
79512177|NCT01333488|Drug|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
79819959|NCT02578719|Drug|saline|%0.9 sodium chloride
79361137|NCT02735928|Device|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
79361138|NCT02657551|Drug|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
79993379|NCT04844567|Device|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
79361139|NCT02624271|Other|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
79361140|NCT02580604|Drug|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
79361141|NCT02580604|Drug|Placebo|Saline Infusion
79361142|NCT02531048|Device|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
79361143|NCT02531048|Device|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
79361144|NCT02531048|Device|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
79361145|NCT02531048|Device|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
79361146|NCT02527434|Biological|Tremelimumab monotherapy|IV infusion
79512178|NCT01335204|Drug|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
79512179|NCT06244979|Other|Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)|100 MBq +/- 10% [68Ga]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)
79512180|NCT06244966|Diagnostic Test|HIV diagnostic testing|Finger-prick capillary blood will be tested alongside venous blood
79512181|NCT06244953|Other|TIER-HF-PC|The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
79361147|NCT02527434|Biological|MEDI4736 monotherapy|IV infusion
79361148|NCT02527434|Biological|MEDI4736 + tremelimumab combination therapy|IV infusion
79361149|NCT02508038|Procedure|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
79512182|NCT06244953|Other|Usual Care|Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
79512183|NCT06244940|Diagnostic Test|Whole Genome Sequencing (WGC) from subject samples|Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
79512184|NCT06244927|Procedure|Replantation surgery|Surgery
79819960|NCT00742508|Drug|SK&F-105517-D 10 mg capsule|1 capsule once a day
79819961|NCT00742508|Drug|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
79819962|NCT00742508|Drug|SK&F-105517-D 20 mg capsule|1 capsule once a day
79819963|NCT00742508|Drug|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
79819964|NCT00742508|Drug|Carvedilol-IR 10 mg tablet|1 tablet twice a day
79819965|NCT04085016|Device|Keratograph 5M, Oculus, Wetzlar, Germany|
79819966|NCT02590614|Dietary Supplement|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
79671526|NCT00470925|Drug|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
79819967|NCT02590614|Dietary Supplement|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
79819968|NCT02575443|Drug|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
79819969|NCT02575443|Drug|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
79361150|NCT02508038|Drug|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
79512185|NCT06244914|Device|tDCS stimulation|tDCS 1mA will be applied for 20min. tDCS will be applied around the infract area. taVNS or sham taVNS wil be applied before tDCS. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
79512186|NCT06244914|Device|taVNS stimulation|taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of taVNS will be adjusted under the patient's pain threshold. After taVNS, tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
79671527|NCT00470964|Procedure|Titanium Sapphire laser trabeculoplasty|
79671528|NCT00431678|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
79671529|NCT00431678|Drug|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
79671530|NCT00471003|Drug|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
79361151|NCT02460835|Radiation|Adaptive Radiation Therapy|
79361152|NCT02432690|Drug|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
79671531|NCT04704128|Other|Salivic sample|Collection of total saliva not stimulated
79819970|NCT03975842|Other|Sinonasal and otologic evaluation|"At onset, each participant had:~sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
79819971|NCT02589912|Device|Nucleus Profile ABI541 Auditory Brainstem Implant|
79819972|NCT04071093|Other|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
79819973|NCT02596334|Drug|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
79819974|NCT02596334|Drug|dolutegravir|
79671532|NCT00462267|Behavioral|Enriched lifestyle intervention|Multi-component lifestyle intervention
79512187|NCT06244914|Device|sham tDCS stimulation|sham tDCS 1mA will be applied for 20min. sham tDCS will be applied around the infract area. The stimulation will be applied for only 10 seconds and no stimulation afterward. taVNS or sham taVNS wil be applied before sham tDCS.The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
79512188|NCT06244914|Device|sham taVNS stimulation|sham taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of sham taVNS will be adjusted under the patient's pain threshold. The stimulation was only applied for 5 seconds and no stimulation afterward. After sham taVNS, tDCS or sham tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
79512189|NCT06244901|Device|Ankle Exoskeleton|Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.
79512190|NCT06244901|Other|Normal walking|Normal walking for twenty minutes on real-world terrain every day for a week.
79512191|NCT06244888|Behavioral|Intervention Targeting Stress and Emotion Regulation|This intervention involves learning and practicing relaxation exercises and setting aside time for pleasurable activities.
79512192|NCT06244888|Behavioral|Intervention Targeting Motivation and Self-efficacy for Weight Management|This intervention involves identifying values related to weight, lifestyle, and health; identifying barriers to value-consistent living; exploring the consequences of letting barriers drive behavior; and 4) setting goals that are small, specific, attainable, and values-consistent.
79512193|NCT06244888|Behavioral|Intervention for Normalization of Eating|This intervention involves dietary self-monitoring with the goal of staying within a calorie goal ranging from 1,200 kcal/day to 1,800 kcal/day. Participants are also provided with meal planning tools and encouraged to addresses hunger and cravings by promoting feelings of satiety via consumption of foods that are high in volume but low in calories.
79512194|NCT06244888|Behavioral|Intervention Targeting Physical Activity and Sleep|This simple intervention prompts participants at the start of the day to schedule up to 30 minutes of moderate-to-vigorous intensity physical activity; brisk walking is encouraged. Participants also set a bedtime and wake time and are encouraged to set a reminder alarm to ensure at least 8 hours of sleep.
79512195|NCT06244875|Other|Sampling|Blood and cerebrospinal fluid sampling during the diagnostic visit
79512196|NCT06244862|Drug|Ruxolitinib|Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
79512197|NCT06244849|Biological|Blood samples|A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine
79512198|NCT06244849|Biological|Stool simple|A fresh stool sample will be collected and conserved at room temperature until shipment
79512199|NCT06244849|Biological|Ileocolonic biopsies|An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
79671533|NCT00471042|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
79819975|NCT00719706|Drug|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
79993380|NCT03055338|Drug|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
79361153|NCT02422550|Device|MRI|Participants enrolled on this protocol may undergo multiple MRI examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
79361154|NCT02358811|Device|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~Before any examination, the manipulator will check the absence of contraindication to MRI.~During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~Throughout the examination, a physician will always be present."
79512200|NCT06244836|Other|Implementation of a bundle of care|
79671534|NCT00471120|Other|P2x7 assay|compare P2X7 assay to biopsy
79671535|NCT02957669|Behavioral|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
79671536|NCT02957669|Behavioral|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
79671537|NCT00462540|Drug|Formoterol Fumurate inhalation solution 20 mcg|
79671538|NCT00462540|Drug|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
79671539|NCT04703972|Behavioral|clinical assessment (mood relapses identification)|clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
79819976|NCT00719706|Drug|Placebo|Placebo
79512201|NCT06244823|Drug|Fremanezumab Prefilled Syringe|MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
79993381|NCT03055338|Drug|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
79512202|NCT06244810|Device|Lingual retainer from Fiber|lingual retainer manufactured from fiber using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
79512203|NCT06244810|Device|Lingual retainer from metal|lingual retainer manufactured from metal using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
79512204|NCT06244810|Device|Traditional retianer from braided|lingual retainer manufactured using traditional technique from stainless steel applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
79512205|NCT06244797|Procedure|L-PRF and H-PRF|Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.
79512206|NCT06244797|Procedure|Impacted Tooth Removal|All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.
79512207|NCT06244732|Procedure|Postoperative pain control|Postoperative analgesia after OR-AAA
79512208|NCT06244719|Device|Vibrotactile Stimulation|Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
79671540|NCT04703465|Drug|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
79993382|NCT03055338|Drug|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
79671541|NCT00471159|Drug|docetaxel|
79671542|NCT00471159|Drug|PF-3512676|
79671543|NCT04703582|Diagnostic Test|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
79993383|NCT03055338|Drug|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
79993384|NCT03913130|Drug|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
79671544|NCT00462618|Drug|Quetiapine|
79671545|NCT00462618|Behavioral|Cogntive behavioral therapy|
79993385|NCT03645746|Drug|REGN5069|REGN5069 will be administered by IV infusion or SC injection
79671546|NCT00431795|Drug|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m^2 IV every 4 weeks for 6 consecutive cycles
79993386|NCT03645746|Drug|Placebo|Placebo-matching REGN5069
79993387|NCT03715907|Behavioral|Financial Incentives|Incentives for gap closure.
79993388|NCT03715907|Behavioral|Information|Information on care gap and closure process.
79993389|NCT03628482|Procedure|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
79993390|NCT03628482|Procedure|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
79993391|NCT03645668|Drug|Meropenem Injection|Different administration types between two groups
79993392|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
79993393|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
79671547|NCT00431795|Drug|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m^2 IV every 3 weeks for 6 consecutive cycles
79993394|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
79993395|NCT03712163|Drug|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
79993396|NCT03712163|Drug|Placebo Oral Capsule|Placebo
79993397|NCT04052360|Drug|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
79993398|NCT04052360|Drug|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
79993399|NCT01311167|Drug|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
79671548|NCT03271203|Other|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
79361155|NCT02358811|Behavioral|Cognitive assessment|"This cognitive assessment will include the following executive tests :~test of Stroop~left Trail Making Test A and B~verbal fluence test~test of memory of figures direct and inverse in order~completion of matrices~Paced Auditory Serial Addition Test (PASAT)"
79361156|NCT02320292|Other|Quality-of-Life Assessment|Ancillary studies
79361157|NCT02320292|Biological|Rituximab|Given IV
79361158|NCT02320292|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
79361159|NCT02315534|Drug|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
79361160|NCT02315534|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m^2.
79361161|NCT02278887|Procedure|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
79361162|NCT02278887|Drug|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
79361163|NCT02278887|Drug|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
79512209|NCT06244706|Combination Product|Opioid drug + CNS-acting add-on drug|Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
79361164|NCT02278887|Drug|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
79361165|NCT02278887|Drug|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
79671549|NCT03271203|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
79671550|NCT00431912|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
79819977|NCT02575599|Behavioral|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
79993400|NCT01311167|Drug|Placebo|Daily administration of 2 mg of placebo for 4 days
79993401|NCT05691192|Behavioral|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
79361166|NCT02231749|Biological|Nivolumab|
79361167|NCT02231749|Biological|Ipilimumab|
79361168|NCT02231749|Drug|Sunitinib|
79361169|NCT02212886|Drug|GA Depot 80 mg|Recruitment completed
79361170|NCT02212886|Drug|GA Depot 40 mg|Recruitment completed
79361171|NCT02188745|Drug|17B-estradiol|Anti-estrogen
79361172|NCT02188745|Drug|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
79361173|NCT02188745|Drug|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
79671551|NCT00462657|Genetic|polymerase chain reaction|
79671552|NCT00462657|Other|bronchoalveolar lavage|
79671553|NCT00462657|Other|immunoenzyme technique|
79671554|NCT00462657|Other|laboratory biomarker analysis|
79671555|NCT00462657|Procedure|bronchoscopy|
79993402|NCT03628326|Other|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
79512210|NCT06244693|Other|No intervention|No intervention
79512211|NCT06244680|Device|MRI of the prostate|Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.
79512212|NCT06244667|Procedure|facet median block with prilocain|facet median block with prilocain
79671556|NCT00462657|Procedure|management of therapy complications|
79671557|NCT00431990|Drug|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
79671558|NCT00431990|Drug|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
79512213|NCT06244667|Procedure|facet median block with lidocaine|facet median block with lidocaine
79512214|NCT06244654|Device|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones|After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.
79512215|NCT06244654|Other|No VR|After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
79512216|NCT06244641|Other|Auto-questionnaires, hetero-questionnaires and Evoked-potentials|Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
79671559|NCT00431990|Drug|dexamethasone|20mg for 2 days with each dose of bortezomib
79361174|NCT02188745|Drug|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
79512217|NCT06244628|Drug|Iguratimod|Oral administration of Iguratimod, 25mg twice daily
79512218|NCT06244615|Device|Verum (WO 6607)|Mouth and throat rinse and gargle solution
79512219|NCT06244615|Device|Placebo (WO 6608)|Mouth and throat rinse and gargle solution
79512220|NCT06244576|Behavioral|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
79671560|NCT00462696|Drug|docetaxel|
79671561|NCT00462696|Drug|epirubicin hydrochloride|
79671562|NCT00462696|Procedure|conventional surgery|
79671563|NCT00462696|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79993403|NCT03419741|Device|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
79361175|NCT02024607|Drug|BBI608|
79361176|NCT02024607|Drug|Fluorouracil|
79361177|NCT02024607|Drug|Oxaliplatin|
79361178|NCT02024607|Drug|Leucovorin|
79361179|NCT02024607|Drug|Irinotecan|
79361180|NCT02024607|Drug|Bevacizumab|
79671564|NCT00462696|Procedure|neoadjuvant therapy|
79361181|NCT02024607|Drug|Capecitabine|
79512221|NCT06244563|Device|Face mask with Hybrid-Hyrax|Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.
79512222|NCT06244563|Device|Face mask with Bonded RME|Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.
79512223|NCT06244563|Procedure|Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)|In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
79671565|NCT00462696|Procedure|radiomammography|
79671566|NCT00462774|Procedure|Intramyocardial injection of autologous CD133+ marrow cells|
79671567|NCT00462813|Drug|oral microencapsulated diindolylmethane|
79671568|NCT00462813|Genetic|polymerase chain reaction|
79671569|NCT00462813|Other|cervical Papanicolaou test|
79671570|NCT00462813|Other|cytology specimen collection procedure|
79671571|NCT00462813|Procedure|colposcopic biopsy|
79671572|NCT01052012|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
79361182|NCT02024607|Drug|Regorafenib|
79361183|NCT01966159|Device|SYNERGY Investigational Device|percutaneous coronary intervention
79361184|NCT01966159|Device|PE Plus Investigational Device|percutaneous coronary intervention
79512224|NCT06244563|Procedure|Routine Rapid Maxillary Expansion Protocol|In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
79361185|NCT01938248|Drug|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
79671573|NCT01052012|Drug|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
79671574|NCT01052012|Drug|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
79671575|NCT00462852|Drug|dalteparin|
79671576|NCT00462852|Drug|gemcitabine hydrochloride|
79671577|NCT00462852|Other|diagnostic laboratory biomarker analysis|
79361186|NCT01938248|Drug|aspirin|aspirin 81 mg once daily
79361187|NCT01776307|Drug|BBI608|BBI608 is administered at 500 mg po bid continuously.
79361188|NCT01776307|Drug|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
79361189|NCT01776307|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
79361190|NCT01776307|Drug|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
79361191|NCT01622322|Drug|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
79361192|NCT01622322|Other|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
79361193|NCT01531803|Drug|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
79361194|NCT01531803|Drug|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
79361195|NCT01325441|Drug|BBI608|
79361196|NCT01325441|Drug|Paclitaxel|
79361197|NCT01073475|Other|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
79361198|NCT00900419|Other|immunohistochemistry staining method|Laboratory test
79361199|NCT00900419|Other|laboratory biomarker analysis|Laboratory Test
79361200|NCT00900419|Other|sputum cytology|Laboratory Test
79361201|NCT00900419|Procedure|biopsy|Laboratory Test
79512226|NCT06244524|Other|High indoor CO2 exposure|The participants will stay and sleep for eight hours in a closed bedroom.
79512227|NCT06244511|Other|Early Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the first four weeks.
79671578|NCT00471393|Drug|1.5% diclofenac in 45.5% DMSO (topical treatment)|
79671579|NCT00471393|Drug|45.5% DMSO (topical placebo)|
79671580|NCT00432029|Procedure|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
79671581|NCT00432029|Device|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
79671582|NCT03273348|Procedure|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
79671583|NCT00432068|Drug|Octreotide pamoate|
79671584|NCT03273309|Other|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
79671585|NCT03273309|Other|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
79671586|NCT00432107|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
79671587|NCT03273231|Drug|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
79671588|NCT03273231|Drug|Saline|0.9% saline solution
79671589|NCT00432146|Drug|lugol's solution|
79671590|NCT00462891|Other|IT System|
79671591|NCT00432224|Procedure|photodynamic therapy|
79671592|NCT00432263|Drug|Genotropin (PN-180,307) Somatropin|
79671593|NCT00462969|Procedure|Sonohysterography|Sonohysterography
79993404|NCT04233840|Drug|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
79512228|NCT06244511|Other|Late Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the last four weeks.
79512229|NCT06244498|Drug|Tranexamic acid injection|Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
79512230|NCT06244485|Drug|Valemetostat tosylate|Administered orally once daily
79993405|NCT04233840|Drug|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
79512231|NCT06244485|Drug|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
79512232|NCT06244485|Drug|Dato-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle.
79512233|NCT06244472|Device|Experiment 1: visual and auditory attention task|We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.
79512234|NCT06244472|Device|Experiment 2: language production and rest tasks|We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.
79512235|NCT06244472|Device|Experiment 3: visuo-motor task|We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).
79512236|NCT06244472|Device|Experiment 4: brain activity at rest|We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
79512237|NCT06244446|Other|No intervention|No intervention. It is an observational study
79993406|NCT03787758|Drug|SAGE-718|SAGE-718
79993407|NCT02896400|Behavioral|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
79512238|NCT06244433|Genetic|whole genome sequencing|Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants
79512239|NCT06244420|Other|Clinical data review|review the medical records, radiological imaging, and histological data of these patients
79512240|NCT06244394|Radiation|intensity-modulated radiotherapy|All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
79512241|NCT06244368|Drug|GVM±R regimen|"Mitoxantrone hydrochloride liposome (18 mg/m^2) on day 1； Gemcitabine (800 mg/m^2) on day 1,8； Vinorelbine (20mg/m^2) on day 1,8； Rituximab (375mg/m^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician."
79512242|NCT06244355|Other|Extra blood tubes|Extra blood tubes
79512243|NCT06244329|Device|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.
79512244|NCT06244316|Drug|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
79512245|NCT06244316|Drug|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
79512246|NCT06244316|Drug|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
79512247|NCT06244303|Drug|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)|Toothpaste, toothbrush & mouthwash regime
79512248|NCT06244303|Drug|manual toothbrush + Colgate dental cream|toothpaste + toothbrush
79512249|NCT06244290|Drug|Colgate SNF|toothpaste
79512250|NCT06244290|Drug|Sensodyne Extra Whitening|toothpaste
79993408|NCT02896400|Drug|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
79512251|NCT06244290|Drug|Colgate Fluoride (CDC)|toothpaste
79671594|NCT00432302|Drug|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg [14C]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
79671595|NCT00463008|Drug|methotrexate|
79671596|NCT00463008|Other|pharmacological study|
79993409|NCT02896400|Other|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
79993410|NCT02896400|Other|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
79993411|NCT03405935|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
79993412|NCT03644888|Other|Cycle ergometer training|Already in arm/group descriptions
79993413|NCT03644888|Other|Airway clearance program|Already in arm/group descriptions
79993414|NCT03644888|Device|Vibration therapy|Already in arm/group descriptions
79512252|NCT06244277|Drug|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
79512253|NCT06244277|Drug|Zolpidem|Zolpidem 10Mg Tab 10mg tablet once daily
79512254|NCT06244251|Procedure|TU-LESS|TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
79512255|NCT06244251|Procedure|MPLS|Patients with uterine who plan to receive MPLS for myomectomy
79512257|NCT06244225|Drug|Donafenib； Sintilimab； HAIC|"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."
79512258|NCT06244212|Other|Demonstration of applying triamcinolone cream|Live demonstration of applying 1 fingertip unit of triamcinolone cream
79512259|NCT06244212|Behavioral|Mobile App Use|Additional mobile application that provides amount dispensed and adherence data.
79993415|NCT03644888|Device|Sham vibration therapy|Already in arm/group descriptions
79993416|NCT03055260|Device|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
79512260|NCT06244212|Other|Standard of Care|Written/verbal instructions only
79512261|NCT06244199|Behavioral|T2CR Intervention|The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.
79512262|NCT06244199|Other|Usual Care|Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
79512263|NCT06244186|Dietary Supplement|Probiotics|Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
79993417|NCT03055260|Device|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
79819978|NCT02575521|Drug|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
79993418|NCT03404843|Drug|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
79993419|NCT03404843|Other|Saline|100 mL saline bag.
79993420|NCT05283902|Biological|ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine|In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
79993421|NCT05284448|Drug|pentoxifylline (Trental SR®)|400 mg three times daily
79361202|NCT00815789|Behavioral|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
79361203|NCT00742807|Drug|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
79361204|NCT00742807|Drug|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
79361205|NCT00590850|Procedure|ORIF with Plate and Screws|ORIF with plate and screws
79361206|NCT00590850|Procedure|Pin Fixation|Clavicle fixation with clavicle pin
79361207|NCT00484770|Device|Brain Natriuretic Peptide Levels -- Diagnostic testing|
79361208|NCT00484770|Other|clinical assessment|
79993422|NCT03627936|Drug|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
79993423|NCT03627936|Drug|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
79671597|NCT00432419|Procedure|autologous peripheral blood cell transplantation|
79993424|NCT03717779|Diagnostic Test|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
79512264|NCT06244186|Dietary Supplement|Placebo|Placebo is provided by TCI CO., Ltd.
79361209|NCT05805046|Device|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
79361210|NCT05795296|Drug|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
79361211|NCT05795296|Drug|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
79361212|NCT05792631|Device|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
79512265|NCT06244160|Other|High flow oxygen therapy|High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels
79512266|NCT06244134|Procedure|ultrasound guided autologous blood injection|guided
79512267|NCT06244134|Procedure|non guided autologous blood injection|non guided
79512268|NCT06244121|Drug|Pyridoxine|pyridoxine (Vitamin B6) will be given as an anti oxidant.
79512269|NCT06244121|Drug|Placebo|Placebo will be given in control group
79671598|NCT00463086|Drug|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
79671599|NCT00463086|Drug|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
79671600|NCT02957435|Drug|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
79671601|NCT03271359|Behavioral|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
79671602|NCT03271359|Behavioral|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
79819979|NCT02575521|Drug|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
79819980|NCT00742274|Device|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
79361213|NCT05792345|Procedure|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
79361214|NCT05792345|Procedure|Control|Infiltration by surgeon
79361215|NCT05783648|Drug|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
79512270|NCT06244108|Other|Occupational therapy home program|"After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback."
79361216|NCT05783076|Drug|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
79361217|NCT05783076|Drug|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
79361218|NCT05752786|Behavioral|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
79512271|NCT06244095|Other|Perturbation Therapy|The applicants were instructed to perform various exercises, including rotating their trunks, tossing a ball, and maintaining pelvis neutrality. They were also asked to reach the toy sideways with one hand. The 6-week intervention was conducted four days a week for 60 minutes each day, focusing on trunk rotation, standing, tossing, and catching the ball in various directions. The training sessions lasted for 20 minutes each.
79671603|NCT02957591|Dietary Supplement|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
79671604|NCT02957591|Other|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
79671605|NCT00432536|Other|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
79361219|NCT05746884|Procedure|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
79361220|NCT05746884|Procedure|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
79679726|NCT04690959|Other|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
79361221|NCT05739474|Biological|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
79671606|NCT03271125|Behavioral|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
79361222|NCT05739474|Biological|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
79361223|NCT05733169|Other|Frequency lowering intervention|Modified parametrization of the current frequency lowering parametrization.
79361224|NCT05733169|Other|Frequency lowering reference|Current frequency lowering parametrization
79671607|NCT03271125|Behavioral|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
79671608|NCT00471471|Biological|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
79993425|NCT03646682|Procedure|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
79993426|NCT03032250|Other|Communication Intervention|Attend interventionist sessions
79993427|NCT03032250|Other|Watch video|Watch video on a DVD
79512272|NCT06244095|Other|Trunk Control Therapy|For the duration of each session, the manual pushes and pulls were administered around once per minute and lasted for 20 minutes. A platform that can be moved in four directions.Choosing to step and stroll when there is an outside disturbance. When routine motions such as sit-to-stand transitions, disruptions are applied when standing, walking, or other activities. Training with continuous disruptions simulates scenarios such as uneven terrain. Both rope and cable excursions are above ground and last for 20 minutes. Briefly explain the platform to the participants. Asked the participants to push the torso and waist against the wall during the session. Emerging barriers during training sessions like small obstacles (e.g. pair of bricks) then Lean the participants with the support of the therapist and let them go. Asked them to Step on a mushy or slick surface in session for 20 minutes. Each intervention session took place for 60 minutes per day four days of week for 6 weeks.
79512273|NCT06244082|Drug|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
79819981|NCT00742274|Other|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
79819982|NCT04711473|Behavioral|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
79993428|NCT03032250|Other|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
79993429|NCT03032250|Other|Quality-of-Life Assessment|Ancillary studies
79993430|NCT03032250|Other|Survey Administration|Ancillary studies
79361225|NCT05726669|Other|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
79361226|NCT05726084|Biological|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
79361227|NCT05726084|Biological|Placebo|solution for intramuscular injection, 0.5 ml
79361228|NCT05721690|Device|UED-A Videolaryngoscopy|Tracheal Intubation with UED-A videolaryngoscope
79361229|NCT05721690|Device|Glidescope Videolaryngoscopy|Tracheal Intubation with Glidescope Titanium videolaryngoscope
79361230|NCT05716087|Drug|LP-168|Subjects to take LP-168 orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
79361231|NCT05700331|Procedure|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
79361232|NCT05700331|Procedure|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
79361233|NCT05690698|Drug|Quatiapine|Atypical antipsychotic
79361234|NCT05690698|Drug|Haloperidol|Antipsychotic
79361235|NCT05687695|Other|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
79361236|NCT05687695|Other|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
79361237|NCT05686278|Device|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
79361238|NCT05661123|Other|Complete decongestive therapy|"Education.~Skin care .~Pneumatic compression device .~Manual lymph draining .~Multilayer short stretch compression bandages.~Exercises."
79361239|NCT05650749|Biological|GPC2 CAR T cells|The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
79993431|NCT03032250|Other|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
79993432|NCT03645512|Behavioral|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
79993433|NCT03444155|Dietary Supplement|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
79671609|NCT00471471|Biological|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
79679727|NCT04690959|Other|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
79819983|NCT04711473|Behavioral|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
79819984|NCT04711473|Behavioral|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
79819985|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
79361240|NCT05640843|Other|Whole Foods Plant-based Diet|"The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing.~Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a health coach daily. Patients will also receive dietary education and counselling from a research dietitian every 4 weeks for the 12-week intervention period. They will have access to the team for questions and support as needed"
79361241|NCT05640843|Dietary Supplement|Algae omega 3|Algae omega 3 given twice daily.
79361242|NCT05640843|Other|Placebo supplements|Placebo supplements given twice daily.
79361243|NCT05636189|Procedure|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
79512274|NCT06244069|Diagnostic Test|Temporal arterial biopsy|Collection of 30 ml of peripheral blood in ethylenediaminetetraacetic acid (EDTA) tubes performed at baseline, 6 months, 12 months and in case of flare before month 12. In addition, the temporal artery specimen (at least 5 mm in length) exceeding that used for clinical activity (at least 10 mm in length in accordance with current clinical recommendations) will be digested to use for research purposes (about protocols for collecting, processing, storing and sending biopsy, refer to Standard Operating Procedures, SOP).
79671610|NCT00471471|Biological|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
79671611|NCT02273492|Drug|Asasantin ER|
79671612|NCT02273492|Other|Standardized breakfast|
79671613|NCT00471510|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
79361244|NCT05636189|Procedure|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
79361245|NCT05627349|Device|wrist splinting|standard wrist splinting at night for 2 weeks
79671614|NCT02273531|Drug|Asasantin ER, new formulation|
79671615|NCT02273531|Drug|Asasantin ER, present commercial formulation|
79671616|NCT01580345|Dietary Supplement|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
79671617|NCT01580345|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
79671618|NCT00463203|Drug|Bevacizumab|10 mg/kg every 2 weeks
79671619|NCT00463203|Drug|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
79671620|NCT00471549|Drug|Statin (simvastatin)|
79671621|NCT00432575|Drug|surinabant (SR147778)|oral administration
79671622|NCT00432575|Drug|placebo|oral administration
79671623|NCT00432614|Drug|SR58611A|oral administration
79671624|NCT00432614|Drug|escitalopram|oral administration
79671625|NCT00432614|Drug|placebo|oral administration
79671626|NCT00463320|Drug|Pazopanib eye drops and Allergen Refresh Plus eye drops|
79512275|NCT06244069|Diagnostic Test|Whole exome sequencing|"Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. M-CHIP will be further characterized by:~i) clone dimension as defined by Variant Allele Fraction (VAF); ii) mutations in specific genes such as DNMT3A, Tet methylcytosine dioxygenase 2 (TET2), Additional Sex combs (ASXL1), or Janus kinase 2 (JAK2); iii) multiple mutations.~L-CHIP will be further characterized by:~i) clone dimension as defined by the VAF; ii) mutations in specific genes such as Dual Specificity Phosphatase 22 (DUSP22), FAT atypical cadherin 1 (FAT1), (Histone-lysine N-methyltransferase 2D (KMT2D); iii) multiple mutations; iv) co-occurrence of mutations heralding M- and L-CHIP."
79361246|NCT05627349|Device|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
79361247|NCT05626998|Drug|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
79512276|NCT06244069|Diagnostic Test|Single cell transcriptomics|The investigators will identify actively inflamed arterial biopsies from three treatment-naïve patients without CHIP, and three treatment-naïve patients with CHIP driven by the most relevant gene mutation. Arterial wall Cluster of Differentiation (CD) 45+ leukocytes will be isolated after digestion of arterial tissue and characterized by single cell transcriptomics, with a specific focus on wall infiltrating T cells and macrophages and their subsets (eg: Vascular dendritic cells, Th1, Th2, Th17, Treg, M1- and M2-like,…). Frequencies of these subsets and their genetic expression will be compared between wall-infiltrating leukocytes from GCA patients with or without CH, focusing on histological events supposed to be pathogenic in GCA, or known to be dysfunctional in CHIP.
79512277|NCT06244056|Procedure|Stellate Ganglion Block|A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
79361248|NCT05626998|Drug|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
79671627|NCT00432653|Drug|rituximab|
79671628|NCT00471588|Drug|Pramipexole, Amisulpride|Study Drug
79671629|NCT00432692|Procedure|Falls Prevention Program|
79671630|NCT00463359|Drug|Imiquimod cream|
79671631|NCT00463359|Procedure|curettage and cautery|
79671632|NCT00432731|Biological|VARIVAX®|
79361249|NCT05620225|Device|Axon Therapy and CMM|transcutaneous magnetic stimulation (TMS)
79361250|NCT05620225|Device|Sham and CMM|Sham and CMM
79361251|NCT05607121|Device|intermittent theta burst stimulation|transcranial magnetic stimulation
79671633|NCT00432731|Biological|M-M-RTM II|
79671634|NCT00432770|Drug|ARC1779|
79512278|NCT06244043|Other|Initial Coaching Call|Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
79512279|NCT06244043|Other|Email Support|Email-based support throughout study period
79512280|NCT06244043|Other|Text Messages|All participants with receive text messages encouraging them to engage in the practices taught in the app.
79512281|NCT06244030|Other|core stabilization group|The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
79512282|NCT06244004|Drug|Antiandrogen Therapy|Undergo SOC ADT
79361252|NCT05607121|Device|continuous theta burst stimulation|transcranial magnetic stimulation
79512283|NCT06244004|Procedure|Bone Scan|Undergo bone scan
79512284|NCT06244004|Procedure|Computed Tomography|Undergo CT
79819986|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
79819987|NCT02576457|Biological|BMS-936559|
79361255|NCT05583292|Other|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
79361256|NCT05583292|Other|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
79361257|NCT05583292|Other|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
79361258|NCT05582174|Drug|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
79361259|NCT05582174|Drug|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
79361260|NCT05578664|Drug|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
79512285|NCT06244004|Drug|Cytotoxic Chemotherapy|Receive SOC cytotoxic chemotherapy
79512286|NCT06244004|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET
79512287|NCT06244004|Radiation|Radiation Therapy|Undergo MDRT
79512288|NCT06243991|Device|in vivo Corneal Confocal Microscopy|CCM was performed using the Heidelberg Retinal Tomograph 3 with the Rostock Cornea Module (HRT3-RCM, Heidelberg Engineering GmbH, Germany) under topical anesthesia. A viscous gel (Viscotears, Novartis Pharmaceuticals UK) served as a coupling agent between the cornea and the applanation cap. The subjects were instructed to focus on the fixation light with the unexamined eye to ensure proper positioning. Five high-quality images of the SNP were selected and analyzed using the automated tracing of nerve fibers program (ACCMetrics, M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, England).
79819988|NCT02576457|Other|Placebo|
79819989|NCT05276102|Other|Emollient cream|Commercially available emollient cream
79819990|NCT01192971|Drug|Apatinib|apatinib p.o. once daily for 4 weeks
79819991|NCT04090814|Device|HeatTens (HV-F311-E)|(1) 2~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
79819992|NCT01918215|Device|ICD|
79819993|NCT01918215|Device|ILR|
79512289|NCT06243991|Diagnostic Test|Corneal Sensitivity|Corneal sensitivity was evaluated using a Cochet-Bonnet esthesiometer (Luneau Ophtalmologue, Chartres, France), comprising a nylon filament measuring 60 mm in length and 0.12 mm in diameter. Participants were instructed to maintain a forward gaze while the esthesiometer gently made perpendicular contact. The procedure involved gradually decreasing the filament length in 5 mm increments, starting from 60 mm, until the initial response from the subject was detected.
79512290|NCT06243991|Device|Non invasive tear break up time|Noninvasive tear break-up time (NI-TBUT) was assessed using a Sirius Scheimpflug camera (CSO, Florence, Italy) and the device automatically provided the average NI-TBUT value
79671635|NCT00471627|Procedure|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
79993434|NCT03444155|Dietary Supplement|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
79361261|NCT05578664|Other|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
79361262|NCT05576493|Procedure|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
79361263|NCT05576493|Procedure|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
79993435|NCT03644810|Diagnostic Test|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
79361264|NCT05576493|Procedure|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
79361265|NCT05576493|Procedure|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
79512291|NCT06243991|Diagnostic Test|Ocular Surface Disease Index Qestionnaire|The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = [(sum of scores for all questions answered) × 100] / [(total number of questions answered) × 4].
79512292|NCT06243991|Device|Corneal tomography|Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
79512293|NCT06243978|Behavioral|liebria|Participants will receive access to the digital health intervention liebria in addition to TAU
79512294|NCT06243978|Other|information brochure on hypertension|Participants will receive an information brochure on hypertension
79512295|NCT06243952|Device|ARC-BSI Lumbar system|Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
79671636|NCT00432887|Drug|caffeine administration|
79671637|NCT00471744|Drug|Treatment with levetiracetam or sulthiame over a six-month period.|
79671638|NCT01051817|Drug|AIN457|infusion 10 mg/Kg
79671639|NCT01051817|Drug|Placebo|infusion
79671640|NCT00471783|Procedure|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
79993436|NCT03644810|Diagnostic Test|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
79361266|NCT05569629|Procedure|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
79361267|NCT05568134|Diagnostic Test|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
79361268|NCT05555901|Drug|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
79671641|NCT04703660|Procedure|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
79671642|NCT01327846|Drug|Canakinumab|
79671643|NCT01327846|Drug|Placebo|
79671644|NCT01327846|Drug|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
79671645|NCT00463515|Drug|carboplatin/gemcitabine|
79671646|NCT00463515|Procedure|cisplatin/radiation therapy|
79671647|NCT00432926|Behavioral|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
79671648|NCT00432926|Behavioral|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
79361269|NCT05555901|Drug|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
79361270|NCT05540028|Biological|IVT PCV-25|25 valent pneumococcal conjugate vaccine
79361271|NCT05540028|Biological|PCV 20|20 valent pneumococcal conjugate vaccine
79361272|NCT05531136|Other|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
79361273|NCT05515445|Drug|Chiglitazar|Oral single dose 48 mg
79361274|NCT05494671|Procedure|conjunctival limbal autologous transplant|"Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view.~Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)"
79361275|NCT05490654|Procedure|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
79361276|NCT05489484|Device|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
79512296|NCT06243939|Behavioral|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
79512297|NCT06243926|Other|Sperm selection for ICSI|Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
79671649|NCT00432926|Behavioral|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
79671650|NCT00433043|Drug|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
79671651|NCT00433043|Procedure|CRT (cardiac resynchronization therapy)|Both arms
79671652|NCT00433082|Behavioral|Ramadan Fasting|
79671653|NCT01051739|Procedure|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
79671654|NCT03273075|Drug|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
79671655|NCT03273075|Drug|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
79671656|NCT03273075|Drug|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
79671657|NCT03273075|Drug|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
79512298|NCT06243913|Procedure|IUI with vitrified sperm from donor:|"After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol."
79512299|NCT06243887|Other|Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy|Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.
79512300|NCT06243887|Other|standard of care approaches in minimal invasive esophagectomy|standard of care approaches other than ERAS
79512301|NCT06243874|Procedure|greater occipital nerve block|greater occipital nerve block
79512302|NCT06243874|Procedure|transnasal sphenopalatine ganglion block|transnasal sphenopalatine ganglion block
79512303|NCT06243848|Procedure|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
79512304|NCT06243848|Procedure|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
79512305|NCT06243835|Drug|Kindolor Tosylate|Kindolor Tosylate enteric coated tablets containing the specified amount of drug product
79361277|NCT05485181|Behavioral|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
79361278|NCT05479006|Device|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
79361279|NCT05469828|Drug|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
79361280|NCT05469828|Other|control|Standard of care
79361281|NCT05460845|Behavioral|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
79512306|NCT06243835|Drug|Placebo|Placebo enteric coated tablets identically matched to the Kindolor Tosylate tablets with equal amount of Prosolv SMCC replacing the Kindolor Tosylate
79512307|NCT06243822|Drug|Ketamine|ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
79512308|NCT06243822|Drug|Propofol|Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
79512309|NCT06243783|Behavioral|Montreal Imaging Stress Test|In the Montreal Imaging Stress Test, participants are required to solve basic mathematical tasks, but the allowed reaction time is set lower than their average.
79512310|NCT06243770|Drug|mRNA-0184|Intravenous infusion
79512311|NCT06243757|Other|MDASI-GI|"The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine)."
79512313|NCT06243731|Other|No Intervention|This is a non-interventional study.
79361282|NCT05451524|Behavioral|Insomnia prevention program|Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
79361283|NCT05451524|Behavioral|General health education|Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
79512314|NCT06243705|Device|Robot-Pet|The robot-pet makes sounds like a real cat and responds to touch and petting
79671658|NCT00471900|Drug|dehydroepiandrosterone (DHEA)|
79993437|NCT03644810|Procedure|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
79512315|NCT06243705|Device|Virtual Reality Glasses|VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
79512316|NCT06243692|Drug|Lacosamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
79671659|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
79671660|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
79671661|NCT01051661|Biological|Placebo|Intramuscular injection, one dose
79819994|NCT04090892|Procedure|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
79512317|NCT06243692|Drug|Topiramate 50Mg Tab|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
79512318|NCT06243679|Drug|Immunotherapy|Monotherapy with PD-1 inhibitors, up to 1 year.
79512319|NCT06243666|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
79671662|NCT00471939|Drug|I-020502|1 mcg/mL TG-PDGF.AB
79671663|NCT04448548|Other|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
79671664|NCT04448782|Diagnostic Test|Asynchronies detection|Asycnhronies detection
79671665|NCT01051466|Drug|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
79671666|NCT04448197|Other|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
79671667|NCT04446247|Diagnostic Test|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
79671668|NCT00463125|Drug|Platelet Gel|
79819995|NCT05412836|Device|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
79993438|NCT03017898|Procedure|Laser Coagulation|Laser coagulation of anal fistula
79512320|NCT06243666|Other|No intervention|No intervention was implemented.
79512321|NCT06243666|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
79671669|NCT01051349|Biological|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
79819996|NCT00719472|Drug|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
79361284|NCT05450926|Procedure|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
79361285|NCT05450185|Procedure|Critically ill patients with continuous renal replacement therapy|Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
79671670|NCT01051349|Biological|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
79512322|NCT06243653|Diagnostic Test|CMD test|Measured CFR and IMR
79512323|NCT06243640|Drug|Buagafuran capsules, 15mg/ capsule|Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
79512324|NCT06243640|Drug|Buagafuran capsules mimic, 0mg/ capsule|Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
79512325|NCT06243627|Other|Sunscreen C Color 2.0 SPF 70|Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.
79512326|NCT06243627|Other|Sunscreen C Color 3.0 SPF 70|Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.
79512327|NCT06243627|Other|Sunscreen M Very Light SPF 50|Sunscreen M very light SPF 50 will be applied topically on half of the face.
79512328|NCT06243627|Other|Sunscreen M Golden Color SPF 50|Sunscreen M golden color SPF 50 will be applied topically on half of the face.
79512329|NCT06243614|Drug|Buagafuran capsules, 15mg/ capsule|Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
79512330|NCT06243614|Drug|Buspirone tablets, 5mg/ tablet|Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
79512331|NCT06243614|Drug|Buagafuran capsules mimic, 0mg/ capsule|Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
79671671|NCT04329208|Device|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
79993439|NCT03715673|Diagnostic Test|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
79361286|NCT05447026|Device|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
79361287|NCT05447026|Device|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
79512332|NCT06243614|Drug|Buspirone tablets mimic, 0mg/ tablet|Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
79512333|NCT06243601|Biological|Aloe vera Gel|A fresh aloe vera (Aloe Barbadensis) leaf will be plucked from the plant. The leaf will be washed with normal saline, peeled with scalpel and the inner gel will be blended in a blender to convert it into a watery consistency. The solution will be stored in an autoclaved flask.
79512334|NCT06243588|Other|clinical records review|review the medical records, radiological imaging, and histological data of these patients
79512335|NCT06243575|Drug|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
79512336|NCT06243575|Drug|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
79512337|NCT06243536|Drug|Semaglutide|Semaglutide will be administered through 12 weeks.
79512338|NCT06243536|Drug|standard of care|Patients not assigned to receive semaglutide will receive standard of care.
79512339|NCT06243510|Other|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
79512340|NCT06243510|Other|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
79512341|NCT06243497|Procedure|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
79512342|NCT06243484|Dietary Supplement|TOTUM-070|12 weeks of TOTUM-070 supplementation (4.995g:day corresponding to 8 capsules per day)
79512343|NCT06243471|Procedure|Minimally invasive procedures for the Hallux Abductus Valgus.|Minimally invasive procedures for the Hallux Abductus Valgus
79512344|NCT06243471|Procedure|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
79512345|NCT06243458|Drug|RVU120 (SEL120)|RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
79671672|NCT04444336|Behavioral|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
79671673|NCT00472017|Drug|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
79671674|NCT02894203|Behavioral|Mindfulness|
79671675|NCT02894203|Behavioral|Yoga|
79671676|NCT00433121|Drug|Risperidone|
79671677|NCT00433121|Drug|Olanzapine|
79671678|NCT00433121|Drug|Haloperidole|
79671679|NCT00433121|Drug|Quetiapin|
79671680|NCT00433121|Drug|Escitalopram|
79671681|NCT00433121|Drug|Citalopram|
79671682|NCT00433121|Drug|Sertralin|
79671683|NCT00463671|Drug|N-acetylcysteine|
79671684|NCT04442659|Diagnostic Test|pre hospital triage tool|EMS workers fill in an application containing 10-13 vclinical items
79671685|NCT04442386|Other|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
79671686|NCT04703543|Device|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
79512346|NCT06243445|Diagnostic Test|Transthoracic echocardiography for central venous catheter tip location|Measure of time between injection of echographic contrast in the distal lumen of a central venous catheter, inserted via supra/infra clavicular right veins, and visualization, using transthoracic echocardiography, of micro bubbles in right atrium with the catheter tip positioned under transesophageal ultrasound control in four different positions: right atrium, cavo-atrial junction (CAJ), at 4 centimeters proximal to CAJ, in superior vena cava and at 8 centimeters proximal to CAJ
79512347|NCT06243419|Device|vein viewer|The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.
79512348|NCT06243419|Device|virtual reality|The child watched the application by wearing virtual glasses during the PIC insertion
79671687|NCT00591526|Drug|Arac|Ommit ARAC in the chemotherapy
79819997|NCT00719472|Drug|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
79819998|NCT00719472|Drug|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
79512349|NCT06243419|Device|vein viewer and virtual reality|"The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion"
79512350|NCT06243393|Drug|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG)
79512351|NCT06243393|Drug|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
79512352|NCT06243367|Other|Placebo drink|Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
79512353|NCT06243367|Dietary Supplement|Carbohydrate|Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
79512354|NCT06243341|Dietary Supplement|Lepidium meyenii (MACA)|The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
79512355|NCT06243328|Device|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
79512356|NCT06243315|Device|Ellansé-S|It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs
79512357|NCT06243302|Procedure|OTSC Closure After VAAFT|Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
79671688|NCT04440397|Other|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
79671689|NCT00463710|Drug|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
79671690|NCT02894008|Drug|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
79671691|NCT04440124|Other|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
79819999|NCT00719472|Drug|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
79820000|NCT02599064|Drug|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
79820001|NCT05410262|Other|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
79820002|NCT00579501|Drug|Trabectedin|Trabectedin 1.5 mg/m^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
79361288|NCT05447026|Device|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
79512359|NCT06243250|Diagnostic Test|Hyperpolarized 13C-MRI|Metabolic MRI using IV injection of hyperpolarized [1-13C]pyruvate.
79671692|NCT02893735|Other|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
79671693|NCT02893735|Other|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
79820003|NCT00579501|Drug|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
79993440|NCT02962128|Dietary Supplement|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high [10% energy] LA-containing diet for 12 weeks.
79993441|NCT02962128|Dietary Supplement|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low [2.5% energy] LA-containing diet for 12 weeks.
79512360|NCT06243237|Procedure|Acupuncture|Applied acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
79993442|NCT02898116|Drug|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
79993443|NCT02898116|Drug|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
79993444|NCT03717701|Drug|metformin|Patients will take metformin single dose of 1000 mg orally once a day
79361289|NCT05447026|Device|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
79512361|NCT06243237|Procedure|Sham Acupuncture(Superficial Acupuncture)|Applied superficial acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
79993445|NCT03717701|Drug|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
79993446|NCT03717701|Drug|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
79993447|NCT04114110|Other|RTLS data|data extraction from RTLS
79993448|NCT03931902|Device|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
79993449|NCT03931902|Device|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
79671694|NCT03271086|Behavioral|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
79671695|NCT03271086|Behavioral|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
79820004|NCT02590458|Procedure|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
79993450|NCT03712085|Other|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
79361290|NCT05441306|Device|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
79993451|NCT03712085|Other|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
79993452|NCT03628170|Other|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
79993453|NCT03628170|Other|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
79993454|NCT03658304|Drug|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
79993455|NCT03422159|Drug|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
79993456|NCT03422159|Drug|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
79361291|NCT05441306|Device|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
79361292|NCT05432011|Procedure|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
79361293|NCT05432011|Procedure|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
79820005|NCT02590458|Behavioral|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
79993457|NCT03422159|Drug|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
79361294|NCT05432011|Procedure|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
79361295|NCT05419908|Drug|Fezolinetant|Oral Capsule
79512362|NCT06243224|Other|High intensity interval training|High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
79512363|NCT06243224|Other|Moderate intensity continuous training|Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
79512364|NCT06243198|Drug|Lebrikizumab|Administered subcutaneously (SC)
79512365|NCT06243198|Drug|Placebo|Administered subcutaneously (SC)
79512366|NCT06243185|Drug|Dalpiciclib plus letrozole|Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
79361296|NCT05419908|Drug|Placebo|Oral Capsule
79361297|NCT05418972|Drug|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
79993458|NCT03422159|Drug|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
79993459|NCT04538040|Drug|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
79993460|NCT04033692|Device|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
79993461|NCT03950024|Diagnostic Test|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
79361298|NCT05403697|Procedure|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
79361299|NCT05399173|Device|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine & prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
79993462|NCT03964506|Drug|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
79671696|NCT03271086|Behavioral|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
79671697|NCT00433238|Behavioral|Participants will be screened for depression and cognitive impairment, then receive screening results.|
79671698|NCT00463749|Drug|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
79993463|NCT03403751|Drug|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
79671699|NCT00463749|Drug|Placebo|NaCl as placebo
79993464|NCT03403751|Drug|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
79671700|NCT00433277|Drug|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
79671701|NCT00463827|Drug|Atorvastatin|
79671702|NCT00463827|Drug|atorvastatin|atorvastatin 40mg
79671703|NCT00463827|Drug|matched placebo|Matched placebo
79993465|NCT02297412|Drug|Minocycline Hydrochloride|Given PO
79993466|NCT02297412|Other|Placebo|Given PO
79993467|NCT02297412|Other|Quality-of-Life Assessment|Ancillary studies
79993468|NCT02297412|Other|Questionnaire Administration|Ancillary studies
79993469|NCT03644576|Drug|ozanimod|ozanimod
79993470|NCT03644576|Drug|Pseudoephedrine|Pseudoephedrine
79361300|NCT05399173|Drug|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) & advice
79361301|NCT05396534|Procedure|Atrial Fibrillation transcatheter ablation|We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation
79671704|NCT00433316|Drug|ropivacaine|1% ropivacaine
79671705|NCT00433316|Device|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
79671706|NCT00472095|Other|Fotonovela|
79671707|NCT00472095|Other|Placebo Fotonovela|
79671708|NCT00433394|Procedure|cancer prevention intervention|
79671709|NCT00433394|Procedure|educational intervention|
79671710|NCT00472134|Drug|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
79993471|NCT03644576|Drug|ozanimod placebo|ozanimod placebo
79512367|NCT06243159|Genetic|JY231|Infusion of JY231 Injection by dose of 1-10×10^6 TU/kg、 1-5×10^7 TU/kg、5-10 ×10^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
79512368|NCT06243146|Other|Titration of Inspired Oxygen|Titration of Inspired Oxygen During One-Lung Ventilation
79512369|NCT06243133|Drug|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
79512370|NCT06243133|Drug|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
79361302|NCT05394246|Drug|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
79993472|NCT04812821|Other|questionnaire|questionnaire post delivery
79993473|NCT03418727|Drug|Brimonidine|Two products delivered in sequence twice daily.
79361303|NCT05388877|Drug|Dabrafenib|Given PO
79361304|NCT05388877|Drug|MEK-1/MEKK-1 Inhibitor E6201|Given IV
79512371|NCT06243120|Drug|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
79993474|NCT03418727|Drug|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
79993475|NCT03418727|Drug|sodium carboxymethylcellulose|Placebo given twice daily.
79993476|NCT03418727|Drug|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
79993477|NCT01180374|Drug|Cannabidiol|Active Cannabidiol 5mg.
79993478|NCT01180374|Drug|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
79993479|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
79512372|NCT06243107|Behavioral|Tai-chi|Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
79512373|NCT06243094|Drug|Antibiotic|All antibiotic therapy characteristics are monitored.
79671711|NCT00472134|Device|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
79993480|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
79993481|NCT03418571|Biological|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
79361305|NCT05371899|Drug|Chiauranib|Take Chiauranib 50mg orally once daily
79361306|NCT05362578|Device|transcutaneous electrical accustimulation at treatment point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
79671712|NCT00433433|Drug|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
79993482|NCT03418571|Other|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
79993483|NCT03887520|Diagnostic Test|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
79993484|NCT03715595|Other|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
79993485|NCT05545943|Other|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
79993486|NCT05545943|Other|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
79993487|NCT05545943|Other|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
79361307|NCT05362578|Device|transcutaneous electrical accustimulation at sham point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
79361308|NCT05353959|Other|No intervention|No intervention
79361309|NCT05353881|Other|No intervention|No intervention
79512374|NCT06243081|Other|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
79361310|NCT05353868|Other|No intervention|No intervention
79361311|NCT05353842|Behavioral|WOWii Program|Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
79361312|NCT05353322|Behavioral|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
79512375|NCT06243068|Behavioral|Educate and Engage|Nephrology practices implement a bundle in which they will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.
79671713|NCT00433433|Drug|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
79671714|NCT00433433|Radiation|IN-RT 30 Gy (+ boost 6 Gy residual)|
79671715|NCT00433433|Procedure|FDG-PET scan|
79361313|NCT05353322|Behavioral|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
79361314|NCT05353322|Behavioral|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
79671716|NCT00463905|Procedure|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
79671717|NCT00433472|Device|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
79671718|NCT00463944|Behavioral|Effect of an electronic voting system|
79671719|NCT00433667|Drug|RWJ-333369|
79671720|NCT00463983|Drug|octreotide|
79993488|NCT05545943|Other|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
79993489|NCT03717545|Other|second allogeneic stem cell transplantation|"Change another donor~conditioning regimen: FLU/CY/anti-CD25 moAb"
79361315|NCT05341960|Behavioral|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
79820006|NCT02596178|Device|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
79361316|NCT05341960|Other|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
79671721|NCT03270813|Behavioral|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
79820007|NCT04085952|Procedure|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
79671722|NCT03270813|Behavioral|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
79671723|NCT00464022|Device|Carbon dioxide|
79361317|NCT05334797|Other|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
79361318|NCT05322707|Drug|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
79361319|NCT05322707|Drug|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
79512376|NCT06243068|Behavioral|Educate and Engage Plus Kidney Supportive Care Program|"In addition to bundle described under Educate and Engage, nephrology practices offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist."
79671724|NCT01050998|Biological|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
79671725|NCT01050998|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
79671726|NCT01050998|Biological|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
79512377|NCT06243055|Other|questionnare|laval questionnare
79512378|NCT06243055|Other|questionnare|Obese-Specific Quality of Life
79820008|NCT04085952|Procedure|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
79361320|NCT05322707|Drug|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
79361321|NCT05316233|Device|VOLITE XC|Intradermal Injection
79361322|NCT05316233|Device|VOLITE XC|Subdermal Injection
79361323|NCT05295160|Behavioral|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
79512379|NCT06243055|Other|questionnare|SF-12 Quality of Life scale
79512380|NCT06243042|Diagnostic Test|serum vitamin D|blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.
79671727|NCT01050998|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
79671728|NCT01050998|Other|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
79671729|NCT00472173|Drug|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
79671730|NCT00472173|Drug|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
79820009|NCT02589834|Other|Quran group|
79671731|NCT00472329|Procedure|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
79512381|NCT06243042|Diagnostic Test|urine osmolality|"nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg."
79671732|NCT00472329|Drug|fludarabine|
79671733|NCT00472329|Procedure|TBI|
79361324|NCT05278598|Procedure|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
79820010|NCT02576301|Drug|Phase 1 - OXi4503|Determination of MTD of OXi4503
79820011|NCT02576301|Drug|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
79512382|NCT06243042|Other|Frequency volume chart|volume and frequency from time of sleep till 8 am
79512383|NCT06243029|Device|ECG Patch|Wearable ECG Patch designed to record and transmit physiological parameters to a mobile device or a data cloud. The device stores data locally in a memory cache designed for >96 hours of continuous data. It continuously records a one-lead ECG and has a three-axis accelerometer. On-board algorithms use those data to compute heart rate, heart rate variability, RR-interval, respiratory rate, and an activity level indicator. The company also provides optional arrhythmia detection and reporting services, the results of which may be delivered to healthcare professionals.
79512384|NCT06242847|Diagnostic Test|Oral glucose tolerance test (OGTT)|Participants ingest 75 g of glucose in 10 fl oz aqueous solution (fruit flavored) after an overnight fast. Blood is drawn at baseline (t = 0 min) and at 120 min after ingestion. This test is non-experimental.
79512385|NCT06242847|Procedure|Skin punch biopsy|Punch biopsies are taken from lesional (psoriatic) and non-lesional skin after an overnight fast and at 120 min after ingestion of glucose during OGTT. This procedure is non-experimental.
79512386|NCT06242535|Biological|GLY-LOW|The supplement, GLY-LOW, is FDA approved for use as a dietary supplement (IND 162006)
79512387|NCT06242405|Biological|umbilical cord-mesenchymal stem cells|Umbilical cord mesenchymal stem cells injected through peripheral veins
79671734|NCT00464139|Procedure|Laparoscopy|Laparoscopy
79671735|NCT00464217|Drug|ARA-C|
79671736|NCT00464217|Drug|Idarubicin|
79671737|NCT00464217|Drug|Leucomax|
79671738|NCT00433706|Procedure|Control position by 3DOBI before the fraction|
79820012|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
79820013|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
79671739|NCT00433706|Procedure|Standard imaging|
79671740|NCT03270852|Device|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
79671741|NCT03270852|Other|No Enhanced reality|Identical rehabilitation without enhanced reality
79512388|NCT06242275|Diagnostic Test|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab. The samples will be then stored at -70°C until analysis."
79361325|NCT05278598|Procedure|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
79512389|NCT06242262|Other|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
79512390|NCT06242262|Other|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
79512391|NCT06242184|Procedure|Group A(Nano-fortified Adhesive)|Nano-fortified dentin adhesive
79512392|NCT06242184|Procedure|Group B(Adhesive without nanoparticles)|Conventional adhesives without nanoparticles
79512393|NCT06242119|Diagnostic Test|J-PET scan|Diagnostic Test: Positron-Emission Tomography Imaging Examination of radiation distribution in the patient body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of [18F]FDG), [68Ga]Ga-PSMA, [18F]choline or [68Ga]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
79512394|NCT06241846|Drug|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
79512395|NCT06241482|Procedure|Enhanced recovery after surgery|"The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~Early assessment and treatment~Optimized anesthetic protocol~Reducing surgical stress~Multi-modal comprehensive monitoring~Comprehensive diagnosis and treatment in neurosurgical intensive care~Intensive early rehabilitation treatment"
79512396|NCT06241482|Procedure|Conventional therapy|Conventional therapy in neurocritical care.
79512398|NCT06240858|Procedure|Laparoscopic transabdominal preperitoneal hernia repair.|The TAPP group used self-gripping mesh for laparoscopic transperitoneal preperitoneal hernia repair.
79512399|NCT06240858|Procedure|Lichtenstein hernia repair.|The Lichtenstein group used self-gripping mesh for Lichtenstein hernia repair.
79512400|NCT06240598|Procedure|Second Look Laparoscopy|Second Look Laparoscopy (SLL)
79512401|NCT06240455|Drug|WP1302|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
79671742|NCT00433784|Drug|Clopidogrel|
79671743|NCT00433784|Procedure|Blood sampling - platelet aggregation|
79671744|NCT00433784|Procedure|Blood sampling - genotyping|
79671745|NCT00464256|Drug|rimonabant|
79671746|NCT00433823|Drug|Atorvastatin, Ezetimibe|
79671747|NCT00464295|Drug|Capecitabine in HCC|
79671748|NCT03273036|Drug|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
79671749|NCT03273036|Drug|Placebos|no injected agent
79671750|NCT00433901|Behavioral|Targeted parental instruction for positive lifestyle change with follow-up calls.|
79671751|NCT03270735|Drug|Snake venom thrombin (Treatment)|Snake venom thrombin
79671752|NCT03270735|Drug|Placebo|No snake venom thrombin
79671753|NCT04702841|Drug|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
79671754|NCT04703114|Diagnostic Test|Blood count|Blood count at each visit
79361326|NCT05278598|Procedure|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
79361327|NCT05278247|Diagnostic Test|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
79361328|NCT05273931|Other|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
79361329|NCT05270512|Device|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
79361330|NCT05267080|Device|CLINIPORATOR|The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.
79361331|NCT05259852|Behavioral|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
79361332|NCT05259852|Behavioral|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
79512402|NCT06240455|Drug|WP1302 placebo|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
79512403|NCT06240455|Combination Product|methimazole|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
79512404|NCT06240065|Dietary Supplement|Green bean puree|Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.
79512405|NCT06239896|Behavioral|Facilitated Group ACP Session|Group Facilitators will adhere to the standardized scripts and protocols to engage participants in ACP through group sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
79671755|NCT04703114|Diagnostic Test|Blood collection|Blood collection to understanding of the immunological profile at each visit
79671756|NCT04703114|Diagnostic Test|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
79671757|NCT04703114|Diagnostic Test|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
79671758|NCT04703114|Diagnostic Test|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
79671759|NCT04703114|Genetic|Genetic blood collection|Collection to further research at each visit
79512406|NCT06239896|Behavioral|Facilitated one-on-one ACP visits|Facilitator adheres to the scripts and protocols to engage participants in advance care planning through one-on-one ACP sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook that they can use to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
79361333|NCT05254340|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
79361334|NCT05254054|Other|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
79820014|NCT02589756|Other|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
79361335|NCT05254054|Other|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
79361336|NCT05251636|Radiation|Episcleral Brachytherapy|Minimally invasive, single fraction brachytherapy
79361337|NCT05251636|Drug|Aflibercept Injection|Standard of Care intravitreal aflibercept injection
79361338|NCT05221697|Device|PRESAGE CARE|Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
79361339|NCT05216003|Behavioral|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
79671760|NCT04703114|Other|Data collection|Demographics, symptoms, biological constants
79671761|NCT04053153|Device|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
79820015|NCT02589756|Other|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (~1400 kcal ~100 grams walnuts, ~50 grams hazelnuts and ~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
79820016|NCT02589756|Other|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
79361340|NCT05214820|Biological|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
79820017|NCT00918762|Procedure|assessment of therapy complications|
79820018|NCT00918762|Procedure|diagnostic endoscopic surgery|
79512407|NCT06239675|Device|tDCS|tDCS will be delivered anodal for 20 minutes at an intensity between 1mA and 2mA for 15 sessions.
79512408|NCT06239675|Behavioral|CIMT|CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
79512409|NCT06239675|Device|sham tDCS|sham tDCS
79512410|NCT06239038|Procedure|total knee arthroplasty|total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
79512411|NCT06238778|Drug|HDV-Lispro|HDV-L will be used as the mealtime insulin
79820019|NCT00918762|Procedure|quality-of-life assessment|
79671762|NCT04702685|Drug|Ropivacaine|Local anesthetic for injection
79671763|NCT04702685|Other|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
79512412|NCT06238778|Drug|Lispro|Lispro will be used as the mealtime insulin
79671764|NCT00464373|Drug|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
79671765|NCT00464373|Drug|Placebo|4ml NaCl 0.9%
79671766|NCT00472368|Drug|LBH589|
79820020|NCT00918762|Procedure|therapeutic conventional surgery|
79820021|NCT00918762|Procedure|therapeutic endoscopic surgery|
79820022|NCT00918762|Procedure|transoral robotic surgery|
79820023|NCT00918762|Procedure|video-assisted surgery|
79993490|NCT03715517|Procedure|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
79993491|NCT03715517|Procedure|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in <5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
79993492|NCT03715517|Drug|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
79512413|NCT06238024|Drug|Tocilizumab|Single dose intravenous application
79512414|NCT06238024|Drug|NaCl 0.9% 100ml|Single dose intravenous application
79671767|NCT00106028|Drug|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
79671768|NCT00106028|Drug|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
79993493|NCT03715517|Drug|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
79993494|NCT03715517|Drug|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
79993495|NCT03715517|Drug|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
79993496|NCT03715517|Drug|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
79361341|NCT05212649|Diagnostic Test|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
79512415|NCT06237998|Device|Telemedicine|Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
79671769|NCT00464412|Behavioral|Education|
79671770|NCT00464451|Drug|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
79671771|NCT00464451|Drug|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
79671772|NCT00464529|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
79820024|NCT04019067|Diagnostic Test|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
79993497|NCT03402893|Drug|ONEXTON Topical Gel|Onexton gel applied once daily to face
79993498|NCT03715361|Diagnostic Test|SL-ECG|additional SL-ECG measurement
79993499|NCT03717467|Drug|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
79993500|NCT03717467|Drug|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
79993501|NCT03717389|Other|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
79993502|NCT04464954|Device|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
79993503|NCT04464954|Device|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
79993504|NCT04464954|Device|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
79512416|NCT06237270|Procedure|Nerve transfer surgery for elbow flexion|A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.
79512417|NCT06236633|Procedure|Ischemic preconditioning|Embolization performed via a common right femoral or radial approach, depending on the patient's conformation. Minor complications such as hematoma at the puncture site are rare in less than 1% of cases, and serious complications are exceptional. Proximal occlusion of the inferior mesenteric artery, before its dividing branches, using material adapted to arterial occlusion according to anatomical findings. Proximal occlusion during embolization is evaluated by intravascular injection into the inferior mesenteric artery, and resumption of vascularization of the distal inferior mesenteric artery is controlled by the border arcade injecting into the superior mesenteric artery. In the event of a high-risk anatomical variant, or absence of a border arcade, no embolization will be performed and the patient will be excluded from the study; this will represent no more than 1-2% of patients (surgical series describing 0.83% of ischemia in connection with absence of a border arcade).
79671773|NCT00433940|Drug|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
79993505|NCT03628248|Procedure|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
79993506|NCT03628248|Procedure|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
79993507|NCT03442985|Drug|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
79671774|NCT00433979|Drug|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
79671775|NCT01050764|Drug|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~T-reg: 1 x 10e5/kg~T-con: 3 x10e5/kg~Cohort 2~T-reg: 3 x 10e5/kg~T-con: 1 x 10e6/kg~Cohort 3~T-reg: 1 x 10e6/kg~T-con: 3 x 10e6/kg~Cohort 4~T-reg: 3 x 10e6/kg~T-con: 1 x 10e7/kg"
79671776|NCT01050764|Drug|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
79671777|NCT01050764|Drug|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
79820025|NCT02575287|Device|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
79993508|NCT03442985|Drug|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
79993509|NCT03442985|Other|Placebo|Subjects received placebo, once daily, for up to 24 months.
79671778|NCT01050764|Drug|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
79820026|NCT02575287|Device|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
79512418|NCT06236633|Procedure|Arteriogram|The interventional radiologist performs an arteriogram of the inferior and superior mesenteric arteries (IMA and SMA respectively) to check that the SMA is free of anomalies and that the IMA has a proximal trunk long enough for embolization. The radiologist also checks for the presence of a colonic border arcade. If this is absent, embolization will not be performed: the patient will be excluded from the study.This arteriogram is carried out under local anaesthetic specifically for research purposes, as follows: Common right femoral or radial approach and placement of a small introducer. Selective arteriogram of the inferior and superior mesenteric arteries to check perfusion of the border arcade.Arterial closure system or manual compression. Return to surgery or interventional radiology department. Patient discharged the same day after medical assessment (surgeon or interventional radiologist).Telephone check-up on Day1 (standard management) and Day 7 (added as part of the protocol).
79820027|NCT02575287|Device|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
79820028|NCT04086186|Procedure|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
79993510|NCT03715283|Other|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
79361342|NCT05211141|Device|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
79512419|NCT06235996|Procedure|Office-based procedure indicated for chronic pain with music|Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
79512420|NCT06235996|Procedure|Office-based procedure indicated for chronic pain without music|Office-based procedure indicated for chronic pain without music
79671779|NCT01050764|Device|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
79671780|NCT01050764|Drug|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
79671781|NCT01050764|Drug|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
79671782|NCT00464607|Drug|hMG-IBSA|
79671783|NCT00464607|Procedure|Ovarian stimulation|
79820029|NCT04086186|Procedure|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
79820030|NCT00741338|Biological|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
79820031|NCT00741338|Drug|Cyclosporine A (CsA)|Orally three times daily.
79671784|NCT00472485|Procedure|eye movement therapy|
79820032|NCT00741338|Drug|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
79820033|NCT03971396|Other|Physiotherapists working in intensive care|Physiotherapists working in intensive care will be reached by mail or telephone. Physiotherapists will be asked to complete the prepared questionnaire.
79820034|NCT02575131|Other|whole wheat bread yeast basis|
79361343|NCT05191797|Drug|Bomedemstat|Given PO
79361344|NCT05191797|Biological|Atezolizumab|Given IV
79361345|NCT05179889|Drug|mFOLFIRINOX|"Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion] 12 cycles per 2 weeks~mFOLFOX 6 [Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week"
79671785|NCT00434096|Drug|rimonabant (SR141716)|oral administration once daily
79820035|NCT02575131|Other|Oatmeal|
79361346|NCT05179889|Drug|mFOLFOX 6|Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
79993511|NCT03715283|Other|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
79512421|NCT06235606|Drug|Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
79512422|NCT06235606|Drug|Dexmedetomidine 0.5milligram (50micrograms)|Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
79361347|NCT05173506|Other|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
79361348|NCT05163522|Drug|VH4004280|VH4004280 will be administered.
79361349|NCT05163522|Drug|Placebo|Placebo will be administered.
79512423|NCT06234553|Procedure|surgery of pituitary adenomas|evaluate pathological type and treatment effect after treatment
79512424|NCT06232434|Drug|Prospidelong|Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.
79512425|NCT06232434|Procedure|chemotherapy|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1"
79512426|NCT06232421|Drug|Foscelantan|"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus"
79512427|NCT06232421|Drug|Povidon-iodine|Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
79512428|NCT06232369|Device|Active repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration."
79512429|NCT06232369|Device|Sham repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration."
79512430|NCT06231368|Biological|CNCT19 CAR-T cell therapy|CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
79512431|NCT06228807|Combination Product|The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.|Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.
79671786|NCT00434096|Drug|placebo|oral administration once daily
79671787|NCT00472524|Procedure|Mydriasis/cycloplegia via different modes of administration|
79671788|NCT01050569|Drug|Nicotine Patch|21 mg
79671789|NCT01050569|Other|VLNC Cigarette|Cigarette where the tobacco contains <0.1 mg of nicotine yield.
79671790|NCT01050569|Other|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
79361350|NCT05163522|Drug|Midazolam|Midazolam will be administered
79361351|NCT05163158|Other|Central vs brachial systolic blood pressure targeting|Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be <130 mmHg.
79820036|NCT02575131|Other|Cheerios|
79820037|NCT02575131|Other|whole wheat sourdough bread|
79820038|NCT02575131|Other|standard breakfast|
79820039|NCT02598830|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
79820040|NCT02598830|Dietary Supplement|Placebo|Olive oil, encapsuled
79820041|NCT02578251|Drug|Paracetamol|
79820042|NCT02578251|Drug|Pethidine|
79512432|NCT06225921|Drug|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
79993512|NCT01311635|Drug|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
79361352|NCT05159960|Procedure|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
79361353|NCT05156723|Biological|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
79361354|NCT05156723|Biological|Placebo|solution for intramuscular injection, 0.5 ml
79993513|NCT01311635|Drug|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
79993514|NCT01311635|Drug|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
79361357|NCT05140915|Behavioral|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
79361358|NCT05140915|Behavioral|Peer Coaching via Text|Peer coaching, facilitated by texting
79512433|NCT06225921|Drug|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
79512434|NCT06225921|Drug|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
79512435|NCT06225817|Dietary Supplement|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
79512436|NCT06222957|Other|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
79512437|NCT06222138|Other|The samples described below will be collected:|"For each included patient, blood samples will be collected during baseline visit (before initiation of radio-chemotherapy), then before initiation of TTFields and every 3 months during TTFields treatment. Additional blood samples will be scheduled at recurrence (if applicable).~Moreover, tumor samples (formalin paraffin embedded (FFPE) tumor block and fresh samples) will be collected from surgery specimen on primary tumor by the sponsor for analysis. In case of recurrence, and if a second surgery is possible, tumor samples will also be collected.~Tumor samples will be collected from biopsies taken in the course of routine practice and from surgical specimens collected during surgical procedure."
79512438|NCT06219187|Other|Questionnaire completion|"To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~Demographics~Disease data"
79512439|NCT06218472|Other|Day Hospital Treatment|Scheduling of 12 half-day sessions per week, alternating between sessions with only the patients or involving the entire family. Close medical monitoring and multidisciplinary interventions during sessions (pediatrician, psychiatrist, dietitian, recovered former patients...).
79512440|NCT06218472|Other|"Multidisciplinary follow-up as usual within the service"|"Multidisciplinary follow-up as usual within the service"
79512441|NCT06218472|Other|Conduct semi-structured qualitative interviews|Conduct semi-structured qualitative interviews
79512442|NCT06217679|Other|Control Oral Glucose Tolerance Test|control oral glucose tolerance test
79512443|NCT06217679|Other|Mixed Exercise|exercise performed in randomized order
79512444|NCT06217627|Biological|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
79512445|NCT06216275|Behavioral|Integrated Snoezelen-Aromatherapy-Personal Item Therapy|"Intervention Description:~This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation.~Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals.~Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized"
79512446|NCT06214741|Drug|BI 456906|once weekly subcutaneous injection
79512447|NCT06214741|Drug|Placebo matching BI 456906|Once weekly subcutaneous injection
79512448|NCT06211569|Other|Usual follow-up|Usual follow-up
79512449|NCT06209879|Drug|SYSTANE™ Hydration Lubricant Eye Drops|SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid [HA] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
79671791|NCT00464724|Procedure|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
79671792|NCT04702490|Drug|MET409 Active|MET409 Active (50mg)
79512450|NCT06208514|Behavioral|Brief pain exposure therapy (BPET)|"Participants will complete daily logs for 7-days pre-treatment baseline, along with 21 days during the intervention protocol, and 7 for days post-treatment.~Brief Pain Exposure Therapy will be given for 3 weeks, 1.5 hours per week, telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, mindfulness meditation, and graded exposure techniques for improving tolerance of painful or feared activities. Participants will also be provided handouts and pre-recorded meditation and imagery scripts that participants can use to facilitate between-session practices. In addition, participants will complete surveys through-out the study."
79361359|NCT05140915|Behavioral|Gamification|Gamification, designed to motivate participation
79361360|NCT05140915|Other|E-Cigarette Cessation Materials|Written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
79361361|NCT05134363|Drug|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
79512451|NCT06208501|Diagnostic Test|Urine sample for proteomic analysis|Urine sample for proteomic analysis in screen visit (before renal denervation procedure).
79512452|NCT06208501|Diagnostic Test|ABPM|ABPM in screen visit and 3 months after renal denervation procedure.
79993515|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
79361362|NCT05134363|Drug|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
79361363|NCT05134363|Drug|Placebo|equal volume of normal saline
79361364|NCT05113758|Diagnostic Test|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
79361365|NCT05110976|Drug|AZD8630|Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
79512453|NCT06208501|Diagnostic Test|OBPM|OBPM in screen visit and 3 months after renal denervation procedure.
79512454|NCT06205043|Device|StimSearch programming algorithm software|This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease
79671793|NCT04702490|Drug|MET409 Placebo|MET409 Placebo (50mg)
79993516|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
79993517|NCT02954159|Drug|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
79993518|NCT02954159|Drug|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
79993519|NCT02954159|Other|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
79361366|NCT05110976|Drug|Placebo|Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
79361367|NCT05104658|Other|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
79361368|NCT05091060|Device|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
79361369|NCT05078047|Drug|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
79361370|NCT05072743|Device|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
79361371|NCT05072340|Behavioral|Resilience Skills Enhancement (RISE)|The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton & Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
79512455|NCT06205043|Device|Clinician based programming|This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease
79512456|NCT06204237|Drug|[89Zr]Zr-DFO-APAC|All participants will receive a single i.v. injection of [89Zr]Zr-DFO-APAC 15 MBq (Megabecquerel).
79512457|NCT06204237|Radiation|PET/CT scan|The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
79512458|NCT06203041|Dietary Supplement|Vitamin D|Orally administered, daily dose of 5000 IU (125 mcg) Vitamin D3 for 28 days.
79512459|NCT06202664|Procedure|Erector Spinae Block|Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.
79512460|NCT06202664|Drug|Opioid Analgesic|This group of patient will receive general anesthesia induction with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given towards the end of surgery if suggested by intra-operative course.
79512461|NCT06202248|Device|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
79512462|NCT06202118|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
79512463|NCT06202066|Procedure|Biospecimen Collection|Undergo blood sample collection
79512464|NCT06202066|Procedure|Computed Tomography|Undergo CT scan
79512465|NCT06202066|Biological|Incomplete Freund''s Adjuvant|Given SC
79512466|NCT06202066|Procedure|Magnetic Resonance Imaging|Undergo MRI
79671794|NCT04702490|Drug|Empagliflozin|Empagliflozin (10mg)
79671795|NCT00464763|Drug|Dexmedetomidine|
79512467|NCT06202066|Biological|Sargramostim|Given SC
79512468|NCT06202066|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
79512469|NCT06202066|Drug|Temozolomide|Given PO
79512470|NCT06199817|Behavioral|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
79512471|NCT06196580|Drug|repaglinide; midazolam; SHR4640|repaglinide; midazolam; SHR4640
79512472|NCT06196580|Drug|repaglinide; midazolam; SHR4640; SHR4640 placebo|repaglinide; midazolam; SHR4640; SHR4640 placebo
79512473|NCT06196580|Drug|repaglinide; midazolam; SHR4640 placebo|repaglinide; midazolam; SHR4640 placebo
79512474|NCT06195956|Other|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
79512475|NCT06192979|Drug|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
79512476|NCT06192979|Drug|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
79671796|NCT00464763|Drug|Placebo|
79671797|NCT00434135|Drug|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&8
79671798|NCT00472563|Drug|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
79671799|NCT01050530|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
79671800|NCT01050530|Drug|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
79512477|NCT06192979|Drug|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
79512478|NCT06192979|Drug|Venetoclax|All patients received venetoclax 400mg daily.
79671801|NCT03272880|Behavioral|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
79671802|NCT01050257|Drug|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
79671803|NCT01050257|Drug|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
79671804|NCT03272802|Drug|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
79671805|NCT03272802|Drug|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
79671806|NCT00472719|Biological|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
79671807|NCT00472719|Biological|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
79671808|NCT00472719|Biological|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
79361372|NCT05068648|Other|Manual Wheelchair (MWC) backrest configuration|Wheelchair backrest fitting, postural and functional assessment
79361373|NCT05063435|Diagnostic Test|Carotid ultrasonography|"Study takes 10 - 15 minutes to complete~Subject will be asked to lay still and quietly during procedure~The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~Blood pressure and heart rate will be obtained during the study~Results will be anonymized, digitized and stored on CD with unique identifier"
79512479|NCT06192069|Other|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
79671809|NCT01050062|Drug|Telmisartan 80mg|Combination tablet
79671810|NCT01050062|Drug|Telmisartan 40mg|Combination tablet
79671811|NCT01050062|Drug|Hydrochlorothiazide 12.5mg|Combination tablet
79671812|NCT00464802|Drug|MOA-728|
79671813|NCT00464841|Procedure|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
79671814|NCT00464841|Procedure|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
79512480|NCT06191159|Device|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
79512481|NCT06191159|Device|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
79512482|NCT06191159|Device|Standard Electrocautery|Standard Electrocautery for entire surgery.
79512483|NCT06189742|Biological|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
79671815|NCT00464880|Drug|Aliskiren|
79671816|NCT00464919|Drug|Sorafenib|
79361374|NCT05063435|Diagnostic Test|Echocardiography, transthoracic|"Study takes 15 - 20 minutes to complete~Subject will be asked to lay still and quietly during procedure~The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~Results will be digitized and stored on CD"
79820043|NCT03971552|Procedure|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
79820044|NCT05285358|Drug|Cisplatin|Given IV
79820045|NCT05285358|Drug|Gemcitabine|Given IV
79820046|NCT05285358|Drug|Nab-paclitaxel|Given via PIPAC
79820047|NCT05285358|Other|Quality-of-Life Assessment|Ancillary studies
79820048|NCT05285358|Other|Questionnaire Administration|Ancillary studies
79993520|NCT01311245|Behavioral|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
79361375|NCT05063435|Procedure|Venipuncture|"10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
79671817|NCT00464919|Drug|tegafur/uracil (UFUR®)|
79671818|NCT00434174|Drug|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
79820049|NCT00746330|Drug|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
79820050|NCT00746330|Drug|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
79993521|NCT01311245|Behavioral|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
79361376|NCT05063045|Behavioral|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
79512484|NCT06188624|Drug|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
79512485|NCT06183203|Procedure|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
79512486|NCT06183203|Procedure|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
79512487|NCT06181370|Drug|AGMB-447|AGMB-447 inhaled drug
79512488|NCT06181370|Other|placebo|placebo inhaled drug
79512489|NCT06171789|Drug|PRO1107|Intravenous infusion of PRO1107
79512490|NCT06170190|Biological|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
79671819|NCT00434174|Drug|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
79671820|NCT00464958|Drug|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
79671821|NCT01055912|Drug|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
79671822|NCT01055912|Drug|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
79820051|NCT00746330|Drug|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
79820052|NCT00746330|Drug|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
79820053|NCT00746330|Drug|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
79820054|NCT00714207|Behavioral|NOT program|Students in this arm of the study received the reformatted NOT intervention
79361377|NCT05059834|Behavioral|online mindfulness resources|a free mindfulness resource online for patients with general anxiety disorder
79361378|NCT05059834|Behavioral|usual care|patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
79361379|NCT05057026|Other|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~the use of contact-based education,~skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
79361380|NCT05056662|Diagnostic Test|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
79361381|NCT05056311|Other|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
79361382|NCT05054309|Dietary Supplement|Bifidobacterium longum|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
79361383|NCT05047510|Drug|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
79361384|NCT05046704|Device|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
79361385|NCT05043961|Procedure|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
79361386|NCT05034224|Device|Swan-Ganz catheter placed in the coronary sinus - deflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
79361387|NCT05034224|Device|Swan-Ganz catheter placed in the coronary sinus - inflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
79361388|NCT05028881|Other|blood sampling|blood sampling for determining antibody responses
79361389|NCT05020899|Behavioral|Sessions with a trained counselor|4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
79361390|NCT05020899|Other|Cell phone messages|Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
79993522|NCT03442829|Behavioral|Sweet food consumption|Sweet food consumption at breakfast
79993523|NCT03442829|Behavioral|Non-sweet food consumption|Non-sweet food consumption at breakfast
79512491|NCT06170047|Behavioral|Chicago Parent Program for Foster Care|CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.
79512492|NCT06170047|Other|Usual Care|The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
79671823|NCT00472758|Biological|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
79820055|NCT00714207|Behavioral|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
79820056|NCT00714207|Behavioral|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
79820057|NCT00714207|Behavioral|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
79993524|NCT05218512|Other|WB-EMS|"The group has been submitted to 2 experimental conditions:~At rest with superimposed WB-EMS.~During uphill walking exercise with superimposed WB-EMS."
79993525|NCT03442595|Other|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
79361391|NCT05020899|Other|Offered nicotine replacement therapy|Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
79361392|NCT05020899|Other|Self-help guide for quitting smoking|Participants will be offered a self-help guide with information about quitting smoking.
79361393|NCT05008120|Other|No intervention|No intervention
79361394|NCT05000385|Other|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
79671824|NCT00472758|Other|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
79361395|NCT05000385|Diagnostic Test|body mass index|as an indication of nutritional status
79361396|NCT04997109|Other|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
79671825|NCT01055444|Drug|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
79671826|NCT01055015|Drug|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
79671827|NCT01055015|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
79671828|NCT00472875|Drug|Glibenclamide|
79671829|NCT00434291|Drug|TG-873870(Nemonoxacin)|
79671830|NCT03275051|Other|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
79671831|NCT00434369|Drug|CoFactor (ANX-510)|
79671832|NCT00472914|Device|portable surface electromyography|
79671833|NCT00434447|Drug|Zoledronic acid|
79671834|NCT00472953|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
79671835|NCT00472953|Drug|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
79671836|NCT02957630|Drug|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
79671837|NCT02957630|Drug|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
79820058|NCT02590224|Drug|Ferrous bis-glycinate|
79993526|NCT03717311|Other|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
79361397|NCT04997109|Behavioral|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
79361398|NCT04997109|Behavioral|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
79361399|NCT04982328|Diagnostic Test|Th17 cytokine profile|Screening for the components of metabolic syndrome
79361400|NCT04982328|Diagnostic Test|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
79361401|NCT04982328|Diagnostic Test|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
79361402|NCT04978610|Behavioral|Virtual Acceptance Commitment Therapy|"For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes."
79361403|NCT04978129|Behavioral|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
79361404|NCT04965649|Genetic|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
79361405|NCT04953767|Device|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
79361406|NCT04953767|Other|White light|White light is used as sham control.
79361407|NCT04948671|Other|there will be no intervention, this is an observational study|this is an observational study
79512493|NCT06167083|Diagnostic Test|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
79512494|NCT06166082|Device|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
79512495|NCT06166082|Device|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
79671838|NCT02957630|Drug|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
79671839|NCT00465036|Dietary Supplement|Whole flaxseeds, flaxseed mucilage, glucomannan|
79679728|NCT02949206|Drug|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
79820059|NCT02590224|Drug|Ferrous glycine sulphate|
79820060|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
79820061|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
79820062|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
79820063|NCT05340816|Other|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
79820064|NCT05340816|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
79993527|NCT03763422|Drug|Temozolomide|Oral Administration of Temozolomide
79993528|NCT03763422|Radiation|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
79993529|NCT03763422|Procedure|Surgery|Surgery
79361408|NCT04948632|Other|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
79361409|NCT04948632|Other|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
79993530|NCT05658029|Drug|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
79993531|NCT05520281|Behavioral|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
79361410|NCT04942665|Drug|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
79361411|NCT04942665|Device|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
79512496|NCT06163274|Device|Placebo Intravaginal Ring A|Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.
79512497|NCT06163274|Device|Placebo Intravaginal Ring B|Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.
79512498|NCT06161831|Behavioral|Text Message/automated phone reminder|Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
79512499|NCT06161519|Drug|PLX038|PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
79512500|NCT06157502|Drug|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
79512501|NCT06157502|Other|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
79671840|NCT04702061|Other|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
79993532|NCT03715049|Procedure|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device [510(k) approval] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
79361412|NCT04934748|Drug|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
79361413|NCT04934748|Drug|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
79361414|NCT04934748|Drug|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
79361415|NCT04934748|Drug|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
79361416|NCT04895982|Biological|BNT162b2|Intramuscular Injection
79361417|NCT04895605|Device|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
79512503|NCT06149793|Drug|Empagliflozin|Sodium glucose co-transporter 2 inhibitor
79512504|NCT06149793|Other|Placebo Control|Placebo Control
79512505|NCT06146686|Device|Fanta AF blue rotary files 20 taper 4|single rotary file Fanta AF blue rotary files 20 taper 4
79512506|NCT06146686|Device|Fanta AF baby rotary files 20 , 25 , 30 taper 4|multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
79512507|NCT06145724|Behavioral|Maternal Sepsis Safety Bundle|Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
79512508|NCT06138795|Drug|AZD2389|Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
79512509|NCT06138795|Drug|Placebo|Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
79512510|NCT06138249|Dietary Supplement|Vitamin D|Vitamin D
79512511|NCT06134830|Drug|RAI|Radioactive iodine
79512512|NCT06133179|Procedure|Transtemporal ultrasound with contrast product (Sonovue)|"During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke"
79512513|NCT06133075|Drug|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
79512514|NCT06133075|Drug|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
79512515|NCT06128915|Other|vaccine|Vaccination against 20 serotypes of S. pneumoniae
79512516|NCT06127004|Other|Metacognitive Training for Negative Symptoms (MCT)|See arm/group descriptions
79512517|NCT06127004|Other|Supportive Counselling|Se arm/group descriptions
79512518|NCT06126796|Diagnostic Test|CxBladder Monitor|CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.
79512519|NCT06126796|Diagnostic Test|Cystoscopy|Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.
79512520|NCT06124196|Device|wearable technology|Three wearable devices
79512521|NCT06123013|Behavioral|Music Assisted Relation Intervention (MARI)|A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
79512522|NCT06122740|Other|Turkish Validity and Reliability of The MAM-36 Scale|The aim of this study is to adapt the Manual Ability Measure-36 (MAM-36) scale to Turkish society and to make its validity and reliability in Turkish.
79512523|NCT06121635|Combination Product|Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.
79512524|NCT06121635|Combination Product|Sham ts-DCS and sham t-DCS|Sham ts-DCS and sham t-DCS
79671841|NCT04702061|Other|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
79993533|NCT03714971|Behavioral|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
79993534|NCT03712007|Device|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
79993535|NCT03712007|Device|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
79993536|NCT05218122|Other|cross-sectional study without intervention|cross-sectional study without intervention
79361418|NCT04895605|Device|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
79993537|NCT03695406|Behavioral|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
79993538|NCT03633786|Procedure|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
79993539|NCT03633786|Procedure|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
79993540|NCT03633786|Diagnostic Test|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
79993541|NCT03633786|Diagnostic Test|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
79993542|NCT03633786|Diagnostic Test|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
79993543|NCT03421392|Other|non interventional study|non interventional study
79993544|NCT05217732|Drug|ZX-7101A|tablet
79993545|NCT05217732|Drug|Placebo|Tablet
79993546|NCT05217576|Device|NBM-200|Finger Prick and Venipuncture
79993547|NCT03440411|Drug|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
79993548|NCT03440411|Drug|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
79993549|NCT03440411|Drug|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
79361419|NCT04894500|Diagnostic Test|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
79671842|NCT00465075|Drug|Bazedoxifene/conjugated estrogens combination|
79671843|NCT00434486|Drug|SKI-606|
79993550|NCT03714893|Device|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
79308266|NCT02503553|Behavioral|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
79361420|NCT04889495|Drug|Zirabev|Bevacizumab biosimilar
79361421|NCT04868591|Other|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
79671844|NCT00465114|Procedure|Hemodynamic Monitoring|
79671845|NCT00434525|Procedure|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
79671846|NCT00434525|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
79671847|NCT00465153|Dietary Supplement|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
79671848|NCT00465153|Behavioral|Resistance exercise training|Resistance training
79671849|NCT02957552|Biological|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
79671850|NCT00465192|Drug|estradiol, 10 mcg|
79671851|NCT00465192|Drug|estradiol, 25 mcg|
79361422|NCT04868591|Other|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
79361423|NCT04856319|Procedure|Dental implant placement|Insertion of not more than two dental implants at the same area
79512525|NCT06120699|Other|Pelvic floor muscle training with 360 degree expanded diaphragm exercises|Women in this group will be taught 360-degree expanded diaphragm exercises with the Ohmbelt device. Two Ohmbelt devices will be used in this study. The anterior sensor will be placed in the inguinal cavity to visualize the expansion of the anterior abdominal wall, and the posterior sensor will be placed contralaterally in the upper lumbar triangle to visualize the expansion of the posterior wall. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.
79361424|NCT04856319|Drug|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
79361425|NCT04856319|Other|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
79361426|NCT04852796|Other|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
79361427|NCT04830813|Drug|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
79361428|NCT04830813|Drug|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
79361429|NCT04813120|Behavioral|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
79361430|NCT04813120|Behavioral|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
79361431|NCT04813120|Behavioral|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
79512526|NCT06120699|Other|Pelvic floor muscle training with standard diaphragm exercises|"Women in this group will be taught standard diaphragm exercises. In the supine position, with the head and knees supported by a pillow, the patient will first be asked to close his or her eyes to focus. With one hand on the chest and the other hand on the abdomen, Take a deep breath through your nose and direct all the air as much as possible under your lower hand. inflate your belly. Now exhale all the air slowly through your mouth. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied."
79512527|NCT06119061|Drug|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
79671852|NCT00465192|Drug|placebo|
79361432|NCT04813120|Behavioral|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
79361433|NCT04806503|Drug|UNR844|Ophthalmic solution for topical ocular administration
79993551|NCT03717233|Device|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
79512528|NCT06115057|Dietary Supplement|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
79512529|NCT06113237|Drug|Epidiolex|Oral solution
79820065|NCT00746252|Drug|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
79993552|NCT03714737|Biological|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
79361434|NCT04806503|Drug|Placebo|Placebo
79512530|NCT06112652|Device|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
79512531|NCT06112652|Device|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
79512532|NCT06112652|Device|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
79993553|NCT03714737|Biological|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
79993554|NCT03714737|Biological|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
79993555|NCT03438539|Behavioral|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
79993556|NCT03438539|Behavioral|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
79361435|NCT04788108|Drug|Dydrogesterone|Dydrogesterone tablet
79361436|NCT04788108|Drug|Placebo|Placebo tablet
79361437|NCT04747405|Other|therapy group|therapy group of maximum 8 people repeated twice
79361438|NCT04741724|Device|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
79361439|NCT04741438|Drug|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
79361440|NCT04741438|Drug|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
79361441|NCT04731961|Procedure|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
79361442|NCT04731961|Procedure|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
79361443|NCT04692337|Procedure|Intra-operative Ommaya Reservoir placement|An Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
79512533|NCT06112652|Device|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
79512534|NCT06112652|Device|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
79671853|NCT00434564|Procedure|Stress nuclear scan|
79820066|NCT00746252|Drug|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
79820067|NCT02574975|Drug|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
79820068|NCT02574975|Drug|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
79820069|NCT02574975|Drug|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
79993557|NCT03438539|Behavioral|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
79993558|NCT05656625|Other|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
79993559|NCT03400787|Device|Latera Implant|Treatment with implant
79993560|NCT03400787|Device|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
79993561|NCT03639077|Device|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
79993562|NCT03639077|Device|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
79361444|NCT04682652|Device|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
79361445|NCT04675411|Device|Smart care|Home based nursing intervention with smart assisted technology
79361446|NCT04675411|Device|usual care|Routine hospital care with only in-hospital rehabilitation
79993563|NCT03417245|Drug|fitusiran|by SC injection
79993564|NCT03417245|Drug|factor concentrates|by intravenous (IV) injection
79993565|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
79993566|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
79993567|NCT03711851|Other|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
79512535|NCT06109441|Biological|ALTB-268|ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
79512536|NCT06108206|Other|Adaptive Radiotherapy|"Each patient will undergo a brain MRI at the following time points:~Baseline- within 2 weeks prior to the start of chemo-RT,~Week #1- on Fractions # 4 or 5~Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~Week #6- +/- 3 days of Fraction #30 (end of RT)"
79512537|NCT06103968|Device|LMA BLOCKBUSTER|In this study we wish to evaluate weather gastric tube inserted through LMA helps in maintaining the LMA blockbuster placement by comparing fibreoptic bronchoscope (FOB) scores recorded immediately after LMA placement and at the end of the surgical procedure.
79671854|NCT00434603|Behavioral|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
79671855|NCT00434681|Drug|paracetamol 4.8% paediatric oral suspension|
79671856|NCT00473070|Drug|Tobradex AF|
79671857|NCT03272646|Procedure|surgery|gastric resection or total gastrectomy
79671858|NCT00434798|Biological|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10^6-10^9 CFU
79671859|NCT00473109|Procedure|Dialysis without systemic heparinization|Dialysis without systemic heparinization
79993568|NCT03389555|Drug|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
79671860|NCT00434915|Drug|DHEA|
79671861|NCT00473148|Procedure|BNP-guided weaning|BNP-guided weaning
79671862|NCT00473148|Procedure|Standard physician-directed weaning|Standard physician-directed weaning
79671863|NCT00435032|Procedure|early appendectomy|Appendectomy within 24 hours of admission
79993569|NCT03389555|Drug|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
79671864|NCT00435032|Procedure|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
79671865|NCT00435071|Procedure|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
79671866|NCT00435071|Procedure|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
79671867|NCT00473187|Drug|somatropin|
79671868|NCT00435110|Procedure|standard ventilatory settings|
79671869|NCT00435110|Procedure|PEEP and FiO2|
79671870|NCT00473304|Device|Johnson&Johnson Acuevue daily disposable lenses|
79671871|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
79671872|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
79679729|NCT02949206|Drug|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
79679730|NCT02949206|Drug|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
79679731|NCT02939001|Device|iris recognition scanner|
79671873|NCT03272568|Drug|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
79993570|NCT03714581|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
79671874|NCT03272568|Drug|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
79671875|NCT03272568|Device|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
79671876|NCT00435227|Biological|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
79993571|NCT03711461|Device|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
79361447|NCT04675073|Procedure|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
79361448|NCT04672655|Behavioral|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM & social situations; Session 4: Building trust with your CGM
79361449|NCT04671693|Other|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
79361450|NCT04660331|Other|Communication Intervention|Undergo communication strategy intervention
79361451|NCT04660331|Other|Communication Skills Training|Undergo communication training sessions
79361452|NCT04660331|Behavioral|Healthcare Activity|Participate in interview
79361453|NCT04660331|Behavioral|Healthcare Activity|Undergo environmental scan
79512538|NCT06100575|Behavioral|Website (www.mee-leven.be)|"The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives"
79993572|NCT03711461|Device|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
79361454|NCT04660331|Other|Survey Administration|Complete survey
79512539|NCT06095778|Device|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
79361455|NCT04648540|Drug|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~Dexmedetomidine 0.5 mic/kg/h~Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
79361456|NCT04648540|Drug|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
79512540|NCT06092892|Procedure|Breast Surgery (BCS or mastectomy) with TAD/SNB|Breast surgery (BCS or mastectomy) with TAD/SNB & Adjuvant Radiation therapy
79512541|NCT06092892|Radiation|Adjuvant Radiation Therapy|Breast surgery (BCS or mastectomy) with TAD/SNB & Adjuvant Radiation therapy
79671877|NCT00435227|Other|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
79361457|NCT04645823|Drug|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
79361458|NCT04645823|Drug|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
79361459|NCT04645823|Drug|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
79361460|NCT04645628|Other|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
79361461|NCT04629508|Drug|itacitinib|itacitinb Immediate Release (IR) will be dosed orally twice a day
79361462|NCT04602468|Drug|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
79361463|NCT04594382|Diagnostic Test|Pupillometry-Opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes."
79512542|NCT06092489|Other|graded motor imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
79512543|NCT06092489|Other|traditional physiotherapy method|This protocol included stretching and strengthening exercises. Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening.
79671878|NCT02956512|Drug|Dexibuprofen|Dexibuprofen 300mg
79512544|NCT06091254|Drug|Odronextamab|Administered by intravenous infusion (IV)
79512545|NCT06091254|Drug|Rituximab|Rituximab will be administered by IV, or subcutaneously (SC)
79671879|NCT00465309|Procedure|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat < 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH > 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
79308267|NCT02503553|Behavioral|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
79361464|NCT04594382|Diagnostic Test|Pupillometry -standardized opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes."
79361465|NCT04579094|Other|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
79361466|NCT04573543|Diagnostic Test|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
79361467|NCT04573543|Diagnostic Test|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
79361468|NCT04573543|Diagnostic Test|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
79361469|NCT04573543|Diagnostic Test|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
79361470|NCT04558112|Drug|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
79361471|NCT04558112|Drug|Placebo|two gel capsules of placebo
79361472|NCT04532866|Behavioral|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
79361473|NCT04530071|Biological|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10^7 cells)
79512546|NCT06091254|Drug|Cyclophosphamide|Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy
79512547|NCT06091254|Drug|Doxorubicin|Administered by IV as part of CHOP chemotherapy
79512548|NCT06091254|Drug|Vincristine|Administered by IV as part of CHOP, and CVP chemotherapy
79512549|NCT06091254|Drug|Prednisone/prednisolone|Administered orally (PO) as part of CVP chemotherapy
79512550|NCT06091254|Drug|Bendamustine|Administered by IV as part of chemotherapy (Rituximab-Bendamustine)
79512551|NCT06089551|Drug|SmofKabiven|Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
79512552|NCT06088667|Other|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
79512553|NCT06082739|Other|Exercises|Stretching exercises with and without a bolster, ball, or foam roller.
79820070|NCT02574975|Device|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
79820071|NCT02574975|Drug|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
79820072|NCT00718770|Drug|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
79820073|NCT00714363|Procedure|LASIK|Refractive surgery
79820074|NCT00714363|Procedure|SBK|Refractive surgery
79512559|NCT06078579|Diagnostic Test|Leptin|Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
79512560|NCT06077565|Other|foot-in-the-door technique and self-determination theory|the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.
79993573|NCT03395639|Drug|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to <18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
79993574|NCT03395639|Drug|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
79993575|NCT03353922|Drug|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
79993576|NCT03353922|Drug|Placebo Oral Tablet|sugar pill
79993577|NCT05677932|Device|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
79993578|NCT05677932|Device|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
79361474|NCT04530071|Biological|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10^7 cells)
79993579|NCT03711383|Dietary Supplement|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
79361475|NCT04530071|Biological|Placebo|HA + saline + placebo comparator
79361476|NCT04519775|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
79361477|NCT04508751|Other|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
79361478|NCT04506255|Device|Silicone tape|Medical grade tape with silicone adhesive
79361479|NCT04489225|Other|Observational|Observational only without any intervention
79361480|NCT04473482|Behavioral|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
79361481|NCT04472936|Procedure|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is >80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
79361482|NCT04472936|Procedure|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
79361483|NCT04467619|Device|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory & motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
79361484|NCT04440735|Biological|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
79361485|NCT04440735|Biological|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
79361486|NCT04432311|Behavioral|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
79361487|NCT04432311|Behavioral|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
79361488|NCT04422392|Drug|Carboplatin|(IV, Q3W)
79361489|NCT04422392|Drug|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
79361490|NCT04422392|Drug|PD-1 antibody|(IV, Q3W)
79671880|NCT04702334|Drug|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
79671881|NCT04702334|Drug|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
79671882|NCT00473421|Procedure|Barium Sulphate and Zirconium Oxide|
79993580|NCT03711383|Dietary Supplement|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
79993581|NCT03711383|Dietary Supplement|Placebo|isocaloric maltodextrin before test day
79820075|NCT02599142|Device|Group A: Closed-face shell|As for arm description
79820076|NCT02599142|Device|Group B: Open-face shell|As for arm description
79993582|NCT03387683|Drug|dapagliflozin|dapagliflozin 10mg
79361491|NCT04414761|Drug|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
79361492|NCT04414761|Drug|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
79361493|NCT04400994|Drug|Rituximab|"Rituximab would be given intravenously.~IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~Maximum infusion rate is 400 mg/hr (400 ml/hr)~Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
79361494|NCT04400994|Other|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min & beyond: 180ml/hour"
79361495|NCT04378062|Procedure|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
79361496|NCT04372485|Behavioral|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
79512561|NCT06077565|Other|Follow-up booster intervention|For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.
79671883|NCT04702412|Other|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
79671884|NCT00465387|Behavioral|Falls, Fractures & Osteoporosis Risk Assessment & Management|
79671885|NCT00435266|Procedure|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
79993583|NCT03387683|Drug|placebo|placebo to match dapagliflozin
79993584|NCT03714347|Device|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
79993585|NCT03714347|Device|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
79993586|NCT05467553|Drug|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
79993587|NCT05467553|Drug|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
79993588|NCT05467553|Drug|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
79993589|NCT03387059|Device|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
79993590|NCT02942004|Drug|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
79993591|NCT02942004|Drug|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
79993592|NCT02942004|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
79671886|NCT00473460|Drug|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
79671887|NCT00473460|Drug|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
79671888|NCT00435305|Drug|Meropenem|
79671889|NCT00435305|Drug|Vancomycin|
79671890|NCT00435305|Drug|Linezolid|
79671891|NCT00435305|Drug|Piperacillin/Tazobactam|
79671892|NCT00435305|Drug|Cefepim|
79671893|NCT00435305|Drug|Ceftazidim|
79993593|NCT03394391|Behavioral|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
79993594|NCT03394391|Behavioral|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
79993595|NCT03711695|Device|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
79993596|NCT01311791|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
79993597|NCT01311791|Drug|Standard medical therapy|as defined per protocol
79993598|NCT03714269|Other|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
79820077|NCT02590302|Other|Implementation Phase|"Core Components of the implementation intervention include:~Hospital and CMHA project commitment~Site champion teams (from hospital and CMHA)~Memorandum of Agreement between Hospital and CMHA~Pre-intervention site visits~Education sessions~Posters/reminders~Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
79993599|NCT03714269|Other|measurement evaluated with an 2D ultrasound|"simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
79993600|NCT03714269|Other|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
79993601|NCT01311869|Dietary Supplement|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
79993602|NCT01311869|Dietary Supplement|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
79993603|NCT03386435|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
79993604|NCT03714191|Other|Patient Outcomes|The intervention includes different versions of the BPA design and message.
79993605|NCT03714191|Other|Billing documentation|The intervention includes different versions of the BPA design and message.
79993606|NCT03714191|Other|Regulatory|The intervention includes different versions of the BPA design and message.
79361497|NCT04354233|Device|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
79361498|NCT04318678|Drug|CD123-CAR T|To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
79361499|NCT04318678|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
79512562|NCT06077565|Other|Control group|The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
79512563|NCT06077396|Procedure|radial artery cannulation|radial artery cannulation
79993607|NCT02912208|Drug|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
79993608|NCT02912208|Other|Placebo|The administration is the same of eltrombopag
79993609|NCT02793258|Device|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
79993610|NCT02726880|Behavioral|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
79993611|NCT02726880|Behavioral|Referral for care|Referral for mental health issues and family support services
79993612|NCT03275389|Biological|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
79512564|NCT06076746|Behavioral|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
79993613|NCT03275389|Biological|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
79361500|NCT04318678|Drug|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
79993614|NCT03275389|Biological|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
79361501|NCT04318678|Drug|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
79361502|NCT04318678|Drug|Rituximab|Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
79361503|NCT04315142|Device|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
79512565|NCT06076746|Behavioral|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
79512566|NCT06076213|Drug|Artesunate-amodiaquine|Tablets
79512567|NCT06076213|Drug|Artemether-lumefantrine|Tablets
79512568|NCT06076135|Radiation|Intestinal Low Dose Radiotherapy-1Gy|ILDR will be administered as single fractions every 3 weeks (Q3W). The total dose of radiotherapy was 1 Gy in 1 fractions. The radiation treatment volume included the jejunum and ileum.
79512569|NCT06076135|Radiation|Intestinal Low Dose Radiotherapy-2Gy|ILDR will be administered as single fractions every 3 weeks (Q3W). The total dose of radiotherapy was 2 Gy in 2 fractions. The radiation treatment volume included the jejunum and ileum.
79993615|NCT03275389|Biological|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
79512570|NCT06076135|Radiation|Intestinal Low Dose Radiotherapy-3Gy|ILDR will be administered as single fractions every 3 weeks (Q3W). The total dose of radiotherapy was 3 Gy in 3 fractions. The radiation treatment volume included the jejunum and ileum.
79512571|NCT06076135|Drug|PD-1 Inhibitors|The immunotherapy regimen is determined by the physician in charge. PD-1 inhibitors were given on the day after each ILDR, with a treatment frequency of once every 3 weeks（Q3W） until progression.
79512572|NCT06074406|Device|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO
79512573|NCT06073821|Drug|Sonrotoclax|Administered orally
79512574|NCT06073821|Drug|Zanubrutinib|Administered orally
79993616|NCT03275389|Biological|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
79512575|NCT06073821|Drug|Venetoclax|Administered orally
79993617|NCT03275389|Biological|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
79512576|NCT06073821|Drug|Obinutuzumab|Administered intravenously
79512577|NCT06070701|Procedure|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
79512578|NCT06070701|Procedure|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
79512579|NCT06070701|Drug|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
79361504|NCT04315142|Device|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
79361505|NCT04310358|Other|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
79361506|NCT04310358|Other|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
79361507|NCT04307238|Diagnostic Test|PLR|PLR measurements will be performed within the first 2 postoperative hours.
79820078|NCT04561791|Device|Tethered Capsule Endomicroscopy|Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
79361508|NCT04307238|Diagnostic Test|Alertness testing|Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
79512580|NCT06070701|Drug|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
79993618|NCT03275389|Biological|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
79671894|NCT00435344|Behavioral|Pediatric Practice-Based Smoking Intervention|
79361509|NCT04307238|Procedure|Propofol anesthesia|Maintenance of anesthesia will be performed using propofol.
79361510|NCT04307238|Procedure|Sevoflurane anesthesia|Maintenance of anesthesia will be performed using sevoflurane.
79512581|NCT06067828|Drug|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
79512582|NCT06067828|Drug|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
79512583|NCT06067828|Drug|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
79512584|NCT06066554|Device|Puva (psoralin and uva )|Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
79512585|NCT06062342|Behavioral|FPI|The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
79671895|NCT00473499|Device|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
79671896|NCT00465465|Biological|MVA 85A|i.d. injection
79671897|NCT00465504|Procedure|iontophoresis|See Detailed Description.
79671898|NCT00435422|Procedure|Stroke volume optimization|Stroke volume optimization
79671899|NCT00465543|Other|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
79671900|NCT00465543|Other|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
79671901|NCT00435500|Drug|Fluoride varnish|
79671902|NCT03272412|Diagnostic Test|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
79671903|NCT00435578|Drug|Glufosfamide|
79671904|NCT00435617|Device|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
79671905|NCT00435695|Drug|GSK163090|
79671906|NCT00473538|Behavioral|Structured exercise training|
79671907|NCT00473538|Behavioral|Hypocaloric hyperproteic diet|
79671908|NCT00473577|Drug|CRA-24781|
79671909|NCT00473616|Drug|AZD7762|intravenous infusion
79671910|NCT00473616|Drug|Irinotecan|intravenous injection
79671911|NCT00435734|Behavioral|obesity intervention|
79671912|NCT00481221|Procedure|Observation of results from laboratory tests|Laboratory data summary only
79671913|NCT00435773|Procedure|Single Leeching|
79671914|NCT00435773|Procedure|Repeated Leeching after 4 weeks|
79671915|NCT00435773|Procedure|Placebo Leeching|
79671916|NCT00473733|Procedure|GLP receptors expression|
79671917|NCT00473733|Procedure|ESOPHAGOGASTRODUODENOSCOPY|
79671918|NCT00481260|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
79671919|NCT00435851|Drug|Thyrogen, thyroid hormone withdrawal, iode 131|
79993619|NCT03275389|Biological|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
79993620|NCT03275389|Biological|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
79361511|NCT04289961|Diagnostic Test|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
79512586|NCT06057038|Biological|GEN1042|Intravenous
79512587|NCT06057038|Drug|Pembrolizumab|Intravenous
79512588|NCT06057038|Drug|Cisplatin|Intravenous
79512589|NCT06057038|Drug|Carboplatin|Intravenous
79512590|NCT06057038|Drug|5-Fluorouracil|Intravenous
79671920|NCT00435890|Behavioral|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
79671921|NCT00435968|Drug|CVT E002 (Cold-fX)|
79308268|NCT03212183|Behavioral|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
79308269|NCT03212183|Other|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
79361512|NCT04282642|Behavioral|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
79361513|NCT04282642|Behavioral|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
79361514|NCT04281940|Device|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
79512591|NCT06056518|Other|AI-based risk prediction for kidney graft loss|Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
79512592|NCT06055426|Other|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
79671922|NCT00481338|Procedure|X-rays|X-rays (hip and knee) every 2 years
79671923|NCT00481338|Biological|biological samples|biological sample (blood and urine) every 2 years
79671924|NCT00481338|Other|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
79671925|NCT00436085|Behavioral|Cognitive behavioral stress management training|
79993621|NCT03275389|Biological|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
79993622|NCT03275389|Biological|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
79993623|NCT03414359|Drug|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
79671926|NCT00473772|Device|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
79671927|NCT03272165|Drug|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
79671928|NCT03272165|Drug|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
79993624|NCT03414359|Drug|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
79993625|NCT03285295|Device|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79671929|NCT00481377|Procedure|ablation|
79671930|NCT00436124|Drug|oseltamivir [Tamiflu]|
79671931|NCT00473811|Behavioral|Low GI|low-GI education
79820079|NCT04084158|Drug|Toripalimab injection (JS001)|Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
79820080|NCT04084158|Drug|Paclitaxel, Albumin-Bound|Paclitaxel
79820081|NCT04084158|Radiation|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
79820082|NCT04084158|Drug|Platinum-Based Drug|carboplatin
79820083|NCT00714441|Behavioral|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
79820084|NCT00714441|Behavioral|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
79993626|NCT03285295|Device|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79512593|NCT06050070|Other|FMRI with sham controlled feedback|"During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real."
79671932|NCT00473811|Behavioral|ADA diet|ADA dietary education
79671933|NCT01240473|Drug|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
79993627|NCT03285295|Device|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79993628|NCT03285295|Device|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79993629|NCT03285295|Device|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79671934|NCT02957474|Drug|GED-0301|
79671935|NCT02957474|Drug|Omeprazole|
79361515|NCT04278534|Other|Educational Intervention|Complete radiation therapist-led education module using virtual reality
79361516|NCT04278534|Other|Educational Intervention|Receive the usual verbal and written education materials
79671936|NCT00481416|Device|PillCam Eso|
79671937|NCT00434720|Device|GlideScope Specific Stylet|
79671938|NCT00465231|Drug|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
79671939|NCT00465231|Drug|preservative free saline|10mL saline solution
79671940|NCT00436202|Behavioral|Iron supplement|
79671941|NCT00473928|Drug|POT-4|Single intravitreal injection.
79671942|NCT00436241|Drug|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
79671943|NCT00436241|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
79671944|NCT00481455|Drug|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
79671945|NCT00481455|Drug|Temozolomide|Fixed dose
79671946|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
79993630|NCT03285295|Device|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79361517|NCT04278534|Other|Educational Intervention|Complete radiation therapist-led face-to-face education module
79361518|NCT04278534|Other|Survey Administration|Ancillary studies
79993631|NCT02583048|Drug|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
79993632|NCT02583048|Drug|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
79361519|NCT04249557|Behavioral|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
79993633|NCT02583048|Drug|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
79993634|NCT02583048|Drug|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
79512594|NCT06050070|Other|FMRI with real time feedback|During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
79993635|NCT02939599|Drug|QCC374|0.015mg and 0.06mg
79993636|NCT05217186|Diagnostic Test|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
79993637|NCT05198622|Procedure|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
79361520|NCT04244656|Biological|CTX120|CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
79361521|NCT04237857|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
79361522|NCT04224571|Drug|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
79512595|NCT06049446|Device|Pintuition|Magnetic seed localization
79512596|NCT06049082|Drug|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
79512597|NCT06048978|Other|Commercial native starch without processing|A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
79671947|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
79671948|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
79361523|NCT04224571|Drug|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
79679732|NCT02949440|Procedure|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
79361524|NCT04222062|Drug|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
79361525|NCT04218604|Procedure|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
79361526|NCT04215029|Behavioral|Exercise Intervention|Receive exercise plan
79361527|NCT04215029|Other|Informational Intervention|Receive printed exercise materials
79361528|NCT04215029|Other|Informational Intervention|Receive physical activity and healthy eating information/materials
79361529|NCT04215029|Other|Interview|Participate in interview
79361530|NCT04215029|Other|Nutritional Assessment|Complete nutrition counseling sessions
79361531|NCT04215029|Other|Questionnaire Administration|Ancillary studies
79361532|NCT04215029|Behavioral|Telephone-Based Intervention|Receive coaching calls
79361533|NCT04211506|Behavioral|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
79361534|NCT04123054|Device|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
79512598|NCT06048978|Other|Modified starch with extrusion processing|A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
79993638|NCT05198622|Procedure|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
79993639|NCT05186766|Device|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
79993640|NCT05160714|Radiation|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
79361535|NCT04123054|Device|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
79512599|NCT06046157|Other|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
79512600|NCT06046157|Other|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
79512601|NCT06046040|Drug|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
79671949|NCT00436319|Procedure|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2<80 pg/ml and progesterone <1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
79671950|NCT00481533|Drug|Methyl-Ergonovine-Oxytocin|
79671951|NCT00481533|Drug|Oxytocin|
79671952|NCT00436358|Other|Not applicable: none|Please refer to the detailed description section
79308270|NCT04496843|Diagnostic Test|HWA09 Measurement|Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
79671953|NCT00481572|Drug|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
79671954|NCT00481572|Drug|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
79361538|NCT04098354|Diagnostic Test|home BP telemonitoring system .|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
79820085|NCT00714441|Behavioral|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
79993641|NCT02816658|Other|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
79993642|NCT02816658|Other|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
79993643|NCT05142774|Drug|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily
79308271|NCT04496765|Procedure|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
79308272|NCT03211325|Procedure|Biopsy|
79308273|NCT02610777|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
79361539|NCT04064840|Drug|IVF: Decapeptyl and hCG|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
79512602|NCT06039709|Combination Product|5-ALA and Low-Intensity Focused Ultrasound (SDT)|5-ALA (20mg/kg orally) given ~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
79512603|NCT06036212|Device|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
79512604|NCT06036212|Device|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
79671955|NCT00481572|Drug|Norepinephrine|titrated norepinephrine over a period of 48 hrs
79671956|NCT00436397|Radiation|radiation therapy|
79512605|NCT06033885|Device|PONDUS®|"PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported."
79512606|NCT06031818|Other|The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.
79671957|NCT00436514|Behavioral|diet and absorption of ColoPEG|4l of PEG during 2 days
79671958|NCT00436514|Procedure|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
79671959|NCT00436514|Procedure|Standard colonoscopy|1l of PEG the morning just before colonoscopy
79671960|NCT00481650|Drug|Leios/Alesse|
79820086|NCT00746096|Drug|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
79671961|NCT00436592|Device|NeuroFlo™ Catheter|45 minute Treatment
79671962|NCT00473967|Biological|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
79820087|NCT00746096|Drug|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
79993644|NCT03274687|Radiation|Hypofractionated radiation therapy|66.6 Gy in 37 daily fractions of 1.8 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
79993645|NCT03274687|Radiation|Conventional radiation therapy|62.5 Gy in 25 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
79993646|NCT03274687|Drug|Optional androgen deprivation therapy|Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
79993647|NCT03909750|Procedure|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
79993648|NCT03909750|Procedure|AD-cSVF|Isolation of AD-cSVF
79993649|NCT03909750|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
79993650|NCT04651218|Behavioral|exericse|participants perform aerobic exercise until they expend 500 kcal
79993651|NCT05114382|Procedure|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
79993652|NCT02542956|Drug|Exparel|receive Exparel by injection
79361540|NCT04064840|Drug|FET: Decapeptyl|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
79361541|NCT04064840|Drug|IVF: hCG and normal saline|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
79361542|NCT04064840|Drug|FET: Normal Saline|On the day of FET, normal saline will be injected subcutaneously.
79361543|NCT04052126|Other|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
79671963|NCT04701554|Other|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
79993653|NCT02542956|Drug|Marcaine|receive Marcaine in a pain pump
79671964|NCT04701554|Other|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
79671965|NCT00474006|Drug|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
79671966|NCT04697745|Drug|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
79993654|NCT02542956|Drug|Marcaine|receive Marcaine by injection
79993655|NCT03274453|Drug|Ketamine|0.12 mg/kg/hr of ketamine post surgery
79993656|NCT03274453|Drug|Saline|Saline will be administered at the same rate as the ketamine infusion.
79993657|NCT02313870|Drug|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
79993658|NCT02313870|Drug|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
79671967|NCT04697745|Drug|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
79671968|NCT00436631|Behavioral|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
79993659|NCT02847949|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein
79993660|NCT01942122|Drug|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
79671969|NCT00481689|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
79308274|NCT02610777|Drug|Pevonedistat|Pevonedistat intravenous infusion.
79361544|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
79361545|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
79361546|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
79820088|NCT04084236|Device|electrical stimulation|electrical stimulation
79361547|NCT04042740|Drug|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
79361548|NCT04042740|Drug|Ribavirin (RBV)|Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol.
79993661|NCT01942122|Drug|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
79993662|NCT01942122|Drug|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
79512607|NCT06031818|Other|The model prediction|The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.
79993663|NCT04297345|Device|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
79361549|NCT04009161|Procedure|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
79361550|NCT04007744|Biological|Pembrolizumab|Given IV
79361551|NCT04007744|Drug|Sonidegib|Given PO
79361552|NCT03983434|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
79512608|NCT06031818|Other|The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
79512609|NCT06022926|Procedure|warmed with electric blankets|warmed with electric blankets
79512610|NCT06022926|Other|patients without warming|patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
79512611|NCT06022484|Other|The present study does not contain any intervention|The present study does not contain any intervention
79512612|NCT06022003|Drug|AzaCITIDine Oral Tablet|AML study treatment
79512613|NCT06022003|Drug|Xospata|R/R FLT3-mutated AML standard treatment
79512614|NCT06020950|Other|Control|Low-calorie diet with the use of placebo pearls (containing sunflower oil)
79512615|NCT06020950|Dietary Supplement|Omega-3 supplementation|Low-calorie diet with the use of marine omega-3 pearls (containing 1200 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid/day)
79671970|NCT00436709|Biological|bevacizumab|
79671971|NCT00436709|Biological|pegfilgrastim|
79671972|NCT00436709|Drug|cyclophosphamide|
79671973|NCT00436709|Drug|doxorubicin hydrochloride|
79671974|NCT00436709|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
79671975|NCT00436709|Other|flow cytometry|
79671976|NCT00436709|Other|immunoenzyme technique|
79820089|NCT04084236|Device|Sham|no stimulation
79671977|NCT00436709|Other|immunologic technique|
79671978|NCT00436709|Other|laboratory biomarker analysis|
79671979|NCT00436709|Procedure|adjuvant therapy|
79671980|NCT00436709|Procedure|immunoscintigraphy|
79671981|NCT00474084|Device|Intravascular Coronary Stent|
79671982|NCT00436787|Drug|Fondaparinux Sodium|
79671983|NCT00481728|Drug|Tolterodine|Single dose per patient as determined by protocol.
79820090|NCT00714519|Drug|Xenaderm® Ointment|Topical, BID or as needed
79820091|NCT00714519|Drug|Placebo Comparator|Topical, BID or as needed
79993664|NCT01816932|Procedure|Home Visit|The intervention is the location of the insertion visit.
79993665|NCT01816932|Procedure|Office visit|
79993666|NCT01783704|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
79820092|NCT03950934|Other|no intervention, observational study, perioperative survey|no intervention
79820093|NCT04070859|Procedure|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes & Screws, Tension bands. etc)
79820094|NCT00709527|Drug|ARC1905|intravitreal injection
79820095|NCT00715026|Device|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
79993667|NCT01783704|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
79993668|NCT01783704|Behavioral|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
79361553|NCT03970057|Behavioral|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
79361554|NCT03970057|Other|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
79512616|NCT06020950|Other|Chia seed|Low-calorie diet with the consumption of 30 grams of powdered chia seeds
79671984|NCT00481728|Procedure|Filling cystometry|This is a procedure.
79671985|NCT00481728|Procedure|Intravesical neurostimulation|This is a procedure.
79671986|NCT00436865|Behavioral|Weight loss|
79671987|NCT00436943|Drug|nicotine replacement therapy and bupropion|3-6 months
79671988|NCT00436943|Behavioral|smoking cessation counseling and referrals|Organizational counseling and referrals
79671989|NCT00437060|Procedure|Cognitive Assessment|Ancillary studies
79217866|NCT02126943|Drug|Opsumit (macitentan)|10 mg tablets
79217867|NCT02121015|Behavioral|Share|
79217868|NCT02121015|Behavioral|Self-Directed|
79217869|NCT02121093|Procedure|vibration|
79512617|NCT06018805|Other|BMI≥30; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
79512618|NCT06018805|Other|BMI:18,5-24,9; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
79512619|NCT06018129|Biological|GEN3017|Subcutaneous injection
79512620|NCT06017739|Device|Bronchial Clearance A|EFA technology: the patient has to breathe at tidal volume by a mouthpiece at level 5 for half an hour twice a day.
79512621|NCT06017739|Device|Bronchial Clearance B|High Flow Technology: patient has to wear nasal cannula and breathe his nose for one hour twice a day. After he has to use EFA technology level 5 for half an hour twice a day.
79671990|NCT00437060|Procedure|Diffusion Tensor Imaging|Correlative studies
79671991|NCT00437060|Other|Laboratory Biomarker Analysis|Correlative studies
79820096|NCT00714675|Dietary Supplement|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
79671992|NCT00437060|Other|Pharmacological Study|Correlative studies
79671993|NCT00437060|Procedure|Psychosocial Assessment and Care|Ancillary studies
79671994|NCT00474162|Drug|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
79671995|NCT00474162|Drug|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
79820097|NCT00714675|Dietary Supplement|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
79993669|NCT03627780|Diagnostic Test|DNA extraction|DNA will be extracted from white cells
79993670|NCT04246021|Drug|Ferric carboxymaltose (FCM)|intravenous iron formulation
79820098|NCT00714948|Drug|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) > 2.1), after consultation with the Principal Investigator.
79671996|NCT00437099|Drug|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
79671997|NCT00437099|Drug|Placebo|Placebo
79671998|NCT00481884|Other|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
79361555|NCT03955627|Behavioral|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
79820099|NCT02575053|Procedure|assessment of a new latex protocol|"All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~Removal of all materials containing latex from the resuscitation carts.~Further requirements in case of latex allergic patients:~Identification of patients with (suspected) latex allergy.~All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~All staff present in the room should use latex free synthetic gloves.~Operating tables and supports should be made of latex free material or should be covered with blankets.~The entire OR staff is thoroughly educated concerning the latex safe protocol."
79820100|NCT00714831|Behavioral|Physical activity intervention|3-months physical activity intervention
79820101|NCT00714831|Behavioral|Health educational program|Health education sessions and stretching sessions
79993671|NCT03627702|Radiation|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
79993672|NCT02236806|Drug|Bisoprolol|5 mg daily
79993673|NCT02236806|Drug|Ramipril|5 mg daily
79993674|NCT02236806|Drug|Placebo|1 capsule daily
79993675|NCT01578954|Drug|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
79993676|NCT00659646|Drug|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
79217870|NCT02127021|Drug|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
79217871|NCT02127021|Drug|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
79217872|NCT03551847|Drug|Antibiotic|The intervention involves giving an infected patient antibiotics.
79217873|NCT03551847|Drug|No antibiotics|The intervention involves not giving an infected patient antibiotics.
79217874|NCT02121171|Device|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
79361556|NCT03948724|Behavioral|Therapeutic education program|Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment
79361557|NCT03948724|Behavioral|Usual Information|Patient receive usual informations
79217875|NCT02121171|Procedure|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
79361558|NCT03934814|Drug|TJ011133|TJ011133 will be administered weekly.
79361559|NCT03934814|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
79361560|NCT03934814|Drug|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
79361561|NCT03919799|Drug|Belumosudil (KD025)|ROCK-2 Inhibitor
79361562|NCT03919799|Drug|Placebo|Inactive substance
79993677|NCT00659646|Drug|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
79993678|NCT02236572|Drug|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~Anastrozole 1 mg~Letrozole 2.5 mg~Exemestane 25 mg"
79993679|NCT03054870|Drug|Xe-133|Xe-133 ventilation scintigraphy
79993680|NCT03054870|Drug|Technegas|Technegas ventilation scintigraphy
79993681|NCT03414047|Drug|Prexasertib|Administered IV
79993682|NCT03711227|Diagnostic Test|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
79361563|NCT03913351|Behavioral|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
79361564|NCT03911128|Other|Observational|Observational study - no intervention
79512622|NCT06013072|Dietary Supplement|Dietary Supplement: Experimental|Combination of pre-probiotic
79512623|NCT06013072|Dietary Supplement|Dietary Supplement: Placebo|Inert compound
79993683|NCT03709901|Other|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
79217876|NCT02127177|Device|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
79993684|NCT03709901|Other|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
79361565|NCT03885128|Device|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
79993685|NCT05448677|Drug|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
79671999|NCT00481884|Other|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
79672000|NCT00481923|Drug|rimonabant (SR141716)|
79993686|NCT05448677|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
79993687|NCT05448677|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
79993688|NCT04858932|Device|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
79672001|NCT00437138|Behavioral|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
79217877|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
79217878|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
79217879|NCT03551223|Biological|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
79217880|NCT02121249|Device|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
79217881|NCT02121249|Procedure|free hand technique|"No specific device is necessary in the free hand technique"
79217882|NCT02121327|Other|disease management|disease management program include self management education
79672002|NCT00481962|Drug|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
79672003|NCT00437177|Drug|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
79820102|NCT00714870|Behavioral|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
79993689|NCT04858932|Device|Wrist Actigraphy Device|a watch like wearable sensor
79993690|NCT04858932|Device|Food Weight Scale|a scale to measure food weight
79993691|NCT04858932|Device|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
79217883|NCT02121327|Other|usual care|usual care group receive regular outpatient treatment
79308275|NCT03210779|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
79361566|NCT03885128|Device|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
79361567|NCT03884010|Other|No intervention|Cross-sectional
79361568|NCT03867578|Diagnostic Test|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
79361569|NCT03867578|Diagnostic Test|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
79672004|NCT00437177|Drug|[(123)I] iodobenzamide|[(123)I] iodobenzamide 185 MBq I.V., at discharge.
79820103|NCT02575209|Other|GENDER|
79820104|NCT00714714|Drug|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
79820105|NCT00714714|Drug|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
79993692|NCT05216718|Procedure|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
79993693|NCT05216718|Procedure|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
79993694|NCT03351335|Device|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
79993695|NCT05216640|Device|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
79672005|NCT00482040|Device|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
79820106|NCT00441337|Biological|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
79361570|NCT03867578|Diagnostic Test|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
79820107|NCT00709605|Drug|VRC-HIVADV014-00-VP|
79993696|NCT03711149|Other|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
79993697|NCT00472680|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
79217884|NCT02121561|Behavioral|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
79217885|NCT00150462|Drug|Carfilzomib|Administered as an IV bolus dose
79217886|NCT00150462|Drug|Dexamethasone|Administered orally prior to carfilzomib
79217887|NCT02287740|Behavioral|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
79217888|NCT02287740|Behavioral|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
79217889|NCT02287740|Behavioral|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
79217890|NCT00095550|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
79217891|NCT00095550|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
79361571|NCT03830476|Behavioral|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
79361572|NCT03830476|Behavioral|Treatment as usual.|Treatment as usual within outpatient disability services.
79361573|NCT03820232|Device|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
79512624|NCT06012487|Drug|Low BPV Regimen|Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
79672006|NCT00437333|Drug|Metformin cloridrate|
79217892|NCT00095550|Drug|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
79217893|NCT00095394|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
79217894|NCT00095394|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
79217895|NCT00093132|Drug|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
79217896|NCT00093054|Drug|Cranberry juice|TID dosage for UTI treatment
79217897|NCT00093054|Dietary Supplement|Placebo cranberry juice|TID placebo dosage to match active comparator
79361574|NCT03775343|Diagnostic Test|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
79672007|NCT00482079|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
79672008|NCT00482079|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
79672009|NCT00437372|Drug|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
79820108|NCT00578877|Device|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
79820109|NCT00578877|Combination Product|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
79820110|NCT00578877|Combination Product|Buffer Gel|Buffer Gel
79672010|NCT00437372|Radiation|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
79672011|NCT00437411|Behavioral|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
79820111|NCT02590146|Behavioral|Non-pharmacologic pain control adjuncts|
79820112|NCT01032343|Dietary Supplement|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
79820113|NCT01032343|Dietary Supplement|Gelatine|One capsule daily for 3 months
79993698|NCT00472680|Behavioral|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
79993699|NCT00472680|Behavioral|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
79820114|NCT05263050|Drug|Cabozantinib|Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
79217898|NCT00089466|Drug|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
79820115|NCT02573727|Drug|Nor adrenaline + albumin|
79820116|NCT02573727|Drug|Terlipressin + albumin|
79820117|NCT00709683|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79820118|NCT04085874|Behavioral|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
79820119|NCT04085874|Behavioral|Nutrition counseling from standard health services care|once nutrition counselling from health services
79361575|NCT03775343|Diagnostic Test|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
79361576|NCT03759678|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
79361577|NCT03733886|Device|Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
79361578|NCT03709199|Diagnostic Test|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
79512625|NCT06012331|Procedure|concentrated growth factors in open apex|"Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration"
79512626|NCT06012331|Procedure|Blood Clot (BC)|"Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~Stop bleeding at a level that allows for 3-4 mm of restorative material.~Then white MTA as a coronal plug material be followed by GIC, then composite restoration."
79512627|NCT06012253|Other|Home Based Walking Program|"The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period."
79512628|NCT06011148|Device|Perceval S sutureless heart valve|Aortic Valve Replacement with Perceval S sutureless heart valve
79672012|NCT00482196|Drug|MK0493|
79820120|NCT00918840|Biological|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
79820121|NCT00918840|Biological|Placebo|Dextrose/glucose solution
79820122|NCT00918840|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
79217899|NCT00080106|Biological|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
79672013|NCT00437450|Drug|Epoetin/Atra|
79672014|NCT00482235|Drug|MK0359|
79672015|NCT04701710|Drug|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
79672016|NCT01240707|Other|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
79217900|NCT00080106|Other|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
79672017|NCT00437567|Dietary Supplement|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
79217901|NCT00335244|Drug|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
79217902|NCT00335244|Drug|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
79217903|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
79361579|NCT03709199|Diagnostic Test|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
79361580|NCT03709199|Diagnostic Test|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
79672018|NCT00437567|Other|Placebo|Similar quantity of sterile water to be added to milk
79672019|NCT02274129|Device|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
79672020|NCT00437606|Drug|GK Activator (2)|100mg po
79672021|NCT00437606|Drug|Ethanol|40g po
79672022|NCT00482313|Drug|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
79672023|NCT00482313|Drug|Placebo|Sugar pill
79672024|NCT00437684|Drug|LPV/r|200/50 mg 2 cpr bid monotherapy
79672025|NCT00437684|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
79672026|NCT00437684|Drug|Ribavirin|Ribavirin 1-1.2 g/day
79820123|NCT02574897|Other|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
79820124|NCT02574897|Other|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
79820125|NCT00918528|Procedure|Internal urethrotomy|
79993700|NCT05670912|Drug|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
79512629|NCT06011070|Behavioral|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
79512630|NCT06010732|Drug|0 ppm F (placebo, negative control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
79993701|NCT05670912|Drug|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
79820126|NCT00918528|Drug|Mitomycin C - local injection|
79820127|NCT00468481|Drug|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
79820128|NCT00468481|Drug|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
79820129|NCT00714168|Behavioral|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
79820130|NCT00714168|Behavioral|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
79993702|NCT03619746|Behavioral|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
79993703|NCT04811898|Biological|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
79993704|NCT05223270|Other|wound dressing under the NIMV mask|wound dressing under the NIMV mask
79217904|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
79361581|NCT03709199|Diagnostic Test|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
79512631|NCT06010732|Drug|1100 ppm F as sodium fluoride (positive control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
79672027|NCT00437684|Drug|NUCS|Nucleoside Reverse Transcriptase Inhibitors
79820131|NCT02574819|Drug|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
79217905|NCT00333216|Other|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
79361582|NCT03709199|Diagnostic Test|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
79361583|NCT03709199|Diagnostic Test|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
79361584|NCT03709199|Diagnostic Test|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
79361585|NCT03709199|Diagnostic Test|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
79512632|NCT06010732|Drug|1100 ppm F as sodium fluoride Test Product|• Each subject will use this product during one of the three treatment periods in the crossover study design.
79672028|NCT00437723|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
79672029|NCT00482430|Drug|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
79672030|NCT00482430|Drug|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
79672031|NCT00437762|Drug|Botulinum Toxin A Injection|Botulinum Toxin A Injection
79672032|NCT00437762|Drug|Placebo injection|Placebo Injection
79672033|NCT00482508|Drug|Omalizumab|
79672034|NCT00437840|Drug|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
79672035|NCT00437840|Drug|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
79672036|NCT00482586|Other|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
79993705|NCT05669898|Behavioral|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
79993706|NCT05669898|Other|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
79993707|NCT05669898|Behavioral|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
79993708|NCT05223114|Other|Not applicable (N/A)|Not applicable to this study
79993709|NCT05222958|Device|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
79820132|NCT02574819|Drug|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
79820133|NCT00709839|Drug|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
79820134|NCT00709839|Drug|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
79217906|NCT05715372|Behavioral|Mediterranean diet|12-week structured program for Mediterranean diet.
79820135|NCT02591316|Other|no intervention|
79820136|NCT00715065|Procedure|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting ~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
79217907|NCT05715372|Behavioral|AHA walking program|12-week structured AHA walking program.
79217908|NCT05715372|Behavioral|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
79217909|NCT05715372|Behavioral|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
79512633|NCT06010160|Behavioral|Game Changers for Cervical Cancer Prevention|The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
79217910|NCT05715372|Behavioral|Unstructured walking program|Unstructured 12-week walking program.
79672037|NCT00482586|Other|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
79672038|NCT00482586|Procedure|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
79820137|NCT00713700|Device|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
79217911|NCT05715372|Behavioral|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
79217912|NCT00332748|Drug|Oral Taxane|
79217913|NCT00329082|Drug|LY2062430|"100mg QW IV for 12 weeks~100mg Q4W IV for 12 weeks~400mg QW IV for 12 weeks~400mg Q4W IV for 12 weeks"
79512634|NCT06008912|Other|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
79820138|NCT03949153|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Single Nivolumab 240 mg infusion at D0
79820139|NCT03949153|Procedure|Cryotherapy|Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1
79512635|NCT06008912|Other|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
79512636|NCT06006546|Biological|426c.Mod.Core-C4b|100 mcg and 300 mcg
79512637|NCT06006546|Other|Adjuvant 3M-052-AF+Alum|5 mcg
79820140|NCT03949153|Drug|Ipilimumab Injection|In situ injection with ipilimumab at D2.
79820141|NCT00709917|Drug|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
79217914|NCT00329082|Drug|Placebo|5: Placebo QW IV for 12 weeks
79217915|NCT03530436|Dietary Supplement|Native turmeric extract|207 mg curcumin
79217916|NCT03530436|Dietary Supplement|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
79217917|NCT03530436|Dietary Supplement|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
79217918|NCT03530436|Dietary Supplement|Cyclodextrin complex of curcuminoids|207 mg curcumin
79217919|NCT03530436|Dietary Supplement|Turmeric oleoresin|207 mg curcumin
79217920|NCT03530436|Dietary Supplement|Liposomal curcumin|207 mg curcumin
79217921|NCT03530436|Dietary Supplement|Phytosomal curcumin|207 mg curcumin
79512638|NCT06005974|Drug|REC-4881|REC-4881 4mg capsules
79512639|NCT06005441|Drug|CBL-514 injection|Provided as a ready for use injectable CBL-514 solution
79672039|NCT00437918|Drug|nateglinide|
79217922|NCT03530436|Dietary Supplement|Micellar turmeric extract|207 mg curcumin
79217923|NCT03530280|Drug|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
79217924|NCT03530280|Drug|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
79217925|NCT03530280|Drug|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
79217926|NCT00079482|Drug|CEP-701|
79217927|NCT00079482|Drug|high-dose cytarabine|Chemotherapy
79217928|NCT00079482|Drug|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
79217929|NCT00073866|Drug|celecoxib|
79217930|NCT00073866|Drug|docetaxel|
79217931|NCT00073866|Drug|irinotecan hydrochloride|
79217932|NCT00073398|Biological|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
79217933|NCT00325650|Drug|Rimonabant|Tablet, oral administration
79217934|NCT00325650|Drug|Placebo (for Rimonabant)|Tablet, oral administration
79672040|NCT00437918|Drug|acarbose|
79672041|NCT00482742|Device|CiTop(TM) Guidewire|
79672042|NCT00437957|Drug|Temozolomide|75 Mg/m2/day for all Cohorts
79672043|NCT00437957|Drug|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
79672044|NCT00437957|Procedure|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
79672045|NCT00482781|Biological|Infanrix|
79672046|NCT00482781|Biological|Pediatrix|
79820142|NCT02574741|Behavioral|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
79993710|NCT04641156|Other|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
79217935|NCT03133572|Device|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
79993711|NCT04618614|Device|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
79993712|NCT04618614|Device|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
79993713|NCT04618614|Device|Sham control|Sham stimulation of the right primary somatosensory cortex
79993714|NCT05222646|Drug|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
79993715|NCT05222568|Behavioral|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
79993716|NCT05222568|Device|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
79993717|NCT05222490|Device|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
79217936|NCT03133572|Device|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
79217937|NCT00317694|Drug|Fermagate|Film coated tablet 500mg
79217938|NCT00317694|Drug|Placebo|Oral administration, film coated tablet, 0mg
79217939|NCT00070590|Drug|Bosentan|
79217940|NCT00067782|Drug|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
79512640|NCT06005441|Drug|CBL-A1 Injection|Provided as a ready for use injectable CBL-A1 solution
79512641|NCT06005441|Drug|CBL-A2 Injection|Provided as a ready for use injectable CBL-A2 solution
79217941|NCT00067782|Drug|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
79512642|NCT06005441|Drug|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
79820143|NCT02574741|Drug|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
79993718|NCT05222490|Device|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
79993719|NCT05222334|Procedure|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
79217942|NCT00058266|Dietary Supplement|genistein|Given orally
79217943|NCT00058266|Procedure|conventional surgery|Patients undergo surgery
79217944|NCT03530202|Drug|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
79217945|NCT03530202|Drug|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
79217946|NCT03530046|Combination Product|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
79217947|NCT03530046|Combination Product|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
79217948|NCT00313794|Drug|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
79512643|NCT06001996|Procedure|Pericapsular nerve group (PENG) block|Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.
79308276|NCT03210779|Dietary Supplement|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
79512644|NCT06001996|Procedure|Suprainguinal fascia iliaca plane block|Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
79512645|NCT06000540|Device|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
79512646|NCT05999799|Drug|GSK1070806|GSK1070806 will be administered.
79512647|NCT05999799|Drug|Placebo|Placebo will be administered.
79672047|NCT03270176|Drug|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
79820144|NCT02574741|Drug|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
79820145|NCT00468169|Drug|Cetuximab|250mg/m2(day 1, weekly x 10);
79820146|NCT00468169|Drug|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
79820147|NCT00468169|Drug|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
79993720|NCT05222334|Procedure|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
79217949|NCT03529968|Procedure|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
79217950|NCT00040404|Drug|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
79217951|NCT00040404|Drug|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
79217952|NCT00040404|Drug|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
79217953|NCT00040404|Other|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
79217954|NCT00313248|Drug|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
79361586|NCT03709199|Diagnostic Test|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
79361587|NCT03709199|Diagnostic Test|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
79512648|NCT05999240|Drug|Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]|Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
79512649|NCT05999240|Drug|Placebo|Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE [NUPLAZID]
79672048|NCT03270176|Drug|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
79820148|NCT00468169|Radiation|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
79993721|NCT05222334|Drug|Bupivacaine|bupivacaine
79993722|NCT04465266|Drug|Tolperisone|tablets
79217955|NCT00313248|Drug|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
79217956|NCT00310830|Drug|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
79217957|NCT00035568|Drug|Glucovance (metformin HCl/glyburide)|
79361588|NCT03709199|Diagnostic Test|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
79361589|NCT03709199|Diagnostic Test|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
79217958|NCT00035568|Drug|or Metformin HCl alone|
79217959|NCT00035568|Drug|or Glyburide alone.|
79217960|NCT00030186|Drug|CEP-701 60mg|60mg orally 2 times a day for 28 days
79217961|NCT00030186|Drug|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
79217962|NCT00030186|Drug|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
79217963|NCT03529812|Behavioral|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
79217964|NCT02287974|Drug|Stem cell infusion|Unique stem cell infusion of the randomized group
79217965|NCT03529734|Other|12 min running|This was already explained in the description of arm
79308277|NCT01628692|Drug|Daclatasvir|Tablets, oral, 30 mg, once daily
79361590|NCT03703115|Behavioral|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
79361591|NCT03697811|Drug|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
79361592|NCT03691649|Drug|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
79512650|NCT05997277|Drug|Deucravacitinib|Deucravacitinib is a stable deuterium-containing compound (where deuterium is a stable, nonradioactive isotope of hydrogen) and a potent, highly selective small molecule inhibitor of TYK2. Deucravacitinib has a unique mode of binding that provides the high selectivity over the other members of the JAK family of nonreceptor tyrosine kinases. 1 active oral tablet (6mg) in the morning and evening for 16weeks.
79512651|NCT05997277|Drug|Placebo|Placebo will consist of a tablet (0mg) and will be administered orally BID for 16weeks.
79512652|NCT05995249|Drug|TAK-279|TAK-279 capsules
79361593|NCT03691649|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
79512653|NCT05995249|Drug|Erythromycin|Erythromycin tablets
79512654|NCT05995249|Drug|Phenytoin|Phenytoin capsules
79672049|NCT00474279|Drug|Orally active growth hormone secretagogue (MK-677)|
79672050|NCT03270618|Device|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
79672051|NCT03270696|Drug|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
79672052|NCT03278600|Genetic|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
79672053|NCT00437996|Drug|Clonidine|
79820149|NCT00468169|Drug|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
79820150|NCT00468169|Radiation|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
79993723|NCT04434300|Drug|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
79993724|NCT04434300|Drug|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
79993725|NCT05214690|Drug|DW1809-T2|pelubiprofen 25mg
79993726|NCT05214690|Drug|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
79217966|NCT03529734|Other|Local strengthening exercises|This was already explained in the description of arm
79217967|NCT03529656|Behavioral|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
79217968|NCT00307398|Drug|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
79217969|NCT00307398|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
79361594|NCT03687190|Behavioral|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
79361595|NCT03687190|Drug|conventional medicine|participants without Tai chi training still received routine conventional medicine
79512655|NCT05995249|Drug|Efavirenz|Efavirenz tablets
79512656|NCT05991635|Behavioral|Gatekeeper training (e-learning)|"The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~Background information on suicide in Flanders (rates)~Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~Debunking existing myths about suicide~The role of the pharmacist in suicide prevention~Signal Recognition~Talking about suicide and suicidal thoughts (start the conversation)~How and to whom to refer as pharmacist or FTA~Medication management and medication in the context of suicide~Rights and obligations of a pharmacist/PTA in the context of suicide prevention~Self-care"
79512657|NCT05988671|Drug|normal Saline|Intraperitoneal route
79672054|NCT00437996|Drug|Levobupivacaine|
79993727|NCT03055806|Drug|IX-01 400 mg|IX-01 400 mg caplet
79993728|NCT03055806|Drug|Placebo|Placebo caplet(s)
79993729|NCT03055806|Drug|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
79993730|NCT03055806|Drug|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
79993731|NCT05194644|Other|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
79217970|NCT01368081|Drug|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
79217971|NCT01368081|Drug|BI 10773|BI 10773 low dose tablet once daily
79217972|NCT01368081|Drug|Placebo (low dose)|Placebo tablets once daily
79217973|NCT01368081|Drug|BI 10773|BI 10773 high dose tablet once daily
79512658|NCT05988671|Drug|Dexamethasone|Intraperitoneal route
79512659|NCT05988671|Drug|Dexmedetomidine|Intraperitoneal route
79993732|NCT05194644|Other|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
79993733|NCT04397796|Biological|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
79993734|NCT04397796|Biological|Placebo|plasmalyte and human albumin
79993735|NCT04315896|Drug|Hydroxychloroquine|hydroxychloroquine 400mg day for 10 days
79993736|NCT04315896|Drug|Placebo oral tablet|Placebo oral tablet
79993737|NCT04311216|Other|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
79512660|NCT05988671|Drug|Combination of dexamethasone + dexmedetomidine|Intraperitoneal route
79512661|NCT05987254|Procedure|suprainguinal fascia iliaca block|ultrasound guided suprainguinal fascia iliaca block
79512662|NCT05987254|Procedure|pericapsular nerve group block|ultrasound guided pericapsular nerve group block
79993738|NCT03628092|Device|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
79217974|NCT01368081|Drug|Placebo (high dose)|Placebo tablets once daily
79217975|NCT02127411|Behavioral|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
79217976|NCT02127489|Drug|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
79217977|NCT02127645|Procedure|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
79512663|NCT05984420|Device|LimpiAD 2,5% plus cream|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
79672055|NCT00437996|Drug|Sufentanil|
79672056|NCT03270579|Drug|[18F]JNJ-64511070|An IV injection of 185 MBq [18F]JNJ-64511070 will be administered.
79672057|NCT04701125|Device|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
79672058|NCT00474357|Behavioral|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
79672059|NCT00474396|Behavioral|Low fat dairy diet|
79672060|NCT04701242|Drug|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
79672061|NCT03270267|Other|Questionnaires|
79820151|NCT02589990|Behavioral|Strength training|see arm description
79993739|NCT03628092|Device|Placebo|Sham Device
79820152|NCT04015830|Other|electroencephalography (EEG) and event related potentials (ERP)|This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
79820153|NCT00918606|Drug|LIPO-102|LIPO-102
79820154|NCT05685030|Dietary Supplement|Placebo|product vehicle (sunflower oil)
79217978|NCT02127645|Procedure|LRT-TEM|TEM following 46 Gy RT
79361596|NCT03682523|Behavioral|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
79512664|NCT05984420|Other|Vehicle|"Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component."
79217979|NCT02127645|Procedure|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
79217980|NCT02127645|Procedure|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
79361597|NCT03655002|Drug|Cyclophosphamide|Given IV
79512665|NCT05984420|Other|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
79512666|NCT05977127|Biological|Comirnaty|Administration of Comirnaty vaccine
79512667|NCT05976022|Device|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
79512668|NCT05974800|Behavioral|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
79512669|NCT05973214|Behavioral|Cognitive Behavioral Therapy|CBT for IEI
79512670|NCT05971355|Device|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
79512671|NCT05971355|Other|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
79512672|NCT05971355|Other|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
79512673|NCT05969288|Other|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
79820155|NCT05685030|Dietary Supplement|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
79820156|NCT05685030|Dietary Supplement|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
79820157|NCT05334576|Other|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
79820158|NCT02959320|Procedure|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
79820159|NCT02589444|Dietary Supplement|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
79820160|NCT02589444|Other|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
79820161|NCT02589444|Other|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
79993740|NCT03628014|Other|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~Daily orientation and visiting program~Basic active movements~Meal assistance~Recreational activities"
79217981|NCT02124135|Behavioral|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
79217982|NCT02124213|Drug|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
79820162|NCT02589444|Other|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
79820163|NCT02589444|Procedure|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
79820164|NCT05325684|Drug|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
79217983|NCT02124213|Drug|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
79308278|NCT01628692|Drug|Simeprevir|Capsule, oral, 150 mg, once daily
79820165|NCT00435487|Drug|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
79820166|NCT00435487|Drug|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg [units per kilogram] and initial infusion of 12 U/kg/h [units per kilogram per hour]).
79820167|NCT00918918|Dietary Supplement|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
79820168|NCT00918918|Dietary Supplement|Orange juice|200 mL orange juice
79217984|NCT02124213|Drug|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
79217985|NCT00303498|Drug|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
79217986|NCT00303498|Drug|Placebo|placebo identical to the study drug in description, dose and duration
79217987|NCT02124291|Device|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
79217988|NCT02588092|Drug|ADCT-301|Intravenous infusion
79217989|NCT02121717|Drug|Chiglitazar|Take orally
79217990|NCT02121717|Drug|Placebo|Take orally
79217991|NCT03529578|Procedure|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
79217992|NCT00004914|Biological|epoetin alfa|
79217993|NCT00004914|Procedure|physical therapy|
79217994|NCT00286806|Drug|AT-101|
79217995|NCT02124447|Drug|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
79217996|NCT02124447|Drug|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
79217997|NCT02124447|Drug|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
79217998|NCT02124447|Drug|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
79217999|NCT00004908|Drug|cyclophosphamide|
79218000|NCT00004908|Procedure|peripheral blood stem cell transplantation|
79218001|NCT00004908|Radiation|radiation therapy|
79218002|NCT03551769|Drug|tricaprilin|Tricaprilin formulated as AC-SD-01
79218003|NCT03551769|Other|standard meal|standard meal
79218004|NCT03551769|Other|high-fat meal|high-fat meal
79218005|NCT03551769|Other|overnight fast|fasting for at least 9 hours
79218006|NCT00004902|Drug|tocladesine|
79218007|NCT04426162|Other|Multi-domain Intervention|Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
79218008|NCT02127801|Drug|REGN1908-1909|
79218009|NCT02127801|Drug|placebo|
79218010|NCT05725590|Procedure|External pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
79218011|NCT05725590|Procedure|Internal pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
79361598|NCT03655002|Biological|Cytokine-based Biologic Agent IRX-2|Given SC
79361599|NCT03655002|Biological|Nivolumab|Given IV
79512674|NCT05968742|Behavioral|Abstinence of oral hygiene on select teeth|Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
79512675|NCT05963867|Drug|BI 764532|BI 764532
79820169|NCT02589678|Biological|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
79820170|NCT02589678|Biological|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
79820171|NCT02590848|Dietary Supplement|Walnut intake|Nutritional intervention: 30g walnut kernels per day
79820172|NCT05234970|Other|Wysa|Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.
79820173|NCT05234970|Other|Harvard College App|Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
79820174|NCT05319288|Device|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
79218012|NCT05474482|Other|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
79218013|NCT05474482|Other|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
79820175|NCT04084782|Device|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
79993741|NCT05221788|Procedure|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased >10%, 200 ml of electrolyte solution was continued until SV increased <10%. After fluid shock, if SV increases <10% but mean arterial pressure (MAP) <65 mmHg and/or cardiac index (CI) <2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output <0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
79218014|NCT05474482|Other|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
79993742|NCT05178654|Drug|[14C]PF-07321332|Single oral dose of 300 mg [14C]PF-07321332 containing approximately 100 µCi [14C]PF-07321332 coadministered with 100 mg ritonavir.
79993743|NCT04108962|Drug|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
79993744|NCT04015362|Procedure|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
79218015|NCT02127879|Device|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
79820176|NCT02591004|Drug|Magesium sulphate|*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
79993745|NCT04015362|Procedure|Sham|Application of sham magnetic stimulation to spinal cord
79218016|NCT02127879|Device|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
79308279|NCT01628692|Drug|Ribavirin|Tablets, oral, 500-600 mg, twice daily
79308280|NCT02503007|Dietary Supplement|Placebo|
79512676|NCT05963867|Drug|[89Zr]Zr-BI 764532|[89Zr]Zr-BI 764532
79512677|NCT05963802|Other|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
79512678|NCT05962034|Drug|Aspirin|650 mg aspirin (Acetylsalicylic acid)
79308281|NCT02503007|Dietary Supplement|HMB-FA|
79308282|NCT02503163|Drug|KCT-0809 ophthalmic solution|
79308283|NCT04496921|Dietary Supplement|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
79512679|NCT05962034|Other|Placebo|placebo capsule
79512680|NCT05954871|Drug|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
79512681|NCT05954871|Drug|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
79512682|NCT05954871|Drug|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
79820177|NCT02591004|Drug|Nifedipine|*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
79820178|NCT02591004|Radiation|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
79820179|NCT05310786|Other|Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)|This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
79672062|NCT03279965|Diagnostic Test|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
79993746|NCT05221710|Behavioral|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
79993747|NCT04002102|Other|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
79993748|NCT04002102|Other|Usual care|Remain in standard care after randomization and educational materials.
79993749|NCT04002102|Other|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
79993750|NCT04989582|Other|The trauma recovery nursing intervention program|The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
79993751|NCT04928040|Diagnostic Test|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
79993752|NCT04907292|Other|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
79993753|NCT05221476|Other|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
79308284|NCT04496921|Dietary Supplement|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
79361600|NCT03645226|Diagnostic Test|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
79361601|NCT03621735|Device|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
79512683|NCT05954286|Drug|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
79512684|NCT05954286|Drug|Placebo (PO)|Oral Capsules
79512685|NCT05954026|Device|ExVent|ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
79672063|NCT00474435|Drug|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~emtricitabine 200 mg~tenofovir DF 300 mg~efavirenz 600 mg"
79308285|NCT04860609|Other|Conventional Physiotherapy|"The treatment will be given in the following way.~Tens~Infrared/Moist Heat heat for 10 minutes at low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Bed Rest with lumbar Sacral Support~Home plan:~Exercises Posture Correction Precautions Contra indication"
79672064|NCT00438035|Procedure|ECG spectral|
79512686|NCT05953363|Device|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
79672065|NCT04701320|Drug|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
79672066|NCT04701320|Drug|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
79820180|NCT04085562|Drug|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
79820181|NCT04085562|Drug|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
79820182|NCT02591160|Procedure|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
79820183|NCT05307978|Drug|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
79820184|NCT05307978|Drug|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
79820185|NCT04084002|Other|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
79820186|NCT05683626|Drug|Humira|subcutaneous injection
79820187|NCT04082832|Drug|Cu(II)ATSM|oral suspension
79820188|NCT04082832|Drug|Placebos|oral suspension
79993754|NCT04865796|Other|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
79993755|NCT04865796|Other|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
79993756|NCT04865796|Other|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
79993757|NCT04811118|Drug|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
79993758|NCT04811118|Drug|Taxotere|Taxotere
79993759|NCT04979988|Drug|Lortlatinib|as provided in real world practice
79993760|NCT05221164|Drug|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
79993761|NCT03627546|Drug|Sofosbuvir and Velpatasvir|Sofosbuvir/velpatasvir (Epclusa) is an FDA-approved treatment for HCV. It is provided in the intervention arm as part of a rapid treatment strategy,
79993762|NCT04620798|Behavioral|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
79993763|NCT04940208|Other|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
79512687|NCT05952297|Device|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
79679733|NCT02949440|Procedure|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
79993764|NCT04940208|Diagnostic Test|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
79993765|NCT05685966|Other|no intervention|no intervention
79993766|NCT05220618|Behavioral|Autobiographical Memory Specificity Training PESCAR|An autobiographical memory specificity training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017). The training group will receive a self-guided intervention, which consists of an initial session (lasting 30 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 15-20 min approximately.
79993767|NCT05684328|Procedure|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed by cold snare. Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
79993768|NCT05684328|Procedure|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed by cold snare. Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
79993769|NCT05220150|Device|FFC-MRI scan|Undergo one FFC-MRI scan.
79993770|NCT05220072|Drug|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
79993771|NCT05672862|Device|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
79993772|NCT05219682|Other|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
79361602|NCT03621735|Device|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
79361603|NCT03606980|Drug|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
79361604|NCT03606980|Procedure|Iontophoresis|Iontophoresis on affected knee
79361605|NCT03606980|Procedure|Physical Therapy|Physical therapy of affected knee
79361606|NCT03596424|Drug|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
79361607|NCT03596424|Drug|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
79361608|NCT03596424|Combination Product|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
79361609|NCT03592563|Behavioral|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
79361610|NCT03579277|Procedure|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
79361611|NCT03579277|Procedure|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
79361612|NCT03569488|Diagnostic Test|FT-LARS questionnaire|FT-LARS questionnaire
79361613|NCT03531918|Drug|Cladribine|Given IV
79512688|NCT05949125|Other|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
79512689|NCT05949125|Other|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
79512690|NCT05949125|Drug|R-TM123|Intravenous infusion over 20 days
79512691|NCT05949125|Drug|Allo-RevCAR01-T|A single dose of Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1. Allo-RevCAR01-T will not be administered again within this study.
79218017|NCT03529500|Diagnostic Test|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
79218018|NCT03529500|Diagnostic Test|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: < 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and > 2.0 ml/min = high flow.
79218019|NCT03529500|Diagnostic Test|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
79218020|NCT03551145|Other|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
79218021|NCT03551145|Other|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
79218022|NCT04441476|Other|Questionnaires|"An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected."
79218023|NCT04441476|Other|psychological and sociological interviews|"conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social."
79361614|NCT03531918|Drug|Cytarabine|Given IV
79361615|NCT03531918|Drug|Gemtuzumab Ozogamicin|Given IV
79512692|NCT05945225|Device|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
79512693|NCT05945225|Device|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
79512694|NCT05945225|Device|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
79672067|NCT03270423|Device|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
79672068|NCT03270423|Device|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
79361616|NCT03531918|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
79361617|NCT03531918|Other|Laboratory Biomarker Analysis|Correlative studies
79361618|NCT03531918|Drug|Mitoxantrone Hydrochloride|Given IV
79361619|NCT03499704|Drug|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
79361620|NCT03499704|Drug|Alogliptin|Alogliptin tablets.
79361621|NCT03499704|Drug|Metformin|Metformin tablets.
79361622|NCT03499704|Drug|Dapagliflozin|Dapagliflozin tablets.
79361623|NCT03498612|Other|Laboratory Biomarker Analysis|Correlative studies
79512695|NCT05945225|Device|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
79672069|NCT00438113|Drug|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
79672070|NCT03270228|Other|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
79672071|NCT00474474|Procedure|Virtual patient is NOT introduced|
79672072|NCT00438152|Drug|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
79361624|NCT03498612|Biological|Pembrolizumab|Given IV
79361625|NCT03494660|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
79361626|NCT03362515|Drug|Furosemide|furosemide
79361627|NCT03362515|Drug|Placebo|placebo
79512696|NCT05943782|Procedure|onlay manufactured by milling|indirect restorations for treating mutilated molars manufactured by CAD/CAM subtractive technique
79512697|NCT05943782|Procedure|Onlay manufactured by 3D printing|indirect restorations for treating mutilated molars manufactured by CAD/CAM additive technique
79820189|NCT05038488|Drug|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
79820190|NCT05038488|Drug|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
79361628|NCT03339492|Device|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
79993773|NCT03822780|Drug|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.
79820191|NCT05038488|Other|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
79993774|NCT04765644|Drug|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
79672073|NCT00438152|Drug|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
79672074|NCT03279926|Behavioral|PLAY|Activity trackers + curriculum information
79672075|NCT03279926|Behavioral|PLAY Parents|Enhanced parental engagement
79672076|NCT03279926|Behavioral|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
79672077|NCT00474513|Drug|GSK239512|
79993775|NCT04765644|Other|Placebo|2 capsules/day for 7 days
79993776|NCT04765644|Other|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
79218024|NCT05474326|Device|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
79218025|NCT02127957|Other|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
79218026|NCT04441398|Drug|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
79218027|NCT04441398|Drug|Placebo|Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
79218028|NCT02128035|Procedure|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
79218029|NCT05474248|Behavioral|Experimental group|Diaphragmatic Breathing Training
79218030|NCT03551067|Drug|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
79218031|NCT03551067|Combination Product|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
79361629|NCT03328598|Behavioral|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
79512698|NCT05942898|Other|The present study does not contain any intervention|The present study does not contain any intervention
79512699|NCT05937425|Other|LungCaNN|The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
79672078|NCT00438230|Drug|Warfarin|
79672079|NCT00438269|Drug|Site-specific empiric regimens included: Meropenem|
79672080|NCT00438269|Drug|Piperacillin/tazobactam|
79672081|NCT00438269|Drug|Ciprofloxacin and cefazolin +/- metronidazole|
79672082|NCT00474552|Drug|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
79672083|NCT00474591|Drug|Fondaparinux|
79672084|NCT03279848|Other||Stroke rehabilitation
79672085|NCT03279809|Drug|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
79820192|NCT02589366|Drug|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
79820193|NCT05218044|Procedure|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
79820194|NCT00919230|Drug|Ferrous sulphate tablets|200mg twice daily for four weeks
79820195|NCT02589132|Other|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
79218032|NCT05474170|Other|AHA resuscitation sequence|Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations
79993777|NCT04765644|Other|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
79993778|NCT05216874|Device|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
79993779|NCT04720872|Other|Manual therapy and vestibular rehabilitation treatment|The experimental group received manual therapy and vestibular rehabilitation treatment.
79993780|NCT05649774|Procedure|Therapy|Only Myofascial Release will be provided
79820196|NCT05684562|Other|Cardiopulmonary exercise test|CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.
79820197|NCT05684562|Other|Pulmonary function test|Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.
79820198|NCT05684562|Other|Respiratory muscle strength test|Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.
79820199|NCT00918996|Procedure|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
79820200|NCT00919308|Other|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
79820201|NCT02588196|Drug|Dexamethasone acetate|
79820202|NCT02588274|Device|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
79820203|NCT02588274|Device|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
79218033|NCT05474170|Other|ERC resuscitation sequence|Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations
79218034|NCT02288052|Behavioral|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
79218035|NCT02288052|Behavioral|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
79512700|NCT05934435|Other|Empowered Relief|psycho-educational pain skills training
79512701|NCT05933980|Drug|Rego+Tori+Cele|combination of Toripalimab,regorafenib and celecoxib
79512702|NCT05932472|Drug|Aspirin|Aspirin at currently prescribed dose
79672086|NCT03279809|Drug|Placebo|Case with placebo medication for 6 months after stenting
79218036|NCT03552237|Dietary Supplement|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
79218037|NCT03529266|Biological|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
79672087|NCT00474825|Drug|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
79361630|NCT03328598|Behavioral|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
79361631|NCT03328598|Other|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
79361632|NCT03324477|Drug|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
79361633|NCT03292926|Drug|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
79361634|NCT03292926|Device|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
79512703|NCT05928325|Other|Comprehensive Geriatric Assessment|Complete geriatric assessments
79361635|NCT03292926|Drug|Dexamethasone|Dexamethasone will be used to prolong block duration
79512704|NCT05928325|Behavioral|Health Education|Receive survivorship care education
79512705|NCT05928325|Other|Medical Device Usage and Evaluation|Wear activity tracking device
79512706|NCT05928325|Other|Supportive Care|Receive geriatric assessment-guided interventions
79672088|NCT00474825|Drug|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
79672089|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
79672090|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
79672091|NCT00438347|Behavioral|Aerobic Exercise|One hour per day three times a week for one year
79993781|NCT05649774|Procedure|Taping technique|Only Kinesiotaping will be provided
79218038|NCT03529266|Procedure|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
79361636|NCT03291392|Genetic|Gene expression or biomarkers exploration|
79361637|NCT03288324|Drug|Tofacitinib|Tofacitinib 5 mg twice daily
79512707|NCT05927688|Behavioral|Therapeutic management following access by the physician to his patient's ePROs|Therapeutic management following access by the physician to his patient's ePROs
79993782|NCT05649774|Procedure|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
79993783|NCT05649774|Procedure|SHAM|Placebo Treatment will be given
79361638|NCT03282994|Device|Dermal Cooling System|Cryotherapy
79512708|NCT05925140|Drug|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
79512709|NCT05925140|Drug|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
79672092|NCT00438347|Behavioral|Stretching and toning|One hour per day three times a week for one year
79672093|NCT00474981|Behavioral|IMNCI|Implementation of IMNCI in the intervention sites
79672094|NCT00438386|Drug|Aripiprazole|
79672095|NCT00475059|Drug|cimetidine arrow|patients who received cimétidine
79672096|NCT00438425|Dietary Supplement|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
79218039|NCT02128191|Drug|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
79218040|NCT02128191|Drug|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
79218041|NCT04393636|Other|Digital cardiac Counseling|"Screening for reduced physical fitness and digital counseling.~Screening for smoking and digital counseling.~Screening for malnutrition and obesity and digital counseling.~Screening for anxiety and depression and digital counseling.~Screening for elevated pulmonary risk score and digital counseling."
79218042|NCT00004896|Drug|busulfan|
79218043|NCT00004896|Drug|cyclophosphamide|
79218044|NCT00004896|Procedure|allogeneic bone marrow transplantation|
79218045|NCT00004896|Procedure|bone marrow ablation with stem cell support|
79218046|NCT00004896|Radiation|radiation therapy|
79679734|NCT02938884|Device|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
79679735|NCT05135052|Device|Rhenium-SCT|Rhenium-SCT irradiation device
79218047|NCT02121951|Procedure|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
79218048|NCT02121951|Procedure|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
79218049|NCT02121951|Drug|MAC|Incremental doses are given to the targed sedation and analgesia
79361639|NCT03266016|Other|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
79361640|NCT03266016|Diagnostic Test|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
79361641|NCT03266016|Diagnostic Test|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
79361642|NCT03266016|Diagnostic Test|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
79361643|NCT03266016|Diagnostic Test|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
79512710|NCT05925140|Drug|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
79993784|NCT05214846|Behavioral|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
79993785|NCT03052764|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
79993786|NCT03052764|Drug|Placebo (saline)|Placebo (saline) injection into the bladder.
79993787|NCT05638698|Biological|TG01 Vaccine|used to assess molecular disease control rate when combined with other interventional methods.
79993788|NCT05638698|Drug|QS-21|used to assess molecular disease control rate when combined with other interventional methods.
79218050|NCT05473858|Drug|OraVerse Injectable Product|injection of oraverse,
79218051|NCT05473858|Device|diode laser|patient exposed to diode laser
79672097|NCT00438425|Dietary Supplement|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
79361644|NCT03249220|Device|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
79361645|NCT03245151|Drug|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
79672098|NCT00438425|Dietary Supplement|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
79672099|NCT00475098|Drug|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
79672100|NCT00438503|Procedure|Procedure|
79993789|NCT05638698|Drug|Balstilimab|used to assess molecular disease control rate when combined with other interventional methods.
79218052|NCT00004584|Drug|Atazanavir|
79218053|NCT00004584|Drug|Ritonavir|
79361646|NCT03245151|Drug|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
79993790|NCT05637138|Device|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
79993791|NCT05637138|Device|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
79993792|NCT05637138|Device|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
79993793|NCT05637138|Device|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
79993794|NCT05707338|Procedure|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
79218054|NCT00004584|Drug|Saquinavir|
79361647|NCT03216343|Drug|Chiauranib|CS2164
79993795|NCT05197374|Drug|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
79218055|NCT04363528|Other|Doppler Echo|2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
79218056|NCT03552159|Behavioral|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
79218057|NCT03552159|Other|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
79218058|NCT00004230|Drug|captopril|
79218059|NCT00004230|Drug|cyclophosphamide|
79218060|NCT00004230|Procedure|autologous bone marrow transplantation|
79218061|NCT00004230|Procedure|peripheral blood stem cell transplantation|
79218062|NCT00004230|Radiation|radiation therapy|
79218063|NCT02252367|Drug|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
79218064|NCT02252367|Other|Placebo|Placebo tablet once daily for 12 weeks.
79218065|NCT00004182|Drug|irinotecan hydrochloride|
79218066|NCT02122029|Behavioral|Lifestyle counselling|Behavioral techniques for weight management
79218067|NCT02122029|Procedure|Bariatric Surgery|Vertical Banding Gastroplasty
79820204|NCT02588820|Drug|Antiretroviral Therapy (Experimental)|"Initial ART until HLA-B5701 results became available (48 hours):~Tenofovir 245 mg once a day~Emtricitabine 200 mg once a day~Dolutegravir 50 mg once a day~Darunavir 800 mg once a day~Ritonavir 100 mg once a day~Maraviroc 150 mg twice a day~Three months continuation treatment (after HLA-B5701 confirmed as negative):~Dolutegravir 50 mg once a day.~Abacavir 600 mg once a day~Lamivudine 300 mg once a day~Darunavir 800 mg once a day~Ritonavir 100 mg once a day~Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~Nine months continuation treatment (till complete 12 months treatment):~Abacavir, 600mg once a day~Lamivudine, 300 mg once a day~Dolutegravir, 50 mg once a day"
79820205|NCT04083768|Device|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
79820206|NCT00579345|Biological|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
79993796|NCT05707104|Other|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~Pelvic curl Abdominals, Hamstrings & Quadriceps Femoris, Gluteus Maximums. 05~Chest lift Rectus Abdominus, Internal & External Oblique Muscles 10~Leg lift supine Quadriceps Femoris, Internal & External Oblique Muscles 10~Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal & External Oblique Muscle 10~Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~Spine twist supine Abdominals,Quadriceps & Hamstring group of Muscles 10~Chest lift with rotation Internal & External Oblique, Rectus & Transverses Abdominus Muscles 5 on each side~Back extension BACK EXTENSION Abdominal group, Gluteus Maximus & Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
79993797|NCT05707104|Other|plyometrics exercises|"SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
79993798|NCT02951819|Drug|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
79993799|NCT02951819|Drug|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m^2 ) on Days 1, 8, 15, and 22 for every 28 days.
79993800|NCT02951819|Drug|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
79218068|NCT05556460|Device|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
79218069|NCT05201742|Other|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
79218070|NCT05201742|Other|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
79512711|NCT05925140|Other|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins [D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if <80kg, or 60mg/12h if >80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
79672101|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
79672102|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
79672103|NCT00438581|Drug|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
79218071|NCT02124525|Drug|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
79512712|NCT05923086|Drug|ORE001|Administration before major meal
79512713|NCT05923086|Drug|Placebo|Administration before major meal
79512714|NCT05920941|Drug|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
79218072|NCT02124681|Drug|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
79218073|NCT02124681|Other|Placebo|Placebo PO for 13±1 weeks
79218074|NCT05611060|Behavioral|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
79820207|NCT00579345|Biological|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
79820208|NCT00579345|Biological|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV_a administered.
79218075|NCT03551613|Dietary Supplement|honey supplementation|honey supplementation
79993801|NCT02951819|Drug|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
79993802|NCT03707717|Drug|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
79218076|NCT05556304|Other|assessment in the 8th month of pregnancy and during delivery|"Day 0: presentation of the study~During pregnancy between Day 0 and 36-38SA: inclusion~During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
79308286|NCT04860609|Other|Lumber Spinal Decompression|"The treatment will be given in the following way.~Tens~Infrared/Moist Heat heat for 10 minutes at low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~Home plan:~Exercises Posture Correction Precautions Contra indication"
79993803|NCT05191290|Drug|unfractionated heparin|standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
79993804|NCT05191290|Drug|Sodium Citrate|8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
79993805|NCT05627544|Procedure|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
79993806|NCT05627544|Procedure|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
79993807|NCT05627544|Procedure|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
79361648|NCT03173534|Device|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
79361649|NCT03173534|Device|TAVR|Transcatheter Aortic Valve Replacement
79361650|NCT03127761|Other|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
79361651|NCT03108443|Diagnostic Test|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
79361652|NCT03106376|Other|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
79512715|NCT05919940|Dietary Supplement|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~to a level of 1,2g/kg/d on day 1 after ICU admission~to a level of 1,4g/kg/d on day 2 after ICU admission~to a level of 1,6g/kg/d on day 3 after ICU admission~to a level of 1,8g/kg/d on day 4 after ICU admission~to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~to 0,125g/kg/d on day 1 after ICU admission~to 0,2g/kg/d on day 2 after ICU admission~to 0,25g/kg/d on day 3 after ICU admission~to 0,3g/kg/d from day 4 after ICU admission onwoards"
79672104|NCT00438620|Behavioral|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
79361653|NCT03106376|Other|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
79361654|NCT03096275|Drug|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
79512716|NCT05919940|Device|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
79512717|NCT05919940|Other|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
79512718|NCT05916092|Device|TransLoc 3D|TransLoc 3D SI Joint Fusion System
79512719|NCT05913908|Device|DUO Transcatheter Tricuspid Coaptation Valve System|Reduction of tricuspid regurgitation through a transcatheter approach
79512720|NCT05913869|Behavioral|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
79512721|NCT05913193|Other|Oral Nutritional Supplement (ONS)|Diabetes specific oral nutritional supplement
79672105|NCT00438698|Other|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
79672106|NCT00438698|Other|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
79672107|NCT00475293|Drug|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
79672108|NCT00438737|Biological|bevacizumab|
79672109|NCT00438737|Biological|cetuximab|
79672110|NCT00438737|Drug|fluorouracil|
79672111|NCT00438737|Drug|leucovorin calcium|
79672112|NCT00438737|Drug|oxaliplatin|
79672113|NCT00438737|Procedure|adjuvant therapy|
79672114|NCT00438737|Procedure|conventional surgery|
79672115|NCT00438737|Procedure|neoadjuvant therapy|
79672116|NCT00475371|Drug|MKC253 Inhalation Powder|Inhalation powder
79820209|NCT00579345|Biological|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
79820210|NCT00715377|Drug|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
79820211|NCT04083924|Other|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
79820212|NCT00718575|Procedure|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
79820213|NCT02572713|Procedure|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
79820214|NCT02572713|Procedure|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
79820215|NCT02572713|Drug|DaTSCAN™|
79820216|NCT00710073|Device|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
79361655|NCT03096275|Drug|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
79672117|NCT00438776|Drug|olanzapine|2.5mg to 15mg daily
79218077|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
79361656|NCT03096275|Drug|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
79218078|NCT05556070|Other|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
79218079|NCT05556070|Other|Arm 2|Boxes of fresh fruits and vegetables (F&V), each containing approximately 50 servings of F&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F&V boxes will be distributed to families every 2 weeks over 32 weeks.
79218080|NCT05556070|Other|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
79308287|NCT03343613|Drug|LY3381916|IDO-1 inhibitor administered orally
79308288|NCT03343613|Drug|LY3300054|PD-L1 inhibitor administered IV
79361657|NCT03096275|Drug|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
79361658|NCT03096275|Drug|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
79361659|NCT03070223|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
79361660|NCT03070223|Drug|Placebos|One tablet taken once daily, orally with or without food
79361661|NCT03012321|Drug|Olaparib|
79512722|NCT05910203|Other|The effectiveness of education|Training will be provided on smoking cessation.
79512723|NCT05910047|Dietary Supplement|Supplement|Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
79672118|NCT00438776|Drug|sugar pill|matching placebo to olanzapine
79672119|NCT00475410|Drug|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
79672120|NCT00475410|Drug|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
79679736|NCT02948972|Procedure|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
79820217|NCT04070937|Diagnostic Test|vestibular test 1|videonystagmography
79308289|NCT03043287|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
79308290|NCT02503241|Procedure|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
79361662|NCT03012321|Drug|Abiraterone Acetate|
79361663|NCT03012321|Drug|Prednisone|
79361664|NCT03000101|Other|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
79361665|NCT03000101|Other|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
79361666|NCT02988895|Radiation|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
79361667|NCT02985593|Drug|KHK4083|
79512724|NCT05910047|Dietary Supplement|Placebo|Inert substance
79512725|NCT05907304|Drug|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
79512726|NCT05907304|Drug|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
79512727|NCT05901545|Biological|Panitumumab|Given by IV
79512728|NCT05901545|Other|Indium In 111 Panitumumab|Given by IV
79218081|NCT05556070|Other|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
79218082|NCT02128425|Drug|FOLFOXIRI|"irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~*reduced in UGT1A1 7/7 patients"
79361668|NCT02985593|Drug|Placebo|
79361669|NCT02981888|Radiation|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
79512729|NCT05901545|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
79672121|NCT00438893|Dietary Supplement|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
79672122|NCT00439010|Drug|[123I] AV 39|
79672123|NCT00475527|Drug|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
79672124|NCT00475566|Device|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
79672125|NCT00475566|Device|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
79672126|NCT00439166|Drug|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
79672127|NCT00439166|Drug|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
79672128|NCT00439166|Drug|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
79672129|NCT00439166|Drug|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
79672130|NCT00439205|Device|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
79672131|NCT00439205|Device|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
79218083|NCT02128425|Drug|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
79218084|NCT05555992|Device|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
79218085|NCT02122419|Other|lateral|spinal anesthesia performed during lateral position
79218086|NCT02122419|Other|sitting|spinal anesthesia performed during sitting position
79361670|NCT02975895|Device|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
79672132|NCT00475683|Other|Mouth wash|Mouth wash with chlorehexidin, three times a day
79512730|NCT05901545|Procedure|Computed Tomography|Undergo SPECT/CT
79512731|NCT05901545|Procedure|Surgical Procedure|Undergo standard of care surgery
79512732|NCT05901545|Other|Imaging agent|Receive local injection of optical dye
79672133|NCT00475683|Dietary Supplement|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
79672134|NCT00439283|Drug|infliximab|
79672135|NCT00439283|Drug|methotrexate|
79672136|NCT00475800|Drug|Lumiracoxib|
79672137|NCT00475839|Device|Tension-free Vaginal Tape|
79672138|NCT00475839|Device|Monarc sub-fascial hammock|
79672139|NCT00439361|Drug|Bortezomib|1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
79820218|NCT04070937|Diagnostic Test|vestibular test 2|video head impulse test
79218087|NCT05639790|Combination Product|Electronic cigarettes + Health Counselling|Ad libitum use of electronic cigarettes for 1 month
79218088|NCT05639790|Other|Health Counselling|Health Counselling from a licensed mental health counselor
79361671|NCT02975895|Device|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
79361672|NCT02943525|Procedure|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
79361673|NCT02934477|Other|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
79361674|NCT02858921|Drug|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
79512733|NCT05901545|Procedure|Intraoperative Imaging|Undergo Intraoperative Imaging
79512734|NCT05901545|Procedure|Near Infrared Imaging|Undergo Near Infrared Imaging
79512735|NCT05901545|Procedure|Electrocardiography|Undergo Electrocardiography
79512736|NCT05901545|Procedure|Biospecimen Collection|Undergo blood sample collection
79512737|NCT05897996|Device|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
79672140|NCT00439361|Drug|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
79672141|NCT00439361|Drug|Etoposide|100 mg/m^2 By Vein Over 2 Hours On Days 1-3
79672142|NCT00439361|Drug|Ifosfamide|5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1
79672143|NCT00439361|Drug|Mesna|5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
79672144|NCT00475917|Drug|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
79672145|NCT00475917|Drug|Gemcitabine|once-weekly 30-minute IV infusion
79672146|NCT00474669|Drug|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
79672147|NCT00439400|Drug|doxycycline|
79820219|NCT04070937|Diagnostic Test|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
79820220|NCT04070937|Diagnostic Test|audiometry|tonal liminar audiometric thresholds
79218089|NCT05555680|Other|Ferriman-Gallwey Score|The Ferriman-Gallwey score is used to evaluate hirsutism. The examiner scores the subjects on a scale of 0-4 for terminal hair growth on eleven different body areas according to the Ferriman-Gallwey scoring system. A Ferriman-Gallwey score of 8 or more was considered diagnostic of hirsutism
79218090|NCT02122497|Procedure|abdominal aortic surgery|
79820221|NCT04070937|Diagnostic Test|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
79512738|NCT05890846|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
79993808|NCT05627544|Procedure|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
79993809|NCT05707026|Other|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
79993810|NCT05707026|Other|stretching techniques(sleeper stretch and cross body adduction stretch)|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
79820222|NCT04070937|Genetic|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
79993811|NCT05609058|Device|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
79512739|NCT05890846|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
79512740|NCT05890846|Behavioral|traditional 1on1 course|Between every two iTBS sessions, the participant will receive a personalized 30-minutes one-on-one behavioral course, 2 courses per day, 5 days per week for 12 weeks.
79512741|NCT05884827|Device|EMG|Measure the electrical activity of the muscle and nerve
79820223|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
79361675|NCT02858921|Drug|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
79361676|NCT02858921|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
79512742|NCT05884775|Other|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
79218091|NCT02128503|Other|HBV DNA level monitoring|HBV DNV level being monitoring regularly
79672148|NCT00439400|Drug|placebo|
79218092|NCT02128581|Drug|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
79218093|NCT02128581|Other|Saline|
79218094|NCT03532620|Drug|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
79218095|NCT03532620|Drug|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
79218096|NCT05612854|Procedure|Mechanical embolectomy: by hydromechanical defragmentation by pigtail|Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
79672149|NCT00475956|Drug|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
79672150|NCT00475956|Drug|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
79672151|NCT00439439|Radiation|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
79672152|NCT00476034|Drug|lumiracoxib|
79672153|NCT00439478|Drug|Radioiodine|
79672154|NCT00476073|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
79672155|NCT00439595|Device|Hemocue 210 meter|Diagnostic device
79672156|NCT00439595|Device|Copack HBCS|
79672157|NCT00476112|Drug|Vernakalant Injection 20 mg/mL|
79672158|NCT00476268|Drug|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
79672159|NCT00476268|Drug|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
79993812|NCT05169606|Other|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
79993813|NCT05169606|Other|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
79993814|NCT05169606|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
79512743|NCT05883631|Device|EGF-Mapping and EGF-Guided Ablation of AF Sources|Ablacath™ Mapping Catheter, Ablacath™ Mapping Catheter Accessory Cables, Ablamap® System inclusive of Amplifier, Monitor/Workstation with installed Ablamap® Software
79512744|NCT05883631|Device|EGF-Mapping of AF Sources (no ablation)|Ablacath™ Mapping Catheter, Ablacath™ Mapping Catheter Accessory Cables, Ablamap® System inclusive of Amplifier, Monitor/Workstation with installed Ablamap® Software
79218097|NCT05612854|Device|Suction embolectomy by the Penumbra Indigo aspiration system|"The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX"
79218098|NCT02122653|Other|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
79218099|NCT02122653|Device|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
79218100|NCT05612776|Other|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
79361677|NCT02836080|Behavioral|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
79361678|NCT02836080|Other|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
79512745|NCT05873686|Drug|NXP900|NXP900 is an orally administered SRC/YES1 kinase inhibitor
79512746|NCT05868421|Behavioral|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
79512747|NCT05868421|Behavioral|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
79672160|NCT00476268|Drug|Formoterol powder 12 µg/unit dose|2 inhalations bid
79672161|NCT00105989|Drug|Duloxetine|
79820224|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
79512748|NCT05868421|Behavioral|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
79672162|NCT00105989|Drug|placebo|
79672163|NCT00476307|Biological|Fluarix™/Influsplit SSW® 2007/2008|
79672164|NCT00476346|Dietary Supplement|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
79672165|NCT00476385|Drug|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
79672166|NCT00476424|Drug|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
79672167|NCT00439712|Drug|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
79672168|NCT00439712|Drug|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
79672169|NCT00476463|Drug|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
79672170|NCT00439751|Drug|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
79672171|NCT00439790|Procedure|Microneurography|Microneurography
79672172|NCT00438243|Drug|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
79672173|NCT00438243|Drug|Refresh Plus|1 drop in the affected eye twice daily
79679737|NCT02948972|Procedure|In vitro fertilization without surgery|IVF without endometriosis surgery
79218101|NCT05612776|Other|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
79218102|NCT02288130|Drug|GnRHa|
79361679|NCT02764476|Other|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
79361680|NCT02764476|Other|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
79512749|NCT05861141|Other|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~Balance and postural control exercises for 15 minutes, including the following:~Standing on balance board.~Stoop and recovery.~Gait training for 45 minutes, including the following:~Forward, backward, and sideways walking.~Walking with obstacles using wedges and rolls with different diameters and heights."
79512750|NCT05861141|Device|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
79512751|NCT05856370|Device|Follow-up schedule: pre-operative baseline to index surgery|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Medtronic Powered Systems, Instruments, and Imaging device(s)
79512752|NCT05856370|Device|Follow-up schedule: pre-operative baseline to discharge|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Advanced Energy device(s)
79512753|NCT05856370|Device|Follow-up schedule: pre-operative baseline up to 24-months post-procedure|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Medtronic Robotics and Navigation, Rods and Screws, Interbodies and Biologics, Spinal Tethers, and Other Spinal Hardware device(s)
79512754|NCT05853133|Other|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
79672174|NCT00439829|Drug|Gonal F|"450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
79672175|NCT00439829|Drug|Luveris|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
79672176|NCT00439829|Drug|Cetrotide|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
79672177|NCT00439829|Drug|hCG|"- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o > 3 follicles are > 17 mm in diameter"
79672178|NCT03278769|Procedure|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
79672179|NCT00439868|Drug|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
79218103|NCT02288130|Drug|Ulipristal|
79218104|NCT02128659|Behavioral|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
79218105|NCT03529032|Drug|Methadone|methadone for control postoperative pain
79672180|NCT00439868|Drug|placebo|Matching placebo tablets to WELLBUTRIN XL.
79672181|NCT03279653|Procedure|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
79218106|NCT02128737|Behavioral|Sleep|
79218107|NCT02122731|Drug|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
79218108|NCT05458726|Drug|Osimertinib|Osimertinib or chemotherapy
79218109|NCT01367847|Behavioral|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon & Forehand) for parents of 3 to 8 y.o. children with externalizing problems
79218110|NCT01367847|Behavioral|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
79361681|NCT02667951|Other|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
79218111|NCT05612698|Behavioral|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
79218112|NCT05612698|Behavioral|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
79512755|NCT05853133|Other|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
79512756|NCT05852925|Other|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
79672182|NCT03277248|Biological|Ublituximab|Administered as an IV infusion.
79672183|NCT03277248|Drug|Teriflunomide|Film coated tablets administered orally.
79672184|NCT03277248|Drug|Oral Placebo|Administered orally.
79672185|NCT03277248|Drug|IV Placebo|Administered as an IV Infusion.
79820225|NCT00715455|Drug|Unfractionated Heparin|Heparin will be administered per standard of care at sites
79218113|NCT05612698|Behavioral|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) [25, 78, 79]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
79218114|NCT05612620|Diagnostic Test|coulture|Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
79672186|NCT03279614|Drug|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
79672187|NCT00439907|Procedure|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
79218115|NCT02122809|Drug|Chiauranib|Take orally
79218116|NCT02124837|Behavioral|Park walk during lunch break|
79218117|NCT02124837|Behavioral|Relaxation during lunch break|
79361682|NCT02645149|Drug|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
79672188|NCT00439907|Procedure|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
79672189|NCT03279822|Other|not any intervention|not any intervention
79672190|NCT00439985|Behavioral|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
79672191|NCT03279783|Device|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
79820226|NCT02574663|Drug|TGR-1202|TGR-1202 oral daily dose
79820227|NCT02574663|Drug|nab-paclitaxel + gemcitabine|IV infusion
79820228|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
79820229|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
79820230|NCT00718653|Dietary Supplement|Lutein|Lutein (12 mg/d)
79820231|NCT00718653|Dietary Supplement|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
79820232|NCT00718731|Drug|GSI-136|
79820233|NCT00718731|Other|Placebo|
79820234|NCT04083846|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
79218118|NCT03552081|Other|Fragmented DNA evaluation in blood and semen samples|The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
79361683|NCT02645149|Drug|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
79361684|NCT02645149|Drug|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
79361685|NCT02645149|Drug|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
79361686|NCT02645149|Drug|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
79361687|NCT02600429|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
79361688|NCT02600429|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
79218119|NCT00150618|Drug|SPD503 (1 mg)|
79361689|NCT02523859|Drug|Propofol|Hypnotic drug used for anesthesia
79361690|NCT02523859|Drug|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
79672192|NCT00440024|Drug|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
79218120|NCT00150618|Drug|SPD503 (2 mg)|
79218121|NCT00150618|Drug|SPD503 (3 mg)|
79218122|NCT00150618|Drug|SPD503 (4 mg)|
79218123|NCT00150618|Drug|Placebo|
79361691|NCT02510625|Procedure|Anatomic Glenoid Reconstruction|Distal tibia bone graft
79512757|NCT05852925|Device|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
79512758|NCT05847387|Diagnostic Test|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
79512759|NCT05846594|Diagnostic Test|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
79672193|NCT00440024|Drug|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
79672194|NCT00440024|Drug|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
79218124|NCT05610904|Diagnostic Test|Prediction model evaluation|a machine learning based anastomotic leakage prediction model
79672195|NCT00476502|Genetic|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
79672196|NCT00440063|Drug|epoetin beta [NeoRecormon]|
79218125|NCT02124993|Other|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
79218126|NCT02128815|Other|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
79218127|NCT03532464|Drug|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
79218128|NCT03532464|Drug|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
79218129|NCT02128893|Drug|Isavuconazole|oral
79361692|NCT02510625|Procedure|Arthroscopic bankart Repair|Arthroscopic bankart Repair
79361693|NCT02370329|Other|Laboratory Biomarker Analysis|Correlative studies
79361694|NCT02370329|Other|Quality-of-Life Assessment|Ancillary studies
79361695|NCT02370329|Biological|Ropeginterferon Alfa-2B|Given SC
79361696|NCT02229422|Drug|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
79361697|NCT02158793|Procedure|Craniomaxillofacial allotransplantation|Transplantation of donor face
79361698|NCT02087865|Drug|donepezil HCL|
79361699|NCT02087865|Drug|Placebo|
79512760|NCT05846594|Diagnostic Test|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
79218130|NCT02128893|Drug|Esomeprazole|oral
79218131|NCT02124369|Drug|Abraxane|125mg/m2, IV, on days 1,8 & 15 of each 28 day cycle, up to 6 cycles.
79361700|NCT01980823|Drug|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
79218132|NCT02124369|Drug|Gemcitabine|1000mg/m2, IV, on days 1,8 & 15 of a 28 day cycle, up to 6 cycles.
79218133|NCT05555602|Device|Cold-air cooling|Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
79512761|NCT05843643|Drug|Upadacitinib|Oral Tablets
79512762|NCT05843643|Drug|Placebo|Oral Tablet
79512763|NCT05842096|Diagnostic Test|Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study
79672197|NCT00438282|Behavioral|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
79672198|NCT00440102|Drug|Ketamine|Ketamine
79672199|NCT00440102|Drug|Etomidate|Etomidate
79672200|NCT00476541|Drug|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
79512764|NCT05842096|Diagnostic Test|Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms
79672201|NCT00476580|Behavioral|Questionnaire|Questions to collect health information specific to Sri Lankans.
79218134|NCT05447728|Diagnostic Test|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
79512765|NCT05842096|Diagnostic Test|Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms
79512766|NCT05841927|Dietary Supplement|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
79512767|NCT05841927|Dietary Supplement|ASD placebo|ASD placebo
79512768|NCT05839912|Procedure|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
79512769|NCT05839912|Procedure|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
79512770|NCT05839756|Drug|budesonide|2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
79512771|NCT05839756|Drug|normal saline|5 ml normal saline will be nebulized preoperatively
79512772|NCT05839041|Drug|AVD-104|Intravitreal injection
79512773|NCT05839041|Drug|Avacincaptad|Intravitreal injection of 2 mg avacincaptad
79512774|NCT05838768|Drug|HRO761|Tablet
79512775|NCT05838768|Biological|tislelizumab|Concentrate for solution for infusion
79672202|NCT00440141|Drug|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
79672203|NCT00440141|Drug|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
79672204|NCT00475449|Procedure|percutaneous coronary intervention|
79218135|NCT05447728|Diagnostic Test|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
79218136|NCT05725356|Other|Basic body awareness therapy|Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
79308291|NCT02503241|Procedure|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
79308292|NCT03043443|Drug|Melatonin|Natural health product for sleep problems treatment
79308293|NCT03043443|Drug|Placebo|Lactose containing pills
79672205|NCT00475449|Procedure|coronary artery bypass grafting|
79672206|NCT03279575|Behavioral|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
79672207|NCT03279575|Behavioral|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
79672208|NCT03279575|Behavioral|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
79672209|NCT03279575|Behavioral|Control|Physicians in this arm will serve as a no-contact control group.
79218137|NCT05299905|Procedure|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
79218138|NCT05299905|Procedure|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
79218139|NCT02128971|Dietary Supplement|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
79218140|NCT02128971|Dietary Supplement|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
79218141|NCT02128971|Dietary Supplement|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
79218142|NCT02128971|Dietary Supplement|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
79672210|NCT00438321|Drug|Zoladex|
79672211|NCT00438321|Drug|Testosterone gel|
79512776|NCT05838768|Drug|irinotecan|Concentrate for solution for infusion
79218143|NCT02128971|Dietary Supplement|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
79361701|NCT01980823|Drug|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
79361702|NCT01980823|Procedure|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
79218144|NCT02128971|Dietary Supplement|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
79361703|NCT01972347|Drug|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
79361704|NCT01972347|Drug|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
79361705|NCT01942616|Other|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
79361706|NCT01942616|Other|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
79361707|NCT01942616|Other|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
79361708|NCT01889992|Radiation|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short & long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
79672212|NCT00438321|Drug|Anastrozole Pill|
79672213|NCT00438321|Other|Placebo|
79672214|NCT00476619|Drug|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
79672215|NCT03279536|Combination Product|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
79218145|NCT05555446|Dietary Supplement|Bovine colostrum|Subject will receive bovine colostrum with gluten.
79672216|NCT03279536|Combination Product|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
79672217|NCT03279497|Behavioral|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
79672218|NCT03279497|Behavioral|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
79672219|NCT00438438|Behavioral|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
79672220|NCT00476697|Device|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
79820235|NCT04083846|Drug|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
79361709|NCT01889992|Procedure|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
79512777|NCT05833061|Other|The Stroke-Specific Quality of Life (SS-QoL) scale|The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.
79512778|NCT05833061|Other|The Stroke Self-Efficacy Questionnaire (SSEQ)|The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
79512779|NCT05832255|Drug|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
79218146|NCT05555446|Dietary Supplement|Placebo|Subject will receive a placebo with gluten.
79218147|NCT02288208|Drug|Antiviral Therapy (tenofovir or entecavir)|
79361710|NCT01889992|Other|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
79820236|NCT04083846|Drug|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
79672221|NCT00440219|Drug|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
79672222|NCT00440219|Drug|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
79672223|NCT00438477|Drug|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
79672224|NCT00438477|Procedure|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
79672225|NCT00438477|Radiation|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
79672226|NCT00440258|Drug|Cabergoline|
79672227|NCT00440258|Procedure|MR|
79672228|NCT00440258|Procedure|Ultrasound|
79672229|NCT00440258|Procedure|Blood Analysis|
79672230|NCT00438516|Behavioral|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
79820237|NCT02574507|Behavioral|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
79820238|NCT04069845|Drug|liposomal doxorubicin|intravenous liposomal doxorubicin
79672231|NCT00440336|Drug|Cosopt|
79672232|NCT00440336|Drug|Xalatan|
79672233|NCT03276780|Behavioral|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
79672234|NCT03276780|Drug|combination NRT|Both groups will receive combination NRT to help with smoking cessation
79672235|NCT00440375|Drug|Rosiglitazone|
79672236|NCT04700930|Other|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
79672237|NCT00438555|Behavioral|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
79820239|NCT04070625|Other|Communication book group|Communication book
79820240|NCT04070625|Other|Control group|Simple speech therapy
79820241|NCT02573805|Device|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
79820242|NCT04068987|Diagnostic Test|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2* mapping, ECV mapping) to determine the MR signal characteristics of the body
79820243|NCT02574585|Biological|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
79218148|NCT02288208|Drug|Birinapant|
79218149|NCT02288208|Drug|Placebo (for birinapant)|
79218150|NCT05700682|Device|Shoulder/Hip/Knee Embolization with Embozene Microspheres|Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
79218151|NCT03550833|Behavioral|Questionnaire|Questionnaire
79218152|NCT03550833|Biological|blood sample|7 ml whole blood for Peripheral blood
79218153|NCT02129049|Other|educational intervention|Participate in the Enhancing Connections Telephone Program
79308294|NCT02502929|Behavioral|Social Services|
79218154|NCT02129049|Behavioral|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
79218155|NCT02129049|Other|questionnaire administration|Ancillary studies
79820244|NCT05198466|Device|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
79993815|NCT05706792|Device|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
79361711|NCT01889992|Drug|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
79361712|NCT01889992|Procedure|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
79361713|NCT01889992|Genetic|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
79361714|NCT01889992|Other|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
79512780|NCT05828108|Drug|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
79512781|NCT05819775|Biological|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
79672238|NCT00438555|Behavioral|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
79672239|NCT00440414|Drug|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
79672240|NCT00440414|Drug|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
79993816|NCT05061186|Other|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique [Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
79672241|NCT00476736|Drug|Effect on small airways (N-Acetylcystein)|
79218156|NCT02125071|Other|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
79218157|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
79218158|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
79218159|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
79512782|NCT05814627|Drug|Upadacitinib|Oral Tablets
79512783|NCT05814627|Drug|Adalimumab|Subcutaneous Injection
79512784|NCT05814627|Drug|Upadacitinib Matching Placebo|Oral Tablets
79672242|NCT00440453|Other|Nutritional therapy|Nutritional therapy by dietician
79672243|NCT00438594|Behavioral|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
79820245|NCT05198466|Device|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
79820246|NCT00919074|Procedure|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
79218160|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
79218161|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
79218162|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
79218163|NCT02251977|Drug|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
79308295|NCT02502929|Behavioral|Lifestyle|
79672244|NCT00440492|Drug|PLA-695|
79218164|NCT02251977|Drug|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
79218165|NCT02251977|Drug|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
79820247|NCT00919074|Procedure|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
79218166|NCT03528954|Drug|Propofol|Those who received intravenous propofol
79218167|NCT02252055|Biological|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
79361715|NCT01858740|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
79361716|NCT01858740|Drug|Fludarabine Phosphate|Given IV
79361717|NCT01858740|Other|Laboratory Biomarker Analysis|Correlative studies
79361718|NCT01858740|Drug|Methotrexate|Given IV
79361719|NCT01858740|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
79361720|NCT01858740|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
79512785|NCT05814627|Drug|Adalimumab Matching Placebo|Subcutaneous Injection
79512786|NCT05813847|Drug|local anaesthetic injection|Local infiltration of study drug
79512787|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
79672245|NCT00476775|Behavioral|after school ethnic dance program - ballet folklorica|
79672246|NCT00476775|Behavioral|culturally-tailored, home-based screen time reduction|
79672247|NCT00476775|Behavioral|culturally-tailored health and nutrition education|
79361721|NCT01858740|Drug|Tacrolimus|Given IV or PO
79361722|NCT01858740|Drug|Thiotepa|Given IV
79361723|NCT01858740|Radiation|Total-Body Irradiation|Undergo TBI
79512788|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions BID over 14 days
79512789|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
79512790|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
79512791|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every QD over 14 days
79512792|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
79512793|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
79512794|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
79512795|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
79672248|NCT00440570|Device|Low levels of amplitude-modulated electromagnetic fields|
79361724|NCT01839734|Drug|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
79820248|NCT05196126|Procedure|Permament pacemaker implantation|PM implantation
79820249|NCT05196126|Procedure|Cardioneuroablation|Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
79361725|NCT01682083|Drug|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
79361726|NCT01682083|Drug|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
79361727|NCT01682083|Drug|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
79361728|NCT01511068|Drug|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
79361729|NCT01437969|Genetic|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
79361730|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
79672249|NCT00440570|Device|Emitter of low levels of amplitude-modulated electromagnetic fields|
79672250|NCT03270462|Drug|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
79672251|NCT00440609|Drug|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
79672252|NCT00440648|Drug|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
79820250|NCT00710307|Procedure|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
79361731|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
79218168|NCT03532386|Procedure|ICSI|ICSI for both couples
79361732|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
79361733|NCT01180790|Drug|Placebo|Powder in capsule once daily
79361734|NCT01180790|Drug|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
79361735|NCT01180790|Drug|Ribavirin|400 mg or 600 mg (morning [AM]) and 600 mg (evening [PM]) capsules taken orally twice daily
79361736|NCT00798122|Procedure|Intravascular ultrasound|intravascular ultrasound
79361737|NCT00798122|Procedure|MRI|cardiac MRI
79361738|NCT00792675|Other|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
79361739|NCT00721526|Drug|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
79361740|NCT00679042|Biological|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
79512796|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
79672253|NCT00440648|Drug|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
79820251|NCT00710307|Genetic|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
79512797|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
79512798|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
79512799|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
79512800|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
79512801|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
79512802|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
79218169|NCT02131077|Biological|ALLO-ASC-TI|
79218170|NCT02131077|Drug|Placebo|
79218171|NCT05612464|Other|No intervention|No intervention
79361741|NCT00505063|Biological|Immunization Schedule patients <7 years.|"Time 0 months: Prevnar 13 #1, Hib #1~Time 1 months: Pediarix #1~Time 2 months: Prevnar 13 #2, Hib #2~Time 3-4 months: Pediarix #2~Time 4-6 months: Draw post vaccine titers~Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
79361742|NCT00505063|Biological|Immunization Schedule patients > or = to 7 years and <11 years of age|"Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~Time 2-3 months: Prevnar 13 #2, Hib #2~Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
79361743|NCT00505063|Biological|Immunization Schedule patients > or = to 11 years of age|"Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~Time 3-6 months: IPV, Draw post vaccine titers~Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
79361744|NCT00350272|Drug|Elvucitabine|Elvucitabine 10 mg orally daily
79361745|NCT00350272|Drug|Lamivudine|Lamivudine 300 mg orally daily
79361746|NCT00350272|Drug|Tenofovir|Tenofovir open-label 300 mg orally daily
79361747|NCT00350272|Drug|Efavirenz|Efavirenze open-label 600 mg orally daily
79361748|NCT00349011|Procedure|Personalized risk assessment|
79361749|NCT00349011|Procedure|genetic counseling intervention|
79361750|NCT02028884|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
79361751|NCT02028884|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
79512803|NCT05807490|Drug|PF-07328948|Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
79512804|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
79512805|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions QD over 14 days
79512806|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
79512807|NCT05807490|Drug|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
79512808|NCT05807490|Drug|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
79512809|NCT05803382|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
79218172|NCT02288442|Other|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
79218173|NCT02125227|Drug|Rosuvastatin, Metformin, YH14755|single dose
79512810|NCT05803382|Procedure|Biopsy|Undergo biopsy
79672254|NCT00440687|Drug|Fluticasone 500mcg BD via accuhaler or identical placebo|
79672255|NCT03271047|Drug|binimetinib|Orally, twice daily.
79672256|NCT03271047|Drug|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
79218174|NCT02125227|Drug|YH14755|single dose
79218175|NCT03532230|Procedure|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
79308296|NCT02502929|Behavioral|Lifestyle Plus Medication Therapy Management|
79820252|NCT05012592|Behavioral|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
79218176|NCT02129127|Device|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
79820253|NCT00715689|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79820254|NCT00715689|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79820255|NCT00715689|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79218177|NCT05555134|Behavioral|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
79218178|NCT03532152|Device|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
79218179|NCT03532152|Device|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
79361752|NCT02028884|Drug|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
79512811|NCT05803382|Procedure|Biospecimen Collection|Undergo collection of blood samples
79218180|NCT03550599|Other|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
79512812|NCT05803382|Drug|Capecitabine|Given PO
79512813|NCT05803382|Procedure|Computed Tomography|Undergo CT and PET/CT
79218181|NCT03528876|Drug|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
79218182|NCT03550755|Biological|V3-Cervix|Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
79218183|NCT05554900|Procedure|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
79361753|NCT02020694|Drug|Vitamin D|
79361754|NCT02020694|Drug|Placebo (for vitamin D)|
79512814|NCT05803382|Procedure|Magnetic Resonance Imaging|Undergo MRI
79512815|NCT05803382|Procedure|Positron Emission Tomography|Undergo PET/CT
79512816|NCT05803083|Dietary Supplement|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
79361755|NCT02019875|Drug|Rifampin|P450 inducer
79512817|NCT05803083|Dietary Supplement|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
79512818|NCT05803083|Dietary Supplement|Placebo|Take 2 capsules per day at any time.
79512819|NCT05800275|Drug|Tucatinib Oral Tablet|300 mg, twice daily
79672257|NCT03271047|Drug|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
79672258|NCT00440765|Drug|bortezomib|dose as determined (observational study) by treating physician
79672259|NCT00440804|Drug|ibuprofen l-lysine iv solution (NeoProfen (R) )|
79361756|NCT02019875|Drug|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
79361757|NCT02019875|Other|Grapefruit Juice|CYP3A4 inhibitor in intestine
79512820|NCT05800275|Drug|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
79512821|NCT05800275|Drug|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
79672260|NCT03276936|Drug|FMX103 1.5%|FMX103 1.5% minocycline foam
79672261|NCT00440843|Drug|Olanzapine (Zyprexa)|OLZ
79672262|NCT00440843|Drug|Typicals|Stay on typicals regimen
79672263|NCT00438789|Drug|eculizumab|600mg IV every week and 900mg IV every 2 weeks
79672264|NCT00440921|Drug|Single donor Allogenous Fibrin Sealant|
79672265|NCT00440960|Drug|propofol|
79672266|NCT00440960|Drug|midazolam|
79672267|NCT00440960|Drug|alfentanil|
79672268|NCT00440960|Drug|lidocaine|
79672269|NCT00438828|Drug|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
79361758|NCT02019875|Other|Placebo|
79820256|NCT00715689|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79820257|NCT00715689|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79820258|NCT00715689|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79820259|NCT00715689|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79820260|NCT00715689|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79820261|NCT05012046|Other|Orange juice|Matched for volume (240 mL/ 8 oz) of other test beverages. 100% orange juice.
79820262|NCT05012046|Other|Orange flavoured drink|Matched for volume (240 mL/ 8 oz) of other test beverages. Orange flavoured drink
79820263|NCT05012046|Other|Water|Matched for volume (240 mL/ 8 oz) of other test beverages. Water control
79361759|NCT01907009|Drug|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
79218184|NCT02129283|Behavioral|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
79218185|NCT00264732|Drug|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
79218186|NCT00264732|Drug|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
79218187|NCT00264732|Other|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
79218188|NCT05554822|Drug|Aspirin 100mg|Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
79820264|NCT00715767|Behavioral|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
79218189|NCT05554822|Drug|Aspirin 100 mg OD plus clopidogrel 75 mg OD|Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
79820265|NCT00919542|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
79218190|NCT02125305|Drug|Metformin|
79361760|NCT01907009|Drug|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
79361761|NCT01882933|Drug|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
79218191|NCT02125383|Procedure|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
79218192|NCT02125383|Procedure|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
79361762|NCT01882933|Procedure|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
79361763|NCT01821976|Procedure|Ertl Procedure|
79361764|NCT01821976|Procedure|Burgess Procedure|
79361765|NCT01787929|Procedure|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
79361766|NCT01778738|Procedure|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
79672270|NCT00441038|Behavioral|The Back Guide|Education on postural hygiene and handout of The Back Guide
79672271|NCT00441038|Behavioral|The Back Book|Education on active management and Handout of The Back Book
79672272|NCT00441038|Behavioral|Cardiovascular and general health|Education on cardiovascular and general health
79672273|NCT00438867|Genetic|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
79672274|NCT00438867|Genetic|Placebo|Control group
79672275|NCT00441077|Behavioral|Education|
79820266|NCT00919542|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
79820267|NCT00715845|Procedure|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
79820268|NCT00719121|Drug|Talarozole|Topical Application (20 mg)
79361767|NCT01778738|Procedure|Sleeve gastrecomy|Vertical sleeve gastrectomy
79820269|NCT00719121|Drug|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
79361768|NCT01778738|Procedure|Bastric bypass|Gastric bypass surgery
79512822|NCT05792436|Device|1-min interval oscillometric method|"Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period."
79512823|NCT05792436|Device|arterial catheterization method|During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
79512824|NCT05785377|Drug|Bupivacaine-Neostigmine|20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)
79512825|NCT05785377|Drug|Bupivacaine|20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
79512826|NCT05778942|Device|Eyestil SYNFO|Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
79512827|NCT05776563|Other|Magnetic Resonance Spectroscopy Imaging (MRSI)|baseline 1HMRSI imaging study, then will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region
79512828|NCT05769153|Drug|AR-14034 SR implant lower dose|AR-14034 SR administered as an intravitreal implant
79512829|NCT05769153|Drug|Aflibercept Injection|Aflibercept administered as a 2 milligram (mg) intravitreal injection
79820270|NCT00715923|Other|Modified consent form|modified consent form used
79820271|NCT00715923|Other|Standard consent form|standard consent form used
79820272|NCT00719199|Drug|IMO-2055|SC weekly injections
79820273|NCT00719199|Drug|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
79218193|NCT05554744|Procedure|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
79361769|NCT01744145|Other|Interventional 40-60|This group will receive the intervention aged 40-60
79361770|NCT01744145|Other|Interventional 60 and above|This group will receive the intervention aged 60 and above.
79361771|NCT01713062|Device|Vitelene|THA
79512830|NCT05769153|Drug|Sham procedure|Needleless syringe used to simulate an intravitreal injection
79512831|NCT05769153|Drug|AR-14034 SR implant higher dose|AR-14034 SR administered as an intravitreal implant
79512832|NCT05766124|Drug|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
79672276|NCT00441155|Drug|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
79672277|NCT00106002|Drug|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
79672278|NCT00441194|Device|Visual Field (Octopus 311 and the HFA 700 series)|
79672279|NCT00476853|Drug|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
79672280|NCT00441233|Device|Silicone hydrogel contact lens|
79820274|NCT00719199|Drug|FOLFIRI|Given day 1 of each cycle
79820275|NCT00719277|Device|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
79820276|NCT04068675|Behavioral|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
79672281|NCT00438906|Procedure|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
79820277|NCT02589288|Procedure|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
79820278|NCT02589288|Procedure|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
79218194|NCT02131389|Device|Iconacy Hip System|
79218195|NCT04469322|Diagnostic Test|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at ~45 SNP markers covering 16 genes
79218196|NCT04469322|Diagnostic Test|Sham Test|"Names of 53 medications listed with use as directed"
79361772|NCT01713062|Device|XLPE|THA
79361773|NCT01686126|Drug|Levonorgestrel|Intrauterine device
79361774|NCT01686126|Drug|Metformin|oral medication
79672282|NCT00438906|Drug|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
79512833|NCT05761249|Other|HeartInsight activation|HeartInsight is activated at enrollment. The attending physicians are free on how to integrate HeartInsight in the patient care. Any treatment is based on routine care according to guidleines. Only documentation occurs on how the physicians use HeartInsight and actions taken in response to HeartInsight alerts
79218197|NCT04330222|Diagnostic Test|7 Tesla Magnetic Resonance Imaging|Diagnostic Imaging
79512834|NCT05760378|Drug|Famitinib|TKI
79672283|NCT00441311|Behavioral|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
79672284|NCT00438945|Drug|Eprosartan|
79672285|NCT00476892|Procedure|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
79672286|NCT00441428|Drug|solifenacin|
79218198|NCT04330222|Other|Brief Memory and Executive Test|Cognitive Assessment
79672287|NCT00438984|Drug|cyclophosphamide|Given IV
79672288|NCT00438984|Biological|therapeutic autologous lymphocytes|Given IV
79672289|NCT00438984|Biological|aldesleukin|Given IV or SC
79672290|NCT00438984|Other|immunohistochemistry staining method|Correlative studies
79218199|NCT04469400|Dietary Supplement|Low fat diet intensive intervention|education and Compound protein solid beverage
79218200|NCT04469400|Other|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
79218201|NCT02125539|Behavioral|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
79218202|NCT02125539|Behavioral|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
79361775|NCT01531582|Drug|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
79361776|NCT01512888|Genetic|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
79361777|NCT01512888|Drug|Busulfan|Given intravenously (IV).
79361778|NCT01512888|Device|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
79672291|NCT00438984|Procedure|biopsy|Optional correlative studies
79820279|NCT00710463|Device|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
79361779|NCT01500733|Drug|PCI 32765|420 mg daily
79512835|NCT05760378|Drug|Camrelizumab|PD1 inhibitor
79512836|NCT05760378|Drug|nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin|TPC
79512837|NCT05759572|Drug|Apatinib|TKI
79512838|NCT05759572|Drug|Dalpiciclib|CDK4/6 inhibitor
79512839|NCT05759572|Drug|Fulvestrant/AI|Endocrine therapy
79512840|NCT05759546|Drug|Fluzoparib|Parp inhibitor
79672292|NCT00438984|Other|laboratory biomarker analysis|Correlative studies
79672293|NCT00438984|Other|immunologic technique|Correlative studies
79820280|NCT00716001|Drug|N-acetylcysteine|
79820281|NCT02574429|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions & 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
79820282|NCT00710229|Drug|Ranibizumab|intravitreal injection
79512841|NCT05759546|Drug|Dalpiciclib|CDK4/6 inhibitor
79218203|NCT05554588|Procedure|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
79218204|NCT05554588|Procedure|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
79218205|NCT05329324|Other|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
79512842|NCT05759546|Drug|Fulvestrant/AI|Endocrine therapy
79512843|NCT05756322|Drug|LBS-007|Open Label.
79512844|NCT05753826|Drug|Adebrelimab|20mg/kg，D1，q3W
79512845|NCT05753826|Drug|Fuzuloparib|100 mg bid
79512846|NCT05752474|Behavioral|Exercise|Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.
79820283|NCT00710229|Drug|Bevacizumab|intravitreal injection
79820284|NCT05684406|Genetic|Genotyping|Genotyping by Real Time PCR
79361780|NCT01493453|Genetic|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
79512847|NCT05752474|Behavioral|Nutrition|One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).
79512848|NCT05752474|Behavioral|Meditation|One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.
79820285|NCT00710541|Device|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
79820286|NCT00710619|Drug|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
79820287|NCT00710619|Drug|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
79820288|NCT00710697|Drug|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79820289|NCT05684250|Behavioral|Auditory biofeedback training|For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
79820290|NCT00710775|Procedure|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
79820291|NCT02572245|Device|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
79820292|NCT02572245|Device|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
79361781|NCT01436864|Biological|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
79361782|NCT01422187|Drug|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
79361783|NCT01191775|Drug|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
79672294|NCT00438984|Genetic|polymerase chain reaction|Correlative studies
79672295|NCT00441506|Drug|daily interruption of sedatives|
79672296|NCT04700852|Device|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
79672297|NCT00439023|Procedure|dialysis with glucose in dialysis water|
79672298|NCT00441623|Behavioral|observational|effect of protein-bound uremic retention solutes
79672299|NCT00476970|Behavioral|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
79672300|NCT00441662|Drug|Sub-Tenon triamcinolone 40mg|
79672301|NCT00439062|Drug|Roxithromycin|
79672302|NCT00477009|Device|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
79672303|NCT02957162|Drug|Atorvastatin|
79820293|NCT05192460|Biological|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
79820294|NCT00719433|Device|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
79361784|NCT01116765|Other|no stimulation of the oral structure|
79218206|NCT05329324|Other|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
79361785|NCT01116765|Other|stimulation of the oral structure|
79672304|NCT02957162|Other|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
79672305|NCT00439101|Drug|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
79302629|NCT04998513|Procedure|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
79361786|NCT01041989|Behavioral|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
79820295|NCT00719433|Other|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
79512849|NCT05752474|Behavioral|Cognitive Behavioral Intervention|A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
79218207|NCT05725278|Behavioral|Tiko Platform Behavioural cum mHealth Intervention|Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
79672306|NCT00439101|Other|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
79820296|NCT02589054|Other|Monitoring|
79820297|NCT03897699|Device|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
79820298|NCT03897699|Behavioral|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
79361787|NCT01041989|Behavioral|Exercise|Guided muscle strength training and aerobic exercise.
79512850|NCT05751590|Device|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
79361788|NCT01041989|Behavioral|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
79361789|NCT01041989|Other|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
79361790|NCT00667199|Drug|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
79361791|NCT00605982|Procedure|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
79361792|NCT00537225|Behavioral|exercise|tailored multifactor CVD risk reduction
79512851|NCT05751590|Device|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
79512852|NCT05750992|Procedure|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
79361793|NCT00472212|Device|Spectacles|Hyperopic spectacle lenses
79512853|NCT05750992|Procedure|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
79512854|NCT05749068|Device|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
79820299|NCT03897699|Other|Sham|Weak electrical current (~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
79308297|NCT04383795|Drug|Antithyroid Drug|Administration of antithyroid Drug for 6 months
79361794|NCT00472212|Device|Control|Plano (no power, control) spectacle lenses
79361795|NCT00460486|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
79361796|NCT00139477|Drug|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
79361797|NCT00139477|Behavioral|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
79672307|NCT00441740|Drug|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
79672308|NCT00441740|Drug|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
79672309|NCT00441740|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
79672310|NCT00441740|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
79672311|NCT02274012|Drug|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
79672312|NCT02274012|Drug|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
79820300|NCT02589210|Other|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
79820301|NCT04069689|Drug|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
79820302|NCT04069689|Drug|Placebos|Placebo to match EPX-100
79512855|NCT05746455|Behavioral|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
79512856|NCT05745207|Drug|E2086|E2086 tablets.
79820303|NCT00719511|Drug|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
79820304|NCT00719511|Drug|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
79820305|NCT00719511|Drug|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
79820306|NCT00719511|Drug|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
79512857|NCT05745207|Drug|Placebo|E2086 matched placebo tablets.
79820307|NCT04984122|Procedure|LEEP|According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
79820308|NCT00795821|Drug|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
79820309|NCT00795821|Drug|Placebo|Dose: 3 tablets QD for 10 weeks
79820310|NCT04978272|Drug|Dihydroartemisinin-piperaquine (DP)|Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
79820311|NCT04978272|Other|DP Placebo|Placebos will be identical appearance to DP.
79820312|NCT00719667|Other|coronary artery bypass grafting|on pump off pump
79218208|NCT05725278|Other|Standard of Care / Business as Usual|Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
79512858|NCT05739149|Diagnostic Test|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
79512859|NCT05739149|Procedure|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
79512860|NCT05738291|Drug|BI 1839100|BI 1839100
79512861|NCT05738291|Drug|Placebo matching BI 1839100|Placebo matching BI 1839100
79820313|NCT00710853|Other|YiRen Qi gong|One hour weekly class for 8 week duration
79820314|NCT00710853|Other|Tai Chi|One hour weekly class for 8 week duration
79820315|NCT00710853|Other|Hatha yoga|One hour weekly class for 8 week duration
79820316|NCT04971720|Drug|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
79820317|NCT04971720|Drug|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
79820318|NCT00711165|Drug|Placebo|2 puffs, qd
79820319|NCT00711165|Drug|Mometasone Furoate|400 mcg, qd for 8 weeks
79512862|NCT05738291|Drug|midazolam|midazolam
79512863|NCT05738291|Drug|digoxin|digoxin
79512864|NCT05738291|Drug|rosuvastatin|rosuvastatin
79512865|NCT05738252|Diagnostic Test|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
79512866|NCT05738252|Diagnostic Test|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
79820320|NCT02588040|Biological|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
79820321|NCT00719745|Drug|Prograf|oral
79218209|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
79218210|NCT00254904|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
79512867|NCT05736341|Drug|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
79512868|NCT05736341|Drug|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
79512869|NCT05730751|Procedure|spinal anesthesia|spinal anesthesia
79512870|NCT05730751|Procedure|caesarean section|LSCS
79820322|NCT00719745|Drug|MR4|oral
79820323|NCT02587416|Drug|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
79820324|NCT02587416|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
79820325|NCT02587416|Drug|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
79820326|NCT00719823|Drug|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
79820327|NCT00919776|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
79820328|NCT00919776|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
79820329|NCT00719979|Behavioral|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
79820330|NCT00719979|Behavioral|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
79218211|NCT00254904|Drug|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
79361798|NCT00139477|Behavioral|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
79361799|NCT00004935|Drug|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
79672313|NCT00477048|Drug|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
79672314|NCT00441818|Drug|TNX-650|
79672315|NCT00477126|Drug|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
79672316|NCT03279419|Diagnostic Test|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
79672317|NCT03279380|Other|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
79672318|NCT03279380|Other|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
79361800|NCT00004935|Drug|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
79361801|NCT00119158|Drug|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
79361802|NCT00119158|Drug|pimecrolimus|apply daily with fluticasone cream for flares
79512871|NCT05730400|Drug|BMAC loaded on bovine graft|Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation
79512872|NCT05730400|Drug|Bovine graft only|Bovine graft only for sinus floor augmentation
79512873|NCT05728502|Drug|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
79512874|NCT05728502|Drug|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
79512875|NCT05723692|Biological|ALTB-268|monoclonal antibody
79512876|NCT05723692|Other|Placebo|formulation buffer
79512877|NCT05721859|Device|revision hip arthroplasty|revision hip arthroplasty
79512878|NCT05719909|Behavioral|Cognitive Training|8 sessions of web-based cognitive training
79672319|NCT03279380|Other|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
79672320|NCT03277521|Other|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
79672321|NCT03279341|Drug|polyethylene glycol|osmotic laxative
79672322|NCT03279341|Drug|Bisacodyl|stimulant laxative
79672323|NCT03279341|Drug|Prucalopride|prokinetic
79672324|NCT00441857|Behavioral|plant stanol consumption|
79218212|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
79218213|NCT00254904|Drug|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
79218214|NCT04329988|Other|questionnaire|A questionnaire will be made available to all eligible patients in general practitioners waiting rooms. This questionnaire will be composed by the single question, followed by the AUDIT and FACE questionnaires, and three socio-demographic questions. This questionnaire will be anonymous. Patients who agree to fill out a questionnaire will place it in a sealed box once completed.
79361803|NCT00119392|Biological|rituximab|Given IV
79361804|NCT00119392|Drug|cyclosporine|Given orally
79361805|NCT00119392|Drug|fludarabine phosphate|Given IV
79361806|NCT00119392|Drug|mycophenolate mofetil|Given orally
79361807|NCT00119392|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
79361808|NCT00119392|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
79361809|NCT00119392|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
79361810|NCT00119392|Radiation|total-body irradiation|Undergo TBI
79361811|NCT00218062|Drug|D-Amphetamine 30mg|
79512879|NCT05719909|Behavioral|Sham Training|8 sessions of web-based sham training
79512880|NCT05710224|Biological|V181|0.5 mL SC dose of V181
79512881|NCT05710224|Biological|Butantan-DV|0.5 mL SC dose of Butantan-DV
79512882|NCT05709990|Drug|Solifenacin Succinate 5 MG Oral Tablet [Vesicare]|These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
79820331|NCT00719979|Behavioral|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
79820332|NCT00720135|Biological|DI-Leu16-IL2 immunocytokine|Given IV
79820333|NCT00720135|Biological|rituximab|Given IV
79820334|NCT00720135|Other|flow cytometry|Correlative studies
79820335|NCT00720135|Other|immunohistochemistry staining method|Correlative studies
79820336|NCT00720135|Other|pharmacological study|Correlative studies
79820337|NCT00720135|Other|laboratory biomarker analysis|Correlative studies
79820338|NCT00720135|Other|enzyme-linked immunosorbent assay|Correlative studies
79820339|NCT00720135|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
79820340|NCT02574273|Behavioral|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
79820341|NCT02574273|Other|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
79820342|NCT02588118|Drug|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
79218215|NCT05295082|Procedure|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
79218216|NCT05295082|Procedure|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
79218217|NCT05554510|Other|Observational|No interventions planned. Observational data collection only.
79218218|NCT05725122|Procedure|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
79218219|NCT05725122|Procedure|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
79512883|NCT05709990|Drug|Vitamin D3|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
79512884|NCT05709990|Behavioral|Standard urotherapy|These patients will receive standard urotherapyfor 8 weeks.
79679738|NCT05108454|Drug|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
79218220|NCT03880396|Radiation|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
79218221|NCT03532074|Diagnostic Test|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
79218222|NCT03532074|Diagnostic Test|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
79361812|NCT00218062|Drug|D-Amphetamine 60mg|
79361813|NCT00218062|Drug|Modafinil 200mg|
79512885|NCT05706805|Device|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
79512886|NCT05703009|Drug|Sacrosidase Oral Solution|Study drug
79512887|NCT05703009|Drug|Placebo|Placebo
79512888|NCT05701722|Device|Flourish HEC Vaginal Care System|BioNourish, a component of the Flourish HEC system, is a class II medical device. In addition to BioNourish, the system includes Balance intimate wash and BiopHresh homeopathic vaginal suppository with probiotics. All products are available over the counter and have been on the market for several years.
79679739|NCT04694222|Device|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
79680143|NCT02935998|Drug|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
79680144|NCT02930616|Device|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
79993817|NCT05061186|Other|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
79993818|NCT05706480|Diagnostic Test|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
79218223|NCT03532074|Diagnostic Test|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
79218224|NCT03532074|Diagnostic Test|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
79993819|NCT05706480|Diagnostic Test|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
79993820|NCT05706480|Diagnostic Test|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
79993821|NCT03383783|Drug|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
79218225|NCT04441164|Other|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
79218226|NCT04441164|Other|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
79218227|NCT04441164|Other|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
79218228|NCT04441164|Other|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
79218229|NCT04441164|Other|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
79218230|NCT04441164|Other|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
79218231|NCT04441164|Other|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
79512889|NCT05687266|Drug|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
79680145|NCT02930616|Device|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
79993822|NCT03383783|Drug|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
79361814|NCT00218062|Drug|Modafinil 400mg|
79993823|NCT03383783|Drug|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
79993824|NCT03383783|Drug|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
79218232|NCT01359046|Device|silver SPC|subject randomized to receive silver alloy impregnated catheter
79218233|NCT01359046|Device|standard SPC|subject randomized to receive standard catheter
79218234|NCT00253968|Drug|Eplivanserin|oral administration
79361815|NCT00218062|Behavioral|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
79361816|NCT00218062|Drug|Placebo|
79361817|NCT00121186|Drug|fludarabine phosphate|30 mg/m^2 on days -6 to -2 (2-6 days before transplant).
79361818|NCT00121186|Drug|melphalan|70 mg/m^2 on days -3 and -2 (2-3 days before transplant).
79361819|NCT00121186|Drug|methotrexate|5 mg/m^2 on days 1, 3, and 7 post-transplant.
79361820|NCT00121186|Drug|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
79361821|NCT00121186|Procedure|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
79218235|NCT00253968|Drug|placebo|oral administration
79218236|NCT05612308|Other|Vertical Oscillatory Pressure (VOP)|The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
79218237|NCT05612230|Other|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
79218238|NCT05543304|Diagnostic Test|radiological evaluation|All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
79218239|NCT05612152|Other|Referral to Quitline|An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
79218240|NCT05612152|Other|Choose2Quit|An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
79218241|NCT05549986|Other|Observational|Observational
79218242|NCT05549830|Other|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
79672325|NCT00439452|Other|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
79672326|NCT00439452|Other|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
79820343|NCT02588118|Drug|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
79820344|NCT00716391|Other|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
79820345|NCT00716391|Other|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
79820346|NCT02588898|Device|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
79820347|NCT04068129|Device|photoscreen|Determine amblyopia risk factors
79218247|NCT03544606|Drug|isosorbide mononitrate|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
79218248|NCT03544606|Drug|Placebos|70 patients induced by placebo (pyridoxine) administered in the posterior vaginal fornix.
79218249|NCT02741310|Drug|Placebo|Administered by intravenous infusion
79218250|NCT02741310|Drug|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
79218251|NCT02741310|Drug|Erenumab|Administered by intravenous infusion
79218252|NCT03531684|Dietary Supplement|MMFS-205-SR|Twice daily, oral, 500 mg tablets
79218253|NCT03531684|Dietary Supplement|Placebo|Twice daily, oral
79218254|NCT00243906|Drug|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
79218255|NCT00243906|Procedure|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS >/= 10) treated within 3 hours of symptoms onset.
79218256|NCT03532360|Other|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
79218257|NCT03531606|Drug|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
79218258|NCT03531606|Drug|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
79361822|NCT00121186|Procedure|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
79361823|NCT00121810|Drug|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
79218259|NCT01367457|Other|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
79218260|NCT05553652|Dietary Supplement|ASTARTE™ oral capsules|1 Capsule daily for 6 months
79361824|NCT00121810|Drug|Corticosteroids|As prescribed
79361825|NCT00121810|Drug|Calcineurin inhibitors|As prescribed
79361826|NCT00121810|Drug|Sirolimus|As prescribed
79361827|NCT00053014|Biological|therapeutic allogeneic lymphocytes|
79672327|NCT03279302|Drug|Glepaglutide|Solution for injection
79672328|NCT03279263|Drug|MLR-1023|MLR-1023 Tablets
79361828|NCT00053014|Drug|cyclosporine|
79361829|NCT00053014|Drug|fludarabine|
79512890|NCT05687266|Drug|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
79512891|NCT05687266|Drug|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
79512892|NCT05687266|Drug|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
79512893|NCT05687266|Drug|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
79512894|NCT05687266|Drug|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
79672329|NCT03279263|Other|Placebo|Matching Placebo Tablets
79672330|NCT03276741|Dietary Supplement|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
79672331|NCT03279146|Drug|Tenofovir exalidex (TXL)|Oral formulations
79672332|NCT00439491|Behavioral|Hypocaloric diet|
79361830|NCT00053014|Drug|mycophenolate mofetil|
79361831|NCT00053014|Procedure|peripheral blood stem cell transplantation|
79361832|NCT00053014|Radiation|radiation therapy|
79361833|NCT00123604|Drug|Carvedilol|25 mg twice daily for five months.
79512895|NCT05687266|Drug|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
79512896|NCT05683483|Other|WEsleep Interventions|1) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
79672333|NCT00441935|Device|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
79672334|NCT03275571|Behavioral|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
79672335|NCT00442052|Drug|aspirin|
79672336|NCT00442052|Drug|omeprazole|
79672337|NCT00477243|Behavioral|Questionnaire|8 questionnaires will take about 40 minutes to complete.
79361834|NCT00123604|Drug|Metoprolol|200 mg twice daily for five months.
79361835|NCT00123682|Procedure|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
79361836|NCT00123682|Procedure|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
79361837|NCT00123682|Procedure|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
79672338|NCT00442091|Drug|dandelion juice|10 ml bid for 20-30 days
79672339|NCT00477282|Drug|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
79820348|NCT00716469|Drug|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
79820349|NCT04082598|Drug|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
79218261|NCT05553652|Dietary Supplement|Placebo oral capsules|1 Capsule daily for 6 months
79218262|NCT05553496|Drug|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
79218263|NCT05553496|Drug|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
79218264|NCT00239694|Biological|Pneumococcal Vaccine|One time preventative vaccine
79218265|NCT00239694|Biological|Meningococcal Vaccine|One time preventative vaccine
79218266|NCT02129361|Behavioral|Adapted Screening and Brief Intervention (Adapted SBI)|
79218267|NCT02129361|Behavioral|Screening & Education Attention Control|
79361838|NCT00123682|Procedure|Self-help|Project staff send out self-help materials for smoking cessation
79361839|NCT00125788|Drug|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
79361840|NCT00125788|Drug|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
79361841|NCT00221338|Drug|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
79361842|NCT00223678|Drug|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
79361843|NCT04752436|Behavioral|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
79672340|NCT00477282|Drug|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
79820350|NCT04082598|Dietary Supplement|Bifidobacterium longum and Lactoferrin|
79218268|NCT02129439|Drug|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
79820351|NCT02587494|Procedure|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
79218269|NCT02129439|Drug|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
79218270|NCT05549440|Device|Orsiro Mission|Percutaneous intervention using Orsiro Mission stent
79218271|NCT05549440|Device|Resolute Onyx|Percutaneous intervention using Resolute Onyx stent
79218272|NCT02131467|Drug|Perampanel|oral drug
79361844|NCT00053482|Biological|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
79361845|NCT00053482|Biological|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
79512897|NCT05674955|Diagnostic Test|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
79218273|NCT05549284|Drug|Orelabrutinib,Rituximab and Methotrexate|Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
79512898|NCT05674552|Drug|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
79672341|NCT00442130|Biological|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
79672342|NCT00442130|Procedure|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
79672343|NCT00477321|Drug|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
79672344|NCT03279107|Other|Soluble corn fiber|soluble corn fiber
79672345|NCT03279107|Other|maltodextrin|maltodextrin
79672346|NCT00439530|Drug|oseltamivir|
79672347|NCT00439530|Drug|probenecid|
79672348|NCT00442208|Drug|PN 200|
79672349|NCT00442247|Device|Pelvicol|
79672350|NCT00439686|Drug|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
79672351|NCT00477360|Device|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
79672352|NCT03278990|Behavioral|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
79218274|NCT03531528|Other|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
79672353|NCT03278990|Behavioral|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
79820352|NCT04095195|Radiation|MRCP|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
79820353|NCT04095195|Procedure|Endoultrasonography|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
79218275|NCT02129517|Other|IMPACT intervention|Tailored, web-based educational short video clips
79218276|NCT02129517|Other|Online education materials|Online NCI-based educational materials
79820354|NCT00716547|Drug|ketoprofen in Diractin®|50 mg (b.i.d.)
79820355|NCT00716547|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
79218277|NCT02129517|Other|survey administration|Ancillary studies
79361846|NCT00130780|Drug|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
79361847|NCT00130780|Drug|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
79361848|NCT04752748|Drug|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score> 3.2 and the Physician's Global Assessment (PGA)> 4.0 [0-10 cm]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~Failure 1: failure of the first DMARD (MTX) in week 12.~Failure 2: failure of the second DMARD (leflunomide) at week 24~Failure 3: failure of the first immunobiological (adalimumab) at week 48."
79361849|NCT00041392|Drug|Magnesium|100 mg/kg
79361850|NCT00041392|Drug|0.9% saline|Placebo
79361851|NCT02091778|Device|Fast gelling dressing|
79361852|NCT04752046|Procedure|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
79361853|NCT04752202|Behavioral|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
79512899|NCT05671081|Drug|Dexmedetomidine|patients will receive combined general anesthesia and bilateral bilevel at T5 &T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
79512900|NCT05671081|Drug|Magnesium sulfate|patients will receive combined general anesthesia and bilateral bilevel at T5 &T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
79512901|NCT05671081|Drug|Narcotic Analgesics|patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
79820356|NCT00716547|Drug|Placebo|b.i.d.
79820357|NCT00716547|Drug|celecoxib|100 mg (b.i.d.)
79820358|NCT02573025|Drug|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
79820359|NCT02573025|Drug|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
79820360|NCT00720291|Drug|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
79820361|NCT00720291|Drug|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
79820362|NCT00711399|Device|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
79820363|NCT00711633|Dietary Supplement|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
79820364|NCT00711633|Dietary Supplement|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
79820365|NCT05684016|Other|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
79820366|NCT05684016|Other|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
79820367|NCT05684016|Other|EDSS|Extended Disability Status Score
79820368|NCT05684016|Other|Physical Examination|Physical Examination
79218278|NCT03065218|Drug|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
79218279|NCT00232752|Device|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
79218280|NCT02125617|Drug|Abiraterone|1000 mg/day
79218281|NCT02125617|Drug|Prednisolone|10 mg/day
79218282|NCT05553262|Behavioral|Behavioral support|Behavioral support as described under 'Arm description'.
79218283|NCT02288598|Device|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
79820369|NCT02587338|Device|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anadal, right cathodal
79512902|NCT05670847|Drug|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
79820370|NCT02587338|Device|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
79820371|NCT04842006|Drug|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
79820372|NCT04842006|Diagnostic Test|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
79820373|NCT04842006|Radiation|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
79820374|NCT00578643|Drug|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
79993825|NCT03627390|Drug|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
79993826|NCT03627390|Drug|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
79993827|NCT05576376|Procedure|calcaneal osteotomy for intractable plantar fasciitis|plantar displacement calcaneal osteotomy
79361854|NCT04752202|Behavioral|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
79512903|NCT05668611|Other|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
79672354|NCT03279744|Drug|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm^2 and properly cover the entire lesion.
79820375|NCT00578643|Biological|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
79820376|NCT00578643|Drug|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
79218284|NCT02288598|Behavioral|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
79218285|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
79218286|NCT02131545|Drug|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
79218287|NCT02131545|Drug|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
79218288|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
79218289|NCT00229008|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
79218290|NCT00229008|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
79218291|NCT02125695|Procedure|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
79672355|NCT03278951|Behavioral|Video Conferencing Group|
79672356|NCT03278951|Behavioral|In Person Group|
79672357|NCT03279705|Device|Water jet channel|The separate water jet channel was used for infusing water.
79820377|NCT00578643|Drug|Fludarabine|"Day -5 through Day -2~30 mg/m^2"
79820378|NCT00578643|Drug|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
79993828|NCT05576376|Procedure|plantar fascia open release|open partial release with or without baxter's nerve decompression
79993829|NCT05576376|Procedure|plantar fascia endoscopic release|endoscopic partial plantar fascia release
79993830|NCT03709745|Drug|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
79993831|NCT03709745|Drug|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
79993832|NCT05570526|Dietary Supplement|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
79993833|NCT05570526|Other|Placebo|Placebo tablet once daily.
79993834|NCT03707639|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
79993835|NCT03707639|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
79672358|NCT03279705|Device|Accessory channel|The accessory channel was used for infusing and/or suctioning water
79672359|NCT03278834|Device|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
79993836|NCT05343689|Procedure|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
79993837|NCT05542914|Behavioral|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
79361855|NCT02091856|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
79512904|NCT05668611|Other|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
79820379|NCT00578643|Procedure|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10^8/kg recipient weight; for cord blood ≥ 3 X 10^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10^/kg CD34+ cells.
79672360|NCT03278834|Device|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
79672361|NCT00477399|Behavioral|The Evje Model|
79672362|NCT04700813|Diagnostic Test|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
79218292|NCT02125695|Procedure|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
79218293|NCT02125695|Procedure|Skin Biopsy|As described in the treatment arm
79361856|NCT00225784|Drug|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
79218294|NCT03551535|Behavioral|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
79820380|NCT04082286|Other|Yttrium-90 labelled monoclonal antibody against CD66|
79672363|NCT00477477|Other|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
79672364|NCT00477477|Other|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
79672365|NCT00442325|Drug|Atorvastatin (Lipitor)|
79672366|NCT00439764|Behavioral|General health talk|Routine clinical practice and talk on general health
79820381|NCT02587884|Procedure|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
79820382|NCT00716703|Other|CT Scan using IV contrast alone|CT scan using IV contrast alone
79218295|NCT05549128|Device|Photobiomodulation|The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.
79218296|NCT05549128|Device|Photobiomodulation sham|The red laser (DMC) will be applied off. I
79218297|NCT03528564|Drug|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
79218298|NCT03528564|Drug|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
79218299|NCT03528564|Drug|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
79308298|NCT04429737|Dietary Supplement|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
79361857|NCT00225784|Procedure|Radiotherapy|Daily radiotherapy for 28 days
79672367|NCT00439764|Behavioral|Handout of The Back Book|Talk on health of the back and handout of The Back Book
79672368|NCT00439764|Behavioral|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
79820383|NCT02588508|Procedure|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
79820384|NCT02588508|Procedure|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
79820385|NCT00720447|Biological|alemtuzumab|
79820386|NCT00720447|Biological|donor lymphocytes|
79820387|NCT00720447|Drug|carmustine|
79820388|NCT00720447|Drug|cytarabine|
79820389|NCT00720447|Drug|etoposide|
79820390|NCT00720447|Drug|melphalan|
79820391|NCT00720447|Procedure|allogeneic bone marrow transplantation|
79820392|NCT00720447|Procedure|peripheral blood stem cell transplantation|
79361858|NCT02092168|Drug|BIA 9-1067|
79361859|NCT00132964|Device|Below knee walking cast|Not required
79361860|NCT00132964|Device|Removable ankle brace|not required
79361861|NCT01897246|Procedure|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
79820393|NCT02587806|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
79820394|NCT02587806|Other|Liberation therapy|
79993838|NCT05542914|Behavioral|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
79993839|NCT03334721|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
79993840|NCT03334721|Drug|Placebo Oral Capsule|5 day trial of matched placebo
79993841|NCT05144880|Other|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
79361862|NCT01897246|Procedure|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
79361863|NCT00133978|Other|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
79361864|NCT00133978|Other|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
79361865|NCT00133978|Other|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
79361866|NCT00133978|Other|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
79361867|NCT01897324|Drug|Growth hormone (Norditropin, Novo nordisk)|
79361868|NCT01897948|Other|Milk-based beverage without DHA|
79361869|NCT01897948|Other|Milk-based beverage with DHA at mid level|
79361870|NCT01897948|Other|Milk-based beverage with DHA at high level|
79361871|NCT00253708|Procedure|management of therapy complications|
79361872|NCT00253708|Procedure|massage therapy|
79361873|NCT00253708|Procedure|pain therapy|
79993842|NCT03709589|Other|Modified Early Warning Score|Modified Early Warning Score
79361874|NCT00253708|Procedure|psychosocial assessment and care|
79361875|NCT00253708|Procedure|quality-of-life assessment|
79361876|NCT00254410|Drug|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
79361877|NCT00254410|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
79361878|NCT00254410|Drug|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
79361879|NCT00254410|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
79672369|NCT03278756|Behavioral|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
79672370|NCT03278756|Behavioral|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
79672371|NCT00477516|Procedure|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
79361880|NCT00254410|Drug|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
79361881|NCT00254488|Drug|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
79672372|NCT00477555|Device|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
79672373|NCT03278639|Behavioral|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
79672374|NCT03278639|Behavioral|Kinesiology|Training will be directed to ameliorate gait and balance
79361882|NCT00254488|Drug|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
79672375|NCT00477711|Drug|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
79361883|NCT00255970|Other|DFDBA|Demineralized Freeze Dried Allograft bone
79361884|NCT00255970|Device|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
79361885|NCT01899118|Radiation|Preoperative irradiation|50.4Gy/28F/5.5w
79361886|NCT01899118|Drug|Nimotuzumab|400mg/w，0-5w
79361887|NCT01899118|Drug|Oxaliplatin|130mg/m2 d1
79361888|NCT01899118|Drug|Capecitabine|825mg/m2 bid d1-5/w,1-5w
79361889|NCT00256984|Procedure|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
79361890|NCT00231868|Drug|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
79672376|NCT03278561|Procedure|Sputum induction|Sputum induction according to the ERS protocol
79672377|NCT03278561|Procedure|Blood sample|A blood sample of 100ml will be taken.
79672378|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
79672379|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
79672380|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
79993843|NCT03707561|Diagnostic Test|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
79993844|NCT05706246|Diagnostic Test|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
79993845|NCT05114538|Behavioral|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
79308299|NCT04429737|Dietary Supplement|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
79361891|NCT00231868|Procedure|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
79361892|NCT00231868|Drug|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
79993846|NCT03627312|Combination Product|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
79993847|NCT03627312|Combination Product|Placebo|Fruit juice drink only
79993848|NCT03627312|Other|Treatment as Usual|Young Offenders Intervention Programme
79993849|NCT03627000|Other|failure after reimplantation|description of cinical and microbiological failure
79993850|NCT03515551|Drug|IMCnyeso|Weekly IV infusions of IMCnyeso
79993851|NCT05558592|Dietary Supplement|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
79993852|NCT05558592|Dietary Supplement|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
79993853|NCT03626844|Procedure|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
79993854|NCT03626844|Procedure|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
79993855|NCT04694443|Procedure|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
79993856|NCT04694443|Other|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
79993857|NCT05706090|Drug|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
79993858|NCT05706090|Procedure|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
79993859|NCT04418791|Behavioral|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
79993860|NCT04418791|Behavioral|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
79993861|NCT03380429|Drug|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
79361893|NCT00257686|Drug|Pitavastatin|
79361894|NCT00257686|Drug|Pravastatin|
79672381|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
79672382|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
79993862|NCT03380429|Drug|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
79308300|NCT04429737|Dietary Supplement|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
79361895|NCT00234286|Behavioral|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
79361896|NCT01469013|Drug|Placebo|
79361897|NCT01469013|Drug|Baricitinib|
79361898|NCT01469013|Drug|Baricitinib|
79361899|NCT01469013|Drug|Baricitinib|
79361900|NCT01469013|Drug|Methotrexate|Administered orally as background therapy
79361901|NCT01493427|Drug|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
79672383|NCT00439803|Biological|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
79672384|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
79672385|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
79820395|NCT04828824|Drug|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
79820396|NCT00578565|Drug|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
79820397|NCT04082208|Device|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
79820398|NCT04082208|Device|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
79820399|NCT00716937|Procedure|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
79820400|NCT00716937|Procedure|laying open|laying open the site of excision of sinus or cyst without any flap
79820401|NCT02572089|Drug|Naloxone|
79820402|NCT00919620|Behavioral|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
79993863|NCT03380429|Device|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
79993864|NCT03380429|Device|HCP Dashboard|The information from sensors will be reviewed by the HCP via an online dashboard.
79218300|NCT03028792|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
79218301|NCT03028792|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
79218302|NCT00207168|Behavioral|Compliance|
79218303|NCT02131701|Behavioral|Physical activity|
79512905|NCT05668611|Other|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
79512906|NCT05668611|Other|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
79672386|NCT00442403|Drug|chloroquine|
79672387|NCT00442403|Drug|dehydroepiandrosterone sulphate|
79672388|NCT00477789|Drug|allopurinol|
79672389|NCT00442442|Device|mosquito coils|mosquito coil / night mosquito coil & LLIN / night
79672390|NCT00442442|Device|LLIN|Sleep under LLIN every night
79820403|NCT04069377|Device|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
79820404|NCT04069377|Other|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
79820405|NCT02588742|Dietary Supplement|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
79820406|NCT02588742|Dietary Supplement|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
79820407|NCT00720603|Drug|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
79820408|NCT04936854|Drug|Sirolimus 1 mg Oral Tablet|2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
79993865|NCT03380429|Device|Sensors|Clip-on sensors will be fitted to electronically record the actuation data.
79993866|NCT01313143|Drug|AOP200704|Comparison of AOP200704 with Esmolol
79993867|NCT01313143|Drug|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
79672391|NCT00439842|Behavioral|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
79672392|NCT00442481|Drug|Escitalopram|
79672393|NCT00442481|Procedure|A baseline overnight polysomnography (oPSG)|
79672394|NCT00439881|Drug|SB-681323|
79672395|NCT03279666|Other|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
79672396|NCT00442637|Drug|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
79672397|NCT00442637|Other|observation|observation after induction treatment
79672398|NCT00477828|Device|Continuous positive airway pressure|
79672399|NCT00442676|Drug|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
79672400|NCT00442676|Drug|Placebo|Gelatin capsules of lactose
79672401|NCT00477867|Procedure|quality-of-life assessment|
79820409|NCT04936854|Drug|Methylprednisolone|500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
79820410|NCT00711789|Drug|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
79820411|NCT00711789|Drug|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
79820412|NCT04082052|Behavioral|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
79820413|NCT00717171|Device|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
79512907|NCT05668611|Other|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
79820414|NCT00717171|Device|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
79820415|NCT05683938|Device|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
79820416|NCT00717327|Other|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
79218304|NCT05724810|Device|Active deep transcranial magnetic stimulation (dTMS)|"First, we find the position of the right abductor pollicis brevis (APB) motor cortex, finding the minimal motor threshold (MT) required for its activation, which determines the strength of the pulses. After determining the MT, dTMS stimulation is applied 6 cm anterior to the motor hot spot, at 120% of the MT. The target threshold is built toward gradually. During the first treatment, participants receive stimulation at 100% of the MT. During the second treatment, stimulation intensity increases to 110% of the MT. Beginning at the third treatment and continuing onward, participants receive treatment at 120% of the MT for the course of the treatment."
79361902|NCT01523457|Drug|Folfirinox|"Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~Leucovorin 400 mg/m2 IV over two hours~Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
79820417|NCT00741260|Drug|Neratinib|Neratinib orally once daily continually
79820418|NCT00741260|Drug|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
79512908|NCT05668611|Other|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
79512909|NCT05660967|Biological|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
79512910|NCT05660967|Drug|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
79820419|NCT02587260|Drug|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
79218305|NCT05724810|Device|Sham dTMS|Sham group will go through the same procedure. The only difference is that the sham card does not deliver stimulation.
79512911|NCT05660850|Drug|GDC-6599|GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
79512912|NCT05660850|Other|GDC-6599-matching placebo|GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
79512913|NCT05660850|Diagnostic Test|Mannitol|Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
79512914|NCT05660642|Drug|BPL-003|Experimental BPL-003 arms: will investigate one of two doses of BPL-003
79512915|NCT05658874|Drug|Multimodal Bundle Drugs|multimodal pain therapy
79820420|NCT02587260|Drug|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
79820421|NCT02587260|Drug|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
79820422|NCT02572011|Other|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
79820423|NCT04231344|Device|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
79820424|NCT02596256|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
79820425|NCT02596256|Drug|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
79820426|NCT04934358|Behavioral|Physical and motivational follow-up treatment|Physical and motivational follow-up treatment
79820427|NCT04934358|Behavioral|Usual care|Usual rehabilitation program
79218306|NCT03550521|Behavioral|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
79218307|NCT02926768|Drug|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
79361903|NCT01523301|Drug|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
79820428|NCT04090580|Diagnostic Test|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
79820429|NCT02571933|Other|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
79820430|NCT02571933|Other|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
79820431|NCT02571933|Other|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
79361904|NCT01523301|Drug|Placebo|"Transdermal Patch~Size:~10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
79361905|NCT02985567|Other|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
79361906|NCT01806506|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
79512916|NCT05658874|Procedure|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
79672402|NCT00442715|Procedure|Exercise chalenge test|
79820432|NCT04089722|Drug|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
79993868|NCT03280615|Dietary Supplement|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
79993869|NCT03280615|Dietary Supplement|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
79993870|NCT05705934|Other|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
79993871|NCT05071794|Drug|Propofol|Antiemetic effect of propofol
79993872|NCT05071794|Drug|saline 0.9%|Placebo
79993873|NCT03711071|Other|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
79993874|NCT03710993|Device|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
79218308|NCT03531372|Device|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
79218309|NCT03531372|Device|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
79218310|NCT02129595|Dietary Supplement|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
79218311|NCT02129595|Dietary Supplement|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
79218312|NCT00207012|Drug|BMS-599626|
79512917|NCT05658874|Behavioral|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
79512918|NCT05658874|Other|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
79512919|NCT05658874|Other|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
79512920|NCT05658874|Drug|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
79672403|NCT00477906|Biological|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
79672404|NCT00442754|Biological|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
79218313|NCT02648620|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
79672405|NCT00477945|Drug|clofarabine|"Cohort N Clofarabine (mg/m2/day)~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
79672406|NCT00442793|Drug|Epoetin beta|As prescribed, 3 times weekly
79672407|NCT00442793|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
79218314|NCT02648620|Procedure|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
79218315|NCT02131857|Behavioral|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
79820433|NCT05093166|Drug|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
79820434|NCT00720837|Procedure|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
79820435|NCT03973892|Diagnostic Test|Cere|Magnetic Rseonance imaging for brain tumour follow-up
79820436|NCT03977948|Other|semi-structured systemic interview|Semi-structured systemic interviews will be conducted with families who have benefited from the preparation for surgery through play. Other tools such as the logbook and the socio-demographic questionnaire will also be used. The themes that will emerge from these interviews will provide a better understanding of what these families are going through, how the proposed intervention may or may not have met their expectations, and provide insights so that health care services can build their own surgical preparation programs.
79820437|NCT00712023|Device|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
79820438|NCT05683314|Procedure|Tranditional open reduction and internal fixation|Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
79820439|NCT02598986|Dietary Supplement|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
79820440|NCT00717561|Drug|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
79218316|NCT05548894|Device|stabilization splint|upper acrylic splint rest on the maxillary teeth and had flat surface
79361907|NCT01806506|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
79361908|NCT01766336|Drug|Group 1 ELND005|
79218317|NCT05548894|Device|laser therapy|The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
79218318|NCT05548894|Device|stabilization splint and laser therapy|the stabilization splint used in combination of treatment with laser therapy
79218319|NCT02129673|Drug|VS101 Insert Dose A|Sustained release of latanoprost into the eye
79512921|NCT05658874|Drug|Vaginal estrogen|Topical vaginal estradiol application
79512922|NCT05658874|Drug|Methenamine|UTI prevention/bladder therapeutic
79512923|NCT05658874|Drug|Amitriptyline/Gabapentin|Part of multimodal pain therapy
79512924|NCT05653596|Behavioral|Virtual reality-based cognitive intervention|This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
79512925|NCT05650632|Drug|ABBV-383|Intravenous Infusion
79361909|NCT01766336|Drug|Group 2 ELND005|
79218320|NCT02129673|Drug|VS101 Insert Dose B|Sustained release of latanoprost into the eye
79218321|NCT02129673|Drug|VS101 Insert Dose C|Sustained release of latanoprost into the eye
79218322|NCT02129673|Drug|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
79512930|NCT05642312|Drug|Vamikibart|Participants will receive vamikibart IVT injection
79512931|NCT05642312|Other|Sham|Participants will receive a sham procedure that mimics an IVT injection.
79672408|NCT00439920|Drug|High-dose anthracycline|
79672409|NCT00442832|Drug|TD-1792|TD-1792 2 mg/kg/day IV
79218323|NCT05724732|Biological|GT201|Autologous tumor infiltrating lymphocyte injection
79218324|NCT02125773|Behavioral|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
79218325|NCT05552872|Diagnostic Test|mNGS, IDSeq UltraTM|pathogen detection
79218326|NCT02125851|Other|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
79218327|NCT02125851|Other|Honey|esophageal mucosal contact time of honey vs sucralose slurry
79218328|NCT02260557|Drug|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
79218329|NCT02260557|Drug|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
79218330|NCT04469166|Procedure|tourniquet|Use of tourniquet
79218331|NCT04469166|Procedure|No tourniquet|No use of tourniquet
79361910|NCT01797536|Drug|Elbasvir|
79361911|NCT01797302|Dietary Supplement|Vitamin D3|Tablet form
79361912|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
79672410|NCT00442832|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
79672411|NCT00477984|Drug|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
79672412|NCT00442871|Drug|eltrombopag|eltrombopag 50 mg oral
79672413|NCT00439959|Drug|GSK625433/placebo|
79672414|NCT00442910|Drug|3% SPL7013 Gel (VivaGel)|3% vaginal gel
79672415|NCT00442910|Drug|Placebo Gel|Placebo for SPL7013 gel
79672416|NCT00442910|Drug|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
79820441|NCT00717561|Drug|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
79820442|NCT00720915|Other|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
79820443|NCT00720915|Other|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
79820444|NCT00717639|Procedure|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
79820445|NCT02571699|Other|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
79820446|NCT02571855|Drug|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
79820447|NCT02571855|Drug|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
79820448|NCT02571855|Drug|Placebo|Placebo capsules matching the ACT-541468 formulations
79361913|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
79820449|NCT00740870|Device|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
79218332|NCT02553616|Behavioral|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
79218333|NCT02125929|Procedure|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
79361914|NCT04413968|Diagnostic Test|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
79361915|NCT04413968|Diagnostic Test|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
79512932|NCT05639426|Behavioral|Culturally Responsive Practices (CRP)|The CRP component of the intervention targets pedagogy, curriculum, and potential teacher biases and discriminatory behavior. This component will consist of two intensive 4-hour workshops delivered by Morton and Billingsley in each school's first intervention year as well as one-hour annual boosters (Backpacks for Success and Culturally Relevant Pedagogy). All teachers and school administrators will participate in the workshops. The purpose of Backpacks for Success is to increase participants' awareness of structural racism, empathy for students, and motivation to change, while identifying equity targets and strategies to reach those targets. Culturally Relevant Pedagogy comprises classroom based strategies to promote equity, including use of culturally responsive curriculum, language, attitudes, and actions, with the goal of reducing interpersonal and cultural racism. Ongoing group coaching sessions will provide a space for peer support and learning around increasing CRP.
79361916|NCT04413968|Diagnostic Test|Stool collection|Stool collection in children
79512933|NCT05639426|Behavioral|Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS)|We will implement SWPBS according to the equity-focused framework established by the Center on PBIS, with an increased emphasis on community integration. SWPBS involves creating a school team of 6-10 people, including at least one administrator, teachers, and staff members. We will include at least three community stakeholders on each C-SWPBS team to integrate the culture of the community, reducing institutional and cultural racism. Community stakeholders may be parents or other invested members of the local community not employed by the school district. The school climate specialists serve on the C-SWPBS team and provide consultation for the management of violence incidents and mental health concerns.
79672417|NCT00478101|Drug|oxycodone fentanyl|
79672418|NCT00442949|Procedure|Catheterization immediate PCI|Catheterization immediate PCI
79672419|NCT00442949|Procedure|delayed PCI|delayed PCI
79672420|NCT00439998|Procedure|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
79672421|NCT00443027|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
79820450|NCT00712101|Drug|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
79218334|NCT02125929|Procedure|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
79218335|NCT02125929|Procedure|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
79361917|NCT01804946|Drug|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
79672422|NCT00440076|Drug|Velcade|
79672423|NCT00443105|Drug|Tacrolimus 0.03% ointment (Protopic)|
79672424|NCT00443144|Drug|recombinant human growth hormone|
79672425|NCT00440154|Drug|AVE5530|
79672426|NCT00440154|Drug|placebo|
79672427|NCT00440154|Drug|ezetimibe|
79361918|NCT01804946|Drug|Oseltamivir|Safety and Efficiency in treatment of Influenza
79361919|NCT01737398|Drug|Inotersen|
79361920|NCT01737398|Drug|Placebo|
79361921|NCT01795898|Drug|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
79361922|NCT01736696|Drug|tofacitinib|5 mg BID For 13 days and once on Day 14
79361923|NCT01736696|Drug|tofacitinib|10 mg BID for 13 days and once on Day 14*
79361924|NCT01736696|Drug|tofacitinib|20 mg BID for 13 days and once on Day 14
79361925|NCT01736696|Drug|tofacitinib|30 mg BID for 13 days and once on Day 14
79361926|NCT01736696|Drug|tofacitinib|60 mg tablet once a day (QD) for 14 days
79672428|NCT00478374|Drug|Sorafenib|Sorafenib 400mg bid
79820451|NCT00712101|Drug|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
79820452|NCT00717717|Behavioral|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
79993875|NCT03709433|Behavioral|ACT groups and mobile app|See arm description.
79218336|NCT04468854|Dietary Supplement|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
79218337|NCT04468854|Other|Placebo|mannitol formulated for oral administration (capsules)
79512934|NCT05635045|Drug|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
79512935|NCT05631899|Biological|KRAS-EphA-2-CAR-DC|5~10 × 10^6 CAR-DCs per dose will be administered by intravenous injection.
79218338|NCT02129829|Drug|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
79820453|NCT04082130|Procedure|(XCM)+(CAF)|The description of this intervention has been already given before.
79820454|NCT04082130|Procedure|(SCTG)+(CAF)|The description of this intervention has been already given before.
79512936|NCT05631899|Drug|Abraxane|Intravenous abraxane 125 mg/m^2/day on day-5.
79820455|NCT02574351|Biological|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
79820456|NCT02587182|Device|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
79672429|NCT00478374|Procedure|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
79820457|NCT00712257|Device|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
79672430|NCT00478452|Biological|DC-Ova|
79820458|NCT00740792|Drug|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
79820459|NCT00740792|Drug|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
79820460|NCT00740792|Drug|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
79218339|NCT02288754|Diagnostic Test|Blood test|No intervention except to collect blood for diagnostic test development
79218340|NCT04468698|Other|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
79218341|NCT02129985|Drug|Exenatide|Exenatide (10 ug/bid for 3 months)
79218342|NCT02129985|Drug|Metformin|Metformin 850 mg/bid for 3 months
79218343|NCT01730638|Drug|• TF2 and 68 Ga-IMP-288|
79672431|NCT00478452|Biological|DC Ova with Cyclophosphamide|
79672432|NCT03279549|Procedure|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
79820461|NCT00740792|Drug|placebo|placebo one spray per nostril BID
79820462|NCT03728049|Diagnostic Test|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
79820463|NCT03728049|Other|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
79820464|NCT02595788|Other|Change from supine to prone position|Change from supine to prone position
79820465|NCT00721071|Drug|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
79820466|NCT00917774|Device|Standard LPS flex TKA|TKA by Standard LPS flex TKA
79820467|NCT00917774|Device|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
79820468|NCT00721305|Drug|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
79820469|NCT00721305|Other|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
79820470|NCT00717951|Drug|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
79820471|NCT00721383|Behavioral|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
79993876|NCT05705778|Procedure|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
79993877|NCT03280537|Drug|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
79993878|NCT03280537|Drug|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
79218344|NCT02126007|Behavioral|Sleep and Rhythm Intervention|
79218345|NCT02126007|Behavioral|Dietary Modifications|
79361927|NCT01736696|Drug|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
79361928|NCT01736540|Device|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively).
79361929|NCT01794338|Device|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
79512937|NCT05631899|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m^2/day on day -4.
79512938|NCT05631899|Drug|Anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
79512939|NCT05631899|Drug|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
79993879|NCT04799327|Drug|SHR20004|SHR20004：low dose
79993880|NCT04799327|Drug|SHR20004|SHR20004: medium dose
79218346|NCT05700136|Behavioral|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
79218347|NCT00162942|Device|Adacolumn|"Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
79218348|NCT00162942|Device|Sham|Sham, ten apheresis sessions within 9 weeks
79218349|NCT02132013|Behavioral|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
79218350|NCT05548504|Radiation|Photon|50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
79218351|NCT05548504|Radiation|Proton|50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
79218352|NCT02252523|Drug|Dexmedetomidine|
79218353|NCT05552170|Other|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
79218354|NCT02132091|Other|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
79218355|NCT02132091|Dietary Supplement|400 IU Vitamin E|once each day in morning; oral pill form
79218356|NCT02132091|Dietary Supplement|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
79361930|NCT01794338|Device|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
79361931|NCT01609478|Drug|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
79361932|NCT01609478|Drug|placebo|placebo delivered via Concept 1 inhaler
79672433|NCT03279549|Procedure|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
79672434|NCT03279549|Procedure|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
79218357|NCT05552014|Behavioral|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
79218358|NCT05552014|Behavioral|Mental Health Education|Mental Health Education Seminar
79218359|NCT02130141|Dietary Supplement|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
79512940|NCT05628805|Device|iTBS|intermittent theta burst stimulation with TMS
79512941|NCT05628350|Other|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
79512942|NCT05628350|Other|Standard UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet maintaining usual UPF intake (59% energy). Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
79512943|NCT05627258|Biological|VRC-HIVMAB0115-00-AB|VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
79680146|NCT02930304|Other|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
79820472|NCT00721383|Behavioral|CSBI|Caregiver skill-building
79993881|NCT04799327|Drug|SHR20004|SHR20004: high dose
79993882|NCT04799327|Drug|placebo|Placebo
79993883|NCT03842826|Diagnostic Test|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
79218360|NCT02130141|Other|Dietary counselling|Usual snacks are limited.
79218361|NCT05548348|Drug|Furmonertinib 160 mg, Q.D.|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
79218362|NCT03550365|Other|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
79218363|NCT03550365|Other|Rye bread intervention|4 week dietary intervention rich in rye bread
79218364|NCT03550365|Other|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
79361933|NCT01609478|Drug|mometasone furoate|via Twisthaler inhaler
79361934|NCT01764854|Drug|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
79361935|NCT01764854|Drug|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
79361936|NCT01764854|Drug|AZD1722 (out-patient)|doses between 5 and 45 mg BID
79361937|NCT01764854|Drug|Placebo|Placebo, size and color matched to experimental drug
79361938|NCT01764464|Drug|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
79218365|NCT02130219|Device|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
79361939|NCT01764464|Drug|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
79218366|NCT02130219|Device|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume."
79218367|NCT02130219|Procedure|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
79218368|NCT02130375|Procedure|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
79993884|NCT05029050|Drug|Dexmedetomidine|Continous intravenous infusion
79993885|NCT05029050|Drug|Clonidine|Continous intravenous infusion
79993886|NCT05029050|Drug|Natriumchlorid|Continous intravenous infusion NaCl
79993887|NCT04690231|Drug|Apatinib Mesylate|apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
79993888|NCT04690231|Drug|ifosfamide and etoposide|ifosfamide and etoposide
79993889|NCT03280381|Other|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
79993890|NCT03280381|Other|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
79218369|NCT02126085|Procedure|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
79361940|NCT01764386|Drug|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
79361941|NCT01764386|Behavioral|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
79361942|NCT01764386|Behavioral|Usual Care|Usual Care is a self-directed lifestyle intervention program
79361943|NCT01763918|Biological|Evolocumab|Administered by subcutaneous injection
79672435|NCT03279549|Procedure|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
79672436|NCT00478530|Procedure|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
79993891|NCT03270085|Drug|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
79672437|NCT00443183|Behavioral|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
79993892|NCT03270085|Other|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
79361944|NCT01763918|Drug|Placebo|Administered by subcutaneous injection
79361945|NCT01763684|Device|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
79361946|NCT01763684|Procedure|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
79361947|NCT01606748|Biological|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
79820473|NCT00721461|Biological|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
79820474|NCT00712413|Drug|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
79820475|NCT02574117|Procedure|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
79820476|NCT02572947|Drug|Dolutegravir|
79820477|NCT00712491|Drug|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
79820478|NCT00712491|Drug|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
79820479|NCT04083066|Drug|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
79820480|NCT04070547|Device|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
79361948|NCT01606748|Drug|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
79820481|NCT04070547|Device|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
79820482|NCT05082402|Diagnostic Test|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
79820483|NCT04069455|Other|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
79820484|NCT05683782|Drug|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
79218370|NCT03528330|Device|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
79308301|NCT03209843|Procedure|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
79308302|NCT03043131|Drug|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
79308303|NCT03043131|Drug|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
79672438|NCT00443183|Behavioral|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
79672439|NCT03275142|Device|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
79672440|NCT03271983|Drug|Metronidazole gel 1|RLD gel
79672441|NCT03271983|Drug|Metronidazole gel 2|generic gel
79672442|NCT03271983|Drug|Metronidazole cream|generic cream
79672443|NCT04700982|Other|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
79672444|NCT00443222|Drug|Infliximab|
79672445|NCT00440349|Drug|Tamoxifen|
79672446|NCT00440349|Drug|Prednisone|
79672447|NCT03270930|Procedure|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
79672448|NCT00443339|Drug|Darbepoetin|
79672449|NCT03272763|Device|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
79820485|NCT05683782|Drug|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
79361949|NCT01606748|Drug|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
79820486|NCT00712569|Behavioral|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
79820487|NCT00712569|Behavioral|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
79993893|NCT05615454|Device|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
79993894|NCT05615454|Device|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
79993895|NCT05703204|Drug|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
79218371|NCT03528330|Device|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
79672450|NCT04700228|Drug|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
79218372|NCT03550053|Device|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
79218373|NCT02126163|Behavioral|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
79361950|NCT01597622|Drug|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
79361951|NCT01761266|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79361952|NCT01761266|Drug|Sorafenib|400 mg twice daily (BID) oral dosing.
79361953|NCT01760954|Drug|Elagolix|Elagolix tablets administered orally
79361954|NCT01760876|Device|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
79361955|NCT01759862|Drug|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
79361956|NCT01759862|Other|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
79512944|NCT05623800|Other|PREM-Kit|The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
79672451|NCT04700228|Drug|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
79672452|NCT00440427|Drug|Desvenlafaxine Sustained Release (DVS SR)|
79672453|NCT00443378|Behavioral|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
79672454|NCT00478686|Procedure|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
79672455|NCT03278522|Drug|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
79672456|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
79672457|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
79820488|NCT00712569|Behavioral|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
79218374|NCT04440852|Behavioral|TEACCH|The Treatment and Education of Autistic and Communication Handicapped Children
79820489|NCT04877184|Device|Transcranial ultrasound stimulation and rehabilitation|"The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.~transcranial ultrasound stimulation: during 4 weeks~rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
79820490|NCT04877184|Device|Rehabilitation|"The participants in control group would received rehabilitation therapy.~- rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
79820491|NCT00740714|Drug|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
79218375|NCT02126241|Other|NICaS guided CRT optimization|"Baseline CO measurement by NICaS~AV delay optimization:~AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~The AV delay yielding the maximal CO, will be considered the optimal AV delay~The device will be programmed using the optimal AV delay~VV delay optimization:~After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~The VV delay yielding the maximal CO, will be considered the optimal VV delay~The device will be programmed using the optimal VV delay"
79361957|NCT01759862|Drug|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
79820492|NCT00740714|Drug|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
79820493|NCT04068285|Other|Aerobic Exercise|Participants will be making aerobic exercise
79993896|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
79218376|NCT04469010|Dietary Supplement|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
79218377|NCT04469010|Dietary Supplement|Iron Bis-Glycinate Chelate|28 mg iron
79218378|NCT04469010|Dietary Supplement|Placebo|Matched placebo
79218379|NCT02130531|Drug|Emixustat HCl Tablet|Tablet for oral administration
79820494|NCT02587026|Other|Blood sample collection|
79820495|NCT02587026|Other|Tumor tissue sample collection|
79820496|NCT02588352|Dietary Supplement|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
79820497|NCT00721773|Drug|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
79993897|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
79218380|NCT02130531|Other|Placebo Tablet|Tablet for oral administration
79218381|NCT01121224|Device|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
79218382|NCT01121224|Device|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
79361958|NCT04579874|Diagnostic Test|LIVERFASt|blood draw
79361959|NCT01793792|Device|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
79218383|NCT01121224|Drug|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
79218384|NCT01121224|Drug|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
79361960|NCT01790984|Other|High sugar low starch diet|
79361961|NCT01790984|Other|Low sugar high starch diet|
79361962|NCT01735994|Behavioral|Healthy Weight|Eating Disorder Prevention Program for Athletes
79361963|NCT01735994|Other|Brochure|Brochure on the Female athlete triad
79361964|NCT01790828|Drug|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
79672458|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
79672459|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
79672460|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
79672461|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
79672462|NCT04700306|Behavioral|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
79672463|NCT00440583|Drug|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
79820498|NCT00721773|Drug|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
79993898|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
79993899|NCT03267511|Drug|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
79993900|NCT05003544|Procedure|Group A|PENG BLOCK
79993901|NCT05003544|Procedure|Group B|Intra-articular
79993902|NCT05003544|Procedure|Group C|Quadratus lumborum block
79993903|NCT04234945|Drug|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
79218385|NCT01121224|Drug|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
79218386|NCT00138762|Drug|torcetrapib/atorvastatin|
79218387|NCT00138762|Drug|atorvastatin|
79361965|NCT01790594|Biological|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
79361966|NCT01790594|Drug|methylprednisolone|
79820499|NCT00721773|Drug|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
79820500|NCT00721773|Drug|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
79361967|NCT01790594|Biological|Anti-thymocyte Globulin (Rabbit)|
79361968|NCT01790594|Drug|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
79361969|NCT01790594|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
79993904|NCT04234945|Drug|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
79993905|NCT03627156|Behavioral|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
79993906|NCT03802110|Device|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
79361970|NCT01790516|Drug|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
79361971|NCT01790516|Drug|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
79361972|NCT01790516|Radiation|Radiation|daily radiation for 7 weeks
79361973|NCT01790438|Drug|LY2605541|
79993907|NCT03316807|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
79993908|NCT03316807|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
79993909|NCT04948710|Diagnostic Test|Sonography|Sonographic Venous Doppler Imaging
79993910|NCT04931550|Device|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
79993911|NCT03379259|Drug|BGB-A333|Anti-PD-L1 antibody
79993912|NCT03379259|Drug|BGB-A317|Anti-PD-1 antibodies
79993913|NCT05586048|Drug|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
79218388|NCT00138762|Drug|placebo|
79218389|NCT02130609|Device|Skintel|
79218390|NCT02252601|Other|HFDT test|
79218391|NCT02252601|Other|Pure tone Audiogram|
79218392|NCT02132325|Behavioral|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
79218393|NCT02130843|Device|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
79218394|NCT02126397|Procedure|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
79218395|NCT02126397|Procedure|polyps resection with bipolar electrode|
79218396|NCT03531294|Drug|Aflibercept Injection|intravitreal 2mg aflibercept injection
79218397|NCT05551702|Behavioral|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
79218398|NCT03549975|Drug|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
79308304|NCT02502851|Device|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
79361974|NCT01790438|Drug|Human Insulin NPH|
79820501|NCT02572869|Other|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
79820502|NCT02572869|Behavioral|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
79820503|NCT04377945|Drug|Part 1, JM-010 component Group A|JM-010 component Group A
79820504|NCT04377945|Drug|Part 1, JM-010 component Group B|JM-010 component Group B
79218399|NCT05482152|Behavioral|Nurse-led care by a nurse specialist in pain|A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
79218400|NCT05551624|Drug|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
79218401|NCT00134238|Drug|torcetrapib/atorvastatin|
79820505|NCT04377945|Drug|Part 1, JM-010 component Group C|JM-010 component Group C
79820506|NCT04377945|Drug|Part 1, Placebo Group|Placebo Group
79218402|NCT00134238|Drug|atorvastatin|
79361975|NCT01790438|Drug|Oral Antihyperglycemic Medications (OAM)|
79361976|NCT01735916|Device|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
79361977|NCT01735916|Device|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
79361978|NCT01790126|Drug|ARN-509|
79512946|NCT05617079|Other|Survey|an electronic survey will be conducted
79820507|NCT04377945|Drug|Part 2, JM-010 combination Group A|JM-010 combination Group A
79820508|NCT04377945|Drug|Part 2, JM-010 combination Group B|JM-010 combination Group B
79820509|NCT04377945|Drug|Part 2, JM-010 component Group C|JM-010 component Group C
79218403|NCT02786901|Drug|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
79218404|NCT02786901|Drug|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
79218405|NCT02786901|Drug|Vehicle Gel|Gel
79218406|NCT02130921|Behavioral|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
79308305|NCT02502851|Device|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
79361979|NCT01790126|Drug|LHRH Agonist|
79512947|NCT05611736|Other|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
79512948|NCT05611736|Other|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
79672464|NCT04700384|Behavioral|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
79672465|NCT04700384|Behavioral|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
79672466|NCT00440622|Drug|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
79672467|NCT00440622|Drug|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
79672468|NCT00440622|Drug|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
79672469|NCT00443417|Drug|SK-PC-B70M|dosage, frequency
79820510|NCT04377945|Drug|Part 2, Placebo Group|Placebo Group
79820511|NCT00718185|Procedure|Obtain blood specimens|Obtain blood samples at multiple timepoints.
79820512|NCT04070469|Drug|Amoxicillin|dosage of plasma concentration of amoxicillin
79820513|NCT00712647|Drug|Beta Carotene and Retinol|"Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard & Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
79820514|NCT00712647|Other|Placebo|Two placebos, one each/day
79820515|NCT00788957|Drug|Panitumumab|Panitumumab for intravenous infusion
79820516|NCT00788957|Drug|Ganitumab|Ganitumab for intravenous infusion
79820517|NCT00788957|Drug|Rilotumumab|Rilotumumab for intravenous infusion
79820518|NCT00788957|Drug|Placebo|Placebo intravenous infusion
79820519|NCT04067817|Drug|norepinephrine|patient who was received the treatment of norepinephrine
79820520|NCT04067817|Drug|Phenylephrine|patient who was received the treatment of phenylephrine
79820521|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
79820522|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
79820523|NCT00718341|Drug|AF056|
79218407|NCT03550677|Procedure|general anesthesia|The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
79218408|NCT03550677|Procedure|ankle block|ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
79218409|NCT02132403|Drug|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
79820524|NCT00718341|Drug|Placebo|
79820525|NCT00721929|Procedure|MRI|Magnetic Resonance Imaging
79218410|NCT02132403|Drug|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
79218411|NCT02132403|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
79361980|NCT01734902|Drug|Hyoscine butylbromide|sugar coated tablets for oral administration
79218412|NCT05700058|Other|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
79218413|NCT04264806|Drug|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m^2.
79361981|NCT01734902|Drug|Hyoscine butylbromide|drops for oral administration
79361982|NCT01790048|Dietary Supplement|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
79672470|NCT00440661|Drug|Diacerhein|
79672471|NCT03278444|Other|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
79672472|NCT03278444|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
79820526|NCT05592665|Other|Survey Questionnaire|Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
79820527|NCT02595632|Other|No intervention|
79218414|NCT04264806|Drug|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
79672473|NCT03278444|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
79672474|NCT00440739|Drug|etoricoxib|etoricoxib 120 mg
79672475|NCT00440739|Drug|flavoxate|flavoxate 200 mg 3 times
79672476|NCT00440739|Drug|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
79672477|NCT00440739|Drug|placebo|placebo once and placebo 3 times
79672478|NCT00443495|Drug|Chitin microparticles by nasal route|
79672479|NCT00478725|Drug|GW786034, oral|oral, 800 mg
79672480|NCT00478725|Drug|GW786034, IV|IV, 5 mg
79672481|NCT00478725|Drug|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
79672482|NCT00443573|Drug|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
79820528|NCT02572635|Biological|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
79820529|NCT02572635|Biological|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
79820530|NCT02603159|Drug|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
79820531|NCT02603159|Radiation|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
79820532|NCT02595554|Radiation|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
79820533|NCT02595554|Drug|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
79993914|NCT05405556|Diagnostic Test|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~only study-related eGFR values >25% below baseline will be reported to patients and providers~all study-related eGFR will be provided to patients and providers"
79218415|NCT02132481|Other|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
79218416|NCT02132481|Other|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
79361983|NCT01790048|Dietary Supplement|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
79361984|NCT01789970|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
79361985|NCT01789970|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
79361986|NCT01788566|Drug|Necitumumab|Administered IV
79361987|NCT01788566|Drug|Gemcitabine|Administered IV
79361988|NCT01788566|Drug|Cisplatin|Administered IV
79512949|NCT05611125|Other|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
79512950|NCT05609539|Device|Endovascular Aortic Repair (EVAR)|"Techniques for delivery and deployment of the standard device have been well described by different papers, but for the prototype some attention is required.~Once the device was advanced at the level of the lowest RA the C-Arm has been moved to correct the parallax effect and positioned orthogonally to the origin of the artery. This procedure permits perfectly matching the scallop with the artery takeoff.~A selective angiogram was performed to assure the patency of the lower RA. After the deployment of the main body proper iliac extensions were delivered to completely exclude the aneurysm as standard practice."
79672483|NCT00478764|Drug|intraocular triamcinolone and gatifloxicin|
79512951|NCT05604235|Other|Therapeutic upper limb strength exercise treatment|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.
79672484|NCT00440778|Drug|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
79820534|NCT02595554|Procedure|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
79820535|NCT02595554|Drug|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
79993915|NCT04924998|Drug|current treatment of AL-CM|current treatment of AL-CM
79512952|NCT05604235|Other|Treatment with passive and active mobilization of the upper limb.|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
79308306|NCT03209765|Other|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
79672485|NCT03278405|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
79672486|NCT00440817|Other|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
79672487|NCT00443612|Drug|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
79672488|NCT00443612|Drug|Irbesartan|Administration of irbesartan 150 mg/day
79820536|NCT04069065|Drug|Conversion to Once-daily Tacrolimus|"Orally, once-daily in the morning~The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~10ng/ml."
79672489|NCT00478803|Procedure|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
79820537|NCT00735254|Device|pulsed dye laser|patient will have scar treated with pulsed dye laser
79820538|NCT00735254|Device|Affirm Laser|patient will have scar treated with Affirm laser
79993916|NCT03328897|Drug|Omalizumab|injection of 150mg or 300 mg
79993917|NCT03328897|Drug|Placebo|Injection of placebo
79993918|NCT04918758|Device|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
79993919|NCT04918758|Drug|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
79218417|NCT02132481|Other|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
79361989|NCT01733732|Other|SYSTANE® BALANCE Lubricant Eye Drops|
79672490|NCT00478803|Device|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
79672491|NCT00443690|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
79820539|NCT00735254|Device|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
79993920|NCT03266107|Device|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
79361990|NCT01733732|Other|SYSTANE® Gel|
79361991|NCT01732874|Drug|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
79512953|NCT05603897|Other|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
79672492|NCT00443690|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
79993921|NCT03378635|Drug|Dasiglucagon|Glucagon analog
79993922|NCT03378635|Drug|GlucaGen|Native glucagon
79672493|NCT00440856|Behavioral|Presentation of excised intervertebral disc fragments|
79993923|NCT03378635|Drug|Placebo|Placebo for dasiglucagon
79993924|NCT03326869|Device|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
79672494|NCT00443807|Device|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
79672495|NCT00443807|Device|EEGo vs BIS|comparison of two processed EEG monitors.
79993925|NCT05692284|Other|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
79218418|NCT02132481|Other|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
79361992|NCT01732874|Drug|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
79361993|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
79361994|NCT01732796|Drug|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
79361995|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
79361996|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
79361997|NCT01732796|Drug|BI 201335 (Faldaprevir)|24 weeks of BI 201335
79512954|NCT05603897|Other|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
79820540|NCT00735254|Other|Placebo|patient will receive no treatment
79820541|NCT04067583|Other|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
79820542|NCT04070391|Dietary Supplement|vitamin B6|oral administration
79820543|NCT04070391|Other|control|oral administration
79218419|NCT05699902|Procedure|PECs block during mastectomy|The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
79218420|NCT05699902|Procedure|Sham block|Female undergone mastectomy and have received conventional analgesic methods
79361998|NCT01732796|Drug|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
79218421|NCT02135991|Behavioral|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
79361999|NCT01732796|Drug|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
79362000|NCT01732796|Drug|Faldaprevir (BI 201335)|24 weeks of 201335
79362001|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
79362002|NCT01732640|Drug|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
79362003|NCT01732640|Drug|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
79362004|NCT01732640|Drug|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
79218422|NCT02135991|Behavioral|Project CHOICE|Sites will receive standard training for Project CHOICE.
79218423|NCT02132559|Drug|DHEA|
79218424|NCT05551468|Behavioral|StayFine guided app-based personalised intervention modules|Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).
79218425|NCT05551468|Behavioral|StayFine app-based monitoring|Monitoring six times per day for two weeks in the StayFine app.
79218426|NCT00126984|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
79218427|NCT00126984|Biological|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
79362005|NCT01732640|Drug|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
79362006|NCT01732640|Radiation|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
79362007|NCT01732484|Procedure|intraocular lens implantation|
79362008|NCT01786148|Behavioral|mobile phone application|
79362009|NCT04560686|Drug|Bintrafusp Alfa|Given IV
79362010|NCT04560686|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79362011|NCT01785602|Drug|QAW039|Capsules
79362012|NCT01785602|Drug|Placebo|Capsules
79672496|NCT00440895|Drug|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
79362013|NCT01785524|Drug|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
79820544|NCT04089800|Other|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
79820545|NCT04070235|Drug|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
79820546|NCT04070235|Drug|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
79820547|NCT02593760|Other|Placebo|Placebo will be administered PO QD for up to 48 weeks.
79820548|NCT02593760|Drug|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
79993926|NCT05692284|Other|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
79993927|NCT03710837|Other|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
79993928|NCT03710837|Other|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
79218428|NCT00126984|Biological|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
79218429|NCT00126984|Biological|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
79218430|NCT05700370|Diagnostic Test|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
79218431|NCT05551390|Other|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
79308307|NCT03209453|Other|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
79672497|NCT04697706|Dietary Supplement|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
79680147|NCT02930304|Other|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
79820549|NCT02593760|Drug|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
79820550|NCT02604329|Device|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
79820551|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
79820552|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
79308308|NCT03047421|Diagnostic Test|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
79218432|NCT05551390|Other|three-times umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
79993929|NCT01182727|Drug|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
79993930|NCT00624715|Drug|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
79512959|NCT05602636|Drug|bupivacaine, midazolam|Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
79993931|NCT00624715|Drug|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
79218433|NCT02132715|Behavioral|Resistance Exercise|
79218434|NCT02132715|Behavioral|KAATSU exercise|
79218435|NCT05558722|Drug|Anlotinib|Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
79218436|NCT03551379|Device|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
79512961|NCT05594771|Procedure|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
79820553|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
79218437|NCT05699746|Drug|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
79218438|NCT05699746|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
79218439|NCT02136225|Behavioral|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
79218440|NCT05551312|Other|Virtual Essential Newborn Care (vENC) training|Essential Newborn Care Mobile Virtual Reality Simulation
79218441|NCT02136303|Dietary Supplement|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
79218442|NCT02136303|Other|S2: Kale extract versus kale purée|
79820554|NCT00795509|Drug|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
79820555|NCT03615573|Other|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
79820556|NCT02603003|Drug|JinFuKang|po.tid.30ml
79993932|NCT03334409|Drug|Ascorbic Acid|Given IV
79993933|NCT03334409|Drug|Pazopanib Hydrochloride|Given PO
79993934|NCT04821726|Device|Drug eluting balloon (Vmoky)|Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis
79993935|NCT02891915|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
79218443|NCT02136303|Other|S3: Kale extract: AMD-patients|
79820557|NCT02603003|Drug|Cisplatin|According to the individual patient's condition
79218445|NCT04324372|Drug|HEC68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
79218446|NCT02132793|Behavioral|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
79308309|NCT04866615|Diagnostic Test|Optvue OCT|Optical coherence tomography
79308310|NCT02502773|Drug|Hydroxethyl starch|
79308311|NCT04866225|Drug|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
79308312|NCT04866225|Drug|Oral PF-06865571|Oral PF-06865571
79308313|NCT04866225|Drug|IV [14C]PF-06865571|IV radiolabeled PF-06865571
79512962|NCT05594771|Procedure|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
79512963|NCT05594095|Drug|PIK3CA inhibitor|PIK3CA inhibitor
79512964|NCT05594095|Drug|AKT inhibitor|AKT inhibitor
79512965|NCT05594095|Drug|Carrelizumab|Pd-1 mab
79512966|NCT05594095|Drug|Famitinib|VEGFR inhibitor
79512967|NCT05594095|Drug|Fluzoparib|PARP inhibitor
79512968|NCT05594095|Drug|Dalpiciclib|CDK4/6 inhibitor
79512969|NCT05594095|Drug|SHR-A1811|HER2 ADC
79512970|NCT05594095|Drug|TROP2 ADC|TROP2 ADC
79820558|NCT02603003|Drug|Pemetrexed|According to the individual patient's condition
79820559|NCT00722163|Other|Cognitive Behavioural Therapy|
79820560|NCT00722163|Other|befriending|
79820561|NCT04106141|Other|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
79820562|NCT04106141|Other|4 weeks changing of archwire|changing the archwire every 4 weeks
79820563|NCT04106297|Drug|GLPG3970 oral solution|GLPG3970 for oral administration
79218447|NCT02132793|Behavioral|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
79820564|NCT04106297|Drug|Placebo oral solution|Placebo for oral administration
79993936|NCT02891915|Drug|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
79993937|NCT02891915|Drug|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
79362014|NCT01785524|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
79362015|NCT01757288|Drug|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
79672498|NCT04697706|Other|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
79672499|NCT00440934|Device|Amplitude-modulated electromagnetic fields|
79362016|NCT01757288|Drug|PACLITAXEL|
79218448|NCT05551234|Other|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
79218449|NCT03549897|Drug|Placebo|Placebo Product
79218450|NCT03549897|Drug|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]
79218451|NCT03549897|Drug|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]
79218452|NCT03549897|Drug|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA [AMNEAL IRELAND LIMITED]
79218453|NCT05551078|Biological|thrombophilia screening|In the IUGR group systematic thrombophilia screening had already been performed.
79362017|NCT01757288|Drug|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
79362018|NCT01756898|Drug|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
79362019|NCT01756898|Drug|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
79362020|NCT01756898|Drug|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
79362021|NCT01756898|Drug|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
79362022|NCT01731938|Biological|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
79512971|NCT05594095|Drug|Everolimus|mTOR inhibior
79672500|NCT00440973|Drug|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
79672501|NCT00440973|Drug|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation
79672502|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
79820565|NCT04106297|Drug|GLPG3970 capsule|GLPG3970 for oral administration
79820566|NCT04105673|Other|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
79820567|NCT04067193|Other|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
79993938|NCT02891915|Other|Placebo|Placebo
79993939|NCT04096092|Other|No intervention|No intervention
79218454|NCT02132871|Device|Impedance cardiography Physioflow ®|
79308314|NCT03047187|Diagnostic Test|ACLR|"quadriceps and hamstring isometric muscles test~single hop for distance~IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
79308315|NCT03209297|Other|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
79308316|NCT03042897|Dietary Supplement|Dietary Intervention|Undergo DASH diet
79308317|NCT03042897|Behavioral|Exercise Intervention|Undergo in aerobic exercise
79672503|NCT00443924|Drug|Placebo|One drop of placebo in each eye every 12 hours for three days
79672504|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
79672505|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
79820568|NCT02603081|Drug|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
79820569|NCT04105829|Other|Bond-a braid|Stainless steel lingual retainer application
79820570|NCT04105829|Other|EverStick-Ortho|Fiber reinforced lingual retainer
79820571|NCT04105829|Other|Ribbond|Fiber reinforced lingual retainer
79820572|NCT00787787|Drug|sunitinib malate|Given PO
79820573|NCT00787787|Drug|capecitabine|Given PO
79820574|NCT02571387|Behavioral|Mindfulness-based intervention|
79820575|NCT02571387|Behavioral|Sham meditation|
79820576|NCT02571309|Device|Asthmatuner|Asthmatuner is an app for self-management of asthma.
79820577|NCT00722475|Drug|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
79820578|NCT00722475|Drug|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
79820579|NCT04108169|Procedure|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
79218455|NCT02136381|Behavioral|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
79218456|NCT02136381|Behavioral|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
79218457|NCT05547802|Biological|BBIBP-CorV and/or BNT162b2 vaccine|Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
79362023|NCT01731938|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
79362024|NCT01731470|Biological|Liposomes|Intravesical instillation of liposomes.
79512972|NCT05594095|Drug|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
79672506|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
79820580|NCT00713037|Procedure|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
79820581|NCT04067349|Other|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
79820582|NCT00787319|Other|no intervention|Outpatients with age-related macular degeneration (AMD)
79820583|NCT00713115|Procedure|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
79820584|NCT02571465|Other|Passive leg raising test and fluid challenge|
79820585|NCT02571231|Device|HFV + and - VG|High frequency ventilation with and without volume guarantuee
79308318|NCT03042897|Other|Laboratory Biomarker Analysis|Correlative studies
79308319|NCT03042897|Other|Quality-of-Life Assessment|Ancillary studies
79362025|NCT01756352|Drug|18F-FET|Radiotracer, surrogate marker for protein synthesis
79362026|NCT01756274|Device|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
79362027|NCT01756274|Device|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
79362028|NCT01756274|Device|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
79362029|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
79512973|NCT05594095|Drug|Goserelin|For premenopause
79512974|NCT05594095|Drug|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
79512975|NCT05594095|Drug|RTK Inhibitor|Sorafenib, Apatinib, Famitinib
79512976|NCT05588128|Drug|18F-DCFpyL|Administered to Cohort.
79512977|NCT05586490|Device|Multifunctional RehabilitationDevice (MRD)|Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
79512978|NCT05586490|Device|existing standard rehabilitation device|existing standard rehabilitation device to be used for in-home comparison testing for aim 3
79512979|NCT05583773|Drug|ShengXian-QuYu Decoction|Specification: 30ml/bag, given twice daily, per oral use.
79672507|NCT00441051|Drug|Diclofenac sodium 1mg/g|
79672508|NCT00443963|Drug|Esomeprazole Magnesium|PPI compared to H2RA
79672509|NCT00441207|Drug|Ascorbic Acid|Delivered via IV Infusion.
79672510|NCT04701255|Procedure|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
79672511|NCT04701255|Device|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront & internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
79672512|NCT00444041|Drug|Bevacizumab|neoadjuvant therapy prior to elective surgery
79672513|NCT00441246|Drug|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
79820586|NCT00915239|Drug|Pantoprazole|40 mg pantoprazole once daily for 28 days
79820587|NCT00915239|Drug|Placebo|identical placebo once daily for 28 days
79820588|NCT02604485|Drug|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
79820589|NCT02604485|Drug|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
79820590|NCT02604485|Drug|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
79820591|NCT02604485|Drug|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
79820592|NCT00722631|Drug|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
79820593|NCT00722631|Drug|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
79820594|NCT02604095|Dietary Supplement|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
79820595|NCT02571543|Drug|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
79820596|NCT02574039|Dietary Supplement|Oat bran|66g oat bran made up in 350ml skimmed milk
79218458|NCT03551301|Other|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
79218459|NCT02133027|Procedure|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
79218460|NCT02133027|Device|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
79218461|NCT05700838|Behavioral|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
79218462|NCT05551000|Other|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
79362030|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
79362031|NCT01731002|Drug|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
79362032|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
79512980|NCT05583773|Other|Placebo|Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
79512981|NCT05583552|Drug|Imetelstat|Intravenous injection
79218463|NCT02136459|Other|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
79218464|NCT02136459|Other|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
79218465|NCT02136537|Device|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
79218466|NCT02136537|Other|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
79308320|NCT02502695|Other|VATS-associated best practices|
79308321|NCT02502539|Procedure|Controlled physical activity|
79362033|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
79362034|NCT01783886|Procedure|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
79362035|NCT01609556|Drug|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
79512982|NCT05582616|Device|Transcranial Direct Current Stimulation|See treatment arm description
79512983|NCT05582616|Device|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
79680148|NCT02930304|Other|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
79680149|NCT00524147|Procedure|Pigtail drainage|
79680150|NCT02930109|Drug|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
79820597|NCT02574039|Dietary Supplement|refined grain|refined grain product and 350ml skimmed milk
79820598|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
79820599|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
79820600|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
79820601|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
79820602|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
79820603|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
79820604|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
79820605|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
79820606|NCT04107779|Other|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
79820607|NCT04107779|Other|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
79820608|NCT04107779|Other|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
79820609|NCT04067505|Drug|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
79820610|NCT04067505|Drug|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
79820611|NCT04067505|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
79362036|NCT00234832|Drug|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
79362037|NCT00234832|Drug|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
79362038|NCT00234832|Drug|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
79218468|NCT04468620|Behavioral|Assistive Soft Skills & Employment Training (ASSET)|The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude & Enthusiasm; (d) Teamwork; (e) Problem Solving & Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self & Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
79218469|NCT05550844|Radiation|Chest HRCT|A chest HRCT to identify emphysema
79820612|NCT00794963|Drug|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
79218470|NCT05550844|Genetic|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
79218471|NCT05550844|Other|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
79218472|NCT02133105|Drug|Levosimendan|
79512984|NCT05580263|Behavioral|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
79512985|NCT05580263|Behavioral|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
79820613|NCT00794963|Other|As selected by community physician|As selected by community physician
79218473|NCT02133105|Drug|Dobutamine|
79218474|NCT04468464|Other|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
79308322|NCT02612727|Device|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
79512986|NCT05572138|Diagnostic Test|Body Impedance Analysis|Body Impedance Analysis
79362039|NCT00259090|Drug|Fulvestrant|500 mg intramuscular injection
79362040|NCT00259090|Drug|Anastrazole|oral tablet
79512987|NCT05571059|Drug|Ifetroban Sodium|Once daily oral ifetroban
79512988|NCT05571059|Drug|Placebo|Matching oral placebo
79820614|NCT00713271|Drug|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
79820615|NCT00713271|Drug|Placebo|
79820616|NCT00713271|Drug|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
79820617|NCT00713271|Drug|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
79820618|NCT02573961|Device|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
79820619|NCT02573961|Behavioral|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
79820620|NCT02573961|Behavioral|low caloric diet|Tailored balanced low caloric diet
79820621|NCT04105361|Procedure|Posterior neurectomy|Cut of posterior nasal nerve
79820622|NCT05673135|Drug|Anti-Hypertensive|For control of the blood pressure
79820623|NCT05673135|Radiation|Ultrasound|For assessment of gestational age and fetal weight
79820624|NCT05673135|Radiation|Doppler ultrasound|Umbilical artery Doppler assessment
79820625|NCT05673135|Diagnostic Test|complete blood count|For assessment of platelet count
79820626|NCT05673135|Diagnostic Test|Body mass index|for assessment of maternal weight during pregnancy
79820627|NCT02602925|Other|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
79820628|NCT02602925|Other|Usual care|Usual care
79820629|NCT00722709|Drug|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
79820630|NCT00722709|Drug|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
79820631|NCT00722943|Other|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
79820632|NCT00722943|Other|no intervention|The infant will not be touched by the therapist.
79820633|NCT04105205|Drug|Apramycin injection|30-min infusion
79820634|NCT04105205|Drug|Placebo injection|30-min infusion
79820635|NCT00794573|Drug|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
79820636|NCT00794573|Other|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
79218475|NCT04468464|Other|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
79362041|NCT00235456|Procedure|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
79362042|NCT00235456|Procedure|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
79820637|NCT00584844|Biological|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (< 1:20).
79820638|NCT05675748|Drug|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
79820639|NCT02587104|Other|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
79820640|NCT00919464|Device|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
79820641|NCT00919464|Device|Compartmental fracture pressure monitoring|
79820642|NCT00919464|Device|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
79362043|NCT00236938|Drug|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
79362044|NCT00236938|Drug|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
79362045|NCT01898728|Drug|topical povidone-iodine after premedication with topical liquid eye drops|
79820643|NCT05683704|Drug|AK105，Anrotinib hydrochloride|AK105 administered IV at day 1 every 3 weeks for 8-12 cycles Anrotinib administered PO at day 1-14 every 3 weeks for 8-12 cycles
79820644|NCT00723333|Procedure|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
79820645|NCT05373693|Device|Single vision lens|Wear single vision lens
79820646|NCT05373693|Device|+2D PDL|Wear Peripheral defocus lense with +2D
79820647|NCT05373693|Device|+3D PDL|Wear Peripheral defocus lense with +3D
79820648|NCT05373693|Device|+4D PDL|Wear Peripheral defocus lense with +4D
79820649|NCT02570451|Other|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
79218476|NCT02136693|Drug|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
79218477|NCT02136693|Drug|Placebo|3.5 g /day of inert compound for 180 days after STARR
79218478|NCT05726136|Drug|acetated Ringers|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
79362046|NCT01898728|Drug|topical povidone-iodine after premedication with topical gel|
79362047|NCT00260962|Drug|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
79362048|NCT00260962|Behavioral|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
79362049|NCT00261040|Procedure|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
79512989|NCT05557981|Behavioral|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
79512990|NCT05552469|Drug|DFV890|DFV890 Single Agent
79820650|NCT02570451|Other|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
79820651|NCT02570451|Other|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
79820652|NCT02570451|Other|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
79512991|NCT05545020|Drug|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
79820653|NCT02570451|Other|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
79820654|NCT02570451|Other|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
79218479|NCT05726136|Drug|albumin 5%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
79218480|NCT05726136|Drug|albumin 20%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
79820655|NCT02570451|Other|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
79218481|NCT05547334|Behavioral|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
79512992|NCT05544188|Diagnostic Test|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
79820656|NCT02570451|Other|Grip Strength|Measured using the JAMAR dynamometer
79820657|NCT05667792|Device|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
79820658|NCT05667792|Other|Pediatric Rehabilitation|Bobath therapy
79820659|NCT04018911|Device|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
79820660|NCT04018911|Device|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
79820661|NCT04018911|Device|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
79993940|NCT02891681|Device|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
79218482|NCT05451186|Other|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
79362050|NCT00261040|Procedure|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
79362051|NCT00237718|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
79362052|NCT00237718|Drug|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
79362053|NCT00237718|Drug|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
79362054|NCT00237718|Drug|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
79362055|NCT00238108|Drug|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
79993941|NCT03707483|Combination Product|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
79218483|NCT02133339|Drug|TRN-157|
79218484|NCT02133339|Drug|Placebo|
79218485|NCT02136771|Dietary Supplement|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
79218486|NCT02136771|Dietary Supplement|Placebo|
79218487|NCT00125970|Biological|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
79218488|NCT00125970|Biological|VRC-HIVADV014-00-VP|1 x 10^10 PU administered in deltoid
79218489|NCT00125970|Biological|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
79218490|NCT00125970|Biological|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
79308323|NCT02612727|Device|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
79308324|NCT03209219|Drug|Interferon Alfa-2A|3×10^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
79362056|NCT00238108|Drug|Placebo|Placebo
79512993|NCT05543785|Drug|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
79993942|NCT03626766|Behavioral|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
79993943|NCT03626766|Behavioral|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
79993944|NCT03626766|Behavioral|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
79218491|NCT05579457|Other|Short Physical Performance Battery|The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance
79993945|NCT05683145|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
79993946|NCT04671342|Device|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
79993947|NCT04764929|Device|Helmet CPAP|Vyatil nonpowered oxygen tent system
79512994|NCT05543785|Other|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
79993948|NCT03627078|Other|motor interference therapy|
79993949|NCT03627078|Other|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
79993950|NCT05560854|Behavioral|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
79993951|NCT03051217|Other|Placebo|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use Q2W"
79993952|NCT03051217|Drug|Certolizumab Pegol|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
79512995|NCT05541718|Behavioral|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
79512996|NCT05541718|Behavioral|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
79993953|NCT05114785|Diagnostic Test|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
79218492|NCT03528252|Other|Written advice LDL Cholesterol|One A4 paper with written information on both sides
79512997|NCT05541718|Behavioral|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
79512998|NCT05536856|Drug|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
79512999|NCT05536856|Drug|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
79993954|NCT05080621|Drug|Ripretinib|50 mg tablets
79513000|NCT05533775|Drug|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
79513001|NCT05533775|Drug|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
79513002|NCT05533775|Drug|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
79993955|NCT05080621|Drug|binimetinib|15 mg tablets
79218493|NCT03528252|Other|Written advice Triglycerides|One A4 paper with written information on both sides
79218494|NCT02133417|Device|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
79308325|NCT03209219|Drug|Cyclosporine Pill|100mg， oral, bid
79513003|NCT05533775|Drug|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
79513004|NCT05533775|Drug|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
79993956|NCT05035303|Procedure|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
79993957|NCT03637621|Other|ORIF|open reduction internal fixation of the distal humerus
79993958|NCT04179097|Diagnostic Test|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
79993959|NCT03046056|Drug|Filgotinib|Tablet(s) administered orally once daily
79993960|NCT03046056|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
79993961|NCT02849587|Drug|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
79993962|NCT04647786|Device|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
79993963|NCT03347279|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
79993964|NCT03347279|Other|Placebo|Placebo subcutaneous injection
79820662|NCT04018911|Drug|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
79820663|NCT04070079|Drug|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
79820664|NCT00739934|Drug|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
79820665|NCT00713505|Other|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
79513005|NCT05533775|Drug|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
79820666|NCT00713505|Procedure|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
79820667|NCT02586948|Device|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
79820668|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
79820669|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
79993965|NCT03998683|Drug|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
79513006|NCT05533775|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
79820670|NCT00723411|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
79513007|NCT05525013|Drug|Simvastatin Powder|Simvastatin gel placed as an intracanal medication
79820671|NCT02586558|Other|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
79820672|NCT02586558|Other|Reference group|Ready-to-feed infant formula to be fed ad libitum
79993966|NCT03998683|Drug|Placebo|Placebo will be administered as SC injection.
79993967|NCT03637465|Behavioral|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
79993968|NCT03262441|Drug|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
79993969|NCT05201664|Procedure|Surgical Extrusion|Relocation of the remaining tooth structure to a more coronal position within the same original socket.
79218495|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
79218496|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
79513008|NCT05525013|Drug|Calcium Hydroxide|Calcium hydroxide intracanal medication
79513009|NCT05512754|Drug|Ibuprofen 400 mg|400 mg tablet
79513010|NCT05510271|Other|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
79513011|NCT05510271|Other|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
79513012|NCT05501600|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
79513013|NCT05501600|Drug|Lidocaine IV|Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
79513014|NCT05498103|Drug|Methazolamide 25 MG|25 mg tablets
79513015|NCT05498103|Drug|Methazolamide 50 MG|50 mg tablets
79820673|NCT02586636|Drug|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
79993970|NCT04580394|Drug|AD109|Oral administration before bed
79218497|NCT01561521|Drug|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
79993971|NCT04580394|Drug|Atomoxetine|Oral administration before bed
79993972|NCT04580394|Drug|R-oxybutynin|Oral administration before bed
79993973|NCT04580394|Drug|Placebo|Oral administration before bed
79218498|NCT03531216|Other|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
79218499|NCT03531216|Other|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
79218500|NCT02253303|Other|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
79308326|NCT04866381|Drug|SHR-6390|SHR-6390
79308327|NCT04866381|Drug|SHR-6390 + Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
79308328|NCT04866381|Drug|Camrelizumab (SHR-1210) + SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
79513016|NCT05495399|Procedure|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
79820674|NCT02586636|Drug|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
79993974|NCT04580394|Diagnostic Test|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
79993975|NCT02781727|Drug|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
79993976|NCT02781727|Drug|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
79218501|NCT03531138|Other|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
79513017|NCT05495399|Radiation|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
79218502|NCT03531060|Drug|IRL790|IRL790 capsule 10 mg
79218503|NCT03531060|Drug|Placebo|Placebo capsule
79218504|NCT02136927|Drug|SPARC1210|
79218505|NCT02136927|Drug|Reference1210|
79218506|NCT03527784|Device|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
79218507|NCT03527784|Device|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
79218508|NCT03527784|Device|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
79218509|NCT02133495|Procedure|Non Cadaveric Human Acellular Dermal Tissue|
79218510|NCT05723952|Other|Barcelona scoliosis physical therapy school|procedure for treating Adolescent Idiopathic scoliosis
79218511|NCT05723952|Other|International scoliosis schroth therapy|procedure for treating Adolescent Idiopathic scoliosis
79218512|NCT02260713|Biological|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
79218513|NCT03133494|Other|ABG analysis|ABG analysis was performed and compared between two groups
79218514|NCT05723796|Procedure|nasal endoscopy|nasal endoscopy and mucosal biopsy
79308329|NCT03209141|Diagnostic Test|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
79362057|NCT01899196|Biological|blood sampling,|
79362058|NCT01898962|Procedure|Complete Surgical Removal|
79362059|NCT01898962|Radiation|Stereotactic Radiosurgery|
79362060|NCT01898962|Radiation|Ablative external beam radiation dose|
79362061|NCT01898962|Procedure|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
79362062|NCT01898962|Radiation|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
79362063|NCT04752124|Other|Exercise Therapy|High intensity speed based interval treadmill training
79362064|NCT04752124|Other|conventional therapy|conventional physical therapy
79362065|NCT00266110|Biological|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
79362066|NCT00266110|Biological|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
79513018|NCT05494736|Drug|MK-8527|MK-8527 capsule taken by mouth.
79680151|NCT02930109|Drug|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
79680152|NCT00524186|Drug|fluorouracil|Given IV
79680153|NCT00524186|Drug|irinotecan hydrochloride|Given IV
79680154|NCT00524186|Drug|leucovorin calcium|Given IV
79993977|NCT03626610|Behavioral|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
79993978|NCT03707327|Other|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
79993979|NCT03707327|Other|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
79993980|NCT01343082|Drug|DE-111 ophthalmic solution|
79993981|NCT03374189|Device|EZ close|EZ close used.
79993982|NCT03374189|Device|Carter Thomason|Carter Thomason used.
79680155|NCT00524186|Drug|sunitinib malate|Taken Orally
79680156|NCT00524186|Other|flow cytometry|Correlative Study
79680157|NCT00524186|Other|pharmacological study|Correlative Study
79680158|NCT04442178|Drug|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
79680159|NCT04442178|Drug|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
79820675|NCT02586636|Drug|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
79218515|NCT03549663|Drug|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
79993983|NCT04385173|Drug|B7-H3 CAR-T|The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
79218516|NCT03549663|Drug|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
79218517|NCT02137083|Drug|Docetaxel|75mg/m2 D2 every 21 days
79218518|NCT02137083|Drug|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
79513019|NCT05492266|Device|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (3-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
79513020|NCT05492266|Device|Maintenance Training|"At visit 2, participants with improved (decreased) PWSS of 2 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
79513021|NCT05491317|Biological|GEN1042|Intravenous
79513022|NCT05491317|Drug|Pembrolizumab|Intravenous
79513023|NCT05491317|Radiation|Radiotherapy|Radiotherapy
79513024|NCT05490992|Other|Behavioral Skills Training In-person|"Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person."
79513025|NCT05478746|Device|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
79513026|NCT05478746|Other|Control - no intervention|No intervention; participants only receive routine care.
79820676|NCT00739310|Device|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
79993984|NCT04385173|Drug|Temozolomide|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
79513029|NCT05475236|Behavioral|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
79218519|NCT05428800|Behavioral|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
79513030|NCT05473910|Drug|SOC + TSC-100|HA-1 positive
79993985|NCT03261037|Other|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
79993986|NCT03261037|Other|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
79218520|NCT02137161|Drug|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
79218521|NCT02137161|Drug|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
79218522|NCT02252991|Other|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
79513031|NCT05473910|Drug|SOC + TSC-101|HA-2 positive or HA-1 negative
79513032|NCT05473910|Other|Control|SOC alone
79513033|NCT05472038|Biological|BNT162b5 Bivalent (WT/OMI BA.2)|BNT162b5 Wild Type and BNT162b5 OMICRON [B.1.1.529 sublineage BA.2]
79513034|NCT05472038|Biological|BNT162b2 Bivalent (WT/OMI BA.1)|BNT162b2 Wild Type and BNT162b2 OMICRON [B.1.1.529 sublineage BA.1]
79513035|NCT05472038|Biological|BNT162b2 Bivalent (WT/OMI BA.4/BA.5)|BNT162b2 Wild Type and BNT162b2 OMICRON [B.1.1.529 sublineage BA.4/BA.5]
79513036|NCT05472038|Biological|BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|BNT162b5 Wild Type and BNT162b5 OMICRON [B.1.1.529 sublineage BA.4/BA.5]
79820677|NCT04089644|Device|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
79820678|NCT04089644|Device|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
79820679|NCT00713739|Drug|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
79820680|NCT00713739|Drug|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
79820681|NCT00713739|Drug|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
79820682|NCT00713739|Drug|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
79820683|NCT04081662|Behavioral|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
79820684|NCT03908151|Device|CMK21 Hip system|Total hip arthroplasty
79218523|NCT05211999|Behavioral|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
79362067|NCT00266110|Biological|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
79513037|NCT05472038|Biological|BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|BNT162b6 Wild Type and BNT162b6 OMICRON [B.1.1.529 sublineage BA.4/BA.5]
79820685|NCT05373069|Procedure|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~10 min of clamping with single-use microvascular forceps~10 min declamping~10 min of tightening with pliers~10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
79513038|NCT05472038|Biological|BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|BNT162b7 Wild Type and BNT162b7 OMICRON [B.1.1.529 sublineage BA.4/BA.5]
79820686|NCT02595476|Drug|Remifentanil|
79820687|NCT02595476|Drug|propofol|
79820688|NCT02595476|Device|TCI|
79820689|NCT02595476|Procedure|Tetanic stimulation|
79820690|NCT02595476|Device|Algiscan|Pupillometry
79820691|NCT02586402|Drug|pegol-Sihematide|
79820692|NCT02586402|Drug|Epoetin Alfa|
79362068|NCT00266110|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
79513039|NCT05472038|Biological|BNT162b7 Monovalent (OMI BA.4/BA.5)|BNT162b7 OMICRON [B.1.1.529 sublineage BA.4/BA.5]
79513040|NCT05471843|Drug|BGB-11417|Administered orally
79513041|NCT05470907|Device|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
79218524|NCT05211999|Behavioral|Control Group|No intervention in control group just theoretical education was done for them.
79513042|NCT05470491|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg*h/L, on days -3 and -2.
79218525|NCT05401266|Procedure|mild hypercapnia|Ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored
79218526|NCT02253069|Device|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
79362069|NCT00240526|Biological|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
79820693|NCT00713895|Behavioral|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
79218527|NCT02253069|Device|Applying Placebo to tie-over dressings|Placebo control
79218528|NCT03528096|Device|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
79362070|NCT00240526|Biological|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
79362071|NCT01899274|Device|bant iPhone application|
79362072|NCT00242632|Drug|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
79362073|NCT01899352|Procedure|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
79362074|NCT01899040|Device|neuromodulation for episodic migraine headache|
79362075|NCT01899430|Drug|liraglutide|
79513043|NCT05470491|Drug|GVHD prophylaxis|Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
79513044|NCT05470491|Procedure|allo HCT|bone marrow transplant
79362076|NCT01899430|Drug|metformin|
79362077|NCT00245518|Drug|Isoflavone|
79362078|NCT00245518|Drug|Placebos|
79362079|NCT00267670|Drug|Pentoxifylline|400mg PO TID
79513045|NCT05470491|Drug|Plerixafor|In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
79362080|NCT00267670|Drug|Placebo|1 pill PO TID
79218529|NCT03528096|Other|Sound|Sound of the moving bed was recorded and played back during the baseline night.
79218530|NCT05362656|Device|VX1+ dispersion mapping|Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
79218531|NCT03528018|Device|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
79362081|NCT00247624|Drug|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
79362082|NCT00247624|Drug|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
79362083|NCT00247624|Drug|Placebo|Placebo every night for 8 weeks
79362084|NCT00248560|Drug|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
79362085|NCT00248560|Drug|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
79362086|NCT00248638|Drug|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
79362087|NCT00248638|Drug|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
79362088|NCT00249496|Behavioral|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
79362089|NCT00249496|Behavioral|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
79362090|NCT00268762|Drug|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
79513046|NCT05470491|Drug|Maraviroc|Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
79513047|NCT05468489|Drug|Serplulimab + chemotherapy (carboplatin-etoposide)|"Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics"
79513048|NCT05468489|Drug|Atezolizumab + chemotherapy (carboplatin-etoposide)|"Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics"
79513049|NCT05465330|Drug|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and remifentanil 0.05-0.2 μg/kg/min
79513050|NCT05465330|Drug|Desflurane, Propofol|After induction, anesthesia will be maintained with 0.5 MAC desflurane, propofol 1.5-2.5 μg/ml and remifentanil 0.05-0.2 μg/kg/min
79513051|NCT05462821|Device|Eye Patch|adhesive patch to cover eye
79513052|NCT05460039|Other|Dance mediated by tecnhology|A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
79820694|NCT00713895|Behavioral|Standard Self-Help|standard smoking cessation self-help manual
79820695|NCT00734630|Drug|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
79820696|NCT00734630|Drug|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
79820697|NCT02570997|Drug|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
79820698|NCT02570997|Drug|Placebo|Matching placebo administered.
79820699|NCT02570529|Drug|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
79993987|NCT03261037|Other|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
79993988|NCT03710759|Other|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
79218532|NCT03528018|Other|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
79218533|NCT03530982|Other|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
79362091|NCT00252382|Drug|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
79362092|NCT00270634|Drug|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
79362093|NCT00270634|Drug|tacrolimus|tacrolimus 0.05 mg/kg po BID
79513053|NCT05455463|Behavioral|Online aphasia-adapted physical activity class|Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
79362094|NCT01899586|Other|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
79362095|NCT01899586|Other|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
79362096|NCT04110340|Drug|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
79513054|NCT05451771|Drug|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
79513055|NCT05451771|Device|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
79513056|NCT05451771|Drug|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
79513057|NCT05451771|Drug|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
79513058|NCT05451771|Drug|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
79513059|NCT05451771|Drug|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
79513060|NCT05451771|Drug|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m^2 intravenously on days 1 and 2 in each 28-day cycle.
79672514|NCT03278288|Device|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
79672515|NCT00478842|Device|Deep brain stimulation|Deep brain stimulation
79672516|NCT00478959|Drug|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
79672517|NCT00444158|Drug|MOA-728|
79672518|NCT00441324|Procedure|recombinant human LH|
79672519|NCT00444197|Behavioral|Mentoring and violence prevention curriculum with parental monitoring|
79672520|NCT00444236|Drug|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
79672521|NCT00444236|Drug|Placebo|matching placebo for active drug
79820700|NCT02570529|Drug|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
79993989|NCT03372551|Device|somofilcon A 1 day test lens|Contact lens
79993990|NCT03372551|Device|somofilcon A 1 day control lens|Contact lens
79993991|NCT03707249|Drug|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
79672522|NCT00478998|Drug|Tamsulosin|
79672523|NCT02957279|Drug|Antibiotics|In the sepsis group, antibiotics were used when needed.
79672524|NCT00479076|Drug|aflibercept (AVE0005)|intravenous infusion
79672525|NCT00479076|Drug|S-1|oral administration
79672526|NCT00441519|Drug|aspirin|
79672527|NCT00441519|Drug|omeprazole|
79993992|NCT03707249|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
79993993|NCT03326323|Procedure|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
79993994|NCT05682911|Drug|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
79362097|NCT04110340|Drug|Streptomycin|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
79362098|NCT04110340|Drug|Gentamicin|"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
79362099|NCT00270790|Drug|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
79362100|NCT00270790|Drug|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
79362101|NCT00270790|Drug|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
79362102|NCT00270790|Device|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
79993995|NCT05682911|Drug|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
79993996|NCT05480592|Drug|HS-10380|Administered orally as a tablet
79362103|NCT00271570|Drug|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
79513061|NCT05451771|Drug|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
79513062|NCT05451771|Drug|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
79993997|NCT05480592|Drug|Placebo|Administered orally as a tablet
79362104|NCT00271570|Biological|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
79362105|NCT00273364|Procedure|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
79362106|NCT00273364|Drug|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
79513063|NCT05451771|Drug|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
79672528|NCT03278171|Behavioral|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
79993998|NCT04990531|Diagnostic Test|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
79993999|NCT04990531|Diagnostic Test|Blood sample|Blood sample for diagnostic testing
79994000|NCT05467332|Device|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
79994001|NCT04680390|Behavioral|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
79994002|NCT04680390|Behavioral|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
79994003|NCT04663620|Behavioral|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
79994004|NCT04663620|Behavioral|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
79994005|NCT04625088|Other|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
79362107|NCT05237596|Drug|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
79362108|NCT02102932|Drug|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
79362109|NCT02102932|Drug|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
79513064|NCT05445466|Device|High-Definition Transcranial Electrical-Current Stimulation|Non-frequency dependent transcranial electrical stimulation condition for 5 days of twice a day treatment
79513065|NCT05445466|Device|High-Definition Transcranial Alternate-Current Stimulation|Active-control stimulation condition will target alpha (10 Hz) for 5 days of twice a day treatment
79513066|NCT05445466|Device|High-Definition Personalized Beta-Gamma Electrical Stimulation|Personalized beta-gamma electrical stimulation for 5 days of twice a day treatment
79672529|NCT00441597|Drug|atorvastatin|atorvastatine 80mg, during 3 days
79672530|NCT03278132|Biological|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
79218534|NCT05723718|Other|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
79513067|NCT05442359|Drug|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
79820701|NCT05372835|Other|La Chlogen mouthwash|Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
79820702|NCT05372835|Other|water|Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
79820703|NCT05372835|Other|La Chlogen mouthwash and La Chlogen periodontal flosser|Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
79820704|NCT02586480|Device|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
79820705|NCT02570607|Biological|BNP dosage|
79820706|NCT02570763|Device|Active tDCS stimulation|
79820707|NCT02570763|Device|Sham tDCS stimulation|
79820708|NCT04079556|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
79994006|NCT04625088|Drug|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
79218535|NCT03527628|Drug|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
79218536|NCT03527628|Drug|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
79218537|NCT03527628|Drug|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
79362110|NCT02102932|Drug|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
79362111|NCT02102932|Drug|850 mg metformin|850mg metformin tablet
79362112|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
79513068|NCT05442359|Device|stent|Applied as a palatal stent for palatal wound
79994007|NCT03568422|Drug|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 & 16
79513075|NCT05436600|Other|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
79218538|NCT03527628|Drug|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
79218539|NCT03527628|Drug|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
79362113|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
79362114|NCT02102932|Drug|850 mg metformin|850 mg metformin
79362115|NCT02102932|Drug|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
79362116|NCT02102932|Drug|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
79362117|NCT02102932|Drug|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
79362118|NCT02102932|Drug|500 mg metformin|500 mg metformin
79513076|NCT05435339|Biological|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
79513077|NCT05433636|Behavioral|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
79513078|NCT05433636|Behavioral|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
79513079|NCT05433636|Behavioral|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
79513080|NCT05433636|Behavioral|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
79513081|NCT05433636|Behavioral|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
79820709|NCT00584454|Biological|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
79362119|NCT02102932|Drug|500 mg metformin|500 mg metformin
79362120|NCT00273754|Drug|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
79820710|NCT02586324|Biological|global medium|
79994008|NCT03568422|Drug|Paclitaxel|80 mg/m2 IV days 1, 8 & 15 every 28 days
79820711|NCT02586324|Biological|SSM|
79820712|NCT04081272|Drug|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
79820713|NCT02586246|Drug|CDP870|Self-injection
79820714|NCT00920244|Procedure|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
79994009|NCT03484494|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
79994010|NCT03937141|Drug|ADU-S100|intratumoral
79994011|NCT02547493|Biological|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
79994012|NCT02547493|Biological|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
79994013|NCT02547493|Drug|Abatacept|Abatacept started on frst day
79218540|NCT03527628|Drug|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
79218541|NCT03530904|Other|mobilization|Early mobilization after CIED implantation
79218542|NCT03530826|Other|No intervention|No Intervention
79994014|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
79218543|NCT03530748|Procedure|Endovascular therapy and Imaging Acquisition|"Endovascular repair for renal artery stenosis;~Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney"
79513082|NCT05425459|Device|Corvia Atrial Shunt System / IASD System II|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
79513083|NCT05425459|Other|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
79513084|NCT05415982|Other|Ketogenic Diet|The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
79218544|NCT04466748|Drug|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
79672531|NCT04701372|Behavioral|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
79218545|NCT04466748|Drug|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
79218546|NCT04466670|Drug|acetylsalicylic acid|acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
79218547|NCT04466670|Drug|Unfractionated heparin nebulized|unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
79218548|NCT04468542|Drug|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
79362121|NCT00273754|Drug|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
79362122|NCT04751344|Drug|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
79672532|NCT00479193|Drug|bacitracin/xeroform|single layer, change every 3 days
79672533|NCT00479193|Drug|Polymem|single layer of Polymen, change every 3 days
79672534|NCT03278054|Other|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
79672535|NCT03278054|Other|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
79820715|NCT00920244|Drug|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
79994015|NCT03259789|Drug|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
79994016|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
79362123|NCT04751344|Drug|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
79362124|NCT05211232|Drug|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
79820716|NCT00920244|Drug|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency < 60 beat/min.
79820717|NCT00920244|Drug|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
79820718|NCT00920244|Device|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
79218549|NCT04468542|Drug|Superior laryngeal nerve block - Placebo (saline)|2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
79218550|NCT04468308|Other|Questionnaire|Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
79820719|NCT00920010|Other|biologic sample preservation procedure|
79218551|NCT04615260|Device|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
79218552|NCT03525522|Device|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
79218553|NCT03525522|Drug|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
79218554|NCT04466436|Other|tryptophan|measurement of tryptophan in serum
79218555|NCT04466514|Drug|ASTX029|Form: tablet; Route of Administration: oral
79513085|NCT05414851|Other|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
79672536|NCT03278054|Other|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
79218556|NCT04500834|Biological|Metal Panel T.R.U.E. Test|Diagnostic patch test
79218557|NCT04467450|Drug|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
79218558|NCT04467450|Drug|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
79218559|NCT03525366|Other|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
79218560|NCT03008382|Drug|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
79218561|NCT03008382|Drug|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
79362125|NCT05211232|Drug|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
79362126|NCT00273910|Drug|gp100:209-217 (210M)|
79362127|NCT00273910|Drug|Montanide ISA-51|
79362128|NCT00273910|Drug|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
79362129|NCT04389034|Drug|Pollinex Quattro with tree- and grass pollen extracts and their mixtures|retrospective analysis of patient records of allergen-specific immunotherapy
79820720|NCT00578175|Biological|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
79820721|NCT00578175|Biological|ProQuad®|One subcutaneous injection.
79820722|NCT00578175|Biological|Havrix®|Two intramuscular injections.
79820723|NCT00578175|Biological|Prevnar®|One intramuscular injection.
79672537|NCT00441636|Device|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
79672538|NCT03278015|Drug|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
79218562|NCT02137239|Drug|Thymoglobulin|
79218563|NCT02137239|Drug|Belatacept|
79218564|NCT02137239|Drug|mycophenolate mofetil(MMF)|
79218565|NCT02137239|Drug|Corticosteroids|
79218566|NCT02137239|Drug|Everolimus(EVL)|
79218567|NCT02137239|Drug|Tacrolimus(TAC)|
79218568|NCT05229354|Biological|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
79218569|NCT05229354|Biological|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
79362130|NCT00274768|Drug|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
79362131|NCT00280384|Drug|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
79820724|NCT00723879|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
79218570|NCT05227794|Behavioral|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
79218571|NCT05227794|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
79218572|NCT04468152|Behavioral|Dietary habits and intake|Optical coherence tomography (OCT) withdrawals and central foveal thickness (CFT) evaluations of those included in the study were made by the doctor and directed to the dietician (researcher). The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ) (21). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant.
79218573|NCT02137317|Device|LAPPE (locally adapted personal protective equipment)|"Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
79218574|NCT03522792|Other|Neurotensin|Intravenous infusion of neurotensin
79218575|NCT03522792|Other|Saline|Intravenous infusion of saline
79218576|NCT03522792|Other|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
79218577|NCT03522792|Other|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
79513086|NCT05411302|Other|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
79513087|NCT05409976|Device|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
79513088|NCT05400265|Drug|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
79513089|NCT05400265|Drug|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
79672539|NCT03278015|Drug|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
79672540|NCT03278015|Drug|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
79672541|NCT00441675|Procedure|Symptom Score|Symptom Score
79820725|NCT00723879|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
79218578|NCT02137395|Drug|Dexamethasone|dexamethasone administration, intravenously
79994017|NCT03259555|Drug|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
79994018|NCT03259555|Drug|Placebo|Administered orally daily for 3 weeks.
79218579|NCT02137395|Drug|Placebo|saline administration intravenously
79218580|NCT02137551|Other|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
79218581|NCT02137629|Drug|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
79218582|NCT02137707|Drug|Gilenya|All patients will receive Gilenya
79218583|NCT02253381|Procedure|Right|Right lateral decubitus position during spinal anesthesia
79218584|NCT02253381|Procedure|Left|Left lateral decubitus position during spinal anesthesia
79218585|NCT04252014|Behavioral|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
79218586|NCT02261025|Drug|acetylsalicylic acid|75-100mg,per day
79218587|NCT05579067|Procedure|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
79218588|NCT05579067|Procedure|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
79218589|NCT05578989|Device|Virtual reality glasses|watching a video with music with virtual reality glasses.
79218590|NCT05578833|Diagnostic Test|HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
79218591|NCT05578833|Diagnostic Test|p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
79820726|NCT00723879|Behavioral|Patient assistance program|"Patient assistance programs will be classified as follows:~medications, including psychiatric medications (antidepressants);~other interventions, including nurse telephone calls and nurse support in the office: and~educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
79362132|NCT00280384|Drug|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
79994019|NCT03702751|Procedure|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
79994020|NCT03702751|Procedure|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
79362133|NCT01763996|Drug|Febuxostat|Febuxostat capsules
79362134|NCT01763996|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
79362135|NCT01790464|Drug|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
79362136|NCT01790464|Drug|placebo|
79994021|NCT03259087|Drug|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
79994022|NCT03257995|Drug|Indacaterol maleate|150 μg via Concept1 device
79994023|NCT03257995|Drug|Indacaterol acetate|150 μg via Concept1 device
79994024|NCT03257995|Drug|Placebo|Capsule containing no active ingredients delivered via Concept1 device
79362137|NCT01790542|Other|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
79362138|NCT01790542|Other|Iron fortified cereal with fruit|
79362139|NCT01790542|Other|Meat|
79362140|NCT01899820|Drug|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
79513090|NCT05389163|Device|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
79994025|NCT03049488|Biological|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
79994026|NCT03049488|Other|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
79994027|NCT04484922|Drug|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
79994028|NCT04484922|Drug|Normal saline|continuous infusion of normal saline during the surgery
79994029|NCT04481958|Behavioral|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
79362141|NCT01899820|Drug|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
79994030|NCT04446390|Other|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
79513091|NCT05389163|Device|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
79513092|NCT05387525|Drug|Tirbanibulin (Klisyri®) 10 mg/g ointment|Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm^2 of the face or scalp with Actinic Keratosis (AK).
79820727|NCT03907605|Other|anti- mullerian hormone|All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
79994031|NCT04446390|Other|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
79218592|NCT05578833|Diagnostic Test|standard conventional cytology PAP test|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
79994032|NCT03257137|Other|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
79994033|NCT02338921|Drug|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
79994034|NCT02338921|Drug|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
79218593|NCT03527082|Other|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
79218594|NCT02137863|Drug|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
79218595|NCT02137863|Drug|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
79218596|NCT02137863|Drug|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
79218597|NCT02137941|Behavioral|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
79362142|NCT02099266|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
79218598|NCT02137941|Behavioral|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
79218599|NCT02133729|Other|Blood sampling and OGTT|
79362143|NCT04511338|Device|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
79513093|NCT05387525|Drug|Diclofenac Sodium 3% Gel|Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
79513094|NCT05386472|Drug|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
79513095|NCT05386472|Drug|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
79513096|NCT05382442|Drug|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
79218600|NCT03522558|Behavioral|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
79362144|NCT04480528|Other|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
79362145|NCT04480528|Other|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
79513097|NCT05382442|Drug|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
79513098|NCT05382442|Drug|Oxaliplatin|Oxaliplatin via IV infusion
79994035|NCT02338921|Drug|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
79994036|NCT02338921|Drug|Glimepirde|
79994037|NCT02338921|Drug|Metformin|
79362146|NCT02100748|Drug|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
79362147|NCT02100748|Drug|Morphine|Morphine 4 mg will be administered every 4 hours
79362148|NCT02100748|Drug|Placebo|Placebo will be administered every 4 hours
79513099|NCT05382442|Drug|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
79513100|NCT05382442|Drug|Irinotecan|Irinotecan via IV infusion
79513101|NCT05382442|Drug|Leucovorin|Leucovorin via IV infusion
79513102|NCT05382442|Drug|5-fluorouracil|5-fluorouracil via IV infusion
79513103|NCT05381909|Drug|BGB-24714|administered orally
79513104|NCT05381909|Drug|Paclitaxel|administered intravenously
79513105|NCT05381909|Drug|Carboplatin|administered intravenously
79513106|NCT05380323|Drug|LY3541105|Administered SC.
79513107|NCT05380323|Drug|Placebo|Administered SC.
79513108|NCT05369390|Drug|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
79513109|NCT05369390|Drug|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
79672542|NCT00441675|Procedure|Symptom Score and PD20|Symptom Score and PD20
79994038|NCT01313845|Drug|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
79994039|NCT01313845|Drug|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
79994040|NCT04782661|Drug|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
79994041|NCT04782661|Drug|Placebo|Placebo solution will be administered orally.
79362149|NCT00283504|Drug|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
79362150|NCT04407676|Other|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
79218601|NCT03522558|Behavioral|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
79218602|NCT02138019|Procedure|Fibrin Glue assisted external eye surgery|
79218603|NCT02138019|Device|Fibrin glue|
79513110|NCT05369390|Other|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
79513111|NCT05369390|Other|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
79513112|NCT05349318|Device|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
79994042|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
79218604|NCT02252757|Device|CoVa|
79994043|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
79218605|NCT02133807|Procedure|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
79218606|NCT02138331|Biological|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
79994044|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
79218607|NCT05578521|Drug|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
79218608|NCT05578521|Drug|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
79218609|NCT03548649|Device|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
79218610|NCT02138409|Drug|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
79218611|NCT02138409|Drug|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
79218612|NCT02138487|Other|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
79218613|NCT02138487|Other|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
79218614|NCT02134041|Other|traumatic brain injury|mild TBI, GCS >/=13 after traumatic brain injury
79218615|NCT02134197|Drug|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
79218616|NCT02138565|Procedure|Gastric by-pass surgery|
79218617|NCT02138643|Procedure|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
79218618|NCT02138643|Procedure|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
79513113|NCT05349318|Device|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
79513114|NCT05347212|Drug|Nivolumab|Given by IV
79513115|NCT05347212|Drug|Relatlimab|Given by IV
79513116|NCT05344170|Drug|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
79513117|NCT05344170|Drug|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
79672543|NCT00444314|Drug|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
79994045|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
79218619|NCT02138799|Drug|enzalutamide|oral
79362151|NCT04370236|Drug|INB03|Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
79362152|NCT04370236|Drug|Placebo|Patients will receive up to two once per week subcutaneous injections of Placebo
79362153|NCT00283816|Drug|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
79362154|NCT00283816|Drug|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
79362155|NCT00283816|Behavioral|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study
79362156|NCT00283816|Behavioral|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
79362157|NCT00283816|Procedure|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
79218620|NCT02138799|Drug|rifampin|oral
79362158|NCT00283816|Procedure|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
79362159|NCT00283816|Procedure|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
79513118|NCT05344170|Drug|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
79513119|NCT05342220|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to systolic blood pressure values > 200mmHg for 5 minutes (3 times) each before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
79513120|NCT05342220|Procedure|Sham preconditioning|Inflation of a blood pressure cuff to systolic blood pressure values ~ 20mmHg for 5 minutes (3 times) each before electrocardioversion
79513121|NCT05335486|Device|RELEARN Neurofeedback|"Standard care + The RELEARN intervention.~Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception."
79513122|NCT05335486|Other|Standard care control|"Standard Care control.~Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
79513123|NCT05328375|Behavioral|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
79994046|NCT04492098|Diagnostic Test|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
79994047|NCT04683991|Procedure|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
79218621|NCT02138877|Procedure|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
79218622|NCT02138877|Procedure|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
79362160|NCT00283816|Procedure|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
79362161|NCT00283816|Drug|placebo|placebo capsules, two capsules BID
79994048|NCT04361838|Behavioral|prayer|receive prayers daily while in ICU
79362162|NCT00284518|Biological|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
79362163|NCT00284518|Drug|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
79362164|NCT04339426|Drug|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
79362165|NCT01899898|Other|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~Pictorial representation of various food items and exchange lists will be provided.~Instead of weights, we will provide standardized measures~We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~We will formulate recipes and diets based on locally available and culturally acceptable foods.~We will develop a parent instruction manual.~We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
79362166|NCT01899898|Drug|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
79362167|NCT00286078|Device|Precision|Implantable neurostimulator
79362168|NCT04217902|Other|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
79218623|NCT02134275|Behavioral|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
79513124|NCT05328375|Behavioral|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
79218624|NCT02134275|Behavioral|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
79513125|NCT05327530|Drug|Avelumab|Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
79672544|NCT00444314|Drug|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
79218625|NCT02975271|Drug|Serlopitant|
79218626|NCT02975271|Drug|Placebo|Matching placebo
79218627|NCT02741076|Drug|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
79218628|NCT02741076|Drug|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
79218629|NCT02973633|Device|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
79218630|NCT02973633|Drug|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
79218631|NCT02139033|Drug|Retaine™|
79218632|NCT01666444|Drug|pegylated liposomal doxorubicin (PLD)|
79218633|NCT01666444|Drug|VTX-2337|TLR8 Agonist
79218634|NCT01666444|Drug|Placebo|
79362169|NCT04217902|Other|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
79362170|NCT00287716|Drug|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
79362171|NCT00287716|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
79362172|NCT00287872|Drug|bortezomib|
79218635|NCT02134431|Device|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
79218636|NCT02253225|Other|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
79218637|NCT02134509|Behavioral|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
79218638|NCT02134509|Behavioral|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
79218639|NCT05159622|Behavioral|Water Up! at Home|1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety & affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
79218640|NCT02139111|Drug|Placebo|Oral placebo capsule
79362173|NCT00287872|Drug|thalidomide|
79362174|NCT00288574|Drug|Fluoxetine|
79362175|NCT00288574|Drug|Placebo|
79362176|NCT01791010|Other|Inspiratory muscle training|
79362177|NCT01791010|Other|Training sham|Conducting fake training with the aim of blind the control group
79362178|NCT00288886|Behavioral|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
79362179|NCT00288886|Behavioral|Control arm|Routine residential treatment and orientation to continuing care.
79672545|NCT00479271|Behavioral|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
79672546|NCT00479271|Behavioral|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
79672547|NCT00444353|Device|DL6049 (injectable poly-L-lactic acid)|
79218641|NCT02139111|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
79994049|NCT03242863|Other|Food proportionality|Proportions of high and low energy dense foods manipulated
79994050|NCT03044106|Device|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
79218642|NCT02139111|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
79218643|NCT02139111|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
79218644|NCT02139111|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
79218645|NCT03522480|Device|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
79994051|NCT03196986|Drug|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
79218646|NCT03522480|Other|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
79218647|NCT02139189|Device|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
79218648|NCT05120934|Drug|Amitriptyline 25 MG|25 mg orally for 4 weeks
79218649|NCT05120934|Drug|Amitriptyline 50 MG|50 mg orally for 4 weeks
79218650|NCT05120934|Drug|Duloxetine 30 MG|30mg orally for 4 weeks
79994052|NCT03196986|Drug|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
79994053|NCT04051632|Device|Medtronic 670G insulin pump|"percent of patients who continue to use Medtronic 670G over time~impact of 670G on glycemic control: hemoglobin A1c, time in range"
79218651|NCT05120934|Drug|Duloxetine 60 MG|60mg orally for 4 weeks
79218652|NCT05120934|Drug|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
79218653|NCT05120934|Drug|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
79218654|NCT03548493|Drug|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
79994054|NCT03170856|Other|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
79218655|NCT03548493|Drug|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
79218656|NCT03548493|Drug|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
79218657|NCT05550610|Behavioral|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
79218658|NCT03525132|Procedure|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
79994055|NCT03139968|Device|(sham) radiation absorbing drape (RADPAD®)|
79994056|NCT04377919|Dietary Supplement|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
79218659|NCT02139267|Biological|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
79218660|NCT02139345|Device|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
79218661|NCT02139345|Device|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
79218662|NCT03549819|Drug|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
79218663|NCT03549819|Drug|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
79362180|NCT00289120|Drug|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
79362181|NCT00289120|Drug|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
79362182|NCT04061590|Drug|Cisplatin|Given IV
79362183|NCT04061590|Biological|Pembrolizumab|Given IV
79362184|NCT04061590|Drug|Pemetrexed|Given IV
79994057|NCT04377919|Dietary Supplement|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
79994058|NCT04408092|Drug|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
79672548|NCT00444392|Behavioral|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
79820728|NCT00435409|Drug|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day [1000 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
79820729|NCT00435409|Drug|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day [1250 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
79820730|NCT00724035|Drug|Midazolam|"Procedural sedation before the execution of the block.~0.03 mg/kg iv bolus"
79994059|NCT03043560|Drug|Ezogabine|daily for 5 weeks
79994060|NCT03043560|Drug|Placebos|placebo pill daily for 5 weeks
79994061|NCT04051554|Other|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
79994062|NCT04051554|Other|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
79994063|NCT04051476|Other|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
79218664|NCT02139423|Other|CMV PCR|
79362185|NCT04061590|Drug|Pemetrexed Disodium|Given IV
79362186|NCT04061590|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79994064|NCT04051476|Other|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
79994065|NCT04051476|Other|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
79994066|NCT04051476|Other|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
79218665|NCT01665430|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
79218666|NCT03524976|Device|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
79218667|NCT05578053|Drug|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
79362187|NCT01791088|Drug|sirolimus|Given PO
79994067|NCT02145403|Drug|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
79994068|NCT02145403|Drug|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
79994069|NCT03255733|Device|Intense Therapeutic Ultrasound Treatment|
79362188|NCT01791088|Other|pharmacological study|Correlative studies
79362189|NCT01791088|Other|laboratory biomarker analysis|Correlative studies
79994070|NCT03255655|Device|Intense Therapeutic Ultrasound Treatment - ITU|
79994071|NCT02899988|Drug|Mirikizumab|Administered SC
79994072|NCT02899988|Drug|Placebo|Administered SC
79362190|NCT00289744|Biological|TWINRIX™ ADULT|2 doses IM injection in primary study
79218668|NCT02134743|Procedure|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
79362191|NCT00289744|Biological|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
79362192|NCT00291226|Drug|Glycine|Glycine 0.4 g/kg bid
79362193|NCT00291226|Drug|Placebo|Placebo
79362194|NCT01791166|Biological|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
79672549|NCT00444431|Procedure|Pyeloplasty|
79672550|NCT00441714|Procedure|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
79672551|NCT03277898|Behavioral|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
79672552|NCT03277898|Behavioral|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
79672553|NCT02274051|Dietary Supplement|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
79672554|NCT03277859|Behavioral|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
79362195|NCT00291694|Drug|celecoxib|Celecoxib 400 mg BID
79362196|NCT00291694|Other|placebo|placebo
79362197|NCT00292162|Procedure|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
79362198|NCT00292162|Drug|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
79362199|NCT00292162|Drug|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
79513126|NCT05327530|Drug|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
79513127|NCT05327530|Drug|M6223|Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains [anti-TIGIT]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
79513128|NCT05327530|Drug|NKTR-255|Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
79513129|NCT05323916|Behavioral|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
79513130|NCT05323916|Behavioral|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
79513131|NCT05323916|Behavioral|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
79513132|NCT05323916|Behavioral|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
79218669|NCT04466202|Other|Music with Structured Verbal Training|Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
79218670|NCT05542888|Procedure|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
79218671|NCT05542888|Procedure|Standard therapy|Postural education, Hot pack, Antenatal exercises
79218672|NCT03549741|Drug|Clomiphene Citrate 50mg|oral tablets
79362200|NCT00292162|Drug|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
79513133|NCT05319405|Device|Sana Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
79513134|NCT05314855|Device|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
79218673|NCT03549741|Drug|Cabergoline Oral Tablet|oral tablets
79218674|NCT03549741|Drug|Placebo Oral Tablet|oral tablets
79218675|NCT05542810|Combination Product|Use sports drinks as polyethylene glycol solvents|Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
79362201|NCT00296296|Drug|Cyclosporin|Dose adjustment to pre-established targets
79362202|NCT00296296|Drug|Tacrolimus|Dose adjustment to pre-established targets
79362203|NCT00296296|Behavioral|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
79362204|NCT03880786|Device|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
79513135|NCT05310110|Drug|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
79513136|NCT05310110|Drug|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
79513137|NCT05310110|Drug|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
79513138|NCT05310110|Drug|Placebo of cisatracurium|Intravenous normal saline during induction
79513139|NCT05310110|Drug|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
79513140|NCT05306457|Biological|CNS10-NPC-GDNF|Unilateral injections of CNS10-NPC-GDNF into the motor cortex
79362205|NCT01791400|Drug|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
79820731|NCT00724035|Drug|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
79820732|NCT00724035|Drug|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
79218676|NCT03522402|Drug|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
79218677|NCT05577975|Device|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
79218678|NCT05542732|Device|CardioWatch 287-2|CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
79820733|NCT00724035|Procedure|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
79362206|NCT01791400|Drug|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
79820734|NCT00724035|Procedure|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
79218679|NCT05698966|Other|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
79218680|NCT02139501|Drug|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
79218681|NCT02134821|Procedure|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
79218684|NCT05577897|Other|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
79362207|NCT00298090|Device|StO2 monitoring|placement of the StO2 device/ external noninvasive
79362208|NCT00298558|Behavioral|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
79362209|NCT00299416|Drug|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
79362210|NCT00299416|Procedure|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
79362211|NCT00300430|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
79218685|NCT05542654|Other|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
79218686|NCT02134899|Drug|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
79218687|NCT02134899|Drug|Calcineurin inhibitors maintenance|Usual treatment
79218688|NCT02135055|Other|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
79362212|NCT00300430|Drug|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
79362213|NCT00300430|Drug|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
79362214|NCT02104414|Drug|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
79994073|NCT02939131|Behavioral|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
79362215|NCT02104414|Drug|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
79362216|NCT02104414|Drug|Normal Saline|30mL Normal Saline
79362217|NCT02100826|Drug|Cephalexin|Administered orally.
79362218|NCT02101918|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
79362219|NCT02101918|Other|Laboratory Biomarker Analysis|Correlative studies
79362220|NCT02101918|Biological|Ziv-Aflibercept|Given IV
79362221|NCT04271722|Other|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
79513141|NCT05300464|Device|Clinical investigation medical device class IIa marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
79513142|NCT05296135|Diagnostic Test|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
79513143|NCT05292287|Device|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
79218689|NCT02135055|Drug|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
79513144|NCT05289063|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
79513145|NCT05289063|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
79994074|NCT02939131|Behavioral|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
79513146|NCT05289063|Other|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
79513147|NCT05286866|Procedure|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
79672555|NCT00444470|Drug|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
79218690|NCT02135055|Drug|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
79218691|NCT02135055|Procedure|Sedation interruption|Sedation interruption is performed at 8 am every morning.
79218692|NCT02139579|Drug|Bevacizumab|7.5 mg/kg every 3 weeks
79672556|NCT00444470|Drug|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
79672557|NCT00479310|Drug|Summers 5% L.A.|
79672558|NCT00444509|Drug|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
79672559|NCT00444509|Drug|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
79672560|NCT02957175|Other|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
79218693|NCT04425928|Procedure|occupational therapy based activity training programs|Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
79994075|NCT04052282|Device|Mobile Health App|There is no intervention
79218694|NCT04425928|Procedure|Physiotherapy based exercise training programs|Cawthorne-cooksey exercises were performed at vestibular rehabilitation
79672561|NCT00444548|Drug|[S,S]-Reboxetine|
79672562|NCT00444665|Drug|Travatan-Z|
79672563|NCT00479349|Drug|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
79672564|NCT00444704|Drug|PRA-027|
79680160|NCT00525005|Drug|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
79680161|NCT00525200|Drug|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
79680162|NCT00525200|Drug|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
79218695|NCT02139657|Biological|RIG-C|
79218696|NCT03526926|Drug|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
79218697|NCT02135211|Behavioral|Lifestyle counseling|
79218698|NCT04076826|Drug|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
79362222|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
79513148|NCT05282628|Behavioral|Building Better Brains and Behavior program (B4 Preterm)|The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
79513149|NCT05271409|Drug|Satralizumab|Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
79513150|NCT05271409|Other|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
79513151|NCT05256290|Drug|BDTX-1535 monotherapy|BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
79994076|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
79994077|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
79994078|NCT03643718|Procedure|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
79994079|NCT03646370|Drug|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
79994080|NCT03643640|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
79994081|NCT03643640|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
79371088|NCT00949234|Drug|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
79672565|NCT03279354|Behavioral|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
79994082|NCT04166994|Behavioral|Exercise and diet|IMPACT Intervention
79994083|NCT04166994|Other|No Intervention: Usual Care|No exercise or diet specialization.
79994084|NCT03644420|Diagnostic Test|Clinical evaluation|Functional scores for the pathological joint will be determined
79994085|NCT03644420|Diagnostic Test|Radiology|
79994086|NCT03644420|Diagnostic Test|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
79994087|NCT03644420|Diagnostic Test|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
79218699|NCT04076826|Drug|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
79218700|NCT04076826|Diagnostic Test|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
79218701|NCT02139735|Other|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
79218702|NCT02139735|Other|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
79218703|NCT02139735|Other|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
79994088|NCT03646292|Drug|Pioglitazone|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
79994089|NCT03646292|Drug|Empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
79994090|NCT03646292|Drug|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
79994091|NCT03345407|Drug|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
79513152|NCT05250908|Device|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
79513153|NCT05250908|Device|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
79513154|NCT05237739|Procedure|Non-Surgical Periodontal treatment (NSPT)|Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.
79513155|NCT05237739|Procedure|Open Flap Debridement (OFD)|Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips
79371089|NCT02984787|Procedure|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
79218704|NCT05535634|Diagnostic Test|Sound Ear Check|Hearing test, measurement of the input impedance of the middle-ear transmission system
79513156|NCT05234307|Drug|Adenosine A2B Receptor Antagonist PBF-1129|Given PO
79513157|NCT05234307|Procedure|Biospecimen Collection|Correlative studies
79513158|NCT05234307|Biological|Nivolumab|Given IV
79513159|NCT05231408|Other|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
79513160|NCT05231408|Other|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
79513161|NCT05226663|Procedure|Computed Tomography|Undergo [18F]FFT PET/CT
79513162|NCT05226663|Radiation|Fluorine F 18 Fluorthanatrace|Given IV
79513163|NCT05226663|Procedure|Positron Emission Tomography|Undergo [18F]FFT PET/CT
79994092|NCT03345407|Drug|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
79513165|NCT05225272|Other|Enhanced Recovery Program for on-pump cardiac surgery|Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
79513166|NCT05222373|Behavioral|CBT-based lifestyle intervention|The standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English). Trained CHWs will promote CBT-based lifestyle-change aims and assist in goal setting with participants to reach the primary goal of appropriate glycemic control (fasting blood glucose and HbA1c) and weight reduction, in addition to decrease in depressive symptoms and stress and an increase in quality of life. Participants' body weight, body composition, metabolic measures, and mental health outcomes will be obtained at enrollment and at the end of the intervention.
79994093|NCT03345407|Drug|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
79994094|NCT03345407|Drug|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
79218705|NCT05577585|Drug|Ketamine 50 MG/ML|See also Arm description
79218706|NCT05577585|Drug|Midazolam|See also Arm description
79513167|NCT05213858|Diagnostic Test|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
79513168|NCT05213858|Diagnostic Test|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
79218707|NCT04465968|Drug|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
79680163|NCT02929992|Other|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
79218708|NCT04465968|Drug|S1|80 - 120 mg/day, PO, day 1-14
79218709|NCT04465968|Radiation|concurrent radiotherapy|66 Gy/33 Fr
79218710|NCT04465968|Drug|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
79218711|NCT04465968|Procedure|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
79371090|NCT02984787|Procedure|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
79371091|NCT03090880|Drug|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
79513169|NCT05213858|Diagnostic Test|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
79513170|NCT05213858|Diagnostic Test|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
79218712|NCT04465968|Drug|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
79218713|NCT02139813|Procedure|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~an Omega loop of 200 cm~a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
79513171|NCT05213858|Diagnostic Test|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
79513172|NCT05213858|Diagnostic Test|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
79513173|NCT05213858|Diagnostic Test|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
79994095|NCT03345407|Drug|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
79994096|NCT03345407|Drug|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
79218714|NCT02139813|Procedure|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~a small gastric pouch (about 30cc)~an antecolic alimentary limb~a gastro-jejunal anastomosis using a linear stapler~a 150cm long alimentary limb~a 50cm biliary limb~a latero-lateral jejuno-jejunal anastomosis~closure of the mesenteric defects"
79218715|NCT03526770|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
79218716|NCT03526770|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
79218717|NCT03526770|Drug|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
79218718|NCT03526770|Other|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
79218719|NCT03526770|Other|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
79218720|NCT03526770|Other|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
79218721|NCT02135367|Biological|PRP|injections of Platelet rich Plasma
79218722|NCT05699512|Behavioral|Multiprofessional, tailored rehabilitation|Patients receive individual, tailored, multiprofessional rehabilitation
79218723|NCT04189458|Other|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
79218724|NCT02139891|Device|Cardiac Resynchronization Therapy with MultiPoint Pacing|
79218725|NCT02135523|Radiation|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
79513174|NCT05213858|Diagnostic Test|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~Mean sleep latency~The number and duration of awakenings.~Subjective total sleep time~Subjective wake after sleep onset~Sleep efficiency"
79218726|NCT05535400|Behavioral|Physical-Psychological Integrative Intervention|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real & Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
79218727|NCT05535400|Device|Brief online didactic education|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
79218728|NCT05577429|Other|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
79218729|NCT05577429|Other|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
79218730|NCT05577429|Other|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
79218731|NCT05542186|Procedure|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
79218732|NCT01565655|Drug|peficitinib|oral
79218733|NCT01565655|Drug|Placebo|oral
79218734|NCT05535322|Drug|GLP-1RA|All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
79218735|NCT05535322|Drug|SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
79218736|NCT05535322|Drug|Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
79218737|NCT05535322|Drug|Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
79218738|NCT05592574|Other|Blood sample|Blood samples required to performe IL-17 Dosage
79218739|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
79218740|NCT05577273|Drug|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
79218741|NCT02252913|Drug|Volitinib|oral administration
79218742|NCT02252913|Drug|Docetaxel|intravenous injection
79218743|NCT05698030|Other|Food allergy|Oral immunotherapy to pistachio
79218744|NCT03548259|Procedure|Platelet-rich plasma|Platelet-rich plasma injection
79218745|NCT03548259|Procedure|Platelet-poor plasma|Platelet-poor plasma injection
79218746|NCT05542108|Behavioral|Multisensory Stimulation and Family Education Group|Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.
79218747|NCT05542108|Behavioral|Family Education Only Group (FEG)|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
79513175|NCT05213858|Diagnostic Test|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
79513176|NCT05213858|Diagnostic Test|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
79680164|NCT02929992|Other|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
79513177|NCT05213858|Diagnostic Test|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
79513178|NCT05213858|Diagnostic Test|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range [-2g, 2g]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
79679740|NCT04690881|Behavioral|Psychodrama group psychotherapy|In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
79218748|NCT05698576|Device|TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)|A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.
79218749|NCT02135835|Drug|Shenfu Zhusheye|
79994097|NCT03345407|Drug|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
79994098|NCT03345407|Drug|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
79994099|NCT03621332|Other|Questionnaire|Online/paper questionnaires
79994100|NCT01264549|Device|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
79994101|NCT05692752|Other|No intervention|Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
79994102|NCT03626298|Drug|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
79218750|NCT02135835|Drug|5% glucose injection|
79218751|NCT05546008|Device|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
79362223|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
79362224|NCT02102230|Behavioral|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
79362225|NCT00300742|Drug|Topiramate|Topiramate up to 300 mg per day.
79218752|NCT02253459|Drug|UTD1 Injection plus capecitabine|
79362226|NCT00301756|Drug|Belinostat|Given IV
79362227|NCT00301756|Other|Laboratory Biomarker Analysis|Correlative studies
79362228|NCT00302068|Behavioral|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
79362229|NCT00302068|Drug|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
79362230|NCT00302068|Drug|Placebo Pill.|Placebo pill, daily, for 16 weeks.
79362231|NCT00302848|Drug|Drospirenone|
79513179|NCT05209100|Procedure|Sigmoidoscopy|During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.
79513180|NCT05202873|Diagnostic Test|Gait analysis|Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the 6 'gait test, mobility, dynamic balance, gait ability and risk of falling through the Up and Go test.
79513181|NCT05199571|Biological|Ofatumumab|Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab
79218753|NCT02253459|Drug|Capecitabine|
79513182|NCT05196269|Device|Artificial Intelligence and Digital Health Arm|A previous large database repository of images having thousands of pre and postoperative photographs of breast cancer patients proposed for locoregional treatment with clinical and biometric data will be matched using artificial intelligence within the CANKADO platform. Patients proposed for breast cancer locoregional treatment will have access to the software installed, and they will have access to all the information about the type of treatment they will receive. All the questions and questionnaires will be filled out online, and they can visualise the expected outcome from excellent to poor.
79218754|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
79218755|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
79218756|NCT02140047|Biological|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
79218757|NCT02135913|Dietary Supplement|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
79218758|NCT02140125|Drug|ASP2408|subcutaneous administration
79218759|NCT02140125|Drug|Placebo|subcutaneous administration
79513183|NCT05195918|Combination Product|EGCG 300 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
79218760|NCT02140203|Other|Yoga Training|one-year experimental training (three times per week and one hour per session)
79218761|NCT05576961|Drug|RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
79218762|NCT05576961|Drug|Mixed bacteria|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
79994103|NCT03626298|Drug|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
79994104|NCT03626298|Drug|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
79218763|NCT05576961|Drug|High dose RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
79218764|NCT05592496|Procedure|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
79218765|NCT05592496|Device|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
79218766|NCT05592496|Procedure|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
79994105|NCT03255187|Dietary Supplement|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA [24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)].
79218767|NCT05592496|Diagnostic Test|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
79218768|NCT05576727|Other|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
79218769|NCT05697796|Procedure|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
79218770|NCT03548181|Behavioral|Virtual Autonomous Physiotherapist Agent (VAPA)|A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
79362232|NCT00302848|Drug|Levonorgestrel|
79362233|NCT00302848|Drug|Other progestin containing oral contraceptive|
79362234|NCT00138034|Procedure|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
79362235|NCT00303862|Drug|cediranib maleate|Given orally
79218771|NCT05545696|Device|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
79362236|NCT00303862|Other|laboratory biomarker analysis|Correlative studies
79362237|NCT00304096|Biological|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
79362238|NCT05267392|Drug|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
79362239|NCT05267392|Other|standard of care RT/RCT|standard of care RT/RCT
79218772|NCT05545696|Device|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
79218773|NCT05492643|Biological|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
79513184|NCT05195918|Combination Product|EGCG 300 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
79513185|NCT05195918|Combination Product|Placebo 2 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
79994106|NCT03255187|Dietary Supplement|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
79218774|NCT05492643|Other|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
79218775|NCT05492643|Other|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
79994107|NCT03646136|Procedure|Retained fluid|Retained fluid
79994108|NCT03646136|Procedure|Emptied fluid|Emptied fluid
79218776|NCT05492643|Other|Safety|all the 500 participants enrolled will undergo safety observation
79362240|NCT00142168|Drug|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
79362241|NCT00142168|Drug|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
79362242|NCT02501434|Drug|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
79362243|NCT02247232|Drug|Z-100|
79513186|NCT05195918|Combination Product|EGCG 600 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
79513187|NCT05195918|Combination Product|EGCG 600 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
79362244|NCT02247232|Drug|Placebo|
79513188|NCT05195918|Combination Product|Placebo 4 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
79513189|NCT05189028|Drug|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
79513190|NCT05188508|Drug|Pembrolizumab|Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
79513191|NCT05188508|Combination Product|Olaparib and Temozolomide|Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
79513192|NCT05183360|Drug|BI 706321|BI 706321
79513193|NCT05183360|Drug|Placebo|Placebo
79218777|NCT02739594|Drug|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
79218778|NCT02739594|Drug|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
79218779|NCT05545618|Diagnostic Test|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
79218780|NCT05541562|Diagnostic Test|clinical laboratory tests, and imaging characteristics|Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
79218781|NCT03548025|Device|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
79218782|NCT02140281|Drug|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
79218783|NCT02140281|Drug|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
79218784|NCT05592106|Diagnostic Test|T1 mapping on gadoxetic acid-enhanced MRI|All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
79218785|NCT05489133|Behavioral|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
79362245|NCT01791634|Procedure|proximal chevron osteotomy|
79679741|NCT00519233|Drug|AGS-1C4D4|IV
79362246|NCT01791634|Procedure|proximal open wedge osteotomy with LPS system|
79362247|NCT02159560|Device|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
79362248|NCT05267314|Device|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
79362249|NCT01594372|Procedure|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
79218786|NCT05592028|Device|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
79513194|NCT05180474|Biological|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
79513195|NCT05173844|Other|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
79513196|NCT05172973|Device|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
79513202|NCT05169580|Drug|FTX-6058 oral capsule(s)|Participants will receive FTX-6058
79513203|NCT05168423|Drug|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
79218787|NCT05541328|Other|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
79218788|NCT05545462|Drug|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
79218789|NCT05545462|Other|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
79218791|NCT05699356|Other|Non Surgical treatment|Non Surgical
79218792|NCT05699356|Procedure|laparoscopic drilling|Surgical intervension
79218793|NCT05699356|Behavioral|Treatment of Poly cystic ovary for infertility by Life style modification|Non Surgical
79218794|NCT05699356|Procedure|Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Surgical intervention
79218795|NCT05478447|Procedure|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
79218796|NCT05591872|Drug|LD+I+TRB|Same as in the arm description
79218797|NCT02140359|Behavioral|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
79218798|NCT03989232|Drug|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
79362250|NCT01594372|Procedure|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
79218799|NCT03989232|Drug|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
79362251|NCT00147316|Drug|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
79513204|NCT05156047|Drug|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
79218800|NCT02140437|Drug|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
79218801|NCT02140437|Drug|Anastrozole|standard endocrine therapy
79218802|NCT05697640|Drug|Vericiguat Oral Tablet|The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
79218803|NCT03549195|Procedure|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
79218804|NCT03549195|Procedure|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
79218805|NCT03549195|Procedure|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
79218806|NCT05697562|Procedure|Rubber band ligatures (RBL)|This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
79362252|NCT00148798|Drug|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
79362253|NCT00148798|Drug|cisplatin + vinorelbine|cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
79994109|NCT05508672|Other|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
79218807|NCT05697562|Procedure|Superior Rectal Artery Embolization (SRAE)|"This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks."
79513205|NCT05156047|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
79513206|NCT05155709|Drug|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
79513207|NCT05155709|Drug|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
79513208|NCT05155709|Drug|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
79513209|NCT05152134|Behavioral|Empowered Relief On-Demand|Tailored interactive digital health treatment for chronic pain
79994110|NCT05508672|Other|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
79994111|NCT03643406|Other|Mental Fatigue|modified stroop task
79994112|NCT03643406|Other|Control|documentary
79513210|NCT05152134|Behavioral|Health Education|The HE digital intervention is roughly 65 minutes with content discussing pain and health topics generally; it is devoid of pain education, psychological skills, and has no active strategies, worksheets, or supportive tools.
79994113|NCT03643328|Biological|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
79672566|NCT03279354|Behavioral|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
79672567|NCT02957045|Procedure|Cough pressure measurement|
79672568|NCT02957045|Device|Pcough|
79672569|NCT00479583|Drug|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
79994114|NCT03643328|Biological|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
79994115|NCT04097262|Other|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
79994116|NCT04097262|Other|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
79994117|NCT03644264|Drug|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
79994118|NCT03644264|Drug|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
79362254|NCT00148954|Device|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
79362255|NCT00148954|Device|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
79362256|NCT00149734|Drug|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
79362257|NCT00149734|Drug|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
79362258|NCT00198328|Combination Product|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
79513211|NCT05150873|Other|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
79513212|NCT05129319|Drug|prabotulinumtoxinA|Injection of glabellar rhytids
79513213|NCT05124847|Behavioral|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
79672570|NCT00479583|Drug|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
79513214|NCT05124847|Behavioral|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
79513215|NCT05118178|Diagnostic Test|echocardiography, computed tomography|echocardiography - including GLS and MWI computed tomography - with calcium score index
79820735|NCT00724035|Procedure|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
79218808|NCT05697562|Procedure|Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)|The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
79218809|NCT05697484|Device|educational game|"Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~Game will be presented in Arabic language.~The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level."
79362259|NCT00198328|Procedure|Surgical Excision|Patients have their tumor surgically removed.
79362260|NCT00305578|Drug|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
79362261|NCT00305578|Drug|Placebo|No active medication, only placebo
79362262|NCT01790074|Other|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
79362263|NCT01790074|Other|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
79362264|NCT01492101|Drug|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
79362265|NCT01492101|Drug|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
79362266|NCT01468311|Procedure|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
79362267|NCT01468311|Drug|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
79362268|NCT01468311|Radiation|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
79362269|NCT01468311|Radiation|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
79672571|NCT04699643|Drug|EVER4010001|Please refer to information in arm/group descriptions.
79672572|NCT04699916|Other|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
79672573|NCT02274090|Drug|Placebo gel|Placebo gel consist of drug without the active component.
79513216|NCT05115110|Drug|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
79672574|NCT02274090|Drug|1% Metformin gel|Metformin gel consist of active component.
79513217|NCT05115110|Drug|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
79513218|NCT05115110|Drug|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
79513219|NCT05113342|Drug|Descartes-25|allogeneic Mesenchymal Stem Cell product.
79513220|NCT05111249|Drug|Branaplam|messenger ribonucleic acid (RNA) splicing modifier
79513221|NCT05111249|Drug|Placebo|Matching placebo oral solution once weekly
79513222|NCT05109637|Device|Konectom NMD Application|Administered as specified in the treatment arm.
79672575|NCT03278327|Procedure|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
79672576|NCT03278327|Device|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
79672577|NCT04700748|Radiation|Brain metastases radiation|Brain metastases radiation according to clinical practice.
79679742|NCT02940561|Drug|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
79513223|NCT05096481|Biological|PEP-CMV|The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
79513224|NCT05096481|Drug|Temozolomide|Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
79672578|NCT04699955|Behavioral|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
79820736|NCT04335591|Drug|75 mg linzagolix tablet|For oral administration once daily
79820737|NCT04335591|Drug|200 mg linzagolix tablet|For oral administration once daily
79820738|NCT04335591|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
79820739|NCT04335591|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
79820740|NCT04335591|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
79994119|NCT04051788|Other|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
79362270|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
79994120|NCT04051788|Other|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
79218810|NCT05545228|Behavioral|Link work intervention|Intervention from a link worker to support participants to access dental services.
79218811|NCT03547401|Device|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
79218812|NCT03547401|Device|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
79218813|NCT03526692|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
79218814|NCT03940872|Diagnostic Test|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
79362271|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
79513225|NCT05096481|Biological|Tetanus Diphtheria Vaccine|Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
79513226|NCT05090787|Device|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
79513227|NCT05090787|Device|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
79513228|NCT05088070|Drug|SPH 3348|2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
79513229|NCT05088070|Drug|SPH 3348|1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
79672579|NCT03279315|Dietary Supplement|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
79672580|NCT00444743|Drug|MM-093|60 mg, administered subcutaneously, weekly
79820741|NCT04335591|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
79820742|NCT04126824|Drug|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
79820743|NCT04126824|Drug|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
79820744|NCT04126824|Other|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
79513230|NCT05088070|Drug|SPH 3348|2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
79820745|NCT00724113|Procedure|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
79672581|NCT00444743|Other|Placebo|Placebo
79672582|NCT00479622|Drug|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
79672583|NCT00444782|Biological|GV1001|
79672584|NCT03279159|Other|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
79672585|NCT03279159|Other|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
79820746|NCT00724113|Procedure|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
79820747|NCT04581330|Device|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
79218815|NCT05451069|Diagnostic Test|Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells|"Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry."
79218816|NCT05575635|Drug|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
79218817|NCT05591560|Drug|Itraconazole capsule|Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
79218818|NCT05591560|Drug|Placebo|4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
79672586|NCT00444860|Biological|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
79218819|NCT05540470|Drug|PART|"Chloroquine(150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. (Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A, Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria."
79218820|NCT05540470|Drug|Malakit|"delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~1 laminated sheet with illustrated instruction~1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~Two 15 mg tablets of primaquine, to be given as a single dose (145)~1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies."
79513231|NCT05088070|Drug|SPH 3348|4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
79672587|NCT00479661|Drug|Dexmedetomidine|Continuous infusion
79513232|NCT05088070|Drug|SPH 3348|6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
79513233|NCT05088070|Drug|SPH 3348|8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
79513234|NCT05085821|Device|HEART|In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
79672588|NCT00479661|Drug|Propofol|Continuous infusion
79672589|NCT00444899|Behavioral|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
79672590|NCT00444899|Other|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
79672591|NCT04700670|Biological|measurement of anti-Xa activities|"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~STA-Liquid anti-Xa (STAGO) (not containing dextran)~Biophen Heparin LRT (Hyphen) (reactive containing dextran)~Berichrom (Siemens) with dextran~Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."
79672592|NCT00444938|Device|H1 -coil TMS device|
79680165|NCT02929992|Other|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
79994121|NCT03641534|Procedure|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
79994122|NCT03641534|Procedure|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
79218821|NCT05540470|Other|CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS|Surveys will include the collection of a detailed questionnaire on recent malaria and mobility history, a clinical examination, and a venous blood sample
79218822|NCT05540470|Other|QUALITATIVE STUDY|Systematic mapping of stakeholders in the pre-intervention period Semi-structured interviews and focus groups. Observational techniques Participatory approach. Participatory design of a community-based adverse event surveillance system
79218823|NCT05429073|Drug|RGLS8429|solution for subcutaneous injection
79218824|NCT05429073|Drug|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
79513235|NCT05085821|Device|Placebo|In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
79218825|NCT05591482|Procedure|mesh repair|mesh repair of diaphragmatic hernia
79218826|NCT02140515|Drug|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
79218827|NCT02140515|Drug|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
79218828|NCT05544838|Device|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
79218829|NCT05579535|Other|gait training exercises|walking exercises in different directions
79820748|NCT05683236|Other|Health education|Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
79218830|NCT05591326|Procedure|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
79218831|NCT02260947|Drug|PF-06273340|PF-06273340 50 mg
79218832|NCT02260947|Drug|PF-06273340|PF-06273340 400 mg
79218833|NCT02260947|Drug|Pregabalin|Pregabalin 300 mg
79218834|NCT02260947|Drug|Ibuprofen|Ibuprofen 600 mg
79218835|NCT02260947|Drug|Placebo|Matching Placebo
79218836|NCT05698498|Other|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
79218837|NCT05698498|Other|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
79362272|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
79362273|NCT05267002|Procedure|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
79362274|NCT00308230|Procedure|Six minute walk test|
79362275|NCT00308230|Behavioral|Minnesota Living with Heart Failure Questionnaire|
79362276|NCT00325078|Drug|Infliximab|
79362277|NCT00325780|Drug|Pitavastatin|Pitavastatin 4 mg once daily
79362278|NCT00326170|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
79362279|NCT00326170|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
79513236|NCT05085496|Biological|Atezolizumab|Given IV
79513237|NCT05085496|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79513238|NCT05083481|Drug|ASP1570|Oral tablet
79513239|NCT05083481|Drug|Pembrolizumab|Intravenous Infusion
79513240|NCT05071092|Behavioral|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
79513241|NCT05069168|Diagnostic Test|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
79513242|NCT05067842|Diagnostic Test|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
79513243|NCT05065970|Drug|Felzartamab|anti-CD38+ monoclonal antibody
79513244|NCT05065970|Other|Placebo|Placebo comparator
79513245|NCT05062044|Dietary Supplement|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
79513246|NCT05062044|Dietary Supplement|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
79513247|NCT05062044|Drug|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
79513248|NCT05062044|Dietary Supplement|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
79513249|NCT05052281|Behavioral|Mothers and Babies (MB) Course|The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress.
79513250|NCT05052281|Behavioral|Just in Time Intervention (JITI) Content|"Participants will also receive additional MB intervention content in the form of just-in-time text messages, which will be sent to participants' smartphones every other day for up to 12 weeks. During the current trial, participants will receive text message prompts with links to additional stress reduction content based on a combination of their objective (sensor) and subjective (EMA) stress responses from the previous day."
79513251|NCT05052281|Device|Biostamp nPoint Device|During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
79218838|NCT05415423|Behavioral|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
79994123|NCT03641534|Procedure|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
79994124|NCT03641534|Procedure|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
79218839|NCT05540236|Other|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
79218840|NCT05540236|Other|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
79362280|NCT00326170|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
79218841|NCT05544448|Other|Blood sample taken at a single time point|At inclusion, a blood sample will be taken for research purpose
79218842|NCT05589532|Device|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
79362281|NCT00326872|Drug|Cediranib Maleate|
79362282|NCT05266690|Dietary Supplement|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
79362283|NCT05266690|Dietary Supplement|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
79362284|NCT05266690|Dietary Supplement|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
79994125|NCT03641534|Procedure|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
79362285|NCT05266690|Dietary Supplement|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
79362286|NCT00328042|Behavioral|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
79362287|NCT00328042|Behavioral|Information Only|This is an individual self-paced at home study program.
79994126|NCT03641534|Procedure|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
79513252|NCT05028790|Device|Single vision contact lens|Participants will wear a single vision soft contact lens during the study visit
79513253|NCT05028790|Device|Multifocal contact lens|Participants will wear a multifocal soft contact lens during the study visit
79513254|NCT05028751|Drug|Lanraplenib|Orally via tablets
79820749|NCT05683236|Other|Comfort care|Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
79820750|NCT05683236|Other|Pain care|Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
79994127|NCT03641534|Procedure|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
79218843|NCT03547791|Drug|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
79218844|NCT03547791|Drug|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
79218845|NCT04819113|Biological|Nimenrix|MenACWY-TT vaccine
79218846|NCT04818177|Drug|Institutional standard intravenous immune globulin treatment|No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
79218847|NCT04809129|Device|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
79362288|NCT00329524|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
79362289|NCT01730534|Drug|Dapagliflozin 10 mg|Oral dose (od)
79362290|NCT01730534|Drug|Placebo tablet|Oral dose (od)
79513255|NCT05028751|Drug|Gilteritinib|Orally via tablets
79513256|NCT05022459|Drug|Emicizumab|Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
79994128|NCT03641534|Procedure|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
79362291|NCT00329836|Other|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
79994129|NCT03641534|Procedure|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
79994130|NCT03641534|Procedure|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
79994131|NCT03643250|Other|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
79362292|NCT00330382|Drug|Bowman-Birk inhibitor concentrate|Given orally
79362293|NCT00330382|Other|placebo|Given orally
79362294|NCT00330382|Other|laboratory biomarker analysis|Correlative studies
79362295|NCT01791712|Procedure|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
79513257|NCT05022459|Drug|FVIII|Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
79513258|NCT05006716|Drug|BGB-16673|Orally administered
79513259|NCT05005403|Drug|ABBV-514|Intravenous (IV) Infusion
79513260|NCT05005403|Drug|Budigalimab|IV Infusion
79513261|NCT04999852|Device|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
79362296|NCT01791712|Procedure|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
79362297|NCT05266534|Drug|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
79672593|NCT00441870|Drug|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
79672594|NCT00441870|Drug|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
79994132|NCT03643250|Other|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
79672595|NCT00444977|Behavioral|Case-management linkage intervention|dental care
79672596|NCT04700592|Other|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
79680166|NCT02929992|Other|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
79218848|NCT05544370|Behavioral|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
79513262|NCT04999852|Behavioral|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
79218849|NCT05544370|Behavioral|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
79218850|NCT04799691|Procedure|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
79218851|NCT04799691|Procedure|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
79218852|NCT05544292|Other|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
79362298|NCT05266534|Drug|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
79218853|NCT04776057|Other|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
79218854|NCT05539768|Biological|HS-IT101|Adoptive transfer of 1x10^9-6x10^10 autologous TIL to patients i.v. in 30-60 minutes.
79218855|NCT04775745|Drug|LP-168|For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
79218856|NCT04775745|Drug|LP-168|For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
79362299|NCT05266534|Drug|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
79362300|NCT01730378|Biological|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
79218857|NCT05544058|Other|Retrospective study|Retrospective study
79218858|NCT04425460|Drug|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
79362301|NCT01730378|Biological|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
79362302|NCT01783496|Device|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
79362303|NCT04559750|Behavioral|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
79820751|NCT05683236|Other|Dietary care|The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
79218859|NCT04425460|Other|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
79994133|NCT03643250|Other|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
79218860|NCT03547323|Device|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
79218861|NCT03547323|Device|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
79218862|NCT03547713|Behavioral|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
79362304|NCT00314236|Device|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
79362305|NCT00314236|Procedure|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
79362306|NCT01729208|Device|Dual Focus Soft Contact Lens|
79362307|NCT01729208|Device|Single Vision Soft Contact Lens|
79362308|NCT00331162|Drug|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
79362309|NCT00331162|Drug|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr < 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
79513263|NCT04995497|Drug|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
79680167|NCT03458780|Drug|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
79994134|NCT03643250|Other|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
79362310|NCT01790230|Device|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
79218863|NCT03547713|Behavioral|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
79218864|NCT03547713|Behavioral|Reward vs. punishment task|Reception of monetary gains vs. losses
79218865|NCT03547713|Behavioral|Emotional reactivity task|Exposure to emotional faces vs. shapes
79218866|NCT05576272|Drug|QL1706|5 mg/kg#D1#Q3W IV, 4-6 cycles
79218867|NCT05576272|Drug|Carrelizumab|200mg#D1#Q3W IV, 4-6 cycles
79218868|NCT05576272|Drug|Gemcitabine|1000mg/m2#D1&D8#Q3W IV, 4-6 cycles
79218869|NCT05576272|Drug|Cisplatin|80mg/m2#D1#Q3W IV, 4-6 cycles
79218870|NCT05576116|Procedure|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
79218871|NCT05576116|Procedure|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
79218872|NCT05381025|Dietary Supplement|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
79218873|NCT05539690|Behavioral|Balance training|"Step-by-step training (5 levels)~30 minute per training~3 times per week~4 weeks"
79218874|NCT03758313|Other|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
79218875|NCT05504512|Other|No intervention|No intervention
79218876|NCT05478460|Other|Hookwire localization|Patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
79218877|NCT05337501|Other|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
79218878|NCT05543980|Device|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
79218879|NCT05543980|Device|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
79218880|NCT04725981|Procedure|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
79218881|NCT05543902|Behavioral|Breastfeeding Problems Management Model (BPMM)|The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
79218882|NCT05334849|Device|Circulating exosomal lncRNA-GC1 detection|"Collect peripheral blood sample of 80 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect circulating exosomal lncRNA-GC1. Tumor response evaluation will be performed after two cycles of immunotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
79218883|NCT05543824|Drug|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
79218884|NCT05698420|Device|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
79218885|NCT05698420|Device|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
79218886|NCT04703673|Drug|Cineole|self administration according to directions for use
79218887|NCT04703673|Drug|Nasal Decongestant|self administration according to directions for use
79218888|NCT05543746|Drug|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
79218889|NCT03526536|Drug|IV Novolin R human insulin|Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
79218890|NCT05543590|Drug|Plasmapheresis|5 sessions of plasma exchanges
79218891|NCT05543590|Other|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
79218892|NCT05543590|Other|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
79218893|NCT05543590|Other|PET scan|PET scan at baseline and M6
79218894|NCT05543590|Other|Cycle ergometer stress test|Cycle ergometer stress test at M6
79513264|NCT04995497|Drug|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
79218895|NCT05543590|Other|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
79218896|NCT05543590|Other|Medical consultations|Medical consultations
79362311|NCT01790308|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
79362312|NCT01790308|Drug|Liraglutide|CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
79362313|NCT01609010|Drug|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
79362314|NCT01609010|Drug|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
79362315|NCT01608308|Drug|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
79513265|NCT04989075|Other|Oral prophylactic intervention|The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
79218897|NCT03512184|Behavioral|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
79362316|NCT01608308|Drug|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
79218898|NCT05573529|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
79218899|NCT05573529|Device|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
79362317|NCT00332644|Drug|nicotine patch|used according to FDA package label
79362318|NCT00332644|Drug|nicotine lozenge|used according to FDA-approved package directions
79218900|NCT03546309|Device|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
79218901|NCT03546309|Device|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
79218902|NCT05439850|Procedure|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
79362319|NCT00332644|Drug|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
79362320|NCT00332644|Drug|bupropion|dosage according to FDA-approved instructions
79362321|NCT00332644|Drug|bupropion + lozenge|dosage according to FDA approved standard instructions
79362322|NCT00332644|Drug|placebo|dosage same as active drug conditions
79362323|NCT01755416|Drug|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
79362324|NCT01755416|Drug|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
79672597|NCT04699526|Other|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
79672598|NCT00441909|Drug|UC-781|0.1% UC-781 Vaginal Gel
79218903|NCT05439850|Biological|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
79362325|NCT01755026|Drug|cefazolin|2 gram dose for pre-operative prophylaxis
79362326|NCT01755026|Drug|cefazolin|4 gram dose for pre-operative prophylaxis
79362327|NCT00332722|Procedure|Cervical facet joint nerve blocks|
79513266|NCT04983186|Device|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
79218904|NCT05439850|Diagnostic Test|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
79513267|NCT04980391|Biological|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
79513268|NCT04980391|Drug|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
79672599|NCT00441909|Drug|UC-781 placebo|Vaginal Gel Placebo
79672600|NCT00445016|Procedure|peripheral regional anesthesia|evaluation and description of adverse effects
79218905|NCT03524586|Procedure|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
79362328|NCT01491945|Device|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
79362329|NCT00333814|Drug|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
79362330|NCT00333814|Drug|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
79672601|NCT00445055|Drug|Droperidol|Intravenous injection
79362331|NCT00333814|Drug|Sham injection|Sham injection at Day 0
79362332|NCT01728584|Drug|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
79672602|NCT00479700|Drug|SAM-531|
79672603|NCT02957201|Other|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
79672604|NCT00479739|Drug|Salmeterol/fluticasone propionate or formoterol/budesonide|
79672605|NCT03277820|Dietary Supplement|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
79672606|NCT00441948|Device|Peterio|
79672607|NCT00445094|Drug|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
79513269|NCT04973605|Drug|BGB-11417|Administered orally daily
79218906|NCT03524586|Procedure|Contralateral rotation of head|Contralateral rotation of head against fixed tube
79218907|NCT03526380|Behavioral|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
79218908|NCT05539222|Other|Food vouchers and education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group. Family food purchases were assessed using electronically recorded supermarket-obtained transactions.
79513270|NCT04973605|Drug|Dexamethasone|Once weekly either orally or intravenously
79218909|NCT05543434|Drug|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
79218910|NCT04963140|Other|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
79218911|NCT04963140|Other|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
79218912|NCT05289141|Device|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
79513271|NCT04973605|Drug|Carfilzomib|Administered intravenously weekly
79513272|NCT04968236|Other|Deep Dry Needling|In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
79218913|NCT05289141|Device|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
79218914|NCT05539144|Radiation|Delineation for organs at risks (OARs) in IMRT plan|An adaptive contouring brush within the planning software was used to create a new structure: the air cavity within oral cavity, oropharynx, larynx and hypopharynx, and the new structure was expanded and shrunk uniformly 2 mm to create the oral cavity, oropharynx, larynx and hypopharynx
79218915|NCT04675047|Other|no intervention for healthy control|observational study - no intervention
79218916|NCT05539066|Device|AI health assistant|To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
79218917|NCT05538988|Drug|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
79218918|NCT04467060|Drug|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
79218919|NCT04467060|Drug|Placebo|single dose, fasting oral administration
79218920|NCT04667637|Drug|edaravone dexborneol|Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
79218921|NCT03871894|Other|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
79218922|NCT03871894|Other|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
79218923|NCT01511328|Other|HPV testing|Testing for Human Papilloma Virus
79218924|NCT02253927|Drug|BILR 355 - D1|
79218925|NCT02253927|Drug|BILR 355 - D2|
79218926|NCT02253927|Drug|BILR 355 - D3|
79218927|NCT02253927|Drug|BILR 355 - D4|
79362333|NCT01728584|Other|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~Low insufflation pressure - a starting pressure of 8 mmHg will be used."
79362334|NCT01728584|Drug|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
79362335|NCT00315328|Drug|Atropine|Atropine 1% each weekend day in the sound eye
79362336|NCT00315328|Device|Patching|Patching 2 hours per day
79362337|NCT00315328|Procedure|Near activities|near visual activities for at least one hour per day
79513273|NCT04968236|Other|Superficial Dry Needling|This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
79513274|NCT04968236|Other|passive stretching|Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
79513275|NCT04960579|Biological|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
79513276|NCT04960579|Drug|Rimiducid|Safety switch activator
79672608|NCT00445094|Drug|Comparator: amikacin / Duration of Treatment: 3 Days|
79672609|NCT00445094|Drug|Comparator: tazocin / Duration of Treatment: 3 Days|
79672610|NCT00445094|Drug|Comparator: vancomycin / Duration of Treatment: 3 Days|
79672611|NCT00479778|Drug|Bazedoxifene/conjugated estrogens|
79672612|NCT00445133|Device|Magnetic Sleep Pad|
79672613|NCT00442026|Drug|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
79672614|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
79672615|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
79513277|NCT04951479|Device|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
79513278|NCT04943042|Drug|Avatrombopag|According to prescription
79513279|NCT04939428|Drug|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
79513280|NCT04939428|Drug|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
79513283|NCT04914325|Combination Product|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
79513284|NCT04907370|Drug|PD-1 blocking antibody|"IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
79218928|NCT02253927|Drug|Ritonavir|
79513285|NCT04907370|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
79513286|NCT04907370|Drug|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
79513287|NCT04907370|Drug|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
79994135|NCT03643250|Other|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
79218929|NCT02253927|Other|high fat breakfast|
79513288|NCT04907370|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
79513289|NCT04905446|Other|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
79513290|NCT04905446|Procedure|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
79672616|NCT00479895|Drug|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
79672617|NCT00445250|Drug|Calcipotriol|
79672618|NCT00442065|Device|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
79672619|NCT00445289|Device|SmartCare/PS|
79994136|NCT05692674|Radiation|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
79218930|NCT03745144|Drug|Cladribine|Participants will receive cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
79218931|NCT03745144|Drug|Placebo|Participants will receive placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
79218932|NCT03745144|Drug|Microgynon®|Participants will receive Microgynon® tablet once daily for 21 days in treatment period 1 and 2.
79218933|NCT05571657|Behavioral|Reminder/Recall Sent Via Preferred Method of Communication|Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
79362338|NCT05265988|Drug|Cabozantinib|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
79362339|NCT04345822|Procedure|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
79362340|NCT01522443|Drug|cabozantinib|Tablets taken orally once daily.
79362341|NCT01522443|Drug|mitoxantrone|Given by IV once every 3 weeks.
79362342|NCT01522443|Drug|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
79362343|NCT00334204|Device|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
79672620|NCT00442143|Procedure|Stem cell implantation|
79672621|NCT02957006|Device|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
79672622|NCT03279120|Drug|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
79672623|NCT03279120|Drug|Placebo|Used for 90 days (Continuous or Interrupted)
79994137|NCT03643094|Dietary Supplement|Golden Black Seed|1 capsule per day for 8 weeks.
79362344|NCT00336700|Drug|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
79672624|NCT04699760|Dietary Supplement|Fish Oil|8 weeks, 2.2 G EPA/day
79672625|NCT04699760|Dietary Supplement|Placebo|Placebo
79994138|NCT02929329|Drug|Omecamtiv Mecarbil|Omecamtiv mecarbil tablets for oral administration
79994139|NCT02929329|Drug|Placebo|Matching placebo tablets
79362345|NCT00336700|Drug|Erlotinib|150 mg/d Daily, oral 12 months
79362346|NCT01468233|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79362347|NCT01468233|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
79513291|NCT04905446|Procedure|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
79362348|NCT01468077|Drug|Tocilizumab|8 mg/kg infusion
79513292|NCT04893109|Drug|trastuzumab-emtansine|intravenous infusion
79513293|NCT04893109|Drug|Trastuzumab SC|Muscular injection
79513294|NCT04893109|Drug|Paclitaxel|intravenous infusion
79513295|NCT04883073|Device|Use of Endo App|Use of Endo App
79513296|NCT04881461|Drug|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
79513297|NCT04881461|Drug|Placebo|Placebo
79513298|NCT04876391|Drug|Spesolimab|Spesolimab
79362349|NCT01522365|Device|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
79513299|NCT04871308|Drug|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
79513300|NCT04871308|Drug|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
79513301|NCT04867369|Drug|Pecs II block|Patients will receive an interscalene nerve block with 15 mL 0.5% bupivacaine + a Pecs II fascial plane block with 20 mL 0.25% bupivacaine
79513302|NCT04867369|Drug|Surgical infiltration|Patients will receive an interscalene nerve block with 20 mL 0.5% bupivacaine + local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL
79513303|NCT04862260|Drug|Cholesterol metabolism disruption|Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
79513304|NCT04848584|Biological|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
79513305|NCT04848584|Biological|BNT162b2 BA.4/5 bivalent|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
79513306|NCT04848584|Biological|XBB.1.5-adapted vaccinated|Vaccinated with XBB.1.5-adapted vaccine
79362350|NCT01522365|Device|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
79672626|NCT00479934|Drug|imatinib mesylate|6 month treatment with 400mg/day (per os)
79820752|NCT05683236|Other|Psychological and social support care|"Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions."
79820753|NCT05683236|Other|routine nursing intervention|The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
79362351|NCT03026673|Other|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
79362352|NCT01783418|Behavioral|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
79362353|NCT01521897|Biological|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
79362354|NCT01782872|Procedure|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline
79513307|NCT04838613|Drug|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
79513308|NCT04838613|Drug|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
79513309|NCT04825886|Device|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
79513310|NCT04824794|Biological|GEN3014|GEN3014 is administered by IV infusion.
79513311|NCT04824794|Drug|Daratumumab|Daratumumab is administered by SC injections.
79513312|NCT04824014|Diagnostic Test|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
79513313|NCT04812093|Device|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
79513314|NCT04810273|Behavioral|Early progressive mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
79513315|NCT04805671|Drug|ADG20|Single dose of ADG20
79513316|NCT04805671|Drug|Normal saline|Single dose of normal saline
79513317|NCT04788615|Drug|Ofatumumab|20mg Subcutaneous injection
79672627|NCT03274778|Drug|Ruxolitinib 20 MG|tablets
79672628|NCT00442182|Drug|ITF2357|
79672629|NCT03274700|Drug|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
79672630|NCT03274700|Drug|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
79672631|NCT00442221|Drug|Sumatriptan and Naproxen sodium|
79994140|NCT02929329|Drug|Standard of Care|Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
79513318|NCT04788615|Drug|First line DMT|any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
79994141|NCT03240133|Drug|BCX7353|oral liquid formulation
79513319|NCT04781088|Drug|Lenvatinib|Given PO
79513320|NCT04781088|Drug|Paclitaxel|Given IV
79672632|NCT00479973|Dietary Supplement|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
79672633|NCT00479973|Dietary Supplement|Placebo|Placebo. 2 capsules after the two largest meals of the day
79994142|NCT03240133|Drug|Placebo|oral liquid formulation to match BCX7353
79218934|NCT05697016|Drug|Sivelestat Sodium for Injection|Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl]amino-acetate tetrahydrate]
79218935|NCT05697016|Drug|The Placebo|Excipients used for the sivelestat sodium
79218936|NCT02253771|Device|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
79218937|NCT02253771|Device|placebo shockwave therapy|sham shockwave therapy by an identically looking device without any function
79218938|NCT05538442|Other|Physiological recordings|Physiological, cognitive, biological measurments
79362355|NCT01782872|Procedure|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
79362356|NCT01782872|Procedure|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
79362357|NCT01782872|Procedure|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
79362358|NCT01490697|Drug|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
79820754|NCT02584374|Other|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
79218939|NCT04664907|Other|Videomusic listening|Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
79218940|NCT05696860|Device|Capnography Monitoring|Capnography monitoring
79218941|NCT04425772|Drug|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
79218942|NCT04425772|Drug|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
79218943|NCT03327376|Device|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
79362359|NCT01490697|Drug|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
79362360|NCT01490697|Drug|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
79362361|NCT01490697|Drug|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
79672634|NCT00454259|Drug|Fentanyl/Placebo injection|Ultra low dose intravenous injection
79672635|NCT00454298|Drug|AGG-523 (Aggrecanase Inhibitor)|
79218944|NCT01567995|Drug|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
79218945|NCT01567995|Drug|Vehicle (base cream)|Vehicle (base cream)
79362362|NCT01728194|Drug|Escitalopram|20 mg target dose for 12 weeks
79362363|NCT01728194|Other|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
79362364|NCT04408911|Drug|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
79513321|NCT04781088|Biological|Pembrolizumab|Given IV
79513322|NCT04780971|Diagnostic Test|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
79672636|NCT03279042|Procedure|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
79820755|NCT04070001|Drug|400 Mg Ibuprofen|1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
79820756|NCT04070001|Device|laser application|A single irradiation of laser after elastomeric separator placement
79994143|NCT03814356|Drug|Methylphenidate|IV MPH
79994144|NCT03642860|Drug|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
79994145|NCT03642860|Drug|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
79994146|NCT03707171|Drug|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
79994147|NCT03707171|Drug|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
79994148|NCT03795246|Procedure|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
79218946|NCT05277909|Other|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
79218947|NCT05277909|Other|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
79218948|NCT04627389|Procedure|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
79218949|NCT04627389|Procedure|modified millard technique|no z-plasty modification
79218950|NCT03547557|Device|Exablate 2000 strappable system|
79994149|NCT03795246|Biological|Biological Test|"Blood test:~FSH, LH, E2 and AMH~4 tubes of 7 mL"
79994150|NCT03795246|Procedure|Pelvic Ultrasound|Antral Follicles Count
79994151|NCT03642704|Drug|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight < 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
79994152|NCT03706937|Other|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
79218951|NCT03547479|Behavioral|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
79218952|NCT03547479|Behavioral|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
79672637|NCT03279042|Procedure|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
79218953|NCT05567523|Drug|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
79218954|NCT05567523|Drug|Normal saline|normal saline
79218955|NCT05567523|Drug|Midazolam|midazolam
79994153|NCT05682833|Procedure|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
79362365|NCT01782482|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
79362366|NCT01782482|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
79994154|NCT03372083|Drug|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
79994155|NCT03044886|Dietary Supplement|vitamin D|Subjects took vitamin D or placebo
79994156|NCT02961764|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
79362367|NCT01466673|Drug|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
79362368|NCT01466673|Drug|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
79362369|NCT01753856|Drug|Teriparatide|Administered SC
79362370|NCT01753856|Drug|Denosumab|Administered SC
79362371|NCT01753856|Drug|Demeclocycline|Administered orally
79513323|NCT04779489|Radiation|personalized ultrafractionated stereotactic ablative radiotherapy|next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
79513324|NCT04778527|Drug|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
79513325|NCT04778527|Drug|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
79672638|NCT00454337|Drug|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
79672639|NCT00454337|Drug|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
79362372|NCT01753856|Drug|Tetracycline|Administered orally
79513326|NCT04764188|Drug|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
79994157|NCT02961764|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
79994158|NCT03371459|Drug|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
79994159|NCT03371459|Drug|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
79994160|NCT03642548|Drug|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
79513327|NCT04755439|Procedure|DHCA|DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
79513328|NCT04751487|Drug|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
79513329|NCT04751487|Drug|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
79513330|NCT04747431|Drug|PBFT02|PBFT02
79513331|NCT04740892|Other|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
79513332|NCT04740892|Other|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
79513333|NCT04739696|Behavioral|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
79513334|NCT04739696|Behavioral|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
79513335|NCT04738422|Drug|Alkaline glycine|Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
79672640|NCT00480012|Device|rTMS|repetitive transcranial meagnetic stimulation of the brain
79820757|NCT04070001|Other|placebo tablets|Placebo lactose tablets 1-hour before elastomeric separator placement
79513336|NCT04725032|Drug|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
79218956|NCT02584504|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
79218957|NCT02584504|Drug|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
79218958|NCT02584504|Drug|Atorvastatin|Atorvastatin 5 mg tablet orally.
79218959|NCT02584504|Drug|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
79218960|NCT02584504|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
79218961|NCT04607889|Other|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
79218962|NCT04599777|Drug|TACE combined with sorafenib and tislelizumab|Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
79218963|NCT02253615|Other|Machines exercises|Resistance training in pneumatic machines.
79218964|NCT02253615|Other|Elastic exercises|Resistance training with elastic tubes.
79218965|NCT05698264|Device|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
79362373|NCT01753856|Drug|Calcium Supplement|Administered orally
79362374|NCT01753856|Drug|Vitamin D|Administered orally
79362375|NCT01464255|Device|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
79513337|NCT04725032|Drug|Sevoflurane|Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
79513338|NCT04720157|Drug|177Lu-PSMA-617|administered intravenously once very 6 weeks (1 cycle) for 6 cycles
79513339|NCT04720157|Drug|68Ga-PSMA-11|Single intravenous dose of approx. 150 Megabecquerel (MBq)
79513340|NCT04720157|Drug|ARDT|Administered orally on a continuous basis as per package insert and guideline
79362376|NCT01464255|Device|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
79513341|NCT04720157|Drug|ADT|ADT are administered as per physician order
79513342|NCT04712539|Drug|Baloxavir Marboxil|Given PO
79513343|NCT04712539|Drug|Oseltamivir|Given PO
79513344|NCT04706624|Behavioral|High intensity contingency management|Participants receive 12 weeks of contingency management.
79672641|NCT00454376|Other|questionnaire administration|
79672642|NCT00454376|Procedure|quality-of-life assessment|
79672643|NCT00480051|Device|Cardiac Resynchronization Pacing|
79672644|NCT00454493|Drug|Omacor (omega-3-acid ethyl esters)|
79672645|NCT00454610|Behavioral|FLOW|
79672646|NCT00454610|Behavioral|SelfHelp|
79362377|NCT04559204|Biological|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
79362378|NCT04559204|Biological|IIV4|administrated with IIV4 only
79820758|NCT04081506|Other|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
79820759|NCT00724191|Procedure|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
79362379|NCT04559204|Biological|PPV23|administrated with PPV23 only
79362380|NCT01753310|Biological|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
79362381|NCT01753310|Drug|Placebo|Up to 2mL
79362382|NCT01463631|Drug|LY3007113|Administered orally
79513345|NCT04706624|Behavioral|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
79218966|NCT05698264|Device|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
79513346|NCT04706624|Behavioral|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
79672647|NCT00454688|Drug|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
79672648|NCT00454688|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
79218967|NCT05061160|Other|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
79672649|NCT03278808|Drug|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
79672650|NCT03278808|Drug|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
79218968|NCT05061160|Other|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
79218969|NCT05007262|Drug|Tangningtongluo tablets|Four pills each time and three times a day after meals.
79218970|NCT05007262|Drug|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
79218971|NCT05150613|Other|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible & distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed & inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale & post-exercise exhaustion scale will be assessed upon completion of exercise testing.
79218972|NCT05150613|Other|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible & distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed & inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale & post-exercise exhaustion scale will be assessed upon completion of exercise testing.
79218973|NCT05150613|Other|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible & distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed & inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale & post-exercise exhaustion scale will be assessed upon completion of exercise testing.
79218974|NCT03546153|Behavioral|Aerobic exercise program|Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
79513347|NCT04706624|Behavioral|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
79513348|NCT04706624|Behavioral|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
79513349|NCT04706507|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
79513350|NCT04704999|Drug|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
79513351|NCT04704999|Drug|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
79672651|NCT03278808|Drug|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
79672652|NCT00480090|Drug|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
79672653|NCT00454766|Behavioral|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
79672654|NCT00480129|Behavioral|Probiotic or placebo yogurt consumed daily|
79218975|NCT04549857|Behavioral|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~The placebo group only used base oil (sweet almond oil).~The control group did not provide any interventional measures and only received conventional treatment."
79672655|NCT00480129|Device|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
79672656|NCT00480129|Procedure|Blood sample|
79672657|NCT00480129|Procedure|Nasal lavage|
79672658|NCT03274622|Behavioral|Impact Parent Training|
79672659|NCT03274622|Behavioral|No Impact|
79672660|NCT00442299|Device|Fractionated Plasma Separation and Adsorption (FPSA)|
79672661|NCT00454883|Drug|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
79672662|NCT00442377|Procedure|exposure to malaria sporozoites|
79218976|NCT03547089|Device|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
79218977|NCT03546075|Dietary Supplement|Resveratrol|
79218978|NCT03546075|Other|Placebo|
79218979|NCT04535895|Radiation|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
79218980|NCT05515107|Device|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
79218981|NCT03547011|Procedure|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
79218982|NCT03547011|Procedure|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
79218983|NCT05537584|Drug|Sertraline|Subjects will receive 8 weeks of sertraline while monitored by the study physician
79218984|NCT05537584|Drug|Bupropion|Subjects will receive 8 weeks of bupropion while monitored by the study physician
79218985|NCT03546933|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
79218986|NCT05537506|Device|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
79218987|NCT05537506|Device|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
79218988|NCT04459377|Drug|S-Ketamine|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
79362383|NCT04100577|Other|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
79362384|NCT01521507|Device|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
79362385|NCT01521507|Device|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
79362386|NCT01521117|Drug|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
79362387|NCT01521117|Drug|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
79513352|NCT04704999|Drug|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
79513353|NCT04696185|Drug|Dapagliflozin 10 MG|Dapagliflozin 10 mg (daily oral dose)
79513354|NCT04693533|Drug|Fremanezumab Prefilled Syringe [Ajovy]|The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
79513355|NCT04676646|Drug|Sodium zirconium cyclosilicate|Investigational medicinal product
79513356|NCT04676646|Drug|Placebo|Placebo comparator
79513357|NCT04676646|Other|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
79672663|NCT00454922|Behavioral|standard of care|no intervention
79672664|NCT00454922|Other|education|meet with trained glaucoma educator 6 times over life of study
79672665|NCT03278652|Other|Consumption of drugs for analgesic use|"Regular assessment of pain~Drug data will be collected (name, dosage, route of administration, time of delivery)"
79672666|NCT00454961|Drug|artemether-lumefantrine|
79672667|NCT03278574|Procedure|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
79672668|NCT03278574|Device|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
79672669|NCT03278574|Device|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
79218989|NCT04459377|Drug|Sodium Chloride 0.9% Inj|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
79218990|NCT00748618|Dietary Supplement|vitamin D3|10,000 I.U./wk of vitamin D3 orally for 6 months
79218991|NCT00748618|Dietary Supplement|vitamin D3|50,000 I.U./wk of vitamin D3 orally for 6 months
79218992|NCT04450563|Drug|14-day outpatient intervention|The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
79218993|NCT04425694|Device|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
79218994|NCT04731922|Drug|TAK-510|TAK-510 solution.
79672670|NCT00455000|Biological|PF-04360365|Monoclonal antibody
79820760|NCT02573649|Device|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
79820761|NCT02573649|Device|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
79218995|NCT04731922|Drug|TAK-510 Placebo|TAK-510 placebo-matching solution.
79820762|NCT00467857|Procedure|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
79218996|NCT05537350|Dietary Supplement|Lumenato|Supplementation of 12 weeks
79218997|NCT05698186|Drug|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
79218998|NCT05698186|Drug|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
79218999|NCT05698186|Drug|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
79219000|NCT05698186|Drug|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
79219001|NCT03546855|Drug|Apatinib|Apatinib 500mg/d po,28 days as one cycle
79362388|NCT01466595|Drug|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
79362389|NCT02073747|Drug|Normal Saline|One hour inhaled normal saline
79513358|NCT04663347|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
79219002|NCT04675606|Behavioral|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
79219003|NCT04675606|Behavioral|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
79362390|NCT02073747|Drug|Albuterol|One hour inhaled ten milligrams of albuterol
79362391|NCT01728116|Device|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
79362392|NCT01728116|Procedure|Sham Procedure|Endoscopic evaluation but no device placement
79362393|NCT01465659|Drug|temozolomide|Given PO
79513359|NCT04663347|Drug|rituximab and lenalidomide|28-day cycles
79672671|NCT00455000|Drug|Placebo|Placebo
79362394|NCT01465659|Drug|pazopanib hydrochloride|Given PO
79362395|NCT03027531|Behavioral|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
79362396|NCT01753076|Drug|Ozanezumab|Ozanezumab injection solution
79362397|NCT01753076|Drug|Placebo|Normal saline (0.9% sodium chloride) infusion
79362398|NCT01463007|Radiation|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
79362399|NCT01463007|Other|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
79513360|NCT04663347|Drug|rituximab and bendamustine|28-day cycles
79513361|NCT04663347|Drug|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|21-day cycles
79513362|NCT04663347|Drug|gemcitabine and oxaliplatin|28-day cycles
79672672|NCT00455078|Procedure|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
79672673|NCT00455078|Other|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
79219004|NCT05679310|Dietary Supplement|Hydroxytyrosol/Essential oils|A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
79219005|NCT05537272|Drug|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
79219006|NCT05537272|Drug|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
79672674|NCT00455078|Procedure|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
79672675|NCT00455078|Procedure|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
79672676|NCT00455078|Procedure|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
79672677|NCT00480207|Dietary Supplement|folic acid|
79219007|NCT05537272|Other|Placebo|Administration of placebo ( Vitamin C [ascorbic acid] 500mg tablet) once daily seven days before and seven days after prostate biopsy
79219008|NCT03546777|Device|magnetic resonance imaging|magnetic resonance imaging of shoulder
79219009|NCT04634110|Drug|Brigatinib|At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
79219010|NCT05059353|Device|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
79219011|NCT05537194|Drug|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
79219012|NCT05696704|Other|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
79219013|NCT05696704|Other|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
79219014|NCT05536882|Drug|Benzoyl peroxide|See arm description
79219015|NCT05536882|Drug|Adapalene Gel|See arm description
79219016|NCT03956355|Drug|Tapinarof|Tapinarof cream, 1%, applied once daily
79219017|NCT03956355|Drug|Vehicle Cream|Vehicle cream applied once daily
79219018|NCT03931161|Drug|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
79219019|NCT03931161|Drug|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
79219020|NCT05037123|Drug|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
79219021|NCT05037123|Drug|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
79219022|NCT05037123|Other|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
79219023|NCT05536648|Other|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
79219024|NCT03892005|Procedure|Total Hip Arthroplasty using MOTIVATION HIP Total Hip System|To systemically document the clinical safety and performance of the commercially available MOTIVATION HIP Total Hip System in primary THA.
79219025|NCT05695612|Other|Novaloc Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
79513363|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
79994161|NCT03642548|Drug|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
79994162|NCT02961920|Device|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
79994163|NCT02961920|Device|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
79513364|NCT04663347|Drug|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|21-day cycles
79513365|NCT04663347|Drug|Lenalidomide|28-day cycles
79513366|NCT04663347|Drug|rituximab, ifosfamide, carboplatin, and etoposide phosphate|21-day cycles
79513367|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
79513368|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.
79513369|NCT04663347|Biological|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
79513370|NCT04663347|Biological|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
79672678|NCT00480207|Dietary Supplement|omega-3|
79672679|NCT00480207|Dietary Supplement|vit B12|
79513371|NCT04663347|Biological|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
79513372|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
79513373|NCT04663347|Biological|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.
79513374|NCT04657991|Drug|Encorafenib|Encorafenib
79513375|NCT04657991|Drug|Binimetinib|Binimetinib
79513376|NCT04657991|Drug|Pembrolizumab|Pembrolizumab
79994164|NCT05283668|Biological|i-PRF|"Local anesthesia was achieved using field block technique.~A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~Laser irradiation parameters were adjusted as follows: Wavelength [940 ± 10 nm], irradiation mode [contact continuous wave], Power [2 W] and 300 μm fiber tip diameter (Jokar et al., 2019).~The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
79219026|NCT05695612|Other|Locator Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
79362400|NCT01462929|Drug|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
79362401|NCT01462929|Drug|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
79362402|NCT01462929|Drug|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
79362403|NCT01462695|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79513377|NCT04657289|Drug|Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
79513378|NCT04657289|Device|Port Delivery System with Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
79513379|NCT04655326|Biological|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
79513380|NCT04654858|Procedure|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
79820763|NCT00467857|Other|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
79513382|NCT04637815|Behavioral|Motivational Network Intervention|See earlier description
79513383|NCT04637815|Other|Usual Care|See earlier description
79513384|NCT04637763|Genetic|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
79513385|NCT04637763|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
79994165|NCT05283668|Procedure|Diode Laser|"Local anesthesia was achieved using field block technique.~A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~Laser irradiation parameters were adjusted as follows: Wavelength [940 ± 10 nm], irradiation mode [contact continuous wave], Power [2 W] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
79672680|NCT00480207|Other|folic acid placebo|
79820764|NCT02573571|Other|Development of biomarkers|Blood sampling
79820765|NCT05328219|Other|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
79219027|NCT04366167|Other|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
79219028|NCT05695534|Other|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
79219029|NCT04365075|Device|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
79219030|NCT04365075|Device|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
79362404|NCT01462695|Other|Pharmacological Study|Correlative studies
79362405|NCT01462695|Drug|Sunitinib Malate|Given PO
79362406|NCT01465347|Drug|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
79362407|NCT03027687|Device|tDCS|tDCS is an electrical brain stimulation method
79362408|NCT01465191|Drug|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
79362409|NCT01519947|Drug|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
79362410|NCT01462227|Drug|Naltrexone High Dose|Naltrexone 100mg for two administrations.
79513386|NCT04637763|Drug|Fludarabine|Chemotherapy for lymphodepletion
79219031|NCT05678920|Other|patient-administered questionnaires|patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
79219032|NCT05678842|Other|Descriptive|Descriptive
79219033|NCT04354155|Drug|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
79219034|NCT05032833|Drug|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
79219035|NCT05032833|Other|Placebo|A single dose of placebo will be administered intranasally
79513387|NCT04635358|Behavioral|Hypnosis|Setting up hypnosis sessions
79513388|NCT04635358|Behavioral|Psychological support|Setting up psychological support
79513389|NCT04635358|Behavioral|Nutrional support|Setting up nutritional support
79513390|NCT04628494|Biological|Epcoritamab|Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.
79362411|NCT01462227|Drug|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
79672681|NCT00480207|Other|omega-3 placebo|
79672682|NCT03274583|Diagnostic Test|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
79672683|NCT00442455|Drug|Erlotinib chlorhydrate|150 mg/day for 7 weeks
79362412|NCT01464879|Drug|Testosterone Gel (FE 999303)|
79362413|NCT01519869|Drug|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
79672684|NCT00442455|Drug|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
79672685|NCT00442455|Procedure|Radiation therapy|63 Gy, five days a week, for 7 weeks
79219036|NCT04450654|Drug|Gamunex-C|Gamunex-C IVIG will be given at week 0 and week 4
79219037|NCT04450654|Drug|Albumin|1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
79219038|NCT05536570|Drug|IncobotulinumtoxinA 100 UNT|Scalene injection
79219039|NCT05001165|Other|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
79219040|NCT04376008|Procedure|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
79219041|NCT04376008|Procedure|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
79513391|NCT04628494|Drug|Investigator's Choice Chemotherapy|Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
79513392|NCT04625283|Drug|Ketamine|Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
79513393|NCT04625283|Drug|Placebo|Participants in the placebo arm will receive intraoperative and postoperative saline.
79513394|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
79219042|NCT05678764|Device|Conversational Information Collection Tool|Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
79219043|NCT03877965|Drug|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
79362414|NCT03026205|Drug|ARMS-I|
79362415|NCT01519791|Biological|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
79362416|NCT01519791|Other|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
79513395|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
79513396|NCT04623541|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
79513397|NCT04623541|Drug|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
79513398|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
79513399|NCT04623541|Drug|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
79513400|NCT04619745|Other|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
79513401|NCT04606316|Drug|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
79672686|NCT02956655|Other|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
79672687|NCT02956655|Drug|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
79820766|NCT05328219|Other|Standard of care|Standard of care
79513402|NCT04606316|Drug|Nivolumab|Given as intravenous (IV) infusion into a vein.
79513403|NCT04606316|Drug|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
79219044|NCT02586064|Behavioral|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
79219045|NCT02586064|Behavioral|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
79219046|NCT02253849|Drug|Carbamazepine|
79219047|NCT02253849|Drug|Tipranavir|
79219048|NCT02253849|Drug|Ritonavir|
79219049|NCT04981197|Behavioral|Baduanjin exercise|Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
79219050|NCT04233489|Behavioral|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
79219051|NCT03545997|Drug|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
79219052|NCT03545997|Drug|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
79219053|NCT05678608|Procedure|surgical excision|posterior midline approach and total excision for spinal cord tumors
79219054|NCT05696548|Drug|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
79219055|NCT05696548|Drug|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
79219056|NCT05536024|Diagnostic Test|Prediction of glioma grading and molecular subtype|Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status
79219057|NCT05696470|Device|DePuy Synthes Conduit 3D printed titanium cages|DePuy Conduit 3D printed titanium cages supplemented with SKYLINE Anterior Cervical Plate System and 1 CC DBM
79219058|NCT03810729|Diagnostic Test|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
79219059|NCT03810729|Diagnostic Test|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
79219060|NCT03810495|Drug|naltrexone implant|1.8 g implant containing 60% naltrexone
79219061|NCT04980885|Drug|AK117|Subjects receive AK117 intravenously.
79219062|NCT04980885|Drug|Azacitidine|Subjects receive Azacitidine subcutaneously.
79219063|NCT03545685|Other|specific memory and attention realtime training|The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
79362417|NCT01519791|Biological|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
79362418|NCT01461993|Biological|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
79362419|NCT01461993|Biological|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
79362420|NCT01461993|Biological|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
79362421|NCT01782326|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
79513404|NCT04606316|Drug|Ipilimumab|Given as intravenous (IV) infusion into a vein.
79513405|NCT04606316|Procedure|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
79513406|NCT04603625|Other|postural management|postural management in sitting position
79513407|NCT04599010|Other|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
79513408|NCT04579835|Other|External Cephalic Version|External Cephalic Version Twin A
79513409|NCT04578912|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is a manualized treatment program focused on tic management skills
79672688|NCT02956655|Other|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
79219064|NCT03545841|Other|HIT|Participants completed 6 weeks of HIT
79820767|NCT00724269|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
79820768|NCT00724269|Device|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
79820769|NCT05315661|Drug|ET-STEM|mesenchymal stem cells preconditioned with ethionamide
79219065|NCT03545841|Other|MICT|Participants completed 6 weeks of MICT
79219066|NCT04184505|Drug|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
79820770|NCT00435019|Drug|insulin detemir|s.c. injection, once or twice daily.
79219067|NCT04184505|Drug|Standard Chemotherapy|"cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
79219068|NCT04184505|Procedure|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
79219069|NCT03754023|Diagnostic Test|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
79219070|NCT03546543|Procedure|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
79219071|NCT02782923|Device|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
79219072|NCT03546465|Drug|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
79219073|NCT02148003|Procedure|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
79219074|NCT02148003|Procedure|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
79219075|NCT02148003|Device|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
79219076|NCT03760458|Drug|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
79219077|NCT03760458|Drug|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
79219078|NCT02066415|Biological|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
79219079|NCT02066415|Drug|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
79219080|NCT02583256|Biological|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
79219081|NCT02583256|Biological|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
79219082|NCT03745794|Other|Best Practice|Given standard of care
79219083|NCT03745794|Drug|Quadratus Lumborum Block|Undergo QL block
79362422|NCT01782326|Drug|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
79362423|NCT01439373|Drug|GSK2336805|Active Investigational Drug
79362424|NCT01439373|Drug|Pegylated interferon alfa-2a|Standard of Care drug
79362425|NCT01439373|Drug|Ribavirin|Standard of Care drug
79362426|NCT01439373|Drug|GSK2336805 Matching Placebo|Placebo of Investigational Drug
79219084|NCT03745794|Other|Quality-of-Life Assessment|Ancillary studies
79219085|NCT03745794|Other|Questionnaire Administration|Ancillary studies
79219086|NCT04467918|Drug|Cannabidiol|Already described
79219087|NCT04467918|Other|PLACEBO|Already described
79219088|NCT03133104|Other|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
79219089|NCT03522090|Diagnostic Test|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
79219090|NCT03522012|Drug|Tocilizumab|Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
79362427|NCT04077801|Diagnostic Test|diagnostic test|diagnostic test
79362428|NCT01461369|Drug|Diclofenac|35 mg bid Capsules
79362429|NCT01461369|Drug|Diclofenac|35 mg tid Capsules
79362430|NCT01461369|Drug|Placebo|Capsules
79362431|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
79362432|NCT04414124|Other|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
79672689|NCT02956655|Behavioral|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
79672690|NCT02956655|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
79672691|NCT00480246|Drug|BL 1020|
79672692|NCT00480246|Drug|Perphenazine|
79672693|NCT00455117|Drug|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
79672694|NCT00442494|Drug|intravenous hydrocortisone|
79679743|NCT02940561|Drug|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
79679744|NCT00519974|Other|counseling intervention|
79679745|NCT00519974|Other|study of socioeconomic and demographic variables|
79219091|NCT05698108|Device|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
79219092|NCT05698108|Other|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
79219093|NCT05695456|Other|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
79219094|NCT05695456|Other|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
79219095|NCT05535868|Other|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
79219096|NCT04720612|Biological|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
79219097|NCT04720612|Other|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
79219098|NCT02584660|Drug|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
79219099|NCT02584660|Drug|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
79219100|NCT04862286|Drug|Risankizumab|Subcutaneous (SC) injection.
79219101|NCT02254083|Drug|BIBT 986 BS - low|
79219102|NCT02254083|Drug|BIBT 986 BS - high|
79219103|NCT02254083|Drug|Placebo|
79219104|NCT03576573|Device|PROCOTYL® C|Hip Arthroplasty
79219105|NCT04467138|Drug|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
79219106|NCT05535790|Other|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
79219107|NCT05535790|Other|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
79219108|NCT02143323|Drug|Augmentin tablet|
79219109|NCT04467216|Device|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
79219110|NCT05689762|Behavioral|Healthy lifestyle|Promotion of healthy lifestyle behaviors
79219111|NCT04043650|Behavioral|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
79219112|NCT04466826|Other|Headache Journal|Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns
79362433|NCT04575662|Radiation|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
79362434|NCT01727258|Device|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
79362435|NCT01727258|Drug|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
79362436|NCT01727258|Drug|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
79362437|NCT04583306|Other|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
79362438|NCT01781390|Other|Placebo|Matching placebo solution for infusion.
79362439|NCT01781390|Biological|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
79362440|NCT01781390|Biological|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
79362441|NCT01781234|Drug|Intranasal Insulin|
79362442|NCT01781234|Drug|Placebo|
79513410|NCT04578912|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
79513411|NCT04578912|Device|Continuous Theta Burst Stimulation (cTBS)|During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
79679746|NCT00519974|Procedure|management of therapy complications|
79219113|NCT04466826|Drug|Sphenopalatine Block|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
79219114|NCT04466826|Device|Tx360|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
79219115|NCT05678452|Procedure|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
79362443|NCT01752842|Drug|Fenofibrate|
79362444|NCT01752842|Drug|Placebo for fenofibrate|
79362445|NCT01461057|Drug|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
79362446|NCT01461057|Drug|Cisplatin|80 mg/m2 on Day 1 of each cycle
79362447|NCT01461057|Drug|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
79362448|NCT01461057|Drug|Pertuzumab|840 mg once every three weeks
79362449|NCT01461057|Drug|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
79679747|NCT00519974|Procedure|psychosocial assessment and care|
79219116|NCT04841616|Procedure|Endoscopic Ultrasound -Guided Fine Needle Biopsy|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
79513412|NCT04572906|Combination Product|NTX-001|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
79219117|NCT04841616|Procedure|Contrast-Enhanced Harmonic Endoscopic Ultrasound|After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
79513413|NCT04563858|Diagnostic Test|Validation|Assessment of Polish version of the 4AT
79994166|NCT03371381|Biological|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
79994167|NCT03371381|Drug|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
79994168|NCT03710681|Biological|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
79994169|NCT03044730|Drug|Capecitabine|Given PO
79994170|NCT03044730|Other|Laboratory Biomarker Analysis|Correlative studies
79994171|NCT03044730|Biological|Pembrolizumab|Given IV
79219118|NCT03544593|Device|Revolve System|Fat grafting system
79362450|NCT01460901|Biological|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
79362451|NCT01519635|Drug|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
79513414|NCT04548349|Drug|Altreno|Acne patients will be assigned to Altreno once daily.
79672695|NCT03274427|Device|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
79994172|NCT03737058|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
79994173|NCT05476887|Drug|KP104|KP104 intravenously (IV loading + subcutaneous [SC] maintenance every week [QW] or every 2 weeks [Q2W]) will be administered.
79994174|NCT02961374|Drug|Erlotinib|Given PO
79362452|NCT01519635|Drug|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
79513415|NCT04548349|Drug|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
79672696|NCT03274427|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
79672697|NCT03274427|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
79672698|NCT03274388|Procedure|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
79672699|NCT03274388|Procedure|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
79672700|NCT00480285|Procedure|Laparoscopic Nissen Fundoplication|
79672701|NCT00480285|Procedure|Laparoscopic anterior partial fundoplication|
79672702|NCT03274349|Procedure|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
79672703|NCT03274349|Procedure|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
79820771|NCT00435019|Drug|insulin NPH|s.c. injection, once or twice daily.
79820772|NCT00435019|Drug|insulin aspart|s.c. injection, at main meals.
79994175|NCT02961374|Drug|Erlotinib Hydrochloride|Given PO
79994176|NCT05468853|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
79994177|NCT05468853|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
79994178|NCT04700787|Drug|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
79994179|NCT04783233|Biological|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
79513416|NCT04546230|Procedure|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle & a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later & continued throughout the procedure."
79362453|NCT01519323|Drug|vemurafenib|Cohort 1 (participants >=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants <45 kg): starting dose 480 mg
79513417|NCT04546230|Procedure|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen & infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
79513418|NCT04542824|Biological|epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
79513419|NCT04542824|Biological|epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
79513420|NCT04542824|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
79513421|NCT04542824|Drug|gemcitabine and oxaliplatin|28-day cycles
79513422|NCT04542824|Biological|epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
79672704|NCT00442650|Drug|Efalizumab|
79672705|NCT02273687|Device|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
79672706|NCT00442728|Device|ELECTRICAL STIMULATION|
79362454|NCT01519245|Drug|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
79672707|NCT00455234|Drug|Intramuscular Olanzepine 10 mg|
79219119|NCT04466904|Drug|IBI362|Administrated by subcutaneous injection
79362455|NCT01519245|Drug|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
79362456|NCT01519167|Drug|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
79672708|NCT00455234|Drug|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
79994180|NCT04783233|Biological|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
79994181|NCT05248035|Other|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
79219120|NCT04466904|Drug|Placebo|Administrated by subcutaneous injection
79219121|NCT04466904|Drug|Dulaglutide|Administrated by subcutaneous injection
79219122|NCT03524274|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
79219123|NCT03524274|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
79513423|NCT04542824|Drug|rituximab and lenalidomide|28-day cycles.
79513424|NCT04533438|Device|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
79513425|NCT04533438|Device|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
79513426|NCT04511234|Device|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
79672709|NCT00480363|Procedure|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
79672710|NCT00442806|Drug|Injection of ADRC's|ADRC's are injected
79672711|NCT00442806|Other|Injection of Placebo|Placebo is injected
79672712|NCT00455390|Procedure|Post-immediate Psychotherapeutic Intervention|
79994182|NCT02714049|Behavioral|sex therapy|60 minutes each time, in person or on the telephone
79362457|NCT01519167|Drug|Midazolam|0.025 - 2 mg/kg IV
79672713|NCT00442845|Drug|Atorvastatin (Lipitor)|
79219124|NCT02143479|Drug|Tacrolimus|oral
79362458|NCT01519167|Drug|Fentanyl|0.5 - 3 mcg/kg IV
79362459|NCT00343564|Drug|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
79362460|NCT00343564|Drug|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
79672714|NCT00455468|Procedure|Day-care treatment vs. hospital care|
79672715|NCT00455507|Drug|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
79362461|NCT00318136|Drug|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
79362462|NCT00318136|Drug|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
79513427|NCT04511234|Device|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
79513428|NCT04510129|Diagnostic Test|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
79513429|NCT04503759|Other|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
79513430|NCT04498078|Dietary Supplement|Creatine|Creatine monohydrate (20 g per day)
79672716|NCT00455507|Drug|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
79994183|NCT02714049|Drug|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
79219125|NCT03524196|Other|Manage Your Life Online (MYLO)|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
79362463|NCT00318136|Drug|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
79672717|NCT00455507|Drug|Placebo|Two placebo tablets orally once daily for 12 weeks
79672718|NCT00442884|Behavioral|Trier Social Stress Test (TSST)|
79672719|NCT00455546|Drug|A-002|
79994184|NCT04777539|Other|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
79994185|NCT02951429|Drug|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
79362464|NCT00318292|Drug|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
79362465|NCT00318292|Drug|Placebo|20 ml normal saline injection.
79362466|NCT01791868|Drug|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
79362467|NCT01791868|Drug|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
79513431|NCT04493736|Behavioral|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
79994186|NCT02951429|Drug|Placebo|Placebo matched with sildenafil.
79994187|NCT02951429|Drug|Sildenafil|Sildenafil will be given as 20 mg, TID.
79513432|NCT04486716|Drug|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
79994188|NCT04622709|Drug|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd & 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd & 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
79994189|NCT03706859|Procedure|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
79513433|NCT04486378|Drug|RO7198457 intravenous (i.v.)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
79513434|NCT04486378|Other|Observational group (no intervention)|watchful waiting
79513435|NCT04482309|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
79672720|NCT00442923|Drug|Coreg|
79672721|NCT00480402|Drug|200 mg of Progesterone|Administration of 200 mg of Progesterone
79672722|NCT00480402|Drug|400 mg Progesterone|Administration of 400 mg Progesterone
79672723|NCT00480402|Drug|Placebo|Administration of a Placebo
79672724|NCT00455585|Drug|nevirapine, stavudine, lamivudine|
79672725|NCT00455624|Drug|Androgen deprivation therapy|According to standard medical care
79672726|NCT01240005|Biological|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
79672727|NCT00455819|Procedure|home treatment|
79672728|NCT00443157|Biological|Meningococcal B Vaccine NZ|
79672729|NCT00455897|Drug|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
79672730|NCT00455897|Drug|CHOP|Administered as part of standard care
79672731|NCT00455897|Drug|Rituximab|Administered as part of standard treatment
79672732|NCT00480480|Behavioral|Trauma and Grief Component Therapy for Adolescents (Group Version)|
79672733|NCT00455936|Drug|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
79362468|NCT01791946|Procedure|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
79994190|NCT05682755|Drug|Chidamide|initial time：platelet count ≥50×10^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10^9/L-increased by 5 mg 20×10^9/L≤ platelet count <50×10^9/L-remains unchanged platelet count <50×10^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
79219126|NCT03521778|Other|Fascial Distortion Model|"Patients will receive manual treatment according to FDM procedures:~Triggerbands - therapist put a pressure by the thumb along the presented pathway.~Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~Folding Distortions - therapist conduct traction or compression of the affected joint.~Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~Cylinder Distortions - therapist compress and stretch by the hands affected area.~Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble."
79219127|NCT03521778|Other|Mulligan Concept|"Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure."
79362469|NCT01791946|Procedure|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
79513436|NCT04469465|Drug|Danicopan|Oral tablet
79513437|NCT04469465|Drug|Placebo|Oral tablet
79513438|NCT04469465|Drug|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
79219128|NCT03521778|Other|Traditional physiotherapy|"Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment"
79219129|NCT02143557|Other|Fat-Modified Breast Milk|
79219130|NCT02143557|Other|MCT formula|
79219131|NCT02254239|Drug|Brentuximab Vedotin|Given IV
79219132|NCT02254239|Drug|Everolimus|Given PO
79219133|NCT02254239|Other|Laboratory Biomarker Analysis|Correlative studies
79513439|NCT04461691|Procedure|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
79513440|NCT04461639|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
79513441|NCT04439032|Other|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
79513442|NCT04432090|Drug|Placebo|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
79513443|NCT04432090|Drug|Study Medication (MBX-2982)|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
79513444|NCT04432090|Other|No medication for this group|This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
79513445|NCT04431453|Drug|Remdesivir|Administered as an intravenous infusion
79513446|NCT04429919|Drug|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
79513447|NCT04429919|Drug|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
79513448|NCT04420585|Drug|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if <50 % improvement
79513449|NCT04419779|Device|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
79513450|NCT04419779|Device|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
79513451|NCT04417660|Drug|M7824|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
79672734|NCT00455936|Procedure|chemotherapy|gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
79672735|NCT00443196|Procedure|MiCK Assay|Physician determined treatment
79994191|NCT01312103|Behavioral|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
79219134|NCT02254239|Other|Pharmacological Study|Correlative studies
79362470|NCT02105740|Behavioral|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
79219135|NCT05581732|Dietary Supplement|Nutrinidrink with Dietary Fiber|Nutrinidrink with Dietary Fiber is a specialized nutrition for children during illness and recovery period, as well as with increased protein and energy needs: mental and / or physical stress, chronic diseases, growth and / or weight deficiency
79219136|NCT02254317|Dietary Supplement|0 mg placebo|Not containing GSE (Placebo)
79219137|NCT02254317|Dietary Supplement|300 mg GSE|300 mg GSE
79219138|NCT02254317|Dietary Supplement|600 mg GSE|Containing 600 mg of GSE
79219139|NCT02254317|Dietary Supplement|900 mg GSE|Containing 900 mg of GSE
79219140|NCT05088369|Drug|HM201|HM201 will be administered intravenously.
79219141|NCT05088369|Drug|Placebo|Placebo will be administered intravenously.
79219142|NCT05088369|Drug|HM201|HM201 will be administered intravenously.
79219143|NCT05088369|Drug|Placebo|Placebo will be administered intravenously.
79219144|NCT02143635|Drug|HDM201|
79219145|NCT02143635|Drug|ancillary treatment|
79219146|NCT05262582|Procedure|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
79219147|NCT05262582|Procedure|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
79219148|NCT05678062|Diagnostic Test|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
79219149|NCT04467528|Device|Electroacupuncture|"Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
79219150|NCT04467528|Drug|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
79219151|NCT02143791|Procedure|Burst stimulation|
79219152|NCT02143791|Device|Prodigy system|
79219153|NCT04770324|Device|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
79219154|NCT02143869|Device|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
79362471|NCT02105740|Behavioral|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
79513452|NCT04405700|Other|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
79219155|NCT04311970|Device|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
79219156|NCT03545139|Biological|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
79219157|NCT03545139|Biological|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
79219158|NCT03521700|Drug|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L.
79219159|NCT02144025|Drug|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
79219160|NCT03524040|Device|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
79219161|NCT05567224|Other|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
79219162|NCT04748094|Device|Compression belt|The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
79513453|NCT04403763|Drug|AGN-241622|Topical eye drop
79219163|NCT04748094|Other|Visual Guided Breath-hold|A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
79219164|NCT03523884|Other|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
79219165|NCT03523884|Other|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
79219166|NCT01099761|Biological|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
79513454|NCT04403763|Drug|Vehicle|Topical eye drop
79219167|NCT01099761|Biological|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
79513455|NCT04387227|Drug|Carboplatin|Given IV
79513456|NCT04387227|Biological|Pembrolizumab|Given IV
79513457|NCT04387227|Procedure|Computed Tomography|Undergo CT
79513458|NCT04387227|Procedure|Magnetic Resonance Imaging|Undergo MRI
79513459|NCT04387227|Procedure|Biospecimen Collection|Undergo blood sample collection
79513460|NCT04383912|Drug|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
79513461|NCT04383912|Other|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
79362472|NCT01792180|Behavioral|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
79219168|NCT01099761|Other|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
79362473|NCT00320242|Device|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
79513462|NCT04381195|Diagnostic Test|REALS Development|Complete drafting of an item pool (adults with ASD, parents, adult service providers); Assign items to all parts of our conceptual framework to ensure sufficient construct coverage across employment, social, and independent living domains; and Conduct cognitive interviews with 25 caregivers of adults with ASD and 25 self-reporting adults with ASD.
79219169|NCT05566444|Device|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
79219170|NCT03523650|Drug|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
79219171|NCT03523650|Drug|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
79219172|NCT01025505|Drug|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
79362474|NCT00347308|Behavioral|Eyebrow Position|Photography of brow positions
79513463|NCT04381195|Diagnostic Test|REALS Testing|A national sample of proxy reporters (e.g., parents, clinicians, group home staff) for 1000 autistic adults and self-reporting autistic adults and adults with other IDD will complete the REALS draft items and a co-calibration battery to establish psychometrics, generate short-forms, and ensure applicability across adults with ASD.
79513464|NCT04378790|Other|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
79513465|NCT04378790|Other|Glasses|Eye Glasses are created and worn by patient to improve vision
79513466|NCT04373473|Drug|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
79513467|NCT04373473|Drug|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
79219173|NCT01025505|Drug|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
79219174|NCT02582632|Drug|ombitasvir/paritaprevir/ritonavir|Tablet
79219175|NCT02582632|Drug|dasabuvir|Tablet
79219176|NCT02144103|Other|Subtenon administration of autologous ADRC|
79362475|NCT00348946|Drug|androgen oxandrolone|Oxandrolone ,06 >mg/kg/day, orally, for 2 years
79362476|NCT00348946|Other|placebo|an inactive substance
79362477|NCT00349336|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
79362478|NCT00349336|Drug|XELOX|As prescribed
79362479|NCT00349336|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
79362480|NCT00349336|Drug|FOLFOX-4|As prescribed
79513468|NCT04369456|Other|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
79672736|NCT03274310|Behavioral|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
79672737|NCT00443235|Drug|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
79513469|NCT04365205|Procedure|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
79219177|NCT02144103|Procedure|Liposuction|
79513470|NCT04357795|Drug|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
79513471|NCT04344665|Other|Virtual Care and Remote Automated Monitoring|Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
79994192|NCT01312103|Behavioral|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
79994193|NCT03708887|Drug|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1 g/d by mouth for 1 year
79219178|NCT02144103|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
79219179|NCT05677672|Biological|Human TH-SC01 Cell Injection|Single injection of 0.6×10^7,1.2×10^8, 1.8×10^8 cells/kg
79994194|NCT03708887|Drug|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
79219180|NCT05677672|Other|Saline solution|saline solution will be given at the same quantity and following the same schedule
79219181|NCT05399836|Behavioral|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
79219182|NCT00307476|Device|Rusch Nasopharyngeal Airway|For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.
79219183|NCT04683354|Drug|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
79219184|NCT02178722|Drug|MK-3475|IV infusion
79219185|NCT02178722|Drug|INCB024360|Oral daily dosing
79219186|NCT03523572|Drug|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
79362481|NCT04888468|Biological|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
79362482|NCT04751188|Drug|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
79362483|NCT04751188|Drug|Placebo|Placebo one tablet every 12 hours for six months.
79362484|NCT04751188|Drug|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
79362485|NCT00352612|Drug|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
79362486|NCT00352612|Drug|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
79362487|NCT01793584|Procedure|Laparoscopic hysterectomy|LAVH, TLH
79513472|NCT04344262|Drug|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
79513473|NCT04344262|Drug|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
79513474|NCT04323436|Drug|Spartalizumab|Concentrate for solution for infusion
79513475|NCT04323436|Drug|Capmatinib|Film-coated tablet
79362488|NCT01793584|Procedure|Abdominal hysterectomy|TAH
79362489|NCT01793740|Behavioral|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
79362490|NCT00323284|Device|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
79513476|NCT04323436|Drug|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
79513477|NCT04312022|Dietary Supplement|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
79513478|NCT04312022|Other|Placebo|Placebo (flour capsule)
79513479|NCT04301076|Procedure|Biospecimen Collection|Undergo tissue and blood sample collection
79513480|NCT04301076|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79513481|NCT04301076|Procedure|Computed Tomography|Undergo PET/CT or CT
79513482|NCT04301076|Drug|Cyclophosphamide|Given IV
79513483|NCT04301076|Drug|Doxorubicin Hydrochloride|Given IV
79513484|NCT04301076|Drug|Etoposide|Given IV
79513485|NCT04301076|Drug|Lenalidomide|Given PO
79672738|NCT00443235|Drug|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
79672739|NCT03274232|Device|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
79672740|NCT00456053|Drug|FG2216|
79994195|NCT03708887|Drug|Control drug|Matching placebo capsules,1 g/d by mouth for 1 year
79219187|NCT03523572|Drug|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
79219188|NCT00972309|Biological|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
79219189|NCT00972309|Biological|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
79362491|NCT00323284|Procedure|Cataract surgery only|Cataract surgery only
79362492|NCT00323362|Drug|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
79219190|NCT03133026|Device|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
79219191|NCT03526224|Drug|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
79219192|NCT03526224|Drug|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
79219193|NCT03748329|Device|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
79219194|NCT03639246|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
79219195|NCT03639246|Drug|Paclitaxel (Pac)|Paclitaxel is active comparator
79219196|NCT03639246|Drug|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
79219197|NCT03639246|Other|Placebo|Placebo comparator
79219198|NCT00594620|Dietary Supplement|Flav-ein capsules|Soy/isoflavone supplementation
79219199|NCT00594620|Drug|Placebo|Placebo
79362493|NCT00323362|Drug|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
79362494|NCT01793896|Behavioral|Control period|Analysis at recruitment and after a month without any intervention
79362495|NCT01793896|Behavioral|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
79513486|NCT04301076|Procedure|Positron Emission Tomography|Undergo PET/CT
79513487|NCT04301076|Drug|Prednisone|Given PO
79513488|NCT04301076|Drug|Vincristine Sulfate|Given IV
79513489|NCT04298151|Drug|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
79513490|NCT04298151|Drug|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
79513491|NCT04284397|Drug|Low dose ASA|A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
79513492|NCT04284397|Other|Control|All participants will be tested with no treatment.
79513493|NCT04284293|Biological|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
79513494|NCT04275908|Device|MHSAFE app|App to detect presence of mental state
79513495|NCT04247542|Drug|Ibezapolstat|Investigational antibacterial agent
79672741|NCT00456131|Behavioral|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
79513496|NCT04247542|Drug|Vancomycin|Active comparator
79513497|NCT04240704|Drug|JBH492|Anti-CCR7 antibody-drug conjugate (ADC)
79513498|NCT04236388|Dietary Supplement|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
79513499|NCT04236388|Dietary Supplement|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
79672742|NCT00480519|Procedure|Meatotomy|
79672743|NCT00456170|Procedure|Performing Vaginal hysterectomy with Harmonic Scalpel|
79672744|NCT03278535|Diagnostic Test|CAREN-based gait analysis|subjects only walk at CAREN at different speed
79679748|NCT02940366|Drug|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
79994196|NCT05321537|Other|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
79994197|NCT04595019|Radiation|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
79362496|NCT01793896|Behavioral|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
79362497|NCT01793896|Behavioral|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
79362498|NCT00390364|Drug|everolimus|
79362499|NCT00390364|Procedure|antiangiogenesis therapy|
79362500|NCT00390364|Procedure|biopsy|
79362501|NCT00390364|Procedure|diagnostic procedure|
79513500|NCT04231071|Device|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
79513501|NCT04227184|Drug|Trospium|Drug to treat overactive bladder
79513502|NCT04227184|Drug|Placebo oral tablet|Placebo tablet containing no active drug
79513503|NCT04226053|Other|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
79672745|NCT04700943|Procedure|Regional awake anesthesia|We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
79672746|NCT00456248|Drug|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
79672747|NCT00480558|Biological|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10^7
79219200|NCT03544515|Device|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
79219201|NCT03544515|Procedure|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
79994198|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
79219202|NCT03544515|Device|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
79219203|NCT03550170|Behavioral|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
79219204|NCT03550170|Behavioral|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
79219205|NCT03550170|Behavioral|1-to-1, in-person|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
79219206|NCT00545324|Drug|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
79219207|NCT00545324|Drug|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
79219208|NCT02582242|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
79219209|NCT04467684|Drug|CB-0406 100 mg|Single oral dose
79219210|NCT04467684|Drug|CB-0406 200 mg|Single oral dose
79219211|NCT04467684|Drug|CB-0406 400 mg|Single oral dose
79219212|NCT04467684|Drug|CB-0406 800 mg|Single oral dose
79219213|NCT04467684|Drug|CB-0406 1,000 mg|Single oral dose
79219214|NCT04467684|Drug|Matched placebo|Color and size matched placebo
79219215|NCT05004038|Biological|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
79219216|NCT00663351|Device|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
79219217|NCT00663351|Device|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
79219218|NCT02288988|Procedure|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
79219219|NCT04976270|Drug|GLPG3667|GLPG3667 capsules
79362502|NCT00390364|Procedure|gene expression analysis|
79362503|NCT00390364|Procedure|immunohistochemistry staining method|
79362504|NCT00390364|Procedure|laboratory biomarker analysis|
79362505|NCT00390364|Procedure|mutation analysis|
79672748|NCT00456287|Device|CPAP (Continuous Positive Airway Pressure)|
79679749|NCT02940366|Drug|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
79513504|NCT04225572|Behavioral|Physical Therapy: Dependent on Patient's Needs|"Therapeutic exercise:~ROM: Begin with passive upper extremity ROM and progress to active ROM.~Strengthening: Progressive upper extremity resistive exercises starting with light weights.~Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema."
79362506|NCT00390364|Procedure|protein tyrosine kinase inhibitor therapy|
79362507|NCT00390364|Procedure|reverse transcriptase-polymerase chain reaction|
79362508|NCT00354484|Drug|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
79362509|NCT00354484|Drug|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
79362510|NCT00354640|Drug|anastrozole|1 milligram tablet PO QD for 14 days
79362511|NCT00354640|Drug|simvastatin|40 milligram tablet PO QD for 14 days
79513505|NCT04221529|Drug|Atezolizumab|1200 mg i.v. on day 1 of each cycle
79513506|NCT04220983|Radiation|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
79513507|NCT04219085|Device|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
79672749|NCT04700709|Drug|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/ml.
79672750|NCT04700709|Drug|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
79672751|NCT04698317|Procedure|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
79672752|NCT04698317|Other|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
79219220|NCT04976270|Drug|Placebo|Matching placebo capsules
79362512|NCT00354640|Other|pharmacological study|laboratory analysis
79362513|NCT00354640|Procedure|adjuvant therapy|laboratory analysis
79219221|NCT03526146|Behavioral|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
79362514|NCT02107300|Drug|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
79362515|NCT02107300|Drug|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
79362516|NCT00392236|Device|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
79362517|NCT00392236|Behavioral|Treatment as usual|Participants will receive treatment as usual.
79362518|NCT00392392|Drug|nab-paclitaxel|ABI-007
79513508|NCT04219085|Other|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
79362519|NCT00392392|Drug|Bevacizumab|Bevacizumab
79362520|NCT00392392|Drug|Trastuzumab|Trastuzumab
79672753|NCT04698317|Other|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
79672754|NCT04700475|Device|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
79672755|NCT04700475|Drug|citric acid solution|citric acid solution applied as a mouth rinse
79362521|NCT01519089|Drug|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
79362522|NCT01519089|Drug|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
79362523|NCT00392704|Drug|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
79219222|NCT05677516|Procedure|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
79994199|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
79994200|NCT05228145|Genetic|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
79219223|NCT05677516|Procedure|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
79362524|NCT00392704|Drug|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
79219224|NCT05677516|Procedure|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
79513509|NCT04219007|Drug|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
79219225|NCT05677516|Procedure|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
79672756|NCT00456404|Drug|peppermint water|
79672757|NCT04700436|Drug|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|"IP~Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)"
79362525|NCT00392704|Drug|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
79219226|NCT05677516|Diagnostic Test|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
79219227|NCT05677516|Other|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
79513510|NCT04214067|Procedure|Biospecimen Collection|Undergo collection of blood
79219228|NCT04971512|Drug|EDP-721|Oral administration (Part 1)
79219229|NCT04971512|Drug|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
79219230|NCT04971512|Drug|EDP-721 (Part 2)|Oral administration (Part 2)
79219231|NCT04971512|Drug|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
79219232|NCT04971512|Drug|EDP-514|Oral administration
79219233|NCT04971512|Drug|Placebo (Part 2)|Placebo to match EDP-514
79219234|NCT03523260|Device|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
79362526|NCT00392704|Drug|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
79362527|NCT00392704|Radiation|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
79513511|NCT04214067|Radiation|Brachytherapy|Undergo vaginal brachytherapy
79672758|NCT00456443|Procedure|Historical records|
79672759|NCT00480597|Drug|gemcitabine|
79513512|NCT04214067|Procedure|Computed Tomography|Undergo CT
79513513|NCT04214067|Radiation|External Beam Radiation Therapy|Undergo EBRT
79672760|NCT00480597|Drug|cisplatin|
79672761|NCT00480597|Drug|vinorelbine|
79672762|NCT00480597|Drug|capecitabine|
79672763|NCT00456482|Drug|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
79672764|NCT00456482|Drug|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
79219235|NCT03526068|Device|SafeZoneUVC|SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
79672765|NCT00480675|Procedure|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
79219236|NCT04217356|Biological|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
79219237|NCT04217356|Drug|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
79219238|NCT04217356|Drug|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
79219239|NCT03389126|Drug|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
79219240|NCT04446104|Drug|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
79219241|NCT04446104|Drug|Ivermectin 3mg Tab|Ivermectin tablet 12mg single dose
79219242|NCT04446104|Drug|Zinc|Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
79219243|NCT04446104|Drug|Povidone-Iodine|Povidone-iodine throat spray (3 times daily) for 42 days
79672766|NCT00480675|Procedure|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
79219244|NCT04446104|Dietary Supplement|Vitamin C|Vitamin C tablet 500mg daily for 42 days
79219245|NCT03385070|Diagnostic Test|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
79219246|NCT05346718|Other|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
79219247|NCT03389048|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
79219248|NCT03389048|Diagnostic Test|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
79219249|NCT03388970|Drug|Vitamin K 1|Research group use Vitamin K1
79219250|NCT03388970|Drug|normal saline|Placebo group use normal saline
79219251|NCT04799210|Device|Eximis CS (Contained Segmentation) System|Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
79219252|NCT04735094|Diagnostic Test|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
79219253|NCT00616941|Biological|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
79219254|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
79219255|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
79219256|NCT00105560|Radiation|radiation therapy|Radiation therapy with proton beam to standard doses
79219257|NCT05695066|Procedure|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
79219258|NCT03393104|Behavioral|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
79219259|NCT03393104|Behavioral|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
79672767|NCT00456560|Drug|AV650|
79219260|NCT03388892|Device|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
79219261|NCT03388892|Device|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
79219262|NCT02577718|Drug|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
79362528|NCT00392782|Biological|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
79672768|NCT00456560|Drug|Fluvoxamine|
79672769|NCT00456560|Drug|Paroxetine|
79672770|NCT04700358|Other|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
79672771|NCT00456638|Drug|Depodur|Depodur vs. traditional management
79820773|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
79994201|NCT05214807|Device|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
79994202|NCT05214807|Device|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
79994203|NCT02454855|Drug|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
79994204|NCT02454855|Drug|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
79994205|NCT03343067|Drug|elagolix|Tablets
79994206|NCT03343067|Drug|estradiol/norethindrone acetate (E2/NETA)|Capsules
79219263|NCT00520533|Biological|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st & 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available."
79362529|NCT00392782|Drug|fludarabine phosphate|Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
79362530|NCT00392782|Drug|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
79362531|NCT00392782|Procedure|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
79362532|NCT00392782|Radiation|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
79994207|NCT05205525|Other|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
79994208|NCT05205525|Other|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
79994209|NCT05196165|Other|No Intervention|No investigational product (IP) will be administered in this study
79219264|NCT00520533|Drug|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study."
79362533|NCT01795300|Radiation|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
79513514|NCT04214067|Procedure|Magnetic Resonance Imaging|Undergo MRI
79672772|NCT04700085|Device|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
79672773|NCT00480714|Biological|BCG (SSI Strain)|
79672774|NCT00456677|Drug|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
79672775|NCT00456677|Drug|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
79994210|NCT04707183|Drug|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
79994211|NCT04707183|Drug|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
79994212|NCT04703205|Drug|Ivermectin 3 MG|Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
79994213|NCT04703205|Drug|Placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
79994214|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
79513515|NCT04214067|Biological|Pembrolizumab|Given IV
79672776|NCT03278496|Behavioral|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
79672777|NCT03278496|Behavioral|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
79672778|NCT03278496|Behavioral|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
79672779|NCT00456716|Drug|sorafenib|400mg po bid
79219265|NCT03388814|Drug|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
79994215|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
79994216|NCT04681365|Other|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
79994217|NCT03706703|Drug|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
79219266|NCT03388814|Drug|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
79219267|NCT04680988|Drug|SHR-1210|SHR-1210 intravenously every 3 weeks
79672780|NCT04700397|Diagnostic Test|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
79219268|NCT04680988|Drug|SHR-1020|SHR-1020 Orally once daily
79219269|NCT04680988|Drug|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
79362534|NCT01795300|Radiation|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
79513516|NCT04214067|Other|Quality-of-Life Assessment|Ancillary studies
79513517|NCT04214067|Other|Questionnaire Administration|Ancillary studies
79672781|NCT00456794|Drug|Istradefylline (KW-6002)|
79672782|NCT00456833|Drug|RAD001|
79994218|NCT03706703|Drug|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
79994219|NCT03706703|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
79994220|NCT03706703|Drug|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
79994221|NCT05279573|Dietary Supplement|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
79994222|NCT05279573|Other|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
79219270|NCT05174390|Diagnostic Test|Coala Heart Monitor Pro|thumb- and chest-ECG
79513518|NCT04214067|Procedure|X-Ray Imaging|Undergo x-rays
79513519|NCT04204291|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
79513520|NCT04202094|Diagnostic Test|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
79672783|NCT00456833|Drug|erlotinib|
79672784|NCT04700319|Drug|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T,Infusion,iv,0.2×10^6-5×10^6γδT /kg,once
79672785|NCT00456872|Drug|lidocaine|
79672786|NCT00480753|Drug|Nitroglycerin|
79672787|NCT00456911|Behavioral|Fat and carbohydrate controlled diet|
79672788|NCT03274154|Dietary Supplement|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
79672789|NCT03274115|Device|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
79672790|NCT04700241|Dietary Supplement|Potassium nitrate|Acute intervention (5.5 hours)
79672791|NCT04700241|Dietary Supplement|Placebo|Acute intervention (5.5 hours)
79672792|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
79672793|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
79362535|NCT01795300|Radiation|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
79513521|NCT04202094|Diagnostic Test|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
79672794|NCT00480792|Biological|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
79994223|NCT05182905|Drug|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
79994224|NCT05682287|Device|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
79994225|NCT05682287|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
79219271|NCT02289144|Drug|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
79219272|NCT03388736|Behavioral|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
79219273|NCT03544983|Behavioral|Web + Streamlined Telephone Genetic Counseling|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
79219274|NCT05340244|Device|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
79219275|NCT03393026|Drug|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
79219276|NCT03384992|Other|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
79219277|NCT03384992|Other|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
79362536|NCT01795300|Radiation|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
79362537|NCT01518699|Drug|Ha44|Abametapir Lotion 0.74%
79994226|NCT05642403|Drug|XW001|Inhaled XW001
79994227|NCT05642403|Drug|Placebo|Matched inhaled placebo
79219278|NCT03384992|Other|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
79219279|NCT03384992|Other|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
79219280|NCT03384992|Other|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
79219281|NCT02144415|Drug|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
79219282|NCT02144415|Drug|EB-1020 800 mg|8 x EB-1020 100-mg capsules
79513522|NCT04202094|Diagnostic Test|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
79672795|NCT00457067|Drug|Ranibizumab|
79672796|NCT00480870|Drug|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
79672797|NCT00480870|Drug|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
79672798|NCT00457106|Drug|Paroxetine|
79672799|NCT00457106|Drug|Risperidone|
79672800|NCT00480948|Behavioral|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
79994228|NCT03706547|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
79994229|NCT03706547|Drug|Fludarabine|30mg/m2/d
79219283|NCT02144415|Drug|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
79362538|NCT01518699|Drug|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
79362539|NCT01518699|Drug|Moxifloxacin Placebo|Moxifloxacin Placebo
79513523|NCT04202094|Diagnostic Test|Semen analysis|A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
79513524|NCT04192591|Device|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
79513525|NCT04184674|Other|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
79513526|NCT04184674|Other|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
79513527|NCT04184674|Other|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
79513528|NCT04184674|Other|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
79513529|NCT04167969|Drug|(64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
79513530|NCT04167969|Diagnostic Test|PET/MRI|Imaging will be performed using the GE Signa PET/MRI.
79513531|NCT04167969|Other|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
79513532|NCT04167969|Procedure|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
79219284|NCT02144415|Drug|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
79219285|NCT02144415|Drug|Placebo|8 x matching placebo capsules
79219286|NCT01664104|Drug|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
79219287|NCT03392870|Other|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
79513533|NCT04167514|Biological|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
79513534|NCT04167514|Drug|Placebo|Albumin solution administered intravenously
79219288|NCT03392870|Other|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
79362540|NCT01518699|Drug|Moxifloxacin|Moxifloxacin 400mg
79362541|NCT04556266|Biological|CAR T-Cell Infusion|Dose Level -1: 1 x 10^4 cells/kg Dose Level 1: 1 x 10^5 cells/kg Dose Level 2: 2 x 10^5 cells/kg Dose Level 3: 4 x 10^5 cells/kg
79362542|NCT01792648|Other|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
79362543|NCT01792648|Other|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
79513535|NCT04146051|Drug|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
79513536|NCT04141696|Drug|Ketamine|Given intravenously over 40 minutes
79513537|NCT04141696|Drug|Midazolam (placebo)|Given intravenously over 40 minutes
79513538|NCT04139733|Procedure|Prone positon|Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
79513539|NCT04139733|Procedure|Supine positon|Conventional supine position ventilation, no prone position.
79672801|NCT00480948|Dietary Supplement|Control|Standard vegetable oil based infant formula
79672802|NCT00457145|Drug|Ranibizumab|
79679750|NCT00519272|Behavioral|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
79679751|NCT02940405|Drug|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
79679752|NCT02940405|Drug|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
79679753|NCT02940444|Drug|Heparin|
79219289|NCT02739984|Biological|Evolocumab|Administered by subcutaneous injection with an automated mini doser
79219290|NCT02739984|Drug|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
79219291|NCT03545529|Other|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
79362544|NCT01792648|Other|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
79362545|NCT01792726|Radiation|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
79513540|NCT04136951|Other|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
79219292|NCT02254161|Drug|Matching placebo|Tablet
79362546|NCT01518309|Drug|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
79362547|NCT04067895|Procedure|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
79362548|NCT01419717|Drug|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
79362549|NCT04748133|Device|acupuncture needles|"Site of acupuncture points:~Du 26: At junction of the upper and middle third of philtrum.~Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
79513541|NCT04098068|Drug|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
79513542|NCT04090099|Other|Erector spina plane block|While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
79513543|NCT04088370|Other|Blood Draw|Blood Draw Only
79513544|NCT04084314|Biological|Erenumab|Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
79513545|NCT04083599|Biological|GEN1042|Intravenous
79513546|NCT04083599|Drug|Pembrolizumab|Intravenous
79513547|NCT04083599|Drug|Cisplatin|Intravenous
79672803|NCT00443469|Device|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
79672804|NCT00443469|Device|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
79820774|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
79362550|NCT04748133|Other|placebo|no treatment
79362551|NCT01458951|Drug|tofacitinib|10 mg oral BID
79362552|NCT01458951|Drug|Placebo|Placebo oral BID
79513548|NCT04083599|Drug|Carboplatin|Intravenous
79513549|NCT04083599|Drug|5-FU|Intravenous
79513550|NCT04083599|Drug|Gemcitabine|Intravenous
79820775|NCT00724425|Drug|IPI-493|Capsules, Multiple Schedules
79820776|NCT01028989|Dietary Supplement|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
79219293|NCT02254161|Drug|BI 1181181 healthy elderly|Tablet
79219294|NCT02254161|Drug|BI 1181181 Healthy young|Tablet
79219295|NCT02140749|Dietary Supplement|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
79219296|NCT02140749|Dietary Supplement|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
79219297|NCT02140749|Dietary Supplement|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
79219298|NCT02140749|Dietary Supplement|Placebo|Chewing tablets without short-chain Fructooligosaccharides
79513551|NCT04083599|Drug|Nab paclitaxel|Intravenous
79513552|NCT04083599|Drug|Pemetrexed|Intravenous
79513553|NCT04083599|Drug|Paclitaxel|Intravenous
79513554|NCT04059484|Drug|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
79513555|NCT04059484|Drug|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
79513556|NCT04059484|Drug|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
79513557|NCT04059484|Drug|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
79672805|NCT00457184|Procedure|Blood tests|
79820777|NCT01028989|Dietary Supplement|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
79994230|NCT03706547|Drug|Cyclophosphamide|300mg/m2/d
79513558|NCT04059484|Drug|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
79513559|NCT04059484|Drug|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
79672806|NCT01240044|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
79679754|NCT00520052|Drug|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
79820778|NCT01029067|Behavioral|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
79820779|NCT01029067|Behavioral|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
79219299|NCT00496730|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
79219300|NCT00496730|Drug|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
79219301|NCT02140827|Other|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
79219302|NCT04467372|Dietary Supplement|Tart cherry juice concentrate|Two 8oz bottles of tart cherry juice concentrate daily for 30 days
79219303|NCT04467372|Dietary Supplement|Juice placebo|Two 8oz bottles of placebo juice daily for 30 days
79219304|NCT04467372|Dietary Supplement|Freeze dried tart cherry powder|Two freeze dried tart cherry powder capsules daily for 30 days
79362553|NCT01458639|Drug|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
79362554|NCT01458639|Drug|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
79362555|NCT01437423|Biological|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
79362556|NCT00393796|Drug|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
79362557|NCT00393796|Other|Placebo|
79362558|NCT00393874|Behavioral|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
79513560|NCT04057677|Behavioral|Bed Rest Intervention|The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.
79513561|NCT04057677|Behavioral|Exercise Program|During the first 4 weeks following bed rest, participants will perform a combination of aerobic and resistance exercise training with a certified exercise physiologist 3 days per week at the TRI exercise training facility.
79513562|NCT04054778|Behavioral|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
79513563|NCT04054778|Behavioral|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
79679755|NCT04690647|Other|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
79820780|NCT05188599|Diagnostic Test|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
79219305|NCT04467372|Dietary Supplement|Capsule placebo|Two placebo capsules daily for 30 days
79219306|NCT00446186|Drug|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
79219307|NCT00446186|Drug|Comparator: placebo / Duration of Treatment: 2 Weeks|
79219308|NCT02140983|Drug|Liraglutide|90 days of liraglutide up to 1.8mg/day.
79219309|NCT02140983|Drug|Placebo|Placebo medication
79219310|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation A|
79362559|NCT00393874|Drug|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
79219311|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation B|
79219312|NCT00394160|Drug|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
79219313|NCT02144493|Other|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
79513564|NCT04051203|Biological|Autologous Platelet Rich Plasma Injection|60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP.
79513565|NCT04051203|Drug|Depo-Medrol and lidocaine|Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.
79513566|NCT04051203|Other|Normal Saline|2mL normal saline.
79672807|NCT01240044|Procedure|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
79362560|NCT00393874|Drug|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
79672808|NCT00457223|Procedure|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
79362561|NCT01458249|Drug|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
79219314|NCT02144493|Other|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
79362562|NCT00394888|Device|MRI|MRI of the spine.
79820781|NCT00724581|Drug|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
79219315|NCT03392792|Drug|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
79219316|NCT03392792|Procedure|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
79219317|NCT02739828|Biological|Adalimumab|Adalimumab
79219318|NCT02141139|Drug|NSAIDS (ketorolac and ibuprofen)|
79219319|NCT03392714|Drug|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
79219320|NCT02144571|Behavioral|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
79672809|NCT00443508|Drug|adding Certican to therapy|
79672810|NCT00443508|Drug|reducing Tacrolimus|
79672811|NCT00457262|Procedure|soy consumption|
79672812|NCT03278418|Procedure|Tricuspid Valve Repair|It will be performed according to the surgeon preference
79219321|NCT05673538|Drug|TT-00973-MS tablets treatment|The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
79219322|NCT03392636|Procedure|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
79219323|NCT03384758|Device|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
79219324|NCT02289300|Drug|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
79219325|NCT02289300|Drug|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
79362563|NCT00394888|Device|MRI of head and neck|MRI of head and C-spine
79672813|NCT03278418|Procedure|Left-sided valve surgery|It will be performed according to the surgeon preference
79672814|NCT00457340|Drug|Atorvastatin 80mg|
79672815|NCT03278379|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
79820782|NCT02570841|Drug|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
79820783|NCT02570841|Drug|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
79219326|NCT02289300|Drug|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
79219327|NCT02144649|Dietary Supplement|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
79219328|NCT02144649|Dietary Supplement|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
79219329|NCT02144649|Other|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
79219330|NCT02144649|Other|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
79672816|NCT00457379|Behavioral|physical exercise|
79672817|NCT01240083|Device|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
79219331|NCT05297032|Dietary Supplement|Quercetin Phytosome|All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
79219332|NCT03388580|Procedure|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
79219333|NCT03525912|Drug|Ketamine|continuous infusion of low dose ketamine for postoperative pain
79219334|NCT03388502|Other|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
79219335|NCT03388502|Other|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education & teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
79219336|NCT02289378|Drug|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
79219337|NCT03392558|Other|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
79219338|NCT03392558|Other|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
79219339|NCT03851614|Biological|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
79219340|NCT03851614|Drug|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
79219341|NCT03851614|Drug|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
79219342|NCT03133416|Other|PRP preparation|
79219343|NCT03133416|Device|Physiotherapy|
79219344|NCT03133416|Other|PRP and physiotherapy|
79672818|NCT01240083|Device|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
79672819|NCT01240083|Device|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
79820784|NCT05079009|Device|ECCO2R pulsatile configuration|Use of the pulsatile extracorporeal blood flow configuration.
79362564|NCT00394888|Other|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
79362565|NCT00394888|Other|Cardiac examination|Complete cardiac examination
79362566|NCT00394888|Device|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
79362567|NCT01458171|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
79362568|NCT00395044|Drug|Placebo|Placebo
79362569|NCT00395044|Drug|Gabapentin|
79672820|NCT02956538|Drug|Thalidomide|
79513567|NCT04046614|Drug|nintedanib-nivolumab combination therapy|"Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease."
79513568|NCT04040452|Drug|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
79513569|NCT04038359|Drug|Duvelisib|PI3K Inhibitor
79513570|NCT04029142|Diagnostic Test|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
79513571|NCT04024761|Biological|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
79513572|NCT04024761|Drug|Fludarabine|Fludarabine is a chemotherapy agent
79672821|NCT02956538|Drug|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
79672822|NCT01240161|Drug|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
79672823|NCT00457496|Behavioral|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
79672824|NCT00443586|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
79672825|NCT00443586|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
79672826|NCT00443586|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
79219345|NCT03521622|Behavioral|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
79219346|NCT04565600|Drug|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
79679756|NCT04690647|Other|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
79219347|NCT04486898|Other|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
79219348|NCT03523182|Dietary Supplement|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
79219349|NCT03523182|Dietary Supplement|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
79362570|NCT01457703|Drug|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
79362571|NCT01457703|Drug|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
79362572|NCT01457703|Drug|Recombinant LH|Used to stimulate ovarian function in women.
79219350|NCT04435808|Drug|Hydroxychloroquine|"Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily"
79362573|NCT01457703|Drug|Letrozole|An aromatase inhibitor.
79513573|NCT04024761|Drug|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
79513574|NCT04017533|Procedure|GMK Sphere TKR|Se earlier
79513575|NCT04014335|Drug|IONIS-FB-LRx|Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
79513576|NCT04013542|Biological|Ipilimumab|Given IV
79513577|NCT04013542|Biological|Nivolumab|Given IV
79513578|NCT04013542|Radiation|Radiation Therapy|Undergo radiation therapy
79513579|NCT04000321|Other|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
79820785|NCT03534531|Procedure|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
79219351|NCT03133338|Device|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
79219352|NCT04674748|Drug|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
79219353|NCT02290080|Drug|Oxygen|see arm description
79219354|NCT03388424|Diagnostic Test|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
79219355|NCT02289612|Other|Yellow Mustard Gum Fibre|
79219356|NCT02289612|Other|Soluble Flaxseed Gum Fibre|
79219357|NCT02289612|Other|Fenugreek Gum Fibre|
79219358|NCT05646004|Device|Cataract surgery|Implantation of 621 lens
79362574|NCT04445428|Biological|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
79362575|NCT04445428|Behavioral|Information|Advice regarding how to protect oneself from COVID-19
79362576|NCT00356434|Device|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
79362577|NCT00356434|Device|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
79362578|NCT01419015|Device|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
79362579|NCT00357214|Dietary Supplement|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
79219359|NCT03521544|Other|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
79362580|NCT00357214|Dietary Supplement|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
79513580|NCT04000321|Other|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
79219360|NCT03388112|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5*10^7CFU for 2 weeks
79513581|NCT03992352|Diagnostic Test|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
79513582|NCT03984357|Drug|PD-1 blocking antibody|"Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
79513583|NCT03984357|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
79219361|NCT05631730|Drug|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
79219362|NCT05631730|Drug|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
79219363|NCT03521388|Behavioral|Take care of your mood (CUIDA TU ANIMO in Spanish)|The adolescents will be registered in the Website www.cuidatuanimo.org
79219364|NCT03521388|Other|Control|The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
79362581|NCT00357214|Dietary Supplement|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
79219365|NCT00092144|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
79362582|NCT00357214|Dietary Supplement|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
79513584|NCT03984357|Drug|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
79513585|NCT03984357|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
79513586|NCT03964389|Other|"Pain Neuroscience Education (PNE)"|A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
79219366|NCT00092144|Drug|Comparator: placebo / Duration of Treatment: 4 weeks|
79219367|NCT02289768|Drug|5-fluorouracil/salicylic acid|
79219368|NCT02289768|Drug|Vehicle|
79219369|NCT03125876|Drug|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
79219370|NCT03712514|Other|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
79513587|NCT03955510|Other|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
79513588|NCT03955510|Other|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
79513589|NCT03955510|Procedure|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
79679757|NCT04690647|Drug|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
79219371|NCT03125954|Other|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
79219372|NCT03523026|Device|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
79219373|NCT03523026|Other|Inspirator Muscle Training|Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
79362583|NCT01418937|Biological|CervarixTM (GSK580299)|Three intramuscular injections
79219374|NCT03523026|Other|Peripheral Muscle Training|Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
79362584|NCT02076321|Drug|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
79513590|NCT03955510|Procedure|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
79219375|NCT04330430|Drug|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
79513591|NCT03955510|Other|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
79513592|NCT03931005|Other|Collaboration Decision Support Guide|Electronic toolkit intended to help organizational leaders select partners and negotiate partnerships for implementation. This will contain: 1) a brief summary of collaboration approaches associated with implementation, 2) detailed descriptions of collaboration strategies, 3) a decision analysis tool that guides the selection of collaborative strategies given the community context, and 4) sample contract or agreement language that specifies the nature of the partnership and expectations.
79513593|NCT03931005|Other|General Collaboration Support|Electronic description of collaborative implementation strategies and their definitions.
79994231|NCT04640727|Procedure|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
79994232|NCT04640727|Procedure|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
79994233|NCT05682209|Drug|Octreotide Injection|100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
79994234|NCT05682209|Other|Sterile water|1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
79994235|NCT05258513|Dietary Supplement|Placebo Supplementation|8 weeks of placebo supplementation
79219376|NCT03387956|Drug|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
79219377|NCT03387956|Drug|dexamethasone|intravenous 8 mg dexamethasone (2ml).
79219378|NCT03817606|Device|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
79513594|NCT03917381|Biological|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles)
79219379|NCT03817606|Device|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
79219380|NCT02290158|Other|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
79219381|NCT04465656|Diagnostic Test|Serology test for COVID-19|"In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~ELISA test~Rapid Diagnostic tests (only if ELISA test is positive)"
79219382|NCT03384524|Drug|Bromocriptine 2.5 MG|Administered daily
79219383|NCT03384524|Drug|Metoprolol 25 MG|Administered daily
79219384|NCT03384524|Drug|Tamsulosin 0.4 MG|Administered daily
79219385|NCT03384524|Other|Placebo|Three pills, matching active drugs to be administered daily
79362585|NCT02076321|Drug|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
79362586|NCT01417377|Drug|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
79362587|NCT00358462|Drug|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
79513595|NCT03917381|Biological|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days
79679758|NCT00519311|Behavioral|Health Intervention Package|CHAP and Ask Diary
79994236|NCT05258513|Dietary Supplement|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
79362588|NCT00358462|Drug|Doxycycline|one 100mg capsule administered twice daily for seven days
79362589|NCT00396292|Drug|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
79994237|NCT04637841|Other|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
79219386|NCT05194228|Behavioral|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
79994238|NCT04637841|Other|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
79994239|NCT05682131|Drug|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
79994240|NCT05682131|Combination Product|Conventional chemotherapy|conventional chemotherapy
79219387|NCT03387800|Behavioral|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
79219388|NCT03387800|Behavioral|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
79513596|NCT03917381|Biological|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively
79513597|NCT03917381|Biological|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days
79672827|NCT00443586|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
79672828|NCT00457574|Drug|GMX1777|
79219389|NCT02294136|Behavioral|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
79362590|NCT00396292|Drug|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
79362591|NCT00397150|Behavioral|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
79362592|NCT01437267|Biological|Vi-CRM197 vaccine|
79513598|NCT03913845|Drug|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
79513599|NCT03913845|Drug|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
79513600|NCT03907969|Drug|AZD7648|Core: AZD7648 will be administered orally
79513601|NCT03907969|Drug|PLD|The starting dose of PLD is 40 mg/m^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
79672829|NCT00443625|Drug|SK3530|
79672830|NCT00457613|Drug|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
79672831|NCT00481026|Device|transcranial direct current stimulation (tDCS)|tDCS
79820786|NCT02570919|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
79672832|NCT00481026|Device|active tDCS|Active tDCS
79672833|NCT00457652|Drug|Rosuvastatin|7 day treatment rosuvastatin 20mg
79219390|NCT02294136|Behavioral|Educational Control|Attention Control
79219391|NCT04465578|Procedure|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
79219392|NCT04465578|Procedure|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
79362593|NCT01437267|Biological|Pneumococcal conjugate vaccine|
79362594|NCT01437267|Biological|Vi Polysaccharide (PS) vaccine|
79362595|NCT00397462|Device|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
79672834|NCT00443664|Device|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
79820787|NCT02570919|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
79820788|NCT04732416|Drug|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
79219393|NCT05599282|Drug|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
79362596|NCT01794052|Other|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~Treating patients as per a standard clinical guidelines~Giving health education to patients on lifestyle changes for better self-care~Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
79513602|NCT03900793|Drug|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for > 4 hours prior to dosing
79513603|NCT03900793|Drug|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
79513604|NCT03898180|Biological|Pembrolizumab|IV infusion
79513605|NCT03898180|Drug|Lenvatinib|oral capsule
79513606|NCT03898180|Drug|Placebo for lenvatinib|oral capsule
79820789|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
79994241|NCT03632577|Device|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
79219394|NCT05599282|Other|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
79362597|NCT01437111|Drug|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
79362598|NCT04767477|Other|Face-to-face rehabilitation|Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
79362599|NCT04767477|Other|Telerehabilitation|The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
79362600|NCT04065555|Drug|TAK-981|Intratumoral microdose injection by the CIVO device.
79994242|NCT03632577|Device|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
79219395|NCT02290236|Device|Pulseoximetry|Peripheral saturation will be recorded continuously
79219396|NCT03387644|Drug|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
79219397|NCT03387644|Drug|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
79362601|NCT04065555|Biological|Cetuximab|Intratumoral microdose injection by the CIVO device.
79513607|NCT03892993|Other|Decision Aid|Use decision aid
79994243|NCT04620993|Other|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
79994244|NCT04620993|Other|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
79219398|NCT02290002|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
79219399|NCT02290002|Other|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
79219400|NCT05172830|Device|Ovation Alto™ Abdominal Stent Graft System|Single occurrence permanent implantation of AAA device
79362602|NCT04065555|Biological|Avelumab|Intratumoral microdose injection by the CIVO device.
79362603|NCT04065555|Combination Product|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
79362604|NCT04065555|Combination Product|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
79362605|NCT00359944|Drug|AC-3933|5mg twice daily
79362606|NCT00359944|Drug|AC-3933|AC-3933, 20 mg twice daily
79362607|NCT00359944|Other|Sugar Pill|Sugar Pill twice daily
79362608|NCT00360724|Drug|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
79513608|NCT03892993|Other|Questionnaire Administration|Ancillary studies
79513609|NCT03878459|Drug|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
79513610|NCT03878459|Drug|Placebo|PATIENTS WILL RECEIVE PLACEBO
79513611|NCT03875638|Drug|Levetiracetam|Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
79513612|NCT03875638|Drug|Placebo oral capsule|The placebo is a capsule that is identical in appearance to the levetiracetam
79513613|NCT03866837|Dietary Supplement|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
79219401|NCT02294214|Device|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
79219402|NCT02294214|Device|Active ingredient|Transfluthrin (Active ingredient)
79219403|NCT02294214|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
79362609|NCT00398398|Drug|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
79513614|NCT03866837|Dietary Supplement|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
79219404|NCT03654092|Behavioral|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
79219405|NCT04132804|Behavioral|Tai Chi|Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
79513615|NCT03866837|Dietary Supplement|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg [(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg].
79219406|NCT02294292|Drug|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
79219407|NCT02294292|Drug|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
79219408|NCT02294292|Procedure|Endoscopic Variceal Ligation|
79362610|NCT00398476|Drug|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
79362611|NCT00398476|Drug|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
79362612|NCT01436643|Drug|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
79362613|NCT01436643|Drug|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
79362614|NCT01436643|Drug|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
79362615|NCT01436643|Drug|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
79362616|NCT00399880|Behavioral|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
79820790|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
79820791|NCT02586168|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
79513616|NCT03865498|Behavioral|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
79513617|NCT03865498|Behavioral|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
79513618|NCT03836079|Device|preCARDIA system|Intermittent occlusion of the SVC
79513622|NCT03809000|Radiation|Radiation Therapy|Radiation Therapy
79513623|NCT03809000|Drug|Enzalutamide|Anti-androgen
79820792|NCT02586168|Drug|Placebo|Placebo
79219409|NCT03387566|Drug|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
79219410|NCT03387488|Device|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
79219411|NCT02290314|Procedure|minimally invasive MID-line Lumbar Fusion (MIDLF)|
79513624|NCT03809000|Drug|Bicalutamide|Anti-androgen
79513625|NCT03809000|Drug|GnRH analog|Anti-androgen
79513626|NCT03801616|Device|Virtual Reality|Virtual Reality in controlling pain
79820793|NCT04079478|Other|AI|Artificial intellignece colonoscopy
79820794|NCT04081116|Other|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
79820795|NCT04081116|Other|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
79219412|NCT02290314|Procedure|Posterior lumbar interbody fusion (PLIF)|
79219413|NCT03391856|Drug|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
79362617|NCT04239196|Drug|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
79513627|NCT03778944|Procedure|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
79513628|NCT03778944|Procedure|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
79513629|NCT03778944|Procedure|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
79513630|NCT03764293|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
79513631|NCT03764293|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
79513632|NCT03764293|Drug|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
79820796|NCT04081116|Other|Preinclusion settings|Settings in use at start of study
79219414|NCT03391856|Other|supportive therapy|prophylactic platelet transfusion was given when platelet count <20000/ul
79219415|NCT03514758|Procedure|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
79219416|NCT04176614|Other|cereal-legume snack|cereal-legume biscuit
79362618|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
79362619|NCT01795378|Biological|donor natural killer cell infusion|"Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
79362620|NCT00361972|Drug|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
79362621|NCT00361972|Drug|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
79362622|NCT00362440|Drug|Leptin|
79362623|NCT00362440|Drug|Pioglitazone or metformin|
79362624|NCT00362440|Drug|Placebo|
79513633|NCT03761446|Behavioral|Bed rest|The participant will remain in bed rest for 10 complete days.
79513634|NCT03752307|Drug|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
79513635|NCT03752307|Drug|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
79219417|NCT04176614|Other|cereal snack|cereal biscuit
79219418|NCT01664494|Drug|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
79219419|NCT02290470|Drug|Olanzapine|"Drug: Olanzapine 10 mg oral~Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
79219420|NCT02290470|Drug|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
79362625|NCT00401518|Device|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
79513636|NCT03752307|Drug|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
79513637|NCT03737734|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79672835|NCT00457769|Drug|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
79672836|NCT00457769|Drug|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
79672837|NCT00481104|Drug|Tesofensine|
79219421|NCT03387410|Drug|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
79362626|NCT00401518|Device|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
79362627|NCT00401518|Device|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
79362628|NCT02109640|Drug|Targinact|Post-operative analgesia
79362629|NCT02109640|Drug|Oxycodone|Postoperative analgesia
79362630|NCT02109640|Procedure|Laparoscopic segmental colectomy|
79362631|NCT00401986|Device|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
79672838|NCT00457808|Drug|Rapamycin, sirolimus|
79672839|NCT00443742|Procedure|Validation|
79219422|NCT04314388|Other|Intervention: Outdoor Walking Rehabilitation Programme|Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.
79513638|NCT03714828|Drug|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
79219423|NCT04314388|Other|Control: The light Stretches Programme|Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
79219424|NCT05172518|Drug|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
79362632|NCT00365872|Biological|Dendritic Cell (DC) Injections|"DCs (10^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~One additional DC injection was given before surgery to assess DC migration~Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
79362633|NCT00365872|Procedure|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
79362634|NCT00365872|Procedure|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
79219425|NCT05172518|Drug|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
79219426|NCT05172518|Drug|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 ~8 cycles(For the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
79362635|NCT00366028|Behavioral|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
79362636|NCT00366028|Behavioral|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
79362637|NCT01454739|Drug|rFVIIIFc|Administered as specified in the treatment arm.
79362638|NCT00366106|Drug|bortezomib|Patients will be treated with bortezomib at 1.3mg/m^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
79362639|NCT00366106|Drug|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
79362640|NCT00366106|Drug|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m^2 on Day 4 every 28 days (cycle).
79513639|NCT03714828|Drug|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL withapproximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
79513640|NCT03714828|Drug|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
79513641|NCT03714828|Drug|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
79513642|NCT03703908|Drug|CCX140-B|Orally administered tablet
79513643|NCT03684694|Drug|Loncastuximab Tesirine|Intravenous (IV) infusion.
79513644|NCT03684694|Drug|Ibrutinib|Oral capsule.
79672840|NCT03278301|Device|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
79362641|NCT01794286|Other|Provider bulletins|
79672841|NCT00457925|Drug|GSK221149A|
79672842|NCT00481143|Drug|ICL670/Deferasirox|
79362642|NCT01794286|Other|Trigger alerts|
79362643|NCT03858868|Behavioral|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
79362644|NCT03858868|Behavioral|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
79362645|NCT00368290|Drug|Modafinil|300mg a day for 8 weeks
79362646|NCT00368290|Drug|placebo|placebo pills for 8 weeks
79994245|NCT04620993|Other|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
79219427|NCT05172518|Drug|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
79362647|NCT00368290|Behavioral|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
79513645|NCT03684460|Device|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
79513646|NCT03684460|Device|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
79513647|NCT03675620|Device|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
79513648|NCT03675620|Other|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
79513649|NCT03671018|Drug|Mosunetuzumab (IV)|Participants will receive intravenous (IV) mosunetuzumab.
79513650|NCT03671018|Drug|Mosunetuzumab (SC)|Participants will receive subcutaneous (SC) mosunetuzumab.
79513651|NCT03671018|Drug|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin.
79513652|NCT03671018|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed.
79513653|NCT03671018|Drug|Rituximab|Participants will receive IV rituximab.
79513654|NCT03665051|Procedure|Muscle Tissue Biopsy|A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
79672843|NCT00457964|Drug|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
79994246|NCT03708497|Drug|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
79994247|NCT03708497|Drug|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
79362648|NCT00369226|Drug|Bortezomib (Velcade)|Infusion for a total of 3 doses
79994248|NCT03708497|Drug|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
79994249|NCT02961218|Drug|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
79994250|NCT02961218|Drug|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
79994251|NCT02949947|Drug|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
79994252|NCT02949947|Dietary Supplement|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
79994253|NCT02949947|Behavioral|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
79994254|NCT03642392|Other|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
79994255|NCT05681975|Diagnostic Test|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
79994256|NCT03642314|Diagnostic Test|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
79994257|NCT03341507|Device|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
79219428|NCT02298270|Behavioral|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
79219429|NCT03724084|Drug|Cytarabine|Given IV
79219430|NCT03724084|Drug|Daunorubicin|Given IV
79219431|NCT03724084|Drug|Daunorubicin Hydrochloride|Given IV
79219432|NCT03724084|Drug|Pinometostat|Given IV
79362649|NCT00369226|Drug|Tacrolimus|Taken until Doctor determines it is not necessary any more
79362650|NCT00369226|Drug|Methotrexate|Infusion for a total of 4 doses
79362651|NCT00369226|Procedure|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
79362652|NCT01416441|Drug|Aripiprazole|Aripiprazole tablets orally once daily.
79362653|NCT01793194|Other|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
79820797|NCT00577863|Drug|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
79820798|NCT00724737|Procedure|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
79820799|NCT00724737|Procedure|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
79820800|NCT04019223|Diagnostic Test|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
79219433|NCT03621488|Other|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
79362654|NCT00406276|Drug|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
79513655|NCT03665051|Other|Maximal Oxygen Consumption (V02max)|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
79513656|NCT03655782|Behavioral|PATH neurotraining|Improve visual timing and sensitivity in the dorsal stream. The mTBI subject will sit 57 cm in front of a computer monitor. During the presentation, the bars in the 'fish-shaped' window in the center of the screen formed by a sinusoidal grating, move left or right very briefly. When the screen goes blank, the subject reports which way the center pattern moved by pushing the left or right arrow key. A brief tone is presented after incorrect responses. The program adaptively changes the contrast of the test pattern so that the subject detects motion at lowest contrast possible. A sequence of patterns in each training cycle that are designed to optimally activate magnocellular neurons are shown to the subject. There are two programs, the first measures the contrast needed to see one direction of movement, and the second program measures the contrast needed to see two directions of movement, requiring memory.
79513657|NCT03655782|Behavioral|Orientation Discrimination|The sham intervention will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key components of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
79672844|NCT01240395|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
79672845|NCT00458042|Drug|treprostinil sodium|
79219434|NCT03621488|Other|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
79672846|NCT00458081|Drug|Rimonabant|20 mg once per day + slightly reduced calorie diet
79820801|NCT04019223|Diagnostic Test|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
79219435|NCT03133182|Drug|Polypharmacy|Patients who are taking >=5 unique prescription drugs in the 3 months prior to surgery
79219436|NCT02290548|Device|high flow nasal cannula|High flow nasal cannula used in postextubation patients
79219437|NCT03387332|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
79362655|NCT00406276|Drug|Docetaxel|In combination with RAD001
79672847|NCT00458081|Drug|Placebo|placebo once per day + slightly reduced calorie diet
79362656|NCT01436253|Behavioral|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
79362657|NCT01436253|Drug|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
79994258|NCT03341507|Device|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
79219438|NCT02290626|Drug|Elmental diet|elemental diet is administered using PEG.
79219439|NCT02290626|Drug|Semi-solid diet|Semi-solid diet is administered using PEG.
79219440|NCT02294448|Drug|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
79219441|NCT04446572|Biological|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
79362658|NCT03854656|Other|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
79513658|NCT03655782|Behavioral|N-Back Working Memory Training|Participants are required to compare each item on a computer screen to the item that they saw n-items back in the sequence. The participant plays a simple game where they control the movement of an astronaut that needs to collect correct gems, avoid incorrect gems, and also obstacles, to succeed at the game. If the participants performs well then they can be advanced to the 2-back, 3-back, 4-back, etc where they make similar matches but to earlier items in the sequence. This gamified task consists of a color n-back with 6 colors (a new color every 3 seconds, requiring subjects respond to targets by tapping the screen and navigating the astronaut to the targets, and avoiding the distractors) with 30% targets, and where the n-level will change every 2 minutes depending on performance (increase if performance is >85% and decrease if <75%). Sessions consist of 10 ~2 minute blocks, each with n-level as determined by the adaptive procedure and with user paced breaks between blocks.
79219442|NCT03384368|Device|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
79362659|NCT00408070|Drug|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
79513659|NCT03628209|Drug|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
79513660|NCT03628209|Drug|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m^2. Dose level 3: 75 mg/m^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
79513661|NCT03628209|Procedure|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
79513662|NCT03617328|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
79513663|NCT03617328|Drug|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
79513664|NCT03617328|Drug|polyICLC|polyICLC, local adjuvant
79820802|NCT04962789|Diagnostic Test|transvaginal ultrasound on the uterus|"Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer"
79513665|NCT03617328|Drug|CDX-1127|CDX-1127, anti-CD27 monoclonal antibody
79513666|NCT03617250|Other|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
79513667|NCT03617185|Other|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
79219443|NCT05661292|Diagnostic Test|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
79219444|NCT05661292|Diagnostic Test|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
79219445|NCT05661292|Biological|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
79219446|NCT02294526|Other|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
79362660|NCT00408070|Drug|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
79362661|NCT00408070|Drug|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
79362662|NCT00408460|Drug|imatinib mesylate|Given PO
79362663|NCT00408460|Drug|paclitaxel|Given IV
79994259|NCT05216744|Drug|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
79362664|NCT02111200|Drug|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
79362665|NCT02111200|Drug|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
79513668|NCT03617185|Other|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
79513669|NCT03617185|Procedure|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
79513670|NCT03577522|Device|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
79820803|NCT04956627|Drug|BMS-986166|Specified dose on specified days
79820804|NCT04956627|Drug|Itraconazole|Specified dose on specified days
79820805|NCT04956627|Drug|Extended Phenytoin Sodium|Specified dose on specified days
79820806|NCT04956627|Drug|Gemfibrozil|Specified dose on specified days
79820807|NCT00920088|Drug|darunavir/ritonavir|DRV/RTV 600/100mg
79820808|NCT00920088|Drug|lopinavir/ritonavir|LPV/RTV 400/100mg
79513671|NCT03577522|Device|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
79513672|NCT03554473|Drug|M7824|Arm A &amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
79513673|NCT03554473|Drug|Topotecan|Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.
79513674|NCT03554473|Drug|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
79513675|NCT03550092|Behavioral|Abstract Semantic Association Network Training (AbSANT)|In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
79219447|NCT05172440|Drug|tislelizumab combined with axitinib|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
79219448|NCT02290860|Procedure|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
79219449|NCT02298426|Behavioral|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
79362666|NCT02111746|Drug|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
79362667|NCT02111746|Drug|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
79513676|NCT03513107|Other|ospeoporosis score|"Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass & Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein & Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
79513677|NCT03494946|Procedure|Liver transplantation|
79513678|NCT03494946|Drug|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
79513679|NCT03484507|Drug|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
79513680|NCT03484507|Drug|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
79513681|NCT03484507|Drug|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
79672848|NCT00458120|Biological|rDEN1delta30|Live attenuated 10^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
79219450|NCT02298426|Behavioral|General Management|We provide general information about health. Information is provided through telephones and materials.
79362668|NCT02111746|Drug|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
79362669|NCT02111980|Device|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
79513682|NCT03484507|Drug|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
79513683|NCT03484507|Drug|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
79513684|NCT03484507|Drug|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
79513685|NCT03474588|Behavioral|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
79513686|NCT03474588|Behavioral|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
79513687|NCT03457142|Biological|Abatacept|Given IV and SC
79513688|NCT03457142|Drug|Dexamethasone|Given PO
79513689|NCT03457142|Drug|Ixazomib Citrate|Given PO
79513690|NCT03457142|Other|Laboratory Biomarker Analysis|Correlative studies
79513691|NCT03448393|Biological|CD19/CD22 CAR T-Cells|CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.
79513692|NCT03448393|Drug|Fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
79513693|NCT03448393|Drug|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
79672849|NCT00458120|Biological|rDEN2/4delta30(ME)|Live attenuated 10^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
79672850|NCT00458120|Biological|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
79672851|NCT00481182|Drug|fosamprenavir + ritonavir + methadone|
79820809|NCT00920088|Drug|Midazolam|Midazolam 3mg
79513694|NCT03445988|Behavioral|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
79513695|NCT03445988|Behavioral|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
79513696|NCT03445988|Other|Usual Care|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
79219451|NCT02298426|Other|Placebo|We use placebo to replace the health product.
79362670|NCT01793272|Other|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
79362671|NCT00369928|Drug|PG-760564|100 mg BID, of oral PG-760564
79362672|NCT00369928|Drug|Placebo dose|placebo, BID, oral for 12 weeks
79513697|NCT03436368|Procedure|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
79513698|NCT03436368|Procedure|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
79513699|NCT03396315|Drug|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
79820810|NCT00920088|Drug|Dextromethorphan|Dextromethorphan 30mg
79820811|NCT00920088|Drug|Flurbiprofen|Flurbiprofen 50mg
79513700|NCT03396315|Drug|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
79513701|NCT03394066|Device|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
79513702|NCT03389347|Procedure|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
79219452|NCT02298426|Dietary Supplement|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
79219453|NCT02298582|Drug|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
79219454|NCT02298660|Drug|BOTOX|"BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
79219455|NCT04446806|Drug|Ruxolitinib|Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore
79362673|NCT00369928|Drug|PG-760564|25 mg BID, of oral PG-760564
79513703|NCT03389347|Device|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
79513704|NCT03389347|Other|Laboratory Biomarker Analysis|Correlative studies
79820812|NCT00920088|Drug|GSK2248761|NNRTI under investigation
79820813|NCT02570685|Behavioral|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
79820814|NCT02570685|Behavioral|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
79362674|NCT03650920|Procedure|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
79362675|NCT00409240|Other|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
79362676|NCT02110108|Device|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
79362677|NCT05287750|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
79219456|NCT05575414|Behavioral|Didactic dietary sessions|Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
79219457|NCT05575414|Behavioral|Education Tool|The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
79672852|NCT00458159|Drug|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, & 50mg, taken once daily, orally.
79820815|NCT02570685|Behavioral|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
79219458|NCT03387254|Device|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
79219459|NCT03387254|Device|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
79219460|NCT03517878|Behavioral|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
79219461|NCT03387176|Other|Implementation of a gluten-free diet|Patients will be placed on gluten free diet for 9-12 months.
79219462|NCT03384290|Drug|PRS-060|Drug
79219463|NCT03384290|Drug|Placebo|PRS-060 Matching Placebo
79219464|NCT02290938|Behavioral|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
79219465|NCT02290938|Other|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
79219466|NCT03571334|Drug|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
79219467|NCT03571334|Drug|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
79219468|NCT02291094|Drug|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
79219469|NCT02291094|Drug|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
79219470|NCT03384056|Device|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
79219471|NCT03384056|Device|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
79219472|NCT03387098|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
79219473|NCT03387098|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79219474|NCT03387098|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79219475|NCT03387098|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79219476|NCT03387098|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
79219477|NCT03387098|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
79219478|NCT03387098|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
79672853|NCT00443937|Drug|enteric-coated mycophenolate sodium|oral
79672854|NCT00443937|Drug|everolimus|oral
79219479|NCT03387098|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79672855|NCT00455780|Behavioral|Weight Loss Phase|Weight loss using CBT and meal replacements
79672856|NCT00455780|Behavioral|Continued CBT|Using CBT during weight loss maintenance
79672857|NCT00455780|Behavioral|reduced energy density education|Additional nutritional learning
79672858|NCT00455780|Behavioral|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
79820816|NCT04018833|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
79820817|NCT04018833|Drug|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
79513705|NCT03377361|Biological|Nivolumab|Specified dose on specified days
79513706|NCT03377361|Drug|Trametinib|Specified dose on specified days
79513707|NCT03377361|Biological|Ipilimumab|Specified dose on specified days
79513708|NCT03377361|Drug|Regorafenib|Specified dose on specified days
79513709|NCT03345420|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79513710|NCT03340519|Device|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
79513711|NCT03338205|Drug|Ketamine|1 mg/kg ketamine bolus IV
79513712|NCT03337399|Other|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
79820818|NCT04066803|Drug|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
79994260|NCT05216744|Drug|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
79219480|NCT03387098|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79362678|NCT05287438|Diagnostic Test|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
79362679|NCT05287438|Diagnostic Test|Standard Culture|Standard of care culture and sensitivity
79513713|NCT03337399|Other|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
79513714|NCT03333616|Drug|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
79219481|NCT03387098|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79820819|NCT04066803|Drug|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
79219482|NCT03387098|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79820820|NCT04066803|Drug|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
79820821|NCT02570373|Drug|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
79219483|NCT03387098|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
79219484|NCT03387098|Drug|lovaza|Omega-3-acid ethyl esters
79362680|NCT00410488|Drug|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
79362681|NCT00410488|Drug|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
79362682|NCT00410488|Drug|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
79362683|NCT00410488|Drug|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
79362684|NCT00410488|Drug|Zinecard|750 mg/m2 as an IV bolus.
79362685|NCT00410488|Drug|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
79362686|NCT00410488|Drug|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
79513715|NCT03333616|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
79513716|NCT03310879|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
79513717|NCT03283761|Drug|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
79513718|NCT03283761|Drug|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
79513719|NCT03283761|Drug|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
79513720|NCT03283761|Drug|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
79513721|NCT03258723|Behavioral|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
79513722|NCT03258723|Drug|Metformin|At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
79513723|NCT03230916|Drug|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
79219485|NCT03387098|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79362687|NCT00410488|Drug|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
79672859|NCT00458198|Behavioral|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
79672860|NCT00487929|Device|nasal CPAP|Nocturnal
79672861|NCT00487929|Device|Sham CPAP|Nocturnal
79513724|NCT03230435|Other|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
79672862|NCT00458315|Drug|Cisplatin|
79672863|NCT00458315|Drug|Paclitaxel|
79672864|NCT00458315|Drug|Gemcitabine|
79820822|NCT02569827|Drug|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
79820823|NCT02569827|Drug|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
79820824|NCT02569827|Drug|Placebo|Placebo Q6H for 5 days
79219486|NCT03387098|Procedure|SBRT|Stereotactic Body Radiation Therapy
79219487|NCT02298972|Behavioral|Nurse support and selfmanagement intervention|
79219488|NCT02577016|Drug|Sitagliptin|50 mg tablet administered orally
79219489|NCT02577016|Drug|Placebo|Placebo to sitagliptin administered orally
79219490|NCT02577016|Drug|Ipragliflozin|50 mg tablet administered orally as background medication
79219491|NCT03520010|Behavioral|Externally-facilitated implementation|NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.
79362688|NCT01794598|Behavioral|Receiving educational material of depression care|The educational material provides patients about depression management
79362689|NCT00412516|Biological|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
79820825|NCT02569827|Drug|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
79994261|NCT05681897|Procedure|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
79994262|NCT03641222|Device|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
79219492|NCT03520010|Behavioral|Internally-driven implementation|Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
79219493|NCT04465110|Dietary Supplement|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
79219494|NCT03391700|Drug|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
79362690|NCT01793350|Drug|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
79362691|NCT03303898|Procedure|Blood sampling|sampling of 7 blood tubes
79362692|NCT01794676|Genetic|Blood draw|Blood draw
79362693|NCT05286970|Drug|AK115|Abdominal subcutaneous injection
79513725|NCT03211663|Device|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
79513726|NCT03203239|Device|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
79513727|NCT03203239|Drug|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
79672865|NCT00458315|Drug|Avastin (Bevacizumab)|
79672866|NCT00458354|Device|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
79219495|NCT03391700|Drug|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
79219496|NCT02294760|Device|Subsensory|The stimulation is set to 90% of the sensory threshold.
79362694|NCT05286970|Drug|Placebo|Abdominal subcutaneous injection
79362695|NCT00414700|Drug|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
79362696|NCT00414700|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
79672867|NCT00458354|Procedure|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
79672868|NCT00444015|Drug|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
79672869|NCT00444054|Behavioral|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
79672870|NCT00458471|Device|Insertion of a urinary catheter coated with benign E. coli|
79219497|NCT02294760|Device|OFF|The stimulation is turned OFF.
79219498|NCT02294838|Device|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
79820826|NCT05648565|Device|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
79820827|NCT03907761|Procedure|Hydrodissection|high velocity stream of normal saline is given to the dissection area by help of 10 ml syringe
79219499|NCT02294838|Other|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
79219500|NCT02294838|Other|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
79219501|NCT03391544|Procedure|V4c toric ICL implantation surgery|The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
79219502|NCT03383822|Drug|Intranasal insulin|Humalog lispro 40 IU intranasally
79362697|NCT00415870|Behavioral|Printed Material|Printed Material
79820828|NCT00725439|Drug|Talarozole|Oral Dose 1.0 mg once daily
79219503|NCT03383822|Drug|Intranasal placebo|Diluent intranasally
79219504|NCT02294916|Device|AWS|Video-laryngoscopy 1
79219505|NCT02294916|Device|Intubrite|Video-laryngoscopy 2
79219506|NCT02294916|Device|AirTraq|Optical-laryngoscopy
79219507|NCT02294916|Device|MIL|Direct-laryngoscopy
79362698|NCT00415870|Behavioral|Weekly Weighing|Weekly Weighing
79362699|NCT00415870|Behavioral|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
79362700|NCT00415870|Device|Text Message|Text Message
79362701|NCT00415870|Behavioral|Diet Goals via Cell Phone|Diet Goals via Cell Phone
79672871|NCT00487968|Drug|eltrombopag|
79672872|NCT00458510|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
79672873|NCT00488007|Device|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
79672874|NCT00458549|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
79672875|NCT00458549|Procedure|biopsy|
79672876|NCT00458588|Other|physiologic testing|
79820829|NCT00920166|Dietary Supplement|Pétunia 1|Infant formula used for non breastfed children
79219508|NCT05101252|Device|senofilcon A C3|TEST Lens
79219509|NCT05101252|Device|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
79219510|NCT03391310|Other|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
79219511|NCT02291172|Behavioral|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
79219512|NCT03514524|Other|PET-MR imaging|Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
79219513|NCT03514446|Drug|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
79219514|NCT03386786|Behavioral|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
79219515|NCT03386786|Behavioral|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
79219516|NCT03383744|Dietary Supplement|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
79362702|NCT00415870|Behavioral|Food Monitoring|Food Monitoring
79362703|NCT01795612|Other|physical activity|
79362704|NCT00416182|Drug|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
79362705|NCT00416182|Drug|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
79362706|NCT00416494|Biological|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
79362707|NCT00416494|Drug|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
79362708|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
79362709|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
79362710|NCT02616172|Genetic|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
79362711|NCT02463760|Other|Medical imaging|
79362712|NCT02460484|Biological|Autologous Cord Blood Infusion|Intravenous infusion
79672877|NCT00458588|Other|questionnaire administration|
79672878|NCT00458588|Procedure|breast imaging study|
79672879|NCT00458588|Procedure|dual x-ray absorptometry|
79672880|NCT00458588|Procedure|evaluation of cancer risk factors|
79672881|NCT00458588|Procedure|magnetic resonance imaging|
79820830|NCT00920166|Dietary Supplement|Regular formula|Infant formula used for non breastfed children
79820831|NCT02570217|Device|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
79513728|NCT03194789|Device|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
79994263|NCT01345058|Drug|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~Week 1: 50 mg twice a day~Beginning Week 2: 100 mg twice a day."
79362713|NCT00416572|Behavioral|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
79513729|NCT03194789|Other|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
79513730|NCT03194672|Behavioral|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
79513731|NCT03179176|Other|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
79219517|NCT02291250|Dietary Supplement|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
79219518|NCT02291250|Dietary Supplement|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
79994264|NCT01345058|Drug|levetiracetam|Low dose ≤1500 mg/day, High dose >1500 mg/day
79513732|NCT03173248|Drug|AG-120|Tablets administered orally
79513733|NCT03173248|Drug|Placebo|Tablets administered orally
79513734|NCT03173248|Drug|Azacitidine|Administered SC or IV
79513735|NCT03149822|Drug|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
79994265|NCT05393739|Device|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
79308401|NCT04848207|Other|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
79513736|NCT03149822|Drug|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
79513737|NCT03146156|Behavioral|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
79513738|NCT03139305|Drug|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
79513739|NCT03139305|Drug|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
79513740|NCT03139305|Drug|Placebo|Intravenous infusion of saline for 72 hours
79513741|NCT03114319|Drug|TNO155|TNO155 for oral administration
79513742|NCT03114319|Drug|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
79513743|NCT03093961|Device|IASD implant|Single arm for implant
79513744|NCT03093844|Device|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
79513745|NCT03084081|Device|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
79513746|NCT03084081|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
79513747|NCT03084081|Device|Thermocoagulator|Thermoablation
79219519|NCT02291250|Dietary Supplement|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
79513748|NCT03068130|Drug|Bardoxolone methyl|Capsules of Bardoxolone methyl
79513749|NCT03065062|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
79513750|NCT03065062|Drug|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
79513751|NCT03036098|Biological|Nivolumab|Specified Dose on Specified Days
79513752|NCT03036098|Biological|Ipilimumab|Specified Dose on Specified Days
79513753|NCT03036098|Drug|Gemcitabine|Specified Dose on Specified Days
79513754|NCT03036098|Drug|Cisplatin|Specified Dose on Specified Days
79513755|NCT03036098|Drug|Carboplatin|Specified Dose on Specified Days
79219520|NCT02291250|Dietary Supplement|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
79219521|NCT05662358|Drug|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
79219522|NCT05662358|Drug|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
79219523|NCT05662358|Drug|Placebo|oral placebo weekly
79219524|NCT02299128|Other|Physical Therapy Treatment|
79219525|NCT03383510|Other|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
79219526|NCT03383510|Other|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
79219527|NCT03383510|Other|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
79219528|NCT03383510|Other|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
79219529|NCT03517800|Other|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
79219530|NCT02291328|Other|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
79219531|NCT02291328|Other|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
79362714|NCT00416572|Behavioral|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
79362715|NCT00417274|Drug|Quinacrine|100 mg daily
79362716|NCT01793428|Other|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
79362717|NCT04749940|Other|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
79672882|NCT00488046|Biological|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
79513756|NCT03015129|Drug|Durvalumab|
79513757|NCT03015129|Drug|Tremelimumab|
79513758|NCT02989948|Device|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
79513759|NCT02965690|Procedure|Zimmer Biomet NexGen CR|Total Knee Replacement
79513760|NCT02965690|Procedure|Medacta International GMK Sphere|Total Knee Replacement
79672883|NCT00444132|Drug|clopidogrel|
79820832|NCT02570217|Device|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
79513761|NCT02962557|Device|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
79820833|NCT03205761|Drug|Olaparib|see information in arm description
79820834|NCT02584218|Procedure|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
79219532|NCT03391154|Drug|levothyroxin|90 female received levothroxine
79820835|NCT02584218|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
79219533|NCT03391076|Diagnostic Test|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
79219534|NCT02294994|Drug|tirofiban|
79219535|NCT03386630|Drug|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
79219536|NCT03386630|Drug|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
79219537|NCT03514290|Radiation|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
79219538|NCT03514290|Other|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
79219539|NCT03514290|Other|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
79219540|NCT03386552|Drug|Isifera+|Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
79219541|NCT03386552|Drug|Buffer|Pertubation solution of Ringer-Acetate buffer
79219542|NCT02291406|Procedure|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
79219543|NCT02291406|Procedure|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
79219544|NCT03383432|Device|Intrauterine device|Copper T 380 A
79219545|NCT03383432|Radiation|Ultrasound|Transabdominal ultrasound
79219546|NCT03383432|Procedure|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
79820836|NCT00725517|Drug|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
79820837|NCT00920751|Procedure|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
79820838|NCT00920751|Procedure|Air insufflation|Conventional air insufflation colonoscopy
79219547|NCT03132714|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
79362718|NCT01976962|Radiation|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
79362719|NCT05286346|Drug|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
79362720|NCT05286346|Drug|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
79513762|NCT02929810|Behavioral|sleep extension|
79513763|NCT02929810|Behavioral|sleep maintenance|
79219548|NCT03132714|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
79219549|NCT03132714|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
79219550|NCT03132714|Drug|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
79219551|NCT03132714|Procedure|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
79219552|NCT03132714|Procedure|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
79219553|NCT03386318|Drug|Oxycodone|Serum concentration per hour from 1 to 5 h
79219554|NCT03514212|Behavioral|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
79219555|NCT03339284|Drug|Dexamethasone sodium phosphate|Dexamethasone injection
79219556|NCT03339284|Drug|Ropivacaine Hydrocloride|Ropivacaine injection
79219557|NCT03339284|Drug|Sodium Chloride 9mg/mL|Sodium Chloride injection
79219558|NCT02295072|Behavioral|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
79219559|NCT03517644|Other|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
79308402|NCT02728895|Drug|Vedolizumab|Vedolizumab Injection.
79308403|NCT04848363|Procedure|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
79219560|NCT03517644|Other|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
79994266|NCT03642236|Drug|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
79994267|NCT03642158|Device|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
79994268|NCT05389215|Drug|DWN12088|DWN12088 Xmg Tablet (BID)
79219561|NCT03517644|Other|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
79219562|NCT03517644|Other|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
79219563|NCT03517644|Other|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
79219564|NCT02291484|Device|Cardiac CT scan|CT-guided management
79219565|NCT02291562|Drug|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
79219566|NCT02291562|Drug|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
79219567|NCT02291562|Drug|placebo|placebo (capsule, once) oral intake
79219568|NCT03514056|Diagnostic Test|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
79219569|NCT03514056|Diagnostic Test|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
79219570|NCT03316586|Drug|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
79219571|NCT03316586|Drug|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
79219572|NCT02291640|Device|MIL|direct laryngoscopy
79219573|NCT02291640|Device|CoPilot|video laryngoscopy
79219574|NCT03513978|Other|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
79219575|NCT03513978|Other|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
79219576|NCT03390920|Other|Umbilical Allograft|The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
79219577|NCT03383276|Drug|IL-1Ra|custom eye drop to be applied to the left eye.
79219578|NCT02295150|Drug|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
79219579|NCT03517410|Other|Smart phone use|Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
79219580|NCT03386084|Device|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
79219581|NCT03390608|Drug|Endocrine therapy|Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
79994269|NCT05389215|Drug|Placebo|Placebo 0mg Tablet (BID)
79994270|NCT01345292|Device|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
79994271|NCT01345292|Drug|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
79994272|NCT01345292|Drug|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
79994273|NCT03340961|Drug|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
79994274|NCT03340961|Drug|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
79219582|NCT03390608|Radiation|Radiotherapy|Radiotherapy versus no radiotherapy.
79219583|NCT03390608|Drug|Herceptin|Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
79219584|NCT03390608|Drug|Chemotherapy|Chemotherapy versus no chemotherapy.
79513764|NCT02924571|Device|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
79513765|NCT02924571|Device|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
79513766|NCT02924571|Procedure|Autograft|Autograft with bone marrow aspirate.
79513767|NCT02879448|Device|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
79513768|NCT02879448|Device|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
79513769|NCT02861794|Procedure|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
79513770|NCT02859337|Drug|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
79994275|NCT03340961|Drug|Oraycea® (doxycycline) Capsules|Oral Treatment
79994276|NCT03340961|Drug|Placebo Capsules|Oral Treatment
79994277|NCT04077879|Drug|ASP1617|Oral
79219585|NCT03390608|Procedure|Type of breast cancer surgery|Type of surgery (partial mastectomy, mastectomy, other).
79219586|NCT03390608|Other|Age at diagnosis|Age at diagnosis (<35, 35-<50, 50-<70, ≥70).
79362721|NCT05286268|Diagnostic Test|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
79362722|NCT00422032|Drug|Clofarabine|"Group A: 15 mg/m^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m^2 IV over 1 hour daily for 5 days"
79362723|NCT01856140|Biological|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
79362724|NCT01388920|Drug|Tesamorelin|
79362725|NCT01388920|Drug|Placebo|
79362726|NCT00422656|Drug|Perifosine|
79362727|NCT00422812|Drug|Inhaled Placebo|Inhaled Staccato Placebo
79513771|NCT02859337|Drug|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
79513772|NCT02817659|Drug|Glucagon|Glucagon infusion
79994278|NCT04077879|Drug|Placebo|Oral
79994279|NCT03340025|Device|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
79219587|NCT03390608|Other|Screen detected tumor|Screening detected tumor (yes, no).
79219588|NCT03390608|Other|Menopausal status at diagnosis|Menopausal status (premenopausal, postmenopausal).
79219589|NCT03390608|Other|Tumor size|Tumor size (≤5 mm, 6-≤10 mm).
79219590|NCT03390608|Other|Estrogen receptor (ER) status|ER-status (positive, negative).
79219591|NCT03390608|Other|Tumor grade|Tumor grade (1, 2, 3).
79362728|NCT00422812|Drug|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
79362729|NCT00422812|Drug|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
79362730|NCT00422812|Drug|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
79362731|NCT00423358|Dietary Supplement|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
79362732|NCT00423358|Dietary Supplement|placebo|matching placebo
79362733|NCT00423436|Behavioral|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
79362734|NCT00423436|Behavioral|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
79362735|NCT00423436|Behavioral|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
79513773|NCT02812290|Procedure|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
79513774|NCT02769845|Drug|Hydroxyurea|drug to be administered
79513775|NCT02769845|Procedure|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
79513776|NCT02765256|Drug|Fluconazole|400mg orally once daily (Day 1-14)
79513777|NCT02765256|Drug|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
79219592|NCT03390608|Other|HER2-status|HER2-status (positive, negative).
79219593|NCT03390608|Other|Intrinsic subgroups of breast cancer|Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
79219594|NCT03390608|Other|Nodal status|N-status (N0, N1).
79219595|NCT02295228|Other|No intervention|There are no interventions. This is an observational trial.
79219596|NCT03521076|Device|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
79308404|NCT04847895|Drug|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
79362736|NCT00424840|Drug|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
79362737|NCT00424840|Drug|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
79362738|NCT00424840|Drug|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
79362739|NCT00424840|Drug|Carboplatin AUC 6|Carboplatin AUC6
79362740|NCT00424840|Drug|Bevacizumab|Bevacizumab 15 mg/kg
79362741|NCT00424840|Drug|Taxotere|Taxotere 70 + G-CSF
79362742|NCT00425386|Drug|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily"
79362743|NCT00425386|Drug|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
79513778|NCT02765256|Drug|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
79513779|NCT02765256|Drug|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
79513780|NCT02765256|Drug|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
79513781|NCT02765256|Drug|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
79513782|NCT02765256|Drug|Fluconazole placebo|Once daily
79994280|NCT03340025|Device|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
79219597|NCT05171582|Procedure|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
79513783|NCT02759744|Device|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
79513784|NCT02739087|Procedure|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
79219598|NCT05171582|Procedure|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
79219599|NCT02141373|Device|Glubran 2|
79362744|NCT00425386|Procedure|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
79219600|NCT02144727|Procedure|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
79513785|NCT02739087|Device|Magnetic resonance imaging|
79362745|NCT04345978|Behavioral|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
79362746|NCT01164202|Drug|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
79513786|NCT02737579|Procedure|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
79513787|NCT02717650|Other|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
79513788|NCT02717650|Other|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
79513789|NCT02717650|Other|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
79513790|NCT02657356|Drug|Placebo capsules|
79513791|NCT02657356|Drug|Bardoxolone methyl capsules|
79513792|NCT02622581|Other|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
79994281|NCT05283434|Drug|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
79219601|NCT02144727|Procedure|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
79219602|NCT03296696|Drug|AMG 596|Drug
79219603|NCT03296696|Drug|AMG 404|Drug
79219604|NCT03513822|Drug|Ketamine 10 MG/ML|Ketamine infusion 1mg/kg with electric syringe during 2 hours.
79513793|NCT02620826|Procedure|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
79513794|NCT02620826|Procedure|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
79513795|NCT02594124|Drug|nusinersen|Administered by intrathecal (IT) injection
79513796|NCT02576613|Other|MPP-S|> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
79513797|NCT02576613|Other|TAU|standard medical treatment without structured psychotherapeutic intervention
79513798|NCT02562235|Drug|Riociguat (Adempas, BAY63-2521)|For children with body-weight <50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
79994282|NCT05283434|Drug|Placebo|Sugar pill placebo
79994283|NCT03643874|Drug|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
79994284|NCT03643874|Drug|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
79994285|NCT03641144|Device|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
79994286|NCT03641144|Device|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
79994287|NCT03642002|Other|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
79219605|NCT03513822|Drug|Placebos|Sodium chloride infusion with the same rate, electric syringe during 2 hours.
79994288|NCT03642002|Other|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
79994289|NCT03642002|Other|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
79994290|NCT03642002|Behavioral|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
79994291|NCT03642002|Other|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
79219606|NCT03513822|Drug|Midazolam 1 MG/ML|Bolus of Midazolam 1mg before each perfusion.
79219607|NCT02990091|Drug|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
79362747|NCT01164202|Drug|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
79994292|NCT03339713|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp.
79994293|NCT03339713|Biological|Fluarix|Fluarix will be administered as intramuscular injection.
79994294|NCT03339713|Biological|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
79994295|NCT03641066|Device|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions [1] un-braced, [2] Active Ankle 329 Ankle Sleeve, [3] AS1Pro (a lace-up brace), [4] Eclipse 1 (single-upright brace), and [5] Eclipse 2 (double upright brace)
79219608|NCT02990091|Dietary Supplement|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
79219609|NCT02299284|Other|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
79994296|NCT03641768|Device|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
79219610|NCT03383120|Device|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
79219611|NCT03383120|Procedure|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
79219612|NCT03545451|Device|Videogames|Videogames
79219613|NCT03175328|Procedure|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
79308128|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
79362748|NCT01164202|Procedure|transarterial chemoembolization|Chimioembolisation
79362749|NCT01794910|Other|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
79513799|NCT02556762|Radiation|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
79513800|NCT02556762|Radiation|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
79513801|NCT02556762|Drug|PF|Chemotherapy: Cisplatin and 5fluorouracil
79513802|NCT02542683|Other|structured physical activity program|a structured modest physical activity program
79994297|NCT03641768|Device|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
79679759|NCT02938845|Behavioral|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
79820839|NCT04620291|Biological|UB-421 SC|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
79994298|NCT03641768|Device|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
79994299|NCT03641768|Device|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
79994300|NCT03254485|Drug|IW-1973|Oral Tablet
79994301|NCT03254485|Drug|Placebo Oral Tablet|Oral Tablet
79994302|NCT03621176|Other|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
79994303|NCT03641612|Other|one shape|canal fluid sample before and after root canal instrumentation
79219614|NCT03544437|Procedure|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
79219615|NCT02144805|Procedure|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
79219616|NCT02144805|Procedure|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
79362750|NCT05281588|Procedure|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
79362751|NCT02112370|Drug|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
79362752|NCT02112370|Other|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
79362753|NCT02112838|Drug|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
79362754|NCT02112838|Drug|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
79362755|NCT02112838|Drug|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
79994304|NCT03641612|Other|protaper next|canal fluid sample before and after root canal instrumentation
79994305|NCT00769327|Drug|imatinib mesylate|
79219617|NCT00153036|Drug|rt-PA 0.9 mg/kg verum or placebo Intravenous|
79362756|NCT00427336|Drug|Fludarabine|30 mg/m^2 by vein daily over 30 minutes
79362757|NCT00427336|Drug|Cyclophosphamide|300 mg/m^2 by vein daily over 2 hours
79679760|NCT02938845|Procedure|total laparoscopic hysterectomy(TLH)|
79679761|NCT02938845|Procedure|total abdominal hysterectomy(TAH)|
79679762|NCT00519350|Procedure|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
79994306|NCT00769327|Drug|nilotinib|
79994307|NCT00769327|Genetic|cytogenetic analysis|
79994308|NCT00769327|Genetic|fluorescence in situ hybridization|
79994309|NCT00769327|Genetic|microarray analysis|
79362758|NCT00427336|Drug|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
79679763|NCT00519467|Drug|Chlorproguanil-dapsone-artesunate (CDA)|
79679764|NCT02940483|Drug|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
79679765|NCT04974684|Device|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
79679766|NCT04974684|Drug|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
79820840|NCT04434417|Device|2019-nCoV IgG/IgM Rapid Test Cassette|The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
79994310|NCT00769327|Genetic|mutation analysis|
79219618|NCT02915445|Biological|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
79219619|NCT02144883|Behavioral|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
79219620|NCT02144883|Behavioral|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
79219621|NCT02141529|Procedure|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
79362759|NCT00371176|Behavioral|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
79362760|NCT00371176|Drug|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
79362761|NCT00371176|Other|Placebo pill|
79362762|NCT00371644|Behavioral|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
79513803|NCT02532439|Device|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
79672884|NCT03274037|Diagnostic Test|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
79672885|NCT02956733|Procedure|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
79679767|NCT00520091|Drug|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
79679768|NCT00520091|Drug|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
79820841|NCT02586714|Other|No intervention|Observation only
79362763|NCT00371644|Behavioral|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
79362764|NCT00428584|Drug|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
79362765|NCT00428584|Drug|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
79362766|NCT00428974|Drug|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
79362767|NCT00428974|Drug|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
79362768|NCT00428974|Drug|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
79362769|NCT00428974|Drug|Placebo|Placebo tablets q12 hours for 12 weeks
79513804|NCT02532439|Device|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
79513805|NCT02532439|Device|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
79513806|NCT02502617|Dietary Supplement|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
79994311|NCT00769327|Genetic|polymerase chain reaction|
79994312|NCT00769327|Genetic|polymorphism analysis|
79994313|NCT00769327|Other|laboratory biomarker analysis|
79994314|NCT01068704|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
79362770|NCT05187286|Drug|Apixaban|Administered as directed by treating physician
79513807|NCT02500693|Biological|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
79513808|NCT02500407|Drug|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
79513809|NCT02500407|Drug|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
79672886|NCT02956733|Procedure|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
79672887|NCT00458744|Drug|talotrexin|
79820842|NCT02059551|Procedure|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
79994315|NCT01068704|Drug|Lapatinib|Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
79219622|NCT02141529|Procedure|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
79219623|NCT03513432|Dietary Supplement|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
79219624|NCT03513432|Dietary Supplement|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
79219625|NCT03513432|Dietary Supplement|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
79219626|NCT02145117|Behavioral|MBSR|Behavioral
79219627|NCT03513354|Other|Soil group|Exercises in soil.
79219628|NCT03513354|Other|Pool group|Exercises in pool.
79219629|NCT02299440|Other|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
79219630|NCT02299440|Drug|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
79362771|NCT00372970|Drug|Botulinum toxin A|200 U given by injection into the pylorus.
79362772|NCT00372970|Drug|Placebo|saline injection into pylorus.
79994316|NCT01068704|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
79219631|NCT02299440|Drug|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
79362773|NCT00373360|Drug|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
79362774|NCT00430768|Biological|rAAV1-CB-hAAT|
79362775|NCT00455650|Drug|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
79362776|NCT00455650|Drug|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
79513810|NCT02500407|Drug|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
79513811|NCT02498600|Biological|Ipilimumab|Given IV
79219632|NCT02299440|Other|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
79219633|NCT02299440|Drug|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
79219634|NCT02299440|Drug|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
79513812|NCT02498600|Biological|Nivolumab|Given IV
79672888|NCT00458744|Procedure|chemotherapy|
79219635|NCT02254395|Device|Deep Brain Stimulation|
79513813|NCT02489682|Other|Long-form written Informed consent information|
79362777|NCT00455650|Drug|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
79513814|NCT02489682|Other|Short-form written Informed consent information|
79513815|NCT02489682|Other|Video Informed consent information|
79513816|NCT02467270|Drug|Ponatinib|Tablet, taken orally once daily.
79513817|NCT02400944|Behavioral|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
79513818|NCT02400944|Other|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
79513819|NCT02370199|Device|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
79513820|NCT02370199|Drug|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
79513821|NCT02364115|Radiation|Stereotactic Body Radiotherapy|
79513822|NCT02320435|Drug|Pertuzumab|In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
79513823|NCT02320435|Drug|Trastuzumab|If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
79513824|NCT02320435|Drug|Other Combination Anti-Cancer Therapies|If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
79362778|NCT01794988|Behavioral|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
79513825|NCT02274805|Procedure|Adults presenting for surgery in the neck area|
79513826|NCT02215889|Procedure|Liver transplantation|
79362779|NCT01794988|Behavioral|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
79362780|NCT01794988|Behavioral|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
79362781|NCT01794988|Behavioral|NO TIVR|Control - no intervention
79362782|NCT02114164|Device|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
79513827|NCT02202772|Drug|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
79513828|NCT02202772|Drug|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
79513829|NCT02202772|Drug|Cisplatin|Intravesical installation of Cisplatin for 2hours
79513830|NCT02179359|Drug|Reduced Toxicity Ablative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan~Stem Cell Infusion Day 0"
79513831|NCT02179359|Drug|Reduced Intensity Preparative Regimen|"Alemtuzumab~Cyclophosphamide~Fludarabine~Total Body Irradiation (TBI)~Stem Cell Infusion Day 0"
79513832|NCT02179359|Drug|Myeloablative Preparative Regimen|"Alemtuzumab~Cyclophosphamide~Busulfan~Stem Cell Infusion Day 0"
79513833|NCT02022982|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
79513834|NCT02022982|Drug|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
79513835|NCT01981551|Drug|PF-03084014|Treatment with the selective small-molecule >=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
79219636|NCT02141763|Drug|UCB4940 40 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
79219637|NCT02141763|Drug|UCB4940 80 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
79219638|NCT02141763|Drug|UCB4940 160 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
79513836|NCT01979393|Drug|Cabozantinib|
79820843|NCT02585856|Device|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
79820844|NCT02585856|Device|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
79994317|NCT05179681|Other|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
79994318|NCT03339401|Other|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
79219639|NCT02141763|Drug|UCB4940 240 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
79362783|NCT02114164|Device|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
79219640|NCT02141763|Drug|UCB4940 320 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
79219641|NCT02141763|Drug|UCB4940 560 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
79219642|NCT02141763|Other|Placebo|"Pharmaceutical Form: solution~Concentration: 0.9 % sodium chloride~Route of Administration: intravenous"
79362784|NCT00374842|Biological|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
79362785|NCT00374842|Biological|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
79362786|NCT00431626|Drug|Dutasteride (Avodart)|
79362787|NCT00431626|Drug|Placebo|Placebo before and after treatment of TURP
79362788|NCT01796626|Device|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
79513837|NCT01979393|Drug|Placebo|
79513838|NCT01911091|Behavioral|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
79820845|NCT00794417|Drug|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
79820846|NCT00794417|Drug|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
79820847|NCT00794417|Drug|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
79820848|NCT04066101|Genetic|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
79994319|NCT03339401|Drug|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
79994320|NCT05179525|Drug|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
79513839|NCT01823562|Drug|lyophilized black raspberry confection|Given PO
79513840|NCT01823562|Other|laboratory biomarker analysis|Correlative studies
79513841|NCT01823562|Dietary Supplement|dietary intervention|Follow a low polyphenol diet
79994321|NCT05179525|Drug|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
79219643|NCT02295384|Other|Retrospective Audit|Retrospective Audit
79219644|NCT02145195|Dietary Supplement|Vitamin D3 (cholecalciferol)|
79219645|NCT03517020|Drug|Torrent's Nebivolol Tablets|
79219646|NCT03517020|Drug|Forest Pharmaceuticals Inc's Bystolic Tablets|
79362789|NCT00376558|Behavioral|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
79362790|NCT00455962|Drug|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
79362791|NCT00455962|Drug|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
79362792|NCT00434278|Drug|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
79362793|NCT00434278|Drug|placebo|2.5 mg inhalation dose twice daily for 14±2 days
79362794|NCT00434356|Drug|bevacizumab|Intravenous repeating dose
79219647|NCT02145273|Behavioral|Interpersonal Psychotherapy for Depression -Group|
79219648|NCT02295462|Other|Person-centered Care|Medication Review + Person-centered Care
79513842|NCT01823562|Dietary Supplement|dietary intervention|Follow a low ellagitannin diet
79513843|NCT01823562|Procedure|quality-of-life assessment|Ancillary studies
79513844|NCT01823562|Other|questionnaire administration|Ancillary studies
79362795|NCT00434356|Drug|sunitinib|Oral repeating dose
79672889|NCT00444171|Procedure|insulin infusion rate controled by computer algorithm|
79672890|NCT00444171|Procedure|insulin infusion rate guided by in-house glucose management protocol|
79672891|NCT00458900|Drug|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
79672892|NCT00488124|Drug|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
79219649|NCT02295462|Other|Optimised Treatment|Medication Review only
79219650|NCT03516864|Device|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
79672893|NCT00459017|Device|Portable blood pressure wrist manometer|
79672894|NCT00444210|Device|DL6049 (injectable poly-L-lactic acid)|
79672895|NCT03273959|Other|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
79672896|NCT00488163|Drug|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
79219651|NCT03516864|Device|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
79672897|NCT00459173|Drug|rimonabant (SR141716)|
79219652|NCT02254629|Drug|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
79219653|NCT02254629|Drug|Laxative Polyethylene Glycol|laxative：2000 ml.
79219654|NCT02145585|Device|Test of pharmacologic anesthesia robot (labVIEW® software)|
79219655|NCT02291796|Drug|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
79672898|NCT00444249|Procedure|White Alcon IOL|Implantation of white Alcon IOL
79672899|NCT00444249|Procedure|Yellow Alcon IOL|Implantation of yellow Alcon IOL
79672900|NCT00444249|Procedure|White Hoya IOL|Implantation of white Hoya IOL
79672901|NCT00444249|Procedure|Yellow Hoya IOL|Implantation of yellow Hoya IOL
79672902|NCT00459212|Drug|GTI-2040|Given IV
79672903|NCT00459212|Procedure|pharmacological study|Correlative study
79672904|NCT00459212|Procedure|laboratory biomarker analysis|Correlative study
79219656|NCT03544827|Drug|Atropine|Atropine 0.01% then atropine 0.1%
79219657|NCT03544827|Drug|Atropine|Atropine 0.1% then atropine 0.01%
79219658|NCT02295618|Device|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
79219659|NCT02295618|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
79362796|NCT00434356|Drug|paclitaxel|Intravenous repeating dose
79513845|NCT01796197|Drug|Trastuzumab|
79513846|NCT01796197|Drug|Pertuzumab|
79513847|NCT01796197|Drug|Paclitaxel|
79513848|NCT01796197|Drug|Doxorubicin|
79513849|NCT01796197|Drug|Cyclophosphamide|
79513850|NCT01796197|Procedure|Mastectomy|
79513851|NCT01796197|Radiation|Radiation Therapy|
79362797|NCT00376948|Dietary Supplement|genistein|
79362798|NCT00376948|Drug|erlotinib hydrochloride|
79362799|NCT00376948|Drug|gemcitabine hydrochloride|
79362800|NCT01795768|Drug|AZD 4547|
79362801|NCT01795924|Drug|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
79362802|NCT01796080|Other|Mueller manoeuvre|
79362803|NCT01796080|Other|Inspiratory threshold|
79362804|NCT01796080|Other|Expiratory apnoea|
79362805|NCT01796080|Other|Steady state normal breathing|
79362806|NCT00438100|Drug|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
79362807|NCT00438100|Drug|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
79362808|NCT00438490|Drug|Recombinant Human Prolactin|
79513852|NCT01793662|Procedure|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
79672905|NCT00459329|Behavioral|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
79219660|NCT00107991|Drug|etanercept|etanercept 50 mg/week subcutaneous injection
79362809|NCT00456508|Drug|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
79513853|NCT01772472|Drug|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
79513854|NCT01772472|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
79672906|NCT00459407|Dietary Supplement|defined green tea catechin extract|Given orally
79820849|NCT04066101|Other|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
79219661|NCT02299674|Other|Level overground ambulation|
79219662|NCT03513276|Drug|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
79219663|NCT03513276|Drug|Saline Solution|Multimodal analgesia + Saline solution
79219664|NCT03513276|Drug|Adrenaline 10mcg/ml|
79219665|NCT02299752|Procedure|single-gloving system|single-gloving system was used during Catheterization
79219666|NCT02299752|Procedure|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
79219667|NCT02291874|Drug|Ipragliflozin|oral
79219668|NCT02145819|Drug|hCG|
79219669|NCT02145819|Other|LH peak|
79219670|NCT02299830|Procedure|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
79219671|NCT02299830|Procedure|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
79219672|NCT02299830|Procedure|stent placement|use stent placement to open the airway compressed by out neoplasm
79219673|NCT02299830|Procedure|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
79219674|NCT03747705|Other|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
79219675|NCT02291952|Behavioral|Meal schedule|
79219676|NCT02145897|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
79362810|NCT02115646|Device|fractionated carbon dioxide laser|patients will have serial laser treatments
79362811|NCT00457366|Drug|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
79219677|NCT02145897|Biological|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
79219678|NCT02145897|Other|Control|
79362812|NCT00457366|Drug|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
79513855|NCT01703806|Procedure|Early Surgery|MItral valve surgery
79513856|NCT01703806|Procedure|Watchful Observation|Watchful observation
79513857|NCT01659606|Biological|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
79513858|NCT01659606|Drug|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
79513859|NCT01659606|Drug|Cyclosporins|
79513860|NCT01659606|Drug|Mycophenolate mofetil|
79219679|NCT03516630|Drug|Trazodone 20 mg|Oral drops
79219680|NCT03516630|Drug|Trazodone 60 mg|Oral drops
79219681|NCT03516630|Drug|Trazodone 140 mg|Oral drops
79219682|NCT03516630|Drug|Placebo|Oral drops
79219683|NCT03516630|Drug|Moxifloxacin 400mg|Tablet
79219684|NCT02142075|Drug|Daptomycin|
79219685|NCT03544749|Device|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
79219686|NCT03544749|Device|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
79219687|NCT02292030|Drug|HTEA|usually high thoracic epidural anesthesia
79362813|NCT00457366|Drug|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
79362814|NCT00457366|Drug|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
79362815|NCT00458848|Drug|asparaginase|
79362816|NCT00458848|Drug|daunorubicin hydrochloride|
79362817|NCT00458848|Drug|etoposide|
79362818|NCT00458848|Drug|idarubicin|
79362819|NCT00458848|Drug|imatinib mesylate|
79362820|NCT00458848|Drug|mercaptopurine|
79362821|NCT00458848|Drug|methotrexate|
79362822|NCT00458848|Drug|methylprednisolone|
79513861|NCT01659606|Drug|Tacrolimus|
79513862|NCT01643954|Procedure|robotic radical prostatectomy|robotic assisted surgery
79513863|NCT01542437|Drug|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."
79513864|NCT01525082|Drug|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
79513865|NCT01525082|Drug|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
79513866|NCT01525082|Biological|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 & 15
79513867|NCT01351103|Drug|LGK974|
79513868|NCT01351103|Biological|PDR001|
79513869|NCT01008787|Behavioral|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
79672907|NCT00459407|Drug|placebo|Given orally
79672908|NCT00459407|Other|immunohistochemistry staining method|Correlative studies
79219688|NCT02145975|Drug|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
79219689|NCT02145975|Drug|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
79219690|NCT02295696|Behavioral|EMMA|Consultations using dialogue tools
79219691|NCT02146053|Dietary Supplement|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
79219692|NCT02146053|Dietary Supplement|Placebo|placebo capsules: methyl cellulose
79219693|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
79219694|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
79219695|NCT02295930|Other|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
79219696|NCT02295930|Other|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
79219697|NCT02142231|Device|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
79362823|NCT00458848|Drug|mitoxantrone hydrochloride|
79513870|NCT01008787|Behavioral|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
79362824|NCT00458848|Drug|prednisone|
79362825|NCT00458848|Drug|vincristine sulfate|
79362826|NCT00458848|Procedure|allogeneic hematopoietic stem cell transplantation|
79362827|NCT00458848|Procedure|autologous hematopoietic stem cell transplantation|
79362828|NCT00458848|Procedure|peripheral blood stem cell transplantation|
79513871|NCT01008787|Behavioral|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
79513872|NCT01008787|Behavioral|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
79672909|NCT00459407|Other|immunoenzyme technique|Correlative studies
79672910|NCT00459407|Other|laboratory biomarker analysis|Correlative studies
79672911|NCT00459407|Procedure|biopsy|Undergo biopsy
79672912|NCT00459407|Other|mass spectrometry|Correlative studies
79672913|NCT00459407|Other|high performance liquid chromatography|Correlative studies
79820850|NCT01459107|Procedure|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
79219698|NCT02142231|Device|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
79362829|NCT00458848|Radiation|radiation therapy|
79362830|NCT00459862|Other|laboratory biomarker analysis|Correlative study
79362831|NCT00459862|Drug|pazopanib hydrochloride|Given orally
79362832|NCT00461734|Other|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
79362833|NCT00438802|Drug|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
79362834|NCT00377572|Biological|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
79513873|NCT00936936|Drug|Gemcitabine|1800 mg/m^2 IV over 3 hours on Days -5 to Day -2.
79513874|NCT00936936|Drug|Docetaxel|Docetaxel 300 mg/m^2 IV over 2 hours on Day -5.
79513875|NCT00936936|Drug|Melphalan|50 mg/m^2 IV over 15 minutes on Days -4 to Day -2.
79672914|NCT03278262|Drug|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
79219699|NCT02142309|Drug|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
79219700|NCT02142309|Drug|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) <45 mL/min
79362835|NCT00377572|Biological|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
79362836|NCT00438880|Drug|Agatolimod Sodium|Given IV
79362837|NCT00438880|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
79362838|NCT00438880|Other|Laboratory Biomarker Analysis|Correlative study
79362839|NCT00438880|Procedure|Radionuclide Imaging|Undergo imaging scans
79362840|NCT00438880|Biological|Rituximab|Given IV
79362841|NCT00438880|Procedure|Single Photon Emission Computed Tomography|Undergo imaging scans
79362842|NCT00438880|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
79362843|NCT00462124|Device|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
79362844|NCT00378352|Drug|Epoetin alfa|Randomized
79672915|NCT03273803|Diagnostic Test|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
79672916|NCT00488280|Behavioral|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
79219701|NCT02142309|Drug|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
79219702|NCT02142309|Drug|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
79362845|NCT00462280|Drug|lovastatin|Given PO
79362846|NCT00462280|Other|placebo|Given PO
79362847|NCT00462280|Procedure|biopsy|Correlative studies
79672917|NCT00459446|Drug|MS-325 Injection (Gadofosveset Trisodium)|
79679769|NCT00520091|Drug|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
79219703|NCT03516474|Device|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
79219704|NCT02146209|Drug|Metronidazole benzoate|Single oral dose of 400 mg
79219705|NCT02146209|Drug|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
79219706|NCT02146209|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
79219707|NCT02299908|Drug|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
79219708|NCT02299908|Drug|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
79219709|NCT02142543|Drug|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
79219710|NCT02142543|Drug|Placebo Comparator|
79362848|NCT00462280|Procedure|laboratory biomarker analysis|Correlative studies
79362849|NCT00381004|Drug|Cyclophosphamide|Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
79362850|NCT00381004|Drug|Fludarabine|Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
79362851|NCT00381004|Drug|Sargramostim|Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10
79362852|NCT00381004|Drug|Rituximab|Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1
79362853|NCT00440050|Drug|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
79362854|NCT00440050|Drug|Placebo|2 placebo capsules twice a day for 18 months
79362855|NCT00440596|Behavioral|Mindfulness based stress reduction|8 weeks group MBSR
79362856|NCT00440596|Behavioral|Progressive Muscle Relaxation|8 weeks PMR in group format
79362857|NCT00381550|Drug|fludarabine phosphate|Given IV
79362858|NCT00381550|Drug|triapine|Given IV
79362859|NCT00381550|Procedure|laboratory biomarker analysis|Correlative study
79362860|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
79362861|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
79362862|NCT00440830|Drug|placebo|placebo patch applied to smokers
79362863|NCT00440830|Drug|placebo|placebo patch applied to nonsmokers
79362864|NCT00464464|Behavioral|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
79362865|NCT00381628|Procedure|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
79362866|NCT00427804|Drug|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
79362867|NCT00381862|Drug|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
79362868|NCT00381862|Drug|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
79362869|NCT00381862|Drug|fluorouracil|as per institutional standard of care
79513876|NCT00936936|Drug|Carboplatin|"Cycle 1: 333 mg/m^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m^2 IV over 2 hours on Days -6 to -3."
79513877|NCT00936936|Drug|Mesna|3,000 mg/m^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
79994322|NCT05179291|Other|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
79994323|NCT05179291|Other|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
79362870|NCT00381862|Drug|irinotecan hydrochloride|as per institutional standard of care
79219711|NCT02299986|Other|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
79513878|NCT00936936|Drug|Ifosfamide|3,000 mg/m^2 IV over 6 hours on Days -6 to -3
79513879|NCT00936936|Drug|Etoposide|200 mg/m^2 IV over 3 hours, every 12 hours on Days -6 to -4.
79513880|NCT00936936|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
79513881|NCT00770809|Other|Laboratory Biomarker Analysis|Correlative studies
79513882|NCT00770809|Drug|Lapatinib Ditosylate|Given PO
79679770|NCT00520091|Radiation|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
79679771|NCT00520091|Procedure|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
79994324|NCT05692206|Other|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
79219712|NCT03749265|Other|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
79219713|NCT02142621|Other|transpyloric feeding|
79219714|NCT02142621|Other|gastric feeding|
79219715|NCT03120806|Procedure|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
79219716|NCT03120806|Procedure|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
79219717|NCT02142699|Drug|Heme arginate|
79219718|NCT03390452|Behavioral|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
79219719|NCT03390374|Drug|Nystatin Oral|Nystatin oral suspension
79219720|NCT03545373|Drug|Azithromycin|Azithromycin tablet taken orally
79219721|NCT03545373|Drug|Amoxicillin|Amoxicillin tablets taken orally
79219722|NCT00492856|Drug|mercaptopurine|Given orally
79219723|NCT00492856|Drug|methotrexate|Given orally
79219724|NCT00492856|Drug|tretinoin|Given orally
79219725|NCT02146287|Other|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
79219726|NCT05161910|Other|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
79219727|NCT05152550|Other|Non-severe pre-eclampsia|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
79513883|NCT00770809|Drug|Paclitaxel|Given IV
79513884|NCT00770809|Biological|Trastuzumab|Given IV
79513885|NCT00646022|Drug|[18F]-DOPA|
79219728|NCT03545295|Procedure|Quadratus Lumborum Block type 2|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
79219729|NCT03545295|Procedure|Quadratus Lumborum Block type 3|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
79219730|NCT04446026|Drug|teneligliptin|teneligliptin 20mg PO qd for 24weeks
79219731|NCT04446026|Drug|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
79219732|NCT03383042|Drug|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
79219733|NCT03383042|Drug|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
79219734|NCT03383042|Drug|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
79219735|NCT03383042|Drug|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
79362871|NCT00381862|Drug|leucovorin calcium|as per institutional standard of care
79362872|NCT00381862|Drug|oxaliplatin|as per institutional standard of care
79362873|NCT00381862|Drug|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
79362874|NCT00381862|Procedure|quality-of-life assessment|baseline
79362875|NCT00464698|Drug|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
79362876|NCT00465088|Drug|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
79362877|NCT00465088|Drug|atorvastatin|40 mg at bedtime
79513886|NCT00392353|Drug|Azacitidine|Given SC
79513887|NCT00392353|Other|Laboratory Biomarker Analysis|Correlative studies
79994325|NCT03370289|Biological|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
79994326|NCT01344824|Biological|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
79362878|NCT01796782|Drug|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
79362879|NCT01796782|Drug|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
79362880|NCT00441766|Drug|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
79362881|NCT00441766|Drug|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
79362882|NCT00441766|Drug|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
79362883|NCT00441766|Drug|placebo|Part A: placebo capsule every 12 hours for 4 weeks
79362884|NCT00466960|Biological|sargramostim|Given SC
79362885|NCT00466960|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
79994327|NCT01344824|Drug|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
79219736|NCT03383042|Drug|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
79513888|NCT00392353|Other|Pharmacological Study|Correlative studies
79513889|NCT00392353|Drug|Vorinostat|Given PO
79994328|NCT01344824|Drug|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
79219737|NCT03383042|Drug|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
79362886|NCT00466960|Other|laboratory biomarker analysis|Correlative studies
79362887|NCT00466960|Other|immunologic technique|Correlative studies
79362888|NCT00383266|Drug|Pemetrexed|
79362889|NCT00383266|Drug|Carboplatin|
79994329|NCT01344824|Drug|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
79994330|NCT04320511|Device|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
79219738|NCT03383042|Drug|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
79362890|NCT00384670|Biological|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
79513890|NCT00390325|Drug|Sorafenib Tosylate|Given PO
79513891|NCT00104676|Biological|bleomycin sulfate|At least one course administered
79513892|NCT00104676|Drug|cisplatin|At least one course administered
79513893|NCT00104676|Drug|etoposide|At least one course administered
79513894|NCT00104676|Drug|ifosfamide|Given in a dose-dense sequential fashion
79513895|NCT00104676|Drug|oxaliplatin|Given in a dose-dense sequential fashion
79513896|NCT00104676|Drug|paclitaxel|Given in a dose-dense sequential fashion
79513897|NCT00060541|Procedure|Laboratory tests|
79513898|NCT00060541|Procedure|Radiological exams|
79513899|NCT01335750|Other|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
79513900|NCT01335750|Other|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
79994331|NCT04292197|Drug|18-MC Compound|18-MC
79994332|NCT01311947|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
79994333|NCT05137496|Drug|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
79219739|NCT03383042|Drug|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
79219740|NCT03383042|Drug|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
79219741|NCT02142777|Drug|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
79362891|NCT00384670|Biological|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
79362892|NCT00467038|Behavioral|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
79362893|NCT00467350|Drug|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
79362894|NCT00467350|Drug|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
79362895|NCT00444028|Drug|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
79362896|NCT00444028|Drug|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
79362897|NCT00444028|Drug|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
79362898|NCT00444028|Drug|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
79362899|NCT00444028|Drug|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
79362900|NCT00444028|Drug|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
79362901|NCT00444964|Drug|Nutropin AQ|0.0125 mg/kg/day
79362902|NCT00445588|Drug|erlotinib hydrochloride|150mg Given orally once daily
79362903|NCT00445588|Drug|sorafenib tosylate|400mg Given orally twice daily
79362904|NCT00445588|Other|pharmacological study|Correlative studies
79362905|NCT00445744|Drug|cyclophosphamide|Given IV
79513901|NCT01335750|Other|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
79513902|NCT01335750|Other|Multipurpose Solution #4|Saline Solution
79513903|NCT01336296|Drug|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
79513904|NCT01337076|Device|cochlear implant|Cochlear implant surgery
79994334|NCT05137496|Drug|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
79994335|NCT03708185|Dietary Supplement|Beta-alanine|N/A: see arm description
79994336|NCT03708185|Dietary Supplement|Placebo|N/A: see arm description
79513905|NCT01337700|Drug|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
79513906|NCT01337700|Drug|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
79513907|NCT01339260|Drug|Netupitant and Palonosetron|
79513908|NCT01339260|Drug|Palonosetron|
79513909|NCT01339260|Drug|Dexamethasone|
79219742|NCT02142777|Drug|Placebo|The placebo has no active ingredients but is made to look like the study drug.
79219743|NCT02142855|Behavioral|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
79219744|NCT02142855|Behavioral|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
79219745|NCT03390218|Behavioral|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
79994337|NCT03640676|Device|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
79219746|NCT03390218|Behavioral|Treatment as usual|Individual and group therapy, generic in nature
79219747|NCT02146443|Other|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
79219748|NCT02146443|Other|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
79362906|NCT00445744|Drug|busulfan|Given IV
79362907|NCT00445744|Drug|tacrolimus|Given IV or PO
79362908|NCT00445744|Drug|methotrexate|Given IV
79362909|NCT00445744|Genetic|cytogenetic analysis|Correlative studies
79513910|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
79513911|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
79513912|NCT01341912|Biological|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
79513913|NCT01342458|Other|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
79513914|NCT01342770|Other|Laboratory Biomarker Analysis|Correlative studies
79513915|NCT01342770|Drug|Pioglitazone Hydrochloride|Given PO
79513916|NCT01342770|Other|Quality-of-Life Assessment|Ancillary studies
79994338|NCT03640598|Procedure|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
79994339|NCT03640598|Procedure|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
79219749|NCT02146443|Device|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
79219750|NCT02142933|Other|vagino-perineal swab|
79513917|NCT01343004|Drug|Placebo|Placebo 0 mcg subcutaneous daily
79513918|NCT01343004|Drug|BA058 80 mcg|BA058 80 mcg subcutaneous daily
79513919|NCT01343004|Drug|teriparatide|teriparatide 20 mcg subcutaneous daily
79513920|NCT01343160|Device|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
79513921|NCT01347060|Drug|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
79513922|NCT01347060|Drug|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
79994340|NCT03339245|Other|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
79362910|NCT00445744|Other|flow cytometry|Correlative studies
79362911|NCT00445744|Other|pharmacological study|Correlative studies
79362912|NCT00445744|Other|pharmacogenomic studies|Correlative studies
79362913|NCT00445744|Procedure|peripheral blood stem cell transplantation|Undergo PBPC transplantation
79362914|NCT00445744|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
79362915|NCT00468208|Drug|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~500 mg of abatacept for body weight less than 60 kg~750 mg of abatacept for body weight between 60 and 100 kg~1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
79513923|NCT01351740|Drug|atazanavir|switch to unboosted atazanavir 400 mg daily
79513924|NCT01351740|Drug|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
79994341|NCT03339245|Other|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
79994342|NCT03044574|Device|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
79513925|NCT01352286|Genetic|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
79219751|NCT02143011|Other|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
79513926|NCT01352442|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
79513927|NCT01352598|Radiation|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
79994343|NCT03044574|Device|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
79362916|NCT00384748|Behavioral|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
79994344|NCT03044574|Drug|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
79219752|NCT02143011|Other|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
79362917|NCT00384748|Behavioral|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
79362918|NCT00384748|Behavioral|Usual care|Routine VA care.
79362919|NCT00385138|Drug|Cangrelor|cangrelor bolus (30 mcg/kg) & cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
79362920|NCT00385138|Drug|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
79362921|NCT00385138|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
79362922|NCT00385138|Drug|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
79362923|NCT00385138|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
79362924|NCT00446290|Drug|Docetaxel, Capecitabine and Oxaliplatin|
79362925|NCT00385216|Drug|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
79362926|NCT00385216|Other|Placebo|Placebo nasal spray 0mg x 1 before surgery
79362927|NCT00385996|Drug|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
79679772|NCT05095623|Other|Natural History Observation|This is a natural history study.
79679773|NCT00520169|Drug|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
79679774|NCT00519506|Other|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
79994345|NCT02959892|Drug|Amphetamine|Amphetamine tablets.
79994346|NCT02959892|Drug|TAK -041|TAK-041 oral suspension.
79219753|NCT02143089|Device|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
79219754|NCT02143167|Drug|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
79219755|NCT02143167|Drug|Placebo|
79219756|NCT05150132|Device|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
79362928|NCT01796158|Behavioral|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
79513928|NCT01257438|Device|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
79513929|NCT01257438|Device|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
79513930|NCT01353144|Drug|aspirin|aspirin, 100 mg, qd x 8 weeks
79513931|NCT01355484|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
79219757|NCT05150132|Device|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
79513932|NCT01355484|Drug|placebo|subject will receive placebo for the duration of the trial
79513933|NCT01355796|Drug|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
79513934|NCT01355796|Drug|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
79219758|NCT05150132|Device|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
79513935|NCT01356498|Biological|pegloticase|8 mg intravenous infusion
79219759|NCT03544671|Dietary Supplement|Vitamin D|
79308405|NCT02502227|Behavioral|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
79513936|NCT01357356|Drug|SER120 (750 ng/day)|
79513937|NCT01357356|Drug|SER120 (1000 ng/day)|SER120 (1000 ng/day)
79513938|NCT01357356|Drug|SER120 (1500 ng/day)|
79362929|NCT01796158|Behavioral|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
79362930|NCT00470392|Drug|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
79362931|NCT00470392|Drug|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
79362932|NCT00470548|Drug|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
79513939|NCT01357356|Drug|Placebo|
79513940|NCT01357512|Device|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
79513941|NCT01362192|Device|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~Spot Size: 5 mm~Fluence: 13-15 J/cm2~Pulse Duration: 40 ms~Epidermal contact-cooling: 5° Celsius"
79513942|NCT01362894|Device|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
79513943|NCT01362894|Device|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
79513944|NCT01363050|Drug|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
79513945|NCT01363128|Drug|Cyclophosphamide|Given IV
79994347|NCT02959892|Drug|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|[11C]PHNO injection.
79362933|NCT00470548|Drug|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
79362934|NCT04388488|Device|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
79513946|NCT01363128|Drug|Cytarabine|Given IV
79513947|NCT01363128|Drug|Dexamethasone|Given IV or PO
79513948|NCT01363128|Drug|Doxorubicin Hydrochloride|Given IV
79513949|NCT01363128|Other|Laboratory Biomarker Analysis|Correlative studies
79513950|NCT01363128|Drug|Methotrexate|Given IV
79513951|NCT01363128|Biological|Ofatumumab|Given IV
79513952|NCT01363128|Drug|Vincristine Sulfate|Given IV
79513953|NCT01365624|Drug|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
79513954|NCT01367262|Drug|LY2886721|Administered orally
79513955|NCT01369758|Device|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
79513956|NCT01371786|Drug|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
79513957|NCT01371786|Drug|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
79513958|NCT01373580|Device|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
79513959|NCT01374438|Drug|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
79513960|NCT01374438|Drug|Placebo|Placebo capsules given once daily for 90 days
79513961|NCT01377636|Drug|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
79513962|NCT01378416|Drug|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m^2 of decitabine.
79513963|NCT01379664|Drug|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
79362935|NCT04388488|Device|Any conventional handmade socket|Subjects current socket
79362936|NCT00472576|Drug|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
79513964|NCT01379664|Drug|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
79513965|NCT01380366|Drug|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
79513966|NCT01380366|Procedure|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
79513967|NCT01380366|Procedure|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
79513968|NCT01380366|Other|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
79513969|NCT01380366|Other|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
79513970|NCT01380366|Other|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
79362937|NCT00472576|Drug|Placebo|Daily double-blind administration of placebo
79362938|NCT00388414|Drug|duloxetine|30-60mg of duloxetine daily
79362939|NCT00388414|Drug|Placebo|Placebo pill once daily
79362940|NCT00475150|Drug|cediranib maleate|Given orally
79362941|NCT00475150|Other|laboratory biomarker analysis|Correlative studies
79362942|NCT04388410|Biological|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
79362943|NCT00450424|Other|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
79362944|NCT00450424|Other|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
79513971|NCT01383720|Device|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
79513972|NCT01386528|Drug|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
79513973|NCT01387464|Drug|ISV-303|0.075% bromfenac in DuraSite dosed QD
79513974|NCT01387464|Drug|Bromday™|0.09% bromfenac dosed QD
79513975|NCT01388946|Drug|Ropivacaine 0.75|
79513976|NCT01388946|Drug|Normal saline|
79513977|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
79679775|NCT02938533|Behavioral|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
79219761|NCT03382964|Biological|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
79513978|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
79513979|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
79513980|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
79513981|NCT01391286|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
79513982|NCT01391286|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
79513983|NCT01391364|Device|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
79513984|NCT01391364|Device|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
79219762|NCT05081037|Device|Wearable Care Group|"Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels."
79362945|NCT00451048|Drug|sunitinib malate|Given orally
79362946|NCT00388804|Procedure|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
79513985|NCT01393392|Behavioral|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
79362947|NCT00388804|Drug|Bicalutamide|50 mg By Mouth (PO) Daily
79362948|NCT00388804|Drug|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
79362949|NCT00388804|Drug|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
79362950|NCT00388804|Drug|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
79513986|NCT01393392|Behavioral|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
79513987|NCT01393704|Drug|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
79513988|NCT01395966|Drug|DF289|Ear drops
79672918|NCT04698044|Diagnostic Test|Hospital Anxiety Depression Scale|HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
79362951|NCT00388804|Behavioral|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
79513989|NCT01395966|Drug|DF277|Ear drops
79362952|NCT01795066|Device|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
79513990|NCT01395966|Drug|DF289 plus DF277|Ear drops
79513991|NCT01396044|Other|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
79513992|NCT01396044|Other|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
79513993|NCT01399008|Drug|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
79513994|NCT01399008|Drug|Allopurinol|Allopurinol 300 mg as active comparator
79672919|NCT00459485|Dietary Supplement|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
79672920|NCT00459485|Dietary Supplement|Placebo|Daily placebo for 3 weeks
79672921|NCT00459524|Behavioral|Questionnaire|Questionnaires taking about 30 minutes to complete.
79672922|NCT00459524|Behavioral|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
79219763|NCT02877836|Other|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
79362953|NCT00389818|Biological|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
79362954|NCT00389818|Biological|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
79513995|NCT01399008|Drug|Colchicine|0.6 mg colchicine daily as flare prophylaxis
79679776|NCT00520208|Drug|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
79219764|NCT03545217|Behavioral|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
79219765|NCT02430987|Diagnostic Test|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of >23 and > 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria > 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
79219766|NCT02430987|Diagnostic Test|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol < 50mg/dL; (3) triglycerides > 150mg/dL; (4) arterial blood pressure (SAH) > 130/85mmHg; and (5) fasting glucose > 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
79219767|NCT02430987|Diagnostic Test|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
79219768|NCT03385850|Other|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
79219769|NCT03390062|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
79362955|NCT00389818|Biological|rituximab|375 mg/m2 IV Day 1 of each cycle
79362956|NCT00389818|Biological|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
79362957|NCT00389818|Drug|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
79362958|NCT00389818|Drug|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
79362959|NCT00389818|Drug|prednisone|100 mg PO Days 1-5 of each cycle
79362960|NCT00389818|Drug|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
79513996|NCT01399008|Drug|Placebo|Placebo
79513997|NCT01399866|Drug|D-cycloserine|2 single weekly doses, 50 mg capsule
79219770|NCT02410629|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
79219771|NCT02410629|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
79308406|NCT04496531|Device|Portable Neuromodulation Stimulator|
79362961|NCT00389818|Other|immunohistochemistry staining method|tissue specimen collected at baseline
79362962|NCT00389818|Other|laboratory biomarker analysis|tissue specimen collected at baseline
79362963|NCT00452374|Drug|Cytarabine|1 g/m^2 given IV for two days (Days 2 and 3).
79362964|NCT00452374|Drug|Fludarabine|30 mg/m^2 given IV for two days (Days 2 and 3).
79362965|NCT00452374|Drug|Oxaliplatin|Starting dose of 17.5 mg/m^2 IV for 4 days (Days 1 through 4).
79362966|NCT00452374|Drug|Rituximab|375 mg/m^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
79362967|NCT01454583|Drug|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
79362968|NCT01454583|Drug|ACE-I/ARB|
79362969|NCT01454583|Drug|No RAS-inhibition|
79362970|NCT03286114|Drug|Pembrolizumab|200mg IV every 21 days
79362971|NCT00476242|Drug|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
79362972|NCT00476242|Drug|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
79362973|NCT00476788|Device|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
79362974|NCT01795144|Drug|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
79362975|NCT01795144|Drug|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
79513998|NCT01399866|Drug|Placebo|
79513999|NCT01401582|Other|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
79514000|NCT01402050|Drug|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
79514001|NCT01402050|Device|FOLEY BALLOON|INDUCTION OF LABOR
79514002|NCT01402128|Dietary Supplement|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
79514003|NCT01402128|Dietary Supplement|Placebo|Placebo for 12 weeks
79219772|NCT03382886|Drug|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
79219773|NCT03382886|Drug|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
79219774|NCT03385772|Procedure|Sphenopalatine ganglion block|The patient will be placed supine, with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain or discomfort, the physician will stop and redirect the applicator. The applicators will be left in place for 10 minutes, and then removed by the anesthesia provider.
79219775|NCT03389984|Diagnostic Test|cutaneous|SKIN BIOPSY
79219776|NCT02855918|Other|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~A clinical assessment by psychiatrist~Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…~A neuropsychological assessment for the evaluations of cognitive performances~A routine blood sampling to the realization of a standard blood test~A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
79308129|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
79308130|NCT03044145|Behavioral|Treatment as usual|Standard mental health treatment at FHMC
79514004|NCT01403376|Drug|teriflunomide|"Film-coated tablet~Oral administration"
79514005|NCT01403376|Drug|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
79514006|NCT01403376|Biological|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
79514007|NCT01404078|Drug|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
79514008|NCT01404078|Drug|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
79514009|NCT01404936|Drug|Interferon-2A|4 (x106 IU/m^2) subcutaneously on days 1-4.
79514010|NCT01404936|Drug|Adriamycin|25 mg/m^2 by vein on day 4.
79514011|NCT01404936|Drug|Bleomycin|10 mg/m^2 by vein on day 4.
79514012|NCT01404936|Drug|Velban|6 mg/m^2 by vein on day 4.
79514013|NCT01404936|Drug|Dacarbazine|375 mg/m^2 by vein on day 4.
79679777|NCT00520247|Drug|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
79994348|NCT05425277|Behavioral|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
79514014|NCT01405794|Drug|32ppm Silver Particle|Oral silver dose of 32ppm
79514015|NCT01405794|Drug|Placebo|Sterile Water No Silver
79514016|NCT01408992|Procedure|Audiometry|Standard hearing test performed by audiologists
79514017|NCT01408992|Other|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
79514018|NCT01410084|Dietary Supplement|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
79514019|NCT01410084|Dietary Supplement|Vitamin E|400 IU vitamin E once monthly for 5 months
79514020|NCT01410552|Device|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
79514021|NCT01411488|Device|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
79514022|NCT01413750|Drug|Paclitaxel|Given IV
79514023|NCT01413750|Drug|Carboplatin|Given IV
79514024|NCT01413750|Drug|Vorinostat|Given PO
79514025|NCT01413750|Other|Placebo|Given PO
79514026|NCT01413750|Other|Laboratory Biomarker Analysis|Correlative studies
79514027|NCT01415232|Device|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
79514028|NCT01415934|Other|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
79514029|NCT01417026|Drug|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
79514030|NCT01420146|Drug|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
79679778|NCT00519545|Behavioral|Prayer|Data collection on physiological biomarkers
79514031|NCT01420848|Other|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
79219777|NCT03382808|Behavioral|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
79362976|NCT01436175|Drug|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
79362977|NCT00453388|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
79362978|NCT00453388|Drug|Cyclophosphamide|Given IV
79362979|NCT00453388|Drug|Cyclosporine|Given IV or PO
79362980|NCT00453388|Drug|Fludarabine Phosphate|Given IV
79362981|NCT00453388|Other|Laboratory Biomarker Analysis|Correlative studies
79362982|NCT00453388|Drug|Mycophenolate Mofetil|Given PO
79362983|NCT00453388|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
79362984|NCT00453388|Radiation|Total-Body Irradiation|Undergo TBI
79514032|NCT01420848|Other|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
79514033|NCT01421472|Drug|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
79994349|NCT05425277|Behavioral|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
79994350|NCT03252145|Device|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
79994351|NCT03252145|Other|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
79362985|NCT00389974|Drug|sunitinib malate|Given PO
79362986|NCT01453725|Biological|Golimumab|Golimumab 50 mg SC injection every 4 weeks
79362987|NCT01453725|Biological|Placebo|Placebo SC injection every 4 weeks
79362988|NCT04076241|Other|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
79514034|NCT01421472|Drug|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
79514035|NCT01428336|Procedure|1 ug ACTH stimulation test|1 ug cortrosyn dose
79514036|NCT01428336|Procedure|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
79514037|NCT01428336|Procedure|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
79514038|NCT01428336|Procedure|Insulin tolerance test|subjects will undergo an insulin tolerance test
79672923|NCT03278145|Genetic|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
79672924|NCT00459563|Drug|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
79514039|NCT01429272|Drug|Minocycline|100 mg po bid for 6 weeks
79514040|NCT01429272|Drug|Aspirin|81 mg po bid for 6 weeks
79514041|NCT01429272|Drug|placebo|placebo for minocycline and/or aspirin
79514042|NCT01429350|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
79514043|NCT01429350|Device|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
79514044|NCT01431300|Drug|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
79219778|NCT03382808|Behavioral|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
79219779|NCT02853812|Other|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
79362989|NCT04076241|Other|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
79514045|NCT01431846|Behavioral|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
79514046|NCT01432236|Drug|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
79514047|NCT01432236|Drug|placebo|placebo capsules twice a day for 14 weeks
79514048|NCT01434030|Behavioral|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
79514049|NCT01434186|Drug|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
79514050|NCT01434186|Drug|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
79362990|NCT00454324|Drug|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
79514051|NCT01434186|Drug|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
79514052|NCT01434186|Drug|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
79514053|NCT01434342|Drug|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, & 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
79514054|NCT01435512|Behavioral|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
79514055|NCT01435824|Drug|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
79514056|NCT01435824|Drug|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
79514057|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
79514058|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
79514059|NCT01437852|Biological|StrataGraft Skin Tissue|
79219780|NCT03389906|Other|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
79362991|NCT00454324|Drug|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
79362992|NCT02076399|Drug|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
79672925|NCT00459563|Drug|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
79672926|NCT00459563|Drug|Placebo|Placebo once a week for 3 weeks
79672927|NCT01242384|Device|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
79514060|NCT01438008|Drug|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
79514061|NCT01438008|Drug|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
79514062|NCT01438710|Drug|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
79219781|NCT04927208|Other|exercise and nutritional support|"resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks"
79514063|NCT01438710|Drug|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
79514064|NCT01442844|Device|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
79514065|NCT01443546|Drug|HCG|hCG Trigger
79994352|NCT05124002|Drug|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10^12 vp) if the maximum diameters of lesion is > 10 cm.
79219782|NCT03125486|Drug|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
79362993|NCT02076399|Drug|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
79362994|NCT02110264|Drug|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
79362995|NCT02110264|Behavioral|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
79362996|NCT02110264|Behavioral|ETAU|Participants assigned to the ETAU group will receive drug education.
79362997|NCT01795222|Drug|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
79362998|NCT01795222|Drug|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
79362999|NCT01415349|Drug|SSP-002358|1 mg, oral, once
79363000|NCT01415349|Drug|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
79514066|NCT01443546|Drug|Lupron Trigger|leuprolide acetate 2 mg SQ
79514067|NCT01443546|Drug|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
79514068|NCT01444716|Biological|Ofatumumab|Given IV
79514069|NCT01445028|Drug|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
79514070|NCT01447914|Drug|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
79514071|NCT01447914|Other|Diagnostic laboratory biomarker analysis|Correlative studies
79514072|NCT01447914|Other|Questionnaire administration|Ancillary studies
79994353|NCT05124002|Drug|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
79219783|NCT02252211|Drug|DS-8895a 1 mg/kg|Patients received infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
79219784|NCT02252211|Drug|DS-8895a 3 mg/kg|Patients received infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
79363001|NCT00528190|Drug|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
79363002|NCT02334813|Drug|Prednisone|Continuous daily therapy
79363003|NCT02334813|Drug|Dexamethasone|4-day pulses every 3 weeks
79363004|NCT00478036|Drug|Acular LS|Details covered in arm description
79363005|NCT00478036|Drug|Pred Forte|Details covered in arm description
79363006|NCT00478036|Other|Refresh Tears|Placebo
79363007|NCT04048863|Device|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
79363008|NCT04048863|Device|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
79514073|NCT01447914|Procedure|Quality-of-life assessment|Ancillary studies
79514074|NCT01449240|Other|No treatment|
79514075|NCT01449864|Radiation|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
79514076|NCT01452126|Drug|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
79994354|NCT02959814|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
79994355|NCT03666624|Behavioral|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
79994356|NCT03368807|Device|Continuous Glucose Monitoring|Commercially available
79994357|NCT03368807|Drug|Insulin Lispro|As prescribed.
79219785|NCT02252211|Drug|DS-8895a 10 mg/kg|Patients were to receive infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
79219786|NCT02173353|Device|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
79219787|NCT02146677|Other|Osteopathic manipulative treatment|
79219788|NCT02146677|Other|Sham therapy|
79219789|NCT02146677|Other|Usual care|
79363009|NCT04522557|Drug|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
79363010|NCT01453023|Drug|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
79363011|NCT01453023|Drug|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
79994358|NCT05225129|Other|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
79994359|NCT05179213|Drug|Azacitidine|75 mg/m2 subcutaneously on days 1-7
79994360|NCT05179213|Drug|Chidamide|20mg orally per week continuously
79219790|NCT02147847|Behavioral|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
79219791|NCT02147847|Behavioral|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
79219792|NCT02147925|Drug|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
79363012|NCT04767321|Drug|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
79219793|NCT02147925|Drug|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
79363013|NCT04767321|Drug|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
79363014|NCT01452789|Drug|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
79363015|NCT01452789|Drug|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
79363016|NCT01451931|Other|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
79363017|NCT01451931|Radiation|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
79514077|NCT01456494|Other|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
79514078|NCT01456494|Other|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
79672928|NCT00488397|Other|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
79219794|NCT02147925|Drug|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
79672929|NCT00459641|Drug|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
79994361|NCT03338855|Drug|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
79994362|NCT05499624|Device|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
79994363|NCT03367793|Device|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
79219795|NCT03544047|Drug|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
79219796|NCT03544125|Biological|Durvalumab|Given IV
79219797|NCT03544125|Drug|Olaparib|Given PO
79219798|NCT02151357|Drug|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
79219799|NCT02146911|Drug|Bupropion|
79219800|NCT02146911|Drug|Varenicline|
79308131|NCT03222167|Drug|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
79219801|NCT02146911|Behavioral|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
79363018|NCT01451931|Other|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
79514079|NCT01457196|Diagnostic Test|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
79514080|NCT01457430|Drug|Icatibant|30 mg subcutaneous dose of Icatibant
79514081|NCT01458288|Drug|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
79514082|NCT01458990|Drug|Omeprazole|20mg PO BID for 20 days
79514083|NCT01460940|Drug|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
79514084|NCT01460940|Drug|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
79514085|NCT01462812|Drug|Sumatriptan|Sumatriptan 20mg
79514086|NCT01462812|Drug|Placebo|Matching placebo
79514087|NCT01463202|Drug|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
79514088|NCT01463202|Drug|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
79514089|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
79219802|NCT02148159|Device|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
79219803|NCT02148159|Device|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
79219804|NCT02146989|Other|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
79363019|NCT00478192|Drug|Conivaptan|premix bag
79514090|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
79514091|NCT01467882|Drug|Triptorelin|Powder and solution for solution for injection
79514092|NCT01468350|Drug|dalfampridine-ER 10mg|
79219805|NCT02148315|Behavioral|garden|
79363020|NCT00478192|Drug|Placebo|premix bag
79514093|NCT01468350|Other|Placebo|
79514094|NCT01468584|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
79514095|NCT01468584|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
79514096|NCT01468584|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
79514097|NCT01468974|Device|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
79219806|NCT02776683|Drug|BI 695502|
79219807|NCT02776683|Drug|Avastin|
79219808|NCT02731742|Biological|MK-1966|MK-1966 administered as an intravenous (IV) infusion
79514098|NCT01471626|Device|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
79514099|NCT01472718|Device|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
79672930|NCT00459641|Other|Standard of Care|Bone marrow aspirate or steroids
79219809|NCT02731742|Drug|SD-101|SD-101 administered as an intratumoral (IT) injection
79219810|NCT02254707|Drug|BILB 1941 ZW|
79219811|NCT02254707|Drug|Placebo|
79219812|NCT03543891|Other||
79219813|NCT02963714|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
79219814|NCT02963714|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
79219815|NCT02148393|Procedure|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
79514100|NCT01472718|Device|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
79514101|NCT01472874|Drug|Once a day Trientine|Trientine at a dosage of ~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
79514102|NCT01474122|Drug|Macitentan 3 mg|Macitentan 3-mg tablet once daily
79514103|NCT01474122|Drug|Macitentan 10 mg|Macitentan 10-mg tablet once daily
79514104|NCT01474122|Drug|Placebo|Placebo tablet matching macitentan tablet, once daily
79514105|NCT01474590|Drug|Epiduo/Tactuo|topical to the face, once daily in the evening
79514106|NCT01474590|Other|vehicle gel|topical to the face, once daily in the evening
79514107|NCT01474590|Drug|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
79514108|NCT01474590|Drug|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
79672931|NCT00488436|Drug|Antithymocyte globulin|
79672932|NCT00488436|Drug|Cyclosporine|
79994364|NCT03367793|Device|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
79994365|NCT03367793|Device|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
79994366|NCT01209234|Behavioral|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
79363021|NCT04048551|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
79514109|NCT01477320|Drug|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
79994367|NCT01209234|Drug|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
79219816|NCT02148393|Procedure|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
79514110|NCT01477320|Other|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
79514111|NCT01477710|Procedure|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
79219817|NCT02148393|Drug|Pregnyl®|1500 IU
79514112|NCT01477710|Procedure|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
79514113|NCT01477710|Procedure|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
79514114|NCT01478256|Drug|Erythromycin|Topical erythromycin ointment twice a day
79514115|NCT01478256|Drug|Besifloxocin|Topical Besifloxocin twice a day
79514116|NCT01479270|Drug|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
79514117|NCT01479348|Drug|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
79994368|NCT04151953|Diagnostic Test|Blood sample collection|Blood sample collection for markers of myocardial injury
79514118|NCT01479348|Drug|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m^2, IV
79994369|NCT03626220|Procedure|acupuncture|manually manipulate acupuncture at CV6 and three acupoints on each arms and legs
79994370|NCT05571241|Behavioral|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
79994371|NCT05691894|Drug|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
79994372|NCT05691894|Drug|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
79514119|NCT01479348|Drug|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
79514120|NCT01479348|Diagnostic Test|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
79514121|NCT01479426|Dietary Supplement|EFLA400|EFLA400(960mg/day)for 12 weeks
79514122|NCT01479426|Dietary Supplement|Placebo|Placebo(960mg/day) for 12 weeks
79514123|NCT01483560|Drug|Metformin|3 years treatment duration
79219818|NCT02148393|Drug|Utrogestan®|200 mg tid
79219819|NCT02148393|Drug|Progynova®|2 mg bid
79514124|NCT01483560|Drug|Placebo|3 years duration
79672933|NCT00459680|Device|Laser acupoint treatment|Laser
79219820|NCT02148393|Device|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
79219821|NCT03385694|Diagnostic Test|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
79994373|NCT05178511|Drug|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
79219822|NCT03125252|Other|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~thirst~noise~pain and well-being~sleep~isolation"
79363022|NCT04048551|Behavioral|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
79363023|NCT01414257|Drug|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
79219823|NCT03125252|Other|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:~Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~Use of reference antipsychotic pharmacological means"
79363024|NCT00528268|Drug|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
79219824|NCT02416154|Procedure|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
79219825|NCT03382184|Device|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
79219826|NCT03382184|Device|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
79219827|NCT02324816|Device|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
79219828|NCT02314364|Radiation|SBRT with protons or photons|
79363025|NCT04490044|Other|Under & Over rehabilitation tool|Under & Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
79363026|NCT00528580|Drug|Simvastatin|80 mg once daily PO/NG x 4 days
79363027|NCT00528580|Drug|Identical-appearing placebo|once daily x 4 days
79219829|NCT03385616|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
79219830|NCT00104871|Drug|Bortezomib|Administered IV at the dose of 1.3 mg/m^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
79219831|NCT03385538|Drug|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
79219832|NCT03385460|Other|ESWL BOTOX|ESWL after intrravesical BOTOX
79219833|NCT03543033|Drug|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
79363028|NCT00529126|Drug|SKY0402|SKY0402
79363029|NCT00529126|Drug|Bupivacaine HCl|Bupivacaine HCl
79363030|NCT01434693|Biological|Trichuris suis ova|single dose
79219834|NCT03380702|Procedure|whitening photoactivation gel|35 subjects in active comparator group
79363031|NCT01434693|Other|Placebo|
79363032|NCT00529204|Drug|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
79363033|NCT01451541|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
79514125|NCT01484340|Drug|Nicotine|"The nicotine patch be given in three phases:~2 weeks of patches at enrollment~6 weeks of patches at two-week follow-up visit~2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
79994374|NCT05571163|Drug|AMG 510|Tablets
79219835|NCT03380702|Procedure|placebo|35 subjects in placebo comparator group
79219836|NCT04723160|Diagnostic Test|Software assisted imaging diagnosis|In the test group, diagnoses are given with the help of the software.
79219837|NCT02147223|Dietary Supplement|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
79219838|NCT02147223|Dietary Supplement|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
79219839|NCT02147379|Drug|Lurasidone|
79363034|NCT01451541|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
79363035|NCT01451541|Drug|Placebo|Placebo - one dose per nostril
79514126|NCT01484340|Behavioral|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~Baseline~2-week follow-up (Quit Day)~1-month follow-up~2-month follow-up~3-month follow-up~6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
79514127|NCT01484652|Drug|COV795|2 tablets taken every 12 hours
79363036|NCT00530764|Drug|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
79514128|NCT01484652|Drug|Placebo|2 tablets taken every 12 hours
79514129|NCT01485588|Drug|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
79514130|NCT01485588|Drug|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
79514131|NCT01485588|Drug|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
79514132|NCT01488318|Drug|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
79219840|NCT02148549|Drug|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
79363037|NCT00530764|Drug|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
79363038|NCT00530764|Drug|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
79514133|NCT01488318|Drug|Dasatinib|Dasatinib 150 mg po
79514134|NCT01488708|Drug|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
79514135|NCT01488708|Drug|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
79514136|NCT01490892|Drug|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
79219841|NCT04690400|Other|Experimental: Active care group|Stretching exercise program remotely supervised. Total of approximately 40 minutes per session by WhatsApp, individually and supervised by a professional (physiotherapist or physical education teacher). As recommended for flexibility improving, 30 seconds of stretching in each exercise will be perform fractionated (3 series of 10 seconds of static position at the point of moderate discomfort, with 10 seconds interval between series). There will be two stretching protocol models with exercises variations, but for the same muscle groups, intensity, volume, and duration. The position at the point of moderate discomfort will be self-adjusted by subjective perception over 12 weeks of intervention. The protocol model will change after seven weeks. In order to make the interventions more similar, the guide and videos of control group will be also sent to experimental group
79363039|NCT00532480|Drug|Duloxetine|60 mg capsules
79363040|NCT00483262|Drug|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
79363041|NCT00483262|Drug|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
79363042|NCT00483496|Drug|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
79363043|NCT00483496|Drug|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
79363044|NCT00483496|Drug|bisoctrizole 10% alone (formula RV3131A-MV1237)|
79363045|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
79363046|NCT00483496|Drug|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
79363047|NCT00483496|Drug|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
79363048|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
79363049|NCT00483496|Drug|V0096 CR vehicle (formula RV3131A-MV1197)|
79514137|NCT01491984|Device|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
79514138|NCT01491984|Device|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
79514139|NCT01495572|Drug|Fludarabine|25 mg/m^2 IV (in the vein) for 5 days (day -5 to -1)
79514140|NCT01495572|Drug|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
79514141|NCT01495572|Drug|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
79514142|NCT01495572|Drug|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
79514143|NCT01496352|Drug|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
79514144|NCT01496352|Drug|Placebo|DFA-02 placebo
79672934|NCT00459680|Procedure|Acupuncture|Needle acupuncture on ST36 and LI11.
79363050|NCT00484354|Drug|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
79363051|NCT00484354|Other|Normal saline|IV Normal saline with volume given determined by patient weight
79363052|NCT00484354|Other|Bicarbonate|IV bicarbonate, dosed by weight
79363053|NCT00484354|Other|Placebo|Normal saline, with volume given based on patient weight
79514145|NCT01497756|Device|CAPP use|Any abdominal pelvic pressure
79514146|NCT01499862|Device|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
79514147|NCT01504854|Drug|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
79514148|NCT01504854|Drug|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
79514149|NCT01505166|Biological|Vigil™ Vaccine|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
79514150|NCT01505166|Drug|Placebo|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
79219842|NCT04690400|Other|Active Comparator: Self-care group|The participants will receive counseling to stretching by guide and explanatory video that will be send by WhatsApp. The stretching exercise protocols will be the same performed by the experimental group. In addition, participants will receive recommendation to perform the protocol with the same weekly frequency, intensity, volume, and duration perform by the experimental group After the guide and explanatory video are sent, participants will receive a call for clarification. As well as in the experimental group, the protocol model will change after seven weeks; so, other guide and explanatory video will be sent for participants.
79219843|NCT05044767|Device|total hip arthroplasty|hip replacement surgery
79219844|NCT03375476|Diagnostic Test|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
79219845|NCT03375476|Diagnostic Test|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
79219846|NCT03375476|Diagnostic Test|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
79363054|NCT00485836|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
79363055|NCT00485836|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
79363056|NCT00485836|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
79363057|NCT00534118|Biological|donor lymphocytes|Given IV
79363058|NCT00487396|Device|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
79514151|NCT01508052|Device|sequential compression device|applying sequential compression device during the surgery
79514152|NCT01508052|Device|elastic stockings|applying elastic stockings during the surgery
79514153|NCT01508832|Drug|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
79514154|NCT01508832|Drug|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
79514155|NCT01509612|Drug|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
79514156|NCT01509612|Drug|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
79514157|NCT01510704|Drug|APD421|IV
79514158|NCT01510704|Drug|Placebo|IV
79514159|NCT01511016|Drug|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
79514160|NCT01511016|Drug|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
79514161|NCT01511640|Drug|Pregabalin|pregabalin 2x daily for duration of study
79514162|NCT01511640|Drug|Placebo|placebo 2x daily for duration of study
79219847|NCT03375398|Dietary Supplement|Rice|Test food #1: White Rice <63.0 g (dry) Jasmine rice consumed together with 250 mL water
79219848|NCT03375398|Dietary Supplement|Sugardown™|Test food #2: White Rice < 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice < 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
79219849|NCT04868942|Other|Assisting to the event|"Participant will attend a concert respecting the Following measures :~Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~Health mediation, information on barrier measures~Physical distancing (sitting participation)~Person flow management"
79219850|NCT02147535|Drug|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
79514163|NCT01513122|Drug|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
79514164|NCT01513122|Drug|2-3N(t)RTI|
79672935|NCT03277950|Other|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
79219851|NCT02148627|Drug|LY3041658 (SC)|Administered SC
79219852|NCT02148627|Drug|LY3041658 (IV)|Administered as slow IV infusion
79219853|NCT02148627|Drug|Placebo|Administered as slow IV infusion
79514165|NCT01513122|Drug|raltegravir|raltegravir 400mg 1 tablet twice daily.
79672936|NCT03277950|Other|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
79672937|NCT03277950|Other|Healthy|Healthy do not play game
79672938|NCT00488553|Behavioral|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
79672939|NCT00459719|Drug|Tacrolimus modified-release|oral
79672940|NCT00459719|Drug|Prograf|oral
79672941|NCT00495144|Drug|TH-302|
79672942|NCT00459758|Device|Hans unit|
79672943|NCT00495183|Drug|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
79672944|NCT00495183|Drug|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
79672945|NCT00495183|Drug|Placebo|Placebo
79219854|NCT03487796|Behavioral|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
79219855|NCT03487796|Other|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
79514166|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
79514167|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
79219856|NCT02151825|Dietary Supplement|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
79219857|NCT02151825|Other|Placebo|3 capsules of Maltodextrin per day
79219858|NCT02155569|Procedure|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
79363059|NCT04249024|Device|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
79363060|NCT04249024|Procedure|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
79363061|NCT04249024|Behavioral|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
79363062|NCT04200508|Other|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
79363063|NCT00488488|Drug|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
79363064|NCT00489268|Device|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~******Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
79363065|NCT01450761|Biological|Ipilimumab|
79514168|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing <30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
79514169|NCT01514292|Device|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
79994375|NCT03708107|Device|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
79994376|NCT03708107|Other|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
79994377|NCT04110457|Procedure|spinal decompression|spinal surgery by decompression or fixation
79363066|NCT01450761|Biological|Placebo matching Ipilimumab|
79363067|NCT01450761|Drug|Etoposide|
79363068|NCT01450761|Drug|Cisplatin|
79363069|NCT01450761|Drug|Carboplatin|
79514170|NCT01515072|Other|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
79514171|NCT01515540|Drug|lidocaine|5% lidoderm patch
79514172|NCT01515540|Drug|placebo|placebo
79672946|NCT00459797|Device|Conventional (reusable) Glidescope|
79514173|NCT01515696|Drug|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
79514174|NCT01515696|Drug|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
79514175|NCT01516632|Behavioral|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
79514176|NCT01518270|Other|No treatment|No treatment will be provided
79514177|NCT01519284|Drug|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
79514178|NCT01519284|Drug|Entacapone|Entacapone 200 mg
79514179|NCT01519284|Drug|Placebo|placebo (four times a day)
79514180|NCT01519284|Drug|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
79994378|NCT05691582|Device|GRAIL|"The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed"
79994379|NCT03532555|Dietary Supplement|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
79994380|NCT03532555|Other|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
79994381|NCT01347307|Radiation|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
79219859|NCT02155569|Procedure|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
79219860|NCT02148705|Drug|NexoBrid|
79994382|NCT01347307|Radiation|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
79994383|NCT03373110|Behavioral|Online Mindfulness Based Cognitive Therapy|see arm description
79363070|NCT04075539|Other|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
79994384|NCT03373110|Behavioral|Online Cognitive Behavioral Therapy|see arm description
79994385|NCT03373110|Behavioral|Fitbit Alone|see arm description
79994386|NCT03993457|Drug|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
79219861|NCT02148705|Procedure|Standard of Care (SOC)|
79219862|NCT02148705|Drug|Gel Vehicle|
79363071|NCT04075539|Other|usual care|A prescription of 6 sessions of outpatient physiotherapy
79514181|NCT01519284|Drug|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
79514182|NCT01519284|Drug|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
79219863|NCT02254785|Drug|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
79219864|NCT02254785|Drug|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
79219865|NCT02254785|Drug|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
79219866|NCT03446612|Drug|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
79219867|NCT03446612|Drug|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
79219868|NCT03446612|Drug|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
79514183|NCT01520454|Drug|Saline|IV saline at 0.83 mL/kg/hr for six hours
79514184|NCT01520454|Drug|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
79514185|NCT01520454|Dietary Supplement|Water|Water by mouth
79514186|NCT01520454|Dietary Supplement|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
79514187|NCT01520454|Drug|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
79514188|NCT01520532|Other|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
79514189|NCT01520688|Drug|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
79514190|NCT01520688|Drug|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
79514191|NCT01520688|Drug|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
79514192|NCT01520688|Drug|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
79994387|NCT03993457|Drug|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
79994388|NCT05571085|Other|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
79994389|NCT05571085|Other|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
79514193|NCT01520688|Drug|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
79219869|NCT03446612|Drug|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
79514194|NCT01520688|Drug|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
79514195|NCT01521546|Drug|eplerenone|25mg tablet, once daily by mouth for 12 months
79514196|NCT01521546|Drug|placebo|one tablet by mouth daily for 12 months
79672947|NCT00459797|Device|Single-use Glidescope videolaryngoscope|
79672948|NCT00488670|Drug|Escitalopram|See Detailed Description.
79994390|NCT05571007|Other|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
79994391|NCT05571007|Other|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
79994392|NCT03348306|Device|MRI|Brain and cardiac MRI in one time with gadolinium injection.
79994393|NCT03348306|Biological|Blood sample collection|A blood sampling is also collected for hematocrit measure.
79994394|NCT05570773|Other|peer support program|Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
79994395|NCT04677439|Drug|Flumatinib|600 mg of Flumatinib orally daily for 24 months
79994396|NCT03309072|Device|tDCS|active tDCS
79994397|NCT03309072|Device|sham tDCS|sham tDCS
79994398|NCT03625908|Device|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
79219870|NCT03446612|Drug|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
79219871|NCT02148783|Drug|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with [11C]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
79219872|NCT02148783|Drug|Placebo|
79219873|NCT02155803|Drug|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
79219874|NCT02148861|Drug|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
79219875|NCT02148861|Drug|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
79219876|NCT02148861|Drug|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
79219877|NCT02149017|Radiation|SNUBH-NM-333(18F)|5-10 mCi
79219878|NCT02152059|Drug|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
79219879|NCT03124316|Behavioral|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
79514197|NCT01521780|Procedure|MRI|Participants undergo volumetric & diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
79514198|NCT01521780|Procedure|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
79514199|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
79514200|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
79514201|NCT01523496|Drug|Vitamin D control dose|18,000 IU per month
79514202|NCT01523496|Drug|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
79514203|NCT01523808|Drug|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
79672949|NCT00459836|Drug|PR-104|
79672950|NCT00459836|Drug|docetaxel|
79672951|NCT00459836|Drug|gemcitabine hydrochloride|
79672952|NCT00459836|Other|laboratory biomarker analysis|
79672953|NCT00459836|Other|pharmacological study|
79672954|NCT00495261|Behavioral|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
79672955|NCT00495261|Behavioral|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
79672956|NCT00459914|Device|cpap treatment during sleep|CPAP
79672957|NCT00488709|Drug|Topotecan|
79672958|NCT00488709|Drug|Fludarabine|
79672959|NCT00488709|Drug|Cytarabine|
79672960|NCT00459992|Drug|Betahistine Hydrochloride|
79994399|NCT03625908|Device|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
79219880|NCT03124316|Behavioral|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
79994400|NCT05570695|Behavioral|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
79219881|NCT03124316|Behavioral|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
79219882|NCT02149095|Drug|TransCon PEG treprostinil|
79514204|NCT01523964|Other|Testing with EIM|
79672961|NCT00495339|Drug|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
79672962|NCT00460148|Drug|Ropinirole|
79672963|NCT01242423|Device|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
79672964|NCT00460187|Device|Percutaneous intervention of the carotid artery|
79672965|NCT00460226|Drug|lamotrigine|lamotrigine treatment for 12weeks
79672966|NCT00495378|Drug|epoetin alfa|
79672967|NCT00460304|Drug|pramlintide|
79672968|NCT00460304|Procedure|continuous glucose monitoring|
79994401|NCT05570695|Behavioral|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
79994402|NCT05570695|Behavioral|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
79994403|NCT05570695|Behavioral|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
79994404|NCT02986789|Device|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
79994405|NCT03223428|Drug|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
79219883|NCT04925739|Other|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
79219884|NCT04925739|Other|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
79219885|NCT04925739|Other|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
79219886|NCT04925739|Other|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
79219887|NCT04925739|Other|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
79219888|NCT04925739|Other|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
79219889|NCT04925739|Other|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
79219890|NCT04925739|Other|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
79514205|NCT01526538|Drug|d-cycloserine|50 mg d-cycloserine
79994406|NCT02777424|Drug|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
79514206|NCT01526538|Drug|sugar pill|placebo
79514207|NCT01527162|Device|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
79219891|NCT02520050|Behavioral|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
79219892|NCT02520050|Behavioral|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
79514208|NCT01527162|Other|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
79514209|NCT01528332|Device|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
79672969|NCT01242462|Procedure|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 & Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
79679779|NCT02949050|Biological|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
79219893|NCT02520050|Behavioral|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
79363072|NCT02120716|Behavioral|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
79514210|NCT01528332|Device|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
79514211|NCT01528878|Radiation|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
79514212|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
79514213|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
79514214|NCT01529502|Drug|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
79514215|NCT01532700|Drug|Ofatumumab with GSK2110183|"GSK2110183 125mg OD continuously~Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
79514216|NCT01533948|Drug|axitinib|Given PO
79514217|NCT01533948|Other|laboratory biomarker analysis|Correlative studies
79514218|NCT01534416|Drug|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
79514219|NCT01534416|Drug|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
79514220|NCT01535664|Other|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~On drug Day-7 (visit 1) through Day 1 (visit 2)~Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~On drug Day 15±2 days (visit 5)"
79514221|NCT01535976|Drug|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
79219894|NCT02149251|Genetic|Pre-genetic diagnosis|
79363073|NCT00491374|Drug|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
79363074|NCT00491374|Drug|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
79514222|NCT01535976|Drug|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
79514223|NCT01536366|Drug|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
79514224|NCT01536366|Drug|Repaglinide|0.5 mg repaglinide (single-dose)
79994407|NCT02777424|Biological|Fresh Frozen Plasma|Pooled collection of plasma from donors
79514225|NCT06115291|Other|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
79994408|NCT05360550|Drug|LSP-5415|pregnancy prevention
79514226|NCT06115265|Behavioral|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
79514227|NCT06115265|Behavioral|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
79219895|NCT02149329|Drug|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
79219896|NCT03255512|Drug|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
79219897|NCT03255512|Drug|Placebo|Matching placebo
79219898|NCT03255512|Drug|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
79219899|NCT02149407|Drug|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
79219900|NCT02149407|Procedure|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
79363075|NCT00538642|Drug|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
79363076|NCT00539110|Drug|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
79363077|NCT00539110|Drug|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
79514228|NCT06115252|Behavioral|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
79514229|NCT06115239|Other|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
79514230|NCT06115213|Behavioral|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
79514231|NCT06115187|Diagnostic Test|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
79514232|NCT06115187|Diagnostic Test|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
79672970|NCT01242462|Other|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
79994409|NCT05255874|Other|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
79679780|NCT02949050|Biological|SCIT|Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT
79679781|NCT02940132|Drug|SC10914|SC10914 will be administered orally.
79219901|NCT02149407|Other|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
79219902|NCT03380312|Procedure|rTARUP technique|robot-assisted rTARUP technique
79219903|NCT03543657|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
79219904|NCT03543657|Drug|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
79219905|NCT03543657|Drug|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
79219906|NCT03543657|Drug|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
79219907|NCT04404998|Other|Lower Energy Density|Test meal with lower energy density
79219908|NCT04404998|Other|Higher Energy Density|Test meal with higher energy density
79219909|NCT04404998|Other|Lower Satiation|Information on lower satiation
79219910|NCT04404998|Other|Higher Satiation|Information on higher satiation
79219911|NCT03380234|Other|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
79219912|NCT03380234|Other|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change [15]. They can then forward selected messages to other members of their household, especially smokers.
79219913|NCT03380234|Other|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
79219914|NCT03380234|Other|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
79219915|NCT02152215|Procedure|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
79363078|NCT03846232|Other|No intervention|No intervention
79363079|NCT00539656|Biological|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
79363080|NCT01433991|Drug|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
79363081|NCT01433991|Drug|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
79363082|NCT01433991|Drug|Lenvatinib|Participants will receive lenvatinib 24 mg (1*4 mg capsule + 2*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
79219916|NCT02152215|Procedure|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
79514233|NCT06115174|Drug|Pentoxifylline|"Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy [15].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) [16]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes [17]."
79514234|NCT06115174|Radiation|FOLFOX|(leucovorin, fluorouracil, oxaliplatin)
79514235|NCT06115174|Radiation|XELOX|(oxaliplatin + capecitabine)
79514236|NCT06115174|Drug|Monoclonal antibodies (target therapy)|target therapy (Bevacizumab).
79514237|NCT06115161|Device|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
79514238|NCT06115148|Other|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
79219917|NCT03380156|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
79219918|NCT03380156|Device|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
79219919|NCT02155959|Device|toric intraocular lens|toric intraocular lens
79219920|NCT02730728|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
79219921|NCT02730728|Drug|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
79514239|NCT06115148|Other|Fasting|Water will be consumed as described during the Fasting Arm.
79514240|NCT06115122|Other|Pre-eclampsia screening program|Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.
79514241|NCT06115083|Other|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
79994410|NCT03247543|Drug|Placebo|Placebo was administered once daily
79514242|NCT06115070|Drug|Alteplase|intravenous alteplase(0.9 mg/kg;maximum dose, 90mg; 10% administered as a 1-minute bolus,the remaining infused over 1 hour)
79672971|NCT00460343|Other|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
79672972|NCT00460343|Other|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
79672973|NCT00495417|Biological|AFFITOPE AD01|s.c. injection
79672974|NCT00495417|Biological|AFFITOPE AD01 adjuvanted|s.c. injection
79672975|NCT00460382|Drug|raltegravir potassium|400 mg twice a day
79672976|NCT00460382|Drug|darunavir/ritonavir|2 pills of 300 mg twice a day
79672977|NCT00460382|Drug|etravirine|2 pills of 100 mg twice a day
79672978|NCT00460382|Drug|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
79672979|NCT01242501|Behavioral|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
79672980|NCT01242501|Behavioral|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
79672981|NCT00460460|Drug|AZD4877|
79672982|NCT01242579|Drug|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
79219922|NCT02730728|Drug|5ml bolus of 0.5% ropivicaine|Local anesthetic
79219923|NCT02156037|Behavioral|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
79219924|NCT02156037|Behavioral|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
79219925|NCT03379922|Behavioral|Stress balls|Squeezing stress balls while receiving ESWL treatment
79219926|NCT03379922|Behavioral|Headphones|Listening to music while receiving ESWL treatment
79219927|NCT03381794|Procedure|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
79672983|NCT01242579|Drug|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
79672984|NCT01242579|Drug|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
79672985|NCT01242579|Drug|Matching Placebo Gel|Matching placebo gel containing 2.5g
79994411|NCT03247543|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
79994412|NCT03247543|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
79994413|NCT05351190|Device|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
79994414|NCT03637153|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
79219928|NCT02156193|Procedure|Prophylactic clip|Prophylactic clipping
79219929|NCT02156193|Procedure|No prophylactic management|No prophylaxis
79219930|NCT03379766|Device|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
79820851|NCT01459107|Drug|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
79994415|NCT03637153|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
79363083|NCT01450683|Drug|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
79994416|NCT05569525|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy according to the full-mouth debridement protocol.
79219931|NCT03379766|Device|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
79219932|NCT02149563|Device|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
79363084|NCT01433055|Drug|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
79514243|NCT06115018|Procedure|Palatal surgery|Palate surgery has evolved from the ablative partial palate resections, which favored the removal of the soft tissue that obstructed the upper airway (UA), to more recent innovative reconstructive procedures that not only address the level of palatal obstruction, but the type of palatal or lateral pharyngeal wall collapse.
79994417|NCT01347073|Drug|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
79219933|NCT03381716|Drug|drug|Application bracket
79514244|NCT06115018|Behavioral|Oropharyngeal rehabilitation|Oropharyngeal rehabilitation (OPR) focus on the upper airway muscle including tongue muscle, palatal muscles and paryngeal muscles. The OPR for the treatment groups included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress.
79219934|NCT03381716|Procedure|Surgery|Surgery
79514245|NCT06115018|Combination Product|Palatal surgery combined oropharyngeal rehabilitation|Participants will receive palatal surgery and post-surgery oropharyngeal rehabilitation (OPR). The palatal surgery and OPR describe as above.
79219935|NCT02149641|Radiation|Intensity modulated radiotherapy with chemotherapy|
79219936|NCT03379610|Diagnostic Test|Nasopharngeal brush|"Baseline nasopharngeal brush before treatment~Post-treatment reassessment of residual NPC"
79219937|NCT04319822|Other|blood sample and muscular biopsy|blood sample and muscular biopsy
79219938|NCT02152449|Dietary Supplement|Oral nutritional supplementation|
79219939|NCT02520128|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
79219940|NCT03542955|Device|ActiPatch|A Pulsed Shortwave Therapy Device
79514246|NCT06115005|Biological|Plasma rich in growth factors ( PRGF )|"Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes.~This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration"
79514247|NCT06114979|Drug|Silodosin|Each patient will receive 8 mg of silodosin tablet once daily.
79514248|NCT06114979|Drug|Placebo|Each patient will receive placebo tablet.
79514249|NCT06114966|Other|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
79219941|NCT03542955|Drug|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
79219942|NCT03542331|Drug|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
79219943|NCT03542331|Device|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
79219944|NCT03381638|Device|Blink Reflexometer|The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
79308132|NCT04860999|Procedure|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
79363085|NCT01433055|Drug|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
79363086|NCT01450137|Drug|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
79363087|NCT01450137|Drug|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
79363088|NCT01412229|Drug|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
79363089|NCT01412229|Drug|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
79514250|NCT06114953|Drug|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
79514251|NCT06114953|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
79514252|NCT06114940|Drug|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
79514253|NCT06114940|Drug|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
79514254|NCT06114940|Drug|Lenvatinib|18 mg by mouth once each day for 12 weeks prior to nephrectomy
79514255|NCT06114940|Drug|Sunitinib|Subjects will receive a 21-day cycle of oral 50mg once a day for 14 days and then rest for 7days, requiring 4 cycles for a total of 12 weeks
79514256|NCT06114901|Other|SleepFix|SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.
79514257|NCT06114901|Other|Sleep health Education modules|Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
79363090|NCT01412229|Drug|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
79363091|NCT01412151|Drug|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
79514258|NCT06114823|Procedure|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
79994418|NCT05569447|Procedure|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
79363092|NCT01432275|Device|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
79514259|NCT06114823|Procedure|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
79514260|NCT06114797|Other|Chamomile|"Chamomile was topically applied to the oral mucosa as oral rinse.~Based on this protocol, patients had oral rinses 3 times per day.~Patients were instructed to perform chamomile rinses in the oral mucosa.~Patients were instructed not to swallow the chamomile oral rinse."
79514261|NCT06114797|Other|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
79514262|NCT06114771|Other|strepsilis|Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
79514263|NCT06114771|Other|Placebo|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
79363093|NCT01432275|Device|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
79514264|NCT06114758|Drug|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
79514265|NCT06114758|Drug|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
79514266|NCT06114706|Behavioral|Physicians assess patients|Physicians are asked to assess patients following the current Swedish guideline
79514267|NCT06114706|Behavioral|Nurses assess patients|Nurses are asked to assess patients following the current Swedish guideline
79514268|NCT06114706|Behavioral|Pharmacists assess patients|Pharmacists are asked to assess patients following the current Swedish guideline
79514269|NCT06114641|Drug|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
79363094|NCT01432275|Device|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
79363095|NCT03025815|Other|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
79363096|NCT03025815|Other|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
79363097|NCT01411995|Drug|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
79994419|NCT02618551|Procedure|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
79514270|NCT06114576|Other|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
79219945|NCT03543501|Device|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
79363098|NCT01411995|Drug|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
79363099|NCT01411917|Procedure|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
79363100|NCT01411839|Behavioral|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
79363101|NCT01411215|Drug|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
79363102|NCT01449279|Drug|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
79363103|NCT01449279|Radiation|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
79363104|NCT04408053|Device|Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)|6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
79363105|NCT01447719|Drug|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
79363106|NCT01431963|Drug|Lamictal|No comparison.
79363107|NCT01447407|Biological|NDV-3 vaccine with alum IM|One dose administered IM
79363108|NCT01447407|Biological|NDV-3 vaccine without alum IM|One dose administered IM
79363109|NCT01447407|Biological|Placebo with alum IM|One dose administered ID
79363110|NCT01447407|Biological|NDV-3 vaccine without alum ID|One dose administered ID
79363111|NCT04056819|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
79514271|NCT06114576|Other|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
79672986|NCT00460499|Drug|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
79994420|NCT05569057|Drug|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
79308133|NCT04867005|Behavioral|Impact of a training program|Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
79308134|NCT03221855|Drug|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
79363114|NCT01446237|Other|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
79363115|NCT00540982|Drug|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
79363116|NCT00540982|Drug|lidocaine|1 mg/kg will be administered to determine metabolic capacity
79363117|NCT00540982|Drug|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
79363118|NCT00540982|Other|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
79363119|NCT00540982|Other|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
79363120|NCT00540982|Other|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
79363121|NCT00540982|Other|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
79363122|NCT00540982|Other|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
79672987|NCT00460499|Drug|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
79672988|NCT00460499|Drug|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
79672989|NCT00495573|Drug|acyclovir|400 mg acyclovir, orally three times a day for 5 days
79672990|NCT00460538|Dietary Supplement|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
79363123|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
79363124|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
79514272|NCT06114537|Drug|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
79514273|NCT06114524|Other|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
79514274|NCT06114485|Behavioral|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
79514275|NCT06114485|Behavioral|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
79219946|NCT03543501|Device|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
79514276|NCT06114459|Drug|Sodium Chloride|Post surgery disinfection
79514277|NCT06114420|Procedure|salvage surgery|Some patients who cannot undergo surgery
79672991|NCT00460538|Dietary Supplement|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
79219947|NCT04312828|Procedure|Orthopedic management of the Z-foot|Orthopedic treatment with femoropedic plasters and slotted splints in 1st intention
79672992|NCT00488787|Drug|intranasal ketamine|low dose
79994421|NCT01315236|Drug|Liposomal amikacin for inhalation (LAI)|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~Subjects can continue with 84 additional days of dosing in the open label extension."
79219948|NCT02149797|Procedure|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
79363125|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
79363126|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
79308135|NCT03221855|Drug|Placebo|Capsules 10mg orally each 8 hours for 7 days.
79308136|NCT03043521|Drug|Dexlansoprazole 60 MG|
79308137|NCT03043521|Drug|CJ-12420 50mg|
79308138|NCT03043521|Drug|CJ-12420 100mg|
79363127|NCT00543400|Drug|M118|intravenous (IV) infusion
79363128|NCT00543400|Drug|Unfractionated Heparin|IV infusion
79363129|NCT01796938|Drug|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
79363130|NCT00492544|Biological|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
79363131|NCT00492622|Drug|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
79363132|NCT00492622|Drug|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
79363133|NCT00494494|Drug|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
79363134|NCT00494494|Drug|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
79363135|NCT00494806|Other|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
79363136|NCT03145558|Drug|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
79672993|NCT00488787|Drug|intranasal ketamine|medium dose
79308139|NCT03043521|Drug|CJ-12420 200mg|
79308140|NCT03221933|Biological|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
79308141|NCT03221933|Biological|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
79363137|NCT03145558|Drug|Doxorubicin|Standard of care for TACE
79363138|NCT03837496|Other|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
79363139|NCT03837496|Other|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
79672994|NCT00488787|Drug|intranasal ketamine|high dose
79672995|NCT00488787|Drug|placebo|placebo
79672996|NCT00460616|Drug|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
79219949|NCT02149797|Procedure|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
79219950|NCT02149797|Procedure|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
79219951|NCT05431426|Drug|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
79219952|NCT04988074|Drug|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
79219953|NCT00104637|Drug|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
79219954|NCT00104637|Drug|Placebo|25 mg po tid
79514278|NCT06114381|Other|Home Based Physical Exercise|"Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response."
79672997|NCT00495651|Drug|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
79672998|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
79672999|NCT00495651|Drug|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
79219955|NCT03379142|Behavioral|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
79673000|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
79994422|NCT01315236|Drug|placebo|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are similar to LAI.~Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
79363140|NCT04750018|Other|surgery|Patients were divided into surgery and no disease.
79994423|NCT03730051|Drug|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
79219956|NCT05534776|Other|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
79363141|NCT01797874|Drug|Pazopanib|Experimental
79514279|NCT06114381|Dietary Supplement|Vitamin D3 Supplements|Vitamin D3 supplement (400mg) once daily.
79219957|NCT04810208|Drug|Docetaxel|Docetaxel in NanoZolid formulation, for intratumoural injection
79219958|NCT05428774|Other|Test product 1|Participants will receive TP1 during one experimental visit.
79219959|NCT05428774|Other|Test product 2|Participants will receive TP2 during one experimental visit.
79363142|NCT01797874|Drug|Placebo|placebo arm
79363143|NCT04750174|Other|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
79514280|NCT06114381|Other|Diet Management|Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.
79673001|NCT00460694|Biological|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
79673002|NCT01244841|Procedure|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
79673003|NCT00460733|Drug|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
79219960|NCT05428774|Other|Placebo|Participants will receive placebo during one experimental visit.
79219961|NCT02156349|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
79219962|NCT02156349|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
79219963|NCT03125330|Behavioral|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
79673004|NCT00460733|Drug|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
79994424|NCT03730051|Drug|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
79994425|NCT03232567|Biological|NasoVAX|Single ascending dose study
79363144|NCT00497770|Drug|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
79363145|NCT00498550|Drug|Clozapine|Clozapine up to 550mg per day
79363146|NCT00498550|Drug|Treatment as usual|Remain on pre-study antipsychotic treatment
79514281|NCT06114381|Behavioral|Sun Exposure|Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
79514282|NCT06114355|Procedure|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
79363147|NCT00498628|Drug|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
79514283|NCT06114316|Behavioral|individualized nursing interventions based on the Roy Adaptation Model /experimental|"The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
79514284|NCT06114303|Other|Stool sampling|1 stool sample is taken during the study with a stool sample kit
79514285|NCT06114264|Behavioral|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
79514286|NCT06114264|Other|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
79514287|NCT06114251|Diagnostic Test|Diagnosis of postoperative recurrence of liver cancer|HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
79514288|NCT06114238|Drug|Itepekimab AI|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous AI
79363148|NCT00498628|Other|Placebo|Placebo
79363149|NCT04749706|Behavioral|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
79363150|NCT04749706|Behavioral|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
79363151|NCT04749472|Other|Sling|Participants wore six different shoulder slings in a randomized order.
79514289|NCT06114238|Drug|Itepekimab PFS|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous PFS
79673005|NCT00488904|Dietary Supplement|supportan|2 sip feed pr. day
79673006|NCT00488904|Dietary Supplement|supportan placebo|2 sip feed pr. day
79363152|NCT00498706|Behavioral|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
79363153|NCT00498706|Behavioral|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
79514290|NCT06114225|Combination Product|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
79673007|NCT00460850|Drug|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
79673008|NCT00495690|Drug|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
79219964|NCT04445636|Drug|Dexmedetomidine|Caudal block with Dexametomedine as an adjuvant to bupivacaine.
79219965|NCT04445636|Drug|Morphine|Addition of morphine as adjuvant to bupivacaine during caudal block.
79219966|NCT03542253|Procedure|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
79219967|NCT03744273|Procedure|breast capsule biopsy|
79219968|NCT04445480|Procedure|Popliteal block|Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
79219969|NCT04445480|Other|Control|Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
79219970|NCT05649124|Behavioral|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
79363154|NCT01446159|Drug|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
79363155|NCT01446159|Drug|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
79363156|NCT00498940|Device|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
79363157|NCT00498940|Device|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
79363158|NCT00499096|Behavioral|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
79514291|NCT06114212|Device|dTMS stimulation via the H4 coil|Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
79514292|NCT06114173|Drug|Cardunilizumab|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
79514293|NCT06114134|Dietary Supplement|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
79363159|NCT00499408|Dietary Supplement|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
79514294|NCT06114134|Dietary Supplement|Placebo|Placebo
79363160|NCT00499408|Dietary Supplement|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
79363161|NCT01446003|Drug|MK-8457|10 x 10-mg capsule BID for 10 days
79363162|NCT01446003|Drug|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
79514295|NCT06114121|Procedure|erector spinae plane block (ESP)|nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
79514296|NCT06114121|Drug|Duramorph|100 micrograms (mcg) of morphine administered in the spinal medications one time.
79679782|NCT00519662|Drug|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
79994426|NCT04621045|Behavioral|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
79994427|NCT04621045|Behavioral|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
79994428|NCT01348490|Drug|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
79994429|NCT03040674|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
79994430|NCT03232333|Device|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
79994431|NCT02310204|Behavioral|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
79994432|NCT02310204|Other|standard psoriasis care alone|
79308142|NCT03047733|Device|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
79514297|NCT06114121|Drug|Ropivacaine|Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.
79219971|NCT02768103|Behavioral|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
79514298|NCT06114121|Drug|Bupivacaine Injection|Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
79514299|NCT06114082|Procedure|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
79514300|NCT06114082|Procedure|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
79514301|NCT06114069|Procedure|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
79514302|NCT06114030|Procedure|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
79219972|NCT02152839|Behavioral|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
79219973|NCT03375086|Drug|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
79219974|NCT02152917|Drug|Tranexamic acid|
79219975|NCT02152917|Drug|Floseal®|
79219976|NCT03111212|Drug|Iloprost|Iloprost nebulized
79363163|NCT03025659|Other|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
79363164|NCT03019666|Biological|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"Cyclophosphamide 40 mg/kg x 1 day on Day -5~Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)"
79514303|NCT06114017|Behavioral|Social Media Abstention|People will stop or reduce their social media use for one week.
79514304|NCT06114004|Drug|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
79219977|NCT03111212|Drug|control|sodium chloride 0,9% nebulized
79219978|NCT03170206|Drug|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
79219979|NCT03170206|Drug|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
79219980|NCT02156427|Device|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
79219981|NCT02156427|Device|PLACEBO|hyaluronic acid alone
79219982|NCT03060746|Other|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
79219983|NCT02156505|Procedure|placement of double bare stent|
79219984|NCT02156505|Device|DoubleBare stent|
79219985|NCT03381014|Drug|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
79219986|NCT05649046|Device|thoracic scan Low dose|within 3 months after the V0 visit
79219987|NCT05649046|Biological|BLOOD SAMPLE|within 3 months after the V0 visit
79219988|NCT05649046|Biological|FECES SAMPLE|within 3 months after the V0 visit
79219989|NCT03543423|Other|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
79363165|NCT00500578|Drug|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
79363166|NCT00500578|Drug|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
79363167|NCT01430559|Drug|Meloxicam|7.5mg x2 once a day for 12 weeks
79363168|NCT01430559|Drug|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
79514305|NCT06114004|Drug|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
79514306|NCT06113978|Procedure|Thoracoscopic sympathectomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
79514307|NCT06113978|Procedure|Thoracoscopic sympathotomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
79514308|NCT06113978|Procedure|Thoracoscopic sympathetic chain clipping|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
79219990|NCT03543423|Other|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
79219991|NCT03375008|Diagnostic Test|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
79219992|NCT02149953|Dietary Supplement|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
79219993|NCT03380936|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
79219994|NCT03380936|Other|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
79219995|NCT02150031|Drug|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
79514309|NCT06113965|Other|Peripheral Nerve Stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
79514310|NCT06113926|Other|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist… acknowledgment of the participants experience, …this shouldn't have happened, and I'm really sorry it did… an apology, and …I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
79514311|NCT06113900|Drug|Dapagliflozin 10mg Tab orally once daily|Sodium glucose co-transporter 2 inhibitors
79514312|NCT06113874|Other|Hurriseal desensitizer|"Patients will receive Hurriseal desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
79514313|NCT06113874|Other|Gluma desensitizer|"Patients will receive Gluma desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
79219996|NCT02150031|Drug|1% Chlorhexidine|subgingival irrigation
79219997|NCT02150031|Drug|1% Chlorhexidine|supragingival irrigation
79219998|NCT02150031|Procedure|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
79219999|NCT02150031|Drug|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
79220000|NCT02150031|Procedure|Tooth extraction|dental extraction
79220001|NCT03374852|Drug|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
79220002|NCT03374852|Drug|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
79220003|NCT04655170|Drug|Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
79220004|NCT04655170|Drug|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
79220005|NCT03378986|Procedure|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
79514320|NCT06113848|Drug|Intra-Arterial TNK and Albumin|The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
79514321|NCT06113848|Drug|Intra-Arterial TNK|The study population was divided into four groups, one of which had intra-arterial TNK .
79514322|NCT06113848|Drug|Intra-Arterial Albumin|The study population was divided into four groups, one of which had intra-arterial albumin.
79673009|NCT00460889|Procedure|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
79673010|NCT00495729|Drug|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
79673011|NCT00495729|Drug|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
79673012|NCT00495729|Drug|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
79220006|NCT03378986|Procedure|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
79514323|NCT06113848|Other|sham|The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.
79514324|NCT06113835|Procedure|CTO PCI|percutaneous coronary intervention
79514325|NCT06113796|Other|Surgery|Robotic rectal resection, either sphincter preserving or extirpation
79514326|NCT06113783|Device|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
79673013|NCT00460928|Drug|intravenous immune globulin (IVIG)|
79673014|NCT00495768|Behavioral|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
79673015|NCT00460967|Device|Rheopheresis|8 rheopheresis treatments over 10 wks.
79673016|NCT00460967|Device|Rheopheresis|Sham treatment
79679783|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
79220007|NCT02156661|Drug|Oxytocin|
79220008|NCT04797026|Other|Letters to increase social connection with goal to alleviate loneliness|Our hypothesis is that a social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitiative measures of loneliness
79363169|NCT01410357|Behavioral|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
79514327|NCT06113757|Device|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
79220009|NCT04310488|Other|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
79514328|NCT06113757|Other|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
79514329|NCT06113718|Procedure|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~Patients will try to defecate while sitting on the toilet."
79514330|NCT06113705|Diagnostic Test|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
79514331|NCT06113705|Diagnostic Test|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
79514332|NCT06113705|Other|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
79673017|NCT00461084|Drug|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
79673018|NCT00461084|Drug|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
79673019|NCT00495807|Behavioral|No Words|Without any words was given during pain management
79673020|NCT00495807|Behavioral|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
79673021|NCT00495807|Behavioral|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
79220010|NCT02150187|Dietary Supplement|HCap Formula|Pill should be taken every other day during the treatment phase.
79220011|NCT02150187|Dietary Supplement|Placebo|Similar pills without active ingredients
79220012|NCT03374774|Drug|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
79220013|NCT02156817|Other|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
79514333|NCT06113705|Other|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
79673022|NCT00495807|Behavioral|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
79679784|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
79820852|NCT02602847|Biological|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
79514334|NCT06113705|Other|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
79514335|NCT06113692|Biological|mRNA-1273|intramuscular injection
79514336|NCT06113653|Other|Prospective study|Prospective study of outcomes and predictors of mortality among preterm infants with neonatal sepsis
79994433|NCT04080505|Drug|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
79220014|NCT03374696|Behavioral|SAFETY|
79220015|NCT03374696|Behavioral|Standard education|
79220016|NCT02150265|Behavioral|SMART manual cognitive behavioral therapy|
79220017|NCT03380858|Device|colectomy|colectomy resection
79220018|NCT03124472|Procedure|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
79308143|NCT03047733|Drug|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
79363170|NCT00500656|Drug|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
79363171|NCT00500656|Drug|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
79514337|NCT06113627|Other|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
79220019|NCT03124472|Procedure|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~Closure of the anterior abdominal wall in layers"
79220020|NCT05386966|Other|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (<20 day or >20 day ).Expectance for permanent infirmity
79220021|NCT03125408|Diagnostic Test|HCV Assay|Molecular diagnostic test to detect Hepatitus C
79220022|NCT03374618|Other|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
79220023|NCT02767323|Device|rTMS|excitatory 5Hz rTMS will be used
79514338|NCT06113601|Other|There is no intervention.|There is no intervention in the study.
79220024|NCT02767323|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
79514339|NCT06113562|Procedure|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
79673023|NCT00461162|Behavioral|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
79820853|NCT04391907|Procedure|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
79820854|NCT04483206|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79308144|NCT03222011|Procedure|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
79673024|NCT00461162|Behavioral|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
79820855|NCT04483206|Drug|Melphalan|Given IV
79820856|NCT04483206|Other|Questionnaire Administration|Ancillary studies
79820857|NCT04107545|Behavioral|athletes|Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
79820858|NCT00725829|Drug|simvastatin|Simvastatin 40mg/d
79363172|NCT00500656|Drug|Oral Placebo|hard capsule matched to tranexamic acid
79363173|NCT00500656|Drug|S.C. Placebo|solution for injection, matched to icatibant for injection
79820859|NCT00725829|Drug|ezetimibe|ezetimibe 10mg/d
79820860|NCT00725829|Drug|placebo|placebo
79820861|NCT02603939|Procedure|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
79994434|NCT05572411|Other|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
79363174|NCT01409811|Drug|zoledronic acid|Given IV
79363175|NCT01409811|Other|laboratory biomarker analysis|Correlative studies
79363176|NCT01409811|Procedure|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
79363177|NCT01445847|Drug|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
79363178|NCT01445847|Other|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
79363179|NCT00501592|Drug|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
79363180|NCT00501592|Drug|Placebo|Placebo
79514340|NCT06113536|Diagnostic Test|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
79514341|NCT06113523|Biological|monogenic obesity|The DNA samples will be sequenced for the 71 obesity genes especially for the study.
79514342|NCT06113419|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
79994435|NCT05610696|Other|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
79220025|NCT03370094|Diagnostic Test|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
79220026|NCT05534698|Procedure|PCI|Revascularization by PCI
79220027|NCT05534698|Procedure|CABG|Revascularization by CABG
79363181|NCT01445769|Drug|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 & 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10^9/L at wk 12 or ≥ 150 x 10^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets <100 x 10^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level < 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
79363182|NCT00502216|Drug|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
79363183|NCT00502216|Drug|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
79363184|NCT00545662|Drug|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
79363185|NCT00545662|Drug|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
79363186|NCT00545974|Drug|memantine|memantine 10mg BID
79514343|NCT06113406|Behavioral|Classroom Training|Active Comparator
79514344|NCT06113406|Behavioral|Virtual Reality Training|Experimental
79514345|NCT06113393|Procedure|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
79673025|NCT00461162|Behavioral|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
79220028|NCT03374540|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
79363187|NCT00545974|Drug|Placebo pill|Placebo pill BID
79514346|NCT06113380|Device|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
79514347|NCT06113380|Other|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
79673026|NCT00495846|Drug|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
79673027|NCT00495846|Other|Locoregional treatments|
79673028|NCT00461201|Procedure|Nurse practitioner care of patients|
79673029|NCT04697316|Device|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
79220029|NCT03374540|Drug|Vitamin K antagonist (VKA)|Individually adjusted dose
79220030|NCT04304950|Drug|Evening Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
79220031|NCT04304950|Drug|Morning Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
79220032|NCT03374462|Behavioral|Telemedicine Intervention|Home-based telemedicine visits
79220033|NCT03374384|Other|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
79363188|NCT02928718|Procedure|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
79363189|NCT00507208|Device|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
79363190|NCT00507208|Other|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
79363191|NCT00548470|Drug|Varenicline|Varenicline 1-2 mg/day
79220034|NCT02780115|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
79220035|NCT02780115|Drug|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
79220036|NCT02780115|Drug|AGN-199201 Vehicle|Vehicle to AGN-199201
79220037|NCT02780115|Drug|AGN-190584 Vehicle|Vehicle to AGN-190584
79220038|NCT03378752|Procedure|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
79220039|NCT02808208|Biological|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
79514348|NCT06113367|Other|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
79673030|NCT04697316|Device|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
79363192|NCT02732704|Device|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
79363193|NCT00548860|Drug|Ferric Carboxymaltose|
79514349|NCT06113289|Drug|ASTX727|Given by PO
79363194|NCT00548860|Drug|Standard Medical Care (SMC)|
79514350|NCT06113289|Drug|ASTX029-01|Given by PO
79363195|NCT00508300|Procedure|Epidural analgesia|Thoracic epidural analgesia until day 2
79363196|NCT00508300|Procedure|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
79514351|NCT06113250|Device|shortwave diathermy|Shortwave diathermy (SWD) is a modality that produces heat by converting electromagnetic energy into thermal energy. pulsed shortwave diathermy (PSWD), uses high-frequency electromagnetic waves to heat tissues up to 5 cm deep. Heat is produced by the resistance of tissue to the passage of energy. Although it heats to the same depth as 1-MHz ultrasound, PSWD heats a much larger area than ultrasound does, making it ideal to heat larger joints, such as the elbow, shoulder, hip, knee, and ankle
79514352|NCT06113250|Device|ultrasound waves|Ultrasound is sound with a frequency above 20,000 Hertz (Hz) and is undetectable by the human ear. However, clinical ultrasound uses much high frequencies of between 1 and 20 megahertz (MHz) and sometimes up to 75 MHz in specialized areas such as dermatology and ophthalmology. Clinically, ultrasound is used for a number of applications ranging from visualizing structures to allow safe insertion of lines and catheters to diagnostic imaging including the assessment of the movement of cardiac Production of ultrasound waves is the first part of the clinical ultrasound process. Ultrasound is generated by piezoelectric crystals. These crystalline materials contain randomly oriented electric dipoles, and when a force is applied that deforms the crystal, the dipoles are rearranged and a net charge induced across the crystal
79514353|NCT06113250|Other|traditional physical therapy program|splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises
79673031|NCT00495924|Procedure|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
79994436|NCT05610696|Other|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
79220040|NCT02808208|Drug|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
79220041|NCT02808208|Biological|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
79220042|NCT04736446|Device|I-gel® supraglottic device|Use of an i-gel® supraglottic device to deliver ventilations
79220043|NCT04736446|Device|Face mask ventilation|Use of a face mask to deliver ventilations
79220044|NCT03369938|Other|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
79220045|NCT02156973|Other|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
79220046|NCT03378674|Drug|Remifentanil Injectable Product|remifentanil: 0,15 mcg/kg/min
79363197|NCT00509002|Drug|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
79363198|NCT02231008|Drug|tasimelteon|
79363199|NCT02231008|Drug|placebo|
79363200|NCT00509392|Device|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
79363201|NCT00509392|Device|Endovenous Laser|laser catheter
79363202|NCT01797172|Procedure|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
79673032|NCT00461279|Behavioral|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
79673033|NCT00461279|Behavioral|Interpersonal Psychotherapy|Established psychotherapy for depression
79679785|NCT04925466|Device|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
79514354|NCT06113224|Procedure|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
79514355|NCT06113224|Procedure|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
79514356|NCT06113198|Biological|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
79220047|NCT02157207|Dietary Supplement|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
79220048|NCT02157207|Other|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
79220049|NCT04178408|Other|No intervention|No intervention
79673034|NCT04697082|Procedure|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
79673035|NCT04697082|Procedure|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
79673036|NCT04697082|Other|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
79514357|NCT06113172|Other|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
79673037|NCT00105482|Drug|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
79673038|NCT00105482|Drug|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
79673039|NCT00105482|Behavioral|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
79673040|NCT00495963|Procedure|bronchoaleolar lavage|
79514358|NCT06113133|Diagnostic Test|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
79514359|NCT06113055|Drug|L-serine|Active comparator
79514360|NCT06113055|Drug|Placebo|Placebo comparator
79514361|NCT06112977|Procedure|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
79514362|NCT06112951|Procedure|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
79514363|NCT06112938|Drug|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
79673041|NCT00495963|Procedure|Bronchoscopy|
79673042|NCT00489021|Procedure|sub-acute hospitalization|
79673043|NCT00496002|Drug|Clevudine|
79673044|NCT00496002|Drug|Adefovir|
79673045|NCT03273725|Other|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
79673046|NCT03273686|Procedure|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
79673047|NCT00489060|Procedure|Cryoablation and External Beam Radiation|
79673048|NCT03273647|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
79673049|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot A|
79673050|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot B|
79220050|NCT02261103|Drug|Pramipexole ER tablets|
79220051|NCT02261103|Drug|Pramipexole IR tablets|
79220052|NCT02261103|Drug|Placebo matching Pramipexole ER tablets|
79220053|NCT02261103|Drug|Placebo matching Pramipexole IR tablets|
79220054|NCT02261103|Other|Standard high-fat breakfast|
79220055|NCT03378596|Dietary Supplement|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
79220056|NCT03378596|Dietary Supplement|L-arginine|L-arginine - sachet dissolved in water
79220057|NCT03378596|Dietary Supplement|L-citrulline|L-citrulline - sachet dissolved in water
79220058|NCT03378596|Dietary Supplement|Placebo|Placebo (corn starch) - sachet dissolved in water
79308145|NCT03222011|Procedure|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
79308146|NCT03119519|Radiation|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
79514364|NCT06112925|Other|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, & smoking cessation), drug adherence, and self-monitoring of the diseases.
79514365|NCT06112912|Other|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
79514366|NCT06112899|Behavioral|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
79514367|NCT06112886|Other|There was no intervention in this study|There was no intervention in this study
79514368|NCT06112873|Other|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
79514369|NCT06112834|Biological|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
79514370|NCT06112821|Other|Data collection in medical records|Data collection in medical records
79514371|NCT06112821|Other|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
79514372|NCT06112717|Other|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
79514373|NCT06112158|Behavioral|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support"
79514374|NCT06111846|Drug|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10^6 cells/kg (participant's body weight) administered twice (n=4)
79673051|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot C|
79673052|NCT00489099|Biological|V232 Current Process Hepatitis B Vaccine|
79673053|NCT03273569|Procedure|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
79673054|NCT00496158|Drug|Clevudine|
79994437|NCT05610696|Other|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
79363203|NCT01797172|Procedure|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
79363204|NCT00550654|Other|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
79363205|NCT00550654|Radiation|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
79363206|NCT00550654|Radiation|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
79673055|NCT00496158|Drug|Adefovir|
79673056|NCT03273530|Other|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
79673057|NCT00489138|Drug|Ertapenem|1g a day by drip of 30 min
79994438|NCT03364049|Drug|MK-7162|oral tablets
79994439|NCT03364049|Biological|Pembrolizumab|IV infusion
79994440|NCT03708029|Other|Revita Allograft|Human placental allograft
79994441|NCT05348772|Drug|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
79994442|NCT05681819|Drug|SHR-1707|Multiple-ascending Dose
79994443|NCT05681819|Drug|SHR-1707 placebo|Multiple-ascending Dose
79514375|NCT06111144|Behavioral|Polarized training intensity distribution (TID) and mental training using mindfulness|Polarized TID model group with mindfulness program (POL+)
79514376|NCT06111144|Behavioral|Pyramidal training intensity distribution (TID) and mental training using mindfulness|Pyramidal TID model group with mindfulness program (PYR+)
79673058|NCT00461396|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
79220059|NCT03543345|Diagnostic Test|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~Written consent.~Complete history.~Complete physical examination.~Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
79220060|NCT02153151|Other|Cytology specimen|Correlative studies
79220061|NCT02153151|Other|Laboratory biomarker analysis|Correlative studies
79220062|NCT04525742|Other|Difficulties lived by disabled children's parents in the period of COVID-19 pandemic|It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
79363207|NCT00550654|Radiation|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
79363208|NCT00550654|Radiation|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
79363209|NCT00887380|Drug|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
79363210|NCT00887380|Radiation|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
79514377|NCT06111144|Behavioral|Polarized training intensity distribution (TID) without mindfulness|Polarized TID model group without mindfulness program (POL-)
79514378|NCT06111144|Behavioral|Pyramidal training intensity distribution (TID) without mindfulness|Pyramidal TID model group without mindfulness program (PYR-).
79514379|NCT06111092|Other|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
79514380|NCT06111092|Other|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
79514381|NCT06110689|Other|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
79514382|NCT06110559|Device|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~Patients received 1.5 mA stimulation for 30 minutes."
79673059|NCT00489177|Device|A|QuickOpt intra-cardiac electrogram optimization
79994444|NCT05343078|Drug|Dapagliflozin 10Mg Tab|Participants will take a single-dose Dapagliflozin 10mg P.O. prior to the hemodialysis session for the single-dose pharmacokinetics protocol. In the multiple-dose protocol, Dapagliflozin 10mg P.O. will be taken daily in the morning for one week.
79220063|NCT04833465|Other|No Intervention|No Intervention
79363211|NCT00887380|Drug|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
79363212|NCT01445613|Device|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
79514383|NCT06110559|Device|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
79514384|NCT06110169|Device|Anodal Transcranial Direct Current Stimulation (Anodal tDCS)|Battery driven tDCS will be applied at 2 mA intensity to the dorsolateral prefrontal cortex and primary motor cortex for 20 minutes.
79514385|NCT06110169|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of sham anodal tDCS
79220064|NCT05475340|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
79514386|NCT06110130|Drug|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
79514387|NCT06110130|Drug|Placebo|Take Placebo 10 mg orally daily for 4 months
79673060|NCT00489177|Device|B|Single optimization in initial month post-implant
79673061|NCT00461435|Procedure|hyperbaric oxygen therapy|
79673062|NCT01327651|Drug|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
79673063|NCT01327651|Drug|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
79673064|NCT01327651|Drug|Event-driven dosing|TDF/FTC as needed with a post exposure dose
79220065|NCT03369860|Behavioral|Interactivity of Experimental Condition|The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
79220066|NCT02766777|Drug|Lubiprostone|12 or 24 mcg soft capsules for oral administration.
79514389|NCT06109532|Other|hyponatremia|hyponatremia at admission in dengue infected patients
79514390|NCT06108895|Other|ilio-inguinal/ilio-hypogastric nerve block (IINB)|Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
79514391|NCT06108895|Other|intrathecal morphine|200 mcg morphine intrathecally with bupivacaine
79363213|NCT00551200|Drug|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
79363214|NCT00551200|Drug|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
79363215|NCT00557284|Drug|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
79363216|NCT00557284|Drug|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
79363217|NCT00551746|Dietary Supplement|Purple Grape Juice|Grape Juice
79363218|NCT00552448|Device|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
79363219|NCT00557362|Drug|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
79514392|NCT06108817|Other|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
79363220|NCT00557362|Drug|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
79363221|NCT00557362|Procedure|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
79363222|NCT00558844|Drug|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
79514393|NCT06108817|Other|No Intervention|These practices do not receive information material
79673065|NCT00496236|Drug|TNFerade biologic|
79673066|NCT00461474|Behavioral|Shoulder strengthening exercises|
79994445|NCT03706235|Other|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
79220067|NCT05534308|Procedure|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
79673067|NCT00461474|Behavioral|Movement Optimization|
79673068|NCT00496275|Drug|Zactima (ZD6474)|
79220068|NCT05534308|Other|No trasoperative taping|Patients will received only compression stockings after surgery
79673069|NCT00496275|Drug|Vinorelbine plus cisplatin|
79994446|NCT03238963|Drug|BI 1467335|Once daily
79994447|NCT03238963|Drug|Placebo|Once daily
79673070|NCT00496275|Drug|Gemcitabine plus cisplatin|
79994448|NCT05693298|Device|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
79994449|NCT05693298|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
79220069|NCT03374306|Drug|Atropine (0.01%)|tropical application
79220070|NCT03374306|Drug|Artificial tear|tropical application
79220071|NCT05534230|Drug|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
79220072|NCT05534230|Drug|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
79220073|NCT03369782|Drug|Rocuronium|rocuronium is administered in bolus and continuous infusion
79220074|NCT03369782|Drug|Sugammadex|Sugammadex is administered just before reduction of the joint
79673071|NCT03273491|Behavioral|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
79673072|NCT03273491|Behavioral|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
79514394|NCT06106230|Combination Product|Bee venom phonophoresis|Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products & Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
79514395|NCT06106178|Other|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
79514396|NCT06106178|Other|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
79994450|NCT03701035|Behavioral|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
79514398|NCT06102083|Drug|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
79673073|NCT04329169|Other|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
79994451|NCT03701035|Behavioral|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
79220075|NCT03369782|Drug|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
79220076|NCT00157014|Drug|Tacrolimus|Oral
79220077|NCT00157014|Drug|Cyclosporine|Oral
79363223|NCT00558844|Drug|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
79220078|NCT00157014|Drug|Mycophenolate mofetil|Intravenous and Oral
79220079|NCT00157014|Drug|Methylprednisolone|Intravenous
79220080|NCT00157014|Drug|Prednisone|Oral
79220081|NCT03374228|Drug|BMS-986205|Specified Dose on Specified Days
79220082|NCT02778867|Other|1 Food Elimination Diet Therapy|
79220083|NCT02778867|Other|6 Food Elimination Diet Therapy|
79220084|NCT02778867|Other|6 Food Elimination Diet (after 1FED failure)|
79220085|NCT02778867|Drug|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
79220086|NCT03374150|Behavioral|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
79220087|NCT04232072|Other|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
79308147|NCT03119519|Drug|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
79514399|NCT06101303|Other|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (<1 mm²) and texture."
79673074|NCT00461669|Procedure|ultrasound examination of the hip|
79673075|NCT00489294|Drug|Syntropin|
79673076|NCT00591604|Drug|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
79679786|NCT04925466|Device|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
79679787|NCT00520364|Other|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
79514400|NCT06101303|Behavioral|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
79514401|NCT06101303|Diagnostic Test|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
79673077|NCT00591643|Procedure|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
79673078|NCT00591643|Radiation|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
79994452|NCT03337139|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
79220088|NCT04232072|Other|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
79220089|NCT02157285|Behavioral|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
79220090|NCT03369626|Behavioral|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
79220091|NCT02300064|Other|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
79514402|NCT06101303|Procedure|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
79220092|NCT02300064|Other|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
79308148|NCT03221699|Other|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
79514403|NCT06099353|Behavioral|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
79673079|NCT00461747|Drug|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
79994453|NCT03337139|Behavioral|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
79514404|NCT06099353|Behavioral|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
79514405|NCT06099353|Behavioral|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
79514406|NCT06099223|Device|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
79673080|NCT00461747|Drug|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
79673081|NCT00461747|Drug|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
79220093|NCT02300064|Other|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
79994454|NCT03337139|Behavioral|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
79220094|NCT02300064|Other|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
79220095|NCT05473390|Other|functional electrical stimulation|functional electrical stimulation on back muscles
79220096|NCT05473390|Other|kinesotaping|no intervention
79363224|NCT00558844|Drug|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
79220097|NCT02778555|Behavioral|Questionnaires|
79220098|NCT03513198|Diagnostic Test|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNA will be performed in all pancreatic masses with at least four passes."
79220099|NCT03513198|Other|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
79308149|NCT03221699|Other|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
79363225|NCT00558844|Drug|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
79514407|NCT06098742|Drug|Antareit|A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
79673082|NCT00489333|Drug|ProAlgaZyme|
79673083|NCT04328935|Behavioral|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
79673084|NCT00496314|Device|e2TM Cervical Cell Collector|
79673085|NCT00461825|Drug|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
79673086|NCT00461825|Drug|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
79673087|NCT00461825|Drug|Group B: CsA + CellCept(500 mg x 2/day)|
79673088|NCT00461825|Drug|Group C: CsAm|
79673089|NCT04433026|Diagnostic Test|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
79673090|NCT00489372|Drug|Se-methyl-seleno-L-cysteine|Given orally
79673091|NCT00489372|Other|placebo|Given orally
79673092|NCT00489372|Other|pharmacological study|Correlative studies
79673093|NCT00489372|Other|laboratory biomarker analysis|Correlative studies
79673094|NCT04431739|Device|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
79514408|NCT06090266|Drug|OR502|IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
79514409|NCT06090266|Drug|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
79220100|NCT03513198|Other|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
79363226|NCT00558844|Drug|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
79514410|NCT06087419|Drug|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
79514411|NCT06087419|Drug|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
79514412|NCT06087419|Drug|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
79363227|NCT00512278|Drug|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
79363228|NCT00512278|Drug|Placebo|Placebo
79514413|NCT06085508|Behavioral|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
79514414|NCT06083246|Other|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
79514415|NCT06083246|Other|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
79514416|NCT06082921|Behavioral|Beef Diet Intervention|Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
79220101|NCT03513198|Diagnostic Test|Contrast-enhanced computed tomography (CT)|"Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~A template will be used to report the imaging results.~The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
79363229|NCT01445535|Biological|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
79363230|NCT01445535|Drug|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
79514417|NCT06082921|Behavioral|Impossible Beef Diet Intervention|Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
79514418|NCT06078150|Behavioral|Active video games intervention（1-6weeks）|"Experimental:~Experimental group for weeks 1-3: enter the subject's basic information. The Fitness Ring Adventure requires subjects to be proficient in wearing two Joy-Con devices. Therefore, during the three interventions in the first week, subjects were able to fully understand how the AVG was worn, the game mechanics, and the game modes. Familiarise yourself with the warm-up and stretching patterns in the preparation phase of the game in order to be better prepared for subsequent interventions.~Experimental group for weeks 4-6: to supervise and assist subjects during this intervention phase and to organize a speed passing competition at the end of week 6 to reward the subjects. Variables related to the subjects' activity, mental health, and physical composition were tested and recorded while testing proficiency in the game."
79673095|NCT04430686|Other|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
79673096|NCT00461864|Procedure|ultrasound examination of the hip|
79673097|NCT04430023|Other|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
79363231|NCT01445535|Biological|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
79363232|NCT01445535|Drug|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
79363233|NCT01445535|Drug|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
79363234|NCT01445535|Drug|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
79363235|NCT01445535|Drug|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
79673098|NCT00496353|Drug|MK2461|MK2461 treatment, bid, 28-day
79679788|NCT02949089|Drug|ACH04|The subjects will receive the study medication in each group
79514419|NCT06078150|Behavioral|Active video games intervention（7-12weeks）|"Experimental:~Experimental group in weeks 7-9: continue to warm up before each game and then play the game. Passing tasks were set for each subject from week 7 onwards, and they had to pass 2 tasks during each weekly intervention.~Experimental group in weeks 10-12: weekly intervention ensured that subjects were able to complete the pass 2 task, and if they completed the pass within the allotted time they were able to review the previously passed task. A boss fight was held in week 12, with a prize awarded to the person who took the shortest time."
79220102|NCT03369548|Other|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
79220103|NCT03369548|Other|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
79363236|NCT01445301|Drug|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
79363237|NCT01445301|Drug|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
79363238|NCT01409031|Drug|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
79363239|NCT01409031|Other|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
79363240|NCT01430403|Biological|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
79220104|NCT03369548|Dietary Supplement|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
79220105|NCT03369548|Other|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
79514420|NCT06075290|Behavioral|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
79514421|NCT06075290|Behavioral|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
79514422|NCT06074263|Drug|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
79514423|NCT06074263|Other|Placebo|Placebo capsule which looks identical to dexamethasone capsule
79514424|NCT06064695|Device|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
79514425|NCT06063876|Procedure|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
79514426|NCT06063876|Procedure|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
79363241|NCT01430403|Drug|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
79220106|NCT02150577|Behavioral|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
79363242|NCT01430403|Biological|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
79514427|NCT06059794|Other|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
79514428|NCT06059794|Other|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
79514429|NCT06054516|Diagnostic Test|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized [1-13C]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
79514430|NCT06048107|Drug|Teniposide|Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
79514431|NCT06047119|Procedure|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
79679789|NCT02940210|Device|Mediclore® (adhesion barrier)|
79220107|NCT03373994|Diagnostic Test|18F-FDG PET/CT initial-time imaging|18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
79514432|NCT06047119|Procedure|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
79514433|NCT06047119|Procedure|Tidal volume|Tidal volume during general anesthesia
79514434|NCT06047119|Procedure|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
79514435|NCT06046001|Device|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
79514436|NCT06041841|Drug|LB54640|LB54640 QD Oral
79514437|NCT06041581|Behavioral|Sleep Healthy Using The Internet (SHUTi)|Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
79514438|NCT06041581|Behavioral|Telephonic CBT-I|Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
79994455|NCT05439096|Other|Functional Exercise|Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.
79363243|NCT01430403|Biological|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
79994456|NCT05439096|Other|High Frequency Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
79363244|NCT01429623|Drug|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
79363245|NCT01429623|Drug|Placebo|Placebo comparator
79363246|NCT01408641|Drug|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
79363247|NCT01408641|Drug|Placebo|Placebo capsules without topiramate
79363248|NCT01429077|Drug|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
79363249|NCT01429077|Drug|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
79363250|NCT01428453|Drug|250mg rilapladib|Experimental Drug
79994457|NCT03964363|Behavioral|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
79363251|NCT01428453|Drug|placebo|Placebo comparator
79363252|NCT01408563|Drug|Fludarabine|30 mg/m2/day IV x 6 days
79363253|NCT01408563|Drug|Melphalan|100 mg/m2/day IV x 1 day
79363254|NCT01408563|Radiation|Total Body Radiation|200 cGy on Day 0
79363255|NCT01408563|Biological|Cord Blood|2 cord blood units IV
79363256|NCT01442493|Other|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
79363257|NCT01442493|Other|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
79363258|NCT04069923|Other|Magnesium-based Bone Void Filler|Given intraoperatively
79363259|NCT01442181|Procedure|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
79363260|NCT01442181|Other|Medical therapy|Patients are treated with rhythm and rate control medications.
79363261|NCT04407975|Other|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
79363262|NCT04407975|Other|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
79363263|NCT01442103|Device|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
79514439|NCT06041581|Behavioral|Face-to-Face CBT-I|Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
79673099|NCT04429477|Device|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
79673100|NCT00461318|Procedure|Individual placement and support (vocational rehabilitation)|
79673101|NCT04428229|Other|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
79220108|NCT03373994|Diagnostic Test|18F-FDG PET/CT balanced-time imaging|18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
79514440|NCT06041581|Other|Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care|A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
79514441|NCT06038617|Biological|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
79514442|NCT06038617|Biological|Routine Childhood Vaccinations|ACIP Recommended Vaccines
79514443|NCT06035263|Other|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
79994458|NCT03710447|Other|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
79220109|NCT03520764|Dietary Supplement|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
79220110|NCT03520764|Dietary Supplement|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
79220111|NCT03369470|Behavioral|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
79363264|NCT04069767|Procedure|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
79363265|NCT04069767|Procedure|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
79363266|NCT01428219|Drug|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
79363267|NCT01428063|Drug|Daclatasvir|
79363268|NCT01428063|Drug|Asunaprevir|
79363269|NCT01428063|Drug|Pegylated interferon alfa-2a|
79363270|NCT01428063|Drug|Ribavirin|
79363271|NCT00513292|Drug|Cyclophosphamide|Given IV
79363272|NCT00513292|Drug|Epirubicin Hydrochloride|Given IV
79363273|NCT00513292|Other|Laboratory Biomarker Analysis|Correlative studies
79363274|NCT00513292|Drug|Paclitaxel|Given IV
79363275|NCT00513292|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79514444|NCT06035263|Other|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
79514445|NCT06035198|Other|Stroke|No intervention
79514446|NCT06033859|Diagnostic Test|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
79514447|NCT06033859|Diagnostic Test|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
79673102|NCT00461903|Drug|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
79679790|NCT02948816|Behavioral|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
79220112|NCT03369470|Behavioral|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
79363276|NCT00513292|Biological|Trastuzumab|Given IV
79514448|NCT06033859|Procedure|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
79679791|NCT02948816|Behavioral|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
79679792|NCT02948816|Behavioral|Colouring|Participants will spend 30 minutes colouring quietly.
79679793|NCT04880694|Drug|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
79220113|NCT04640038|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
79363277|NCT00513370|Biological|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
79363278|NCT00559468|Drug|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
79363279|NCT00559468|Drug|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
79363280|NCT00559468|Drug|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
79363281|NCT00559468|Drug|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
79363282|NCT00560560|Biological|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
79363283|NCT00561418|Drug|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
79514449|NCT06031662|Device|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting MT
79514450|NCT06031662|Device|Sham Intermittent Theta-Burst Stimulation|Magventure Active/Placebo B70 coil specifically designed for randomized clinical trials with TMS. This system uses electrodes placed on the scalp to provide stimulation mimicking the active treatment condition
79514451|NCT06025721|Behavioral|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking>medication>sleep>physical activity>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
79514452|NCT06004336|Drug|Pembrolizumab|Given by vein (IV)
79514453|NCT06004336|Radiation|Radiation therapy|Given by vein (IV)
79679794|NCT04880694|Drug|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
79679795|NCT00520442|Drug|ibuprofen|
79220114|NCT02296008|Device|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
79220115|NCT03378284|Drug|Tegoprazan|Tegoprazan QD for 7 days
79363284|NCT00561418|Other|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
79363285|NCT00514852|Drug|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
79363286|NCT00514852|Drug|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
79363287|NCT00555880|Drug|Midodrine hydrochloride|one dose, 10-30mg, given orally
79363288|NCT00555880|Drug|Placebo|Placebo
79363289|NCT00563290|Drug|dasatinib|Given PO
79363290|NCT00563290|Other|laboratory biomarker analysis|Correlative studies
79363291|NCT00556504|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
79363292|NCT00556504|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
79363293|NCT00556504|Drug|Ribavirin|conventional treatment of Hepatitis C
79363294|NCT00556504|Drug|Placebo|Placebo, without acting ingredient.
79363295|NCT05560828|Other|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
79514454|NCT05997732|Drug|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
79514455|NCT05997732|Drug|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
79514456|NCT05997732|Drug|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
79514457|NCT05997732|Drug|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
79514458|NCT05997732|Drug|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
79514459|NCT05997732|Drug|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
79514460|NCT05997732|Drug|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
79514461|NCT05997732|Drug|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
79514462|NCT05979454|Diagnostic Test|Krebs von den Lungen-6 (KL6)|KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
79514463|NCT05970614|Other|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
79679796|NCT00520442|Drug|acetamin w codeine|
79679797|NCT02948894|Device|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
79514464|NCT05961514|Diagnostic Test|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
79514465|NCT05961514|Diagnostic Test|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
79514466|NCT05958628|Other|Conventional physiotherapy|"The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes."
79514467|NCT05958628|Other|Robotic Hand Exoskeleton System|In the treatment applications with the robotic hand exoskeleton system, which is designed to accelerate the healing process of patients in need of hand rehabilitation, to gain motor skills, to provide strength training and to increase participation in treatment, the patient will be asked to allow the system to move the hand at adjusted angles for 10 minutes and to accompany this movement. In the applications, while the patient is sitting comfortably and safely, the patient will be asked to place the stroke-affected hand into the system. The hand of patients who may have difficulty due to the functional status of the upper extremity and the severity of spasticity will be placed with the help of the physiotherapist. The physiotherapist will be with the patient throughout the application.
79514468|NCT05943314|Biological|CLL1/+CD33 CAR-T|CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
79514469|NCT05942326|Behavioral|Sleep GOALS|Web-based interventions
79514470|NCT05942326|Behavioral|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
79220116|NCT03378284|Drug|Revaprazan|Revaprazan QD for 7 days
79994459|NCT03710447|Other|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
79220117|NCT03516396|Behavioral|Training Plus|Training plus enhanced community development activities
79363296|NCT02127892|Biological|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
79220118|NCT03516396|Behavioral|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
79220119|NCT03516396|Behavioral|No Inputs then Community development and training|No inputs for 24 months then add community development and training
79514471|NCT05941858|Other|Best Practice|Receive standard cessation treatments
79514472|NCT05941858|Procedure|Carbon Monoxide Measurement|Undergo CO test
79220120|NCT03369392|Other|Panda application|A smartphone-based postoperative pain management tool
79220121|NCT02617550|Drug|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
79220122|NCT02617550|Drug|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets [o.d.].
79220123|NCT02617550|Drug|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat [trough] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat [peak] or placebo) on day 13, day 27 and day 41
79220124|NCT03512886|Other|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
79220125|NCT03512886|Other|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
79220126|NCT03369314|Drug|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
79363297|NCT02127892|Biological|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
79363298|NCT02127892|Biological|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
79363299|NCT02127892|Device|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
79363300|NCT02128828|Drug|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
79220127|NCT05533840|Diagnostic Test|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
79220128|NCT03520530|Device|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
79220129|NCT03378206|Device|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
79363301|NCT00520234|Drug|Caspofungin|50 mg IV daily
79363302|NCT00520234|Drug|Normal Saline|100 cc IV daily
79363303|NCT05560672|Other|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
79363304|NCT00520468|Drug|Erythropoietin|40,000 units injected under the skin (SQ) weekly
79363305|NCT00520468|Drug|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
79363306|NCT00520468|Drug|G-CSF|300 mcg injected under the skin (SQ) two times per week
79363307|NCT00520468|Drug|Prednisone|60 mg per day for 7 days, taper over 1 month
79363308|NCT01908712|Drug|Lamazym|ERT, i.v. infusions weekly
79363309|NCT05622526|Drug|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
79514473|NCT05941858|Other|Internet-Based Intervention|Receive access to WaQi program
79514474|NCT05941858|Drug|Nicotine Replacement|Receive referral for NRT
79514475|NCT05941858|Other|Survey Administration|Ancillary studies
79514476|NCT05941858|Other|Tai Chi|Practice Tai Chi
79220130|NCT03378206|Device|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
79220131|NCT03512808|Drug|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
79220132|NCT03512808|Drug|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
79220133|NCT05533762|Device|arch insole and sham insole|children wear insoles on feet
79220134|NCT03520452|Other|Green coffee extract|Reconstituted in water and given to subjects
79220135|NCT03520452|Other|Placebo|Placebo
79363310|NCT05622526|Other|Group 2 or Control group|capsules of placebo
79363311|NCT05560438|Device|Tyromotion Amadeo and Armeo Senso|Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
79363312|NCT05622448|Other|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
79363313|NCT05622448|Other|RPD with metallic framework|removable partial denture with cobalt chromium framework
79363314|NCT05559268|Drug|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
79363315|NCT05559268|Drug|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
79363316|NCT02338960|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
79514477|NCT05935917|Drug|Brincidofovir|100 mg tablet of Form H and 100 mg tablet of Form II
79220136|NCT02519582|Drug|Niclosamide|2 g per day orally
79220137|NCT03512730|Device|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
79220138|NCT03512730|Other|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
79363317|NCT02338960|Drug|Placebo|Placebo
79363318|NCT05622214|Dietary Supplement|Else nutrition formula|Plant based nutrition from almond and buckwheat
79363319|NCT05621902|Other|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
79363320|NCT02121418|Drug|Cytarabine|Given IV
79363321|NCT02121418|Drug|Decitabine|Given IV
79363322|NCT02121418|Other|Laboratory Biomarker Analysis|Correlative studies
79363323|NCT01441635|Drug|Elagolix|Elagolix tablets
79363324|NCT01441635|Drug|Placebo|Matching placebo tablets
79363325|NCT01441635|Drug|Estradiol/Norethindrone acetate (E2/NETA)|A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
79363326|NCT01441635|Drug|Estradiol|1.0 mg micronized estradiol tablets administered once a day
79363327|NCT01441635|Drug|Progesterone|Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
79514478|NCT05918302|Drug|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
79514479|NCT05918302|Drug|Everolimus|10 mg orally once daily (QD)
79514480|NCT05910567|Diagnostic Test|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
79514481|NCT05910567|Other|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
79514482|NCT05895825|Drug|EOC237|EOC237 for orally
79514483|NCT05891548|Drug|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
79673103|NCT00591682|Drug|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
79673104|NCT00496392|Drug|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
79673105|NCT04329013|Other|Left lateral Position during intervention|Left lateral position during EGD
79673106|NCT04329013|Other|Prone Position during intervention|Prone position during EGD
79363328|NCT01408485|Device|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~IBI 1500T9 V1.43 RF Generator"
79363329|NCT01427907|Drug|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
79514484|NCT05891548|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
79673107|NCT02893696|Other|Various sitting time|Various sitting time
79673108|NCT00496509|Drug|ZD6474 (Zactima) 100mg|
79673109|NCT00496509|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
79673110|NCT00496509|Procedure|Biomarker Draws|
79673111|NCT00496509|Drug|ZD6474 (Zactima) 300mg|
79679798|NCT04870320|Behavioral|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
79679799|NCT04870320|Behavioral|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
79363330|NCT01427907|Drug|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
79220139|NCT03378050|Behavioral|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
79363331|NCT03026595|Other|no intervention|no intervention
79220140|NCT03378050|Other|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
79220141|NCT05167968|Other|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~Self-questioning of medication adherence: Girerd questionnaire~Assessment of the Medication Possession Ratio~Social and demographic data~Comorbidities~PH characteristics"
79220142|NCT03516318|Behavioral|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
79220143|NCT05467462|Drug|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
79220144|NCT05467462|Drug|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
79363332|NCT02985333|Drug|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
79363333|NCT02985333|Drug|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
79363334|NCT02985333|Drug|Dexamethasone|Dexamethasone 20mg iv d1-4
79363335|NCT01427751|Drug|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
79363336|NCT01427751|Biological|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
79363337|NCT01920061|Drug|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
79363338|NCT01920061|Drug|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m^2
79363339|NCT01920061|Drug|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m^2
79363340|NCT01920061|Drug|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
79363341|NCT01426425|Device|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
79363342|NCT02074995|Biological|BVS857|Group 1A&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
79363343|NCT02074995|Other|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
79363344|NCT01426347|Drug|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
79363345|NCT01426347|Drug|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
79363346|NCT01882465|Device|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
79363347|NCT01882465|Device|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
79363348|NCT01882465|Device|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
79363349|NCT04612309|Drug|Immunotherapy|patient treated with at least 1 immunotherapy administration
79363350|NCT04415983|Drug|Nitazoxanide|Nitazoxanide twice daily
79363351|NCT04415983|Drug|Clarithromycin|Klacid twice daily
79363352|NCT04415983|Drug|Metronidazole|Metronidazole twice daily
79363353|NCT04415983|Drug|Proton pump inhibitor|Omeprazoe twice daily
79363354|NCT01426269|Drug|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads), oral, one capsule daily in the morning
79514486|NCT05881161|Behavioral|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
79514487|NCT05881161|Behavioral|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
79514488|NCT05881148|Other|Carbon sprinting spiked-shoes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
79514489|NCT05881148|Other|Standard carbon-free sprinting spiked-shoes|cf
79514490|NCT05871996|Other|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
79514491|NCT05870670|Drug|NNC0519-0130|Administered subcutaneously.
79220145|NCT05467462|Drug|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
79220146|NCT05467462|Drug|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
79994460|NCT03710447|Other|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
79994461|NCT03710447|Other|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
79994462|NCT03710369|Drug|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
79994463|NCT03710369|Drug|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
79994464|NCT05681663|Other|Electroshock Wave therapy|Randomized- Controlled trial
79994465|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
79220147|NCT03373838|Other|Census|Survey and interview
79363355|NCT01426269|Drug|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
79363356|NCT01426269|Drug|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
79363357|NCT01426113|Drug|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
79363358|NCT01426113|Drug|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
79363359|NCT01426113|Drug|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
79363360|NCT01864603|Other|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
79363361|NCT01864603|Other|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
79994466|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
79514492|NCT05870670|Drug|Placebo|Administered subcutaneously.
79514493|NCT05869838|Device|Colonoscopy|Screening or surveillance colonoscopy
79994467|NCT03707795|Drug|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
79994468|NCT01312025|Procedure|conventional laparoscopic cholecystectomy|
79994469|NCT01312025|Procedure|modified laparoscopic cholecystectomy|
79994470|NCT05176535|Dietary Supplement|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
79220148|NCT03516240|Other|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
79220149|NCT03516240|Other|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
79220150|NCT03516162|Other|There is no study-specific intervention|There is no study-specific intervention
79220151|NCT03369002|Drug|seladelpar|Oral single dose 10 mg
79363362|NCT01864603|Other|Targeted PrEP and Targeted testing interventions|
79363363|NCT01864603|Other|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
79363364|NCT01892293|Drug|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
79514494|NCT05869383|Drug|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
79514495|NCT05869383|Drug|Placebo|Placebo 2x5 grams
79514496|NCT05862792|Drug|Liposomal bupivacaine|We will inject liposomal bupivacaine into the surgical bed.
79220152|NCT03520296|Other|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
79220153|NCT03373526|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
79220154|NCT03373526|Other|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
79220155|NCT02778399|Drug|Placebo|Placebo tablets for oral administration once daily
79514497|NCT05855317|Other|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
79363365|NCT04415593|Dietary Supplement|High dose of peanuts|Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
79514498|NCT05849454|Device|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory."
79514499|NCT05849337|Behavioral|Brief imagery-competing task|Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.
79514500|NCT05849337|Behavioral|Brief psychoeducation and signposting task|Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.
79514501|NCT05849337|Other|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events
79514502|NCT05845788|Procedure|Peripheral nerve block|Ultrasound guided peripheral nerve block
79514503|NCT05832268|Other|Obstetric Anal Sphincter Injury|We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
79514504|NCT05831293|Behavioral|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
79673112|NCT04136197|Diagnostic Test|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
79673113|NCT00496548|Procedure|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
79220156|NCT02778399|Drug|OBE2109|OBE2109 tablets for oral administration once daily
79220157|NCT03520218|Device|Performance of R-PEM|R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
79514505|NCT05829603|Drug|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
79673114|NCT00496548|Procedure|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
79673115|NCT04135222|Diagnostic Test|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
79673116|NCT02893618|Drug|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
79673117|NCT03273452|Drug|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
79673118|NCT00496665|Drug|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
79220158|NCT03377894|Procedure|blunt uterine incision expansion|blunt uterine incision expansion
79220159|NCT03377894|Procedure|sharp uterine incision expansion|sharp uterine incision expansion
79220160|NCT03516084|Drug|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
79220161|NCT03516084|Drug|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
79308150|NCT03221465|Behavioral|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
79308151|NCT03221465|Behavioral|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
79363366|NCT04415593|Dietary Supplement|Low dose of peanuts|Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
79363367|NCT01393899|Drug|Placebo|oral tablets twice daily
79363368|NCT01393899|Drug|CP-690,550|oral tablets twice daily
79363369|NCT01393899|Drug|CP-690,550|oral tablets twice daily
79514506|NCT05804708|Drug|GH001|GH001 is administered via inhalation
79514507|NCT05798975|Other|Aerobic Exercise. 1 session of acute exercise|40 minutes on cycle ergometer, 60% of heart rate reserve
79514508|NCT05798975|Other|Resistance Exercise. 1 session of acute exercise|2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes
79220162|NCT03368924|Other|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, … Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein … The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
79363370|NCT01393743|Drug|Perampanel|
79514509|NCT05798975|Other|no exercise|Rest
79514510|NCT05788783|Behavioral|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
79514511|NCT05788783|Other|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
79514512|NCT05787496|Drug|NC525|Monoclonal antibody specific for LAIR-1
79220163|NCT05366452|Device|IMPELLA CP|Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT >250 s. As soon as the device is in place it will be started.
79308152|NCT02118766|Drug|AN2728 Topical Ointment, 2%|
79363371|NCT01393743|Drug|Placebo comparator|
79673119|NCT00496665|Drug|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
79673120|NCT00496665|Drug|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
79673121|NCT04423003|Procedure|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
79673122|NCT00496704|Drug|capecitabine|
79673123|NCT00496704|Drug|gemcitabine hydrochloride|
79673124|NCT00496704|Drug|oxaliplatin|
79994471|NCT03042312|Drug|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
79994472|NCT05171231|Device|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
79308153|NCT02118766|Drug|Matching vehicle control|
79363372|NCT02078193|Drug|Belatacept|Patients will be converted from their MMF to Belatacept
79363373|NCT01405911|Drug|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
79363374|NCT01405911|Drug|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
79363375|NCT01405911|Drug|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
79363376|NCT01405911|Drug|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
79363377|NCT01425801|Drug|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
79363378|NCT01425801|Drug|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
79363379|NCT01425801|Drug|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
79363380|NCT01425801|Drug|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
79363381|NCT01425801|Drug|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
79363382|NCT01425801|Drug|Salbutamol placebo|Pressurized inhalation, once-daily
79363383|NCT01425801|Drug|LAS100977 placebo|Dry powder inhalation, once-daily
79363384|NCT03025503|Other|nipple stimulation|
79363385|NCT02335125|Behavioral|Motivational Interviewing|
79673125|NCT04420117|Other|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
79673126|NCT04698005|Dietary Supplement|25g Ketone monoester without added salts|oral supplementation of ketone monoester
79673127|NCT04698005|Other|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
79673128|NCT00496743|Device|Low-dose total skin electron beam therapy (4 Gy)|
79673129|NCT04419064|Diagnostic Test|Point of care ultrasound|Tracheal and lung ultrasonography
79673130|NCT04418050|Procedure|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
79679800|NCT04870320|Other|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
79679801|NCT03458013|Behavioral|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
79220164|NCT05366452|Other|Conventional therapy|The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
79514513|NCT05784402|Drug|Semaglutide J|Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
79514514|NCT05784402|Drug|Semaglutide C|Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
79514515|NCT05782517|Device|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
79514516|NCT05782517|Device|Endotracheal Tube|Placement of an Endotracheal Tube.
79220165|NCT03377738|Diagnostic Test|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
79363386|NCT02335125|Behavioral|Cognitive Behavioral Therapy Elements|
79514517|NCT05781958|Drug|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
79363387|NCT02335125|Drug|Psychotropic Drugs|
79363388|NCT02335125|Other|Care Management|
79363389|NCT01425723|Biological|rFIXFc|Administered as specified in the treatment arm.
79363390|NCT02076243|Drug|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
79514521|NCT05769478|Drug|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
79514522|NCT05757206|Diagnostic Test|Syn-One Test|Participating subjects will have three small skin punch biopsies.
79994473|NCT03706001|Other|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
79994474|NCT05692986|Diagnostic Test|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of >5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
79673131|NCT04417426|Other|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
79673132|NCT02893852|Behavioral|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
79679802|NCT02948738|Behavioral|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
79220166|NCT02300376|Drug|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
79220167|NCT02300454|Device|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
79363391|NCT01424397|Drug|SB-705498|12mg intranasal
79363392|NCT01424397|Drug|FP|200ug intranasal
79363393|NCT01424397|Drug|placebo|placebo intranasal
79220168|NCT02300454|Device|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
79220169|NCT02157363|Procedure|Repositioning|
79220170|NCT02157363|Procedure|Single positioning|
79220171|NCT03368846|Drug|Varlitinib|[14C]-Varlitinib
79363394|NCT01392963|Drug|botulinum toxin type A neurotoxin complex|29-40 U injection
79363395|NCT01392963|Drug|Placebo|29-40 U 0.9% NaCl injection
79514523|NCT05755152|Other|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
79514524|NCT05755152|Other|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
79514525|NCT05753930|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
79514526|NCT05737602|Behavioral|3RP-VHL|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
79994475|NCT03360071|Drug|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
79994476|NCT03360071|Drug|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
79363396|NCT01392573|Drug|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
79363397|NCT01392573|Drug|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
79363398|NCT01392495|Drug|Imatinib|200 mg or 400 mg qd
79363399|NCT01405053|Drug|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
79514527|NCT05729282|Drug|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
79514528|NCT05729282|Drug|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
79514529|NCT05729282|Drug|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
79514530|NCT05729282|Device|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
79514531|NCT05729282|Drug|Deuterated water (2H2O/D2O)|All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
79994477|NCT05692830|Drug|Alcohol|Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
79994478|NCT05092776|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
79994479|NCT05092776|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
79994480|NCT03710213|Behavioral|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
79220172|NCT05533450|Device|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
79220173|NCT05533450|Device|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
79220174|NCT02153385|Other|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
79220175|NCT04525040|Dietary Supplement|ProbioKid®|Probiokid formulation includes three probiotic strains and fructooligosaccharides.
79220176|NCT04525040|Other|Pragmatic comparator|Standard of care as usual without a preventive intervention
79363400|NCT01405053|Drug|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
79363401|NCT01403805|Biological|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
79363402|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
79514532|NCT05724316|Dietary Supplement|Vitamin D supplement|N/A (says not to repeat information here)
79514533|NCT05724264|Diagnostic Test|Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays|"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."
79220177|NCT03377582|Other|Exercise|Both interventions uses exercises
79220178|NCT03377504|Behavioral|mirror therapy|Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
79220179|NCT03377504|Behavioral|Routine physical therapy and exercise program|Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
79220180|NCT02157441|Procedure|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
79220181|NCT05361460|Other|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
79220182|NCT02296398|Drug|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
79514534|NCT05724134|Drug|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
79514535|NCT05724134|Drug|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
79514536|NCT05724134|Drug|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
79514537|NCT05724134|Drug|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
79220183|NCT02153463|Behavioral|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
79220184|NCT03377426|Drug|LYS228|LYS228 IV infusion
79220185|NCT03377426|Drug|Standard of care therapy|IV infusion of standard of care antibiotics
79514538|NCT05724134|Other|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
79994481|NCT04745507|Other|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
79220186|NCT03520062|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for ~6 weeks
79220187|NCT02150655|Biological|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
79220188|NCT02150655|Biological|Placebo|
79220189|NCT03373292|Procedure|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
79363403|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
79514539|NCT05724134|Drug|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
79220190|NCT03373292|Procedure|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
79363404|NCT01403805|Other|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
79363405|NCT01423617|Dietary Supplement|Zenoctil|3 tablets 2 times daily
79363406|NCT01423617|Other|Placebo|3 tablets 2 times daily
79514540|NCT05724134|Dietary Supplement|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
79673133|NCT02893852|Behavioral|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
79673134|NCT00496821|Drug|ALN-RSV01|
79673135|NCT00461942|Drug|Green Tea Polyphenols (EGCG/ECG)|
79994482|NCT05681429|Drug|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
79220191|NCT03516006|Drug|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
79363407|NCT01392183|Drug|Pazopanib|800 mg by mouth daily in 4 week study cycle.
79363408|NCT01392183|Drug|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
79363409|NCT01392183|Behavioral|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
79363410|NCT01392183|Drug|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
79363411|NCT02985489|Dietary Supplement|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
79514541|NCT05724134|Dietary Supplement|CORE Bar|Energy bar used as a standardized snack on the day before the pancreatic clamp.
79514542|NCT05724134|Device|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
79514543|NCT05724134|Device|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
79514544|NCT05723588|Device|active repetitive transcranial magnetic stimulation|Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
79673136|NCT04416022|Diagnostic Test|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
79994483|NCT05024760|Drug|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
79514545|NCT05723588|Device|sham repetitive transcranial magnetic stimulation|Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
79514546|NCT05723588|Behavioral|cognitive behavioral therapy for smoking cessation|All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
79514547|NCT05723588|Drug|nicotine replacement therapy|"All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum."
79994484|NCT05024760|Drug|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
79994485|NCT05176067|Radiation|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
79994486|NCT03705689|Other|validation of Bitts|No intervention, observation of photographs of stool
79994487|NCT05319522|Behavioral|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
79994488|NCT02949011|Drug|Baloxavir Marboxil|Tablets taken orally
79994489|NCT02949011|Drug|Placebo to Baloxavir Marboxil|Matching tablets taken orally
79363412|NCT01402947|Drug|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
79514548|NCT05722873|Behavioral|Fasting arm|Study participants will fast one day per week for 12 weeks
79514549|NCT05722873|Behavioral|Weight maintenance|Study participants will be counseled to maintain body weight
79514550|NCT05722873|Behavioral|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
79514551|NCT05705492|Procedure|Biospecimen Collection|Undergo blood specimen collection
79514552|NCT05705492|Procedure|Computed Tomography|Undergo a CT scan
79514553|NCT05705492|Drug|Olanzapine|Given PO
79514554|NCT05705492|Drug|Placebo Administration|Given PO
79514555|NCT05705492|Other|Questionnaire Administration|Ancillary studies
79363413|NCT01402947|Drug|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
79514556|NCT05704543|Drug|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
79363414|NCT03025893|Drug|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
79994490|NCT02949011|Drug|Oseltamivir|Capsules taken orally
79994491|NCT02949011|Drug|Placebo to Oseltamivir|Matching placebo capsules taken orally
79363415|NCT03025893|Drug|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
79363416|NCT01402869|Drug|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
79514557|NCT05673902|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
79514558|NCT05669911|Device|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
79514559|NCT05661448|Behavioral|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
79514560|NCT05661448|Behavioral|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
79514561|NCT05631743|Behavioral|VR-CBT|The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).
79673137|NCT00462059|Behavioral|Treatment|
79679803|NCT02948738|Behavioral|Standard Asthma Education|Basic review of asthma action plan and inhaler use
79994492|NCT03787368|Drug|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
79994493|NCT03787368|Drug|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
79994494|NCT03705611|Diagnostic Test|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
79994495|NCT03705611|Behavioral|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
79994496|NCT05145725|Behavioral|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
79514562|NCT05631743|Behavioral|Self-management|The previously developed commercial VR program involves guided relaxation and meditation techniques.
79514563|NCT05627375|Drug|Full-dose anticoagulant therapy (AC)|Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
79514564|NCT05627375|Drug|Antiplatelet therapy (AP)|Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
79679804|NCT02938572|Drug|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
79679805|NCT02938572|Drug|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
79220192|NCT03516006|Drug|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
79363417|NCT01402869|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
79514565|NCT05623683|Other|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
79220193|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
79220194|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
79220195|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
79220196|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
79363418|NCT01391793|Drug|Placebo|Twice daily for 3 days
79673138|NCT00591877|Procedure|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~CV-12: 4 finger breadths superior to the umbilicus."
79673139|NCT00591877|Procedure|Sham Acupuncture|"The acupoints for SAC are:~LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
79820862|NCT02584296|Behavioral|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, ~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
79994497|NCT03705533|Drug|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
79994498|NCT03705533|Drug|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
79220197|NCT03512652|Device|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
79220198|NCT02157597|Other|NIRS based management|"Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~Deepen anesthesia with volatile or intravenous agent.~Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
79220199|NCT02157597|Other|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
79220200|NCT02300532|Other|No intervention|
79220201|NCT03373214|Biological|Na-GST-1|Na-GST-1/Alhydrogel®
79220202|NCT03373214|Biological|CPG 10104|CPG 10104
79220203|NCT02157675|Dietary Supplement|Polyherbal capsule|
79220204|NCT02157675|Dietary Supplement|Placebo capsule|
79220205|NCT03512574|Drug|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
79220206|NCT03512574|Drug|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
79220207|NCT03512574|Other|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
79363419|NCT01391793|Drug|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
79363420|NCT01422915|Drug|Colestipol|2 grams morning and bedtime for 90 days.
79363421|NCT04037943|Dietary Supplement|Walnuts 30 grams|Roasted walnuts without salt or sugar.
79363422|NCT04037943|Dietary Supplement|Walnuts 60 grams|Roasted walnuts without salt or sugar.
79363423|NCT01727024|Drug|Tiotropium|Tiotropium via Respimat® device once a day
79363424|NCT01727024|Drug|Indacaterol|Indacaterol via Breezhaler® device once a day
79363425|NCT01422213|Drug|Placebo|capsules; daily; orally
79363426|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
79363427|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
79363428|NCT01390857|Drug|Valaciclovir|
79363429|NCT01725386|Drug|Capecitabine|Oral tablet(s) administered according to prescribing information
79363430|NCT01402011|Procedure|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
79363431|NCT01402011|Procedure|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
79514566|NCT05623683|Other|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
79514567|NCT05614947|Dietary Supplement|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
79514568|NCT05614947|Dietary Supplement|Placebo|500 mg colored cornstarch per capsule
79514569|NCT05606133|Diagnostic Test|NavDx(R)|NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
79820863|NCT04321317|Other|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
79994499|NCT05177627|Other|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~classroom lessons on philosophies and theories on communication and trust~small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
79994500|NCT05177627|Other|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
79220208|NCT03512574|Drug|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
79220209|NCT03373136|Device|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
79220210|NCT01994980|Drug|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
79514570|NCT05599958|Diagnostic Test|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
79514571|NCT05599958|Genetic|genetic testing|detection of CFTR mutation
79514572|NCT05557578|Drug|Tislelizumab combined with GEMOX (GOT) regimen|Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
79820864|NCT04079322|Other|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
79820865|NCT02583438|Drug|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
79220211|NCT03368768|Other|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
79220212|NCT02296554|Procedure|SLAP Repair|SLAP repair for SLAP tear
79220213|NCT02296554|Procedure|Biceps Tenodesis|Biceps tenodesis for SLAP tear
79220214|NCT02153697|Device|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
79820866|NCT02570061|Behavioral|telephone|information given at the primary contact by phone, or at a scheduled later time
79820867|NCT02570061|Behavioral|consultation face-to-face|information given at a scheduled consultation at the hospital
79820868|NCT00725907|Biological|PGRF|injection of 6cc into injured area
79820869|NCT00725907|Biological|placebo saline|injection of 6cc into injured area
79514573|NCT05549479|Behavioral|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
79514574|NCT05549479|Behavioral|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
79514575|NCT05531487|Other|Questionnaire Survey|All students received a 'QR code' link to the survey.
79514576|NCT05523778|Procedure|placement of pancreatic duct stents before enucleation surgery|Advance placement of pancreatic stents endoscopically
79514577|NCT05523778|Procedure|Direct enucleation surgery|Patients will receive direct enucleation surgery
79994501|NCT05177627|Other|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~attendance of clinical internship~analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
79994502|NCT05143541|Device|AEON Endostapler|Surgery with AEON Endostapler
79220215|NCT02153697|Drug|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
79363432|NCT01402011|Procedure|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
79363433|NCT01421667|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
79363434|NCT01421667|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion
79363435|NCT01390779|Device|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
79220216|NCT03373058|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2, respectively, 43°C, 90min.
79220217|NCT03373058|Procedure|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
79220218|NCT03373058|Drug|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
79220219|NCT02292342|Dietary Supplement|Water|Control
79220220|NCT02292342|Dietary Supplement|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
79363436|NCT01891669|Drug|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
79363437|NCT01891669|Drug|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
79363438|NCT01421511|Drug|TR-701 FA|"TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~TR-701 FA Tablets, 200 mg, orally once daily"
79514578|NCT05500586|Drug|Glucagon response study|Please see information in group descriptions
79514579|NCT05483127|Device|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
79514580|NCT05483127|Device|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
79514581|NCT05482516|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
79514582|NCT05482516|Drug|Bevacizumab|Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
79514583|NCT05482269|Other|no intervention|no intervention
79673140|NCT00591877|Other|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
79820870|NCT00726141|Behavioral|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
79363439|NCT01421511|Drug|Linezolid|"Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~Linezolid Tablets, 600 mg, orally every 12 hours"
79363440|NCT01864525|Drug|Octanoic acid|
79363441|NCT01864525|Drug|Inactive capsule|
79363442|NCT01421277|Drug|Statin Therapy|Investigator's choice of any statin.
79363443|NCT01891357|Procedure|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
79363444|NCT01891357|Drug|paclitaxel|
79363445|NCT01891357|Drug|lapatinib|
79514584|NCT05479552|Diagnostic Test|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
79673141|NCT00591916|Drug|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
79514585|NCT05476276|Drug|ISA specific|ISA specific interventions will be listed in their protocols.
79514586|NCT05475873|Drug|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
79514587|NCT05475873|Drug|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
79673142|NCT00591916|Procedure|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
79673143|NCT00591916|Procedure|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
79673144|NCT00496938|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
79363446|NCT01891357|Drug|trastuzumab|
79363447|NCT01420965|Drug|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
79994503|NCT03710057|Drug|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
79673145|NCT04413916|Diagnostic Test|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
79673146|NCT00462098|Device|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
79994504|NCT03357731|Drug|HNO Donor|Infusion
79994505|NCT03357731|Drug|Nitroglycerin (NTG)|Infusion
79994506|NCT03357731|Other|Placebo|Infusion
79994507|NCT04563702|Biological|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
79994508|NCT03709979|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
79994509|NCT03357341|Device|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
79994510|NCT03357341|Device|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
79994511|NCT03357341|Drug|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
79994512|NCT03357341|Device|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
79994513|NCT03357341|Other|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
79994514|NCT03357341|Other|CAT|Subjects will be required to complete CAT monthly.
79994515|NCT03357341|Other|ACT|Subjects will be required to complete ACT monthly.
79994516|NCT05177549|Other|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
79994517|NCT04900818|Drug|TJ033721|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
79994518|NCT05177237|Drug|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
79363448|NCT01420965|Other|Sipuleucel-T (Provenge)|Vaccine
79994519|NCT05177081|Device|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
79994520|NCT05671289|Diagnostic Test|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
79994521|NCT04747067|Device|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
79994522|NCT05646953|Other|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
79220221|NCT02292342|Dietary Supplement|Epicatechin 0.5 mg/kg|EC 0.5
79220222|NCT02292342|Dietary Supplement|Epicatechin 1.0 mg/kg|EC 1.0
79220223|NCT02151045|Procedure|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
79220224|NCT02151045|Procedure|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
79363449|NCT01420965|Drug|Cyclophosphamide|Low dose- Immune Enhancer
79363450|NCT04033575|Drug|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
79363451|NCT04033575|Drug|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
79363452|NCT04767087|Drug|Honey|0.5 gm/Kg/day honey
79363453|NCT04767087|Drug|Nigella sativa seed|40 mg/Kg/day
79363454|NCT04767087|Other|Placebo|empty capsule with sugar water
79514588|NCT05475873|Drug|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
79514589|NCT05470595|Drug|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
79514590|NCT05464186|Behavioral|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
79514591|NCT05464186|Behavioral|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
79220225|NCT02296632|Behavioral|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
79514592|NCT05462977|Behavioral|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
79514593|NCT05458271|Device|VCMX|A flap will be raised and VCMX will be placed in order to increase the soft tissue volume
79514594|NCT05458271|Procedure|CTG|A flap will be raised and a CTG will be harvested from the palate and placed in order to increase the soft tissue volume
79994523|NCT03039738|Device|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) & Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
79994524|NCT03039738|Device|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
79994525|NCT05681117|Other|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
79994526|NCT05007899|Drug|Ferrous sulfate|Alternate day dosing of ferrous sulfate
79994527|NCT05147142|Device|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
79994528|NCT05636345|Other|pain science education|A full day of pain science education
79220226|NCT03377348|Procedure|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
79220227|NCT02157831|Biological|CP-870,893|
79220228|NCT02296710|Procedure|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
79363455|NCT01390389|Drug|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~Visit 1 (baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
79363456|NCT03835533|Drug|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
79363457|NCT03835533|Drug|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
79363458|NCT03835533|Radiation|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
79363459|NCT03835533|Drug|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
79363460|NCT03835533|Drug|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
79514595|NCT05441670|Behavioral|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
79514596|NCT05441670|Behavioral|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
79514597|NCT05432193|Drug|[Ga-68]-PNT6555|[Ga-68]-PNT6555 IV administered as imaging agent for PET/CT
79363461|NCT03835533|Drug|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
79363462|NCT03835533|Device|Cellectra 2000|Electroporation device
79363463|NCT03025347|Other|Control|Participants complete a resting control condition instead of a run.
79514598|NCT05432193|Drug|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the [Ga-68]-PNT6555 screening PET/CT will receive [Lu-177]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
79994529|NCT04507373|Drug|Simvastatin 40mg|40mg oral daily for 10 weeks
79363464|NCT03025347|Other|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
79363465|NCT01401465|Drug|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
79363466|NCT01401465|Drug|mometasone|200 mcg mometasone aqueous nasal spray once daily
79363467|NCT01401153|Other|Skipping lunch|Just water.
79514600|NCT05412875|Other|Best Practice|Given usual care
79514601|NCT05412875|Drug|Nicotine Replacement|Given JUUL
79514602|NCT05412875|Other|Quality-of-Life Assessment|Ancillary studies
79514603|NCT05412875|Other|Questionnaire Administration|Ancillary studies
79673147|NCT00462098|Device|non-treated control group|no change from routine care, no HBO
79994530|NCT01312337|Drug|salvage iressa|Iressa 250mg per day until progression
79673148|NCT00462137|Procedure|Sleep Studies|
79673149|NCT04413487|Other|Extra echocardiogram|Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
79673150|NCT04412902|Drug|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
79514604|NCT05385796|Other|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
79514605|NCT05385796|Other|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
79514608|NCT05342493|Drug|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
79514609|NCT05318469|Drug|Ivermectin|Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
79514610|NCT05318469|Drug|Balstilmab|Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
79514611|NCT05318131|Other|Sleep and Lifestyle Advice Website|Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
79514612|NCT05318131|Other|Surveys and Sleep Monitors|At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
79514613|NCT05288283|Drug|GWP42003-P|oral solution
79514614|NCT05288283|Drug|Placebo|oral solution
79673151|NCT00462176|Procedure|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
79363468|NCT01890967|Drug|LY3015014|Administered SC
79363469|NCT01890967|Drug|Placebo|Administered SC
79363470|NCT01890967|Drug|Statin|Administered orally
79220229|NCT02153775|Behavioral|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
79220230|NCT03368690|Dietary Supplement|Oligopin®|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
79220231|NCT03368690|Other|Placebo|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
79363471|NCT01890967|Drug|Ezetimibe|Administered orally
79363472|NCT01400919|Device|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
79220232|NCT03515928|Other|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
79363473|NCT01864291|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
79363474|NCT01400841|Device|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
79363475|NCT01863667|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
79363476|NCT01863667|Drug|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
79363477|NCT01863667|Drug|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
79363478|NCT01863667|Drug|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
79220233|NCT03515928|Diagnostic Test|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
79363479|NCT01614769|Drug|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
79514615|NCT05259280|Other|Wellinks|Digital health and virtual care program for COPD management.
79514616|NCT05227014|Procedure|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
79994531|NCT05174897|Behavioral|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
79994532|NCT05232149|Drug|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
79220234|NCT03368612|Other|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
79220235|NCT03368612|Other|Electronic evaluation system|AirGo recording
79363480|NCT01614769|Drug|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
79220236|NCT02255253|Drug|Telmisartan|capsule,40mg per day,2 months
79514617|NCT05226780|Drug|NBI-921352|Administered orally
79514618|NCT05218850|Drug|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
79514619|NCT05209802|Other|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
79514620|NCT05209802|Other|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
79514621|NCT05189262|Other|Blood and urine collection|No intervention - Biological specimen collection
79514622|NCT05186363|Drug|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
79514623|NCT05186363|Drug|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
79220237|NCT02255253|Drug|Hydrochlorothiazide|tablet, 25mg per day, 2 months
79220238|NCT02296788|Behavioral|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
79220239|NCT02300688|Drug|Treatment A|administration of 1 time administration of the test drug (Treatment A)
79363481|NCT01614769|Drug|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
79514624|NCT05140876|Behavioral|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
79220240|NCT02300688|Drug|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
79220241|NCT02151201|Behavioral|Influenza vaccination video education|Influenza vaccination video education
79220242|NCT02151201|Behavioral|Hand washing video education|Hand washing video education
79220243|NCT03368378|Procedure|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
79514625|NCT05136703|Behavioral|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months.
79994533|NCT05232149|Drug|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
79994534|NCT05552495|Drug|CKD-386(4) F1|1 Tablet
79994535|NCT05552495|Drug|CKD-386(4) F2|1 Tablet
79994536|NCT05552495|Drug|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
79220244|NCT03896984|Drug|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
79363482|NCT01614769|Procedure|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
79363483|NCT01614457|Drug|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
79363484|NCT01614457|Drug|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
79363485|NCT01863433|Biological|Trivalent Influenza Vaccine|
79363486|NCT01862029|Drug|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
79363487|NCT01835431|Drug|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
79994537|NCT05076227|Drug|IM injection of vaccination (mRNA vaccination)|mRNA vaccination
79994538|NCT05076227|Drug|IM injection of vaccination (vector based vaccination)|vector based vaccination
79514626|NCT05136703|Behavioral|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
79514627|NCT05131451|Diagnostic Test|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
79820871|NCT02583750|Behavioral|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
79820872|NCT02583750|Behavioral|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
79820873|NCT02603861|Drug|LY3154207|LY3154207 administered orally.
79820874|NCT02603861|Drug|Placebo|Placebo administered orally.
79820875|NCT02603861|Drug|Modafinil|Modafinil administered orally.
79820876|NCT02569905|Drug|parecoxib sodium|parecoxib sodium 40mg
79820877|NCT02569905|Drug|flurbiprofen|flurbiprofen 50mg
79994539|NCT04420403|Other|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
79994540|NCT04420403|Other|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
79994541|NCT05551949|Drug|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
79220245|NCT03896984|Drug|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
79220246|NCT03896984|Drug|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
79220247|NCT02292498|Device|FLIR ONE|
79220248|NCT02151279|Other|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
79220249|NCT02151279|Other|Control|
79220250|NCT03519828|Other|No intervention has been conducted|It is an observational study, and no intervention has been conducted
79220251|NCT02157987|Drug|bevacuzimab spray|
79220252|NCT03861728|Device|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
79220253|NCT03861728|Other|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
79220254|NCT02159313|Drug|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
79220255|NCT03377114|Procedure|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
79220256|NCT03377114|Procedure|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
79363488|NCT01835431|Drug|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
79363489|NCT01835431|Drug|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
79363490|NCT01835431|Drug|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
79363491|NCT01880593|Drug|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
79363492|NCT01880593|Drug|Ketamine|
79363493|NCT01880593|Drug|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
79514628|NCT05122897|Device|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
79679806|NCT02940054|Other|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
79679807|NCT02940093|Other|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
79820878|NCT02569905|Drug|saline|normal saline
79820879|NCT02603783|Other|Capsaicin|capsaicin 1,5 mg
79220257|NCT03515772|Drug|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
79220258|NCT02158065|Other|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
79514629|NCT05122897|Device|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
79514630|NCT05121948|Drug|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
79820880|NCT02603783|Other|Placebo|0,9% saline 75 ml
79220259|NCT02296944|Other|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
79220260|NCT03368300|Other|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
79220261|NCT02300844|Drug|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
79220262|NCT02300844|Drug|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
79220263|NCT03124628|Other|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
79220264|NCT03124628|Other|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
79220265|NCT03519750|Drug|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
79220266|NCT02159391|Behavioral|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
79220267|NCT03372668|Other|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
79363494|NCT01400451|Drug|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
79363495|NCT01400451|Drug|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
79363496|NCT01400139|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
79363497|NCT01399905|Drug|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
79363498|NCT01725308|Drug|FK949E|Taken by mouth (orally).
79363499|NCT01725308|Drug|Placebo|Taken by mouth (orally).
79363500|NCT01724528|Drug|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
79363501|NCT01724528|Drug|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
79363502|NCT01779440|Behavioral|Electronic Decision Support System|
79363503|NCT01750346|Drug|Topical acetyl hexapeptide-8|
79363504|NCT01750346|Drug|Placebo|
79514631|NCT05115968|Procedure|Tonsillectomy|Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI <1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
79514632|NCT05112809|Device|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
79514633|NCT05110456|Behavioral|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~encourage the use of online material;~identify strategies for overcoming obstacles;~help apply content to real-life settings; and~underscore the participants' success in using effective coping strategies"
79673152|NCT00462176|Other|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
79220268|NCT03512340|Drug|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
79514634|NCT05108922|Drug|Donanemab|Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
79220269|NCT02158143|Dietary Supplement|vitamin D3|
79220270|NCT03372590|Other|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
79363505|NCT01750268|Behavioral|Medical Management Counseling|Brief alcohol and medication counseling
79363506|NCT01750268|Drug|Topiramate|Experimental medication
79363507|NCT01750268|Drug|Placebo|Placebo comparator
79363508|NCT01880437|Drug|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
79363509|NCT01880437|Drug|vismodegib|Cohorts 1 and 2: 150 mg orally daily
79363510|NCT01861717|Drug|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
79363511|NCT01834729|Drug|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
79363512|NCT01834729|Other|Placebo|placebo capsule identical to the study drug
79363513|NCT01860703|Drug|Deferiprone|Ferriprox 500 mg tablets
79363514|NCT01860703|Drug|deferiprone matching placebo tablets|deferiprone matching placebo tablets
79363515|NCT01860703|Drug|moxifloxacin|Active control
79363516|NCT01860703|Drug|placebo|moxifloxacin-matching placebo
79673153|NCT02893969|Behavioral|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
79673154|NCT02893969|Behavioral|Rest|Complete physical rest until asymptomatic.
79679808|NCT02948699|Dietary Supplement|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
79679809|NCT00521417|Behavioral|short-term dynamic therapy|
79220271|NCT03372590|Other|Standard of care|Standard NICU care
79363517|NCT01399593|Drug|Eculizumab|
79363518|NCT01833169|Drug|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
79363519|NCT03814083|Device|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
79363520|NCT03814083|Device|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
79220272|NCT02158221|Drug|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
79220273|NCT02292576|Other|Cocoa Pure|Cocoa Pure.
79220274|NCT02292576|Other|Placebo|Placebo.
79220275|NCT02158299|Drug|Avitene|
79220276|NCT02158299|Drug|Sapylin|
79220277|NCT02158299|Behavioral|axillary drainage|
79363521|NCT03814083|Other|Wait-list|No intervention
79363522|NCT01860079|Procedure|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
79363523|NCT04407819|Radiation|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
79363524|NCT01388985|Biological|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
79514635|NCT05108922|Drug|Aducanumab|Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
79514636|NCT05101317|Drug|HMI-115|HMI-115 is human monoclonal antibody
79514637|NCT05101317|Drug|Placebo|Placebo
79994542|NCT05283954|Drug|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
79363525|NCT01388907|Other|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
79363526|NCT01388907|Device|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
79363527|NCT01388361|Drug|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
79363528|NCT01388361|Drug|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
79363529|NCT01388361|Drug|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
79363530|NCT04028895|Diagnostic Test|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
79363531|NCT05368935|Drug|Nitazoxanide|500 mg Twice Daily for 7 days
79363532|NCT01399125|Drug|Rivastigmine Patch|Once-daily target patch size 10 cm²
79363533|NCT01399125|Drug|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
79363534|NCT01399125|Drug|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
79363535|NCT01399125|Drug|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
79363536|NCT04015791|Other|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
79363537|NCT04026633|Behavioral|CAA|Participants will write about the use of PBS and alcohol use.
79363538|NCT04026633|Behavioral|Control|Participants will write about eating and exercise.
79363539|NCT01399047|Drug|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
79363540|NCT01399047|Drug|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
79363541|NCT05369169|Behavioral|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
79363542|NCT05369169|Behavioral|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
79363543|NCT01387737|Drug|TA-7284-Low|TA-7284-Low
79679810|NCT00521417|Behavioral|long-term dynamic therapy|
79994543|NCT05283954|Drug|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
79994544|NCT01312415|Drug|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
79994545|NCT01312415|Drug|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
79363544|NCT01387737|Drug|TA-7284-High|TA-7284-High
79363545|NCT01387347|Drug|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
79679811|NCT02938728|Other|Biopsies|
79363546|NCT01387347|Drug|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
79363547|NCT04012827|Drug|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
79363548|NCT01859923|Drug|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
79514638|NCT05094804|Drug|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
79514639|NCT05094804|Drug|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
79679812|NCT02938650|Drug|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
79514640|NCT05094804|Drug|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
79514641|NCT05077748|Other||
79514642|NCT05076032|Drug|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
79514643|NCT05076032|Drug|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
79514644|NCT05047237|Behavioral|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
79514645|NCT05045872|Drug|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
79514646|NCT05030415|Drug|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
79514647|NCT05027464|Behavioral|Moving to COVID-19 Vaccine Acceptance Intervention|The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
79514648|NCT05021562|Drug|Niraparib|Niraparib capsules
79514649|NCT05020951|Other|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
79514650|NCT04995029|Drug|Transmucosal Buprenorphine|Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
79514651|NCT04995029|Drug|Extended-release Buprenorphine|Administered by subcutaneous injection
79514652|NCT04982926|Drug|TAS2940|Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
79514653|NCT04982926|Drug|TAS2940|Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
79514654|NCT04982874|Drug|Furosemide 40 mg|Administered with 240 mL of water
79220278|NCT02158299|Other|reexamine|
79220279|NCT03512106|Other|Acupuncture|Chinese traditional acupuncture
79514655|NCT04982874|Drug|Lasix® 40 mg Tablet|Administered with 240 mL of water
79514656|NCT04966585|Drug|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
79514657|NCT04966585|Drug|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
79514658|NCT04923880|Other|Implementation of Primary Palliative Care Intervention in CF Centers|"Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale).~Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide.~Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers).~In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant."
79514659|NCT04919369|Biological|Atezolizumab|Given IV
79514660|NCT04919369|Drug|Tretinoin|Given PO
79514661|NCT04910308|Radiation|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
79514662|NCT04908956|Drug|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
79514663|NCT04908956|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
79514664|NCT04900298|Device|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
79994546|NCT05143775|Procedure|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
79994547|NCT03036852|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
79220280|NCT02519816|Other|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
79220281|NCT02297022|Device|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
79220282|NCT02519894|Behavioral|Dietary Scanning Calculator|
79220283|NCT03372512|Diagnostic Test|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
79220284|NCT02301000|Biological|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
79220285|NCT02301000|Drug|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
79514665|NCT04899024|Behavioral|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
79514666|NCT04899024|Behavioral|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
79994548|NCT04979117|Device|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
79514667|NCT04899024|Behavioral|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
79820881|NCT04110275|Drug|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
79220286|NCT02154165|Other|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
79220287|NCT02158455|Procedure|NT SVG grafts|
79514668|NCT04884594|Drug|AAV8-hCocH|2e12 vg/kg single infusion intravenous
79514669|NCT04884594|Drug|AAV8-hCocH|6e12vg/kg single infusion intravenous
79514670|NCT04884594|Drug|AAV8-hCocH|2e13 vg/kg single infusion intravenous
79673155|NCT04328896|Other|CGM-Tele-monitoring|"Baseline Visit-Visit 0~Obtain informed consent~Administer questionnaires~Measure A1C~Start study Dexcom CGM device (those already on CGM will change to the study device).~The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~14 days worth of data will be downloaded from the patient's CGM device.~Systems will be checked to be sure they are functioning~Remote monitoring program will be activated.~Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~Administer questionnaires~Measure A1C.~Collect CGM data and compare to baseline~Testing and Assessments:~Continuous glucose monitoring~Tidepool cloud upload~HbA1c~T1D REDEEM diabetes distress questionnaire~Hypoglycemia Fear Survey~Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
79994549|NCT01312493|Drug|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
79994550|NCT01312493|Radiation|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
79220288|NCT02292732|Drug|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter [mm]) to be taken orally and once daily
79514671|NCT04883411|Device|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
79514672|NCT04882904|Device|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
79514673|NCT04880837|Other|Educational Intervention|Attend educational session
79514674|NCT04880837|Other|Informational Intervention|Receive handouts
79994551|NCT05309837|Dietary Supplement|Polydextrose|Polydextrose-enriched food products
79220289|NCT02292732|Drug|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
79363549|NCT01859923|Drug|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
79363550|NCT01859923|Drug|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
79514675|NCT04880837|Other|Survey Administration|Complete surveys
79514676|NCT04874636|Drug|LY3556050|Administered orally
79514677|NCT04874636|Drug|Placebo|Administered orally
79514678|NCT04863872|Other|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
79514679|NCT04863872|Behavioral|my hypo compass education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
79820882|NCT04110275|Drug|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)&Co,
79994552|NCT05309837|Dietary Supplement|placebo-controlled|Control food products
79220290|NCT02292732|Drug|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
79820883|NCT04250883|Other|Low intra-abdominal pressure|8 mmHg
79820884|NCT04250883|Other|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
79820885|NCT04250883|Other|Standard intra-abdominal pressure|14 mmHg
79820886|NCT04250883|Other|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
79514680|NCT04851184|Device|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
79514681|NCT04851184|Behavioral|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
79514682|NCT04848675|Other|Inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
79673156|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
79673157|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
79220291|NCT02292732|Drug|Placebo|Each green tablet will contain only inert ingredients: D&C yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
79220292|NCT03376958|Drug|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
79220293|NCT02159625|Device|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
79514683|NCT04848675|Other|Brisk walking|Participants will perform brisk walking.
79220294|NCT02297178|Procedure|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
79220295|NCT02297178|Procedure|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
79220296|NCT03376802|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
79220297|NCT03376802|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
79220298|NCT03515694|Drug|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
79220299|NCT03376724|Other|Functional Exercise Protocol|Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.
79514684|NCT04840849|Biological|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
79220300|NCT03376724|Other|Minimal|Analgesic use when necessary and a single back scholl class
79220301|NCT03541707|Device|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
79220302|NCT03367676|Drug|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
79514685|NCT04840849|Other|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
79673158|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
79673159|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
79220303|NCT03367676|Drug|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w*4
79220304|NCT03515616|Diagnostic Test|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
79220305|NCT02158611|Other|Lifestyle counseling|
79220306|NCT03367598|Genetic|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism.
79308407|NCT02502383|Behavioral|ACTION PAC|Adolescents enrolled in ACTION PAC will meet with SBHC providers. SBHC providers will use Motivational Interviewing to motivate students to adopt strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI results discussion with providers. Overweight/Obese adolescents will meet with providers for 16 sessions over 2 years.
79673160|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
79673161|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
79673162|NCT04410640|Other|survey|Members chosen for this study group are general surgery residents. A quintet with stations composed of normal pancreaticobiliary anatomy, common bile duct tumor, stony cholecystitis, pancreatic head cancer and cholelithiasis was assembled for the study. Each station contained CT, 3D-STL images and 1:1 solid models of cases. Each imaging method associated with the scenarios of the quintet is observed by the residents of the study. An explanatory assessment measure is being used as data collection method where the perception of each imaging method is being evaluated based on their effectiveness in problem identification as well as their efficiency in diverse diagnosis and pre-surgery organization. Participants' perception of residency training was evaluated with a multi-entry survey. The focus of the survey, which was applied by our team was by domains, self determined decision-making, diverse diagnosis, academic scholarship, and scientific appraisal.
79514686|NCT04838639|Drug|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
79820887|NCT04469634|Diagnostic Test|Assessing antibody responses, neutralizing capacity and memory B-cell function|Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
79220307|NCT02292810|Device|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
79673163|NCT00462254|Drug|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
79673164|NCT00462254|Drug|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
79673165|NCT00496977|Procedure|annual CT screening|
79673166|NCT04410172|Diagnostic Test|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
79673167|NCT04328545|Device|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
79673168|NCT04328545|Device|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
79820888|NCT04465500|Radiation|External Beam Radiation|EBRT will be administered every 5 consecutive days for 5 consecutive weeks. This is standard of care practice for this therapy. This may be revised as applicable per treating physician discretion. The dose of radiation will be in accordance with standard clinical practice guidelines for the treatment of prostate cancer.
79820889|NCT04465500|Radiation|HDR Brachytherapy|HDR brachytherapy will be administered per standard clinical practice (per NCCN guidelines version 1.2020 for prostate cancer), however standard clinical practice may vary between clinicians. Therefore, the dose of 15Gy in 1 fraction and a set of dosimetry guidelines are to be followed for the purposes of this study. A diagnostic MRI will be co-registered with Transrectal Ultrasound (TRUS) to perform the HDR brachytherapy.
79220308|NCT02292810|Device|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
79220309|NCT03515538|Drug|RRx-001|RRx-001 for injection
79220310|NCT03515538|Drug|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
79220311|NCT03515538|Radiation|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
79220312|NCT02158689|Drug|Letrozole|
79220313|NCT02158689|Drug|human menopausal gonadotropin (hMG)|
79220314|NCT03372200|Drug|FYU-981|Oral daily dosing for 14 weeks
79220315|NCT03372200|Drug|Febuxostat|Oral daily dosing for 14 weeks
79220316|NCT02159781|Procedure|periodontal treatment - scaling and root planning|
79220317|NCT03372122|Drug|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
79220318|NCT03372122|Combination Product|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
79220319|NCT02292888|Other|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
79514687|NCT04838639|Drug|Placebo|Two subjects per cohort will take a matched placebo.
79514688|NCT04812379|Drug|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
79514689|NCT04796272|Other|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
79514690|NCT04796272|Other|traditional training program|Same training program for all patients in this group
79514691|NCT04787497|Dietary Supplement|High Phenolic Extra Virgin Olive Oil|Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
79514692|NCT04766892|Drug|mavacamten|mavacamten capsules
79514693|NCT04707157|Drug|LY3556050|given orally
79514694|NCT04707157|Drug|Placebo|given orally
79514695|NCT04700449|Drug|Double-Blind 0.2mg CBP-307|0.2 mg capsule oral administration
79514696|NCT04700449|Drug|Double-Blind Placebo|Placebo capsule oral administration
79514697|NCT04700449|Drug|Open-label CBP-307|0.2 mg capsule oral administration
79363551|NCT01832155|Behavioral|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
79220320|NCT02158845|Drug|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
79220321|NCT02158845|Drug|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
79220322|NCT03372044|Drug|PF-06865571 Immediate release suspension|Suspension
79220323|NCT03372044|Drug|PF-06865571 Slow release MR tablets|Modified release tablets
79220324|NCT03372044|Drug|PF-06865571 Fast release MR tablets|Modified release tablets
79220325|NCT03372044|Drug|PF-06865571 Immediate release tablets|Immediate release tablets
79220326|NCT02301078|Procedure|Percutaneous Needle Aponeurotomy|single procedure (day 0)
79220327|NCT02301078|Drug|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
79220328|NCT04786977|Other|No Intervention, Observational Study|No Intervention
79220329|NCT03367520|Behavioral|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
79220330|NCT02292966|Drug|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
79220331|NCT02159937|Other|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
79220332|NCT03519672|Other|No intervention|This is a non-interventional study.
79220333|NCT02519660|Drug|Lidocaine/Tetracaine patch|
79220334|NCT02519660|Drug|Lidocaine/Prilocaine cream|
79363552|NCT01832155|Behavioral|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
79363553|NCT05364333|Procedure|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
79363554|NCT01879579|Other|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
79363555|NCT01386645|Other|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index <35) for 4 weeks with all food provided by the Human Nutrition Lab
79514698|NCT04700449|Drug|Double-Blind 0.1mg CBP-307|0.1 mg capsule oral administration
79514699|NCT04696471|Device|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
79514700|NCT04696471|Device|Sham Continuous Theta Burst Stimulation (Sham cTBS)|Sham cTBS goes through the motions of applying cTBS to the brain but administers very low current so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
79514701|NCT04695691|Device|Cutera Laser System|Subjects will receive laser treatments
79514702|NCT04683718|Device|Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management|The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
79514703|NCT04681833|Drug|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
79514704|NCT04681833|Drug|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
79514705|NCT04681833|Drug|Placebo|Liquid diluent/Lyophilised Powder
79514706|NCT04667377|Drug|BI 456906|BI 456906
79514707|NCT04667377|Drug|Placebo|Placebo
79514708|NCT04655651|Other|No intervention|There is no intervention for both groups.
79514709|NCT04647526|Drug|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of [Lu-177]-PNT2002 every 8 weeks for 4 cycles
79673169|NCT04328545|Device|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
79673170|NCT00462371|Device|Insulin pump (CSII)|
79673171|NCT00497016|Drug|atorvastatin 80 mg|
79673172|NCT04406701|Other|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
79673173|NCT00462410|Other|counseling intervention|
79673174|NCT00462410|Procedure|psychosocial assessment and care|
79994553|NCT04977947|Behavioral|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
79994554|NCT04294290|Biological|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
79994555|NCT05108909|Device|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
79220335|NCT03511872|Other|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
79673175|NCT02893891|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
79673176|NCT02893891|Procedure|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
79673177|NCT02893891|Procedure|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
79673178|NCT02893891|Device|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
79220336|NCT02297334|Device|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
79220337|NCT03376412|Device|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
79220338|NCT03371966|Dietary Supplement|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
79220339|NCT03371966|Dietary Supplement|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
79220340|NCT03541473|Dietary Supplement|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
79514710|NCT04647526|Drug|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
79514711|NCT04647526|Drug|Enzalutamide|Enzalutamide (160 mg orally qd)
79514712|NCT04634513|Biological|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
79514713|NCT04634513|Other|Placebo|Sodium bicarbonate buffer
79514714|NCT04629729|Drug|FT819|Experimental Interventional Therapy
79514715|NCT04629729|Drug|Cyclophosphamide|Lympho-conditioning agent
79514716|NCT04629729|Drug|Fludarabine|Lympho-conditioning agent
79673179|NCT04405414|Other|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
79673180|NCT00462566|Device|motor cortex stimulation|
79673181|NCT00497094|Device|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
79514717|NCT04629729|Drug|IL-2|Biologic response modifier
79514718|NCT04629729|Drug|Bendamustine|Lympho-conditioning agent
79514719|NCT04617717|Procedure|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
79514720|NCT04617717|Diagnostic Test|Cardiopulmonary exercise testing|Standard ergometer bicycle test
79514721|NCT04617717|Diagnostic Test|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
79514722|NCT04617717|Diagnostic Test|Holter monitoring|24h 5 lead or 12 lead ECG recording
79514723|NCT04617717|Diagnostic Test|Transthoracic echocardiography|2D echocardiography
79514724|NCT04617717|Diagnostic Test|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
79514725|NCT04609202|Behavioral|Nurse led person centred care|Person centred care include patiens narratives, partnership and documentation of a health plan.
79514726|NCT04609202|Other|Usual care|Usual care provided by doctors
79220341|NCT03541473|Dietary Supplement|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
79673182|NCT00222872|Drug|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
79220342|NCT03371888|Biological|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
79220343|NCT03371888|Biological|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
79308408|NCT02502383|Behavioral|Comparison|Annual BMI results will not be discussed with participants in comparison schools; however, a letter containing BMI results and obesity prevention recommendations will be sent to parent/guardians.
79363556|NCT01386645|Other|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
79363557|NCT01386645|Drug|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
79363558|NCT01387269|Drug|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
79363559|NCT01387269|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
79363560|NCT01859143|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
79363561|NCT01859143|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
79673183|NCT00222872|Drug|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
79673184|NCT00497172|Device|CYPHER Sirolimus-eluting stent|drug-eluting stent
79673185|NCT00497172|Device|Bx SONIC bare metal stent|bare-metal stent
79673186|NCT03273296|Drug|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
79363562|NCT01878253|Device|Sidus Stem-Free Total Shoulder Arthroplasty System|
79514727|NCT04602728|Behavioral|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
79514728|NCT04599101|Device|Nose Frida nasal suction device|Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
79514729|NCT04599101|Device|Bulb syringe nasal suction device|Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
79514730|NCT04597099|Drug|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
79673187|NCT03273296|Drug|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
79673188|NCT03273296|Drug|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
79673189|NCT00497211|Procedure|Intracoronary mononuclear cell infusion|
79673190|NCT00497250|Drug|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
79673191|NCT00497250|Device|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
79673192|NCT00462878|Drug|Meropenem|antibiotic
79673193|NCT00462878|Drug|Vancomycin|Antibiotic
79673194|NCT00462878|Drug|Teicoplanin|Antibiotic
79673195|NCT01242618|Biological|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
79673196|NCT00222911|Device|dorsiflexion night splint|
79673197|NCT00222911|Device|medial arch support|
79673198|NCT01242696|Procedure|Coronary artery stenting|Coronary artery stenting with drug eluting stents
79363563|NCT01878175|Behavioral|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
79514731|NCT04597099|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
79514732|NCT04597099|Drug|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
79514733|NCT04597099|Drug|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
79363564|NCT01878097|Behavioral|Green Dot Bystander Intevention|Intervention allocated at the school level
79363565|NCT01878097|Behavioral|Control|Awareness Education
79363566|NCT01750190|Drug|Roxadustat|Oral tablets
79363567|NCT01750190|Drug|Placebo|Oral tablets
79514734|NCT04584866|Procedure|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
79514735|NCT04584866|Procedure|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
79673199|NCT00462956|Drug|Tykerb|lapatinib 1500mg daily
79673200|NCT01242735|Behavioral|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
79673201|NCT01242735|Behavioral|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
79673202|NCT00462995|Drug|Erlotinib|150mg once a day for 28 days
79673203|NCT00462995|Drug|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
79820890|NCT04465500|Drug|Androgen Deprivation Therapy|The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
79820891|NCT05432076|Device|Sleep Band and White Noise|"Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~Being extubated~A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~Baby dreams of boredom~Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation)."
79363568|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
79363569|NCT01831765|Drug|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
79363570|NCT01831765|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
79514736|NCT04583839|Behavioral|Patient Navigation Program|SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
79514737|NCT04582383|Drug|Spironolactone|Dispensation of spironolactone according to the arm description.
79514738|NCT04582383|Drug|Doxycycline Hyclate|Dispensation of doxycycline hyclate according to the arm description.
79673204|NCT00489450|Drug|SK3530|
79363571|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
79363572|NCT01749800|Device|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
79363573|NCT01749800|Device|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
79514739|NCT04576832|Behavioral|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
79673205|NCT00489528|Drug|Somatropin; Recombinant human growth hormone (r hGH)|
79673206|NCT00463034|Genetic|microarray analysis|
79673207|NCT00463034|Genetic|polymerase chain reaction|
79673208|NCT00463034|Genetic|polymorphism analysis|
79363574|NCT01749800|Device|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
79363575|NCT04556396|Diagnostic Test|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
79514740|NCT04569799|Drug|Lumason|2.4 mL per lesion
79514741|NCT04546672|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
79673209|NCT00463034|Other|high performance liquid chromatography|
79673210|NCT00463034|Other|immunohistochemistry staining method|
79673211|NCT00463034|Other|laboratory biomarker analysis|
79673212|NCT00463034|Other|questionnaire administration|
79679813|NCT04694417|Other|Compression stocking|Please see the description of the intervention in another section
79679814|NCT04694417|Dietary Supplement|Magnesium tablet|Please see the description of the intervention in another section
79820892|NCT04080726|Drug|HIP1601|Oral esomeprazole
79220344|NCT02154321|Device|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
79220345|NCT02297490|Drug|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
79514742|NCT04546672|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
79514743|NCT04738292|Drug|Onapristone|Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
79514744|NCT04738292|Drug|Fulvestrant|Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
79220346|NCT02297490|Biological|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
79220347|NCT03371810|Behavioral|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
79363576|NCT04414891|Device|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
79363577|NCT01830595|Drug|Recombinant Lactoferrin|
79514745|NCT04537923|Drug|Tirzepatide|Administered SC
79363578|NCT01830595|Drug|Placebo|
79363579|NCT01748552|Drug|Placebo|Administered orally as capsules
79514746|NCT04537923|Drug|Insulin Lispro (U100)|Administered SC
79514747|NCT04513080|Behavioral|Video-chat psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
79514748|NCT04513080|Behavioral|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
79673213|NCT01242852|Procedure|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS & hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions & endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
79673214|NCT03273140|Device|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
79820893|NCT04080726|Drug|HGP1705|Oral Nexium Tab
79820894|NCT04080726|Drug|HIP1601 Placebo|Oral Placebo
79820895|NCT04080726|Drug|HGP1705 Placebo|Oral Placebo
79363580|NCT01748552|Drug|LY2922083|Administered orally as capsules
79363581|NCT01748162|Drug|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
79363582|NCT01748162|Drug|Prednisolone IF needed|
79363583|NCT01724216|Device|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
79363584|NCT01723904|Drug|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
79363585|NCT01747772|Device|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
79363586|NCT01830127|Drug|Ribavirin|24 Weeks
79514749|NCT04513080|Behavioral|Message-based psychotherapy with monthly video chat (Premium Plan)|The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
79514750|NCT04513080|Behavioral|Message-based psychotherapy with weekly video chat (Ultimate Plan)|The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
79514751|NCT04508543|Other|Non-verbal communication score|1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
79994556|NCT05309694|Combination Product|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
79673215|NCT01242891|Device|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
79514752|NCT04502732|Other|NSSM and GEBT|The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
79514753|NCT04496817|Other|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
79673216|NCT00463073|Drug|Cetuximab|
79673217|NCT00463073|Drug|Bevacizumab|
79673218|NCT00463073|Drug|Irinotecan|
79220348|NCT03371810|Behavioral|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
79220349|NCT03511716|Device|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
79220350|NCT02154399|Drug|EF5|Given IV
79220351|NCT02154399|Other|Laboratory Biomarker Analysis|Correlative studies
79363587|NCT01830127|Drug|BI 207127 high dose|24 Weeks
79363588|NCT01830127|Drug|Faldaprevir|24 Weeks
79363589|NCT01830127|Drug|Ribavirin|24 Weeks
79673219|NCT00222989|Drug|PPI|
79363590|NCT01830127|Drug|BI 207127 low dose|24 Weeks
79363591|NCT01830127|Drug|Faldaprevir|24 Weeks
79514754|NCT04496817|Other|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
79514755|NCT04489017|Dietary Supplement|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
79514756|NCT04489017|Dietary Supplement|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
79514757|NCT04488666|Device|npSIMS|incisional NPWT
79673220|NCT00489567|Procedure|Blood sample collection|
79673221|NCT00463112|Drug|Sibutramine|
79673222|NCT00489606|Drug|SK3530|
79673223|NCT00223028|Drug|sirolimus, mycophenolat mofetil, fluvastatin|
79820896|NCT04080570|Other|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
79220352|NCT02154399|Procedure|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
79820897|NCT02585544|Procedure|day-care surgery|day-care surgery
79673224|NCT00489645|Drug|placebo|placebo SC during euglycemia
79673225|NCT00489645|Drug|pramlintide|pramlintide SC during eglycemia
79673226|NCT00489645|Drug|placebo|placebo during hyperglycemia
79673227|NCT00489645|Drug|pramlintide|pramlintide SC during hyperglycemia
79673228|NCT00465686|Device|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
79673229|NCT00465686|Device|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
79220353|NCT02154399|Other|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
79363592|NCT04611295|Procedure|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
79363593|NCT01614067|Drug|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
79673230|NCT01243008|Drug|Application of SHB001|"Cohort 1: Application of SHB001 on the skin of right thigh~Cohort 2:~Application of SHB001 on the skin of right thigh~punch biopsies of treated skin areas"
79673231|NCT04697199|Drug|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
79673232|NCT04697199|Procedure|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
79673233|NCT00463190|Drug|Biothree|
79514758|NCT04484623|Drug|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
79514759|NCT04484623|Drug|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
79514760|NCT04484623|Drug|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
79514761|NCT04484623|Drug|Bortezomib|Proteasome Inhibitor will be administered.
79514762|NCT04437485|Behavioral|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
79514763|NCT04437485|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
79673234|NCT00463268|Drug|alendronate|alendronate 70 mg every 2 weeks
79363594|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
79363595|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
79220354|NCT02519192|Device|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
79220355|NCT02519192|Procedure|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
79220356|NCT02519192|Procedure|ostomy bag|Non Vac Arm will receive ostomy bag applications.
79220357|NCT02519192|Procedure|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
79220358|NCT02293200|Device|Standard BLS|basic life support without any feedback device
79363596|NCT01397409|Drug|AGN-150998|AGN-150998 Intravitreal injection.
79363597|NCT01397409|Drug|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
79363598|NCT01397409|Other|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
79363599|NCT04407429|Diagnostic Test|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
79673235|NCT00463268|Dietary Supplement|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
79673236|NCT00463268|Drug|placebo|identical placebo every 2 weeks
79673237|NCT00489723|Drug|tamsulosin 0.4mg|
79220359|NCT02293200|Device|TrueCPR|CPR with feedback device
79220360|NCT03542799|Biological|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
79220361|NCT02519972|Device|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
79220362|NCT02297568|Drug|Calciferol|Comparison 25OHD levels between calciferol and placebo
79220363|NCT02297568|Drug|placebo|
79673238|NCT00463424|Device|NeuFlex metacarpophalangeal implant|
79673239|NCT00463424|Device|Swanson metacarpophalangeal implant|
79679815|NCT04694417|Other|Placebo tablet|Please see the description of the intervention in another section
79220364|NCT02154555|Procedure|debridement|post-operative debridement at 1 week follow-up visit
79220365|NCT03376334|Other|Mental Motor Imagery|
79220366|NCT03515382|Drug|GLPG1690|A single oral dose of GLPG1690.
79220367|NCT03515382|Drug|Itraconazole|A single oral dose of itraconazole.
79220368|NCT03515382|Drug|Voriconazole|A single oral dose of voriconazole.
79220369|NCT02154633|Behavioral|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
79679816|NCT00520598|Biological|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
79679817|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
79220370|NCT02154633|Behavioral|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
79820898|NCT00726219|Other|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
79820899|NCT00920322|Device|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
79820900|NCT00920322|Device|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
79820901|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
79820902|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
79820903|NCT00726531|Behavioral|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
79820904|NCT00726531|Behavioral|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
79820905|NCT00726531|Other|Treatment As Usual|Treatment as usual by the general practitioner
79820906|NCT02583516|Drug|vemurafenib and cobimetinib|Comparison between different treatment regimens
79220371|NCT02297646|Behavioral|Endurance Training|
79220372|NCT02519426|Procedure|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
79363600|NCT01397253|Other|Automated communication tools|"Automated communication tools will include:~PCP notification of patient admission and location~Data on medications begun on admission~Automated alerts on changes in patient status and location while the patient is hospitalized~Links to the EMR and to hospital physician contact information on all email alerts~Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~Automatic reporting to PCPs of test results pending at discharge~Electronic delivery of final discharge summaries"
79363601|NCT04766775|Device|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
79363602|NCT01777334|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
79220373|NCT03738189|Other|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
79363603|NCT01777334|Drug|Tiotropium 18 mcg|Inhalation Powder
79363604|NCT03024879|Drug|Erythromycin|
79363605|NCT03024879|Drug|Saline|
79673240|NCT04697433|Device|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
79673241|NCT00489762|Procedure|Installation of an energy efficient heater|
79673242|NCT00105443|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
79673243|NCT00105443|Drug|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
79673244|NCT00489801|Other|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
79673245|NCT01243047|Drug|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
79673246|NCT00489840|Drug|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
79673247|NCT00489840|Drug|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
79673248|NCT00463463|Drug|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
79673249|NCT00489879|Device|Mobile Health Care System (DrUB)|
79673250|NCT00465725|Drug|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
79994557|NCT05131529|Other|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
79994558|NCT05131529|Other|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
79514764|NCT04437485|Drug|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
79220374|NCT03519360|Other|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
79363606|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
79363607|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
79673251|NCT00463502|Drug|Metformin|
79220375|NCT03519360|Other|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
79220376|NCT02158923|Procedure|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
79220377|NCT02158923|Procedure|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
79514765|NCT04437485|Other|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
79514766|NCT04359472|Device|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
79673252|NCT00489996|Drug|gemcitabine|
79673253|NCT00489996|Drug|cisplatin|
79673254|NCT00465764|Other|Alternate protein infant formula|Feed as per HCP directions
79673255|NCT00465764|Other|Standard infant formula|Feed as per HCP directions
79673256|NCT00490074|Biological|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
79673257|NCT00490074|Biological|NYVAC-C|NYVAC-C 1 ml IM
79673258|NCT04696926|Other|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
79673259|NCT00463541|Drug|solifenacin succinate|oral
79673260|NCT00490113|Drug|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
79673261|NCT00463619|Drug|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
79673262|NCT01243164|Other|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
79673263|NCT00465881|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
79673264|NCT01243203|Drug|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
79673265|NCT03273101|Device|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
79220378|NCT02158923|Procedure|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
79673266|NCT03273101|Other|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
79679818|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
79679819|NCT00520598|Biological|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
79220379|NCT03690518|Other|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
79220380|NCT02297802|Drug|PD-0325901|
79220381|NCT02159001|Device|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
79220382|NCT03511560|Drug|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
79514767|NCT04338399|Drug|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
79514768|NCT04306510|Procedure|Blood samples for immunoglobulins|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
79514769|NCT04306510|Procedure|Blood samples for inflammatory markers|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
79673267|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
79363608|NCT05369637|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
79673268|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
79220383|NCT03511560|Drug|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
79220384|NCT02160171|Device|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
79363609|NCT05369637|Behavioral|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
79363610|NCT05369637|Behavioral|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
79220385|NCT03519126|Other|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
79514770|NCT04306510|Procedure|Blood samples for anti-drug antibodies|Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
79514771|NCT04286425|Other|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
79220386|NCT03688802|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
79220387|NCT03688802|Drug|Placebo (vehicle control) nasal spray|Placebo
79220388|NCT02159157|Behavioral|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
79363611|NCT05369637|Behavioral|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
79220389|NCT03511482|Device|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
79220390|NCT03511482|Device|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
79363612|NCT05369637|Other|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
79363613|NCT05368545|Drug|High intensity lipid lowering|Two different regimens of drugs with different effects on LDL lowering
79363614|NCT01396395|Drug|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
79514772|NCT04286425|Other|saline solution|saline solution
79220391|NCT02160249|Behavioral|Community-based rehabilitation|
79220392|NCT02160249|Other|Facility based care|
79308409|NCT03208829|Other|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
79308410|NCT03208829|Other|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
79220393|NCT03518970|Other|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
79308411|NCT04857957|Drug|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
79363615|NCT01396395|Drug|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
79363616|NCT01396317|Drug|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
79363617|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
79363618|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
79363619|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
79363620|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
79363621|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
79363622|NCT01396083|Drug|Ranibizumab|
79514773|NCT04254198|Behavioral|TERTULIAS structured dialogue peer support groups|"TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy."
79514774|NCT04254198|Behavioral|Modified Attention Placebo Control (MAPC)|MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
79514775|NCT04241029|Dietary Supplement|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12*10^9 cfu/day) for eight weeks.
79673269|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
79673270|NCT00465920|Behavioral|modified cognitive behavioural therapy (mCBT)|
79673271|NCT01245036|Drug|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
79673272|NCT00466037|Biological|Influenza vaccine|
79673273|NCT00490191|Drug|Somatropin|
79679820|NCT00520598|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
79363623|NCT01396083|Drug|Dexamethasone implant and sham injections|
79363624|NCT04345263|Procedure|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
79363625|NCT01723826|Drug|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
79363626|NCT01721954|Drug|FOLFOX6m|
79363627|NCT01721954|Device|SIR-Spheres microspheres|
79363628|NCT01776554|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
79363629|NCT01776008|Drug|Akt Inhibitor MK2206|Given PO
79363630|NCT01776008|Drug|Anastrozole|Given PO
79363631|NCT01776008|Drug|Goserelin Acetate|Given SC
79363632|NCT01776008|Other|Laboratory Biomarker Analysis|Correlative studies
79363633|NCT01776008|Procedure|Neoadjuvant Therapy|Given before standard-care surgery
79514776|NCT04232306|Drug|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
79363634|NCT01776008|Other|Pharmacological Study|Correlative studies
79363635|NCT01776008|Procedure|Therapeutic Conventional Surgery|Undergo standard-care surgery
79363636|NCT01746368|Other|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
79514777|NCT04232306|Drug|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
79514778|NCT04210024|Other|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
79514779|NCT04171830|Other|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as >0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~Edmonton Symptom Assessment System Revised: scores >6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
79514780|NCT04168320|Radiation|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
79514781|NCT04160468|Drug|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
79994559|NCT05131529|Other|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
79220394|NCT03511404|Other|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
79220395|NCT03656744|Drug|HTD1801|HTD1801 tablets, 250mg
79363637|NCT01746368|Other|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
79220396|NCT03656744|Drug|Placebo|tablets manufactured to mimic HTD1801 tablets
79220397|NCT02297880|Other|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
79363638|NCT01381575|Biological|GSK Biologicals' HPV vaccine 580299|Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
79363639|NCT01858363|Device|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
79363640|NCT01858363|Device|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
79363641|NCT01877551|Drug|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
79363642|NCT01877551|Other|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
79363643|NCT01396005|Drug|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
79363644|NCT01396005|Drug|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
79363645|NCT01396005|Drug|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
79363646|NCT01877239|Other|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
79363647|NCT03024957|Drug|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
79363648|NCT03024957|Drug|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
79514782|NCT04160468|Drug|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
79514783|NCT04099121|Device|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
79679821|NCT00520598|Biological|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
79220398|NCT02297880|Other|Still water|Still water (no flavour)
79308412|NCT03208595|Diagnostic Test|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
79363649|NCT03024957|Drug|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
79363650|NCT03025113|Drug|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
79679822|NCT02939898|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
79679823|NCT02939898|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
79679824|NCT00520637|Drug|EZN-2208|
79994560|NCT04784598|Other|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
79994561|NCT05097677|Other|Not applicable (observational study)|Not applicable (observational study)
79994562|NCT05268822|Other|Home exercise|Movement control exercise with or without specific breathing techniques
79994563|NCT05268510|Drug|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
79514784|NCT04087109|Other|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
79514785|NCT04082442|Drug|Evolocumab|420 mg evolocumab.
79514786|NCT04082442|Drug|Placebos|Matching placebo.
79514787|NCT04065399|Drug|SNDX-5613|SNDX-5613 orally
79514788|NCT04065399|Drug|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
79514789|NCT04054752|Biological|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
79514790|NCT04054752|Biological|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
79514791|NCT04054752|Biological|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
79514792|NCT04039191|Behavioral|SMS education|Patients will receive additional educational SMS messages post-operatively
79514793|NCT04039191|Behavioral|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
79514794|NCT04003285|Drug|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
79673274|NCT00463658|Other|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
79820907|NCT00790907|Drug|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein [GP] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) [maximum two additional bolus doses]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
79220399|NCT02298036|Behavioral|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
79220400|NCT02293356|Drug|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
79363651|NCT03025113|Drug|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
79363652|NCT01877083|Drug|Lenvatinib|Starting dose of 24 mg orally, once per day
79363653|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
79514795|NCT04003285|Drug|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
79514796|NCT04003285|Drug|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
79673275|NCT00497328|Drug|N-acetylcysteine|
79673276|NCT00497328|Drug|Sodium Bicarbonate|
79673277|NCT00466076|Drug|Copaxone (Glatiramer acetate)|
79220401|NCT03518892|Diagnostic Test|Resting Metabolic Rate|30 minute test to determine daily caloric needs
79514797|NCT03989492|Other|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
79673278|NCT01245075|Other|Deep brain stimulation|Deep brain stimulation on
79673279|NCT01245075|Other|Placebo|deep brain stimulation off
79673280|NCT00463697|Drug|GW642444H (100mcg)|H salt
79673281|NCT00463697|Drug|placebo|placebo
79994564|NCT05268510|Drug|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
79220402|NCT03518892|Diagnostic Test|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
79673282|NCT00463697|Drug|GW642444M (25, 100 & 400 mcg)|M salt
79673283|NCT00490230|Drug|WR 279396|
79673284|NCT00466154|Drug|Aspirin|
79673285|NCT00490308|Drug|Treatment with estradiol valerate|
79673286|NCT00463736|Drug|Magnesium sulfate|
79673287|NCT00490347|Device|VentrAssist Left Ventricular Assist Device|
79673288|NCT00490425|Drug|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
79673289|NCT00497367|Device|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
79673290|NCT00497406|Procedure|Salivary gland transfer|Retrograde flow method
79994565|NCT05268510|Drug|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
79994566|NCT05268510|Drug|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
79514798|NCT03987841|Behavioral|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
79514799|NCT03983720|Other|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
79514800|NCT03983720|Other|Questionnaires|"Fatigue Severity Scale (FSS)~Modified Fatigue Impact Scale (MFIS)~Godin Leisure-Time Exercise Questionnaire (GLTEQ)~Scale of life quality of multiple sclerosis (SEP-59)~Center for Epidemiologic Studies Depression (CES-D)~Pittsburgh Sleep Quality Index (PSQ-I)"
79220403|NCT03518892|Behavioral|Dietary Assessment|Self administered dietary logs
79514801|NCT03983720|Biological|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
79514802|NCT03983720|Other|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
79514803|NCT03983720|Device|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
79514804|NCT03983720|Device|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
79994567|NCT05042453|Device|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
79220404|NCT03616418|Drug|antiplatelet drugs;statins;antihypertensive drugs|
79220405|NCT03515148|Procedure|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
79220406|NCT03515148|Procedure|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
79220407|NCT03371576|Device|intraocular lenses|
79363654|NCT01380327|Other|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume [w/v]) was achieved.
79363655|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
79363656|NCT01829425|Drug|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
79514805|NCT03983720|Device|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
79514806|NCT03983720|Other|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~Fatigue test~Measure of voluntary isometric force~Surface electromyography~Peripheral nerve stimulation~Transcranial Magnetic Stimulation (TMS)~Perceived fatigue~Cognitive fatigue~Thermoregulation"
79514807|NCT03970590|Behavioral|CTC Intervention|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
79673291|NCT00497406|Procedure|Helical Tomotherapy treatment|total of 30 fractions
79673292|NCT00497445|Procedure|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
79673293|NCT00497445|Procedure|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
79673294|NCT00497484|Drug|recombinant human somatotropin|
79673295|NCT00490464|Drug|Nicardipine and Nipride|
79673296|NCT00497523|Drug|Beclomethasone dipropionate|
79673297|NCT00497523|Drug|Beclomethasone dipropionate/Salbutamol combination|
79673298|NCT00497523|Drug|Salbutamol|
79673299|NCT00463775|Drug|Topiramate|SSRI plus topiramate SSRI plus placebo
79514808|NCT03970590|Behavioral|Control|6-month HTN management assessment text messages without narrative component
79514809|NCT03961945|Device|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
79514810|NCT03957434|Other|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
79514811|NCT03933800|Device|High flow nasal cannula|High flow nasal cannula therapy
79514812|NCT03933800|Device|Continuous positive airway pressure|Continuous positive airway pressure therapy
79514813|NCT03924856|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
79514814|NCT03924856|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle
79514815|NCT03924856|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle
79673300|NCT00463853|Procedure|Autologous stem cell therapy|
79673301|NCT00463853|Procedure|CABG|
79673302|NCT00463853|Radiation|CMRI|
79994568|NCT05309681|Other|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
79514816|NCT03924856|Procedure|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
79514817|NCT03924856|Drug|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
79673303|NCT00490620|Drug|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
79673304|NCT00490620|Drug|Placebo|placebo BID for 6 months
79673305|NCT00466232|Drug|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
79673306|NCT00466232|Drug|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
79673307|NCT00490659|Drug|gemcitabine|
79820908|NCT00790907|Drug|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
79363657|NCT01829425|Behavioral|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
79363658|NCT03796689|Device|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
79363659|NCT03796689|Device|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
79514818|NCT03919162|Drug|PQ912|PQ912 150 mg tablets
79673308|NCT00490659|Drug|cisplatin|
79820909|NCT00790907|Drug|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
79820910|NCT02569983|Other|Observational cohort|No intervention - observational study
79220408|NCT03511170|Drug|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
79220409|NCT03511170|Drug|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
79220410|NCT03518814|Other|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
79673309|NCT00490659|Procedure|radical surgery|
79673310|NCT00490659|Procedure|chemoradiotherapy|
79220411|NCT02301312|Device|POSS-PCU vascular graft|New vascular access graft
79220412|NCT03376178|Combination Product|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
79220413|NCT02298114|Device|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
79220414|NCT02298114|Other|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
79220415|NCT03514836|Biological|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
79220416|NCT03514836|Drug|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
79514819|NCT03919162|Other|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
79514820|NCT03884101|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
79514821|NCT03884101|Biological|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
79514822|NCT03884101|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
79514823|NCT03884101|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
79514824|NCT03850054|Procedure|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
79673311|NCT00463892|Procedure|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
79673312|NCT00490737|Drug|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
79673313|NCT00497562|Drug|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
79673314|NCT00497562|Drug|amitriptyline, fluoxetine and tramadol alone (control group)|
79673315|NCT00497601|Drug|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 & 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 & 5 mg/kg on day 1 & 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 & 2.5 mg/kg on day 1 & 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
79514825|NCT03847480|Radiation|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
79514826|NCT03844399|Device|Ablation|The medical device will passively record image data during the standard care ablation
79220417|NCT03511014|Device|Microcurrent|Micrucurrent will be apply
79514827|NCT03844399|Device|Biopsy|The medical device will passively record image data during the standard care biopsy
79514828|NCT03843034|Genetic|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
79514829|NCT03834766|Drug|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
79514830|NCT03834766|Drug|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
79673316|NCT00497601|Drug|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
79820911|NCT03109353|Drug|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
79220418|NCT03376100|Procedure|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
79363660|NCT05630079|Device|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
79363661|NCT05630079|Device|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% [-] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
79363662|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
79514831|NCT03780309|Behavioral|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
79220419|NCT03376100|Procedure|Hematoma Block|Conventional local anesthetic method using hematoma block
79514832|NCT03780309|Behavioral|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
79220420|NCT03376022|Other|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
79220421|NCT03518580|Other|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
79220422|NCT03371342|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
79514833|NCT03761056|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
79514834|NCT03761056|Drug|Fludarabine|Administered according to package insert
79673317|NCT00497601|Drug|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
79673318|NCT00466388|Drug|Cevimeline|
79673319|NCT00497640|Procedure|Artificial Neural Network|Use of a predicted optimal CPAP
79673320|NCT00497679|Drug|AZD1152|7-day continuous intravenous infusion
79673321|NCT00466466|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
79673322|NCT00490854|Drug|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
79673323|NCT00490854|Drug|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
79673324|NCT00463970|Behavioral|Brief Intervention|Physical examination, education and follow up by a physiotherapist
79220423|NCT03371342|Drug|Botox|Botox(Botulinum toxin type A)
79220424|NCT02302326|Drug|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
79220425|NCT02302326|Dietary Supplement|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
79220426|NCT03367130|Behavioral|Mobile phone reminder|Intervention described already in arm/group descriptions.
79220427|NCT02293590|Drug|Certolizumab Pegol|
79220428|NCT02302404|Drug|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
79514835|NCT03761056|Drug|Cyclophosphamide|Administered according to package insert
79514836|NCT03747120|Drug|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
79514837|NCT03747120|Drug|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
79514838|NCT03747120|Drug|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
79514839|NCT03747120|Drug|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
79514840|NCT03729557|Procedure|Nephrectomy|Unilateral nephrectomy
79514841|NCT03602105|Behavioral|Exercise|Exercises in group and/or individually
79514842|NCT03592888|Drug|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
79514843|NCT03586089|Drug|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
79514844|NCT03586089|Drug|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
79514845|NCT03585764|Drug|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
79514846|NCT03585764|Device|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
79514847|NCT03546686|Drug|Pembrolizumab|Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
79514848|NCT03546686|Procedure|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
79514849|NCT03546686|Procedure|Breast Surgery|Standard-of-care definitive surgery.
79220429|NCT02302404|Drug|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
79220430|NCT02302404|Drug|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
79220431|NCT02302404|Drug|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
79220432|NCT03124082|Drug|Remifentanil|continuous infusion intraop
79220433|NCT03124082|Drug|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
79220434|NCT03124082|Drug|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
79220435|NCT03124082|Drug|Clonidine|clonidine 4 mcg/kg
79220436|NCT03109860|Behavioral|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
79220437|NCT02301702|Biological|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
79220438|NCT02301702|Biological|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
79220439|NCT03552224|Procedure|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
79363663|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
79220440|NCT03518502|Procedure|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
79363664|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
79363665|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
79371092|NCT03490695|Other|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
79514850|NCT03546686|Drug|Ipilimumab|ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
79514851|NCT03546686|Drug|Nivolumab|nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
79514852|NCT03508921|Drug|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
79514853|NCT03508921|Drug|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
79673325|NCT00463970|Behavioral|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
79673326|NCT00463970|Dietary Supplement|Seal oil|20 capsules per day for 3 months
79220441|NCT03518502|Drug|Sorafenib|Standard therapy for advanced HCC
79220442|NCT02301780|Drug|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
79673327|NCT00463970|Dietary Supplement|Soy oil|20 capsules per day for 3 months
79673328|NCT00497718|Procedure|Chiropractic Manipulation|
79220443|NCT02301780|Drug|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
79679825|NCT02938338|Procedure|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
79514854|NCT03508921|Procedure|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
79514855|NCT03494127|Device|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
79514856|NCT03494127|Device|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
79514857|NCT03493295|Drug|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
79514858|NCT03426826|Biological|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
79994569|NCT05033717|Other|Tissue Flossing Technique|"Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total."
79514859|NCT03401047|Drug|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
79514860|NCT03349450|Biological|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
79220444|NCT03124004|Procedure|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
79363666|NCT04407663|Other|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
79363667|NCT05632653|Procedure|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF <50%).
79220445|NCT02302482|Other|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
79220446|NCT03124238|Other|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
79371093|NCT03490695|Other|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
79220447|NCT04527068|Drug|Bevacizumab|7.5 mg/kg intravenously every 3week
79220448|NCT04527068|Drug|Tripleitriumab|240mg intravenously every 3week
79220449|NCT02302638|Other|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
79371094|NCT03489993|Diagnostic Test|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
79371095|NCT03489993|Diagnostic Test|FGF23 and klotho|Measured using ELISA's.
79514861|NCT03349450|Biological|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
79514862|NCT03349450|Drug|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
79514863|NCT03315026|Drug|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
79514864|NCT03315026|Behavioral|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
79514865|NCT03307616|Biological|Ipilimumab|Given IV
79514866|NCT03307616|Biological|Nivolumab|Given IV
79514867|NCT03307616|Radiation|Radiation Therapy|Undergo radiation therapy
79514868|NCT03289195|Procedure|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
79514869|NCT03287453|Other|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
79514870|NCT03287453|Other|Survey Administration|Ancillary studies
79679826|NCT00521495|Device|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
79679827|NCT00521495|Device|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
79679828|NCT00521495|Device|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
79679829|NCT02939703|Other|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
79679830|NCT02938221|Device|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
79679831|NCT00520754|Drug|levocetirizine dihydrochloride|
79220450|NCT04526756|Procedure|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
79220451|NCT02739360|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
79220452|NCT03510936|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5*10^7CFU for 2 weeks
79308413|NCT02502305|Behavioral|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
79514871|NCT03280147|Drug|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
79514872|NCT03280147|Drug|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
79514873|NCT03276572|Drug|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
79363668|NCT01829347|Biological|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
79514874|NCT03261622|Device|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
79514875|NCT03240406|Other|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
79220453|NCT03375944|Other|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
79820912|NCT04066569|Other|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
79994570|NCT05033717|Other|Static Stretching Technique|"Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total."
79220454|NCT03132870|Other|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
79514876|NCT03240406|Other|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
79514877|NCT03240289|Behavioral|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
79514878|NCT03220893|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
79220455|NCT03123770|Drug|Pegylated liposomal doxorubicin|a new kind of doxorubicin
79220456|NCT03123770|Drug|Cyclophosphamide|traditional chemotherapy drug
79220457|NCT03123770|Drug|Epirubicin|traditional chemotherapy drug used in breast cancer
79220458|NCT03123770|Drug|Docetaxel|traditional chemotherapy drug used in breast cancer
79220459|NCT04464642|Drug|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
79363669|NCT01829347|Other|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
79363670|NCT01394523|Drug|Bupivacaine|0.25% or 0.5%
79363671|NCT01857973|Device|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
79363672|NCT04304469|Other|surveys|delivery of the survey at a domestic violence consultation
79514879|NCT03220893|Radiation|Scintimammography|Undergo MBI
79220460|NCT04464642|Drug|Tofacitinib|tofacitinib 10 mg given in group B
79220461|NCT02293668|Drug|FSH 225IU and hMG 225IU|
79220462|NCT02293668|Drug|FSH 150IU and hMG 150IU|
79220463|NCT02293668|Drug|Letrozole 5mg and hMG 150IU|
79220464|NCT04526678|Dietary Supplement|Iron supplement (27mg)|The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
79308414|NCT04429269|Diagnostic Test|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
79514880|NCT03202069|Other|Even protein|Intake of even protein 5 day rotating menu
79514881|NCT03202069|Other|Skewed protein|Intake of skewed protein 5 day rotating menu
79514882|NCT03200236|Behavioral|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
79308415|NCT02450513|Drug|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
79308416|NCT04859283|Drug|Dexmedetomidine|Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
79363673|NCT04304469|Other|follow-up|follow-up of women 6 months after their consultation
79363674|NCT04407273|Drug|observational|observational study
79363675|NCT01857583|Drug|15mg DU-176b|
79363676|NCT01857583|Drug|30mg DU-176b|
79514883|NCT03200236|Behavioral|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
79514884|NCT03181152|Diagnostic Test|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
79514885|NCT03125642|Drug|Etoposide|"BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
79994571|NCT05026931|Other|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
79220465|NCT02302014|Other|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
79220466|NCT03123692|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
79220467|NCT03123692|Drug|Placebo|14 days treatment with placebo
79220468|NCT03367052|Procedure|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
79220469|NCT03367052|Procedure|Hybrid|The hybrid method will be used in one group of patients.
79363677|NCT01857583|Drug|Fondaparinux|
79363678|NCT04000347|Drug|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
79994572|NCT05026931|Other|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
79220470|NCT03510858|Other|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
79363679|NCT04000347|Drug|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
79514886|NCT03125642|Drug|BCNU|BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6
79363680|NCT01829191|Device|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
79514887|NCT03125642|Drug|AraC|BEAM: 100 mg/m^2 IV over 1 hour BID on Days -5, -4, -3, -2
79514888|NCT03125642|Drug|Melphalan|BEAM: 140 mg/m^2 IV over 20 minutes on Day -1
79679832|NCT00520832|Device|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
79679833|NCT00520832|Device|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
79679834|NCT02939859|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
79363681|NCT01829191|Device|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
79363682|NCT05360745|Dietary Supplement|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
79363683|NCT05360745|Dietary Supplement|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
79363684|NCT00211185|Drug|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
79363685|NCT00211185|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
79308417|NCT04859283|Drug|Placebo|Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
79363686|NCT00211185|Drug|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
79363687|NCT00211185|Drug|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
79679835|NCT02939859|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
79679836|NCT02939859|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
79679837|NCT00521534|Device|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
79679838|NCT02277132|Drug|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
79679839|NCT02277132|Drug|Placebo|Placebo tablets three times daily orally from randomization until delivery
79679840|NCT00520871|Drug|Blueberry juice|
79514889|NCT03125642|Procedure|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
79514890|NCT03125642|Biological|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3
79514891|NCT03125642|Drug|Cyclophosphamide|"CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
79514892|NCT03125642|Radiation|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
79673329|NCT00464009|Behavioral|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
79220471|NCT03510858|Other|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
79220472|NCT04465032|Other|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
79220473|NCT03375632|Drug|FYU-981|Oral daily dosing for 14 weeks
79220474|NCT02302170|Biological|H. pylori vaccine|
79220475|NCT02302170|Biological|placebo|
79220476|NCT02302794|Procedure|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
79363688|NCT00211185|Drug|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
79363689|NCT00211185|Other|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm^2) for 2 days post-nadir.
79363690|NCT00210639|Drug|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
79363691|NCT05632029|Device|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
79514893|NCT03105843|Drug|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
79514894|NCT03105843|Diagnostic Test|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
79514895|NCT03105843|Drug|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
79673330|NCT00464048|Procedure|controlled physical exercise|
79673331|NCT00490893|Drug|Detemir|
79220477|NCT02302794|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
79220478|NCT03366896|Diagnostic Test|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
79220479|NCT03366896|Diagnostic Test|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
79220480|NCT02302872|Device|ARTO System|
79220481|NCT03363698|Other|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
79220482|NCT03371186|Other|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
79673332|NCT00464126|Other|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
79514896|NCT03068910|Drug|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
79514897|NCT03068910|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
79514898|NCT03068910|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
79514899|NCT03028246|Device|ExAblate 4000 System|Focused ultrasound
79514900|NCT03005418|Biological|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
79363692|NCT05632029|Device|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
79363693|NCT05631873|Other|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
79363694|NCT01829113|Drug|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
79371096|NCT00951808|Biological|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
79220483|NCT03371186|Other|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
79514901|NCT02984761|Radiation|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
79514902|NCT02984761|Procedure|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
79514903|NCT02978638|Device|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
79514904|NCT02925195|Dietary Supplement|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
79514905|NCT02925195|Drug|Placebo|
79220484|NCT03371186|Other|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
79220485|NCT03371186|Other|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
79371097|NCT00951808|Behavioral|Standard care|Participants will receive standard care for ACS while in the hospital.
79371098|NCT03030508|Other|No intervention|
79514906|NCT02921581|Radiation|FDG-PET guided dose painting|
79514907|NCT02864277|Procedure|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
79514908|NCT02864277|Procedure|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
79514909|NCT02840877|Behavioral|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
79514910|NCT02835287|Other|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
79514911|NCT02831985|Procedure|general practice follow-up|Post-surgery follow-up by general practitioner
79514912|NCT02831985|Procedure|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
79514913|NCT02795533|Behavioral|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~A medical examination~Quality of life questionnaires~Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
79514914|NCT02694185|Other|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
79673333|NCT00464126|Other|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
79820913|NCT04066569|Other|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
79820914|NCT04071795|Behavioral|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
79220486|NCT03371186|Other|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
79220487|NCT02302248|Behavioral|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
79220488|NCT02302248|Behavioral|Expressive writing intervention|3 week access to a web-based expressive writing platform.
79363695|NCT01829113|Drug|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
79220489|NCT03366818|Device|thrombectomy|mechanical thrombectomy
79363696|NCT00219297|Drug|Patupilone|
79363697|NCT01857271|Drug|Erlotinib Hydrochloride|Given PO
79363698|NCT01857271|Procedure|Therapeutic Conventional Surgery|Undergo thoracotomy
79220490|NCT02302950|Drug|raltegravir|HIV therapy component
79220491|NCT02293746|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
79220492|NCT03366740|Other|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
79363699|NCT01857271|Other|Laboratory Biomarker Analysis|Correlative studies
79673334|NCT00490932|Drug|Hypo-osmolar ORS|
79673335|NCT03272399|Other|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
79673336|NCT00491010|Procedure|radiofrequency catheter ablation|
79673337|NCT03272126|Drug|Vitamin D|vitamin D given as bolus versus daily dosing
79363700|NCT00216255|Drug|Pagoclone|
79363701|NCT00216255|Drug|Placebo|
79363702|NCT01745120|Genetic|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
79363703|NCT03024723|Device|nasal mask CPAP|CPAP and ventilation administered via nasal mask
79363704|NCT01828567|Behavioral|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
79363705|NCT04019535|Device|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
79363706|NCT01721486|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
79363707|NCT01721486|Drug|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
79673338|NCT03272126|Drug|Placebo|identical looking as vitamin D
79673339|NCT00491049|Drug|0.5% levofloxacin eye drops|
79673340|NCT00464165|Drug|rimonabant|
79673341|NCT00497913|Drug|NaCl 0.9%|
79673342|NCT00497913|Drug|Botulinum Toxin A|
79673343|NCT00497991|Drug|AZD1152|
79673344|NCT03272321|Drug|Oxytocin|Syntocinon nasal spray
79514915|NCT02684903|Behavioral|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
79220493|NCT03366740|Other|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
79820915|NCT04071795|Behavioral|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
79820916|NCT04066179|Drug|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
79994573|NCT05477693|Biological|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
79994574|NCT05477693|Biological|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp & Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
79220494|NCT03366740|Other|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
79220495|NCT03510780|Procedure|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
79220496|NCT03510780|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
79220497|NCT03363620|Device|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
79363708|NCT04610905|Behavioral|Reducing sedentary behaviour|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
79363709|NCT04610905|Behavioral|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
79363710|NCT05631639|Device|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
79363711|NCT05366517|Device|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
79514916|NCT02633111|Other|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
79514917|NCT02633111|Other|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
79514918|NCT02633111|Device|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
79514919|NCT02621424|Device|RTMS|stimulation of the brain with magnetic pulses
79673345|NCT03272321|Drug|Placebo|Placebo nasal spray
79994575|NCT03638843|Procedure|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
79994576|NCT04927325|Other|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
79994577|NCT05309447|Other|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
79994578|NCT05309213|Biological|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10^4 CAR+ T cells/kg,1x 10^5 CAR+ T cells/kg,3 x 10^5 CAR+ T cells/kg,1 x 10^6 CAR+ T cells/kg
79220498|NCT03363620|Device|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
79220499|NCT02293824|Drug|Caffeine|Given per standard of care.
79220500|NCT03366662|Device|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
79363712|NCT05631483|Device|DAISe|Use of the DAISe Thrombectomy Device
79673346|NCT00491088|Device|CPAP|CPAP for 12 weeks
79673347|NCT00466544|Device|Plasmaknife|
79673348|NCT00466544|Device|Monopolar|
79673349|NCT00491127|Drug|gemcitabine|
79820917|NCT04066179|Drug|Prednisolone|Prednisolone 40 mg for initial 7 days
79820918|NCT04110119|Drug|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
79820919|NCT04110119|Other|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
79820920|NCT04052061|Biological|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
79820921|NCT02585310|Other|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
79994579|NCT05309057|Dietary Supplement|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
79514920|NCT02621424|Device|sham|sham noise to block the sound of stimulation
79514921|NCT02616185|Biological|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
79514922|NCT02616185|Biological|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
79514923|NCT02616185|Device|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
79514924|NCT02616185|Biological|Tremelimumab|PF-06753388 will be administered every 28 days.
79994580|NCT05438303|Drug|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
79220501|NCT03510702|Diagnostic Test|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
79220502|NCT03363542|Dietary Supplement|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
79220503|NCT04464330|Other|no intervention|This is an observation study, with no intervention
79220504|NCT03370796|Other|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
79220505|NCT03510624|Drug|Rebaudioside A|Rebaudioside A 3g
79220506|NCT03510624|Drug|Placebo|Empty capsules
79220507|NCT03366584|Dietary Supplement|Beta carotene|Beta carotene 25,000 IU
79220508|NCT03366584|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU
79363713|NCT01775930|Drug|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
79363714|NCT01856569|Other|no intervention|in real life of drug,dosage,frequency and duration
79363715|NCT03024645|Behavioral|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
79514925|NCT02616185|Biological|PF-06801591|PF-06801591 will be administered every 28 days.
79673350|NCT00491127|Drug|cisplatin|
79673351|NCT00491127|Drug|dexamethasone|
79673352|NCT00491166|Drug|Bromfenac ophthalmic solution|
79994581|NCT05438303|Drug|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
79220509|NCT03366584|Dietary Supplement|Zinc|Zinc 50 mg
79363716|NCT03024645|Other|Treatment as usually (TAU)|performed in primary care settings
79363717|NCT01721408|Drug|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
79363718|NCT01721408|Drug|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
79371099|NCT03030430|Biological|BAT1706 injection|1mg/kg, IV on day 1
79514926|NCT02616185|Biological|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
79514927|NCT02611128|Other|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
79514928|NCT02560129|Other|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
79514929|NCT02520362|Drug|denosumab|subcutaneous injection
79514930|NCT02520362|Drug|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate [Fosamax®], risedronate [Actonel®], ibandronate [Boniva®/Bonviva®] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate [Reclast®/Aclasta®].
79514931|NCT02453737|Radiation|Brachytherapy APBI|
79220510|NCT03366584|Drug|Dexamethasone|Dexamethasone 6 mg
79220511|NCT03507972|Radiation|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
79220512|NCT03507972|Radiation|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
79220513|NCT03366506|Other|Observation|
79514932|NCT02453737|Radiation|3D-CRT (photon) APBI|
79514933|NCT02453737|Radiation|Proton APBI|
79514934|NCT02346747|Biological|Vigil|The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
79514935|NCT02346747|Other|Placebo|"To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media [10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection."
79673353|NCT00491283|Device|Swab Specimen Collection (QuickVue)|
79673354|NCT00498069|Device|Harvest Smartprep2 BMAC System|injection of 40cc bmac
79673355|NCT00498069|Device|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
79673356|NCT00498069|Biological|placebo|injection of placebo into ischemic tissue of the lower extremity
79673357|NCT03273062|Drug|Tolcapone 200 MG|Tolcapone 200 MG TID
79514936|NCT02324387|Procedure|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
79514937|NCT02324387|Drug|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
79514938|NCT02291523|Biological|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
79514939|NCT02278744|Radiation|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
79673358|NCT03273062|Other|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
79220514|NCT02293278|Behavioral|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
79220515|NCT03363386|Procedure|Proprioceptive Exercises|Patients trained for proprioceptive exercises
79363719|NCT03998709|Drug|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
79514940|NCT02278744|Device|MRI and/or CT|
79514941|NCT02267252|Other|Antibody-sperm binding|
79673359|NCT00498108|Drug|Rotigotine|
79673360|NCT00464321|Biological|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
79673361|NCT00464321|Biological|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
79673362|NCT00464321|Biological|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
79673363|NCT00464321|Biological|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
79673364|NCT03272984|Procedure|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
79673365|NCT03272984|Procedure|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
79673366|NCT00498147|Other|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
79673367|NCT00466583|Drug|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
79673368|NCT00498225|Drug|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
79673369|NCT00498225|Drug|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
79673370|NCT00498225|Drug|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
79673371|NCT00466622|Drug|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
79673372|NCT00466622|Drug|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
79820922|NCT04630392|Other|Treadmill Training|Ten minutes of treadmill walking at 110% self-selected overground walking speed
79820923|NCT04630392|Other|Whole Body Vibration & Treadmill Training|Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
79220516|NCT03363386|Procedure|Resistive Exercises|Patients trained for resistive exercises
79363720|NCT03998709|Other|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
79363721|NCT03998709|Drug|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
79363722|NCT03998709|Other|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
79363723|NCT03025191|Behavioral|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
79371100|NCT03030430|Biological|EU-sourced Avastin|1mg/kg, IV on day 1
79371101|NCT03030430|Biological|US-sourced Avastin|1mg/kg, IV on day 1
79994582|NCT05438303|Drug|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
79514942|NCT02266329|Drug|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
79514943|NCT02266329|Drug|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
79820924|NCT04019691|Device|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
79820925|NCT04019691|Device|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
79220517|NCT03363386|Procedure|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
79220518|NCT03518346|Behavioral|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
79220519|NCT03518346|Behavioral|Standard of Care|Books, movies, TV
79220520|NCT03363308|Behavioral|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
79363724|NCT03025191|Behavioral|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
79363725|NCT03025191|Behavioral|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
79363726|NCT03025191|Behavioral|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
79363727|NCT01744496|Drug|Rotigotine|Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
79514944|NCT02155933|Other|Blood sampling|Blood sampling for later hormone measurements
79371102|NCT00089661|Drug|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
79371103|NCT00089661|Drug|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
79514945|NCT01967888|Drug|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
79514946|NCT01967888|Drug|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
79514947|NCT01961219|Procedure|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
79220521|NCT03518268|Drug|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
79220522|NCT03518268|Drug|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
79220523|NCT03366350|Procedure|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
79220524|NCT03363230|Behavioral|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
79220525|NCT03363230|Behavioral|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
79220526|NCT02519114|Procedure|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
79220527|NCT03370562|Drug|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
79514948|NCT01961219|Procedure|Arthroscopic capsular release|Arthroscopic capsular release
79514949|NCT01910818|Device|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
79514950|NCT01910818|Other|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
79820926|NCT04019691|Device|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
79220528|NCT03370562|Drug|Placebo|Administration of normal saline
79673373|NCT00498264|Behavioral|walking program, resistance muscular exercise|
79673374|NCT01327612|Drug|Modified FOLFOX6|The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
79673375|NCT01327612|Biological|Conatumumab|Administered by intravenous infusion Q2W or Q3W.
79820927|NCT00726687|Drug|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
79820928|NCT00726687|Drug|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
79514951|NCT01873131|Drug|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
79514952|NCT01873131|Device|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
79514953|NCT01508949|Drug|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
79673376|NCT01327612|Biological|Ganitumab|Administered by intravenous infusion Q3W or Q4W.
79994583|NCT05438303|Drug|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
79994584|NCT05438303|Drug|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
79994585|NCT05432141|Biological|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
79994586|NCT05432141|Biological|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
79220529|NCT03370484|Dietary Supplement|Control|Water with 80 mg sucralose
79220530|NCT03370484|Dietary Supplement|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
79220531|NCT03507738|Biological|MT-5625 low dose|Intramuscular injection
79220532|NCT03507738|Biological|MT-5625 middle dose|Intramuscular injection
79220533|NCT03507738|Biological|MT-5625 high dose|Intramuscular injection
79220534|NCT03507738|Biological|Rotarix|Oral administration
79220535|NCT03507738|Biological|Placebo|Intramuscular injection
79220536|NCT04524806|Other|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
79363728|NCT01744496|Drug|Placebo|Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
79363729|NCT05366205|Dietary Supplement|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
79673377|NCT01327612|Biological|Bevacizumab|Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
79673378|NCT01243281|Drug|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
79673379|NCT00464399|Drug|everolimus|
79673380|NCT04132882|Drug|Sodium Thiosulfate (STS)|
79220537|NCT03507660|Other|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
79220538|NCT03370328|Other|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
79673381|NCT01243359|Drug|sunitinib malate|Given PO
79673382|NCT01243359|Biological|bevacizumab|Given IV
79220539|NCT03370328|Other|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
79673383|NCT01243359|Other|pharmacological study|Correlative studies
79673384|NCT01243359|Other|laboratory biomarker analysis|Correlative studies
79673385|NCT01243359|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
79673386|NCT01243359|Procedure|positron emission tomography|Undergo FLT PET/CT
79673387|NCT01243359|Procedure|computed tomography|Undergo FLT PET/CT
79514954|NCT01508949|Drug|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
79514955|NCT01507285|Drug|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
79514956|NCT01507285|Drug|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
79514957|NCT01486862|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
79514958|NCT01428089|Drug|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
79514959|NCT01428089|Drug|Placebo|Placebo
79514960|NCT01425541|Drug|estrace|0.5-1 mg once a day PO for 7 days
79514961|NCT01425541|Drug|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
79514962|NCT01388244|Other|Screening|Screening by risk factor assessment (FRAX) followed by DXA
79673388|NCT04403581|Other|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
79673389|NCT02893579|Behavioral|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
79220540|NCT03507582|Other|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
79220541|NCT03507582|Other|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
79220542|NCT02303106|Drug|Lamotrigine|
79673390|NCT02893579|Behavioral|Delayed SR intervention|Activity tracking only for the first month
79673391|NCT00498303|Biological|trivalent split influenza vaccine|
79220543|NCT04525664|Drug|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
79220544|NCT04525664|Drug|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
79363730|NCT05366205|Behavioral|Nutrition consultation|Nutritional treatment advice will be given
79363731|NCT01721330|Drug|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
79363732|NCT01721330|Drug|Placebo|Placebo twice a day for 6 weeks
79363733|NCT05366127|Other|IGA score|IGA score will be assessed by 2 blinded investigators
79514963|NCT01388244|Other|Control|Observation by use of register data
79673392|NCT04402567|Other|No Intervention|Not Apply
79673393|NCT01243398|Procedure|quality-of-life assessment|
79673394|NCT04400812|Other|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
79363734|NCT05366127|Other|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
79514964|NCT01167114|Drug|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
79514965|NCT01156155|Radiation|Digital xray of jaw and teeth|one time xray of jaw and teeth
79514966|NCT01156155|Procedure|Blood draw|Three to four tablespoons of blood drawn.
79514967|NCT01156155|Other|questionnaires|completed questionnaires regarding patient's health and functional ability.
79673395|NCT04400461|Other|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
79673396|NCT00498342|Drug|N-acetylcysteine|
79673397|NCT04399174|Device|US|
79679841|NCT00520949|Drug|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
79220545|NCT04525664|Drug|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
79363735|NCT05631015|Other|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
79363736|NCT03595605|Behavioral|Ambulation|This group will be encouraged twice daily to ambulate
79363737|NCT03595605|Other|Standard of Care|Care as usual at inpatient NYU Langone
79363738|NCT04407195|Other|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
79363739|NCT03592407|Drug|Epacadostat|Given PO
79363740|NCT03592407|Other|Laboratory Biomarker Analysis|Correlative studies
79363741|NCT03592407|Biological|Pembrolizumab|Given IV
79363742|NCT03592407|Other|Pharmacodynamic Study|Correlative studies
79363743|NCT03593187|Drug|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
79363744|NCT04254159|Other|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
79514968|NCT01156155|Procedure|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
79514969|NCT01156155|Other|Bilateral digital xray of hands|One time digital xray of hands
79514970|NCT00930228|Drug|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
79514971|NCT00930228|Drug|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
79514972|NCT00918151|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study
79220546|NCT04525664|Drug|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
79363745|NCT04254159|Other|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
79673398|NCT00466856|Drug|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~<10% Administer full dose of SIR-Spheres~10% to 15% Reduce dose of SIR-Spheres by 20%~16% to 20% Reduce dose of SIR-Spheres by 40%~>20% Do not give SIR-Spheres"
79673399|NCT00466856|Radiation|yttrium Y 90 resin microspheres|radiation
79363746|NCT04254159|Behavioral|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
79363747|NCT04254159|Other|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
79514973|NCT00874159|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
79514974|NCT00849316|Drug|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
79514975|NCT00773851|Procedure|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
79514976|NCT00773851|Procedure|mesh fixation by staples|mesh fixation by staples
79514977|NCT00773773|Other|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
79673400|NCT04398979|Procedure|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
79363748|NCT03978585|Device|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
79363749|NCT03978585|Device|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
79514978|NCT00745433|Drug|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
79514979|NCT00745433|Drug|metformin|Start dose and frequency at the discretion of the physician following clinical practice
79679842|NCT00520949|Drug|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
79363750|NCT02079987|Behavioral|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
79363751|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
79514980|NCT00712478|Drug|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79514981|NCT00705172|Drug|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
79514982|NCT00701155|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
79514983|NCT00687453|Drug|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
79679843|NCT00520949|Drug|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
79679844|NCT00520949|Drug|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
79220547|NCT03510546|Drug|Pyridostigmine|Study dose as per protocol.
79220548|NCT03510546|Drug|Placebo oral capsule|Study dose as per protocol.
79220549|NCT03505008|Drug|Methotrexate|Route of Administration: Oral
79220550|NCT03505008|Drug|Adalimumab|Route of Administration: Subcutaneous
79220551|NCT03363074|Device|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
79514984|NCT00687453|Drug|NPH twice-daily|Addition of morning NPH to bedtime NPH
79514985|NCT00687063|Drug|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
79514986|NCT00653068|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
79514987|NCT00653068|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
79514988|NCT00653068|Drug|Carboplatin|Given IV
79514989|NCT00653068|Drug|Cisplatin|Given IV
79514990|NCT00653068|Drug|Cyclophosphamide|Given IV
79514991|NCT00653068|Drug|Etoposide|Given IV
79514992|NCT00653068|Biological|Filgrastim|Given IV or SC
79363752|NCT03996135|Device|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
79514993|NCT00653068|Other|Laboratory Biomarker Analysis|Correlative studies
79514994|NCT00653068|Drug|Leucovorin Calcium|Given IV or PO
79514995|NCT00653068|Drug|Methotrexate|Given IV
79514996|NCT00653068|Drug|Thiotepa|Given IV
79514997|NCT00653068|Drug|Vincristine Sulfate|Given IV
79673401|NCT02893189|Genetic|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
79673402|NCT00498381|Device|CPAP|
79514998|NCT00521690|Drug|insulin detemir|
79514999|NCT00504673|Drug|insulin detemir|
79363753|NCT03995511|Procedure|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
79515000|NCT00504673|Drug|insulin NPH|
79515001|NCT00504673|Drug|insulin aspart|
79363754|NCT03595137|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
79363755|NCT03595137|Device|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
79371104|NCT00941668|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
79371105|NCT00941668|Drug|sodium monofluorophosphate toothpaste|Twice daily usage
79515002|NCT00476437|Drug|biphasic insulin aspart|
79515003|NCT00476437|Drug|biphasic human insulin|
79515004|NCT00414648|Drug|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
79515005|NCT00414648|Drug|Placebo|A placebo dose of 2 tablets per day for 1 year.
79515006|NCT00337155|Drug|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
79673403|NCT00464516|Drug|placebo|once daily for 14 days orally
79673404|NCT00464516|Drug|Estetrol|once daily for 14 days orally
79515007|NCT00313742|Drug|insulin detemir|
79515008|NCT00313742|Drug|insulin glargine|
79515009|NCT00313742|Drug|insulin NPH|
79515010|NCT00267683|Drug|insulin aspart|
79515011|NCT00267683|Drug|glibenclamide|
79515012|NCT00101751|Drug|biphasic insulin aspart|
79515013|NCT00101751|Behavioral|dietary regimen|
79515014|NCT00077285|Biological|filgrastim|
79515015|NCT00077285|Drug|carboplatin|
79515016|NCT00077285|Drug|cyclophosphamide|
79515017|NCT00077285|Drug|dexrazoxane hydrochloride|
79515018|NCT00077285|Drug|doxorubicin hydrochloride|
79515019|NCT00077285|Drug|etoposide|
79515020|NCT00077285|Drug|ifosfamide|
79515021|NCT00077285|Drug|irinotecan hydrochloride|
79515022|NCT00077285|Drug|vincristine sulfate|
79515023|NCT00077285|Procedure|conventional surgery|
79515024|NCT00077285|Radiation|radiation therapy|
79515025|NCT01537302|Device|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
79515026|NCT01537926|Drug|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
79515027|NCT01537926|Drug|Placebo|sugar pill manufactured to minic NAC 600mg capsule
79515028|NCT01538862|Drug|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
79515029|NCT01540266|Procedure|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
79515030|NCT01540266|Procedure|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
79515031|NCT01541358|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
79515032|NCT01541358|Procedure|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
79515033|NCT01542372|Drug|Medication augmentation|
79515034|NCT01542372|Behavioral|CBT|
79515035|NCT01542684|Drug|Azacytidine|Starting dose: 40 mg/m^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
79515036|NCT01542684|Drug|GM-CSF|250 mcg/m^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
79515037|NCT01543074|Dietary Supplement|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
79515038|NCT01543074|Dietary Supplement|Garlic oil|1 pill = 30 mg garlic oil/day
79515039|NCT01543074|Drug|BSE|2 pills = 200 micromoles of Sulforaphane/day
79515040|NCT01543074|Dietary Supplement|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
79515041|NCT01544088|Behavioral|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
79515042|NCT01544088|Behavioral|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
79515043|NCT01544166|Drug|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants <2 years of age.
79515044|NCT01545336|Drug|Anastrozole|1 mg tablet to be taken 1 time daily
79515045|NCT01545336|Drug|Placebo|1 mg tablet to be taken 1 time daily
79515046|NCT01546194|Other|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
79515047|NCT01548690|Drug|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) & ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (~6 Cohort 1 & ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
79515048|NCT01551030|Drug|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
79515049|NCT01551186|Dietary Supplement|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
79515050|NCT01551264|Device|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
79220552|NCT03363074|Device|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
79371106|NCT03488121|Behavioral|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
79515051|NCT01551888|Drug|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
79515052|NCT01551888|Drug|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
79220553|NCT03362996|Dietary Supplement|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
79220554|NCT03362996|Combination Product|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
79220555|NCT03362996|Other|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
79371107|NCT03488121|Behavioral|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
79220556|NCT03507504|Other|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
79220557|NCT03366038|Procedure|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
79220558|NCT02311452|Device|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
79371108|NCT05056792|Other|Isometric strength training for 8 week|Plyometric training for 8 week
79515053|NCT01553058|Drug|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
79515054|NCT01553058|Drug|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
79515055|NCT01553058|Other|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
79673405|NCT01243437|Drug|ciprofloxacin|"For adults and children aged > 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
79371109|NCT05056792|Other|Conventional training|Conventional training for 8 week
79515056|NCT01553292|Device|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
79515057|NCT01553292|Device|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
79515058|NCT01556100|Drug|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
79673406|NCT01243437|Drug|doxyxcycline|"For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
79220559|NCT03507426|Procedure|Retrobulbar block|Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% & Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.
79220560|NCT03507426|Procedure|Ketamine|Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.
79220561|NCT03362918|Behavioral|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
79220562|NCT03362918|Behavioral|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
79220563|NCT02311530|Drug|Felodipine|Extended Release Tablets, 10mg
79220564|NCT02311530|Drug|Felodipine (Plendil®)|
79220565|NCT04522466|Drug|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
79220566|NCT02306772|Drug|TP05 Coating A|One radio-labelled tablet given to subjects
79220567|NCT02306772|Drug|TP05 Coating B|One radio-labelled tablet given to subjects
79220568|NCT03358394|Behavioral|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
79220569|NCT03132558|Drug|Radiopaque Media|
79220570|NCT04463472|Biological|AG0301-COVID19|1.0 mg of AG0301-COVID19 twice at 2-week intervals
79363756|NCT03594903|Behavioral|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
79363757|NCT03594903|Behavioral|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
79673407|NCT00591994|Drug|piribedil|50 mg once a day, after lunch 3 month therapy
79673408|NCT00464594|Behavioral|Standard lifestyle guidance|
79673409|NCT00464594|Drug|Lifestyle guidance and monotherapy with acarbose|
79673410|NCT00464594|Drug|Lifestyle guidance and monotherapy with metformin|
79673411|NCT00464594|Drug|Lifestyle guidance and monotherapy with gliclazide|
79673412|NCT00592033|Other|oxygen from a portable concentrator|2 l/minute during exercise
79673413|NCT02893345|Behavioral|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
79515059|NCT01556724|Drug|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
79515060|NCT01557894|Other|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
79673414|NCT02893345|Other|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
79220571|NCT04463472|Biological|AG0301-COVID19|2.0 mg of AG0301-COVID19 twice at 2-week intervals
79994587|NCT04868279|Behavioral|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
79220572|NCT04524650|Diagnostic Test|the level of vWF|the peripheral level of vWF
79363758|NCT05633589|Biological|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
79363759|NCT01828021|Biological|Margetuximab|Anti-HER2 monoclonal antibody
79515061|NCT01558128|Drug|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
79220573|NCT03507348|Drug|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
79220574|NCT03507348|Drug|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
79673415|NCT04397302|Diagnostic Test|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
79673416|NCT03272945|Procedure|Linked-color imaging|Linked-color imaging colonoscopy
79220575|NCT03507348|Drug|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
79220576|NCT03507348|Other|Transplant Day-0|TRANSPLANTATION
79994588|NCT04859231|Other|Control|Cow's milk-based formula
79515062|NCT01558128|Procedure|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
79515063|NCT01559064|Device|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
79220577|NCT03362840|Behavioral|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
79363760|NCT03594669|Other|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
79673417|NCT04396210|Other|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
79673418|NCT04395898|Procedure|pancreaticoduodenectomy|Whipple's procedure
79673419|NCT00466895|Drug|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
79673420|NCT04395664|Device|C3+ Holter Monitor|ECG monitoring
79363761|NCT03994653|Other|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
79363762|NCT03994653|Other|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
79363763|NCT05633199|Other|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
79515064|NCT01559922|Drug|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
79515065|NCT01559922|Device|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
79515066|NCT01560624|Drug|Treprostinil Diolamine|Active
79673421|NCT04395313|Other|no intervention carried out|no intervention was done
79673422|NCT00498459|Behavioral|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
79673423|NCT04132258|Other|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
79673424|NCT03272087|Device|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
79673425|NCT03272087|Device|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
79820929|NCT03950115|Device|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
79820930|NCT00727077|Biological|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
79820931|NCT00727077|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
79220578|NCT03362840|Behavioral|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
79220579|NCT03450252|Device|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
79220580|NCT03450252|Device|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
79220581|NCT03365960|Dietary Supplement|Watermelon Rind|watermelon rind
79220582|NCT03365960|Dietary Supplement|Watermelon Flesh|watermelon flesh
79220583|NCT03365960|Dietary Supplement|Watermelon Seeds|watermelon seeds
79220584|NCT03365960|Dietary Supplement|Placebo|Control Comparator
79220585|NCT02518802|Drug|Gefitinib|Gefitinib 250mg per day for 2 years.
79515067|NCT01560624|Drug|Placebo|Placebo
79515068|NCT01561716|Device|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
79515069|NCT01562886|Drug|Rilpivirine|Rilpivirine 26mg
79515070|NCT01563198|Behavioral|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
79515071|NCT01564914|Drug|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
79515072|NCT01564914|Drug|Bevacizumab|IV
79515073|NCT01565538|Drug|Erlotinib|150 mg Given orally
79673426|NCT02893306|Biological|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
79515074|NCT01565538|Drug|Pemetrexed|500mg/m2 Given IV
79673427|NCT02893540|Drug|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
79220586|NCT02518802|Drug|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
79220587|NCT02303340|Radiation|Dual Energy X-ray Absorptiometry|
79220588|NCT04524026|Drug|Letrozole 5 mg|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
79673428|NCT04393090|Other|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
79673429|NCT01327573|Drug|eculizumab|"Eculizumab Induction 600mg IV every 7 days for 4 doses~Eculizumab 900mg IV 7 days later~Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
79673430|NCT04328428|Other|acupuncture|Use one acupuncture needle insert in a acupoint.
79673431|NCT02893384|Drug|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
79673432|NCT02893228|Procedure|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
79820932|NCT04080336|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
79994589|NCT04859231|Other|Investigational|Cow's milk-based formula with added source of enriched whey protein
79994590|NCT05308823|Procedure|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
79363764|NCT03594279|Behavioral|Community Mobilization|Community Mobilization
79363765|NCT03594279|Behavioral|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
79820933|NCT04080336|Drug|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
79994591|NCT04804319|Other|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
79994592|NCT05308745|Dietary Supplement|Yakult®|Fermented milk drink containing over 6.5×10^9 CFUs of L. casei Shirota/65 ml
79994593|NCT05308745|Dietary Supplement|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
79994594|NCT04803227|Drug|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
79363766|NCT03784599|Drug|Trastuzumab emtansine|Infusion
79820934|NCT04080336|Drug|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
79994595|NCT04803227|Other|Placebo|Placebo BID *days 1-14). Oral (capsule) administration.
79994596|NCT04735913|Drug|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
79994597|NCT04910867|Behavioral|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
79994598|NCT04910867|Diagnostic Test|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
79994599|NCT04910867|Other|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
79994600|NCT04906889|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
79994601|NCT04906889|Drug|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
79994602|NCT04906889|Drug|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
79994603|NCT02945657|Drug|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
79994604|NCT05358743|Other|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
79994605|NCT05358743|Other|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
79994606|NCT05308589|Device|CPPF|Continuous Postoperative Pericardial Flush
79220589|NCT04523948|Behavioral|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
79220590|NCT02311608|Drug|Terlipressin|administered as a first-line medicine or as salvage
79220591|NCT02311608|Drug|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
79220592|NCT02311608|Drug|High Dose Somatostatin/Octreotide|administered as salvage
79220593|NCT02307006|Drug|Ceftaroline|Surgical prophylaxis
79220594|NCT02307006|Drug|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
79363767|NCT03784599|Drug|Osimertinib|Tablet
79363768|NCT01827943|Drug|Temsirolimus|Temsirolimus
79363769|NCT03594201|Other|semen pretreatment|semen pretreatment
79363770|NCT02985255|Drug|Docetaxel|Neoadjuvant Arm
79363771|NCT02985255|Drug|Cisplatin|Neoadjuvant Arm
79363772|NCT02985255|Drug|5FU|Neoadjuvant Arm
79363773|NCT02985255|Radiation|Radiotherapy|Neoadjuvant Arm
79363774|NCT02985255|Procedure|Glossectomy|Neoadjuvant Arm
79363775|NCT04609813|Diagnostic Test|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
79363776|NCT03593967|Behavioral|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~Week 1: Food and Play as our National Heritage~Week 2: Our Voices, Our Singapore: Strengthening Bonds~Week 3: Overcoming Adversities: Stories of Resilience~Week 4: Beholding the Future: Dreams and Aspirations~Week 5: Passing It On: The Stories We Share"
79820935|NCT00727155|Behavioral|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
79994607|NCT04716959|Procedure|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
79515075|NCT01565616|Drug|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
79994608|NCT04716959|Procedure|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
79363777|NCT05632887|Other|no intervention|no intervention
79363778|NCT05632731|Procedure|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
79363779|NCT03596541|Device|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
79363780|NCT00214851|Drug|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
79363781|NCT00212121|Radiation|high dose boost|high dose boost
79363782|NCT00212121|Procedure|boost|low dose versus high dose
79363783|NCT00217971|Drug|Dronabinol|Dronabinol
79515076|NCT01566084|Drug|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
79515077|NCT01566084|Other|placebo|Placebo tablets are administered to maintain the low sodium condition.
79515078|NCT01566162|Drug|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
79515079|NCT01566630|Drug|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
79994609|NCT02948777|Drug|Evolocumab|
79994610|NCT04868747|Drug|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
79994611|NCT04868747|Drug|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
79994612|NCT04693325|Procedure|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted [NMP1]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) [PNMP3] and consequently 6 hours (n=6) [PNMP6].
79994613|NCT04684823|Device|Patch Cap|A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
79220595|NCT03362762|Other|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
79220596|NCT02307084|Procedure|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
79363784|NCT00217971|Drug|Placebo|placebo
79363785|NCT03593421|Drug|synthetic PreImplantation Factor|peptide
79363786|NCT00217581|Biological|Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
79363787|NCT00217581|Drug|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
79363788|NCT00217581|Drug|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
79363789|NCT03991455|Device|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
79363790|NCT03593343|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
79363791|NCT03593265|Other|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
79363792|NCT01856257|Biological|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
79515080|NCT01566630|Drug|RLX030|RLX030 1 mg/mL vials
79515081|NCT01567020|Other|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
79515082|NCT01569126|Drug|LY110140|Administered orally as capsules
79820936|NCT00793871|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
79994614|NCT04684823|Device|Patch App|A mobile app that is used with Patch Cap to track adherence to medication regimen
79994615|NCT05357651|Drug|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
79515083|NCT01569126|Drug|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
79515084|NCT01569828|Drug|LCZ696A|
79515085|NCT01569828|Drug|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
79515086|NCT01573260|Other|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
79673433|NCT02893228|Drug|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
79673434|NCT00466973|Device|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
79994616|NCT03638609|Device|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
79673435|NCT00466973|Device|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
79673436|NCT00466973|Device|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
79673437|NCT00466973|Device|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
79673438|NCT00466973|Device|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
79515087|NCT01573260|Other|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
79673439|NCT00466973|Device|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
79673440|NCT00498537|Drug|spironolactone|
79994617|NCT05330273|Drug|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
79994618|NCT05330273|Combination Product|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
79994619|NCT05330273|Drug|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
79994620|NCT01312259|Other|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
79220597|NCT03362684|Drug|Cetuximab|Cetuximab every 2 weeks
79220598|NCT03362684|Drug|FOLFOX|FOLFOX-4 every 2 weeks
79220599|NCT02311686|Dietary Supplement|10 g ethanol|Alcohol single oral dose
79220600|NCT02311686|Dietary Supplement|20 g ethanol|Alcohol single oral dose
79220601|NCT02311686|Dietary Supplement|40 g ethanol|Alcohol single oral dose
79220602|NCT02311686|Dietary Supplement|60 g ethanol|Alcohol single oral dose
79220603|NCT02311686|Dietary Supplement|80 g ethanol|Alcohol single oral dose
79220604|NCT03362606|Biological|OC-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
79220605|NCT02311764|Drug|Carboplatin|Carboplatin will be administered weekly
79515088|NCT01573572|Drug|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
79515089|NCT01575522|Other|Laboratory Biomarker Analysis|Correlative studies
79515090|NCT01575522|Drug|Tivantinib|Given PO
79515091|NCT01575756|Biological|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
79673441|NCT04387747|Other|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
79673442|NCT04387513|Procedure|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
79673443|NCT00464750|Device|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
79820937|NCT04065945|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
79363793|NCT01856257|Biological|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
79363794|NCT01856257|Drug|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
79363795|NCT01856257|Biological|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
79673444|NCT00491478|Drug|sertraline|
79673445|NCT03272204|Behavioral|No pubic hair|Natural pubic hair to fully removed pubic hair
79673446|NCT03272204|Behavioral|Pubic Hair|Removed pubic hair to natural pubic hair
79673447|NCT00491517|Drug|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
79515092|NCT01575756|Biological|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
79673448|NCT00491517|Drug|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
79994621|NCT05329259|Biological|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
79994622|NCT03638531|Device|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
79994623|NCT03638531|Device|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
79994624|NCT03638765|Biological|DCVax-Direct|activated, autologous dendritic cells
79363796|NCT01856257|Drug|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
79363797|NCT01856257|Drug|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
79994625|NCT05254847|Drug|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
79994626|NCT05249699|Drug|Isoniazid|prevent the development of tuberculosis
79994627|NCT05249699|Other|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
79515093|NCT01575912|Other|experimental pain tests|
79515094|NCT01577238|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
79994628|NCT04751669|Dietary Supplement|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
79994629|NCT04751669|Dietary Supplement|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
79994630|NCT04640909|Other|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
79515095|NCT01577238|Drug|Placebo|Vaginal gel, daily for 7 days
79515096|NCT01577706|Drug|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
79994631|NCT04738019|Diagnostic Test|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
79994632|NCT05292053|Drug|TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation|TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
79363798|NCT00215943|Drug|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
79363799|NCT00215943|Drug|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
79673449|NCT00464789|Drug|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
79673450|NCT00491595|Drug|High Dose Soy isoflavones|
79673451|NCT00467012|Drug|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
79994633|NCT04584203|Diagnostic Test|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
79363800|NCT00215943|Drug|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
79363801|NCT00215943|Drug|vincristine|As outlined in VAD Treatment Arm
79515097|NCT01577706|Drug|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
79515098|NCT01577706|Other|Placebo|Placebo, gel-capsule, single-dose, 1-day
79515099|NCT01580592|Drug|Omalizumab|150mg, s.c., every 4 weeks
79515100|NCT01580592|Drug|Omalizumab|300mg, s.c., every 4 weeks
79515101|NCT01580592|Drug|Placebo|Placebo, s.c., every 4 weeks
79515102|NCT01580904|Behavioral|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
79673452|NCT00467012|Drug|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
79673453|NCT03272867|Dietary Supplement|ProManna|
79673454|NCT00498654|Biological|Ty800 (Salmonella typhi) Oral Vaccine|
79673455|NCT01327495|Other|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
79673456|NCT01327495|Other|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
79673457|NCT01327495|Drug|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
79673458|NCT01327495|Drug|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
79673459|NCT01327495|Drug|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
79673460|NCT01327495|Drug|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
79673461|NCT01327495|Drug|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
79994634|NCT04584203|Procedure|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
79994635|NCT04584203|Diagnostic Test|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
79994636|NCT04584203|Diagnostic Test|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
79994637|NCT04584203|Diagnostic Test|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
79515103|NCT01583868|Device|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
79515104|NCT01583868|Device|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
79515105|NCT01583868|Device|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
79515106|NCT01583868|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
79515107|NCT01588158|Drug|Acetaminophen|325 mg
79515108|NCT01588158|Drug|Vicodin|Vicodin 5/325 mg
79515109|NCT01588236|Drug|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
79515110|NCT01588236|Drug|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
79515111|NCT01588236|Drug|Placebo|3 capsules of placebo tid (morning, midday, and evening)
79673462|NCT01327495|Drug|Acyline|300 ug/kg subcutaneous injection every 2 weeks
79673463|NCT00491634|Drug|treosulfan|12 g/m2 x 3 days
79673464|NCT00491634|Drug|Treosulfan|12 g/m2 x 3
79673465|NCT04328155|Procedure|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
79820938|NCT02585154|Procedure|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
79820939|NCT02585154|Procedure|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
79820940|NCT02585154|Procedure|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
79820941|NCT02585154|Device|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
79228460|NCT04787874|Behavioral|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
79363802|NCT00215943|Drug|adriamycin|As outlined in VAD Treatment arm
79363803|NCT03593031|Behavioral|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
79363804|NCT03990207|Device|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
79363805|NCT01827163|Drug|Paclitaxel|
79363806|NCT01827163|Drug|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
79363807|NCT01827163|Drug|Lapatinib|
79363808|NCT01827163|Drug|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
79363809|NCT00215553|Drug|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
79363810|NCT00215553|Other|B.3 SoC|Standard ARDS management and ICU care
79363811|NCT00215553|Drug|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
79363812|NCT00215553|Drug|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
79363813|NCT00215553|Drug|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
79363814|NCT00215553|Drug|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
79363815|NCT00215553|Drug|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
79515112|NCT01588470|Drug|pioglitazone|45 mg per day for 6 months
79515113|NCT01589484|Device|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
79515114|NCT01590264|Device|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
79515115|NCT01591044|Drug|Placebo|1 puff bid or 2 puffs bid
79515116|NCT01591044|Drug|R940343 1mg|R343 1mg, 1 puff bid
79515117|NCT01591044|Drug|R940343 2mg|R343 2mg, 2 puffs bid
79515118|NCT01591746|Drug|Botulinum Toxin Type A|
79820942|NCT00727233|Drug|Nexavar (BAY 43-9006) (Sorafenib)|
79820943|NCT00727233|Drug|Toxicity, Pharmacokinetics|
79820944|NCT00727233|Drug|Pharmacodynamics|
79515119|NCT01591746|Drug|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
79673466|NCT04328155|Procedure|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
79220606|NCT03365726|Diagnostic Test|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
79363816|NCT03592953|Other|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
79363817|NCT00214461|Biological|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
79363818|NCT00214461|Biological|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
79363819|NCT00214461|Biological|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
79363820|NCT00214461|Biological|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
79363821|NCT03592875|Behavioral|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
79363822|NCT03599583|Behavioral|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
79363823|NCT04407351|Device|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
79363824|NCT04407351|Device|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
79363825|NCT00214383|Behavioral|CHESS Internet telehealth|CHESS Internet telehealth
79363826|NCT03599973|Other|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
79363827|NCT00212355|Drug|NPC-02|zinc acetate
79363828|NCT03599895|Procedure|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
79994638|NCT04584203|Diagnostic Test|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
79220607|NCT02307162|Drug|RPL554|Phosphodiesterase 3 and 4 Inhibitor
79220608|NCT02307162|Drug|Placebo|Dummy solution
79220609|NCT03358160|Behavioral|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
79363829|NCT03599895|Procedure|non 3D printing model|da Vinci robot assisted radical gastrectomy
79363830|NCT03592797|Other|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
79363831|NCT03592797|Other|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
79363832|NCT03592719|Behavioral|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
79363833|NCT03592719|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
79515120|NCT01597128|Device|Flex HD|Flex HD mesh for hernia repair
79515121|NCT01597128|Device|Strattice|Strattice mesh for hernia repair
79515122|NCT05566860|Procedure|Positional Therapy|After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
79515123|NCT05566860|Procedure|Intraoral Negative Pressure Therapy|If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
79673467|NCT04328155|Procedure|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
79820945|NCT00727233|Drug|Radiographic Evaluation|
79994639|NCT05288621|Device|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
79515124|NCT05566860|Procedure|Oral Appliances|If the patient is effective with oral appliances use, it was used be for three months.
79820946|NCT00727233|Drug|QOL assessment, Neuropsychological|
79515125|NCT05566860|Procedure|Surgery|If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
79515126|NCT05566860|Procedure|Tongue Muscle Strength Training|If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
79673468|NCT04328155|Procedure|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
79673469|NCT01327339|Drug|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
79820947|NCT00727233|Drug|Bony Toxicity|
79994640|NCT05306639|Other|Rehabilitation|rehabilitation sessions using spinal magnetic stimulation or neuromodulation
79220610|NCT02303418|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
79220611|NCT02303418|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
79220612|NCT03365648|Dietary Supplement|Lertal® + standard therapy|"Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine."
79220613|NCT03365648|Other|Placebo + standard therapy|"Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine"
79220614|NCT03362528|Device|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
79220615|NCT03510000|Drug|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
79363834|NCT00211887|Drug|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
79363835|NCT00211887|Drug|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
79363836|NCT00211887|Other|placebo|an inactive substance
79363837|NCT04002453|Procedure|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
79363838|NCT03599817|Behavioral|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
79363839|NCT03592485|Procedure|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
79363840|NCT03592485|Procedure|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
79994641|NCT05207111|Drug|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
79994642|NCT03256097|Device|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
79994643|NCT03256097|Device|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
79220616|NCT03510000|Device|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
79228461|NCT03469206|Procedure|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
79515127|NCT05566470|Diagnostic Test|Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors|Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
79820948|NCT04105283|Biological|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
79994644|NCT03256097|Device|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
79220617|NCT03510000|Behavioral|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
79363841|NCT03592485|Drug|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
79363842|NCT03592485|Procedure|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
79363843|NCT03592485|Drug|paracetamol|Paracetamol will be given i.v. every 6 hours.
79363844|NCT04199013|Drug|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
79363845|NCT04199013|Drug|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
79363846|NCT03592251|Dietary Supplement|Olive Oil Placebo|6 months placebo supplementation
79363847|NCT03592251|Dietary Supplement|EPA-rich|6 months placebo supplementation
79515128|NCT05566314|Dietary Supplement|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
79515129|NCT05566314|Other|Placebo|12 oz. flavored beverage
79673470|NCT01243515|Device|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
79820949|NCT02584062|Procedure|no-touch fluid-air exchange|
79515130|NCT05566236|Behavioral|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
79673471|NCT01243515|Procedure|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
79673472|NCT03272789|Other|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
79820950|NCT02584062|Procedure|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
79994645|NCT03256097|Device|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
79994646|NCT03256097|Device|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
79994647|NCT03256097|Device|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
79994648|NCT03256097|Device|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
79363848|NCT03592251|Dietary Supplement|DHA-rich|6 months placebo supplementation
79363849|NCT04747665|Other|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
79363850|NCT03592095|Device|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
79363851|NCT03592095|Device|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
79363852|NCT04198935|Device|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
79363853|NCT01855945|Biological|Swine Influenza|Comparison of different dosages of vaccines
79515131|NCT05565924|Other|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
79363854|NCT03592017|Device|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
79220618|NCT03504930|Other|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
79363855|NCT04198389|Procedure|PARTIAL KNEE REPLACEMENT|PARTIAL KNEE REPLACEMENT
79220619|NCT03362450|Other|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
79220620|NCT03365492|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
79220621|NCT03507270|Diagnostic Test|FABP|Assessment of changes in FABP concentrations
79220622|NCT03358082|Drug|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
79220623|NCT03358082|Drug|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
79363856|NCT04766541|Other|no intervention|There is no intervention.
79220624|NCT03358004|Drug|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
79220625|NCT03358004|Drug|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
79220626|NCT03507192|Device|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
79363857|NCT04198467|Biological|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
79363858|NCT04198467|Drug|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
79363859|NCT04198155|Radiation|stereotactic body radiotherapy (SBRT)|Image-guided stereotactic body radiation therapy
79363860|NCT03591705|Drug|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
79363861|NCT03591705|Drug|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
79363862|NCT03599505|Procedure|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
79820951|NCT02947971|Device|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
79363863|NCT03599427|Drug|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
79363864|NCT03599427|Drug|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
79363865|NCT01855789|Drug|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to [>/=] 100 kilograms [kg]) or every 2 weeks (if body weight was less than [<] 100 kg).
79363866|NCT01855789|Drug|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
79363867|NCT01855789|Drug|Placebo (PBO)|PBO matching to MTX will be administered orally.
79363868|NCT03591627|Diagnostic Test|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
79515132|NCT05565924|Other|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
79515133|NCT05565924|Other|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
79820952|NCT04105127|Device|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
79220627|NCT03509922|Drug|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
79220628|NCT03509922|Drug|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
79220629|NCT03365336|Drug|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
79220630|NCT03365336|Drug|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
79363869|NCT04198233|Drug|Diazepam|Diazepam 10 mg compounded suppository
79363870|NCT04198233|Drug|Placebos|Placebo suppository
79363871|NCT04197375|Behavioral|Thermal stress and performance using a pre-cooling protocol|One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
79363872|NCT04197375|Biological|Thermal stress and performance without a pre-cooling protocol|During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
79515134|NCT05565924|Other|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
79515135|NCT05565924|Other|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
79673473|NCT01327300|Drug|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
79994649|NCT03256097|Device|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
79515136|NCT05565690|Device|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
79673474|NCT01327300|Other|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
79994650|NCT05195567|Diagnostic Test|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
79363873|NCT03986853|Procedure|Blood sampling|Blood sampling under general anesthesia
79363874|NCT03591471|Drug|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
79363875|NCT03591471|Drug|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
79363876|NCT03591471|Drug|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
79363877|NCT03591471|Drug|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
79515137|NCT05565300|Other|Cycling exercise|30 minutes of cycling (90 rpm).
79515138|NCT05565300|Other|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
79673475|NCT00491673|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
79820953|NCT04105127|Device|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
79673476|NCT00491673|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
79994651|NCT05195567|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
79363878|NCT03591471|Drug|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
79673477|NCT00467129|Genetic|microarray analysis|
79673478|NCT00467129|Genetic|mutation analysis|
79673479|NCT00467129|Genetic|polymerase chain reaction|
79673480|NCT00467129|Genetic|polymorphism analysis|
79820954|NCT02583906|Device|CPAP|Treatment with CPAP for six months in the CPAP arm.
79673481|NCT00467129|Other|laboratory biomarker analysis|
79673482|NCT00467129|Other|questionnaire administration|
79994652|NCT04697381|Biological|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
79994653|NCT04697381|Biological|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
79994654|NCT04697381|Biological|somatropin - adult cohort|somatropin 0.084 mg/kg/week
79994655|NCT01312571|Behavioral|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
79994656|NCT01312571|Behavioral|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
79994657|NCT04732793|Device|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
79994658|NCT04732793|Device|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
79673483|NCT04381273|Other|No intervention|questionnaire-based assessment
79673484|NCT00464828|Procedure|Internal jugular vein cannulation|
79673485|NCT00464828|Device|ultrasound|
79673486|NCT00467168|Behavioral|Diet|
79820955|NCT04066257|Drug|Tegoprazan|Tegoprazan 50 mg tablet
79820956|NCT04066257|Drug|Metronidazole|Metronidazole 250 mg tablet
79673487|NCT04379245|Other|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~Data crossing (Excel / Access) and statistical analysis~Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
79515139|NCT05564988|Other|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
79515140|NCT05564832|Drug|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
79220631|NCT03509844|Behavioral|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
79363879|NCT03591471|Drug|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
79363880|NCT03591471|Drug|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
79363881|NCT03591471|Drug|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
79515141|NCT05564676|Dietary Supplement|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
79515142|NCT05564676|Dietary Supplement|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
79515143|NCT05564442|Drug|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
79820957|NCT04066257|Drug|Tetracycline|Tetracycline hydrochloride 250 mg capsule
79820958|NCT04066257|Drug|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
79363882|NCT04407039|Device|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
79363883|NCT04406805|Diagnostic Test|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
79363884|NCT01610791|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
79515144|NCT05564442|Device|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
79820959|NCT00915707|Other|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
79820960|NCT00915707|Other|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
79820961|NCT00915707|Other|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
79820962|NCT04080102|Other|High Intensity Interval Training|Exercise
79820963|NCT04080102|Dietary Supplement|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
79820964|NCT04080102|Other|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
79820965|NCT02604251|Device|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
79820966|NCT02604251|Device|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
79820967|NCT02583126|Behavioral|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
79820968|NCT00920712|Drug|Weiqi decotion|Decoction ,two times a day
79820969|NCT03655821|Drug|Pemetrexed|Dosing is either based on BSA or renal function
79820970|NCT04104971|Diagnostic Test|blood tests , abdominal US and doppler|
79820971|NCT02585076|Other|Standard of care|As prescribed by treated physician
79820972|NCT00733863|Biological|Placebo|
79820973|NCT00733863|Biological|CAD106|
79820974|NCT04524702|Drug|Gemcitabine|Given IV
79220632|NCT03362216|Drug|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
79220633|NCT03362216|Drug|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
79220634|NCT03365258|Dietary Supplement|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
79363885|NCT03832491|Other|Home based therapy|Airway clearence techniques
79363886|NCT03832491|Other|Game and home based therapy|Game based approach programme and airway clearence techniques
79515145|NCT05564442|Drug|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
79363887|NCT03591315|Diagnostic Test|resting state fMRI|Define the visual resting state network.
79515146|NCT05564442|Other|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
79515147|NCT05532774|Device|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
79515148|NCT05493540|Drug|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~Moderate/Severe PDA on Echocardiography~Prolonged ventilation or Increased ventilatory setting~Prolonged use of inotropes or vasopressors or escalating dose~Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
79673488|NCT04328389|Behavioral|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
79673489|NCT04328389|Procedure|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
79220635|NCT03365258|Dietary Supplement|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
79220636|NCT02303496|Biological|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
79673490|NCT00467207|Drug|Botulinum Toxin A|
79363888|NCT03591315|Diagnostic Test|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
79673491|NCT00467207|Behavioral|Resistance training|
79673492|NCT04378855|Other|Questionnaire|Quality of life assessment
79363889|NCT03591315|Diagnostic Test|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
79363890|NCT03591315|Diagnostic Test|automated visual field|Identify the existence and type of visual field defect.
79363891|NCT03591315|Diagnostic Test|visual acuity|Assess the visual acuity by using ETDRS scales.
79363892|NCT03591081|Other|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
79673493|NCT00592111|Drug|COPP/ABV|4 courses of COPP/ABV hybrid
79673494|NCT00592111|Drug|COPP/ABV|6 courses of COPP/ABV hybrid
79673495|NCT00592111|Drug|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
79673496|NCT00592150|Drug|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
79220637|NCT02303496|Biological|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
79220638|NCT03362138|Device|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
79220639|NCT03507114|Behavioral|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings & vignettes of participants experiences of the therapy.
79220640|NCT03123536|Device|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
79220641|NCT03504696|Other|Non-interventional|Non-interventional
79228462|NCT03469206|Drug|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
79363893|NCT01876381|Drug|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
79363894|NCT03591003|Diagnostic Test|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
79371110|NCT03487887|Device|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
79673497|NCT00592150|Drug|Placebo|Placebo infusion for 3 hours
79673498|NCT00464867|Biological|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
79673499|NCT00592189|Procedure|blood draw|blood collection
79673500|NCT00592228|Device|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~FFR group: if FFR<0.75~Routine DES group"
79673501|NCT00592306|Drug|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
79820975|NCT04524702|Drug|Hydroxychloroquine|Given PO
79515149|NCT05493540|Drug|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~Prolonged Ventilation or Escalating Ventilatory Setting~Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~After 5 days of recruitment~Moderate/Severe PDA on Echocardiography~Prolonged ventilation or Increased ventilatory setting~Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
79820976|NCT04524702|Drug|Nab-paclitaxel|Given IV
79820977|NCT04524702|Drug|Paricalcitol|Given IV
79820978|NCT00727389|Behavioral|Physiotherapy|Exercise two days a week for six month
79515153|NCT05214924|Biological|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
79673502|NCT00592306|Drug|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
79673503|NCT00467246|Drug|Levemir|
79220642|NCT03357770|Drug|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature [5]. The low-dose is 1 × 10^7cells / 3mL, the medium-dose is 5 × 10^7cells / 3mL and the high dose is 1 × 10^8cells / 3mL
79220643|NCT02307240|Drug|CUDC-907|CUDC-907 oral with meals.
79220644|NCT03365180|Device|Starter Kit Algorithm|Long acting insulin titration to target
79220645|NCT02307396|Drug|Olanzapine|
79363895|NCT03984513|Behavioral|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
79515154|NCT05214924|Biological|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
79515155|NCT05672940|Behavioral|Aerobic plus resistance training|Aerobic plus resistance training
79515156|NCT05672940|Behavioral|Stretching plus breathing training|Stretching plus breathing training
79515157|NCT05672706|Procedure|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
79515158|NCT05672472|Drug|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
79673504|NCT00592345|Radiation|Proton Beam Radiation|Administered over a period of 12 weeks.
79673505|NCT00592345|Radiation|Photon Beam Radiation|Administered over a period of 12 weeks.
79220646|NCT02307396|Drug|Amisulpride|
79673506|NCT00592345|Radiation|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
79220647|NCT02307396|Drug|Risperidone|
79220648|NCT02307396|Drug|Haloperidol|
79371111|NCT01597414|Drug|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
79673507|NCT00498732|Device|CPAP|CPAP treatment for 4 weeks
79673508|NCT04377295|Drug|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
79673509|NCT00491712|Procedure|Glaucoma drainage implant with/without triamcinolone|
79673510|NCT00467324|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
79673511|NCT02893111|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
79820979|NCT00727467|Device|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
79820980|NCT00733941|Behavioral|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
79220649|NCT02307396|Drug|Quetiapine|
79220650|NCT02307396|Drug|Perphenazine|
79220651|NCT02307396|Drug|Sulpiride|
79220652|NCT02307396|Drug|bromperidol|
79220653|NCT02307396|Drug|Zuclopenthixol|
79220654|NCT02307396|Drug|Thioridazine|
79220655|NCT02307396|Drug|Paliperidone|
79220656|NCT02307396|Drug|Ziprasidone|
79220657|NCT02307396|Drug|Benperidol|
79220658|NCT02307396|Drug|Fluspirilene|
79220659|NCT02307396|Drug|Pimozide|
79220660|NCT02307396|Drug|Perazine|
79220661|NCT02307396|Drug|Fluphenazine|
79220662|NCT02307396|Drug|Flupentixole|
79220663|NCT02307396|Drug|Sertindole|
79220664|NCT03357692|Procedure|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
79220665|NCT04523636|Device|Splinting|Pre-fabricated or custom resting hand splints
79673512|NCT00498771|Behavioral|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
79994659|NCT04908761|Procedure|Transmuscular quadratus lumborum block|Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
79220666|NCT03509688|Drug|entecavir+resveratrol|entecavir+resveratrol
79220667|NCT03509688|Drug|Entecavir|Entecavir
79363896|NCT03984513|Behavioral|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
79363897|NCT01855399|Behavioral|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
79363898|NCT01855399|Behavioral|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
79363899|NCT01875991|Drug|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
79363900|NCT01875991|Drug|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
79363901|NCT04203927|Drug|Empagliflozin 25 MG|SGLT-2 inhibitor
79363902|NCT04196985|Diagnostic Test|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
79371112|NCT01597414|Drug|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
79515159|NCT05672394|Procedure|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
79673513|NCT00464984|Behavioral|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
79673514|NCT04328272|Drug|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
79673515|NCT04328272|Drug|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
79673516|NCT04328272|Dietary Supplement|Glucose tablets|administered orally with water
79673517|NCT04328194|Diagnostic Test|Serum Autotaxin|Marker
79673518|NCT04328194|Radiation|chest x-ray|chest x- ray will be done for the study group
79673519|NCT04328194|Diagnostic Test|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
79673520|NCT04328194|Diagnostic Test|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
79220668|NCT03509688|Drug|entecavir+thymosin α1|entecavir+thymosin α1
79220669|NCT03365024|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
79994660|NCT04908761|Procedure|Placebo|For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
79994661|NCT03324581|Drug|OPC-64005|OPC-64005 film coated tablets
79994662|NCT03324581|Drug|Atomoxetine|Atomoxetine gelatin capsules
79994663|NCT03324581|Drug|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
79220670|NCT03365024|Behavioral|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
79220671|NCT03132402|Diagnostic Test|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
79220672|NCT03361904|Procedure|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
79220673|NCT02307474|Radiation|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
79228463|NCT02467400|Drug|Atenolol|beta blocker
79673521|NCT04328194|Radiation|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
79820981|NCT00733941|Behavioral|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
79820982|NCT04080258|Other|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
79220674|NCT02307474|Drug|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
79220675|NCT02518880|Other|Parabolic flight|
79220676|NCT02518880|Other|plasma volume measurements|
79220677|NCT03504618|Drug|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
79220678|NCT02518412|Other|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
79220679|NCT02518412|Other|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
79220680|NCT02303652|Procedure|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
79220681|NCT02303652|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
79220682|NCT03357458|Behavioral|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
79220683|NCT02303730|Drug|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose<2.9 mmol/l or < 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
79673522|NCT04328194|Diagnostic Test|Peripheral haemogram|blood sample will be taken from the patients
79228464|NCT02467400|Drug|Nebivolol|beta blocker
79363903|NCT04196985|Diagnostic Test|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
79363904|NCT04201431|Biological|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
79363905|NCT01855243|Drug|regular insulin|
79363906|NCT01855243|Drug|70/30 insulin|
79363907|NCT01855243|Drug|Glargine|
79363908|NCT01855243|Drug|glulisine|
79363909|NCT03590847|Behavioral|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
79371113|NCT04984330|Drug|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
79515160|NCT05672394|Procedure|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
79515161|NCT05672394|Drug|Bupivacaine|bupivacaine
79515162|NCT05672394|Drug|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
79515163|NCT05672160|Diagnostic Test|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
79673523|NCT04328194|Diagnostic Test|Renal and liver functions|to exclude any other morbidity
79673524|NCT04328194|Diagnostic Test|Prothrombin time and concentration|blood sample will be taken from the patients
79673525|NCT04328194|Diagnostic Test|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
79673526|NCT04328194|Other|Full medical history|full medical history will be taken from all patients
79673527|NCT04328194|Other|Full clinical examination|full clinical examination will be done for the patients
79673528|NCT03272750|Dietary Supplement|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
79515164|NCT05672004|Other|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
79673529|NCT03272750|Dietary Supplement|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
79673530|NCT03272750|Dietary Supplement|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
79673531|NCT00498810|Procedure|complete repair|
79673532|NCT00498810|Procedure|partial repair of the abdominal wall|
79673533|NCT04374682|Other|exercises|stretching exercises - physiotherapy modalities - self care instructions
79673534|NCT04374370|Biological|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
79673535|NCT00465023|Procedure|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
79673536|NCT00491790|Drug|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
79673537|NCT00491790|Other|Sterile water|Sterile water
79820983|NCT04080258|Other|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
79994664|NCT02943473|Drug|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
79994665|NCT03629873|Drug|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m^2 IVD d-6; Etoposide 150mg/m^2/d qd IVD d-5~-2; Cytarabine 150mg/m^2 q12h IVD d-5~-2; Cyclophosphamide 1.0g/m^2/d qd IVD d-5~-2
79994666|NCT04294043|Drug|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
79994667|NCT05019833|Device|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
79220684|NCT02303730|Drug|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c <8% use 0.1 -0.2 U/kg per day;HbA1c >8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) > 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose <70mg/dl（3.9mmol/l）: 10%-20%; blood glucose <40mg/dl（2.2mmol/l）: 20%-40%."
79220685|NCT04524728|Drug|Palbociclib|tablets
79220686|NCT04524728|Drug|Letrozole 2.5mg|tablets
79220687|NCT04524728|Drug|Fulvestrant|intramuscolar injections
79220688|NCT04523792|Drug|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
79220689|NCT02303808|Device|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
79363910|NCT04196829|Drug|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
79363911|NCT04196829|Drug|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
79363912|NCT03023787|Drug|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
79363913|NCT03023787|Drug|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
79371114|NCT04984330|Drug|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
79673538|NCT02892994|Other|ultrasound|
79673539|NCT04371328|Other|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
79220690|NCT03364946|Other|No intervention|No intervention, observational study
79220691|NCT02312232|Drug|levodopa, carbidopa, ODM-104|
79363914|NCT03832725|Other|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
79515165|NCT05672004|Other|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
79363915|NCT03832725|Other|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
79515166|NCT05597904|Genetic|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
79515167|NCT05572242|Procedure|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
79673540|NCT04371211|Behavioral|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
79220692|NCT04524884|Drug|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
79220693|NCT04524884|Drug|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
79673541|NCT00498849|Device|CPAP|
79220694|NCT03509610|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
79363916|NCT01825837|Drug|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
79220695|NCT02307708|Device|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
79220696|NCT02307708|Other|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
79220697|NCT04521530|Other|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
79363917|NCT01825837|Drug|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
79220698|NCT04521530|Other|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
79220699|NCT03506958|Procedure|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
79363918|NCT01825837|Drug|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
79220700|NCT04521452|Drug|Evogliptin|Subjects will receive evogliptin 5 mg daily
79220701|NCT03504540|Procedure|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
79363919|NCT01825837|Drug|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
79363920|NCT03599115|Behavioral|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
79363921|NCT04196673|Device|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
79363922|NCT04196673|Device|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
79363923|NCT03590379|Drug|CHF 5993 DPI|BDP/FF/GB DPI
79363924|NCT03590379|Drug|CHF5993 pMDI|BDP/FF/GB pMDI
79220702|NCT03361670|Other|Observational Study|
79220703|NCT03509532|Device|PCI|PCI
79363925|NCT03590379|Drug|CHF 1535 pMDI|BDP/FF pMDI
79228465|NCT02467400|Drug|Propranolol|beta blocker
79228466|NCT02467400|Drug|placebo|placebo
79228467|NCT02467322|Drug|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
79228468|NCT02467322|Drug|ascitic fluid|
79363926|NCT03590379|Drug|Placebo DPI|CHF 5993 DPI matched placebo
79220704|NCT03364790|Procedure|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
79673542|NCT04369261|Drug|Synovian®|Synovian® Inj.
79673543|NCT03272009|Drug|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
79673544|NCT03272009|Drug|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
79673545|NCT03272009|Drug|Entecavir|Tablets administered orally
79220705|NCT03364790|Procedure|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
79220706|NCT03504462|Procedure|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
79673546|NCT03272009|Drug|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
79220707|NCT02303886|Drug|Methylene blue|In NaCL0.9% 100 ml
79220708|NCT02303886|Drug|Methylene blue|in NaCl 0.9% 100 ml
79363927|NCT03590379|Drug|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
79363928|NCT03590301|Behavioral|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
79673547|NCT04327882|Diagnostic Test|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
79220709|NCT02518958|Drug|RRx-001|
79515168|NCT05572242|Procedure|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
79673548|NCT00498888|Procedure|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
79673549|NCT00498888|Procedure|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
79220710|NCT02518958|Drug|Nivolumab|
79220711|NCT03506802|Radiation|18F-FHBG|Given IV
79515169|NCT05464992|Other|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
79673550|NCT00498888|Procedure|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
79673551|NCT00498888|Procedure|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
79673552|NCT02893072|Behavioral|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
79673553|NCT04369105|Other|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
79673554|NCT04368754|Other|Questionnaire|Patients evaluated with different questionnaire.
79673555|NCT00491868|Drug|R744|100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
79673556|NCT00491868|Drug|R744|150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
79220712|NCT03506802|Biological|Aldesleukin|Given SC
79220713|NCT03506802|Biological|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
79220714|NCT03506802|Procedure|Computed Tomography|Undergo PET/CT
79220715|NCT03506802|Biological|Filgrastim|Given SC
79220716|NCT03506802|Other|Laboratory Biomarker Analysis|Correlative studies
79220717|NCT03506802|Drug|Lenalidomide|Given PO
79220718|NCT03506802|Procedure|Leukapheresis|Undergo leukapheresis
79220719|NCT03506802|Drug|Melphalan|Given IV
79220720|NCT03506802|Drug|Plerixafor|Given SC
79220721|NCT03506802|Procedure|Positron Emission Tomography|Undergo PET/CT
79220722|NCT02518724|Procedure|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
79220723|NCT02518724|Procedure|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
79220724|NCT03364712|Other|routine medical care, venipuncture|
79220725|NCT03364634|Diagnostic Test|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
79673557|NCT00491868|Drug|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
79673558|NCT00491868|Drug|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
79673559|NCT00491868|Drug|R744 placebo|0 μg/4week for 24 weeks
79673560|NCT00491868|Drug|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
79515170|NCT05392296|Other|Power ball|experimental group getting the power ball training with conventional treatment.
79515171|NCT05392296|Other|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
79515172|NCT05194956|Procedure|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
79515173|NCT05194956|Procedure|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
79515174|NCT04997616|Dietary Supplement|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
79515175|NCT04594200|Behavioral|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
79515176|NCT04493658|Diagnostic Test|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
79515177|NCT04493658|Diagnostic Test|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
79220726|NCT03361592|Procedure|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
79220727|NCT03361592|Procedure|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
79363929|NCT03590301|Behavioral|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
79363930|NCT03599037|Other|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
79363931|NCT03598881|Other|Treatment|
79363932|NCT04196517|Other|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
79515178|NCT04493658|Diagnostic Test|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
79515179|NCT04421352|Drug|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
79515180|NCT03861468|Other|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
79515181|NCT03729258|Drug|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
79515182|NCT03729258|Drug|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
79515183|NCT03593772|Behavioral|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
79220728|NCT03504384|Other|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
79228469|NCT03472638|Device|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
79363933|NCT04196517|Other|WebMD|WebMD is a widely used educational platform for health information.
79363934|NCT03590223|Procedure|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
79363935|NCT04196361|Diagnostic Test|Ultrasound|Point of care ultrasound as part of routine physical examination
79515184|NCT03355170|Combination Product|Lansoprazole/Domperidone|Experimental
79515185|NCT03355170|Drug|Lansoprazole|Active comparator
79515186|NCT02819778|Procedure|usual care|
79515187|NCT02819778|Procedure|S100B|
79515188|NCT02538666|Biological|Nivolumab|
79515189|NCT02538666|Biological|Ipilimumab|
79515190|NCT02538666|Other|Placebo|
79515191|NCT02438358|Drug|LUM015|
79515192|NCT02438358|Device|LUM 2.6 Imaging Device|
79515193|NCT02407236|Drug|Placebo IV|Placebo will be administered as intravenous infusion.
79363936|NCT03590067|Other|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
79515194|NCT02407236|Drug|Placebo SC|Placebo will be administered Subcutaneously.
79515195|NCT02407236|Drug|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
79515196|NCT02407236|Drug|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
79515197|NCT01893138|Other|Placebo|Placebo control is the vehicle solution used for the study product.
79515198|NCT01893138|Biological|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10^6 cells.
79515199|NCT00221598|Procedure|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
79994668|NCT05019677|Drug|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
79994669|NCT02899793|Drug|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
79363937|NCT01854697|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79515200|NCT05120076|Drug|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
79363938|NCT01854697|Drug|Ribavirin|Tablet
79363939|NCT01854697|Drug|Telaprevir|Film-coated tablet
79363940|NCT01854697|Drug|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
79363941|NCT03591159|Other|Membran Sweeping|Cervical Membrane Sweeping by digital examination
79363942|NCT03590535|Diagnostic Test|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
79363943|NCT03590535|Diagnostic Test|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
79363944|NCT01824979|Device|CPAP mask ( Pilairo)|
79363945|NCT01824979|Procedure|Other CPAP mask|
79515201|NCT05120076|Drug|NaCl 0.9%|s. arm/group description
79515202|NCT05079204|Other|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
79515203|NCT05079204|Other|No intervention|No intervention
79515204|NCT05030844|Behavioral|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
79515205|NCT04946916|Diagnostic Test|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
79515206|NCT04868760|Drug|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
79515207|NCT04868760|Drug|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
79515208|NCT04865952|Procedure|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
79515209|NCT04865952|Other|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
79515210|NCT04803708|Biological|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10^9 plaque forming units per milliliter (PFU/mL).
79515211|NCT04651452|Behavioral|Value Affirmation|Participants will complete writing tasks regarding their personal values.
79679845|NCT02938104|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
79679846|NCT02938104|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
79994670|NCT04981145|Drug|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
79994671|NCT04981145|Drug|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
79994672|NCT04258631|Drug|Hydromorphone|Given IT
79994673|NCT04258631|Procedure|Laparotomy|Undergo laparotomy
79363946|NCT03598803|Other|Survey|Urinary Incontinence Survey
79363947|NCT04195971|Diagnostic Test|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
79363948|NCT01824823|Drug|afatinib|Given PO
79363949|NCT01824823|Other|placebo|Given PO
79363950|NCT04196205|Biological|Anti-CD19 CAR-T|1 - 2×10^6 Anti-CD19 CAR-T cells/kg body weigh
79363951|NCT03598725|Drug|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
79363952|NCT03598725|Drug|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
79363953|NCT03598725|Drug|Rituximab|375mg/Square meter for consecutive 4 months
79994674|NCT04258631|Drug|Liposomal Bupivacaine|Drug
79994675|NCT04258631|Other|Questionnaire Administration|Ancillary studies
79515212|NCT04651452|Behavioral|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
79220729|NCT03361514|Behavioral|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
79363954|NCT04196127|Other|Bite force testing|Maximum bite force examination with a force intra-oral measuring device
79363955|NCT03598569|Other|dyspnea|dyspnea assessment
79363956|NCT04766307|Drug|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
79363957|NCT03024801|Drug|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
79363958|NCT03024801|Drug|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
79363959|NCT03591237|Behavioral|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
79363960|NCT04195191|Other|ANM|communication intervention
79363961|NCT04195191|Other|Placebo|regular assistance in community pharmacies
79515213|NCT04508166|Drug|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
79515214|NCT04508166|Drug|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
79515215|NCT04508166|Drug|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
79515216|NCT04508166|Behavioral|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
79515217|NCT04420026|Radiation|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
79515218|NCT04309500|Behavioral|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
79515219|NCT04279236|Other|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
79515220|NCT04279236|Other|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
79515221|NCT04279236|Other|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
79363962|NCT01875367|Drug|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
79363963|NCT01875367|Drug|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
79363964|NCT01875367|Drug|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
79515222|NCT04265196|Other|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
79515223|NCT04265196|Other|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
79515224|NCT04175964|Behavioral|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
79515225|NCT04175964|Combination Product|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
79515226|NCT04175964|Behavioral|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
79679847|NCT02938104|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
79363965|NCT04194879|Diagnostic Test|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
79363966|NCT04197999|Drug|GMI-1359|Injection 10 mg/mL
79363967|NCT04195659|Procedure|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
79363968|NCT03598335|Device|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
79363969|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
79363970|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G>A or c.2846A>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
79363971|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
79363972|NCT04194645|Drug|BI 474121|Single dose
79363973|NCT04194645|Drug|Placebo|Single dose
79363974|NCT03023943|Other|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
79363975|NCT03024021|Device|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia [36.5 C]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
79515227|NCT03678402|Device|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
79673561|NCT04367896|Other|Survey Group|"The survey sought to elucidate equity principles that are influencing transplant decision making. The group of respondents included solid organ transplant doctors (surgeons, referring doctors, transplant physicians, transplant coordinators, ICU transplant doctors), COVID-doctors (ICU doctors, Infectious Disease Doctors, Pulmonologists, Internists), and Ethicists with experience of transplant related issues.~Respondent identification:~A. The e-mail addresses of corresponding authors from Scopus January 1, 2017 and march 20, 2020:~All (surgery) AND subj (medi) and key (transplantation), All (critical care) AND subj (medi) and key (transplantation), All (ethics) AND subj (medi) and key (transplantation). B. Emailing through the mailing list of scientific societies. C. The link to the survey published online. D. The link to the survey circulated through personal contacts and via social media sites."
79673562|NCT02893033|Device|repetitive transcranial magnetic stimulation|rTMS
79673563|NCT00491907|Drug|folic acid 5mg/day|
79673564|NCT03271931|Behavioral|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
79673565|NCT03271931|Behavioral|Passive choice|EHR passive alert to cardiologists about prescribing a statin
79994676|NCT04877015|Device|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
79220730|NCT03361514|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
79220731|NCT02307864|Drug|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
79363976|NCT03598101|Device|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
79363977|NCT04194567|Other|Black Ragi|Pancakes made out of the dark ragi
79363978|NCT04194567|Other|White Ragi|Pancakes made out of the white ragi
79363979|NCT04177797|Drug|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
79363980|NCT04194255|Dietary Supplement|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
79220732|NCT02307864|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
79220733|NCT02307864|Drug|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
79220734|NCT02307864|Drug|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
79220735|NCT03504306|Other|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
79220736|NCT03364556|Other|No intervention|
79515228|NCT03626532|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
79515229|NCT03626532|Behavioral|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
79515230|NCT03624270|Drug|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
79515231|NCT03588468|Other|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
79515232|NCT03588468|Other|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
79515233|NCT03455088|Behavioral|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
79515234|NCT03455088|Drug|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
79515235|NCT02481336|Other|Questionnaires|EORTC CIPN20 and EQ-5D-3L
79515236|NCT02481336|Procedure|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
79220737|NCT03509376|Procedure|Suture repair|The diastasis is repaired with continous nylon suture
79220738|NCT03509376|Procedure|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
79220739|NCT04444778|Device|CPAP|Continuous positive airway pressure
79515237|NCT02481336|Genetic|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
79673566|NCT00467441|Drug|VSF-173|
79673567|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
79673568|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
79673569|NCT00465140|Drug|creatine supplementation|
79673570|NCT00465140|Behavioral|aerobic exercise training|
79673571|NCT04327765|Combination Product|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
79673572|NCT04327765|Combination Product|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
79220740|NCT03504150|Behavioral|SPHERE|Comprehensive Internet-based CBT program with no human support
79220741|NCT03504150|Behavioral|PRISM|Brief Internet-based CBT program with no human support
79220742|NCT03364478|Procedure|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
79220743|NCT03364478|Procedure|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
79220744|NCT02303964|Biological|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
79220745|NCT02303964|Drug|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
79363981|NCT04194255|Dietary Supplement|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
79363982|NCT04194255|Dietary Supplement|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
79363983|NCT04194255|Dietary Supplement|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
79363984|NCT03598023|Device|Cytal® Burn Matrix|Cytal® Burn Matrix
79363985|NCT03598023|Device|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
79673573|NCT04327765|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
79673574|NCT04362163|Device|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
79673575|NCT00491946|Drug|Actinomycin-D|
79673576|NCT00491946|Drug|Vincristine|
79673577|NCT03272048|Behavioral|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, & Rudd, 2011; Jin, Khazem, & Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, & Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
79673578|NCT04361344|Biological|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
79994677|NCT04877015|Device|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
79994678|NCT03638063|Diagnostic Test|Adenosine Triphosphate|Adenosine Triphosphate aerosol
79363986|NCT04406883|Drug|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
79994679|NCT03638063|Diagnostic Test|capsaicin|capsaicin aerosol
79220746|NCT04520984|Other|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
79673579|NCT04358848|Device|X-PLO2R|Portable Oxygen Concentrator (POC)
79673580|NCT01245231|Genetic|protein expression analysis|
79820984|NCT04018443|Diagnostic Test|common carotid artery diameter measurement|measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: [(dia-mpost/dia-mpre) × 100] - 100 [11].
79820985|NCT02583984|Procedure|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
79820986|NCT02583984|Procedure|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
79820987|NCT02569203|Dietary Supplement|standard enteral nutrition|standard enteral nutrition
79820988|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
79820989|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
79820990|NCT00920478|Other|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
79994680|NCT04869371|Drug|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
79994681|NCT04869371|Drug|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
79994682|NCT04869371|Drug|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
79994683|NCT03320369|Other|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
79994684|NCT02650895|Biological|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
79220747|NCT04520984|Other|Standard nephrology care|Standard nephrology care
79220748|NCT02304042|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
79363987|NCT04199949|Behavioral|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
79515238|NCT01597440|Drug|N-carbamylglutamate|"Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
79515239|NCT01597440|Other|Standard of Care|Standard of Care
79515240|NCT01598064|Dietary Supplement|GK#10|GK#10, 1 pack tid
79673581|NCT01245231|Genetic|western blotting|
79673582|NCT01245231|Other|flow cytometry|
79673583|NCT01245231|Other|laboratory biomarker analysis|
79673584|NCT01245231|Other|medical chart review|
79820991|NCT00920478|Other|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
79994685|NCT02650895|Drug|Saline|0.9% sodium chloride
79994686|NCT04742231|Device|Hand-held dynamometer|Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
79820992|NCT00730197|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
79820993|NCT00730197|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
79820994|NCT00727545|Other|iron bisglycine chelate|
79820995|NCT00727545|Other|placebo|
79820996|NCT00730431|Drug|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
79994687|NCT03320057|Drug|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
79515241|NCT01598064|Drug|Placebo|Placebo 1 pack tid po
79673585|NCT03272672|Other|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
79673586|NCT00592423|Other|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
79673587|NCT00592462|Procedure|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
79820997|NCT00730431|Drug|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
79820998|NCT02583204|Device|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
79820999|NCT02583204|Other|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
79821000|NCT00727701|Behavioral|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
79821001|NCT02582892|Drug|Vit D|20 mg/day
79821002|NCT00734175|Biological|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
79994688|NCT03320057|Other|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
79994689|NCT04741139|Drug|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
79994690|NCT03316547|Other|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises [passive range of motion (PROM), gentle stretching]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
79363988|NCT04194177|Other|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
79363989|NCT04199559|Drug|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
79363990|NCT03597867|Other|Placebo|Artificial tears for 3 days preoperatively
79363991|NCT03597867|Drug|Dicloftil|Dosing of drug 3 days prior to surgery
79363992|NCT03597867|Drug|Nevanac|Dosing of drug 3 days prior to surgery
79515242|NCT01600170|Drug|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
79220749|NCT02304042|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
79228470|NCT03914469|Behavioral|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
79515243|NCT01600170|Drug|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
79673588|NCT00592540|Procedure|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
79673589|NCT00491985|Biological|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
79673590|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
79673591|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
79363993|NCT03597867|Drug|Indom|Dosing of drug 3 days prior to surgery
79673592|NCT04355884|Diagnostic Test|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
79363994|NCT03597867|Drug|Yellox|Dosing of drug 3 days prior to surgery
79363995|NCT03597477|Drug|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
79363996|NCT04199715|Biological|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
79363997|NCT04193319|Drug|Fluzoparib|PARP inhibitor
79515244|NCT01600482|Device|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
79515245|NCT01600638|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79363998|NCT04193319|Drug|Fluconazole|inhibitor
79673593|NCT03272594|Other|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
79994691|NCT02740205|Other|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
79673594|NCT03272594|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
79821003|NCT04079946|Procedure|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
79994692|NCT02738255|Device|Varnum mouthpiece|An adhesive mouthpiece with a central opening applied during sleep
79994693|NCT04824989|Behavioral|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
79994694|NCT04824989|Behavioral|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
79821004|NCT04079946|Procedure|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
79994695|NCT04824989|Behavioral|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
79673595|NCT02892916|Drug|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
79673596|NCT02892916|Drug|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
79363999|NCT04192851|Procedure|Tent Pole Technique|"All patients were operated under local or general anaesthesia according to the case and patient tolerability.~The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution* for thirty seconds.~Full thickness incision down to the bone with blade no.15.~A periosteal elevator was used to perform mucoperiosteal flap.~Gentle elevation of the flap~Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~Bone graft was mixed with the patient blood and placed to cover the screws completely.~PRF membrane was be placed over the grafted sites.~Repositioning of the flap and suturing with 3/0 black silk suture material"
79364000|NCT03957135|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
79364001|NCT03957135|Procedure|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
79364002|NCT04190901|Behavioral|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
79364003|NCT04190901|Behavioral|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
79515246|NCT01600950|Drug|LY2963016|Single 0.3 U/kg dose administered subcutaneously
79515247|NCT01600950|Drug|Lantus|Single 0.3 U/kg dose administered subcutaneously
79515248|NCT01603056|Biological|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
79515249|NCT01603056|Biological|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
79515250|NCT01604772|Drug|Akt Inhibitor MK2206|Given PO
79515251|NCT01604772|Other|Laboratory Biomarker Analysis|Correlative studies
79821005|NCT00730509|Dietary Supplement|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
79821006|NCT04512456|Behavioral|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
79821007|NCT02584764|Behavioral|Cognitive behavior therapy|
79220750|NCT04521218|Other|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
79220751|NCT04521218|Other|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
79220752|NCT02307942|Procedure|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
79821008|NCT02584764|Behavioral|Internet support|
79821009|NCT04764513|Biological|Ex-vivo expanded γδ T cell infusion|"Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10^6、 1×10^7 and 5×10^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1."
79821010|NCT02584530|Procedure|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
79821011|NCT00727779|Behavioral|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
79821012|NCT02582736|Drug|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
79364004|NCT04190901|Behavioral|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
79364005|NCT04190901|Behavioral|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
79515252|NCT01605942|Drug|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
79364006|NCT03597321|Biological|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
79515253|NCT01605942|Drug|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
79515254|NCT01607112|Biological|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
79515255|NCT01607658|Drug|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
79515256|NCT01607658|Drug|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
79515257|NCT01607658|Drug|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
79515258|NCT01607658|Drug|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
79515259|NCT01608672|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
79515260|NCT01610154|Drug|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
79515261|NCT01611948|Drug|Aprepitant|125mg/day for 8 weeks
79515262|NCT01611948|Drug|Placebo|125mg/d placebo pill for 8 weeks
79515263|NCT01611948|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
79515264|NCT01612494|Drug|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
79515265|NCT01612494|Other|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
79673597|NCT01245309|Procedure|scratching|endometrial scratching before COH in IVF
79673598|NCT01245309|Procedure|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
79673599|NCT04354792|Diagnostic Test|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
79364007|NCT03597243|Other|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
79515266|NCT01612884|Drug|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
79515267|NCT01612884|Drug|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
79673600|NCT04354285|Other|Observational|Observational
79673601|NCT02956304|Other|PMv stimulation (iTBS)|PMv stimulation (iTBS)
79673602|NCT02956304|Other|PMv inhibition (cTBS)|PMv inhibition (cTBS)
79673603|NCT02956304|Other|Control (SHAM)|Control (SHAM)
79673604|NCT04354753|Other|No Intervention|No intervention
79673605|NCT00492102|Drug|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing >1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
79673606|NCT00465218|Procedure|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
79515268|NCT01614210|Drug|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
79364008|NCT04193007|Drug|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
79673607|NCT00499044|Other|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
79673608|NCT00499044|Other|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
79673609|NCT02892838|Device|mobile bearing knee system for total knee arthroplasty|
79364009|NCT04193007|Radiation|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
79364010|NCT04190355|Other|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
79364011|NCT04190355|Drug|5.25% NaOCl|5.25% NaOCl solution
79364012|NCT04190355|Drug|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
79364013|NCT04193163|Device|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
79364014|NCT03023475|Device|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
79673610|NCT02892838|Device|fixed bearing total knee prosthesis|
79673611|NCT00467636|Procedure|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
79515269|NCT01614210|Procedure|Breast cancer surgery|Breast cancer surgery
79364015|NCT03023475|Device|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
79364016|NCT03596931|Drug|Statins (Cardiovascular Agents)|Prescribed with statins
79515270|NCT01616082|Behavioral|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
79673612|NCT00467636|Drug|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI < 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
79673613|NCT00492141|Drug|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
79220753|NCT03364322|Other|Observation|Observation
79220754|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
79220755|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
79220756|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
79220757|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
79220758|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
79220759|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
79220760|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
79515271|NCT01616082|Drug|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
79515272|NCT01616160|Drug|mometasone furoate|2 sprays/nostril BID
79220761|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
79220762|NCT02308176|Behavioral|APP + health advice|health advice and reinforcement to it
79220763|NCT02308176|Behavioral|health advice|health advice
79364017|NCT03596853|Other|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
79364018|NCT03596853|Other|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
79220764|NCT03364166|Procedure|surgical excision|"Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~A neck dissection will be done in all cases of negative or positive neck lymph node.~Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
79220765|NCT03504072|Drug|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
79364019|NCT04192617|Drug|SM03|SM03: 600 mg intravenous (IV)
79364020|NCT04192617|Drug|Placebo|Placebo: 600 mg intravenous (IV)
79364021|NCT04192617|Drug|Methotrexate|methotrexate: 7.5-20 mg/week oral
79364022|NCT04192539|Diagnostic Test|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
79679848|NCT02948504|Procedure|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
79679849|NCT02938260|Drug|Metoprolol vs Diltiazem|
79220766|NCT03504072|Drug|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
79220767|NCT03361280|Drug|Beta blocker|Beta blockers are administered as described in arms.
79364023|NCT04192383|Radiation|Cyberknife stereotactic radiosurgery|Hypofractionated stereotactic radiosurgery
79364024|NCT01874665|Drug|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
79364025|NCT04192305|Procedure|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
79364026|NCT04192305|Procedure|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
79364027|NCT04192149|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
79364028|NCT03596619|Device|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
79364029|NCT04191525|Dietary Supplement|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
79364030|NCT04191525|Dietary Supplement|Placebo|Placebo masked with the same presentation as the experimental product 1 capsule/day
79364031|NCT04029987|Procedure|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
79220768|NCT02308254|Drug|Lixisenatide|Abdominal administration
79220769|NCT02308254|Drug|Placebo|Abdominal administration
79220770|NCT03361202|Other|blood sampling|"atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~control group:before coronary angiography and at hospital discharge."
79220771|NCT03357146|Device|Optical coherence tomography angiography|OCTA scans per built-in device protocol
79220772|NCT02304120|Other|Proprioceptive postural training|
79220773|NCT02304120|Other|Treadmill training|
79515273|NCT01618422|Other|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
79220774|NCT02304120|Other|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
79220775|NCT03361124|Drug|Oxytocin|Administration of additional 20 mU Oxytocin
79515274|NCT01618422|Other|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
79515275|NCT01619982|Drug|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
79515276|NCT01619982|Drug|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
79515277|NCT01620216|Other|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
79673614|NCT00492141|Drug|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
79673615|NCT04350112|Other|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
79994696|NCT04762433|Device|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
79994697|NCT04752761|Behavioral|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
79994698|NCT04853147|Drug|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
79994699|NCT04853147|Drug|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
79994700|NCT03315689|Drug|Vehicle|Vehicle Topical Solution
79994701|NCT03315689|Drug|ATI-50002|ATI-50002 Topical Solution
79364032|NCT04029987|Procedure|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
79364033|NCT04029987|Procedure|Control|Conventional analgesia
79994702|NCT03436901|Diagnostic Test|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
79220776|NCT02312388|Other|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
79220777|NCT02312388|Other|Thin-wall needle technique|using 18 - 21 G introducer needle
79220778|NCT03364088|Procedure|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
79220779|NCT03364088|Procedure|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
79364034|NCT04191837|Other|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
79515278|NCT01620216|Drug|Dasatinib|Given PO
79515279|NCT01620216|Drug|Idelalisib|Given PO
79515280|NCT01620216|Other|Laboratory Biomarker Analysis|Correlative studies
79515281|NCT01620216|Drug|Pacritinib|Given PO
79673616|NCT00467675|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
79673617|NCT04350151|Behavioral|no intervention|no intervention
79821013|NCT02582736|Drug|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
79220780|NCT03364088|Procedure|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
79220781|NCT03364088|Procedure|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
79220782|NCT03364088|Drug|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
79220783|NCT02304198|Drug|Udenafil|Udenafil 50mg tablet
79220784|NCT02304276|Radiation|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
79364035|NCT04191837|Other|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
79220785|NCT02304276|Radiation|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
79364036|NCT04191759|Diagnostic Test|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
79364037|NCT03596463|Other|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
79364038|NCT04191603|Device|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
79364039|NCT04191603|Device|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
79364040|NCT04029909|Drug|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
79364041|NCT04029909|Drug|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
79364042|NCT04029909|Drug|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
79364043|NCT04190979|Device|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
79364044|NCT03596307|Dietary Supplement|Ashwagandha extract|Shoden 180 mg capsule.
79364045|NCT03596307|Dietary Supplement|Placebo|Placebo 180 mg (Sucrose) capsule.
79515282|NCT01620216|Other|Pharmacological Study|Correlative studies
79515283|NCT01620216|Drug|Ponatinib|Given PO
79515284|NCT01620216|Drug|Ponatinib Hydrochloride|Given PO
79515285|NCT01620216|Drug|Ruxolitinib|Given PO
79515286|NCT01620216|Drug|Sorafenib|Given PO
79515287|NCT01620216|Drug|Sorafenib Tosylate|Given PO
79515288|NCT01620216|Drug|Sunitinib|Given PO
79515289|NCT01620216|Drug|Sunitinib Malate|Given PO
79515290|NCT01621230|Drug|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
79673618|NCT04327726|Drug|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
79673619|NCT04327726|Other|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
79673620|NCT00499161|Behavioral|New model of nursing care|
79673621|NCT04349254|Device|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
79673622|NCT00492219|Device|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
79515291|NCT01621230|Drug|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
79515292|NCT01621776|Drug|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
79515293|NCT01621776|Drug|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
79673623|NCT00492219|Device|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
79673624|NCT00465257|Drug|artesunate + amodiaquine|
79673625|NCT04131127|Device|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
79364046|NCT04406337|Device|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm^2 (0.03 W/cm^2 ) and 20% duty cycle.
79220786|NCT04524260|Behavioral|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
79220787|NCT04524260|Behavioral|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
79364047|NCT04406337|Device|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm^2 and 100% duty cycle.
79364048|NCT04029441|Other|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
79220788|NCT02308332|Drug|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
79220789|NCT03361046|Device|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
79220790|NCT02308410|Procedure|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
79220791|NCT03360968|Procedure|Variable-PS|Variable-PS mode switched on for 1 hour
79364049|NCT04766151|Drug|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
79364050|NCT04766151|Drug|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
79364051|NCT04029207|Procedure|Cesarean section|Abdominal, operative delivery of the fetus
79364052|NCT04191213|Dietary Supplement|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
79364053|NCT04191213|Dietary Supplement|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
79364054|NCT03024177|Drug|Vapendavir|Vapendavir Tablets, 264 mg
79364055|NCT03024177|Drug|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
79515294|NCT01621776|Drug|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
79515295|NCT01622010|Behavioral|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
79673626|NCT01245465|Other|Profermin|Medical Food (food for special medical purposes)
79673627|NCT04130776|Diagnostic Test|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from <1% to >95% of a man having aggressive cancer in a prospective biopsy.
79673628|NCT00492258|Drug|sorafenib tosylate|
79673629|NCT00492258|Procedure|adjuvant therapy|
79673630|NCT04327648|Device|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
79220792|NCT03360968|Procedure|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
79220793|NCT03360968|Procedure|Variable-PS|Variable-PS mode switched on for 1 hour
79220794|NCT01822522|Drug|Cabozantinib S-malate|Given PO
79220795|NCT01822522|Other|Laboratory Biomarker Analysis|Correlative studies
79220796|NCT01822522|Other|Pharmacological Study|Correlative studies
79220797|NCT03509298|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
79220798|NCT03509298|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
79220799|NCT03360812|Other|Online training resource|Please see information included in the description of the intervention group.
79364056|NCT01874431|Drug|Finerenone (BAY94-8862)|
79364057|NCT01874431|Drug|Placebo|
79364058|NCT04028817|Device|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
79364059|NCT04028817|Device|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
79515296|NCT01622010|Other|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
79220800|NCT03503994|Drug|Inhaled Beclomethasone Dipropionate Monohydrate|"Beclomethasone Dipropionate (HFA-BDP, QVAR*) in the following doses will be evaluated:~200 mcg bid~400 mcg bid~600 mcg bid~800 mcg bid"
79364060|NCT04190511|Dietary Supplement|Prebiotic-containing dairy|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
79364061|NCT04190511|Dietary Supplement|Dietary intervention|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
79994703|NCT03314519|Diagnostic Test|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
79364062|NCT04028739|Dietary Supplement|curmin|curcumin 90mg/day cross-over
79515297|NCT01622010|Device|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
79515298|NCT01624350|Device|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
79673631|NCT04327648|Device|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
79994704|NCT03314519|Diagnostic Test|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
79364063|NCT04028661|Device|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
79994705|NCT04699799|Other|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
79994706|NCT01856855|Radiation|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
79220801|NCT04520828|Other|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
79220802|NCT03509220|Drug|PBK-1701TC|The subject will receive PBK-1701TC for colonoscopy.
79220803|NCT03509220|Drug|Standard oral preparation|The subject will receive the standard oral preparation for colonoscopy
79220804|NCT04524494|Other|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
79220805|NCT04524494|Other|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
79220806|NCT04524494|Other|urine collection|Midstream Urine collection
79220807|NCT01796002|Drug|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
79220808|NCT01796002|Drug|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
79364064|NCT04028583|Other|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
79515299|NCT01624740|Device|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
79515300|NCT01624740|Device|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
79515301|NCT01627002|Biological|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
79515302|NCT01627002|Other|Placebo|Subcutaneous
79673632|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment.
79673633|NCT00467714|Procedure|rhinoplasty|COLUMELLA STRUT PLACEMENT
79673634|NCT03272438|Device|Accelerometer|Participants use an accelerometer to monitor their steps activity
79673635|NCT03272438|Behavioral|Step goal|Participants are given a daily step goal to aim for
79673636|NCT03272438|Behavioral|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
79673637|NCT03272438|Behavioral|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
79673638|NCT02955810|Drug|Daratumumab|
79821014|NCT02582736|Drug|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
79673639|NCT02955810|Drug|Cyclophosphamide|
79673640|NCT02955810|Drug|Bortezomib|
79673641|NCT02955810|Drug|Dexamethasone|
79673642|NCT04342468|Other|non-interventional|No intervention
79994707|NCT04689347|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
79994708|NCT04689347|Drug|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
79994709|NCT04689347|Drug|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
79994710|NCT04689347|Drug|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
79994711|NCT04689347|Drug|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
79994712|NCT03313037|Biological|Multivalent|Pneumococcal conjugate vaccine
79994713|NCT03313037|Biological|Prevnar 13|Pneumococcal conjugate vaccine
79821015|NCT02582736|Drug|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
79515303|NCT01628016|Behavioral|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
79515304|NCT01628718|Behavioral|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
79673643|NCT04339855|Other|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
79673644|NCT00465296|Drug|rosiglitazone|
79220809|NCT04524338|Device|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
79673645|NCT00492414|Drug|Paroxetine CR|
79673646|NCT04337983|Device|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
79821016|NCT00734565|Biological|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
79220810|NCT03509142|Device|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
79220811|NCT04520360|Drug|Carisbamate|Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
79220812|NCT03132480|Other|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
79673647|NCT04337983|Device|Echocardiography|Daily echocardiography evaluation
79673648|NCT04337320|Other|newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers
79673649|NCT03272555|Other|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
79673650|NCT00499200|Drug|SRA-444|
79673651|NCT04327492|Diagnostic Test|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
79673652|NCT00499278|Behavioral|Rehabilitation after joint replacement surgery|
79673653|NCT04334395|Procedure|primary tumor resection group|resection of cancer at colon
79673654|NCT04333186|Other|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
79821017|NCT04503564|Device|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
79821018|NCT04019652|Drug|CS-3150|Single, oral administration; 10-mg or 40-mg dose
79220813|NCT03356912|Drug|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
79220814|NCT03356912|Drug|Prednisone|Prednisone should be administred by oral route
79220815|NCT02308566|Procedure|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
79220816|NCT02308566|Procedure|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
79220817|NCT00102687|Drug|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
79220818|NCT04509440|Drug|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
79220819|NCT04509440|Drug|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
79220820|NCT02312544|Drug|OTX-TP|OTX-TP and placebo drops
79220821|NCT02312544|Drug|Timolol|Timolol drops and placebo punctum plug
79821019|NCT04019652|Drug|Moxifloxacin|Single, oral administration; 400 mg-tablet
79821020|NCT04019652|Drug|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
79821021|NCT04019652|Drug|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
79821022|NCT00734721|Behavioral|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
79821023|NCT04400370|Device|Diaphragm ultrasound|"Diaphragm ultrasound is performed at the following three time points.~At the entrance of the operating room before induction of anesthesia~1 hour after surgery~24 hours after surgery"
79515305|NCT01628718|Behavioral|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
79515306|NCT01630200|Drug|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
79515307|NCT01630200|Drug|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
79673655|NCT01243632|Drug|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
79673656|NCT00467909|Behavioral|micronutrients|
79220822|NCT03360734|Drug|First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)|Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
79515308|NCT01631682|Drug|Propranolol|40mg single pill
79994714|NCT03313037|Biological|PPSV23|Pneumococcal polysaccharide vaccine
79515309|NCT01631682|Behavioral|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
79821024|NCT00734955|Device|49-channel optical spectrometer|
79994715|NCT03313037|Other|Saline|Placebo
79994716|NCT04685759|Other|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
79994717|NCT04685759|Other|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
79220823|NCT02308644|Drug|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
79515310|NCT01631682|Drug|Mifepristone|1800mg, 9 tablets
79515311|NCT01631682|Drug|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
79673657|NCT04327375|Other|Observational|Observational
79673658|NCT00499356|Device|pressure reducing insole|
79673659|NCT00499356|Device|GlideSoft®|
79673660|NCT04327453|Device|double antibiotic paste with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
79673661|NCT04327453|Device|double antibiotic paste with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
79821025|NCT04078464|Other|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
79994718|NCT02420795|Drug|Akt/ERK Inhibitor ONC201|Given PO
79994719|NCT02420795|Other|Laboratory Biomarker Analysis|Correlative studies
79994720|NCT02420795|Other|Pharmacological Study|Correlative studies
79994721|NCT04674995|Procedure|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
79220824|NCT04510636|Drug|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
79220825|NCT04510636|Drug|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
79220826|NCT05618626|Other|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
79220827|NCT02308722|Radiation|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)"
79220828|NCT03540849|Drug|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
79821026|NCT04078464|Other|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
79994722|NCT02384759|Drug|aflibercept|
79994723|NCT02384759|Drug|LV5FU2|
79994724|NCT03638219|Other|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
79994725|NCT05276843|Combination Product|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
79515312|NCT01633398|Genetic|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
79515313|NCT01634256|Dietary Supplement|Placebo|Placebo(3.0g/day)
79515314|NCT01634256|Dietary Supplement|Fermented turmeric|Fermented turmeric(3.0g/day)
79515315|NCT01635504|Biological|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
79515316|NCT01636206|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year
79515317|NCT01636206|Drug|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year
79515318|NCT01636284|Biological|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
79515319|NCT01638468|Device|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
79821027|NCT04078464|Other|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
79220829|NCT04509362|Device|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
79364065|NCT04028583|Other|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
79364066|NCT04028505|Drug|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
79515320|NCT01639872|Drug|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
79515321|NCT01639872|Drug|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
79515322|NCT01640340|Drug|aprepitant|Given by mouth
79515323|NCT01640340|Drug|palonosetron hydrochloride|Given IV(intervenous infusion)
79515324|NCT01640340|Drug|ondansetron|Given PO
79515325|NCT01640340|Drug|dexamethasone|Given PO
79515326|NCT01641042|Biological|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
79821028|NCT00735033|Other|Physiotherapy with Swiss Ball|
79821029|NCT00735111|Other|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
79821030|NCT00735189|Other|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
79821031|NCT00735189|Other|usual care|patient receives usual anticoagulation care from their regular primary care physician
79821032|NCT00735345|Drug|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
79821033|NCT00735345|Drug|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
79994726|NCT05276765|Procedure|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
79220830|NCT02160405|Dietary Supplement|native potato|
79220831|NCT03509064|Other|Collection sheet|Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
79220832|NCT03356678|Drug|Pralatrexate|"Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
79515327|NCT01641120|Drug|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
79515328|NCT01642056|Drug|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
79515329|NCT01642056|Drug|Placebo|
79515330|NCT01643382|Drug|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
79515331|NCT01643382|Drug|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
79515332|NCT01643616|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
79515333|NCT01643616|Drug|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
79515334|NCT01643616|Drug|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
79821034|NCT00735345|Drug|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
79821035|NCT00735345|Biological|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
79515335|NCT01643616|Drug|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
79515336|NCT01643616|Device|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
79515337|NCT01643616|Device|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
79515338|NCT01644240|Drug|TD-8954|Intravenous infusion
79515339|NCT01644240|Drug|Placebo - saline|Intravenous infusion
79515340|NCT01644396|Biological|Adalimumab|
79515341|NCT01645098|Drug|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
79515342|NCT01645098|Drug|Dexmedetomidine|0.5 mcg/kg/hr IV
79673662|NCT04327453|Device|double antibiotic paste with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
79673663|NCT04330105|Device|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
79673664|NCT00467948|Drug|cefazolin|
79673665|NCT01245504|Other|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
79673666|NCT00592579|Drug|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
79673667|NCT04327414|Behavioral|Intervention group|Standing desks
79673668|NCT00592618|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
79673669|NCT00465374|Procedure|Change ventilatory parameters with stress index monitoring|
79220833|NCT02160483|Other|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
79673670|NCT01243710|Device|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
79220834|NCT03503760|Device|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
79220835|NCT04509206|Behavioral|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
79364067|NCT01824355|Device|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
79673671|NCT00622843|Biological|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
79673672|NCT00622843|Biological|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
79673673|NCT03271736|Behavioral|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
79673674|NCT03271736|Device|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
79673675|NCT00592735|Procedure|laparoscopic gastric banding|standard surgical procedure
79679850|NCT00520988|Behavioral|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
79679851|NCT04781244|Device|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
79364068|NCT04042623|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
79515343|NCT01646346|Radiation|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
79515344|NCT01647438|Behavioral|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
79679852|NCT04781244|Device|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
79821036|NCT00735345|Radiation|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
79228471|NCT03308864|Behavioral|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
79364069|NCT04190745|Drug|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
79364070|NCT04190745|Drug|paclitaxel|paclitaxel 80mg/m2, q3w
79364071|NCT01823341|Device|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
79673676|NCT00592813|Behavioral|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
79673677|NCT00592813|Behavioral|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
79994727|NCT05276765|Procedure|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
79994728|NCT03334175|Drug|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
79994729|NCT05276687|Drug|Betadine|Wound irrigation
79994730|NCT05276687|Drug|Vancomycin|instillation in the wound
79994731|NCT04616339|Drug|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
79994732|NCT02942771|Drug|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
79994733|NCT02942771|Drug|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
79220836|NCT05532826|Other|donor EBV-specific T lymphocytes|"EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped."
79515345|NCT01647438|Other|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
79515346|NCT01648452|Biological|NT-501 CNTF-releasing implant|20 ng/day released into the eye
79515347|NCT01648530|Other|No Treatment|No Treatment
79515348|NCT01648920|Device|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
79515349|NCT01650324|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
79515350|NCT01650324|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
79515351|NCT01650402|Other|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
79994734|NCT02942771|Drug|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
79994735|NCT02942771|Drug|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
79994736|NCT02942771|Drug|Placebo|0.9% sodium chloride
79673678|NCT01245543|Drug|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
79994737|NCT05276375|Drug|Bronchipret|Bronchipret syrup (3x 5,4 ml daily) until day 14
79994738|NCT05275985|Diagnostic Test|68Ga-FAPI Positron Emission Tomography-Computed Tomography|The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
79994739|NCT05275829|Other|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
79220837|NCT02160561|Other|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
79220838|NCT02304354|Drug|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
79220839|NCT05615350|Other|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
79220840|NCT05615350|Other|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
79515352|NCT01650402|Other|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
79515353|NCT01651104|Biological|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
79515354|NCT01651806|Drug|Tranexamic Acid standard dose|Uniform 1 gram dosing
79515355|NCT01651806|Drug|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
79515356|NCT01651806|Drug|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
79515357|NCT01651806|Drug|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
79994740|NCT03036150|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
79673679|NCT01245543|Drug|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
79821037|NCT00735501|Drug|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
79821038|NCT00727935|Drug|Lidocaïne|
79821039|NCT00727935|Drug|Ropivacaïne|
79994741|NCT03036150|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
79994742|NCT03332771|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79220841|NCT03356600|Combination Product|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
79821040|NCT00727935|Drug|Placebo|
79364072|NCT04028427|Behavioral|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston & Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
79364073|NCT04028427|Behavioral|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
79515358|NCT01652040|Device|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
79994743|NCT03332771|Drug|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
79821041|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
79364074|NCT04190121|Dietary Supplement|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
79364075|NCT04028349|Drug|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
79515359|NCT01652040|Drug|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
79821042|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
79821043|NCT02569749|Other|Berlin and Epworth questionaries|
79994744|NCT03332771|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79994745|NCT03332771|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79515360|NCT01652976|Drug|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
79515361|NCT01652976|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
79673680|NCT00592891|Drug|Hyperbaric oxygen therapy|Total body pressurized oxygen
79673681|NCT00592930|Drug|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
79673682|NCT00592930|Drug|placebo|
79673683|NCT00468026|Device|ProstaPlant Stent|
79673684|NCT00592969|Drug|metformin|
79673685|NCT00592969|Drug|biphasic insulin aspart|
79673686|NCT01245582|Drug|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
79673687|NCT01245582|Drug|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
79673688|NCT01245582|Drug|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
79679853|NCT00521027|Device|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
79821044|NCT02569749|Other|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
79821045|NCT02569749|Other|Night polygraph / Polysomnography|
79821046|NCT00728247|Procedure|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
79821047|NCT00577707|Drug|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
79821048|NCT00577707|Drug|Pemetrexed|pemetrexed 500 mg/m^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
79994746|NCT03332771|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
79994747|NCT03625830|Device|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
79994748|NCT03625830|Device|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
79994749|NCT04123704|Drug|Sitravatinib|sitravatinib capsule
79994750|NCT04108104|Drug|Cyproheptadine|3-month treatment
79994751|NCT04108104|Drug|Alpress LP|3-month treatment
79821049|NCT00577707|Drug|Cisplatin|cisplatin 75 mg/m^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
79994752|NCT05304468|Radiation|IMRT|Patients in experimental group received reduced dose IMRT
79994753|NCT05304468|Drug|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
79364076|NCT01853137|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
79364077|NCT04028271|Device|Comfort-in injection system|local anesthesia during dental treatment
79364078|NCT04028271|Other|conventional injection with dental needle|for local anesthesia during dental treatment
79364079|NCT03595839|Procedure|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
79364080|NCT03595839|Procedure|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
79364081|NCT01823107|Device|Meso BioMatrix Device|
79364082|NCT04190277|Device|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
79364083|NCT04190277|Device|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
79515362|NCT01653288|Behavioral|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
79515363|NCT01654068|Radiation|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
79515364|NCT01598922|Behavioral|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
79515365|NCT01656252|Drug|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
79515366|NCT01656252|Drug|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
79673689|NCT00593008|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
79673690|NCT00593008|Drug|Gemcitabine|Given intravenously every other week of each 28-day cycle.
79673691|NCT00593047|Drug|KB2115|tablet formulation given once daily for 12 weeks
79821050|NCT00577707|Procedure|Resection|
79821051|NCT00728325|Behavioral|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
79364084|NCT01874275|Device|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
79673692|NCT00465413|Device|Small volume spacer and/or Rinsing the mouth with water|
79673693|NCT00593086|Procedure|Pain management|Pain mamagement for burn care procedures.
79673694|NCT00593086|Other|Standard of care/no virtual reality game|no intervention for standard of care
79673695|NCT02956200|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
79679854|NCT00521027|Procedure|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
79679855|NCT02938182|Drug|clopidogrel|clopidogrel troche 75 mg daily for three months
79994754|NCT05304468|Drug|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
79994755|NCT03310775|Behavioral|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
79994756|NCT03619434|Procedure|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
79994757|NCT03619434|Procedure|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
79994758|NCT05250102|Device|Pulse oximeter sensors|Pulse oximeter reading will be compared to CO-oximeter reading.
79364085|NCT01873729|Drug|Naltrexone|Adults with ADHD
79994759|NCT05275595|Other|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
79994760|NCT05275595|Other|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
79994761|NCT04582799|Device|ECCO2R|Extracorporeal CO2 Removal
79994762|NCT04582799|Device|NIV|Non-invasive ventilation
79220842|NCT04464018|Other|working grup|After each student received theoretical training, they performed an intravenous injection on the model. In the study group performed hybrid simulation. After finishing the simulation application. the students went to the analysis room and watched their own application videos. The analysis session was held immediately after all the students in the group completed their applications.The IM injection success Test and Student Satisfaction and self-confidence scale were applied to the study and control groups after the laboratory application was completed.
79220843|NCT00102531|Drug|Cisplatin liposomal|
79220844|NCT03360266|Combination Product|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
79220845|NCT03360266|Combination Product|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
79220846|NCT03360266|Drug|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
79994763|NCT05248308|Device|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
79364086|NCT01873495|Drug|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
79364087|NCT04027959|Dietary Supplement|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
79994764|NCT04236245|Device|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
79515367|NCT01656252|Drug|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
79515368|NCT01660230|Biological|3K3A-APC, diluted in 0.9% sodium chloride in water|
79515369|NCT01660230|Drug|0.9% NaCl in water|
79515370|NCT01660698|Dietary Supplement|Maltodextrin|maltodextrin powder
79515371|NCT01660698|Dietary Supplement|Probiotic|probiotic blended in maltodextrin powder
79515372|NCT01661088|Drug|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
79220847|NCT02154789|Drug|polidocanol|
79364088|NCT04027569|Other|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
79364089|NCT04027569|Other|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
79220848|NCT02154789|Procedure|infra-red coagulation|
79220849|NCT02154789|Procedure|cryotherapy|
79220850|NCT05532748|Device|Respiratory exercise protocol with the modified Pachon's incentive|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a slow, deep breath, fully stretching the condom, and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe for 3 minutes at a gentle intensity through your nose without extra effort.~All these instructions will be explained through a video."
79673696|NCT00593125|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
79673697|NCT00593164|Device|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
79673698|NCT00593164|Device|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
79673699|NCT01316107|Drug|ipragliflozin|oral
79673700|NCT01316107|Drug|nateglinide|oral
79220851|NCT05532748|Device|"Respiratory exercise protocol with Branded respiratory incentive, Triflo II®"|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a smooth deep breath lifting as many spheres as you can and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe gently through your nose for 3 minutes without extra effort.~All these instructions will be explained through a video."
79220852|NCT03506490|Other|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
79364090|NCT01852825|Biological|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
79364091|NCT01852825|Other|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
79364092|NCT01852825|Biological|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
79364093|NCT04027413|Dietary Supplement|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
79364094|NCT04027413|Dietary Supplement|preOp|(100% carbohydrate).
79515373|NCT01661088|Radiation|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
79515374|NCT01661088|Procedure|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
79515375|NCT01661712|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
79515376|NCT01661712|Device|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
79515377|NCT01661946|Drug|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
79515378|NCT01661946|Drug|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
79515379|NCT01662882|Drug|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
79515380|NCT01662960|Behavioral|Mirror therapy|A home-based therapy involving mirrored visual feedback
79515381|NCT01662960|Behavioral|Divider therapy|A home-based therapy involving removed visual feedback.
79515382|NCT01663272|Drug|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
79515383|NCT01663272|Drug|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
79515384|NCT01667250|Device|GammaCore Active Device|
79515385|NCT01667250|Device|GammaCore Sham Device|
79515386|NCT01667406|Drug|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
79515387|NCT01667406|Drug|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
79515388|NCT01667406|Drug|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
79515389|NCT01667406|Drug|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
79515390|NCT01667406|Drug|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
79515391|NCT01667406|Drug|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
79515392|NCT01667406|Drug|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
79515393|NCT01667796|Dietary Supplement|Vitamin D3|
79515394|NCT01668030|Drug|Enzymatic agent|Enzymatic agent
79515395|NCT01668030|Drug|Bacitracin|
79515396|NCT01669434|Drug|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
79515397|NCT01669434|Drug|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
79515398|NCT01670760|Device|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
79515399|NCT01673022|Drug|IC Green|IC Green
79515400|NCT01673256|Device|SJM Confirm ICM|
79515401|NCT01673568|Device|ETO garments|patients wearing abdominal binder for 7 days postoperatively
79515402|NCT01673802|Drug|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
79515403|NCT01675830|Device|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
79515404|NCT01676298|Device|Spartan FRX CYP2C19 Test System|
79364095|NCT04344951|Drug|UNIKINON (Chloroquine phosphate) 200mg tablets|Two and a half tablets (500mg) twice daily for seven days.
79821052|NCT00728325|Behavioral|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
79821053|NCT00730743|Procedure|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
79673701|NCT00492453|Procedure|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
79220853|NCT03503682|Radiation|standard treatment|3000 cGy in 10 daily fractions
79220854|NCT03503682|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
79220855|NCT05532592|Other|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
79515405|NCT01676532|Other|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
79515406|NCT01677312|Procedure|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
79515407|NCT01677312|Procedure|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
79515408|NCT01678794|Drug|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
79673702|NCT01316185|Drug|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
79673703|NCT05654194|Drug|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
79673704|NCT05654155|Other|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
79673705|NCT00468065|Device|VeinViewer|Veinveiwer is used to view veins subQ
79673706|NCT00468065|Device|Veinviewer|near infrared light reveals veins subcutaneously
79673707|NCT00492492|Procedure|trans-styloid and intrafocal pinning on the one side|
79220856|NCT02771145|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
79220857|NCT02771145|Device|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
79220858|NCT02771145|Device|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
79673708|NCT00492492|Procedure|volar fixed-angle plating on the other side|
79220859|NCT02308800|Device|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
79220860|NCT02308800|Device|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
79220861|NCT05260840|Other|Evaluation study - provision of an online questionnaire|Evaluation study - provision of an online questionnaire
79364096|NCT01822561|Drug|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
79364097|NCT02080455|Drug|lomitapide|20 mg dose
79364098|NCT02080455|Drug|Atorvastatin|80 mg
79364099|NCT01852591|Biological|PCV 13|
79515409|NCT01678794|Drug|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
79515410|NCT01679028|Drug|T89 Group A|150mg single dose on day 1
79515411|NCT01679028|Drug|Placebo Group A|150mg single dose
79515412|NCT01679028|Drug|Placebo Group B|300mg single dose
79515413|NCT01679028|Drug|T89 Group B|300mg single dose
79515414|NCT01679028|Drug|Placebo Group C|225mg bid
79515415|NCT01679028|Drug|T89 Group C|225mg bid
79515416|NCT01680666|Procedure|central line placement|central line placement
79515417|NCT01680666|Device|Ultrasound|Ultrasound guided central venous access
79515418|NCT01680900|Drug|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
79515419|NCT01680900|Drug|placebo capsules|placebo capsules matched to drug capsules.
79515420|NCT01682538|Drug|Nitisinone, capsule|
79220862|NCT04444414|Other|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
79364100|NCT04027491|Behavioral|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
79364101|NCT04596241|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
79220863|NCT04444414|Other|Control group|The control group received no treatment, they only attended the evaluations.
79220864|NCT03506256|Drug|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
79364102|NCT04406493|Diagnostic Test|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
79364103|NCT04021251|Device|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
79364104|NCT03961581|Behavioral|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
79364105|NCT04021407|Device|LMA group|patients were ventilated with LMA
79364106|NCT04021407|Device|AirQ group|patients were ventilated with AirQ airway
79364107|NCT04021173|Drug|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
79515421|NCT01682538|Drug|Nitisinone, suspension|
79364108|NCT04021173|Drug|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
79515422|NCT01684020|Biological|ARTISS human fibrin sealant|
79515423|NCT01684410|Biological|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
79673709|NCT05653453|Device|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
79220865|NCT04508660|Drug|CGB-400|BID application
79220866|NCT02308956|Behavioral|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
79364109|NCT04027881|Behavioral|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
79515424|NCT01684410|Biological|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
79364110|NCT04027335|Device|leva|Vaginal device used for pelvic floor muscle exercises
79515425|NCT01684410|Biological|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
79515426|NCT01684566|Device|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
79364111|NCT04027725|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
79515427|NCT01684566|Other|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
79515428|NCT01686750|Behavioral|Integrated care centers|
79673710|NCT05653453|Drug|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
79673711|NCT00468182|Drug|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
79673712|NCT05653375|Other|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
79220867|NCT02308956|Behavioral|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
79220868|NCT03356444|Drug|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
79515429|NCT01688310|Procedure|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
79994765|NCT03330119|Drug|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
79220869|NCT03356444|Drug|Docetaxel|"Docetaxel: intravenously, 75 mg/m^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
79220870|NCT05597176|Other|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
79994766|NCT03330119|Drug|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
79994767|NCT05123274|Behavioral|Social Support Mobilization|Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
79364112|NCT01852045|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
79220871|NCT04520438|Procedure|Leukocyte and platelet rich fibrin|L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT
79515430|NCT01688310|Procedure|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
79364113|NCT04027257|Behavioral|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
79673713|NCT05653375|Other|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
79673714|NCT05653297|Device|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
79679856|NCT00521066|Device|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
79679857|NCT02931552|Behavioral|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
79364114|NCT03960957|Biological|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
79364115|NCT03960957|Other|Placebo|Treatment of glabellar facial lines with placebo
79364116|NCT03960645|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
79364117|NCT04020939|Device|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
79364118|NCT04020939|Drug|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
79364119|NCT04027179|Drug|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
79364120|NCT04027179|Procedure|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
79364121|NCT04027179|Drug|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
79364122|NCT04199169|Biological|HeV-sG-V|A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.
79364123|NCT04199169|Biological|Normal Saline Placebo|0.9% Saline
79364124|NCT04021095|Device|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
79364125|NCT04026789|Other|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
79364126|NCT04026789|Other|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
79364127|NCT04191291|Behavioral|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
79364128|NCT04026555|Other|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
79994768|NCT05123274|Behavioral|Individual Care Counseling|Twenty-minute individual counseling session focused on HIV medical care
79994769|NCT03040986|Other|Laboratory Biomarker Analysis|Correlative studies
79994770|NCT03040986|Drug|Selumetinib Sulfate|Given by mouth (PO)
79994771|NCT05261022|Behavioral|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
79994772|NCT03983382|Diagnostic Test|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
79364129|NCT04026555|Other|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
79515431|NCT01688856|Device|Electrical Stimulator|"The 12-week treatment period consists of two components:~Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
79515432|NCT01689324|Biological|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
79515433|NCT01692756|Drug|Kenalog or placebo|
79364130|NCT04026321|Drug|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
79364131|NCT04026321|Drug|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
79364132|NCT04026321|Drug|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
79364133|NCT04026321|Drug|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
79364134|NCT04026321|Drug|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
79364135|NCT04026243|Procedure|QL block|U/S guided Transmuscular Quadratus Lumborum Block
79515434|NCT01692756|Drug|Kenalog then Placebo|
79515435|NCT01692756|Drug|Kenalog|
79515436|NCT01692756|Drug|Placebo|
79515437|NCT01695330|Drug|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
79515438|NCT01698528|Device|Tablet Computer|
79821054|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
79364136|NCT04026243|Procedure|TF block|U/S guided Transversalis Fascia Plane Block
79364137|NCT01821937|Drug|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
79364138|NCT01821937|Drug|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
79364139|NCT03832335|Diagnostic Test|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
79364140|NCT03820089|Diagnostic Test|Ultrasonography TP|TP us will be made to the included women
79515439|NCT01698684|Drug|Placebo|One dose 15 minutes before attempting intercourse
79515440|NCT01698684|Drug|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
79515441|NCT01698684|Drug|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
79994773|NCT03936660|Other|Intense Education Intervention|Intervention will involve guideline-based care education.
79994774|NCT03039192|Drug|Esketamine|Intranasal esketamine solution 84 milligram (mg)
79994775|NCT03039192|Other|Placebo|Intranasal Placebo solution
79994776|NCT03039192|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
79994777|NCT05370612|Device|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
79994778|NCT05370612|Other|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
79994779|NCT02428842|Procedure|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
79364141|NCT01821625|Drug|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
79364142|NCT03022929|Behavioral|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
79364143|NCT03022695|Device|High Intensity Focused Ultrasound|
79364144|NCT04406571|Other|Data record|Data record
79364145|NCT04020783|Other|NO Intervention|NO Intervention
79364146|NCT01821391|Drug|NDL-PDT|Metvix natural daylight photodynamic therapy
79364147|NCT01821391|Drug|c-PDT|Metvix conventional photodynamic therapy
79364148|NCT01821391|Drug|placebo c-PDT|Metvix placebo conventional photodynamic therapy
79515442|NCT01699542|Device|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
79515443|NCT01699542|Device|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
79994780|NCT02428842|Procedure|Blood sampling|Blood sampling will be performed before and after treatment.
79515444|NCT01699698|Other|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
79515445|NCT01701024|Drug|ACYC|ACYC active, topically applied to the face for 12 weeks
79994781|NCT02367690|Drug|Selinexor|Topical gel
79220872|NCT04520438|Procedure|Non-Surgical Periodontal treatment|The control group only received NSPT (scaling and root planing) in one treatment session.
79220873|NCT03737487|Procedure|Multidisciplinary fall risk and geriatric comprehensive assessment|"Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~Calculation of BMI~A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
79220874|NCT03503604|Biological|hPV19 mAb|Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks
79220875|NCT03503604|Biological|hPV19 mAb|Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
79364149|NCT04020393|Procedure|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
79364150|NCT04020705|Device|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
79364151|NCT04020705|Other|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
79515446|NCT01701024|Drug|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
79673715|NCT05649163|Drug|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
79673716|NCT00499395|Procedure|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
79821055|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
79994782|NCT02367690|Other|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
79994783|NCT02367690|Other|Vehicle Gel|Topical vehicle gel with no active ingredients.
79994784|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
79994785|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
79994786|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
79220876|NCT03503604|Drug|5-Fluorouracil|400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
79220877|NCT03503604|Drug|Oxaliplatin|IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
79220878|NCT03503604|Drug|Leucovorin|IV infusion, 400 mg/m2 every 2 weeks
79220879|NCT03503604|Drug|Paclitaxel|IV infusion, 175 mg/m2 every 3 weeks
79220880|NCT03503604|Drug|Carboplatin|IV infusion, AUC=6 every 3 weeks
79220881|NCT03503604|Drug|Gemcitabine|IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
79220882|NCT03503604|Drug|Carboplatin|IV infusion, AUC=4 every 3 weeks
79220883|NCT03503604|Drug|Irinotecan|IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
79364152|NCT04020627|Other|BiPAP Group|"BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
79364153|NCT04020627|Other|CPAP Group|"CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
79364154|NCT01873417|Drug|BG00012 (DMF)|
79364155|NCT04025697|Other|Complete Denture|A conventional CD will be constructed
79364156|NCT04025697|Other|Rapid prototyped denture|A 3d printed complete denture will be constructed
79515447|NCT01701102|Procedure|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
79515448|NCT01701102|Procedure|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
79515449|NCT01701102|Procedure|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
79515450|NCT01701102|Procedure|Mepivacaine|Mepivacaine 37.5 mg
79821056|NCT00728403|Dietary Supplement|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
79515451|NCT01701414|Drug|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
79515452|NCT01701414|Drug|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
79364157|NCT03934827|Drug|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
79673717|NCT00499395|Procedure|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
79994787|NCT03698279|Biological|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
79994788|NCT03698279|Biological|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
79515453|NCT01703598|Device|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
79673718|NCT00465452|Drug|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
79994789|NCT03628950|Procedure|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
79673719|NCT05652010|Device|Iris - new coupling|"SenSura Mio Click maxi bag (open, wide outlet), 50mm Ø with new coupling and lock ring~Baseplate flat: SenSura Mio, click base plate with belt ears, 50 mm, 10-45 mm with improved weld-ing bead~Baseplate Concave: Item 18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
79821057|NCT00735735|Other|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
79220884|NCT05334706|Biological|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
79220885|NCT02154867|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
79220886|NCT02154867|Other|Placebo fecal transplant|Fecal transplantation with own feces
79364158|NCT03934827|Drug|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
79364159|NCT01872715|Drug|Oracea|
79364160|NCT04025385|Other|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
79364161|NCT01871545|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
79364162|NCT04020315|Procedure|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
79515454|NCT01703598|Procedure|DBS surgery|Placement of DBS electrodes
79515455|NCT01706952|Drug|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
79515456|NCT01706952|Drug|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
79515457|NCT01707108|Device|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
79821058|NCT04065867|Behavioral|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
79821059|NCT00730821|Drug|BIBW 2992|
79821060|NCT00730821|Drug|BIBF 1120|
79821061|NCT00728559|Drug|bupivacain 0.5%|trocar site injection
79821062|NCT00735813|Device|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
79821063|NCT00735813|Device|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
79364163|NCT04020549|Behavioral|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
79515458|NCT01707420|Drug|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
79515459|NCT01707420|Drug|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
79515460|NCT01707654|Device|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
79515461|NCT01708122|Drug|Fentanyl|100 mcg in 1 mL intranasal spray
79515462|NCT01708122|Drug|saline|Sodium Chloride 0.9% intranasal spray
79515463|NCT01708278|Drug|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
79364164|NCT04020549|Behavioral|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
79515464|NCT01708278|Other|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
79515465|NCT01708590|Drug|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
79994790|NCT03628950|Procedure|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
79994791|NCT05275283|Other|PEEP|6 cmH2O of PEEP
79364165|NCT03933657|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
79364166|NCT04020237|Behavioral|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~1) Start air purifier~2) Do not go out and make it to the minimum when absolutely necessary~3) It is recommended to wear a mask when going out.~4) The investigators recommend a lot of water, fresh fruit and vegetables.~5) Prepare an inhaler and use it when symptoms get worse."
79364167|NCT04025307|Drug|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
79515466|NCT01708590|Drug|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
79515467|NCT01708590|Drug|placebo|Placebo administered subcutaneous (SC)
79220887|NCT04508816|Drug|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
79220888|NCT03503526|Behavioral|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
79220889|NCT03356210|Behavioral|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
79220890|NCT02304588|Biological|Mesenchymal stem cells|10-20 x 10^6 cells/20mL
79220891|NCT02160639|Other|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
79220892|NCT03359876|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
79364168|NCT01613599|Drug|Rituximab|Participants received rituximab at the discretion of their treating physicians.
79515468|NCT05711004|Behavioral|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
79515469|NCT05710458|Device|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
79515470|NCT05710458|Device|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
79515471|NCT05710302|Other|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
79821064|NCT00736047|Biological|NIC002|
79821065|NCT00736047|Biological|Placebo|
79994792|NCT01529034|Drug|USL261|
79994793|NCT05275049|Combination Product|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
79994794|NCT05275049|Combination Product|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
79994795|NCT03036072|Other|Strict normothermia|
79994796|NCT03036072|Device|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
79220893|NCT03359876|Drug|Warfarin sodium|Individually adjusted dose
79515472|NCT05710146|Drug|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
79515473|NCT05710146|Drug|Placebo|1 injection of 100mL of normal saline
79821066|NCT04064775|Behavioral|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
79220894|NCT02309034|Behavioral|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
79220895|NCT02309034|Behavioral|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
79364169|NCT04025619|Device|tape|Sports tape
79515474|NCT05710068|Device|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
79220896|NCT02309034|Other|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
79220897|NCT03541395|Drug|GnRH antagonist|
79364170|NCT01850641|Drug|PA21|
79515475|NCT05710068|Drug|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
79673720|NCT05652010|Device|Sensura Mio Click|"SenSura Mio Click 2p bag, item #11472. Open, wide outlet, maxi, neutral grey. 50mm with inspection window and circle filter 430~Baseplate flat: Item #10512 SenSura Mio Click Base Plate with belt ears, 50 mm, 10-45 mm~Baseplate concave: Item #18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
79673721|NCT05650684|Other|data collection|continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
79673722|NCT00465491|Drug|picoplatin|IV picoplatin 150mg/m2 q3wk
79364171|NCT04020081|Other|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
79220898|NCT03503448|Procedure|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
79220899|NCT03503448|Procedure|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
79364172|NCT01850563|Device|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
79364173|NCT03931473|Other|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
79515476|NCT05709522|Behavioral|Neurocognitive tools|Neurocognitve and psychological tools
79515477|NCT05706636|Drug|oral mini pulse|5mg / week oral dexamethasone
79821067|NCT04064619|Drug|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
79994797|NCT03619512|Genetic|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
79994798|NCT03619512|Genetic|RNA sequencing|Characterization of tumor transcriptomic profile.
79994799|NCT03619512|Other|Mass spectrometry|Characterization of tumor proteomic profiles.
79673723|NCT00465491|Other|best supportive care|best supportive care
79673724|NCT00499512|Behavioral|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
79673725|NCT00468221|Drug|Ozone Exposure|Low dose ozone exposure in chamber
79673726|NCT01379521|Drug|everolimus|
79673727|NCT01379521|Drug|everolimus placebo|
79673728|NCT00499551|Device|Iontophoresis second generation Eyegate II device|
79673729|NCT00468260|Drug|Patupilone|
79228472|NCT03308864|Behavioral|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
79364174|NCT03930771|Drug|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
79364175|NCT03930771|Drug|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
79364176|NCT04024683|Procedure|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
79364177|NCT04024527|Drug|Esomeprazole|Proton pump inhibitor
79364178|NCT04024527|Drug|Amoxicillin|Antibiotic for H. pylori eradication
79364179|NCT04024527|Drug|Metronidazole|Antibiotic for H. pylori eradication
79515478|NCT05706636|Drug|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
79515479|NCT05706636|Device|targeted phototherapy|twice weekly targeted excimer light sessions
79515480|NCT05703438|Other|Nutritionally balanced low-calorie diet|Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
79515481|NCT05683548|Drug|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
79515482|NCT05683548|Drug|Tenofovir Disoproxil Fumarate|
79515483|NCT05683548|Drug|Pegylated interferon alpha2a|
79515484|NCT05661942|Drug|Calcium pre-treatment|The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
79515485|NCT05661942|Other|No Intervention|Placebo/ no calcium pre-treatment.
79673730|NCT01371994|Drug|solifenacin succinate|oral
79673731|NCT01371994|Drug|Placebo|oral
79673732|NCT00465608|Drug|propranolol|propranolol by mouth (per os)
79220900|NCT05236582|Drug|Herombopag|The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
79364180|NCT04024215|Device|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
79994800|NCT03038880|Drug|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
79220901|NCT03354650|Diagnostic Test|blood culture|blood culture to determine causative organisms of neonatal sepsis
79220902|NCT02160951|Drug|LGH447|LGH447, QD
79220903|NCT02304666|Procedure|Colonoscopy for biopsies samples|
79220904|NCT05226832|Procedure|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
79220905|NCT03354572|Drug|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
79220906|NCT03354572|Drug|Placebos|saline 0.9% prior to surgery
79364181|NCT06061965|Behavioral|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
79364182|NCT06061887|Other|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
79515486|NCT05648214|Drug|ALN-PNP|Solution for subcutaneous (SC) injection
79994801|NCT03038880|Drug|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
79220907|NCT03508674|Device|Levita Magnetic Surgical System|use of surgical tool
79220908|NCT02161029|Device|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
79220909|NCT02161029|Device|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
79364183|NCT06061874|Diagnostic Test|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET/CT.
79364184|NCT06061835|Other|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
79371115|NCT03030352|Behavioral|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
79515487|NCT05648214|Drug|Placebo (PB)|matching placebo, solution for SC injection
79515488|NCT05647824|Device|Capillary Testing|Testing Contour Fit BGMS with capillary blood
79515489|NCT05647824|Device|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
79515490|NCT05647824|Device|Venous Testing|Testing Contour Fit BGMS with venous blood
79673733|NCT01245777|Drug|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
79673734|NCT00468338|Device|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
79673735|NCT01371877|Drug|High Dose Vitamin D3|Vitamin D 4000 IU per day for 3 months
79994802|NCT03038880|Drug|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
79994803|NCT05038644|Drug|XmAb18968 - Dose level -1|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
79994804|NCT05038644|Drug|XmAb18968 - Dose level 0 (starting dose)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
79994805|NCT05038644|Drug|XmAb18968 - Dose level 1|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
79220910|NCT03359798|Behavioral|Narcotic counseling script|Script regarding post-cesarean section narcotic use
79673736|NCT01371877|Drug|Low Dose Vitamin D3|Vitamin D 600 IU per day
79673737|NCT00468416|Device|Compression Anastomosis Ring (CAR)|
79364185|NCT06061835|Other|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
79515491|NCT05641740|Device|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
79515492|NCT05641740|Device|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
79673738|NCT01245816|Drug|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
79220911|NCT03359798|Behavioral|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
79821068|NCT00728637|Behavioral|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
79220912|NCT02309346|Drug|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
79220913|NCT03541239|Device|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
79515493|NCT05639010|Device|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
79673739|NCT01245816|Drug|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
79994806|NCT05038644|Drug|XmAb18968 - Dose level 2|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
79994807|NCT05038644|Drug|XmAb18968 - Dose level 3|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
79994808|NCT03035916|Other|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
79220914|NCT03356054|Combination Product|R-DHAP|3 cycles q 3 weeks
79220915|NCT03356054|Drug|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
79220916|NCT05531032|Other|Phone Interview|Phone interview questionnaire
79515494|NCT05639010|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
79673740|NCT01245816|Drug|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
79220917|NCT02161107|Biological|Grass-SPIRE|Intradermal injection
79364186|NCT06061822|Diagnostic Test|AI-assisted cardiac magnetic resonance imaging|An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
79364187|NCT06061783|Drug|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
79673741|NCT00468455|Procedure|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
79673742|NCT00492687|Drug|carboplatin|
79673743|NCT00492687|Drug|tamoxifen citrate|
79673744|NCT00492687|Drug|temozolomide|
79673745|NCT00492687|Procedure|adjuvant therapy|
79673746|NCT00492687|Radiation|radiation therapy|
79673747|NCT01371838|Drug|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
79220918|NCT02161107|Biological|Placebo|Intradermal injection
79220919|NCT03508596|Other|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
79673748|NCT01371838|Drug|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
79673749|NCT01245855|Drug|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
79673750|NCT00473603|Drug|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
79673751|NCT00492765|Drug|Interferon-beta-1a|dosage and frequency as per label
79515495|NCT05636436|Biological|Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
79515496|NCT05636436|Biological|High Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
79515497|NCT05636436|Biological|Low dose adjuvant|0.5 mL per dose, containing low dose MA105 adjuvant.
79821069|NCT00728637|Behavioral|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
79821070|NCT00730977|Drug|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
79821071|NCT00728715|Drug|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
79821072|NCT00728715|Drug|High dose of budesonide|1600 mcg/d of budesonide
79821073|NCT00728715|Drug|A|medium dose of budesonide-formoterol
79515498|NCT05636436|Biological|High dose adjuvant|0.5 mL per dose, containing high dose MA105 adjuvant.
79364188|NCT06061783|Drug|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
79364189|NCT06061770|Other|Adapted physical activity program|Rehabilitation
79364190|NCT06061770|Other|Adapted physical activity self-program|Rehabilitation
79673752|NCT00492765|Drug|Simvastatin|dosage and frequency as per Biogen Idec protocol
79673753|NCT00492765|Drug|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
79364191|NCT06061757|Device|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
79515499|NCT05636436|Biological|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
79515500|NCT05636436|Biological|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
79515501|NCT05463354|Biological|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
79673754|NCT00468533|Drug|Aripiprazole|
79673755|NCT00473681|Behavioral|Self-Help Intervention Program-High Blood Pressure|
79673756|NCT00499629|Drug|FXR 450|capsule, single oral doses from 10 mg to 450 mg
79220920|NCT03354494|Drug|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
79821074|NCT00728715|Drug|B|High Dose Inhaled Budesonide
79821075|NCT00731289|Drug|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
79994809|NCT03035916|Other|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
79994810|NCT03035916|Other|control|The Control group receives standard IV-inhaled general anesthesia.
79515502|NCT05463354|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
79515503|NCT05449470|Device|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
79673757|NCT00499629|Drug|placebo|capsule similar to active drug
79673758|NCT01371721|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
79673759|NCT00473720|Drug|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
79673760|NCT00473720|Drug|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
79673761|NCT00492804|Procedure|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
79673762|NCT00492804|Procedure|Neurectomy|Neurectomy
79673763|NCT01605448|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
79679858|NCT00521105|Other|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
79821076|NCT00731289|Drug|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
79220921|NCT03727581|Diagnostic Test|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
79220922|NCT02312700|Behavioral|Interactive empowerment tool|
79220923|NCT02518568|Drug|V0355|Oral administration (2 tablets)
79220924|NCT03359720|Other|no intervention survey|survey
79220925|NCT02304744|Other|Observational study, no intervention.|Observational study, no intervention.
79220926|NCT05532514|Other|MICRONUCLEI COUNT|MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE
79220927|NCT03354338|Drug|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
79220928|NCT03354338|Other|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
79220929|NCT02304822|Drug|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
79220930|NCT02304822|Drug|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
79364192|NCT06061744|Other|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
79364193|NCT06061731|Drug|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
79515504|NCT05449470|Device|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
79515505|NCT05293548|Biological|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
79673764|NCT00468572|Behavioral|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
79673765|NCT00468572|Behavioral|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
79994811|NCT01702571|Drug|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
79220931|NCT02304822|Drug|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
79220932|NCT05532436|Other|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
79220933|NCT03359564|Procedure|micro endoscopic discectomy|the patients receive micro endoscopic discectomy surgery therapy
79364194|NCT06061718|Drug|iDose TR|anchored intracameral implant containing travoprost
79364195|NCT06061692|Drug|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
79364196|NCT06061679|Device|Omron C28P nebuliser|switch from portable inhalers to the Omron C28P nebuliser
79364197|NCT06061666|Other|Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)|Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
79515506|NCT05293548|Biological|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
79515507|NCT05157360|Drug|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
79515508|NCT05157360|Drug|Placebo|normal saline solution
79673766|NCT00499668|Drug|aprepitant|125 mg orally for 7 days
79515509|NCT05136066|Other|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
79515510|NCT04988412|Dietary Supplement|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
79515511|NCT04988412|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
79515512|NCT04988412|Dietary Supplement|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
79673767|NCT00499668|Drug|ondansetron hydrochloride|24 mg orally for 7 days
79673768|NCT00499707|Drug|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
79673769|NCT00468611|Drug|MBP8298|500mg MBP8298 IV every six months for a period of two years
79994812|NCT03675516|Other|No specific intervention|Usual care
79994813|NCT01637688|Dietary Supplement|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
79220934|NCT04688164|Drug|REL-1017|REL-1017 tablet
79220935|NCT04688164|Drug|Placebo|Placebo tablet
79220936|NCT02309424|Dietary Supplement|Vinegar|0,50mmol vinegar (6% acetic acid)
79220937|NCT02309424|Other|Placebo|50 ml water
79220938|NCT03359486|Behavioral|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
79220939|NCT03359486|Behavioral|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
79364198|NCT06061601|Device|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
79364199|NCT06061549|Biological|AAV1/SERCA2a|3E13 viral genomes fixed dose
79364200|NCT06061497|Other|Abdomino-diaphragmatic breathing|Breathing should be done twice a day for 10 minutes.
79364201|NCT06061497|Behavioral|Usual Care|Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
79364202|NCT06061484|Dietary Supplement|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
79364203|NCT06061484|Drug|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
79673770|NCT03270995|Behavioral|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
79673771|NCT03270995|Behavioral|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
79515513|NCT04988412|Dietary Supplement|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
79515514|NCT04943874|Device|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
79515515|NCT04943874|Device|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
79673772|NCT01366534|Biological|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
79673773|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
79673774|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
79994814|NCT05655000|Procedure|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
79994815|NCT01632930|Other|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
79994816|NCT03231943|Drug|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
79994817|NCT03231943|Drug|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
79994818|NCT01578239|Drug|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
79364204|NCT06061445|Combination Product|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
79673775|NCT01366534|Other|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
79673776|NCT00492843|Drug|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
79994819|NCT01578239|Drug|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
79994820|NCT05274893|Drug|SYHX2011 and Abraxane®|IV infusion, 260 mg/m^2
79220940|NCT03506178|Drug|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
79220941|NCT03506178|Drug|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
79220942|NCT03506178|Drug|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
79371116|NCT04951102|Behavioral|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
79515516|NCT04676802|Drug|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
79515517|NCT04676802|Drug|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
79515518|NCT04627896|Device|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
79515519|NCT04174482|Procedure|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
79673777|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
79994821|NCT01220531|Biological|Cultured Thymus Tissue|Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
79673778|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
79364205|NCT06061432|Procedure|Endoscopic restoration of gastrointestinal continuity after Hartmann procedure|EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
79673779|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
79673780|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
79673781|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
79673782|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
79673783|NCT03271775|Other|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
79994822|NCT01220531|Procedure|Blood Draw|
79994823|NCT01220531|Drug|Rabbit anti-thymocyte globulin|Three IV doses of 2 mg/kg RATGAM are given prior to implantation of cultured thymus tissue for immune suppression groups 2, 3, and 4. Each dose is given over 12 hours. RATGAM is usually given on days -5, -4, and -3 prior to implantation of cultured thymus tissue.
79994824|NCT01220531|Drug|Cyclosporine|Csa may be given every 8 or every 12 hours orally or IV before and after implantation of cultured thymus tissue for immune suppression groups 3 and 4. The Csa dose is dependent on T cell numbers and the target CSA trough levels. Csa is weaned as per protocol.
79364206|NCT06061419|Other|Huel Powder|Huel Powder v3.0 white, vanilla flavour
79364207|NCT06061406|Device|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
79364208|NCT06061380|Other|no intervation taken|
79364209|NCT06061341|Diagnostic Test|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
79364210|NCT06061315|Dietary Supplement|Effect of collagen peptides, in combination with resistance training, on body composition and muscle strength compared to placebo in untrained men|The effects of collagen peptide consumption in combination with resistance training will be tested
79364211|NCT06061315|Dietary Supplement|Placebo Control intervention: Effect of resistance training in combination with placebo (silicon dioxide), on body composition and muscle strength in untrained men|The effects of placebo consumption in combination with resistance training will be tested
79371117|NCT04951102|Behavioral|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
79515520|NCT03979560|Other|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
79515521|NCT03828708|Other|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
79515522|NCT03671304|Device|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
79515523|NCT03447990|Drug|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
79515524|NCT03447990|Drug|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
79994825|NCT01220531|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 or every 12 hours orally or IV before and after implantation of cultured thymus tissue. FK506 dose is dependent on T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
79515525|NCT03032640|Other|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
79515526|NCT03032640|Other|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
79515527|NCT03032640|Other|Stool sampling|Subjects will provide a stool sample.
79673784|NCT03271775|Other|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
79673785|NCT00499824|Behavioral|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
79994826|NCT01220531|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and/or after implantation of cultured thymus tissue. Steroid administration and dosage depends on T cell numbers. Steroids are weaned as per protocol.
79673786|NCT01365910|Drug|linifanib|Given PO
79364212|NCT06061289|Dietary Supplement|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
79673787|NCT00473798|Behavioral|Questionnaire|Questionnaire
79673788|NCT01605526|Drug|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
79364213|NCT06061276|Procedure|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
79364214|NCT06061276|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79364215|NCT06061276|Drug|Camrelizumab|200mg intravenously every 2 weeks
79364216|NCT06061263|Other|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
79673789|NCT01605526|Drug|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
79994827|NCT01220531|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) may be given if the T cell count remains elevated 5 days after implantation of cultured thymus tissue. If MMF is given, the dose is 15 mg/kg/dose every 8 hours IV or orally. MMF may be stopped at 35 days or continued for up to six months after implantation of cultured thymus tissue.
79673790|NCT00492882|Drug|usual administration of exogenous recombinant FSH|
79994828|NCT05572099|Diagnostic Test|ExoDx Prostate|Observational only.
79994829|NCT05255471|Drug|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
79994830|NCT05255471|Drug|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
79220943|NCT03506178|Device|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
79220944|NCT04519034|Other|no intervention|There will be no intervention
79220945|NCT02312778|Other|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
79515528|NCT03032640|Other|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
79673791|NCT00468689|Drug|SB-751689 oral tablets (100 and 400 ng)|
79673792|NCT00468689|Drug|Ketoconazole (NIZORAL) oral tablets (200 mg)|
79673793|NCT02274480|Device|cardiac MRI with DWI|
79673794|NCT00473915|Drug|fluticasone furoate|corticosteroid nasal spray
79679859|NCT02938065|Procedure|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
79679860|NCT02938065|Other|2% milk|16 participants will drink 10 ounces of 2% milk
79515529|NCT03032640|Other|Placebo|Subjects in group 2 will be provided with placebo.
79515530|NCT03032640|Other|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
79515531|NCT01376778|Drug|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
79994831|NCT03241927|Biological|Pembrolizumab|Day 1 of each 3 week cycle
79994832|NCT03936751|Device|CPAP|This is the standard treatment for OSA.
79515532|NCT01376778|Other|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
79515533|NCT01309074|Drug|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
79515534|NCT01309074|Drug|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
79515535|NCT01074294|Drug|OPDC-34712|OPDC-34712 tablets, daily, Orally.
79515536|NCT01074294|Drug|Placebo|Matching-placebo tablets, daily, Orally.
79515537|NCT01074294|Drug|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
79515538|NCT01074138|Drug|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
79515539|NCT00951132|Drug|rosuvastatin|10mg tablets, once daily in three months
79994833|NCT03936751|Device|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
79994834|NCT05571865|Dietary Supplement|Probiotic|Oral administration of a probiotic
79994835|NCT03329885|Drug|BMS-986251|Escalating oral dose
79994836|NCT03329885|Other|Placebo|Escalating oral dose
79364217|NCT06061224|Behavioral|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
79364218|NCT06061198|Device|a virtual reality device|the patient will wear a masque tht will provide a virtual reality experience using a VR Gear connected to a mobile phone through an application installed on the mobile phone
79364219|NCT06061120|Device|Recording of an extended high-resolution ECG|Recording of an extended high-resolution ECG
79364220|NCT06061094|Drug|Imatinib|Imatinib 600mg QD plus Chemotherapy
79364221|NCT06061094|Drug|Ponatinib|Ponatinib 45 mg QD plus chemotherapy
79364222|NCT06061094|Drug|Blinatumomab|Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
79364223|NCT06061094|Other|Indication for stem cell transplantation|Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
79364224|NCT06061081|Drug|VH3739937|VH3739937 will be administered.
79364225|NCT06061081|Drug|Placebo|Placebo will be administered.
79364226|NCT06061055|Device|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
79364227|NCT06061055|Device|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
79364228|NCT06061042|Behavioral|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
79364229|NCT06061042|Behavioral|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
79364230|NCT06061029|Behavioral|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
79515540|NCT00951132|Drug|Placebo|tablet, once daily, three months
79994837|NCT05255315|Behavioral|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
79994838|NCT04663841|Other|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
79994839|NCT00490763|Behavioral|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
79994840|NCT02941523|Drug|NOX66|NOX66 administration
79994841|NCT02941523|Drug|Carboplatin|Carboplatin administration
79994842|NCT03666143|Drug|Sitravatinib|120 mg orally once daily in combination with tislelizumab
79364231|NCT06060990|Other|trace elements|trace elements as biomarkers for response to systemic therapy in metastatic BTCs
79515541|NCT01710306|Behavioral|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
79515542|NCT01713660|Device|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
79515543|NCT01715064|Behavioral|Exercise|1 hour of moderate-intensity exercise
79515544|NCT01716468|Other|Ketogenic Diet|modified ketogenic diet
79515545|NCT01717014|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
79515546|NCT01717872|Device|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
79515547|NCT01718028|Other|Propylene glycol 0.6% ocular emulsion|
79515548|NCT01718028|Other|Sodium chloride 0.9% saline solution|
79673795|NCT00499902|Drug|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
79679861|NCT02938065|Other|apple juice|16 participants will drink 10 ounces of apple juice
79679862|NCT02938065|Other|ensure clear|16 participants will drink 10 ounces of ensure clear
79515549|NCT01719900|Dietary Supplement|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
79515550|NCT01719900|Dietary Supplement|Control|Control biscuit with no yellow pea hull fibre.
79994843|NCT03666143|Drug|Tislelizumab|200 mg IV once every 3 weeks
79994844|NCT03609203|Other|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
79994845|NCT03609203|Other|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
79515551|NCT01721226|Device|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
79673796|NCT00473954|Genetic|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
79515552|NCT01721226|Other|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
79515553|NCT01721460|Drug|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
79515554|NCT01722318|Drug|Plecanatide|
79515555|NCT01722318|Drug|Placebo|
79515556|NCT01722552|Behavioral|adherence feedback|
79515557|NCT01722552|Behavioral|standard of care|
79515558|NCT01723722|Drug|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
79515559|NCT01723722|Drug|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
79515560|NCT01728636|Drug|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
79515561|NCT01729338|Drug|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles [10,12,14, etc.]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
79515562|NCT01729338|Drug|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
79673797|NCT00468767|Drug|Vernakalant Injection 20 mg/mL|
79673798|NCT00493077|Drug|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
79673799|NCT00474071|Drug|Remifentanil|See Detailed Description.
79673800|NCT00468884|Drug|Increasing doses of GLP-1|
79673801|NCT00468884|Drug|PYY3-36|
79673802|NCT00474110|Drug|Ketamine & hydromorphone|See Detailed Description
79994846|NCT00360425|Drug|ferumoxytol|
79994847|NCT00360425|Drug|moxifloxacin|
79994848|NCT00360425|Drug|placebo|
79994849|NCT02938585|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
79994850|NCT02938585|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
79994851|NCT00233597|Drug|ferumoxytol or oral iron|
79673803|NCT00500058|Drug|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
79994852|NCT04661267|Dietary Supplement|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
79220946|NCT03354260|Other|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
79220947|NCT02304900|Other|white implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant~nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
79515563|NCT01729338|Drug|Revlimid|"Lenalidomide (odd cycles [9,11,13, etc.]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
79994853|NCT04661267|Dietary Supplement|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
79515564|NCT01729494|Drug|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
79515565|NCT01729494|Drug|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
79515566|NCT01729494|Drug|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
79515567|NCT01729494|Drug|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
79994854|NCT05571631|Other|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
79994855|NCT04282811|Drug|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
79220948|NCT02304900|Other|yellow implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant~nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
79220949|NCT04517006|Behavioral|Self-focused acts|Completion of daily acts for personal enjoyment.
79220950|NCT04517006|Behavioral|Prosocial acts|Completion of daily acts for the benefit of others.
79515568|NCT01729494|Drug|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
79515569|NCT01729494|Drug|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
79994856|NCT05220059|Dietary Supplement|Polyphenol extract|Single dose
79515570|NCT05317338|Behavioral|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
79515571|NCT05317260|Drug|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
79515572|NCT05316948|Other|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
79994857|NCT05220059|Dietary Supplement|Placebo|Maltodextrin
79994858|NCT03229759|Drug|Octenidine Dihydrocloride in aqueous solution|application of investigational product
79994859|NCT03229759|Other|Vehicle Control|application of vehicle control
79994860|NCT03229759|Other|Saline Control|application of placebo
79994861|NCT03558191|Drug|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
79994862|NCT03476681|Drug|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
79994863|NCT03620825|Other|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
79994864|NCT03620825|Drug|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
79994865|NCT01312649|Behavioral|Experimental psychology methods (computer tests)|
79220951|NCT03503214|Diagnostic Test|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
79220952|NCT03503214|Diagnostic Test|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
79220953|NCT02578186|Drug|Diphenhydramine Hydrochloride|30 mL at bedtime
79220954|NCT02578186|Drug|Placebo|30 mL at bedtime
79220955|NCT02304978|Biological|Group CRC|blood samples
79220956|NCT02304978|Biological|Group control|Blood samples
79220957|NCT03123458|Biological|clonal fetal MSCs|
79220958|NCT05530876|Other|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
79364232|NCT06060964|Other|Breathe Easier Progressive Web Application|The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
79220959|NCT03123224|Behavioral|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
79220960|NCT03123224|Behavioral|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
79220961|NCT02305056|Drug|C13 N15 Valine|C13 N15 Valine administration
79220962|NCT03506100|Other|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
79220963|NCT03123146|Behavioral|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
79515573|NCT05316870|Behavioral|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
79515574|NCT05316870|Behavioral|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
79673804|NCT00500058|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered by IV infusion.
79673805|NCT00468923|Drug|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
79364233|NCT06060951|Diagnostic Test|Estimated intraperitoneal pressure|"The following anthropometric measurements are required:~Height: measured standing with shoes off~Weight: dry weight should be used~The distance from the decubitus plane to the mid-axillary line was measured~Waist circumference: measured with a tape measure wrapped above the iliac crests around the level of the umbilicus.~The estimated IPP will be assessed using different equations."
79673806|NCT00468923|Drug|Rosuvastatin|Rosuvastatin 10 mg once daily
79364234|NCT06060925|Diagnostic Test|Ultrasound imaging|B-mode, color Doppler, shear wave elastography
79364235|NCT06060925|Diagnostic Test|Bioimpedance spectroscopy|Multifrequency bioimpedance spectroscopy
79515575|NCT05316792|Other|walking|30 min walking on the treadmill and tartan floor
79515576|NCT05316636|Device|Vibrational forces|
79515577|NCT05316636|Procedure|Orthodontic treatment with clear aligners|
79515578|NCT05316480|Drug|Nimotuzumab|nimotuzumab 200mg/week
79515579|NCT05316402|Other|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
79515580|NCT05316402|Other|dosimetry|dosimetry
79673807|NCT00500097|Device|Digital retina image|
79673808|NCT00500097|Device|direct ophthalmoscopy|
79673809|NCT00500097|Procedure|comprehensive eye exam|
79673810|NCT01365481|Drug|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
79673811|NCT01365481|Drug|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
79673812|NCT01365481|Drug|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
79673813|NCT03271619|Other|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
79673814|NCT01605604|Behavioral|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
79673815|NCT00493116|Drug|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
79673816|NCT00493116|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
79673817|NCT00468962|Drug|FACOS (functional food)|
79673818|NCT01605682|Dietary Supplement|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
79673819|NCT00493155|Drug|RG1530|Administered po at escalating doses (10 cohorts)
79673820|NCT01357915|Procedure|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
79515581|NCT05316246|Drug|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
79515582|NCT05316090|Procedure|Core stability exercises program|Strengthening to the trunk muscles
79673821|NCT01357915|Biological|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
79673822|NCT00474227|Behavioral|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
79673823|NCT00493194|Drug|sirolimus|
79673824|NCT00493194|Drug|cyclosporine|
79364236|NCT06060925|Diagnostic Test|Electromyography|High density electromyography
79364237|NCT06060925|Diagnostic Test|Physical examination|Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
79364238|NCT06060886|Drug|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
79364239|NCT06060886|Drug|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
79364240|NCT06060834|Dietary Supplement|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
79364241|NCT06060808|Genetic|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
79364242|NCT06060795|Diagnostic Test|Electro-conductance measurement|Interventions are done to diagnose Autonomic Nervous system Troubles
79673825|NCT00493194|Drug|daclizumab|
79673826|NCT01350973|Drug|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
79673827|NCT01350973|Drug|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
79364243|NCT06060782|Drug|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
79673828|NCT00500136|Procedure|mortality salience|
79673829|NCT03270722|Device|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
79673830|NCT03270722|Procedure|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
79673831|NCT01350544|Behavioral|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
79673832|NCT01350505|Behavioral|White light exposure|~200 lux of broad spectrum white light
79673833|NCT01350505|Behavioral|Dim white light exposure|~28 lux of broad spectrum white light
79673834|NCT01350505|Behavioral|Very dim white light exposure|<0.5 lux of broad spectrum white light
79220964|NCT02309502|Device|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
79220965|NCT02309502|Device|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
79364244|NCT06060743|Other|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
79364245|NCT06060717|Device|F&P Caramel|Nasal mask
79673835|NCT01350505|Behavioral|Dim orange light exposure|~28 lux of orange light
79673836|NCT00500175|Device|TempTouchRM|
79673837|NCT00500175|Device|Offloading|
79673838|NCT00469001|Procedure|Treatment according NT Pro BNP level|
79673839|NCT01605721|Device|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
79220966|NCT04128436|Other|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
79220967|NCT03354182|Procedure|Open flap surgery|Elevation of a flap in order to access the treated furcation
79220968|NCT03354182|Device|Bio-oss collagen|Biomaterial for periodontal surgery
79220969|NCT03354182|Device|Bio-gide|Biomaterial for periodontal surgery
79220970|NCT02313012|Drug|CC-90003|CC-90003 PO once daily
79220971|NCT03359330|Other|Degradable Conduit Small Gap Tublization|Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
79364246|NCT06060574|Device|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
79364247|NCT06060561|Other|Non-Interventional Study|Non-interventional study
79364248|NCT06060535|Behavioral|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
79364249|NCT06060483|Device|CGM|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR>70%, TBR<4%, TAR<25%, and HbA1c<7.0%. After the treatment reaches the standard, CGM is worn every six months.
79364250|NCT06060444|Other|Telemedicine Consult|Neurological consultation completed remotely
79364251|NCT06060444|Other|In-person Consult|Neurological consultation completed in-person
79364252|NCT06060431|Other|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
79364253|NCT06060327|Drug|Tranexamic acid|Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
79364254|NCT06060314|Procedure|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
79364255|NCT06060314|Procedure|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
79364256|NCT06060301|Drug|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
79673840|NCT01605760|Drug|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
79673841|NCT00469040|Drug|GW642444M for 14 days|M salt
79673842|NCT01350271|Drug|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
79673843|NCT01350271|Drug|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
79364257|NCT06060301|Drug|corticosteroids|The patients will use topical corticosteroids 4 times per day.
79364258|NCT06060184|Genetic|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
79364259|NCT06060158|Behavioral|Cognitive Behavioral Therapy for Insomnia|6 sessions
79364260|NCT06060145|Other|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
79673844|NCT01350271|Drug|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
79673845|NCT00469118|Device|DRX9000™|Nonsurgical spinal decompression
79673846|NCT00474305|Behavioral|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
79364261|NCT06060145|Other|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
79673847|NCT00493233|Drug|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
79673848|NCT00493233|Drug|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
79673849|NCT00469157|Drug|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
79673850|NCT00500214|Procedure|elective ilioinguinal nerve excision|
79994866|NCT01312727|Other|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
79515583|NCT05316090|Procedure|Traditional physical therapy program|Neurodevelopmental training excercises
79515584|NCT05315856|Biological|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
79515585|NCT05315778|Biological|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
79364262|NCT06060132|Drug|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
79515586|NCT05315466|Procedure|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
79515587|NCT05315466|Procedure|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
79220972|NCT03506022|Other|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram [chin], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
79220973|NCT02309658|Drug|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
79364263|NCT06060119|Device|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
79364264|NCT06060106|Procedure|Endoscopic submucosal dissection|The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
79364265|NCT06060106|Procedure|Esophagectomy|The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
79364266|NCT06060093|Dietary Supplement|Placebo|Water, 5% collagen(w/w), octoacetate (1 mM)
79515588|NCT05315388|Other|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
79515589|NCT05315154|Procedure|No axillary surgery|In the study arm will be omitted surgery in axilla
79515590|NCT05315154|Procedure|SLNB|in the control arm will be realized SLNB
79515591|NCT05309850|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
79515593|NCT05237232|Other|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
79673851|NCT03270410|Other|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
79673852|NCT00493272|Drug|Fibrinogen|Fibrinogen behandling
79673853|NCT00500253|Device|exhaled nitric oxide measurement|exhaled nitric oxide measurement
79994867|NCT03228433|Drug|TAK-418|TAK-418 Capsule.
79220974|NCT02309658|Drug|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
79515594|NCT05237232|Other|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling & Simulation) requires several inputs:~The MRA images~The cardiac function curve~The cerebral blood flow~Measurement of systolic, diastolic and mean arterial blood pressure"
79673854|NCT00500253|Procedure|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
79220975|NCT02309658|Radiation|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
79994868|NCT03228433|Drug|TAK-418 Placebo|TAK-418 placebo-matching capsules.
79220976|NCT04508738|Other|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
79220977|NCT04508738|Other|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
79220978|NCT02309736|Device|ReSure Sealant|
79220979|NCT05532280|Drug|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
79364267|NCT06060093|Dietary Supplement|Ketone ester|A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
79364268|NCT06060080|Drug|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
79364269|NCT06060067|Biological|TDV|TDV SC injection on Day 1 and Day 90 of the study
79364270|NCT06060067|Biological|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
79364271|NCT06060015|Drug|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
79994869|NCT04463797|Other|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
79364272|NCT06060015|Drug|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
79364273|NCT06060002|Procedure|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
79364274|NCT06060002|Diagnostic Test|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
79364275|NCT06059989|Drug|Infliximab subcutaneous|Mono and combination therapy group
79364276|NCT06059989|Drug|Immunosuppressive Agents|Combination group only
79364277|NCT06059950|Behavioral|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
79673855|NCT00500253|Procedure|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
79673856|NCT00469196|Procedure|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
79821077|NCT00728793|Drug|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
79994870|NCT04463797|Other|Stretching and strengthening|whole-body stretching and upper extremity strengthening
79994871|NCT03930121|Other|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
79994872|NCT01496118|Drug|panobinostat|Specified dose on specified days
79994873|NCT01496118|Drug|carfilzomib|Specified dose on specified days
79364278|NCT06059937|Other|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
79220980|NCT05532280|Drug|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
79220981|NCT04508426|Drug|[14C]AR882|Single dose of [14C]AR882
79364279|NCT06059924|Other|Anastomotic leakage|Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
79515595|NCT05202366|Drug|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
79994874|NCT02936869|Behavioral|Performance-based monetary incentives|
79994875|NCT05083884|Other|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
79994876|NCT03606096|Biological|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
79515596|NCT05009706|Other|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
79515597|NCT04894188|Radiation|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
79515598|NCT04894188|Drug|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
79515599|NCT04894188|Procedure|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
79364280|NCT06059898|Device|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
79364281|NCT06059898|Procedure|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
79515600|NCT04866420|Behavioral|The MenFAS Study|A cross over repeated exposure randomized design observational study
79515601|NCT04775628|Procedure|Inferior glide humerus in GH joint|Supine inferior glide GH joint
79515602|NCT04769544|Device|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
79515603|NCT04767750|Other|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~Total RNA extraction from PBMCs by Trizol reagent and spin column.~Reverse transcription to cDNA.~The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
79515604|NCT04724772|Drug|Tranexamic acid injection|Injection of tranexamic acid preoperatively
79515605|NCT04717518|Other|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
79994877|NCT03606096|Biological|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
79515606|NCT04696614|Behavioral|exercise|intervention groups provided different sequential modality of exercise
79515607|NCT04648878|Other|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
79515608|NCT04648878|Other|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
79515609|NCT04648878|Other|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
79515610|NCT04398264|Other|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
79515611|NCT04379076|Drug|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
79515612|NCT04379076|Drug|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
79515613|NCT04320498|Biological|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
79673857|NCT03270566|Device|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
79220984|NCT04508114|Behavioral|Technology-assisted Index|The participant will be informed the ATP testing result and explanation in pretest.
79220985|NCT02305134|Drug|Tipepidine Hibenzate|
79220986|NCT02305134|Drug|Placebo|
79220987|NCT05532202|Behavioral|NICU Mom and Baby Net|See arm descriptions.
79220988|NCT05532202|Other|NICU Developmental Awareness System|See arm description.
79673858|NCT00469235|Drug|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
79994878|NCT03606096|Biological|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
79220989|NCT00103311|Drug|ispinesib|Given IV
79220990|NCT00103311|Other|laboratory biomarker analysis|Correlative studies
79220991|NCT04517162|Drug|Collagen-Polyvinylpyrrolidone|1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
79220992|NCT02305212|Behavioral|Cogmed|
79220993|NCT02155023|Drug|Insulin dosing|
79515614|NCT04320498|Drug|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
79364282|NCT06059885|Drug|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
79673859|NCT01243788|Drug|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
79673860|NCT03270605|Procedure|Myomectomy|Surgical removal of uterine fibroid
79994879|NCT03606096|Biological|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
79994880|NCT03309605|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
79821078|NCT00728871|Procedure|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
79994881|NCT03309605|Drug|Placebo|Placebo
79220994|NCT02155023|Device|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
79220995|NCT04444232|Other|Media Intervention|View an educational video
79220996|NCT04444232|Other|Survey Administration|Complete survey
79220997|NCT03542721|Drug|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
79364283|NCT06059859|Procedure|Augmented reality robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
79364284|NCT06059859|Device|Mixed reality intraoperative frozen section analysis|Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
79220998|NCT03542721|Drug|Placebo of DA-5515|Placebo (three times a day)
79364285|NCT06059859|Procedure|Robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
79364286|NCT06059833|Diagnostic Test|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
79364287|NCT06059807|Device|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
79371118|NCT04951102|Behavioral|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
79371119|NCT04951102|Behavioral|Standard Care|Standard Care for asthma.
79515615|NCT04320498|Behavioral|sitz bath|participants were told to take a hot water sitz bath once a day
79515616|NCT04320498|Dietary Supplement|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
79515617|NCT04270500|Behavioral|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
79673861|NCT01243827|Drug|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
79673862|NCT01243827|Drug|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
79220999|NCT02305368|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
79673863|NCT00500409|Drug|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
79221000|NCT05530564|Procedure|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
79221001|NCT05530564|Procedure|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
79221002|NCT04507958|Diagnostic Test|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
79673864|NCT00500409|Drug|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
79673865|NCT00469352|Drug|Ranibizumab|Ranibizumab as needed
79673866|NCT01243866|Other|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
79821079|NCT00736281|Other|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
79821080|NCT00736437|Drug|ME-609|Cream applied topically 6 times daily over the UVR exposed area
79515618|NCT04187742|Behavioral|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
79515619|NCT04187742|Behavioral|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
79515620|NCT04187742|Behavioral|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
79515621|NCT04086732|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
79515622|NCT03878472|Drug|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
79994882|NCT02936635|Drug|tirasemtiv|Oral
79221003|NCT04507958|Diagnostic Test|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
79221004|NCT05530486|Device|CC|Application of placebo LASER
79221005|NCT05530486|Device|LG1|Application of LASER GasAs 660nm 4 J/cm².
79221006|NCT05530486|Device|LG2|Application of LASER GasAs 660nm 8 J/cm².
79221007|NCT05530486|Device|LG3|Application of LASER GasAs 660nm 12 J/cm².
79221008|NCT05530486|Procedure|Dressing|Application of Helianthus annuus oil dressing.
79221009|NCT04444388|Dietary Supplement|cocoa|Sachets of 5 grams of cocoa daily supplementation
79221010|NCT04444388|Dietary Supplement|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
79364288|NCT06059781|Other|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
79515623|NCT03878472|Drug|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
79515624|NCT03878472|Drug|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
79515625|NCT03878472|Drug|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
79515626|NCT03772626|Device|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
79515627|NCT03721926|Other|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
79821081|NCT00736437|Drug|Vehicle|Treatment applied 6 times daily over the UVR exposed area
79994883|NCT03227029|Biological|RSV ΔNS2/Δ1313/I1314L|10^6 plaque-forming units (PFU); administered as nose drops
79221011|NCT02163213|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
79371120|NCT03030196|Drug|Denosumab|NaCl 0.9% injection is used as placebo
79994884|NCT03227029|Biological|RSV 276|10^5 PFU; administered as nose drops
79994885|NCT03227029|Biological|Placebo|Isotonic diluent, administered as nose drops
79994886|NCT05571475|Other|Simulated competition|During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
79994887|NCT03487614|Behavioral|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
79221012|NCT02305602|Biological|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
79221013|NCT04443920|Drug|Tranexamic acid (TXA)|Randomly assigned [1:1 ratio] using a computer generated table of random numbers to 1 of the 2 intervention groups
79221014|NCT04443920|Drug|Placebo Normal Saline (NS)|Randomly assigned [1:1 ratio] using a computer generated table of random numbers to 1 of the 2 intervention groups
79673867|NCT01243866|Other|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
79673868|NCT00469430|Drug|cefotaxim and metronidazol|iv administration for at least 24 h
79673869|NCT00500487|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
79673870|NCT00500487|Behavioral|HIV Prevention Skills|12-session group intervention including sexual health skills training.
79673871|NCT00500487|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of health topics.
79673872|NCT00474422|Behavioral|Proactive assignment to attend a breastfeeding clinic|
79673873|NCT01243905|Other|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
79221015|NCT02309814|Device|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
79221016|NCT03542643|Dietary Supplement|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
79221017|NCT03542643|Dietary Supplement|Placebo|Olive oil ethyl esters
79364289|NCT06059781|Other|Rhtyhmical auditory stimulation (Control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
79364290|NCT06059755|Other|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
79515628|NCT03721926|Other|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
79673874|NCT01243905|Other|Treatment as usual|Treatment as usual administered by physicians
79673875|NCT00474461|Biological|Treatment group|Intracoronary injection of cardiac stem cells
79673876|NCT00500526|Other|Singing practice|
79673877|NCT00500526|Other|Singing classes|
79673878|NCT00500526|Other|Hand craft classes|
79821082|NCT00736515|Drug|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
79821083|NCT00736515|Drug|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
79821084|NCT00731367|Device|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
79221018|NCT02313090|Other|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
79221019|NCT03359018|Drug|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
79221020|NCT03359018|Drug|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
79673879|NCT03270488|Other|Laser|Laser (power of 3.0w).
79673880|NCT03270488|Other|Placebo|Laser (power 0,0w)
79673881|NCT00493350|Procedure|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
79673882|NCT00469469|Drug|Bevacizumab|
79673883|NCT00500565|Drug|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
79673884|NCT00500565|Drug|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
79673885|NCT03270293|Device|Profhilo|
79221021|NCT05530252|Drug|Oral biological antimicrobial gel|The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
79515629|NCT03681912|Behavioral|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
79515630|NCT03681912|Behavioral|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
79515631|NCT03681912|Behavioral|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
79515632|NCT03485820|Behavioral|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
79821085|NCT00731367|Device|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
79364291|NCT06059755|Other|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
79221022|NCT05530252|Drug|minocycline hydrochloride ointment|The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
79364292|NCT06059742|Other|Action Observation Therapy with Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
79221023|NCT05530252|Other|SRP|only scaling and root planning was performed on the patient
79364293|NCT06059742|Other|Action Observation Therapy without Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
79364294|NCT06059716|Behavioral|Continuous telemedicine monitoring plus gluten detection technology|Portable technologies to sense gluten before or after ingestion
79364295|NCT06059716|Behavioral|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
79515633|NCT03485820|Behavioral|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
79821086|NCT00731445|Drug|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
79821087|NCT00736593|Drug|Nexagon™ or Nexagon™ vehicle|
79821088|NCT02569359|Dietary Supplement|shea nut oil extract|
79821089|NCT02569359|Other|Placebo|
79821090|NCT00731523|Drug|fingolimod (FTY720)|
79821091|NCT02569125|Drug|Everolimus|4.5 mg/m² daily
79821092|NCT00731601|Drug|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
79221024|NCT03505866|Behavioral|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
79364296|NCT06059703|Procedure|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
79364297|NCT06059703|Procedure|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
79364298|NCT06059703|Procedure|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
79364299|NCT06059690|Diagnostic Test|pH Measurement of in vivo tissue|The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
79364300|NCT06059677|Drug|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
79515634|NCT03404076|Diagnostic Test|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
79515635|NCT03245580|Diagnostic Test|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
79515636|NCT03162510|Drug|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
79515637|NCT03162510|Drug|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
79515638|NCT03162510|Drug|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
79221025|NCT02305524|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
79221026|NCT02305524|Device|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
79221027|NCT02163291|Drug|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
79221028|NCT03358940|Other|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
79221029|NCT05532124|Biological|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
79221030|NCT05532124|Other|normal saline|Intravenous Injection
79221031|NCT03358862|Device|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
79221032|NCT02313168|Other|observation, inspection|
79221033|NCT03354104|Device|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
79364301|NCT06059677|Drug|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
79364302|NCT06058546|Drug|Jiuweihuaban Pill placebo|Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
79364303|NCT06058546|Drug|low dose Jiuweihuaban Pill|Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
79364304|NCT06058546|Drug|high dose Jiuweihuaban Pill|High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
79515639|NCT03162510|Drug|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
79515640|NCT03049644|Procedure|Mechanical Diagnosis and Therapy|Identification of directional preference.
79821093|NCT00731601|Drug|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
79821094|NCT02568969|Device|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
79821095|NCT02569593|Dietary Supplement|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
79221034|NCT03354104|Device|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
79221035|NCT05531968|Biological|BMI2006|IM
79221036|NCT05531968|Biological|BOTOX®|IM
79221037|NCT03354026|Drug|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
79221038|NCT03354026|Drug|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
79364305|NCT06058468|Procedure|Cardioneuroablation of right anterior ganglionated plexus|Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration >30% is achieved or if radiofrequency time exceeds 120 seconds.
79221039|NCT03354026|Drug|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
79221040|NCT05524792|Other|no interventional study|no interventional study
79221041|NCT02309892|Drug|L-DOS47|A treatment cycle will be 21 days, with patients receiving L DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
79221042|NCT02163369|Drug|Peppermint and Lavender Essential Oils|
79221043|NCT03505788|Drug|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
79221044|NCT03505788|Drug|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
79221045|NCT03358784|Procedure|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
79221046|NCT03358784|Procedure|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
79515641|NCT03049644|Procedure|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
79515642|NCT02996760|Drug|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
79515643|NCT02987946|Device|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
79515644|NCT02987946|Drug|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
79515645|NCT02733900|Procedure|femoral head removal|
79515646|NCT02718300|Drug|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
79515647|NCT02718300|Drug|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
79515648|NCT02718300|Drug|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
79221047|NCT04967313|Behavioral|Behavioral Change Techniques|"Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~Action planning: prompt detailed planning of performance of behavior (must include a setting [walking to the mailbox], frequency, duration, and intensity. Example: Develop a plan to walk today.~Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline."
79221048|NCT02309970|Drug|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
79221049|NCT02309970|Drug|alteplase|subject in this group will receive intravenous tPA
79821096|NCT02569281|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
79221050|NCT02309970|Procedure|endovascular|
79364306|NCT06058468|Procedure|Pulmonary vein isolation|Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
79515649|NCT02718300|Drug|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
79515650|NCT02718300|Drug|Parsaclisib|"2 dose strategies will be compared:~5 mg parsaclisib beginning on Day 1 until end of treatment.~20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
79515651|NCT02542644|Device|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
79515652|NCT02394132|Drug|Imiquimod|
79221051|NCT03353948|Drug|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
79515653|NCT02394132|Radiation|Radiotherapy|
79221052|NCT03353948|Drug|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
79221053|NCT02161653|Drug|Prednisone plus Metadoxine|
79221054|NCT02161653|Drug|Pentoxifylline plus Metadoxine|
79221055|NCT03386526|Drug|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
79221056|NCT02576938|Drug|Baricitinib|Administered orally
79221057|NCT02576938|Drug|Placebo|Administered orally
79221058|NCT02576938|Drug|Triamcinolone (Optional)|Administered topically
79221059|NCT03358628|Other|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
79221060|NCT02163603|Procedure|Pelvic osteotomy|
79221061|NCT03505632|Device|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
79364307|NCT06058026|Other|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
79364308|NCT06057896|Dietary Supplement|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
79364309|NCT06057714|Combination Product|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
79364310|NCT06057662|Other|personalized comprehensive diabetes support|personalized comprehensive diabetes support
79515654|NCT02102880|Genetic|the polymerase chain reaction (PCR)|
79821097|NCT02569281|Other|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
79821098|NCT02202681|Device|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
79821099|NCT02568813|Behavioral|Multiscore Depression Inventory for Children scale|
79515655|NCT01894542|Dietary Supplement|Cod protein from presscake|6g protein per day for 8wk
79221062|NCT03505632|Device|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
79221063|NCT03355586|Combination Product|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
79515656|NCT01894542|Dietary Supplement|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
79673886|NCT01243983|Drug|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
79673887|NCT00469547|Other|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
79221064|NCT03542487|Behavioral|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
79221065|NCT03542487|Behavioral|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
79221066|NCT03542487|Behavioral|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
79221067|NCT03542487|Behavioral|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
79221068|NCT03355508|Device|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
79221069|NCT02313246|Behavioral|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
79221070|NCT05524636|Device|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
79515657|NCT01894542|Dietary Supplement|Control|
79515658|NCT00700596|Drug|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
79515659|NCT00700596|Drug|Placebo|Control or Placebo SA (30 % ethanolic solution)
79515660|NCT01733472|Drug|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
79515661|NCT01733472|Drug|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
79515662|NCT01736358|Drug|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
79515663|NCT01736358|Drug|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
79515664|NCT01737684|Drug|Vibegron|50 mg tablet, oral
79515665|NCT01740258|Radiation|Radiation Therapy|
79515666|NCT01740258|Drug|Temozolomide|
79515667|NCT01740258|Drug|Bevacizumab|
79515668|NCT01740414|Drug|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
79515669|NCT01740414|Drug|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
79673888|NCT00469547|Drug|Placebo|15% ethanol in emollient gel used as a topical male microbicide
79673889|NCT00469547|Other|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
79673890|NCT00500604|Drug|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
79673891|NCT00500604|Drug|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
79673892|NCT00500604|Drug|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
79673893|NCT03270215|Procedure|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
79515670|NCT01740726|Behavioral|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
79515671|NCT01740726|Drug|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
79515672|NCT01741350|Behavioral|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
79673894|NCT01348828|Device|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
79994888|NCT05015634|Other|Active Arm|Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.
79994889|NCT05015634|Other|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
79673895|NCT00493389|Drug|Adrenocorticotrophic hormone|
79994890|NCT03329573|Drug|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
79221071|NCT05524636|Other|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
79221072|NCT02310048|Drug|MT-1303-FormA|
79221073|NCT02310048|Drug|MT-1303-FormB|
79221074|NCT03355430|Procedure|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
79221075|NCT03355430|Procedure|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
79221076|NCT02305836|Procedure|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
79221077|NCT02305836|Drug|donepezil|cholinesterase inhibitors (ChE-Is)
79364311|NCT06057636|Behavioral|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
79673896|NCT03270254|Device|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
79994891|NCT03329573|Drug|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
79994892|NCT00604201|Biological|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
79994893|NCT00492349|Drug|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
79364312|NCT06057636|Behavioral|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
79364313|NCT06057623|Other|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
79364314|NCT06057610|Drug|SHR-A1811 Injection|SHR-A1811 Injection
79515673|NCT01741350|Behavioral|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
79515674|NCT01741272|Procedure|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
79515675|NCT01741272|Procedure|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
79515676|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
79673897|NCT01348789|Device|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
79673898|NCT01605994|Drug|BMS-933043|
79673899|NCT01605994|Drug|Placebo matching with BMS-933043|
79994894|NCT00492349|Drug|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
79994895|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
79364315|NCT06057610|Drug|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
79821100|NCT04065633|Drug|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
79821101|NCT04065633|Drug|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
79221078|NCT04522934|Behavioral|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
79821102|NCT04065633|Drug|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
79821103|NCT04065633|Drug|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
79821104|NCT00731835|Procedure|Endovascular Revascularization|"angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~stent placement~atherectomy"
79821105|NCT03903237|Other|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
79821106|NCT00736905|Drug|TMC278|
79221079|NCT04522934|Behavioral|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
79364316|NCT06057610|Drug|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
79364317|NCT06057584|Behavioral|somatosensory-motor integration training|Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
79994896|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
79994897|NCT03308825|Biological|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
79994898|NCT04235855|Device|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
79515677|NCT01742208|Drug|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
79515678|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
79994899|NCT04235855|Device|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
79221080|NCT02161809|Behavioral|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
79221081|NCT03353714|Other|Pudendal block|Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
79221082|NCT02576860|Drug|CLS001 (Omiganan)|Topical gel
79221083|NCT02576860|Drug|Vehicle|Vehicle gel
79515679|NCT01742364|Device|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
79515680|NCT01742364|Device|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
79515681|NCT01745952|Device|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
79515682|NCT01745952|Device|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
79515683|NCT01745952|Device|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
79221084|NCT03503136|Drug|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
79221085|NCT03503136|Drug|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
79221086|NCT03503136|Drug|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
79515684|NCT01746264|Dietary Supplement|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
79673900|NCT01605994|Drug|Antacid Buffer Predose Solution|
79673901|NCT01606033|Other|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
79673902|NCT01606033|Other|questionnaire|understanding of the implications of participating in a clinical trial
79673903|NCT00500721|Drug|HCV-796|HCV-796 500mg BID x 14 days
79673904|NCT00500721|Drug|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
79673905|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
79821107|NCT00736983|Drug|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
79821108|NCT00736983|Drug|ciprofloxacin|12 weeks; daily 2 x 500mg
79821109|NCT00713349|Drug|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
79821110|NCT00713349|Other|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
79994900|NCT05196503|Biological|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
79221087|NCT03503136|Drug|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
79364318|NCT06057584|Behavioral|pure somatosensory training|Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
79364319|NCT06057584|Behavioral|pure motor training|Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
79515685|NCT01746420|Drug|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
79515686|NCT01746420|Drug|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
79515687|NCT01748916|Other|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
79515688|NCT01748916|Other|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
79994901|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
79994902|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
79221088|NCT03503136|Drug|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
79515689|NCT01748916|Other|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
79994903|NCT03476603|Drug|Irbesartan|Patients are tested for their normal prescription irbesartan medication
79994904|NCT03476525|Drug|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
79221089|NCT03503136|Drug|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
79364320|NCT06057558|Biological|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
79364321|NCT06057545|Drug|Envarsus®|Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
79515690|NCT01749930|Drug|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
79515691|NCT01749930|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening.
79515692|NCT01749930|Drug|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
79515693|NCT01750086|Drug|Teriparatide 40-mcg subcutaneous injection|
79515694|NCT01750086|Drug|Denosumab Injection|One-time Denosumab injection
79673906|NCT00469586|Drug|metformin|Tablets, 2000 mg/day.
79673907|NCT00469586|Drug|glimepiride|Tablets, 4 mg/day.
79673908|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
79673909|NCT01606111|Drug|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
79221090|NCT04445168|Behavioral|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
79221091|NCT02305992|Procedure|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
79221092|NCT02305992|Procedure|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
79364322|NCT06057545|Drug|Prograf|Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
79515695|NCT01750086|Drug|Alendronate Oral Tablet|weekly alendronate for 8 weeks
79515696|NCT01750398|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
79515697|NCT01750398|Drug|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
79515698|NCT01750398|Drug|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
79673910|NCT01606111|Drug|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
79673911|NCT01606267|Other|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
79515699|NCT01751022|Device|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
79515700|NCT01752426|Other|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
79221093|NCT02305992|Procedure|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
79515701|NCT01752426|Drug|PCI-32765|420 mg orally once daily.
79515702|NCT01753362|Drug|liraglutide|
79515703|NCT01753362|Drug|placebo|
79515704|NCT01757964|Biological|Bacteriotherapy|
79515705|NCT01758588|Drug|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
79673912|NCT00493428|Drug|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
79673913|NCT01342510|Drug|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
79221094|NCT03355352|Drug|Sufentanil|Sufentail sublingual 15ug nanopills
79221095|NCT05529940|Drug|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
79221096|NCT02313324|Device|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
79221097|NCT02313324|Device|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
79221098|NCT03353636|Dietary Supplement|Magnesium|150mg elemental magnesium
79221099|NCT03353636|Dietary Supplement|Placebo|Rice flour
79221100|NCT05524558|Device|Pulmonary artery catheter|PAC already in place
79221101|NCT05524558|Device|Esophagal pressure|Esophagal pressure already in place
79364323|NCT06057532|Dietary Supplement|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
79364324|NCT06057532|Dietary Supplement|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
79364325|NCT06057506|Device|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
79364326|NCT06057506|Device|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
79364327|NCT06057441|Device|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
79515706|NCT01759602|Drug|C1-esterase inhibitor (Cinryze)|
79221102|NCT04463160|Other|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
79221103|NCT04523402|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
79364328|NCT06057441|Device|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
79673914|NCT01342510|Drug|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
79673915|NCT01342510|Drug|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
79673916|NCT01342510|Drug|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
79364329|NCT06057415|Procedure|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
79364330|NCT06057389|Dietary Supplement|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
79364331|NCT06057376|Other|Low-FODMAP diet group (LFD)|Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.
79515707|NCT01760304|Drug|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
79673917|NCT01606345|Drug|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
79221104|NCT04463784|Drug|Efavirenz 400Mg Oral Tablet|The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
79515708|NCT01760304|Drug|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
79515709|NCT01761084|Behavioral|Exercise and behaviour change strategies|"cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~perform muscle strengthening and balance training exercises ≥ 3 days a week~the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
79515710|NCT01762722|Device|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
79515711|NCT01763346|Drug|Metformin|metformin 1000 mg bid
79515712|NCT01763346|Device|gastric banding|LAP-BAND
79515713|NCT01763970|Radiation|SBRT|
79821111|NCT00729261|Procedure|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
79221105|NCT04463784|Drug|Efavirenz 600Mg Oral Tablet|The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
79221106|NCT04507880|Device|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
79221107|NCT04507880|Device|Hemiarthroplasty|The shoulder hemiarthroplasty
79221108|NCT02310282|Device|Telemedicine|In-hospital telemedicine
79221109|NCT03355196|Drug|LRX712|Ascending single dose on Day 1
79221110|NCT03355196|Drug|Placebo|Ascending single dose on Day 1
79515714|NCT01765530|Device|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
79515715|NCT01766466|Drug|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
79673918|NCT01244022|Procedure|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
79673919|NCT00474500|Drug|Coca, Cola, Diet Coke|
79364332|NCT06057376|Other|Low Sugar diet group (LAS)|Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.
79673920|NCT01245894|Drug|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
79673921|NCT01245894|Drug|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
79673922|NCT00469625|Drug|paricalcitol (initial dose 1 mcg orally per day)|
79673923|NCT01316367|Behavioral|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
79364333|NCT06057363|Other|volumetric evaluation of gingival augmentation around dental implants|objective volumetric and clinical assesment of vestibular gingival soft tissues changes upon treatment with laser-aided pouch roll augmentation technique and implant placement over a 12-month follow-up
79515716|NCT01766466|Drug|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
79515717|NCT01767636|Drug|Pazopanib Hydrochloride|Given PO
79673924|NCT01316367|Behavioral|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
79673925|NCT00469664|Drug|Guanfacine/Tenex|
79673926|NCT00469703|Drug|Thalidomide|
79673927|NCT01244100|Drug|PL2200 fasted|Fasted state
79673928|NCT01244100|Drug|PL2200 fed|Fed state
79821112|NCT00729261|Procedure|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
79515718|NCT01769274|Drug|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
79515719|NCT01769274|Drug|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
79515720|NCT01769586|Drug|Diphenhydramine|
79515721|NCT01769586|Drug|Midazolam|
79515722|NCT01770366|Device|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
79515723|NCT01770366|Device|Usual Care|
79515724|NCT01773954|Drug|Intravitreal Aflibercept Injection|Increased or decreased time between visits
79515725|NCT01778634|Drug|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
79515726|NCT01778634|Drug|Placebo|D5W
79515727|NCT01779024|Drug|Ghrelin|
79515728|NCT01779024|Drug|Placebo|
79221111|NCT03502902|Drug|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
79221112|NCT03502902|Drug|Placebo|Placebo
79221113|NCT04507802|Device|Non invasive ventilation via helmet|Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
79221114|NCT02310360|Radiation|Fallypride|
79221115|NCT03353558|Device|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
79221116|NCT02310438|Other|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
79221117|NCT05524324|Device|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
79221118|NCT05524324|Device|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
79221119|NCT02310516|Device|preoperative adequate explanations about awake surgery|
79221120|NCT02310516|Other|no preoperative explanation|
79221121|NCT03353480|Drug|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
79515729|NCT01779024|Procedure|fMRI|
79515730|NCT01779024|Drug|Alcohol|
79515731|NCT01780350|Device|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
79673929|NCT04697888|Drug|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
79673930|NCT01340872|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
79673931|NCT01340872|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
79673932|NCT00474656|Device|High-frequency oscillation|
79673933|NCT00474656|Device|Conventional lung-open mechanical ventilation|
79673934|NCT00469781|Drug|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
79221122|NCT03353480|Drug|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
79515732|NCT01781208|Device|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
79515733|NCT01783080|Behavioral|Behavioral Activation for return to work|See Arm Description
79515734|NCT01783236|Drug|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
79515735|NCT01783236|Drug|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
79515736|NCT01783470|Drug|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
79515737|NCT01783860|Drug|Azithromycin|
79515738|NCT01783860|Drug|Doxycycline|
79515739|NCT04420182|Other|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
79515740|NCT01784796|Behavioral|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
79515741|NCT01784796|Behavioral|Health Education Program|8 week Health Education Program
79515742|NCT01785186|Drug|SQ109|SQ109 300 mg
79515743|NCT01785186|Drug|Rifampicin|Rifampicin 10 to 35 mg/kg
79515744|NCT01785186|Drug|Moxifloxacin|Moxifloxacin 400mg
79515745|NCT01785186|Drug|isoniazid|isoniazid 75 mg
79515746|NCT01785186|Drug|pyrazinamide|pyrazinamide 400 mg
79515747|NCT01785186|Drug|ethambutol|ethambutol 275 mg
79515748|NCT01785186|Dietary Supplement|pyridoxine|pyridoxine 25 mg
79673935|NCT00469781|Drug|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
79673936|NCT01244139|Drug|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
79673937|NCT01244139|Drug|Placebo|IV infusion dummy drug
79994905|NCT03366467|Other|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
79515749|NCT01785810|Drug|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
79515750|NCT01786902|Drug|DA-3002|
79994906|NCT03366467|Other|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
79994907|NCT05039489|Drug|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
79994908|NCT05039489|Device|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
79221123|NCT02306070|Drug|Metformin|metformin treatment + standard of care dietary and exercise advice
79221124|NCT02306070|Drug|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
79364341|NCT06057285|Device|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
79364342|NCT06057259|Device|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
79515751|NCT01787604|Procedure|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
79515752|NCT01787604|Procedure|Aortic Valve Reimplantation Procedure|David I
79515753|NCT01787916|Drug|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
79994909|NCT05039489|Device|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
79994910|NCT05008289|Device|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
79515754|NCT01787916|Drug|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
79364343|NCT06057220|Other|No intervention sample collection only|No intervention
79364344|NCT06057207|Diagnostic Test|serum levels of adiponectin|adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery
79364345|NCT06057207|Diagnostic Test|IL-6|IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery
79515755|NCT01788150|Device|Coronary Stenting|
79515756|NCT01790178|Procedure|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
79515757|NCT01790490|Drug|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
79515758|NCT01790490|Drug|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
79515759|NCT01790490|Drug|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
79673938|NCT01340794|Other|Laboratory Biomarker Analysis|Correlative studies
79673939|NCT01340794|Drug|Pazopanib Hydrochloride|Given PO
79364346|NCT06057207|Other|Postoperative systemic infflamation|systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate>90/min, body temperature >38 C or <36 C, WBC >12 000 or <4000, hyperventilation, CRP >50mg/L, PCT > 0.5 ug/L.
79515760|NCT01791972|Drug|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
79673940|NCT00469820|Biological|autologous tumor cell vaccine|
79673941|NCT00469820|Biological|peripheral blood lymphocyte therapy|
79515761|NCT01791972|Drug|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
79515762|NCT01792986|Behavioral|water-only 24-hour fasting once per week for 6 weeks|
79221125|NCT04513886|Procedure|Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate|A SCTG was harvested using the single incision technique described by Hürzeler & Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
79364347|NCT06057207|Other|Postoperative complications|Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic dehiscence, wound/local infection, postoperative bleeding, reoperation and systemic complications: sepsis, pneumonia, uroinfection, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation >24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure. Length of ICU and overall hospital stay with final outcome after discharge from hospital will be documented.
79515763|NCT01794702|Drug|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
79515764|NCT01794702|Drug|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
79221126|NCT05304130|Biological|Otilimab|Otilimab will be administered via pre-filled syringe.
79515765|NCT01794702|Drug|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
79673942|NCT00500838|Device|Transthoracic Impedance|Impedance measures will be automatically collected via the device
79821113|NCT00731913|Other|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
79821114|NCT00731991|Other|ART|ART to the levator scapulae.
79821115|NCT00731991|Other|PNF|PNF to the levator scapulae.
79821116|NCT00731991|Other|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
79821117|NCT00729339|Drug|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
79821118|NCT00729339|Drug|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
79821119|NCT00737139|Procedure|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
79821120|NCT00737139|Procedure|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
79821121|NCT00732147|Drug|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
79821122|NCT00732147|Drug|Placebo|120 micrograms given subcutaneously before each meal x 3.
79821123|NCT00737217|Behavioral|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
79673943|NCT00474695|Drug|Lucentis|0.05 mg intravitreal injection
79515766|NCT01794702|Drug|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
79221127|NCT02306148|Other|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
79221128|NCT04512326|Procedure|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
79515767|NCT01795716|Drug|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
79515768|NCT01795716|Drug|Glivec|Single and multiple oral Glivec 400mg qd
79515769|NCT01800318|Device|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
79673944|NCT00500877|Behavioral|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
79673945|NCT00474734|Device|Intravascular ultrasound of the liver|
79673946|NCT00500916|Device|ProSeal LMA|GEB vs digital vs introducer tool
79673947|NCT03271502|Procedure|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
79673948|NCT03271502|Procedure|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
79673949|NCT00500955|Drug|Rosiglitazone|
79673950|NCT00474773|Drug|Celecoxib|
79673951|NCT00474890|Drug|cetericine and pseudoephedrine|
79515770|NCT01800318|Behavioral|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
79515771|NCT01800318|Device|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
79515772|NCT01800318|Behavioral|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
79515773|NCT01800786|Device|CPAP|
79515774|NCT01803204|Other|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
79515775|NCT01805154|Device|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
79221129|NCT03502824|Device|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
79221130|NCT03502824|Other|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
79221131|NCT05524090|Other|Implementation - International best-practice care|The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
79221132|NCT03358550|Diagnostic Test|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
79221133|NCT04445324|Behavioral|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
79364348|NCT06057194|Drug|Letermovir 240 mg Oral Tablet|Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
79364349|NCT06057181|Genetic|Exome sequencing|Exome sequencing will be completed on each sample submitted.
79364350|NCT06057168|Drug|Elucirem|Intravenous administration
79364351|NCT06057168|Drug|Dotarem|Intravenous administration
79364352|NCT06057116|Other|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
79364353|NCT06057103|Drug|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
79364354|NCT06057103|Drug|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
79515776|NCT01809834|Device|Etafilcon A|
79515777|NCT01809834|Device|Stenfilcon A|
79364355|NCT06057103|Drug|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
79364356|NCT06057103|Drug|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
79364357|NCT06057103|Drug|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
79364358|NCT06057103|Drug|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
79515778|NCT01769352|Drug|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
79515779|NCT01810692|Device|Group1:Spiriva® Respimat®|COPD patients using Respimat®
79515780|NCT01810692|Device|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
79515781|NCT01811004|Device|miraDry|miraDry
79515782|NCT01811004|Device|Nd:YAG Laser|Nd:YAG 1440 nm Laser
79515783|NCT01811004|Device|Botox®|Botox®
79515784|NCT01811316|Other|Probiotics|
79515785|NCT01811940|Drug|Adderall-ER|MAS-ER 60mg/day
79515786|NCT01811940|Drug|Topiramate|Topiramate 100 mg bid.
79515787|NCT01811940|Other|Placebo|Placebo
79515788|NCT01813110|Drug|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
79515789|NCT01813110|Drug|Placebo|olive oil
79515790|NCT01813734|Drug|Ponatinib|28 day cycle
79515791|NCT01816230|Drug|NiCord®|
79673952|NCT00501033|Device|Mechanical induction of labor|
79673953|NCT00501033|Device|Double Balloon|
79515792|NCT01816776|Device|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
79821124|NCT00737295|Procedure|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
79821125|NCT02569671|Device|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
79994911|NCT05008289|Device|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
79994912|NCT04967105|Device|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
79994913|NCT04098497|Behavioral|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
79673954|NCT00501033|Device|Foley Catheter|
79221134|NCT04445324|Other|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
79364359|NCT06057103|Drug|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
79364360|NCT06057090|Behavioral|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
79364361|NCT06057077|Drug|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
79515793|NCT01816776|Device|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
79515794|NCT01817712|Behavioral|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
79515795|NCT01817712|Behavioral|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
79364362|NCT06057025|Biological|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
79364363|NCT06056986|Diagnostic Test|multimodal ultrasound|Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
79673955|NCT03271463|Behavioral|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
79673956|NCT00501072|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
79673957|NCT01340482|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
79673958|NCT03271697|Drug|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
79364364|NCT06056973|Drug|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
79364365|NCT06056960|Other|Tailored Physical Activity|"The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR.~Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem."
79515796|NCT01818414|Drug|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D&E
79515797|NCT01818414|Drug|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D&E
79994914|NCT04045223|Other|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
79364366|NCT06056947|Drug|EVEGYN A|EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
79364367|NCT06056947|Drug|EVEGYN B|EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
79515798|NCT06020651|Diagnostic Test|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
79515799|NCT06020638|Device|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
79515800|NCT06020638|Device|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
79515801|NCT06020625|Genetic|Diagnostic Test|"In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size >50 genes, if <40 ng material available."
79515802|NCT06020612|Other|Assessment by dermatopathologists|Histological assessment of the cSCCs by eight dermatopathologists.
79515803|NCT06020586|Other|hair lotion|ECOHAIR
79673959|NCT03271697|Drug|Placebo|as a comparator comparing with AM group
79364368|NCT06056947|Drug|Gynomax® XL Vaginal Ovule|200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
79515804|NCT06020560|Drug|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
79515805|NCT06020560|Drug|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
79515806|NCT06020495|Drug|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
79673960|NCT00501111|Drug|AZD3480|3 oral doses
79994915|NCT04003961|Other|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
79221135|NCT02306304|Other|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
79364369|NCT06056921|Biological|CD19 targeted CAR-T cells|A single infusion of CD19 CAR-T cells will be administered intravenously
79364370|NCT06056882|Other|CLE-guided cryobiopsy|During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
79364371|NCT06056856|Procedure|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
79515807|NCT06020495|Drug|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
79515808|NCT06020482|Other|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
79515809|NCT06020456|Drug|Desmopressin|For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
79515810|NCT06020378|Drug|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
79515811|NCT06020365|Other|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
79673961|NCT00501111|Drug|Donepezil|
79673962|NCT00475007|Device|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
79673963|NCT03271541|Drug|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
79994916|NCT03986957|Other|No interventions|No interventions - observational study
79221136|NCT04299802|Drug|Leukocyte-Rich Platelet-Rich Plasma|LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
79221137|NCT04299802|Procedure|Percutaneous Ultrasonic Tenotomy|Discussed in Percutaneous Ultrasonic Tenotomy Arm section
79364372|NCT06056856|Procedure|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
79673964|NCT00501189|Biological|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
79673965|NCT01340209|Drug|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
79673966|NCT01340209|Drug|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
79673967|NCT01340209|Drug|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
79673968|NCT00475046|Behavioral|Motivational Interviewing|
79515812|NCT06020352|Drug|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
79515813|NCT06020313|Dietary Supplement|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
79515814|NCT06020300|Drug|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
79515815|NCT06020300|Drug|Oral Pyridoxine 10 mg|Colchicine look alike placebo
79515816|NCT06020287|Procedure|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
79673969|NCT01246089|Drug|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
79994917|NCT03665545|Drug|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
79994918|NCT03665545|Drug|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
79994919|NCT03305081|Device|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
79221138|NCT03353402|Procedure|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
79221139|NCT03508362|Device|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
79364373|NCT06056817|Device|Calyan Pacemaker|The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
79364374|NCT06056726|Procedure|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
79364375|NCT06056713|Behavioral|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
79515817|NCT06020235|Drug|5% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
79515818|NCT06020235|Drug|10% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
79515819|NCT06020235|Drug|Placebo|Placebo gel is either applied once per day or twice per day to the infected ulcer.
79515820|NCT06020222|Device|cryotherapy|Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.
79515821|NCT06020222|Other|education|Provide preventive CIPN education leaflets
79515822|NCT06020196|Procedure|surgical rectus sheath block|Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)
79515823|NCT06020196|Procedure|subdermal local anaesthetic infiltration|After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
79515824|NCT06020131|Procedure|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
79515825|NCT06020131|Procedure|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
79515826|NCT06020131|Procedure|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
79515827|NCT06020092|Procedure|Bone augmentation with I-BCP|The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
79673970|NCT00598897|Drug|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
79673971|NCT04697732|Other|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
79673972|NCT00501267|Drug|solabegron and oxybutynin|
79994920|NCT04079881|Drug|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
79994921|NCT03891329|Device|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
79994922|NCT03891329|Device|Plexa S DX|Implantation, measurements and follow-up schedule
79994923|NCT03325673|Device|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
79673973|NCT00598936|Device|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
79515828|NCT06020092|Procedure|Bone augmentation with BX|The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
79515829|NCT06020079|Other|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
79515830|NCT06020066|Drug|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
79515831|NCT06020066|Radiation|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
79673974|NCT04326244|Diagnostic Test|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
79673975|NCT04326244|Diagnostic Test|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
79673976|NCT04326244|Diagnostic Test|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
79673977|NCT04326244|Diagnostic Test|Epworth Sleepiness Scale|Epworth Sleepiness Scale
79994924|NCT03325673|Device|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
79364376|NCT06056700|Behavioral|Education|All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
79364377|NCT06056622|Other|Combined Exercises|"The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces."
79515832|NCT06020053|Procedure|saline irrigation at various temperatures (4°C, 25°C)|cold serum application
79515833|NCT06020040|Device|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
79673978|NCT04326244|Diagnostic Test|cephalometry|Evaluation of craniofacial morphology in OSA patients
79994925|NCT03223909|Drug|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
79994926|NCT03223909|Drug|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
79994927|NCT03223909|Drug|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
79673979|NCT04326244|Diagnostic Test|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
79673980|NCT00599209|Other|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
79673981|NCT01326910|Drug|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
79673982|NCT01326910|Device|Topical Cream|Topical cream applied twice daily (or as needed)
79673983|NCT00469937|Drug|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
79673984|NCT00469937|Procedure|cognitive assessment|cognitive assessment
79673985|NCT00469937|Procedure|quality-of-life assessment|quality-of-life assessment
79673986|NCT00469937|Radiation|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
79994928|NCT03733925|Drug|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
79221140|NCT04444934|Other|histological examination|Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
79221141|NCT02310828|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
79221142|NCT02310828|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
79221143|NCT03353324|Drug|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
79364378|NCT06056622|Other|Placebo Exercise|Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
79515834|NCT06019936|Drug|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
79821126|NCT02569671|Device|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
79515835|NCT06019936|Drug|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
79221144|NCT03353324|Radiation|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
79221145|NCT02313402|Device|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
79221146|NCT04298944|Diagnostic Test|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
79221147|NCT04298944|Diagnostic Test|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep
79221148|NCT04298944|Diagnostic Test|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
79221149|NCT04298944|Behavioral|Emotional/ Behavioural assessments|Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
79221150|NCT04444856|Drug|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
79364379|NCT06056609|Other|Yoga|An 8 week online mother and baby yoga programme to include daily diary completion and questionnaires at designated study timepoints
79364380|NCT06056570|Drug|dontinurad|dotinurad alone
79364381|NCT06056570|Drug|dotinurad + allopurinol|dotinurad + allopurinol 300mg
79364382|NCT06056570|Drug|allopurinol|allopurinol 300 mg alone
79364383|NCT06056531|Other|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
79515836|NCT06019858|Other|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
79515837|NCT06019715|Behavioral|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
79515838|NCT06019689|Behavioral|CAMI|Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
79673987|NCT00599287|Drug|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
79673988|NCT00599287|Drug|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
79673989|NCT00599287|Drug|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
79821127|NCT02569515|Drug|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
79821128|NCT00737373|Drug|Docetaxel|50mg/m2 qd15
79221151|NCT04444856|Other|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
79221152|NCT03355040|Other|induction of labour|induction of labour
79221153|NCT03508206|Dietary Supplement|SBRP|SBRP capsules
79221154|NCT03508206|Dietary Supplement|PLACEBO|Placebo capsules
79221155|NCT03354962|Combination Product|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
79221156|NCT03354962|Combination Product|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
79221157|NCT03502590|Device|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
79221158|NCT04463550|Other|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
79221159|NCT05531500|Drug|Injection|Injection of local anesthetic + steroids
79673990|NCT00599365|Other|Pharmacy care arm|"The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~You will need to give a complete list of medications to the pharmacist.~You will need to describe how you take these medications.~The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~The pharmacist will give you a medication schedule, and other papers about your medications."
79673991|NCT00599404|Drug|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
79515839|NCT06019663|Behavioral|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
79515840|NCT06019650|Behavioral|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
79515841|NCT06019585|Device|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
79515842|NCT06019585|Device|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
79515843|NCT06019572|Procedure|Spine decompression and fixation surgery|Surgery is performed by either an anterior or posterior approach. Anterior approach is performed with either discectomy or corpectomy accompanied fusion, while the posterior approach consist in a bilateral laminectomy accompanied by fusion.
79221160|NCT05531500|Device|Radiofrequency|Application of radiofrequency on the diseased nerve
79673992|NCT00475124|Device|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
79673993|NCT00475124|Device|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
79221161|NCT04511468|Dietary Supplement|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
79364384|NCT06056531|Other|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
79673994|NCT04326166|Drug|Evogliptin|Evogliptin
79673995|NCT04326166|Drug|Evogliptin|Evogliptin
79673996|NCT04326166|Drug|Metformin and Evogliptin|Metformin and Evogliptin
79221162|NCT04511468|Behavioral|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
79221163|NCT04511468|Other|Placebo|Placebo with inactive ingredients
79515844|NCT06019533|Combination Product|LVDS|Levonorgestrel Vaginal Delivery System
79515845|NCT06019520|Drug|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
79515846|NCT06019520|Drug|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
79673997|NCT00599443|Biological|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
79673998|NCT00599443|Biological|Placebo Comparator|0.5 mL im, single dose
79673999|NCT00501384|Drug|satavaptan (SR121463B)|
79674000|NCT00599482|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
79821129|NCT00737373|Drug|5-Fluorouracil|2600mg/m2 qd15
79821130|NCT00737373|Drug|Oxaliplatin|85mg/m2 qd15
79821131|NCT00737373|Drug|folinic acid|200mg/m2 qd15
79821132|NCT02569047|Procedure|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
79994929|NCT03649711|Drug|Ticagrelor 90mg|Ticagrelor Pill
79994930|NCT03649711|Drug|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
79221164|NCT02313480|Other|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
79221165|NCT05531422|Drug|Fentanyl|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
79221166|NCT03354884|Drug|cabozantinib|cabozantinib 60 mg orally once daily
79221167|NCT03354806|Procedure|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
79364385|NCT06056492|Behavioral|Experience of nitrous oxide sedation at assessment|Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
79674001|NCT00599560|Genetic|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
79674002|NCT00599599|Behavioral|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
79674003|NCT02891668|Drug|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
79994931|NCT03649711|Drug|Aspirin 81 mg|Aspirin Pill
79364386|NCT06056453|Behavioral|Interpersonal Psychotherapy|IPT group-virtual
79674004|NCT02956343|Device|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
79515847|NCT06019429|Behavioral|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 & 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 & 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
79515848|NCT06019429|Behavioral|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
79821133|NCT02569047|Procedure|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
79674005|NCT00599677|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
79821134|NCT00729495|Drug|celecoxib|dose form
79674006|NCT00599677|Drug|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
79821135|NCT00737451|Behavioral|blood sampling|blood sampling 10ml from the study subjects
79821136|NCT00737685|Drug|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 & -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 & -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 & -1)
79221168|NCT03354806|Procedure|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
79821137|NCT00732459|Device|Electro-acupuncture preconditioning|electro-acupuncture
79221169|NCT03508128|Other|surgical procedure|Surgical procedure
79364387|NCT06056440|Procedure|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
79364388|NCT06056440|Other|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
79364389|NCT06056427|Biological|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
79364390|NCT06056414|Other|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
79674007|NCT00599716|Drug|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
79674008|NCT00599716|Drug|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
79674009|NCT01246284|Drug|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
79674010|NCT01246284|Other|Normal saline|
79674011|NCT00599833|Biological|cetuximab|
79674012|NCT00599833|Radiation|3-dimensional conformal radiation therapy|
79674013|NCT00469976|Drug|bevacizumab|
79674014|NCT00469976|Drug|carboplatin|
79674015|NCT00469976|Drug|enzastaurin hydrochloride|
79674016|NCT00469976|Drug|gemcitabine hydrochloride|
79674017|NCT00599911|Drug|Lu AA24530|per oral, once daily for 6 weeks
79674018|NCT00599911|Drug|Duloxetine|per oral, once daily for 6 weeks
79221170|NCT04443998|Device|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
79221171|NCT03122912|Dietary Supplement|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
79821138|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
79364391|NCT06056401|Behavioral|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
79515849|NCT06019429|Behavioral|School as usual|Any amount of classes offered to promote social-emotional development
79821139|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
79994932|NCT05181631|Other|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
79221172|NCT03122912|Dietary Supplement|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
79364392|NCT06056388|Device|Straumann BLX implant|Implant system with a deep fixture thread depth.
79364393|NCT06056388|Device|Straumann BLT implant|Implant system with a regular fixture thread depth.
79364394|NCT06056375|Behavioral|Reclaiming Nature Intervention|The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
79221173|NCT02313714|Device|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
79515850|NCT06019416|Behavioral|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
79221174|NCT02313714|Device|Sham|very low electric muscular stimulation
79221175|NCT04504058|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
79221176|NCT05529082|Other|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
79515851|NCT06019390|Device|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
79821140|NCT00729729|Drug|PCA|Placebo tablet, once
79821141|NCT00729729|Drug|PCA|PO, 700mg, once
79821142|NCT00729729|Drug|PCA|PO, 1000mg, once
79821143|NCT00732537|Drug|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If >5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If > 5% drop in oxygen saturation or >5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
79821144|NCT00732537|Drug|Oxygen (>90% by hood) - standard therapy|"Oxygen (>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
79821145|NCT00712725|Drug|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
79821146|NCT00712725|Drug|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
79994933|NCT03303521|Drug|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
79221177|NCT05529082|Other|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
79515853|NCT06019351|Device|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
79221178|NCT03350360|Behavioral|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
79221179|NCT03350360|Behavioral|Comparison Task|Neutral- neutral stimuli prior to response task
79221180|NCT05529004|Drug|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
79221181|NCT05529004|Device|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
79221182|NCT03350282|Dietary Supplement|GAA-creatine|
79221183|NCT03350282|Dietary Supplement|Creatine|
79221184|NCT02316210|Device|electrical stimulation|
79221185|NCT03350204|Procedure|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
79221186|NCT03350204|Other|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
79364395|NCT06056362|Diagnostic Test|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
79364396|NCT06056362|Diagnostic Test|68Ga-DOTATATE|All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
79364397|NCT06056362|Diagnostic Test|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
79364398|NCT06056362|Diagnostic Test|68Ga-NODAGA-LM3|All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
79364399|NCT06056336|Drug|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
79515854|NCT06019312|Dietary Supplement|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
79515855|NCT06019299|Behavioral|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
79674019|NCT00599911|Drug|Placebo|per oral, once daily for 6 weeks
79674020|NCT00501462|Drug|GSK189075|single 250 mg dose of drug
79674021|NCT00599950|Drug|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
79674022|NCT00475163|Behavioral|Behavior modification|
79674023|NCT00600145|Drug|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
79674024|NCT00600145|Other|Placebo|Placebo
79674025|NCT00501501|Procedure|Cesarean section|
79674026|NCT00501501|Procedure|Vaginal delivery|
79674027|NCT00600223|Behavioral|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
79674028|NCT00470015|Biological|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
79674029|NCT00470015|Biological|IL-2|0.5x10^6/m^2
79674030|NCT00470015|Biological|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
79674031|NCT00470015|Biological|GM-CSF|300mcg
79674032|NCT00470015|Biological|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
79674033|NCT00600262|Drug|intravitreal bevacizumab|
79674034|NCT00600301|Drug|Triamcinolone Acetonide and Bevacizumab|
79674035|NCT04325971|Other|Neuroimaging|MR, EEG recordings
79674036|NCT04326127|Device|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
79674037|NCT00501579|Drug|Difluprednate|
79674038|NCT00501579|Drug|Prednisolone Acetate|
79674039|NCT00600379|Device|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
79674040|NCT02891707|Device|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
79674041|NCT00501618|Drug|Fazaclo|single-arm
79674042|NCT00600457|Device|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
79674043|NCT02891434|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
79674044|NCT02891434|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
79674045|NCT02891434|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
79674046|NCT00600535|Drug|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
79821147|NCT00712725|Drug|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
79221187|NCT02316288|Behavioral|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
79221188|NCT02316288|Behavioral|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
79515856|NCT06019286|Diagnostic Test|SCINEXA score|- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
79515857|NCT06019247|Other|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
79515858|NCT06019169|Other|Yoga arm|Participation in YOGA classes. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
79674047|NCT00600535|Drug|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
79674048|NCT00600535|Drug|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
79674049|NCT00600535|Drug|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
79674050|NCT00600535|Drug|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
79674051|NCT00600535|Drug|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
79674052|NCT00600535|Drug|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
79821148|NCT00712725|Drug|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
79821149|NCT00712725|Drug|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
79821150|NCT00712725|Drug|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
79821151|NCT00712725|Drug|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
79821152|NCT00737763|Drug|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
79821153|NCT00737763|Drug|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
79221189|NCT02313792|Drug|Palifermin|
79221190|NCT05285878|Drug|Fingolimod|0.5 mg daily
79364400|NCT06056284|Behavioral|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
79674053|NCT00600574|Other|physical therapy|weekly pool physiotherapy with muscle stretching
79674054|NCT00600574|Other|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
79364401|NCT06056206|Radiation|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
79674055|NCT00470171|Drug|Ursodesoxycholic acid|
79674056|NCT00600691|Drug|Finasteride|one tablet (5mg) of finasteride
79821154|NCT00732693|Drug|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
79221191|NCT05285878|Drug|Placebo|0.5 mg daily
79364402|NCT06056193|Procedure|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list
79674057|NCT00623077|Biological|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
79674058|NCT00623077|Drug|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
79674059|NCT00623077|Drug|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
79674060|NCT00623077|Drug|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
79515859|NCT06019169|Other|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
79515860|NCT06019156|Behavioral|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
79515861|NCT06019156|Behavioral|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
79515862|NCT06019143|Behavioral|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
79515863|NCT06019143|Behavioral|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
79515864|NCT06019130|Drug|Nivolumab|Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
79674061|NCT00623077|Drug|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
79674062|NCT00623077|Drug|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
79674063|NCT00623077|Procedure|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
79674064|NCT00623077|Radiation|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
79674065|NCT00623077|Radiation|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
79994934|NCT03303521|Drug|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
79994935|NCT03214081|Drug|Vonoprazan|Vonoprazan tablets
79364403|NCT06056167|Drug|Degludec insulin|"Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital & Research Center (KFSH&RC) protocol.~Patients with two capillary point of care glucose levels of > 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol."
79364404|NCT06056115|Drug|Tislelizumab,Platinum|"Induction therapy stage:~Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
79364405|NCT06056089|Dietary Supplement|ready-to-use supplementary food (RUSF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
79364406|NCT06056089|Dietary Supplement|ready-to-use therapeutic food (RUTF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
79364407|NCT06056089|Drug|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
79674066|NCT00623077|Drug|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
79674067|NCT00623077|Radiation|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
79821155|NCT00732693|Drug|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
79821156|NCT00737841|Drug|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
79821157|NCT00737841|Drug|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
79821158|NCT00732771|Drug|LCI699|
79994936|NCT05181397|Drug|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
79994937|NCT02888171|Drug|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
79994938|NCT02888171|Drug|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
79515865|NCT06019130|Drug|Cisplatin|Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
79515866|NCT06019130|Drug|5-Fluorouracil|5-Fluoruracil during induction chemotherapy in all groups except of adults > 25 years with metastatic disease at diagnosis
79515867|NCT06019130|Drug|Gemcitabine|Gemcitabine during induction chemotherapy in patients > 25 years with metastatic disease at diagnosis
79674068|NCT00475358|Drug|Duloxetine|
79674069|NCT00475358|Drug|Placebo|
79679863|NCT00521183|Drug|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
79821159|NCT02568657|Device|Celox group|
79821160|NCT02568657|Device|Bakri Balloon|
79674070|NCT00623116|Drug|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
79674071|NCT00623155|Drug|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
79821161|NCT00737919|Dietary Supplement|Plant Stanol|Plant stanols in margarines daily 2 grams
79994939|NCT02932891|Drug|DSXS topical|topical treatment
79221192|NCT02314182|Procedure|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~Within 3 weeks after randomization~Immunonutrition given 7 days prior to PT resection~Mechanical bowel preparation performed before surgery according to the local practices~Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~Must be performed within 4 weeks after surgery~CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~Within 4 weeks after the surgery~Chemotherapy administered according to the usual scheme for the chosen protocol~All validated and/or registered perioperative rectal cancer treatments authorized~The duration of one treatment cycle depending on the type of treatment administered~Radiotherapy is allowed after randomization if indicated"
79364408|NCT06056076|Other|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
79364409|NCT06056076|Other|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
79364410|NCT06056037|Behavioral|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
79515868|NCT06019130|Radiation|Radiotherapy|After induction therapy in all patients
79515869|NCT06019130|Drug|Interferon beta-1a|In patients < 26 years after end of radiochemotherapy for 6 months
79515870|NCT06019130|Procedure|MRI|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
79515871|NCT06019130|Procedure|PET|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
79515872|NCT06019130|Behavioral|Patient-Reported Outcomes|For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
79515873|NCT06019117|Dietary Supplement|Probiotic K10|clinical trial using 90 days of probiotic K10
79515874|NCT06019117|Drug|Placebo|clinical trial using 90 days of placebo controlled
79515875|NCT06019104|Other|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
79515876|NCT06019104|Other|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
79515877|NCT06019065|Drug|AJA001|AJA001
79515878|NCT06019065|Other|Placebo|Placebo
79674072|NCT00600730|Procedure|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
79994940|NCT04517903|Other|eye rubbing questionnaire|eye rubbing questionnaire
79994941|NCT05181319|Other|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
79994942|NCT03302975|Device|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
79994943|NCT03212521|Drug|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
79515879|NCT06019039|Drug|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
79674073|NCT00600730|Procedure|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
79674074|NCT00600769|Drug|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
79674075|NCT00600808|Drug|BPLG-003|
79821162|NCT00737919|Dietary Supplement|Plant Sterol|Plant sterols in margarines daily 2 grams
79994944|NCT05181241|Drug|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
79994945|NCT05181163|Diagnostic Test|swab|Swabs from site of infection will be taken
79994946|NCT03212365|Drug|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
79994947|NCT03212365|Drug|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
79515880|NCT06019039|Device|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
79515881|NCT06019013|Drug|QLF3108|QLF3108 will be administered independent of body weight.
79221193|NCT02314182|Drug|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
79364411|NCT06056037|Behavioral|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
79364412|NCT06056011|Device|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
79674076|NCT00470210|Drug|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
79994948|NCT03487627|Behavioral|Electronic and Care Support Manager Contact|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3 months after discharge. The electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
79364413|NCT06055907|Diagnostic Test|Serum anti-Xa activity|4 hours after third dose of dalteparin, serum anti-Xa activity is measured
79221194|NCT04503980|Biological|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10^5 CAR+ T cells/kg will be infused on day 0.
79221195|NCT02316444|Biological|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
79221196|NCT05267860|Device|Prophylactic Drain|We want to put a prophylactic drain after cholecystectomy.
79364414|NCT06055868|Other|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
79364415|NCT06055868|Other|Questionnaires|Given electronically or via phone by study team staff
79515882|NCT06018948|Drug|Dexmedetomidine 0.6|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
79515883|NCT06018948|Drug|Dexmedetomidine 0.3|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
79515884|NCT06018948|Drug|Saline|Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
79515885|NCT06018922|Behavioral|Psychological treatment|The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
79674077|NCT00470210|Drug|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
79674078|NCT00470210|Drug|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
79364416|NCT06055829|Drug|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
79674079|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 20mg
79674080|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 5 mg
79674081|NCT00600847|Drug|placebo|single dose for 7 days, oral
79674082|NCT04325932|Drug|Urinary Kallikrein|
79674083|NCT00501657|Drug|Sitagliptin|100mg mane for 2 days
79674084|NCT00501657|Drug|Placebo|100mg mane for 2 days
79364417|NCT06055816|Drug|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
79515886|NCT06018909|Behavioral|Cognitive-Behavioral Interventions Package|CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
79515887|NCT06018896|Drug|Ascorbate|For patients with baseline serum Vitamin C concentration < 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
79515888|NCT06018779|Other|Cryoultrasound therapy plus high-intensity laser therapy|Group A received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and cryo-sound therapy.
79515889|NCT06018779|Other|diathermy plus high-intensity laser therapy|Group B received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and diathermy.
79515890|NCT06018714|Drug|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
79221197|NCT02316600|Device|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
79821163|NCT00729885|Device|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
79821164|NCT00729885|Device|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
79821165|NCT00732849|Drug|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
79221198|NCT03350048|Diagnostic Test|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
79221199|NCT05531344|Device|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
79364418|NCT06055777|Drug|SZEY-2108 for injetion|Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1~D7 and on the morning of D8.
79364419|NCT06055777|Drug|Placebo|Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1~D7 and on the morning of D8.
79364420|NCT06055764|Device|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
79515891|NCT06018675|Other|kinesiotherapy|Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
79674085|NCT00600964|Drug|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
79674086|NCT00600964|Drug|GX15-070MS|GX15-070MS at various doses and schedules
79674087|NCT00475397|Drug|Duloxetine|
79674088|NCT00475397|Drug|Placebo|
79674089|NCT02891512|Other|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
79674090|NCT02891512|Other|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
79674091|NCT02891512|Other|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
79674092|NCT00601042|Other|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
79674093|NCT00601042|Other|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
79674094|NCT00501696|Drug|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
79674095|NCT00501696|Drug|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
79821166|NCT00729963|Drug|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
79821167|NCT00729963|Device|CPAP|
79515892|NCT06018103|Behavioral|MBCT-vision|8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
79515893|NCT06015425|Device|MINDD STIM+|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79515894|NCT06014944|Drug|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
79515895|NCT06014359|Drug|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
79674096|NCT00601120|Procedure|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
79221200|NCT05531344|Drug|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
79221201|NCT02311140|Other|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
79364421|NCT06055738|Drug|Zimberelimab|240mg,d1,iv,Q21D
79364422|NCT06055738|Drug|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
79364423|NCT06055738|Drug|Cisplatin|75mg/m2,d1,iv,Q21D
79364424|NCT06055699|Other|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
79364425|NCT06055699|Other|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
79364426|NCT06055673|Genetic|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
79515896|NCT06014359|Drug|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
79515897|NCT06014229|Device|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
79515898|NCT06014229|Device|radiofrequency ablation|Single session with a radio frequency ablation device; an specific applicator will be used for the treatments; high impedance rates for RFA with moving-shot technique; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
79674097|NCT00475436|Drug|GSK573719|
79515899|NCT06011746|Drug|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
79674098|NCT04326322|Dietary Supplement|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
79674099|NCT04326088|Other|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
79674100|NCT04326088|Other|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
79221202|NCT04504292|Drug|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
79221203|NCT04504292|Drug|Golytely Oral Product|Bowel prep prior to colonoscopy
79221204|NCT03505242|Device|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
79221205|NCT03505242|Device|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
79515900|NCT06011746|Drug|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
79674101|NCT00601237|Behavioral|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
79674102|NCT00601237|Behavioral|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
79674103|NCT00475475|Behavioral|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
79674104|NCT00475475|Behavioral|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
79821168|NCT00737997|Drug|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
79821169|NCT00737997|Other|Saline|10 ml saline alone
79221206|NCT02311218|Dietary Supplement|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
79515901|NCT06011473|Device|CGM (FreeStyle Libre 3)|"FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3"
79515902|NCT06010563|Device|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
79515903|NCT06010563|Device|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~Transcatheter Pulmonary Valve (TPV)~Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
79515904|NCT06010173|Drug|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
79515905|NCT06010173|Drug|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
79515906|NCT06007872|Device|Intracardiac Echocardiography (ICE)|ICE will be used to guide trans-septal puncture and to guide device implant.
79674105|NCT00475475|Behavioral|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
79221207|NCT02311218|Dietary Supplement|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
79364427|NCT06055660|Genetic|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
79364428|NCT06055647|Genetic|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
79364429|NCT06055634|Genetic|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
79364430|NCT06055595|Diagnostic Test|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
79515907|NCT06005077|Other|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
79515908|NCT06005077|Other|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
79674106|NCT00601276|Drug|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
79221208|NCT05531266|Other|hUC-MSCs|Participants will be treated with hUC-MSCs at a dose of 1×10^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.
79221209|NCT05531266|Other|glucocorticoids|Participants were treated with glucocorticoids only.
79674107|NCT00601276|Drug|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
79674108|NCT00601315|Drug|Clarithromycin|
79674109|NCT02274714|Other|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
79821170|NCT00732927|Drug|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
79821171|NCT00732927|Drug|aspirin|tablets, 100 mg for 3 months
79821172|NCT00733083|Drug|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
79821173|NCT00733083|Drug|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
79221210|NCT04504214|Other|Upper limb repeated multi-site tendon vibrations|Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
79221211|NCT03502512|Other|Questionnaire Administration|Ancillary studies
79221212|NCT03502512|Procedure|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
79364431|NCT06055296|Other|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
79364432|NCT06054945|Procedure|SIFIB (suprainguinal fascia iliaca block)|Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients
79364433|NCT06054945|Other|IPACK (Interspace between the popliteal artery and capsule of the posterior knee )|Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients
79994949|NCT03487627|Behavioral|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the electronic and CSM intervention.
79994950|NCT05328505|Radiation|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
79994951|NCT03273257|Drug|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
79994952|NCT03273257|Drug|Placebo|Placebo will be given analogue to riociguat with matching tablets.
79364434|NCT06054945|Device|Patient controlled anagesia device|Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.
79364435|NCT06054724|Other|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
79364436|NCT06054724|Other|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
79515909|NCT06005077|Other|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
79674110|NCT00601393|Behavioral|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
79994953|NCT03273257|Procedure|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
79994954|NCT04316741|Behavioral|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
79221213|NCT03502512|Procedure|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
79221214|NCT05523544|Behavioral|schematherapy|psychotherapy
79364437|NCT06054399|Other|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
79515910|NCT06004986|Drug|Dupilumab|Administering Dupilumab 300 mg at different dosing intervals.
79674111|NCT00601393|Other|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
79221215|NCT05523466|Other|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
79221216|NCT05523466|Other|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
79364438|NCT06054165|Other|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
79515911|NCT06004167|Radiation|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
79515912|NCT06000943|Other|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
79515913|NCT05997134|Drug|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
79515914|NCT05997134|Drug|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
79674112|NCT00470249|Drug|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
79674113|NCT00470249|Drug|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
79221217|NCT04507490|Device|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
79221218|NCT03501810|Device|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
79221219|NCT03501732|Behavioral|Values Affirmation|Experimental Group selects two values and describes why they are important
79221220|NCT03501732|Behavioral|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
79221221|NCT03349814|Procedure|Diagnostic laparoscopy without appendectomy|A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
79221222|NCT03349814|Procedure|Diagnostic laparoscopy with appendectomy|A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
79221223|NCT05528536|Behavioral|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
79221224|NCT05528536|Other|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
79221225|NCT05528536|Other|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
79364439|NCT06053723|Other|Fonseca's Anamnestic Questionnaire|The questionnaire includes 10 questions about joint, head and neck pain, pain during masticatory activity, parafunctional habits, decreased joint motion, impaired occlusion and emotional stress.
79221226|NCT05528536|Other|Treatment as usual|treatment as usual within their community centres
79364440|NCT06053723|Other|Numeric Pain Scale|It is a simple, reliable and short-term method that is frequently used to measure pain intensity in the clinic.
79221227|NCT03501654|Device|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
79221228|NCT03349736|Other|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
79364441|NCT06053723|Other|Jaw Functionality Limitation Scale-20|"It includes a total of 20 items, with 0 indicating no limitation and 10 indicating severe limitation in each item, about the function of the TMJ during different activities, difficulty in chewing and jaw limitation."
79364442|NCT06053502|Other|filtering facepiece respirator|Graded exercise test with filtering facepiece respirator
79364443|NCT06053385|Other|Melatonin sleep lotion|7 g of lotion applied to hands and arms one hour before bedtime
79515915|NCT05997134|Drug|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
79515916|NCT05984290|Device|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
79515917|NCT05982990|Drug|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
79515918|NCT05982990|Drug|ADVAIR DISKUS® 250/50|2 inhalations in one study period
79515919|NCT05981105|Device|ambIT pump with catheter|0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
79515920|NCT05981105|Device|ambIT pump with sham catheter|sham catheter with no infusion
79515921|NCT05980650|Other|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
79674114|NCT04325893|Drug|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
79674115|NCT04325893|Drug|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
79674116|NCT00601432|Drug|levofloxacin oral solution|
79674117|NCT00501813|Procedure|Hepatectomy|irregular Hepatectomy
79674118|NCT00501813|Procedure|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
79821174|NCT00733083|Drug|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
79364444|NCT06053385|Other|Placebo control lotion|7 g of lotion applied to hands and arms one hour before bedtime
79674119|NCT00601471|Other|proximal tibiofibular manipulation|proximal tibiofibular manipulation
79674120|NCT00601471|Other|distal tibiofibular manipulation|distal tibiofibular manipulation
79674121|NCT00601471|Other|no intervention|no intervention / control
79674122|NCT00601510|Drug|capecitabine|
79674123|NCT00601510|Drug|cisplatin|
79674124|NCT00601510|Drug|imatinib mesylate|
79674125|NCT00501930|Drug|GSK189075|
79674126|NCT00470288|Procedure|bladder flap during cesarean section|
79674127|NCT00601549|Procedure|Laparoscopic surgery|Laparoscopic surgery
79515922|NCT05979740|Drug|Disitamab Vedotin and Toripalimab|Each patient received RC48 injection [2.0 mg/kg, Q2W, iv] and Toripalimab injection [3mg/kg, Q2W, iv] for 1~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
79515923|NCT05976854|Other|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler & Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
79515924|NCT05972655|Radiation|Modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
79515925|NCT05972655|Drug|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
79221229|NCT05531110|Device|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
79221230|NCT05531110|Device|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
79221231|NCT02314338|Other|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
79221232|NCT03349658|Other|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
79364445|NCT06053294|Other|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include preand post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79221233|NCT03349658|Other|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
79221234|NCT02314416|Biological|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
79221235|NCT03353012|Drug|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
79221236|NCT03353012|Drug|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
79221237|NCT02316756|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
79221238|NCT02316756|Drug|Placebo|Placebo which will be given as oral suspension
79221239|NCT03352856|Other|Barley starch|Highly purified barley starch
79221240|NCT03352856|Other|Maize starch|Maize starch
79221241|NCT05523232|Other|Vibration training with 42 Hz|Vibration exposure was given using a handheld vibration device.
79221242|NCT05523232|Other|Vibration training with 63 Hz|Vibration exposure was given using a handheld vibration device.
79221243|NCT04462614|Drug|Decrease per-dialytic heparin therapy|Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
79364446|NCT06053294|Other|CS+Fast|(CS+): Flavored beverage solution with 75 calories of sucrose. Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement preand post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79515926|NCT05972655|Drug|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
79515927|NCT05972655|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
79515928|NCT05971719|Diagnostic Test|Air Leaks: Aerosol glycerine System|A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
79515929|NCT05962502|Drug|Cetuximab and irinotecan|chemotherapy plus targeted therapy
79674128|NCT00601549|Procedure|Traditional open surgery|Open surgery
79674129|NCT00601588|Drug|Sertraline|
79674130|NCT00601666|Drug|Zolpidem|
79821175|NCT00733083|Drug|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
79221244|NCT03349580|Behavioral|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
79515930|NCT05959343|Behavioral|Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion|In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
79515931|NCT05957757|Drug|RC48|"RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
79515932|NCT05957757|Drug|Tislelizumab|"Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
79364447|NCT06053294|Other|CS+Slow|(CS+): Flavored beverage solution with 75 calories of maltodextrin and fiber. Participants will consume flavored beverage solutions containing 75 calories of maltodexrin in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry easurement preand post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79515933|NCT05954169|Drug|SHR4640|SHR4640 single-dose
79515934|NCT05935020|Other|Usual care - Municipal exercise-based rehabilitation|"The patients in this group follow prescribed (by the orthopedic surgeon) usual care municipal exercise-based rehabilitation. The content of the rehabilitation is planned in collaboration between the patient and the physical therapist, based on the offered municipal treatment options (which varies between municipalities) and patient preferences (i.e., home-based exercise, outpatient exercise, group-based exercise, or a combination thereof). The contents of the municipal services offered will be described in detail in the trial report.~A prescribed therapeutic rehabilitation exercise plan could for instance be a 6-week combined home-exercise (1-2 times/week) and group-exercise (1 time/week) intervention, followed by encouragement to continue self-administered home exercise after the 6 weeks."
79364448|NCT06052956|Drug|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
79515935|NCT05935020|Other|Return to Everyday life|"The patients in this group return to their desired pre-surgical activities, at their own speed, when they feel that they are ready for it. They are not prescribed any exercise-based rehabilitation (usual care) by their orthopedic surgeon.~This effectively means they will not receive a therapeutic progressive exercise plan; designed and prescribed to restore previous function or reducing pain or disability caused by injury, disease, or surgery - typically referred to as exercise therapy or therapeutic exercise."
79515936|NCT05935020|Behavioral|Symptom guide and encouragement to follow DHA/WHO recommendations for physical activity|"Participants in both groups receive a recovery-guide pamphlet at discharge, containing the following information: 1) Recommendations to follow DHA/WHO guidelines for physical activity, 2) Figures and tables describing common post-operative symptoms (symptom guide), and when to react (when the symptoms may require attention from a health-professional), 3) What to expect from the post-surgical period in relation to activities of daily living, 4) Common short- and long-term complications to total knee arthroplasty and 5) Trial-participant and ethics-committee information documents. Parts 2-4 are usual clinical practice, with slight variations in descriptions between sites.~After surgery, participants in both groups are encouraged to resume their desired pre-surgical activities when they feel they are able (within the limits given from the orthopedic wards)."
79674131|NCT00601744|Behavioral|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
79674132|NCT00601744|Behavioral|Questionnaire|5-10 minute questionnaire to be completed after the interview.
79674133|NCT01246362|Drug|Control|Given placebo
79221245|NCT05518552|Other|Manual lumbar traction|Patient in the group were treated with manual traction
79221246|NCT05518552|Other|Prone traction|Patient in the group were placed on prone traction
79221247|NCT02314494|Behavioral|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
79221248|NCT02316912|Drug|ATX2417|Randomised double blind parallel group ascending dose assessment
79221249|NCT02316912|Drug|Placebo|Randomised double blind parallel group ascending dose assessment
79674134|NCT01246362|Drug|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
79221250|NCT03349424|Drug|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
79221251|NCT02314572|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
79674135|NCT04325854|Procedure|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
79674136|NCT00470405|Drug|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
79515937|NCT05934227|Drug|Amoxicillin 500 milligrams capsules plus metronidazole 400 milligrams|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of amoxicillin (500 milligrams) + metronidazole (400 milligrams) three times a day for 7 days after SRP
79515938|NCT05934227|Other|placebo|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of placebo containing corn starch capsules three times a day for 7 days after SRP
79515939|NCT05933148|Device|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
79515940|NCT05933148|Device|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
79994955|NCT02700035|Other|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
79994956|NCT02522507|Behavioral|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
79994957|NCT03637751|Behavioral|Behavioral|Trier Social Stress Test
79994958|NCT03637751|Behavioral|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
79221252|NCT04506710|Behavioral|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
79221253|NCT02572570|Device|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.
79221254|NCT02572570|Device|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
79364449|NCT06052956|Drug|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
79364450|NCT06052956|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
79364451|NCT06052956|Device|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
79364452|NCT06052956|Device|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
79364453|NCT06052956|Device|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
79364454|NCT06052956|Procedure|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
79364455|NCT06052943|Behavioral|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
79515941|NCT05928650|Other|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
79515942|NCT05918783|Combination Product|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
79515943|NCT05917899|Behavioral|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and [if in attendance] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
79515944|NCT05912790|Device|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
79515945|NCT05911880|Behavioral|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
79515946|NCT05911269|Other|TiMBRe|"1 & 2 Music Listening~Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~3 & 4 Music Facilitated Breathing~The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~5 & 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~Using music as a structured auditory cue for tensing and releasing of muscles.~7 & 8 Body Percussion~The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body."
79515947|NCT05911269|Other|Control|Standard of care study staff calls and cancer survivorship resources
79515948|NCT05898217|Other|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
79515949|NCT05898217|Other|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
79515950|NCT05898217|Other|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
79515951|NCT05898217|Other|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
79515952|NCT05886296|Behavioral|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
79515953|NCT05884138|Other|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
79221255|NCT03122990|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
79674137|NCT00470405|Drug|pemetrexed disodium|a novel antifolate with multiple targets.
79674138|NCT04207372|Dietary Supplement|whey protein isolate|whey protein isolate
79674139|NCT04207372|Dietary Supplement|Zein|zein protein
79221256|NCT03122990|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
79221257|NCT03349346|Drug|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
79221258|NCT03349346|Drug|Rituximab|375 mg/m^2 administered intravenously
79221259|NCT03349346|Drug|Ifosfamide|3 mg/m^2 administered intravenously
79221260|NCT03349346|Drug|Carboplatin|635 mg/m^2 administered intravenously
79221261|NCT03349346|Drug|Etoposide|100 mg/m^2 administered intravenously
79221262|NCT03502434|Drug|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
79364456|NCT06052943|Behavioral|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
79364457|NCT06052943|Behavioral|Physical Activity|Combines aerobic and resistance training though game play.
79364458|NCT06052943|Behavioral|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
79364459|NCT06052943|Behavioral|Preschool Curriculum|Preschool age children learn about and try new foods.
79364460|NCT06052943|Behavioral|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
79364461|NCT06052787|Drug|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
79674140|NCT04207372|Other|protein-free|protein free
79674141|NCT00601822|Behavioral|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
79674142|NCT00601822|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
79674143|NCT00502008|Drug|Coccinia Cordifolia (herbal extract)|
79674144|NCT00601861|Drug|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
79674145|NCT00470444|Procedure|Transfusion with Red Blood Cells|Units of donated Red blood cells
79674146|NCT00470444|Biological|1 unit of donated red blood cells|Units of red blood cells
79674147|NCT00470444|Biological|1 unit of donated red blood cells|Units of donated red blood cells
79674148|NCT00601978|Drug|carbidopa/levodopa|
79674149|NCT00601978|Drug|Carbidopa/Levodopa/Entacapone|
79674150|NCT00601159|Drug|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
79674151|NCT00502047|Drug|Plantago ovata husk|
79674152|NCT00602017|Drug|Amlodipine|
79221263|NCT03502434|Other|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
79994959|NCT04495673|Device|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
79994960|NCT04495673|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
79221264|NCT03502434|Other|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
79364462|NCT06052787|Drug|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
79994961|NCT04495673|Behavioral|Cognitive Training|Executive functioning tasks
79994962|NCT04270877|Drug|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
79364463|NCT06052774|Procedure|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
79515954|NCT05880706|Drug|BL-B01D1|Administration by intravenous infusion
79515955|NCT05880706|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
79515956|NCT05877924|Drug|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
79515957|NCT05877820|Biological|Tislelizumab|Intravenous infusion
79515958|NCT05877820|Drug|Lenvatinib|Oral tablet
79515959|NCT05875207|Behavioral|Mindfulness based practice|Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
79515960|NCT05875207|Behavioral|Control/Standard Physical Therapy|Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
79515961|NCT05875077|Drug|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
79515962|NCT05875077|Drug|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
79515963|NCT05868902|Device|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
79674153|NCT00470483|Drug|Placebo treatment during 8 weeks|comparator
79821176|NCT00738075|Device|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
79994963|NCT04270877|Drug|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
79994964|NCT03271307|Behavioral|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
79994965|NCT03271307|Diagnostic Test|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
79221265|NCT03502434|Other|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
79674154|NCT00470483|Drug|Paroxetine treatment during 8 weeks|treatment drug
79674155|NCT00602056|Other|Redesigned immunization card|A low cost nad simplified redesigned immunization card
79674156|NCT00602056|Other|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
79674157|NCT00602056|Other|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
79674158|NCT00602095|Drug|misoprostol|0.025mg tablet vaginally every 4 hour until progress
79674159|NCT00602095|Drug|dinoprostone|2mg vaginal gel every 6 hours until progress
79821177|NCT00712335|Drug|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
79515964|NCT05866107|Device|self-monitoring of weight using smart body fat scale with high-precision weighing chip (Huawei Scale 2pro), a mobile phone app (Huawei Health), dietary management, and exercise management.|Participants will use a mobile phone app (Huawei Health) to collect data on sleep log, daily activities and calorie consumption. The smart body fat scale with high-precision weighing chip (Huawei Scale 2pro) will be used to collect heart rate, weight, BMI, body type, basal metabolic rate, fat rate, fat free body weight, skeletal muscle mass, bone salt content, visceral fat grade, body water (%), body protein rate and body composition, and all data will be uploaded to the app. Participants could also record their daily dietary intake (for calculation of calorie intake) in the health app; psychiatrists evaluate the patient's condition and conduct laboratory tests; nutrition instructors conduct dietary education and formulate individualized energy-limited balanced diet prescriptions; exercise instructors conduct behavioral ways and sports education, and individualized exercise prescriptions.
79994966|NCT03271307|Diagnostic Test|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
79994967|NCT03271151|Drug|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
79515965|NCT05864612|Behavioral|Screening Questionnaires|Standard care screening questionnaires on anxiety and depression
79994968|NCT03271151|Other|Placebo|Placebo to compare outcomes against Duloxetine
79994969|NCT03245723|Procedure|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
79994970|NCT03245723|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
79994971|NCT03245723|Procedure|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
79221266|NCT04302142|Device|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
79994972|NCT03245723|Procedure|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
79515966|NCT05852184|Other|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., <=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
79515967|NCT05852158|Drug|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
79515968|NCT05852158|Drug|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
79515969|NCT05844228|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
79515970|NCT05833529|Behavioral|Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks|"40 10 mins VRCEs for cocaine craving (desensitization to only cocaine craving cues; no others interventions). 4 VRCE and 2 different VRCE situations by meeting. Same VRCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard VRCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous VRCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention in any case of distress still over convenient levels. VRCE use Meta Quest 2, are visuo-auditively immersive (360°; 1st person), interactive (using virtual objects), semi-stationnary (360°-rotating stool and teleportation system). Participant skin color and cocaine using mode individualized."
79515971|NCT05833529|Other|Memory Focused Cognitive Therapy (MFCT) - 1 week|"In accordance with the Memory Focused Cognitive Therapy for Cocaine Use Disorder Therapist Guide (Marsden and Goetz, 2018), MFCT meetings will consist in 5 sequential components: Cognitive case conceptualisation of cocaine use disorder maintaining processes to inform a treatment plan; Education about cocaine's cognitive and physical effects; Cocaine related cue-induction to elicit images and affective responses; Memory reconsolidation procedures; Standard CBT techniques (e.g. behavioural experiments of cocaine-related expectancies and skills for adaptive emotion regulation)."
79674160|NCT00602095|Device|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
79674161|NCT00502086|Dietary Supplement|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
79994973|NCT02349971|Device|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
79994974|NCT05003921|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79994975|NCT03301649|Drug|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
79994976|NCT03301649|Drug|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
79994977|NCT03301649|Drug|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
79994978|NCT03637439|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
79515972|NCT05833529|Behavioral|Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks|"60 x 10 mins PCE (desensitization to only cocaine craving cues; no others interventions). A standard audio of VRE songs is played in PCE. 4 PCE and 2 different PCE situations by meeting. Same PCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard PCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous PCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention if any distress over convenient levels. PCE use a laptop standard PowerPoint slide show (2D pictures from VRCE; non-spatialized audio from laptop speakers), are non-interactive (seated on a stool). Participant skin color and cocaine using mode individualized."
79515973|NCT05824377|Other|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
79674162|NCT00502086|Other|Placebo|Placebo three sachets daily during 96 weeks
79674163|NCT00475553|Other|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
79994979|NCT03637439|Other|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
79994980|NCT04647617|Behavioral|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
79221267|NCT04302142|Device|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
79515974|NCT05824377|Other|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
79674164|NCT00475553|Other|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
79221268|NCT02317068|Device|HBR|
79221269|NCT02317068|Device|DD|
79221270|NCT03352700|Drug|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
79221271|NCT03352700|Drug|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
79221272|NCT05522998|Drug|Ciprofol|Ciprofol (0.4-0.5mg/kg) for anesthesia induction
79364464|NCT06052644|Other|Exercise Dose-Response|"The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise."
79364465|NCT06052579|Procedure|new hand-held retractor systems-assisted WiltseTLIF surgery|patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
79364466|NCT06052540|Dietary Supplement|Probiotic supplement|"Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin."
79674165|NCT01326481|Drug|TRC105|IV
79994981|NCT03222973|Drug|BIIB033 (opicinumab)|Administered as specified in the treatment arm
79994982|NCT03222973|Drug|Placebo|Administered as specified in the treatment arm
79364467|NCT06052540|Dietary Supplement|Placebo|"Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~Stick: Maltodextrin."
79994983|NCT01144416|Biological|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
79364468|NCT06052020|Drug|Alirocumab|alirocumab (75 mg every 2 weeks)
79364469|NCT06052020|Drug|Atorvastatin|Atorvastatin 20-40mg
79364470|NCT06051565|Drug|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
79364471|NCT06051487|Other|titanium dioxide nanoparticles in test group|Titanium dioxide nanoparticles added to acrylic baseplate in test group
79674166|NCT01326481|Drug|Capecitabine|oral
79674167|NCT00502125|Procedure|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
79674168|NCT03271346|Behavioral|intensive trauma-focused therapy|
79674169|NCT00502164|Drug|AZD2171|
79674170|NCT00475592|Device|Esophageal Capsule Endoscopy|
79221273|NCT05522998|Drug|Propofol|propofol(2-2.5mg/kg) for anesthesia induction
79221274|NCT03349190|Drug|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
79674171|NCT00475592|Device|Upper Gastrointestinal Endoscopy|
79674172|NCT00502281|Drug|highly purified urinary FSH|
79364472|NCT06051253|Drug|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
79515975|NCT05783362|Behavioral|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
79515976|NCT05738213|Device|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
79515977|NCT05738213|Device|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
79515978|NCT05738213|Behavioral|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
79515979|NCT05738213|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
79515980|NCT05738213|Behavioral|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
79515981|NCT05738213|Behavioral|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
79515982|NCT05738213|Diagnostic Test|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
79515983|NCT05738213|Other|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
79515984|NCT05727397|Drug|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
79515985|NCT05727397|Drug|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
79674173|NCT00502281|Behavioral|timed intercourses, intrauterine insemination|
79674174|NCT00470522|Drug|Methotrexate and folic acid|
79674175|NCT00502359|Device|capillary blood glucose measurement|
79674176|NCT00475748|Procedure|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
79674177|NCT01244178|Drug|Insulin|Intravenous Hyperinsulinemic therapy
79994984|NCT01144416|Biological|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
79994985|NCT01144416|Drug|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
79674178|NCT01244178|Drug|Insulin|Standard Intravenous Insulin Therapy
79674179|NCT00470561|Drug|Aspirin|Two 325 mg doses of aspirin per day for 6 months
79674180|NCT00470561|Drug|Placebo|Two placebo pills per day for 6 months
79674181|NCT00502398|Procedure|Blood test|
79674182|NCT00475826|Drug|Statins and Ezetimibe|
79674183|NCT00493506|Drug|ProAlgaZyme|
79674184|NCT00502437|Drug|GRANISETRON|
79674185|NCT00470678|Drug|ranibizumab|
79515986|NCT05717842|Radiation|Nuclear Medicine Scan|Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
79994986|NCT01144416|Drug|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
79364473|NCT06051253|Drug|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
79364474|NCT06051058|Behavioral|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
79515987|NCT05711628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79515988|NCT05711628|Drug|Bendamustine|Given IV
79515989|NCT05711628|Drug|Brentuximab Vedotin|Given IV
79515990|NCT05711628|Drug|Carboplatin|Given IV
79674186|NCT00502476|Procedure|Bathing with Chlorhexidine Impregnated Washcloths|
79674187|NCT00470756|Other|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
79364475|NCT06051045|Drug|Bulevirtide|Hepcludex, 2 mg daily subcutaneous injection
79364476|NCT06048991|Diagnostic Test|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
79994987|NCT00335777|Drug|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
79364477|NCT06048497|Device|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was > 327 ms.
79364478|NCT06048276|Drug|Herbal medicines (e.g., Yunkang granules, Duzhong granules)|Herbal medicines (e.g., Yunkang granules, Duzhong granules) exposure at the early gestation.
79994988|NCT00335777|Drug|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
79364479|NCT06046456|Other|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
79364480|NCT06045676|Device|ECG|ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.
79364481|NCT06045468|Other|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
79364482|NCT06045468|Other|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
79364483|NCT06045351|Drug|Vitamin D|"Intervention Group Initial 12 weeks;~VD supplementation (600,000 IU I/M) once during the study period~Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~Glucophage XR 750 mg once at dinner for 15 days then twice daily~Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~Calcium 1000 mg/day"
79364484|NCT06045351|Other|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~Standard PCOS;~Glucophage XR 750 mg once at dinner for 15 days then twice daily~Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~VD supplementation (600,000 IUI/M) once during the study period~Calcium 1000 mg/day~Standard PCOS Continued"
79364485|NCT06044558|Drug|Combined with voriconazole|Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.
79364486|NCT06044558|Drug|Combined with caspofungin|Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.
79364487|NCT06044558|Drug|Tacrolimus-alone treatment|Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
79364488|NCT06043063|Procedure|Topical lidocaine|Topical anesthetic
79515991|NCT05711628|Procedure|Computed Tomography|Undergo PET/CT and CT
79515992|NCT05711628|Drug|Etoposide|Given IV
79515993|NCT05711628|Drug|Gemcitabine|Given IV
79515994|NCT05711628|Drug|Ifosfamide|Given IV
79515995|NCT05711628|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79515996|NCT05711628|Biological|Pembrolizumab|Given IV
79515997|NCT05711628|Procedure|Positron Emission Tomography|Undergo PET/CT
79515998|NCT05711628|Radiation|Radiation Therapy|Undergo RT
79515999|NCT05711628|Other|Transplant Conditioning|Receive standard preparative chemotherapy regimen
79516000|NCT05711628|Drug|Vinorelbine|Given IV
79516001|NCT05677490|Drug|Fluorouracil|Given IV
79516002|NCT05677490|Drug|Leucovorin Calcium|Given IV
79516003|NCT05677490|Drug|Oxaliplatin|Given IV
79516004|NCT05677490|Drug|Irinotecan|Given IV
79516005|NCT05677490|Biological|Nivolumab|Given IV
79516006|NCT05677490|Procedure|Magnetic Resonance Imaging|Undergo MRI
79516007|NCT05677490|Procedure|Computed Tomography|Undergo a CT Scan
79674188|NCT00470795|Other|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
79821178|NCT00712335|Drug|Montelukast|PO 10 mg QHS for 3 weeks
79516008|NCT05677490|Procedure|Biospecimen Collection|Undergo blood sample collection
79516009|NCT05677490|Other|Questionnaire Administration|Ancillary studies
79516010|NCT05676489|Drug|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-[F-18]fluoro-2-methyl-2-(methylamino)propanoic acid ([F-18]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
79302467|NCT03321071|Behavioral|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
79516011|NCT05673278|Diagnostic Test|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~+ Image quality"
79364489|NCT06043063|Procedure|EMLA cream|Topical anesthetic
79516012|NCT05656664|Dietary Supplement|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
79516013|NCT05656664|Other|Placebo|Placebo group to assess arsenic metabolite excretion
79516014|NCT05654012|Device|MRI|Grey Matter Volume (T1) Resting state BOLD
79516015|NCT05654012|Device|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
79674189|NCT00470795|Procedure|placebo/sham acupuncture|acupuncture at sham points without skin penetration
79674190|NCT00493545|Biological|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
79674191|NCT00470873|Drug|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
79674192|NCT00493584|Procedure|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
79364490|NCT06043063|Procedure|Periurethral block|5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
79364491|NCT06041308|Other|valve|bioprothetic valve versus mechanical valve
79364492|NCT06036810|Other|Shared Medical Decision Tool|standard of care
79364493|NCT06036810|Behavioral|Engaging Patients in Decision Making|standard of care
79364494|NCT06036810|Behavioral|Literacy Spanish Language|standard of care
79364495|NCT06036238|Behavioral|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
79364496|NCT06036238|Behavioral|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
79674193|NCT00493584|Procedure|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
79674194|NCT00493623|Drug|Placebo|Placebo i.v. single dose
79674195|NCT00493623|Drug|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
79674196|NCT02955849|Device|SLT laser|Patients will be offered initial SLT laser by doctors
79364497|NCT06035250|Drug|Neoadjuvant Chemotherapy|Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
79364498|NCT06035003|Behavioral|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
79821179|NCT00712335|Drug|Salmeterol|DPI 50mg BID for 3 weeks
79516016|NCT05654012|Device|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
79516017|NCT05654012|Behavioral|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
79516018|NCT05654012|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
79516019|NCT05654012|Behavioral|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
79516020|NCT05654012|Diagnostic Test|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
79516021|NCT05654012|Behavioral|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
79516022|NCT05654012|Behavioral|Neural assessments|MRI and fMRI scans
79221275|NCT05528224|Other|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
79516023|NCT05654012|Diagnostic Test|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
79516024|NCT05653089|Procedure|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~Choice and adjustments of the wheelchair~Choice and adjustments of the wheelchair/patient interface"
79516025|NCT05644223|Drug|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
79516026|NCT05636371|Other|Written Communication|Written patient care updates provided to families of ICU patients each day
79516027|NCT05633147|Drug|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
79516028|NCT05633147|Drug|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
79221276|NCT05528224|Other|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
79364499|NCT06034821|Drug|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
79516029|NCT05633147|Drug|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
79516030|NCT05629728|Behavioral|Tai Chi exercise|Sun-style Tai Chi (21 forms)
79516031|NCT05622318|Drug|Cyclophosphamide|25 mg/kg by IV on Days +3 and +4.
79516032|NCT05622318|Drug|Tacrolimus|Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level [IV:PO ratio = 1:4]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
79516033|NCT05622318|Drug|Mycophenolate Mofetil|15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
79516034|NCT05622318|Drug|Ruxolitinib|5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
79516035|NCT05612048|Other|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
79516036|NCT05612048|Other|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
79516037|NCT05612048|Other|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
79302468|NCT03321071|Behavioral|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
79302469|NCT03203941|Biological|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
79302470|NCT02486237|Other|None, observational study|None, it is an observational study
79674197|NCT00476099|Drug|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
79674198|NCT00476099|Drug|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
79516038|NCT05611840|Procedure|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
79516039|NCT05611840|Procedure|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
79994989|NCT04424004|Other|COVID-19 PCR and serology testing|"PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
79221277|NCT05528224|Drug|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
79516040|NCT05608083|Behavioral|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
79516041|NCT05608083|Behavioral|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
79994990|NCT03764137|Drug|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
79221278|NCT03498534|Drug|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
79221279|NCT03498534|Drug|Isoniazid 300 MG|+ TST test will receive isoniazid 300MG Tab for 6 months
79364500|NCT06034821|Device|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
79516042|NCT05597488|Device|EUS guided portal pressure gradient measurement|EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
79516043|NCT05593900|Behavioral|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
79516044|NCT05584475|Behavioral|Mindful Awareness Practices (MAPs)|MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
79516045|NCT05572697|Behavioral|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
79516046|NCT05572697|Behavioral|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
79516047|NCT05566574|Drug|RP-3500|RP-3500 on Days 1-5.
79516048|NCT05566574|Radiation|External Beam Radiotherapy (EBRT)|Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
79516049|NCT05563779|Other|Volume Control mode|Volume Control mode for mechanical ventilation
79516050|NCT05563779|Other|Pressure Control mode|Pressure Control mode for mechanical ventilation
79516051|NCT05563779|Other|Adaptive Pressure Control mode|Adaptive Pressure Control mode for mechanical ventilation
79516052|NCT05535829|Other|Laboratory analysis of samples|Laboratory analysis of samples
79994991|NCT03625518|Drug|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
79994992|NCT03625518|Device|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
79994993|NCT03469297|Device|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
79994994|NCT00972738|Drug|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
79994995|NCT00972738|Drug|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
79221280|NCT03498534|Drug|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
79221281|NCT02518178|Device|NFC Necklace|
79221282|NCT02518178|Device|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
79221283|NCT02518178|Device|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
79364501|NCT06034756|Other|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
79994996|NCT00972738|Drug|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
79994997|NCT03452839|Drug|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
79994998|NCT04701281|Combination Product|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
79994999|NCT05012670|Drug|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
79995000|NCT04313478|Behavioral|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
79995001|NCT05180929|Device|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
79995002|NCT05180929|Device|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
79364502|NCT06034756|Other|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
79364503|NCT06034756|Other|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
79364504|NCT06034756|Other|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
79364505|NCT06034756|Other|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
79995003|NCT05180929|Device|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
79995004|NCT04249830|Biological|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
79364506|NCT06034756|Other|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
79995005|NCT04249830|Device|CliniMACS TCR α/β Reagent Kit and CliniMACS CD19|The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
79221284|NCT03502356|Drug|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
79221285|NCT05518318|Drug|GLS-010|Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
79221286|NCT05518318|Drug|Chemotherapy of Investigator's choice|Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
79516053|NCT05534854|Genetic|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
79516054|NCT05534477|Device|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
79221287|NCT04509518|Other|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
79674199|NCT00476099|Drug|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
79674200|NCT00493662|Drug|Polyethylene Glycol 400 0.4%|
79674201|NCT00493662|Drug|Propylene Glycol 0.3%|
79221288|NCT05522920|Other|Therapy with and without spinal cord stimulation|Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
79221289|NCT03498456|Drug|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
79221290|NCT03498456|Drug|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
79221291|NCT03352622|Other|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
79674202|NCT00493662|Drug|0.15% sodium Hyaluronate|
79674203|NCT00493662|Drug|sodium chloride|
79516055|NCT05534477|Device|Verily Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
79516056|NCT05534477|Device|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
79516057|NCT05534477|Device|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
79516058|NCT05528848|Drug|Carfentanil, C-11|Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
79516059|NCT05528848|Drug|Naloxone|Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
79674204|NCT00493662|Drug|sodium phosphate monobasic|
79221292|NCT03352622|Other|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
79221293|NCT05518240|Device|Stent Retrievers|Procedure: Embotrap device
79364507|NCT06032533|Device|Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
79221294|NCT05518240|Device|Stent Retriever|Procedure: Solitaire device
79364508|NCT06032533|Device|Sham Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
79364509|NCT06029413|Procedure|myo + fascial injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as well as for fascial layers as described.
79364510|NCT06029413|Procedure|traditional trigger point injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as described.
79364511|NCT06028360|Other|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
79674205|NCT00470912|Drug|sunscreen RV 2547C|
79364512|NCT06028360|Device|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
79371121|NCT03029962|Behavioral|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
79516060|NCT05525065|Drug|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
79674206|NCT02274519|Other|Tai Chi|Arm 1
79221295|NCT02317146|Drug|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
79221296|NCT04463238|Combination Product|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
79221297|NCT04463238|Procedure|Microfracture|Operate in accordance with the clinical microfracture surgery method.
79516061|NCT05519527|Drug|Part 1 (STI-6129)|Given by vein (IV)
79221298|NCT04509830|Other|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator
79221299|NCT04509830|Other|quadriceps strengthening, stretch hamstring,cuff muscles|multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
79516062|NCT05519527|Drug|Part 2 (STI-6129)|Given by vein (IV)
79516063|NCT05508542|Behavioral|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
79516064|NCT05504044|Other|Glucose control|50 g glucose dissolved in 250 mL water
79516065|NCT05504044|Other|Bread control|91.4 g white bread
79516066|NCT05504044|Other|Almond paste|88.7 g white bread and 15 g almond paste
79516067|NCT05504044|Other|Almond paste and inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
79516068|NCT05504044|Other|Low dose almond paste and inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
79516069|NCT05492552|Behavioral|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
79516070|NCT05488301|Other|chest physiotherapy|"chest physiotherapy session including:~nasal ventilation~decrease of respiratory rate without increasement of Tidal volume~abdomino-diaphragmatic ventilation"
79674207|NCT02274519|Other|Education|Arm 2
79674208|NCT00476138|Drug|Epigallocatechin-gallate|
79674209|NCT02955888|Drug|PBI4050|Investigational Medicinal Product
79674210|NCT02955888|Drug|Placebo|Comparator
79221300|NCT05528146|Dietary Supplement|Psyllium huks|psyllium in 250ml of water
79674211|NCT00470951|Procedure|open rectal resection|open rectal resection
79674212|NCT00470951|Procedure|laparoscopic rectal resection|laparoscopic assisted rectal resection
79674213|NCT02956083|Other|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
79516071|NCT05486078|Device|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
79674214|NCT02956083|Other|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
79995006|NCT03243305|Drug|AMPHORA|non-hormonal contraceptive vaginal gel
79995007|NCT04168632|Other|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
79995008|NCT03882918|Drug|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
79995009|NCT03222583|Drug|Placebo|Matching placebo tablet for oral administration
79995010|NCT03222583|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
79995011|NCT05282329|Device|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
79995012|NCT05282329|Device|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
79364513|NCT06028048|Behavioral|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
79364514|NCT06017687|Device|OptiBP Study app|Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
79371122|NCT03035578|Drug|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
79516072|NCT05481320|Behavioral|REACH VN Phone Intervention|4-6 intervention sessions delivered via phone over the course of 1-3 months.
79516073|NCT05481320|Behavioral|Enhanced Control|A single phone session providing education about dementia.
79674215|NCT02956083|Other|saline|Saline - no brand name
79674216|NCT00470990|Drug|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
79674217|NCT01246440|Drug|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
79674218|NCT03271112|Other|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
79674219|NCT00493740|Procedure|chocolate cake|
79674220|NCT00471029|Drug|esomeprazole|
79995013|NCT01314391|Genetic|mutation analysis|
79995014|NCT01314391|Genetic|polymerase chain reaction|
79995015|NCT01314391|Other|laboratory biomarker analysis|
79221301|NCT02317224|Procedure|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
79221302|NCT02317224|Procedure|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
79221303|NCT02317224|Procedure|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
79674221|NCT00476177|Biological|Infusion of donor dendritic cells|Given in the outpatient setting
79674222|NCT00476177|Biological|Infusion of donor lymphocytes|Given in outpatient setting
79674223|NCT00493818|Drug|GSK690693|
79674224|NCT00476216|Drug|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 & 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
79674225|NCT00502632|Drug|Urokinase and Dornase alfa|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
79674226|NCT00502632|Drug|Urokinase|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
79674227|NCT00471185|Drug|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
79995016|NCT04180397|Drug|Furosemide|Furosemide 10 mg/ml for injection/infusion
79995017|NCT04180397|Drug|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
79516074|NCT05476328|Device|OPAL Sound Processing Strategy.|OPAL Sound Processing Strategy. OPAL sound processing strategy designed to improve perception of fundamental frequency (F0) as cue to lexical tone in tonal languages and to pitch in music. This research strategy will be implemented in the Nucleus 6 CP900 sound processors. The programming will be performed by the investigational software Cochlear Device Interface Tool (CDI Tool). Investigational firmware will be written on a commercially available N6 sound processor sound processor.
79516075|NCT05476328|Device|OPAL-EM|OPAL-EM (Enhanced Modulation) is a version of OPAL that improves temporal accuracy in the coding of F0 amplitude-modulation in the stimulus envelope. It is specifically designed to address the need for use of low stimulation rates (i.e., lower than the recommended OPAL rate of around 1200 pps/ch) but it is also expected to provided improvements for all stimulation rates by virtue of the improved temporal accuracy it provides.
79516076|NCT05476328|Device|SPACE|SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
79516077|NCT05476328|Device|FAST|FAST (Fundamental Asynchronous Stimulus Timing) is a low- and variable-rate coding strategy that has been shown to be power efficient and significantly increase sensitivity to ITD cues in bilateral subjects. It also explicitly codes low F0s as the rate of stimulation and may have tone and music benefits. It has been implemented on the Nucleus 5 CP800 sound processor for CIC4-based implants.
79674228|NCT01325701|Drug|ibrutinib|ibrutinib is an inhibitor of BTK
79516078|NCT05476328|Device|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
79995018|NCT04540445|Other|Pupillary Assessment|Pupillary assessment with handheld pupillometer
79995019|NCT04629911|Device|THRIVE|Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
79995020|NCT03625674|Behavioral|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
79995021|NCT03295721|Drug|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
79995022|NCT03295721|Drug|Saline Placebo|Saline placebo by instillation
79995023|NCT03295721|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
79995024|NCT03295721|Device|Luer-lock applicator|Applicator for instillation
79995025|NCT03295721|Device|Vial access device|Device for withdrawal of drug product
79995026|NCT00803790|Drug|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
79364515|NCT06016673|Procedure|Transcranial Magnetic Stimulation (TMS)|Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
79364516|NCT06016465|Drug|Dexamethasone Oral|Two 4mg pills
79516079|NCT05476328|Device|FAST-OPAL|FAST-OPAL (combined FAST and OPAL strategy) strategy was developed to improve FAST strategy performance in noisy environments. The processing techniques employed by FAST-OPAL retain the sparse, yet temporally precise coding of temporal envelope information, while improving coding of that information in noise and coding of relative across-channel intensity in noise.
79674229|NCT00493857|Drug|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
79674230|NCT00493857|Drug|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
79674231|NCT00476255|Behavioral|Enhanced Standard Care (ESC)|Reading material
79674232|NCT00476255|Behavioral|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
79674233|NCT00476294|Other|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
79674234|NCT01325623|Device|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
79674235|NCT00494052|Behavioral|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
79995027|NCT00803790|Drug|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
79995028|NCT00803790|Dietary Supplement|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
79995029|NCT03637985|Device|resistive exercise|resistive exercise by elastic band for 12 weeks
79995030|NCT03637985|Device|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
79364517|NCT06016465|Drug|Placebo|2 placebo pills
79364518|NCT06008314|Other|ePNa|"Real-time, automated clinical decision support tool for pneumonia (called ePNa)"
79364519|NCT06006117|Drug|Mosunetuzumab + Lenalidomide|"Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~C2 to C12: 45 mg D1 28-days cycles~Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
79371123|NCT03035578|Drug|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
79371124|NCT04933942|Drug|Lomustine|Oral administration of Lomustine
79516080|NCT05476328|Device|Cochlear Device Interface Tool|For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
79995031|NCT03568188|Procedure|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
79221304|NCT05528068|Behavioral|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
79221305|NCT05528068|Behavioral|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
79221306|NCT02518334|Other|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
79221307|NCT02317302|Device|FDG-PET/MR|
79221308|NCT02317302|Device|FDG-PET/CT|
79995032|NCT03568188|Biological|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
79221309|NCT05518084|Other|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
79221310|NCT04503824|Diagnostic Test|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
79221311|NCT05522686|Other|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
79516081|NCT05465642|Other|Collect stool and blood samples from patients|Collect stool and blood samples from patients
79995033|NCT03568188|Device|MRI|MRI exam will be regularly performed during patient follow up.
79995034|NCT03568188|Other|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
79995035|NCT03568188|Procedure|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
79221312|NCT05522686|Other|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
79221313|NCT05522686|Other|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
79221314|NCT05522686|Other|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
79221315|NCT03352544|Behavioral|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
79221316|NCT02317458|Biological|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
79221317|NCT02317458|Biological|Sham comparator|One arm with standard of care undergoing a sham procedure
79221318|NCT05518006|Dietary Supplement|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
79221319|NCT05518006|Dietary Supplement|Placebo Drink|Blended Placebo drink
79221320|NCT03349112|Behavioral|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
79221321|NCT03349112|Behavioral|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
79221322|NCT03501420|Other|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
79674236|NCT00494052|Behavioral|Physician Education Session|A physician education session will be included in the program.
79674237|NCT00476333|Device|APOS biomechanical gait system|
79516082|NCT05459272|Dietary Supplement|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
79516083|NCT05459272|Other|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
79516084|NCT05451576|Dietary Supplement|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
79995036|NCT03568188|Biological|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
79995037|NCT03568188|Biological|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
79995038|NCT00442338|Drug|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
79995039|NCT00442338|Drug|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
79995040|NCT00442338|Drug|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
79995041|NCT03506412|Drug|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
79995042|NCT03420768|Drug|BMS-986263|Administered by intravenous (IV) infusion
79995043|NCT03420768|Other|Placebo|Administered by intravenous (IV) infusion
79221323|NCT03501420|Other|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
79221324|NCT03501420|Other|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
79221325|NCT02320890|Device|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79221326|NCT02320890|Device|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79364520|NCT06006117|Drug|- Rituximab + Lenalidomide (28-days cycles|"Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
79516085|NCT05451576|Dietary Supplement|Placebo|Placebo will be given for 7 weeks (5 days/week).
79674238|NCT01246518|Drug|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
79995044|NCT03625440|Diagnostic Test|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
79995045|NCT03625440|Diagnostic Test|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
79995046|NCT02316834|Other|Laboratory Biomarker Analysis|Correlative studies
79995047|NCT02316834|Drug|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
79995048|NCT00250458|Drug|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
79221327|NCT03352466|Biological|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
79674239|NCT01325584|Drug|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
79674240|NCT04207294|Other|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
79674241|NCT04207294|Other|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
79674242|NCT00502749|Behavioral|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
79674243|NCT00502749|Behavioral|Questionnaires|Questionnaires taking 15 minutes to complete.
79221328|NCT03352466|Biological|BioThrax|Commercially available anthrax vaccine
79221329|NCT03352466|Other|Placebo|Normal saline
79364521|NCT06006117|Drug|- Rituximab + Bendamustine (28-days cycles)|"Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~Rituximab* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6** (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). **For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
79674244|NCT02891473|Other|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
79674245|NCT02891473|Other|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
79674246|NCT04126915|Genetic|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
79674247|NCT00502788|Drug|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
79995049|NCT00250458|Drug|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
79995050|NCT01965132|Drug|Biologic or targeted synthetic DMARD|
79516086|NCT05436756|Other|Biological sampling and collection|"Biological sampling and collection:~whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~urine: 1 bottle of 30ml~Freezing of serum after centrifugation~Storage~Collection of clinico-biological data on a dedicated eCRF"
79516087|NCT05420948|Drug|Pembrolizumab|A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
79821180|NCT04065711|Device|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
79821181|NCT00738621|Drug|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
79821182|NCT00738621|Drug|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
79221330|NCT02320968|Other|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
79221331|NCT05522608|Procedure|transabdominal preperitoneal hernia repair|It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
79221332|NCT05511350|Drug|TJ210001|
79221333|NCT03498222|Drug|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
79221334|NCT03498222|Drug|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
79221335|NCT03498222|Drug|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
79221336|NCT03498222|Drug|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
79221337|NCT05522530|Other|Assessment scale|Evaluation scale to carry out its cross-cultural adaptation and study its validity
79221338|NCT02518022|Drug|Insulin|Insulin for beer
79221339|NCT03352388|Dietary Supplement|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
79221340|NCT03498144|Device|Anterior segment OCT|lower punctum examination by AS-OCT
79364522|NCT06006117|Drug|- Rituximab + CHOP (21-days cycles)|"CHOP, IV standard dose from cycle 1 to 6~Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
79364523|NCT05991323|Drug|Dupilumab|Injection solution; subcutaneous
79364524|NCT05988892|Behavioral|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors >60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors >60 years of age and/or those of any age residing at a rural address.
79821183|NCT00733239|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
79221341|NCT03497988|Drug|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
79221342|NCT03497988|Drug|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
79221343|NCT04610476|Drug|Prednisolone|Prednisolone oral 1-5 mg/day
79221344|NCT04610476|Drug|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
79221345|NCT04610476|Drug|Leflunomide|Leflunomide oral 20 mg/day
79221346|NCT04610476|Drug|Methotrexate|Methotrexate oral > 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
79221347|NCT04610476|Drug|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
79221348|NCT04610476|Drug|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
79221349|NCT04610476|Drug|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
79221350|NCT04610476|Drug|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
79221351|NCT04610476|Drug|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
79221352|NCT04610476|Drug|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
79221353|NCT04610476|Drug|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
79221354|NCT04610476|Drug|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
79221355|NCT04610476|Drug|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
79364525|NCT05985590|Drug|BMS-986278|Specified dose on specified days
79516088|NCT05420948|Drug|Carboplatin|A chemotherapy drug used to treat cancer.
79516089|NCT05420948|Drug|Paclitaxel|A chemotherapy drug used to treat cancer.
79516090|NCT05419999|Device|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
79364526|NCT05985590|Drug|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
79364527|NCT05979493|Drug|Bupivacain|30cc IM injection in each quadratus lumborum muscle (60cc total).
79364528|NCT05979493|Drug|Saline|30cc IM injection in each quadratus lumborum muscle (60cc total).
79516091|NCT05419999|Other|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
79516092|NCT05419999|Behavioral|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
79516093|NCT05418348|Drug|GTX-104|new formulation of nimodipine injection for IV infusion
79516094|NCT05418348|Drug|Nimodipine Capsules|Nimodipine capsules (reference formulation)
79516095|NCT05416320|Drug|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
79516096|NCT05416320|Drug|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
79821184|NCT00738153|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79821185|NCT04065165|Drug|Telotristat Ethyl|250 mg TID orally
79221356|NCT04610476|Drug|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
79221357|NCT04610476|Drug|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
79221358|NCT03348800|Procedure|Dental anesthesia|A tooth extraction will be performed
79221359|NCT03501342|Other|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
79221360|NCT03501342|Other|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
79221361|NCT03352310|Biological|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
79221362|NCT03352310|Procedure|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
79221363|NCT02314806|Drug|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
79221364|NCT02314806|Drug|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
79364529|NCT05978388|Diagnostic Test|Analysis of coronary CT Angiography and CAC scoring prior to catheter ablation|Analysis of coronary CT angiography and CAC scoring and derived treatment prior to catheter ablation.
79364530|NCT05976828|Drug|IBRX-042|"Dose cohort 1: 1e11 virus particles (VP)/dose~Dose cohort 2: 5e11 VP/dose~If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
79221365|NCT02314806|Drug|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
79221366|NCT04502654|Device|Actiwatch 2 (Philips Respironics, Murrysville, USA)|Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm* 2.3 cm* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
79221367|NCT03501186|Other|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
79364531|NCT05973240|Other|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
79364532|NCT05971147|Dietary Supplement|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
79364533|NCT05967247|Other|The experimental group used App for MBSR intervention|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
79364534|NCT05967247|Other|"the Heart Care Life app"|"Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app."
79364535|NCT05967247|Other|Phone interview once a week|Phone interview once a week
79364536|NCT05966961|Device|Novosyn® in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
79516097|NCT05403216|Other|no intervention|
79516098|NCT05399121|Behavioral|Piano Learning then Free Improvisation|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
79364537|NCT05966961|Device|Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
79364538|NCT05965427|Other|No intervention|Study is retrospective data collection only
79364539|NCT05965089|Biological|Placebo|Placebo
79364540|NCT05965089|Biological|AX-202|Humanized monoclonal antibody
79364541|NCT05963243|Other|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
79364542|NCT05954494|Biological|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
79364543|NCT05953337|Device|EYE90 Microspheres Treatment|Y90 glass microspheres
79364544|NCT05952726|Other|Expiratory cycling change at different levels of pressure support ventilation|"Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow."
79364545|NCT05950477|Diagnostic Test|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
79364546|NCT05945953|Other|Incentive spirometer as visual feedback|"Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
79364547|NCT05945953|Other|Diaphragmatic breathing exercise (Mirror mediated therapy)|"Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
79364548|NCT05939765|Drug|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
79364549|NCT05937971|Other|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
79364550|NCT05937971|Other|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
79364551|NCT05937295|Drug|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
79364552|NCT05936346|Dietary Supplement|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
79364553|NCT05936346|Dietary Supplement|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
79364554|NCT05931770|Procedure|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
79364555|NCT05931770|Procedure|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
79364556|NCT05928585|Drug|HIB210|Experimental monoclonal antibody
79364557|NCT05928585|Drug|Placebo|Placebo
79371125|NCT04933942|Drug|Romiplostim|Subcutaneous administration of Romiplostim
79371126|NCT00089583|Drug|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
79371127|NCT00089583|Drug|Ritonavir|Ritonavir solution bid
79371128|NCT04902664|Behavioral|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
79516099|NCT05399121|Behavioral|Free Improvisation then Piano Learning|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
79995051|NCT01667133|Drug|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
79516100|NCT05393557|Other|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR < 60, or SBP <100 mmHg) + 2 cycles of intermittent balloon inflation
79674248|NCT00502788|Drug|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight > 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
79995052|NCT01667133|Drug|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
79995053|NCT03947775|Drug|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) [38]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
79995054|NCT01498770|Drug|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
79995055|NCT01498770|Drug|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
79995056|NCT01498770|Drug|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
79995057|NCT01498770|Drug|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
79674249|NCT00602134|Drug|6-Mercaptopurine|
79995058|NCT01498770|Drug|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
79221368|NCT04506476|Device|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
79221369|NCT03497754|Device|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
79371129|NCT04902664|Behavioral|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
79371130|NCT04902664|Behavioral|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
79821186|NCT04065165|Drug|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
79995059|NCT01498770|Drug|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
79995060|NCT01498770|Drug|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
79995061|NCT01498770|Drug|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
79995062|NCT01498770|Drug|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
79995063|NCT01498770|Drug|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
79221370|NCT02321124|Other|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
79221371|NCT02321124|Behavioral|life style advice|We will apply life style advice for four weeks.
79221372|NCT05522218|Device|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
79221373|NCT02321202|Drug|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
79371131|NCT04902664|Behavioral|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
79995064|NCT01498770|Drug|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
79995065|NCT01498770|Drug|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
79995066|NCT01498770|Drug|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
79995067|NCT00140946|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
79995068|NCT00140946|Drug|Comparator: placebo / Duration of Treatment: 16 weeks|
79995069|NCT00095004|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
79995070|NCT00095004|Drug|Comparator: placebo / Duration of Treatment: 1 day|
79995071|NCT00967746|Drug|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
79516101|NCT05387720|Procedure|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
79364558|NCT05926479|Other|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
79364559|NCT05926479|Other|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
79221374|NCT02321202|Drug|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
79364560|NCT05926479|Other|Reliability|The reliability of the materials will be tested with Cronbach alpha.
79516102|NCT05387720|Procedure|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
79516103|NCT05387720|Procedure|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
79516104|NCT05381285|Other|No intervention|Non-interventional study
79516105|NCT05378672|Drug|Dasiglucagon|Dasiglucagon, 0.6 mg/0.6 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the abdominal region.
79674250|NCT00471224|Other|Observational Trial|No intervention is being used in this study.
79674251|NCT02891590|Drug|DTRMWXHS-12|
79995072|NCT00967746|Drug|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
79995073|NCT00967746|Drug|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
79221375|NCT00709202|Drug|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
79221376|NCT00709202|Drug|Placebo Oral Tablet|
79221377|NCT02314884|Drug|Cafusertib Hydrochloride|
79221378|NCT05517538|Device|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
79674252|NCT00502827|Behavioral|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
79221379|NCT05517538|Drug|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
79221380|NCT02321280|Drug|Denosumab|Single dose subcutaneous administration
79221381|NCT03501108|Other|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
79221382|NCT03348644|Dietary Supplement|Phosphate tablets.|
79221383|NCT03348644|Dietary Supplement|High cheese intake.|
79221384|NCT03348644|Dietary Supplement|High milk intake.|
79221385|NCT03501030|Behavioral|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
79221386|NCT02317536|Dietary Supplement|Carnipure Product 1|
79674253|NCT00502827|Other|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
79674254|NCT00494208|Drug|Testosterone|Testosterone ester
79995074|NCT00967746|Device|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
79221387|NCT02317536|Dietary Supplement|Carnipure Product 2|
79221388|NCT02317536|Other|Placebo|Placebo
79221389|NCT03352154|Diagnostic Test|P300 - Auditory long latency potential|Perform the P300 exams.
79221390|NCT02321358|Behavioral|Two-time implementation intention|Will be given intervention and booster at six weeks
79221391|NCT02321358|Behavioral|One-time implementation intention|Will only be given the intervention once
79221392|NCT02321358|Behavioral|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
79674255|NCT00471341|Drug|Celecoxib|
79674256|NCT00471341|Drug|placebo|
79674257|NCT01325428|Drug|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
79674258|NCT01325428|Drug|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
79674259|NCT00502983|Behavioral|Interview|Interview lasting approximately 50 minutes.
79364561|NCT05926336|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
79674260|NCT00476411|Biological|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
79674261|NCT00494247|Device|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
79674262|NCT00471419|Drug|Rimexolone|
79674263|NCT01325350|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79674264|NCT01325350|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79674265|NCT01325350|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79674266|NCT01325350|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79674267|NCT01325350|Drug|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
79674268|NCT01324999|Drug|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
79674269|NCT00503022|Drug|ACZ885|
79674270|NCT02891356|Device|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
79995075|NCT00092118|Drug|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
79995076|NCT00092118|Drug|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
79221393|NCT02321358|Behavioral|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
79221394|NCT05527366|Other|Vagus stimulation|The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.
79364562|NCT05926336|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
79364563|NCT05925621|Drug|Lecanemab|Observational study
79364564|NCT05921591|Drug|IRL201104|Lyophilised powder for reconstitution for IV dosing
79674271|NCT03273335|Device|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
79674272|NCT00494286|Behavioral|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
79674273|NCT00494286|Behavioral|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
79821187|NCT00577629|Drug|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
79821188|NCT00577629|Drug|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
79364565|NCT05921591|Drug|Placebo|Matching placebo for IRL201104
79364566|NCT05920577|Other|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
79364567|NCT05920577|Other|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
79821189|NCT00577629|Drug|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
79516106|NCT05378087|Radiation|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
79516107|NCT05378087|Procedure|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
79516108|NCT05377606|Procedure|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
79516109|NCT05377606|Procedure|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
79516110|NCT05374681|Other|Medical treatment|Medical treatment alone
79516111|NCT05374681|Other|Surgical treatment|Surgical treatment alone
79516112|NCT05374681|Other|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
79516113|NCT05374577|Other|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
79516114|NCT05374577|Other|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
79516115|NCT05374018|Diagnostic Test|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
79516116|NCT05372367|Drug|BI 907828|BI 907828
79516117|NCT05372367|Drug|Rifampicin|Rifampicin
79516118|NCT05372367|Drug|Itraconazole|Itraconazole
79516119|NCT05359562|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
79516120|NCT05351242|Other|Thermotherapy/sauna bath|Thermotherapy/sauna bath
79516121|NCT05350371|Drug|Pirfenidone Oral Tablet|Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
79516122|NCT05350371|Drug|Placebo|The placebo tablets will be an exact replica of the pirfenidone tablet.
79516123|NCT05348200|Drug|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
79516124|NCT05348200|Drug|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
79516125|NCT05348200|Drug|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
79516126|NCT05348200|Drug|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
79516127|NCT05348200|Drug|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
79516128|NCT05338216|Behavioral|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
79516129|NCT05338216|Behavioral|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
79516130|NCT05325502|Dietary Supplement|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
79516131|NCT05325502|Dietary Supplement|mannitol|two doses per day: 200 mg in the morning & 100 mg in the afternoon
79516132|NCT05321108|Other|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
79821190|NCT00577629|Drug|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
79821191|NCT00577629|Drug|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
79516133|NCT05321108|Other|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
79516134|NCT05307744|Dietary Supplement|PS128|Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
79516135|NCT05307744|Other|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
79221395|NCT05527366|Other|Consevative treatment|A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
79221396|NCT04502342|Combination Product|Hydroxycloroquine and Azythromycine|dual treatment with Hydroxycloroquine and Azythromycine
79221397|NCT04502342|Combination Product|Cospherunate/Azythromycine|dual treatment with Cospherunate and Azythromycine
79221398|NCT04502342|Combination Product|Cospherunate/Phytomedicine/Azythromycien|triple treatment with Cospherunate, Asen and Azythromycine
79221399|NCT02315040|Device|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
79221400|NCT02315040|Other|Standard Intrauterine Insemination|standard intrauterine insemination procedure
79364568|NCT05916677|Other|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
79221401|NCT04462848|Biological|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
79221402|NCT00709124|Device|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
79364569|NCT05916677|Other|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
79516136|NCT05290961|Other||The study is an observational trial, which don't have any intervention.
79516137|NCT05285384|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
79364570|NCT05916625|Other|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
79221403|NCT00709124|Device|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
79221404|NCT03500952|Other|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
79221405|NCT03500952|Other|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
79221406|NCT02315118|Drug|T-cell therapy + Rituximab + IL-2|"T cells collection~T cells expansion and modification in the laboratory~T cells infusion back to the patients"
79221407|NCT03500796|Procedure|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
79221408|NCT03500796|Procedure|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
79364571|NCT05916625|Other|biological sample|10 mL intravenous whole blood collection in EDTA tube
79364572|NCT05916625|Procedure|medical imagery|Pet scan with the specific radioligand [11C]SB207145 and MRI
79364573|NCT05915390|Dietary Supplement|walnuts|walnuts will provide 15% of the total energy
79364574|NCT05915390|Dietary Supplement|Habitual diet|continue with habitual diet and abstain from walnuts
79364575|NCT05914688|Drug|LY3209590 (Formulation 1)|Administered SC.
79364576|NCT05914688|Drug|LY3209590 (Formulation 2)|Administered SC.
79516138|NCT05265195|Other|Mixed Methods study|Mixed Methods study
79364577|NCT05912062|Drug|Trastuzumab (neoadjuvant)|Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
79364578|NCT05912062|Drug|Pertuzumab (neoadjuvant)|Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
79516139|NCT05261191|Biological|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
79516140|NCT05261191|Biological|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
79516141|NCT05250778|Behavioral|Nudge|Room intervention
79516142|NCT05249127|Drug|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
79516143|NCT05235737|Drug|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
79516144|NCT05235737|Drug|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
79995077|NCT00920634|Drug|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
79995078|NCT05167578|Behavioral|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
79995079|NCT00092040|Drug|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
79221409|NCT05527288|Drug|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent [18F]florbetaben at a radioactive dose of 300 MBq.
79221410|NCT03497598|Drug|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
79221411|NCT03497598|Drug|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
79221412|NCT05521750|Procedure|Transforaminal Percutaneous Endoscopic Lumbar Decompression|TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
79221413|NCT03122756|Drug|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
79221414|NCT03122756|Other|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
79221415|NCT03500718|Device|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
79221416|NCT03122678|Drug|Thiamine|
79364579|NCT05912062|Drug|Paclitaxel (neoadjuvant)|Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
79995080|NCT00092040|Drug|Comparator: risedronate / Duration of Intervention: 12 mo|
79995081|NCT04925154|Behavioral|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
79995082|NCT05582928|Device|Neurofeedback|Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
79995083|NCT04914780|Behavioral|Education|Education intervention with mobile application for 4 weeks
79364580|NCT05904990|Device|High Intensity Laser|High Intensity Laser
79364581|NCT05904236|Drug|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
79364582|NCT05902234|Behavioral|interdiciplinary treatment|Normal interdiciplinary treatment path
79516146|NCT05222763|Behavioral|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
79995084|NCT05225142|Procedure|Modified minimally invasive surgery|Surgical intervention alone
79995085|NCT05225142|Procedure|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
79995086|NCT05225142|Procedure|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
79995087|NCT03261947|Drug|TAK-931|TAK-931 hard gelatin capsules
79995088|NCT05654844|Radiation|LC images|Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
79364583|NCT05900453|Other|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
79221417|NCT03122678|Drug|Placebos|
79221418|NCT05521594|Procedure|Fine Needle Aspiration Cytology|Comparison between FNAC and post operative specimen after thyroid surgery
79221419|NCT04506398|Procedure|liver transplant|Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
79221420|NCT04506398|Diagnostic Test|ctDNA|Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
79221421|NCT04506398|Diagnostic Test|whole exome sequencing|xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
79221422|NCT03348488|Procedure|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
79221423|NCT03502122|Other|VR rehabilitation for motor function|rehabilitation for motor function
79221424|NCT02315274|Other|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
79221425|NCT02317770|Drug|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
79516147|NCT05222763|Behavioral|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
79516148|NCT05218356|Drug|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
79221426|NCT02317770|Drug|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
79516149|NCT05218356|Diagnostic Test|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
79364584|NCT05897905|Behavioral|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~Detailed biopsychosocial review.~Understand participant priorities and jointly set goals.~Agreeing onward referrals if needed.~Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~Review priorities identified in post stroke review checklist.~Review goals and plans from first appointment.~Address any new or persistent information gaps.~Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~Agreeing onward referrals and action plan.~Written summary and plan sent to GP."
79516150|NCT05218356|Diagnostic Test|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
79516151|NCT05218356|Diagnostic Test|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
79674274|NCT03271385|Diagnostic Test|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
79221427|NCT03348410|Behavioral|Motivational interviewing|Motivational interviewing with insurance officer
79221428|NCT02317848|Other|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
79364586|NCT05893134|Other|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
79364587|NCT05891821|Drug|Balstilimab|An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody
79516152|NCT05218356|Diagnostic Test|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
79221429|NCT04506242|Drug|SHR-1210|PD-1
79221430|NCT04506242|Drug|Apatinib|VEGFR2
79221431|NCT05526898|Device|SyntrFuge System|Microsized Adipose Tissue
79364588|NCT05891353|Other|Cold Water Immersion|Cold Water Immersion task of hand
79364589|NCT05891353|Other|Pain Inducing Stretch|Moderately painful stretch of the neck
79364590|NCT05891353|Other|Pain Free Stretch|Pain free stretch of the neck
79516153|NCT05218356|Other|NEWS-2 score|assessment of the participant by the NEWS-2 score.
79516154|NCT05218356|Other|WHO score|assessment of the participant by the score of the World Health Organization.
79516155|NCT05218356|Other|Physical examination|evaluation by the principal investigator or assistant physician
79516156|NCT05218356|Other|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
79516157|NCT05204719|Procedure|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
79516158|NCT05176015|Device|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
79674275|NCT01324570|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
79821192|NCT00577629|Drug|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
79821193|NCT00733317|Drug|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
79821194|NCT00733317|Drug|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
79221432|NCT05526898|Drug|Triamcinolone Injection|Corticosteroid
79221433|NCT02317926|Drug|Levothyroxine|
79221434|NCT02317926|Drug|Levothyroxine Plus Liothyronine|
79221435|NCT02317926|Drug|Desiccated Thyroid Extract|
79221436|NCT05526820|Biological|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
79221437|NCT02321592|Drug|AFM13|
79516159|NCT05176015|Diagnostic Test|Diagnostic Algorithm|"A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score"
79516160|NCT05175430|Drug|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
79995089|NCT05654844|Radiation|CBCT images|Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
79995090|NCT05224284|Other|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
79674276|NCT05645653|Behavioral|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
79221438|NCT03352076|Drug|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
79221439|NCT03352076|Drug|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
79516161|NCT05175430|Drug|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
79516162|NCT05175430|Drug|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
79995091|NCT05224128|Drug|Imatinib 200mg|Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
79995092|NCT05224128|Drug|Placebo|Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
79995093|NCT04976946|Other|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
79995094|NCT04949880|Device|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
79995095|NCT04050852|Drug|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
79995096|NCT05065242|Behavioral|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
79995097|NCT04051086|Biological|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~Medical examination : birth, weight, gender, blood pressure, medical history~Urine and blood samples"
79221440|NCT02321670|Procedure|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
79364591|NCT05889104|Other|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
79364592|NCT05889104|Other|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
79364593|NCT05886335|Drug|Cyclophosphamide|Time of administration
79364594|NCT05883488|Other|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
79364595|NCT05883488|Other|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
79221441|NCT02321670|Procedure|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
79364596|NCT05883137|Device|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
79364597|NCT05880446|Other|Bowel symptoms & QoL assessment|QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
79516163|NCT05169398|Device|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea)
79516164|NCT05168995|Drug|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
79674277|NCT03271229|Biological|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
79674278|NCT03271229|Biological|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
79674279|NCT04325698|Drug|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
79995098|NCT04051086|Biological|Urine and blood samples|"Only one visit for each participant~Medical history~Urine and blood samples"
79221442|NCT05521282|Drug|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
79995099|NCT05223660|Drug|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
79995100|NCT05223660|Drug|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
79995101|NCT05223660|Drug|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
79995102|NCT05223660|Drug|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
79995103|NCT03590730|Device|ICD implantation|ICD will be implanted according to current guidelines recommendations.
79995104|NCT03625206|Behavioral|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
79516165|NCT05148117|Diagnostic Test|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
79516166|NCT05148117|Diagnostic Test|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
79674280|NCT04325698|Drug|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
79674281|NCT04325698|Drug|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
79364598|NCT05880394|Drug|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
79674282|NCT04325698|Drug|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
79221443|NCT05311124|Device|Integra Dermal Regeneration template (IDRT)|Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
79364599|NCT05880394|Drug|Copper-64 DOTATATE|Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
79364600|NCT05880095|Other|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
79364601|NCT05880095|Other|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
79995105|NCT03625206|Behavioral|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
79995106|NCT05223426|Other|Cognitive training|A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.
79364602|NCT05880095|Other|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
79364603|NCT05875259|Drug|BR1019-1|Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
79995107|NCT05223426|Other|Usual Care|Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
79364604|NCT05875259|Drug|BR1019-2|Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
79364605|NCT05875259|Drug|BR1019-1 + BR1019-2|Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
79364606|NCT05874791|Behavioral|Goal Management training|metacognitive group intervention
79221444|NCT03502044|Device|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
79221445|NCT03502044|Device|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
79516167|NCT05140343|Diagnostic Test|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
79516168|NCT05139277|Diagnostic Test|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
79516169|NCT05139277|Other|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
79516170|NCT05138432|Behavioral|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
79221446|NCT03497442|Drug|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
79221447|NCT03497442|Drug|Placebo Vehicle Gel|Vehicle Gel
79221448|NCT05516602|Other|Peer Support|"Peer-led support groups over the weekend will include the following activities:~Peer leader counselling on oral PrEP and HIV risk reduction~Peer leader discussion to dispel myths and misconceptions around oral PrEP~Peer leader sharing of experiences of daily pill taking~Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~1-2 role plays per support group session."
79221449|NCT04503122|Procedure|pulmonary vein isolation|pulmonary vein isolation : cryoablation or radiofrequency
79221450|NCT02738580|Drug|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
79221451|NCT02738580|Drug|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
79221452|NCT03348332|Behavioral|Exercise pregnant women|A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
79221453|NCT02318004|Other|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
79221454|NCT04505696|Other|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
79221455|NCT05521204|Drug|Olverembatinib|Given PO
79821195|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
79221456|NCT03497364|Drug|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173~174cm, 1.65 ml for 170~172cm, 1.6 ml for 168~169cm, 1.55 ml for 165~167cm, 1.5 ml for 163~164cm, 1.45 ml for 160~162cm, 1.4 ml for 158~159cm, 1.35 ml for 155~157cm, 1.3 ml for 153~154cm, 1.25 ml for 150~152cm, 1.2 ml for 148~149cm)，1.15 ml for 145~147cm).
79364607|NCT05871437|Drug|Huaier granule|Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
79516171|NCT05133791|Drug|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
79516172|NCT05127915|Device|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
79516173|NCT05127915|Device|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
79995108|NCT04897776|Device|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
79221457|NCT03497364|Drug|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173~174cm, 2.225 ml for 170~172cm, 2.15 0ml for 168~169cm, 2.075 ml for 165~167cm, 2.000 ml for 163~164cm, 1.925 ml for 160~162cm, 1.850 ml for 158~159cm, 1.775 ml for 155~157cm, 1.700 ml for 153~154cm, 1.625 ml for 150~152cm, 1.55 0ml for 148~149cm, 1.475 ml for 145~147cm)
79221458|NCT03348254|Drug|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
79221459|NCT03348254|Drug|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
79516174|NCT05125822|Other|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
79221460|NCT03348176|Other|Vegetable exposure|Repeated exposure to variety of vegetables
79221461|NCT03348176|Behavioral|VIPP-Feeding Infants|Promoting responsive feeding practices
79221462|NCT03348176|Other|Control|Phone calls with mother about development of child, no advice on complementary feeding
79364608|NCT05871320|Drug|[99mTc]Tc-TECANT1|only one arm - the administration of [99mTC]-Tc-TECANT1 in all patients included
79674283|NCT00503100|Device|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
79674284|NCT01324141|Drug|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
79674285|NCT01324141|Drug|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
79674286|NCT01324141|Drug|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
79674287|NCT01324141|Procedure|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
79364609|NCT05867056|Drug|IMC-I109V-101 Single Ascending Dose|Single dose administration of IMC-I109V-101
79364610|NCT05867056|Drug|IMC-I109V-101 Multiple Ascending Doses|Multidose administration of IMC-I109V-101
79364611|NCT05860673|Procedure|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
79364612|NCT05860673|Procedure|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
79364613|NCT05857735|Other|Observational registry with no intervention.|No intervention
79516175|NCT05115513|Drug|Medium THC|Marijuana flower with medium THC
79516176|NCT05115513|Drug|Placebo THC|Marijuana flower with no THC
79674288|NCT00471575|Procedure|ultra sound examination|
79674289|NCT00503217|Drug|Tryptorelin|
79221463|NCT02315508|Drug|AUT00063|800 mg orally, once a day, for 4 weeks
79221464|NCT02315508|Drug|Placebo|orally, once a day, for 4 weeks
79221465|NCT05516446|Device|DEB for de Novo Lesions|The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
79516178|NCT05105542|Drug|11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor|The radiotracer, [11C]EMO, will be administered at the beginning of each PET scan.
79516179|NCT05101707|Device|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
79221466|NCT05516446|Device|DES for de Novo Lesions|The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
79221467|NCT02318082|Drug|Interleukin-2|
79302471|NCT03223831|Other|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 & 12cm.
79674290|NCT01324102|Behavioral|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
79674291|NCT00503256|Behavioral|Questionnaire|Questionnaires each taking 60 minutes to complete.
79516180|NCT05101707|Other|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
79516181|NCT05099991|Device|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
79516182|NCT05099991|Device|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
79516183|NCT05089760|Other|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
79516184|NCT05080075|Biological|Platelet Rich Plasma Injection|Research participants own blood will be used to prepare the platelet rich plasma injectate, which will be injected into the affected knee using ultrasound guidance.
79674292|NCT01324024|Drug|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
79221468|NCT04994470|Behavioral|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
79221469|NCT04994470|Behavioral|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
79221470|NCT02318160|Other|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
79364614|NCT05857150|Diagnostic Test|Treadmill Test|Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
79364615|NCT05857150|Diagnostic Test|Strength Test|Measure the strength of leg muscles by kicking against a machine with resistance.
79364616|NCT05857150|Diagnostic Test|Dual-Energy X-Ray Absorptiometry|Body composition measurement.
79516185|NCT05071170|Behavioral|Ad libitum energy intake|Investigate post meal satiety and subsequent post meal energy intake according to degree of food processing and eating behaviour
79516186|NCT05067244|Drug|MDMA|MDMA assisted psychotherapy
79674293|NCT01324024|Drug|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
79674294|NCT00476528|Behavioral|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
79674295|NCT00476528|Behavioral|Reality Orientation|A quasiexperimental study
79674296|NCT00494520|Procedure|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
79364617|NCT05857150|Procedure|Muscle Biopsy|Obtain a small piece of muscles from the upper part of the legs
79364618|NCT05857150|Procedure|Fat Biopsy|Fat sample taken from abdomen
79516187|NCT05063487|Other|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
79995109|NCT04897776|Device|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
79995110|NCT04852848|Behavioral|Connect2Test Intervention|Brief assessment based feedback and motivational interviewing intervention
79995111|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
79364619|NCT05857150|Diagnostic Test|Resting Energy Expenditure|Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
79364620|NCT05857150|Diagnostic Test|Magnetic resonance imaging|MRI on upper leg to look at fat and muscle
79995112|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
79995113|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
79674297|NCT00494520|Procedure|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
79995114|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
79995115|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
79995116|NCT03098979|Drug|Placebo|Orally once daily for 20 weeks
79995117|NCT03625362|Dietary Supplement|Hydrogen|Hydrogen-rich water
79995118|NCT03625362|Dietary Supplement|Placebo|Tap water
79221471|NCT02518100|Device|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
79221472|NCT02518100|Device|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
79821196|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
79364622|NCT05857007|Device|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
79516188|NCT05063487|Other|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
79516189|NCT05062057|Device|Adhesive ambulatory ECG recording patches|All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
79674298|NCT00476567|Other|standard|standard antenatal care
79674299|NCT00476567|Behavioral|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
79674300|NCT00502554|Procedure|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
79674301|NCT00503295|Biological|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
79674302|NCT00471614|Drug|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
79674303|NCT01244217|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
79674304|NCT00471653|Drug|temozolomide|
79674305|NCT00471653|Genetic|comparative genomic hybridization|
79674306|NCT00471653|Genetic|polymorphism analysis|
79674307|NCT00471653|Other|laboratory biomarker analysis|
79221473|NCT04301674|Device|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
79221474|NCT03501888|Behavioral|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
79221475|NCT03501888|Behavioral|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
79221476|NCT03347006|Dietary Supplement|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
79516190|NCT05060887|Biological|OVX836-003|One single administration intramuscularly at Day 1.
79516191|NCT05060887|Biological|Saline solution|One single administration intramuscularly at Day 1.
79674308|NCT00471653|Other|pharmacological study|
79674309|NCT00471653|Radiation|radiation therapy|
79674310|NCT00471692|Drug|Ropivicaine|
79674311|NCT01244295|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
79674312|NCT01244295|Behavioral|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
79995119|NCT03625596|Dietary Supplement|L-Arginine|Acute intervention (3 hours)
79995120|NCT03625596|Dietary Supplement|Nitrate / Nitrite|Acute intervention (3 hours)
79995121|NCT03625596|Dietary Supplement|Placebo|Acute intervention (3 hours)
79995122|NCT04802304|Other|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
79995123|NCT05416827|Procedure|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
79995124|NCT05416671|Behavioral|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
79674313|NCT00476684|Procedure|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
79221477|NCT03497286|Behavioral|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
79221478|NCT03497286|Behavioral|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
79221479|NCT03348098|Drug|Apatinib|500 mg, po, qd. 12weeks
79221480|NCT03348098|Drug|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
79221481|NCT02315742|Behavioral|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
79221482|NCT02321826|Behavioral|Music|Participants choice among 4 genres of music matched on music characteristics
79221483|NCT02321826|Behavioral|Audiobook|Participants choice among 4 types of audiobooks
79221484|NCT05526274|Diagnostic Test|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
79221485|NCT03351920|Other|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
79221486|NCT02318238|Other|6 minutes walking test|
79221487|NCT02318238|Other|6 minutes step test|
79221488|NCT02318238|Other|4 meters gait speed|
79221489|NCT04503356|Procedure|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
79364623|NCT05854992|Drug|Acute migraine treatment with any prescribed triptans|Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
79364624|NCT05854992|Drug|Standard of care management of acute migraine without triptans|Any standard of care management without triptans
79674314|NCT00476684|Procedure|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
79674315|NCT00494559|Drug|Pioglitazone|Actos 15mg once a day before breakfast
79674316|NCT00494559|Drug|Placebo|Placebo drug with the same appearance as actos
79221490|NCT04503356|Procedure|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
79221491|NCT02318316|Other|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
79221492|NCT03346928|Procedure|Head and neck reconstruction|Head and neck free flap reconstruction
79221493|NCT02318394|Biological|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
79364625|NCT05853276|Behavioral|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
79364626|NCT05852145|Drug|Stevioside|"355 ml of tea lemon flavor added with 2.2 gr. of stevioside should be drunk~Salivary pH will be collected at 0, 5, 10, 15, 30, 45 and 60 minutes later.~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later.~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be determined at 0 and 120 minutes later.~Operative Taxonomic Units of dental biofilm will be analyzed at 0 and 120 minutes later."
79221494|NCT05516368|Behavioral|TF-CBT|Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
79516192|NCT05041036|Drug|Nirogacestat (Gamma Secretase Inhibitor)|Patients will receive nirogacestat tablets to be taken orally.
79516193|NCT05032703|Device|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
79221495|NCT03351842|Drug|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
79221496|NCT03351842|Procedure|Undergo surgery|Therapeutic conventional surgery, R0 resection
79221497|NCT02321904|Procedure|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
79221498|NCT02321904|Procedure|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
79516194|NCT05031468|Biological|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
79674317|NCT00503334|Dietary Supplement|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
79674318|NCT00494598|Drug|Sufentanil|200 mcg intra-arterial one time bolus
79674319|NCT00503412|Drug|AZD2171|oral 14C
79674320|NCT00503451|Drug|LBH589|
79516195|NCT05031117|Procedure|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
79516196|NCT05031117|Procedure|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
79516197|NCT05028166|Drug|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
79516198|NCT05027945|Drug|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
79221499|NCT02321904|Procedure|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
79221500|NCT02321904|Procedure|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
79516199|NCT05027945|Drug|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
79674321|NCT00471809|Drug|Budesonide + Salmeterol + Azithromycin|
79221501|NCT02321904|Procedure|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
79364627|NCT05850494|Drug|HFA MDI|"Dose formulation: MDI~Unit dose strength(s): Reference (propellant only)~Dosage Level: 4 inhalations, single dose~Route of administration: Oral inhalation~Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
79364628|NCT05850494|Drug|HFO MDI|"Dose formulation: MDI~Unit dose strength(s): Experimental (propellant only)~Dosage Level: 4 inhalations, single dose~Route of administration: Oral inhalation~Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
79674322|NCT00471809|Drug|Budesonide + Salmeterol + Montelukast|
79364629|NCT05850351|Other|Virtual reality|Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
79516200|NCT05027945|Drug|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
79674323|NCT00471809|Drug|Budesonide + Salmeterol + Placebo|
79674324|NCT00503490|Drug|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
79221502|NCT05520970|Biological|AdCLD-CoV19-1|All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
79221503|NCT02315820|Procedure|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
79221504|NCT04505306|Procedure|Macular Laser|All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
79516201|NCT05027945|Radiation|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
79516202|NCT05027945|Drug|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
79674325|NCT00503490|Drug|placebo|BID
79674326|NCT00476801|Device|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
79674327|NCT04696965|Other|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
79674328|NCT04696965|Other|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
79674329|NCT00494637|Drug|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
79674330|NCT00471965|Drug|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
79674331|NCT00471965|Drug|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
79674332|NCT00472004|Drug|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
79221505|NCT02571244|Behavioral|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
79364630|NCT05850351|Other|Online|Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
79364631|NCT05846113|Diagnostic Test|Renasight|"The Renasight™ test is a next generation sequencing (NGS) gene mutation assay for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 380 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders.~Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.~RenasightTM is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
79364632|NCT05842512|Drug|ADI-PEG20|Treatment for NASH
79364633|NCT05842512|Other|Placebo|Treatment for NASH
79364634|NCT05839743|Other|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
79364635|NCT05839743|Other|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
79364636|NCT05839743|Other|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
79364637|NCT05839639|Drug|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
79364638|NCT05839639|Drug|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
79516203|NCT05027945|Drug|Sirolimus|Sirolimus: on day +5 5mg PO loading dose q4h for 3 doses, then 5 mg PO q24h starting on day +6
79516204|NCT05027945|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
79516205|NCT05027945|Drug|Busulfan test dose|0.8 mg/kg IV over 2 hours
79516206|NCT05027945|Procedure|Allogeneic HSCT|stem cell transplant on day 0
79674333|NCT00472004|Drug|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
79674334|NCT00494715|Drug|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
79364639|NCT05839639|Drug|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
79364640|NCT05839145|Other|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
79516211|NCT05006157|Device|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
79516212|NCT04999059|Other|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
79516213|NCT04987541|Device|intermittent theta burst stimulation|stimulatory protocol
79364641|NCT05839145|Other|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
79364642|NCT05839145|Other|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
79674335|NCT00494715|Drug|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
79674336|NCT00494715|Drug|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
79516214|NCT04986943|Device|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
79516215|NCT04978805|Behavioral|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
79674337|NCT00472043|Procedure|PDT with Metvix 160 mg/g cream and Placebo cream|
79674338|NCT00503529|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
79821197|NCT00733395|Dietary Supplement|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
79821198|NCT00733395|Dietary Supplement|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
79821199|NCT02568735|Drug|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
79221506|NCT03497208|Procedure|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
79221507|NCT03497208|Procedure|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
79221508|NCT03497208|Radiation|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
79221509|NCT02447406|Drug|AZD6094|
79221510|NCT02447406|Drug|docetaxel|
79516216|NCT04978298|Other|Placebo|Placebo
79821200|NCT02568735|Drug|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
79821201|NCT00733473|Drug|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
79821202|NCT00733473|Drug|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
79221511|NCT05584982|Device|AtbFinder|In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
79364643|NCT05839145|Other|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
79364644|NCT05839145|Device|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
79516217|NCT04978298|Drug|Rasigiline|Rasigiline
79821203|NCT00733551|Drug|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
79821204|NCT00733551|Drug|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
79221512|NCT02315976|Drug|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
79221513|NCT03122210|Device|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
79221514|NCT02321982|Other|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
79221515|NCT04505150|Behavioral|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
79364645|NCT05839145|Other|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
79821205|NCT00710385|Drug|Heroin|Heroin (25 mg)
79364646|NCT05839145|Other|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
79364647|NCT05837897|Drug|Vedolizumab IV|Vedolizumab IV infusion
79364648|NCT05837897|Drug|Placebo|Vedolizumab placebo-matching IV infusion
79364649|NCT05821868|Device|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
79516218|NCT04978298|Drug|Phenelzine|Phenelzine
79516219|NCT04978298|Drug|Ozanimod|Ozanimod
79821206|NCT00710385|Drug|Naloxone|.4 mg
79821207|NCT00710385|Drug|Low Bup Dose|4 and 8 mg
79516222|NCT04941222|Other|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
79516223|NCT04939727|Other|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
79516224|NCT04935619|Behavioral|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
79516225|NCT04935619|Behavioral|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
79674339|NCT02273999|Device|RecoveryRx™|Appliance of the device after surgery
79674340|NCT01323946|Biological|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
79674341|NCT03271073|Drug|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
79821208|NCT00710385|Drug|High Bup Dose|8mg and 16 mg
79821209|NCT00710385|Drug|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
79821210|NCT00710385|Drug|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
79821211|NCT00710385|Drug|Placebo (PCB)|Placebo control administration
79516226|NCT04930341|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
79674342|NCT01246557|Drug|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
79674343|NCT01246557|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
79516227|NCT04921527|Drug|chiauranib|50mg orally once daily
79221516|NCT02322060|Procedure|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
79221517|NCT02322060|Procedure|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
79221518|NCT02322060|Procedure|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
79221519|NCT02322060|Procedure|Ovarian superficial cut|Superficial cut of the ovarian cortex by laparoscopy or laparotomy
79221520|NCT04505228|Drug|Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy|The designed Chinese herb formulas
79221521|NCT04505228|Drug|Atropine Sulfate|The basic treatment for heart disease
79221522|NCT02316054|Device|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
79516228|NCT04921527|Drug|Placebo|50mg orally once daily
79516229|NCT04921527|Drug|Paclitaxel|at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
79221523|NCT02322138|Other|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
79221524|NCT02322138|Other|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
79221525|NCT02322138|Other|Reference Group|Breast fed ad libitum
79221526|NCT05584826|Drug|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (~84 mg MDMA) + 40 mg MDMA HCl (~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
79221527|NCT02318628|Device|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
79221528|NCT02324400|Device|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
79221529|NCT02324400|Device|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
79221530|NCT02573350|Drug|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
79221531|NCT02573350|Drug|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
79221532|NCT02322294|Dietary Supplement|Glucodia™|
79221533|NCT02322294|Other|Placebo|
79221534|NCT02322372|Drug|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
79221535|NCT02322372|Drug|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
79221536|NCT01376804|Drug|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
79221537|NCT02322450|Drug|QGC001|
79221538|NCT02322450|Drug|Placebo|
79221539|NCT03500250|Other|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
79674344|NCT00476879|Drug|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
79674345|NCT00472121|Device|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
79221540|NCT05526118|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
79364650|NCT05821868|Device|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
79364651|NCT05817175|Procedure|pre-pectoral breast reconstruction|to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
79364652|NCT05813132|Drug|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
79364653|NCT05813132|Drug|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
79221541|NCT02324478|Procedure|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
79516230|NCT04902378|Device|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
79516231|NCT04898504|Drug|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.
79516232|NCT04898504|Procedure|Liver Transplantation|Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
79516233|NCT04896021|Diagnostic Test|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
79516234|NCT04896021|Diagnostic Test|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
79516235|NCT04876079|Other|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
79516236|NCT04876079|Device|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
79516237|NCT04876079|Other|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
79221542|NCT03122132|Drug|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
79221543|NCT03122132|Drug|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
79364654|NCT05812989|Behavioral|Social Engage Coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
79364655|NCT05812989|Behavioral|Connect for Caregivers|Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
79364656|NCT05811442|Drug|50561 high dose|study drug
79364657|NCT05811442|Drug|50561 low dose|study drug
79516238|NCT04876079|Drug|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
79364658|NCT05811442|Drug|Placebo|Non-active study drug
79364659|NCT05800834|Drug|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
79516239|NCT04865523|Other|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
79516240|NCT04852211|Procedure|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~Laparoscopic group: LMH~Open group: OMH"
79995125|NCT04958421|Device|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
79516241|NCT04832113|Other|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
79516242|NCT04832113|Other|conventional management|Dietary and hydratation advices according to the recommendations
79995126|NCT04980690|Biological|IBC0966|IBC0966 is an investigational product.
79302472|NCT03223831|Other|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
79364660|NCT05800834|Drug|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
79364661|NCT05798325|Other|2MWT|Two minutes walk tests.
79516243|NCT04811573|Drug|EU-sourced Otezla®|Test product
79221544|NCT04461912|Device|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
79516244|NCT04811573|Drug|US-sourced Otezla®|Reference product 1
79516245|NCT04811573|Drug|Japan-sourced Otezla®|Reference product 2
79516246|NCT04801316|Behavioral|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
79516247|NCT04801316|Behavioral|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
79221545|NCT03351686|Drug|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
79221546|NCT03347942|Behavioral|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
79221547|NCT03347942|Other|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
79221548|NCT04461990|Procedure|Multidisciplinary cooperative comprehensive treatment|Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.
79221549|NCT02318862|Procedure|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
79516248|NCT04795362|Biological|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
79516249|NCT04789694|Other|Physiological intervention|"Rehabilitation specialist consultation (3x)~Individualized home-based exercise plan~Functional capacity measuring"
79221550|NCT03347864|Drug|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
79221551|NCT03494400|Other|Aerobic Training Presential|The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
79221552|NCT03494400|Other|Aerobic Training Home-based|The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
79364662|NCT05798325|Other|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
79364663|NCT05798325|Other|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
79364664|NCT05798325|Other|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
79364665|NCT05798325|Diagnostic Test|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
79364666|NCT05798325|Device|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
79364667|NCT05798325|Other|10mWT|10 meters walking Test.
79516250|NCT04789694|Behavioral|Psychological intervention|"Clinical psychologist consultation (3x)~Anxiety and depression scoring~Psychological support"
79516251|NCT04789694|Dietary Supplement|Nutritional intervention|"Nutritional specialist consultation (3x)~Malnutrition scoring~Dietary supplementation"
79516252|NCT04783207|Dietary Supplement|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
79516253|NCT04783207|Dietary Supplement|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
79516255|NCT04774094|Drug|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
79995127|NCT05076513|Drug|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
79995128|NCT05076513|Radiation|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
79516256|NCT04770545|Drug|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
79516257|NCT04768270|Other|no intervention|It is an observation trial.
79516258|NCT04753437|Drug|Clarithromycin|Clarithromycin tablets.
79221553|NCT04503200|Procedure|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
79221554|NCT04503200|Procedure|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
79221555|NCT02319018|Drug|Alisertib|Given PO
79221556|NCT02319018|Drug|Fluorouracil|Given IV
79221557|NCT02319018|Other|Laboratory Biomarker Analysis|Correlative studies
79516259|NCT04753437|Drug|Amoxicillin|Amoxicillin capsules.
79995129|NCT05450094|Behavioral|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
79995130|NCT05450094|Behavioral|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically supported enhancements: 1) Voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities. 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
79221558|NCT02319018|Drug|Leucovorin Calcium|Given IV
79221559|NCT02319018|Drug|Oxaliplatin|Given IV
79674346|NCT00494793|Procedure|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
79674347|NCT00476918|Drug|Intravitreal injection (triamcinolone acetonide)|
79995131|NCT01119183|Behavioral|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
79995132|NCT01119183|Behavioral|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
79221560|NCT05584748|Device|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
79221561|NCT02574520|Drug|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
79221562|NCT02574520|Drug|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
79221563|NCT02574520|Drug|Saline Placebo|5 ml once at end of surgery
79221564|NCT02574520|Drug|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
79221565|NCT04425226|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
79516260|NCT04753437|Drug|Bismuth potassium citrate|Bismuth potassium citrate tablets.
79516261|NCT04753437|Drug|Esomeprazole|Esomeprazole tablets.
79516262|NCT04753437|Drug|Vonoprazan|Vonoprazan tablets.
79221566|NCT04425226|Drug|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
79221567|NCT03497052|Other|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
79221568|NCT03497052|Other|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
79221569|NCT03351452|Device|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
79221570|NCT03351452|Device|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
79221571|NCT03351452|Device|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
79516263|NCT04743310|Drug|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
79516264|NCT04743310|Device|Canvas imaging system|imaging device attached to surgical microscope
79516265|NCT04743310|Procedure|Surgical resection of tumor|Standard of care surgical resection of tumor
79516266|NCT04725058|Other|Medical Group Visit|A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
79674348|NCT01246635|Device|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
79674349|NCT01246635|Procedure|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
79674350|NCT00472160|Procedure|Non Invasive Ventilation|Non Invasive Ventilation
79516267|NCT04725058|Other|Dietitian Individual Visit|Participant receives obesity management individually from a registered dietitian.
79516268|NCT04722237|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, & Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
79516269|NCT04653220|Other|Control 1|25g glucose dissolve in 250ml of water
79364668|NCT05798325|Other|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
79516270|NCT04653220|Other|Control 2|25g glucose dissolve in 250ml of water
79516271|NCT04653220|Other|Standard Crokao|Standard Crokao containing 25g of available carbohydrate
79674351|NCT00472238|Behavioral|endurance training|control group.
79674352|NCT00472238|Behavioral|exercise training|Treadmill exercise training to optimize physical endurance
79221572|NCT05520658|Drug|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
79221573|NCT05520658|Drug|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
79221574|NCT02324634|Device|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
79674353|NCT01323790|Drug|NKTR-118|12.5 mg oral tablet once daily
79221575|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
79221576|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
79221577|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
79221578|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
79221579|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
79364669|NCT05798325|Other|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
79364670|NCT05798325|Other|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
79221580|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
79221581|NCT05526040|Dietary Supplement|Immunonutrient-enriched oral nutrition supplementation|"Individualized dietary assessment and counselling with additional high energy, high protein, immunonutrient-enriched oral nutrition supplement; taken 3 servings per day, from 1 week prior to cancer treatment and continued throughout the cancer treatment.~Oral Impact® is an oral nutrition supplement product enriched with arginine (3.3g/sachet), omega-3 fatty acids (0.8g/sachet) and nucleotides (0.3g/sachet). The immunonutrient-enriched formula is also a complete and balanced formula, and is gluten free. The osmolality of the formula is 620 mOsm/kg water."
79364671|NCT05798325|Other|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
79364672|NCT05798325|Other|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
79364673|NCT05798325|Other|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
79364674|NCT05798325|Other|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
79516272|NCT04653220|Other|Low sugar variant 1|Low sugar variant 1 containing 25g of available carbohydrate
79516273|NCT04653220|Other|Low sugar variant 2|Low sugar variant 2 containing 25g of available carbohydrate
79516274|NCT04653220|Other|Low sugar variant 3|Low sugar variant 3 containing 25g of available carbohydrate
79516275|NCT04653220|Other|Low sugar variant 4|Low sugar variant 4 containing 25g of available carbohydrate
79516276|NCT04653220|Other|Low sugar variant 5|Low sugar variant 5 containing 25g of available carbohydrate
79364675|NCT05798325|Other|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
79364676|NCT05798325|Other|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
79364677|NCT05798325|Other|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
79364678|NCT05798325|Other|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
79516277|NCT04647630|Diagnostic Test|urine test|test for pneumococcal antigen in urine
79516278|NCT04619017|Biological|Segmental allergen challenge|All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
79516279|NCT04613557|Biological|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
79516280|NCT04613557|Drug|Endoxan|Preconditioning chemotherapy
79674354|NCT01323790|Drug|NKTR-118|25 mg oral tablet once daily
79674355|NCT01323790|Drug|Placebo|Placebo to NKTR-118
79674356|NCT00477035|Drug|CIK cells|2x10e8 cells/kg
79674357|NCT00477035|Drug|etoposide|60 mg/kg
79674358|NCT00477035|Drug|bcnu|15 mg/kg
79674359|NCT00477035|Drug|cyclophosphamide|100 mg/kg
79674360|NCT00477035|Drug|gemcitabine|1250 mg/m2
79674361|NCT00477035|Drug|vinorelbine|30 mg/m2
79674362|NCT00477035|Drug|melphalan|200 mg/m2
79516281|NCT04613557|Drug|Fludara|Preconditioning chemotherapy
79516282|NCT04605094|Biological|Benralizumab|Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
79674363|NCT00494832|Drug|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
79364679|NCT05798325|Other|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
79516283|NCT04605094|Biological|Placebo / Benralizumab|Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
79516284|NCT04605081|Drug|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
79674364|NCT00494832|Drug|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
79674365|NCT00477074|Procedure|bronchoalveolar lavage, blood analysis|
79674366|NCT01323673|Drug|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
79995133|NCT05066919|Procedure|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
79221582|NCT05526040|Dietary Supplement|Standard medical nutrition therapy|Individualized dietary assessment and counselling and standard nutrition supplementation via oral nutrition supplementation or enteral nutrition as necessary.
79364680|NCT05798325|Device|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
79516285|NCT04605081|Other|Placebo|Placebo will be inactive and taken daily in pill form.
79516286|NCT04599504|Drug|Lisdexamfetamine Dimesylate (Medication)|Medication will be taken daily in pill form.
79516287|NCT04599504|Other|Placebo|Placebo will be inactive and taken daily in pill form.
79516288|NCT04599478|Drug|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
79674367|NCT01323673|Drug|Vehicle / Placebo|2 times a day, 14 total days of study treatment
79221583|NCT03351374|Other|Software|multi-module system of web software tools
79221584|NCT05520580|Procedure|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
79221585|NCT04462926|Diagnostic Test|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
79516289|NCT04599478|Behavioral|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
79516290|NCT04599478|Other|Placebo|Placebo will be inactive and taken daily in pill form.
79516291|NCT04599439|Diagnostic Test|Cardiac magnetic resonance imaging|All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
79674368|NCT00494949|Drug|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
79674369|NCT00494949|Drug|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
79674370|NCT00472316|Behavioral|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
79674371|NCT01246752|Biological|Human Stem Cell Transplantation|Human allogenic stem cells
79221586|NCT02319096|Other|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
79221587|NCT05525962|Behavioral|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~M0: cognitive test, psychiatric classification and psychologic assessments~M12 and M24: psychiatric classification and psychologic assessments"
79221588|NCT03494244|Procedure|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
79221589|NCT03494244|Device|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
79516292|NCT04578639|Drug|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
79674372|NCT01246752|Drug|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
79674373|NCT01323634|Drug|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
79674374|NCT01323634|Drug|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
79674375|NCT05645302|Drug|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
79674376|NCT00494988|Drug|insulin aspart|
79674377|NCT00494988|Drug|insulin NPH|
79674378|NCT01323478|Drug|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
79674379|NCT00472355|Drug|apomorphine|
79674380|NCT04325581|Drug|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
79516293|NCT04578639|Drug|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
79516294|NCT04573296|Device|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
79516295|NCT04573296|Behavioral|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
79516296|NCT04555577|Drug|Peposertib|Given PO
79516297|NCT04555577|Radiation|Radiation Therapy|Undergo radiation therapy
79516298|NCT04555577|Procedure|Resection|Undergo surgical resection
79221590|NCT05584592|Other|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
79221591|NCT05584592|Other|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
79221592|NCT02322684|Device|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
79221593|NCT05516056|Other|ERAS clinical pathway|Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
79364681|NCT05798325|Other|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~Upper limbs: hands to head~Lower limbs: Sit to stand with or without the help of a person~Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
79364682|NCT05798325|Device|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
79364683|NCT05797766|Behavioral|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
79364684|NCT05793905|Combination Product|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
79364685|NCT05793905|Drug|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
79516299|NCT04555577|Drug|Temozolomide|Given PO
79516300|NCT04555265|Device|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
79516301|NCT04534296|Other|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
79516302|NCT04534296|Other|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
79516303|NCT04526639|Behavioral|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
79516304|NCT04526639|Behavioral|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
79516305|NCT04526210|Drug|ALXN1840|ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
79516306|NCT04526210|Drug|Bupropion Hydrochloride|Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
79674381|NCT04325581|Drug|Placebos|Normal Saline SC daily
79674382|NCT02956161|Device|Stimulation of up-phase of sleep slow oscillation|
79674383|NCT02956161|Device|Random stimulation of up phase of sleep slow oscillation|
79674384|NCT02956161|Device|No stimulation|
79995134|NCT05066919|Other|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
79221594|NCT02324712|Device|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
79364686|NCT05793099|Other|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
79364687|NCT05793099|Other|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
79364688|NCT05792046|Device|Visual field|test for detecting loss in visual function
79364689|NCT05786534|Dietary Supplement|Green Seaweed|400 mg per day
79364690|NCT05785819|Drug|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
79221595|NCT02324712|Device|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
79516307|NCT04504968|Other|Multimodal intervention|"Optimal control: HbA1c between 7.6-8.5% (60-69 mmol/mol) and Blood Pressure<150/90 mmHg~The physical exercise program that will be used will be the Vivifrail program (Erasmus + UE). Vivifrail includes: Strength for arms and legs, balance and gait, flexibility and resistance. The duration will be 16 weeks. (3 weeks to explain the program in the Trial site and the rest of weeks, it will be carried out at home).~Nutritional and educational program to increase diabetes knowledge, develop practical self-care skills for diabetes and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status and help to maintain functional status. Seven separate sessions of 45 minutes each one twice a week for a period of 3-4 weeks in small groups. They will be moderated by a physician or diabetes educator and focused on behavioral changes and key points."
79221596|NCT04503044|Other|Retrospective observational study|No intervention to occur
79995135|NCT05422482|Biological|GC1123|ICV-administered Hunterase, Idursulfase-ß
79221597|NCT02322918|Genetic|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
79221598|NCT03351140|Other|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
79221599|NCT03351140|Other|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
79221600|NCT02319252|Device|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
79221601|NCT02319252|Device|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
79221602|NCT03499938|Device|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
79364691|NCT05785819|Drug|Placebo|Placebo matching VLX-1005
79364692|NCT05783661|Other|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
79364693|NCT05783661|Other|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
79995136|NCT05418465|Drug|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
79995137|NCT05418465|Drug|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
79995138|NCT03261167|Drug|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
79995139|NCT03261167|Drug|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
79995140|NCT05416359|Drug|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
79995141|NCT05418309|Drug|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
79221603|NCT05520424|Dietary Supplement|The Daily Supplement|"The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)"
79364694|NCT05782153|Device|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
79364695|NCT05782153|Device|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
79364696|NCT05781711|Drug|levodopa-carbidopa|levodopa-carbidopa is the standard therapy used in Parkinson's disease
79364697|NCT05781711|Drug|Metformin|Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
79995142|NCT05137548|Drug|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
79995143|NCT05137548|Drug|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
79995144|NCT04534842|Drug|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
79221604|NCT02319330|Behavioral|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
79221605|NCT02319330|Behavioral|Treatment as Usual|Routine HIV clinic-based counseling
79221606|NCT05081362|Other|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
79221607|NCT02324790|Device|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
79221608|NCT03351062|Drug|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
79221609|NCT03351062|Drug|Toremifene|Patients will be given 60mg Toremifene once a day.
79221610|NCT02324868|Device|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
79364698|NCT05778591|Drug|Placebo|Placebo.
79364699|NCT05778591|Drug|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
79364700|NCT05774353|Other|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
79364701|NCT05767762|Other|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
79364702|NCT05766488|Device|Continuous glucose monitor|A continuous glucose monitor will be provided in the experimental arm of this study for 6 months. This monitor will be a Freestyle Libre 2 device.
79364703|NCT05766488|Device|Traditional glucometer|A traditional glucometer device will be assigned in the standard of care arm of this study for 6 months.
79995145|NCT04534842|Drug|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
79995146|NCT04526093|Other|TruTrace™ verified Medical Cannabis products|With the introduction of TruTrace™ verification, cannabis products can be clearly identified. Key information, including cannabinoid and terpene compositions can be collated into a Master Strain Certificate.
79995147|NCT05091294|Other|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
79995148|NCT02725853|Device|tDCS|Application of 1.5 mA tDCS for 30 minutes
79995149|NCT02725853|Device|sham tDCS|Application of sham tDCS for 30 minutes
79221611|NCT02324868|Device|Conventional IV catheter protection|No Shower patch will be provided during study period
79995150|NCT02725853|Behavioral|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
79995151|NCT02725853|Behavioral|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
79995152|NCT04505891|Behavioral|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
79364704|NCT05766215|Behavioral|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
79821212|NCT04063605|Other|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
79221612|NCT05515900|Dietary Supplement|Sodium|Daily sodium supplementation of 2000 mg.
79364705|NCT05761795|Drug|IVMED 85|Eye drop
79364706|NCT05761795|Drug|Placebo|Placebo eye drop
79364707|NCT05759260|Other|Observation|Observation
79221613|NCT05515900|Dietary Supplement|HMB|Daily HMB supplementation of 3 g.
79221614|NCT05515900|Other|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
79221615|NCT03496740|Procedure|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
79364708|NCT05754697|Other|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
79221616|NCT03496740|Procedure|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
79364709|NCT05754697|Other|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
79364710|NCT05754697|Other|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
79221617|NCT03496740|Drug|Bupivacaine (Block Drug)|Block drug
79364711|NCT05753878|Drug|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
79364712|NCT05753878|Drug|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
79364713|NCT05753878|Drug|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
79674385|NCT05645263|Other|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
79364714|NCT05753878|Drug|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
79364715|NCT05753878|Other|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
79364716|NCT05753787|Other|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
79364717|NCT05752045|Device|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
79364718|NCT05750121|Behavioral|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
79364719|NCT05746871|Device|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
79364720|NCT05746871|Other|standard care|Subjects will continue with their standard care for 5 weeks
79674386|NCT00623272|Other|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
79674387|NCT04325776|Drug|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
79221618|NCT04888676|Procedure|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
79221619|NCT03499860|Diagnostic Test|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
79364721|NCT05745961|Radiation|TSPO PET scan (11C-PBR28)|PET scan
79364722|NCT05743400|Drug|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
79516308|NCT04504968|Other|Usual care group|The level of usual health care that a patient with diabetes receives from their local national health system
79516309|NCT04478201|Other|back sleep positioning|sleeping on the back.
79516310|NCT04478201|Other|side sleep positioning|sleeping on the side
79364723|NCT05743400|Biological|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~1 after each end of perfusion ;~1 though concentration before each perfusion ;~3 blood samples in 3 different days during the first week;~1 weekly for 2 weeks post HSCT."
79995153|NCT04505891|Behavioral|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
79995154|NCT05340894|Procedure|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
79221620|NCT04504760|Drug|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
79364724|NCT05739422|Procedure|Neuropilates online exercise class|Online, remotely supervised neuropilates exercise class
79364725|NCT05739422|Procedure|Online generalised exercise class|Online, remotely supervised generalised exercise class
79364726|NCT05739422|Procedure|Unsupervised home exercise programme|Unsupervised, home based generalised exercise programme
79364727|NCT05734820|Diagnostic Test|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
79516311|NCT04477005|Device|ERCP and insertion ofBio-degradable bile duct stent|ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.
79516312|NCT04473222|Behavioral|Sleep Well!|Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
79516313|NCT04473222|Behavioral|Sleep education|Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
79674388|NCT04325776|Drug|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
79674389|NCT03276845|Diagnostic Test|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
79674390|NCT01322386|Drug|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
79364728|NCT05734820|Diagnostic Test|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
79364729|NCT05734807|Drug|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
79364730|NCT05734807|Drug|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
79674391|NCT00495027|Behavioral|Internet-delivered Stress Innoculation Training|
79821213|NCT04063605|Other|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
79364731|NCT05734807|Drug|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
79364732|NCT05732077|Drug|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
79364733|NCT05732077|Diagnostic Test|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
79821214|NCT04063527|Drug|adjuvant chemotherapy|combination of paclitaxel and carboplatin
79821215|NCT00738777|Drug|Anastrozole|1 mg,QD,PO
79821216|NCT00738777|Drug|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
79995155|NCT05340894|Procedure|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
79995156|NCT03294941|Combination Product|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
79995157|NCT03632499|Other|rehabilitation|rehabilitation
79995158|NCT03098433|Drug|Liothyronine|Single dose
79995159|NCT03098433|Drug|Levothyroxine|Active comparator
79995160|NCT03098433|Drug|Placebos|Placebo
79221621|NCT04504760|Drug|Placebo|Single dose of placebo will be administered orally.
79221622|NCT04504760|Drug|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
79221623|NCT04504760|Drug|Placebo|Multiple dose of placebo will be administered orally.
79221624|NCT05525884|Other|non-invasive method, Fibroscan|Liver Ultrasound and transient elastography (FibroScan®)
79221625|NCT02324946|Other|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
79364734|NCT05732077|Device|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
79364735|NCT05731271|Drug|TST003|IV humanized anti-GREM1 monoclonal antibody
79364736|NCT05730192|Device|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
79364737|NCT05725460|Procedure|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
79821217|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
79821218|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
79821219|NCT03901443|Other|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
79821220|NCT00733707|Behavioral|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
79821221|NCT00733785|Drug|Rosiglitazone XR|Rosiglitazone extended release formulation
79821222|NCT00738855|Other|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
79821223|NCT00738855|Other|Nothing per os|A nasogastric tube
79821224|NCT00738933|Dietary Supplement|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
79821225|NCT00738933|Dietary Supplement|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
79221626|NCT05520268|Behavioral|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
79221627|NCT05520268|Behavioral|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
79221628|NCT02443896|Procedure|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
79221629|NCT02443896|Procedure|No sealant of permanent molars|No sealant applied to permanent molars.
79221630|NCT05515822|Drug|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
79221631|NCT05515822|Drug|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
79221632|NCT05515822|Drug|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
79221633|NCT05520112|Biological|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
79221634|NCT05520112|Other|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
79221635|NCT03496584|Other|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
79364738|NCT05722184|Diagnostic Test|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
79364739|NCT05717062|Drug|Varespladib intravenous form|This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
79516314|NCT04451213|Diagnostic Test|MRI head|MRI head
79516315|NCT04443608|Drug|Patiromer Powder for Oral Suspension [Veltassa]|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
79516316|NCT04443608|Drug|Placebo|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
79516317|NCT04435444|Other|Masterful supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form* (MSAS-SF)"
79821226|NCT00738933|Dietary Supplement|placebo|Margarine product without plant stanol or sterol esters
79821227|NCT05740917|Drug|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
79821228|NCT03898713|Diagnostic Test|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
79821229|NCT00739011|Device|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
79821230|NCT05740761|Other|Gene editing in vitro|Testing of gene editing efficiency in vitro in human cellular models derived from patients
79995161|NCT05044650|Dietary Supplement|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
79516318|NCT04435444|Other|Attention control supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form* (MSAS-SF)"
79516319|NCT04422652|Drug|Bupropion|Bupropion is an anti-depressant medication.
79516320|NCT04422652|Behavioral|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
79516321|NCT04422652|Drug|Placebo|Double-blind placebo.
79516322|NCT04422652|Other|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
79221636|NCT03496584|Other|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
79995162|NCT03294317|Device|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
79221637|NCT02322996|Other|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
79221638|NCT04294654|Drug|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
79221639|NCT02325102|Other|No intervention|As this is an observational study, no intervention was conducted.
79221640|NCT04772144|Behavioral|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
79221641|NCT05525728|Other|Neurosensory|Physiological and neurophysiological investigations
79221642|NCT03496506|Drug|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
79516326|NCT04402541|Drug|CB-5339|25mg and 75mg capsules
79221643|NCT03496506|Drug|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
79221644|NCT02325024|Drug|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
79221645|NCT05525650|Drug|House Dust Mite Extract, Dermatophagoides Farinae|"[Group 1] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~[Group 2] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~[Group 3] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
79221646|NCT03132324|Drug|INCB059872|INCB059872 tablets
79821231|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
79821232|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
79821233|NCT04063449|Drug|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
79995163|NCT05320926|Drug|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
79995164|NCT05320926|Drug|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
79995165|NCT05320926|Device|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
79364740|NCT05717062|Drug|varespladib-methyl- oral form|Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
79364741|NCT05717062|Drug|Placebo intravenous form|The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
79364742|NCT05717062|Drug|Placebo - oral form|Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
79364743|NCT05714943|Behavioral|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
79674392|NCT03275909|Behavioral|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
79674393|NCT00495066|Drug|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
79674394|NCT00477308|Procedure|salvage therapy|
79221647|NCT05519956|Radiation|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
79221648|NCT05519956|Radiation|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
79674395|NCT01246908|Drug|Placebo|Placebo administered twice per day for six weeks.
79674396|NCT01246908|Drug|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
79674397|NCT00472433|Drug|Alemtuzumab|
79821234|NCT04063449|Drug|endostar|Antiangiogenic therapy plus chemotherapy
79821235|NCT04062747|Device|I-gel|After standard anesthesia i-Gel was placed into the patient
79821236|NCT04062747|Device|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
79221649|NCT03346616|Other|Texting Group|See above in arm/group description
79221650|NCT03346616|Other|Non Texting Group|See above in arm/group description
79364744|NCT05713890|Other|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|"Observation of a VR scenario depicting multiple repetitions of a specific upper limb motor task belonging to typical activities of daily living, followed by mental imagination of the action observed and then by the execution of the same task, using objects provided in a kit.~In each session, patients will watch 2 different videos and will perform the two corresponding actions. The time scheduled for observation, imagery and execution of each action will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes. New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
79371132|NCT03030040|Behavioral|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
79674398|NCT00495105|Behavioral|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
79821237|NCT00700011|Drug|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
79821238|NCT00700011|Drug|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
79821239|NCT05740683|Diagnostic Test|RT-QuiC|RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
79821240|NCT04064541|Other|Virtual Visit|Virtual Visit
79821241|NCT05512767|Other|Best Practice|Undergo self-manual lymphatic drainage
79674399|NCT00472472|Device|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
79674400|NCT01247025|Other|No intervention|This study will not contain a specific intervention
79674401|NCT00477347|Device|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
79674402|NCT00477347|Device|Manual administration|intraoperative manual administration of propofol and remifentanil
79821242|NCT05512767|Other|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
79821243|NCT05512767|Procedure|Diagnostic Imaging|Undergo photographs of face and neck
79821244|NCT05512767|Other|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
79821245|NCT05512767|Procedure|Modified Barium Swallow|Undergo swallow study
79821246|NCT05512767|Procedure|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
79821247|NCT05512767|Device|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
79821248|NCT05512767|Other|Quality-of-Life Assessment|Ancillary studies
79821249|NCT05512767|Other|Questionnaire Administration|Ancillary studies
79821250|NCT05512767|Other|Voice Handicap Index-10|Ancillary studies
79221651|NCT02319564|Drug|Beclomethasone|
79221652|NCT02319564|Drug|Beclomethasone and Salbutamol|
79221653|NCT02319564|Drug|Placebo|
79221654|NCT02319564|Device|Aerochamber Max®|
79221655|NCT05515666|Diagnostic Test|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
79302473|NCT03223987|Dietary Supplement|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
79302474|NCT03320993|Other|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
79221656|NCT03122054|Procedure|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
79516327|NCT04377451|Drug|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing <60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
79674403|NCT01244568|Behavioral|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
79674404|NCT00503568|Biological|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient
79821251|NCT05740527|Device|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
79821252|NCT04063293|Biological|Platelet Rich Plasma|PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
79821253|NCT04064385|Device|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
79821254|NCT04063059|Behavioral|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
79821255|NCT02567955|Biological|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
79821256|NCT02567955|Biological|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
79821257|NCT00739479|Dietary Supplement|Weight Loss|Participants will reduce their total dietary intake by ~800 kcal/day. ~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of ~700 kcal/day.
79221657|NCT05515510|Other|FU-APP|"FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age."
79371133|NCT03029494|Device|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
79371134|NCT03029494|Drug|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
79371135|NCT03029494|Device|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
79371136|NCT03029494|Dietary Supplement|Vitamin C|1000 mg
79371137|NCT03087279|Behavioral|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
79516332|NCT04363307|Device|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
79516333|NCT04363307|Device|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
79516334|NCT04351776|Other|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
79516335|NCT04351776|Other|VR-Distraction|Participants will be instructed to use one of three applications
79516336|NCT04351776|Other|360 Video|Participants will be instructed which video to view
79674405|NCT00472550|Drug|esomeprazole 20 mg|
79674406|NCT01244607|Drug|Placebo|single i.v. administration
79674407|NCT01244607|Drug|NI-0801|single i.v. administration
79674408|NCT00503607|Drug|BLI-800|
79674409|NCT00503607|Drug|Polyethylene glycol 3350 based bowel preparation|
79516337|NCT04335942|Other|"Alert AFNOR 3.6."|This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
79516338|NCT04335942|Other|"Alertes  AFNOR 3.6  et alertes  Guidelines ."|By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
79516339|NCT04329325|Biological|Blinatumomab|Please see detailed summary.
79674410|NCT00477503|Drug|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
79221658|NCT05515510|Other|Oral health recommendations|"Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020"
79221659|NCT02325180|Drug|Dihydroartemisinin-Piperaquine|
79221660|NCT02325180|Drug|Artemether-lumefantrine|
79221661|NCT05052658|Procedure|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
79221662|NCT03499626|Drug|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
79221663|NCT00709592|Biological|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
79674411|NCT00477503|Drug|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
79221664|NCT00709592|Radiation|Total-Body Irradiation|Undergo TBI
79221665|NCT00709592|Procedure|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
79221666|NCT00709592|Drug|Tacrolimus|Given PO
79221667|NCT00709592|Drug|Mycophenolate Mofetil|Given PO
79221668|NCT02325258|Other|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
79221669|NCT05515354|Other|Timing of nicotine replacement therapy start date|Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
79221670|NCT05515354|Drug|Nicotine Replacement Therapy Agent|Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
79221671|NCT03499548|Other|INSPiRe Programme|Intensive CBT for suicide
79221672|NCT05052190|Behavioral|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
79221673|NCT05052190|Behavioral|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
79674412|NCT00472628|Procedure|Blood samples collected|
79674413|NCT00503646|Other|communication intervention|
79371138|NCT03035266|Other|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
79516340|NCT04329325|Drug|dasatinib|Please see detailed summary.
79516341|NCT04329325|Drug|dexamethasone|Please see detailed summary.
79221674|NCT05052190|Behavioral|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
79674414|NCT00503646|Other|counseling intervention|
79821258|NCT04062903|Behavioral|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
79302475|NCT02485769|Drug|PF-06650833|Suspension
79302476|NCT02485769|Drug|Placebo|Suspension
79516342|NCT04329325|Drug|methotrexate|Please see detailed summary.
79516343|NCT04317781|Biological|Tagraxofusp-erzs|Given IV
79221675|NCT05052190|Behavioral|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
79221676|NCT05052190|Behavioral|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
79221677|NCT05052190|Behavioral|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
79516344|NCT04283175|Other|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
79516345|NCT04283175|Other|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
79516346|NCT04281485|Genetic|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
79516347|NCT04281485|Other|Placebo|Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
79516348|NCT04281485|Other|Placebo|Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
79516349|NCT04281485|Genetic|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
79516350|NCT04273347|Other|standard of care for patient with brain trauma and spinal cord injury|neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy
79221678|NCT03496350|Behavioral|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
79221679|NCT05525182|Drug|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
79221680|NCT05525182|Drug|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
79221681|NCT05525182|Drug|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
79221682|NCT05525182|Drug|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
79221683|NCT02325336|Device|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
79221684|NCT03499470|Other|Protocol for structured discharge and follow-up|
79221685|NCT05051878|Device|T-scan|occlusal analysis T-scan
79221686|NCT05051878|Other|articulating paper|articulating paper occlusal analysis
79221687|NCT05519722|Behavioral|Expectation-focused online intervention|Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
79221688|NCT02325492|Drug|Aramchol|
79221689|NCT02325492|Drug|Placebo|
79221690|NCT02325492|Device|Ultrasound|
79221691|NCT04745468|Device|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
79995166|NCT05415891|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
79516351|NCT04272463|Other|No intervention|Patients currently in treatment with benralizumab as per approved indication and clinical practice
79221692|NCT03499392|Other|psychological tests|psychological tests psychological interviews
79221693|NCT02437370|Drug|Pembrolizumab|Given IV
79221694|NCT02437370|Drug|Docetaxel|Given IV
79221695|NCT02437370|Drug|Gemcitabine Hydrochloride|Given IV
79221696|NCT05515120|Drug|Rivaroxaban 20 MG [Xarelto]|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
79371139|NCT03035266|Other|Standard rehabilitation|Standard of care for post-operative condition
79371140|NCT05346705|Behavioral|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
79371141|NCT04832230|Other|Hearing test|"The hearing test is composed of several examinations:~pure tone audiogram~otoscopy~tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
79371142|NCT04832230|Other|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
79371143|NCT04832230|Other|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
79516352|NCT04239157|Biological|Canakinumab|Given SC
79221697|NCT05515120|Drug|Aspirin 300mg|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
79221698|NCT05515120|Drug|Acenocoumarol Oral Tablet|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
79221699|NCT02323074|Procedure|Brain Computer Interface|
79302477|NCT02485769|Drug|PF-06650833|Tablet (Modified Release)
79302478|NCT02485769|Drug|Placebo|Tablet (Modified Release)
79516353|NCT04216719|Behavioral|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
79516354|NCT04216667|Procedure|Catheter ablation|Catheter ablation
79995167|NCT05415891|Device|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
79516355|NCT04209946|Procedure|Less Invasive Surfactant Administration LISA|Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
79516356|NCT04209946|Procedure|Continuous Positive Airway Pressure CPAP|Infant will remain on CPAP Therapy during spontaneous respirations
79516357|NCT04190056|Biological|Pembrolizumab|Given IV
79516358|NCT04190056|Drug|Tamoxifen|Given PO
79516359|NCT04190056|Drug|Vorinostat|Given PO
79516360|NCT04189757|Drug|Acalabrutinib|Given PO
79516361|NCT04179539|Diagnostic Test|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
79674415|NCT00503646|Other|questionnaire administration|
79674416|NCT00503646|Procedure|psychosocial assessment and care|
79995168|NCT05418075|Other|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
79995169|NCT04928118|Other|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
79995170|NCT04375553|Other|Aerobic exercise|Intradialytic aerobic exercise
79674417|NCT01244334|Drug|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
79674418|NCT01244334|Drug|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
79995171|NCT05417997|Dietary Supplement|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
79221700|NCT03496116|Other|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
79221701|NCT05515042|Drug|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
79995172|NCT05417997|Drug|Favipiravir|Antiviral medication used to treat influenza
79221702|NCT04664270|Behavioral|e-CBT|e-CBT + Mindfulness + Problem Solving
79221703|NCT02323152|Behavioral|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
79371144|NCT04832230|Other|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
79371145|NCT04832230|Other|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
79371146|NCT04832230|Other|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
79371147|NCT04832230|Other|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
79516362|NCT04179539|Diagnostic Test|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
79674419|NCT00477542|Drug|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
79674420|NCT00503724|Drug|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
79995173|NCT05417997|Drug|Enoxaparin|Anticoagulant medication
79995174|NCT05417997|Drug|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
79995175|NCT05417997|Drug|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
79995176|NCT05417997|Drug|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
79516363|NCT04162171|Radiation|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
79516364|NCT04149964|Drug|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
79516365|NCT04149964|Drug|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
79674421|NCT00472667|Procedure|Procalcitonin guided strategy|Procalcitonin guided strategy
79674422|NCT00503763|Drug|Simvastatin|
79674423|NCT00477581|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
79221704|NCT02323152|Other|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
79674424|NCT00477581|Drug|sitagliptin|oral administration (100mg), once a day in the morning
79221705|NCT04502108|Behavioral|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
79221706|NCT02323230|Biological|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
79221707|NCT02323230|Drug|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
79221708|NCT02323308|Other|blood sampling|
79364745|NCT05713890|Other|Home-based landscape observation with virtual-reality for upper limb rehabilitation|"Observation of virtually explorable landscapes followed by rest with eyes closed without focusing on any thought in particular and then execution of the same actions requested to VR-AOT-group. In each session, patients will explore 2 different landscapes and perform 2 different actions. The time scheduled for observation, rest and action execution will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes.New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
79364746|NCT05711251|Other|Physical Activity in Health Promotion|During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
79364747|NCT05709548|Drug|Indocyanine green|Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
79364748|NCT05709301|Drug|Donepezil Hydrochloride|Donepezil 10mg once daily
79674425|NCT00503802|Procedure|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
79674426|NCT00503802|Procedure|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
79674427|NCT00477620|Behavioral|Wearing of reading glasses during prolonged near work|
79221709|NCT03121898|Device|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
79364749|NCT05709301|Drug|Placebo|Matching placebo
79364750|NCT05704803|Diagnostic Test|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
79364751|NCT05694546|Behavioral|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
79364752|NCT05691686|Other|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
79364753|NCT05691686|Other|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
79364754|NCT05691686|Other|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
79364755|NCT05691686|Other|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
79674428|NCT00477737|Drug|Sevoflurane|
79674429|NCT00477737|Drug|propofol|
79674430|NCT01247103|Drug|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
79221710|NCT02319720|Biological|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
79221711|NCT02319720|Biological|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
79674431|NCT01247103|Drug|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
79674432|NCT01247103|Other|Placebo|Placebo to match AZD4316
79674433|NCT00477776|Drug|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
79674434|NCT00477776|Drug|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
79821259|NCT04062903|Behavioral|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
79674435|NCT00504699|Procedure|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
79821260|NCT00921063|Drug|PD 0332334|250 mg capsule, BID for 4 weeks
79821261|NCT00921063|Drug|PD 0332334|100 mg capsule, BID for 4 weeks
79364756|NCT05691595|Other|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
79995177|NCT05417997|Drug|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
79516366|NCT04149964|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
79995178|NCT04292574|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
79995179|NCT03292913|Behavioral|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
79995180|NCT03292913|Behavioral|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
79221712|NCT02319720|Procedure|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
79221713|NCT04610060|Behavioral|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~Week 3 70-75 % of the target heart rate (THR) >=10,000 steps/day~Week 4 75-80 % of the target heart rate (THR) >12,500 steps per day"
79221714|NCT04610060|Behavioral|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
79221715|NCT02319798|Other|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
79221716|NCT02319798|Other|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
79302479|NCT03223519|Drug|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
79302480|NCT03223519|Drug|Placebo|Powder for oral solution administered TID for 3 days
79364757|NCT05687279|Biological|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
79516367|NCT04149964|Drug|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
79516368|NCT04146649|Procedure|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
79516369|NCT04115657|Other|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
79674436|NCT00477815|Biological|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
79821262|NCT00921063|Drug|placebo|0 mg capsule, BID for 4 weeks
79821263|NCT00921063|Drug|Alprazolam extended release|1 mg capsule, BID for 4 weeks
79821264|NCT00707031|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
79302481|NCT03223519|Drug|Ibuprofen|Powder for oral solution administered TID for 3 days
79364758|NCT05687279|Other|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
79364759|NCT05683600|Biological|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
79516370|NCT04115657|Other|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
79516371|NCT04115657|Other|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
79516372|NCT04115657|Other|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
79516373|NCT04115657|Other|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
79516374|NCT04115657|Other|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
79516375|NCT04114981|Radiation|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
79516376|NCT04114981|Radiation|Fractionated Stereotactic Radiosurgery|Undergo FSRS
79516377|NCT04114981|Procedure|Quality-of-Life Assessment|Ancillary studies
79516378|NCT04114981|Other|Questionnaire Administration|Ancillary studies
79674437|NCT00477815|Drug|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
79674438|NCT00477815|Biological|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
79674439|NCT00477815|Biological|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
79516379|NCT04088669|Other|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
79516380|NCT04088669|Other|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
79516381|NCT04076579|Drug|Olaparib|Olaparib taken by mouth twice daily
79516382|NCT04076579|Drug|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
79516383|NCT04071366|Drug|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
79516384|NCT04071366|Drug|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
79516385|NCT04071366|Drug|Placebo|Participants will receive placebo twice daily.
79516386|NCT04071366|Biological|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
79221717|NCT05512468|Drug|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
79221718|NCT05583734|Device|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
79516387|NCT04049110|Drug|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
79516388|NCT04049110|Drug|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
79821265|NCT00707031|Device|Pen auto-injector|
79821266|NCT00707031|Drug|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
79821267|NCT00707031|Device|Prefilled pen injector|
79821268|NCT00707031|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
79221719|NCT04461756|Drug|PPP001|inhalation (vape)
79221720|NCT04297306|Behavioral|Exercise Prescription|Standardised Exercise Prescription.
79221721|NCT04297306|Device|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
79221722|NCT05583656|Procedure|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
79221723|NCT02325570|Device|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
79221724|NCT02325570|Procedure|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
79221725|NCT01977638|Drug|CXD101|Capsules, administered orally
79221726|NCT03495804|Drug|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
79364760|NCT05683600|Biological|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
79364761|NCT05674448|Biological|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
79364762|NCT05674448|Biological|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
79364763|NCT05665309|Procedure|3D anatomical model of aneurysm|Surgery prepared with 3D anatomical model of aneurysm
79516389|NCT04016415|Behavioral|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
79674440|NCT00477815|Radiation|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
79221727|NCT03495804|Drug|mannitol|Active comparator group was given mannitol as oral contrast agent.
79302482|NCT03223519|Drug|Magnesium|Powder for oral solution administered TID for 3 days
79302483|NCT03223519|Drug|Vitamin C|Powder for oral solution administered TID for 3 days
79364764|NCT05659602|Biological|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
79364765|NCT05656898|Device|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
79364766|NCT05656898|Device|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
79364767|NCT05656898|Device|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
79674441|NCT00477815|Biological|111In Zevalin|5.0 mCi by IV
79674442|NCT01247181|Other|Mobile phone text message|Weekly message with motivational content
79674443|NCT01247181|Other|Usual care|Usual care provided at clinic
79674444|NCT01244685|Device|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
79516390|NCT04016415|Behavioral|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
79516391|NCT04000659|Device|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
79516392|NCT04000659|Procedure|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
79516393|NCT03995758|Device|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
79516394|NCT03974932|Drug|HTX-011|Dual-acting local anesthetic. Dose 1.
79516395|NCT03974932|Drug|Ibuprofen|NSAID.
79516396|NCT03974932|Drug|Acetaminophen|Analgesic.
79995181|NCT04167995|Drug|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
79995182|NCT03704844|Other|non applicable|non applicable
79995183|NCT04005144|Drug|Binimetinib|Given PO
79221728|NCT05580926|Behavioral|Watch your Weight During Holidays|"Participants in this group will have an individual face-to-face session (with a maximum duration of half an hour) and a face-to-face group session. This intervention will include strategies for self-monitoring (body weight, diet and physical activity), information on healthy lifestyles, as well as information about the energy contained in local festive foods and their equivalent in minutes of physical activity or steps per day.~Participants will be asked to weight themselves at least twice a week, as a form of self-monitoring of weight, from the start of the intervention. They will have access to weekly forms with boxes, where they can fill in the data obtained for each day of weight self-monitoring, energy intake restriction report and minutes of physical activity performed."
79221729|NCT05580926|Other|Control Group (minimal intervention)|Participants in this group will receive a printed information, as well as a PDF file, brochure during a face-to-face session at the beginning of the 8-week period. This information will be about having a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
79221730|NCT03499158|Other|nerve conduction study|nerve conduction study
79221731|NCT04968496|Other|Food Secure Group|Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
79221732|NCT05580848|Procedure|Wrist arthroscopy|"Wrist arthroscopy is a minimally invasive endoscopic method that enables the diagnosis and treatment of certain diseases and injuries of the radiocarpal, mediocarpal and distal radioulnar joints.~Wrist arthroscopy enables a direct view of the articular surface of the wrist and the assessment and adequate treatment of articular fractures The wrist arthroscopy procedure also enables the detection and necessary treatment of associated soft tissue injuries (scapho-lunate and/or luno-triquetral ligament, i.e. triangular fibrocartilaginous complex) and/or cartilage lesions in extra-articular and articular fractures."
79302484|NCT03320915|Drug|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
79302485|NCT03220165|Drug|MGL-3196|oral, 100 mg
79302486|NCT02488889|Drug|Varenicline|
79302487|NCT02488889|Drug|Placebo pill (for varenicline)|
79302488|NCT02488889|Drug|Alcohol|
79516397|NCT03974932|Drug|Celecoxib|NSAID.
79516398|NCT03974932|Drug|+/- Bupivacaine HCl|Local anesthetic.
79516399|NCT03974932|Device|Luer Lock Applicator|Applicator for instillation.
79516400|NCT03974932|Drug|HTX-011|Dual-acting local anesthetic. Dose 2.
79674445|NCT00477854|Drug|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
79674446|NCT01247259|Drug|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
79674447|NCT00477893|Drug|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
79674448|NCT00477893|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
79674449|NCT01245426|Drug|GW870086 2mg|oral inhalation
79821269|NCT00739635|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
79995184|NCT04005144|Drug|Brigatinib|Given PO
79995185|NCT05418933|Other|Family workshop|Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
79995186|NCT03291587|Other|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
79995187|NCT03856788|Drug|Saline|40 mL sterile normal saline
79516401|NCT03967522|Drug|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
79516402|NCT03930316|Device|NOX T3|portable sleep study device
79364768|NCT05655195|Device|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
79516403|NCT03900403|Other|Walnut Intake|40g of daily walnut intake for 12 weeks
79516404|NCT03842969|Drug|RO7234292 (RG6042)|Intrathecal injection
79516405|NCT03835312|Procedure|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
79516406|NCT03823690|Device|EUS-guided gastrojejunstomy|As listed in the arms description
79995188|NCT03856788|Drug|Bupivacaine|40 mL 0.25% bupivacaine
79221733|NCT02325648|Drug|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
79221734|NCT05519410|Drug|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
79221735|NCT05519410|Drug|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
79364769|NCT05655195|Device|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
79364770|NCT05650320|Drug|0.3% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
79364771|NCT05650320|Drug|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
79364772|NCT05650320|Other|0% OPA-15406 vehicle|Twice-daily administration for 4 weeks.
79516407|NCT03823690|Device|The pyloro-duodenal stent|As listed in the arms description
79516408|NCT03819387|Drug|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
79516409|NCT03777813|Drug|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
79516410|NCT03777813|Combination Product|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
79516411|NCT03754933|Biological|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
79516412|NCT03754933|Drug|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used to treatment patients with chronic lymphocytic leukemia.
79674450|NCT01245426|Drug|GW870086 4mg|oral inhalation
79674451|NCT01245426|Drug|GW870086 Placebo|oral inhalation
79674452|NCT01245426|Drug|GW870086 1mg|oral inhalation
79674453|NCT01245426|Drug|GW870086 3mg|oral inhalation
79674454|NCT00478010|Other|counseling intervention|
79674455|NCT00478010|Other|study of socioeconomic and demographic variables|
79674456|NCT00478010|Procedure|psychosocial assessment and care|
79674457|NCT00478010|Procedure|quality-of-life assessment|
79821270|NCT00739635|Drug|Placebo|Double-blind treatment period of 17 weeks placebo
79821271|NCT00739713|Dietary Supplement|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
79674458|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
79995189|NCT03625284|Dietary Supplement|Placebo|Edible oil
79995190|NCT03625284|Dietary Supplement|FucoVital|Microalgae oil extract
79221736|NCT05578586|Drug|Meropenem 1000 mg|given as 6 or 3 infusions in 15 minues or 3 hours.
79302489|NCT02488889|Drug|placebo beverage (for alcohol)|
79995191|NCT03210961|Drug|PF-06826647 tablet|PF-06826647 tablet for oral administration
79995192|NCT03210961|Drug|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
79995193|NCT03210961|Other|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
79995194|NCT03210961|Other|Placebo tablet|Matching placebo tablet
79364773|NCT05649059|Drug|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
79364774|NCT05649059|Drug|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
79516416|NCT03722654|Behavioral|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
79674459|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
79674460|NCT00478049|Drug|Gefitinib|250 mg oral tablet
79674461|NCT00478049|Drug|Docetaxel|intravenous infusion
79674462|NCT01248975|Drug|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
79674463|NCT01248975|Drug|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
79221737|NCT05514886|Device|Gene Expert molecular Point-of-Care (POC) (Xpert® Xpress SARS-CoV-2/Flu/RSV test|POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso.
79221738|NCT03121976|Device|Ultrasound|Femoral catheter inserted using ultrasound only
79221739|NCT03121976|Device|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
79221740|NCT02570152|Procedure|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever [body temperature ≥ 38°C/≥ 100.4°F] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
79221741|NCT03495726|Behavioral|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
79221742|NCT02323386|Device|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
79364777|NCT05640167|Behavioral|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
79371148|NCT04832230|Biological|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
79674464|NCT01248975|Drug|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
79674465|NCT01248975|Drug|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
79995195|NCT04797078|Procedure|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
79221743|NCT02325726|Procedure|Renal Resistive Index compared with NephroCheckTM|
79221744|NCT03495570|Diagnostic Test|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
79674466|NCT01248975|Drug|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
79674467|NCT01248975|Drug|Placebo capsule (PM)|Placebo capsule (PM)
79674468|NCT02955927|Drug|0.01% atropine eye drops|
79674469|NCT02955927|Device|ortho-k|
79821272|NCT00739713|Dietary Supplement|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
79821273|NCT00739791|Behavioral|exercise intervention|
79674470|NCT00478283|Other|survey administration|
79674471|NCT01247454|Behavioral|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
79674472|NCT01247454|Behavioral|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
79674473|NCT01247454|Behavioral|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
79821274|NCT00739791|Genetic|gene expression analysis|
79821275|NCT00739791|Genetic|polymerase chain reaction|
79821276|NCT00739791|Genetic|proteomic profiling|
79674474|NCT00478322|Drug|Placebo|Matching placebo of 100 mg BID
79995196|NCT04797078|Procedure|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
79516417|NCT03721120|Diagnostic Test|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
79674475|NCT00478322|Drug|INCB013739|INCB013739 100 mg BID
79995197|NCT03638921|Drug|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
79221745|NCT03494010|Other|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
79995198|NCT05417919|Other|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
79221746|NCT03495492|Device|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
79221747|NCT03495492|Dietary Supplement|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
79221748|NCT03495336|Other|coffee abstention phase|no coffee consumption for 2 weeks
79221749|NCT03495336|Other|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
79221750|NCT03495336|Other|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
79221751|NCT02570074|Drug|Fosfomycin|Broad spectrum antibiotic
79221752|NCT03499002|Other|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
79221753|NCT03498924|Diagnostic Test|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
79221754|NCT02569996|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
79221755|NCT03498846|Procedure|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
79221756|NCT03498846|Procedure|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
79221757|NCT02325882|Drug|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
79221758|NCT02325882|Drug|Fentanyl 1|conventional fentanyl-based epidural PCA
79221759|NCT02325882|Drug|Fentanyl 2|conventional fentanyl based intravenous PCA
79221760|NCT05519332|Procedure|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
79516418|NCT03694262|Drug|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
79221761|NCT03498768|Other|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
79221762|NCT03498690|Behavioral|Integrative|Stakeholder groups: a-b
79674476|NCT01322347|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
79674477|NCT01322347|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
79674478|NCT01247493|Drug|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
79674479|NCT00478439|Dietary Supplement|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
79221763|NCT03498690|Behavioral|Role specific|Stakeholder groups: a or b
79221764|NCT03498690|Behavioral|Consecutive|Stakeholder groups: a=> b
79221765|NCT04424836|Device|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
79221766|NCT02323542|Other|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
79221767|NCT04424758|Other|Video information about mammography screening|A video informing about mammography screening
79221768|NCT04424758|Other|Video information about smart energy systems|A video informing about smart energy systems
79302490|NCT03220087|Other|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
79674480|NCT00478439|Dietary Supplement|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
79821277|NCT00739791|Genetic|reverse transcriptase-polymerase chain reaction|
79821278|NCT00739791|Other|laboratory biomarker analysis|
79995199|NCT04853667|Other|Interview|Semi-structured interview, lasting a maximum of one hour
79995200|NCT03242759|Drug|nintedanib|Drug
79995201|NCT03242759|Drug|pirfenidone|Drug
79674481|NCT04325425|Drug|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
79221769|NCT05144646|Other|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
79674482|NCT04325425|Drug|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 [the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
79221770|NCT05144646|Other|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
79674483|NCT02891395|Drug|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
79674484|NCT00478478|Procedure|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
79674485|NCT05645185|Diagnostic Test|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
79674486|NCT01247532|Behavioral|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
79674487|NCT00478517|Drug|Erythropoetin (rHuEPO, EPREX®)|
79221771|NCT02323620|Procedure|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
79364778|NCT05638620|Drug|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
79516419|NCT03694262|Drug|Bevacizumab|15mg/kg IV on day 1 of every cycle
79516420|NCT03694262|Drug|Atezolizumab|1,200mg IV on day 1 of every cycle
79516421|NCT03685539|Procedure|Dual-Energy Computed Tomography|Undergo DECT
79516422|NCT03653702|Drug|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
79674488|NCT03273218|Device|Tiger catheter|
79674489|NCT03273218|Device|Judkins catheter|
79674490|NCT01321879|Drug|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
79674491|NCT03271853|Device|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
79674492|NCT01321723|Drug|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
79674493|NCT01321723|Drug|Placebo|
79674494|NCT01321723|Drug|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
79221772|NCT02572882|Dietary Supplement|p-inulin|12 week self-administered treatment phase
79516423|NCT03646812|Other|Glucose Reference 1|Glucose contains 50g of available carbohydrates
79516424|NCT03646812|Other|Glucose Reference 2|Glucose contains 50g of available carbohydrates
79516425|NCT03646812|Other|Glucose Reference 3|Glucose contains 50g of available carbohydrates
79516426|NCT03646812|Other|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
79516427|NCT03646812|Other|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
79516428|NCT03646812|Other|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
79516429|NCT03646812|Other|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
79821279|NCT00739791|Other|medical chart review|
79821280|NCT00739791|Other|questionnaire administration|
79995202|NCT04050930|Other|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
79516430|NCT03646812|Other|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
79995203|NCT05415579|Other|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
79995204|NCT03416010|Behavioral|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
79221773|NCT02319954|Procedure|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
79821281|NCT00739791|Procedure|psychosocial assessment and care|
79821282|NCT00739791|Procedure|quality-of-life assessment|
79364779|NCT05637606|Drug|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
79364780|NCT05637606|Drug|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
79821283|NCT00739791|Procedure|support group therapy|
79821284|NCT00739791|Procedure|therapeutic dietary intervention|
79821285|NCT02568579|Procedure|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
79821286|NCT05388825|Drug|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
79821287|NCT05388825|Drug|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
79821288|NCT05388825|Drug|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
79995205|NCT03656029|Drug|Cannabis|Participants will smoke as much of the cigarette as they wish
79995206|NCT03656029|Drug|Placebo|Participants will smoke a placebo cigarette
79221774|NCT00708500|Drug|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
79221775|NCT00708500|Biological|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
79364781|NCT05637606|Drug|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
79364782|NCT05637606|Diagnostic Test|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
79364783|NCT05633160|Drug|64Cu-SAR-BBN|64Cu-SAR-BBN
79516431|NCT03646812|Other|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
79516432|NCT03639935|Drug|Rucaparib|Rucaparib 600 mg PO BID days 1-28
79516433|NCT03639935|Drug|Nivolumab|Nivolumab 240 mg IV days 1 and 15
79516434|NCT03624231|Drug|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
79516435|NCT03624231|Drug|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
79516436|NCT03624231|Radiation|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
79516437|NCT03603405|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
79516438|NCT03596086|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
79821289|NCT05388825|Drug|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
79821290|NCT05388825|Drug|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
79821291|NCT00711477|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
79821292|NCT00711477|Drug|Placebo|
79221776|NCT00708500|Drug|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
79221777|NCT00708500|Drug|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
79821293|NCT00711477|Other|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
79821294|NCT05372913|Device|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
79221778|NCT05144100|Procedure|Surgery with or without Neck Dissection|An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
79516439|NCT03568669|Other|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
79516440|NCT03564509|Drug|FE 999302 (1 μg) and follitropin delta|Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
79516441|NCT03564509|Drug|FE 999302 (2 μg) and follitropin delta|Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
79516442|NCT03564509|Drug|FE 999302 (4 μg) and follitropin delta|Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
79516443|NCT03564509|Drug|FE 999302 (8 μg) and follitropin delta|Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
79674495|NCT01247649|Device|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
79674496|NCT00478634|Drug|RAD001, Cetuximab, Irinotecan|
79674497|NCT01247688|Drug|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
79821295|NCT05372913|Behavioral|CBT-Light Teletherapy|The CBT-Light teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
79821296|NCT00739947|Other|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
79995207|NCT03097029|Drug|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
79995208|NCT02545517|Biological|Rabipur|Subjects in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm
79995209|NCT02545517|Procedure|Blood sampling|Blood samples were drawn from all subjects at day 1 and then at subsequent year intervals from extension study day 1 onwards.
79221779|NCT05144100|Radiation|Radiation|Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
79516444|NCT03564509|Drug|FE 999302 (12 μg) and follitropin delta|Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
79516445|NCT03564509|Other|Placebo and follitropin delta|Daily dose of placebo; individualized follitropin delta dose.
79995210|NCT03636841|Device|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
79995211|NCT04206995|Other|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
79364784|NCT05633160|Drug|67Cu-SAR-BBN|67Cu-SAR-BBN
79364785|NCT05632640|Other|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
79364786|NCT05632640|Device|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
79516446|NCT03556384|Drug|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
79516447|NCT03507894|Behavioral|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
79674498|NCT01247688|Drug|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
79674499|NCT01247688|Radiation|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
79674500|NCT01247688|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
79674501|NCT01321606|Dietary Supplement|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
79674502|NCT01321606|Dietary Supplement|sugar pill (placebo)|Placebo identical to the active product will be given
79674503|NCT00503919|Procedure|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
79821297|NCT00734474|Drug|LY2189265|
79995212|NCT04206995|Other|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
79364787|NCT05626985|Diagnostic Test|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
79364788|NCT05626192|Other|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
79364789|NCT05623774|Drug|Imatinib Mesylate|400mg tablet
79364790|NCT05623774|Drug|IkT-001Pro|100mg or 400mg tablet
79821298|NCT00734474|Drug|Sitagliptin|
79821299|NCT00734474|Drug|Placebo solution|
79221780|NCT05144100|Drug|Cisplatin based chemotherpay|Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
79221781|NCT04552340|Other|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
79221782|NCT02320032|Drug|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
79221783|NCT05514652|Drug|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
79221784|NCT05573282|Other|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
79221785|NCT03495258|Procedure|Clarion Evolve Laser Vaporization System|
79221786|NCT03495258|Procedure|Olympus TURis Plasma Vaporization|
79221787|NCT05143398|Dietary Supplement|Diet + protein|Comparison of the efficacy
79221788|NCT05143398|Dietary Supplement|Diet + EAA|Comparison of the efficacy
79221789|NCT05143398|Dietary Supplement|Diet + EAA and TCA|Comparison of the efficacy
79221790|NCT05143398|Other|Diet|Comparison of the efficacy
79221791|NCT00673244|Drug|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
79221792|NCT05568992|Device|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
79221793|NCT04424680|Behavioral|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
79516450|NCT03483597|Other|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
79674504|NCT00478790|Device|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
79674505|NCT02956187|Behavioral|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
79674506|NCT02956187|Dietary Supplement|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
79674507|NCT04517682|Diagnostic Test|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
79221794|NCT04501016|Behavioral|Tailored behavioral counseling|Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
79221795|NCT04501016|Drug|Tobacco cessation pharmacotherapy|Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
79221796|NCT02320188|Other|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
79221797|NCT02320188|Other|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
79302491|NCT02485847|Procedure|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
79302492|NCT02485535|Other|Laboratory Biomarker Analysis|Correlative studies
79302493|NCT02485535|Drug|Selinexor|Given PO
79674508|NCT01320943|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
79674509|NCT01320943|Other|Stop TDF|Participants will stop TDF therapy
79674510|NCT04519008|Device|Mobile app|Medical device for improving emotion dysregulation
79674511|NCT04519008|Combination Product|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
79821300|NCT00734474|Drug|Placebo tablet|
79821301|NCT00734474|Drug|Metformin|
79821302|NCT00583362|Biological|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
79821303|NCT00577473|Drug|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
79821304|NCT00577473|Drug|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
79821305|NCT00740103|Drug|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
79821306|NCT05722665|Other|Categorization of chest xrays images|Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
79995213|NCT03625128|Drug|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
79516451|NCT03426579|Device|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
79516452|NCT03400137|Diagnostic Test|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
79516453|NCT03366012|Device|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
79221798|NCT05143242|Procedure|Hard tissue augmentation at the buccal aspect of single implants.|One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.
79221799|NCT05143242|Procedure|Soft tissue augmentation at the buccal aspect of single implants.|A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
79995214|NCT03625050|Procedure|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
79221800|NCT05561348|Device|Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time. In the sham stimulation group, the electrodes were fixed at the same position without releasing current.
79516454|NCT03327532|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
79221801|NCT05512078|Procedure|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
79221802|NCT02517788|Drug|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
79221803|NCT02517788|Drug|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
79516455|NCT03327532|Procedure|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
79221804|NCT02517788|Drug|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
79221805|NCT02323776|Other|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
79221806|NCT05143086|Other|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
79221807|NCT05143086|Other|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
79221808|NCT05143086|Other|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
79221809|NCT05143086|Other|Placebo|Use 10 ml of mouthwash without fluoride
79516456|NCT03327532|Biological|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
79516457|NCT03327532|Other|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
79516458|NCT03327532|Biological|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
79516459|NCT03327532|Procedure|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
79516460|NCT03259503|Drug|Busulfan|Given IV
79516461|NCT03259503|Drug|Gemcitabine|Given IV
79516462|NCT03259503|Drug|Melphalan|Given IV
79516463|NCT03259503|Drug|Olaparib|Given PO
79516464|NCT03259503|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
79516465|NCT03259503|Other|Pharmacokinetic Study|Correlative studies
79516466|NCT03259503|Biological|Rituximab|Given IV
79516467|NCT03259503|Drug|Vorinostat|Given PO
79221810|NCT03347630|Diagnostic Test|MRI|Thoraco-abominal MRI
79302494|NCT03219931|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
79302495|NCT03219931|Drug|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
79516471|NCT03240016|Drug|Pembrolizumab|200mg IV D1
79516472|NCT03240016|Drug|Abraxane|100mg/m^2 D1 and D8
79516473|NCT03229499|Drug|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
79516474|NCT03229499|Drug|Placebo Oral Tablet|matching placebo tablet
79516475|NCT03223025|Drug|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
79221811|NCT04293406|Other|Decision Navigation Intervention (DNI)|This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
79221812|NCT02320344|Behavioral|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
79995215|NCT03625050|Drug|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
79995216|NCT03257813|Drug|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
79302496|NCT03320759|Behavioral|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
79364792|NCT05622045|Behavioral|Voice data|Recorded response to a question about their participation in a weight loss study.
79364793|NCT05611775|Device|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
79364794|NCT05608707|Behavioral|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
79364795|NCT05608707|Dietary Supplement|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
79364796|NCT05601986|Other|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
79516476|NCT03223025|Drug|Nordilet®|0.03 mg/kg daily subcutaneous injections
79516477|NCT03190889|Other|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
79516478|NCT03190889|Other|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
79516479|NCT03135730|Genetic|ROHHAD|Suspected and Confirmed ROHHAD cases
79516480|NCT03118037|Device|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
79516481|NCT03007030|Drug|Brentuximab Vedotin|Given IV
79516482|NCT03007030|Other|Laboratory Biomarker Analysis|Correlative studies
79674512|NCT04325347|Other|Virtual Reality application|Virtual Reality application with a VR goggle
79674513|NCT00472706|Procedure|excision|excision 3 mm margin
79674514|NCT00472706|Procedure|Photodynamic therapy|Photodynamic therapy
79674515|NCT02955459|Drug|VNRX-5133|
79674516|NCT02955459|Drug|Placebo|
79674517|NCT00478907|Drug|KETAMINE, PROPOFOL, THIOPENTAL|
79674518|NCT02275377|Other|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
79821307|NCT02568111|Drug|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
79995217|NCT03257813|Drug|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
79995218|NCT03210259|Drug|Humira®|Duration - 58 weeks
79995219|NCT03210259|Drug|BI 695501|Duration - 58 weeks
79995220|NCT04773678|Drug|CBP-201|CBP-201 subcutaneous (SC) injection.
79995221|NCT04773678|Drug|Placebo|Placebo subcutaneous (SC) injection.
79516483|NCT02976389|Other|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
79516484|NCT02976389|Other|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
79516485|NCT02976389|Other|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
79516486|NCT02972580|Genetic|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
79516487|NCT02947633|Drug|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
79995222|NCT03257657|Behavioral|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
79221813|NCT03347552|Behavioral|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
79221814|NCT05128266|Procedure|Endodontical Retreatment|"Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique."
79221815|NCT05514262|Other|The stress ball|Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
79221816|NCT05514262|Device|The Buzzy® device|Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
79371149|NCT03029026|Other|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
79821308|NCT02568111|Drug|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
79821309|NCT02568111|Drug|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
79821310|NCT00785291|Biological|Bevacizumab|Given IV
79821311|NCT00785291|Drug|Ixabepilone|Given IV
79995223|NCT03257657|Behavioral|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
79995224|NCT04319757|Drug|ACE1702|ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
79821312|NCT00785291|Other|Laboratory Biomarker Analysis|Correlative studies
79821313|NCT00785291|Drug|Nab-paclitaxel|Given IV
79821314|NCT00785291|Drug|Paclitaxel|Given IV
79821315|NCT00785291|Other|Questionnaire Administration|Ancillary studies
79995225|NCT04319757|Drug|Cyclophosphamide|Lympho-conditioning agent
79221817|NCT02320422|Behavioral|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
79221818|NCT03493776|Biological|VZV subunit vaccine|VZV subunit vaccine
79995226|NCT04319757|Drug|Fludarabine|Lympho-conditioning agent
79995227|NCT04576806|Other|Body temperature|Warming of administered fluid bolus
79221819|NCT04599790|Drug|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
79221820|NCT02517632|Behavioral|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
79221821|NCT02517632|Behavioral|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
79221822|NCT03132168|Behavioral|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
79364797|NCT05601986|Other|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
79221823|NCT03132168|Procedure|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
79364798|NCT05599503|Behavioral|Behavioral Interventions|Traditional SimpleC Wellness
79364799|NCT05599503|Behavioral|Robot Interventions|Robot interventions
79364800|NCT05598138|Biological|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
79364801|NCT05591404|Behavioral|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
79364802|NCT05589675|Other|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
79364803|NCT05589675|Other|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
79674519|NCT02275377|Other|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
79674520|NCT00478946|Drug|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
79674521|NCT00478946|Drug|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
79995228|NCT04576806|Drug|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
79995229|NCT04576806|Other|Room temperature|Cooling of administered fluid bolus
79674522|NCT00478946|Drug|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
79995230|NCT05180461|Drug|emodepside|emodepside tablet
79995231|NCT05180461|Drug|matching placebo of emodepside|emodepside matching placebo tablet
79995232|NCT05180461|Drug|ivermectin|ivermectin tablet (overencapsulated for blinding)
79995233|NCT05180461|Drug|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
79516488|NCT02947633|Drug|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
79516489|NCT02830360|Drug|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
79516490|NCT02830360|Procedure|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
79221824|NCT03132168|Other|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
79516491|NCT02768766|Drug|Selumetinib, 100mg|"100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
79516492|NCT02768766|Drug|Selumetinib, 125mg|"125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
79674523|NCT01247844|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
79221825|NCT04937062|Drug|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf)."
79221826|NCT04256408|Device|Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal|Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
79674524|NCT01247961|Drug|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
79364804|NCT05585450|Device|Electroacupuncture|"BL32 and BL33 will be inserted by needles of 0.30×75mm size at an angle of 45°, inward and downward, to the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, to the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm to the depth of 25-30mm. The needles will be lifted, thrust, and twisted evenly three times after insertion to induce the sensation of deqi.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hertz (Hz) and an electric current of 2-6.5 milliampere (mA) for BL32, BL33 and BL35, and 0.5 mA-2mA for SP6."
79364805|NCT05585450|Device|Sham electroacupuncture|"The four pairs of acupoints will be inserted by needles of 0.30×25mm or 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hz and a minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on."
79674525|NCT01247961|Other|Placebo|Normal saline
79821316|NCT04063137|Dietary Supplement|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
79821317|NCT00705939|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
79821318|NCT02568891|Dietary Supplement|Probiotic|multispecies probiotic
79821319|NCT02568891|Dietary Supplement|Placebo|matrix
79821320|NCT00740259|Drug|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
79995234|NCT05229861|Behavioral|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
79221827|NCT02320500|Behavioral|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
79364806|NCT05582538|Drug|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
79364807|NCT05582538|Drug|Durvalumab|1500 mg i.v. day 1 (q28)
79364808|NCT05582538|Drug|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
79364809|NCT05580653|Other|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
79516493|NCT02768766|Drug|Selumetinib, 150mg|"150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
79995235|NCT05229861|Behavioral|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
79995236|NCT05180305|Diagnostic Test|Mitomic Prostate Test|Mitomic Prostate Test
79364810|NCT05580653|Other|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
79364811|NCT05578547|Other|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
79821321|NCT04079010|Procedure|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
79364812|NCT05578547|Other|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
79516494|NCT02768766|Drug|Selumetinib, 175mg|"175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
79674526|NCT01248000|Procedure|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
79821322|NCT04079010|Dietary Supplement|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
79995237|NCT05415345|Biological|Cecolin|Bivalent HPV Vaccine
79995238|NCT05415345|Biological|Hecolin|Hepatitis E vaccine
79995239|NCT05205889|Behavioral|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
79995240|NCT03704454|Dietary Supplement|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
79995241|NCT03704454|Dietary Supplement|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
79995242|NCT03704454|Dietary Supplement|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
79674527|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
79221828|NCT02320500|Other|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
79674528|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
79674529|NCT01248078|Drug|saline solution|100cc administered before skin incision
79674530|NCT00472823|Dietary Supplement|Vitamin D3|Orally for one year
79674531|NCT00472823|Dietary Supplement|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
79221829|NCT00708734|Behavioral|functional exercise training|twice weekly group sessions for 5 weeks
79674532|NCT02275416|Drug|Ipilimumab|
79221830|NCT02320578|Procedure|3D Laparoscopy|3D Laparoscopy approach
79221831|NCT02320578|Procedure|Standard Laparoscopy|Standard laparoscopy approach
79221832|NCT04923724|Device|tourniquet|tourniquet is a device used during total knee surgery.
79221833|NCT04923724|Device|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
79364813|NCT05576610|Procedure|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following are advice that will be given face-to-face to parent and participant and a take home pamphlet would be provided:~Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~To not share toothbrushes.~To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~To store toothbrushes apart to prevent spread of diseases through the bristles.~To brush teeth at least twice a day, after meals and before bed.~To brush for as long as two to three minutes.~Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
79221834|NCT03347474|Procedure|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
79221835|NCT02323932|Behavioral|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
79516495|NCT02768766|Drug|Selumetinib, 200mg|"200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
79221836|NCT04502498|Diagnostic Test|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
79221837|NCT02324010|Drug|Sitagliptin|100mg mane for 2 days
79221838|NCT02324010|Drug|Placebo|Inactive drug (Placebo)
79221839|NCT05513794|Device|MRI Imaging|Neuromelanin sequence imaging
79221840|NCT02517710|Procedure|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
79221841|NCT02517476|Dietary Supplement|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
79221842|NCT02320656|Other|Blood sampling|Longitudinal (3 stages of the disease)
79221843|NCT02320656|Other|Bone marrow aspirate|Longitudinal (3 stages of the disease)
79221844|NCT02320656|Other|Skin biopsy|Single biopsy (optional)
79221845|NCT02320656|Other|Buccal swab|Single sampling.
79516496|NCT02768766|Drug|Selumetinib, 225mg|"225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
79221846|NCT03346304|Other|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
79674533|NCT02275416|Biological|UV1 vaccine|
79674534|NCT02275416|Biological|GM-CSF|
79516497|NCT02764541|Drug|Letrozole|
79674535|NCT00472862|Behavioral|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
79995243|NCT03704454|Dietary Supplement|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
79516498|NCT02764541|Drug|Tamoxifen|
79516499|NCT02764541|Drug|Palbociclib|
79516500|NCT02764541|Drug|Endocrine Therapy|
79516501|NCT02750826|Other|Health Education Program|
79516502|NCT02750826|Other|Weight Loss Intervention|
79221847|NCT03493308|Other|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
79221848|NCT03493308|Other|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
79516503|NCT02745184|Biological|Lung stem cells|Patients will receive 0.5-5x10^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
79674536|NCT00472901|Drug|Afamelanotide (CUV1647)|16mg implant
79674537|NCT00479024|Drug|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
79674538|NCT02482233|Behavioral|ENDD (NJOY)|As described above.
79674539|NCT02482233|Drug|NRT (NicoDerm CQ)|As described above.
79221849|NCT02320734|Drug|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
79221850|NCT03346226|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
79221851|NCT03346226|Drug|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
79221852|NCT03347240|Procedure|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
79221853|NCT03347240|Procedure|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
79221854|NCT03347240|Device|Deep brain stimulation|Bilateral DBS
79221855|NCT03347240|Device|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
79221856|NCT02324088|Drug|Docetaxel|
79221857|NCT02324088|Drug|Cyclophosphamide|
79674540|NCT02482233|Behavioral|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
79995244|NCT05417529|Other|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
79995245|NCT05417529|Drug|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
79516504|NCT02649790|Drug|KPT-8602|Participants will receive KPT-8602 oral tablets.
79516505|NCT02649790|Drug|ASTX727|ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
79516506|NCT02649790|Drug|Dexamethasone|Participants will receive dexamethasone oral tablets.
79516507|NCT02595060|Drug|inhaled molgramostim (rhGM-CSF)|
79674541|NCT02482233|Behavioral|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
79674542|NCT02482233|Behavioral|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
79221858|NCT02324088|Drug|Epirubicin|
79221859|NCT04597294|Combination Product|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
79221860|NCT04597294|Combination Product|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
79221861|NCT02324166|Drug|Cefazolin|cephalosporin antibiotic
79221862|NCT02324166|Drug|Lidocaine|local anesthetic
79221863|NCT05518942|Behavioral|sensorimotor rhythm neurofeedback training|In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
79221864|NCT03346538|Drug|Continuous infusion high-dose MCI-186|intravenous injection
79221865|NCT03346538|Drug|Continuous infusion low-dose MCI-186|intravenous injection
79221866|NCT03346538|Drug|Continuous infusion placebo|intravenous injection
79221867|NCT03346538|Drug|Approved dosing regimen MCI-186|intravenous injection
79221868|NCT03346538|Drug|Approved dosing regimen placebo|intravenous injection
79221869|NCT05513170|Procedure|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
79221870|NCT05513170|Procedure|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
79221871|NCT02513342|Biological|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
79221872|NCT02513342|Drug|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
79221873|NCT02513342|Drug|Cisplatin|d4，cisplatin，75（mg/m2），iv；
79221874|NCT05513092|Diagnostic Test|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
79221875|NCT02517320|Drug|MT-3995 Low|
79221876|NCT02517320|Drug|MT-3995 Middle|
79221877|NCT02517320|Drug|MT-3995 High|
79221878|NCT02517320|Drug|Placebo|
79221879|NCT03491826|Biological|rupture of membrane|
79221880|NCT04589962|Other|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
79221881|NCT02512952|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
79516508|NCT02595060|Drug|inhaled placebo|formulated as the active substance without molgramostim
79516509|NCT02587065|Drug|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
79516510|NCT02572856|Device|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
79516511|NCT02544503|Device|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
79516512|NCT02544503|Device|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
79516513|NCT02544503|Device|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
79221882|NCT02512952|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
79516514|NCT02544503|Device|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
79516515|NCT02492867|Radiation|Response-driven Adaptive Radiation Therapy|
79516516|NCT02492867|Drug|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
79674543|NCT02489526|Drug|VVZ-149 Injections|Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
79674544|NCT02489526|Drug|Placebo|Placebo group will receive the corresponding amount of placebo.
79674545|NCT00473018|Behavioral|standard versus enhanced risk reduction counseling|
79674546|NCT00479102|Drug|Ferripel-3 - iron polysaccharide complex for prevention|
79221883|NCT02512952|Procedure|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
79221884|NCT03493230|Biological|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
79221885|NCT02513108|Procedure|same day discharge|same day discharge after PCI for stable CAD
79221886|NCT03495024|Drug|Varenicline|Oral medication approved to facilitate smoking cessation
79221887|NCT02513030|Procedure|Defibrillation testing during ICD replacement|
79221888|NCT02512796|Drug|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
79221889|NCT05040048|Other|Clinical, biological and imaging assessment|
79221890|NCT04188314|Drug|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
79364814|NCT05576610|Procedure|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following are advice that will be given face-to-face to parent and participant and a take home pamphlet would be provided:~Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~To not share toothbrushes.~To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~To store toothbrushes apart to prevent spread of diseases through the bristles.~To brush teeth at least twice a day, after meals and before bed.~To brush for as long as two to three minutes.~Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
79364815|NCT05575947|Device|da Vinci Surgical System|da Vinci Surgical System
79364816|NCT05575947|Procedure|laparoscopic bariatric surgery|laparoscopic bariatric surgery
79364817|NCT05570305|Drug|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
79364818|NCT05570305|Drug|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
79364819|NCT05570305|Drug|Placebo|Matching placebo.
79364820|NCT05570305|Drug|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
79364821|NCT05568680|Biological|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
79516517|NCT02492867|Drug|Paclitaxel|40 mg/m^2 IV concurrent with RT; 200 mg/m^2 during consolidation. Given IV
79516518|NCT02492867|Device|FDG-PET|
79221891|NCT04188314|Drug|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
79221892|NCT05512780|Drug|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
79221893|NCT04501172|Behavioral|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
79516519|NCT02492867|Device|V/Q SPECT|
79995246|NCT02496611|Drug|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
79995247|NCT02496611|Drug|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
79516520|NCT02492867|Drug|Durvalumab|10 mg/kg during consolidation. Given IV
79516521|NCT02375204|Drug|paclitaxel|IV
79516522|NCT02375204|Drug|ifosfamide|IV
79516523|NCT02375204|Drug|cisplatin|IV
79516524|NCT02375204|Drug|pegylated G-CSF|IV
79516525|NCT02375204|Drug|G-CSF|IV
79516526|NCT02375204|Drug|carboplatin|IV
79516527|NCT02375204|Drug|etoposide phosphate|IV
79674547|NCT01248117|Drug|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
79674548|NCT00479141|Behavioral|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
79516528|NCT02375204|Procedure|stem cell reinfusion|surgical procedure
79516529|NCT02365792|Procedure|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
79516530|NCT02343042|Drug|Selinexor|Oral tablets
79516531|NCT02343042|Drug|Dexamethasone|Oral tablets
79516532|NCT02343042|Drug|Lenalidomide|Oral capsule
79516533|NCT02343042|Drug|Pomalidomide|Oral tablets
79516534|NCT02343042|Drug|Bortezomib|Subcutaneous Injection (single use vial)
79516535|NCT02343042|Drug|Daratumumab|Intravenous Infusion
79674549|NCT00479141|Behavioral|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
79221894|NCT02324322|Device|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
79674550|NCT00479180|Biological|Vascugel|One time implant on the day of surgery
79674551|NCT00479180|Biological|Placebo Comparator|One time implant on the day of surgery
79221895|NCT02324322|Other|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
79221896|NCT02324322|Other|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
79221897|NCT02517242|Device|Pens Device|
79364822|NCT05565716|Other|Support Person|"Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly."
79516536|NCT02343042|Drug|Carfilzomib|Intravenous infusion
79516537|NCT02343042|Drug|Ixazomib|Oral capsule
79221898|NCT02517242|Device|Syringe|
79221899|NCT02517242|Other|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
79221900|NCT03494712|Drug|S 95010|Single administration of S 95010 in healthy volunteers
79221901|NCT03494712|Other|Placebo|Single administration of placebo in healthy volunteers
79516538|NCT02343042|Drug|Elotuzumab|Intravenous infusion
79516539|NCT02343042|Drug|Clarithromycin|Tablets
79674552|NCT01248234|Drug|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
79221902|NCT02517164|Other|Measurement of serum 25-hydroxyvitamin D|
79221903|NCT02517164|Other|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
79516540|NCT02343042|Drug|Belantamab Mafodotin|Intravenous infusion
79516541|NCT02339168|Drug|Enzalutamide|Given PO
79674553|NCT01248234|Drug|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
79516542|NCT02339168|Drug|Metformin Hydrochloride|Given PO
79516543|NCT02295891|Device|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
79995248|NCT03105570|Procedure|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
79995249|NCT04767048|Procedure|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
79516547|NCT02269319|Drug|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
79516548|NCT02269319|Drug|Linezolid|Oral linezolid 600mg given twice a day for 10 days
79516549|NCT02120404|Drug|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
79674554|NCT01248234|Drug|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
79674555|NCT00479219|Drug|GSI-953|
79674556|NCT00479219|Other|Placebo|
79674557|NCT00479297|Drug|SAM-531|
79674558|NCT00503958|Genetic|DNA methylation analysis|
79674559|NCT00503958|Genetic|DNA stability analysis|
79674560|NCT00503958|Genetic|gene expression analysis|
79674561|NCT00503958|Other|epidemiologic study|
79674562|NCT00503958|Other|study of socioeconomic and demographic variables|
79674563|NCT00503958|Procedure|biopsy|
79674564|NCT00503958|Procedure|evaluation of cancer risk factors|
79674565|NCT00503958|Procedure|study of high risk factors|
79516550|NCT02103491|Dietary Supplement|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
79516551|NCT02103491|Dietary Supplement|Placebo administration|
79516552|NCT02055456|Drug|Nandrolone Decanoate|
79516553|NCT02031250|Drug|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
79221904|NCT05511376|Device|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
79221905|NCT05511376|Behavioral|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
79221906|NCT05511376|Behavioral|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
79221907|NCT03346460|Other|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
79221908|NCT03346460|Radiation|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
79221909|NCT03346460|Radiation|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
79221910|NCT04834362|Drug|Analog Insulin|"For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG >15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is >10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG >15 mmol/L."
79221911|NCT04834362|Drug|Human insulin|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
79221912|NCT05507710|Diagnostic Test|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
79221913|NCT03121274|Procedure|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
79221914|NCT03493074|Diagnostic Test|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
79364823|NCT05565716|Other|Social Norms|Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
79516554|NCT02031250|Drug|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
79516555|NCT02031250|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
79516556|NCT02031250|Radiation|Boost Radiation to Hypoperfused Volumes|
79674566|NCT00473057|Other|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
79364824|NCT05562518|Drug|Estrogen|1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
79364825|NCT05562518|Drug|dehydroepiandrosterone|1 vaginal ovule daily
79516557|NCT01995669|Other|Laboratory Biomarker Analysis|Correlative studies
79516558|NCT01995669|Drug|Lenalidomide|Given PO
79516559|NCT01995669|Biological|Obinutuzumab|Given IV
79516560|NCT01880567|Drug|Ibrutinib|Given PO
79516561|NCT01880567|Other|Laboratory Biomarker Analysis|Correlative studies
79516562|NCT01880567|Biological|Rituximab|Given IV
79516563|NCT01750567|Drug|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
79516564|NCT01740557|Biological|Aldesleukin|Given IV
79516565|NCT01740557|Biological|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
79516566|NCT01740557|Drug|Cyclophosphamide|Given IV
79516567|NCT01740557|Drug|Fludarabine Phosphate|Given IV
79674567|NCT00473096|Behavioral|Informed breast cancer surgical treatment|
79995250|NCT04767048|Procedure|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
79221915|NCT05512702|Drug|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
79221916|NCT05512702|Drug|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
79221917|NCT02516930|Behavioral|crowdsourced video|video promoting condom use
79221918|NCT02516930|Behavioral|social marketing video|
79221919|NCT03494634|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
79221920|NCT05507632|Combination Product|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
79221921|NCT05512546|Drug|Aspir-Low Pill|patients were prescribed 75 mg/day of either aspirin
79221922|NCT02517086|Other|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
79221923|NCT02517086|Other|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
79221924|NCT02517086|Other|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
79364826|NCT05562518|Drug|Estrogen + probiotics|2 vaginal ovules daily for 5 consecutive days, repeated every 4 weeks
79364827|NCT05562518|Drug|Moisturizer|1 vaginal ovule daily for 10 consecutive days, followed by 1 vaginal ovule every three days
79364828|NCT05556356|Drug|Acetaminophen|pre-operative acetaminophen (1000mg)
79364829|NCT05556356|Other|Placebo: Multivitamin|pre-operative Multivitamin
79364830|NCT05553522|Combination Product|Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine|"SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles until tumor progression, participant withdrawal, a severe adverse event deemed related to the study drug, or the treating physician discontinues the drug. There are three dosing levels of tucatinib (Dose Level 0, Dose Level -1, or Dose Level -2) using a dose de-escalation scheme. Dosing of capectabine (1000 mg/m2 BID Days 1-14) and trastuzumab (6 mg/kg once per 21 days; 8 mg/kg initial loading dose) per cycle will remain the same regardless of tucatinib dosing.~Dose Level 0: 300 mg twice a day (BID) continuously for 2 wk post SRS, then 300 mg BID continuously per cycle.~Dose Level -1: 250 mg twice a day (BID) continuously for 2 wk post SRS, then 250 mg BID continuously per cycle.~Dose Level -2: 200 mg twice a day (BID) continuously for 2 wk post SRS, then 200 mg BID continuously per cycle."
79516568|NCT01740557|Other|Laboratory Biomarker Analysis|Correlative studies
79516569|NCT01740557|Biological|NGFR-transduced Autologous T Lymphocytes|Given IV
79221925|NCT04879498|Drug|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
79221926|NCT04879498|Other|Veneered zirconia|To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures
79221927|NCT04879498|Other|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
79221928|NCT05511220|Behavioral|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
79516570|NCT01740557|Other|Quality-of-Life Assessment|Ancillary studies
79516571|NCT01705977|Biological|Placebo plus standard therapy|Placebo plus standard therapy
79516572|NCT01705977|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
79516573|NCT01705977|Other|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
79516574|NCT01686711|Drug|AD-4833 15 mg|
79516575|NCT01686711|Drug|AD-4833 30 mg|
79516576|NCT01686711|Drug|Placebo|
79516577|NCT01664234|Other|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
79516578|NCT01664234|Other|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
79674568|NCT00473135|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10^3 PFU
79674569|NCT00473135|Biological|Placebo|Placebo for rDEN1delta30
79674570|NCT01248273|Biological|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
79674571|NCT00479375|Procedure|Adding Human Papillomavirus testing to organised cervical screening|
79674572|NCT01248312|Device|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
79674573|NCT01248312|Device|sentec monitor|transcutaneous monitoring
79221929|NCT05511220|Behavioral|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
79221930|NCT03345134|Drug|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
79221931|NCT05605496|Drug|NP137|IV infusion, 14mg/kg, Q3W
79516579|NCT01568177|Behavioral|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
79516580|NCT01568177|Other|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
79516581|NCT01568177|Other|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
79516582|NCT01568177|Other|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
79674574|NCT01248351|Other|autologous stored platelets|Administration of autologous stored platelets
79674575|NCT01248351|Other|administration of autologous stored platelets|administration of autologous stored platelets
79221932|NCT05605496|Drug|anti-PD-1/PD-L1|IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
79221933|NCT02512562|Drug|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
79221934|NCT02512562|Drug|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
79221935|NCT02512562|Drug|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
79221936|NCT03489096|Device|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
79221937|NCT05511142|Other|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
79221938|NCT05511142|Other|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
79364831|NCT05553132|Combination Product|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
79371150|NCT03029026|Procedure|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
79516583|NCT01568177|Procedure|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
79516584|NCT01503632|Behavioral|Behavioral Intervention|Receive intervention program
79516585|NCT01503632|Behavioral|Compliance Monitoring|Correlative studies
79516586|NCT01503632|Other|Laboratory Biomarker Analysis|Correlative studies
79516587|NCT01503632|Drug|Mercaptopurine|Given orally
79516588|NCT01503632|Other|Questionnaire Administration|Ancillary studies
79516589|NCT01503632|Procedure|Standard Follow-Up Care|Receive usual standard of care
79221939|NCT02516774|Drug|Adalimumab|
79516590|NCT01474889|Device|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
79516591|NCT01407081|Behavioral|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
79516592|NCT01231906|Drug|Cyclophosphamide|Given IV
79516593|NCT01231906|Drug|Dexrazoxane|
79516594|NCT01231906|Drug|Doxorubicin Hydrochloride|Given IV
79516595|NCT01231906|Drug|Etoposide|Given IV
79516596|NCT01231906|Drug|Ifosfamide|Given IV
79516597|NCT01231906|Other|Laboratory Biomarker Analysis|Correlative studies
79674576|NCT01248351|Biological|autologous stored platelets|transfusion of autologous stored platelets
79674577|NCT00473174|Drug|Ramipril|Dosing on awakening versus bedtime
79674578|NCT00473174|Device|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
79995251|NCT03237481|Drug|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
79995252|NCT03237481|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
79995253|NCT03237481|Drug|Saline placebo|Saline placebo by instillation
79516598|NCT01231906|Drug|Topotecan Hydrochloride|Given IV
79516599|NCT01231906|Drug|Vincristine Sulfate|Given IV
79516600|NCT01154257|Procedure|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
79516601|NCT01154257|Procedure|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
79995254|NCT03237481|Device|Luer-lock applicator|Applicator for instillation
79995255|NCT03237481|Device|Vial access device|Device for withdrawal of drug product
79221940|NCT05510986|Drug|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
79364832|NCT05550753|Behavioral|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
79364833|NCT05550753|Behavioral|No intervention - placebo control|No intervention - placebo control
79221941|NCT05510986|Drug|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
79221942|NCT04856358|Drug|GLPG3121|GLPG3121 modified-release tablet
79364834|NCT05547867|Procedure|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
79364835|NCT05544734|Drug|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
79364836|NCT05544734|Drug|Acetaminophen 1000mg|1000 mg tablet
79364837|NCT05544734|Drug|Ibuprofen 400 mg|400 mg tablet
79364838|NCT05542030|Diagnostic Test|EMR with CAD-Eye™|"Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure.~The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis."
79364839|NCT05542030|Diagnostic Test|EMR without CAD-Eye™|"Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert.~The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis."
79364840|NCT05542030|Diagnostic Test|Follow-up colonoscopy with CAD-Eye™|"Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions.~For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis."
79221943|NCT04856358|Drug|Placebo|Matching placebo
79221944|NCT02512640|Procedure|Volume-controlled ventilation|a tidal volume of 8 ml/kg
79371151|NCT03029026|Procedure|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
79371152|NCT03029026|Radiation|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
79516602|NCT01143961|Device|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
79221945|NCT02512640|Procedure|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
79221946|NCT02512406|Other|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
79516603|NCT00899223|Other|biologic sample preservation procedure|
79516604|NCT00788164|Biological|TA-HPV|Given intramuscularly
79516605|NCT00788164|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
79516606|NCT00788164|Drug|imiquimod|Given topically
79516607|NCT00724048|Drug|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
79995256|NCT03704220|Drug|Warfarin|Removal of anticoagulation with warfarin
79995257|NCT03222349|Drug|Diazepam Buccal Film|Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
79995258|NCT02927925|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
79995259|NCT03208933|Drug|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
79995260|NCT05168917|Diagnostic Test|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
79995261|NCT05163951|Procedure|Trabeculectomy|trabeculectomy
79221947|NCT02512406|Other|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
79516608|NCT00724048|Other|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
79516609|NCT00579605|Behavioral|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
79516610|NCT00572416|Behavioral|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
79674579|NCT01248390|Behavioral|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
79674580|NCT00473213|Drug|Interferon Beta 1|
79221948|NCT02512406|Other|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
79364841|NCT05539040|Procedure|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
79364842|NCT05539040|Diagnostic Test|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
79364843|NCT05539040|Procedure|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
79364844|NCT05539040|Procedure|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
79364845|NCT05539040|Diagnostic Test|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
79364846|NCT05539040|Other|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
79516611|NCT00572416|Behavioral|Healthy Eating Control|Equal time and attention and information about healthy eating
79516612|NCT00468234|Drug|nicotine polacrilex|
79371153|NCT03029026|Procedure|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
79516613|NCT00468234|Drug|nicotine transdermal system|
79516614|NCT00468234|Drug|nicotine inhaler|
79516615|NCT00354393|Drug|Cisplatin|
79516616|NCT00354393|Drug|Methotrexate|
79674581|NCT02274831|Other|Email Reminder of need to follow up with primary physician|
79674582|NCT01320202|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
79516617|NCT00354393|Drug|Vinorelbine ditartrate|
79516618|NCT00354393|Procedure|Adjuvant therapy|
79516619|NCT00354393|Procedure|Conventional surgery|
79516620|NCT00354393|Procedure|Neoadjuvant Therapy|
79516621|NCT00354393|Radiation|3-dimensional conformal radiation therapy|
79516622|NCT00354393|Radiation|Intensity-modulated radiation therapy|
79674583|NCT01320202|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
79674584|NCT00479531|Device|AirCast Sequential Compression Device|
79674585|NCT00479570|Drug|PF-00446687|Single 200mg dose
79674586|NCT00479570|Drug|Placebo|
79995262|NCT05163951|Procedure|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
79821323|NCT04079010|Dietary Supplement|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
79821324|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
79516630|NCT00160680|Drug|Levocetirizine|"Pharmaceutical form: Tablet~Concentration: 5 mg~Route of administration: Oral use"
79821325|NCT04109651|Other|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
79221949|NCT02512406|Other|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
79364847|NCT05538000|Other|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment~telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment"
79364848|NCT05537714|Behavioral|Qualitative interviews/focus groups|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
79364849|NCT05530694|Behavioral|Clinician communication training|The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
79516631|NCT01818804|Dietary Supplement|n-3PUFA|
79516632|NCT01818804|Dietary Supplement|olive oil|
79221950|NCT02512406|Other|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
79516633|NCT01820754|Drug|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
79674587|NCT01319383|Drug|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
79674588|NCT00479609|Drug|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
79674589|NCT00479609|Drug|Placebo|Placebo gel
79674590|NCT04325113|Drug|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
79674591|NCT02275104|Device|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
79674592|NCT02275104|Device|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
79221951|NCT02512406|Other|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
79516634|NCT01820754|Drug|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
79516635|NCT01821378|Drug|Lurasidone|Lurasidone 20 mg once daily
79516636|NCT01821378|Drug|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
79516637|NCT01821378|Drug|Placebo|Once Daily
79516638|NCT01821534|Other|No Intervention|No treatment (intervention) was administered.
79516639|NCT01822548|Drug|Vildagliptin|100 mg daily
79516640|NCT01822548|Drug|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
79516641|NCT01822548|Drug|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
79674593|NCT02275104|Device|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
79674594|NCT02275104|Device|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
79221952|NCT00101907|Drug|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
79221953|NCT00101907|Biological|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
79221954|NCT00101907|Drug|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m^2.
79364850|NCT05530694|Behavioral|Patient activation|"The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health."
79516642|NCT01825122|Drug|Nadolol|
79516643|NCT01825122|Drug|Placebo|
79516644|NCT01825512|Drug|Deferiprone|Deferiprone 80 mg/mL oral solution
79516645|NCT01825512|Drug|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
79221955|NCT00101907|Drug|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m^2.
79516646|NCT01827462|Biological|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
79516647|NCT01827462|Biological|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
79516648|NCT01827462|Biological|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
79516649|NCT01827930|Drug|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
79821326|NCT04063839|Drug|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
79516650|NCT01827930|Drug|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
79221956|NCT02512484|Procedure|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
79221957|NCT03491748|Drug|ETX0282|Oral Gelatin capsules
79516651|NCT01827930|Drug|Imatinib Mesylate|Imatinib Mesylate for CP CML
79221958|NCT03491748|Drug|Cefpodoxime proxetil|Oral tablets
79516652|NCT01828164|Device|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
79221959|NCT03491748|Drug|Placebo|Oral Gelatin capsules
79221960|NCT04769206|Drug|Galantamine|4mg daily titrating up to 8mg twice a day
79221961|NCT04769206|Drug|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
79221962|NCT03791840|Diagnostic Test|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
79221963|NCT02517008|Other|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
79221964|NCT03492996|Drug|LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose|To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose to healthy subjects
79221965|NCT02161965|Drug|Rivaroxaban|20mg or 15mg
79221966|NCT02161965|Drug|Fluindione|
79221967|NCT02161965|Drug|Warfarin|
79221968|NCT02565784|Device|Restylane|Facial tissue augmentation
79516653|NCT01828164|Device|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
79516654|NCT01828476|Drug|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
79516655|NCT01828476|Drug|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
79516656|NCT01828476|Drug|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
79221969|NCT02565784|Device|Perlane|Facial tissue augmentation
79221970|NCT02050308|Other|Internet-All Nations Breath of Life (I-ANBL)|"Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~Weekly procedures will follow the same format as for the first session"
79516657|NCT01828554|Drug|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
79516658|NCT01832610|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
79516659|NCT01833078|Drug|ghrelin|ghrelin administration subcutaneously for 7 days
79821327|NCT04078074|Device|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
79821328|NCT04078074|Device|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
79221971|NCT02050308|Other|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
79364851|NCT05530694|Behavioral|RA Medication summary guide and RA Choice|RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
79364852|NCT05528900|Diagnostic Test|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
79516660|NCT01833936|Device|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
79221972|NCT02050308|Drug|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
79516661|NCT01833936|Device|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
79516662|NCT01834326|Biological|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
79516663|NCT01834326|Biological|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
79516664|NCT01834404|Drug|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
79516665|NCT01834404|Drug|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
79516666|NCT01834716|Behavioral|Aerobic vs. Non-Aerobic exercise|
79516667|NCT01835262|Drug|Morphine|Morphine: 0.1 mg /kg given as IVP
79516668|NCT01835262|Drug|Ketamine|Ketamine:0.3 mg/given as IVP
79516669|NCT01835496|Drug|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
79516670|NCT01766076|Other|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
79516671|NCT01766076|Drug|Placebo|PBMC collected for immune activation assays using flowcytometry
79516672|NCT01767792|Drug|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
79516673|NCT01794312|Device|T4020|
79516674|NCT01794312|Device|Vehicle|
79674595|NCT02275104|Procedure|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
79674596|NCT05644717|Drug|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
79674597|NCT01248429|Biological|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
79221973|NCT02164071|Other|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
79221974|NCT03345056|Procedure|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
79221975|NCT05502718|Other|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
79221976|NCT05502718|Other|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
79364853|NCT05521737|Procedure|Electroacupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
79364854|NCT05521737|Procedure|Sham Acupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
79516675|NCT01797822|Drug|Dexamethasone|
79674598|NCT01248429|Other|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
79821329|NCT04078074|Device|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
79221977|NCT02164149|Other|Patients with primary colon cancer|CT scan two days after surgery
79221978|NCT04790916|Drug|RO7049665|RO7049665, subcutaneous injection, Q2W.
79221979|NCT04790916|Other|Placebo|RO7049665-matching placebo, subcutaneous injection, Q2W.
79221980|NCT02516852|Other|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
79516676|NCT01797822|Drug|Artificial tear|
79516677|NCT01809054|Drug|Arixtra|
79516678|NCT01809054|Device|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
79516679|NCT01809054|Drug|Aspirin|
79516680|NCT01827306|Drug|Biofreeze|
79364855|NCT05519150|Diagnostic Test|low dose radiation abdomen/pelvis CT scan (stone protocol)|Kidney donors who consent will undergo a low dose radiation abdominal CT scan to identify new kidney stones in the remaining kidney. The will come to an IU Health Hospital for a low dose radiation abdomen/pelvis CT scan (stone protocol).
79364856|NCT05519150|Procedure|Blood draw|To compare the changes changes in eGFR in evaluated kidney donors Blood will be draw by a trained phlebotomist.
79674599|NCT01316614|Device|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
79674600|NCT00479648|Biological|CSL412|
79674601|NCT00479648|Biological|Inactivated trivalent influenza vaccine|
79516681|NCT01833546|Drug|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
79516682|NCT01833546|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
79516683|NCT01837524|Behavioral|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
79516684|NCT01837524|Behavioral|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
79516685|NCT01838226|Behavioral|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
79364857|NCT05519150|Other|24 hour urine collection|To compare the changes in metabolic kidney stone risk parameters in 24-hour urine assessments to pre-donation urine studies in evaluated kidney donors.
79516686|NCT01838304|Device|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
79221981|NCT05510830|Procedure|diagnostic cervical conization|For the patients who met the inclusion criteria, the gynecologists perform cervical conization and pathological examinations. Then the patients will be followed-up for at least two years with the tests of cervical TCT & HPV, and colposcopy if necessary. The data will be analyzed and see if the patients with high risk factors benefit from the surgery or not.
79674602|NCT01316575|Device|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
79221982|NCT02516618|Drug|Fasinumab|
79221983|NCT02516618|Drug|Placebo|
79364858|NCT05517200|Diagnostic Test|Machine Learning Test for Migraine|Resting EEG, and Visual and Auditory Stimulation
79364859|NCT05515939|Device|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
79364860|NCT05515029|Combination Product|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
79364861|NCT05514483|Drug|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
79364862|NCT05514483|Drug|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
79364863|NCT05508087|Diagnostic Test|electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan|We use electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after high dose chemotherapy and hematopoietic cell transplantation in patients with haemoblasts.
79364864|NCT05500235|Behavioral|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
79674603|NCT01316575|Device|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
79221984|NCT05507554|Drug|Opioid|"Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
79221985|NCT05507554|Drug|Non-Opioid Analgesic|"Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later."
79371154|NCT03029026|Procedure|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
79674604|NCT02955771|Combination Product|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
79821330|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
79516687|NCT01838304|Device|Monitoring|Manual recording of drug doses determined by CRNA
79221986|NCT05507554|Drug|Non-Opioid|"Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
79516688|NCT01839318|Device|Nelfilcon A contact lenses|
79516689|NCT01839318|Device|Omafilcon A contact lenses|
79516690|NCT01839318|Device|Etafilcon A contact lenses|
79221987|NCT02512328|Device|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
79221988|NCT05502640|Other|Education model|Chicken legs will be used for each student in the study. Intermittent and continuous suture techniques will be studied on the incision made on the chicken leg.
79516691|NCT01839708|Behavioral|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
79821331|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
79221989|NCT05502640|Other|Routine Education model|In the study, 15 cm x 20 cm sponge will be used for each student. Intermittent and continuous suture techniques will be practiced on the sponge.
79221990|NCT02516384|Biological|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (>18 year old) patients with active ulcerative colitis (UC).
79221991|NCT04110366|Biological|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
79221992|NCT04110366|Other|Vehicle control|Vehicle control nasal challenge
79221993|NCT05507320|Behavioral|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
79221994|NCT02512016|Other|Study Procedures|"Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~Measures of strength and body habitus:~8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
79221995|NCT00995202|Procedure|Standard Monitoring CEA|No specific follow-up of CEA
79221996|NCT00995202|Procedure|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
79221997|NCT00995202|Procedure|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
79364865|NCT05500235|Behavioral|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
79516692|NCT01840722|Other|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
79516693|NCT01842594|Drug|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
79516694|NCT01842906|Device|Theravent|nasal EPAP device
79516695|NCT01842906|Device|Control|Sham device without EPAP
79516696|NCT01843920|Drug|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
79516697|NCT01843920|Drug|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
79516698|NCT01844388|Drug|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
79516699|NCT01844388|Drug|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
79821332|NCT00785213|Drug|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
79821333|NCT00577317|Procedure|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
79821334|NCT00577317|Procedure|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
79821335|NCT00577317|Other|Quality-of-Life Assessment|Ancillary studies
79821336|NCT02583594|Drug|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
79516700|NCT01845636|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
79516701|NCT01845636|Drug|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
79516702|NCT01845792|Drug|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
79516703|NCT01845792|Drug|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
79516704|NCT01846728|Drug|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
79516705|NCT01847196|Device|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
79516706|NCT01847430|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
79516707|NCT01848054|Drug|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
79516708|NCT01848054|Drug|Buprenorphine|Buprenorphine sublingual tablets
79516709|NCT01848366|Device|Biowave Treatment|Twelve weekly treatments
79516710|NCT01849068|Drug|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
79516711|NCT01849068|Drug|Placebo|Placebo for 12 weeks
79821337|NCT02583594|Drug|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
79821338|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
79821339|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
79821340|NCT02583594|Drug|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
79821341|NCT02583594|Drug|Loratadine|Pharmaceutical form:tablet Route of administration: oral
79221998|NCT00995202|Procedure|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
79221999|NCT02516462|Device|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
79222000|NCT02516462|Drug|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
79821342|NCT02583594|Drug|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
79821343|NCT02583594|Drug|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
79222001|NCT02516072|Other|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
79222002|NCT04650204|Drug|Anticonvulsant Agent|Given ASD
79364866|NCT05499052|Drug|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
79371155|NCT03029026|Other|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
79516712|NCT01849692|Drug|ESBA1008 solution|Intravitreal injection or infusion
79516713|NCT01849692|Drug|Ranibizumab|Intravitreal injection
79516714|NCT01849770|Drug|Mexiletine|
79516715|NCT01849770|Drug|Placebo|
79516716|NCT01850394|Drug|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
79516717|NCT01850394|Drug|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
79516718|NCT01850550|Behavioral|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
79222003|NCT04650204|Drug|Perampanel|Given PO
79222004|NCT04650204|Other|Quality-of-Life Assessment|Ancillary studies
79222005|NCT04650204|Other|Questionnaire Administration|Ancillary studies
79222006|NCT04501250|Drug|Rinsulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
79222007|NCT04501250|Drug|Humulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
79222008|NCT02761629|Drug|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
79222009|NCT02761629|Drug|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing less than (<) 75 kilograms (kg) or as 1200 mg (3*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing greater than or equal to (>/=) 75 kg.
79516719|NCT01851876|Device|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
79516720|NCT01852032|Radiation|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
79516721|NCT01852032|Radiation|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
79516722|NCT01852344|Drug|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
79516723|NCT01852344|Drug|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
79516724|NCT01852344|Behavioral|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
79995263|NCT03207763|Device|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
79222010|NCT03345992|Drug|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
79222011|NCT03345992|Drug|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
79222012|NCT03488940|Device|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
79302497|NCT03203863|Diagnostic Test|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
79302498|NCT03320681|Device|Electrical Stimulation|Percutaneous electrical nerve stimulation
79302499|NCT03320681|Other|Dry Needling Stimulation|Percutaneous nerve stimulation
79364867|NCT05497973|Behavioral|E-health ecosystem of stepped psychosocial care|"Screening and monitoring: weekly administration of an emotional state thermometer. If the score is >5, participants are asked to complete the HADS. If HADS' score >10, step 2 is assigned. The same procedure is followed for steps 3 & 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q&As.~Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
79364868|NCT05497973|Behavioral|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
79364869|NCT05492695|Drug|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
79364870|NCT05492695|Other|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
79364871|NCT05484557|Drug|Apixaban|treatment for 6 to 12 weeks
79364872|NCT05484557|Drug|Enoxaparin Sodium|treatment for 6 to 12 weeks
79516725|NCT01852344|Behavioral|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
79516726|NCT01854138|Device|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
79516727|NCT01856712|Drug|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
79222013|NCT03488940|Device|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
79364873|NCT05482854|Other|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
79302500|NCT03203785|Dietary Supplement|Carbohydrate (maltodextrin)|maltodextrin flavored
79364874|NCT05482347|Other|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
79995264|NCT03207763|Device|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
79364875|NCT05477823|Radiation|External beam radiation therapy|Standard of care EBRT
79364876|NCT05477823|Radiation|Prostate brachytherapy boost|Standard of care BTX
79364877|NCT05477823|Drug|Androgen deprivation therapy|Standard of care ADT
79674605|NCT02955771|Combination Product|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
79674606|NCT02955771|Device|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
79674607|NCT00473408|Device|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
79995265|NCT02423772|Behavioral|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
79995266|NCT03220711|Device|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
79364878|NCT05477823|Diagnostic Test|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
79516728|NCT01857258|Dietary Supplement|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
79995267|NCT03220711|Drug|Fluorescein|Fluorescent dye used for imaging contrast only.
79995268|NCT04767165|Diagnostic Test|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
79995269|NCT02417688|Device|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
79364879|NCT05474794|Diagnostic Test|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
79364880|NCT05474794|Diagnostic Test|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
79516729|NCT01857882|Other|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~Social worker (30 mins): values clarification exercise~Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
79516730|NCT01858428|Device|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
79516731|NCT01858428|Device|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
79995270|NCT05136729|Behavioral|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
79364881|NCT05473962|Diagnostic Test|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
79364882|NCT05467072|Device|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
79516732|NCT01861002|Drug|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
79516733|NCT01861002|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
79516734|NCT01861002|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
79516735|NCT01861002|Drug|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~- 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~- 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
79516736|NCT01861002|Drug|Intrathecal Methotrexate (IT MTX)|"Intrathecally to patients with ALL on day 1 of course 1 and 2.~Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~- 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~- 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~- 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
79516737|NCT01861704|Device|Lyric|Extended wear hearing instrument
79222014|NCT03488940|Device|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
79222015|NCT02511860|Dietary Supplement|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
79222016|NCT02511860|Dietary Supplement|Placebo|Methylcellulose (inert) tablet taken as placebo
79364883|NCT05464784|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound
79364884|NCT05464784|Drug|MN-001 placebo|The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
79364885|NCT05464030|Drug|M9140|M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined.
79364886|NCT05459389|Other|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
79516738|NCT01861704|Device|Lyric2|Extended wear hearing instrument
79364887|NCT05458843|Procedure|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
79364888|NCT05458843|Procedure|No fluid replacement|Participants will not be permitted to drink.
79516739|NCT01863030|Device|Phasix mesh implant|
79516740|NCT01863498|Other|Epidural|Patients will have an epidural for pain control
79516741|NCT01863498|Other|PCA|Patients will have PCA for pain control
79516742|NCT01864434|Device|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
79516743|NCT01864434|Device|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
79516744|NCT01866306|Biological|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
79516745|NCT01866306|Drug|LABA|Asthmatic participants were treated with LABA as part of their standard of care
79516746|NCT01867164|Drug|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
79516747|NCT01867164|Drug|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
79222017|NCT02162121|Procedure|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
79222018|NCT02162121|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
79302501|NCT03203785|Other|Placebo|non-caloric drink
79302502|NCT02485457|Procedure|Volume loading|Volume loading with Ringer Lactate
79516748|NCT01867632|Device|Acellular Dermal Matrix|
79222019|NCT02162121|Procedure|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
79995271|NCT04766034|Behavioral|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
79995272|NCT03237013|Behavioral|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
79995273|NCT03237013|Behavioral|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
79995274|NCT02415036|Device|Delcath Hepatic Delivery System|
79364889|NCT05455281|Device|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
79222020|NCT02162121|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times a day
79222021|NCT02162121|Procedure|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS>4
79222022|NCT02162121|Drug|Mepivacaine 1%|
79222023|NCT02162121|Drug|Levobupivacaine 0,5%|
79222024|NCT02162121|Drug|Ropivacaine 0,2%|
79222025|NCT02162121|Drug|Ketorolac 30mg|
79222026|NCT02162121|Drug|Buprenorphine 0,2mg|
79222027|NCT02162121|Device|Stimulong, Pajunk, Germany.|
79222028|NCT02162121|Procedure|Continuous lumbar plexus: non-stimulating catheter|
79222029|NCT02511938|Other|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
79222030|NCT02511938|Other|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
79222031|NCT02164227|Other|Respiratory pattern|
79222032|NCT02511548|Other|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
79674608|NCT00473408|Procedure|Blood sample|See protocol.
79995275|NCT02415036|Drug|Melphalan|
79222033|NCT02164305|Other|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
79222034|NCT02164305|Other|Neuromuscular group|Closed-chain exercise for shoulder muscles
79364890|NCT05453292|Procedure|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
79222035|NCT02164305|Other|Control|No exercise training
79222036|NCT03345758|Other|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
79364891|NCT05453097|Diagnostic Test|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
79674609|NCT00473408|Procedure|Tumor sample|See protocol.
79674610|NCT02891161|Drug|durvalumab|1500 mg Q4 weekly
79674611|NCT02891161|Radiation|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
79674612|NCT00478985|Behavioral|Imatinib ending|Interruption of the treatment by Imatinib
79674613|NCT02955732|Device|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
79995276|NCT04752267|Procedure|Computed Tomography|Undergo PET/CT
79995277|NCT04752267|Drug|18F-FMAU|Given IV
79995278|NCT04752267|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79995279|NCT04752267|Procedure|Positron Emission Tomography|Undergo PET/CT
79995280|NCT02117700|Dietary Supplement|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
79995281|NCT02117700|Dietary Supplement|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
79222037|NCT03730467|Behavioral|Phone call to the patient|Phone call to the patient
79222038|NCT02507492|Drug|RM-493|
79222039|NCT02162199|Drug|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
79222040|NCT02162199|Drug|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
79674614|NCT00473447|Behavioral|Modified Constraint-induced movement therapy|
79995282|NCT02117700|Other|Placebo twice/day|Placebo capsules twice/day for 16 weeks
79364892|NCT05452850|Diagnostic Test|Left and Right Ventricular Global Strain Imaging|Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
79222041|NCT02507414|Other|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
79222042|NCT02507414|Other|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
79222043|NCT02507414|Other|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
79222044|NCT03540693|Procedure|RYGB|RYGB-weight loss surgery
79222045|NCT03540693|Procedure|SG|SG- weight loss surgery
79222046|NCT03540693|Procedure|LAGB|LAGB- weight loss surgery
79516749|NCT01868334|Behavioral|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
79516750|NCT01868334|Behavioral|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
79674615|NCT01315678|Drug|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
79995283|NCT04864080|Behavioral|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
79222047|NCT02511470|Other|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
79222048|NCT02511470|Other|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
79222049|NCT02760927|Device|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
79222050|NCT04500782|Other|Observation at home.|An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, & Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
79222051|NCT02511704|Drug|Nicotine|Multiple dose nicotine
79222052|NCT02511704|Drug|Nicotine|Multiple dose nicotine
79222053|NCT02164461|Biological|ADXS11-001|
79222054|NCT02511392|Procedure|rTMS-1Hz|
79222055|NCT02511392|Procedure|rTMS-10 Hz|
79222056|NCT02511392|Procedure|Sham rTMS|
79302503|NCT02485457|Drug|Ringer solution|
79364893|NCT05452200|Behavioral|Solicitation for lung cancer screening|3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups
79364894|NCT05452200|Other|added exams to the usual lung cancer screening|"spirometry examination~Questionnaires~Blood samples and breath samples to find biomarkers"
79364895|NCT05448716|Diagnostic Test|Left Atrial Strain Imaging|Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
79516751|NCT01868334|Behavioral|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
79516752|NCT01868334|Behavioral|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
79995284|NCT04864080|Behavioral|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
79995285|NCT03236779|Other|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
79995286|NCT03096483|Device|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
79222057|NCT02162277|Device|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
79222058|NCT04500704|Drug|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79222059|NCT04500704|Drug|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
79222060|NCT02164617|Other|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
79222061|NCT02507180|Other|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: > 1 point"
79222062|NCT02166567|Procedure|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
79222063|NCT02166567|Procedure|Swim-up|Semen processing will be carried out with the conventional swim-up method.
79222064|NCT04500314|Device|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
79222065|NCT04500314|Other|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
79222066|NCT02166645|Other|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
79222067|NCT02166645|Other|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
79364896|NCT05448716|Diagnostic Test|Electrocardiography|Electrocardiography will be taken at baseline and the follow-up periods
79516753|NCT01870596|Drug|Cytarabine|Given IV
79516754|NCT01870596|Drug|CHK1 Inhibitor SCH 900776|Given IV
79516755|NCT01870596|Other|Laboratory Biomarker Analysis|Correlative studies
79516756|NCT01874262|Device|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
79516757|NCT01874262|Device|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
79516758|NCT01875510|Dietary Supplement|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
79516759|NCT01875510|Dietary Supplement|soybean-oil emulsion|soybean-oil emulsion
79222068|NCT02507258|Device|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
79222069|NCT02164773|Drug|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
79222070|NCT02164773|Drug|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
79222071|NCT03540459|Diagnostic Test|sleep polygraphy|sleep polygraphy (one night) in all included patients
79222072|NCT02507024|Other|Online questionnaire|
79302504|NCT03220009|Procedure|Conventional Surgery|Undergo surgery
79516760|NCT01875978|Dietary Supplement|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
79516761|NCT01876212|Biological|DC vaccine|
79516762|NCT01876212|Drug|Dasatinib|
79516763|NCT01876992|Drug|Metformin|
79364897|NCT05445375|Other|PAD education video|20-min online multi-media video
79364898|NCT05444712|Procedure|Chemotherapy + follow up|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
79516764|NCT01877148|Device|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
79516765|NCT01877148|Behavioral|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
79516766|NCT01877538|Other|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand [11C]donepezil
79516767|NCT01878006|Drug|Morphine|
79516768|NCT01878006|Drug|Placebo|
79516769|NCT01879176|Device|CytoSorb|
79222073|NCT02166723|Device|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
79364899|NCT05444712|Procedure|Chemotherapy + ASCT + follow up|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
79516770|NCT01879332|Drug|Placebo|Matching placebo tablets for oral administration
79516771|NCT01879332|Drug|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
79516772|NCT01879332|Drug|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
79516773|NCT05329272|Other|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display [HMD] in delivering the VR intervention), audio, and motor equipment.
79516774|NCT05328882|Other|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
79516775|NCT05327478|Procedure|NRP|Normothermic Regional Perfusion
79516776|NCT05327478|Procedure|DHOPE|Dual Hypothermic Oxygenated Perfusion
79516777|NCT05327478|Procedure|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
79516778|NCT05327088|Drug|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
79516779|NCT05327088|Drug|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
79364900|NCT05430828|Drug|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
79516780|NCT05310474|Device|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
79516781|NCT05290194|Radiation|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
79516782|NCT05290194|Drug|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
79516783|NCT05290194|Drug|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
79674616|NCT01315678|Drug|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~Nebulization time is approximately 20 minutes for each administration.~Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
79302505|NCT03220009|Biological|Ipilimumab|Given IV
79516784|NCT05279196|Other|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
79516785|NCT05029674|Device|Whoop|Wear WHOOP Strap, complete surveys
79516786|NCT04774068|Drug|Parsaclisib|Given PO
79674617|NCT02955693|Drug|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
79516787|NCT04774068|Drug|Romidepsin|Given IV
79516788|NCT04621344|Diagnostic Test|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
79516789|NCT04304742|Procedure|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
79674618|NCT00479726|Drug|duloxetine hydrochloride|
79674619|NCT04697121|Dietary Supplement|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
79674620|NCT04697121|Combination Product|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
79674621|NCT03270761|Other||
79674622|NCT01315249|Drug|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
79674623|NCT01315249|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
79674624|NCT01315249|Drug|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
79302506|NCT03220009|Other|Laboratory Biomarker Analysis|Correlative studies
79516790|NCT04260672|Behavioral|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
79364901|NCT05430191|Other|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
79516791|NCT04233138|Other|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
79516792|NCT04132206|Other|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
79516793|NCT04103034|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
79516794|NCT04103034|Drug|Desmopressin|Sterile solution for injection
79516795|NCT04103034|Drug|Placebo|Sterile saline for injection
79516796|NCT03916614|Behavioral|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,[30] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
79516797|NCT03916614|Behavioral|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
79995287|NCT05100277|Genetic|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
79222074|NCT02166723|Device|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
79222075|NCT02511158|Procedure|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
79222076|NCT02511314|Device|TENA Identifi|TENA Identifi
79364902|NCT05428631|Device|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
79516798|NCT03820596|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
79516799|NCT03820596|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
79674625|NCT01315249|Drug|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
79995288|NCT05100277|Other|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
79222077|NCT00101439|Drug|ezetimibe|
79222078|NCT00101439|Drug|Comparator: placebo|
79222079|NCT02507102|Device|Voyager|Non-invasive RFE therapy
79302507|NCT03220009|Biological|Nivolumab|Given IV
79516800|NCT03776760|Device|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
79516801|NCT03776760|Drug|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
79222080|NCT02166801|Behavioral|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand & Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
79516802|NCT03776760|Drug|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
79222081|NCT02166801|Behavioral|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
79222082|NCT03345680|Other|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
79516803|NCT03423888|Device|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
79222083|NCT02166879|Behavioral|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
79222084|NCT03344822|Diagnostic Test|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
79222085|NCT03344822|Diagnostic Test|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
79222086|NCT02166957|Procedure|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
79222087|NCT02506712|Device|SmartDrive assisting device|oxygen consumption
79222088|NCT02506712|Device|Standard manuel wheelchair|oxygen consumption
79364903|NCT05428488|Drug|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
79364904|NCT05428488|Drug|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
79364905|NCT05428488|Drug|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
79516804|NCT03394248|Device|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
79516805|NCT03393390|Diagnostic Test|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
79516806|NCT03393390|Other|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
79364906|NCT05428007|Drug|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
79516807|NCT03252834|Diagnostic Test|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
79516808|NCT03191526|Drug|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
79516809|NCT03191526|Drug|Placebo (saline)|Intravenous injection every 12 weeks.
79516810|NCT03158298|Other|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
79516811|NCT03021096|Other|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
79516812|NCT02885220|Other|Conventional Program|No scheduled intermediate weight loss goals provided to patient
79516813|NCT02885220|Other|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
79995289|NCT04763538|Other|Standard of care|Patients are treated according to the standard of care for each individual disease.
79516814|NCT02232282|Device|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
79516815|NCT02232282|Device|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
79516816|NCT01643460|Procedure|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size & amount of fluid aspirated from the cyst.
79516817|NCT00954876|Drug|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
79516818|NCT01879800|Behavioral|Acceptance and Commitment Therapy plus Illness Management|
79995290|NCT05417373|Other|calculated radscore|The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
79364907|NCT05428007|Drug|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
79995291|NCT04543812|Drug|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
79222089|NCT02162355|Drug|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
79222090|NCT02162355|Drug|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
79995292|NCT04543812|Drug|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
79222091|NCT02162355|Drug|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
79516819|NCT05748132|Procedure|combined conventional and pulsed RF|"the classic Hartle technique is used to reach the Gasserian ganglion~Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
79516820|NCT05747898|Procedure|cannula- based subcision|Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
79222092|NCT02162355|Drug|Placebo|1 or 2 matching placebo tablets once daily for 10 days
79222093|NCT03345602|Diagnostic Test|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
79516821|NCT05747898|Procedure|common- needle based subcision|Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
79674626|NCT03270800|Biological|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
79674627|NCT03270800|Biological|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
79674628|NCT04207411|Drug|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
79995293|NCT02932579|Other|Pharmacogenomic Testing|Saliva collection (5mL)
79222094|NCT02515838|Drug|Sevuparin|The Drug Product sevuparin solution for IV infusion
79222095|NCT02515838|Other|Placebo|Placebo for IV infusion
79222096|NCT04033068|Biological|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
79995294|NCT02932579|Drug|Ibuprofen|400 mg
79995295|NCT02932579|Drug|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
79995296|NCT02932579|Drug|acetominophen|650 mg
79995297|NCT02932579|Drug|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
79995298|NCT03701412|Radiation|MRI|MRI brain
79995299|NCT05417295|Procedure|Inflating air into the bronchial cuff before changing position|Inflating air into the bronchial cuff before or after changing position
79222097|NCT04033068|Biological|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
79302508|NCT03220009|Other|Patient Observation|Undergo active surveillance
79302509|NCT03220009|Radiation|Radiation Therapy|Undergo RT
79364908|NCT05428007|Drug|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
79516822|NCT05747820|Other|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
79995300|NCT05417295|Procedure|Inflating air into the bronchial cuff after changing position|Inflating air into the bronchial cuff after changing position
79995301|NCT03624894|Other|impression|common polyvinylsiloxane oral impression
79222098|NCT04033068|Biological|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
79222099|NCT04033068|Other|Two placebo injection|"In this arm of the study, 8 participants will receive:~V1= day 0; placebo treatment~V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
79222100|NCT02162589|Procedure|POEM|Per oral endoscopic myotomy
79222101|NCT02162745|Drug|Isotonic solution (NaCl 0.9%)|
79222102|NCT02162745|Drug|Hypertonic solution (NaCl 3%)|
79222103|NCT02506790|Drug|metformin|
79222104|NCT02506790|Drug|Melatonin|
79222105|NCT02506790|Drug|Toremifene|
79222106|NCT02162901|Behavioral|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
79364909|NCT05423119|Behavioral|conventional therapy|upper limb rehabilitation with and without technologies
79516823|NCT05747664|Drug|DWP16001|0.3mg
79516824|NCT05747508|Combination Product|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
79516825|NCT05747508|Combination Product|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
79516826|NCT05747508|Combination Product|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
79516827|NCT05747040|Diagnostic Test|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
79995302|NCT04748757|Drug|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
79995303|NCT04748757|Drug|Placebo|Normal saline 50 ml
79995304|NCT03207451|Drug|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
79516828|NCT05746728|Drug|Surufatinib|"Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase"
79516829|NCT05746728|Drug|Tislelizumab|200mg, d1, iv, Q3W
79516830|NCT05743686|Device|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
79516831|NCT05714670|Drug|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
79516832|NCT05670132|Other|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
79995305|NCT03207451|Drug|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
79995306|NCT03207451|Drug|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
79995307|NCT03207451|Drug|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
79995308|NCT03704142|Device|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
79995309|NCT03704142|Device|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
79995310|NCT03704142|Device|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
79995311|NCT03704142|Device|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
79995312|NCT05040451|Device|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
79995313|NCT05089123|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
79222107|NCT02162901|Behavioral|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
79222108|NCT02162901|Behavioral|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
79516833|NCT05670132|Other|Standard of care|No intervention during the neurocardiac rehabilitation program
79516834|NCT05606718|Drug|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
79516835|NCT05606718|Other|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
79516836|NCT05592522|Other|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
79674629|NCT04207411|Drug|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
79674630|NCT01248663|Procedure|antecolic reconstruction|see study arm description
79995314|NCT05089123|Biological|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
79364910|NCT05419934|Behavioral|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~History of the patient (collection of anamnesis)~Securing the patient, preparing for the desensitization phases~Desensitization phases, to be repeated for each traumatic event to be desensitized:~Evaluation of the target to be treated~Desensitization~Installation of positive beliefs~Body scanner (verification of body non-response)~Closure, verification that the patient is in a stable emotional state allowing him to leave the session~Reassessment phase, to be repeated for each traumatic event that has been desensitized:~Reassessment of the traumatic target, verification of complete desensitization."
79222109|NCT02162901|Behavioral|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
79222110|NCT02162901|Behavioral|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
79222111|NCT02511080|Device|Spot-On|use of active hot measures
79364911|NCT05419934|Behavioral|Routine Care|Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy
79674631|NCT01248663|Procedure|retrocolic reconstruction|see study arm description
79674632|NCT00473486|Drug|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
79674633|NCT00473486|Drug|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
79995315|NCT04540770|Drug|HuL001|Anti-ENO1 monoclonal antibody
79995316|NCT03671421|Procedure|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
79364912|NCT05415722|Drug|TERN-501|Investigational drug
79302510|NCT03316703|Procedure|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
79995317|NCT02361125|Drug|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
79364913|NCT05415722|Drug|TERN-101|Investigational drug
79364914|NCT05415722|Other|Placebo|Matching placebo
79364915|NCT05412407|Other|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
79674634|NCT05644483|Drug|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
79364916|NCT05409131|Device|Omnipod 5 System|Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
79674635|NCT05644483|Drug|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
79674636|NCT01315132|Device|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
79674637|NCT00479804|Device|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
79674638|NCT00479804|Device|spirometry|spirometry for testing the ventilatory function
79674639|NCT00479804|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
79674640|NCT00504036|Device|inflatable intra-gastric balloon|inflatable intra-gastric balloon
79995318|NCT02361125|Behavioral|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
79995319|NCT03350503|Device|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
79995320|NCT03350503|Procedure|Cataract surgery|Removal of cataractous lens and implantation of IOL
79995321|NCT03701256|Procedure|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
79516837|NCT05592522|Other|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
79516838|NCT05592522|Other|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
79516839|NCT05584566|Device|OSSIX Breeze|barrier membrane
79995322|NCT03701256|Drug|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
79516840|NCT05584566|Device|Jason membrane|barrier membrane
79516841|NCT05548374|Device|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
79674641|NCT01248702|Other|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
79674642|NCT00479843|Behavioral|Nutritional programme|
79674643|NCT01248819|Drug|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
79995323|NCT04780581|Drug|Dexamethasone|6 mg/24h - 10 days
79995324|NCT04780581|Drug|Methylprednisolone|250 mg/ 24h - 3 days
79995325|NCT01526135|Drug|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
79222112|NCT04649736|Other|Respiratory and psychological rehabilitation|"Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies."
79995326|NCT01526135|Drug|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
79995327|NCT03701178|Other|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
79995328|NCT05417139|Other|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
79222113|NCT03540615|Drug|BAY1830839|Dose escalation in healthy male subjects
79364917|NCT05406453|Other|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
79364918|NCT05405738|Procedure|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
79995329|NCT03703752|Diagnostic Test|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
79995330|NCT03288779|Device|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
79995331|NCT03206749|Drug|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
79222114|NCT03540615|Drug|Placebo|Matching placebo
79364919|NCT05405738|Other|normal group|control normal group
79364920|NCT05405738|Procedure|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
79995332|NCT03206749|Drug|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
79364921|NCT05400031|Biological|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
79364922|NCT05400031|Biological|Placebo|Placebo
79995333|NCT03206749|Drug|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
79516842|NCT05548374|Device|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
79674644|NCT01248819|Drug|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
79674645|NCT01313767|Drug|Botulinum toxin type A|Botulinum toxin type A
79222115|NCT04500002|Drug|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
79222116|NCT04500002|Drug|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
79222117|NCT05149716|Dietary Supplement|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
79222118|NCT05149716|Dietary Supplement|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
79222119|NCT03345524|Other|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
79222120|NCT03345524|Other|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
79222121|NCT02444130|Device|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
79222122|NCT02515682|Dietary Supplement|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
79222123|NCT02515682|Dietary Supplement|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
79222124|NCT02515682|Dietary Supplement|Placebo|Participants will be give placebo for 24 weeks.
79222125|NCT03492684|Procedure|total hip arthroplasty|total hip arthroplasty and EMG
79364923|NCT05398380|Other|Liver transplantation|Liver transplantation
79364924|NCT05394831|Drug|JIN-A02|PO, QD
79364925|NCT05393674|Drug|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
79516843|NCT05472948|Drug|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
79222126|NCT02510924|Device|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
79364926|NCT05393674|Drug|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
79222127|NCT02510846|Behavioral|Intensive educative management|5 hours a week
79364927|NCT05393284|Drug|OPL-0401 Dose 1|Pharmaceutical Form: Capsule; Route of Administration: Oral
79364928|NCT05393284|Drug|Placebo|Pharmaceutical Form: Capsule; Route of Administration: Oral
79364929|NCT05392803|Device|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
79516844|NCT05472948|Drug|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
79516845|NCT05472948|Drug|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
79516846|NCT05460624|Other|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
79222128|NCT02510768|Device|ELAPR002f|Intradermal implant
79222129|NCT02510768|Device|ELAPR002g|Intradermal implant
79222130|NCT02510768|Device|Saline|Intradermal implant
79222131|NCT02515604|Drug|Misoprostol|
79222132|NCT02510534|Drug|Menopur 150 international units|Menopur 150 international units given x 1 dose
79222133|NCT02510534|Drug|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
79222134|NCT03799146|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
79222135|NCT03799146|Other|Waiting List|Waiting List control group
79222136|NCT02510612|Drug|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
79364930|NCT05392803|Device|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
79364931|NCT05381961|Device|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
79364932|NCT05380427|Drug|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
79364933|NCT05379790|Drug|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
79516847|NCT05460624|Other|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
79516848|NCT05448534|Diagnostic Test|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
79516849|NCT05294796|Combination Product|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
79516850|NCT05294796|Combination Product|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
79995334|NCT04635969|Behavioral|Sexual Health and Development Education for Children With Intellectual Disability|Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
79222137|NCT02510612|Drug|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
79222138|NCT03749616|Drug|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
79222139|NCT03749616|Drug|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
79222140|NCT03491514|Other|Test Granola|51 g Test Granola
79364934|NCT05379790|Drug|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
79364935|NCT05379023|Behavioral|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
79364936|NCT05379023|Behavioral|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
79516851|NCT05215470|Drug|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
79516852|NCT05215470|Drug|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
79516853|NCT05166720|Behavioral|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
79995335|NCT04754646|Device|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
79222141|NCT03491514|Other|Control Granola|54.1 Control Granola
79222142|NCT04499222|Device|Portex|nasotracheal intubation with PORTEX POLAR [Smiths Medical International, Hythe, United Kingdom] nasotracheal tube.
79222143|NCT04499222|Device|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard [Covidien, Ireland] nasotracheal tube.
79222144|NCT04532502|Drug|Anesthetics, Inhalation|Work environmental exposure
79364937|NCT05374538|Drug|VIC-1911|VIC-1911 tablets for oral administration
79364938|NCT05374538|Drug|sotorasib|Sotorasib tablets for oral administration
79364939|NCT05373264|Drug|Hydrochlorothiazide 25 mg|An oral capsule containing 25mg of hydrochlorothiazide
79364940|NCT05373264|Drug|Placebo|A matching oral capsule containing placebo
79364941|NCT05370521|Drug|Tildacerfont|Oral tablet formulation taken once daily.
79364942|NCT05370521|Drug|Placebo|Non-active dosage form taken once daily.
79364943|NCT05370040|Biological|AAHI-SC2 Vaccine|AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
79364944|NCT05370040|Biological|AAHI-SC3 Vaccine|AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
79364945|NCT05370040|Biological|EUA or approved vaccine|Janssen or Pfizer vaccines (control arm)
79364946|NCT05369962|Device|Ultrasound|Ultrasound measurements of the Qcsa
79516854|NCT05151588|Drug|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
79516855|NCT05151588|Drug|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
79516856|NCT05151588|Drug|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
79516857|NCT05151588|Drug|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
79516858|NCT05151588|Procedure|Surgery|Radical surgery
79516859|NCT05151588|Other|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
79524777|NCT05768659|Behavioral|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
79516860|NCT05117892|Other|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
79516861|NCT05034354|Device|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
79516862|NCT04929834|Other|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
79516863|NCT05260788|Procedure|Cystoscopy|Standard of care cystoscopy procedure
79516864|NCT04921332|Device|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
79516865|NCT04894734|Device|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
79364947|NCT05368649|Other|Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
79364948|NCT05368376|Drug|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
79516866|NCT04894734|Device|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
79516867|NCT04576182|Behavioral|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
79516868|NCT04576182|Behavioral|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
79516869|NCT04470804|Drug|Sirolimus|Sirolimus treats in experimental group
79516870|NCT04470804|Drug|Cyclosporine A|Cyclosporine A uses for active comparator group.
79222145|NCT02506478|Other|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
79222146|NCT02506166|Device|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
79222147|NCT03491436|Device|iHealth Align|remote monitor glucometer
79516871|NCT04418466|Combination Product|Risperidone|Risperidone Implant
79222148|NCT02762565|Device|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
79222149|NCT03488550|Biological|ANX007|Single ascending dose
79222150|NCT02506322|Behavioral|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~behavior changes, (social, problem solving) skill training, communication skills, crisis management"
79364949|NCT05368376|Drug|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
79364950|NCT05366751|Drug|SAGE-324|SAGE-324 oral tablets
79364951|NCT05364463|Procedure|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
79364952|NCT05360680|Drug|CUE-102|CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
79364953|NCT05358171|Other|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
79516873|NCT04360044|Drug|THC ~5%|4 puffs of vaporized flower containing THC ~5%
79516874|NCT04360044|Drug|CBD ~12%|4 puffs of vaporized flower containing CBD ~12%
79674646|NCT01313767|Drug|Botulinum Toxin type A|Botulinum Toxin type A
79516875|NCT04360044|Drug|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC ~5% and CBD ~12%
79516876|NCT04360044|Drug|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
79222151|NCT02506322|Behavioral|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
79222152|NCT03488394|Genetic|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10^6 CD34+ cells/Kg, with a minimum dose of 4x10^6 CD34+ cells/Kg and a maximum dose of 35x10^6 CD34+ cells/Kg.~The product will be injected intravenously."
79222153|NCT02515526|Drug|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
79222154|NCT02515526|Drug|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
79364954|NCT05358171|Other|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
79364955|NCT05357144|Behavioral|Loyalty card program at drug shops & supply of HIVST and SRH products|"Consenting drug shops will receive:~training on Malkia Klabu implementation;~HIVST training (same as comparison drug shops);~procedures for referring to youth-friendly HIV/SRH services;~a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~reimbursement for SRH products given to AGYW (e.g., birth control pills)."
79364956|NCT05357144|Behavioral|Comparison drug shops|Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
79364957|NCT05356962|Behavioral|StOP?-protocol|The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
79364958|NCT05348317|Behavioral|VetReach|Telehealth-delivered MI-CBT substance use disorder care model
79674647|NCT00479921|Biological|Trivalent influenza subunit vaccine|
79674648|NCT01248858|Drug|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
79674649|NCT00481286|Behavioral|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
79222155|NCT03492450|Other|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
79222156|NCT04497662|Drug|KPL-404|humanized IgG4 monoclonal antibody
79222157|NCT04497662|Other|Matching Placebo|Placebo
79222158|NCT05135130|Drug|ON101 Cream|Not applicable in this retrospective study
79516877|NCT04337814|Drug|EMLA Cream|Topical anaesthetic cream
79516878|NCT04337814|Drug|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
79516879|NCT04337814|Drug|Placebo syrup|Placebo syrup similar to Ibuprofen
79516880|NCT04337814|Drug|Placebo cream|Placebo cream similar to EMLA
79516881|NCT04336332|Combination Product|Hydroxychloroquine Sulfate + Azithromycin|Given PO
79516882|NCT04336332|Drug|Hydroxychloroquine Sulfate|Given PO
79516883|NCT03953508|Other|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
79516884|NCT03931356|Other|Pulmonary function tests|analysis of lung volume and diffusion capacity
79516885|NCT03882840|Biological|NK cell therapy|Infusion of itNK cells
79516886|NCT03671148|Biological|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
79516887|NCT03671148|Biological|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
79674650|NCT00481286|Behavioral|Standard of Care|Standard of care for diabetes patients
79674651|NCT01313728|Drug|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
79674652|NCT01313728|Drug|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
79674653|NCT01248897|Other|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
79674654|NCT00481364|Drug|atorvastatin|atorvastatin 40 mg/day
79516888|NCT03465852|Behavioral|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
79516889|NCT03295344|Other|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
79516890|NCT03295344|Other|Tissue Doppler|Determine the threshold value for diaphragm mobility
79674655|NCT00481364|Drug|placebo|1 tb/day
79222159|NCT02505932|Procedure|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
79995336|NCT04754646|Device|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
79995337|NCT03705923|Procedure|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
79995338|NCT03255941|Drug|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
79995339|NCT03255941|Drug|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
79995340|NCT03703674|Drug|GCSF|Granulocyte-colony stimulating factors (G-CSF)
79995341|NCT03705390|Drug|ILB|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
79222160|NCT02505932|Procedure|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
79222161|NCT04460976|Behavioral|Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Psychoeducation in groups
79222162|NCT04460976|Behavioral|Treatment as usual/standard care|Standard care at disability/habilitation services.
79222163|NCT02167191|Behavioral|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
79222164|NCT02515448|Drug|gentamicin|
79222165|NCT02506088|Behavioral|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
79222166|NCT02170857|Drug|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
79222167|NCT04460820|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
79364959|NCT05343130|Device|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
79364960|NCT05343130|Device|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
79364961|NCT05342402|Other|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
79364962|NCT05342402|Other|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
79364963|NCT05337228|Drug|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
79516891|NCT03198546|Biological|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
79674656|NCT00479960|Behavioral|commercially available omega-3 fatty acids supplementation|
79674657|NCT01249014|Other|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
79364964|NCT05337228|Drug|RPN301|RPN301 will be injected continuously for 3 days.
79364965|NCT05329506|Other|patient population|questionnaires, standard of care
79364966|NCT05328076|Drug|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
79516892|NCT03064542|Drug|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
79674658|NCT01249014|Other|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
79674659|NCT01249014|Device|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
79674660|NCT01249014|Device|Bair hugger warming blanket|Bair hugger warming blanket laid on body
79995342|NCT04805424|Procedure|Lipo-abdominoplasty|Abdominoplasty plus liposuction
79995343|NCT04805424|Procedure|Abdominoplasty|Abdominoplasty
79995344|NCT03705312|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
79995345|NCT03705312|Other|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
79995346|NCT03701100|Device|tDCS|tDCS
79995347|NCT03701022|Drug|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
79995348|NCT04221165|Drug|Opioids|Opioids will be prescribed as per institutional standards.
79995349|NCT04221165|Drug|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
79516893|NCT01430442|Drug|Rimegepant|Rimegepant capsules
79516894|NCT01430442|Drug|Placebo|Rimegepant placebo-matching capsules
79516895|NCT01430442|Drug|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
79516896|NCT01420926|Drug|Bortezomib|Given SC
79516897|NCT01420926|Drug|Decitabine|Given IV
79364967|NCT05328076|Device|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
79222168|NCT02510378|Radiation|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
79674661|NCT01240460|Drug|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
79222169|NCT02170935|Drug|BIBR 1048 capsule|
79222170|NCT03345368|Device|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
79222171|NCT03345368|Device|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
79222172|NCT03345368|Other|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
79364968|NCT05327270|Drug|Nivolumab|Given by IT
79364969|NCT05317806|Drug|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
79364970|NCT05317299|Other|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
79222173|NCT03488316|Procedure|Carie removal|Carie removal with a low speed handpiece
79222174|NCT03488316|Procedure|Absolute isolation|Absolute isolation with rubber dam
79222175|NCT03488316|Drug|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
79364971|NCT05316142|Procedure|AGV implantation|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
79222176|NCT03488316|Drug|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
79222177|NCT03488316|Procedure|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
79364972|NCT05309928|Drug|Amoxicillin|medication administration
79364973|NCT05309421|Drug|EVX-01|Investigational drug given in combination with standard of care
79364974|NCT05309421|Drug|Pembrolizumab 25 MG/ML|Standard of care
79364975|NCT05306925|Dietary Supplement|Arginine|The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
79364976|NCT05301036|Device|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
79364977|NCT05300568|Other|No Intervention|This is a non-product related survey.
79364978|NCT05299099|Drug|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
79516898|NCT01420926|Other|Laboratory Biomarker Analysis|Correlative studies
79516899|NCT01420926|Other|Pharmacological Study|Correlative studies
79364979|NCT05299099|Drug|RCN301|RCN301 will be injected continuously for 3 days.
79364980|NCT05295056|Device|AFGen1 Device Wear Test|Participant wears the device for 7 days
79516900|NCT01420926|Other|Quality-of-Life Assessment|Ancillary studies
79516901|NCT01420926|Other|Questionnaire Administration|Ancillary studies
79516902|NCT00941538|Diagnostic Test|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
79516903|NCT00626964|Procedure|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
79674662|NCT01240460|Drug|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
79516904|NCT00626964|Behavioral|Conservative Treatment:|Intensive Lifestyle Intervention Program
79516905|NCT01881828|Drug|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
79516906|NCT01881828|Other|oral placebo|
79516907|NCT01882062|Drug|Triheptanoin 1g/kg/day|
79516908|NCT01882764|Drug|HMPL-004|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
79524778|NCT05768646|Behavioral|Neuropsychological instruments|Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features
79674663|NCT01249170|Behavioral|First year program|Information on group that underwent new educational program
79674664|NCT01249170|Other|Control comparison|Information from group that did not undergo new first year program
79674665|NCT00479999|Drug|VRC-HIVADV027-00-VP|
79674666|NCT00479999|Drug|VRC-HIVADV038-00-VP|
79516909|NCT01882764|Drug|Placebo|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
79222178|NCT03488316|Procedure|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
79674667|NCT01249209|Device|lifestyle advice|
79222179|NCT03488316|Procedure|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
79364981|NCT05295056|Device|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
79364982|NCT05293392|Behavioral|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
79364983|NCT05293392|Behavioral|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
79364984|NCT05291611|Behavioral|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
79516910|NCT01883856|Device|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
79516911|NCT01883856|Device|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
79516912|NCT01887132|Drug|Donepezil|
79516913|NCT01887132|Drug|Placebo|
79516914|NCT01887990|Drug|Ketamine|single dose IV 0.2 mg/kg ketamine
79516915|NCT01887990|Drug|placebo|saline infusion
79516916|NCT01890642|Device|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
79516917|NCT01890642|Other|Pain Ease Spray|Cold Spray used to anesthetize the skin
79516918|NCT01890642|Drug|1% buffered lidocaine|Lidocaine placed using Jet Injection
79516919|NCT01890642|Other|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
79516920|NCT01890642|Other|Sucrose|Oral Sucrose used for children < 1 year
79222180|NCT03488316|Procedure|Definitve restoration|Definitve restoration confecction.
79516921|NCT01891734|Other|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
79516922|NCT01891734|Other|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
79516923|NCT01891968|Drug|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
79516924|NCT01893372|Drug|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
79516925|NCT01893372|Drug|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
79516926|NCT01895088|Device|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
79674668|NCT00481442|Drug|Phenylephrine|
79674669|NCT01249248|Device|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
79674670|NCT00480038|Other|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
79674671|NCT04697537|Drug|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
79222181|NCT03540537|Other|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
79516927|NCT01895634|Device|Rev-01|Treatment arm patients have used Rev-01 at least once
79516928|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
79516929|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
79516930|NCT01898754|Other|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
79516931|NCT01899300|Device|Metal Stent (WallFlex™ Esophageal RX)|
79516932|NCT01900392|Behavioral|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
79516933|NCT01900704|Drug|SER120 750 ng|SER120 750 ng
79516934|NCT01900704|Drug|SER120 1500 ng|SER120 1500 ng
79516935|NCT01900704|Drug|Placebo|Placebo
79516936|NCT01901250|Dietary Supplement|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
79516937|NCT01901250|Dietary Supplement|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
79516938|NCT01901250|Behavioral|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
79674672|NCT04697537|Drug|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
79516939|NCT01901250|Device|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
79516940|NCT01901250|Device|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
79516941|NCT01904448|Device|Auditory Brainstem Implantation in Children|
79516942|NCT01904526|Drug|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
79516943|NCT01906866|Drug|Circadin 2/5/10 mg|Active arm
79516944|NCT01906866|Drug|Placebo|
79516945|NCT01907334|Drug|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
79516946|NCT01907334|Drug|Flovent Diskus 100 µg|Flovent Diskus 100 µg
79516947|NCT01907334|Drug|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
79516948|NCT01907334|Drug|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
79516949|NCT01907490|Drug|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
79821344|NCT05571761|Behavioral|Cognitive stimulation program|"The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality."
79222182|NCT03540537|Other|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
79364985|NCT05290727|Other|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
79516950|NCT01908972|Drug|Prednisolone|2mg/kg/day for 16weeks
79516951|NCT01908972|Drug|Propranolol|2mg/kg/day for 16weeks
79516952|NCT01910064|Drug|GK530G|
79364986|NCT05290727|Other|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
79364987|NCT05290402|Other|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
79364988|NCT05285202|Other|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative for eligible for TPT (interested after counseling and either positive tuberculin skin test or known HIV infection).
79364989|NCT05283252|Device|3-D printed Guide|Guided Endodontic micro-surgery
79364990|NCT05283252|Other|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
79516953|NCT01910688|Device|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
79516954|NCT01911390|Dietary Supplement|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
79516955|NCT01911390|Dietary Supplement|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
79674673|NCT01249326|Other|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
79364991|NCT05282953|Drug|KIO-301|KIO-301 intravitreal injection at ascending doses
79516956|NCT01911390|Dietary Supplement|Control arm|No bean or rice bran additive in smoothie or muffin.
79516957|NCT01911390|Dietary Supplement|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
79516958|NCT01912716|Drug|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
79516959|NCT01912716|Drug|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
79516960|NCT01914510|Drug|ENMD-2076|
79516961|NCT01918800|Behavioral|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
79516962|NCT01918800|Behavioral|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
79516963|NCT01920282|Drug|Nebivolol|
79516964|NCT01920282|Other|Lifestyle Modification|
79516965|NCT01920282|Other|Nebivolol plus Lifestyle Modification|
79516966|NCT01921296|Drug|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
79674674|NCT01313650|Drug|62.5/25mcg|GSK573719/GW64244
79995350|NCT03255629|Drug|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
79364992|NCT05278663|Drug|E6742|E6742 tablet.
79516967|NCT01921452|Device|Quantitative POC TSH Kit|A drop (approximately 30 microliter [mcL]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
79516968|NCT01921452|Device|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
79516969|NCT01921452|Device|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
79995351|NCT03255629|Device|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
79995352|NCT03031938|Drug|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
79222183|NCT03540537|Other|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
79222184|NCT02510222|Dietary Supplement|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
79222185|NCT02510222|Other|Placebo|
79222186|NCT02444910|Drug|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
79222187|NCT04497818|Other|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale & Modified Dental Anxiety 5 item Likert Scale).
79516970|NCT01929642|Drug|Sirolimus|
79821345|NCT00740415|Biological|rituximab|Rituximab, 375 mg/m2 Intraveinous
79821346|NCT00740415|Drug|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
79516971|NCT01929642|Drug|Everolimus|
79821347|NCT00740415|Drug|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
79821348|NCT00740415|Drug|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
79821349|NCT02581722|Device|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
79821350|NCT00734162|Drug|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
79995353|NCT03587571|Procedure|Surgical intervention|Open reduction and plate osteosynthesis.
79995354|NCT01143779|Drug|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
79222188|NCT02167269|Device|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
79674675|NCT01313650|Drug|62.5mcg|GSK573719
79222189|NCT03491358|Device|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
79222190|NCT03491358|Device|Aerogen Solo|Aerogen Ltd., Galway, Ireland
79222191|NCT02167347|Behavioral|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
79222192|NCT02505776|Drug|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
79222193|NCT03540381|Other|neoatherosclerosis|
79222194|NCT03491124|Other|Auricular Acupuncture|Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
79222195|NCT03491124|Other|Sham Treatment|Laser pointer pointed at the ear, but not turned on.
79364993|NCT05278663|Other|Placebo|E6742-matching placebo tablet.
79364994|NCT05271604|Biological|Ozuriftamab Vedotin|Conditionally active biologic anti-ROR2 antibody drug conjugate
79364995|NCT05271604|Biological|PD-1 inhibitor|PD-1 inhibitor
79364996|NCT05270408|Device|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
79364997|NCT05270408|Device|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
79821351|NCT00734162|Drug|Placebo|TDF placebo tablet once daily
79821352|NCT00740493|Drug|warfarin|18 months of warfarin therapy
79995355|NCT03558737|Other|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
79995356|NCT03558737|Other|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
79364998|NCT05270408|Device|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
79674676|NCT01313650|Drug|25mcg|GW642444
79674677|NCT01313650|Drug|Placebo|Placebo
79674678|NCT02274909|Other|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
79516972|NCT01932060|Drug|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
79516973|NCT01932606|Drug|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
79516974|NCT01932606|Drug|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
79222196|NCT02505854|Dietary Supplement|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
79516975|NCT01933230|Device|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
79821353|NCT00740493|Drug|placebo of warfarin|18 months of placebo of warfarin therapy
79821354|NCT02582580|Other|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
79995357|NCT03703596|Drug|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
79222197|NCT02505854|Dietary Supplement|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
79222198|NCT02505854|Dietary Supplement|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
79222199|NCT02171013|Drug|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
79222200|NCT02171013|Drug|Dabigatran polymorph I|
79364999|NCT05266079|Drug|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
79365000|NCT05266079|Drug|Control Group|Er-Xian decoction
79516976|NCT01933464|Drug|Cromolyn Sodium|
79516977|NCT01933464|Drug|Normal Saline|
79365001|NCT05265351|Diagnostic Test|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
79516978|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
79222201|NCT03490890|Other|Microwave ablaton|Patients with pathology verified GGO were treated with MWA.
79222202|NCT02261181|Device|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
79516979|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
79516980|NCT01935180|Device|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
79516981|NCT01936662|Device|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
79674679|NCT04697615|Device|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
79995358|NCT03703596|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
79995359|NCT01137773|Drug|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
79365002|NCT05265351|Diagnostic Test|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
79365003|NCT05261646|Drug|Hetrombopag|"Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)"
79365004|NCT05261646|Drug|Matching placebo|Matching placebo（Stage 1；Stage 2）
79365005|NCT05257278|Device|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
79516982|NCT01936662|Device|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
79516983|NCT01936896|Drug|Alpha 1-Antitrypsin|
79516984|NCT01937520|Device|acupuncture|One half of subjects will receive a standardized acupuncture regiment
79222203|NCT02509832|Device|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
79222204|NCT02509832|Device|PCI only|Standard of Care for PCI
79516985|NCT01937520|Device|no acupuncture|placebo
79222205|NCT02165163|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
79222206|NCT04166214|Other|Imaging using intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
79222207|NCT02510066|Device|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
79365006|NCT05255302|Drug|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
79365007|NCT05255302|Drug|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
79365008|NCT05255302|Drug|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
79365009|NCT05255302|Drug|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
79365010|NCT05249387|Drug|A-967079 and BAM8-22 application|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
79365011|NCT05249387|Drug|A-967079 and BAM8-22 application after 5 minutes.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
79995360|NCT01137773|Drug|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
79995361|NCT03700944|Other|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
79222208|NCT02510066|Device|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
79365012|NCT05249387|Drug|A-967079 application.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
79516986|NCT01937598|Drug|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
79365013|NCT05249387|Drug|Vehicle and BAM8-22 application.|Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
79365014|NCT05249322|Other|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~An usual in-hospital consult of about 1h30 with paramedical and medical consult."
79365015|NCT05248269|Procedure|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
79516987|NCT01937598|Other|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
79516988|NCT01937598|Drug|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
79516989|NCT01937598|Drug|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
79516990|NCT01938066|Device|Procellera|bioelectric wound dressing
79516991|NCT01938066|Device|negative pressure therapy|
79516992|NCT01938378|Biological|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
79995362|NCT03632031|Device|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
79995363|NCT01568385|Drug|TAK-438|
79516993|NCT01939938|Device|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
79516994|NCT01942668|Drug|Estradiol|
79516995|NCT01942668|Drug|Progesterone|
79516996|NCT01942668|Drug|Placebo|
79516997|NCT01944930|Device|Laparoscopic narrow band imaging|
79516998|NCT01944930|Device|Standard white-light laparoscopy|
79516999|NCT01948518|Drug|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
79222209|NCT02757963|Other|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score >=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
79222210|NCT02757963|Other|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score >=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
79222211|NCT02509754|Procedure|Atrial fibrillation catheter ablation|
79222212|NCT02509754|Procedure|Rate control|Composite of optimal medical therapy and device implantation
79222213|NCT02167425|Other|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
79222214|NCT02509676|Other|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
79365016|NCT05243550|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
79674680|NCT00504114|Procedure|ACL Reconstruction Surgery|
79222215|NCT03111732|Biological|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
79222216|NCT03111732|Drug|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
79365017|NCT05243290|Dietary Supplement|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
79517000|NCT01948986|Drug|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
79517001|NCT01949844|Drug|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
79517002|NCT01949844|Drug|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
79517003|NCT01949844|Device|Myocardial perfusion MRI|
79517004|NCT01950780|Drug|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
79517005|NCT01951326|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
79517006|NCT01951326|Drug|Placebo|5 placebo capsules administered orally BID
79674681|NCT00504114|Procedure|Cartilage Resurfacing Surgery|
79674682|NCT00504114|Procedure|Total Knee Replacement|
79517007|NCT01951950|Drug|Nicardipine|
79517008|NCT01951950|Drug|Esmolol|
79517009|NCT01952418|Device|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
79517010|NCT01953432|Drug|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
79517011|NCT01953432|Drug|Placebo|Matched placebo daily dosing
79517012|NCT01955382|Drug|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
79674683|NCT00481481|Drug|tacrolimus|immunosuppression
79674684|NCT04516317|Other|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
79674685|NCT04516317|Other|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
79674686|NCT02891239|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
79674687|NCT02891083|Drug|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
79674688|NCT02891083|Radiation|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
79674689|NCT02891083|Other|Control group (Surgery alone)|
79674690|NCT02890966|Drug|SHR4640|Day1~Day7:oral administration
79517013|NCT01955382|Drug|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
79222217|NCT03111732|Drug|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
79517014|NCT01955382|Drug|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
79517015|NCT01957410|Drug|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
79517016|NCT01957410|Drug|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
79222218|NCT01663714|Biological|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
79222219|NCT02165319|Device|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
79222220|NCT02165319|Device|Tapered|Tapered-shaped tube will be used during general anesthesia.
79517017|NCT01958112|Drug|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
79517018|NCT01958112|Drug|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
79222221|NCT02505308|Other|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
79517019|NCT01958346|Other|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
79674691|NCT02890966|Drug|placebo|Day1~Day7:oral administration
79674692|NCT02890927|Other|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~Low risk patients are expected to do well and will not receive co-management.~Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
79222222|NCT02941146|Device|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
79222223|NCT02515136|Behavioral|Stimulus-response|See summary
79365018|NCT05243290|Dietary Supplement|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
79222224|NCT02514902|Device|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
79222225|NCT05510752|Behavioral|Cognitive Behavioural Group Therapy|CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.
79365019|NCT05240599|Procedure|Exercise Training|Exercise training will be applied in sets of 10x3, 3 times a day for 8 weeks.
79365020|NCT05239546|Drug|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
79365021|NCT05236517|Drug|Semaglutide D Dose 1|Tablet given orally
79365022|NCT05236517|Drug|Semaglutide D Dose 2|Tablet given orally
79365023|NCT05236517|Drug|Semaglutide D Dose 3|Tablet given orally
79365024|NCT05236517|Drug|Semaglutide C Dose 4|Tablet given orally
79365025|NCT05236517|Drug|Semaglutide C Dose 5 (50 mg)|Tablet given orally
79365026|NCT05236517|Drug|Placebo (Semaglutide C)|Tablet given orally
79365027|NCT05236517|Drug|Placebo ( Semaglutide D)|Tablet given orally
79517020|NCT01958346|Other|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
79517021|NCT01958346|Device|Fiberoptic Intubation|
79517022|NCT05739864|Biological|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
79517023|NCT05739864|Other|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
79517024|NCT05739786|Drug|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
79222226|NCT05510752|Behavioral|Psychoeducation|Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
79821355|NCT02582580|Device|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
79995364|NCT03700866|Procedure|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
79222227|NCT03490578|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
79517025|NCT05739786|Drug|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
79222228|NCT03490578|Device|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
79222229|NCT02255487|Device|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
79674693|NCT05644405|Diagnostic Test|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
79674694|NCT02891005|Device|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
79674695|NCT02891005|Device|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
79674696|NCT02891044|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-040)
79674697|NCT00481559|Drug|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
79674698|NCT00504816|Drug|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
79365028|NCT05236127|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
79674699|NCT00504816|Drug|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
79674700|NCT00623350|Other|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
79674701|NCT00623350|Other|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
79674702|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
79517026|NCT05739630|Drug|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
79517027|NCT05739630|Drug|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
79517028|NCT05739318|Device|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
79222230|NCT02255487|Other|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
79222231|NCT02505386|Drug|Ertapenem|
79995365|NCT04525092|Device|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
79995366|NCT04525092|Device|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
79222232|NCT03488160|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
79222233|NCT02509364|Other|No intervention|
79222234|NCT05507086|Other|Antimicrobial therapy|Antimicrobial therapy
79365029|NCT05236127|Other|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
79365030|NCT05230251|Drug|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
79365031|NCT05230251|Radiation|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
79365032|NCT05222685|Behavioral|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
79365033|NCT05213806|Other|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
79365034|NCT05213806|Other|Continued feeds around transfusion|Continued enteral feeds
79365035|NCT05213559|Other|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
79517029|NCT05739318|Device|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
79517030|NCT05739084|Radiation|pre-operative radiation|As per standard of care and institutional guidelines
79365036|NCT05213559|Other|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
79365037|NCT05210751|Other|Physical and psychosocial assessments|Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
79365038|NCT05200702|Device|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
79365039|NCT05199246|Device|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
79365040|NCT05193552|Drug|Hizentra|subjects level of IGRT will be adjusted for bioavailability as per manufacturer's instructions
79517031|NCT05739084|Procedure|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
79517032|NCT05738928|Diagnostic Test|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
79517033|NCT05738772|Diagnostic Test|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
79674703|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
79674704|NCT00480116|Biological|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
79674705|NCT00504855|Other|Casting using Gortex (waterproof) cast padding materials|
79674706|NCT00504855|Other|Casting using cotton/cotton-poly cast padding materials|
79674707|NCT00481598|Procedure|magnet resonance spectroscopy|magnet resonance spectroscopy
79674708|NCT00504933|Drug|bilastine|20 mg (encapsulated) tablets QD/14days
79674709|NCT00504933|Drug|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
79222235|NCT02514980|Drug|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
79222236|NCT02514980|Drug|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
79674710|NCT00504933|Drug|Placebo|(encapsulated) Tablets QD/14 days
79674711|NCT01313299|Biological|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
79674712|NCT01313299|Biological|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
79674713|NCT01313299|Drug|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
79517034|NCT05738616|Combination Product|Lenvatinib combined with TACE and Camrelizumab|After all subjects sign informed consent and pass screening, they are randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib alone), and randomization is stratified according to the number of tumors (single versus multiple) and portal vein tumor thrombus (Vp1 ~ 3 vs. Vp4). Eight sites in China will be included in this study with follow-up of 2 years.
79517035|NCT05738538|Drug|ziftomenib|
79517036|NCT05738460|Drug|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
79517037|NCT05738382|Drug|BG2109|oral administration once daily
79674714|NCT00480155|Biological|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
79674715|NCT00480155|Other|Placebo|
79674716|NCT00504972|Drug|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
79222237|NCT03344588|Procedure|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
79222238|NCT03344588|Procedure|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
79222239|NCT04412044|Drug|Mepolizumab Injection [Nucala]|Patients receive monthly injection with 100 mg mepolizumab
79222240|NCT02165475|Behavioral|Biofeedback|
79222241|NCT02165475|Drug|Loperamide|
79222242|NCT02165475|Drug|Stool bulking agent (stericulia or isphagula husk)|
79222243|NCT02165475|Other|Combination of biofeedback and medical treatment|
79222244|NCT03345212|Other|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
79222245|NCT04862338|Dietary Supplement|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
79222246|NCT02171325|Drug|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
79222247|NCT03344432|Diagnostic Test|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
79222248|NCT03344432|Diagnostic Test|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
79222249|NCT01663636|Behavioral|SMS message reminding mothers to come for their scheduled vaccines|Reminder
79222250|NCT02509286|Drug|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
79222251|NCT02509286|Drug|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
79222252|NCT02509286|Drug|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
79222253|NCT02509286|Drug|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
79222254|NCT02509286|Drug|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
79222255|NCT02509286|Drug|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
79222256|NCT02509286|Radiation|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
79365041|NCT05190081|Other|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
79365042|NCT05188703|Behavioral|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
79517038|NCT05738382|Drug|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
79517039|NCT05738226|Device|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
79517040|NCT05737680|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg daily
79517041|NCT05737680|Drug|Colchicine|Colchicine continued
79674717|NCT01313221|Biological|etanercept|Administered by subcutaneous injection
79517042|NCT05737290|Device|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
79517043|NCT05737290|Device|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
79674718|NCT01313221|Drug|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~hydrocortisone 2.5%~betamethasone valerate 0.1%~betamethasone dipropionate 0.05%~clobetasol 0.05%~calcitriol~calcipotriol plus betamethsone dipropionate 0.05%"
79674719|NCT01313182|Drug|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
79674720|NCT01313182|Drug|3M Skin and Nasal Antiseptic|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
79674721|NCT04516512|Biological|Blood draw|For each participants to the research a peripherical blood draw will be performed
79674722|NCT04512495|Other|Blood samples will be collected at two times :|"at Baseline,~after surgery or at the time of post-chemotherapy evaluation."
79517044|NCT05736510|Other|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
79517045|NCT05736510|Other|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
79517046|NCT05735964|Drug|Indocyanine green|Intravenous and endoluminal dosing
79517047|NCT05735574|Other|IPG infections|Infected IPGs
79517048|NCT05735418|Dietary Supplement|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10^8 CFU/day.
79517049|NCT05735418|Dietary Supplement|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
79222257|NCT02165553|Dietary Supplement|Hibiscus sabdariffa calyces extract as a cold drink|
79222258|NCT03065244|Drug|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
79365043|NCT05187819|Diagnostic Test|predictive value of a blood test|Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
79365044|NCT05187585|Diagnostic Test|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
79222259|NCT03065244|Drug|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
79365045|NCT05187585|Diagnostic Test|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
79517050|NCT05735028|Drug|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
79517051|NCT05735028|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
79517052|NCT05734950|Other|Translational study|Non-interventional, translational study
79517053|NCT05734872|Device|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
79517054|NCT05734872|Other|Routine mental health course training|Conduct mental health education for patients by making a speech.
79517055|NCT05734482|Biological|Secukinumab|for subcutaneous injection only
79517056|NCT05725200|Drug|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
79517057|NCT05725200|Drug|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517058|NCT05725200|Drug|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517059|NCT05725200|Drug|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79222260|NCT05502484|Behavioral|Integrative Dialectical Behavioural Therapy (DBT)|8 weeks outpatient pre-treatment DBT followed by integrative, inpatient DBT of 40 weeks, using standard DBT, augmented with an experience-oriented, body-oriented skills training based on DBT-principles by trained DBT-therapists, and a follow-up phase of 12 weeks outpatient aftercare (maximal 8 sessions individual DBT and 4 booster sessions) and 12 weeks no DBT. The inpatient treatment takes place in a living environment that is based on the principles of DBT and takes into account several aspects of autism.
79517060|NCT05725200|Drug|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
79517061|NCT05725200|Drug|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517062|NCT05725200|Drug|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
79517063|NCT05725200|Drug|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517064|NCT05725200|Drug|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79222261|NCT02171481|Drug|Dabigatran etexilate polymorph II|
79222262|NCT02171481|Drug|Dabigatran etexilate polymorph I|
79517065|NCT05725200|Drug|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79995367|NCT04525092|Device|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
79222263|NCT02171559|Drug|Enoxaparin prefilled syringes|
79517066|NCT05725200|Drug|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517067|NCT05725200|Drug|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517068|NCT05725200|Drug|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517069|NCT05725200|Drug|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517070|NCT05725200|Drug|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79222264|NCT02171559|Drug|Dabigatran etexilate capsules|
79365046|NCT05183113|Other|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
79365047|NCT05177289|Device|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
79365048|NCT05177289|Device|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
79365049|NCT05177263|Other|Placebo|Sterile Water
79365050|NCT05177263|Drug|10% Oral Dextrose Solution|10% Oral Dextrose Solution
79365051|NCT05177263|Drug|20% Oral Dextrose Solution|20% Oral Dextrose Solution
79365052|NCT05177263|Drug|30% Oral Dextrose Solution|30% Oral Dextrose Solution
79365053|NCT05176665|Drug|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses). All patients will be premedicated with a histamine-1 (H1) receptor antagonist diphenhydramine (25 or 50 mg) intravenously 30-60 minutes prior to dosing in the first two cycles. Premedication for subsequent treatment cycles will depend on whether the patient develops infusion-related reactions (IRR), at the discretion of the investigator.
79365054|NCT05174832|Drug|Cisplatin|75 mg/m2 IV days 1 of each 21-day cycle
79365055|NCT05174832|Drug|Nab-paclitaxel|125 mg/m2 IV days 1 and 8 of each 21-day cycle
79365056|NCT05174832|Drug|Pembrolizumab|200 mg IV every 21 days
79517071|NCT05725200|Drug|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79365057|NCT05174832|Drug|Olaparib|300 mg PO BID
79995368|NCT03703518|Other|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
79995369|NCT03703518|Other|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
79222265|NCT02165709|Procedure|Salpingectomy|
79222266|NCT02165709|Procedure|Traditional sterilization|
79222267|NCT02964780|Procedure|Gastric bypass surgery|
79222268|NCT02964780|Behavioral|Conservative weight loss program|
79222269|NCT03343808|Procedure|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
79365058|NCT05173922|Behavioral|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
79517072|NCT05725200|Drug|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
79517073|NCT05724966|Device|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
79517074|NCT05714592|Other|Blood sample|The referring haematologist will suggest that the patient participate in the study during the consultation. In these patients, the investigators will perform OGM on the cytogenetic sample
79517075|NCT05606484|Other|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
79517076|NCT05606484|Other|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
79517077|NCT05599698|Other|Chemotherapy|Standard chemotherapy protocols for adjuvant & neoadjuvant treatment for different types of solid malignancies
79517078|NCT05574894|Drug|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
79517079|NCT05574894|Drug|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
79517080|NCT05530278|Drug|Galicaftor|Oral
79517081|NCT05530278|Drug|ABBV-576|Oral
79222270|NCT04901754|Drug|Camrelizumab Plus Apatinib|"-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD."
79517082|NCT05530278|Drug|Navocaftor|Oral
79517083|NCT05530278|Drug|Midazolam|Oral
79517084|NCT05438628|Diagnostic Test|Point of care ultrasound|Measurement of thickness of rectus abdominis, biceps brachii muscles
79517085|NCT05436288|Drug|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
79517086|NCT05434962|Device|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be <3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be <2,5V@0,5ms"
79365059|NCT05166369|Behavioral|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
79517087|NCT05378568|Other|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
79517088|NCT05378568|Other|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
79517089|NCT05312658|Procedure|External aortic compression|External aortic compression by assistant in cesarean section.
79674723|NCT00505050|Other|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
79674724|NCT00480194|Drug|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
79674725|NCT00505089|Drug|ACZ885|
79674726|NCT00505089|Drug|ACZ885|
79222271|NCT03343730|Diagnostic Test|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
79222272|NCT03343730|Diagnostic Test|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
79517090|NCT05245734|Drug|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
79517091|NCT05242692|Drug|S-ketamine|Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
79517092|NCT05242692|Drug|Dexmedetomidine|Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
79674727|NCT00505089|Drug|ACZ885|
79674728|NCT00505089|Drug|ACZ885|
79674729|NCT00481715|Behavioral|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
79674730|NCT00481715|Behavioral|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
79674731|NCT00505128|Procedure|Endoscopic sphincterotomy|procedure
79674732|NCT00505167|Drug|Memantine|Patients randomized to receive either memantine or donepezil
79674733|NCT00505167|Drug|Donepezil|Patients randomized to receive either memantine or donepezil
79365060|NCT05166369|Behavioral|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
79517093|NCT05242692|Drug|Normal saline|Refer to either S-ketamine or Dexmedetomidine
79821356|NCT02582580|Other|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
79222273|NCT04499378|Diagnostic Test|Lung CT|Computed tomography of the thorax
79222274|NCT02514590|Device|Freedom SCS System|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
79222275|NCT02509208|Device|SurgiClot haemostatic dressing|haemostatic dressing
79222276|NCT02505620|Procedure|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
79222277|NCT02505620|Procedure|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
79222278|NCT02505152|Procedure|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
79222279|NCT02514356|Behavioral|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
79365061|NCT05165056|Device|Intimleds|INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
79365062|NCT05163717|Combination Product|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery [POD®]-olanzapine)
79222280|NCT02514356|Behavioral|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
79365063|NCT05163717|Combination Product|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery [POD®]-placebo)
79517094|NCT05175534|Procedure|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
79365064|NCT05157243|Drug|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
79365065|NCT05157243|Dietary Supplement|Vitamin Super-B Complex|Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
79365066|NCT05157243|Drug|Placebo|Two matching placebo tablets administered orally with food twice daily for 5 days
79517095|NCT05131620|Procedure|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
79517096|NCT05131620|Procedure|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
79674734|NCT00480272|Drug|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
79674735|NCT00480272|Drug|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
79674736|NCT04517058|Other|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
79222281|NCT02504996|Drug|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
79222282|NCT02504996|Drug|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
79222283|NCT02504996|Drug|Placebo|Intravenous 100 ml normal saline
79222284|NCT02508818|Other|Parabolic flight|
79222285|NCT02508818|Other|Cardiovascular measurements|
79517097|NCT05110404|Other|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
79995370|NCT03700710|Behavioral|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
79995371|NCT03700710|Behavioral|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
79222286|NCT02508896|Biological|AFFITOPE® AT04A+adjuvant|subcutaneous injection
79222287|NCT02508896|Biological|AFFITOPE® AT06A+adjuvant|subcutaneous injection
79222288|NCT02508896|Biological|Adjuvant without active component|subcutaneous injection
79222289|NCT02514434|Radiation|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
79222290|NCT02514434|Radiation|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
79222291|NCT02504606|Drug|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
79222292|NCT02504606|Drug|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
79222293|NCT00100815|Biological|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
79222294|NCT00100815|Drug|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
79222295|NCT00100815|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
79222296|NCT00708422|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
79222297|NCT00708422|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
79222298|NCT02165865|Procedure|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
79222299|NCT02514200|Procedure|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
79222300|NCT02514200|Procedure|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
79222301|NCT02514200|Drug|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
79222302|NCT02514200|Device|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
79222303|NCT04645797|Drug|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
79365067|NCT05157243|Other|Standard of Care|Local standard of care for COVID-19
79365068|NCT05156125|Drug|VTX002|Dose A tablet administered orally once daily
79517098|NCT05110404|Other|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
79517099|NCT05087940|Drug|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
79222304|NCT02165943|Device|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
79222305|NCT02508740|Drug|bevenopran|Single oral dose
79365069|NCT05156125|Drug|VTX002|Dose B Tablet administered orally once daily
79365070|NCT05156125|Drug|Placebo|Placebo Tablet for VTX002 administered orally once daily
79365071|NCT05153434|Drug|ARD-101|Twice Daily, Oral Administration
79365072|NCT05137132|Dietary Supplement|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
79365073|NCT05137132|Dietary Supplement|Placebo|MCT oil
79365074|NCT05136820|Device|Atrial Flow Regulator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
79517100|NCT05077566|Other|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
79517101|NCT05077566|Other|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
79365075|NCT05136820|Device|Sham Comparator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
79517102|NCT05069220|Drug|18F-MFBG|Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
79517103|NCT04993326|Behavioral|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
79517104|NCT04930770|Drug|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
79517105|NCT04922658|Drug|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
79517106|NCT04922658|Drug|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 40 mg , each week d1, d3, d5; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
79222306|NCT02167659|Device|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and <10% above pre-surgical baseline.
79365076|NCT05128630|Drug|Durvalumab|Patients will receive 1500 mg durvalumab via IV infusion q3w concomitant with chemotherapy (Cisplatin/carboplatin plus etoposide) for up to a maximum of 3 cycles, then via IV infusion at the same interval during sequential radiotherapy and then every 4 weeks for up to a maximum of 12 months or until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
79365077|NCT05123612|Behavioral|Fiber|Additional 20 grams of fiber/day.
79365078|NCT05123612|Behavioral|Fermented Foods|6 servings of fermented foods/day
79365079|NCT05122663|Behavioral|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
79365080|NCT05122663|Other|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
79365081|NCT05119660|Device|Intermittent Theta Burst Stimulation|iTBS
79365082|NCT05111587|Other|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
79365083|NCT05109429|Behavioral|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
79517107|NCT04915404|Drug|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
79517108|NCT04879602|Behavioral|suction with bronchoscopy|suction with bronchoscopy
79517109|NCT04794660|Diagnostic Test|HPV DNA Test|Screening for HPV using a HPV DNA test
79517110|NCT04794660|Diagnostic Test|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
79674737|NCT00480311|Other|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
79674738|NCT04519788|Drug|AT-301B|Nasal Spray
79674739|NCT04519788|Drug|AT-301A|Nasal Spray
79674740|NCT00480350|Behavioral|rice based food supplement|
79222307|NCT02504684|Device|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
79222308|NCT02504684|Device|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
79517111|NCT04794660|Procedure|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
79517112|NCT04794660|Procedure|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
79524779|NCT05768633|Behavioral|Counterfactual Inference Test|All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
79524780|NCT05768581|Other|Concurrent Training|Participants should perform strength training and aerobic exercises
79524781|NCT05768581|Other|Strength Training|Participants should perform strength exercises
79517113|NCT04660968|Behavioral|Dyadic health behaviour change intervention|The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
79524782|NCT05768581|Other|Aerobic training|Participants should perform aerobic exercises
79821357|NCT03897231|Other|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH, AH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (TM) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
79821358|NCT00790751|Drug|placebo|30 minutes orally prior to initiation of sexual activity
79222309|NCT03540303|Drug|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
79222310|NCT05142579|Other|ENDOTRAKEAL TUBE HOLDER|During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
79222311|NCT05142579|Other|BANDAGE|On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
79222312|NCT02504450|Drug|Adasuve|Inhaled medication to treat acute agitation in the emergency department
79222313|NCT02504450|Drug|Alternative medications|Medication given to treat acute agitation in the emergency department
79821359|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
79222314|NCT02504762|Procedure|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
79222315|NCT02504762|Procedure|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
79222316|NCT02171637|Drug|BIBW 2992|escalating doses
79222317|NCT02166021|Biological|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
79222318|NCT02504528|Other|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
79524783|NCT05768568|Device|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
79524784|NCT05768542|Drug|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
79524785|NCT05768542|Drug|Saline|5 ml given IV
79674741|NCT04519593|Procedure|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
79674742|NCT04519593|Procedure|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
79674743|NCT00480389|Drug|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
79995372|NCT03700632|Other|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
79995373|NCT03698604|Procedure|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
79995374|NCT03698526|Device|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
79365084|NCT05109429|Behavioral|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
79365085|NCT05109429|Behavioral|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
79365086|NCT05094401|Device|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
79365087|NCT05094115|Behavioral|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~Questions from the attendees about applying the concepts in their lives.~Comments and questions from the booster session facilitators to encourage application of the concepts."
79365088|NCT05092750|Device|FerroTraceTM|A magnetic
79517114|NCT04660968|Behavioral|Dyadic nutrition counselling intervention|The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
79517115|NCT04594902|Behavioral|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
79517116|NCT04594902|Other|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
79517117|NCT04438902|Drug|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
79222319|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
79222320|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
79674744|NCT04519554|Device|Endometrial sampling|Endometrial sampling with 2 different forceps
79674745|NCT00482027|Biological|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
79674746|NCT02275455|Behavioral|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
79674747|NCT03272243|Procedure|short segment posterior spine fixation|
79674748|NCT03272243|Procedure|long segment posterior spine fixation|
79821360|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
79821361|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
79821362|NCT00740571|Drug|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
79821363|NCT00740571|Drug|pregabalin|Strategy in which patient starts with pregabalin
79995375|NCT03624426|Device|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
79222321|NCT02171715|Drug|BIBW 2992 MA2|powder for oral solution
79365089|NCT05092750|Drug|indocyanine green (ICG)|Given by SC injection
79995376|NCT03703362|Other|Resistance training|30 supervised training-sessions over 12 weeks
79222322|NCT02760069|Drug|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
79222323|NCT02760069|Drug|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
79222324|NCT02760069|Drug|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
79517118|NCT04329390|Drug|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
79517119|NCT04326036|Procedure|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
79517120|NCT04326036|Device|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
79365090|NCT05091489|Other|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
79517121|NCT04326036|Procedure|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
79517122|NCT04326036|Drug|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
79517123|NCT04326036|Drug|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
79517124|NCT04303572|Drug|Eloctate ITI|This is a factor VIII-Fc infusion protein.
79517125|NCT04303572|Drug|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
79517126|NCT04177602|Combination Product|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
79517127|NCT04177602|Combination Product|Capecitabine based chemoradiation|Capecitabine based chemoradiation
79517128|NCT04135482|Other|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
79517129|NCT04098822|Device|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
79517130|NCT03849066|Other|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
79517131|NCT03816618|Drug|Medihoney Gel in A Tube|TREATMENT1
79517132|NCT03816618|Drug|Hydrogel|PURLOIN GEL
79517133|NCT03816618|Drug|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
79517134|NCT03770598|Behavioral|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
79517135|NCT03770598|Behavioral|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
79517136|NCT03770598|Behavioral|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
79517137|NCT03770598|Behavioral|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
79222325|NCT02760069|Drug|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
79222326|NCT02504138|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
79821364|NCT02582502|Other|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
79821365|NCT00740649|Drug|HSD-016|
79222327|NCT02504138|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
79365091|NCT05087082|Other|Virtual Hospital at Home - Home admission of epidemic patients|Admitting COVID-19 patients at home
79821366|NCT00740649|Drug|placebo|
79821367|NCT04107155|Dietary Supplement|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
79821368|NCT04107155|Dietary Supplement|Placebo|Placebo
79821369|NCT04107155|Other|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
79365092|NCT05080803|Drug|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
79365094|NCT05072665|Device|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
79517138|NCT03692208|Behavioral|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
79517139|NCT03662646|Other|no intervention performed- observational only|no intervention performed- observational only
79821370|NCT04107155|Other|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
79821371|NCT02582424|Other|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
79821372|NCT02582424|Other|placebo|placebo
79821373|NCT05248893|Drug|AGN-151586|Intramuscular Injection
79821374|NCT00784979|Drug|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
79517140|NCT03616236|Drug|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
79517141|NCT03616236|Other|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
79821375|NCT02595242|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
79995377|NCT01568151|Behavioral|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
79517143|NCT03590574|Biological|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
79222328|NCT04499144|Procedure|modified buccal flap and subepithelial connective palatal flap|The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
79222329|NCT02166099|Procedure|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
79222330|NCT02508584|Biological|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
79365095|NCT05072067|Procedure|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
79222331|NCT02166177|Drug|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
79517144|NCT03551730|Combination Product|PRT064445/Enoxaparin|
79517145|NCT03551730|Combination Product|Placebo/Enoxaparin|
79517146|NCT03551730|Drug|Placebo|
79517147|NCT03491592|Behavioral|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
79517148|NCT03491592|Behavioral|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
79517149|NCT03366480|Drug|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
79365096|NCT05065801|Combination Product|GABRINOX|Patients in the experimental arm received sequential treatment: 3 cycles of GEMBRAX followed by 2 cycles of FOLFIRINOX
79365097|NCT05065801|Combination Product|FOLFIRINOX|Patients in this arm received reatment: 3 cycles of FOLFIRINOX
79365098|NCT05064943|Diagnostic Test|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
79517150|NCT03267108|Combination Product|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
79517151|NCT03267108|Combination Product|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
79517152|NCT03267108|Combination Product|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
79517153|NCT03239808|Procedure|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
79517154|NCT03239808|Procedure|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
79517155|NCT02923362|Procedure|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
79517156|NCT02923362|Device|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
79517157|NCT02890758|Biological|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10^7 cells/kg), dose Level-1 (1x10^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10^7) and Dose level 3 (5X10^7) is dependent on DLT
79517158|NCT02890758|Biological|ALT803|given at 6mcg/kg weekly for four weeks
79517159|NCT02683200|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
79995378|NCT01568151|Behavioral|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
79517160|NCT02683200|Radiation|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
79517161|NCT02534844|Drug|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
79517162|NCT02534844|Other|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
79222332|NCT02508662|Other|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
79222333|NCT02171793|Drug|BI 1744 CL|
79222334|NCT02171793|Drug|Placebo|
79365101|NCT05057754|Behavioral|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
79517163|NCT02534376|Drug|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
79517164|NCT02216838|Drug|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
79821376|NCT02595242|Drug|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
79365102|NCT05057754|Behavioral|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
79821377|NCT02595242|Drug|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
79222335|NCT02508506|Drug|ALKS 5461|Single dose, given orally
79222336|NCT02171871|Other|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
79222337|NCT02513810|Device|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
79821378|NCT04487106|Drug|Azacitidine|Given IV or SC
79821379|NCT04487106|Drug|Trametinib|Given PO
79821380|NCT04487106|Drug|Venetoclax|Given PO
79821381|NCT00740883|Drug|warfarin|18 months of warfarin therapy, once daily
79995379|NCT03698292|Drug|Itopride|Prokinetic Drug
79222338|NCT02513810|Device|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
79365103|NCT05057754|Behavioral|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
79365104|NCT05057754|Behavioral|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
79365105|NCT05057754|Behavioral|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
79995380|NCT03698292|Drug|Metoclopramide 10mg|Prokinetic Drug
79517165|NCT02216838|Other|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
79517166|NCT02065596|Drug|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
79517167|NCT02065596|Procedure|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
79517168|NCT01976286|Other|Salicylic Acid Peels|
79517169|NCT01976286|Other|Glycolic Acid Peels|
79517170|NCT01818492|Biological|NI-0501|
79517171|NCT01372566|Device|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
79517172|NCT01372566|Other|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
79517173|NCT01239030|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
79517174|NCT01239030|Drug|Placebo|Placebo capsules
79517175|NCT01129050|Dietary Supplement|Fish Oil|Fish oil capsule
79517176|NCT01129050|Dietary Supplement|Flaxseed Oil|Flaxseed oil capsule
79821382|NCT00740883|Drug|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
79517177|NCT01129050|Dietary Supplement|Placebo|Soybean oil capsule
79517178|NCT01086540|Biological|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
79517179|NCT01086540|Other|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
79517180|NCT01086540|Diagnostic Test|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
79517181|NCT01086540|Drug|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
79517182|NCT01086540|Drug|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
79517183|NCT01086540|Drug|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
79674749|NCT03270137|Device|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
79821383|NCT00738920|Behavioral|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
79995381|NCT04615455|Drug|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
79995382|NCT04615455|Drug|Cryostor CS10|CryoStor® CS10 freeze medium
79995383|NCT03703284|Other|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
79222339|NCT02167737|Behavioral|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
79222340|NCT02167737|Behavioral|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
79222341|NCT03121742|Behavioral|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
79222342|NCT03121742|Behavioral|Treatment as Usual|Standard care as part of inpatient hospitalization.
79365106|NCT05057754|Behavioral|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
79222343|NCT02166255|Biological|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
79222344|NCT02166255|Other|laboratory biomarker analysis|Correlative studies
79365107|NCT05055830|Drug|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
79365108|NCT05053971|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
79365109|NCT05053971|Procedure|Core Biopsy|Undergo core needle biopsy
79365110|NCT05053971|Drug|Entinostat|Given PO
79365111|NCT05053412|Diagnostic Test|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
79517184|NCT01086540|Drug|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
79517185|NCT01959048|Drug|fecal microbiota transplantation|
79517186|NCT01962558|Device|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
79517187|NCT01962558|Device|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
79821384|NCT00738920|Behavioral|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
79517188|NCT01962714|Behavioral|Loving-Kindness Meditation|12-week loving-kindness meditation course
79517189|NCT01962714|Behavioral|Cognitive Processing Therapy|12-week CPT course
79517190|NCT01962870|Drug|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
79674750|NCT03270137|Device|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
79674751|NCT04519398|Genetic|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~Factor V Leiden~Factor V 4070 A>G (Hr2)~Factor II G20210A~Methylenetetrahydrofolate reductase (MTHFR) C677T~MTHFR A1298C~Cystathionine β-synthase (CBS) 844ins68~PAI-1 4G/5G~Glycoprotein IIIa T1565C (HPA-1a/b)~ACE-DEL/INS~Apolipoprotein E (ApoE)~AGT M235T~Angiotensin II type 1 receptor (ATR-1) A1166C~Fibrinogen - 455 G>A~Factor XIII Val34Leu"
79365112|NCT05048069|Drug|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
79365113|NCT05046496|Diagnostic Test|Intra-arterial digital subtraction angiography|Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
79365114|NCT05044195|Biological|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
79365115|NCT05044195|Biological|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
79365116|NCT05041166|Drug|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
79365117|NCT05029063|Drug|Rivaroxaban 10 MG|Identical comparator drug
79365118|NCT05027503|Other|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
79365119|NCT05027503|Other|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
79365120|NCT05024591|Device|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
79517191|NCT01962870|Drug|Placebo|
79517192|NCT01965288|Device|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
79517193|NCT01965288|Device|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
79821385|NCT00738920|Behavioral|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
79821386|NCT02568033|Drug|Pemetrexed|
79821387|NCT02568033|Drug|Carboplatin|
79821388|NCT02568033|Drug|Cisplatin|
79365121|NCT05018611|Behavioral|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
79365122|NCT05009394|Procedure|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
79365123|NCT05009394|Procedure|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
79365124|NCT05009394|Procedure|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
79517194|NCT01965366|Behavioral|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
79517195|NCT01965366|Drug|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
79821389|NCT02568033|Drug|Docetaxel|
79821390|NCT02568033|Drug|Paclitaxel|
79821391|NCT02568033|Radiation|stereotactic radiosurgery|
79821392|NCT00582972|Drug|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
79821393|NCT02595086|Procedure|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
79821394|NCT02595086|Procedure|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
79995384|NCT01567917|Procedure|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
79517196|NCT01965756|Drug|Metformin|
79517197|NCT01965756|Drug|Placebos|
79517198|NCT01966380|Device|Leia|
79517199|NCT01966458|Device|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
79995385|NCT03698214|Other|reversed shock index < 1|Among patients with isolated TBI, those with an RSI < 1 had higher mortality
79517200|NCT01966458|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
79517201|NCT01966770|Device|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
79517202|NCT01966770|Device|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
79995386|NCT03698214|Other|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
79995387|NCT03698136|Other|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
79995388|NCT03698058|Dietary Supplement|Toddler milk|Commercially available toddler milk
79995389|NCT04613271|Drug|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
79995390|NCT04613271|Drug|Azithromycin|Azithromycin 500 mg once a day for 5 days.
79222345|NCT02166411|Procedure|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
79222346|NCT02166411|Procedure|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
79222347|NCT02508350|Drug|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
79365125|NCT05004298|Other|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
79365126|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 2 mg oral capsules.
79995391|NCT05415189|Other|Not relevant|This is a non-intervention cohort study
79995392|NCT03094611|Biological|Inotuzumab Ozogamicin|Given IV
79995393|NCT03631953|Drug|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
79995394|NCT03631953|Drug|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
79995395|NCT03631953|Biological|Blood sample|Therapeutic biomarkers
79995396|NCT03631953|Device|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
79995397|NCT01030575|Drug|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
79365127|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 5 mg oral capsules.
79365128|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 15 mg oral capsules.
79365129|NCT04999839|Drug|NDI-034858 study drug|NDI-034858 30 mg (2*15 mg) oral capsules.
79365130|NCT04999839|Other|Placebo|Placebo matched to NDI-034858 oral capsules.
79365131|NCT04994808|Drug|Clofarabine|Given IV
79365132|NCT04994808|Drug|Fludarabine|Given IV
79365133|NCT04994808|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
79365134|NCT04994808|Radiation|Total-Body Irradiation|Undergo TBI
79517203|NCT01966770|Device|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
79517204|NCT01966770|Device|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
79995398|NCT01030575|Drug|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
79995399|NCT01030575|Drug|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
79995400|NCT01030575|Drug|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
79995401|NCT04314687|Biological|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
79365135|NCT04994808|Drug|Treosulfan|Given IV
79365136|NCT04992598|Other|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
79365137|NCT04992598|Procedure|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
79517205|NCT01966770|Device|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
79517206|NCT01966770|Device|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
79517207|NCT01966926|Behavioral|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
79517208|NCT01967784|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
79517209|NCT01967862|Procedure|computed tomography|Undergo CT
79674752|NCT00482066|Drug|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
79995402|NCT04314687|Biological|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
79995403|NCT04314687|Other|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
79222348|NCT02508350|Other|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
79222349|NCT02171949|Biological|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
79995404|NCT04215471|Drug|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
79995405|NCT04561011|Behavioral|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
79995406|NCT04105725|Behavioral|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
79995407|NCT04105725|Other|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
79365138|NCT04991402|Device|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
79365139|NCT04991311|Drug|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
79365140|NCT04990401|Behavioral|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
79365141|NCT04986865|Drug|ATG-101|ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
79365142|NCT04974008|Drug|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
79365143|NCT04956744|Biological|IMS001|IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).
79365144|NCT04954781|Drug|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79517210|NCT01967862|Procedure|bone scan|Undergo bone scan
79674753|NCT04519047|Biological|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
79674754|NCT00482105|Other|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
79222350|NCT02503826|Drug|Sufentanil|low dose
79222351|NCT02503826|Drug|Sufentanil|moderate dose
79222352|NCT02503826|Drug|Sufentanil|high dose
79222353|NCT02503826|Drug|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
79222354|NCT02503826|Drug|propofol|
79222355|NCT02503826|Drug|cisatracurium|
79517211|NCT01967862|Procedure|3-Tesla magnetic resonance imaging|Undergo axial MRI
79517212|NCT01967862|Procedure|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
79517213|NCT01967862|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
79517214|NCT01967862|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
79517215|NCT01967862|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
79517216|NCT01967862|Other|laboratory biomarker analysis|Correlative studies
79517217|NCT01974102|Behavioral|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
79222356|NCT02172027|Device|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
79517218|NCT01974102|Behavioral|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
79995408|NCT04066023|Drug|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm^2 array) is attached to a 5 cm^2 adhesive patch.
79222357|NCT02166489|Biological|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
79517219|NCT01975974|Device|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
79517220|NCT01976988|Drug|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
79517221|NCT01978314|Device|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
79517222|NCT01980654|Drug|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
79517223|NCT01980654|Drug|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
79517224|NCT01981590|Device|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
79222358|NCT03121664|Drug|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
79222359|NCT02174679|Drug|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
79365145|NCT04954781|Combination Product|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
79365146|NCT04948502|Device|SaExten vena cava filter system|Subjects will undergo intervention, be implanted with a SaExten filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
79365147|NCT04948502|Device|Denali inferior vena cava filter|Subjects will undergo intervention, be implanted with a Denali filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
79517225|NCT01983228|Behavioral|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
79517226|NCT01984398|Drug|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
79517227|NCT01984398|Drug|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
79517228|NCT01984398|Drug|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
79222360|NCT02503904|Procedure|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
79222361|NCT02503904|Device|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
79222362|NCT02503904|Drug|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
79222363|NCT02172105|Drug|BI 1744 CL|
79222364|NCT02172105|Drug|Placebo|
79517229|NCT01984398|Drug|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
79517230|NCT01985958|Device|Radiation therapy|
79517231|NCT01987752|Drug|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
79517232|NCT01988376|Device|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
79517233|NCT01988376|Device|Conventional Pap smear|Conventional Pap smear
79517234|NCT01988922|Drug|ketamine|0.4 mg/kg oral racemic ketamine
79995409|NCT04066023|Drug|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
79995410|NCT03106987|Drug|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
79222365|NCT05142423|Drug|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
79222366|NCT04498676|Other|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
79365148|NCT04942405|Biological|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
79517235|NCT01991808|Radiation|Radiotherapy|
79517236|NCT01992354|Device|PET MR Device|GE PET/MRI system
79517237|NCT01994538|Other|Longer therapy duration|14 days of antimicrobial treatment
79517238|NCT01994538|Other|Shorter therapy duration|7 days of antimicrobial treatment
79517239|NCT01996644|Drug|Placebo vs Setraline|Placebo
79517240|NCT01996644|Drug|Setraline|250mg DCS
79517241|NCT01998360|Procedure|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
79517242|NCT01998360|Procedure|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
79517243|NCT01998438|Drug|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
79517244|NCT01999530|Drug|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
79517245|NCT01999920|Drug|Vilazodone|10mg to 40mg per day for 12 weeks
79517246|NCT01999920|Drug|Placebo|One to two pills per day for 12 weeks
79517247|NCT02000154|Drug|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
79517248|NCT02001714|Behavioral|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
79674755|NCT04519242|Procedure|Surgery|"ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon."
79674756|NCT00482144|Procedure|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
79674757|NCT00482144|Procedure|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
79222367|NCT02261259|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
79365149|NCT04942405|Biological|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
79222368|NCT02513654|Drug|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
79222369|NCT02504060|Drug|Starch Placebo|
79222370|NCT02504060|Drug|N-acetyl-D-glucosamine|
79222371|NCT03538977|Procedure|Hydrotherapy|A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.
79222372|NCT03538977|Procedure|Conventional Physiotherapy|Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
79222373|NCT02503748|Other|Online tutorial|website informing about treatment options in localized prostate cancer
79365150|NCT04940598|Other|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
79517249|NCT02002494|Other|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
79517250|NCT02002650|Drug|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
79517251|NCT02002650|Drug|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
79222374|NCT02167971|Other|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
79365151|NCT04940598|Other|No-exercise control group|No-exercise control group
79517252|NCT02003352|Procedure|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
79517253|NCT02004132|Drug|Axiron|Solution administered topically using pump and applicator
79517254|NCT02004288|Dietary Supplement|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
79517255|NCT02004366|Drug|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
79517256|NCT02004366|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
79517257|NCT02004366|Drug|Linagliptin|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
79674758|NCT04519359|Other|Stop NAs therapy|Stop NAs therapy
79674759|NCT00482183|Drug|Pioglitazone|
79674760|NCT04518774|Biological|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
79995411|NCT03106987|Drug|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
79674761|NCT01312909|Drug|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
79674762|NCT01312909|Drug|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
79821395|NCT05236413|Behavioral|High Intensity Interval Exercise|"Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same."
79995412|NCT02932267|Drug|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
79995413|NCT04930705|Device|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
79517258|NCT02004366|Drug|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
79517259|NCT02004366|Drug|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
79517260|NCT02004990|Procedure|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
79517261|NCT02005536|Biological|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
79674763|NCT01312909|Drug|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
79674764|NCT00482222|Biological|cetuximab|
79995414|NCT03217591|Drug|IW-1973|Oral Tablet
79995415|NCT03217591|Drug|IW-1973|Oral Tablet
79995416|NCT03217591|Drug|Placebo|Oral Tablet
79222375|NCT02167971|Other|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
79222376|NCT02513888|Dietary Supplement|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
79222377|NCT02513888|Dietary Supplement|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
79995417|NCT04927195|Drug|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
79995418|NCT04927195|Drug|Placebo|Placebo oral capsule
79222378|NCT00101595|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
79222379|NCT02513576|Other|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
79517262|NCT02006160|Drug|dalfampridine|10 mg bid
79517263|NCT02006160|Drug|placebo|10 mg bid
79517264|NCT02010216|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
79517265|NCT02010996|Procedure|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
79517266|NCT02010996|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
79517267|NCT02011464|Drug|Exparel|Exparel is infiltrated into posterior compartment for pain control
79674765|NCT00482222|Drug|capecitabine|
79674766|NCT00482222|Drug|fluorouracil|
79995419|NCT03636763|Drug|data report|"the information gliptin exposure will be reported"
79995420|NCT03031782|Drug|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
79995421|NCT03031782|Other|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
79517268|NCT02011464|Other|Saline|Saline is infiltrated into posterior compartment for control
79517269|NCT02058420|Drug|Low tocotrienols group|300 mg tocotrienols daily
79517270|NCT02058420|Drug|High tocotrienols group|600 mg tocotrienols daily
79995422|NCT03697902|Diagnostic Test|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
79995423|NCT03697824|Drug|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
79995424|NCT03697824|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
79995425|NCT03697824|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
79995426|NCT03697824|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
79995427|NCT03700398|Device|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
79674767|NCT00482222|Drug|leucovorin calcium|
79222380|NCT02503592|Other|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
79222381|NCT02174757|Drug|Inersan|Probiotic
79222382|NCT02174757|Drug|Doxycycline|Antibiotic
79222383|NCT03121196|Other|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
79222384|NCT02168049|Device|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
79517271|NCT02015442|Dietary Supplement|Sucrose|
79222385|NCT02168049|Device|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
79222386|NCT02168049|Device|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
79222387|NCT03121508|Behavioral|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
79517272|NCT02016612|Device|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
79517273|NCT02020278|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
79517274|NCT02020590|Drug|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
79517275|NCT02023944|Other|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
79517276|NCT02024646|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
79517277|NCT02024646|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
79517278|NCT02024646|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
79517279|NCT02024724|Drug|Bupivacaine|4 mL of 0.25% bupivacaine
79517280|NCT02024724|Drug|Triamcinolone|40 mg of Triamcinolone
79517281|NCT02024724|Drug|Dexamethasone|4 mg of Dexamethasone
79517282|NCT02025426|Drug|Phenylephrine|
79517283|NCT02025426|Drug|Ephedrine|
79524786|NCT05768503|Drug|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
79674768|NCT00482222|Drug|oxaliplatin|
79674769|NCT00482222|Other|study of socioeconomic and demographic variables|
79674770|NCT00482222|Procedure|adjuvant therapy|
79674771|NCT00482222|Procedure|neoadjuvant therapy|
79674772|NCT00482222|Procedure|quality-of-life assessment|
79674773|NCT01312129|Drug|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
79674774|NCT01312129|Drug|Placebo|Placebo capsule x 3 doses 12 hours apart
79674775|NCT00480467|Drug|SAM-315|
79995428|NCT03700398|Device|first WLI|the routine in the clinical practice
79995429|NCT03702894|Drug|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
79995430|NCT03702894|Drug|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
79995431|NCT03697746|Drug|paracetamol|paracetamol 1000 mg vial
79995432|NCT03697746|Drug|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
79995433|NCT03697746|Drug|Ibuprofen|ıbuprofen 400 mg vial
79995434|NCT03216265|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
79995435|NCT03216265|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
79995436|NCT03216265|Other|No treatment|No treatment.
79517284|NCT02026206|Device|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
79821396|NCT05236413|Behavioral|Dietary Approaches to Stop Hypertension (DASH) Diet|Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
79821397|NCT05236413|Behavioral|Exercise + DASH Diet|Patients will undergo both the exercise training intervention and DASH diet as explained above.
79517285|NCT02026206|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
79517286|NCT02028780|Drug|Placebo to dose|placebo
79674776|NCT04518852|Combination Product|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
79821398|NCT02597972|Procedure|Fracture repair|
79821399|NCT02597972|Procedure|Fracture repair with joint replacement|
79222388|NCT02168127|Drug|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
79222389|NCT02168127|Drug|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
79222390|NCT02513420|Behavioral|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
79674777|NCT02955615|Drug|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
79674778|NCT02955615|Drug|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
79674779|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
79674780|NCT01311661|Drug|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
79821400|NCT05224401|Drug|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
79821401|NCT05224401|Drug|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
79821402|NCT02598206|Drug|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
79995437|NCT03697668|Drug|Imatinib|triple combination for the treatment of malaria
79995438|NCT03697668|Drug|Dihydroartemisinin-piperaquine|standard malaria treatment
79222391|NCT02172183|Drug|Psychopharmacological treatment|methylphenidate or atomoxetine
79222392|NCT02172183|Behavioral|CBT group|
79222393|NCT02174835|Drug|AVP-786|
79222394|NCT02174835|Drug|AVP-923|
79222395|NCT02255877|Device|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
79222396|NCT02255877|Device|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
79517287|NCT02028780|Drug|Idarucizumab|short infusion
79517288|NCT02028780|Drug|Placebo to Idarucizumab|Placebo to Idarucizumab
79517289|NCT02028780|Drug|dabigatran|2 capsules dabigatran
79517290|NCT02028780|Drug|Idarucizumab|short infusion
79517291|NCT02029872|Drug|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
79674781|NCT01311661|Drug|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
79222397|NCT02174991|Drug|Rho-Kinase Inhibitor (AR-12286)|
79222398|NCT02255955|Drug|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
79222399|NCT02255955|Drug|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
79222400|NCT02255955|Drug|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
79222401|NCT02172261|Drug|BI 10773|
79222402|NCT02172261|Drug|Glimepiride|
79222403|NCT02501564|Drug|Naproxen Sodium Codeine|One tablet twice a day
79222404|NCT02501564|Drug|Placebo|One tablet twice a day
79222405|NCT02172339|Drug|Tiotropium, solution ampoules|
79222406|NCT02503670|Behavioral|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
79222407|NCT02503670|Other|Control Group|Continue with standard care.
79222408|NCT02172417|Drug|Cimetidine + Tiotropium|
79222409|NCT02172417|Drug|Ranitidine + Tiotropium|
79222410|NCT02172417|Drug|Tiotropium|
79222411|NCT02501486|Other|ACTH stimulation test|An ACTH stimulation test will be done
79674782|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
79674783|NCT01311661|Drug|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
79222412|NCT02255643|Device|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
79517292|NCT02029872|Drug|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
79222413|NCT03343340|Other|Early CRRT|Continous Renal Replacement Therapy
79674784|NCT01311661|Drug|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
79821403|NCT00740961|Behavioral|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
79222414|NCT03343340|Other|Late CRRT|Continous Renal Replacement Therapy
79222415|NCT03343340|Other|Standard Medical Therapy|Standard Medical Therapy
79222416|NCT02168205|Drug|Pomalidomide|Capsules
79365152|NCT04938258|Behavioral|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
79365153|NCT04936685|Biological|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
79365154|NCT04936061|Device|CoolStat active device|The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
79365155|NCT04936061|Device|CoolStat sham device|The CoolStat sham device will administer a sham flow of ambient air into the nostril.
79365156|NCT04934098|Device|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
79365157|NCT04934098|Device|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
79365158|NCT04930367|Behavioral|Radio Ads|Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
79517293|NCT02029872|Drug|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
79517294|NCT02030574|Drug|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
79517295|NCT02030886|Device|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
79517296|NCT02032212|Other|EVP unflavoured|
79517297|NCT02032212|Other|EVP flavoured|
79517298|NCT02032212|Other|Nicotine inhalator|15 mg nicotine Nicorette
79517299|NCT02032212|Other|Conventional cigarette|
79674785|NCT04518735|Other|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
79674786|NCT00482261|Drug|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
79222417|NCT02168205|Other|Caffeine|Capsules
79222418|NCT02168205|Other|Tobacco|Cigarettes
79222419|NCT04496570|Procedure|periodontal therapy|Non surgical periodontal therapy was performed to patients with peridontitis
79222420|NCT02168283|Combination Product|treatment arm|Hypertonic peritoneal dialysis cycles
79222421|NCT02168283|Behavioral|Control arm|Dietary counseling
79222422|NCT03343652|Drug|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
79222423|NCT03343652|Drug|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
79674787|NCT00482261|Drug|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
79674788|NCT00482261|Drug|aspirin|100mg/day
79674789|NCT04518618|Drug|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
79222424|NCT02175069|Procedure|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
79222425|NCT02175069|Drug|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
79222426|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
79222427|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
79222428|NCT02175069|Drug|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
79674790|NCT04518618|Drug|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
79674791|NCT00480584|Drug|gemcitabine|Levels 1 through 4: 1000 mg/m^2
79517300|NCT02032680|Behavioral|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
79995439|NCT04387812|Device|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
79995440|NCT03700164|Other|Temperature|Water-perfused suit.
79517301|NCT02032680|Behavioral|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
79517302|NCT02032680|Other|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
79222429|NCT02175069|Procedure|Shoulder Surgery|As per individual requirement (patient-dependent)
79222430|NCT02503280|Drug|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs.
79222431|NCT02503280|Drug|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
79222432|NCT02503280|Drug|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).
79222433|NCT02503280|Device|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
79365159|NCT04930367|Behavioral|Community Sensitization Campaign|Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
79365160|NCT04930367|Behavioral|Informational Posters|Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
79365161|NCT04930367|Behavioral|Motivation Walls|Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.
79365162|NCT04930367|Other|Pill Container|A discreet pill container to support ART adherence.
79365163|NCT04930367|Other|CombinADO-specific training for healthcare workers|Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
79365164|NCT04930367|Other|One Stop Shop Model of Care|Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
79365165|NCT04930367|Other|Treatment Toolkit|A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
79365166|NCT04930367|Other|Self-reflection Kit|A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.
79365167|NCT04930367|Behavioral|Peer Support|Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
79365168|NCT04930367|Behavioral|Informational and motivational Video|An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
79365169|NCT04930367|Behavioral|Support groups- caregivers of adolescents and young adults living with HIV|A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
79365170|NCT04930367|Behavioral|Support groups- adolescents and young adults living with HIV|A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
79517303|NCT02032758|Drug|Propranolol|Single oral dose of 10 mg propranolol
79517304|NCT02032758|Device|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
79517305|NCT02032758|Procedure|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
79517306|NCT02032758|Device|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
79995441|NCT03700086|Device|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
79222434|NCT02503046|Other|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
79517307|NCT02033694|Device|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
79517308|NCT02036424|Drug|Ozurdex|intravitreal steroid
79517309|NCT02036424|Drug|Bevacizumab|antiVEGF
79995442|NCT03700086|Device|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
79674792|NCT00480584|Drug|capecitabine|Level 1: 500 mg/m^2; Level 2: 825 mg/m^2; Level 3: 1000 mg/m^2; Level 4: 1250 mg/m^2
79995443|NCT04050384|Device|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
79674793|NCT00480584|Drug|erlotinib|Levels 1 through 4: 100 mg
79995444|NCT03700008|Diagnostic Test|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
79995445|NCT03700008|Diagnostic Test|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
79517310|NCT02037204|Other|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
79517311|NCT02037438|Other|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
79517312|NCT02037438|Other|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
79365171|NCT04930367|Behavioral|Mental health screening and linkage to adolescent-focused mental health support|HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.
79365172|NCT04923568|Device|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
79517313|NCT02038218|Drug|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
79517314|NCT02042274|Dietary Supplement|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
79517315|NCT02044380|Drug|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
79222435|NCT02503046|Genetic|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
79228057|NCT05195658|Device|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
79517316|NCT02045238|Drug|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
79365173|NCT04921371|Other|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
79517317|NCT02045238|Radiation|Chest X-Ray|
79517318|NCT02045238|Other|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
79517319|NCT02047032|Procedure|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
79517320|NCT02047032|Drug|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
79674794|NCT01311505|Drug|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
79674795|NCT01311505|Drug|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
79674796|NCT05644366|Other|Postural Control Balance Assessment|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
79228058|NCT04205162|Device|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
79517321|NCT02047032|Procedure|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
79517322|NCT02047344|Drug|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
79674797|NCT05644327|Behavioral|Cardiovascular training (CT)|12 weeks of CT
79674798|NCT05644327|Behavioral|Resistance training (RT)|12 weeks of RT
79674799|NCT05644327|Behavioral|Multimodal training (MT)|12 weeks of MT
79674800|NCT01240538|Biological|wild-type reovirus|Given IV
79674801|NCT01240538|Drug|cyclophosphamide|Given PO
79821404|NCT00740961|Drug|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
79821405|NCT00740961|Other|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
79517323|NCT02047500|Drug|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
79821406|NCT00740961|Other|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
79995446|NCT03697434|Behavioral|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
79517324|NCT02047500|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
79517325|NCT02047500|Drug|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
79517326|NCT02048670|Device|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
79517327|NCT02051790|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
79517328|NCT02054754|Drug|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
79995447|NCT03702738|Drug|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
79222436|NCT04498520|Drug|Abexinostat Tosylate|Given PO
79222437|NCT04498520|Drug|Fulvestrant|Given IM
79674802|NCT01240538|Other|laboratory biomarker analysis|Correlative studies
79821407|NCT00740961|Other|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
79821408|NCT00740961|Procedure|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
79995448|NCT03702660|Other|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
79995449|NCT03702660|Other|Peripheral venous cannulation|Intravenous access for infusions
79365174|NCT04921371|Other|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
79517329|NCT02054754|Drug|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
79821409|NCT00740961|Procedure|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
79821410|NCT04319718|Combination Product|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
79995450|NCT03702660|Other|GLP-1|Peptide infusion
79995451|NCT04486950|Drug|TAK-951|TAK-951 intravenous infusion.
79222438|NCT04498520|Drug|Palbociclib|Given PO
79517330|NCT02054754|Drug|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
79517331|NCT02054754|Drug|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
79517332|NCT02054754|Drug|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
79517333|NCT02054754|Drug|Placebo|
79222439|NCT02168595|Drug|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
79222440|NCT02168595|Drug|Placebo|
79222441|NCT03344276|Diagnostic Test|Neurocognitive Assessments|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.
79222442|NCT03344276|Diagnostic Test|Measurements of inflammatory biomarkers|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.
79222443|NCT03344276|Procedure|Carotid Artery Stenting|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
79365175|NCT04921371|Other|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
79365176|NCT04921371|Other|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
79365177|NCT04921371|Other|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
79365178|NCT04921371|Other|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
79517334|NCT02057640|Drug|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
79517335|NCT02057640|Drug|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
79674803|NCT01240538|Other|pharmacological study|Correlative studies
79674804|NCT04518579|Procedure|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
79674805|NCT01310803|Drug|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
79517336|NCT02057640|Drug|MLN9708|4mg on day 1, 8, 15, 28
79517337|NCT02057952|Behavioral|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
79517338|NCT02059512|Procedure|Group 1|Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
79821411|NCT04319718|Combination Product|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
79821412|NCT00918086|Dietary Supplement|Vitamin D pill|Oral tablet taken for 16 weeks
79222444|NCT02172495|Drug|Tiotropium bromide|Tiotropium bromide 18 micrograms
79222445|NCT02172573|Drug|Pramipexole|
79222446|NCT02172573|Drug|Bromocriptine|
79222447|NCT02172573|Drug|Placebo pramipexole|
79821413|NCT00918086|Dietary Supplement|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
79821414|NCT02567487|Drug|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
79995452|NCT04486950|Drug|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
79222448|NCT02172573|Drug|Placebo bromocriptine|
79222449|NCT02175303|Biological|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals.
79222450|NCT03344120|Other|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
79365179|NCT04920123|Device|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
79365180|NCT04911491|Device|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
79365181|NCT04911491|Device|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
79365182|NCT04911465|Device|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
79365183|NCT04909970|Other|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
79365184|NCT04909970|Other|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
79517339|NCT02059512|Procedure|Group 0|Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
79517340|NCT02059512|Procedure|Group 2|Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
79517341|NCT02059902|Drug|Lidocaine|Lidocaine infusion runs for a total of 24 hours
79821415|NCT02598050|Other|No Interventions as this is a observational study|
79821416|NCT04062435|Drug|Drop application in the inferior fornix|See Arms
79821417|NCT04062435|Drug|Drop application on the cornea|See Arms
79821418|NCT02597894|Procedure|Biopsy of Prostate|Undergo biopsy
79821419|NCT02597894|Other|Laboratory Biomarker Analysis|Correlative studies
79821420|NCT04311996|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
79821421|NCT04311996|Other|TSST|Participants will, via an online session, complete the TSST which is a standardized speech & math performance known to elicit a cortisol stress response.
79821422|NCT04372602|Drug|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
79821423|NCT04372602|Procedure|Peripheral blood draw|"First 10 patients enrolled~Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
79222451|NCT02507882|Biological|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
79821424|NCT04372602|Drug|Placebo|-Provided by Verastem
79222452|NCT02507882|Biological|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
79222453|NCT02175381|Drug|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
79222454|NCT02175381|Drug|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
79222455|NCT03540225|Drug|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
79222456|NCT02501252|Procedure|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
79222457|NCT02507648|Drug|Oseltamivir|1 tablet contains 75 mg oseltamivir
79222458|NCT02507648|Drug|Tamiflu®|1 tablet contains 75 mg oseltamivir
79222459|NCT02172729|Drug|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
79222460|NCT02503124|Behavioral|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
79222461|NCT02503124|Device|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
79517342|NCT02059902|Other|Placebo|Normal saline runs for a total of 24 hours
79517343|NCT02060058|Drug|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
79517344|NCT02060526|Drug|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase [rhHNS]
79517345|NCT02060838|Procedure|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
79821425|NCT04366908|Drug|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
79995453|NCT03699852|Radiation|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
79222462|NCT02503124|Other|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
79222463|NCT02503124|Other|Informative meeting|A short sleep hygiene consultation.
79821426|NCT04366908|Drug|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
79821427|NCT00733304|Drug|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
79222464|NCT02503124|Drug|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
79222465|NCT02172807|Drug|Tiotropium low|Tiotropium 18 µg inhalation capsule
79222466|NCT02172807|Drug|Tiotropium high|Tiotropium 36 µg inhalation capsule
79222467|NCT02172807|Drug|Placebo MDI|Placebo metered dose inhaler (MDI)
79222468|NCT02172807|Drug|Placebo inhalation capsule|
79821428|NCT00711243|Drug|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
79995454|NCT03699852|Other|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
79995455|NCT03697200|Other|APA|Light touch using vaccaria seeds on specific points of the ear
79995456|NCT03697200|Other|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
79222469|NCT02172807|Drug|Oxitropium|Oxitropium MDI (100 µg/puff)
79222470|NCT03343262|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
79222471|NCT03343262|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
79222472|NCT04568421|Drug|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
79365185|NCT04899245|Diagnostic Test|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
79365186|NCT04895215|Drug|AB-2004|Taken 3 times daily with food
79222473|NCT02502968|Drug|Cytarabine|
79222474|NCT02502968|Drug|BL-8040|
79222475|NCT02502968|Drug|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
79222476|NCT04496648|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
79517346|NCT02061384|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
79222477|NCT04496648|Procedure|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
79222478|NCT02172963|Biological|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10^6 cells/kg.
79228059|NCT04205162|Device|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
79228060|NCT02229981|Drug|ABC294640|
79365187|NCT04895215|Drug|Placebo|Take 3 times daily with food
79674806|NCT01310803|Other|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
79995457|NCT03697200|Other|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
79995458|NCT03697044|Procedure|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
79222479|NCT02502578|Drug|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
79222480|NCT02502812|Drug|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
79365188|NCT04893096|Drug|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
79365189|NCT04889183|Drug|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
79365190|NCT04889183|Drug|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
79365191|NCT04888741|Drug|Thymoglobulin|GVHD prophylaxis
79365192|NCT04888741|Drug|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
79365193|NCT04888741|Drug|Cyclosporine|immunosuppressant
79365194|NCT04888741|Drug|Sirolimus|immunosuppressant
79517347|NCT02061384|Drug|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
79517348|NCT02061696|Device|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
79517349|NCT02061696|Procedure|Standard Manual Compression|Closure procedure by Manual Compression
79517350|NCT02061774|Drug|Acetaminophen|1 gram of intravenous Acetaminophen
79517351|NCT02061774|Drug|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
79517352|NCT02062008|Device|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
79821429|NCT00711243|Drug|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
79995459|NCT04693416|Other|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
79995460|NCT04693416|Other|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
79222481|NCT02502812|Drug|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
79222482|NCT02502812|Drug|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
79222483|NCT02175537|Behavioral|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
79222484|NCT02168751|Drug|propofol|
79222485|NCT02168751|Drug|Sevoflurane|
79365195|NCT04888741|Drug|Mycophenolate Mofetil|immunosuppressant
79365196|NCT04886388|Device|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
79365197|NCT04886388|Other|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
79995461|NCT03699774|Drug|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
79365198|NCT04883814|Diagnostic Test|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
79365199|NCT04883554|Other|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
79365200|NCT04883554|Other|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
79517353|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
79517354|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
79517355|NCT02062710|Drug|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
79517356|NCT02062710|Drug|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
79517357|NCT02062710|Drug|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
79674807|NCT01240577|Drug|IPdR|
79674808|NCT04518540|Drug|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
79674809|NCT04518540|Drug|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
79674810|NCT00480623|Drug|Satraplatin plus radiation therapy|
79995462|NCT03699774|Drug|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
79517358|NCT02062710|Drug|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
79517359|NCT02063178|Behavioral|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
79517360|NCT02063178|Behavioral|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
79517361|NCT02063178|Behavioral|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
79517362|NCT02063178|Behavioral|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
79517363|NCT02063178|Behavioral|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
79517364|NCT02063178|Behavioral|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
79517365|NCT02063178|Behavioral|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
79517366|NCT02063178|Behavioral|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
79821430|NCT00711243|Drug|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
79222486|NCT02507726|Device|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
79222487|NCT02173041|Other|Prevention Awareness Groups (PAG)|
79222488|NCT02173041|Other|Standard Care|
79365201|NCT04881604|Device|Adjustable Compression Wrap|"Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
79517367|NCT02063178|Behavioral|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
79517368|NCT02063178|Behavioral|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
79517369|NCT02063178|Behavioral|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
79995463|NCT03699696|Drug|Propofol|Induction of anesthesia prior to surgery with propofol
79995464|NCT03699618|Drug|Anti-VEGF|Standard of care treatment with anti-VEGF only
79995465|NCT03699618|Other|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
79995466|NCT03696966|Dietary Supplement|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
79995467|NCT03696966|Behavioral|Low-Calorie Diet|Restrict calorie intake daily
79222489|NCT02507570|Drug|Enzalutamide|used concomitantly
79517370|NCT02064270|Device|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
79517371|NCT02064270|Device|Standard postsurgical dressings|Use of Standard postsurgical dressings
79517372|NCT02064582|Drug|Enzalutamide|160mg by mouth each day
79995468|NCT03696966|Behavioral|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
79995469|NCT03702426|Drug|GMCSF|GMCSF 1.5mcg/Kg
79995470|NCT03702426|Drug|Norfloxacin|Tablet Norfloxacin 400 mg
79995471|NCT00265941|Drug|cetuximab|Cetuximab 400 mg/m^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m^2 IV weekly for 7 weeks
79995472|NCT00265941|Drug|cisplatin|Cisplatin 100 mg/m^2 IV on days 1 and 22
79995473|NCT00265941|Radiation|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
79222490|NCT02507570|Radiation|Radium ra 223 dichloride|
79222491|NCT03344042|Drug|Fentanyl|100mcg Fentanyl
79222492|NCT03344042|Drug|Sufentanil|10mcg sufentanil
79222493|NCT02173119|Other|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
79222494|NCT03343964|Diagnostic Test|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
79222495|NCT03538509|Other|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
79222496|NCT04495322|Drug|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
79222497|NCT04495322|Drug|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
79222498|NCT02175927|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
79222499|NCT02175927|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
79995474|NCT00265941|Radiation|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
79995475|NCT03696732|Other|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
79995476|NCT03696732|Other|VAS questionnaire|verbal numerical scale (VNS) anxiety score
79995477|NCT01568541|Drug|Regular toothpastes|One tooth brushing
79995478|NCT01568541|Drug|Children's toothpastes|One tooth brushing
79517373|NCT02064582|Drug|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
79222500|NCT02175927|Drug|Metronidazole|antibiotic of each quadruple therapy
79517374|NCT02064582|Radiation|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
79995479|NCT03699462|Drug|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
79995480|NCT03699462|Drug|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
79821431|NCT04366518|Drug|Rivastigmine Capsule|Consistent with safety and efficacy demonstrated in prior studies, a 6 mg capsule of Rivastigmine will be dosed. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first oral treatment and a visit for the second oral treatment. All visits include fMRI scans. The first capsule will be administered during the 1-hour treatment. After the washout period, a second capsule will be administered. Blood levels will be used to verify absorption of Rivastigmine and used as a regressor in subsequent analyses. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
79674811|NCT00505323|Device|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
79365202|NCT04881604|Device|Compression Sleeve|"Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
79365203|NCT04870515|Other|Best Practice|Receive standard lifestyle recommendations
79365204|NCT04870515|Other|Dietary Intervention|Receive dietary instructions
79517375|NCT02067000|Behavioral|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
79674812|NCT01240655|Drug|LCL161|
79995481|NCT03699384|Drug|Azacitidine|AZA 75 mg/m^2 SC or IV D 1-7 28 day cycle x 1
79517376|NCT02067468|Device|HPV test|QIAGEN - The Digene HPV test®
79674813|NCT01240655|Drug|Paclitaxel|
79674814|NCT01240031|Other|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~Thorough sensory and nutrition assessment (questionnaire).~Nutrition plan adjusted daily according to the assessment.~Serving appetising, energy- and protein-dense meals, snacks and drinks."
79995482|NCT03699384|Drug|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
79995483|NCT03702348|Other|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
79995484|NCT03702192|Device|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
79995485|NCT03699306|Procedure|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
79995486|NCT03624738|Procedure|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
79995487|NCT04014231|Procedure|Diagnostic Imaging|Undergo placement of single wave application
79995488|NCT04014231|Other|Laboratory Biomarker Analysis|Correlative studies
79995489|NCT03697590|Drug|No curettage|Standard PDT without curettage
79995490|NCT03697590|Drug|Curettage|Standard PDT
79365205|NCT04870515|Other|Exercise Intervention|Complete aerobic and strength/resistance exercises
79365206|NCT04870515|Other|Quality-of-Life Assessment|Ancillary studies
79517377|NCT02067468|Procedure|COLPOSCOPY|Colposcopy routine health services
79517378|NCT02067468|Device|cytology|Cytology routine health services
79222501|NCT02175927|Drug|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
79222502|NCT02175927|Drug|Tetracycline|antibiotic of classical quadruple therapy
79222503|NCT00707486|Device|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
79222504|NCT00707486|Device|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
79222505|NCT03539991|Other|Internet-Based Intervention|Complete online courses
79517379|NCT02067858|Radiation|Stereotactic Radiosurgery|
79517380|NCT02069184|Drug|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
79517381|NCT02069184|Other|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
79517382|NCT02070276|Procedure|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
79674815|NCT01240031|Other|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
79674816|NCT04518189|Drug|lidocaine patch|lidocaine patch applied 3 hours before the procedure
79674817|NCT04518189|Drug|Sham patch|Sham patch applied 3 hours before the procedure
79674818|NCT00482300|Procedure|Systematic pelvic lymphadenectomy|
79674819|NCT00505401|Biological|recombinant HIV-1 Tat protein|
79517383|NCT02070276|Procedure|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
79674820|NCT00505440|Behavioral|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
79674821|NCT00505440|Behavioral|Usual care|Usual care with mailed screening results
79222506|NCT03539991|Other|Meeting|Participate in virtual meetings
79821432|NCT04366518|Drug|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
79821433|NCT04366518|Drug|Placebo Capsule|Participants in Aim 2 will receive a placebo capsule versus rivastigmine capsule.
79222507|NCT03539991|Other|Survey Administration|Ancillary studies
79222508|NCT05460884|Dietary Supplement|Seaweed extract LD and white bread|109g of white bread with 0.5g of seaweed extract
79222509|NCT05460884|Dietary Supplement|Seaweed extract HD and white bread|109g of white bread with 1g of seaweed extract
79222510|NCT05460884|Dietary Supplement|White bread|109g of white bread
79222511|NCT05452460|Behavioral|Mindfulness intervention|"The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes."
79222512|NCT02759055|Other|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
79222513|NCT03343106|Behavioral|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
79222514|NCT03343106|Behavioral|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
79365207|NCT04870515|Other|Questionnaire Administration|Ancillary studies
79365208|NCT04869358|Drug|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
79365209|NCT04868214|Device|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
79517384|NCT02134314|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
79517385|NCT02134314|Drug|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
79517386|NCT02135016|Drug|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
79517387|NCT02135016|Drug|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
79517388|NCT02135016|Drug|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
79517389|NCT02135094|Device|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
79674822|NCT00482378|Drug|Pamidronate|90 mg by IV monthly.
79821434|NCT04366518|Drug|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
79821435|NCT02568501|Behavioral|Daily feedback|Daily feedback on glucose levels from wireless glucometers
79222515|NCT02496182|Drug|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
79365210|NCT04866576|Dietary Supplement|Q CAN PLUS|Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy
79365211|NCT04866576|Dietary Supplement|Placebo|Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
79222516|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
79222517|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
79222518|NCT02496026|Device|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
79222519|NCT02496026|Device|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
79222520|NCT02168907|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
79365212|NCT04840797|Device|HeartStart HS1|Automated External Defibrillator
79517390|NCT02135094|Device|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
79674823|NCT00482378|Drug|Zoledronic acid|4 mg by IV monthly.
79674824|NCT00482378|Radiation|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
79674825|NCT04517955|Device|Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
79674826|NCT00480818|Drug|SAM-531|
79674827|NCT01310413|Biological|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
79995491|NCT05375799|Other|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
79517391|NCT02137512|Device|Closed-Loop Control System|"This investigational device system included the following components:~DiAs - a smart-phone medical platform;~Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
79517392|NCT02137512|Device|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~Dexcom G4 Platinum CGM system;~Roche Accu-Chek insulin pump"
79995492|NCT03636997|Procedure|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
79517393|NCT02139228|Biological|Hib-CRM197|No vaccine administered in V37_07E2 study
79222521|NCT02168907|Drug|bendamustine hydrochloride|Given IV
79222522|NCT02168907|Biological|rituximab|Given IV
79222523|NCT02168907|Other|laboratory biomarker analysis|Correlative studies
79222524|NCT03343028|Other|Psychotherapy|
79222525|NCT02500784|Drug|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
79222526|NCT02500784|Other|Formoterol B (placebo)|2mL, BID inhaler for 12 months
79222527|NCT02176317|Biological|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
79222528|NCT03538353|Other|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
79222529|NCT02495870|Other|Pork|
79222530|NCT02168985|Behavioral|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
79222531|NCT02495792|Device|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
79222532|NCT02176395|Drug|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
79222533|NCT02176395|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
79222534|NCT02176395|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
79222535|NCT02500940|Drug|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
79365213|NCT04825223|Drug|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
79365214|NCT04825223|Drug|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
79517394|NCT02139228|Biological|Hib-TT|No vaccine administered in V37_07E2 study
79517395|NCT02139540|Drug|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
79517396|NCT02139540|Drug|Placebo|50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup
79517397|NCT02146482|Other|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
79821436|NCT02568501|Behavioral|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
79821437|NCT00733226|Drug|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
79222536|NCT02500940|Drug|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
79365215|NCT04825223|Drug|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
79821438|NCT00733226|Drug|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
79821439|NCT04076436|Other|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
79222537|NCT02500940|Radiation|Radiation therapy|Intensity-Modulated Radiation Therapy
79222538|NCT02500940|Drug|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
79228061|NCT02523378|Behavioral|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
79228062|NCT02523378|Behavioral|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
79365216|NCT04825223|Drug|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
79995493|NCT03636997|Procedure|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
79995494|NCT05420883|Other|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
79222539|NCT02176473|Behavioral|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
79222540|NCT02500472|Dietary Supplement|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
79222541|NCT02495636|Drug|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
79222542|NCT02495636|Drug|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
79517398|NCT02148588|Drug|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
79517399|NCT02149290|Device|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
79517400|NCT02149524|Drug|Herceptin (trastuzuamb)|Intravenous administration
79222543|NCT02176551|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
79222544|NCT02176551|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
79222545|NCT02495714|Behavioral|Active learning|Physical activity one hour a day as part of academic learning
79365217|NCT04825223|Drug|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
79365218|NCT04822649|Diagnostic Test|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
79517401|NCT02149524|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
79517402|NCT02150460|Procedure|One-site peribulbar injection|injection into the inferior medial orbital compartment
79517403|NCT02150460|Procedure|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
79517404|NCT02154048|Drug|Ropivacaine|
79517405|NCT02154048|Drug|Dexamethasone|
79517406|NCT02154048|Other|Placebo|
79517407|NCT02154906|Device|DFDBA|
79517408|NCT02154906|Device|autologous platelet rich fibrin|
79517409|NCT02156154|Drug|Intravenous Acetaminophen|
79524787|NCT05768503|Drug|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
79674828|NCT01310413|Biological|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
79674829|NCT02275572|Procedure|Pharmacist Intervention|
79674830|NCT00482417|Drug|MK0359|
79674831|NCT02275689|Procedure|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
79674832|NCT02275689|Procedure|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
79674833|NCT00482456|Drug|Nitrous oxide|
79674834|NCT00480896|Drug|tacrolimus ointment|Topical application
79674835|NCT00480896|Drug|Placebo ointment|Topical application
79674836|NCT01309828|Drug|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
79674837|NCT01309828|Drug|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
79674838|NCT00482820|Behavioral|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
79674839|NCT00482495|Biological|bevacizumab|
79674840|NCT00482495|Genetic|gene expression analysis|
79674841|NCT00482495|Genetic|protein expression analysis|
79674842|NCT00482495|Other|laboratory biomarker analysis|
79674843|NCT00480935|Drug|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
79517410|NCT02157168|Behavioral|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
79517411|NCT02158494|Device|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
79674844|NCT02955264|Dietary Supplement|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
79674845|NCT00480974|Other|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
79674846|NCT04518150|Device|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
79674847|NCT04518150|Procedure|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
79821440|NCT04076436|Other|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
79821441|NCT04364178|Biological|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
79365219|NCT04819386|Other|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
79365220|NCT04815096|Drug|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|[18F]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
79674848|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution with epinephrine 1:100,000~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
79365221|NCT04812678|Procedure|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
79365222|NCT04812678|Procedure|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
79365223|NCT04810052|Behavioral|Behavioral Intervention|Perform 1 nice thing
79365224|NCT04810052|Behavioral|Behavioral Intervention|Write a letter or note of gratitude
79365225|NCT04810052|Behavioral|Behavioral Intervention|Track daily activities
79674849|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution without vasoconstrictor~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
79821442|NCT04364178|Biological|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
79365226|NCT04810052|Other|Interview|Ancillary studies
79365227|NCT04810052|Other|Quality-of-Life Assessment|Ancillary studies
79517412|NCT02158494|Device|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
79517413|NCT02158572|Drug|AG200-15|Transdermal contraceptive delivery system
79995495|NCT05420883|Other|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
79365228|NCT04810052|Other|Questionnaire Administration|Ancillary studies
79365229|NCT04792970|Drug|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
79517414|NCT02159118|Device|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
79517415|NCT02159118|Device|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
79674850|NCT00482898|Drug|MK0359|
79674851|NCT00482937|Drug|CD-NP|
79674852|NCT00482651|Radiation|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
79365230|NCT04778501|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
79517416|NCT02159898|Device|EndoMAXX Endoluminal Valve Technology (EVT)|
79517417|NCT02159898|Device|EndoMAXX|
79517418|NCT02159976|Drug|Pantoprazole|Pantoprazole 40mg bid
79517419|NCT02159976|Drug|Amoxicillin|Amoxicillin 1000mg bid
79674853|NCT00482651|Procedure|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
79222546|NCT02495714|Behavioral|Dietary councelling|Teaching children and parents about a healthy diet
79222547|NCT02169063|Radiation|carbon-11 acetate|Given IV
79222548|NCT02169063|Radiation|fluorine F 18 sodium fluoride|Given IV
79821443|NCT04364178|Biological|Epstein-Barr Virus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Epstein-Barr viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
79995496|NCT05420883|Other|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
79222549|NCT02169063|Procedure|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
79222550|NCT02169063|Other|laboratory biomarker analysis|Correlative studies
79222551|NCT02495558|Other|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
79222552|NCT04496882|Drug|Vemlidy|25mg Tenofovir Alafenamide
79517420|NCT02159976|Drug|Clarithromycin|Clarithromycin 500mg bid
79517421|NCT02159976|Drug|Metronidazole|Metronidazole 500mg tid
79517422|NCT02159976|Drug|Tetracycline|Tetracycline 1000mg bid
79517423|NCT02159976|Drug|Bismuth|Bismuth 600mg bid
79674854|NCT00482651|Procedure|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
79674855|NCT00482651|Procedure|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
79674856|NCT00482976|Drug|Ruboxistaurin|
79674857|NCT00482976|Drug|Placebo|
79674858|NCT00481013|Drug|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
79674859|NCT00481013|Drug|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
79674860|NCT00483015|Behavioral|smoking|
79674861|NCT00482768|Behavioral|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
79222553|NCT02176629|Other|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
79222554|NCT02176629|Other|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
79222555|NCT02502500|Drug|Celecoxib|
79222556|NCT02502500|Drug|AKB-6548|
79517424|NCT02160288|Drug|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
79222557|NCT02500394|Procedure|Ionosteril|biomarker guided volume substitution with Ionosteril
79517425|NCT02160288|Drug|Normal Saline|Dispensed in a 5 cc syringe
79517426|NCT02160990|Drug|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
79517427|NCT02160990|Drug|Placebo|placebo subcutaneously twice daily for 30 days
79517428|NCT02161536|Device|Motus Cleansing System|
79674862|NCT01309243|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
79674863|NCT01309243|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
79674864|NCT01240070|Other|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
79674865|NCT04517409|Procedure|Goal-directed hemodynamic therapy|Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
79222558|NCT02502422|Device|Classic laryngeal mask airway|"measurement of head and neck~Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip~sternal notch), modified mallampati classification under sitting position, thyromental distance.~laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~# 4.0 for female, #5.0 for male~initial cuff volume(air) : maximum volume recommended by the manufacturer~check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
79222559|NCT02173587|Dietary Supplement|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
79222560|NCT02173587|Dietary Supplement|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
79222561|NCT02495480|Device|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
79222562|NCT02173665|Drug|BI 1356 BS - Powder in bottle (PIB)|
79517429|NCT02163486|Device|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
79517430|NCT02163486|Device|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
79517431|NCT02164422|Drug|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
79517432|NCT02164422|Drug|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
79517433|NCT02164422|Drug|Placebo|
79517434|NCT02165124|Device|Artificial Embolization Device|Embosphere Microspheres
79517435|NCT02165904|Biological|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
79517436|NCT02167074|Device|25G FNA needle|
79517437|NCT02167074|Device|20G ProCore FNB needle|
79222563|NCT02173665|Drug|BI 1356 BS - Tablet|
79222564|NCT02173665|Drug|Placebo|
79222565|NCT02495324|Drug|Placebo|2 weeks of placebo PO daily
79222566|NCT02495324|Drug|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
79222567|NCT02495324|Drug|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
79222568|NCT02495324|Drug|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
79222569|NCT02173743|Other|PRP|platelet enriched autologous blood plasma
79222570|NCT02173743|Other|Control|Regular barbotage/care as usual
79222571|NCT02500238|Other|Saliva sample|All participants will provide a saliva sample.
79222572|NCT02500238|Other|Urine Sample|All participants will provide a urine sample.
79365231|NCT04755309|Behavioral|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
79365232|NCT04755309|Behavioral|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
79517438|NCT02170662|Drug|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
79517439|NCT02170662|Drug|Placebo|
79517440|NCT02173392|Drug|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
79517441|NCT02178540|Drug|Placebo|one dose (4 capsules) of placebo
79517442|NCT02178540|Device|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
79517443|NCT02178696|Other|Placebo, identified as placebo to participants|White tablets
79517444|NCT02178696|Drug|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
79517445|NCT02178696|Other|"Placebo, identifed to participants as Active medication"|Blue Capsule
79365233|NCT04753372|Drug|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
79365234|NCT04748042|Drug|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
79365235|NCT04748042|Drug|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
79365236|NCT04748042|Radiation|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
79365237|NCT04748042|Biological|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
79365238|NCT04748042|Drug|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
79365239|NCT04743492|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
79821444|NCT02567721|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
79222573|NCT02500238|Other|Toe nail clippings|All participants will provide toe nail clippings.
79222574|NCT02500238|Other|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
79222575|NCT02173821|Procedure|Blood sampling|Blood sample will be collected at a single visit
79222576|NCT02495246|Biological|ChAd3-EBO-Z|
79222577|NCT02495246|Biological|Ad26.ZEBOV|
79222578|NCT02495402|Behavioral|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
79222579|NCT02256033|Drug|Istradefylline|One 40 mg-tablet administered on Day 1
79365240|NCT04742374|Biological|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
79517446|NCT02179788|Behavioral|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
79821445|NCT02581800|Other|App group|
79365241|NCT04741516|Drug|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
79517447|NCT02179788|Drug|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
79517448|NCT02179788|Drug|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
79517449|NCT02180100|Drug|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
79517450|NCT02180100|Drug|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
79517451|NCT02180646|Other|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
79517452|NCT02180646|Other|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
79517453|NCT02181426|Drug|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
79517454|NCT02184624|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
79222580|NCT02502110|Drug|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
79222581|NCT02173899|Biological|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
79365242|NCT04741282|Other|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
79365243|NCT04741282|Other|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
79365245|NCT04730609|Drug|Dexmedetomidine|Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
79365246|NCT04726215|Drug|[18F]F AraG|PET imaging agent specific to activated T cells
79365247|NCT04717869|Diagnostic Test|Ultrasound|2D ultrasound image collection
79517455|NCT02184624|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
79517456|NCT02184624|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
79517457|NCT02184624|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
79517458|NCT02184624|Device|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
79517459|NCT02184624|Device|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
79365248|NCT04717869|Diagnostic Test|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
79365249|NCT04717869|Other|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
79365250|NCT04713176|Drug|DWJ1248 with Remdesivir|1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
79365251|NCT04713176|Drug|Placebo with Remdesivir|1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
79517460|NCT02185404|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
79517461|NCT02186808|Device|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
79517462|NCT02189382|Device|Potassium Oxalate|
79517463|NCT02189382|Other|Water|
79517464|NCT02189850|Drug|BLI800 - Dose 1|BLI800 oral solution
79517465|NCT02189850|Drug|BLI800 - Dose 2|BLI800 oral solution
79222582|NCT02173899|Biological|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
79222583|NCT02173899|Biological|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
79222584|NCT02173977|Other|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
79222585|NCT02173977|Other|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
79365252|NCT04710303|Biological|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 [E1-, E2b-, E3-] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
79517466|NCT02190552|Device|EmboTrap® Revascularization Device|
79517467|NCT02192814|Drug|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
79517468|NCT02195232|Drug|Isoquercetin|
79517469|NCT02195622|Device|Lumenis VersaCut Morcellator|
79517470|NCT02195622|Device|Wolf Piranha Morcellator|
79517471|NCT02196168|Drug|Cisplatin|Given IV
79517472|NCT02196168|Other|Laboratory Biomarker Analysis|Correlative studies
79517473|NCT02196168|Other|Pharmacological Study|Correlative studies
79517474|NCT02196168|Other|Placebo|Given PO
79517475|NCT02196168|Drug|WEE1 Inhibitor AZD1775|Given PO
79517476|NCT02200458|Device|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
79222586|NCT02502344|Behavioral|healthy lifestyle|food control and intensive exercise to lose weight
79365253|NCT04703621|Drug|Daratumumab Injection|subcutaneious daratumumab administration
79365254|NCT04703569|Procedure|Dressing with monolayer high compression elastic bandage|The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
79365255|NCT04703569|Procedure|Dressing with Unna boot|The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
79517477|NCT02200536|Other|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
79517478|NCT02200536|Other|Infant oral health pamphlet|Infant oral health pamphlet
79517479|NCT02201394|Drug|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
79517480|NCT02201394|Drug|Aspirin loading dose|Single loading dose of Aspirin 325 mg
79517481|NCT02201394|Drug|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
79517482|NCT02201394|Drug|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
79517483|NCT02202252|Procedure|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
79517484|NCT02202252|Procedure|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
79517485|NCT02202252|Procedure|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
79517486|NCT02203578|Drug|romidepsin|Given IV
79995497|NCT04665973|Behavioral|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
79222587|NCT02502344|Drug|Metformin|use metformin to reduce insulin resistance
79222588|NCT04496180|Device|Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
79821446|NCT00741117|Procedure|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
79821447|NCT00741117|Procedure|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
79365258|NCT04702113|Diagnostic Test|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
79517487|NCT02203578|Other|laboratory biomarker analysis|Correlative studies
79517488|NCT02204124|Device|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
79517489|NCT02204124|Device|Standard of care scissors, ligatures, clips, and sutures|
79517490|NCT02204748|Device|DePuy Attune posterior stabilizing fixed bearing knee system|
79517491|NCT02206776|Drug|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
79517492|NCT02206776|Drug|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
79517493|NCT02207322|Other|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
79517494|NCT02207478|Procedure|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
79517495|NCT02207478|Procedure|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
79517496|NCT02209272|Drug|bacteriostatic saline|
79517497|NCT02209272|Drug|buffered lidocaine|
79517498|NCT02210052|Device|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
79517499|NCT02210286|Dietary Supplement|Magtein|
79821448|NCT00741117|Procedure|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
79995498|NCT04665973|Behavioral|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
79821449|NCT03900819|Other|dexterity measurement|4 non-invasive tests will be performed
79995499|NCT03696654|Procedure|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
79995500|NCT05420571|Procedure|digital impression|3D printed models after digital impressions
79995501|NCT05420571|Procedure|alginate impression|Alginate impressions after plaster model infusion to make models
79222589|NCT02174211|Drug|Ranibizumab|Intravitreal injection of ranibizumab
79222590|NCT02174211|Drug|Aflibercept|Intravitreal injection of aflibercept
79995502|NCT03696420|Other|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
79222591|NCT02500160|Device|Patient specific instrumentation (MRI)|
79222592|NCT02500160|Device|Patient specific instrumentation (CT)|
79222593|NCT02169141|Other|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
79222594|NCT02495012|Drug|placebo|Freeze-dried powder without snake venom will be dissovled in saline
79222595|NCT02495012|Drug|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
79222596|NCT02169297|Procedure|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter [maximum pump infusion rate]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
79222597|NCT02169297|Procedure|PCA only|Patients received intravenous PCA post-operatively
79222598|NCT02494934|Behavioral|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
79365259|NCT04701723|Other|cardiac coherence|standard care associated to cardiac coherence training during 3 months
79517500|NCT02211456|Procedure|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
79222599|NCT02494934|Behavioral|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
79222600|NCT02169375|Other|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
79222601|NCT04496492|Drug|Tocotrienol|Tocotrienol 200 mg orally twice a day
79222602|NCT02500004|Radiation|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
79222603|NCT02500004|Radiation|DXA scanning|Body composition: DXA scanning, D2O and MRI.
79365260|NCT04697784|Device|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
79365261|NCT04696146|Drug|Berinert|Intrarenal dose of 500 U of Berinert
79365262|NCT04696146|Drug|Placebo|Normal Saline placebo
79365263|NCT04693676|Biological|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
79517501|NCT02211534|Device|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
79821450|NCT02567565|Other|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
79821451|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
79821452|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
79821453|NCT02582346|Procedure|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
79365264|NCT04685486|Other|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
79517502|NCT02211534|Device|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
79517503|NCT02213250|Drug|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
79517504|NCT02214420|Drug|Simeprevir|
79517505|NCT02214420|Drug|Sofosbuvir|
79517506|NCT02214420|Drug|Ribavirin|
79995503|NCT00188695|Procedure|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
79674866|NCT04517409|Procedure|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment."
79674867|NCT01240109|Drug|Remifentanil|"propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
79995504|NCT05420415|Other|CSTME|Tumor microenvironment collagen signature
79222604|NCT02500004|Procedure|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
79222605|NCT02500004|Procedure|Blood sampling|Systemic inflammatory profile: blood sampling.
79995505|NCT03882957|Behavioral|Sustained attention|participants will complete a sustained attention task
79995506|NCT03882957|Behavioral|media multi-task|participants will complete multiple media tasks at the same time
79222606|NCT02500004|Other|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
79222607|NCT02500004|Device|Accelerometry|Physical activity level: accelerometry.
79995507|NCT03882957|Other|Video|participants will watch a video of media tasks being completed
79222608|NCT02500004|Other|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
79222609|NCT02500082|Drug|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
79222610|NCT02499848|Drug|PRX302|Single prostate cancer lesion injected with PRX302.
79222611|NCT02502188|Drug|CC-90005|
79222612|NCT02502188|Drug|Placebo|
79222613|NCT02502032|Drug|Cisatracurium|Different groups received different pretreatments of cisatracurium.
79222614|NCT04495244|Diagnostic Test|Syantra DX Breast Cancer|Blood test for detecting the presence of breast cancer.
79228063|NCT03309566|Drug|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
79365265|NCT04684719|Biological|low titer whole blood|low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site
79365266|NCT04684719|Biological|Standard Care|crystalloid infusion or blood component transfusion resuscitation
79365267|NCT04681248|Drug|DKN-01|Administered by IV infusion
79365268|NCT04680897|Behavioral|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
79365269|NCT04680897|Behavioral|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
79517507|NCT02215200|Drug|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
79517508|NCT02215200|Drug|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
79517509|NCT02215200|Drug|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
79517510|NCT02215200|Drug|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
79517511|NCT02217618|Drug|LY2409021|
79517512|NCT02218242|Device|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
79517513|NCT02218320|Drug|Raltegravir|
79517514|NCT02218320|Drug|Dolutegravir|
79821454|NCT00741195|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
79821455|NCT00741195|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
79995508|NCT04333290|Drug|[11C]MeDAS|PET radiotracer
79995509|NCT03201211|Biological|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
79995510|NCT03201211|Biological|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79821456|NCT05338632|Drug|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
79222615|NCT03343496|Procedure|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I~II, aged 18~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
79222616|NCT02494856|Drug|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
79222617|NCT02494856|Drug|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
79222618|NCT04495010|Biological|Nivolumab|Specified dose on specified days
79222619|NCT04495010|Biological|Ipilimumab|Specified dose on specified days
79222620|NCT02169531|Drug|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
79222621|NCT03539913|Biological|Probiotic : Saccharomyces boulardii|Treatment for 5 days
79365272|NCT04669665|Drug|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
79517515|NCT02218320|Procedure|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
79517516|NCT02219256|Drug|TAK-079|TAK-079 solution
79517517|NCT02219256|Drug|Placebo to TAK-079|Placebo to TAK-079 solution
79517518|NCT02222610|Drug|0.5 mg ranibizumab|
79517519|NCT02222610|Procedure|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
79517520|NCT02223702|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
79517521|NCT02223702|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
79517522|NCT02223702|Drug|Moxifloxacin|400 mg, once in a day for 7 days.
79517523|NCT02224404|Device|Fast Gelling Dressing (Exufiber)|
79365273|NCT04669665|Drug|Placebo|Intranasal placebo
79517524|NCT02224482|Behavioral|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
79517525|NCT02225106|Drug|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
79517526|NCT02227836|Device|Allergy Patch Testing|
79517527|NCT02229318|Dietary Supplement|FruitiVits|Daily administration of FruitiVits dietary supplement
79517528|NCT02229474|Behavioral|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
79517529|NCT02230566|Drug|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
79821457|NCT05338632|Drug|Naloxone Hydrochloride|naloxone 0.4mg/ml, up to 4 doses 2mg intramuscularly, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
79821458|NCT02597816|Radiation|Three dimensional ultrasound|
79222622|NCT03539913|Biological|Probiotic : Bacillus clausii|Treatment for 5 days
79365274|NCT04669665|Other|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
79365275|NCT04669665|Device|Intranasal device|Device to deliver intranasal solution
79517530|NCT02230566|Other|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
79517531|NCT02233296|Drug|Lasmiditan|2 discrete doses separated by 6 days.
79517532|NCT02233530|Behavioral|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
79517533|NCT02233842|Behavioral|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
79517534|NCT02233998|Other|Mouth Rinse 1|
79517535|NCT02233998|Other|Mouth Rinse 2|
79517536|NCT02233998|Other|Mouth Rinse 3|
79517537|NCT02235870|Device|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
79517538|NCT02235870|Device|Sham Device|Sham Intragastric Balloon
79517539|NCT02235870|Behavioral|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
79517540|NCT02236338|Procedure|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
79517541|NCT02236338|Device|ClosureFAST radiofrequency catheter|
79365280|NCT04660396|Device|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
79365281|NCT04658940|Device|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
79365282|NCT04650256|Other|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
79517542|NCT02236338|Device|EVLT 980nm diode laser system|
79995511|NCT03201211|Biological|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79995512|NCT03201211|Drug|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79995513|NCT03727191|Other|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
79222623|NCT03539835|Other|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
79222624|NCT03539835|Behavioral|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
79222625|NCT03343418|Drug|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
79222626|NCT03343418|Drug|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
79228064|NCT00735657|Device|needle|Peribulbar blockade with standard (25 mm) needle
79365283|NCT04644055|Diagnostic Test|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
79365284|NCT04642443|Device|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
79365285|NCT04640441|Other|Sit-to-stand care|"Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20~30 min, once daily.~Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20~30min, once daily.~Stepping exercise and sit-to-stand exercise, 20~30min, once daily."
79365286|NCT04631770|Procedure|Systemic mediastinal lymph node dissection|Systematic hilar and mediastinal lymph node dissection.
79365287|NCT04631770|Procedure|Spared mediastinal lymph node dissection|Mediastinal lymph node is spared in this group.
79517543|NCT02237898|Behavioral|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application & Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
79517544|NCT02237898|Behavioral|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
79674868|NCT04517526|Drug|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
79674869|NCT01309204|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
79674870|NCT01309204|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
79674871|NCT01309204|Drug|Brinzolamide 1% ophthalmic suspension|
79674872|NCT01309204|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
79228065|NCT00735657|Device|needle|Peribulbar blockade with short (12.5 mm) needle
79995514|NCT03727191|Other|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
79365288|NCT04629066|Behavioral|Remote Cardiac Rehabilitation (CR)|"Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR."
79365289|NCT04626050|Behavioral|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
79222627|NCT03539757|Device|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
79517545|NCT02237898|Device|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
79222628|NCT02499926|Dietary Supplement|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
79222629|NCT03539679|Other|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
79222630|NCT03341780|Procedure|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
79222631|NCT05504096|Device|Actxa BGM Tracker (GLO2)|Wrist-worn wearable
79222632|NCT05504096|Device|SVT In-Ear Prototype (IEP)|In-Ear wearable
79222633|NCT03341702|Other|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
79222634|NCT02174289|Device|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
79222635|NCT03341624|Procedure|cataract surgery cataract extraction and intraocular implantation|
79222636|NCT02176785|Device|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
79365290|NCT04626050|Behavioral|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
79517546|NCT02237898|Device|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
79995515|NCT04633837|Device|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
79995516|NCT03622437|Behavioral|Patient-led follow-up|"Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
79995517|NCT03622437|Other|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~outpatient visits at 3, 12 and 36 months~access to stoma care by specialist nurses~All patients:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
79995518|NCT05598879|Other|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
79222637|NCT02501798|Drug|Methylphenidate|Drug: Methylphenidate
79222638|NCT02501798|Drug|Placebo|Drug: Placebo
79222639|NCT02501720|Procedure|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
79365291|NCT04626050|Behavioral|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
79365292|NCT04626050|Behavioral|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
79222640|NCT02501720|Procedure|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
79222641|NCT02501720|Procedure|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
79222642|NCT02174367|Device|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
79365293|NCT04625023|Other|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
79995519|NCT03540069|Behavioral|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
79995520|NCT04490343|Diagnostic Test|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
79995521|NCT03696264|Dietary Supplement|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
79365294|NCT04624074|Behavioral|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
79995522|NCT04472949|Drug|Durvalumab|Durvalumab: 1500 mg iv
79995523|NCT04472949|Drug|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
79995524|NCT04472949|Drug|etoposide|Etoposide: 100 mg/m2 iv
79517547|NCT02239380|Drug|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to < 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
79517548|NCT02239770|Drug|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
79674873|NCT01309165|Behavioral|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
79674874|NCT01309165|Behavioral|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
79674875|NCT01308853|Device|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
79674876|NCT02890888|Other|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
79674877|NCT04517331|Procedure|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
79222643|NCT05503004|Behavioral|Prehabilitation|10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.
79222644|NCT05503004|Behavioral|Standard care|Standard care before surgery
79222645|NCT02169609|Drug|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
79228066|NCT00735657|Procedure|Pars Plana Vitrectomy|Peribulbar block
79995525|NCT04472949|Radiation|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
79995526|NCT03696186|Drug|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
79995527|NCT03696186|Drug|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
79995528|NCT03696186|Drug|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
79995529|NCT03696186|Drug|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
79995530|NCT03696186|Drug|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
79995531|NCT03696186|Drug|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
79995532|NCT03699072|Device|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
79995533|NCT03698916|Drug|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
79995534|NCT03698838|Device|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
79365295|NCT04623710|Drug|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
79517549|NCT02239770|Drug|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
79517550|NCT02241486|Drug|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
79517551|NCT02241720|Drug|regorafenib|
79995535|NCT03695952|Drug|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
79222646|NCT02499614|Drug|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
79222647|NCT02169687|Device|HIFU|High Intensity focalized Ultrasounds
79995536|NCT03695874|Other|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
79365296|NCT04618757|Behavioral|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
79365297|NCT04618757|Behavioral|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
79517552|NCT02244840|Device|Electronic bidet|commercial electronic bidet
79517553|NCT02244840|Device|Sitz bath|Conventional sitz bath
79517554|NCT02244918|Drug|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
79517555|NCT02244918|Behavioral|Smoking Cessation Counseling|
79995537|NCT03695874|Other|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
79995538|NCT04458597|Radiation|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
79222648|NCT02501876|Other|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
79222649|NCT02169765|Other|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
79222650|NCT02169765|Other|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
79222651|NCT03341468|Device|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
79222652|NCT02169843|Drug|Sevoflurane|inhale Sevoflurane
79222653|NCT02169843|Drug|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
79222654|NCT02169843|Drug|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
79222655|NCT03341390|Drug|Aspirin|1 x 325 mg tablet of aspirin administered once daily
79365298|NCT04618757|Device|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
79517556|NCT02246010|Dietary Supplement|Lactose- free milk|Lactose- free milk
79517557|NCT02247336|Behavioral|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
79517558|NCT02249052|Drug|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
79517559|NCT02249052|Drug|placebo|Placebo
79517560|NCT02250612|Drug|1 drop of 0.375% SYL040012 (bamosiran)|
79517561|NCT02250612|Drug|1 drop of 0.750% SYL040012 (bamosiran)|
79517562|NCT02250612|Drug|1 drop of 1.125% SYL040012 (bamosiran)|
79517563|NCT02250612|Drug|1 drop of 1.5% SYL040012 (bamosiran)|
79517564|NCT02250612|Drug|1 drop of 0.5 % timolol maleate|
79517565|NCT02251236|Drug|Stribild|To be administered orally, once daily with food.
79517566|NCT02251236|Drug|Genvoya|To be administered orally, once daily with food.
79517567|NCT02251938|Drug|DE-109 440 μg|Medium Dose
79517568|NCT02252562|Device|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
79517569|NCT02252718|Other|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
79517570|NCT02255604|Drug|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
79517571|NCT02255604|Drug|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
79517572|NCT02255604|Drug|0.1 ml Isoton saline|4 injection into a lymphnode
79517573|NCT02256072|Other|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
79517574|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
79995539|NCT03695796|Diagnostic Test|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
79517575|NCT02258256|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
79995540|NCT03695640|Drug|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
79222656|NCT03341390|Drug|BMS-986177|200 mg of BMS-986177 administered twice daily
79222657|NCT03341390|Drug|Placebo|200 mg of Placebo administered twice daily
79222658|NCT02169921|Device|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
79517576|NCT02258412|Drug|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
79517577|NCT02258412|Drug|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
79222659|NCT02499536|Device|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
79222660|NCT02174445|Drug|Imatinib|Imatinib, 400 to 800 mg p.o., daily
79222661|NCT02174445|Drug|Nilotinib|300mg p.o., twice-daily
79222662|NCT02501408|Device|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
79222663|NCT02499458|Other|None- observational study|
79222664|NCT00708032|Device|spectacles|habitual spectacles
79222665|NCT00708032|Device|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
79222666|NCT02178267|Dietary Supplement|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
79222667|NCT00707174|Drug|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
79517578|NCT02260440|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
79517579|NCT02260440|Drug|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
79517580|NCT02262078|Drug|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
79517581|NCT02262078|Other|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
79995541|NCT03695640|Procedure|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
79995542|NCT03702114|Device|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
79995543|NCT03698760|Diagnostic Test|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
79995544|NCT03702036|Drug|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
79995545|NCT03698682|Drug|Levofloxacin 500mg|One tablet per day for 7 days.
79674878|NCT04517331|Procedure|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
79995546|NCT03695562|Procedure|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
79995547|NCT03695328|Behavioral|physical activity level|
79365299|NCT04606459|Device|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
79365300|NCT04606459|Other|Optimal medical therapy|Guideline-directed medical therapy
79517582|NCT02267226|Drug|Octafibrin|
79517583|NCT02267382|Drug|VT-1161|
79995548|NCT03695328|Behavioral|Dietary Intake|
79222668|NCT00707174|Drug|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
79517584|NCT02267382|Drug|Placebo|
79674879|NCT01240148|Drug|AZD3161|Single dose, intradermal injection
79674880|NCT01240148|Drug|Lidocaine|Single dose, intradermal injection
79674881|NCT01240148|Drug|AZD3161 Placebo|
79674882|NCT04325191|Dietary Supplement|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
79674883|NCT04325191|Other|Placebo|aily consumption of a high sodium diet and placebo for 10 days
79674884|NCT04324879|Drug|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
79674885|NCT04517292|Drug|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
79674886|NCT04517292|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
79222669|NCT02177019|Other|Personalized health plan|
79222670|NCT03341234|Drug|Bupivacaine|30 ml %0,25 bupivacaine
79222671|NCT03341234|Drug|Saline|2 ml saline subcutaneously
79222672|NCT03341234|Device|Ultrasound|Ultrasound guided block
79222673|NCT02178423|Procedure|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
79365301|NCT04601363|Device|Patient Specific Rod|Posterior spinal fusion rod
79365302|NCT04598269|Drug|ATI-1777|ATI-1777 topical solution 2.0% w/w
79365303|NCT04598269|Drug|Vehicle|Vehicle topical solution containing no ATI-1777
79365304|NCT04593407|Procedure|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
79517585|NCT02267538|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
79674887|NCT00482846|Biological|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
79674888|NCT00482846|Drug|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
79674889|NCT00482846|Other|questionnaire administration|Day -5 to Day +28
79674890|NCT00482846|Procedure|autologous peripheral blood stem cell transplantation|Day 0
79674891|NCT00482846|Other|quality-of-life assessment|Day -5 to Day +28
79674892|NCT01308736|Drug|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
79674893|NCT01308736|Drug|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
79674894|NCT04517214|Drug|Toripalimab|PD-1 inhibitor
79674895|NCT04517214|Radiation|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
79995549|NCT04648098|Other|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
79995550|NCT03029832|Drug|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
79995551|NCT03029832|Drug|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
79517586|NCT02267538|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation after surgery."
79517587|NCT02267772|Drug|IV Acetaminophen|IV Acetaminophen
79517588|NCT02267772|Drug|IV Morphine|IV Morphine
79517589|NCT02267850|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
79517590|NCT02267850|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
79517591|NCT02267850|Device|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
79674896|NCT04517214|Drug|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
79674897|NCT04517214|Drug|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
79674898|NCT01240187|Drug|perampanel|Single dose of 6 tablets 2 mg orally
79674899|NCT01240187|Drug|perampanel|Single dose of 1 tablet 12 mg orally
79674900|NCT00483054|Drug|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
79674901|NCT00483054|Drug|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
79222674|NCT02499224|Drug|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
79222675|NCT02169999|Other|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
79222676|NCT03120416|Behavioral|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
79365305|NCT04593407|Procedure|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
79365306|NCT04593212|Diagnostic Test|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
79517592|NCT02268942|Device|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
79517593|NCT02268942|Procedure|Thoracotomy|Thoracotomy implant technique
79517594|NCT02269488|Drug|MEDI3250|MEDI3250
79674902|NCT01240226|Drug|GDC-0941|Oral repeating dose
79517595|NCT02271906|Drug|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
79674903|NCT01240226|Drug|GDC-0941|Oral repeating dose
79674904|NCT01240226|Drug|ketoconazole|Oral repeating dose
79674905|NCT01240824|Drug|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
79517596|NCT02272686|Drug|Ibrutinib|560 mg by mouth daily.
79674906|NCT00482924|Other|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
79674907|NCT01240941|Drug|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
79674908|NCT01240941|Drug|Exemestane|25 mg orally daily
79222677|NCT02177097|Biological|Blood samples|4 x 10 ml blood samples.
79222678|NCT02178501|Dietary Supplement|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
79222679|NCT04496102|Device|Triathlon|Modern TKA design (Triathlon) with patellar resurfacing
79222680|NCT02499068|Device|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
79222681|NCT03337022|Drug|CC-90006|CC-90006
79222682|NCT03337022|Other|Placebo|Placebo
79222683|NCT02178735|Procedure|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
79517597|NCT02273310|Behavioral|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
79517598|NCT02274870|Drug|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
79517599|NCT02274870|Drug|Bupivacaine HCl|Administered via CFNB
79524788|NCT05768490|Radiation|brain radiotherapy|Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.
79524789|NCT05768490|Drug|Almonertinib|almonertinib po 110mg QD
79524790|NCT05768464|Drug|Toripalimab|240mg intravenously every 3 weeks
79674909|NCT01240941|Drug|Goserelin|3.6 mg orally monthly
79674910|NCT04517097|Biological|blood sample|one blood sample and one questionnaire to each patient and salaried staff included
79674911|NCT00482963|Drug|levonorgestrel, efavirenz|
79674912|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
79365307|NCT04591015|Behavioral|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
79517600|NCT02277054|Device|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
79222684|NCT02178735|Procedure|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
79222685|NCT03120494|Drug|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
79517601|NCT02278146|Device|ParaPatch|A device for the treatment of urinary incontinence
79517602|NCT02279082|Drug|DFN-02|Active Experimental Drug
79517603|NCT02279160|Drug|APD811|
79517604|NCT02279160|Drug|Placebo|Placebo
79517605|NCT02281344|Drug|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
79517606|NCT02281422|Drug|BIA 2-093|
79674913|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
79517607|NCT02282514|Biological|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
79517608|NCT02282514|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
79517609|NCT02282514|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
79517610|NCT02282514|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
79674914|NCT01240980|Drug|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
79674915|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
79674916|NCT01240980|Drug|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
79674917|NCT01240980|Drug|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
79674918|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
79821459|NCT04078932|Behavioral|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
79222686|NCT03537573|Behavioral|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
79365308|NCT04591015|Behavioral|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
79517611|NCT02282514|Drug|Methylprednisolone|Steroid
79517612|NCT02282514|Drug|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
79517613|NCT02282514|Drug|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
79517614|NCT02282904|Drug|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
79517615|NCT02282904|Biological|Donor peripheral blood stem cells.|Infuse donor graft.
79517616|NCT02282904|Drug|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
79517617|NCT02282904|Radiation|Total body 200cGy|Day -1
79674919|NCT01240980|Drug|Placebo|Solution, Oral, 0 mg, once daily, 1 day
79674920|NCT01240980|Drug|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
79674921|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
79674922|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
79674923|NCT01240980|Drug|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
79674924|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
79674925|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
79517618|NCT02282904|Drug|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
79517619|NCT02282904|Drug|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
79517620|NCT02282904|Drug|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
79222687|NCT03537573|Behavioral|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
79517621|NCT02283528|Device|Stryker Hybrid|Place Hybrid arch bars
79517622|NCT02283528|Device|Erich|Control group is Erich arch bars
79517623|NCT02283840|Drug|BIA 2-093|
79517624|NCT02284386|Drug|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
79517625|NCT02284386|Drug|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
79517626|NCT02284464|Drug|Prednisone withdrawal|Withdrawal of steroids
79228067|NCT03309488|Diagnostic Test|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
79228068|NCT02230059|Other|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
79365309|NCT04588233|Dietary Supplement|Melatonin|Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
79365310|NCT04588233|Other|Placebo|Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
79365311|NCT04583891|Behavioral|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
79365312|NCT04583891|Behavioral|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
79365313|NCT04583891|Behavioral|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
79517627|NCT02284464|Drug|Prednisone continuation|Continuation of steroids
79517628|NCT02284854|Drug|BIA 2-093|
79365314|NCT04582994|Behavioral|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
79365315|NCT04582994|Behavioral|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
79517629|NCT02284854|Drug|Carbamazepine|
79517630|NCT02285634|Drug|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
79517631|NCT02285634|Drug|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
79517632|NCT02285634|Drug|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
79517633|NCT02285634|Drug|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
79517634|NCT02287350|Drug|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
79517635|NCT02288364|Drug|1% Lidocaine|
79517636|NCT02288364|Drug|1% Lidocaine plus sodium bicarbonate|
79517637|NCT02289222|Drug|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
79517638|NCT02289222|Drug|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
79517639|NCT02289222|Drug|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
79517640|NCT02291016|Drug|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
79517641|NCT02291016|Other|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
79517642|NCT02291718|Drug|Isovue|iodine contrast
79517643|NCT02292186|Drug|Revusiran (ALN-TTRSC)|
79517644|NCT02293044|Device|Crest® Sensi-Stop™ Strips|
79517645|NCT02293512|Behavioral|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
79517646|NCT02293512|Behavioral|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
79222688|NCT03537573|Behavioral|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
79222689|NCT03120962|Drug|Oxycodone|Oxycodone 20mg/day, for 4 weeks
79821460|NCT00732758|Dietary Supplement|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
79222690|NCT03120962|Drug|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
79222691|NCT03120962|Drug|Famciclovir|Famciclovir 500mg three-times daily for 7 days
79222692|NCT02178813|Drug|Administration of minocycline|"Administration of minocycline with the following schedule:~Day prior to procedure: 800mg p.o., 700mg p.o.~Day of procedure: 600mg i.v., 500mg p.o.~Day after procedure: 400mg p.o., 400mg p.o."
79517647|NCT02293512|Behavioral|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
79517648|NCT02296164|Drug|Valchlor|Valchlor gel 0.016%
79365316|NCT04582994|Behavioral|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
79365317|NCT04570943|Combination Product|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
79517649|NCT02297100|Drug|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
79517650|NCT02297100|Procedure|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
79517651|NCT02297100|Procedure|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
79222693|NCT03341000|Device|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
79222694|NCT03340922|Device|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
79222695|NCT03340922|Device|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
79517652|NCT02299050|Drug|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
79517653|NCT02302092|Drug|Flomoxef|Flomoxef intravenous infusion
79517654|NCT02302092|Drug|Cefepime|Cefepime intravenous infusion
79821461|NCT00732758|Dietary Supplement|Placebo Tablet|Placebo Tablet once daily for 6 months
79821462|NCT00741351|Drug|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
79821463|NCT00741351|Drug|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
79995552|NCT04412187|Diagnostic Test|[18F]-GE-180 PET|serial [18F]-GE-180 PET imaging to assess microglia activation
79365318|NCT04570943|Radiation|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
79517655|NCT02303184|Drug|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
79517656|NCT02303184|Drug|Sham|suprachoroidal sham procedure
79517657|NCT02303184|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
79517658|NCT02304432|Drug|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
79517659|NCT02304432|Drug|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
79517660|NCT02304432|Drug|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
79517661|NCT02306928|Other|Blood draw|
79517662|NCT02307318|Device|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
79524791|NCT05768464|Drug|Axitinib|5mg orraly twice daily
79674926|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
79674927|NCT01240772|Device|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
79674928|NCT01240772|Device|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
79674929|NCT01241019|Drug|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
79674930|NCT01240928|Drug|MSK-2206|Level 1: MK-2206 135mg weekly
79517663|NCT02307552|Device|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
79517664|NCT02312154|Device|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
79517665|NCT02312310|Dietary Supplement|Cocoa Flavanol|12 weeks administration of cocoa flavanol
79517666|NCT02314104|Drug|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
79517667|NCT02314260|Other|bishop score calculation|Assessment of bishop score by vaginal examination
79517668|NCT02314260|Other|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
79995553|NCT04412187|Diagnostic Test|3T MRI|serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
79517669|NCT02314260|Other|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
79517670|NCT02314260|Procedure|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
79995554|NCT04412187|Diagnostic Test|immune cell profiling in blood|Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
79222696|NCT02170311|Drug|Z-213|
79365319|NCT04568226|Other|ConquerFear Intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
79365320|NCT04568226|Other|Active control: Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
79517671|NCT02320812|Biological|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
79517672|NCT02321748|Drug|Montelukast|
79222697|NCT03121040|Dietary Supplement|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
79517673|NCT02321748|Drug|ASP2151|
79517674|NCT02322528|Drug|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
79517675|NCT02323854|Device|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
79517676|NCT02323854|Procedure|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
79517677|NCT02327052|Other|No intervention was performed.|No intervention was performed.
79517678|NCT02330094|Drug|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
79517679|NCT02330094|Drug|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
79517680|NCT02330172|Other|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
79674931|NCT01240928|Drug|Exemestane|Level 1: Exemestane - 25mg daily
79674932|NCT01240928|Drug|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
79995555|NCT03695016|Behavioral|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
79995556|NCT04391595|Drug|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
79222698|NCT02177253|Drug|Ipratropium bromide / Salbutamol|
79222699|NCT02177253|Drug|Placebo Inhalation solution|
79222700|NCT02177253|Drug|Ipratropium bromide|
79222701|NCT02177253|Drug|COMBIVENT Inhalation Aerosol|
79222702|NCT02177253|Drug|Placebo Inhalation Aerosol|
79222703|NCT03121118|Other|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
79517681|NCT02331108|Drug|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
79222704|NCT02170467|Other|assessment of the intestinal permeability|
79517682|NCT02340156|Genetic|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
79365321|NCT04567615|Biological|Nivolumab|Specified dose on specified days
79517683|NCT02340156|Drug|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
79222705|NCT02178891|Device|extra short implant|
79995557|NCT04391595|Drug|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
79995558|NCT04252638|Behavioral|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
79222706|NCT03120884|Procedure|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
79222707|NCT03120884|Procedure|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
79365322|NCT04567615|Biological|Relatlimab|Specified dose on specified days
79365323|NCT04566692|Biological|IGSC 20%|SC infusion pump.
79517684|NCT02343276|Drug|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
79517685|NCT02343276|Other|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
79365324|NCT04564183|Other|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
79517686|NCT02347410|Device|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
79517687|NCT02347488|Device|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
79517688|NCT02347488|Procedure|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
79517689|NCT02348658|Drug|TAK-536TCH|TAK-536TCH tablets
79995559|NCT04252638|Behavioral|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
79222708|NCT02498990|Behavioral|Low calorie diet followed by life style intervention|"Low calorie diet of 800 kcal/day for 7 weeks.~Life style intervention for the remaining study period"
79222709|NCT02177331|Drug|Lacidipine|
79222710|NCT03336788|Device|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
79222711|NCT03336788|Device|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
79222712|NCT02170545|Other|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
79222713|NCT05233046|Behavioral|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
79222714|NCT05233046|Behavioral|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
79222715|NCT02179125|Device|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
79222716|NCT03340688|Procedure|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
79222717|NCT02177409|Drug|Telmisartan|
79222718|NCT02177409|Device|Amlodipine|
79517690|NCT02349438|Device|senofilcon A|A soft spherical contact lens
79995560|NCT05598567|Other|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
79222719|NCT02177409|Drug|Placebo|
79365325|NCT04564183|Other|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
79365326|NCT04564183|Radiation|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
79365327|NCT04564183|Diagnostic Test|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
79365328|NCT04548063|Other|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
79517691|NCT02349438|Device|lotrafilcon B|
79517692|NCT02350998|Drug|OTO-201|
79674933|NCT04517175|Diagnostic Test|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
79517693|NCT02351700|Drug|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
79517694|NCT02351700|Drug|IV Placebo|IV Placebo intraoperatively and postoperatively
79222720|NCT02494388|Procedure|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
79674934|NCT00481169|Drug|Bazedoxifene Acetate (TSE-424)|
79995561|NCT05598567|Other|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
79222721|NCT02170623|Drug|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
79222722|NCT02170623|Drug|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
79222723|NCT02170623|Drug|Pantoprazole|40 mg pantoprazole
79222724|NCT02170623|Drug|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
79365329|NCT04548063|Other|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
79365330|NCT04548063|Other|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
79365331|NCT04548050|Other|Nurses training|"Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~Presentation to all staff of a service protocol for early colostrum donation."
79365332|NCT04547010|Dietary Supplement|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
79365333|NCT04536857|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
79517695|NCT02353806|Drug|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
79517696|NCT02354352|Drug|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
79517697|NCT02354352|Drug|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
79517698|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1|packet containing 10^9 cells of Bifidobacteria adolescentis BD1
79517699|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12
79517700|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
79517701|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
79517702|NCT02355210|Dietary Supplement|galactooligosaccharide|5 g galactooligosaccharide
79517703|NCT02355210|Dietary Supplement|Placebo|lactose powder, 5 grams
79517704|NCT02356692|Device|enfilcon A|Test lens
79517705|NCT02356692|Device|senofilcon A|Control lens
79517706|NCT02357394|Device|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
79517707|NCT02357706|Device|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
79517708|NCT02357706|Device|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
79517709|NCT02359110|Drug|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
79517710|NCT02359110|Other|Placebo|Patient will receive placebo tab less than 1 hour before surgery
79517711|NCT02360124|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
79517712|NCT02360124|Other|Water as placebo|topical application of water as a placebo in the control arm
79517713|NCT02360124|Other|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
79517714|NCT02364570|Other|Glucose (100g)|Ingestion of glucose (100g)
79517715|NCT02364570|Other|Glucose (75g)|Ingestion of glucose (75g)
79517716|NCT02364570|Other|Whole Eggs|Ingestion of 1.5 whole eggs
79674935|NCT04516980|Other|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
79674936|NCT01240421|Drug|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
79674937|NCT04516863|Diagnostic Test|German Autobiographical Memory Interview short-form|Diagnostic Test
79674938|NCT01240967|Drug|TC-5214|Oral tablets, single dose
79995562|NCT03701880|Drug|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
79995563|NCT03701880|Drug|Bisoprolol|Bisoprolol is beta-blocker
79995564|NCT03692754|Drug|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
79995565|NCT03692754|Drug|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
79517717|NCT02364570|Other|Egg Whites|Ingestion of 7 egg whites
79517718|NCT02364570|Other|Egg Yolks|Ingestion of 2 egg yolks
79517719|NCT02367066|Drug|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
79517720|NCT02367066|Other|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
79517721|NCT02369172|Drug|Bupropion|
79517722|NCT02369172|Drug|ASP2151|
79821464|NCT00741351|Drug|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
79821465|NCT02582268|Device|intrauterine device TCu 380A|
79995566|NCT03692754|Drug|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
79995567|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
79517723|NCT02369796|Drug|TAK-448|TAK-448 solution for subcutaneous injection
79995568|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
79222725|NCT02494544|Device|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith & Nephew, or Stryker
79222726|NCT02494544|Device|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
79222727|NCT02170701|Drug|BIBR 1048|Ascending doses (in mg) given twice daily
79222728|NCT02498756|Biological|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
79222729|NCT02498756|Drug|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
79365334|NCT04536142|Diagnostic Test|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
79517724|NCT02370810|Behavioral|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
79517725|NCT02371668|Biological|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
79517726|NCT02371668|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
79222730|NCT02255721|Behavioral|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
79222731|NCT02255721|Behavioral|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
79222732|NCT03336632|Drug|Chidamide|20 mg orally, twice weekly from D-7 to D+14
79365335|NCT04536142|Diagnostic Test|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
79365336|NCT04534153|Drug|Fexofenadine Hydrochloride without sodium lauryl sulfate|without sodium lauryl sulfate
79517727|NCT02372682|Device|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
79517728|NCT02373852|Device|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
79517729|NCT02374164|Drug|Febuxostat XR|Febuxostat XR capsules
79517730|NCT02374398|Drug|Tranexamic Acid|see arm/group descriptions
79517731|NCT02374398|Device|Aquamantys System|see arm/group descriptions
79674939|NCT04517019|Device|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
79821466|NCT02582268|Radiation|Trans-abdominal sonography|
79821467|NCT02582190|Drug|Colchicine group|antiarrhythmic therapy plus colchicine & antiarrhythmic therapy alone.
79821468|NCT00699153|Drug|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
79821469|NCT00699153|Drug|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
79821470|NCT02582112|Other|Active Comparator: Warming group|Placebo Comparator: Control group
79821471|NCT05742243|Drug|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
79821472|NCT05742243|Drug|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
79821473|NCT04077918|Dietary Supplement|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
79821474|NCT04076748|Drug|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
79821475|NCT04076748|Drug|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
79995569|NCT03694860|Other|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
79995570|NCT03694782|Behavioral|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
79222733|NCT03336632|Drug|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
79365337|NCT04534153|Drug|Fexofenadine Hydrochloride with sodium lauryl sulfate|with sodium lauryl sulfate
79365338|NCT04533412|Behavioral|Self-management barrier support|For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.
79365339|NCT04533412|Behavioral|Basic COPD Education|"The attention control will consist of 4 visits by a COPD educator to the home to review the COPD education booklet. During the first visit, this COPD educator will review the COPD 1-2-3 booklet in its entirety with the patient. During visits 2 and 3, the COPD educator will make a visit to check in with the patient, ask how they are doing with their respiratory symptoms, and review any sections of the COPD 1-2-3 booklet the patient chooses. The COPD educator will recommend visits every 2 months but the patient and COPD educator may choose to modify the interval as needed. If the patient appears to be experiencing worsening respiratory symptoms during any visit, the COPD educator will notify the patient's physician."
79365340|NCT04525014|Drug|RRx-001|RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
79365341|NCT04525014|Drug|Temozolomide|100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children <0.5 m2) daily for 5 days beginning on day 1 of each cycle
79517732|NCT02374398|Other|Control|Standard Electro-cautery and Saline
79517733|NCT02377752|Biological|Olaratumab|Administered IV
79517734|NCT02377752|Drug|Doxorubicin|Administered IV
79517735|NCT02377986|Behavioral|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
79517736|NCT02377986|Behavioral|In-Home Decluttering|In-home decluttering practice
79674940|NCT00483093|Drug|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
79674941|NCT00483093|Drug|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
79674942|NCT00487916|Drug|AMA1-C1/ISA 720|
79674943|NCT00483132|Drug|interferon alpha 2a|
79674944|NCT00483080|Drug|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
79222734|NCT03336632|Drug|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
79222735|NCT02498288|Drug|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
79222736|NCT02498288|Drug|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
79222737|NCT02498288|Drug|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
79222738|NCT02756403|Drug|Azithromycin|500 mg
79674945|NCT00483210|Drug|Fenofibrate|
79674946|NCT00487955|Procedure|Resting Energy Expenditure examination|
79674947|NCT00483288|Other|educational intervention|
79222739|NCT02756403|Drug|Doxycycline|200 mg
79222740|NCT02756403|Drug|Metronidazole|500 mg
79222741|NCT02756403|Drug|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
79222742|NCT03336476|Device|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
79222743|NCT03336476|Device|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
79674948|NCT00483288|Other|questionnaire administration|
79674949|NCT00483288|Other|study of socioeconomic and demographic variables|
79674950|NCT00483288|Other|survey administration|
79674951|NCT00487994|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
79674952|NCT00487994|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
79674953|NCT00487994|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
79674954|NCT04516824|Procedure|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
79674955|NCT02955342|Other|no intervention|no intervention
79222744|NCT03539289|Behavioral|MUFA Diet|Control of patient MUFA Diet
79517737|NCT02377674|Device|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
79517738|NCT02378844|Device|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
79222745|NCT03539289|Behavioral|SFA Diet|Control of patient SFA Diet
79222746|NCT02493296|Other|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
79517739|NCT02378844|Device|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
79517740|NCT02379858|Drug|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
79365342|NCT04525014|Drug|Irinotecan|90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
79365343|NCT04524611|Drug|Risankizumab|Intravenous (IV) Infusion
79674956|NCT00483158|Drug|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
79517741|NCT02379858|Drug|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
79517742|NCT02381418|Biological|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
79517743|NCT02382744|Device|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
79517744|NCT02382744|Device|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
79674957|NCT00488111|Other|Ringer's Lactate|Ringer's Lactate was used 15min before operation
79222747|NCT02179281|Device|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
79222748|NCT03336320|Device|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
79222749|NCT02494310|Device|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
79222750|NCT03537417|Procedure|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
79222751|NCT02494466|Drug|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
79674958|NCT00488111|Other|6% Starch|6% Starch was used 15min before operation
79222752|NCT02179593|Other|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
79674959|NCT02955381|Device|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
79674960|NCT02955381|Device|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
79365344|NCT04524611|Drug|Risankizumab|Subcutaneous (SC) Injection
79365345|NCT04524611|Drug|Ustekinumab|Intravenous (IV) infusion
79365346|NCT04524611|Drug|Ustekinumab|Subcutaneous (SC) injection
79674961|NCT00483197|Device|VentrAssistTM Left Ventricular Assist Device|
79674962|NCT02955420|Drug|BC 007|
79674963|NCT02955420|Drug|NaCl 0.9 %|
79674964|NCT02955303|Other|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
79674965|NCT01308580|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
79674966|NCT01308580|Drug|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
79365347|NCT04519580|Diagnostic Test|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
79365348|NCT04515147|Biological|CVnCoV 6 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
79365349|NCT04515147|Biological|CVnCoV 12 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
79365350|NCT04515147|Biological|Hepatitis A vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
79365351|NCT04515147|Biological|Pneumococcal vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
79365352|NCT04515147|Biological|CVnCoV 12μg|Participants will receive an intramuscular injection by needle in the deltoid area.
79674967|NCT00483275|Drug|Alfacalcidol|
79517745|NCT02384070|Procedure|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
79517746|NCT02384070|Drug|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
79674968|NCT00483275|Behavioral|Balance, gait and strength training|
79674969|NCT00483275|Behavioral|Patient education|
79674970|NCT00483444|Behavioral|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
79674971|NCT02890810|Other|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
79821476|NCT00698997|Behavioral|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
79821477|NCT00698997|Behavioral|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
79222753|NCT02179593|Other|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
79222754|NCT03537339|Other|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
79821478|NCT00711087|Drug|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
79222755|NCT02177487|Drug|Telmisartan/hydrochlorothiazide|
79222756|NCT02177565|Biological|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
79222757|NCT03342872|Behavioral|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
79365353|NCT04511494|Dietary Supplement|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
79365354|NCT04493411|Procedure|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~Baseline: (before or after 1-2 cycles of induction therapy)~Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~Between Week 24 - 36 (before starting maintenance therapy)~Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
79365355|NCT04493411|Procedure|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~Baseline: (before or after 1-2 cycles of induction therapy)~Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~Between Week 24 - 36 (before starting maintenance therapy)~Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
79365356|NCT04493177|Behavioral|Educational intervention|Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.
79365357|NCT04493177|Other|Conventional treatment Guia de Practica Clinica IMSS-029-08|Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
79674972|NCT02890810|Other|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
79674973|NCT00483314|Drug|N-acetylcysteine|2 g p.o. BID x 60 days
79674974|NCT04516629|Diagnostic Test|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
79674975|NCT01308463|Device|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
79674976|NCT04324918|Drug|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
79674977|NCT04324918|Drug|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
79674978|NCT00483353|Procedure|Intra-nasal allergen challenge with Phleum pratense.|
79674979|NCT00483353|Procedure|Collection of nasal effluent using filter paper.|
79674980|NCT00483353|Procedure|Measurement of nasal congestion using acoustic rhinometry.|
79674981|NCT00483483|Behavioral|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
79821479|NCT00711087|Other|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
79517747|NCT02384070|Drug|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
79517748|NCT02384070|Drug|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
79222758|NCT03342872|Behavioral|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
79222759|NCT02177643|Drug|Diacerein|Diacerein oral capsules
79222760|NCT02177643|Drug|Placebo|Placebo oral capsules
79365358|NCT04491877|Biological|RSV vaccine formulation 1|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
79365359|NCT04491877|Biological|RSV vaccine formulation 2|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
79365360|NCT04491877|Biological|Placebo|Pharmaceutical form: Suspension Route of administration: Intranasal
79365361|NCT04479618|Device|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
79517749|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
79517750|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Reference)|
79517751|NCT02385240|Drug|Placebo gel|
79821480|NCT04078308|Biological|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 & 3
79821481|NCT04078308|Other|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
79222761|NCT03340376|Drug|Atezolizumab|atezolizumab
79222762|NCT03340376|Drug|Doxorubicin|Doxorubicin
79517752|NCT02385318|Drug|Ingenol Mebutate (Perrigo)|
79674982|NCT00483483|Behavioral|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
79674983|NCT01308424|Drug|BTL TML HSV|Sublingual micro-dosing for 7 days
79674984|NCT01308424|Drug|Matching placebo|sublingual dosing for 7 days
79517753|NCT02385318|Drug|Ingenol Mebutate (Reference)|
79517754|NCT02385318|Drug|Placebo gel|
79517755|NCT02387268|Device|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
79517756|NCT02387502|Device|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
79517757|NCT02387502|Device|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
79517758|NCT02387502|Device|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
79517759|NCT02387814|Drug|Abemaciclib|Administered Orally
79674985|NCT05644288|Other|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
79674986|NCT00483522|Behavioral|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
79674987|NCT00483392|Drug|metformin, rosiglitazone|
79674988|NCT00483431|Dietary Supplement|Placebo|
79674989|NCT00483431|Dietary Supplement|MK7|
79222763|NCT02030223|Procedure|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
79517760|NCT02391714|Procedure|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
79517761|NCT02391714|Drug|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
79995571|NCT03694782|Behavioral|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
79517762|NCT02391714|Drug|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
79517763|NCT02391714|Other|Oxygen|100% oxygen via nasal mask.
79674990|NCT00483600|Drug|fondaparinux|injections of 2.5mg every other day for 4 weeks
79821482|NCT02582034|Radiation|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~A dose at the treated healthy liver < 120 Gy in case of lobar treatment~Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
79995572|NCT03694782|Behavioral|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
79222764|NCT03340298|Dietary Supplement|fiber|the intervention of different sources of dietary fibers
79995573|NCT03688308|Procedure|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
79222765|NCT03537105|Procedure|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
79365362|NCT04479618|Device|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
79365363|NCT04479618|Device|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
79517764|NCT02391714|Other|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
79222766|NCT02182167|Drug|IV N-acetylcysteine (NAC)|
79222767|NCT02182167|Drug|Water|
79222768|NCT03537885|Diagnostic Test|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
79222769|NCT03537885|Diagnostic Test|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
79222770|NCT03537885|Diagnostic Test|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
79517765|NCT02392494|Drug|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
79222771|NCT03336086|Combination Product|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
79517766|NCT02392806|Device|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
79517767|NCT02392806|Device|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B&B Bubbler at time of extubation
79517768|NCT02394912|Device|vena cava filter implantation (LUMIFI with Crux VCF System)|
79517769|NCT02395692|Other|Treatment|Correlative studies
79517770|NCT02395692|Drug|Methoxyamine|Given PO
79517771|NCT02395692|Drug|Temozolomide|Given PO
79517772|NCT02396160|Dietary Supplement|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
79674991|NCT00488189|Drug|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
79674992|NCT04516551|Biological|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
79674993|NCT00488228|Behavioral|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
79674994|NCT00483639|Other|Medical chart review|medical chart review
79995574|NCT03688308|Procedure|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
79995575|NCT03692520|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
79995576|NCT04224558|Drug|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
79222772|NCT02030145|Procedure|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
79674995|NCT00483639|Other|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
79674996|NCT00483639|Procedure|management of therapy complications|management of therapy complications
79674997|NCT00483639|Procedure|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
79674998|NCT00483639|Other|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
79674999|NCT02956421|Biological|RABIPUR®|Biological rabies vaccine
79821483|NCT02582034|Radiation|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
79365364|NCT04476238|Dietary Supplement|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
79517773|NCT02396160|Other|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
79365365|NCT04476238|Other|Placebo|250 ml water taken by mouth
79675000|NCT02956421|Biological|PIKA rabies vaccine|Biological rabies vaccine
79365366|NCT04476043|Drug|INCB054707|Oral; Tablet
79365367|NCT04476043|Drug|Placebo|Oral; Tablet
79517774|NCT02397564|Device|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
79517775|NCT02401464|Drug|TAK-536 Tablet|TAK-536 10 mg tablet
79821484|NCT02581956|Behavioral|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
79821485|NCT02581956|Behavioral|No walking exercise|no exercise
79222773|NCT02030145|Procedure|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
79228069|NCT03309410|Diagnostic Test|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
79365368|NCT04473534|Behavioral|web based cognitive-behavioral therapy|one web session of psycho-education about sleep
79517776|NCT02401464|Drug|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
79517777|NCT02401464|Drug|TAK-536 Ganule Formulation|TAK-536 granule formulation
79517778|NCT02401542|Drug|Vofatamab|
79517779|NCT02401542|Drug|Docetaxel|
79517780|NCT02401542|Drug|Placebo|
79517781|NCT02408796|Drug|OTO-201|
79821486|NCT05275920|Other|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
79821487|NCT05275920|Other|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
79995577|NCT04224558|Drug|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
79995578|NCT04224558|Drug|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of >1000/μL"
79517782|NCT02411916|Biological|misoprostol|rectal insertion
79517783|NCT02413008|Drug|estriol|0.005% estriol vaginal gel
79517784|NCT02413008|Drug|Placebo|placebo vaginal gel
79517785|NCT02413320|Drug|Paclitaxel|
79517786|NCT02413320|Drug|Carboplatin|
79517787|NCT02413320|Drug|Doxorubicin|
79517788|NCT02413320|Drug|Cyclophosphamide|
79517789|NCT02413320|Drug|Docetaxel|
79517790|NCT05719038|Diagnostic Test|observational study|observational study
79517791|NCT05718804|Other|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
79517792|NCT05718726|Other|Questionnaire, interview or observation study|Questionnaire administered by telephone
79517793|NCT05718492|Procedure|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
79675001|NCT04516239|Device|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
79675002|NCT04516239|Device|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
79675003|NCT00483470|Biological|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
79675004|NCT00483470|Biological|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
79517794|NCT05718492|Drug|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
79821488|NCT04250688|Device|Ekso Training with FES|
79517795|NCT05718414|Device|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
79821489|NCT00738530|Drug|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
79995579|NCT04224558|Procedure|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
79821490|NCT00738530|Drug|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
79821491|NCT00738530|Drug|Placebo|IV every 2 weeks
79995580|NCT04224558|Procedure|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10^6 CD34+ cells/kg body weight.
79222774|NCT02498366|Other|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
79365370|NCT04471818|Drug|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
79675005|NCT00483678|Other|counseling intervention|
79675006|NCT00483678|Other|questionnaire administration|
79821492|NCT00711009|Drug|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
79365371|NCT04471818|Other|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
79222775|NCT02182245|Drug|BIBF 1120|
79821493|NCT00711009|Drug|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
79821494|NCT00711009|Drug|raltegravir (RAL)|RAL 400 mg BID
79222776|NCT02182245|Drug|Paclitaxel|
79222777|NCT02182245|Drug|Carboplatin|
79222778|NCT05233124|Drug|Rivaroxaban 15 MG|Rivaroxaban 15mg
79517796|NCT05718336|Other|Integrated care|multi-discipline care program
79995581|NCT04224558|Drug|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
79995582|NCT04224558|Drug|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
79222779|NCT05233124|Drug|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
79222780|NCT05233124|Drug|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
79228070|NCT02230137|Behavioral|Text message arm|Text message sent before each injection of insulin
79228071|NCT05232422|Behavioral|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
79675007|NCT00483678|Procedure|psychosocial assessment and care|
79675008|NCT00483587|Drug|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
79675009|NCT04516590|Other||There was no intervention in this observational study
79675010|NCT00488306|Drug|tigecycline|
79675011|NCT01307800|Drug|LY2140023|Administered orally
79675012|NCT01307800|Drug|Placebo|Administered orally
79675013|NCT04516044|Behavioral|Video games|See arm description
79675014|NCT00483626|Drug|oral sildenafil|
79675015|NCT00483795|Drug|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
79675016|NCT05644210|Drug|Telitacicept|160mg once a week for 24 weeks
79675017|NCT05644210|Drug|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
79675018|NCT05644210|Drug|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
79821495|NCT04076124|Device|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
79821496|NCT04076124|Device|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
79821497|NCT04076124|Device|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
79821498|NCT02592902|Procedure|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
79821499|NCT02592902|Procedure|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
79821500|NCT04062513|Other|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
79821501|NCT04062513|Other|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
79821502|NCT04062513|Other|Standard care|Preterm infants will receive sucrose during heel prick.
79365372|NCT04464434|Procedure|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~Mobilisation~Infusions of CYC 2g/m2 on 1 day.~Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10^6 CD34+ cells per kilogram body weight.~Conditioning~CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10^6/kg."
79517797|NCT05717868|Other|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
79517798|NCT05717868|Other|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
79517799|NCT05717790|Drug|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
79517800|NCT05717790|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
79222781|NCT04494620|Diagnostic Test|Visual Inspection of Oral Cavity for Precancers and Cancer|Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
79517801|NCT05717790|Drug|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
79675019|NCT05644210|Drug|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
79222782|NCT03342794|Procedure|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
79222783|NCT03335930|Behavioral|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
79222784|NCT02493218|Behavioral|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
79222785|NCT02493218|Behavioral|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
79222786|NCT03340142|Device|VIVO™|Diagnose the area of a PVC or VT onset
79222787|NCT03339986|Behavioral|Reduction or Replacement|
79222788|NCT02498054|Behavioral|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
79365373|NCT04463914|Behavioral|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
79517802|NCT05717790|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
79675020|NCT05644210|Drug|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
79675021|NCT05644210|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
79675022|NCT00488384|Drug|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
79222789|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m^2 or 1.1 mg/m^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
79995583|NCT04224558|Drug|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
79222790|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m^2 or 1.1 mg/m^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
79222791|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m^2 as IV infusion on Day 1 and 8 of 21-day cycle
79222792|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle
79222793|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
79222794|NCT03335852|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
79228072|NCT02470442|Drug|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
79821503|NCT04075890|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
79821504|NCT04087850|Behavioral|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
79821505|NCT03825510|Radiation|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to <=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
79995584|NCT04224558|Drug|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
79995585|NCT04224558|Drug|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
79222795|NCT02177721|Biological|Collection of samples|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA."
79222796|NCT03335618|Other|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
79222797|NCT03335618|Other|Passive Activity Monitoring|Passive step tracking without check-ins
79222798|NCT04494464|Other|No intervention|
79365374|NCT04463914|Behavioral|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
79365375|NCT04463914|Behavioral|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
79365376|NCT04454658|Drug|ABBV-744|Tablet; Oral
79365377|NCT04454658|Drug|Navitoclax|Tablet; Oral
79365378|NCT04454658|Drug|Ruxolitinib|Tablet; Oral
79365379|NCT04452526|Other|Best Practice|Receive usual care
79365380|NCT04452526|Other|Educational Intervention|Receive educational materials
79517804|NCT05717634|Diagnostic Test|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
79517805|NCT05717556|Procedure|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
79222799|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
79365381|NCT04452526|Other|Questionnaire Administration|Ancillary studies
79365382|NCT04452526|Other|Reminder|Receive reminder letter
79365383|NCT04434482|Drug|IMP4297(senaparib)|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
79365384|NCT04433091|Drug|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
79365385|NCT04433091|Other|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
79365386|NCT04431518|Drug|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
79517806|NCT05707728|Device|intraoperative ultrasound|intraoperative cranial ultrasound
79821506|NCT00921219|Drug|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
79995586|NCT04224558|Drug|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia & Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
79995587|NCT04224558|Biological|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
79995588|NCT04224558|Drug|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
79365387|NCT04419909|Drug|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
79517807|NCT05602272|Procedure|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
79524792|NCT05768451|Other|Ultrasonic image analysis|Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
79517808|NCT05562648|Other|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
79517809|NCT05562648|Other|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
79517810|NCT05543694|Drug|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
79517811|NCT05542602|Behavioral|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
79222800|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
79517812|NCT05537142|Drug|BV100|Rifabutin for Infusion
79365388|NCT04418843|Procedure|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
79222801|NCT03342482|Other|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
79222802|NCT02180139|Device|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
79365389|NCT04418843|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
79517813|NCT05519748|Behavioral|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
79995589|NCT03089697|Biological|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
79222803|NCT02493140|Dietary Supplement|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
79365390|NCT04418765|Drug|Eptinezumab|Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
79365391|NCT04418765|Drug|Placebo|concentrate for solution for infusion, intravenously
79365392|NCT04417634|Diagnostic Test|RFR|Measurement of resting flow ratio
79365393|NCT04417634|Diagnostic Test|FFR|Measurement of fractional flow reserve
79365394|NCT04416321|Device|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
79517814|NCT05495568|Biological|CT-P17|CT-P17 40mg will be subcutaneous administered
79517815|NCT05495568|Biological|EU-approved Humira|subcutaneous administration
79821507|NCT04076514|Procedure|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
79821508|NCT02567097|Behavioral|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
79821509|NCT02580552|Drug|Cobomarsen|
79995590|NCT03089697|Other|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
79222804|NCT02493140|Dietary Supplement|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
79995591|NCT05598411|Drug|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
79995592|NCT05598411|Drug|Oral placebo|oral placebo 24mg qd, 2-week duration
79995593|NCT03688230|Drug|abituzumab|1000 mg IV
79365395|NCT04413461|Other|TENS|Transcutaneous Electro Neuro Stimulation
79365396|NCT04413461|Other|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
79365397|NCT04399252|Dietary Supplement|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
79365398|NCT04399252|Dietary Supplement|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
79365399|NCT04379687|Other|Virtual reality|Use of virtual reality glasses for balance work
79365400|NCT04379687|Other|Control group|Balance treatment with according to Bayouk physiotherapy
79365401|NCT04378699|Other|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
79517816|NCT05493774|Other|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
79517817|NCT05493774|Other|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
79517818|NCT05488548|Drug|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
79675023|NCT04325074|Other|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
79995594|NCT03688230|Combination Product|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
79222805|NCT03339674|Behavioral|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
79222806|NCT03339674|Behavioral|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
79222807|NCT00707954|Drug|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
79995595|NCT03694314|Dietary Supplement|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
79222808|NCT00707954|Drug|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
79222809|NCT03339518|Behavioral|BRIM3 educational intervention|Breast Cancer risk education and counseling
79365402|NCT04378699|Other|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
79365403|NCT04378023|Drug|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
79365404|NCT04378023|Procedure|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
79517819|NCT05481762|Device|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
79517820|NCT05476536|Behavioral|self-management skills and healthy technology APP|self-management skills and healthy technology APP
79365405|NCT04373837|Behavioral|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
79517821|NCT05429424|Other|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
79517822|NCT05429424|Other|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
79517823|NCT05429424|Other|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
79821510|NCT02567331|Drug|Capecitabine|Participants will receive 1250 mg/m^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
79821511|NCT02580396|Device|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
79821512|NCT04077606|Other|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
79821513|NCT04077606|Other|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
79995596|NCT03694314|Dietary Supplement|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
79675024|NCT04325074|Other|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
79821514|NCT04077450|Behavioral|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
79222810|NCT03339518|Behavioral|Wait List|Booklet at the end of study
79222811|NCT03339362|Procedure|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
79222812|NCT03339362|Procedure|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
79222813|NCT03339050|Behavioral|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
79222814|NCT03335462|Other|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
79365406|NCT04373837|Other|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
79365407|NCT04371666|Drug|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
79365408|NCT04371666|Drug|Placebo|Matching placebo per schedule specified in the arm description
79365409|NCT04371666|Drug|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
79365410|NCT04367506|Behavioral|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
79365411|NCT04367506|Behavioral|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
79524793|NCT05768438|Other|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
79675025|NCT04325074|Other|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
79675026|NCT00483834|Drug|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
79365412|NCT04364776|Drug|Durvalumab|In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).
79222815|NCT03335462|Other|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
79222816|NCT03335384|Diagnostic Test|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
79222817|NCT03335384|Diagnostic Test|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
79222818|NCT03335384|Diagnostic Test|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
79228073|NCT02470442|Drug|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
79228074|NCT04021797|Device|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
79517824|NCT05367102|Behavioral|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education [using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
79222819|NCT02497898|Biological|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
79222820|NCT03120338|Diagnostic Test|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
79222821|NCT02494154|Device|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
79222822|NCT02494154|Device|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
79222823|NCT02498210|Other|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
79365413|NCT04362059|Device|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
79517825|NCT05365308|Behavioral|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
79517826|NCT05358834|Dietary Supplement|Melatonin|Oral melatonin administered as a single pill.
79517827|NCT05358834|Dietary Supplement|Placebo|Oral placebo administered as a single pill.
79517828|NCT05336682|Procedure|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
79517829|NCT05336682|Procedure|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
79517830|NCT05336682|Procedure|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
79675027|NCT00483834|Drug|Irinotecan|200mg/m^2, IV, day 1 each cycle
79222824|NCT02497820|Drug|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
79228075|NCT02470520|Procedure|CRRT|continuous renal replacement therapy
79228076|NCT03519711|Drug|PTC923|PTC923 will be administered per dose and schedule specified in arm description.
79365414|NCT04362059|Other|Standard of Care|Standard of care treatment for respiratory illness
79365415|NCT04357288|Other|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
79365416|NCT04357288|Other|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
79365417|NCT04340596|Biological|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
79365418|NCT04340596|Biological|VRC07-523LS|Administered by intravenous (IV) infusion
79675028|NCT00483834|Drug|Capecitabine|1000mg/m^2 or 750mg/m^2 for patients over 65yrs old PO BID, day 1-14 each cycle
79365419|NCT04340596|Biological|10-1074|Administered by intravenous (IV) infusion
79365420|NCT04338529|Drug|Binosto 70Mg Effervescent Tablet|As discussed in group descriptions
79517831|NCT05333016|Behavioral|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
79517832|NCT05273346|Behavioral|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
79517833|NCT05273346|Behavioral|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
79365421|NCT04337684|Drug|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
79517834|NCT05273346|Behavioral|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
79517835|NCT05273346|Other|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
79365422|NCT04329767|Device|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
79517836|NCT05273346|Behavioral|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
79517837|NCT05273346|Behavioral|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
79517838|NCT05273346|Behavioral|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
79995597|NCT03694236|Drug|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
79995598|NCT04043364|Behavioral|LIVE|Learning, Innovation, Volunteers and Empowerment
79365423|NCT04307212|Other|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
79365424|NCT04307212|Other|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
79365425|NCT04307212|Other|Control no exercise|Trained and untrained participants will have a no exercise control day
79517839|NCT05273346|Other|Oral painkillers|NSAID drugs, if necessary.
79995599|NCT03692364|Device|Ceramic-on-ceramic uncemented hip arthroplasty|
79995600|NCT03692364|Device|Metal-on-polyethylene uncemented total hip arthroplasty|
79365426|NCT04300205|Device|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
79365427|NCT04300205|Device|Sham LED light device|Participants have the light treatment moved off their wound after masking
79365428|NCT04283942|Behavioral|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
79995601|NCT03688152|Drug|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
79821515|NCT00577005|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
79222825|NCT02493920|Other|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
79365429|NCT04283942|Behavioral|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × [height (cm) - 100] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
79821516|NCT00577005|Drug|Placebo|
79821517|NCT05162157|Device|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
79222826|NCT02493920|Device|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
79222827|NCT02492906|Other|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
79222828|NCT02492906|Other|Healthy|Healthy and non-symptomatic volunteers.
79222830|NCT03120260|Other|Diet|Intervention 'Diet+ short sleep versus normal sleep
79222831|NCT03338738|Diagnostic Test|Stool culture ans swab|"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."
79365430|NCT04281992|Biological|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
79517840|NCT05248776|Drug|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
79517841|NCT05248776|Drug|Placebo|Matching placebo tablet.
79517842|NCT05228730|Biological|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
79222832|NCT03338660|Biological|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
79222833|NCT03338660|Biological|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
79222834|NCT03338660|Biological|Placebo|Subjects will receive infusion placebo (saline).
79675029|NCT04324801|Other|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
79675030|NCT01307449|Biological|PNEUMOVAX|1 dose of PNEUMOVAX
79675031|NCT01307449|Biological|Prevnar|1 dose of Prevnar
79675032|NCT00483665|Procedure|Computed tomography angiography|Computed tomography angiography
79675033|NCT00483665|Procedure|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
79675034|NCT00483912|Device|Molecular adsorbent recirculating system|
79821518|NCT04077060|Diagnostic Test|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
79222835|NCT02497742|Other|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
79222836|NCT02497586|Radiation|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
79222837|NCT02497508|Drug|nivolumab|
79365431|NCT04273672|Diagnostic Test|Cognitive Battery|Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
79365432|NCT04273672|Behavioral|Voice, Speech and Language Analysis|Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
79675035|NCT00488423|Procedure|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
79675036|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
79517843|NCT05228730|Biological|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
79517844|NCT05228730|Biological|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
79222838|NCT02493842|Device|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
79995602|NCT03688152|Drug|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
79995603|NCT03692286|Combination Product|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
79365433|NCT04273672|Behavioral|Questionnaires and Clinical Assessments|Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
79517845|NCT05228730|Biological|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
79517846|NCT05226234|Device|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
79517847|NCT05194254|Other|MRI-ET|coupled fMRI and Eye Tracking tools
79995604|NCT03692286|Drug|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
79995605|NCT03692286|Drug|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
79517848|NCT05146986|Device|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
79517849|NCT05131776|Device|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
79995606|NCT05654766|Diagnostic Test|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
79995607|NCT05654766|Diagnostic Test|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
79995608|NCT03694080|Combination Product|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
79995609|NCT03624348|Behavioral|meditation|10 minute per day, 8 week digital meditation
79222839|NCT03334994|Procedure|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
79222840|NCT02497352|Dietary Supplement|flaxseed|
79222841|NCT02497352|Behavioral|lifestyle modification|
79222842|NCT03338426|Drug|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
79222843|NCT03338426|Drug|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
79365434|NCT04273672|Genetic|DNA Analysis|Participants will have their blood drawn for DNA analysis.
79365435|NCT04266795|Drug|Pevonedistat|Pevonedistat IV infusion.
79365436|NCT04266795|Drug|Venetoclax|Venetoclax tablets.
79365437|NCT04266795|Drug|Azacitidine|Azacitidine IV or SC injection.
79365438|NCT04265586|Behavioral|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
79365439|NCT04265586|Behavioral|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
79517850|NCT05118906|Drug|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
79517851|NCT05118906|Drug|Placebo|2 tablets of placebo per day
79675037|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
79675038|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
79675039|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
79675040|NCT01307020|Drug|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
79675041|NCT01307020|Drug|Placebo|Placebo, oral film-coated table, once
79995610|NCT04059900|Drug|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
79995611|NCT04059900|Drug|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
79222844|NCT03338426|Drug|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
79222845|NCT03338426|Drug|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
79222846|NCT03338348|Drug|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
79365440|NCT04262466|Drug|IMC-F106C|IMC-F106C weekly IV infusions or SC injections
79995612|NCT04295148|Procedure|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
79995613|NCT04295148|Procedure|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
79995614|NCT03692130|Behavioral|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
79517852|NCT05105802|Behavioral|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
79222847|NCT03338348|Drug|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
79222848|NCT02497274|Other|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
79995615|NCT03692130|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson
79995616|NCT04203498|Drug|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
79222849|NCT03334916|Drug|YMC026|YMC026 20mL TID
79365441|NCT04262466|Drug|IMC-F106C and atezolizumab and pembrolizumab|IMC-F106C weekly IV infusions and atezolizumab Q3W IV infusion and pembrolizumab Q6W IV infusion
79365442|NCT04262466|Drug|IMC-F106C and chemotherapy|IMC-F106C weekly IV infusions and chemotherapy Q1-3W IV infusion
79365443|NCT04262466|Drug|IMC-F106C and tebentafusp|IMC-F106C weekly IV infusions and tebentafusp weekly IV infusions
79365444|NCT04259944|Drug|CAPOX|"DAY 1~OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting."
79365445|NCT04259944|Drug|Capecitabine|"DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting."
79517853|NCT05105802|Behavioral|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
79675042|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
79675043|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
79675044|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
79675045|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
79675046|NCT00483743|Drug|TPI 1020|250 mcg/caps 2 caps BID x 42 days
79675047|NCT00483743|Drug|Budesonide|400mcg mcg capsules- 2 capsules BID
79675048|NCT00483743|Drug|Placebo|2 caps BID x42 days
79995617|NCT04203498|Drug|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
79995618|NCT03687918|Other|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
79995619|NCT03691896|Dietary Supplement|Cholecalciferol 400|dose 400 UNT/day for 12 months
79995620|NCT03691896|Dietary Supplement|Cholecalciferol 800|dose 800 UNT/day for 12 months
79995621|NCT03691896|Drug|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
79995622|NCT03691818|Drug|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
79995623|NCT03691818|Drug|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
79995624|NCT03691818|Drug|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
79222850|NCT03334916|Drug|Placebo|Placebo 20mL TID
79222851|NCT02497196|Device|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
79222852|NCT02497196|Device|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
79222853|NCT02497196|Device|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
79995625|NCT03691818|Drug|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
79995626|NCT03687840|Diagnostic Test|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
79995627|NCT03693924|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
79675049|NCT04515654|Other|IDEAS (Identity Evolution and Sharing) Performance|60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
79995628|NCT03687606|Drug|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
79222854|NCT02497196|Device|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
79517854|NCT05083260|Drug|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
79517855|NCT05083260|Drug|placebo|Hard gelatin capsule containing only common excipients for oral formulations
79675050|NCT04324996|Biological|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
79675051|NCT00483782|Biological|bevacizumab|
79675052|NCT00483782|Drug|carboplatin|
79995629|NCT03687606|Drug|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
79995630|NCT03691740|Device|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
79995631|NCT04059978|Drug|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
79995632|NCT04059978|Drug|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
79995633|NCT04059978|Drug|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
79222855|NCT03334838|Drug|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
79365446|NCT04259944|Drug|FOLFIRI|"Day 1:~IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest."
79365447|NCT04256941|Drug|Abemaciclib|Given PO
79365448|NCT04256941|Drug|Anastrozole|Given PO
79517856|NCT05081622|Behavioral|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
79675053|NCT00483782|Drug|paclitaxel|
79995634|NCT03199963|Drug|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
79995635|NCT03199963|Drug|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
79995636|NCT04547257|Device|Seraph 100|Bloodfiltration with Seraph 100
79995637|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
79222856|NCT02497118|Drug|Endostatin|Endostatin,7.5mg/m^2,intravenous, d1-14;
79365449|NCT04256941|Drug|Fulvestrant|Given IM
79365450|NCT04256941|Drug|Letrozole|Given PO
79365451|NCT04256941|Drug|Palbociclib|Given PO
79675054|NCT00483782|Other|questionnaire administration|
79675055|NCT00483782|Other|study of socioeconomic and demographic variables|
79675056|NCT00483782|Procedure|quality-of-life assessment|
79675057|NCT00483951|Device|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
79675058|NCT00483951|Device|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
79675059|NCT00488462|Device|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
79222857|NCT02497118|Drug|Vinorelbine|vinorelbine,25mg/m^2,intravenous, d1, d8;
79222858|NCT02497118|Drug|Cisplatin|Cisplatin，75mg/m^2 intravenous,divide into d1-3
79365452|NCT04256941|Drug|Ribociclib|Given PO
79365453|NCT04254692|Drug|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
79365454|NCT04254692|Other|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
79365455|NCT04250857|Device|HeartStart FRX|Automated External Defibrillator
79517857|NCT05068128|Other|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
79517858|NCT05068128|Other|PERFUSION TEST|"The test will be performed will include:~Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~Recording of the opening pressure for 10 minutes~The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
79517859|NCT05062668|Procedure|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
79517860|NCT05062668|Procedure|cataract operation only|Patients have a classic postoperative treatment after cataract.
79517861|NCT05046288|Other|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
79517862|NCT05016258|Device|KONTACT MB|Dental implant surgery
79517863|NCT05717946|Dietary Supplement|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
79995638|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
79365456|NCT04240808|Biological|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes)
79365457|NCT04238676|Drug|PP353|active administered by intradiscal injection
79365458|NCT04238676|Other|Placebo|Sham injection
79517864|NCT05717946|Other|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
79517865|NCT04992546|Drug|PRN473 (SAR444727)|White to off-white gel suspension
79517866|NCT04992546|Drug|Placebo|White to off-white gel suspension
79517867|NCT04950894|Device|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
79675060|NCT04516005|Procedure|foot reflexology|Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
79675061|NCT02890732|Device|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
79995639|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
79365459|NCT04236154|Other|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
79517868|NCT04921410|Device|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
79517869|NCT04921410|Device|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
79517870|NCT04916886|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
79517871|NCT04916886|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
79517872|NCT04907682|Drug|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
79517873|NCT04907682|Drug|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
79675062|NCT02890771|Procedure|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
79995640|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
79365460|NCT04236154|Other|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
79675063|NCT02890771|Procedure|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
79365461|NCT04236154|Other|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
79675064|NCT02890771|Procedure|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
79675065|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
79675066|NCT01306162|Drug|Dabigatran etexilate|150 mg as single dose
79675067|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
79675068|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
79821519|NCT04077060|Diagnostic Test|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
79821520|NCT02581566|Drug|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
79821521|NCT02581566|Drug|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
79365462|NCT04234113|Drug|SO-C101|SO-C101
79675069|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
79675070|NCT04327960|Diagnostic Test|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
79675071|NCT00483821|Other|medical chart review|medical chart review
79675072|NCT04515732|Drug|Apremilast Oral Tablet|As in description
79821522|NCT02581566|Drug|Bupivacaine|Intrathecal Bupivacaine
79821523|NCT02567019|Other|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
79821524|NCT05237076|Diagnostic Test|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
79821525|NCT04077216|Dietary Supplement|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
79222859|NCT03334760|Other|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
79222860|NCT02496962|Drug|Atorvastatin|atorvastatin were taken daily for 5 days
79222861|NCT02496962|Drug|placebo|placebo were taken daily for 5 days
79222862|NCT03334604|Dietary Supplement|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10^9 Colony Forming Units (CFU), twice daily, orally.
79365463|NCT04234113|Drug|pembrolizumab|pembrolizumab
79365464|NCT04230590|Other|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
79675073|NCT01305577|Drug|Deoxycholic acid injection|
79675074|NCT01305577|Drug|Placebo|Phosphate buffered saline placebo for injection
79675075|NCT00483990|Drug|PSD502|
79675076|NCT01304329|Drug|BI 10773|Medium dose oral administration
79675077|NCT01304329|Drug|simvastatin|Medium dose oral administration
79675078|NCT01304329|Drug|simvastatin|Medium dose oral administration
79675079|NCT01304329|Drug|BI 10773|Medium dose oral administration
79675080|NCT04515420|Drug|noradrenaline|noradrenaline infusion
79675081|NCT00488540|Drug|Paracetamol|Suppository
79675082|NCT00488540|Drug|Placebos|Suppository
79675083|NCT00484068|Drug|enalapril|
79675084|NCT00484068|Procedure|chicken diet|
79675085|NCT00483860|Drug|Topotecan|once a day
79675086|NCT01241097|Drug|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
79675087|NCT00483899|Drug|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
79675088|NCT00483899|Drug|Placebo|Placebo matching GW870086X will be administered by subjects
79675089|NCT01303861|Drug|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
79675090|NCT01303861|Drug|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
79517874|NCT04880304|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
79517875|NCT04880304|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
79222863|NCT03334604|Other|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
79222864|NCT02492594|Other|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~at the start of neutropenic fever~after 24 hours~after 48 hours~before the start of antimycotic therapy, if pertinent~at the end of antimycotic therapy, if pertinent"
79222865|NCT03338270|Diagnostic Test|MRI|MRI sequence without intravenous contrast
79517876|NCT04840992|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
79517877|NCT04840992|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
79365465|NCT04225585|Behavioral|CST-PSP|skills training and experiential learning exercises
79365466|NCT04225585|Behavioral|General health education|general health education intervention that focuses on improving overall health
79365467|NCT04222257|Drug|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
79365468|NCT04222257|Drug|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
79517878|NCT04840992|Biological|Placebo for Inhalation|Aerogen Solo
79517879|NCT04840992|Biological|Placebo|Intramuscular administration
79517880|NCT04793022|Drug|TIVA with Propofol|Total intravenous anesthesia with propofol
79675091|NCT01303861|Drug|Nicotine patches|"Nicotine Replacement Therapy Groups:~For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~For smokers with high baseline CO: 42 mg/24 h for 1 week~For smokers with low baseline CO: 21 mg/24 h for 1 week"
79675092|NCT01303861|Drug|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
79675093|NCT05661136|Device|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
79675094|NCT05661136|Other|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
79675095|NCT01241136|Procedure|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
79675096|NCT01241136|Procedure|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
79222866|NCT02493686|Diagnostic Test|audiogram|hearing test
79222867|NCT02496728|Behavioral|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
79222868|NCT02496728|Behavioral|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
79675097|NCT00488579|Drug|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
79675098|NCT01303627|Drug|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
79675099|NCT01303510|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
79365469|NCT04216472|Drug|Alpelisib|Given PO
79365470|NCT04216472|Drug|Nab-paclitaxel|Given IV
79365471|NCT04212364|Behavioral|Peer Education|In this intervention, people who use opiates will be trained to be peer educators.
79365472|NCT04212364|Drug|Narcan Nasal Product|All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
79365473|NCT04212169|Drug|MEDI3506|multiple doses
79365474|NCT04212169|Drug|Placebo|multiple doses
79365475|NCT04205643|Biological|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
79365476|NCT04205643|Other|Placebo SC|Subcutaneous injection of Placebo SC
79365477|NCT04195945|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79365478|NCT04195945|Drug|Cladribine|Given IV
79365479|NCT04195945|Drug|Cytarabine|Given IV
79365480|NCT04195945|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
79365481|NCT04195945|Drug|Mitoxantrone|Given IV
79365482|NCT04195945|Other|Questionnaire Administration|Ancillary studies
79517881|NCT04793022|Drug|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
79222869|NCT02496728|Behavioral|Social Support|Participants may interact with each other through a private Facebook group.
79222870|NCT02496728|Behavioral|Educational Materials|Educational materials regarding healthy behaviors.
79222871|NCT02496806|Dietary Supplement|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
79675100|NCT00505557|Procedure|Transaxillary dual plane technique|
79222872|NCT03342326|Other|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
79222873|NCT03342326|Other|Music Experience Questionnaire|questions about the past music training
79675101|NCT00488657|Device|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
79222874|NCT03342326|Other|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
79222875|NCT03342326|Other|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
79222876|NCT04494230|Behavioral|Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities|to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
79222877|NCT03338114|Drug|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
79222878|NCT03334136|Drug|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
79222879|NCT03334136|Drug|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
79222880|NCT03342248|Other|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
79365483|NCT04195945|Other|Quality-of-Life Assessment|Ancillary studies
79365484|NCT04193072|Behavioral|Assessment of imagery ability|Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
79222881|NCT03120728|Drug|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
79222882|NCT02496650|Drug|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
79517882|NCT04682496|Procedure|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
79675102|NCT02890654|Other|First time measure|"Initial Interview~Initial Survey,~Quality of life Scale~Kinesitherapy Review~Anxiety Scale"
79222883|NCT03334058|Drug|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
79222884|NCT03333902|Procedure|QLB|QLB, quadratus lumborum block.
79675103|NCT02890654|Other|Second time measure|"Kinesitherapy review~Second survey including numeric scale of pain~Anxiety scale~Scoliosis Research Society 22 quality of life scale"
79675104|NCT02890654|Other|Third time measure|"Scoliosis Research Society 22 quality of life Scale~Anxiety scale~Numeric scale of pain~Kinesitherapy review"
79222885|NCT03333902|Procedure|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
79222886|NCT02492438|Biological|PPV23 vaccination or PCV13 vaccination|
79365485|NCT04184050|Drug|HPN217|HPN217 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains
79365486|NCT04176120|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
79675105|NCT02890576|Other|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
79675106|NCT01241175|Drug|Magnesium Sulfate|
79675107|NCT01241175|Drug|normal saline|
79675108|NCT02890615|Behavioral|Depression self-care|Toolkit and coaching
79675109|NCT05644015|Other|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
79821526|NCT00576927|Drug|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
79821527|NCT00576927|Drug|Placebo|
79821528|NCT05742087|Other|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
79675110|NCT04324723|Behavioral|WhatsApp message|"The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear [First name], Your BP reading during Beirut Marathon was [reading]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team"
79675111|NCT05643937|Behavioral|Routine health education|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
79675112|NCT05643937|Behavioral|Routine health education + precise health education|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
79821529|NCT05742087|Other|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
79821530|NCT05674578|Behavioral|Patient Navigation|Assigned a patient navigator and receive coaching
79821531|NCT05674578|Other|Quality-of-Life Assessment|Ancillary studies
79222887|NCT03337958|Device|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
79222888|NCT03337880|Other|instrumental delivery|the birth was assisted with an extractor.
79222889|NCT02496572|Drug|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
79222890|NCT03342170|Genetic|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
79365487|NCT04176120|Other|Standard Care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
79365488|NCT04169282|Device|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
79365489|NCT04166604|Drug|Trifluridine/Tipiracil|"After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery"
79365490|NCT04166097|Other|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
79365491|NCT04157361|Diagnostic Test|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
79675113|NCT02955498|Drug|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
79675114|NCT02955498|Drug|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
79821532|NCT05674578|Other|Questionnaire Administration|Ancillary studies
79821533|NCT02580630|Behavioral|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
79821534|NCT02580630|Other|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
79821535|NCT02580630|Drug|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
79365492|NCT04145440|Drug|MOR202|Patients will receive 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing will occur weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
79365493|NCT04144751|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
79821536|NCT02580630|Drug|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
79821537|NCT00698841|Drug|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes.
79821538|NCT03787290|Drug|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
79821539|NCT03787290|Drug|Placebo|participants will receive a single subcutaneous injection of saline
79821540|NCT03787290|Device|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
79222891|NCT03333824|Drug|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
79365494|NCT04144179|Biological|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
79517883|NCT04633356|Device|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
79517884|NCT04592484|Biological|CDK-002|CDK-002 administered intratumorally
79517885|NCT04567524|Drug|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
79222892|NCT03333824|Drug|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
79222893|NCT03333824|Drug|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
79995641|NCT03788941|Procedure|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
79365495|NCT04144179|Biological|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
79222894|NCT03333824|Drug|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
79222895|NCT03333824|Drug|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
79222896|NCT03121430|Device|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
79365496|NCT04144179|Biological|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
79365497|NCT04144179|Biological|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
79365498|NCT04144179|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
79365499|NCT04127227|Drug|sintilimab,pegaspargase,gemcitabine,oxaliplatin|"All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimens their first-line therapy.~Patients with CR or PR will receive sintilimab maintenance therapy"
79517886|NCT04549038|Other|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
79517887|NCT04506060|Other|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
79365500|NCT04120935|Other|Observation|Prospective Observation of standard clinical practice.
79365501|NCT04111705|Drug|Lorlatinib|100 mg once daily
79365502|NCT04110353|Other|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
79365503|NCT04110353|Other|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
79517888|NCT04481412|Drug|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
79517889|NCT04481412|Drug|Placebo|96% ethanol that will be applied once daily.
79517890|NCT04481412|Drug|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
79517891|NCT04475718|Behavioral|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
79517892|NCT04465188|Procedure|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
79821541|NCT00577395|Drug|placebo|oral tablet once a month for 12 months
79821542|NCT00577395|Drug|risedronate|tablet, 150 mg once a month for 12 months
79517893|NCT04441554|Diagnostic Test|7 Tesla MRI|7 Tesla MRI of cervical spine
79821543|NCT04062357|Drug|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
79821544|NCT04062357|Other|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
79821545|NCT05190120|Procedure|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
79821546|NCT05190120|Procedure|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
79222897|NCT03121430|Device|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
79222898|NCT02492516|Biological|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
79222899|NCT03342092|Other|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
79222900|NCT04494152|Diagnostic Test|Transthoracic echocardiography|Standard Point-of-Care echocardiographic examination in the intensive care unit.
79222901|NCT03337568|Procedure|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
79365504|NCT04110353|Other|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
79365505|NCT04109313|Drug|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
79821547|NCT05190120|Drug|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
79821548|NCT05190120|Drug|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
79821549|NCT02581332|Behavioral|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
79821550|NCT03896061|Device|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
79821551|NCT00738374|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
79821552|NCT00738374|Drug|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
79222902|NCT02496338|Other|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
79365506|NCT04106219|Drug|LY3295668 Erbumine|Administered orally.
79365507|NCT04106219|Drug|Topotecan|Administered IV.
79365508|NCT04106219|Drug|Cyclophosphamide|Administered IV.
79365509|NCT04103580|Behavioral|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
79821553|NCT04076982|Dietary Supplement|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
79517894|NCT04423458|Device|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
79517895|NCT04412616|Biological|ZZ06|"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."
79821554|NCT04076982|Other|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
79821555|NCT04088474|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
79821556|NCT04088474|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
79821557|NCT05016999|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
79222903|NCT02496494|Drug|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
79222904|NCT03337412|Other|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
79365510|NCT04099940|Behavioral|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
79517896|NCT04371276|Other|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
79517897|NCT04317300|Drug|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
79821558|NCT02594930|Procedure|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
79222905|NCT03337334|Device|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
79222906|NCT03337256|Diagnostic Test|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~75 2.5 Haemoglobin(g/L)~10.0 0 <9.9 2 Systolic blood pressure (mmHg)~110 0 90-109 1.5 <90 2.5 Pulse (beats per min) <100 0~100 1.5 Creatinine (mmol/L) <200 0~200 3.5 Number of blood transfusion 0 0~1 1.5~2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
79995642|NCT03883581|Drug|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
79995643|NCT03824535|Procedure|Computed Tomography|Undergo PET/CT
79995644|NCT03824535|Drug|Fludeoxyglucose F-18|Given IV
79675115|NCT05643898|Behavioral|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
79995645|NCT03824535|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
79995646|NCT03824535|Procedure|Positron Emission Tomography|Undergo PET/CT
79995647|NCT03113643|Drug|Azacitidine|Chemotherapy
79222907|NCT03337178|Behavioral|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
79222908|NCT03337178|Behavioral|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
79222909|NCT03333512|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
79365511|NCT04099940|Behavioral|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
79365512|NCT04097418|Behavioral|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
79365513|NCT04096625|Device|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
79365514|NCT04096625|Behavioral|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
79365515|NCT04096625|Device|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
79995648|NCT03113643|Drug|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
79995649|NCT03113643|Drug|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
79365516|NCT04089865|Drug|Tranexamic Acid|Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
79365517|NCT04088773|Diagnostic Test|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
79222910|NCT03333434|Device|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
79222911|NCT03333434|Device|Hinged AFO|
79222912|NCT03333278|Drug|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
79222913|NCT03333278|Drug|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
79365518|NCT04088773|Diagnostic Test|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
79222914|NCT03333278|Drug|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
79365519|NCT04088773|Diagnostic Test|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
79365520|NCT04075305|Radiation|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
79821559|NCT02581176|Drug|Apixaban|
79821560|NCT03746184|Other|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
79995650|NCT03091491|Drug|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
79995651|NCT03091491|Drug|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
79995652|NCT05293353|Other|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
79995653|NCT04733235|Drug|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
79995654|NCT05598177|Drug|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
79222915|NCT04494308|Other|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
79821561|NCT04075500|Device|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
79821562|NCT05119608|Behavioral|CBT/ACT|10-session ACT-re-enforced CBT intervention.
79222916|NCT04847596|Other|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
79365521|NCT04074993|Drug|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
79365522|NCT04074512|Drug|Copper Histidinate|Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
79365523|NCT04062708|Drug|Durvalumab|"Preoperative Treatment:~Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
79517898|NCT04317300|Other|brief behavioral therapy|brief behavioral therapy
79517899|NCT04300218|Behavioral|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
79517900|NCT04300218|Other|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
79517901|NCT04251390|Device|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
79517902|NCT04205370|Device|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
79821563|NCT00697593|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
79821564|NCT05012475|Behavioral|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
79821565|NCT05325021|Diagnostic Test|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
79222917|NCT04847596|Other|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
79365524|NCT04062708|Procedure|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
79365525|NCT04062708|Radiation|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
79517903|NCT04205370|Device|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
79517904|NCT04176510|Behavioral|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
79517905|NCT04143204|Other|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
79517906|NCT03977922|Other|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
79517907|NCT03971136|Diagnostic Test|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
79517908|NCT03946332|Behavioral|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
79821566|NCT05325021|Diagnostic Test|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
79821567|NCT04075578|Drug|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
79517909|NCT03946332|Behavioral|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
79517910|NCT03920982|Diagnostic Test|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
79517911|NCT03904914|Other|TOCI|TOCI staging evaluated
79222918|NCT02565706|Behavioral|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
79222919|NCT02565706|Behavioral|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
79222920|NCT05510518|Diagnostic Test|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
79365526|NCT04059185|Other|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
79517912|NCT03886740|Procedure|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
79517913|NCT03876288|Device|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
79517914|NCT03876288|Drug|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
79517915|NCT03876288|Procedure|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
79517916|NCT03818256|Drug|Miricorilant|Miricorilant 600mg
79517917|NCT03818256|Drug|Miricorilant|Placebo tablets for once daily oral dosing
79675116|NCT01303159|Device|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
79995655|NCT05598177|Drug|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
79995656|NCT03740529|Drug|Pirtobrutinib|Oral
79995657|NCT03740529|Drug|Venetoclax|Oral
79222921|NCT03339752|Drug|Rosuvastatin|10 mg tablet
79222922|NCT03339752|Drug|ACT-541468|25 mg hard capsule
79222923|NCT00706628|Drug|BIBF 1120|
79517918|NCT03812172|Drug|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
79517919|NCT03623958|Device|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
79517920|NCT03623958|Procedure|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
79675117|NCT00484107|Drug|Conjugated Estrogen Cream (Premarin®)|
79675118|NCT00505596|Behavioral|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
79675119|NCT00488735|Behavioral|Cognitive-behavioral rehabilitation|
79675120|NCT00488735|Behavioral|Traditional primary care|
79995658|NCT03740529|Drug|Rituximab|IV
79222924|NCT00706628|Drug|BIBW 2992|
79222925|NCT00706628|Drug|Sequential BIBF 1120 + BIBW 2992|
79222926|NCT05502406|Procedure|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
79995659|NCT03029208|Drug|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
79222927|NCT05502406|Procedure|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
79222928|NCT03332966|Diagnostic Test|Psychiatric questionnaires|"Participants will fill in the following questionnaires as part of routine intake assessments:~Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale"
79222929|NCT03332966|Diagnostic Test|Semi-structured psychiatric interview|Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
79222930|NCT05465252|Dietary Supplement|Krill Oil 500 MG|Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 3 capsules of krill oil per day.
79222931|NCT05465252|Dietary Supplement|Olive Oil 500MG|Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 3 capsules of olive oil , which has the same color and smell as the krill oil.
79365527|NCT04059185|Other|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
79365528|NCT04059185|Other|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
79365529|NCT04057131|Drug|Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
79365530|NCT04047992|Device|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
79675121|NCT01302964|Drug|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
79675122|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
79821568|NCT05741931|Device|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
79821569|NCT04445025|Drug|Elagolix 200 MG|Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
79821570|NCT04445025|Drug|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
79995660|NCT03029208|Drug|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
79995661|NCT03029208|Drug|Iron therapy|Iron therapy will be administered if ferritin is <=100 ng/mL and/or TSAT is <=20%.
79995662|NCT03693534|Diagnostic Test|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
79995663|NCT03687294|Device|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
79995664|NCT03198715|Drug|DS1040b|DS-1040b in solution for intravenous infusion
79995665|NCT03198715|Drug|Placebo|Saline solution for intravenous infusion
79365531|NCT04046445|Drug|ATP128|5-6 SC injections
79675123|NCT04515381|Other|Therapeutic Touch|Therapeutic Touch
79675124|NCT04515381|Other|Control group|Making measurements at the beginning of the research and 4 weeks
79675125|NCT04515381|Other|Sham Therapeutic Touch|Sham Therapeutic Touch
79675126|NCT00484055|Drug|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
79675127|NCT00484055|Procedure|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
79995666|NCT03693456|Other|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
79517921|NCT03601026|Behavioral|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
79995667|NCT04191330|Device|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
79365532|NCT04046445|Drug|BI 754091|≥ 7 IV infusions
79517922|NCT03370302|Drug|TAK-228|TAK-228 Capsules.
79517923|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
79517924|NCT03327324|Behavioral|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
79517925|NCT03252522|Combination Product|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
79517926|NCT03252522|Dietary Supplement|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
79517927|NCT03191370|Other|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
79517928|NCT03191370|Drug|Local Anesthetics,Topical|Anesthetic spray
79517929|NCT03179436|Biological|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
79517930|NCT03179436|Biological|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
79517931|NCT03179436|Drug|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
79517932|NCT03149874|Drug|Hepatitis B recombinant DNA vaccine|Hepatitis B recombinant DNA vaccine
79517933|NCT03149874|Drug|Combined hepatitis A and B vaccine|Combined hepatitis A and B vaccine given to the patients
79517934|NCT03142074|Other|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
79675128|NCT01302691|Drug|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
79675129|NCT01302691|Drug|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
79821571|NCT04445025|Diagnostic Test|Lab work|Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
79821572|NCT02580474|Drug|Daclatasvir plus Asunaprevir|
79365533|NCT04046445|Drug|VSV-GP128|1 single IV injection
79365534|NCT04036435|Drug|BMS-986165|Specified dose on specified days
79517935|NCT03142074|Radiation|ECG-gated CT|Image analysis of ECG-gated CT.
79517936|NCT02834052|Drug|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
79517937|NCT02834052|Drug|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
79517938|NCT02756364|Drug|Fulvestrant|Fulvestrant IM injection.
79517939|NCT02756364|Drug|Sapanisertib|Sapanisertib capsule.
79675130|NCT01302691|Drug|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
79675131|NCT01302691|Drug|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
79675132|NCT01302691|Drug|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
79675133|NCT01302691|Drug|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
79675134|NCT01241084|Dietary Supplement|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
79675135|NCT01241084|Dietary Supplement|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
79675136|NCT05643820|Drug|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
79675137|NCT05643820|Drug|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
79675138|NCT01302418|Device|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
79517940|NCT02752542|Behavioral|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
79675139|NCT01241123|Procedure|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
79675140|NCT01241123|Drug|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
79675141|NCT01241123|Radiation|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
79675142|NCT01241123|Device|pedometers|to record the amount of ambulation
79222932|NCT03331172|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
79222933|NCT05463614|Drug|Propafenone and Propranolol|Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
79675143|NCT00484263|Drug|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
79222934|NCT02491658|Biological|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
79675144|NCT01242449|Drug|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
79675145|NCT01242449|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
79675146|NCT00484302|Behavioral|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
79675147|NCT00484302|Behavioral|Non-manualized standard treatment|Treatment by case-manager
79675148|NCT01241162|Biological|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
79675149|NCT04515303|Other|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
79675150|NCT00484133|Drug|Dopamine|
79222935|NCT05232968|Other|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
79222936|NCT05232968|Other|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
79222937|NCT03332888|Drug|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
79675151|NCT00484133|Drug|dobutamine|
79675152|NCT00484133|Drug|enoximone|
79365535|NCT04035447|Behavioral|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
79365536|NCT04033211|Device|Novosyn® CHD for fascia and skin closure|Experimental
79365537|NCT04033211|Device|Novosyn® for fascia and skin closure|Comparator
79675153|NCT00484133|Drug|nitroglycerine|
79821573|NCT04061811|Diagnostic Test|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
79675154|NCT00484133|Drug|noradrenaline|
79675155|NCT00484341|Drug|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
79675156|NCT00484341|Drug|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
79675157|NCT00484341|Drug|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
79675158|NCT01242566|Drug|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
79675159|NCT04515225|Other|Blood Sample|Blood Sample
79675160|NCT00484172|Procedure|blood draws|
79517941|NCT02752542|Drug|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
79821574|NCT00697515|Drug|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
79365538|NCT04033107|Drug|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
79821575|NCT00697515|Drug|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
79821576|NCT03951636|Procedure|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
79222938|NCT03332810|Behavioral|SME family based physical activity|"One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
79517942|NCT02679378|Device|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
79821577|NCT03951636|Procedure|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
79821578|NCT03951636|Procedure|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
79365539|NCT04033107|Drug|Metformin|Participants will orally take metformin 4g daily.
79821579|NCT00738062|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
79821580|NCT00738062|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
79821581|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
79821582|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
79821583|NCT04156074|Dietary Supplement|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
79821584|NCT04156074|Dietary Supplement|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
79995668|NCT03691506|Other|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
79222939|NCT03332810|Behavioral|Gathering activity|- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
79222940|NCT03332732|Drug|VNRX-5133|β-lactamase inhibitor
79222941|NCT03332732|Drug|VNRX-5022|Approved β-lactam antibiotic
79222942|NCT03332732|Drug|Metronidazole|Approved antibiotic and antiprotozoal medication
79222943|NCT03332732|Drug|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
79995669|NCT03691506|Other|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
79222944|NCT03324854|Procedure|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
79222945|NCT03324854|Procedure|Drainage|Placement of active-close drainage in surgical site.
79222946|NCT03324854|Drug|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
79365540|NCT04030312|Dietary Supplement|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
79365541|NCT04030312|Dietary Supplement|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
79365542|NCT04029129|Other|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
79365543|NCT04028492|Drug|Tradipitant|BID
79365544|NCT04028492|Drug|Placebo|BID
79222947|NCT02492360|Procedure|Blood sample collection|Six tubes of blood will be collected during one blood draw.
79365545|NCT04028310|Other|Phonological|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
79222948|NCT02492360|Behavioral|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
79222949|NCT02492282|Device|Closed-Loop propofol and remifentanil system by Bispectral Index|
79365546|NCT04028310|Other|Visual-attention|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
79365547|NCT04025957|Drug|SHR-1501|Administered subcutaneously
79365548|NCT04021316|Other|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
79365549|NCT04021316|Other|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
79365550|NCT04017832|Drug|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
79365551|NCT04017832|Drug|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
79517943|NCT02649738|Procedure|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
79517944|NCT02519322|Biological|Ipilimumab|Given IV
79517945|NCT02519322|Other|Laboratory Biomarker Analysis|Correlative studies
79517946|NCT02519322|Biological|Nivolumab|Given IV
79675161|NCT04514835|Drug|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
79365552|NCT04017832|Drug|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
79675162|NCT00484211|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
79675163|NCT00488813|Drug|Third generation cephalosporins|
79675164|NCT00484380|Procedure|Coronary scanner|multislice spiral computed tomography coronary angiography
79675165|NCT00484250|Drug|metronidazole,doxycycline|
79365553|NCT04017832|Drug|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
79365554|NCT04006262|Drug|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
79517947|NCT02519322|Biological|Relatlimab|Given IV
79517948|NCT02519322|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79517949|NCT02460042|Procedure|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
79517950|NCT02460042|Device|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
79517951|NCT02210988|Other|acupuncture|Intervention with acupuncture
79675166|NCT00484458|Device|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
79675167|NCT00484458|Device|Total Disc Replacement|Total disc
79675168|NCT00488891|Drug|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
79675169|NCT00488891|Drug|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
79675170|NCT00484497|Drug|cyclamax|
79675171|NCT00484328|Drug|Ribavirin|different dosing regimes of Ribavirin
79675172|NCT04514640|Behavioral|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
79675173|NCT00488930|Other|Observational|data collection ONLY
79675174|NCT00484575|Drug|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
79675175|NCT00484575|Drug|propofol|propofol given intravenously for sedation in control group
79222950|NCT02492282|Device|Open-Loop propofol and remifentanil by Target Controlled Infusion|
79222951|NCT02492282|Drug|propofol|
79222952|NCT02492126|Other|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
79222953|NCT03331016|Behavioral|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
79222954|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
79222955|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
79517952|NCT02000934|Drug|TAK-659|TAK-659 tablet
79517953|NCT01906476|Behavioral|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
79517954|NCT01906476|Behavioral|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
79517955|NCT01793922|Procedure|PD|pneumodilation
79222956|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
79222957|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
79222958|NCT05464862|Drug|Lidocaine Hydrochloride 10 MG/ML [Xylocaine]|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
79222959|NCT03324776|Drug|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
79222960|NCT03332654|Other|Determine prevalence of stress urinary incontinence|
79222961|NCT02561806|Drug|Ixekizumab|Administered SC
79365555|NCT04006262|Drug|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
79365556|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
79365557|NCT04005378|Other|Usual Care|Usual Care provided by CSC center
79365558|NCT03999515|Drug|Abiraterone Acetate|Given PO
79365559|NCT03999515|Drug|Enzalutamide|Given PO
79365560|NCT03999515|Drug|Erdafitinib|Given PO
79365561|NCT03995472|Drug|SHR-1501|Administered subcutaneously
79365562|NCT03995472|Drug|SHR-1316|Administered intravenously
79365563|NCT03994952|Device|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
79365564|NCT03994952|Device|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
79365565|NCT03994627|Drug|Olaratumab|Administered intravenously (IV)
79365566|NCT03981978|Behavioral|Physical Activity|Self-report questionnaires assessing physical activity level.
79365567|NCT03980626|Behavioral|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
79821585|NCT04061889|Other|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
79995670|NCT03687216|Procedure|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
79517956|NCT01793922|Procedure|POEM|peroral endoscopic myotomy
79995671|NCT03687216|Procedure|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
79222962|NCT02561806|Drug|Ustekinumab|Administered SC
79517957|NCT05723094|Radiation|Ga-Al-As diode laser (Ilase, USA)|The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2
79517958|NCT05723094|Other|placebo|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
79517959|NCT05723016|Other|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
79517960|NCT05722626|Procedure|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
79517961|NCT05722626|Other|Normal Saline|NaCl 0.9%
79222963|NCT02561806|Drug|Placebo|Administered SC
79222964|NCT03324620|Other|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
79222965|NCT03332576|Biological|DPX-Survivac|SubQ injection
79222966|NCT03332576|Biological|DPX-Survivac(Aqueous)|SubQ injection
79222967|NCT03332576|Drug|Cyclophosphamide|PO BID
79222968|NCT03330938|Behavioral|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
79222969|NCT03330938|Behavioral|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
79517962|NCT05722548|Drug|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
79995672|NCT05212623|Biological|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
79222970|NCT03330860|Other|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
79517963|NCT05722548|Other|Standard Medical Treatment|Standard Medical Treatment
79517964|NCT05722470|Behavioral|eating disorders|Assessment of eating disorders among adolescents
79222971|NCT03330860|Other|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
79675176|NCT04697342|Behavioral|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
79222972|NCT03324542|Drug|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
79222973|NCT03324386|Behavioral|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
79365568|NCT03980262|Behavioral|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
79365569|NCT03980262|Behavioral|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
79365570|NCT03978611|Drug|Relatlimab|Specified dose on specified days
79675177|NCT04514796|Drug|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
79995673|NCT05212623|Biological|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
79222974|NCT03324386|Behavioral|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
79222975|NCT03324386|Behavioral|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
79222976|NCT03324386|Other|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
79222977|NCT02561572|Other|Acupuncture|Yintang point acupuncture
79222978|NCT03330782|Drug|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
79222979|NCT03330782|Drug|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
79365571|NCT03978611|Drug|Ipilimumab|Specified dose on specified days
79365572|NCT03969654|Device|PERSONA Total Knee|Primary Total Knee Arthroplasty
79365573|NCT03969654|Device|Vanguard Total Knee|Primary Total Knee Arthroplasty
79675178|NCT00484367|Behavioral|Adolescent group therapy|Adolescent group therapy
79675179|NCT00484367|Behavioral|Transitional family therapy|Transitional family therapy
79995674|NCT05212623|Biological|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
79995675|NCT05212623|Biological|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
79995676|NCT03960138|Device|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
79222980|NCT03332342|Other|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
79365574|NCT03969654|Device|NexGen Total Knee|Primary Total Knee Arthroplasty
79517965|NCT05722392|Procedure|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
79517966|NCT05721924|Procedure|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
79517967|NCT05721924|Procedure|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
79675180|NCT00484614|Procedure|Positron Emission Mammography|Molecular Imaging Device
79675181|NCT00484614|Procedure|Magnetic Resonance Imaging|Imaging Device
79675182|NCT00488969|Drug|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
79675183|NCT00488969|Drug|Placebo|
79821586|NCT04076670|Other|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
79995677|NCT03960138|Device|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
79517968|NCT05721534|Other|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
79222981|NCT02492048|Device|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
79222982|NCT02492048|Procedure|Split Thickness Skin Graft|Split Thickness Skin Graft
79222983|NCT05506540|Drug|ENN0403 1mg|ENN0403 capsules for oral use
79222984|NCT05506540|Drug|ENN0403 4mg|ENN0403 capsules for oral use
79222985|NCT05506540|Drug|ENN0403 10mg|ENN0403 capsules for oral use
79365575|NCT03966781|Procedure|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
79517969|NCT05721456|Biological|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
79995678|NCT03691272|Device|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
79365576|NCT03966781|Procedure|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
79222986|NCT05506540|Drug|ENN0403 20mg|ENN0403 capsules for oral use
79365577|NCT03966781|Procedure|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
79365578|NCT03966781|Procedure|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
79821587|NCT04062045|Drug|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
79675184|NCT00484653|Procedure|cervical smear|biological analysis
79675185|NCT04697108|Other|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
79365579|NCT03952806|Drug|Verdiperstat|300mg 2 oral tablets, twice daily
79675186|NCT00484692|Drug|sustained-release bupropion (Zyban(R))|
79675187|NCT00484692|Behavioral|Psychodynamic Model Training (R) = PDM(R)|
79365580|NCT03952806|Drug|Placebo|Matching placebo
79995679|NCT03691272|Device|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
79222987|NCT05506540|Drug|ENN0403 30mg|ENN0403 capsules for oral use
79222988|NCT05506540|Drug|ENN0403 20mg (Fed)|ENN0403 capsules for oral use
79222989|NCT05506540|Drug|ENN0403 6mg QD X 14 Days|ENN0403 capsules for oral use
79222990|NCT05506540|Drug|ENN0403 12mg QD X 14 Days|ENN0403 capsules for oral use
79222991|NCT05506540|Drug|ENN0403 20mg QD X 14 Days|ENN0403 capsules for oral use
79222992|NCT05506540|Drug|Placebo|Placebo capsules for oral use
79222993|NCT03332186|Drug|BMS-986231|Intravenous infusion administration
79365581|NCT03944876|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
79365582|NCT03944876|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
79675188|NCT00489008|Procedure|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 & 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
79675189|NCT00484731|Procedure|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
79675190|NCT00484731|Procedure|Infiltration with Bupivacaine|
79821588|NCT04062045|Drug|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
79995680|NCT03693222|Drug|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
79222994|NCT05506462|Drug|Ketamine Hydrochloride|Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
79517970|NCT05721300|Drug|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
79995681|NCT03693222|Drug|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
79517971|NCT05721300|Drug|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
79995682|NCT04059744|Device|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
79517972|NCT05721066|Diagnostic Test|ClotPro assessment|Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
79517973|NCT05721066|Diagnostic Test|Laboratory analysis|Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
79517974|NCT05721066|Other|Interview|Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
79517975|NCT05720910|Other|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
79675191|NCT04515069|Procedure|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
79222995|NCT03330704|Drug|3% Sodium Chloride|3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
79365583|NCT03944577|Drug|Evolocumab|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
79821589|NCT05007015|Procedure|Transanal Irrigation|Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
79821590|NCT04064073|Drug|DWP16001|Tablets, Oral, once daily single dose
79995683|NCT03693066|Other|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
79365584|NCT03941236|Drug|dasiglucagon|Glucagon analog
79365585|NCT03935724|Biological|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
79995684|NCT03693066|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
79995685|NCT03693066|Other|Control|
79995686|NCT03631641|Biological|Nivolumab|Given IV
79995687|NCT03631875|Drug|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
79222996|NCT03330704|Drug|23.4% Sodium Chloride|23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
79222997|NCT03330704|Drug|8.4% Sodium Bicarbonate|8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
79222998|NCT05506306|Other|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
79222999|NCT03330626|Device|InBody group|As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
79223000|NCT03330626|Other|IO group|Fluid removal are guided by intake-output balance.
79223001|NCT03330548|Behavioral|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
79223002|NCT03330548|Behavioral|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
79223003|NCT05501938|Procedure|Physical Exam Indicated Cerclage|Transvaginal cervical cerclage
79995688|NCT05598099|Behavioral|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
79995689|NCT03631563|Drug|Immunosuppressive Agent|ATG-Fresenius versus ATG
79995690|NCT03019653|Drug|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
79995691|NCT03019653|Drug|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
79995692|NCT02653755|Device|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
79995693|NCT05077293|Other|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
79995694|NCT05077293|Other|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
79995695|NCT05069181|Other|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
79995696|NCT05069181|Other|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
79223004|NCT03330470|Behavioral|exercise|participants will be subjected to 3 months supervised exercise intervention
79223005|NCT03330470|Dietary Supplement|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
79365586|NCT03932799|Other|Prospective prior authorization (PA) with hard stops in Washington|"Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority."
79365587|NCT03932799|Other|Retrospective review (RR) with prescriber notification in Ohio|In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
79517976|NCT05720598|Procedure|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
79675192|NCT04515069|Procedure|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
79675193|NCT00484484|Drug|Ketamine|Ketamine
79675194|NCT00484523|Procedure|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
79821591|NCT04064073|Drug|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
79995697|NCT05069181|Other|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
79995698|NCT01383603|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
79995699|NCT05065203|Procedure|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
79995700|NCT01568775|Drug|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
79995701|NCT01015989|Other|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
79223006|NCT03330470|Behavioral|stretching|participants will be subjected to 3 months supervised stretching program
79223007|NCT03330470|Dietary Supplement|supplementation with placebo|participants will be instructed to take placebo 2 times daily
79228077|NCT03108950|Behavioral|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
79517977|NCT05720598|Procedure|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
79517978|NCT05720598|Procedure|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
79517979|NCT05720442|Drug|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
79517980|NCT05720442|Drug|Mosapride Citrate|The mosapride citrate tablets will be administrated.
79517981|NCT05720286|Device|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
79517982|NCT05720208|Device|SCiP|Noninvasive Spinal Cord Neuromodulator
79223008|NCT03332108|Other|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past [x] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
79223009|NCT03332108|Other|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
79365588|NCT03930576|Other|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
79365589|NCT03930459|Procedure|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
79365590|NCT03930459|Device|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
79365591|NCT03928041|Device|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
79365592|NCT03925025|Drug|Magnesium Sulfate|Treatment in addition to standard therapy
79365593|NCT03925025|Drug|Nimodipine|Treatment in addition to standard therapy
79365594|NCT03924947|Drug|Pancrelipase|Delayed release capsules
79365595|NCT03924947|Drug|Pancrelipase|Delayed release capsules
79365596|NCT03918577|Other|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
79365597|NCT03914118|Drug|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
79517983|NCT05720052|Drug|MS-553|MS-553 oral tablet BID x 28-days
79517984|NCT05719974|Other|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
79517985|NCT05719896|Drug|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
79517986|NCT05719896|Drug|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
79517987|NCT05719896|Drug|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
79517988|NCT05719818|Drug|biphosphonates|Initiation of bisphosphonate therapy
79365598|NCT03914118|Drug|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
79365599|NCT03914118|Drug|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
79365600|NCT03903653|Drug|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
79365601|NCT03903653|Device|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
79517989|NCT05719818|Procedure|Dental care|Surgical dental care
79517990|NCT05719740|Diagnostic Test|osteocrin|laboratory routine test
79517991|NCT05719662|Other|Weight bearing exercises|Weight bearing exercises
79821592|NCT04064073|Drug|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
79223010|NCT03324152|Other|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
79223011|NCT03324152|Other|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
79223012|NCT03324152|Other|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
79821593|NCT04075344|Other|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
79821594|NCT02580942|Device|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
79365602|NCT03898388|Procedure|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
79223013|NCT03331952|Other|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
79223014|NCT03331952|Other|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
79223015|NCT03331952|Other|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
79223016|NCT05506228|Other|No intervention|
79223017|NCT03330392|Dietary Supplement|AGP|take two tablets per day (500 mg/day) for 8 weeks
79223018|NCT03330392|Dietary Supplement|Placebo|take two tablets per day (500 mg/day) for 8 weeks
79223019|NCT04820218|Device|With Try-on glasses|Subjects will be asked to measure their visual acuity with their try-on glasses
79223020|NCT02491346|Procedure|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
79223021|NCT02491346|Procedure|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
79223022|NCT05506072|Other|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
79228078|NCT04491734|Dietary Supplement|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
79517992|NCT05719662|Other|Jaffrey's core stability exercises|Jaffrey's core stability exercises
79365603|NCT03892928|Drug|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
79675195|NCT04514601|Other|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
79228079|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
79228080|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
79228081|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
79365604|NCT03889197|Drug|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine [Na] below threshold; for each subsequent time urine [Na] below threshold, add additional 2 mEq/kg/d.
79675196|NCT00484562|Device|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
79675197|NCT00484562|Device|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
79675198|NCT00484562|Device|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
79821595|NCT02580942|Device|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
79821596|NCT02580942|Drug|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
79821597|NCT02565927|Device|Traditional airway stent|process airway stenting
79821598|NCT02565927|Drug|Iodine-125 seeds|process intraluminal brachytherapy
79675199|NCT00484562|Device|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
79675200|NCT00484601|Drug|Ifosfamide|
79675201|NCT00484601|Drug|Doxorubicin|
79675202|NCT00484640|Drug|Coumadin|
79223023|NCT05506072|Other|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
79675203|NCT04514718|Device|Holmium laser|low energy holmium laser
79365605|NCT03888651|Other|Quality-of-Life Assessment|Complete quality of life assessment
79821599|NCT04137354|Other|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
79821600|NCT04137354|Other|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
79821601|NCT04137354|Other|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
79223024|NCT03330314|Biological|HM12460A|HM12460A is a long-acting insulin
79675204|NCT00489125|Other|physiologic testing|physical testing of range of motion, grip strength etc.
79675205|NCT00484757|Drug|Orexine A|
79223025|NCT05501782|Other|questionnaire|A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
79223026|NCT03331874|Diagnostic Test|Reflectance Confocal Microscopy|In-vivo microscope
79223027|NCT05501626|Device|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
79223028|NCT05501626|Device|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
79365606|NCT03888651|Other|Questionnaire Administration|Complete questionnaire
79365607|NCT03886818|Device|Standard dressings|Standard dressings will be used from surgery to wound healing
79365608|NCT03886818|Device|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
79365609|NCT03885232|Behavioral|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
79365610|NCT03885232|Other|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
79365611|NCT03871556|Diagnostic Test|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
79365612|NCT03864094|Drug|Ephedrine|0,1 mg/kg
79365613|NCT03864094|Drug|Phenylephrine|1 microg/kg
79365614|NCT03864094|Drug|Norepinephrine|0,1 microg/kg
79365615|NCT03864094|Drug|Sodium chloride|0,1 ml/kg
79365616|NCT03864094|Drug|Propofol|2 mg/kg
79365617|NCT03864094|Drug|Remifentanil|1,7 microg/kg
79365618|NCT03863184|Drug|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
79365619|NCT03863184|Drug|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
79365620|NCT03863184|Drug|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
79365621|NCT03860792|Behavioral|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
79675206|NCT00489164|Device|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
79675207|NCT00484809|Drug|Enbrel (Etanercept)|
79675208|NCT00489242|Procedure|Procedure / Percutaneous angioplasty|
79675209|NCT04514094|Drug|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
79675210|NCT04514094|Procedure|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
79675211|NCT00489320|Device|Cypher Stent|
79675212|NCT00484848|Device|Vortex port and Celsite port|
79675213|NCT00484796|Procedure|MED-SEP|intraoperative neurophysiological monitoring
79675214|NCT00484796|Procedure|TRI-SEP|intraoperative neurophysiologic monitoring
79675215|NCT00484796|Procedure|neuropsychological tests|neurological short- and longterm outcome
79675216|NCT04514289|Drug|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
79675217|NCT00484835|Procedure|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
79223029|NCT03323996|Other|Semi-Structured interviews|individual semi-structured interviews
79517993|NCT05719584|Other|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
79517994|NCT05719584|Other|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
79517995|NCT05719506|Other|normal saline without drug|nebulizer session with normal saline only preoperative
79517996|NCT05719506|Drug|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
79517997|NCT05719506|Drug|Ketamine|nebulizer session with ketamine preoperative
79223030|NCT05505994|Drug|DWP16001|DWP16001 A mg tablet
79365622|NCT03860792|Behavioral|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
79223031|NCT05505994|Drug|Dapagliflozin|Dapagliflozin tablet
79223032|NCT05505994|Drug|DWP16001 Placebo|DWP16001 Placebo tablet
79223033|NCT05505994|Drug|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
79223034|NCT03323918|Other|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
79223035|NCT03323918|Other|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
79223036|NCT05501392|Behavioral|STEPS-PreK|Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
79365623|NCT03855813|Other|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
79517998|NCT05717322|Behavioral|TENS|apply TENS after orthognathic surgery
79517999|NCT05717322|Behavioral|sham TENS|apply non active TENS after orthognathic surgery
79223037|NCT02180217|Drug|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
79223038|NCT02180217|Drug|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
79223039|NCT03323840|Other|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
79223040|NCT05501314|Other|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
79223041|NCT03323762|Device|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
79365624|NCT03855813|Other|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
79365625|NCT03851640|Drug|HC-1119|oral
79518000|NCT05717010|Device|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
79518001|NCT05716932|Procedure|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
79223042|NCT02491424|Device|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
79223043|NCT02491268|Drug|Cilostazol|
79365626|NCT03851640|Drug|placebo|oral
79223044|NCT02491268|Drug|Placebo|
79228082|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
79228083|NCT01320956|Behavioral|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
79518002|NCT05716776|Diagnostic Test|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
79675218|NCT00484913|Procedure|abdominal hot compress|
79675219|NCT00484926|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
79821602|NCT04137354|Other|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
79518003|NCT05716698|Dietary Supplement|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
79675220|NCT00484926|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
79675221|NCT01242683|Behavioral|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
79995702|NCT01015989|Other|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
79995703|NCT04722549|Dietary Supplement|Placebo|Cellulose
79995704|NCT04722549|Dietary Supplement|Butyrate|Sodium butyrate
79995705|NCT05003427|Drug|68Ga-FAPI-04|68Ga-FAPI-04 were injected into the patients before the PET/CT scans
79995706|NCT04941261|Biological|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
79995707|NCT04941261|Biological|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
79223045|NCT05509504|Other|Low-intensity online intervention|The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for ~45 minutes. Participants will attend these sessions once a week.
79365627|NCT03845985|Behavioral|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
79365628|NCT03842007|Diagnostic Test|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
79518004|NCT05716698|Dietary Supplement|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
79518005|NCT05716620|Diagnostic Test|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
79821603|NCT05006859|Other|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
79821604|NCT02566629|Other|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
79821605|NCT02566941|Device|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
79821606|NCT05000073|Other|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
79995708|NCT04941261|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
79821607|NCT05000073|Other|dialysis|dialysis
79821608|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
79821609|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
79995709|NCT00335049|Device|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
79995710|NCT00335049|Device|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
79995711|NCT01383525|Device|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
79223046|NCT02182323|Drug|BI 201335 NA|
79223047|NCT02182323|Drug|Placebo solution|
79223048|NCT03323684|Other|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
79365629|NCT03842007|Diagnostic Test|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
79365630|NCT03832790|Other|observation|observation
79518006|NCT05716464|Behavioral|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
79675222|NCT01242722|Device|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
79675223|NCT00484965|Procedure|Coronary stenting|
79995712|NCT05597709|Procedure|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
79675224|NCT02275806|Drug|Irinotecan|
79675225|NCT02275806|Drug|Cisplatin|
79675226|NCT01241409|Drug|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
79675227|NCT01241409|Drug|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
79821610|NCT04063917|Device|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
79821611|NCT04075032|Dietary Supplement|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
79821612|NCT04075032|Other|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
79995713|NCT04908969|Behavioral|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
79995714|NCT05420181|Other|Short 10hr fast|Participants will fast from 11pm the night before the study day
79995715|NCT05420181|Other|Long 16h fast|Participants will fast from 5pm the night before the study day
79995716|NCT03087513|Drug|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
79995717|NCT03087513|Drug|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
79995718|NCT05420103|Other|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
79675228|NCT01241409|Drug|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
79675229|NCT01242839|Device|CACICOL20|CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
79675230|NCT01242839|Device|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
79675231|NCT02275845|Drug|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
79675232|NCT02275845|Other|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
79223049|NCT03323684|Other|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
79223050|NCT03323684|Other|Control group (C)|No intervention will be done
79223051|NCT03323684|Drug|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
79223052|NCT03323684|Drug|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
79223053|NCT03323684|Drug|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
79223054|NCT02182401|Drug|BI 207127 NA|Days 3-8 and days 25-30
79223055|NCT02182401|Drug|BI 201335 NA|Days 15-30
79223056|NCT02182401|Drug|Midazolam|Days 1, 7, 23 and 29
79223057|NCT02182401|Drug|Tolbutamide|Days 1, 7, 23 and 29
79223058|NCT04292080|Drug|Dimethyl Fumarate (TECFIDERA™)|Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
79675233|NCT01241201|Dietary Supplement|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
79675234|NCT02275884|Dietary Supplement|Dark chocolate (85% cocoa)|
79675235|NCT02275884|Dietary Supplement|White chocolate (0% cocoa)|
79518007|NCT05716464|Behavioral|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
79223059|NCT04292080|Other|No active : no treatment|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
79223060|NCT03323606|Behavioral|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
79365631|NCT03827174|Other|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
79223061|NCT03323606|Behavioral|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
79223062|NCT02177955|Drug|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
79223063|NCT02177955|Drug|10 mg diazepam|10 mg midazolam 45 minutes before surgery
79223064|NCT04290988|Device|EEG Neurofeedback|Active EEG neurofeedback
79223065|NCT04290988|Device|Sham Feedback|Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
79223066|NCT03323528|Drug|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
79365632|NCT03827174|Behavioral|Behaviour Change Ability Program|"Return to work coordination~Education for employers and employees in pain neuroscience, validation and problem-solving.~Patient-specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
79365633|NCT03826693|Drug|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
79365634|NCT03826693|Drug|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
79365635|NCT03809598|Behavioral|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
79365636|NCT03806842|Device|Easytech group|total shoulder replacement
79821613|NCT04245345|Device|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
79821614|NCT02580786|Behavioral|Breastfeeding peer support|
79365641|NCT03769415|Device|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
79518008|NCT05716308|Behavioral|A continuous nursing intervention group was established.|Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
79675236|NCT00489398|Drug|epinastine HCL and olopatadine HCL|
79675237|NCT01241357|Device|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
79675238|NCT00485004|Device|Cutting balloon|Cutting balloon
79675239|NCT00485004|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
79223067|NCT03323528|Drug|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
79223068|NCT02180295|Biological|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
79223069|NCT02180295|Biological|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
79223070|NCT02180295|Biological|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
79675240|NCT01241396|Other|Any MMY treatment|Any line of treatment for MMY
79675241|NCT00485043|Behavioral|Modified T'ai Chi: T'ai Chi for Arthritis|
79675242|NCT00484991|Drug|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
79675243|NCT00485121|Drug|Ezetimibe|
79675244|NCT00489437|Device|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
79223071|NCT05501158|Drug|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
79223072|NCT03329534|Other|Gluten free diet|A month long gluten free diet
79223073|NCT03537807|Drug|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
79228084|NCT01320956|Other|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
79675245|NCT00489437|Procedure|Clinical Prediction Score-HIT Score Card|"clinical prediction rule~rapid immunoassay"
79675246|NCT00485160|Drug|Continuous indomethacin|
79995719|NCT04868643|Device|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
79365642|NCT03765983|Drug|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
79365643|NCT03765983|Drug|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
79223074|NCT03323450|Behavioral|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~Baseline before the participant is introduced to the CogMed® training program~Within 2 weeks of completion of the CogMed® program~At 3 months of completion of the CogMed® program to establish maintenance of gains~At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
79365644|NCT03761225|Drug|Masitinib|
79995720|NCT03631485|Other|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
79365645|NCT03761225|Drug|Docetaxel|
79365646|NCT03761225|Drug|Prednisone|
79365647|NCT03761225|Drug|Placebo|
79995721|NCT02917629|Other|Laboratory Biomarker Analysis|Correlative studies
79365648|NCT03755804|Drug|bendamustine|Given intravenously (IV)
79365649|NCT03755804|Drug|Etoposide|Given intravenously (IV)
79365650|NCT03755804|Drug|Doxorubicin|Given intravenously (IV)
79995722|NCT02917629|Drug|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
79365651|NCT03755804|Drug|Bleomycin|Given intravenously (IV)
79365652|NCT03755804|Drug|Vincristine|Given intravenously (IV)
79365653|NCT03755804|Drug|Vinblastine|Given intravenously (IV)
79365654|NCT03755804|Drug|Prednisone|Given orally (PO)
79675247|NCT00485160|Drug|ibuprofen|
79675248|NCT00485030|Device|Cypher|sirolimus-eluting stent
79675249|NCT00485030|Device|Xience-V|everolimus-eluting stent
79675250|NCT00485199|Procedure|Pneumatic Retinopexy|
79365655|NCT03755804|Drug|Filgrastim|Given subcutaneously (SQ) or IV
79365656|NCT03755804|Drug|Brentuximab Vedotin|Given intravenously (IV)
79675251|NCT00485199|Procedure|Vitrectomy with Gas|
79675252|NCT04514172|Device|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
79995723|NCT02917629|Other|Pharmacological Study|Correlative studies
79223075|NCT02182479|Drug|Berodual® via Respimat®, high dose|
79223076|NCT02182479|Drug|Berodual® via Respimat®, low dose|
79675253|NCT04514172|Other|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
79675254|NCT04513821|Drug|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
79675255|NCT00485108|Drug|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
79675256|NCT00485108|Drug|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
79223077|NCT02182479|Drug|Berodual® via MDI, high dose|
79365657|NCT03755804|Drug|Cyclophosphamide|Given intravenously (IV)
79675257|NCT00485108|Drug|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
79675258|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
79675259|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79995724|NCT02917629|Other|Placebo|Given PO
79365658|NCT03755804|Drug|DTIC|Given intravenously (IV)
79365659|NCT03755804|Other|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
79365660|NCT03755804|Radiation|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
79365661|NCT03754660|Drug|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
79365662|NCT03745651|Drug|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
79365663|NCT03745651|Drug|Vehicle cream|Ruxolitinib matching vehicle cream.
79365664|NCT03745638|Drug|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
79365665|NCT03745638|Drug|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
79995725|NCT05418543|Procedure|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
79995726|NCT03692988|Behavioral|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
79995727|NCT05417841|Drug|Insulin Degludec and Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp BID in T2DM
79995728|NCT05417841|Drug|Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
79518009|NCT05716230|Other|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
79995729|NCT03691194|Dietary Supplement|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
79675260|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79821615|NCT03900507|Procedure|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
79821616|NCT05741775|Other|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
79995730|NCT03691194|Dietary Supplement|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
79995731|NCT03691116|Behavioral|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
79995732|NCT03691116|Behavioral|Treatment as usual|Ordinary psychological assessment and counseling.
79995733|NCT03691038|Drug|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
79995734|NCT03691038|Drug|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
79995735|NCT03686982|Other|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
79995736|NCT03686982|Other|Placebo Bar|No active ingredients
79995737|NCT05597319|Procedure|Liver resection|Liver resection, different kind of according to pathology
79365666|NCT03742050|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
79365667|NCT03713515|Behavioral|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
79365668|NCT03704948|Behavioral|RCT Treatment -Listening Visits delivered by NICU nurse in person|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
79365669|NCT03704948|Behavioral|RCT Control Usual mental health care delivered by NICU social workers|RCT Control Usual mental health care delivered by NICU social workers
79675261|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79675262|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79675263|NCT04513704|Drug|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
79675264|NCT01241474|Dietary Supplement|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
79675265|NCT01241474|Dietary Supplement|Maize (corn) oil|6 x 1g capsules per day for 9 months
79675266|NCT00485238|Procedure|Argon laser Iridoplasty|
79675267|NCT00485238|Drug|Intravenous acetazolamide|
79675268|NCT00485277|Biological|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
79675269|NCT01242956|Behavioral|verum group|video-based training after stroke
79675270|NCT01242956|Behavioral|Placebo group|non-video group
79995738|NCT03690960|Procedure|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
79995739|NCT03690960|Procedure|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
79675271|NCT00485316|Procedure|Laparoscopic assisted resection of colorectal carcinoma|
79675272|NCT00485147|Procedure|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
79518010|NCT05716152|Diagnostic Test|Morning blood sample and skin punch biopsy of 4 mm diameter.|"Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
79518011|NCT05716074|Other|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
79518012|NCT05716074|Other|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
79518013|NCT05715840|Drug|SG001 injection|360 mg，Q3W，IV infusion
79518014|NCT05715840|Drug|Paclitaxel|175 mg/m^2，Q3W，IV infusion
79518015|NCT05715840|Drug|Cisplatin|50 mg/m^2，Q3W，IV infusion
79518016|NCT05715840|Drug|Carboplatin|AUC=5，Q3W，IV infusion
79518017|NCT05715840|Drug|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
79518018|NCT05715840|Drug|SG001 placebo|Q3W，IV infusion
79223078|NCT02182479|Drug|Placebo Respimat®|
79518019|NCT05715762|Behavioral|prone postion|ventilation at prone positioning
79675273|NCT00485355|Procedure|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
79365670|NCT03704948|Behavioral|Open trial: Listening Visits delivered by a NICU nurse via zoom|Open trial: Listening Visits delivered by a NICU nurse via zoom
79365671|NCT03701737|Other|questionnaires|"VAS on the feeling of hunger~Evaluation of food wanting by the Finlayson test~PREFQUEST Questionnaire~24-hour food recall~Stunkard Questionnaire~Measurement of daytime sleepiness by Epworth score"
79675274|NCT00485355|Procedure|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
79675275|NCT04513509|Drug|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
79675276|NCT00485342|Drug|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
79675277|NCT00485342|Drug|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
79675278|NCT00485394|Drug|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
79675279|NCT00485394|Drug|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
79821617|NCT05741775|Other|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
79821618|NCT05741619|Other|Long-term outcome|Autonomy, physical examination, behavioural disorders
79223079|NCT02182479|Drug|Placebo MDI|
79365672|NCT03701737|Device|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
79365673|NCT03701737|Biological|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
79365674|NCT03699475|Biological|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
79365675|NCT03699475|Drug|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
79365676|NCT03699475|Drug|Cyclophosphamide|GVHD prophylaxis
79365677|NCT03699475|Procedure|haplo-HSCT|treatment for disease
79365678|NCT03696160|Drug|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
79518020|NCT05715762|Drug|NO inhalation|NO inhalation at 20 ppm
79518021|NCT05715294|Other|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
79223080|NCT02560558|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
79223081|NCT03329456|Drug|Ropivacaine|Minimum effective volume
79228085|NCT02230215|Device|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
79518022|NCT05713734|Diagnostic Test|Thrombin generation|Measurement of thrombin generation by ST Genesia
79518023|NCT05713734|Diagnostic Test|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
79518024|NCT05713734|Diagnostic Test|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
79518025|NCT05713734|Diagnostic Test|Coated platelets|Measurement of coated platelets by flow cytometry
79518026|NCT05713656|Other|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
79223082|NCT02178033|Drug|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
79518027|NCT05713344|Other|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
79518028|NCT05713344|Other|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
79518029|NCT05713344|Other|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
79518030|NCT05713344|Other|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
79518031|NCT05713344|Diagnostic Test|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
79518032|NCT05698758|Drug|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
79518033|NCT05696184|Diagnostic Test|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
79518034|NCT05696184|Diagnostic Test|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
79675280|NCT00485394|Drug|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
79675281|NCT01242995|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
79675282|NCT04513587|Behavioral|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
79675283|NCT04513587|Behavioral|Control|Treatment as usual
79675284|NCT00489593|Drug|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
79675285|NCT01241487|Drug|valsartan/amlodipine|160/10 mg
79365679|NCT03696160|Drug|Symtuza|Protease inhibitor used to treat HIV-1 infection
79675286|NCT00489632|Behavioral|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
79365680|NCT03680586|Drug|Radiation Therapy|Undergo ultra low-dose radiation
79821619|NCT00921297|Procedure|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
79365681|NCT03678376|Other|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
79223083|NCT02491736|Drug|Ketoprofen|2.5% ketoprofen gel
79223084|NCT02491736|Other|Placebo|Placebo gel
79223085|NCT05501080|Other|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
79365682|NCT03675126|Drug|SRP-5051|SRP-5051 administered as an IV infusion.
79365683|NCT03674424|Drug|Avelumab|Chemotherapy with or without avelumab followed by surgery
79675287|NCT00505791|Drug|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
79675288|NCT00485420|Other|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
79821620|NCT04902729|Drug|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
79518035|NCT05661864|Behavioral|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
79223086|NCT05501080|Drug|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
79223087|NCT02256657|Behavioral|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
79365684|NCT03674424|Procedure|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
79675289|NCT02955108|Procedure|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
79365685|NCT03674424|Combination Product|CG|Chemotherapy 4 cycles of 3 weeks
79365686|NCT03674424|Combination Product|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
79821621|NCT04902729|Drug|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
79365687|NCT03674424|Combination Product|PG|Chemotherapy 2 cycles of 4 weeks
79365688|NCT03672747|Device|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
79518036|NCT05642520|Procedure|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
79675290|NCT02955108|Procedure|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
79675291|NCT04697303|Other|anorectal function test|anorectal function test
79675292|NCT02274207|Device|NPWT application|NPWT mode is cyclic mode : -125~-50 mmHg
79675293|NCT00485459|Drug|Atomoxetine Hydrochloride|
79675294|NCT00485459|Drug|Placebo|
79821622|NCT03674814|Drug|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
79995740|NCT03683160|Other|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
79995741|NCT03683082|Drug|Oxygen supplementation|40% FiO2 via Venturi mask
79995742|NCT03683082|Drug|Sham O2 (medical air)|Medical air supplementation via Venturi mask
79995743|NCT03686826|Procedure|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
79223088|NCT03331406|Other|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
79365689|NCT03668613|Drug|secukinumab low dose|dose depends on the weight group
79675295|NCT04513431|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
79675296|NCT02274246|Drug|gadobutrol|Gadobutrol administration in healthy volunteers
79821623|NCT03674814|Drug|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
79821624|NCT03912558|Procedure|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
79821625|NCT05087394|Other|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
79995744|NCT03682926|Other|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
79365690|NCT03668613|Drug|secukinumab high dose|dose depends on the weight group
79365691|NCT03650413|Drug|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
79365692|NCT03649503|Other|No intervention|
79365693|NCT03637205|Procedure|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
79365694|NCT03637205|Other|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
79365695|NCT03628989|Behavioral|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
79518037|NCT05642520|Procedure|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
79518038|NCT05598918|Procedure|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
79995745|NCT03690882|Other|systematic review of medical imaging|
79365696|NCT03613909|Device|CP950 OTE Sound processor|CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor
79675297|NCT01241630|Procedure|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
79223089|NCT04721938|Behavioral|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~Counselling with a Nutritionist Nurse on diet and exercise~Online Smartphone coaching program (Life-sum App)~Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
79223090|NCT02491970|Drug|Fluticasone/Formoterol|
79675298|NCT00489749|Procedure|Protected early weightbearing/Achilles tendon surgery|
79821626|NCT00698685|Drug|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
79995746|NCT03686748|Behavioral|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
79675299|NCT04513275|Drug|non-medicine intervention|rating by MCCB only one time
79675300|NCT02274194|Device|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
79675301|NCT02274194|Device|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
79675302|NCT00505830|Other|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
79675303|NCT02274233|Drug|SP-420|
79675304|NCT04697511|Drug|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
79675305|NCT04697511|Drug|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
79675306|NCT00485511|Drug|Hydroxyurea|
79675307|NCT02274272|Other|ADR-1|two ADR-1 capsules, once daily, QD
79995747|NCT03686748|Behavioral|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
79995748|NCT02927847|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
79223091|NCT02491970|Drug|Fluticasone/Salmeterol|
79223092|NCT02491814|Other|1% M.F. Milk|
79223093|NCT02491814|Other|Yogurt Beverage|
79223094|NCT02491814|Other|Soy Beverage|
79223095|NCT02491814|Other|Almond Beverage|
79223096|NCT02491814|Other|Water|
79223097|NCT02491814|Other|Breakfast cereal|
79223098|NCT02182557|Drug|WAL 801 CL Dry Syrup|
79223099|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup|
79223100|NCT02182557|Drug|WAL 801 CL Dry Syrup placebo|
79223101|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup placebo|
79223102|NCT02182635|Drug|Ba253BINEB|
79223103|NCT02182713|Drug|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
79223104|NCT02182713|Drug|Salbutamol|Salbutamol 100 mcg per puff
79223105|NCT02490644|Procedure|Blood sampling|Blood sampling 5ml
79223106|NCT03331328|Device|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
79365697|NCT03611374|Procedure|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
79365698|NCT03608631|Drug|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
79675308|NCT02274272|Other|GMNL-263|two GMNL-263 capsules, once daily, QD
79675309|NCT02274272|Other|placebo|two placebo capsules, once daily, QD
79675310|NCT04512963|Drug|Progerinin|100 mg/g nano-suspension for oral use
79995749|NCT02927847|Drug|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
79995750|NCT02927847|Behavioral|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
79223107|NCT03323372|Drug|3% potassium nitrate and 0.25% sodium fluoride|
79821627|NCT00698685|Biological|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
79223108|NCT03323372|Drug|5% potassium nitrate and 2% sodium fluoride|
79223109|NCT02178111|Other|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
79223110|NCT02178111|Procedure|episiotomy|
79223111|NCT03329222|Other|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
79223112|NCT03329222|Other|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
79223113|NCT05509426|Behavioral|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
79518039|NCT05598918|Procedure|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
79518040|NCT05582226|Procedure|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
79223114|NCT02180529|Drug|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
79223115|NCT02180529|Drug|Placebo|
79223116|NCT04412122|Other|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
79223117|NCT04412122|Other|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
79365699|NCT03597555|Drug|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
79365700|NCT03597555|Drug|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
79518041|NCT05582226|Procedure|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
79675311|NCT04512963|Drug|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
79675312|NCT00485498|Drug|Olanzapine Hydrochloride|
79223118|NCT04412122|Other|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
79223119|NCT04412122|Other|Control Group|No intervention was performed to reduce pain in the control group.
79223120|NCT02178189|Other|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
79365701|NCT03596242|Other|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
79365702|NCT03596242|Behavioral|blood pressure control education|standard blood pressure control education given during visits
79675313|NCT00485498|Drug|Risperidone|
79675314|NCT01302067|Drug|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
79675315|NCT01302067|Drug|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
79675316|NCT01302067|Drug|Placebo|Oral, 1 tablet per day, 12 weeks duration
79675317|NCT00485550|Drug|Atomoxetine Hydrochloride|
79675318|NCT00485550|Drug|Methylphenidate Hydrochloride|
79675319|NCT00485550|Drug|Placebo|
79821628|NCT00698685|Procedure|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
79821629|NCT00737672|Device|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
79821630|NCT00737672|Procedure|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
79223121|NCT02178189|Other|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
79675320|NCT04697147|Behavioral|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
79675321|NCT00485537|Procedure|oocyte retrieval and ICSI procedure|
79675322|NCT00485628|Drug|Atomoxetine Hydrochloride|
79675323|NCT00485576|Drug|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
79995751|NCT02927847|Behavioral|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
79223122|NCT03323216|Diagnostic Test|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the CRT implantation and 6 months after the CRT implantation."
79365703|NCT03580759|Behavioral|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
79223123|NCT03323216|Diagnostic Test|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior the CRT implantation and 6 months after the CRT implantation."
79365704|NCT03575364|Device|ClotTriever|Thrombectomy
79365705|NCT03575026|Behavioral|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
79365706|NCT03575026|Behavioral|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
79675324|NCT00485667|Drug|SKY0402|Subects received either 300mg or 450mg
79675325|NCT00485667|Drug|Moxifloxacin 400mg|
79675326|NCT00485667|Drug|Placebo injection|
79675327|NCT00485667|Drug|Placebo tablet|
79675328|NCT01301950|Other|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
79675329|NCT01301950|Other|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
79675330|NCT00489905|Drug|Zolderonic acid (Zometa)|
79675331|NCT00485615|Drug|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
79223124|NCT03323216|Procedure|Blood collection|"Blood collection during surgery:~coronary sinus~arterial~peripheral venous~Blood collection 6 months after surgery:~- peripheral venous"
79223125|NCT02182791|Drug|Nevirapine|
79223126|NCT02182791|Drug|EE/NET|
79228087|NCT02230293|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
79228088|NCT02230293|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
79365707|NCT03571308|Drug|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
79365708|NCT03565575|Behavioral|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
79365709|NCT03555708|Other|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
79365710|NCT03552783|Behavioral|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
79365711|NCT03552783|Behavioral|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~Personal responsibility~Personal responsibility to your child~Responsibility to your family and community"
79365712|NCT03548792|Radiation|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
79365713|NCT03548792|Behavioral|Clinical comparison|ActivePAL, walking speed
79675332|NCT00489944|Drug|cisplatin|
79675333|NCT00489944|Drug|sunitinib malate|
79675334|NCT00489944|Drug|tamoxifen citrate|
79821631|NCT02580084|Procedure|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
79995752|NCT03690804|Device|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
79365714|NCT03529695|Behavioral|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
79995753|NCT03682692|Drug|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
79995754|NCT03682692|Drug|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
79223127|NCT03329144|Behavioral|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
79223128|NCT03329066|Behavioral|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
79223129|NCT03329066|Behavioral|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
79365715|NCT03529695|Behavioral|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
79365716|NCT03529448|Drug|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
79518042|NCT05557812|Drug|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
79675335|NCT00489944|Procedure|adjuvant therapy|
79675336|NCT00485706|Procedure|high calcium dialysate|
79675337|NCT00505869|Behavioral|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
79675338|NCT00505869|Behavioral|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
79518043|NCT05557812|Drug|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
79675339|NCT00505869|Behavioral|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
79995755|NCT02886585|Drug|Pembrolizumab|
79995756|NCT02886585|Radiation|MRI|
79223130|NCT03329066|Behavioral|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
79223131|NCT03536325|Drug|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
79223132|NCT03536325|Drug|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
79518044|NCT05549466|Drug|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
79518045|NCT05549466|Drug|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
79518046|NCT05549466|Drug|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
79675340|NCT00505947|Drug|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
79675341|NCT00505947|Drug|placebo|placebo 5 mg/Kg body weight by intravenous infusion
79675342|NCT00489983|Drug|pemetrexed|
79675343|NCT00489983|Drug|gemcitabine|
79675344|NCT01241682|Biological|DC + CTX|3x 50x10e6 DC + cyclophosphamide
79675345|NCT01241669|Drug|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
79223133|NCT03536325|Drug|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
79223134|NCT03536325|Drug|Placebo|Participants will receive matching placebo on Day 1.
79675346|NCT01241669|Drug|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
79995757|NCT02886585|Radiation|PET/CT|
79675347|NCT00505986|Procedure|endometrial biopsy|
79675348|NCT01241825|Other|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
79675349|NCT01241825|Other|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
79675350|NCT01241721|Device|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
79518047|NCT05549466|Drug|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.
79821632|NCT02580084|Procedure|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
79518048|NCT05544318|Other|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
79518049|NCT05540652|Behavioral|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
79821633|NCT05673954|Diagnostic Test|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
79995758|NCT02886585|Procedure|Stereotactic Radiosurgery|
79995759|NCT01568853|Drug|Norepinephrine|Intravenously, 10 ug/min, 24 hours
79995760|NCT01568853|Procedure|Open abdomen|IAH >=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
79995761|NCT01568853|Other|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
79995762|NCT01568853|Other|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
79995763|NCT02960438|Drug|E6011|subcutaneous administration
79995764|NCT02960438|Drug|Placebo|subcutaneous administration
79995765|NCT03690726|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
79223135|NCT03536637|Drug|DMT310|Topical Powder
79223136|NCT03536637|Drug|Hydrogen Peroxide|Liquid Diluent
79223137|NCT03536637|Drug|Placebo|Placebo Topical Powder
79223138|NCT02488538|Drug|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
79223139|NCT02488538|Drug|Fluoxetine|women will receive oral fluoxetine 20 mg daily
79223140|NCT02488538|Drug|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
79223141|NCT02488538|Drug|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
79995766|NCT03690726|Other|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
79995767|NCT02853591|Procedure|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
79995768|NCT03686592|Other|Measurement of body awareness|Questionnaires+ interviews
79995769|NCT03808506|Diagnostic Test|Fecal calprotectin|Stool test to look at baseline burden of inflammation
79995770|NCT03686436|Device|ocular coherence tomography|imaging by ocular coherence tomography
79995771|NCT03686358|Procedure|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~Identification of prognostic factors"
79821634|NCT02594696|Other|Proactive Psychiatry Consultation (PPC)|"The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~Recommendations are documented in the medical record and communicated directly to the oncology team"
79821635|NCT00737438|Drug|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
79995772|NCT03686280|Other|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
79995773|NCT03686280|Other|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
79821636|NCT00737282|Drug|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
79821637|NCT00737282|Drug|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
79821638|NCT03884478|Behavioral|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
79365717|NCT03529448|Drug|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
79365718|NCT03529448|Radiation|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
79365719|NCT03526250|Other|Laboratory Biomarker Analysis|Correlative studies
79821639|NCT03448458|Procedure|CT (Computed Tomography)|Undergo PET/CT
79821640|NCT03448458|Drug|Gallium Ga 68-DOTATATE|Given IV
79821641|NCT03448458|Procedure|Positron Emission Tomography|Undergo PET/CT
79821642|NCT04075422|Drug|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
79821643|NCT04075968|Other|Cognitive exercise|Cognitive exercise will be applied
79821644|NCT04075968|Other|Home exercise|Home exercise will be applied
79223142|NCT02488538|Procedure|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
79223143|NCT02180685|Other|Anchor fixation|
79365720|NCT03526250|Drug|Palbociclib|Given PO
79675351|NCT01241942|Device|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
79675352|NCT01241942|Other|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
79223144|NCT04492826|Procedure|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
79223145|NCT02568046|Drug|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
79223146|NCT02568046|Drug|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m^2 IV bolus, then 2400 mg/m^2 infused over 46 hours).
79223147|NCT02180763|Biological|Gammanorm|Sub-Q IgG
79223148|NCT02488460|Behavioral|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
79223149|NCT03536481|Drug|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
79223150|NCT03536481|Drug|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
79223151|NCT02488616|Other|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
79223152|NCT02488616|Other|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
79518050|NCT05520450|Behavioral|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
79518051|NCT05519436|Other|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
79675353|NCT00490178|Drug|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
79675354|NCT01241799|Procedure|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
79675355|NCT01241799|Procedure|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
79675356|NCT01241838|Device|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
79675357|NCT00485771|Drug|Olanzapine|
79675358|NCT00485771|Drug|Fluoxetine|
79675359|NCT00485771|Drug|Lamotrigine|
79675360|NCT01241877|Dietary Supplement|astaxanthin|astaxanthin
79821645|NCT03414372|Behavioral|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
79995774|NCT03686280|Other|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
79223153|NCT02488616|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
79223154|NCT02488616|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
79223155|NCT02488616|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
79365721|NCT03526250|Other|Pharmacological Study|Correlative studies
79365722|NCT03519412|Drug|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
79675361|NCT01241877|Dietary Supplement|placebo|placebo
79675362|NCT04512729|Diagnostic Test|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
79675363|NCT00485784|Other|Blood test|Blood test
79675364|NCT00485810|Drug|Olanzapine Hydrochloride|
79679864|NCT00521183|Drug|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
79675365|NCT04512651|Other|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
79995775|NCT03686280|Other|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
79223156|NCT05094219|Other|No intervention will be offered|No intervention will be offered
79223157|NCT03323138|Procedure|Ex-PRESS and phacoemulsification|
79223158|NCT03323060|Device|Transanal endoscopic surgical procedure|Resection of tumors or lesions
79223159|NCT03328910|Device|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
79518052|NCT05517252|Other|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
79518053|NCT05517252|Other|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
79223160|NCT02256423|Drug|REFERENCE 1: Nurofen® 200 mg tablet|
79223161|NCT02256423|Drug|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
79518054|NCT05508360|Device|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
79518055|NCT05505162|Drug|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
79518056|NCT05505162|Drug|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
79518057|NCT05505084|Procedure|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
79518058|NCT05504304|Procedure|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
79223162|NCT02256423|Drug|ibuprofen 200 mg soft gel capsule|
79223163|NCT03322982|Behavioral|Low-fat diet|less than 20% calories from fat daily
79223164|NCT05141097|Other|Integrative medicine approach|By treated by integrative medicine approaches instead of conventional medicine
79223165|NCT02185677|Other|Clinical evaluation|
79223166|NCT02185677|Other|neuropsychological battery test|
79223167|NCT02185677|Other|MRI|
79223168|NCT02185677|Other|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
79223169|NCT05464472|Device|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
79223170|NCT03320486|Drug|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
79675366|NCT04512651|Other|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
79675367|NCT00490373|Drug|pemetrexed|
79675368|NCT00485823|Drug|Olanzapine Hydrochloride|
79675369|NCT00485823|Procedure|Weight Management Program|
79675370|NCT00485849|Drug|Atomoxetine Hydrochloride|
79223171|NCT03320486|Drug|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
79223172|NCT02180919|Device|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
79228089|NCT04491656|Other|WALANT Technique|A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
79228090|NCT02499900|Drug|Copaxone®|Subcutaneous Injections
79675371|NCT04512417|Drug|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
79518059|NCT05504304|Procedure|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
79518060|NCT05473572|Behavioral|Fluency shaping exercises|Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
79821646|NCT03414372|Behavioral|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
79365723|NCT03519412|Biological|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
79223173|NCT03322904|Diagnostic Test|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula [IEC-PC¬] - [CC-PC] / [CC-PC]."
79223174|NCT02567656|Drug|RP6530|Tablet starting at 200 mg
79223175|NCT02182869|Drug|Combivent® HFA inhalation aerosol|
79223176|NCT02182869|Drug|Combivent® CFC inhalation aerosol|
79518061|NCT05436678|Drug|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
79518062|NCT05436678|Drug|Ciprofloxacin 750 MG|Ciprofloxacin
79223177|NCT03109106|Device|PCT Arm|PCT-guided antibiotic therapy per study protocol
79223178|NCT02185833|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
79518063|NCT05436678|Drug|Celecoxib 200mg|Celecoxib
79365724|NCT03517761|Biological|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
79223179|NCT02185833|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
79365725|NCT03517761|Other|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
79365726|NCT03514433|Other|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 6 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
79675372|NCT04512417|Drug|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
79675373|NCT00485888|Drug|Cipralex|10-20mg; one per day
79675374|NCT00485888|Drug|Placebo|Matched to Cipralex
79675375|NCT00485862|Drug|Atomoxetine Hydrochloride|
79675376|NCT00485862|Drug|Sertraline|
79675377|NCT00485862|Drug|Placebo|
79223180|NCT02488382|Drug|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
79223181|NCT05505682|Biological|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
79223182|NCT02180997|Drug|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
79223183|NCT02180997|Drug|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
79223184|NCT02180997|Drug|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
79223185|NCT03328754|Device|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
79223186|NCT03328754|Device|Group 2 Forsus|Forsus placed bilaterally for class II correction
79223187|NCT03322826|Procedure|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
79223188|NCT03322826|Procedure|lymphadenectomy|Routine lymph nodes dissection in lung cancer
79223189|NCT02491502|Device|Echopulse|HIFU Under ultrasound guidance
79675378|NCT00485927|Behavioral|stress|
79675379|NCT00485901|Drug|Olanzapine Hydrochloride|
79675380|NCT00485901|Drug|Haloperidol|
79675381|NCT00490412|Dietary Supplement|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
79675382|NCT00490412|Other|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
79675383|NCT01241955|Behavioral|video decision aid|video of CPR
79518064|NCT05426772|Other|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
79518065|NCT05425134|Diagnostic Test|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
79518066|NCT05405010|Other|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
79518067|NCT05405010|Other|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
79675384|NCT00485966|Drug|CX-3543|360 mg/m2 daily x 5 q 21 days
79223190|NCT03328520|Behavioral|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
79821647|NCT03414372|Behavioral|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
79821648|NCT00582816|Device|Clinimacs Cell Separation System|Depletion of T-cells
79821649|NCT00582816|Drug|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
79995776|NCT03686280|Other|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
79223191|NCT05505526|Other|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
79365727|NCT03513406|Drug|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
79223192|NCT05505526|Other|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
79365728|NCT03513406|Drug|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
79365729|NCT03513406|Drug|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
79365730|NCT03504163|Drug|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
79365731|NCT03504163|Drug|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
79365732|NCT03500458|Behavioral|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
79365733|NCT03492944|Drug|Ultrasound Microbubble Contrast Agent|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
79518068|NCT05405010|Other|Seated control|Seated control
79675385|NCT00485940|Drug|Prucalopride|2 mg o.d.
79675386|NCT00485940|Other|Placebo|Placebo o.d.
79675387|NCT00485940|Drug|Prucalopride|4 mg o.d.
79675388|NCT00486005|Drug|Olanzapine Hydrochloride|
79675389|NCT00486005|Drug|Nizatidine|
79675390|NCT00486005|Drug|Placebo|
79675391|NCT00485979|Drug|larotaxel (XRP9881)|intravenous administration
79675392|NCT00485979|Drug|docetaxel|intravenous administration
79675393|NCT00485979|Drug|trastuzumab|intravenous administration
79675394|NCT00486083|Drug|Atomoxetine Hydrochloride|
79675395|NCT00486083|Drug|Methylphenidate Hydrochloride|
79675396|NCT04512027|Other|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
79821650|NCT00582816|Other|DLI|NK Cell selected DLI
79821651|NCT00737048|Drug|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
79675397|NCT04512027|Other|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
79675398|NCT00490685|Drug|Sorafenib (BAY-43-9006)|
79675399|NCT00486122|Drug|Atomoxetine Hydrochloride|
79675400|NCT00486122|Drug|Placebo|
79821652|NCT00737048|Drug|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
79995777|NCT03686280|Other|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
79223193|NCT02488226|Other|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
79518069|NCT05403060|Behavioral|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
79223194|NCT05509114|Device|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
79365734|NCT03492944|Device|Ultrasound Imaging|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
79223195|NCT02488304|Radiation|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2."
79223196|NCT03322748|Other|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
79365735|NCT03481387|Device|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
79518070|NCT05352282|Procedure|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
79518071|NCT05352282|Procedure|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
79518072|NCT05343624|Device|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
79518073|NCT05333328|Drug|Ovarian function suppression with endocrine treatments|"Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~Either goserelin acetate or leuprorelin Acetate is allowed.~These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~Chemotherapy is omitted in these patients."
79675401|NCT04511715|Drug|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
79675402|NCT04511715|Other|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
79223197|NCT03322748|Other|Usual physical therapy|Usual physical therapy
79223198|NCT03322670|Other|Signs of CAP and a positive chest X-Ray|"collection of clinical examination data~biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~self-reported questionnaires on duration of symptoms and restriction of activity~telephone contact on day 28 and day 90 if hospitalized before day 28"
79675403|NCT00486135|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
79675404|NCT00486135|Drug|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
79223199|NCT03322670|Other|Patients directly hospitalized|"collection of clinical examination data~telephone contact on day 28 and retrieval of hospitalization report~telephone contact on day 90"
79223200|NCT03322670|Diagnostic Test|Control patients|- bacteriological examinations (urine)
79223201|NCT03322670|Other|Patients with partial participation|- collection of clinical examination data
79223202|NCT03322670|Other|Signs of CAP and a negative chest X-Ray|"collection of clinical examination data~telephone contact on day 28"
79223203|NCT02560012|Drug|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
79365736|NCT03471078|Drug|Avatrombopag|Oral avatrombopag tablet
79675405|NCT00486317|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
79675406|NCT04511910|Procedure|Early Laparoscopic Cholecystectomy|
79675407|NCT00490880|Drug|gemcitabine|
79675408|NCT00490880|Drug|cisplatin|
79675409|NCT00490880|Procedure|radical cystectomy|
79675410|NCT00490880|Procedure|radiotherapy|
79223204|NCT02560012|Drug|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
79223205|NCT02560012|Drug|Sorafenib|400 mg (2 tablets) orally twice daily without food
79223206|NCT02560012|Drug|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
79821653|NCT00737048|Drug|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
79223207|NCT02560012|Drug|Everolimus|10 mg orally once daily with or without food
79365737|NCT03471078|Drug|Placebo Oral Tablet|Placebo comparator tablet
79365738|NCT03469960|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
79675411|NCT01241994|Other|AASD dialysis technique|
79518074|NCT05322330|Drug|Selinexor|40-60mg QW,w-3～d-3,PO
79995778|NCT03686280|Other|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
79223208|NCT02560012|Drug|Axitinib|5 mg orally twice daily
79223209|NCT03320174|Drug|Tafenoquine|Tafenoquine 200mg
79223210|NCT03320174|Other|Placebo|Placebo
79223211|NCT05500768|Procedure|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
79365739|NCT03469960|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
79365740|NCT03465748|Device|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
79518075|NCT05322330|Drug|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
79518076|NCT05322330|Drug|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
79518077|NCT05322330|Drug|CAR-T|2-5×10^6 CAR-T/kg，ivgtt。
79518078|NCT05319990|Drug|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
79365741|NCT03464955|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
79518079|NCT05319990|Drug|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
79518080|NCT05720754|Drug|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
79518081|NCT05720754|Device|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
79518082|NCT05311020|Dietary Supplement|Placebo drink|consume 1 bottle per day
79518083|NCT05311020|Dietary Supplement|Pitaya Ovule Extract Drink|consume 1 bottle per day
79675412|NCT01242033|Dietary Supplement|red raspberries|single serving of one, two or four cups red raspberries
79675413|NCT01242033|Dietary Supplement|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
79223212|NCT05500768|Procedure|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
79223213|NCT03328442|Procedure|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
79223214|NCT03328442|Procedure|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
79223215|NCT03328364|Drug|enzalutamide|oral
79223216|NCT03328364|Drug|docetaxel|intravenous infusion
79223217|NCT05505370|Device|Colonoscopy|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
79223218|NCT03328286|Behavioral|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
79223219|NCT03322592|Diagnostic Test|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
79223220|NCT03322592|Diagnostic Test|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
79223221|NCT03322436|Diagnostic Test|HeartLinc kit|Samples are collected and analyzed afterwards
79365742|NCT03451916|Drug|PLX-PAD|PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
79365743|NCT03451916|Drug|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
79365744|NCT03435952|Drug|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
79365745|NCT03435952|Biological|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10^4 spores followed by dose escalation."
79518084|NCT05301504|Biological|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
79518085|NCT05286684|Procedure|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
79518086|NCT05286684|Procedure|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
79518087|NCT05286684|Biological|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
79675414|NCT00486174|Drug|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
79675415|NCT04511793|Device|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
79675416|NCT00490958|Drug|telmisartan|
79995779|NCT02957942|Device|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
79518088|NCT05251038|Drug|Sotorasib|Intervention instruction outlined in protocol
79518089|NCT05251038|Drug|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
79995780|NCT04059354|Behavioral|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
79995781|NCT03640910|Device|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
79995782|NCT03640910|Device|Locator® (Zest)|Attachment systems to retain an implant overdenture
79995783|NCT03686046|Other|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
79995784|NCT03682380|Drug|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
79995785|NCT03682380|Drug|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
79995786|NCT03640442|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
79223222|NCT03328052|Device|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
79223223|NCT03328052|Other|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
79995787|NCT03640442|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
79995788|NCT03690492|Other|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
79223224|NCT04514302|Drug|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
79518090|NCT05251038|Drug|5 Fluorouracil (5FU)|Per standard of care
79518091|NCT05251038|Drug|Leucovorin (LV)|Per standard of care
79518092|NCT05251038|Drug|Gemcitabine (GEM)|Per standard of care
79518093|NCT05251038|Drug|Nab paclitaxel|Per standard of care
79518094|NCT05244096|Other|No intervention|Observational study
79518095|NCT05220306|Device|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
79675417|NCT00486213|Dietary Supplement|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
79518096|NCT05203692|Drug|DS-7011a|Intravenous or subcutaneous administration, single dose
79518097|NCT05203692|Drug|Placebo|Intravenous or subcutaneous administration, single dose
79518098|NCT05195502|Diagnostic Test|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
79675418|NCT00486213|Other|Placebo|
79675419|NCT00486395|Device|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
79675420|NCT00486395|Device|Mechanical ventilation|Volume guarantee strategy
79675421|NCT00486369|Drug|Oral salmon calcitonin|
79675422|NCT00490997|Drug|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
79675423|NCT00490997|Drug|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
79679865|NCT00521183|Radiation|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
79679866|NCT02938026|Procedure|Bariatric surgery|
79995789|NCT03690414|Drug|Experimental BHVI2|Experimental BHVI2 eye drops
79995790|NCT03690414|Drug|Atropine sulfate 0.02% eye drops|Atropine eye drops
79995791|NCT03690414|Combination Product|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
79995792|NCT02959970|Drug|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
79518099|NCT05184894|Behavioral|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
79365746|NCT03435952|Drug|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
79821654|NCT00737048|Drug|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
79365747|NCT03421145|Device|3M™ Oral Rinse|The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).
79821655|NCT03627624|Other|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
79995793|NCT03690258|Device|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
79223225|NCT04514302|Drug|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
79223226|NCT05508958|Procedure|Anterior approach|Anterior approach
79223227|NCT05508958|Procedure|Posterolateral approach|Posterolateral approach
79223228|NCT03327974|Other|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
79223229|NCT03327896|Other|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
79365748|NCT03421145|Other|Vehicle Control Oral Rinse|The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.
79365749|NCT03421145|Device|PerioShield™ Oral Health Rinse|PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.
79365750|NCT03421145|Other|Water|Purified bottled water containing no active ingredients.
79518100|NCT05181072|Behavioral|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
79518101|NCT05181072|Behavioral|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
79679867|NCT02938026|Behavioral|Telephone Intensive Lifestyle Counselling|
79518102|NCT05173428|Behavioral|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
79518103|NCT05166018|Diagnostic Test|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
79679868|NCT00521573|Other|Dark chocolate|
79679869|NCT02937714|Other|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents & school based interventions for various psychiatric problems
79821656|NCT00731822|Drug|GW685698/GW642444|GW685698/GW642444
79821657|NCT04076358|Behavioral|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
79821658|NCT02593448|Procedure|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~30 minutes after anaesthesia induction,~directly after the sternotomy,~during CPB - 20 minutes after aortic cross-clamping ,~40 minutes after aortic cross-clamping,~20 minutes after the release of the aortic cross-clamp,~45 minutes after weaning of CPB."
79995794|NCT03921996|Procedure|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
79995795|NCT03921996|Procedure|Radical prostatectomy (RP) only|Radical prostatectomy
79995796|NCT03690180|Diagnostic Test|serum magnesium|assessment of serum magnesium in all patients
79365751|NCT03418779|Drug|The Yi-Qi-Qing-Jie herbal compound|The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
79518104|NCT05151822|Other|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
79518105|NCT05151822|Other|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
79518106|NCT05151822|Other|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
79675424|NCT04511949|Diagnostic Test|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
79675425|NCT00486473|Drug|Multihance|0.5 Molar at a single dose injection
79675426|NCT00486473|Drug|Magnevist|0.5M at a single dose injection
79675427|NCT00486408|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5x10^10 Ad vg
79675428|NCT00486590|Procedure|Prolact-Plus Human Milk Fortifier|
79675429|NCT04511637|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
79995797|NCT03623880|Behavioral|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
79223230|NCT03319862|Procedure|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
79223231|NCT04796038|Device|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
79223232|NCT03319784|Drug|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
79223233|NCT03319784|Drug|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
79675430|NCT04511637|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
79675431|NCT00491036|Device|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
79675432|NCT00486486|Drug|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
79821659|NCT02593448|Procedure|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
79995798|NCT03623880|Behavioral|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
79995799|NCT03681990|Drug|3M CHG/IPA Prep|Apply topically to intact skin
79995800|NCT03681834|Other|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
79995801|NCT04690413|Device|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
79223234|NCT03319706|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
79223235|NCT03319706|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
79365752|NCT03418779|Drug|Immunosuppressants|Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes < 3.0 × 109/L and platelets < 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
79365753|NCT03418779|Other|Optimized Supportive Care|"The optimized supportive care included:~Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~The use of renin-angiotensin system blockade: lowering blood pressure to a target below 135/85 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c≤ 7.0%~Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid <6 mg/dL in female, <7 mg/dL in male"
79518107|NCT05151822|Other|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
79518108|NCT05132478|Other|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
79518109|NCT05132478|Other|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
79675433|NCT00486486|Drug|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
79675434|NCT04511481|Other|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
79821660|NCT02593448|Procedure|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
79995802|NCT02740335|Drug|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
79223236|NCT05045170|Drug|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
79365754|NCT03418779|Other|Yi-Qi-Qing-Jie herbal compound placebo|Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. The major component of the placebo is malt dextrin which looks, smells and tastes like YQF compound, and it comes in packaging with a similar appearance to YQF compound; it is also dissolved in 150 ml boiled water and taken orally twice a day.
79365755|NCT03418038|Dietary Supplement|Ascorbic Acid|Given IV
79365756|NCT03418038|Drug|Carboplatin|Given IV or PO
79365757|NCT03418038|Drug|Cisplatin|Given IV or PO
79365758|NCT03418038|Drug|Cytarabine|Given IV or PO
79675435|NCT00491114|Drug|Gemcitabine|
79675436|NCT00486564|Drug|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
79821661|NCT00731666|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
79365759|NCT03418038|Drug|Dexamethasone|Given IV or PO
79365760|NCT03418038|Drug|Etoposide|Given IV or PO
79365761|NCT03418038|Drug|Gemcitabine Hydrochloride|Given IV or PO
79365762|NCT03418038|Drug|Ifosfamide|Given IV or PO
79365763|NCT03418038|Other|Laboratory Biomarker Analysis|Correlative studies
79365764|NCT03418038|Drug|Oxaliplatin|Given IV or PO
79365765|NCT03418038|Other|Placebo Administration|Given normal saline IV
79518110|NCT05117970|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
79675437|NCT00486668|Drug|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
79675438|NCT00486668|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
79675439|NCT00486668|Drug|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
79675440|NCT00486668|Drug|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
79675441|NCT00486668|Drug|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
79675442|NCT04511598|Device|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
79675443|NCT04511598|Device|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
79675444|NCT00486681|Device|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
79365766|NCT03418038|Other|Questionnaire Administration|Ancillary studies
79365767|NCT03418038|Biological|Rituximab|Given IV
79365768|NCT03409588|Drug|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
79365769|NCT03404297|Other|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
79675445|NCT00486707|Behavioral|Questionnaire|A questionnaire will be completed.
79821662|NCT05015166|Behavioral|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
79821663|NCT05015166|Behavioral|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
79995803|NCT02740335|Drug|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
79821664|NCT02592746|Drug|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
79365770|NCT03387085|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
79821665|NCT02592746|Drug|Exemestane|Exemestane 25mg, orally once daily
79995804|NCT03690102|Other|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
79821666|NCT02592746|Drug|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
79821667|NCT02592746|Drug|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
79675446|NCT04510935|Procedure|general anesthesia|the patient will receive general anesthesia during surgery in this group.
79821668|NCT02833428|Device|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
79821669|NCT03922464|Device|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
79821670|NCT00731120|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
79365771|NCT03387085|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79995805|NCT03690102|Other|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
79223237|NCT05045170|Drug|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
79365772|NCT03387085|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79365773|NCT03387085|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79365774|NCT03387085|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
79365775|NCT03387085|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79365776|NCT03387085|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
79365777|NCT03387085|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
79675447|NCT04510935|Procedure|local anesthesia|the patient will receive local anesthesia during surgery in this group.
79365778|NCT03387085|Biological|haNK for Infusion|NK-92 [CD16.158V, ER IL-2]
79365779|NCT03387085|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
79365780|NCT03387085|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
79365781|NCT03387085|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79675448|NCT00491192|Drug|Diclofenac|
79675449|NCT04510974|Other|Spinal Cord Injury|Spinal Cord Injury
79675450|NCT00486746|Behavioral|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
79675451|NCT00486746|Behavioral|General information on healthy lifestyle habits|A single session
79675452|NCT04510896|Other|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
79675453|NCT04510896|Other|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
79675454|NCT04510896|Other|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
79223238|NCT05045170|Drug|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
79365782|NCT03387085|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
79675455|NCT00486798|Drug|Quetiapine|
79675456|NCT00486798|Procedure|Rating Scales|
79675457|NCT00486798|Procedure|Self Assessment Form|
79223239|NCT03322202|Behavioral|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
79365783|NCT03387085|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79365784|NCT03387085|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79365785|NCT03387085|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79365786|NCT03387085|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
79675458|NCT00486798|Procedure|Blood and urine samples|
79675459|NCT00486798|Procedure|Sleeping pattern|
79821671|NCT00731120|Drug|Placebo|Vortioxetine placebo-matching capsules
79821672|NCT02580006|Drug|EPORON|single dose administration subcutaneously
79821673|NCT02580006|Drug|EPREX|single dose administration subcutaneously
79223240|NCT05505058|Behavioral|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
79365787|NCT03387085|Procedure|SBRT|Stereotactic Body Radiation Therapy
79365788|NCT03385928|Drug|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
79365789|NCT03385928|Drug|Normal saline|Placebo given within 2 hours of symptom onset
79365790|NCT03382340|Drug|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
79365791|NCT03374254|Biological|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
79365792|NCT03374254|Drug|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
79365793|NCT03374254|Drug|Oxaliplatin|85 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
79365794|NCT03374254|Drug|Leucovorin|400 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
79365795|NCT03374254|Drug|5-Fluorouracil [5-FU]|2400 mg/m^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
79365796|NCT03374254|Drug|Irinotecan|180 mg/m^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
79365797|NCT03356028|Behavioral|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
79518111|NCT05103540|Behavioral|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
79821674|NCT00731042|Drug|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
79821675|NCT00731042|Drug|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
79518112|NCT05101044|Behavioral|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
79518113|NCT05071872|Device|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
79518114|NCT05035602|Other|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
79518115|NCT05034978|Other|no intervention|evaluating the performance of a novel point-of-care test
79518116|NCT05027646|Drug|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
79518117|NCT05027646|Drug|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
79518118|NCT05006976|Other|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
79518119|NCT05006976|Other|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
79518120|NCT04988646|Drug|Acyclovir 200 MG|Administered with 240 mL of water
79518121|NCT04988646|Drug|Acyclovir 400 MG|Administered with 240 mL of water
79518122|NCT04988646|Drug|Zovirax 200 MG Tablet|Administered with 240 mL of water
79365798|NCT03356028|Other|salivary biological collection|Saliva sampling will be done using a specific kit
79518123|NCT04988646|Drug|Zovirax 400 MG Tablet|Administered with 240 mL of water
79518124|NCT04912674|Device|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
79518125|NCT04888104|Procedure|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
79518126|NCT04876638|Drug|Minocyclin|10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
79518127|NCT04854798|Device|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
79518128|NCT04844190|Diagnostic Test|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
79518129|NCT04844190|Diagnostic Test|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
79518130|NCT04789746|Behavioral|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
79365799|NCT03356028|Behavioral|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
79518131|NCT04764318|Behavioral|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
79675460|NCT01301833|Drug|teneligliptin|
79675461|NCT01301833|Drug|glinide|
79675462|NCT01301833|Drug|biguanide|
79223241|NCT02488148|Behavioral|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
79365800|NCT03356028|Behavioral|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
79365801|NCT03356028|Behavioral|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
79365802|NCT03356028|Behavioral|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
79675463|NCT01301833|Drug|alpha-glucosidase inhibitor|
79675464|NCT00486785|Drug|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
79518132|NCT04764318|Behavioral|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
79518133|NCT04754334|Drug|ORMD-0801|Oral Insulin
79675465|NCT04324411|Drug|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
79365803|NCT03356028|Behavioral|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
79518134|NCT04754334|Other|Placebo|Fish Oil
79675466|NCT04324489|Drug|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
79675467|NCT00486876|Drug|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
79675468|NCT05643703|Procedure|Suture method|One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
79223242|NCT02488148|Behavioral|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
79675469|NCT00491270|Device|VS Sense|An applicator to diagnose pH increase above 5.2
79365804|NCT03354728|Other|Laboratory Biomarker Analysis|Correlative studies
79675470|NCT05643586|Drug|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
79675471|NCT05643586|Drug|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
79995806|NCT03685812|Diagnostic Test|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
79223243|NCT02487992|Biological|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
79223244|NCT03327818|Procedure|hysterectomy|
79223245|NCT03327818|Procedure|uterine conservative study|
79223246|NCT05508802|Other|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
79675472|NCT01242059|Dietary Supplement|yellow pea protein|Served in a tomato soup
79675473|NCT01242059|Other|yellow pea fiber|Served in a tomato soup
79995807|NCT05390151|Procedure|Laser treatment of anal fistula|using a radial laserprobe to treat transsphincteric fistula
79365805|NCT03354728|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
79365806|NCT03350126|Drug|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
79365807|NCT03350126|Drug|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
79675474|NCT01242059|Dietary Supplement|Control|Served in a tomato soup
79365808|NCT03347929|Drug|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
79365809|NCT03347929|Drug|Placebo|10 days treatment with Placebo1 tablet twice daily
79365810|NCT03341130|Device|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
79365811|NCT03341130|Device|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
79365812|NCT03335917|Other|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
79675475|NCT01242072|Drug|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
79675476|NCT05643352|Procedure|Barbed reposition pharyngoplasty|Barbed reposition pharyngoplasty was performed in all patients
79365813|NCT03335917|Other|Exercise|Graded cycling exercise to volitional fatigue
79365814|NCT03326726|Drug|2% CHG|Chlorhexidine Gluconate
79675477|NCT00491348|Drug|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
79675478|NCT01242098|Drug|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
79675479|NCT01242098|Drug|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
79675480|NCT01301092|Biological|LY2189265|administered intravenous, subcutaneous or intramuscular
79821676|NCT02787642|Drug|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
79995808|NCT05390151|Procedure|RAF|current golden standard in transsphincteric fistula surgery
79995809|NCT03689790|Procedure|sleeve gastrectomy|sleeve gastrectomy
79518135|NCT04749732|Behavioral|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
79518136|NCT04749732|Behavioral|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
79365815|NCT03308188|Behavioral|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
79518137|NCT04749732|Behavioral|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
79821677|NCT02787642|Radiation|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
79995810|NCT03689790|Procedure|gastric bypass|gastric bypass
79995811|NCT03681756|Behavioral|WALK|Walking program
79995812|NCT05567757|Biological|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
79365816|NCT03300336|Behavioral|STRIDE|Implementation of STRIDE inpatient hospital mobility program
79365817|NCT03297307|Behavioral|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
79365818|NCT03294278|Other|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
79518138|NCT04748796|Other|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
79821678|NCT02740218|Other|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
79821679|NCT02594774|Other|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
79995813|NCT03752814|Device|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
79995814|NCT05370027|Device|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
79995815|NCT03689556|Diagnostic Test|FLT PET/CT|Patients will receive 3'-deoxy-3'-[18F]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
79995816|NCT03685656|Other|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
79365819|NCT03248570|Drug|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
79365820|NCT03248570|Drug|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
79518139|NCT04748796|Drug|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
79518140|NCT04744194|Other|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
79995817|NCT03685656|Other|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
79995818|NCT05339919|Diagnostic Test|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
79365821|NCT03244189|Behavioral|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
79518141|NCT04744194|Other|Assisted nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
79679870|NCT00521612|Drug|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
79821680|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
79821681|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
79995819|NCT04059432|Diagnostic Test|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
79995820|NCT01749709|Behavioral|Music listening|
79821682|NCT02580162|Behavioral|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
79995821|NCT01749709|Behavioral|Audiobook listening|
79223247|NCT05508802|Other|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
79223248|NCT03327740|Drug|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
79365822|NCT03244189|Behavioral|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
79365823|NCT03244189|Behavioral|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
79365824|NCT03237689|Drug|Hydrocortisone|Low dose hydrocortisone (10mg)
79821683|NCT04075188|Drug|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
79821684|NCT00726986|Drug|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
79995822|NCT01568931|Drug|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
79365825|NCT03237689|Drug|Placebo Oral Tablet|capsules of starch 1500 powder
79679871|NCT00521612|Drug|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
79679872|NCT02937909|Other|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
79995823|NCT01568931|Drug|Saline|intracoronary, saline, bolus 1 cc
79995824|NCT05300763|Device|senofilcon A prototype|Test
79995825|NCT05300763|Device|Dailies Total 1|Control
79995826|NCT05279859|Drug|ERAS-007|Administered orally
79995827|NCT05279859|Drug|ERAS-601|Administered orally
79995828|NCT05279859|Drug|Gilteritinib|Administered orally
79995829|NCT05233995|Procedure|Damage Control Surgery|Delayed anastomosis
79223249|NCT03327740|Drug|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
79223250|NCT03327740|Drug|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
79223251|NCT03327740|Drug|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
79365826|NCT03233204|Drug|Olaparib|Given PO
79365827|NCT03216525|Drug|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
79365828|NCT03216525|Drug|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
79365829|NCT03206060|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
79365830|NCT03206060|Drug|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
79365831|NCT03206060|Drug|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
79518142|NCT04725084|Other|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
79518143|NCT04725084|Other|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
79518144|NCT04725084|Other|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
79675481|NCT01242150|Device|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
79675482|NCT01242150|Device|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
79675483|NCT05643157|Device|Adaptive optics imaging|adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
79675484|NCT04510623|Other|ARBs and/or ACE inhibitors|This is an observational study only.
79675485|NCT04510623|Other|Usual Care|This is an observational study only.
79995830|NCT03713658|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
79223252|NCT03327740|Drug|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
79223253|NCT03327662|Other|Active CTC Assessment|CTC Counts used to guide treatment switch
79365832|NCT03206060|Drug|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
79675486|NCT05643040|Other|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
79365833|NCT03198494|Other|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
79365834|NCT03198494|Other|Sham Background Noise|Background Noise used as a control
79365835|NCT03190915|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
79518145|NCT04707846|Device|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
79675487|NCT05643040|Other|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
79675488|NCT05643040|Other|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
79675489|NCT05367622|Behavioral|Self-regulation health education|"Insert the continuous blood glucose monitor~Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~Use Telecommunications on the modifications of health promotion behaviors for 7 days"
79675490|NCT05367622|Behavioral|Usual diabetes health education|"Practice self-monitoring of blood glucose~Give usual diabetes health education"
79675491|NCT02274350|Radiation|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
79223254|NCT03322124|Drug|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
79223255|NCT03322124|Other|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
79365836|NCT03190915|Drug|Trametinib|Given PO
79365837|NCT03190863|Behavioral|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
79365838|NCT03190863|Behavioral|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
79518146|NCT04707846|Device|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
79675492|NCT04510818|Drug|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
79675493|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
79675494|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
79679873|NCT00521261|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
79679874|NCT02931591|Drug|Metformin|Metformin is administered as an oral solution
79995831|NCT03713658|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
79995832|NCT03713658|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
79995833|NCT03713658|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
79675495|NCT01243307|Drug|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
79675496|NCT00486941|Behavioral|Exercise and diet - based on DPS and DPP|
79679875|NCT02931591|Drug|Growth Hormone|Growth Hormone- no specific band
79365839|NCT03190863|Behavioral|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
79223256|NCT02567266|Behavioral|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
79821685|NCT00726986|Drug|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
79821686|NCT00726986|Drug|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
79365840|NCT03189420|Procedure|Tumor resection|The tumors will be resected in routine therapeutic surgeries
79365841|NCT03175159|Behavioral|IMPACT|Ten counseling sessions
79365842|NCT03175159|Behavioral|Standard of Care|Two counseling sessions
79365843|NCT03143270|Drug|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
79518147|NCT04673994|Behavioral|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
79518148|NCT04628442|Procedure|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
79518149|NCT04628442|Procedure|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
79518150|NCT04628442|Procedure|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
79518151|NCT04625244|Other|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
79518152|NCT04609722|Other|Solution-Focused Support Program|All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
79679876|NCT02931591|Drug|Placebo|
79821687|NCT02594852|Device|+ laser|Use of laser in the treatment
79518153|NCT04599816|Drug|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
79223257|NCT02567266|Behavioral|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
79223258|NCT02567266|Behavioral|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
79223259|NCT03327584|Procedure|Arthrocentesis|Athrocentesis
79223260|NCT04442984|Drug|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
79223261|NCT04442984|Drug|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
79518154|NCT04599816|Drug|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
79518155|NCT04599816|Drug|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
79518156|NCT04572204|Other|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
79821688|NCT02594540|Device|Mechanical Peripheral Stimulation (GONDOLA)|
79821689|NCT02594306|Device|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
79821690|NCT02594306|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
79821691|NCT02594306|Procedure|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
79223262|NCT04442984|Drug|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
79223263|NCT04442984|Drug|5-FU|d1 5-FU 250 mg/m² every two weeks
79223264|NCT04442984|Drug|Leucovorin|d1 Leucovorin 400 mg every two weeks
79518157|NCT04566276|Biological|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
79675497|NCT05642689|Other|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
79223265|NCT04442984|Drug|5-FU|d1 5-FU 400 mg/m² every two weeks
79675498|NCT05642689|Other|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
79675499|NCT00486915|Procedure|Left Atrial Appendage Ligation|
79675500|NCT01243502|Drug|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
79675501|NCT01243502|Drug|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
79675502|NCT01300819|Other|Placebo|"Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
79675503|NCT01300819|Drug|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
79223266|NCT04442984|Drug|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
79675504|NCT00486980|Drug|Peramivir 150mg|
79675505|NCT00486980|Drug|Peramivir 300mg|
79675506|NCT00486993|Behavioral|Dietary and nutritional modification|
79821692|NCT02594306|Procedure|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
79223267|NCT03327506|Drug|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
79223268|NCT02567188|Other|MIRCERA|
79365844|NCT03143270|Drug|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
79675507|NCT00486993|Behavioral|Stop smoking|
79675508|NCT00486993|Behavioral|Regular physical activities|
79518158|NCT04566276|Other|Placebo|Saline
79518159|NCT04563390|Behavioral|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
79223269|NCT02487914|Device|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
79518160|NCT04563390|Behavioral|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
79518161|NCT04535310|Device|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
79518162|NCT04531878|Drug|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
79675509|NCT00486993|Behavioral|Weight reduction to normal ranges|
79675510|NCT00486993|Behavioral|Regular intake of polyphenols, esp. from Ilex paraguayensis|
79675511|NCT01300741|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
79675512|NCT01300741|Device|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
79995834|NCT03713658|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
79995835|NCT03713658|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
79223270|NCT02487914|Drug|Lidocaine 10% was sprayed at the identified region|
79223271|NCT02487914|Device|interferential current|
79223272|NCT02487680|Dietary Supplement|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
79223273|NCT02487680|Dietary Supplement|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
79223274|NCT04411888|Other|observation|observation
79223275|NCT03319550|Dietary Supplement|Casein|see experimental description
79223276|NCT03319550|Dietary Supplement|Whey|see experimental description
79518163|NCT04509414|Drug|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
79518164|NCT04509414|Drug|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
79518165|NCT04430400|Diagnostic Test|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level <500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
79518166|NCT04417764|Procedure|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
79365845|NCT03130439|Drug|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
79675513|NCT01300741|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
79675514|NCT02275962|Drug|K-877|
79365846|NCT03123731|Behavioral|Control Arm|Wearing Physical Activity Monitor
79223277|NCT03319550|Dietary Supplement|Leucine-enriched whey|see experimental description
79223278|NCT05508490|Diagnostic Test|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
79223279|NCT04442906|Drug|Dexmedetomidine|Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
79365847|NCT03123731|Behavioral|iSTEP|Physical Activity Intervention
79365848|NCT03123731|Behavioral|iSTEP|Physical Activity and Diet Intervention
79365849|NCT03113968|Procedure|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
79365850|NCT03113968|Drug|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
79365851|NCT03112174|Drug|Ibrutinib|Administered orally once daily
79365852|NCT03112174|Drug|Venetoclax|Administered orally once daily
79365853|NCT03112174|Drug|Placebo Oral tablet to match Venetoclax|Administered orally once daily
79223280|NCT04442906|Drug|Fentanyl|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
79365854|NCT03095066|Drug|Placebo|Administered as capsules
79518167|NCT04417764|Biological|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
79518168|NCT04320342|Drug|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
79518169|NCT04320342|Drug|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
79518170|NCT04320342|Drug|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
79518171|NCT04307550|Drug|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
79675515|NCT02275962|Drug|Rifampin|
79223281|NCT04442906|Drug|Bupivacain|Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
79223282|NCT05500456|Device|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
79675516|NCT00487058|Drug|Gimatecan|
79675517|NCT00487032|Drug|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
79675518|NCT00487032|Drug|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
79675519|NCT00487032|Drug|Prazosin hydrochloride|Prazosin 1mg one dose only
79675520|NCT00487032|Drug|Placebo to Prazosin|Placebo 1 tablet one dose only
79223283|NCT05500456|Device|Fixed appliances|Conventional wires and brackets will be used.
79365855|NCT03095066|Drug|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
79365856|NCT03095066|Drug|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
79365857|NCT03085173|Biological|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10^5, 3 x 10^5, 1 x 10^6, and 3 x 10^6 CAR T cells/kg.
79365858|NCT03081390|Other|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
79518172|NCT04307550|Other|Placebo|10 inhalations of a sterile saline pad
79675521|NCT05642377|Drug|HGR4113|Once-daily oral administration
79675522|NCT05642377|Drug|Placebo|Once-daily oral administration
79675523|NCT00491426|Drug|Ampicillin|Drug prescribed per routine medical care.
79675524|NCT00491426|Drug|Metronidazole|Drug prescribed per routine medical care.
79675525|NCT00491426|Drug|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
79675526|NCT00491426|Drug|Acyclovir|Drug prescribed per routine medical care.
79675527|NCT00491426|Drug|Amphotericin B|Drug prescribed per routine medical care.
79675528|NCT00491426|Drug|Ambisome|Drug prescribed per routine medical care.
79518173|NCT04299594|Other|Questionnaire|For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
79821693|NCT03334266|Behavioral|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
79995836|NCT03713658|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
79995837|NCT03713658|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
79675529|NCT00491426|Drug|Anidulafungin|Drug prescribed per routine medical care.
79675530|NCT00491426|Drug|Caspofungin|Drug prescribed per routine medical care.
79223284|NCT03322046|Behavioral|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
79365859|NCT03081390|Other|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
79365860|NCT03081390|Other|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
79675531|NCT05642338|Diagnostic Test|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
79995838|NCT03713658|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
79995839|NCT03681522|Procedure|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
79995840|NCT03681522|Procedure|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
79223285|NCT02487602|Device|Gelesis100|Gelesis100 capsules
79995841|NCT03681444|Other|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
79365861|NCT03076658|Radiation|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
79223286|NCT02487602|Other|Placebo|Sucrose (sugar) capsules
79365862|NCT03055533|Behavioral|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
79365863|NCT03047135|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
79518174|NCT04297488|Dietary Supplement|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
79679877|NCT00521300|Drug|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
79679878|NCT00521300|Procedure|Direct surgery for acromegaly|Direct transsphenoidal surgery
79679879|NCT02931435|Procedure|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
79679880|NCT02931435|Procedure|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
79995842|NCT03681444|Other|Clear fluid diet|"Patients will be provided with~Plain water~Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~Soup broth (bouillon or consommé)~Clear sodas, such as ginger ale and Sprite~Gelatin (Jell-O)~Tea or coffee with no cream or milk added~Sports drinks that don't have color"
79995843|NCT03681444|Other|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
79995844|NCT03681444|Diagnostic Test|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
79518175|NCT04294446|Device|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
79518176|NCT04240314|Biological|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
79675532|NCT05642299|Device|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
79995845|NCT05475717|Drug|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
79995846|NCT03689322|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
79223288|NCT05504980|Procedure|Repositioning|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
79995847|NCT03689322|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
79223289|NCT02487836|Device|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
79223290|NCT05500300|Device|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79365864|NCT03042650|Behavioral|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
79223291|NCT05500300|Device|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79365865|NCT03042650|Behavioral|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
79223292|NCT05500300|Device|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79223293|NCT05500300|Device|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79365866|NCT03028857|Drug|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
79518177|NCT04208412|Drug|KVD900|KVD900 tablet 600 mg
79518178|NCT04208412|Other|Placebo|KVD900-matched Placebo Tablet
79518179|NCT04194996|Procedure|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
79223294|NCT05500300|Device|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
79223295|NCT02487758|Procedure|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
79518180|NCT04156854|Diagnostic Test|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
79675533|NCT02274363|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
79675534|NCT00487097|Dietary Supplement|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
79223296|NCT04696354|Diagnostic Test|IVUS|Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.
79365867|NCT03028857|Dietary Supplement|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
79223297|NCT04696354|Other|Continued Compression Therapy/Stockings|Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
79223298|NCT02491034|Behavioral|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
79223299|NCT04510012|Other|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
79223300|NCT03327350|Device|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
79365868|NCT03011398|Procedure|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
79223301|NCT03327350|Drug|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
79365869|NCT02994576|Drug|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
79675535|NCT01300546|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
79675536|NCT01300546|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
79675537|NCT00487071|Device|Anal fistula plug|
79223302|NCT03327272|Drug|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
79223303|NCT03327272|Drug|Saline|Administration of saline at surgical site prior to incision closure
79223304|NCT00706238|Biological|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
79223305|NCT03321968|Biological|Quadrivalent VLP Influenza Vaccine|Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
79223306|NCT04493450|Other|Documentation of cancer treatment side effects|Standardized documentation of occurred side effects
79365870|NCT02983357|Radiation|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
79365871|NCT02983357|Other|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
79365872|NCT02983357|Other|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
79518181|NCT04095858|Drug|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
79518182|NCT04095858|Drug|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
79518183|NCT04095858|Drug|Methotrexate|IV, 15 mg/m^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
79518184|NCT04095858|Drug|Tacrolimus|Begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted
79518185|NCT04092348|Other|complete blood count|"total RNA is isolated from fresh blood samples~RNA is converted into complementary DNA c.DNA~cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
79675538|NCT05642104|Drug|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
79675539|NCT00487110|Drug|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
79223307|NCT05508178|Biological|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
79675540|NCT00487110|Drug|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
79675541|NCT00487136|Drug|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
79675542|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
79995848|NCT03689322|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
79995849|NCT04171375|Device|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
79995850|NCT03685266|Other|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
79995851|NCT05133687|Drug|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
79995852|NCT03689088|Device|Goldfish|Goldfish will be placed in the eye for 24h monitoring
79223308|NCT05508178|Biological|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
79223309|NCT05508178|Drug|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
79223310|NCT03327194|Device|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
79223311|NCT03327116|Drug|Methotrexate|oral, 15 mg per week, 24 weeks
79223312|NCT04678960|Behavioral|Trust-based Relational Intervention Training|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release."
79365873|NCT02973789|Device|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
79995853|NCT03689088|Device|Tonometry|Fellow eye will be measured by tonometry
79365874|NCT02973789|Drug|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
79365875|NCT02903667|Device|Bone grafting|
79365876|NCT02901821|Genetic|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
79365877|NCT02897973|Other|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
79518186|NCT04073862|Other|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
79518187|NCT04008108|Other|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
79995854|NCT01383135|Drug|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
79518188|NCT03958266|Device|MyIBD Care|Novel mobile phone application
79518189|NCT03937986|Drug|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
79518190|NCT03937986|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
79518191|NCT03937986|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
79675543|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
79675544|NCT02276001|Drug|K-877|
79675545|NCT02276001|Drug|Cyclosporine|
79675546|NCT00491543|Drug|ALT-2074|
79675547|NCT02276118|Device|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
79675548|NCT02276118|Device|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
79675549|NCT00491582|Drug|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
79223313|NCT04678960|Behavioral|Trust-based Relational Intervention In-Home Structured Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions."
79821694|NCT03334266|Other|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
79821695|NCT03334266|Other|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
79821696|NCT00696657|Drug|semaglutide|0.1 mg, once weekly, s.c. injection
79821697|NCT00696657|Drug|semaglutide|0.2 mg, once weekly, s.c. injection
79821698|NCT00696657|Drug|semaglutide|0.4 mg, once weekly, s.c. injection
79995855|NCT03685032|Drug|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
79223314|NCT04678960|Behavioral|Trust-based Relational Intervention In-Home Responsive Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed."
79223315|NCT06036420|Device|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
79675550|NCT00491621|Procedure|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
79223316|NCT06036420|Behavioral|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
79821699|NCT00696657|Drug|semaglutide|0.8 mg, once weekly, s.c. injection
79821700|NCT00696657|Drug|semaglutide|0.8 mg with titration, once weekly, s.c. injection
79223317|NCT06036407|Diagnostic Test|Hearing test|Participants visit a local hearing aid shop to assess their hearing function
79365878|NCT02890940|Behavioral|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
79365879|NCT02883049|Drug|Clofarabine|Given IV
79365880|NCT02883049|Drug|Cyclophosphamide|Given IV
79365881|NCT02883049|Drug|Cytarabine|Given IT, IV, or SC
79365882|NCT02883049|Drug|Dasatinib|Given PO
79365883|NCT02883049|Drug|Daunorubicin Hydrochloride|Given IV
79675551|NCT04510155|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
79675552|NCT00487175|Drug|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
79675553|NCT00487227|Drug|caffeine|
79675554|NCT00487227|Drug|Placebo|
79675555|NCT00487266|Other|Acupuncture|Acupuncture of low back and legs.
79821701|NCT00696657|Drug|semaglutide|1.6 mg with titration, once weekly, s.c. injection
79821702|NCT00696657|Drug|placebo|0.1 mg, once weekly, s.c. injection
79365884|NCT02883049|Drug|Dexamethasone|PO or IV
79675556|NCT00491660|Behavioral|supine positioning|
79821703|NCT00696657|Drug|placebo|0.2 mg, once weekly, s.c. injection
79821704|NCT00696657|Drug|placebo|0.4 mg, once weekly, s.c. injection
79821705|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
79821706|NCT00696657|Drug|placebo|1.6 mg, once weekly, s.c. injection
79821707|NCT00696657|Drug|liraglutide|1.2 mg with titration, once daily, s.c. injection
79821708|NCT00696657|Drug|liraglutide|1.8 mg with titration, once daily, s.c. injection
79821709|NCT00730886|Device|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
79995856|NCT03685032|Drug|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
79365885|NCT02883049|Drug|Doxorubicin Hydrochloride|Given IV
79365886|NCT02883049|Drug|Etoposide|Given IV
79365887|NCT02883049|Drug|Hydrocortisone Sodium Succinate|Given IT
79365888|NCT02883049|Other|Laboratory Biomarker Analysis|Correlative studies
79675557|NCT00491660|Behavioral|lateral positioning|
79675558|NCT00487344|Procedure|Non-Personalized Meal Planning|
79675559|NCT00487344|Procedure|Personalized Meal Planning and Dietetic Consultation|
79675560|NCT01300351|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
79675561|NCT01300351|Drug|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
79675562|NCT00487253|Drug|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
79821710|NCT00730886|Procedure|Myomectomy|Invasive surgical procedure for fibroid removal
79518192|NCT03911856|Other|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
79518193|NCT03911856|Other|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
79675563|NCT00487253|Drug|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
79675564|NCT04510233|Drug|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
79821711|NCT01877772|Procedure|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
79995857|NCT03685032|Drug|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
79675565|NCT04510233|Drug|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
79995858|NCT04109274|Behavioral|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
79995859|NCT04109274|Behavioral|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
79365889|NCT02883049|Drug|Leucovorin Calcium|Given PO or IV
79365890|NCT02883049|Drug|Mercaptopurine|Given PO
79821712|NCT01877772|Procedure|Control|The control group will undergo standard rotator cuff repair.
79821713|NCT02592590|Behavioral|Group A|"This condition receives three study components:~The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
79995860|NCT04109274|Behavioral|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
79365891|NCT02883049|Drug|Methotrexate|Given IT and IV
79518194|NCT03851796|Behavioral|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
79518195|NCT03851796|Behavioral|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
79518196|NCT03836196|Radiation|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
79365892|NCT02883049|Drug|Pegaspargase|Given IV
79365893|NCT02883049|Drug|Prednisone|Given PO or IV
79365894|NCT02883049|Radiation|Radiation Therapy|Undergo radiation therapy
79365895|NCT02883049|Drug|Thioguanine|Given PO
79365896|NCT02883049|Drug|Vincristine Sulfate|Given IV
79365897|NCT02870699|Device|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
79365898|NCT02870699|Device|Placebo excipient|film forming excipient solution
79365899|NCT02864251|Biological|Nivolumab|Specified dose on specified days
79365900|NCT02864251|Biological|Ipilimumab|Specified dose on specified days
79365901|NCT02864251|Drug|Pemetrexed|Specified dose on specified days
79365902|NCT02864251|Drug|Cisplatin|Specified dose on specified days
79365903|NCT02864251|Drug|Carboplatin|Specified dose on specified days
79518197|NCT03835884|Drug|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
79518198|NCT03835884|Drug|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
79675566|NCT04510233|Other|standard care|oxygen via masks or ventilators
79675567|NCT00487292|Behavioral|naps and pulses of bright light|
79675568|NCT05641909|Drug|Remifentanil|Remifentanil
79675569|NCT05641909|Drug|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
79675570|NCT00487331|Other|Acupuncture|Acupuncture sessions 1-3 times per week.
79675571|NCT00487331|Behavioral|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
79675572|NCT05639179|Biological|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10^6 cells/kg;Dose level two:2×10^6 cells/kg;Dose level three:5×10^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
79675573|NCT04510077|Behavioral|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
79675574|NCT04510077|Other|Survey Administration|Ancillary studies
79821714|NCT02592590|Behavioral|Group B|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
79821715|NCT02592590|Behavioral|Group C|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
79821716|NCT02592590|Behavioral|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
79821717|NCT02712762|Other|Cross-sectional study|
79365904|NCT02838836|Procedure|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
79821718|NCT03301116|Behavioral|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
79821719|NCT03301116|Behavioral|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
79365905|NCT02816021|Drug|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
79365906|NCT02816021|Drug|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
79518199|NCT03835884|Drug|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
79675575|NCT05637892|Other|No intervention|This is a prospective observational study with no intervention
79675576|NCT02274389|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
79675577|NCT05637619|Device|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
79675578|NCT05637619|Device|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
79675579|NCT05637619|Behavioral|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
79675580|NCT02276196|Drug|Lixisenatide|GLP-1 receptor agonist
79675581|NCT02276196|Drug|Insulin glulisine|Insulin analogue
79821720|NCT00726752|Drug|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
79821721|NCT00917930|Behavioral|physical training|intensive cardiac rehabilitation program
79365907|NCT02789956|Device|Internal vs. external cad cam co/cr framework|
79365908|NCT02779751|Drug|Abemaciclib|Administered orally
79518200|NCT03835884|Drug|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
79518201|NCT03813030|Procedure|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
79518202|NCT03813030|Drug|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
79518203|NCT03813030|Drug|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
79675582|NCT00487370|Procedure|Implantation of gold beads around a knee through needles|
79675583|NCT00487370|Procedure|Sham implantation: Insertion of needles around a knee|
79675584|NCT00487422|Drug|prucalopride|2 mg o.d.
79365909|NCT02779751|Drug|Pembrolizumab|Administered IV
79365910|NCT02779751|Drug|Anastrozole|Administered orally
79365911|NCT02774148|Drug|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
79365912|NCT02774148|Drug|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
79365913|NCT02771197|Drug|Fludarabine|
79365914|NCT02771197|Drug|Melphalan|
79365915|NCT02771197|Drug|Pembrolizumab|
79365916|NCT02722421|Drug|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
79365917|NCT02722421|Drug|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
79675585|NCT00487422|Drug|Prucalopride|4 mg o.d.
79675586|NCT00487422|Other|Placebo|o.d.
79518204|NCT03813030|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
79518205|NCT03813030|Device|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
79518206|NCT03813030|Procedure|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
79518207|NCT03813030|Procedure|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
79518208|NCT03738150|Biological|Sotatercept|Sotatercept injection
79518209|NCT03738150|Other|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
79518210|NCT03718728|Behavioral|Mind&Life|Acceptance and mindfulness-based group intervention program.
79518211|NCT03718728|Behavioral|Standard|Personalized diet and physical exercise recommendations.
79675587|NCT00491699|Drug|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
79995861|NCT02451111|Drug|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
79223318|NCT06036394|Diagnostic Test|The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT|The radiation plans and dose-volume histogram will be obtained from TPS. All the images and radiation-related data will be downloaded from the PACS and TPS, applying anonymization filters. Clinical features (patient, disease, treatment-related characteristics, and outcomes) will be extracted by review of electronic medical records. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences(e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality
79223319|NCT06036381|Diagnostic Test|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
79223320|NCT06036368|Device|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
79365918|NCT02693184|Other|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
79365919|NCT02693184|Other|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
79365920|NCT02676349|Drug|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
79365921|NCT02676349|Radiation|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
79365922|NCT02676349|Procedure|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
79365923|NCT02676349|Drug|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
79365924|NCT02669810|Drug|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
79518212|NCT03654690|Diagnostic Test|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
79675588|NCT05620615|Other|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
79675589|NCT00506181|Drug|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
79365925|NCT02669810|Drug|Standard Treatment for CHF post AMI|
79365926|NCT02659241|Drug|Adavosertib|Given PO
79365927|NCT02659241|Other|Laboratory Biomarker Analysis|Correlative studies
79365928|NCT02647385|Drug|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
79518213|NCT03654690|Behavioral|Counseling|Post-Test HIV Risk ReductionCounseling
79518214|NCT03653052|Drug|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
79518215|NCT03640728|Drug|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
79518216|NCT03640728|Drug|Entecavir|Entecavir 0.5 mg/day orally
79518217|NCT03640728|Drug|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
79518218|NCT03607500|Behavioral|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
79518219|NCT03567174|Other|Integrated care van (ICV)|Structural service delivery intervention
79518220|NCT03562572|Procedure|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
79518221|NCT03562572|Other|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
79518222|NCT03522870|Device|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
79518223|NCT03522870|Device|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
79675590|NCT00506181|Drug|Placebo|
79675591|NCT00487409|Procedure|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
79518224|NCT04194138|Procedure|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
79518225|NCT03445650|Drug|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
79675592|NCT00487409|Procedure|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
79675593|NCT00623662|Other|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
79675594|NCT00623662|Other|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
79821722|NCT02594462|Drug|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
79995862|NCT02451111|Drug|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
79995863|NCT03689010|Drug|Azelaic acid foam 15%|Azelaic acid foam 15%
79223321|NCT06036355|Drug|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
79223322|NCT06036342|Diagnostic Test|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
79223323|NCT06036329|Device|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
79223324|NCT06036329|Device|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
79223325|NCT06036277|Other|General data|General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
79223326|NCT06036277|Other|Other data|Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
79365929|NCT02643043|Other|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
79518226|NCT03445650|Drug|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
79518227|NCT03393780|Drug|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
79518228|NCT03202758|Drug|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
79518229|NCT03186534|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
79675595|NCT02274402|Biological|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
79675596|NCT00491777|Device|Noninvasive Hemodynamic Patient Monitor|
79995864|NCT03689010|Drug|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
79995865|NCT03689010|Drug|Vehicle of the test product|Vehicle of the test product
79995866|NCT03681288|Behavioral|Mindful Self-Compassion|Mindful Self-Compassion Intervention
79223327|NCT06036264|Other|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
79223328|NCT06036264|Other|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
79223329|NCT06036095|Drug|Sevoflurane|Inhalational maintenance of anesthesia group using sevoflurane
79223330|NCT06036095|Drug|Propofol|Intravenous maintenance of anesthesia group using propofol
79365930|NCT02597504|Other|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
79518230|NCT03186534|Behavioral|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
79518231|NCT03132948|Behavioral|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
79365931|NCT02597504|Device|Quick Test|Quick Test, computerized test will be administered to all subjects.
79995867|NCT02414139|Drug|INC280 (capmatinib)|
79365932|NCT02588677|Drug|Masitinib (4.5)|4.5 mg/kg/day
79365933|NCT02588677|Drug|Riluzole|
79365934|NCT02588677|Drug|Placebo|
79365935|NCT02588677|Drug|Masitinib (3.0)|3 mg/kg/day
79675597|NCT04327531|Behavioral|turkish physicians|turkish physicians, who work active in pandemic hospital.
79518232|NCT03122262|Drug|Dolutegravir|DTG 50mg Oral Tablet once daily
79518233|NCT03122262|Drug|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
79518234|NCT03122262|Drug|Truvada|
79518235|NCT03122262|Drug|Atripla|
79518236|NCT03055416|Other|Mobile Men App Prototype|Testing of app functionality
79821723|NCT02664558|Drug|ubenimex|
79821724|NCT02664558|Other|placebo|
79821725|NCT02566707|Drug|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
79821726|NCT02566707|Drug|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
79223331|NCT06036043|Drug|Botulinum toxin type A|"The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study."
79223332|NCT06036030|Drug|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
79223333|NCT06036030|Drug|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
79675598|NCT04697355|Dietary Supplement|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
79223334|NCT06036030|Drug|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
79365936|NCT02587897|Other|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
79518237|NCT03042546|Drug|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
79365937|NCT02587897|Other|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
79518238|NCT03042546|Drug|PMMA|PMMA with abx will be used in the defect
79518239|NCT03042546|Other|No treatment|The defect will not be treated
79365938|NCT02570113|Device|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
79365939|NCT02565914|Drug|TEZ/IVA|Fixed dose tablet for oral administration.
79365940|NCT02565914|Drug|IVA|Tablet for oral administration.
79365941|NCT02565524|Other|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
79365942|NCT02543320|Other|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
79518240|NCT02948244|Dietary Supplement|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
79518241|NCT02948244|Dietary Supplement|Placebo|Placebo
79675599|NCT00491816|Drug|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
79675600|NCT00487500|Device|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
79518242|NCT02734134|Procedure|One-stage exchange joint replacement surgery|
79675601|NCT00491855|Drug|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
79518243|NCT02734134|Procedure|Two-stage exchange joint replacement surgery|
79518244|NCT02561754|Dietary Supplement|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
79675602|NCT00491855|Drug|Oxaliplatin|Starting dose level 25 mg/m^2 given intraperitoneally on day 2.
79675603|NCT00491855|Drug|Paclitaxel|Starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
79821727|NCT02566707|Drug|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
79821728|NCT04063683|Drug|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
79821729|NCT02578290|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
79995868|NCT03680976|Drug|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
79995869|NCT03680976|Drug|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
79995870|NCT01383057|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
79995871|NCT03684954|Other|Prf|Take 10 cc blood from patient and gain prf
79995872|NCT03680898|Device|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
79518245|NCT02561754|Dietary Supplement|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
79223335|NCT06036030|Other|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
79223336|NCT06035991|Procedure|Heart transplantation|Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
79675604|NCT04697277|Drug|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
79518246|NCT02561754|Behavioral|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
79518247|NCT02561754|Behavioral|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
79518248|NCT02561754|Other|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
79518249|NCT02545998|Other|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
79518250|NCT02524938|Dietary Supplement|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
79518251|NCT02524938|Dietary Supplement|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
79675605|NCT00487448|Drug|Fludarabine|
79675606|NCT00487448|Drug|Cytarabine|
79223337|NCT06035978|Drug|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
79223338|NCT06035978|Drug|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
79675607|NCT00487448|Drug|G-CSF|
79223339|NCT06035978|Drug|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
79365943|NCT02543320|Other|Questionnaire Administration|Ancillary studies
79365944|NCT02535078|Drug|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
79675608|NCT00487448|Drug|Idarubicin|
79365945|NCT02535078|Drug|durvalumab|anti-PD-L1 monoclonal antibody
79365946|NCT02535078|Drug|tremelimumab|anti-CTLA-4 monoclonal antibody
79365947|NCT02520791|Biological|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
79365948|NCT02520791|Other|Laboratory Biomarker Analysis|Correlative studies
79365949|NCT02520791|Other|Pharmacological Study|Correlative studies
79365950|NCT02464644|Other|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
79365951|NCT02440295|Procedure|Lower Extremity Amputation|
79365952|NCT02440295|Device|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
79365953|NCT02440295|Drug|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
79518252|NCT02524626|Procedure|Sham stimulation|Sham stimulation
79518253|NCT02524626|Procedure|Vagus stimulation|Vagus stimulation
79675609|NCT00487448|Procedure|Peripheral blood stem cell transplantation|
79675610|NCT00487448|Procedure|Bone marrow transplantation|
79675611|NCT00506259|Drug|dTR Melatonin (NIH CC PDS)|
79675612|NCT00506259|Device|Phototherapy (Bright Light)|
79675613|NCT00506259|Drug|Melatonin CR|
79675614|NCT00506298|Drug|bezafibrate + diflunisal|bezafibrate + diflunisal
79675615|NCT00506298|Drug|bezafibrate + placebo|bezafibrate + placebo
79675616|NCT01242215|Device|ipragliflozin|oral
79675617|NCT01242215|Drug|Placebo|oral
79675618|NCT01242215|Drug|Sulfonylurea|oral
79675619|NCT00487617|Procedure|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
79675620|NCT00491933|Procedure|Quantiferon-TB Gold assay|
79675621|NCT00491933|Procedure|Tuberculin skin test|
79223340|NCT06035978|Drug|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
79675622|NCT01242228|Drug|ipragliflozin|oral
79675623|NCT01242228|Drug|DPP-4 inhibitor|oral
79675624|NCT02274428|Drug|pneumostem|human umbilical cord blood derived mesenchymal stem cells
79679881|NCT02931825|Behavioral|Reminder letter|"The letter will consist in several parts:~Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~Request information if they've done their follow-up or if we have incorrect information~Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
79679882|NCT00523133|Drug|naltrexone|50 mg naltrexone daily for 3 months
79679883|NCT00523133|Drug|naltrexone|50 mg of naltrexone daily for 6 months
79365954|NCT02436213|Other|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
79995873|NCT03688932|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
79995874|NCT03688932|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
79995875|NCT03688932|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
79995876|NCT05084313|Other|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
79995877|NCT05084313|Other|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
79518254|NCT02420652|Drug|Aspirin|Given PO
79223341|NCT06035978|Drug|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
79365955|NCT02436213|Procedure|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
79365956|NCT02408588|Other|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
79365957|NCT02405169|Device|4 vs 6 implant treatment in the maxilla|
79518255|NCT02420652|Other|Laboratory Biomarker Analysis|Correlative studies
79518256|NCT02420652|Drug|Metformin Hydrochloride|Given PO
79518257|NCT02420652|Other|Placebo|Given metformin hydrochloride placebo PO
79518258|NCT02420652|Other|Placebo|Given aspirin placebo PO
79518259|NCT02257242|Drug|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
79518260|NCT02257242|Drug|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
79675625|NCT00506337|Drug|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
79675626|NCT01316354|Other|Bread types|Bread with 50 g available carbohydrate
79675627|NCT00487526|Procedure|duodenal jejunal bypass|
79675628|NCT00491465|Behavioral|Intensive Physical activity|
79518261|NCT02257242|Drug|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
79518262|NCT02034630|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
79518263|NCT02025036|Drug|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
79518264|NCT02025036|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
79223342|NCT06035978|Drug|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
79223343|NCT06035952|Diagnostic Test|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
79223344|NCT06035926|Other|questionnaire|questionnaire
79223345|NCT06035913|Drug|Dihydroergot mesylate|take medicine
79518265|NCT02025036|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
79518266|NCT02002572|Other|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
79518267|NCT01943916|Device|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
79518268|NCT01943916|Device|Imagio gray scale ultrasound|gray scale ultrasound alone
79518269|NCT01921686|Other|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
79518270|NCT01825356|Procedure|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
79518271|NCT01825356|Procedure|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
79223346|NCT06035900|Drug|Psilocin|single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
79223347|NCT06035887|Diagnostic Test|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
79223348|NCT06035887|Diagnostic Test|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
79995878|NCT05084313|Other|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
79995879|NCT03688854|Dietary Supplement|SCFA mixture|Intracolonic administration
79995880|NCT01382979|Behavioral|AlcoholEdu for College|Online course for college freshmen.
79995881|NCT05042193|Other|SARS-CoV-2|Observational
79365958|NCT02380092|Device|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
79995882|NCT03688776|Other|1805AA|A moist snuff product
79995883|NCT03688776|Other|1805AB|A moist snuff product
79995884|NCT03684798|Other|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
79223349|NCT06035887|Diagnostic Test|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
79223350|NCT06035887|Diagnostic Test|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
79223351|NCT06035861|Drug|XBD173|Participants will be treated with XBD173 90mg, once or twice daily, for 8 weeks
79223352|NCT06035835|Combination Product|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
79518272|NCT01768338|Drug|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
79518273|NCT01564368|Procedure|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
79518274|NCT01345344|Behavioral|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
79518275|NCT01345344|Behavioral|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
79223353|NCT06035835|Combination Product|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
79518276|NCT00596154|Other|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
79365959|NCT02338518|Drug|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
79365960|NCT02338518|Drug|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
79365961|NCT02338518|Drug|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
79518277|NCT00281658|Drug|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
79675629|NCT00491465|Behavioral|Control- regular physical activity|
79675630|NCT01242306|Drug|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
79675631|NCT01242345|Device|Capnography|Monitoring of the capnography curve for early detection of apnea
79675632|NCT04511364|Other|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
79675633|NCT00492011|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
79995885|NCT03684798|Other|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
79995886|NCT05407857|Behavioral|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
79365962|NCT02338518|Drug|S-1|80~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
79518278|NCT00281658|Drug|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
79995887|NCT03688698|Radiation|PET/MRI|PET/MRI scans
79995888|NCT05387343|Diagnostic Test|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
79518279|NCT00281658|Drug|Placebo|Paclitaxel Matching Placebo
79995889|NCT04220775|Drug|Bintrafusp Alfa|Given IV
79995890|NCT04220775|Other|Quality-of-Life Assessment|Ancillary studies
79995891|NCT04220775|Other|Questionnaire Administration|Ancillary studies
79518280|NCT02417376|Device|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
79518281|NCT02417376|Device|Gracey curettes|set of 7 instruments number #1-14
79675634|NCT00492011|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
79518282|NCT02417532|Device|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
79675635|NCT00492011|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
79675636|NCT00492011|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
79675637|NCT01242254|Biological|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
79223354|NCT06035796|Device|tNGS|By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
79675638|NCT04513353|Device|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
79675639|NCT04513353|Other|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
79675640|NCT00492128|Drug|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
79995892|NCT04220775|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79995893|NCT02925312|Other|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
79675641|NCT00487734|Radiation|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
79675642|NCT00487734|Drug|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
79223355|NCT06035783|Device|Orbital Atherectomy|The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
79995894|NCT04108299|Behavioral|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
79223356|NCT06035770|Other|Mental Health First Aid (educational training program)|"The MHFA program is a 12-hour face-to-face training program delivered in four sessions of three hours each across four consecutive weeks by two accredited MHFA instructors. The class was administered in small groups with a maximum of 10-15 students.The program included didactic lectures and role playing to teach students how to recognize and react to the signs and symptoms of mental health illness. Participants enrolled in the intervention group received an accompanying manual with content that covered helping people in mental health crises and/or the early stages of mental health problems.~The mental health problems addressed during the training session included depressive symptoms, anxiety, psychotic disorders, and substance use disorders. The mental health crisis situations included suicidal thoughts/attempts and behaviors, acute stress reactions,panic attacks, and acute psychotic behaviors."
79518283|NCT02417844|Drug|tamsulosin (Astellas)|
79518284|NCT02417844|Drug|Tamsulosin HCL|
79518285|NCT02418234|Other|mutation detection|
79518286|NCT02418234|Other|ARMS and ddPCR|
79995895|NCT04108299|Behavioral|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
79518287|NCT02418234|Genetic|ctDNA analysis|
79518288|NCT02418312|Drug|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
79518289|NCT02418312|Drug|Placebo|placebo plus thienopyridine
79518290|NCT02418546|Behavioral|In-Person Nutritional Counseling by a Registered Dietitian|
79518291|NCT02418546|Behavioral|Nutritional counseling using an e-Health Application|
79518292|NCT02421354|Other|Laboratory Biomarker Analysis|Correlative studies
79518293|NCT02421354|Biological|Nivolumab|Given IV
79518294|NCT02421354|Other|Quality-of-Life Assessment|Ancillary studies
79518295|NCT02422290|Drug|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
79518296|NCT02425956|Device|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
79518297|NCT02427672|Device|Transcranial direct current stimulation|
79223357|NCT06035757|Drug|Bridion 200 MG in 2 ML Injection|Sugammadex and neostigmine are administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each revesal agent is determined with response to TOF or PTC.
79518298|NCT02427672|Device|Sham transcranial direct current stimulation|
79223358|NCT06035757|Drug|Neostigmine Methylsulfate|Sugammadex and neostigmine are administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each revesal agent is determined with response to TOF or PTC.
79518299|NCT02427750|Biological|Aggripal®|TIV
79518300|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
79223360|NCT06035666|Other|Your World|Your World consists of a vitality session and use of the Your World app
79518301|NCT02430090|Drug|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
79365963|NCT02336672|Device|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
79365964|NCT02286687|Other|Laboratory Biomarker Analysis|Correlative studies
79675643|NCT01242293|Other|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
79675644|NCT01242293|Other|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
79675645|NCT01242293|Other|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
79675646|NCT01300234|Drug|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
79821730|NCT03895281|Diagnostic Test|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
79821731|NCT02578524|Other|Survey|
79821732|NCT00921531|Drug|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
79365965|NCT02286687|Other|Pharmacological Study|Correlative studies
79995896|NCT01382823|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
79518302|NCT02430090|Drug|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
79518303|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
79675647|NCT01300234|Drug|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
79675648|NCT04510701|Other|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
79675649|NCT01242332|Drug|Pregabalin|75 mg po 2 hrs before surgery
79675650|NCT00487773|Drug|budesonide|budesonide
79223361|NCT06035666|Other|Control app|Control app, no effect on stress/vitality
79223362|NCT06035640|Other|Interview|Participants will be engaged in a semi-structured interview.
79223363|NCT06035627|Other|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
79223364|NCT06035614|Device|exciplex|exciplex, excimer lamp 308nm produced by clarteis
79223365|NCT06035614|Drug|Tacrolimus ointment|tacrolimus monohydrate ointment 0.1% TACRUS
79365966|NCT02286687|Drug|Talazoparib|Given PO
79518304|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
79518305|NCT02431572|Other|PBR PET|
79518306|NCT02431572|Biological|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
79518307|NCT02431572|Radiation|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
79518308|NCT02431650|Drug|OZ439|
79518309|NCT02431650|Drug|Primaquine|
79518310|NCT02435706|Procedure|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
79518311|NCT02435706|Procedure|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
79518312|NCT02435706|Device|Implant and temporary crown|Both groups receive this intervention
79518313|NCT02437344|Drug|CI-581aa|92 minute infusion of CI-581aa
79675651|NCT00487773|Drug|D3 vitamin|D3 vitamin
79675652|NCT00487773|Drug|montelukast sodium|montelukast sodium
79675653|NCT00487773|Drug|salbutamol|salbutamol
79675654|NCT01299961|Drug|abatacept|125 mg once a week up to 12 months.
79223366|NCT06035588|Other|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
79223367|NCT06035588|Other|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
79365967|NCT02270658|Device|CPAP|
79821733|NCT00921531|Drug|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
79821734|NCT04072692|Other|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
79821735|NCT04072692|Other|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
79223368|NCT06035562|Behavioral|PVSET|6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
79223369|NCT06035510|Dietary Supplement|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
79995897|NCT01980381|Other|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
79995898|NCT01381965|Procedure|Vitreous surgery for macular hole|Vitreous surgery for macular hole
79223370|NCT06035484|Other|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
79223371|NCT06035484|Other|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
79223372|NCT06035471|Diagnostic Test|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --> unmethylated C-nucleotide trabsformed in uracil.--> PCR --> next generation sequencing (NGS) --> localization methylated nucleotides (enzym LpnPI).
79223373|NCT06035432|Other|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
79223374|NCT06035432|Other|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
79365968|NCT02248701|Drug|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
79365969|NCT02248701|Drug|Finasteride|Subjects receive finasteride (5 mg/day) orally
79365970|NCT02248701|Drug|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
79365971|NCT02248701|Drug|Placebo pill|Subjects receive placebo pill (daily) orally
79365972|NCT02224261|Other|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
79518314|NCT02437344|Drug|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
79518315|NCT02440308|Drug|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
79518316|NCT02440308|Procedure|Magnetic Resonance Imaging (MRI) scan|
79518317|NCT02440308|Procedure|Positron Emission Tomography (PET) scan|
79518318|NCT02444988|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
79223375|NCT06035432|Other|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
79223376|NCT06035432|Other|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
79518319|NCT02444988|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
79223377|NCT06035419|Other|education|breastfeeding education for migrant mothers
79223378|NCT06035406|Drug|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
79223379|NCT06035380|Other|placebo group|aromatherapy
79223380|NCT06035380|Other|mint oil group|aromatherapy
79365973|NCT02224261|Other|Control|Control protocol includes standard progressive active and action-assisted arm exercises & patient education.
79821736|NCT04072692|Other|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
79365974|NCT02204982|Drug|Duvelisib|PI3K Inhibitor
79365975|NCT02204982|Drug|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
79518320|NCT02446314|Dietary Supplement|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
79518321|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
79518322|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
79821737|NCT04094415|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
79995899|NCT01381887|Drug|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
79365976|NCT02204982|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
79365977|NCT02184663|Other|without APA program|Control Arm : chemotherapy alone
79518323|NCT02446314|Dietary Supplement|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
79518324|NCT02448654|Drug|Tolcapone|Tolcapone will be compared to sugar pill
79518325|NCT02448654|Drug|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
79518326|NCT02449356|Device|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
79675655|NCT00487643|Procedure|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
79675656|NCT04327297|Dietary Supplement|Amino acid-based formula|Amino acid based formula is formula which is used as dietary supplement instead of dairy products in cow's milk allergic infants
79675657|NCT00492245|Procedure|PTK with mitomycin in Adenoviral Opacities|
79518327|NCT02451150|Drug|Azilsartan|Azilsartan tablets
79675658|NCT00487812|Procedure|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
79675659|NCT01299805|Drug|Vortioxetine|Encapsulated tablet
79675660|NCT01299805|Drug|Placebo|Vortioxetine placebo-matching capsules.
79223381|NCT06035380|Other|rose oil group|aromatherapy
79518328|NCT02452866|Drug|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
79518329|NCT02452944|Device|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
79518330|NCT02452944|Device|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
79518331|NCT02460666|Behavioral|Tai-Chi-Chih (TCC)|
79518332|NCT02460666|Behavioral|Health Education and Wellness Classes (HEW)|
79518333|NCT02461992|Drug|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
79518334|NCT02462070|Drug|IDP-118 Lotion|Lotion
79518335|NCT02462070|Drug|IDP-118 Vehicle Lotion|Lotion
79675661|NCT00487682|Drug|ASP2151|oral
79675662|NCT00487682|Drug|Valacyclovir hydrochloride|oral
79675663|NCT00487851|Procedure|surgery|hepaticojejunostomy and gastroenterostomy
79675664|NCT00487851|Procedure|endoscopic strategy|Stent insertion
79223382|NCT06035367|Device|Non-invasive continuous monitoring device to record photoacoustic signal|"Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.~A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal."
79365978|NCT02184663|Other|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
79675665|NCT01299766|Behavioral|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
79675666|NCT01299766|Behavioral|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
79675667|NCT04512261|Drug|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
79995900|NCT01381887|Drug|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
79365979|NCT02138734|Biological|BCG+N-803|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
79365980|NCT02138734|Biological|BCG|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
79518336|NCT02462148|Drug|Dexamethasone|Used in nerve block mixture
79518337|NCT02462148|Drug|Bupivacaine|Used in nerve block mixture
79223383|NCT06035354|Drug|AK120|subcutaneous injection once a week
79223384|NCT06035354|Drug|AK120|subcutaneous injection once a week
79223385|NCT06035354|Drug|Placebo|subcutaneous injection once a week.
79223386|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
79223387|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
79223388|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
79518338|NCT02462148|Drug|Epinephrine|Used in nerve block mixture
79518339|NCT02462148|Procedure|Saphenous Peripheral Nerve Block|Peripheral nerve block.
79518340|NCT02462382|Procedure|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
79518341|NCT02462382|Drug|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
79518342|NCT02462382|Drug|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
79518343|NCT02464176|Drug|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
79675668|NCT04512261|Drug|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
79675669|NCT04512261|Drug|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
79675670|NCT00492362|Behavioral|ergometer exercise during hemodialysis|
79675671|NCT00492362|Behavioral|pedometer activity outside of hemodialysis|
79675672|NCT04519515|Device|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
79675673|NCT00487799|Drug|Ularitide|
79223389|NCT06035354|Drug|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
79365981|NCT02134392|Biological|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
79518344|NCT02464176|Drug|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
79675674|NCT04516785|Diagnostic Test|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
79675675|NCT05149248|Biological|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
79675676|NCT05149248|Biological|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
79995901|NCT01381887|Drug|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
79995902|NCT01381887|Drug|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
79995903|NCT03680664|Device|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
79675677|NCT05149248|Other|Control group|HPV vaccination at 12 months
79675678|NCT05149248|Biological|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
79675679|NCT01243541|Procedure|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
79675680|NCT01243541|Other|questionnaire administration|Ancillary studies
79675681|NCT01243541|Procedure|quality-of-life assessment|Ancillary studies
79679884|NCT00523133|Behavioral|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
79679885|NCT00523133|Behavioral|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
79821738|NCT00730028|Drug|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child < 40 kg dose). Study drug will be administered for 10 days.
79995904|NCT03680664|Other|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
79223390|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks
79223391|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
79223392|NCT06035354|Drug|AK120|subcutaneous injection every 2 weeks.
79223393|NCT06035341|Other|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
79223394|NCT06035328|Other|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
79365982|NCT02101385|Drug|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
79679886|NCT02937792|Drug|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
79679887|NCT00521729|Procedure|Exposure to Cold Temperature|
79365983|NCT02101385|Other|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
79365984|NCT02086175|Drug|Imprime PGG|
79365985|NCT02086175|Drug|Rituximab|
79365986|NCT02073838|Drug|Ribavirin|
79365987|NCT02073838|Drug|Vismodegib|
79365988|NCT02073838|Drug|Decitabine|
79365989|NCT02068443|Drug|Alogliptin|Alogliptin tablets
79821739|NCT00730028|Other|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
79223395|NCT06035315|Dietary Supplement|Multiple Micronutrients during pregnancy|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
79675682|NCT01243541|Procedure|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
79821740|NCT00730028|Drug|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
79995905|NCT03680664|Behavioral|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
79365990|NCT02068443|Drug|Metformin hydrochloride|Metformin hydrochloride tablets
79365991|NCT02068443|Drug|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
79365992|NCT02065869|Biological|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
79518345|NCT02464176|Drug|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
79518346|NCT02464176|Procedure|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
79821741|NCT05673642|Other|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
79821742|NCT02594228|Behavioral|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
79821743|NCT02594228|Behavioral|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
79821744|NCT03356223|Drug|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
79821745|NCT04087694|Procedure|Microdecompression|comparative surgical treatment
79821746|NCT04060875|Device|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
79995906|NCT04878471|Drug|Pudexacianinium chloride|Intravenous
79995907|NCT04878471|Drug|Placebo|Intravenous
79365993|NCT02065869|Drug|Rimiducid|0.4mg/kg administered IV to treat GVHD
79365994|NCT02021006|Drug|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
79365995|NCT02021006|Other|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
79365996|NCT02021006|Drug|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
79365997|NCT02021006|Drug|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
79518347|NCT02464176|Drug|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
79675683|NCT01243541|Procedure|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
79518348|NCT02466126|Behavioral|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
79518349|NCT02467842|Biological|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
79518350|NCT02467842|Biological|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
79518351|NCT02467842|Biological|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
79518352|NCT02468154|Device|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
79518353|NCT02468154|Other|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
79518354|NCT02468700|Drug|Dexamethasone|
79518355|NCT02468700|Other|Placebo Vehicle|
79518356|NCT02469714|Behavioral|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
79518357|NCT02469870|Behavioral|Autism Parent Trainer (APT)|Experimental condition
79518358|NCT02469870|Behavioral|Teaching Routines (Control)|Content comparison group.
79518359|NCT02470494|Device|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
79821747|NCT04088084|Dietary Supplement|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
79365998|NCT02021006|Drug|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
79365999|NCT02018861|Drug|Parsaclisib|
79366000|NCT02018861|Drug|Itacitinib|
79366001|NCT02018861|Drug|Rituximab|
79366002|NCT02018861|Drug|Ifosfamide|
79366003|NCT02018861|Drug|Carboplatin|
79366004|NCT02018861|Drug|Etoposide|
79366005|NCT01995578|Drug|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
79518360|NCT02472522|Drug|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
79821748|NCT02593370|Drug|Lidocaine-epinephrine added gadoterate meglumine|
79366006|NCT01949337|Drug|enzalutamide|Enzalutamide 160 mg daily, orally
79366007|NCT01949337|Drug|abiraterone|abiraterone 1000 mg daily, orally
79366008|NCT01949337|Drug|prednisone|prednisone 5 mg twice daily, orally
79366009|NCT01934881|Device|voltage adjustment only|Only voltage will be adjusted in all programming sections.
79518361|NCT02472522|Other|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
79518362|NCT02476032|Device|Prof applied oxalate|Crest Sensi-Stop strips (Procter & Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
79518363|NCT02476032|Device|Self applied oxalate|Subjects will apply the strips (Procter & Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
79518364|NCT02476032|Device|Prof applied placebo|Crest Sensi-Stop strips (Procter & Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
79518365|NCT02476890|Drug|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
79518366|NCT02476890|Drug|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
79675684|NCT04518033|Device|Various commercially available face coverings|Various commercially available face coverings
79679888|NCT02931474|Drug|Tesamorelin|Growth Hormone-Releasing
79679889|NCT02931474|Other|Placebo|
79518367|NCT02480166|Drug|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
79518368|NCT02480166|Drug|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
79518369|NCT02481258|Drug|Ataciguat (HMR1766)|
79518370|NCT02481258|Other|Placebo Comparator: Matching Placebo|
79518371|NCT02483676|Device|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
79518372|NCT02483676|Behavioral|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
79518373|NCT02484222|Drug|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
79518374|NCT02486016|Drug|Duragesic reference fentanyl TDS|25 µg/hour
79518375|NCT02486016|Drug|Apotex generic fentanyl TDS|25 µg/hour
79518376|NCT02486016|Drug|Mylan generic fentanyl TDS|25 µg/hour
79518377|NCT02486328|Drug|Midazolam|Dosage adjustment
79518378|NCT02486328|Drug|Meperidine|Dosage adjustment
79821749|NCT04061109|Drug|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
79223398|NCT06035224|Drug|AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally|AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(<60kg，8 mg qd；≥60kg，12mg qd, orally.
79223399|NCT06035185|Procedure|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
79366010|NCT01934881|Device|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
79366011|NCT01893307|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79518379|NCT02486328|Drug|Remifentanil|Dosage adjustment
79518380|NCT02486328|Drug|Propofol|Dosage adjustment
79821750|NCT04087616|Behavioral|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
79821751|NCT04087616|Behavioral|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
79366012|NCT01893307|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMPT
79366013|NCT01893307|Other|Laboratory Biomarker Analysis|Correlative studies
79366014|NCT01893307|Radiation|Photon Beam Radiation Therapy|Undergo IMRT
79366015|NCT01893307|Radiation|Proton Beam Radiation Therapy|Undergo IMPT
79366016|NCT01893307|Other|Quality-of-Life Assessment|Ancillary studies
79366017|NCT01872598|Drug|Masitinib|
79366018|NCT01872598|Drug|Placebo|
79366019|NCT01872598|Drug|Standard of care|stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
79518381|NCT02491788|Drug|Suvorexant|
79518382|NCT02491788|Drug|Placebo|
79518383|NCT02491944|Drug|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
79518384|NCT02491944|Drug|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of [14C] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
79518385|NCT02492802|Drug|posaconazole|collection plasma samples for measuring posaconazole drug concentration
79518386|NCT02493036|Drug|SYN-010|
79518387|NCT02494518|Behavioral|Forced Exercise & Upper Extremity Repetitive Task Practice|
79518388|NCT02494518|Behavioral|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
79518389|NCT02494518|Behavioral|Stroke Education & Upper Extremity Repetitive Task Practice|
79518390|NCT02495454|Drug|Ga101|
79518391|NCT02500368|Device|silicone hydrogel lens (test)|contact lens
79518392|NCT02500368|Device|enfilcon A lens (control)|contact lens
79518393|NCT02500602|Drug|doxazosin|active medication
79518394|NCT02500602|Drug|placebo|placebo pill
79518395|NCT02500836|Drug|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
79518396|NCT02500836|Drug|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
79518397|NCT02500836|Drug|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
79518398|NCT02503410|Behavioral|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
79518399|NCT02503410|Behavioral|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
79518400|NCT02507388|Drug|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
79518401|NCT02507388|Drug|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
79518402|NCT02508480|Behavioral|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
79223400|NCT06035172|Behavioral|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
79223401|NCT06035172|Behavioral|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
79366020|NCT01827384|Drug|Adavosertib|Given by mouth (PO)
79518403|NCT02508480|Behavioral|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
79518404|NCT02508636|Drug|Enzalutamide|Given orally
79518405|NCT02508636|Drug|Leuprolide|Given via intramuscular injection
79223402|NCT06035146|Procedure|Mechanical energy monitoring|Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.
79223403|NCT06035146|Procedure|Conventional mechanical ventilation|The conventional procedure of mechanical ventilation controlled according to the physician's decision.
79223404|NCT06035133|Drug|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
79223405|NCT06035133|Drug|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
79223406|NCT06035133|Radiation|radiotherapy|radiotherapy
79366021|NCT01827384|Drug|Carboplatin|Given intravenous (IV)
79518406|NCT02508636|Radiation|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
79675685|NCT05149209|Procedure|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
79675686|NCT00487877|Device|SenseWear Pro3 Armband|
79366022|NCT01827384|Drug|Everolimus|Given by mouth (PO)
79675687|NCT00487877|Device|i-button DS2191 H|
79366023|NCT01827384|Drug|Temozolomide|Given by mouth (PO)
79366024|NCT01827384|Drug|Trametinib|Given by mouth (PO)
79366025|NCT01827384|Drug|Veliparib|Given by mouth (PO)
79366026|NCT01825694|Behavioral|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
79223407|NCT06035107|Diagnostic Test|Radar blood pressure device|The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
79223408|NCT06035055|Drug|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
79223409|NCT06035016|Drug|pyrotinib combined with Capecitabine|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
79223410|NCT06035016|Drug|treatment of physician's choice|Treatment of physician's choice
79366027|NCT01758653|Other|No study intervention|There is no study-related intervention.
79366028|NCT01704157|Device|Cryo-Touch III|Study treatment at Day 0.
79366029|NCT01585194|Biological|Ipilimumab|Given IV
79366030|NCT01585194|Other|Laboratory Biomarker Analysis|Correlative studies
79366031|NCT01585194|Biological|Nivolumab|Given IV
79366032|NCT01560663|Drug|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
79366033|NCT01463371|Drug|Azithromycin|250 mg three times a week during three months
79675688|NCT00495209|Other|Qigong|EQT daily for 5 consecutive days prior to surgery.
79518407|NCT02512224|Device|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
79223411|NCT06034977|Drug|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
79518408|NCT02512224|Device|Enteral nutrition|Participants are retrospectively selected with propensity score matching
79518409|NCT02513940|Drug|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
79223412|NCT06034964|Drug|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
79223413|NCT06034951|Dietary Supplement|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
79518410|NCT02513940|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
79223414|NCT06034938|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Switch previous therapy with DOR/TDF/3TC
79518411|NCT02513940|Drug|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
79518412|NCT02513940|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
79518413|NCT02515656|Drug|POLYGYNAX®|
79518414|NCT02515656|Drug|GYNODAKTARIN®|
79518415|NCT02515656|Drug|Placebo|
79223415|NCT06034886|Drug|Troriluzole|
79223416|NCT06034860|Drug|MT-8421|Experimental treatment with MT-8421
79223417|NCT06034860|Drug|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
79223418|NCT06034847|Device|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
79223419|NCT06034847|Device|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
79518416|NCT02515890|Drug|Dexmedetomidine|Selected subjects received this drug during a portion of the study
79518417|NCT02515890|Drug|Midazolam|Selected subjects received this drug during a portion of the study
79518418|NCT02515890|Device|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
79518419|NCT02515890|Drug|Ketamine|Selected subjects received this drug during a portion of the study
79518420|NCT02516046|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
79223420|NCT06034834|Diagnostic Test|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
79223421|NCT06034782|Diagnostic Test|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
79223422|NCT06034782|Procedure|Histologic Examination|Histologic examination of resected salivary tumor
79223423|NCT06034730|Device|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
79223424|NCT06034704|Other|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
79518421|NCT02516046|Procedure|PET Scan|positron emission tomography (PET) scan
79518422|NCT02517996|Drug|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
79518423|NCT02517996|Drug|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
79518424|NCT02518230|Device|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
79518425|NCT02518230|Device|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
79675689|NCT05149170|Drug|Anti-PD-1 monoclonal antibody|inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
79675690|NCT02956226|Drug|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
79675691|NCT02956226|Drug|Placebo|Olive oil and flavors solution.
79518426|NCT02519244|Device|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
79675692|NCT02956226|Drug|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
79995908|NCT03684720|Other|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
79995909|NCT04877379|Drug|VNRX-7145|β-lactamase inhibitor
79223425|NCT06034704|Other|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
79995910|NCT04877379|Drug|VNRX-5024 (ceftibuten)|β-lactam antibiotic
79995911|NCT04877379|Drug|Placebo|Placebo
79518427|NCT02520414|Device|Symphion® Bipolar Hysteroscopic Tissue Resection System|
79223426|NCT06034691|Biological|pcsk9 inhibitor|The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.
79366034|NCT01419067|Procedure|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
79366035|NCT01419067|Device|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
79518428|NCT02521974|Biological|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
79223427|NCT06034678|Behavioral|Food Allergy Mastery Program|Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
79223428|NCT06034626|Procedure|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
79223429|NCT06034626|Drug|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
79518429|NCT02522442|Device|CPAP|Continuous positive airway pressure
79518430|NCT02522442|Device|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
79518431|NCT02523690|Drug|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
79518432|NCT02523690|Drug|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
79518433|NCT02523924|Drug|18F-DCFPyL|18F-DCFPyL PET/CT
79518434|NCT02525718|Drug|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
79518435|NCT02525718|Drug|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
79675693|NCT04516473|Procedure|Abdominal Body Contouring|These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
79675694|NCT00492440|Biological|recombinant interleukin-7|
79675695|NCT00492440|Genetic|gene expression analysis|
79675696|NCT00492440|Genetic|polymerase chain reaction|
79995912|NCT01382745|Drug|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
79995913|NCT01382745|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
79995914|NCT03684330|Dietary Supplement|Vitamin D|a dose once a week
79995915|NCT03684330|Other|whole body vibration (WBV)|03 months of WBV training three times per week
79995916|NCT03680430|Radiation|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
79995917|NCT03688386|Behavioral|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
79995918|NCT03688386|Behavioral|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
79995919|NCT03688386|Behavioral|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
79995920|NCT03688386|Behavioral|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
79995921|NCT03688386|Behavioral|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
79223430|NCT06034613|Behavioral|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
79995922|NCT03684252|Behavioral|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
79366036|NCT01419067|Drug|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
79995923|NCT03684252|Other|Treatment as Usual|Participants' will receive treatment as usual.
79223431|NCT06034587|Diagnostic Test|multimodal ultrasound|An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
79223432|NCT06034587|Radiation|radioisotope applicator therapy|The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
79223433|NCT06034574|Device|Continuous glucose monitoring|Assessment of accuracy of two different continuous glucose monitoring devices during exercise
79366037|NCT01419067|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
79366038|NCT01377389|Drug|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
79366039|NCT01377389|Drug|Leuprolide|7.5 mg intramuscular once a month for 8 months
79366040|NCT01377389|Drug|Goserelin|3.6 mg subcutaneous once a month for 8 months
79518436|NCT02526654|Diagnostic Test|Heidelberg Edge Perimeter|HEP measures peripheral vision
79518437|NCT02526654|Diagnostic Test|Octopus Visual Field|OVF measures peripheral vision
79518438|NCT02526654|Diagnostic Test|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
79518439|NCT02527512|Drug|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
79995924|NCT03684174|Device|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
79995925|NCT03623802|Other|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
79518440|NCT02527512|Other|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
79518441|NCT02528370|Device|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
79675697|NCT00492440|Genetic|protein expression analysis|
79675698|NCT00492440|Other|flow cytometry|
79366041|NCT01377389|Drug|Degarelix|80 mg subcutaneous once a month for 8 months
79675699|NCT00492440|Other|immunoenzyme technique|
79675700|NCT00492440|Other|immunologic technique|
79518442|NCT02529072|Drug|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
79675701|NCT00492440|Other|laboratory biomarker analysis|
79675702|NCT00492440|Other|pharmacological study|
79675703|NCT04518501|Drug|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
79675704|NCT00495248|Behavioral|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
79675705|NCT00495248|Behavioral|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
79675706|NCT05149053|Dietary Supplement|Hydrolyzed Collagen|Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
79223434|NCT06034561|Drug|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
79223435|NCT06034548|Behavioral|diabetes and hypertension self-management|12-weeks of 75 minutes of educational sessions
79366042|NCT01326676|Drug|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
79675707|NCT05149053|Other|Placebo|Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
79366043|NCT01326676|Drug|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
79366044|NCT01287611|Procedure|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
79675708|NCT00495287|Drug|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
79675709|NCT00495326|Drug|Nevirapine based therapy|"Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
79675710|NCT00495326|Drug|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
79675711|NCT00495326|Drug|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~Continuation phase: 4 months daily H(RMP).~Patients with meningitis will receive Streptomycin instead of E during intensive phase."
79675712|NCT00492479|Drug|Kinerase Pro+Therapy Line day repair, serum, night repair|
79995926|NCT03623802|Other|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
79223436|NCT06034522|Device|Adipearl|Injection of the investigational device in the face.
79223437|NCT06034483|Other|Pelvic floor exercise training|"Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~In the pelvic floor muscle training program:~Fast and slow pelvic floor muscle contractions will be taught,~Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~Individuals will be tracked with exercise diaries.~At the end of the 8th week, post-intervention evaluations will be made again.~The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
79366045|NCT01287611|Procedure|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
79366046|NCT01194271|Drug|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
79366047|NCT01194271|Drug|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
79675713|NCT00492479|Drug|Kinerase Pro+Therapy Line Ultra rich day repair|
79675714|NCT00492479|Drug|LubriDerm|
79675715|NCT00506766|Behavioral|Bladder Health Class consisting of 6 weekly group sessions|1 time
79675716|NCT00506766|Behavioral|Practice PFMT and BT|As needed for 4 years
79675717|NCT00506766|Behavioral|Clinic examination for pelvic muscle function|1/year for 4 years
79675718|NCT00506766|Behavioral|Record keeping in 3-day voiding diary|Every 6 months for 4 years
79675719|NCT00495365|Drug|Epoetin alfa|
79675720|NCT04515927|Drug|JS002|Biological: JS002 Administered by subcutaneous injection
79675721|NCT00492518|Drug|Acetylcysteine|
79675722|NCT00492518|Drug|Theophylline|
79675723|NCT00492518|Drug|Placebo|
79675724|NCT05148936|Other|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
79675725|NCT05148936|Other|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
79995927|NCT03680118|Device|autogenous rings with GBR and autogenous graft with ti-mesh|"Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
79223438|NCT06034483|Other|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~Explaining menopause and menopausal symptoms~Defining the Genitourinary Syndrome of Menopause (MGS)~The effect of MGS on sexual function cycle and sexual function,~Conservative recommendations on MGS management~Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
79223439|NCT06034444|Other|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
79223440|NCT06033638|Other|Score assessment|PBS Score
79302511|NCT03316703|Procedure|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
79366048|NCT01194271|Procedure|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
79366049|NCT01192048|Other|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
79366050|NCT01172418|Drug|Alemtuzumab|Alemtuzumab used as part of combined Induction.
79366051|NCT01172418|Drug|Daclizumab|Daclizumab used as part of combined induction.
79366052|NCT01172418|Drug|Thymoglobulin|Thymoglobulin used as part of combined induction.
79366053|NCT01163968|Behavioral|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
79366054|NCT01119508|Drug|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
79366055|NCT01119508|Drug|Temozolomide|Induction Phase, 200 mg/m^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
79366056|NCT01092156|Behavioral|Education|Education on Infant-led latching
79518443|NCT02529072|Biological|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
79366057|NCT01074814|Drug|Approved therapy will be assigned based on molecular profile and RPMA results|treatment will be assigned based on IHC< FISH, DNA microarray and RPMA results
79518444|NCT02530476|Drug|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
79366058|NCT00958737|Drug|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
79366059|NCT00958737|Drug|CAPOX|4 or 8 cycles
79518445|NCT02530476|Drug|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
79518446|NCT02530554|Drug|CHG|Single application
79518447|NCT02531022|Behavioral|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
79518448|NCT02531022|Behavioral|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
79675726|NCT05148936|Other|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
79675727|NCT05148936|Other|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
79675728|NCT00495404|Behavioral|Physician Treatment Guidelines|
79675729|NCT04513860|Drug|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
79675730|NCT00495443|Device|Peterio|
79518449|NCT02532036|Biological|Aerosol inhaled MVA85A|
79366060|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
79366061|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
79518450|NCT02532036|Biological|Intramuscular MVA85A|
79518451|NCT02532036|Biological|Intramuscular Saline placebo|
79366062|NCT00907868|Radiation|partial breast irradiation|Patients undergo radiation tumor bed boost
79518452|NCT02532036|Biological|Aerosol inhaled Saline placebo|
79675731|NCT04510545|Diagnostic Test|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
79675732|NCT00506805|Drug|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
79995928|NCT01783041|Drug|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
79223441|NCT06033417|Other|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
79366063|NCT00907868|Radiation|whole breast irradiation|Patients undergo whole breast irradiation
79366064|NCT00754338|Drug|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
79366065|NCT00754338|Drug|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
79366066|NCT00754338|Drug|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
79366067|NCT00752154|Drug|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
79518453|NCT02536248|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
79366068|NCT00745134|Drug|Capecitabine|Given PO
79366069|NCT00745134|Dietary Supplement|Curcumin|Given PO
79366070|NCT00745134|Other|Laboratory Biomarker Analysis|Correlative studies
79366071|NCT00745134|Other|Pharmacological Study|Optional correlative studies
79366072|NCT00745134|Other|Placebo|Given PO
79366073|NCT00745134|Other|Quality-of-Life Assessment|Ancillary studies
79518454|NCT02536248|Drug|Placebo|Placebo for 6 weeks
79518455|NCT02537730|Device|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
79518456|NCT02537730|Device|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
79675733|NCT00495560|Drug|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
79675734|NCT00506376|Behavioral|Interview|Interview that will take about 20 minutes to complete.
79366074|NCT00745134|Radiation|Radiation Therapy|Undergo radiation therapy
79366075|NCT00673010|Radiation|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
79518457|NCT02537730|Device|comfilcon A|contact lens
79518458|NCT02538042|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking <10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked <10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
79518459|NCT02538042|Drug|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
79518460|NCT02538042|Behavioral|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
79518461|NCT02538042|Behavioral|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
79518462|NCT02538354|Dietary Supplement|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
79675735|NCT00495599|Procedure|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
79675736|NCT00506844|Drug|Cetuximab, Irinotecan, Capecitabine|
79675737|NCT04515693|Other|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
79675738|NCT00495833|Behavioral|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
79518463|NCT02540226|Drug|Intravenous tranexamic acid|
79675739|NCT00495833|Behavioral|Promotional gift|half of participants who go to a fire station will receive a gift card.
79675740|NCT00506961|Drug|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
79821752|NCT00918320|Drug|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
79223442|NCT06033417|Other|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
79223443|NCT06032351|Other|Innovation-integrated curriculum for dementia care and care management|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).
79223444|NCT06032351|Other|Traditional classroom teaching course programs|The conventional teaching group will receive only traditional classroom teaching course programs.
79995929|NCT01783041|Drug|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
79995930|NCT01569321|Device|MRI|
79223445|NCT06032273|Behavioral|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
79223446|NCT06032260|Other|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
79223447|NCT06032260|Other|Panettone standard|Volunteers consumed 100 grams of panettone standard
79223448|NCT06032221|Device|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
79223449|NCT06030713|Drug|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
79366076|NCT00610883|Drug|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
79675741|NCT00506961|Drug|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
79675742|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
79675743|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
79675744|NCT00492635|Drug|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
79675745|NCT00492674|Device|APOS biomechanical gait system|
79995931|NCT01569321|Device|PET-CT scan|
79995932|NCT01569321|Device|PEM scan with ClearPemSonic|
79995933|NCT01381809|Drug|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
79995934|NCT01381809|Drug|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
79302512|NCT03316625|Diagnostic Test|Bone densitometry measurement|Bone Densitometry and measurement of body composition
79366077|NCT00574496|Drug|cyclophosphamide|
79366078|NCT00574496|Drug|cyclosporine|
79366079|NCT00574496|Drug|fludarabine phosphate|
79366080|NCT00574496|Drug|gemcitabine hydrochloride|
79366081|NCT00574496|Drug|ifosfamide|
79366082|NCT00574496|Drug|mechlorethamine hydrochloride|
79366083|NCT00574496|Drug|melphalan|
79366084|NCT00574496|Drug|methotrexate|
79366085|NCT00574496|Drug|mycophenolate mofetil|
79366086|NCT00574496|Drug|prednisone|
79366087|NCT00574496|Drug|procarbazine hydrochloride|
79366088|NCT00574496|Drug|vincristine sulfate|
79518464|NCT02540226|Drug|Topical tranexamic acid|
79518465|NCT02540226|Drug|Intravenous saline|
79675746|NCT00492674|Procedure|Physical Therapy|
79675747|NCT00507000|Drug|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
79675748|NCT00507000|Drug|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
79366089|NCT00574496|Drug|vinorelbine tartrate|
79366090|NCT00574496|Procedure|allogeneic bone marrow transplantation|
79366091|NCT00574496|Procedure|allogeneic hematopoietic stem cell transplantation|
79518466|NCT02540226|Drug|Topical saline|
79518467|NCT02540772|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
79675749|NCT00495872|Drug|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
79675750|NCT00495872|Drug|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
79821753|NCT02593292|Behavioral|PROSPERO|"The intervention is carried out in 3 steps:~At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
79821754|NCT02593292|Other|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
79223450|NCT06027632|Other|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
79223451|NCT06027632|Other|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
79223452|NCT06023108|Device|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
79223453|NCT06023108|Device|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
79223454|NCT06022393|Behavioral|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
79223455|NCT06022393|Behavioral|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
79366092|NCT00574496|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79366093|NCT00574496|Procedure|peripheral blood stem cell transplantation|
79366094|NCT00574496|Procedure|umbilical cord blood transplantation|
79366095|NCT00574496|Radiation|total-body irradiation|
79518468|NCT02541864|Drug|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
79518469|NCT02541864|Drug|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
79675751|NCT00495872|Drug|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
79675752|NCT00495872|Drug|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
79675753|NCT00495872|Drug|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
79821755|NCT03960632|Diagnostic Test|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
79821756|NCT00729560|Drug|Flutamide|250 mg twice daily for 4 weeks
79223456|NCT06021418|Device|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
79821757|NCT00729560|Drug|Placebo|Placebo twice daily for 4 weeks
79995935|NCT03679806|Other|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
79366096|NCT00533624|Drug|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
79366097|NCT00533624|Drug|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
79366098|NCT00515060|Other|Sensory Tests|Tests to find the threshold at which perceive stimuli.
79366099|NCT00499083|Biological|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
79366100|NCT00499083|Drug|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
79675754|NCT00495872|Drug|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
79675755|NCT00495872|Drug|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
79679890|NCT02931357|Device|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
79366101|NCT00499083|Drug|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
79366102|NCT00499083|Drug|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
79366103|NCT00499083|Drug|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
79518470|NCT02541942|Other|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
79518471|NCT02542410|Drug|Cabergoline|
79518472|NCT02542410|Drug|Norethindrone acetate|
79518473|NCT02544984|Drug|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
79518474|NCT02544984|Drug|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
79518475|NCT02546388|Drug|Indium-111 Pentreotide|
79518476|NCT02546388|Drug|Gallium-68 DOTATATE|
79518477|NCT02547012|Drug|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
79518478|NCT02547012|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
79518479|NCT02547714|Drug|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
79518480|NCT02548728|Drug|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
79518481|NCT02548728|Drug|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
79223457|NCT06021379|Drug|Trastuzumab|AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
79518482|NCT02549040|Drug|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
79675756|NCT00507039|Procedure|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
79675757|NCT00507078|Procedure|Surgical treatment for OSA|
79518483|NCT02549040|Drug|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1
79821758|NCT03202017|Procedure|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
79821759|NCT03202017|Procedure|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
79518484|NCT02549040|Drug|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet [30% drug loaded granule])administered orally at the start of Period 3
79518485|NCT02549040|Drug|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet [50% drug loaded granule])administered orally at the start of Period 4
79518486|NCT02549040|Drug|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5
79518487|NCT02549508|Device|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
79518488|NCT02549508|Device|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
79821760|NCT00918008|Genetic|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
79223458|NCT06020417|Device|O-ARM (Medtronic, Inc, Louisville, CO)|scanner that allows imaging of screws intraoperatively
79223459|NCT06020417|Procedure|Conventional corrective surgery for arthrodesis|Conventional procedure without neuronavigation guide
79223460|NCT06020404|Procedure|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate < 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
79518489|NCT02550132|Procedure|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
79518490|NCT02550132|Device|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
79675758|NCT00492713|Other|dark chocolate|dark chocolate
79675759|NCT00492713|Other|Milk chocolate 1|Milk chocolate 1
79675760|NCT00492713|Other|Milk chocolate 2|Milk chocolate 2
79675761|NCT00507117|Drug|Lunesta|Lunesta 3mg prior to PSG
79675762|NCT00507117|Drug|Placebo control|matching placebo
79675763|NCT00492791|Device|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
79821761|NCT03960320|Other|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
79821762|NCT04088162|Device|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
79821763|NCT00736190|Drug|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
79821764|NCT04060797|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
79675764|NCT00492830|Drug|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
79675765|NCT01299727|Biological|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
79675766|NCT01299727|Biological|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
79821765|NCT02565771|Other|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
79821766|NCT00729326|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
79821767|NCT00729326|Drug|sitagliptin|oral administration (100mg), once a day in the morning
79821768|NCT00729326|Drug|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
79228091|NCT03505749|Behavioral|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
79366104|NCT00499083|Drug|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
79366105|NCT00499083|Genetic|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
79366106|NCT00499083|Genetic|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
79366107|NCT00499083|Genetic|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
79366108|NCT00499083|Other|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
79518491|NCT02550210|Device|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
79518492|NCT02551224|Other|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
79518493|NCT02551770|Procedure|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
79518494|NCT02551770|Procedure|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
79675767|NCT01299727|Biological|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
79675768|NCT00492908|Device|Helistent Titan2 (Titanium coated stent)|Titan2
79675769|NCT00492908|Device|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
79675770|NCT01299571|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
79675771|NCT01243736|Drug|Combination Prep|"combination bowel preparation, which consists of:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
79675772|NCT02274467|Device|Trans-catheter electric stimulation test|
79675773|NCT01299376|Drug|L50/H12.5/A5|
79821769|NCT00729326|Drug|placebo|oral administration (100mg), once a day in the morning
79821770|NCT02565303|Procedure|Intervertebral space|
79821771|NCT02565303|Drug|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
79995936|NCT03679806|Other|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
79995937|NCT03679728|Behavioral|First trimester|Analysis of sensorimotor outcomes
79518495|NCT02551770|Device|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
79995938|NCT03679728|Behavioral|Second trimester|Analysis of sensorimotor outcomes
79995939|NCT03679572|Procedure|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
79223461|NCT06020404|Procedure|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
79223462|NCT06019871|Procedure|Dialysis|Patients who have decided for dialysis either center haemo-dialysis or peritoneal dialysis
79223463|NCT06008834|Procedure|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
79223464|NCT06007014|Drug|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
79223465|NCT06007014|Drug|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
79223466|NCT06003933|Drug|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
79366109|NCT00499083|Other|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
79366110|NCT00499083|Other|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
79366111|NCT00499083|Procedure|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
79518496|NCT02553798|Drug|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
79518497|NCT02557698|Other|Balneum oil bath|
79518498|NCT02560038|Drug|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
79518499|NCT02560038|Drug|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
79518500|NCT02560038|Drug|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
79518501|NCT02560584|Drug|Hexaminolevulinate hydrochloride|Instillation in bladder
79675774|NCT01299376|Drug|L50/H12.5|
79675775|NCT01299376|Drug|Placebo to L50/H12.5/A5|
79223467|NCT06003933|Drug|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
79223468|NCT06003933|Device|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
79518502|NCT02560584|Device|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
79518503|NCT02561130|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
79518504|NCT02561130|Drug|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
79518505|NCT02561130|Drug|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
79518506|NCT02561130|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
79675776|NCT01299376|Drug|Placebo to L50/H12.5|
79675777|NCT04324450|Device|MRI|"The MRI protocol is composed of:~T1-weighted anatomical sequences~DTI sequences~resting functional MRI~3D MR spectroscopic imaging"
79675778|NCT04324450|Behavioral|Cognitive assessment|Battery of neuropsychological tests
79675779|NCT02890537|Drug|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
79223469|NCT06003933|Device|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
79995940|NCT03679572|Procedure|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
79675780|NCT02890537|Drug|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
79675781|NCT00492947|Biological|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
79675782|NCT02890225|Procedure|3 days after|in 3 days after RIRS.
79675783|NCT02890225|Procedure|10days after|in10 days after RIRS.
79675784|NCT02890225|Procedure|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
79223470|NCT06002256|Procedure|Mostafa Maged maneuver|While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
79223471|NCT06002256|Procedure|Bimanual uterine compression|the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
79995941|NCT03677466|Drug|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
79223472|NCT06000267|Procedure|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
79223473|NCT05999513|Drug|AB521|Administered as specified in the treatment arm
79223474|NCT05994807|Drug|DC-806|Oral tablets
79223475|NCT05994807|Drug|Itraconazole|Oral capsules
79675785|NCT01299025|Other|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
79675786|NCT00492986|Drug|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
79675787|NCT04324528|Device|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
79675788|NCT04324528|Device|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
79995942|NCT03677466|Procedure|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
79995943|NCT03196297|Drug|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
79995944|NCT03196297|Drug|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
79995945|NCT03677310|Drug|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
79995946|NCT03677310|Drug|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
79223476|NCT05994807|Drug|Carbamazepine|Oral tablets
79223477|NCT05993117|Device|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
79223478|NCT05983913|Behavioral|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
79518507|NCT02562066|Drug|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
79518508|NCT02562066|Drug|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
79518509|NCT02562924|Device|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
79518510|NCT02562924|Drug|Budesonide|Topical steroid
79518511|NCT02562924|Drug|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
79518512|NCT02562924|Drug|Prednisone|Post-operatively, 40 mg daily for 7 days
79518513|NCT02562924|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
79518514|NCT02562924|Drug|nasal saline spray|saline nasal mist every hour while awake
79518515|NCT02563860|Drug|Lovastatin|dose escallating
79518516|NCT02564016|Drug|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
79518517|NCT02564016|Other|Capped Epidural|epidural will be capped with no saline infusion.
79518518|NCT02566044|Other|Placebo|Placebo
79518519|NCT02566044|Drug|QBW276|0.3 mg and 1.5 mg strengths
79518520|NCT02566590|Device|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
79518521|NCT02566590|Dietary Supplement|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
79995947|NCT03447132|Drug|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
79518522|NCT02566590|Dietary Supplement|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
79675789|NCT01298596|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
79675790|NCT01298596|Procedure|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
79675791|NCT02890108|Dietary Supplement|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
79675792|NCT02890108|Dietary Supplement|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
79223479|NCT05983913|Behavioral|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
79675793|NCT00493259|Behavioral|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
79675794|NCT00493259|Behavioral|Depression Scale for Children (CES-DC)|questionnaire
79821772|NCT05476809|Behavioral|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
79223480|NCT05976139|Device|subthreshold treatment with micropulsed laser|"The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~Power: 5% Duty Cycle~Power 250 mw~Pulse duration 200 ms~Spot size 100 micron~Pattern spacing 0.0 confluente, griglie 7x7"
79223481|NCT05975216|Other|Contact the patient|Phone call, email or letter to contact the patient to relink them.
79223482|NCT05964296|Other|The MAURISSE application use|"Exchanges with the care team via the messaging system,~Postponement of consumption,~Monitoring of consumption,~Access to information on the To Do List,~Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~Postponement of a feeling of boredom,~Access to proposals to fight against this feeling."
79223483|NCT05964296|Other|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
79366112|NCT00499083|Procedure|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
79366113|NCT00499083|Procedure|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
79366114|NCT00499083|Procedure|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
79518523|NCT02568852|Procedure|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
79518524|NCT02568852|Procedure|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
79518525|NCT02569086|Other|Blood draw|
79518526|NCT02569632|Biological|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
79675795|NCT04324138|Drug|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
79675796|NCT04324138|Drug|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
79821773|NCT00696423|Biological|Infanrix™|Intramuscular injection, one dose
79821774|NCT00696423|Biological|Hiberix™|Intramuscular injection, one dose
79995948|NCT03447132|Drug|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
79223484|NCT05961865|Diagnostic Test|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
79518527|NCT02570022|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
79518528|NCT02570022|Procedure|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
79675797|NCT00493337|Behavioral|advanced adherence counseling+reminder|
79675798|NCT00493337|Device|Compliance Card|
79675799|NCT01243814|Device|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
79675800|NCT01243814|Device|placebo injection|joint injection with saline solution for placebo
79675801|NCT01243853|Dietary Supplement|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
79675802|NCT01298518|Drug|PF-04620110|5 mg of PF-04620110 given once daily
79675803|NCT01298518|Drug|PF-04620110|2.5 mg of PF-04620110 given twice daily
79675804|NCT01298518|Drug|Placebo|Matching placebo giving for 4 weeks
79223485|NCT05957926|Procedure|hyaluronic acid added to hydroxyapetite|"The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~The whole pathological tissues will be enucleated and sent for histopathological examination.~The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
79518529|NCT02570022|Drug|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
79518530|NCT02572752|Drug|Nintedanib|1 soft gelatine capsule, single dose, oral
79518531|NCT02572752|Drug|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
79518532|NCT02572752|Drug|Nintedanib|
79518533|NCT02574858|Drug|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
79518534|NCT02577042|Drug|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
79518535|NCT02577042|Drug|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
79518536|NCT02577042|Drug|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
79518537|NCT02577510|Drug|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament [7]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic [7]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
79675805|NCT01243970|Drug|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg *~* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
79675806|NCT01243970|Drug|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. *~* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
79675807|NCT04515576|Drug|LY3493269|Administered SC
79675808|NCT04515576|Drug|Dulaglutide|Administered SC
79366115|NCT00499083|Radiation|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
79366116|NCT00418886|Drug|Vandetanib|oral once daily tablet
79366117|NCT00418886|Drug|Pemetrexed|intravenous infusion
79675809|NCT04515576|Drug|Placebo|Administered SC
79675810|NCT01298362|Drug|Aromatase Inhibitors|
79366118|NCT00284726|Device|Celsior Cold Storage Solution|
79366119|NCT00230659|Other|Blood sample to be taken.|Blood sample to be taken.
79518538|NCT02577510|Drug|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle [6]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
79518539|NCT02577822|Device|Taperloc standard length stem|
79675811|NCT01298362|Drug|Chemotherapy|
79675812|NCT00493376|Procedure|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
79675813|NCT00493376|Procedure|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
79675814|NCT00493376|Procedure|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
79518540|NCT02577822|Device|Taperloc short length stem|
79518541|NCT02577900|Device|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
79518542|NCT02577900|Device|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
79518543|NCT02577900|Device|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
79518544|NCT02580318|Device|breathalyzer|
79675815|NCT00493376|Procedure|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
79675816|NCT00493415|Drug|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
79675817|NCT00493415|Drug|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
79675818|NCT01244009|Drug|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
79679891|NCT02931357|Drug|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
79679892|NCT00521768|Behavioral|Prolonged exposure|
79518545|NCT02582970|Drug|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
79675819|NCT04511832|Drug|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
79223486|NCT05957926|Procedure|Hydroxyapatite alone|"The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~The whole pathological tissues will be enucleated and sent for histopathological examination.~The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~hydroxyapetite will be inserted in the bony cavity to initiate healing .~The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
79675820|NCT00495950|Behavioral|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
79675821|NCT05148507|Device|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2001. PROKERA is considering it investigational for the study
79223487|NCT05955872|Drug|VX-147|Tablets for oral administration.
79366120|NCT00089024|Drug|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 & 2; Repeat one 3-week cycle starting day 22
79366121|NCT00089024|Drug|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 & 2; Repeat one 3-week cycle starting day 22
79518546|NCT02582970|Drug|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
79366122|NCT00089024|Drug|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
79366123|NCT00089024|Drug|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
79366124|NCT00089024|Procedure|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
79366125|NCT00089024|Procedure|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 [negative margins] or R1 [positive microscopic margins]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
79366126|NCT00089024|Procedure|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
79518547|NCT02582970|Drug|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
79518548|NCT02582970|Drug|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
79675822|NCT00495989|Procedure|saliva sampling + dental calculus collection|
79675823|NCT05148273|Behavioral|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
79675824|NCT01244204|Dietary Supplement|Vitamin D|Daily dose of 800IU of vitamin D
79675825|NCT01244204|Dietary Supplement|Placebo|Identically appearing capsules
79675826|NCT00496028|Drug|AZD0530|oral tablet
79675827|NCT00496028|Drug|Carboplatin|intravenous infusion
79995949|NCT03447132|Drug|Goserelin 3.6 MG|Only for pre or peri menopausal patient
79995950|NCT03447132|Drug|Placebos|Placebo
79995951|NCT04133623|Drug|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
79223488|NCT05954676|Other|CareOrbit|CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
79223489|NCT05947695|Behavioral|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
79518549|NCT02583360|Diagnostic Test|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
79518550|NCT02584140|Behavioral|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
79518551|NCT02584140|Behavioral|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of <1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of <1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
79675828|NCT00496028|Drug|Paclitaxel|intravenous infusion
79223490|NCT05946902|Drug|tolterodine|tolterodine 4 mg per day
79223491|NCT05946902|Drug|mirabegron|mirabegron 25 mg per day
79223492|NCT05946902|Drug|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
79223493|NCT05929183|Device|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
79223494|NCT05929183|Device|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
79223495|NCT05919277|Diagnostic Test|Dengue Immunoglobulin G antibodies performed with ELISA|All participants who agree to participate by signing an informed consent form will undergo a finger prick for the determination of Immunoglobulin G antibodies measured by ELISA. In a subgroup of persons who test positive, they will be invited to have blood drawn for neutralization determination in order to study serotypes and the presence of other flaviviruses.
79366127|NCT00089024|Radiation|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
79366128|NCT00081809|Drug|autologous human tumor-derived HSPPC-96|
79366129|NCT01819129|Drug|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
79366130|NCT01819129|Drug|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
79366131|NCT01819129|Drug|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
79366132|NCT04147065|Drug|Duration of eradication regimen|14 day eradication regimen
79366133|NCT04024137|Drug|ZSP1273 200 mg|1 X 200-mg tablet taken orally
79366134|NCT04024137|Drug|Placebo|2 tablets taken orally
79366135|NCT04024137|Drug|ZSP1273-400 mg|2 X 200-mg tablet taken orally
79366136|NCT04024137|Drug|Placebo|1 tablet taken orally
79366137|NCT04024137|Drug|ZSP1273-600 mg|3 X 200-mg tablet taken orally
79366138|NCT04024137|Drug|Placebo|3 tablets taken orally
79366139|NCT04024137|Drug|Placebo|Subjects will receive matching placebo of ZSP1273
79518552|NCT02584140|Drug|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
79518553|NCT02584608|Drug|ACTIMMUNE|
79675829|NCT00493493|Procedure|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
79675830|NCT00496067|Device|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
79675831|NCT04516278|Biological|bevacizumab|1.25 mg, intravitreal injection
79821778|NCT02592668|Device|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
79821779|NCT00736034|Dietary Supplement|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
79821780|NCT00918164|Drug|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
79675832|NCT04516200|Device|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
79675833|NCT04516200|Other|designed physical therapy program|sensory training and balance training
79675834|NCT00493532|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
79518554|NCT02584686|Drug|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
79821781|NCT00576693|Device|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
79518555|NCT02584686|Drug|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
79518556|NCT02584998|Other|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
79518557|NCT02584998|Other|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
79366140|NCT04146831|Drug|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
79366141|NCT04025775|Device|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
79675835|NCT01297465|Drug|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
79675836|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
79675837|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
79995952|NCT04133623|Drug|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
79821782|NCT00576693|Other|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
79366142|NCT04025775|Other|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
79366143|NCT03926481|Behavioral|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
79366144|NCT04028193|Dietary Supplement|Calogen|Polyunsaturated liquid fat supplement
79366145|NCT04028193|Dietary Supplement|Resource Energy|Carbohydrate Supplement
79518558|NCT02585700|Biological|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
79518559|NCT02585700|Other|Placebo|0.5 mL of phosphate buffered saline
79518560|NCT05249166|Other|ALINFA|Comparing the usual recommendations with the healthy diet designed and developed
79518561|NCT05249166|Other|Control|control group
79518562|NCT05248698|Behavioral|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
79518563|NCT05248698|Other|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
79675838|NCT01297465|Drug|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
79675839|NCT02276508|Drug|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
79223500|NCT05906979|Other|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
79223501|NCT05906979|Other|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
79223502|NCT05905081|Other|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
79675840|NCT00496106|Behavioral|Telephone counseling|6 telephone counseling sessions
79675841|NCT00496106|Behavioral|Telephone interview|telephone interview
79821783|NCT00698451|Drug|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
79223503|NCT05901987|Genetic|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
79223504|NCT05901259|Device|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
79223505|NCT05898763|Drug|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
79223506|NCT05898737|Device|NOL-Index|NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
79366146|NCT04406181|Behavioral|HADS|Hospital Anxiety and Depression Scale
79366147|NCT04406181|Behavioral|a survey|made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
79518564|NCT05248542|Other|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
79821784|NCT00921375|Drug|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
79821785|NCT00697827|Device|Interspinous Spacer device|Device: In-Space
79821786|NCT00697827|Device|Interspinous Process Distraction Device|Device: X STOP
79821787|NCT02566551|Procedure|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
79821788|NCT02566551|Device|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
79821789|NCT02566551|Procedure|TURP|Bipolar transurethral resection of the prostate
79821790|NCT02566551|Device|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
79223507|NCT05891509|Procedure|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
79223508|NCT05891509|Other|Best Medical Therapy|Best medical therapy
79223509|NCT05886023|Dietary Supplement|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
79223510|NCT05886023|Dietary Supplement|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
79223511|NCT05884242|Drug|Adalimumab|Adalimumab will be administered subcutaneously.
79223512|NCT05884242|Drug|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
79223513|NCT05868837|Drug|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
79223514|NCT05868837|Other|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
79223515|NCT05866627|Drug|Famotidine|Specified dose on specified days
79223516|NCT05866627|Drug|Afimetoran|Specified dose on specified days
79518565|NCT05248152|Combination Product|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
79518566|NCT05248152|Drug|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
79518567|NCT05248152|Drug|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
79675842|NCT04511286|Behavioral|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
79675843|NCT00493571|Drug|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
79675844|NCT02276586|Procedure|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
79675845|NCT02276586|Procedure|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
79675846|NCT00496145|Behavioral|Spanish Diabetes Self-Management Program|small-group self management education program
79675847|NCT01297309|Drug|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
79675848|NCT04518462|Drug|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
79821791|NCT00728936|Drug|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
79223517|NCT05860049|Device|istrument assisted soft tissue mobilization|"Each subject in group (A) will receive 12 sessions of physical therapy 3 sessions per week for 4 weeks).~Each subject in group (B) will receive 8 sessions of physical therapy(two sessions per week for four weeks)."
79821792|NCT00728936|Drug|Saline placebo|saline placebo given subcutaneously
79223519|NCT05850078|Other|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
79821793|NCT03980925|Drug|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
79223520|NCT05841667|Drug|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
79223521|NCT05835453|Other|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
79223522|NCT05835284|Device|Investigational Edge-on Silicon Photon Counting CT device|Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
79223523|NCT05833711|Drug|Froniglutide|SC Weekly Injection
79223524|NCT05833711|Drug|Placebo|SC Weekly Injection
79223525|NCT05828953|Drug|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
79223526|NCT05828953|Drug|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
79366148|NCT04765917|Other|Selected physical Therapy program|"-Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~Strengthening exercises for weakened muscles in upper and lower limbs muscle.~Strengthening exercises for back and abdominal muscles.~Stretching exercises for tight muscles in upper and lower limbs.~Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~Jumping in place and jumping a board."
79518568|NCT05247996|Procedure|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
79518569|NCT05247996|Drug|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight < 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
79518570|NCT05247996|Drug|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
79675849|NCT04518462|Drug|Bupivacaine Hydrochloride|0.25% bupivacaine
79675850|NCT00496184|Drug|Nifedipine cream topical application|
79675851|NCT00493610|Drug|N-acetylcysteine(Mucomyst)|
79675852|NCT02274506|Drug|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
79675853|NCT02274506|Drug|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
79675854|NCT02274506|Procedure|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
79675855|NCT04519632|Other|Qualitative study|Qualitative interviews
79821794|NCT03980925|Drug|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
79223527|NCT05825534|Other|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
79366149|NCT04765917|Other|Motor imagery training program|"As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes."
79366150|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
79366151|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
79366152|NCT04023981|Device|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
79366153|NCT04146675|Device|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
79366154|NCT04146675|Device|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
79366155|NCT03022149|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
79366156|NCT03022149|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
79366157|NCT04194333|Procedure|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
79366158|NCT04023279|Other|TENS|100 Hz and 100 usec for 20 minutes
79366159|NCT04023279|Other|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
79366160|NCT04023123|Other|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
79821795|NCT03980925|Drug|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
79821796|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
79821797|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
79821798|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
79821799|NCT02565693|Drug|Apixaban|
79821800|NCT02565693|Drug|Aspirin|
79518571|NCT05247996|Procedure|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
79518572|NCT05247762|Device|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
79518573|NCT05247684|Drug|AK112|IV infusion
79518574|NCT05247684|Drug|Carboplatin|IV infusion
79518575|NCT05247684|Drug|Cisplatin|IV infusion
79821801|NCT02565693|Drug|Carbasalate calcium|
79821802|NCT02565693|Drug|Clopidogrel|
79518576|NCT05247684|Drug|Paclitaxel|IV infusion
79518577|NCT04990986|Other|Complex intervention|Will be co-developed during the study.
79518578|NCT04845828|Procedure|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3. Sentinel lymph node is excised"
79821803|NCT02565693|Drug|Dipyridamole|
79223528|NCT05824975|Drug|GI-102|"Dose escalation phase:~GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles)."
79995953|NCT03623724|Behavioral|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
79366161|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
79518579|NCT04845828|Procedure|Routine lymph node dissection|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~Lymph node detection is performed."
79518580|NCT04808466|Drug|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
79223529|NCT05824975|Drug|GI-102|"Dose expansion phase:~GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles)."
79223530|NCT05809713|Other|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
79675856|NCT00496223|Drug|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
79821804|NCT02565693|Other|No antithrombotic treatment|
79821805|NCT04603989|Drug|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
79821806|NCT04603989|Drug|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
79821807|NCT00728468|Drug|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
79821808|NCT04061655|Drug|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
79821809|NCT04061655|Other|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
79518581|NCT04808466|Drug|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
79223531|NCT05809713|Other|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
79223532|NCT05792917|Drug|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
79223533|NCT05792917|Drug|tafolecimab (a original manufacturing process)|450mg，SC，single dose
79223534|NCT05786066|Drug|Perampanel 6 MG|Perampanel will be administered 2.5 hours before Ketamine infusion
79366162|NCT04146519|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
79366163|NCT04146519|Other|Placebo|Saline solution
79366164|NCT04022811|Drug|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
79518582|NCT04597554|Dietary Supplement|Cranberry|Cranberry beverage and gummies supplement
79518583|NCT04597554|Dietary Supplement|Placebo|Placebo beverages and gummies supplement
79675857|NCT00496223|Drug|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
79675858|NCT02593422|Behavioral|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
79675859|NCT02593422|Behavioral|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
79679893|NCT02937597|Behavioral|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
79223535|NCT05786066|Drug|Ketamine|Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
79223536|NCT05786066|Drug|Placebo|Placebo will be administered 2.5 hours before Ketamine infusion
79223537|NCT05782101|Diagnostic Test|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
79223538|NCT05781087|Diagnostic Test|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
79821810|NCT04061265|Drug|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
79366165|NCT04022889|Device|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
79821811|NCT04061265|Drug|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
79821812|NCT02592980|Genetic|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
79518584|NCT04003740|Device|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
79518585|NCT03939234|Combination Product|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
79518586|NCT03907176|Drug|HTX-011|300 mg
79675860|NCT00496301|Drug|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
79675861|NCT00493688|Other|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
79223539|NCT05781087|Diagnostic Test|Cardiac magnetic resonance angiogram|1.5T
79675862|NCT02597985|Other|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
79223540|NCT05776888|Other|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
79223541|NCT05776641|Device|GENUS|Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
79821813|NCT02592980|Drug|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
79821814|NCT03963284|Procedure|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
79223542|NCT05774587|Behavioral|mHealth control group|Cardiac rehab control group
79223543|NCT05774587|Behavioral|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
79366166|NCT04146129|Drug|CDX-0159|Single dose of one of four dosages of CDX-0159
79366167|NCT04146129|Drug|Normal saline|Single infusion of normal saline
79821815|NCT03963284|Device|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
79821816|NCT00727844|Drug|Immediate Start Linezolid|
79821817|NCT00727844|Drug|Delayed Start Linezolid|
79821818|NCT00735878|Drug|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
79821819|NCT02594150|Other|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
79821820|NCT02593838|Other|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
79223544|NCT05769244|Other|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
79366168|NCT04022655|Other|ICU Care|No intervention
79366169|NCT04022577|Behavioral|Adherence Therapy|Motivational interviewing-based AT in this study was based on Gray et al.'s eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
79366170|NCT04022577|Behavioral|control group|The control group received routine care
79518587|NCT03907176|Device|Luer lock applicator|Applicator for instillation
79518588|NCT03907176|Drug|Ibuprofen|600 mg
79518589|NCT03907176|Drug|Acetaminophen|1 g
79518590|NCT02692950|Other|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
79518591|NCT02692950|Behavioral|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
79821821|NCT00695955|Drug|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
79821822|NCT00695955|Drug|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
79821823|NCT04547205|Drug|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
79366171|NCT04145583|Drug|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
79518592|NCT02108496|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
79223545|NCT05767372|Other|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
79518593|NCT02108496|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
79518594|NCT02108496|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
79518595|NCT02108496|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
79518596|NCT02056236|Drug|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
79675863|NCT02597985|Other|Usual Care|
79675864|NCT00496418|Device|Mesh in permanent colostomy|
79223546|NCT05767372|Device|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~Progress slowly and monitor carefully.~As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~The session was repeated three times per week for 12 weeks."
79675865|NCT05141838|Drug|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
79223547|NCT05750550|Other|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
79223548|NCT05749627|Drug|Neoantigen peptide vaccine|Personalized tumor neoantigen peptide vaccine
79366172|NCT04145583|Drug|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
79366173|NCT04022421|Drug|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
79366174|NCT04022031|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
79675866|NCT05141838|Dietary Supplement|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
79366175|NCT03947151|Drug|Degarelix injection(s)|1 or 2 degarelix injection(s)
79675867|NCT00493727|Drug|N-acetylcysteine(Mucomyst)|
79675868|NCT05143788|Procedure|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
79675869|NCT00493766|Drug|LBH589|
79821824|NCT00693225|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
79366176|NCT04145505|Procedure|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
79366177|NCT04022109|Device|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
79675870|NCT05140005|Diagnostic Test|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
79675871|NCT00496457|Drug|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
79675872|NCT00496457|Drug|Placebo comparator|4 Capsules of PBO per day before noon meal
79675873|NCT02598648|Other|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
79675874|NCT02598648|Other|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
79675875|NCT00493844|Other|Exercise testing|Exercise testing
79675876|NCT00493844|Other|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
79675877|NCT05146479|Procedure|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
79223549|NCT05749627|Drug|Neoantigen-based DC immune preparation|Personalized tumor neoantigen DC therapeutic immune preparation
79223550|NCT05744843|Behavioral|exercise|cardiovascular and lower limb strengthening exercise programme
79223551|NCT05744843|Procedure|Deep venous stenting|Planned surgical intervention
79223552|NCT05744648|Procedure|Composite resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Composite resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
79223553|NCT05744648|Procedure|Composite resin restoration without Titania nanoparticle incorporated bonding agent|Composite resin restoration without Titania nanoparticle incorporated bonding agent
79223554|NCT05738954|Other|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
79675878|NCT01297270|Drug|BI201335|QD BI 201335
79675879|NCT01297270|Drug|PegIFN/RBV|
79821825|NCT03773757|Behavioral|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
79223555|NCT05726409|Other|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
79223556|NCT05718674|Procedure|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
79366178|NCT04022109|Procedure|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
79366179|NCT04022109|Diagnostic Test|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
79366180|NCT04022109|Diagnostic Test|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
79366181|NCT04145739|Other|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
79366182|NCT04145661|Device|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
79366183|NCT04145661|Device|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
79366184|NCT03923673|Procedure|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
79518597|NCT02056236|Other|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
79518598|NCT01962246|Drug|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
79518599|NCT01962246|Other|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
79518600|NCT02588586|Drug|3BNC117|3BNC117 infusions
79675880|NCT01297270|Drug|BI201335|QD (once daily) BI 201335
79675881|NCT01297270|Drug|Placebo|
79675882|NCT00496535|Drug|TNFerade biologic|
79675883|NCT05145621|Drug|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
79675884|NCT00493883|Device|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
79675885|NCT01296568|Drug|LY2603618|Administered intravenously
79675886|NCT01296568|Drug|Pemetrexed|Administered intravenously
79675887|NCT01296568|Drug|Gemcitabine|Administered intravenously
79821826|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
79995954|NCT03623724|Other|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
79223557|NCT05718063|Behavioral|MAP for Coaches - Complete Course|The MAP for Coaches is an eLearning (web-based) knowledge translation training course aimed at providing youth sport coaches with the evidence-based education and motivation they need to reduce the risk of musculoskeletal injuries in young athletes. Course modules include a description of: (1) musculoskeletal injuries in youth sport; (2) the importance of injury prevention, and instructions on: (1) applying best practices for musculoskeletal athletic injury prevention, including neuromuscular training programs; (2) using behavioral strategies to successfully implement neuromuscular training warm-up programs in coaching sessions.
79223558|NCT05718063|Behavioral|Map for Coaches - Overview|This is a summarized version of the MAP for Coaches. It comprises a 2-page sport-specific injury prevention e-book (reading) containing an overview of the MAP for Coaches training and an infographic summary.
79223559|NCT05710341|Dietary Supplement|Water with added nitrate|Water with added nitrate
79223560|NCT05710341|Dietary Supplement|Water without added nitrate|Water without added nitrate
79366185|NCT04021953|Behavioral|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~Increase viewers' knowledge and perceptions of HIV and other STI risk;~Address homophobia and sexual orientation disclosure;~Increase safer-sex negotiation self-efficacy;~Promote positive attitudes towards condom use and other safe sex behaviors;~Build skills and self-efficacy for practicing safer sex;~Provide information on HIV and other STI testing and its benefits;~Provide information on resources for HIV/STI testing and other mental health services;~Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
79518601|NCT02588586|Other|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
79366186|NCT04021953|Behavioral|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
79518602|NCT02588976|Device|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
79518603|NCT02592486|Biological|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
79518604|NCT02592486|Biological|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
79675888|NCT05140668|Device|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
79675889|NCT00496574|Biological|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
79366187|NCT02979717|Dietary Supplement|High protein, high fiber dietary supplement|
79675890|NCT02598999|Drug|ALX-009|Solution for inhalation administered through nebulization
79675891|NCT02598999|Drug|OSCN-|Solution for inhalation administered through nebulization
79675892|NCT02598999|Drug|bLF|Solution for inhalation administered through nebulization
79366188|NCT02979717|Other|Low protein, low fiber comparator|
79366189|NCT04145193|Drug|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
79518605|NCT02593032|Device|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
79518606|NCT05371938|Procedure|Volar locking plate|Volar locking plate is the intervention
79518607|NCT05371938|Procedure|external fixation|surgery with external fixation
79518608|NCT05371704|Dietary Supplement|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
79518609|NCT05371704|Other|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
79518610|NCT05371236|Other|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
79675893|NCT02598999|Drug|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
79675894|NCT00493922|Procedure|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
79675895|NCT00493922|Procedure|Microscopy|Microscopy for diagnosis of malaria
79675896|NCT00493922|Procedure|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
79995955|NCT03192475|Behavioral|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
79821827|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
79821828|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
79821829|NCT00735644|Biological|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
79821830|NCT00735644|Biological|Hepatitis A vaccine|0.5 mL, Intramuscular
79821831|NCT03718299|Drug|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
79821832|NCT02591888|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
79366190|NCT04145193|Drug|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
79518611|NCT05371158|Behavioral|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
79675897|NCT01296412|Drug|sitagliptin|100 mg tablet, orally, once daily.
79675898|NCT01296412|Drug|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
79675899|NCT01296412|Drug|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
79675900|NCT01296412|Drug|metformin|metformin tablets at a dose of ≥1500 mg per day
79675901|NCT05605561|Other|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
79675902|NCT05146128|Other|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
79821833|NCT02591888|Drug|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
79821834|NCT00724958|Biological|Infliximab|Not specified in the protocol.
79821835|NCT04086836|Device|TAVR|Patient recieving a TAVR
79821836|NCT03717441|Diagnostic Test|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
79821837|NCT04088006|Device|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
79821838|NCT02593136|Dietary Supplement|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
79821839|NCT02593136|Other|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
79821840|NCT04087928|Device|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
79223561|NCT05708365|Other|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~Plateau Pressure ≤ 30 cm of water~PEEP and FiO2 set according to ARDSnet table~Driving Pressure ≤ 15 cm of water~Respiratory rate between 8 and 30 breaths per minute"
79223562|NCT05708365|Other|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~Plateau Pressure ≤ 30 cm of water~PEEP and FiO2 set according to ARDSnet table~Driving Pressure ≤ 15 cm of water~Respiratory rate between 8 and 30 breaths per minute"
79675903|NCT00496652|Radiation|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
79675904|NCT00496652|Drug|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
79675905|NCT01295905|Device|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
79675906|NCT01295905|Device|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
79821841|NCT04087928|Device|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
79821842|NCT00695565|Drug|Placebo Gel|TID x 12 weeks
79821843|NCT00695565|Drug|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
79223563|NCT05708053|Drug|Metformin|Metformin 500 mg twice
79223564|NCT05701020|Other|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
79675907|NCT02956148|Radiation|Radioligand [18F]MNI-659|The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
79821844|NCT00727532|Drug|Sorafenib|400mg by mouth twice daily for 28 consecutive days
79821845|NCT00742599|Drug|NPO-11|20 ml NPO-11
79821846|NCT00742599|Drug|Placebo|20 ml NPO-11(Placebo)
79821847|NCT00742677|Procedure|nutritional support|Given orally
79518612|NCT05370846|Other|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
79675908|NCT02597634|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
79675909|NCT02597634|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
79675910|NCT00494039|Procedure|Radioactive seed implant to prostate|
79223565|NCT05699122|Other|Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day."
79223566|NCT05699122|Other|Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution."
79675911|NCT05148429|Other|Ultrasound exam|Ultrasound exam
79675912|NCT05148429|Other|Fetal MRI|Fetal MRI
79675913|NCT05148429|Other|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
79223567|NCT05699122|Other|Low Level Laser Therapy - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
79223568|NCT05699122|Other|Low Level Laser Therapy - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
79223569|NCT05674292|Device|Erchonia Violet Zerona Z6|405nm violet diode low level laser device
79675914|NCT05148429|Other|Pediatric Follow up|Pediatric Follow up
79675915|NCT00496691|Behavioral|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
79223570|NCT05671861|Device|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
79223571|NCT05671861|Other|Questionnaires|Surveys will be administered to participants
79223572|NCT05671861|Other|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
79675916|NCT05145972|Other|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
79675917|NCT00496847|Drug|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
79675918|NCT00496847|Drug|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
79675919|NCT02591199|Drug|URG101|
79675920|NCT02591199|Drug|Placebo|
79675921|NCT02591199|Drug|Lidocaine|
79675922|NCT02591199|Drug|Heparin|
79675923|NCT00494078|Device|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
79675924|NCT00494078|Drug|intensive insulin therapy|intensive insulin therapy according to an algorithm
79675925|NCT02596035|Drug|Nivolumab|
79675926|NCT00494117|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
79675927|NCT05147883|Behavioral|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
79518613|NCT05365854|Procedure|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
79518614|NCT05365620|Device|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
79995956|NCT03192475|Behavioral|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
79995957|NCT03683862|Other|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
79995958|NCT03189745|Biological|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
79995959|NCT03188263|Other|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
79995960|NCT03188263|Other|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
79223573|NCT05671523|Procedure|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
79366191|NCT04145193|Drug|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
79366192|NCT04145193|Drug|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
79366193|NCT04021563|Drug|SR419|Ascending single and multiple doses of SR419 orally
79518615|NCT05365620|Procedure|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
79518616|NCT05346276|Diagnostic Test|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
79995961|NCT03188185|Drug|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
79366194|NCT04021563|Drug|Placebo|Ascending single and multiple doses of placebo orally
79366195|NCT03021837|Other|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
79518617|NCT04970004|Other|No intervention|No study intervention will be administered as part of this study.
79675928|NCT00494156|Drug|heparin|
79675929|NCT00494156|Drug|aspirin and clopidogrel|
79675930|NCT02595489|Dietary Supplement|vitamin D3|Daily oral supplement provided by study investigators
79675931|NCT00494195|Genetic|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
79675932|NCT00494195|Genetic|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
79995962|NCT03188185|Drug|ALKS 5461 Placebo|Placebo tablet, administered sublingually
79995963|NCT03679182|Drug|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
79366196|NCT04765839|Other|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
79518618|NCT04946214|Behavioral|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
79223574|NCT05671523|Other|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
79518619|NCT04945122|Drug|Pitavastatin|Pitavastatin 4mg Qn
79518620|NCT04945122|Drug|Atorvastatin|Atorvastatin 20mg Qn
79518621|NCT04803630|Other|Quality-of-Life Assessment|Ancillary studies
79518622|NCT04803630|Other|Questionnaire Administration|Ancillary studies
79675933|NCT00497003|Drug|Treatment with either metoprolol or carvedilol|
79675934|NCT00494273|Behavioral|Cognitive Behavioral and Standard Care with Healthy Living|
79366197|NCT04145271|Device|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
79366198|NCT04141215|Biological|BIOBank bone paste|BIOBank bone paste (PPT322)
79366199|NCT04141215|Biological|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
79366200|NCT04141059|Dietary Supplement|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
79366201|NCT04141059|Dietary Supplement|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
79366202|NCT03022227|Other|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
79366203|NCT04747743|Other|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
79995964|NCT03679104|Procedure|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
79995965|NCT03679104|Procedure|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
79366204|NCT04144335|Biological|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
79366205|NCT04144335|Biological|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
79366206|NCT02707497|Drug|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
79366207|NCT02707497|Drug|Placebo|The control group will not use any platelet-increased drugs.
79366208|NCT02702895|Behavioral|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
79366209|NCT04144257|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
79366210|NCT04144257|Drug|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo [C-11]MRB-PET (norepinephrine transporter binding).
79366211|NCT04147845|Other|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
79518623|NCT04803630|Procedure|Thermotherapy|Undergo thermal therapy
79518624|NCT04445064|Biological|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
79518625|NCT04445064|Biological|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
79518626|NCT04227366|Biological|BCD-089|BCD-089 162 mg SC
79518627|NCT04227366|Biological|Placebo|Placebo
79518628|NCT04227366|Drug|Methotrexat|15 to 25 mg/week
79518629|NCT04113252|Other|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
79518630|NCT04113252|Other|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
79518631|NCT04113252|Behavioral|Coaching|Subjects will receive coaching prior to starting pain medication.
79518632|NCT04087122|Device|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
79675935|NCT00494312|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
79675936|NCT00494312|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
79518633|NCT03963492|Other|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
79675937|NCT05145348|Biological|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, <2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
79366212|NCT04147845|Other|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
79821848|NCT02593058|Behavioral|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
79821849|NCT02593058|Behavioral|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
79821850|NCT02565459|Biological|Mesenchymal Stromal Cells|
79821851|NCT03957824|Diagnostic Test|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
79821852|NCT03957512|Procedure|Heart surgery|All invasive procedures
79995966|NCT03623568|Drug|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
79223577|NCT05661188|Drug|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
79223578|NCT05656469|Other|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
79821853|NCT00742755|Behavioral|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
79821854|NCT03567213|Device|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
79223581|NCT05649787|Behavioral|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
79366213|NCT04147845|Other|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
79821855|NCT00721214|Drug|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
79821856|NCT02564601|Behavioral|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
79995967|NCT03186781|Biological|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
79366214|NCT04147845|Other|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
79366215|NCT03920709|Other|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
79366216|NCT01849783|Drug|dexamethasone|Given PO
79366217|NCT01849783|Drug|cisplatin|Given IV
79366218|NCT01849783|Drug|doxorubicin|Given IV
79366219|NCT01849783|Drug|cyclophosphamide|Given IV or PO
79366220|NCT01849783|Drug|etoposide|Given IV
79366221|NCT01849783|Drug|bortezomib|Given IV
79366222|NCT01849783|Drug|thalidomide|Given PO
79366223|NCT01849783|Drug|melphalan|Given IV
79366224|NCT01849783|Procedure|autologous stem cell transplant|
79366225|NCT01611883|Drug|Ezetimibe|10 mg oral dose once daily for 24 weeks
79366226|NCT01611883|Drug|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
79366227|NCT04170517|Diagnostic Test|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
79518634|NCT03945162|Combination Product|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
79518635|NCT03917316|Other|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
79518636|NCT03560466|Drug|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
79518637|NCT03560466|Drug|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
79518638|NCT03560466|Drug|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
79518639|NCT03376698|Drug|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
79675938|NCT00494351|Procedure|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
79675939|NCT02595372|Drug|Omeprazole|
79518640|NCT03376698|Drug|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
79518641|NCT03376698|Drug|Placebo|oral administration of Placebo once daily for 12 weeks
79518642|NCT03295734|Behavioral|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
79675940|NCT00497042|Device|Self Adjusting File|
79821857|NCT02564601|Behavioral|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
79223582|NCT05649787|Behavioral|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
79366228|NCT01848457|Drug|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 & 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 & 2 of treatment Cycles 1 & 2 (Treatment Arms 1, 3) OR Cycles 3 & 4 (Treatment Arms 2, 4)
79366229|NCT01848457|Drug|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
79366230|NCT01817725|Biological|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those <= 20 years old and 40μg in those > 20 years old.
79675941|NCT05142969|Other|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
79675942|NCT01244867|Biological|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
79995968|NCT03186781|Biological|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
79223583|NCT05649787|Behavioral|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
79223584|NCT05640674|Drug|Ibuprofen|Non-opioid
79223585|NCT05640674|Drug|Hydrocodone/acetaminophen|Opioid
79223586|NCT05640674|Drug|Acetaminophen|Non-opioid
79223587|NCT05629689|Drug|GEH200520 Injection / GEH200521 (18F) Injection - Part A|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
79366231|NCT01870999|Drug|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
79518643|NCT03295734|Drug|Perindopril|4 mg qd titrated to 8 mg qd perindopril
79518644|NCT03295734|Drug|Losartan|50 mg qd titrated to 100 qd losartan
79366232|NCT01870999|Drug|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
79518645|NCT03295734|Drug|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
79518646|NCT03084666|Device|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
79518647|NCT02928978|Drug|Ruxolitinib|tablet (taken by mouth)
79675943|NCT01244867|Biological|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
79821858|NCT02592512|Other|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
79366233|NCT01870921|Drug|Ticagrelor|90mg/tablet, 1 tablet bid
79366234|NCT00526474|Drug|Vorapaxar|2.5-mg tablet daily for at least 1 year
79366235|NCT00526474|Drug|Placebo|matching tablet daily for at least 1 year
79518648|NCT02928978|Drug|Placebo (for Ruxolitinib)|tablet (taken by mouth)
79518649|NCT00394758|Procedure|CO2 laser surgery|
79518650|NCT00394758|Procedure|ultrasonic surgical aspiration|
79518651|NCT02594826|Behavioral|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
79518652|NCT02594826|Behavioral|General health education control|General health and cancer education
79518653|NCT02595684|Drug|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
79518654|NCT02595684|Drug|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
79518655|NCT02599194|Drug|18F-FSPG|Administered intravenously (IV)
79518656|NCT02599194|Drug|18F-FDG|Administered intravenously (IV)
79518657|NCT02604810|Biological|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
79518658|NCT02604810|Biological|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
79675944|NCT01244867|Biological|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
79675945|NCT01244867|Biological|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
79675946|NCT01244867|Biological|Placebo|2 doses given 21 days apart of the placebo
79675947|NCT02596503|Drug|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
79675948|NCT02596503|Drug|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
79675949|NCT02596503|Other|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
79675950|NCT00494429|Drug|Morphine|Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
79675951|NCT00494429|Drug|Morphine|Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
79675952|NCT01245023|Procedure|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
79675953|NCT01245023|Procedure|Placebo-surgery|skin incisions without laparoscopy or related procedures
79675954|NCT00497120|Drug|acetazolamide|
79675955|NCT00497120|Drug|placebo|
79675956|NCT00497120|Procedure|uvulopalatopharygoplasty|
79675957|NCT02276352|Drug|Treatment 1|
79675958|NCT02276352|Drug|Treatment 2|
79223588|NCT05629689|Diagnostic Test|Dynamic and Static - PET/CT scan|Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
79675959|NCT02276352|Drug|Treatment 3|
79518659|NCT02606604|Device|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
79821859|NCT02592512|Other|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
79821860|NCT02593214|Device|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
79995969|NCT03683706|Behavioral|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
79223589|NCT05629689|Drug|GEH200520 Injection / GEH200521 (18F) Injection - Part B|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
79223590|NCT05629689|Diagnostic Test|Static - PET/CT scan|Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
79223591|NCT05620784|Drug|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
79223592|NCT05619471|Device|VIO|Skin conditions that are candidates for skin biopsies
79223593|NCT05596760|Behavioral|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
79366236|NCT01848145|Drug|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
79366237|NCT01847755|Drug|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
79518660|NCT02606838|Device|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
79518661|NCT02607618|Drug|Iclaprim|Experimental treatment
79518662|NCT02607618|Drug|Vancomycin|Active comparator
79518663|NCT02609100|Procedure|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
79675960|NCT00494468|Drug|Zolpidem|
79675961|NCT00497237|Drug|Beclomethasone plus formoterol fixed combination|100+6 pMDI
79675962|NCT00497237|Drug|Fluticasone plus salmeterol fixed combination|diskus 250/50
79675963|NCT05144061|Drug|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
79675964|NCT01244282|Procedure|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
79821861|NCT02592200|Dietary Supplement|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
79821862|NCT02592200|Dietary Supplement|Placebo|Two doses per day for 28 days
79821863|NCT00720902|Procedure|Blood draws|Subjects will have serum cardiovascular markers assessed
79821864|NCT00720902|Drug|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
79821865|NCT00720902|Procedure|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
79821866|NCT00720902|Procedure|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
79995970|NCT03623412|Diagnostic Test|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
79995971|NCT03623412|Diagnostic Test|75g GTT|post-partum GTT
79995972|NCT02830165|Other|Laboratory Biomarker Analysis|Correlative studies
79995973|NCT02830165|Other|Quality-of-Life Assessment|Ancillary studies
79995974|NCT02830165|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79995975|NCT03184987|Drug|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
79223594|NCT05595629|Behavioral|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
79995976|NCT03184987|Drug|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
79223595|NCT05595629|Behavioral|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
79223596|NCT05586477|Drug|Placebo|A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
79223597|NCT05586477|Drug|Diphenhydramine|Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
79223598|NCT05578651|Device|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
79223599|NCT05577338|Behavioral|Theory of Mind psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
79223600|NCT05577338|Behavioral|health education|disease-related health knowledge
79223601|NCT05573763|Device|F&P Toffee|Nasal pillows mask
79223602|NCT05572450|Other|Infectious Titre 1|Approximately 10^5.5 TCID50/mL (titre may be adjusted based on stock titre)
79223603|NCT05572450|Other|Infectious Titre 2|Approximately 10^4.5 TCID50/mL (titre may be adjusted based on stock titre)
79366238|NCT00527566|Biological|Mepolizumab|IV mepolizumab, 750 mg
79366239|NCT00527644|Device|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
79366240|NCT00527722|Device|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
79366241|NCT00527722|Other|No lung plug|Standard lung biopsy without placement of the plug.
79366242|NCT01847443|Drug|Nicotine (2 mg)|2 mg nicotine gum in two formulations
79366243|NCT01847443|Drug|Nicotine (4 mg)|4 mg nicotine gum in two formulations
79366244|NCT00527878|Drug|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
79366245|NCT00527878|Drug|Placebo|
79366246|NCT01847209|Procedure|Video-Assisted Thoracic Surgery (VATS) wedge resection|
79366247|NCT05558878|Drug|Ambroxol Oral Product|"Drug: Ambroxol (75 mg capsule)~Ambroxol is a mucolytic and expectorant drug. Ambroxol has been approved as lozenges for topical analgesia of sore throat in pharyngitis owing to its local anesthetic properties. Anti-inflammatory properties of ambroxol were confirmed by numerous studies. Ambroxol affect neuronal transduction by blocking (TTX)-resistant Na+ channels (Nav1.8) in small (pain-sensing) dorsal root ganglion neurons more potently than TTX-sensitive channels."
79366248|NCT01846741|Device|M106 VNS Therapy System|
79366249|NCT05621590|Drug|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
79366250|NCT05621590|Drug|Placebo|placebo capsules filled with stevia sweetened powder
79366251|NCT05554042|Diagnostic Test|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
79366252|NCT05621434|Drug|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
79366253|NCT05621356|Other|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
79366254|NCT01870843|Drug|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
79366255|NCT01797952|Drug|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
79366256|NCT01797952|Other|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
79366257|NCT04725838|Device|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
79518664|NCT02609100|Procedure|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
79518665|NCT02609100|Device|1.0 X 2.5 cm 'pill' containing a camera|
79675965|NCT00494546|Procedure|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
79675966|NCT00497276|Procedure|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
79675967|NCT00497315|Drug|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
79675968|NCT00497315|Radiation|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
79223604|NCT05572450|Other|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
79223605|NCT05572450|Other|Infectious Titre 4|TBD, depending on outcome of Part A
79366258|NCT01816477|Device|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
79366259|NCT01816477|Drug|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
79995977|NCT03184987|Drug|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
79995978|NCT03184987|Other|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
79223606|NCT05570266|Diagnostic Test|Breast Cancer Risk Prediction Software|Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
79223607|NCT05568706|Drug|EDP-938|Subjects will take EDP-938 once daily for 5 days
79223608|NCT05568706|Drug|Placebo|Subjects will take matching placebo, once daily for 5 days
79223609|NCT05564598|Biological|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
79366260|NCT01846507|Drug|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
79366261|NCT05615038|Procedure|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
79366262|NCT05615038|Procedure|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
79366263|NCT05613790|Device|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
79366264|NCT05613790|Device|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
79366265|NCT01846039|Device|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
79366266|NCT01610167|Device|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
79366267|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
79366268|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
79366269|NCT04478500|Drug|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
79366270|NCT01816243|Drug|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
79366271|NCT01816243|Drug|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
79366272|NCT05484778|Procedure|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
79366273|NCT05576896|Drug|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
79675969|NCT05142072|Drug|Vitamin D3|intranasal film
79675970|NCT00497354|Drug|Variation in volume of local anesthetic|
79675971|NCT00497354|Procedure|Ultrasound-guided interscalene brachial plexus block|
79675972|NCT00497393|Behavioral|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
79675973|NCT05140785|Diagnostic Test|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
79675974|NCT00494624|Drug|prednisolone|
79675975|NCT00507156|Procedure|Standard primary PCI|Acute re-opening of the occluded coronary artery
79675976|NCT00507156|Procedure|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
79995979|NCT03184519|Diagnostic Test|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
79995980|NCT03184441|Device|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
79223610|NCT05564598|Drug|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~Reduce dose by 50% for ANC less than 500 cells/mm3~Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~Treatment will continue for 6 months"
79223611|NCT05549219|Drug|GLM101|GLM101 IV Infusion
79223612|NCT05547919|Radiation|18F-PSMA PET/CT|Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
79223613|NCT05542628|Other|No intervention included|No intervention included
79223614|NCT05538871|Diagnostic Test|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
79366274|NCT01845805|Drug|oral azacitidine|
79518666|NCT02610972|Device|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
79223615|NCT05537792|Device|Robotic Knee/Ankle Prosthesis|The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
79223616|NCT05536739|Device|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton that has been previously developed by the team. It is used to improve walking gait performance.
79518667|NCT02612688|Behavioral|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
79675977|NCT00494663|Drug|DIO-902|150mg tablet once per day for 16 weeks
79675978|NCT00494663|Drug|DIO-902|300mg tablet once per day for 16 weeks
79223617|NCT05535023|Drug|SAR444245|Given by vein (IV)
79675979|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
79995981|NCT05241145|Drug|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
79995982|NCT05241145|Other|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
79675980|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
79675981|NCT00494663|Drug|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
79675982|NCT00494663|Drug|DIO-902|300mg DIO-902 tablet daily for 16 weeks
79223618|NCT05535023|Drug|Cemiplimab|Given by vein (IV)
79821867|NCT00720902|Procedure|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
79223620|NCT05506891|Behavioral|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
79223621|NCT05506891|Drug|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
79366275|NCT01845805|Other|Observation|
79821868|NCT02592278|Drug|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
79821869|NCT02592278|Drug|Control Group|Twice a day brush with fluoride toothpaste.
79366278|NCT04415125|Diagnostic Test|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
79366279|NCT04371094|Device|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
79366280|NCT01845025|Drug|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
79366281|NCT01845025|Drug|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
79675983|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet for 16 weeks
79675984|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
79679894|NCT02937597|Behavioral|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
79679895|NCT02937597|Behavioral|HSE|National HSE e-learning programme only
79679896|NCT04694027|Drug|Omega 3 fatty acid|omega 3 1000 mg
79679897|NCT04694027|Drug|VitaE|vitamin e 400 mg
79518668|NCT05732064|Drug|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
79518669|NCT05732064|Drug|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
79995983|NCT05240443|Procedure|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
79223622|NCT05505500|Behavioral|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
79518670|NCT05732064|Drug|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
79821870|NCT00695019|Drug|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
79821871|NCT00695019|Drug|placebo lozenges|200 mg matching placebo lozenges
79821872|NCT00918398|Drug|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
79518673|NCT05731752|Drug|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
79675985|NCT05146674|Drug|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
79675986|NCT00494702|Procedure|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
79675987|NCT00494702|Procedure|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
79223624|NCT05503316|Other|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
79675988|NCT00507195|Drug|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
79675989|NCT00497471|Drug|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
79675990|NCT00497471|Drug|iron (2 mg/kg/daily)|
79223625|NCT05503316|Other|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
79223626|NCT05500976|Other|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
79675991|NCT05146635|Drug|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
79223627|NCT05500976|Other|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
79223628|NCT05487183|Behavioral|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
79675992|NCT05146635|Drug|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
79675993|NCT00494741|Drug|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
79675994|NCT00494741|Drug|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
79675995|NCT00507234|Drug|formoterol fumarate inhalation solution|
79675996|NCT00507273|Other|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
79675997|NCT00497510|Procedure|Chiropractic manipulation|
79821873|NCT00918398|Drug|AZD1981|514 mg oral solution, single dose
79821874|NCT00918398|Drug|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
79821875|NCT00918398|Drug|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
79821876|NCT04019600|Other|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
79821877|NCT04086602|Drug|IZD334|Active Drug
79821878|NCT04086602|Drug|Placebos|Placebo to Match
79821879|NCT00742833|Drug|KUC-7483|
79821880|NCT00742833|Drug|Placebo|
79821881|NCT04060953|Other|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
79518674|NCT05731674|Other|Random selection of excercises|Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
79518675|NCT05731206|Other|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
79223629|NCT05487183|Behavioral|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
79223630|NCT05487183|Behavioral|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
79675998|NCT00507312|Device|HD medical device (ViScope)|Device
79223631|NCT05485974|Drug|HBI-2438|KRAS G12C Inhibitor
79223632|NCT05484076|Other|breastfeeding counseling|"A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training."
79223633|NCT05457907|Device|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
79223634|NCT05455658|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
79223635|NCT05455658|Biological|Sargramostim|Given ID
79223636|NCT05450679|Procedure|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at > 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
79366282|NCT01845025|Drug|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
79223637|NCT05449366|Drug|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
79223638|NCT05447806|Device|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
79366283|NCT01845025|Drug|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
79366284|NCT01845025|Drug|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
79366285|NCT03830632|Other|Plyometric Training|
79366286|NCT03830632|Other|Traditional Training|
79366287|NCT04257760|Behavioral|Palliative Care consultation outside standard of care|The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
79366288|NCT04242940|Device|Fitting of Ponto 4|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
79518676|NCT05731206|Other|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
79518677|NCT05731050|Drug|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
79518678|NCT05730738|Drug|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
79518679|NCT05730738|Drug|Placebo|placebo similar to Dalfampridine capsule
79675999|NCT00507312|Device|CSIRO device|device
79679898|NCT00521807|Procedure|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
79679899|NCT04577274|Dietary Supplement|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
79518680|NCT05730660|Dietary Supplement|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
79518681|NCT05730660|Dietary Supplement|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
79518682|NCT05725434|Biological|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
79518683|NCT05725434|Biological|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
79518684|NCT05665842|Other|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
79518685|NCT05665842|Other|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal & Nunes, 2014; Dinis & Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
79223639|NCT05444855|Other|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
79366289|NCT04233424|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
79676000|NCT00497549|Procedure|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
79676001|NCT00497549|Procedure|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
79676002|NCT05148546|Drug|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
79676003|NCT05148546|Drug|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
79223640|NCT05440214|Behavioral|Dialectical Behavior Therapy Skills Training|Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
79223641|NCT05422248|Device|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
79223642|NCT05422248|Device|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
79223643|NCT05415462|Biological|mRNA-1010|Sterile liquid for injection
79223644|NCT05415462|Biological|Licensed quadrivalent inactivated seasonal influenza vaccine|Sterile suspension for injection
79223645|NCT05413135|Drug|ARO-APOC3|ARO-APOC3 Injection
79366290|NCT04233424|Other|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
79366291|NCT04185610|Other|Qi Gong|Guided Qi Gong class
79366292|NCT05534932|Device|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
79366293|NCT05367856|Drug|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
79223646|NCT05411523|Other|Quality-of-Life Assessment|Complete quality of life assessment
79223647|NCT05411523|Other|Questionnaire Administration|Complete questionnaires
79223648|NCT05411523|Procedure|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
79518686|NCT05629416|Behavioral|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~Support simplified and improved strategies for booking an interpreter to increase uptake.~Implement retention strategies to ensure interpreters receive workplace support.~Provide training in health terminology for interpreters.~Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
79518687|NCT05627388|Other|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
79518688|NCT05555082|Other|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
79366294|NCT02124304|Device|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
79223649|NCT05400161|Behavioral|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
79223650|NCT05400161|Behavioral|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
79223651|NCT05395494|Drug|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
79223652|NCT05395494|Drug|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
79223653|NCT05395494|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
79223654|NCT05394064|Genetic|SBT101|SBT101 Treatment
79223655|NCT05394064|Procedure|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
79223656|NCT05393297|Diagnostic Test|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
79223657|NCT05393297|Radiation|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
79366295|NCT02124460|Behavioral|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
79366296|NCT04148872|Other|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
79518689|NCT05541120|Device|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
79518690|NCT05515458|Drug|Chiglitazar|Oral single dose 48 mg
79676004|NCT05148546|Drug|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
79518691|NCT05466552|Procedure|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
79518692|NCT05460702|Diagnostic Test|Soluble immune checkpoints|Blood collection from breast cancer patients with stage I-II
79518693|NCT05446272|Device|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
79518694|NCT05446272|Device|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
79518695|NCT05419674|Drug|Vonoprazan|Potassium-competitive acid blocker
79518696|NCT05419674|Drug|Rabeprazole|Proton pump inhibitor
79518697|NCT05419674|Drug|Amoxicillin|Antibiotic for H. pylori eradication
79518698|NCT05419674|Drug|Clarithromycin|Antibiotic for H. pylori eradication
79518699|NCT05419674|Drug|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
79676005|NCT00507351|Behavioral|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
79676006|NCT00497588|Procedure|surgery|
79223658|NCT05389787|Device|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is ~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
79518700|NCT05409300|Biological|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
79518701|NCT05386524|Drug|sintilimab|sintilimab 200mg, ivgtt，d1
79518702|NCT05386524|Drug|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
79518703|NCT05386524|Drug|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
79518704|NCT05357664|Device|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
79518705|NCT05357664|Device|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
79518706|NCT05338554|Device|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
79518707|NCT05338554|Device|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
79518708|NCT05318040|Drug|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
79518709|NCT05318040|Drug|Placebo|Placebo will be provided as visually matching placebo capsules.
79524794|NCT05768438|Other|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
79676007|NCT00497588|Radiation|radiotherapy|
79676008|NCT00506532|Drug|Surfactant (calfactant)|
79676009|NCT00494858|Behavioral|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
79223659|NCT05374304|Other|Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool|The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
79223660|NCT05371873|Procedure|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
79676010|NCT00494858|Behavioral|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
79676011|NCT05143983|Behavioral|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
79518710|NCT05214456|Other|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
79524795|NCT05768412|Procedure|Radial Artery Access|The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
79366297|NCT04148872|Drug|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
79223661|NCT05341310|Behavioral|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
79676012|NCT05143983|Behavioral|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
79223662|NCT05341310|Other|Treatment as usual|Treatment as usual in the outpatient clinic
79223663|NCT05341297|Behavioral|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
79223664|NCT05338333|Device|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
79223665|NCT05338333|Device|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
79366298|NCT04148872|Other|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
79366299|NCT04129294|Drug|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~[Part 1] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks [Part 2] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
79676013|NCT05149560|Drug|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
79676014|NCT00494897|Drug|Asparaginase|
79676015|NCT00494897|Drug|Cyclophosphamide|
79676016|NCT00494897|Drug|Cytarabine|
79676017|NCT00494897|Drug|Daunorubicin|
79676018|NCT00494897|Drug|Mercaptopurine|
79676019|NCT00494897|Drug|Prednisone|
79223666|NCT05338333|Device|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
79223667|NCT05338268|Behavioral|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth.
79676020|NCT00494897|Drug|Vincristine|
79223668|NCT05338268|Behavioral|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
79223669|NCT05337618|Diagnostic Test|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
79223670|NCT05337618|Combination Product|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
79223671|NCT05336864|Other|Non-invasive cerebral oximetry monitoring|"Main study (all patients): Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the duration of general anesthesia. Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+.~Postoperative hemodynamics substudy (facultative): Cerebral NIRS monitoring will be continued postoperatively in a subset of patients being admitted to the ICU."
79223672|NCT05336864|Other|additional perioperative blood sampling|"Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin~Neurological injury substudy (facultative): Neurofilament Light Chain (NFL)"
79223673|NCT05336864|Other|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year MACE).
79223674|NCT05336864|Other|Non-invasive somatic oximetry monitoring|Tissue perfusion substudy (facultative): Continuous somatic NIRS monitoring of an extremity (i.e. on skin of leg or arm) will be performed intraoperatively and postoperatively in a subset of patients being admitted postoperatively to the ICU.
79223675|NCT05335668|Procedure|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
79223676|NCT05334433|Procedure|Local anesthesia injection|Local anesthesia administration
79366300|NCT05310994|Dietary Supplement|Placebo drink|consume 1 bottle per day
79366301|NCT05310994|Dietary Supplement|Wasabi Leaf Extract Drink|consume 1 bottle per day
79676021|NCT00494897|Drug|Methotrexate|
79676022|NCT00494897|Procedure|Intrathecally treatment|
79676023|NCT05148624|Procedure|embryo transfer|immediate ambulation after embryo transfer
79676024|NCT00497666|Drug|Rosiglitasone (retrospective observation)|
79679900|NCT04577274|Dietary Supplement|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
79518711|NCT05214456|Other|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
79676025|NCT05144919|Behavioral|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~Where to locally source inputs and expected price~How/when to prepare plots using organic inputs~Planting and best-practice management practices~Seed saving and storage~Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
79821882|NCT03472989|Device|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
79821883|NCT03472989|Device|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
79223677|NCT05332769|Genetic|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
79366302|NCT05272306|Other|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
79676026|NCT05144568|Other|Nutrition education|Nutrition education will be given to improve PMS
79676027|NCT05144217|Drug|Placebo|1 capsule per day of placebo
79676028|NCT05144217|Drug|2x 140 mg per day|2 capsule per day of silimarit
79676029|NCT05144217|Drug|3x 280 mg per day|3 capsule per day of silimarit
79676030|NCT05144217|Drug|1x 1120 mg|8 capsule per day of silimarit
79676031|NCT00497744|Drug|Intraperitoneal Cefepime|
79676032|NCT00495053|Drug|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
79676033|NCT00495053|Other|Placebo|Matching placebo (PBS-20% sucrose)
79821884|NCT03472989|Behavioral|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
79223678|NCT05327309|Drug|Bleomycin|
79223679|NCT05318794|Drug|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
79223680|NCT05312593|Other|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
79366303|NCT05272306|Diagnostic Test|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
79366304|NCT05272306|Diagnostic Test|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
79676034|NCT00497783|Drug|Lactoserum|
79366305|NCT04997668|Device|SOLTIVE Thulium Fiber Laser|Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.
79366306|NCT04997668|Device|Ho:YAG Laser|Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
79676035|NCT05143515|Behavioral|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
79676036|NCT00495092|Drug|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
79676037|NCT00495092|Drug|Biperiden|Biperiden 2-4 mg/d p.o.
79676038|NCT00495092|Drug|Placebo|Placebo + Placebo
79821885|NCT03472989|Behavioral|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
79223681|NCT05312593|Other|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
79223682|NCT05296538|Other|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
79223683|NCT05296538|Other|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
79518712|NCT05044182|Procedure|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
79518713|NCT05044182|Procedure|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
79518714|NCT05016024|Device|Colilen IBS|Patients will take Colilen IBS in First or Second Period
79518715|NCT05016024|Other|Placebo|Patients will take PlaceboS in First or Second Period
79518716|NCT04986540|Drug|SHR-1906；Placebo|"Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose"
79223684|NCT05263830|Other|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
79223685|NCT05256901|Drug|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or greater.
79518717|NCT04965714|Biological|Nivolumab|Given IV
79676039|NCT05143359|Diagnostic Test|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
79676040|NCT05143359|Diagnostic Test|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
79223686|NCT05256901|Drug|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
79223687|NCT05245955|Device|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
79223688|NCT05243524|Other|Maveropepimut-S|SC injection on days 7, 28, then q8w
79223689|NCT05243524|Drug|Cyclophosphamide 50mg|PO BID, one week on, one week off
79223690|NCT05226455|Drug|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
79223691|NCT05223205|Procedure|Air|Test if air is sufficient for macular hole closure.
79366307|NCT05246488|Diagnostic Test|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
79366308|NCT04907188|Biological|HB-adMSCs|The subject will receive 6 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10^8 cells) cells approximately every 28 days.
79518718|NCT04965714|Biological|Pegargiminase|Given IM
79518719|NCT04965714|Procedure|Resection|Undergo surgical resection
79518720|NCT04939350|Other|questionnaire|patients will complete a vaccination questionnaire
79518721|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
79518722|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
79518723|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
79518724|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
79518725|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
79518726|NCT04780698|Diagnostic Test|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
79518727|NCT04669236|Behavioral|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
79676041|NCT00497822|Procedure|Aerobic exercise training|
79676042|NCT00497861|Procedure|Activator Methods Chiropractic Technique|
79223692|NCT05223205|Procedure|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
79223693|NCT05215418|Drug|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
79223694|NCT05215418|Drug|Phentermine|Phentermine 30 mg capsule
79223695|NCT05215418|Drug|Placebo|Inactive oral capsule
79366309|NCT04847440|Drug|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
79518728|NCT04355130|Dietary Supplement|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
79223696|NCT05211388|Procedure|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
79518729|NCT04293198|Device|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
79518730|NCT04293198|Device|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
79518731|NCT04199832|Dietary Supplement|Dietary guidance|Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
79518732|NCT04116996|Device|DEEP BRAIN STIMULATION|NEUROMODULATION
79366310|NCT04847440|Drug|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
79223697|NCT05211388|Procedure|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
79518733|NCT04107168|Drug|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
79518734|NCT04107168|Drug|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
79676043|NCT01244360|Dietary Supplement|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
79676044|NCT01244360|Other|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
79676045|NCT00506571|Drug|S-1, irinotecan, oxaliplatin|
79676046|NCT00497900|Drug|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
79676047|NCT05143125|Biological|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
79676048|NCT01244555|Other|ultrasound|Twice weekly ultrasound sessions for 6 weeks
79366311|NCT04847440|Drug|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
79366312|NCT04812106|Other|No Intervention|No Intervention
79366313|NCT03692572|Dietary Supplement|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
79676049|NCT01244555|Other|massage|Twice weekly massage sessions for 6 weeks
79676050|NCT05143008|Behavioral|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
79821886|NCT00742911|Drug|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
79366314|NCT03692572|Dietary Supplement|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
79366315|NCT03516760|Drug|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
79676051|NCT00497939|Drug|Saw palmetto and sanmiaoshan capsule|
79366316|NCT01870297|Drug|LY3025876|Administered SQ
79366317|NCT01870297|Drug|Placebo|Administered SQ
79366318|NCT01870297|Drug|Liraglutide|Administered SQ
79366319|NCT01814761|Drug|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
79366320|NCT05141110|Drug|NVP-1705|NVP-1705
79366321|NCT05141110|Drug|NVP-1705-R|NVP-1705-R
79518735|NCT04107168|Drug|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
79518736|NCT04107168|Drug|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
79676052|NCT05142930|Other|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
79676053|NCT05142930|Other|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
79676054|NCT01244594|Other|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
79223698|NCT05210387|Other|Duration of therapy|"In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1)."
79223699|NCT05209425|Dietary Supplement|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
79366322|NCT01843933|Device|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
79995984|NCT05240443|Other|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
79366323|NCT01798030|Other|Vitamin D|N/A, frozen specimen study
79366324|NCT03329950|Drug|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
79518737|NCT04107168|Drug|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
79518738|NCT04107168|Drug|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
79518739|NCT04107168|Drug|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
79518740|NCT03958344|Drug|Prednisolone|Oral Tablet
79995985|NCT03026166|Drug|Ipilimumab|Administered by intravenous infusion
79518741|NCT03958344|Drug|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
79676055|NCT00497978|Dietary Supplement|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
79676056|NCT00497978|Dietary Supplement|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
79995986|NCT03026166|Drug|Nivolumab|Administered by intravenous infusion
79995987|NCT03026166|Drug|Rovalpituzumab tesirine|Administered by intravenous infusion
79995988|NCT03573648|Drug|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
79995989|NCT03573648|Drug|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
79995990|NCT03573648|Drug|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
79995991|NCT03683472|Behavioral|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
79366325|NCT03329950|Drug|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
79366326|NCT03329950|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
79366327|NCT03329950|Drug|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
79366328|NCT01814371|Drug|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
79366329|NCT01814371|Other|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
79366330|NCT01814371|Behavioral|Hygiene Protocol|"Follow key hygiene tips:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors, brushes, or deodorant.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
79518742|NCT03901950|Drug|XNW7201 tablets|A wnt pathway inhibitor
79518743|NCT03780816|Other|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
79518744|NCT03734952|Radiation|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
79518745|NCT03734952|Drug|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
79676057|NCT00506610|Drug|T-62|
79518746|NCT03734952|Procedure|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
79518747|NCT03734952|Radiation|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
79518748|NCT03712410|Behavioral|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
79676058|NCT01244672|Procedure|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
79676059|NCT01244672|Procedure|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
79676060|NCT05142852|Device|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
79223700|NCT05201040|Device|JETKNEE Synovial Fluid Supplement|2mL of JETKNEE Synovial Fluid Supplement
79366331|NCT05124652|Device|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
79518749|NCT03139344|Other|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
79366332|NCT03232138|Dietary Supplement|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
79223701|NCT05201040|Device|Normal saline|2mL of normal saline
79223702|NCT05198557|Drug|Inebilizumab|Participants will receive IV inebilizumab.
79366333|NCT03232138|Drug|Placebo|Inactive ingredients
79366334|NCT02131402|Device|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
79366335|NCT02131402|Device|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
79223703|NCT05198557|Drug|Placebo|Participants will receive IV placebo matched to inebilizumab.
79366336|NCT02131402|Device|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
79366337|NCT01814137|Drug|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
79366338|NCT01814137|Drug|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
79366339|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
79223704|NCT05177601|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
79366340|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
79366341|NCT04084288|Other|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
79676061|NCT05142852|Other|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
79223705|NCT05177601|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
79366342|NCT04084288|Device|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
79518750|NCT03139344|Other|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
79518751|NCT02960646|Drug|Cyclophosphamide|Given IV
79518752|NCT02960646|Biological|Filgrastim|Given SC
79518753|NCT02960646|Drug|Fludarabine Phosphate|Given IV
79518754|NCT02960646|Other|Laboratory Biomarker Analysis|Correlative studies
79518755|NCT02960646|Drug|Melphalan|Given IV
79518756|NCT02960646|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
79518757|NCT02960646|Biological|Rituximab|Given IV
79518758|NCT02960646|Drug|Tacrolimus|Given IV or PO
79518759|NCT02960646|Radiation|Total-Body Irradiation|Undergo TBI
79518760|NCT02909556|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
79518761|NCT02894658|Device|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
79676062|NCT00498056|Biological|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
79518762|NCT02894658|Procedure|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
79223706|NCT05177601|Drug|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
79223707|NCT05177601|Drug|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
79223708|NCT05172479|Diagnostic Test|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
79223709|NCT05172479|Diagnostic Test|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
79518763|NCT02758626|Drug|ataluren|Powder formulation
79518764|NCT02758626|Drug|Placebo|Powder formulation
79223710|NCT05172479|Diagnostic Test|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
79223711|NCT05172479|Diagnostic Test|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
79223712|NCT05172479|Diagnostic Test|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
79518765|NCT02587572|Biological|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
79518766|NCT02357784|Device|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
79676063|NCT00498056|Biological|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
79676064|NCT00498056|Biological|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
79821887|NCT00742911|Drug|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
79995992|NCT03676920|Behavioral|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
79223713|NCT05164991|Behavioral|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
79223714|NCT05163028|Drug|HBI-2376|SHP2 Inhibitor
79223715|NCT05152914|Drug|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
79223716|NCT05150639|Other|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
79223717|NCT05149781|Procedure|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
79223718|NCT05136807|Other|Quality-of-Life Assessment|Complete questionnaires
79223719|NCT05136807|Other|Questionnaire Administration|Complete questionnaires
79223720|NCT05134545|Device|Genoss® DCB|Peripheral Drug Coated Balloon
79223721|NCT05134545|Device|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
79223722|NCT05114018|Dietary Supplement|Pasteurized A. muciniphila|Daily oral dose
79518767|NCT02022384|Other|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
79676065|NCT00498056|Biological|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
79676066|NCT00498095|Procedure|Renal biopsy|
79676067|NCT05141331|Device|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
79676068|NCT00498134|Drug|Triple therapy for H. pylori infection|
79676069|NCT00498134|Drug|Cox-2 inhibitor|
79518768|NCT01448616|Drug|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
79518769|NCT01448616|Drug|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
79518770|NCT01448616|Drug|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
79518771|NCT01448616|Drug|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
79518772|NCT01320696|Biological|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
79518773|NCT00853632|Device|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
79518774|NCT00074412|Drug|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
79518775|NCT00074412|Drug|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
79518776|NCT02618772|Drug|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
79518777|NCT02618772|Drug|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
79676070|NCT05146557|Other|Dental examination|In this cross sectional observational study only Dental examination and a self response survey was applied.
79223723|NCT05114018|Dietary Supplement|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
79223724|NCT05108519|Other|Electronic Health Record Review|Medical records are reviewed
79223725|NCT05072795|Behavioral|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
79518778|NCT02619396|Procedure|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
79518779|NCT02619396|Procedure|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
79518780|NCT02619396|Procedure|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
79518781|NCT02619396|Procedure|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
79518782|NCT02620878|Device|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
79223726|NCT05067621|Drug|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
79223727|NCT05067621|Drug|Placebo|Injection pen contains excipients.
79366343|NCT01813435|Drug|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
79366344|NCT01813435|Drug|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
79518783|NCT02620878|Other|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
79518784|NCT02621892|Drug|Tenapanor|
79518785|NCT02621892|Drug|Placebo|
79676071|NCT00502580|Behavioral|Interview|Interview taking about 10 minutes to complete.
79679901|NCT04577274|Dietary Supplement|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
79366345|NCT01813435|Drug|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
79223728|NCT05053750|Drug|Paclitaxel/Bev (control)|Given by PO
79223729|NCT05053750|Drug|Paclitaxel/Bev + ZA (experimental)|Given by PO
79223730|NCT05051774|Behavioral|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
79518786|NCT02624700|Drug|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
79518787|NCT02624700|Drug|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
79366346|NCT05037526|Device|Dexcom G System|Continuous glucose monitoring system
79679902|NCT02937675|Drug|Tomivosertib (eFT-508)|eFT508
79679903|NCT00523172|Procedure|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
79679904|NCT00523172|Procedure|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
79679905|NCT00523172|Procedure|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
79223731|NCT05051774|Behavioral|2. Exercise|"The exercise intervention comprised of two elements as follows:~Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
79679906|NCT02937519|Device|Chrono-chemotherapy pump:Melodie|
79995993|NCT03026088|Drug|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
79223732|NCT05051774|Behavioral|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
79223733|NCT05051579|Drug|LY3502970|Administered orally
79223734|NCT05051579|Drug|Placebo|Administered orally
79223735|NCT05045404|Drug|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
79223736|NCT05045404|Biological|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
79223737|NCT05044676|Other|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
79223738|NCT05044546|Behavioral|Behavioral Activation Therapy|Participate in BA counseling
79223739|NCT05044546|Procedure|Discussion|Participate in focus group
79223740|NCT05044546|Behavioral|Health Education|Participate in health and wellness education counseling
79223741|NCT05044546|Other|Questionnaire Administration|Ancillary studies
79223742|NCT05044546|Other|Tobacco Cessation Counseling|Participate in smoking cessation counseling
79223743|NCT05041998|Device|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~Soft socket (Socket made from softer material than unmodified original)~Stiff socket (Socket made from stiffer material than unmodified original)~moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~Oversized socket (The socket volume is 6% larger than the unmodified original)~Undersized socket (The socket volume is 6% smaller than the unmodified original)~CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
79518788|NCT02624700|Drug|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
79223744|NCT05031494|Drug|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
79223745|NCT05031494|Drug|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
79223746|NCT05031494|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
79223747|NCT05031494|Drug|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
79223748|NCT05024955|Procedure|Discussion|Attend a focus group
79223749|NCT05024955|Other|Interview|Attend interview
79223750|NCT05023889|Drug|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
79223751|NCT05022368|Device|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
79223752|NCT05019703|Biological|Atezolizumab|Given IV
79223753|NCT05019703|Drug|Cabozantinib|Given PO
79518789|NCT02624700|Drug|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
79518790|NCT02625402|Behavioral|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
79518791|NCT02625402|Behavioral|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
79518792|NCT02627118|Device|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
79518793|NCT02627118|Device|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
79518794|NCT02631954|Drug|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
79518795|NCT02631954|Drug|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
79518796|NCT02632812|Drug|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
79223754|NCT05019651|Device|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
79223755|NCT05014074|Other|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
79223756|NCT05010681|Drug|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79223757|NCT05010681|Drug|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79676072|NCT05146518|Behavioral|Supportive and Dignified Maternity Care|"The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor."
79223758|NCT05010668|Drug|cryoablation|Cryoablation treatment starts at day 0.
79821888|NCT00742989|Other|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
79223759|NCT05010668|Drug|Sintilimab|Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79518797|NCT02632812|Drug|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
79518798|NCT02632812|Drug|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
79518799|NCT02633358|Device|Therapeutic hypothermia group|Therapeutic hypothermia
79676073|NCT00498251|Drug|inhalation of salbutamol (5 mg)|
79676074|NCT00498251|Drug|ipratropium|
79676075|NCT05146401|Other|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
79676076|NCT00502619|Procedure|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
79676077|NCT00502619|Other|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
79676078|NCT00498290|Procedure|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
79366347|NCT05037526|Device|Self monitoring blood glucose|Standard Care
79366348|NCT04008160|Device|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
79676079|NCT00498290|Procedure|control|normal recovery protocol as usually
79821889|NCT00742989|Other|Sham OLT|Therapeutic massage performed
79821890|NCT02678871|Device|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
79821891|NCT02678871|Device|WATCHMAN|LAA closure with the WATCHMAN device
79821892|NCT02565069|Device|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
79821893|NCT00694707|Drug|Placebo|Placebo was supplied in capsules.
79821894|NCT00694707|Drug|Cariprazine|Cariprazine was supplied in capsules
79821895|NCT00694707|Drug|Risperidone|Risperidone was supplied in capsules
79821896|NCT00692913|Drug|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
79366349|NCT01798498|Device|Princess® VOLUME|
79366350|NCT02554708|Device|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
79366351|NCT01813357|Drug|Rosuvastatin|encapsulated tablet 20mg daily
79518800|NCT02634684|Drug|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
79518801|NCT02634684|Drug|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
79518802|NCT02635542|Drug|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
79223760|NCT05010668|Drug|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79223761|NCT05008874|Other|Natural History Observation|Data collection on progression of disease
79223762|NCT04996940|Device|E-cigarette product|"Participants will be randomized 1:1 to e-cigarette flavor order either:~tobacco e-cigarette~menthol e-cigarette"
79223763|NCT04979377|Other|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
79366352|NCT01813357|Other|Placebo|Placebo arm included to maintain blinding
79366353|NCT01812655|Device|Virtual Reality|
79366354|NCT01812655|Other|Passive Distraction|
79366355|NCT02346526|Procedure|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
79518803|NCT02635542|Drug|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
79518804|NCT02636712|Device|ImageReady™ MR Conditional Pacing System|
79676080|NCT00502658|Behavioral|Dietary supplement containing vitamins, minerals, and herbs|
79676081|NCT00502658|Behavioral|Shakes with nutrients and herbs|
79223764|NCT04979377|Diagnostic Test|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
79223765|NCT04979377|Diagnostic Test|A1c (%)|High Performance Liquid Chromatography (HPLC)
79223766|NCT04979377|Diagnostic Test|Total cholesterol|Determined by enzymatic methods
79223767|NCT04979377|Other|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
79223768|NCT04979377|Diagnostic Test|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
79223769|NCT04979377|Diagnostic Test|Polycystic ovary morphology|Sonographic assessment
79223770|NCT04979377|Diagnostic Test|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
79223771|NCT04979377|Diagnostic Test|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
79223772|NCT04979377|Diagnostic Test|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
79223773|NCT04979377|Other|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
79366356|NCT02346526|Procedure|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
79366357|NCT02346526|Procedure|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
79366358|NCT02346526|Drug|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
79366359|NCT02346526|Procedure|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
79518805|NCT02637804|Device|stenfilcon A|contact lens
79518806|NCT02637804|Device|narafilcon A|contact lens
79518807|NCT02637804|Device|delefilcon A|contact lens
79518808|NCT02638974|Other|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
79518809|NCT02639286|Drug|ISIS 304801|300 mg of ISIS 304801 administered as SC
79518810|NCT02639286|Drug|Placebo|Placebo administered via SC
79518811|NCT02642952|Other|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
79518812|NCT05588544|Procedure|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
79518813|NCT05588076|Other|no intervention|no intervention
79518814|NCT05587218|Behavioral|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
79676082|NCT00502658|Behavioral|Control dietary supplement|
79676083|NCT00502658|Behavioral|Isocaloric, isonitrogenous control shakes without herbs|
79676084|NCT00502658|Behavioral|Personal energy tracking tool|
79676085|NCT00502736|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
79676086|NCT02954679|Other|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
79676087|NCT01246505|Device|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
79676088|NCT05146089|Other|Hypoxic exposure|30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
79679907|NCT02937519|Device|Routine intravenous drip|
79679908|NCT02937519|Drug|induction Chrono-chemotherapy|
79518815|NCT05585658|Biological|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
79518816|NCT05522634|Drug|TJAOA101|Once enrolled, participants will be administrated TJAOA101
79223774|NCT04979377|Other|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
79518817|NCT05510856|Other|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
79518818|NCT05510856|Other|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
79518819|NCT05510856|Other|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
79518820|NCT05462028|Device|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
79518821|NCT05462028|Behavioral|ergometer exercise|ergometer exercise training
79223775|NCT04979377|Other|Body composition|Vital Scan HW7-HW6T
79223776|NCT04979377|Diagnostic Test|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
79223777|NCT04979377|Diagnostic Test|Time in target range (hours)|Continuous glucose monitoring (GCM) records
79366360|NCT01812109|Device|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes ~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
79518822|NCT05393466|Drug|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
79518823|NCT05281770|Drug|Erenumab|treatment with erenumab as chosen by treating physician
79518824|NCT05281770|Drug|Fremanezumab|treatment with fremanezumab as chosen by treating physician
79821897|NCT00692913|Dietary Supplement|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
79223778|NCT04979377|Diagnostic Test|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
79518825|NCT05281770|Drug|Galcanezumab|treatment with galcanezumab as chosen by treating physician
79518826|NCT05225610|Other|Valsalva Manoeuvre|Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
79518827|NCT05225610|Drug|Dexmedetomidine Injection [Precedex]|The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
79518828|NCT05225610|Drug|normal Saline|5 ml saline will be administered.
79995994|NCT03676842|Combination Product|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
79223779|NCT04979377|Other|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
79223780|NCT04979377|Other|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
79223781|NCT04979377|Diagnostic Test|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
79223782|NCT04979377|Diagnostic Test|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
79223783|NCT04979377|Diagnostic Test|Triglycerides (mg/dL)|Determined by enzymatic methods
79518829|NCT05185830|Other|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
79679909|NCT02937519|Drug|induction Routine-chemotherapy|
79679910|NCT02937519|Drug|cisplatin chrono-chemotherapy|
79679911|NCT02937519|Drug|cisplatin routine-chemotherapy|
79679912|NCT02937519|Radiation|intensity-modulated radiation therapy|
79223784|NCT04965181|Behavioral|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
79223785|NCT04965181|Drug|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
79366361|NCT01811953|Drug|Empagliflozin|medium dose oral administration
79366362|NCT01811953|Drug|Metformin|oral administration
79518830|NCT05079906|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
79821898|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
79821899|NCT00743067|Drug|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
79223786|NCT04965181|Behavioral|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
79223787|NCT04965181|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
79223788|NCT04964167|Combination Product|Plant extract|Natural plant extract
79366363|NCT01811953|Drug|Empagliflozin|low dose of Empagliflozin oral administration
79518831|NCT05079906|Device|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
79518832|NCT04922190|Behavioral|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
79518833|NCT04444050|Drug|BMS-986331|Specified dose on specified days
79518834|NCT04444050|Other|Placebo, Matching BMS-986331|Specified dose on specified days
79676089|NCT05146089|Other|modified Oxford test|An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
79676090|NCT05146089|Drug|Oral Bosentan 62.5 mg|Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
79676091|NCT05146089|Other|Hypoxic ventilatory response test|Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
79821900|NCT00743223|Other|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
79821901|NCT00743301|Other|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
79223789|NCT04964128|Device|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
79223790|NCT04954794|Drug|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79223791|NCT04954794|Combination Product|TACE|TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
79366364|NCT01811953|Drug|Empagliflozin/Metformin|low dose of Empagliflozin
79518835|NCT04225416|Other|Questionnaire/Structured Interview|No intervention
79518836|NCT03693846|Drug|Nivolumab|IV infusion per institutional guidelines and the Package Insert
79676092|NCT02955030|Biological|NSV0001|sublingual
79676093|NCT02955030|Biological|"Influenza HA vaccine Biken HA"|subcutaneous
79676094|NCT02955030|Biological|Placebo|sublingual
79366365|NCT01811953|Drug|Metformin|oral administration
79366366|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
79366367|NCT01811953|Drug|Empagliflozin|medium dose oral administration
79821902|NCT00694551|Biological|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
79821903|NCT00694551|Drug|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
79821904|NCT00743379|Drug|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
79821905|NCT00689871|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
79821906|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
79366368|NCT01811953|Drug|Metformin|oral administration
79366369|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
79676095|NCT00498407|Drug|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
79676096|NCT02954913|Procedure|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
79676097|NCT00498524|Device|ICD|Received an ICD
79223792|NCT04943341|Procedure|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
79676098|NCT00498524|Device|ICD|Have not received an ICD
79223793|NCT04931056|Device|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
79676099|NCT02954757|Procedure|HIFU treatment|High intensity focused ultrasound
79676100|NCT00502814|Procedure|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
79821907|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
79821908|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
79821909|NCT00793793|Drug|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
79223794|NCT04931056|Device|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
79223795|NCT04931056|Device|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
79366370|NCT03926728|Biological|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
79366371|NCT03926728|Biological|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
79366372|NCT03926728|Biological|CTH522 ID|24 microgram CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 ml syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
79518837|NCT03693846|Drug|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
79518838|NCT03529890|Drug|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
79518839|NCT03529890|Radiation|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
79518840|NCT03529890|Procedure|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
79518841|NCT02751060|Other|No intervention|
79676101|NCT00502814|Procedure|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
79676102|NCT00502814|Procedure|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
79676103|NCT00502814|Procedure|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
79821910|NCT00793793|Drug|Placebo|
79676104|NCT02954640|Biological|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
79821911|NCT00743457|Device|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
79676105|NCT00498563|Procedure|altitude exposure in hypobaric chamber|
79679913|NCT03457974|Other|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
79821912|NCT02483637|Device|RejuvenAir|Device: RejuvenAir
79821913|NCT02602613|Device|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
79518842|NCT02703480|Biological|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
79676106|NCT02954796|Drug|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
79676107|NCT00502892|Drug|Topotecan|0.5 mg/m^2 IV Daily x 3 Days
79676108|NCT00502892|Drug|Ifosfamide|1.8 grams/m^2 IV Over 1 Hour x 5 Days
79518843|NCT02703480|Biological|Ti-mesh|Titanium mesh
79995995|NCT03678948|Device|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
79366373|NCT03926728|Biological|CTH522 TO|24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
79366374|NCT03926728|Biological|Placebo (Saline)|Placebo only given as IM, ID and TO
79676109|NCT00502892|Drug|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days [for patients > 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days]
79366375|NCT03895762|Drug|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
79676110|NCT02954835|Device|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
79676111|NCT02954835|Device|Traditional Dressing|Sterile gauze dressing secured by tape.
79676112|NCT00502970|Drug|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
79676113|NCT00502970|Drug|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
79676114|NCT00506649|Other|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
79995996|NCT03678948|Device|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
79223796|NCT04931056|Device|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
79223797|NCT04901156|Device|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
79366376|NCT01811563|Device|Zimmer|
79366377|NCT01811563|Device|Stryker|
79676115|NCT00498641|Procedure|computer program and patching|
79676116|NCT05140980|Other|Data collection|evaluation of women's knowledge concerning sexuality
79676117|NCT00498680|Drug|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
79995997|NCT03678792|Drug|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
79995998|NCT03678792|Drug|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
79995999|NCT03678792|Drug|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
79366378|NCT01033552|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
79366379|NCT01033552|Drug|Fludarabine|40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2.
79366380|NCT01033552|Drug|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
79518844|NCT01690728|Behavioral|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
79518845|NCT00938106|Radiation|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
79676118|NCT00498680|Drug|Sildenafil|100mg
79676119|NCT00498680|Drug|Vardenafil|20mg
79676120|NCT00498680|Drug|Sildenafil & Vardenafil|50mg & 10 mg
79676121|NCT05146011|Procedure|Gatsric balloon insertion|Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
79366381|NCT01033552|Drug|Cyclosporine A|Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
79676122|NCT00498719|Behavioral|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
79676123|NCT00498719|Other|Control Group|Standard educational support.
79676124|NCT00498758|Device|APOS System - biomechanical wedge shoe|
79676125|NCT00507390|Dietary Supplement|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
79676126|NCT00507390|Dietary Supplement|olive oil|1 capsule day
79676127|NCT00503087|Procedure|Saline Injection|
79676128|NCT00503087|Device|Pneumatic Skin Flattening (PSF)|
79676129|NCT00498953|Drug|carboplatin|
79996000|NCT03683238|Dietary Supplement|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
79223798|NCT04901156|Behavioral|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
79223799|NCT04901156|Device|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
79223800|NCT04890067|Other|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
79223801|NCT04887987|Radiation|strengthening training and LED PBMT|Participants will be submitted to a supervised 8-wk training program (3 d/week) involving a specific lumbar extension exercise on the Roman bench and four complementary exercises to improve core strength and spine stabilization. Participants will receive LED PBMT 30 minutes before each training session, through a device containing 264 LEDs, which will be placed on the lumbar region (between L1 and L5).
79223802|NCT04887987|Radiation|strengthening training and placebo PBMT|Participants will be submitted to a supervised 8-wk training program (3 d/week) involving a specific lumbar extension exercise on the Roman bench and four complementary exercises to improve core strength and spine stabilization. Participants will receive placebo PBMT 30 minutes before each training session, through a off-line device (turned off) containing 264 LEDs, which will be placed on the lumbar region (between L1 and L5).
79223803|NCT04881760|Drug|LY3437943|Administered SC
79223804|NCT04881760|Drug|Placebo|Administered SC
79366382|NCT01033552|Drug|Mycophenolate mofetil|15 mg/kg intravenous twice per day on days -3 through 30.
79366383|NCT01033552|Procedure|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
79366384|NCT01033552|Radiation|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
79366385|NCT01033552|Procedure|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
79366386|NCT00997906|Drug|carboplatin,|Given IV
79366387|NCT00997906|Drug|cisplatin|Given IV
79366388|NCT00997906|Drug|gemcitabine hydrochloride|Given IV
79366389|NCT00997906|Drug|paclitaxel|Given IV
79366390|NCT00997906|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
79366391|NCT01811485|Drug|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
79366392|NCT01811485|Drug|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
79366393|NCT01811485|Drug|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
79366395|NCT03832036|Diagnostic Test|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
79366396|NCT01798888|Procedure|Implantation of Deep Brain Stimulation|
79366397|NCT01810939|Drug|Patiromer|
79366398|NCT01810939|Drug|Placebo|
79518846|NCT00793806|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
79518847|NCT00580944|Procedure|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
79518848|NCT00540540|Device|Diffuse Optical Spectroscopy|Breast properties scanning
79518849|NCT00540306|Device|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
79518850|NCT02644278|Drug|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
79518851|NCT02644278|Drug|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
79676130|NCT00498953|Drug|cisplatin|
79676131|NCT00498953|Drug|docetaxel|
79676132|NCT00498953|Drug|fluorouracil|
79676133|NCT00498953|Drug|lapatinib ditosylate|
79676134|NCT00498953|Genetic|cytogenetic analysis|
79676135|NCT00498953|Genetic|fluorescence in situ hybridization|
79676136|NCT00498953|Genetic|in situ hybridization|
79676137|NCT00498953|Genetic|polymerase chain reaction|
79676138|NCT00498953|Genetic|reverse transcriptase-polymerase chain reaction|
79366399|NCT01798576|Drug|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
79366400|NCT01798576|Drug|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
79366401|NCT00565084|Drug|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
79518852|NCT02644278|Drug|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
79518853|NCT02644278|Drug|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
79518854|NCT02645760|Other|Core stabilization exercise|7-weeks of core stabilization exercise
79518855|NCT02645760|Other|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
79996001|NCT03678714|Behavioral|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
79223805|NCT04879797|Other|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
79223806|NCT04879797|Other|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
79366402|NCT00565084|Drug|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
79223807|NCT04857645|Drug|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
79223808|NCT04857645|Other|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
79366403|NCT01810783|Drug|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
79366404|NCT00565864|Drug|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
79366405|NCT01808209|Device|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
79518856|NCT02648022|Behavioral|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
79518857|NCT02648178|Device|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
79518858|NCT02648646|Other|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
79223809|NCT04845893|Other|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
79676139|NCT00498953|Other|immunohistochemistry staining method|
79676140|NCT00498953|Other|laboratory biomarker analysis|
79676141|NCT00498953|Procedure|conventional surgery|
79676142|NCT00498953|Procedure|neoadjuvant therapy|
79676143|NCT00498953|Radiation|fludeoxyglucose F 18|
79676144|NCT00498953|Radiation|radiation therapy|
79996002|NCT03678714|Behavioral|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
79996003|NCT03676686|Device|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
79223810|NCT04844099|Drug|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
79223811|NCT04837014|Other|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
79223812|NCT04837014|Other|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
79223813|NCT04834349|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
79223814|NCT04834349|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
79366406|NCT01808209|Device|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
79366407|NCT05246332|Device|Grounding|The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
79676145|NCT00506688|Drug|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
79676146|NCT00506688|Drug|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
79676147|NCT00503126|Drug|bivalirudin|anticoagulation
79676148|NCT05145894|Device|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
79366408|NCT05246176|Device|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
79366409|NCT03698032|Dietary Supplement|Water|Participants will consume water only
79366410|NCT03698032|Dietary Supplement|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
79676149|NCT00503165|Biological|Menitorix (MenC and Hib conjugate)|
79676150|NCT05145543|Drug|Saline 0.9%|0.9 NaCl % (Saline) (5 ml) will be applied
79676151|NCT05145543|Drug|Levobupivacaine Hydrochloride|0.25 % levobupivacaine (5 ml) will be applied.
79676152|NCT05145543|Drug|Fentanyl|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
79996004|NCT03305094|Procedure|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
79996005|NCT03676608|Biological|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
79223815|NCT04834349|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79223816|NCT04834349|Biological|Pembrolizumab|Given IV
79223817|NCT04834349|Other|Quality-of-Life Assessment|Ancillary studies
79223818|NCT04834349|Other|Questionnaire Administration|Ancillary studies
79223819|NCT04834349|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79223820|NCT04815668|Other|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
79223821|NCT04815668|Other|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
79366411|NCT03698032|Dietary Supplement|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
79366412|NCT05246020|Procedure|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
79518859|NCT02648880|Behavioral|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
79518860|NCT02648880|Other|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
79518861|NCT02649192|Biological|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
79676153|NCT05145543|Drug|Dexamethasone|Dexamethasone plus levobupivacaine (5 ml) will be applied.
79676154|NCT00503204|Drug|Cediranib|oral tablet
79676155|NCT00503204|Drug|Lomustine|oral capsule
79676156|NCT05145504|Diagnostic Test|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
79676157|NCT00503243|Drug|Delayed and extended release mesalazine|
79676158|NCT05145465|Other|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
79676159|NCT00498992|Dietary Supplement|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
79679914|NCT00521963|Biological|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
79679915|NCT02937402|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
79679916|NCT02937402|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
79679917|NCT02937363|Dietary Supplement|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
79676160|NCT04696107|Behavioral|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~Neurology and psychoneuroimmunology.~The role of beliefs in our manifestation of the disease.~Body language and modulation of pain perception.~Relaxation body-mind techniques.~Creative visualization for pain management.~Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
79223822|NCT04815668|Other|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
79223823|NCT04813042|Behavioral|Working Out Dads|"The WOD is a manualised group intervention underpinned by solution-focused therapy and social cognitive theories. Psychoeducation about the transition to fatherhood and its potential impacts on wellbeing and family relationships is provided. Fathers are encouraged to share practical ideas for managing stress, revisit previous strategies, validate what they are doing well, and explore solutions.~The group discussion is followed by a structured group fitness session provided by a personal trainer. This session focuses on body weight exercises, cardio-based activities, stretching, mobility and incidental activity.~Fathers in the WOD study arm receive 10 weeks of encouraging text messages - one each week during the intervention, and four in the weeks after. These will be sent via the WhatsApp group created for each WOD group. These text messages and the WhatsApp group are designed to facilitate fathers' active engagement with the intervention, and to maintain contact with each other."
79223824|NCT04813042|Behavioral|Usual care|The Usual Care arm, also known as 'Talking about being dad' comprises a telephone consultation with a qualified mental health professional. Topics including in this consultation include: (a) discuss family and fathering; (b) health and wellbeing; (c) mental health symptoms and conduct a risk assessment for suicidal ideation; (d) current supports and support needs; (e) provide referral options to telephone support services (PANDA; MensLine); and (f) encourage a general practitioner visit to discuss a mental health care plan.
79676161|NCT02276391|Drug|Telmisartan/HCTZ combination|
79676162|NCT02276391|Drug|Telmisartan|
79223825|NCT04794634|Diagnostic Test|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
79223826|NCT04794634|Diagnostic Test|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
79223827|NCT04779918|Device|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
79223828|NCT04776213|Drug|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants will be followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants are not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
79366413|NCT05246020|Procedure|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
79366414|NCT01807117|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
79676163|NCT05145270|Dietary Supplement|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
79679918|NCT02937363|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
79996006|NCT03676608|Other|Usual educational care|The WHO protocol for maternal lactation.
79996007|NCT03678558|Other|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
79996008|NCT03672786|Dietary Supplement|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
79366415|NCT01807117|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
79366416|NCT01807117|Procedure|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
79366417|NCT01807117|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
79366418|NCT02804854|Drug|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
79996009|NCT03678480|Drug|HTD1801|HTD1801 capsules, 250mg
79518862|NCT02649192|Dietary Supplement|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
79518863|NCT02649192|Other|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
79518864|NCT02650440|Procedure|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
79996010|NCT03678480|Drug|Ursodeoxycholic Acid|UDCA capsules, 125mg
79518865|NCT02650440|Procedure|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
79676164|NCT05145270|Device|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
79996011|NCT03676530|Device|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
79223829|NCT04774393|Drug|Decitabine and Cedazuridine|Given PO
79223830|NCT04774393|Drug|Enasidenib|Given PO
79821914|NCT02602379|Other|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
79996012|NCT03117985|Other|no drug|Stopping antiretroviral therapy
79996013|NCT03678246|Procedure|Ramped position|LSFOI glottis view
79996014|NCT03678246|Procedure|Supine position|LSFOI glottis view
79996015|NCT03672708|Diagnostic Test|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
79366419|NCT05245630|Procedure|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
79366420|NCT05245630|Procedure|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
79366421|NCT05363410|Dietary Supplement|MagnéVie B6®|micronutrient supplement
79366422|NCT05363410|Other|Placebo|placebo supplement
79366423|NCT01613131|Drug|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
79366424|NCT01613131|Drug|Estradiol|Topical, .06%, Applied once daily for 50 days.
79996016|NCT03672552|Other|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
79996017|NCT03678168|Other|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
79996018|NCT03678168|Other|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
79996019|NCT03678090|Drug|tPA standard dosage|Tissue plasminogen activator 25mg dosage
79223831|NCT04774393|Drug|Ivosidenib|Given PO
79223832|NCT04774393|Drug|Venetoclax|Given PO
79223833|NCT04762069|Drug|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
79223834|NCT04762069|Drug|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
79223835|NCT04749797|Drug|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
79223836|NCT04749797|Drug|Bupivacaine Injection|Used as cranial block for craniotomy surgery
79223837|NCT04749797|Drug|Saline|Used as cranial block for craniotomy surgery
79366425|NCT01613131|Drug|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
79518866|NCT02652390|Drug|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
79518867|NCT02652390|Drug|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
79518868|NCT02652390|Other|Saline|2 mL saline + 1 mL lidocaine
79676165|NCT05145270|Drug|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
79223838|NCT04748861|Other|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
79676166|NCT02276625|Biological|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
79676167|NCT02276664|Behavioral|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
79676168|NCT02276664|Behavioral|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
79223839|NCT04747275|Drug|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
79676169|NCT01245296|Procedure|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
79676170|NCT04695990|Drug|Wenyang Huoxue Decoction|Wenyang Huoxue granules
79821915|NCT03999593|Procedure|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
79821916|NCT02603705|Drug|Oxycodone extended-release|
79821917|NCT00776789|Other|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
79821918|NCT00776789|Other|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
79518869|NCT02652780|Biological|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
79518870|NCT02652780|Device|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
79821919|NCT00776555|Drug|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
79821920|NCT00776555|Drug|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
79996020|NCT03678090|Drug|tPA low dosage|Tissue plasminogen activator 2.5mg
79223840|NCT04747275|Drug|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
79223841|NCT04728724|Drug|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
79223842|NCT04728724|Drug|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
79223843|NCT04699981|Other|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
79228092|NCT03505749|Behavioral|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
79366426|NCT01798342|Dietary Supplement|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
79996021|NCT03678012|Drug|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
79996022|NCT03678012|Drug|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
79996023|NCT03678012|Drug|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
79366427|NCT01798342|Dietary Supplement|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
79366428|NCT04410835|Diagnostic Test|Online Survey|Psychological questionnaires
79366429|NCT05363098|Other|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
79366430|NCT05362942|Drug|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
79366431|NCT01868893|Drug|Obinutuzumab|
79366432|NCT01868893|Drug|Chlorambucil|
79518871|NCT02653560|Drug|Potassium chloride powder|
79821921|NCT05538533|Radiation|46 Gy Radiation Therapy|Dose per fraction of 4.6.
79821922|NCT05538533|Radiation|40 Gy Radiation Therapy|Dose per fraction 5.7.
79821923|NCT05538533|Radiation|35 Gy Radiation Therapy|Dose per fraction 7.0.
79821924|NCT00915785|Drug|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
79821925|NCT04104581|Other|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
79518872|NCT02653560|Drug|Potassium magnesium Citrate (KMgCit)|
79518873|NCT02653560|Drug|Potassium citrate powder|
79676171|NCT04695990|Drug|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
79676172|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
79676173|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
79223844|NCT04699981|Other|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
79366433|NCT03459898|Device|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
79518874|NCT02653560|Drug|Placebo|
79518875|NCT02653872|Drug|AZD7986|Oral solution, single dose, dilution from concentrate
79518876|NCT02653872|Drug|Verapamil|Extended release tablet for oral use
79676174|NCT02276703|Device|Skin Conductance Monitor|monitors skin conductance values
79676175|NCT00499070|Genetic|polymerase chain reaction|
79676176|NCT00499070|Other|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
79676177|NCT00499070|Other|immunologic technique|
79676178|NCT00499070|Procedure|biopsy|
79676179|NCT00503360|Drug|SAD448|
79676181|NCT00503477|Drug|AZD2171|oral tablet
79366434|NCT01868503|Drug|lapatinib ditosylate|Given PO
79366435|NCT01868503|Radiation|radiation therapy|Undergo radiation therapy
79366436|NCT01868503|Other|laboratory biomarker analysis|Correlative studies
79366437|NCT05362708|Device|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
79518877|NCT02653872|Drug|Itraconazole|Oral solution
79518878|NCT02653872|Drug|Diltiazem|Extended release capsule
79518879|NCT02654652|Dietary Supplement|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
79518880|NCT02654652|Dietary Supplement|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
79518881|NCT02654808|Device|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
79518882|NCT02654808|Device|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
79518883|NCT02655354|Behavioral|Motivational Interviewing|
79518884|NCT02655354|Behavioral|Cognitive Behavioral Therapy Elements|
79676182|NCT00499148|Other|herbal extract; root of woody shrub grown in India/Sri-Lanka|
79676183|NCT05144295|Drug|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
79676184|NCT05144295|Drug|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
79676185|NCT05144295|Drug|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years
79676186|NCT05144295|Drug|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
79676187|NCT01245452|Drug|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
79676188|NCT01245452|Drug|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
79676189|NCT00503516|Drug|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
79676190|NCT00503516|Drug|Placebo|1 sachet of 160 mg of placebo b.i.d.
79676191|NCT05148195|Drug|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
79676192|NCT05148195|Drug|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
79676193|NCT05148195|Drug|Docetaxel|75mg/m2，Q3W
79676194|NCT05148195|Drug|Irinotecan|180 mg/m2，Q2W
79676195|NCT05148195|Drug|Leucovorin calcium|400mg/m2，Q2W
79518885|NCT02655354|Behavioral|Care Management|
79518886|NCT02655354|Drug|Fluoxetine|Anti-depressant
79518887|NCT02655354|Drug|Fluvoxamine|Anti-depressant
79518888|NCT02655354|Drug|Paroxetine|Anti-depressant
79676196|NCT05148195|Drug|5-Fluorouridine|2400 mg/m2，Q2W
79676197|NCT04696991|Behavioral|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
79223845|NCT04696289|Diagnostic Test|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
79821926|NCT04104581|Other|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
79821927|NCT04104581|Other|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
79821928|NCT04104581|Other|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
79223846|NCT04695600|Drug|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
79518889|NCT02655354|Drug|Sertraline|Anti-depressant
79518890|NCT02655354|Drug|Citalopram|Anti-depressant
79518891|NCT02655354|Drug|Venlafaxine|Anti-depressant
79821929|NCT04104581|Other|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
79821930|NCT04104737|Device|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
79821931|NCT00720434|Drug|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
79821932|NCT00720434|Drug|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
79821933|NCT00720434|Drug|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
79821934|NCT00720434|Drug|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
79821935|NCT00776009|Drug|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
79366438|NCT04602169|Procedure|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise >38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
79518892|NCT02655354|Drug|Duloxetine|Anti-depressant
79518893|NCT02655354|Drug|Mirtazapine|Anti-depressant
79518894|NCT02655354|Drug|Diphenhydramine|Sleep medication
79518895|NCT02655354|Drug|Trazodone|Sleep medication
79518896|NCT02655354|Drug|Prazosin|Sleep medication
79518897|NCT02655510|Drug|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
79518898|NCT02656836|Other|Home tonometry, diagnostic study|Evaluating intraocular pressure
79518899|NCT02657538|Other|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
79518900|NCT02657538|Other|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
79518901|NCT02657538|Device|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
79518902|NCT02657538|Other|Visual examination and bitewing (BW) radiography|established diagnostic methods
79518903|NCT02657928|Other|Laboratory Biomarker Analysis|Correlative studies
79676198|NCT05146869|Drug|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
79821936|NCT00776009|Drug|Placebo|Placebo Comparator
79821937|NCT00694161|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
79821938|NCT00720356|Drug|bevacizumab|10mg/kg administered intravenously every 2 weeks
79821939|NCT00720356|Drug|erlotinib hydrochloride|150 mg/daily orally
79821940|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
79518904|NCT02657928|Drug|Letrozole|Given PO
79821941|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
79223847|NCT04685577|Drug|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
79518905|NCT02657928|Drug|Ribociclib|Given PO
79223848|NCT04685577|Other|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
79223849|NCT04671810|Biological|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
79518906|NCT02658240|Drug|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
79518907|NCT02658240|Drug|Epinephrine|0.5 mg epinephrine
79518908|NCT02660112|Drug|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
79676199|NCT01245491|Other|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
79223850|NCT04667039|Biological|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
79223851|NCT04667039|Biological|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
79223852|NCT04666584|Device|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
79223853|NCT04666584|Device|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
79223854|NCT04643899|Device|Muscle Electrostimulation|"Scheduled sessions of 20 minutes per day; 5 days a week~In physiotherapy or in their room for the most dependent patients~Installation and monitoring by a physiotherapist or by the trained clinical research nurse~Modalities:~Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~4 electrodes (2 per thigh): large model (5 * 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
79518909|NCT02661126|Drug|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
79518910|NCT02661828|Other|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
79518911|NCT02661828|Other|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
79518912|NCT02662608|Drug|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
79518913|NCT02665260|Drug|Cantharidin|cantharidin 0.7% topical liquid
79676200|NCT05143827|Other|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
79821942|NCT02564913|Other|clinical evaluation|
79821943|NCT00745953|Drug|Valsartan|Valsartan 320mg PO daily for 8 months
79821944|NCT00745953|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
79518914|NCT02665260|Drug|Placebo|Placebo topical liquid
79518915|NCT02665260|Device|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
79518916|NCT02665728|Drug|BLI400 Laxative|
79518917|NCT02666352|Drug|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
79518918|NCT02666352|Drug|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
79518919|NCT02666508|Other|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
79518920|NCT02666508|Other|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
79518921|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
79676201|NCT05143827|Other|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
79676202|NCT00499187|Procedure|Blood Draws|A single whole blood sample was collected for genomic analysis.
79676203|NCT05147259|Drug|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
79676204|NCT00499265|Drug|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
79676205|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
79676206|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
79821945|NCT00720278|Drug|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
79518922|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
79518923|NCT02671032|Device|Nucleus CI532 cochlear implant|
79518924|NCT02672514|Device|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
79518925|NCT02672514|Device|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
79821946|NCT00720278|Drug|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
79821947|NCT00720278|Drug|Placebo|0 mcg Placebo daily
79821948|NCT00743613|Behavioral|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
79821949|NCT00743613|Procedure|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
79821950|NCT00743691|Other|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
79821951|NCT00746031|Drug|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
79821952|NCT00746031|Drug|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
79223859|NCT04633187|Drug|EDP-938|"EDP-938 800mg~Dose adjustments will be made for subjects taking azole antifungals."
79223860|NCT04633187|Drug|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 21 days
79366439|NCT04602169|Procedure|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
79223861|NCT04628988|Drug|CC-90011|Capsule
79223862|NCT04628988|Drug|Abiraterone|Tablet
79518926|NCT02673138|Drug|canagliflozin|basal interruption with canagliflozin
79518927|NCT02673138|Other|basal interruption without canagliflozin|basal interruption
79518928|NCT02673372|Drug|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
79518929|NCT02673372|Drug|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
79676207|NCT05147064|Procedure|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
79676208|NCT05147064|Procedure|conventional open surgery|open interlaminar lumbar decompression
79676209|NCT01246622|Drug|cytarabine|Given IV
79223863|NCT04628988|Drug|Prednisone|Tablet
79223864|NCT04621435|Drug|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
79223865|NCT04621435|Procedure|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
79223866|NCT04621435|Drug|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
79223867|NCT04598009|Drug|Binimetinib|Taken orally (PO) twice a day (BID)
79223868|NCT04598009|Drug|Imatinib|Taken orally (PO) once a day (QD)
79366440|NCT05204368|Drug|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
79366441|NCT05204368|Drug|Meropenem|Meropenem 1g for injection
79524796|NCT05768308|Behavioral|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
79676210|NCT01246622|Drug|lenalidomide|Given PO
79676211|NCT01245530|Drug|Aricept|Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
79676212|NCT01245530|Drug|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
79676213|NCT00499382|Procedure|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
79821953|NCT00720122|Drug|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
79821954|NCT00746109|Procedure|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
79821955|NCT00746109|Procedure|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
79821956|NCT03961490|Other|No interventional study|No interventional study
79821957|NCT04087382|Device|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
79518930|NCT02673918|Other|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
79518931|NCT02677428|Behavioral|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
79518932|NCT02677428|Behavioral|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
79223869|NCT04596852|Device|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
79223870|NCT04595188|Other|Sulphur amino acids|"For the total sulphur amino acid requirement, there are 7 different methionine test levels (without dietary cysteine) ranging from 5 to 40 mg of methionine per kilogram body weight per day.~For the minimum methionine requirement, there are 7 different methionine test levels (with excess dietary cysteine)."
79223871|NCT04583072|Diagnostic Test|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
79518933|NCT02677740|Device|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
79518934|NCT02677740|Device|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
79518935|NCT02678442|Device|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
79676214|NCT00499382|Procedure|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
79676215|NCT05148312|Drug|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
79366442|NCT03394846|Behavioral|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
79366443|NCT05362240|Procedure|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
79366444|NCT05362240|Procedure|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
79366445|NCT02132572|Device|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
79821958|NCT04087382|Other|non intervention group|medical treatment (Asprin, statin, nootropic drug)
79821959|NCT03880929|Other|no intervention|no intervention
79223872|NCT04558593|Procedure|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
79223873|NCT04558593|Procedure|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
79518936|NCT02678442|Device|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
79518937|NCT02679690|Behavioral|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
79518938|NCT02679690|Behavioral|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
79518939|NCT02680158|Device|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
79821960|NCT02564835|Other|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
79518940|NCT02680158|Device|Sham|Sham device (control), intranasal application for approximately 3 minutes.
79518941|NCT02680158|Device|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
79223874|NCT04556552|Device|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
79223875|NCT04556552|Drug|Oxygen (15-O) Water|Injection of radiolabelled water. H2[15-O] is a radioactive material. Each patient will have eight H2[15-O] blood flow scans. For each O-15 water scan 20 mCi of H2[15O] will be injected as an intravenous bolus.
79366446|NCT01868035|Drug|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
79518942|NCT02681172|Drug|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
79518943|NCT02681172|Procedure|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
79518944|NCT02682030|Device|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
79518945|NCT02682030|Device|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
79518946|NCT02682420|Device|everlinQ endoAVF System|
79518947|NCT02682498|Drug|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
79821961|NCT02564835|Other|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
79821962|NCT04085666|Drug|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
79821963|NCT04085666|Other|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
79223876|NCT04556552|Device|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
79223877|NCT04553718|Other|experimental group|provide mHealth program, which has pregnant women using wearable device and app
79518948|NCT02682498|Drug|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
79518949|NCT02684136|Drug|suvorexant|suvorexant 20 mg taken before sleep
79518950|NCT02684136|Drug|placebo|placebo taken before sleep
79518951|NCT02687412|Procedure|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
79518952|NCT02687412|Procedure|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
79518953|NCT02687412|Procedure|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
79518954|NCT02687412|Procedure|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
79518955|NCT02687412|Procedure|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
79676216|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
79676217|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
79676218|NCT05142306|Biological|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) [COVID-HIG] is a purified liquid immunoglobulin G (IgG) preparation
79821964|NCT00746265|Behavioral|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
79821965|NCT00743769|Drug|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
79821966|NCT00743769|Other|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
79821967|NCT02563977|Device|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
79821968|NCT00743847|Drug|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
79223878|NCT04546958|Dietary Supplement|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
79223879|NCT04546958|Other|Nutritional counseling|Nutritional counseling by dietitians for 3 months
79223880|NCT04540107|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
79223881|NCT04540107|Procedure|Magnetic Resonance Imaging|Undergo MRI
79223882|NCT04540107|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
79223883|NCT04534556|Device|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
79223884|NCT04534556|Device|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
79223885|NCT04529889|Other||
79223886|NCT04529252|Other|Specimen collection|Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
79366447|NCT05162482|Biological|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
79366448|NCT05162482|Biological|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
79366449|NCT05162482|Biological|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
79518956|NCT02687412|Procedure|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
79518957|NCT02687412|Procedure|Postoperative glycaemic control|Postoperative glycaemic control;
79518958|NCT02687412|Procedure|postoperative nausea and vomiting (PONV) control;|
79518959|NCT02687412|Procedure|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
79518960|NCT02687412|Procedure|pre-operative fasting at least 8h|
79518961|NCT02687412|Procedure|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
79518962|NCT02687412|Procedure|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
79518963|NCT02693262|Device|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
79518964|NCT02693262|Device|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
79518965|NCT02694198|Other|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
79518966|NCT02695290|Drug|Afatinib|
79518967|NCT02695446|Drug|Minocycline|Oral extended release minocycline
79518968|NCT02696070|Device|Provant Therapy System|
79676219|NCT05143437|Behavioral|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
79676220|NCT00499499|Drug|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
79676221|NCT05148663|Diagnostic Test|CCM Hemorrhagic Panel|Biomarker
79676222|NCT01246817|Drug|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
79821969|NCT00743847|Drug|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
79223887|NCT04523493|Combination Product|Toripalimab combined with Lenvatinib|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
79223888|NCT04523493|Combination Product|Placebo combined with Lenvatinib|"Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
79223889|NCT04503551|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
79223890|NCT04503551|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
79223891|NCT04497909|Behavioral|Mindfulness|Mindfulness online training
79223892|NCT04496167|Drug|EN3835|Collagenase clostridium histolyticum
79223893|NCT04496167|Drug|Placebo|Placebo comparator
79223894|NCT04485195|Drug|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
79223895|NCT04485195|Drug|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
79223896|NCT04485130|Drug|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
79223897|NCT04485130|Drug|Placebo|This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
79223898|NCT04469491|Drug|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
79223899|NCT04469491|Drug|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
79518969|NCT02697240|Drug|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
79518970|NCT02698566|Drug|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
79518971|NCT02698800|Device|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
79518972|NCT02698800|Device|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
79518973|NCT02701062|Device|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
79223900|NCT04460924|Drug|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
79223901|NCT04458948|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
79223902|NCT04458948|Drug|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
79223903|NCT04432857|Drug|AN0025|oral administration
79223904|NCT04432857|Drug|Pembrolizumab|Infusion
79223905|NCT04386746|Drug|Gemcitabine|1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
79518974|NCT02701062|Drug|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
79518975|NCT02704104|Device|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
79223906|NCT04386746|Drug|Docetaxel|37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
79223907|NCT04383119|Drug|Trabectedin|Trabectedin in monotherapy
79223908|NCT04383119|Drug|Gemcitabine|Gemcitabine, control arm
79223909|NCT04383119|Drug|No Intervention: Observational Cohort|Treatment according clinical practice
79518976|NCT02705352|Drug|5-Fluorouracil|Treatment medication
79518977|NCT02705352|Other|Normal saline|Placebo
79518978|NCT02707146|Behavioral|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
79518979|NCT02707146|Other|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
79518980|NCT02707146|Device|iPad|
79518981|NCT02707770|Other|Pulmonary Rehabilitation|
79518982|NCT02708238|Dietary Supplement|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
79518983|NCT02708238|Dietary Supplement|Lactobacillus reuteri DSM 17938 (108 CFU)|
79518984|NCT02708238|Drug|Simethicone|
79518985|NCT02708862|Device|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
79996024|NCT03676452|Behavioral|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
79996025|NCT03676296|Drug|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
79996026|NCT03676296|Drug|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
79996027|NCT03672474|Device|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
79996028|NCT03672474|Device|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
79223910|NCT04357756|Drug|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
79366450|NCT04414969|Drug|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
79223911|NCT04357756|Drug|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
79223912|NCT04350502|Procedure|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day).
79223913|NCT04350502|Biological|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
79223914|NCT04350502|Drug|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
79223915|NCT04339101|Drug|Fludarabine|Given via infusion
79223916|NCT04339101|Drug|Itacitinib Adipate|Given PO
79366451|NCT04817098|Behavioral|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
79223917|NCT04339101|Drug|Melphalan|Given IV
79223918|NCT04339101|Other|Quality-of-Life Assessment|Ancillary studies
79223919|NCT04339101|Other|Questionnaire Administration|Ancillary studies
79223920|NCT04339101|Drug|Sirolimus|Given PO
79223921|NCT04339101|Drug|Tacrolimus|Given IV or PO
79223922|NCT04305548|Drug|Trabectedin|Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
79223923|NCT04294134|Behavioral|MIO-CPP|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months."
79366452|NCT01609933|Drug|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
79366453|NCT01609933|Drug|ABT-267|ABT-267 (tablets)
79366454|NCT01609933|Drug|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
79366455|NCT01609933|Drug|Ribavirin (RBV)|Ribavirin (tablets)
79366456|NCT03255928|Diagnostic Test|PAS assay, TGT|Evaluation of platelet function
79366457|NCT03241420|Device|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
79996029|NCT03672240|Drug|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
79996030|NCT03676140|Drug|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
79996031|NCT03676140|Drug|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
79996032|NCT03676140|Drug|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
79996033|NCT03676140|Drug|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
79996034|NCT03676140|Drug|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
79518986|NCT02709018|Drug|losartan|Angiotensin receptor blocker (ARB)
79518987|NCT02709018|Drug|Placebo|Placebo
79518988|NCT02713230|Drug|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
79518989|NCT02713230|Drug|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
79518990|NCT02713230|Drug|Placebo|20 mL normal saline as single-injection
79518991|NCT02713698|Drug|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
79518992|NCT02714400|Drug|Venlafaxine|Venlafaxine 50mg before sleep
79518993|NCT02714400|Drug|Placebo|One piece of placebo before sleep
79518994|NCT02716506|Procedure|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
79518995|NCT02716818|Drug|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
79518996|NCT02716818|Drug|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
79223924|NCT04294134|Behavioral|MIO-CPP-CRS|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based…model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders."
79223925|NCT04293224|Other|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
79366458|NCT01843777|Behavioral|Standard-of-Care|the standard of care in audiologic practice
79366459|NCT01843777|Behavioral|Treatment|motivational interviewing
79366460|NCT05361772|Drug|colchicine|colchicine 0.5mg per day for 24 months
79366461|NCT05361772|Drug|Placebo|placebo 0.5mg per day for 24 months
79518997|NCT02719158|Drug|6 mg ciprofloxacin|Single administration of OTO-201
79518998|NCT02719158|Drug|12 mg ciprofloxacin|Single administration of OTO-201
79518999|NCT02719158|Other|Sham|
79996035|NCT03676062|Other|exercise|All exercises programs applied three sessions per week, totally six week.
79996036|NCT03675984|Behavioral|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
79996037|NCT03677856|Procedure|Paravertebral blockade|Type of anaesthesia
79366462|NCT05360368|Drug|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
79366463|NCT05355376|Procedure|Bundle of measures to decreased SSI|
79366464|NCT04810702|Other|no intervention|no intervention
79519000|NCT02719938|Behavioral|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
79519001|NCT02723916|Behavioral|ezParent Program|Tablet-based behavioral parent training program.
79519002|NCT02723916|Behavioral|Health-e Kids Control App|Tablet based health promotion information App
79519003|NCT02726178|Drug|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
79519004|NCT02726178|Drug|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
79519005|NCT02727816|Device|filcon IV I (BC 8.6)|control lens
79519006|NCT02727816|Device|filcon IV I (BC 8.7)|control lens
79519007|NCT02727816|Device|ocufilcon D|test lens
79519008|NCT02727816|Device|methafilcon A (BC 8.6)|control lens
79519009|NCT02727816|Device|methafilcon A (BC 8.7)|control lens
79519010|NCT02727816|Device|somofilcon A|test lens
79519011|NCT02730234|Device|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
79519012|NCT02733588|Drug|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
79519013|NCT02734056|Other|Music|Listening to music that the patient likes
79519014|NCT02734056|Other|Control|Control
79519015|NCT02735382|Behavioral|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
79519016|NCT02735382|Behavioral|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
79519017|NCT02737332|Drug|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
79996038|NCT03677856|Procedure|Thoracic epidural block|Type of anaesthesia
79519018|NCT02737332|Drug|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
79519019|NCT05446428|Other|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
79519020|NCT05446116|Procedure|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
79519021|NCT05445960|Procedure|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
79996039|NCT03504774|Drug|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
79996040|NCT03677700|Other|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
79996041|NCT03677622|Drug|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
79996042|NCT03672162|Procedure|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
79996043|NCT04059120|Other|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
79996044|NCT04059120|Other|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
79996045|NCT04059198|Drug|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
79223926|NCT04293224|Other|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
79223927|NCT04293224|Other|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
79996046|NCT04059198|Drug|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
79996047|NCT04058964|Biological|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
79996048|NCT04058964|Biological|Pembrolizumab|Given IV
79996049|NCT03024606|Behavioral|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
79996050|NCT03675906|Other|hypoalbuminemia|hypoalbuminemia and acute kidney injury
79223928|NCT04288245|Device|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
79366465|NCT01842607|Biological|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
79366466|NCT04794478|Device|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
79366467|NCT04760938|Behavioral|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
79366468|NCT04760938|Behavioral|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
79366469|NCT01803607|Drug|odanacatib|odanacatib 50 mg oral tablet
79366470|NCT01803607|Other|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
79519022|NCT05445180|Behavioral|Contingency management|Contingency management will be used to encourage abstinence
79519023|NCT05445102|Procedure|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
79519024|NCT05444088|Drug|Adebrelimab|intravenous infusion
79519025|NCT05444088|Drug|Bevacizumab|intravenous infusion
79519026|NCT05444088|Drug|SHR-8068|intravenous infusion
79821970|NCT00743847|Drug|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
79519027|NCT05443854|Drug|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines [3, 28, 50].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
79519028|NCT05443854|Behavioral|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
79223929|NCT04288245|Device|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
79223930|NCT04286607|Drug|Topical roflumilast|Active treatment
79519029|NCT05443854|Other|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines [3, 28, 50].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
79366471|NCT02958514|Device|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of *500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
79366472|NCT02958514|Drug|Tobramycin and Dexamethasone Ophthalmic Ointment|
79366473|NCT04388722|Device|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
79366474|NCT04667260|Procedure|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
79821971|NCT00746343|Behavioral|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
79821972|NCT00746343|Behavioral|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
79366475|NCT04667260|Procedure|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
79366476|NCT05290168|Diagnostic Test|abdominal Doppler|"Inferior vena cava diameter and distensibility~Hepatic vein Doppler~Portal vein Doppler~Splenic artery and vein Doppler~Renal artery and vein Doppler"
79366477|NCT01867021|Biological|Fluvirin(TIVf)|
79366478|NCT01867021|Biological|Agriflu (TIV)|
79366479|NCT01866709|Drug|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
79223931|NCT04270136|Procedure|total mastectomy|breast cancer non conserving surgery
79679919|NCT04693871|Device|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
79679920|NCT02948348|Drug|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
79679921|NCT02948348|Drug|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
79679922|NCT02937480|Other|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
79223932|NCT04246177|Drug|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) via oral capsules once a day during each 21-day cycle.
79223933|NCT04246177|Biological|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
79223934|NCT04246177|Drug|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
79679923|NCT02937480|Other|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
79679924|NCT04693910|Other|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
79223935|NCT04246177|Drug|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
79223936|NCT04246177|Procedure|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
79223937|NCT04238481|Drug|Pudexacianinium chloride|Intravenous
79366480|NCT01866709|Drug|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
79366481|NCT04621630|Drug|PN-235|Active Drug
79366482|NCT04621630|Drug|Placebo|Matching Placebo
79366483|NCT01841593|Drug|Raltegravir|Isentress 400mg tablet taken twice daily
79519030|NCT05443854|Other|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~High-efficiency air filtration [filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better]~Geographical isolation in an individual room~Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
79519031|NCT05443776|Other|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
79519032|NCT05443308|Diagnostic Test|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral [15O]H2O PET before and after diamox infusion
79519033|NCT05443152|Behavioral|Fetal movement and position tracking training|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
79519034|NCT05442996|Drug|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
79519035|NCT05442996|Drug|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
79519036|NCT05441046|Drug|Genakumab|genakumab plus tislelizumab 200 mg
79519037|NCT05412264|Behavioral|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
79519038|NCT05394870|Other|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
79519039|NCT05394870|Other|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
79676223|NCT04696341|Procedure|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
79676224|NCT04696341|Procedure|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
79519040|NCT05350332|Device|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
79676225|NCT05147025|Other|Revascularization|Regain pulp vascularity for young permenant teeth
79676226|NCT00499538|Drug|SKI-606|
79223938|NCT04234386|Radiation|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
79223939|NCT04227054|Device|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
79223940|NCT04222010|Drug|loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
79524797|NCT05768308|Behavioral|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
79223941|NCT04222010|Drug|Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
79223942|NCT04222010|Drug|Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
79223943|NCT04179526|Behavioral|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
79223944|NCT04179500|Drug|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
79519041|NCT05350332|Device|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test to evaluate lung function. PFT is an outpatient procedure that consist of two parts: spirometry and body plethysmography. In spirometry, participants are asked to breathe through a mouthpiece that measures airflow and volume. Several breathing maneuvers are used to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants are placed in an enclosed chamber where they are asked again to breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing can be used to calculate the volume of air that remains in the lung after expiration. The combination of values measured on spirometry and body plethysmography allow for calculation of residual lung volumes including the functional residual capacity and expiratory reserve volume.
79676227|NCT01245803|Drug|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
79676228|NCT01245803|Drug|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
79821973|NCT00717860|Drug|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
79223945|NCT04179500|Drug|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
79223946|NCT04179500|Drug|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
79223947|NCT04179500|Drug|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
79223948|NCT04166643|Behavioral|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
79366484|NCT01841593|Drug|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
79366485|NCT05238298|Device|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
79366486|NCT02520544|Device|Accolade stem|Total hip replacement
79366487|NCT02520544|Device|Accolade II stem|Total hip replacement
79519042|NCT05350332|Device|Transcutaneous Phrenic Nerve Stimulation|Phrenic nerve stimulation (PNS) will be performed trancutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS7A High Voltage Constant Current Stimulators). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
79519043|NCT05340270|Drug|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
79519044|NCT05340270|Drug|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
79676229|NCT05148975|Diagnostic Test|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
79676230|NCT01246934|Other|ASR METHOD|
79676231|NCT05146947|Device|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
79223949|NCT04166643|Behavioral|Education only control|Education at the start of the project
79223950|NCT04145700|Drug|Ramucirumab|Ramucirumab given IV
79223951|NCT04145700|Drug|Gemcitabine|Gemcitabine given IV
79223952|NCT04145700|Drug|Docetaxel|Docetaxel given IV
79223953|NCT04140110|Other|Intensive BP lowering|The aim is to achieve a systolic BP level of <120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
79223954|NCT04128683|Drug|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
79223955|NCT04128683|Drug|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
79366488|NCT02520544|Device|Trident/Tritanium cup|Total hip replacement
79366489|NCT02454322|Drug|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
79366490|NCT04505566|Drug|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
79366491|NCT04505566|Drug|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
79366492|NCT04505566|Other|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
79366493|NCT04387864|Device|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
79676232|NCT01247012|Dietary Supplement|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
79366494|NCT02132650|Behavioral|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
79676233|NCT01247012|Dietary Supplement|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
79676234|NCT03454191|Procedure|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
79676235|NCT03454191|Procedure|No injection|No injection
79821974|NCT00717860|Drug|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
79519045|NCT05313594|Diagnostic Test|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
79519046|NCT05313594|Diagnostic Test|MRI|MRI imaging
79519047|NCT05313594|Diagnostic Test|DEXA|DEXA scan
79519048|NCT05313594|Device|Freestyle Libre|Continuous blood glucose measurement
79519049|NCT05313594|Device|ActivPAL3|Continuous physical activity measurement
79519050|NCT05289414|Device|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency treatment
79519051|NCT05289414|Procedure|Greater occipital nerve block|patients with diagnosis of cervicogenic headache will be subjected to Greater occipital nerve block
79519052|NCT05269368|Procedure|Wicking|Absorbable or non-absorbable wicking
79223956|NCT04125537|Behavioral|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
79519053|NCT05269368|Procedure|No wicking|No wicking after surgery
79676236|NCT00499577|Biological|CMV pp65 peptide|Given intramuscularly
79676237|NCT00499577|Biological|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
79676238|NCT00499577|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
79676239|NCT00499577|Biological|survivin Sur1M2 peptide vaccine|Given subcutaneously
79676240|NCT03450096|Other|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
79223957|NCT04117126|Behavioral|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
79676241|NCT02274740|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
79676242|NCT02274740|Drug|metformin|Pharmaceutical form:tablet Route of administration: oral
79223958|NCT04111497|Drug|Glasdegib|Given PO
79223959|NCT04108156|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
79223960|NCT04108156|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
79676243|NCT00499733|Drug|cyclophosphamide|500 mg/m^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
79223961|NCT04079738|Drug|TAK-659|TAK-659
79223962|NCT04079738|Drug|Ixazomib|Ixazomib
79223963|NCT04066504|Drug|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
79366495|NCT02132650|Behavioral|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
79223964|NCT04063085|Device|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
79366496|NCT05122936|Combination Product|SRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
79519054|NCT05266404|Drug|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
79519055|NCT05266404|Drug|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
79519056|NCT05266404|Drug|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
79519057|NCT05212584|Biological|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
79519058|NCT05206188|Behavioral|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
79519059|NCT05184738|Other|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
79519060|NCT05184738|Other|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
79519061|NCT05175924|Other|Nanpharmacological method|Virtual Reality
79519062|NCT05150418|Drug|Oxygen gas|Oxygen 15 l/min
79519063|NCT05150418|Drug|Air|Room air 15 l/min
79524798|NCT05768243|Drug|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
79676244|NCT00499733|Device|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
79676245|NCT03452202|Device|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
79519064|NCT05146206|Other|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
79821975|NCT02564679|Procedure|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
79519065|NCT05127564|Drug|Diroximel fumarate|Administered as specified in the treatment arm
79519066|NCT05122494|Drug|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
79223965|NCT04063085|Device|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
79519067|NCT05122494|Drug|Lapatinib+Capecitabine|Take the pills according to the instructions
79519068|NCT05097924|Other|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
79223966|NCT04063085|Other|No treatment|No anti-adhesion agent applied
79519069|NCT05063604|Drug|Citalopram|20 mg tablet one or twice daily for 12 weeks
79519070|NCT05063604|Behavioral|Psychotherapy|One session weekly for 12 weeks
79676246|NCT03452202|Device|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
79676247|NCT06155825|Behavioral|no intervention|Group 4 will receive no intervention
79223967|NCT04063085|Device|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
79676248|NCT06155825|Drug|nonnutritive suckling|Group 1 will receive nonnutritive suckling
79676249|NCT06155825|Drug|oral glucose 25%|Group 2 will receive oral glucose 25%
79676250|NCT06155825|Behavioral|facilitated tuckling|Group 3 will undergo facilitated tuckling
79676251|NCT06155812|Other|Simultaneous administration of vasopressors|Early, simultaneous administration of norepinephrine, angiotensin II, and vasopressin.
79676252|NCT06155812|Other|Successive administration of vasopressors|Administration and titration of norepinephrine and administration of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II, dobutamine, or dopamine) as per clinical team.
79519071|NCT05051514|Diagnostic Test|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
79676253|NCT06155799|Device|Freehand zygomatic implant placement|Zygomatic implants will be placed without any guidance after preoperative virtual planning has been performed.
79676254|NCT06155760|Drug|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
79519072|NCT04978428|Drug|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
79676255|NCT06155760|Other|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
79676256|NCT06155760|Drug|Placebo|Placebo
79676257|NCT06155734|Drug|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
79519073|NCT04960332|Device|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
79519074|NCT04940364|Drug|Pozelimab|Administered intravenous (IV) or subcutaneous (SC) per protocol
79519075|NCT04940364|Drug|Cemdisiran|Administered SC per protocol
79519076|NCT04844736|Procedure|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
79519077|NCT04814706|Dietary Supplement|Carbohydrate drinking|Administration of carbohydrate fluid
79519078|NCT04804488|Procedure|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
79519079|NCT04660422|Other|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
79524799|NCT05768243|Procedure|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
79676258|NCT06155682|Device|repetitive transcranial magnetic stimulation|non-invasive repetitive stimulation applied to the scalp surface
79223968|NCT04063085|Device|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
79223969|NCT04054635|Device|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
79366497|NCT04959994|Device|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
79366498|NCT04815070|Procedure|Ultrasonic measurement of antral area|"Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures."
79366499|NCT04789330|Drug|Norepinephrine|Norepinephrine administered during anesthesia
79519080|NCT04660422|Other|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
79519081|NCT04660422|Other|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
79519082|NCT04660422|Other|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
79519083|NCT04601922|Other|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
79519084|NCT04376658|Other|COVID-19 Severity|Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
79519085|NCT04352010|Behavioral|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
79524800|NCT05768230|Drug|levosimendan|Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
79676259|NCT06155630|Other|mandibular implant-overdenture|Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
79366500|NCT04789330|Drug|Phenylephrine|Phenylephrine administered during anesthesia
79676260|NCT06155617|Other|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
79676261|NCT06155604|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
79821976|NCT02564679|Behavioral|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
79821977|NCT00746499|Drug|Raltegravir|400mg raltegravir BID x 7 days
79223970|NCT04048239|Procedure|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
79223971|NCT04048239|Other|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
79223972|NCT04048239|Other|electromyograph|electromyographic verification of the facial nerve
79223973|NCT04033510|Other|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
79223974|NCT04017247|Drug|Oxytocin|Intermittent oxytocin Infusion
79223975|NCT04017247|Drug|Oxytocin|Continous oxytocin Infusion for 16 hours
79223976|NCT03953235|Biological|GRT-C903|a shared neoantigen cancer vaccine prime
79223977|NCT03953235|Biological|GRT-R904|a shared neoantigen cancer vaccine boost
79821978|NCT03888417|Device|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
79223978|NCT03953235|Biological|nivolumab|anti-PD-1 monoclonal antibody
79223979|NCT03953235|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
79366501|NCT02339038|Drug|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
79366502|NCT04497298|Biological|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
79366503|NCT04497298|Biological|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
79821979|NCT02592122|Drug|Salbutamol Aerosol|
79821980|NCT02592122|Drug|No drugs|
79821981|NCT01497015|Behavioral|memory training|10 1-hour sessions over 6-8 weeks
79366504|NCT04497298|Biological|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
79519086|NCT04352010|Behavioral|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
79821982|NCT01497015|Behavioral|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
79223980|NCT03935997|Other|Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program|"Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff."
79223981|NCT03933696|Device|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
79223982|NCT03904875|Other|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
79519087|NCT04352010|Other|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
79519088|NCT04185792|Diagnostic Test|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
79519089|NCT04076202|Device|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
79676262|NCT06155604|Drug|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (<=1.5 g/D) or Azathioprine (<=150 mg/D)
79676263|NCT06155578|Drug|Topical 25% sodium metabisulfite (SM) in pediatric cold cream|Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
79519090|NCT03947814|Drug|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
79676264|NCT06155578|Drug|Placebo|Pediatric cold cream will be applied twice daily on hand calcinosis.
79676265|NCT06155539|Other|No intervention|No intervention
79366505|NCT04497298|Other|Placebo|Physiological saline solution (0.9% NaCl)
79366506|NCT04387786|Drug|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
79676266|NCT06155526|Other|Activity|patients taking an active rest after swimming sets
79676267|NCT06155487|Drug|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
79676268|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 100 mg
79676269|NCT06155487|Drug|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
79676270|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 200 mg
79223983|NCT03897998|Drug|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
79223984|NCT03897998|Other|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
79366507|NCT02136004|Device|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
79676271|NCT06155487|Drug|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
79366508|NCT00569530|Drug|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
79366509|NCT00569530|Drug|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
79366510|NCT04509622|Drug|Venetoclax|Tablet; Oral
79524801|NCT05768230|Drug|5% glucose injection|5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
79821983|NCT01497015|Behavioral|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
79366511|NCT04509622|Drug|Cytarabine|Subcutaneous Injection
79366512|NCT04388098|Other|Diagnosis of caries experience and periodontal health|
79524802|NCT05768204|Drug|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
79676272|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 300 mg
79676273|NCT06155487|Drug|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
79676274|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 400 mg
79676275|NCT06155487|Drug|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
79676276|NCT06155487|Drug|Placebo|Oral Tablet,Single dose of Placebo 600 mg
79821984|NCT02564445|Behavioral|Gamification|All participants will be entered with their teammate into a game that includes points and levels
79821985|NCT02564445|Behavioral|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
79821986|NCT02564445|Behavioral|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
79821987|NCT02564445|Behavioral|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
79519091|NCT03797586|Other|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
79366513|NCT00570700|Drug|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
79223985|NCT03891706|Drug|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
79821988|NCT02564367|Drug|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks"
79223986|NCT03891706|Drug|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
79223987|NCT03885401|Behavioral|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
79223988|NCT03862417|Other|Schroth exercises|An exercise program begun individually and then continued in groups.
79223989|NCT03852992|Drug|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
79223990|NCT03852992|Drug|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
79366514|NCT00571324|Drug|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
79519092|NCT03797586|Other|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
79223991|NCT03852992|Device|Laser|Fractional ablative, deep mode, 5% fractional coverage
79223992|NCT03852992|Drug|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
79519093|NCT03770130|Drug|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
79676277|NCT06155487|Drug|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
79676278|NCT06155487|Drug|Placebo|Oral Tablet, Single dose of Placebo 800 mg
79676279|NCT06155487|Drug|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
79223993|NCT03852992|Drug|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
79223994|NCT03852992|Drug|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
79223995|NCT03832569|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
79223996|NCT03826342|Behavioral|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
79223997|NCT03826342|Behavioral|Time, attention, and information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
79223998|NCT03820726|Drug|Nintedanib|Bid
79223999|NCT03774446|Drug|Seliciclib|Drug: Seliciclib
79224000|NCT03754634|Drug|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
79676280|NCT06155487|Drug|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
79676281|NCT06155487|Drug|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
79676282|NCT06155487|Drug|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
79676283|NCT06155487|Drug|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
79366515|NCT00571324|Other|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
79366516|NCT04338646|Other|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
79366517|NCT00573508|Drug|Placebo|Oral Administration
79366518|NCT00573508|Drug|Solifenacin Succinate|Oral Administration
79366519|NCT00574834|Drug|Ramipril|Ramipril 20 mg once daily for 6 months
79366520|NCT00574834|Drug|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
79366521|NCT00574834|Drug|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
79366522|NCT00575146|Dietary Supplement|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
79676284|NCT06155487|Drug|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
79676285|NCT06155474|Dietary Supplement|Prebiotic galacto-oligosaccharide (GOS) Powder|"Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product"
79519094|NCT03770130|Drug|Saline|Saline, a kind of crystalloid widely used in clinical treatment
79519095|NCT03758664|Drug|ICP-192|"Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,"
79519096|NCT03694626|Device|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
79519097|NCT03694626|Device|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
79519098|NCT03694626|Device|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
79519099|NCT03694626|Device|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
79519100|NCT03694626|Device|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
79366523|NCT04095520|Procedure|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
79519101|NCT03670914|Diagnostic Test|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
79224001|NCT03751618|Procedure|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
79519102|NCT03642834|Drug|ICP-105|25mg, 100mg capsule
79821989|NCT00923637|Drug|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
79224002|NCT03745404|Drug|Lidocaine 5% medicated Plaster|
79519103|NCT03449784|Other|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
79524803|NCT05768204|Other|placebo|A placebo consistent in appearance with the prednisolone acetate.
79224003|NCT03745404|Drug|Placebo Plaster|
79821990|NCT00717314|Drug|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
79821991|NCT00717314|Drug|CNI (50%)|50% reduction from BL
79821992|NCT00717314|Drug|CNI (≥75%)|≥75% reduction from BL
79224004|NCT03744312|Drug|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
79224005|NCT03744312|Drug|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
79821993|NCT01090089|Drug|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
79224006|NCT03737123|Drug|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
79224007|NCT03737123|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
79224008|NCT03737123|Drug|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
79224009|NCT03737123|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
79224010|NCT03712813|Device|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
79224012|NCT03651687|Other||
79224013|NCT03650374|Other|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
79366524|NCT04095520|Procedure|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
79366525|NCT04251520|Diagnostic Test|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
79996051|NCT03675828|Behavioral|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
79676286|NCT06155474|Dietary Supplement|Starch Only|The Starch Solution is a low-fat diet.
79676287|NCT06155474|Dietary Supplement|RUTF + Starch|ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
79676288|NCT06155461|Procedure|Preoperative Ultrasonographic Evaluation of Caval Aorta Diameter Index|to evaluate the ability of preoperative ultrasound measurements of IVC to aorta diameter index and the inferior vena cava collapsibility index (IVCCI) for predicting post induction hypotension after general anesthesia in geriatric patients.
79366526|NCT04251520|Other|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
79676289|NCT06155448|Other|Perennial Malaria Chemoprevention effect|Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
79676290|NCT06155422|Drug|Cadonilimab|recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
79676291|NCT06155370|Other|construction of organoids from gynecological tumor|organoids construction
79676292|NCT06155305|Procedure|Biopsy|Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
79676293|NCT06155279|Drug|Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab|"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
79676294|NCT06155253|Procedure|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 & L1 in 2ESP group)"
79676295|NCT06155240|Behavioral|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
79676296|NCT06155201|Behavioral|functional training|Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
79996052|NCT02864160|Behavioral|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
79224014|NCT03650374|Other|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
79224015|NCT03639714|Biological|GRT-C901|a patient-specific neoantigen cancer vaccine prime
79224016|NCT03639714|Biological|GRT-R902|a patient-specific neoantigen cancer vaccine boost
79366527|NCT01592110|Drug|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
79366528|NCT01592110|Other|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
79366529|NCT01592110|Drug|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
79366530|NCT01592110|Drug|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
79224017|NCT03639714|Biological|nivolumab|anti-PD-1 monoclonal antibody
79366531|NCT03843580|Device|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
79519104|NCT03447834|Other|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
79366532|NCT00604552|Device|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
79366533|NCT00605644|Drug|MOA-728|Oral Capsules
79366534|NCT00605644|Drug|Placebo|Placebo
79519105|NCT03447834|Other|Standard PPCI|PPCI per routine
79524804|NCT05768152|Device|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
79996053|NCT02864160|Behavioral|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
79519106|NCT03064074|Drug|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
79519107|NCT03012282|Diagnostic Test|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
79519108|NCT02945436|Behavioral|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
79519109|NCT02945436|Behavioral|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
79519110|NCT02445456|Drug|Sienna+ injection|Endoscopic injection of magnetic tracer
79519111|NCT02445456|Other|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
79519112|NCT02445456|Procedure|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
79821994|NCT01090089|Drug|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
79224018|NCT03639714|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
79224019|NCT03634267|Radiation|Internal Radiation Therapy|Undergo brachytherapy
79224020|NCT03634267|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79224021|NCT03633162|Other||
79366535|NCT00578734|Drug|Lucinactant|Slow intra-tracheal instillation
79996054|NCT03671616|Biological|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
79996055|NCT03675594|Device|CAD/CAM titanium denture base|metallic denture base made of titanium
79224022|NCT03631056|Biological|Human Acellular Vessel (HAV)|
79224023|NCT03625102|Drug|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
79224024|NCT03625102|Other|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
79224025|NCT03567876|Drug|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
79366536|NCT00578734|Other|Sham Comparator|Slow intra-tracheal instillation
79366537|NCT00578968|Drug|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
79366538|NCT00578968|Drug|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
79366539|NCT00579280|Drug|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
79366540|NCT00579280|Drug|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
79366541|NCT00579280|Drug|placebo|placebo
79519113|NCT02445456|Device|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
79519114|NCT02316132|Drug|Stress|Corticotropin-Releasing Hormone
79519115|NCT02316132|Drug|Control|Saline 0.9%
79519116|NCT01770756|Behavioral|Self-Care Training|
79519117|NCT01276002|Procedure|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
79224026|NCT03518801|Behavioral|Prolonged Exposure|psychotherapy
79224027|NCT03518801|Drug|Cannabidiol|active medication
79224028|NCT03518801|Drug|placebo|non-active medication
79224029|NCT03502707|Biological|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
79224030|NCT03502707|Biological|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
79224031|NCT03502707|Biological|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
79224032|NCT03502707|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1*10^11 vp.
79366542|NCT00579436|Drug|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
79366543|NCT00579436|Drug|placebo|4 inert capsules daily by mouth for 12 weeks.
79366544|NCT03573466|Procedure|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
79366545|NCT00580294|Drug|Oxymorphone|IV PO
79366546|NCT00580372|Drug|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
79366547|NCT00580372|Drug|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
79519118|NCT05452746|Device|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
79519119|NCT05452746|Other|Treatment as usual|Inpatient psychiatric care for depression
79519120|NCT05452434|Drug|mirabegron|mirabegron 50mg QD for 12 weeks.
79519121|NCT05451342|Diagnostic Test|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
79519122|NCT05450874|Procedure|hepatectomy|
79676297|NCT06155201|Other|Observation|Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
79676298|NCT06155188|Procedure|applying of FLU+CY post-HSCT|The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
79366548|NCT00580372|Procedure|Hemopoietic stem cell procurement|Collection target = 10 x 10^6 cells/kg
79676299|NCT06155162|Behavioral|The HuggyPuppy Intervention|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
79996056|NCT03675594|Device|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
79996057|NCT03675438|Other|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
79676300|NCT06155110|Drug|cardiomyopeptidin|cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
79676301|NCT06155084|Drug|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
79519123|NCT05450328|Drug|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
79821995|NCT00689793|Drug|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
79821996|NCT00689793|Drug|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
79224033|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
79224034|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
79366549|NCT00580372|Drug|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
79366550|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
79366551|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
79366552|NCT00580372|Drug|Maintenance|3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse
79366553|NCT00581230|Device|Laryngoscopy with RAMP|inflatable positioning ramp
79524805|NCT05768126|Drug|Rivastigmine Transdermal Product|The patches will be administered when a patient is starting ECT treatment (first four weeks 4.6 mg and then 9.5. mg). When the ECT treatment is completed, the administration of rivastigmine patches will be halted.
79676302|NCT06155084|Drug|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
79821997|NCT04086290|Procedure|RARP|Radical prostatectomy + extended pelvic lymph node dissection
79821998|NCT04086290|Radiation|SBRT|Stereotactic body radiotherapy to osseous lesions
79821999|NCT04086290|Drug|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
79996058|NCT03180619|Drug|TAF|Tablet administered orally once daily
79224035|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
79224036|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
79224037|NCT03502707|Biological|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
79224038|NCT03480334|Other|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
79519124|NCT05450328|Drug|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
79519125|NCT05450172|Other|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
79519126|NCT05449938|Procedure|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
79519127|NCT03018912|Other|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~How many days a week are you satisfied with your sleep?~How many days a week is sleepiness a problem?"
79519128|NCT05449860|Procedure|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
79519129|NCT05449782|Dietary Supplement|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
79676303|NCT06155084|Drug|HP518 -Dose Expansion|Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
79676304|NCT06155058|Procedure|SYREBO|Serial ADL training of upper extremities with robotic aid
79224039|NCT03473535|Combination Product|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
79224040|NCT03473535|Behavioral|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
79224041|NCT03467750|Drug|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
79228093|NCT03901430|Behavioral|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
79366554|NCT00581230|Device|Laryngoscopy without RAMP|Laryngoscopy without RAMP
79366555|NCT00581386|Device|LTS-D|supra-glottic airway device
79366556|NCT00581386|Device|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
79366557|NCT00581386|Device|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
79519130|NCT05449782|Other|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
79228094|NCT03314090|Drug|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
79366558|NCT02134210|Drug|Etanercept|Head-to-head comparison
79366559|NCT02134210|Drug|CHS-0214|
79366560|NCT02134522|Device|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
79366561|NCT02134756|Drug|NutraStem Active|
79366562|NCT02134756|Drug|NutraStem Placebo|
79366563|NCT01798732|Procedure|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
79366564|NCT00607126|Device|Lokomat|locomotor training using body weight support on a treadmill
79366565|NCT00607126|Procedure|resistive training|resistive training using theraband and/or weights
79366566|NCT00607594|Drug|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
79519131|NCT05449704|Drug|DA-5218|single dose administration (DA-5218 one tablet once a day)
79519132|NCT05449704|Drug|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
79519133|NCT05449158|Procedure|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
79366567|NCT01866319|Biological|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
79366568|NCT01866319|Biological|Ipilimumab|3 mg/kg IV Q3W.
79366569|NCT00607672|Drug|Placebo|Placebo
79366570|NCT00607672|Drug|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
79366571|NCT00607672|Drug|Candesartan|Candesartan 16mg/d
79366572|NCT01802515|Drug|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
79366573|NCT01802515|Drug|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
79519134|NCT05449080|Diagnostic Test|Karyotype|Patients were subjected to karyotype to determine their genotype
79676305|NCT06155058|Procedure|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
79679925|NCT02937441|Other|Ultrasonic Measurement|"How we measure;~First measurement shall be taken in 4 hours.~Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~Third measurement shall be taken after fluid treatment.~Fourth measurement shall be taken at patients polyclinic control."
79679926|NCT00523211|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
79519135|NCT05448924|Diagnostic Test|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
79519136|NCT05447832|Device|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
79519137|NCT05447832|Device|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
79519138|NCT05447832|Diagnostic Test|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
79676306|NCT06155006|Diagnostic Test|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
79676307|NCT06154993|Other|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
79822000|NCT05431491|Device|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
79822001|NCT00723944|Device|Osseotite Certain Prevail|Root form titanium dental implant
79224042|NCT03467750|Drug|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
79366574|NCT01802515|Drug|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
79366575|NCT01802437|Drug|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
79366576|NCT01802437|Behavioral|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
79366577|NCT01802437|Behavioral|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
79366578|NCT00608062|Drug|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
79524806|NCT05768126|Other|Sham|The sham patches will be administered when a patient is starting ECT treatment. When the ECT treatment is completed, the administration of rivastigmine patches will be halted.
79524807|NCT05768074|Other|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
79679927|NCT00523211|Drug|Placebo|One tablet of placebo once daily.
79679928|NCT02931318|Behavioral|Nevsehir|The data of the study were collected with the questionnaire
79822002|NCT00723944|Device|Osseotite Certain|Dental implant without the lateralized design
79822003|NCT04086134|Other|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
79822004|NCT04060329|Behavioral|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
79822005|NCT02591264|Other|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
79822006|NCT04060563|Device|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
79996059|NCT03669744|Other|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
79519139|NCT05447754|Other|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
79519140|NCT05447754|Other|balance exercises|TBT
79224043|NCT03447951|Drug|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
79519141|NCT05447364|Drug|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
79519142|NCT05447364|Drug|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
79519143|NCT05446974|Other|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
79519144|NCT05446896|Device|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
79519145|NCT05446818|Dietary Supplement|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
79822007|NCT00744315|Procedure|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
79224044|NCT03445559|Behavioral|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
79366579|NCT00608062|Drug|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
79519146|NCT05446818|Other|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
79519147|NCT05444322|Drug|RD14-01 cell infusion|Autologous CAR T cells
79519148|NCT05439018|Other|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
79519149|NCT05439018|Other|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
79519150|NCT05418036|Drug|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
79519151|NCT05392920|Other|assessment study|there is no intervention in this study
79519152|NCT05378178|Drug|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
79996060|NCT03671538|Drug|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
79996061|NCT03671538|Drug|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
79519153|NCT05316714|Procedure|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
79519154|NCT05234346|Drug|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
79519155|NCT05234346|Other|Placebo|No Description for the intervention
79996062|NCT03671538|Drug|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
79996063|NCT05426941|Behavioral|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
79996064|NCT05426941|Behavioral|Music Listening|Up to 15 participants will be randomized to independent music listening.
79996065|NCT05420467|Drug|Docetaxel|75 mg/m2, d1, q3w,6 cycles
79366580|NCT00608062|Drug|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
79366581|NCT02138578|Radiation|SBRT|
79366582|NCT02138578|Radiation|RFA|
79519156|NCT05028426|Procedure|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
79519159|NCT05021172|Other|Best Practice|Receive usual care
79519160|NCT05021172|Other|Informational Intervention|Receive Passport to Health booklet
79519161|NCT05021172|Other|Questionnaire Administration|Complete ePrognosis
79224045|NCT03445559|Behavioral|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
79366583|NCT00608140|Procedure|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
79366584|NCT00608140|Drug|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
79366585|NCT02135146|Drug|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
79366586|NCT02135146|Drug|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
79366587|NCT02829268|Drug|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
79519162|NCT05021172|Other|Survey Administration|Ancillary studies
79519163|NCT04962048|Device|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
79519164|NCT04962048|Other|Control - no intervention|The other leg serves as non-treated control
79519165|NCT04949568|Behavioral|Diabetes Self-Management Behaviors|The intervention is to be delivered by a diabetes educator.
79519166|NCT04944810|Procedure|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
79519167|NCT04944810|Procedure|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
79519168|NCT04944810|Procedure|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
79519169|NCT04944810|Procedure|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
79822008|NCT00689481|Drug|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
79224046|NCT03445559|Behavioral|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
79224047|NCT03432741|Drug|Belinostat|Given intralesionally
79224048|NCT03432741|Drug|Carfilzomib|Given intralesionally
79519170|NCT04944810|Procedure|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
79822009|NCT00689481|Drug|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
79822010|NCT00744393|Drug|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
79996066|NCT05420467|Drug|Carboplatin|AUC 6, d1, q3w,6 cycles
79996067|NCT05420467|Drug|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
79224049|NCT03432741|Drug|Copanlisib Hydrochloride|Given intralesionally
79224050|NCT03432741|Biological|Daratumumab|Given intralesionally
79366588|NCT00581854|Drug|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
79366589|NCT00610480|Drug|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
79366590|NCT00610480|Drug|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
79366591|NCT00582400|Drug|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
79366592|NCT00582946|Device|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
79366593|NCT00583414|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
79366594|NCT00583492|Biological|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
79366595|NCT00583492|Radiation|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
79519171|NCT04914702|Device|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
79519172|NCT04914702|Device|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
79519173|NCT04881708|Device|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
79519174|NCT04532658|Behavioral|Coaching program|"Charting system for outcomes feedback~Profiling of individual surgeon~Modules of improvement"
79519175|NCT04522206|Drug|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
79519176|NCT04510116|Behavioral|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
79524808|NCT05768022|Other|Cura Kensio-tapping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.
79524809|NCT05768022|Other|placebo|placebo taping
79822011|NCT00744393|Drug|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
79822012|NCT00746577|Other|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
79224051|NCT03432741|Drug|Fludeoxyglucose F-18|Undergo FDG-PET
79224052|NCT03432741|Drug|Gemcitabine Hydrochloride|Given intralesionally
79224053|NCT03432741|Other|Laboratory Biomarker Analysis|Correlative studies
79224054|NCT03432741|Biological|Nivolumab|Given intralesionally
79224055|NCT03432741|Biological|Obinutuzumab|Given intralesionally
79224056|NCT03432741|Biological|Pembrolizumab|Given intralesionally
79224057|NCT03432741|Procedure|Positron Emission Tomography|Undergo FDG-PET
79224058|NCT03432741|Biological|Rituximab|Given intralesionally
79224059|NCT03432741|Drug|Romidepsin|Given intralesionally
79224060|NCT03432741|Other|Saline|Given intralesionally
79224061|NCT03432741|Biological|Trastuzumab|Given intralesionally
79224062|NCT03425006|Drug|Itacitinib|a JAK 1 selective small molecule inhibitor
79224063|NCT03425006|Biological|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
79366596|NCT04583527|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
79366597|NCT01801735|Drug|Meloxicam Test Capsules|
79519177|NCT04505592|Drug|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
79519178|NCT04505592|Drug|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
79519179|NCT04460508|Drug|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
79519180|NCT04460508|Drug|rhG-CSF|rhG-CSF:5ug/kg/d
79519181|NCT04415892|Other|Cinnamaldehyde and capsaicin|Topical application of cinnamaldehyde and capsaicin on the fingers
79676308|NCT06154993|Other|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
79822013|NCT02563353|Other|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
79224064|NCT03407157|Dietary Supplement|Probiotic supplementation|Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)
79224065|NCT03407157|Other|Placebo|Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
79224066|NCT03401073|Drug|Intravenous immunoglobulin|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
79224067|NCT03401073|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
79224068|NCT03359954|Radiation|Radiation Therapy|Undergo radiation therapy
79224069|NCT03359954|Procedure|Therapeutic Conventional Surgery|Undergo breast surgery
79822014|NCT02563353|Drug|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
79366598|NCT00612430|Drug|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG & 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data & order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
79519182|NCT04256070|Behavioral|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
79519183|NCT04226118|Device|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
79822015|NCT00688701|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
79822016|NCT00688701|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
79822017|NCT00688701|Device|Pen auto-injector|
79822018|NCT02563743|Behavioral|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
79224072|NCT03285581|Device|truSculpt RF|Subjects will receive RF treatments
79224073|NCT03273374|Device|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
79224074|NCT03269422|Radiation|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
79366599|NCT01571128|Other|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
79519184|NCT04176354|Drug|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
79519185|NCT04176354|Drug|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
79519186|NCT04176354|Drug|Letrozole|Letrozole monotherapy
79519187|NCT04128540|Drug|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
79519188|NCT04128540|Procedure|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
79519189|NCT05448612|Other|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
79676309|NCT06154967|Radiation|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
79676310|NCT06154954|Diagnostic Test|Semen analysis|Semen analysis for extracellular matrix proteins analysis
79519190|NCT04104438|Drug|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
79519191|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
79366600|NCT01571128|Other|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
79366601|NCT01571128|Drug|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
79519192|NCT04007640|Radiation|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
79519193|NCT04007640|Procedure|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
79519194|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
79519195|NCT03703206|Drug|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
79519196|NCT03476928|Drug|Vilaprisan (BAY1002670)|2mg, once daily, oral
79519197|NCT03427320|Drug|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
79519198|NCT03086616|Drug|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
79519199|NCT03026712|Device|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
79519200|NCT03026712|Device|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
79519201|NCT02952924|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
79519202|NCT02952924|Other|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
79519203|NCT02952924|Drug|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
79519204|NCT02823834|Device|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
79224075|NCT03227419|Drug|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
79822019|NCT02563743|Behavioral|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
79224076|NCT03227419|Drug|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight <60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight >100 mg) 24 hours before the first subcutaneous injection."
79224077|NCT03213730|Other|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
79366602|NCT01571128|Behavioral|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
79366603|NCT00614458|Drug|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
79822020|NCT00999609|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
79366604|NCT01429168|Drug|Etoricoxib|One 60-mg tablet orally daily
79366605|NCT01429168|Drug|Placebo for etoricoxib|One 60-mg tablet orally daily
79366606|NCT00771160|Drug|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
79366607|NCT00756418|Drug|montelukast|montelukast 5 mg QD 4-weeks.
79366608|NCT00756418|Drug|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
79519205|NCT02770638|Device|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
79519206|NCT02770638|Device|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
79519207|NCT02509962|Dietary Supplement|Slow sodium tablets|6 g sodium chloride per day over 14 days
79519208|NCT02476500|Procedure|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
79519209|NCT02199366|Procedure|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
79519210|NCT02021448|Other|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
79519211|NCT01368666|Device|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
79676311|NCT06154941|Procedure|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
79822021|NCT02563119|Procedure|Gastric Bypass or Sleeve gastrectomy|
79224078|NCT03213730|Other|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
79224079|NCT03187925|Procedure|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
79366609|NCT00615472|Drug|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
79822022|NCT00744549|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
79224080|NCT03183245|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
79519212|NCT00860730|Device|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
79676312|NCT06154941|Procedure|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
79676313|NCT06154928|Other|Drinking Warm Water Intervention|Patients in the Warm Water Group (WG) received a warm water drinking intervention post-laparoscopic cholecystectomy. Before intake, the bed head was elevated to 45°C, and gagging and swallowing reflexes were assessed using an Abeslang to touch the oropharynx. Nausea indicated a positive reflex. Two patients with negative reflexes were excluded from WG. To maintain water temperature, individual insulated cups with thermal features were used, preventing infection transmission. Water was boiled in a clinic kettle, cooled to 37-38°C, and given to patients to drink within 15 minutes. Swallowing ability was monitored after the first sip; successful swallowing allowed the patient to continue. Patients were observed for 15 minutes with an aspirator on standby for aspiration risks. No complications occurred during the water drinking process in WG.
79679929|NCT03458897|Diagnostic Test|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
79822023|NCT00744549|Drug|Placebo|Twice a day with meals.
79822024|NCT00746655|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
79224081|NCT03183245|Procedure|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
79224082|NCT03181971|Behavioral|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
79822025|NCT00746655|Procedure|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
79822026|NCT02564133|Device|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
79366610|NCT00615472|Drug|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
79519213|NCT00677586|Procedure|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
79519214|NCT00677586|Procedure|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
79822027|NCT00746811|Drug|P-OM3|4 grams/day - 4 one gram capsules
79822028|NCT00746811|Drug|Placebo|4 grams/day - 4 one gram capsules
79822029|NCT04060173|Drug|ABP-671|ABP-671 is an investigational drug
79822030|NCT04060173|Other|Placebo|Matching placebo
79822031|NCT00741429|Drug|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
79822032|NCT00741429|Drug|Comparator|Subjects previously treated with other anti-diabetic medications
79822033|NCT02563197|Device|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
79822034|NCT00741507|Behavioral|Alcohol drinking|Never drinking of alcohol
79366611|NCT00615472|Drug|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
79224083|NCT03164265|Biological|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
79366612|NCT00615784|Drug|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
79366613|NCT00755794|Drug|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
79366614|NCT00652444|Drug|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
79366615|NCT00652444|Drug|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
79366616|NCT00652444|Drug|Placebo (Unspecified)|Matching ezetimibe placebo
79366617|NCT00585910|Drug|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
79996068|NCT05420467|Drug|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
79996069|NCT05420467|Drug|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
79366618|NCT00489346|Drug|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
79366619|NCT00489346|Drug|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
79366620|NCT00617188|Drug|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
79822035|NCT00741507|Behavioral|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
79822036|NCT00741507|Behavioral|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
79224084|NCT03127774|Drug|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
79224085|NCT03127774|Drug|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
79224086|NCT03127774|Procedure|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
79366621|NCT00618436|Drug|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
79366622|NCT00618436|Drug|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
79366623|NCT04345900|Drug|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
79366624|NCT04345900|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
79366625|NCT00619060|Drug|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
79366626|NCT00619060|Drug|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
79366627|NCT00092716|Drug|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
79676314|NCT06154915|Other|medical treatments|All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
79676315|NCT06154902|Drug|Idecabtagene vicleucel|According to approved product label in France
79676316|NCT06154902|Other|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
79676317|NCT06154876|Device|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
79676318|NCT06154850|Other|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
79676319|NCT06154850|Other|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
79676320|NCT06154837|Drug|GSK3862995B|GSK3862995B will be administered.
79822037|NCT00741507|Behavioral|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
79822038|NCT00741507|Behavioral|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
79822039|NCT00688623|Drug|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
79822040|NCT02563821|Procedure|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
79822041|NCT02563821|Drug|Levobupivacaine|
79676321|NCT06154837|Drug|Placebo|Placebo will be administered.
79822042|NCT02563821|Drug|sufentanil|
79822043|NCT02563821|Drug|clonidine|
79822044|NCT02563821|Device|epidural catheter|
79996070|NCT05420467|Drug|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
79996071|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
79996072|NCT05420467|Drug|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
79519215|NCT05454930|Other|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
79519216|NCT05454774|Genetic|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10^13 vg/ kg
79519217|NCT05454540|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
79996073|NCT05420467|Drug|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
79676322|NCT06154798|Behavioral|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
79676323|NCT06154759|Other|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
79996074|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
79224087|NCT03120325|Device|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
79519218|NCT05454384|Other|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
79676324|NCT06154746|Diagnostic Test|slit lamb & OCT|"The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
79676325|NCT06154733|Procedure|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
79224088|NCT03116529|Combination Product|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as >10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
79996075|NCT05420467|Drug|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
79224089|NCT03104504|Behavioral|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
79224090|NCT03104504|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
79224091|NCT03104504|Behavioral|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
79996076|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
79996077|NCT03671460|Biological|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
79224092|NCT03104504|Behavioral|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
79519219|NCT05453838|Dietary Supplement|oral intake of one serving of the original and new product|1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
79519220|NCT05453448|Drug|tenofovir alafenamide|Antiviral therapy
79519221|NCT05453448|Drug|Entecavir|entecavir
79519222|NCT05453214|Drug|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
79996078|NCT03675204|Other|No intervention|No intervention
79822045|NCT02563587|Other|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
79519223|NCT05452980|Procedure|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
79519224|NCT05452980|Procedure|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
79519225|NCT05451498|Dietary Supplement|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum [1RM]) and endurance (repetitions to fatigue [RTF] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
79519226|NCT05451498|Dietary Supplement|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum [1RM]) and endurance (repetitions to fatigue [RTF] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
79224093|NCT03099681|Other|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
79519227|NCT05448300|Device|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
79519228|NCT05354466|Drug|Sugammadex injection|sugammadex as reversal agent
79519229|NCT05354466|Drug|Neostigmine|neostigmine as a reversal agent
79822046|NCT02563587|Other|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
79996079|NCT03671382|Behavioral|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
79996080|NCT02915874|Behavioral|Acceptance and Commitment Therapy|
79996081|NCT02818218|Procedure|Liver Transplant|liver transplant recipient surgery
79996082|NCT03675048|Dietary Supplement|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
79996083|NCT03675048|Dietary Supplement|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
79996084|NCT03022578|Procedure|Laser Interstitial Thermal Therapy|Undergo LITT
79996085|NCT03022578|Drug|Lomustine|Given PO
79996086|NCT03022422|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
79224094|NCT03080948|Behavioral|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
79224095|NCT03080948|Other|Saliva samples|Germline DNA analysis
79366628|NCT00092716|Drug|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
79366629|NCT00619684|Drug|lenalidomide|Given PO
79996087|NCT03022422|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
79224096|NCT03004833|Drug|Nivolumab|Infusion of Nivolumab
79224097|NCT03004833|Drug|Adriamycin|Infusion of Adriamycin
79224098|NCT03004833|Drug|Vinblastine|Infusion of Vinblastine
79224099|NCT03004833|Drug|Dacarbazine|Infusion of Dacarbazine
79366630|NCT00619762|Device|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
79366631|NCT01799122|Device|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
79366632|NCT05246956|Other|Intradialytic exercise|Intradialytic exercise group
79366633|NCT05246800|Other|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
79366634|NCT00588406|Drug|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
79366635|NCT00588406|Drug|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
79366636|NCT00588406|Drug|Ipratropium bromide|2.5 mg, one dose
79366637|NCT00588406|Drug|Prednisone|60mg PO
79519230|NCT05347602|Dietary Supplement|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
79366638|NCT00668434|Drug|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
79366639|NCT00668434|Drug|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
79519231|NCT05347602|Dietary Supplement|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
79224100|NCT02957981|Behavioral|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
79224101|NCT02957981|Behavioral|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
79224102|NCT02932111|Procedure|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
79224103|NCT02932111|Procedure|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
79224104|NCT02915263|Drug|IGIV-C|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
79224105|NCT02915263|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
79224106|NCT02845947|Behavioral|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
79224107|NCT02825160|Drug|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
79366640|NCT00668902|Drug|[13C]Pantoprazole|[13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
79519232|NCT05346432|Dietary Supplement|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
79676326|NCT06154733|Procedure|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
79676327|NCT06154733|Procedure|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
79676328|NCT06154694|Radiation|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~Relaxed standing (0 degree of abduction)~45 degree of abduction in the coronal plane~90 degree of abduction in the coronal plane~120 degree of abduction in the coronal plane~45 degree anterior flexion in the sagittal plane~90 degree anterior flexion in the sagittal plane~120 degree of anterior flexion in the sagittal plane~45 degree extension in the sagittal plane"
79822047|NCT02563587|Drug|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
79366641|NCT00669214|Drug|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
79519233|NCT05236140|Device|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
79519234|NCT05144490|Other|Exercise|A single session of bodyweight exercise
79366642|NCT00669214|Drug|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
79822048|NCT00717236|Drug|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
79822049|NCT00717236|Other|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
79224108|NCT02807597|Drug|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
79996088|NCT03023826|Drug|LY3202626 (R-Fasting)|Administered orally
79996089|NCT03023826|Drug|LY3202626 (T1-Fasting)|Administered orally
79996090|NCT03023826|Drug|LY3202626 (T1-Fed)|Administered orally
79996091|NCT03671070|Drug|Epinephrine|IV Low dose Boluses
79996092|NCT03671070|Drug|Traditional management of shock|"Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
79996093|NCT03670992|Procedure|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
79224109|NCT02807597|Device|Cancer Vision Goggles and standard fluorescence imaging systems|-Member of the operating team will wear the CVG during surgery
79224110|NCT02807597|Procedure|Surgery|-Standard of care
79224111|NCT02777892|Other|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
79224112|NCT02777606|Drug|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
79224113|NCT02777476|Device|B-Lite- Light Weight Breast Implants|
79224114|NCT02737462|Drug|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
79676329|NCT06154681|Other|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
79224115|NCT02735083|Biological|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
79366643|NCT00589888|Drug|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
79676330|NCT06154655|Other|E-zine|Health education will be delivered through an electronic magazine
79519235|NCT05137704|Other|No intervention|This is a non-interventional study.
79519236|NCT04971096|Dietary Supplement|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
79679930|NCT02937246|Device|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
79996094|NCT03670758|Diagnostic Test|Protein S activity|Intravenous blood sample
79996095|NCT03674658|Drug|Propafenone|oral, TID
79996096|NCT03674580|Behavioral|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
79996097|NCT03674502|Drug|ADU-1604|anti-CTLA-4 monoclonal antibody
79519237|NCT04971096|Dietary Supplement|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
79519238|NCT04971096|Dietary Supplement|Placebo|The placebo capsule contains microcrystalline cellulose.
79519239|NCT04880616|Drug|NBI-827104|Capsules for oral administration
79519240|NCT04880616|Drug|Placebo|Capsules matching NBI-827104 for oral administration
79519241|NCT04757766|Drug|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
79524810|NCT05767983|Other|Fat-free milk|Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
79822050|NCT04085354|Drug|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
79224116|NCT02631447|Drug|LGX818|LGX818 450 mg p.o. od
79224117|NCT02631447|Drug|MEK162|MEK162 45 mg p.o. bid
79224118|NCT02631447|Drug|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
79366644|NCT00589888|Drug|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
79519242|NCT04720404|Behavioral|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
79519243|NCT04720404|Other|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
79519244|NCT04720404|Other|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
79676331|NCT06154642|Diagnostic Test|Determination of arterial compliance using blood pressure waveform analysis|Measurement of arterial stiffness using a non-invasive pressure transducer placed on the skin of the wrist, which records the pulse wave at the level of the radial artery in order to analyze the characteristics of the arterial wall. The parameters of interest are the arterial stiffness of large- and small-caliber arteries (ml/mmHg).
79676332|NCT06154642|Diagnostic Test|Measurement of plasma Vascular Endothelium Growth Factor|Measurement of plasma Vascular Endothelium Growth Factor levels by ELISA
79822051|NCT04085354|Drug|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
79822052|NCT04085354|Drug|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
79822053|NCT04085354|Drug|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
79822054|NCT00719810|Drug|delafloxacin|300 mg intravenous every 12 hours
79822055|NCT00719810|Drug|delafloxacin|450 mg intravenous every 12 hours
79224119|NCT02631447|Drug|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
79224120|NCT02630615|Other|Blood draw|Whole blood will be collected using standard phlebotomy procedures
79822056|NCT00719810|Drug|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
79224122|NCT02483312|Biological|IL-12|
79224123|NCT02463266|Behavioral|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
79366645|NCT00589888|Drug|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
79519245|NCT04683900|Other|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
79524811|NCT05767983|Other|Fat-free yogurt|Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
79679931|NCT02937246|Device|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
79679932|NCT00522158|Drug|simvastatin|
79822057|NCT02591498|Behavioral|Computerized cognitive training|
79822058|NCT00719732|Device|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
79822059|NCT02590718|Procedure|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
79996098|NCT03623256|Drug|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
79996099|NCT03623256|Drug|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
79996100|NCT03623256|Drug|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
79224124|NCT02424656|Procedure|MRI|EEG-functional MRI, structural MRI, diffusion MRI
79224125|NCT02424656|Procedure|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
79366646|NCT00589888|Dietary Supplement|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
79822060|NCT00723710|Biological|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
79996101|NCT03623256|Drug|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
79519246|NCT04683900|Other|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
79519247|NCT04608396|Drug|AXS-05|AXS-05 taken daily for up to 52 weeks, until relapse.
79519248|NCT04608396|Drug|Placebo|Placebo taken daily for up to 52 weeks, until relapse.
79519249|NCT04561128|Drug|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
79519250|NCT04561128|Drug|Placebo|Placebo will be subcutaneously administered with different dose levels
79519251|NCT04095624|Behavioral|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
79519252|NCT04095624|Other|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
79519253|NCT03745716|Drug|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
79519254|NCT03745716|Drug|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
79519255|NCT03651336|Device|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
79676333|NCT06154642|Diagnostic Test|Skin temperature gradient|Measurement of skin surface temperature gradient, defined as the difference in temperature between the skin surface of the forearm and that of the fingertip (forearm-to-fingertip)
79676334|NCT06154642|Diagnostic Test|Vaso-occlusion test|Measurement of endothelial function by a vaso-occlusion test performed by inflating a cuff on the arm to occlude arterial flow for 3 min. Reactive hyperemia on deflation of the cuff is measured by photoplethysmography placed on the index finger, and tissue oxygen saturation (StO2) by near-infrared spectroscopy (NIRS). The amplitude of the reperfusion flow corresponding to the peak of the perfusion index (ΔPI Peak) and the time to reach this peak (time to peak) are the parameters recorded by photoplethysmography. Tissue resaturation rate (rStO2) is the parameter recorded by NIRS.
79676335|NCT06154642|Diagnostic Test|Transthoracic echocardiography|The diameter of the left ventricular outflow tract is measured in the tele systolic parasternal long-axis view. The pulsed Doppler flow profile is acquired at the level of the left ventricular chamber in the apical five-chamber view. The time-velocity integral of the aortic flow is then calculated. Left ventricular end-diastolic and end-systolic volumes are also measured using Simpson's method in the 4-cavity monoplane view. Measurements of vena cava diameter and respiratory variability of vena cava diameter provide an estimate of right atrial pressure. These measurements estimate cardiac output and systemic vascular resistance.
79224126|NCT02424656|Procedure|FDG-PET|
79224127|NCT02424656|Other|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
79224128|NCT02415933|Behavioral|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~Provision of seed grants to assist in business start-ups through microfinance loans;~One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~Trainings on financial planning and household livelihoods."
79366647|NCT00589888|Dietary Supplement|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
79366648|NCT00669682|Other|Congestive heart failure|Spontaneous occurrence of fluid overload.
79519256|NCT03395340|Drug|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
79676336|NCT06154642|Diagnostic Test|Photoplethysmography|The perfusion index (PI) is derived from the signal and represents the ratio between the absorbance or reflectance of pulsatile and non-pulsatile light of the photoplethysmography signal. PI is measured non-invasively using a photoplethysmographic sensor placed on the earlobe or finger.
79366649|NCT00669916|Biological|AIN457|single infusion of 3 mg/kg
79366650|NCT00669916|Drug|Placebo|single infusion of placebo
79679933|NCT00522158|Drug|atorvastatin|
79996102|NCT03674268|Diagnostic Test|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
79996103|NCT02661672|Device|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
79366651|NCT00621946|Drug|Placebo|Placebo Matching Escitalopram
79366652|NCT00621946|Drug|Escitalopram|Active Escitalopram
79366653|NCT00591760|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
79224129|NCT02415933|Behavioral|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
79519257|NCT03395340|Drug|vehicle cream|Matching vehicle cream applied as a thin film
79676337|NCT06154642|Procedure|Transcatheter aortic valve insertion (TAVI)|TAVI is a treatment for aortic valve stenosis. A new valve is inserted with minimally invasive procedure without removing the old, damaged valve.
79224130|NCT02390869|Drug|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
79676338|NCT06154603|Procedure|Surgical treatment type|This observational design will study the clinical outcome for each type of upper gastrointestinal perforation in relation to surgical or non-surgery treatment and in relation to treatment centre.
79679934|NCT02937324|Device|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
79679935|NCT02937324|Other|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
79224131|NCT02390869|Drug|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
79224132|NCT02343952|Drug|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
79366654|NCT00623506|Drug|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
79224133|NCT02281513|Other|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
79224134|NCT02281513|Other|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
79224135|NCT02281513|Other|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
79224136|NCT02250937|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
79366655|NCT00623506|Drug|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
79366656|NCT02139358|Drug|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
79519258|NCT03341676|Drug|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
79519259|NCT03341676|Drug|Placebo|Sodium Chloride 0.9% w/v solution for injection
79519260|NCT03121716|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
79519261|NCT03121716|Drug|Gemcitabine|gemcitabine
79519262|NCT03121716|Drug|cis-platinum|cis-platinum
79519263|NCT02714634|Drug|Methotrexate + targeted therapy administration|"Methotrexate or leflunomide + adalimumab or~Methotrexate or leflunomide + certolizumab or~Methotrexate or leflunomide + etanercept or~Methotrexate or leflunomide + golimumab or~Methotrexate or leflunomide + infliximab or~Methotrexate or leflunomide + abatacept or~Methotrexate or leflunomide + rituximab or~Methotrexate or leflunomide + tocilizumab or~Methotrexate or leflunomide + sarilumab or~Methotrexate or leflunomide + filgotinib or~Methotrexate or leflunomide + upadacitinib or~Methotrexate or leflunomide + Tofacitinib or~Methotrexate or leflunomide + baricitinib"
79519264|NCT02714634|Drug|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
79519265|NCT00553800|Drug|bevacizumab|
79519266|NCT00553800|Drug|Erlotinib|
79679936|NCT00522197|Dietary Supplement|multi-herbal agent ACAPHA|
79679937|NCT00522197|Dietary Supplement|Sugar Pill|
79996104|NCT02661672|Device|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
79224137|NCT02250937|Drug|Busulfan|Given IV
79224138|NCT02250937|Drug|Cladribine|Given IV
79224139|NCT02250937|Drug|Fludarabine Phosphate|Given IV
79224140|NCT02250937|Other|Laboratory Biomarker Analysis|Correlative studies
79224141|NCT02250937|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
79366657|NCT02139358|Drug|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
79366658|NCT02139358|Drug|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
79366659|NCT02140372|Drug|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
79519267|NCT02747628|Drug|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
79676339|NCT06154590|Drug|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
79366660|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
79996105|NCT03669510|Other|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
79996106|NCT03674190|Procedure|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
79996107|NCT03674190|Procedure|Total Disc Replacement|Total Disc Replacement
79224142|NCT02250937|Other|Pharmacological Study|Correlative studies
79366661|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
79366662|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
79366663|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
79366664|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
79366665|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
79676340|NCT06154590|Drug|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
79996108|NCT03674034|Other|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
79996109|NCT03670290|Procedure|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
79224143|NCT02250937|Drug|Venetoclax|Given PO
79224144|NCT02223208|Drug|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~14mg/ms day +1 and +8~10mg/ms day +1 and +8~8mg/ms day +1 and +8~CHOEP-21~Doxorubicin 50 mg/ms iv day +1 or +2,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~Cyclophosphamide 750 mg/ms iv day +1 or +2~Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
79224145|NCT02223208|Drug|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~Romidepsin dose according to phase I iv day +1 and +8~Doxorubicin 50 mg/ms iv day +1 or +2,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~Cyclophosphamide 750 mg/ms iv day +1 or +2~Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
79366666|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
79366667|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
79366668|NCT00624442|Drug|Placebo|IV infusion for 2 hours
79519268|NCT02747628|Drug|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
79366669|NCT00624442|Drug|Placebo|IV infusion for 24 hours
79519269|NCT02747628|Drug|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
79519270|NCT02748096|Procedure|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
79519271|NCT02748096|Procedure|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
79519272|NCT02754570|Drug|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
79519273|NCT02756910|Device|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
79366670|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
79366671|NCT00624442|Drug|Placebo|IV infusion for 72 hours
79366672|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
79366673|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
79366674|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
79366675|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
79519274|NCT02760264|Drug|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
79519275|NCT02760264|Drug|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
79519276|NCT02760264|Drug|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
79519277|NCT02760264|Drug|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
79822061|NCT04085198|Procedure|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
79996110|NCT03670290|Procedure|epidural catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
79676341|NCT06154577|Diagnostic Test|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
79676342|NCT06154551|Diagnostic Test|Paxillin biomarker|Paxillin used as a salivary biomarker
79224146|NCT02043964|Procedure|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
79676343|NCT06154538|Drug|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
79224147|NCT01891422|Other|Non-interventional.|
79366676|NCT00670462|Behavioral|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
79366677|NCT00670462|Behavioral|Maintenance-Tailored Treatment (MTT)|
79366678|NCT00670774|Drug|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
79366679|NCT00672100|Drug|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
79676344|NCT06154538|Drug|FOLFOX regimen|FOLFOX chemotherapy
79676345|NCT06154499|Procedure|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
79676346|NCT06154486|Drug|semaglutide use|patient using semaglutide for at least 7 days
79676347|NCT06154473|Procedure|Open heart surgery group.|Patients undergoing open heart surgery.
79676348|NCT06154473|Procedure|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
79822062|NCT04085198|Procedure|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
79224148|NCT01872208|Biological|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
79676349|NCT06154460|Procedure|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
79676350|NCT06154460|Procedure|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
79996111|NCT03670290|Procedure|patient controlled analgesia|Patient will evaluate and if VAS score >3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
79996112|NCT03166735|Drug|BI 1467335|once daily
79996113|NCT03166735|Drug|Placebo|once daily
79996114|NCT03082014|Drug|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
79676351|NCT06154460|Procedure|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
79676352|NCT06154395|Procedure|OCT-guided PCI|The OCT guidance team routinely conducts OCT examinations on patients after standard angiography and/or thrombus aspiration. The OCT examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on OCT image features. After stent implantation, a follow-up OCT examination of the stent segment, as well as angiographic examination, is performed. Based on the OCT results, the operator decides whether post-dilation is necessary.
79822063|NCT02590796|Other|No intervention given to participants|This is an observational study. Participants will receive no intervention.
79822064|NCT00688545|Drug|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
79996115|NCT03082014|Drug|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
79996116|NCT03082014|Drug|Atenolol|blood pressure lowering agent - beta-blocker
79996117|NCT02750605|Device|DEB|Intervention with drug eluting balloon.
79996118|NCT02750605|Device|POBA|Intervention with old technology as comparison
79519278|NCT02764164|Device|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
79519279|NCT02767128|Drug|Triferic|
79519280|NCT02767128|Drug|Fer-In-Sol|
79519281|NCT02767128|Drug|Shohl's solution|
79519282|NCT02769702|Drug|Acthar|Acthar 80 IU SC twice a week
79366680|NCT00672100|Drug|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
79519283|NCT02770014|Drug|Erlotinib|
79519284|NCT02771340|Biological|ICON-1|Intravitreal injection of ICON-1
79519285|NCT02771574|Drug|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
79519286|NCT02771574|Drug|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
79519287|NCT02772432|Behavioral|Relaxation Response Resiliency Training for Parents of SPLD|
79822065|NCT00688545|Drug|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
79822066|NCT02563275|Other|motion analysis system|
79822067|NCT02563275|Other|parabolic flight|
79822068|NCT04060407|Drug|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
79366681|NCT00672100|Drug|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
79366682|NCT00593866|Radiation|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
79366683|NCT00593866|Drug|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
79366684|NCT00624910|Drug|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
79366685|NCT00624910|Drug|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
79366686|NCT00594022|Device|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
79519288|NCT02772666|Device|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
79519289|NCT02772666|Other|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
79519290|NCT02773758|Other|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
79519291|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
79519292|NCT02773836|Other|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
79519293|NCT02774226|Drug|Tetrahydrobiopterin (BH4)|12 week intervention
79519294|NCT02774226|Dietary Supplement|Antioxidant Cocktail|12 week intervention
79519295|NCT02774616|Device|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
79519296|NCT02774616|Device|Plexa ICD lead|predefined follow-up schedule
79519297|NCT02775240|Drug|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
79519298|NCT02775240|Drug|Maribavir|200mg twice a day for 8 days
79519299|NCT02775240|Drug|Dextromethorphan|30 mg oral dose
79519300|NCT02777268|Drug|Infacort|Multi-particulate granules
79519301|NCT02777268|Drug|Hydrocortisone|Tablet
79519302|NCT05350020|Drug|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
79519303|NCT05350020|Drug|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
79519304|NCT05349942|Device|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
79519305|NCT05349786|Other|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
79822069|NCT04060407|Drug|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
79822070|NCT04060407|Drug|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
79822071|NCT00741585|Drug|Any antihypertensive medication alone or in combination|All drugs on awakening
79366687|NCT00594022|Device|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
79366688|NCT00626626|Drug|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
79519306|NCT05349708|Device|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
79519307|NCT05349396|Drug|Eszopiclone 3mg Test Drug T-1 Coated Tablets|Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
79519308|NCT05349396|Drug|Eszopiclone 3mg Test Drug T-2 Coated Tablets|Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
79519309|NCT05349396|Drug|Eszopiclone 3mg Reference Product Coated Tablets|Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
79519310|NCT05349162|Device|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
79519311|NCT05348148|Drug|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
79519312|NCT05348148|Drug|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
79519313|NCT05348148|Drug|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
79519314|NCT05348070|Procedure|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
79519315|NCT05266482|Other|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
79519316|NCT05264688|Diagnostic Test|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
79822072|NCT00741585|Drug|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
79519317|NCT05456022|Drug|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying < 4 % _ Purity (HPLC) > 95 %"
79822073|NCT00741585|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
79224149|NCT01798407|Device|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
79224150|NCT01798407|Other|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
79822074|NCT00746967|Drug|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
79519318|NCT05456022|Drug|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
79519319|NCT05456022|Drug|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
79676353|NCT06154395|Procedure|60 MHz HD-IVUS-guided PCI|The IVUS guidance team routinely conducts IVUS examinations on patients after standard angiography and/or thrombus aspiration. The IVUS examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on IVUS image features. After stent implantation, a follow-up IVUS examination of the stent segment, as well as angiographic examination, is performed. Based on the IVUS results, the operator decides whether post-dilation is necessary.
79676354|NCT06154395|Procedure|Angiography-guided PCI|After routine angiography and/or thrombus aspiration, the operator assesses the lesion based on treatment standards to determine whether stent implantation is necessary. For patients undergoing stent implantation, a follow-up angiography is performed postoperatively, and the decision for post-dilation is made by the operator based on experience.
79676355|NCT06154382|Drug|Eltroxin administration|eltroxin administration
79822075|NCT02563041|Drug|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
79822076|NCT02563041|Drug|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
79366689|NCT00626626|Drug|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
79366690|NCT00673114|Biological|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
79366691|NCT00626782|Drug|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
79366692|NCT00626782|Drug|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
79822077|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
79519320|NCT05455866|Device|central venous catheter|collection and descriptionof central venous catheter-related complications
79519321|NCT05455788|Drug|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
79519322|NCT05455554|Diagnostic Test|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
79822078|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
79822079|NCT00745017|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
79366693|NCT00594256|Drug|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
79366694|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
79519323|NCT05455554|Diagnostic Test|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
79519324|NCT05455398|Procedure|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
79519325|NCT05455398|Procedure|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
79519326|NCT05455242|Behavioral|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
79519327|NCT05455164|Dietary Supplement|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
79676356|NCT06154369|Behavioral|JoyPop|Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
79676357|NCT06154343|Drug|GQ1005|an antibody drug conjugate
79676358|NCT06154304|Drug|Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)|90 mcg
79676359|NCT06154304|Drug|Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1|90 mcg
79676360|NCT06154304|Drug|Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2|180 mcg
79676361|NCT06154304|Drug|Placebo|Placebo
79676362|NCT06154200|Drug|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
79224151|NCT01793493|Other|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~body awakening (10 minutes)~cognitive stimulation (1 hour and a half) scheduled as follow:~temporospatial orientation~attentional abilities~one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
79519328|NCT05451420|Drug|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
79676363|NCT06154200|Drug|Vehicle gel|Vehicle gel applied to eyelids twice per day
79822080|NCT00745017|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
79822081|NCT00745017|Drug|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
79822082|NCT00688467|Drug|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
79822083|NCT00688467|Drug|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
79224152|NCT01793493|Other|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
79224153|NCT01744418|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
79224154|NCT01710176|Drug|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
79224155|NCT01710176|Drug|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
79224156|NCT01710176|Drug|trabectedin 1.3 mg/m2|
79224157|NCT01710176|Drug|high-dose ifosfamide 14 g/m2, given in in 14 days|
79224158|NCT01710176|Drug|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
79224159|NCT01710176|Drug|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
79366695|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
79366696|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
79519329|NCT05324124|Drug|Selpercatinib|Administered orally.
79519330|NCT05305092|Device|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
79519331|NCT05273814|Drug|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
79822084|NCT00741741|Drug|TMC278|
79822085|NCT02562807|Drug|TAS-303 18mg single-dose|
79224160|NCT01660971|Drug|Dasatinib|Given PO
79224161|NCT01660971|Drug|Erlotinib Hydrochloride|Given PO
79224162|NCT01660971|Drug|Gemcitabine Hydrochloride|Given IV
79224163|NCT01644357|Other|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
79224164|NCT01639573|Drug|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
79224165|NCT01592370|Biological|Nivolumab|Administered by intravenous (IV) infusion
79224166|NCT01592370|Biological|Ipilimumab|Administered by IV infusion
79224167|NCT01592370|Biological|Lirilumab|Administered by IV infusion
79366697|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
79519332|NCT05273814|Drug|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
79519333|NCT05273814|Drug|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
79676364|NCT06154187|Drug|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
79676365|NCT06154187|Drug|Placebo|Placebo was formulated similar to abaloparatide-SC.
79676366|NCT06149299|Procedure|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
79676367|NCT06149234|Behavioral|Fruit leather on the tongue|The patient holds a fruit leather strip on the tongue while being exposed.
79676368|NCT06149234|Behavioral|Chewing gum strip|The patient holds a banana-tasting gum strip on the tongue while being exposed.
79822086|NCT02562807|Drug|Placebo 18mg single-dose|
79822087|NCT02562807|Drug|TAS-303 9mg single-dose|
79822088|NCT02562807|Drug|Placebo 9mg single-dose|
79822089|NCT00745173|Drug|Premarin|
79822090|NCT00747045|Other|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
79519334|NCT05215080|Dietary Supplement|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
79224168|NCT01592370|Biological|Daratumumab|Administered by IV infusion
79366698|NCT00673738|Drug|Cetuximab|"Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
79366699|NCT00673738|Radiation|Conformal Thoracic Radiotherapy (CTRT)|"Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study."
79676369|NCT06149234|Behavioral|Celluloid matrix group|The patient holds a celluloid matrix stirp gum strip on the tongue while being exposed.
79676370|NCT06149182|Behavioral|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
79366700|NCT00674206|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
79366701|NCT00674206|Drug|Oxaliplatin|Oxaliplatin 100mg/m^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
79366702|NCT00595270|Biological|IC51|
79996119|NCT03673566|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
79224169|NCT01592370|Drug|Pomalidomide|Administered PO
79366703|NCT00628498|Drug|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
79366704|NCT00628498|Drug|Defibrotide|
79366705|NCT00629122|Drug|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
79519335|NCT05006118|Drug|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
79519336|NCT04963218|Diagnostic Test|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
79519337|NCT04867044|Other|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
79519338|NCT04867044|Other|Control|healthy woman volunteers
79519339|NCT04784208|Diagnostic Test|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
79519340|NCT04775004|Other|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
79676371|NCT06149182|Behavioral|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
79996120|NCT05320159|Drug|Secukinumab|Included all the patients treated with secukinumab
79996121|NCT03670212|Drug|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
79996122|NCT03670212|Drug|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
79224170|NCT01592370|Drug|Dexamethasone|Administered PO and by IV infusion
79224171|NCT01552356|Other|Laboratory Biomarker Analysis|Correlative studies
79224172|NCT01552356|Drug|Pazopanib Hydrochloride|Given PO
79224173|NCT01552356|Other|Pharmacological Study|Correlative studies
79224174|NCT01495637|Drug|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
79224175|NCT01437709|Biological|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
79676372|NCT06148818|Other|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
79676373|NCT06148818|Other|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
79224176|NCT01437709|Other|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 & 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
79224177|NCT01093183|Drug|lenalidomide|Given PO
79224178|NCT01093183|Drug|cyclophosphamide|Given PO
79224179|NCT01093183|Other|laboratory biomarker analysis|Correlative studies
79224180|NCT01093183|Other|questionnaire administration|Ancillary studies
79224181|NCT01093183|Other|quality-of-life assessment|Ancillary studies
79224182|NCT00848315|Behavioral|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
79224183|NCT00777036|Drug|Dasatinib|
79224184|NCT00720720|Dietary Supplement|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
79366706|NCT00629122|Drug|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
79366707|NCT00629122|Drug|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
79519341|NCT04775004|Other|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
79519342|NCT04504188|Device|Heart Rate Monitor Enhanced Treatment Optimization|Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
79996123|NCT03670212|Drug|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
79224185|NCT00720720|Dietary Supplement|placebo margarine|
79224186|NCT00641225|Drug|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
79224187|NCT00176644|Drug|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
79224188|NCT00106171|Drug|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
79224189|NCT00045201|Drug|Erlotinib Hydrochloride|Given orally
79224190|NCT00045201|Drug|Irinotecan Hydrochloride|Given IV
79224191|NCT03327038|Behavioral|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
79224192|NCT03327038|Other|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
79519343|NCT04063956|Behavioral|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
79519344|NCT04063956|Behavioral|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
79519345|NCT04024878|Drug|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
79519346|NCT04024878|Biological|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
79676374|NCT06148636|Drug|[212Pb] VMT-α-NET|Up to 2 infusions with [212Pb] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
79676375|NCT06148636|Diagnostic Test|[203Pb] VMT-α-NET SPECT/CT|The [203Pb] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . [203Pb] VMT-α-NET, a radioactive tracer drug.
79996124|NCT03673488|Device|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
79996125|NCT03165955|Drug|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
79224193|NCT03327038|Behavioral|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
79224194|NCT03327038|Other|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
79366708|NCT00629122|Drug|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
79366709|NCT00596440|Drug|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
79366710|NCT00631852|Drug|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
79519347|NCT04024878|Procedure|Core Needle Biopsy|Surgical procedure
79519348|NCT04004520|Behavioral|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
79519349|NCT04004520|Behavioral|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
79519350|NCT04004520|Behavioral|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
79519351|NCT03686514|Biological|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
79519352|NCT03004248|Biological|Botulinum Toxins, Type A|Intramuscular Injection
79519353|NCT02529930|Biological|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
79676376|NCT06145360|Drug|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
79519354|NCT00039780|Drug|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
79519355|NCT00039780|Drug|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
79519356|NCT04961034|Procedure|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
79519357|NCT04951518|Other|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
79519358|NCT04945356|Other|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
79224195|NCT03327038|Other|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
79224196|NCT03326960|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
79224197|NCT03326960|Drug|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
79224198|NCT03326960|Drug|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
79224199|NCT03319394|Behavioral|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
79224200|NCT03319394|Behavioral|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
79366711|NCT00632632|Drug|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
79366712|NCT00632632|Other|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
79366713|NCT00633256|Drug|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
79366714|NCT00633256|Drug|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
79366715|NCT00634270|Drug|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
79366716|NCT00635128|Biological|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
79366717|NCT00676780|Drug|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
79366718|NCT00678418|Drug|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
79366719|NCT00678418|Drug|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
79519359|NCT04902300|Other|Data collection|evaluation of internet addiction
79519360|NCT04845282|Dietary Supplement|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
79676377|NCT06145360|Drug|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
79519361|NCT04845282|Dietary Supplement|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
79519362|NCT04763226|Drug|BMS-986308|Specified dose on specified days
79519363|NCT04763226|Other|Placebo (for BMS-986308)|Specified dose on specified days
79224201|NCT04669444|Device|Ventilator|The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
79224202|NCT03319238|Other|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
79519364|NCT04763226|Drug|Furosemide|Specified dose on specified days
79224203|NCT04664608|Device|wearable EEG sensor|Wireless wearable EEG devices offer a new, non-invasive, and easy way of performing EEG monitoring.
79224204|NCT03321890|Drug|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
79224205|NCT03321890|Drug|prednisone|oral, 20mg / day,after breakfast
79224206|NCT03321890|Drug|Cyclophosphamide|oral, 50mg / day,after lunch
79224207|NCT03321890|Drug|etoposide|oral, 50mg / day,after dinner
79224208|NCT03321890|Drug|Methotrexate|oral, 10mg / times, once a week,after breakfast
79224209|NCT02487368|Device|Needle stimulation pad|
79224210|NCT05499910|Behavioral|NSBAA|The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
79519365|NCT04695678|Diagnostic Test|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
79519366|NCT04636008|Drug|Sintilimab|Sintilimab+Hypofractionated radiotherapy
79676378|NCT06143644|Other|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
79676379|NCT06126419|Drug|High-Dose Insulin Therapy|A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is > mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is < 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
79676380|NCT06117761|Other|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
79366720|NCT00678496|Other|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
79366721|NCT00678496|Other|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
79519367|NCT04636008|Radiation|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
79519368|NCT04549428|Drug|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
79676381|NCT06117761|Other|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
79224211|NCT03319160|Device|Defibrillation|Wearable Cardioverter Defibrillator
79224212|NCT05504824|Other|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
79224213|NCT04492748|Combination Product|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
79224214|NCT04492748|Combination Product|Collagen|Ultrasound guided injections
79224215|NCT04492748|Combination Product|Platelet rich plasma (PRP)|Ultrasound guided injections
79519369|NCT06085378|Drug|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
79519370|NCT06085378|Other|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
79519371|NCT06085365|Drug|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
79519372|NCT06085365|Drug|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
79519373|NCT06085352|Drug|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
79519374|NCT06085352|Device|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
79519375|NCT06085287|Device|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
79519376|NCT06085274|Procedure|ICG guided sentinel lymph node biopsy|During sentinel lymph node biopsy the surgeon will inject a volume of 0.1ml divided into 2 doses (0.05ml each) of 2.5mg/mL ICG into the periareolar dermis of the involved breast. Technetium and blue dye will also be administered as per standard of care. The surgeon will assess the axilla with the the SPY-PHI near infrared imaging system to identify and remove ICG-fluorescent nodes; Any other sentinel lymph nodes identified will also be removed as per standard of care. If there is no progression of ICG towards the axilla, or if no ICG sentinel lymph node can be identified, an alternate injection technique involving peritumoural injection at 2-3 locations near the cancer site in the subcutaneous or dermal space of 0.05ml will be utilized.
79676382|NCT06117761|Other|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
79676383|NCT06115993|Drug|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
79676384|NCT06115993|Drug|Placebo|Placebo will be administered subcutaneously. CHB patients not receiving any NA therapy will not receive placebo.
79676385|NCT06107335|Drug|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to >13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
79224216|NCT05504668|Dietary Supplement|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
79224217|NCT03326882|Device|Endotracheal intubation|
79224218|NCT05464394|Drug|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
79224219|NCT05464394|Drug|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
79366722|NCT00599248|Biological|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
79524812|NCT05767983|Other|Low-fat cheese|Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
79524813|NCT05767983|Other|Fruit juice|Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
79524814|NCT05767983|Other|Snack skipping|Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
79524815|NCT05767957|Other|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
79676386|NCT06107335|Drug|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
79996126|NCT03669978|Procedure|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
79224220|NCT05464316|Device|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
79366723|NCT00599248|Biological|Placebo|Placebo control (DMEM)
79366724|NCT00599872|Biological|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
79366725|NCT00599872|Biological|Placebo|Placebo, sublingual oral
79366726|NCT00600340|Biological|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
79366727|NCT00600340|Biological|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
79366728|NCT01799356|Drug|Moxifloxacin|daily 400 mg moksifloksasin
79366729|NCT01799356|Drug|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
79366730|NCT01799356|Drug|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
79996127|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
79519377|NCT06085261|Behavioral|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
79676387|NCT06107335|Device|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
79676388|NCT06101290|Device|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
79676389|NCT06100549|Other|No intervention|No intervention will be provided.
79676390|NCT06099691|Behavioral|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
79224221|NCT05464316|Device|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
79224222|NCT05499754|Other|pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL|a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
79224223|NCT03321812|Procedure|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
79224224|NCT03321812|Procedure|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
79224225|NCT05499598|Procedure|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
79224226|NCT05499598|Procedure|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
79224227|NCT04476082|Other|No intervention - observational study only|No intervention - observational study only
79224228|NCT05232656|Behavioral|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
79224229|NCT04442750|Procedure|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
79366731|NCT00602290|Drug|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
79366732|NCT00602290|Drug|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
79519378|NCT06085261|Behavioral|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
79224230|NCT04442750|Procedure|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
79676391|NCT06095687|Behavioral|Mindfulness Meditation|Five, 20-minute audio-recorded training sessions of mindfulness of breath and body meditation, practiced over consecutive days, delivered remotely via Qualtrics.
79224231|NCT04442750|Drug|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
79224232|NCT04442750|Drug|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
79224233|NCT04442750|Drug|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
79519379|NCT06085248|Device|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
79224234|NCT05499364|Behavioral|TinCat|7-10 minute personalized video sessions based in tobacco cessation modules.
79224235|NCT05499364|Behavioral|Quit.gov program|7-10 minute generic videos directing participants through quit.gov program
79224236|NCT03319004|Device|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
79224237|NCT03318848|Other|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
79519380|NCT06085248|Behavioral|Active walking|walking without RAS cue
79519381|NCT06085235|Behavioral|exercise|cycling exercise for 15min, with 5min warm up
79519382|NCT06085196|Behavioral|Mindful walking activity|Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months
79676392|NCT06095687|Behavioral|Clinical Hypnosis|Five, 20-minute audio-recorded training sessions of clinical hypnosis with suggestions targeting pain management, practiced over consecutive days, delivered remotely via Qualtrics.
79822091|NCT04060095|Procedure|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
79519383|NCT06085183|Other|Saline Injection 0.9%|Placebo
79676393|NCT06091969|Dietary Supplement|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
79676394|NCT06091969|Dietary Supplement|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
79676395|NCT06066359|Drug|Fludarabine phosphate|Given by (IV) vein
79676396|NCT06066359|Drug|Cyclophosphamide|Given by (IV) vein
79676397|NCT06066359|Drug|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
79224238|NCT05333224|Other|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
79224239|NCT05333224|Other|Control|Family-centered, goal-oriented early physiotherapy approaches will be applied.
79224240|NCT02490566|Other|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
79224241|NCT05504200|Other|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
79224242|NCT02487290|Device|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
79224243|NCT05294458|Drug|cotadutide solution for injection|cotadutide solution for injection
79224244|NCT02491190|Behavioral|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
79519384|NCT06085183|Drug|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
79519385|NCT06085170|Diagnostic Test|Acoustic Analysis by MDVP|Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
79519386|NCT06085118|Other|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
79519387|NCT06085105|Behavioral|CPIPE Training|A two day training covering the following topics: understanding stress & burnout and developing positive coping mechanisms, bias awareness & mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
79519388|NCT06085105|Behavioral|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
79519389|NCT06085105|Behavioral|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
79519390|NCT06085105|Behavioral|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
79676398|NCT06049199|Other|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
79676399|NCT06039566|Drug|IV N-acetylcysteine|N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
79676400|NCT06039566|Drug|IV Placebo|Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
79996128|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
79224245|NCT05564572|Other|Routine Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
79224246|NCT02490410|Dietary Supplement|protein supplement|
79224247|NCT03326648|Other|Strength training|Heavy load strength training performed twice a week for 10 weeks.
79224248|NCT03326648|Dietary Supplement|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
79224249|NCT04649164|Behavioral|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
79519391|NCT06085105|Behavioral|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
79519392|NCT06085079|Drug|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
79519393|NCT06085027|Procedure|Labor analgesia|Perform epidrual analgesia for parturients between 18 to 45 year-old
79519394|NCT06085014|Other|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
79519395|NCT06085014|Other|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
79676401|NCT06030622|Drug|C3 (Metformin, Simvastatin, and Digoxin)|Combination treatment of Metformin, Simvastatin and Digoxin, with standard of care Gemcitabine.
79996129|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
79224250|NCT04649164|Other|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
79519396|NCT06085001|Diagnostic Test|Lumella finger prick blood test|Finger prick blood test
79996130|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
79224251|NCT02490956|Biological|Verorab® (PVRV; Purified Vero Cell Vaccine)|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
79224252|NCT03326570|Behavioral|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
79224253|NCT03326414|Procedure|Constant PEEP - low tidal volume|The respirator is set according to study protocol
79224254|NCT03326414|Procedure|Constant PEEP - high tidal volume|The respirator is set according to study protocol
79676402|NCT06029010|Drug|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
79676403|NCT06025253|Device|Negative Pressure Wound Therapy|Application of negative-pressure wound therapy (NPWT) post major lower extremity amputation
79676404|NCT06025253|Device|Standard Wound Dressing|Application of standard wound dressing post major lower extremity amputation
79676405|NCT06023433|Device|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
79996131|NCT05192473|Device|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
79996132|NCT05184673|Other|Behavioral and environmental|These are all active comparator yoga sequences
79996133|NCT03055494|Biological|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
79996134|NCT03055494|Biological|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
79519397|NCT06084975|Procedure|Splenic vessels preservation|preservation the splenic vessels
79519398|NCT06084962|Biological|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
79519399|NCT06084949|Device|Nordic walking or inspiratory muscle training|Nordic walking is a form of low-impact aerobic exercise that incorporates the use of walking poles. And inspiratory muscle training is a type of exercise that provides resistance during the inhalation phase.
79996135|NCT03673410|Procedure|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
79996136|NCT03673410|Procedure|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
79519400|NCT06084923|Other|Observation|Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
79519401|NCT06084910|Behavioral|Cultural Pride Reinforcement for Early School Readiness|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) is based on the nationwide Reach Out and Read (ROR) program adapted to reinforce cultural pride. ROR provides children's books, brief book-sharing advice, and developmental surveillance at pediatric well child visits. Each of the 5 CPR4ESR sessions provides 1 children's book with a cultural pride theme, 1 parent handout, and modeling of book-sharing.
79519402|NCT06084910|Behavioral|Reach Out and Read|ROR provides children's books and brief book-sharing advice at pediatric well child visits
79366733|NCT00602290|Drug|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
79519403|NCT06084858|Other|Dialysate bicarbonate modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
79519404|NCT06084819|Drug|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"Azacytidine (75mg/m2/day, days 1 to 7).~Cytarabine (75-100mg/m2 q12h, days 1 to 5).~Aclacinomycin(20mg/day, days 1,3,5).~Chidamide(30mg/day , days 1,4,8,11).~Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
79519405|NCT06084819|Drug|Best-Available Therapy(BAT) Regimen|"FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5)."
79519406|NCT06084806|Drug|[18F]F-ARAG PET|Two imaging sessions
79224255|NCT03326414|Procedure|constant tidal volume - low PEEP|The respirator is set according to study protocol
79224256|NCT03326414|Procedure|constant tidal volume - high PEEP|The respirator is set according to study protocol
79224257|NCT03326258|Drug|Glembatumumab Vedotin|Given IV
79366734|NCT00637780|Drug|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
79366735|NCT00638014|Device|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
79224258|NCT03326258|Biological|Ipilimumab|Given IV
79224259|NCT03326258|Other|Laboratory Biomarker Analysis|Correlative studies
79224260|NCT03326258|Biological|Nivolumab|Given IV
79224261|NCT03326258|Other|Pharmacological Study|Correlative studies
79366736|NCT00638014|Device|Conventional wire closure|Conventional wire closure of sternum
79366737|NCT00680524|Other|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
79366738|NCT01799902|Drug|Solifenacin|Oral
79366739|NCT00602446|Drug|deferasirox|20 mg/kg once daily orally for 6 months
79366740|NCT00635830|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
79224262|NCT05564260|Behavioral|Kaleidescope|watching kaleidescope
79224263|NCT05564260|Behavioral|Virtual Reality|wearing virtual reality glasses
79224264|NCT05564182|Device|High intensity laser therapy|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). It will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect.
79366741|NCT00638716|Drug|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
79366742|NCT00638716|Drug|Placebo|Placebo
79366743|NCT00602836|Biological|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m^2 by IV on day 2 Cycle 2-6: 375 mg/m^2 by IV on day 1 (every 21 days)
79366744|NCT00602836|Drug|Cyclophosphamide|600 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
79366745|NCT00602836|Drug|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
79996137|NCT02445768|Other|Cognitive multisensory rehabilitation|
79224265|NCT05564182|Other|Therapeutic Exercise|Therapeutic Exercise As therapeutic exercise program; A multidisciplinary stroke rehabilitation program will be implemented in the presence of a specialist physiotherapist. In addition, a therapeutic exercise program including passive, actively supported and active ROM exercises, stretching, strengthening and mobilization exercises will be applied to all patients by physiotherapists according to the level of pain and limitation.It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes.
79224266|NCT02487212|Drug|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
79366746|NCT00602836|Drug|Pentostatin|2 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
79524816|NCT05767957|Other|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
79676409|NCT05994924|Behavioral|Educational Handout|Educational handout describing responsive feeding practices.
79996138|NCT03673332|Drug|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
79996139|NCT02914548|Drug|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
79519407|NCT06084780|Procedure|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~Isolated small bowel transplant (SBT): transplantation of the donor small intestine~Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
79519408|NCT06084780|Drug|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
79519409|NCT06084780|Drug|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
79519410|NCT06084780|Drug|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
79519411|NCT06084741|Other|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
79519412|NCT06084741|Other|Using intraabdominal drains|The investigators will put intraabdominal drains
79519413|NCT06084715|Other|Nutritional support|The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
79519414|NCT06084637|Biological|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
79519415|NCT06084637|Biological|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
79519416|NCT06084637|Biological|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
79519417|NCT06084624|Drug|Rebamipide mouthwash|Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
79519418|NCT06084624|Drug|Betamethasone mouthwash|Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
79519419|NCT06084611|Device|Provox Life|Compliant use of Provox Life HMEs
79519420|NCT06084585|Dietary Supplement|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
79519421|NCT06084585|Dietary Supplement|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
79224267|NCT02487212|Drug|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
79519422|NCT06084585|Dietary Supplement|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
79519423|NCT06084572|Other|Questionnaires|FSSG & BEDQ
79519424|NCT06084559|Other|Supplemental oxygen therapy|Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied
79519425|NCT06084559|Other|Sham Oxygen therapy|Patients will reveice pressurized air via a nasal cannula
79224268|NCT02487212|Device|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
79519426|NCT06084546|Device|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
79519427|NCT06084507|Drug|GST-HG171/ritonavir|Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
79519428|NCT06084507|Drug|ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
79676410|NCT05994924|Behavioral|Video Series|Videos geared toward responsive feeding practices.
79996140|NCT02914548|Drug|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
79996141|NCT03048084|Drug|Levetiracetam|Antiepileptic drug levetiracetam
79224269|NCT03318614|Dietary Supplement|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
79224270|NCT03318614|Other|Control group|No probiotic intervention was given to the control group for three months.
79224271|NCT03318536|Drug|Granisetron Hydrochloride|Patients received Granisetron.
79224272|NCT03318536|Drug|No Granisetron|Patients who did not receive Granisetron.
79996142|NCT03048084|Drug|Valproic Acid|Antiepileptic drug valproic acid
79996143|NCT03165721|Drug|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
79996144|NCT02224872|Procedure|Bone marrow transplant|Day 0
79996145|NCT02224872|Drug|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
79996146|NCT02224872|Drug|Fludarabine|30 mg/M2 IV on days -6 to -2
79996147|NCT02224872|Drug|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
79996148|NCT02224872|Radiation|TBI|200 cGy on day -1
79224273|NCT05504122|Procedure|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
79519429|NCT06084494|Diagnostic Test|analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature|The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
79519430|NCT06084442|Procedure|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
79524817|NCT05767879|Drug|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
79366747|NCT00683020|Behavioral|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
79676411|NCT05994924|Behavioral|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
79676412|NCT05989763|Device|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
79996149|NCT02224872|Drug|Mesna|40 mg/kg IV on days 3, 4
79996150|NCT02224872|Drug|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
79224274|NCT02181153|Other|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
79224275|NCT04283812|Device|DBS Electrode Implantation using D1 Sterotactic System|Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
79224276|NCT03318458|Other|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
79224277|NCT03537027|Dietary Supplement|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
79224278|NCT04396041|Device|Microvascular Plug (MVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
79224279|NCT04396041|Device|Amplatzer Vascular Plug (AVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
79224280|NCT04396041|Device|Detachable coils|Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
79224281|NCT04282876|Drug|Degarelix|Patients receiving Degarelix
79224282|NCT02183025|Drug|Meloxicam 7.5 mg|
79224283|NCT02183025|Drug|Meloxicam 15 mg|
79366748|NCT00683332|Drug|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
79366749|NCT00683410|Biological|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
79366750|NCT00639418|Biological|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
79676413|NCT05989763|Device|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
79676414|NCT05986370|Procedure|lumbar spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
79822092|NCT02562885|Device|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
79224284|NCT02183025|Drug|Mefenamic acid 500 mg|
79366751|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
79996151|NCT02224872|Drug|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
79996152|NCT02187198|Drug|Buprenorphine|
79224285|NCT02183025|Drug|Placebo matching 7.5 mg meloxicam|
79224286|NCT02183025|Drug|Placebo matching 15 mg meloxicam|
79224287|NCT02183025|Drug|Placebo matching 500 mg mefenamic acid|
79224288|NCT05464004|Other|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
79519431|NCT06084351|Drug|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
79519432|NCT06084351|Other|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
79519433|NCT06084325|Device|Respiration resistance sensitivity task (RRST)|The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
79519434|NCT06084325|Behavioral|Heartbeat Tracking (HBT)|The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
79519435|NCT06084325|Device|Heartbeat evoked potential (HEP)|The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
79519436|NCT06084325|Device|Libet task|Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
79822093|NCT00745329|Other|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
79996153|NCT03672942|Behavioral|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
79996154|NCT03672942|Behavioral|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
79996155|NCT03672942|Behavioral|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
79996156|NCT02642029|Device|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
79996157|NCT02642029|Device|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
79224289|NCT04282174|Device|CliniMACS|allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
79224290|NCT04282174|Procedure|Bone Marrow Transplant|Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
79224291|NCT04282174|Drug|Hyperfractionated Total Body Irradiation|Hyperfractionated Total Body Irradiation is administered at a dose rate of < 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
79224292|NCT04282174|Drug|Thiotepa|Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
79366752|NCT00640822|Drug|Tacalcitol Ointment|Once daily application for up to 8 weeks
79366753|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
79366754|NCT01799434|Other|treadmill run|
79366755|NCT02998216|Procedure|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
79224293|NCT04282174|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is > 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
79224294|NCT04282174|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
79224295|NCT04282174|Drug|Melphalan|Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
79366756|NCT00642694|Drug|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
79366757|NCT00642694|Drug|Ramelteon|Ramelteon 8 mg qd
79366758|NCT00642694|Other|Placebo|Matching placebo qd
79366759|NCT02998294|Device|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
79996158|NCT02642029|Device|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
79996159|NCT04058574|Device|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
79996160|NCT04058730|Procedure|Laparoscopic Roux en Y Gastric by pass surgery|
79996161|NCT04058730|Procedure|Laparoscopic Sleeve Surgery|
79996162|NCT04058730|Other|Standard Medical Management|
79996163|NCT02639923|Procedure|Drawing of 7ml peripheral blood|puncture peripheral vein
79519437|NCT06084299|Biological|Autologous Tumor Infiltrating Lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
79519438|NCT06084286|Biological|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
79676415|NCT05986370|Procedure|sham spinal manipulative therapy|Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
79676416|NCT05986370|Procedure|full spine spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
79676417|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
79676418|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
79676419|NCT05980065|Drug|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
79822094|NCT00741897|Drug|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
79822095|NCT00688155|Behavioral|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
79519439|NCT06084273|Other|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
79676420|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
79366760|NCT02998294|Device|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
79366761|NCT00705874|Drug|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
79366762|NCT00705874|Drug|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
79676421|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
79676422|NCT05980065|Drug|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
79676423|NCT05977036|Device|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
79676424|NCT05977036|Drug|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
79822096|NCT00688155|Behavioral|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
79822097|NCT00688155|Behavioral|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
79224296|NCT04282174|Drug|Fludarabine|"Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory."
79224297|NCT03321500|Other|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
79224298|NCT03321500|Other|Silicone-based soft liner|gold standard for denture relining material
79224299|NCT02185989|Other|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
79366763|NCT00705874|Drug|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
79366764|NCT00705874|Drug|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
79822098|NCT00741975|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
79822099|NCT00741975|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
79822100|NCT00745407|Drug|fenofibrate|
79822101|NCT00745485|Drug|zoledronic acid|
79822102|NCT02562729|Procedure|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
79822103|NCT00745563|Device|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
79519440|NCT06084273|Other|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~Breathe calmly and slowly through the nose.~Pucker the lips as if whistling or inflating a balloon.~Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
79519441|NCT06084221|Behavioral|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
79224300|NCT03321422|Other|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
79224301|NCT02186067|Other|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
79366765|NCT00705874|Drug|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
79366766|NCT00705874|Drug|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
79676425|NCT05974488|Device|McMurray Enhanced Airway|The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.
79676426|NCT05974488|Device|Nasal Cannula|Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
79996164|NCT05239897|Device|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
79224302|NCT05503888|Drug|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
79366767|NCT00705874|Drug|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
79224303|NCT05503888|Drug|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
79366768|NCT00646048|Device|TriVascular Stent-Graft System|TriVascular Stent-Graft System
79366769|NCT00647998|Drug|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
79366770|NCT00647998|Other|Standard care|
79366771|NCT00649792|Drug|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
79366772|NCT00685516|Dietary Supplement|green tea|6 cups of green tea daily for 2-8 weeks
79366773|NCT00685516|Dietary Supplement|placebo|6 cups of water daily for 2-8 weeks
79366774|NCT00685516|Dietary Supplement|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
79366775|NCT00686842|Drug|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
79366776|NCT00686842|Genetic|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
79224304|NCT02490332|Device|Ventilation tube treatment|Tympanostomy
79366777|NCT00686842|Genetic|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
79366778|NCT00686842|Genetic|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
79366779|NCT00686842|Other|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
79366780|NCT00686842|Other|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
79366781|NCT00686842|Other|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
79366782|NCT00686842|Procedure|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
79366783|NCT00687076|Drug|Ezetimibe|Daily dose of 10 mg of Ezetimibe
79366784|NCT00687076|Drug|Niaspan|Daily dose of 1500 mg of Niaspan
79676427|NCT05973435|Other|Blood sampling|Blood sample would be taken from the participants in the study for these analyses on three occasions in 3 test tubes (before cesarean section, during cesarean section and after cesarean section).
79676428|NCT05970094|Other|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
79224305|NCT02181309|Drug|Meloxicam, low dose|
79224306|NCT02181309|Drug|Meloxicam, medium dose|
79224307|NCT02181309|Drug|Meloxicam, high dose|
79224308|NCT02186145|Drug|Association of metronidazole; nystatin and dexamethasone|
79224309|NCT02186145|Drug|Flagyl|Vaginal cream of metronidazole and nystatin
79224310|NCT03325868|Drug|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
79224311|NCT02183103|Drug|meloxicam rapid release tablet, 12mg, UH AC62MU|
79224312|NCT03325790|Drug|200mg SPI-1005 BID|Active: low dose
79224313|NCT03325790|Drug|400mg SPI-1005 BID|Active: high dose
79224314|NCT03325790|Other|Placebo|Placebo Comparator
79224315|NCT02181465|Biological|G17DT|
79366785|NCT00687076|Drug|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
79366786|NCT00687076|Behavioral|Standard care|Standard of medical care for PAD
79224316|NCT02490020|Biological|mesenchymal stem cell|
79224317|NCT02186379|Behavioral|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
79224318|NCT02186379|Behavioral|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
79366787|NCT00687076|Drug|Aspirin|Daily dose of 325 mg of aspirin
79366788|NCT00687076|Drug|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
79224319|NCT04493918|Combination Product|Mesenchymal Stem cell + Nacl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
79224320|NCT04493918|Combination Product|NaCl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
79224321|NCT02181543|Drug|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
79366789|NCT00687076|Drug|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
79224322|NCT02181621|Device|Iodosorb|Cadexomer iodine gel
79224323|NCT02181621|Device|Solosite gel|Hydrogel
79366790|NCT00687076|Drug|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
79366791|NCT00687076|Procedure|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
79366792|NCT00687544|Biological|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
79366793|NCT00687544|Drug|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is <65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is >85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
79366794|NCT02998060|Procedure|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
79366795|NCT02998060|Device|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
79366796|NCT02998060|Device|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
79366797|NCT02143648|Drug|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
79366798|NCT02143648|Drug|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
79366799|NCT02143648|Drug|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
79366800|NCT02997982|Drug|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
79366801|NCT00689260|Device|easypod|Subjects is aware that the device records injection information that can be viewed by user
79366802|NCT00689260|Device|easypod|Subjects is not aware that the device records injection information that can be viewed by user
79366803|NCT00689572|Drug|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
79366804|NCT00689572|Drug|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
79366805|NCT01840579|Biological|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
79366806|NCT01840579|Biological|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
79366807|NCT01840579|Biological|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
79519442|NCT06084221|Behavioral|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
79519443|NCT06084208|Device|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
79224324|NCT02490176|Drug|liraglutide|Liraglutide were taken daily for 7 days
79519444|NCT06084182|Other|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
79224325|NCT02490176|Drug|placebo|Placebo were taken daily for 7 days
79366808|NCT01840579|Drug|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
79519445|NCT06084169|Device|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
79519446|NCT06084156|Drug|HSK7653|Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
79519447|NCT06084156|Drug|Metformin|Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
79519448|NCT06084130|Drug|Zolpidem|10 milligrams zolpidem contained in white-color opaque medicine capsule
79519449|NCT06084130|Drug|Placebo|corn-starch contained in identical white-color opaque medicine capsule
79519450|NCT06084065|Device|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
79224326|NCT02181699|Drug|KHK2823|single agent KHK2823
79224327|NCT03318302|Other|Survey|Survey of the adult population in Israel
79224328|NCT02181777|Behavioral|GRASP|GRoup trAining for Social skills in Psychosis
79519451|NCT06084052|Device|Path Active|Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). Participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.
79519452|NCT06083961|Drug|Alirocumab|Initial alirocumab, single dose of 300mg, subcutaneous injection
79519453|NCT06083935|Drug|Daflon|Daflon; two film coated tablets 500 mg daily
79224329|NCT02181777|Behavioral|Standard care|Treatment as usual
79224330|NCT03321344|Device|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
79224331|NCT02181855|Procedure|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
79224332|NCT03325478|Other|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
79224333|NCT02183181|Drug|Meloxicam capsule|
79224334|NCT02183181|Drug|Meloxicam tablet|
79224335|NCT02490098|Other|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
79366809|NCT01840579|Drug|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
79366810|NCT01840579|Drug|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
79366811|NCT01840579|Drug|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
79366812|NCT01840579|Drug|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
79366813|NCT01840579|Drug|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
79366814|NCT01840579|Biological|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
79366815|NCT01840579|Drug|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
79366816|NCT01840579|Drug|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
79519454|NCT06083935|Drug|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
79519455|NCT06083935|Drug|Metformin|Glucophage ® 500 tablets twice daily
79519456|NCT06083779|Genetic|low-depth whole-genome sequencing technology|the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
79519457|NCT06083740|Device|Granudacyn/Veriforte|Wound irrigation solution for all kinds of wounds (Acute, chronic or contaminated wounds).
79519458|NCT06083727|Other|rate of cesarean section|rate of primary cesarean section in primigravida and multigravida
79519459|NCT06083714|Other|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
79822104|NCT00742131|Drug|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid [5 milligrams/milliliter] or 1000 milligrams of GSK1363089 in 50 milliliters liquid [20 milligrams/milliliter]) or as solid capsules of 20, 100, and/or 200 milligrams.
79224336|NCT02490098|Other|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
79224337|NCT02490098|Other|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
79224338|NCT02490098|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
79224339|NCT02490098|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
79224340|NCT02490098|Device|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
79224341|NCT02490098|Device|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
79224342|NCT02183259|Drug|ESR 1150 CL, Capsule, oral|
79224343|NCT02183259|Drug|ESR 1150 CL, solution, intravenous|
79224344|NCT02486822|Procedure|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
79676429|NCT05968963|Behavioral|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
79519460|NCT06083714|Other|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
79366817|NCT00690040|Device|Foley catheter|Single balloon catheter
79366818|NCT00690040|Device|Atad catheter|Double balloon catheter
79519461|NCT06083701|Drug|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;"
79519462|NCT06083688|Drug|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
79676430|NCT05968963|Behavioral|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
79822105|NCT00747201|Behavioral|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
79822106|NCT00747201|Behavioral|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
79224345|NCT02486822|Drug|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
79224346|NCT02486822|Procedure|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
79366819|NCT00690274|Drug|BF2.649|up to 20mg per day
79822107|NCT03884283|Device|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
79822108|NCT02563509|Biological|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
79822109|NCT00747279|Other|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
79224347|NCT02186457|Drug|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
79224348|NCT02186457|Other|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
79224349|NCT03321266|Device|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
79224350|NCT02256501|Biological|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
79366820|NCT00690274|Drug|Placebo|up to 20mg per day
79366821|NCT00650260|Device|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
79519463|NCT06083688|Drug|Chloroquine|"Treatment will be with CQ alone if female and 13 years old or older in all study arms.~Treatment in combination with SP in Arm 2 (females less than 13 years old and all males)."
79519464|NCT06083688|Drug|Sulfadoxine pyrimethamine|"Treatment in combination with CQ in Arm 2 (females less than 13 years old and all males).~Treatment in combination with AQ in Arm 3 (females less than 13 years old and all males)."
79519465|NCT06083688|Drug|Sulfadoxine-pyrimethamine-amodiaquine|Treatment in Arm 3 (females less than 13 years old and all males).
79519466|NCT06083636|Other|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
79519467|NCT06083636|Other|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
79519468|NCT06083623|Biological|TNM001|single dose intramuscular injection
79519469|NCT06083623|Biological|placebo|single dose intramuscular injection
79519470|NCT06083610|Other|miRNA levels analysis from saliva samples|Each participant will be given two 50-mL Falcon tubes and will be asked to expectorate a small amount (about 1 mL) of saliva before and immediately after the end of exercise. Part of each saliva sample will be mixed with an equal volume of denaturing solution included in the mirVanaTM PARISTM kit from Ambion, Foster City, CA, in order to inactivate ribonucleases. Serum samples will be separated by centrifugation at 4000 rpm from the saliva samples taken into the biochemistry tubes of the participants and controls and will be raised to -80 centigrade degrees until the study day. Micro RNA will be isolated from serum samples on the working day. Determination of microRNA expression levels (micro RNA-1 and micro RNA-133a) will be determined by reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems 7500 Fast Real-Time PCR).
79519471|NCT06083597|Other|Qualitative interview|Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.
79519472|NCT06083584|Other|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
79224351|NCT02486900|Device|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
79224352|NCT02486978|Other|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
79996165|NCT05239819|Behavioral|Inspiratory muscle training|The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
79224353|NCT02486978|Dietary Supplement|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
79519473|NCT06083545|Behavioral|App|The low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.
79519474|NCT06083532|Behavioral|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity & Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity & repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
79996166|NCT05239819|Behavioral|Regulated care and education|Regulated care and education will be applied
79996167|NCT04969705|Drug|Dexmedetomidine|"60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) ."
79224354|NCT02486978|Dietary Supplement|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
79224355|NCT02186535|Dietary Supplement|Vitamin D and Calcium|
79366822|NCT00650260|Device|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
79366823|NCT00651040|Drug|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
79366824|NCT00651040|Drug|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
79366825|NCT01184950|Other|Trainer Curriculum|
79676431|NCT05967663|Device|PCI-immediate complete revascularisation|In patients allocated to the immediate complete revascularisation group, PCI of the culprit lesion was attempted first and followed by all other lesions deemed to be clinically significant by the operator during the index procedure.
79519475|NCT06083532|Behavioral|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity & Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity & repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
79519476|NCT06083532|Behavioral|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity & Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity & repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
79519477|NCT06083532|Behavioral|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity & repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity & Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
79676432|NCT05967663|Device|PCI-staged complete revascularisation|In the staged complete revascularisation group, only the culprit lesion was treated during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator was planned at a later stage through an elective re-admission within 15-45 days after randomisation.
79676433|NCT05966896|Device|implanted epidural stimulator|implantable multi-programmable neurostimulation system to deliver electrical stimulation to neural targets in the spinal cord
79676434|NCT05949047|Behavioral|Cognitive Emotion Regulation Training via Psychological Distancing|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.
79996168|NCT03676374|Drug|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
79996169|NCT03676374|Drug|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
79224356|NCT03325400|Other|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
79366826|NCT02997748|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
79366827|NCT00654784|Drug|idebenone|idebenone 450 mg/day (150 mg three times a day)
79366828|NCT00654784|Drug|placebo|
79996170|NCT03178669|Drug|cobitolimod|Rectal administration
79996171|NCT03178669|Drug|Placebo|Solution manufactured to mimic cobitolimod
79366829|NCT02997514|Behavioral|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
79366830|NCT02997514|Behavioral|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
79366831|NCT01799824|Biological|ANT-1403|
79366832|NCT01799824|Biological|placebo|
79366833|NCT04387396|Other|Exercise|Exercise specific to knee osteoarthritis.
79366834|NCT01801111|Drug|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
79366835|NCT01801111|Drug|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
79366836|NCT00691600|Drug|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
79366837|NCT00691600|Drug|Placebo|Placebo caps or suspension every 12 hours for 10 days
79366838|NCT00655642|Drug|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
79366839|NCT00655642|Drug|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
79366840|NCT00655642|Drug|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
79366841|NCT00655642|Drug|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
79996172|NCT03178201|Drug|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
79224357|NCT02186613|Behavioral|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
79224358|NCT03325244|Other|EEG monitor|sleep patterns will be monitored using EEG monitor
79519478|NCT06083441|Diagnostic Test|SeeMe|"A video-recorded SeeMe command following assessment by a trained professional once a day Each session involves three command sets that are played from an audio recording 10 times over the course of 8 minutes. These commands are Stick out your tongue, Open your eyes, and Show me a smile Each command set is recorded separately for a total of 3 videos per session. These videos are then analyzed by SeeMe to detect if subjects are responding to commands."
79519479|NCT06083441|Diagnostic Test|Coma Recovery Scale-Revised (CRS-R)|A video-recorded CRS-R score assessment by a trained professional once a day. A score of 10 or greater, an auditory score >2, or an arousal score > 0 means that a subject is responding to commands
79519480|NCT06083415|Other|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system.
79224359|NCT03325244|Other|FitBit|activity levels will be monitored
79224360|NCT02181933|Drug|Nevirapine|
79996173|NCT04833127|Behavioral|Gender-Enhanced -- Masibambane|"The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators."
79676435|NCT05949047|Behavioral|Cognitive Emotion Regulation Training via Reinterpretation|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
79224361|NCT02181933|Drug|Zidovudine (ZDV)|
79224362|NCT02181933|Drug|Lamivudine (3TC)|
79224363|NCT02183337|Drug|BI 1356|
79224364|NCT02183337|Drug|BI 1356 + Pioglitazone|
79366842|NCT02997436|Device|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
79366843|NCT02997280|Drug|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight > 40 kg, 0.08 mg/kg bid for children with body weight < 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
79366844|NCT01773967|Drug|LGG|LGG 10^10 cfu PO BID X 5 days
79519481|NCT06083402|Dietary Supplement|HyaCera™|1 Ritual HyaCera capsule once daily
79676436|NCT05940584|Device|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
79676437|NCT05940584|Other|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
79676438|NCT05940584|Other|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
79996174|NCT04833127|Behavioral|Individually accessed|The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
79224365|NCT02183337|Drug|Pioglitazone|
79366845|NCT01773967|Drug|micro-crystalline cellulose|1 capsule PO bid x 5 days
79366846|NCT00656656|Drug|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
79519482|NCT06083402|Dietary Supplement|Placebo|1 placebo capsule once daily
79519483|NCT06083389|Behavioral|kabat technique for rehabilitation of facial palsy|To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.
79519484|NCT06083389|Device|electrotherapy|electrical stimulation of facial nerve supplied muscles.3 sessions per week.
79519485|NCT06083350|Dietary Supplement|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
79224366|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except friday|
79224367|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except thursday and friday|
79224368|NCT02489786|Drug|patients take 0.125 mg of digoxin daily|
79224369|NCT02489786|Drug|digoxin dose is calculated using Jusko-Koup method and given daily|
79224370|NCT02489864|Drug|Terlipressin|
79224371|NCT02182011|Drug|Tenecteplase|
79224372|NCT02182011|Drug|Alteplase|
79224373|NCT02182011|Drug|Streptokinase|
79224374|NCT02486744|Drug|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
79224375|NCT02186769|Drug|Risperdal® Consta®|
79224376|NCT02186769|Drug|LY03004|
79519486|NCT06083350|Dietary Supplement|Starch|Produced by Angel Yeast Co., LTD
79676439|NCT05939492|Behavioral|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
79676440|NCT05932589|Other|EEG and Auditory and Visual Evoked Potentials (AEP and VEP)|Through up to seven standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.
79676441|NCT05932589|Other|Clinical assessment|Established clinical measures for RTT will be collected for RTT participants
79224377|NCT02486432|Drug|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
79224378|NCT05182047|Drug|Butamirate citrate|Butamirate citrate syrup will be administered orally.
79366847|NCT01773889|Drug|Denileukin Diftitox/SC Pegylated IFNα-2a|
79366848|NCT00656968|Drug|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
79366849|NCT00656968|Drug|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
79366850|NCT00657280|Drug|Sitagliptin|No one is blinded to the treatments.
79366851|NCT00692692|Procedure|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
79366852|NCT00692692|Procedure|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
79366853|NCT00693160|Drug|ketorolac|single intrathecal injection of ketorolac 2 mg
79366854|NCT00693160|Drug|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
79519487|NCT06083337|Device|CaRi-Heart device|Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
79676442|NCT05929664|Biological|Cemiplimab|Given IV
79676443|NCT05929664|Procedure|Computed Tomography|Undergo CT scan
79519488|NCT06083324|Other|Dose esclated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
79519489|NCT06083311|Dietary Supplement|Probiotic|Participants in this arm will receive a daily dose of 3x10^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
79519490|NCT06083311|Dietary Supplement|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
79676444|NCT05929664|Procedure|Biospecimen Collection|Undergo collection of blood samples
79676445|NCT05929664|Other|Quality-of-Life Assessment|Ancillary studies
79996175|NCT01829958|Drug|rituximab|
79996176|NCT01829958|Drug|prednisone|
79996177|NCT01829958|Behavioral|Geriatric Assessment|
79996178|NCT03021642|Drug|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 1 (Day 1)
79224379|NCT05182047|Drug|Sinecod|Sinecod syrup will be administered orally.
79224380|NCT02489240|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
79224381|NCT02489240|Drug|placebo|2000 IU placebo tablets were taken daily for 6 days
79224382|NCT02183415|Drug|BI 1356 BS, low dose|
79224383|NCT02183415|Drug|BI 1356 BS, medium dose|
79224384|NCT02183415|Drug|BI 1356 BS, high dose|
79224385|NCT02183415|Drug|Placebo|
79224386|NCT02486510|Drug|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
79366855|NCT00693160|Drug|remifentanil|All subjects will receive a remifentanil infusion
79366856|NCT00693160|Drug|Capsaicin|Topical capsaicin pain model utilized for each subject
79366857|NCT00694018|Other|Education and standard care|Educational program for individuals with chronic back pain.
79366858|NCT00694018|Behavioral|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
79366859|NCT00694564|Drug|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
79366860|NCT00695188|Drug|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
79366861|NCT00695188|Drug|methotrexate|25 mg oral administration
79366862|NCT00658138|Device|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
79519491|NCT06082817|Drug|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
79519492|NCT06082726|Dietary Supplement|SCFA|Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
79519493|NCT06082232|Drug|Dexmedetomidine|Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
79519494|NCT06082232|Drug|Midazolam|1 mg midazolam intrathecal administration
79519495|NCT06082232|Drug|Bupivacain|20 mg bupivacaine intrathecal administration
79224387|NCT02190123|Drug|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
79224388|NCT04493840|Drug|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
79366863|NCT00658138|Device|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
79366864|NCT00706264|Device|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
79366865|NCT04344964|Other|None - NA|Observational study
79366866|NCT00695500|Drug|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
79676446|NCT05929235|Drug|FX-909|FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
79366867|NCT00695500|Drug|Placebo|Placebo tablets, 0 mg per day for 3 weeks
79676447|NCT05927519|Device|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
79676448|NCT05918757|Other|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
79676449|NCT05918757|Other|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
79224389|NCT04493840|Drug|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
79224390|NCT04493528|Combination Product|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
79224391|NCT04493528|Combination Product|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
79224392|NCT02190201|Device|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
79519496|NCT06082206|Procedure|thoracic paravertebral block (TPVB)|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
79519497|NCT06082206|Procedure|PECS group|entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
79519498|NCT06081231|Device|AndroidAPS-rt-CGM;|a real-time continuous glucose monitoring, an insulin pump, and an intelligent algorithm.
79519499|NCT06080958|Device|NPWT|the NPWT dressing applied to fasciocutaneous flap
79519500|NCT06080958|Other|Conventional dressing|Conventional dressing ( topical care ) applied to fasciocutaneous flap
79519501|NCT06078293|Behavioral|Home-based Exercise Program|12-week home-based exercise program that involves individualized exercise prescription and motivational health coaching calls.
79519502|NCT06077214|Drug|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
79676450|NCT05915104|Drug|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
79676451|NCT05915104|Drug|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
79676452|NCT05898230|Device|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
79822110|NCT00747279|Drug|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
79224393|NCT02190201|Device|Direct laryngoscope|A kind of traditional laryngoscopes
79224394|NCT02183493|Drug|BI 1356|
79822111|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
79224395|NCT02187081|Procedure|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
79224396|NCT02187081|Procedure|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
79224397|NCT02485106|Drug|Rifaximin|400mg three times per day for 28 days
79224398|NCT02485106|Drug|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
79224399|NCT02187237|Device|YOLO TOUCH Low Level Laser|
79224400|NCT02485028|Drug|Dapoxetine 30mg tablet|
79224401|NCT02485028|Drug|Mirodenafil 50mg tablet|
79224402|NCT02183571|Drug|Merck Glucophage® high dose|Part I: Treatment A
79224403|NCT02183571|Drug|BMS Glucophage® high dose|Part I: Treatment B
79224404|NCT02183571|Drug|Merck Glucophage® low dose|Part II: Treatment C
79224405|NCT02183571|Drug|BMS Glucophage® low dose|Part II: Treatment D
79366868|NCT00695578|Drug|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
79366869|NCT00695578|Drug|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
79366870|NCT01792102|Drug|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
79519503|NCT06077214|Drug|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
79519504|NCT06077032|Drug|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
79519505|NCT06077032|Drug|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
79519506|NCT06077032|Drug|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
79224406|NCT03318146|Device|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
79676453|NCT05897021|Behavioral|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
79822112|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
79224407|NCT03318146|Drug|XALATAN®|one drop in the affected eye(s) once daily in the evening
79224408|NCT03536091|Diagnostic Test|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
79224409|NCT02183649|Drug|pentoxyverine citrate|
79224410|NCT02183649|Drug|Placebo|
79224411|NCT03318068|Other|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
79366871|NCT02996734|Procedure|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
79224412|NCT02187315|Device|Chrono-chemotherapy pump:Melodie|
79224413|NCT02187315|Device|Routine intravenous drip|
79224414|NCT02187315|Drug|induction chemotherapy|
79224415|NCT02187315|Drug|cisplatin chrono-chemotherapy|
79224416|NCT02187315|Radiation|intensity-modulated radiation therapy|
79224417|NCT02187315|Drug|cisplatin routine-chemotherapy|
79224418|NCT02489396|Behavioral|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal & breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
79224419|NCT02489396|Behavioral|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
79366872|NCT00699010|Drug|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
79366873|NCT00699010|Drug|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
79366874|NCT02996812|Drug|Exendin (9-39)|
79366875|NCT00661570|Device|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
79366876|NCT00706810|Drug|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
79366877|NCT00706810|Drug|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
79366878|NCT00661960|Drug|raltegravir|400mg tablet twice daily by mouth for nine months
79366879|NCT00661960|Drug|efavirenz|600mg capsule once daily by mouth without regard to food
79519507|NCT06076798|Device|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
79519508|NCT06075654|Other|no intervention it is considered (Epidemiological Study)|It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
79519509|NCT06074302|Device|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
79519510|NCT06073158|Procedure|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
79822113|NCT00747513|Behavioral|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
79822114|NCT00745719|Procedure|parathyroidectomy|total parathyroidectomy with forearm autografting
79519511|NCT06071247|Other|3D printed models|3D printed simulation models of the stomach, duodenum, common bile duct, and pancreatic duct structures using a combination of soft and hard materials
79519512|NCT06058572|Drug|Rifaximin with allogeneic stem cell transplant|Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
79519513|NCT06058572|Procedure|Allogeneic stem cell transplant|Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
79519514|NCT06058260|Other|Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition|Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
79519515|NCT06058221|Device|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
79519516|NCT06058221|Device|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
79519517|NCT06042933|Other|Post operative early oral feeding|To start oral feeding 6 hours after perforated peptic ulcer repairs
79519518|NCT06042933|Other|Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs|To start oral feeding after 48 hours
79519519|NCT06034353|Behavioral|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
79519520|NCT06028984|Device|Intervention app|An app-based intervention for depression
79366880|NCT00662818|Drug|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
79224420|NCT02489396|Behavioral|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
79224421|NCT02489396|Behavioral|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
79519521|NCT06028984|Other|Control app|An app with non-therapeutic content
79519522|NCT05992181|Other|NEORTHO|early orofacial stimulation
79519523|NCT05980169|Device|SensoniQ Treatment Station|The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
79519524|NCT05978362|Procedure|Latarjet technique|Realization of a stop according to Latarjet
79519525|NCT05958888|Behavioral|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
79519526|NCT05958888|Behavioral|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
79224422|NCT02489162|Device|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
79366881|NCT00662818|Drug|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
79366882|NCT00662818|Drug|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
79519527|NCT05958888|Behavioral|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
79519528|NCT05958888|Behavioral|Barcode label|Barcode is shown in white square label on the can of soup
79822115|NCT00745797|Radiation|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
79366883|NCT00662818|Drug|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
79366884|NCT00699556|Drug|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
79366885|NCT00699556|Drug|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
79366886|NCT00699556|Drug|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
79366887|NCT00700336|Drug|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
79366888|NCT00700336|Drug|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
79519529|NCT05955937|Other|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
79519530|NCT05955937|Other|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
79519531|NCT05954702|Procedure|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
79822116|NCT00742287|Dietary Supplement|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
79519532|NCT05954702|Procedure|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
79519533|NCT05942521|Behavioral|Very brief extinction|"The very brief extinction presents a very short (33ms) repetitive sequence of alcohol cues, followed by a masking stimulus(117ms), which masks the alcohol cues. In the case of repeated exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
79519534|NCT05942521|Behavioral|Clearly visible extinction|"The clearly visible extinction presents a repetitive sequence of alcohol cues(150ms) without a masking stimulus. In the case of repeat exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of conscious processing."
79822117|NCT00742287|Dietary Supplement|Placebo|placebo
79822118|NCT00747669|Drug|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
79224423|NCT02489162|Device|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
79224424|NCT02256735|Drug|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
79519535|NCT05942521|Behavioral|Very brief neutral extinction|"The very brief neutral extinction presents a very short (33ms) repetitive sequence of neutral cues, followed by a masking stimulus(117ms), which masks the neutral cues. In the case of repeated exposure to neutral stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
79519536|NCT05942352|Drug|Ligustrazine by intravenously administration|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
79519537|NCT05942352|Drug|Ligustrazine by mouth|50 mg Ligustrazine tablet by mouth would be maintained for 1 year
79519538|NCT05942352|Drug|Placebo by intravenously administration|Intravenous administration of 250ml saline per day for 15 days
79519539|NCT05942352|Drug|Placebo by mouth|50 mg placebo tablet by mouth would be maintained for 1 year
79519540|NCT05936489|Drug|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
79519541|NCT05936489|Drug|Aceclidine|LNZ100 (Aceclidine) non-preserved ophthalmic solution
79519542|NCT05934903|Device|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
79519543|NCT05932745|Other|E-liquid coolant (no WS-3) (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
79519544|NCT05932745|Other|E-liquid coolant (Low WS-3) (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
79676454|NCT05897021|Behavioral|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker & Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
79676455|NCT05895747|Drug|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
79822119|NCT00742365|Device|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
79822120|NCT00742365|Device|Red light placebo|One hour of exposure to red light.
79822121|NCT00690573|Biological|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
79822122|NCT00742443|Drug|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
79224425|NCT02256735|Drug|Treatment B|
79224426|NCT02256735|Drug|Treatment C|
79224427|NCT02256735|Drug|Treatment D|
79224428|NCT02256735|Drug|Placebo|
79224429|NCT02256735|Drug|Moxifloxacin|
79224430|NCT02484794|Behavioral|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
79224431|NCT02484794|Behavioral|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
79519545|NCT05932745|Other|E-liquid coolant (High WS-3) (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
79519546|NCT05932745|Other|E-liquid coolant (no WS-3) (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
79519547|NCT05932745|Other|E-liquid coolant (Low WS-3) (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
79519548|NCT05932745|Other|E-liquid coolant (High WS-3) (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
79676456|NCT05895747|Drug|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
79676457|NCT05895747|Drug|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
79676458|NCT05895747|Drug|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
79676459|NCT05895747|Drug|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
79676460|NCT05893225|Drug|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
79676461|NCT05893225|Drug|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
79224432|NCT02183805|Drug|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
79224433|NCT03316352|Procedure|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
79224434|NCT03316352|Procedure|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
79366889|NCT00700336|Drug|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
79366890|NCT02996422|Behavioral|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
79366891|NCT02996422|Behavioral|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
79366892|NCT01795846|Other|Allergen specific immunotherapy and placebo injections|
79366893|NCT00701896|Drug|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
79822123|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
79519549|NCT05932745|Other|E-liquid coolant (no WS-3) (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
79676462|NCT05887141|Behavioral|Double Standards|We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).
79366894|NCT00701896|Drug|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
79676463|NCT05887141|Behavioral|Self-criticism avatar|We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
79676464|NCT05881252|Procedure|Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP >= 160 mmHg.
79224435|NCT03316352|Device|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
79366895|NCT00701896|Other|Biological Control|No treatment intervention only information and procedures.
79519550|NCT05932745|Other|E-liquid coolant (Low WS-3) (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
79519551|NCT05932745|Other|E-liquid coolant (High WS-3) (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
79519552|NCT05932732|Device|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
79676465|NCT05881252|Procedure|Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP >= 180 mmHg.
79676466|NCT05880160|Other|Phased withdrawal of heart failure medications|As per arm/group description
79676467|NCT05870982|Behavioral|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
79519553|NCT05932732|Drug|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
79519554|NCT05932732|Device|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
79676468|NCT05870982|Behavioral|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
79676469|NCT05870982|Behavioral|DCR|Participants will be instructed to reduce caloric intake by 25%.
79366896|NCT00701896|Behavioral|Motivational Interview|60 minute one-on-one Interview
79676470|NCT05863520|Behavioral|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
79676471|NCT05863520|Behavioral|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
79224436|NCT03316352|Drug|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
79366897|NCT01797406|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
79366898|NCT01797406|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
79366899|NCT01839487|Drug|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
79366900|NCT01839487|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
79366901|NCT01839487|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
79366902|NCT01839487|Drug|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
79366903|NCT01839487|Drug|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
79366904|NCT00665470|Drug|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
79366905|NCT00665704|Behavioral|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
79366906|NCT00666406|Drug|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
79366907|NCT00666406|Drug|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
79676472|NCT05861076|Other|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
79676473|NCT05861076|Other|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
79676474|NCT05861076|Other|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
79676475|NCT05851508|Drug|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
79224437|NCT02187549|Device|HYMOVIS|Intra-articular injection
79224438|NCT02187549|Device|Placebo|Intra-Articular Injection
79224439|NCT02484560|Drug|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
79224440|NCT02030301|Biological|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
79224441|NCT02030301|Biological|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
79676476|NCT05851508|Drug|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
79676477|NCT05844436|Drug|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
79676478|NCT05838196|Diagnostic Test|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
79822124|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
79822125|NCT00719264|Drug|RAD001(everolimus)|10 mg qd
79224442|NCT02030301|Biological|PBS|Phosphate-buffered saline
79224443|NCT02484482|Drug|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
79366908|NCT02996344|Other|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
79366909|NCT02996344|Other|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
79366910|NCT02999152|Other|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
79366911|NCT02996188|Procedure|routine therapeutic paracentesis|
79366912|NCT02996032|Other|Vascular and Pulmonary Ultrasound|
79366913|NCT02995954|Drug|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
79366914|NCT01799941|Drug|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
79366915|NCT00702364|Drug|atomoxetine|
79366916|NCT00702364|Drug|placebo|
79366917|NCT00667186|Other|Targeted Screening|Selection method for screening is based on risk
79996179|NCT03021642|Drug|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 2 (Day 22)
79366918|NCT00667186|Other|Routine Screening|Selection method for screening is not based on risk
79366919|NCT01799239|Device|Test product|The test product consists of an adhesive with a new top film
79519557|NCT05902325|Drug|Mepolizumab 100 MG Injection|Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
79519558|NCT05876910|Behavioral|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
79676479|NCT05830643|Behavioral|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
79366920|NCT01799239|Device|SenSura|SenSura is the CE-marked and commercially available comparator product
79366921|NCT02995798|Other|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
79366922|NCT00713284|Drug|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
79996180|NCT03021642|Drug|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 1 (Day 1)
79224444|NCT02187627|Drug|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6924963 injected will be </=10 micrograms (mcg), injection volume </=20 milliliters (mL). Target injected activity for [11C]RO6924963 will be 370-740 megabecquerel (MBq) [10-20 millicurie (mCi)].
79224445|NCT02187627|Drug|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6931643 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [11C]RO6931643 will be 370-740 MBq (10-20 mCi).
79366923|NCT00702754|Biological|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
79366924|NCT02995720|Drug|Fimasartan/Amlodipine combination drug, Rosuvastatin|
79822126|NCT00719264|Drug|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
79822127|NCT00719264|Drug|bevacizumab|10 mg/kg every 2 weeks
79822128|NCT00749151|Behavioral|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
79996181|NCT03021642|Drug|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 2 (Day 22)
79996182|NCT00354120|Drug|Alentuzumab|Alentuzumab
79996183|NCT00354120|Drug|Globulina antilinfocitaria|Globulina antilinfocitaria
79366925|NCT02990728|Drug|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
79366926|NCT02990728|Device|Mirena®|
79366927|NCT02995486|Other|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
79366928|NCT02995564|Behavioral|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
79366929|NCT04387006|Other|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
79519559|NCT05856162|Behavioral|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
79519560|NCT05856162|Behavioral|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
79822129|NCT00687609|Drug|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
79519561|NCT05840302|Device|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
79519562|NCT05840302|Other|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
79822130|NCT00742521|Procedure|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
79676480|NCT05830643|Behavioral|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
79822131|NCT00742521|Procedure|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
79519563|NCT05839457|Behavioral|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
79519564|NCT05826171|Behavioral|High-Intensity Aerobic Exercise Prior to Balance Training|20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
79366930|NCT04387006|Other|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
79676481|NCT05823220|Behavioral|Homeless diversion (HD)|Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
79676482|NCT05823220|Behavioral|Treatment-as-usual (TAU)|Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
79822132|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
79822133|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
79822134|NCT00747825|Drug|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
79822135|NCT00751959|Drug|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
79822136|NCT00751959|Drug|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
79822137|NCT00723554|Drug|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
79822138|NCT00723554|Drug|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
79822139|NCT00687219|Biological|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
79366931|NCT04386772|Procedure|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
79366932|NCT04386772|Procedure|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
79366933|NCT02990884|Drug|ketamine|
79822140|NCT00687219|Drug|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
79519565|NCT05826171|Behavioral|Low-Intensity Exercise Prior to Balance Training|"20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components."
79519566|NCT05806385|Device|Cryoablation|Tumor ablation before neoadjuvant chemotherapy
79519567|NCT05806385|Combination Product|Cryoablation combined with PD1 Inhibitor|Combination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
79676483|NCT05822297|Device|Neuromuscular electrical stimulation|NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
79676484|NCT05816369|Other|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
79519568|NCT05788185|Biological|RVM-V001 30 µg|For BNT162b2 subjects
79519569|NCT05788185|Biological|RVM-V002 30 µg|For BNT162b2 subjects
79519570|NCT05788185|Biological|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BNT162b2 subjects
79224446|NCT02187627|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [18F]RO6958948 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of [18F] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
79366934|NCT02990650|Behavioral|Balance Task Training with therapist guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The therapist will provide guarding support"
79519571|NCT05788185|Biological|RVM-V001 30 µg|For BBIBP-CorV or CoronaVac subjects
79996184|NCT04058808|Other|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
79996185|NCT04058808|Other|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
79366935|NCT02990650|Behavioral|Balance task training with robotic guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
79366936|NCT02990650|Behavioral|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
79366937|NCT02995018|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-174)
79366938|NCT02995018|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
79366939|NCT02992990|Procedure|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
79366940|NCT02997592|Device|SpinCare|The burn wound is treated using the SpinCare Systen
79366941|NCT02990494|Behavioral|STANDARD|Standard Internet-delivered behavioral weight loss
79366942|NCT02990494|Behavioral|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
79366943|NCT02990494|Behavioral|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
79519572|NCT05788185|Biological|RVM-V002 30 µg|For BBIBP-CorV or CoronaVac subjects
79224447|NCT02484638|Drug|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
79224448|NCT02484638|Drug|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
79519573|NCT05788185|Biological|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BBIBP-CorV or CoronaVac subjects
79519574|NCT05785065|Drug|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
79519575|NCT05785065|Other|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
79366944|NCT02990416|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
79519576|NCT05784285|Behavioral|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
79519577|NCT05779033|Behavioral|scapular stabilization exercises|scapular stabilization exercises 3 times per week for 4 weeks.
79519578|NCT05779033|Device|ultrasound|Ultrasound 3 times per week for 4 weeks.continuous US operated at a frequency of 1 MHz and at an intensity of 1.5 W/cm2 for 5 minutes
79676485|NCT05809011|Drug|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
79996186|NCT04058808|Other|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
79676486|NCT05809011|Drug|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
79676487|NCT05801419|Device|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
79996187|NCT04058808|Other|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
79996188|NCT04058808|Other|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
79996189|NCT04058808|Other|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
79996190|NCT00169806|Other|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
79996191|NCT03021564|Other|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
79366945|NCT02990416|Biological|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
79366946|NCT02990416|Radiation|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
79366947|NCT02994862|Other|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
79366948|NCT02994862|Other|Conventional Bonding|Normal Bonding Protocol
79366949|NCT02990260|Dietary Supplement|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
79366950|NCT02990260|Dietary Supplement|Lynside Wall Basic|yeast cell walls
79366951|NCT02990260|Dietary Supplement|Placebo|Maize starch and magnesium stearate
79366952|NCT02994706|Procedure|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
79676488|NCT05801419|Device|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
79366953|NCT02994706|Other|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
79676489|NCT05801419|Device|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
79676490|NCT05801419|Combination Product|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
79366954|NCT02999776|Device|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
79366955|NCT02999776|Drug|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
79366956|NCT02999776|Drug|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
79366957|NCT02999698|Other|Observational|Observational
79822141|NCT02562105|Procedure|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
79224449|NCT02187705|Drug|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
79519579|NCT05779033|Other|Kinesio Tape|"Kinesiotape 3 times per week for 4 weeks. We will apply taping to two muscles (deltoideus and supraspinatus). A Y' tape was placed over the deltoid muscle using the muscle stimulation (KT strip arms were located by stretching slightly by 15%-25%) and mechanical correction techniques (KT strip arms were located with maximal stretching). Another Y tape was placed over the supraspinatus muscle using the muscle inhibition technique (the starting point of the tape was attached to the sub acromial-greater tubercle with submaximal (75%) stretching and without stretching on strip arms)."
79519580|NCT05779020|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
79519581|NCT05779020|Biological|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
79366958|NCT02990026|Behavioral|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
79366959|NCT02996656|Drug|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
79366960|NCT02996656|Drug|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
79366961|NCT04270162|Device|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
79366962|NCT04270162|Other|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
79366963|NCT04270162|Other|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
79519582|NCT05779020|Biological|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
79519583|NCT05756803|Device|Low-intensity acoustic shockwave therapy|The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
79519584|NCT05751096|Device|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
79519585|NCT05751096|Device|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
79519586|NCT05742919|Drug|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
79519587|NCT05742919|Drug|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
79519588|NCT05742919|Drug|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
79519589|NCT05722925|Drug|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
79519590|NCT05713461|Behavioral|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
79676491|NCT05801419|Combination Product|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
79676492|NCT05789069|Drug|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
79996192|NCT03669900|Procedure|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
79996193|NCT03023046|Drug|Cyclophosphamide|Given IV
79224450|NCT03317912|Drug|Lidocaïne 2%|Continuous infusion during per and postoperative periods
79224451|NCT03317912|Drug|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
79224452|NCT02183961|Other|Restech|
79224453|NCT02183961|Other|Peptest|
79676493|NCT05789069|Drug|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
79996194|NCT03023046|Drug|Dasatinib|Given PO
79224454|NCT02183961|Other|Detection of pepsin in adenoid specimen|
79224455|NCT03321110|Other|Placebo|Placebo (dextrin)
79224456|NCT03321110|Dietary Supplement|Coenzyme Q10|150 mg or 300 mg
79366964|NCT04387630|Drug|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
79366965|NCT04387630|Drug|Placebo oral tablet|Simethicone 60 mg three times daily.
79366966|NCT04270318|Other|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
79366967|NCT04270318|Other|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
79519591|NCT05713461|Behavioral|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
79679938|NCT00522236|Biological|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
79679939|NCT02931123|Drug|lattulose and rifaximine|
79679940|NCT02948114|Other|Control: Cow milk-based infant formula|
79822142|NCT00749229|Device|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
79366968|NCT04270318|Other|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
79366969|NCT04270318|Other|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
79996195|NCT03023046|Drug|Doxorubicin|Given IV
79366970|NCT02998372|Procedure|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
79366971|NCT02994472|Radiation|Gastric emptying scintigraphy using 99mTc-DTPA|
79366972|NCT02993692|Device|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
79366973|NCT04386382|Procedure|ridge splitting flapless technique using interchangeable guide followed by implant placement|"An informed consent is taken from all the patients~I. Presurgical phase:~Proper dental and medical history.~Scaling and oral hygiene measurements.~Clinical examination.~Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~Optical scanning of the dental casts was done using Ceramill map 400~surgical stent was designed using Mimics Innovation Suite 19 ™ software.~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately"
79366974|NCT02999854|Biological|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
79366975|NCT02999854|Drug|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
79519592|NCT05704751|Device|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
79519593|NCT05669235|Diagnostic Test|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
79996196|NCT03023046|Drug|Etoposide|Given IV
79996197|NCT03023046|Drug|Imatinib Mesylate|Given PO
79366976|NCT02999854|Procedure|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
79366977|NCT02999854|Procedure|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
79519594|NCT05656417|Behavioral|Temporary cessation of all oral hygiene|Participants will refrain from all oral hygiene for 3 weeks.
79996198|NCT03023046|Other|Laboratory Biomarker Analysis|Correlative studies
79366978|NCT02999542|Other|Music|Children will be randomised to receive either music via headphones or silence via headphones
79366979|NCT02999542|Other|No music|Children will be randomised to receive either music via headphones or silence via headphones
79366980|NCT02999620|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
79366981|NCT02999620|Dietary Supplement|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
79366982|NCT04270708|Drug|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
79366983|NCT04270708|Drug|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
79366984|NCT02999464|Other|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
79366985|NCT02999464|Other|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
79366986|NCT02999308|Other|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
79366987|NCT00704938|Biological|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
79519595|NCT05637216|Drug|Losartan 25 milligram capsule|Losartan 25 milligram oral capsule
79519596|NCT05637216|Drug|Placebo|Placebo 25 milligram oral capsule
79519597|NCT05628337|Other|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
79996199|NCT03023046|Drug|Prednisone|Given PO
79676494|NCT05775978|Behavioral|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
79519598|NCT05628337|Other|Control|Non-motivational text messages containing no specific health information
79519599|NCT05616585|Other|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
79519600|NCT05616585|Other|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
79676495|NCT05775978|Behavioral|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
79224457|NCT02187939|Other|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
79224458|NCT03317756|Other|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
79224459|NCT03317756|Other|Patient Control|Patients will receive an attention control
79224460|NCT03321032|Device|Polymer-free amphilimus-eluting stents|Cre8 Evo coronary stent system (CID, Saluggia, Italy)
79224461|NCT03321032|Device|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
79676496|NCT05775978|Behavioral|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
79676497|NCT05763810|Other|Erector Spinae Plane Block|Erector Spinae Plane Block
79228095|NCT03314012|Device|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
79228096|NCT02230371|Drug|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
79366988|NCT00704938|Biological|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10^8 cells to 5 x 10^10 cells.
79366989|NCT00704938|Biological|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
79676498|NCT05763810|Other|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
79676499|NCT05763693|Drug|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
79366990|NCT00704938|Biological|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
79676500|NCT05763693|Drug|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
79676501|NCT05763693|Other|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
79676502|NCT05763693|Other|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
79679941|NCT02948114|Other|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
79822143|NCT04085120|Procedure|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
79822144|NCT04085120|Procedure|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
79519601|NCT05612984|Combination Product|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
79822145|NCT00747903|Drug|aminolevulinic acid hydrochloride|
79822146|NCT00749307|Dietary Supplement|Docosahexaenoic acid (DHA)|
79822147|NCT00749307|Dietary Supplement|Placebo|
79822148|NCT02562573|Drug|PBI4050|
79519602|NCT05612984|Dietary Supplement|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
79519603|NCT05604014|Behavioral|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
79519604|NCT05594017|Drug|Scopolamine (5ug/kg)|Patient receives a dose of scopolamine (5ug/kg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
79519605|NCT05594017|Drug|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
79366991|NCT00704938|Drug|cyclophosphamide|60mg/kg/day (Days-7,-6)
79519606|NCT05591274|Device|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
79519607|NCT05581511|Other|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
79519608|NCT05581108|Dietary Supplement|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
79519609|NCT05581108|Dietary Supplement|Placebo|matched placebo (2 capsules)
79519610|NCT05579392|Device|Bright Light Therapy|Device: Bright Light Therapy Retimer
79519611|NCT05579392|Device|Placebo Retimer Device|Device: Placebo Retimer Device with no bright light therapy
79224462|NCT04335279|Other|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
79519612|NCT05576038|Drug|L-Tryptophan|L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
79366992|NCT00704938|Drug|fludarabine phosphate|25mg/m^2 (Days -5, -4, -3, -2, and -1)
79676503|NCT05758857|Behavioral|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
79366993|NCT02994316|Other|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
79676504|NCT05758857|Behavioral|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
79676505|NCT05758857|Behavioral|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
79676506|NCT05750264|Drug|Ibuprofen|800 mg of IV ibuprofen
79676507|NCT05746754|Radiation|CSI|30 Gy in 10 fractions to CNS
79822149|NCT02562183|Drug|kallikrein|Using kallikrein
79822150|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"30 quality of life questions for the participant to answer~The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
79996200|NCT03023046|Biological|Rituximab|Given IV
79996201|NCT03023046|Drug|Vincristine Sulfate|Given IV
79366994|NCT02994628|Other|Water|Water only without carbohydrate
79366995|NCT02994628|Other|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
79366996|NCT02994628|Other|Cavendish banana|Ingest Cavendish banana (common banana)
79366997|NCT02994628|Other|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
79366998|NCT02994004|Other|no intervention|
79366999|NCT02995408|Behavioral|Relaxation Response Resiliency Program for Parents of Children with ASD|
79519613|NCT05576038|Drug|Freedom SimpleCap Powder|Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
79519614|NCT05570916|Device|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
79676508|NCT05742685|Behavioral|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
79822151|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"13 quality of life questions for the participant to answer~The answers range from 1 (Not at All) to 4 (Very Much)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
79822152|NCT02562027|Behavioral|Modified Medical Research Council|"Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
79224463|NCT03320954|Behavioral|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
79224464|NCT02488850|Procedure|Surgery|
79367000|NCT02994082|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
79367001|NCT02994082|Behavioral|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
79367002|NCT02994082|Behavioral|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
79519615|NCT05570916|Device|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
79224465|NCT02488850|Radiation|SABR|
79224466|NCT02188017|Drug|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
79224467|NCT03317600|Device|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
79224468|NCT03317600|Drug|Placebo|"Intervention is a placebo nerve block with isotonic saline"
79224469|NCT02184117|Drug|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
79224470|NCT02184117|Drug|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
79519616|NCT05529069|Drug|Pirtobrutinib|Given by PO
79519617|NCT05529069|Drug|Venetoclax|Given by PO
79822153|NCT02562027|Behavioral|EQ-5D|"5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
79224471|NCT02184117|Drug|Resting conditions|Baseline measurement of aortic and coronary pressures
79822154|NCT02562027|Behavioral|Center for Epidemiological Studies Depression Scale|"20 quality of life questions for the participant to answer~Answers range from Rarely or none of the time to Most or all of the time~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
79519618|NCT05528770|Device|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
79224472|NCT02486354|Drug|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
79224473|NCT02184273|Drug|Magnesium metamizol|
79224474|NCT02184273|Drug|Placebo|
79224475|NCT02486198|Drug|placebo|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
79228097|NCT02230371|Drug|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
79228098|NCT03859700|Biological|DBV712 250 mcg|DBV712 250 mcg, once daily
79367003|NCT02994082|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
79367004|NCT02994082|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
79367005|NCT02994082|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
79676509|NCT05736848|Device|OviTex® PRS|OviTex® PRS is a reinforced tissue matrix intended to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
79679942|NCT02948114|Other|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
79367006|NCT02994082|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
79676510|NCT05736679|Device|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
79822155|NCT02562027|Behavioral|Medical Outcomes Study Social Support Survey|"19 quality of life questions for the participant to answer~Answers from from 1 (None of the time) to 5 (All of the time)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
79224476|NCT02486198|Drug|GM|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
79224477|NCT02486198|Drug|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
79224478|NCT03536013|Other|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
79224479|NCT03316040|Behavioral|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
79822156|NCT00723398|Dietary Supplement|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
79822157|NCT00723398|Drug|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
79822158|NCT00723398|Drug|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
79224480|NCT02188173|Drug|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
79224481|NCT03535935|Drug|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
79367007|NCT02994082|Drug|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
79367008|NCT02994082|Drug|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
79519619|NCT05528770|Device|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
79519620|NCT05525000|Device|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
79224482|NCT03535935|Other|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
79519621|NCT05523596|Drug|ICM20|small molecules
79519622|NCT05523596|Drug|Benznidazole|small molecule
79822159|NCT00723398|Drug|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
79996202|NCT03668262|Drug|Cis-atracurium|Different concentration of cis-atracurium
79367009|NCT02994082|Drug|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
79367010|NCT02994082|Drug|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
79367011|NCT02994082|Behavioral|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
79519623|NCT05482568|Drug|SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316|"Drug: SHR-A1811 & Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 & SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous"
79519624|NCT05477147|Device|Catheter Ablation|Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
79519625|NCT05476796|Drug|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
79676511|NCT05730335|Device|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
79679943|NCT02948114|Other|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
79996203|NCT03669198|Diagnostic Test|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
79996204|NCT03019458|Dietary Supplement|MINGO|6 20oz sachets will be taken daily by intervention group
79996205|NCT04058340|Dietary Supplement|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
79996206|NCT04058340|Other|Placebo|0.9% NaCl solution in nebulization
79676512|NCT05726123|Device|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
79676513|NCT05712538|Drug|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
79224483|NCT03315884|Procedure|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
79224484|NCT03315884|Procedure|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
79224485|NCT02184351|Drug|Roxanes's clotrimazole troches|
79224486|NCT02184351|Drug|Mycelex® troches|
79367012|NCT02994082|Behavioral|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
79367013|NCT01270048|Drug|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
79676514|NCT05712538|Other|Placebo|Normal saline
79996207|NCT03669120|Other|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
79996208|NCT03669120|Behavioral|Telephone-Based Intervention|Receive individualized text based messages
79996209|NCT04058106|Procedure|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
79367014|NCT01270048|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
79676515|NCT05707871|Drug|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
79676516|NCT05707871|Other|usual brand of Cigarettes|Usual Brand of Cigarettes
79676517|NCT05705115|Drug|Ringer acetate|Ringer acetate 5 ml/kg.
79676518|NCT05705115|Other|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
79676519|NCT05703152|Other|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
79367015|NCT02995096|Procedure|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
79367016|NCT02995096|Drug|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
79367017|NCT02993848|Other|No intervention|
79367018|NCT01275820|Dietary Supplement|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
79519626|NCT05476796|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
79676520|NCT05701072|Procedure|Oocyte Pick Up|The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.
79367019|NCT02993536|Other|Biospecimen Collection|
79367020|NCT02993770|Procedure|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
79367021|NCT02993770|Procedure|External DCR|External DCR
79367022|NCT00709306|Device|UV-Detect Photos|UV-Detect Photos
79367023|NCT00709306|Behavioral|Motivational Interviewing|Motivational Interviewing
79367024|NCT00709306|Behavioral|Education|Education
79367025|NCT01275976|Drug|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
79367026|NCT01275976|Other|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
79679944|NCT02937207|Drug|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
79679945|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
79679946|NCT02937207|Drug|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
79519627|NCT05476796|Drug|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
79519628|NCT05476796|Drug|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
79676521|NCT05701072|Procedure|Embryo Transfer|When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
79996210|NCT04058262|Other|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
79519629|NCT05456997|Procedure|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
79224487|NCT02188251|Dietary Supplement|Activamp|
79224488|NCT02188251|Other|Placebo|
79224489|NCT03320798|Other|Data record|
79367027|NCT00725530|Device|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
79367028|NCT00725530|Device|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
79519630|NCT05455619|Drug|Evexomostat|Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
79676522|NCT05685927|Drug|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
79676523|NCT05685927|Procedure|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
79676524|NCT05681858|Diagnostic Test|CT coronary angiography and [12N] NH3 PET-MR|Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
79676525|NCT05673993|Biological|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
79996211|NCT04058262|Other|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
79224490|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
79224491|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
79224492|NCT02184429|Drug|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
79224493|NCT02184429|Drug|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
79224494|NCT02184429|Drug|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
79676526|NCT05673993|Biological|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
79676527|NCT05673993|Drug|Placebo|Subjects will be given subcutaneous placebo once a week.
79676528|NCT05673148|Procedure|Stereotactic Ablative Radiotherapy|Undergo SABR
79224495|NCT02184429|Drug|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
79224496|NCT02184429|Drug|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
79996212|NCT04058262|Other|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
79224497|NCT03315806|Other|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
79224498|NCT03315806|Other|Placebo|140 mL of beetroot juice isent of nitrate
79224499|NCT03317366|Drug|ARQ 092|Open-label expanded access for ARQ 092 capsules
79224500|NCT02030379|Behavioral|QPL-CT|Use the QPL-CT to prioritize questions
79224501|NCT03320720|Other|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
79224502|NCT03320720|Other|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
79367029|NCT01270360|Device|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
79367030|NCT01270438|Drug|FOLFOX regimen|Given IV
79367031|NCT01270438|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
79367032|NCT01270438|Biological|bevacizumab|Given IV
79367033|NCT01270438|Drug|oxaliplatin|Given IV
79367034|NCT01270438|Drug|leucovorin calcium|Given IV
79367035|NCT01270438|Drug|fluorouracil|Given IV
79367036|NCT01270594|Behavioral|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
79519631|NCT05433493|Behavioral|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
79519632|NCT05427084|Drug|Canagliflozin|Canagliflozin tablet 300mg PO daily
79676529|NCT05673148|Procedure|Resection|undergo surgical resection
79676530|NCT05673148|Procedure|Microwave Ablation|undergo microwave ablation
79676531|NCT05673148|Drug|Chemotherapy|Receive SOC chemotherapy
79996213|NCT04058262|Other|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
79224503|NCT02484170|Drug|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
79224504|NCT02484170|Drug|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
79367037|NCT01270594|Behavioral|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
79367038|NCT01270672|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
79367039|NCT01270672|Drug|carvedilol|50 mg per os, single dose
79367040|NCT01270672|Drug|placebo|capsules identical to MDMA or carvedilol
79367041|NCT02992834|Biological|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
79367042|NCT02992834|Biological|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
79996214|NCT05654688|Other|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
79996215|NCT03668964|Dietary Supplement|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
79996216|NCT03668964|Dietary Supplement|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
79996217|NCT03668964|Dietary Supplement|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
79996218|NCT03668964|Dietary Supplement|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
79367043|NCT01276210|Drug|sorafenib tosylate|Given PO
79367044|NCT01276210|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
79519633|NCT05427084|Drug|Placebo|Placebo tablet
79676532|NCT05673148|Procedure|Computed Tomography|Undergo CT scan
79676533|NCT05673148|Procedure|Magnetic Resonance Imaging|Undergo MRI
79676534|NCT05673148|Procedure|Positron Emission Tomography|Undergo PET scan
79676535|NCT05649579|Drug|Dupilumab|Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
79996219|NCT03668964|Dietary Supplement|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
79996220|NCT03668964|Dietary Supplement|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
79996221|NCT03668964|Dietary Supplement|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
79996222|NCT03668886|Other|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
79996223|NCT02923830|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
79996224|NCT02923830|Drug|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
79224505|NCT02188407|Drug|Sevoflurane|MAC 3-5 V% during surgery
79224506|NCT02188407|Drug|Propofol|Propofol group (P group)- The group anaesthesied with propofol
79228099|NCT03996447|Drug|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
79367045|NCT01276210|Other|laboratory biomarker analysis|Correlative studies
79367046|NCT00727636|Biological|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
79367047|NCT01270750|Drug|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
79367048|NCT00709696|Drug|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
79367049|NCT00709696|Drug|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
79367050|NCT01270906|Drug|CHIR-258 (TKI258)|
79519634|NCT05414123|Device|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
79519635|NCT05394818|Drug|SHR-A2009|The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
79519636|NCT05391503|Behavioral|Light therapy|Morning bright light for 60 minutes after awakening
79519637|NCT05391503|Behavioral|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
79519638|NCT05387317|Biological|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
79224507|NCT02484326|Other|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
79224508|NCT02188563|Other|Comprehensive smoking cessation intervention|
79224509|NCT02188563|Behavioral|Enhanced usual care|
79224510|NCT02184507|Dietary Supplement|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
79519639|NCT05387317|Biological|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
79519640|NCT05387317|Biological|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
79519641|NCT05387317|Biological|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
79519642|NCT05387317|Biological|Moderna Standard dose|Standard dose (50ug in 0.25ml)
79519643|NCT05387317|Biological|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
79519644|NCT05384821|Drug|Vincristine|IV, D1-D22-D43 and D64
79996225|NCT03668730|Radiation|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
79224511|NCT02184507|Dietary Supplement|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
79224512|NCT02184507|Dietary Supplement|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
79224513|NCT02184507|Drug|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
79224514|NCT03317210|Drug|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
79224515|NCT03317210|Drug|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
79224516|NCT02184585|Drug|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
79224517|NCT02184585|Drug|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
79519645|NCT05384821|Drug|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
79519646|NCT05384821|Drug|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
79519647|NCT05384821|Drug|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
79519648|NCT05384821|Drug|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
79676536|NCT05646459|Drug|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
79676537|NCT05646459|Device|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
79224518|NCT02184585|Drug|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
79224519|NCT03317132|Behavioral|IPS|One year of IPS Support
79224520|NCT02188641|Other|Diet|
79224521|NCT02188641|Other|Exercise|
79224522|NCT02188641|Other|Diet and Exercise|
79224523|NCT02188641|Other|Healthy Lifestyle (Control) Group|
79224524|NCT02488772|Device|Sleep mask|
79224525|NCT02488772|Other|Standard of care|Standard of care as decided by treating emergency physician
79224526|NCT02488772|Device|Ear Plugs|
79224527|NCT02188797|Behavioral|Group MI risk reduction program|
79224528|NCT02483780|Behavioral|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
79224529|NCT03536403|Radiation|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
79224530|NCT03536403|Other|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
79224531|NCT02488694|Drug|Afatinib|40 mg/d
79224532|NCT02488694|Drug|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
79519649|NCT05377723|Device|Neodyne Device|See Arm Description: Neodyne Device
79519650|NCT05369260|Other|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
79519651|NCT05369260|Other|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
79996226|NCT03668730|Drug|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
79224533|NCT02188875|Behavioral|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
79224534|NCT02188875|Behavioral|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
79519652|NCT05368350|Device|Transcranial direct current stimulation|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
79224535|NCT02480192|Other|CBT for Menopausal Symptoms (CBT-Meno)|This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
79519653|NCT05317455|Drug|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
79519654|NCT05293197|Device|SonoCloud® (9 transducers)|SonoCloud®, sonication: dose escalation 6 cycles of sonication
79519655|NCT05281198|Dietary Supplement|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
79519656|NCT05281198|Dietary Supplement|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
79519657|NCT05217459|Device|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
79519658|NCT05207085|Drug|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
79519659|NCT05207085|Other|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
79519660|NCT05206695|Behavioral|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
79519661|NCT05201469|Drug|VIB4920|Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
79224536|NCT02483858|Drug|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
79224537|NCT03316898|Drug|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
79676538|NCT05646459|Device|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
79676539|NCT05638633|Drug|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
79676540|NCT05638633|Drug|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
79676541|NCT05638633|Drug|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
79676542|NCT05638633|Drug|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
79224538|NCT03316898|Drug|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
79224539|NCT03316898|Drug|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
79519662|NCT05201469|Drug|Placebo for VIB4920|Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
79676543|NCT05635604|Drug|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
79679947|NCT02937207|Drug|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
79996227|NCT03668730|Drug|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
79224540|NCT03316898|Drug|Memantine|Memantine as prescribed by the physician as per standard of care.
79224541|NCT02188953|Drug|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
79519663|NCT05199285|Biological|Ipilimumab|Given IV
79519664|NCT05199285|Biological|Nivolumab|Given IV
79519665|NCT05198518|Device|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
79519666|NCT05198518|Device|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
79519667|NCT05175664|Other|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
79224542|NCT02188953|Drug|Calcium carbonate placebo|
79224543|NCT02030613|Genetic|Blood test|
79519668|NCT05175664|Other|Short-term study|No intervention. Investigations: blood samples and pupillometry.
79519669|NCT05175664|Other|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
79996228|NCT03668730|Drug|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
79996229|NCT03623178|Other|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
79224544|NCT03316820|Drug|K0706|Study treatment with water after an overnight fast
79224545|NCT03316820|Drug|K0706|Study treatment with water after food
79519670|NCT05148156|Device|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
79224546|NCT02483702|Other|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
79224547|NCT02483702|Other|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
79224548|NCT02184819|Drug|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
79224549|NCT02184819|Drug|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
79519671|NCT05146700|Drug|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
79519672|NCT05146700|Drug|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
79519673|NCT05138393|Other|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
79224550|NCT02189109|Drug|NVX-108|0.2% emulsion administered i.v.
79224551|NCT02189187|Behavioral|Mindfulness|
79224552|NCT02189187|Behavioral|Psychoeducation|
79224553|NCT02484014|Other|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
79224554|NCT02484014|Other|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~Awareness generation activities for all stakeholders in school~Wall-magazine~Speak-out box~Competitions~School Health Promotion Committee~School health policies~Peer groups of students of standard IX~Workshops and talks for all the students from standard IX, and for teachers~Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
79519674|NCT05138393|Other|Observation|Non-specific physical activity 60 minutes per day.
79519675|NCT05136976|Drug|Rituximab infusion|2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
79519676|NCT05136976|Drug|Placebo infusion|2 infusions of placebo at a 2 week interval.
79519677|NCT05136976|Drug|Premedications|"Premedications prior to rituximab or placebo infusions:~IV Dexchlorpheniramine Maleate IV: 10 mg~IV Methylprednisolone: 40 mg~PO Paracetamol : 1 gram"
79519678|NCT05136352|Procedure|adductor canal block|loco-regional anesthesia using adductor canal block
79996230|NCT03623178|Other|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
79996231|NCT03668652|Device|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
79519679|NCT05136352|Procedure|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
79524818|NCT05767853|Other|Immune-phenotyping of tissue and peripheral blood myeloid compartment|"Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2).~BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis."
79996232|NCT03668652|Procedure|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
79996233|NCT03668574|Other|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
79224555|NCT02483546|Device|Laerdal®|simulation- based educational intervention
79224556|NCT02483546|Behavioral|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
79519680|NCT05128838|Other|RISE (Reinvent, Integrate, Strengthen, Expand) Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
79519681|NCT05123222|Other|ZIKV-SJRP/2016-184 Strain|Zika Virus Strain
79996234|NCT03668574|Other|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
79519682|NCT05123222|Other|Experimental: ZIKV-Nicaragua/2016 Strain|Zika Virus Strain
79996235|NCT03021018|Drug|Brivaracetam|"Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
79996236|NCT03021018|Drug|Lorazepam|"Pharmaceutical Form: Solution for injection~Route of Administration: intravenous"
79224557|NCT02483546|Behavioral|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
79519683|NCT05123222|Biological|Placebo|Not an active strain of Zika
79224558|NCT02256813|Drug|BIRT 2584 XX|
79224559|NCT02256813|Drug|Warfarin sodium|
79519684|NCT05107310|Procedure|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
79519685|NCT05107310|Procedure|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
79996237|NCT03669042|Device|PhotoFix|PhotoFix Patch Implantation
79996238|NCT02509507|Drug|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 & 2, up to 8mL in Cohorts 3 & 4 of the Group A & Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10^6 PFU/mL to the 2nd dose at 10^7 or 10^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 & 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 [dated 26 October 2021], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
79224560|NCT02256813|Drug|Omeprazole|
79224561|NCT02256813|Drug|Dextromethorphan hydrobromide|
79224562|NCT02256813|Drug|Caffeine|
79367051|NCT01270984|Drug|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
79367052|NCT01270984|Drug|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
79519686|NCT05107310|Procedure|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
79224563|NCT02256813|Drug|Midazolam hydrochloride|
79367053|NCT01276366|Other|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
79367054|NCT01276366|Other|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
79519687|NCT05101798|Drug|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
79519688|NCT05101213|Biological|Virus-specific Cytotoxic T-lymphocytes|Given IV
79679948|NCT02937207|Drug|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
79224564|NCT02256813|Drug|Vitamin K1|
79224565|NCT02479958|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
79224566|NCT02479958|Procedure|Tooth drying|The tooth was dried with air jet.
79224567|NCT02479958|Procedure|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
79228100|NCT03996447|Drug|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
79228101|NCT01111110|Device|anti-static then static|Albuterol using static chambers
79228102|NCT01111110|Device|Static then anti-static chamber|albuterol with Static then anti-static chambers
79367055|NCT01276366|Other|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
79996239|NCT02509507|Drug|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
79519689|NCT05090722|Device|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
79519690|NCT05073588|Other|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
79519691|NCT05073588|Other|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
79519692|NCT05068726|Drug|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
79519693|NCT05040282|Device|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
79519694|NCT05039801|Biological|Bevacizumab|Given IV
79996240|NCT03176407|Diagnostic Test|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
79996241|NCT03175549|Drug|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
79224568|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
79367056|NCT02992678|Drug|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
79367057|NCT02992678|Drug|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
79367058|NCT01276444|Device|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
79519695|NCT05039801|Drug|Glutaminase-1 Inhibitor IACS-6274|Given by PO
79519696|NCT05039801|Drug|Paclitaxel|Given by IV (vein)
79519697|NCT05039801|Drug|Capivasertib|Given by PO
79519698|NCT05034198|Behavioral|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
79519699|NCT05034198|Behavioral|Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
79519700|NCT05034198|Behavioral|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
79996242|NCT03175549|Drug|Placebo|Identical placebo pills taken orally for 14 days
79996243|NCT03174925|Device|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
79996244|NCT01314937|Drug|Mebendazole|Single-dose 500 mg mebendazole tablet
79996245|NCT01314937|Other|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
79996246|NCT04718155|Drug|Atorvastatin|will receive 40 mg atrorvastatin 2 days
79996247|NCT04718155|Other|placebo|will receive 40 mg placebo 2 days
79228103|NCT05338736|Diagnostic Test|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
79228104|NCT05338736|Diagnostic Test|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
79367059|NCT01276444|Device|transpulmonary thermodilution + central venous saturation|Described in details above
79367060|NCT01271062|Procedure|gastric bypass surgery|
79367061|NCT01271062|Procedure|abdominal surgery|
79367062|NCT01271062|Behavioral|very low caloric diet|
79367063|NCT02992912|Drug|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
79367064|NCT02992912|Procedure|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
79367065|NCT01276522|Drug|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
79367066|NCT02992444|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
79822160|NCT00716456|Drug|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
79822161|NCT03945890|Other||
79822162|NCT00684645|Drug|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
79367067|NCT02992444|Other|Experimental adhesive strip|This is a strip of a newly developed adhesive.
79676544|NCT05635604|Drug|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
79822163|NCT04054869|Other|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
79822164|NCT04054869|Other|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
79822165|NCT00752037|Drug|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
79822166|NCT00747981|Procedure|Thoracic CT Scan|Perform a CT Scan and an endoscopy
79822167|NCT05416983|Procedure|Discussion|Attend discussion
79224569|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
79519701|NCT05032183|Drug|Cyclophosphamide|Given IV
79822168|NCT05416983|Other|Questionnaire Administration|Complete questionnaire
79519702|NCT05032183|Drug|Cytarabine|Given IT
79519703|NCT05032183|Drug|Dexamethasone|Given IV or PO
79519704|NCT05032183|Biological|Filgrastim-sndz|Given SC
79996248|NCT04668859|Drug|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
79224570|NCT02189265|Other|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
79224571|NCT02483624|Drug|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
79224572|NCT02483624|Drug|Placebo|Placebo
79224573|NCT02184897|Drug|lenograstim 10 microgram/kg/day|
79367068|NCT01271140|Drug|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
79519705|NCT05032183|Drug|Leucovorin|Given IV
79519706|NCT05032183|Drug|Mercaptopurine|Given PO
79224574|NCT02483390|Other|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
79519707|NCT05032183|Drug|Mesna|Give IV
79519708|NCT05032183|Drug|Methotrexate|Given IT
79519709|NCT05032183|Biological|Pegfilgrastim|Given SC
79519710|NCT05032183|Drug|Prednisone|Given PO
79519711|NCT05032183|Biological|Rituximab|Given IV
79519712|NCT05032183|Biological|Tagraxofusp-erzs|Given IV
79519713|NCT05032183|Drug|Vincristine|Given IV
79519714|NCT05032079|Procedure|cryoablation|single probe ultrasound guided cryoablation
79519715|NCT05026125|Drug|Remifentanil Injection|Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
79524819|NCT05767827|Drug|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
79676545|NCT05630378|Behavioral|outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients|Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.
79676546|NCT05630378|Other|waiting group|Patients receive no intervention
79822169|NCT00716144|Drug|Talarozole|Oral Capsule Once Daily
79822170|NCT00752115|Drug|sildenafil|50mg, day1,8 and 15 in each cycle
79822171|NCT00752115|Drug|placebo|1 tab, day 1,8 and 15 in each cycle.
79822172|NCT00752115|Drug|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
79822173|NCT00752115|Drug|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
79996249|NCT04668859|Drug|Methylcellulose|Placebo will consist of inert methylcellulose
79996250|NCT02320201|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
79367069|NCT01271218|Other|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
79519716|NCT05026125|Drug|Remifentanil Injection plus 30%|Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
79519717|NCT05012943|Biological|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
79224575|NCT03535779|Biological|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
79224576|NCT03535779|Biological|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
79367070|NCT01271218|Other|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
79676547|NCT05625490|Drug|Ga-68 Galmydar|Two intravenous injection of the PET radiotracer 68Ga-Galmydar.
79676548|NCT05625490|Drug|13N-ammonia|Two intravenous Injection of PET radiotracer 13N-Ammonia.
79224577|NCT02184975|Procedure|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
79224578|NCT02184975|Procedure|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
79367071|NCT01271296|Dietary Supplement|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
79367072|NCT01271296|Dietary Supplement|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
79367073|NCT01271374|Drug|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
79367074|NCT01271374|Drug|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
79367075|NCT00710944|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
79519718|NCT05012943|Other|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
79519719|NCT05012943|Biological|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
79519720|NCT04997369|Device|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
79519721|NCT04994990|Drug|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
79519722|NCT04994990|Drug|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
79224579|NCT02189343|Drug|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
79224580|NCT03535701|Dietary Supplement|Dietary Intervention|Undergo ketogenic diet
79224581|NCT03535701|Other|Laboratory Biomarker Analysis|Correlative studies
79224582|NCT03535701|Drug|Paclitaxel|Given standard of care therapy with paclitaxel
79519723|NCT04992260|Biological|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
79519724|NCT04992260|Biological|Controlled vaccine|The placebo was manufactured by Sinovac Research& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
79676549|NCT05625425|Behavioral|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
79676550|NCT05625425|Behavioral|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
79676551|NCT05625425|Behavioral|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
79676552|NCT05625425|Behavioral|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
79676553|NCT05621772|Other|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)|MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
79676554|NCT05619302|Drug|[68Ga]CBP8 PET/MRI|Simultaneous cardiac PET/MRI images will be obtained following injection of [68Ga]CBP8
79676555|NCT05618782|Drug|LEVI-04|Intravenous infusion
79996251|NCT02261389|Other|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
79224583|NCT03535701|Other|Quality-of-Life Assessment|Ancillary studies
79519725|NCT04990895|Other|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
79519726|NCT04984317|Drug|onabotulinumtoxin A|One-time injection of 100U BOTOX
79519727|NCT04981184|Device|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
79519728|NCT04977479|Biological|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
79519729|NCT04977479|Other|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
79676556|NCT05618782|Other|Placebo:|Placebo dose intravenous infusion
79676557|NCT05615285|Other|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
79676558|NCT05613803|Drug|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
79367076|NCT01271530|Other|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
79676559|NCT05613803|Other|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
79822174|NCT00918476|Drug|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
79224584|NCT03535701|Other|Questionnaire Administration|Ancillary studies
79367077|NCT01271608|Device|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
79367078|NCT01276834|Drug|everolimus|comparison of everolimus-based and CNI-based immunosuppression
79224585|NCT02486276|Drug|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79224586|NCT02486276|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79367079|NCT01276912|Drug|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
79367080|NCT01276912|Behavioral|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
79367081|NCT00728260|Biological|None administered in this study|N/A in this study
79519730|NCT04977479|Biological|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
79519731|NCT04976621|Behavioral|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
79822175|NCT00749385|Drug|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
79224587|NCT02486276|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79224588|NCT02189421|Device|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
79367082|NCT01276990|Drug|BI 224436|Oral drinking solution
79367083|NCT01276990|Drug|BI 224436|Oral drinking solution
79519732|NCT04976621|Other|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
79519733|NCT04974515|Device|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
79519734|NCT04954690|Behavioral|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
79519735|NCT04954690|Behavioral|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
79519736|NCT04954690|Behavioral|Usual Care|Usual Care
79519737|NCT04947189|Drug|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
79519738|NCT04947189|Drug|Docetaxel|Use of docetaxel chemotherapy for solid tumours
79519739|NCT04916678|Other|R-TEP EMDR intervention|"During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment."
79519740|NCT04912479|Device|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
79519741|NCT04858620|Drug|Xlear Nasal Spray|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours
79519742|NCT04858620|Drug|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
79519743|NCT04854486|Other|GSE and Xylitol|Participants are given the experimental treatment to be used for 7 days.
79224589|NCT02485886|Drug|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
79224590|NCT02480036|Radiation|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
79224591|NCT02480036|Device|Intrabeam®|
79224592|NCT02189499|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
79224593|NCT05714228|Procedure|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
79367084|NCT01276990|Drug|BI 224436|Oral drinking solution
79367085|NCT01276990|Drug|BI 224436|Oral drinking solution
79367086|NCT01276990|Drug|BI 224436|Oral drinking solution
79519744|NCT04854486|Drug|Control Placebo|Saline
79519745|NCT04821310|Drug|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
79519746|NCT04821310|Drug|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
79519747|NCT04810260|Behavioral|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
79519748|NCT04805437|Device|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
79519749|NCT04805437|Device|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
79822176|NCT00749385|Drug|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
79367087|NCT01276990|Drug|BI 224436|Oral drinking solution
79367088|NCT01276990|Drug|BI 224436|Oral drinking solution
79367089|NCT01276990|Drug|BI 224436|Oral drinking solution
79519750|NCT04790487|Drug|CPM|one spray dose (~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
79519751|NCT04790487|Drug|Placebo|Saline
79822177|NCT00749385|Drug|EC naproxen|Enteric-coated naproxen tablet (500mg)
79519754|NCT04789239|Drug|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
79519755|NCT04789239|Other|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
79224594|NCT05714228|Procedure|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
79224595|NCT02189577|Drug|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
79224596|NCT02189577|Drug|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
79224597|NCT02189655|Procedure|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
79224598|NCT02485652|Drug|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
79367090|NCT01276990|Drug|BI 224436|Oral drinking solution
79367091|NCT01276990|Drug|Placebo|Oral drinking solution
79367092|NCT01277068|Procedure|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
79367093|NCT01271764|Other|no drug|The role of G9a protein in patients with endometrial cancer
79367094|NCT01277146|Drug|OMP-59R5|IV infusion
79367095|NCT00711022|Device|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
79367096|NCT00728728|Drug|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
79367097|NCT00728728|Dietary Supplement|Placebo|Placebo
79367098|NCT04270006|Biological|adipose derived stem cells exosomes|they are small extracellular vesicles
79367099|NCT01271998|Drug|TR-701 FA|200 mg, oral, once daily for 3 days.
79367100|NCT00717418|Drug|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
79367101|NCT00717574|Drug|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
79519756|NCT04786119|Device|CORI Robotics|Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
79519757|NCT04745754|Other|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
79519758|NCT04720053|Device|Wearable brain sensing wellness device headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
79519759|NCT04713618|Procedure|Pelvic Examination|Undergo pelvic exam
79224599|NCT02189733|Biological|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
79676560|NCT05612295|Behavioral|MBPP|"MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions."
79224600|NCT02185365|Radiation|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
79367102|NCT00717574|Drug|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
79367103|NCT00718120|Biological|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
79519760|NCT04713618|Other|Survey|Complete surveys
79519761|NCT04706793|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
79676561|NCT05612295|Behavioral|Self-talk|self-talk sessions include: Session 1 & 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 & 8. general practice for learned self-talk techniques.
79224601|NCT02485808|Other|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
79676562|NCT05601583|Device|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
79676563|NCT05600907|Biological|JSP191|A monoclonal antibody that targets human CD117
79822178|NCT00749385|Drug|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
79224602|NCT02485808|Procedure|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
79224603|NCT02485808|Other|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
79367104|NCT02992054|Other|stimulating activities|
79367105|NCT01277614|Behavioral|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
79367106|NCT01277692|Drug|GSK2336805 10mg|single dose once daily
79367107|NCT01277692|Drug|GSK2336805 30mg|single dose once daily
79367108|NCT01277692|Drug|GSK2236805 100mg|single dose once daily
79367109|NCT01277692|Drug|GSK2236805 200mg|single dose once daily
79367110|NCT01277692|Drug|GSK2236805 10mg|repeat dose once daily for 7 days
79367111|NCT01277692|Drug|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
79367112|NCT01277692|Drug|GSK2236805 5mg|single dose in HCV infected patients
79367113|NCT01277692|Drug|GSK2236805 30mg|single dose in HCV infected patients
79519762|NCT04706793|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
79519763|NCT04694131|Device|TMS|The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
79519764|NCT04677049|Drug|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
79224604|NCT02485808|Other|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
79224605|NCT02189811|Biological|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
79224606|NCT02189811|Biological|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
79367114|NCT01277692|Drug|GSK2236805 100mg|single dose in HCV infected patients
79367115|NCT00719134|Drug|Maxalt|anti-migraine drug
79367116|NCT00719134|Drug|placebo pill|placebo pills
79367117|NCT00719134|Drug|placebo pills|placebo pills
79524820|NCT05767827|Drug|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
79524821|NCT01689792|Drug|MOVIPREP|
79524822|NCT01689792|Drug|CitraFleet|
79996252|NCT02924688|Drug|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily [QD] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
79224607|NCT02189811|Biological|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
79367118|NCT04146363|Biological|Lebrikizumab|Subcutaneous injection
79367119|NCT04146363|Other|Placebo|Subcutaneous Injection
79519765|NCT04650100|Procedure|ultrasound-guided PENG bloc realized before surgery|ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
79519766|NCT04610801|Drug|Nasal Spray|Randomized to placebo and Xlear
79519767|NCT04607148|Drug|Galegenimab|Intravitreal (ITV) injections of galegenimab
79519768|NCT04603326|Procedure|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
79519769|NCT04560712|Procedure|Acupuncture Therapy|Undergo acupuncture
79676564|NCT05588570|Behavioral|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
79676565|NCT05566873|Behavioral|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
79996253|NCT02924688|Drug|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
79224608|NCT02189811|Biological|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
79224609|NCT02189811|Biological|tOPV|tOPV till 22 weeks of age
79224610|NCT04492592|Behavioral|Workshop|Workshop
79224611|NCT04492592|Behavioral|SMS/Texting|SMS/Texting
79224612|NCT02189967|Radiation|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
79224613|NCT02189967|Radiation|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
79367120|NCT01272154|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
79367121|NCT01277770|Drug|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
79519770|NCT04560712|Other|Best Practice|Undergo usual care
79519771|NCT04560712|Other|Questionnaire Administration|Ancillary studies
79996254|NCT02924688|Drug|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
79367122|NCT01277770|Other|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
79519772|NCT04551170|Drug|Theophylline|oral theophylline
79224614|NCT03316664|Behavioral|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
79224615|NCT03316664|Behavioral|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
79224616|NCT03316664|Other|COGPACK|Information already included in arm/group description.
79224617|NCT04633863|Device|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
79224618|NCT03315494|Drug|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
79224619|NCT03315494|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
79224620|NCT03315416|Other|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
79519773|NCT04551170|Drug|Placebo|Placebo capsule or elixir
79519774|NCT04542057|Drug|Ensifentrine|"Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks"
79519775|NCT04542057|Drug|Placebo|"Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks"
79519776|NCT04522570|Device|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
79519777|NCT04522570|Device|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
79676566|NCT05566873|Behavioral|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
79822179|NCT02592044|Procedure|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
79367123|NCT01277770|Drug|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
79224621|NCT02193633|Drug|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
79224622|NCT02193633|Drug|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
79224623|NCT03315338|Drug|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
79367124|NCT02992210|Genetic|4SCAR-GD2|
79367125|NCT00721162|Biological|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
79367126|NCT01838941|Drug|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~6 g/day in children < 30 kg, in 3 divided doses (2 g at meal time)~12 g/day in children > 30 kg, in 4 divided doses (3 g at meal time and bed time)."
79676567|NCT05555732|Drug|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
79676568|NCT05555732|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
79367127|NCT01773109|Drug|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
79676569|NCT05555732|Drug|Pemetrexed|Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
79676570|NCT05555732|Drug|Carboplatin|Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
79822180|NCT02592044|Procedure|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
79367128|NCT02991976|Procedure|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
79367129|NCT01772719|Drug|Simvastatin and zoledronic acid|"Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
79822181|NCT02592044|Procedure|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
79367130|NCT05582265|Drug|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
79367131|NCT05582265|Drug|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
79367132|NCT05582265|Drug|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
79367133|NCT05582265|Procedure|Surgical resection|Standard of care
79224624|NCT03315338|Drug|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
79224625|NCT03315338|Drug|Glucose|75 g in 300 mL solution, orally administered
79224626|NCT03315338|Drug|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
79676571|NCT05555732|Drug|Cisplatin|Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
79676572|NCT05555264|Behavioral|Self-Guided|Clients who select or are assigned the self-guided condition will be able to contact the Online Therapy Unit regarding any technical issues through the secure treatment platform; monitoring staff will respond by secure message to messages received however, no psychological intervention will be provided by monitoring staff as part of the ACCE treatment intervention. If there is a significant clinical issue requiring attention (e.g., a sudden increase in symptoms) monitoring staff will make a telephone call and crisis support will be provided if necessary.
79822182|NCT00748059|Procedure|Standing or upright tilt|stand upright or tilt table test
79822183|NCT00748059|Procedure|Microneurography|Recording from sympathetic nerve
79822184|NCT00748059|Procedure|QSweat|quantitative sweat testing
79996255|NCT02924688|Drug|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
79367134|NCT05582265|Drug|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
79367135|NCT05582265|Drug|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
79679949|NCT02937207|Drug|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
79679950|NCT02937207|Drug|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
79822185|NCT00748059|Device|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
79822186|NCT00748059|Drug|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
79367136|NCT05582265|Radiation|Radiation|Recommended, standard of care
79822187|NCT00748059|Drug|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
79822188|NCT00748059|Procedure|BodPod|Determination of body composition
79822189|NCT00748059|Procedure|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~0.5% proparacaine (Alcaine, Allergan, Inc)~Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~0.5%, 1% tropicamide (Mydriacyl, Alcon)~Over-the-counter preservative-free artificial tears~0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~1% cyclopentolate hydrochloride (Alcon)"
79822190|NCT00748059|Procedure|Sleep study|Recording of sleep pattern overnight
79822191|NCT00748059|Procedure|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
79519778|NCT04522570|Device|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
79676573|NCT05555264|Behavioral|Therapist-Guided|Therapists will spend ~15 minutes/week communicating with each client who selects the therapist-guided condition, primarily using secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist does not feel can be addressed in a message (e.g., a question about the materials that cannot be easily addressed in a text format, a sudden increase in symptoms, increased suicide risk).
79224627|NCT03315338|Drug|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
79367137|NCT01798927|Device|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
79676574|NCT05547191|Device|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
79676575|NCT05546723|Biological|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
79679951|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
79822192|NCT00748059|Procedure|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
79822193|NCT00748059|Procedure|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
79224628|NCT03315338|Drug|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
79224629|NCT03315338|Drug|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
79996256|NCT02924688|Drug|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
79996257|NCT02924688|Drug|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
79224630|NCT03315338|Drug|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
79224631|NCT03315338|Drug|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
79224632|NCT03315338|Drug|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
79367138|NCT00729430|Drug|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
79367139|NCT00729430|Drug|Placebo|Placebo tablets taken orally once per day for 6 months
79367140|NCT04144101|Drug|Etoricoxib|Etoricoxib 60 mg QD Oral
79367141|NCT04144101|Drug|Aceclofenac|Aceclofenac 100 mg BID Oral
79224633|NCT03315338|Drug|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
79367142|NCT01278004|Drug|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
79367143|NCT01278004|Drug|Placebo|Capsule
79679952|NCT02937207|Drug|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
79679953|NCT02937207|Drug|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
79822194|NCT00748059|Procedure|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
79822195|NCT00576381|Drug|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
79822196|NCT00748137|Device|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
79224634|NCT03315338|Drug|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
79224635|NCT03315338|Drug|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
79224636|NCT03315338|Drug|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
79224637|NCT03315338|Drug|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
79224638|NCT03315338|Drug|Placebo oral capsule|Placebo capsules, orally administered
79367144|NCT02700009|Behavioral|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
79367145|NCT02700009|Other|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
79367146|NCT01278238|Drug|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
79519779|NCT04520503|Drug|Propofol|The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
79519780|NCT04520503|Device|EEG monitoring|The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
79676576|NCT05530642|Behavioral|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire & Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
79519781|NCT04518748|Drug|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
79676577|NCT05530330|Diagnostic Test|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
79676578|NCT05529693|Dietary Supplement|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
79224639|NCT03315338|Drug|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
79224640|NCT02185599|Device|DySIS|Colposcopy performed with the DySIS digital colposcope
79996258|NCT02924688|Drug|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
79996259|NCT02924688|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
79996260|NCT02924688|Device|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
79996261|NCT02924688|Device|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
79676579|NCT05529693|Dietary Supplement|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
79224641|NCT02479724|Device|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
79224642|NCT02193711|Other|Topical Arthritis Cream|
79224643|NCT02193789|Procedure|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
79224644|NCT02193789|Device|Covered Self-expandable Metallic Stents|
79224645|NCT02483156|Drug|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
79224646|NCT02483156|Drug|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
79224647|NCT02483156|Drug|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
79224648|NCT02194413|Procedure|therapeutic touch|receiving healing touch
79224649|NCT02194413|Other|quality-of-life assessment|Ancillary studies
79224650|NCT02194413|Other|questionnaire administration|Ancillary studies
79224651|NCT02483234|Drug|secukinumab|
79519782|NCT04518748|Device|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
79519783|NCT04518748|Radiation|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
79519784|NCT04518748|Diagnostic Test|PET/CT|Within 3 hours of completing Y-90 SIRT
79367147|NCT01278238|Device|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
79367148|NCT01278238|Other|Placebo|Neither phenylephrine nor lower limb bandaging
79367149|NCT02706795|Biological|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
79367150|NCT00722020|Device|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
79367151|NCT04143867|Device|Nolix Device|For temporary management of SUI
79519785|NCT04518748|Device|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
79519786|NCT04514757|Device|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
79519787|NCT04514757|Device|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
79519788|NCT04505267|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or intranodally
79519789|NCT04505267|Radiation|Radiation Therapy|Undergo RT
79519790|NCT04482621|Drug|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m^2/day Dosage: 10mg/m^2/day IV day x 5 days (1 cycle only)"
79676580|NCT05529693|Dietary Supplement|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
79676581|NCT05521958|Procedure|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
79676582|NCT05521958|Procedure|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
79519791|NCT04482621|Other|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
79519792|NCT04447872|Procedure|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
79676583|NCT05521958|Procedure|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
79996262|NCT02924688|Device|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
79996263|NCT03668496|Drug|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
79996264|NCT03668496|Drug|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
79519793|NCT04423211|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
79996265|NCT03668418|Drug|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996266|NCT03668418|Drug|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79676586|NCT05504707|Biological|HER2 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million"
79996267|NCT03668418|Drug|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79679954|NCT02937207|Drug|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
79519794|NCT04423211|Drug|Apalutamide|Given PO
79519795|NCT04423211|Procedure|Computed Tomography|Undergo PET/CT
79519796|NCT04423211|Drug|Degarelix|Given SC
79519797|NCT04423211|Radiation|External Beam Radiation Therapy|Undergo EBRT
79679955|NCT02937207|Drug|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
79679956|NCT00522314|Device|NIV and ACBT|
79679957|NCT00522314|Other|Active Cycle of Breathing Techniques|
79996268|NCT03668418|Drug|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996269|NCT03668418|Drug|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996270|NCT03668418|Drug|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996271|NCT03668418|Drug|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996272|NCT03668418|Drug|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996273|NCT03668418|Drug|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
79996274|NCT03666702|Other|Upper limb physiotherapy programme|Web-based physio programme
79996275|NCT03666702|Other|Usual care|Usual physiotherapy care
79996276|NCT03011892|Drug|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
79996277|NCT03011892|Drug|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
79996278|NCT03011892|Drug|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
79519798|NCT04423211|Other|Fluciclovine F18|Given IV
79519799|NCT04423211|Drug|Goserelin Acetate|Given SC
79224652|NCT00706004|Drug|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
79224653|NCT02485340|Drug|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79679958|NCT04690062|Drug|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
79996279|NCT03011892|Drug|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
79996280|NCT03011892|Drug|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
79996281|NCT03011892|Drug|Vehicle Cream BID|Vehicle cream BID
79996282|NCT03017742|Device|Pulse Oximeter|
79996283|NCT02125513|Drug|carboplatin and paclitaxel followed by surgery|
79996284|NCT03667950|Procedure|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
79996285|NCT03667872|Procedure|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
79224654|NCT02485340|Drug|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79224655|NCT02485340|Drug|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79224656|NCT05459870|Biological|4SCAR T cells|Infusion of 4SCAR T cells at 10^6 cells/kg body weight via IV
79519800|NCT04423211|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
79519801|NCT04423211|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79519802|NCT04423211|Drug|Leuprolide Acetate|Given IM
79519803|NCT04423211|Procedure|Magnetic Resonance Imaging|Undergo PET/MR
79996286|NCT03667794|Diagnostic Test|body plethysmography|measurement of conventional lung function parameters
79996287|NCT03667794|Diagnostic Test|impulse oscillometry|measurement of central and peripheral airway resistance
79996288|NCT03667794|Diagnostic Test|multiple breath washout|measurement of ventilation heterogeneity
79996289|NCT03667638|Combination Product|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
79367152|NCT01272310|Biological|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
79367153|NCT01272466|Biological|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
79367154|NCT04143789|Drug|AP-002|Dose escalation
79367155|NCT01272700|Procedure|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
79367156|NCT01272700|Procedure|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
79367157|NCT02991742|Other|contrast media|Compare 2 contrast media
79367158|NCT01278316|Behavioral|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
79367159|NCT01278316|Behavioral|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
79367160|NCT02991664|Other|Equia Forte|Glass ionomer restorative system
79367161|NCT02991664|Other|G-aenial Posterior|Micro hybrid composite resin
79367162|NCT04386850|Drug|Oral 25-Hydroxyvitamin D3|Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
79367163|NCT01278472|Device|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
79367164|NCT01278472|Device|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
79367165|NCT01272778|Drug|Lorazepam|Oral capsule, 0.2 mg, single acute dose
79367166|NCT01272778|Drug|Lorazepam|oral capsule, 0.5 mg, single acute dose
79367167|NCT01272778|Drug|Lorazepam|oral capsule, 1.0 mg, single acute dose
79367168|NCT01272778|Drug|Lorazepam|oral capsule, 2.0 mg, single acute dose
79996290|NCT03666546|Drug|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
79996291|NCT03666546|Drug|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
79367169|NCT01272778|Drug|Placebo|oral capsule, single acute dose
79367170|NCT01272856|Drug|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
79519804|NCT04423211|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MR
79519805|NCT04423211|Other|Quality-of-Life Assessment|Ancillary studies
79519806|NCT04423211|Other|Questionnaire Administration|Ancillary studies
79519807|NCT04423211|Drug|Relugolix|Given PO
79519808|NCT04423211|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79519809|NCT04423211|Drug|Triptorelin|Given IM
79519810|NCT04423211|Radiation|Volume Modulated Arc Therapy|Undergo VMAT
79519811|NCT04422951|Behavioral|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
79519812|NCT04422951|Behavioral|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
79996292|NCT03666546|Drug|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
79996293|NCT03666546|Drug|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
79367171|NCT01273090|Drug|imetelstat sodium|
79367172|NCT01273090|Other|laboratory biomarker analysis|
79367173|NCT01273090|Other|pharmacological study|
79367174|NCT04386694|Device|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
79367175|NCT04386694|Device|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
79519813|NCT04410302|Procedure|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
79519814|NCT04404088|Drug|Acalabrutinib|Given PO
79519815|NCT04404088|Drug|Lenalidomide|Given PO
79519816|NCT04404088|Biological|Rituximab|Given IV
79519817|NCT04353154|Diagnostic Test|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
79519818|NCT04340570|Behavioral|Medication management via televisit to home|Pharmacist led home based televisit for medication management
79519819|NCT04335292|Drug|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
79224657|NCT05451368|Other|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
79519820|NCT04335292|Drug|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
79519821|NCT04335292|Drug|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
79996294|NCT03666546|Drug|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
79224658|NCT04492514|Drug|Mavrilimumab|treatment infusion
79519822|NCT04317534|Drug|Pembrolizumab|Pembrolizumab 400mg IV
79519823|NCT04312802|Diagnostic Test|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~they cannot continue~cadence falls to <55 rpm due to fatigue or dyspnoea~they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
79996295|NCT03666546|Drug|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
79676587|NCT05504707|Biological|HER3 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million"
79996296|NCT03012828|Drug|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
79996297|NCT03012828|Other|Placebo|
79224659|NCT04492514|Drug|Placebo|Placebo infusion
79367176|NCT01273246|Biological|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
79367177|NCT01273246|Biological|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
79367178|NCT01273246|Biological|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
79996298|NCT03667560|Procedure|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
79676588|NCT05497089|Drug|Temelimab 54mg/kg|Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
79676589|NCT05497089|Drug|Placebo|Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
79996299|NCT03667560|Procedure|FlexHD|Patient will be implanted with FlexHD.
79676590|NCT05491538|Behavioral|Social Cognition and Interaction Training-Work Edition (SCIT-WE)|Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
79224660|NCT02485262|Drug|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
79224661|NCT05432726|Other|calculating CARG score|"Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored."
79367179|NCT01273246|Biological|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
79367180|NCT00730522|Drug|CPP-109 vigabatrin|tablets, bid for 12 weeks
79367181|NCT00730522|Drug|Matching Placebo|tablets, bid, 12 weeks
79367182|NCT04345276|Drug|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
79519825|NCT04294901|Behavioral|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
79519826|NCT04276922|Behavioral|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
79519827|NCT04276922|Behavioral|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
79524823|NCT05767814|Other|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
79524824|NCT05767801|Procedure|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
79676591|NCT05483296|Other|Low light condition|"During the Dim light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level."
79676592|NCT05483296|Other|Moderate light condition|"During the Moderate light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level."
79996300|NCT03666936|Other|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
79996301|NCT04598724|Other|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
79996302|NCT03010254|Device|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
79224662|NCT02479490|Drug|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
79996303|NCT03010254|Device|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
79367183|NCT02991352|Device|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
79367184|NCT01278628|Other|exercise training|exercise class once a year
79367185|NCT00731614|Behavioral|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
79367186|NCT00731614|Behavioral|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
79367187|NCT00731614|Behavioral|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
79367188|NCT01273324|Device|ADM Cup|ADM Cup
79676593|NCT05483296|Other|High light condition|"During the High light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level."
79676594|NCT05480111|Drug|Local anesthesia at incision site|20 ml of 0.25% Bupivacaine will be given at incision site
79996304|NCT03010254|Procedure|Cataract surgery|IOL bilateral implantation
79224663|NCT02479256|Drug|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
79224664|NCT02479256|Drug|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
79224665|NCT02479256|Drug|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
79367189|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
79822197|NCT00748137|Other|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
79822198|NCT02562417|Drug|Normal saline|
79822199|NCT02562417|Drug|IV dexamethasone|
79822200|NCT00748293|Other|Low-residue diet|Commercialized (not yet marketed)low-residue diet
79822201|NCT00749619|Other|Catheter Lock Solution Taurolidine and Citrate|
79822202|NCT00749619|Other|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
79367190|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
79822203|NCT00749619|Other|Catheter Lock Solution : Heparin|
79822204|NCT00749697|Other|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
79822205|NCT02561403|Behavioral|EVO multitask video game|Participants will play a multitasking game for 4 weeks
79822206|NCT02561403|Behavioral|EVO words video game|Participants will play a word puzzle game for 4 weeks
79822207|NCT00752349|Procedure|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
79822208|NCT00748371|Drug|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
79996305|NCT04050150|Behavioral|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
79996306|NCT03666468|Other|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
79224666|NCT02479256|Drug|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
79224667|NCT02482844|Other|pacemaker implantation|
79224668|NCT02482844|Other|holter implantation|
79224669|NCT02482766|Drug|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
79224670|NCT02482766|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
79367191|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
79367192|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
79367193|NCT02991274|Procedure|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
79676595|NCT05480111|Drug|Sham QL|20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
79676596|NCT05480111|Drug|Sham Local|20 mls of normal saline given at incision site
79822209|NCT00748371|Drug|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
79822210|NCT00748371|Drug|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
79224671|NCT02482766|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
79367194|NCT02991508|Drug|Placebo|
79367195|NCT02991508|Drug|Adrecizumab|
79822211|NCT03879291|Other|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
79367196|NCT01273558|Drug|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
79367197|NCT00733096|Drug|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
79822212|NCT00749853|Drug|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
79822213|NCT00749853|Drug|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
79822214|NCT00748449|Procedure|Colonoscopy|1 Colonoscopy
79822215|NCT00748449|Procedure|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
79367198|NCT00733096|Drug|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
79822216|NCT02561325|Drug|Sodium Bicarbonate and Sodium chloride|
79996307|NCT03666468|Other|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
79996308|NCT03666468|Other|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
79996309|NCT03666390|Drug|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
79996310|NCT03666390|Drug|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
79367199|NCT00733096|Drug|normal saline|Two transforaminal epidural saline injections, two weeks apart
79519828|NCT04276922|Behavioral|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
79519829|NCT04276922|Behavioral|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
79519830|NCT04276922|Behavioral|Control|Control Group will only complete surveys at baseline and 12 weeks later.
79996311|NCT03008460|Drug|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
79224672|NCT04492280|Drug|Hydrocortisone|After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone & fludrocortisone), group H (hydrocortisone) and group C (control group).
79224673|NCT02724644|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
79224674|NCT02724644|Biological|Placebo Comparator|
79224675|NCT02479178|Drug|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
79519831|NCT04267315|Procedure|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
79519832|NCT04267315|Procedure|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
79224676|NCT02479334|Other|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
79224677|NCT02479334|Other|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
79224678|NCT02479334|Other|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
79224679|NCT02479334|Other|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
79519833|NCT04267315|Other|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
79524825|NCT05767788|Other|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
79822217|NCT02562495|Device|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
79996312|NCT03008460|Drug|Klean-Prep®|Oral solution taken the evening before the colonoscopy
79224680|NCT02482922|Other|Exercise & Dietary Supplement|
79224681|NCT02482688|Behavioral|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
79367200|NCT02991196|Drug|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered [90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
79367201|NCT01278706|Procedure|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
79996313|NCT02914236|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
79996314|NCT03623022|Drug|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
79996315|NCT03623022|Drug|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
79519834|NCT04260607|Drug|Ketamine Hydrochloride|"Experimental Procedure~Baseline evaluation of suicidal severity (BSSI) & degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
79519835|NCT04260607|Drug|Normal saline|"Experimental Procedure~Baseline evaluation of suicidal severity (BSSI) & degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
79367202|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
79367203|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
79822218|NCT00684567|Radiation|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
79996316|NCT03666078|Procedure|cesarean delivery|women delivered by cesarean section
79367204|NCT01278784|Device|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
79367205|NCT01278784|Device|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
79519836|NCT04260347|Drug|Alteplase|Intravenous injection
79519837|NCT04259411|Device|MitraClip procedure|MitraClip procedure with MitraClip NTR System or MitraClip XTR System
79519838|NCT04207190|Drug|Gemtuzumab Ozogamicin|Given IV
79519839|NCT04207190|Other|Quality-of-Life Assessment|Ancillary studies
79367206|NCT04386226|Dietary Supplement|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
79519840|NCT04207190|Other|Questionnaire Administration|Ancillary studies
79224682|NCT04492202|Other|Survey|The survey will be sent to health professionals via online link.
79224683|NCT03314870|Genetic|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
79224684|NCT03314792|Drug|Tapentadol|"Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
79224685|NCT03314792|Drug|Oxycodone|"OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
79519841|NCT04207190|Drug|Talazoparib|Given PO
79519842|NCT04207190|Drug|Talazoparib Tosylate|Given PO
79519843|NCT04198558|Drug|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
79996317|NCT03665376|Dietary Supplement|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
79996318|NCT03665376|Combination Product|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
79996319|NCT03003390|Drug|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given <24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
79367207|NCT04386226|Dietary Supplement|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
79367208|NCT04386226|Other|Placebo|Maltodextrin
79519844|NCT04198558|Drug|Placebo|Placebo
79822219|NCT00684567|Drug|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
79822220|NCT00752427|Drug|Paliperidone ER OROS®|
79996320|NCT03003000|Drug|ibuprofen|
79519845|NCT04197921|Device|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
79519846|NCT04193527|Drug|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie [mCi]) per participant at a maximum volume of 5 milliliter [mL]) intravenously on Day 1.
79367209|NCT04386070|Drug|RESP301|RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
79519847|NCT04191824|Diagnostic Test|APOL1 status|Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.
79519848|NCT04186416|Other|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
79519849|NCT04186416|Other|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
79679959|NCT04694495|Diagnostic Test|16S rRNA gene sequencing of cervical secretions|"16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
79822221|NCT04053621|Dietary Supplement|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
79822222|NCT04053621|Other|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
79996321|NCT03003000|Drug|caffeine|
79224686|NCT02476604|Behavioral|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
79224687|NCT02476526|Drug|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
79224688|NCT02476526|Drug|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
79224689|NCT02476526|Drug|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
79367210|NCT04386148|Procedure|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
79519850|NCT04172259|Drug|Doxorubicin liposome|PLD
79519851|NCT04172259|Drug|Cyclophosphamide|CTX
79996322|NCT03003000|Drug|placebo|
79996323|NCT03665298|Behavioral|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
79996324|NCT03665220|Other|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
79996325|NCT03665220|Other|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
79519852|NCT04172259|Drug|Trastuzumab|H
79519853|NCT04172259|Drug|Docetaxel|DOC
79519854|NCT04172259|Drug|Epirubicin|EPI
79996326|NCT03665220|Other|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
79996327|NCT03666156|Other|No intervention|No Intervention
79224690|NCT02476526|Procedure|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
79224691|NCT04491812|Other|Kinesio Tape|Elastic Kinesiology Tape
79224692|NCT04491812|Other|Physical therapy program|designed physical therapy program
79224693|NCT02478944|Device|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
79519855|NCT04172259|Drug|Pertuzumab|P
79822223|NCT04053621|Drug|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
79822224|NCT00684411|Drug|Imatinib mesylate|
79822225|NCT02561793|Drug|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
79822226|NCT02561793|Drug|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
79822227|NCT02562651|Drug|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
79822228|NCT02562651|Other|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
79822229|NCT00748527|Drug|carboplatin|Given IV
79822230|NCT00748527|Drug|decitabine|Given IV
79822231|NCT00686829|Drug|Vicriviroc maleate|VCV 30 mg tablet once daily by mouth.
79822232|NCT00687297|Drug|vandetanib induction|100 mg daily by mouth
79996328|NCT03514680|Behavioral|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
79519856|NCT04172259|Drug|Paclitaxel|paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week
79519857|NCT04172259|Drug|Paclitaxel-albumin|albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
79519858|NCT04155424|Drug|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
79519859|NCT04128501|Drug|Azacitidine|Given SC
79676597|NCT05480111|Drug|QL|QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
79676598|NCT05439005|Drug|Dexmedetomidine|Dexmedetomidine+Lidocaine
79996329|NCT04055454|Biological|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
79224694|NCT02479022|Drug|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
79224695|NCT02479022|Drug|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
79519860|NCT04128501|Drug|Venetoclax|Given PO
79519861|NCT04103216|Other|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
79996330|NCT04055454|Other|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
79996331|NCT03665844|Device|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
79996332|NCT03665844|Device|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
79996333|NCT04056390|Procedure|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
79224696|NCT02479022|Drug|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
79224697|NCT02478866|Drug|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
79224698|NCT02482454|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
79367211|NCT01276288|Drug|BI 10773|multiple oral doses
79367212|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
79367213|NCT01276288|Drug|torasemide|multiple oral doses
79367214|NCT01276288|Drug|BI 10773|multiple oral doses
79367215|NCT01276288|Drug|torasemide|multiple oral doses
79367216|NCT01276288|Drug|BI 10773|multiple oral doses
79367217|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
79367218|NCT02702271|Device|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
79367219|NCT00722566|Drug|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
79367220|NCT00722566|Drug|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
79367221|NCT04143633|Other|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
79367222|NCT04143633|Other|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
79519862|NCT04103216|Other|Nitazoxanide|Nitazoxanide with placebo
79519863|NCT04079296|Biological|ASP7517|Intravenous (IV)
79676599|NCT05437263|Drug|Brepocitinib|Oral Brepocitinib
79676600|NCT05437263|Drug|Placebo|Oral Placebo
79676601|NCT05436613|Device|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
79676602|NCT05434442|Other|simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator."
79822233|NCT00687297|Drug|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
79676603|NCT05434442|Other|mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher."
79676604|NCT05434442|Other|control group|Clinical routine training will be given to caregivers in this group.
79676605|NCT05432024|Device|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
79676606|NCT05429580|Drug|Tranexamic acid|given intravenous tranexamic acid
79822234|NCT00687297|Drug|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
79822235|NCT00687297|Drug|Placebo|
79822236|NCT00687297|Drug|Vandetanib maintenance|300 mg daily by mouth
79224699|NCT02482454|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
79224700|NCT02476760|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79224701|NCT02476760|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
79224702|NCT02476760|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
79224703|NCT02476760|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79224704|NCT02476760|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79367223|NCT05581563|Procedure|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
79676607|NCT05429580|Other|5% Dextrose|given placebo.
79676608|NCT05426993|Other|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
79224705|NCT02476760|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79224706|NCT02476760|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
79367224|NCT00722722|Drug|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
79822237|NCT00748683|Other|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
79822238|NCT00684177|Drug|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
79996334|NCT03665766|Drug|Cycloserine,Tacrolimus|
79996335|NCT03002610|Other|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
79996336|NCT03002610|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
79367225|NCT04143555|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
79519864|NCT04075747|Drug|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
79519865|NCT04075747|Drug|Venetoclax|Will be administered over specified duration during induction and consolidation courses
79519866|NCT04075747|Drug|Midostaurin|Will be administered over specified duration during induction and consolidation courses
79519867|NCT04075747|Drug|Enasidenib|Will be administered over specified duration during induction and consolidation courses
79519868|NCT04061746|Biological|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
79519869|NCT04061746|Other|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
79519870|NCT04022213|Drug|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
79519871|NCT04022213|Radiation|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
79519872|NCT03992456|Biological|Panitumumab|Given IV
79519873|NCT03992456|Other|Quality-of-Life Assessment|Ancillary studies
79519874|NCT03992456|Other|Questionnaire Administration|Ancillary studies
79519875|NCT03992456|Drug|Regorafenib|Given PO
79519876|NCT03992456|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79519877|NCT03960424|Other|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
79224707|NCT02476760|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
79519878|NCT03960424|Behavioral|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
79224708|NCT02476292|Other|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
79224709|NCT02478554|Other|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
79367226|NCT03021603|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
79519879|NCT03945812|Drug|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
79676609|NCT05401565|Drug|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
79676610|NCT05401565|Drug|Placebo|Matching placebo
79676611|NCT05397106|Device|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
79676612|NCT05389670|Device|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
79676613|NCT05389670|Device|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
79822239|NCT00684177|Drug|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
79822240|NCT00684021|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
79822241|NCT00684021|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
79224710|NCT05460338|Drug|Cholecalciferol|native form of Vitamin D.
79224711|NCT02482220|Behavioral|Physical activity intervention|
79224712|NCT02482142|Dietary Supplement|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
79224713|NCT02482064|Other|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
79367227|NCT00723580|Drug|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
79224714|NCT02476136|Drug|paroxetine, duloxetine, fluoxetine or venlafaxine|
79676614|NCT05385783|Drug|CYB003|CYB003 is a synthetic psilocybin analog.
79519880|NCT03945812|Other|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
79519881|NCT03945812|Other|Saline|Saline 9%
79519882|NCT03927131|Biological|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
79676615|NCT05385783|Behavioral|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
79822242|NCT00748761|Behavioral|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
79822243|NCT00748761|Behavioral|Waitlist|Contact waitlist weekly for 12 weeks
79822244|NCT04057911|Device|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
79822245|NCT04057911|Device|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
79224715|NCT02476370|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
79224716|NCT02476370|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
79519883|NCT03927131|Biological|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
79519884|NCT03927131|Biological|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
79519885|NCT03927131|Biological|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
79676616|NCT05385783|Drug|Placebo|Placebo
79519886|NCT03927131|Biological|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
79519887|NCT03927131|Biological|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
79676617|NCT05385783|Behavioral|Psychological Support|Manualized psychological support performed by facilitators
79676618|NCT05382598|Procedure|Renal replacement therapy|Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
79676619|NCT05365672|Biological|MIC|Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
79676620|NCT05365672|Other|Standard of Care|No application of the investigational medicinal product MIC
79822246|NCT02561871|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 in Group 2.
79224717|NCT02476214|Behavioral|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
79519888|NCT03915470|Drug|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
79519889|NCT03915470|Drug|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
79519890|NCT03813381|Behavioral|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
79676621|NCT05362318|Drug|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke >10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke <10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
79676622|NCT05362318|Behavioral|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
79676623|NCT05362318|Behavioral|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
79822247|NCT02561871|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 85 in Group 2.
79367228|NCT05581251|Behavioral|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
79822248|NCT02561871|Drug|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
79822249|NCT02561949|Behavioral|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
79822250|NCT02561949|Other|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
79822251|NCT02562339|Behavioral|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
79224718|NCT05437094|Drug|CRD-740|CRD-740
79224719|NCT05437094|Drug|Itraconazole|Itraconazole
79367229|NCT01273948|Drug|Bavituximab|"Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
79822252|NCT00750009|Other|educational intervention|Patients receive a tailored intervention or generic information
79519891|NCT03791970|Device|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
79519892|NCT03791970|Device|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
79519893|NCT03784326|Drug|Atezolizumab|Given IV (vein)
79676624|NCT05362318|Behavioral|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
79676625|NCT05350046|Device|Ear-worn prototype devices|Hearing instrument including sensors to track movement and estimations of biological information.
79679960|NCT02936934|Drug|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
79996337|NCT03002610|Other|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
79519894|NCT03784326|Procedure|Conventional Surgery|Undergo surgical resection
79519895|NCT03784326|Drug|Fluorouracil|Given IV (vein)
79519896|NCT03784326|Drug|Oxaliplatin|Given IV (vein)
79519897|NCT03784326|Drug|Tiragolumab|Given IV (vein)
79519898|NCT03776487|Drug|Fluorouracil|Given IV
79519899|NCT03776487|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79224720|NCT05413772|Other|Temocillin|To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
79519900|NCT03776487|Biological|Ipilimumab|Given IV
79519901|NCT03776487|Biological|Nivolumab|Given IV
79224721|NCT03314402|Drug|Jaktinib Dihydrochloride Monohydrate|Active Substance
79519902|NCT03776487|Drug|Oxaliplatin|Given IV
79519903|NCT03776487|Procedure|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
79519904|NCT03751436|Drug|Enzalutamide|Given PO
79519905|NCT03751436|Drug|Venetoclax|Given PO
79519906|NCT03750903|Behavioral|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
79519907|NCT03750903|Behavioral|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
79519908|NCT03735875|Drug|Quizartinib|Given PO
79519909|NCT03735875|Drug|Venetoclax|Given PO
79519910|NCT03723694|Dietary Supplement|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
79224722|NCT03314402|Drug|placebo|Placebo
79519911|NCT03723694|Dietary Supplement|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
79676626|NCT05336370|Behavioral|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
79679961|NCT02936934|Drug|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
79224723|NCT05713292|Drug|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
79822253|NCT03879369|Diagnostic Test|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
79822254|NCT00755703|Biological|Pandemic Influenza Vaccine|Undetermined
79224724|NCT05713292|Drug|Pirfenidone placebo|Pirfenidone placebo
79224725|NCT03314324|Drug|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
79224726|NCT03314324|Drug|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
79822255|NCT00755703|Biological|Placebo|
79224727|NCT02475902|Behavioral|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
79224728|NCT02475902|Behavioral|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
79228105|NCT05338736|Diagnostic Test|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
79519912|NCT03697148|Diagnostic Test|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79519913|NCT03629327|Drug|ASA 81mg|Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
79519914|NCT03629327|Other|Control Group|Participants will be randomized to take nothing on a daily basis for a duration of 6 months
79519915|NCT03629327|Drug|ASA 325mg|Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
79519916|NCT03575468|Behavioral|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
79519917|NCT03575468|Behavioral|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
79519918|NCT03570801|Other|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
79519919|NCT03555981|Other|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
79519920|NCT03555981|Other|Standard care|Incubator or radiant heater care until stable, off oxygen and >24h of admission, at which point will start intermittent or continuous kangaroo mother care
79519921|NCT03522324|Drug|Cannabis Edible|Self-Directed Use (ad-libitum)
79367230|NCT01273948|Drug|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
79367231|NCT00734344|Drug|Raltegravir|Raltegravir 400 mg. BID
79519922|NCT03513744|Dietary Supplement|human milk oligosaccharides|mixture of five different human milk oligosaccharides
79822256|NCT00752661|Drug|Tramadol Hydrochloride; JNS013|
79519923|NCT03491384|Drug|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
79519924|NCT03450122|Biological|Aldesleukin|Given SC
79519925|NCT03450122|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
79676627|NCT05336370|Device|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus [36]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds [37], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
79224729|NCT02481752|Other|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
79224730|NCT02481752|Other|SHAM Training|
79822257|NCT00576303|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
79367232|NCT00734344|Drug|Efavirenz|600 mg once daily
79822258|NCT00752739|Dietary Supplement|selenium|Given orally
79822259|NCT00752739|Other|placebo|Given orally
79822260|NCT00755781|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
79822261|NCT00755859|Drug|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
79367233|NCT00734344|Drug|Emtricitibine|200mg once daily
79822262|NCT00755859|Drug|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
79996338|NCT03665142|Other|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
79996339|NCT03665142|Other|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
79996340|NCT03005106|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
79996341|NCT03005106|Procedure|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
79367234|NCT00734344|Drug|Tenofovir disoproxil once daily|300mg once daily
79519926|NCT03450122|Drug|Cyclophosphamide|Given IV
79519927|NCT03450122|Biological|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
79519928|NCT03382834|Drug|Tamoxifen|20 mg orally
79519929|NCT03382834|Drug|Vorinostat|400 mg orally
79519930|NCT03382834|Drug|Antiretroviral drugs|Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
79519931|NCT03368742|Genetic|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
79822263|NCT00752817|Other|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
79822264|NCT00752817|Other|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
79519935|NCT03350516|Dietary Supplement|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
79519936|NCT03350516|Dietary Supplement|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
79519937|NCT03348670|Drug|Abiraterone - Usual|"Oral~Abiraterone Combined Chemotherapy (high dose)"
79519938|NCT03348670|Drug|Abiraterone - Study|"Oral~Abiraterone Combined Chemotherapy (low dose)"
79367235|NCT00734344|Drug|Tenofovir disoproxil twice daily|300mg twice daily
79367236|NCT04148937|Drug|LY3475070|Administered orally
79367237|NCT04148937|Drug|Pembrolizumab|Administered IV
79519939|NCT03308942|Drug|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
79519940|NCT03308942|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
79996342|NCT01004861|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
79224731|NCT02475824|Drug|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
79224732|NCT02475824|Drug|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
79224733|NCT02475824|Drug|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
79367238|NCT03021057|Drug|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
79367239|NCT00734500|Drug|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
79519941|NCT03308942|Biological|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
79224734|NCT02475824|Drug|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
79519942|NCT03301857|Drug|Denosumab (Cohort A)|Cohort A: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
79519943|NCT03291431|Device|Intermittent theta burst transcranial magnetic stimulation|20 iTBS sessions (active or sham) administered over the course of 2 weeks
79519944|NCT03289949|Drug|Psilocybine|Oral dose of psilocybine.
79519945|NCT03289949|Drug|Ketanserin|Oral dose of ketanserin.
79519946|NCT03261401|Drug|M5717|Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
79519947|NCT03261401|Drug|Placebo|Participants received placebo matched to M5717
79519948|NCT03261401|Drug|M5717|Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
79524826|NCT05767788|Other|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
79996343|NCT03637361|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
79996344|NCT03637361|Drug|Placebo|
79224735|NCT02478242|Drug|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
79224736|NCT02478242|Drug|Normal saline|
79224737|NCT02475746|Drug|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
79224738|NCT02475746|Drug|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
79224739|NCT02475590|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
79224740|NCT02475590|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
79224741|NCT02481908|Device|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
79224742|NCT04492046|Other|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
79224743|NCT04492046|Other|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
79224744|NCT02481362|Other|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
79367240|NCT04148391|Drug|Placebo Oral Capsule|Matching placebo capsules.
79367241|NCT04148391|Drug|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
79367242|NCT00734734|Biological|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
79367243|NCT04143321|Drug|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
79996345|NCT03637673|Other|No intervention|No intervention
79996346|NCT00038675|Drug|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
79996347|NCT02974907|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
79367244|NCT00734968|Drug|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
79367245|NCT00734968|Other|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
79367246|NCT03753945|Diagnostic Test|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
79367247|NCT03918837|Other|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
79519949|NCT03191461|Diagnostic Test|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
79519950|NCT03166644|Device|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
79519951|NCT03043976|Device|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
79676628|NCT05336370|Device|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
79822265|NCT00756015|Other|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
79224745|NCT02481362|Other|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
79224746|NCT03314246|Other|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
79224747|NCT03314246|Other|Standard of care|Standard of care
79224748|NCT05354180|Other|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
79367248|NCT03918837|Other|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
79519953|NCT02998528|Biological|Nivolumab|Specified dose on specified days
79519954|NCT02998528|Drug|Cisplatin|Specified dose on specified days
79224749|NCT05354180|Other|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
79822266|NCT00756015|Other|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
79224750|NCT05354180|Other|Navicular Mobilization and Rigid Taping|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
79224751|NCT02475512|Other|Wash wipes (3M)|
79519955|NCT02998528|Drug|Vinorelbine|Specified dose on specified days
79822267|NCT00686517|Biological|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
79822268|NCT00686517|Drug|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
79822269|NCT00686205|Device|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
79224752|NCT02475512|Other|water and pH neutral soap|
79228106|NCT03473652|Other|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
79228107|NCT03436797|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
79822270|NCT00571701|Drug|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
79228108|NCT03313934|Combination Product|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
79367249|NCT04143399|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
79367250|NCT04143399|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
79367251|NCT00735436|Drug|Gliadel/Avastin/CPT-11|
79367252|NCT04143165|Drug|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
79519956|NCT02998528|Drug|Gemcitabine|Specified dose on specified days
79519957|NCT02998528|Drug|Docetaxel|Specified dose on specified days
79519958|NCT02998528|Drug|Pemetrexed|Specified dose on specified days
79519959|NCT02998528|Drug|Carboplatin|Specified dose on specified days
79519960|NCT02998528|Drug|Paclitaxel|Specified dose on specified days
79519961|NCT02998528|Biological|Ipilimumab|This arm is closed and no longer enrolling patients.
79519962|NCT02933255|Biological|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x109 infectious units.
79224753|NCT05712980|Device|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
79224754|NCT02475668|Device|Pulse oximeter|Hypoxia
79224755|NCT02481518|Drug|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
79519963|NCT02933255|Drug|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 60-minutes via IV infusion.
79519964|NCT02897427|Other|Biomarker Analysis|Complete HPV testing
79519965|NCT02897427|Procedure|Biospecimen Collection|Undergo collection of blood and oral gargle samples
79519966|NCT02897427|Procedure|Ultrasonography|Undergo transcervical ultrasonography
79519967|NCT02828917|Device|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
79676629|NCT05333627|Behavioral|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
79822271|NCT00571701|Drug|placebo|similar appearing capsules containing inert ingredients
79996348|NCT02974907|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
79224756|NCT02481518|Other|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
79822272|NCT00686127|Drug|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
79224757|NCT05712902|Drug|DZD9008|Daily dose of DZD9008
79224758|NCT05715164|Device|E-cigarettes device plus liquid|The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
79224759|NCT05715164|Drug|Nicotine Pouches|The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
79224760|NCT05715164|Other|Basic care counseling about smoking cessation|The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
79367253|NCT04143087|Drug|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
79367254|NCT00735670|Drug|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
79367255|NCT00735670|Other|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
79996349|NCT03254459|Drug|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
79996350|NCT03254459|Drug|Morphine|4 mg Intravenous Injection
79996351|NCT03254459|Drug|Oxycodone Hydrochloride|10 mg tablet
79996352|NCT03254459|Drug|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
79996353|NCT03620591|Drug|Lidocaine|Intraoperative administration of lidocaine
79996354|NCT03620591|Drug|Placebo|Intraoperative administration of normal saline
79367256|NCT00735826|Drug|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
79519968|NCT02768090|Device|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
79996355|NCT03637283|Procedure|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
79996356|NCT03637283|Procedure|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
79519969|NCT02736045|Device|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
79519970|NCT02726997|Drug|Carboplatin|Given IV
79519971|NCT02726997|Biological|Durvalumab|Given IV
79519972|NCT02726997|Other|Laboratory Biomarker Analysis|Correlative studies
79519973|NCT02726997|Drug|Paclitaxel|Given IV
79519974|NCT02726997|Other|Pharmacological Study|Correlative studies
79519975|NCT02726997|Other|Quality-of-Life Assessment|Ancillary studies
79519976|NCT02718911|Drug|LY3022855|Administered IV
79519977|NCT02718911|Drug|Durvalumab|Administered IV
79676630|NCT05333627|Behavioral|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
79676631|NCT05333627|Behavioral|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
79224761|NCT02481284|Device|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
79676632|NCT05321784|Other|Dermoscopy|Take digital dermoscopy images (DDI)
79224762|NCT02475356|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
79224763|NCT05710562|Other|Name not applicable|In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
79224764|NCT05708768|Other|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
79224765|NCT02481128|Procedure|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
79224766|NCT02475200|Device|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
79224767|NCT02474966|Device|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
79224768|NCT02475122|Other|azygos blood flow measurements by MRI|
79224769|NCT02475044|Behavioral|Cognitive-Behavioral Therapy|16 Sessions of CBT.
79224770|NCT05715008|Other|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
79224771|NCT05715008|Other|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
79224772|NCT02480894|Drug|BMS-663068|BMS-663068
79224773|NCT02480894|Drug|Maraviroc|Maraviroc
79519978|NCT02718911|Drug|Tremelimumab|Administered IV
79519979|NCT02707887|Behavioral|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
79519980|NCT02707887|Behavioral|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
79519981|NCT02707887|Behavioral|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
79519982|NCT02633943|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant
79519983|NCT02605551|Procedure|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~OM Occipitomastoid release technique~Sub-Occipital Release Technique~Rib Raising Technique~Rotatory stimulation of posterior Chapman's Reflexes~Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
79519984|NCT02605551|Behavioral|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
79519985|NCT02573896|Drug|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
79519986|NCT02573896|Biological|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
79519987|NCT02573896|Drug|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
79519988|NCT02542267|Device|Gore VIABAHN Endoprosthesis|
79519989|NCT02480283|Procedure|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
79519990|NCT02480283|Radiation|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
79519991|NCT02480283|Procedure|Venipuncture|To collect blood cells and serum for analyses.
79676633|NCT05321784|Other|Digital Photography|Take smartphone clinical images (SCI)
79676634|NCT05321784|Procedure|Self-Skin Examination|Perform self-skin exam (SSE)
79676635|NCT05321784|Device|Skin Examination with Sklip|Apply Sklip System
79676636|NCT05321784|Procedure|Skin Examination|Undergo in-person full body skin examination (FBSE)
79676637|NCT05321784|Other|Survey Administration|Ancillary studies
79996357|NCT04363463|Other|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
79224774|NCT05356364|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|cognitive and behavioral treatment for perinatal insomnia.
79224775|NCT05356364|Behavioral|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness and behavioral based therapy for perinatal insomnia.
79996358|NCT05178953|Drug|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
79224776|NCT02478086|Dietary Supplement|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
79224777|NCT02478086|Dietary Supplement|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
79224778|NCT02480816|Dietary Supplement|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
79224779|NCT02480660|Behavioral|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
79367257|NCT04765995|Drug|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
79367258|NCT04765995|Drug|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
79367259|NCT04765995|Drug|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
79367260|NCT04765995|Drug|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
79367261|NCT04765995|Drug|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
79367262|NCT04765995|Drug|Placebo|Matching placebo will be administered intramuscularly.
79367263|NCT01276054|Radiation|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
79367264|NCT01276054|Drug|methylene blue|Given subcutaneously
79367265|NCT01276054|Drug|indocyanine green solution|Given subcutaneously
79367266|NCT01276054|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
79367267|NCT01276054|Procedure|axillary lymph node biopsy|Undergo axillary lymph node biopsy
79367268|NCT01276054|Procedure|bioimpedance spectroscopy|Correlative studies
79367269|NCT01276054|Procedure|quality-of-life assessment|Ancillary studies
79367270|NCT01276054|Other|lymphedema management|Undergo axillary reverse mapping
79367271|NCT05580627|Other|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment group.
79367272|NCT05580627|Other|Live Modality (control)|For this evaluation, the live modality is considered the control group.
79367273|NCT01798849|Drug|MK-8892|
79367274|NCT01798849|Drug|Placebo for MK-8892|
79367275|NCT05580471|Device|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
79367276|NCT05580393|Diagnostic Test|RFLP analysis of SSU rRNA|"Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
79367277|NCT04405947|Procedure|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
79367278|NCT00724594|Drug|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
79367279|NCT00724594|Drug|Control|Saline was given in the same volume, at the same timing as NAC infusions
79676638|NCT05312801|Drug|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
79676639|NCT05292313|Procedure|Single distal femur implant|Single implant fixation
79676640|NCT05292313|Procedure|Dual distal femur implants|Dual implant fixation
79519992|NCT02480283|Procedure|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
79519993|NCT02477202|Device|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
79996359|NCT05178953|Drug|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
79822273|NCT00686127|Drug|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
79822274|NCT02561715|Behavioral|Questionnaires|Pre and post deep brain surgery questionnaires
79822275|NCT00718718|Drug|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
79224780|NCT02474888|Other|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
79224781|NCT02474732|Device|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
79224782|NCT02474654|Drug|Bupivicaine|15mg
79224783|NCT02474654|Drug|Fentanyl|15mcg
79224784|NCT02474654|Drug|Epimorphine|150mcg
79996360|NCT02736617|Drug|Ibrutinib|Given PO
79519994|NCT02416128|Drug|Euphrasia|1 drop in the treated eye QID X 10 days
79822276|NCT00718718|Drug|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
79519995|NCT02416128|Drug|Prednisolone acetate|1 drop in the treated eye QID X 10 days
79519996|NCT02344121|Radiation|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
79519997|NCT02330653|Biological|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
79224785|NCT02474654|Drug|Normal Saline|0.3 ml
79224786|NCT02474654|Drug|Normal Saline|30ml
79224787|NCT02474654|Drug|Normal Saline|100 ml
79519998|NCT02330653|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
79676641|NCT05275166|Behavioral|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
79224788|NCT02474654|Drug|Ropivicaine|100 ml
79224789|NCT02474654|Drug|Epinephrine|600 mcg
79224790|NCT02474654|Drug|Ketorolac|30 mg
79996361|NCT02736617|Biological|Obinutuzumab|Given IV
79996362|NCT05178719|Device|PMA-zeolite|given for a total period of 4 years
79676642|NCT05275166|Other|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
79676643|NCT05258305|Device|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
79822277|NCT00718718|Drug|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
79996363|NCT03637907|Other|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
79996364|NCT05572619|Device|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
79224791|NCT02474654|Drug|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
79224792|NCT05284604|Drug|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
79224793|NCT05272514|Other|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
79224794|NCT02478008|Device|CardiAQ TMVI System (Transapical DS)|
79224795|NCT02477930|Other|No interventions are done|No intervention is done. This is a registry study.
79224796|NCT02477852|Drug|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
79519999|NCT02218606|Drug|Abiraterone acetate 1000 mg po daily|
79520000|NCT02218606|Drug|Cabazitaxel 25 mg/m2 IV|
79520001|NCT02218606|Drug|prednisone 5 mg po BID|
79520002|NCT02096055|Drug|Cladribine|Given IV
79520003|NCT02096055|Drug|Guadecitabine|Given SC
79676644|NCT05246527|Behavioral|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
79676645|NCT05246527|Behavioral|Control Intervention|30 min of watching a movie
79822278|NCT00718718|Drug|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
79822279|NCT00718718|Drug|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
79822280|NCT04085822|Device|SMA-001|Intra-dermal injection of SMA-001 and control device.
79822281|NCT00683787|Drug|docetaxel|Given IV once every 3 weeks
79822282|NCT00683787|Drug|vandetanib|Oral vandetanib once daily
79822283|NCT02560935|Drug|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
79822284|NCT02560935|Drug|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
79520004|NCT02096055|Drug|Idarubicin|Given IV
79520005|NCT02017717|Biological|Nivolumab|specified dose on specified days
79676646|NCT05242822|Drug|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
79996365|NCT05572619|Device|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
79224797|NCT02477852|Drug|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
79996366|NCT04670393|Dietary Supplement|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
79996367|NCT04670393|Other|Placebo|400 mcg folic acid
79520006|NCT02017717|Biological|Bevacizumab|specified dose on specified days
79520007|NCT02017717|Biological|Ipilimumab|specified dose on specified days
79224798|NCT02477852|Drug|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
79520008|NCT01761305|Procedure|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
79996368|NCT05178251|Procedure|appendectomy|appendectomy for acute appendicitis
79996369|NCT03251963|Drug|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
79996370|NCT03251963|Drug|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
79996371|NCT03287219|Drug|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
79996372|NCT03286751|Drug|LY900014|Administered SC
79224799|NCT02477852|Drug|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
79224800|NCT02480738|Behavioral|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
79224801|NCT02474810|Drug|Alteplase|Alteplase for CVC dysfunction.
79224802|NCT02480504|Other|dietary intervention intermittent energy restriction|Randomized clinical trial
79224803|NCT02480504|Other|continuous energy restriction|
79224804|NCT02725268|Drug|Paclitaxel|Paclitaxel intravenous solution.
79224805|NCT02725268|Drug|Sapanisertib|Sapanisertib capsules.
79224806|NCT02725268|Drug|MLN1117|MLN1117 capsules.
79520009|NCT01761305|Behavioral|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
79520010|NCT01761305|Other|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
79520011|NCT01539863|Other|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
79676647|NCT05235958|Other|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
79676648|NCT05235958|Other|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
79224807|NCT02480426|Device|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
79224808|NCT02480426|Drug|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
79224809|NCT05212142|Behavioral|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
79676649|NCT05229042|Drug|Ricolinostat|Oral
79996373|NCT03286751|Drug|Insulin Lispro|Administered SC
79224810|NCT05212142|Behavioral|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
79520012|NCT01539863|Other|Treatment as needed|Participants may never receive treatment, there is no upper limit
79520013|NCT00942331|Biological|Bevacizumab|Given IV
79520014|NCT00942331|Drug|Cisplatin|Given IV
79520015|NCT00942331|Drug|Gemcitabine Hydrochloride|Given IV
79520016|NCT00942331|Other|Laboratory Biomarker Analysis|Correlative studies
79520017|NCT00942331|Other|Placebo Administration|Given IV
79520018|NCT00828919|Drug|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
79520019|NCT00828919|Drug|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
79520020|NCT00827372|Drug|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
79520021|NCT00687856|Procedure|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
79224811|NCT02480348|Device|Polymer-free DES (Drug Eluting Stent)|
79367280|NCT04142931|Combination Product|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
79224812|NCT02474576|Procedure|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
79224813|NCT02724956|Device|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
79520022|NCT00590902|Drug|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
79520023|NCT00577122|Drug|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
79520024|NCT00577122|Drug|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
79520025|NCT00419770|Drug|deferasirox|20 mg/kg enterally per day
79520026|NCT00419770|Drug|Placebo|
79520027|NCT00419770|Drug|Liposomal amphotericin B|
79520028|NCT00129701|Procedure|Telephone consultation|
79367281|NCT00724750|Device|Gauze suction (G-SUC)|Negative pressure wound therapy
79367282|NCT00724750|Device|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
79367283|NCT04140825|Device|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
79996374|NCT03249935|Drug|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
79367284|NCT01797835|Behavioral|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
79996375|NCT05572151|Procedure|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
79224814|NCT02724956|Device|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
79367285|NCT01797835|Behavioral|usual care|Youth receive a brochure with information on AOD use.
79520029|NCT00076310|Drug|Docetaxel|60 mg/m^2 IV repeated every 21 days.
79520030|NCT00076310|Drug|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
79520031|NCT00076310|Drug|Cisplatin|75 mg/m^2 IV every 21 days.
79520032|NCT04498416|Diagnostic Test|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
79520033|NCT04350606|Biological|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
79520034|NCT04340856|Procedure|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
79996376|NCT03622073|Other|Misoprostol treatment by Midwife|Medical management of incomplete abortion
79996377|NCT03622073|Other|Misoprostol treatment by Doctor|Medical management of incomplete abortion
79224815|NCT02724956|Device|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
79520035|NCT04340856|Drug|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
79520036|NCT04335240|Other|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
79822285|NCT00723008|Device|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
79996378|NCT03285113|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
79996379|NCT03000348|Drug|Cysteamine|Oral Cysteamine Capsule
79822286|NCT00750399|Drug|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
79996380|NCT03000348|Drug|Placebo Oral Capsule|Placebo Oral Capsule
79996381|NCT03283709|Device|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
79996382|NCT03283709|Device|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
79224817|NCT04991246|Other|Antigenic tests (on saliva samples)|SARS-CoV-2 screening tests: two massive antigenic tests campaigns (on salivary samples).
79224818|NCT04991246|Other|Individual electronic sensor port|Individual electronic sensor recording contacts but not their location (in the form of a bracelet, a key ring or a badge) Contact data collection points (5 maximum, located at compulsory passage points for participants). When a sensor is close to one of these terminals, it discharges its contacts in seconds.
79367286|NCT01275430|Device|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
79367287|NCT01275430|Other|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
79367288|NCT04142775|Other|complication versus no complication|development of ICH
79367289|NCT01838551|Drug|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
79367290|NCT03021369|Device|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
79367291|NCT04142853|Other|Training intervention + Dance intervention|Training intervention + Dance intervention
79367292|NCT05580081|Behavioral|i-CAN|online support and consultation to providers
79367293|NCT05587413|Procedure|periodontal care|periodontal treatment
79996383|NCT03664986|Drug|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
79996384|NCT03492918|Drug|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
79996385|NCT03247673|Drug|CT-P16|CT-P16 is a biosimilar product for Avastin
79367294|NCT04143477|Drug|peficitinib|Oral
79367295|NCT04142463|Other|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
79367296|NCT04144803|Diagnostic Test|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
79367297|NCT05586009|Drug|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
79367298|NCT03020979|Drug|Apatinib|Patients will take 500mg apatinib daily orally.
79367299|NCT04142151|Drug|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
79367300|NCT04142151|Drug|Aspirin|Aspirin produced by Bayer Co., Ltd.
79367301|NCT04142151|Drug|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
79520037|NCT04301154|Biological|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
79520038|NCT04301154|Biological|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
79822287|NCT00750399|Drug|ranibizumab|intravitreal ranibizumab 0.5 mg
79822288|NCT00756171|Drug|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
79822289|NCT00756171|Drug|placebo|2 times 3 625mg tablets daily
79676650|NCT05220566|Behavioral|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
79224819|NCT04991246|Other|Atmospheric measurements of CO2|Atmospheric measurements of CO2 in the relevant closed places of the faculty (lectures / practical work / BU / refectory): battery operated sensors. When a sensor is installed in a place, the ventilation conditions (number of open windows, etc.) as well as the number of people present will be noted.
79676651|NCT05207345|Other|Interventional programme|"90-minute session divided into:~45 minutes of core stability treatment~45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
79996386|NCT03247673|Drug|EU-approved Avastin|EU-approved Avastin
79224820|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~Low dose: 1x10e7 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
79224821|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~Mid dose: 5x10e7 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
79224822|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~High dose: 1x10e8 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
79224823|NCT00705536|Drug|Humalog|
79224824|NCT00705536|Drug|Humulin-R|
79224825|NCT00705536|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
79224826|NCT04940936|Behavioral|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
79367302|NCT04142151|Drug|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
79520039|NCT04301154|Biological|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
79520040|NCT04239846|Drug|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
79520041|NCT04239846|Other|Placebo Gel|Placebo Gel, BID
79367303|NCT02985099|Drug|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
79367304|NCT02985099|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
79676652|NCT05207345|Other|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
79676653|NCT05200325|Other|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
79996387|NCT03247673|Drug|US-licensed Avastin|US-licensed Avastin
79996388|NCT03665610|Drug|ozanimod|ozanimod
79996389|NCT03665532|Behavioral|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
79996390|NCT03664908|Other|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
79224827|NCT02477540|Drug|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20~25℃~Injection Method: Intramuscular"
79367305|NCT04142229|Device|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
79520042|NCT04233060|Drug|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
79520043|NCT04040790|Device|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
79520044|NCT04040790|Device|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
79224828|NCT02474264|Other|Endothelial function assessment|reactive hyperemia index
79367306|NCT04142229|Other|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
79367307|NCT04149873|Procedure|MIE|MIE
79367308|NCT03904329|Drug|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
79676654|NCT05197608|Other|System Navigator|Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.
79676655|NCT05197608|Other|Tailored list of resources|Control group will be provided a tailored list of resources
79676656|NCT05196620|Other|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
79676657|NCT05196607|Other|Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service
79367309|NCT04149561|Other|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
79224829|NCT02474264|Other|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
79224830|NCT02474264|Other|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
79224831|NCT02474420|Drug|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
79367310|NCT04141683|Diagnostic Test|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
79367311|NCT04141683|Diagnostic Test|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
79367312|NCT04141683|Procedure|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
79367313|NCT04149483|Drug|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
79367314|NCT04149483|Drug|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
79367315|NCT04149639|Dietary Supplement|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
79996391|NCT03622944|Procedure|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
79224832|NCT02474420|Drug|Deferasirox|Deferasirox administered per standard of care by the treating physician
79996392|NCT03622944|Procedure|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
79224833|NCT05595980|Dietary Supplement|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
79224834|NCT05595980|Dietary Supplement|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
79224835|NCT02474108|Procedure|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
79224836|NCT02474108|Device|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
79224837|NCT02474186|Radiation|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
79367316|NCT04141371|Drug|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
79367317|NCT04141371|Drug|physiological serum|daily saline infusion over 3 hours during the vasospasm period
79367318|NCT04140981|Device|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
79367319|NCT04149093|Diagnostic Test|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
79367320|NCT04149327|Drug|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
79367321|NCT04149327|Procedure|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
79224838|NCT02474186|Drug|Xeloda|chemotherapy agent daily for two weeks
79224839|NCT02474186|Drug|paclitaxel|chemotherapy agent weekly for two weeks
79367322|NCT05582733|Other|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
79367323|NCT05582733|Other|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
79676658|NCT05195710|Drug|Yttrium-90 (Y-90) resin microspheres|Given by scan
79224840|NCT02477462|Other|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
79676659|NCT05194488|Device|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
79224841|NCT02477462|Other|Baseline visit|Blood draw and quality of life surveys
79224842|NCT02477306|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
79367324|NCT05582655|Behavioral|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
79676660|NCT05194488|Drug|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
79676661|NCT05194488|Device|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
79996393|NCT03622944|Procedure|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
79996394|NCT03247517|Drug|Placebo|Placebo was administered once daily
79520045|NCT04040790|Device|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
79822290|NCT00750477|Dietary Supplement|NEM|see Treatment Arms
79996395|NCT03247517|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
79996396|NCT03247517|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
79996397|NCT03665454|Drug|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
79996398|NCT03665454|Drug|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
79224843|NCT02477306|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
79224844|NCT04868786|Drug|Mycophenolate Mofetil|Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
79367325|NCT05582655|Behavioral|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, & Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, & Arbuckle, 2021).
79367326|NCT05582577|Combination Product|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
79367327|NCT05582577|Drug|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
79367328|NCT04149015|Drug|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
79367329|NCT04140591|Drug|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
79367330|NCT04140591|Drug|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure >90mmHg) PPI: Pariet EC 20mg/QDAC
79520046|NCT04040790|Drug|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
79520047|NCT04027998|Diagnostic Test|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
79822291|NCT00750477|Dietary Supplement|Placebo|Placebo comparator containing inactives
79996399|NCT03664440|Drug|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
79996400|NCT03664440|Drug|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
79996401|NCT03663738|Behavioral|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
79996402|NCT03283553|Other|Checklist, MyChart, OpenNotes|1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
79224845|NCT02472548|Biological|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
79224846|NCT02472548|Biological|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
79224847|NCT02472548|Other|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
79224848|NCT02477228|Procedure|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
79367332|NCT05582109|Drug|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
79367333|NCT04140123|Drug|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
79520048|NCT03707184|Procedure|Computed Tomography|Undergo PET/CT scan
79520049|NCT03707184|Drug|Fluciclovine F18|Given IV
79520050|NCT03707184|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79520051|NCT03556800|Drug|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~Reference IMP: a single-dose of 1.25g EstroGel"
79520052|NCT03551886|Behavioral|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
79520053|NCT03551886|Behavioral|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
79822292|NCT00718640|Drug|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
79520054|NCT04741620|Other|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
79224849|NCT02477228|Procedure|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
79367334|NCT04140123|Drug|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
79520055|NCT04741620|Other|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
79520056|NCT04741620|Other|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
79520057|NCT04741620|Other|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
79520058|NCT04741620|Other|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
79520059|NCT04741620|Other|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
79520060|NCT03034902|Device|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
79520061|NCT02952846|Other|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
79520062|NCT00800514|Drug|amantadine|amantadine twice daily
79996403|NCT03283553|Other|Usual Care|Routine medical oncology care
79996404|NCT03664596|Dietary Supplement|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
79996405|NCT03664596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
79996406|NCT03283319|Biological|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
79367335|NCT03020901|Drug|Teicoplanin for Injection|Use Teicoplanin for Injection
79367336|NCT04140201|Drug|Simvastatin 40mg|Drugs that lower lipid level
79367337|NCT04140201|Drug|Fenofibrate 200mg|Drugs that lower lipid levels
79367338|NCT04140201|Drug|Omega 3 fatty acid|Drugs that lower lipid levels
79367339|NCT05581875|Drug|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
79367340|NCT05581875|Drug|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
79367341|NCT05581875|Drug|Pomalidomide|Pomalidomide will be administered per os.
79224850|NCT02473796|Other|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight <2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term & weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
79367342|NCT05581875|Drug|Dexamethasone|Dexamethasone will be administered intravenously or per os.
79367343|NCT03945045|Procedure|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
79367344|NCT03945045|Procedure|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
79367345|NCT04148469|Procedure|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
79367346|NCT04148469|Procedure|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
79367347|NCT04148469|Procedure|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
79520063|NCT00800514|Drug|amantadine|amantadine 100 mg twice daily
79520064|NCT02780622|Drug|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
79520065|NCT02780622|Drug|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
79520066|NCT02781480|Biological|AAV RPE65|Comparison of different dosages of AAV RPE65
79520067|NCT02783820|Drug|MMV390048 40 mg|
79520068|NCT02783820|Drug|Placebo to match MMV390048 40 mg|
79996407|NCT03283319|Biological|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
79996408|NCT03283319|Biological|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
79996409|NCT03283319|Biological|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
79996410|NCT03283319|Biological|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
79996411|NCT03549533|Other|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
79520069|NCT02783820|Drug|MMV390048 80 mg|
79520070|NCT02783820|Drug|Placebo to match MMV390048 80 mg|
79520071|NCT02783820|Drug|MMV390048 120 mg|
79520072|NCT02783820|Drug|Placebo to match MMV390048 120 mg|
79520073|NCT02783898|Device|AliveCor Heart Monitor|Smart phone based ECG event recorder
79520074|NCT02784444|Drug|MSDC-0602K|MSDC-0602K capsules
79676662|NCT05187182|Drug|CA-4948|Provided by Curis, Inc.
79676663|NCT05187182|Biological|Nivolumab|240 mg IV on Day 1 of each cycle
79224851|NCT02477150|Biological|Zostavax|Vaccination of a zoster vaccine (Zostavax)
79224852|NCT02477150|Biological|placebo|placebo administration
79224853|NCT02472626|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
79224854|NCT02472626|Drug|Cytarabine|Given IV
79224855|NCT02472626|Drug|Daunorubicin Hydrochloride|Given IV
79224856|NCT05593952|Other|Dual task|exercise with dual task + usual treatment
79224857|NCT05593952|Other|Single task|exercise without dual task + usual treatment.
79224858|NCT02472392|Drug|Rabbit anti-thymocyte globulin|Active treatment
79367348|NCT04406025|Procedure|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
79367349|NCT04406025|Procedure|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
79367350|NCT04140045|Other|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
79520075|NCT02784444|Drug|Placebo|Placebo capsules
79822293|NCT00718640|Drug|Bortezomib|Bortezomib 1.3 milligram per meter^2 (mg/m^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
79822294|NCT00756249|Drug|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
79822295|NCT00756249|Drug|Placebo|Vials with solution for IV infusion
79996412|NCT03637829|Other|Control|Water
79224859|NCT02472392|Drug|Busulfan|comparitor
79224860|NCT02472392|Drug|Melphalan|comparitor
79224861|NCT02472392|Drug|Fludarabine|comparitor
79224862|NCT02472392|Drug|Cyclophosphamide|comparitor
79520076|NCT02787564|Behavioral|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
79520077|NCT02788188|Biological|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
79676664|NCT05187182|Biological|Pembrolizumab|400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years
79676665|NCT05187182|Drug|Trastuzumab|6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
79676666|NCT05187182|Drug|mFOLFOX7|Standard of care
79676667|NCT05174559|Other|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
79224863|NCT02472158|Device|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
79224864|NCT02472158|Device|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
79224865|NCT02472080|Drug|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
79224866|NCT02473562|Drug|Varenicline|Tablet 1 mg BID
79224867|NCT02473562|Drug|Placebo (for varenicline)|Tablet 1 mg BID
79224868|NCT05585996|Biological|CD19 CAR-T and CD19 CAR-DC|Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
79224869|NCT02724020|Drug|Everolimus|Everolimus capsules.
79224870|NCT02724020|Drug|MLN0128|MLN0128 capsules.
79224871|NCT02724020|Drug|MLN1117|MLN1117 capsules.
79224872|NCT02660034|Biological|Tislelizumab|
79224873|NCT02660034|Drug|Pamiparib|
79224874|NCT02816736|Drug|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
79367351|NCT05587881|Biological|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
79367352|NCT05587881|Biological|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
79676668|NCT05167669|Device|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
79676669|NCT05146739|Drug|Cytarabine|Given IV and IT
79676670|NCT05146739|Drug|Fludarabine|Given IV
79676671|NCT05146739|Drug|Leucovorin|Give PO or IV
79676672|NCT05146739|Drug|Triple Intrathecal Chemotherapy|Given IT
79676673|NCT05146739|Drug|Uproleselan|Given IV
79676674|NCT05137327|Behavioral|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
79822296|NCT02591810|Procedure|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
79996413|NCT03637829|Other|White chocolate|Experimental snack treatment
79996414|NCT03637829|Other|Dark chocolate 1|Experimental snack treatment
79520078|NCT02788188|Other|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
79520079|NCT02791308|Drug|Pimecrolimus Cream 1% (Valeant)|
79520080|NCT02791308|Drug|Vehicle cream|
79996415|NCT03637829|Other|Dark chocolate 2|Experimental snack treatment
79996416|NCT03282227|Drug|M207 Microneedle System|M207 Microneedle System 3.8 mg
79224875|NCT02816736|Drug|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
79367353|NCT05586165|Behavioral|Reminder to boost protection against COVID-19|Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
79224876|NCT02816736|Drug|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
79224877|NCT02816736|Drug|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
79367354|NCT05586165|Behavioral|Flu Tag Along|This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
79367355|NCT05586165|Behavioral|COVID-19 Booster & Flu Bundle|This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
79367356|NCT03944265|Other|Counseling|Participate in treatment decision counseling session
79367357|NCT03944265|Other|Questionnaire Administration|Ancillary studies
79367358|NCT03944265|Other|Medical Chart Review|Ancillary studies
79520081|NCT02791308|Drug|Pimecrolimus Cream, 1%|
79520082|NCT02796144|Drug|Lorcaserin|Max dose of 10 mg BID
79520083|NCT02796144|Drug|Metformin|Max dose of 1,000 mg BID
79224878|NCT02477072|Procedure|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
79520084|NCT02796144|Drug|Placebo|Matching placebos will be administered for each drug.
79520085|NCT02796300|Device|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
79520086|NCT02796300|Device|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
79520087|NCT02796924|Device|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
79520088|NCT02798952|Biological|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
79367359|NCT04148547|Device|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
79676675|NCT05137327|Behavioral|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
79676676|NCT05135715|Drug|RC48-ADC|2.0 mg/kg IV every 2 weeks
79676677|NCT05122325|Device|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
79676678|NCT05122325|Device|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
79996417|NCT04696835|Diagnostic Test|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
79996418|NCT05158127|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79996419|NCT05157035|Behavioral|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
79996420|NCT05571605|Behavioral|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
79996421|NCT05571605|Behavioral|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
79996422|NCT03240575|Drug|Tiotropium|Fixed Dose Combination
79996423|NCT03240575|Drug|Olodaterol|Fixed Dose Combination
79996424|NCT03240575|Drug|Fluticasone propionate|Fixed Dose Combination
79224879|NCT02477072|Procedure|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
79224880|NCT02477072|Procedure|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
79224881|NCT02477072|Procedure|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
79224882|NCT02477072|Drug|Heparin|Heparin doses will be administered according to the assigned group.
79367360|NCT04148547|Device|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
79367361|NCT03588897|Dietary Supplement|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
79520089|NCT02800356|Procedure|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
79520090|NCT02801370|Drug|12 mg ciprofloxacin|Single administration of OTO-201
79367362|NCT03941847|Other|music|listening music
79520091|NCT02801370|Drug|Sham Control|Simulated, single adminstration
79367363|NCT05582421|Drug|Diclofenac Sodium|intracanal medication
79520092|NCT02803164|Device|Wound Vacuum-assisted dressing|The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
79520093|NCT02803164|Other|Control group|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
79224883|NCT03490422|Procedure|Pulpotomy|Pulpotomy in mature carious permanent teeth
79822297|NCT02591810|Procedure|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
79224884|NCT05103410|Drug|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
79224885|NCT05103410|Drug|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
79224886|NCT04867746|Other|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
79224887|NCT04867746|Other|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
79228109|NCT03313934|Combination Product|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
79228110|NCT03941301|Device|Light therapy|Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
79228111|NCT03313856|Drug|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
79228112|NCT03313856|Drug|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
79228113|NCT04548024|Device|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
79367364|NCT03897933|Procedure|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
79367365|NCT03897933|Procedure|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
79520094|NCT02806908|Drug|JZP-110|
79520095|NCT02806908|Drug|Placebo|
79520096|NCT02813070|Drug|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
79520097|NCT02815644|Drug|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
79520098|NCT02816346|Biological|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
79520099|NCT02820324|Drug|Oliceridine|
79520100|NCT02820324|Drug|Placebo|
79520101|NCT02820324|Drug|Morphine|
79520102|NCT02820870|Behavioral|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
79520103|NCT02821338|Drug|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
79520104|NCT02823600|Device|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
79520105|NCT02829294|Device|E002 - cerumen removal aid|topical treatment
79367366|NCT03588663|Device|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) [Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
79224888|NCT04867746|Other|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 * 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
79224889|NCT04867746|Other|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
79224890|NCT04867746|Other|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
79520106|NCT02830074|Behavioral|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
79520107|NCT02830074|Behavioral|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
79367367|NCT03588663|Other|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
79520108|NCT02835846|Drug|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
79520109|NCT02837328|Drug|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
79224891|NCT04704882|Other|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
79224892|NCT02472236|Drug|PEX168|200µg,injected subcutaneously,once a week.
79224893|NCT02472236|Drug|Digoxin|0.5mg,oral,two times.
79520110|NCT02837328|Drug|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
79676679|NCT05122325|Device|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
79676680|NCT05111002|Drug|Lefamulin|600mg tablet orally twice daily
79676681|NCT05111002|Drug|Doxycycline|100mg tablet orally twice daily
79224894|NCT03492294|Diagnostic Test|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
79224895|NCT02193867|Drug|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
79367368|NCT03588663|Other|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
79520111|NCT02839902|Drug|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
79520112|NCT02839902|Other|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
79520113|NCT02840916|Procedure|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
79520114|NCT02840916|Procedure|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
79520115|NCT02842242|Drug|MYK-461|
79520116|NCT02844582|Drug|Cabazitaxel|Given IV
79520117|NCT02844582|Drug|Prednisone|Given PO
79676682|NCT05105373|Behavioral|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~Poor parental bonding and child attachment;~Harsh parenting~Inequitable socialisation by gender~Parental conflict."
79676683|NCT05091346|Drug|E7386|E7386 tablet.
79676684|NCT05091346|Drug|Pembrolizumab|Pembrolizumab IV infusion.
79676685|NCT05091346|Drug|Lenvatinib|Lenvatinib capsule.
79676686|NCT05088655|Drug|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
79996425|NCT03240575|Drug|Salmeterol|Fixed Dose Combination
79676687|NCT05054790|Biological|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
79676688|NCT05048433|Behavioral|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
79520118|NCT02845674|Drug|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
79520119|NCT02845752|Drug|Stiolto Respimat|Oral inhalation spray
79520120|NCT02845752|Drug|Placebo Respimat|Oral inhalation spray
79676689|NCT05048433|Behavioral|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
79676690|NCT05039216|Biological|Blood sampling|4 tubes of 7 mL will be sampled
79224896|NCT02472002|Biological|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~Registry Type: autologous~Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~Route of administration: endomyocardial injection~Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
79676691|NCT05037812|Drug|Saline injection|Saline
79676692|NCT05037812|Drug|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
79224897|NCT03108872|Device|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
79224898|NCT03108872|Drug|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
79224899|NCT03490266|Procedure|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
79224900|NCT03490266|Procedure|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
79224901|NCT02194491|Other|[11C]AS2471907|intravenous radiotracer
79224902|NCT02194491|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
79224903|NCT02194491|Drug|ASP3662|oral
79224904|NCT03108560|Procedure|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
79224905|NCT03108560|Procedure|lobectomy|patients receive lobectomy
79224906|NCT03487770|Drug|Aripiprazole Oral Solution|Aripiprazole 2~15 mg/day (2~15 mL/day)
79367369|NCT03588663|Other|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
79676693|NCT05019638|Drug|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
79676694|NCT05019638|Drug|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
79224907|NCT03487770|Drug|Placebo Oral Solution|Placebo 2~15 mg/day (2~15 mL/day)
79224908|NCT02194569|Drug|Citrate|
79224909|NCT02473328|Drug|Atazanavir 200 mg/r|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
79224910|NCT03132090|Diagnostic Test|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
79676695|NCT05019430|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
79676696|NCT05019430|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
79676697|NCT05019430|Drug|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
79224911|NCT02473406|Drug|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
79822298|NCT02591810|Procedure|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
79822299|NCT00753051|Drug|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
79822300|NCT00753051|Drug|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
79996426|NCT05571371|Other|Measuring inflammatory serum biomarkers|Measuring inflammatory serum biomarkers
79224912|NCT02473406|Drug|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
79367370|NCT03580473|Drug|SATURNO II association|opthalmic solution, 4 times a day
79367371|NCT03580473|Drug|Vigadexa®|opthalmic solution, 4 times a day
79367372|NCT03581721|Device|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
79520121|NCT02849184|Drug|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
79520122|NCT02849184|Other|Placebo|Placebo once daily before bedtime.
79822301|NCT02591108|Device|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
79676698|NCT05013749|Procedure|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
79996427|NCT03385265|Behavioral|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
79224913|NCT03487536|Other|Nutritional assessment|BMI and cholesterol levels evaluation
79520123|NCT02849418|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
79520124|NCT02849418|Drug|Placebo|Placebo injection contains sodium chloride (0.9 milligrams [mg]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
79996428|NCT03385265|Other|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
79520125|NCT02856828|Device|DIE|digital image enhancement
79996429|NCT05571449|Procedure|Open reduction and internal fixation|Internal fixation of the fracture
79996430|NCT05571449|Procedure|Standard osteosynthesis planning|Plain radiograph and CT images are used
79224914|NCT02194023|Drug|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
79520126|NCT02861118|Other|No Intervention|
79520127|NCT02862912|Drug|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
79520128|NCT02862912|Drug|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
79224915|NCT02194023|Drug|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
79224916|NCT02194023|Drug|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
79520129|NCT02862912|Drug|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
79822302|NCT02591108|Device|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
79996431|NCT05571449|Procedure|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
79996432|NCT03280121|Device|EsophyX ZR transoral device|TIF
79224917|NCT02194023|Drug|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
79224918|NCT02473172|Device|Pressure Support ventilation|Assisted mechanical ventilation
79224919|NCT02473172|Device|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
79224920|NCT03490188|Behavioral|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
79520130|NCT02862912|Drug|Saline|Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml
79520131|NCT02864706|Drug|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
79520132|NCT02864706|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
79520133|NCT02864706|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
79520134|NCT02864706|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
79996433|NCT03233009|Other|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
79996434|NCT03233009|Other|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
79996435|NCT03233009|Other|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
79996436|NCT03233009|Other|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
79996437|NCT03233009|Other|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
79520135|NCT02865720|Drug|CINRYZE 500 U|IV infusion administered twice weekly
79224921|NCT03534843|Procedure|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
79520136|NCT02865720|Drug|CINRYZE 1000 U|IV infusion administered twice weekly
79520137|NCT02867202|Device|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
79367373|NCT04148859|Procedure|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
79520138|NCT02867202|Device|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
79520139|NCT02871570|Drug|Rivipansel|A single dose of IV Rivipansel over 20 minutes
79520140|NCT02873286|Biological|MVA-BN-RSV|MVA-mBN294B
79224922|NCT03534843|Other|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
79520141|NCT02873286|Other|Placebo|Tris Buffered Saline, sterile
79520142|NCT02874066|Drug|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
79224923|NCT02473016|Drug|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].
79224924|NCT03131856|Behavioral|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
79224925|NCT03132012|Behavioral|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
79520143|NCT02874846|Drug|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
79676699|NCT05013749|Procedure|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
79676700|NCT05008965|Biological|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
79676701|NCT05008965|Other|Placebo|Formulation buffer
79676702|NCT05005078|Drug|WST-057|WST-057 topical solution
79224926|NCT03132012|Behavioral|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
79224927|NCT02473094|Drug|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
79676703|NCT05005078|Drug|Placebo|WST-057 Matching placebo
79676704|NCT04994327|Other|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
79224928|NCT02473094|Drug|Metformin|Metformin up to 2500mg/d
79224929|NCT02473094|Radiation|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
79224930|NCT02473094|Drug|Placebo|Placebo up to 2500mg/d
79224931|NCT03534765|Diagnostic Test|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
79224932|NCT03534765|Diagnostic Test|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
79224933|NCT03534765|Procedure|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
79224934|NCT03492138|Drug|ONC201|625mg
79224935|NCT03492138|Drug|Ixazomib|Dose to be determined in Phase 1 of study
79224936|NCT03492138|Drug|Dexamethasone|40mg
79224937|NCT02472938|Drug|dimethyl fumarate|dimethyl fumarate 120 mg capsules
79224938|NCT02472938|Other|Placebo|Placebo for BG00012
79520144|NCT02874846|Other|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
79520145|NCT02880228|Drug|Dexamethasone|Given PO
79520146|NCT02880228|Other|Laboratory Biomarker Analysis|Correlative studies
79520147|NCT02880228|Drug|Lenalidomide|Given PO
79520148|NCT02880228|Biological|Pembrolizumab|Given IV
79520149|NCT02880852|Drug|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
79520150|NCT02886234|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
79520151|NCT02886234|Behavioral|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
79520152|NCT02887404|Other|Spine surgery analgesic pathway|Enhanced pain management care
79520153|NCT02887404|Other|Usual Care|Standard of pain management care
79520154|NCT02889510|Drug|liraglutide|7-week subcutaneous liraglutide once daily
79520155|NCT02889510|Drug|placebo|7-week subcutaneous placebo once daily
79520156|NCT02893878|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
79520157|NCT02899650|Other|exercise|acute downhill running
79520158|NCT02899884|Other|No Intervention|
79520159|NCT02902146|Device|Bougie|
79520160|NCT02902146|Device|Endotracheal tube|
79520161|NCT02902770|Drug|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
79520162|NCT02902770|Drug|Ketorolac Tromethamine|IV ketorolac 30mg push
79520163|NCT02902770|Drug|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
79676705|NCT04978454|Biological|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
79676706|NCT04978454|Other|Placebo|Sucrose phosphate glutamate (SPG) inoculum
79996438|NCT04034225|Drug|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
79996439|NCT04034225|Drug|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
79676707|NCT04973956|Other|Relaxation|This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
79822303|NCT00753129|Procedure|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
79224939|NCT03131700|Biological|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
79676708|NCT04973956|Other|Control|No intervention
79224940|NCT03131700|Biological|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
79224941|NCT02194101|Procedure|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
79676709|NCT04964830|Device|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
79822304|NCT00753207|Drug|epirubicin hydrochloride|
79822305|NCT00753207|Drug|lapatinib ditosylate|
79224942|NCT02471768|Procedure|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
79224943|NCT03534999|Device|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
79224944|NCT03534999|Other|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
79228114|NCT02230605|Other|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
79228115|NCT02230605|Other|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
79520164|NCT02902770|Drug|Normal Saline Push|Normal Saline Push Placebo
79520165|NCT02903394|Device|mLCI Device|imaging of cervical epithelium using mLCI device
79520166|NCT02907918|Drug|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
79520167|NCT02907918|Drug|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
79520168|NCT02907918|Biological|Trastuzumab|"Or FDA approved biosimilar~Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery."
79520169|NCT02907918|Drug|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
79520170|NCT02907918|Procedure|Breast surgery|Standard of care
79520171|NCT02907918|Procedure|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
79520172|NCT02907918|Procedure|Research bone marrow (OPTIONAL)|Baseline and surgery
79520173|NCT02907918|Procedure|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
79520174|NCT02907918|Genetic|Research blood for germline DNA|Baseline
79676710|NCT04951219|Drug|Resmetirom|Tablet
79676711|NCT04949399|Drug|OnabotulinumtoxinA|Injection
79676712|NCT04949399|Drug|Placebo|Injection
79822306|NCT00753207|Other|biomarker analysis|
79822307|NCT00753207|Other|immunohistochemistry staining method|
79822308|NCT00753207|Other|liquid chromatography|
79822309|NCT00753207|Other|mass spectrometry|
79822310|NCT00715910|Biological|Nimenrix|One dose, as intramuscular injection
79520175|NCT02907918|Procedure|Blood for detection of circulating tumor cells|Baseline
79520176|NCT02908620|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
79676713|NCT04942626|Drug|Kineret 100 MG in 0.67 ML Prefilled Syringe|Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
79520177|NCT02908620|Drug|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
79676714|NCT04942626|Drug|Capecitabine|Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
79676715|NCT04942626|Radiation|Radiotherapy|PTV: 1.8 Gy to 45 Gy (#28 fractions) to the primary tumor and pelvic lymph nodes; followed by a sequential boost of 1.8 Gy to 9 Gy (#5 fractions) to the gross tumor volume
79367374|NCT03588507|Combination Product|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
79367375|NCT03897309|Biological|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
79520178|NCT02908620|Combination Product|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
79520179|NCT02908620|Drug|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
79676716|NCT04942626|Procedure|Watch and Wait (cCR) or TME surgery (non-cCR)|Restaging to evaluate tumor response will be conducted 10 weeks after completion of CRT. For patients achieving a clinical complete response (cCR), a Watch and Wait (W&W) option with close follow-up is scheduled. In case of non-cCR, immediate total mesorectal excision (TME) surgery is recommended. According to the current German S3-guidelines, adjuvant chemotherapy is optional.
79822311|NCT00715910|Procedure|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
79822312|NCT04056663|Behavioral|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
79822313|NCT00750711|Procedure|Radiofrequency ablation for atrial flutter by catheters|
79822314|NCT00750789|Dietary Supplement|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
79822315|NCT02590484|Procedure|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
79822316|NCT04086914|Procedure|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
79822317|NCT00715676|Drug|Placebo|oral, once daily
79822318|NCT00715676|Drug|DP001|oral, once daily
79822319|NCT05163470|Other|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
79224945|NCT02368002|Behavioral|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
79228116|NCT02230605|Other|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
79228117|NCT02230605|Other|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
79367376|NCT03897309|Biological|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
79367377|NCT03897309|Biological|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
79367378|NCT03588429|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
79367379|NCT03588429|Drug|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
79367380|NCT03581019|Procedure|uterus transplantation|uterus transplantation from deceased donor
79520180|NCT02910102|Drug|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
79520181|NCT02910102|Drug|Placebo|Placebo once daily, oral
79520182|NCT02911818|Behavioral|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
79996440|NCT05571215|Device|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
79822320|NCT05163470|Other|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
79996441|NCT05571215|Behavioral|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
79996442|NCT03690947|Drug|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
79996443|NCT03690947|Procedure|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
79996444|NCT03690947|Drug|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
79996445|NCT01313741|Device|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
79996446|NCT02999178|Drug|Nintedanib|
79224946|NCT02368002|Behavioral|Portion-controlled meals|"Participants continue with behavioral weight loss therapy, but this is augmented with portion-controlled meals (PCM). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. PCMs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. PCMs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
79224947|NCT02368002|Behavioral|Acceptance-based treatment|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance-based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
79224948|NCT04706936|Biological|anti-BCMA CAR-T|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
79224949|NCT04706936|Drug|Cyclophosphamid|300mg/m2/d
79367381|NCT03580161|Other|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79367382|NCT03580161|Other|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79367383|NCT03580161|Other|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79367384|NCT03580161|Other|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79520183|NCT02911818|Drug|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
79520184|NCT02911818|Other|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
79520185|NCT02911818|Drug|Placebo Oral Tablet|
79520186|NCT02911818|Drug|Phentermine 15 MG|
79996447|NCT02999178|Drug|Placebo|
79520187|NCT02911818|Behavioral|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
79520188|NCT02912364|Drug|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
79520189|NCT02912364|Drug|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
79822321|NCT00718328|Drug|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
79822322|NCT00718328|Drug|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
79996448|NCT02959190|Drug|Galcanezumab|Administered SC
79367385|NCT03580161|Other|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79367386|NCT03580161|Other|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79367387|NCT03580161|Other|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
79367388|NCT03583437|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
79996449|NCT02031614|Procedure|Phlebotomy|Withdrawal of 500 mL of whole blood.
79996450|NCT01344356|Radiation|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
79996451|NCT01344356|Radiation|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
79996452|NCT03640130|Behavioral|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
79996453|NCT03618992|Other|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
79520190|NCT02913924|Drug|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
79996454|NCT03722810|Other|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
79996455|NCT03722810|Other|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
79996456|NCT02236676|Behavioral|Nap after rehearsal trials|Behavioral
79224950|NCT04706936|Drug|Fludarabine|30mg/m2/d
79520191|NCT02913924|Drug|Placebo|
79520192|NCT02916498|Device|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
79520193|NCT02917122|Device|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
79520194|NCT02917122|Drug|Sertraline|Patients will take Sertraline.
79367389|NCT03588351|Drug|chitosan nanoparticles gel|intracanal medicament
79996457|NCT03618368|Device|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
79996458|NCT03618368|Device|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
79996459|NCT03618914|Biological|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
79367390|NCT03588351|Drug|chitosan gel|intracanal medicament
79367391|NCT03588351|Drug|chlorhexidine gluconate|intracanal medicament
79676717|NCT04915079|Behavioral|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
79996460|NCT02956460|Device|fanfilcon A|contact lens
79996461|NCT02956460|Device|senofilcon A|contact lens
79520195|NCT02917122|Device|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
79520196|NCT02917278|Dietary Supplement|Meals|High Protein renal-specific meals
79520197|NCT02921412|Device|fanfilcon A|contact lens
79520198|NCT02921490|Device|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
79224951|NCT02257203|Behavioral|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
79224952|NCT02257203|Behavioral|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
79224953|NCT02194881|Drug|CF patients with a G551D mutation and treated with Ivacaftor|
79224954|NCT02194959|Behavioral|Peer PN|Navigation by Peer Patient Navigators
79224955|NCT02194959|Behavioral|Pro PN|Navigation by Standard Hospital Navigators
79520199|NCT02922582|Drug|DepoTXA|
79520200|NCT02922582|Drug|Tranexamic Acid|
79520201|NCT02922738|Other|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
79520202|NCT02925078|Device|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with <2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
79520203|NCT02925858|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
79520204|NCT02925858|Drug|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
79520205|NCT02933034|Drug|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
79520206|NCT02933034|Drug|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
79676718|NCT04914403|Biological|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
79676719|NCT04893174|Biological|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
79996462|NCT03618290|Diagnostic Test|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
79367392|NCT03940209|Behavioral|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
79996463|NCT02999100|Drug|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
79367393|NCT03588273|Drug|Amoxil 500 MG Oral Capsule|
79367394|NCT03588195|Other|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
79367395|NCT03588195|Device|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
79367396|NCT03585621|Radiation|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
79520207|NCT02933502|Drug|DSXS topical product|treatment daily for 28 days
79520208|NCT02935062|Behavioral|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
79676720|NCT04893174|Device|Hyaluronic acid|IA injection of hyaluronic acid.
79224956|NCT03534609|Device|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
79224957|NCT02194179|Drug|NVP XR 400 mg (KCR 25%)|
79224958|NCT02194179|Drug|NVP XR 400 mg (KCR 20%)|
79367397|NCT03588819|Radiation|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
79520209|NCT02935062|Behavioral|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
79520210|NCT02935062|Behavioral|Placebo Therapy|No intervention to improve speech.
79520211|NCT02936076|Other|Exercise intervention|
79520212|NCT02936076|Other|Delayed exercise intervention|
79520213|NCT02937168|Drug|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
79520214|NCT02937168|Drug|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
79520215|NCT02937168|Drug|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
79520216|NCT02937558|Drug|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
79520217|NCT02937558|Other|Placebo|Isotonic saline
79520218|NCT02938494|Drug|IDP-123 Lotion|Lotion
79520219|NCT02938494|Drug|Tazorac Cream|Cream
79520220|NCT02938494|Drug|Vehicle Lotion|Lotion
79520221|NCT02938494|Drug|Vehicle Cream|Cream
79676721|NCT04858503|Other|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
79676722|NCT04838600|Device|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
79676723|NCT04835467|Device|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
79676724|NCT04829916|Drug|RMC-035|Multiple dosing during 48 hours following cardiac surgery
79224959|NCT02194179|Drug|NVP XR 300 mg (KCR 25%)|
79224960|NCT02194179|Drug|NVP XR 300 mg (KCR 20%)|
79224961|NCT02194179|Other|high-fat breakfast|
79224962|NCT02194179|Drug|NVP IR 200 mg (Viramune®)|
79224963|NCT02194257|Drug|[14C]-cyclohexane ambroxol oral solution|
79224964|NCT02194257|Drug|[14C]-benzyl ambroxol oral solution|
79224965|NCT02194257|Drug|Ambroxol lozenge|
79520222|NCT02941614|Behavioral|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
79520223|NCT02941692|Drug|Oxytocin|
79520224|NCT02941692|Drug|Placebo|Placebo for Oxytocin
79676725|NCT04829916|Drug|Placebo|Multiple dosing during 48 hours following cardiac surgery
79996464|NCT02999100|Drug|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
79367398|NCT03588117|Behavioral|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
79520225|NCT02942160|Biological|Collagenase Clostridium Histolyticum|
79520226|NCT02953860|Drug|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
79520227|NCT02956044|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
79676726|NCT04825860|Drug|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
79676727|NCT04825860|Drug|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
79676728|NCT04825860|Drug|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
79996465|NCT02999100|Drug|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
79996466|NCT02999100|Device|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
79996467|NCT02749370|Drug|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
79996468|NCT03622866|Device|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
79996469|NCT03622866|Device|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
79996470|NCT03619070|Other|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
79996471|NCT03619070|Other|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
79676729|NCT04816812|Behavioral|Exercise intervention|A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
79996472|NCT03619070|Other|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
79676730|NCT04816812|Behavioral|Lifestyle - online lesson intervention|The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
79996473|NCT03619070|Other|Control group, CG|The CG groups do not will performed the exercise.
79996474|NCT03618836|Other|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
79996475|NCT03435536|Other|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
79520228|NCT02956044|Drug|Metformin|1000 mg metformin
79520229|NCT02956044|Drug|Glimepiride|4 mg glimepiride
79996476|NCT03618602|Drug|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
79996477|NCT03723200|Other|Fibrinogen and blood products|Fibrinogen and blood products
79996478|NCT03618212|Diagnostic Test|MRI|Skeletal MRI and pelvic and spinal MRI
79996479|NCT05001386|Biological|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
79996480|NCT02031848|Other|Diet Intervention|
79996481|NCT02031848|Other|Assessments and Diet Intake|
79996482|NCT03617978|Procedure|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
79996483|NCT03617900|Drug|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
79996484|NCT03617900|Drug|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
79996485|NCT03617900|Drug|Paracetamol|500 mg paracetamol. use in need
79996486|NCT05384366|Drug|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
79996487|NCT05572385|Behavioral|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
79224966|NCT02195115|Procedure|Laparoscopic Cholecystectomy|
79224967|NCT02195115|Drug|amitriptyline|
79520230|NCT02956044|Drug|Sitagliptin|100 mg sitagliptin
79520231|NCT02956122|Biological|GLASSIA|GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
79520232|NCT02956122|Drug|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
79520233|NCT02956122|Biological|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
79520234|NCT02956746|Biological|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
79520235|NCT02956746|Biological|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
79520236|NCT02956746|Biological|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
79520237|NCT02956746|Biological|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
79367399|NCT03545607|Biological|MultiStem|single intravenous infusion 18-36 hours after stroke
79367400|NCT03545607|Biological|Placebo|single intravenous infusion 18-36 hours after stroke
79520238|NCT02961894|Device|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
79676737|NCT04786405|Behavioral|Mindfulness meditation|Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
79676738|NCT04786405|Behavioral|Clinical hypnosis|Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
79822323|NCT05346848|Drug|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~78 Gy with classical 2 Gy/fractions, 5 days/7~Or 60 Gy with 3 Gy/fractions, 5 days/7~Use of IMRT and IGRT is mandatory~Clinical Target Volume Definition according to GETUG Guidelines~Organ at risk dose constraints according to RECORAD"
79822324|NCT05346848|Drug|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~78 Gy with classical 2 Gy/fractions, 5 days/7~Or 60 Gy with 3 Gy/fractions, 5 days/7~Use of IMRT and IGRT is mandatory~Clinical Target Volume Definition according to GETUG Guidelines~Organ at risk dose constraints according to RECORAD"
79822325|NCT02591186|Procedure|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
79224968|NCT02195115|Other|low-fat and low cholesterol diet|
79224969|NCT02194335|Drug|BIBN 4096 BS - in single rising doses|
79224970|NCT02194335|Drug|Placebo|
79224971|NCT02031003|Dietary Supplement|Infant formula|Infant formula
79224972|NCT02195973|Drug|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
79224973|NCT02196129|Drug|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
79224974|NCT02196129|Drug|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
79224975|NCT02195193|Other|Integrated care|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
79367401|NCT04148235|Other|No Intervention|There is no intervention for this study
79367402|NCT03587649|Drug|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
79367403|NCT04148313|Other|No Intervention|There is no intervention for this study.
79367404|NCT03589755|Behavioral|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
79520239|NCT02963376|Drug|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
79676739|NCT04779424|Other|POCT|Capillary blood sample antibody point of care test
79996488|NCT03616808|Other|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
79996489|NCT03616652|Drug|Placebo|Placebo pill
79224976|NCT02257281|Device|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
79367405|NCT03589599|Other|Flavored tobacco|Effects of flavored tobacco
79367406|NCT03589599|Other|Non-flavored tobacco|Effects of non-flavored tobacco
79996490|NCT03616652|Other|Film sequence|The experimental group watches a film about the power of placebo effects.
79224977|NCT02257281|Device|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
79224978|NCT02196207|Drug|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
79224979|NCT02196207|Drug|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
79224980|NCT02196207|Drug|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
79367407|NCT02984865|Drug|Sulfentanyl|
79676740|NCT04779294|Diagnostic Test|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
79996491|NCT03616652|Other|Film sequence|The control group watches a film about sleep.
79996492|NCT03618524|Other|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
79996493|NCT02031926|Device|Positive expiratory pressure|
79996494|NCT03607994|Device|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
79996495|NCT03607994|Device|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
79224981|NCT02196207|Drug|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
79224982|NCT02195271|Device|Transcranial Direct Current Stimulation (tDCS)|
79224983|NCT02195271|Drug|Melatonin|
79224984|NCT05124483|Biological|AKS-452X|subcutaneous injection of 90 µg AKS-452X
79224985|NCT02196285|Biological|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
79224986|NCT04229979|Biological|Galinpepimut-S|Sargramostim 70 µg (2 days), then galinpepimut-S admixed with the adjuvant Montanide following specified schedule
79224987|NCT04229979|Drug|Azacitidine|injection
79224988|NCT04229979|Drug|Venetoclax|tablet
79224989|NCT04229979|Drug|Decitabine|injection
79367408|NCT02984865|Drug|Nalbuphine|
79367409|NCT02984865|Drug|flubiprofen axetil|
79367410|NCT02984865|Procedure|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
79367411|NCT03696069|Other|Non-Interventional|Non-Interventional
79367412|NCT03589521|Behavioral|ABCT_Military|15 Weekly Couple Therapy Sessions
79367413|NCT03589443|Drug|Multiplexed heptapeptides|Heptapeptides QRH and KSP
79367414|NCT03589365|Other|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
79996496|NCT03617510|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
79996497|NCT03617510|Drug|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
79996498|NCT03617432|Drug|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
79224990|NCT04229979|Drug|Cytarabine|injection
79224991|NCT04229979|Other|Observation|palliative management
79676741|NCT04772040|Dietary Supplement|Fish oil supplementation|Fish oil capsules.
79676742|NCT04768881|Drug|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
79676743|NCT04768881|Drug|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter [mg/mL]) Solution
79996499|NCT03617432|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
79996500|NCT03617432|Drug|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
79996501|NCT03617432|Drug|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
79224992|NCT02196441|Drug|2% tetracaine local anaesthetic drops|topical anaesthetic drops
79224993|NCT02196441|Drug|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
79224994|NCT02195661|Dietary Supplement|Melatonin|
79520240|NCT02963376|Drug|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
79520241|NCT02963376|Drug|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
79520242|NCT02963376|Drug|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
79224995|NCT02195661|Drug|Chloral Hydrate|
79520243|NCT02963376|Drug|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
79520244|NCT02963376|Drug|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
79224996|NCT03534297|Drug|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
79367415|NCT03587415|Diagnostic Test|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
79367416|NCT03020433|Device|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
79367417|NCT03020433|Device|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
79520245|NCT02967354|Radiation|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer [11C]5-hydroxy-tryptophan
79520246|NCT02967510|Drug|Estriol|
79520247|NCT02967510|Drug|Placebo|
79676744|NCT04768790|Other|multidisciplinary program|multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
79676745|NCT04768790|Other|General program|exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
79676746|NCT04761822|Biological|Moderna COVID-19 Vaccine|Intramuscular injection
79996502|NCT03617432|Drug|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
79224997|NCT03534297|Drug|Placebo capsules|Hard opaque capsules containing 0 mg of API.
79224998|NCT02196519|Device|Sylys Surgical Sealant|
79224999|NCT02195817|Drug|Selincro® 18 mg with continuous psychosocial support: Cohort A|
79225000|NCT02195817|Other|Initial psychosocial support: Cohort B|
79225001|NCT02200770|Drug|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
79225002|NCT02200770|Other|Placebo|Participants will receive IV placebo matched to inebilizumab.
79225003|NCT03534063|Genetic|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
79225004|NCT03534219|Device|EarPopper|The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
79225005|NCT02197143|Drug|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
79367418|NCT03020433|Device|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
79367419|NCT03020433|Device|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
79367420|NCT01797445|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
79367421|NCT01797445|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
79520248|NCT02968134|Drug|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
79520249|NCT02968368|Drug|Ferric maltol|
79520250|NCT02968368|Other|Placebo|
79520251|NCT02968758|Device|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
79520252|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
79520253|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
79520254|NCT02970006|Device|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
79520255|NCT02970162|Drug|Amifampridine Phosphate|
79520256|NCT02970162|Drug|Placebo Oral Tablet|
79520257|NCT02970552|Drug|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
79996503|NCT03617432|Drug|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
79996504|NCT03464916|Biological|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
79225006|NCT02197143|Drug|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
79367422|NCT01797445|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
79520258|NCT02970552|Drug|Placebo|Indistinguishable placebo vaginal suppository
79520259|NCT02971488|Other|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
79520260|NCT02973438|Device|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
79520261|NCT02973438|Device|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
79520262|NCT02973516|Drug|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
79520263|NCT02973516|Drug|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
79520264|NCT02974296|Device|transcranial magnetic stimulation|non invasive brain stimulation approach
79520265|NCT02978508|Drug|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
79996505|NCT05058716|Diagnostic Test|blood sample|weekly blood sample - coenzym q10 levels
79996506|NCT04057950|Other|cosmetic product|Disulfure de sélénium versus placebo formula
79996507|NCT03616340|Drug|Shoulder injection|intra articular or subacromial shoulder injection
79996508|NCT03616340|Drug|knee injection|intra-articular knee injection
79996509|NCT03663660|Other|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
79996510|NCT05035004|Device|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
79996511|NCT05035004|Device|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
79225007|NCT02197143|Drug|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
79225008|NCT02096874|Drug|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
79225009|NCT03489954|Other|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
79225010|NCT02197299|Dietary Supplement|L-carnitine|
79225011|NCT02197299|Dietary Supplement|Placebo|
79228118|NCT02230605|Other|Short Form 36 Health Survey|To be completed at the Screening Visit
79367423|NCT01797445|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
79367424|NCT03587181|Procedure|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
79367425|NCT04765683|Other|questionnaire|Survey of views on outpatient consultation format
79367426|NCT03589131|Procedure|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
79520266|NCT02978508|Drug|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
79520267|NCT02979054|Device|T4020|
79520268|NCT02979054|Device|Placebo|
79676747|NCT04761822|Biological|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
79996512|NCT05035004|Device|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
79996513|NCT02996682|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79996514|NCT02996682|Drug|RBV|Capsules administered orally in a divided daily dose
79996515|NCT03664284|Procedure|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
79367427|NCT03589131|Procedure|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
79520269|NCT02979444|Behavioral|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
79676748|NCT04761822|Biological|Placebo|Intramuscular injection
79822326|NCT04087070|Device|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
79822327|NCT02590874|Drug|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
79996516|NCT02873702|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
79822328|NCT02590874|Drug|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
79520270|NCT02881008|Drug|Entecavir|
79520271|NCT02881008|Drug|Myrcludex B|
79520272|NCT02987868|Drug|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
79520273|NCT02987868|Drug|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
79520274|NCT02987868|Drug|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
79520275|NCT02987868|Drug|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
79520276|NCT02988882|Drug|Dexamethasone|
79676749|NCT04729543|Biological|Adoptive therapy with autologous MC2 TCR T cells|Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
79676750|NCT04709692|Drug|(+)-SJ000557733 (SJ733)|Anti-Malarial
79822329|NCT02590952|Drug|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
79676751|NCT04706962|Drug|TH1902|Intravenous infusion
79996517|NCT02873702|Drug|Lansoprazole|Lansoprazole capsules.
79676752|NCT04692285|Drug|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
79676753|NCT04692285|Drug|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
79676754|NCT04690855|Drug|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
79996518|NCT02873702|Drug|Placebo|Dexlansoprazole placebo-matching capsules.
79822330|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
79822331|NCT00715520|Drug|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
79996519|NCT03617120|Device|Ergonomic Brace vs hard brace|"Visit 1:~Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~Pressure measurement of participant wearing their hard brace~Visit 2:~Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~3D body scanning (before wearing the Ergonomic Brace)~Fitting of the Ergonomic Brace~Pressure measurement of participant wearing the Ergonomic Brace (instant)~Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~3D body scanning (after wearing the Ergonomic Brace for 2 hours)~Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~Standing in-brace radiograph of the Ergonomic Brace~Doctor consultation"
79228119|NCT02230605|Other|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
79228120|NCT02230605|Other|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
79367428|NCT03589131|Procedure|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
79367429|NCT03589131|Procedure|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
79367430|NCT03589131|Procedure|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
79520277|NCT02988882|Other|Placebo Vehicle|
79520278|NCT02992236|Drug|VAS203|Infusion of NO-Synthase inhibitor VAS203
79520279|NCT02992236|Drug|Saline|Infusion of saline
79676755|NCT04690855|Drug|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
79676756|NCT04690855|Radiation|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
79228121|NCT02230605|Other|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
79520280|NCT02994732|Drug|[14C]-BVD-523|[14C]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
79822332|NCT00715520|Drug|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
79520281|NCT03001674|Device|Conductance catheterization|CD Leycom Conductance Catheter
79822333|NCT00715520|Drug|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
79822334|NCT00715520|Drug|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
79822335|NCT00715520|Other|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
79520282|NCT03002454|Drug|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
79520283|NCT03004638|Drug|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
79676757|NCT04676100|Other|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
79676758|NCT04663100|Other|Patient-reported outcome measure|Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
79676759|NCT04663100|Other|Comprehensive Medication Review|Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
79676760|NCT04663100|Other|Pharmacist communication|Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
79676761|NCT04643015|Diagnostic Test|MRI|"Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol."
79996520|NCT03616262|Drug|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
79228122|NCT03313700|Procedure|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
79228123|NCT03313700|Procedure|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
79520284|NCT03004638|Drug|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
79520285|NCT03004638|Drug|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
79520286|NCT03004638|Drug|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
79520287|NCT03004638|Drug|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
79520288|NCT03004638|Drug|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
79520289|NCT03009162|Drug|Lasmiditan|200 mg, single oral tablet
79520290|NCT03009396|Drug|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
79520291|NCT03010488|Behavioral|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
79520292|NCT03010488|Behavioral|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
79520293|NCT03010488|Device|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
79520294|NCT03010800|Device|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
79225012|NCT02196753|Other|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV> 40% of the background."
79225013|NCT01186848|Device|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
79520295|NCT03010800|Device|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
79367431|NCT03589131|Procedure|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission & 30-days mortality. All were analyzed and compared
79676762|NCT04634539|Drug|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
79225014|NCT01186848|Device|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
79367432|NCT03589053|Device|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
79367433|NCT03589053|Device|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
79367434|NCT03587103|Behavioral|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
79367435|NCT03587103|Behavioral|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
79367436|NCT03587103|Behavioral|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
79367437|NCT01611259|Drug|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
79367438|NCT04147767|Dietary Supplement|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)***, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~*** Equivalent to 2% Free Plant Sterols"
79225015|NCT02196909|Other|motor function and strength assessment|
79225016|NCT02196909|Other|NMR assessment|
79225017|NCT02196909|Other|24h urine and serum collection|
79367439|NCT04147767|Dietary Supplement|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
79367440|NCT03586869|Drug|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
79520296|NCT03012594|Drug|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
79676763|NCT04634539|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
79225018|NCT03489876|Device|Synthetic Cartilage Implant|The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.
79367441|NCT03586869|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79367442|NCT03586869|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79367443|NCT03586869|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
79367444|NCT03586869|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79367445|NCT03586869|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
79367446|NCT03586869|Biological|GI-4000|RAS yeast
79367447|NCT03586869|Biological|GI-6207|Carcinoembryonic Antigen (CEA) yeast
79367448|NCT03586869|Biological|GI-6301|Brachyury yeast
79520297|NCT03014700|Biological|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
79520298|NCT03014700|Biological|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
79228124|NCT03473496|Biological|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
79520299|NCT03017508|Drug|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
79520300|NCT03017508|Drug|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
79676764|NCT04634539|Drug|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
79367449|NCT03586869|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
79676765|NCT04619264|Drug|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
79225019|NCT03489876|Procedure|Osteochondral Autograft Transfer|The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
79225020|NCT02196987|Other|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
79367450|NCT03586869|Biological|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
79367451|NCT03586869|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79367452|NCT03586869|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79367453|NCT03586869|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79520301|NCT03020004|Drug|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
79520302|NCT03020004|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
79676766|NCT04619264|Procedure|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
79225021|NCT02196987|Other|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
79225022|NCT03487458|Procedure|Rib Fixation Surgery|Rib Fixation Surgery
79225023|NCT02198547|Drug|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
79225024|NCT02198547|Drug|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
79367454|NCT03586869|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79367455|NCT03586869|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
79367456|NCT03586869|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79367457|NCT03586869|Biological|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
79367458|NCT03586869|Procedure|SBRT|Stereotactic Body Radiation Therapy
79367459|NCT04147377|Behavioral|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
79367460|NCT03581253|Other|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
79367461|NCT03581253|Other|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
79367462|NCT03581175|Procedure|Colonoscopy|
79367463|NCT03581175|Drug|Bowel cleansing regimen|
79520303|NCT03020004|Drug|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
79520304|NCT03020004|Drug|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)
79520305|NCT03020082|Drug|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
79520306|NCT03020082|Drug|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
79520307|NCT03020082|Drug|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
79520308|NCT03020082|Drug|RBV|RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
79520309|NCT03020472|Biological|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
79520310|NCT03026556|Drug|Dabigatran vs. Rivaroxaban|observed for 6 years
79520311|NCT03026556|Drug|Dabigatran vs. Apixaban|Observed for 6 years
79520312|NCT03028974|Biological|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
79520313|NCT03028974|Biological|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
79520314|NCT03029988|Drug|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
79520315|NCT03029988|Procedure|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
79520316|NCT03033108|Drug|Emixustat|Once daily, tablet for oral administration
79520317|NCT03035760|Drug|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
79520318|NCT03036384|Drug|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
79520319|NCT03036384|Drug|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
79520320|NCT03036384|Drug|Sufentanil|2.5µg sufentanyl
79520321|NCT03036384|Drug|Morphine|100 µg Morphine
79520322|NCT03040362|Drug|[14C]-lasmiditan|[14C]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
79520323|NCT03041298|Procedure|MR mammography with Dotarem|
79520324|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
79225025|NCT01024608|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
79676767|NCT04615819|Other|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
79225026|NCT01024608|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
79676768|NCT04615819|Other|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
79676769|NCT04611854|Behavioral|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
79676770|NCT04611854|Behavioral|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
79996521|NCT03616262|Drug|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
79996522|NCT02236754|Drug|18F-FP-DTBZ|The drug, no carrier added [18F]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce [18F]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 mCi of [18F]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
79996523|NCT02236754|Radiation|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
79225027|NCT02197533|Other|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
79225028|NCT02198625|Other|Moderate FiO2 and Protective Lung Ventilation Using|
79225029|NCT03489798|Procedure|6 misoprostol|Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
79225030|NCT03489798|Procedure|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
79225031|NCT02197689|Device|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
79225032|NCT05145114|Procedure|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
79225033|NCT02198703|Dietary Supplement|Probiotics bacterial strains|
79225034|NCT02198703|Dietary Supplement|Placebo|
79228125|NCT05137626|Drug|AT-527 + digoxin|"Day 1: A single dose of digoxin will be administered.~Day 15: A single dose of AT-527 and digoxin will be co-administered."
79367464|NCT03586791|Procedure|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
79520325|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
79520326|NCT03044028|Device|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
79520327|NCT03044418|Other|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
79520328|NCT03046212|Device|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
79676771|NCT04602611|Other|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
79676772|NCT04596267|Drug|Pitolisant|8.9mg Pitolisant for 5 days
79676773|NCT04596267|Drug|Placebo|Inert ingredients
79520329|NCT03046212|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
79996524|NCT03615950|Diagnostic Test|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
79996525|NCT03615950|Diagnostic Test|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
79996526|NCT03615950|Diagnostic Test|Height measurement|Height will be measured at baseline and 12 months.
79996527|NCT03615950|Other|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
79520330|NCT03048006|Procedure|MRI with Dotarem|
79225035|NCT05144958|Device|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
79225036|NCT05144958|Device|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
79225037|NCT05144958|Device|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
79225038|NCT04461522|Procedure|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
79367465|NCT03586791|Procedure|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
79367466|NCT03586791|Procedure|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
79520331|NCT03051672|Drug|Pembrolizumab|Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.
79520332|NCT03051672|Radiation|Palliative radiotherapy|Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
79520333|NCT03052530|Device|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
79676774|NCT04557878|Drug|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
79676775|NCT04557878|Biological|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
79676776|NCT04538742|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
79676777|NCT04538742|Drug|Durvalumab|Durvalumab: administered as an IV infusion
79676778|NCT04538742|Drug|Paclitaxel|Paclitaxel: administered as an IV infusion
79996528|NCT02911116|Drug|Ustekinumab|Subcutaneous Injection
79996529|NCT02911116|Drug|Ustekinumab|Intravenous Infusion
79996530|NCT03615872|Device|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
79996531|NCT03664050|Drug|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
79996532|NCT03664050|Procedure|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
79996533|NCT02998554|Drug|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
79520334|NCT03055650|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
79520335|NCT03057132|Device|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
79225039|NCT02031081|Drug|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
79520336|NCT03057366|Drug|Pevonedistat|Pevonedistat intravenous infusion.
79520337|NCT03057366|Drug|[14C]-Pevonedistat|[14C]-Pevonedistat intravenous infusion.
79520338|NCT03057366|Drug|Docetaxel|Docetaxel intravenous infusion.
79520339|NCT03057366|Drug|Carboplatin|Carboplatin intravenous infusion.
79520340|NCT03057366|Drug|Paclitaxel|Paclitaxel intravenous infusion.
79520341|NCT03060486|Device|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
79676779|NCT04538742|Drug|Pertuzumab|Pertuzumab: administered as an IV infusion
79676780|NCT04538742|Drug|Tucatinib|Tucatinib administered orally (tablet) twice daily
79225040|NCT02031081|Drug|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
79520342|NCT03061812|Drug|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
79520343|NCT03061812|Drug|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
79822336|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
79676781|NCT04537416|Other|No intervention|No intervention
79676782|NCT04517266|Radiation|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
79676783|NCT04517266|Radiation|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
79676784|NCT04513912|Drug|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
79676785|NCT04513912|Drug|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
79822337|NCT05306132|Drug|ASKC202|Dosage Forms: Tablets; Administration: Oral administration
79822338|NCT05684978|Drug|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
79996534|NCT02998554|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
79225041|NCT02198859|Drug|Lithium Carbonate|
79225042|NCT02198937|Other|Blood sample|
79225043|NCT02199093|Other|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
79520344|NCT03061812|Drug|Dexamethasone|Oral tablet.
79520345|NCT03063294|Other|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
79520346|NCT03063294|Other|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
79520347|NCT03064152|Device|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
79520348|NCT03066102|Other|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
79520349|NCT03067506|Other|No intervention|No intervention
79520350|NCT03070470|Drug|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
79676786|NCT04513912|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
79676787|NCT04513912|Drug|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
79676788|NCT04510311|Drug|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) [18F]3F-PHPG
79676789|NCT04510311|Drug|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi [123I]MIBG
79676790|NCT04510311|Diagnostic Test|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of [18F]3F-PHPG
79676791|NCT04510311|Diagnostic Test|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of [123I]MIBG
79822339|NCT00756873|Drug|Administration of placebo|Placebo qd orally day 0-14
79822340|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
79822341|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
79822342|NCT00790205|Drug|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
79822343|NCT00790205|Drug|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
79822344|NCT04056039|Drug|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
79822345|NCT04056039|Drug|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
79822346|NCT00750945|Other|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
79822347|NCT00750945|Other|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
79225044|NCT02199093|Other|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
79225045|NCT02199171|Drug|carboplatin|Given via HIPEC
79225046|NCT02199249|Device|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
79367467|NCT01795495|Drug|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
79520351|NCT03070470|Drug|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
79520352|NCT03070470|Drug|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
79520353|NCT03070470|Drug|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
79520354|NCT03070470|Drug|Placebo|Placebo (administered orally)
79520355|NCT03070470|Drug|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
79520356|NCT03070548|Drug|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
79520357|NCT03072186|Device|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
79520358|NCT03072732|Device|u-Cor System|Monitoring System
79676792|NCT04510311|Diagnostic Test|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of [123I]MIBG
79676793|NCT04508764|Other|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
79676794|NCT04504253|Dietary Supplement|Creatine monohydrate|Creatine monohydrate loose powder
79676795|NCT04504253|Drug|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
79676796|NCT04484337|Drug|Cabotegravir sodium (Oral Lead In)|CAB will be available as 30 mg tablets for oral administration.
79676797|NCT04484337|Drug|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
79822348|NCT00750945|Other|Home program|Home walking program 6 days/wk x 4 weeks
79822349|NCT04104815|Other|Experimental Thickener|Use to thicken liquids
79822350|NCT00715208|Drug|rituximab|
79225047|NCT02199249|Device|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
79225048|NCT02257359|Drug|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
79367468|NCT01795495|Drug|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
79367469|NCT01795495|Drug|Remifentanil|
79367470|NCT04765527|Dietary Supplement|Turmeric Strength for Joint|Turmeric-based tablets
79367471|NCT04765527|Dietary Supplement|Placebo|Placebo tablets
79367472|NCT04570111|Other|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
79520359|NCT03072732|Device|ZOE Fluid Status Monitor|Monitoring System
79520360|NCT03074682|Device|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
79520361|NCT03074682|Device|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
79520362|NCT03074682|Device|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
79822351|NCT00715208|Drug|cyclophosphamide|
79822352|NCT00715208|Drug|doxorubicin|
79822353|NCT00715208|Drug|VELCADE|
79822354|NCT00715208|Drug|prednisone|
79520363|NCT03078504|Device|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
79520364|NCT03080142|Drug|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
79225049|NCT00910650|Biological|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
79520365|NCT03080142|Drug|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
79520366|NCT03085836|Drug|TAK-438|TAK-438 tablets.
79520367|NCT03088800|Drug|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
79822355|NCT04104503|Drug|Lu AF11167|Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
79822356|NCT04104503|Drug|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
79367473|NCT04570111|Other|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
79225050|NCT00910650|Drug|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
79367474|NCT04170907|Other|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
79225051|NCT02257437|Dietary Supplement|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
79367475|NCT03156387|Procedure|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
79367476|NCT03156387|Procedure|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
79367477|NCT03586713|Diagnostic Test|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
79367478|NCT01794949|Device|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
79367479|NCT04414501|Behavioral|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
79367480|NCT03586557|Device|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
79367481|NCT03586557|Drug|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper
79520368|NCT03088800|Drug|APAP|Oral APAP at 15mg/kg dose
79520369|NCT03092934|Drug|LY3295668|Oral capsules
79520370|NCT03094806|Device|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
79520371|NCT03094806|Device|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
79520372|NCT03095976|Procedure|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
79225052|NCT02257437|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
79225053|NCT02257437|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
79520373|NCT03096444|Drug|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
79676798|NCT04484337|Drug|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
79676799|NCT04484337|Drug|Topical non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drug will be available for topical application
79676800|NCT04484337|Drug|Topical steroid|Steroid will be available for topical application
79676801|NCT04484337|Drug|Placebo creams/gels|Placebo creams/gels will be available for topical application
79676802|NCT04484337|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be available for administration by SC Injection
79822357|NCT04104503|Drug|Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)|Single oral dose
79822358|NCT05186870|Other|Outcome measures|Observational study
79520374|NCT03096444|Drug|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
79225054|NCT02257437|Dietary Supplement|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
79520375|NCT03096444|Drug|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
79520376|NCT03096444|Combination Product|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
79520377|NCT03096444|Drug|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
79520378|NCT03100500|Drug|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
79225055|NCT04461366|Device|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
79225056|NCT04461366|Device|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
79367482|NCT05702775|Procedure|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
79367483|NCT05702697|Device|focus extracorporeal shock wave therapy|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
79520379|NCT03100968|Procedure|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
79520380|NCT03100968|Device|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
79520381|NCT03104322|Other|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
79996535|NCT02996448|Drug|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
79996536|NCT03663972|Behavioral|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
79225057|NCT02199327|Drug|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
79225058|NCT02199327|Drug|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
79225059|NCT00756288|Procedure|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
79225060|NCT00756288|Procedure|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
79996537|NCT03663972|Behavioral|phonologic treatment|children receive instruction in producing new sounds at the word level
79520382|NCT03104322|Other|usual care|usual care
79520383|NCT03107754|Drug|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
79520384|NCT03107754|Drug|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
79520385|NCT03118596|Device|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
79520386|NCT03118596|Device|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
79676803|NCT04473053|Drug|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
79996538|NCT02995980|Device|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
79225061|NCT02198001|Drug|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
79520387|NCT03124368|Drug|Danicopan|Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
79996539|NCT02995980|Device|digital mammography|routine digital mammography
79996540|NCT04058496|Other|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
79520388|NCT03124602|Device|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
79520389|NCT03124758|Device|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
79996541|NCT04055688|Device|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
79996542|NCT04055688|Drug|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
79996543|NCT02872142|Biological|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
79367484|NCT05702697|Behavioral|Home stretching program|The leaflet on hamstring stretching exercises (in a sitting posture)
79225062|NCT02198001|Procedure|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
79225063|NCT03491982|Device|Remote Cardiac Rehab|Remote Cardiac Rehab
79367485|NCT02947503|Drug|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
79367486|NCT03586323|Drug|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
79367487|NCT03586245|Dietary Supplement|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
79367488|NCT03586245|Dietary Supplement|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
79520390|NCT03124836|Device|Pulse Oximeter Sensor|
79520391|NCT03125226|Device|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
79520392|NCT03127956|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
79520393|NCT03132246|Diagnostic Test|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
79822359|NCT00919178|Biological|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
79225064|NCT02198079|Biological|Sputum|
79225065|NCT05147688|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79225066|NCT05116800|Drug|Gemcitabine|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
79225067|NCT05116800|Drug|9-ING-41|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
79225068|NCT05116800|Drug|Docetaxel|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
79367489|NCT03586245|Dietary Supplement|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
79367490|NCT03890991|Behavioral|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
79520394|NCT03138330|Other|this study is observational, it is not an intervention|
79520395|NCT03138798|Device|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
79520396|NCT03138876|Device|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
79676804|NCT04473053|Drug|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
79225069|NCT02199405|Other|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
79225070|NCT02199405|Other|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
79225071|NCT02199405|Other|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
79520397|NCT03138876|Drug|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
79225072|NCT02199405|Other|Cervical traction|
79367491|NCT03890991|Behavioral|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
79367492|NCT03890991|Behavioral|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
79367493|NCT05702619|Drug|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
79367494|NCT05702619|Diagnostic Test|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
79520398|NCT03138876|Procedure|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
79520399|NCT03139032|Drug|APD334|APD334 active treatment for 12 weeks.
79520400|NCT03139578|Device|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
79996544|NCT02872142|Procedure|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
79996545|NCT02994654|Device|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
79996546|NCT04882280|Behavioral|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
79996547|NCT04055610|Device|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
79225073|NCT03673254|Device|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
79225074|NCT02198157|Other|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
79225075|NCT04078737|Drug|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
79225076|NCT04078737|Drug|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
79225077|NCT03491904|Drug|Fasinumab AI|Self-administered with auto injector
79225078|NCT03491904|Drug|Fasinumab PFS|Prefilled syringe administered by study staff
79225079|NCT03487146|Device|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
79225080|NCT05039112|Device|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
79225081|NCT05039112|Device|Stenfilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
79225082|NCT05150808|Other|IRS insecticide: Vectron T500|public health insecticide
79367495|NCT05702619|Diagnostic Test|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
79367496|NCT05702619|Procedure|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
79520401|NCT03139578|Device|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
79520402|NCT03139578|Device|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
79520403|NCT03139578|Device|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
79676805|NCT04473053|Other|Standard care|Patients will receive standard care.
79225083|NCT02198313|Drug|BIIX 1 XX - D1|
79367497|NCT05702619|Diagnostic Test|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
79822360|NCT00919178|Biological|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
79367498|NCT05702619|Diagnostic Test|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
79367499|NCT05702619|Other|Baseline bloods - for germline testing|"Arm 1 -~1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
79367500|NCT05702619|Other|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
79367501|NCT05702619|Other|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
79367502|NCT01770379|Biological|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
79367503|NCT01770379|Biological|Placebo|
79367504|NCT01986881|Drug|Ertugliflozin|Oral, once daily, for up to approximately 6 years
79367505|NCT01986881|Drug|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
79520404|NCT03141372|Device|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
79225084|NCT02198313|Drug|BIIX 1 XX - D2|
79225085|NCT02198313|Drug|BIIX 1 XX - D3|
79225086|NCT02198313|Drug|Placebo|
79228126|NCT05137626|Drug|AT-527 + digoxin|"Day 1: A single dose of digoxin will be administered.~Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
79228127|NCT05114226|Drug|Tetrahydrobiopterin|BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
79520405|NCT03141528|Other|Self-learning|Training without supervision
79520406|NCT03141528|Other|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
79520407|NCT03145818|Other|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
79520408|NCT03147690|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
79520409|NCT03148236|Drug|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
79520410|NCT03148236|Other|Placebo|50mL infused over 30 minutes
79520411|NCT03148470|Device|Sham iTBS|Placebo stimulation for the iTBS group
79520412|NCT03148470|Device|Sham cTBS|Placebo stimulation for the cTBS group
79520413|NCT03148470|Device|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
79676806|NCT04473053|Biological|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
79676807|NCT04469452|Device|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
79676808|NCT04466228|Device|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
79228128|NCT02233023|Drug|Pramipexole|
79228129|NCT02233023|Drug|Bromocriptine and other dopamine agonists|
79676809|NCT04461080|Behavioral|Community Health Worker|Trained Community Health Worker
79676810|NCT04455750|Drug|Enzalutamide|Given PO
79676811|NCT04455750|Drug|Rucaparib camsylate|Given PO
79676812|NCT04455750|Drug|Placebo|Given PO
79996548|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
79225087|NCT03249090|Other|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
79225088|NCT03249090|Other|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
79367506|NCT01986881|Drug|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea [SU], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
79367507|NCT03156075|Behavioral|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
79367508|NCT03585855|Other|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
79520414|NCT03148470|Device|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
79520415|NCT03149172|Device|Equimatrix®|Ridge preservation bone grafting after tooth extraction
79520416|NCT03149172|Device|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
79520417|NCT03149172|Device|Endobon®|Ridge preservation bone grafting after tooth extraction
79225089|NCT02199561|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
79367509|NCT03580395|Drug|Apatinib|500mg, day1-21,neoadjuvant therapy
79520418|NCT03150108|Drug|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
79520419|NCT03150108|Drug|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
79520420|NCT03150108|Drug|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
79520421|NCT03154710|Device|MOOVCARE|web-mediated follow up
79520422|NCT03160170|Device|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator & Retractor (SISTER) device during surgery
79996549|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
79228130|NCT03473106|Device|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
79228131|NCT03322137|Drug|SNA-120|Pegcantratinib ointment
79367510|NCT03580395|Drug|paclitaxel|paclitaxel 165mg/m2 day 1
79367511|NCT03580395|Drug|cisplatin|cisplatin 40mg, day 1-3
79367512|NCT01609543|Drug|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
79520423|NCT03162354|Other|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
79520424|NCT03163134|Device|Lumbar Drain|
79520425|NCT03163758|Device|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
79520426|NCT03163758|Device|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
79520427|NCT03164538|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
79367513|NCT03585699|Diagnostic Test|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
79367514|NCT03585699|Diagnostic Test|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
79520428|NCT03164538|Behavioral|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
79520429|NCT03169062|Device|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
79520430|NCT03170388|Drug|IDP-126 Gel|Gel
79225090|NCT03533439|Diagnostic Test|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
79228132|NCT03322137|Drug|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
79367515|NCT03580239|Drug|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
79367516|NCT03580239|Drug|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
79367517|NCT03156153|Drug|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
79367518|NCT03156153|Drug|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
79367519|NCT03155919|Dietary Supplement|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
79367520|NCT03155919|Dietary Supplement|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
79996550|NCT04054284|Dietary Supplement|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
79367521|NCT02003183|Radiation|[F-18]FDDNP|Each participant was injected with [F-18]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
79367522|NCT03156231|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79367523|NCT03156231|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79367524|NCT03585387|Procedure|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
79367525|NCT05702151|Procedure|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
79367526|NCT05702151|Drug|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
79367527|NCT01986647|Behavioral|On the Move exercise - exercise leader|exercise physiologists
79520431|NCT03170388|Drug|IDP-126 Component A|Component A
79520432|NCT03170388|Drug|IDP-126 Component B|Component B
79520433|NCT03170388|Drug|IDP-126 Component C|Component C
79520434|NCT03170388|Drug|IDP-126 Vehicle Gel|Vehicle Gel
79520435|NCT03172884|Drug|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
79520436|NCT03174366|Drug|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
79996551|NCT04054284|Dietary Supplement|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
79996552|NCT04494438|Drug|Rituximab|
79996553|NCT03662490|Device|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
79996554|NCT04057482|Drug|D|treatment of BV with dequalinium chloride vaginal tablets
79996555|NCT04056936|Procedure|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
79228133|NCT03710642|Drug|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
79367528|NCT01986647|Behavioral|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
79367529|NCT01986647|Behavioral|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
79367530|NCT01986647|Behavioral|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
79367531|NCT03582657|Device|dental implant (KONTACT N)|Implant-supported prosthetic restoration
79367532|NCT03585309|Procedure|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
79367533|NCT03585231|Behavioral|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
79367534|NCT03585231|Behavioral|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
79367535|NCT03585231|Behavioral|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
79367536|NCT02002091|Other|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
79520437|NCT03177798|Drug|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
79520438|NCT03177798|Drug|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
79520439|NCT03178344|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
79520440|NCT03178344|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
79520441|NCT05364216|Behavioral|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
79520442|NCT05364216|Procedure|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
79520443|NCT05364216|Behavioral|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
79822361|NCT05184140|Procedure|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
79822362|NCT04083872|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
79996556|NCT03663426|Procedure|study group|"High dose corticoids pre-operative and 24h postoperative~Opioid free general anesthesia~Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
79996557|NCT03663426|Procedure|control|"No corticoids pre-operative.~Opioid anesthesia~Opioids post-operative after NSAID and paracetamol."
79996558|NCT03662412|Drug|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
79996559|NCT03663270|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
79996560|NCT02870972|Drug|BCX7353|Plasma kallikrein inhibitor
79996561|NCT02870972|Drug|Placebo|
79996562|NCT03663192|Device|strain echocardiography|strain echocardiography during septic shock
79996563|NCT03214367|Drug|LY900014|Administered SC
79996564|NCT03214367|Drug|Insulin Lispro|Administered SC
79996565|NCT03214367|Drug|Insulin Glargine|Administered SC
79996566|NCT03214367|Drug|Insulin Degludec|Administered SC
79996567|NCT02994108|Behavioral|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
79367537|NCT02926521|Device|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
79367538|NCT02926521|Device|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
79367539|NCT03584997|Procedure|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
79367540|NCT03584997|Procedure|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
79367541|NCT01985321|Drug|ethanol/glycolic acid solution|ethanol/glycolic acid solution
79367542|NCT01985321|Drug|Placebo/Ethanol|ethanol solution
79367543|NCT03584919|Drug|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
79520444|NCT05353920|Other|Cognitive training|cognitive related training bu virtual reality system
79520445|NCT05304000|Behavioral|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
79520446|NCT05304000|Behavioral|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
79367544|NCT03584919|Drug|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
79676813|NCT04455750|Drug|Leuprolide Acetate|Given IM
79676814|NCT04455750|Drug|Goserelin Acetate|Given SC
79822363|NCT04083872|Drug|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
79822364|NCT05183672|Procedure|Telecare consultation|Using Zoom to communicate with patients
79822365|NCT05183672|Procedure|Usual face-to-face consultation|Face-to-face communication with patients
79996568|NCT02994108|Behavioral|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
79367545|NCT03584919|Other|control subjects|no intervention
79367546|NCT03584841|Diagnostic Test|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
79367547|NCT02000921|Other|VLNC cigarettes|Modified risk tobacco product
79367548|NCT02000921|Other|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
79367549|NCT02000921|Other|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
79822366|NCT05684354|Other|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
79996569|NCT03663036|Diagnostic Test|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
79676815|NCT04455750|Drug|Degarelix|Given SC
79367550|NCT02000921|Other|CN cigarettes|Experimental cigarettes with conventional nicotine content.
79676816|NCT04455750|Other|Quality-of-Life Assessment|Ancillary studies
79676817|NCT04455750|Other|Questionnaire Administration|Ancillary studies
79676818|NCT04439903|Other|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
79367551|NCT03584685|Device|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
79367552|NCT03584685|Procedure|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
79367553|NCT03587337|Other|POEM|Pt. are going to submit a POEM procedure.
79676819|NCT04410107|Diagnostic Test|Lung Function tests|Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
79676820|NCT04410107|Diagnostic Test|Exercise capacity|6-minute walk test (6MWT distance)
79676821|NCT04410107|Diagnostic Test|Exercise physiology|Cardiopulmonary exercise test (CPET)
79676822|NCT04410107|Diagnostic Test|Health-related quality of life|Short-Form Health Survey Questionnaire (SF-36)
79367554|NCT03586947|Drug|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
79367555|NCT04765215|Biological|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
79676823|NCT04410107|Diagnostic Test|Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening|"Adapted translation American Thoracic Society respiratory symptoms questionnaire;~Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~Questionnaire for screening for post-traumatic stress symptoms (PTSD)."
79225091|NCT03487068|Device|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
79225092|NCT02199873|Drug|BIIX 1 XX - single rising dose|
79225093|NCT02199873|Drug|Placebo|
79225094|NCT04740606|Device|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
79225095|NCT05150730|Other|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
79225096|NCT02199951|Drug|Dihydroartemisinin and piperaquine|Antimalarial
79225097|NCT03533361|Drug|Lenvatinib|Oral capsules: 4 milligrams (mg) and 10 mg
79225098|NCT03485742|Other|No intervention|No intervention. Collection of data on statin eligibility in patients admitted with MI
79225099|NCT02200029|Drug|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
79225100|NCT02200029|Drug|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
79225101|NCT03489642|Behavioral|Telehealth Program|Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
79225102|NCT02200107|Behavioral|self management education|
79225103|NCT01433328|Drug|Lidocaine|Lidocaine
79520447|NCT05304000|Behavioral|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: <20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
79676824|NCT04387201|Drug|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
79225104|NCT01433328|Drug|Placebo|Placebo
79225105|NCT02198469|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
79225106|NCT02198469|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
79225107|NCT04448574|Other|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
79225108|NCT02200185|Drug|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
79225109|NCT02200185|Drug|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
79225110|NCT02200185|Drug|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
79225111|NCT03485664|Procedure|tooth extraction|tooth extraction
79225112|NCT02200263|Dietary Supplement|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
79225113|NCT02200263|Dietary Supplement|Placebo|two softgels once-daily with a meal
79225114|NCT02201043|Drug|Thalidomide 150mg|
79225115|NCT02201043|Drug|Thalidomide 100mg|
79225116|NCT02201043|Drug|Placebo|
79225117|NCT02200341|Behavioral|MBCT|
79225118|NCT02200341|Behavioral|PRT-PsyEd|
79225119|NCT02956434|Behavioral|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
79228134|NCT03710642|Drug|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
79676825|NCT04387201|Drug|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
79520448|NCT05304000|Behavioral|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
79520449|NCT05192772|Device|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
79520450|NCT05133882|Drug|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
79520451|NCT05037474|Procedure|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
79520452|NCT05015400|Other|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
79520453|NCT04936074|Procedure|Muscle preserving selective laminectomy|Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
79520454|NCT04936074|Procedure|Laminectomy with instrumented fusion|A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
79520455|NCT04933344|Other|patients having had BJI or PJI treated with daptomycin|patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
79367556|NCT03155763|Procedure|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
79520456|NCT04847544|Drug|ADX-629|ADX-629 administered orally twice daily (BID) for up to 28 days.
79676826|NCT04373330|Behavioral|Intensive Lifestyle Intervention|There will be 14 sessions delivered over the course of 6 months; materials consist of CHW lesson plans, participant workbooks, and the DVD series. These materials will be adapted for use in HELP-VM and will include information on migraine and its management as well as mental health resources available to Veterans for common illnesses like depression and post-traumatic stress disorder and modifying physical activity recommendations for Veterans with limited mobility.
79676827|NCT04369066|Diagnostic Test|Blood samples (collection of 5 mL of blood in a dry tube)|"A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie."
79822367|NCT02590250|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
79225120|NCT02201121|Other|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
79225121|NCT03485586|Device|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
79225122|NCT03485586|Device|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
79225123|NCT02200419|Other|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
79225124|NCT02200575|Drug|Telmisartan|
79225125|NCT03486756|Behavioral|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
79225126|NCT03485508|Diagnostic Test|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
79225127|NCT02201199|Drug|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79225128|NCT02201199|Drug|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79225129|NCT02201199|Drug|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79367557|NCT03155529|Procedure|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
79367558|NCT04764981|Other|Essence oils|Consists in olfactory training using essence oils
79367559|NCT03584451|Behavioral|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
79520457|NCT04847544|Drug|Placebo|Placebo administered orally BID for up to 28 days.
79822368|NCT05293418|Other|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
79822369|NCT02589782|Drug|Bedaquiline|
79822370|NCT02589782|Drug|Pretomanid|
79822371|NCT02589782|Drug|Moxifloxacin|
79822372|NCT02589782|Drug|Linezolid|
79822373|NCT02589782|Drug|Clofazimine|
79367560|NCT03584529|Drug|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
79520458|NCT05406804|Behavioral|Olfactory stimulation|1) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time > 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
79520459|NCT05406804|Behavioral|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
79520460|NCT05406648|Other|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
79520461|NCT05406492|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
79676828|NCT04369066|Diagnostic Test|Nasopharyngeal swabs|"The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total."
79520462|NCT05406336|Other|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
79520463|NCT05406180|Biological|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
79520464|NCT05406024|Device|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
79676829|NCT04349839|Device|Acrodat software|Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
79520465|NCT05405946|Behavioral|Computerized Cognitive Remediation Therapy|"Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials."
79676830|NCT04347967|Biological|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
79676831|NCT04331288|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
79996570|NCT03614000|Other|Screening Questionnaires|"Measurement tools:~Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~The VG&O The VG&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
79996571|NCT02032160|Biological|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
79996572|NCT02032160|Biological|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
79225130|NCT03533205|Diagnostic Test|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
79996573|NCT03662958|Drug|Lutrate|a novel leuprolide acetate 3.75mg depot
79996574|NCT03662958|Drug|Enantone|market reference leuprolide acetate 3.75 mg depot
79996575|NCT02032082|Other|Carbone monoxide|
79996576|NCT04057170|Other|accelerated protocol and mulligan method|manual therapy technic
79996577|NCT03615638|Other|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
79225131|NCT03486600|Other|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
79225132|NCT02200653|Drug|High dose of MICARDIS®, once daily|
79225133|NCT02200653|Drug|Low dose of MICARDIS®, once daily|
79225134|NCT02200653|Drug|Low dose of COZAAR® / LORZAAR®, once daily|
79676832|NCT04331288|Other|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
79676833|NCT04329156|Other|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
79996578|NCT03636737|Other|pathology associated|list of pathology associated to Pyoderma gangrenosum
79996579|NCT03662256|Other|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
79225135|NCT02200653|Drug|High dose of COZAAR® / LORZAAR®, once daily|
79225136|NCT02200653|Drug|Placebo|
79676834|NCT04329156|Other|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
79676835|NCT04324762|Behavioral|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
79225137|NCT04461444|Genetic|Skin biopsy|"COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~risk of pain due to the procedure performed under local anaesthesia~can leave a visible scar (about 2 x 1 cm)"
79676836|NCT04317820|Behavioral|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
79996580|NCT03662256|Other|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
79225138|NCT02257593|Other|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
79225139|NCT04461132|Other|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
79225140|NCT04461132|Other|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
79225141|NCT04461132|Other|Exercise|breathing and foot pump exercise was prescribed
79225142|NCT04461132|Other|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
79225143|NCT02200731|Behavioral|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
79225144|NCT03999411|Drug|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
79225145|NCT03999411|Behavioral|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
79225146|NCT03999411|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
79225147|NCT03999411|Behavioral|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
79225148|NCT03999411|Behavioral|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
79225149|NCT03996876|Device|RePS (Resolving Psychological Stress) - Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
79225150|NCT03996876|Device|RePS (Resolving Psychological Stress) - Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
79225151|NCT02200809|Device|MR-guided focal laser ablation|
79225152|NCT02201355|Radiation|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
79676837|NCT04303715|Procedure|No SLNB|BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
79520466|NCT05405946|Other|Treatment as Usual|Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
79520467|NCT05405712|Behavioral|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
79676838|NCT04303715|Procedure|SLNB|BCS with SLNB(+/-ALND)
79676839|NCT04298970|Dietary Supplement|Intervention|Freeze-dried Brassica oleracea var. acephala
79676840|NCT04298970|Dietary Supplement|Placebo|Placebo product
79996581|NCT03518216|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
79996582|NCT03231371|Drug|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
79225153|NCT02200965|Other|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
79225154|NCT04979754|Other|standard of care|retrospective study : standard of care
79520468|NCT05405478|Drug|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
79520469|NCT05405478|Diagnostic Test|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
79676841|NCT04293055|Behavioral|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
79676842|NCT04293055|Behavioral|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
79676843|NCT04292496|Procedure|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
79676844|NCT04280783|Behavioral|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
79676845|NCT04280783|Behavioral|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
79676846|NCT04272268|Device|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
79676847|NCT04250922|Drug|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
79676848|NCT04250922|Drug|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
79225155|NCT02206347|Behavioral|attention focus|
79367561|NCT00724984|Drug|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
79520470|NCT05333952|Procedure|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
79996583|NCT03662880|Radiation|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
79225156|NCT02201511|Drug|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
79676849|NCT04250922|Radiation|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
79676850|NCT04230759|Drug|Chemotherapy|"Patients recieve chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
79676851|NCT04230759|Radiation|Radiation|PTV_A (primary tumor): T1-T2<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
79676852|NCT04230759|Drug|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
79676853|NCT04222790|Drug|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
79676854|NCT04222790|Other|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
79676855|NCT04219917|Other|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
79225157|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
79225158|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
79225159|NCT02201511|Drug|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
79225160|NCT05261997|Procedure|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
79520471|NCT05333952|Procedure|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
79520472|NCT05276310|Biological|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
79520473|NCT05233254|Behavioral|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
79520474|NCT05169918|Other|Core stabilization|"The progressive core stabilization exercise approach created by Kumar et al. will be used.~Stage 1; Isolation and facilitation of target muscles~Stage 2; Trunk stabilization training with increased load under static conditions~Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described."
79524827|NCT05767775|Other|Assessment of synovial- and adipose tissue-derived inflammatory biomarkers|"Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients."
79676856|NCT04219826|Drug|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
79676857|NCT04219826|Drug|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
79676858|NCT04219826|Drug|Placebo for CK-3773274|Placebo administered orally
79676859|NCT04216342|Biological|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min*), 1h (+/- 10min*), 2h (+/- 10min*), 4h (+/- 15min*), 8h (+/- 30min*), 12h (+/- 30min*), and 24h (+/- 30min*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
79225161|NCT05261997|Drug|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
79225162|NCT02206425|Drug|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79225163|NCT02206425|Drug|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79225164|NCT02206425|Drug|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79225165|NCT02206425|Drug|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79225166|NCT02206425|Dietary Supplement|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79225167|NCT02206425|Drug|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79996584|NCT03662880|Radiation|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
79996585|NCT03613766|Other|Physical activity program|
79996586|NCT04057092|Dietary Supplement|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
79524828|NCT05767723|Drug|Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
79676860|NCT04214041|Other|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
79996587|NCT03613922|Other|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
79996588|NCT03613922|Other|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
79996589|NCT03663114|Drug|Lenvatinib|Lenvatinib capsule
79996590|NCT03526679|Drug|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
79996591|NCT03526679|Drug|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
79225168|NCT02206425|Drug|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79676861|NCT04214041|Other|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
79676862|NCT04206007|Biological|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
79367562|NCT03583983|Behavioral|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
79367563|NCT03583983|Behavioral|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
79822374|NCT02589782|Drug|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
79367564|NCT05703165|Behavioral|animal-assisted intervention|horse-assisted intervention
79524829|NCT05767723|Drug|Monotherapy: Ticagrelor alone OR Prasugrel alone|Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
79524830|NCT05767710|Behavioral|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
79822375|NCT00587795|Device|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
79996592|NCT03615092|Procedure|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
79996593|NCT04056780|Other|Sample collection study|Sample collection and collection of laboratory values
79996594|NCT04844684|Other|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
79996595|NCT04057404|Device|Alivecor Heart Monitor|
79996596|NCT03613688|Dietary Supplement|Deepure|Pu'erh Tea extract
79996597|NCT04057326|Drug|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
79996598|NCT04057326|Drug|Placebo|2 tablets/time, 3 times daily,Oral Administration.
79225169|NCT02206425|Drug|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
79225170|NCT02201667|Drug|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
79225171|NCT02201667|Drug|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
79225172|NCT02201667|Drug|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
79225173|NCT02201667|Procedure|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
79228135|NCT04458870|Behavioral|Acceptance and Commitment Therapy|Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
79520475|NCT05169918|Other|Sensorial Discrimination Training|Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
79520476|NCT05083806|Device|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
79520477|NCT05023512|Behavioral|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
79996599|NCT04573829|Procedure|Home visit|Psychologist come once a week for the carer and three times a week for the patient
79225174|NCT02206503|Drug|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
79225175|NCT02206503|Drug|Lenalidomide|
79225176|NCT02206503|Drug|Dexamethasone|
79367565|NCT05703165|Behavioral|watching the countryside|just watching the countryside
79367566|NCT03589287|Biological|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
79367567|NCT03113253|Drug|Tranexamic Acid|
79367568|NCT03113253|Drug|Placebo|0.9% sodium chloride to mimic tranexamic acid
79367569|NCT03020277|Other|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
79367570|NCT02800317|Procedure|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
79367571|NCT02753751|Other|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
79520478|NCT04890366|Drug|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
79676863|NCT04200365|Drug|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
79996600|NCT02870348|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
79225177|NCT02201823|Drug|ABTL0812|ABTL0812. Five cohorts and one extension phase.
79996601|NCT03615014|Other|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
79996602|NCT03614936|Other|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
79225178|NCT05261919|Procedure|Acupuncture manipulation|The investigator used directional supplementation and draining manipulation. The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.
79367572|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
79367573|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
79367574|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
79367575|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
79367576|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
79367577|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
79367578|NCT03020121|Procedure|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
79367579|NCT01275196|Drug|Nilotinib|
79367580|NCT01275196|Drug|Imatinib|
79367581|NCT03584139|Device|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
79367582|NCT03584139|Device|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
79996603|NCT03614936|Other|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~the socio-cultural evaluation scale,~the ADL autonomy questionnaire,~assessment of locomotor disorders,~nutritional assessment,~the MMSE Cognitive Function Evaluation Questionnaire,~the GDS-4 mood rating scale,~the comorbidity assessment test (Charlson Index)"
79996604|NCT03281720|Procedure|TAD|the same intervention as listed in the arm description
79996605|NCT03613610|Radiation|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
79822376|NCT00587795|Other|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
79367583|NCT03152643|Procedure|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
79996606|NCT03239873|Biological|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
79996607|NCT03239873|Biological|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
79367584|NCT03152643|Procedure|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
79367585|NCT03153579|Drug|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
79520479|NCT04723368|Device|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
79520480|NCT04520256|Behavioral|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
79520481|NCT04520256|Behavioral|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
79520482|NCT04520256|Behavioral|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
79520483|NCT04520256|Behavioral|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
79520484|NCT04520256|Behavioral|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
79822377|NCT00587639|Device|rTMS Treatment|Active rTMS treatment.
79225179|NCT02206581|Device|Hydration Monitor|
79225180|NCT02201979|Procedure|Vertical breast lift with implants|
79225181|NCT02206659|Drug|Telmisartan|
79225182|NCT02206659|Drug|Placebo|
79225183|NCT02206737|Device|No nicotine e-cigarette|
79225184|NCT02206737|Device|Low dose nicotine e-cigarette|
79225185|NCT02206737|Device|High dose nicotine e-cigarette|
79996608|NCT03239873|Biological|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
79996609|NCT05384210|Drug|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
79996610|NCT05384210|Drug|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
79996611|NCT05384210|Drug|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
79996612|NCT03613376|Other|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
79996613|NCT03614780|Behavioral|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
79225186|NCT02202057|Other|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
79228136|NCT02259309|Drug|Misoprostol - buccal|buccal administration
79228137|NCT02259309|Drug|Misoprostol - vaginal|vaginal administration
79676864|NCT04186260|Behavioral|NAFLD-specific weight loss intervention|This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.
79996614|NCT04804592|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
79367586|NCT03153579|Drug|Placebo|Capsules containing mannitol looking identical to LSD
79996615|NCT04804592|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
79367587|NCT03583905|Drug|CKD-330|CKD-330 Tab.
79367588|NCT03583905|Drug|Placebo of CKD-330|Placebo of CKD-330 Tab.
79676865|NCT04186260|Other|Wait-list control|Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.
79676866|NCT04177095|Diagnostic Test|Allosure|Monthly monitoring of dd-cfDNA levels in blood
79520485|NCT04520256|Behavioral|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
79676867|NCT04177095|Drug|Immunosuppression reduction|Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
79676868|NCT04177095|Diagnostic Test|Trugraf|Monthly monitoring of Trugraf result
79520486|NCT04098978|Other|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
79520487|NCT03811470|Other|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
79676869|NCT04170153|Drug|M1774|M1774 will be administered orally throughout the study.
79676870|NCT04170153|Drug|Niraparib|Niraparib will be administered orally throughout the study.
79676871|NCT04168203|Drug|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
79225187|NCT02202057|Other|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
79367589|NCT03583905|Drug|D086|D086 Tab.
79822378|NCT00916175|Dietary Supplement|P1&P2|"First period (4 weeks) intake food product P1&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from AG&CC group, 4 weeks intake food product P1&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
79225188|NCT03660345|Procedure|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
79225189|NCT03660345|Drug|Intravitreal injection|Intravitreal ziv-Aflibercept
79225190|NCT02206893|Behavioral|Self-monitoring via Smartphone|
79367590|NCT03583905|Drug|Placebo of D086|Placebo of D086 Tab.
79367591|NCT03583905|Drug|D723|D723 Tab.
79367592|NCT03583905|Drug|Placebo of D723|Placebo of D723 Tab.
79367593|NCT01984697|Biological|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
79367594|NCT03583827|Other|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
79367595|NCT03583827|Other|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
79367596|NCT03155607|Behavioral|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
79676872|NCT04168203|Drug|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
79676873|NCT04158050|Drug|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
79676874|NCT04150731|Radiation|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
79676875|NCT04142996|Device|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
79676876|NCT04119271|Other|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
79676877|NCT04118062|Behavioral|Questionnaires|Questionnaires
79676878|NCT04118062|Behavioral|Semi-structured individual interviews|Semi-structured individual interviews
79676879|NCT04118062|Other|Focus Group|Focus Group
79676880|NCT04118062|Other|DELPHI Consensus Method|DELPHI Consensus Method
79225191|NCT02206893|Behavioral|Peer support via Smartphone|
79225192|NCT02206893|Behavioral|Professional support via Smartphone|
79225193|NCT02206893|Behavioral|Self-monitoring via Web (Static)|
79676881|NCT04110379|Behavioral|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
79996616|NCT04804592|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
79225194|NCT02206971|Other|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
79520488|NCT03780426|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
79520489|NCT03780426|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
79520490|NCT03192774|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
79520491|NCT03058614|Drug|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
79520492|NCT03058614|Diagnostic Test|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
79520493|NCT03058614|Diagnostic Test|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
79676882|NCT04110379|Behavioral|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
79225195|NCT02202213|Drug|Placebo|
79225196|NCT02202213|Drug|Lu AF11167|
79225197|NCT02207205|Drug|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
79225198|NCT02202291|Genetic|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
79225199|NCT03533127|Drug|LY01008|LY01008+Carboplatin/Paclitaxel
79367597|NCT03583749|Drug|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
79367598|NCT03583749|Drug|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
79367599|NCT02000531|Drug|Erlotinib|150 mg oral dose of erlotinib given once daily
79367600|NCT02000531|Drug|Chemotherapy|Cisplatin (75 mg/m^2 intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
79367601|NCT05647161|Device|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
79367602|NCT05647161|Device|No Intervention|Control Group
79367603|NCT01609231|Drug|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
79367604|NCT01609231|Drug|Irinotecan|Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
79676883|NCT04097652|Biological|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
79676884|NCT04083183|Biological|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
79676885|NCT04083183|Drug|Fludarabine|Given IV
79676886|NCT04083183|Drug|Cyclophosphamide|Given IV
79676887|NCT04083183|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
79676888|NCT04083183|Radiation|Total-Body Irradiation|Undergo TBI
79225200|NCT03533127|Drug|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
79367605|NCT01609231|Drug|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
79367606|NCT03583593|Dietary Supplement|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
79225201|NCT02207361|Drug|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
79520494|NCT03048240|Device|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
79225202|NCT02207361|Drug|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
79225203|NCT03533049|Other|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
79225204|NCT02207517|Procedure|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
79225205|NCT02202447|Drug|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
79225206|NCT02202447|Other|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
79225207|NCT02202525|Drug|Micardis®|
79225208|NCT02202525|Drug|Other hypertensives|
79225209|NCT02202603|Drug|Teriparatide|single oral tablet
79225210|NCT02202603|Drug|Teriparatide|subcutaneous standard injection
79225211|NCT02202603|Drug|placebo|Oral placebo
79225212|NCT02207595|Drug|UCB5857|"Active Substance: UCB5857~Pharmaceutical Form: Capsule~Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~Route of Administration: Oral Use"
79225213|NCT02207595|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Capsule~Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~Route of Administration: Oral Use"
79225214|NCT02207673|Procedure|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
79225215|NCT02202915|Behavioral|Behavioral Checklist|
79225216|NCT02202993|Drug|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
79225217|NCT02190357|Drug|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
79367607|NCT03583593|Dietary Supplement|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
79367608|NCT03583515|Behavioral|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
79367609|NCT03583515|Behavioral|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
79367610|NCT04438187|Other|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
79367611|NCT03583125|Drug|EOC317|tablet(s) PO
79520495|NCT03048240|Drug|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
79676889|NCT04083183|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
79676890|NCT04083183|Drug|Mycophenolate Mofetil|Given PO or IV
79367612|NCT01793935|Drug|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
79520496|NCT02893800|Device|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
79520497|NCT02856126|Procedure|Hepatic arterial infusion chemotherapy|
79520498|NCT02856126|Procedure|Transarterial chemoembolization|
79676891|NCT04083183|Drug|Sirolimus|Given PO
79225218|NCT02257671|Drug|Oral contraceptive|Neovletta
79225219|NCT02208219|Behavioral|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
79676892|NCT04069273|Drug|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
79676893|NCT04069273|Drug|Ramucirumab|Ramucirumab 10 mg/kg IV
79676894|NCT04069273|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV
79676895|NCT04060849|Drug|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
79520499|NCT02856126|Drug|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
79520500|NCT02856126|Drug|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
79520501|NCT02856126|Drug|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
79520502|NCT04682574|Drug|Vitamin C|mega dose is given to the selected critically ill patients
79520503|NCT04589364|Drug|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
79520504|NCT04553484|Diagnostic Test|Measuring cardiovascular performance and blood flow|Measuring cardiovascular performance and blood flow
79520505|NCT04492488|Drug|MRG002|Administrated intravenously
79520506|NCT04473924|Drug|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
79520507|NCT04473924|Drug|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
79520508|NCT04426500|Drug|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
79225220|NCT02208219|Behavioral|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
79520509|NCT04426500|Drug|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
79520510|NCT04426500|Drug|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
79520511|NCT04251546|Diagnostic Test|p2PSA|p2PSA test(for calculation of PHI)
79228138|NCT04459026|Procedure|combination|instillation and infiltration of ropivacaine
79228139|NCT04459026|Procedure|infiltration|local infiltration ropivacaine
79367613|NCT01793935|Drug|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
79367614|NCT03292029|Diagnostic Test|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
79676896|NCT04060849|Other|Best Practice|Receive standard of care
79676897|NCT04052334|Drug|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
79676898|NCT04052334|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
79676899|NCT04052334|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
79367615|NCT02092025|Drug|Azilsartan|Azilsartan tablets
79367616|NCT04405011|Drug|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
79367617|NCT04405011|Drug|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
79367618|NCT01769443|Drug|bortezomib|Bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
79520512|NCT04251546|Diagnostic Test|Ultrasonic parameters|Ultrasonic parameters(TPV)
79676900|NCT04052334|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
79520513|NCT04251546|Diagnostic Test|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
79520514|NCT04131192|Drug|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
79520515|NCT04131192|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
79520516|NCT04123626|Drug|QR-1123|unilateral IVT injection
79520517|NCT04123626|Other|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
79520518|NCT03925116|Other|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
79520519|NCT03923868|Drug|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
79520520|NCT03883074|Device|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
79520521|NCT03883074|Device|Placebo|tablets with the same aspect of the active device
79520522|NCT03708900|Drug|LCI699|osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
79520523|NCT03670836|Device|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
79520524|NCT03670836|Drug|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
79520525|NCT03449628|Dietary Supplement|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
79520526|NCT03449628|Dietary Supplement|PLACEBO|1 capsule, b.i.d. for 12 weeks
79996617|NCT03213509|Other|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
79225221|NCT02208219|Behavioral|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~Passive mobilization: controlled manipulation of movements to release a joint.~Stretch and progressive resistance training.~Task-specific training: reaching and manipulation of different objects.~Intense physical training: repetition of sequence of movements."
79225222|NCT02208453|Device|InSpace Implantation|InSpace device Implantation
79225223|NCT02190669|Other|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
79225224|NCT02208531|Behavioral|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
79225225|NCT01460160|Drug|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
79225226|NCT02203227|Dietary Supplement|Placebo|
79225227|NCT02203227|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
79520527|NCT03409614|Drug|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
79520528|NCT03409614|Drug|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
79520529|NCT03409614|Other|Chemotherapy|Platinum-based doublet chemotherapy Part 1
79520530|NCT03409614|Drug|Placebo|Matching placebo Part 2
79225228|NCT02203227|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
79225229|NCT02203227|Dietary Supplement|MaQxan|
79225230|NCT02208609|Other|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
79225231|NCT02208609|Other|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
79996618|NCT04802798|Dietary Supplement|Fibre 1|Food derived fibre presented as a white powder
79225232|NCT02190825|Device|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
79225233|NCT02208687|Behavioral|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
79520531|NCT03320382|Device|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
79520532|NCT02767830|Behavioral|Excercise and Nutrition Program|
79996619|NCT04802798|Dietary Supplement|Fibre 2|Food derived fibre presented as a white powder
79225234|NCT02208687|Other|Control group|Usual care
79225235|NCT02203383|Device|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
79225236|NCT01170702|Drug|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
79225237|NCT01170702|Drug|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
79228140|NCT04459026|Procedure|instillation|intraperitoneal ropivacaine instillation
79228141|NCT02470052|Device|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
79520533|NCT02651844|Drug|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
79520534|NCT02341716|Procedure|WA|Walk advice with Nordic Poles and best medical treatment
79520535|NCT02341716|Procedure|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
79520536|NCT02341716|Procedure|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
79520537|NCT02155452|Procedure|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
79520538|NCT01952340|Dietary Supplement|Flaxseed|Milled flaxseed
79520539|NCT01952340|Dietary Supplement|Placebo|Wheat germ/wheat bran and mixed dietary oils
79676901|NCT04044794|Behavioral|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
79520540|NCT01463670|Drug|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
79520541|NCT00682032|Dietary Supplement|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
79520542|NCT00151398|Drug|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
79520543|NCT00151398|Drug|Donepezil|10 mg donepezil QD dosed up to 40 weeks
79520544|NCT03181308|Drug|Carotuximab (TRC105)|Anti Endoglin Antibody
79520545|NCT03181308|Drug|OPDIVO|Programmed Death Receptor-1
79520546|NCT03184428|Other|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
79520547|NCT03187002|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
79520548|NCT03187002|Drug|Moderate IV Sedation|IV sedation with fentanyl and versed
79520549|NCT03187002|Other|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
79520550|NCT03187002|Other|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
79996620|NCT04802798|Dietary Supplement|Placebo|Simple sugar, presented as a white powder
79520551|NCT03193398|Drug|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
79520552|NCT03193398|Drug|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
79225238|NCT01170702|Drug|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
79676902|NCT04044794|Behavioral|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
79228142|NCT04286958|Drug|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
79228143|NCT03473418|Drug|Ketoconazole|Ketoconazole as a topical vaginal gel
79367619|NCT01769443|Procedure|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
79367620|NCT03154827|Drug|BL-8040|Subjects will receive once daily SC injections of 1.25 mg/kg of BL-8040 on the first 3 days of each cycle.
79367621|NCT03154827|Drug|Atezolizumab|Subjects will receive Atezolizumab 1200 mg by IV infusion on Day 2 of every cycle.
79520553|NCT03194334|Behavioral|Vegetarian diet|
79520554|NCT03194334|Dietary Supplement|creatine|1g creatine/day
79520555|NCT03194334|Dietary Supplement|Placebo|pills
79520556|NCT03194334|Dietary Supplement|Beta-alanine|0.8g beta-alanine per day
79996621|NCT02032394|Drug|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
79996622|NCT02032394|Drug|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
79996623|NCT02032394|Drug|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
79996624|NCT03239483|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
79996625|NCT03239483|Drug|Placebo gel|Universal HEC placebo gel; administered rectally
79520557|NCT03199872|Biological|RV001V|Sc injection
79676903|NCT04004416|Other|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
79822379|NCT00916175|Dietary Supplement|P1&CC|"First period (4 weeks) intake food product P1&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from AG&P2 group, 4 weeks intake food product P1&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
79996626|NCT02868554|Device|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
79996627|NCT02868554|Device|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
79225239|NCT01170702|Drug|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
79367622|NCT03159507|Dietary Supplement|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
79367623|NCT01768117|Biological|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
79367624|NCT03582969|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
79367625|NCT03582969|Other|Placebo|Placebo capsules
79367626|NCT01767493|Drug|[18F]Florbetapir PET imaging|[18F]Florbetapir and PET imaging
79520558|NCT03202134|Other|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
79520559|NCT03204942|Device|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
79676904|NCT04004416|Drug|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
79676905|NCT04003363|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
79676906|NCT03972202|Diagnostic Test|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
79676907|NCT03972202|Device|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
79676908|NCT03972202|Behavioral|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
79996628|NCT01068912|Drug|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
79996629|NCT01068912|Drug|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
79225240|NCT02258061|Procedure|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
79225241|NCT02258061|Procedure|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
79225242|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
79225243|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
79225244|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
79225245|NCT03489408|Device|Conventus Cage™ PH|Proximal humeral fracture fixation
79225246|NCT04880148|Dietary Supplement|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
79225247|NCT04880148|Dietary Supplement|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
79225248|NCT02191059|Drug|Icotinib|
79225249|NCT02191059|Drug|Docetaxel|
79228144|NCT03473418|Drug|Terconazole|Terconazole 80 mg as a topical vaginal cream
79367627|NCT03159429|Behavioral|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
79367628|NCT03159429|Behavioral|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
79367629|NCT03159819|Genetic|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
79996630|NCT01068912|Drug|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
79996631|NCT03614624|Device|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
79996632|NCT03614546|Radiation|SBRT|Stereotactic Body Radiation Therapy (SBRT)
79996633|NCT03614546|Radiation|IMRT|Intensity-modulated Radiation Therapy (IMRT)
79996634|NCT03614546|Procedure|Hepatectomy|Hepatectomy
79996635|NCT03614546|Procedure|TACE|transarterial chemoembolization (TACE)
79367630|NCT01274182|Biological|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
79367631|NCT01274182|Biological|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
79367632|NCT01274182|Biological|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
79520560|NCT03204942|Device|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
79367633|NCT01984229|Drug|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
79520561|NCT03204942|Drug|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
79520562|NCT03207438|Drug|Quetiapine 50 MG Extended Release Oral Tablet|OD
79520563|NCT03207438|Drug|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
79520564|NCT03207438|Drug|Placebos|Placebo
79520565|NCT03218592|Drug|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
79520566|NCT03218592|Drug|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
79520567|NCT03218592|Drug|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
79520568|NCT03219294|Drug|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
79520569|NCT03219294|Drug|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
79520570|NCT03219840|Drug|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
79676909|NCT03964116|Other|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
79676910|NCT03963843|Behavioral|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
79996636|NCT03229109|Device|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
79367634|NCT01984229|Drug|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
79822380|NCT00916175|Dietary Supplement|AG&P2|"First period (4 weeks) intake food product AG&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P1&CC group, 4 weeks intake food product AG&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
79996637|NCT03614468|Other|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
79367635|NCT03582735|Other|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
79367636|NCT03582501|Other|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
79367637|NCT01835899|Drug|Placebo|Placebo to BI 1015550
79367638|NCT01835899|Drug|BI 1015550|medium dose 1 powder for oral solution
79367639|NCT01835899|Drug|BI 1015550|medium dose 2 powder for oral solution
79367640|NCT01835899|Drug|BI1015550|low dose 2 powder for oral solution
79367641|NCT01835899|Drug|BI 1015550|low dose 1 powder for oral solution
79367642|NCT03582423|Other|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
79520571|NCT03219840|Drug|Xylitol only chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
79520572|NCT03222414|Device|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
79996638|NCT03614468|Other|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
79996639|NCT01314131|Behavioral|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~an interest questionnaire for patients. It contains 40 questions about activities.~the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
79520573|NCT03222414|Device|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
79822381|NCT00916175|Dietary Supplement|AG&CC|"First period (4 weeks) intake food product AG&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from P1&P2 group, 4 weeks intake food product AG&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
79822382|NCT00916175|Dietary Supplement|TA (concentrated 5:1 aloe vera gel)|"First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
79520574|NCT03222414|Other|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
79822383|NCT00916175|Dietary Supplement|P3|"First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
79367643|NCT01274104|Dietary Supplement|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
79822384|NCT00916487|Dietary Supplement|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
79822385|NCT00774995|Biological|EngerixTM-B|Intramuscular injection, one dose.
79520575|NCT03223272|Drug|Reserpine|Open label reserpine 0.1 mg pill orally
79520576|NCT03224520|Behavioral|Recommender CTHC|Enhanced Messaging
79676911|NCT03963843|Other|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
79822386|NCT00918554|Drug|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
79822387|NCT00918554|Drug|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
79822388|NCT05684822|Other|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
79996640|NCT03614390|Behavioral|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
79996641|NCT04056234|Procedure|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
79225250|NCT03586596|Behavioral|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
79367644|NCT01274104|Other|Placebo|Placebo
79520577|NCT03224520|Behavioral|Standard CTHC|Standard Messaging
79520578|NCT03224520|Other|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
79520579|NCT03224520|Other|Standard Online Recruitment|Search Engine and Social Media Advertisements
79520580|NCT03237156|Drug|TAK-906|TAK-906 capsules.
79520581|NCT03237156|Drug|TAK-906 Placebo|Placebo capsules.
79520582|NCT03239106|Drug|Apremilast|Apremilast 30 mg BID daily
79520583|NCT03239574|Device|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
79520584|NCT03242148|Device|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
79520585|NCT03257202|Drug|Clindamycin 1% Gel|topical clindamycin
79520586|NCT03257202|Drug|Benzoyl peroxide 5% gel|topical benzoyl peroxide
79822389|NCT04104113|Other|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
79822390|NCT04104113|Other|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
79822391|NCT00713648|Drug|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
79822392|NCT04102085|Other|no intervention|no intervention
79996642|NCT05181215|Drug|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
79996643|NCT05181215|Drug|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
79996644|NCT02032316|Device|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
79520587|NCT03257202|Drug|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
79225251|NCT03586596|Behavioral|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
79822393|NCT02590016|Drug|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
79367645|NCT03582345|Procedure|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
79367646|NCT01766401|Drug|Placebo|
79367647|NCT01766401|Drug|Vilazadone|Viibryd
79367648|NCT03159273|Dietary Supplement|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
79367649|NCT01279096|Drug|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
79367650|NCT03582267|Dietary Supplement|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
79367651|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
79520588|NCT03260790|Biological|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
79520589|NCT03260790|Biological|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
79679962|NCT02936973|Device|Real catgut implantation at acupoints|"Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
79822394|NCT00768053|Drug|Etanercept|Etanercept 50 mg once a week
79822395|NCT00683475|Biological|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
79996645|NCT04566575|Other|trans vaginal ultrasound (TVUS)|In the TVUS, the residual myometrium is determined after surgery and the appearance of new cysts in the area of the caesarian section scar is assessed.
79996646|NCT04566575|Other|patient questionnaire|exploratory patient questionnaire regarding satisfaction after correction of isthmocele
79225252|NCT02203539|Other|exposure to normal light|exposure for 60 minutes in duration
79225253|NCT02203539|Other|exposure to bright light|exposure to bright light for 60 minutes of duration
79225254|NCT02203539|Other|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
79225255|NCT04460118|Procedure|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
79225256|NCT04460118|Procedure|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
79225257|NCT02203617|Behavioral|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
79367652|NCT03582111|Other|Study of medical records|Study of medical records
79367653|NCT01272934|Drug|Diclofenac Sodium|Topical gel 1%-4 times daily
79367654|NCT01272934|Other|Placebo|Topical gel-4 times daily
79367655|NCT03159117|Drug|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
79367656|NCT01279252|Drug|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
79520590|NCT03261960|Drug|BLI4700|Oral bowel preparation
79520591|NCT03261960|Drug|Magnesium bowel preparation|Oral bowel preparation
79520592|NCT03273270|Radiation|transcranial magnetic stimulation|transcranial magnetic stimulation
79520593|NCT03273426|Procedure|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
79520594|NCT03273426|Procedure|wide excision|Surgical wide excision of the biopsied area.
79520595|NCT03274518|Device|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
79520596|NCT03274518|Device|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
79520597|NCT03275766|Other|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
79822396|NCT00683475|Drug|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
79996647|NCT03613298|Device|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
79520598|NCT03275766|Other|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
79676912|NCT03947515|Procedure|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
79996648|NCT03661710|Other|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
79367657|NCT03159351|Device|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
79367658|NCT03159351|Device|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
79367659|NCT01279330|Other|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
79367660|NCT01279330|Other|Control|No intervention (Patients receive by mail the materials needed for stool samples).
79367661|NCT00739336|Behavioral|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
79367662|NCT03158415|Behavioral|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
79367663|NCT04385836|Drug|alpha one antitrypsin inhalation|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
79367664|NCT04385524|Biological|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
79520599|NCT03275766|Other|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
79520600|NCT03275766|Other|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
79520601|NCT03278886|Drug|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
79520602|NCT03278886|Drug|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
79520603|NCT03281538|Drug|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
79520604|NCT03285984|Other|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
79822397|NCT00683475|Drug|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
79996649|NCT03212261|Behavioral|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
79225258|NCT02203617|Behavioral|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
79520605|NCT03285984|Other|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
79520606|NCT03285984|Other|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
79520607|NCT03285984|Other|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
79225259|NCT02209077|Device|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
79367665|NCT01274260|Drug|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
79367666|NCT01274260|Drug|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
79520608|NCT03287310|Drug|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
79520609|NCT03287310|Drug|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
79367667|NCT03154983|Drug|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
79520610|NCT03287310|Drug|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
79520611|NCT03292614|Diagnostic Test|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
79520612|NCT03292692|Behavioral|OurRelationship|Online intervention with coach support
79520613|NCT03295266|Drug|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
79520614|NCT03301272|Drug|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
79520615|NCT03301272|Other|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
79520616|NCT03303144|Drug|Triferic|ferric pyrophosphate citrate
79520617|NCT03306420|Drug|M4112|All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
79520618|NCT03312348|Device|Infrared imaging|Infrared image image acquisition of study participants
79225260|NCT03356106|Device|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
79225261|NCT02191215|Drug|Nevirapine (Viramune®)|
79225262|NCT03104478|Procedure|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
79225263|NCT02209155|Drug|R-verapamil 75 mg tablet|
79225264|NCT02209155|Drug|Placebo|
79225265|NCT03486366|Other|non interventional trial|other
79367668|NCT01274416|Behavioral|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
79367669|NCT01274416|Behavioral|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
79367670|NCT03154593|Other|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
79367671|NCT00252850|Genetic|CERE-120: AAV2-NTN|
79367672|NCT01983683|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
79520619|NCT03315702|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
79520620|NCT03315780|Drug|Dulaglutide|Administered SC
79225266|NCT03485118|Drug|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
79367673|NCT01983683|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
79520621|NCT03315780|Drug|Placebo|Administered SC
79520622|NCT03319134|Device|active anodal HD-tDCS|1) active anodal HD-tDCS with memory task
79520623|NCT03319134|Device|sham HD-tDCS|2) sham HD-tDCS with memory task
79520624|NCT03319134|Device|active cathodal HD-tDCS|3) active cathodal HD-tDCS with memory task
79996650|NCT04056702|Drug|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
79520625|NCT03329352|Device|F&P Full-Face Mask|The F&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
79676913|NCT03947515|Other|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
79676914|NCT03947515|Other|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
79676915|NCT03906422|Device|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
79676916|NCT03906422|Device|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
79676917|NCT03906422|Device|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
79996651|NCT03613142|Procedure|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
79367674|NCT01983683|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
79225267|NCT03485118|Drug|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
79520626|NCT03330834|Biological|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
79676918|NCT03906175|Device|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
79228145|NCT03917511|Behavioral|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
79676919|NCT03871361|Drug|Abatacept 125 MG/ML Prefilled Syringe|Abatacept 125 MG/ML Prefilled Syringe [Orencia] weekly
79676920|NCT03870334|Drug|BT-11 880 mg|Oral once daily tablet
79676921|NCT03870334|Drug|Placebo|Oral once daily tablet
79676922|NCT03799718|Biological|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
79676923|NCT03795701|Drug|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
79822398|NCT00683475|Biological|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
79822399|NCT02589158|Drug|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
79822400|NCT02589158|Drug|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
79367675|NCT01983683|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
79367676|NCT05610111|Device|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
79367677|NCT05610111|Device|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
79367678|NCT04405713|Procedure|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
79676924|NCT03795701|Other|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
79676925|NCT03786471|Other|Health System-based Dementia Care|Active comparator
79676926|NCT03786471|Other|Community-based Dementia Care|Active comparator
79367679|NCT04405713|Procedure|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
79367680|NCT04405713|Procedure|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
79676927|NCT03786471|Other|Usual Care|Control
79676928|NCT03781791|Drug|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
79676929|NCT03781791|Drug|Placebo Treatment|Placebo will be administered in tablet form, once daily.
79676930|NCT03776643|Drug|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
79822401|NCT04083482|Procedure|continous venovenous hemofiltraion|CVVH
79822402|NCT04083716|Drug|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
79822403|NCT04083716|Drug|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
79822404|NCT00918788|Other|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
79822405|NCT00918788|Other|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
79676931|NCT03775187|Biological|Burosumab|
79676932|NCT03775174|Drug|Mepsevii|
79822406|NCT00918788|Other|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC).
79996652|NCT03613142|Procedure|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
79225268|NCT03485118|Drug|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
79225269|NCT02209233|Other|Massage Therapy|
79225270|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
79367681|NCT03154515|Drug|Ingavirin|
79367682|NCT03154515|Drug|Placebo|
79367683|NCT03158103|Drug|MEK162|MEK162 at 30mg twice daily
79520627|NCT03334734|Drug|PBTZ169|Once a day for 14 days
79520628|NCT03334734|Drug|Isoniazid|Once a day for 14 days
79520629|NCT03334812|Biological|LNA043|LNA043 Single dose
79225271|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
79228146|NCT03917511|Behavioral|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
79367684|NCT03158103|Drug|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
79367685|NCT03581799|Other|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
79367686|NCT03158025|Drug|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
79520630|NCT03334812|Biological|placebo to LNA043|placebo to LNA043 single dose
79520631|NCT03336450|Drug|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
79520632|NCT03336450|Drug|MHOS/SHP615|MHOS/SHP615
79520633|NCT03338556|Drug|PrEP-001|
79367687|NCT03158025|Drug|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
79367688|NCT03158025|Drug|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
79520634|NCT03338556|Other|Placebo|
79520635|NCT03606408|Drug|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
79676933|NCT03773770|Drug|Triheptanoin|Liquid for oral (PO) or enteral tube administration
79676934|NCT03763838|Other|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
79676935|NCT03763838|Other|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
79822407|NCT00918788|Other|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
79367689|NCT03158025|Drug|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
79367690|NCT03158025|Drug|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
79367691|NCT03158025|Drug|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
79367692|NCT01998893|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
79520636|NCT03256968|Drug|Ataluren|ataluren
79520637|NCT03339570|Procedure|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
79520638|NCT03340350|Drug|Minocycline|Minocycline capsule
79520639|NCT03340428|Behavioral|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
79520640|NCT03341910|Drug|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
79520641|NCT03341910|Drug|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
79520642|NCT03341910|Drug|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
79367693|NCT01791985|Drug|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
79367694|NCT03157869|Device|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
79676936|NCT03763838|Other|Standard of Care|Fatigue management provided by participants' health care providers.
79676937|NCT03749499|Other|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
79520643|NCT03341910|Drug|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
79676938|NCT03749499|Other|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
79676939|NCT03749499|Other|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
79676940|NCT03749499|Other|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
79676941|NCT03744871|Other|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
79996653|NCT03662802|Other|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
79225272|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
79225273|NCT02191293|Drug|Viramune® tablets|
79225274|NCT03532815|Behavioral|Lifestyle Modification|
79225275|NCT02880540|Drug|Fentanyl|
79225276|NCT02880540|Drug|Morphine|
79225277|NCT02880540|Drug|Dexmedetomidine|
79225278|NCT02191371|Drug|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
79520644|NCT03343080|Drug|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
79520645|NCT03343080|Other|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
79520646|NCT03345108|Device|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
79676942|NCT03735212|Behavioral|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
79225279|NCT02191371|Drug|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
79225280|NCT04460274|Other|Model Building|Model building
79225281|NCT04460274|Other|Model validation|Model validation
79225282|NCT02209311|Procedure|Oral mucosa biopsy|
79225283|NCT02209311|Procedure|Sinus lift with implantation of tissue engineered construction|
79225284|NCT02209311|Device|Dental implant|
79822408|NCT00918788|Procedure|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
79822409|NCT00918788|Procedure|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
79367695|NCT03157869|Other|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
79996654|NCT03613064|Other|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
79225285|NCT02209389|Device|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
79225286|NCT03532737|Drug|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
79225287|NCT05151978|Diagnostic Test|Transcranial Doppler|Transcranial Doppler on middle cerebral arteries
79225288|NCT02209467|Other|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
79225289|NCT02741388|Drug|selinexor|
79225290|NCT02741388|Drug|Rituximab|
79225291|NCT02741388|Drug|Dexamethasone|
79225292|NCT02741388|Drug|Oxaliplatin|
79225293|NCT02741388|Drug|Cisplatin|
79225294|NCT02741388|Drug|Cytarabine|
79225295|NCT02741388|Drug|Gemcitabine|
79225296|NCT02191527|Device|PIMA® for quantitative analysis of CD4-count|
79367696|NCT04664621|Diagnostic Test|HepQuant|Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
79367697|NCT04176497|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
79367698|NCT03157947|Behavioral|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
79367699|NCT03157947|Behavioral|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
79367700|NCT03157947|Behavioral|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
79225297|NCT02191527|Device|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
79225298|NCT02191527|Device|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
79225299|NCT03484962|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
79225300|NCT03484962|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
79367701|NCT02665377|Drug|ANP|
79367702|NCT02665377|Drug|Placebo|
79367703|NCT03154437|Biological|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
79367704|NCT05703087|Behavioral|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
79367705|NCT01791517|Other|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
79367706|NCT01791517|Other|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
79367707|NCT01791517|Other|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
79367708|NCT01791517|Other|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
79367709|NCT01998581|Device|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
79367710|NCT01998581|Device|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
79367711|NCT03154203|Other|No intervention in this study|No intervention in this study
79822410|NCT00918788|Procedure|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
79822411|NCT00756951|Drug|Placebo|Placebo
79822412|NCT00756951|Drug|SCV-07|0.02 mg/kg
79822413|NCT00756951|Drug|SCV-07|0.10 mg/kg
79996655|NCT03612986|Dietary Supplement|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
79996656|NCT03612986|Dietary Supplement|Placebo|Placebo comparator. No chemical effect expected
79996657|NCT03612440|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
79225301|NCT03484728|Behavioral|placebo manipulation|application of nonactive body cream on forearm
79225302|NCT05261373|Other|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
79225303|NCT05261373|Other|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
79367712|NCT03581565|Other|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
79367713|NCT03154281|Drug|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
79367714|NCT03154281|Drug|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
79225304|NCT05261373|Other|Behavioral: Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
79367715|NCT03157791|Drug|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
79367716|NCT01983293|Device|QLV based implant strategy|
79367717|NCT01983293|Device|Standard of care implant strategy|
79367718|NCT04765293|Other|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
79367719|NCT03157479|Drug|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
79367720|NCT03157479|Drug|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
79367721|NCT03157479|Diagnostic Test|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
79367722|NCT03157479|Diagnostic Test|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
79367723|NCT03031587|Other|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
79367724|NCT03031587|Device|MRI|cardiac MRI
79367725|NCT01670331|Behavioral|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
79520647|NCT03345108|Device|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
79520648|NCT03345108|Other|No Adhesive|No adhesive applied.
79520649|NCT03346902|Drug|EB-001|Injection of EB-001 into area of scarring (forehead)
79520650|NCT03346902|Drug|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
79520651|NCT03349632|Device|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
79225305|NCT01331616|Drug|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
79822414|NCT00916253|Drug|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
79996658|NCT03612440|Other|normal saline|receive matching placebo (equal volum of normal saline)
79225306|NCT02209623|Biological|TDAP|
79225307|NCT02191761|Drug|SM04755|Escalating Doses
79225308|NCT02209701|Drug|Porfiromycin|
79225309|NCT02191839|Drug|Alpha 1-Antitrypsin|
79367726|NCT03013491|Drug|CX-072|
79367727|NCT03013491|Drug|ipilimumab|
79225310|NCT02191995|Behavioral|yoga|
79367728|NCT03013491|Drug|vemurafenib|
79367729|NCT01272232|Drug|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
79367730|NCT01272232|Drug|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
79367731|NCT01272232|Drug|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
79367732|NCT03157401|Drug|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
79367733|NCT03157401|Drug|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
79367734|NCT03157401|Drug|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
79367735|NCT03153735|Device|CMDHA0101|Maximum injection dose : 22 ml
79367736|NCT03153735|Device|PowerFill®|Maximum injection dose : 22 ml
79367737|NCT03153891|Other|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
79367738|NCT03153891|Other|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
79520652|NCT03349632|Device|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
79367739|NCT01670643|Behavioral|Video camera magnifier|reading with video camera magnifier
79225311|NCT05261295|Diagnostic Test|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
79225312|NCT05261295|Diagnostic Test|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
79225313|NCT03535467|Other|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
79225314|NCT02209779|Drug|BIBR 796 BS|
79225315|NCT02209779|Drug|Placebo|
79225316|NCT05238987|Dietary Supplement|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
79225317|NCT04911075|Drug|85% TCA Solution|"TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
79225318|NCT02192073|Procedure|Suprapectoral Biceps tenodesis|
79225319|NCT02192073|Procedure|Subpectoral biceps tenodesis|
79225320|NCT02204163|Drug|Eutropin|
79225321|NCT02204163|Drug|Genotropin|
79225322|NCT05238441|Biological|SCTV01E|D0; intramuscular injection
79225323|NCT05238441|Biological|Comirnaty|D0; intramuscular injection
79367740|NCT03153813|Drug|capsaicin 8% patches (Qutenza)|
79367741|NCT03153813|Other|Placebo patches|
79367742|NCT03157167|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
79367743|NCT03157245|Diagnostic Test|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
79367744|NCT03156855|Drug|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
79520653|NCT03349632|Device|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
79520654|NCT03349632|Device|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
79520655|NCT03350724|Device|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
79520656|NCT03350724|Device|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
79520657|NCT03365154|Device|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
79520658|NCT03365154|Device|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
79520659|NCT03365778|Other|Patient Educational Intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
79520660|NCT03365778|Other|Usual Care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
79676943|NCT03733067|Drug|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
79367745|NCT03156855|Drug|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
79367746|NCT01791127|Device|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
79520661|NCT03365778|Other|Ophthalmologist Educational Intervention|Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
79520662|NCT03369756|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
79520663|NCT03373890|Behavioral|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
79520664|NCT03375294|Drug|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
79520665|NCT03377244|Behavioral|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
79520666|NCT03377244|Behavioral|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
79520667|NCT03377244|Behavioral|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
79676944|NCT03733067|Other|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
79225324|NCT05238441|Biological|SCTV01E|D180; intramuscular injection
79225325|NCT05238441|Biological|Comirnaty|D180; intramuscular injection
79367747|NCT03157011|Other|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
79367748|NCT01274650|Procedure|Indirect Calorimetry|Indirect Calorimetry
79367749|NCT00739960|Drug|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
79520668|NCT03379662|Device|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
79996659|NCT03662724|Drug|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
79996660|NCT03662568|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
79225326|NCT02190981|Device|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
79225327|NCT05263323|Other|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
79225328|NCT05263323|Other|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
79225329|NCT02204397|Drug|INGAP Peptide, Ustekinumab|
79225330|NCT02192229|Drug|50.000 IU vitamin D3 (Biodal 50,000 IU)|
79225331|NCT02192229|Drug|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
79225332|NCT02192463|Drug|NVP ER 300 mg (KCR 20%) Medium Release|
79225333|NCT02192463|Drug|NVP ER 300 mg (KCR 25%) Medium Release|
79225334|NCT02192463|Drug|NVP ER 300 mg (KCR 30%) Slow Release|
79225335|NCT02192463|Drug|NVP ER 400 mg (KCR 25%) Medium Release|
79225336|NCT02192463|Drug|NVP ER 300 mg (KCR 40%) Slow Release|
79520669|NCT03379662|Device|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
79520670|NCT03379740|Other|E-cigarette|Subject's own e-cigarette
79520671|NCT03379740|Other|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
79520672|NCT03379740|Other|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
79520673|NCT03379740|Other|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
79520674|NCT03379740|Other|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
79676945|NCT03729544|Behavioral|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
79676946|NCT03711929|Drug|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
79676947|NCT03711929|Other|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
79676948|NCT03711929|Drug|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
79996661|NCT03662568|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
79676949|NCT03711929|Drug|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
79996662|NCT03662568|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
79367750|NCT05537181|Device|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
79996663|NCT03662568|Drug|TDF|Administered TDF 300 mg orally once daily in fasted state
79996664|NCT03612362|Device|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence & HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements & suitably short follow-up period to decrease attrition."
79367751|NCT00751972|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
79996665|NCT03661554|Biological|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
79996666|NCT02993250|Drug|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
79367752|NCT03153657|Drug|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
79367753|NCT03153657|Drug|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
79367754|NCT01670955|Dietary Supplement|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
79367755|NCT01670955|Drug|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
79996667|NCT02993250|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
79996668|NCT02993250|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
79225337|NCT02192463|Drug|NVP ER 300 mg (ECR 20%) Fast Release|
79225338|NCT02192463|Drug|NVP ER 400 mg (KCR 20%) Medium Release|
79225339|NCT02192463|Drug|NVP ER 400 mg (KCR 30%) Slow Release|
79225340|NCT02192463|Drug|NVP ER 400 mg (KCR 40%) Slow Release|
79225341|NCT02192463|Drug|NVP ER 400 mg (ECR 20%) Fast Release|
79225342|NCT02192463|Drug|Nevirapine immediate release (IR) 200 mg|
79367756|NCT01274806|Other|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
79367757|NCT01274884|Procedure|Tightrope fixation|Arthroscopic repair
79367758|NCT03156933|Other|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
79367759|NCT01275040|Other|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
79367760|NCT01275040|Other|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
79367761|NCT01275274|Drug|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of < 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to < 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
79367762|NCT01275274|Drug|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
79367763|NCT01671033|Behavioral|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
79225343|NCT02209935|Other|Early Rehabilitation Protocol|
79225344|NCT02209935|Other|Usual care|
79225345|NCT02204475|Drug|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
79225346|NCT02204475|Drug|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
79225347|NCT02204475|Drug|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
79225348|NCT02204475|Drug|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
79996669|NCT03612284|Device|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
79996670|NCT03661476|Behavioral|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
79225349|NCT02210169|Drug|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
79996671|NCT03612830|Procedure|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
79225350|NCT02257047|Dietary Supplement|Tea|
79225351|NCT02257047|Dietary Supplement|RYR|red yeast rice
79367764|NCT01671033|Behavioral|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
79367765|NCT01997333|Drug|CDX-011|
79367766|NCT01997333|Drug|Capecitabine|
79225352|NCT02210949|Drug|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
79225353|NCT02204553|Drug|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
79225354|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
79225355|NCT01109004|Drug|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
79367767|NCT01271920|Drug|AUY922|
79367768|NCT01271920|Drug|Trastuzumab|
79367769|NCT05479149|Other|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
79367770|NCT05479149|Other|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
79367771|NCT01275352|Drug|Eplerenone|Eplerenone 50 mg/day
79367772|NCT01275352|Drug|placebo|placebo
79367773|NCT01279720|Biological|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
79367774|NCT01676259|Drug|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
79367775|NCT01676259|Drug|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
79367776|NCT01676259|Drug|Folfirinox|Folfirinox or modified Folfirinox
79367777|NCT01270282|Drug|AM-101 0.81 mg/mL|
79367778|NCT01270282|Drug|Placebo|
79367779|NCT01671189|Other|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
79367780|NCT01273012|Drug|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
79367781|NCT01676337|Other|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
79367782|NCT00746122|Procedure|Open repair|Standard treatment of emergency open surgery
79367783|NCT00746122|Procedure|EVAR|Emergency endovascular aneurysm repair
79367784|NCT04538079|Device|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
79367785|NCT02662257|Drug|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
79996672|NCT03612830|Procedure|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
79225356|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
79996673|NCT03661788|Drug|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
79367786|NCT02662257|Drug|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
79996674|NCT03661788|Drug|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
79996675|NCT03661398|Device|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
79996676|NCT03612128|Other|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
79367787|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
79520675|NCT03390114|Behavioral|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
79520676|NCT03391986|Device|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
79520677|NCT03391986|Procedure|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
79520678|NCT03392532|Device|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
79520679|NCT03392532|Device|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
79520680|NCT03395808|Drug|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
79520681|NCT03395886|Drug|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
79225357|NCT02204631|Other|Head and Neck Educational Handbook|
79520682|NCT03395886|Drug|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
79996677|NCT03612128|Other|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
79225358|NCT02211729|Drug|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
79225359|NCT02211729|Drug|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
79228147|NCT04282278|Drug|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
79228148|NCT04282278|Drug|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
79367788|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
79367789|NCT03153267|Drug|Controls without a history of lyme disease.|No intervention.
79367790|NCT03153501|Diagnostic Test|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
79367791|NCT01671579|Procedure|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
79520683|NCT03396432|Device|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
79520684|NCT03396432|Device|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
79520685|NCT03398928|Other|Acupuncture|Acupuncture added to usual care
79520686|NCT03400800|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
79520687|NCT03400800|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
79520688|NCT03410628|Device|gammaCore|Non-invasive vagal nerve stimulator
79520689|NCT03410862|Drug|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
79520690|NCT03410862|Drug|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
79520691|NCT03415152|Drug|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
79520692|NCT03416946|Device|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
79520693|NCT03416946|Other|Traditional|Traditional cutting method
79996678|NCT03612752|Dietary Supplement|CMI-168|Dietary supplement
79996679|NCT03612752|Other|Placebo|Placebo
79996680|NCT03611660|Behavioral|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
79676950|NCT03697980|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
79676951|NCT03664895|Drug|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
79822415|NCT00916253|Drug|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
79822416|NCT04087226|Device|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
79822417|NCT02561637|Behavioral|Case management|
79996681|NCT03611660|Behavioral|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
79996682|NCT03612674|Procedure|Standard colonoscopy|Current standard of care colonoscopy.
79996683|NCT03612674|Device|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
79996684|NCT02989194|Drug|VIS410 low dose|Single intravenous fixed low dose of VIS410
79996685|NCT02989194|Drug|VIS410 high dose|Single intravenous fixed high dose of VIS410
79367792|NCT01671579|Procedure|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
79225360|NCT02212041|Other|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
79520694|NCT03418662|Device|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
79520695|NCT03423186|Drug|SOBI003|Weekly i.v.infusion
79520696|NCT03426228|Diagnostic Test|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~At baseline (second day of the menstrual period)~Triggering phase (post-egg retrieval procedure)~Embryo transfer phase (post-transfer procedure)~Week 4 (positive bHCG)~4. Week 8 of pregnancy"
79676952|NCT03658395|Procedure|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
79996686|NCT02989194|Drug|Placebo|Single intravenous infusion of placebo
79225361|NCT05151510|Procedure|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
79225362|NCT05151510|Drug|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
79367793|NCT00746512|Drug|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
79520697|NCT03429270|Device|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
79822418|NCT02561637|Behavioral|Control group|
79822419|NCT00757029|Genetic|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
79996687|NCT03612518|Behavioral|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
79996688|NCT03612518|Behavioral|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
79225363|NCT02212119|Drug|Botulinum Toxin|
79225364|NCT02212119|Drug|Saline|
79228149|NCT04282278|Drug|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
79367794|NCT00746512|Drug|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
79822420|NCT04101929|Drug|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
79822421|NCT04101929|Drug|S-1 capsule|Patients receive S-1 capsule According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
79676953|NCT03658395|Procedure|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
79676954|NCT03631420|Biological|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
79676955|NCT03599544|Behavioral|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
79676956|NCT03599544|Behavioral|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
79822422|NCT04101929|Drug|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
79822423|NCT04083638|Diagnostic Test|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
79367795|NCT00746512|Drug|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
79676957|NCT03592368|Device|IBT|Interpretation bias training
79676958|NCT03559413|Biological|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
79822424|NCT00757107|Device|Taperloc Microplasty|primary total hip arthroplasty
79822425|NCT00757107|Device|Taperloc standard|primary total hip arthroplasty
79367796|NCT00746512|Drug|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
79367797|NCT05409027|Drug|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
79367798|NCT05409027|Drug|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
79367799|NCT01275742|Behavioral|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
79367800|NCT04385134|Other|No intervention|No intervention
79367801|NCT03153423|Procedure|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
79367802|NCT00746668|Behavioral|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
79367803|NCT00746668|Behavioral|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
79367804|NCT00746668|Behavioral|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation [RSVP]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
79367805|NCT01275118|Device|Tecnis Multifocal IOL|Presbyopia correcting IOL
79367806|NCT01275118|Device|crystalens Accommodating IOL|Presbyopia correcting IOL
79367807|NCT01982435|Drug|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
79367808|NCT01982435|Drug|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
79367809|NCT00747214|Drug|CRx-102|
79367810|NCT00747214|Drug|Placebo|
79367811|NCT00747214|Drug|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
79367812|NCT01279798|Biological|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
79367813|NCT03808012|Other|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
79520698|NCT03429348|Other|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
79520699|NCT03430050|Drug|Progesterone|Progesterone capsule
79520700|NCT03430050|Drug|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
79520701|NCT03430206|Device|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
79520702|NCT03433794|Behavioral|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
79520703|NCT03433794|Behavioral|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
79822426|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
79225365|NCT05151354|Other|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
79225366|NCT02257125|Behavioral|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
79367814|NCT00753142|Drug|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
79520704|NCT03433794|Behavioral|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
79520705|NCT03440424|Drug|Lemborexant|oral tablet
79676959|NCT03546335|Drug|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
79676960|NCT03495427|Drug|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
79676961|NCT03495427|Diagnostic Test|PSMA PET|PSMA PET imaging (for men with high GC >0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
79676962|NCT03467867|Drug|Venetoclax|Venetoclax will be administered as described in the reporting arm.
79676963|NCT03467867|Drug|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
79822427|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
79822428|NCT00918632|Drug|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
79225367|NCT02257125|Behavioral|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
79225368|NCT03484650|Drug|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
79225369|NCT03484650|Drug|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
79367815|NCT00753142|Drug|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m^2/min for 20 hours.
79225370|NCT03484650|Other|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
79367816|NCT00762424|Drug|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
79367817|NCT00762424|Drug|placebo|cornstarch
79367818|NCT01620983|Behavioral|Pain Coping Skills Training|
79367819|NCT01620983|Behavioral|Arthritis Education|
79367820|NCT01620983|Other|Usual Care|
79367821|NCT01279876|Drug|Melatonin|3mg oral, daily, one hour before sleep
79367822|NCT01996709|Device|Hydrogen peroxide-based contact lens solution|
79367823|NCT01996709|Device|Habitual contact lens solution|Biguanide-preserved
79676964|NCT03467867|Drug|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
79676965|NCT03458728|Drug|Copanlisib (BAY806946)|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
79676966|NCT03432806|Other|blood draws|Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
79520706|NCT03444090|Procedure|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size <10 mm are removed as they are identified on insertion and withdrawal. Polyps with size >10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
79520707|NCT03448068|Drug|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
79520708|NCT03448068|Drug|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
79996689|NCT03661242|Behavioral|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
79996690|NCT05383820|Drug|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
79225371|NCT05151276|Behavioral|mobile phone-based distance video education group|Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
79367824|NCT01996709|Device|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
79520709|NCT03453060|Drug|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
79520710|NCT03453060|Drug|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
79520711|NCT03453060|Drug|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
79520712|NCT03453060|Drug|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
79676967|NCT03432806|Procedure|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected."
79676968|NCT03432806|Diagnostic Test|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
79822429|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
79225372|NCT02213601|Behavioral|Yoga|
79225373|NCT02192697|Drug|ASP8273|Oral administration
79225374|NCT03486210|Behavioral|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
79367825|NCT00753220|Biological|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells"
79367826|NCT00753220|Drug|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
79367827|NCT01279642|Device|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
79367828|NCT01279642|Other|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
79367829|NCT00753298|Device|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
79367830|NCT00753298|Device|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
79367831|NCT01996319|Drug|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
79367832|NCT01996319|Drug|Placebo|Placebo once a day via Breezhaler® device
79676969|NCT03352765|Drug|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
79676970|NCT03352765|Drug|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
79822430|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
79996691|NCT04055766|Device|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
79367833|NCT04276948|Dietary Supplement|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
79520713|NCT03453060|Other|Placebo|Participants received a single intravenous dose of placebo.
79520714|NCT03457116|Drug|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
79520715|NCT03457116|Drug|NSAID|Ibuprofen 400mg for post-operative pain
79996692|NCT03612050|Behavioral|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
79225375|NCT03486210|Other|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
79225376|NCT03486132|Procedure|repair of episiotomy|Different techniques for repair of episiotomy incsicion
79367834|NCT01279954|Drug|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
79367835|NCT01278862|Device|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
79367836|NCT01278862|Device|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
79367837|NCT03807388|Device|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
79367838|NCT03807388|Other|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
79367839|NCT00763048|Drug|Fluoride|Brush twice daily for 6 weeks
79367840|NCT00763048|Drug|Fluoride, triclosan|Brush twice daily
79367841|NCT03807466|Behavioral|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
79367842|NCT03807466|Behavioral|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
79367843|NCT01278394|Drug|AN2690 Solution, 5.0%|Once daily application for 360 days
79367844|NCT01981187|Drug|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
79225377|NCT02030691|Device|Nasal continuous airway positive pressure (nCPAP)|
79225378|NCT02030691|Device|Nasal high frequency percussive ventilation (nHFPV)|
79225379|NCT03481452|Behavioral|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
79225380|NCT02204865|Device|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
79367845|NCT00240916|Biological|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
79367846|NCT00240916|Biological|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
79367847|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
79367848|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
79367849|NCT01278160|Drug|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
79367850|NCT01996241|Behavioral|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
79367851|NCT00248404|Drug|NB1011|
79367852|NCT02091869|Other|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
79367853|NCT02091869|Device|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
79367854|NCT00748072|Drug|DDAVP|0.3 mcg/kg subcutaneous
79367855|NCT00748072|Drug|saline solution|saline solution 1 ml subcutaneous
79367856|NCT03806920|Dietary Supplement|Intervention A|
79367857|NCT03806920|Dietary Supplement|Intervention B|
79367858|NCT03806920|Dietary Supplement|Intervention C|
79367859|NCT03806920|Dietary Supplement|Intervention D|
79367860|NCT04731701|Diagnostic Test|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
79367861|NCT00248794|Behavioral|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
79520716|NCT03459612|Drug|Lasmiditan|Administered orally
79520717|NCT03459612|Drug|Placebo|Administered orally
79520718|NCT03459612|Drug|Diphenhydramine|Administered orally
79520719|NCT03463512|Drug|Racecadotril plus ORS|Racecadotril plus ORS
79520720|NCT03463512|Drug|ORS|ORS
79520721|NCT03467412|Drug|FOL-005|intradermal injection
79822431|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
79225381|NCT03481374|Diagnostic Test|autonomic function testing|"autonomic function testing, ergospirometry, three questionnaires~Other Names:~The autonomic function tests consist of five tests:~The Valsalva maneuver~The isometric handgrip test~The deep breathing test~The cold pressor test~A short head-up tilt test~A maximal ergospirometry~Three questionnaires:~EQ-5D-3L: quality of life~IPAQ: capacity to do physical activities"
79225382|NCT03481218|Other|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
79225383|NCT03481218|Other|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
79822432|NCT00751257|Drug|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
79225384|NCT03481218|Other|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
79225385|NCT02204943|Device|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
79996693|NCT03660774|Other|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
79225386|NCT02204943|Drug|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
79225387|NCT05153928|Drug|Norethisterone acetate|Norethisterone acetate for 5 months
79367862|NCT00248794|Behavioral|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
79367863|NCT00248794|Behavioral|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
79367864|NCT03806686|Biological|Placebo|Sterile normal saline
79225388|NCT02214771|Drug|Fidaxomicin|oral
79520722|NCT03467412|Drug|Placebo|intradermal injection
79520723|NCT03468816|Device|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
79676971|NCT03352765|Drug|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
79676972|NCT03352765|Procedure|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
79676973|NCT03289923|Device|Sham TMS + Cognitive therapy|Placebo Transcranial Magnetic Stimulation with cognitive therapy
79822433|NCT00751257|Drug|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
79996694|NCT03611894|Other|radiological comparison|comparison between clinical and radiological characteristics
79996695|NCT03622554|Other|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
79225389|NCT02214771|Drug|Treatment for CDI other than fidaxomicin Type|Oral
79225390|NCT03484572|Diagnostic Test|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
79225391|NCT02192853|Drug|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
79225392|NCT02192853|Drug|Placebo|Day 4: placebo tablet
79367865|NCT03806686|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
79520724|NCT03473184|Drug|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
79367866|NCT01995539|Behavioral|therapy regimen|Subjects will be recommend changes in therapy regimens.
79367867|NCT01835587|Drug|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
79367868|NCT01736917|Drug|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
79367869|NCT01736917|Drug|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
79676974|NCT03289923|Device|Active TMS + Cognitive therapy|Active Transcranial Magnetic Stimulation with cognitive therapy.
79676975|NCT03271372|Drug|Avelumab|Given IV
79676976|NCT03271372|Other|Peripheral Blood Collection|Correlative studies
79676977|NCT03271372|Other|Placebo|Given IV
79676978|NCT03252249|Other|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
79676979|NCT03252249|Other|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
79822434|NCT00753441|Procedure|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
79822435|NCT00753441|Procedure|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
79822436|NCT05685134|Device|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
79996696|NCT03622554|Other|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
79520725|NCT03473886|Behavioral|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
79520726|NCT03475992|Device|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
79225393|NCT05151042|Procedure|wafer-less approach|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment & tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
79225394|NCT05151042|Procedure|Computer Guided orthognathic surgery using occlusal wafers|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment & tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
79225395|NCT03131778|Procedure|Liver resection|liver resections for colorectal liver metastases
79367870|NCT01736917|Drug|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
79367871|NCT01277302|Drug|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
79367872|NCT04414579|Drug|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
79367873|NCT01980875|Drug|Idelalisib|150 mg tablet administered orally twice daily
79367874|NCT01980875|Drug|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
79367875|NCT01980875|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
79520727|NCT03476850|Procedure|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
79676980|NCT03241732|Other|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
79367876|NCT01995461|Drug|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
79367877|NCT04731623|Drug|ION904|ION904 will be administered by SC injection.
79367878|NCT04731623|Drug|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
79367879|NCT01980095|Drug|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
79367880|NCT01980095|Drug|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
79367881|NCT04667741|Other|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
79367882|NCT01980017|Behavioral|Ottawa Model for Smoking Cessation|
79520728|NCT03476850|Procedure|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
79676981|NCT03241732|Dietary Supplement|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
79676982|NCT03241732|Behavioral|Neuro Emotive Technique|Neuro Emotive Technique sessions
79676983|NCT03220035|Other|Laboratory Biomarker Analysis|Correlative studies
79676984|NCT03220035|Drug|Vemurafenib|Given PO
79676985|NCT03215706|Biological|Ipilimumab|Specified dose on specified day
79676986|NCT03215706|Biological|Nivolumab|Specified dose on specified day
79676987|NCT03215706|Drug|Carboplatin|Specified dose on specified day
79676988|NCT03215706|Drug|Paclitaxel|Specified dose on specified day
79996697|NCT02032472|Other|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
79996698|NCT03611504|Device|Hemospray®|Hemospray® application
79996699|NCT03622710|Other|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
79996700|NCT02954510|Drug|ferumoxytol|ferumoxytol will assess patency of coronary arteries
79367883|NCT04416347|Other|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
79367884|NCT04659707|Drug|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
79367885|NCT01978145|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
79520729|NCT03477006|Biological|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
79520730|NCT03478254|Biological|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
79520731|NCT03478254|Biological|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years.~One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
79520732|NCT03478254|Biological|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
79367886|NCT01978145|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
79367887|NCT01967537|Drug|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
79520733|NCT03480048|Behavioral|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
79225396|NCT03486054|Device|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
79367888|NCT01967537|Procedure|Radio-guided surgery|Using 68Gallium DOTATATE
79367889|NCT01967225|Drug|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
79367890|NCT01967225|Drug|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
79520734|NCT03485976|Drug|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
79520735|NCT03486990|Drug|TIMP-GLIA|intravenous infusion.
79520736|NCT03490110|Behavioral|State regulation skill training|Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total ~4.5 hours per week).
79520737|NCT03490110|Other|Treatment-as-usual|Participants receive clinical care as usual over a matched time period.
79520738|NCT03495648|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
79520739|NCT03496428|Device|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
79520740|NCT03496974|Drug|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
79520741|NCT03496974|Drug|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
79520742|NCT03498300|Biological|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
79676989|NCT03215706|Drug|Pemetrexed|Specified dose on specified day
79676990|NCT03215706|Drug|Cisplatin|Specified dose on specified day
79676991|NCT03214354|Drug|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
79676992|NCT03214354|Radiation|Total Body Irradiation|TBI 300 cGy on Day -2
79676993|NCT03214354|Drug|Sirolimus|Sirolimus is used for GVHD prophylaxis
79676994|NCT03213691|Other|Laboratory Biomarker Analysis|Correlative studies
79996701|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
79225397|NCT03486054|Device|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
79520743|NCT03501264|Behavioral|Online Game|LGBTQ Bullying game
79520744|NCT03501264|Behavioral|LGBTQ Resources|This group receives LGBTQ Resources
79520745|NCT03503292|Drug|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
79520746|NCT03503292|Drug|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
79520747|NCT03506724|Drug|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
79676995|NCT03213691|Drug|Selumetinib|Given PO
79676996|NCT03213691|Drug|Selumetinib Sulfate|Given PO
79676997|NCT03213665|Drug|Tazemetostat|Given PO
79676998|NCT03184038|Procedure|Cognitive Assessment|Undergo assessment of neurocognitive function
79676999|NCT03184038|Radiation|Stereotactic Radiosurgery|Undergo SRS
79225398|NCT02205021|Other|No intervention|
79520748|NCT03506724|Drug|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
79225399|NCT05153694|Procedure|Cystectomy|Removal of the urinary bladder
79367891|NCT01967147|Drug|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
79677000|NCT03184038|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79677001|NCT03184038|Other|Quality-of-Life Assessment|Ancillary studies
79225400|NCT02216643|Procedure|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
79225401|NCT02216643|Device|Stentriever Solitaire FR® or Penumbra System®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
79225402|NCT04574154|Procedure|FIB|FIB with ultrasound: Ropivacaine 0.5% 40 ml
79225403|NCT04574154|Procedure|ESPB|ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
79225404|NCT04574154|Procedure|spinal anesthesia|bupivacaine 0,5% 2.2 ml
79225405|NCT03481140|Device|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
79225406|NCT02217813|Drug|Tafamidis|20 mg of current commercial formulation
79225407|NCT02217813|Drug|Tafamidis|20 mg of new formulation
79225408|NCT05232903|Biological|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
79225409|NCT03484416|Drug|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
79225410|NCT02257827|Radiation|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
79225411|NCT02219295|Dietary Supplement|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
79225412|NCT02219295|Dietary Supplement|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
79225413|NCT02219295|Dietary Supplement|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
79225414|NCT02219295|Other|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
79225415|NCT05153616|Diagnostic Test|Polysomnography|Full night attended polysomnography to diagnose periodic limb movements
79225416|NCT03484338|Behavioral|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
79225417|NCT02219529|Device|MCE|
79225418|NCT02219529|Device|Standard gastroscopy|
79225419|NCT04459494|Procedure|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
79367892|NCT01967147|Drug|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
79367893|NCT01967069|Drug|DFD01 Spray|
79367894|NCT01967069|Drug|Vehicle Spray|
79367895|NCT01790503|Drug|PLX3397|
79367896|NCT01790503|Radiation|Radiation Therapy|
79367897|NCT01790503|Drug|Temozolomide|
79367898|NCT01790113|Device|Univers™|Control
79367899|NCT01790113|Device|Eclipse™ Total Shoulder Replacement|Investigational
79520749|NCT03507036|Device|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
79677002|NCT03151005|Drug|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
79677003|NCT03151005|Drug|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
79677004|NCT03143153|Biological|Nivolumab|Specified dose on specified days
79677005|NCT03143153|Biological|Ipilimumab|Specified dose on specified days
79677006|NCT03143153|Drug|Cisplatin|Specified dose on specified days
79520750|NCT03509766|Device|Histamine skin testing|skin testing using histamine
79367900|NCT01789567|Device|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
79996702|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
79225420|NCT04459494|Procedure|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
79367901|NCT01765543|Drug|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
79367902|NCT01765543|Drug|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
79367903|NCT01765153|Behavioral|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
79367904|NCT01765153|Behavioral|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
79367905|NCT00248170|Drug|Letrozole|2.5 mg tablets
79367906|NCT00248170|Drug|Anastrozole|1 mg tablets
79367907|NCT01764997|Drug|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
79367908|NCT01764997|Drug|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
79367909|NCT01764997|Drug|Methotrexate|Dispensed according to local practice.
79367910|NCT01764997|Drug|Placebo (for sarilumab)|
79520751|NCT03511638|Device|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
79996703|NCT02032784|Drug|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
79996704|NCT02032784|Other|No Octreotide|No drug
79996705|NCT03611426|Drug|rhThrombin ( Topical )|Active Substance
79367911|NCT01764997|Drug|Placebo (for etanercept)|
79367912|NCT01764997|Drug|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
79367913|NCT01276756|Drug|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
79367914|NCT01276756|Drug|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
79367915|NCT01276756|Drug|Ribavirin|Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
79520752|NCT03511638|Device|Alcon VISCOAT®|Ophthalmic viscosurgical device
79520753|NCT03519282|Device|comfilcon A multifocal toric lens|contact lens
79520754|NCT03519282|Device|omafilcon A Multifocal Toric Lens|contact lens
79520755|NCT03520998|Drug|GRF6019|GRF6019 for IV infusion
79996706|NCT03611426|Drug|placebo|saline solution
79996707|NCT03658824|Other|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
79996708|NCT03658746|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
79367916|NCT00246376|Behavioral|Diet|ATP-III diet
79367917|NCT00246376|Behavioral|Exercise|Supervised exercise in study gym
79367918|NCT00246376|Drug|Niacin|Niaspan, titrated up to 2 grams per day
79367919|NCT00246376|Drug|Fenofibrate|Tricor, 120 mg per day
79367920|NCT00246376|Other|Placebos|Placebos for Niaspan and Tricor
79367921|NCT03806218|Device|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
79367922|NCT03806218|Device|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
79520756|NCT03525210|Biological|9-valent HPV vaccine|Vaccination
79520757|NCT03532308|Drug|Fermented Soy|Two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
79520758|NCT03532308|Other|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
79520759|NCT03532776|Drug|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
79520760|NCT03532776|Drug|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
79520761|NCT03532776|Drug|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
79520762|NCT03533244|Drug|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
79520763|NCT03533244|Drug|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
79677007|NCT03143153|Drug|Fluorouracil|Specified dose on specified days
79677008|NCT03076242|Other|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
79677009|NCT02979574|Procedure|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
79367923|NCT03806218|Device|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
79677010|NCT02979574|Procedure|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
79996709|NCT03658746|Drug|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
79677011|NCT02979574|Device|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
79996710|NCT03658746|Drug|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
79996711|NCT02032862|Drug|Sage extract, 3400 mg , DER 1:17|
79225421|NCT02205255|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
79225422|NCT02205255|Drug|Placebo|
79225423|NCT02220153|Biological|UCB7665 Intravenous 1|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
79225424|NCT02220153|Biological|UCB7665 Intravenous 2|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
79225425|NCT02220153|Biological|UCB7665 Intravenous 3|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
79225426|NCT02220153|Biological|UCB7665 Intravenous 4|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
79367924|NCT03806218|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
79367925|NCT03806062|Drug|domperidone|10 mg domperidone 3 times a day after meals
79367926|NCT03806062|Device|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
79367927|NCT03806062|Device|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
79677012|NCT02927392|Drug|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
79367928|NCT04385914|Other|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
79367929|NCT00754156|Device|ABRA Abdominal Closure System|ABRA Abdominal Closure System
79367930|NCT00754156|Device|V.A.C. Therapy|V.A.C. Therapy Alone
79677013|NCT02914067|Other|Neurocognitive testing|
79996712|NCT03611192|Other|Multicomponent exercise|Aerobic exercise: 15~20 mins Resistance exercise: 15 mins Balance exercise: 15~20 mins Flexibility exercise: 10 mins
79225427|NCT02220153|Biological|UCB7665 Intravenous 5|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
79225428|NCT02220153|Biological|UCB7665 Subcutaneous 1|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: subcutaneous infusion"
79225429|NCT02220153|Biological|UCB7665 Subcutaneous 2|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: subcutaneous infusion"
79225430|NCT02220153|Biological|Intravenous Placebo|"Active substance: Placebo~Pharmaceutical form: solution~Concentration: 0.9 % saline~Route of Administration: intravenous infusion"
79367931|NCT00754156|Device|KCI ABThera|KCI ABThera
79677014|NCT02914067|Device|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
79677015|NCT02902757|Procedure|Computed Tomography|Undergo FDG PET/CT
79996713|NCT03611192|Other|Home-program exercise|60 mins exercise
79225431|NCT02220153|Biological|Subcutaneous Placebo|"Active substance: Placebo~Pharmaceutical form: solution~Concentration: 0.9 % saline~Route of Administration: subcutaneous infusion"
79225432|NCT04911582|Dietary Supplement|Cafestol 12 mg|Capsule with 12 mg cafestol
79367932|NCT03805984|Drug|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
79367933|NCT03805984|Drug|Placebo|Placebo will be administered ID on Day 0 and Week 4.
79367934|NCT03805984|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
79367935|NCT03805906|Procedure|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
79822437|NCT05685134|Device|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
79677016|NCT02902757|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
79996714|NCT02990910|Drug|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
79996715|NCT02990910|Device|conventional opioid analgesia|(b) all received 25μg/kg morphine
79367936|NCT03805828|Other|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
79367937|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
79367938|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
79677017|NCT02902757|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
79367939|NCT00754546|Drug|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
79367940|NCT00754546|Drug|Placebo: Normal Saline|Normal saline was nebulized.
79367941|NCT00754546|Other|Treadmill Exercise|
79677018|NCT02872116|Drug|Nivolumab|Specified dose on specified days
79677019|NCT02872116|Drug|Ipilimumab|Specified dose on specified days
79677020|NCT02872116|Drug|Oxaliplatin|Specified dose on specified days
79367942|NCT00754546|Other|Cycle Exercise|
79677021|NCT02872116|Drug|Capecitabine|Specified dose on specified days
79677022|NCT02872116|Drug|Leucovorin|Specified dose on specified days
79677023|NCT02872116|Drug|Fluorouracil|Specified dose on specified days
79677024|NCT02867384|Drug|Obinutuzumab|B cell depletion
79520764|NCT03533244|Drug|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
79520765|NCT03541356|Combination Product|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
79520766|NCT03541356|Combination Product|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
79822438|NCT00757185|Drug|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
79822439|NCT00757185|Drug|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
79996716|NCT04056000|Dietary Supplement|Caffeine|200 mg of caffeine, 60 minutes before exercise
79996717|NCT04056000|Dietary Supplement|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
79996718|NCT04056000|Behavioral|60-minutes of steady state exercise|See intervention name
79225433|NCT04911582|Dietary Supplement|Placebo|Placebo capsule without cafestol
79520767|NCT03541356|Combination Product|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
79520768|NCT03541356|Combination Product|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
79520769|NCT03541356|Combination Product|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
79520770|NCT03545412|Device|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
79520771|NCT03546270|Behavioral|Swimming|This group completed 20-weeks of swimming
79677025|NCT02867384|Drug|Placebo|Placebo
79677026|NCT02852486|Drug|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
79677027|NCT02852486|Other|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
79677028|NCT02828358|Drug|Azacitidine|Given IV
79225434|NCT04911582|Dietary Supplement|Cafestol 6 mg|Capsule with 6 mg cafestol
79225435|NCT03535389|Diagnostic Test|Knee 4DCT|Dynamic knee 4DCT
79225436|NCT03476772|Drug|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
79225437|NCT02220231|Procedure|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
79367943|NCT03806140|Behavioral|text messages|receive about one health-related text message a day for 16 weeks
79367944|NCT01764841|Drug|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
79367945|NCT01764841|Drug|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
79677029|NCT02828358|Drug|Cyclophosphamide|Given IV
79677030|NCT02828358|Drug|Cytarabine|Given IV, SC, IT
79677031|NCT02828358|Drug|Daunorubicin|Given IV
79677032|NCT02828358|Drug|Daunorubicin Hydrochloride|Given IV
79677033|NCT02828358|Drug|Dexamethasone|Given PO, NG, IV
79677034|NCT02828358|Drug|Hydrocortisone Sodium Succinate|Given IT
79677035|NCT02828358|Other|Laboratory Biomarker Analysis|Correlative studies
79677036|NCT02828358|Drug|Leucovorin|Given PO, IV
79822440|NCT04084808|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
79520772|NCT03549234|Drug|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
79367946|NCT00245050|Dietary Supplement|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
79225438|NCT03476694|Procedure|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
79520773|NCT03549234|Drug|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
79225439|NCT02220387|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
79225440|NCT02220387|Other|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
79225441|NCT04798872|Other|Web-based educational program|The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
79225442|NCT03535233|Drug|Triamcinolone Acetonide|
79225443|NCT03535233|Drug|Minoxidil 5 % Topical Spray|
79520774|NCT03557658|Drug|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
79677037|NCT02828358|Drug|Leucovorin Calcium|Given PO, IV
79677038|NCT02828358|Drug|Mercaptopurine|Given PO, NG
79677039|NCT02828358|Drug|Methotrexate|Given IT, IV, PO
79225444|NCT03535233|Drug|clobetasol propionate|
79367947|NCT00245050|Drug|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
79367948|NCT00245050|Drug|doxorubicin HCL liposome|IV, 40mg/m2
79367949|NCT04345588|Drug|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
79996719|NCT03611348|Drug|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
79367950|NCT00778648|Dietary Supplement|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
79225445|NCT04712292|Procedure|Surgical procedure for confirmed or suspected colorectal cancer|"Surgical procedure for cancer may include:~any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~surgery for radicalization of cancer polyps previously removed endoscopically~surgery for excision of large polyps which are not removable endoscopically~staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~palliative surgery (defined as any surgery with no curative intent)"
79225446|NCT02205411|Device|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
79225447|NCT02205411|Device|Control VAD|The HeartMate II® VAD or HVAD®
79225448|NCT02205489|Drug|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
79367951|NCT00778648|Dietary Supplement|Placebo|Four capsules of placebo daily.
79520775|NCT03564444|Biological|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
79225449|NCT02205489|Drug|cetirizine|Pharmaceutical form:tablet Route of administration: oral
79677040|NCT02828358|Drug|Pegaspargase|Given IV
79677041|NCT02828358|Other|Pharmacological Study|Correlative studies
79225450|NCT02205489|Drug|ranitidine|Pharmaceutical form:tablet Route of administration: oral
79225451|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
79367952|NCT03806374|Drug|Ketamine|ketamine
79367953|NCT03806374|Drug|Propofol|propofol
79367954|NCT03806374|Drug|Fentanyl|fentanyl
79367955|NCT03806374|Drug|Cisatracurium|cisatracurium
79367956|NCT03806374|Drug|Lidocaine|lidocaine
79367957|NCT00763360|Device|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
79367958|NCT00763360|Drug|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
79367959|NCT00763360|Drug|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
79367960|NCT00763750|Drug|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
79520776|NCT03564444|Other|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
79520777|NCT03567252|Behavioral|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
79520778|NCT03569748|Device|IQOS|IQOS USE FOR 12 WEEKS
79520779|NCT03569748|Device|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
79520780|NCT03572478|Drug|Rucaparib|600 mg taken by mouth twice daily.
79677042|NCT02828358|Drug|Prednisolone|Given PO, NG
79677043|NCT02828358|Drug|Thioguanine|Given PO, NG
79677044|NCT02828358|Drug|Vincristine|Given IV
79677045|NCT02828358|Drug|Vincristine Sulfate|Given IV
79677046|NCT02721732|Other|Laboratory Biomarker Analysis|Correlative studies
79677047|NCT02721732|Biological|Pembrolizumab|Given IV
79677048|NCT02721732|Other|Questionnaire Administration|Ancillary studies
79677049|NCT02679430|Device|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
79822441|NCT04084808|Behavioral|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
79822442|NCT04084808|Procedure|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). ] Measured with near-infrared spectroscopy (NIRS)."
79225452|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
79225453|NCT02205489|Drug|aciclovir|Pharmaceutical form:tablet Route of administration: oral
79225454|NCT02205489|Drug|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
79225455|NCT02205489|Drug|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
79225456|NCT02205489|Drug|paracetamol|Pharmaceutical form:tablet Route of administration: oral
79225457|NCT05230719|Procedure|Radial Artery Approach|dTRA or conventional TRA for radical artery approach
79225458|NCT02205567|Dietary Supplement|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
79225459|NCT02220465|Behavioral|PA+ Smoking Cessation (LMPA)|
79367961|NCT00756106|Drug|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
79520781|NCT03572478|Drug|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
79520782|NCT03574818|Drug|Necitumumab-Gemcitabine-Cisplatin|"Gemcitabine 1250mg/m2 IV on D1, D8~Cisplatin 75mg / m2 IV on D1~Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
79520783|NCT03574818|Diagnostic Test|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
79520784|NCT03575754|Device|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
79225460|NCT02220465|Behavioral|Standard Care Smoking Counseling (SCC)|
79225461|NCT02220543|Other|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
79367962|NCT00756106|Other|Imaging biomarker analysis|MRI
79367963|NCT00756106|Radiation|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
79520785|NCT03593538|Drug|Metformin|Metformin capsule
79520786|NCT03593538|Drug|Placebo|Sucrose filler in gel capsules
79520787|NCT03610464|Drug|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
79520788|NCT03613818|Behavioral|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
79520789|NCT03614130|Device|LID011121 contact lens|Investigational silicone hydrogel contact lens
79520790|NCT03614130|Device|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
79520791|NCT03618030|Drug|PRC-063 oral capsules|Daily dose
79225462|NCT02220543|Other|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
79225463|NCT02523846|Drug|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
79520792|NCT03618030|Drug|Placebo oral capsules|Daily dose
79367964|NCT00243412|Drug|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
79367965|NCT00243412|Drug|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
79367966|NCT00243412|Drug|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
79225464|NCT02523846|Behavioral|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
79822443|NCT04084808|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
79225465|NCT05262699|Device|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
79822444|NCT04084808|Procedure|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
79822445|NCT04084808|Behavioral|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, & Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
79225466|NCT05262699|Other|Placebo Control|Devices mounted, no stimulation
79367967|NCT00243412|Drug|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
79367968|NCT00243412|Drug|Rituximab|500 mg or 1000 mg IV*2.
79367969|NCT00765232|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
79367970|NCT00765232|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
79520793|NCT03619590|Other|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
79520794|NCT03623334|Radiation|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
79520795|NCT03630198|Drug|Corticosteroid with lidocaine|Intralesional corticosteroid injection
79520796|NCT03630198|Drug|Corticosteroid with normal saline|Intralesional corticosteroid injection
79520797|NCT03633084|Drug|RBM-007 Injectable Solution|(No additional description)
79677050|NCT02676050|Other|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
79677051|NCT02676050|Device|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
79677052|NCT02676050|Device|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
79677053|NCT02641145|Radiation|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
79677054|NCT02641145|Device|MRI|Cardiac MRI with gadolinium contrast.
79677055|NCT02641145|Radiation|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
79822446|NCT04084808|Behavioral|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
79822447|NCT00751413|Drug|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
79822448|NCT00757263|Genetic|polymorphism analysis|
79822449|NCT00757263|Other|laboratory biomarker analysis|
79822450|NCT00757263|Other|questionnaire administration|
79822451|NCT00919334|Device|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
79822452|NCT00751491|Drug|Adenosin|Intracoronary Adenosin 50 microg;
79822453|NCT00751491|Other|placebo|no intervention
79822454|NCT00751491|Drug|Clopidogrel|Clopidogrel 300/600 mg
79225467|NCT03480984|Other|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
79225468|NCT03480984|Other|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
79225469|NCT05224323|Other|Airway pressure, flow, esophageal pressure, ventilation distribution|After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.
79367971|NCT03805282|Drug|Lidocaine|Continuous infusion, variable dose of lidocaine.
79367972|NCT03805750|Drug|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
79367973|NCT03805750|Drug|Placebo oral capsule|Matched Placebo
79367974|NCT04385446|Procedure|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
79367975|NCT03804268|Other|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
79822455|NCT05685056|Behavioral|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
79225470|NCT03484260|Drug|Testosterone Product|Men used testosterone product following prescription
79225471|NCT03480906|Drug|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
79367976|NCT03804268|Drug|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
79367977|NCT00765856|Drug|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
79367978|NCT03805126|Behavioral|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
79367979|NCT03805126|Behavioral|Usual Care|Usual care includes consultation with a social worker and a community health worker.
79822456|NCT02561169|Drug|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
79225472|NCT03480906|Drug|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
79225473|NCT04527198|Diagnostic Test|Brainstem Responses Assessment Sedation Score (BRASS)|"It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning."
79225474|NCT04527198|Diagnostic Test|Electroencephalogram with EKG lead|"A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity)."
79225475|NCT05262465|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
79225476|NCT05262465|Drug|Azacitidine|azacytidine 50-75mg/m2
79225477|NCT05262465|Drug|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
79225478|NCT02205645|Device|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
79225479|NCT02193321|Biological|Amniotic Membrane Patch|
79225480|NCT02220621|Device|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
79225481|NCT02220621|Device|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
79367980|NCT00756496|Device|Mammography screening and diagnosis|Mammography screening and diagnosis
79520798|NCT03637296|Other|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
79677056|NCT02598219|Drug|Pre-operative SN mapping with radionucleide|"Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
79520799|NCT03637842|Drug|Lorcaserin|Lorcaserin XR 20mg per day
79822457|NCT02561169|Other|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
79225482|NCT04370418|Drug|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
79225483|NCT02220777|Drug|ASP8477|oral
79520800|NCT03637842|Drug|Placebo oral capsule|Placebo
79520801|NCT03638622|Combination Product|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
79677057|NCT02598219|Drug|Intra-operative SN mapping with patent V blue dye|"Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~SN are detected by direct visualization of blue colored lymphatics and node"
79225484|NCT02220777|Drug|omeprazole|oral
79225485|NCT02220777|Drug|Placebo|oral
79225486|NCT03484104|Diagnostic Test|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
79520802|NCT03643692|Device|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
79520803|NCT03645954|Procedure|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
79520804|NCT03645954|Procedure|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle & Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
79520805|NCT03647046|Device|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
79520806|NCT03649932|Dietary Supplement|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
79520807|NCT03655080|Radiation|Radiation therapy|Using the View Ray System
79225487|NCT02205723|Behavioral|Asthma teaching in ER|Asthma teaching
79225488|NCT02205723|Behavioral|Smartphone Asthma Control|Smartphone Asthma Control
79225489|NCT03484026|Dietary Supplement|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
79520808|NCT03655080|Drug|nab-Paclitaxel|"Dose 15 mg/m^2~Should be administered by IV over 30 minutes"
79520809|NCT03663816|Device|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
79225490|NCT02258295|Drug|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
79367981|NCT00780208|Drug|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
79367982|NCT00243022|Drug|Boswellia serrata extract|given orally
79367983|NCT00243022|Dietary Supplement|cyanocobalamin|given orally
79677058|NCT02598219|Drug|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
79822458|NCT00753597|Drug|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
79822459|NCT00751569|Other|blood donation|obtaining cord blood
79822460|NCT00757341|Drug|SKI-606|
79225491|NCT02258295|Drug|Saline|Saline
79225492|NCT03476616|Drug|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM.
79228150|NCT03916731|Device|STARgraft AV|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
79367984|NCT03805360|Drug|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
79367985|NCT03805360|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
79520810|NCT03674970|Drug|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
79520811|NCT03679494|Other|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
79520812|NCT03685968|Device|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
79520813|NCT03687450|Behavioral|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga & Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
79520814|NCT03687684|Drug|TAK-831|TAK-831 Tablets.
79520815|NCT03687684|Drug|Placebo|TAK-831 Matching Placebo Tablets.
79367986|NCT03805048|Procedure|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
79520816|NCT03688542|Other|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
79520817|NCT03697122|Device|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
79677059|NCT02598219|Procedure|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
79677060|NCT02598219|Procedure|Current initial staging protocols|Current French initial staging protocols
79677061|NCT02592824|Drug|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
79677062|NCT02592824|Drug|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
79996720|NCT03611348|Device|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
79996721|NCT04055532|Other|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
79225493|NCT03476616|Drug|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM.
79996722|NCT04055064|Dietary Supplement|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
79996723|NCT02033018|Drug|Aflibercept Injection|Aflibercept intravitreal injection
79996724|NCT02033096|Drug|Stannsoporfin|No intervention was administered during this observational study
79996725|NCT02033096|Drug|Placebo Control|No intervention was administered during this observational study
79996726|NCT02033096|Other|Phototherapy (as needed)|No intervention was administered during this observational study
79996727|NCT03661164|Procedure|corneal cross linking|Iontophoretic corneal cross linking
79996728|NCT03658590|Drug|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
79677063|NCT02551068|Other|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
79677064|NCT02551068|Other|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
79677065|NCT02519140|Drug|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
79677066|NCT02446262|Behavioral|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
79520818|NCT03704376|Drug|30 ml of 0.2% ropivacaine|
79520819|NCT03704376|Drug|15 ml of 0.2% ropivacaine|
79225494|NCT02220933|Drug|MD1003 100mg capsule|
79225495|NCT02220933|Drug|Placebo|
79367987|NCT03801772|Device|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
79996729|NCT03658590|Drug|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
79996730|NCT03622476|Drug|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
79996731|NCT03658434|Radiation|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
79996732|NCT03227861|Drug|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
79225496|NCT04248972|Device|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
79367988|NCT00756964|Drug|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
79367989|NCT00756964|Drug|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
79367990|NCT00780442|Drug|D-cycloserine|50 mg DCS
79520820|NCT03704376|Drug|100 mcg clonidine|
79520821|NCT03704376|Device|High-frequency linear ultrasound transducer|
79520822|NCT03711396|Behavioral|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
79677067|NCT02446262|Behavioral|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
79677068|NCT02446262|Behavioral|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
79677069|NCT02446262|Behavioral|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
79677070|NCT02414399|Drug|Azithromycin|oral administration of Azithromycin
79677071|NCT02414399|Drug|Placebo|5 days of taste/appearance/bottle-matched inactive substance
79996733|NCT03451955|Other|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
79996734|NCT03428945|Drug|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
79996735|NCT03428945|Drug|Placebo|Placebo tablet identical to active drug
79225497|NCT04248972|Other|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
79225498|NCT02205879|Drug|Pregabalin|
79225499|NCT02205879|Drug|Placebo|
79225500|NCT05007756|Radiation|UVB Challenge|UVB challenge will be administered dermally through Lumera Phototherapy System.
79367991|NCT00780442|Drug|Placebo|Placebo
79367992|NCT00767338|Behavioral|Timed intercourse|Timed intercourse
79367993|NCT00767338|Procedure|Microsurgical varicocelectomy|Microsurgical varicocelectomy
79367994|NCT00767338|Procedure|Intrauterine insemination|Intrauterine insemination
79367995|NCT04384666|Drug|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
79367996|NCT04384666|Other|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
79367997|NCT00767572|Drug|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
79367998|NCT00767572|Drug|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
79367999|NCT00240370|Drug|Muraglitazar|
79368000|NCT03804736|Biological|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
79677072|NCT02363374|Drug|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
79520823|NCT03715452|Device|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
79677073|NCT02363374|Radiation|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
79677074|NCT02363374|Radiation|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
79677075|NCT02363374|Drug|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
79677076|NCT02363374|Procedure|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
79677077|NCT02348112|Device|Altis Single Incision Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
79677078|NCT02348112|Device|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
79677079|NCT02314481|Drug|MPDL3280A|Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
79822461|NCT00751647|Other|Physical Therapy|Treatment
79225501|NCT02193399|Other|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
79368001|NCT03804736|Biological|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
79368002|NCT04384588|Biological|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
79677080|NCT02314481|Drug|Vemurafenib|Film coated tablet
79677081|NCT02314481|Drug|Alectinib|capsule
79677082|NCT02314481|Drug|Trastuzumab emtansine|Powder for concentrate for solution for infusion
79368003|NCT00780676|Drug|Dasatinib|100 mg tablet by mouth daily
79368004|NCT00780676|Drug|AZD6244|75 mg by mouth twice daily.
79677083|NCT02307630|Biological|124I-Humanized 3F8|
79677084|NCT02286726|Other|Laboratory Biomarker Analysis|Correlative studies
79677085|NCT02286726|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79822462|NCT00757419|Drug|AZD3355|capsules, oral, single or twice daily dose
79996736|NCT05181059|Diagnostic Test|Dual-layer spectral computerized tomography (DLSCT)|Contrast enhanced DLSCT scan using a 128-slice dual-layer detector (IQon Spectral CT, Philips Health Systems) will be performed. Patients will be placed in prone position during the DLSCT scan in order to improve the visualisation of breast tissue and comparability with MRI images. During the examination we will administer a nonionic low-osmolar iodinated contrast agent (Optiray©) in order to visualise tumor angiogenesis.
79520824|NCT03716076|Drug|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
79225502|NCT03480828|Diagnostic Test|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
79225503|NCT05262309|Drug|Pamrevlumab|"Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks."
79225504|NCT03483948|Drug|HMPL-523|HMPL-523 tablet
79225505|NCT03483948|Drug|Azacitidine|Azacitidine Injection
79677086|NCT02217540|Other|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
79822463|NCT00757419|Drug|Placebo|To match dosing of AZD3355
79822464|NCT00757497|Behavioral|Electrical Polarization|
79822465|NCT00757653|Device|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
79822466|NCT00757653|Device|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
79822467|NCT00757653|Device|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
79822468|NCT03877887|Diagnostic Test|echo cardiogram|Assessment of left ventricular systolic and diastolic function
79822469|NCT00757731|Drug|milnacipran|hard capsule
79822470|NCT00757731|Drug|Placebo|hard capsule
79822471|NCT00757809|Drug|neratinib|HKI-272
79822472|NCT00753831|Procedure|Aurosling|Silicon rod to be used in frontalis suspension surgery
79822473|NCT00753909|Drug|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
79822474|NCT00753909|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
79822475|NCT00753909|Drug|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
79822476|NCT04015544|Dietary Supplement|Watermelon|Pureed whole (100%) watermelon
79996737|NCT03409289|Device|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
79520825|NCT03835728|Drug|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
79520826|NCT03835728|Drug|Saline|This will be the matching placebo used in the study.
79520827|NCT03848910|Device|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
79677087|NCT02217540|Other|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
79677088|NCT02174666|Dietary Supplement|Red clover extract|Aglycone isoflavones 80mg/d
79677089|NCT02174666|Dietary Supplement|Supplementation (placebo)|
79996738|NCT05180747|Other|Frequency of physical therapy sessions|Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
79225506|NCT02221011|Device|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
79225507|NCT02221089|Drug|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
79225508|NCT02221089|Dietary Supplement|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
79677090|NCT02074631|Drug|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
79677091|NCT02074631|Drug|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
79677092|NCT02004691|Drug|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
79677093|NCT02004691|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
79677094|NCT01991379|Drug|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
79677095|NCT01991379|Drug|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
79677096|NCT01991379|Other|Blood draws|
79677097|NCT01991379|Procedure|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
79677098|NCT01936935|Other|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
79677099|NCT01936935|Other|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
79996739|NCT01336712|Procedure|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
79996740|NCT03208127|Drug|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
79996741|NCT02865122|Drug|NTRA-9620|Oral daily dose
79225509|NCT02221089|Other|Placebo|Placebo capsules identical in appearance to Retaron capsules
79368005|NCT03800212|Drug|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
79368006|NCT03806998|Dietary Supplement|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
79368007|NCT03806998|Dietary Supplement|Placebo|Provision of placebo capsules similar to active supplement
79368008|NCT03804502|Device|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
79520828|NCT03861780|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
79520829|NCT03861780|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
79677100|NCT01893710|Procedure|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
79677101|NCT01859858|Dietary Supplement|curcumin|
79996742|NCT02865122|Drug|Placebo|Oral daily dose
79677102|NCT01859858|Drug|Irinotecan|
79520830|NCT03861780|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
79225510|NCT03483870|Drug|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
79520831|NCT03889158|Biological|Typhoid Vaccine|All participants will receive the typhoid vaccine.
79677103|NCT01739062|Genetic|Genetic risk assessment|
79677104|NCT01613118|Drug|RE-021 (Sparsentan)|Oral, once-daily
79677105|NCT01613118|Drug|Irbesartan|Oral, once-daily
79225511|NCT03483870|Drug|Placebo|2 mL of normal saline 0.9% IV injection
79225512|NCT03483870|Drug|Granisetron|2 mL of 2 mg granisetron IV injection
79677106|NCT01470105|Other|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
79677107|NCT01416077|Other|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~Crystalloid infusion (2,5 ml/kg/t) throughout surgery~3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase > 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI > 2,5.~If despite CI > 2,5 Mean Arterial Pressure <65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
79677108|NCT01300962|Drug|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
79677109|NCT01300962|Drug|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
79677110|NCT01300962|Drug|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
79677111|NCT01300962|Drug|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
79677112|NCT01300962|Drug|Lapatinib|lapatinib daily for 21 days in each cycle.
79225513|NCT02221167|Other|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
79225514|NCT02523612|Procedure|Biopsy|
79225515|NCT02523612|Procedure|Blood sample|
79225516|NCT02221245|Procedure|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
79225517|NCT03483792|Biological|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
79368009|NCT03804658|Device|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
79368010|NCT00768118|Dietary Supplement|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
79520832|NCT03889158|Dietary Supplement|Ascorbic Acid|All participants will receive ascorbic acid.
79677113|NCT01107340|Device|AMIStem Hip System|
79677114|NCT00752479|Biological|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
79996743|NCT05383430|Diagnostic Test|: Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment
79996744|NCT03611114|Dietary Supplement|Blood orange juice|
79996745|NCT03611114|Dietary Supplement|Control drink|
79996746|NCT02033330|Dietary Supplement|phenolics form orange peel|
79996747|NCT03611036|Other|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
79368011|NCT00768118|Genetic|electrophoretic mobility shift assay|
79368012|NCT00768118|Other|laboratory biomarker analysis|
79520833|NCT04018794|Device|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
79520834|NCT04096482|Device|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
79520835|NCT04096482|Device|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
79520836|NCT04138758|Drug|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
79520837|NCT04138758|Drug|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
79677115|NCT00752479|Drug|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
79996748|NCT03611036|Other|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
79996749|NCT03610958|Device|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
79520838|NCT04323852|Drug|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
79520839|NCT04323852|Drug|Placebo|Placebo
79520840|NCT04381728|Device|Womed Leaf|Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
79520841|NCT04420572|Drug|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
79520842|NCT04420572|Drug|betamethasone|1ml betamethasone will be used for steroid injection.
79520843|NCT04709484|Drug|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
79520844|NCT04709484|Drug|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
79520845|NCT03541980|Drug|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
79520846|NCT03541980|Drug|Normal saline|Normal saline volume equivalent
79520847|NCT04511520|Other|Physical training program|
79996750|NCT04603157|Behavioral|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
79996751|NCT05453747|Other|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
79996752|NCT05453747|Other|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
79996753|NCT05432687|Diagnostic Test|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
79225518|NCT03483792|Genetic|placental biopsy|Immediately following delivery (<12h postpartum), placental biopsies (Collection of 4 placental fragments)
79225519|NCT05262153|Procedure|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
79225520|NCT04960254|Behavioral|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy & Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
79225521|NCT02221323|Drug|Insulin LISPRO|
79225522|NCT03483714|Procedure|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
79368013|NCT04278586|Behavioral|Live-Online M-ROCC|"LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
79520848|NCT04511520|Drug|Trimetazidine|
79520849|NCT04491240|Drug|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.
79520850|NCT04491240|Drug|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.
79520851|NCT04491240|Drug|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
79520852|NCT04463004|Drug|Mavrilimumab|Treatment infusion
79520853|NCT04463004|Drug|Placebos|Placebo infusion
79520854|NCT04430634|Other|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
79520855|NCT04430634|Other|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
79520856|NCT04430634|Other|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
79520857|NCT04430634|Other|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
79520858|NCT04430634|Other|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
79520859|NCT04430634|Other|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
79520860|NCT04430634|Other|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
79520861|NCT04430634|Other|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
79996754|NCT03913481|Procedure|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
79225523|NCT02193477|Device|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
79368014|NCT04278586|Behavioral|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
79520862|NCT04429932|Other|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
79225524|NCT02193477|Device|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
79225525|NCT03480516|Device|SDF|38% silver diamine fluoride solution
79225526|NCT03480516|Device|Fluoride varnish|5% sodium fluoride varnish
79520863|NCT04429932|Other|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
79520864|NCT04429932|Other|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
79520865|NCT04429932|Other|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
79520866|NCT04429932|Other|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
79520867|NCT04429932|Other|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
79520868|NCT04429932|Other|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
79520869|NCT04429932|Other|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
79225527|NCT03476460|Drug|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
79225528|NCT03476460|Drug|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
79225529|NCT02193555|Device|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
79225530|NCT02206113|Behavioral|Standing workstation|
79996755|NCT03913481|Procedure|Standard care|Best available treatment without ANH
79996756|NCT03661944|Diagnostic Test|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
79996757|NCT02864498|Drug|DS107|
79996758|NCT02864498|Drug|Placebo|
79996759|NCT03238781|Drug|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
79225531|NCT03131076|Diagnostic Test|IPMN follow up|Follow up with MRI and laboratory blood tests
79225532|NCT02221401|Drug|Linagliptin/Metformin FDC|
79225533|NCT02221401|Drug|Linagliptin|
79520870|NCT04409886|Biological|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
79520871|NCT04399980|Drug|Mavrilimumab|Treatment infusion
79520872|NCT04399980|Drug|Placebos|Placebo infusion
79520873|NCT04397094|Drug|Theracal LC|pulpotomy
79520874|NCT04397094|Drug|Formocresol|Pulpotomy
79520875|NCT04385238|Other|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
79520876|NCT04383132|Device|Abdominal Binder|abdominal binder is a kind of elastic abdominal compression device
79520877|NCT04335552|Other|Standard of care|Standard of care
79520878|NCT04335552|Drug|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
79520879|NCT04335552|Drug|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
79996760|NCT03238781|Drug|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
79996761|NCT02033408|Drug|AB (antibiotics)|"PO Vancomycin 250mgX4/d for 3 weeks~PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
79996762|NCT02033408|Drug|CS (corticosteroids) Only|"methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
79225534|NCT02221401|Drug|Metformin|
79225535|NCT03483636|Drug|Lemborexant|Film-coated oral tablet
79520880|NCT04321980|Drug|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
79520881|NCT04288752|Device|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
79368015|NCT04275076|Procedure|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
79225536|NCT03483636|Drug|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
79368016|NCT04273438|Device|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
79996763|NCT02033252|Device|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
79996764|NCT03610880|Drug|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
79996765|NCT03610880|Drug|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
79996766|NCT02097121|Biological|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
79225537|NCT03483636|Drug|Placebo|Film-coated oral tablet
79368017|NCT04273438|Device|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
79368018|NCT03809572|Behavioral|Mindfulness Based Cognitive Therapy|See Arm description
79368019|NCT04274218|Other|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
79368020|NCT05744284|Device|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
79225538|NCT03483558|Other|Control|A standardized diet without any vegetables was provided.
79225539|NCT03483558|Other|Spinach|A standardized diet with 200g spinach was provided.
79225540|NCT03483558|Other|Celery|A standardized diet with 200g celery was provided.
79225541|NCT03483558|Other|Onion|A standardized diet with 200g onion was provided.
79368021|NCT05744206|Other|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
79368022|NCT04345432|Drug|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
79225542|NCT03483558|Other|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
79368023|NCT03803410|Procedure|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
79368024|NCT05744128|Biological|Zirconium 89Zr crefmirlimab berdoxam|Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
79996767|NCT02033486|Device|TOBI + DBT|
79368025|NCT05744050|Behavioral|Low energy density lunch|Particpants will be provided with a lunch low in energy density (~1.1kcal/g)
79368026|NCT05744050|Behavioral|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(~1.7kcal/g)
79368027|NCT05744050|Behavioral|High energy density lunch|Participants will be provided with a lunch high in energy density (~3kcal/g)
79520882|NCT04288752|Device|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
79520883|NCT04287036|Device|JJVC Investigational Contact Lens|TEST
79225543|NCT02221479|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
79225544|NCT02221479|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
79225545|NCT03476382|Device|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
79225546|NCT02206269|Device|Alair System|The Alair system is used for doing bronchial thermoplasty.
79225547|NCT03476304|Device|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
79368028|NCT03804190|Other|questionaire|dutch musculoskeletal questionaire
79368029|NCT00757666|Device|Rate adaptive pacemaker|Accelerometer sensor
79368030|NCT00757666|Device|Rate adaptive pacemaker|Minute ventilation sensor
79520884|NCT04287036|Device|1-DAY ACUVUE® DEFINE® Radiant Sweet™|CONTROL
79520885|NCT04284930|Drug|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
79368031|NCT03803956|Device|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
79368032|NCT03803956|Device|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
79677116|NCT00732212|Device|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
79822477|NCT00685035|Device|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
79822478|NCT00685035|Device|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
79225548|NCT03476304|Device|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
79225549|NCT03476304|Device|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
79228151|NCT03916731|Device|ePTFE AV graft (control)|Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
79368033|NCT01736683|Drug|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
79368034|NCT05743972|Diagnostic Test|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
79368035|NCT05743972|Diagnostic Test|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
79368036|NCT00757822|Drug|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
79368037|NCT00757822|Drug|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
79368038|NCT04561765|Device|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
79368039|NCT04561765|Device|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
79368040|NCT01788163|Genetic|EGFR mutation test|EGFR mutation being tested in tissue and blood
79368041|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
79368042|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
79520886|NCT04284930|Drug|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
79520887|NCT04284930|Drug|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
79520888|NCT04267770|Drug|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
79520889|NCT04267770|Drug|Insulin (flat rate)|Participant's own insulin set to flat basal rates
79520890|NCT04252092|Other|Sensory training|15 session,20 minutes sensory training program
79520891|NCT04252092|Other|Electrical stimulation|15 session,20 minutes electrical stimulation program
79520892|NCT04204200|Dietary Supplement|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
79677117|NCT00732212|Other|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage & visual cues for risk stratification and completion of endoscopic treatment.
79677118|NCT00592280|Drug|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
79822479|NCT02560857|Other|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
79225550|NCT02224833|Behavioral|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~Determination of recommended pharmacotherapeutic alternatives.~Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
79368043|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
79368044|NCT00783952|Device|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
79368045|NCT00783952|Device|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
79368046|NCT00784030|Other|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
79368047|NCT03803644|Drug|CC-92480|Part 1 dose escalation
79368048|NCT03803644|Drug|CC-92480|CC-92480
79368049|NCT01787461|Dietary Supplement|Imedeen|Two tablets per day for 6 months
79368050|NCT01787461|Dietary Supplement|Placebo|Two tablets per day for 6 months
79368051|NCT03803488|Device|DropSafe safety pen needle|
79368052|NCT03803722|Device|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
79368053|NCT00758836|Drug|placebo|
79520893|NCT04204200|Dietary Supplement|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
79520894|NCT04204200|Dietary Supplement|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
79996768|NCT05298215|Biological|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
79520895|NCT04179474|Drug|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily [Intervention A=single dose and Intervention D=repeated daily dose].
79225551|NCT02221635|Procedure|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
79822480|NCT00753987|Drug|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
79996769|NCT05298215|Other|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
79520896|NCT04179474|Drug|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg [Intervention B].
79520897|NCT04179474|Drug|Galcanezumab|2 SC injections of galcanezumab 120 mg [Intervention C].
79225552|NCT02221635|Drug|Risperidone|Risperidone (2-4 mg) was took orally.
79368054|NCT00758836|Drug|ibuprofen|
79822481|NCT00757887|Biological|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
79368055|NCT00758836|Drug|acetominophen|
79822482|NCT00757965|Genetic|polymorphism analysis|
79822483|NCT00757965|Other|laboratory biomarker analysis|
79822484|NCT00757965|Other|questionnaire administration|
79368056|NCT00758836|Drug|telcagepant|
79368057|NCT03809806|Procedure|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
79368058|NCT03809806|Diagnostic Test|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
79368059|NCT03809806|Diagnostic Test|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
79368060|NCT03809806|Diagnostic Test|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
79368061|NCT03809806|Diagnostic Test|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
79368062|NCT03809806|Diagnostic Test|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
79368063|NCT03803800|Other|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
79822485|NCT05435079|Device|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher & Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
79996770|NCT02747420|Device|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
79225553|NCT04832334|Other|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
79225554|NCT04832334|Other|Berg Balance Scale, Functional Reach Test|Balance level was determined.
79225555|NCT04832334|Other|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
79225556|NCT02224911|Device|Laser Interstitial Thermal Therapy|
79677119|NCT00592280|Device|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
79520898|NCT04174638|Other|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
79520899|NCT04152642|Device|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
79520900|NCT04152642|Other|Water control|negative control
79677120|NCT00589875|Biological|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
79677121|NCT00589875|Drug|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
79822486|NCT02560155|Drug|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
79520901|NCT04152642|Device|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
79677122|NCT00589875|Drug|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
79822487|NCT02560155|Drug|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
79225557|NCT03483480|Procedure|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
79225558|NCT03483480|Procedure|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
79225559|NCT02230917|Drug|Sotatercept|
79225560|NCT02230917|Drug|Placebo|
79225561|NCT02224989|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
79225562|NCT03483402|Procedure|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
79225563|NCT02723864|Drug|Veliparib + VX-970 + Cisplatin|Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
79225564|NCT02221791|Dietary Supplement|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
79225565|NCT02221791|Dietary Supplement|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
79225566|NCT02221791|Dietary Supplement|Placebo|Participants will consume 70g white chocolate + placebo capsules
79225567|NCT03476148|Device|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
79225568|NCT03476148|Other|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
79225569|NCT02231073|Behavioral|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
79225570|NCT05138757|Drug|Prebiotic|A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
79225571|NCT05138757|Drug|Placebo|A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
79368064|NCT03803800|Other|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
79225572|NCT03483168|Behavioral|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
79225573|NCT03483168|Behavioral|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
79225574|NCT02231151|Behavioral|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
79368065|NCT03803800|Dietary Supplement|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
79368066|NCT04384432|Other|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
79520902|NCT04150224|Drug|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
79225575|NCT05259618|Other|Tasso+ SST|alternative site blood sample collection.
79225576|NCT02231229|Other|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
79822488|NCT05331638|Behavioral|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
79822489|NCT05331638|Behavioral|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
79822490|NCT00758121|Device|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
79225577|NCT02231229|Drug|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
79225578|NCT02523456|Behavioral|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
79225579|NCT02523456|Behavioral|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
79368067|NCT04384432|Other|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
79520903|NCT04150224|Drug|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
79520904|NCT04150224|Drug|PBTZ169 960 mg SD|Once a day fasted
79520905|NCT04150224|Drug|PBTZ169 1280 mg SD|Once a day fasted
79520906|NCT04150224|Drug|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
79520907|NCT04116684|Device|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
79520908|NCT04102956|Drug|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
79520909|NCT04086576|Device|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
79520910|NCT04086576|Device|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
79368068|NCT01786993|Device|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
79368069|NCT01786993|Device|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
79368070|NCT00769600|Drug|Itraconazole|Itraconazole 200 mg once daily
79225580|NCT02225067|Drug|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
79225581|NCT00705146|Device|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
79368071|NCT00769600|Drug|Pemetrexed|Pemetrexed every 21 days.
79368072|NCT05743894|Device|Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter|Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled. The RDN works mainly by selectively ablating the sympathetic fibres around the renal arteries and damping the sympathetic overdrive. Blood pressure response by renal nerve stimulation (RNS) during the RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the intra-procedure efficacy and predict the BP response 6 months after RDN
79368073|NCT03809650|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
79677123|NCT00589875|Radiation|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
79822491|NCT02559921|Biological|rhRIG（20 IU/kg）|
79822492|NCT02559921|Biological|rhRIG（40 IU/kg）|
79225582|NCT00705146|Device|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
79225583|NCT03483090|Dietary Supplement|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
79677124|NCT00503594|Drug|Methotrexate and temozolomide|Methotrexate and temozolomide
79677125|NCT00503594|Drug|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
79677126|NCT04696302|Behavioral|Focus of attention|Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
79677127|NCT05146791|Procedure|Inlay Bristow|A modified Bristow procedure
79677128|NCT05146791|Procedure|Bristow|Traditional Bristow procedure
79677129|NCT00499811|Drug|vorinostat|Given orally
79822493|NCT02559921|Biological|HRIG（20 IU/kg）|
79225584|NCT03483090|Other|Placebo|No therapeutic effect
79368074|NCT01966445|Biological|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
79368075|NCT03809494|Device|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
79368076|NCT03809494|Other|Saline|Normal (0.9%) saline
79368077|NCT04384042|Other|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
79368078|NCT03809260|Drug|Metformin (part 1)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
79368079|NCT03809260|Drug|Vancomycin|11d: Vancomycin 250 mg bid, 12~17d: Vancomycin 500 mg bid
79368080|NCT03809260|Drug|Metformin (part 2)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
79677130|NCT00499811|Other|pharmacological study|Correlative studies
79822494|NCT02559921|Biological|rhRIG（20 IU/kg） and vaccine|
79822495|NCT02559921|Biological|rhRIG（40 IU/kg） and vaccine|
79822496|NCT02559921|Biological|HRIG（20 IU/kg） and vaccine|
79822497|NCT02559921|Biological|placebo and vaccine|
79822498|NCT00754143|Drug|FG-3019|Placebo every 2 weeks IV for all infusions
79822499|NCT00754143|Drug|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
79822500|NCT00754143|Drug|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
79822501|NCT02588768|Device|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
79822502|NCT04083248|Behavioral|Feasibility group|Same as arm description
79996771|NCT02747420|Device|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
79996772|NCT03238001|Device|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
79228152|NCT00705224|Biological|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
79368081|NCT01763905|Biological|Evolocumab|Subcutaneous injection
79368082|NCT01763905|Drug|Placebo to Evolocumab|Subcutaneous injection
79368083|NCT01763905|Drug|Ezetimibe|Tablet for oral administration
79368084|NCT01763905|Drug|Placebo to Ezetimibe|Tablet for oral administration
79368085|NCT02091167|Device|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
79368086|NCT03803254|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
79368087|NCT03803254|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
79368088|NCT03803254|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79368089|NCT03803254|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
79368090|NCT02091089|Device|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
79368091|NCT03803176|Procedure|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
79368092|NCT04730999|Drug|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
79520911|NCT04086576|Device|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
79520912|NCT04086576|Device|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
79520913|NCT04086576|Device|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
79520914|NCT04086576|Device|Floome|Floome branded smartphone-paired breathalyzer
79368093|NCT04730999|Drug|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
79368094|NCT04730999|Drug|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
79520915|NCT04086576|Device|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
79520916|NCT04075812|Device|Neuromuscular Stimulator|
79520917|NCT04061694|Procedure|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
79520918|NCT04061694|Procedure|Immediate loading|Only subjected to immediate loading. Conventional procedure.
79520919|NCT04057248|Device|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
79520920|NCT04057248|Behavioral|CDE|Certified Diabetes Educator Sessions
79520921|NCT04053270|Drug|Afamelanotide|16mg subcutaneous implant
79520922|NCT04053270|Drug|Placebo|Placebo subcutaneous implant
79520923|NCT04051710|Drug|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
79822503|NCT05266040|Drug|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
79368095|NCT04730999|Drug|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
79520924|NCT04051710|Drug|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
79822504|NCT05266040|Drug|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
79520925|NCT04051710|Drug|Placebo|Placebo Product
79996773|NCT02747108|Behavioral|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
79520926|NCT04047342|Behavioral|Welcome email|Email
79996774|NCT02747108|Behavioral|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
79996775|NCT05256095|Behavioral|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
79225585|NCT02222025|Other|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
79520927|NCT04047342|Behavioral|Loss frame|Email
79520928|NCT04022694|Behavioral|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
79520929|NCT04022694|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
79520930|NCT04015440|Behavioral|HBMT|Individual is presented with words with some letters missing and told to complete the word.
79520931|NCT04015440|Behavioral|Other Training|Alternative to HBMT training
79520932|NCT04030104|Device|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
79520933|NCT04030104|Device|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
79520934|NCT04030104|Device|Mammography|Mammography as available per standard of care
79996776|NCT02075671|Drug|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
79996777|NCT02075671|Device|Blu-U Light Therapy|Intervention used in experimental and sham arms
79996778|NCT02075671|Other|Placebo vehicle only|Intervention only includes the placebo vehicle solution
79996779|NCT02560298|Drug|Capecitabine|
79996780|NCT02560298|Drug|Carboplatin|Given IV
79996781|NCT02560298|Drug|Cisplatin|Given IV
79520935|NCT04027218|Device|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
79520936|NCT04027218|Device|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
79520937|NCT04027218|Device|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
79520938|NCT04026750|Drug|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
79225586|NCT03475836|Dietary Supplement|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
79368096|NCT00759772|Drug|Placebo|sc daily for 6 months
79368097|NCT00759772|Drug|Teriparatide|20 mcg sc daily for 6 months
79520939|NCT04020822|Device|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
79520940|NCT03979872|Diagnostic Test|MC1R Genetic Testing|[See arm/group descriptions]
79822505|NCT02588924|Other|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
79677131|NCT05146752|Device|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
79520941|NCT03979872|Other|Skin Cancer Education|[See arm/group descriptions]
79520942|NCT03979872|Device|UV Photo|[See arm/group descriptions]
79520943|NCT03993210|Device|Magnetic Resonance Fingerprinting (MRF)|In MRF, multiple tissue properties are acquired simultaneously.
79368098|NCT01763203|Behavioral|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
79520944|NCT03993210|Device|Q-space Trajectory Imaging (QTI)|By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
79520945|NCT03993210|Device|Magnetic Resonance Imaging Machine (MRI)|MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
79996782|NCT02560298|Drug|Fluorouracil|Given IV
79225587|NCT03475836|Dietary Supplement|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
79225588|NCT02225379|Device|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
79368099|NCT01763203|Behavioral|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
79520946|NCT03988374|Drug|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
79520947|NCT03976752|Drug|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
79225589|NCT03482934|Device|sphygmomanometer|device used for measurement of brachial blood pressure
79225590|NCT03482934|Device|mobilogragh|device used for measurement of central blood pressure
79225591|NCT03482934|Diagnostic Test|ECG|Electrocardiogram
79225592|NCT03482934|Diagnostic Test|Echocardiography|Echocardiography
79368100|NCT00771238|Device|P500 Mattress|Study mattress
79368101|NCT03809416|Device|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
79368102|NCT03809416|Other|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
79368103|NCT03809416|Combination Product|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
79368104|NCT03802942|Dietary Supplement|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
79368105|NCT03803098|Device|reference measure|measure of a physiological parameter performed with the gold standard medical device
79520948|NCT03974802|Device|somofilcon A contact lens|Contact Lens
79520949|NCT03974802|Device|fanfilcon A contact lens|Contact Lens
79520950|NCT03966924|Device|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
79520951|NCT03965754|Behavioral|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
79677132|NCT05146752|Other|routine care|routine care
79677133|NCT00503711|Drug|Vandetanib|100 mg every other day, 100mg once daily
79677134|NCT00503711|Drug|Vandetanib 300 mg|300mg once daily
79677135|NCT03451188|Device|Cerecare compression garments|all Cerecare compression garments
79677136|NCT00499850|Drug|ZD6474 (vandetanib)|once daily oral dose
79677137|NCT00499850|Drug|5-Fluorouracil|intravenous infusion
79677138|NCT00499850|Drug|Leucovorin|intravenous infusion
79677139|NCT00499850|Drug|Oxaliplatin|intravenous infusion
79822506|NCT02588924|Other|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
79822507|NCT05325710|Behavioral|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
79822508|NCT00773747|Drug|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
79822509|NCT00773747|Drug|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
79996783|NCT02560298|Other|Laboratory Biomarker Analysis|Correlative studies
79996784|NCT02560298|Drug|Paclitaxel|Given IV
79996785|NCT02560298|Other|Quality-of-Life Assessment|Ancillary studies
79822510|NCT00773747|Drug|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
79225593|NCT02231307|Drug|SUBLIVAC FIX Birch|
79368106|NCT03803098|Device|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
79677140|NCT05146713|Dietary Supplement|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
79368107|NCT01763047|Device|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
79368108|NCT01763047|Device|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
79225594|NCT03475758|Drug|Goserelin|adding goserelin with chemotherapy
79225595|NCT03479970|Other|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
79225596|NCT03479970|Other|GNPT|It's a computeritzed program of cognitive telerehabilitation
79225597|NCT03479892|Drug|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
79368109|NCT04384120|Device|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
79677141|NCT05146713|Drug|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
79677142|NCT00503789|Procedure|fecal bacteria analysis|ad lib feeding
79822511|NCT04104269|Diagnostic Test|Heart rupture|Free wall rupture and Ventricular septal rupture
79996786|NCT02033642|Behavioral|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
79996787|NCT02033642|Behavioral|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
79996788|NCT03226769|Device|TrueTear™|Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
79368110|NCT04384120|Procedure|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
79996789|NCT03226769|Device|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
79996790|NCT01330615|Drug|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
79368111|NCT05743348|Behavioral|Telepsychotherapy|Remotely delivered psychotherapy sessions
79368112|NCT03809338|Diagnostic Test|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
79520952|NCT03965754|Behavioral|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
79520953|NCT03965754|Behavioral|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
79520954|NCT03962634|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
79520955|NCT03962634|Drug|Articaine Injection|Local anesthetic
79520956|NCT03933774|Drug|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
79822512|NCT04104191|Device|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
79822513|NCT00784277|Drug|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
79822514|NCT00784277|Drug|oxycodone IR|10mg for 14 days
79822515|NCT00784277|Drug|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
79822516|NCT00784277|Drug|Tapentadol IR (CG5503)|50mg for 14 days
79225598|NCT03479892|Drug|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
79368113|NCT01977677|Radiation|radiation therapy|Undergo radiation therapy
79368114|NCT01977677|Drug|temozolomide|Given PO
79368115|NCT01977677|Drug|plerixafor|Given IV
79368116|NCT01977677|Other|laboratory biomarker analysis|Correlative studies
79368117|NCT01977677|Other|pharmacological study|Correlative studies
79368118|NCT01762345|Device|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
79368119|NCT04384744|Drug|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
79368120|NCT03803020|Other|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
79368121|NCT01761565|Drug|Single dose of SUF NT 15 mcg|
79368122|NCT01761565|Drug|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
79368123|NCT04385056|Biological|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
79822517|NCT00784277|Drug|Tapentadol IR (CG5503)|75mg for 14 days
79520957|NCT03933774|Drug|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
79225599|NCT02231385|Drug|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
79520958|NCT03933618|Drug|Anastrozole 1mg|
79996791|NCT01330615|Drug|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
79225600|NCT02523768|Drug|ATG-F|
79996792|NCT03636529|Dietary Supplement|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
79677143|NCT05149989|Device|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
79996793|NCT03636529|Other|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
79996794|NCT05034029|Drug|Metformin hydrochloride sustained release tablets|Oral
79996795|NCT05034029|Drug|Placebo|Placebo
79996796|NCT03637127|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
79996797|NCT03637127|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
79225601|NCT02523768|Drug|Simulect|
79368124|NCT04576741|Behavioral|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
79225602|NCT02225457|Other|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
79225603|NCT02225457|Dietary Supplement|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
79225604|NCT02225457|Dietary Supplement|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
79225605|NCT05259384|Procedure|Robotic pancreaticoduodenectomy|The Intervention of MIPD-ROB group
79368125|NCT04576741|Behavioral|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
79368126|NCT01619579|Device|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
79368127|NCT01736215|Drug|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
79368128|NCT04384900|Procedure|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
79520959|NCT03933618|Drug|Clomiphene Citrate 25mg|
79520960|NCT03933618|Drug|Placebo - Cap|
79520961|NCT03930264|Drug|Azathioprine 50Mg Tab|tablet
79520962|NCT03930264|Drug|Azathioprine 10mg/mL oral suspension|oral suspension
79520963|NCT03919422|Procedure|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
79520964|NCT03919422|Procedure|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
79520965|NCT03926208|Procedure|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
79520966|NCT03926208|Procedure|Clorhexadine scrub|Clorhexadine scrub (standard of care).
79520967|NCT03901092|Drug|flortaucipir F 18|No study drug will be administered.
79520968|NCT03887286|Device|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
79677144|NCT00499928|Drug|SB-751689|
79677145|NCT00503828|Drug|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
79996798|NCT02864342|Device|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
79225606|NCT05259384|Procedure|Laparoscopic pancreaticoduodenectomy|The Intervention of MIPD-LAP group
79225607|NCT05259384|Procedure|Robotic Distal Pancreatectomy|The Intervention of MIDP-ROB group
79520969|NCT03887286|Device|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
79520970|NCT03882528|Biological|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
79520971|NCT03881670|Device|Lotrafilcon B|commercially available contact lens
79520972|NCT03881670|Device|lotrafilcon B with Hydraluxe|commercially available contact lens
79520973|NCT03861000|Drug|[C-11]T-1650|radio-labeled drug
79996799|NCT02864342|Device|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
79996800|NCT03237065|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
79520974|NCT03861000|Drug|BPN14770|selective compound
79225608|NCT05259384|Procedure|Laparoscopic Distal Pancreatectomy|The Intervention of MIDP-LAP group
79225609|NCT02222259|Procedure|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
79225610|NCT02225535|Other|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
79225611|NCT02225535|Other|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
79520975|NCT03863496|Procedure|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
79520976|NCT03856944|Device|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
79520977|NCT03865446|Drug|Dacomitinib|anti-cancer agent
79996801|NCT03237065|Drug|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
79368129|NCT03808714|Behavioral|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
79225612|NCT02225535|Other|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
79368130|NCT03808714|Behavioral|Control Group|Alabama Quitline
79368131|NCT01786603|Drug|Rasagiline|Rasagiline 2mg once a day for 12 months.
79368132|NCT01786603|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
79225613|NCT03482700|Behavioral|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
79225614|NCT03482700|Behavioral|Control Arm|Usual standard of care
79520978|NCT03868254|Device|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
79520979|NCT03868254|Procedure|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
79520980|NCT03862482|Device|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
79520981|NCT03862482|Device|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
79520982|NCT03862482|Device|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
79225615|NCT03479814|Radiation|IMRT-SIB plus sequential IG-RT boost|
79225616|NCT02225613|Other|Usual protocol|
79520983|NCT03848208|Drug|cytisine|cytisine film-coated oral tablet
79520984|NCT03848208|Drug|placebo|matching placebo oral tablet
79520985|NCT03858894|Drug|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
79520986|NCT03858894|Drug|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
79520987|NCT03856164|Drug|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
79520988|NCT03856164|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
79520989|NCT03849690|Drug|TAK-906|TAK-906 capsules.
79520990|NCT03849690|Drug|Esomeprazole|Esomeprazole capsules.
79996802|NCT05121077|Other|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
79368133|NCT00786916|Drug|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
79368134|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
79368135|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
79368136|NCT03802708|Diagnostic Test|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
79368137|NCT04414267|Biological|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
79520991|NCT03843372|Device|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
79520992|NCT03822078|Drug|Placebo|Administered by subcutaneous injection
79996803|NCT03171415|Drug|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
79225617|NCT02225613|Other|Spa protocol|
79368138|NCT04414267|Biological|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
79368139|NCT01619423|Drug|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
79225618|NCT03479736|Drug|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
79225619|NCT03479736|Drug|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
79368140|NCT01619423|Drug|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
79368141|NCT01619423|Drug|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
79368142|NCT01619423|Drug|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
79368143|NCT03802552|Drug|Cefadroxil|oral one-time dose of cefadroxil
79368144|NCT03802552|Drug|Cephalexin|oral one-time dose of cephalexin
79520993|NCT03822078|Biological|Denosumab|Administered by subcutaneous injection
79520994|NCT03806556|Drug|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
79520995|NCT03806556|Drug|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
79368145|NCT01735279|Drug|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
79520996|NCT03809052|Drug|GB1211|Hard capsules for oral use
79520997|NCT03809052|Drug|Placebo|Hard capsules for oral use
79520998|NCT03812328|Drug|SelK2|I.V., single-dose
79520999|NCT03812328|Biological|Enoxaparin|SC, QD for up to 10 ± 2 days
79368146|NCT01735279|Drug|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
79368147|NCT03802786|Drug|Imeglimin|Single administration dose of imeglimin
79368148|NCT03808792|Diagnostic Test|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
79368149|NCT01759381|Device|Negative pressure wound therapy (NPWT)|
79368150|NCT03802318|Drug|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
79521000|NCT03816696|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
79521001|NCT03816696|Drug|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
79521002|NCT03815292|Drug|MMH-MAP|Oral administration
79521003|NCT03815292|Drug|Placebo|Oral administration
79521004|NCT03809910|Device|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
79677146|NCT00503828|Drug|naproxen|Naproxen 500 mg/day for 4 weeks
79996804|NCT03171415|Drug|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
79521005|NCT03809910|Device|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
79521006|NCT03809910|Device|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
79677147|NCT05149677|Behavioral|Music therapy|Music therapy intervention + Standard of Care for labor pain
79677148|NCT03455478|Device|spectacles|dispending spectacles for uncorrected refractive error
79677149|NCT00499967|Drug|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
79368151|NCT04662671|Device|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
79677150|NCT00499967|Drug|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
79677151|NCT00499967|Drug|Placebo|Placebo matching GS-9191 ointment
79368152|NCT01758523|Drug|Dutasteride|
79521007|NCT03809910|Device|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
79521008|NCT03806790|Drug|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
79521009|NCT03806790|Drug|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
79368153|NCT01758523|Drug|sugar pill|
79996805|NCT03829241|Drug|Troriluzole|100 mg capsule
79677152|NCT00500006|Drug|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
79677153|NCT00500006|Drug|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
79368154|NCT00773422|Drug|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
79368155|NCT00773422|Drug|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
79368156|NCT00773422|Drug|placebo|placebo
79368157|NCT00786994|Drug|Oleogel-S10 100 mg/g|topical use once or twice daily
79368158|NCT00786994|Drug|Placebo (petroleum jelly)|topical use once or twice daily
79521010|NCT03805386|Drug|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
79521011|NCT03805386|Drug|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
79677154|NCT01247051|Procedure|Precoating|preoperative filling of heart lung machine with patients blood
79677155|NCT01247051|Procedure|Standard priming|preoperative filling of heart lung machine with colloids
79677156|NCT00506727|Drug|Mixed amphetamine salts (ADDERALL XR)|
79368159|NCT01757821|Device|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
79368160|NCT01757821|Device|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
79368161|NCT01757821|Device|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
79521012|NCT03802344|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
79521013|NCT03802344|Drug|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
79521014|NCT03802344|Drug|Vehicle|Vehicle cream
79521015|NCT03799614|Device|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
79521016|NCT03799614|Device|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
79521017|NCT03796260|Drug|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
79521018|NCT03796260|Drug|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
79677157|NCT00506727|Drug|Atomoxetine hydrochloride|
79677158|NCT01247168|Drug|AZD2461|oral capsules, continuous dosing and intermittent dosing
79677159|NCT00500162|Behavioral|Tri-Luma Maintenance regimen|
79677160|NCT00500201|Drug|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
79677161|NCT00500201|Drug|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
79677162|NCT00500201|Drug|Placebo|Placebo tablets will be administered orally by subjects.
79822518|NCT00784277|Drug|placebo|1 capsule for 14 days
79996806|NCT03829241|Drug|Placebo|Placebo matched to troriluzole
79996807|NCT05210959|Other|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
79521019|NCT03796182|Drug|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
79225620|NCT03479736|Other|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
79368162|NCT00774202|Drug|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
79225621|NCT02225691|Device|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
79368163|NCT00774202|Drug|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
79368164|NCT01735201|Drug|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
79368165|NCT01735201|Drug|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
79368166|NCT01735201|Drug|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
79368167|NCT01735201|Drug|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
79521020|NCT03796182|Drug|PF-04965842|PF 04965842 100 mg tablets
79521021|NCT03779724|Other|exercises|
79521022|NCT03786744|Biological|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
79521023|NCT03786744|Other|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
79225622|NCT02225769|Other|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
79225623|NCT02225769|Other|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
79368168|NCT05742880|Other|Wearing a mask|6 Minute walking test while wearing a Mask
79368169|NCT03808324|Diagnostic Test|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
79368170|NCT01734811|Biological|Biological vaccine|daily spray (2 puff of 100 µL) for six months
79368171|NCT03802006|Diagnostic Test|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
79368172|NCT03808168|Drug|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
79368173|NCT03802162|Drug|CKD-355A (D797/Memantine HCl 20mg)|once a day
79368174|NCT03802162|Drug|CKD-355B (D797/Memantine HCl 20mg)|once a day
79368175|NCT03802162|Drug|D797|once a day
79521024|NCT03790878|Behavioral|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
79677163|NCT01247246|Drug|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
79677164|NCT01247246|Drug|Placebo|Placebo
79677165|NCT04696536|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
79677166|NCT04696536|Other|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
79677167|NCT04696536|Other|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
79368176|NCT03802162|Drug|D324 (Memantine HCl 10mg)|twice a day
79368177|NCT01757275|Drug|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
79368178|NCT01757275|Drug|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
79368179|NCT01757275|Drug|Esomeprazole Mg|40 mg tablet once daily for 27 days
79521025|NCT03790878|Behavioral|Habituation|An exposure procedure that reduces emotional distress through habituation
79521026|NCT03790878|Behavioral|Control|No emotion regulation intervention, placebo
79521027|NCT03789474|Device|HUNTLEIGH FLOWTRON ACS900|
79677168|NCT04696536|Other|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
79677169|NCT04696536|Other|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
79677170|NCT00500279|Drug|Celecoxib|
79677171|NCT03459651|Behavioral|ANS training|In-home computer-based ANS training
79677172|NCT00500396|Procedure|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
79822519|NCT00784277|Drug|placebo|Tablets and capsules 2 x a day for 28 days
79677173|NCT00507468|Procedure|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
79677174|NCT01245881|Device|Non-ablative fractional photothermolysis laser|"Wavelength: 1,550 nm;~Energy: 15 mJ/MTZ;~Total coverage: 20%;~Total density: 1,048 MTZs/cm2;~Density per pass: 131 MTZ/cm2;~Number of passes: 8."
79677175|NCT01245881|Other|broad-spectrum sunblock (SPF 50+)|
79677176|NCT00500435|Procedure|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
79225624|NCT03479658|Behavioral|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
79368180|NCT00787852|Drug|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
79368181|NCT00787852|Drug|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
79368182|NCT01757197|Drug|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
79521028|NCT03765996|Other|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
79521029|NCT03765996|Other|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
79521030|NCT03765762|Drug|GRF6019|GRF6019 for IV infusion
79521031|NCT03765762|Other|Placebo|Placebo for IV infusion
79521032|NCT03756012|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
79677177|NCT01247402|Device|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
79677178|NCT01247402|Device|standard balloon angioplasty|standard balloon angioplasty
79677179|NCT01247441|Other|Clinical data|
79677180|NCT00508170|Behavioral|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
79677181|NCT00500474|Procedure|endolymphatic sac drainage with steroids|
79677182|NCT03458247|Drug|Abiraterone acetate standard dose|1000 mg/day
79677183|NCT03458247|Drug|Abiraterone acetate escalated dose|2000 mg/day
79677184|NCT01247519|Other|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
79677185|NCT03453216|Behavioral|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
79677186|NCT00500513|Procedure|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
79677187|NCT00500513|Procedure|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
79677188|NCT00500513|Radiation|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
79677189|NCT02954718|Other|activity training|
79677190|NCT01247558|Other|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for >120 days
79677191|NCT01247558|Other|Not treated with Metanx®|Non-treated comparative cohort
79822520|NCT05116748|Biological|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
79521033|NCT03748992|Drug|gNO|"This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires."
79521034|NCT03748758|Combination Product|Drug: OP0201|Drug OP0201
79677192|NCT02954445|Biological|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
79996808|NCT05090423|Other|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
79225625|NCT03479658|Behavioral|Nutritional education|School-based nutritional education on healthy dietary habits
79225626|NCT02225847|Other|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
79225627|NCT02225847|Procedure|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
79225628|NCT02225847|Behavioral|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
79225629|NCT03940092|Other|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (>18 years), and female patients (>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
79225630|NCT03940092|Other|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
79225631|NCT03203642|Drug|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
79225632|NCT03203642|Drug|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
79225633|NCT03475680|Drug|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
79225634|NCT03475680|Drug|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
79368183|NCT00788008|Drug|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
79368184|NCT00760006|Drug|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
79368185|NCT00760006|Other|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
79677193|NCT00500552|Drug|Perhexiline/Placebo|
79822521|NCT05254964|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
79225635|NCT03475680|Drug|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
79225636|NCT03475680|Drug|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
79225637|NCT03475680|Drug|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
79225638|NCT03475602|Diagnostic Test|PLA2R|Determination of serum concentration of anti PLA2R antibody
79225639|NCT03475602|Diagnostic Test|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
79368186|NCT01784965|Drug|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
79368187|NCT01784965|Drug|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
79368188|NCT05742724|Drug|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
79521035|NCT03748758|Combination Product|Drug: Placebo|Placebo
79225640|NCT02231463|Other|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
79225641|NCT02231463|Other|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
79996809|NCT05090423|Other|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
79368189|NCT01784419|Drug|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
79368190|NCT01784419|Drug|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
79368191|NCT03801850|Device|3D surface scan|measurement of inter fractional deformations by surface scanning
79521036|NCT03745092|Device|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
79521037|NCT03745092|Device|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
79677194|NCT02954250|Behavioral|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
79677195|NCT00500591|Behavioral|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
79822522|NCT05071274|Device|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
79996810|NCT01984879|Other|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
79225642|NCT02231463|Other|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
79225643|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
79225644|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
79225645|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
79225646|NCT04621136|Drug|Ripasudil ophthalmic solution 0.4%|"Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.~Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks."
79225647|NCT03475524|Drug|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
79225648|NCT03475524|Drug|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
79225649|NCT03475524|Drug|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
79225650|NCT03475524|Drug|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
79225651|NCT02259075|Drug|Botulinum Toxin Type A|
79225652|NCT02471846|Drug|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
79368192|NCT03808246|Other|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
79521038|NCT03744780|Behavioral|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
79521039|NCT03730116|Drug|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
79677196|NCT02954289|Behavioral|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
79677197|NCT00500630|Device|Body fixed 3D sensors|
79677198|NCT00508209|Drug|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
79677199|NCT04696913|Diagnostic Test|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
79677200|NCT04696913|Diagnostic Test|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
79996811|NCT03620461|Drug|Gemcitabine - nabpaclitaxel|efficacy and safety
79225653|NCT02471846|Drug|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
79225654|NCT04458714|Procedure|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
79225655|NCT02259153|Behavioral|Changes in cholesterol metabolism|
79225656|NCT02259153|Other|Lean red meat diet|
79225657|NCT02259153|Other|Fat red meat diet|
79225658|NCT03108716|Procedure|hamate hook removal|The patients were assigned to treat with hamate hook removal.
79225659|NCT03108716|Procedure|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
79225660|NCT03108716|Other|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
79225661|NCT03482622|Diagnostic Test|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
79225662|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
79225663|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is turned off.
79225664|NCT02231619|Behavioral|Baseline verbal instruction on LSUPT|
79225665|NCT02222415|Dietary Supplement|Exercise + Protein drink|
79225666|NCT02737722|Drug|Bisphosphocin Nu-3|
79225667|NCT02737722|Drug|Placebo|
79225668|NCT02231853|Biological|MVST|MVST Infusion
79225669|NCT02231853|Biological|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
79225670|NCT02472782|Drug|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
79225671|NCT02472860|Behavioral|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
79225672|NCT02472860|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition
79225673|NCT02258607|Drug|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
79225674|NCT02258607|Drug|Trametinib|Trametinib tablet administered orally once daily
79368193|NCT01784029|Drug|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
79368194|NCT00789256|Drug|Melphalan|Melphalan: 2mg orally, once daily
79368195|NCT00789256|Drug|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
79368196|NCT00789256|Drug|Melphalan and bortezomib|
79368197|NCT01733329|Drug|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
79368198|NCT01733329|Drug|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
79368199|NCT01783483|Device|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
79521040|NCT03729960|Other|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
79521041|NCT03729024|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
79521042|NCT03728790|Device|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
79677201|NCT02954016|Device|ePass|Subject is implanted with the device for up to 3 years.
79677202|NCT00500669|Drug|Betadine|Topically
79677203|NCT00507585|Drug|Fluorouracil|300 mg/m^2 IV over 10 Minutes, then 600 mg/m^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
79677204|NCT00507585|Drug|Avastin|10 mg/m^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
79677205|NCT00507585|Drug|Leucovorin|200 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
79677206|NCT00507585|Drug|Oxaliplatin|60 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
79677207|NCT01247636|Other|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
79677208|NCT01247636|Other|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
79225675|NCT02472704|Dietary Supplement|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
79521043|NCT03727854|Dietary Supplement|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
79521044|NCT03727854|Behavioral|Dietary modification|Subjects in this group will follow diabetes diet education.
79996812|NCT05056493|Other|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
79996813|NCT01314781|Drug|solifenacin|solifenacin 5mg tablet once daily
79996814|NCT01314781|Procedure|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
79225676|NCT02472704|Dietary Supplement|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
79225677|NCT02222571|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
79225678|NCT02222571|Behavioral|Supervision for Safety|group-based safety intervention for parents
79521045|NCT03544242|Other|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
79677209|NCT00508248|Dietary Supplement|omega 3 fatty acids|1g daily
79677210|NCT00508248|Dietary Supplement|placebo|olive oil capsule
79996815|NCT01330693|Drug|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
79225679|NCT02472470|Device|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
79225680|NCT02226237|Procedure|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
79677211|NCT01247714|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
79677212|NCT01247714|Dietary Supplement|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
79677213|NCT01247714|Dietary Supplement|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
79677214|NCT01247714|Dietary Supplement|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
79996816|NCT01330693|Drug|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
79996817|NCT01913977|Device|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
79996818|NCT01913977|Device|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
79225681|NCT02226237|Procedure|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
79368200|NCT01783483|Device|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
79368201|NCT02145676|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
79368202|NCT02145676|Drug|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
79368203|NCT01607593|Drug|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
79368204|NCT00789724|Drug|Anakinra|100 mg daily subcutaneous injection for 14 days
79368205|NCT00789724|Drug|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
79368206|NCT01755637|Drug|Albendazole|Albendazole tablets 400 mg
79368207|NCT03801538|Drug|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
79368208|NCT03801538|Drug|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
79368209|NCT03801226|Drug|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
79521046|NCT03544242|Drug|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
79521047|NCT03544242|Drug|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
79521048|NCT03500406|Device|RestoreX|Penile traction therapy in the straight position
79521049|NCT03500406|Other|Control|No treatment
79521050|NCT03423654|Other|Spatial Training|Spatial Training using a 5x5 grid
79996819|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
79225682|NCT02471534|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
79521051|NCT03423654|Other|Letter number matching|Letter number matching
79225683|NCT03096548|Behavioral|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
79225684|NCT03096548|Behavioral|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
79225685|NCT03792750|Drug|BMS-986205|Specified Dose on Specified Day
79225686|NCT03792750|Biological|Nivolumab|Specified Dose on Specified Day
79225687|NCT03311048|Other|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
79225688|NCT03311048|Other|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
79368210|NCT03801226|Drug|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
79521052|NCT03370536|Device|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
79521053|NCT03370536|Procedure|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
79521054|NCT03370536|Drug|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
79996820|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
79996821|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
79996822|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
79996823|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
79996824|NCT01330771|Drug|hMG-HP/r-FSH|
79677215|NCT00507663|Drug|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
79677216|NCT00508287|Drug|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
79677217|NCT00508287|Drug|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
79677218|NCT00508287|Drug|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
79368211|NCT02145754|Other|MKP media|one half of skin specimen was put in MKP media
79368212|NCT02145754|Other|BSK-H media|one half of skin specimen was put in BSK-H media
79368213|NCT03837808|Drug|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
79368214|NCT03837808|Drug|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
79521055|NCT03161964|Drug|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
79521056|NCT03161964|Drug|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
79521057|NCT03078270|Drug|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
79677219|NCT00507702|Procedure|phlebotomy|Standard of care
79677220|NCT00500747|Biological|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
79677221|NCT00500747|Drug|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
79677222|NCT00508326|Drug|Paclitaxel|Starting dose 150 mg/m^2 HAI once every 4 weeks
79996825|NCT03164551|Device|GERI+ incubator|The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
79996826|NCT03164551|Device|Conventional incubator|The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
79996827|NCT02863328|Drug|semaglutide|Oral administration once-daily.
79996828|NCT02863328|Drug|empagliflozin|Oral administration once-daily.
79996829|NCT03040141|Drug|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
79996830|NCT03040141|Drug|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
79996831|NCT03040141|Drug|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
79996832|NCT02033564|Device|Macintosh/Miller Laryngoscope|
79996833|NCT02033564|Device|Glidescope Laryngoscope|
79996834|NCT02937701|Biological|ABP 710|Administered by intravenous infusion
79521058|NCT03078270|Other|Placebo|single treatment visit for 5 injections of normal saline
79521059|NCT03042780|Drug|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
79521060|NCT03042780|Drug|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
79225689|NCT02226393|Behavioral|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
79521061|NCT03017040|Device|CT scan|A CT scan of the wrist
79521062|NCT03017040|Device|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
79521063|NCT02985840|Drug|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
79225690|NCT02226393|Behavioral|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
79225691|NCT02258763|Drug|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
79225692|NCT02258763|Drug|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
79225693|NCT03479424|Other|Observational|The MYIA in-home suite of devices.
79225694|NCT02469974|Drug|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
79225695|NCT02469974|Drug|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
79368215|NCT05741398|Device|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
79521064|NCT02985840|Drug|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
79521065|NCT02974686|Drug|Everolimus|
79521066|NCT02974686|Drug|Mycophenolic Acid|
79996835|NCT02937701|Biological|Infliximab|Administered by intravenous infusion
79225696|NCT02469974|Drug|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
79368216|NCT05739838|Device|Biolase ;Low Level Laser|Low Level laser ,940 nm
79996836|NCT05186623|Drug|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
79996837|NCT01330849|Behavioral|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
79225697|NCT03131622|Behavioral|Digital Therapeutics|
79225698|NCT03131310|Other|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
79368217|NCT03801070|Procedure|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
79368218|NCT05596708|Drug|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
79368219|NCT01732549|Drug|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
79368220|NCT01732549|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
79368221|NCT04383964|Device|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
79368222|NCT02148874|Biological|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
79368223|NCT01755091|Drug|Dronabinol|
79368224|NCT01755091|Drug|Placebo (for Dronabinol)|
79368225|NCT00789802|Drug|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
79521067|NCT02966184|Drug|preservative free albuterol|Preservative free albuterol for nebulization
79521068|NCT02950896|Other|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
79996838|NCT01330849|Other|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
79996839|NCT04602845|Drug|Fentanyl|50ug Fentanyl intravenously
79996840|NCT04602845|Drug|Flurbiprofen|50mg Fentanyl intravenously
79996841|NCT04602845|Drug|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
79996842|NCT04602845|Drug|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
79521069|NCT02877732|Device|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
79521070|NCT02877732|Other|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
79521071|NCT02877732|Other|DEM|Participant will be asked to read list of numbers out loud from a card
79521072|NCT02877732|Other|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
79521073|NCT02877732|Other|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
79521074|NCT02808390|Drug|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
79677223|NCT01247753|Behavioral|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
79677224|NCT00507780|Drug|GnRH antagonist|
79225699|NCT03482544|Drug|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
79996843|NCT01330927|Drug|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
79225700|NCT03482544|Other|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
79225701|NCT02750709|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
79225702|NCT02750709|Drug|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
79521075|NCT02808390|Drug|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
79521076|NCT02808390|Drug|Placebo|Placebo BID for 8 Weeks
79996844|NCT04966325|Drug|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
79996845|NCT04966325|Drug|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
79996846|NCT04966325|Drug|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
79225703|NCT02750709|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
79225704|NCT03131544|Device|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
79225705|NCT03131388|Diagnostic Test|Access AMH Assay|
79225706|NCT02222649|Dietary Supplement|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
79225707|NCT02222649|Dietary Supplement|Placebo|Capsules of starch, no therapeutic action
79225708|NCT03130998|Behavioral|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
79521077|NCT02744352|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
79521078|NCT02744352|Drug|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
79521079|NCT02745210|Diagnostic Test|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
79521080|NCT02679066|Device|Sugar-tong splint|Plaster immobilization including the elbow
79521081|NCT02679066|Device|Short forearm cast|Fiberglass immobilization with elbow free
79521082|NCT02590068|Drug|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
79521083|NCT02587650|Drug|Capmatinib|Given PO
79521084|NCT02587650|Drug|Ceritinib|Given PO
79521085|NCT02587650|Drug|Entrectinib|Given PO
79521086|NCT02587650|Other|Laboratory Biomarker Analysis|Correlative studies
79521087|NCT02587650|Drug|Regorafenib|Given PO
79677225|NCT00500786|Biological|CYT006-AngQb|
79677226|NCT00507858|Drug|Pemetrexed|Starting dose of 500 mg/m^2 IV Once Over 10 Minutes Every 3 Weeks
79677227|NCT00507858|Drug|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
79822523|NCT02588534|Device|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
79822524|NCT02588534|Other|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
79996847|NCT04966325|Drug|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
79996848|NCT05096377|Other|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
79996849|NCT03169153|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
79996850|NCT03169153|Device|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
79996851|NCT03168919|Radiation|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
79521088|NCT02514252|Drug|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
79677228|NCT01245920|Biological|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
79996852|NCT03168919|Drug|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
79996853|NCT03168919|Device|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
79996854|NCT05089669|Other|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
79225709|NCT03130998|Behavioral|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
79225710|NCT02859519|Drug|MOB015B|MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
79225711|NCT02859519|Drug|MOB015B Vehicle|MOB015B Vehicle without the active ingredient Terbinafine
79225712|NCT03475446|Device|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
79677229|NCT01245920|Other|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
79996855|NCT05089669|Other|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
79996856|NCT05080387|Other|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
79225713|NCT03475446|Device|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
79225714|NCT03475446|Device|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
79225715|NCT03475446|Device|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
79225716|NCT03475446|Device|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
79225717|NCT03475446|Device|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
79368226|NCT00789802|Drug|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
79677230|NCT00500825|Procedure|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
79225718|NCT03475446|Device|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
79368227|NCT00789802|Drug|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
79677231|NCT00508365|Drug|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
79677232|NCT00508365|Drug|Placebo|Placebo capsules to match each dose level will be provided.
79368228|NCT04567225|Drug|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
79368229|NCT04567225|Drug|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
79368230|NCT04567225|Other|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
79368231|NCT04567225|Other|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
79677233|NCT00508365|Drug|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
79677234|NCT01316393|Other|XER2020|mucoprotective product
79677235|NCT00500864|Drug|Magnesium Sulfate 2 grams|
79822525|NCT05103878|Drug|BT051 100mg|Single oral dose of 100mg BT051
79822526|NCT05103878|Drug|BT051 300mg|Single oral dose of 300mg BT051
79822527|NCT05103878|Drug|BT051 700mg|Single oral dose of 700mg BT051
79822528|NCT05103878|Drug|BT051 1500mg|Single oral dose of 1500mg BT051
79521089|NCT02514252|Behavioral|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
79822529|NCT05103878|Drug|BT051 3500mg|Single oral dose of 3500mg BT051
79996857|NCT04108819|Dietary Supplement|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
79996858|NCT03205163|Biological|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
79822530|NCT05103878|Drug|Matching Placebo|Placebo Matching BT051
79822531|NCT00682929|Drug|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
79822532|NCT00682929|Drug|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
79822533|NCT00682929|Drug|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
79822534|NCT00682929|Drug|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
79822535|NCT02588690|Procedure|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
79822536|NCT02588690|Other|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol <190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
79822537|NCT02588690|Procedure|Blood pressure measurement|Blood pressure measurement
79822538|NCT00758199|Drug|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
79996859|NCT03205163|Biological|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
79996860|NCT03205163|Biological|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
79368232|NCT04384510|Procedure|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
79368233|NCT04384510|Procedure|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
79368234|NCT01754467|Behavioral|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
79822539|NCT00758199|Drug|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
79822540|NCT00758199|Drug|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
79822541|NCT05683808|Drug|Apixaban|Open label
79822542|NCT02559999|Other|Painful tonic stimuli|
79822543|NCT02559999|Other|non-painful stimuli|
79996861|NCT03205163|Biological|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
79996862|NCT01781143|Device|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
79996863|NCT03681145|Behavioral|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
79368235|NCT01753999|Device|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
79368236|NCT01753999|Device|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
79368237|NCT02149342|Drug|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
79368238|NCT02149342|Drug|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
79822544|NCT00919490|Drug|ABT-333|Tablet, see arms for interventional description
79822545|NCT00919490|Drug|Placebo|Tablet, see arms for interventional description.
79822546|NCT05683652|Device|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
79822547|NCT05434611|Diagnostic Test|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
79822548|NCT05081570|Device|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
79822549|NCT02589470|Other|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
79225719|NCT03475446|Device|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
79521090|NCT02514252|Behavioral|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
79521091|NCT02514252|Behavioral|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
79996864|NCT01759537|Device|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
79996865|NCT01759537|Device|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
79996866|NCT04859075|Other|Bifidobacterium longum 35624|1 capsule daily
79225720|NCT03475446|Device|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
79225721|NCT02222727|Drug|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
79225722|NCT03475368|Other|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
79225723|NCT03475368|Other|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
79225724|NCT03475368|Other|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
79225725|NCT02723786|Biological|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
79225726|NCT02723786|Drug|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
79225727|NCT03482466|Behavioral|Neurofeedback|Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
79225728|NCT02222805|Procedure|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
79225729|NCT02222805|Procedure|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
79228153|NCT00705224|Drug|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
79368239|NCT03800446|Diagnostic Test|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
79368240|NCT03800368|Other|Exercise|Indoor cycling exercise intervention
79368241|NCT03800368|Other|Non-exercise|Psycho-education
79368242|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
79368243|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
79368244|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
79521092|NCT02434146|Drug|Topical Phenylephrine Solution|Given topically via spray
79521093|NCT02431494|Device|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
79677236|NCT00508560|Behavioral|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
79368245|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
79368246|NCT01782859|Drug|Prednisone|
79368247|NCT01782859|Drug|Hydrocortisone|
79368248|NCT01782859|Drug|Placebo (for Prednisone)|
79368249|NCT05723536|Procedure|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
79368250|NCT05723536|Procedure|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
79368251|NCT05718622|Device|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
79677237|NCT00508560|Behavioral|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
79677238|NCT01247831|Procedure|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
79677239|NCT00507975|Drug|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
79677240|NCT01247909|Drug|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
79677241|NCT02954328|Device|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
79677242|NCT01247948|Procedure|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
79677243|NCT01247948|Procedure|traditional spine surgery|traditional spine surgery without navigation assist
79225730|NCT03475290|Behavioral|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support & cognitive distortions, social skills & peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
79677244|NCT02954211|Device|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
79996867|NCT03204539|Drug|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
79368252|NCT05718622|Device|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
79996868|NCT01331317|Drug|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
79225731|NCT03475290|Behavioral|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support & cognitive distortions, social skills & peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
79225732|NCT03475290|Behavioral|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
79225733|NCT03475290|Behavioral|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support & cognitive distortions, social skills & peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
79368253|NCT01782313|Drug|tivozanib|Given PO
79225734|NCT02226705|Procedure|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
79225735|NCT02471456|Other|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
79368254|NCT01782313|Other|laboratory biomarker analysis|Correlative studies
79368255|NCT04575259|Drug|ANAVEX2-73|Oral capsules
79368256|NCT00790192|Drug|Lurasidone|Lurasidone 80 mg tablets
79368257|NCT00790192|Drug|Lurasidone|Lurasidone 4 40 mg tablets
79996869|NCT03638947|Device|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
79368258|NCT00790192|Drug|Quetiapine XR|Quetiapine XR 600mg
79368259|NCT00790192|Drug|Placebo|Matching Placebo to Lurasidone or Quetiapine
79368260|NCT01781611|Drug|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
79368261|NCT01781611|Drug|81mg aspirin|half a tablet twice daily for 24 weeks
79368262|NCT00777634|Other|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
79368263|NCT01781299|Device|AlloDerm RTU|
79368264|NCT01781299|Device|SurgiMend PRS|
79368265|NCT01732471|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
79368266|NCT00790270|Drug|Cyclobenzaprine|5 mg orally every 8 hours as needed
79368267|NCT00790270|Drug|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
79368268|NCT00790270|Drug|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
79368269|NCT01780987|Drug|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
79368270|NCT01780987|Drug|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
79368271|NCT01780987|Drug|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
79368272|NCT00790738|Drug|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
79368273|NCT00790738|Drug|placebo|placebo
79368274|NCT03800290|Drug|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
79368275|NCT03800290|Drug|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
79521094|NCT02431494|Device|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
79521095|NCT02431494|Device|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
79521096|NCT02382588|Drug|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
79521097|NCT02382588|Drug|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
79521098|NCT02345460|Drug|Irinotecan Hydrochloride|Given IV
79521099|NCT02345460|Drug|Oxaliplatin|Given IV
79996870|NCT01722019|Device|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
79225736|NCT02471456|Other|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
79225737|NCT03479346|Drug|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
79225738|NCT03479346|Drug|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
79225739|NCT02222883|Genetic|Testing of BRCA status regarding germline and somatic mutation|
79368276|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79225740|NCT03310814|Other|Personalized nutrition|Receives individualized nutrition information
79521100|NCT02345460|Drug|Leucovorin Calcium|Given IV
79228154|NCT04217382|Other|patient with melanoma pre transplantation|survival time without melanoma recurrence
79368277|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79996871|NCT01722019|Device|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
79996872|NCT01666873|Procedure|patients that undergo a total knee prosthesis|
79228155|NCT03267147|Other|no intervention is given|no intervention is given
79368278|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79996873|NCT03502681|Drug|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m^2;~Dose level 0: 1.1 mg/m^2;~Dose level +1: 1.4 mg/m^2"
79996874|NCT03502681|Drug|Avelumab|Days 1, 15 Avelumab (10mg/kg)
79996875|NCT02860130|Drug|Prismocitrate 18|Modality of CVVHDF
79996876|NCT02860130|Other|No Anticoagulation|Modality of CVVHDF
79996877|NCT05051605|Biological|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
79996878|NCT04938817|Biological|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
79996879|NCT04938817|Drug|lenvatinib|Oral administration
79996880|NCT04938817|Biological|MK-4830|IV infusion
79996881|NCT04938817|Biological|coformulation favezelimab/pembrolizumab|IV infusion
79228156|NCT02457156|Procedure|Blumgart Anastomosis|"Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~Pancreatic duct to jejunal mucosa sutures, inserted and tied.~Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
79368279|NCT05535478|Behavioral|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
79368280|NCT00808834|Device|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
79368281|NCT00808834|Device|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
79521101|NCT02345460|Drug|Fluorouracil|Given IV
79521102|NCT02345460|Other|Laboratory Biomarker Analysis|Correlative studies
79521103|NCT02345772|Drug|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
79521104|NCT02345772|Drug|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
79521105|NCT02345772|Drug|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
79521106|NCT02345772|Drug|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
79822550|NCT02588378|Procedure|multi-modal cSLO imaging|
79521107|NCT02280252|Drug|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
79521108|NCT02280252|Radiation|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
79521109|NCT02266914|Device|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
79521110|NCT02262000|Radiation|Image Guided Stereotactic Ablative Radiotherapy|
79521111|NCT02248740|Procedure|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
79521112|NCT02242578|Device|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
79521113|NCT02242578|Device|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
79521114|NCT02133534|Drug|Atorvastatin|
79521115|NCT02009982|Procedure|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
79677245|NCT02954211|Behavioral|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
79996882|NCT04114994|Diagnostic Test|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
79996883|NCT01366729|Device|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
79996884|NCT01366729|Device|Cane walking|All walking activities must take place with cane from waking until sleeping
79996885|NCT04485325|Drug|Tofacitinib|5 mg twice daily, p.o.
79996886|NCT04485325|Biological|Etanercept|50 mg once per week, s.c.
79996887|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.1 mmol/L fasting and <7.0 mmol/L postprandial) are not achieved insulin therapy is started
79996888|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.3 mmol/L fasting and <7.8 mmol/L postprandial) are not achieved insulin therapy is started
79225741|NCT03310736|Diagnostic Test|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
79225742|NCT02222961|Drug|BIIR 561 CL|
79225743|NCT02222961|Drug|Placebo|
79996889|NCT02033798|Drug|Tamsulosin|Once Daily 0.2mg per oral for 6 months
79996890|NCT03609632|Other|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
79225744|NCT03479190|Procedure|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
79521116|NCT02009982|Device|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
79521117|NCT02013414|Device|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
79521118|NCT02015910|Drug|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
79521119|NCT02015910|Drug|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
79521120|NCT01996410|Device|Acupuncture|
79521121|NCT01980342|Drug|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
79521122|NCT01881984|Drug|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
79822551|NCT00680745|Drug|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
79225745|NCT03479190|Procedure|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
79822552|NCT00680745|Drug|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
79822553|NCT00680745|Drug|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
79225746|NCT03000998|Behavioral|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
79225747|NCT03000998|Behavioral|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
79368282|NCT00809146|Drug|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
79225748|NCT02226783|Drug|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
79225749|NCT02226783|Drug|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
79225750|NCT02226783|Drug|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
79822554|NCT00680745|Drug|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
79225751|NCT03479112|Behavioral|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
79368283|NCT00809146|Drug|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
79368284|NCT00791908|Procedure|Electrodessication|Treatment applied to a third of the torso at each study visit.
79368285|NCT00791908|Procedure|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
79368286|NCT00791908|Procedure|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
79368287|NCT05709184|Combination Product|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
79368288|NCT05709184|Drug|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
79368289|NCT00794170|Behavioral|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
79368290|NCT03831334|Drug|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
79368291|NCT04843774|Drug|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
79368292|NCT04383652|Other|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
79368293|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
79368294|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
79368295|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
79368296|NCT00809848|Drug|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
79368297|NCT00809848|Drug|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
79521123|NCT01878786|Drug|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
79677246|NCT01245998|Drug|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
79677247|NCT01245998|Drug|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
79677248|NCT02954484|Drug|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
79677249|NCT02954484|Drug|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
79677250|NCT02954484|Drug|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
79677251|NCT02954484|Drug|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
79677252|NCT02954484|Drug|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
79677253|NCT02954484|Drug|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
79521124|NCT01878786|Drug|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
79521125|NCT01878786|Drug|Mycophenolate mofetil (MMF/MPA)|Control Drug
79521126|NCT01851174|Drug|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m^2) IV over 30 minutes after nab-paclitaxel infusion
79521127|NCT01851174|Drug|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m^2) IV over 30 minutes before Gemcitabine infusion
79521128|NCT01846182|Drug|Duloxetine|serotonin norepinephrine reuptake inhibitor
79225752|NCT03479112|Behavioral|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
79225753|NCT03479112|Behavioral|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
79225754|NCT03479112|Behavioral|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
79521129|NCT01846182|Drug|Pregabalin|alpha-2-alpha subunit calcium channel ligand
79521130|NCT01846182|Drug|Placebo|Placebo
79677254|NCT01247987|Procedure|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
79677255|NCT01247987|Procedure|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
79677256|NCT02954367|Dietary Supplement|PROTEIN|Immediately (<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
79822555|NCT00680745|Drug|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
79996891|NCT04491110|Other|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
79996892|NCT04491110|Other|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
79225755|NCT03310658|Device|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
79225756|NCT02223117|Biological|Thrombosomes|Freeze-dried platelets
79225757|NCT02223117|Biological|Placebo|
79225758|NCT04559438|Other|Rotary Neoniti GPS file|Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.
79225759|NCT04559438|Other|Manual stainless steel K-files|Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
79225760|NCT02226861|Device|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
79225761|NCT02226861|Biological|ULD IL-2|sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
79521131|NCT01800162|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
79521132|NCT01800162|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
79521133|NCT01800162|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
79521134|NCT01794936|Device|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
79521135|NCT01756560|Drug|dexamethsone|
79521136|NCT01756560|Drug|Bupivacaine|
79521137|NCT01738698|Drug|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
79521138|NCT01738698|Drug|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
79521139|NCT01738698|Drug|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
79521140|NCT01738698|Drug|Placebo|Oral administration once-daily for 12 weeks
79521141|NCT01717482|Drug|Metformin|
79521142|NCT01717482|Other|Placebo Comparator|Standard of Care Observation
79521143|NCT01702896|Drug|Interleukin-2|Interleukin-2
79677257|NCT02954367|Dietary Supplement|CARBOHYDRATE|Immediately (<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
79677258|NCT01248026|Other|Buttermilk|"Consumption of the 2 experimental periods~buttermilk (45 g/d)~placebo (45 g/d,)"
79822556|NCT05428293|Drug|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
79996893|NCT02986854|Biological|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
79996894|NCT02887183|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
79521144|NCT01682928|Drug|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
79521145|NCT01682928|Other|Hydrotherapy|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
79677259|NCT02954133|Device|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
79677260|NCT02954133|Device|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
79225762|NCT02997020|Other|EDSPD|The equipment & conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
79225763|NCT03482388|Behavioral|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
79225764|NCT03482388|Other|Control|Participants will not view any images or videos promoting HBV and HCV testing.
79225765|NCT02226939|Drug|BILN 2061 ZW|
79225766|NCT02226939|Drug|Placebo|
79225767|NCT02232165|Other|Hypotension avoidance|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP >= 65 mmHg is not inferior to induced hypertension.
79225768|NCT02232165|Other|Induced hypertension|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
79368298|NCT03839836|Other|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
79368299|NCT04382716|Other|No intervention|No intervention; observation only
79521146|NCT01683864|Drug|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
79521147|NCT01648296|Drug|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
79677261|NCT02954133|Device|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
79677262|NCT02954133|Device|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
79677263|NCT00500942|Behavioral|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
79677264|NCT00500981|Procedure|Volume challenge|
79677265|NCT00500981|Procedure|Ultrasound evaluation of internal jugular vein|
79677266|NCT00501020|Drug|Rosiglitazone|
79677267|NCT00508014|Other|Usual Care|Usual Care with primary care provider during time period
79996895|NCT03167359|Radiation|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
79225769|NCT03482232|Drug|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
79368300|NCT01730053|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
79368301|NCT01730053|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
79368302|NCT01730053|Drug|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
79368303|NCT01730053|Drug|Placebo|Placebo for alirocumab and ezetimibe.
79677268|NCT00508014|Behavioral|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
79822557|NCT05428293|Drug|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
79225770|NCT03482232|Drug|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
79225771|NCT03482232|Drug|paracetamol|paracetamol 1g for more than 3 days
79521148|NCT01608906|Drug|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
79368304|NCT00794560|Behavioral|patient education|"Possible, individualized interventions:~Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~First self-injection under control of a specially trained pharmacist"
79368305|NCT01752985|Drug|BMS-813160|
79368306|NCT01752985|Drug|Placebo matching with BMS-813160|
79677269|NCT00501098|Drug|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
79677270|NCT00508053|Procedure|Small stitches|
79521149|NCT01608906|Drug|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
79521150|NCT01602198|Drug|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
79521151|NCT01602198|Drug|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
79677271|NCT00508053|Procedure|Mass closure|
79521152|NCT01577628|Drug|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
79677272|NCT00501137|Biological|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
79677273|NCT00508131|Other|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
79677274|NCT01248260|Dietary Supplement|Folic Acid|4mg of higher strength folic acid once a day until delivery
79677275|NCT00508950|Procedure|Large volume blood draw|Large volume blood draw
79677276|NCT00503945|Device|Nasal continuous positive airway pressure (nCPAP)|
79225772|NCT03482232|Drug|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
79677277|NCT01246037|Drug|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
79677278|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
79677279|NCT00501215|Behavioral|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
79677280|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
79677281|NCT00501215|Behavioral|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
79677282|NCT00509184|Drug|Rituximab|375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap
79368307|NCT01751113|Drug|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
79368308|NCT01751113|Drug|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
79521153|NCT01550562|Device|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
79677283|NCT00508599|Other|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
79677284|NCT00501254|Drug|Slow release acetyl salicylic acid|
79677285|NCT00501254|Behavioral|Antithrombotic effect|
79225773|NCT03482232|Drug|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
79225774|NCT03482232|Diagnostic Test|Prostate cancer|Screening for prostate cancer in asymptomatic patients
79225775|NCT03482232|Radiation|Lumbago|image tests in non-specific lumbago
79225776|NCT03482232|Drug|Antimicrobial agent|antibiotics for pharyngitis (infants)
79225777|NCT03482232|Drug|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
79225778|NCT03482232|Drug|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
79677286|NCT00509301|Drug|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
79677287|NCT01248338|Drug|metoprolol succinate|once daily 50 or 100 mg for one year
79677288|NCT01248338|Drug|Nebivolol|once daily 5 mg capsule for one year
79677289|NCT01248377|Procedure|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
79677290|NCT01246154|Other|EXERCISE TRAINING|EXERCISE TRAINING
79677291|NCT02953743|Drug|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
79677292|NCT01246193|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
79677293|NCT01246193|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
79368309|NCT01751113|Drug|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
79225779|NCT02996864|Other|Healthy Detours App|"The app features:~Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
79225780|NCT02996864|Other|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
79225781|NCT03474978|Device|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
79677294|NCT00509340|Behavioral|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
79677295|NCT02274935|Other|Exercise|Balance and gait exercise twice a week for an hour
79677296|NCT00509379|Drug|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
79677297|NCT00509379|Drug|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
79996896|NCT03658356|Other|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
79225782|NCT03474900|Device|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
79368310|NCT04761406|Dietary Supplement|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
79368311|NCT04761406|Dietary Supplement|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
79368312|NCT01750879|Drug|Peanut Flour|Peanut Flour
79677298|NCT00509418|Dietary Supplement|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
79677299|NCT00509418|Other|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
79677300|NCT02274974|Drug|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
79677301|NCT02274974|Drug|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
79996897|NCT03660462|Dietary Supplement|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
79996898|NCT03660462|Dietary Supplement|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
79996899|NCT03660462|Dietary Supplement|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
79996900|NCT03660462|Dietary Supplement|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
79368313|NCT01750879|Drug|Oat Flour|Oat Flour
79368314|NCT01719380|Drug|LGX818|
79368315|NCT01719380|Drug|Cetuximab|
79368316|NCT01719380|Drug|BYL719|
79368317|NCT00792142|Drug|bortezomib|Given IV
79368318|NCT00792142|Drug|dexamethasone|Given orally
79368319|NCT00792142|Drug|melphalan|Given IV
79368320|NCT00792142|Drug|thalidomide|Given orally
79368321|NCT00792142|Genetic|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
79368322|NCT00792142|Genetic|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
79368323|NCT00792142|Other|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
79368324|NCT00792142|Other|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
79368325|NCT00792142|Procedure|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
79368326|NCT00792142|Procedure|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
79368327|NCT00792610|Biological|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
79368328|NCT00792688|Drug|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
79368329|NCT00792688|Drug|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
79677302|NCT00509457|Biological|GV 1001 Telomerase peptide|
79677303|NCT02274545|Biological|H7N9 Anhui 2013/AA ca|10^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
79677304|NCT02274545|Biological|Inactivated subvirion H7N9 vaccine|30 mcg
79677305|NCT02953470|Behavioral|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
79677306|NCT02953470|Behavioral|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
79677307|NCT02275013|Drug|Levosimendan|
79677308|NCT00509535|Drug|vitreoscilla filiformis cream|
79677309|NCT02274584|Genetic|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
79225783|NCT03474900|Device|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
79225784|NCT02227017|Drug|TPV capsule|
79225785|NCT02227017|Drug|TPV solution|
79225786|NCT02227017|Drug|RTV capsule|
79368330|NCT00792688|Drug|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
79996901|NCT01331395|Other|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
79996902|NCT03660306|Procedure|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
79996903|NCT03660306|Procedure|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
79996904|NCT03658200|Other|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
79225787|NCT02227017|Drug|RTV solution|
79225788|NCT02227017|Other|standard meal|
79225789|NCT04542200|Biological|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
79225790|NCT04537832|Other|No Intervention|No Intervention
79225791|NCT02227095|Behavioral|Exercise|Heart rate monitors worn by each child at each session
79225792|NCT02227095|Behavioral|After-school program|Supervised recreational program with token economy
79225793|NCT02223273|Behavioral|Multifaceted Strategy|"Simulation Based Team Training~Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~Reminders -~Check lists - decision support algorithm~Distribution of educational materials: guidelines and recommendations for best practices"
79225794|NCT05259072|Diagnostic Test|99m-technetium pyrophosphate scintigraphy|Imaging test
79225795|NCT02227173|Drug|BMS-986020|
79225796|NCT02227173|Drug|Montelukast|
79225797|NCT02227173|Drug|Flurbiprofen|
79225798|NCT02227173|Drug|Digoxin|
79225799|NCT03482154|Procedure|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
79225800|NCT02468726|Device|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
79225801|NCT02468726|Drug|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
79225802|NCT02872701|Drug|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
79225803|NCT02872701|Device|Near infrared camera imaging system|Near infrared camera imaging system
79225804|NCT02872701|Procedure|Endoscopic or Thoracic Surgery|Endoscopic or Thoracic Surgery
79368331|NCT01743560|Drug|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
79368332|NCT01743560|Drug|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
79368333|NCT00796744|Drug|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
79368334|NCT01743092|Behavioral|Webinar|Some clients will receive a webinar as part of their treatment.
79225805|NCT03479034|Other|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
79225806|NCT04489004|Procedure|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
79225807|NCT04489004|Procedure|Stepwise ablation|Patients receive stepwise ablation.
79225808|NCT02227407|Device|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
79368335|NCT01743092|Behavioral|Tutuorial workbook|A work book about their addiciton
79368336|NCT00797212|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
79368337|NCT00792922|Drug|Azithromycin|Comparison of community coverage rate
79368338|NCT00792922|Drug|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
79368339|NCT01780831|Drug|Raltegravir|RAL was given as oral granules for suspension.
79225809|NCT03482076|Diagnostic Test|transferrin receptor concentration|Sandwich radio-imunoassay
79225810|NCT02031549|Other|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
79225811|NCT02227563|Device|Active tDCS|repetitive daily tDCS sessions for a period of one week
79225812|NCT02227563|Device|control|
79822558|NCT05428293|Drug|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
79225813|NCT02469740|Drug|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
79225814|NCT02469740|Drug|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
79225815|NCT03474666|Procedure|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
79368340|NCT04383730|Drug|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
79677310|NCT02274623|Drug|CTAP101 Capsules|escalating doses
79368341|NCT04383730|Drug|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
79368342|NCT04382170|Drug|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
79368343|NCT01778023|Drug|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
79368344|NCT04933006|Diagnostic Test|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
79677311|NCT00509613|Drug|Sorafenib|
79368345|NCT01753297|Drug|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
79368346|NCT04382794|Drug|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
79677312|NCT00509613|Drug|Sirolimus|
79677313|NCT02953626|Behavioral|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
79677314|NCT00501332|Biological|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
79822559|NCT05427825|Other|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
79822560|NCT05427825|Other|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
79822561|NCT00680121|Drug|Benfotiamine|Benfotiamine 600 mg
79822562|NCT00680121|Drug|Placebo|Placebo
79822563|NCT00754533|Other|Continuous versus interval training|Influence of different exercise training programs
79822564|NCT00754689|Drug|Rimonabant|Tablet, oral administration
79368347|NCT04929496|Procedure|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
79368348|NCT04920370|Drug|ALXN1720 SC|ALXN1720 will be administered via SC route.
79822565|NCT00754689|Drug|Metformin|Tablet, oral administration
79368349|NCT04920370|Drug|ALXN1720 IV|ALXN1720 will be administered via IV route.
79822566|NCT00754689|Drug|placebo|Tablet, oral administration
79822567|NCT05375175|Other|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
79822568|NCT05375175|Other|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
79822569|NCT00767819|Drug|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
79822570|NCT00758277|Drug|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
79822571|NCT00758277|Drug|Placebo|Sugar Pill
79368350|NCT04920370|Drug|rHuPH20|rHuPH20 will be administered via SC route.
79225816|NCT03474666|Procedure|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
79225817|NCT04459221|Drug|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
79225818|NCT04432220|Drug|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
79368351|NCT04920370|Drug|Placebo SC|Placebo will be administered via SC route.
79368352|NCT04920370|Drug|Placebo IV|Placebo will be administered via IV route.
79368353|NCT01777321|Biological|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
79368354|NCT04718350|Drug|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
79368355|NCT04718350|Drug|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
79368356|NCT01729819|Drug|Tolterodine tartrate extended release capsules|
79368357|NCT01729819|Drug|Desmopressin orally disintegrating tablets|
79368358|NCT01729819|Drug|Placebo orally disintegrating tablets|
79368359|NCT01776541|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
79521154|NCT01545648|Drug|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
79368360|NCT00811564|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
79368361|NCT00811564|Drug|latanoprost 0.005%|1 drop of study medication taken once daily
79996905|NCT03658200|Other|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
79996906|NCT03660150|Other|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
79996907|NCT03659994|Dietary Supplement|Multivitamin|Vitabeard
79996908|NCT03659994|Dietary Supplement|Placebo|Placebo
79996909|NCT01068600|Drug|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
79225819|NCT04457739|Other|Tidal volume challenge|Increasing tidal volume from 6 to 8 mL/kg during 1 min
79225820|NCT04457739|Other|End-expiratory occlusion test|Interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output
79225821|NCT04457739|Other|Trendelenburg maneuver|Patients remained in prone position with a 13° upward bed angulation throughout the study and then be positioned in a declining position at -12 ° for 1 minute
79368362|NCT00811798|Biological|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
79368363|NCT01742078|Drug|LY2541546 - IV|Administered IV
79368364|NCT01742078|Drug|LY2541546 - SC|Administered SC
79368365|NCT01742078|Drug|Placebo|Administered IV or SC
79368366|NCT01741688|Biological|Tocilizumab|Tocilizumab was administered according to the local label.
79521155|NCT01527942|Drug|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
79822572|NCT04022447|Drug|Dupilumab|retrospective data collection
79822573|NCT03984617|Other|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
79996910|NCT01068600|Drug|Placebo to indacaterol|Once daily via SDDPI
79225822|NCT04417712|Device|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
79225823|NCT02223507|Drug|BIIR 561 CL|
79225824|NCT02223507|Drug|Placebo|
79228157|NCT02457156|Procedure|Cattell-Warren Anastomosis|"Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~Pancreatic duct to jejunal mucosa sutures, inserted and tied.~Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
79368367|NCT01709084|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
79368368|NCT01709084|Drug|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
79368369|NCT01709084|Drug|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
79368370|NCT01709084|Drug|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
79521156|NCT01527942|Drug|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
79521157|NCT01507584|Device|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
79521158|NCT01483872|Drug|NAC/Tigecycline/Heparin combination lock solution|
79521159|NCT01483872|Drug|Standard anticoagulant (Heparin or Citrate)|
79996911|NCT01067976|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
79996912|NCT02858492|Drug|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
79225825|NCT03478800|Procedure|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
79368371|NCT01729039|Behavioral|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
79521160|NCT01385280|Biological|therapeutic estradiol|Given orally (PO)
79521161|NCT01385280|Drug|exemestane|Given PO
79521162|NCT01385280|Other|laboratory biomarker analysis|Correlative studies
79521163|NCT01385280|Other|enzyme-linked immunosorbent assay|Correlative studies
79521164|NCT01365156|Procedure|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
79521165|NCT01365156|Radiation|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
79822574|NCT00584870|Drug|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
79822575|NCT00584870|Drug|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
79996913|NCT02858492|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
79996914|NCT01067508|Other|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
79996915|NCT03609554|Other|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
79225826|NCT04405622|Drug|Toripalimab plus gemcitabine|Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
79521166|NCT01350258|Drug|Fludarabine|Part of the conditioning regimen
79521167|NCT01350258|Drug|Thiotepa|Part of the conditioning regimen
79677315|NCT02953353|Device|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
79521168|NCT01350258|Radiation|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
79521169|NCT01350258|Biological|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
79521170|NCT01350258|Drug|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
79677316|NCT02953353|Other|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
79677317|NCT02953353|Other|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
79677318|NCT00501371|Drug|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
79677319|NCT00501371|Drug|Placebo|soft-gel capsule, Qd, 12 weeks
79677320|NCT00509652|Procedure|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
79677321|NCT00509652|Procedure|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
79677322|NCT00501410|Drug|5-FU|2400 mg/m^2 by vein over 46 Hours On Days 1 & 2.
79677323|NCT00501410|Drug|Cetuximab|Initial Dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8
79225827|NCT02223585|Other|Animal-based protein diet|
79521171|NCT01350258|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
79521172|NCT01319760|Device|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
79521173|NCT01319760|Other|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
79521174|NCT01302444|Drug|Tadalafil|Tadalafil 40mg for 12 weeks
79521175|NCT01302444|Drug|Placebo|Placebo for 12 weeks
79521176|NCT01292070|Biological|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm."
79521177|NCT01292070|Biological|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
79521178|NCT01292070|Biological|Positive Control - Histamine Prick|1.0 mg/mL
79521179|NCT01292070|Biological|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
79521180|NCT01284504|Drug|Celecoxib|200 mg tablet oral
79521181|NCT01284504|Other|placebo|Placebo, tab
79521182|NCT01204788|Procedure|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
79521183|NCT01204788|Procedure|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
79521184|NCT01183416|Drug|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are ~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
79225828|NCT02223585|Other|Vegan-based protein diet|
79521185|NCT01169610|Drug|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
79521186|NCT01166724|Drug|Sirolimus|Tacrolimus to Sirolimus
79521187|NCT01166724|Drug|Tacrolimus|dosage per trough level
79521188|NCT01151904|Drug|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
79677324|NCT00501410|Drug|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
79677325|NCT00501410|Drug|Leucovorin|400 mg/m^2 by vein on day 1.
79996916|NCT01067352|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
79996917|NCT02986074|Device|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
79225829|NCT03478722|Other|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
79225830|NCT03478722|Other|Stable Isotope Amino Acid Infusion|Continuous infusion of L-[1-13C]leucine (0.13 μmol⋅kg⋅min) and L-[ring- 2H5]phenylalanine (0.05 μmol⋅kg⋅min)
79225831|NCT02227641|Biological|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
79677326|NCT00501410|Drug|Oxaliplatin|85 mg/m^2 by vein on day 1.
79677327|NCT02953392|Device|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
79677328|NCT02953392|Device|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
79996918|NCT02986074|Device|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
79225832|NCT02723084|Drug|ABT-493/ABT-530|Co-formulated tablet
79225833|NCT02723084|Drug|sofosbuvir (SOF)|Tablet
79225834|NCT02723084|Drug|ribavirin (RBV)|Capsule
79225835|NCT02750943|Drug|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
79225836|NCT02750943|Drug|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
79225837|NCT03446118|Diagnostic Test|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
79521189|NCT01151904|Drug|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
79521190|NCT01110174|Diagnostic Test|HD PET/CT|imaging
79521191|NCT01115244|Drug|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
79521192|NCT01079598|Device|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
79521193|NCT01031550|Drug|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
79521194|NCT01031550|Drug|propofol|standard of care
79822576|NCT00584870|Drug|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
79677329|NCT02953392|Device|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
79677330|NCT02953392|Device|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
79677331|NCT00501449|Behavioral|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
79677332|NCT00508833|Biological|287615 containing HBsAg with adjuvants|
79368372|NCT01729039|Behavioral|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
79677333|NCT02955953|Drug|LY2963016|Administered SC
79677334|NCT02953275|Drug|vedolizumab|standard of care
79677335|NCT02953275|Drug|Pentoxifylline|added to vedolizumab
79677336|NCT02953275|Drug|placebo|added to vedolizumab
79822577|NCT00679341|Drug|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
79822578|NCT00679341|Drug|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
79822579|NCT00679341|Drug|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
79822580|NCT00679263|Drug|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
79368373|NCT01729039|Behavioral|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
79822581|NCT00679263|Drug|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
79822582|NCT00679263|Drug|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
79996919|NCT03658122|Behavioral|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
79677337|NCT00501488|Drug|rosiglitazone|
79677338|NCT02953119|Other|Prehabilitation|
79677339|NCT02955563|Other|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
79677340|NCT00508911|Drug|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
79677341|NCT00508911|Drug|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
79677342|NCT02955719|Drug|Sertraline|
79677343|NCT02955719|Drug|Venlafaxine|
79822583|NCT02588300|Procedure|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
79677344|NCT02955719|Other|CBT/Psychological Therapy|
79677345|NCT02955719|Other|Psychiatric Consultation|
79677346|NCT02955719|Other|Lifestyle Intervention Resources|
79677347|NCT00509691|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
79677348|NCT00509691|Genetic|polymerase chain reaction|
79677349|NCT00509691|Other|diagnostic laboratory biomarker analysis|
79677350|NCT00509691|Other|flow cytometry|
79677351|NCT00509691|Other|immunologic technique|
79677352|NCT00501527|Biological|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
79677353|NCT00501527|Other|Placebo|Placebo 2 drops daily
79677354|NCT00509730|Procedure|Urodynamics|
79677355|NCT02955524|Drug|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
79677356|NCT02955524|Drug|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
79677357|NCT02953041|Drug|Glycopyrronium|long-acting muscarinic antagonist
79677358|NCT02953041|Drug|Indacaterol|ultra long-acting beta agonist
79677359|NCT00501566|Drug|satavaptan (SR121463B)|
79996920|NCT02920242|Drug|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
79996921|NCT02920242|Drug|Rifaximin (Xifaxan)|200 mg tablet administered orally
79368374|NCT01775995|Behavioral|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
79225838|NCT02471066|Device|rTMS|"Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
79225839|NCT03481920|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
79368375|NCT01775995|Other|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
79368376|NCT01741532|Drug|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
79521195|NCT00986310|Drug|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
79521196|NCT00986310|Drug|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
79521197|NCT00907218|Drug|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
79225840|NCT03481920|Drug|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
79225841|NCT02227797|Drug|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
79521198|NCT00895284|Procedure|Robotic hysterectomy|Robotic hysterectomy.
79677360|NCT00509808|Device|Electrostimulation|"1st month GN wearing (activated or sham mode)~2nd month wearing (opposite mode)~3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
79677361|NCT00501605|Drug|AZD2171|
79225842|NCT02470988|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|
79822584|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
79225843|NCT02470988|Behavioral|CBASP Without DPI|
79225844|NCT05784337|Device|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
79225845|NCT05784324|Other|No intervention|No intervention
79225846|NCT05784259|Behavioral|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
79521199|NCT00895284|Procedure|Standard Hysterectomy|Standard hysterectomy.
79521200|NCT00903396|Drug|palonosetron hydrochloride|Given IV
79521201|NCT00903396|Other|placebo|Given IV
79521202|NCT00875394|Drug|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
79521203|NCT00875394|Drug|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
79521204|NCT00875394|Drug|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
79521205|NCT00875394|Drug|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
79225847|NCT05784220|Behavioral|DPP Curriculum for Lifestyle Intervention|See arms.
79225848|NCT05784207|Other|Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern|The aim is to evaluate the performance of AI with the performance of doctors
79228158|NCT02457156|Drug|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
79368377|NCT01741532|Drug|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
79677362|NCT00509847|Drug|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
79677363|NCT01248494|Drug|BEZ235|"Dose level 1: 400mg PO BID~Dose level -1: 400mg PO in AM and 200mg PO in PM~Dose level -2: 200mg PO BID"
79677364|NCT01248494|Drug|BKM 120|"Dose Level 1: BKM120, 100 mg PO daily~Dose level -1: BKM120, 80 mg PO daily~Dose Level -2: BKM120, 60 mg PO daily"
79677365|NCT01248494|Drug|Letrozole|All levels: 2.5mg/day PO
79822585|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
79822586|NCT00680043|Drug|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
79225849|NCT05784168|Other|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
79225850|NCT05784168|Other|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
79225851|NCT05784155|Drug|Test Drug(JW0302) or Reference Drug(C2206)|"Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
79225852|NCT05784142|Radiation|hypofractionated radiation therapy|"Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
79521206|NCT00832572|Drug|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
79521207|NCT00832572|Drug|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
79521208|NCT00811590|Drug|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~directly on the tumor cells by inhibiting tumor cell growth and proliferation~indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
79521209|NCT00749658|Drug|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
79521210|NCT00749658|Drug|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
79521211|NCT00738972|Drug|valsartan|80 mg valsartan. Duration: 12 months. Tablets
79225853|NCT05784090|Other|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
79521212|NCT00738972|Drug|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
79521213|NCT00738972|Drug|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
79521214|NCT00738972|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
79225854|NCT05784077|Diagnostic Test|Polysomnography|Study of the sleep pattern
79225855|NCT05784077|Behavioral|Lifestyle counselling|Weight loss counselling
79225856|NCT05784064|Behavioral|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
79225857|NCT05784038|Diagnostic Test|Viral genomic|Evaluation of mpox viral genomic
79521215|NCT00726180|Drug|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
79225858|NCT05784038|Diagnostic Test|Untargeted Metabolomics|Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
79225859|NCT05783986|Other|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
79225860|NCT05783947|Diagnostic Test|Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera|Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
79225861|NCT05783934|Diagnostic Test|18F-florbetaben PET/CT|"The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.~Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.~A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.~Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake."
79521216|NCT00704496|Drug|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
79521217|NCT00692094|Biological|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
79521218|NCT00692094|Biological|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
79521219|NCT00692094|Biological|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
79521220|NCT00692094|Biological|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
79822587|NCT00918944|Other|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~A data entry tool for capturing asthma control data~Standardized documentation templates to facilitate severity classification~Order sets to facilitate ordering controller medications~An asthma care plan that can be supplied to families"
79368378|NCT01719224|Procedure|elevated body position|45 degrees elevated upper body position
79368379|NCT01719224|Procedure|supine body position|non-elevated upper body position
79521221|NCT00676026|Drug|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
79677366|NCT01248494|Drug|BKM120|"Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
79677367|NCT00509886|Drug|Drysol|20% aluminum chloride hexahydrate
79225862|NCT05783895|Diagnostic Test|Post screening diagnostic test|1) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
79225863|NCT05783882|Drug|Prolgolimab|250 mg Q3W
79225864|NCT05783856|Combination Product|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
79225865|NCT05783856|Drug|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
79225866|NCT05783830|Drug|ACD856|IV injection 100 mcg
79225867|NCT05783778|Diagnostic Test|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
79225868|NCT05783752|Behavioral|Stair Stepping|1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal
79368380|NCT01717976|Behavioral|DISPO ED|primary care based nurse telephone support
79368381|NCT01740440|Device|BMR Face|BMR Face used in accordance with manufacturer IFU
79368382|NCT01740128|Device|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
79368383|NCT01740128|Other|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
79225869|NCT05783752|Behavioral|No exercise control|Participants avoid exercise within 1 hour of eating a meal
79368384|NCT01976741|Drug|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
79368385|NCT01976741|Drug|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
79368386|NCT01976741|Drug|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
79368387|NCT01727713|Drug|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
79368388|NCT04658927|Drug|Dexamethasone, 0.4mg|iLUX + dextenza
79368389|NCT04658927|Drug|Prednisone acetate|Prednisolone acetate 1% and iLux
79521222|NCT00676026|Drug|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
79368390|NCT04658927|Other|Control|iLUX alone.
79521223|NCT00676026|Drug|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
79521224|NCT00679926|Drug|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
79677368|NCT00509886|Drug|Drioff|1% aluminum acetate
79677369|NCT00501683|Drug|Radiolabelled GSK189075|
79822588|NCT00918944|Other|Intervention|"Three alerts and two reminders will be programmed:~Alert providers to enter asthma severity classification if none is on file~Alert providers to prescribe controller medications for persistent asthma if none on file~Alert providers to complete an asthma care plan if none on file~Remind providers to review the asthma care plan if it is already on file by providing a link to the form~Remind providers that educational content is available on-line by providing a web link"
79368391|NCT01965431|Drug|BI 207127|Medium dose oral administration
79368392|NCT01965431|Drug|BI 207127 placebo|
79368393|NCT01965431|Drug|Faldaprevir placebo|
79368394|NCT01965431|Drug|Faldaprevir|Medium dose oral administration
79368395|NCT01965431|Drug|Moxifloxacin (Avalox®)|
79521225|NCT00680316|Drug|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
79521226|NCT00680316|Drug|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
79521227|NCT00656916|Drug|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
79521228|NCT00629850|Device|Powerlung Performer|Inspiratory/Expiratory muscle trainer
79677370|NCT02952573|Drug|JNJ-42756493|Once daily dosing
79677371|NCT02952573|Drug|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
79677372|NCT03459963|Device|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
79822589|NCT02560545|Drug|Cannabis oil|Cannabis oil 20% THC
79996922|NCT02920242|Drug|Placebo|Matching Placebo tablet administered orally
79996923|NCT02985996|Drug|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
79521229|NCT00619242|Drug|sorafenib|2 tablets with water by mouth twice a day for two weeks.
79521230|NCT00601848|Drug|chemotherapy|
79368396|NCT01976663|Device|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
79996924|NCT02985996|Drug|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
79996925|NCT03225833|Drug|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
79996926|NCT03225833|Drug|Placebo|0.9% Sodium Chloride
79225870|NCT05783713|Other|Influenza Vaccination|Describe and measure any differences in total influenza vaccination coverage, in different categories of professionals and in different operational units.
79368397|NCT01976663|Device|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
79368398|NCT01775137|Drug|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
79368399|NCT01976507|Drug|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
79677373|NCT01248572|Device|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
79677374|NCT02953080|Other|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
79677375|NCT00501722|Drug|satavaptan (SR121463B)|
79677376|NCT02952768|Behavioral|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
79677377|NCT01248611|Drug|fentanyl|nasally, dose titrated to effect
79677378|NCT00509964|Drug|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
79677379|NCT00509964|Drug|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
79677380|NCT04696874|Procedure||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
79996927|NCT03659760|Other|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
79996928|NCT03659682|Drug|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
79228159|NCT03313466|Behavioral|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
79368400|NCT04661579|Biological|RTS,S/AS01E|Vaccine
79228160|NCT03313466|Behavioral|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
79228161|NCT02470130|Behavioral|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
79228162|NCT02523300|Procedure|TEVAR|The patients will be undertaken TEVAR
79368401|NCT04661579|Biological|Abhayrab rabies vaccine|Vaccine
79368402|NCT01964963|Drug|Alogliptin|Alogliptin tablets
79368403|NCT04739657|Device|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
79521231|NCT00601848|Drug|porfimer sodium|
79521232|NCT00601848|Other|immunohistochemistry staining method|
79521233|NCT00601848|Other|laboratory biomarker analysis|
79521234|NCT00601848|Procedure|spectroscopy|
79521235|NCT00601848|Procedure|therapeutic conventional surgery|
79521236|NCT00586716|Drug|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
79521237|NCT00571194|Drug|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
79521238|NCT00570258|Drug|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
79521239|NCT00570258|Drug|erlotinib|150 mg PO QD
79521240|NCT00570258|Drug|Fulvestrant|250 mg IM Q 4 weeks
79521241|NCT00570258|Drug|Placebo|Placebo 150 mg PO QD
79521242|NCT00568698|Drug|Hydroxyurea|
79521243|NCT00568698|Drug|Placebo to match hydroxyurea|
79521244|NCT00577356|Drug|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
79521245|NCT00577356|Biological|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
79677381|NCT02952729|Drug|XMT-1522|one intravenous dose administered in-clinic every 21 days
79677382|NCT00501761|Behavioral|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
79996929|NCT03203447|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
79996930|NCT03203447|Drug|suprachoroidal sham|sham suprachoroidal procedure
79996931|NCT03203447|Drug|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
79996932|NCT03659526|Diagnostic Test|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
79996933|NCT02858726|Drug|CR845 0.5 mcg/kg|IV medication delivered three times/week
79996934|NCT02858726|Drug|CR845 1 mcg/kg|IV medication delivered three times/week
79996935|NCT02858726|Drug|CR845 1.5mcg/kg|IV medication delivered three times/week
79996936|NCT02858726|Drug|Placebo|IV medication delivered three times/week
79225871|NCT05783674|Other|Brain Breaks® Video Exercises|A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.
79368404|NCT04739657|Device|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
79521246|NCT00569868|Drug|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
79521247|NCT05599854|Procedure|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
79521248|NCT05599542|Other|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
79521249|NCT05599542|Other|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
79521250|NCT05599230|Drug|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
79521251|NCT05573256|Behavioral|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
79521252|NCT05573256|Behavioral|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
79677383|NCT00501761|Behavioral|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
79677384|NCT00501761|Behavioral|Suggested Exercise Program|Exercise program performed over 7 days.
79677385|NCT01248650|Drug|nalfurafine hydrochloride|
79677386|NCT00510471|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
79677387|NCT00501839|Drug|clomiphene citrate|
79677388|NCT00510003|Drug|Pimecrolimus|Pimecrolimus cream 1 %
79677389|NCT00501878|Drug|2.5% or 10% phenylephrine|
79677390|NCT00510549|Procedure|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
79677391|NCT00501917|Drug|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
79677392|NCT00510588|Other|training|regular physical exercise training for 6 months
79677393|NCT00510588|Other|training + metformin|regular physical exercise training in combination with metformin for 6 months
79677394|NCT00510588|Other|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
79677395|NCT00501956|Drug|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
79228163|NCT02523300|Drug|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
79368405|NCT01964105|Device|3D Imaging|
79368406|NCT01974323|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
79368407|NCT01974323|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
79368408|NCT01963403|Drug|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
79677396|NCT00510627|Device|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
79677397|NCT00510627|Drug|Chemotherapy|Standard of care chemotherapy regimen
79677398|NCT02953236|Procedure|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
79677399|NCT02953236|Procedure|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
79677400|NCT00502034|Drug|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
79677401|NCT00502034|Drug|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
79677402|NCT00510666|Drug|Saline|Saline infusion adjunct to morphine PCA pump
79677403|NCT00510666|Drug|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
79677404|NCT00510666|Drug|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
79677405|NCT00510666|Drug|Saline|Preemptive saline as a control group to tramadol one
79521253|NCT05533476|Behavioral|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
79677406|NCT00508092|Procedure|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
79677407|NCT01248845|Other|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
79677408|NCT00510705|Other|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
79822590|NCT02560467|Drug|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
79996937|NCT03203291|Device|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
79996938|NCT03609476|Procedure|Room temperature saline instillation|Saline is used as room temperature
79996939|NCT03609476|Procedure|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
79996940|NCT03609476|Procedure|No saline instillation|No saline is used prior to catheter removal
79225872|NCT05783674|Other|Posture training|All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
79225873|NCT05783557|Drug|Clevidipine Butyrate Injectable Emulsion|intravenous injection
79368409|NCT01963403|Drug|Placebo|1 pill per day; daily during study participation (up to 84 days)
79677409|NCT00510705|Other|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
79677410|NCT00510705|Other|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
79996941|NCT04549610|Dietary Supplement|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
79677411|NCT00502073|Drug|cyclosporine|
79996942|NCT04549610|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
79996943|NCT01068678|Drug|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
79996944|NCT01068678|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
79225874|NCT05783557|Drug|Cleviprex®|intravenous injection
79225875|NCT05783531|Other|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
79225876|NCT05783531|Other|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
79996945|NCT03202511|Drug|Probenecid Oral Tablet|Included in arm/group descriptions.
79996946|NCT03202511|Drug|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
79996947|NCT03609710|Device|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
79996948|NCT03609710|Procedure|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
79225877|NCT05783518|Drug|desflurane|Intraoperative anesthesia maintenance
79225878|NCT05783518|Drug|propofol|Intraoperative anesthesia maintenance
79225879|NCT05783492|Drug|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
79225880|NCT05783479|Drug|estradiol|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
79368410|NCT04416503|Other|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
79368411|NCT01973387|Drug|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
79368412|NCT01973387|Drug|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
79368413|NCT04657445|Diagnostic Test|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
79996949|NCT03609710|Procedure|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
79225881|NCT05783479|Drug|Hyaluronic acid|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
79368414|NCT01973231|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
79368415|NCT01973231|Drug|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
79368416|NCT01961687|Device|Resorbable Mesh|Phasix Mesh
79521254|NCT05533476|Behavioral|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
79368417|NCT04656275|Drug|BI 1323495|BI 1323495
79521255|NCT05403762|Other|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
79521256|NCT05403762|Other|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
79521257|NCT05381376|Diagnostic Test|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
79521258|NCT05381376|Diagnostic Test|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
79521259|NCT05330442|Behavioral|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
79521260|NCT05288946|Other|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
79521261|NCT05288946|Other|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
79677412|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
79677413|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
79677414|NCT01248923|Drug|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
79677415|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
79677416|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
79677417|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
79996950|NCT03609710|Device|Robotic surgery|Robotic low anterior resection for rectal cancer
79996951|NCT03637049|Drug|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
79996952|NCT03636971|Drug|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
79225882|NCT05783453|Other|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~Formula: 2039055 06~Aspect: Emulsion~Batch nº: RAUO0063~Expiry date: 10/2022~Application area: Face and Body~Application mode: Apply to face and body twice a day.~Quantity of product to be applied: About 1 flask (400g) per month"
79225883|NCT05783440|Behavioral|direct patient feedback|"Participants in the intervention group report postoperative pain scores and other pain related outcomes with their own smartphone. Pain scores reported by smartphone > 3 (NRS 0-10) are immediately passed on to the nurse who will receive a notification on a smartphone.~All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward."
79225884|NCT05783284|Device|Holocare Studio 2 (HS2)|3D HV
79225885|NCT05783193|Drug|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
79225886|NCT05783193|Drug|Placebo|Placebo capsules
79228164|NCT02523300|Drug|saline|The other 120 patients will be given saline as control group
79368418|NCT04656275|Drug|Placebo|Placebo
79368419|NCT04174391|Behavioral|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
79368420|NCT04174391|Behavioral|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
79368421|NCT02151994|Drug|BIA 5-1058|oral administration
79521262|NCT05288946|Other|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
79521263|NCT05164614|Combination Product|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
79521264|NCT05164614|Drug|Forteo|A commercial formulation of PTH for SC control (20 µg)
79677418|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
79677419|NCT01249001|Drug|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
79225887|NCT05783154|Biological|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
79677420|NCT01249001|Drug|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
79677421|NCT01249040|Procedure|Physical therapy|
79677422|NCT01249040|Procedure|steroid intraarticular injection|
79677423|NCT00502112|Drug|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
79677424|NCT00502112|Drug|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
79677425|NCT04695912|Device|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
79996953|NCT03636971|Drug|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
79996954|NCT03636971|Drug|Placebos|single shot injection of saline, same volume
79225888|NCT05783128|Other|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
79225889|NCT05783115|Procedure|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
79225890|NCT05783115|Procedure|Tibial Transportation|transverse bone transport
79225891|NCT05782959|Biological|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
79225892|NCT05782933|Drug|Rituximab|Rituximab combined with or without cyclosporine
79225893|NCT05782933|Drug|Modified Ponticelli regimen|Corticosteroid and cyclophosphamide
79225894|NCT05782920|Device|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
79368422|NCT02151994|Drug|Placebo|oral administration
79368423|NCT04640974|Device|Cingal|CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
79368424|NCT00812110|Drug|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
79368425|NCT05356468|Other|Structured pain neuroscience education|"Structured pain neuroscience~Neurophysiology of pain~The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~Metaphor Alarm system: Your nerves working like an alarm system to protect you.~BOOKLET Consist of education about pain neurophysiology.(31)~Steps of booklet :~Extract content~English to Urdu translation~Content Validity~Expert Panel review by Physiotherapists~Content validity Analysis review(Focus Group)~Pilot study 4 to 5 patients~Content improved (PNE) and Finalized~After Analysis RCT"
79521265|NCT05164614|Combination Product|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
79521266|NCT05001048|Drug|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
79521267|NCT05001048|Other|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
79521268|NCT05001048|Other|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
79521269|NCT05001048|Other|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
79677426|NCT03459495|Device|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
79677427|NCT03459495|Device|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
79677428|NCT00502190|Device|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
79677429|NCT01249079|Other|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
79677430|NCT00510822|Drug|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
79677431|NCT00510822|Drug|Placebo|tablet
79677432|NCT00502229|Drug|Clomiphene citrate, metformin, highly purified urinary FSH|
79677433|NCT02953158|Other|Haas Avocado|Hypocaloric weight loss diet
79677434|NCT02953158|Behavioral|Dietary Counseling|Dietary Counseling
79677435|NCT00502268|Drug|Doxercalciferol administration|Doxercalciferol administration
79677436|NCT00502268|Drug|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
79677437|NCT02953197|Radiation|FDG-PET guided radiation dose escalation|Selective dose escalation
79677438|NCT00502346|Drug|PM10|
79996955|NCT03610100|Drug|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
79996956|NCT03610100|Drug|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
79996957|NCT03657966|Biological|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
79996958|NCT03657966|Drug|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
79996959|NCT03659370|Other|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
79225895|NCT05782920|Device|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
79225896|NCT05782920|Device|topical HA gel|the standard treatment of vaginal atrophy and dryness
79368426|NCT05356468|Other|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~Hot pack(27)~Therapeutic exercises~Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~good posture when sitting standing and while driving~Avoid weight lifting~Avoid too much bed rest~Sit in firm places. (30)"
79368427|NCT04382950|Combination Product|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
79521270|NCT04954638|Other|endodontic desinfection|"outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~using microbiological methods~outcome assessed by radiological method and clinical evaluation"
79521271|NCT04906200|Other|Best Practice|Receive usual care
79521272|NCT04906200|Other|Internet-Based Intervention|Receive access to YES portal
79521273|NCT04906200|Other|Survey Administration|Complete survey
79521274|NCT04848870|Other|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
79996960|NCT03659370|Other|Acupuncture|Acupuncture
79996961|NCT03659292|Other|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
79996962|NCT03659292|Other|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
79521275|NCT04772742|Drug|Placebo|Placebo - solution for infusion
79225897|NCT05782829|Dietary Supplement|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
79225898|NCT05782829|Dietary Supplement|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
79225899|NCT05782803|Behavioral|Exercises Group|A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
79521276|NCT04772742|Drug|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
79521277|NCT04702386|Behavioral|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
79996963|NCT03659292|Other|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
79996964|NCT03659292|Other|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
79996965|NCT03659058|Drug|silymarin|silymarin 140 three times daily
79996966|NCT03659058|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
79996967|NCT03659058|Drug|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
79996968|NCT03659058|Drug|Colchicine|Colchicine 0.6
79228165|NCT03313388|Dietary Supplement|Drink|Beverage to be consumed
79228166|NCT03471546|Behavioral|Palliative Care|Initial consultation and follow-up with a palliative care provider
79521278|NCT04702386|Behavioral|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
79521279|NCT04575090|Drug|Simvastatin|Simvastatin 40 mg daily.
79521280|NCT04302948|Other|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
79677439|NCT01249196|Drug|SK-PC-B70M|for dosage
79677440|NCT00510081|Device|Calcium Hydroxylapatite injection|filler injection
79677441|NCT00502385|Drug|AZD2171|
79996969|NCT03659058|Other|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
79996970|NCT01331473|Procedure|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
79521281|NCT04234152|Other|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
79521282|NCT04234152|Other|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
79521283|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
79521284|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
79521285|NCT04012008|Other|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
79521286|NCT04012008|Other|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
79521287|NCT03472872|Drug|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
79368428|NCT04382560|Other|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
79521288|NCT03472872|Drug|Acetaminophen|1,000mg acetaminophen IVPB
79521289|NCT02836470|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
79521290|NCT02836470|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
79521291|NCT02808702|Behavioral|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
79521292|NCT02411526|Drug|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
79521293|NCT02411526|Drug|Risperdal Consta|Risperdal Consta administered as a IM injection
79521294|NCT02411526|Drug|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
79521295|NCT02400060|Behavioral|Telephone-Based Intervention|Receive text messaging
79521296|NCT02400060|Other|Survey Administration|Ancillary studies
79521297|NCT02400060|Other|Laboratory Biomarker Analysis|Correlative studies
79521298|NCT00564876|Drug|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
79521299|NCT00558870|Drug|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
79521300|NCT00558870|Drug|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
79521301|NCT00548886|Drug|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
79521302|NCT00538980|Drug|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
79996971|NCT01331473|Procedure|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
79521303|NCT00529464|Procedure|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
79521304|NCT00529464|Procedure|Colposcopy|A standard colposcopy will be performed.
79996972|NCT03635905|Drug|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
79225900|NCT05782777|Drug|ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
79225901|NCT05782777|Drug|high-intensity statin monotherapy (atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
79228167|NCT04491500|Behavioral|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
79996973|NCT03635905|Drug|Placebo|Methylcellulose placebo capsule
79368429|NCT04382560|Other|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
79368430|NCT01961609|Biological|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
79225902|NCT05782764|Drug|To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).|immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
79225903|NCT05782751|Procedure|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
79225904|NCT05782751|Procedure|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
79368431|NCT04468672|Behavioral|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
79996974|NCT02960113|Drug|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
79368433|NCT00800254|Device|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
79368434|NCT00800254|Other|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
79225905|NCT05781074|Drug|Sintilimab|a PD-1 immune checkpoint inhibitor
79225906|NCT05781074|Drug|Lenvatinib|Lenvatinib capsules
79225907|NCT05781074|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision
79225908|NCT05780047|Diagnostic Test|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
79225909|NCT05779657|Drug|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
79368435|NCT03753646|Other|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
79368436|NCT04383418|Drug|dexmedetomidine nasal spray|dexmedetomidine nasal spray
79225910|NCT05779657|Drug|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
79225911|NCT05779657|Drug|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
79225912|NCT05779267|Drug|NRX-101|D-cycloserine/lurasidone fixed dose combination
79225913|NCT05777473|Behavioral|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
79368437|NCT04383418|Drug|dexmedetomidine hydrochloride nasal spray blank preparation|dexmedetomidine hydrochloride nasal spray blank preparation
79368438|NCT03414112|Biological|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
79368439|NCT02152540|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
79368440|NCT02152540|Device|Sham rTMS|Placebo Device that simulates active rTMS treatment
79368441|NCT04383184|Procedure|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
79368442|NCT05287204|Diagnostic Test|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
79368443|NCT05287204|Diagnostic Test|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
79368444|NCT05287204|Diagnostic Test|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
79368445|NCT03839134|Device|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
79368446|NCT03839134|Drug|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
79521305|NCT00529464|Procedure|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
79677442|NCT02952651|Procedure|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
79996975|NCT02960113|Device|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
79996976|NCT04850365|Procedure|Hysteropexy|"Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion."
79996977|NCT02919696|Drug|Abemaciclib|Administered orally
79225914|NCT05777473|Behavioral|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
79225915|NCT05777473|Behavioral|Adopt-a-Friend|"The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed."
79225916|NCT05774054|Drug|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)> 65 mmHg despite adequate fluid resuscitation
79225917|NCT05774054|Drug|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
79225918|NCT05773651|Other|Data collection|The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
79225919|NCT05766761|Behavioral|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
79996978|NCT02740452|Device|ligamys technique|Ligamys technique (device) or standard technique
79996979|NCT02740452|Other|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
79225920|NCT05751148|Drug|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
79225921|NCT05751148|Drug|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
79225922|NCT05741697|Drug|bi-level ventillation|non-invasive mechanical ventilation
79225923|NCT05717985|Procedure|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
79225924|NCT05717985|Procedure|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
79225925|NCT05711199|Drug|Glyceroltrinitrat|transdermal patch
79225926|NCT05703074|Dietary Supplement|Nicotinamide Riboside (NR)|4 capsules (a total of 1000 mg) 2 times daily for 84 days
79225927|NCT05703074|Behavioral|Mind-body reprocessing therapy (MBRT)|4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
79225928|NCT05703074|Behavioral|Care as usual|A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
79225929|NCT05703074|Dietary Supplement|Placebo|4 capsules (empty) 2 times daily for 84 days.
79521306|NCT00519090|Drug|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
79521307|NCT00519090|Drug|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
79521308|NCT00506064|Drug|Melatonin|0.15 mg/kg by mouth (PO) Daily
79521309|NCT00506064|Drug|Placebo|Two, three, or four starch tablet or capsules before bed
79996980|NCT02935673|Drug|lumicitabine|Oral administration of lumicitabine as tablet.
79996981|NCT02935673|Drug|Placebo|Oral administration of matching placebo.
79996982|NCT03622398|Procedure|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
79996983|NCT03622398|Procedure|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
79996984|NCT03201809|Device|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
79521310|NCT00506064|Behavioral|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
79677443|NCT01249235|Procedure|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
79677444|NCT00510120|Behavioral|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
79996985|NCT03201809|Drug|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
79996986|NCT04458324|Drug|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
79996987|NCT04458324|Drug|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
79225930|NCT05701865|Behavioral|Alcohol Intoxication- Ascending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the ascending limb
79225931|NCT05701865|Behavioral|Alcohol Intoxication- Descending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the descending limb
79225932|NCT05701865|Behavioral|No Alcohol Control|Participants will be assigned to a no alcohol control condition
79225933|NCT05684809|Other|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
79225934|NCT05684809|Other|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
79225935|NCT05684809|Other|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
79225936|NCT05680051|Device|Drug-eluting balloon|Drug eluting balloon was used in the experimental group
79225937|NCT05680051|Device|Drug-eluting stent|Drug eluting stent was used in the control group
79225938|NCT05676255|Behavioral|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
79368447|NCT03180580|Behavioral|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
79368448|NCT03906526|Drug|VTX-2337|Motolimod
79368449|NCT03906526|Drug|Nivolumab|IV Nivolumab
79368450|NCT03088930|Drug|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
79368451|NCT03035188|Drug|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
79368452|NCT05265754|Behavioral|sujok therapy|sujok therapy
79368453|NCT02923882|Other|'$100Kitchen and improved cookstove'|
79368454|NCT02152696|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
79368455|NCT02152696|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
79368456|NCT02152696|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
79368457|NCT02153476|Drug|2.0mg of ALG-1001|
79368458|NCT02153476|Drug|Balanced Salt Solution|
79368459|NCT03839290|Procedure|Early neonatal cheiloplasty|
79368460|NCT03834922|Other|Prospective data collection|No intervention. It's a prospective data collection.
79368461|NCT03839992|Diagnostic Test|spirometry|measure spirometry and lung CT
79368462|NCT05172232|Diagnostic Test|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
79368463|NCT02009176|Procedure|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
79368464|NCT02009176|Procedure|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
79368465|NCT01905436|Drug|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
79677445|NCT00510120|Behavioral|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
79677446|NCT00510120|Behavioral|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
79677447|NCT00502424|Device|Splint|
79677448|NCT00510159|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
79225939|NCT05676255|Behavioral|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
79368466|NCT00802204|Radiation|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride [18F] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
79368467|NCT00802204|Procedure|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
79996988|NCT04458324|Device|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
79996989|NCT04458324|Device|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
79225940|NCT05676255|Behavioral|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
79225941|NCT05674721|Drug|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
79225942|NCT05674721|Drug|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
79225943|NCT05668598|Diagnostic Test|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
79225944|NCT05667766|Diagnostic Test|Release of Extended Pharmacogenomics Report at Week 1|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
79225945|NCT05667766|Diagnostic Test|Release of Extended Pharmacogenomics Report at Week 13|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
79368468|NCT00802204|Procedure|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
79368469|NCT00802204|Behavioral|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
79368470|NCT00802204|Other|Caloric Restriction|Obese participants only complete a short-term (~10days) very low calorie diet
79368471|NCT01853020|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
79368472|NCT01853020|Drug|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
79368473|NCT01256086|Drug|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
79368474|NCT01256086|Drug|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
79368475|NCT01256086|Drug|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
79368476|NCT01256086|Drug|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
79368477|NCT01149850|Biological|bevacizumab|Given IV
79368478|NCT01149850|Drug|temozolomide|Given orally
79368479|NCT01149850|Other|laboratory biomarker analysis|Correlative studies
79677449|NCT00510159|Drug|Praziquantel|
79677450|NCT00502502|Behavioral|Questionnaire|Weekly questionnaires lasting about 30 minutes.
79677451|NCT01249391|Device|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
79677452|NCT02952807|Drug|Misoprostol|vaginal Misoprostol Plus Foley Catheter
79677453|NCT02952807|Device|Foley Catheter|
79677454|NCT02275130|Procedure|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
79677455|NCT02275130|Device|Radiesse Voice (Calcium Hydroxyapatite)|
79521311|NCT00475332|Drug|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm^3) total body radiation dose can be calculated."
79677456|NCT03459417|Procedure|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
79677457|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
79677458|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
79677459|NCT00502541|Drug|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
79677460|NCT00502541|Procedure|Standard of Care|Repeat macular grid laser or observation
79677461|NCT03459378|Other|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
79677462|NCT01249430|Drug|Azacitidine|Given IV
79677463|NCT01249430|Drug|Cytarabine|Given IV
79677464|NCT01249430|Drug|Etoposide Phosphate|Given IV
79677465|NCT01249430|Other|Laboratory Biomarker Analysis|Correlative studies
79996990|NCT04458324|Other|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
79225946|NCT05664516|Drug|TNX-1900 (Tonix Pharmaceuticals)|oxytocin nasal spray
79225947|NCT05664516|Drug|Placebo|Nasal solution without oxytocin
79225948|NCT05664464|Drug|Gabapentin|Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
79225949|NCT05664464|Drug|Sulfasalazine|Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
79225950|NCT05664464|Drug|Memantine|Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
79225951|NCT05664464|Drug|Temozolomide|Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
79225952|NCT05664464|Radiation|Radiotherapy|30 x 2 Gy involved field radiotherapy with concomitant temozolomide
79225953|NCT05657457|Drug|Tenecteplase|intra-arterial tenecteplase
79225954|NCT05652647|Drug|Oral [14C]PF-07081532|A single oral dose of [14C]PF-07081532, will be administered as a liquid formulation in study period 1.
79225955|NCT05652647|Drug|Oral PF-07081532 and IV [14C]PF-07081532|In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-07081532 will be administered via intravenous infusion.
79225956|NCT05641831|Procedure|Biospecimen Collection|Undergo peripheral blood collection
79521312|NCT00475332|Procedure|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
79677466|NCT01249430|Drug|Mitoxantrone Hydrochloride|Given IV
79996991|NCT02858154|Other|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
79996992|NCT02858154|Other|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
79996993|NCT03657420|Drug|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
79996994|NCT03657420|Drug|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
79225957|NCT05641831|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
79225958|NCT05641831|Drug|Canakinumab|Given SC
79225959|NCT05641831|Procedure|Chest Radiography|Undergo chest x-ray
79225960|NCT05641831|Procedure|Echocardiography|Undergo ECHO
79225961|NCT05641831|Drug|Placebo Administration|Given SC
79225962|NCT05641831|Other|Quality-of-Life Assessment|Ancillary studies
79225963|NCT05633797|Device|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
79368480|NCT01149850|Other|immunohistochemistry staining method|Correlative studies
79368481|NCT01149850|Genetic|microarray analysis|Correlative studies
79368482|NCT01149850|Genetic|DNA methylation analysis|Correlative studies
79368483|NCT01774981|Drug|Placebo|Administered IV
79368484|NCT01774981|Drug|LY3016859|Administered IV
79368485|NCT01972841|Drug|Solifenacin succinate|Oral tablet
79368486|NCT01972841|Drug|Mirabegron|Oral tablet
79368487|NCT01972841|Drug|Placebo to match solifenacin succinate|Oral tablet
79368488|NCT01972841|Drug|Placebo to match mirabegron|Oral tablet
79677467|NCT01249430|Other|Pharmacological Study|Correlative studies
79677468|NCT02952963|Drug|Chenodeoxycholic Acid|
79677469|NCT02952963|Drug|Colesevelam|
79225964|NCT05633173|Procedure|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
79225965|NCT05633173|Procedure|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
79677470|NCT00510939|Drug|Tipifarnib plus Bortezomib|
79368489|NCT01774903|Drug|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
79368490|NCT01774591|Drug|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
79368491|NCT01774591|Drug|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
79368492|NCT01708915|Drug|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
79996995|NCT03657420|Drug|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
79368493|NCT01708915|Drug|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
79368494|NCT01708915|Drug|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
79996996|NCT02684214|Behavioral|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
79368495|NCT01708915|Drug|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
79368496|NCT01708291|Behavioral|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
79368497|NCT01708291|Behavioral|only pre and post evaluation measures|
79368498|NCT01708057|Drug|AZD8683|AZD8683 administered via inhalation
79368499|NCT01708057|Drug|Placebo|Placebo administered via inhalation
79368500|NCT01708057|Drug|Tiotropium|Tiotropium administered via inhalation
79368501|NCT01972529|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
79368502|NCT01972529|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
79368503|NCT01972529|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
79677471|NCT00504062|Drug|budesonide|
79677472|NCT00504062|Drug|fluticasone|
79677473|NCT03459339|Device|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
79677474|NCT00504101|Drug|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
79677475|NCT00504101|Drug|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
79677476|NCT00504101|Drug|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
79677477|NCT00504101|Biological|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
79677478|NCT00510978|Biological|Bifidobacterium infantis 35624|1 sachet/day for one year
79677479|NCT00510978|Biological|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
79368504|NCT01972529|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
79368505|NCT01747915|Drug|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
79368506|NCT01747915|Drug|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
79368507|NCT01747915|Drug|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
79368508|NCT03189004|Behavioral|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"Identification and registration of pregnant women and services for them~Birth notification~Childhood vaccination services under EPI~Newly married couple identification~e-Referral.~e-monitoring"
79677480|NCT00510978|Biological|Placebo|1 sachet per day for 1 year
79521313|NCT00478062|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
79677481|NCT02952690|Device|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
79368509|NCT01961297|Drug|Sodium oxybate|Sodium oxybate
79677482|NCT02952690|Device|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
79996997|NCT02684214|Behavioral|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
79996998|NCT03657498|Procedure|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
79996999|NCT03657498|Procedure|Standard orthodontic treatment|treatment with standard orthodontic procedures
79225966|NCT05633095|Device|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
79997000|NCT03657186|Dietary Supplement|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
79997001|NCT03657186|Other|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
79521314|NCT00478062|Procedure|adjuvant therapy|
79997002|NCT02985450|Biological|Engerix-B|Hepatitis B Vaccine
79997003|NCT03657030|Drug|CVN424|SAD / MAD
79997004|NCT03657030|Drug|Placebo|Placebo
79225967|NCT05783089|Biological|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
79225968|NCT05630989|Other|combination therapy with no MEKi|This cohort will receive combination therapy with no MEKi.
79225969|NCT05630989|Drug|combination therapy with MEKi-HCQ|This cohort will receive combination therapy with MEKi-HCQ.
79225970|NCT05630989|Drug|combination therapy with MEKi-EGFRi|This cohort will receive combination therapy with MEKi-EGFRi.
79225971|NCT05630989|Drug|combination therapy with MEKi.|This cohort will receive combination therapy with MEKi.
79368510|NCT04656041|Drug|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~2) Oxaliplatin via IV, predetermined dosage per protocol~3) Leucovorin via IV, predetermined dosage per protocol~4) 5-Fluorouracil via IV, predetermined dosage per protocol"
79521315|NCT00470574|Biological|QS21|
79225972|NCT05626530|Drug|Letermovir|Open label 480 mg given daily for 60 days
79368511|NCT04656041|Drug|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
79368512|NCT04656041|Drug|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
79997005|NCT02908464|Device|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
79368513|NCT04656041|Radiation|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
79368514|NCT01960907|Device|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
79521316|NCT00470574|Biological|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
79997006|NCT02907216|Biological|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
79997007|NCT02907216|Biological|Rotarix|Two doses administered orally
79997008|NCT02984982|Drug|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
79997009|NCT02984982|Drug|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
79997010|NCT02984982|Drug|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
79521317|NCT00470574|Other|immunoenzyme technique|
79521318|NCT00470574|Other|immunologic technique|
79521319|NCT00470574|Other|laboratory biomarker analysis|
79521320|NCT03053700|Drug|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
79225973|NCT05624333|Other|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
79368515|NCT01747837|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
79368516|NCT01971203|Drug|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
79368517|NCT01971203|Behavioral|CBT|16 weeks of treatment
79368518|NCT04654325|Diagnostic Test|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
79368519|NCT01605877|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
79368520|NCT01970501|Drug|bucindolol hydrochloride|
79521321|NCT03053700|Device|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
79521322|NCT00442260|Drug|DOXIL|
79521323|NCT00442260|Drug|Abraxane|
79521324|NCT00386724|Device|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
79997011|NCT02984982|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
79997012|NCT02984982|Drug|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
79521325|NCT00386724|Device|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
79997013|NCT02984982|Drug|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
79997014|NCT02984982|Drug|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
79225974|NCT05624333|Other|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
79368521|NCT01970501|Drug|metoprolol succinate|
79225975|NCT05610618|Other|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
79521326|NCT00325572|Drug|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
79521327|NCT00325572|Other|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
79677483|NCT00510237|Behavioral|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
79521328|NCT00333762|Device|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
79521329|NCT00333762|Device|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
79521330|NCT00145704|Drug|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
79677484|NCT00504140|Drug|Etoposide|100 mg/m^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
79521331|NCT00145704|Dietary Supplement|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
79521332|NCT00145704|Dietary Supplement|Calcium|calcium supplement given to patients with growth hormone deficiency
79677485|NCT00504140|Drug|Interferon Alpha|5x10^6 mu/m^2 Subcutaneously Daily for 5 Days
79677486|NCT00510315|Other|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
79677487|NCT02955992|Behavioral|Improving communication during the end-of-life process|
79677488|NCT00511017|Drug|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
79521333|NCT00108342|Drug|Nicotine gum - 2 mg and 4 mg|
79677489|NCT00504179|Procedure|Osteopathic Manipulative Treatment|
79225976|NCT05607381|Behavioral|Meditation|Participants will complete 8 sessions of meditation training with therapy as a means of coping with chronic pain and opioid-related issues.
79997015|NCT02984982|Drug|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
79997016|NCT04357158|Device|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with >2 weeks in between).
79997017|NCT03622242|Device|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
79997018|NCT03622242|Device|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
79997019|NCT03656796|Other|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
79368522|NCT01970501|Other|Placebo oral capsule|
79368523|NCT01969799|Drug|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
79368524|NCT01969799|Drug|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
79368525|NCT01969721|Drug|fluticasone propionate|low dose
79368526|NCT01969721|Drug|salmeterol|
79368527|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
79368528|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
79368529|NCT01969721|Drug|tiotropium|tiotropium high dose
79368530|NCT01969721|Drug|olodaterol|
79368531|NCT01969721|Drug|olodaterol|
79368532|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
79521334|NCT00108342|Drug|Nicotine lozenges - 2 mg and 4 mg|
79521335|NCT00108342|Drug|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
79521336|NCT00108342|Other|Computer learning|
79521337|NCT00090870|Biological|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
79521338|NCT00090870|Biological|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
79521339|NCT00090870|Drug|thalidomide|200mg daily by mouth
79677490|NCT02955875|Behavioral|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
79677491|NCT00511212|Drug|intravenous immunoglobulin|
79677492|NCT00510354|Drug|Imatinib mesylate|
79677493|NCT01241006|Drug|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
79677494|NCT01241006|Drug|Prednisone|Prednisone 60mg PO q day for 5 days
79677495|NCT04695951|Dietary Supplement|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
79225977|NCT05607381|Other|Usual care|Participants will receive usual care for chronic low back pain (e.g., analgesic medication, pain management consultant from a physician, physical therapy, etc.).
79368533|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
79521340|NCT00074724|Procedure|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
79521341|NCT00074724|Drug|Modern medical management|Therapies with evidence-based recommendations.
79521342|NCT00074724|Device|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
79521343|NCT00074724|Drug|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
79677496|NCT04695951|Other|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
79677497|NCT01249508|Other|nutrition label|
79677498|NCT00510393|Device|XIENCE V everolimus eluting coronary stent system|
79368534|NCT01969721|Drug|tiotropium|tiotropium low dose
79677499|NCT00510393|Device|MULTILINK VISION coronary stent system|
79677500|NCT01249547|Drug|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
79677501|NCT02952339|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
79677502|NCT02952339|Biological|Placebo|Administered as nose drops
79677503|NCT00504608|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
79677504|NCT00504647|Device|Biventricular Pacemaker|
79368535|NCT01969721|Drug|fluticasone propionate|low dose
79521344|NCT00058188|Dietary Supplement|cholecalciferol|Given orally
79521345|NCT00058188|Drug|calcium gluconate|Given orally
79521346|NCT00058188|Drug|zoledronic acid|Given IV
79677505|NCT02952495|Behavioral|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
79521347|NCT00003726|Biological|lepirudin|lepirudin
79368536|NCT01969721|Drug|salmeterol|
79521348|NCT02595996|Drug|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
79521349|NCT03198156|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
79521350|NCT03198156|Device|Sham stimulation|Sham stimulation
79677506|NCT01249586|Other|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
79677507|NCT00511719|Drug|Technosphere Insulin|48U
79997020|NCT03656796|Other|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
79225978|NCT05601674|Other|: Conventional flow Anesthesia|During the initial wash-in period 2 L/min Fresh gas flow will be used.
79225979|NCT05601674|Other|Low Flow Anesthesia|Fresh gas flow rate will be 0.5 L/min throughout the procedure.
79521351|NCT04422210|Drug|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
79368537|NCT01969565|Drug|Carfilzomib|
79677508|NCT00511719|Drug|Actrapid|24IU
79368538|NCT01969565|Drug|Dexamethasone|
79368539|NCT04173923|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
79368540|NCT04173923|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
79368541|NCT04173923|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
79368542|NCT04173923|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79368543|NCT04173923|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79677509|NCT00504686|Other|manual therapy|manual therapy - thoracic spine thrust manipulation
79677510|NCT00504686|Other|exercise|therapeutic exercise
79677511|NCT00511758|Procedure|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
79997021|NCT02258490|Biological|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
79997022|NCT03656484|Drug|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
79997023|NCT03656484|Drug|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
79997024|NCT04309578|Drug|Trastuzumab, Capecitabine and Cisplatin|"Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
79225980|NCT05600855|Drug|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
79997025|NCT03656952|Drug|PF-06700841|a single oral dose of 200 mg PF-06700841
79368544|NCT04173923|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
79368545|NCT04173923|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
79997026|NCT03656952|Drug|Placebo|Placebo matching PF-06700841
79368546|NCT01968707|Drug|ChloraPrep Hi-Lite Orange|Apply topically.
79997027|NCT03656952|Drug|moxifloxacin|a single oral dose of 400 mg moxifloxacin
79997028|NCT03656406|Behavioral|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
79997029|NCT03656406|Device|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
79368547|NCT01968707|Drug|Normal saline|Apply topically.
79368548|NCT01968707|Drug|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
79368549|NCT01968707|Drug|3M CHG/IPA Prep Tint 26-mL|Apply topically
79368550|NCT04650191|Other|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
79368551|NCT01959581|Device|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
79997030|NCT02237976|Behavioral|Self-hypnosis|
79368552|NCT01746901|Drug|Placebo|Placebo solution + Placebo ALO-02 (intact)
79368553|NCT01746901|Drug|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
79368554|NCT01746901|Drug|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
79368555|NCT01746901|Drug|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
79997031|NCT02237976|Behavioral|Routine practice|
79368556|NCT01746901|Drug|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
79368557|NCT01746901|Drug|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
79368558|NCT01968551|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
79368559|NCT01968551|Drug|DRV|800 mg tablet administered orally once daily
79368560|NCT01968551|Drug|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
79368561|NCT01707992|Drug|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
79368562|NCT01707992|Drug|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
79368563|NCT01946165|Drug|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
79677512|NCT01245335|Device|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
79677513|NCT01245335|Device|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
79677514|NCT00511290|Other|no generic names|
79677515|NCT00511368|Drug|matching placebo|
79677516|NCT00511368|Drug|Bevirimat|
79677517|NCT01246232|Drug|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
79677518|NCT01246232|Drug|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
79677519|NCT00511407|Device|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
79225981|NCT05599724|Other|Biocollection|"For the FERTITHEQUE, will be collected:~Clinical characteristics~Biological characteristics measured as part of the usual follow-up~consultation n°2 : DNA~consultation n°2 : plasma~consultation n°2 : serum~consultation n°2 : vaginal microbiota~consultation n°3 : follicular fluid (puncture fluid)~consultation n°4 : plasma~consultation n°4 : vaginal microbiota."
79225982|NCT05586880|Other|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
79225983|NCT05586880|Other|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
79822591|NCT05352633|Drug|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
79997032|NCT03656250|Diagnostic Test|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
79822592|NCT05352633|Drug|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP <140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
79225984|NCT05559034|Behavioral|Cognitive intervention|This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
79225985|NCT05541237|Dietary Supplement|Food|Food
79225986|NCT05533190|Device|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
79368564|NCT01946165|Drug|Prednisone|5 mg by mouth once daily for each 28 day cycle.
79677520|NCT01248962|Drug|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
79822593|NCT05058092|Device|Immediate Remedee Solution|"D0 to M3: Remedee Solution + medical care~M3 to M6: Remedee Solution without personalized support + medical care~M6 to M9: medical care only"
79822594|NCT05058092|Device|Delayed Remedee Solution|"D0 to M3: medical care only~M3 to M6: Remedee Solution + medical care~M6 to M9: Remedee Solution without personalized support + medical care"
79822595|NCT05435937|Behavioral|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
79822596|NCT05435937|Behavioral|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
79997033|NCT02981472|Drug|Apixaban|Specified dose on specified days
79997034|NCT02981472|Drug|Vitamin K Antagonist (VKA)|Specified dose on specified days
79225987|NCT05527314|Drug|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
79225988|NCT05527314|Drug|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
79677521|NCT01248962|Drug|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
79997035|NCT02981472|Drug|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
79997036|NCT03656172|Biological|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
79997037|NCT03656094|Drug|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
79997038|NCT03656094|Drug|Placebo plus chemotherapy|Placebo plus chemotherapy
79997039|NCT04298034|Drug|Labetalol, Nifedipine|Antihypertensive treatment that is safe and well studied in peripartum women.
79997040|NCT02982720|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously.
79997041|NCT02982720|Drug|Sylatron|Sylatron will be administered subcutaneously.
79822597|NCT05057078|Behavioral|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
79997042|NCT03655938|Procedure|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
79997043|NCT03656640|Drug|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
79997044|NCT00849667|Drug|Farletuzumab|Farletuzumab IV infusion.
79997045|NCT00849667|Drug|Carboplatin|Carboplatin IV infusion.
79225989|NCT05527314|Drug|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
79225990|NCT05527314|Drug|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
79225991|NCT05527314|Drug|Remifentanil|After the LoC, remifentanil 0.1~0.3 ug/kg/min inject intravenously until the end of surgery.
79368565|NCT01946165|Drug|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
79368566|NCT01946165|Drug|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
79368567|NCT01707667|Drug|prucalopride|One 2 mg tablet orally administered on Day 1
79822598|NCT02587754|Device|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
79822599|NCT00682539|Drug|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
79997046|NCT00849667|Drug|Taxane|Taxane (Paclitaxel or Docetaxel) IV infusion.
79997047|NCT00849667|Drug|Farletuzumab-matched placebo|Farletuzumab-matched placebo IV infusion.
79997048|NCT03201419|Drug|FE 201836|Oral solution for daily intake
79225992|NCT05521802|Biological|B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell|Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
79225993|NCT05497011|Device|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
79225994|NCT05494242|Other|Surgical intervention|Pars-plana vitrectomy.
79225995|NCT05484505|Drug|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~14 mg: Next 4 weeks~7 mg: Last 4 weeks"
79225996|NCT05484505|Behavioral|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's & 5 R's) at Day 0, 1 month, 3,6,9 & 12 months
79368568|NCT01707667|Drug|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
79368569|NCT01959503|Device|Progel Vascular Sealant|
79368570|NCT01959503|Device|Gelfoam Plus|
79368571|NCT01605799|Behavioral|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
79368572|NCT01605799|Behavioral|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
79368573|NCT01706575|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
79368574|NCT01706575|Drug|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
79368575|NCT01959425|Other|Off OAT Group (Test)|Discontinuation of OAT Therapy
79368576|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
79368577|NCT01725529|Drug|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
79368578|NCT01725529|Drug|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms [μg] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
79997049|NCT03201419|Drug|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
79997050|NCT03201419|Drug|Placebo oral solution|Manufactured to mimic experimental drug
79997051|NCT03201419|Drug|Placebo ODT|Manufactured to mimic experimental drug
79997052|NCT01331629|Other|ART-THERAPIE|8 sessions of art therapy during radiotherapy
79368579|NCT01725529|Drug|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is < 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
79521352|NCT04422210|Drug|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
79521353|NCT04422210|Drug|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
79677522|NCT02952183|Device|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
79997053|NCT02924389|Drug|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
79997054|NCT02924389|Drug|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
79225997|NCT05484505|Drug|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
79225998|NCT05478161|Device|(ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
79225999|NCT05476822|Diagnostic Test|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
79226000|NCT05473364|Drug|Acetazolamide|Diuretic and carbonic anhydrase inhibitor medication
79226001|NCT05453591|Device|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
79226002|NCT05443763|Other|An interdisciplinary intensive therapy program|Children will receive physical, occupation, and/or speech therapy 1-3 hours/day each for 4-5 days/week x 4 weeks.
79226003|NCT05428943|Drug|OPT101|15-mer peptide derived from the sequence of mouse CD154.
79226004|NCT05407974|Procedure|pleurectomy|"All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax & surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months."
79226005|NCT05382494|Drug|Mometasone Furoate 50mcg Nasal Spray|Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks
79226006|NCT05382494|Drug|Sodium Chloride 0.9 % Nasal Spray|Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
79226007|NCT05351346|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
79226008|NCT05351346|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
79226009|NCT05351346|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
79368580|NCT01725529|Drug|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
79368581|NCT01605097|Radiation|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
79368582|NCT01605019|Device|CoSeal|3 - 8mls of Coseal
79368583|NCT01605019|Device|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
79368584|NCT04413721|Procedure|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
79368585|NCT04413565|Procedure|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
79368586|NCT04413565|Procedure|Sequenced bilateral TKA|Single surgeon bilateral TKA group
79521354|NCT04422210|Drug|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m^2 as per the dosing schedules described above.
79521355|NCT00000108|Behavioral|Exercise|
79521356|NCT00000126|Procedure|Surgery|
79521357|NCT00000132|Drug|Betaxolol|
79521358|NCT00000132|Procedure|Argon Laser Trabeculoplasty|
79521359|NCT00000138|Drug|Prednisolone Phosphate|
79521360|NCT00000138|Drug|Acyclovir|
79521361|NCT00000162|Procedure|Macular Argon Laser Photocoagulation|
79521362|NCT00000162|Procedure|Peripheral Scatter Argon Laser Photocoagulation|
79521363|NCT00000162|Procedure|Scatter Argon Laser Photocoagulation|
79521364|NCT00000174|Drug|Rivastigmine|
79521365|NCT00000192|Drug|Lamotrigine|
79521366|NCT00000198|Drug|Piracetam|
79521367|NCT00000204|Drug|Buprenorphine|
79521368|NCT00000210|Drug|Buprenorphine|
79521369|NCT00000222|Drug|Buprenorphine|
79521370|NCT00000228|Drug|Buprenorphine|
79521371|NCT00000234|Drug|Buprenorphine|
79521372|NCT00000240|Drug|Buprenorphine|
79521373|NCT00000246|Drug|Flumazenil|
79521374|NCT00000264|Drug|30% Nitrous oxide|
79679963|NCT02936973|Device|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
79368587|NCT01744483|Device|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
79368588|NCT01744483|Device|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
79368589|NCT01744483|Device|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
79226010|NCT05351346|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
79226011|NCT05351346|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
79368590|NCT01744093|Drug|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
79677523|NCT01249742|Behavioral|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
79997055|NCT02924389|Drug|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
79226012|NCT05351346|Drug|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
79226013|NCT05351346|Drug|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
79368591|NCT01744093|Drug|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
79226014|NCT05351346|Drug|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
79368592|NCT01725451|Drug|Testosterone|Administered topically to axillae
79226015|NCT05350904|Other|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
79226016|NCT05327322|Behavioral|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
79226017|NCT05327322|Behavioral|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
79226018|NCT05327322|Behavioral|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
79368593|NCT01725451|Other|Deodorant Spray|Administered topically to axillae
79368594|NCT01725451|Other|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
79368595|NCT01725451|Other|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
79368596|NCT01707290|Drug|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
79368597|NCT01717040|Drug|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
79368598|NCT01717040|Drug|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
79368599|NCT04552262|Drug|BAY2327949|Single dose of 90 mg BAY2327949
79368600|NCT04552262|Drug|Placebo|Single dose of placebo to BAY 2327949
79368601|NCT00803062|Biological|Bevacizumab|Given IV
79368602|NCT00803062|Drug|Cisplatin|Given IV
79368603|NCT00803062|Other|Laboratory Biomarker Analysis|Correlative studies
79368604|NCT00803062|Drug|Paclitaxel|Given IV
79368605|NCT00803062|Other|Quality-of-Life Assessment|Ancillary studies
79368606|NCT00803062|Other|Questionnaire Administration|Ancillary studies
79368607|NCT00803062|Drug|Topotecan Hydrochloride|Given IV
79368608|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
79368609|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
79368610|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
79368611|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
79368612|NCT01743001|Drug|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
79368613|NCT01743001|Drug|Placebo|Macitentan-matching placebo oral tablet once daily
79368614|NCT00362284|Behavioral|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
79368615|NCT03839368|Procedure|fixation of angle fracture|open reduction and internal fixation of angle fracture
79368616|NCT00821626|Device|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
79368617|NCT00821626|Other|Control|No rapid flu test
79368618|NCT01704079|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
79521375|NCT00000264|Other|0.35 g/Kg ethanol|
79997056|NCT05440981|Device|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
79997057|NCT01315093|Drug|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
79997058|NCT01315093|Drug|no heparin|
79368619|NCT01704079|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
79368620|NCT04556695|Other|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
79997059|NCT03235349|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
79997060|NCT01331707|Device|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
79997061|NCT01331707|Device|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
79997062|NCT03235115|Device|Methafilcon A IV|Contact Lens
79997063|NCT03235115|Device|Ocufilcon B|Contact Lens
79997064|NCT03235115|Device|Omafilcon A|Contact Lens
79997065|NCT03953807|Drug|Dexamethasone Intravitreal Implant|Implant 700 μg
79997066|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/vilanterol
79226019|NCT05323279|Device|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
79226020|NCT05323019|Behavioral|Psychotherapy|Participants will receive 8 remote therapy sessions conducted via phone or video, Therapy sessions consists of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participant. Participants will also receive supportive text messages on selected days during the 28 day study.
79368621|NCT04556695|Device|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
79368622|NCT04556695|Other|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
79368623|NCT01703845|Drug|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
79368624|NCT01703845|Drug|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
79368625|NCT01724359|Drug|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
79368626|NCT01703221|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
79368627|NCT01703221|Drug|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
79368628|NCT01703221|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
79368629|NCT01703221|Drug|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
79368630|NCT01722877|Device|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
79368631|NCT00822094|Drug|CPX-351|
79368632|NCT00822094|Drug|Intensive Salvage Therapy|
79368633|NCT00822328|Dietary Supplement|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
79368634|NCT00822328|Dietary Supplement|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
79368635|NCT05098600|Other|Exposure of interest|Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
79368636|NCT00803686|Drug|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
79368637|NCT00803686|Drug|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
79368638|NCT00803686|Drug|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
79368639|NCT00803686|Drug|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
79368640|NCT01703065|Drug|Cabozantinib|Given orally once a day
79368641|NCT00823966|Drug|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
79368642|NCT01702987|Dietary Supplement|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
79368643|NCT01702987|Dietary Supplement|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
79368644|NCT01702987|Drug|statin|statin was given for 1 month to 21 patients
79521376|NCT00000264|Other|0.7 g/Kg ethanol|
79997067|NCT03662711|Drug|Bronchodilator Agents|Tiotropium
79997068|NCT03662711|Drug|Bronchodilator Agents|Indacaterol
79997069|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium/vilanterol
79997070|NCT03662711|Drug|Bronchodilator Agents|Fluticasone propionate/salmeterol
79997071|NCT03662711|Drug|Bronchodilator Agents|Beclometasone dipropionate/formoterol
79521377|NCT00000264|Other|0 g/Kg ethanol|
79997072|NCT03662711|Drug|Bronchodilator Agents|Budesonide formoterol
79997073|NCT03662711|Drug|Bronchodilator Agents|Glycopyrronium
79997074|NCT03662711|Drug|Bronchodilator Agents|Aclidinium
79368645|NCT00824044|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
79368646|NCT00824044|Drug|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
79521378|NCT00000270|Drug|Cocaine|
79521379|NCT00000276|Drug|Bupropion|
79677524|NCT00511446|Drug|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
79677525|NCT02956109|Drug|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
79226021|NCT05323019|Behavioral|Treatment as Usual|Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.
79677526|NCT02956109|Drug|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
79997075|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium
79997076|NCT03662711|Drug|Bronchodilator Agents|Formoterol
79997077|NCT03662711|Drug|Bronchodilator Agents|Indacaterol glycopyrronium
79997078|NCT03662711|Drug|Bronchodilator Agents|Salmeterol
79997079|NCT03662711|Drug|Bronchodilator Agents|Tiotropium olodaterol
79226022|NCT05323019|Drug|Intranasal Ketamine (esketamine)|Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
79368647|NCT01702519|Drug|nicotine|nicotine transdermal patch
79521380|NCT00000282|Drug|Pemoline|
79677527|NCT02956109|Drug|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
79677528|NCT02952300|Procedure|neolix|single rotation file
79677529|NCT02952300|Procedure|wave one|single reciprocation file
79677530|NCT02955446|Drug|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
79677531|NCT00511524|Drug|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
79677532|NCT00511524|Drug|[carbonyl-^11C]GW842166|[carbonyl-^11C]GW842166 will b available as Intravenous solution.
79677533|NCT00511563|Drug|GW876008 and GSK561679|GW876008 and GSK561679
79226023|NCT05319821|Behavioral|Receive ECHO training|Active Intervention
79997080|NCT03662711|Drug|Bronchodilator Agents|Aclidinium/formoterol
79997081|NCT03662711|Drug|Bronchodilator Agents|Olodaterol
79997082|NCT03662711|Drug|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
79997083|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
79997084|NCT02923531|Drug|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
79997085|NCT02923531|Drug|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
79997086|NCT02934503|Biological|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
79997087|NCT02934503|Drug|Cisplatin|75 mg/m2
79226024|NCT05319821|Behavioral|Offered ECHO training in year 5|Delayed Intervention
79997088|NCT02934503|Drug|Carboplatin|AUC 6
79997089|NCT02934503|Drug|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
79997090|NCT02934503|Radiation|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
79997091|NCT03636217|Other|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
79997092|NCT03636217|Other|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
79226025|NCT05315453|Behavioral|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
79521381|NCT00000288|Drug|Cotinine fumarate|
79521382|NCT00000294|Drug|Carvedilol|
79521383|NCT00000300|Drug|LAAM|
79521384|NCT00000306|Drug|Dextroamphetamine|
79521385|NCT00000312|Drug|M-CPP|
79521386|NCT00000318|Drug|Buprenorphine|"Experimental Maintenance treatment with daily medication~Experimental Maintenance treatment with thrice-weekly medication"
79521387|NCT00000330|Drug|Opioid-Related Disorders|
79521388|NCT00000336|Drug|Selegiline|
79521389|NCT00000342|Drug|Risperidone|
79521390|NCT00000348|Drug|Dihydrexidine|
79521391|NCT00000354|Drug|Lofexidine|
79521392|NCT00000372|Drug|D-cycloserine|
79677534|NCT02955368|Drug|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
79997093|NCT03636217|Other|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
79997094|NCT04563247|Diagnostic Test|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
79368648|NCT01739803|Behavioral|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
79368649|NCT00824434|Device|PROMUS Element™|Drug eluting coronary stent system
79226026|NCT05313555|Device|Ultraviolet Light (UV-B)|This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.
79521393|NCT00000372|Drug|Glycine|
79521394|NCT00000372|Drug|Clozapine|
79521395|NCT00000372|Drug|Placebo|
79521396|NCT00000384|Behavioral|Cognitive Behavior Therapy|
79521397|NCT00000384|Behavioral|Educational Support|
79521398|NCT00000384|Drug|Sertraline|
79521399|NCT00000390|Drug|Imipramine hydrochloride|
79521400|NCT00000396|Behavioral|Patient self-care education|
79521401|NCT00000402|Drug|Calcium|
79521402|NCT00000438|Drug|naltrexone (Revia)|
79521403|NCT00000444|Drug|nicotine replacement patch|
79521404|NCT00000450|Drug|Naltrexone Tablet|
79677535|NCT02955368|Drug|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
79521405|NCT00000450|Drug|Matched Placebo Tablet|
79521406|NCT00000486|Procedure|coronary artery bypass|
79677536|NCT02955368|Drug|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
79677537|NCT00511602|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
79521407|NCT00000510|Drug|aspirin|
79521408|NCT00000510|Drug|dipyridamole|
79226027|NCT05313555|Device|Ultraviolet lights (UV-C)|Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will choose, based on availability, to be in groups that deliver 1 cycle, 10 cycles, 15 cycles or 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.
79521409|NCT00000510|Procedure|angioplasty, transluminal, percutaneous coronary|
79521410|NCT00000546|Behavioral|meditation|
79521411|NCT00000570|Drug|pulmonary surfactant|
79521412|NCT00000582|Drug|factor ix|
79677538|NCT00511602|Drug|Technosphere Placebo|Technosphere Inhalation Powder
79677539|NCT00511641|Behavioral|Questionnaire|Questionnaires lasting up to 30 minutes.
79226028|NCT05300100|Behavioral|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~Trial 1 : Straightening: passage from sitting to sitting.~Trial 2 : Movement with difficulty of balance: heel-toe walking~Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~Trial 4 : Move to a target, 5 m away~Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
79521413|NCT00000600|Drug|Vitamin E|
79677540|NCT01248455|Drug|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
79997095|NCT02937545|Other|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
79997096|NCT02937545|Other|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
79521414|NCT00000600|Drug|Vitamin C|
79521415|NCT00000630|Biological|HIVAC-1e|
79521416|NCT00000630|Biological|gp160 Vaccine (MicroGeneSys)|
79521417|NCT00000636|Drug|Isoniazid|
79521418|NCT00000636|Drug|Pyrazinamide|
79521419|NCT00000636|Drug|Pyridoxine hydrochloride|
79521420|NCT00000636|Drug|Rifampin|
79521421|NCT00000648|Drug|Penicillin G potassium|
79521422|NCT00000648|Drug|Ceftriaxone sodium|
79521423|NCT00000654|Drug|Fialuridine|
79521424|NCT00000660|Drug|Etoposide|
79521425|NCT00000702|Drug|Zidovudine|
79521426|NCT00000714|Drug|Trimetrexate glucuronate|
79521427|NCT00000714|Drug|Leucovorin calcium|
79521428|NCT00000732|Drug|Sulfamethoxazole-Trimethoprim|
79521429|NCT00000732|Drug|Zidovudine|
79521430|NCT00000738|Drug|Nimodipine|
79521431|NCT00000738|Drug|Zidovudine|
79521432|NCT00000750|Drug|Zidovudine|
79521433|NCT00000756|Drug|Lymphocytes, Activated|
79521434|NCT00000774|Biological|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
79521435|NCT00000774|Biological|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
79521436|NCT00000774|Biological|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
79521437|NCT00000774|Biological|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
79521438|NCT00000804|Drug|Indinavir sulfate|
79679964|NCT00522353|Dietary Supplement|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
79997097|NCT03636139|Device|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
79997098|NCT03636139|Device|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
79997099|NCT05435131|Diagnostic Test|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
79679965|NCT00522353|Dietary Supplement|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
79997100|NCT05435131|Diagnostic Test|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
79997101|NCT05435131|Diagnostic Test|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
79997102|NCT01314209|Drug|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
79226029|NCT05297877|Other|Experimental AI Echo Machine|Participants will go through the training programme using an AI machine for learning.
79226030|NCT05297877|Other|Conventional Echo Machine|Participants will go through the training programme using a conventional machine for learning.
79226031|NCT05284877|Other|No intervention|The study is an observational study without intervention.
79226032|NCT05284071|Device|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
79226033|NCT05278949|Other|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
79368650|NCT01739335|Drug|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
79368651|NCT01739335|Drug|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
79368652|NCT00824512|Drug|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
79368653|NCT00824512|Drug|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
79368654|NCT00824746|Drug|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
79368655|NCT01702363|Drug|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
79368656|NCT05049928|Other|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~Mobile applications and website usable on smartphone and tablet for the patient.~Teleconsultation solution for the patient and the doctors.~Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~Withings® connected objects"
79368657|NCT01722097|Drug|Rocuronium|
79368658|NCT01722097|Drug|placebo|
79368659|NCT04383106|Other|no intervention|no intervention
79368660|NCT00824824|Drug|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
79368661|NCT00824824|Drug|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
79368662|NCT01701973|Drug|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
79368663|NCT01701973|Drug|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
79368664|NCT01701973|Drug|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
79368665|NCT01701973|Drug|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
79368666|NCT01701973|Drug|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
79368667|NCT00825370|Drug|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
79368668|NCT00825370|Drug|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
79368669|NCT01721317|Drug|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
79368670|NCT01721317|Drug|Placebo|Matching placebo will be available
79521439|NCT00000810|Drug|Delavirdine mesylate|
79521440|NCT00000810|Drug|Zidovudine|
79521441|NCT00000810|Drug|Didanosine|
79521442|NCT00000834|Drug|Lamivudine|
79521443|NCT00000834|Drug|Methotrexate|
79521444|NCT00000834|Drug|Zidovudine|
79521445|NCT00000846|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
79521446|NCT00000846|Biological|HIV-1 Peptide Immunogen, Multivalent|
79521447|NCT00000852|Procedure|Allogeneic lymphocyte transfer|
79521448|NCT00000864|Drug|Abacavir sulfate|
79521449|NCT00000864|Drug|Zidovudine|
79521450|NCT00000876|Drug|CD4-IgG2|
79521451|NCT00000894|Drug|Cidofovir|
79521452|NCT00000894|Drug|Probenecid|
79521453|NCT00000894|Drug|Ganciclovir|
79521454|NCT00000912|Drug|Indinavir sulfate|
79679966|NCT04690296|Device|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
79679967|NCT00522470|Drug|rosiglitazone|
79679968|NCT04689789|Diagnostic Test|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
79679969|NCT00522509|Drug|Floxuridine FUDR|
79521455|NCT00000912|Drug|Abacavir sulfate|
79521456|NCT00000912|Drug|Amprenavir|
79521457|NCT00000912|Drug|Nelfinavir mesylate|
79521458|NCT00000912|Drug|Efavirenz|
79226034|NCT05276258|Device|cryoSPHERE Ablation|The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
79226035|NCT05276258|Drug|Bupivacaine|A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
79997103|NCT05434429|Other|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
79997104|NCT05431075|Drug|Amoxicillin|Included in quadruple eradication medication.
79226036|NCT05275946|Drug|Targeted alpha therapy|Single intravenous administration
79521459|NCT00000912|Drug|Levocarnitine|
79521460|NCT00000912|Drug|Adefovir dipivoxil|
79521461|NCT00000912|Drug|Saquinavir|
79997105|NCT05431075|Drug|Tetracycline tid|Included in quadruple eradication medication.
79226037|NCT05275218|Procedure|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
79226038|NCT06145152|Procedure|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
79226039|NCT06145152|Procedure|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
79226040|NCT06145126|Other|Prednisolone|Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.
79226041|NCT06145126|Other|Placebo|Placebo to predinisolon
79521462|NCT00000918|Drug|Indinavir sulfate|
79521463|NCT00000918|Drug|Lamivudine/Zidovudine|
79226042|NCT06145113|Device|Continuous positive airway pressure (CPAP), ResMed AirMini|Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
79226043|NCT06145100|Diagnostic Test|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
79226044|NCT06145087|Dietary Supplement|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
79226045|NCT06145087|Dietary Supplement|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
79226046|NCT06145074|Drug|Propranolol|Oral administration.
79521464|NCT00000918|Drug|Ritonavir|
79521465|NCT00000918|Drug|Amprenavir|
79521466|NCT00000918|Drug|Efavirenz|
79521467|NCT00000918|Drug|Saquinavir|
79521468|NCT00000918|Drug|Lamivudine|
79521469|NCT00000918|Drug|Stavudine|
79521470|NCT00000918|Drug|Zidovudine|
79521471|NCT00000918|Drug|Didanosine|
79521472|NCT00000924|Drug|Ritonavir|
79521473|NCT00000924|Drug|Nelfinavir mesylate|
79521474|NCT00000924|Drug|Nevirapine|
79997106|NCT05431075|Drug|Tetracycline qid|Included in quadruple eradication medication.
79521475|NCT00000924|Drug|Stavudine|
79521476|NCT00000924|Drug|Didanosine|
79521477|NCT00000936|Drug|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
79521478|NCT00000936|Drug|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
79521479|NCT00000936|Drug|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
79521480|NCT00000942|Drug|Nevirapine|
79521481|NCT00000948|Drug|Aldesleukin|Il-2
79521482|NCT00000948|Drug|ART|antiretroviral therapy for the treatment of HIV
79521483|NCT00000954|Drug|Bleomycin sulfate|
79521484|NCT00000954|Drug|Vincristine sulfate|
79521485|NCT00000954|Drug|Doxorubicin hydrochloride|
79521486|NCT00000954|Drug|Zalcitabine|
79521487|NCT00000954|Drug|Didanosine|
79521488|NCT00000960|Drug|Zidovudine|
79521489|NCT00000984|Drug|CD4 Antigens|
79521490|NCT00000990|Drug|Zidovudine|
79521491|NCT00000996|Drug|Doxorubicin hydrochloride|
79521492|NCT00001026|Biological|gp160 Vaccine (Immuno-AG)|
79521493|NCT00001026|Biological|rgp120/HIV-1IIIB|
79521494|NCT00001026|Biological|rgp120/HIV-1MN|
79997107|NCT05431075|Drug|Bismuth Potassium Citrate|Included in quadruple eradication medication.
79997108|NCT05431075|Drug|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
79997109|NCT05431075|Drug|Esomeprazole 20mg|Included in quadruple eradication medication.
79677541|NCT00511680|Behavioral|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
79677542|NCT00511953|Drug|Gabapentin Extended Release tablets|1800mg
79677543|NCT00511953|Drug|Gabapentin|1800mg
79677544|NCT01249820|Drug|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
79677545|NCT01249820|Drug|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
79677546|NCT02952378|Drug|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
79677547|NCT01247090|Drug|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
79677548|NCT01247090|Drug|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
79521495|NCT00001026|Biological|rgp120/HIV-1 SF-2|
79521496|NCT00001026|Biological|HIVAC-1e|
79521497|NCT00001044|Biological|Aluminum hydroxide|
79226047|NCT06145074|Drug|Placebo|Oral administration.
79521498|NCT00001044|Biological|QS-21|
79677549|NCT01247090|Drug|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
79677550|NCT02952417|Other|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
79226048|NCT06145061|Device|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
79521499|NCT00001044|Biological|rgp120/HIV-1MN|
79521500|NCT00001056|Biological|gp160 Vaccine (Immuno-AG)|
79521501|NCT00001062|Drug|Ganciclovir|
79521502|NCT00001068|Drug|Lamivudine|
79521503|NCT00001080|Biological|Influenza Virus Vaccine|
79677551|NCT00504764|Drug|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
79521504|NCT00001080|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
79521505|NCT00001080|Drug|Lamivudine|
79521506|NCT00001104|Drug|Zidovudine|
79521507|NCT00001110|Procedure|Bronchoalveolar lavage|
79521508|NCT00001122|Drug|Nelfinavir mesylate|
79521509|NCT00001122|Drug|Efavirenz|
79521510|NCT00001122|Drug|Stavudine|
79521511|NCT00001122|Drug|Didanosine|
79521512|NCT00001128|Drug|Interleukin-12|
79521513|NCT00001128|Drug|Paromomycin sulfate|
79521514|NCT00001128|Drug|Azithromycin|
79521515|NCT00001182|Procedure|current standard of care treatments|
79677552|NCT00504764|Procedure|Autologous Transplantation|Autologous Transplantation
79677553|NCT00504764|Procedure|Allogenic Transplantation|Allogenic Transplantation
79677554|NCT00504764|Drug|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
79677555|NCT04519073|Biological|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
79677556|NCT02952027|Behavioral|Use-recording, patient-reminder alarm for incentive spirometry|
79677557|NCT00504335|Drug|BIO 300 Capsules|
79679970|NCT02937090|Other|Blood Draw|Blood sample will be drawn from participants at study entry.
79521516|NCT00001188|Procedure|radiation therapy following surgery|
79521517|NCT00001272|Drug|taxol|
79521518|NCT00001296|Drug|melphalan|
79521519|NCT00001296|Drug|tumor necrosis factor|
79521520|NCT00001296|Drug|interferon-gamma|
79521521|NCT00001296|Procedure|hyperthermic isolated limb perfusion|
79521522|NCT00001338|Drug|FLAC chemotherapy with GM-CSF|
79521523|NCT00001422|Drug|fludarabine|
79521524|NCT00001428|Drug|5-fluorouracil|
79521525|NCT00001440|Procedure|Autologous T cells|
79521526|NCT00001440|Drug|Interleukin-2|
79521527|NCT00001446|Drug|thalidomide|
79521528|NCT00001512|Drug|Id-KLH Vaccine|
79521529|NCT00001512|Drug|GM-CSF|
79521530|NCT00001572|Drug|Id-KLH Vaccine|
79521531|NCT00001572|Drug|QS-21 (Stimulation-QS-21) Drug|
79368671|NCT01701193|Drug|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
79521532|NCT00001614|Drug|Chicken type II collagen|
79677558|NCT02951910|Device|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
79226049|NCT06145022|Behavioral|lifestyle modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.
79226050|NCT06145022|Behavioral|waitlist control group|Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
79226051|NCT06145009|Behavioral|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
79226052|NCT06144983|Drug|Alvogyl|In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
79226053|NCT06144983|Drug|Chlorhexidine Gluconate|in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
79226054|NCT06144970|Biological|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
79226055|NCT06144970|Biological|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
79226056|NCT06144970|Biological|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
79226057|NCT06144970|Biological|Sham Control|Single subcutaneous injection of normal saline
79521533|NCT00001626|Drug|antithymocyte globulin|antithymocyte globulin
79677559|NCT04516577|Other|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
79521534|NCT00001626|Drug|cyclophosphamide|cyclophosphamide
79677560|NCT02951754|Drug|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
79226058|NCT06144931|Procedure|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
79226059|NCT06144918|Drug|SBI-100 Ophthalmic Emulsion, 0.5%|0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
79226060|NCT06144918|Drug|SBI-100 Ophthalmic Emulsion, 1.0%|1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
79521535|NCT00001626|Drug|cyclosporine|cyclosporine
79368672|NCT01701193|Drug|Physiologic saline|Placebo
79368673|NCT00826150|Biological|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
79368674|NCT04382092|Diagnostic Test|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
79521536|NCT00001680|Drug|Thalidomide|
79521537|NCT00001698|Drug|Ketorolac Rinse|
79521538|NCT00001716|Drug|Nitric Oxide|
79521539|NCT00001716|Drug|Nitroglycerin|
79521540|NCT00001812|Drug|Nystatin|
79521541|NCT00001830|Drug|Th2 cells in allo HSCTT|
79521542|NCT00001830|Drug|Th2 Cells|
79521543|NCT00001842|Drug|Granulocyte colony-stimulating factor|
79521544|NCT00001842|Drug|Dexamethasone|
79521545|NCT00001848|Drug|Raloxifene|
79521546|NCT00001854|Drug|Ribavirin|
79521547|NCT00001860|Drug|Sandostatin LAR Depot versus transsphenoidal surgery|
79521548|NCT00001866|Procedure|horizontal muscles of the eye will be cut and then reattached in the same position|
79521549|NCT00001890|Drug|Estrogen therapy|
79521550|NCT00001926|Drug|O15|
79521551|NCT00001926|Device|Cadwell rTMS|
79521552|NCT00001944|Drug|Vinorelbine|
79521553|NCT00001944|Drug|XR9576|
79521554|NCT00001956|Procedure|Blood draw|
79521555|NCT00001956|Procedure|Oral surgery|
79521556|NCT00001956|Procedure|Tissue biopsy|
79521557|NCT00001968|Drug|Amprenavir|
79521558|NCT00001968|Drug|Ritonavir|
79521559|NCT00001968|Drug|Abacavir|
79521560|NCT00001968|Drug|Lamivudine|
79521561|NCT00001986|Drug|1-Octanol|
79521562|NCT00001992|Biological|rgp120/HIV-1IIIB|
79677561|NCT00504374|Behavioral|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
79677562|NCT02952066|Procedure|Bronchial biopsy|Bronchial tissue taken during biopsy
79679971|NCT02937090|Other|Stool collection|Stool will be collected from participants at study entry.
79679972|NCT00522587|Drug|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
79521563|NCT00001998|Drug|Nystatin|
79521564|NCT00002004|Drug|CD4 Antigens|
79521565|NCT00002010|Drug|Fluconazole|
79521566|NCT00002016|Drug|Sevirumab|
79521567|NCT00002022|Drug|Epoetin alfa|
79521568|NCT00002028|Drug|Didanosine|
79521569|NCT00002034|Drug|Zidovudine|
79997110|NCT04709393|Other|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
79997111|NCT03758417|Biological|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
79997112|NCT01329835|Behavioral|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
79997113|NCT01329835|Other|brochure|brochure given after randomization
79997114|NCT03636659|Drug|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
79226061|NCT06144918|Drug|SBI-100 Ophthalmic Emulsion, Placebo|Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
79226062|NCT06144905|Other|standard care treatment program|The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
79677563|NCT00504413|Drug|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
79677564|NCT00504413|Drug|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
79677565|NCT00504413|Drug|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
79997115|NCT03636659|Drug|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
79997116|NCT04892173|Drug|NBTXR3|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
79997117|NCT04892173|Drug|Cetuximab|Solution for infusion
79226063|NCT06144892|Device|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
79226064|NCT06144879|Procedure|double rods without dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
79677566|NCT00513045|Behavioral|IRT|Cognitive behavior intervention
79521570|NCT00002034|Drug|Ganciclovir|
79521571|NCT00002040|Drug|Fluconazole|
79521572|NCT00002046|Drug|Zidovudine|
79521573|NCT00002052|Drug|Ceftriaxone sodium|
79521574|NCT00002052|Drug|Ampicillin sodium|
79677567|NCT00513045|Behavioral|Exposure|Exposure intervention
79677568|NCT00513084|Behavioral|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
79677569|NCT02275325|Other|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
79677570|NCT00513123|Procedure|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
79997118|NCT04892173|Radiation|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
79997119|NCT03199391|Device|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
79997120|NCT01329913|Drug|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
79997121|NCT01329913|Drug|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
79997122|NCT01329913|Drug|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
79997123|NCT01329913|Drug|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
79997124|NCT01329913|Drug|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
79521575|NCT00002052|Drug|Amoxicillin trihydrate|
79521576|NCT00002058|Drug|Clofazimine|
79521577|NCT00002064|Drug|Pyrimethamine|
79521578|NCT00002064|Drug|Clindamycin|
79521579|NCT00002070|Drug|Sargramostim|
79521580|NCT00002070|Drug|Ganciclovir|
79521581|NCT00002076|Drug|Fluconazole|
79521582|NCT00002082|Drug|Azithromycin|
79521583|NCT00002088|Drug|Saccharomyces boulardii|
79521584|NCT00002094|Drug|Atevirdine mesylate|
79521585|NCT00002100|Drug|Curdlan sulfate|
79521586|NCT00002106|Drug|Ranitidine hydrochloride|
79521587|NCT00002112|Drug|Nystatin|
79521588|NCT00002112|Drug|Fluconazole|
79521589|NCT00002118|Drug|Zalcitabine|
79521590|NCT00002124|Drug|Delavirdine mesylate|
79521591|NCT00002124|Drug|Lamivudine|
79521592|NCT00002124|Drug|Zidovudine|
79521593|NCT00002130|Drug|Vesnarinone|
79521594|NCT00002136|Drug|Tecogalan sodium|
79521595|NCT00002142|Drug|Cidofovir|
79521596|NCT00002142|Drug|Probenecid|
79521597|NCT00002148|Drug|OPC 14117|
79521598|NCT00002154|Drug|Thioctic acid|
79521599|NCT00002154|Drug|Selegiline hydrochloride|
79521600|NCT00002160|Drug|Ziconotide|
79521601|NCT00002166|Drug|Nevirapine|
79521602|NCT00002172|Biological|HIV-1 Immunogen|
79822600|NCT00682539|Drug|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
79997125|NCT01329913|Drug|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
79997126|NCT01329991|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
79997127|NCT01329991|Drug|Placebo|Matching placebo for PLX5622
79997128|NCT03198767|Drug|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
79521603|NCT00002178|Drug|Ritonavir|
79677571|NCT02275403|Procedure|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
79997129|NCT03198767|Dietary Supplement|Carbohydrate 50%|50% carbohydrate in breakfast meal
79997130|NCT03198767|Dietary Supplement|Carbohydrate 25%|25% carbohydrate in breakfast meal
79997131|NCT03198767|Dietary Supplement|Carbohydrate 8%|8% carbohydrate in breakfast meal
79997132|NCT03198767|Dietary Supplement|Carbohydrate 0%|0% carbohydrate in breakfast meal
79226065|NCT06144879|Procedure|three rods with one dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
79226066|NCT06144879|Procedure|four rods with two dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
79226067|NCT06144853|Other|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
79226068|NCT06144814|Drug|Hyaluronic acid vaginal gel|. Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
79226069|NCT06144814|Drug|Estrogen vaginal use form|Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
79521604|NCT00002178|Drug|Nelfinavir mesylate|
79521605|NCT00002178|Drug|Saquinavir|
79677572|NCT02275403|Other|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
79521606|NCT00002178|Drug|Delavirdine mesylate|
79521607|NCT00002184|Drug|Nelfinavir mesylate|
79677573|NCT04517825|Diagnostic Test|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
79677574|NCT01249976|Other|blood culture|blood culture
79677575|NCT01244438|Drug|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
79679973|NCT00522587|Drug|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
79997133|NCT03198767|Dietary Supplement|Psyllium|Powder 6 grams
79997134|NCT03198767|Dietary Supplement|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
79521608|NCT00002184|Drug|Levocarnitine|
79521609|NCT00002184|Drug|Adefovir dipivoxil|
79521610|NCT00002184|Drug|Saquinavir|
79521611|NCT00002184|Drug|Lamivudine|
79521612|NCT00002184|Drug|Stavudine|
79521613|NCT00002184|Drug|Zidovudine|
79521614|NCT00002190|Drug|Saquinavir|
79521615|NCT00002190|Drug|Lamivudine|
79521616|NCT00002190|Drug|Zidovudine|
79997135|NCT03162055|Drug|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
79997136|NCT03162055|Drug|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
79521617|NCT00002196|Drug|CI-1012|
79521618|NCT00002202|Drug|Indinavir sulfate|
79521619|NCT00002202|Drug|Amprenavir|
79521620|NCT00002208|Drug|Indinavir sulfate|
79521621|NCT00002208|Drug|Lamivudine|
79521622|NCT00002208|Drug|Stavudine|
79521623|NCT00002208|Drug|Zidovudine|
79521624|NCT00002214|Drug|Capravirine|
79521625|NCT00002220|Drug|Indinavir sulfate|
79521626|NCT00002220|Drug|Efavirenz|
79521627|NCT00002220|Drug|Levocarnitine|
79521628|NCT00002220|Drug|Adefovir dipivoxil|
79521629|NCT00002226|Drug|SU5416|
79521630|NCT00002232|Biological|APL 400-003|
79521631|NCT00002238|Drug|Interferon beta-1b|
79521632|NCT00002238|Drug|Zidovudine|
79521633|NCT00002244|Drug|WF10|
79521634|NCT00002250|Drug|CD4-IgG|
79521635|NCT00002256|Drug|Zalcitabine|
79521636|NCT00002262|Drug|Tumor Necrosis Factor|
79521637|NCT00002268|Drug|Sevirumab|
79521638|NCT00002274|Drug|Didanosine|
79521639|NCT00002280|Drug|Didanosine|
79521640|NCT00002286|Drug|Zidovudine|
79679974|NCT00522587|Drug|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
79521641|NCT00002292|Drug|Pentamidine isethionate|
79521642|NCT00002298|Drug|Ribavirin|
79521643|NCT00002304|Drug|Ketoconazole|
79521644|NCT00002304|Drug|Fluconazole|
79521645|NCT00002310|Drug|Crofelemer|
79521646|NCT00002316|Drug|Lobradimil|
79521647|NCT00002316|Drug|Amphotericin B|
79226070|NCT06144801|Device|CoolSense Group|Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
79226071|NCT06144788|Drug|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
79997137|NCT02927145|Biological|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
79997138|NCT03980535|Procedure|Magnetic Resonance Imaging|Undergo MRI
79997139|NCT03980535|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
79226072|NCT06144775|Other|Kinematics measures|In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
79226073|NCT06144749|Drug|HBI-002|Oral liquid carbon monoxide drug product.
79226074|NCT06144736|Procedure|Robot-assisted retroperitoneal lymph node dissection|"Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)"
79226075|NCT06144736|Drug|Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin|The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
79226076|NCT06144723|Drug|HS-20105|Administered intravenously every 21 days.
79226077|NCT06144697|Drug|BMS-986465|Specified dose on specified days
79521648|NCT00002322|Drug|Atevirdine mesylate|
79521649|NCT00002322|Drug|Zidovudine|
79521650|NCT00002328|Drug|Azithromycin|
79521651|NCT00002334|Drug|Saquinavir|
79521652|NCT00002334|Drug|Zidovudine|
79521653|NCT00002334|Drug|Zalcitabine|
79521654|NCT00002340|Drug|Atovaquone|
79521655|NCT00002340|Drug|Pentamidine isethionate|
79521656|NCT00002346|Drug|Adefovir dipivoxil|
79521657|NCT00002352|Drug|Lobucavir|
79521658|NCT00002358|Drug|Sorivudine|
79521659|NCT00002364|Drug|Abacavir sulfate|
79521660|NCT00002370|Drug|Itraconazole|
79521661|NCT00002376|Drug|Indinavir sulfate|
79521662|NCT00002376|Drug|Lamivudine|
79521663|NCT00002376|Drug|Stavudine|
79521664|NCT00002376|Drug|Zidovudine|
79521665|NCT00002376|Drug|Didanosine|
79521666|NCT00002382|Drug|Saquinavir|
79521667|NCT00002388|Drug|Abacavir sulfate|
79521668|NCT00002394|Drug|Terbinafine hydrochloride|
79521669|NCT00002400|Drug|Indinavir sulfate|
79521670|NCT00002400|Drug|Delavirdine mesylate|
79521671|NCT00002400|Drug|Lamivudine|
79521672|NCT00002400|Drug|Zidovudine|
79521673|NCT00002406|Drug|Indinavir sulfate|
79521674|NCT00002412|Drug|Emivirine|
79521675|NCT00002412|Drug|Hydroxyurea|
79521676|NCT00002412|Drug|Stavudine|
79521677|NCT00002412|Drug|Didanosine|
79521678|NCT00002418|Drug|Emivirine|
79521679|NCT00002418|Drug|Hydroxyurea|
79521680|NCT00002418|Drug|Nevirapine|
79521681|NCT00002418|Drug|Stavudine|
79521682|NCT00002418|Drug|Didanosine|
79521683|NCT00002424|Drug|L-756423|
79521684|NCT00002424|Drug|Indinavir sulfate|
79521685|NCT00002424|Drug|Lamivudine|
79521686|NCT00002424|Drug|Stavudine|
79521687|NCT00002430|Drug|Indinavir sulfate|
79521688|NCT00002430|Drug|Nelfinavir mesylate|
79521689|NCT00002430|Drug|Lamivudine|
79521690|NCT00002430|Drug|Stavudine|
79521691|NCT00002436|Drug|Lamivudine|
79521692|NCT00002436|Drug|Zidovudine|
79521693|NCT00002436|Drug|Zalcitabine|
79521694|NCT00002442|Drug|Indinavir sulfate|
79521695|NCT00002442|Drug|Nelfinavir mesylate|
79521696|NCT00002442|Drug|Lamivudine|
79521697|NCT00002442|Drug|Stavudine|
79521698|NCT00002448|Drug|Ritonavir|
79521699|NCT00002448|Drug|Efavirenz|
79521700|NCT00002448|Drug|Saquinavir|
79521701|NCT00002454|Biological|autologous tumor cell vaccine|
79521702|NCT00002460|Drug|goserelin acetate|
79521703|NCT00002460|Drug|tamoxifen citrate|
79521704|NCT00002460|Procedure|ablative endocrine surgery|
79521705|NCT00002460|Procedure|oophorectomy|
79521706|NCT00002466|Drug|cyclophosphamide|
79521707|NCT00002466|Drug|doxorubicin hydrochloride|
79521708|NCT00002466|Drug|etoposide|
79521709|NCT00002466|Drug|ifosfamide|
79521710|NCT00002466|Drug|vincristine sulfate|
79521711|NCT00002466|Procedure|conventional surgery|
79521712|NCT00002466|Radiation|radiation therapy|
79997140|NCT03688919|Behavioral|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
79997141|NCT01331785|Drug|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
79226078|NCT06144697|Other|Placebo|Specified dose on specified days
79226079|NCT06144697|Drug|Pegasys|Specified dose on specified days
79226080|NCT06144697|Drug|Famotidine|Specified dose on specified days
79226081|NCT06144658|Device|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
79226082|NCT06144619|Genetic|Genomic and Histological Evaluation|Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
79521713|NCT00002472|Drug|cisplatin|
79226083|NCT06144580|Other|Community Health and Wellbeing Worker|Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
79997142|NCT01382589|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
79226084|NCT06144528|Other|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
79226085|NCT06144489|Dietary Supplement|Tart Cherry|Tart cherry supplementation in two doses
79521714|NCT00002472|Drug|etoposide|
79521715|NCT00002472|Procedure|conventional surgery|
79521716|NCT00002472|Procedure|neoadjuvant therapy|
79521717|NCT00002472|Radiation|radiation therapy|
79677576|NCT02951793|Other|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C>4 versus AUDIT-C of 4 or below.
79677577|NCT02951793|Other|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
79677578|NCT02951793|Other|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
79679975|NCT00522587|Drug|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
79679976|NCT00522587|Drug|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
79226086|NCT06144489|Dietary Supplement|Placebo|Control group
79226087|NCT06144450|Other|Web-Based Monitoring Program|"The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module."
79521718|NCT00002478|Drug|etoposide|
79521719|NCT00002484|Radiation|radiation therapy|
79521720|NCT00002490|Biological|BCG vaccine|
79521721|NCT00002490|Drug|mitomycin C|
79521722|NCT00002490|Radiation|radiation therapy|
79521723|NCT00002496|Drug|chemotherapy|
79521724|NCT00002496|Drug|cisplatin|
79521725|NCT00002496|Drug|fluorouracil|
79521726|NCT00002496|Procedure|conventional surgery|
79521727|NCT00002496|Radiation|low-LET cobalt-60 gamma ray therapy|
79521728|NCT00002496|Radiation|low-LET electron therapy|
79521729|NCT00002496|Radiation|low-LET photon therapy|
79521730|NCT00002502|Drug|busulfan|
79521731|NCT00002502|Drug|cyclophosphamide|
79521732|NCT00002502|Drug|cytarabine|
79521733|NCT00002502|Procedure|allogeneic bone marrow transplantation|
79521734|NCT00002508|Drug|carboplatin|
79521735|NCT00002508|Drug|etoposide|
79521736|NCT00002508|Procedure|autologous bone marrow transplantation|
79521737|NCT00002508|Procedure|peripheral blood stem cell transplantation|
79521738|NCT00002526|Biological|filgrastim|
79521739|NCT00002526|Drug|doxorubicin hydrochloride|
79521740|NCT00002526|Drug|ifosfamide|
79521741|NCT00002532|Biological|filgrastim|
79679977|NCT00522587|Drug|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
79679978|NCT00522587|Drug|Fixed remifentanil dose 1|Dose 1 of remifentanil
79521742|NCT00002532|Drug|asparaginase|
79521743|NCT00002532|Drug|cytarabine|
79521744|NCT00002532|Drug|daunorubicin hydrochloride|
79521745|NCT00002532|Drug|dexamethasone|
79521746|NCT00002532|Drug|etoposide|
79521747|NCT00002532|Drug|idarubicin|
79521748|NCT00002532|Drug|ifosfamide|
79521749|NCT00002532|Drug|leucovorin calcium|
79521750|NCT00002532|Drug|methotrexate|
79521751|NCT00002532|Drug|prednisolone|
79521752|NCT00002532|Drug|vindesine|
79997143|NCT01382589|Device|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
79521753|NCT00002538|Procedure|laparoscopic surgery|
79997144|NCT01381653|Other|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
79997145|NCT03671759|Behavioral|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
79997146|NCT03671759|Behavioral|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
79521754|NCT00002544|Drug|docetaxel|
79521755|NCT00002544|Drug|mitoxantrone hydrochloride|
79521756|NCT00002550|Drug|cisplatin|
79521757|NCT00002550|Drug|etoposide|
79521758|NCT00002550|Procedure|conventional surgery|
79677579|NCT00512187|Other|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
79677580|NCT02951715|Drug|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
79677581|NCT01243658|Drug|Oxytocin|Oxytocin
79677582|NCT01243658|Other|placebo|placebo
79677583|NCT02951676|Procedure|Extraction|Extraction of impacted third molar teeth
79997147|NCT01384227|Drug|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
79997148|NCT01315171|Dietary Supplement|Medium chain triglycerides|4 tablespoons/day for 2 weeks
79521759|NCT00002550|Radiation|radiation therapy|
79521760|NCT00002556|Drug|vincristine sulfate|Given IV
79521761|NCT00002556|Drug|carmustine|Given IV
79521762|NCT00002556|Drug|melphalan|Given PO
79521763|NCT00002556|Drug|cyclophosphamide|Given IV
79521764|NCT00002556|Drug|prednisone|Given PO
79521765|NCT00002556|Biological|recombinant interferon alfa-2b|Given SC
79521766|NCT00002556|Other|laboratory biomarker analysis|Correlative studies
79521767|NCT00002562|Drug|paclitaxel|
79521768|NCT00002568|Drug|cisplatin|
79521769|NCT00002568|Drug|paclitaxel|
79521770|NCT00002568|Procedure|conventional surgery|
79521771|NCT00002574|Biological|recombinant interferon alfa|
79521772|NCT00002574|Drug|omacetaxine mepesuccinate|
79521773|NCT00002580|Drug|cyclophosphamide|
79521774|NCT00002580|Drug|fluorouracil|
79521775|NCT00002580|Drug|goserelin acetate|
79521776|NCT00002580|Drug|leuprolide acetate|
79521777|NCT00002580|Drug|methotrexate|
79521778|NCT00002580|Drug|tamoxifen citrate|
79521779|NCT00002580|Procedure|conventional surgery|
79521780|NCT00002580|Procedure|laparoscopic surgery|
79521781|NCT00002580|Procedure|oophorectomy|
79521782|NCT00002580|Radiation|radiation therapy|
79521783|NCT00002586|Drug|13-cis retinoic acid|
79521784|NCT00002586|Dietary Supplement|Tocopherol|
79521785|NCT00002592|Biological|c-myb antisense oligonucleotide G4460|
79521786|NCT00002592|Biological|filgrastim|
79521787|NCT00002592|Drug|busulfan|
79521788|NCT00002592|Drug|cyclophosphamide|
79521789|NCT00002592|Procedure|autologous bone marrow transplantation|
79521790|NCT00002592|Procedure|in vitro-treated bone marrow transplantation|
79521791|NCT00002598|Biological|recombinant interferon alfa|
79521792|NCT00002598|Biological|sargramostim|
79521793|NCT00002598|Drug|cyclophosphamide|
79521794|NCT00002598|Drug|cytarabine|
79521795|NCT00002598|Drug|etoposide|
79521796|NCT00002598|Drug|methotrexate|
79521797|NCT00002598|Drug|mitoxantrone hydrochloride|
79521798|NCT00002598|Procedure|bone marrow ablation with stem cell support|
79521799|NCT00002598|Radiation|radiation therapy|
79521800|NCT00002604|Drug|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
79521801|NCT00002604|Drug|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
79521802|NCT00002604|Drug|chemosensitization/potentiation therapy|
79521803|NCT00002610|Biological|dactinomycin|
79521804|NCT00002610|Biological|filgrastim|
79521805|NCT00002610|Drug|carboplatin|
79521806|NCT00002610|Drug|cyclophosphamide|
79677584|NCT01249664|Biological|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
79677585|NCT01249664|Procedure|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
79677586|NCT00513162|Drug|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
79677587|NCT00513162|Drug|Etoposide|25 - 50 mg/m^2 By Mouth Daily
79677588|NCT00512226|Other|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
79677589|NCT04513418|Dietary Supplement|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
79521807|NCT00002610|Drug|doxorubicin hydrochloride|
79997149|NCT04631835|Drug|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
79997150|NCT04646369|Behavioral|"screening as usual"|Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
79997151|NCT04646369|Behavioral|Screening Wizard 2.0|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
79997152|NCT04646369|Behavioral|Screening Wizard 2.0 + SOVA|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
79997153|NCT01382511|Drug|Simvastatine|80 mg
79997154|NCT02888119|Device|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
79997155|NCT03631329|Diagnostic Test|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
79997156|NCT03684447|Drug|Propofol|Series of 6 treatments with propofol.
79226088|NCT06144437|Diagnostic Test|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
79226089|NCT06144411|Other|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
79521808|NCT00002610|Drug|etoposide|
79521809|NCT00002610|Drug|vincristine sulfate|IV
79521810|NCT00002610|Procedure|conventional surgery|
79521811|NCT00002610|Radiation|radiation therapy|
79521812|NCT00002616|Biological|aldesleukin|
79521813|NCT00002616|Biological|filgrastim|
79677590|NCT00513201|Drug|lyspro|
79677591|NCT00513201|Drug|regular insulin|
79677592|NCT00513279|Drug|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
79677593|NCT00513279|Drug|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
79521814|NCT00002616|Drug|carboplatin|
79521815|NCT00002616|Drug|cyclophosphamide|
79521816|NCT00002616|Drug|thiotepa|
79521817|NCT00002616|Procedure|peripheral blood stem cell transplantation|
79521818|NCT00002622|Drug|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
79521819|NCT00002622|Drug|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
79521820|NCT00002634|Biological|filgrastim|
79521821|NCT00002634|Biological|monoclonal antibody 3F8|
79521822|NCT00002634|Drug|cisplatin|
79521823|NCT00002634|Drug|cyclophosphamide|
79521824|NCT00002634|Drug|doxorubicin hydrochloride|
79521825|NCT00002634|Drug|etoposide|
79521826|NCT00002634|Drug|mesna|
79521827|NCT00002634|Drug|perfosfamide|
79521828|NCT00002634|Drug|vincristine sulfate|
79521829|NCT00002634|Procedure|autologous bone marrow transplantation|
79521830|NCT00002634|Procedure|in vitro-treated bone marrow transplantation|
79521831|NCT00002634|Radiation|low-LET cobalt-60 gamma ray therapy|
79521832|NCT00002634|Radiation|low-LET photon therapy|
79677594|NCT00512265|Drug|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
79677595|NCT00512265|Drug|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
79677596|NCT00504803|Procedure|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
79677597|NCT00513396|Drug|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
79677598|NCT00513396|Drug|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
79677599|NCT01249274|Drug|Progesterone|100mgs progesterone twice daily
79997157|NCT03684447|Drug|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
79997158|NCT04505059|Procedure|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
79226090|NCT06144372|Device|Electroconductive and Electrohydraulic types|The patients were randomly assigned to two types of lithotripter.
79997159|NCT04505059|Procedure|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
79226091|NCT06144359|Other|specific MRI Acquisition (Diffusion Tensor Imaging) at 3T|"The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation."
79226092|NCT06144346|Radiation|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
79368675|NCT00827944|Device|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
79368676|NCT00827944|Device|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
79677600|NCT01249274|Other|Placebo|Matched placebo pills to be taken twice daily
79521833|NCT00002634|Radiation|radioisotope therapy|
79997160|NCT01382433|Procedure|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
79997161|NCT01382433|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
79521834|NCT00002646|Drug|fenretinide|
79521835|NCT00002646|Drug|tamoxifen citrate|
79677601|NCT00512304|Procedure|association chemotherapy and radiochemotherapy|
79677602|NCT04695834|Procedure|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
79677603|NCT04695834|Other|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
79677604|NCT04695756|Other|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
79677605|NCT00512382|Device|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
79677606|NCT00512421|Procedure|computer-assisted surgery|
79997162|NCT01382433|Behavioral|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
79997163|NCT03549299|Biological|LSC2|Topical application of IMP on target eye
79997164|NCT01315327|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
79997165|NCT01315327|Drug|Olive oil|Placebo
79368677|NCT02153710|Behavioral|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
79368678|NCT02153710|Behavioral|Phonomotor Therapy|Experimental therapy.
79368679|NCT01959347|Procedure|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health & Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
79521836|NCT00002652|Drug|suramin|
79521837|NCT00002658|Biological|filgrastim|
79521838|NCT00002658|Drug|amsacrine|
79521839|NCT00002658|Drug|cyclophosphamide|
79521840|NCT00002658|Drug|cytarabine|
79521841|NCT00002658|Drug|daunorubicin hydrochloride|
79521842|NCT00002658|Drug|etoposide|
79521843|NCT00002658|Drug|idarubicin|
79521844|NCT00002658|Drug|mitoxantrone hydrochloride|
79521845|NCT00002658|Drug|thioguanine|
79521846|NCT00002658|Drug|tretinoin|
79521847|NCT00002658|Procedure|allogeneic bone marrow transplantation|
79521848|NCT00002658|Procedure|autologous bone marrow transplantation|
79521849|NCT00002658|Procedure|peripheral blood stem cell transplantation|
79521850|NCT00002658|Radiation|radiation therapy|
79521851|NCT00002664|Biological|edrecolomab|
79521852|NCT00002664|Biological|sargramostim|
79521853|NCT00002670|Drug|chemotherapy|
79521854|NCT00002670|Drug|cisplatin|
79521855|NCT00002670|Radiation|low-LET cobalt-60 gamma ray therapy|
79521856|NCT00002670|Radiation|low-LET electron therapy|
79521857|NCT00002670|Radiation|low-LET photon therapy|
79677607|NCT00504842|Drug|MRX-801|
79521858|NCT00002676|Drug|carmustine|
79997166|NCT01314599|Drug|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
79677608|NCT00504842|Drug|Placebo|
79677609|NCT00512460|Drug|RTA 744|4.8 mg/m^2 by vein Over 2 Hours On Days 1-3.
79677610|NCT01249157|Device|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
79997167|NCT04243863|Drug|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)
79997168|NCT04243863|Drug|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)
79226093|NCT06144346|Procedure|Locoregional treatment|mastectomy or BCS for the primary tumor
79226094|NCT06144346|Other|Standard of Care|Systemic treatment and palliative treatment
79226095|NCT06144333|Diagnostic Test|RIPH2|"Blood sampling by capillary~Swab sampling~Blood sampling by venous punction~Salivary sample, sputum, expectoration:"
79226096|NCT06144307|Procedure|plane block|injection of local anesthetic to the myofascial plane
79226097|NCT06144229|Diagnostic Test|HPV test using Evalyn Brush|Self-swab collection kits, participates will self-collected vaginal swab for hrHPV test (at home or in the clinic)
79226098|NCT06144151|Device|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
79226099|NCT06144138|Behavioral|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
79226100|NCT06144125|Biological|fresh frozen plasma|transfusion of fresh frozen plasma
79368680|NCT01959347|Other|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
79679979|NCT00522587|Drug|Fixed remifentanil dose 2|Dose 2 of remifentanil
79226101|NCT06144125|Biological|prothrombin complex concentrate|prothrombin complex concentrate administration
79226102|NCT06144112|Biological|fresh frozen plasma|transfusion of fresh frozen plasma
79226103|NCT06144112|Biological|prothrombin complex concentrate|prothrombin complex concentrate administration
79368681|NCT00828178|Drug|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
79368682|NCT00828178|Device|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
79368683|NCT00828178|Other|corn starch|3 capsules qd for 12weeks
79368684|NCT00828412|Device|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
79368685|NCT00828412|Drug|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
79368686|NCT04638335|Biological|Blood test|blood test for Anti-HAV antibodies
79368687|NCT01959035|Drug|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
79521859|NCT00002676|Drug|cyclophosphamide|
79521860|NCT00002676|Drug|cytarabine|
79521861|NCT00002676|Drug|dexamethasone|
79521862|NCT00002676|Drug|doxorubicin hydrochloride|
79521863|NCT00002676|Drug|methotrexate|
79521864|NCT00002676|Drug|vincristine sulfate|
79521865|NCT00002676|Radiation|low-LET cobalt-60 gamma ray therapy|
79521866|NCT00002676|Radiation|low-LET photon therapy|
79521867|NCT00002682|Drug|Amoxicillin|
79521868|NCT00002682|Drug|Bismuth Subsalicylate|
79521869|NCT00002682|Drug|Clarithromycin|
79521870|NCT00002682|Drug|Metronidazole Hydrochloride|
79521871|NCT00002682|Drug|Omeprazole|
79521872|NCT00002682|Drug|Tetracycline Hydrochloride|
79521873|NCT00002688|Drug|cyclosporine|
79521874|NCT00002688|Drug|etoposide|
79521875|NCT00002688|Drug|mitoxantrone hydrochloride|
79521876|NCT00002700|Drug|asparaginase|
79521877|NCT00002700|Drug|cyclophosphamide|
79521878|NCT00002700|Drug|cytarabine|
79677611|NCT00512499|Behavioral|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
79677612|NCT00512499|Behavioral|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
79677613|NCT00512499|Behavioral|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
79521879|NCT00002700|Drug|daunorubicin hydrochloride|
79677614|NCT00504452|Drug|KP-1461|Oral dosage, 1600 mg bid for 124 days
79226104|NCT06144073|Behavioral|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
79521880|NCT00002700|Drug|dexamethasone|
79822601|NCT00682539|Drug|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
79226105|NCT06144060|Drug|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
79226106|NCT06144060|Drug|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
79677615|NCT00512538|Device|Bi-layered cell therapy (Apligraf)|
79677616|NCT00504920|Behavioral|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
79226107|NCT06144047|Device|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
79677617|NCT00513513|Drug|TMC114 (darunavir) / ritonavir|
79677618|NCT00504959|Drug|ranibizumab|
79677619|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79677620|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79677621|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79677622|NCT00504998|Genetic|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
79226108|NCT06144034|Device|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
79368688|NCT01700959|Drug|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
79368689|NCT01700959|Drug|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
79368690|NCT00829036|Device|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
79368691|NCT01738477|Biological|Boostrix|Single dose intramuscular administration.
79368692|NCT00829738|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
79521881|NCT00002700|Drug|doxorubicin hydrochloride|
79521882|NCT00002700|Drug|leucovorin calcium|
79521883|NCT00002700|Drug|mercaptopurine|
79521884|NCT00002700|Drug|methotrexate|
79521885|NCT00002700|Drug|mitoxantrone hydrochloride|
79521886|NCT00002700|Drug|prednisolone|
79521887|NCT00002700|Drug|prednisone|
79521888|NCT00002700|Drug|therapeutic hydrocortisone|
79521889|NCT00002700|Drug|vincristine sulfate|
79521890|NCT00002700|Procedure|allogeneic bone marrow transplantation|
79521891|NCT00002700|Procedure|autologous bone marrow transplantation|
79521892|NCT00002700|Radiation|radiation therapy|
79368693|NCT01737931|Drug|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
79521893|NCT00002706|Procedure|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
79997169|NCT02635633|Device|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7*(DEF-DM1) [DEF = distance over EF; DM1 = distance over M1]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
79997170|NCT03197129|Other|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
79521894|NCT00002706|Other|Quality-of-Life Assessment|Ancillary studies
79226109|NCT06144034|Device|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
79997171|NCT04217135|Drug|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
79226110|NCT06143982|Behavioral|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
79226111|NCT06143969|Procedure|ultrasound-assisted, catheter-directed thrombolysis|After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
79226112|NCT06143930|Other|strengthening ex with BFR training|Therapeutic strengthening training with blood flow restriction of trained limb.
79226113|NCT06143930|Other|strengthening ex|Therapeutic strengthening training program for lower extremities.
79997172|NCT01337401|Drug|Cediranib|30mg once daily, oral until disease progression
79226114|NCT06143917|Behavioral|parent-child sleep intervention|The intervention plan is as follows: (1) Parent-child sleep education includes two in-person session and four pre-recorded online sessions. Additionally, it provides educational handbooks tailored to the course content, segmented into sections for both parents and newborns. Each session lasts approximately 20 minutes; (2) Heart rate variability measurement and Heart rate variability biofeedback are conducted in classes in person. It guides parents through breathing exercises to activate the parasympathetic nervous system, thereby easing emotions and improving psychological health; (3) Professional counseling and support are provided separately at two weeks, one month, three months, and six months postpartum.
79679980|NCT00522587|Drug|Fixed remifentanil dose 3|Dose 3 of remifentanil
79226115|NCT06143904|Drug|Genz-112638|Pharmaceutical form:Solution-Route of administration:IV
79226116|NCT06143904|Drug|Genz-112638|Pharmaceutical form:Capsule-Route of administration:Oral
79521895|NCT00002706|Procedure|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
79997173|NCT01337401|Drug|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
79997174|NCT01331863|Procedure|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
79226117|NCT06143904|Drug|[14C]-Genz-112638|Pharmaceutical form:Solution-Route of administration:Oral
79368694|NCT01737931|Drug|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
79521896|NCT00002718|Biological|anti-thymocyte globulin|
79521897|NCT00002718|Biological|filgrastim|
79521898|NCT00002718|Drug|cyclophosphamide|
79521899|NCT00002718|Drug|cytarabine|
79521900|NCT00002718|Drug|methylprednisolone|
79521901|NCT00002718|Drug|thiotepa|
79521902|NCT00002718|Procedure|in vitro-treated bone marrow transplantation|
79521903|NCT00002718|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79521904|NCT00002718|Radiation|radiation therapy|
79521905|NCT00002730|Drug|buthionine sulfoximine|
79521906|NCT00002730|Drug|melphalan|
79521907|NCT00002742|Drug|amphotericin B deoxycholate|
79521908|NCT00002742|Drug|nystatin|
79521909|NCT00002748|Biological|gene-modified tumor cell vaccine therapy|
79521910|NCT00002748|Biological|interleukin-2 gene|
79521911|NCT00002754|Biological|monoclonal antibody Me1-14 F(ab')2|
79521912|NCT00002760|Drug|ketoconazole|400 mg PO tid for as long as treatment is effective
79521913|NCT00002760|Drug|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
79521914|NCT00002760|Other|Withdrawal of antiandrogen therapy|no drugs given
79521915|NCT00002772|Biological|filgrastim|
79521916|NCT00002772|Drug|carboplatin|
79521917|NCT00002772|Drug|carmustine|
79521918|NCT00002772|Drug|cisplatin|
79679981|NCT00522587|Drug|Fixed remifentanil dose 4|Dose 4 of remifentanil
79822602|NCT00682539|Procedure|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
79997175|NCT04178603|Other|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
79822603|NCT02587910|Dietary Supplement|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
79997176|NCT01333891|Drug|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
79997177|NCT01333891|Drug|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
79997178|NCT01333891|Device|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
79997179|NCT01333891|Device|Goldmann applanation tonometer|intraocular pressure measurements
79997180|NCT01333891|Device|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
79226118|NCT06143865|Other|Closed system aspiration|Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
79368695|NCT04564261|Behavioral|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
79521919|NCT00002772|Drug|cyclophosphamide|
79521920|NCT00002772|Drug|doxorubicin hydrochloride|
79677623|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
79997181|NCT04853875|Drug|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
79997182|NCT04853875|Drug|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
79226119|NCT06143826|Other|Progressive muscle relaxation exercises|Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
79226120|NCT06143813|Diagnostic Test|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
79677624|NCT04695561|Other|Self Myofascial Relaxation|Total of 12 times for 6 weeks
79677625|NCT04695561|Other|Instrument Assisted Soft Tissue Mobilization|Total of 12 times for 6 weeks
79677626|NCT04695561|Other|Only Exercise (Control)|Every day for 6 weeks
79677627|NCT04512794|Device|AcQMap High Resolution Imaging and Mapping System|Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
79677628|NCT00512616|Drug|Ceftriaxone|
79677629|NCT01249118|Drug|GDC-0973 IV Infusion|IV infusion.
79677630|NCT01249118|Drug|GDC-0973 Oral Capsules|Oral dose.
79677631|NCT00512655|Behavioral|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
79677632|NCT00505037|Drug|ASP1585|Oral
79677633|NCT00505037|Drug|Placebo|Oral
79677634|NCT00505037|Drug|Sevelamer hydrochloride|Oral
79679982|NCT00522587|Drug|Fixed remifentanil dose 5|Dose 5 of remifentanil
79822604|NCT02587910|Dietary Supplement|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
79997183|NCT03196973|Drug|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
79997184|NCT03196973|Drug|DF289|1 vial into the affected ear twice daily for 7 days
79997185|NCT03196973|Drug|DF277|1 vial into the affected ear twice daily for 7 days
79521921|NCT00002772|Drug|paclitaxel|
79521922|NCT00002772|Drug|tamoxifen citrate|
79521923|NCT00002772|Drug|thiotepa|
79521924|NCT00002772|Procedure|autologous bone marrow transplantation|
79521925|NCT00002772|Procedure|peripheral blood stem cell transplantation|
79521926|NCT00002772|Radiation|radiation therapy|
79521927|NCT00002778|Biological|sargramostim|
79521928|NCT00002778|Biological|therapeutic allogeneic lymphocytes|
79521929|NCT00002778|Procedure|allogeneic bone marrow transplantation|
79521930|NCT00002778|Procedure|in vitro-treated bone marrow transplantation|
79521931|NCT00002784|Biological|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
79679983|NCT00522587|Drug|Fixed remifentanil dose 6|Dose 6 of remifentanil
79822605|NCT00682461|Drug|Nicotine|Marketed nicotine replacement therapy formulation
79368696|NCT04564261|Behavioral|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
79822606|NCT00682461|Drug|Nicotine|Nicotine prototype
79822607|NCT02589002|Other|Sucralose|
79822608|NCT00755001|Device|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
79822609|NCT00755001|Device|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
79368697|NCT01958489|Drug|Evacetrapib|Administered orally
79368698|NCT01958489|Drug|Pravastatin|Administered orally
79368699|NCT01721161|Biological|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
79677635|NCT00513552|Drug|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
79677636|NCT02275169|Drug|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
79677637|NCT02275169|Other|Placebo|Placebo ampoules administered three times a week for three months
79521932|NCT00002784|Drug|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
79677638|NCT02275208|Procedure|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
79822610|NCT04082546|Procedure|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
79822611|NCT02560311|Other|observation|
79822612|NCT02587364|Drug|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
79822613|NCT02587364|Drug|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
79822614|NCT02587364|Drug|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
79822615|NCT02587364|Drug|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
79226121|NCT06143800|Behavioral|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
79226122|NCT06143800|Behavioral|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
79226123|NCT06143787|Drug|Tranexamic acid|7 days Oral rinsing following tooth extraction
79368700|NCT01721161|Drug|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
79677639|NCT00513630|Drug|Glipizide|
79822616|NCT02587364|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
79822617|NCT02587364|Drug|Placebo|Placebo once daily (QD)
79822618|NCT00921765|Drug|Saline|Saline single bolus dose followed by saline single bolus dose iv
79822619|NCT00921765|Drug|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
79368701|NCT01699867|Device|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
79521933|NCT00002784|Drug|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
79521934|NCT00002784|Drug|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
79521935|NCT00002784|Drug|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
79521936|NCT00002784|Drug|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
79521937|NCT00002784|Drug|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
79521938|NCT00002784|Drug|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
79521939|NCT00002784|Drug|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
79677640|NCT00513630|Drug|Metformin|
79677641|NCT02275247|Drug|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
79677642|NCT00513669|Biological|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
79822620|NCT00921765|Drug|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
79822621|NCT00921765|Drug|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
79822622|NCT05435781|Drug|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
79822623|NCT05435781|Drug|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
79822624|NCT02560233|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
79822625|NCT02560233|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
79822626|NCT05435625|Procedure|FCO2|Fractional Carbon dioxide laser
79822627|NCT05435625|Procedure|FRF|Fractional Microneedling Radiofrequency
79822628|NCT00755157|Drug|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
79677643|NCT00513669|Biological|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
79677644|NCT04696679|Other|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
79997186|NCT01333969|Procedure|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
79368702|NCT00830284|Procedure|Recruitment maneuver|"Three types of maneuvers will be performed.~6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
79228168|NCT05057871|Device|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
79368703|NCT00830362|Drug|Propranolol|40 mg administered once
79368704|NCT00830362|Drug|Placebo|administered once
79677645|NCT04696679|Other|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
79677646|NCT04515719|Biological|Belimumab|Belimumab 2mg/kg intravenously
79677647|NCT04515719|Biological|Placebo|Placebo intravenously
79677648|NCT00513786|Drug|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
79677649|NCT00513786|Drug|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
79677650|NCT00513786|Drug|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
79997187|NCT03196505|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
79997188|NCT03196505|Drug|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
79997189|NCT01334047|Biological|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
79997190|NCT01337557|Drug|Bepotastine|1.5% bid
79997191|NCT03636815|Other|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
79368705|NCT01699789|Other|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
79368706|NCT01699789|Behavioral|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
79368707|NCT01699789|Behavioral|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
79368708|NCT00830596|Other|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
79368709|NCT00830596|Other|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
79997192|NCT01337713|Other|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
79997193|NCT01337713|Other|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
79997194|NCT03196349|Drug|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
79368710|NCT00830596|Other|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
79368711|NCT00805870|Drug|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
79368712|NCT00805870|Drug|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
79368713|NCT01944059|Drug|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
79368714|NCT01944059|Other|Placebo (l-alanine)|Theramine like placebo comparator
79368715|NCT04646057|Device|DuraSorb®|Monofilament Surgical Mesh
79368716|NCT01720225|Drug|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
79677651|NCT00504491|Drug|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
79677652|NCT00512811|Drug|furosemide|
79997195|NCT03196349|Drug|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
79997196|NCT03196349|Drug|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
79226124|NCT06143774|Drug|TRX-920 Oral Gel (10 mg and 30 mg)|"TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified."
79368717|NCT01720225|Drug|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
79822629|NCT00755157|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
79997197|NCT01331941|Drug|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
79997198|NCT01331941|Drug|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
79226125|NCT06143761|Drug|PD-1 inhibitor+carboplatin+albumin-bound paclitaxel|A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
79521940|NCT00002784|Procedure|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
79521941|NCT00002784|Radiation|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
79521942|NCT00002784|Radiation|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
79521943|NCT00002790|Drug|cyclosporine|
79521944|NCT00002790|Drug|methotrexate|
79521945|NCT00002790|Drug|sirolimus|
79997199|NCT02886715|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
79997200|NCT02886715|Drug|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
79368718|NCT01943591|Device|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
79997201|NCT02886715|Drug|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
79997202|NCT04403737|Device|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
79997203|NCT04360837|Procedure|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
79997204|NCT01337791|Drug|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
79368719|NCT01699087|Procedure|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
79521946|NCT05752578|Other|Neuropsychological testing|During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
79521947|NCT05752422|Device|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
79679984|NCT04689633|Procedure|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
79822630|NCT00919880|Drug|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
79822631|NCT00919880|Drug|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
79822632|NCT02560077|Other|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
79822633|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
79997205|NCT01334203|Drug|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
79997206|NCT03085797|Drug|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
79368720|NCT01699087|Device|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
79521948|NCT05752344|Other|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
79521949|NCT05752188|Other|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
79368721|NCT01943435|Drug|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
79521950|NCT05751954|Radiation|Postero-anterior weight-bearing full-leg radiograph|Full leg standing X ray of the involved lower extremity (postero-anterior direction)
79521951|NCT05751954|Device|Pedobarographic analysis|Foot pressure analysis during gait on pedobarographic device
79677653|NCT00513825|Drug|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
79521952|NCT05751876|Drug|Dienogest|Dienogest 2mg was prescribed once per day orally
79677654|NCT04518254|Biological|Blood collection|A blood sample will be collected before and after treatment administration
79521953|NCT05751798|Drug|OSE-279 100mg|Human IgG4 mAb against PD-1
79521954|NCT05751798|Drug|OSE-279 300mg|Human IgG4 mAb against PD-1
79521955|NCT05751798|Drug|OSE-279 500mg|Human IgG4 mAb against PD-1
79521956|NCT05751564|Biological|"Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product"|Cryopreserved thaw & inject MSC intra-articular therapy
79521957|NCT05751564|Biological|Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product|Cryopreserved resuspended MSC intra-articular therapy
79521958|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
79521959|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
79677655|NCT04518254|Drug|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
79677656|NCT04518254|Drug|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
79521960|NCT05751486|Biological|Toripalimab /JS001|JS001 IV (if applicable) .
79226126|NCT06143735|Drug|Efgbemalenograstim alfa|Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
79226127|NCT06143722|Radiation|simultaneous with radiotherapy|Chemotherapy combined with immunotherapy simultaneous with radiotherapy
79226128|NCT06143722|Radiation|synchronous with radiotherapy|Chemotherapy combined with immunotherapy synchronous with radiotherapy
79226129|NCT06143709|Other|DNA sample collection|Patients will be asked to provide a blood or mouth wash sample for DNA extraction
79226130|NCT06143696|Drug|Qingxin Zishen decoction|Oral administration, 1 dose daily, twice a day
79226131|NCT06143696|Drug|Femoston|Oral administration, 1 pill each time, once a day
79226132|NCT06143631|Drug|Letrozole 2.5mg|Oral letrozole 2.5mg/day
79226133|NCT06143631|Other|Placebo|Placebo capsule
79226134|NCT06143605|Procedure|salvage treatment|salvage radical surgery or endoscopic resection
79521961|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
79368722|NCT01943435|Procedure|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
79368723|NCT01943435|Other|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
79521962|NCT05751408|Procedure|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
79521963|NCT05751330|Procedure|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
79521964|NCT05751252|Drug|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
79521965|NCT05751252|Drug|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
79521966|NCT05751174|Other|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
79521967|NCT00002628|Biological|filgrastim|
79677657|NCT04518254|Behavioral|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
79679985|NCT00522665|Drug|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
79677658|NCT04518254|Other|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
79677659|NCT04518254|Behavioral|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
79677660|NCT04518254|Device|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
79677661|NCT04518254|Device|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
79677662|NCT00513864|Drug|Dextromethorphan|one time dose - 0.3mg/kg PO
79677663|NCT00513864|Drug|Codeine|one time dose - 2mg/kg PO
79997207|NCT03085797|Drug|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
79997208|NCT03085797|Drug|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).
79997209|NCT04262791|Device|Wrist Actigraphy Device|Wrist Actigraphy Device
79997210|NCT04262791|Device|Sleep Headband|Sleep Headband
79997211|NCT02560597|Procedure|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
79521968|NCT00002628|Drug|carboplatin|
79226135|NCT06143579|Drug|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW < 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
79226136|NCT06143553|Drug|Paclitaxel Polymeric Micelles for Injection|Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
79226137|NCT06143553|Drug|Eribulin Mesilate injection|Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
79226138|NCT06143553|Drug|Capecitabine Tablets|Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
79368724|NCT01943435|Other|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
79368725|NCT01943435|Other|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
79368726|NCT04644809|Drug|LY3561774|Administered SC.
79521969|NCT00002628|Drug|cyclophosphamide|
79521970|NCT00002628|Drug|mesna|
79226139|NCT06143553|Drug|Gemcitabine Hydrochloride for Injection|Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
79368727|NCT04644809|Drug|Placebo|Administered SC.
79521971|NCT00002628|Drug|paclitaxel|
79521972|NCT00002628|Procedure|peripheral blood stem cell transplantation|
79521973|NCT05751018|Drug|Pyrotinib|Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
79521974|NCT05750940|Diagnostic Test|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
79521975|NCT05750784|Procedure|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
79521976|NCT05750706|Other|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
79521977|NCT05750394|Procedure|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
79677664|NCT00513864|Drug|Morphine|one time dose - 0.15mg/kg IV
79677665|NCT01248884|Biological|Infanrix hexa™|3 doses, intramuscular into left thigh
79677666|NCT01248884|Biological|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
79677667|NCT01248884|Biological|GSK217744|3 doses, intramuscular into left thigh
79997212|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
79997213|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
79997214|NCT01334359|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
79997215|NCT01569165|Procedure|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
79997216|NCT01569243|Other|Text messages|"Participants will receive diabetic medical care as usual.~Participants will be given an ActiHealth pedometer to measure daily activity.~In addition, they will be enrolled to receive the study text messages."
79368728|NCT00805948|Device|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
79521978|NCT05750394|Device|Suture Type|Barbed or smooth
79677668|NCT00512850|Dietary Supplement|Folic acid|Intervention group 1g folic acid per day
79677669|NCT00512850|Other|Placebo|One placebo pill per day
79677670|NCT04695522|Biological|ADR-002K administration|ADR-002K administration
79677671|NCT00512889|Biological|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
79679986|NCT00522665|Biological|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
79226140|NCT06143553|Drug|Vinorelbine Tartrate Injection|Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
79997217|NCT01569243|Other|Usual care|"Participants will receive diabetic medical care as usual.~In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
79521979|NCT05750394|Procedure|Endometrium|Included or excluded
79997218|NCT03157531|Device|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
79997219|NCT02535091|Drug|YKP3089|see above
79226141|NCT06143553|Drug|Paclitaxel (albumin-bound)|Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
79226142|NCT06143527|Biological|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79226143|NCT06143501|Diagnostic Test|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
79226144|NCT06143501|Diagnostic Test|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
79226145|NCT06143501|Diagnostic Test|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
79226146|NCT06143475|Device|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
79677672|NCT00512889|Genetic|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
79997220|NCT01382277|Drug|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
79997221|NCT03630939|Drug|ESR-114|ESR-114 Topical Gel
79997222|NCT03630939|Other|Placebo|Placebo Topical Gel
79226147|NCT06143475|Other|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
79226148|NCT06143462|Drug|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
79226149|NCT06143462|Other|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
79226150|NCT06143462|Behavioral|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
79226151|NCT06143423|Drug|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
79521980|NCT05750238|Other|no intervention|no intervention, survey was applied to the participants
79226152|NCT06143423|Drug|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
79228169|NCT05057871|Device|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
79521981|NCT05749614|Drug|Lidocaine cream|Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
79521982|NCT05749614|Drug|Lidocaine cream|Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
79521983|NCT05749380|Drug|AmBisome|Reference, dose of 3 mg/kg.
79997223|NCT02507791|Other|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
79997224|NCT01382199|Drug|Lactoferrin|
79521984|NCT05749380|Drug|DKF-5122|Test, dose of 3 mg/kg
79521985|NCT05749302|Drug|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
79677673|NCT00512889|Drug|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
79677674|NCT00512889|Radiation|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
79679987|NCT00522665|Biological|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
79822634|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
79521986|NCT05749224|Diagnostic Test|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
79226153|NCT06143397|Device|TTNS (Transcutaneous tibial nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active. A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation. Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode. Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency). Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
79226154|NCT06143397|Device|PNS (Parasacral nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active. For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots. A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator. The intensity level will be adjusted according to the tolerance of the patient. Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
79226155|NCT06143397|Device|Sham stimulation|Electrodes will be placed in three areas simultaneously. These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes. Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed. Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes. This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
79677675|NCT01248728|Dietary Supplement|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
79679988|NCT00522704|Other|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
79368729|NCT01942733|Drug|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
79368730|NCT00807586|Drug|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
79368731|NCT00807586|Drug|Placebo|Normal saline (1.6 cc)
79368732|NCT01957865|Device|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
79368733|NCT01957865|Device|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
79368734|NCT01957787|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
79997225|NCT01337869|Procedure|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
79368735|NCT01698775|Drug|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
79368736|NCT01698775|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
79368737|NCT01698775|Drug|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
79368738|NCT01698775|Drug|Placebo to glipizide|Matching placebo to glipizide daily
79368739|NCT01698775|Biological|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
79822635|NCT00755313|Biological|trastuzumab|
79521987|NCT05748912|Procedure|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
79226156|NCT06143397|Behavioral|Behavioral treatment|It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
79997226|NCT01337869|Procedure|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
79997227|NCT01381497|Drug|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
79997228|NCT01381497|Drug|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
79226157|NCT06143384|Device|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
79226158|NCT06143345|Other|High-Intensity Interval Training|"HIIT with Spin sessions that will include a 5-min warm-up, then an interval-based workout phase with steady up-tempo cadences, sprints, and climbs (interspersed with recovery periods), followed by a 5-min cool down.~All participants will wear Polar H10 chest strap heart rate sensors to ensure adequate intensity throughout each session and be instructed daily on their target heart rate range, computed using the Karvonen method. Phone calls will be made to the participants a day before each session to remind them about their scheduled session. Also, a log of the number of exercise sessions attended by each participant will be kept, which will be reviewed regularly to ensure high compliance with the intervention."
79368740|NCT01941095|Drug|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
79368741|NCT01941095|Drug|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
79521988|NCT05748756|Other|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
79521989|NCT05748756|Other|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
79677676|NCT01248728|Dietary Supplement|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
79368742|NCT01941095|Drug|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
79368743|NCT01941095|Drug|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
79521990|NCT05745246|Behavioral|e-health training program|"Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
79521991|NCT05743374|Other|Normal diet|These patients will be given advice about a normal healthy diet.
79521992|NCT05743374|Dietary Supplement|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
79677677|NCT00512928|Drug|acenocoumarol|max 5 mg per day during 10 weeks
79677678|NCT00512928|Dietary Supplement|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
79677679|NCT04695405|Genetic|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
79677680|NCT02951442|Biological|Biological sample|
79677681|NCT02951442|Procedure|Non invasive Arterial investigations|
79677682|NCT02951442|Procedure|Abdominal tomodensitometry|
79677683|NCT02951247|Device|Hearing Aid|Successor of Phonak Virto V90-10 NW O
79677684|NCT00505154|Drug|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
79677685|NCT00505154|Drug|placebo|placebo
79677686|NCT00513903|Behavioral|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
79226159|NCT06143345|Other|Standard exercise recommendations|Recommendation is ≥150 min of moderate-intensity physical activity per week distributed throughout the week with a minimum frequency of thrice a week.
79226160|NCT06143345|Device|Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)|The CGM system includes a sensor, a transmitter, and a receiver. The sensor measures the interstitial fluid glucose levels every 5 minutes, and the transmitter sends glucose data wirelessly from the sensor to the receiver. Participants will undergo measurements at baseline and after 4 weeks of intervention.
79226161|NCT06143332|Other|Aerobic exercise training|Aerobic exercise training on a cycle ergometer
79677687|NCT00513903|Behavioral|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
79677688|NCT00513942|Other|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
79677689|NCT01246973|Drug|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
79677690|NCT01246973|Drug|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
79677691|NCT00514605|Other|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
79677692|NCT00514605|Device|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
79677693|NCT01246466|Device|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
79677694|NCT00513981|Drug|leucovorin calcium|
79677695|NCT00513981|Drug|methotrexate|
79677696|NCT00513981|Other|mass spectrometry|
79997229|NCT01384149|Device|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
79997230|NCT01384149|Device|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
79226162|NCT06143280|Other|Data collection|Data collection using entries in the medical records of the respective patients (surgery reports, progress notes, consultation reports, imaging and pathology reports) who underwent surgery with the new dynamic technique for soft palate reconstruction.
79226163|NCT06143267|Other|Infusion of either NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
79226164|NCT06143241|Device|Threshold IMT|Threshold is used in respiratory muscle training in the form of resistance loading.
79226165|NCT06143241|Drug|Antiepileptic medication|They will continue their antiepileptic medication prescribed by their doctor.
79368744|NCT01941095|Drug|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
79368745|NCT01941095|Drug|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
79368746|NCT01941095|Drug|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
79226166|NCT06143215|Behavioral|2 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.
79226167|NCT06143202|Device|Dexcom Pro CGM|Pediatric participants will wear a blinded Dexcom Pro CGM. Data will not be available, and therefore the device will not be used to modify medical management.
79368747|NCT00831766|Drug|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
79368748|NCT00831766|Drug|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
79368749|NCT00831766|Drug|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
79521993|NCT05739396|Other|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
79521994|NCT05739240|Procedure|Osteosynthesis|Osteosynthesis of distal radius fractures
79521995|NCT05688228|Other|questionnaire|Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
79521997|NCT05677698|Other|Lemon oil|Lemon oil with massage
79521998|NCT05677698|Other|peppermint oil|peppermint oil with massage
79521999|NCT05677698|Other|Almond oil|Almond oil massage
79677697|NCT00513981|Other|pharmacological study|
79677698|NCT00505232|Drug|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~Patients younger than 60 years who will receive 8 chemotherapy cycles~Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets < 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy."
79677699|NCT00514644|Other|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
79997231|NCT04451317|Other|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
79997232|NCT01381419|Drug|GSK1144814|Single dose.
79226168|NCT06143189|Other|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
79226169|NCT06143189|Other|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
79522000|NCT05667168|Procedure|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
79226170|NCT06143176|Behavioral|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
79226171|NCT06143150|Other|transthoracic ultrasound|"The following parameters will be assessed by TUS:~Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )"
79226172|NCT06143124|Drug|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
79368750|NCT01957709|Other|Laboratory Biomarker Analysis|Correlative studies
79522001|NCT05636358|Other|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
79997233|NCT01381419|Drug|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
79997234|NCT01381419|Drug|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
79226173|NCT06143111|Device|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
79226174|NCT06143111|Device|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
79226175|NCT06143085|Procedure|Root surface debridement|Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
79226176|NCT06143007|Drug|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
79226177|NCT06142981|Biological|PRP and PBD-VSEL Stem Cell therapy|The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
79997235|NCT03635827|Combination Product|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
79997236|NCT03635827|Combination Product|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
79226178|NCT06142968|Diagnostic Test|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
79226179|NCT06142916|Other|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
79368751|NCT01957709|Biological|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
79368752|NCT00832390|Drug|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
79368753|NCT01957553|Device|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
79368754|NCT01957553|Device|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
79368755|NCT00807664|Device|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
79368756|NCT00807664|Device|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
79522002|NCT05628870|Drug|HRS-1358|HRS-1358 will be administered daily orally in continuous dosing over 28-day cycles.
79522003|NCT05625282|Procedure|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
79997237|NCT04530201|Device|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
79522004|NCT05625282|Procedure|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
79679989|NCT00522743|Drug|growth hormone and gonadotropin-releasing hormone agonist|GH & GNRHa treatment
79522005|NCT05623254|Other|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) [Time Frame: At Three-six months]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
79522006|NCT05612022|Procedure|AVF creation|AVF is surgically created in the forearm by an anastomosis between a vein and an artery
79522007|NCT05612022|Procedure|AVG creation|Surgery is done using an artificial plastic tube that connects an artery to a vein
79368759|NCT00843622|Drug|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
79677700|NCT00514644|Other|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
79822636|NCT00755313|Drug|aromatase inhibition therapy|
79226180|NCT06142916|Other|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
79368760|NCT00843622|Other|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
79677701|NCT02275442|Other|EPICES scale|
79677702|NCT00514722|Other|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
79522008|NCT05595876|Procedure|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
79522009|NCT05595876|Procedure|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
79677703|NCT01245764|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
79522010|NCT05574582|Procedure|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
79522011|NCT05497674|Drug|Rongliflozin|oral administration, single dose on Day 1 and Day 11
79522012|NCT05497674|Drug|Rifampin|QD for 10 days
79368761|NCT01957475|Device|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
79368762|NCT01957475|Device|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
79522013|NCT05497674|Drug|Rongliflozin|oral administration, single dose on Day 1 and Day 6
79522014|NCT05497674|Drug|Probenecid|twice a day, for 5 days
79677704|NCT01245764|Biological|Placebo|
79677705|NCT00514059|Drug|Boostrix polio|1 dose (0.5 ml) i.m.
79677706|NCT00514761|Drug|AZD6244|oral vial
79677707|NCT00514761|Drug|Capecitabine|oral tablet
79677708|NCT04514315|Procedure|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
79677709|NCT04514315|Procedure|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
79679990|NCT00522743|Drug|growth hormone|GH treatment
79679991|NCT02937012|Drug|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
79822637|NCT00755313|Drug|carboplatin|
79822638|NCT00755313|Drug|cyclophosphamide|
79822639|NCT00755313|Drug|docetaxel|
79822640|NCT00755313|Drug|doxorubicin hydrochloride|
79822641|NCT00755313|Other|metabolic assessment|
79822642|NCT00755313|Other|questionnaire administration|
79822643|NCT00755313|Other|study of socioeconomic and demographic variables|
79822644|NCT00755313|Procedure|cognitive assessment|
79226181|NCT06142903|Other|7 versus 21 medically tailored meals per week|Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
79226182|NCT06142864|Other|Data collection|Data collection
79677710|NCT03459261|Diagnostic Test|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
79522015|NCT05485740|Other|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
79226183|NCT06142851|Other|Data collection|data collection
79822645|NCT00755313|Procedure|positron emission tomography|
79226184|NCT06142838|Behavioral|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
79677711|NCT01245140|Drug|alitretinoin|to receive verum (20 patients)
79226185|NCT06141252|Device|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
79677712|NCT01245140|Drug|Placebo|to receive placebo (10 patients)
79822646|NCT00755313|Radiation|fludeoxyglucose F 18|
79226187|NCT06140511|Diagnostic Test|Polysomnography|Polysomnography for the assessment of the presence of REM sleep without atonia (RSWA). All Units will recruit subjects to be included in the cohort and this will ensure the inclusion of a sufficiently large sample of subjects without and, especially, with RSWA. From a previous study [Ferri et al. Sleep 2018:zsy187] that we carried out on a similar group of subjects, we know that we can expect to find RSWA in approximately 14% of individuals.
79226188|NCT06140485|Dietary Supplement|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
79226189|NCT06140485|Drug|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
79677713|NCT00514800|Behavioral|Intervention - a validated home BP monitor and support from the specialist nurse|
79677714|NCT00514800|Behavioral|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
79822647|NCT00755391|Behavioral|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
79822648|NCT00755391|Behavioral|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
79997238|NCT01382121|Behavioral|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
79997239|NCT01382121|Behavioral|Control|watching a video unrelated to the fitness test and self-efficacy
79226190|NCT06140394|Other|diode laser|low level diode therapy
79226191|NCT06140394|Other|non surgical scaling|non surgical scaling using ultrasonic
79226192|NCT06138990|Diagnostic Test|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
79226193|NCT06138990|Drug|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
79368763|NCT01940939|Device|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
79522016|NCT05485740|Other|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
79822649|NCT04082858|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
79822650|NCT04082858|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
79997240|NCT04095403|Other|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
79997241|NCT04095403|Other|passive cooling|Supine rest.
79997242|NCT01332175|Device|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
79997243|NCT01332175|Device|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
79997244|NCT01332175|Procedure|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
79997245|NCT03159091|Drug|Rengalin|Oral administration.
79228170|NCT03471468|Procedure|kinetics of microparticles under chemotherapy|Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
79368764|NCT01957397|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
79368765|NCT01957397|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
79368766|NCT01957397|Device|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
79368767|NCT01940705|Other|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
79368768|NCT01940705|Other|Hearing-Aid DVD|Take-home DVD about hearing aids
79226194|NCT06138353|Drug|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
79226195|NCT06138184|Behavioral|Anticoagulation Educational Materials|This includes new web-based patient educational materials that have been developed prior to the start of the study
79368769|NCT01940705|Behavioral|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
79368770|NCT01940705|Other|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
79226196|NCT06138184|Behavioral|Control Group: Standard of Care|This will be the current practice for patient education
79226197|NCT06137755|Biological|CVI-VZV-001|Investigational Product
79226198|NCT06137755|Biological|Shingrix|Investigational Product
79226199|NCT06137495|Diagnostic Test|Sensitization to House dust mites|The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays
79368771|NCT00834106|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
79368772|NCT00834106|Biological|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
79522017|NCT05437926|Device|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index <150) or dark skin tone (melanin index >350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
79522018|NCT05437068|Other|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
79522019|NCT05435508|Other|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
79522020|NCT05435508|Other|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
79522021|NCT05435352|Procedure|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
79226200|NCT06136546|Drug|Infliximab|Intravenous infusion of infliximab
79522022|NCT05403372|Device|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
79226201|NCT06136546|Other|Placebo|Intravenous infusion of saline solution (matching in color and consistency in infliximab)
79226202|NCT06134973|Diagnostic Test|ultrasonic testing|ultrasonic testing
79226203|NCT06134414|Drug|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
79226204|NCT06134219|Other|MF course|A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
79368773|NCT01957163|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
79368774|NCT01957163|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
79368775|NCT01957163|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
79522023|NCT05377164|Behavioral|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
79677715|NCT02951637|Drug|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
79677716|NCT02951637|Drug|Gefitinib|Gefitinib (250mg daily)
79677717|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
79997246|NCT03159091|Drug|Placebo|Oral administration.
79226205|NCT06134219|Other|Usual health care|The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
79228171|NCT05278286|Behavioral|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
79368776|NCT01957163|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
79368777|NCT00844090|Drug|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
79368778|NCT00844714|Drug|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
79368779|NCT00834652|Drug|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
79368780|NCT00834652|Drug|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
79522024|NCT05370300|Diagnostic Test|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
79368781|NCT00834808|Drug|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
79822651|NCT05198817|Drug|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
79997247|NCT03196193|Procedure|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
79997248|NCT03196193|Device|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
79226206|NCT06133959|Behavioral|The-Optimal-Lymph-Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
79226207|NCT06130514|Device|Ultrasound|Ultrasound-guided stellate ganglion block with 1% mepivacaine 5 mL
79522025|NCT05360628|Drug|D-0120 in combination with Allopurinol|noted above
79226208|NCT06130514|Device|Fluoroscopy|Fluoroscopic-guided thoracic sympathetic ganglion block with 1% mepivacaine 3 mL
79226209|NCT06129383|Procedure|serratus anterior plane block and pectointercostal plane block in breast surgery|Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
79226210|NCT06125678|Diagnostic Test|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
79522026|NCT05326932|Procedure|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
79226211|NCT06124937|Drug|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
79822652|NCT02587286|Other|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
79226212|NCT06124937|Drug|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
79226213|NCT06116838|Device|Spinal motor evoked responses (sMERs)|Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
79368782|NCT00850096|Other|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
79368783|NCT00850096|Drug|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
79368784|NCT01939223|Drug|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
79522027|NCT05312112|Drug|Venetoclax|Observational study of venetoclax in AML
79522028|NCT05312112|Drug|Gilteritinib|Observational study of gilteritinib in AML
79997249|NCT03196193|Device|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
79997250|NCT01337947|Drug|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
79997251|NCT01338103|Drug|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
79997252|NCT01315405|Behavioral|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
79997253|NCT03529877|Biological|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
79997254|NCT03621761|Behavioral|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
79368785|NCT01939223|Drug|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
79368786|NCT00834886|Dietary Supplement|Melatonin|Capsules, 3 mg, once every night
79368787|NCT00834886|Other|Bright light|Bright light therapy 10.000 lux by Miljølys AS
79368788|NCT00834886|Other|Placebo red light|Red light 400 lux as placebo light
79368789|NCT00834886|Other|Placebo capsule|Capsules containing 3 mng rice flour, once every night
79997255|NCT03621761|Drug|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
79226214|NCT06116838|Device|Continuous stimulation tolerance|Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
79226215|NCT06115109|Other|Non intervention, Observational study|Non intervention, Observational study
79226216|NCT06109922|Dietary Supplement|Active|40g bio-active whey protein concentrate powder containing phospholipids
79226217|NCT06109922|Dietary Supplement|Placebo|Around 40g pea protein powder not containing phospholipids
79226218|NCT06109454|Drug|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
79226219|NCT06109454|Other|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
79226220|NCT06107114|Drug|Cetuximab|Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
79226221|NCT06107114|Drug|Zimberelimab|Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
79226222|NCT06107114|Drug|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
79226223|NCT06107114|Drug|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
79226224|NCT06104891|Dietary Supplement|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
79368790|NCT05125289|Other|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
79522029|NCT05269758|Behavioral|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
79522030|NCT05268432|Procedure|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
79522031|NCT05266170|Device|aerobic and anaerobic exercises|"[aerobic]~Aerobic treadmill walking program without EX1~Aerobic treadmill walking program with EX1~High-intensity interval exercise (HIIT) program with EX1~[anaerobic]~1. Fitness exercise program with EX1"
79226225|NCT06104891|Dietary Supplement|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
79226226|NCT06104891|Dietary Supplement|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
79226227|NCT06104891|Dietary Supplement|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
79226228|NCT06104514|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
79522032|NCT05259462|Behavioral|Intervention|Participants will utilize low-cost, consumer available head-mounted displays to meet with peers and coaches online. The program will last 4 weeks and include 2 x 1-hour sessions per week of supervised peer-to-peer gaming. The coaches will utilize behavioral change and mindfulness techniques to promote autonomy, competence, and relatedness through a respectful, cohesive, and positive atmosphere. These strategies will be framed by the Self-Determination Theory and learned from the National Center on Health, Physical Activity, and Disability (NCHPAD) mindfulness coaching workshops. Some of the mindfulness-based strategies will include guided breathing focused exercises, body scanning, meditation, and acceptance of social anxiety and shyness
79522033|NCT05257746|Procedure|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
79522034|NCT05251428|Procedure|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
79522035|NCT05251428|Procedure|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
79997256|NCT03221387|Device|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
79677718|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
79677719|NCT00514839|Behavioral|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
79822653|NCT00919022|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
79997257|NCT04527575|Biological|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
79997258|NCT04527575|Other|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
79997259|NCT03318861|Genetic|KITE-585|A single infusion of KITE-585 autologous anti-BCMA CAR T cells
79226229|NCT06103552|Behavioral|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
79522036|NCT05248854|Other|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
79997260|NCT03318861|Drug|Cyclophosphamide|Administered intravenously
79997261|NCT03318861|Drug|Fludarabine|Administered intravenously
79997262|NCT01381341|Drug|linifanib|QD on Day 1 of Periods 1 and 2
79522037|NCT05248854|Other|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
79522038|NCT05244174|Device|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
79522039|NCT05241522|Diagnostic Test|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
79677720|NCT02951520|Procedure|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
79677721|NCT01245062|Drug|GSK1120212|MEK inhibitor
79677722|NCT01245062|Drug|Chemotherapy|Investigator Choice of DTIC or paclitaxel
79677723|NCT02951286|Device|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
79677724|NCT02951286|Device|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
79226230|NCT06103331|Other|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
79226231|NCT06099444|Device|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
79368791|NCT05125289|Other|Active release technique group|"Moist hot pack (10 minutes)~Isometric quadriceps exercises (10 repetitions)~Straight leg raise (10 repetitions)~ART steps:~Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
79522040|NCT05226858|Diagnostic Test|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
79677725|NCT01244984|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
79677726|NCT01244984|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
79677727|NCT04695483|Drug|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
79677728|NCT04695483|Drug|Follitropin Beta|Daily controlled ovarian stimulation protocol
79677729|NCT02951403|Procedure|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
79822654|NCT04082156|Device|electrical stimulation|electrical stimulation
79822655|NCT04082156|Device|Sham|no stimulation
79997263|NCT01384071|Device|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
79997264|NCT01384071|Device|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
79226232|NCT06099444|Device|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
79822656|NCT05191953|Procedure|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
79997265|NCT01379391|Drug|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
79226233|NCT06099444|Device|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
79226234|NCT06099444|Device|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
79226235|NCT06099080|Drug|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
79226236|NCT06098170|Behavioral|Unguided use of the My SCI Toolkit program|Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.
79226237|NCT06098170|Behavioral|Coached My SCI Toolkit|Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
79226238|NCT06097910|Procedure|Watchful waiting|Conduct thoracic computed tomography scans every 12 months. If a solid component emerges of if there is an increase in the size of any lung nodules, the treamtent approach would involve surgery of radiotherapy.
79226239|NCT06095596|Drug|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
79226240|NCT06095596|Drug|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
79226241|NCT06095557|Device|Sponsor MCG device|unshielded device measuring cardiac magnetic fields
79226242|NCT06094842|Drug|Bendamustine|Given IV
79522041|NCT05218668|Drug|Fasudil (WP-0512)|Oral fasudil up to 240 mg/day
79226243|NCT06094842|Procedure|Biopsy|Undergo tissue biopsy
79997266|NCT03631251|Drug|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
79226244|NCT06094842|Procedure|Biospecimen Collection|Undergo blood sample collection
79522042|NCT05118360|Drug|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
79522043|NCT05118360|Drug|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
79522044|NCT05118360|Drug|Placebo|Matching placebo orally once daily for 52 weeks.
79226245|NCT06094842|Procedure|Bone Scan|Undergo bone scan
79226246|NCT06094842|Procedure|Bridge Therapy|Undergo bridging therapy
79226247|NCT06094842|Procedure|Computed Tomography|Undergo CT
79226248|NCT06094842|Drug|Cyclophosphamide|Given IV
79226249|NCT06094842|Procedure|Echocardiography|Undergo ECHO
79226250|NCT06094842|Drug|Fludarabine|Given IV
79226251|NCT06094842|Procedure|Leukapheresis|Undergo leukapheresis
79226252|NCT06094842|Procedure|Multigated Acquisition Scan|Undergo MUGA
79226253|NCT06094842|Biological|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
79226254|NCT06094842|Procedure|X-Ray Imaging|Undergo chest x-ray
79522045|NCT05096364|Biological|AK111/Placebo|After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
79522046|NCT05048940|Biological|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
79522047|NCT05048940|Biological|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
79677730|NCT02951403|Other|Conservative treatment|Physiotherapy protocol is introduced to patients.
79677731|NCT01244516|Device|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
79522048|NCT05046990|Diagnostic Test|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
79677732|NCT01244516|Device|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
79522049|NCT04987164|Dietary Supplement|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
79522050|NCT04985682|Biological|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
79522051|NCT04945590|Behavioral|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
79677733|NCT01244516|Device|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
79677734|NCT02951208|Device|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
79677735|NCT02951208|Behavioral|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
79997267|NCT04152213|Behavioral|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
79997268|NCT03084315|Device|E-Cig Zero Nicotine|E-Cig Zero Nicotine
79677736|NCT02951208|Device|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
79997269|NCT03084315|Device|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
79997270|NCT03187301|Drug|APL-130277|APL-130277 single dose
79226255|NCT06094101|Biological|Peptide vaccine IPX|"Peptide vaccine is a combination of~class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~control peptide derived from Survivin.~adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
79226256|NCT06093113|Behavioral|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
79226257|NCT06093113|Behavioral|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
79226258|NCT06086054|Behavioral|Navigation and EMR referral to childcare facility|See arm description
79368792|NCT05125289|Other|Proprioceptive Neuromuscular Facilitation stretching group|"Moist hot pack (10 minutes)~Isometric quadriceps exercises (10 repetitions)~Straight leg raise (10 repetitions)~PNF technique steps:~The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~This sequence is repeated 5 times at a 20 second interval."
79368793|NCT00835198|Drug|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
79368794|NCT00835198|Drug|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
79368795|NCT04636073|Device|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
79368796|NCT00835510|Drug|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
79368797|NCT00835510|Drug|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
79368798|NCT00835510|Drug|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
79677737|NCT02951208|Behavioral|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
79677738|NCT02951325|Other|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~Toxicity:~Weekly RT with toxicity scoring.~RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~QOL will be assessed at baseline f/b 3-6 monthly.~Disease evaluation:~i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
79997271|NCT03187301|Drug|Placebo|Placebo single dose
79997272|NCT03187301|Drug|Moxifloxacin|moxifloxacin 400mg single dose
79997273|NCT01379313|Procedure|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
79997274|NCT01379313|Procedure|1:1 ratio|I:E ratio of 1:1 is applied.
79997275|NCT01379313|Procedure|2:1 group|Inverse I:E ratio of 2:1 is applied.
79997276|NCT01379313|Procedure|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
79997277|NCT01381263|Behavioral|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
79997278|NCT01381263|Other|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
79997279|NCT02963285|Other|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
79997280|NCT01381185|Drug|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
79997281|NCT01383837|Behavioral|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
79997282|NCT01383837|Behavioral|Health Promotion|Health Promotion Intervention
79997283|NCT02946047|Drug|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
79997284|NCT02946047|Drug|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
79226259|NCT06085872|Behavioral|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
79226260|NCT06085872|Behavioral|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive & Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. We will test the efficacy of the app adjunct to other therapeutic tools within the platform in our projects."
79226261|NCT06085872|Behavioral|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
79226262|NCT06084988|Biological|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
79226263|NCT06083506|Device|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
79226264|NCT06080555|Drug|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
79226265|NCT06080555|Drug|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
79368799|NCT01954745|Drug|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
79522052|NCT04935684|Drug|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
79677739|NCT02955680|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
79226266|NCT06079294|Other|FDG PET|Brain FDG PET performed 3 months after treatment initiation
79368800|NCT00835900|Drug|varenicline|variable dosing schedule
79368801|NCT00835900|Drug|placebo|placebo
79997285|NCT02946047|Drug|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
79368802|NCT03838900|Device|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
79368803|NCT01954121|Drug|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~Down-titration Period (Week 30 up to Week 33)"
79368804|NCT01954121|Drug|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~Down-titration Period (Week 30 up to Week 33)"
79368805|NCT04635761|Behavioral|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
79368806|NCT04635761|Behavioral|Questionnaire Administration|Ancillary studies
79679992|NCT02937012|Drug|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
79997286|NCT02946047|Drug|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
79997287|NCT05422287|Other|Virtual Reality Glasses|Group 1
79997288|NCT05422287|Other|Thermomechanical Stimulation Device|Group 2
79997289|NCT05421897|Drug|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
79997290|NCT03077919|Drug|Ropivacaine|0.5% ropivacaine
79226267|NCT06076681|Drug|TNP-2198|On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
79677740|NCT02955680|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
79368807|NCT04634045|Behavioral|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
79822657|NCT05191953|Procedure|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
79997291|NCT03077919|Drug|Sham treatment|preservative-free normal saline
79368808|NCT00850642|Drug|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
79677741|NCT02951169|Other|No intervention|No intervention. Treatment are accordance with clinical practice.
79368809|NCT00850642|Drug|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
79226268|NCT06076681|Drug|Rabeprazole Sodium|On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
79226269|NCT06076681|Drug|Amoxicillin|On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
79368810|NCT00836758|Device|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
79677742|NCT01244126|Drug|Intranasal fentanyl|2mcg/kg fentanyl IN
79677743|NCT01244126|Drug|morphine IM|0.1 mg/kg morphine IM for postop pain
79677744|NCT01244126|Drug|IV morphine|0.1 mg/kg morphine IV
79368811|NCT00852592|Device|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
79368812|NCT00852592|Device|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
79522053|NCT04927806|Device|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~Staphyloccus epidermis~Pseudomonas aeruginosa~Klebsiella pneumoniae~Acinetobacter calcoaceticus~Escherichia coli"
79522054|NCT04911894|Drug|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
79522055|NCT04848402|Device|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
79522056|NCT04848402|Device|Single Auto Injector|Used to administer placebo SC.
79522057|NCT04848402|Drug|Placebo|Administered SC.
79522058|NCT04836780|Drug|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
79522059|NCT04793724|Device|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~clearance of the upper airways before the physiotherapy session~correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~comfortable, relaxed sitting position with straightened spine~controlled cough, which will be encouraged only when it is productive"
79522060|NCT04793724|Device|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~horizontal;~low;~transition of the device from the low position to the horizontal position;~upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
79522061|NCT04782492|Procedure|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
79226271|NCT06069102|Other|BP Threshold for medication initiation|The usual care group will be given anti-hypertensive medications if a subject's BP consistently exceeds 150/100 mmHg at any point. The intervention group will receive BP meds if a subject's hospital BP consistently exceeds 140/90 mmHg or her home BP consistently exceeds 135/85 mmHg.
79522062|NCT04772898|Behavioral|Hippotherapy|The hippotherapy involves occupational therapy while being on a horse.
79522063|NCT04723680|Other|Qualitative interview|Qualitative semi structured interview
79522064|NCT04705818|Drug|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
79522065|NCT04705818|Drug|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
79522066|NCT04703712|Procedure|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
79522067|NCT04703712|Procedure|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
79522068|NCT04637724|Device|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
79522069|NCT04626804|Other|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
79522070|NCT04610736|Drug|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
79522071|NCT04610190|Device|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
79522072|NCT04591236|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
79522073|NCT04591236|Device|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
79522074|NCT04575324|Behavioral|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
79522075|NCT04529538|Biological|Novel Oral Polio Vaccine Type 1 (nOPV1)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10^6.5 CCID50.
79522076|NCT04529538|Biological|Novel Oral Polio Vaccine Type 3 (nOPV3)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10^6.5 CCID50.
79522077|NCT04529538|Biological|Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)|The Sabin mOPV1 control vaccine contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
79522078|NCT04529538|Biological|Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)|the Sabin mOPV3 control vaccine contains ≥ 10^5.8 CCID50 per 0.1 mL (2 drops) dose.
79522081|NCT04521114|Drug|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
79226272|NCT06065631|Device|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
79226273|NCT06065631|Other|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
79226274|NCT06063681|Drug|SR-8541A|orally administered ENPP1 inhibitor
79226275|NCT06063590|Biological|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
79522082|NCT04521114|Drug|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
79522083|NCT04521114|Drug|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
79522084|NCT04510272|Other|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
79522085|NCT04494360|Other|No intervention|No investigational medicinal product will be administered as a part of this study.
79522086|NCT04471974|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
79522087|NCT04471974|Drug|Enzalutamide|Given PO
79522088|NCT04471974|Biological|Pembrolizumab|Given IV
79522089|NCT04470648|Diagnostic Test|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
79522090|NCT04461678|Diagnostic Test|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
79522091|NCT04452084|Radiation|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
79679993|NCT02937012|Drug|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
79677745|NCT04695639|Other|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
79677746|NCT04695639|Other|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
79677747|NCT04695639|Other|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
79677748|NCT01243892|Device|NuSpin|Device for administration of doses of somatropin.
79677749|NCT01243892|Drug|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
79677750|NCT01243775|Drug|Belotaxel|60 mg/m2 3 weekly (day 1)
79822658|NCT02588066|Procedure|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
79822659|NCT02559219|Other|Questionniares|
79822660|NCT05141955|Other|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
79368813|NCT01952015|Biological|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
79822661|NCT05141955|Other|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
79822662|NCT05141955|Other|Group (C) (Control group)|Where patients will be operated under general anesthesia.
79997292|NCT01377675|Other|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
79997293|NCT01380951|Drug|telbivudine|telbivudine 600mg/d 96 weeks
79997294|NCT01377597|Drug|ranibizumab|
79997295|NCT03220217|Drug|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
79997296|NCT03220217|Drug|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
79368814|NCT00838006|Device|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
79368815|NCT00838006|Device|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
79368816|NCT00838006|Device|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
79368817|NCT01951703|Device|senofilcon A|Control, senfilcon A
79368818|NCT01951703|Device|senofilcon A|Test, senofilcon A
79368819|NCT00838162|Drug|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
79368820|NCT00838162|Drug|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
79522092|NCT04452084|Radiation|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
79522093|NCT04389216|Device|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
79522094|NCT04360824|Drug|Intermediate dose thromboprophylaxis|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
79522095|NCT04360824|Drug|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
79522096|NCT04331652|Procedure|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
79522097|NCT04288128|Procedure|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
79522098|NCT04288128|Other|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
79522099|NCT04261296|Other|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
79522100|NCT04261296|Other|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
79522101|NCT04261296|Other|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
79677751|NCT01243775|Drug|Belloxa|70 mg/m2 3 weekly (day 2)
79677752|NCT00514293|Drug|bexarotene|
79677753|NCT00514293|Drug|capecitabine|
79677754|NCT00514293|Drug|carboplatin|
79677755|NCT00514293|Drug|cisplatin|
79368821|NCT00838162|Drug|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
79677756|NCT00514293|Drug|docetaxel|
79677757|NCT00514293|Drug|tretinoin|
79677758|NCT02955641|Drug|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
79368822|NCT00838162|Drug|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
79368823|NCT00838162|Drug|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
79822663|NCT02559531|Device|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
79822664|NCT05122221|Drug|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
79226276|NCT06063109|Drug|THP-00101 (Dapagliflozin) 10mg|Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
79226277|NCT06063109|Drug|THP-00102 (Telmisartan) 80mg|Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
79226278|NCT06056544|Behavioral|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
79226279|NCT06054971|Other|Remote Administration of NSAA|Remote Administration of NSAA
79368824|NCT00838162|Drug|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
79368825|NCT01937351|Device|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
79368826|NCT00853606|Drug|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
79368827|NCT00841204|Drug|sulindac|Given orally
79368828|NCT00841204|Other|placebo|Inactive agent
79368829|NCT00841204|Other|laboratory biomarker analysis|Correlative studies
79368830|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
79368831|NCT00853840|Drug|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
79368832|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
79677759|NCT02955641|Drug|Nepafenac 0.1%|four drops a day for four days after LPI treatment
79677760|NCT02955641|Drug|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
79677761|NCT00514956|Behavioral|Emotional Freedom Techniques (EFT)|
79677762|NCT01243268|Drug|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
79677763|NCT00504530|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
79677764|NCT00514995|Drug|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
79822665|NCT05122221|Drug|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
79677765|NCT01242371|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
79677766|NCT01242371|Dietary Supplement|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
79677767|NCT01242176|Drug|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
79677768|NCT01242176|Drug|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
79677769|NCT00515151|Drug|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
79677770|NCT00515151|Drug|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
79679994|NCT00522782|Drug|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
79822666|NCT05122221|Biological|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
79822667|NCT05119647|Device|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
79822668|NCT02559453|Procedure|Debridement|Removing dead tissue from infected wounds.
79822669|NCT03802305|Device|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~anesthesia of the interdental papilla,~positioning of the needle and perforating of the interdental space,~Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
79822670|NCT03802305|Device|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
79997297|NCT03204695|Device|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
79997298|NCT03204695|Drug|Anticoagulation or Clopidogrel|Subjects either continue on anticoagulation or receive clopidogrel
79522102|NCT04243590|Behavioral|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
79522103|NCT04243590|Behavioral|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
79522104|NCT04243590|Behavioral|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children <six years in this study."
79522105|NCT04198350|Procedure|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
79226280|NCT06052046|Device|TOTAL30 for Astigmatism Contact Lenses|Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
79226281|NCT06036641|Device|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
79522106|NCT04174716|Drug|IDX-1197|Until progression or unacceptable toxicity develops
79226282|NCT06036641|Device|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
79226283|NCT06036641|Other|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
79368833|NCT00853840|Drug|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
79368834|NCT01737697|Drug|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
79368835|NCT01737697|Drug|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
79368836|NCT01737697|Drug|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
79368837|NCT01737697|Drug|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
79677771|NCT01242020|Drug|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
79677772|NCT00514332|Procedure|stent|stent placement for colorectal cancer obstruction
79677773|NCT01241786|Drug|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and < 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
79677774|NCT01241786|Drug|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
79677775|NCT00514410|Drug|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
79997299|NCT03979391|Diagnostic Test|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
79226284|NCT06034327|Device|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
79226285|NCT06034327|Device|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
79677776|NCT00514410|Drug|Placebo|Matching placebo taken once a day for three months
79226286|NCT06033963|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
79226287|NCT06033963|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
79226288|NCT06032234|Other|This is an observational study|This is an observational study
79368838|NCT00853996|Drug|acolbifene hydrochloride|Given orally
79368839|NCT00841828|Drug|Epirubicin|
79368840|NCT00841828|Drug|Cyclophosphamide|
79368841|NCT00841828|Drug|Docetaxel|
79368842|NCT00841828|Drug|Lapatinib|
79368843|NCT00841828|Drug|Trastuzumab|
79368844|NCT00855010|Drug|pioglitazone|pioglitazone 45 mg daily
79368845|NCT00855010|Drug|placebo|one daily
79368846|NCT00855868|Drug|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
79368847|NCT00855868|Drug|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose [11C]-PIB
79368848|NCT00842296|Device|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
79522107|NCT04159740|Other|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
79522108|NCT04122924|Other|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
79522109|NCT04055298|Device|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
79522110|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
79522111|NCT04042038|Behavioral|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
79522112|NCT03990792|Behavioral|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
79522113|NCT03990792|Other|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
79226289|NCT06031220|Other|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
79368849|NCT00842608|Behavioral|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol"
79226290|NCT06026410|Drug|KO-2806|Oral administration
79226291|NCT06026410|Drug|Cabozantinib|Oral administration
79368850|NCT00842608|Procedure|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
79368851|NCT00842608|Drug|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
79368852|NCT00842608|Procedure|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
79368853|NCT00856024|Biological|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
79368854|NCT00856024|Drug|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
79677777|NCT01241318|Drug|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
79677778|NCT01241318|Procedure|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
79677779|NCT00514488|Drug|STI571 (400 mg/day; or 800 mg/day)|
79997300|NCT03192137|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
79997301|NCT03192137|Other|Vehicle|Vehicle twice daily for 16 days
79226292|NCT06025344|Drug|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
79226293|NCT06025344|Drug|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
79226294|NCT06025318|Drug|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
79228172|NCT05278286|Behavioral|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
79228173|NCT02325960|Drug|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
79228174|NCT02325960|Drug|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
79228175|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
79822671|NCT00755469|Procedure|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
79997302|NCT03618095|Device|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
79997303|NCT04542785|Other|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
79997304|NCT03287375|Drug|PIPAC|
79997305|NCT03881059|Other|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
79228176|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
79368855|NCT00856414|Biological|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
79368856|NCT00843466|Other|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
79997306|NCT03881059|Drug|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
79997307|NCT03881059|Drug|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
79997308|NCT03881059|Drug|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
79997309|NCT03881059|Other|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
79997310|NCT01338337|Drug|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
79997311|NCT02861534|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
79997312|NCT02861534|Drug|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
79997313|NCT02034032|Procedure|Regenexx SD|stem cell treatment
79997314|NCT02034032|Behavioral|Exercise Therapy|exercise therapy control
79997315|NCT02034188|Biological|Umbilical cord mesenchymal stem cells|
79997316|NCT03167255|Drug|NS-065/NCNP-01|Received during weekly intravenous infusions
79368857|NCT00856726|Drug|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
79522114|NCT03952338|Other|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
79522115|NCT03952338|Other|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
79522116|NCT03941106|Device|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
79522117|NCT03903666|Other|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
79522118|NCT03853356|Device|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
79522119|NCT03846570|Drug|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
79997317|NCT03140969|Drug|QR-110|RNA antisense oligonucleotide for intravitreal injection
79228177|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
79228178|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
79228179|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
79228180|NCT03471390|Other|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
79228181|NCT05265650|Drug|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
79228182|NCT05265650|Procedure|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
79228183|NCT04136730|Behavioral|Home-based|Resistance exercise carried out unsupervised at home
79522120|NCT03846570|Drug|Placebo|Matching placebo (identically package) administered BID
79522121|NCT03838848|Drug|KN046|3mg/kg, Q2W, intravenous injection (IV)
79522122|NCT03838848|Drug|KN046|5mg/kg, Q2W, intravenous injection (IV)
79522123|NCT03838848|Drug|KN046|5mg/kg, Q3W, intravenous injection (IV)
79522124|NCT03838848|Drug|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
79522125|NCT03838848|Drug|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
79522126|NCT03838848|Drug|Ningetinib|Oral, QD
79522127|NCT03787602|Drug|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
79226295|NCT06020339|Other|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
79522128|NCT03787602|Drug|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
79822672|NCT02587442|Drug|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
79822673|NCT04084184|Drug|HGP1812|Dapagliflozin (Forxiga) 10mg
79822674|NCT04084184|Drug|HGP1602|Dapagliflozin 10mg
79997318|NCT03083847|Drug|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
79997319|NCT03083847|Drug|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
79226296|NCT06019884|Device|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
79228184|NCT03313232|Other|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
79368858|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
79368859|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
79522129|NCT03778164|Other|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
79368860|NCT03696784|Biological|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
79368861|NCT03696784|Drug|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
79368862|NCT03696784|Drug|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
79522130|NCT03778164|Other|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
79522131|NCT03745170|Drug|Sintilimab|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
79522132|NCT03745170|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
79522133|NCT03745170|Drug|Capecitabine|1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
79522134|NCT03745170|Drug|placebo|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
79522135|NCT03737370|Drug|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
79522136|NCT03737370|Radiation|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
79677780|NCT00514527|Drug|oritavancin|Oritavancin as a single, infrequent or daily dose.
79677781|NCT01241279|Device|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
79677782|NCT01241279|Device|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
79677783|NCT00514566|Device|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
79997320|NCT03083847|Biological|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
79997321|NCT01377519|Procedure|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
79997322|NCT01377519|Procedure|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
79822675|NCT00755547|Other|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
79522137|NCT03711786|Other|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
79822676|NCT02587052|Drug|Generic tacrolimus|Generic tacrolimus
79997323|NCT03082677|Drug|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
79997324|NCT03136055|Drug|Pembrolizumab|Given Intravenously (IV)
79997325|NCT03136055|Drug|Irinotecan|Given IV
79997326|NCT03136055|Drug|Paclitaxel|Given IV
79997327|NCT01380873|Drug|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
79997328|NCT01380873|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
79226297|NCT06019884|Device|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
79226298|NCT06019884|Other|Referral pathway: prevention specified|Child identified at higher risk using the The International Caries Classification and Management System (ICCMS) classification due to the presence of caries experience will be referred with explicit inclusion of preventive care using professionally applied fluoride. The children will also be referred to restorative care or pulp therapy depending on their needs.
79228185|NCT03313232|Other|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
79228186|NCT02234349|Procedure|pancreas kidney transplantation|
79228187|NCT02234349|Procedure|kidney transplantation|
79522138|NCT03711786|Other|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
79522139|NCT03701490|Drug|Progesterone subcutaneous|25 mg/twice a day.
79522140|NCT03701490|Drug|Progesterone Vaginal Product|200 mg three times a day.
79677784|NCT01241240|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
79522141|NCT03723720|Device|Colonoscopy|Endoscopic examination of large bowel
79822677|NCT02587052|Drug|Prograf|Prograf, the original tacrolimus
79822678|NCT02587130|Drug|Ketamine|ketamine administered in bolus by subcutaneous injection
79997329|NCT01380873|Drug|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
79997330|NCT03789045|Diagnostic Test|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
79677785|NCT01241240|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
79677786|NCT02950623|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
79677787|NCT02950623|Other|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
79522142|NCT03694392|Biological|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
79997331|NCT03221309|Other|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
79997332|NCT01379235|Other|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
79226299|NCT06019884|Other|Referral pathway: no prevention specified|This follows the standard practice adopted in dental clinics in public facilities. Care is planned by the receiving dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family of the oral health condition for which the child needs care and of available public and private facilities that offer this care. The management plan will not be predetermined, and decisions are left to the receiving dentists without explicit mention of the need for preventive care to control ECC.
79226300|NCT06017414|Behavioral|Systemic Psychotherapy-informed Growth Path|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
79226301|NCT06017414|Behavioral|Systemic Psychotherapy-informed Listener Training|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
79522143|NCT03694392|Biological|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
79522144|NCT03691974|Drug|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
79522145|NCT03691974|Other|Placebo|Subcutaneous (SC) every four weeks (Q4W)
79226302|NCT06016556|Drug|nirmatrelvir, ritonavir|single cohort
79522146|NCT03675360|Behavioral|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
79522147|NCT03652428|Drug|Gemcitabine|see arm description
79677788|NCT00515970|Procedure|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
79677789|NCT00515970|Procedure|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
79677790|NCT00515970|Procedure|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
79679995|NCT00522782|Device|Nitric Oxide Analyzer|Niox NO analyzer
79679996|NCT00522821|Drug|intravenous immunoglobulins|"Adults: 600 mg/kg bodyweight every 3 weeks~Children: 800 mg/kg bodyweight every 3 week"
79822679|NCT00677235|Device|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
79822680|NCT00677235|Procedure|PTA|Treatment of stenoses with PTA only
79522148|NCT03652428|Radiation|Hypofractionated Ablative Proton Therapy|see arm description
79522149|NCT03592290|Diagnostic Test|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
79997333|NCT05421117|Procedure|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
79997334|NCT05421039|Behavioral|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
79997335|NCT03609398|Biological|RVF Vaccine|1.0 mL dose given SQ in upper arm
79226303|NCT06006208|Device|Hamilton C1 ventilator during transport to the ICU|Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
79226304|NCT06005805|Dietary Supplement|Mastic gum|Mastic gum 3g/pack daily for 21 days
79522150|NCT03571776|Procedure|Surgery|Laparoscopic ovarian cystectomy
79822681|NCT04084418|Other|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
79997336|NCT04378400|Procedure|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
79997337|NCT03426657|Combination Product|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
79997338|NCT02858180|Drug|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
79997339|NCT03082599|Device|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
79997340|NCT04232384|Procedure|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
79522151|NCT03571776|Procedure|Sclerotherapy|US-aspiration and alcohol sclerosis
79522152|NCT03398304|Other|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
79997341|NCT04232384|Procedure|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
79997342|NCT03609086|Other|Melatonin analysis|Measurement of 6-hydroxymelatonin
79997343|NCT02034344|Procedure|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
79226305|NCT06005805|Behavioral|Dietary modification|Adhere to the dietary recommendations for Korean dyspepsia patients
79226306|NCT06001827|Device|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
79226307|NCT06001827|Procedure|Untreated AVF Control|AVF creation surgery without any intervention
79226308|NCT06000111|Behavioral|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
79226309|NCT06000111|Behavioral|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
79677791|NCT00515970|Procedure|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
79226310|NCT05999747|Drug|pudexacianinium chloride|Intravenous
79677792|NCT04695249|Behavioral|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
79677793|NCT00516009|Drug|DEXAMETHASONE|
79677794|NCT00516009|Other|PLACEBO|
79226311|NCT05999006|Device|ELIOS Procedure|Treatment with the ELIOS System
79226312|NCT05998941|Drug|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
79226313|NCT05998941|Drug|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
79226314|NCT05998941|Drug|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
79677795|NCT02950584|Other|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
79677796|NCT02950584|Other|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
79822682|NCT04084418|Other|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
79822683|NCT02559141|Drug|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
79822684|NCT05679440|Behavioral|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
79822685|NCT04969965|Drug|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
79822686|NCT03680625|Device|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
79677797|NCT01240811|Drug|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
79226315|NCT05998941|Drug|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
79226316|NCT05998941|Drug|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
79226317|NCT05996965|Other|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
79226318|NCT05993351|Diagnostic Test|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
79226319|NCT05993351|Diagnostic Test|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
79226320|NCT05993351|Behavioral|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
79228188|NCT02234505|Procedure|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
79368863|NCT03696784|Drug|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
79368864|NCT03696784|Drug|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
79368865|NCT00857506|Drug|florbetapir F 18|370 Mega Becquerel (10 mCi)
79677798|NCT01240811|Drug|Levonorgestrel IUD|
79677799|NCT01240811|Drug|Copper T380A IUD|
79677800|NCT03459144|Drug|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
79677801|NCT03459144|Drug|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
79677802|NCT03459105|Procedure|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
79677803|NCT03459105|Procedure|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
79822687|NCT03680625|Device|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
79522153|NCT03398304|Other|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
79368866|NCT00858130|Device|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
79997344|NCT02034344|Procedure|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
79226321|NCT05992246|Diagnostic Test|Ratio of Femoral Vein Diameter to Femoral Artery Diameter|An ultrasound probe will be used to first scan the area of the upper thigh just below the inguinal ligament directing caudally seeking for the femoral vessels. The femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation is an indication of the femoral artery, and its companion is the femoral vein. The mean femoral vein diameter and femoral vein diameter (3-5 diametral lines in different directions) will be measured during cough, crying, or performing the Valsalva maneuvers.
79226322|NCT05992155|Drug|TAK-279|TAK-279 capsules.
79226323|NCT05988463|Drug|Artesunate Oral Product|Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
79522154|NCT03351270|Other|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
79522155|NCT03306576|Device|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
79522156|NCT03306576|Device|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
79522157|NCT03207984|Procedure|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
79522158|NCT03030066|Drug|DS-1001b|Generic not assigned
79522159|NCT02972034|Drug|MK-8353|PO capsule
79522160|NCT02972034|Biological|Pembrolizumab|IV infusion
79997345|NCT02034344|Procedure|Urine collection|Urine will be collected from all participants.
79677804|NCT03459105|Drug|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
79997346|NCT02745587|Radiation|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
79822688|NCT02561013|Device|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
79822689|NCT02561013|Device|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
79822690|NCT04081844|Drug|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
79368867|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
79822691|NCT04081844|Drug|HGP0904|Amlodipine 5mg(Norvasc)
79997347|NCT02691845|Behavioral|BA (brief advice)|
79997348|NCT02691845|Behavioral|SHE (supervised and home-based exercise)|
79226324|NCT05985018|Other|Traditional Diet|Provided as an educational leaflet
79226325|NCT05985018|Other|Mediterranean Diet|Provided as an educational leaflet
79368868|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
79368869|NCT01682863|Drug|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
79368870|NCT01682863|Drug|Placebo|To mimic QAB149
79677805|NCT01240382|Drug|3% DE-089 ophthalmic solution|
79677806|NCT01240382|Drug|0.1% sodium hyaluronate ophthalmic solution|
79679997|NCT00522821|Drug|antibiotics|"Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
79822692|NCT04081844|Drug|HGP0608|Losartan 100mg(Cozaar)
79822693|NCT00676689|Device|SAPIEN Transcatheter Valve Implantation|Device Implantation
79822694|NCT02589314|Device|Mechanical periodontal therapy|
79822695|NCT02589314|Procedure|nonsurgical periodontal therapy|
79822696|NCT04978844|Behavioral|IWOTCH|Arm 1
79822697|NCT04978844|Behavioral|Dyadic therapy|Arm 2
79997349|NCT02691845|Behavioral|HE (health education)|
79997350|NCT02691845|Behavioral|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
79522161|NCT02882802|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
79522162|NCT02882802|Behavioral|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
79522163|NCT02795988|Biological|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
79522164|NCT02795988|Drug|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
79522165|NCT02454972|Drug|lurbinectedin (PM01183)|
79522166|NCT02025270|Biological|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
79822698|NCT02587988|Drug|HCP1302|
79822699|NCT02587988|Drug|HGP0904|
79226328|NCT05979974|Device|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A high energy of high-PEMF with a rate of 3 pulse per second is applied to the patient.
79226329|NCT05979974|Other|physiotherapy|Physiotherapy such as shoulder passive and active-assisted range of motion (ROM) exercises, Pendulum exercises, Codman's exercises and Cross-body reach exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
79522167|NCT01649388|Biological|FCR001|Enriched hematopoietic stem cell infusion
79522168|NCT01394016|Drug|LY2835219|Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
79522169|NCT01394016|Drug|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
79522170|NCT00978822|Drug|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
79522171|NCT00063882|Radiation|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
79522172|NCT00063882|Radiation|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
79679998|NCT02937051|Other|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
79679999|NCT02930928|Other|Accuracy of weight estimation|Computer based comparison
79680000|NCT00522860|Procedure|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
79680001|NCT00522860|Procedure|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
79680002|NCT02936895|Drug|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
79680003|NCT02936895|Drug|Placebo|Placebo for 2 days
79680004|NCT00522899|Behavioral|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
79680005|NCT00522899|Behavioral|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
79226330|NCT05979974|Device|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(high energy, a rate of 3 pulse per second) with the difference that the energy output doesn't export to the patient.
79522173|NCT00063882|Radiation|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
79822700|NCT02587988|Drug|Placebo (for HCP1302)|
79368871|NCT02457832|Behavioral|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
79226331|NCT05979857|Drug|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
79226332|NCT05979727|Drug|RE02|Low, medium or high dose of RE02
79226333|NCT05979727|Drug|Manitol|Placebo Comparator
79226334|NCT05976646|Drug|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
79226335|NCT05976646|Drug|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
79522174|NCT00002796|Drug|fluorouracil|Given IV
79522175|NCT00002796|Drug|sodium phenylbutyrate|Given IV
79522176|NCT00002796|Drug|indomethacin|Given orally
79822701|NCT02587988|Drug|Placebo (for HGP0904)|
79822702|NCT00678795|Drug|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
79822703|NCT00678795|Drug|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
79997351|NCT05336357|Device|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 70 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
79226336|NCT05976321|Drug|TAK-279|TAK-279 capsules.
79226337|NCT05975255|Drug|Remimazolam besylate|Intravenous administration of predetermined dose of Byfavo for 30 seconds
79226338|NCT05973903|Drug|Lenvatinib|Oral Lenvatinib 20 mg once daily
79226339|NCT05973903|Drug|Pembrolizumab|intravenous pembrolizumab 200 mg every three weeks
79226340|NCT05973903|Device|Tumor Treating Fields (TTFields)|TTF extra-dermal scalp electrodes
79226341|NCT05973110|Behavioral|Cognitive Remediation|In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
79368872|NCT02457832|Behavioral|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
79368873|NCT02417818|Device|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
79368874|NCT02417818|Device|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
79368875|NCT01951625|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
79522177|NCT00002796|Biological|recombinant interferon gamma|Given subcutaneously
79522178|NCT00002802|Drug|carboplatin|
79522179|NCT00002802|Drug|cisplatin|
79522180|NCT00002802|Drug|cyclophosphamide|
79522181|NCT00002802|Drug|dacarbazine|
79522182|NCT00002802|Drug|doxorubicin hydrochloride|
79522183|NCT00002802|Drug|etoposide|
79522184|NCT00002802|Drug|ifosfamide|
79522185|NCT00002802|Drug|melphalan|
79522186|NCT00002802|Drug|mesna|
79522187|NCT00002802|Drug|vincristine sulfate|
79522188|NCT00002802|Drug|vindesine|
79522189|NCT00002802|Procedure|autologous bone marrow transplantation|
79522190|NCT00002802|Procedure|conventional surgery|
79522191|NCT00002802|Radiation|low-LET cobalt-60 gamma ray therapy|
79522192|NCT00002802|Radiation|low-LET electron therapy|
79522193|NCT00002802|Radiation|low-LET photon therapy|
79822704|NCT00678639|Other|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
79822705|NCT02587208|Device|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
79368876|NCT01951625|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
79368877|NCT01951625|Drug|Placebo|
79368878|NCT04400890|Drug|Resveratrol|Resveratrol vs placebo given for 15 days.
79368879|NCT04400890|Dietary Supplement|Vitamin D3|Vitamin D3 100,000 IU given on day one.
79368880|NCT01936649|Drug|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
79368881|NCT04330846|Procedure|Surgical resection|The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
79368882|NCT01720069|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
79368883|NCT02337244|Device|Zimmer Persona Total Knee System|No Intervention
79368884|NCT00860314|Procedure|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
79368885|NCT00860314|Procedure|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
79677807|NCT00516087|Biological|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2~Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2~Group Three Day 0 1x10^8 cells/m2 Day 14 2x10^8 cells/m2"
79677808|NCT01244828|Drug|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
79822706|NCT02587208|Procedure|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
79822707|NCT02559063|Behavioral|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
79822708|NCT02559063|Behavioral|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
79822709|NCT04190342|Other|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
79997352|NCT03160885|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
79997353|NCT03160885|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
79368886|NCT04135027|Other|no interventions|no interventions
79368887|NCT00890656|Drug|Cyclophosphamide (CTX)|300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
79368888|NCT00890656|Drug|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
79368889|NCT00890656|Drug|Doxorubicin|50 mg/m^2 by vein (IV) over 24 hours
79368890|NCT00890656|Drug|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
79522194|NCT00002802|Radiation|radioisotope therapy|
79522195|NCT00002814|Biological|filgrastim|
79522196|NCT00002814|Drug|paclitaxel|
79522197|NCT00002814|Drug|topotecan hydrochloride|
79522198|NCT00002832|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
79522199|NCT00002832|Drug|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
79522200|NCT00002832|Drug|Decitabine|IV for 6 hours every 12 hr for 5 days.
79522201|NCT00002832|Procedure|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
79522202|NCT00002832|Procedure|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
79522203|NCT00002838|Biological|Filgrastim (G-CSF)|
79522204|NCT00002838|Drug|Cyclophosphamide|
79522205|NCT00002838|Drug|Fludarabine Phosphate|
79522206|NCT00002838|Procedure|Peripheral Blood Stem Cell Transplantation|
79522207|NCT00002844|Drug|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
79522208|NCT00002844|Procedure|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
79522209|NCT00002844|Procedure|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
79522210|NCT00002844|Radiation|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
79522211|NCT00002862|Drug|perillyl alcohol|
79522212|NCT00002880|Drug|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
79522213|NCT00002892|Biological|recombinant interferon alfa|
79522214|NCT00002898|Biological|dactinomycin|
79822710|NCT04190342|Behavioral|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
79997354|NCT00730717|Drug|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
79997355|NCT00730717|Drug|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
79822711|NCT04772690|Other|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
79997356|NCT01332409|Drug|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
79997357|NCT03181451|Drug|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
79368891|NCT00890656|Drug|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
79368892|NCT00890656|Drug|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
79368893|NCT00890656|Drug|Ara-C|3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
79368894|NCT00890656|Drug|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
79368895|NCT04311112|Drug|Placebos|Placebo
79368896|NCT04311112|Drug|ZA Low dose|ZA low dose
79368897|NCT04311112|Drug|ZA high dose|ZA high dose
79368898|NCT00814138|Drug|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
79677809|NCT00504192|Drug|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
79677810|NCT01243346|Drug|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
79677811|NCT01249443|Drug|vorinostat|Given PO
79822712|NCT03417687|Drug|129Xe MRI|Evaluation of pulmonary function
79368899|NCT00814138|Other|Placebo|Weekly
79368900|NCT00860938|Drug|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
79822713|NCT03417687|Drug|133 Xe scintigraphy|Evaluation of pulmonary function
79822714|NCT04767698|Drug|Belimumab|200 mg SC weekly for 36 months
79822715|NCT04767698|Drug|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
79822716|NCT04767698|Drug|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
79997358|NCT03495973|Drug|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
79997359|NCT00480805|Drug|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
79997360|NCT00480805|Drug|Comparator : ramipril /Duration of Treatment : 8 Weeks|
79997361|NCT00406783|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
79997362|NCT00406783|Drug|Placebo|Placebo tablet, once daily for 15 days
79368901|NCT00862186|Behavioral|'Fatigue Facts & Fixes'|"'Fatigue Facts & Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
79368902|NCT01719757|Drug|Oxycodone/Naloxone|Twice daily
79368903|NCT01718509|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
79368904|NCT01718509|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
79368905|NCT00862810|Biological|Received HPV vaccine first|
79677812|NCT01249443|Other|diagnostic laboratory biomarker analysis|Correlative studies
79677813|NCT01249443|Other|pharmacological study|Correlative studies
79677814|NCT01249443|Drug|carboplatin|Given IV
79368906|NCT00862810|Biological|Received concomitant vaccines first|
79368907|NCT00815698|Procedure|suture|suture for mesh fixation
79368908|NCT00815698|Procedure|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
79368909|NCT00863122|Drug|lapatinib|1500 mg lapatinib by mouth per day for 10 days
79368910|NCT01604941|Drug|SPD602|50 mg/kg/day orally twice daily for 24 weeks
79368911|NCT01604785|Drug|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
79368912|NCT01604785|Drug|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
79522215|NCT00002898|Drug|carboplatin|
79522216|NCT00002898|Drug|cyclophosphamide|
79522217|NCT00002898|Drug|epirubicin hydrochloride|
79522218|NCT00002898|Drug|etoposide|
79522219|NCT00002898|Drug|ifosfamide|
79522220|NCT00002898|Drug|vincristine sulfate|
79522221|NCT00002898|Procedure|adjuvant therapy|
79522222|NCT00002898|Procedure|conventional surgery|
79522223|NCT00002898|Procedure|neoadjuvant therapy|
79522224|NCT00002898|Radiation|brachytherapy|
79522225|NCT00002898|Radiation|radiation therapy|
79522226|NCT00002904|Drug|trabectedin|
79677815|NCT01249443|Drug|paclitaxel|Given IV
79677816|NCT01243073|Drug|Imetelstat|
79677817|NCT01242488|Biological|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
79677818|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
79677819|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
79822717|NCT04785807|Other|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
79822718|NCT04707573|Drug|Vadadustat|oral capsules
79822719|NCT02589080|Behavioral|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
79997363|NCT03179891|Drug|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
79997364|NCT01334671|Drug|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
79226342|NCT05973110|Behavioral|Active Control|In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
79997365|NCT01332565|Drug|GSK1349572|50mg tablet
79368913|NCT01681849|Drug|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
79368914|NCT01681849|Drug|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
79368915|NCT01681849|Other|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
79368916|NCT01681771|Behavioral|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
79368917|NCT01681771|Behavioral|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
79368918|NCT04250350|Biological|Lebrikizumab|Subcutaneous injection
79368919|NCT03839680|Procedure|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
79368920|NCT03839602|Radiation|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
79522227|NCT00002916|Biological|human papillomavirus 16 E7 peptide|
79997366|NCT02973815|Behavioral|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
79677820|NCT01242488|Biological|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
79677821|NCT01242488|Biological|CDP6038|60 mg sc at Weeks 0, 4 and 8
79997367|NCT01338727|Behavioral|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
79997368|NCT01332643|Genetic|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
79226343|NCT05971225|Other|remote monitoring only|remote monitoring only can replace in-office device monitoring
79677822|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 4 and 8
79677823|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 4 and 8
79677824|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
79226344|NCT05967455|Biological|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
79226345|NCT05967455|Biological|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
79368921|NCT00863356|Device|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
79368922|NCT00863434|Drug|clofarabine|Given IV
79368923|NCT00863434|Drug|cytarabine|Given IV
79368924|NCT00863434|Biological|filgrastim|Given SC
79368925|NCT00815776|Device|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
79522228|NCT00002916|Biological|synthetic human papillomavirus 16 E6 peptide|
79522229|NCT00002916|Procedure|adjuvant therapy|
79522230|NCT00002916|Procedure|surgical procedure|
79522231|NCT00002916|Radiation|radiation therapy|
79522232|NCT00002928|Drug|paclitaxel|
79522233|NCT00002940|Drug|hydroxyurea|
79522234|NCT00002946|Drug|penclomedine|
79522235|NCT00002952|Biological|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
79522236|NCT00002952|Biological|recombinant MAGE-3.1 antigen|
79677825|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
79677826|NCT01242488|Other|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
79677827|NCT00516243|Other|placebo|Given PO
79522237|NCT00002952|Biological|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
79522238|NCT00002964|Drug|porfimer sodium|
79522239|NCT00002964|Other|fluorophotometry|
79677828|NCT00516243|Other|quality-of-life assessment|Ancillary studies
79997369|NCT05185765|Other|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
79997370|NCT03160573|Drug|ClōSYS® Unflavored Rinse|
79226346|NCT05962229|Drug|(S)-Nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
79226347|NCT05962229|Drug|(R)- nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
79226348|NCT05962229|Drug|Racemic nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
79226349|NCT05961124|Drug|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
79226350|NCT05960864|Drug|Celecoxib|If we find any behavior that affects the safety of patients in the experiment, we will stop
79368926|NCT00815776|Device|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
79368927|NCT00815776|Other|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
79368928|NCT03535636|Other|Polysomnography|Sleep architecture will be assessed by polysomnography
79677829|NCT00516243|Procedure|questionnaire administration|Ancillary studies
79677830|NCT00516243|Procedure|laboratory biomarker analysis|Correlative studies
79522240|NCT00002970|Drug|nelarabine|Given IV
79522241|NCT00002970|Drug|methotrexate|Given IT
79522242|NCT00002970|Drug|cytarabine|Given IT
79522243|NCT00002970|Drug|therapeutic hydrocortisone|Given IT
79522244|NCT00002976|Drug|conjugated estrogens|
79522245|NCT00002982|Biological|filgrastim|
79522246|NCT00002982|Drug|carboplatin|
79522247|NCT00002982|Drug|carmustine|
79522248|NCT00002982|Drug|cytarabine|
79522249|NCT00002982|Drug|etoposide|
79522250|NCT00002982|Drug|ifosfamide|
79522251|NCT00002982|Drug|melphalan|
79522252|NCT00002982|Procedure|autologous bone marrow transplantation|
79522253|NCT00002982|Procedure|peripheral blood stem cell transplantation|
79522254|NCT00002982|Radiation|radiation therapy|
79522255|NCT00002988|Drug|carmustine|
79522256|NCT00002988|Drug|irinotecan hydrochloride|
79522257|NCT00002994|Biological|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
79522258|NCT00002994|Biological|rhuMAb|90 min IV infusion day 7 of each cycle
79522259|NCT00003000|Drug|fentanyl citrate|
79522260|NCT00003000|Drug|morphine sulfate|
79522261|NCT00003006|Genetic|reverse transcriptase-polymerase chain reaction|
79677831|NCT00516243|Drug|defined green tea catechin extract|Given PO
79677832|NCT01240889|Drug|Fluticasone|nasal spray
79677833|NCT01240889|Drug|Fluticason|2 sprays per day in each nostril
79680006|NCT00522899|Behavioral|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
79522262|NCT00003006|Other|immunohistochemistry staining method|
79522263|NCT00003012|Drug|CMF regimen|
79522264|NCT00003012|Drug|cyclophosphamide|
79522265|NCT00003012|Drug|epirubicin hydrochloride|
79522266|NCT00003012|Drug|fluorouracil|
79522267|NCT00003012|Drug|methotrexate|
79522268|NCT00003048|Drug|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
79522269|NCT00003054|Drug|paclitaxel|
79522270|NCT00003060|Biological|filgrastim|
79522271|NCT00003060|Drug|busulfan|
79522272|NCT00003060|Drug|cyclophosphamide|
79522273|NCT00003060|Drug|cyclosporine|
79522274|NCT00003060|Drug|methotrexate|
79997371|NCT03160573|Drug|ClōSYS® Flavored Rinse|
79997372|NCT03160573|Other|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
79997373|NCT03160573|Other|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
79997374|NCT01314677|Procedure|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
79997375|NCT01314677|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
79522275|NCT00003060|Procedure|allogeneic bone marrow transplantation|
79226351|NCT05957003|Procedure|Combined end-expiratory occlusion and end-inspiratory occlusion test|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 seconds using the end-expiratory hold button available on the ventilator.~The EIO test will be performed by interrupting the mechanical ventilation at end-inspiration over 15 seconds using the end-inspiratory hold button available on the ventilator."
79522276|NCT00003066|Drug|docetaxel|
79522277|NCT00003066|Drug|estramustine phosphate sodium|
79226352|NCT05957003|Procedure|Tidal volume challenge test|elevating tidal volume from 6 ml/kg to 8 ml/kg for only 60 seconds
79522278|NCT00003072|Drug|amifostine trihydrate|
79677834|NCT00516282|Drug|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
79677835|NCT00516282|Drug|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
79677836|NCT02950389|Device|PMMA filter|
79677837|NCT02950389|Device|HFR17 filter|
79226353|NCT05956821|Drug|SIACI of cetuximab and bevacizumab|Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
79226354|NCT05946642|Drug|Sulphadoxine-Pyrimethamine/Amodiaquine|Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
79368929|NCT04209790|Radiation|Neoadjuvant chemoradiation|Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.
79368930|NCT04209790|Drug|Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.
79677838|NCT02950389|Device|F7 filter|
79677839|NCT04511117|Other|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
79226355|NCT05946642|Drug|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
79677840|NCT04511117|Other|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
79680007|NCT00522899|Behavioral|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
79680008|NCT02931006|Other|water|
79522279|NCT00003072|Drug|carboplatin|
79522280|NCT00003072|Drug|paclitaxel|
79522281|NCT00003078|Drug|cisplatin|
79522282|NCT00003078|Drug|fluorouracil|
79522283|NCT00003078|Radiation|brachytherapy|
79522284|NCT00003078|Radiation|radiation therapy|
79522285|NCT00003084|Drug|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
79522286|NCT00003084|Drug|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
79522287|NCT00003084|Drug|Etoposide|Oral etoposide twice daily on days 1-14.
79522288|NCT00003084|Drug|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
79522289|NCT00003084|Drug|Paclitaxel|IV over 1 hour on day 2.
79522290|NCT00003084|Drug|Vinblastine|IV on days 8, 22, and 36.
79522291|NCT00003090|Biological|aldesleukin|
79522292|NCT00003096|Genetic|DNA ploidy analysis|
79522293|NCT00003096|Genetic|comparative genomic hybridization|
79680009|NCT02931006|Other|bovine milk|
79680010|NCT00522938|Drug|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
79522294|NCT00003096|Genetic|cytogenetic analysis|
79522295|NCT00003096|Genetic|fluorescence in situ hybridization|
79522296|NCT00003108|Drug|bryostatin 1|
79522297|NCT00003108|Drug|cisplatin|
79522298|NCT00003114|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
79677841|NCT04512092|Behavioral|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
79677842|NCT01249521|Drug|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
79677843|NCT04513301|Drug|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
79226356|NCT05944731|Device|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
79677844|NCT04513301|Radiation|Radiotherapy|RT 50-60Gy/25-30f
79677845|NCT04516421|Dietary Supplement|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
79677846|NCT04516421|Dietary Supplement|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
79226357|NCT05942560|Behavioral|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
79226358|NCT05942560|Behavioral|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
79368931|NCT04209790|Procedure|Surgery post Radiation and Temozolomide (benzolamide)|Surgical resection of GBM will be done after radiation and Temozolomide treatment.
79368932|NCT03838822|Dietary Supplement|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
79368933|NCT01718353|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
79368934|NCT01718353|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
79522299|NCT00003114|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
79522300|NCT00003114|Drug|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
79522301|NCT00003114|Drug|lomustine|Patients receive oral lomustine on day 1.
79522302|NCT00003114|Drug|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
79522303|NCT00003114|Radiation|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
79522304|NCT00003120|Drug|paclitaxel|135 mg/m2 IV every 28 days
79368935|NCT01718353|Drug|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
79368936|NCT01716715|Drug|Cabozantinib S-malate|Given PO
79368937|NCT01716715|Other|Laboratory Biomarker Analysis|Correlative studies
79368938|NCT01716715|Drug|Paclitaxel|Given IV
79368939|NCT01696279|Drug|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
79522305|NCT00003126|Drug|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
79522306|NCT00003132|Drug|bryostatin 1|
79522307|NCT00003132|Drug|cisplatin|
79522308|NCT00003144|Drug|amifostine trihydrate|
79522309|NCT00003144|Drug|cisplatin|
79522310|NCT00003144|Drug|gemcitabine hydrochloride|
79522311|NCT00003150|Biological|rituximab|
79522312|NCT00003150|Drug|CHOP regimen|
79522313|NCT00003150|Drug|cyclophosphamide|
79522314|NCT00003150|Drug|doxorubicin hydrochloride|
79522315|NCT00003150|Drug|prednisone|
79522316|NCT00003150|Drug|vincristine sulfate|
79522317|NCT00003156|Drug|topotecan hydrochloride|
79522318|NCT00003162|Procedure|pain therapy|
79522319|NCT00003162|Radiation|radiation therapy|
79522320|NCT00003174|Drug|bryostatin 1|
79522321|NCT00003174|Drug|cladribine|
79522322|NCT00003186|Drug|isosulfan blue|
79522323|NCT00003186|Procedure|lymphangiography|
79522324|NCT00003186|Procedure|sentinel lymph node biopsy|
79522325|NCT00003192|Drug|aminocamptothecin|
79522326|NCT00003018|Drug|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
79522327|NCT00003018|Drug|fluorouracil|200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle
79522328|NCT00003018|Drug|leucovorin calcium|30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle
79522329|NCT00003018|Drug|mitomycin C|10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
79522330|NCT00003198|Drug|ifosfamide|
79522331|NCT00003198|Drug|topotecan hydrochloride|
79822720|NCT04082702|Behavioral|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
79822721|NCT04082702|Behavioral|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
79822722|NCT03301311|Other|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
79997376|NCT05185687|Behavioral|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
79997377|NCT05185687|Behavioral|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
79226359|NCT05941286|Device|CGM system with glucose alerts on|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts on
79226360|NCT05941286|Device|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
79677847|NCT01249599|Procedure|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
79677848|NCT04512014|Diagnostic Test|serum lactate|perioperative measurement of lactate levels
79677849|NCT01249677|Drug|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
79226361|NCT05939596|Biological|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
79226362|NCT05939596|Other|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
79226363|NCT05936710|Device|ACETATE based dialysate|Intermittent hemodialysis with an acetate based dialysate.
79226364|NCT05936710|Device|CITRATE based dialysate|Intermittent hemodialysis with an citrate based dialysate.
79677850|NCT04697043|Procedure|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
79677851|NCT04511975|Drug|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
79677852|NCT04511975|Drug|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
79677853|NCT04511663|Combination Product|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
79368940|NCT01696279|Drug|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
79368941|NCT01681069|Dietary Supplement|IQP-VV-102|
79368942|NCT01681069|Other|Placebo|
79368943|NCT04555759|Other|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
79522332|NCT00003204|Drug|cyclophosphamide|Given IV
79522333|NCT00003204|Drug|fludarabine phosphate|Given IV
79522334|NCT00003204|Drug|vincristine sulfate|Given IV
79522335|NCT00003204|Drug|prednisone|Given PO
79522336|NCT00003204|Biological|rituximab|Given IV
79522337|NCT00003204|Other|laboratory biomarker analysis|Correlative studies
79522338|NCT00003210|Biological|recombinant interleukin-12|Given subcutaneously
79522339|NCT00003210|Other|laboratory biomarker analysis|Correlative studies
79368944|NCT01936181|Drug|Remicade (infliximab)|
79368945|NCT01936181|Drug|SB2 (proposed biosimilar to infliximab)|
79522340|NCT00003216|Drug|fluorouracil|
79522341|NCT00003216|Drug|gemcitabine hydrochloride|
79522342|NCT00003216|Radiation|radiation therapy|
79522343|NCT00003234|Drug|vinorelbine tartrate|
79522344|NCT00003240|Drug|cisplatin|
79522345|NCT00003240|Drug|ifosfamide|
79522346|NCT00003240|Drug|mitomycin C|
79522347|NCT00003240|Drug|vinblastine sulfate|
79522348|NCT00003240|Drug|vindesine|
79522349|NCT00003240|Drug|vinorelbine tartrate|
79522350|NCT00003240|Procedure|conventional surgery|
79522351|NCT00003240|Radiation|radiation therapy|
79522352|NCT00003252|Drug|amifostine trihydrate|
79522353|NCT00003264|Drug|cisplatin|
79997378|NCT05185687|Behavioral|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
79997379|NCT04470661|Diagnostic Test|Ultrasonography|"Point-of-care ultrasound:~Kidney length and echogenity,~Bladder scanning~VCI measures~Lung B lines and effusion~Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures"
79997380|NCT02736227|Drug|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
79997381|NCT01334905|Drug|YM178|oral
79226365|NCT05934669|Drug|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
79226366|NCT05934669|Drug|Intranasal Dexmedetomidine|See above
79226367|NCT05934669|Drug|Intranasal Ketamine|See above
79368946|NCT04642235|Other|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
79997382|NCT02623985|Device|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
79997383|NCT02623985|Device|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
79226368|NCT05931341|Dietary Supplement|Rosemary extract|Softgel capsule including rosemary extract
79522354|NCT00003264|Drug|gemcitabine hydrochloride|
79522355|NCT00003276|Drug|irinotecan hydrochloride|
79522356|NCT00003282|Drug|EF5|Given IV
79522357|NCT00003282|Procedure|therapeutic conventional surgery|Undergo resection
79522358|NCT00003282|Procedure|biopsy|Undergo biopsy
79522359|NCT00003282|Other|pharmacological study|Correlative studies
79522360|NCT00003288|Biological|filgrastim|
79522361|NCT00003288|Drug|cyclophosphamide|
79522362|NCT00003288|Drug|tirapazamine|
79522363|NCT00003294|Biological|filgrastim|
79522364|NCT00003294|Drug|amifostine trihydrate|
79522365|NCT00003294|Drug|carboplatin|
79522366|NCT00003294|Drug|paclitaxel|
79522367|NCT00003312|Radiation|iodine I 125|
79522368|NCT00003324|Procedure|conventional surgery|
79522369|NCT00003324|Radiation|radiation therapy|
79522370|NCT00003330|Biological|recombinant interleukin-12|
79522371|NCT00003336|Biological|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
79522372|NCT00003336|Drug|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
79522373|NCT00003336|Drug|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
79522374|NCT00003336|Drug|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
79522375|NCT00003336|Drug|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
79522376|NCT00003336|Procedure|bone marrow ablation with stem cell support|
79522377|NCT00003336|Procedure|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
79522378|NCT00003336|Radiation|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
79522379|NCT00003342|Biological|filgrastim|
79522380|NCT00003342|Drug|carboplatin|
79522381|NCT00003342|Drug|doxorubicin hydrochloride|
79522382|NCT00003342|Drug|gemcitabine hydrochloride|
79522383|NCT00003342|Drug|paclitaxel|
79522384|NCT00003348|Drug|O6-benzylguanine|
79522385|NCT00003348|Drug|carmustine|
79522386|NCT00003354|Procedure|conventional surgery|
79522387|NCT00003354|Procedure|laparoscopic surgery|
79522388|NCT00003360|Radiation|iodine I 131 monoclonal antibody A33|
79522389|NCT00003372|Drug|topotecan hydrochloride|
79522390|NCT00003378|Drug|carboplatin|
79997384|NCT02623985|Device|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
79997385|NCT01332877|Behavioral|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
79997386|NCT01332877|Behavioral|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
79997387|NCT05095337|Drug|[14C]SHR1459|Patients will receive single dose of orally [14C]SHR1459 on Day 1.
79997388|NCT01335139|Biological|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
79226369|NCT05929859|Behavioral|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
79226370|NCT05923944|Behavioral|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
79226371|NCT05923944|Behavioral|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
79226372|NCT05923905|Drug|FB1006|30mg/day
79226373|NCT05923905|Drug|Placebo|30mg/day
79226374|NCT05923138|Dietary Supplement|MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS|"Nutritional intervention (diet, dietetic recommendations and/or supplements). Participants will receive specific recommendations about diet, energetic dietetic supplementation, oral nutritional supplements, exercise... The Nutrition Team (formed by cardiologists, dieticians, nurses...) will closely monitor patients with periodic visits and reassessment of nutritional status and compliance with recommendations."
79226375|NCT05923138|Dietary Supplement|CONTROL|Standard treatment (usual recommendations in patients with heart failure)
79522391|NCT00003378|Drug|gemcitabine hydrochloride|
79522392|NCT00003378|Drug|paclitaxel|
79226376|NCT05921604|Drug|Baclofen 10mg|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
79522393|NCT00003384|Other|Cervical Papanicolaou Test|Undergo Pap smear
79522394|NCT00003384|Procedure|Conization|Undergo cone biopsy
79522395|NCT00003384|Other|Laboratory Biomarker Analysis|Correlative studies
79822723|NCT03301311|Other|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
79368947|NCT04642235|Behavioral|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
79522396|NCT00003390|Drug|irofulven|
79522397|NCT00003396|Biological|anti-thymocyte globulin|
79522398|NCT00003396|Biological|graft-versus-tumor induction therapy|
79522399|NCT00003396|Drug|cyclophosphamide|
79522400|NCT00003396|Drug|melphalan|
79822724|NCT04082624|Behavioral|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
79822725|NCT04082624|Behavioral|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
79997389|NCT01335139|Biological|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
79522401|NCT00003396|Procedure|peripheral blood stem cell transplantation|
79522402|NCT00003396|Radiation|radiation therapy|
79522403|NCT00003402|Drug|carmustine|
79522404|NCT00003402|Drug|cisplatin|
79522405|NCT00003402|Drug|cyclophosphamide|
79522406|NCT00003402|Drug|dexamethasone|
79522407|NCT00003402|Drug|etoposide|
79522408|NCT00003402|Drug|melphalan|
79522409|NCT00003402|Drug|paclitaxel|
79522410|NCT00003402|Procedure|bone marrow ablation with stem cell support|
79522411|NCT00003402|Procedure|peripheral blood stem cell transplantation|
79522412|NCT00003408|Biological|aldesleukin|
79997390|NCT01335139|Other|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
79997391|NCT05030129|Dietary Supplement|5-Hydroxytryptophan / Vitamin B6|5-hydroxytryptophan, also known as 5-HTP has a nutraceutical status and has never been approved as a drug for any indication, but as a dietary supplement has been used extensively for several disorders for many years such as in the therapy of depression, fibromyalgia, obesity, insomnia and chronic headache
79368948|NCT04642235|Other|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
79997392|NCT05030129|Drug|Ergoloid Mesylate|Ergoloid Mesylates, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids, dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine. Ergot alkaloids are dopamine agonists which activate dopamine receptors (in the basal ganglia and other parts of the brain involved in motor function) and a prolactin inhibitor. Ergot is a strong vasoconstrictor and thus helps to reduce bleeding by narrowing of the blood vessels.
79997393|NCT05030129|Other|Placebo|Placebo capsules
79997394|NCT01335217|Procedure|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
79997395|NCT05239559|Device|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~A nasal interface connecting the child's airway with the circuit:~An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
79226377|NCT05921604|Drug|Gabapentin|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
79226378|NCT05917262|Behavioral|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
79368949|NCT04641611|Other|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
79368950|NCT04641611|Other|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
79522413|NCT00003408|Biological|recombinant interferon alfa|
79677854|NCT04511663|Combination Product|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
79226379|NCT05917262|Behavioral|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
79226380|NCT05917262|Behavioral|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
79368951|NCT01696045|Biological|Ipilimumab|
79368952|NCT01716169|Device|Helicoll|Helicoll Collagen I Wound Dressing
79522414|NCT00003408|Biological|sargramostim|
79522415|NCT00003414|Biological|aldesleukin|
79522416|NCT00003414|Biological|recombinant interferon gamma|
79522417|NCT00003414|Drug|busulfan|
79522418|NCT00003414|Drug|cyclophosphamide|
79522419|NCT00003414|Drug|cyclosporine|
79522420|NCT00003414|Procedure|peripheral blood stem cell transplantation|
79522421|NCT00003414|Radiation|radiation therapy|
79522422|NCT00003420|Procedure|computed tomography|
79522423|NCT00003426|Drug|gemcitabine hydrochloride|
79522424|NCT00003426|Radiation|radiation therapy|
79522425|NCT00003432|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
79522426|NCT00003450|Biological|Ad5CMV-p53 gene|
79522427|NCT00003462|Drug|busulfan|
79522428|NCT00003486|Drug|antineoplaston A10|
79522429|NCT00003486|Drug|antineoplaston AS2-1|
79522430|NCT00003486|Procedure|alternative product therapy|
79522431|NCT00003486|Procedure|biological therapy|
79522432|NCT00003486|Procedure|biologically based therapies|
79522433|NCT00003486|Procedure|cancer prevention intervention|
79522434|NCT00003486|Procedure|complementary and alternative therapy|
79522435|NCT00003486|Procedure|differentiation therapy|
79522436|NCT00003516|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
79522437|NCT00003522|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79522438|NCT00003528|Drug|raltitrexed|Given IV
79522439|NCT00003534|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
79522440|NCT00003540|Drug|gemcitabine hydrochloride|
79522441|NCT00003546|Drug|gemcitabine hydrochloride|given IV
79522442|NCT00003546|Radiation|radiation therapy|1.8 Gy to tumor bed
79522443|NCT00003552|Drug|allogeneic lymphocytes|
79522444|NCT00003552|Drug|anti-thymocyte globulin|
79522445|NCT00003552|Drug|cyclophosphamide|
79368953|NCT01716169|Device|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
79522446|NCT00003552|Drug|fludarabine|
79368954|NCT01935947|Drug|Azacitidine|Given SC
79997396|NCT01338961|Procedure|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
79997397|NCT01339039|Drug|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
79997398|NCT01339039|Drug|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
79368955|NCT01935947|Drug|Azacitidine|Given PO
79368956|NCT01935947|Drug|Docetaxel|Given IV
79368957|NCT01935947|Drug|Entinostat|Given PO
79368958|NCT01935947|Drug|Gemcitabine Hydrochloride|Given IV
79368959|NCT01935947|Drug|Irinotecan Hydrochloride|Given IV
79368960|NCT01935947|Other|Laboratory Biomarker Analysis|Correlative studies
79368961|NCT01935947|Drug|Pemetrexed Disodium|Given IV
79368962|NCT04547803|Other|Standard of Care|Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
79368963|NCT04547803|Other|Video Visit|15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
79368964|NCT02986321|Drug|CHF6001|Dose response: Test one of 4 different doses of CHF6001
79522447|NCT00003558|Drug|carboplatin|
79997399|NCT01339039|Drug|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
79997400|NCT01339039|Drug|Plerixafor|Daily administration for 5-9 days prior to surgery
79522448|NCT00003558|Drug|etoposide|
79522449|NCT00003558|Drug|fluorouracil|
79522450|NCT00003558|Drug|leucovorin calcium|
79522451|NCT00003558|Drug|paclitaxel|
79822726|NCT04082624|Behavioral|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
79997401|NCT01339039|Procedure|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 & 15).
79997402|NCT03176459|Drug|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
79368965|NCT02986321|Drug|Budesonide|active control
79368966|NCT02986321|Drug|Placebo|placebo control
79368967|NCT04554667|Behavioral|Exercise Intervention|Heavy Lifting Strength Training
79368968|NCT01618019|Dietary Supplement|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
79368969|NCT01618019|Dietary Supplement|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
79368970|NCT01593787|Drug|LCZ696|100 mg, 200 mg, 400 mg tablets.
79368971|NCT04410601|Procedure|Total thyroidectomy|DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
79368972|NCT01951157|Drug|Docetaxel|Powder for solution for infusion
79368973|NCT01951157|Drug|Gemcitabine|Powder for solution for infusion
79368974|NCT01951157|Drug|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
79368975|NCT01363349|Drug|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
79368976|NCT01363349|Drug|Risperidone|
79368977|NCT00867100|Drug|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
79368978|NCT00867100|Drug|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
79368979|NCT00867100|Drug|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
79368980|NCT00867100|Drug|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
79368981|NCT05310370|Genetic|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
79522452|NCT00003564|Drug|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
79522453|NCT00003564|Drug|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
79522454|NCT00003576|Drug|cisplatin|
79522455|NCT00003576|Drug|fluorouracil|
79522456|NCT00003576|Procedure|surgical procedure|
79522457|NCT00003576|Radiation|radiation therapy|
79522458|NCT00003582|Drug|amifostine trihydrate|
79522459|NCT00003582|Drug|cisplatin|
79522460|NCT00003582|Drug|fluorouracil|
79522461|NCT00003582|Drug|paclitaxel|
79522462|NCT00003582|Procedure|quality-of-life assessment|
79522463|NCT00003582|Radiation|radiation therapy|
79522464|NCT00003588|Biological|Ad5CMV-p53 gene|
79522465|NCT00003588|Procedure|laparoscopic surgery|
79522466|NCT00003594|Drug|irinotecan|
79522467|NCT00003594|Drug|fluorouracil|
79522468|NCT00003594|Drug|leucovorin calcium|
79522469|NCT00003594|Drug|oxaliplatin|
79522470|NCT00003600|Biological|epoetin alfa|
79522471|NCT00003600|Other|placebo|
79522472|NCT00003606|Drug|cisplatin|
79522473|NCT00003606|Drug|cyclophosphamide|
79522474|NCT00003606|Drug|epirubicin hydrochloride|
79522475|NCT00003606|Drug|etoposide|
79522476|NCT00003606|Radiation|radiation therapy|
79522477|NCT00003612|Biological|trastuzumab|
79522478|NCT00003612|Drug|carboplatin|
79522479|NCT00003612|Drug|paclitaxel|
79677855|NCT04519931|Other|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
79677856|NCT02950194|Procedure|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
79822727|NCT04082624|Behavioral|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
79822728|NCT04049253|Drug|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
79822729|NCT00919958|Biological|PLX-PAD IM injection|Single treatment; multiple injections
79226381|NCT05917028|Device|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
79522480|NCT00003624|Drug|amifostine trihydrate|
79522481|NCT00003624|Drug|cisplatin|
79522482|NCT00003624|Drug|paclitaxel|
79522483|NCT00003630|Drug|arsenic trioxide|
79522484|NCT00003636|Drug|carboplatin|
79522485|NCT00003636|Drug|cisplatin|
79522486|NCT00003636|Procedure|conventional surgery|
79522487|NCT00003636|Procedure|neoadjuvant therapy|
79522488|NCT00003642|Drug|cisplatin|
79522489|NCT00003642|Drug|fluorouracil|
79522490|NCT00003642|Radiation|radiation therapy|
79522491|NCT00003648|Genetic|DNA stability analysis|
79522492|NCT00003648|Genetic|gene rearrangement analysis|
79522493|NCT00003654|Drug|patent blue V dye|
79522494|NCT00003654|Procedure|lymphangiography|
79522495|NCT00003654|Procedure|radionuclide imaging|
79522496|NCT00003654|Procedure|sentinel lymph node biopsy|
79522497|NCT00003654|Radiation|technetium Tc 99m sulfur colloid|
79677857|NCT04511936|Device|i-Lumen AMD|Microcurrent stimulator
79677858|NCT04511936|Device|i-Lumen AMD Sham|Sham microcurrent stimulator
79822730|NCT03217851|Diagnostic Test|Blood Collection|blood smear and/or rapid diagnostic
79822731|NCT03217851|Diagnostic Test|Dried Blood Spot|Dried Blood Spot on filter paper
79822732|NCT04082000|Drug|BOL-DP-o-04|BOL-DP-o-04
79822733|NCT04082000|Drug|Placebo|Placebo
79226382|NCT05915910|Diagnostic Test|Specimen Donation|blood donation
79226383|NCT05915897|Diagnostic Test|Specimen Donation|blood donation
79226384|NCT05910853|Diagnostic Test|Specimen Donation|Blood donation
79522498|NCT00003666|Drug|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
79522499|NCT00003678|Drug|tamoxifen citrate|
79226385|NCT05908708|Device|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
79226386|NCT05903001|Diagnostic Test|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
79522500|NCT00003678|Procedure|adjuvant therapy|
79522501|NCT00003684|Drug|theophylline|
79522502|NCT00003684|Procedure|quality-of-life assessment|
79522503|NCT00003690|Drug|alvocidib|
79522504|NCT00003690|Drug|carboplatin|
79522505|NCT00003690|Drug|cisplatin|
79522506|NCT00003696|Drug|carboplatin|
79522507|NCT00003696|Drug|cyclophosphamide|
79522508|NCT00003696|Drug|doxorubicin hydrochloride|
79522509|NCT00003696|Drug|etoposide|
79522510|NCT00003696|Drug|paclitaxel|
79522511|NCT00003708|Drug|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
79522512|NCT00003714|Drug|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
79522513|NCT00003720|Drug|semaxanib|
79522514|NCT00003732|Drug|carboplatin|
79522515|NCT00003732|Drug|paclitaxel|
79522516|NCT00003732|Drug|topotecan hydrochloride|
79522517|NCT00003744|Drug|gemcitabine|
79522518|NCT00003750|Biological|hu14.18-IL2 fusion protein|
79522519|NCT00003762|Drug|docetaxel|
79522520|NCT00003762|Drug|gemcitabine hydrochloride|
79522521|NCT00003768|Drug|fosbretabulin disodium|
79522522|NCT00003780|Biological|tumor infiltrating lymphocyte therapy|
79522523|NCT00003780|Drug|gemcitabine hydrochloride|
79522524|NCT00003786|Drug|irofulven|
79522525|NCT00003792|Biological|MART-1 antigen|
79522526|NCT00003792|Biological|filgrastim|
79522527|NCT00003792|Biological|flu matrix peptide p58-66|
79522528|NCT00003792|Biological|gp100 antigen|
79522529|NCT00003792|Biological|recombinant MAGE-3.1 antigen|
79522530|NCT00003792|Biological|tyrosinase peptide|
79522531|NCT00003792|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79522532|NCT00003798|Drug|motexafin gadolinium|
79522533|NCT00003798|Radiation|radiation therapy|
79522534|NCT00003804|Biological|dactinomycin|
79522535|NCT00003804|Drug|vincristine sulfate|
79522536|NCT00003804|Procedure|conventional surgery|
79522537|NCT00003822|Drug|apomine|
79522538|NCT00003828|Drug|vinorelbine|
79522539|NCT00003834|Drug|fluorouracil|
79677859|NCT01249794|Procedure|non invasive ventilation|continuous positive airways pressure
79822734|NCT03205137|Drug|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
79822735|NCT03205137|Drug|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
79522540|NCT00003834|Drug|leucovorin calcium|
79997403|NCT03176459|Drug|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
79997404|NCT01339117|Other|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
79997405|NCT01339117|Other|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
79997406|NCT01335295|Drug|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
79997407|NCT05239481|Device|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
79997408|NCT05239481|Device|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
79997409|NCT01332955|Drug|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
79997410|NCT01332955|Biological|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
79997411|NCT01332955|Drug|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
79368982|NCT05310214|Other|Acupuncture|"Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment."
79522541|NCT00003834|Drug|oxaliplatin|
79522542|NCT00003840|Biological|DTGM fusion protein|
79522543|NCT00003846|Biological|filgrastim|
79522544|NCT00003846|Drug|carboplatin|
79822736|NCT03205137|Drug|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
79822737|NCT03205137|Drug|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
79822738|NCT04953650|Behavioral|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
79822739|NCT04953650|Other|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
79997412|NCT05224895|Procedure|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
79997413|NCT01335373|Drug|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
79822740|NCT05189522|Device|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
79522545|NCT00003846|Drug|cyclophosphamide|
79522546|NCT00003846|Drug|thiotepa|
79522547|NCT00003846|Drug|vincristine sulfate|
79522548|NCT00003846|Procedure|bone marrow ablation with stem cell support|
79522549|NCT00003846|Procedure|peripheral blood stem cell transplantation|
79522550|NCT00003846|Radiation|radiation therapy|
79522551|NCT00003852|Biological|filgrastim|
79522552|NCT00003852|Drug|carboplatin|
79522553|NCT00003852|Drug|cyclophosphamide|
79226387|NCT05903001|Diagnostic Test|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
79226388|NCT05903001|Diagnostic Test|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
79226389|NCT05903001|Diagnostic Test|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
79226390|NCT05903001|Diagnostic Test|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
79226391|NCT05903001|Diagnostic Test|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
79226392|NCT05903001|Diagnostic Test|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
79226393|NCT05903001|Diagnostic Test|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
79522554|NCT00003852|Drug|epirubicin hydrochloride|
79522555|NCT00003852|Drug|etoposide|
79522556|NCT00003852|Drug|ifosfamide|
79522557|NCT00003852|Drug|paclitaxel|
79522558|NCT00003852|Drug|thiotepa|
79522559|NCT00003852|Procedure|bone marrow ablation with stem cell support|
79997414|NCT05221463|Behavioral|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
79226394|NCT05903001|Diagnostic Test|6-minute walking distance|The maximum walking distance achieved in 6 minutes
79226395|NCT05903001|Diagnostic Test|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
79522560|NCT00003852|Procedure|peripheral blood stem cell transplantation|
79522561|NCT00003858|Drug|mitoxantrone hydrochloride|
79522562|NCT00003870|Drug|cyclophosphamide|
79522563|NCT00003870|Drug|methotrexate|
79522564|NCT00003870|Procedure|allogeneic bone marrow transplantation|
79522565|NCT00003870|Radiation|iodine I 131 monoclonal antibody BC8|
79522566|NCT00003870|Radiation|radiation therapy|
79522567|NCT00003876|Drug|polifeprosan 20 with carmustine implant|
79997415|NCT05221463|Behavioral|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
79522568|NCT00003876|Procedure|surgical procedure|
79226396|NCT05903001|Diagnostic Test|Electromyography|electromyography of the muscles of respiration via superficial electrodes
79522569|NCT00003876|Radiation|iodine I 125|
79522570|NCT00003882|Drug|anhydrovinblastine|
79997416|NCT03204721|Other|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
79522571|NCT00003888|Drug|cisplatin|
79522572|NCT00003888|Drug|docetaxel|
79226397|NCT05903001|Diagnostic Test|Lung Function|Measurement of lung function via body plethysmography
79226398|NCT05903001|Diagnostic Test|CAT-Questionnaire|COPD Assessment Test (CAT)
79226399|NCT05903001|Diagnostic Test|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
79522573|NCT00003888|Drug|fluorouracil|
79522574|NCT00003888|Radiation|radiation therapy|
79226400|NCT05899114|Other|Transitional Multidisciplinary Pharmacotherapeutic Care|"A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~A structured pharmacotherapeutic analysis~A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner."
79522575|NCT00003894|Drug|thalidomide|
79522576|NCT00003900|Drug|docetaxel|
79522577|NCT00003900|Drug|irinotecan hydrochloride|
79522578|NCT00003906|Drug|Raloxifene|60 mg/day plus placebo for 5 years
79522579|NCT00003906|Drug|Tamoxifen|20 mg/day plus placebo for 5 years
79522580|NCT00003912|Drug|carboplatin|
79522581|NCT00003912|Drug|cisplatin|
79522582|NCT00003912|Drug|doxorubicin hydrochloride|
79522583|NCT00003912|Procedure|conventional surgery|
79522584|NCT00003924|Biological|recombinant interferon alfa|
79677860|NCT04519736|Device|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
79680011|NCT00522938|Drug|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
79226401|NCT05896371|Drug|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I&T injected activity
79226402|NCT05896371|Drug|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I&T injected activity
79522585|NCT00003930|Drug|cisplatin|
79522586|NCT00003930|Drug|gemcitabine hydrochloride|
79522587|NCT00003930|Drug|paclitaxel|
79522588|NCT00003930|Procedure|conventional surgery|
79522589|NCT00003930|Radiation|radiation therapy|
79522590|NCT00003936|Drug|bryostatin 1|
79522591|NCT00003942|Biological|RevM10 gene|
79522592|NCT00003942|Biological|RevM10/polAS gene|
79522593|NCT00003942|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79522594|NCT00003942|Procedure|peripheral blood stem cell transplantation|
79522595|NCT00003954|Drug|melphalan|Given IV
79522596|NCT00003954|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
79522597|NCT00003954|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
79522598|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
79522599|NCT00003954|Radiation|total-body irradiation|Undergo TBI
79522600|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo donor PBSCT
79680012|NCT02936856|Device|Hepatic Arteriography|
79680013|NCT04694105|Drug|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
79677861|NCT02950116|Device|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~Patient's breathing pattern is stable for a minimum of 5 breaths~Start of washout by inhaling 100% oxygen (initiated by lab technician)~Continuous stable breathing pattern until end of washout test~End target = 1/40th of start N2 concentration~To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~Three N2-MBW-tests are performed consecutively. Time between each test is [duration of the previous test*1.5] (e.g. test duration = 6 min., time to next test = 6*1.5 = 9 min.)"
79677862|NCT04511897|Drug|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
79680014|NCT04694105|Drug|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
79680015|NCT04694105|Drug|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
79822741|NCT05189522|Other|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
79822742|NCT02588144|Procedure|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
79822743|NCT02588144|Procedure|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
79822744|NCT02586740|Procedure|Pulmonary artery rehabilitation|
79822745|NCT04951544|Other|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
79822746|NCT04951544|Other|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
79997417|NCT05218811|Device|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
79997418|NCT05185219|Drug|Valerian|A natural plant
79822747|NCT02589236|Drug|Cavosonstat|GSNOR inhibitor
79522601|NCT00003954|Drug|cyclosporine|Given IV and PO
79226403|NCT05893979|Device|Spectacle Lenses|Standard Spectacle Lenses
79822748|NCT02589236|Drug|Placebo|Control sample with only capsule excipients and fillers
79226405|NCT05893069|Drug|Oxandrolone|oral oxandrolone for 12 weeks
79226406|NCT05893069|Drug|Placebo|oral placebo for 12 weeks
79822749|NCT04082468|Diagnostic Test|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T & B lymphocyte panel at above time points
79822750|NCT00920036|Device|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
79822751|NCT04684550|Drug|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
79822752|NCT04684550|Drug|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
79226407|NCT05890807|Diagnostic Test|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
79522602|NCT00003954|Drug|mycophenolate mofetil|Given PO
79522603|NCT00003954|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
79522604|NCT00003960|Drug|busulfan|
79522605|NCT00003960|Drug|cyclophosphamide|
79822753|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
79822754|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
79822755|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
79822756|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
79522606|NCT00003960|Drug|methylprednisolone|
79522607|NCT00003960|Procedure|allogeneic bone marrow transplantation|
79522608|NCT00003960|Procedure|in vitro-treated bone marrow transplantation|
79522609|NCT00003966|Drug|defibrotide|
79522610|NCT00003972|Biological|filgrastim|
79522611|NCT00003972|Biological|sargramostim|
79522612|NCT00003972|Drug|busulfan|
79522613|NCT00003972|Drug|carboplatin|
79522614|NCT00003972|Drug|cyclophosphamide|
79522615|NCT00003972|Drug|melphalan|
79522616|NCT00003972|Drug|paclitaxel|
79522617|NCT00003972|Drug|tamoxifen citrate|
79522618|NCT00003972|Drug|thiotepa|
79522619|NCT00003972|Procedure|peripheral blood stem cell transplantation|
79522620|NCT00003972|Radiation|radiation therapy|
79226408|NCT05890222|Behavioral|Community Intervention|Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.
79522621|NCT00003984|Biological|lintuzumab|
79522622|NCT00003996|Drug|carmustine|
79226409|NCT05890222|Behavioral|Healthy Activity Program (HAP)|HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
79226410|NCT05889416|Other|Audit and feedback through a quality registry|Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
79368983|NCT05310214|Other|Laser acupuncture|"The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi."
79368984|NCT00817804|Device|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
79368985|NCT03839524|Drug|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
79368986|NCT00818116|Device|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
79368987|NCT00818272|Biological|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
79368988|NCT00868348|Drug|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
79368989|NCT00868348|Drug|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
79368990|NCT01933919|Drug|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
79368991|NCT01933919|Drug|Placebo|Placebo tablet matching to fluvoxamine maleate
79522623|NCT00003996|Drug|chemotherapy|
79522624|NCT00003996|Drug|cisplatin|
79522625|NCT00003996|Drug|etoposide|
79522626|NCT00003996|Radiation|radiation therapy|
79522627|NCT00004002|Drug|bortezomib|
79522628|NCT00004008|Drug|bryostatin 1|
79522629|NCT00004014|Drug|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
79522630|NCT00004026|Drug|CT-2584|
79522631|NCT00004026|Drug|chemotherapy|
79522632|NCT00004032|Biological|ALVAC-hB7.1|Given IP
79522633|NCT00004032|Biological|recombinant interferon gamma|Given IP
79522634|NCT00004032|Other|laboratory biomarker analysis|Correlative studies
79677863|NCT04695093|Other|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
79522635|NCT00004038|Biological|Ad5CMV-p53 gene|
79522636|NCT00004038|Drug|chemotherapy|
79522637|NCT00004050|Biological|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
79522638|NCT00004056|Biological|filgrastim|
79522639|NCT00004056|Drug|asparaginase|
79522640|NCT00004056|Drug|cytarabine|
79522641|NCT00004056|Drug|daunorubicin hydrochloride|
79677864|NCT04519463|Drug|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
79677865|NCT04519463|Drug|Placebo|Sodium Chloride 0.9%
79677866|NCT02950311|Drug|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
79677867|NCT02950311|Other|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
79997419|NCT01315483|Other|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
79997420|NCT01333267|Drug|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
79997421|NCT01333267|Drug|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
79997422|NCT01333267|Drug|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
79677868|NCT04519424|Biological|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
79677869|NCT04519424|Drug|Placebo|Normal saline (0.9% sodium chloride)
79226411|NCT05889416|Other|Implementation support|On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
79226412|NCT05887479|Drug|Botulinum toxin type A|Toxin of Clostridium Botulinum
79226413|NCT05887479|Drug|%0,9 NaCl|%0,9 NaCl
79226414|NCT05883267|Device|Virtual reality glasses|"PICO model neo 2 VR glasses"
79368992|NCT00819286|Device|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
79368993|NCT00819286|Device|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
79522642|NCT00004056|Drug|melphalan|
79522643|NCT00004056|Drug|thioguanine|
79522644|NCT00004056|Procedure|peripheral blood stem cell transplantation|
79677870|NCT04696770|Behavioral|Mindfulness|Mindfulness techniques will be taught to the participants
79226415|NCT05883267|Device|Vocal-guided affective imagery|Audio via telephone
79368994|NCT04381702|Procedure|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
79368995|NCT05317468|Other|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
79368996|NCT05318170|Procedure|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
79368997|NCT01933217|Drug|Methylphenidate|
79368998|NCT01933217|Drug|Placebo|
79368999|NCT01932437|Biological|ETI-204|monoclonal antibody
79369000|NCT01932437|Other|Placebo|Placebo for ETI-204
79522645|NCT00004062|Drug|azacitidine|
79522646|NCT00004062|Drug|liothyronine sodium|
79522647|NCT00004062|Radiation|iodine I 131|
79522648|NCT00004068|Drug|irinotecan hydrochloride|
79522649|NCT00004068|Drug|temozolomide|
79522650|NCT00004068|Procedure|conventional surgery|
79522651|NCT00004068|Radiation|radiation therapy|
79522652|NCT00004074|Biological|recombinant interleukin-12|Given IV
79522653|NCT00004074|Biological|ABI-007/carboplatin/trastuzumab|Given IV
79522654|NCT00004080|Biological|recombinant adenovirus-p53 SCH-58500|
79522655|NCT00004080|Procedure|conventional surgery|
79522656|NCT00004086|Biological|filgrastim|
79522657|NCT00004086|Drug|cisplatin|
79522658|NCT00004086|Drug|cytarabine|
79522659|NCT00004086|Drug|etoposide|
79522660|NCT00004086|Drug|ifosfamide|
79522661|NCT00004086|Procedure|autologous bone marrow transplantation|
79522662|NCT00004086|Procedure|peripheral blood stem cell transplantation|
79677871|NCT04511780|Other|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
79677872|NCT04696848|Drug|CKD-516 plus Durvalumab|"Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W)."
79677873|NCT04511585|Behavioral|Great Live and Move Challenge|Physical activity program for children
79677874|NCT04519346|Other|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
79680016|NCT02930694|Drug|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
79997423|NCT03155269|Dietary Supplement|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
79997424|NCT03155269|Dietary Supplement|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
79997425|NCT02906670|Drug|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
79226416|NCT05882643|Other|moderate to deep neuromuscular blockade|"Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count > 1)~Rocuronium (intravenous, 1.0 mg/kg at induction period)"
79997426|NCT01339195|Behavioral|French adaptation of NINDS-Canadian Stroke Network battery|"clinical: post-stroke neurological follow-up assessment~neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~MRI"
79997427|NCT01339351|Behavioral|Therapeutic Group by Teleconference|10 sessions
79997428|NCT01335451|Drug|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
79997429|NCT01335451|Drug|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
79997430|NCT01335529|Drug|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"Screen period from Week-8~Standard treatment from day 0 to week 4 (W4)~Three-drug-regimen (Boceprevir introduction) from W4 to W8~HCV RNA determination at W8 determines treatment group and participation duration:~If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
79997431|NCT01335607|Drug|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
79522663|NCT00004086|Radiation|indium In 111 LL2 IgG|
79226417|NCT05882643|Other|shallow to minimal neuromuscular blockade|"Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count < 0.9)~Rocuronium (intravenous, 0.3 mg/kg at induction period)"
79226418|NCT05879120|Drug|Pembrolizumab|Given by IV (vein)
79226419|NCT05879120|Device|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
79997432|NCT01335607|Drug|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
79997433|NCT02906358|Behavioral|Community-based pain self-management|
79997434|NCT02906358|Behavioral|Clinic-based pain self-management|
79226420|NCT05874804|Device|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
79997435|NCT00308347|Drug|MK0954, losartan / Duration of Treatment: mean 3.4 years|
79997436|NCT00308347|Drug|Placebo / Duration of Treatment: mean 3.4 years|
79997437|NCT02186834|Drug|Selinexor|Selinexor orally as outlined in the study treatment arm.
79997438|NCT02186834|Drug|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
79226421|NCT05874804|Drug|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
79226422|NCT05873842|Device|Trans-femoral TAVI|Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)
79997439|NCT02186834|Drug|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
79369001|NCT01949051|Drug|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
79522664|NCT00004086|Radiation|yttrium Y 90 epratuzumab|
79522665|NCT00004104|Biological|liposomal interleukin-2|
79997440|NCT03144687|Drug|Itacitinib|Itacitinib self-administered orally once daily .
79997441|NCT03144687|Drug|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of < 20 mg daily established before entering the study.
79997442|NCT04335890|Biological|Vaccination with IKKb matured Dendritic Cells|IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
79997443|NCT01624532|Biological|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
79226423|NCT05872828|Other|No intervention|Observational study. No intervention will be adopted.
79226424|NCT05864261|Drug|JT1801 60ug|JT1801, 60ug, IV injection
79226425|NCT05864261|Drug|NESP 60ug|NESP, 60ug, IV injection
79369002|NCT01949051|Drug|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
79522666|NCT00004104|Biological|polyvalent melanoma vaccine|
79522667|NCT00004104|Biological|recombinant interferon alfa|
79369003|NCT01948193|Biological|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
79369004|NCT01694485|Biological|Abrilumab|Administered by subcutaneous injection.
79369005|NCT01694485|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
79369006|NCT01931735|Procedure|Randomized Meniscectomy|Arthroscopic meniscectomy
79369007|NCT01931735|Procedure|Randomized Lavage|Arthroscopic Lavage
79822757|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
79997444|NCT03608930|Device|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
79369008|NCT01931735|Procedure|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
79997445|NCT03080961|Device|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
79226426|NCT05862077|Device|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
79369009|NCT01931735|Procedure|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
79369010|NCT01930799|Behavioral|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
79369011|NCT01947491|Drug|DFD01 Spray|
79369012|NCT01947491|Drug|Comp01 Lotion|
79369013|NCT01947491|Drug|Vehicle Lotion|
79369014|NCT01947491|Drug|Vehicle Spray|
79522668|NCT00004110|Biological|monoclonal antibody 3F8|
79522669|NCT00004110|Drug|etoposide|
79522670|NCT00004110|Drug|isotretinoin|
79522671|NCT00004122|Biological|BCG vaccine|
79522672|NCT00004122|Biological|recombinant interferon alfa|
79522673|NCT00004128|Biological|aldesleukin|
79522674|NCT00004128|Biological|filgrastim|
79677875|NCT02950077|Behavioral|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
79677876|NCT04519112|Procedure|Catheter Ablation|Catheter Ablation with RMN and MCN
79997446|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
79997447|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
79997448|NCT01538966|Drug|Pegvisomant|
79997449|NCT01538966|Drug|Octreotide LAR|
79997450|NCT01538966|Drug|Lanreotide|
79997451|NCT01377285|Drug|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
79226427|NCT05862077|Behavioral|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
79226428|NCT05862077|Behavioral|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
79226429|NCT05862077|Device|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
79226430|NCT05861089|Diagnostic Test|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
79369015|NCT04638725|Other|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
79369016|NCT04553575|Biological|serology|biological blood samples withdrawn at 6, 12 and 24 months
79369017|NCT01692301|Drug|LCZ696|200 mg tablet
79369018|NCT01692301|Drug|Olmesartan|20 mg and 40 mg capsules
79369019|NCT01692301|Drug|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
79369020|NCT01692301|Drug|Olmesartan matching placebo|Olmesartan matching placebo capsule
79522675|NCT00004128|Drug|busulfan|
79522676|NCT00004128|Drug|cyclophosphamide|
79522677|NCT00004128|Drug|cytarabine|
79522678|NCT00004128|Drug|daunorubicin hydrochloride|
79522679|NCT00004128|Drug|etoposide|
79522680|NCT00004128|Procedure|autologous bone marrow transplantation|
79522681|NCT00004128|Procedure|peripheral blood stem cell transplantation|
79522682|NCT00004128|Radiation|radiation therapy|
79522683|NCT00004152|Drug|iodinated contrast dye|
79522684|NCT00004152|Procedure|computed tomography|
79522685|NCT00004152|Procedure|positron emission tomography|
79522686|NCT00004152|Radiation|fludeoxyglucose F 18|
79522687|NCT00004158|Drug|melphalan|
79522688|NCT00004158|Procedure|peripheral blood stem cell transplantation|
79522689|NCT00004158|Radiation|holmium Ho 166 DOTMP|
79522690|NCT00004164|Biological|filgrastim|
79522691|NCT00004164|Drug|cisplatin|
79522692|NCT00004164|Drug|docetaxel|
79522693|NCT00004164|Drug|fluorouracil|
79522694|NCT00004164|Drug|leucovorin calcium|
79522695|NCT00004164|Radiation|radiation therapy|
79522696|NCT00004176|Drug|amifostine trihydrate|
79522697|NCT00004176|Drug|cisplatin|
79522698|NCT00004176|Drug|etoposide|
79522699|NCT00004176|Radiation|radiation therapy|
79522700|NCT00004188|Biological|filgrastim|Given IV
79522701|NCT00004188|Drug|carboplatin|Given IV
79677877|NCT01249950|Other|feasibility|feasibility
79822758|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
79822759|NCT00678561|Drug|Placebo Vehicle|Topical treatment once daily for 28 days
79822760|NCT00678561|Drug|Placebo Vehicle|Topical treatment twice daily for 28 days
79522702|NCT00004188|Drug|cisplatin|Given IV
79522703|NCT00004188|Drug|cyclophosphamide|Given IV
79522704|NCT00004188|Drug|doxorubicin hydrochloride|Given IV
79522705|NCT00004188|Drug|etoposide|Given IV
79822761|NCT05613296|Drug|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
79522706|NCT00004188|Drug|isotretinoin|Given IV
79522707|NCT00004188|Drug|melphalan|Given IV
79522708|NCT00004188|Drug|topotecan hydrochloride|Given IV
79822762|NCT04081532|Procedure|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
79822763|NCT04731350|Device|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
79997452|NCT01377285|Drug|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
79822764|NCT04731350|Device|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
79822765|NCT04731350|Other|Exercise|strengthening exercise
79997453|NCT01377285|Drug|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
79369021|NCT01692301|Drug|amlodipine|amlodipine 2.5 mg or 5 mg tablets
79522709|NCT00004188|Drug|vincristine sulfate|Given IV
79522710|NCT00004188|Procedure|autologous bone marrow transplantation|
79677878|NCT00505271|Genetic|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
79680017|NCT02930694|Drug|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
79680018|NCT00523016|Procedure|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
79822766|NCT04081766|Behavioral|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~Signs and symptoms of hypoglycemia.~Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~Acknowledgement by the patient~Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
79822767|NCT02587832|Device|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
79822768|NCT02587832|Device|NCPAP|Bubble CPAP System.
79822769|NCT00920114|Biological|blood sample|
79997454|NCT03609242|Behavioral|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
79997455|NCT03609164|Procedure|Suture-bridge augmentation of single-row repair|
79369022|NCT01692301|Drug|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
79369023|NCT01592773|Drug|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
79369024|NCT01930175|Drug|VAY736|
79369025|NCT01930175|Drug|Placebo|
79369026|NCT01592695|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
79522711|NCT00004188|Procedure|bone marrow ablation with stem cell support|
79522712|NCT00004188|Procedure|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
79522713|NCT00004188|Procedure|peripheral blood stem cell transplantation|
79522714|NCT00004188|Radiation|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
79522715|NCT00004194|Drug|fludarabine phosphate|
79997456|NCT03630783|Behavioral|Combined Cognitive Bias Modification|
79522716|NCT00004200|Drug|prinomastat|
79522717|NCT00004200|Drug|temozolomide|
79522718|NCT00004206|Drug|FOLFOX regimen|
79522719|NCT00004206|Drug|fluorouracil|
79522720|NCT00004206|Drug|leucovorin calcium|
79522721|NCT00004206|Drug|oxaliplatin|
79522722|NCT00004212|Biological|filgrastim|
79522723|NCT00004212|Drug|exatecan mesylate|
79522724|NCT00004218|Drug|chlorambucil|
79522725|NCT00004218|Drug|cyclophosphamide|
79522726|NCT00004218|Drug|doxorubicin hydrochloride|
79522727|NCT00004218|Drug|fludarabine phosphate|
79522728|NCT00004218|Drug|prednisolone|
79522729|NCT00004218|Drug|vincristine sulfate|
79522730|NCT00004224|Drug|cyclophosphamide|
79522731|NCT00004224|Drug|etoposide|
79522732|NCT00004224|Drug|vincristine sulfate|
79522733|NCT00004224|Procedure|adjuvant therapy|
79522734|NCT00004224|Procedure|conventional surgery|
79522735|NCT00004224|Radiation|radiation therapy|
79522736|NCT00004236|Drug|pegylated liposomal doxorubicin hydrochloride|
79522737|NCT00004242|Drug|fluorouracil|
79522738|NCT00004242|Drug|gemcitabine hydrochloride|
79522739|NCT00004242|Drug|oxaliplatin|
79522740|NCT00004248|Biological|aldesleukin|
79522741|NCT00004248|Drug|doxorubicin hydrochloride|
79997457|NCT03630627|Drug|SB26|SB26 administered intravenously
79997458|NCT03630627|Drug|Placebo|Placebo administered intravenously
79226431|NCT05857631|Radiation|Hypofractionated Image guided External Beam Radiation Therapy (EBRT)|"External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks."
79226432|NCT05857631|Drug|Cisplatin|Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.
79369027|NCT01592695|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
79369028|NCT01592695|Behavioral|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
79522742|NCT00004254|Drug|raltitrexed|
79522743|NCT00004260|Biological|recombinant interleukin-12|
79522744|NCT00004260|Biological|rituximab|
79522745|NCT00004266|Drug|Lisinopril|
79522746|NCT00004266|Drug|Nifedipine|
79522747|NCT00004266|Drug|Simvastatin|
79522748|NCT00004278|Drug|ganciclovir|
79522749|NCT00004284|Drug|potassium citrate|
79226433|NCT05857631|Radiation|Vaginal brachytherapy|Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
79522750|NCT00004284|Drug|potassium phosphate|
79822770|NCT04691180|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
79822771|NCT04691180|Drug|Placebo|Placebo given intravenously
79822772|NCT04912622|Diagnostic Test|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
79226434|NCT05846425|Other|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
79226435|NCT05846425|Other|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
79369029|NCT01592695|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79369030|NCT01592695|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79369031|NCT01592695|Drug|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79369032|NCT01592695|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79369033|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79522751|NCT00004314|Drug|aminomidazole carboxamide riboside|
79522752|NCT00004338|Drug|zinc acetate|
79522753|NCT00004344|Drug|leuprolide|
79522754|NCT00004344|Drug|testosterone|
79522755|NCT00004368|Drug|colchicine|
79522756|NCT00004380|Drug|relaxin|
79522757|NCT00004386|Genetic|recombinant adenovirus containing the ornithine transcarbamylase gene|
79522758|NCT00004398|Drug|heme arginate|
79522759|NCT00004398|Drug|tin mesoporphyrin|
79522760|NCT00004404|Drug|clotrimazole|
79522761|NCT00004404|Drug|hydroxyurea|
79522762|NCT00004410|Drug|tauroursodeoxycholic acid|
79522763|NCT00004416|Drug|botulinum toxin type A|
79522764|NCT00004422|Drug|immune globulin|
79522765|NCT00004428|Drug|CPX|
79522766|NCT00004440|Drug|ibuprofen|
79522767|NCT00004446|Drug|fluoxetine|
79522768|NCT00004464|Drug|cyclophosphamide|
79522769|NCT00004464|Drug|filgrastim|
79522770|NCT00004482|Drug|Cyclosporine|
79522771|NCT00004482|Drug|methylprednisolone|
79522772|NCT00004482|Drug|Muromonab-CD3|
79522773|NCT00004482|Drug|prednisone|
79522774|NCT00004488|Drug|alendronate sodium|
79522775|NCT00004488|Drug|calcium carbonate|
79522776|NCT00004488|Drug|cholecalciferol|
79522777|NCT00004554|Drug|naltrexone (Revia)|100mg/day
79522778|NCT00004554|Drug|sertraline (Zoloft)|200mg/day
79522779|NCT00004554|Drug|Placebo|Placebo
79522780|NCT00004560|Device|defibrillator|
79522781|NCT00004572|Procedure|Sustacal challenge|
79522782|NCT00004578|Drug|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
79522783|NCT00004578|Drug|Lamivudine|150 mg, every 12 hours
79522784|NCT00004578|Drug|Stavudine|40 mg every 12 hours
79522785|NCT00004638|Procedure|pathogenesis study|
79522786|NCT00004644|Drug|acyclovir|
79522787|NCT00004650|Drug|conjugated estrogens|
79522788|NCT00004650|Drug|Medroxyprogesterone|
79997459|NCT02905266|Biological|Nivolumab|-Specified dose on specified days
79997460|NCT02905266|Biological|Ipilimumab|-Specified dose on specified days
79997461|NCT03889899|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79680019|NCT00523016|Procedure|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
79997462|NCT01380795|Biological|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
79997463|NCT04339998|Diagnostic Test|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~B lines: absent (< 3 lines), present (> 3 lines), fused~Consolidation: yes or no~a. Bilateral: yes or no~Pleural Effusion: yes or no~Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~Parasternal long axis~Parasternal short axis~Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~EPSS (E-point septal separation): normal (<10 mm), abnormal (>10 mm)~Left ventricular (LV) mass approximation by septal thickness~Left Ventricular Chamber Size by internal diameter at diastole"
79997464|NCT01380717|Drug|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
79997465|NCT01380717|Drug|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
79997466|NCT04292652|Procedure|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
79226436|NCT05844449|Drug|VNZ/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
79226437|NCT05844241|Other|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
79522789|NCT00004656|Procedure|Metabolic assessment with body composition evaluation|
79680020|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
79226438|NCT05844241|Other|Audiobooks|Listening to audiobooks for 30 minutes
79369034|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79369035|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
79522790|NCT00004662|Drug|dehydroepiandrosterone|
79822773|NCT04081376|Drug|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
79822774|NCT04890158|Other|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
79997467|NCT01569399|Other|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
79997468|NCT02982018|Device|senofilcon A with new UV blocker|Investigational Contact Lens
79997469|NCT02982018|Device|senofilcon A|J&J Marketed Contact Lens
79522791|NCT00004686|Drug|methotrexate|
79822775|NCT00920192|Drug|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
79997470|NCT03080493|Drug|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
79997471|NCT03080493|Drug|Placebo oral capsule|Packaged identical to gabapentin dosing
79226439|NCT05840055|Behavioral|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
79997472|NCT03080493|Drug|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
79226440|NCT05839366|Drug|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
79369036|NCT01592695|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
79369037|NCT01592695|Behavioral|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
79997473|NCT03655626|Other|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
79369038|NCT01592695|Behavioral|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
79522792|NCT00004686|Drug|prednisone|
79522793|NCT00004728|Drug|Warfarin|
79522794|NCT00004728|Drug|Aspirin|
79522795|NCT00004734|Drug|pyridoxine|
79522796|NCT00004734|Drug|cyanocobalamin|
79522797|NCT00004734|Drug|folic acid multivitamin|
79522798|NCT00004740|Drug|isoniazid|
79522799|NCT00004758|Drug|carbamazepine|
79522800|NCT00004758|Drug|corticotropin|
79677879|NCT01249989|Behavioral|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
79680021|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
79822776|NCT02584400|Drug|Injection with the hypoxia tracer [18F]HX4,|The [18F]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) [18F]HX4 via a bolus IV injection.
79822777|NCT00676143|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
79822778|NCT00676143|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
79822779|NCT02586272|Device|Daifert|
79226441|NCT05839366|Drug|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
79226442|NCT05839366|Drug|Remifentanil + propofol|Remifentanil + propofol
79226443|NCT05839366|Procedure|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
79369039|NCT01929863|Drug|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID [45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period]
79369040|NCT01929863|Drug|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
79822780|NCT02586272|Procedure|Control Group|
79822781|NCT02586428|Other|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
79822782|NCT04082390|Dietary Supplement|RELEASE|Dietary supplement
79997474|NCT01339910|Drug|Fludarabine and Busulfan|"(Flu/Bu)~Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)~Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
79997475|NCT01339910|Drug|Fludarabine and Melphalan|"(Flu/Mel)~Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)~Melphalan: 140 mg/m^2 on Day -2"
79997476|NCT01339910|Drug|Busulfan and Fludarabine|"(Bu/Flu)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2~Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)"
79997477|NCT01339910|Drug|Busulfan and Cyclophosphamide|"(Bu/Cy)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
79369041|NCT01929863|Drug|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
79369042|NCT01918085|Other|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
79369043|NCT01918085|Other|Strata strip|An adhesive strip made of the Strata adhesive
79369044|NCT01714687|Device|balloon sinus dilation|
79522801|NCT00004758|Drug|nitrazepam|
79522802|NCT00004758|Drug|pyridoxine|
79522803|NCT00004758|Drug|valproic acid|
79522804|NCT00004758|Procedure|Surgery|
79369045|NCT01714687|Other|medical therapy|
79522805|NCT00004770|Drug|thioctic acid|
79522806|NCT00004776|Drug|topiramate|
79522807|NCT00004794|Drug|cidofovir|
79522808|NCT00004800|Biological|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
79522809|NCT00004800|Biological|diphtheria-tetanus vaccine|
79522810|NCT00004806|Genetic|Cystic fibrosis transmembrane conductance regulator|
79522811|NCT00004812|Behavioral|Exercise|
79522812|NCT00004842|Drug|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
79522813|NCT00004854|Drug|Carvedilol|
79522814|NCT00004866|Drug|exatecan mesylate|
79522815|NCT00004872|Biological|recombinant human endostatin|
79522816|NCT00004878|Biological|therapeutic allogeneic lymphocytes|
79522817|NCT00004878|Drug|cytarabine|
79522818|NCT00004878|Drug|fludarabine phosphate|
79522819|NCT00004878|Drug|idarubicin|
79522820|NCT00004878|Drug|methotrexate|
79522821|NCT00004878|Drug|tacrolimus|
79522822|NCT00004878|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79522823|NCT00004878|Procedure|peripheral blood stem cell transplantation|
79522824|NCT00004884|Drug|cisplatin|
79522825|NCT00004884|Drug|docetaxel|
79522826|NCT00004884|Drug|gemcitabine hydrochloride|
79522827|NCT00004890|Biological|aldesleukin|
79522828|NCT00004890|Drug|Biomed 101|
79522829|NCT00004920|Drug|cisplatin|
79522830|NCT00004920|Drug|raltitrexed|
79522831|NCT00004926|Dietary Supplement|vitamin D3 analogue ILX23-7553|
79522832|NCT00004932|Drug|imatinib mesylate|
79677880|NCT01249989|Behavioral|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
79677881|NCT01249989|Behavioral|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
79677882|NCT04511351|Drug|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
79677883|NCT04519268|Diagnostic Test|Adult patients scheduled for an elective general surgical operation.|"The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) & consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations & required preparations, peri-operative course and post-operative outcome will be collected."
79677884|NCT01244256|Drug|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
79822783|NCT04082390|Dietary Supplement|Placebo|Placebo
79997478|NCT01339910|Drug|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~TBI: 1200-1420 cGy on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
79997479|NCT03622164|Radiation|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
79997480|NCT03622164|Radiation|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
79997481|NCT01377207|Procedure|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
79997482|NCT02237066|Device|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
79997483|NCT02237066|Device|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
79369046|NCT01714609|Drug|Placebo|Placebo Comparator: Placebo
79369047|NCT01714609|Drug|Sorafenib|Sorafenib, 400 mg twice daily
79369048|NCT01929707|Drug|LY3050258|
79522833|NCT00004938|Drug|fluconazole|
79522834|NCT00004986|Drug|Nitazoxanide|
79522835|NCT00004992|Behavioral|Intensive lifestyle|
79522836|NCT00004992|Drug|Metformin|
79522837|NCT00004992|Drug|Placebo|
79522838|NCT00004998|Drug|Lamivudine/Zidovudine|
79677885|NCT01244256|Drug|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
79677886|NCT04511507|Procedure|hemoadsorption|three consecutive sessions of hemoadsorption in patients with liver failure
79677887|NCT01249833|Drug|Oseltamivir|Oseltamivir 75mg BID for 5 days
79822784|NCT02587676|Other|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
79822785|NCT02586350|Drug|Anlotinib|
79822786|NCT02586350|Drug|Placebo|Placebo p.o. qd
79226444|NCT05838716|Procedure|Biospecimen Collection|Undergo collection of blood
79226445|NCT05838716|Dietary Supplement|D Vitamin|Given PO
79226446|NCT05838716|Procedure|Dual X-ray Absorptiometry|Undergo DXA scan
79226447|NCT05838716|Drug|Placebo Administration|Given PO
79226448|NCT05838716|Other|Quality-of-Life Assessment|Ancillary studies
79226449|NCT05838716|Other|Questionnaire Administration|Ancillary studies
79226450|NCT05836662|Other|CrashCourse Concussion Education in Virtual Reality|The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.
79369049|NCT01929707|Drug|Placebo|
79369050|NCT01714063|Device|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
79522839|NCT00004998|Drug|Capravirine|
79522840|NCT00004998|Drug|Nelfinavir mesylate|
79522841|NCT00005010|Drug|Irbesartan|
79522842|NCT00005010|Drug|Pravastatin|
79522843|NCT00005022|Drug|cisplatin|
79522844|NCT00005022|Drug|etoposide|
79522845|NCT00005022|Radiation|radiation therapy|
79522846|NCT00005028|Drug|bryostatin 1|
79522847|NCT00005028|Drug|paclitaxel|
79522848|NCT00005040|Drug|arsenic trioxide|
79522849|NCT00005046|Drug|chemotherapy|
79522850|NCT00005046|Drug|paclitaxel|
79522851|NCT00005052|Biological|GM2-KLH vaccine|
79522852|NCT00005052|Biological|QS21|
79522853|NCT00005052|Procedure|adjuvant therapy|
79822787|NCT04504071|Drug|Dacomitinib|Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
79822788|NCT02586194|Drug|ASP015K|Oral
79822789|NCT04079660|Diagnostic Test|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
79822790|NCT02559375|Other|Survey|
79369051|NCT01929395|Device|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
79822791|NCT02584166|Behavioral|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
79997484|NCT03655392|Behavioral|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
79997485|NCT03655392|Diagnostic Test|Induced sputum collection|All participants performed induced sputum collection
79997486|NCT03655392|Diagnostic Test|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
79522854|NCT00005058|Procedure|ultrasound imaging|
79522855|NCT00005064|Drug|bortezomib|Given IV
79522856|NCT00005070|Drug|irofulven|
79369052|NCT04124809|Device|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
79522857|NCT00005076|Biological|cetuximab|
79522858|NCT00005076|Drug|irinotecan hydrochloride|
79369053|NCT01713283|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79997487|NCT03655392|Diagnostic Test|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
79369054|NCT01713283|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79677888|NCT04511546|Device|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
79369055|NCT04768075|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
79369056|NCT04768075|Drug|Placebo|IV infusion Simulator of Camrelizumab
79369057|NCT04768075|Drug|Cisplatin|IV infusion
79677889|NCT02275143|Radiation|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
79822792|NCT02559843|Dietary Supplement|pomegranate juice|
79369058|NCT04768075|Drug|Carboplatin|IV infusion
79369059|NCT04768075|Drug|Pemetrexed|IV infusion
79677890|NCT04511390|Device|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
79677891|NCT02950233|Drug|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
79677892|NCT02950233|Drug|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
79677893|NCT02950233|Drug|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID [first week]; 1 capsule BID [following three weeks]).
79677894|NCT02950233|Drug|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
79369060|NCT04768075|Drug|Paclitaxel|IV infusion
79369061|NCT04768075|Drug|Albumin paclitaxel|IV infusion
79369062|NCT01592383|Drug|erlotinib hydrochloride|Given PO
79369063|NCT01691521|Drug|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
79522859|NCT00005082|Procedure|biopsy|
79522860|NCT00005082|Procedure|magnetic resonance imaging|
79522861|NCT00005088|Drug|cisplatin|
79522862|NCT00005088|Radiation|radiation therapy|
79522863|NCT00005094|Drug|celecoxib|Given orally
79522864|NCT00005094|Other|placebo|Given orally
79522865|NCT00005106|Drug|Lamivudine/Zidovudine|
79522866|NCT00005106|Drug|Abacavir sulfate|
79522867|NCT00005106|Drug|Nelfinavir mesylate|
79522868|NCT00005106|Drug|Lamivudine|
79522869|NCT00005106|Drug|Stavudine|
79522870|NCT00005118|Drug|Indinavir sulfate|
79677895|NCT01249404|Biological|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
79677896|NCT01249404|Drug|Placebo|I.M. injection on day 1 (single treatment cycle)
79677897|NCT04511000|Drug|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
79677898|NCT04511000|Drug|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
79822793|NCT02559843|Behavioral|lifestyle modification|
79822794|NCT02586116|Device|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
79677899|NCT04519385|Drug|Tocilizumab|Tocilizumab therapy
79677900|NCT04519385|Drug|Dexamethasone|dexamethsone pulse therapy
79369064|NCT01691521|Drug|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
79997488|NCT03655392|Other|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
79822795|NCT02586116|Device|C-Plus|C-Plus PEEK IBF Device with autograft
79997489|NCT03655392|Other|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
79997490|NCT03655392|Diagnostic Test|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
79997491|NCT03655392|Diagnostic Test|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
79677901|NCT01249365|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
79226451|NCT05832138|Behavioral|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
79226452|NCT05822960|Device|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
79226453|NCT05822258|Other|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~Normal condition without addition of additional physical and verbal tasks~Condition with added physical tasks: The physical task of holding a ball in the center of a tray~Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
79677902|NCT00506051|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
79226454|NCT05819814|Genetic|Disclosure of high polygenic risk result for coronary artery disease|The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
79677903|NCT00506051|Drug|pemetrexed|intravenous infusion
79997492|NCT03655314|Other|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
79226455|NCT05810792|Drug|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
79226456|NCT05810792|Drug|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
79226457|NCT05810168|Other|Dietary modifications|TDA and low FODMAP diet
79226458|NCT05809258|Procedure|Supraclavicular block|brachial plexus nerve block by supraclavicular route
79369065|NCT01691521|Drug|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
79369066|NCT01691521|Drug|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
79369067|NCT01929317|Drug|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
79369068|NCT01929317|Drug|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
79677904|NCT00506051|Drug|ZD6474 (vandetanib) 300mg|
79677905|NCT00504465|Drug|dinoprostone|
79677906|NCT04518800|Drug|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
79677907|NCT00516360|Device|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
79677908|NCT04510883|Behavioral|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
79677909|NCT04510883|Behavioral|Waiting list + PACO|Waiting list + PACO
79677910|NCT01249131|Drug|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
79997493|NCT03655314|Other|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
79997494|NCT03608618|Biological|MCY-M11|Intraperitoneal administration
79997495|NCT03608618|Drug|Cyclophosphamide|Intravenous administration for preconditioning
79226459|NCT05809258|Procedure|Axillary block|brachial plexus nerve block by axillary route
79677911|NCT04510961|Other|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
79226460|NCT05806450|Behavioral|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
79226461|NCT05806450|Other|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
79677912|NCT04510649|Drug|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
79226462|NCT05801042|Dietary Supplement|Maltodextrin|Placebo product
79226463|NCT05801042|Dietary Supplement|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
79226464|NCT05801042|Dietary Supplement|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
79226465|NCT05796167|Drug|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
79369069|NCT01929317|Drug|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
79677913|NCT04510649|Drug|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
79677914|NCT01249092|Drug|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
79677915|NCT02275182|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
79997496|NCT03655158|Device|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
79997497|NCT03654924|Device|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
79226466|NCT05792163|Drug|SNP318 (A)|Capsule for oral administration
79226467|NCT05792163|Drug|Placebo (B)|Placebo capsules matching the SNP318 capsules
79226468|NCT05789264|Device|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
79226469|NCT05789264|Diagnostic Test|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
79226470|NCT05788172|Other|Iron isotope dilution|Menstrual blood loss will be determined using the iron isotope dilution technique and compared to the amount determined via the alkaline hematin method.
79369070|NCT01711879|Drug|Aflibercept|Details covered in arm description
79369071|NCT00869206|Drug|zoledronic acid|Given IV
79369072|NCT04625231|Behavioral|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
79369073|NCT01689649|Drug|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
79369074|NCT01929083|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
79369075|NCT01929083|Drug|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
79369076|NCT01929083|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
79522871|NCT00005118|Drug|Ritonavir|
79522872|NCT00005520|Drug|Hydrochlorothiazide|
79522873|NCT00005520|Drug|Candesartan|
79522874|NCT00005574|Drug|Gentamicin|
79522875|NCT00005580|Drug|bryostatin 1|
79522876|NCT00005580|Drug|fludarabine phosphate|
79522877|NCT00005586|Drug|L-leucovorin|
79522878|NCT00005586|Drug|fluorouracil|
79677916|NCT02275182|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
79997498|NCT03654846|Device|EmergencyEye|EmergencyEye Smartphone App
79997499|NCT04184648|Other|no interventions|no intervention
79226471|NCT05788172|Other|Alkaline hematin method|Menstrual blood loss will be determined using the alkaline hematin method and compared to the amount determined via the iron isotope dilution technique.
79226472|NCT05784766|Diagnostic Test|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
79226473|NCT05784766|Other|routine care|medical review
79226474|NCT05783232|Dietary Supplement|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
79226475|NCT05783232|Dietary Supplement|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
79226476|NCT05783232|Dietary Supplement|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
79369077|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
79522879|NCT00005586|Procedure|adjuvant therapy|
79522880|NCT00005592|Biological|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
79226477|NCT05783232|Dietary Supplement|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
79522881|NCT00005592|Biological|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
79369078|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
79369079|NCT01689337|Drug|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
79369080|NCT04624529|Other|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
79369081|NCT01688635|Drug|LY2963016|Administered subcutaneously
79677917|NCT05653947|Procedure|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
79677918|NCT01248936|Drug|RO5185426|
79677919|NCT01248780|Drug|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
79677920|NCT01248780|Drug|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
79677921|NCT01248780|Drug|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
79677922|NCT01248468|Drug|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
79997500|NCT04203290|Drug|Bupivacaine|%0.25 bupivacaine solution
79677923|NCT01248468|Drug|Sumatriptan|100 mg Sumatriptan
79997501|NCT04203290|Drug|Sevoflurane|End tidal sevoflurane concentration
79997502|NCT02237144|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
79997503|NCT02237144|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
79226478|NCT05782205|Procedure|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
79226479|NCT05780021|Behavioral|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
79226480|NCT05778968|Procedure|low etco2|Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
79226481|NCT05778968|Procedure|normal etco2|Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
79369082|NCT01688635|Drug|US Approved Lantus|Administered subcutaneously
79369083|NCT04881409|Device|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
79522882|NCT00005592|Radiation|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
79522883|NCT00005598|Drug|amifostine trihydrate|
79997504|NCT02237144|Other|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
79997505|NCT02237144|Behavioral|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
79997506|NCT02981082|Drug|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
79226482|NCT05778968|Procedure|high etco2|Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
79226483|NCT05777018|Procedure|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
79369084|NCT04881409|Device|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
79369085|NCT01591681|Device|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
79369086|NCT04871503|Device|BTL-899 Buttocks|The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
79522884|NCT00005598|Drug|azacitidine|
79522885|NCT00005604|Biological|recombinant interleukin-12|Given IV
79522886|NCT00005604|Biological|aldesleukin|Given SC
79522887|NCT00005604|Other|laboratory biomarker analysis|Correlative studies
79522888|NCT00005610|Biological|sargramostim|
79522889|NCT00005616|Procedure|conventional surgery|
79677924|NCT01248468|Drug|Placebo|placebo
79997507|NCT02981082|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
79522890|NCT00005616|Procedure|neoadjuvant therapy|
79522891|NCT00005616|Procedure|radionuclide imaging|
79997508|NCT02237222|Other|Gait rehabilitation|
79997509|NCT02034266|Dietary Supplement|Omega-3 supplementation|5 mL twice daily, administered under the tongue
79997510|NCT03654612|Drug|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
79677925|NCT02275299|Drug|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
79677926|NCT02275299|Drug|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
79677927|NCT02275299|Drug|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
79677928|NCT02955576|Device|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
79677929|NCT02955576|Device|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
79822796|NCT00761163|Other|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
79997511|NCT03654534|Dietary Supplement|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
79997512|NCT01066104|Drug|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
79369087|NCT02986009|Behavioral|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
79369088|NCT02986009|Behavioral|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
79522892|NCT00005616|Radiation|iodine I 131 monoclonal antibody F19|
79677930|NCT02955576|Other|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
79677931|NCT01247922|Drug|Erlotinib|continuous oral Erlotinib 85 mg/m^2 per day
79677932|NCT04518956|Procedure|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
79677933|NCT04518956|Procedure|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
79997513|NCT01066104|Drug|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
79997514|NCT02736968|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
79997515|NCT02736968|Other|Placebo|Placebo
79997516|NCT02980224|Drug|OmegaD|OmegaD Softgels
79997517|NCT02980224|Drug|Placebo|Placebo Softgels
79997518|NCT03653910|Device|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
79369089|NCT02985931|Other|Diagnostic imaging scans of SPECT and MRI|
79369090|NCT00891436|Drug|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
79369091|NCT00891436|Drug|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
79522893|NCT00005622|Drug|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
79522894|NCT00005622|Radiation|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
79522895|NCT00005628|Biological|vitespen|
79522896|NCT00005634|Drug|vorinostat|
79677934|NCT04518956|Procedure|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
79677935|NCT01246206|Drug|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
79997519|NCT03653910|Device|Macintosh|Macintosh is a traditional laryngoscope for intubation
79369092|NCT01711645|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
79522897|NCT00005640|Procedure|Preoperative Endoscopy|
79522898|NCT00005640|Radiation|Technetium Tc 99m Sulfur Colloid|
79522899|NCT00005640|Procedure|Gamma Probe|
79522900|NCT00005640|Procedure|Biopsy of Sentinel Lymph Nodes|
79522901|NCT00005646|Drug|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
79822797|NCT00761163|Other|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
79997520|NCT03608306|Other|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
79997521|NCT03608306|Other|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
79997522|NCT03654144|Drug|Dienogest|oral tablets
79226484|NCT05777018|Procedure|ultrasound-guided recruitment maneuvers|"Ultrasound guided maneuver will be performed at T2, T3 and T4.~The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
79226485|NCT05775653|Other|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
79522902|NCT00005652|Drug|rituximab|
79522903|NCT00005658|Drug|Glycine|
79226486|NCT05775653|Other|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
79226487|NCT05774067|Drug|Saline|patient received normal saline 4ml/kg/hr with deflation of tourniquet
79226488|NCT05774067|Drug|Norepinephrine|patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
79226489|NCT05774067|Drug|glypressin|patient receive glypressin infusion at rate 2 mcg/kg/hr.
79522904|NCT00005724|Behavioral|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
79522905|NCT00005724|Other|Minimal Intervention Group|Dietary Information pamphlets.
79226490|NCT05774015|Dietary Supplement|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
79226491|NCT05773495|Other|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
79226492|NCT05773495|Other|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
79522906|NCT00005724|Behavioral|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
79522907|NCT00005766|Drug|Creatinine|
79522908|NCT00005772|Device|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
79522909|NCT00005772|Device|Control|Control group: standard care
79677936|NCT04510610|Drug|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
79997523|NCT03654144|Drug|Combined Oral Contraceptive|oral tablets
79522910|NCT00005778|Drug|High-dose immunoablative therapy|"High dose cyclophosphamide for 4 days.~NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
79522911|NCT00005790|Other|laboratory biomarker analysis|
79522912|NCT00005790|Procedure|biopsy|
79522913|NCT00005790|Procedure|magnetic resonance imaging|
79677937|NCT01246011|Drug|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
79677938|NCT04518878|Drug|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
79677939|NCT04518878|Drug|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
79522914|NCT00005790|Radiation|gadopentetate dimeglumine|
79677940|NCT01244490|Drug|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
79997524|NCT03654456|Biological|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
79997525|NCT02591615|Drug|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
79997526|NCT02591615|Drug|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
79522915|NCT00005796|Procedure|filgrastim|GCSF is given after chemo administration
79522916|NCT00005796|Biological|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
79522917|NCT00005796|Drug|lomustine|chemotherapy is administered every 21 days
79522918|NCT00005796|Drug|procarbazine hydrochloride|chemotherapy is administered every 21 days.
79522919|NCT00005796|Drug|vincristine sulfate|chemotherapy is administered every 21 days
79522920|NCT00005796|Procedure|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
79369093|NCT04381546|Other|Functional Electrical Stimulation FES|Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
79522921|NCT00005802|Biological|aldesleukin|
79822798|NCT00761163|Other|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
79822799|NCT02584322|Other|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
79822800|NCT00761241|Drug|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
79822801|NCT00761241|Biological|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
79822802|NCT00761241|Radiation|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
79369094|NCT00820534|Drug|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
79822803|NCT00761241|Procedure|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
79369095|NCT00820534|Drug|Placebo|Placebo every 2 hous during waking hours for 96 hours
79522922|NCT00005802|Biological|filgrastim|
79822804|NCT02558907|Other|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
79997527|NCT02591615|Drug|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
79997528|NCT02591615|Drug|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
79522923|NCT00005802|Biological|therapeutic allogeneic lymphocytes|
79677941|NCT01244490|Drug|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
79677942|NCT01244490|Drug|Placebo Comparator|Placebo
79997529|NCT03077607|Drug|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
79997530|NCT03077607|Drug|Itraconazole|100 mg oral dose
79997531|NCT03077607|Drug|Rifampin|600 mg oral dose
79997532|NCT03608462|Device|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
79226493|NCT05773196|Other|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~10 mL EDTA Vial (Box 1; Frozen)~o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~10 mL EDTA Vial (Box 2; Ambient)~Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
79369096|NCT01590433|Drug|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
79369097|NCT01590433|Drug|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
79369098|NCT01590433|Behavioral|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
79369099|NCT00820612|Drug|Indomethacin|100 mg PR once at the time of ERCP
79522924|NCT00005802|Drug|cytarabine|
79522925|NCT00005802|Drug|etoposide|
79677943|NCT00506090|Procedure|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
79677944|NCT04510376|Device|Test Article|Omeza Collagen Matrix
79369100|NCT00820612|Other|Placebo suppositories|2 placebo suppositories at the time of ERCP
79369101|NCT01928927|Drug|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
79522926|NCT00005802|Drug|fludarabine phosphate|
79522927|NCT00005802|Drug|methotrexate|
79522928|NCT00005802|Drug|mitoxantrone hydrochloride|
79522929|NCT00005802|Drug|therapeutic hydrocortisone|
79522930|NCT00005802|Radiation|radiation therapy|
79522931|NCT00005808|Drug|motexafin lutetium|Given IV
79522932|NCT00005808|Drug|photodynamic therapy|Undergo laser therapy
79522933|NCT00005808|Procedure|loop electrosurgical excision procedure|Undergo LEEP
79677945|NCT04510376|Other|Positive Control|1.0 mg/mL Histamine Base
79677946|NCT04510376|Other|Negative Control|Aqueous Negative Control
79677947|NCT01243944|Drug|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
79522934|NCT00005808|Other|laboratory biomarker analysis|Correlative studies
79677948|NCT01243944|Other|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
79677949|NCT04518488|Other|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
79369102|NCT00871624|Drug|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
79522935|NCT00005814|Biological|cetuximab|
79522936|NCT00005814|Drug|cisplatin|
79522937|NCT00005814|Radiation|radiation therapy|
79522938|NCT00354666|Drug|GSK159797|
79522939|NCT00354822|Drug|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
79522940|NCT00354900|Drug|Aprotinin|
79677950|NCT04518488|Other|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
79677951|NCT04510571|Other|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
79677952|NCT04510571|Other|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
79677953|NCT00516399|Drug|povidone-iodine 1.25% ophthalmic solution|
79822805|NCT04585022|Device|Magnum, Zimmer Biomet, Warsaw, IN|
79677954|NCT00516399|Drug|natamycin ophthalmic suspension, USP 5%|
79822806|NCT04585022|Device|Recap, Zimmer Biomet, Warsaw, IN|
79997533|NCT03608462|Device|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
79997534|NCT04215588|Device|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
79997535|NCT04215588|Device|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
79822807|NCT02981979|Drug|Leflunomide 10mg Tab|20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
79822808|NCT02981979|Drug|Prednisone Acetate|basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
79822809|NCT02981979|Drug|Placebos|used in control group during the induced remission therapy for 24 weeks.
79997536|NCT03608228|Other|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
79302513|NCT03203707|Behavioral|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
79369103|NCT00871624|Drug|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
79369104|NCT05315518|Diagnostic Test|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
79522941|NCT00355212|Procedure|percutaneous ablation of hepatocellular carcinoma|
79522942|NCT00355290|Behavioral|Changes on Oral Vitamin K Intake|
79522943|NCT00355446|Drug|Bimatoprost 0.03%|
79522944|NCT00355524|Drug|TMC114|TMC114 will be administered as oral tablets (75 milligram [mg] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
79522945|NCT00355524|Drug|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
79522946|NCT00355602|Drug|Cefuroxime|
79522947|NCT00355602|Drug|Ciprofloxacin|
79522948|NCT00355602|Drug|Clarithromycin|
79522949|NCT00355602|Drug|Cotrimoxazole|
79522950|NCT00355602|Drug|Coamoxiclav|
79522951|NCT00355602|Drug|metronidazole|
79522952|NCT00355602|Drug|neomycin|
79522953|NCT00355602|Drug|rifaximin|
79522954|NCT00355602|Drug|Vancomycin|
79522955|NCT00355602|Drug|Doxycycline|
79522956|NCT00355680|Device|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
79522957|NCT00355680|Device|Green Laser (Iridex)|Already available green laser
79677955|NCT04518527|Device|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
79677956|NCT00516438|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
79822810|NCT04081064|Behavioral|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
79822811|NCT04049409|Drug|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
79822812|NCT04049409|Drug|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
79822813|NCT04568252|Device|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
79302514|NCT02485613|Drug|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
79522958|NCT00356070|Drug|Strattera|
79522959|NCT00356226|Drug|clonidine|
79522960|NCT00356382|Drug|Lactobacillus (L.) casei|
79522961|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
79522962|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
79522963|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
79522964|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
79677957|NCT00516438|Drug|Topotecan|intravenous infusion
79677958|NCT02275949|Device|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
79677959|NCT02275949|Device|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
79822814|NCT04568252|Device|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
79822815|NCT00920660|Drug|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
79822816|NCT00920660|Drug|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
79822817|NCT00920660|Drug|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
79822818|NCT00920660|Drug|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
79822819|NCT00920660|Drug|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
79822820|NCT00920660|Drug|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
79822821|NCT02903355|Drug|D-methionine|D-methionine, oral liquid suspension
79822822|NCT02903355|Drug|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
79822823|NCT02583464|Drug|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
79369105|NCT01710709|Drug|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
79369106|NCT05318404|Dietary Supplement|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
79522965|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
79522966|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
79522967|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
79677960|NCT02275949|Device|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
79677961|NCT02275949|Device|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
79677962|NCT02275949|Device|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
79522968|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
79522969|NCT00356616|Drug|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
79522970|NCT00356616|Drug|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
79226494|NCT05769036|Device|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
79302515|NCT03223363|Diagnostic Test|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
79522971|NCT00356772|Drug|Azithromycin|
79522972|NCT00356850|Drug|Azithromycin|
79522973|NCT00356928|Drug|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
79522974|NCT00356928|Biological|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
79522975|NCT00357084|Drug|methotrexate|
79522976|NCT00357084|Drug|methylprednisolone|
79522977|NCT00357084|Drug|prednisone|
79522978|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
79522979|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
79522980|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
79522981|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
79522982|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
79522983|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
79522984|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
79522985|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
79522986|NCT00357318|Drug|sunitinib malate|Given PO
79522987|NCT00357318|Biological|bevacizumab|Given IV
79522988|NCT00357318|Other|pharmacological study|Correlative studies
79522989|NCT00357318|Other|laboratory biomarker analysis|Correlative studies
79522990|NCT00357474|Procedure|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
79677963|NCT00516477|Biological|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
79677964|NCT00516516|Dietary Supplement|L-Carnitine|L-Carnitine, 1g orally, twice daily
79677965|NCT00516516|Dietary Supplement|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
79677966|NCT00505349|Behavioral|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
79677967|NCT02275988|Drug|K-877|
79677968|NCT02275988|Drug|Clarithromycin|
79522991|NCT00357474|Procedure|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
79522992|NCT00357630|Drug|gemcitabine hydrochloride|
79522993|NCT00357630|Procedure|quality-of-life assessment|
79522994|NCT00357708|Drug|decitabine|Given IV
79522995|NCT00357708|Drug|vorinostat|Given orally
79522996|NCT00357708|Other|laboratory biomarker analysis|Correlative studies
79522997|NCT00357708|Other|pharmacological study|Correlative studies
79522998|NCT00357786|Drug|Replagal agalsidase alfa|
79522999|NCT00357786|Drug|Replagal|
79523000|NCT00357864|Drug|carbachol|
79523001|NCT00357942|Drug|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
79523002|NCT00357942|Drug|Placebo|Placebo mouthwash
79523003|NCT00357942|Drug|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
79523004|NCT00357942|Drug|Placebo|Placebo solution for injection every 3 hour for 24 hours
79523005|NCT00358020|Drug|THALIDOMIDE|
79523006|NCT00358020|Drug|BORTEZOMIB|
79523007|NCT00358176|Drug|Risedronate (HMR4003)|
79677969|NCT00516594|Procedure|Diet with polyfructans and viscous fibers or soy protein|
79677970|NCT02950155|Drug|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
79677971|NCT02950155|Drug|Sodium Chloride solution|A single infusion of Placebo/Sham.
79369107|NCT01617629|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
79523008|NCT00358410|Drug|GW679769 oral tablets|2x GW679769 60mg tablets
79369108|NCT00874510|Behavioral|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
79369109|NCT01686373|Device|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
79369110|NCT01686373|Device|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
79523009|NCT00358410|Drug|Placebo|Placebo oral tablets to match experimental intervention
79523010|NCT00358488|Drug|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
79523011|NCT00358488|Drug|salbutamol|salbutamol
79523012|NCT00358488|Drug|salmeterol 50mcg|salmeterol 50mcg
79523013|NCT00358488|Drug|placebo|placebo
79523014|NCT00358566|Biological|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
79523015|NCT00358566|Drug|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
79677972|NCT00516633|Behavioral|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
79677973|NCT00516672|Drug|pazopanib|Pazopanib oral tablet
79523016|NCT00358800|Device|REMStar Auto with C-Flex|
79523017|NCT00359112|Drug|metformin|
79523018|NCT00359112|Drug|sulphonylurea|
79523019|NCT00359112|Drug|Avandamet|
79523020|NCT00359190|Drug|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
79523021|NCT00359658|Drug|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
79677974|NCT00516672|Drug|Lapatinib|Lapatinib oral tablet
79677975|NCT00516711|Drug|Sevoflurane|
79677976|NCT00516750|Drug|cisplatin|
79677977|NCT00516750|Drug|doxorubicin hydrochloride|
79677978|NCT00516750|Drug|methotrexate|
79677979|NCT00516750|Drug|vinblastine|
79677980|NCT00516750|Genetic|gene expression profiling|
79369111|NCT03838666|Drug|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
79369112|NCT03838432|Device|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
79369113|NCT03838354|Drug|Chidamide|Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.
79523022|NCT00359658|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
79523023|NCT00359658|Drug|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
79677981|NCT00516750|Procedure|neoadjuvant therapy|
79369114|NCT03838354|Drug|Chidamide|Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
79523024|NCT00359814|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
79523025|NCT00359814|Drug|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
79523026|NCT00359892|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
79523027|NCT00359970|Drug|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
79523028|NCT00359970|Drug|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
79523029|NCT00359970|Drug|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
79523030|NCT00359970|Other|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
79523031|NCT00360048|Drug|oxytocin|
79523032|NCT00360204|Behavioral|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
79523033|NCT00360438|Drug|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
79523034|NCT00360516|Behavioral|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
79523035|NCT00360594|Drug|Acamprosate|3 pills (666 mg) for 1998mg/day
79523036|NCT00360594|Drug|Placebo|3 pills (666mg) for 1998mg/day
79523037|NCT00360750|Drug|carboplatin|
79523038|NCT00360750|Drug|cytarabine|
79523039|NCT00360750|Drug|etoposide|
79523040|NCT00360750|Drug|vincristine sulfate|
79677982|NCT02276105|Other|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
79677983|NCT04694625|Other|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
79523041|NCT00360750|Other|clinical observation|
79369115|NCT01709695|Drug|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
79523042|NCT00360750|Procedure|adjuvant therapy|
79523043|NCT00360750|Radiation|radiation therapy|
79523044|NCT00360906|Drug|Triomar™ (omega-3 fatty acids)|
79226495|NCT05769036|Device|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
79226496|NCT05763043|Drug|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
79302516|NCT02485379|Procedure|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
79369116|NCT01709695|Drug|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
79369117|NCT05312320|Other|Information film|"Sexual activity after MI does not increase risk of recurrence or death~Sexual activity is associated with improved outcome after MI~Resuming sexual activity as normal is recommended and completely safe"
79523045|NCT00360984|Drug|insulin glargine|
79523046|NCT00360984|Device|continuous subcutaneous insulin infusion|
79369118|NCT05310760|Drug|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
79369119|NCT05236504|Dietary Supplement|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
79369120|NCT05236504|Other|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
79677984|NCT04694625|Other|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
79677985|NCT00505427|Dietary Supplement|Alpha Lipoic Acid|
79677986|NCT00506168|Drug|Irinotecan, Capecitabine|
79677987|NCT02950038|Drug|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
79369121|NCT02150044|Device|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
79369122|NCT01685983|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
79369123|NCT01685983|Drug|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
79677988|NCT02950038|Drug|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
79677989|NCT02276144|Other|Liver ultrasound|For evaluate whether fatty liver is exist or not
79677990|NCT02949960|Drug|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
79369124|NCT02151448|Biological|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
79523047|NCT00361062|Behavioral|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
79523048|NCT00361452|Drug|nebulized epinephrine and nebulized albuterol|
79523049|NCT00361530|Drug|Statin|
79523050|NCT00361608|Device|EarlySense ES 16|
79523051|NCT00361686|Drug|tramadol|
79523052|NCT00361686|Drug|remifentanyl|
79523053|NCT00361686|Device|patient contolled analgesia|
79523054|NCT00361920|Drug|prednisone|
79523055|NCT00361998|Drug|NITROFURANTOIN MACROCRYSTALS|
79523056|NCT00362310|Drug|indinavir|
79523057|NCT00362388|Procedure|Intramyocardial injection of autologous bone marrow cells|
79523058|NCT00362544|Drug|Ambisome|
79523059|NCT00362700|Drug|Clevudine|
79523060|NCT00362778|Drug|Insulin|intravenous continuous insulin infusion for 48 hours
79523061|NCT00362856|Drug|larazotide acetate|capsule
79523062|NCT00362856|Drug|Placebo|capsule
79523063|NCT00362934|Drug|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
79523064|NCT00362934|Drug|Atorvastatin|Atorvastatin 10 mg and 20mg
79523065|NCT00355836|Behavioral|Mental Imagery|
79523066|NCT00363090|Biological|alemtuzumab|
79523067|NCT00363090|Drug|cyclophosphamide|
79523068|NCT00363090|Drug|doxorubicin hydrochloride|
79523069|NCT00363090|Drug|prednisone|
79523070|NCT00363090|Drug|vincristine sulfate|
79523071|NCT00363090|Other|flow cytometry|
79523072|NCT00363090|Other|pharmacological study|
79523073|NCT00363324|Procedure|intracoronary injection of bone marrow cells|
79523074|NCT00363402|Procedure|PET-CT|
79523075|NCT00363714|Drug|AGN211745|100microgram single intravitreal injection
79677991|NCT02949960|Drug|Vehicle Control|Topical Vehicle Gel applied twice daily
79523076|NCT00363714|Drug|AGN211745|200microgram single intravitreal injection
79226497|NCT05761015|Drug|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~gastric/duodenal risk: age >65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~cardiovascular risk (according to Agostino scale & SCORE);~The molecule with therefore be:~no risk: niflumic acid, 250 mg per intake;~gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~cardiovascular risk only: ketoprofen, 50-100 mg per intake;~double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
79226498|NCT05753033|Drug|SR750 tablet|Ascending single and multiple doses of SR750 orally
79226499|NCT05753033|Drug|Placebo|Ascending single and multiple doses of placebo orally
79226500|NCT05752266|Dietary Supplement|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
79822824|NCT00675597|Drug|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
79822825|NCT00761397|Behavioral|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
79226501|NCT05752266|Dietary Supplement|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
79226502|NCT05747989|Procedure|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
79226503|NCT05747989|Procedure|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
79226504|NCT05741112|Device|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
79226505|NCT05730764|Diagnostic Test|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
79226506|NCT05730764|Diagnostic Test|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
79523077|NCT00363714|Drug|AGN211745|400microgram single intravitreal injection
79677992|NCT02276183|Dietary Supplement|Nutrition intervention, test formula|
79369125|NCT02151448|Drug|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
79822826|NCT00761397|Behavioral|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
79369126|NCT02151448|Drug|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
79369127|NCT02151448|Biological|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
79369128|NCT01685437|Biological|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
79822827|NCT00761397|Other|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
79523078|NCT00363714|Drug|AGN211745|800microgram single intravitreal injection
79523079|NCT00363714|Drug|AGN211745|1200microgram single intravitreal injection
79523080|NCT00363714|Drug|AGN211745|1600microgram single intravitreal injection
79677993|NCT02276183|Behavioral|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
79523081|NCT00363792|Drug|Glyceryl trinitrate, azetazolamide|
79523082|NCT00363870|Biological|Fluarix vaccine|
79677994|NCT02949999|Drug|Voclosporin|
79677995|NCT04510415|Drug|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
79677996|NCT02949882|Dietary Supplement|Yakult|Containing at least 6,5*10^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
79677997|NCT02949882|Dietary Supplement|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
79677998|NCT04517942|Behavioral|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
79822828|NCT00761397|Other|Questionnaire|Day 1 of study, 10 weeks after starting study, & 12 months after starting study
79822829|NCT04292301|Device|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
79523083|NCT00363948|Drug|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
79523084|NCT00363948|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
79523085|NCT00364026|Drug|darusentan|
79523086|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
79523087|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
79523088|NCT00364104|Drug|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
79523089|NCT00364104|Drug|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
79523090|NCT00364260|Drug|epoetin alfa|
79822830|NCT04255563|Device|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
79226507|NCT05719116|Behavioral|Physical exercise|The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
79226508|NCT05713643|Procedure|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
79369129|NCT00875212|Drug|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
79369130|NCT00875212|Drug|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
79369131|NCT00875212|Drug|fluoride|use of a dentifrice containing fluoride (1500ppm) only
79369132|NCT00875212|Drug|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
79523091|NCT00364338|Behavioral|gourment cooking workshop|
79369133|NCT00875836|Drug|Buspirone|Flexible dose, up to 60 mg daily
79369134|NCT00875836|Drug|Placebo|Flexible dose, up to 60 mg daily
79523092|NCT00364416|Other|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
79677999|NCT04517942|Other|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
79678000|NCT02949609|Other|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
79678001|NCT02949609|Other|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
79369135|NCT05235802|Diagnostic Test|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~3D T1w MPRAGE~3D T2w FLAIR SPACE~3D T2w SPACE~3D T1w PSIR (cortical visualization)~2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~3D SWI~DWI b1000 32 directions and b3000 64 directions."
79369136|NCT05235802|Diagnostic Test|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
79369137|NCT05235802|Diagnostic Test|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
79678002|NCT04510220|Drug|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
79678003|NCT04510220|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
79678004|NCT02949648|Device|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
79678005|NCT04510337|Drug|standard rocuronium dose|0.6 mg/kg rocuronium during induction of anesthesia
79369138|NCT05235802|Diagnostic Test|Clinical assessments / questionnaires|"Glasgow Outcome Scale Extended (functional outcome)~Short-Form 36 (quality of life),~EQ-5D (quality of life),~Mini-Mental State Extended (MMSE) (mental state assessment).~Barthel Index (daily living disabilities),~Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
79369139|NCT00891982|Drug|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
79523093|NCT00364494|Procedure|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht>25% bleed or not
79369140|NCT00891982|Drug|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
79523094|NCT00364572|Drug|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
79997537|NCT03622086|Other|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight & Wellness Center research core.
79523095|NCT00364572|Drug|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
79523096|NCT00364650|Drug|Probiotic Supplement|2 capsules twice daily
79523097|NCT00364650|Other|Placebo|placebo
79369141|NCT05312476|Drug|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~Dose extension study:3 cases (1 dose group)."
79678006|NCT04510337|Drug|Magnesium sulfate|50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
79678007|NCT02949687|Procedure|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
79822831|NCT04078646|Other|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
79997538|NCT02977572|Device|Non-Invasive Ventilation|In arm description
79997539|NCT02977572|Device|Continuous Positive AirwayPressure CPAP|In arm description
79369142|NCT01685203|Drug|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
79523098|NCT00364806|Drug|Prochlorperazine|
79523099|NCT00364806|Drug|Metoclopramide|
79523100|NCT00364884|Drug|ketoaminoacid|
79523101|NCT00365040|Procedure|Prk with mitomycin vs Lasik|
79523102|NCT00365118|Device|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
79523103|NCT00365196|Behavioral|CBT Hostility Reduction Program|
79678008|NCT04510259|Procedure|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
79678009|NCT04694898|Behavioral|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron & folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
79523104|NCT00365430|Behavioral|safety program|Education, patient involvement, tailored implementation and a computerized registration system
79678010|NCT04694898|Behavioral|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
79523105|NCT00365586|Drug|Ketoprofen Topical Patch , 20%|
79523106|NCT00365742|Drug|simvastatin|
79369143|NCT01685203|Drug|ABT-267|Tablet
79369144|NCT01685203|Drug|Ribavirin (RBV)|Tablet
79369145|NCT01928771|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
79369146|NCT01928771|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
79369147|NCT04545229|Other|VR-based Pain Alleviation Tool (VR-PAT)|Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
79369148|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
79369149|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
79369150|NCT01928615|Drug|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
79369151|NCT01928615|Drug|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
79369152|NCT01928615|Drug|Chemotherapy|Standard chemotherapy for early breast cancer.
79523107|NCT00365742|Drug|red yeast rice|
79523108|NCT00365742|Drug|pharmaceutical grade fish oil|
79523109|NCT00365742|Behavioral|therapeutic lifestyle changes|
79523110|NCT00365820|Drug|Tegaserod|
79523111|NCT00365898|Drug|Hydromorphone Hydrochloride Extended-Release|
79523112|NCT00366210|Behavioral|Constraint-Induced Movement (CI) Therapy|
79523113|NCT00366210|Behavioral|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
79678011|NCT00516867|Radiation|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
79678012|NCT00516867|Radiation|UV radiation|UVB 1.4 % and UVA 98.6
79678013|NCT02949765|Drug|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
79678014|NCT02949765|Dietary Supplement|Iron-rich diet|
79678015|NCT04694664|Other|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
79678016|NCT04518176|Procedure|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
79678017|NCT04518176|Drug|Oxytocin|20 units by slow intravenous drip injection
79226509|NCT05713643|Procedure|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
79678018|NCT04694859|Device|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
79678019|NCT04510064|Drug|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
79678020|NCT04510064|Procedure|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
79678021|NCT02275520|Device|NIO Adult device|IO access-1
79369153|NCT01589497|Drug|Rifampicin|Participants with body weight </= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight >50kg were administered one 600 mg tablet orally once daily.
79678022|NCT02275520|Device|Bone Iniection Gun|IO access-2
79678023|NCT02275520|Device|EZ-IO|IO access-3
79678024|NCT02275520|Device|Jamshidi Intraosseous Needle|IO access-4
79678025|NCT02275520|Device|Cook Intraosseous Needle|IO access-5
79678026|NCT04694703|Drug|Covid-19 group|Routine COVID-19 treatment
79302517|NCT03223285|Behavioral|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
79369154|NCT01589497|Drug|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
79369155|NCT01589497|Drug|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
79523114|NCT00366288|Drug|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
79523115|NCT00366366|Biological|Infanrix-Hexa|
79523116|NCT00366522|Drug|LXR-623|
79523117|NCT00366600|Drug|neratinib|HKI-272
79523118|NCT00366834|Drug|Casopitant (GW679769) oral tablets|
79523119|NCT00366834|Drug|Casopitant (GW679769) intravenous|
79523120|NCT00366834|Drug|Dexamethasone intravenous|
79523121|NCT00366834|Drug|Ondansetron oral tablets|
79523122|NCT00366834|Drug|placebo|casopitant placebo
79523123|NCT00366912|Device|non-invasive ventilation|
79523124|NCT00366990|Behavioral|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics with a focus on lowering sodium intake.
79523125|NCT00366990|Behavioral|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics.
79523126|NCT00367068|Drug|baclofen, intrathecal|
79523127|NCT00367068|Device|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
79523128|NCT00367146|Drug|MMF|
79523129|NCT00367224|Procedure|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
79523130|NCT00367224|Procedure|Skin biopsies|4 mm punch biopsies of the skin
79523131|NCT00367302|Drug|buprenorphine|maintenance
79523132|NCT00367302|Drug|methadone|maintenance
79523133|NCT00367536|Drug|bazedoxifene/conjugated estrogens combination tablet|
79523134|NCT00367614|Drug|pantoprazole|
79523135|NCT00367692|Drug|PSI-697|
79523136|NCT00367926|Drug|American ginseng root / polysaccharides|
79523137|NCT00368160|Drug|Eszopiclone|eszopiclone 3 mg
79523138|NCT00368160|Drug|Placebo|Placebo tablet
79523139|NCT00368238|Drug|Recombinant human erythropoietin alfa (drug)|
79523140|NCT00368238|Drug|Aspirin (drug)|
79523141|NCT00368238|Drug|Clopidogrel (drug)|
79523142|NCT00368394|Drug|Insulin glulisine|
79523143|NCT00368628|Procedure|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
79523144|NCT00368706|Drug|solifenacin succinate|Oral
79523145|NCT00368706|Drug|tolterodine|oral
79523146|NCT00368862|Drug|Ebixa (memantine hydrochloride)|
79523147|NCT00368862|Drug|Cipralex (escitalopram)|
79523148|NCT00369018|Drug|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
79523149|NCT00369096|Drug|bemiparin 3500 IU/day|
79523150|NCT00369174|Drug|rosiglitazone maleate|Given orally
79523151|NCT00369174|Other|laboratory biomarker analysis|Correlative studies
79523152|NCT00369252|Drug|Nimotuzumab (TheraCIM h-R3)|
79523153|NCT00369330|Device|external electrical cardioversion|
79523154|NCT00369408|Drug|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
79226510|NCT05713643|Procedure|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
79523155|NCT00369408|Drug|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
79523156|NCT00369642|Behavioral|Cognitive-behavioral therapy|
79369156|NCT01589497|Drug|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
79523157|NCT00369720|Procedure|Titration of oxygen in delivery room|
79523158|NCT00369798|Procedure|PET scan|
79822832|NCT04078646|Other|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
79997540|NCT02746874|Procedure|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
79369157|NCT01589497|Drug|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
79523159|NCT00369798|Drug|Rolipram|
79523160|NCT00369954|Drug|carboplatin|
79226511|NCT05709171|Drug|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
79226512|NCT05709171|Drug|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
79523161|NCT00369954|Drug|gemcitabine hydrochloride|
79678027|NCT04694742|Other|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = [minute ventilation (ml/min) × PaCO2 (mm Hg)]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
79678028|NCT04510181|Dietary Supplement|amino acid-based blend|blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
79523162|NCT00370110|Drug|Itopride 100 mg|100 mg three times daily
79523163|NCT00370110|Other|Placebo|
79523164|NCT00370110|Drug|Itopride 200 mg|200 mg three times daily
79369158|NCT01928381|Drug|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
79369159|NCT01928381|Drug|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
79369160|NCT01928381|Drug|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
79523165|NCT00370188|Drug|Topiramate|
79523166|NCT00370266|Drug|Triamcinolone|
79523167|NCT00370344|Procedure|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
79523168|NCT00370344|Procedure|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
79523169|NCT00370422|Drug|Triamcinolone, Bevacizumab|
79523170|NCT00370500|Drug|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
79523171|NCT00370578|Device|repeated thrombus aspiration during primary PCI|
79523172|NCT00370656|Drug|Pregabalin|capsule, 150mg bd, 300mg bd
79523173|NCT00370656|Drug|Duloxetine|Capsule, 60mg on, 60mg bd
79523174|NCT00370656|Drug|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
79523175|NCT00370734|Drug|Botulinum toxin A injection|
79523176|NCT00370812|Procedure|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
79523177|NCT00370968|Drug|Zinc sulphate|
79369161|NCT01928225|Biological|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
79523178|NCT00371046|Procedure|Transvaginal ultrasound cervical length|
79523179|NCT00371046|Procedure|Cervicovaginal fetal fibronectin|
79523180|NCT00371124|Drug|Atropine Eye drops|
79523181|NCT00371202|Procedure|keratoplasty|
79523182|NCT00371280|Procedure|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
79523183|NCT00371592|Drug|Acyclovir|800 mg tablet taken orally twice daily
79523184|NCT00371592|Drug|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
79523185|NCT00371670|Drug|balicatib (AAE581)|
79523186|NCT00371748|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
79523187|NCT00371748|Device|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
79523188|NCT00371748|Device|Express2|Coronary Stent System
79523189|NCT00371904|Drug|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
79523190|NCT00371904|Drug|Standard Care|Standard care
79523191|NCT00371982|Drug|Fish oil (Maxepa)|
79523192|NCT00372138|Procedure|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
79226513|NCT05701111|Behavioral|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
79226514|NCT05701111|Behavioral|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
79523193|NCT00372216|Drug|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
79523194|NCT00372294|Drug|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
79523195|NCT00372294|Drug|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
79678029|NCT00516945|Drug|Lamivudine|
79997541|NCT02746874|Procedure|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
79997542|NCT01377129|Procedure|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
79369162|NCT04624061|Behavioral|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
79369163|NCT01927757|Biological|Etanercept|Administered by subcutaneous injection
79369164|NCT01927757|Drug|Methotrexate|Background methotrexate at least 15 mg weekly
79369165|NCT01927367|Other|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
79997543|NCT01377129|Procedure|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
79369166|NCT01913639|Drug|Regorafenib|
79523196|NCT00372372|Drug|risedronate|
79523197|NCT00372450|Procedure|management of therapy complications|
79523198|NCT00372450|Procedure|quality-of-life assessment|
79523199|NCT00372606|Behavioral|Online MiDieta Diet and Weight Management Program for Hispanics|
79523200|NCT00372684|Genetic|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
79523201|NCT00372684|Genetic|with uncomplicated malaria|with uncomplicated malaria
79523202|NCT00372762|Drug|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
79369167|NCT01913639|Drug|5-Fluorouracil|
79523203|NCT00372762|Drug|Bumetanide|Equivalent dose to pre-existing furosemide will be used
79523204|NCT00372762|Drug|furosemide|20mg to 80mg orally once or twice daily
79523205|NCT00372762|Drug|bumetanide|0.5mg to 2mg orally once or twice daily
79678030|NCT04510103|Drug|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
79678031|NCT04510103|Other|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
79678032|NCT04510103|Procedure|Regression|2 week regression period after 6 weeks of moisturizer use.
79369168|NCT01913639|Drug|Leucovorin|
79369169|NCT01913639|Drug|Oxaliplatin|
79369170|NCT01913483|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
79523206|NCT00372840|Other|educational intervention|
79369171|NCT01913483|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
79523207|NCT00372840|Procedure|psychosocial assessment and care|
79523208|NCT00372840|Procedure|quality-of-life assessment|
79523209|NCT00372918|Procedure|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
79523210|NCT00373074|Other|Epidural Blood Patch|Use 15 cc of blood
79523211|NCT00373074|Other|Epidural Blood Patch|Inject 20 cc of blood into epidural space
79523212|NCT00373074|Other|Epidural Blood Patch|Inject 30 cc of autologous blood
79523213|NCT00373152|Procedure|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
79523214|NCT00373152|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
79678033|NCT04510103|Procedure|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
79678034|NCT00516984|Procedure|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
79678035|NCT00516984|Procedure|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
79678036|NCT00516984|Procedure|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
79678037|NCT02275598|Drug|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
79678038|NCT02275598|Drug|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
79678039|NCT00517023|Device|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
79678040|NCT00517023|Other|Other|Routine care and tests usually offered for syncope patients.
79523215|NCT00373152|Procedure|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
79369172|NCT04415723|Other|supportive care management programme|nurse-led management programme
79678041|NCT04510025|Diagnostic Test|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
79678042|NCT00517062|Drug|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
79678043|NCT00517062|Drug|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
79678044|NCT00517140|Procedure|Repeat Caesaen section|
79523216|NCT00373152|Radiation|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
79678045|NCT00517140|Procedure|vaginal delivery|
79678046|NCT02275676|Other|bioelectrical impedance analysis|
79822833|NCT04078646|Other|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
79822834|NCT04049565|Diagnostic Test|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
79822835|NCT02677545|Drug|Ticagrelor|
79997544|NCT02558075|Behavioral|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
79997545|NCT01377051|Drug|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
79997546|NCT01377051|Drug|Placebo|Dry powered, same to study drug, only one inhalation
79369173|NCT01913405|Biological|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
79369174|NCT01927055|Drug|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
79997547|NCT03217175|Device|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
79997548|NCT03217175|Device|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
79369175|NCT01927055|Drug|Placebo|Placebo to match droxidopa capsules and strength designations
79369176|NCT01913327|Drug|Aripiprazole|
79369177|NCT01913327|Drug|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
79369178|NCT01913327|Drug|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
79678047|NCT02275676|Other|indirect calorimetry|
79678048|NCT00517179|Drug|Vardenafil 10mg|
79678049|NCT04517981|Behavioral|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
79678050|NCT04517981|Other|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
79678051|NCT00517218|Drug|Genasense® (, oblimersen sodium G3139)|
79678052|NCT00506207|Drug|S-1, Irinotecan, Oxaliplatin|
79678053|NCT00517257|Drug|Atorvastatin|80 mg orally once daily for 24 weeks
79678054|NCT00517257|Drug|Placebo|Placebo tablet orally once daily for 24 weeks
79369179|NCT01926509|Drug|MK-8892|
79822836|NCT02677545|Drug|Clopidogrel|
79822837|NCT02677545|Drug|Aspirin|
79822838|NCT04479644|Drug|BRII-198|BRII-198 given intravenously
79822839|NCT04479644|Drug|Placebo|Placebo given intravenously
79822840|NCT04079426|Other|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
79369180|NCT01926509|Drug|Placebo for MK-8892|
79369181|NCT01926119|Device|Transcranial Magnetic Stimulation|
79369182|NCT01912781|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
79369183|NCT01912781|Device|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
79369184|NCT01912781|Device|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
79369185|NCT04415879|Device|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
79678055|NCT00506246|Drug|Propofol|"intravenous (total intravenous anaesthesia)~induction and maintenance"
79678056|NCT00517335|Procedure|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
79678057|NCT04517708|Other|Nutritional counseling|Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
79822841|NCT00921921|Drug|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
79523217|NCT00373230|Behavioral|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
79822842|NCT00921921|Drug|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
79997549|NCT03217175|Drug|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
79997550|NCT03217175|Drug|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
79997551|NCT01379079|Drug|Acetylsalicylic acid|aspirin intake at bedtime
79997552|NCT01379079|Drug|Acetylsalicylic acid lysinate|aspirin intake on awakening
79997553|NCT02034968|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
79997554|NCT03652506|Device|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
79997555|NCT03652506|Procedure|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
79369186|NCT04415879|Device|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
79369187|NCT04415879|Diagnostic Test|Graded exercise test|No personal protective equipment during a graded exercise test
79369188|NCT01925417|Biological|RBX2660 (microbiota suspension)|
79523218|NCT00366132|Device|Extracorporeal Shockwaves|
79523219|NCT00373464|Drug|etoricoxib|
79997556|NCT03652506|Procedure|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
79997557|NCT03607760|Device|ECMO|the patients with severe respiratory failure were supported by ECMO
79523220|NCT00373620|Drug|paclitaxel|
79523221|NCT00373776|Drug|miltefosine 2.5 mg/kg/day for 28 days|
79997558|NCT03607760|Device|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
79678058|NCT04517240|Other|endoscopy|upper and lower endoscopy and fecal calprotectin test
79678059|NCT01243242|Drug|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
79997559|NCT01380561|Drug|asimadoline|10mg [14]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
79997560|NCT03608150|Device|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
79997561|NCT03608150|Device|Refractive Correction|Standard of care refractive correction (ex. spectacles)
79369189|NCT01911845|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
79369190|NCT01911845|Drug|ABT-333|Tablet
79369191|NCT01911845|Drug|Ribavirin (RBV)|Tablet
79369192|NCT01925183|Drug|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
79369193|NCT01925183|Drug|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients <75kg; orally
79369194|NCT01925183|Drug|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
79369195|NCT01910519|Biological|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
79369196|NCT01910519|Biological|H5N1 vaccine without adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
79369197|NCT01910441|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
79369198|NCT01910441|Drug|Glimepiride|Glimepiride 1-6 mg once daily
79369199|NCT01910441|Drug|Metformin|Metformin (1000-1500 mg daily)
79523222|NCT00373932|Behavioral|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
79523223|NCT00373932|Behavioral|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
79678060|NCT01242813|Drug|ACZ885|
79678061|NCT00517491|Drug|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
79678062|NCT00517569|Genetic|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
79678063|NCT00517569|Drug|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
79822843|NCT02602119|Drug|OTL38|Infusion of OTL38 prior to surgery
79822844|NCT00761475|Procedure|mesh supported closure|onlay mesh supported closure midline laparotomy
79822845|NCT00761475|Procedure|primary closure|primary closure of the midline
79822846|NCT00761475|Procedure|mesh supported closure|sublay mesh supported closure midline laparotomy
79997562|NCT05182983|Other|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
79997563|NCT02522429|Device|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
79997564|NCT02974140|Device|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
79523224|NCT00374010|Behavioral|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~Representational assessment (10 - 15 minutes);~Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~Creating conditions for conceptual change (5 minutes);~Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~Summary (3 - 5 minutes)"
79523225|NCT00374478|Drug|Scopolamine|
79678064|NCT00506363|Procedure|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
79678065|NCT01242111|Drug|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
79678066|NCT04517591|Behavioral|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
79822847|NCT04477538|Other|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
79369200|NCT01923467|Behavioral|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
79369201|NCT01923467|Drug|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
79369202|NCT01910129|Device|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
79226515|NCT05701111|Behavioral|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
79226516|NCT05701111|Behavioral|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
79226517|NCT05701111|Genetic|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
79226518|NCT05700916|Drug|Milk Polar Lipid-Rich Dairy Powder|Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
79369203|NCT01909973|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
79226519|NCT05700916|Dietary Supplement|Dairy Powder|Effects of dairy control powder
79523226|NCT00374634|Drug|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
79523227|NCT00374634|Drug|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
79523228|NCT00374790|Drug|Ferrous sulfate|
79226520|NCT05698693|Behavioral|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
79523229|NCT00374946|Device|THA|
79226521|NCT05698693|Behavioral|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
79523230|NCT00375024|Procedure|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
79822848|NCT00675441|Drug|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
79302518|NCT03223285|Behavioral|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
79302519|NCT02484833|Drug|Cetuximab|
79302520|NCT02484833|Drug|FOLFIRI|
79523231|NCT00375024|Procedure|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
79523232|NCT00375102|Procedure|Acupuncture|
79523233|NCT00375102|Behavioral|Relaxation Response|
79523234|NCT00373542|Drug|ropinirole CR-RLS|
79523235|NCT00375258|Drug|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
79523236|NCT00375258|Drug|Sodium Chloride 0.9%|Visual matched placebo
79369204|NCT01617005|Drug|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
79226522|NCT05685589|Behavioral|MINDful TIME|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
79226523|NCT05681572|Drug|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
79369205|NCT01925339|Device|Test (immediate restoration)|Test (immediate restoration)
79369206|NCT01925339|Device|Control: delayed restoration|Control: delayed restoration
79369207|NCT04621877|Behavioral|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
79369208|NCT04621877|Behavioral|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
79226524|NCT05681572|Drug|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
79369209|NCT01908803|Drug|AL-60371/AL-817 otic suspension|
79369210|NCT01908803|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
79369211|NCT01908101|Drug|Eribulin Mesylate|Given IV
79523237|NCT00375414|Procedure|PEG-Gastropexy|
79523238|NCT00375570|Drug|ME-609|Topical treatment 5 times daily for 5 days
79523239|NCT00375648|Drug|Zoledronic acid|
79678067|NCT04517630|Diagnostic Test|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
79226525|NCT05681572|Drug|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
79226526|NCT05676034|Drug|AMX0035|AMX0035
79369212|NCT01908101|Other|Laboratory Biomarker Analysis|Correlative studies
79369213|NCT01923389|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
79523240|NCT00375726|Biological|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
79523241|NCT00375726|Biological|Placebo|Placebo for rDEN3/4delta30(ME)
79523242|NCT00375882|Procedure|hypothermia|
79226527|NCT05674071|Behavioral|Articulation/HVT|Osteopathy 1
79226528|NCT05674071|Behavioral|Soft-tissue massage|Osteopathy 2
79523243|NCT00375882|Procedure|cochlear implantation with mild hypothermia|
79226529|NCT05674071|Behavioral|Craniosacral techniques|Osteopathy 3
79226530|NCT05674071|Behavioral|Combination of the three interventions: HVT, soft-tissue and craniosacral techniques|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
79302521|NCT03204019|Drug|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
79523244|NCT00375960|Drug|V3381|
79523245|NCT00375960|Drug|Placebo|
79523246|NCT00376038|Drug|GSK189075 oral tablets|
79523247|NCT00376038|Drug|metformin tablets|
79523248|NCT00376116|Device|Cardiac resynchronisation therapy|
79678068|NCT00517608|Device|Laparoscopic colectomy|
79678069|NCT04517201|Drug|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
79678070|NCT04517201|Drug|Physician based insulin regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
79678071|NCT01241604|Device|BiPAP S/T|Mechanical Non-invasive Ventilation
79302522|NCT03204019|Drug|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
79369214|NCT01923389|Drug|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
79369215|NCT01907087|Biological|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
79369216|NCT04620161|Drug|Pradigastat Tablets 20mg|20mg, once daily, oral administration
79369217|NCT04620161|Drug|Pradigastat Tablets 40mg|40mg, once daily, oral administration
79369218|NCT04620161|Drug|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
79369219|NCT04620161|Drug|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
79369220|NCT01616771|Device|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
79369221|NCT01616771|Device|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
79369222|NCT01616771|Device|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
79369223|NCT01589185|Drug|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
79369224|NCT01589185|Drug|Placebo|Placebo administered as a single intravenous infusion
79369225|NCT01588951|Drug|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
79523249|NCT00376116|Device|Implantable cardioverter-defibrillator|
79523250|NCT00376194|Drug|DMSA|
79523251|NCT00376272|Drug|Valsartan|
79523252|NCT00376272|Drug|Placebo|
79523253|NCT00376350|Procedure|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
79678072|NCT01241604|Device|BiPAP Auto SV3|Auto Servo Ventilation Device
79680022|NCT02948153|Other|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
79523254|NCT00376350|Procedure|Light Massage|light pressure massage of the low back.
79822849|NCT00761553|Other|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
79822850|NCT00761553|Dietary Supplement|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
79997565|NCT02974140|Procedure|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
79523255|NCT00376350|Procedure|Pulsed Ultrasound|5 minutes pulsed ultrasound
79822851|NCT02559297|Drug|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
79822852|NCT02559297|Drug|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
79822853|NCT01413399|Drug|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
79822854|NCT04049487|Other|Exercise|Both groups will participate in group exercise as previously described
79822855|NCT02558517|Drug|prednisone discontinuation|randomization
79997566|NCT02311725|Behavioral|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
79523256|NCT00376428|Drug|Gentamicin|
79523257|NCT00376584|Drug|MK-0524A|
79302523|NCT02484521|Device|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
79369226|NCT01588951|Drug|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
79369227|NCT01709383|Device|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
79369228|NCT01709383|Device|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
79523258|NCT00376584|Drug|ER Niacin|
79523259|NCT00376584|Drug|Placebo|
79678073|NCT00517647|Drug|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
79678074|NCT01241292|Biological|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
79678075|NCT01241292|Biological|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
79369229|NCT01588405|Drug|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
79523260|NCT00376662|Drug|Hormone Replacement Therapy and Etidronate|
79523261|NCT00376740|Drug|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
79523262|NCT00376818|Behavioral|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
79678076|NCT00517686|Other|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
79678077|NCT00517725|Drug|carvedilol|
79678078|NCT00517725|Drug|bisoprolol|
79822856|NCT00674973|Drug|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
79822857|NCT00674973|Drug|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
79822858|NCT00673179|Drug|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m^2.
79822859|NCT00673179|Drug|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m^2/day for 2 days continuous infusion.
79822860|NCT00673179|Drug|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m^2, max 20 gm over 4 hours.
79997567|NCT02311725|Behavioral|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
79997568|NCT03653754|Diagnostic Test|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
79822861|NCT00673179|Drug|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
79822862|NCT00673179|Drug|Dexrazoxane|Dose 900 mg/m^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
79997569|NCT02237300|Behavioral|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
79226531|NCT05671874|Behavioral|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
79226532|NCT05669560|Combination Product|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
79226533|NCT05669105|Diagnostic Test|Specimen sample|Participants will have up to 100 mL of whole blood collected.
79226534|NCT05659264|Drug|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
79226535|NCT05659264|Drug|Placebo|0.9% sodium chloride (normal saline) injection
79226536|NCT05651919|Biological|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
79678079|NCT00517725|Drug|Nebivolol|
79678080|NCT04512248|Behavioral|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
79678081|NCT04516889|Procedure|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
79678082|NCT02276261|Procedure|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
79678083|NCT02276261|Procedure|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
79680023|NCT02930733|Drug|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
79680024|NCT02930733|Drug|Saline|2 ml saline subcutaneously bilaterally
79822863|NCT00673179|Drug|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2. Dose 2.8 grams m^2/day.
79226537|NCT05651919|Behavioral|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~Level 1 is coded as a '1' (indicating no problem)~Level 2 is coded as a '2' (indicating some problems)~Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
79369230|NCT01923311|Drug|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
79369231|NCT01923311|Drug|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
79822864|NCT00673179|Behavioral|Questionnaire|Questionnaires to be completed on 5 different days during the study.
79822865|NCT00673179|Drug|Gemcitabine|IV over 1 hour, every other week.
79997570|NCT02237300|Behavioral|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
79226538|NCT05651919|Behavioral|Diet habits questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients."
79369232|NCT01603615|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
79369233|NCT01905683|Drug|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
79822866|NCT00673179|Drug|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
79822867|NCT00673179|Procedure|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
79822868|NCT00673179|Drug|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2/day.
79822869|NCT02584088|Other|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
79822870|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
79226539|NCT05649553|Behavioral|digital game and video animation based diabetes education|While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
79226540|NCT05647564|Diagnostic Test|F-fluorodeoxyglucose positron emission tomography (FDG PET)|Imaging scan
79226541|NCT05647564|Diagnostic Test|prostate-specific membrane antigen positron emission tomography (PSMA PET)|Imaging scan
79226542|NCT05645588|Behavioral|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
79369234|NCT01921829|Drug|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
79369235|NCT04416113|Procedure|photobiomodulation and photodynamic therapy|antiviral treatment
79369236|NCT04619615|Other|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
79369237|NCT04619615|Other|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
79369238|NCT01904903|Drug|Trastuzumab|HER2 therapy
79369239|NCT01904903|Drug|Pertuzumab|HER2 therapy
79369240|NCT01904903|Drug|Ado Trastuzumab Emtansine|HER2 therapy
79523263|NCT00376818|Other|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
79523264|NCT00376818|Other|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
79523265|NCT00376818|Other|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
79523266|NCT00376818|Behavioral|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
79523267|NCT00376818|Procedure|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
79523268|NCT00376896|Drug|GW876008 200mcg|GW876008
79523269|NCT00376896|Drug|GW876008 20mcg|GW876008 20mcg
79523270|NCT00376896|Other|Placebo|placebo
79369241|NCT01921517|Device|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
79523271|NCT00376974|Behavioral|American Academy of Ophthalmology Glaucoma Educational Tape|
79678084|NCT01240863|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
79680025|NCT02931162|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
79822871|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
79822872|NCT00758433|Drug|Placebo patch|Placebo patch q.d. 24 hours for 7 days
79226543|NCT05645588|Behavioral|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
79226544|NCT05639218|Drug|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
79226545|NCT05630976|Drug|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
79226546|NCT05625087|Drug|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
79226547|NCT05625087|Drug|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
79369242|NCT01921517|Device|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
79369243|NCT01921205|Drug|Lacosamide|"Subjects <30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
79369244|NCT01921205|Other|Placebo|"Subjects <30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
79369245|NCT01920893|Drug|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
79822873|NCT00758511|Procedure|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
79997571|NCT04932005|Drug|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
79997572|NCT04932005|Drug|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
79997573|NCT02974842|Device|MAKO 7|Hysteroscopic cell sampling
79997574|NCT03653676|Other|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
79997575|NCT03536247|Procedure|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
79997576|NCT03536247|Procedure|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
79997577|NCT03172481|Drug|PRC-063 oral capsules|Daily dose
79997578|NCT03172481|Drug|Placebo oral capsules|Daily dose
79997579|NCT01163487|Drug|Dichloroacetate|25-50mg/kg per day; oral
79226548|NCT05624359|Drug|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
79369246|NCT01920893|Drug|Dupilumab|Solution for injection; Subcutaneous injection.
79369247|NCT01920893|Drug|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
79369248|NCT01709305|Drug|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
79523272|NCT00377130|Other|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
79523273|NCT00377208|Behavioral|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
79997580|NCT01163487|Device|EF5|21 mg/kg; IV
79997581|NCT02855450|Drug|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
79997582|NCT02855450|Drug|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
79997583|NCT03477045|Dietary Supplement|Single dose fish oil|Fish oil consumed within a single high fat test meal
79997584|NCT03477045|Dietary Supplement|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
79523274|NCT00377286|Dietary Supplement|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
79523275|NCT00377286|Other|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
79523276|NCT00377442|Drug|GK Activator (2)|100mg po
79822874|NCT00758511|Procedure|facilitated tucking|facilitated tucking before, during and after heel stick
79997585|NCT03477045|Dietary Supplement|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
79997586|NCT03477045|Dietary Supplement|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
79997587|NCT01379001|Drug|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
79997588|NCT01379001|Drug|Placebo|IM or PO placebo
79997589|NCT01379001|Drug|Donepezil|donepezil 5mg PO x 1
79997590|NCT02035124|Drug|BKM 120|
79997591|NCT02035124|Drug|Cabazitaxel|
79997592|NCT03172325|Drug|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
79369249|NCT01709305|Drug|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
79369250|NCT01709305|Drug|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
79369251|NCT01709305|Drug|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
79369252|NCT01709305|Drug|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
79369253|NCT01709305|Drug|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
79523277|NCT00377442|Drug|Simvastatin|80mg po
79523278|NCT00377598|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
79997593|NCT03172325|Drug|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
79997594|NCT03172325|Drug|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
79997595|NCT03172325|Drug|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
79997596|NCT03653520|Drug|Diazepam|5 or 10mg
79997597|NCT03653520|Drug|Tramadol|50mg or 100mg
79997598|NCT03653520|Drug|Ondansetron|1 or two tabs
79997599|NCT03653520|Drug|MKO melt|1 or 2 MKO melts
79997600|NCT01378923|Behavioral|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
79997601|NCT01378923|Behavioral|TAU|have access to standard jail programs and services
79997602|NCT02034734|Drug|ASP3652|oral
79997603|NCT03608072|Drug|BI 690517|3 sequential dose groups
79523279|NCT00377598|Drug|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
79523280|NCT00377598|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
79997604|NCT03608072|Drug|Placebo|3 sequential dose groups
79523281|NCT00377598|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
79523282|NCT00377598|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
79523283|NCT00377910|Drug|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
79523284|NCT00377988|Drug|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
79523285|NCT00377988|Drug|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
79523286|NCT00378066|Drug|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
79523287|NCT00378144|Drug|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
79523288|NCT00378222|Procedure|Autologous Stem Cell Transplantation|
79523289|NCT00378300|Drug|Oral Probiotics|
79226549|NCT05624359|Drug|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
79369254|NCT01684423|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
79523290|NCT00378456|Drug|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
79523291|NCT00378456|Drug|Folinic acid|
79226550|NCT05623501|Drug|Dihydromyricetin|Dose-escalation and lysine preparation
79226551|NCT05620641|Drug|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
79226552|NCT05620641|Drug|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
79822875|NCT00758511|Procedure|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
79226553|NCT05619939|Dietary Supplement|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
79302524|NCT02484521|Other|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~GAF- Global assessment of functioning~PANSS- Positive and negative syndrome scale~SANS- Scale for the Assessment of Negative Symptoms~The Calgary Depression Scale for schizophrenia~Demographic Questionnaire~Hamilton Anxiety scale"
79523292|NCT00378456|Drug|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
79523293|NCT00378456|Drug|Placebo|
79523294|NCT00378612|Device|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
79523295|NCT00378690|Drug|leuprorelin acetate|LHRH antagonist
79523296|NCT00378768|Biological|anti-thymocyte globulin|
79523297|NCT00378846|Procedure|infrared thermography|
79678085|NCT01240863|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
79822876|NCT00584012|Drug|Lovastatin|Given PO
79822877|NCT00584012|Drug|Docetaxel|Given IV
79302525|NCT03203629|Device|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
79369255|NCT01684423|Drug|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
79369256|NCT01684423|Drug|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
79523298|NCT00379158|Drug|Micronutrient supplements|
79523299|NCT00379314|Procedure|TVT and TVT-O minimally invasive surgical procedures|
79523300|NCT00379314|Procedure|Surgery for female stress urinary incontinence|
79523301|NCT00379392|Behavioral|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
79523302|NCT00379392|Procedure|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
79523303|NCT00379470|Device|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
79523304|NCT00379548|Behavioral|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
79523305|NCT00379626|Drug|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
79523306|NCT00379782|Other|Navigation|Navigation and escourt
79523307|NCT00379860|Drug|LXR-623|
79523308|NCT00380016|Procedure|Percutaneous Transluminal Angioplasty|
79523309|NCT00380172|Device|Rheopheresis blood filtration|
79523310|NCT00380328|Drug|neratinib|HKI-272
79523311|NCT00380406|Drug|Leuprolide acetate|
79523312|NCT00380484|Drug|Budesonide|200µg daily
79523313|NCT00380484|Drug|Montelukast|5 mg daily
79822878|NCT05435846|Drug|Capmatinib|Given orally
79822879|NCT05435846|Drug|Trametinib|Given orally
79523314|NCT00380562|Behavioral|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
79523315|NCT00380640|Drug|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
79523316|NCT00380640|Drug|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
79523317|NCT00380796|Drug|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
79523318|NCT00380952|Device|Dune Device|
79678086|NCT02275715|Behavioral|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
79678087|NCT04517045|Drug|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
79226554|NCT05619185|Behavioral|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
79226555|NCT05619185|Behavioral|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
79226556|NCT05619185|Behavioral|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
79226557|NCT05619185|Behavioral|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
79226558|NCT05617157|Other|Stair stepping|stepping up and down 32 stairs for 1 minute
79369257|NCT01709227|Drug|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
79523319|NCT00381030|Drug|carvedilol plus nurse management|
79523320|NCT00381108|Drug|Placebo Tablet|Two tablets, twice daily.
79523321|NCT00381108|Drug|Pomegranate Tablet|Two tablets, twice daily.
79523322|NCT00381186|Behavioral|diet- and exercise intervention|
79523323|NCT00381264|Drug|Cesamet™ (nabilone)|
79523324|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
79523325|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
79678088|NCT04517045|Drug|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
79678089|NCT04517045|Other|Conventional treatment|Conventional treatment
79678090|NCT02955485|Other|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
79678091|NCT01240746|Biological|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
79678092|NCT01240746|Biological|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
79678093|NCT01240746|Biological|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to <9 years), Intramuscular
79678094|NCT04513028|Dietary Supplement|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
79523326|NCT00381342|Drug|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
79523327|NCT00381420|Device|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
79523328|NCT00381420|Device|bare-metal stent|un-coated Bx VELOCITY Stent
79678095|NCT04516382|Drug|PTG-300|Active drug
79678096|NCT04517123|Other|Prone Positioning|Prone Positioning
79822880|NCT00920270|Drug|nebulized colistin|nebulized colistin 75 mg every 12 hours
79822881|NCT00920270|Drug|antibiotics|conventional parenteral antibiotics
79678097|NCT01240590|Drug|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
79523329|NCT00381576|Behavioral|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
79678098|NCT01240590|Drug|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
79822882|NCT04080674|Other|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
79822883|NCT04078724|Dietary Supplement|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
79822884|NCT04078724|Other|Without 5-HTP|Subject will not take 5-HTP
79822885|NCT02583386|Behavioral|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
79822886|NCT02583386|Other|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
79226559|NCT05610462|Behavioral|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
79523330|NCT00381654|Drug|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
79822887|NCT04454450|Diagnostic Test|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
79822888|NCT04454450|Diagnostic Test|Contrast enhanced CT|Standard of care contrast enhanced CT
79226560|NCT05610462|Behavioral|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
79226561|NCT05609084|Procedure|Speech therapy|Patients will connect on an interface to pratice speech therapy
79678099|NCT04516187|Diagnostic Test|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
79226562|NCT05609084|Procedure|Speech therapy assessment|Patients will be followed by an speech therapist
79226563|NCT05605080|Device|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
79226564|NCT05605080|Other|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
79226565|NCT05602987|Procedure|enema|receiving enema at the night before anal surgery
79523331|NCT00381732|Drug|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
79822889|NCT02585882|Other|Fluoride table salt|
79822890|NCT04080596|Drug|Dorzagliatin|GKA for T2DM currently under clinical development
79822891|NCT00920738|Other|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
79822892|NCT00920738|Other|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
79822893|NCT02585648|Device|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
79822894|NCT02585648|Device|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
79822895|NCT02584010|Other|Silicon-based aerosol|Apply twice a day over the postoperative scar
79822896|NCT02584010|Other|Silicon-based gel|Apply twice a day over the postoperative scar
79822897|NCT02585804|Drug|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
79822898|NCT02585726|Device|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
79226566|NCT05602987|Procedure|no enema|no enema before anal surgery
79226567|NCT05599347|Drug|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
79226568|NCT05599347|Other|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
79523332|NCT00381732|Drug|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
79523333|NCT00382044|Drug|Eprex; Neorecormon; Aranesp|
79678100|NCT02949804|Behavioral|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
79678101|NCT01240200|Drug|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
79678102|NCT01240200|Device|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
79678103|NCT04516460|Device|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
79678104|NCT00504543|Drug|AEB071|oral, twice daily
79678105|NCT00504543|Drug|Certican|twice daily
79678106|NCT00504543|Drug|Neoral|twice daily
79997605|NCT03630471|Behavioral|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
79997606|NCT03630471|Behavioral|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
79523334|NCT00382278|Procedure|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
79678107|NCT02949570|Drug|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
79226569|NCT05595161|Behavioral|Bright Bodies|The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
79226570|NCT05589948|Dietary Supplement|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
79678108|NCT02949843|Drug|Chemotherapy|Receive other treatment
79226571|NCT05589948|Dietary Supplement|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
79226572|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
79226573|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
79678109|NCT02949843|Biological|Immunotherapy|Receive other treatment
79678110|NCT02949843|Other|Laboratory Biomarker Analysis|Correlative studies
79678111|NCT02949843|Biological|Nivolumab|Given IV
79226574|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
79226575|NCT05589935|Dietary Supplement|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
79226576|NCT05588609|Drug|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
79226577|NCT05588609|Drug|Enzalutamide Pill|second-generation androgen receptor antagonist
79226578|NCT05588609|Drug|Abiraterone acetate tablets|androgen synthesis inhibitor
79226579|NCT05588609|Biological|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
79226580|NCT05581641|Biological|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection
79523335|NCT00382356|Drug|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
79523336|NCT00382434|Procedure|presence of an emergency pharmacist in the ED|
79523337|NCT00382512|Drug|Raptiva (efalizumab)|
79678112|NCT02949843|Biological|Pembrolizumab|Given IV
79678113|NCT02949843|Drug|Targeted Molecular Therapy|Receive drug targeting secondary mutation
79678114|NCT02949843|Drug|Tyrosine Kinase Inhibitor|Given PO
79523338|NCT00382668|Drug|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
79523339|NCT00382668|Drug|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
79523340|NCT00382668|Drug|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
79523341|NCT00382746|Device|EarlySense monitoring device|
79523342|NCT00382902|Device|OptiFree Multi-Purpose Disinfecting Solution|
79523343|NCT00382980|Biological|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
79226581|NCT05581641|Other|Placebo|Placebo
79226582|NCT05580783|Other|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
79226583|NCT05580783|Other|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
79523344|NCT00382980|Biological|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
79678115|NCT04516343|Device|Robotic Ankle Assist Device (RAAD)|The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
79678116|NCT00517764|Drug|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
79678117|NCT04516265|Procedure|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
79523345|NCT00382980|Drug|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
79523346|NCT00383058|Drug|the extract of green tea|
79369258|NCT01709227|Procedure|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
79523347|NCT00383136|Drug|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
79523348|NCT00383136|Drug|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
79678118|NCT04516265|Procedure|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
79678119|NCT04516265|Procedure|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
79822899|NCT04079270|Other|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
79822900|NCT05674760|Device|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
79997607|NCT04054986|Diagnostic Test|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
79678120|NCT00517803|Dietary Supplement|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
79997608|NCT04054986|Other|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
79997609|NCT03653286|Other|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
79369259|NCT01684033|Device|Opti-Free® PureMoist® MPDS|
79369260|NCT01684033|Device|Biotrue™ MPS|
79369261|NCT01684033|Device|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
79523349|NCT00383214|Drug|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
79523350|NCT00383214|Other|Placebo|Intravenous
79523351|NCT00383370|Drug|VEGF Trap|VEGF Trap formulation 1, ITV-1
79523352|NCT00383370|Biological|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
79523353|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
79523354|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
79523355|NCT00383682|Drug|morphine and mexiletine|
79523356|NCT00383838|Behavioral|brief, voluntary substance use intervention|
79523357|NCT00383916|Drug|pantoprazole|
79523358|NCT00383994|Drug|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
79523359|NCT00383994|Drug|Rituximab|375 mg/m^2 by vein followed by 1000 mg/m^2 weekly for 3 weeks for a total of 4 doses.
79523360|NCT00383994|Biological|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
79523361|NCT00384072|Drug|bazedoxifene BZA-20|
79523362|NCT00384228|Drug|Nilotinib|
79523363|NCT00384306|Drug|prednisolone|
79523364|NCT00384384|Drug|oral 18B Glycyrrhetinic acid versus placebo|
79523365|NCT00384540|Procedure|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
79523366|NCT00384618|Drug|pravastatin|
79523367|NCT00384618|Drug|vitamin E|
79523368|NCT00384696|Drug|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke >10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
79523369|NCT00384696|Behavioral|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
79523370|NCT00385086|Drug|TNF blocker|Treatment with TNF-alpha blocker
79523371|NCT00385086|Drug|Placebo|Treatment with placebo
79523372|NCT00385164|Procedure|PET/CT scan for RT planning|
79678121|NCT00517803|Dietary Supplement|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
79678122|NCT00517803|Dietary Supplement|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
79678123|NCT00517803|Dietary Supplement|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
79678124|NCT01243125|Drug|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
79678125|NCT01243125|Drug|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
79678126|NCT04516304|Dietary Supplement|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
79822901|NCT05674760|Other|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
79678127|NCT04516304|Dietary Supplement|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
79678128|NCT01242930|Drug|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
79678129|NCT01242930|Drug|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
79822902|NCT02582996|Drug|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
79822903|NCT02582996|Drug|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
79523373|NCT00385242|Procedure|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
79822904|NCT00674817|Drug|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
79678130|NCT01242930|Drug|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
79822905|NCT00674817|Drug|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
79822906|NCT04078802|Procedure|VNOTES/VH|same as above
79822907|NCT02585570|Drug|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
79226584|NCT05580783|Other|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
79226585|NCT05580744|Other|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
79523374|NCT00385242|Other|PET imaging|PET viability imaging
79523375|NCT00385320|Biological|HRV vaccine|
79523376|NCT00385398|Drug|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
79678131|NCT01241331|Drug|BLI1100|BLI110 topical cream
79678132|NCT01241331|Drug|Vehicle cream|Vehicle topical cream
79678133|NCT04516031|Procedure|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
79822908|NCT02583932|Drug|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
79822909|NCT02583932|Behavioral|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
79822910|NCT02583854|Device|RY-STOP hemostasis device|
79822911|NCT02583854|Device|TR-Band, Terumo|
79523377|NCT00385398|Drug|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
79523378|NCT00385398|Radiation|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
79523379|NCT00385476|Behavioral|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
79523380|NCT00385554|Drug|UC-781 carbomer gel, 0.1% and 0.25%|
79822912|NCT02583074|Procedure|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
79822913|NCT02583074|Procedure|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
79226586|NCT05580744|Other|Mirror therapy using a mirror box|Mirror therapy using a mirror box
79226587|NCT05580744|Other|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
79226588|NCT05580445|Drug|CT-707|Focal Adhesion Kinase (FAK) inhibitor
79226589|NCT05580445|Drug|Toripalimab|Programmed Death 1(PD-1) antibody
79226590|NCT05580445|Drug|Gemcitabine|nucleoside inhibitor
79523381|NCT00385632|Drug|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
79523382|NCT00385710|Drug|valproic acid|Depakine
79523383|NCT00385710|Drug|Placebo|Placebo
79523384|NCT00385866|Behavioral|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
79523385|NCT00385866|Behavioral|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
79678134|NCT04516031|Procedure|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
79680026|NCT02931162|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
79680027|NCT00523055|Drug|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
79680028|NCT02930967|Biological|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
79822914|NCT00764907|Drug|asparaginase|Given IV during reinduction
79822915|NCT00764907|Drug|cyclophosphamide|Given IV during reinduction
79822916|NCT00764907|Drug|cytarabine|Given IV during reinduction
79822917|NCT00764907|Drug|daunorubicin hydrochloride|Given IV during reinduction
79822918|NCT00764907|Drug|dexamethasone|Given IV or orally during reinduction
79822919|NCT00764907|Drug|doxorubicin hydrochloride|Given IV during reinduction
79822920|NCT00764907|Drug|etoposide|Given IV during reinduction
79822921|NCT00764907|Drug|ifosfamide|Given IV during reinduction
79523386|NCT00386178|Drug|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
79226591|NCT05579678|Behavioral|Supportive nursing, nutritional and physical activity with a handheld 'app'|Supportive nursing, nutritional and physical activity with a handheld 'app'
79226592|NCT05578274|Radiation|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
79226593|NCT05578274|Radiation|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
79226594|NCT05575024|Device|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
79226595|NCT05575024|Device|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
79226596|NCT05574075|Diagnostic Test|Diffusion tensor imaging|white matter imaging markers
79369262|NCT00878644|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
79369263|NCT00878644|Other|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
79369264|NCT05312086|Other|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
79369265|NCT05235490|Other|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~Proofreading of tumor sample slides by pathologists~Patients follow-up (imaging, clinical)~Recurrence-free survival"
79369266|NCT00878878|Drug|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
79369267|NCT00878878|Drug|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
79523387|NCT00421590|Drug|SMC021|
79523388|NCT00421668|Drug|Zinc|zinc
79523389|NCT00421668|Drug|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
79523390|NCT00421668|Drug|Placebo|Placebo
79523391|NCT00421746|Drug|Piboserod|
79822922|NCT00764907|Drug|leucovorin calcium|Given IV during reinduction
79226597|NCT05569954|Biological|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
79523392|NCT00421824|Drug|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
79523393|NCT00421824|Drug|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
79523394|NCT00421902|Procedure|Acupuncture|Patients will be have acupuncture (with electro stimulation)
79523395|NCT00421980|Drug|Etanercept|
79523396|NCT00422214|Drug|Quetiapine fumarate (Seroquel) SR|
79523397|NCT00422370|Device|lipid based additives based on vegetable oil & lecithin|
79523398|NCT00422526|Drug|Micronised progesterone (Utrogestan)|
79523399|NCT00422604|Drug|salmeterol|
79226598|NCT05569954|Biological|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
79226599|NCT05567744|Other|Registry|Registry
79226600|NCT05566600|Biological|Human (allogeneic) iPS-cell-derived cardiomyocyte|10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
79226601|NCT05562622|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
79226602|NCT05562622|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
79226603|NCT05562271|Radiation|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
79523400|NCT00422604|Drug|tiotropium|
79523401|NCT00422604|Drug|GSK233705|
79523402|NCT00422682|Drug|bsi-201 + topotecan|21 day cycle
79523403|NCT00422682|Drug|bsi-201 + temozolomide|28 day cycle
79523404|NCT00422682|Drug|bsi-201 + gemcitabine|28 day cycle
79523405|NCT00422682|Drug|bsi-201 + carboplatin/paclitaxel|21 day cycle
79523406|NCT00422838|Procedure|fine-needle aspiration biopsy|aspiration of intrahepatic cells
79523407|NCT00422916|Behavioral|behavioral intervention|
79523408|NCT00422994|Drug|ropinirole dosing for up to 28 days|
79523409|NCT00423228|Drug|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
79822923|NCT00764907|Drug|mercaptopurine|Given orally during reinduction
79226604|NCT05562271|Radiation|sham radiation therapy|sham radiation therapy to involved knee joint
79226605|NCT05552898|Dietary Supplement|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
79226606|NCT05551403|Device|Eyes-closed rest-EEG registration|Recording of spontaneous brain activity while eyes are shut for the duration of 7 minutes using a tablet with instructions
79226607|NCT05551403|Device|Transcranial Magnetic Stimulation during EEG and EMG registrations|Recording of TMS-evoked EEG and EMG responses according to various stimulation protocols
79226608|NCT05551403|Device|Photic stimulation during eyes-closes EEG registration|Recording of visual evoked potentials in the EEG during flash stimulation by light-emitting diode (LED) goggles (while eyes are closed)
79226609|NCT05541380|Other|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
79226610|NCT05537636|Other|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
79226611|NCT05536453|Device|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
79523410|NCT00423228|Drug|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
79523411|NCT00423306|Drug|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
79523412|NCT01799382|Other|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
79226612|NCT05533814|Drug|Perampanel|Perampanel tablets.
79523413|NCT01799382|Device|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
79226613|NCT05519059|Drug|Pelareorep|Pelareorep at 1.5×10^10 TCID50, 3×10^10 TCID50, 4.5×10^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m^2 on Day 1/8/15 per cycle
79226614|NCT05516953|Drug|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
79226615|NCT05516524|Diagnostic Test|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
79226616|NCT05516524|Diagnostic Test|PSG|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
79369268|NCT05311696|Other|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
79369269|NCT00879034|Drug|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
79369270|NCT00879034|Drug|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
79369271|NCT00879034|Drug|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
79369272|NCT04089202|Other|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
79523414|NCT01799616|Drug|Pamidronate|
79523415|NCT01799616|Other|Placebo|
79369273|NCT04089202|Other|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
79369274|NCT00879190|Drug|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
79523416|NCT01799772|Behavioral|Comprehensive Behavioral Intervention|"Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
79523417|NCT01799772|Other|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
79369275|NCT00879190|Drug|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
79369276|NCT01903811|Drug|Carfilzomib|Given IV
79369277|NCT01903811|Drug|Dexamethasone|Given IV
79369278|NCT01903811|Other|Laboratory Biomarker Analysis|Correlative studies
79523418|NCT01799850|Drug|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
79822924|NCT00764907|Drug|methotrexate|Given orally during reinduction
79822925|NCT00764907|Drug|prednisone|Given intrathecally during reinduction
79226617|NCT05515419|Biological|Allogeneic cord blood treatment|Allogeneic cord blood treatment
79226618|NCT05512689|Device|Ventilations while using a respiratory function monitor|Healthcare professionals are able to use a feedback device to guide their ventilations.
79226619|NCT05511818|Dietary Supplement|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
79302526|NCT02484599|Behavioral|Computerized attention training (CAT)|Three sessions of active computerized attention training.
79822926|NCT00764907|Drug|thioguanine|Given orally during reinduction
79822927|NCT00764907|Drug|vincristine sulfate|Given IV during reinduction
79822928|NCT00764907|Drug|vindesine|Given IV during reinduction
79369279|NCT00880360|Drug|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
79822929|NCT02585492|Other|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
79822930|NCT02585492|Other|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
79822931|NCT00672633|Drug|Lovaza|Lovaza , 4 grams/day orally for 6 months
79822932|NCT00672633|Drug|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
79226620|NCT05506241|Device|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
79226621|NCT05503108|Other|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
79226622|NCT05502900|Drug|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
79226623|NCT05502328|Dietary Supplement|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
79369280|NCT01709149|Drug|CK-2017357|CK-2017357 125 mg tablets twice daily
79369281|NCT01709149|Other|Placebo tablets|Tablets
79369282|NCT01709149|Drug|Riluzole|Tablets
79369283|NCT05214196|Drug|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
79369284|NCT05213026|Procedure|Regenerative endodontics|Regenerative endodontic procedure with 3 Mix-MP
79369285|NCT01568593|Device|T2750|1 drop in each eye 3 to 6 times daily during 84 days
79369286|NCT01568593|Device|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
79369287|NCT05311228|Drug|Azithromycin Powder|Azithromicyn intravena for 14 days
79369288|NCT04382014|Dietary Supplement|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
79369289|NCT01683565|Drug|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
79369290|NCT01683565|Other|Canola Oil Placebo|2.5mL per day for 90 days
79369291|NCT00882778|Drug|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
79369292|NCT00892606|Drug|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
79369293|NCT00892606|Drug|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
79369294|NCT04416035|Biological|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
79369295|NCT04416035|Biological|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
79369296|NCT04416035|Drug|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
79369297|NCT04416035|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
79523419|NCT01799850|Drug|placebo|placebo assigned randomly, double blind
79523420|NCT01792050|Drug|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
79523421|NCT01792050|Other|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
79523422|NCT01792050|Drug|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
79523423|NCT01792050|Drug|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
79523424|NCT01790256|Device|Cereve Sleep System at 30 degrees C|
79523425|NCT01790256|Device|Cereve Sleep System at 14-16 degrees C|
79523426|NCT01790100|Drug|VX-135|12 weeks of VX-135
79523427|NCT01790100|Drug|Ribavirin|12 weeks of ribavirin
79523428|NCT01791660|Device|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
79822933|NCT00672555|Procedure|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
79822934|NCT00758823|Device|Paranix|pediculicide product
79822935|NCT00758901|Device|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
79822936|NCT02583698|Drug|Carvedilol|
79822937|NCT02583698|Drug|Placebo|
79822938|NCT05317143|Other|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
79822939|NCT00762099|Drug|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
79822940|NCT00762099|Drug|Placebo|Placebo/sugar tabs will look identical to active drug.
79997610|NCT03653286|Other|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
79226624|NCT05500196|Device|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
79226625|NCT05489172|Behavioral|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
79997611|NCT01208090|Drug|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
79997612|NCT01208090|Drug|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
79226626|NCT05484414|Drug|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
79226627|NCT05484414|Drug|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
79369298|NCT04381858|Drug|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~Further confirmation of a negative PCR test for COVID-19~In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~When quantification of IgG antibodies for COVID-19 is available a title > 1: 640 will be required for inclusion.~Apheresis will be used as the only method for plasma extraction."
79369299|NCT04381858|Drug|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
79369300|NCT04381390|Dietary Supplement|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
79369301|NCT04381390|Dietary Supplement|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
79369302|NCT04088422|Procedure|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
79369303|NCT01903031|Device|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
79997613|NCT03085017|Device|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
79226628|NCT05475002|Other|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
79226629|NCT05475002|Other|dementia education|dementia education manual and family support group
79302527|NCT02484599|Behavioral|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
79369304|NCT01903031|Drug|EFV|Participants received EFV 600 mg daily with two or more NRTIs
79369305|NCT01903031|Drug|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
79302528|NCT02450461|Other|no intervention|
79302529|NCT03223129|Other|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
79369306|NCT01903031|Drug|TDF|Participants received 300 mg of tenofovir in Arm C
79369307|NCT01903031|Drug|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
79369308|NCT00883168|Drug|Placebo|Placebo
79369309|NCT00883168|Drug|azelastineHcl|azelastine hydrochloride 548 mg
79369310|NCT00883168|Drug|fluticasone propionate|fluticasone propionate 200 mcg
79369311|NCT00883168|Drug|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
79369312|NCT01616693|Dietary Supplement|Probiotic|A capsule that contains at least 1 x 10^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
79523429|NCT01793220|Other|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
79523430|NCT01797588|Procedure|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
79302530|NCT03223129|Other|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
79226630|NCT05461976|Behavioral|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
79369313|NCT01616693|Dietary Supplement|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
79369314|NCT01616693|Dietary Supplement|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
79369315|NCT01616693|Dietary Supplement|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
79997614|NCT03085017|Device|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
79997615|NCT04210050|Device|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
79523431|NCT01797588|Procedure|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
79822941|NCT00762255|Drug|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
79997616|NCT04210050|Diagnostic Test|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
79822942|NCT00762255|Drug|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
79997617|NCT04210050|Diagnostic Test|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
79997618|NCT03653130|Behavioral|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
79997619|NCT03215771|Device|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
79226631|NCT05459337|Behavioral|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
79226632|NCT05453994|Drug|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
79226633|NCT05451563|Device|Double-S|Wearable device for intercourse
79226634|NCT05445349|Device|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
79226635|NCT05444608|Behavioral|Breast milk olfactory stimulation|Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.
79226636|NCT05444608|Behavioral|White noise auditory stimulation|Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
79226637|NCT05436652|Drug|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
79226638|NCT05436652|Drug|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
79226639|NCT05436652|Drug|Prednisolone 10mg|Standard of care prednisolone
79226640|NCT05436652|Drug|Additional prednisolone|Over encapsulated prednisolone
79369316|NCT01616693|Biological|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
79369317|NCT01616693|Biological|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
79369318|NCT00883246|Device|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
79369319|NCT04415645|Drug|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
79369320|NCT00893074|Drug|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
79369321|NCT00893074|Drug|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
79369322|NCT00893074|Drug|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
79997620|NCT03215771|Other|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
79997621|NCT04266990|Other|Planned Sweat collection|Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.
79997622|NCT04266990|Other|Spontaneous Sweat collection|As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.
79226641|NCT05436652|Drug|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
79226642|NCT05427318|Behavioral|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
79678135|NCT04515758|Other|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
79678136|NCT04515758|Other|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
79678137|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
79678138|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 4) & matching placebo administered orally once daily
79997623|NCT04266990|Other|Healthy volunteers sweat collection|A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
79997624|NCT03636425|Other|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
79997625|NCT01380483|Drug|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
79678139|NCT01241214|Drug|Cetirizine|Ceterizine administered once daily
79822943|NCT00762255|Drug|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
79822944|NCT04078958|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
79822945|NCT04078958|Dietary Supplement|Whey|Whey with high protein content
79822946|NCT04080206|Drug|188-0551 Spray|Applied topically twice daily for two weeks
79226643|NCT05423951|Drug|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
79226644|NCT05423951|Drug|Propofol|For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
79226645|NCT05423951|Drug|Rocuronium|After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
79369323|NCT00893074|Drug|Placebo|placebo dronabinol administered 3x/day for 5 days
79369324|NCT00884806|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
79369325|NCT00884806|Device|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
79369326|NCT00884806|Device|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
79369327|NCT00884806|Device|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
79226646|NCT05423951|Drug|Sufentanil|During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
79369328|NCT00884806|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
79997626|NCT01380483|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
79369329|NCT05086354|Behavioral|JUMP|Warm-up, stretching, jumping rope, cool-down
79523432|NCT01799460|Drug|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
79997627|NCT02745392|Drug|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
79997628|NCT02745392|Drug|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
79369330|NCT00885742|Biological|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
79523433|NCT01799460|Drug|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
79523434|NCT02994966|Device|Surrosense|
79997629|NCT03622008|Drug|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
79997630|NCT03622008|Other|Placebo|Placebo IV
79369331|NCT04964440|Device|Pure-EP|Advanced Signal Acquisition and Processing
79523435|NCT02994966|Other|Standard care|
79523436|NCT02992080|Other|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
79523437|NCT02995434|Device|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/"
79523438|NCT02995434|Other|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
79997631|NCT04063202|Other|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
79523439|NCT02999880|Procedure|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
79523440|NCT02999724|Drug|Gabapentin|Gabapentin 300-600 mg 1 hour preop
79822947|NCT04080206|Drug|RLD|Applied topically twice daily for two weeks
79226647|NCT05422781|Drug|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
79226648|NCT05417789|Drug|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
79226649|NCT05417789|Drug|Placebo|Matching placebo administered once every 2 weeks (q2w)
79523441|NCT02999724|Other|placebo|placebo capsule(s) 1 hour preop
79678140|NCT01241214|Drug|Placebo|Matching placebo administered twice daily.
79822948|NCT00765219|Behavioral|CBT|10-12 weekly sessions of CBT in person or over the telephone.
79822949|NCT00765219|Other|Usual Care|Treatment as usual provided by participants' physician(s)
79997632|NCT01378845|Drug|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
79226650|NCT05407311|Drug|64Cu-SAR-BBN|64Cu-SAR-BBN
79226651|NCT05397886|Drug|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
79226652|NCT05397886|Drug|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
79369332|NCT05319262|Radiation|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
79369333|NCT05319262|Radiation|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
79369334|NCT00887458|Drug|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
79369335|NCT00887458|Drug|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
79523442|NCT02999490|Radiation|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
79523443|NCT02999568|Other|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
79523444|NCT02999256|Dietary Supplement|Montmorency Tart Cherry Juice|
79997633|NCT01378845|Drug|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
79997634|NCT03606122|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
79523445|NCT02999256|Other|Placebo|
79523446|NCT02999334|Behavioral|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
79523447|NCT02998866|Procedure|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI [means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
79523448|NCT02998632|Procedure|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
79523449|NCT02998632|Procedure|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
79369336|NCT05310682|Other|Data informed Platfrom for health|The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
79997635|NCT03606044|Device|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
79997636|NCT03605888|Behavioral|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
79997637|NCT03076515|Device|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
79369337|NCT03216694|Diagnostic Test|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
79997638|NCT03076515|Device|Sham Nerivio Migra|electrical stimulation- shame mode
79997639|NCT03605810|Other|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
79523450|NCT02998242|Drug|Apatinib|
79680029|NCT02947958|Other|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
79997640|NCT03605732|Behavioral|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
79997641|NCT03605732|Other|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
79226653|NCT05397886|Drug|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
79369338|NCT03216616|Behavioral|Cognitive Behavioural Therapy|
79369339|NCT03275662|Behavioral|Dietary Fiber|
79369340|NCT03275662|Behavioral|Fermented Foods|
79226654|NCT05396118|Drug|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
79226655|NCT05396118|Drug|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized [1-13C]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized [1-13C]Pyruvate followed by MRS / MRSI.
79523451|NCT02998242|Radiation|SBRT to symptomatic bony metastatic bony site(s)|
79523452|NCT02998398|Other|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
79523453|NCT02998320|Drug|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
79822950|NCT02585180|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
79822951|NCT02585180|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
79822952|NCT00765297|Device|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
79822953|NCT00765297|Device|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
79822954|NCT02583542|Drug|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
79226656|NCT05396118|Procedure|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized [1-13C]Pyruvate.
79226657|NCT05390814|Drug|PET-MRI|[18F]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
79226658|NCT05384873|Dietary Supplement|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
79369341|NCT03216304|Drug|100 mg safinamide|"Safinamide will be administered as follows:~Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
79822955|NCT02583542|Drug|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
79369342|NCT03216304|Drug|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
79369343|NCT03216304|Drug|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
79822956|NCT02557971|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
79822957|NCT02583776|Device|Unblinded - CGM|Data from device will be readable and alarms on
79822958|NCT02583776|Device|Blinded - CGM|Data from device will be blinded and alarms off
79822959|NCT04048785|Other|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
79822960|NCT05674682|Procedure|HIV testing|venipuncture or digital puncture for HIV testing
79822961|NCT02557815|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
79369344|NCT03216460|Device|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
79369345|NCT03216538|Drug|AS101 1% oral solution|0.4 ml daily p.o.
79678141|NCT01240512|Drug|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
79678142|NCT04513769|Behavioral|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
79822962|NCT02583620|Genetic|blood sample|A blood test is realized on the subject
79226659|NCT05384873|Other|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
79523454|NCT02998086|Behavioral|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
79302531|NCT03203551|Other|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
79369346|NCT03216538|Drug|Placebo|0.4 ml daily p.o.
79523455|NCT02997696|Drug|ONO-4474|
79678143|NCT00517842|Drug|ViNeuro|
79678144|NCT04515368|Biological|Immunization|Immunisation with one of four licensed vaccines
79678145|NCT01240629|Other|laboratory biomarker analysis|Correlative study
79678146|NCT01240629|Other|questionnaire administration|Correlative study
79226660|NCT05379608|Procedure|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
79523456|NCT02997696|Drug|Placebo matching ONO-4474|
79997642|NCT04951635|Drug|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
79997643|NCT04951635|Drug|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
79997644|NCT03984968|Biological|CD19 CAR-T cells infusion combined with feeding T cells (FTCs)|"Phase1 study Optimal biological doses of feeding T cells identification CAR-T cells infusion combined with FTCs will be given in Philadelphia chromosome positive B-ALL patients with remission. FTCs will be administered at the dose of 5×106/kg, 3.25×106/kg or 2×106/kg two hours after ssCART-19 infusion on day 1 and once again administered at the same dose on day 8.~Phase 2 Expansion Study CAR-T cells infusion combined with FTCs at optimal biological dosage determined in Phase 1 study will be given in expanded Philadelphia chromosome positive B-ALL patients with remission. Bayesian optimal design is applied in this Phase 2 study to monitor the toxicity and efficacy at the specified interim analyses. The total expected sample sizes are 40."
79226661|NCT05379608|Procedure|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
79226662|NCT05377853|Behavioral|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
79524831|NCT05767710|Behavioral|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
79997645|NCT04884399|Drug|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
79226663|NCT05372068|Other|Concrete household floor|Household soil floors will be replaced with concrete floors
79369347|NCT03217396|Procedure|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
79678147|NCT01240629|Drug|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
79678148|NCT04515446|Diagnostic Test|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
79678149|NCT04515446|Diagnostic Test|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
79678150|NCT03459066|Diagnostic Test|Institution-Group|"The study includes three measurement times:~Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
79678151|NCT00506402|Drug|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
79678152|NCT02949531|Drug|oxygen|
79678153|NCT00517959|Radiation|Stereotactic Conformal radiotherapy|SCRT
79226664|NCT05370495|Drug|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
79997646|NCT04884399|Drug|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
79226665|NCT05370495|Drug|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
79226666|NCT05370495|Drug|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
79369348|NCT03218722|Drug|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
79369349|NCT03218722|Drug|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
79369350|NCT03216148|Diagnostic Test|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
79678154|NCT00517959|Radiation|Conventional radiotherapy|
79822963|NCT00765453|Other|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
79822964|NCT00765453|Other|Placebo infusion|Placebo infusion
79822965|NCT05332730|Drug|BAT2506 injection|50 mg, subcutaneous administration
79523457|NCT02997852|Behavioral|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
79226667|NCT05370495|Drug|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
79226668|NCT05369793|Drug|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
79226669|NCT05369793|Drug|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
79226670|NCT05365698|Behavioral|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
79226671|NCT05357859|Dietary Supplement|solubilized vitamin D3|solubilized vitamin D3
79369351|NCT00888628|Biological|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
79369352|NCT00888628|Drug|Etanercept|Given as induction for islet cell transplant
79369353|NCT03215992|Device|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
79369354|NCT03215680|Other|Climate|Hot and temperate climate
79369355|NCT03838276|Procedure|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
79369356|NCT03838276|Procedure|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
79369357|NCT03837886|Dietary Supplement|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
79226672|NCT05357859|Dietary Supplement|medium chain triglyceride|MCT with same amount
79226673|NCT05348356|Drug|Nirogacestat|nirogacestat oral tablet
79226674|NCT05348252|Other|Patient Journey App|The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
79226675|NCT05348252|Other|Information folder|The group will receive all information and instructions on discontinuing PPI use through an information folder.
79369358|NCT03837886|Dietary Supplement|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
79369359|NCT03219970|Drug|Osimertinib|80mg oral daily
79226676|NCT05338866|Radiation|Magnetic resonance guided radiotherapy|Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
79369360|NCT00889330|Drug|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
79369361|NCT00889330|Drug|Placebo|Vehicle without active, one drop in each eye at each of two visits.
79369362|NCT03219580|Drug|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
79369363|NCT03219580|Drug|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
79369364|NCT03215446|Drug|maintenance of anaesthesia with propofol|
79226677|NCT05338866|Drug|Chemotherapy|"For patients with AJCC stage II and III and age < 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses."
79369365|NCT03215446|Drug|maintenance of anaesthesia with sevoflurane|
79369366|NCT03215212|Other|eye mask|eye mask administered from 10 pm to 7 am
79369367|NCT03215212|Other|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
79369368|NCT03215212|Other|ear plug|ear plug administered from 10 pm to 7 am
79523458|NCT02997930|Behavioral|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
79523459|NCT02997930|Behavioral|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
79523460|NCT02997930|Behavioral|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
79822966|NCT05332730|Drug|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
79369369|NCT03215134|Other|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre & Rimes, submitted) and is now being evaluated in a primary mental-health service.
79369370|NCT00896038|Drug|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
79369371|NCT00896038|Drug|Placebo|Non-active placebo
79680030|NCT02947958|Other|Hospital (control)|The patient will keep his usual care at the tertiary care.
79226678|NCT05336045|Procedure|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
79226679|NCT05334407|Procedure|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
79523461|NCT02997930|Behavioral|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
79523462|NCT02997930|Behavioral|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
79523463|NCT02997930|Behavioral|General Depression Scale (GDS)|A measure of the of presence of depression.
79523464|NCT02997774|Other|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
79226680|NCT05334407|Behavioral|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
79369372|NCT03219346|Other|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
79369373|NCT03218956|Dietary Supplement|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
79523465|NCT02997774|Other|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
79523466|NCT02997618|Behavioral|Community based exercise programme|20 week community (home or gym based) exercise programme
79523467|NCT02997618|Other|Control|Usual care consisting of advice.
79226681|NCT05334407|Procedure|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
79226682|NCT05334407|Behavioral|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
79226683|NCT05327452|Behavioral|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
79369374|NCT03219112|Other|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
79523468|NCT02997384|Other|Information|information of women about their risk of breast cancer and the screening methods recommended for them
79523469|NCT02997306|Procedure|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
79523470|NCT02997306|Procedure|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
79523471|NCT02996916|Drug|Olmesartan|10-40mg daily
79523472|NCT02996916|Drug|Amlodipine|2.5-10mg daily
79523473|NCT02997150|Drug|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
79523474|NCT02996838|Drug|TQ-B3234|TQ-B3234 p.o. qd
79523475|NCT02996604|Other|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
79523476|NCT02996370|Other|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
79523477|NCT02996370|Other|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
79523478|NCT02996370|Other|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
79523479|NCT02996370|Other|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
79523480|NCT02996370|Other|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
79523481|NCT02996214|Drug|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
79523482|NCT02996214|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
79523483|NCT02996214|Drug|Cisplatin|Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
79523484|NCT02996058|Drug|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
79680031|NCT04761081|Behavioral|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
79822967|NCT05332730|Drug|Simponi® (US commercially available product)|50 mg, subcutaneous administration
79997647|NCT03605576|Procedure|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
79226684|NCT05327452|Behavioral|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
79523485|NCT02996058|Drug|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
79997648|NCT03605576|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
79226685|NCT05327452|Behavioral|Attention Control|Stretching Program
79226686|NCT05308641|Procedure|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
79226687|NCT05308641|Procedure|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
79226688|NCT05308641|Procedure|standard multimodal pain therapy|standard multimodal pain therapy
79226689|NCT05303064|Drug|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
79369375|NCT03219190|Behavioral|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
79369376|NCT02639260|Drug|N-acetyl D-mannosamine|dose escalation
79369377|NCT04381234|Device|dialyzer|Asymmetric triacetate dialyzer
79369378|NCT04381234|Combination Product|hemodialysis with citrate-containing dialysate|acetate-free dialysate
79369379|NCT04381234|Other|predilution hemodiafiltration|predilution hemodiafiltration
79369380|NCT03218644|Other|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
79523486|NCT02996136|Device|Flu Symptoms|Flu Symptoms
79523487|NCT02995512|Drug|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
79523488|NCT02995590|Drug|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
79523489|NCT02995278|Other|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
79523490|NCT02995200|Behavioral|Accelerometer Based Feedback|
79523491|NCT02995044|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-180)
79523492|NCT02995044|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
79680032|NCT00523289|Drug|Bupivacaine|Dosage: 150mg at once for anesthesia induction
79369381|NCT03218644|Other|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
79369382|NCT03218176|Device|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79680033|NCT00523289|Drug|Ropivacaine|Single dose of ropivacaine, 150mg
79680034|NCT03457857|Other|Cleanser|Cosmetic Baby Cleanser/Shampoo
79997649|NCT01378767|Dietary Supplement|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
79369383|NCT03218176|Device|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79369384|NCT03218176|Device|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79369385|NCT03218176|Device|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79369386|NCT03218176|Device|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79369387|NCT03218176|Device|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79369388|NCT03218176|Device|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79523493|NCT02995122|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-090)"
79523494|NCT02995122|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
79369389|NCT03218176|Device|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
79369390|NCT04380844|Other|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
79369391|NCT03215290|Procedure|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
79523495|NCT02994888|Drug|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
79997650|NCT03607604|Genetic|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
79997651|NCT04868721|Procedure|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
79369392|NCT02537548|Other|Laboratory Biomarker Analysis|Correlative studies
79226690|NCT05303064|Drug|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
79226691|NCT05300074|Other|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
79226692|NCT05288751|Behavioral|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
79369393|NCT02537548|Procedure|Retroperitoneal Lymph Node Dissection|Undergo RPLND
79369394|NCT00897676|Drug|Exendin-(9-39)|100-500pmol/kg/min
79523496|NCT02994810|Other|Breastfeeding guidance|Breastfeeding guidance
79523497|NCT02994342|Device|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
79523498|NCT02994186|Procedure|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
79523499|NCT02994186|Other|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
79369395|NCT00897676|Drug|placebo|placebo (0.9% NaCl)
79369396|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
79369397|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
79369398|NCT01616459|Biological|Synflorix™|Intramuscular injection
79369399|NCT01616459|Biological|Prevnar 13™|Intramuscular injection
79523500|NCT02993952|Device|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
79680035|NCT03457857|Other|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
79680036|NCT04506216|Other|cohort|"During a regular follow-up visit, the following data will be collected:~questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~bio-electric impedance analysis~insulin pump and sensor data collection"
79226693|NCT05280366|Device|Streamline Surgical System|Completion of the Streamline Surgical System procedure
79226694|NCT05280366|Device|iStent Inject W|Implantation of competitor device
79226695|NCT05277194|Behavioral|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
79226696|NCT05270044|Drug|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
79369400|NCT01616459|Biological|Infanrix hexa™|Intramuscular injection
79822968|NCT02581904|Device|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
79226697|NCT05270044|Drug|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
79226698|NCT05267041|Other|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
79226699|NCT05267041|Biological|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
79680037|NCT00524381|Drug|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
79680038|NCT00524381|Drug|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
79369401|NCT03218254|Drug|Methylphenidate|Titration of MTP for treatment of fatigue
79369402|NCT03218254|Drug|Placebo|Placebo
79369403|NCT04415801|Diagnostic Test|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
79369404|NCT03215056|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
79369405|NCT03215056|Drug|Normal saline|Placebo
79369406|NCT04626401|Behavioral|Forearm immobilization|Two days of forearm immobilization
79369407|NCT01919801|Drug|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
79369408|NCT01919801|Drug|Placebo|
79226700|NCT05267041|Other|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
79226701|NCT05267041|Other|Quality of life questionnaire|One questionnaire before second line treatment
79680039|NCT03457779|Dietary Supplement|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of [1,2-13C] glucose as an IV"
79822969|NCT02581904|Device|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
79226702|NCT05267041|Other|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
79523501|NCT02993952|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
79226704|NCT05258539|Other|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~Lifestyle follow-up questionnaire.~Satisfaction questionnaire."
79226705|NCT05254756|Device|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
79523502|NCT02994264|Radiation|adjuvant concurrent chemoradiation|
79997652|NCT03605420|Other|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
79226706|NCT05254756|Device|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
79997653|NCT03170609|Biological|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
79997654|NCT03170609|Biological|Placebo|Saline Control
79997655|NCT03605186|Other|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
79997656|NCT03605186|Other|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
79226707|NCT05253118|Drug|Tislelizumab|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.
79226708|NCT05253118|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
79226709|NCT05251974|Diagnostic Test|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
79226710|NCT05251714|Drug|CFI-402257|Oral once daily in 28 day cycles
79226711|NCT05251714|Drug|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
79226712|NCT05251493|Drug|Iron Isomaltoside 1000, ferric derisomaltose|iron isomaltoside 20 mg/mL
79226713|NCT05251493|Drug|Iron sucrose|iron sucrose 100 mg/mL
79226714|NCT05240807|Diagnostic Test|Photon counting computed tomography (PC-CT)|Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
79369409|NCT01919723|Drug|Ticagrelor|Ticagrelor loading dose
79369410|NCT01919723|Drug|Eptifibatide|i.v. infusion
79369411|NCT01919489|Drug|Liraglutide + OADs|Liraglutide subcutaneously daily
79523503|NCT02993874|Dietary Supplement|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
79680040|NCT03458858|Other|Mixed Berry Diet|Mixed Berry Treatment
79226715|NCT05240235|Other|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
79302532|NCT02485145|Drug|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
79302533|NCT02485145|Drug|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
79369412|NCT01919489|Drug|Glargine + OADs|Glargine once daily subcutaneously
79369413|NCT01919411|Drug|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
79369414|NCT01919411|Drug|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
79369415|NCT01901393|Drug|IV ibuprofen|
79680041|NCT03458858|Other|Carbohydrate Control Jello|Carbohydrate Control
79680042|NCT03458858|Other|Fiber Enriched Jello|Fiber Control
79680043|NCT03458858|Other|Low Fiber Mixed Berry Juice|Anthocyanin Control
79369416|NCT01901393|Drug|Ketorolac|
79997657|NCT01314755|Dietary Supplement|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
79997658|NCT01314755|Dietary Supplement|An iso-caloric, iso-nitrogenous control feed|
79997659|NCT03605108|Dietary Supplement|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs~HU36 - 30 mg~HU58 - 20 mg~Bacillus clausii -25 mg~Bacillus coagulans 10B - 35 mg~Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
79226716|NCT05240235|Other|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
79226717|NCT05231746|Biological|hSTC810|hSTC810 will be administered as an intravenous infusion (IV)
79226718|NCT05230732|Device|neuromodulation device|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks
79226719|NCT05230732|Device|SHAM|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
79226720|NCT05227755|Dietary Supplement|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
79226721|NCT05227755|Dietary Supplement|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
79226722|NCT05227456|Drug|Etonogestrel 68mg implant|Implant will be inserted
79226723|NCT05227456|Device|Etonogestrel 68mg implant|Implant will be inserted
79226724|NCT05223894|Biological|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
79523504|NCT02993874|Dietary Supplement|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
79523505|NCT02993718|Drug|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
79523506|NCT02993718|Drug|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
79523507|NCT02993640|Drug|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
79369417|NCT01890707|Procedure|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
79369418|NCT01890707|Procedure|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
79369419|NCT01900691|Device|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
79523508|NCT02993562|Drug|Levothyroxine|Normal treatment with levothyroxine.
79523509|NCT02993484|Drug|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
79523510|NCT02993484|Biological|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
79226725|NCT05223894|Other|Control|Coronary artery bypass grafting surgery only.
79523511|NCT02993484|Other|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
79680044|NCT03457740|Dietary Supplement|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
79226726|NCT05220904|Device|spectacles|Spectacle is the the most common treatment for refractive errors.
79369420|NCT01890473|Drug|Abatacept|
79680045|NCT03457740|Dietary Supplement|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
79680046|NCT03457740|Dietary Supplement|Placebo|Placebo comparison
79680047|NCT04502667|Drug|Cholecalciferol|1000U or 2000U every 24 hours orally
79680048|NCT00524498|Drug|OPC-18|OPC-18: 500IU * 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
79680049|NCT00524498|Drug|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
79226727|NCT05220904|Device|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
79302534|NCT02485145|Drug|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
79678155|NCT04515992|Behavioral|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
79226728|NCT05220735|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
79226729|NCT05220397|Biological|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
79226730|NCT05220397|Other|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
79226731|NCT05220397|Other|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
79226732|NCT05219617|Drug|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg (not to exceed a total of 400 mg per day).~Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg (not to exceed a total of 600 mg per day)."
79226733|NCT05218642|Drug|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
79369421|NCT01889069|Drug|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
79523512|NCT02993484|Other|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
79523513|NCT02993328|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
79523514|NCT02993328|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
79523515|NCT02993094|Drug|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
79523516|NCT02993094|Drug|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
79523517|NCT02993016|Procedure|patient-specific instruments|
79523518|NCT02993016|Device|The Signature™ Vanguard|
79523519|NCT02993016|Procedure|conventional instruments|
79678156|NCT00518232|Drug|OROS-methylphenidate|
79678157|NCT04515602|Procedure|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
79226734|NCT05218642|Drug|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
79226735|NCT05218642|Drug|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
79226736|NCT05218642|Drug|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
79369422|NCT01889069|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
79369423|NCT01889069|Drug|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
79369424|NCT01889069|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
79369425|NCT01889069|Drug|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
79369426|NCT01889069|Drug|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
79523520|NCT02993016|Device|Vanguard PS(posterior stabilized)|
79523521|NCT02992860|Drug|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by > 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
79523522|NCT02992860|Procedure|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
79523523|NCT02992860|Other|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
79523524|NCT02992860|Other|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
79523525|NCT02992860|Procedure|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
79523526|NCT02992860|Genetic|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
79822970|NCT02581826|Drug|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
79822971|NCT02581826|Drug|Placebo|No column specified.
79822972|NCT00765687|Drug|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
79997660|NCT03605108|Other|Placebo|Rice flour only
79997661|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
79226737|NCT05216666|Procedure|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
79226738|NCT05216666|Procedure|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
79226739|NCT05209074|Drug|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
79523527|NCT02992860|Procedure|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
79523528|NCT02992860|Procedure|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
79523529|NCT02992860|Procedure|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
79523530|NCT02992938|Drug|Acetazolamide|
79523531|NCT02992938|Drug|Placebo Oral Tablet|
79226740|NCT05209074|Drug|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
79226741|NCT05208619|Procedure|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
79678158|NCT04515602|Procedure|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
79678159|NCT04515602|Drug|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
79997662|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
79997663|NCT04904549|Biological|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
79997664|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
79226742|NCT05206838|Procedure|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
79523532|NCT02992704|Drug|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
79678160|NCT00517998|Drug|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
79678161|NCT00505505|Drug|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
79678162|NCT00505583|Drug|MOA-728|
79997665|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
79997666|NCT03605030|Device|Novel Lead Based Armboard|Novel Lead Based Armboard
79997667|NCT03605030|Device|Standard Armboard|Standard Armboard (without lead)
79226743|NCT05201339|Procedure|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
79226744|NCT05201339|Procedure|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
79302535|NCT02637141|Biological|AMG 714|AMG 714 administered by subcutaneous injection
79523533|NCT02992470|Dietary Supplement|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
79523534|NCT02992470|Dietary Supplement|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
79523535|NCT02992548|Drug|Pravastatin|
79523536|NCT02992626|Other|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
79523537|NCT02992626|Other|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
79523538|NCT02992392|Drug|Liposic|one eye of the participant recieved Lipoic
79523539|NCT02992392|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
79678163|NCT00518271|Drug|Rapamune® (Sirolimus)|
79523540|NCT02992314|Device|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
79523541|NCT02992314|Device|Placebo|Placebo formulation with out the active ingredients
79523542|NCT02992002|Other|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
79523543|NCT02992158|Behavioral|behavioral activation|
79678164|NCT00518271|Drug|Tacrolimus|
79678165|NCT00518271|Drug|Corticosteroids|Perioperative
79226745|NCT05200897|Device|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
79678166|NCT04518605|Dietary Supplement|Low protein breakfast|Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume ~60 g bread, 20 g jam and 250 ml juice for breakfast.
79822973|NCT00765921|Drug|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
79369427|NCT02533180|Biological|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
79369428|NCT04381780|Dietary Supplement|Recovery Factors|A unique porcine serum based polypeptide nutritional support
79822974|NCT02583308|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
79822975|NCT02583308|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
79822976|NCT02582606|Other|Regular meal pattern|a 14-day period of eating 6 meal per day
79822977|NCT02582606|Other|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
79822978|NCT02582762|Drug|Nail gel|apply nail gel on affected nails twice daily for 2 months
79822979|NCT00672477|Drug|Methylnaltrexone|
79369429|NCT03218332|Diagnostic Test|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
79822980|NCT00672477|Drug|Placebo|
79822981|NCT04080362|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
79822982|NCT02585336|Behavioral|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
79822983|NCT00766155|Drug|capecitabine|Given orally
79822984|NCT00766155|Drug|oxaliplatin|Given IV
79822985|NCT05314868|Device|PhotoFix|Surgical repair with patch.
79369430|NCT03218098|Procedure|Lobectomy via UVATS|lobectomy with small skin access 4 cm
79822986|NCT00766233|Other|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
79822987|NCT00766311|Other|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
79822988|NCT00766311|Other|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
79226746|NCT05196737|Behavioral|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
79822989|NCT00766311|Other|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
79302536|NCT02637141|Biological|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
79997668|NCT03604952|Diagnostic Test|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
79302537|NCT02637141|Other|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
79302538|NCT02637141|Other|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
79302539|NCT02451709|Device|Activated Smartinhaler or Smartturbo|Medication reminder alarms
79302540|NCT02451709|Other|Feedback of adherence data|Review of adherence data with action planning
79369431|NCT03218020|Other|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
79369432|NCT00898222|Drug|aspirin|81 mg orally daily for two weeks
79678167|NCT04518605|Dietary Supplement|High protein breakfast|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
79678168|NCT04518605|Other|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
79678169|NCT00518310|Drug|Placebo|
79523544|NCT02992158|Behavioral|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
79997669|NCT02237378|Radiation|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
79369433|NCT01830556|Drug|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
79369434|NCT03217630|Other|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
79997670|NCT03607916|Drug|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
79369435|NCT03217942|Drug|NGF|Intramuscular injection
79523545|NCT02991768|Drug|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
79997671|NCT03607916|Drug|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
79997672|NCT03607916|Drug|Morphine|100µg morphine
79997673|NCT04709627|Device|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
79997674|NCT01141712|Procedure|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
79997675|NCT01141712|Drug|BCNU|Participants will receive BCNU 300 mg/m^2 Day -6
79997676|NCT01141712|Drug|Etoposide|Participants will receive Etoposide 100 mg/m^2 BID Days -5 to -2
79523546|NCT02991768|Drug|Placebos|Placebo is matched to the study drug.
79523547|NCT02991612|Drug|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
79523548|NCT02991534|Behavioral|CV Toolkit Components|"Patient completes a CV self screener.~Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
79523549|NCT02991378|Behavioral|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
79369436|NCT03217552|Diagnostic Test|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
79523550|NCT02991222|Drug|SPARC001 type I|Treatment type I
79523551|NCT02991222|Drug|SPARC001 type II|Treatment type II
79523552|NCT02991222|Drug|Reference001 type I|Hydrocodone-Acetaminophen
79523553|NCT02991222|Drug|Reference001 type II|Hydrocodone-Acetaminophen
79523554|NCT02990832|Device|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
79523555|NCT02990754|Behavioral|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
79523556|NCT02990676|Behavioral|Computerised cognitive training|Computerised cognitive training regime
79523557|NCT02990442|Device|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
79523558|NCT02990286|Drug|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
79523559|NCT02990286|Drug|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
79523560|NCT02990286|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
79678170|NCT00518310|Drug|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
79678171|NCT00518388|Behavioral|Focus Group|Focus groups each lasting about 2 hours.
79678172|NCT00518388|Behavioral|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
79997677|NCT01141712|Drug|Cytarabine|Participants will receive Cytarabine 100 mg/m^2 BID Days -5 to -2
79997678|NCT01141712|Drug|Melphalan|Participants will receive Melphalan 140 mg/m^2 Day -1
79997679|NCT00145145|Biological|MAGE-3.A1 peptide and CpG 7909|
79997680|NCT05190263|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
79226747|NCT05195645|Drug|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
79523561|NCT02990208|Behavioral|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens & Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
79678173|NCT02955407|Other|no intervention|observational case-control study
79678174|NCT00518193|Drug|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
79678175|NCT04519814|Procedure|selective laser trabeculoplasty (SLT)|Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
79678176|NCT00518427|Drug|Insulin Glargine|"Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
79226748|NCT05195060|Drug|casirivimab with imdevimab|Monoclonal antibody
79678177|NCT04515173|Diagnostic Test|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
79822990|NCT00766311|Other|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
79822991|NCT00766311|Other|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
79226749|NCT05195060|Drug|sotrovimab|Monoclonal antibody
79226750|NCT05195060|Drug|molnupiravir|antiviral agent
79369437|NCT00903448|Drug|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
79369438|NCT00903448|Drug|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
79369439|NCT01830634|Behavioral|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
79369440|NCT00895180|Biological|olaratumab|Given IV
79226751|NCT05188040|Other|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
79369441|NCT00895180|Biological|ramucirumab|Given IV
79369442|NCT03214042|Device|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
79369443|NCT01830868|Drug|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
79302541|NCT02451709|Device|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
79302542|NCT02484755|Drug|Gefitinib|See Arm Description
79302543|NCT03222817|Behavioral|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
79302544|NCT03316469|Drug|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
79369444|NCT03213964|Biological|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~Dose Level 1: 1 x 10^7 cells/kg IP~Dose Level 2: >1x10^7 cells/kg to ≤3x10^7 cells/kg~Dose Level 3: Complete FATE-NK100 bag (≥3 x 10^7 to ≤ 10 x 10^7 cells/kg)"
79369445|NCT03213964|Drug|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
79226752|NCT05182775|Procedure|Fecal bacteria transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
79226753|NCT05178849|Other|Hypnosis|Hypnosis
79678178|NCT00518466|Drug|topiramate|25 mg modified-release capsules
79997681|NCT03607448|Device|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
79226754|NCT05178849|Drug|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
79523562|NCT02990208|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger & Pauli, 2011)
79226755|NCT05177094|Drug|LY3526318|Administered orally
79523563|NCT02990052|Procedure|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
79523564|NCT02990052|Procedure|Conservative treatment|Closed reduction & casting of distal radius fracture
79369446|NCT03214276|Dietary Supplement|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
79369447|NCT03214276|Dietary Supplement|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
79523565|NCT02991300|Device|BioPoly RS Partial Resurfacing Patella Implant|
79678179|NCT00518466|Drug|phentermine|7.5 mg immediate-release capsules
79678180|NCT00518466|Drug|topiramate|100 and 25 mg immediate-release tablets
79226756|NCT05177094|Drug|Placebo|Administered orally
79302545|NCT03316469|Diagnostic Test|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
79369448|NCT03213808|Other|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
79369449|NCT03217474|Procedure|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
79523566|NCT02999958|Biological|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
79523567|NCT02995746|Drug|Dexamethasone|"On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~Anticipated duration of the study: 6 months"
79678181|NCT00518466|Drug|phentermine|37.5 and 7.5 mg immediate-release tablets
79678182|NCT04518020|Procedure|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
79523568|NCT02990364|Drug|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
79523569|NCT02990364|Drug|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
79678183|NCT00518505|Other|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
79678184|NCT04518761|Procedure|Elective surgery|Any patient who needs to undergo an elective surgery.
79997682|NCT02034890|Drug|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
79678185|NCT00519714|Dietary Supplement|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
79678186|NCT00519714|Dietary Supplement|Placebo|Placebo
79678187|NCT00518544|Drug|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
79680050|NCT04492917|Other|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
79523570|NCT02990364|Drug|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
79369450|NCT03217474|Drug|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
79523571|NCT01270074|Drug|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
79997683|NCT02015351|Drug|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
79997684|NCT03604796|Drug|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
79226757|NCT05176574|Behavioral|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
79523572|NCT01270074|Drug|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
79523573|NCT01270230|Behavioral|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
79523574|NCT01270230|Behavioral|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
79523575|NCT01270308|Drug|Lansoprazole|Lansoprazole DR Capsules 30 mg
79523576|NCT01270386|Drug|apatinib|Apatinib 750 mg p.o. once daily
79523577|NCT01270386|Drug|placebo|placebo p.o. once daily
79523578|NCT01270698|Drug|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
79997685|NCT03604796|Drug|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
79997686|NCT03607292|Procedure|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
79226758|NCT05167786|Device|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
79226759|NCT05167786|Device|Noninvasive spinal stimulation|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation to subjects.
79226760|NCT05167786|Device|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
79226761|NCT05167786|Other|Sham|Subject will not receive either transcutaneous electrical spinal cord stimulation or perform lower limb locomotor activities.
79369451|NCT03217474|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
79369452|NCT03217318|Device|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
79523579|NCT01270854|Other|Plasmalyte A|Intravenous fluid
79523580|NCT01270854|Other|Normal Saline|Intravenous fluid
79523581|NCT01270932|Drug|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
79523582|NCT01271088|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
79523583|NCT01271166|Drug|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
79523584|NCT01271556|Drug|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
79523585|NCT01271556|Procedure|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
79523586|NCT01271556|Other|Placebo|placebo, inhalatory (MDI) once
79523587|NCT01272024|Behavioral|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
79369453|NCT01830946|Other|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
79369454|NCT01830946|Other|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
79226762|NCT05167786|Other|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
79822992|NCT00766311|Other|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
79523588|NCT01272024|Behavioral|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
79822993|NCT00766311|Other|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
79678188|NCT00506480|Procedure|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
79822994|NCT00762489|Other|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
79226763|NCT05165173|Dietary Supplement|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
79523589|NCT01272258|Drug|PRO 140|SC injection
79822995|NCT04078100|Procedure|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
79523590|NCT01272258|Drug|Placebo|SC injection
79523591|NCT01272336|Drug|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
79678189|NCT04694508|Device|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
79678190|NCT04515056|Drug|Papain 10 µg|The area will be exposed to 10 µg of papain.
79822996|NCT00762567|Drug|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
79822997|NCT04338620|Drug|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
79226764|NCT05165173|Dietary Supplement|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
79678191|NCT04515056|Drug|Papain 50 µg|The area will be exposed to 50 µg of papain.
79678192|NCT04515056|Drug|Papain 100 µg|The area will be exposed to 100 µg of papain.
79678193|NCT04515056|Other|Vehicle|The area will be exposed to vehicle
79226765|NCT05164367|Drug|Atropine sulfate gel (0.01%)|A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
79226766|NCT05161793|Device|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
79226767|NCT05156203|Drug|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
79226768|NCT05155800|Device|SDx3|The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
79302546|NCT03217903|Diagnostic Test|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
79822998|NCT04338620|Drug|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
79822999|NCT00759057|Device|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
79823000|NCT00923234|Drug|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
79823001|NCT00923234|Drug|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
79678194|NCT04515056|Drug|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
79523592|NCT01272336|Other|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
79678195|NCT04515056|Drug|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
79678196|NCT04515056|Drug|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
79678197|NCT04515056|Other|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
79823002|NCT00674661|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
79823003|NCT00674661|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
79823004|NCT00766545|Drug|cilostazol|oral tablet 100 mg, twice daily, over 1 year
79823005|NCT00766545|Drug|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
79823006|NCT00766623|Dietary Supplement|high fat meal|milkshake containing 95g fat
79823007|NCT00766623|Dietary Supplement|control meal|milkshake comparable with a normal breakfast
79226769|NCT05149651|Drug|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
79369455|NCT01830946|Other|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
79369456|NCT01831024|Device|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
79678198|NCT00518583|Drug|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
79678199|NCT04514900|Behavioral|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
79678200|NCT04514900|Behavioral|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
79226770|NCT05149651|Drug|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
79226771|NCT05145335|Device|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
79226772|NCT05145335|Device|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
79226773|NCT05125055|Drug|Toripalimab (anti-programmed death-1 inhibitor)|The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
79523593|NCT01272414|Drug|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
79523594|NCT01272414|Drug|Saline injection|Injection of 0.4cc 0.9% normal saline
79523595|NCT01272492|Other|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
79823008|NCT00766701|Procedure|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
79823009|NCT04314128|Diagnostic Test|TOS and TCD|TOS: Transorbital sonography TCD: Transcranial Doppler
79823010|NCT02558205|Radiation|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
79823011|NCT02558205|Radiation|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
79823012|NCT00759369|Other|Water prescription|Water prescription in 12 to 16 equally divided doses
79823013|NCT00766779|Procedure|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
79823014|NCT00766779|Drug|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
79823015|NCT00759447|Device|Genesis and Gemini|3 dimensional breast mammography system
79823016|NCT00759447|Device|Investigational 3D Mammography system|3 dimensional breast mammography system
79823017|NCT02557737|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
79823018|NCT00766857|Drug|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
79523596|NCT01272648|Behavioral|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
79226774|NCT05125055|Drug|Albumin paclitaxel|The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
79226775|NCT05125055|Drug|Cisplatin|The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m^2 of Cisplatin will be used intravenously on the first day of each cycle.
79523597|NCT01273116|Other|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~will be discussed at least once in a multidisciplinary meeting;~a structured medication review will be carried out by a geriatrician;~is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~may receive a consult of a geriatrician, if judged necessary;~will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
79823019|NCT00766857|Drug|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
79823020|NCT02558673|Other|TMAO dietary precursors|
79226776|NCT05125055|Drug|Docetaxel|The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m^2 of Docetaxel will be used intravenously on the first day of each cycle.
79369457|NCT03213886|Drug|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~Will follow the usual hip fracture rehabilitation pathway.~25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
79369458|NCT01831102|Other|none- observational study|
79369459|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
79369460|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
79369461|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
79226777|NCT05125055|Drug|5-Fluorouracil|The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
79226778|NCT05117775|Other|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
79226779|NCT05115955|Drug|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
79369462|NCT01739348|Drug|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
79369463|NCT01739348|Drug|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
79369464|NCT03217084|Drug|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
79523598|NCT01273272|Behavioral|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
79678201|NCT04514900|Behavioral|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
79678202|NCT04514900|Behavioral|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
79678203|NCT00519753|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
79678204|NCT00519792|Drug|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
79823021|NCT02558673|Other|Control (or active comparator)|
79823022|NCT02558283|Device|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
79678205|NCT00519870|Drug|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
79678206|NCT00519870|Drug|losartan|II: losartan
79678207|NCT00519870|Drug|Nifedipine, losartan|I: nifedipine II: losartan
79678208|NCT00518700|Other|new MPS|
79678209|NCT00518700|Other|RepleniSH|
79997687|NCT03607292|Procedure|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
79678210|NCT00519909|Other|Dairy calcium|Diets with different content of calcium and fat
79678211|NCT04694937|Device|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
79823023|NCT02558283|Device|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
79226780|NCT05115955|Drug|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
79226781|NCT05108844|Procedure|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
79226782|NCT05107921|Drug|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
79997688|NCT05134259|Device|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
79997689|NCT03604484|Procedure|Tricuspid annuloplasty|Tricuspid annuloplasty
79369465|NCT03217084|Drug|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
79369466|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
79226783|NCT05104749|Drug|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
79226784|NCT05104749|Other|Placebo|Inert lactose pellets
79369467|NCT00899470|Drug|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
79369468|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
79997690|NCT02311049|Radiation|Hypofractionation|
79997691|NCT02237456|Procedure|Comparison of OCT scans|
79226785|NCT05102981|Procedure|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
79226786|NCT05098041|Drug|Soticlestat|Soticlestat tablets.
79226787|NCT05098041|Drug|Rifampin|Rifampin capsules.
79823024|NCT04624256|Procedure|Discussion|Patients and physicians engage in discussion
79226788|NCT05081310|Device|superior vena cava isolation|SVC isolation by the means of cryoballoon
79226789|NCT05081310|Device|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
79226790|NCT05079984|Behavioral|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
79226791|NCT05079035|Biological|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
79226792|NCT05079035|Biological|Saline|2 mL Sterile, preservative free 0.9% NaCl
79226793|NCT05076838|Drug|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
79226794|NCT05076760|Biological|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
79226795|NCT05076760|Biological|Nivolumab|anti-PD1 monoclonal antibody
79823025|NCT04624256|Radiation|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
79823026|NCT04624256|Radiation|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
79997692|NCT02237456|Procedure|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
79997693|NCT02237534|Drug|Lanthanum carbonate|
79823027|NCT04624256|Other|Laboratory Biomarker Analysis|Correlative studies
79678212|NCT02949492|Drug|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
79823028|NCT04624256|Other|Quality-of-Life Assessment|Ancillary studies
79823029|NCT04624256|Other|Questionnaire Administration|Ancillary studies
79997694|NCT02237534|Drug|Calcium Carbonate|
79997695|NCT03607214|Other|Placebo|"Placebo nasal spray~Film Sequence"
79226796|NCT05076279|Procedure|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
79997696|NCT03602456|Other|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
79226797|NCT05069857|Drug|Camrelizumab (anti-PD-1 inhibitor)|The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
79226798|NCT05069857|Drug|Apatinib (anti-VEGFR inhibitor)|The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
79369469|NCT00899470|Drug|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
79369470|NCT01738646|Drug|Vorinostat|
79369471|NCT01738646|Drug|Bevacizumab|
79369472|NCT03213574|Other|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
79369473|NCT03213574|Other|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
79369474|NCT01831414|Other|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
79369475|NCT01831414|Other|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
79369476|NCT03213340|Other|Catechin Cohort 1|- 4 capsules taken with water 1 hour prior to meal
79678213|NCT04512599|Other|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
79678214|NCT00518739|Drug|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 & beyond).
79823030|NCT04624256|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79997697|NCT03607136|Other|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
79997698|NCT03604328|Drug|PA5108|single ocular implant, administered on day 1
79997699|NCT03606902|Procedure|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
79678215|NCT04514861|Device|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
79823031|NCT02585102|Other|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
79823032|NCT02585102|Other|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
79823033|NCT00767013|Other|DSCT, TTE|One assessment each
79823034|NCT00759837|Drug|Bosutinib|
79823035|NCT00767091|Drug|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
79823036|NCT00767091|Drug|placebo|transdermal patch of placebo
79226799|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
79226800|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
79369477|NCT03213340|Other|Curcuminoid Cohort 2|- 2 capsules taken with water 1 hour prior to meal
79369478|NCT03213340|Other|Flavonoid Cohort 3|- ~ 1 oz. serving consumed 30 minutes before meal
79369479|NCT01716104|Drug|Afalaza|Safety and Efficacy
79369480|NCT01716104|Drug|Placebo|Safety and Efficacy
79369481|NCT03837262|Combination Product|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
79369482|NCT03836170|Procedure|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
79369483|NCT01831492|Device|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
79997700|NCT03606902|Drug|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
79997701|NCT03606902|Drug|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
79997702|NCT03606902|Procedure|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
79823037|NCT00767169|Device|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
79823038|NCT05256381|Drug|SOT101|Subcutaneous (SC) injection.
79523599|NCT01273272|Behavioral|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
79523600|NCT01273350|Device|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
79523601|NCT01273428|Drug|HP011-101|
79523602|NCT01273428|Device|HP-828-101|
79997703|NCT03604250|Dietary Supplement|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
79523603|NCT01273428|Other|Standard Care|
79523604|NCT01273506|Drug|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
79369484|NCT01831492|Device|cellulose|given for 14 weeks
79369485|NCT03213106|Device|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
79523605|NCT01273506|Drug|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
79523606|NCT01273662|Drug|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
79369486|NCT03213106|Device|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
79369487|NCT00904618|Procedure|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
79369488|NCT00904618|Procedure|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
79523607|NCT01273740|Procedure|External support|Bypass surgery with externally supported graft
79523608|NCT01273974|Biological|intradermal influenza vaccine|0.25ml ,intradermal
79523609|NCT01273974|Biological|intramuscular influenza vaccine|0.5ml,intramuscular
79523610|NCT01274130|Drug|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
79523611|NCT01274364|Other|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
79678216|NCT00519948|Drug|new MPS, opti-free express no rub MPS|
79678217|NCT04514666|Other|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
79523612|NCT01274364|Other|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
79523613|NCT01274598|Biological|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10^10 CFU by mouth twice daily for 28 days
79523614|NCT01274676|Device|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
79678218|NCT02949102|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
79678219|NCT02949102|Dietary Supplement|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
79369489|NCT00904618|Drug|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
79523615|NCT01274676|Device|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
79226801|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
79226802|NCT05059275|Procedure|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
79226803|NCT05049863|Drug|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
79226804|NCT05049863|Drug|Allopurinol|Allopurinol is commercially available.
79226805|NCT05049863|Drug|Irinotecan|Irinotecan is commercially available.
79226806|NCT05029206|Procedure|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~A minimum of 2 × 10^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
79226807|NCT05027282|Device|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.|CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
79369490|NCT03213028|Other|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
79369491|NCT03837652|Other|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
79369492|NCT01839136|Procedure|Intrauterine transfer of gametes|
79523616|NCT01274910|Dietary Supplement|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
79523617|NCT01274910|Dietary Supplement|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
79823039|NCT05256381|Drug|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
79823040|NCT02582528|Behavioral|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
79226808|NCT05026580|Behavioral|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
79226809|NCT05026008|Drug|SR1375|The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
79226810|NCT05026008|Drug|Matching placebo|The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
79997704|NCT03604094|Procedure|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
79823041|NCT02582528|Behavioral|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
79369493|NCT01839136|Procedure|Intrauterine transfer of embryos|
79369494|NCT01839214|Drug|VB-201 160mg|
79369495|NCT01839214|Drug|Placebo|
79369496|NCT01839292|Device|uncovered D-type stent insertion|
79369497|NCT01839292|Device|double-layered ComVi stent insertion|
79369498|NCT01839370|Device|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
79523618|NCT01275378|Behavioral|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
79523619|NCT01275378|Behavioral|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
79997705|NCT03602378|Diagnostic Test|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
79997706|NCT03602378|Device|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
79997707|NCT03602378|Device|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
79997708|NCT03602378|Device|AGE reader|for measuring Advanced Glycation End products (AGEs)
79523620|NCT01275456|Procedure|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
79523621|NCT01275612|Biological|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
79226811|NCT05015660|Device|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
79226812|NCT05015660|Device|Right ventricular active fixation lead|Active fixation lead (standard)
79678220|NCT04514822|Diagnostic Test|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
79823042|NCT00767403|Behavioral|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
79226813|NCT04996693|Diagnostic Test|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
79226814|NCT04996693|Diagnostic Test|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
79226815|NCT04996693|Diagnostic Test|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
79226816|NCT04995627|Dietary Supplement|Salt (NaCl)|12 grams of salt (NaCl) per day
79226817|NCT04995627|Other|Placebo|Placebo
79369499|NCT01839448|Biological|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
79369500|NCT04380766|Procedure|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
79369501|NCT04380532|Biological|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
79369502|NCT00906958|Device|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
79369503|NCT00906958|Device|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
79369504|NCT01832116|Drug|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
79369505|NCT01839526|Drug|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
79369506|NCT03212872|Diagnostic Test|Endoscopy|
79369507|NCT01832194|Drug|Botox|
79369508|NCT01832272|Procedure|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
79678221|NCT04514588|Dietary Supplement|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
79678222|NCT02276300|Drug|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
79678223|NCT02276300|Drug|Sargramostim|Sargramostim is part of Her2 vaccination
79678224|NCT02276300|Drug|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
79678225|NCT02276300|Drug|Imiquimod|Imiquimod is part of Her2 vaccination
79226818|NCT04993313|Other|Counseling|Undergo verbal counseling
79226819|NCT04993313|Other|Educational Intervention|View photo guide
79226820|NCT04993313|Behavioral|Questionnaire|Complete questionnaires
79226821|NCT04987658|Drug|OLZ/SAM|Olanzapine and Samidorphan taken once daily over a max period of 21 days
79369509|NCT01832428|Other|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
79369510|NCT00907426|Drug|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
79678226|NCT02949453|Behavioral|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
79997709|NCT03602300|Drug|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
79997710|NCT03602300|Drug|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
79997711|NCT03606824|Drug|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
79997712|NCT03606824|Drug|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
79997713|NCT03602222|Behavioral|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
79226822|NCT04987229|Drug|OLZ/SAM|Olanzapine and Samidorphan fixed dose coated tablet taken once daily
79523622|NCT01275768|Procedure|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
79678227|NCT04514939|Other|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
79226823|NCT04981067|Other|Maintain the concentration of ropivacaine as same as those used in the previous participant|Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
79226824|NCT04981067|Other|Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
79226825|NCT04981067|Other|Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
79226826|NCT04980703|Device|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
79369511|NCT00907426|Drug|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
79369512|NCT01832662|Other|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
79369513|NCT01832662|Other|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
79369514|NCT01832662|Other|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
79369515|NCT00908908|Drug|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
79369516|NCT00909064|Drug|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
79369517|NCT03837340|Other|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
79523623|NCT01275924|Device|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
79523624|NCT01275924|Device|Syndesmotic screw|Quadricortical syndesmotic screw
79523625|NCT01276080|Drug|Donepezil|10 mg tablets
79369518|NCT03837340|Other|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
79523626|NCT01276158|Procedure|Ultrasound|Ultrasound used to place arterial line
79523627|NCT01276158|Procedure|Doppler|Doppler used to place arterial line
79678228|NCT02949414|Procedure|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
79678229|NCT02955173|Procedure|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
79369519|NCT01832896|Drug|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
79523628|NCT01276548|Drug|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
79678230|NCT00520026|Drug|lithium|
79678231|NCT00520026|Drug|placebo|
79678232|NCT00518856|Other|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
79678233|NCT00518856|Other|Standard of care|continued with current standard of care for birth attendants
79678234|NCT02955251|Drug|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
79523629|NCT01276548|Drug|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
79369520|NCT03212014|Other|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
79523630|NCT01276626|Dietary Supplement|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
79523631|NCT01276626|Other|Maltodextrin|Powder containing only maltodextrin
79523632|NCT01276782|Drug|Levothyroxine|It is FDA approved drug for thyroid disease
79523633|NCT01276938|Radiation|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
79523634|NCT01276938|Radiation|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
79997714|NCT03602222|Behavioral|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
79997715|NCT03604016|Drug|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
79997716|NCT03604016|Drug|L-carnitine|Besifovir dipivoxil 150 mg
79523635|NCT01277094|Drug|Placebo|Oral daily doses for 12 weeks
79678235|NCT02955251|Drug|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
79997717|NCT03604016|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
79997718|NCT03219333|Drug|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
79226827|NCT04980703|Device|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
79226828|NCT04980703|Other|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
79226829|NCT04977882|Procedure|abdominal drainage|19 Fr abdominal drainage placed intraoperatively in right colic gutter
79369521|NCT03212014|Other|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
79997719|NCT03168867|Behavioral|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
79997720|NCT01064622|Drug|vismodegib|Given PO
79997721|NCT01064622|Drug|gemcitabine hydrochloride|Given IV
79226830|NCT04977882|Drug|Postoperative antibiotico-prophylaxis|Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
79369522|NCT03212014|Other|Traditional rehabilitation|traditional exercise models in currently clinical use
79369523|NCT03211780|Device|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
79369524|NCT03211936|Procedure|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
79369525|NCT03211936|Device|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
79369526|NCT03211936|Device|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
79523636|NCT01277094|Drug|RO5093151|Oral daily doses for 12 weeks
79523637|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
79523638|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
79523639|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
79523640|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
79523641|NCT01277406|Drug|4SC-201(Resminostat)|oral administration
79523642|NCT01277406|Drug|FOLFIRI|i.v. administration
79523643|NCT01277640|Drug|dapivirine|"dosage form: gel 0.05%~dosage: 2.5g~frequency: once daily~duration: 7 days"
79523644|NCT01277640|Drug|matched placebo|"dosage form: gel, no api~dosage: 2.5g~frequency: once daily~duration: 7 days"
79523645|NCT01277640|Drug|universal placebo|"dosage form: gel, HEC-based~dosage: 2.5g~frequency: once daily~duration: 7 days"
79523646|NCT01277796|Device|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
79523647|NCT01277874|Device|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
79678236|NCT00518895|Drug|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
79997722|NCT01064622|Other|hydrocortisone/placebo|Given PO
79369527|NCT03211936|Other|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
79997723|NCT01376895|Behavioral|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
79226831|NCT04977882|Procedure|Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)|the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
79369528|NCT03211936|Other|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
79369529|NCT01830400|Drug|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
79369530|NCT01830478|Drug|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
79369531|NCT01830478|Drug|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
79369532|NCT01833442|Behavioral|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
79369533|NCT01833442|Behavioral|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
79369534|NCT01835782|Drug|L-Serine|
79369535|NCT00909220|Behavioral|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis & Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
79523648|NCT01277874|Device|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
79523649|NCT01277952|Device|Deep Brain Stimulation|Brain pace maker, implanted in the brain
79523650|NCT01278108|Drug|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
79523651|NCT01278108|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
79997724|NCT01376895|Behavioral|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
79523652|NCT01278108|Drug|GLPG0778|multiple dose, capsule, 7 days
79523653|NCT01278108|Drug|placebo|multiple dose, capsule, 7 days
79523654|NCT01278420|Device|Tecnis MF|30 subjects will be implanted with the Tecnis MF
79523655|NCT01278420|Device|ReSTOR|30 subjects will be implanted with ReSTOR
79523656|NCT01278576|Drug|BOTOX-A®|200 units, single treatment only
79523657|NCT01278654|Behavioral|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
79523658|NCT01278810|Drug|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
79523659|NCT01278966|Other|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
79523660|NCT01279122|Device|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
79523661|NCT01279278|Other|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
79523662|NCT01279278|Other|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
79523663|NCT01279434|Drug|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
79523664|NCT01279434|Drug|Vitamin E|Vitamin E 400 mg BD daily for 12 months
79523665|NCT01279512|Drug|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
79523666|NCT01279512|Drug|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
79523667|NCT01279668|Drug|Montelukast|10mg tablets, once per day for 28 days.
79523668|NCT01279668|Drug|Placebo|tablets, once per day for 28 days.
79523669|NCT01279746|Device|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
79523670|NCT01279902|Drug|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
79678237|NCT00518895|Drug|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
79997725|NCT01380405|Behavioral|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
79678238|NCT02275754|Behavioral|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
79678239|NCT02275754|Behavioral|PN Only|Participants will be navigated by PN on request
79678240|NCT02954978|Drug|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
79678241|NCT02954978|Drug|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
79678242|NCT02954978|Drug|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
79678243|NCT00520065|Other|enteral nutritional formula|Meal glucose tolerance test
79678244|NCT00520065|Other|Diabetes specific enteral product|Meal Glucose tolerance test
79678245|NCT00518934|Other|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
79823043|NCT00767403|Behavioral|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
79226832|NCT04977882|Procedure|Laparoscopic standard D2 right hemicolectomy (STANDARD)|A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
79226833|NCT04965597|Drug|Treosulfan|Given IV
79226834|NCT04965597|Drug|Fludarabine Phosphate|Given IV
79226835|NCT04965597|Drug|Tacrolimus|Given IV and PO
79226836|NCT04965597|Drug|Methotrexate|Given IV
79523671|NCT01279044|Behavioral|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
79523672|NCT01279044|Behavioral|Standard HIV testing with information only|Standard HIV testing with information only
79678246|NCT00520104|Drug|intranasal ketamine|drug interaction
79678247|NCT00519012|Drug|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
79823044|NCT00767403|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
79823045|NCT00767481|Drug|Travoprost/Brinzolamide|Eye drop suspension, once daily
79997726|NCT04850391|Other|Mobile app|To compare changes induced by the movile app intervention among the three study groups
79997727|NCT04163718|Drug|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
79523673|NCT01278342|Drug|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
79226837|NCT04965597|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
79226838|NCT04965597|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
79226839|NCT04965597|Procedure|Allogeneic Bone Marrow Transplantation|Undergo bone marrow transplant
79226840|NCT04965597|Other|Quality-of-Life Assessment|Ancillary studies
79680051|NCT04492917|Other|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
79823046|NCT00767481|Drug|Cosopt|Eye drop solution, one drop BID
79997728|NCT04171635|Radiation|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
79226841|NCT04965597|Procedure|Echocardiography|Undergo ECHO
79997729|NCT04171635|Radiation|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
79997730|NCT01378689|Other|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
79997731|NCT03630549|Other|Standard of Care|Clinic-based HIV care
79226842|NCT04965597|Procedure|Multigated Acquisition Scan|Undergo MUGA
79226843|NCT04965597|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
79226844|NCT04965597|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
79226845|NCT04965597|Procedure|Biospecimen Collection|Undergo blood sample collection
79369536|NCT04426695|Drug|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
79226846|NCT04963803|Device|Active transcranial direct current stimulation (tDCS)|Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
79226847|NCT04963803|Device|Sham transcranial direct current stimulation (tDCS)|Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.
79369537|NCT04426695|Drug|Placebo|Placebo IV Single Dose
79369538|NCT01838200|Biological|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
79523674|NCT01278342|Drug|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
79226848|NCT04963803|Behavioral|Language Specific Attention Treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
79226849|NCT04963374|Other|risk evolution scale|Padua score、Caprini score、Prime score
79523675|NCT01278342|Drug|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
79680052|NCT04492917|Other|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
79997732|NCT03630549|Other|Village-based ART refill|Option to get ART refill and care by the village health worker
79226850|NCT04963127|Diagnostic Test|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
79226851|NCT04963127|Diagnostic Test|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
79369539|NCT01838200|Drug|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
79369540|NCT01838200|Drug|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
79369541|NCT01833754|Drug|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
79226852|NCT04959929|Device|Focal vibration therapy|Myovolt is a wearable rehabilitative device that delivers vibration to the region of the body where the motors are worn. Participants are asked to apply the vibration to specific leg locations twice a day, for about 30 minutes at a time, and to record their response using a provided log. They may be asked to try applying the device at different location or using different vibration parameters (pulse frequency or intensity).
79226853|NCT04956536|Other|Demographic data and MRI images were extracted and analyzed|Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
79523676|NCT01278030|Procedure|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
79226854|NCT04951999|Other|Blood sampling|For 10 visits (out of the 12 of the protocol), ~40 ml of blood is sampled for research purposes in addition to care sampling.
79369542|NCT01720030|Drug|Levosimendan|Verum therapy
79369543|NCT01720030|Drug|Conventional therapy|Placebo therapy to safeguard blinding
79369544|NCT01720108|Drug|rivaroxaban and ASA|
79369545|NCT01720186|Device|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
79369546|NCT03211468|Behavioral|Clinical intervention program to prevent eating disorders|See previous
79369547|NCT04380220|Diagnostic Test|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
79369548|NCT01832974|Drug|IL-13-PE|IL-13-PE intravenous infusion
79997733|NCT04153539|Behavioral|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
79523677|NCT01277718|Drug|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
79226855|NCT04949542|Behavioral|Bolster|Bolster is a native mobile app that provides on-demand content to caregivers of young adults with early psychosis to support their caregiving skills and knowledge of psychosis.
79523678|NCT01277718|Drug|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
79523679|NCT01276236|Drug|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
79523680|NCT01275222|Drug|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
79226856|NCT04949542|Behavioral|Control|Exemplar resources provided in the control arm will include a selection from the National Alliance on Mental Illness and Mental Health America designed to support caregivers helping loved ones access care.
79226857|NCT04946084|Procedure|Tympanocentesis|When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
79523681|NCT01275222|Drug|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
79678248|NCT00519012|Drug|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
79678249|NCT00520143|Biological|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
79678250|NCT03459027|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g) acutely
79823047|NCT04306874|Dietary Supplement|Ensure Max Protein|Liquid shake with 30 g protein per serving
79823048|NCT02557893|Behavioral|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
79823049|NCT02557893|Other|Education|Bimonthly pregnancy education classes
79823050|NCT02557893|Other|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
79823051|NCT00671931|Drug|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
79823052|NCT00671931|Drug|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
79823053|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
79226858|NCT04946084|Other|Nasal Phalangeal Swab and Wash|Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
79369549|NCT01671735|Other|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
79369550|NCT01720342|Procedure|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
79369551|NCT01671813|Drug|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
79823054|NCT00671931|Drug|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
79823055|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
79823056|NCT00767559|Drug|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
79823057|NCT00767559|Drug|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
79823058|NCT00767559|Drug|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
79997734|NCT04153539|Behavioral|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
79997735|NCT01063764|Drug|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
79678251|NCT03459027|Dietary Supplement|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
79997736|NCT04117815|Device|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~Minimum 30 minutes pre-infusion cooling~Cooling for the duration of chemotherapy infusion~Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
79997737|NCT04117815|Other|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~Baseline~at the half-way Point of the cyles~at the last CT cycle~3 months after completion of Treatment~6-9 months after treatment completion~The assesments include the following~Photographs of the head, which are evaluated using the CTCAEv4.0~Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
79997738|NCT03073629|Diagnostic Test|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
79997739|NCT03652350|Procedure|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
79997740|NCT02880189|Device|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
79226859|NCT04946084|Other|Blood Draw|Venipuncture
79226860|NCT04944693|Other|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
79369552|NCT03836404|Device|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
79369553|NCT03021291|Device|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
79369554|NCT01833052|Device|TAVI (Medtronic CoreValve)|
79523682|NCT01275222|Drug|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
79523683|NCT01275144|Drug|LY2216684|Administered orally
79226861|NCT04931745|Device|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
79997741|NCT02880189|Procedure|Endoscopic Ultrasound Guided Core Liver Biopsy|
79997742|NCT04053972|Drug|Lenvatinib|oral lenvatinib after hepatectomy
79997743|NCT01380249|Drug|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
79997744|NCT04054518|Drug|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
79226862|NCT04931745|Device|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
79523684|NCT01275144|Drug|Placebo|Administered orally
79523685|NCT01275144|Drug|Lorazepam|Administered orally
79997745|NCT01378611|Device|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
79997746|NCT03652896|Procedure|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
79226863|NCT04931745|Other|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
79226864|NCT04927637|Procedure|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
79226865|NCT04912817|Other|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
79369555|NCT01833052|Device|Claret-Filter|
79369556|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
79369557|NCT01671969|Other|very low calorie diet|medically supervised diet
79523686|NCT01275066|Drug|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
79823059|NCT00767637|Drug|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
79678252|NCT00520182|Behavioral|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids [MUFA]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
79678253|NCT00520182|Behavioral|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
79997747|NCT04565847|Drug|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
79678254|NCT00520182|Behavioral|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
79997748|NCT04565847|Drug|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
79226866|NCT04912817|Other|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
79226867|NCT04907669|Other|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
79997749|NCT03075891|Drug|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
79226868|NCT04905810|Drug|Azacitidine|Given IV
79226869|NCT04905810|Drug|Decitabine|Given IV
79226870|NCT04905810|Drug|Venetoclax|Given PO
79369558|NCT03211078|Procedure|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
79369559|NCT01833208|Other|Laboratory Biomarker Analysis|Correlative studies
79369560|NCT01833208|Radiation|Radiation Therapy|Undergo single-fraction radiation therapy
79369561|NCT03210922|Device|Miami cervical collar|Collar group is put on the Miami cervical collar.
79369562|NCT03830398|Drug|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
79369563|NCT03830398|Drug|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
79523687|NCT01275066|Drug|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
79523688|NCT01275066|Drug|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
79523689|NCT01273038|Device|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
79523690|NCT01273038|Device|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
79523691|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
79523692|NCT01272180|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
79369564|NCT03830398|Drug|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
79369565|NCT04405323|Drug|Lu AG06466|hard capsules, orally, single doses
79369566|NCT04405323|Drug|Itraconazole|200 and 300 mg, capsules, orally
79369567|NCT01720498|Drug|remifentanil|The effect site concentration of remifentanil
79523693|NCT01272180|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
79523694|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
79678255|NCT02954900|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
79678256|NCT02954900|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
79678257|NCT02949336|Radiation|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
79823060|NCT00767715|Drug|olanzapine|physician determined dose, oral, daily, 5 months
79369568|NCT01672047|Drug|Vitamin D2|25（OH）D level <12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， >116.75nmol/L stopped.
79523695|NCT01271712|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
79523696|NCT01271712|Drug|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
79823061|NCT00767715|Drug|haloperidol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
79523697|NCT01271712|Drug|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
79523698|NCT01271010|Drug|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle.
79523699|NCT01271010|Drug|Fludarabine|Participants received fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle.
79523700|NCT01271010|Drug|Rituximab|Participants received 375 mg/m^2 IV on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle.
79997750|NCT03075891|Drug|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
79226871|NCT04893421|Device|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
79369569|NCT01833286|Procedure|TACE+RFA|TACE first, followed by RFA within 2 months
79369570|NCT01833286|Procedure|re-resection|repeat hepatectomy for recurrent small HCC
79523701|NCT01270620|Drug|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
79523702|NCT01270620|Drug|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
79523703|NCT01270464|Drug|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
79523704|NCT01270464|Drug|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
79523705|NCT01279590|Drug|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
79678258|NCT04514237|Drug|BOS172767 enantiomer E1 or E2|Oral tablets
79678259|NCT04514237|Drug|Placebo|Oral tablets
79823062|NCT00767715|Drug|zuclopentixol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
79523706|NCT01279590|Drug|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
79678260|NCT00520260|Drug|bromfenac|0.09%, BID, 6 weeks
79678261|NCT00520260|Drug|ketorolac|0.4%, BID, 6 weeks
79680053|NCT04492917|Other|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
79823063|NCT02584946|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
79823064|NCT00762957|Drug|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
79823065|NCT00762957|Drug|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
79823066|NCT00762957|Drug|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
79823067|NCT04295720|Device|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
79823068|NCT00763113|Device|Vanguard PS Knee|Vanguard PS Knee
79823069|NCT00763113|Device|Vanguard CR Knee|Vanguard CR Knee
79823070|NCT05292014|Device|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
79997751|NCT03075891|Other|Oral placebo capsules|1 Capsule once-daily for 12 weeks
79997752|NCT02013167|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
79226872|NCT04892342|Drug|ESG401|Administered via intravenous (IV) infusion
79226873|NCT04891809|Drug|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
79369571|NCT01672125|Other|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
79680054|NCT00523406|Procedure|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
79680055|NCT03457662|Combination Product|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
79369572|NCT01720576|Drug|REGN1033 (SAR391786)|
79369573|NCT01720576|Drug|Placebo|
79678262|NCT04514354|Behavioral|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
79678263|NCT00520338|Drug|celecoxib|"placebo~celecoxib 400 mg oral single dose"
79823071|NCT02558127|Genetic|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
79226874|NCT04891809|Drug|Lenalidomide|"Induction: 25mg*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) < 50 mL/min) starting dose is 10 mg"
79823072|NCT00763191|Other|examination of ocular movements|
79226875|NCT04891809|Drug|Dexamethasone Oral|"Induction:~Patients aged <75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
79823073|NCT00763191|Other|MATTIS test|
79369574|NCT01833364|Procedure|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
79823074|NCT00763191|Other|UPDRS test|
79823075|NCT00763191|Other|CRST test|
79823076|NCT00759993|Drug|chromium piccolinate|1000mg tab
79823077|NCT00759993|Drug|placebo for chromium piccolinate|
79823078|NCT00673881|Drug|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
79823079|NCT00763347|Drug|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
79823080|NCT00763347|Drug|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
79823081|NCT00763347|Drug|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
79823082|NCT00763347|Drug|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
79823083|NCT00763347|Drug|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
79823084|NCT00763347|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
79823085|NCT00767793|Drug|Placebo|One drop in each eye every 12 hours for seven days
79823086|NCT00767793|Drug|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
79226876|NCT04883242|Drug|Carfilzomib|Given IV
79226877|NCT04883242|Drug|Dexamethasone|Given PO or IV
79226878|NCT04883242|Biological|Isatuximab|Given IV
79226879|NCT04883242|Drug|Pomalidomide|Given PO
79226880|NCT04881019|Device|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
79369575|NCT01720654|Behavioral|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
79523707|NCT01279590|Drug|Placebo|2 placebo capsules twice daily for 12 weeks
79523708|NCT01271790|Drug|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
79523709|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
79823087|NCT00767793|Drug|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
79226881|NCT04864067|Drug|Oxaliplatin|Consolidation Chemotherapy
79226882|NCT04864067|Drug|5-Fluoracil|Consolidation Chemotherapy
79523710|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
79226883|NCT04864067|Drug|Leucovorin|Consolidation Chemotherapy
79226884|NCT04864067|Drug|Capecitabine|Consolidation Chemotherapy
79226885|NCT04864067|Radiation|5x5 Gy|Neoadjuvant Radiotherapy
79226886|NCT04864067|Behavioral|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
79226887|NCT04864067|Procedure|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
79226888|NCT04859504|Device|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
79226889|NCT04856176|Drug|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
79226890|NCT04856176|Drug|Pembrolizumab|200mg every 3 weeks
79226891|NCT04856176|Drug|pemetrexed|500mg/m2
79523711|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
79523712|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg QD
79523713|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
79523714|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
79523715|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
79369576|NCT00911326|Drug|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
79823088|NCT00767793|Drug|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
79523716|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
79523717|NCT01271790|Drug|GS-9451 placebo|placebo matching GS-9451 tablet QD
79523718|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
79369577|NCT01833676|Drug|Sevoflurane|
79369578|NCT01833676|Drug|Desflurane|
79226892|NCT04856176|Drug|Paclitaxel|200mg/m2
79226893|NCT04856176|Drug|Carboplatin|AUC 5/6
79523719|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
79523720|NCT01270152|Drug|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
79523721|NCT01274988|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
79523722|NCT01274988|Other|methadone maintenance treatment|methadone maintenance treatment
79226894|NCT04853277|Behavioral|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
79369579|NCT01720732|Behavioral|Lifeline NET|Short Version of Narrative Exposure Therapy
79523723|NCT01278498|Drug|Escitalopram|first week:5mg 2nd week~12 week:10mg
79523724|NCT01278498|Drug|sugar pill|first week:5mg 2nd week~12 weeks:10mg
79523725|NCT01279980|Other|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
79369580|NCT03210844|Procedure|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
79523726|NCT01279980|Other|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
79678264|NCT04694391|Genetic|whole exome sequence|To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
79369581|NCT04380376|Drug|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
79369582|NCT04380376|Other|Standard of care|the patients will receive only SOC (standard of care) treatment
79369583|NCT04380298|Drug|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
79369584|NCT04380298|Drug|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
79369585|NCT04380298|Drug|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
79678265|NCT00520377|Drug|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
79823089|NCT00767871|Drug|Lexapro|12 week treatment with lexapro
79823090|NCT00760149|Drug|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
79823091|NCT00767949|Biological|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
79823092|NCT00671853|Drug|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
79823093|NCT00671853|Drug|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
79369586|NCT04164849|Drug|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
79369587|NCT04164849|Procedure|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
79369588|NCT04164849|Procedure|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
79369589|NCT04164849|Procedure|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
79523727|NCT00249834|Drug|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
79523728|NCT00249834|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
79523729|NCT00249444|Drug|Mirtazapine|Mirtazapine
79369590|NCT01833910|Other|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
79369591|NCT01833910|Other|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
79523730|NCT00249444|Drug|Placebo|placebo
79523731|NCT00249288|Drug|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
79523732|NCT00249288|Drug|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
79523733|NCT00247962|Drug|etanercept|50 mg
79678266|NCT00520377|Device|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
79678267|NCT00519051|Other|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
79678268|NCT02948946|Procedure|NETest|5 mL of blood will be drawn from participants for testing.
79678269|NCT00520416|Procedure|Carbon dioxide angiogram|see description of procedure
79678270|NCT02948673|Dietary Supplement|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
79678271|NCT02948673|Other|Placebo|4 oral placebo tablets for 4 weeks
79678272|NCT02597075|Other|standard therapy + physical activity program|
79678273|NCT02597075|Other|standard therapy|
79678274|NCT04694118|Other|rebound therapy|3 days a week in 12 weeks
79678275|NCT00519129|Device|3D-imager|3D-imager vs fluoroscopy during coloscopy
79678276|NCT00519168|Procedure|Urine sample|Standard of care
79678277|NCT00519168|Device|Electrode sleep recorder|Standard of care
79823094|NCT00760227|Other|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
79678278|NCT00519168|Procedure|phlebotomy|Standard of care
79678279|NCT02275832|Drug|3 % Minoxidil lotion|
79823095|NCT00760227|Other|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
79823096|NCT00760227|Other|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
79823097|NCT00768105|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
79823098|NCT00768105|Drug|Placebo|Dosing to match AZD1656
79823099|NCT00768183|Drug|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
79823100|NCT00768183|Drug|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
79369592|NCT03210610|Diagnostic Test|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
79523734|NCT00247962|Drug|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
79523735|NCT00247416|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
79523736|NCT00247416|Drug|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
79523737|NCT00247416|Drug|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
79823101|NCT00768183|Drug|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
79823102|NCT00768183|Drug|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
79823103|NCT00763425|Procedure|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
79823104|NCT00763425|Procedure|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
79823105|NCT00760305|Behavioral|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
79823106|NCT00768339|Drug|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
79369593|NCT01720888|Other|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
79369594|NCT01672281|Other|vibrox- vs. resistance training|Comparison between two exercise interventions
79369595|NCT01834066|Biological|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
79369596|NCT03152955|Drug|Ketamine|Ketamine will be applied in patient-controlled analgesia.
79523738|NCT00246090|Drug|E7389|E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
79678280|NCT02275832|Drug|Placebo|
79678281|NCT00519207|Drug|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
79678282|NCT00519207|Drug|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
79369597|NCT03152955|Other|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
79369598|NCT03152955|Drug|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
79678283|NCT02590094|Drug|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
79678284|NCT00520455|Drug|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
79678285|NCT02275871|Other|MRI|High risk screening MRI will be performed as part of the patient's routine care.
79678286|NCT02275871|Other|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
79678287|NCT02948439|Other|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
79678288|NCT02590757|Device|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
79678289|NCT02590757|Device|N-CPAP|Nasal-continuous positive airway pressure
79678290|NCT02949375|Drug|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
79678291|NCT02949375|Drug|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
79678292|NCT02949375|Drug|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
79523739|NCT00246012|Drug|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
79523740|NCT00246012|Drug|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
79678293|NCT04514432|Other|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
79523741|NCT00246012|Drug|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
79823107|NCT00768417|Behavioral|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
79823108|NCT00768417|Behavioral|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
79226895|NCT04849806|Diagnostic Test|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
79226896|NCT04849806|Diagnostic Test|OSA severity|OSA is defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h) and sleep architecture
79369599|NCT03152955|Drug|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
79523742|NCT00245856|Drug|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
79523743|NCT00245856|Drug|Warfarin|Titrated to INR 2-3 through study month 3
79226897|NCT04849806|Diagnostic Test|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
79523744|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
79226898|NCT04849806|Diagnostic Test|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis.
79523745|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
79523746|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
79523747|NCT00244764|Drug|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
79823109|NCT00768417|Behavioral|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
79226899|NCT04849806|Diagnostic Test|Assessment of systemic inflammation|Based on blood samples taken.
79369600|NCT01720966|Procedure|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
79369601|NCT01676493|Drug|Codeine|
79523748|NCT00244764|Drug|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
79678294|NCT02949180|Device|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
79678295|NCT02598947|Other|Manual therapy|Exercise, behaviour change interventions and manual therapy
79678296|NCT02949258|Drug|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
79678297|NCT02949258|Drug|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
79823110|NCT02557581|Other|No training|
79823111|NCT02557581|Other|Endurance training|
79823112|NCT02557581|Other|Resistance Training|
79823113|NCT02557581|Drug|Terbutaline|
79823114|NCT02557581|Drug|Clenbuterol|
79226900|NCT04837755|Diagnostic Test|Cytokine measurements|The serum concentrations of multiple cytokines are measured.
79226901|NCT04828967|Other|Hypnosis|Hypnosis is added to the conventional group
79226902|NCT04824677|Other|Hospital treatment of COVID disease|Hospital treatment of COVID disease
79226903|NCT04819425|Device|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
79226904|NCT04819425|Device|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
79226905|NCT04814355|Drug|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
79369602|NCT01721434|Drug|Levosimendan|
79369603|NCT01721434|Drug|Placebo|Similar coloured placebo
79369604|NCT01721512|Other|Breastfeeding|
79369605|NCT01721512|Other|Infant formula|
79369606|NCT02563431|Device|SYSTAM - SP-ED|"Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~Daily passive mobilisation of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
79523749|NCT00244374|Biological|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
79523750|NCT00244374|Behavioral|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
79369607|NCT02563431|Device|Ultrasling ER 15°Donjoy - 4P-ED|"Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~A training of the patient and members of family on pathology, risk, use of material~Daily passive mobilization of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
79523751|NCT00244374|Behavioral|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
79678298|NCT02949258|Drug|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
79678299|NCT02949258|Drug|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
79823115|NCT02557581|Drug|Placebo|
79678300|NCT04514081|Drug|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
79678301|NCT04514081|Drug|Decitabine+Camrelizumab|Decitabine+Camrelizumab
79823116|NCT04077944|Diagnostic Test|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
79823117|NCT02558751|Biological|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
79823118|NCT02558751|Biological|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
79226906|NCT04812691|Biological|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
79226907|NCT04809558|Behavioral|Tongue resistance exercise|Participant will complete tongue resistance exercises.
79226908|NCT04802564|Other|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
79226909|NCT04802434|Behavioral|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
79369608|NCT03210532|Drug|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
79369609|NCT03210532|Drug|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
79369610|NCT03210532|Drug|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
79678302|NCT02948517|Other|Time restricted feeding|Time restricted feeding
79823119|NCT00768573|Drug|sildenafil|Oral suspension of sildenafil.
79823120|NCT02558361|Drug|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. [30mg po BID after initial titration]
79823121|NCT02558595|Dietary Supplement|Niacinamide|
79823122|NCT02558595|Other|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
79823123|NCT02585024|Drug|Cytisine|
79823124|NCT00760695|Drug|dronabinol|tablets, twice daily, for 4 weeks
79823125|NCT00760695|Drug|placebo|tablets, twice daily, for 4 weeks
79823126|NCT04048629|Device|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
79823127|NCT04048629|Other|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
79823128|NCT02582372|Drug|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
79823129|NCT02582372|Drug|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
79369611|NCT03210454|Other|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
79369612|NCT03210454|Other|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
79369613|NCT05119413|Drug|New trio de Kligman|Once daily application in addition to the same sunscreen
79997753|NCT02013167|Drug|Standard of Care Chemotherapy|"FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 & 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 & 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
79369614|NCT05119413|Drug|Trio Kligman|Once daily application in addition to the same sunscreen
79678303|NCT04514120|Other|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site [left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
79997754|NCT03805737|Other|Amulez and sunlight|Amulez and sun exposure for 2 hours
79997755|NCT03805737|Other|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
79997756|NCT01378533|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d*8cycles
79369615|NCT01834378|Behavioral|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
79369616|NCT01834378|Behavioral|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
79523752|NCT00244374|Behavioral|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
79523753|NCT00242658|Behavioral|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
79369617|NCT03152565|Drug|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
79523754|NCT00242580|Drug|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
79523755|NCT00242580|Drug|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
79678304|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
79369618|NCT01721590|Drug|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
79369619|NCT01721590|Drug|placebo|3 capsules/time，3times/day for 1 year
79369620|NCT05381181|Biological|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
79523756|NCT00242580|Drug|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
79523757|NCT00241644|Biological|Rotarix™|Two or Three doses, oral administration
79997757|NCT02630199|Drug|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
79997758|NCT02630199|Drug|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
79997759|NCT01378455|Other|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
79997760|NCT01378455|Other|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
79823130|NCT03926468|Diagnostic Test|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
79823131|NCT00768729|Drug|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
79226910|NCT04802434|Behavioral|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
79823132|NCT00768729|Drug|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
79823133|NCT04266080|Other|Fitbit Inspire HR|assessing step counts
79823134|NCT04266080|Other|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
79997761|NCT03759951|Behavioral|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
79997762|NCT03759951|Behavioral|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
79523758|NCT00241644|Biological|Placebo|One or three doses, oral administration.
79823135|NCT00760773|Drug|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
79997763|NCT03759951|Behavioral|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
79997764|NCT03759951|Behavioral|Control|No training will be performed during a 1-year period. Participation only in measurements.
79226911|NCT04798833|Device|Integrated Newborn Care Kit (iNCK)|"Contents of the integrated newborn care kit:~Clean birth kit: sterile blade, clean plastic sheet, plastic gloves, hand soap, cord ties/clamp, maternity pad to absorb post-natal bleeding, 10 cotton balls for applying Chlorhexidine (CHX) to the umbilical stump.~3x200 µg dissolvable tablets of misoprostol to be ingested prophylactically following delivery of the baby and before delivery of the placenta to prevent post-partum hemorrhage~4% CHX solution (15 mL)~Sunflower oil emollient (50 mL)~Temperature monitoring strip or sticker~Fleece blanket for the newborn~Click to heat warmer~Pictorial guide that illustrates how and when to use each kit component~Handheld electronic scale with suspended cloth sling (the scale will not be included with the kit but rather one will be issued to each Lady Health Worker in the experimental arm)~Other Names: Neonatal Care Kit"
79523759|NCT00245622|Biological|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
79523760|NCT00245622|Biological|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
79523761|NCT03800784|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
79523762|NCT03809754|Procedure|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
79523763|NCT03809754|Procedure|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
79678305|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
79997765|NCT04563065|Other|Exercise program|All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
79523764|NCT03809676|Other|periodontal examination|clinical measurements were recorded
79523765|NCT03809832|Diagnostic Test|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
79523766|NCT03808974|Other|Educational video|Short educational video describing the mid-urethral sling procedure
79523767|NCT03808974|Other|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
79523768|NCT03808896|Procedure|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
79523769|NCT03808896|Device|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
79523770|NCT03809130|Other|Internet-Based Intervention|Use Untire application after baseline up to 6 months
79678306|NCT04514042|Procedure|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
79678307|NCT04514042|Procedure|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
79678308|NCT00519246|Drug|Saline|Saline 5 ml administrated intravenously
79678309|NCT00519246|Drug|Opioid|Butorphanol tartrate 1 mg i.v.
79226912|NCT04793334|Procedure|sleeve gastectomy|routine sleeve gastrectomy
79226913|NCT04759716|Other|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
79369621|NCT01834456|Other|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
79523771|NCT03809130|Other|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
79523772|NCT03809130|Other|Quality-of-Life Assessment|Ancillary studies
79523773|NCT03809130|Other|Questionnaire Administration|Ancillary studies
79523774|NCT03808428|Device|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
79523775|NCT03808116|Device|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~To preserve sample unity, including core fragments in their original location along the needle notch.~Avoid sample damaging during sample removal from the needle and the following pathology process."
79678310|NCT00519246|Drug|Opioid|Butorphanol Tartrate 2 mg i.v.
79678311|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 50 mg i.v.
79369622|NCT03210142|Procedure|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
79369623|NCT03210064|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
79369624|NCT03210064|Drug|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
79369625|NCT00905554|Procedure|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
79369626|NCT00905554|Procedure|air insufflation|air insufflation during the insertion phase of colonoscopy
79523776|NCT03808038|Other|None- Observational Study|None- Observational Study
79678312|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 100 mg i.v.
79678313|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 10 mg i.v.
79678314|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 20 mg i.v.
79226914|NCT04759274|Device|Diuretic Tuner|Mobile device application for diuretic dose titration
79226915|NCT04748939|Biological|recombinant subunit herpes zoster vaccine|vaccine administration
79226916|NCT04735705|Device|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
79369627|NCT01721902|Device|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
79369628|NCT01721902|Other|Carrier Solution|Intra-myocardial injection of carrier solution
79369629|NCT01721980|Drug|GLPG0974|
79369630|NCT01721980|Drug|Placebo|
79369631|NCT05372991|Drug|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
79369632|NCT05372991|Drug|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
79369633|NCT05372991|Drug|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
79369634|NCT01672515|Device|RIPC group|
79678315|NCT00519987|Drug|intranasal ketamine|intranasal ketamine
79678316|NCT00519324|Drug|Everolimus|10 mg/day (2 tablets of 5 mg each)
79678317|NCT04514471|Other|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
79678318|NCT04514471|Other|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
79678319|NCT00520650|Drug|Aripiprazole|
79678320|NCT04513535|Other|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
79369635|NCT01672515|Device|Control group|
79523777|NCT03807960|Other|written form|The written form which include PCA usage information.
79523778|NCT03807960|Other|video|The video about PCA usage
79523779|NCT03807960|Other|routine care|The routine description about PCA usage
79678321|NCT04513535|Other|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
79823136|NCT00760773|Drug|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
79523780|NCT03807726|Behavioral|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
79678322|NCT04513535|Other|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
79678323|NCT04513535|Other|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
79523781|NCT03807570|Dietary Supplement|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
79523782|NCT03807570|Dietary Supplement|Placebo|Placebo 30 ml/day for 12 weeks.
79678324|NCT00519363|Drug|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
79997766|NCT04563065|Other|Healthy lifestyle advise|This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
79997767|NCT02588781|Drug|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
79997768|NCT01063062|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
79997769|NCT01063062|Drug|Methotrexate|methotrexate as per standard of care in clinical practice.
79997770|NCT04418739|Drug|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
79226917|NCT04735419|Other|No intervention|No intervention
79226918|NCT04732000|Drug|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
79226919|NCT04732000|Other|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
79369636|NCT00906178|Behavioral|CyberSenga|Internet-based HIV prevention program
79369637|NCT03152721|Device|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
79369638|NCT03152721|Other|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
79523783|NCT03807258|Other|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
79523784|NCT03807180|Other|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
79523785|NCT03806712|Other|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
79226920|NCT04713345|Other|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
79369639|NCT01722058|Drug|Peptide application|
79369640|NCT01722136|Behavioral|Low Dosage|Exercise dose of 8kcal/kg/week
79523786|NCT03807024|Diagnostic Test|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
79226921|NCT04713345|Other|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
79226922|NCT04684628|Drug|68Ga-PSMA PET/CT|Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
79226923|NCT04682158|Drug|Carboplatin|Given IV
79678325|NCT02595710|Other|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
79369641|NCT01722136|Behavioral|High Dosage|Exercise dose of 14kcal/kg/week
79997771|NCT01314989|Drug|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
79369642|NCT03863379|Diagnostic Test|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
79997772|NCT01314989|Drug|Sugar pill|liquid placebo
79369643|NCT01672593|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
79997773|NCT04483115|Drug|TPN171H|Tablets; Oral; Single dose
79369644|NCT01672593|Drug|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
79369645|NCT01672593|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
79369646|NCT01672593|Procedure|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
79369647|NCT03678831|Procedure|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
79523787|NCT03806868|Other|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
79523788|NCT03806868|Other|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
79523789|NCT03806478|Drug|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
79226924|NCT04682158|Radiation|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
79226925|NCT04682158|Drug|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
79226926|NCT04682158|Radiation|Intensity Modulated Radiation Therapy|Undergo IMRT
79226927|NCT04682158|Drug|Paclitaxel|Given IV
79226928|NCT04681807|Behavioral|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
79226929|NCT04681807|Behavioral|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
79226930|NCT04670315|Diagnostic Test|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
79226931|NCT04666831|Behavioral|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
79369648|NCT01834534|Behavioral|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
79369649|NCT04764279|Dietary Supplement|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
79369650|NCT01834612|Device|CM1500|blood volume monitor
79369651|NCT04404621|Behavioral|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
79369652|NCT03219034|Device|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
79523790|NCT03806478|Other|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
79523791|NCT03806010|Procedure|Quantitative sensory testing|Quantitative sensory testing
79523792|NCT03805776|Other|Fasting (diet restruction for specific period)|12-14 hours fasting
79523793|NCT03805620|Other|Combined physical-cognitive training|combined physical-cognitive training
79823137|NCT00760773|Drug|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
79226932|NCT04663607|Behavioral|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
79823138|NCT00768807|Device|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
79823139|NCT04077554|Genetic|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
79823140|NCT00768885|Device|PureVision 1|Currently marketed PureVision soft contact lens.
79226933|NCT04662580|Drug|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
79369653|NCT03219034|Device|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
79823141|NCT00768885|Device|PureVision 2|Alternate design soft contact lens.
79823142|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
79823143|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
79523794|NCT03805620|Other|Physical training|Multi-component physical exercise
79226934|NCT04662580|Drug|Enzalutamide|Enzalutamide is the FDA approved drug
79226935|NCT04658160|Behavioral|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
79226936|NCT04653064|Behavioral|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
79226937|NCT04653064|Behavioral|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
79226938|NCT04651504|Other|Colorectal Cancer Toolkit|The intervention toolkit will include patient education materials and supportive materials for providers. Tracking systems and supports will be jointly developed with participating clinic and providers, in order to maximize their existing systems and develop processes that meet their needs and preferences, and training will be offered to help providers/teams efficiently use the tracking system and clinic resources. The study team will provide technical assistance and support through email, phone and zoom to support the clinic in their implementation process.
79226939|NCT04648241|Biological|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
79226940|NCT04648241|Biological|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
79523795|NCT03805620|Other|Cognitive training|cognitive training
79523796|NCT03805542|Combination Product|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
79523797|NCT03805152|Drug|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
79823144|NCT00769041|Drug|moxifloxacin|400mg
79823145|NCT00769041|Drug|avanafil|100mg single dose
79226941|NCT04646460|Behavioral|Observed Success|"The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain."
79226942|NCT04646460|Behavioral|Observed Failure|The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
79523798|NCT03805152|Drug|Dysport (R)|Intramuscular injection
79523799|NCT03804840|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication (Broyd et al, 2016; Hartman and Huestis, 2013).
79823146|NCT00769041|Drug|avanafil|800mg single dose
79823147|NCT00769041|Drug|sugar pill|single dose
79823148|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
79823149|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
79226943|NCT04646460|Behavioral|Experienced Success|The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
79226944|NCT04646460|Behavioral|Experienced Failure|The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
79226945|NCT04642469|Drug|Durvalumab|Intravenous administration of Durvalumab
79226946|NCT04642469|Other|Placebo|Placebo Comparator
79369654|NCT01722370|Drug|Oxygen|
79369655|NCT01722370|Drug|Medical air equivalent|
79523800|NCT03804840|Drug|Placebo|Placebo
79523801|NCT03804762|Procedure|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
79823150|NCT00763659|Dietary Supplement|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
79997774|NCT04483115|Drug|Placebo|Tablets; Oral; Single dose
79997775|NCT04483115|Drug|Tadalafil|Tablets; Oral; Single dose
79997776|NCT03569865|Device|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
79369656|NCT01721668|Behavioral|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
79523802|NCT03804450|Procedure|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
79997777|NCT04054362|Drug|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
79226947|NCT04630730|Drug|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
79226948|NCT04630730|Drug|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
79226949|NCT04630730|Drug|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
79226950|NCT04630730|Drug|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
79523803|NCT03804372|Drug|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
79523804|NCT03804372|Drug|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
79226951|NCT04630249|Behavioral|Listening to Women|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
79226952|NCT04627701|Device|Omega|Omega Implantation
79226953|NCT04624126|Device|3D-Erect|3D-printed erectile device for intercourse
79523805|NCT03804372|Drug|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
79523806|NCT03803982|Procedure|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
79523807|NCT03803982|Drug|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
79523808|NCT03804216|Other|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
79523809|NCT03803670|Diagnostic Test|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
79523810|NCT03803514|Drug|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
79523811|NCT03803358|Other|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
79523812|NCT03803358|Other|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
79523813|NCT03803124|Drug|Tolvaptan|1 tablet before renography
79523814|NCT03803124|Drug|Placebo|1 tablet before renography
79678326|NCT02595710|Other|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
79678327|NCT02595710|Other|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
79678328|NCT00519402|Other|tonsillar examination and questionnaire completion|
79997778|NCT04054362|Drug|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
79226954|NCT04614779|Drug|CN128 Tablets|Iron chelator, oral tablets
79226955|NCT04614584|Drug|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
79226956|NCT04614584|Drug|Methamphetamine|Methamphetamine 30 mg IV once
79226957|NCT04609644|Other|Digital Tools for Asthma Self-Management|Please see description of active study arm.
79226958|NCT04606264|Drug|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
79369657|NCT01721668|Behavioral|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
79369658|NCT04764435|Other|Physician ownership|"The intervention or exposure is whether the dialysis facility was owned by a physician in 2017"
79369659|NCT04764435|Other|Large dialysis organization ownership|"The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017"
79369660|NCT01722448|Dietary Supplement|Choline|4 capsules with 480 mg choline per day
79369661|NCT01722448|Dietary Supplement|Placebo|
79369662|NCT01834768|Drug|Eplerenone|
79997779|NCT04054362|Drug|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
79997780|NCT04054362|Drug|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
79997781|NCT04467281|Drug|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
79523815|NCT03802734|Device|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
79369663|NCT01672671|Drug|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
79369664|NCT01722682|Biological|Human pancreatic islet transplantation|
79823151|NCT04077476|Behavioral|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
79823152|NCT04077476|Behavioral|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
79823153|NCT00760851|Other|probiotic strain Bb-12|10^9 CFU Bb-12 per 4 oz yogurt
79823154|NCT00760851|Other|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
79823155|NCT04019678|Procedure|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
79226959|NCT04606264|Drug|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
79226960|NCT04606264|Drug|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
79226961|NCT04606264|Drug|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
79369665|NCT02463981|Device|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
79369666|NCT02459457|Drug|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
79369667|NCT02459457|Drug|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
79369668|NCT02459457|Drug|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
79523816|NCT03802500|Diagnostic Test|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is < 2,5 mV."
79678329|NCT02591030|Drug|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~Cisplatin 25 mg/m² over 1 hour at D1 and D8~Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
79226962|NCT04606264|Drug|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
79369669|NCT02459457|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
79823156|NCT00770445|Drug|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
79369670|NCT01835236|Drug|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
79226963|NCT04606264|Drug|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
79226964|NCT04606264|Drug|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
79226965|NCT04606264|Drug|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
79226966|NCT04605263|Device|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
79226967|NCT04605263|Procedure|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
79369671|NCT01835236|Drug|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
79369672|NCT01835236|Drug|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
79523817|NCT03802032|Drug|Lidocaine Gel|topical lidocaine gel
79523818|NCT03802032|Drug|KY jelly|topical KY jelly
79678330|NCT02591030|Drug|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~Oxiplatin: 85 mg/m² (IP/120 minutes)~Irinotecan: 180 mg/m² (IV/90 minutes)~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan~5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
79678331|NCT00519441|Other|pH study|All patients will have 48 hour pH study
79678332|NCT02955017|Behavioral|traditional follow_up|"Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~Two days of a complete medical check at 9 and 15 months"
79678333|NCT02955017|Behavioral|"distance follow-up new technologies"|"Multidisciplinary support with long distance monitoring Mobile apps.~Two days of a complete medical check at 9 and 15 months"
79523819|NCT03802266|Device|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
79369673|NCT01835236|Drug|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
79523820|NCT03802266|Device|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
79678334|NCT00519480|Drug|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
79523821|NCT03801798|Drug|GC1102|NAs antivirals+GC1102 180,000 IU
79523822|NCT03801798|Other|GC1102 Placebo|NAs antivirals+GC1102 Placebo
79523823|NCT03801252|Drug|Cefazolin|intravenous drugs used as prophylactic antibiotics
79997782|NCT04467281|Diagnostic Test|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
79997783|NCT04350879|Other|Data record|Data record
79226968|NCT04604782|Drug|Regadenoson|Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
79226969|NCT04603781|Dietary Supplement|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
79226970|NCT04603781|Dietary Supplement|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
79678335|NCT00519480|Drug|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
79226971|NCT04603781|Dietary Supplement|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
79226972|NCT04603781|Dietary Supplement|Placebo Oil|MCT Oil with mint flavoring
79226973|NCT04602598|Drug|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
79678336|NCT00519480|Drug|Placebo|Placebo will be available as an oral tablets.
79678337|NCT04696211|Other|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
79678338|NCT00520689|Device|Silicone Hydrogel Contact Lens|use of lens over 2 days
79678339|NCT02955056|Drug|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
79678340|NCT00520728|Behavioral|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
79678341|NCT02954939|Drug|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
79678342|NCT02954939|Drug|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
79823157|NCT00770445|Drug|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
79823158|NCT00770445|Drug|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
79997784|NCT03652194|Other|in vitro evaluation of epithelial immune response during C. glabrata infection|"study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~study of protein expression by the Western-Blot method"
79997785|NCT03652194|Other|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~in vivo evaluation measured by a survival study on a CD-1 mouse model."
79997786|NCT04322019|Other|Data record|Data record
79997787|NCT04315467|Drug|SGM-101|A one-time infusion of SGM-101
79226974|NCT04601376|Behavioral|Mobile Monitoring Tool|a text-messaged based outcomes collection system
79226975|NCT04593862|Other|High-Intensity Interval Training|The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
79226976|NCT04589832|Drug|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
79369674|NCT01835236|Drug|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
79369675|NCT01671891|Radiation|radiation therapy|45-55Gy
79369676|NCT01671891|Drug|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
79369677|NCT05025111|Device|Entia Liberty|Home monitoring device
79369678|NCT03835468|Dietary Supplement|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
79369679|NCT03835468|Dietary Supplement|Maltodextrin|sugar based placebo
79523824|NCT03801252|Drug|Placebo|Intravenous saline
79523825|NCT03801252|Drug|Azithromycin|prophylactic antibiotic
79678343|NCT00519519|Drug|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
79678344|NCT00520806|Drug|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
79678345|NCT00520806|Drug|Placebo|Intravenous infusion for 48 h
79678346|NCT00505739|Drug|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
79678347|NCT00519597|Device|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
79678348|NCT00519558|Drug|somatropin|
79678349|NCT05149820|Other|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
79678350|NCT05149820|Drug|Magnesium|Liberal Strategy: magnesium supplementation at serum level < 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level < 1.0 mmol/L
79369680|NCT01830088|Behavioral|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
79369681|NCT01830088|Behavioral|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
79823159|NCT04077398|Drug|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
79823160|NCT00763737|Procedure|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
79823161|NCT04078256|Other|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
79369682|NCT01830166|Radiation|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
79369683|NCT01830322|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
79823162|NCT04078256|Other|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
79678351|NCT02948985|Other|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
79678352|NCT04513457|Other|Liver resection and Neoadjuvant chemotherapy|
79369684|NCT01830322|Drug|Gemcitabine|
79369685|NCT01830322|Drug|Any non-gemcitabine chemotherapies or best supportive care|
79369686|NCT01835314|Drug|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
79369687|NCT03150069|Other|Interview|In-person or telephone in-depth interview
79678353|NCT04513457|Other|Liver resection and Adjuvant chemotherapy|
79678354|NCT04513457|Other|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
79678355|NCT04513457|Procedure|Liver resection|
79678356|NCT02276339|Other|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
79678357|NCT00521040|Drug|Levocetirizine dihydrochloride|
79823163|NCT04079972|Behavioral|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
79823164|NCT04079972|Behavioral|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
79823165|NCT04048707|Drug|Angiotensin II|Intravenous
79823166|NCT04048707|Drug|Midodrine|Pill
79823167|NCT04048707|Drug|Octreotide|Subcutaneous
79823168|NCT04048707|Drug|Albumin solution|Intravenous suspension
79823169|NCT05346458|Device|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
79997788|NCT04315467|Device|Near infrared camera imaging system|Near infrared camera imaging system
79997789|NCT01785342|Other|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
79369688|NCT01722760|Procedure|measurements|
79369689|NCT03427281|Behavioral|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
79369690|NCT01722838|Behavioral|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
79369691|NCT01835392|Procedure|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
79369692|NCT01835392|Other|Control|Sham placement of blood pressure cuff without inflation
79369693|NCT01672905|Other|laboratory biomarker analysis|
79369694|NCT01725646|Drug|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
79369695|NCT01725646|Drug|Placebo|Subjects in placebo group will take this drug
79369696|NCT03293745|Behavioral|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
79369697|NCT03293745|Behavioral|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
79369698|NCT01835704|Other|Radio-frequency dennervation of facet joint|
79369699|NCT01835704|Other|Diagnostic nerve-blocks performed under direct x-ray vision|
79523826|NCT03801018|Other|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
79678358|NCT04513730|Other|Rehabilitation|A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
79369700|NCT03243669|Diagnostic Test|High-definition|High-definition colonoscopy
79369701|NCT03243669|Diagnostic Test|Virtual chromoendoscopy|Virtual chromoendoscopy
79369702|NCT03243669|Diagnostic Test|Standard|Standard colonoscopy
79523827|NCT03801096|Behavioral|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry & Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White & Epston, 1990).
79523828|NCT03801096|Behavioral|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
79523829|NCT03800706|Drug|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
79226977|NCT04589832|Drug|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
79226978|NCT04589312|Biological|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
79369703|NCT00915148|Other|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
79369704|NCT04937127|Behavioral|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
79369705|NCT04937127|Other|usual care|usual care
79523830|NCT03800628|Other|qualitative study|semi-structured interviews
79523831|NCT03800550|Drug|Bedaquiline|Bedaquiline tablet will be administered, orally.
79523832|NCT03800550|Drug|Clarithromycin|Clarithromycin tablet will be administered, orally.
79678359|NCT00521118|Other|Laboratory Biomarker Analysis|Correlative studies
79823170|NCT03925844|Other|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
79823171|NCT00769353|Behavioral|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
79369706|NCT01725724|Procedure|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
79678360|NCT00521118|Procedure|Therapeutic Conventional Surgery|Undergo second curettage
79823172|NCT00769353|Behavioral|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
79369707|NCT01725724|Procedure|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
79523833|NCT03800472|Drug|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
79523834|NCT03800472|Drug|Placebo|Placebo tablets
79523835|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
79678361|NCT04694235|Dietary Supplement|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
79823173|NCT00769431|Other|educational intervention|
79823174|NCT00769431|Other|study of socioeconomic and demographic variables|
79997790|NCT01378143|Drug|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
79226979|NCT04589312|Biological|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
79226980|NCT04585308|Device|transShield Embolic Protection System|Used for embolic protection during TAVR.
79369708|NCT01673139|Behavioral|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
79369709|NCT01673139|Behavioral|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
79369710|NCT01673139|Behavioral|Control|Given information on recommendations for physical activity.
79369711|NCT01725880|Other|Observation|
79369712|NCT04379362|Procedure|Focal laser ablation|Focal laser ablation
79226981|NCT04573192|Drug|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
79369713|NCT03153969|Device|SHOFU Beautifil II LS|Placed under manufacturer's instructions
79678362|NCT04513340|Drug|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
79997791|NCT05073107|Other|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~Day 0 (To be taken at the clinic)~Day 7 (To be taken in the evening after brushing teeth)~Day 14 (To be taken in the evening after brushing teeth)~Day 21(To be taken in the evening after brushing teeth)~Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
79997792|NCT02973048|Drug|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
79678363|NCT02949063|Behavioral|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
79823175|NCT00763893|Drug|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
79823176|NCT00763893|Drug|Losartan|50 mg/day if < weight 50 kg 100 mg/day if weight > 50 kg
79823177|NCT04019366|Other|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
79997793|NCT02973048|Drug|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
79997794|NCT05028413|Behavioral|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
79226982|NCT04573192|Drug|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
79226983|NCT04570891|Procedure|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
79226984|NCT04570891|Procedure|Control|No regional block is provided at the end of surgery.
79678364|NCT04513379|Drug|Efavirenz 600mg|EFV 600 mg per day given orally
79226985|NCT04564521|Drug|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
79369714|NCT03153969|Device|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
79678365|NCT04513379|Drug|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
79678366|NCT05142839|Procedure|EUS-CD|EUS-guided choledochoduodenostomy
79678367|NCT05142839|Procedure|EUS-GEA|EUS-guided gastroenterostomy
79226986|NCT04564521|Drug|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
79226987|NCT04559919|Other|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
79226988|NCT04559919|Diagnostic Test|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
79369715|NCT01706198|Drug|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
79369716|NCT01706198|Drug|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
79369717|NCT03079323|Radiation|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
79369718|NCT01835860|Procedure|Prostate artery embolization|
79369719|NCT04378972|Other|curcumin, homotaurine, vitamin D3|ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
79369720|NCT04378972|Other|control|ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
79369721|NCT01723150|Drug|Ciprofloxacin|
79369722|NCT01723150|Drug|Ceftriaxone|
79369723|NCT01723150|Drug|Trimethoprim/sulfamethoxazole|
79369724|NCT01723150|Drug|Ertapenem|
79369725|NCT01725958|Dietary Supplement|Nutritional supplement and protein shakes|
79678368|NCT00521157|Drug|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
79678369|NCT04694352|Other|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
79678370|NCT04694352|Other|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
79369726|NCT01835938|Drug|1- Erlotinib|"Erlotinib 50 mg tablet by mouth every day for 14 days,~Erlotinib 100 mg tablet by mouth every day for 14 days,~Erlotinib 150 mg tablet by mouth every day for 14 days,"
79369727|NCT01835938|Drug|placebo|"Placebo 50 mg tablet by mouth every day for 14 days,~Placebo 100 mg tablet by mouth every day for 14 days,~Placebo 150 mg tablet by mouth every day for 14 days,"
79369728|NCT01726114|Device|Non-invasive Optical Glucose Monitor™|Test device
79678371|NCT00505817|Drug|Cetrorelix and Leuprolide|
79226989|NCT04559919|Other|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
79997795|NCT04110405|Behavioral|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
79369729|NCT01726114|Device|YSI blood glucose analyzer|Reference device
79369730|NCT01836016|Drug|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
79678372|NCT02948595|Other|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
79678373|NCT02948595|Other|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
79369731|NCT01836016|Drug|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
79369732|NCT01836016|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
79369733|NCT01836016|Drug|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
79369734|NCT01836016|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
79369735|NCT01836016|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
79369736|NCT01836016|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
79369737|NCT01836016|Drug|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
79523836|NCT03800472|Drug|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
79523837|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
79523838|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
79523839|NCT03800472|Drug|Placebo|Placebo optimized tablets
79523840|NCT03800316|Device|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
79678374|NCT04513262|Procedure|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
79678375|NCT00521391|Other|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
79678376|NCT00521430|Biological|anti-thymocyte globulin|
79678377|NCT00521430|Drug|busulfan|
79678378|NCT00521430|Drug|cyclosporine|
79678379|NCT00521430|Drug|fludarabine phosphate|
79678380|NCT00521430|Drug|methotrexate|
79678381|NCT00521430|Drug|methylprednisolone|
79678382|NCT00521430|Procedure|allogeneic hematopoietic stem cell transplantation|
79678383|NCT00521430|Procedure|peripheral blood stem cell transplantation|
79823178|NCT04019366|Other|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
79997796|NCT04110405|Behavioral|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
79997797|NCT02932943|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
79226990|NCT04559919|Other|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
79226991|NCT04559919|Other|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
79226992|NCT04557995|Procedure|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
79226993|NCT04524013|Other|There is no intervention. It is an observational study.|There is not intervention
79823179|NCT00770835|Drug|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
79997798|NCT02932943|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
79226994|NCT04518124|Drug|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
79226995|NCT04515095|Other|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
79369738|NCT04378816|Other|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
79369739|NCT01723306|Genetic|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
79369740|NCT01836094|Drug|Methylene Blue (USP grade, 280mg oral)|
79369741|NCT01836094|Drug|Placebo|oral, one time
79369742|NCT01705730|Drug|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
79369743|NCT01726192|Procedure|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
79369744|NCT01726192|Procedure|Placement of a femoral neurostimulating catheter|
79369745|NCT01836172|Drug|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
79369746|NCT01836328|Drug|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
79678384|NCT00521196|Device|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
79678385|NCT00521469|Device|Pro Adjuster|
79678386|NCT00505973|Drug|SCA-136|
79369747|NCT01836328|Drug|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
79997799|NCT04054206|Drug|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
79997800|NCT03603938|Drug|potassium losartan|treated with bedtime or awakening doses of potassium losartan
79226996|NCT04507685|Other|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
79678387|NCT00521274|Biological|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
79678388|NCT00521274|Drug|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
79678389|NCT05146778|Procedure|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
79678390|NCT05146778|Procedure|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
79997801|NCT03652116|Drug|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
79997802|NCT03652116|Drug|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
79997803|NCT03603860|Device|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
79997804|NCT03602144|Other|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
79997805|NCT03602144|Other|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
79997806|NCT03603782|Dietary Supplement|2.5% protein|2.5%
79369748|NCT01726348|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
79369749|NCT01726426|Dietary Supplement|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
79678391|NCT04694430|Procedure|Blood sample|2 ml venous blood was collected and separated into serum.
79997807|NCT03603782|Dietary Supplement|protein 5%|5%
79997808|NCT03603782|Dietary Supplement|protein 10%|10%
79823180|NCT00770835|Drug|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
79997809|NCT03603782|Dietary Supplement|protein 15%|15%
79997810|NCT03603782|Dietary Supplement|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
79997811|NCT03603782|Dietary Supplement|B2: only breakfast (no product)|only breakfast
79997812|NCT03603782|Dietary Supplement|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
79226997|NCT04504136|Procedure|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
79226998|NCT04487834|Drug|Simethicone Solution|Oral daily treatment for four weeks
79369750|NCT04379128|Other|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
79226999|NCT04487834|Dietary Supplement|Vivatlac Baby|Oral daily treatment for four weeks
79369751|NCT04378894|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
79523841|NCT03805698|Device|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
79678392|NCT04694430|Other|Data collection|"Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~Assess COPD using ABCD assessment tool."
79678393|NCT04694430|Procedure|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
79678394|NCT00505700|Drug|velcade|
79678395|NCT00505700|Drug|Idarubicin|
79678396|NCT00505700|Drug|Cytarabine|
79678397|NCT04694274|Device|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
79678398|NCT04694274|Procedure|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
79678399|NCT04694274|Device|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
79678400|NCT02948283|Other|Laboratory Biomarker Analysis|Correlative studies
79997813|NCT03603782|Dietary Supplement|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
79678401|NCT02948283|Drug|Metformin Hydrochloride|Given PO
79523842|NCT03805698|Other|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
79523843|NCT03804684|Diagnostic Test|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
79678402|NCT02948283|Other|Pharmacological Study|Correlative studies
79678403|NCT02948283|Drug|Ritonavir|Given PO
79678404|NCT02948283|Other|Quality-of-Life|Ancillary studies
79678405|NCT02948283|Other|Questionnaire|Ancillary studies
79678406|NCT02275910|Drug|E7090|
79997814|NCT01946867|Device|NBTXR3 activated by IMRT|
79997815|NCT01550315|Procedure|Pulsitile Arterial Tonometry (PAT) Protocol|"A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~Continuous recording of pulsatile blood volume responses from both hands will be initiated.~After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
79678407|NCT00521508|Procedure|gene transcription and cytometry|samply of 30 ml of blood
79227000|NCT04482634|Other|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
79227001|NCT04482634|Other|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
79227002|NCT04473716|Drug|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
79369752|NCT01705652|Drug|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
79369753|NCT01723540|Procedure|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
79523844|NCT03804684|Diagnostic Test|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
79678408|NCT00523146|Drug|Kanion Capsule|
79678409|NCT00506012|Drug|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
79678410|NCT04693728|Behavioral|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
79678411|NCT04512872|Biological|CT-P41|60 mg/mL single dose, Solution for injection in PFS
79523845|NCT05318430|Device|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
79678412|NCT04512872|Biological|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
79369754|NCT01836406|Drug|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
79678413|NCT00521547|Procedure|Electroacupuncture|
79678414|NCT05144867|Radiation|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
79823181|NCT04228016|Device|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
79823182|NCT00769509|Other|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
79823183|NCT00769509|Other|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
79823184|NCT00769587|Drug|thalidomide|
79997816|NCT01550315|Device|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
79369755|NCT01723618|Drug|CRD007|
79823185|NCT00769665|Other|Systane Ultra|Re-wetting ocular eye drop
79997817|NCT01550315|Device|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
79997818|NCT02972658|Drug|Lanabecestat|Administered orally
79678415|NCT05144672|Diagnostic Test|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
79823186|NCT00769665|Other|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
79369756|NCT01836484|Diagnostic Test|Diffusion-weighted MRI|
79369757|NCT01836484|Diagnostic Test|Fluorodeoxyglucose-18-PET/CT|
79369758|NCT01836484|Diagnostic Test|Fluoro-ethyl-coline-PET/CT|
79369759|NCT01836562|Biological|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
79369760|NCT01726816|Drug|Probucol 250mg/day|Probucol 250mg + Placebo
79823187|NCT00764049|Device|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
79823188|NCT04048083|Behavioral|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
79823189|NCT04048083|Behavioral|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
79369761|NCT01726816|Drug|Probucol 500mg/day|Probucol 500mg + Placebo
79369762|NCT01726816|Drug|Placebo|Probucol matching placebo
79369763|NCT01836796|Dietary Supplement|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
79369764|NCT01836796|Dietary Supplement|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
79369765|NCT01726894|Device|Irreversible Electroporation|
79523846|NCT05744154|Behavioral|Audit & feedback with educational outreach and facilitation|As in arm descriptions
79523847|NCT05744154|Behavioral|Simple audit & feedback (usual practice)|As in arm descriptions
79678416|NCT05144672|Other|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
79678417|NCT05144672|Procedure|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
79678418|NCT05144672|Other|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
79678419|NCT05144672|Other|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
79678420|NCT05144672|Diagnostic Test|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
79678421|NCT05144672|Radiation|Abdominal ultrasound.|It will be performed for patients only.
79678422|NCT02948166|Procedure|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
79823190|NCT04048083|Behavioral|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
79823191|NCT04048083|Other|No trainings|Healthy controls without any kind of training
79997819|NCT02853032|Device|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
79823192|NCT05674604|Procedure|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
79823193|NCT00570921|Drug|Everolimus|Everolimus tablets, two-5 mg tablets a day
79823194|NCT00570921|Drug|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
79997820|NCT02853032|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
79997821|NCT02853032|Device|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
79997822|NCT02232087|Drug|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
79997823|NCT02232087|Drug|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
79997824|NCT03168425|Other|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
79997825|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
79823195|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed.
79823196|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
79823197|NCT00769821|Other|questionnaire administration|
79823198|NCT00769821|Procedure|assessment of therapy complications|
79823199|NCT00769821|Procedure|bioimpedance spectroscopy|
79823200|NCT00769821|Procedure|quality-of-life assessment|
79227003|NCT04473716|Drug|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
79227004|NCT04473716|Drug|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
79369766|NCT00915538|Drug|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
79369767|NCT00915538|Device|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
79369768|NCT01836874|Drug|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
79823201|NCT04076930|Drug|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
79823202|NCT02557425|Other|No intervention in PROTECT|
79823203|NCT05233826|Biological|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
79823204|NCT00769899|Drug|AZD7325|Capsule for oral, single dose
79823205|NCT00769899|Drug|Placebo|Placebo capsule for oral, single dose
79823206|NCT00770055|Other|medical chart review|
79823207|NCT00770055|Other|questionnaire administration|
79823208|NCT00770055|Other|survey administration|
79997826|NCT00004445|Procedure|Surgery|
79997827|NCT00004445|Device|IRS-8|
79227005|NCT04473716|Procedure|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
79227006|NCT04473716|Radiation|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
79227007|NCT04469855|Drug|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
79227008|NCT04458259|Drug|PF-07265807|Given 2 weeks on/1 week off
79227009|NCT04458259|Drug|Sasanlimab|Given SC Q3W
79997828|NCT01380015|Other|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
79823209|NCT00770055|Procedure|psychosocial assessment and care|
79823210|NCT04048317|Drug|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
79823211|NCT04048317|Drug|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
79997829|NCT01380015|Other|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
79227010|NCT04458259|Drug|Axitinib|Dosed per package label starting with 5 mg PO BID
79227011|NCT04456621|Radiation|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
79523848|NCT05743920|Behavioral|Self-help Forest Bathing|The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
79678423|NCT02948166|Procedure|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
79227012|NCT04444973|Procedure|Balloon pulmonary angioplasty|Balloon dilatation of sub segmental pulmonary artery web disease
79227013|NCT04432623|Drug|Benserazide Only Product|Investigational drug
79369769|NCT01724086|Drug|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
79369770|NCT01724086|Drug|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
79369771|NCT01724086|Drug|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
79369772|NCT01724086|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
79523849|NCT05743530|Device|TENS - transcutaneous electrical nerve stimulation|Pre-operative day 1 till postoperative day 14.
79523850|NCT05743530|Other|Placebo|Pre-operative day 1 till postoperative day 14.
79523851|NCT05743452|Device|GBR with CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
79678424|NCT04694040|Device|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
79823212|NCT00764283|Device|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
79823213|NCT00764283|Device|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
79523852|NCT05743218|Other|electropuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675."
79823214|NCT00764283|Device|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
79823215|NCT02582294|Other|Questionnaire|
79823216|NCT04363034|Biological|Convalescent Plasma|1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma
79823217|NCT00920504|Behavioral|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
79997830|NCT03603704|Drug|LY3209590|Administered SC
79997831|NCT03603704|Drug|Placebo|Administered SC
79997832|NCT03652584|Other|High Protein Diet|
79227014|NCT04431258|Drug|ABTL0812|ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
79227015|NCT04431258|Drug|Folfirinox|"FOLFIRINOX will be dosed according to the standard following regimen:~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~leucovorin 400 mg/m2, administered as 2-hour iv infusion~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities."
79523853|NCT05742906|Device|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
79823218|NCT00920504|Other|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
79369773|NCT01724086|Drug|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
79523854|NCT05742750|Drug|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
79523855|NCT05742516|Dietary Supplement|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
79523856|NCT05742516|Dietary Supplement|Placebo|Maltodextrin powder
79523857|NCT05742360|Device|CPAP therapy|CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
79823219|NCT02584712|Other|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
79823220|NCT02582450|Other|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
79227016|NCT04431258|Drug|Placebo|Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
79369774|NCT01724086|Drug|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
79997833|NCT03652584|Other|Control Diet|
79523858|NCT05740878|Dietary Supplement|immunonutrients oral nutritional supplements|1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.
79523859|NCT05740878|Dietary Supplement|standard oral nutritional supplements|1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
79227017|NCT04426591|Drug|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of ~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
79227018|NCT04426591|Device|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
79369775|NCT00913510|Device|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
79369776|NCT00913510|Drug|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
79369777|NCT01727050|Device|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
79523860|NCT05740332|Drug|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
79523861|NCT05737992|Other|Exercise in water|"Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
79523862|NCT05557266|Behavioral|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
79678425|NCT04694469|Procedure|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
79678426|NCT04693923|Procedure|Fluid challenge|Fluid challenge according to the assigned group
79678427|NCT00523185|Drug|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
79678428|NCT00523185|Drug|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
79678429|NCT04512443|Drug|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
79678430|NCT04512404|Drug|HMG-CoA Reductase Inhibitor|
79227019|NCT04425616|Other|Exercise|"At least one and up to three supervised sessions per week including:~aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
79369778|NCT01727050|Device|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
79369779|NCT03836638|Drug|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
79678431|NCT04693962|Diagnostic Test|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
79678432|NCT05149118|Procedure|Polydeoxyribonucleotide (PDRN)|A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
79997834|NCT03330561|Drug|PRS-343|PRS-343
79369780|NCT03836638|Drug|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
79678433|NCT00521664|Biological|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
79997835|NCT03603626|Drug|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
79678434|NCT00521664|Biological|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
79678435|NCT00521703|Drug|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
79369781|NCT01727128|Drug|BKM120|
79997836|NCT03603626|Drug|Placebo oral capsule|Placebo administered 1 hour before surgery
79369782|NCT01727206|Drug|Tocilizumab|
79369783|NCT01724164|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
79369784|NCT01724164|Behavioral|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
79369785|NCT01724164|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
79678436|NCT00521703|Drug|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
79678437|NCT05144321|Other|Impact of environment upon obstetrical|Impact of environment upon obstetrical
79678438|NCT05144321|Other|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
79678439|NCT00523224|Procedure|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
79678440|NCT00523224|Biological|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
79678441|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
79678442|NCT00521742|Drug|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
79678443|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
79678444|NCT00521742|Drug|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
79997837|NCT03652038|Drug|TD-8236|Study drug to be administered via inhaler device
79997838|NCT03652038|Drug|Placebo|Placebo to be administered via inhaler device
79369786|NCT01724164|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
79369787|NCT01724164|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
79369788|NCT01724242|Drug|Vaginal DHEA|
79369789|NCT01724242|Drug|Placebo|
79369790|NCT01724320|Drug|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
79369791|NCT01837030|Dietary Supplement|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
79369792|NCT01837030|Device|Capsule Endoscopy|GIVEN capsule
79369793|NCT01837108|Drug|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
79369794|NCT01837108|Drug|Placebo|
79678445|NCT05144204|Behavioral|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
79678446|NCT05144165|Other|Experts consensus|Consensus opinion using Delphi Methodology
79678447|NCT00521781|Drug|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
79997839|NCT03651960|Other|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
79997840|NCT01377909|Drug|statin|daily statin orally for 48 weeks
79997841|NCT04053660|Procedure|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
79997842|NCT01731522|Behavioral|EF condition|
79997843|NCT05463159|Other|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
79997844|NCT02972502|Drug|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
79678448|NCT00521781|Drug|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
79678449|NCT00521781|Drug|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
79997845|NCT02972502|Drug|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
79997846|NCT02972502|Other|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
79997847|NCT02972502|Drug|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
79997848|NCT05462067|Device|AT LARA IOL|EDOF IOL for treatment of cataract
79997849|NCT05462067|Device|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
79997850|NCT05461911|Dietary Supplement|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
79997851|NCT01569477|Behavioral|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
79369795|NCT01727596|Other|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
79369796|NCT01724398|Other|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
79997852|NCT01569477|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
79369797|NCT01724398|Other|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
79997853|NCT03601988|Radiation|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
79997854|NCT03601988|Drug|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
79369798|NCT01724398|Other|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
79369799|NCT01724398|Other|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
79369800|NCT01724476|Drug|folate with B12|
79369801|NCT01724476|Drug|placebo|
79369802|NCT01724554|Drug|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
79997855|NCT03606590|Device|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
79997856|NCT03606590|Drug|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
79997857|NCT02971800|Drug|sodium fluorescein injection 10%|
79678450|NCT05144126|Other|CT radioraphic assessment|CT radioraphic assessment
79678451|NCT00521820|Drug|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
79997858|NCT03601910|Drug|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
79369803|NCT01724632|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
79369804|NCT01727752|Procedure|Decompression|
79678452|NCT00521820|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
79678453|NCT00523263|Device|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
79678454|NCT00523263|Device|Human umbilical vein femoro-popliteal bypass|
79678455|NCT04696328|Biological|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
79678456|NCT00521859|Drug|Cloretazine|800 mg/m^2 by vein daily
79678457|NCT00521859|Drug|Fludarabine|25 mg/m^2 by vein daily x 5 Days
79678458|NCT02954861|Other|No intervention|No intervention
79678459|NCT00521898|Procedure|Descemet Membrane Endothelial Keratoplasty (DMEK)|
79997859|NCT03601910|Drug|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
79997860|NCT03163667|Drug|Placebo|oral tablets
79997861|NCT03163667|Drug|CB-839|oral tablets
79997862|NCT03163667|Drug|everolimus|oral tablets
79997863|NCT03651570|Device|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
79997864|NCT03651570|Behavioral|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
79997865|NCT03603548|Drug|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
79997866|NCT03603548|Drug|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
79997867|NCT03651492|Behavioral|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
79997868|NCT03954782|Drug|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
79227020|NCT04425616|Behavioral|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
79523863|NCT05557266|Behavioral|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
79678460|NCT02954666|Device|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval < 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval < 600 ms after 5 minute of waiting time; 5 radiofrequency applications > 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
79678461|NCT00521937|Other|Dermagen®|Weekly topical applications
79678462|NCT02954705|Other|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
79678463|NCT04693611|Behavioral|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
79678464|NCT04693611|Procedure|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
79678465|NCT02954822|Drug|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
79823221|NCT02584556|Drug|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
79997869|NCT03954782|Drug|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
79369805|NCT03835936|Other|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
79369806|NCT03835936|Other|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
79369807|NCT01837342|Procedure|Surgical reserction|
79369808|NCT01837342|Other|Radiological percutaneous drainage and washing drainage|
79369809|NCT03835624|Diagnostic Test|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
79369810|NCT01727830|Other|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
79369811|NCT01727908|Other|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
79369812|NCT01837420|Drug|VB-201 80mg|
79997870|NCT01330199|Other|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
79369813|NCT01837420|Drug|VB-201 160mg|
79369814|NCT01837420|Drug|Placebo|
79369815|NCT01727986|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
79369816|NCT01724788|Drug|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
79369817|NCT01724788|Drug|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
79369818|NCT01837498|Drug|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
79369819|NCT01837498|Drug|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
79369820|NCT01705574|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
79369821|NCT01705574|Drug|ATV|300 mg capsule administered orally with food once daily
79523864|NCT05543928|Drug|CTAP101|CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
79523865|NCT05543928|Drug|Placebo|Placebo
79523866|NCT05502978|Behavioral|Blended education of Infant and Young Child Feeding|Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
79227021|NCT04425616|Other|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
79227022|NCT04417257|Drug|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
79227023|NCT04417257|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
79227024|NCT04396587|Drug|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
79227025|NCT04396587|Drug|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
79523867|NCT05441124|Behavioral|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
79227026|NCT04396587|Drug|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
79227027|NCT04396587|Drug|normal Saline|normal saline 10ml
79369822|NCT01705574|Drug|RTV|100 mg tablet administered orally with food once daily
79369823|NCT01705574|Drug|FTC/TDF|200/300 mg tablet administered orally with food once daily
79369824|NCT01705574|Drug|E/C/F/TDF Placebo|Tablet administered orally with food once daily
79369825|NCT01705574|Drug|ATV Placebo|Tablet administered orally with food once daily
79369826|NCT01705574|Drug|RTV Placebo|Capsule administered orally with food once daily
79369827|NCT01705574|Drug|FTC/TDF Placebo|Tablet administered orally with food once daily
79369828|NCT01705574|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
79369829|NCT04378660|Diagnostic Test|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
79997871|NCT03651726|Drug|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
79997872|NCT03651726|Drug|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
79997873|NCT01781039|Device|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (> 50% of the time), and 100 persons reporting little difficulty HIN (< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
79523868|NCT05435742|Biological|SON-080|Recombinant human interleukin-6 (rhIL-6)
79678466|NCT02954822|Drug|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
79997874|NCT03603470|Other|EOS imagery|Whole body EOS imaging in seated and standing position
79997875|NCT00107250|Drug|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
79997876|NCT00107250|Drug|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
79997877|NCT00107250|Drug|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
79997878|NCT00107250|Drug|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
79369830|NCT01837576|Drug|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
79369831|NCT04378738|Behavioral|survey|all people in the cohort
79369832|NCT01728142|Device|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
79369833|NCT01728142|Other|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
79369834|NCT01837732|Other|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
79678467|NCT00522015|Drug|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
79997879|NCT03606434|Other|Hypoxic exposure|30 minutes of intermittent hypoxia
79227028|NCT04393506|Drug|Camrelizumab|Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
79227029|NCT04393506|Drug|Apatinib|Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
79227030|NCT04393506|Procedure|Radical surgery|Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
79369835|NCT01837732|Other|Relational:|Relational: 10 mn verbal patient's centered exchanges
79997880|NCT03603392|Other|Physical activity program|
79997881|NCT03651258|Behavioral|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
79997882|NCT03167411|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
79227031|NCT04393506|Radiation|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
79227032|NCT04381559|Behavioral|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
79369836|NCT04378582|Other|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
79369837|NCT01728298|Biological|SLITone ULTRA HDM immunotherapy|
79369838|NCT01737710|Biological|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
79369839|NCT01737710|Biological|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
79369840|NCT01724944|Procedure|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
79369841|NCT04381000|Other|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
79997883|NCT03167411|Drug|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
79997884|NCT02035436|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
79369842|NCT04379674|Other|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
79369843|NCT04379674|Other|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
79369844|NCT04379674|Other|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
79369845|NCT01725022|Other|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
79369846|NCT01728532|Device|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
79369847|NCT01728532|Device|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
79369848|NCT01837810|Drug|Ibuprofen|800mg every 8 hours as needed for pain
79369849|NCT04378348|Behavioral|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
79678468|NCT02954744|Procedure|HIFU treatment|High intensity focused ultrasound
79678469|NCT00523380|Drug|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
79678470|NCT00523380|Drug|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
79678471|NCT00506870|Device|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
79678472|NCT00506870|Device|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
79678473|NCT02948322|Device|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
79678474|NCT02948322|Drug|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
79227033|NCT04381559|Behavioral|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
79369850|NCT04378348|Behavioral|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
79997885|NCT02035436|Other|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
79997886|NCT03601754|Diagnostic Test|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
79997887|NCT03606356|Drug|Onabotulinum toxin A|Cranial Subcutaneous Injections
79997888|NCT02237768|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
79997889|NCT02237768|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
79227034|NCT04379752|Device|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
79369851|NCT04378348|Behavioral|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
79369852|NCT01725100|Drug|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
79678475|NCT02948322|Procedure|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
79678476|NCT05143580|Behavioral|Cognitive therapy|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education.~Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~Use gamification to evaluate: pain relief skills, lung expansion skills."
79678477|NCT05143580|Behavioral|Routine care|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education."
79678478|NCT00522054|Other|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
79678479|NCT00506987|Drug|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
79678480|NCT00506987|Drug|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
79823222|NCT02584556|Drug|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
79823223|NCT04353986|Drug|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
79227035|NCT04366726|Combination Product|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
79678481|NCT02276820|Biological|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
79678482|NCT00522093|Drug|TJ-100|TJ-100 2.5g three times per day for 6 weeks
79678483|NCT00506558|Procedure|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
79678484|NCT00506558|Procedure|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
79823224|NCT04077008|Procedure|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
79823225|NCT04077008|Procedure|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
79823226|NCT05325554|Behavioral|Multimodal rehabilitation|Multimodal rehabilitation
79823227|NCT02581436|Other|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
79823228|NCT02581436|Other|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
79227036|NCT04333771|Drug|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
79227037|NCT04333771|Drug|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
79227038|NCT04319510|Procedure|Craniosacral therapy|The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
79227039|NCT04319510|Procedure|Craniosacral self-help group training|The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
79823229|NCT00670449|Drug|Fingolimod|Fingolimod was supplied in capsules.
79227040|NCT04319510|Procedure|Treatment as usal / wait list|The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered 2 treatments (4TUS) of 1:1 CST and the participation in the group training.
79227041|NCT04318717|Drug|Pembrolizumab|Pembrolizumab is commercially available
79227042|NCT04318717|Radiation|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
79823230|NCT04168970|Procedure|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
79823231|NCT04160390|Other|Biospecimen Collection-Blood|Undergo collection of blood
79823232|NCT04160390|Other|Biospecimen Collection-Stool|Undergo collection of stool
79369853|NCT01725100|Drug|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
79369854|NCT01725178|Behavioral|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
79678485|NCT00523458|Drug|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
79678486|NCT00507065|Drug|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
79678487|NCT00507065|Drug|Placebo|
79369855|NCT01837888|Device|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
79678488|NCT00522132|Drug|Artesunate|intravenous application
79678489|NCT00523497|Device|Non invasive mechanical ventilation|
79823233|NCT00771147|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
79823234|NCT00771225|Procedure|fascial repair|surgery to treat genital prolapse with fascia repair
79227043|NCT04318041|Drug|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
79369856|NCT01725334|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
79523869|NCT05343468|Device|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
79523870|NCT05311800|Other|Physical activity|Comparison of HIIT mode (running vs cycling)
79523871|NCT05045898|Other|plantar massage|The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
79523872|NCT05045898|Other|textured insoles|"Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks."
79523873|NCT04601454|Device|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
79523874|NCT04544748|Biological|GNR-051|Anti-PD1 monoclonal antibody
79678490|NCT00522210|Drug|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
79678491|NCT00522210|Other|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
79227044|NCT04318041|Drug|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
79678492|NCT05143151|Biological|CD276 CAR-T cells|CD276 CAR-T cells infusion
79678493|NCT00523536|Behavioral|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
79678494|NCT00523575|Dietary Supplement|Cubitan|400 ml/d
79678495|NCT05143112|Biological|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
79823235|NCT00771225|Procedure|mesh repair|surgery to genital prolapse with mesh
79823236|NCT04155710|Biological|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
79823237|NCT04155710|Drug|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
79227045|NCT04298242|Device|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
79227046|NCT04291885|Drug|Avelumab|Avelumab IV infusion
79227047|NCT04291885|Drug|Placebo|Placebo IV infusion
79227048|NCT04273542|Other|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
79227049|NCT04270682|Drug|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
79823238|NCT04155710|Drug|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
79823239|NCT04155710|Drug|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
79823240|NCT02557659|Device|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
79823241|NCT00775047|Other|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
79997890|NCT03606278|Other|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
79678496|NCT00523653|Other|blood test|looking at DNA
79678497|NCT00522249|Drug|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
79678498|NCT00522249|Drug|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
79227050|NCT04270682|Drug|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
79227051|NCT04270682|Drug|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
79227052|NCT04270682|Drug|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
79227053|NCT04270682|Drug|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
79678499|NCT00522249|Drug|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
79678500|NCT05148767|Drug|Neoadjuvant chemoradiotherapy based on irinotecan|"Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
79227054|NCT04269850|Biological|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
79227055|NCT04269850|Drug|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
79369857|NCT04378036|Other|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
79369858|NCT04378036|Device|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
79369859|NCT04378192|Device|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
79678501|NCT00522288|Device|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
79678502|NCT00522288|Device|Spectacle|Spectacles for the treatment of myopia
79678503|NCT00522327|Other|remote simultaneous medical interpreting|remote simultaneous medical interpretation
79678504|NCT00522327|Other|usual and customary|usual and customary interpreting
79678505|NCT00522327|Other|ENglish speaking|English speakers
79678506|NCT05148728|Procedure|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
79678507|NCT00523692|Drug|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
79678508|NCT00523692|Drug|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
79678509|NCT03458949|Other|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
79678510|NCT05148689|Drug|Oxymetazoline hydrochloride Cream, 1%|Cream
79678511|NCT05148689|Drug|Rhofade™ (oxymetazoline) cream, 1%|cream
79678512|NCT05148689|Drug|Placebo|cream
79823242|NCT00775047|Other|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
79823243|NCT00775125|Drug|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
79227056|NCT04269850|Drug|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
79678513|NCT03458910|Behavioral|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
79678514|NCT05148650|Diagnostic Test|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
79823244|NCT02557503|Drug|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
79823245|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
79678515|NCT00523731|Procedure|Angiogenic Cell Precursors (ACPs) or Vescell TM|
79678516|NCT00523770|Procedure|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
79678517|NCT00522405|Procedure|TACE|"Under local anesthesia, the Femoral artery would be punctured~A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~Superselective catheterization of the hepatic artery feeding the tumor would be done~By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~Gelfoam particles would be injected following this for embolization"
79678518|NCT00522444|Drug|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
79678519|NCT00522444|Other|Nebulized normal saline|standard of care
79678520|NCT05148143|Drug|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
79227057|NCT04269590|Behavioral|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
79369860|NCT04378192|Device|face mask|use of face mask before intubation of a morbidly obese patient
79369861|NCT01725412|Dietary Supplement|Thiamine 300mg PO once daily|
79369862|NCT01725412|Dietary Supplement|placebo|
79369863|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
79369864|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
79369865|NCT01725490|Drug|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
79369866|NCT01682876|Biological|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
79369867|NCT01725568|Device|BioMonitor|Implantable cardiac monitor
79369868|NCT01728610|Dietary Supplement|Probiotic (Active high)|Higher dose of probiotic supplement
79678521|NCT00523887|Drug|Fentanyl transdermal therapeutic system|
79369869|NCT01728610|Dietary Supplement|Probiotic (Active low)|Lower dose of probiotic supplement
79369870|NCT01728610|Dietary Supplement|Placebo|Placebo
79369871|NCT03835390|Behavioral|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
79678522|NCT02276534|Behavioral|SENSE Theatre|A peer-mediated, theatre-based intervention.
79369872|NCT01838434|Drug|lenalidomide|given PO
79678523|NCT02276534|Behavioral|Delayed Intervention|
79678524|NCT00506636|Behavioral|Tissue engineering for hair follicle regeneration|
79678525|NCT00522561|Other|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
79369873|NCT01838434|Drug|idelalisib|given PO
79678526|NCT05145218|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
79678527|NCT05145218|Drug|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
79678528|NCT05145218|Drug|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
79678529|NCT00523926|Drug|TMC207|
79823246|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
79227058|NCT04269590|Behavioral|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
79227059|NCT04261855|Drug|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
79227060|NCT04261855|Radiation|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
79227061|NCT04261855|Radiation|Lutetium-177 (177Lu)-DOTATATE|Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
79227062|NCT04261413|Drug|RS-0139|RS-0139 will be administered for the indication of NSCLC.
79227063|NCT04259398|Drug|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
79227064|NCT04259398|Drug|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
79369874|NCT01838668|Drug|Placebo|Two placebo capsules orally BID
79369875|NCT01838668|Drug|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
79369876|NCT01728688|Other|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
79823247|NCT00771303|Other|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
79823248|NCT02558049|Other|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
79227065|NCT04256486|Behavioral|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
79227066|NCT04256018|Drug|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
79227067|NCT04256018|Radiation|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
79369877|NCT01728688|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
79369878|NCT01728766|Other|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at >37 weeks by and birth weight <2500 g
79369879|NCT01728766|Other|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
79678530|NCT05146271|Procedure|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
79678531|NCT00522639|Other|18F-deoxyglucose (FDG)|contrast medium
79678532|NCT00522678|Drug|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
79678533|NCT00522678|Drug|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
79227068|NCT04251975|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
79227069|NCT04250064|Drug|Bevacizumab Injection|Additional concurrent low-dose Bevacizumab with standard EBRT
79227070|NCT04250064|Radiation|Ultra-low-dose RT|Ultra-low-dose EBRT instead of standard dose RT
79227071|NCT04248803|Other|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
79369880|NCT04377646|Drug|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
79369881|NCT04377646|Drug|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
79369882|NCT04377646|Drug|Zinc|15 mg per day up to 2 months
79369883|NCT04377646|Drug|Zinc (Placebo)|1 pill per day up to 2 months
79369884|NCT01728922|Dietary Supplement|5000IU vitamin D|Vigantol Oil
79369885|NCT01728922|Dietary Supplement|10000IU vitamin D|Vigantol Oil
79369886|NCT01728922|Other|Placebo|Placebo Oil
79369887|NCT01682720|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79369888|NCT01682720|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79678534|NCT05140850|Biological|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
79678535|NCT00522717|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
79369889|NCT01682720|Drug|Placebo to match SOF|Placebo to match SOF administered orally once daily
79369890|NCT01682720|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
79678536|NCT00522717|Behavioral|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
79678537|NCT05142098|Drug|Dexamethasone|Intramuscular
79227072|NCT04245514|Drug|Durvalumab|Immunotherapy
79227073|NCT04245514|Radiation|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
79227074|NCT04233398|Device|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
79369891|NCT01838902|Drug|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
79369892|NCT01838902|Drug|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
79369893|NCT01838902|Drug|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
79227075|NCT04220463|Other|Hypnosis + NIV|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
79369894|NCT01838902|Drug|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
79369895|NCT03409822|Device|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
79369896|NCT03401086|Other|Kinesio Taping|Kinesio Taping
79369897|NCT03409510|Radiation|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
79369898|NCT04551014|Device|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
79369899|NCT04551014|Device|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
79369900|NCT01729000|Other|Gloves|All staff must wear gloves for subjects that are in the experimental group.
79369901|NCT01729078|Dietary Supplement|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
79369902|NCT01714544|Drug|Cloderm Cream|
79369903|NCT03401008|Other|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
79369904|NCT03400696|Behavioral|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
79369905|NCT03400696|Behavioral|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
79369906|NCT03400696|Behavioral|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines <https://www.choosemyplate.gov>
79369907|NCT01729234|Dietary Supplement|Nitrate|Dietary Supplement
79369908|NCT01729234|Dietary Supplement|Placebo|Dietary Supplement
79678538|NCT05142098|Drug|Etoricoxib 60 mg|Orally
79678539|NCT00523965|Drug|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
79678540|NCT00523965|Drug|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs <25 mg
79678541|NCT00523965|Drug|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
79823249|NCT00771381|Drug|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
79369909|NCT03409354|Behavioral|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
79369910|NCT03409354|Behavioral|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
79369911|NCT03400462|Drug|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
79523875|NCT04509726|Drug|EBV-specific TCR-T cell with cytokine auto-secreting element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
79523876|NCT04446078|Device|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
79523877|NCT04384302|Other|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
79523878|NCT04295772|Drug|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
79369912|NCT03400462|Device|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
79369913|NCT03400462|Other|dry needling|Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
79523879|NCT04160286|Other|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
79823250|NCT00771381|Drug|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
79523881|NCT03888066|Drug|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
79523882|NCT03888066|Drug|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
79678542|NCT00523965|Drug|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
79227076|NCT04220463|Other|NIV|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
79997891|NCT03606278|Other|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
79523883|NCT03467256|Biological|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
79678543|NCT05141669|Drug|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
79997892|NCT01952847|Other|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
79523884|NCT03467256|Drug|Fludarabine|given IV
79523885|NCT03467256|Drug|Cyclophosphamide|given IV
79678544|NCT00522756|Drug|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
79678545|NCT00522756|Drug|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
79369914|NCT01703858|Drug|BI 113608 PIB|powder for oral solution
79823251|NCT00771459|Drug|Ropivacaine 0.5 %|Local infiltration analgesia
79823252|NCT00771459|Drug|Isotonic NaCl|Local infiltration analgesia
79823253|NCT00775359|Drug|Fenofibrate 160 mg tablets|
79369915|NCT01703858|Drug|BI 113608|conventional tablet formulation
79369916|NCT01703858|Drug|BI 113608|conventional tablet formulation
79369917|NCT01703858|Drug|BI 113608|conventional tablet formulation
79523886|NCT03467256|Drug|Tocilizumab|given IV
79523887|NCT03467256|Drug|Cytarabine|given IV
79523888|NCT03467256|Drug|Etoposide|given IV
79823254|NCT02557347|Behavioral|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
79369918|NCT01703858|Drug|pantoprazole 40 mg STADA|film-coated tablet
79369919|NCT01703858|Drug|BI 113608|conventional tablet formulation
79369920|NCT03409042|Behavioral|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
79823255|NCT04048005|Diagnostic Test|Fractional flow reserve|
79523889|NCT03467256|Drug|Dexamethasone|given IV
79369921|NCT01729390|Other|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
79369922|NCT01729468|Drug|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
79369923|NCT01729468|Drug|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
79997893|NCT01952847|Drug|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
79369924|NCT04550468|Other|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
79369925|NCT04550468|Other|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
79369926|NCT03400384|Other|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
79227077|NCT04211129|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
79369927|NCT01729546|Device|7 Blood glucose monitoring systems|
79369928|NCT04376788|Biological|exchange blood transfusion from normal donor|IV method
79678546|NCT02954783|Behavioral|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
79997894|NCT01952847|Behavioral|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
79997895|NCT03597932|Device|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
79997896|NCT02237846|Biological|Human umbilical cord tissue-derived mesenchymal stem cells|
79997897|NCT03601676|Other|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
79369929|NCT04376788|Biological|plasma from convalescent patients with COVID-19|IV method
79369930|NCT04376788|Drug|Methylene Blue 5 MG/ML|IV method
79369931|NCT03400228|Dietary Supplement|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
79369932|NCT03400228|Dietary Supplement|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
79369933|NCT01729702|Other|blood sample collection|
79369934|NCT03400072|Other|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
79523890|NCT03326388|Drug|Selumetinib|Selumetinib Intermittent Dosing
79523891|NCT03265080|Biological|ADXS-NEO|Intravenous infusion
79523892|NCT03265080|Biological|Pembrolizumab|Intravenous infusion
79523893|NCT02554500|Procedure|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
79523894|NCT02424084|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
79523895|NCT05310318|Procedure|Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.
79369935|NCT03400072|Other|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
79369936|NCT03408496|Other|Myofascial release|Manual therapy
79369937|NCT03408496|Other|Muscle stretching|Muscle stretching
79369938|NCT03408496|Other|Control|Medical appointment
79369939|NCT03408418|Procedure|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
79369940|NCT01714310|Drug|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
79369941|NCT01714310|Drug|Placebo|Initiated at end of study week 4 and continued to study week 12.
79523896|NCT05310006|Other|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
79524832|NCT05767710|Behavioral|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
79678547|NCT02954783|Behavioral|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
79997898|NCT05461833|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
79997899|NCT05461833|Drug|OTILONII BROMIDUM|OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
79997900|NCT05461833|Dietary Supplement|multi-strain probiotic|multi-strain probiotic, oral, 1 capsule BID for 1 month
79997901|NCT01560585|Drug|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
79227078|NCT04211129|Other|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
79369942|NCT01714310|Drug|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
79997902|NCT03603236|Diagnostic Test|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
79678548|NCT04693845|Behavioral|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
79369943|NCT03408262|Biological|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
79997903|NCT03603236|Diagnostic Test|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
79997904|NCT05462847|Drug|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
79997905|NCT01376427|Drug|Dexamethasone|Dexamethasone
79369944|NCT03408262|Biological|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
79997906|NCT01376427|Drug|Methotrexate|Methotrexate
79997907|NCT01376427|Drug|Vincristine|Vincristine
79997908|NCT03601598|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
79997909|NCT03601598|Drug|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
79227079|NCT04206553|Drug|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
79227080|NCT04206553|Drug|Matching Placebo|Matching dupilumab without active substance
79369945|NCT03408262|Biological|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
79369946|NCT04377802|Diagnostic Test|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
79369947|NCT03408184|Drug|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
79369948|NCT03408184|Drug|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
79369949|NCT01713998|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79997910|NCT05462769|Device|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
79997911|NCT05462691|Procedure|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
79997912|NCT03597152|Dietary Supplement|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
79997913|NCT03597152|Dietary Supplement|Placebo|Inert placebo custom manufactured for the sponsor
79227081|NCT04206553|Drug|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
79227082|NCT04202926|Device|real coil|active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
79227083|NCT04202926|Device|sham coil|sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
79997914|NCT03075501|Behavioral|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
79997915|NCT03075501|Drug|Stimulant or sedative|CS+ for paired, CS0 for unpaired
79369950|NCT03409900|Other|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
79997916|NCT03075501|Drug|Placebo|CS- for paired, CS0 for unpaired
79227084|NCT04197102|Drug|CBD Isolate|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
79369951|NCT03409900|Other|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
79369952|NCT03408028|Other|Medical File consultation|Medical File consultation
79369953|NCT04549922|Drug|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
79369954|NCT04549922|Drug|Normal Saline|1.2 mL subcutaneous
79369955|NCT03834376|Drug|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram [mg]) over a time period of 5 days.
79678549|NCT04693845|Behavioral|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
79678550|NCT05141240|Drug|Ribiciclib|Participants who initiated CDK4/6i therapy
79823256|NCT02582138|Other|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~a daily total energy intake of 25-30 kcal/kg body weight;~an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
79678551|NCT05141240|Drug|Palbociclib|Participants who initiated CDK4/6i therapy
79678552|NCT05141240|Drug|Abemaciclib|Participants who initiated CDK4/6i therapy
79369956|NCT01681628|Behavioral|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
79369957|NCT04377958|Diagnostic Test|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
79997917|NCT03597074|Diagnostic Test|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
79997918|NCT03596528|Procedure|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
79997919|NCT05462535|Drug|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
79369958|NCT03405220|Behavioral|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
79369959|NCT03405220|Behavioral|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
79369960|NCT03405220|Behavioral|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
79678553|NCT00522912|Procedure|Trichiasis surgery|Posterior lamella tarsal rotation
79678554|NCT00522912|Procedure|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
79997920|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
79997921|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
79227085|NCT04197102|Other|CBD Broad Spectrum|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
79227086|NCT04197102|Other|Placebo oil|Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
79227087|NCT04188964|Drug|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
79227088|NCT04187820|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
79227089|NCT04184999|Drug|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
79227090|NCT04184999|Drug|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
79369961|NCT03405220|Behavioral|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
79227091|NCT04173416|Behavioral|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
79227092|NCT04168372|Other|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
79227093|NCT04168372|Other|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
79227094|NCT04168372|Other|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
79523897|NCT05313282|Combination Product|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
79227095|NCT04168372|Other|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
79523898|NCT05313282|Combination Product|Apatinib combined with Camrelizumab|Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
79523899|NCT05315622|Other|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
79523900|NCT05315622|Other|Placebo|"Manual tension without reaching the manipulation thrust"
79523901|NCT05318274|Radiation|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
79523902|NCT05312034|Behavioral|Implementation of the predictive model for an antimicrobial management program|"Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."
79227096|NCT04167163|Drug|Abaloparatide|18 month ABL treatment
79227097|NCT04167020|Device|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
79369962|NCT03405220|Behavioral|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
79369963|NCT03405220|Behavioral|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
79523903|NCT05311722|Drug|Dexmedetomidine|Inj dexmedetomidine, will be given in infusion over 10 mins and their effect on post spinal shivering will be assessed.
79523904|NCT05311722|Drug|Ketamine|Ketamine
79227098|NCT04147884|Device|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
79227099|NCT04145401|Device|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
79227100|NCT04137692|Other|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
79227101|NCT04132505|Drug|Binimetinib|Given PO
79369964|NCT03405220|Behavioral|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
79369965|NCT03405220|Behavioral|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
79369966|NCT03405220|Behavioral|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
79369967|NCT01728064|Drug|Placebo|Placebo capsules
79523905|NCT05311722|Drug|Tramadol|Tramadol
79523906|NCT05311644|Other|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
79523907|NCT05310552|Other|No interventions - observational study|No interventions - observational study
79523908|NCT05314062|Dietary Supplement|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
79227102|NCT04132505|Drug|Hydroxychloroquine|Given PO
79678555|NCT02954627|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
79678556|NCT00524004|Biological|Anti-CsbD Bovine IgG|Three times a day for seven days
79678557|NCT00524004|Other|Placebo|Three times a day for seven days
79823257|NCT02582138|Other|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
79823258|NCT00775515|Procedure|laparoscopic prostatectomy|laparoscopic prostatectomy
79227103|NCT04131829|Drug|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
79823259|NCT05338502|Drug|Selpercatinib|Administered orally.
79823260|NCT05338502|Drug|Ranitidine|Administered orally.
79823261|NCT05338502|Drug|Omeprazole|Administered orally.
79369968|NCT01728064|Drug|EPI-743 400 mg|
79369969|NCT01728064|Drug|EPI-743 200 mg|
79369970|NCT03407950|Behavioral|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
79823262|NCT04078334|Other|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
79823263|NCT04078334|Other|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
79369971|NCT03407950|Behavioral|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
79997922|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
79997923|NCT03596216|Other|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
79997924|NCT03596216|Other|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
79997925|NCT05461443|Dietary Supplement|Probiotic|
79369972|NCT03834298|Other|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
79369973|NCT03400774|Other|Stair-climbing|Short bouts of moderate intensity stair-climbing
79369974|NCT04377178|Device|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
79369975|NCT04377178|Device|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
79369976|NCT01720420|Device|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
79369977|NCT03835000|Procedure|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
79369978|NCT03409120|Device|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
79678558|NCT00524004|Biological|Anti-CS17 Bovin IgG|Three times a day for seven days
79678559|NCT05145803|Device|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
79678560|NCT04694079|Procedure|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
79678561|NCT04694079|Procedure|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
79678562|NCT04694079|Procedure|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
79997926|NCT05461365|Drug|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
79997927|NCT03602846|Dietary Supplement|Medical Nutrition Therapy|Only given medical nutrition therapy.
79997928|NCT03602846|Drug|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
79997929|NCT03602846|Drug|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
79997930|NCT02317991|Drug|nab-paclitaxel|nab-paclitaxel 125 mg/m^2 IV
79997931|NCT02317991|Biological|ramucirumab|Ramucirumab 8 mg/kg IV
79997932|NCT03602768|Behavioral|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
79227104|NCT04131829|Drug|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
79227105|NCT04124952|Device|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
79227106|NCT04117555|Diagnostic Test|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
79369979|NCT03405142|Drug|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is < 1/12 of the therapeutic dose.
79523909|NCT05314062|Dietary Supplement|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
79523910|NCT05317884|Behavioral|Reminder|Email
79369980|NCT03405142|Drug|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
79369981|NCT03407872|Drug|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
79523911|NCT03215940|Drug|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
79523912|NCT03215940|Drug|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
79523913|NCT03215940|Drug|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
79678563|NCT05146076|Other|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
79997933|NCT03602768|Behavioral|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
79997934|NCT03602768|Behavioral|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
79997935|NCT00861549|Drug|Phencynonate hydrochloride|2mg/tablet
79997936|NCT03602690|Drug|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
79678564|NCT05146076|Other|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
79678565|NCT04696367|Procedure|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
79997937|NCT01379547|Behavioral|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
79997938|NCT01379547|Behavioral|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
79997939|NCT02237612|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
79997940|NCT02237612|Other|laboratory biomarker analysis|Correlative studies
79227107|NCT04114227|Behavioral|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
79227108|NCT04114227|Behavioral|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
79369982|NCT03407872|Drug|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
79678566|NCT02948127|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
79678567|NCT02948127|Biological|Placebo|Administered as nose drops
79678568|NCT05146583|Procedure|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
79678569|NCT05146583|Procedure|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
79678570|NCT02948010|Device|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher & Paykel Healthcare CPAP Device
79997941|NCT02978495|Drug|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
79997942|NCT02978495|Drug|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
79997943|NCT02978495|Drug|Paclitaxel|80mg/m2 weekly for 12 weeks
79997944|NCT02978495|Drug|Cyclophosphamide|600mg/m2 4 cycles each 21 days
79997945|NCT02237690|Drug|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
79369983|NCT03407872|Drug|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
79823264|NCT04078334|Other|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
79369984|NCT03407872|Drug|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
79523914|NCT03219762|Drug|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
79678571|NCT02948010|Device|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
79523915|NCT03219918|Device|EndoRings II Distal Attachment|Colonoscopy cap
79678572|NCT02948010|Device|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
79227109|NCT04111549|Other|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
79823265|NCT05337722|Behavioral|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
79823266|NCT05337722|Behavioral|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
79227110|NCT04111549|Other|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
79823267|NCT00673257|Other|pharmacological study|pharmacological studies
79823268|NCT00673257|Procedure|dual x-ray absorptimetry|
79227111|NCT04107285|Behavioral|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
79227112|NCT04107285|Diagnostic Test|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
79227113|NCT04107285|Other|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
79227114|NCT04101968|Diagnostic Test|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
79369985|NCT00016354|Drug|benzoylphenylurea|
79523916|NCT03219996|Other|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
79823269|NCT02582060|Other|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
79678573|NCT02948010|Device|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
79997946|NCT03601208|Diagnostic Test|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
79997947|NCT04788017|Drug|Ziresovir|"Planned treatments are:~Cohort 1: 300 mg of ziresovir~Cohort 2: up to 600 mg of ziresovir~Cohort 3: up to 900 mg of ziresovir"
79997948|NCT04788017|Other|Placebo|"Planned treatments are:~Cohort 1: 300 mg of placebo~Cohort 2: up to 600 mg of placebo~Cohort 3: up to 900 mg of placebo"
79369986|NCT03834610|Drug|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
79369987|NCT03834610|Drug|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
79369988|NCT03834610|Diagnostic Test|serum testosterone level|measurement of serum testosterone level
79678574|NCT02948010|Device|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
79678575|NCT02948010|Device|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
79369989|NCT03834610|Diagnostic Test|HbA1C|measurement of HbA1C levels
79369990|NCT03834610|Device|penile doppler|penile doppler to measure the degree of erection and penile vasculature
79678576|NCT02948010|Device|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
79678577|NCT02948010|Device|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
79678578|NCT02948010|Device|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
79678579|NCT05145998|Dietary Supplement|Glucola|50 grams of Glucola sugar beverage
79523917|NCT03219606|Other|Organized education course of Modified Rodnan Skin Scoring|"Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
79523918|NCT03219684|Diagnostic Test|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
79678580|NCT05145998|Dietary Supplement|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
79523919|NCT03218904|Dietary Supplement|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
79227115|NCT04101968|Diagnostic Test|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
79678581|NCT05145998|Dietary Supplement|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
79678582|NCT05145998|Dietary Supplement|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
79678583|NCT05145998|Dietary Supplement|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
79678584|NCT05145959|Device|Maskin Probe|The eyelids are examined using meibography to evaluate which eyelids are more severe (right or left). A drop of proparacaine 0.5% solution is added and a bandage contact lens is placed. To avoid patient discomfort, anesthetic ointment is instilled using a sterile cotton-tipped applicator. In some cases, 4% lidocaine can be directly applied to the lid margin. The Maskin probe will be passed through the gland orifice perpendicular to the lid margin. After first using a 1-mm probe, a 2- or 4-mm probes may be used in cases of persistent resistance. The BCL is removed and the eyes are rinsed with sterile preservative-free saline. The patient is given preservative-free artificial tears to use every hour. A brief slit lamp exam will performed in order to ensure that there is no unanticipated damage to the lid or cornea. The probing device will be properly disposed of in the sharps containers.
79369991|NCT01681472|Drug|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
79523920|NCT03218904|Dietary Supplement|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3- single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
79997949|NCT03601130|Device|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
79678585|NCT02948205|Procedure|3D group|infertility patient get TU-LESS by 3D Laparoscopy
79997950|NCT03601130|Device|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
79678586|NCT02948205|Procedure|normal group|infertility patient get normal laparoscopic surgery
79678587|NCT05148377|Drug|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
79678588|NCT05148377|Drug|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
79678589|NCT00524160|Drug|Fentanyl transdermal patch|
79678590|NCT00523029|Behavioral|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
79678591|NCT00524199|Drug|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
79997951|NCT02942615|Other|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
79997952|NCT03600974|Procedure|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
79997953|NCT03600974|Procedure|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
79997954|NCT03600974|Drug|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
79823270|NCT04344392|Diagnostic Test|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
79997955|NCT03600974|Drug|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
79997956|NCT03600974|Drug|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
79997957|NCT03600974|Drug|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
79997958|NCT03075267|Drug|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
79369992|NCT01681472|Drug|Levoleucovorin 200 mg/m2|i.v. bolus injection
79369993|NCT01681472|Drug|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
79369994|NCT01681472|Drug|Levoleucovorin 60 mg/m2|i.v. bolus injection
79227116|NCT04091243|Drug|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
79227117|NCT04084301|Procedure|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
79369995|NCT01040806|Behavioral|Usual care|Patients will receive their usual medical care
79369996|NCT01040806|Behavioral|Health coaching|Peer health coaches will counsel patients with diabetes
79369997|NCT01049152|Device|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
79523921|NCT03219138|Device|Acceleromyography|Use of an uncalibrated acceleromyography
79678592|NCT00524199|Other|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
79523922|NCT03219060|Behavioral|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
79523923|NCT03219060|Behavioral|Brief advice|Brief advice based on 5As
79523924|NCT03218514|Drug|Dalteparin|
79227118|NCT04081896|Other|Exercise|"Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do >20 repetitions. If they are able to reach >10 but <20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy."
79227119|NCT04080180|Behavioral|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
79369998|NCT00915928|Drug|Perindopril|2,5 mg daily for 3 months
79369999|NCT00915928|Drug|Placebo|Placebo dayli for 3 months
79370000|NCT03407404|Combination Product|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
79370001|NCT03407404|Combination Product|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
79370002|NCT03830086|Drug|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
79370003|NCT03830086|Drug|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
79370004|NCT03830086|Drug|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
79370005|NCT03830086|Drug|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
79370006|NCT03830086|Drug|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
79370007|NCT03830086|Drug|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
79523925|NCT03218436|Procedure|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
79523926|NCT03218280|Drug|Vitamin C|
79370008|NCT03407326|Dietary Supplement|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
79523927|NCT03218124|Other|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
79523928|NCT03217500|Procedure|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
79678593|NCT00523068|Drug|Tolterodine|
79678594|NCT00523068|Procedure|tension free vaginal tape|
79370009|NCT03407326|Dietary Supplement|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
79370010|NCT02240212|Drug|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
79370011|NCT02240212|Drug|Paclitaxel|Paclitaxel sourced locally will be administered IV
79370012|NCT02240290|Drug|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
79370013|NCT02240290|Drug|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
79678595|NCT00524238|Drug|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
79678596|NCT02276378|Drug|Telmisartan low|
79678597|NCT02276378|Drug|Telmisartan high|
79678598|NCT02276378|Drug|Hydrochlorothiazide (HCTZ)|
79678599|NCT02276378|Other|Japanese meal|
79678600|NCT00525954|Drug|A-002|
79823271|NCT04344392|Diagnostic Test|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
79678601|NCT04696250|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
79997959|NCT03075267|Drug|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
79370014|NCT03407092|Other|ADAPT cohort|Thrombectomy with distal aspiration technique
79370015|NCT03407092|Other|Stentriever Cohort|Thrombectomy with stent retriever
79823272|NCT04344392|Diagnostic Test|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
79823273|NCT02557269|Drug|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
79370016|NCT01713686|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79823274|NCT02557269|Drug|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
79823275|NCT02557269|Drug|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
79997960|NCT03075267|Drug|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
79997961|NCT03600896|Drug|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~5 mcg/kg/dose for 3 doses~10 mcg/kg/dose for 3 doses~20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
79370017|NCT01047436|Drug|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
79370018|NCT01047436|Drug|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
79370019|NCT02240446|Device|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
79370020|NCT02240446|Device|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
79370021|NCT03406936|Drug|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
79370022|NCT03406780|Biological|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
79370023|NCT03406780|Drug|Placebo|Placebo
79370024|NCT02240524|Procedure|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
79370025|NCT02240524|Procedure|Systemic chemotherapy|
79370026|NCT02240524|Procedure|HIPEC|
79370027|NCT02240602|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
79370028|NCT02240602|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
79370029|NCT02240602|Drug|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
79370030|NCT03406546|Drug|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
79523929|NCT03217500|Procedure|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
79523930|NCT03217500|Procedure|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
79523931|NCT03217500|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
79523932|NCT03217500|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
79523933|NCT03217734|Biological|Adalimumab|Subcutaneous Injection
79523934|NCT03217734|Drug|Methotrexate|Oral Tablet
79523935|NCT03217734|Drug|Placebo|Oral Tablet
79678602|NCT05145842|Procedure|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
79823276|NCT02557269|Drug|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
79823277|NCT02557269|Other|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
79823278|NCT02557269|Drug|Bilastine 20 mg|1 tablet per os - as needed
79823279|NCT02557269|Drug|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
79997962|NCT03600662|Other|TriRec|Trileaflet Reconstruction of the Aortic Valve
79997963|NCT03600662|Other|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
79997964|NCT03600584|Procedure|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
79997965|NCT03600584|Procedure|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
79370031|NCT03406546|Drug|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
79227120|NCT04080180|Behavioral|Brief Motivational Interviewing + Substance Free Activities + Mindfulness|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
79678603|NCT05145842|Procedure|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
79823280|NCT02581358|Other|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
79823281|NCT00771771|Other|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
79997966|NCT03600506|Drug|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
79370032|NCT03406546|Device|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
79370033|NCT01681004|Device|iFuse Implant System|Placement of iFuse implant system via surgery
79523936|NCT03217032|Biological|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
79227121|NCT04077281|Other|Medication Coordinated care|"Clinical Pharmacology & Toxicology consult~CPT team completes detailed circle of care communication~Telemedicine followup by CPT team (approximately 48 hrs post-discharge & 1 week to1 month post-discharge)"
79523937|NCT03216876|Drug|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
79523938|NCT03216642|Diagnostic Test|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
79523939|NCT03216330|Other|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
79523940|NCT03216408|Drug|Neuronox|
79523941|NCT03216408|Drug|Botox|
79523942|NCT03216564|Drug|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
79523943|NCT03216174|Procedure|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
79678604|NCT00524433|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
79678605|NCT00524433|Drug|placebo|
79823282|NCT00771771|Other|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
79823283|NCT00772083|Behavioral|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
79823284|NCT00772083|Behavioral|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
79823285|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a high total daily dose
79823286|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
79823287|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a low total daily dose
79823288|NCT00779181|Drug|Placebo|Placebo taken three times a day
79823289|NCT00779337|Biological|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
79823290|NCT02556411|Drug|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
79823291|NCT02556411|Drug|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
79823292|NCT04085276|Drug|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
79823293|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
79823294|NCT04085276|Drug|Placebo|Placebo, i.v., q3w;
79823295|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
79997967|NCT03600506|Drug|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
79997968|NCT05266677|Other|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
79370034|NCT01681004|Other|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
79370035|NCT01046110|Drug|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
79370036|NCT01046110|Drug|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
79370037|NCT01713530|Drug|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
79523944|NCT03215862|Drug|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
79523945|NCT03215862|Drug|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
79678606|NCT03458832|Diagnostic Test|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
79997969|NCT05266677|Other|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
79997970|NCT03593486|Device|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
79227122|NCT04058990|Device|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
79227123|NCT04058990|Device|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
79523946|NCT03216018|Behavioral|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
79227124|NCT04028466|Drug|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
79227125|NCT04028466|Drug|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
79227126|NCT04007796|Behavioral|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
79227127|NCT04007796|Behavioral|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
79227128|NCT04007666|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
79227129|NCT04007666|Behavioral|Control Group|Coping-focused treatment drawn from material already offered in selected facilities.
79370038|NCT01713530|Drug|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
79370039|NCT01713530|Drug|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
79370040|NCT01045798|Drug|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
79370041|NCT01045798|Drug|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
79997971|NCT03593486|Device|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
79523947|NCT03215472|Other|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
79523948|NCT03215472|Other|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
79523949|NCT03216096|Drug|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
79523950|NCT03215082|Other|Vestibular-Visual Intervention|vestibular-visual exercises
79523951|NCT03215082|Behavioral|standard care|standard care
79523952|NCT03214926|Device|Moving Through Glass intervention|
79823296|NCT00775827|Drug|fenofibrate 160 mg tablets|
79823297|NCT02580032|Other|No treatment given|No treatment given.
79823298|NCT00775905|Drug|amlodipine 10 mg tablet|
79997972|NCT03593330|Other|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
79997973|NCT03590834|Behavioral|Center-based Intervention|"Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~Staff training and technical assistance~Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~Health contests~Gross motor and physical activity program~Miranos! activity cards based on children storybooks"
79997974|NCT03590834|Behavioral|Home-based Intervention|"Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
79997975|NCT03590834|Behavioral|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
79227130|NCT04007393|Behavioral|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
79523953|NCT03214848|Behavioral|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
79227131|NCT04007393|Drug|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
79227132|NCT04007393|Drug|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
79370042|NCT02240758|Procedure|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
79678607|NCT03458832|Device|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
79823299|NCT00772161|Drug|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
79823300|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
79997976|NCT03600272|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
79227133|NCT03999203|Drug|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
79227134|NCT03999203|Device|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
79227135|NCT03999203|Other|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
79370043|NCT03406390|Procedure|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
79370044|NCT04377256|Procedure|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
79370045|NCT03406234|Other|No intervention.|Cross-sectional observation without interventions.
79370046|NCT02240992|Biological|PBSC|
79370047|NCT02240992|Biological|MSCs|
79370048|NCT02982694|Drug|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
79523954|NCT03214692|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
79523955|NCT03214458|Device|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
79678608|NCT05142878|Device|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
79678609|NCT00524550|Dietary Supplement|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
79523956|NCT03214536|Procedure|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
79523957|NCT03214536|Drug|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
79823301|NCT00776139|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
79823302|NCT03810560|Device|laser device Er,Cr:YSGG laser|laser device with open flap debridement
79823303|NCT00779493|Dietary Supplement|curcumin|curcumin 900mg twice daily by mouth
79997977|NCT03600272|Procedure|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
79997978|NCT05082597|Device|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
79997979|NCT03600038|Behavioral|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
79523958|NCT03214536|Procedure|Spine surgery|Surgery of lumbar spine
79523959|NCT03214536|Procedure|anesthesia|general anesthesia
79997980|NCT03600038|Behavioral|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
79997981|NCT03913286|Device|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
79997982|NCT04856943|Procedure|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
79227136|NCT03999203|Other|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
79227137|NCT03996265|Drug|Bupropion Hydrochloride Controlled-release|Given PO
79370049|NCT02982694|Drug|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
79370050|NCT04377568|Biological|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
79370051|NCT02156674|Drug|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
79370052|NCT02241070|Behavioral|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
79370053|NCT01712984|Biological|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
79370054|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
79370055|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
79370056|NCT01042678|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye
79370057|NCT01042600|Device|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
79370058|NCT01042600|Device|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
79523960|NCT03214770|Drug|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
79523961|NCT03214770|Drug|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
79523962|NCT03214614|Drug|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
79523963|NCT03214614|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
79523964|NCT03214614|Drug|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
79523965|NCT03214614|Drug|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
79997983|NCT04856943|Other|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
79523966|NCT03214146|Biological|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10^6 cells/kg according to the protocol design.
79523967|NCT03213756|Device|Isometric exercises using Hand grip and elastic bands|"Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
79523968|NCT03213444|Drug|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
79997984|NCT03599336|Procedure|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
79227138|NCT03996265|Other|Placebo Administration|Given PO
79227139|NCT03996265|Other|Quality-of-Life Assessment|Ancillary studies
79227140|NCT03996265|Other|Questionnaire Administration|Ancillary studies
79227141|NCT03994887|Device|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
79370059|NCT04377412|Other|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
79370060|NCT01041976|Behavioral|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
79523969|NCT03213444|Drug|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
79227142|NCT03994471|Drug|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
79523970|NCT03213600|Device|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
79523971|NCT03213522|Procedure|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
79370061|NCT01041976|Behavioral|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
79523972|NCT03213522|Procedure|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
79523973|NCT03213054|Biological|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
79678610|NCT05145647|Radiation|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment will be finished within 2 weeks after the first one, a total of 10Gy in 2 fractions will be delivered.
79678611|NCT05145647|Device|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
79227143|NCT03994471|Drug|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
79678612|NCT05148416|Radiation|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
79823304|NCT00779493|Dietary Supplement|placebo|placebo capsule to simulate 900mg curcumin capsule
79523974|NCT03213054|Radiation|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
79523975|NCT03213288|Dietary Supplement|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
79823305|NCT00772239|Device|Rotation thromboelastometry (ROTEM)|Coagulation measurement
79370062|NCT00921310|Drug|Pemetrexed|
79370063|NCT00921310|Drug|Temsirolimus|
79370064|NCT04376710|Other|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
79370065|NCT04376710|Other|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
79823306|NCT00772239|Procedure|Standard coagulation managment procedure|Standard coagulation managment procedure
79370066|NCT04376710|Other|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
79370067|NCT02241148|Drug|Acetaminophen 500mg|500 mg, tablets every 8 hours
79370068|NCT02241148|Device|Kinesio taping|Taping will be changed every week.
79370069|NCT03405688|Procedure|Blood sampling|Extra blood samples taken for laboratory analysis
79370070|NCT01712516|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
79823307|NCT00779571|Behavioral|Crispbread|8 week low calorie diet
79823308|NCT02580344|Drug|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
79227144|NCT03989466|Biological|Alemtuzumab|Given IV
79227145|NCT03989466|Drug|Itacitinib|Given PO
79227146|NCT03988400|Behavioral|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
79370071|NCT01712516|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
79523976|NCT03213288|Dietary Supplement|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
79523977|NCT03213288|Dietary Supplement|Placebo|No anthocyanins
79523978|NCT03212820|Procedure|Drilling at low speed|
79523979|NCT03212820|Procedure|Drilling at conventional or high speed|
79523980|NCT03212664|Other|exercise|physical therapy exercises
79678613|NCT05148416|Device|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
79523981|NCT03212898|Other|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
79523982|NCT03212586|Drug|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
79523983|NCT03212586|Drug|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
79523984|NCT03212430|Drug|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
79523985|NCT03211806|Behavioral|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
79370072|NCT01712516|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
79678614|NCT05148416|Other|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
79997985|NCT03599336|Other|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
79997986|NCT03074331|Drug|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
79997987|NCT03599024|Procedure|PCEA|The patients were able to control the administration of analgesics by themselves.
79997988|NCT03599024|Procedure|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
79370073|NCT01712516|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
79523986|NCT03211806|Device|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
79678615|NCT02947932|Drug|Resveratrol|pre-ERCP intervention
79678616|NCT02947932|Drug|Indomethacin|post-ERCP intervention in high risk patients
79678617|NCT02947893|Drug|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
79997989|NCT03599024|Procedure|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
79997990|NCT02237924|Drug|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
79997991|NCT02237924|Drug|DDP|DDP:100mg/m2 for 2-3 cycles
79997992|NCT02237924|Radiation|IMRT|IMRT:70-74Gy for 2-3 cycles
79997993|NCT04855227|Procedure|robotic-assisted ventral hernia repair|"Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care."
79997994|NCT02238002|Procedure|cataract surgery|The patients of both groups underwent cataract surgery
79997995|NCT04615533|Other|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
79997996|NCT04561089|Diagnostic Test|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
79523987|NCT03212040|Diagnostic Test|needle biopsy|breast biopsy using different needle gauges
79523988|NCT03211962|Other|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
79523989|NCT03211884|Behavioral|Problem-Solving Thearpy|"The problem-solving therapy (PST)-based intervention consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet & greet session, participants received written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7-steps to solve at least one problem together before ending the training. Participants keep a record of their problem-solving efforts between sessions and questions they had related to the application of PST. These records were used as a basis for discussion during the PST training sessions."
79523990|NCT03211728|Drug|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
79523991|NCT03211728|Drug|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
79523992|NCT03211572|Drug|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
79678618|NCT02947893|Drug|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
79227147|NCT03988400|Behavioral|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
79523993|NCT03211494|Device|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
79823309|NCT00779649|Other|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
79997997|NCT03825302|Diagnostic Test|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
79997998|NCT03825302|Diagnostic Test|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
79227148|NCT03987425|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
79370074|NCT03405610|Behavioral|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
79523994|NCT03211494|Other|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
79523995|NCT03211650|Drug|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
79523996|NCT03211650|Drug|hyaluronic acid|Intra-articular injections of hyaluronic acid
79523997|NCT03211650|Drug|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
79523998|NCT03211182|Behavioral|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
79678619|NCT05141747|Drug|MRG002|Administrated intravenously
79678620|NCT05146154|Drug|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
79997999|NCT04851795|Other|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
79998000|NCT04851795|Other|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
79998001|NCT02238392|Procedure|Adenosine test|Testing dormant conduction after PVI
79998002|NCT02238392|Procedure|Termination of AF|Testing AF iducibility and ermination of
79998003|NCT02260193|Drug|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79523999|NCT03211260|Device|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
79524000|NCT03211026|Other|No intervention|No intervention
79998004|NCT02260193|Drug|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79227149|NCT03984214|Drug|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
79370075|NCT04166240|Behavioral|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series [VBTS] Collaborative supplemented with automated surveillance data on test results.
79370076|NCT01703000|Device|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
79524001|NCT03211104|Dietary Supplement|curcumin|
79524002|NCT03211104|Dietary Supplement|Placebo|
79678621|NCT00524667|Drug|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
79370077|NCT01040728|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
79370078|NCT01040728|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
79370079|NCT01040728|Drug|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
79524003|NCT03210636|Device|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
79227150|NCT03984214|Drug|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
79227151|NCT03982381|Drug|Metformin|Active comparator
79227152|NCT03982381|Drug|Dapagliflozin 10 MG|Experimental treatment
79524004|NCT03210792|Device|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
79524005|NCT03210870|Behavioral|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
79524006|NCT03210948|Device|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
79524007|NCT03210948|Device|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
79524008|NCT03210402|Device|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
79524009|NCT03210402|Device|Elevated night pacing off|Device will be programmed to normal lower rates
79524010|NCT03210168|Other|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
79524011|NCT03210246|Drug|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
79524012|NCT03210246|Drug|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
79524013|NCT03210246|Drug|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
79524014|NCT03210246|Drug|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
79524015|NCT03210324|Drug|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
79524016|NCT03210480|Drug|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
79678622|NCT05145686|Diagnostic Test|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
79678623|NCT00524706|Drug|S-1, oral Leucovorin, Oxaliplatin|
79678624|NCT05145179|Drug|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
79678625|NCT04692987|Other|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
79227153|NCT03979365|Drug|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
79227154|NCT03979365|Drug|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
79227155|NCT03971630|Other|Telemedicine|Patients will be followed up using the MyVENT System and APP
79227156|NCT03971448|Device|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
79524017|NCT03210480|Drug|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
79524018|NCT03210012|Diagnostic Test|Transthoracic echocardiography|Diagnostic test done prior and after the dive
79524019|NCT03210012|Diagnostic Test|Blood samples|Diagnostic test done prior and after the dive
79524020|NCT01830114|Behavioral|Web app|The Checkup and Choices web application
79524021|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
79524022|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
79524023|NCT01830348|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
79524024|NCT01830348|Drug|placebo vehicle gel|
79524025|NCT01830582|Procedure|Advanced MR Imaging|
79998005|NCT02260193|Drug|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
79227157|NCT03971448|Device|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
79227158|NCT03969823|Drug|Tagrisso|Osimertinib 80mg once daily until disease progression
79227159|NCT03958838|Behavioral|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
79227160|NCT03948373|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
79227161|NCT03943238|Biological|Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs|Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of >10 x10^6 cells /Kg, 100 x 10^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10^6/Kg.
79524026|NCT01830660|Drug|Hetrombopag Olamine Tablets|
79524027|NCT01830660|Drug|placebo|
79524028|NCT01830738|Procedure|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
79370080|NCT01040728|Drug|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
79524029|NCT01830738|Procedure|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
79524030|NCT01830894|Device|MRI|3 MRI on different times during the study for each arm.
79524031|NCT01831128|Device|ASV Treatment|
79524032|NCT01831206|Procedure|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
79524033|NCT01831284|Procedure|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
79524034|NCT01831362|Behavioral|Mindfulness-Based Cognitive Therapy|
79524035|NCT01831362|Behavioral|Focused Attention (FA)|
79678626|NCT05147870|Procedure|Peritoneal irrigation|For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
79524036|NCT01831362|Behavioral|Open- Monitoring|
79678627|NCT05147870|Procedure|Suction only|In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
79227162|NCT03939689|Drug|I-131-1095|I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
79678628|NCT05142644|Procedure|ultrasound|An extra ultrasound performed during pregnancy
79998006|NCT05763147|Device|Intravenous Access Device Flushing|locking and flushing the end of catheter line at the intervals of different drug treatment.
79370081|NCT01040728|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
79998007|NCT03587402|Other|Transcutaneous perineal stimulation|Surface stimulation
79998008|NCT03587402|Other|Anal stimulation|Intra-cavitary stimulation
79370082|NCT01593020|Drug|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
79370083|NCT01593020|Drug|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
79370084|NCT01593020|Drug|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
79370085|NCT01593020|Drug|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
79524037|NCT01831518|Device|CRT Implant|
79524038|NCT01831518|Device|Body Surface ECG Mapping|
79524039|NCT01831674|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
79524040|NCT01831674|Drug|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
79998009|NCT02035514|Biological|Bone marrow autologous mesenchymal stem cells transplantation|
79998010|NCT04819035|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
79370086|NCT01593020|Drug|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
79370087|NCT01593020|Drug|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
79370088|NCT01040260|Other|Counseling|Smoking cessation counseling
79524041|NCT01831830|Behavioral|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
79524042|NCT01832064|Behavioral|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
79370089|NCT01040260|Behavioral|Contingency management|Use of tangible rewards for abstinence from smoking
79370090|NCT01040260|Drug|Nicotine patches|Nicotine patches
79370091|NCT02241226|Behavioral|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
79370092|NCT01046422|Drug|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
79370093|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
79524043|NCT01832298|Drug|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
79678629|NCT02947542|Device|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
79678630|NCT02947542|Device|Standard catheter|Coronary angiography will be performed using a standard catheter.
79678631|NCT02946762|Other|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
79678632|NCT00507143|Drug|irinotecan|
79678633|NCT00507182|Procedure|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
79524044|NCT01832376|Procedure|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
79678634|NCT00525993|Drug|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
79370094|NCT01046422|Drug|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
79370095|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
79678635|NCT00525993|Drug|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
79678636|NCT00526032|Procedure|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
79998011|NCT02238236|Drug|Alesion®|Dry Syrup
79998012|NCT04306029|Other|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
79998013|NCT02849678|Drug|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
79227163|NCT03939689|Drug|Enzalutamide|Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
79227164|NCT03917940|Dietary Supplement|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
79227165|NCT03917940|Drug|Glimepiride|glimepiride 2 mg or 3 mg per day oral
79227166|NCT03911531|Diagnostic Test|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
79227167|NCT03911531|Diagnostic Test|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
79370096|NCT01046422|Drug|Placebo|Capsule, Oral, 0mg, Daily, 28 days
79998014|NCT02849678|Drug|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
79227168|NCT03906669|Drug|Letrozole|PO daily for 14 days
79370097|NCT01046422|Drug|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
79370098|NCT02241382|Device|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
79370099|NCT02241382|Device|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
79370100|NCT01712438|Biological|Human cl rhFVIII|
79370101|NCT03405376|Drug|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
79524045|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
79678637|NCT05147714|Device|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
79678638|NCT02947854|Drug|Fimaporfin (Photosensitizer)|
79678639|NCT02947854|Biological|Hiltonol (Poly-ICLC)|
79998015|NCT04295577|Other|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15[13].
79998016|NCT02238158|Drug|Atrovent® inhalets|
79998017|NCT02238314|Drug|Tipranavir low dose|
79998018|NCT02238314|Drug|Tipranavir high dose|
79998019|NCT02238314|Drug|Ritonavir|
79998020|NCT02238314|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
79998021|NCT02238314|Drug|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
79370102|NCT02241460|Drug|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
79678640|NCT02947854|Biological|HPV E7 (Human Papilloma Virus E7) peptides|
79678641|NCT02947854|Biological|KLH (Keyhole Limpet Hemocyanin)|
79678642|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
79678643|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
79998022|NCT03587168|Other|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
79998023|NCT03587168|Other|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
79998024|NCT03587168|Other|Four Square Step Test|The Four Square Step Test measures dynamic balance.
79998025|NCT03587168|Other|Functional Reach Test|The Functional Reach Test assesses limits of stability.
79998026|NCT03587168|Other|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
79370103|NCT02241460|Drug|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
79370104|NCT01712204|Drug|Placebo|Placebo Capsule BID for 16 Weeks
79524046|NCT01832844|Procedure|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
79678644|NCT05147363|Device|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
79678645|NCT00526149|Drug|BI 2536|
79678646|NCT00526149|Other|high performance liquid chromatography|
79678647|NCT00526149|Other|mass spectrometry|
79678648|NCT00526149|Other|pharmacological study|
79998027|NCT03587168|Other|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
79998028|NCT03587168|Other|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
79227169|NCT03906669|Drug|Letrozole and Prometrium|PO daily for 14 days
79227170|NCT03906669|Drug|Tamoxifen and Prometrium|PO daily for 14 days
79998029|NCT03587168|Other|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
79998030|NCT03629769|Drug|Proxelan|Administration of one suppository of proxelan once a day for 30 days
79998031|NCT03589742|Device|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
79227171|NCT03906149|Combination Product|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
79370105|NCT01712204|Drug|AC-201|AC-201 50mg Capsule BID for 16 Weeks
79370106|NCT01712204|Drug|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
79370107|NCT01592864|Drug|Stannous Fluoride|dentifice
79370108|NCT01592864|Drug|Sodium Monofluorophosphate|dentifrice
79370109|NCT01592786|Drug|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
79370110|NCT01711736|Biological|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
79524047|NCT01832844|Procedure|"Group  without scan "|
79524048|NCT01832922|Drug|Bendamustine|
79524049|NCT01832922|Drug|Rituximab|
79524050|NCT01833000|Device|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
79524051|NCT01833156|Device|MoistureMeterD|measuring erythema size and the dielectric constant values
79524052|NCT01833234|Other|Interviews and questionnaires|
79678649|NCT05147285|Other|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
79678650|NCT05147285|Other|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
79678651|NCT05147285|Other|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
79678652|NCT00507221|Drug|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
79678653|NCT00507221|Drug|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
79678654|NCT00507221|Drug|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
79370111|NCT01711736|Biological|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
79998032|NCT02238470|Drug|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
79998033|NCT03581708|Other|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
79998034|NCT04119375|Behavioral|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
79998035|NCT04119375|Behavioral|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
79998036|NCT04119375|Behavioral|SMS Reminder|Patients receive a single daily SMS message to take their medication.
79227172|NCT03906149|Combination Product|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
79524053|NCT01833312|Device|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
79370112|NCT01592708|Other|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
79998037|NCT04119375|Other|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
79227174|NCT03885167|Other|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
79370113|NCT01042522|Biological|Bleomycin Sulfate|Given IV
79998038|NCT03586934|Drug|Acetaminophen|Acetaminophen Tablet
79998039|NCT03586934|Drug|Celecoxib 200mg|Celecoxib Tablet
79998040|NCT03586934|Drug|Celecoxib 400 mg|Celecoxib Tablet
79524054|NCT01833312|Drug|Buspirone|anti-shivering treatment
79524055|NCT01833312|Drug|Pethidine|anti-shivering treatment
79998041|NCT03586934|Drug|Ropivacaine|Ropivicaine nerve block (injection)
79227175|NCT03882060|Drug|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
79227176|NCT03882060|Drug|Normal saline|Control group, no intervention.
79370114|NCT01042522|Drug|Carboplatin|Given IV
79370115|NCT01042522|Drug|Cisplatin|Given IV
79370116|NCT01042522|Drug|Etoposide Phosphate|Given IV
79524056|NCT01833390|Drug|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
79524057|NCT01833624|Dietary Supplement|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
79524058|NCT01833624|Dietary Supplement|Sondalis® HP|
79524059|NCT01834014|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
79998042|NCT03586934|Drug|Ketorolac|ketorolac injection
79998043|NCT03586934|Drug|Acetaminophen Injectable Product|Acetaminophen injection
79998044|NCT03586934|Drug|Oxycodone|oxycodone tablet
79998045|NCT03586934|Drug|Tramadol|Tramadol tablet
79998046|NCT03586934|Drug|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
79998047|NCT03586934|Drug|hydrocodone bitartrate and acetaminophen|Norco tablet
79998048|NCT03586934|Drug|Morphine|morphine injection
79998049|NCT03586934|Drug|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
79998050|NCT03586934|Drug|Meloxicam|meloxicam tablet
79998051|NCT01596257|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
79998052|NCT01596257|Device|CliniMACS|
79998053|NCT02084121|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
79227177|NCT03873636|Other|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, & Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
79227178|NCT03839784|Combination Product|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
79227179|NCT03834961|Drug|Larotrectinib Sulfate|Given PO or via NG or G tube
79227180|NCT03831295|Biological|Anti-OX40 Antibody BMS 986178|Given IT or IV
79227181|NCT03831295|Drug|TLR9 Agonist SD-101|Given IT
79227182|NCT03830190|Other|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
79370117|NCT01042522|Other|Laboratory Biomarker Analysis|Correlative studies
79370118|NCT01042522|Drug|Paclitaxel|Given IV
79524060|NCT01834014|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
79524061|NCT01834014|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
79998054|NCT03577964|Diagnostic Test|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
79998055|NCT04749017|Dietary Supplement|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
79998056|NCT04749017|Other|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
79524062|NCT01834014|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
79524063|NCT01834014|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
79227183|NCT03818191|Drug|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
79227184|NCT03818191|Other|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
79227185|NCT03814967|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
79227186|NCT03810131|Other|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
79227187|NCT03792763|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
79227188|NCT03792763|Drug|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
79227189|NCT03792347|Drug|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
79227190|NCT03791788|Diagnostic Test|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
79227191|NCT03775330|Radiation|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy > 2 cm and ≤ 3 cm: 15-18 Gy > 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions > 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions > 15 Gy) when patient is randomized to SRS + WBRT arm"
79370119|NCT01702844|Drug|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
79370120|NCT01702532|Drug|Nicotine|Comparison of different dosage forms of nicotine
79524064|NCT01834014|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
79524065|NCT01834092|Other|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
79524066|NCT01834170|Drug|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
79524067|NCT01834482|Dietary Supplement|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
79524068|NCT01834482|Dietary Supplement|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
79524069|NCT01834638|Drug|ABT-126|capsule(s)
79524070|NCT01834794|Behavioral|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
79524071|NCT01834950|Other|Blood test|
79524072|NCT01835106|Procedure|Epidural catheter is used postoperatively|
79524073|NCT01835106|Procedure|Fascia iliaca compartment catheter is used postoperatively|
79524074|NCT01835184|Drug|cabozantinib-s-malate|Given PO
79678655|NCT04693299|Diagnostic Test|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
79678656|NCT00507260|Behavioral|Food Record|A record of the amount and kind of food and drink you intake will be completed.
79678657|NCT00507260|Other|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
79227192|NCT03775330|Radiation|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
79370121|NCT02241616|Drug|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
79370122|NCT03400306|Drug|Veliparib, capsule|capsule; 50 mg or 100 mg
79370123|NCT03400306|Drug|Veliparib, tablet|tablet; 400 mg
79370124|NCT03400306|Drug|Carboplatin|Intravenous
79370125|NCT03400306|Drug|Paclitaxel|Intravenous
79370126|NCT03405298|Behavioral|Educational Material|Educational material is in the form of a brochure
79370127|NCT03405298|Behavioral|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
79524075|NCT01835184|Drug|vemurafenib|Given PO
79524076|NCT01835184|Other|laboratory biomarker analysis|Correlative studies
79998057|NCT02035592|Other|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
79998058|NCT02035592|Other|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
79227193|NCT03771651|Drug|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
79227194|NCT03770182|Device|NEUROLITH|transcranial pulse stimulation (TPS)
79227195|NCT03768986|Behavioral|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
79370128|NCT03405064|Drug|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
79524077|NCT01835184|Other|pharmacological study|Correlative studies
79524078|NCT01835340|Device|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
79524079|NCT01835574|Behavioral|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete >=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
79524080|NCT01835652|Other|Active Exercise|
79524081|NCT01835652|Other|Passive Exercise|
79524082|NCT01835730|Drug|PE0139 Injection|
79524083|NCT01835730|Drug|Placebo|
79524084|NCT01835886|Other|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
79524085|NCT01836120|Drug|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
79524086|NCT01836120|Drug|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
79998059|NCT02035592|Other|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
79998060|NCT02051673|Biological|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
79998061|NCT03586856|Device|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
79998062|NCT03586856|Device|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
79370129|NCT03405064|Drug|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
79370130|NCT01702454|Biological|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
79370131|NCT02241694|Other|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
79524087|NCT01836588|Procedure|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
79524088|NCT01836822|Procedure|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
79524089|NCT01836822|Procedure|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
79524090|NCT01836822|Procedure|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
79524091|NCT01836822|Procedure|Bronchoalveolar lavage (BAL)|
79524092|NCT01836822|Procedure|Endobronchial forceps biopsy|
79524093|NCT01836900|Device|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
79998063|NCT05763069|Other|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
79998064|NCT03586154|Combination Product|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
79998065|NCT03586154|Drug|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
79998066|NCT04658693|Device|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
79998067|NCT03975621|Behavioral|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
79227196|NCT03768986|Behavioral|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
79370132|NCT02241772|Drug|TA-8995|
79370133|NCT02241772|Drug|Placebo|
79370134|NCT02241850|Other|High intensity training|9 weeks of supervised high intensity training
79678658|NCT03458793|Behavioral|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
79678659|NCT00507338|Procedure|PCI|early PCI for NSTEMI; primary PCI for STEMI
79678660|NCT02946723|Procedure|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
79678661|NCT02946723|Procedure|X-ray|Lead implantation surgery for SNM using X-ray technique
79678662|NCT05140031|Other|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
79678663|NCT02947737|Other|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
79678664|NCT02947737|Other|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
79678665|NCT05147012|Other|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
79678666|NCT04693104|Device|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
79678667|NCT04693104|Device|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
79678668|NCT05146934|Radiation|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
79227197|NCT03768986|Behavioral|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
79370135|NCT04413656|Other|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
79370136|NCT04413656|Other|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
79370137|NCT01702298|Drug|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
79370138|NCT01702298|Drug|Metformin|Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
79370139|NCT03404752|Drug|Peg-Filgrastim|
79678669|NCT05146895|Drug|Imiquimod treatment|As an control arm, for patients with flat warts
79678670|NCT05146895|Device|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
79998068|NCT01413815|Dietary Supplement|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
79227198|NCT03738696|Drug|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
79370140|NCT04377022|Other|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~Combined therapy~Conventional Therapy"
79370141|NCT03405532|Diagnostic Test|DM-ECC|Diabetes mellitus CPB
79370142|NCT03401710|Drug|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
79370143|NCT02241928|Biological|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
79370144|NCT02242006|Other|serial serum sampling for quantification of drug concentration|
79370145|NCT03409978|Device|in-Motion app|mobile phone application for recording fidgety movements at home
79370146|NCT02242084|Drug|Intravenuse Alteplase|
79998069|NCT01413815|Other|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
79998070|NCT03585920|Behavioral|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
79998071|NCT04646603|Drug|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
79998072|NCT04646603|Drug|Placebo|Subjects will receive subcutaneous placebo injections.
79998073|NCT03579992|Behavioral|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
79998074|NCT03579992|Behavioral|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
79227199|NCT03738696|Drug|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
79227200|NCT03735992|Behavioral|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
79227201|NCT03735589|Biological|Alpha-type-1 Polarized Dendritic Cells|Given ID
79524094|NCT01836978|Other|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
79370147|NCT01701362|Drug|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
79524095|NCT01837368|Other|observational research|It is a observational research, no intervention are performed
79524096|NCT01837836|Behavioral|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
79524097|NCT01837992|Drug|Primaquine|
79524098|NCT01837992|Drug|delayed primaquine|
79524099|NCT01838382|Device|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
79524100|NCT01838460|Drug|sublingual nicotine tablets|6 mg = 3 tablets
79370148|NCT01701362|Drug|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
79370149|NCT01673295|Drug|RTX infusions|RTX + Standard of Care
79524101|NCT01838460|Other|Smokeless tobacco|Swedish type moist snuff
79524102|NCT01838538|Drug|Bevacizumab|
79524103|NCT01838538|Drug|TC:paclitaxel + carboplatin|
79524104|NCT01838772|Drug|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
79524105|NCT01838928|Drug|Bupivacaine|
79227202|NCT03735589|Biological|Autologous Natural Killer Cell-like CTLs|Given IP
79308154|NCT03221543|Device|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
79998075|NCT03579992|Behavioral|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
79370150|NCT01673295|Other|Standard of Care|Standard of Care only
79998076|NCT03629847|Drug|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
79370151|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
79370152|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
79370153|NCT00919126|Drug|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
79370154|NCT03404440|Other|L.Reuteri|
79524106|NCT01839006|Procedure|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
79524107|NCT01839084|Drug|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
79524108|NCT01839084|Drug|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
79524109|NCT01839162|Procedure|Coronary angiography|Diagnostic coronary angiography
79524110|NCT01839162|Procedure|PCI|Percutaneous coronary intervention
79524111|NCT01839162|Procedure|Right approach|Right transradial access
79524112|NCT01839162|Procedure|Left approach|Left transradial access
79370155|NCT04375540|Procedure|Upper first premolars extractions|Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
79370156|NCT04375540|Procedure|Upper second premolars extraction|Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
79524113|NCT01839240|Drug|azacitidine|Given IV or SC
79998077|NCT01330589|Drug|Placebo|Non-active placebo for 7 days: PO/TID
79998078|NCT01330589|Drug|St. Johns Wort|For 7 days: 300mg PO/TID
79998079|NCT03577886|Drug|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
79998080|NCT03577886|Drug|Placebo|Phosphate Buffer Diluent oral solution
79524114|NCT01839240|Drug|cytarabine|Given IV
79524115|NCT01839240|Drug|mitoxantrone hydrochloride|Given IV
79524116|NCT01839240|Other|laboratory biomarker analysis|Correlative studies
79998081|NCT01314833|Drug|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC*6"
79998082|NCT01314833|Drug|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF*3-T*3"
79998083|NCT01314833|Drug|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC*4-P*4"
79998084|NCT05763927|Drug|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
79998085|NCT05763927|Drug|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
79998086|NCT05763927|Radiation|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
79998087|NCT05763927|Procedure|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
79524117|NCT01839474|Device|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
79678671|NCT02947776|Behavioral|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
79998088|NCT03579836|Drug|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
79227203|NCT03703609|Behavioral|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
79998089|NCT03579836|Combination Product|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
79370157|NCT03833908|Device|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
79370158|NCT04375618|Drug|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
79370159|NCT04375618|Drug|Plain Collagen|A collagen membrane without FGF-2 will be used.
79370160|NCT01710800|Drug|Esomeprazole|
79370161|NCT01710800|Drug|placebo|
79370162|NCT03404284|Behavioral|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
79524118|NCT01839552|Drug|Fentanyl Citrate Nasal Spray (FCNS)|
79524119|NCT01839630|Drug|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
79678672|NCT02947776|Behavioral|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
79998090|NCT04577781|Drug|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
79370163|NCT03833986|Other|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
79370164|NCT03404128|Other|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
79370165|NCT01710020|Drug|CP-690,550|CP-690,550 10 mg oral powder for constitution
79524120|NCT01839864|Behavioral|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
79524121|NCT01839942|Procedure|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
79524122|NCT01839942|Procedure|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
79524123|NCT01834248|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
79998091|NCT04577781|Drug|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
79998092|NCT02737826|Drug|Buprenorphine Initiation - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
79227204|NCT03686306|Drug|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
79227205|NCT03686306|Drug|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
79524124|NCT01834248|Drug|Decitabine|Given IV
79998093|NCT02737826|Drug|Gabapentin + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
79227206|NCT03681652|Drug|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
79524125|NCT01834248|Other|Laboratory Biomarker Analysis|Correlative studies
79678673|NCT05143073|Behavioral|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
79823310|NCT00779649|Other|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
79998094|NCT02737826|Drug|Placebo + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
79998095|NCT02737826|Drug|Buprenorphine taper - Phase II|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
79998096|NCT03367715|Drug|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
79998097|NCT03367715|Drug|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
79227207|NCT03681652|Drug|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
79370166|NCT03833830|Diagnostic Test|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group >20 injections and shortterm treatment group < 5 injections).
79370167|NCT02982850|Drug|Dabigatran|
79370168|NCT02982850|Drug|Acetylsalicylic acid|
79370169|NCT02982850|Drug|Warfarin|
79524126|NCT01834248|Drug|Poly ICLC|Given SC
79524127|NCT01833858|Drug|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
79524128|NCT01833858|Drug|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
79823311|NCT04074980|Diagnostic Test|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
79823312|NCT04074980|Diagnostic Test|Venous blood draw|Venepuncture to collect blood samples from subjects
79998098|NCT03367715|Radiation|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
79998099|NCT03963063|Procedure|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~individualized optimised stroke volume by mini-fluid challenge first~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg~keep cardiac index ≧ 2.5 L/min/cm2"
79998100|NCT03963063|Procedure|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg"
79998101|NCT03577808|Other|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
79998102|NCT05762913|Other|Manual Diaphragm Release Technique|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
79308155|NCT04484753|Other|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
79370170|NCT01700348|Device|Airflosser|Use of Philips Airflosser
79524129|NCT01834872|Device|Amigo|
79524130|NCT01834872|Device|Manual ablation|
79308156|NCT04484753|Other|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
79370171|NCT01700348|Device|Manual Floss|Active Comparator
79370172|NCT02242162|Procedure|phrenic nerves magnetic stimulations|
79524131|NCT01836432|Drug|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours
79678674|NCT05143073|Behavioral|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
79524132|NCT01836432|Biological|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
79678675|NCT02946372|Procedure|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
79998103|NCT03585218|Biological|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
79227208|NCT03681262|Device|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
79308157|NCT04484753|Behavioral|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
79370173|NCT03404050|Other|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
79370174|NCT02242240|Drug|Formoterol twice daily|
79370175|NCT02242240|Drug|Formoterol once daily|
79524133|NCT01836432|Radiation|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
79370176|NCT02242240|Drug|Tiotropium once daily|
79370177|NCT02242240|Drug|Placebo|
79524134|NCT01836432|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
79998104|NCT01330667|Dietary Supplement|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
79998105|NCT04064931|Diagnostic Test|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
79370178|NCT03403972|Drug|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
79678676|NCT02946567|Other|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
79998106|NCT03577652|Drug|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
79998107|NCT03620513|Drug|Decongestant (oxymetazoline 0.05%)|As described in arm/group
79370179|NCT02242318|Drug|Telmisartan|
79370180|NCT02242318|Drug|Valsartan|
79370181|NCT02242318|Drug|Placebo|
79370182|NCT01700192|Biological|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
79370183|NCT01700192|Biological|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
79370184|NCT01700192|Drug|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
79678677|NCT02946567|Other|Generic Game|Participants will play a generic game without any particular information about hearing health care.
79678678|NCT00524784|Biological|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
79678679|NCT00524862|Drug|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
79678680|NCT00524862|Device|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
79998108|NCT03620513|Drug|Anesthesia (Lidocaine 15%)|As described in arm/group
79998109|NCT03620513|Drug|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
79998110|NCT03620513|Drug|Normal saline|Spray of normal saline as premedication
79998111|NCT03585062|Drug|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
79998112|NCT03585062|Drug|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
79370185|NCT01700192|Drug|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
79370186|NCT01700192|Drug|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
79370187|NCT01700192|Drug|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
79678681|NCT05146817|Other|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
79227209|NCT03681262|Device|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
79227210|NCT03677596|Drug|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
79227211|NCT03677596|Drug|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
79227212|NCT03660722|Other|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
79524135|NCT01836432|Drug|Capecitabine|Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation
79227213|NCT03632343|Other|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
79227214|NCT03632343|Other|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
79227215|NCT03614741|Drug|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
79227216|NCT03614741|Drug|Tinzaparin bolus|4500 IU bolus of Tinzaparin
79823313|NCT00776217|Drug|loratadine 10 mg orally disintegrating tablets|
79227217|NCT03548454|Drug|Duloxetine|Open label prescription
79227218|NCT03548454|Drug|Desipramine|Open label prescription
79227219|NCT03537729|Behavioral|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
79524136|NCT01836432|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes
79524137|NCT01720056|Drug|Verapamil|
79524138|NCT01720056|Drug|Kenalog 10|
79524139|NCT01720212|Drug|YM178|oral
79524140|NCT01720290|Drug|repaglinide|Dose individually adjusted
79823314|NCT00772317|Device|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
79227220|NCT03537729|Behavioral|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
79227221|NCT03534934|Diagnostic Test|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
79227222|NCT03534934|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
79227223|NCT03534934|Other|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
79524141|NCT01720290|Drug|metformin|Dose individually adjusted
79524142|NCT01720290|Drug|metformin|Dose at 1000 mg/day
79524143|NCT01720680|Radiation|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
79524144|NCT01720680|Device|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
79524145|NCT01720992|Other|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
79524146|NCT01721148|Drug|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
79524147|NCT01721304|Other|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
79524148|NCT01721382|Drug|Sitagliptin|
79524149|NCT01721538|Other|Weight reduction program|
79524150|NCT01721538|Other|Lecture on healthy nutrition|
79524151|NCT01721616|Drug|Azithromycin|
79227224|NCT03534934|Diagnostic Test|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
79524152|NCT01721616|Drug|Cefazolin|
79524153|NCT01721694|Drug|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
79524154|NCT01721694|Drug|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
79524155|NCT01722006|Behavioral|Pairing condition|
79524156|NCT01722006|Behavioral|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
79678682|NCT02946450|Drug|Other: Not applicable-observational study|
79678683|NCT05149703|Other|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
79370188|NCT00924118|Drug|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
79998113|NCT03854331|Behavioral|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
79998114|NCT03584906|Procedure|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
79227225|NCT03534934|Diagnostic Test|Duel-energy X-ray absorptiometry scan|Bone density measurement
79227226|NCT03534934|Diagnostic Test|Multi-detector computed tomography|Hip and ankle CT scan
79227227|NCT03534934|Diagnostic Test|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
79227228|NCT03517891|Behavioral|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
79227229|NCT03516838|Drug|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
79227230|NCT03516838|Drug|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
79227231|NCT03513211|Drug|SUBA-itraconazole|150mg PO BD
79227232|NCT03513211|Drug|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
79227233|NCT03504826|Device|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
79524157|NCT01722084|Behavioral|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
79524158|NCT01722396|Dietary Supplement|Vitamin D|
79524159|NCT01722630|Drug|Dopamine|
79678684|NCT00524901|Drug|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
79678685|NCT00524901|Drug|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
79678686|NCT02954588|Dietary Supplement|Pyridoxamine|
79370189|NCT02242396|Drug|Telmisartan|
79524160|NCT01722942|Procedure|ICD implantation|ventricular ICD implantation
79678687|NCT02954588|Dietary Supplement|Placebo|
79370190|NCT02242396|Drug|Telmisartan hydrochlorothiazide|
79524161|NCT01722942|Drug|amiodarone hydrochloride|amiodarone prescription
79524162|NCT01723020|Drug|AMG 232|Given an an oral tablet in escalating doses.
79678688|NCT04692792|Dietary Supplement|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
79678689|NCT04692792|Dietary Supplement|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
79678690|NCT02954549|Dietary Supplement|Vitamin D3|As in Arms
79678691|NCT02946411|Procedure|Cardiac surgery|Glucose level will be measured after cardiac surgery.
79823315|NCT02556957|Behavioral|HealthScouts|
79678692|NCT05145608|Drug|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
79678693|NCT05143034|Dietary Supplement|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
79678694|NCT05143034|Dietary Supplement|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
79678695|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
79678696|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
79678697|NCT05146349|Other|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
79678698|NCT00525018|Device|contact heat evoked potential stimulator|
79678699|NCT05146232|Other|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
79823316|NCT02556957|Other|Standard of Care|
79823317|NCT02580500|Procedure|epidural catheter|epidural anaesthesia application for spinal catheter will be used
79823318|NCT02580500|Procedure|spinal catheter|spinal anesthesia application for spinal catheter will be used
79998115|NCT03584906|Procedure|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
79227234|NCT03468868|Behavioral|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
79227235|NCT03458520|Diagnostic Test|PET/MR imaging|undergo PET/MR imaging
79227236|NCT03458520|Diagnostic Test|MR imaging|Undergo MR imaging
79227237|NCT03458520|Diagnostic Test|PET/CT imaging|Undergo PET/CT imaging
79227238|NCT03458429|Drug|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
79227239|NCT03448757|Other|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
79227240|NCT03448718|Drug|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
79227241|NCT03436979|Device|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
79227242|NCT03431129|Diagnostic Test|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
79227243|NCT03422627|Drug|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
79227244|NCT03422003|Radiation|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
79227245|NCT03403621|Drug|Pentamidine Isethionate|Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
79227246|NCT03403621|Drug|Placebo|No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
79227247|NCT03387917|Drug|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
79227248|NCT03387917|Drug|Caelyx|Caelyx is a liposomal formulation of the anthracycline doxorubicin
79227249|NCT03370900|Other|Testing|Participants either received 20 case testing with or without feedback
79227250|NCT03361735|Drug|Leuprolide Acetate|Intramuscular or subcutaneous injection
79227251|NCT03361735|Drug|Goserelin Acetate|Subcutaneous injection
79227252|NCT03361735|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79227253|NCT03361735|Radiation|Radium Ra 223 Dichloride|Given IV
79227254|NCT03361735|Other|Laboratory Biomarker Analysis|Correlative studies
79227255|NCT03361735|Drug|Degarelix|Subcutaneous injection
79227256|NCT03353974|Device|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
79227257|NCT03353974|Device|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
79227258|NCT03320837|Dietary Supplement|Infant formula|Breast milk substitute containing synbiotics
79524163|NCT01723098|Behavioral|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
79524164|NCT01723176|Procedure|Echocardiography|
79678700|NCT05146232|Other|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
79524165|NCT01723332|Behavioral|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
79227259|NCT03320837|Other|Breast milk|Breast milk
79308158|NCT04484753|Behavioral|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
79308159|NCT03221231|Drug|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
79308160|NCT03221231|Drug|Placebo Oral Tablet|twice daily, placebo
79524166|NCT01723332|Behavioral|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
79524167|NCT01723410|Behavioral|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
79524168|NCT01723410|Other|Writing about places, objects|
79678701|NCT05146232|Other|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
79227260|NCT03306979|Drug|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
79227261|NCT03306979|Other|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
79227262|NCT03298243|Behavioral|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
79227263|NCT03276273|Device|recording of Bispectral Index|recording of Bispectral Index
79524169|NCT01723488|Radiation|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
79227264|NCT03264534|Procedure|limbal relaxing incisions|Manually performed surgical procedure
79227265|NCT03264534|Procedure|astigmatic keratotomy|femtosecond laser guided surgical procedure
79524170|NCT01723644|Other|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
79524171|NCT01723644|Other|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
79227266|NCT03244293|Other|no intervention|
79524172|NCT01723800|Drug|PI3K inhibitor BKM120|Given PO
79524173|NCT01723800|Drug|pemetrexed disodium|Given IV
79524174|NCT01723800|Drug|carboplatin|Given IV
79524175|NCT01723800|Other|laboratory biomarker analysis|Correlative studies
79524176|NCT01723800|Other|pharmacological study|Correlative studies
79524177|NCT01723800|Procedure|quality-of-life assessment|Ancillary studies
79524178|NCT01723956|Procedure|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
79524179|NCT01723956|Procedure|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
79524180|NCT01724034|Other|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
79524181|NCT01724034|Other|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
79524182|NCT01724034|Other|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
79524183|NCT01724034|Other|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
79524184|NCT01724034|Other|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
79227267|NCT03225105|Drug|M3541|Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).
79227268|NCT03225105|Radiation|Palliative Radiotherapy (RT)|Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
79227269|NCT03217071|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
79227270|NCT03217071|Radiation|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
79524185|NCT01724034|Other|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
79370191|NCT03403816|Behavioral|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
79524188|NCT01724268|Drug|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
79524189|NCT01724268|Drug|Anti TNF + Meth|
79678702|NCT05146232|Other|First postoperative analgesia|IV acetaminophen will be administered every 6 h
79823319|NCT04074200|Procedure|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
79998116|NCT03584906|Procedure|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
79227271|NCT03217071|Procedure|Surgery (Non-interventional, standard of care)|Standard of care surgery to remove cancer
79227272|NCT03199053|Drug|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
79227273|NCT03199053|Drug|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
79227274|NCT03199053|Drug|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
79370192|NCT03403738|Behavioral|Bounce Back Now|web/smartphone-based intervention for disaster victims
79524190|NCT01724424|Drug|Melatonin|20 mg oral single dose
79678703|NCT05146232|Other|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
79370193|NCT03403738|Behavioral|enhanced usual care|enhanced usual care with list of resources
79370194|NCT04374994|Drug|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
79370195|NCT04374994|Drug|Placebo oral tablet|lactose and maize starch, Egypt
79370196|NCT02242474|Drug|Anti-TNF suspended perioperatively|
79227275|NCT03195699|Drug|TTI-101|Oral capsule
79524191|NCT01724424|Drug|Melatonin|30 mg oral single dose
79998117|NCT03584906|Procedure|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
79524192|NCT01724424|Drug|Melatonin|50mg oral single dose
79524193|NCT01724424|Drug|Melatonin|100mg oral single dose
79524194|NCT01724502|Behavioral|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
79524195|NCT01724736|Drug|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
79524196|NCT01724736|Drug|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
79678704|NCT00525096|Drug|placebo|2 tablets twice a day per os
79998118|NCT03584906|Procedure|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
79227276|NCT03195699|Drug|TTI-101|Oral tablet
79227277|NCT03186079|Drug|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
79227278|NCT03186079|Drug|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
79370197|NCT02242474|Drug|Anti-TNFα continued perioperatively|
79370198|NCT03403660|Other|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
79678705|NCT00525096|Drug|Celecoxib|2*200 mg tablets twice a day per os
79678706|NCT00525096|Drug|Exemestane|Exemestane 25 mg per day per os
79227279|NCT03186079|Drug|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
79227280|NCT03186079|Behavioral|Toilet training|Toilet training has been considered a routine method in treatment of constipation
79370199|NCT03833752|Diagnostic Test|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
79524197|NCT01724814|Drug|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
79524198|NCT01724814|Drug|Placebo|Singe dose SC administration of Placebo
79524199|NCT01724970|Device|ProSeal|Patients will be ventilated with PLMA
79524200|NCT01724970|Device|Supreme LMA|Patients will be ventilated with SLMA
79678707|NCT05142176|Other|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
79227281|NCT03176173|Radiation|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
79227282|NCT03176173|Drug|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
79678708|NCT05142176|Drug|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
79678709|NCT00525213|Drug|Rob 803|two capsules per day during 12 weeks
79227283|NCT03170453|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
79678710|NCT00525213|Drug|Placebo|two capsules per day during 12 weeks
79678711|NCT04693026|Drug|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
79823320|NCT04074200|Procedure|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
79524201|NCT01725048|Drug|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
79678712|NCT04693026|Drug|Baricitinib|Baricitinib oral tablet form
79524202|NCT01725048|Drug|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
79524203|NCT01725204|Drug|Dasatinib + PegIFN|
79678713|NCT04693026|Drug|Tocilizumab|Tocilizumab IV Infusion
79524204|NCT01725360|Drug|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
79524205|NCT01725516|Procedure|Myofascial release technique|
79524206|NCT01725594|Drug|CAT 2003|
79524207|NCT01725594|Drug|Placebo|
79524208|NCT01725672|Drug|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524209|NCT01725672|Drug|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524210|NCT01725672|Drug|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79678714|NCT02276859|Drug|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
79678715|NCT02276859|Drug|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
79678716|NCT02276859|Drug|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
79678717|NCT05143970|Drug|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
79227284|NCT03170453|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
79227285|NCT03168880|Drug|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
79227286|NCT03168880|Drug|Paclitaxel only|
79678718|NCT00526266|Behavioral|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
79678719|NCT00526266|Behavioral|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
79678720|NCT05149547|Diagnostic Test|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
79678721|NCT04692753|Other|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
79678722|NCT05146115|Other|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
79308161|NCT03221231|Other|Magnetic Resonance Imaging|
79308162|NCT03221231|Other|Neurocognitive measures|
79370200|NCT03833752|Diagnostic Test|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
79370201|NCT03403582|Other|Raspberries|250g frozen whole red raspberries
79370202|NCT04374916|Device|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
79370203|NCT04374916|Device|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
79370204|NCT01709864|Drug|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
79678723|NCT02946606|Drug|GX-H9|Human growth hormone
79678724|NCT02946606|Drug|Genotropin|Human growth hormone
79227287|NCT03149575|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
79227288|NCT03149575|Drug|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
79227289|NCT03149575|Drug|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
79227290|NCT03149575|Drug|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
79308163|NCT03221231|Other|Neuro-inflammatory measures|
79308164|NCT03221621|Procedure|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
79370205|NCT01709864|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
79370206|NCT04878315|Drug|Capoten|Capoten will be administered per the treatment sequence
79370207|NCT04878315|Drug|Captopril|Captopril will be administered per the treatment sequence
79370208|NCT02242708|Behavioral|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
79370209|NCT04374604|Diagnostic Test|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
79524211|NCT01725672|Drug|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524212|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524213|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524214|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524215|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
79524216|NCT01725906|Drug|empirical therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus~Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
79524217|NCT01725906|Drug|Genotypic resistance guided therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus~Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
79524218|NCT01726062|Behavioral|Motivational Interviewing plus Incentives|"Two hospital-based, face-to-face MI+ sessions~Two home-based MI+ sessions~Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
79524219|NCT01726062|Behavioral|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
79524220|NCT01726140|Procedure|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be >200, the patient will stop the treatment.
79524221|NCT01726140|Procedure|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be >200, the patient will stop the treatment.
79370210|NCT01706835|Drug|aldoxorubicin|
79370211|NCT01651533|Behavioral|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
79524222|NCT01726296|Other|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
79524223|NCT01726296|Other|medical chart review|Complete patient medical chart audit
79227291|NCT03149185|Behavioral|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
79524224|NCT01726374|Drug|BEP(500)|"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
79227292|NCT03149185|Behavioral|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
79524225|NCT01726530|Drug|transdermal fentanyl patch (50 mcg/hour)|
79524226|NCT01726530|Drug|Placebo|
79524227|NCT01726608|Procedure|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
79227293|NCT03138629|Drug|VAL-083|VAL-083 will be administered intravenously
79524228|NCT01726686|Drug|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
79524229|NCT01726686|Drug|Placebo|
79524230|NCT01726764|Other|St John's Wort|
79524231|NCT01726764|Drug|Metformin|
79524232|NCT01726842|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
79524233|NCT01726920|Drug|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
79524234|NCT01726920|Drug|naratriptan|Tablets containing naratriptan 2,5 mg
79524235|NCT01726920|Drug|naproxen|Tablets containing naproxen 500 mg
79524236|NCT01726998|Other|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
79524237|NCT01726998|Other|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
79678725|NCT00525252|Drug|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
79678726|NCT00525252|Drug|placebo|Placebo will be orally administered for 12 consecutive weeks
79678727|NCT05149391|Biological|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
79524238|NCT01727076|Other|Laboratory Biomarker Analysis|Correlative studies
79524239|NCT01727076|Other|Pharmacological Study|Correlative studies
79524240|NCT01727076|Biological|Recombinant Human Interleukin-15|Given SC
79524241|NCT01727388|Procedure|lateral decubitus|
79524242|NCT01727388|Procedure|supine decubitus|
79524243|NCT01727466|Behavioral|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
79524244|NCT01727544|Procedure|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
79524245|NCT01727622|Drug|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
79524246|NCT01727622|Other|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
79524247|NCT01727622|Procedure|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
79524248|NCT01727856|Device|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
79524249|NCT01727934|Drug|Miravirsen sodium|Subcutaneous injection
79524250|NCT01728090|Other|hand sanitizer|alcohol-based, hydroalcoholic gel
79524251|NCT01728480|Drug|entolimod|Given SC
79524252|NCT01728480|Radiation|intensity-modulated radiation therapy|Undergo IMRT
79524253|NCT01728480|Drug|cisplatin|Given IV
79524254|NCT01728480|Other|pharmacological study|Correlative studies
79524255|NCT01728480|Other|laboratory biomarker analysis|Correlative studies
79524256|NCT01728558|Other|Early goal Directed Sedation|
79524257|NCT01728558|Other|Standard care sedation|
79524258|NCT01728948|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
79524259|NCT01729104|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
79227294|NCT03137472|Device|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
79227295|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
79678728|NCT02947191|Biological|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
79370212|NCT01651533|Behavioral|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
79370213|NCT03403348|Drug|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
79678729|NCT02947113|Drug|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
79370214|NCT03403348|Drug|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
79678730|NCT02947113|Radiation|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
79678731|NCT02947113|Drug|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
79524260|NCT01729104|Drug|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
79524261|NCT01729104|Drug|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
79524262|NCT01729260|Drug|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
79678732|NCT02947113|Drug|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
79227296|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
79227297|NCT03042936|Behavioral|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
79227298|NCT03029884|Device|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
79370215|NCT02242786|Radiation|External beam radiation therapy|
79524263|NCT01729416|Other|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
79524264|NCT01729416|Other|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
79524265|NCT01729572|Other|Tele-medicine monitoring of medication adherence|
79524266|NCT01729650|Behavioral|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
79524267|NCT01729806|Biological|Ipilimumab|Given IV
79524268|NCT01729806|Other|Laboratory Biomarker Analysis|Correlative studies
79678733|NCT05149274|Drug|DWP14012 Tablet A|DWP14012 10mg
79227299|NCT03029884|Device|Sham Stimulation|No Active Stimulation
79227300|NCT03029884|Device|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
79227301|NCT03027388|Drug|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m^2.
79308165|NCT03221621|Drug|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
79370216|NCT01673451|Drug|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
79370217|NCT01673451|Drug|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
79370218|NCT02242864|Drug|Micardis®|
79370219|NCT02242864|Drug|MicardisPlus®|
79678734|NCT05149274|Drug|DWP14012 Tablet B|DWP14012 40mg
79678735|NCT02947464|Procedure|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
79678736|NCT02947464|Device|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
79998119|NCT05436587|Genetic|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
79998120|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
79823321|NCT04074200|Device|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
79823322|NCT00667875|Drug|Placebo|placebo
79998121|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
79227302|NCT03026582|Device|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
79227303|NCT03010150|Procedure|Biospecimen Collection|Provide blood samples
79998122|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
79998123|NCT01330745|Other|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
79998124|NCT02809443|Biological|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
79227304|NCT03010150|Other|Questionnaire Administration|Ancillary studies
79227305|NCT03007589|Drug|otc sunscreens|Sunscreens of various SPF levels and ingredients
79227306|NCT03007589|Other|sun protection fabrics|fabrics
79227307|NCT03007589|Other|Optical Filters|Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
79227308|NCT03005145|Other|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
79227309|NCT03005145|Other|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
79998125|NCT03584282|Behavioral|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
79998126|NCT03584282|Behavioral|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
79227310|NCT02993029|Drug|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
79227311|NCT02993029|Drug|Celecoxib|Celecoxib capsule 200mg qd by mouth.
79227312|NCT02992964|Drug|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
79227313|NCT02951338|Behavioral|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
79308166|NCT03221153|Procedure|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
79524269|NCT01729806|Biological|Rituximab|Given IV
79524270|NCT01721850|Other|control formula|commercial stage 1 infant formula
79524271|NCT01721850|Other|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
79524272|NCT01721850|Other|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
79524273|NCT01729884|Biological|HER-2/neu peptide vaccine|Given ID
79524274|NCT01724112|Drug|LY2940094|Administered orally
79524275|NCT01724112|Drug|Placebo|Administered orally
79524276|NCT01722864|Drug|COV155|COV155 tablets
79998127|NCT01330823|Dietary Supplement|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
79308167|NCT03220997|Dietary Supplement|Vitaflow Preload|Carbohydrate loading drink
79524277|NCT01724658|Drug|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
79524278|NCT01724658|Drug|placebo|placebo orally twice a week with progynova 1 mg oral daily
79524279|NCT01049334|Drug|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
79524280|NCT01049334|Drug|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
79524281|NCT01048944|Drug|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
79524282|NCT01048944|Drug|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
79227314|NCT02951338|Other|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
79524283|NCT01048944|Drug|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
79227315|NCT02934282|Drug|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
79524284|NCT01048866|Drug|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
79227316|NCT02900976|Biological|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
79678737|NCT00525291|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
79678738|NCT00525291|Device|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
79227317|NCT02900976|Biological|Rituximab|Given IV
79227318|NCT02877433|Device|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
79678739|NCT02276690|Biological|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
79678740|NCT02276690|Biological|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
79678741|NCT02947269|Drug|Prucalopride|Prucalopride 2mg capsule
79678742|NCT02947269|Drug|Placebo Oral Capsule|Placebo capsule
79678743|NCT00526305|Drug|Vincristine|1,5 mg/m2 i.v., days 1 and 8
79678744|NCT00526305|Drug|Daunorubicin|60 mg/m2, i.v., days 1 and 8
79998128|NCT01330823|Dietary Supplement|Placebo|tartaric acid same dose like L-Carnitine as placebo
79998129|NCT03636191|Dietary Supplement|Probiotic strain|Lactobacillus
79227319|NCT02877433|Device|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
79370220|NCT01709708|Drug|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
79370221|NCT01709708|Drug|Saline|Saline
79370222|NCT01673529|Drug|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
79370223|NCT01673529|Drug|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
79370224|NCT02243098|Drug|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
79370225|NCT02243098|Drug|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
79998130|NCT03636191|Dietary Supplement|Placebo|Placebo
79370226|NCT02243098|Drug|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
79370227|NCT03403114|Behavioral|Questionnaire|a 15min questionnaire
79370228|NCT01673607|Procedure|Biopsie liver|
79370229|NCT00920374|Biological|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
79370230|NCT03159039|Other|Conventional Physiotherapy|
79370231|NCT03159039|Other|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
79370232|NCT01673685|Device|Portable Oxygen|
79998131|NCT03579758|Drug|Capecitabine|Given PO
79998132|NCT03579758|Drug|Cisplatin|Given IV
79524285|NCT01048866|Drug|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
79227320|NCT02862210|Drug|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
79227321|NCT02862210|Drug|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
79227322|NCT02825901|Dietary Supplement|Placebo|Ingest placebo drink 100ml/day for 8 weeks
79227323|NCT02825901|Dietary Supplement|Djulis-Buckwheat|Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
79370233|NCT04374292|Behavioral|Family intervention|"Topics covered in each session with intervention group mothers.~Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
79524286|NCT01048866|Drug|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
79524287|NCT01048788|Drug|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
79524288|NCT01048242|Drug|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
79524289|NCT01048242|Drug|Placebo|placebo
79524290|NCT01047306|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
79524291|NCT01046682|Drug|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
79524292|NCT01044732|Device|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
79524293|NCT01044498|Drug|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
79524294|NCT01044498|Drug|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
79524295|NCT01043874|Drug|Nilotinib|400 mg BID
79524296|NCT01042938|Drug|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
79524297|NCT01042938|Drug|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
79524298|NCT01042158|Drug|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
79524299|NCT01046916|Drug|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
79524300|NCT03408912|Diagnostic Test|FFR|FFR from CMR compared to invasive FFR
79227324|NCT02825901|Dietary Supplement|Buckwheat|Ingest Buckwheat drink 100ml/day for 8 weeks
79227325|NCT02717962|Drug|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
79524301|NCT03405870|Drug|Smoflipid|Administration of lipid injectable emulsion
79524302|NCT03409302|Behavioral|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
79524303|NCT03409302|Behavioral|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
79524304|NCT03409146|Device|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
79524305|NCT03409068|Procedure|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
79524306|NCT03409068|Procedure|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
79998133|NCT03579758|Drug|Gemcitabine|Given IV
79227326|NCT02693535|Drug|Palbociclib|drug
79227327|NCT02693535|Drug|Sunitinib|drug
79227328|NCT02693535|Drug|Temsirolimus|drug
79227329|NCT02693535|Drug|Trastuzumab and Pertuzumab|drug
79524307|NCT03408834|Other|pulse variability index|fluid management with pulse variability index or conventional
79524308|NCT03408600|Other|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
79524309|NCT03408288|Other|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
79227330|NCT02693535|Drug|Vemurafenib and Cobimetinib|drug
79227331|NCT02693535|Drug|Regorafenib|drug
79998134|NCT03636113|Device|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
79227332|NCT02693535|Drug|Olaparib|drug
79370234|NCT04374292|Other|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
79370235|NCT04374526|Biological|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
79524310|NCT03408288|Other|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
79678745|NCT00526305|Drug|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
79678746|NCT00526305|Drug|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
79227333|NCT02693535|Drug|Pembrolizumab|drug
79227334|NCT02693535|Drug|Nivolumab and Ipilimumab|drug
79227335|NCT02693535|Drug|Abemaciclib|drug
79227336|NCT02693535|Drug|Talazoparib|drug
79227337|NCT02693535|Drug|Atezolizumab and PHESGO|drug
79524311|NCT03408288|Other|Color description|Describe color of reference sample
79678747|NCT00526305|Drug|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
79678748|NCT00526305|Drug|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
79227338|NCT02693535|Drug|Atezolizumab and Talazoparib|drug
79370236|NCT05284305|Other|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
79370237|NCT04374058|Other|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
79998135|NCT03577574|Procedure|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
79370238|NCT02590809|Drug|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
79524312|NCT03408210|Radiation|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
79678749|NCT00526305|Drug|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
79998136|NCT03577574|Procedure|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
79678750|NCT00526305|Drug|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
79678751|NCT00526305|Drug|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
79678752|NCT00526305|Drug|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
79678753|NCT04696016|Procedure|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
79678754|NCT04696016|Procedure|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
79227339|NCT02693535|Drug|Entrectinib|drug
79227340|NCT02693535|Drug|Larotrectinib|drug
79227341|NCT02693535|Drug|Tucatinib plus Trastuzumab Subcutaneous (SC)|drug
79227342|NCT02693535|Drug|Futibatinib|drug
79227343|NCT02693080|Device|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
79227344|NCT02693080|Drug|Isovue-200|Contrast agent
79227345|NCT02693080|Radiation|Computed Tomography Perfusion Imaging|
79227346|NCT02672917|Drug|MVT-5873|intravenous infusion (IV)
79227347|NCT02672917|Drug|modified FOLFIRINOX (mFOLFIRINOX)|IV
79370239|NCT02590809|Drug|Placebo|Placebo will be given for 30 days
79370240|NCT02590809|Other|Walk distance test|Walk distance test during 6 minutes
79370241|NCT02590809|Other|Exercise echocardiography|
79370242|NCT01709318|Drug|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
79370243|NCT01709318|Drug|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
79370244|NCT01709318|Drug|Ethinyl estradiol (EE)|Daily release of 15 μg
79370245|NCT01709318|Drug|Estradiol (E2)|Daily release of 300 μg
79678755|NCT02276768|Drug|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
79678756|NCT02276768|Drug|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
79678757|NCT02276768|Drug|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
79678758|NCT02276768|Drug|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
79678759|NCT02276768|Other|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
79823323|NCT00667875|Drug|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
79823324|NCT00667875|Drug|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
79823325|NCT05056610|Other|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
79823326|NCT00779727|Procedure|Placement of drainages|
79823327|NCT02579642|Drug|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
79823328|NCT02579642|Drug|Placebo|Normal saline administered with usual induction drugs for ECT
79823329|NCT00779805|Drug|Pseudoephedrine hydrochloride 120 mg ER tablets|
79823330|NCT00772395|Drug|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
79823331|NCT00772395|Drug|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
79823332|NCT03468998|Device|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
79370246|NCT02243254|Drug|high dose remifentanil|high dose remifentanil
79823333|NCT03468998|Device|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
79998137|NCT03577574|Procedure|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
79998138|NCT03070431|Radiation|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
79998139|NCT02238548|Biological|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
79370247|NCT02243254|Drug|Ibuprofen|intravenous ibuprofen
79370248|NCT02243254|Drug|low dose remifentanil|low dose remifentanil
79370249|NCT03402880|Biological|Pembrolizumab|Given IV
79370250|NCT03402880|Drug|Epacadostat|Given PO
79370251|NCT03402880|Other|Laboratory Biomarker Analysis|Correlative studies
79370252|NCT01673763|Device|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
79370253|NCT03402802|Drug|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
79370254|NCT01673841|Procedure|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
79370255|NCT03402724|Other|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
79370256|NCT04374214|Procedure|Complete Pulpotomy using Mineral Trioxide Aggregate|Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
79524313|NCT03408210|Radiation|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
79524314|NCT03408132|Drug|FE203799|FE203799 5 mg subcutaneous once weekly
79524315|NCT03408054|Drug|Oxytocin|Oxytocin 10-5M solution
79524316|NCT03408054|Drug|Nitroglycerin|Nitroglycerin 25-1000mcg
79823334|NCT03468998|Device|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
79823335|NCT03468998|Device|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
79823336|NCT05325398|Dietary Supplement|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
79823337|NCT05325398|Dietary Supplement|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
79823338|NCT00667251|Biological|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
79823339|NCT00667251|Drug|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
79823340|NCT00667251|Drug|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
79998140|NCT02238548|Other|Raw milk|
79998141|NCT01330901|Drug|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
79227348|NCT02672917|Drug|gemcitabine + nab-paclitaxel|IV
79227349|NCT02672475|Drug|Galunisertib|Given PO
79227350|NCT02672475|Other|Laboratory Biomarker Analysis|Correlative studies
79227351|NCT02672475|Drug|Paclitaxel|Given IV
79227352|NCT02654015|Device|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
79227353|NCT02654015|Other|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
79308168|NCT02614287|Drug|Galcanezumab|Administered SC
79524317|NCT03407976|Drug|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
79823341|NCT00667251|Drug|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
79823342|NCT04063124|Drug|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
79227354|NCT02620319|Device|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
79823343|NCT00776529|Other|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
79823344|NCT00776529|Other|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
79823345|NCT00779883|Biological|ISF35|Subjects participating in this study will receive a single dose of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells.
79370257|NCT04374214|Procedure|Complete Pulpotomy using Simvastain -alphatricalcium phosphate|Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
79227355|NCT02601755|Behavioral|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
79227356|NCT02601755|Behavioral|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
79227357|NCT02591563|Other|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
79227358|NCT02572843|Drug|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
79227359|NCT02571946|Radiation|Proton beam therapy|
79227360|NCT02546583|Drug|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
79227361|NCT02546583|Drug|IV Chlorothiazide|
79678760|NCT02946255|Behavioral|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
79823346|NCT05673746|Procedure|Acupuncture|acupuncture administration
79823347|NCT05673746|Drug|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
79227362|NCT02542696|Drug|APL-130277|"Used to treat up to 5 OFF episodes per day"
79227363|NCT02526329|Biological|donor regulatory T lymphocytes|Given IV
79823348|NCT00772473|Other|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
79998142|NCT03584204|Diagnostic Test|imaging|computed tomography, magnetic resosnance imaging, ultrasound
79227364|NCT02526329|Other|laboratory biomarker analysis|Correlative studies
79227365|NCT02503722|Other|Laboratory Biomarker Analysis|Correlative studies
79227366|NCT02503722|Drug|Osimertinib|Given PO
79370258|NCT03153345|Device|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
79823349|NCT00776607|Drug|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
79227367|NCT02503722|Other|Pharmacological Study|Correlative studies
79227368|NCT02503722|Drug|Sapanisertib|Given PO
79227369|NCT02464007|Biological|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
79227370|NCT02378636|Device|600S|Monofocal Aspheric Intraocular Lens (IOL)
79227371|NCT02375165|Procedure|phlebotomy|phlebotomy for collection of plasma and serum, ~30 cc
79370259|NCT03153345|Behavioral|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
79370260|NCT01673997|Drug|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
79370261|NCT04373824|Drug|Ivermectin|Ivermectin 200 to 400 mcg per kg body weight
79227372|NCT02346253|Radiation|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
79227373|NCT02346253|Drug|Bicalutamide|Given PO
79227374|NCT02346253|Drug|Leuprolide Acetate|Given IM or SC
79227375|NCT02346253|Drug|Goserelin Acetate|Given SC
79998143|NCT02428647|Dietary Supplement|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
79227376|NCT02346253|Drug|Triptorelin Pamoate|Given IM
79227377|NCT02346253|Drug|Degarelix|Given SC
79227378|NCT02346253|Other|Laboratory Biomarker Analysis|Correlative studies
79227379|NCT02346253|Other|Quality-of-Life Assessment|Ancillary studies
79227380|NCT02339740|Drug|Arsenic Trioxide|Given IV
79227381|NCT02339740|Drug|Cytarabine|Given IV
79227382|NCT02339740|Drug|Dexamethasone|Given PO or IV
79227383|NCT02339740|Drug|Idarubicin|Given IV
79227384|NCT02339740|Other|Laboratory Biomarker Analysis|Correlative studies
79227385|NCT02339740|Drug|Mitoxantrone Hydrochloride|Given IV
79227386|NCT02339740|Other|Quality-of-Life Assessment|Ancillary studies
79998144|NCT02428647|Dietary Supplement|preventive zinc supplement|7 mg zinc daily as dispersible tablet
79998145|NCT02428647|Dietary Supplement|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
79227387|NCT02339740|Other|Questionnaire Administration|Ancillary studies
79227388|NCT02339740|Drug|Tretinoin|Given PO
79227389|NCT02311179|Device|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
79998146|NCT02428647|Dietary Supplement|preventive placebo supplement|dispersible daily placebo tablet
79227390|NCT02311179|Device|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
79227391|NCT02306993|Other|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
79227392|NCT02306993|Other|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
79227393|NCT02306993|Other|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
79227394|NCT02290145|Drug|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
79227395|NCT02290145|Procedure|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
79227396|NCT02290145|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
79227397|NCT02285543|Drug|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
79227398|NCT02285543|Procedure|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
79227399|NCT02285543|Radiation|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
79524318|NCT03407976|Drug|Pembrolizumab|200 mg Q3 weeks IV
79524319|NCT03407898|Other|intubation time|intubation attempt number and intubation time
79524320|NCT03407820|Procedure|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
79524321|NCT03407820|Procedure|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
79227400|NCT02234219|Procedure|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
79227401|NCT02215928|Genetic|mutation analysis|Correlative studies
79227402|NCT02215928|Other|cytology specimen collection procedure|Correlative studies
79227403|NCT02215928|Other|laboratory biomarker analysis|Correlative studies
79227404|NCT02163395|Device|FullCeram implant|FullCeram implantation
79370262|NCT01676571|Drug|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
79370263|NCT04373980|Device|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
79370264|NCT01699178|Drug|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
79370265|NCT01699178|Drug|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
79524322|NCT03407742|Behavioral|CAPAS Youth|9-week parenting intervention
79370266|NCT02243332|Device|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
79370267|NCT03402646|Behavioral|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
79370268|NCT03402646|Behavioral|Photovoice|Same as described under arm/group descriptions
79370269|NCT02077959|Drug|lenalidomide|Given PO
79998147|NCT02428647|Dietary Supplement|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
79998148|NCT02428647|Dietary Supplement|placebo powder|placebo powder
79998149|NCT01071395|Drug|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
79227405|NCT02161900|Other|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
79227406|NCT02139605|Procedure|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
79227407|NCT01916317|Drug|0.5% lignocaine 60mM|
79227408|NCT01913132|Device|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
79227409|NCT01911897|Device|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
79227410|NCT01910909|Radiation|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
79370270|NCT02077959|Biological|pidilizumab|Given IV
79370271|NCT02077959|Other|pharmacological study|Correlative studies
79524323|NCT03407664|Other|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
79524324|NCT03407586|Diagnostic Test|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
79524325|NCT03407508|Dietary Supplement|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
79370272|NCT02077959|Other|laboratory biomarker analysis|Correlative studies
79524326|NCT03407352|Behavioral|Active Video Game Play|60 minutes of active video game play at a moderate intensity
79524327|NCT03407352|Behavioral|Passive Video Game Play|60 minutes of passive video game play
79524328|NCT03407196|Drug|Forxiga|Oral antidiabetics
79524329|NCT03406416|Device|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
79524330|NCT03406026|Other|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
79524331|NCT03406026|Other|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
79998150|NCT01071395|Drug|Placebo|Sugar pill given 3 times daily
79998151|NCT02970942|Drug|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
79998152|NCT02970942|Drug|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
79998153|NCT05433311|Other|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
79998154|NCT03577496|Other|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
79998155|NCT05429723|Drug|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
79370273|NCT01683409|Drug|Baricitinib|Administered orally
79370274|NCT01683409|Drug|Placebo|Administered orally
79370275|NCT04548518|Biological|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
79370276|NCT04548518|Biological|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
79370277|NCT02243488|Device|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
79524332|NCT03405948|Drug|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
79998156|NCT05429723|Drug|HS-10383 Placebo|Placebo for HS-10383
79998157|NCT03073005|Other|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
79998158|NCT03577340|Other|implant of cardiac device as per guidelines|Observation of performance to validate matrix
79678761|NCT02946255|Behavioral|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
79678762|NCT02946255|Behavioral|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
79678763|NCT05148221|Other|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
79998159|NCT03582878|Drug|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
79998160|NCT03582878|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
79998161|NCT01331057|Other|NEEL test|An assessment for children in French with items extracted from the NEEL test
79998162|NCT01331057|Other|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
79998163|NCT01331057|Other|Interview|For parents of children include in the study: A semi -structured interview
79227411|NCT01785420|Drug|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
79227412|NCT01785420|Drug|Placebo|A 90 minute intravenous infusion of saline as placebo
79227413|NCT01719887|Device|Conservative treatment|Conservative treatment with functional brace.
79227414|NCT01719887|Procedure|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
79524333|NCT03405636|Device|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
79524334|NCT03405402|Procedure|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
79524335|NCT03405324|Device|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
79524336|NCT03405324|Device|sham tDCS|sham tDCS
79524337|NCT03405246|Behavioral|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
79998164|NCT03579524|Procedure|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
79998165|NCT03579524|Procedure|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
79998166|NCT02238704|Dietary Supplement|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
79998167|NCT02238704|Dietary Supplement|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
79998168|NCT03577262|Other|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
79998169|NCT01331135|Drug|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
79998170|NCT03577184|Drug|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
79524338|NCT03405246|Behavioral|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
79524339|NCT03405168|Drug|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
79524340|NCT03404934|Device|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
79524341|NCT03404856|Drug|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
79227415|NCT01719887|Other|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
79524342|NCT03404622|Drug|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
79524343|NCT03404466|Drug|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
79998171|NCT02849171|Device|PET scan|
79998172|NCT02849171|Radiation|C-Choline|
79998173|NCT03888885|Behavioral|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
79998174|NCT02848664|Device|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
79227416|NCT01682941|Dietary Supplement|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
79370278|NCT01699022|Drug|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
79370279|NCT01670175|Drug|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
79370280|NCT03402490|Behavioral|Motivational interviewing|
79998175|NCT03635879|Other|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
79998176|NCT03635879|Other|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
79998177|NCT03635879|Other|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
79998178|NCT03635879|Other|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
79998179|NCT03635879|Other|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
79998180|NCT03635879|Drug|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
79998181|NCT02238860|Drug|Entacavir|Entacavir-0.5 mg ,OD,for
79998182|NCT02238860|Drug|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
79998183|NCT01333709|Drug|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
79998184|NCT01333709|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
79998185|NCT01333709|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
79998186|NCT01333709|Radiation|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
79370281|NCT01674231|Other|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
79370282|NCT01674231|Other|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
79370283|NCT02243566|Drug|MicardisPlus®|
79524344|NCT03404232|Device|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
79524345|NCT03404154|Diagnostic Test|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
79227417|NCT01682941|Dietary Supplement|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
79370284|NCT01670253|Behavioral|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
79524346|NCT03404154|Procedure|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
79524347|NCT03403920|Other|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
79524348|NCT03403764|Other|Wellness Intention|
79524349|NCT03403530|Drug|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
79524350|NCT03403452|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
79524351|NCT03403296|Genetic|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
79227419|NCT01631292|Dietary Supplement|600 IU Vitamin D3|Once daily
79370285|NCT04373590|Behavioral|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
79678764|NCT05148221|Other|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
79227420|NCT01631292|Dietary Supplement|2000 IU Vitamin D3|Once daily
79227421|NCT01631292|Dietary Supplement|4000 IU Vitamin D3|Once daily
79227422|NCT01523223|Biological|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
79370286|NCT01683019|Device|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
79678765|NCT00526383|Drug|Tricyclic antidepressants|antidepressant version medical dispositive
79227423|NCT01447667|Procedure|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
79678766|NCT05145257|Dietary Supplement|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
79227424|NCT01397552|Drug|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
79370287|NCT01683019|Device|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
79227425|NCT01397552|Drug|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
79227426|NCT01256710|Device|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
79370288|NCT03861507|Device|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
79678767|NCT05147753|Drug|Moxonidine|0.6 mg moxonidine daily
79678768|NCT00525408|Biological|Mycobacterium w.|Immunomodulator
79998187|NCT01333709|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
79227427|NCT01096368|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
79227428|NCT01096368|Drug|Carboplatin|Given IV
79227429|NCT01096368|Drug|Cisplatin|Given IV
79227430|NCT01096368|Other|Clinical Observation|Patients undergo observation
79227431|NCT01096368|Drug|Cyclophosphamide|Given IV
79227432|NCT01096368|Drug|Etoposide|Given IV
79227433|NCT01096368|Biological|Filgrastim|Given SC or IV
79227434|NCT01096368|Other|Laboratory Biomarker Analysis|Optional correlative studies
79227435|NCT01096368|Drug|Mesna|Given IV
79227436|NCT01096368|Drug|Vincristine|Given IV
79227437|NCT01090908|Drug|Antibiotic|
79227438|NCT01057173|Procedure|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
79227439|NCT01057173|Procedure|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
79227440|NCT01048281|Procedure|Blood draw|
79227441|NCT01048281|Procedure|Tissue tumor biopsy|
79227442|NCT01020903|Procedure|Aprepitant|40 mg po pre-op
79227443|NCT01020903|Drug|Placebo|Orally, pre-op
79227444|NCT00984321|Behavioral|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
79227445|NCT00984321|Behavioral|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
79308169|NCT03220919|Other|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
79370289|NCT02243644|Drug|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
79370290|NCT02243644|Drug|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
79678769|NCT00525408|Drug|Docetaxel|Chemotherapeutic agent
79998188|NCT02239172|Biological|PA83-FhCMB|
79524352|NCT03403140|Drug|Etanercept|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
79227446|NCT00984321|Behavioral|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
79524353|NCT03402984|Drug|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
79370291|NCT04373356|Device|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
79227447|NCT00938587|Drug|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
79227448|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
79227449|NCT00938587|Drug|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
79227450|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
79227451|NCT00938587|Drug|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
79227452|NCT00938587|Other|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
79227453|NCT00938587|Other|Placebo|Placebo tablet every day for 14 days
79227454|NCT00938587|Other|Placebo for PF-04171327|Placebo tablet every day for 14 days
79370292|NCT04373356|Device|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
79370293|NCT03402412|Other|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
79370294|NCT01745757|Drug|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
79370295|NCT01745757|Drug|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
79370296|NCT03402178|Drug|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
79370297|NCT03402178|Drug|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
79370298|NCT01709162|Biological|Ipilimumab|
79370299|NCT01709162|Drug|Chemotherapy|
79370300|NCT04764201|Drug|HIP2001|Test drug
79524354|NCT03402984|Drug|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
79524355|NCT03402828|Drug|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
79678770|NCT00508235|Behavioral|Questionnaire|Questionnaire about the patient's relationship with their best friend.
79678771|NCT00525447|Drug|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
79678772|NCT00525447|Drug|lenalidomide|Up to 25 mg daily of a 21-day cycle.
79227455|NCT00937937|Drug|Dinaciclib|Given IV
79227456|NCT00900497|Biological|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
79227457|NCT00898313|Genetic|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
79227458|NCT00898313|Genetic|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
79227459|NCT00898313|Genetic|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
79227460|NCT00898313|Other|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
79227461|NCT00898313|Procedure|nasal brushing|Using a brush, superficial cells are removed from the nose.
79227462|NCT00898313|Procedure|Blood draw|Venous blood will be collected
79227463|NCT00898313|Procedure|Urine collection|Subjects will be asked to provide a urine specimen.
79227464|NCT00898313|Procedure|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
79370301|NCT04764201|Drug|HGP2001|Reference drug
79370302|NCT02243800|Other|cholecalciferol versus placebo|
79370303|NCT04764123|Diagnostic Test|AVNRT mapping|AV annuli mapping during AVNRT
79370304|NCT03402100|Drug|eye drops|children who received daily eye drops for myopia
79370305|NCT01674309|Drug|FOLFORINOX|INTRAVENOUS administration
79370306|NCT02243956|Other|Flavanol rich food product|polyphenol rich test product
79370307|NCT04764045|Drug|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
79370308|NCT01698554|Drug|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
79678773|NCT00525447|Drug|dexamethasone|40 mg administered weekly.
79678774|NCT00525486|Drug|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
79678775|NCT05145101|Biological|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
79678776|NCT02946060|Other|Audiobooks|iPods with audiobooks
79678777|NCT02946060|Other|Tempo-pace synchronized playlists|Playlists with or without RAS
79678778|NCT02946060|Other|Usual Care|iPods containing either a silent track or white noise
79227465|NCT00898313|Procedure|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
79678779|NCT00525564|Drug|Placebo|Placebo diskus inhalation powder
79678780|NCT00525564|Drug|Salmeterol diskus inhalation powder|50 micrograms twice a day
79678781|NCT04693143|Other|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
79678782|NCT03453125|Behavioral|Spanish modified Story Memory Technique (mSMT)|
79678783|NCT04692909|Device|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
79678784|NCT02953964|Other|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
79678785|NCT02953964|Other|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
79678786|NCT02953964|Other|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
79678787|NCT02954003|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
79678788|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
79823350|NCT00776607|Drug|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
79823351|NCT04054544|Dietary Supplement|Gluten powder 4g|Gluten powder 4g oral BID
79823352|NCT00776685|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
79823353|NCT00780039|Drug|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
79227466|NCT00898313|Procedure|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
79227467|NCT00898313|Procedure|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
79227468|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
79678789|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
79678790|NCT02954042|Device|Pelvital probe|Pelvital probe
79678791|NCT02954042|Device|Placebo Probe|Placebo Probe
79678792|NCT00526422|Procedure|Dental Preventive|
79678793|NCT03459365|Device|Euflexxa|Aspirations performed before each injection and at six weeks.
79678794|NCT00525681|Drug|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
79678795|NCT00525681|Drug|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
79678796|NCT03455387|Diagnostic Test|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
79227469|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
79227470|NCT00810693|Drug|Placebo|Matching Placebo tid orally for 12 weeks
79227471|NCT00709150|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
79678797|NCT03456635|Other|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
79227472|NCT00709150|Behavioral|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
79227473|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
79227474|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
79678798|NCT04692636|Diagnostic Test|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
79678799|NCT02955095|Device|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
79678800|NCT02276898|Drug|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
79227475|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
79227476|NCT00655200|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79227477|NCT00381641|Other|Laboratory Biomarker Analysis|Optional correlative studies
79678801|NCT02276898|Drug|Isotonic Saline 0.9% (Placebo)|
79370309|NCT01698554|Drug|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
79678802|NCT00508313|Procedure|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
79823354|NCT00780039|Drug|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
79823355|NCT03436550|Procedure|mpMRI|Multiparametric MRI
79823356|NCT03436550|Procedure|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
79823357|NCT00669903|Drug|AZD0328|
79823358|NCT00669903|Drug|Placebo|
79823359|NCT00776763|Drug|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
79370310|NCT01698554|Drug|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
79370311|NCT01698554|Drug|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
79524356|NCT03402672|Other|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
79524357|NCT03402594|Device|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
79524358|NCT03402594|Device|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
79524359|NCT03402516|Device|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
79524360|NCT03402516|Device|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
79524361|NCT03402438|Drug|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
79524362|NCT03402360|Other|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
79524363|NCT03402360|Other|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
79227478|NCT00381641|Other|Pharmacogenomic Study|Optional correlative studies
79227479|NCT00381641|Drug|Sunitinib|Given PO
79227480|NCT00381641|Drug|Sunitinib Malate|Given PO
79227481|NCT00334815|Biological|Bevacizumab|Given IV
79227482|NCT00334815|Drug|Cisplatin|Given IV
79227483|NCT00334815|Drug|Docetaxel|Given IV
79227484|NCT00334815|Drug|Etoposide|Given IV
79227485|NCT00334815|Biological|Filgrastim|Given SC
79370312|NCT03401944|Drug|TPN|
79370313|NCT03401944|Other|Control|
79370314|NCT04404855|Other|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
79678803|NCT02945982|Drug|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
79998189|NCT05202717|Device|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
79227486|NCT00334815|Biological|Pegfilgrastim|Given SC
79678804|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
79678805|NCT00508352|Procedure|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
79678806|NCT02947230|Other|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
79823360|NCT00772551|Drug|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
79823361|NCT00772551|Drug|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
79227487|NCT00334815|Radiation|Radiation Therapy|Undergo thoracic radiotherapy
79227488|NCT00186147|Procedure|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
79227489|NCT05269563|Other|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
79227490|NCT05267834|Procedure|Conization and/or Hysterectomy|Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy
79823362|NCT00776841|Drug|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
79823363|NCT00776841|Drug|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
79823364|NCT00776841|Drug|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
79823365|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
79998190|NCT05202717|Device|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
79998191|NCT02969382|Drug|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
79998192|NCT02969382|Drug|Placebo - Cap|One Placebo capsule daily for 4 weeks
79998193|NCT03579368|Device|Symfony implantation|Bilateral Symfony IOL Implantation
79227491|NCT05266287|Dietary Supplement|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
79227492|NCT05266287|Dietary Supplement|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
79227493|NCT05253547|Behavioral|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
79370315|NCT04404855|Procedure|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
79370316|NCT03401866|Diagnostic Test|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
79524364|NCT03402204|Drug|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
79524365|NCT03402204|Drug|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
79524366|NCT03402048|Drug|Carboplatin|
79227494|NCT05253547|Behavioral|Healthy dietary guidelines|Personalised healthy dietary recommendations
79370317|NCT04763733|Other|laparoscopic splenectomy|surgical
79370318|NCT04376866|Drug|Toripalimab|anti-PD-1 antibody
79370319|NCT00895791|Device|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
79370320|NCT00895791|Device|culotte stenting (Xience V)|implantation of stent
79524367|NCT03402048|Drug|Gemcitabine|
79524368|NCT03402048|Drug|Pemetrexed|
79524369|NCT03402048|Drug|Docetaxel|
79524370|NCT03402048|Drug|Vinorelbine|
79524371|NCT03401892|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
79524372|NCT03401892|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
79823366|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
79998194|NCT01333787|Dietary Supplement|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
79823367|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
79998195|NCT03574922|Other|Balance exercises|Balance Exercises
79998196|NCT03574922|Other|Core Stabilization exercises|Core Stabilization exercises
79823368|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
79823369|NCT04047615|Other|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
79823370|NCT03759392|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
79823371|NCT03759392|Drug|Placebo|Oral placebo twice daily for up to 20 weeks
79227495|NCT05233982|Drug|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
79823372|NCT02556879|Biological|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
79998197|NCT04869137|Drug|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
79998198|NCT04869137|Drug|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
79998199|NCT02239250|Device|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
79998200|NCT03651414|Other|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
79998201|NCT00493961|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
79998202|NCT03077789|Procedure|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
79998203|NCT00175136|Device|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
79998204|NCT03649776|Other|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
79998205|NCT02589509|Behavioral|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
79998206|NCT02589509|Behavioral|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
79227496|NCT05226702|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
79823373|NCT02556879|Biological|Serum bank|Additional samples for serum bank at each visit if possible
79823374|NCT02556879|Biological|DNA bank|Additional sample for DNA bank at inclusion visit if possible
79823375|NCT02556879|Procedure|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
79823376|NCT02556879|Procedure|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
79524373|NCT03401892|Device|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
79524374|NCT03401814|Other|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
79823377|NCT00777075|Drug|L-arginine|
79823378|NCT00777075|Drug|Placebo|
79823379|NCT00772863|Drug|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
79998207|NCT02903238|Drug|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
79227497|NCT05226702|Biological|Saline Placebo|Intramuscular injection of saline placebo
79227498|NCT05221450|Procedure|primary endodontic treatment|
79227499|NCT05209009|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
79227500|NCT05209009|Biological|Saline Placebo|Intramuscular injection of saline placebo
79823380|NCT04075760|Procedure|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
79678807|NCT02954393|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
79524375|NCT03401658|Device|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
79524376|NCT03401580|Drug|Viena II 160/10|once daily
79678808|NCT02954393|Drug|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
79524377|NCT03401580|Drug|Viena II 190/10|once daily
79524378|NCT03401580|Drug|Viena II 160/12|once daily
79678809|NCT02954393|Drug|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
79678810|NCT02954393|Drug|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
79227501|NCT05208567|Diagnostic Test|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
79370321|NCT01674387|Device|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
79227502|NCT05199493|Drug|Angiotensin II|Patients with Delta-renin >= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
79370322|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
79370323|NCT03401632|Other|Enteral nutrition|Enteral nutrition support
79678811|NCT02954393|Drug|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
79678812|NCT02954393|Drug|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
79823381|NCT04075760|Drug|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
79823382|NCT05674058|Other|No intervention|According to clinical practice.
79823383|NCT02580656|Behavioral|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
79998208|NCT02903238|Drug|Placebo Oral Tablet|Lactose capsule
79227503|NCT05199493|Drug|Control|Patients with Delta-renin >= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
79227504|NCT05193279|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
79998209|NCT01331369|Behavioral|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
79998210|NCT01331369|Other|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
79370324|NCT01698320|Drug|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
79370325|NCT01698320|Drug|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
79370326|NCT03401554|Procedure|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
79370327|NCT03401554|Procedure|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
79524379|NCT03401580|Drug|Viena II 190/12|once daily
79524380|NCT03401502|Drug|Ranolazine|Oral, b.i.d
79524381|NCT03401502|Drug|Placebos|Oral, b.i.d
79524382|NCT03401424|Procedure|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
79524383|NCT03401424|Procedure|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
79524384|NCT03401346|Combination Product|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
79524385|NCT03401346|Drug|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
79524386|NCT03401346|Combination Product|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
79678813|NCT02954393|Drug|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
79227505|NCT05189236|Procedure|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~The child is admitted to the unit and evaluated.~The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~The inclusion and exclusion criteria are evaluated.~The group of the child to be included in the study is determined in accordance with the randomization order.~The first section of the patient information and follow-up form is filled out.~The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~Common procedure steps are followed.~The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
79998211|NCT03621852|Device|Endoultrasound guided FNB|EUS FNB with Aquire TM device
79678814|NCT02947152|Drug|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
79678815|NCT02954276|Drug|Omexa Sublingual Sumatriptan tablet|75 mg
79678816|NCT02954276|Drug|Imitrex Oral Product|100 mg
79308170|NCT03220919|Other|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, >10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, > 20 mmol/L."
79678817|NCT02947074|Behavioral|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
79678818|NCT00507494|Drug|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
79370328|NCT01674465|Biological|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m^2 two-three hours prior to their standard of care biopsy
79370329|NCT03401476|Drug|Morphine Sulfate|Morphine Sulfate Tablets
79370330|NCT03884673|Drug|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
79370331|NCT04376944|Other|Survey|questionnaire on their symptoms and their exposures
79370332|NCT04548206|Other|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
79370333|NCT04548206|Other|control|The program consisted of progressive relaxation exercises at home.
79370334|NCT04372810|Procedure|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
79370335|NCT04372810|Procedure|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
79998212|NCT03651024|Device|ED surgery|The surgical implant for ED treatment
79308171|NCT03220763|Other|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
79308172|NCT03220841|Drug|Adalimumab Injection|Standard dose adalimumab induction and maintenance
79524387|NCT03401268|Drug|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
79524388|NCT03400878|Biological|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
79524389|NCT03400878|Biological|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
79524390|NCT03400722|Drug|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
79524391|NCT03400722|Drug|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
79524392|NCT03400644|Device|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
79524393|NCT03400566|Behavioral|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
79524394|NCT03400566|Behavioral|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
79524395|NCT03400488|Drug|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
79678819|NCT00526500|Behavioral|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
79678820|NCT00507533|Procedure|Continuous positive airway pressure|
79678821|NCT00526539|Other|Total hip replacement, Spectron and Taperloc|
79998213|NCT01329809|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
79678822|NCT00507611|Procedure|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
79227506|NCT05189236|Procedure|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~Common procedure steps are followed.~Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
79678823|NCT00507650|Dietary Supplement|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
79678824|NCT00507650|Dietary Supplement|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
79678825|NCT02946957|Behavioral|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
79227507|NCT05178017|Diagnostic Test|Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program|The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
79678826|NCT02946957|Behavioral|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
79678827|NCT00507806|Drug|perflutren lipid microsphere|
79678828|NCT00526578|Behavioral|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
79678829|NCT00508430|Drug|ASP8825|oral
79678830|NCT00508430|Drug|Placebo|oral
79678831|NCT00526617|Drug|ABT-888|Oral capsules
79678832|NCT00526617|Drug|Temozolomide|Oral capsules
79227508|NCT05157906|Behavioral|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
79227509|NCT05157906|Behavioral|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
79227510|NCT05112536|Drug|Trilaciclib|Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
79227511|NCT05112536|Drug|Cylophosphamide|Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
79227512|NCT05112536|Drug|Doxorubicin|Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
79227513|NCT05112536|Drug|Paclitaxel|Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
79227514|NCT05112536|Drug|Carboplatin (Investigator discretion)|Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
79678833|NCT00507845|Drug|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
79227515|NCT05112536|Biological|Pembrolizumab (Investigator discretion)|Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
79227516|NCT05109455|Dietary Supplement|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
79524396|NCT03400488|Other|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
79524397|NCT03400254|Drug|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
79678834|NCT04693065|Other|ponseti|Standard of care, treatment by ponseti method
79678835|NCT02946177|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
79227517|NCT05109455|Dietary Supplement|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
79678836|NCT02946177|Other|Sterile Saline|0.5 mL of sterile Saline administered im
79678837|NCT04693455|Drug|ZD03|ZD03 capsule
79678838|NCT04693455|Other|Placebo|placebo capsule
79678839|NCT02946138|Radiation|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
79678840|NCT00507884|Procedure|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
79678841|NCT00507962|Drug|Cisplatin|100 mg/m^2 Intraarterial On Day 1 Every 4 Weeks
79678842|NCT00507962|Drug|Liposomal Doxorubicin|Starting dose 20 mg/m^2 IV On Day 1 Every 4 Weeks
79678843|NCT02946099|Procedure|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
79678844|NCT02946099|Procedure|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
79678845|NCT02954315|Other|Almonds|
79678846|NCT04692948|Other|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
79823384|NCT03741920|Device|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording.~A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
79823385|NCT00667719|Drug|Aliskiren|300 mg tablet
79998214|NCT02847260|Drug|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
79308173|NCT03220841|Drug|Thiopurine|Dose optimized thiopurine
79678847|NCT00508508|Behavioral|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
79678848|NCT00508508|Behavioral|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
79678849|NCT02485938|Drug|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
79678850|NCT00508586|Drug|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
79678851|NCT02946216|Genetic|ctDNA analysis|
79678852|NCT00508040|Drug|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
79678853|NCT00508040|Drug|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
79678854|NCT02946840|Device|FNA with 25 G Beacon needle|
79678855|NCT00508664|Radiation|Radiation|Radiation start in week 11
79998215|NCT02872571|Drug|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
79998216|NCT03650946|Diagnostic Test|Ga-68 PSMA PET|Ga-68 PSMA PET
79678856|NCT00508664|Drug|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
79678857|NCT00508664|Drug|Docetaxel|75 mg/m2 i.v. day 1 3 times
79998217|NCT01331447|Drug|exemestane|25 mg tablet
79998218|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 500|Experimental arm
79998219|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 1000|Experimental arm
79998220|NCT03574844|Dietary Supplement|Placebo|Placebo comparator arm
79998221|NCT03649620|Dietary Supplement|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
79998222|NCT03649620|Dietary Supplement|Placebo|Placebo for 12 weeks
79998223|NCT02968563|Drug|Tirabrutinib|Tablets administered orally
79998224|NCT02968563|Drug|Idelalisib|Tablets administered orally
79998225|NCT02968563|Drug|Obinutuzumab|Administered intravenously
79998226|NCT01329887|Drug|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
79998227|NCT03579212|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
79308174|NCT03220841|Procedure|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
79308175|NCT03047655|Behavioral|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
79308176|NCT03047655|Dietary Supplement|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
79308177|NCT03220607|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
79308178|NCT04866927|Dietary Supplement|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
79678858|NCT00508664|Drug|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
79823386|NCT00667719|Drug|Amlodipine|5 mg tablet
79823387|NCT00667719|Drug|Hydrochlorothiazide|12.5 mg and 25 mg capsule
79823388|NCT00922077|Behavioral|standard physical therapy program with emphasis on dynamic balance exercises|
79823389|NCT00777387|Procedure|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
79823390|NCT00777387|Procedure|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
79227518|NCT05105269|Other|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
79524398|NCT03400254|Drug|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC >1.0 x 109/L and platelet count > 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to <grade 1 then any further treatment with GED should be stopped."
79678859|NCT00508664|Drug|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
79678860|NCT02946684|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
79678861|NCT02946684|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
79678862|NCT02953379|Drug|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
79678863|NCT02953379|Drug|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
79678864|NCT02946645|Device|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
79678865|NCT02946645|Procedure|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~Place knuckle of index finger between top and bottom teeth.~Remove it, keeping the teeth separated one-knuckle apart.~Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
79678866|NCT02946645|Other|Placebo|No interventions.
79524399|NCT03400098|Drug|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
79678867|NCT02954120|Other|no intervention provided|
79678868|NCT02946801|Drug|Essential oils|
79823391|NCT00780351|Device|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
79823392|NCT03429296|Other|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
79823393|NCT00780585|Drug|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
79823394|NCT00780663|Drug|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
79998228|NCT01334099|Biological|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
79998229|NCT01334099|Radiation|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
79998230|NCT03650868|Procedure|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
79998231|NCT03579134|Device|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
79823395|NCT02581514|Other|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
79823396|NCT04030910|Other|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
79823397|NCT00669669|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
79823398|NCT00669669|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
79998232|NCT03579134|Other|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
79998233|NCT01331525|Biological|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
79227519|NCT05097014|Drug|CHF5993|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
79227520|NCT05097014|Drug|CHF1535|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
79227521|NCT05097014|Other|Matched placebo|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
79227522|NCT05085483|Dietary Supplement|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
79227523|NCT05085483|Dietary Supplement|Isocaloric placebo supplement|Isocaloric placebo supplement
79227524|NCT05079360|Drug|Sabizabulin|32mg each day by mouth
79524400|NCT03400020|Other|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
79524401|NCT03400020|Other|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
79524402|NCT03408444|Device|EMO-114|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
79524403|NCT03408444|Device|EMO-116|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
79823399|NCT00669669|Drug|Carmustine|Given IV
79823400|NCT00669669|Biological|Filgrastim|Given SC
79823401|NCT00669669|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
79823402|NCT00669669|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
79823403|NCT00669669|Other|Laboratory Biomarker Analysis|Correlative studies
79524404|NCT03408444|Device|EMO-118|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
79524405|NCT03408444|Device|EMO-117|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
79678869|NCT02946801|Drug|Essential oils without alcohol|
79678870|NCT02946801|Drug|Sterile water|
79678871|NCT02953808|Drug|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
79227525|NCT05079360|Drug|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
79678872|NCT02953808|Drug|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
79227526|NCT05078060|Biological|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
79678873|NCT02953847|Drug|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
79678874|NCT02953847|Drug|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
79678875|NCT02953847|Drug|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
79678876|NCT00526695|Drug|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
79370336|NCT01674543|Other|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
79370337|NCT01674543|Other|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
79524406|NCT03401190|Drug|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
79678877|NCT02953730|Drug|PEG-rhG-CSF|
79678878|NCT00526929|Drug|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
79678879|NCT02953691|Drug|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
79678880|NCT02953691|Drug|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
79678881|NCT02953535|Drug|Magicbuvir|1 tablet contains 400 mg sofosbuvir
79678882|NCT02953535|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
79678883|NCT02953535|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
79678884|NCT02953613|Device|NIRS/IVUS|Cardiac catheterization using infraredx
79678885|NCT02953574|Procedure|daily sleep enhancement nursing protocol|
79227527|NCT05078060|Biological|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
79678886|NCT00526734|Biological|filgrastim|
79678887|NCT00526734|Biological|pegfilgrastim|
79678888|NCT00526734|Drug|melphalan|
79678889|NCT00526734|Procedure|autologous hematopoietic stem cell transplantation|
79678890|NCT00508703|Radiation|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
79227528|NCT05066373|Drug|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
79678891|NCT00508703|Procedure|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
79678892|NCT00526773|Other|telephone management plus a motivational intervention|heart failure intervention
79678893|NCT00526773|Other|telephone management with standard patient education|heart failure intervention
79678894|NCT02953496|Drug|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
79678895|NCT00508781|Behavioral|Multiphoton laser image in cutaneous pathology|
79678896|NCT00508859|Drug|Sertraline|maintenance treatment with sertraline
79998234|NCT03650790|Diagnostic Test|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
79370338|NCT01674543|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
79678897|NCT00508859|Drug|placebo|placebo
79998235|NCT03792165|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
79678898|NCT00526851|Other|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
79678899|NCT00508898|Drug|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
79823404|NCT00669669|Drug|O6-Benzylguanine|Given IV
79823405|NCT00669669|Drug|Plerixafor|Given SC
79823406|NCT00669669|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
79823407|NCT00669669|Drug|Temozolomide|Given PO
79998236|NCT03792165|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
79998237|NCT03649542|Other|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
79370339|NCT01674699|Device|EXCOR Pediatric|Ventricular Assist Device
79370340|NCT01674777|Drug|ASP1941|oral
79370341|NCT03876717|Drug|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
79370342|NCT03876717|Drug|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
79370343|NCT01674855|Drug|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
79370344|NCT01674855|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
79370345|NCT00924352|Drug|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
79370346|NCT00924352|Drug|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
79370347|NCT01674933|Drug|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
79370348|NCT01674933|Behavioral|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
79370349|NCT03852693|Other|Histopathological review|Histopathological review
79678900|NCT00508898|Drug|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
79678901|NCT02944890|Device|Drug Eluting Balloon Catheters(RESTORE DEB）|
79678902|NCT02944890|Device|Drug Eluting Balloon Catheters(SeQuent® Please）|
79678903|NCT00508937|Other|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
79678904|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
79678905|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
79678906|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
79678907|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
79823408|NCT02579564|Drug|Gemcitabine|
79823409|NCT02579564|Drug|Vinorelbine|
79823410|NCT02579564|Drug|Paclitaxel|
79823411|NCT02579564|Drug|Pemetrexed|
79823412|NCT02579564|Drug|Oncorine|
79998238|NCT01334177|Drug|TLR8 agonist VTX-2337|Given SC
79998239|NCT01334177|Biological|cetuximab|Given IV
79998240|NCT01334177|Other|laboratory biomarker analysis|Correlative studies
79998241|NCT01334177|Other|pharmacogenomic studies|Correlative studies
79998242|NCT03578978|Other|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
79998243|NCT03574766|Behavioral|Meditation|Daily meditation
79998244|NCT03649386|Device|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
79998245|NCT03649386|Device|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
79998246|NCT03574688|Dietary Supplement|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
79998247|NCT05763537|Behavioral|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
79998248|NCT05763537|Behavioral|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
79998249|NCT05761821|Device|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
79998250|NCT05762523|Biological|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
79998251|NCT05762523|Biological|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
79678908|NCT04692558|Biological|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
79524407|NCT03401190|Drug|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
79524408|NCT03406728|Other|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
79678909|NCT04692558|Procedure|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
79678910|NCT02952599|Drug|Edoxaban|Prescribed according to approved label
79678911|NCT00526968|Drug|EVT 101|8 mg capsule, single oral dose
79998252|NCT05762523|Biological|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
79227529|NCT05066373|Drug|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
79370350|NCT04373044|Drug|Baricitinib|Given PO
79524409|NCT03406728|Other|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
79524410|NCT03406728|Device|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
79524411|NCT03403218|Behavioral|Case group|assessment of quality on posture, transfers and displacement
79998253|NCT05762523|Biological|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
79998254|NCT02796261|Drug|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
79998255|NCT02796261|Drug|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
79370351|NCT04373044|Drug|Hydroxychloroquine|Given PO
79370352|NCT04373044|Drug|Placebo Administration|Given Po
79370353|NCT03851991|Drug|Arbidol|oral
79370354|NCT03851991|Drug|Placebos|controle
79370355|NCT01675089|Drug|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
79678912|NCT00526968|Drug|EVT 101|15 mg capsule, single oral dose
79678913|NCT00526968|Drug|placebo|Placebo capsule, single oral dose
79678914|NCT00510419|Drug|"InvestigationalAuto-injector (sumatriptan succinate)"|
79678915|NCT00527007|Other|External cooling|External cooling
79678916|NCT00510536|Drug|Acetaminophen|dose to be determined by investigator
79678917|NCT00510536|Drug|NSAID|dose to be determined by investigator
79678918|NCT03458715|Drug|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
79678919|NCT03458715|Drug|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
79678920|NCT00510575|Device|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
79678921|NCT02944812|Drug|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
79678922|NCT00510614|Drug|tinidazole|1 gram twice weekly for 12 weeks
79227530|NCT05066373|Drug|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
79227531|NCT05063786|Biological|Trastuzumab|"6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)*, or 600 mg SC every 3 weeks.~* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
79227532|NCT05063786|Drug|Alpelisib|300 mg oral once daily.
79370356|NCT01675245|Drug|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
79524412|NCT03400956|Drug|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
79524413|NCT03400956|Drug|Placebo|Orally, coated tablet, once daily
79524414|NCT00012012|Drug|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
79524415|NCT00012012|Drug|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
79678923|NCT00510614|Drug|Placebo|one pill twice weekly for 12 weeks
79678924|NCT00508976|Drug|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
79823413|NCT02579564|Drug|Endostar|
79823414|NCT02579564|Drug|Cisplatin|
79998256|NCT02796261|Drug|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
79998257|NCT02904096|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
79678925|NCT00508976|Drug|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
79678926|NCT00508976|Drug|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
79678927|NCT00508976|Drug|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
79678928|NCT00509015|Drug|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S&25mg P/20 kg, 1 day, single dose
79678929|NCT00509015|Drug|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
79998258|NCT01569711|Procedure|Deep brain stimulation of nucleus accumbens|"Day0 : surgical placement of electrodes~M1 : stimulation of nucleus accumbens~M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
79998259|NCT05202171|Other|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
79227533|NCT05063786|Drug|Fulvestrant|500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
79227534|NCT05063786|Drug|Vinorelbine|Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
79227535|NCT05063786|Drug|Capecitabine|1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
79227536|NCT05063786|Drug|Eribulin|1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
79370357|NCT03850431|Behavioral|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
79370358|NCT03850431|Behavioral|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
79370359|NCT03850431|Behavioral|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
79370360|NCT03850431|Behavioral|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
79370361|NCT01697696|Drug|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
79678930|NCT00509015|Drug|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
79678931|NCT00509015|Drug|placebo tablets|3 days of lactose tablets (160mg) albochin
79678932|NCT04692246|Other|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
79678933|NCT04692246|Other|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
79227537|NCT05054335|Other|Functional Assessment|Undergo walking function assessment with optical motion capture
79678934|NCT00509054|Procedure|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
79678935|NCT00509132|Drug|trodusquemine|
79678936|NCT02945202|Device|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
79227538|NCT05054335|Procedure|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
79678937|NCT02945202|Device|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
79823415|NCT00467779|Drug|cobimetinib|Repeating oral dose
79998260|NCT05202171|Other|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
79227539|NCT05045040|Behavioral|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
79678938|NCT02945202|Device|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
79678939|NCT00509210|Drug|telaprevir (VX-950)|
79678940|NCT00528060|Drug|Atazanavir|2pills/day
79678941|NCT00528060|Drug|Ritonavir|1 pill/day
79678942|NCT00528060|Drug|Tenofovir/emtricitabine|1 pill/day
79678943|NCT03459560|Drug|PolyPill|After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
79678944|NCT00527085|Drug|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
79998261|NCT05763381|Device|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
79227540|NCT05032612|Device|PBM Therapy|After the endodontic treatment, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, NC, USA), with an 8mm tip diameter.The laser tip will be placed on the following external surfaces in a contact mode: mesiobuccal, distobuccal, mesiolingual and distolingual . The power output of the laser will be 50mW and will be verified by Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2 .
79227541|NCT05032612|Device|PBM Sham|For the PBM sham similar procedure as PBM therapy will be performed without activating the laser.
79227542|NCT05012787|Biological|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
79227543|NCT05012787|Biological|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
79370362|NCT01697696|Drug|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
79370363|NCT01697696|Drug|Placebo|Placebo to match QAB149
79370364|NCT04764903|Other|No intervention|There is no intervention in this study
79370365|NCT04404543|Drug|SYHA1807|Escalation Cohort Administration: Orally
79370366|NCT04404543|Drug|SYHA1807|Dose Expansion Cohort Administration: Orally
79678945|NCT00527085|Drug|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
79678946|NCT00509327|Drug|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
79678947|NCT00509327|Drug|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
79678948|NCT02945007|Drug|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
79678949|NCT00509405|Drug|potassium citrate|6 times 10 mEq per day, oral for 24 months
79678950|NCT00528099|Drug|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
79678951|NCT00509444|Behavioral|Educational materials|
79678952|NCT00509444|Behavioral|educational materials, plus patient navigation|
79678953|NCT00528138|Other|Laboratory Test|CRP, white blood cell count, hepatic function tests
79678954|NCT00509483|Radiation|Radioactive iodine|Radioactive iodine preceded by rhTSH
79678955|NCT02945865|Other|Pain assessment|Pain assessment with assessment tools
79678956|NCT00510770|Device|CPAP application|
79678957|NCT02945709|Behavioral|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
79823416|NCT00467779|Drug|dextromethorphan|In Stage III only: single dose of dextromethorphan
79823417|NCT00467779|Drug|midazolam|In Stage III only: single dose of midazolam
79998262|NCT05763381|Device|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
79998263|NCT04053348|Procedure|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
79998264|NCT03648762|Behavioral|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
79227544|NCT05012787|Other|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
79524416|NCT00012012|Radiation|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
79524417|NCT00012012|Radiation|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
79524418|NCT00010374|Device|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
79524419|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
79370367|NCT03849807|Other|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
79227545|NCT04996316|Other|Electronic Health Record Review|Health record reviewed
79678958|NCT02945709|Behavioral|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
79998265|NCT03648762|Behavioral|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
79370368|NCT03849807|Other|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
79524420|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
79524421|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
79370369|NCT01569152|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
79524422|NCT02240004|Device|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
79998266|NCT03648762|Behavioral|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
79227546|NCT04996316|Other|Interview|Participate in interview
79227547|NCT04996316|Other|Media Intervention|Use MammoScreen
79227548|NCT04996316|Other|Survey Administration|Complete survey
79227549|NCT04996316|Other|Training and Education|Undergo training
79227550|NCT04991740|Drug|JNJ-78306358|JNJ-78306358 will be administered.
79227551|NCT04990167|Drug|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
79370370|NCT01569152|Drug|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
79370371|NCT01569152|Drug|Methotrexate|MTX dosed at the stable dose receive upon study entry
79370372|NCT03870009|Other|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
79370373|NCT01675557|Dietary Supplement|Vitamin D3|a single oral dose of vitamin D3
79370374|NCT01675557|Dietary Supplement|Vitamin D2|a single oral dose of vitamin D2
79524423|NCT02240082|Behavioral|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
79524424|NCT02240160|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
79524425|NCT02240238|Drug|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
79524426|NCT02240238|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
79524427|NCT02240550|Device|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
79998267|NCT02586675|Drug|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
79998268|NCT02586675|Drug|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
79227552|NCT04988087|Drug|MHV370|MHV370 for 24 weeks
79227553|NCT04988087|Drug|Placebo|Placebo for 24 weeks
79227554|NCT04981717|Drug|REGN1908-1909|Subcutaneous (SC) for a total of 5 administrations
79227555|NCT04981717|Drug|Matching Placebo|SC for a total of 5 administrations
79524428|NCT02240550|Device|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
79524429|NCT02240940|Device|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
79678959|NCT02945709|Behavioral|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
79227556|NCT04978207|Behavioral|A Faithful Response to COVID-19|See previous description
79998269|NCT02586675|Drug|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
79227557|NCT04969575|Other|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
79678960|NCT00509561|Biological|cetuximab|
79678961|NCT00509561|Drug|capecitabine|
79998270|NCT03648528|Drug|cholecalciferol|
79227558|NCT04969575|Other|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
79227559|NCT04969575|Other|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
79370375|NCT01675557|Dietary Supplement|Placebo|a single oral dose of placebo
79370376|NCT03028454|Dietary Supplement|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
79370377|NCT03028454|Dietary Supplement|Placebo|Capsules containing rice flour powder.
79370378|NCT01675791|Biological|ALK tree AIT 0.5 DU|
79370379|NCT01675791|Biological|ALK tree AIT 1 DU|
79370380|NCT01675791|Biological|ALK tree AIT 2 DU|
79370381|NCT01675791|Biological|ALK tree AIT 4 DU|
79678962|NCT00509561|Drug|cisplatin|
79370382|NCT01675791|Biological|ALK tree AIT 7 DU|
79678963|NCT00509561|Radiation|radiation therapy|
79998271|NCT03648528|Drug|placebo|
79998272|NCT03648294|Other|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
79998273|NCT05202015|Drug|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
79998274|NCT03648216|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
79998275|NCT05201625|Diagnostic Test|real time PCR|real time PCR
79998276|NCT04053114|Other|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
79998277|NCT03629691|Other|lung cavitation|apatinib treated patients developed lung cavitation
79370383|NCT01675791|Biological|ALK tree AIT 12 DU|
79370384|NCT01675791|Biological|ALK tree AIT Placebo|
79370385|NCT04410068|Device|WARMTAC|Randomization to one of the arms previous to surgery.
79370386|NCT04410068|Device|3M Bair Hugger|Randomization to one of the arms previous to surgery.
79370387|NCT03869307|Other|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
79370388|NCT01675869|Behavioral|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
79370389|NCT01675869|Behavioral|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
79524430|NCT02241096|Drug|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
79524431|NCT02241174|Drug|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
79678964|NCT02945943|Other|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
79678965|NCT02945943|Other|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
79678966|NCT00509639|Drug|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
79998278|NCT03648138|Behavioral|Sugary drink warning labels|This information appears in the description of the study arms.
79998279|NCT03161405|Drug|TAK-906 Maleate|TAK-906 capsule
79998280|NCT03161405|Drug|Itraconazole|Itraconazole solution
79524432|NCT02241252|Device|iPhone ECG|Please see detailed description for additional information.
79524433|NCT02241330|Dietary Supplement|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
79998281|NCT03648060|Device|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
79227560|NCT04969575|Other|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
79524434|NCT02241330|Dietary Supplement|Fortification|Wheat flour is fortified before testmeal preparation
79524435|NCT02241330|Dietary Supplement|Control|wheat flour is used as control comparator.
79524436|NCT02241564|Other|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
79678967|NCT02945904|Procedure|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
79678968|NCT02952716|Biological|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
79678969|NCT02952716|Other|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
79678970|NCT00528177|Drug|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
79998282|NCT01813929|Drug|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
79998283|NCT01813929|Drug|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
79227561|NCT04969575|Other|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
79524437|NCT02241564|Drug|Switch from calcineurin inhibitor to an mTOR inhibitor|
79524438|NCT02241642|Device|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
79524439|NCT02241798|Other|oxygen|O2 by nasal prongs
79524440|NCT02241876|Drug|N-acetylcysteine|
79678971|NCT00509678|Drug|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
79678972|NCT00528216|Drug|Capsaicin Dermal Liquid|
79524441|NCT02241954|Device|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
79524442|NCT02242032|Drug|P-321 Ophthalmic Solution|
79524443|NCT02242032|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
79524444|NCT02242344|Drug|Telmisartan|
79524445|NCT02242344|Drug|Placebo|
79524446|NCT02242500|Procedure|Coronally Advanced Flap|
79524447|NCT02242500|Device|Mucograft|
79524448|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
79678973|NCT00528255|Drug|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
79678974|NCT02953106|Drug|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
79678975|NCT02953106|Drug|Placebos|Placebo nasal spray
79678976|NCT02944773|Procedure|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
79678977|NCT02952833|Drug|Saline|Sodium chloride solution.
79678978|NCT02952833|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
79998284|NCT05284968|Drug|Cell injection|All subjects will be treated with cell injection
79998285|NCT03650166|Other|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
79998286|NCT03650166|Other|Personal BP monitor|Battery-powered BP monitor for personal use
79998287|NCT04053738|Device|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
79998288|NCT05285046|Other|No intervention|No intervention
79998289|NCT01502085|Drug|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
79998290|NCT04052802|Other|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
79678979|NCT02952989|Drug|SGN-2FF|SGN-2FF oral daily dosing.
79998291|NCT03648684|Behavioral|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
79998292|NCT03648684|Behavioral|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
79678980|NCT02952989|Drug|pembrolizumab|200 mg every 3 weeks by IV infusion
79998293|NCT03647982|Drug|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
79524449|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
79998294|NCT03647982|Drug|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
79524450|NCT02242812|Drug|Telmisartan|
79524451|NCT02242812|Drug|Metoprolol succinate|
79227564|NCT04962035|Other|Neurocognitive Follow-up|Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
79227565|NCT04946292|Behavioral|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
79227566|NCT04946292|Behavioral|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
79227567|NCT04918927|Drug|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
79227568|NCT04918927|Drug|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
79227569|NCT04918927|Other|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
79227570|NCT04907084|Dietary Supplement|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
79524452|NCT02242812|Drug|Placebo|
79524453|NCT02242890|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
79524454|NCT02243124|Drug|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
79524455|NCT02243124|Drug|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
79524456|NCT02243436|Drug|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
79524457|NCT02243436|Drug|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
79524458|NCT02243436|Drug|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
79678981|NCT00509717|Other|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
79678982|NCT00509717|Other|control|educational manual
79678983|NCT02952794|Procedure|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
79678984|NCT00509756|Drug|FXR-450|capsule, single oral doses from 10 mg to 450 mg
79678985|NCT00509756|Drug|Placebo|capsule similar to active drug
79678986|NCT00510926|Drug|Imatinib Mesilate (Glivec)|
79678987|NCT00509834|Drug|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
79678988|NCT00509834|Drug|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
79998295|NCT03647904|Behavioral|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
79998296|NCT03650010|Procedure|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
79998297|NCT02901054|Drug|Ondansetron|A single 15-min intravenous infusion of ondansetron
79998298|NCT03068715|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
79998299|NCT03068715|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79998300|NCT03068715|Device|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
79678989|NCT00509834|Drug|Placebo|Placebo
79678990|NCT02952560|Other|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
79998301|NCT04053036|Drug|MDMA|Participants will be given 1.5mg/kg of MDMA
79998302|NCT04053036|Drug|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
79998303|NCT03647670|Drug|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
79227571|NCT04907084|Drug|Fenofibrate|Fenofibrate 160mg pill, taken orally
79998304|NCT03647670|Drug|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
79370390|NCT01675947|Drug|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
79678991|NCT03459404|Combination Product|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
79678992|NCT00527202|Drug|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
79678993|NCT03459989|Diagnostic Test|Ultrasound|Samsung H60 Ultrasound
79678994|NCT00527241|Behavioral|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
79678995|NCT00527280|Procedure|Feasibility ot face transplantation|Feasibility ot face transplantation
79678996|NCT02952521|Procedure|Blood Draw|CA125 and ctDNA
79998305|NCT05202951|Other|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
79998306|NCT02966340|Drug|Prazosin|2mg Prazosin
79998307|NCT02966340|Drug|Placebo|Placebo
79998308|NCT05200689|Device|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
79998309|NCT03647748|Device|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
79227572|NCT04901247|Behavioral|media refreshment|20µL of culture medium is aspirated using Eppendorf PCR tips, and freshly, overnight equilibrated 20µL global total LP will be added to the same well
79227573|NCT04901247|Behavioral|embryo grading|embryo grading should be done prior to media refreshment
79227574|NCT04865913|Other|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
79998310|NCT05207007|Procedure|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
79227575|NCT04857983|Drug|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
79370391|NCT01675947|Drug|Lidocaine|Lidocaine 2%
79370392|NCT01676025|Procedure|PRA|
79370393|NCT01676025|Procedure|LA|
79370394|NCT02082717|Drug|potassium chloride replacement|
79370395|NCT02082717|Drug|Experimental - 4% Sodium Bicarbonate|
79370396|NCT03660189|Other|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
79524459|NCT02243436|Drug|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
79524460|NCT02243436|Drug|Ara C|Intravenous use, 2g/m2, day 5
79524461|NCT02243670|Device|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
79524462|NCT02243748|Other|Palliative Therapy|Receive individualized palliative care
79524463|NCT02243748|Other|quality-of-life assessment|Ancillary studies
79678997|NCT02952521|Procedure|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
79227576|NCT04857983|Drug|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
79227577|NCT04850729|Other|non-intervention|non-intervention
79227578|NCT04846790|Behavioral|Nature Only|See above for description.
79227579|NCT04846790|Behavioral|Nature+Mindfulness|See above for description.
79227580|NCT04817267|Device|reSET-O app|The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
79308179|NCT03045393|Drug|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
79678998|NCT00527358|Behavioral|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
79227581|NCT04800588|Diagnostic Test|California Cognitive Assessment Battery|The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
79370397|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
79823418|NCT04076306|Other|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
79823419|NCT04075214|Device|transcutaneous auricular neurostimulation (tAN)|Phoenix tAN system
79823420|NCT04076774|Device|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
79998311|NCT05284734|Procedure|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
79370398|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
79524464|NCT02243748|Other|questionnaire administration|Ancillary studies
79524465|NCT02243826|Drug|50:50 mixture of nitrous oxide/oxygen|
79524466|NCT02244060|Other|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
79524467|NCT02244138|Behavioral|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
79524468|NCT02244216|Drug|Berotec® N 100 µg Metered-dose Inhaler|
79370399|NCT01569074|Drug|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
79524469|NCT02244294|Drug|FLOMAX® capsules|
79370400|NCT01569074|Drug|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
79370401|NCT01569074|Drug|Placebo|Placebo twice daily for 12 weeks
79370402|NCT03842241|Device|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
79370403|NCT03752775|Device|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
79370404|NCT04348773|Procedure|Dehydration|Dehydration of the natural tooth by tooth isolation
79524470|NCT02244294|Drug|Placebo capsules|
79524471|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 0.76 g|
79524472|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.15 g|
79370405|NCT04348773|Procedure|Rehydration|Rehydration
79370406|NCT04403685|Drug|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
79524473|NCT02244372|Dietary Supplement|Placebo|
79524474|NCT02244528|Drug|Sildenafil|
79524475|NCT02245074|Other|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
79524476|NCT02245386|Radiation|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
79524477|NCT02245464|Drug|Telmisartan|
79524478|NCT02245542|Drug|ALNA®OCAS®|
79678999|NCT00509951|Behavioral|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
79679000|NCT00509951|Behavioral|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
79679001|NCT02945670|Behavioral|Focus Group|We had recruited 64 women and completed 7 focus group sessions
79998312|NCT05206851|Other|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~Sitting in comfortable position~One hand is placed over chest and other on abdomen.~Inhale deep through the nose.~Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
79679002|NCT00510965|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
79998313|NCT05206851|Other|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
79998314|NCT03067311|Behavioral|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
79227582|NCT04788836|Other|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
79998315|NCT03067311|Behavioral|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
79308180|NCT01374971|Drug|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
79370407|NCT03746925|Procedure|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
79370408|NCT03746925|Procedure|SuperPATH|SuperPATH approach surgery to replace the hip.
79370409|NCT01604408|Biological|LY2495655|Administered SC
79370410|NCT01604408|Drug|Placebo|Administered SC
79370411|NCT04404231|Radiation|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
79370412|NCT04404231|Other|No Infrared treatment|This is sham treatment. No light is actually given.
79370413|NCT04413578|Device|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
79524479|NCT02245698|Biological|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
79524480|NCT02245776|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
79524481|NCT02246244|Drug|Escitalopram|
79524482|NCT02246244|Other|Placebo|
79524483|NCT02246322|Device|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
79524484|NCT02246322|Device|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
79370414|NCT04413578|Device|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
79370415|NCT01677429|Device|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
79524485|NCT02246400|Behavioral|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
79524486|NCT02246556|Device|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
79524487|NCT02246556|Other|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
79524488|NCT02246556|Device|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
79370416|NCT01677429|Device|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
79370417|NCT01677429|Behavioral|Cognitive Behavioral Therapy|For the treatment of panic disorder
79370418|NCT03658707|Other|questionnaire|Shoulder questionnaire
79370419|NCT01567826|Drug|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor [any dose] and Crestor [less than 40mg]"
79227583|NCT04788836|Other|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
79227584|NCT04784117|Other|Dispatcher protocol change|In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
79227585|NCT04777708|Biological|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
79227586|NCT04777708|Biological|Pembrolizumab|Given IV
79227587|NCT04774016|Other|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
79679003|NCT02945826|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
79679004|NCT02945826|Device|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
79679005|NCT00509990|Drug|Pimecrolimus|Pimecrolimus cream 1 %
79679006|NCT02945358|Procedure|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
79679007|NCT02952209|Device|Xenograft|
79679008|NCT02945397|Behavioral|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
79679009|NCT02945397|Behavioral|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
79227588|NCT04774016|Other|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
79227589|NCT04774016|Other|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
79370420|NCT01567826|Drug|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
79370421|NCT03657459|Other|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities)
79370422|NCT03653481|Dietary Supplement|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
79524489|NCT02246712|Drug|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
79524490|NCT02246712|Other|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
79679010|NCT02952287|Device|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
79679011|NCT04695782|Radiation|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
79679012|NCT00527436|Dietary Supplement|fish oil|Fish oil pills will be taken daily for 12 weeks
79679013|NCT00527436|Dietary Supplement|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
79679014|NCT03459911|Drug|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe & Dohme B.V. , Haarlem, the Netherlands)
79679015|NCT03459911|Drug|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
79679016|NCT02945592|Behavioral|Cueing|
79679017|NCT03459872|Procedure|Acupuncture|Alternative medicine therapeutic intervention
79679018|NCT03459872|Device|RU-Fit|FDA approved medical device for the measurement of fine motor control
79679019|NCT02945514|Other|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
79227590|NCT04769648|Drug|Pro-ocular™ Topical Gel 1%|Pro-ocular™ is a topical gel applied dermally to forehead twice-daily
79227591|NCT04769648|Drug|Placebo|Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
79227592|NCT04765852|Other|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
79227593|NCT04765852|Other|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
79370423|NCT03653481|Dietary Supplement|Maltodextrin|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
79679020|NCT03459833|Drug|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
79998316|NCT05185713|Other|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
79679021|NCT05648487|Drug|HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery|"HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~After the surgery, continue to use standard adjuvant chemotherapy."
79679022|NCT04695665|Other|Cervical pain|Exercise program for cervical spine according to McGill's approach.
79679023|NCT04695665|Other|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
79679024|NCT04695665|Other|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
79998317|NCT05762289|Other|Thrust Manipulation (in weight bearing and non weight bearing)|Pain and Range of cervical motion was assessed before and after manipulation in both groups.
79998318|NCT05174949|Device|Transcranial direct current stimulation (high-definition)|"Three conditions:~anodal stimulation over the ipsilesional primary motor cortex~cathodal one over the contralesional premotor cortex~Sham"
79998319|NCT05200611|Diagnostic Test|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
79998320|NCT05206461|Other|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
79998321|NCT05206149|Drug|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
79998322|NCT05206149|Drug|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
79998323|NCT05206071|Biological|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
79370424|NCT03743025|Drug|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
79524491|NCT02246712|Other|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
79524492|NCT02246712|Genetic|CYP2B6 genotype|The single nucleotide polymorphism 516G>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
79998324|NCT03629457|Behavioral|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
79998325|NCT03629379|Drug|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
79524493|NCT02246790|Procedure|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
79679025|NCT00527553|Dietary Supplement|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
79998326|NCT03629379|Drug|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
79998327|NCT03629301|Behavioral|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
79227594|NCT04765852|Other|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
79227595|NCT04763512|Dietary Supplement|Intact Cow's Milk Protein Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.
79679026|NCT00527553|Dietary Supplement|lutein|daily lutein enriched egg
79998328|NCT03629301|Other|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
79998329|NCT05123079|Drug|Darigabat|Tablets
79998330|NCT05129163|Behavioral|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
79227596|NCT04763512|Dietary Supplement|Partially Hydrolysed Whey Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
79227597|NCT04760093|Dietary Supplement|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
79370425|NCT03743025|Other|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
79370426|NCT02986022|Behavioral|Resilience|Self-efficacy, optimism, altruism, goal setting
79370427|NCT02986022|Behavioral|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
79524494|NCT02246790|Procedure|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
79998331|NCT05129163|Behavioral|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
79227598|NCT04760093|Dietary Supplement|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
79227599|NCT04746248|Other|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
79227600|NCT04746248|Other|Inpatient labor induction|The participants are induced following standard inpatient care
79524495|NCT02246868|Biological|Optivate® (Human Coagulation Factor VIII)|
79524496|NCT02246946|Device|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
79998332|NCT05084157|Diagnostic Test|Echocardiography|Patients will undergo Doppler echocardiography
79524497|NCT02246946|Other|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
79524498|NCT02246946|Procedure|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
79998333|NCT05055999|Drug|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
79998334|NCT05761665|Other|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
79998335|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
79227601|NCT04743206|Device|Standard Airway Clearance device|A large majority of our patients will be using VEST therapy as their standard of care airway clearance
79227602|NCT04743206|Device|Portable Internal Airway Percussion device|Smart One® portable home spirometer
79227603|NCT04730349|Biological|Nivolumab|Specified dose on specified days
79524499|NCT02247102|Dietary Supplement|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
79524500|NCT02247102|Dietary Supplement|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
79679027|NCT00527553|Dietary Supplement|zeaxanthin|daily zeaxanthin enriched egg
79227604|NCT04730349|Biological|NKTR-214|Specified dose on specified days
79524501|NCT02247180|Behavioral|cognitive rehabilitation|
79524502|NCT02247180|Behavioral|standardized cognitive training|
79524503|NCT02247258|Drug|Azathioprine|See arm/group descriptions
79679028|NCT00527553|Dietary Supplement|egg product from enriched eggs|daily egg product from lutein enriched eggs
79524504|NCT02247258|Drug|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
79998336|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
79524505|NCT02247258|Procedure|Ileocolonoscopy|See arm/group descriptions
79524506|NCT02247258|Procedure|Small bowel follow trough|See arm/group descriptions
79998337|NCT05043285|Biological|SCTV01C|intramuscular injection
79998338|NCT05043285|Other|Placebo|Intramuscular injection
79998339|NCT05042115|Other|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
79998340|NCT05042115|Other|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
79998341|NCT04380519|Drug|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
79998342|NCT04380519|Drug|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
79227605|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 10 mg) or placebo
79227606|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 30 mg) or placebo
79227607|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 100 mg) or placebo
79227608|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 300 mg) or placebo
79227609|NCT04720443|Drug|NIP292 tablet|NIP292 (oral tablet at 500 mg) or placebo
79524507|NCT02247414|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
79524508|NCT02247414|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
79524509|NCT02247414|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
79679029|NCT00511082|Drug|OPB-31121|Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
79679030|NCT00527631|Radiation|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
79679031|NCT00511121|Drug|STI571 and PEG INTRON|
79679032|NCT00527670|Procedure|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
79679033|NCT00527670|Procedure|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
79524510|NCT02247414|Drug|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
79524511|NCT02247570|Procedure|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
79679034|NCT00511160|Procedure|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
79227610|NCT04720443|Drug|NIP292 tablets|NIP292 (oral tablet at dosage 1) or placebo
79998343|NCT04380519|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
79227611|NCT04720443|Drug|NIP292 tablets|NIP292 (oral tablet at dosage 2) or placebo
79227612|NCT04719637|Device|PRDS-001 Renal Denervation Ultrasound System|Renal Denervation Ultrasound System
79227613|NCT04704856|Behavioral|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
79370428|NCT03742167|Other|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
79227614|NCT04685252|Other|(BL) NCC3001|Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
79370429|NCT01337505|Drug|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
79998344|NCT05760963|Other|Collection of datas|"Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line >C) and caudally (line <C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, >C, <C on the costiform processes were noted."
79524512|NCT02247648|Drug|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
79524513|NCT02247648|Drug|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
79998345|NCT05004051|Other|ViTAA Analysis|Imaging Analysis Software
79998346|NCT04980573|Other|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
79998347|NCT04980573|Other|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
79998348|NCT02847182|Biological|Cord Blood Infusion|
79227615|NCT04685252|Other|Placebo|Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
79227616|NCT04676451|Device|Femto-AK|Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
79227617|NCT04673513|Other|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
79227618|NCT04671719|Biological|blood sample|blood sample for circulating autotaxin measurement (5ml).
79227619|NCT04655092|Biological|P1101 (Ropeginterferon alfa-2b)|The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
79227620|NCT04639518|Other|Preterm formulas with HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
79370430|NCT03648645|Device|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
79524514|NCT02247882|Other|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
79679035|NCT00511160|Procedure|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
79679036|NCT02953223|Other|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
79679037|NCT00528489|Biological|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
79998349|NCT02847182|Biological|Placebo|
79998350|NCT03578900|Drug|Xeros|
79679038|NCT00528489|Biological|IL-12|Cytokine injection
79679039|NCT00528489|Biological|IL-15|Cytokine injection
79679040|NCT00528684|Biological|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
79998351|NCT03578900|Drug|Citric Acid based Mouthwash|
79998352|NCT03576872|Other|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
79998353|NCT02550002|Drug|Aflibercept|Intravitreal injection
79679041|NCT02953028|Device|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
79679042|NCT02953028|Device|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
79679043|NCT04692051|Drug|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
79227621|NCT04639518|Other|Preterm formulas without HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
79227622|NCT04627545|Other|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
79679044|NCT04692051|Drug|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
79679045|NCT00510029|Drug|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
79998354|NCT03574376|Drug|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
79998355|NCT03574376|Drug|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
79227623|NCT04627545|Other|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
79227624|NCT04610346|Behavioral|Persons with Aphasia Training Dogs Program|Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
79227625|NCT04605497|Diagnostic Test|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission & discharge + additional 10 days during postpartum period
79370431|NCT00003459|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
79370432|NCT03829215|Device|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
79370433|NCT04763811|Other|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
79370434|NCT04763811|Other|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
79370435|NCT02083107|Drug|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
79679046|NCT00528723|Drug|salbutamol 100 mcg|To be used as needed for symptom relief
79679047|NCT00528723|Drug|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
79679048|NCT00528723|Drug|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
79227626|NCT04605497|Diagnostic Test|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
79227627|NCT04597450|Drug|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
79370436|NCT02083107|Other|Placebo|
79370437|NCT04403997|Procedure|Chromoendoscopy|Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
79370438|NCT00925054|Drug|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
79370439|NCT00925054|Drug|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
79370440|NCT00925054|Drug|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
79679049|NCT00510107|Drug|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
79679050|NCT00510107|Drug|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
79679051|NCT00528762|Behavioral|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
79679052|NCT03459326|Other|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~Erectile function (score 1 to 30)~Orgasmic function (score 0 to 10)~Desire (score 2 to 10)~Sexual satisfaction (score 0 to 15)~Overall satisfaction (score 2 to 10)"
79679053|NCT01580514|Drug|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
79370441|NCT00925054|Drug|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
79679054|NCT01580514|Drug|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
79524515|NCT02247882|Other|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
79524516|NCT02248038|Procedure|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
79524517|NCT02248038|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
79679055|NCT00528918|Drug|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
79679056|NCT00510185|Other|systematic coronary intervention|Coronary angiography within 72 hrs
79679057|NCT00510185|Other|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
79679058|NCT00515190|Drug|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
79679059|NCT00511277|Drug|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
79998356|NCT03576794|Drug|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
79998357|NCT03576794|Drug|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
79370442|NCT00925054|Drug|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
79370443|NCT02335905|Drug|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
79524518|NCT02248116|Drug|Talsaclidine|
79524519|NCT02248194|Device|Tactile electrosurgical ablation probe|
79998358|NCT02846558|Other|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
79227628|NCT04597450|Drug|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
79227629|NCT04569435|Drug|ANX005|IV Infusion
79227630|NCT04539639|Drug|Jaktinib|In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
79227631|NCT04539639|Drug|Jaktinib|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
79227632|NCT04539639|Drug|Jaktinib|In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
79227633|NCT04539639|Drug|placebo|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
79227634|NCT04535245|Diagnostic Test|LCI testing|all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
79370444|NCT00925756|Drug|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
79370445|NCT03736005|Other|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
79370446|NCT04372966|Device|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
79524520|NCT02248194|Device|Hysteroscopic endometrial ablation|
79370447|NCT04372654|Device|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
79370448|NCT03731013|Behavioral|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
79370449|NCT03731013|Behavioral|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
79679060|NCT00529074|Device|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
79524521|NCT02248272|Other|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
79679061|NCT02953184|Drug|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
79679062|NCT02953184|Drug|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
79227635|NCT04517396|Other|Fenofibrate/fenofibric acid|The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
79679063|NCT02953184|Drug|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
79679064|NCT02953184|Drug|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
79679065|NCT02953184|Drug|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
79998359|NCT02846558|Behavioral|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
79227636|NCT04517396|Other|Placebo|The control intervention will be a placebo, for 10 days.
79227637|NCT04517396|Other|Usual care|All participants will otherwise receive usual medical care
79370450|NCT03731013|Behavioral|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
79370451|NCT04372888|Behavioral|choice decision frame|active choice for genetic testing
79370452|NCT04372888|Behavioral|opt-in decision frame|"gain frame for genetic testing"
79370453|NCT04372888|Behavioral|opt-out decision frame|"loss frame for genetic testing"
79679066|NCT02953184|Drug|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
79679067|NCT02953184|Procedure|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
79679068|NCT02953184|Procedure|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
79679069|NCT02953184|Procedure|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
79227638|NCT04506619|Other|No Intervention|This is a non-interventional study.
79998360|NCT02846558|Device|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
79998361|NCT04362813|Drug|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
79998362|NCT04362813|Drug|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
79227639|NCT04483167|Drug|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
79227640|NCT04471623|Behavioral|Use of DeTAP App and Home Devices|DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
79370454|NCT04372888|Behavioral|enhanced choice (context) decision frame|consequences of genetic testing
79370455|NCT04372888|Behavioral|enhanced choice (norms) decision frame|social norms for genetic testing
79998363|NCT03578822|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
79998364|NCT03578822|Drug|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
79998365|NCT03578822|Drug|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
79227641|NCT04435392|Drug|Jaktinib Hydrochloride Cream|Subjects in each group were scheduled to give the drug for 8 weeks.
79227642|NCT04435392|Drug|Placebo|Placebo
79227643|NCT04423146|Other|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
79308181|NCT01374971|Procedure|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
79370456|NCT04372888|Behavioral|enhanced choice (affect) decision frame|commitments for genetic testing
79370457|NCT04372732|Diagnostic Test|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
79370458|NCT02245126|Drug|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
79998366|NCT03578822|Drug|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
79227644|NCT04416672|Other|PRO-CTCAE items|"Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:~the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.~the Hospital Anxiety and Depression Scale (HADS)~The Patients' Global Impression of Change (PGIC) Scale."
79227645|NCT04402593|Behavioral|Modified Heidelberg Model of Neuro-Music Therapy|6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
79227646|NCT04390828|Behavioral|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
79227647|NCT04383080|Procedure|Acupuncture|acupuncture at specific acupuncture points
79998367|NCT03578744|Procedure|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
79370459|NCT02245126|Drug|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
79370460|NCT04347382|Drug|Honey|1gm/Kg/Day
79370461|NCT04347382|Drug|Nigella Sativa / Black Cumin|80mg/Kg/day
79370462|NCT04347382|Drug|Placebos|Empty capsule with 250ml of distilled water
79524522|NCT02248272|Other|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
79524523|NCT02248350|Behavioral|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
79524524|NCT02248350|Behavioral|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
79524525|NCT02248428|Drug|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
79524526|NCT02248428|Drug|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
79524527|NCT02248428|Drug|Cyclophosphamide|300mg/m^2 intravenously daily on day 1-3,repeated every 28 days
79679070|NCT00515229|Drug|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
79679071|NCT00511316|Drug|Montelukast/ Singulair|20 mg daily for six months
79524528|NCT02248428|Drug|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
79998368|NCT03576638|Drug|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
79524529|NCT02248506|Other|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
79679072|NCT00511316|Drug|Placebo|Placebo 20 mg daily for 6 months
79679073|NCT02944695|Other|audit|Practice adherence to guidelines
79679074|NCT02952950|Other|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
79679075|NCT02951091|Other|biomarker screening|immunohistochemistry and in situ hybridization
79679076|NCT00511394|Drug|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
79679077|NCT00511394|Drug|Normal Saline|Infusion of 100 mL of Normal Saline
79679078|NCT00529230|Behavioral|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
79998369|NCT03576638|Drug|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
79998370|NCT04284657|Drug|Pravastatin|Pravastatin 40 mg QD
79998371|NCT04284657|Drug|sodium citrate|sodium citrate up to 30 ml TID
79227648|NCT04383080|Device|Low-level laser therapy|low level laser emission on specific acupuncture points
79308182|NCT03220295|Drug|Single Dose of VU319|Single dose of VU319
79308183|NCT03220295|Drug|Single Dose Placebo|Single dose of placebo
79308184|NCT03220295|Other|Fed State|drug is given 30 minutes after a high fat breakfast
79308185|NCT03220295|Other|Fasted State|drug is given after an overnight fast
79823421|NCT04076774|Device|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
79524530|NCT02248584|Dietary Supplement|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
79679079|NCT00529230|Other|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
79998372|NCT03578666|Other|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
79998373|NCT03578666|Other|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
79227649|NCT04382352|Biological|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.|Usage: intravenous infusion; B002, doses 2, 6, 12, 16, 20 mg / kg, intravenous drip. The infusion time was 120 ± 10 minutes for the first time; if the patient was tolerated, the follow-up time was adjusted to 60 ± 10 minutes. Pre-treatment was performed using phenergan (25 mg, intramuscular) within 30 minutes prior to each study drug infusion. The dosing cycle is administered once every 3 weeks for one cycle and can be administered continuously until the disease progresses or is intolerable.
79227650|NCT04372693|Other|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
79227651|NCT04328207|Other|No Financial Incentive|Standard of care eye health education
79524531|NCT02248896|Drug|Telmisartan|
79524532|NCT02248896|Drug|Other angiotensin-receptor blockers (ARBs)|
79524533|NCT02248896|Drug|Angiotensin-converting enzyme inhibitors (ACEIs)|
79524534|NCT02248896|Drug|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
79524535|NCT02249130|Drug|Tipranavir (TPV)|
79679080|NCT02952443|Behavioral|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
79679081|NCT02952443|Behavioral|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
79823422|NCT00570687|Drug|Technosphere Insulin|Inhalation 15U/30U
79998374|NCT05205135|Behavioral|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
79998375|NCT03576560|Other|Retrospective Chart Review|Retrospective Chart Review
79998376|NCT03574220|Drug|Pembrolizumab|200mg IV every 21 days over 6 months
79679082|NCT00529269|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79998377|NCT03574220|Radiation|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
79998378|NCT03574142|Drug|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
79524536|NCT02249130|Drug|Ritonavir (RTV)|
79524537|NCT02249130|Drug|Delavirdine (DLV)|
79524538|NCT02249130|Drug|Zidovudine (ZDV)|
79524539|NCT02249130|Drug|Lamivudine (3TC)|
79524540|NCT02249130|Drug|Stavudine (d4T)|
79524541|NCT02249208|Device|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
79524542|NCT02249208|Device|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
79524543|NCT02249208|Device|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
79998379|NCT03578588|Drug|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
79998380|NCT04876677|Drug|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
79998381|NCT02966028|Drug|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
79998382|NCT02966028|Drug|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
79998383|NCT03578432|Drug|Everolimus|Given PO
79998384|NCT03578432|Other|Laboratory Biomarker Analysis|Correlative studies
79998385|NCT03578432|Other|Survey Administration|Ancillary studies
79227652|NCT04328207|Behavioral|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
79227653|NCT04317794|Drug|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
79227654|NCT04317092|Drug|Tocilizumab Injection|Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
79227655|NCT04311866|Device|Synthetic pants|The use of synthetic materials is preferred (glass fiber), resistance, durability and low weight makes them optimal. To give some extra strenght to the cast, fiber strips are placed anterior and posterior at the level of the groin, this can facilitate the transportation of the patient avoiding the use of a bar.
79370463|NCT03726489|Device|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
79227656|NCT04311866|Device|Spica cast|The use of the spica cast is a standard practice for the management of the femoral shaft fractures, however its use, under some circumstances has been related to a wrong management of the cast, auto-retrieval, patient discomfort, and a difficult situation trying to maintain personal hygiene for the patient.
79370464|NCT03726489|Device|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
79370465|NCT04372342|Drug|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
79370466|NCT04372342|Drug|remifentanil|remifentanil
79370467|NCT04372264|Drug|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
79370468|NCT04372264|Drug|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
79679083|NCT02952911|Device|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
79679084|NCT00515268|Drug|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
79679085|NCT00515268|Drug|Placebo|Subjects will receive placebo inhaler.
79679086|NCT00515307|Procedure|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
79679087|NCT01356966|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
79679088|NCT01356966|Drug|Placebo|2 placebo pills PO BID for12 weeks
79998386|NCT03578354|Drug|4-aminopyridine|an oral drug to be swallowed
79998387|NCT03578354|Drug|Atenolol|an oral drug to be swallowed
79998388|NCT03578354|Other|Placebo|a masked placebo to be swallowed
79998389|NCT02239718|Procedure|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
79679089|NCT01356966|Dietary Supplement|Folate|Folate 1 mg daily for 12 weeks
79679090|NCT02952677|Behavioral|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
79823423|NCT01021891|Drug|Technosphere®/Insulin|
79823424|NCT04075058|Radiation|Hypofractionated Radiation therapy|
79998390|NCT02239718|Procedure|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
79998391|NCT02925741|Other|Silk-Like Linens|Synthetic moisture-wicking fabric
79998392|NCT03576482|Other|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
79998393|NCT02239796|Device|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
79998394|NCT02239796|Device|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
79227657|NCT04311424|Drug|14C Tirzepatide|Administered SC.
79227658|NCT04307394|Behavioral|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
79823425|NCT01029223|Drug|ivabradine|
79524544|NCT02249286|Behavioral|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
79524545|NCT02249286|Other|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
79998395|NCT02964312|Device|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
79227659|NCT04301414|Drug|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
79370469|NCT04372264|Drug|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
79998396|NCT04155333|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
79227660|NCT04301414|Drug|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
79370470|NCT04366570|Other|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
79370471|NCT02083809|Drug|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
79370472|NCT02083809|Drug|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
79370473|NCT02244112|Drug|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
79823426|NCT01029223|Drug|metoprolol|
79227661|NCT04291456|Drug|Minocycline 100mg|Single-arm trial of minocycline 100 mg twice daily
79370474|NCT02244112|Drug|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
79370475|NCT03723681|Drug|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
79823427|NCT01029223|Drug|placebo|
79227662|NCT04290845|Behavioral|Relief-Hybrid|A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.
79370476|NCT04366180|Dietary Supplement|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10^9 cfu/day) during 2 months
79370477|NCT04366180|Dietary Supplement|Control|The control group will received one placebo capsule per day during 2 months
79370478|NCT03722589|Biological|Flublok|0.5 mL intramuscular dose of Flublok
79370479|NCT03722589|Biological|Flucelvax|0.5 mL intramuscular dose of Flucelvax
79370480|NCT03722589|Biological|Fluarix|0.5 mL intramuscular dose of Fluarix
79370481|NCT03722589|Biological|Fluzone|0.5 mL intramuscular dose of Fluzone
79370482|NCT03722589|Biological|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
79524546|NCT02249364|Procedure|Control|Routine practice
79524547|NCT02249364|Procedure|Hypnosis|Hypnosis session before induction of anesthesia
79524548|NCT02249364|Drug|propofol|Closed-loop administration of propofol for anesthesia induction
79227663|NCT04284449|Other|Whole-practice cognitive optimization|This intervention is a whole-practice intervention that may include nutritional assessment & supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
79227664|NCT04266977|Drug|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
79370483|NCT04372420|Drug|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
79524549|NCT02249442|Drug|Tipranavir (TPV)|
79370484|NCT04372420|Procedure|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
79524550|NCT02249442|Drug|Ritonavir (r)|
79524551|NCT02249598|Biological|lactamica|
79679091|NCT02952677|Behavioral|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
79679092|NCT02952677|Other|Control|Participants received usual care
79679093|NCT02944734|Drug|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
79679094|NCT02944734|Drug|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
79524552|NCT02249598|Biological|Placebo|
79679095|NCT02944734|Drug|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
79679096|NCT02944734|Drug|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
79823428|NCT02556723|Drug|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
79823429|NCT03836677|Combination Product|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
79823430|NCT03836677|Combination Product|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
79679097|NCT00510263|Drug|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
79679098|NCT00510263|Drug|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
79679099|NCT00510263|Drug|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
79679100|NCT00510263|Drug|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
79679101|NCT00515346|Device|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
79679102|NCT00511589|Other|chagas disease diagnostic|
79679103|NCT00515385|Drug|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
79679104|NCT00515385|Drug|MGAWN1|Single IV dose
79679105|NCT00515385|Other|Placebo|Single IV dose
79823431|NCT00777543|Other|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
79823432|NCT00777543|Dietary Supplement|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
79823433|NCT00777543|Dietary Supplement|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
79227665|NCT04263480|Drug|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
79370485|NCT04372576|Diagnostic Test|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
79370486|NCT02244190|Drug|Tipranavir|New oral solution (back up) formulation
79370487|NCT02244190|Drug|Tipranavir|
79823434|NCT03410654|Drug|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
79823435|NCT03401840|Radiation|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
79227666|NCT04263480|Drug|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
79227667|NCT04250441|Device|Focused Transcranial Ultrasound|The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
79370488|NCT02244190|Drug|Ritonavir|
79524553|NCT02249676|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
79524554|NCT02249754|Behavioral|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
79679106|NCT00515424|Drug|RKI983|
79370489|NCT00954915|Biological|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
79370490|NCT00926380|Drug|denosumab|denosumab: 60 mg SC every 6 months
79370491|NCT00926380|Drug|teriparatide|teriparatide: 20 mcg SC QD
79679107|NCT00511628|Drug|Risperidone|As prescribed
79679108|NCT00529347|Device|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
79679109|NCT00510302|Behavioral|Questionnaire|Questionnaire regarding melanoma risk-reduction.
79679110|NCT00510302|Behavioral|Interview|Interview via telephone about topics related to melanoma risk-reduction.
79679111|NCT00529425|Drug|Ropivacaine|
79679112|NCT03459755|Behavioral|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
79679113|NCT00515580|Procedure|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
79679114|NCT00510341|Behavioral|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
79679115|NCT02950974|Drug|Sterofundin|Fluid loading
79679116|NCT02950974|Drug|NSS|Fluid loading
79679117|NCT03459716|Other|No intervention|No intervention
79679118|NCT00529581|Drug|C105|
79679119|NCT02952755|Drug|Co-administration of DWC20155/DWC20156|
79679120|NCT02952755|Drug|DWC20162|
79679121|NCT02950935|Drug|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
79679122|NCT02950935|Drug|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
79679123|NCT02952404|Procedure|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
79679124|NCT00515658|Device|theta-burst rTMS|
79823436|NCT02556645|Other|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
79823437|NCT02556645|Other|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
79823438|NCT01032421|Procedure|IVF procedure|
79823439|NCT04008758|Diagnostic Test|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
79823440|NCT01021969|Other|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
79823441|NCT01032499|Drug|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
79227668|NCT04250376|Device|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
79227669|NCT04245540|Dietary Supplement|Pau d' Arco|Encapsulated herbal Pau d' Arco.
79227670|NCT04196023|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
79370492|NCT04366414|Other|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
79679125|NCT00529620|Drug|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
79679126|NCT00529620|Drug|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
79679127|NCT00529620|Drug|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
79227671|NCT04196023|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
79679128|NCT00529698|Biological|Biologically active recombinant Tat protein|
79823442|NCT01032499|Drug|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
79823443|NCT01022047|Drug|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
79227672|NCT04172922|Drug|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
79679129|NCT02952014|Dietary Supplement|C4 Extreme|Pre-Workout Dietary Supplement
79679130|NCT02952014|Dietary Supplement|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
79679131|NCT02952014|Dietary Supplement|Placebo|Pre-Workout Dietary Supplement
79823444|NCT01022047|Drug|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
79823445|NCT01029301|Device|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
79823446|NCT04001036|Drug|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
79227673|NCT04168567|Diagnostic Test|Microbiome analysis|Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
79227674|NCT04144140|Drug|E7766|E7766, solution, intratumorally
79227675|NCT04139772|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
79308186|NCT03220295|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
79308187|NCT03220295|Drug|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
79308188|NCT03220451|Procedure|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
79679132|NCT00529737|Procedure|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
79679133|NCT00529737|Procedure|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
79679134|NCT00512993|Drug|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
79679135|NCT00529776|Procedure|Continuous lateral rotation therapy|
79679136|NCT00513032|Drug|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
79679137|NCT00529815|Device|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
79679138|NCT00529815|Device|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
79679139|NCT00513110|Genetic|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
79679140|NCT00513110|Drug|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
79679141|NCT00513110|Drug|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
79823447|NCT04001036|Drug|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
79823448|NCT01022125|Drug|TMC435|
79998397|NCT05204979|Other|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
79998398|NCT03576404|Other|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
79998399|NCT03647514|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
79998400|NCT03647514|Drug|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
79227676|NCT04139772|Drug|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
79227677|NCT04129281|Procedure|Surgery|Surgery acconding to clinical practice
79370493|NCT04366414|Other|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
79998401|NCT05759871|Other|GnRH antagonist|The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.
79998402|NCT02239952|Drug|Sunitinib|50 mg once daily, oral use for 14 days
79998403|NCT02239952|Drug|vandetanib|300 mg, once daily, oral use for 14 days
79227678|NCT04121832|Device|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
79227679|NCT04121832|Other|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
79227680|NCT04091204|Drug|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
79227681|NCT04075721|Drug|M3258|Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
79998404|NCT02239952|Drug|Erlotinib|150 mg, once daily, oral use for 14 days
79998405|NCT03647436|Other|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
79227682|NCT04075721|Drug|M3258 20 mg|Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
79227683|NCT04074304|Other|I-HoME|A multi-component technology-based care intervention.
79370494|NCT02244268|Drug|ALNA®|
79370495|NCT04366492|Other|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
79370496|NCT04365946|Procedure|Gastroscopy|Upper GI endoscopy and biopsy
79823449|NCT01032655|Drug|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~Klaricid, 500 mg, bid~Cravit, 250 mg, bid~Tetracycline, 500 mg, bid"
79998406|NCT04089423|Device|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
79998407|NCT03576326|Behavioral|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
79370497|NCT03823209|Behavioral|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
79370498|NCT03823209|Behavioral|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
79370499|NCT00870051|Device|Endurant Stent Graft|Endurant Stent Graft implantation
79370500|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
79679142|NCT00529854|Other|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
79679143|NCT00511745|Drug|Rabeprazol|As prescribed
79679144|NCT02951897|Procedure|lobectomy|
79679145|NCT02951897|Procedure|segmentecomy|
79679146|NCT02951897|Drug|chemotherapy（pemetrexed+CISPLATIN）|
79998408|NCT04739475|Procedure|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
79370501|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
79823450|NCT03654248|Behavioral|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
79370502|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
79998409|NCT03647280|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
79998410|NCT03647280|Drug|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
79998411|NCT03576248|Device|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
79227684|NCT04063514|Other|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
79370503|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
79370504|NCT03630315|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
79370505|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
79370506|NCT03630315|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
79370507|NCT00929344|Drug|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
79370508|NCT00929344|Drug|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
79370509|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
79679147|NCT02951897|Procedure|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
79823451|NCT03654248|Device|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
79823452|NCT02581280|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
79370510|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
79998412|NCT03576248|Device|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
79370511|NCT00929344|Drug|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
79370512|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
79370513|NCT03820557|Other|Educational Intervention|Undergo Decision Counseling Program
79370514|NCT03630159|Biological|Tisagenlecleucel|Gene modified autologous T cells
79370515|NCT03630159|Drug|Pembrolizumab|anti PD-1
79524555|NCT02249754|Behavioral|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
79524556|NCT02249988|Drug|ABX203 therapeutic Hepatitis B vaccine treatment arm|
79227685|NCT04058418|Other|Survey Administration|Completion of a short survey.
79227686|NCT04028245|Drug|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
79524557|NCT02244762|Drug|20 mg HC-ER|1-72 hours
79524558|NCT02244762|Drug|20 mg HC-ER|1-72 hours
79524559|NCT02244762|Drug|20 mg HC-ER|1-72 hours
79524560|NCT02242734|Drug|20 mg HC-ER|1-72 hours
79524561|NCT02242734|Drug|20 mg HC-ER|1-72 hours
79524562|NCT02242734|Drug|20 mg HC-ER|1-72 hours
79524563|NCT02240862|Device|Carotid Artery Stent|Placement of a stent within the carotid artery
79227687|NCT04028245|Drug|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
79524564|NCT02244606|Drug|SCY-078|
79524565|NCT02244606|Drug|Fluconazole|
79679148|NCT02951897|Other|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E&M-) CTCs.
79524566|NCT02244606|Drug|Micafungin|
79823453|NCT03374072|Behavioral|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
79998413|NCT03576248|Device|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
79998414|NCT03576248|Device|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
79227688|NCT03994406|Drug|CLM2 topical gel|Active topical gel for forehead dermal application
79227689|NCT03994406|Drug|Placebo topical gel|Placebo topical gel for forehead dermal application
79524567|NCT02245308|Drug|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
79679149|NCT02945124|Other|K tape|Applying K tape to children to the lower limb muscles during motor activities.
79823454|NCT03374072|Behavioral|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
79823455|NCT05673980|Drug|Vitamin D2|Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
79998415|NCT04721769|Procedure|Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
79227690|NCT03990051|Drug|Pro-ocular™ topical gel|Topical gel for forehead dermal application
79227691|NCT03990051|Drug|Placebo topical gel|Topical gel for forehead dermal application
79227692|NCT03975114|Drug|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
79227693|NCT03975114|Drug|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
79227694|NCT03975114|Drug|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
79227695|NCT03969355|Other|Mortality|Patients who died during PICU stay
79227696|NCT03957343|Device|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
79227697|NCT03955783|Drug|Venetoclax|Given by mouth
79524568|NCT02245308|Behavioral|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
79524569|NCT02245308|Behavioral|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
79823456|NCT05673980|Other|placebo|This group will not do any intervention
79823457|NCT02581124|Drug|JTZ-951|
79823458|NCT02581124|Drug|Lapatinib|
79524570|NCT02245308|Drug|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
79227698|NCT03955783|Drug|Selinexor|Given by mouth
79227699|NCT03942120|Drug|Ustekinumab|Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
79227700|NCT03941613|Procedure|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
79227701|NCT03941613|Procedure|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
79227702|NCT03940742|Drug|Tirzepatide|Administered SC
79227703|NCT03918070|Device|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
79998416|NCT04721769|Procedure|Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
79998417|NCT03646032|Behavioral|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
79998418|NCT03646032|Behavioral|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
79998419|NCT03578120|Biological|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
79998420|NCT03646578|Other|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
79998421|NCT03576170|Other|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
79998422|NCT01566747|Drug|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
79227704|NCT03917654|Biological|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
79370516|NCT04371874|Drug|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
79370517|NCT04371796|Drug|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
79524571|NCT02245308|Drug|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
79524572|NCT02243358|Drug|Folfox6|
79524573|NCT02243358|Drug|Gemcitabine|
79227705|NCT03917654|Biological|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
79370518|NCT02244346|Drug|Secotex®|
79370519|NCT04365712|Device|Piezoelectric tool|
79227706|NCT03917654|Biological|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
79227707|NCT03917654|Biological|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
79370520|NCT04365712|Device|Oscillating Saw|
79370521|NCT04376554|Drug|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h [±1 hour] for 10 days
79370522|NCT04376554|Drug|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h [±1 hour] for 10 days
79524574|NCT02243358|Radiation|Radiation Therapy|
79524575|NCT02243358|Procedure|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
79524576|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
79524577|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
79524578|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
79524579|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
79524580|NCT00559962|Drug|placebo|3 capsules each evening for each 4-week period
79823459|NCT02580968|Device|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
79524581|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
79524582|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
79823460|NCT02580968|Drug|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
79823461|NCT03640520|Device|FACETS: Pediatric Resuscitation|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
79823462|NCT03640520|Device|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
79227708|NCT03917654|Biological|AVAXIM|AVAXIM - Pediatric [Hepatitis A Vaccine Inactivated] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
79227709|NCT03903120|Behavioral|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
79524583|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
79823463|NCT03610646|Drug|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
79227710|NCT03893240|Diagnostic Test|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
79823464|NCT03610646|Drug|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
79823465|NCT04075448|Other|Control|100 grams breakfast cereal
79823466|NCT04075448|Other|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
79823467|NCT00434161|Drug|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 & 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
79823468|NCT00434161|Drug|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
79998423|NCT03621462|Device|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
79998424|NCT03578042|Drug|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
79227711|NCT03875274|Drug|Ropivacaine, Morphine|Morphine added to ropivacaine for fascia iliaca compartment block
79227712|NCT03875274|Drug|Ropivacaine, Saline|Normal saline added to ropivacaine for fascia iliaca compartment block
79227713|NCT03794050|Other|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
79227714|NCT03794050|Other|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
79227715|NCT03775850|Biological|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU)
79227716|NCT03775850|Biological|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
79227717|NCT03762109|Drug|Dantrolene|muscle relaxant
79227718|NCT03762109|Drug|Placebo Oral Tablet|inactive pill
79227719|NCT03732664|Drug|Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab|One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
79524584|NCT00559962|Drug|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
79524585|NCT00559962|Drug|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
79524586|NCT00559962|Drug|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
79524587|NCT00559104|Drug|carmustine|Unique to the Carmustine in Conditioning arm
79524588|NCT00559104|Drug|cyclophosphamide|Used in Both Arms
79524589|NCT00559104|Drug|etoposide|Used in Both Arms
79524590|NCT00559104|Procedure|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
79227720|NCT03727789|Drug|FACT Complex-targeting Curaxin CBL0137|Given IA
79227721|NCT03703583|Other|There is no intervention in this observational study.|There is no intervention in this observational study.
79227722|NCT03679260|Other|Carbohydrate restricted diet|20 grams total carbs/day
79227723|NCT03679260|Other|Non-restricted diet|Subject follows normal diet
79227724|NCT03679260|Other|Phone counseling with dietitian|Weekly calls with dietitian
79227725|NCT03657576|Biological|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
79227726|NCT03651154|Procedure|Hypovolemic Phlebotomy|Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
79524591|NCT00559104|Procedure|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
79524592|NCT00559104|Radiation|total-body irradiation|Unique to the Radiation in Conditioning Arm
79998425|NCT03578042|Drug|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
79524593|NCT00559104|Drug|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
79524594|NCT00558636|Drug|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
79998426|NCT03646500|Procedure|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
79998427|NCT03646500|Procedure|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
79227727|NCT03617237|Other|Retrospective Populations|"All patients who are currently treated by any physician at the University of Texas Southwestern campus Aston Clinic, Seay Clinic, PHHS Clinic, Moncrief Radiation Oncology, St. Paul West Campus Radiation Oncology, East Radiation Oncology Clinic will be included in the registry. The data from the charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number.~The research involves no more than minimal risk to the subjects.~The waiver will not adversely affect the rights and welfare of the subjects.~The research could not practicably be carried out without the waiver.~Whenever appropriate, the subjects will be provided with additional pertinent information after participation."
79524595|NCT00558636|Drug|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
79524596|NCT00558558|Drug|Haelan|4 oz orally twice daily for 8 Weeks
79679150|NCT02944929|Other|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
79998428|NCT03574064|Other|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
79998429|NCT03574064|Other|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
79227728|NCT03613025|Diagnostic Test|Sampling of non-invasive and/or non-targeted respiratory tract specimens|Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
79227729|NCT03561207|Diagnostic Test|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
79227730|NCT03458234|Device|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
79227731|NCT03424109|Behavioral|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
79227732|NCT03410784|Drug|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
79227733|NCT03410784|Drug|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
79227734|NCT03410784|Drug|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
79227735|NCT03396367|Behavioral|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
79998430|NCT03574064|Other|GLP-2+GIP|GLP-2+GIP injection.
79227736|NCT03396367|Behavioral|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
79227737|NCT03363841|Drug|SCY-078|Oral SCY-078
79524597|NCT00557622|Drug|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
79524598|NCT00557622|Other|placebo|placebo
79524599|NCT00557466|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
79998431|NCT03574064|Other|Placebo|Placebo injection.
79998432|NCT03918408|Combination Product|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
79524600|NCT00557466|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
79524601|NCT00557466|Drug|placebo to indacaterol|Placebo TWISTHALER® device
79679151|NCT00511823|Drug|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
79998433|NCT03573986|Biological|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
79998434|NCT03573986|Drug|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
79998435|NCT03573986|Radiation|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
79998436|NCT05204433|Other|no intervention|no intervention
79524602|NCT00557466|Drug|placebo to formoterol|Placebo AEROLIZER® device
79524603|NCT00557466|Drug|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
79823469|NCT00434161|Drug|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
79823470|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
79823471|NCT00441103|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
79998437|NCT03573674|Behavioral|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
79998438|NCT03573674|Behavioral|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
79823472|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
79998439|NCT03959592|Drug|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
79998440|NCT03959592|Other|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
79227738|NCT03329417|Other|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
79679152|NCT00511823|Drug|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
79679153|NCT00511823|Drug|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
79823473|NCT01029613|Drug|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
79823474|NCT03540212|Drug|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
79823475|NCT03268057|Drug|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
79998441|NCT04087395|Device|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
79227739|NCT03323580|Other|GDFT|Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
79308189|NCT02506205|Behavioral|Lee Silverman Voice Treatment (SVLT) LOUD|
79370523|NCT03627741|Drug|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
79370524|NCT04371718|Drug|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
79370525|NCT04371718|Other|Placebo|A capsule has same component but active drug
79370526|NCT03712839|Other|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
79370527|NCT04376164|Radiation|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
79524604|NCT00557310|Drug|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
79524605|NCT00555438|Drug|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
79524606|NCT00553644|Drug|Bortezomib|Given IV
79524607|NCT00553644|Other|Laboratory Biomarker Analysis|Correlative studies
79524608|NCT00553644|Drug|Lenalidomide|Given PO
79524609|NCT00553332|Drug|selumetinib|Given orally
79679154|NCT00511823|Drug|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
79524610|NCT00553332|Other|laboratory biomarker analysis|Correlative studies
79679155|NCT00515736|Drug|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
79679156|NCT00515736|Drug|Placebo|vehicle
79679157|NCT02952482|Procedure|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
79679158|NCT00511940|Drug|acamprosate|999 mg/day - 2997 mg/day, oral
79679159|NCT00511940|Other|placebo|oral, placebo
79998442|NCT04087395|Device|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
79998443|NCT03573596|Drug|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
79998444|NCT03621618|Diagnostic Test|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
79998445|NCT03621618|Diagnostic Test|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
79227740|NCT03323580|Other|traditional fluid therapy|Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
79370528|NCT04365322|Other|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
79370529|NCT03719937|Device|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
79524611|NCT00552396|Drug|Anti-KIR (1-7F9)|human monoclonal antibody
79998446|NCT04038333|Other|No intervention|This is an observational study without any interventions.
79227741|NCT03310619|Biological|JCAR017|Gene modified autologous T cells
79227742|NCT03310619|Drug|Durvalumab|Anti-PD-L1
79227743|NCT03310619|Drug|CC-122|Pleiotropic Pathway Modifier
79227744|NCT03310619|Drug|Ibrutinib|Ibrutinib
79227745|NCT03310619|Drug|CC-220|CC-220
79227746|NCT03310619|Drug|Relatlimab|Relatlimab
79227747|NCT03310619|Drug|Nivolumab|Nivolumab
79370530|NCT03818217|Device|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
79524612|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
79524613|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
79524614|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
79524615|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
79679160|NCT02950857|Drug|EPEG|(Pegylated erythropoeitin)
79679161|NCT00513149|Drug|Clopidogrel|Clopidogrel 600 mg loading
79998447|NCT05204277|Other|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
79998448|NCT05204277|Other|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
79227748|NCT03310619|Drug|CC-99282|CC-99282
79227749|NCT03280589|Other|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex [6]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
79227750|NCT03280589|Other|Sitting Quietly|Participant breaths in their natural way with out instruction
79524616|NCT00552240|Drug|Nevirapine 200 mg BID|200 mg BID
79524617|NCT00552240|Drug|Atazanavir 300 mg|300 mg QD
79524618|NCT00552240|Drug|Ritonavir 100 mg|100 mg QD
79524619|NCT00552084|Drug|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
79524620|NCT00552084|Drug|Placebo|Placebo supplements will be taken daily for 24 weeks.
79524621|NCT00550836|Biological|panitumumab|Given IV
79524622|NCT00550836|Drug|erlotinib hydrochloride|Given orally
79524623|NCT00550836|Drug|gemcitabine hydrochloride|Given IV
79679162|NCT00515814|Device|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.
79679163|NCT02944344|Behavioral|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
79679164|NCT02952326|Procedure|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
79679165|NCT02952326|Procedure|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
79679166|NCT02944227|Drug|Lucentis|Lucentis fixed-treatment arm
79679167|NCT04695938|Diagnostic Test|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
79679168|NCT00513188|Biological|denileukin diftitox|
79679169|NCT00513188|Drug|cyclophosphamide|
79679170|NCT00513188|Drug|cytarabine|
79679171|NCT00513188|Drug|doxorubicin hydrochloride|
79679172|NCT00513188|Drug|leucovorin calcium|
79679173|NCT00513188|Drug|methotrexate|
79679174|NCT00513188|Drug|prednisone|
79998449|NCT05204277|Other|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
79679175|NCT00513188|Drug|vincristine sulfate|
79679176|NCT00513188|Genetic|protein expression analysis|
79823476|NCT03337100|Behavioral|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
79823477|NCT01033903|Drug|misoprostol|800 micrograms intravaginally ONCE
79998450|NCT03619278|Other|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
79998451|NCT03619278|Other|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
79227751|NCT03280589|Other|Deep breathing|Participant is required to pay attention to each breath
79679177|NCT00513188|Other|flow cytometry|
79227752|NCT03279510|Device|hearing aids|Subjects are fit with hearing aids.
79679178|NCT00513188|Other|laboratory biomarker analysis|
79227753|NCT03256240|Other|side-to-side functional end anastomosis|type of anastomosis
79227754|NCT03256240|Other|Kono-S analstomosis|antimesenteric anastomosis
79227755|NCT03244696|Behavioral|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
79308190|NCT02506049|Device|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
79370531|NCT03818217|Device|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
79370532|NCT03626337|Drug|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
79524624|NCT00550680|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
79524625|NCT00559650|Drug|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
79524626|NCT00559650|Drug|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
79679179|NCT02950779|Other|Handgrip Strength Measurement|
79524627|NCT00556920|Drug|COREG CR|
79524628|NCT00554190|Device|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
79679180|NCT00513266|Biological|bevacizumab|
79679181|NCT00513266|Biological|cetuximab|
79679182|NCT00513266|Drug|fluorouracil|
79308191|NCT02505815|Procedure|Surgery|
79823478|NCT03331094|Procedure|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
79823479|NCT03331094|Procedure|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
79998452|NCT05204121|Drug|Elpida|elsulfavirine, capsules
79370533|NCT02244658|Drug|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
79370534|NCT03718845|Behavioral|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
79370535|NCT02982616|Dietary Supplement|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
79370536|NCT02982616|Behavioral|Positive emotion|Positive emotion induced by facial expressions and classic music.
79679183|NCT00513266|Drug|irinotecan hydrochloride|
79679184|NCT00513266|Drug|leucovorin calcium|
79679185|NCT00513266|Drug|oxaliplatin|
79679186|NCT00513266|Other|laboratory biomarker analysis|
79679187|NCT00513266|Procedure|adjuvant therapy|
79679188|NCT00513266|Procedure|biopsy|
79679189|NCT00513266|Procedure|conventional surgery|
79679190|NCT00513266|Procedure|neoadjuvant therapy|
79679191|NCT00513383|Drug|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
79679192|NCT00513383|Drug|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
79679193|NCT00513383|Drug|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
79370537|NCT02982616|Dietary Supplement|saline|saline
79524629|NCT00554190|Device|Merogel Injectable|Bioresorbable hyaluronic acid product
79679194|NCT00513383|Radiation|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
79823480|NCT03329924|Other|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
79679195|NCT00513383|Drug|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
79679196|NCT00513383|Drug|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
79308192|NCT02505815|Procedure|Cortisol Level Measurement|
79823481|NCT00433771|Device|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
79823482|NCT03281954|Drug|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
79998453|NCT04697901|Device|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
79679197|NCT00513383|Drug|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
79679198|NCT00513422|Dietary Supplement|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
79308193|NCT02505815|Procedure|Neurocognitive Testing|
79370538|NCT02982616|Behavioral|neutral emotion|Neutral emotion induced by facial expressions and classic music.
79370539|NCT04403841|Other|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
79370540|NCT04403841|Other|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
79370541|NCT03624621|Behavioral|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
79524630|NCT00552708|Drug|COREG CR|
79524631|NCT00552708|Drug|Lisinopril|
79524632|NCT00556374|Drug|Placebo|
79524633|NCT00556374|Biological|Denosumab|Administered as a subcutaneous injection
79524634|NCT00556374|Drug|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
79524635|NCT00556374|Drug|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
79679199|NCT00513422|Dietary Supplement|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
79679200|NCT00513422|Dietary Supplement|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
79679201|NCT00513422|Dietary Supplement|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
79679202|NCT02944305|Procedure|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
79679203|NCT04695821|Device|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
79679204|NCT00515892|Drug|Immunotoxin therapy|
79679205|NCT00515892|Drug|CAT-8015 Immunotoxin|
79679206|NCT00515892|Procedure|Biological therapy|
79679207|NCT00515892|Procedure|Antibody Therapy|
79679208|NCT00515892|Procedure|Monoclonal Antibody Therapy|
79679209|NCT00513539|Drug|porfimer sodium|
79679210|NCT00513539|Procedure|biliary stenting|
79227756|NCT03244696|Behavioral|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
79227757|NCT03201198|Behavioral|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
79370542|NCT03624621|Device|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
79370543|NCT03624621|Behavioral|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
79370544|NCT03624621|Device|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
79524636|NCT00556374|Other|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
79524637|NCT03029910|Other|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
79524638|NCT03029910|Other|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
79524639|NCT03029754|Procedure|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
79524640|NCT00555204|Drug|ABT-089|10 mg - capsules once daily for 12 weeks
79524641|NCT00555204|Drug|ABT-089|5 mg - capsules once daily for 12 weeks
79524642|NCT00555204|Drug|ABT-089|15 mg - capsules once daily for 12 weeks
79524643|NCT00555204|Drug|ABT-089|20 mg - capsules once daily for 12 weeks
79679211|NCT00515931|Radiation|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
79679212|NCT04695470|Drug|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
79679213|NCT04691973|Behavioral|Health and lifestyle tool|Health and lifestyle tool used online
79308194|NCT04497545|Device|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
79370545|NCT00929500|Behavioral|MAST program|MAST program: twice a week for 4 months
79308195|NCT04497545|Device|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
79370546|NCT03816111|Behavioral|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
79370547|NCT03816111|Behavioral|Current standard PD training|Current PD training materials and plan
79370548|NCT00929578|Drug|Fluphenazine|Intralesional injection of Fluphenazine
79370549|NCT00929578|Drug|Placebo|Intralesional injection of placebo
79370550|NCT04371484|Other|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
79524644|NCT00555204|Drug|ABT-089|30 mg - capsules once daily for 12 weeks
79524645|NCT00555204|Drug|ABT-089|35 mg - capsules once daily for 12 weeks
79524646|NCT00555204|Drug|placebo|placebo - capsules once daily for 12 weeks
79524647|NCT03029676|Drug|benzodiazepines|sedative
79524648|NCT03029676|Drug|opioid|analgetic, sedative
79524649|NCT03029676|Procedure|spinal anesthesia|
79524650|NCT03029520|Other|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
79524651|NCT03029520|Other|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
79524652|NCT03029130|Device|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
79679214|NCT04691973|Other|Usual care|Usual care at ordinary healthcare provider
79679215|NCT00511979|Drug|Technosphere Insulin|
79679216|NCT00511979|Drug|Technosphere insulin|
79679217|NCT00511979|Drug|Technosphere insulin|
79679218|NCT00511979|Drug|Regular human insulin|
79227758|NCT03201198|Behavioral|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
79679219|NCT02950701|Device|Observational data collection.|
79679220|NCT00513578|Biological|PR1 leukemia peptide vaccine|
79370551|NCT04371016|Other|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
79823483|NCT03281954|Drug|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
79998454|NCT04697901|Device|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
79227759|NCT03190785|Other|Benzoic acid washout and exposure|see above
79227760|NCT03188627|Biological|Bronchial basal cells|Transplantation of autologous bronchial basal cells
79227761|NCT03153683|Other|Registry|Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
79227762|NCT03123042|Procedure|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
79370552|NCT04371406|Drug|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
79370553|NCT04371406|Dietary Supplement|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
79370554|NCT04370938|Behavioral|Coping strategies video|No additional description
79370555|NCT03716739|Drug|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
79370556|NCT03716739|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
79370557|NCT03716661|Procedure|ORIF|Open Reduction Internal Fixation
79370558|NCT02245204|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
79524653|NCT03029052|Behavioral|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
79524654|NCT04270344|Drug|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
79679221|NCT00513578|Biological|incomplete Freund's adjuvant|
79679222|NCT00513578|Biological|sargramostim|
79524655|NCT04279548|Device|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
79679223|NCT02950662|Other|Overdenture|Active comparator will be metal housing and peek housing
79823484|NCT03922256|Other|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
79823485|NCT00433537|Drug|bortezomib|Given IV
79823486|NCT00433537|Biological|rituximab|Given IV
79679224|NCT02952053|Device|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
79823487|NCT00433537|Drug|cyclophosphamide|Given IV
79823488|NCT00433537|Drug|doxorubicin hydrochloride|Given IV
79823489|NCT00433537|Drug|vincristine|Given IV
79823490|NCT00433537|Drug|dexamethasone|Given IV
79823491|NCT00433537|Biological|filgrastim|Given SC
79524656|NCT04270032|Diagnostic Test|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
79524657|NCT04277910|Drug|MT2004|MT2004 oral capsules
79823492|NCT00433537|Biological|pegfilgrastim|Given SC
79823493|NCT00433537|Procedure|Autologous stem cell transplantation (ASCT)|
79823494|NCT03935282|Other|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
79823495|NCT02580110|Other|Sucrose|
79823496|NCT02580110|Other|Stevia glycosides|
79823497|NCT02580110|Other|saccharin|
79823498|NCT00570765|Drug|Placebo|Matching placebo tablets were administered orally once daily.
79227763|NCT03093064|Drug|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
79823499|NCT00570765|Drug|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
79823500|NCT00777621|Other|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
79227764|NCT03093064|Other|Placebo: normal saline|Normal saline, intravenous infusion
79823501|NCT00777621|Other|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
79823502|NCT00777621|Other|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
79227765|NCT03060577|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
79227766|NCT03060577|Drug|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
79370559|NCT03611907|Device|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
79370560|NCT03611907|Device|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
79370561|NCT04365010|Drug|Sodium Bicarbonate Ringer's Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
79370562|NCT04365010|Drug|0.9% Sodium Chloride Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
79370563|NCT03609801|Behavioral|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
79370564|NCT03609801|Behavioral|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
79370565|NCT02244814|Behavioral|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
79524658|NCT04277910|Drug|Placebo|Placebo oral capsules
79524659|NCT04275570|Behavioral|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
79524660|NCT04278846|Drug|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
79524661|NCT04278846|Drug|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
79823503|NCT00777699|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
79823504|NCT00777699|Drug|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
79823505|NCT00667563|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
79823506|NCT00667563|Genetic|DNA analysis|Weeks 0, 2, 10, 26, and 52.
79823507|NCT00667563|Genetic|polymerase chain reaction|Screening, week 36, and week 52.
79823508|NCT00667563|Other|cytology specimen collection procedure|Screening, week 36, and week 52.
79998455|NCT02899962|Drug|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
79998456|NCT02899962|Drug|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
79227767|NCT02940236|Other|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
79227768|NCT02916810|Device|Active rTMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
79227769|NCT02916810|Device|Sham rTMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
79227770|NCT02872714|Drug|pemigatinib|Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
79679225|NCT02952053|Device|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
79679226|NCT00513656|Drug|Oxycodone|
79370566|NCT02244814|Behavioral|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
79998457|NCT03647202|Drug|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
79227771|NCT02872714|Drug|pemigatinib|Pemigatinib once a day by mouth continuously.
79227772|NCT02863380|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
79227773|NCT02863380|Device|Individualized rTMS (transcranial magnetic stimulation)|
79370567|NCT03707691|Behavioral|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
79524662|NCT04277988|Device|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
79524663|NCT03832374|Other|Descriptive|
79524664|NCT03838770|Device|Active tDCS|Active target 2.0mA tDCS (n=60)
79823509|NCT00667563|Procedure|colposcopic biopsy|Screening, week 36, and week 52.
79227774|NCT02863380|Device|Classical rTMS (transcranial magnetic stimulation)|
79227775|NCT02863380|Device|Classical tDCS (transcranial direct current stimulation)|
79998458|NCT03647202|Drug|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
79998459|NCT03647202|Drug|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
79227776|NCT02797275|Drug|Albuterol|Beta agonist respiratory inhaler
79227777|NCT02797275|Drug|Placebo|respiratory inhaler with no medication
79370568|NCT03707691|Behavioral|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
79370569|NCT03707691|Behavioral|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
79370570|NCT02156908|Drug|D-serine|D-serine 60 mg/kg
79524665|NCT03838770|Device|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
79524666|NCT03839862|Drug|TNF-inhibition|Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
79524667|NCT03839550|Combination Product|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
79679227|NCT00513656|Drug|Oxycodone/Naloxone|
79679228|NCT00529932|Other|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
79823510|NCT00777777|Device|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
79823511|NCT00780819|Device|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
79998460|NCT03646344|Drug|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
79998461|NCT03646344|Drug|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
79998462|NCT01569945|Drug|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
79998463|NCT01569945|Drug|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
79227778|NCT02787005|Biological|Pembrolizumab|Intravenous infusion
79227779|NCT02755467|Device|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
79227780|NCT02673333|Drug|Pembrolizumab|
79227781|NCT02656394|Drug|GL101|Topical Gel
79227782|NCT02656394|Drug|Placebo|Placebo topical gel
79227783|NCT02633189|Drug|Erlotinib|given orally 150 mg daily
79227784|NCT02633189|Drug|Bevacizumab|15 mg/kg intravenously every 21 days.
79227785|NCT02633085|Device|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
79679229|NCT00529932|Other|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
79679230|NCT00513734|Other|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
79679231|NCT00513734|Other|Lacrilube ointment|lubricant put into eye (inferior formix)
79679232|NCT00531102|Other|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
79679233|NCT00531102|Other|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
79679234|NCT02951858|Behavioral|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
79823512|NCT05118477|Device|Ambulatory monitoring system|Patients will use AMS.
79227786|NCT02621242|Procedure|Upper endoscopy|Upper endoscopy with biopsies
79524668|NCT03839550|Procedure|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
79524669|NCT03839160|Procedure|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
79524670|NCT03839160|Drug|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
79524671|NCT03839238|Biological|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
79524672|NCT03838926|Drug|Trichostatin A|Intravenous Infusion
79524673|NCT03839004|Behavioral|Integrated approach to pregnancy|Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
79524674|NCT03838380|Other|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
79679235|NCT02951858|Behavioral|Control Group|The participants only receive the materials about the harm of substance use.
79679236|NCT00529971|Behavioral|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
79679237|NCT00529971|Other|Control|Treatment as usual, which could include medications or psychotherapy
79679238|NCT02951741|Other|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
79823513|NCT05118477|Device|Active alerting system|Clinical staff alerted if AMS detects deterioration
79679239|NCT00530127|Drug|placebo|Same dose and frequency as treatment
79227787|NCT02621242|Procedure|Anoscopy|Anoscopy with biopsies
79227788|NCT02621242|Drug|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
79227789|NCT02619435|Drug|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
79227790|NCT02618850|Procedure|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
79227791|NCT02618850|Drug|first-line chemotherapy|as prescribed by oncologist
79524675|NCT03838614|Behavioral|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
79679240|NCT00530127|Drug|deferiprone|100 mg/mL
79823514|NCT00667095|Drug|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
79823515|NCT00667095|Drug|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
79679241|NCT00530127|Drug|deferiprone|100 mg/mL
79679242|NCT00530127|Drug|placebo|Same dosage and frequency as study drug
79823516|NCT00777933|Drug|tacrolimus|
79823517|NCT00777933|Drug|cyclosporine|
79823518|NCT00773331|Drug|epoetin beta|As prescribed
79823519|NCT00773331|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
79823520|NCT00778011|Drug|Ondansetron|dosage
79227792|NCT02526368|Drug|Pyruvate (13C)|Given IV
79227793|NCT02526368|Drug|Hyperpolarized 13C,15N2-urea|Given IV
79227794|NCT02526368|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
79227795|NCT02514083|Drug|Ibrutinib|Ibrutinib 420mg PO daily for the duration of the study.
79227796|NCT02514083|Drug|Fludarabine|Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
79227797|NCT02500576|Biological|Aldesleukin|Given IV or SC
79227798|NCT02500576|Drug|Cyclophosphamide|Given IV
79227799|NCT02500576|Drug|Fludarabine Phosphate|Given IVPB
79227800|NCT02500576|Other|Laboratory Biomarker Analysis|Correlative studies
79227801|NCT02500576|Biological|Pembrolizumab|Given IV
79227802|NCT02500576|Other|Quality-of-Life Assessment|Ancillary studies
79679243|NCT00530127|Drug|deferiprone|100 mg/mL
79679244|NCT02951936|Device|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
79679245|NCT02951936|Device|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
79679246|NCT00513851|Drug|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
79679247|NCT00513851|Drug|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
79524676|NCT03838614|Behavioral|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
79227803|NCT02500576|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
79679248|NCT04691934|Procedure|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
79679249|NCT00513890|Device|Infantflow [EME, Brighton, England]|
79227804|NCT02441777|Device|Polarization-Sensitive OFDI|OCT Imaging of the eye
79227805|NCT02395848|Drug|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
79679250|NCT02944266|Other|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
79227806|NCT02364791|Device|standard techniques used to achieve air leak control|
79227807|NCT02364791|Device|Hemopatch|
79823521|NCT00778011|Drug|Ondansetron|4 mg
79227808|NCT02340585|Device|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
79227809|NCT02214381|Drug|Myocet|
79227810|NCT02214381|Drug|Cyclophosphamide|
79227811|NCT02214381|Drug|Paclitaxel|
79370571|NCT04763265|Biological|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
79370572|NCT04763265|Biological|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
79823522|NCT00778011|Drug|Metoclopramide|10 mg IV
79823523|NCT02556021|Drug|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
79823524|NCT02556021|Drug|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
79370573|NCT02244970|Other|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
79823525|NCT02556021|Drug|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
79823526|NCT00778089|Device|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
79823527|NCT00773487|Other|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
79823528|NCT00433381|Biological|Bevacizumab|Given IV
79823529|NCT00433381|Drug|Irinotecan Hydrochloride|Given IV
79227812|NCT02081326|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
79227813|NCT02081326|Biological|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
79227814|NCT02061761|Biological|BMS-986016|Specified Dose on Specified Days
79227815|NCT02061761|Biological|BMS-936558|Specified Dose on Specified Days
79227816|NCT01990053|Behavioral|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
79370574|NCT02244970|Other|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
79524677|NCT03838614|Behavioral|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
79524678|NCT03838614|Other|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
79679251|NCT00512018|Device|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
79823530|NCT00433381|Drug|Temozolomide|Given orally
79998464|NCT03645876|Drug|SHR-1210|200mg
79998465|NCT03645876|Drug|BP102|7.5mg/kg
79998466|NCT03645876|Drug|oxaliplatin|130mg/m2
79998467|NCT03645876|Drug|capecitabine|1000mg/m2
79998468|NCT03645798|Behavioral|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
79998469|NCT03645798|Behavioral|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
79308196|NCT02505737|Behavioral|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
79679252|NCT00512018|Other|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
79679253|NCT00530205|Other|physiologic testing|
79823531|NCT00781053|Drug|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
79227818|NCT01927068|Device|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
79524679|NCT03838224|Other|dry needling|"Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times."
79227819|NCT01898104|Radiation|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
79227820|NCT01898104|Drug|Valproic Acid|
79823532|NCT00773565|Dietary Supplement|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
79823533|NCT00667017|Biological|RFT5-dgA immunotoxin|
79823534|NCT00667017|Other|fluorescence activated cell sorting|
79227821|NCT01898104|Drug|Capecitabine|
79370575|NCT00004143|Drug|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
79679254|NCT00530205|Other|questionnaire administration|
79823535|NCT00667017|Other|immunohistochemistry staining method|
79227822|NCT01817452|Drug|Trastuzumab|
79370576|NCT04364542|Procedure|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
79370577|NCT04364542|Procedure|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
79370578|NCT04364542|Procedure|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
79370579|NCT03705429|Drug|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
79370580|NCT04370782|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
79370581|NCT04370782|Drug|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
79370582|NCT04370782|Drug|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
79679255|NCT00530205|Procedure|management of therapy complications|
79679256|NCT00530205|Radiation|radiation therapy|
79679257|NCT00512057|Drug|allopurinol|allopurinol 300mg twice a day
79679258|NCT00512057|Drug|placebo|placebo
79679259|NCT00531141|Other|examination only|OCT performed twice
79679260|NCT00513929|Dietary Supplement|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
79679261|NCT00531180|Procedure|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
79679262|NCT00531180|Procedure|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
79679263|NCT00512174|Other|BladderScan BVI 3000|
79679264|NCT00531219|Procedure|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
79679265|NCT00531219|Procedure|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
79227823|NCT01817452|Drug|Pertuzumab|
79227824|NCT01817452|Drug|Paclitaxel|
79227825|NCT01815242|Drug|nab-Paclitaxel|
79227826|NCT01815242|Drug|Gemcitabine|
79823536|NCT00781131|Drug|Pregabalin|pregabalin 75 or 150 mg
79823537|NCT00781131|Drug|Placebo|lactulose placebo
79823538|NCT00778245|Drug|cefprozil 500mg tablets|
79823539|NCT00778323|Procedure|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
79823540|NCT00778401|Drug|Gabapentin tablets 800 mg|
79998470|NCT03646266|Drug|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
79227827|NCT01815242|Drug|Carboplatin|
79370583|NCT04370782|Drug|Doxycycline|Doxycycline 200 mg once daily for 5 days
79370584|NCT03604653|Device|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
79679266|NCT00513968|Genetic|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
79679267|NCT00513968|Drug|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
79823541|NCT00773643|Other|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
79823542|NCT00773721|Device|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
79227828|NCT01802749|Drug|Bevacizumab|
79227829|NCT01802749|Drug|Paclitaxel|
79227830|NCT01802749|Drug|Carboplatin|
79227831|NCT01802749|Drug|pegylated liposomal doxorubicin|
79227832|NCT01802749|Drug|Gemcitabine|
79370585|NCT03604653|Drug|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
79227833|NCT01801904|Drug|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
79370586|NCT03604653|Drug|CDDP 50|50mg/m2@T0
79370587|NCT03604653|Drug|CDDP 75|75mg/m2@T0
79370588|NCT03604653|Drug|Doxorubicin|15mg/m2@T0
79679268|NCT00530244|Dietary Supplement|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
79227834|NCT01781338|Other|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
79227835|NCT01779206|Drug|Epirubicin|
79370589|NCT04376320|Device|customised ceramic sheets (Group 1)|guided bone regeneration
79370590|NCT04376320|Combination Product|modified sausage technique (Group 2)|guided bone regeneration
79370591|NCT04376086|Procedure|Epidural anesthesia|Segmental epidural analgesia
79370592|NCT04376086|Procedure|general anesthesia|general anesthesia
79679269|NCT00530244|Dietary Supplement|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
79679270|NCT00514007|Drug|OSI-906|OSI-906 administered orally
79679271|NCT00530283|Other|PET-CT|
79679272|NCT00512213|Dietary Supplement|Immunonutrition for 5 days preoperative|Impact vs Meritene
79370593|NCT04375852|Diagnostic Test|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
79370594|NCT03805659|Device|HD-tDCS|High-Dose transcranial Direct Current Stimulation
79370595|NCT03805659|Device|Sham|Sham sessions (no electric current)
79679273|NCT00512213|Dietary Supplement|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
79679274|NCT02951585|Device|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
79679275|NCT02951585|Device|PLACEBO|Intra-articular injection of physiological serum (saline solution)
79679276|NCT04691349|Drug|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
79679277|NCT02951624|Behavioral|Control|Control intervention
79823543|NCT00778479|Device|Sepraspray|Max. 10g of Sepraspray
79823544|NCT00666705|Drug|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
79823545|NCT00666705|Drug|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
79823546|NCT00666705|Drug|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
79823547|NCT00666705|Drug|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
79227836|NCT01779206|Drug|Cyclophosphamide|
79227837|NCT01779206|Drug|Docetaxel|
79227838|NCT01779206|Drug|Paclitaxel|
79227839|NCT01745965|Drug|T-DM1|
79227840|NCT01745965|Drug|Trastuzumab|
79227841|NCT01706120|Drug|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
79227842|NCT01706120|Drug|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
79227843|NCT01706120|Drug|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
79227844|NCT01656551|Drug|Gemcitabine|
79227845|NCT01656551|Drug|Pemetrexed|500 mg/m2 day 1 every 3 weeks
79227846|NCT01656551|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks
79227847|NCT01649674|Drug|polyethylene glycole (PEG) solution|
79227848|NCT01649674|Drug|sodium picosulphate and magnesium citrate solution|
79227849|NCT01628211|Procedure|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
79227850|NCT01628211|Procedure|peritonectomy|for patients with PCI < 20
79227851|NCT01628211|Drug|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI < 20
79370596|NCT03603795|Drug|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
79679278|NCT02951624|Behavioral|Breaker|Short breaks of physical activity
79679279|NCT02951624|Behavioral|Prolonger|longer breaks of physical activity
79679280|NCT02951624|Behavioral|Intermediate|Intermediate breaks of physical activity
79679281|NCT00531258|Device|rTMS|Bilateral rTMS
79679282|NCT00531258|Device|Sham rTMS|sham rTMS
79823548|NCT00433147|Drug|Afegostat tartrate|
79679283|NCT02951468|Procedure|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed [14]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
79998471|NCT02899338|Drug|BI695501 Prefilled syringe|
79998472|NCT02899338|Drug|BI695501Autoinjector|
79998473|NCT04052100|Other|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
79998474|NCT04052100|Other|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
79227852|NCT01628211|Drug|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI < 20
79227853|NCT01628211|Drug|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI < 20
79679284|NCT03459248|Other|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
79679285|NCT03459248|Other|Monotherapy|10 mg metoclopramide
79679286|NCT03459248|Other|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
79227854|NCT01628211|Drug|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI > 20
79227855|NCT01593488|Drug|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
79227856|NCT01453127|Drug|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
79524680|NCT03838224|Other|Sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
79308197|NCT02505737|Other|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
79370597|NCT03603795|Drug|Placebo|Placebo concomitant with induction chemotherapy patients with AML
79370598|NCT04370314|Other|Dental prosthetics|Implant-supported crowns
79370599|NCT04364464|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
79370600|NCT04746885|Dietary Supplement|DHA|Oral supplement
79370601|NCT04375774|Device|FFP2|Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
79370602|NCT04375774|Device|Facial mask|Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
79370603|NCT04375774|Device|MFS|Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
79370604|NCT03700047|Device|GAL1704|new dermal filler
79679287|NCT00531297|Procedure|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
79679288|NCT00512291|Drug|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
79679289|NCT02944032|Other|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
79823549|NCT04047849|Drug|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
79823550|NCT04047381|Other|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
79370605|NCT03700047|Device|Juvederm Voluma|hyaluronic acid
79524681|NCT03838302|Procedure|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
79679290|NCT02944032|Other|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
79823551|NCT04047927|Device|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
79524682|NCT03838302|Procedure|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
79227857|NCT01453127|Device|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
79227858|NCT01406691|Device|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
79227859|NCT01405586|Drug|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
79227860|NCT01405586|Drug|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
79227861|NCT01405586|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
79227862|NCT01309230|Biological|Vigil™|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
79227863|NCT01238692|Drug|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
79370606|NCT00924040|Drug|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
79524683|NCT03837834|Other|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
79524684|NCT03837210|Drug|Pylorin|Poly Herbal formulation
79524685|NCT03837288|Procedure|Cerclage|Cervical cerclage under effect of spinal anaesthesia
79524686|NCT03837366|Behavioral|Activity tracker and health coaching|Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
79524687|NCT03837054|Biological|Blood collection and Micronuclei assay on binucleate lymphocytes in culture|"The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures."
79679291|NCT00514163|Drug|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
79823552|NCT00778557|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
79823553|NCT00774033|Device|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
79823554|NCT00774033|Procedure|classic skin grafts|classic skin grafts used for the treatment of acute burn
79823555|NCT00778713|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
79823556|NCT00781209|Procedure|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
79823557|NCT00781287|Drug|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
79823558|NCT00781287|Drug|Raltegravir|400 mg BID PO
79370607|NCT04363996|Other|New Bioactive Restorative Material|Filling material
79370608|NCT04363918|Device|bioelectric stimulation|bioelectric stimulation
79370609|NCT03598413|Dietary Supplement|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
79679292|NCT00514163|Drug|gemcitabine|gemcitabine DIV on day one , 8th and 15th
79823559|NCT00774111|Drug|GSK1349572|GSK1349572 50 mg in combination with Etravirine
79308198|NCT02505659|Behavioral|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
79370610|NCT01592240|Drug|PBO|Placebo Q28d
79370611|NCT01592240|Drug|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
79370612|NCT01592240|Drug|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
79370613|NCT01592240|Drug|PBO|Placebo, Q14d
79370614|NCT01592240|Drug|PF-04950615|PF-04950615 50mg, Q14d
79370615|NCT01592240|Drug|PF-04950615|PF-04950615 100 mg, Q14d
79823560|NCT02557191|Other|Observational study|
79227864|NCT01238692|Drug|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
79227865|NCT01173341|Diagnostic Test|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
79227866|NCT01173341|Other|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
79227867|NCT01173341|Other|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
79227868|NCT01035112|Procedure|MRI|
79227869|NCT00996983|Drug|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
79227870|NCT00819832|Procedure|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
79370616|NCT01592240|Drug|PF-04950615|PF-04950615 150mg, Q14d
79524688|NCT03836742|Procedure|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
79524689|NCT03836898|Device|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
79679293|NCT04691466|Procedure|Joint replacement|Routinely performed hip- or knee replacement
79679294|NCT04695548|Other|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
79823561|NCT00778791|Drug|metformin HC1 750 mg extended-release tablets|
79823562|NCT00774189|Drug|clarithromycin 250 mg tablets|
79370617|NCT04370158|Other|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
79370618|NCT05620654|Drug|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
79370619|NCT04357834|Other|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
79370620|NCT04357522|Biological|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
79370621|NCT04357522|Biological|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
79227871|NCT00819832|Procedure|Vertebroplasty|Medical cement will be injected into broken back bone.
79227872|NCT00819832|Device|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
79370622|NCT00937378|Drug|SER120|Nasal Spray, once a day
79370623|NCT00937378|Drug|Placebo|Nasal Spray
79370624|NCT00005901|Drug|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
79370625|NCT04369768|Procedure|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
79679295|NCT04695548|Other|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
79823563|NCT00774423|Drug|Riluzole|50 mg per day during 24 months
79823564|NCT00781521|Drug|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
79823565|NCT02557113|Procedure|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
79823566|NCT02557113|Procedure|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
79823567|NCT00778947|Procedure|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
79227873|NCT00660842|Procedure|carboplatin|AUC 6 IV day 1 every 21 days
79227874|NCT00660842|Drug|paclitaxel|175 mg/m2 IV day 1 every 21 days
79227875|NCT00660842|Drug|carboplatin|AUC 2 IV every week
79227876|NCT00660842|Drug|paclitaxel|60mg/m2 IV every week
79227877|NCT00642057|Drug|tetrabenazine|25 mg titrated to optimal dose per patient
79227878|NCT00526396|Drug|cisplatin|80 mg/m2 on day 1 for 6 cycles
79227879|NCT00526396|Drug|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
79679296|NCT04695548|Other|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
79679297|NCT04695548|Other|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
79679298|NCT04691388|Drug|Amlotinib+Sindili|All patients will receive Sindelizumab combined with Antinib Hydrochloride capsule every 3 weeks
79679299|NCT00530322|Procedure|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
79679300|NCT04695743|Other|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
79679301|NCT02943486|Other|dac-MSCs|Cell-free therapy
79679302|NCT02943486|Other|MSCs|Cell-based therapy
79679303|NCT02943486|Drug|Fitostimoline|Triticum vulgare
79679304|NCT00514202|Drug|Placebo|matched placebo
79679305|NCT00514202|Drug|Dextroamphetamine SR|60 mg/day
79679306|NCT00530361|Drug|Nesiritide|
79679307|NCT00512408|Drug|testosterone|
79679308|NCT00530400|Drug|cefuroxime|preoperative intravenous 1.5g cefuroxime
79679309|NCT00530400|Drug|placebo|preoperative intravenous placebo
79679310|NCT00531336|Drug|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
79679311|NCT00531336|Drug|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
79679312|NCT00530478|Drug|Donepezil|
79679313|NCT00531375|Device|Silicone hydrogel contact lens|
79679314|NCT00530556|Drug|zolpidem|
79679315|NCT00512486|Biological|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~0.03 mg/kg intravenous injection~0.1 mg/kg intravenous injection~0.3 mg/kg intravenous injection~1.0 mg/kg intravenous injection~3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
79679316|NCT00530595|Drug|candesartan or valsartan or losartan|
79679317|NCT02951507|Other|O T unilateral attachment|O T unilateral attachment system
79679318|NCT02951507|Other|New design of extracoronal attachment system|O T unilateral attachment
79679319|NCT00512525|Drug|Ghrelin and saline (as placebo)|Intravenous infusion
79679320|NCT00531492|Behavioral|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
79823568|NCT00778947|Procedure|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
79227880|NCT00526396|Drug|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
79227881|NCT00526396|Drug|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
79227882|NCT00499421|Procedure|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
79227883|NCT00431704|Drug|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
79227884|NCT00431704|Drug|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
79227885|NCT00431704|Drug|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
79227886|NCT00412022|Drug|tamoxifen|20 mg daily for 5 years
79227887|NCT00412022|Drug|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
79227888|NCT00412022|Drug|letrozole|2.5 mg daily for 5 years
79227889|NCT00412022|Drug|zoledronic acid|4 mg every 6 months
79679321|NCT00531492|Other|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
79679322|NCT00512564|Other|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
79679323|NCT02943759|Drug|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
79679324|NCT02943759|Drug|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
79679325|NCT00514241|Device|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
79679326|NCT02944110|Drug|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
79679327|NCT02944110|Drug|Placebo|Oral dose of placebo tablets
79679328|NCT03459209|Other|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
79679329|NCT02943837|Procedure|Device: 22G FNA needle|
79679330|NCT02943837|Procedure|Device: 20G FNB needle|
79524690|NCT03836118|Procedure|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
79524691|NCT03836274|Dietary Supplement|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
79679331|NCT00530751|Other|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool [GREAT]) are explored.
79679332|NCT02951975|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
79679333|NCT00514397|Drug|motexafin gadolinium|
79679334|NCT00514397|Drug|temozolomide|
79679335|NCT00514397|Procedure|adjuvant therapy|
79679336|NCT00514397|Procedure|quality-of-life assessment|
79679337|NCT00514397|Radiation|radiation therapy|
79679338|NCT02943603|Drug|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
79679339|NCT00514436|Behavioral|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
79524692|NCT03835962|Device|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
79524693|NCT03835806|Other|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
79679340|NCT00531687|Drug|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
79679341|NCT00531687|Drug|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
79679342|NCT00531687|Drug|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
79679343|NCT00514475|Drug|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
79679344|NCT00530829|Drug|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
79679345|NCT00512681|Drug|Irinotecan, Oxaliplatin, TS-1|"S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
79679346|NCT00530868|Other|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
79679347|NCT00530868|Drug|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
79679348|NCT00530907|Drug|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
79679349|NCT00530907|Drug|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
79679350|NCT02951663|Dietary Supplement|Protein|
79679351|NCT00530985|Behavioral|Benefits Counseling|Help deciding whether to work
79679352|NCT00530985|Behavioral|VA Orientation|Orientation to services available at VA
79679353|NCT00531024|Drug|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
79679354|NCT00531024|Drug|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
79679355|NCT00512759|Drug|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
79679356|NCT00531726|Device|DBS of Cg25|
79679357|NCT00514670|Other|Alcohol-based hand sanitizer & quaternary ammonium wipes|
79679358|NCT00531063|Drug|Everolimus (RAD001)|
79679359|NCT00512837|Behavioral|Mobile phone technology|
79679360|NCT02943798|Drug|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
79679361|NCT02943798|Drug|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
79679362|NCT00512915|Device|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
79998475|NCT04052178|Device|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
79998476|NCT04052178|Device|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
79998477|NCT04052178|Dietary Supplement|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
79679363|NCT02943369|Drug|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
79679364|NCT02943369|Drug|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
79679365|NCT02943330|Other|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
79679366|NCT00514748|Procedure|DIEP|flap survival, operation time, flap complications, donor site morbidity.
79679367|NCT00514748|Procedure|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
79679368|NCT02943876|Other|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
79679369|NCT00515957|Genetic|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level <100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10^7 cells/m2~1x 10^8 cells/m2 3 x 10^8 cells/m2~1 x 10^9 cells/m2"
79679370|NCT00514826|Other|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
79679371|NCT02943642|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
79679372|NCT02943642|Drug|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
79998478|NCT03645642|Drug|Midodrine|Midodrine 5 mg thrice daily
79998479|NCT03645642|Biological|Albumin|Albumin 20g/l
79370626|NCT03800199|Other|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
79370627|NCT04369534|Drug|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
79370628|NCT04369534|Drug|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
79679373|NCT02943720|Drug|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
79679374|NCT02943720|Drug|placebo|placebo
79998480|NCT03645642|Drug|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
79370629|NCT03590457|Device|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
79370630|NCT04363762|Behavioral|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
79998481|NCT05284266|Procedure|Liposuction early|Liposuction 6-9 months after inclusion
79998482|NCT05284266|Procedure|Liposuction late|Liposuction 18-21 months after inclusion
79370631|NCT04363762|Device|Occlusal splint|Occlusal splint, standard
79524694|NCT03835806|Other|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
79524695|NCT03835572|Other|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
79524696|NCT03835572|Other|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
79524697|NCT03835494|Other|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
79524698|NCT03835104|Device|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
79524699|NCT03834636|Procedure|Restorations with nanoparticulated composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
79524700|NCT03834636|Procedure|Restorations with nanoparticulated composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
79524701|NCT03834636|Procedure|Restorations with nanohybrid composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
79998483|NCT05284266|Other|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
79370632|NCT04763187|Procedure|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
79679375|NCT04695353|Procedure|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
79370633|NCT04363450|Drug|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
79679376|NCT02944149|Procedure|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
79679377|NCT04695509|Drug|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
79679378|NCT04695509|Drug|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
79679379|NCT02943135|Drug|lidocaine in-situ gel|lidocaine in-situ gel
79679380|NCT02943135|Drug|placebo in-situ gel|placebo in-situ gel
79679381|NCT02951234|Other|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
79679382|NCT02951234|Other|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
79823569|NCT00774501|Procedure|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
79998484|NCT05284266|Other|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
79998485|NCT05284422|Procedure|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
79998486|NCT05284422|Procedure|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
79998487|NCT03066609|Drug|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
79998488|NCT03066609|Drug|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
79998489|NCT03066609|Drug|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
79370634|NCT04363450|Drug|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
79370635|NCT03685149|Drug|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
79370636|NCT03685149|Drug|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
79370637|NCT04370080|Device|Silver Diamine Fluoride 38%|Dental caries arrest medication
79679383|NCT00531765|Other|sodium bicarbonate infusion|short infusion of sodium bicarbonate
79679384|NCT00531804|Drug|gantenerumab|Administered iv at escalating doses (7 cohorts)
79998490|NCT03645486|Genetic|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1~10x10^6 gene-modified cells per kg body weight
79998491|NCT03646110|Procedure|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
79370640|NCT01591616|Drug|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
79370641|NCT03681873|Diagnostic Test|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
79370642|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
79679385|NCT02951390|Other|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
79679386|NCT02950610|Device|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
79370643|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
79679387|NCT02943252|Drug|Apatinib|apatinib 500 mg in tablet once daily
79998492|NCT05204043|Other|Peter Hess® sound massage|The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.
79227890|NCT03474510|Drug|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
79227891|NCT03474510|Other|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
79227892|NCT02227953|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79227893|NCT02227953|Device|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79227894|NCT02470832|Drug|RG1662|
79370644|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
79370645|NCT00938314|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
79998493|NCT05204043|Other|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.
79998494|NCT05204043|Other|Questionnaires|"State Trait Anxiety Inventory (STAI)~Pain assessment - Visual Analogic Scale (from 0 to 10)."
79227895|NCT02470832|Drug|itraconazole|
79227896|NCT05258682|Drug|Bromelains|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
79370646|NCT04370392|Procedure|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
79679388|NCT02943252|Drug|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
79679389|NCT00514982|Drug|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
79679390|NCT00514982|Drug|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
79370647|NCT04369378|Behavioral|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
79679391|NCT00514982|Drug|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
79679392|NCT00514982|Drug|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
79998495|NCT03611790|Device|NeVa VS|mechanical dilatation
79998496|NCT05757921|Device|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
79679393|NCT00514982|Drug|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
79998497|NCT05757921|Other|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
79227897|NCT05258682|Drug|Acetylcysteine|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
79998498|NCT03946761|Device|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
79679394|NCT00514982|Drug|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
79998499|NCT02964234|Behavioral|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
79370648|NCT03798327|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
79227898|NCT03310112|Behavioral|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
79227899|NCT03310112|Behavioral|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
79227900|NCT02258841|Behavioral|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
79998500|NCT02964234|Behavioral|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
79227901|NCT02258841|Behavioral|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
79227902|NCT02258841|Behavioral|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
79227903|NCT02258841|Behavioral|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
79227904|NCT02258841|Behavioral|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
79227905|NCT05258604|Procedure|argon plasma coagulation|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
79370649|NCT04357678|Other|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
79370650|NCT04357678|Other|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
79370651|NCT04357444|Drug|1: ILT101|Subcutaneous injections, once-daily administration for 10 consecutive days.
79370652|NCT04357444|Drug|2: Placebo Comparator|placebo in Subcutaneous route
79370653|NCT04369144|Other|Dynamic Scapular Recognition exercise|The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
79370654|NCT03679689|Dietary Supplement|artificially sweetened beverages|artificially sweetened beverages restriction
79370655|NCT04369222|Other|Observational|Maternal consumption of mild analgesics
79370656|NCT04363294|Diagnostic Test|PYP scan|99mTc-labeled pyrophosphate
79370657|NCT01591460|Drug|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
79370658|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
79370659|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
79370660|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
79370661|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
79370662|NCT03584295|Device|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
79227906|NCT05258604|Procedure|endoscopic band ligation|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
79370663|NCT03584295|Other|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
79370664|NCT04363216|Drug|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
79524702|NCT03834636|Procedure|Restorations with nanohybrid composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
79524703|NCT03834480|Other|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
79524704|NCT03834558|Other|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
79524705|NCT03834324|Device|FES|Functional Electrical Stimulation during cycling with Virtual Reality Feedback
79524706|NCT03834012|Drug|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
79998501|NCT03921255|Other|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark & Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark & Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey & Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
79524707|NCT03834012|Drug|Placebo|Intervention: Drug: placebo
79679395|NCT02950532|Other|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
79679396|NCT00531999|Drug|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
79998502|NCT03645252|Procedure|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
79227907|NCT03310034|Dietary Supplement|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
79227908|NCT03310034|Dietary Supplement|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
79370665|NCT04363372|Drug|MRx-4DP0004|MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
79370666|NCT04363372|Drug|Placebo|Placebo capsules will be identical in appearance to active product.
79524708|NCT03834012|Drug|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
79679397|NCT00531999|Drug|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
79679398|NCT00516035|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
79227909|NCT02228031|Drug|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
79524709|NCT03834012|Drug|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
79524710|NCT03834090|Device|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
79370667|NCT04357210|Procedure|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
79370668|NCT03678675|Drug|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
79679399|NCT05318118|Procedure|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith & Nephew) implant.
79823570|NCT04047147|Other|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~Risk stratify eligible Medicare FFS beneficiaries~Provide CVD care management to high-risk beneficiaries~Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
79823571|NCT04047147|Other|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
79998503|NCT03645252|Procedure|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
79679400|NCT05318118|Procedure|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
79998504|NCT03645174|Device|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
79998505|NCT03645174|Device|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
79998506|NCT03773328|Biological|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
79227910|NCT02228031|Other|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
79227911|NCT01799265|Device|Somnetics Transcend Auto|
79524711|NCT03834090|Other|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
79998507|NCT03645018|Diagnostic Test|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
79370669|NCT04363060|Combination Product|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
79370670|NCT04363060|Drug|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
79524712|NCT03833466|Drug|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
79679401|NCT05319912|Drug|ALXN1840 Enteric-coated Tablet|ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
79679402|NCT05319912|Drug|ALXN1840 Non-coated Capsule|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
79227912|NCT01799265|Device|Respironics REMstar Auto with C-Flex|
79679403|NCT05319912|Drug|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
79679404|NCT00515138|Drug|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
79679405|NCT04695587|Diagnostic Test|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
79679406|NCT04695587|Diagnostic Test|MSNA|MSNA in subacute phase and 12 months after the acute episode
79227913|NCT02232321|Other|PsA MDA|
79227914|NCT03478410|Procedure|Epicardial fat biopsy|A 1 cm (~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
79227915|NCT02232399|Drug|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
79227916|NCT02232399|Drug|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
79227917|NCT00704522|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
79227918|NCT00704522|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
79370671|NCT01591382|Drug|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
79370672|NCT01591382|Drug|Placebo|Patients who received ketamine-matching placebo were given saline infusions
79370673|NCT01591382|Drug|Hydromorphone PCA|Intravenous hydromorphone PCA
79370674|NCT04362904|Other|acupressure|
79524713|NCT03833388|Drug|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
79524714|NCT03833388|Drug|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
79524715|NCT03833310|Diagnostic Test|Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
79524716|NCT03832608|Other|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
79823572|NCT00784407|Device|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
79679407|NCT04695587|Diagnostic Test|ABPM|ABPM in subacute phase and 12 months after the acute episode
79370675|NCT03678441|Behavioral|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
79370676|NCT03678441|Procedure|Cognitive Assessment|Receive pen and paper cognitive assessment
79823573|NCT00784485|Drug|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
79823574|NCT00781755|Drug|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
79823575|NCT00781755|Behavioral|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
79227919|NCT00704522|Behavioral|Patient assistance program|"Assistance programs will be classified as follows:~Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
79823576|NCT00781833|Device|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
79370677|NCT03677817|Drug|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
79679408|NCT04695587|Diagnostic Test|ECHO|ECHO in subacute phase and 12 months after the acute episode
79823577|NCT00774735|Drug|GSK1349572|30 mg given in combination with lopinavir/ritonavir
79823578|NCT00774735|Drug|GSK1349572|30 mg in combination with darunavir/ritonavir
79823579|NCT00666237|Procedure|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
79823580|NCT00666237|Procedure|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
79823581|NCT00666237|Drug|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
79823582|NCT00774813|Device|Nexalin 1.3mA Device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of placebo antidepressant"
79823583|NCT00774813|Device|Nexalin 15mA device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a placebo antidepressant"
79370678|NCT03677817|Drug|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
79370679|NCT00931996|Drug|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
79370680|NCT04348305|Drug|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
79370681|NCT04348305|Drug|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
79679409|NCT04695587|Diagnostic Test|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
79679410|NCT04695587|Diagnostic Test|CMR|CMR in 12 months after the acute episode
79679411|NCT00515255|Drug|Minocycline|Capsules
79679412|NCT02943018|Other|anovaginal distance variation|Kappa calculation
79679413|NCT00516113|Drug|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
79823584|NCT00774813|Drug|placebo device and Citalopram|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a a SSRI (Citalopram or similar)"
79823585|NCT00784797|Drug|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
79823586|NCT00784797|Drug|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
79998508|NCT03644394|Device|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
79998509|NCT05203809|Device|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
79998510|NCT03644940|Diagnostic Test|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
79370682|NCT00928174|Drug|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
79370683|NCT01696214|Drug|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
79370684|NCT01696214|Drug|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
79370685|NCT01696214|Drug|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
79679414|NCT02942940|Device|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
79823587|NCT00774969|Drug|Metronidazole|Metronidazole 10% ointment three times a day 7 days
79998511|NCT03864081|Device|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
79823588|NCT00785031|Other|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
79524717|NCT03830658|Behavioral|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
79524718|NCT03830424|Procedure|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
79998512|NCT01345188|Drug|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
79227920|NCT03474432|Device|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
79370686|NCT01696214|Drug|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
79370687|NCT02083263|Device|Bilevel|3 months
79370688|NCT02083263|Device|PEP mask|3 months
79679415|NCT02942940|Other|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
79679416|NCT05317962|Diagnostic Test|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
79679417|NCT00516152|Drug|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~3 Fludarabine 30 mg/m(2)IV~2 REST Tacrolimus 0.01 mg/kg CIVI~1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~1 Methotrexate 5mg/m(2)IV~3 Methotrexate 5mg/m(2)IV~6 Methotrexate 5mg/m(2)IV~7 G-CSF 5mcg/kg SQ daily~11 Methotrexate 5mg/m(2)IV~90 Evaluate Response"
79823589|NCT00785109|Dietary Supplement|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
79370689|NCT04356898|Other|No intervention|No intervention
79823590|NCT00662025|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
79998513|NCT01345188|Drug|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
79998514|NCT03852459|Drug|S-Ibuprofen|Topical Gel 5%
79370690|NCT05347875|Other|ICanWALK© App.|"App containing educational and instructional videos on crutch fitting and walking with key components of these skills highlighted. App video records individual using the taught skills to enable them and their care providers to review their usage of the walking aids."
79370691|NCT04369300|Behavioral|Registery Data Collection|Observational Data Collection
79823591|NCT00662025|Drug|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
79370692|NCT03794037|Drug|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
79370693|NCT03794037|Combination Product|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days & dydrgesterone 10 mg (tab) twice daily oral for 14 days &
79370694|NCT04356508|Drug|Nivolumab|Single dose at 0.3mg/kg
79370695|NCT04362280|Behavioral|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
79370696|NCT04362280|Behavioral|TAU|PE class as usual led by PE teacher.
79998515|NCT03852459|Drug|Vehicle|Vehicle Gel
79998516|NCT03580902|Behavioral|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
79998517|NCT03580902|Drug|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
79998518|NCT03644862|Device|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
79228473|NCT03446352|Other|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
79228474|NCT03446352|Other|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
79228475|NCT03308708|Drug|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
79228476|NCT03443700|Device|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
79228477|NCT03443700|Procedure|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
79228478|NCT03897465|Device|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
79228479|NCT03897465|Device|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
79228480|NCT03472482|Diagnostic Test|non-invasive retinal imaging|
79228481|NCT03143556|Device|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
79228482|NCT04476615|Dietary Supplement|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
79547138|NCT01551589|Radiation|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
79998596|NCT05208255|Other|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
79998597|NCT02963922|Drug|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
79998598|NCT02963922|Drug|Placebo|Injected subcutaneously (s.c., under the skin) once daily
79998599|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~on pre-operative d-1/d, post-operative d1 and d5(+/-2),~one month post-operative,~at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
79228483|NCT04476615|Dietary Supplement|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
79228484|NCT02929056|Biological|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
79228485|NCT02929056|Procedure|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
79228486|NCT02262741|Biological|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
79228487|NCT02262741|Biological|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
79228488|NCT04659408|Dietary Supplement|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
79228489|NCT04659408|Dietary Supplement|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
79547139|NCT01551602|Drug|AK159|transdermal administration of teriparatide acetate
79547140|NCT01551602|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
79228490|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
79680168|NCT02930148|Other|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
79228491|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
79228492|NCT02233569|Device|Ventralight ST implant|
79228493|NCT02233569|Device|ETHICON PHYSIOMESH®|
79998600|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~before starting the therapy~at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~at the end of the study or at the date of disease progression."
79228494|NCT02582073|Biological|Placebo (0.5ml)|
79680169|NCT03458741|Other|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
79680170|NCT02947568|Other|non-interventional study|
79680171|NCT02930265|Drug|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
79228495|NCT02582073|Biological|Placebo (1.0ml)|
79228496|NCT02582073|Biological|Grass MATA MPL (0.5ml) 5100SU|
79228497|NCT02582073|Biological|Grass MATA MPL (1.0ml) 10200SU|
79228498|NCT02582073|Biological|Grass MATA MPL (1.0ml) 18200SU|
79228499|NCT02582073|Biological|Grass MATA (0.5ml) 5100SU|
79228500|NCT02769000|Radiation|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
79228501|NCT02769000|Radiation|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
79228502|NCT02633670|Device|Hemopatch|
79547141|NCT01551602|Drug|Placebo|Multiple administration of placebo AK159
79547142|NCT01551615|Drug|Metformin 1000 mg|2 x 500 mg oral tablets
79680172|NCT02947490|Other|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
79680173|NCT02947490|Other|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
79998601|NCT01340131|Drug|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
79998602|NCT01340131|Drug|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
79998603|NCT00090181|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
79228503|NCT02633670|Device|No Hemopatch|
79228504|NCT00250341|Drug|QVAR|480 mcg
79228505|NCT00250341|Drug|Advair|250/50 mcg
79228506|NCT00250341|Drug|Servent Diskus|50 mcg
79228507|NCT03472248|Behavioral|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
79228508|NCT03711903|Drug|Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).|The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
79228509|NCT03711903|Drug|0.9% Sodium-chloride|normal saline
79228510|NCT01995396|Procedure|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
79228511|NCT01995396|Procedure|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
79228512|NCT05196633|Other|radial extracorporeal shock wave therapy|rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.
79228513|NCT05196633|Other|sham radial extracorporeal shock wave therapy|The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
79228514|NCT03471000|Other|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
79547143|NCT01551615|Drug|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
79547144|NCT01551628|Drug|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
79228515|NCT03471000|Other|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
79680174|NCT02947490|Other|Standard BP management|GP to measure BP and manage BP control
79998604|NCT00090181|Drug|Comparator: diclofenac / Duration of Treatment: 4 weeks|
79998605|NCT05207787|Drug|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
79998606|NCT03643380|Device|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
79228516|NCT03702465|Other|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
79228517|NCT03702465|Other|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
79998607|NCT01336075|Procedure|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
79998608|NCT01336075|Procedure|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
79228518|NCT03702465|Other|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
79228519|NCT02233725|Device|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
79228520|NCT05157204|Procedure|measurment of interleukin-6 at exhaled condensate|the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
79371156|NCT04402047|Other|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
79228521|NCT02236299|Procedure|Right Coronary Artery Percutaneous Coronary Intervention|
79371157|NCT04402047|Drug|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
79228522|NCT02236299|Other|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
79228523|NCT02236299|Other|GLP-1 Infusion|30 minute infusion GLP-1
79228524|NCT02236455|Behavioral|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
79228525|NCT02236455|Behavioral|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
79228526|NCT02236455|Behavioral|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
79228527|NCT02236455|Behavioral|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
79228528|NCT02578095|Drug|VK5211|Capsule
79228529|NCT02578095|Drug|Placebo|Capsule
79228530|NCT00545766|Drug|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
79228531|NCT02262819|Drug|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
79228532|NCT02236533|Dietary Supplement|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
79547145|NCT01551641|Other|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
79228533|NCT05156970|Drug|Camrelizumab|Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
79228534|NCT05156970|Drug|Cisplatin|Cisplatin 75 mg/m^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
79228535|NCT05156970|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
79228536|NCT05156970|Drug|Apatinib Mesylate|Apatinib 250mg qd for up to 24 months
79228537|NCT05156970|Drug|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
79228538|NCT02233881|Drug|Atrovent® - inhalets|
79228539|NCT00157755|Device|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
79547146|NCT01551641|Drug|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
79680175|NCT02947490|Other|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
79228540|NCT02261571|Other|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
79228541|NCT02234037|Drug|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
79228542|NCT02234037|Behavioral|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise > 10 minutes of muscle strengthening, > 10 minutes of aerobic exercise (treadmill walking or cycling), > 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
79228543|NCT04476771|Behavioral|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
79228544|NCT02234193|Device|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
79228545|NCT02234193|Procedure|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
79228546|NCT04476459|Drug|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
79228547|NCT04476459|Drug|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
79228548|NCT02262897|Drug|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
79228549|NCT02653599|Drug|TTP273|
79228550|NCT02653599|Drug|Placebo|
79228551|NCT02653443|Biological|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
79228552|NCT02653443|Biological|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
79228553|NCT02723006|Drug|TAK-580|TAK-580 tablets
79228554|NCT02723006|Drug|TAK-202|TAK-202 infusion
79228555|NCT02723006|Drug|vedolizumab|vedolizumab infusion
79371158|NCT03028714|Behavioral|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
79680176|NCT02929953|Other|chart review|data from charts and from registries will be compared
79228556|NCT02723006|Drug|nivolumab|nivolumab infusion
79228557|NCT02723006|Drug|ipilimumab|ipilimumab infusion
79228558|NCT03308630|Behavioral|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
79228559|NCT03308552|Radiation|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
79228560|NCT03308552|Drug|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
79228561|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
79228562|NCT03308552|Drug|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
79228563|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
79228564|NCT03308318|Procedure|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
79998609|NCT05214261|Other|Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia|"Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction."
79998610|NCT03644238|Diagnostic Test|Oral Glucose Tolerance Test|75g of glucose is consumed
79228565|NCT03308240|Behavioral|Magic Therapy|As described in the arm description
79228566|NCT03308162|Behavioral|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
79371159|NCT03028168|Other|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
79371160|NCT03028168|Other|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
79371161|NCT03028168|Other|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
79371162|NCT03027778|Other|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
79371163|NCT03035110|Behavioral|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
79371164|NCT03017638|Other|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
79371165|NCT03017248|Drug|Ketamine|ketamine
79371166|NCT03017248|Drug|Placebos|0.9% normal saline
79371167|NCT03017248|Drug|Morphine|Morphine
79371168|NCT03035344|Other|Metabolome study|Metabolome study in ALL patients compared to healthy controls
79371169|NCT03034720|Behavioral|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
79371170|NCT03034486|Drug|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
79371171|NCT00088881|Biological|rituximab|Given IV
79371172|NCT00088881|Drug|prednisone|Given orally
79998611|NCT03644238|Behavioral|Inactivity|Lying or sitting down.
79998612|NCT03644238|Behavioral|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
79998613|NCT03619785|Drug|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
79228567|NCT03308084|Drug|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
79371173|NCT00088881|Drug|cyclophosphamide|Given IV
79371174|NCT00088881|Drug|doxorubicin|Given IV
79371175|NCT00088881|Drug|vincristine|Given IV
79371176|NCT00088881|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
79371177|NCT00088881|Radiation|radiation therapy|Undergo radiotherapy
79371178|NCT00088881|Procedure|positron emission tomography|Undergo PET scans
79823878|NCT01030627|Device|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
79823879|NCT00786981|Other|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
79228568|NCT03308084|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
79998614|NCT03619785|Drug|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
79228569|NCT02468492|Biological|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
79228570|NCT02468492|Other|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
79228571|NCT00702962|Drug|Vorinostat, Carboplatin, Etoposide|"Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total."
79228572|NCT01379508|Drug|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
79228573|NCT01379508|Drug|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
79228574|NCT03300206|Device|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
79228575|NCT03300128|Behavioral|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
79228576|NCT03300128|Other|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
79228577|NCT03299972|Dietary Supplement|Whey Protein|25 g whey protein supplementation twice daily (breakfast and lunch)
79228578|NCT03299972|Dietary Supplement|Control|23.75 g maltodextrin twice daily (breakfast and lunch)
79228579|NCT03299972|Other|Resistance Exercise|60 minutes of resistance exercise twice a week
79228580|NCT02261649|Device|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
79228581|NCT02261649|Procedure|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
79228582|NCT02261649|Device|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
79371179|NCT02981914|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
79371180|NCT02981680|Procedure|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
79371181|NCT02981680|Procedure|sham-RIPC|
79371182|NCT03026452|Procedure|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
79371183|NCT03025750|Biological|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
79371184|NCT03025750|Biological|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
79371185|NCT03024892|Procedure|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
79371186|NCT03024892|Procedure|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
79371187|NCT03024892|Procedure|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
79371188|NCT03024892|Procedure|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
79228583|NCT02261649|Other|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
79228584|NCT03299894|Procedure|systematic calculation of qSOFA|calculation of qSOFA for each patient
79547147|NCT01551641|Other|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
79823880|NCT00786981|Other|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
79371189|NCT03024658|Other|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
79524922|NCT05625685|Other|Quitbuddy|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD EMA/GPS smoking data collection. GPS guided NRT usage prompts, via hotspot algorithms, will be provided to participants in the Quitbuddy Arm. Participants will contribute four weeks of post-TQD EMA/GPS data to capture lapses and NRT use in real-time. Carbon Monoxide (CO) levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
79524923|NCT05625685|Other|Control|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD smoking data collection. Participants will contribute four weeks of post-TQD data to capture lapses and NRT use. CO levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
79371190|NCT00952120|Device|GSUC|Gauze-based wall suction negative pressure wound therapy
79524924|NCT05625685|Other|SDoH Augmentation|The SDoH intervention is based on the findhelp.org online platform, with customization to meet the specific needs of the study and communities being served: includes validated SDoH assessments, personalized social needs searching based on priorities, access to the most comprehensive social service database, and a streamlined closed loop referral system that integrates with workflows.
79524925|NCT05625685|Other|SDoH Control|No SDoH intervention
79524926|NCT05623228|Combination Product|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
79524927|NCT05622877|Drug|Qushi Formula|Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.
79680177|NCT02947178|Procedure|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
79680178|NCT02947178|Behavioral|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
79680179|NCT02947178|Behavioral|Pill Count|Patient reported as needed (prn) pain medication usage
79680180|NCT02947178|Drug|Bupivacaine|
79680181|NCT02947178|Drug|Liposomal Bupivacaine|
79680182|NCT02929797|Biological|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
79680183|NCT02929797|Drug|Gemcitabine|gemcitabine
79823881|NCT00430573|Drug|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
79823882|NCT00430573|Drug|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
79823883|NCT00783315|Behavioral|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
79998615|NCT03643302|Device|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
79998616|NCT02881567|Drug|Daclizumab|High yield formulation
79228585|NCT05129397|Behavioral|Mom Power|Virtual Mom Power is a manualized multi-family group intervention consisting of 10 virtual group + 2 individual sessions led by two masters-level co-facilitators. Virtual groups are 90 minutes, following a structured format via secure HIPAA compatible video platform. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice (4) Social Support; & (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs.
79228586|NCT05129397|Behavioral|Mom Power Informational Mailing|This active comparison condition intervention includes two individual sessions along with 10 weeks of informational mailing with content related to Mom Power core concepts.
79228587|NCT04377672|Biological|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
79228588|NCT02263053|Procedure|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
79998617|NCT02962674|Device|prostaFix System|
79371191|NCT00952120|Device|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
79371192|NCT03017482|Device|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~Questionnaires about the utility and impact of the device~Use of the device in children younger than the current FDA approval range"
79371193|NCT04353544|Other|delayed cord clamping|delayed cord clamping
79371194|NCT03017404|Drug|Doxorubicin Hydrochloride Liposome Injection|
79371195|NCT03017404|Drug|Cyclophosphamide|
79371196|NCT03017404|Drug|docetaxel|
79371197|NCT00953212|Drug|beta blockers|metoprolol 25mg by mouth every 6 hours
79371198|NCT00953212|Drug|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
79228589|NCT02263053|Procedure|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
79998618|NCT03280797|Procedure|Blood sample|2ml blood taken into TruCulture tube
79228590|NCT03299738|Biological|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
79228591|NCT04457934|Drug|Plenvu|All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
79228592|NCT05726630|Drug|Divozilimab|anti CD20 monoclonal antibody
79228593|NCT05726630|Drug|Placebo|Placebo
79228594|NCT04306146|Drug|CAD-9303|Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
79228595|NCT04306146|Drug|Placebos|Capsules
79228596|NCT02558439|Drug|CNTX-4975|
79228597|NCT02558439|Other|Placebo|
79228598|NCT05162430|Drug|Propofol|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
79524928|NCT05622877|Drug|Zhu's Wenban Formula|Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome
79524929|NCT05622877|Drug|placebo|The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.
79998619|NCT05184595|Other|Carfilzomib delivered in OH only|Patients receive the whole treatment en OH.
79998620|NCT05184595|Other|Carfilzomib delivered in OH and HaH combined|Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
79228599|NCT05156502|Device|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
79228600|NCT05156502|Device|Fractionated Laser (Pixel CO.2-Alma)|Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
79228601|NCT02615067|Drug|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
79228602|NCT02615067|Diagnostic Test|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
79228603|NCT05006612|Procedure|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
79228604|NCT05005520|Drug|DTRI-031|Investigational drug
79228605|NCT05005520|Drug|Placebo|Matching placebo to DTRI-031
79228606|NCT05162352|Drug|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
79228607|NCT04490408|Procedure|long surgical bypass|long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
79228608|NCT04490408|Procedure|Hybrid approach|Hybrid approach including bypass and endovascular revascularization
79228609|NCT05087121|Behavioral|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
79228610|NCT05087121|Device|Fitbit Inspire HR Wrist Worn Device (NCT04176926)|"The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926"
79228611|NCT05156424|Other|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
79371199|NCT00953212|Drug|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
79547148|NCT01551654|Device|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
79547149|NCT01551667|Biological|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
79998621|NCT05213793|Diagnostic Test|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
79998622|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
79228612|NCT03307928|Diagnostic Test|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
79228613|NCT03307928|Diagnostic Test|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
79228614|NCT02234271|Other|Mobile Health Application|Mobile Health application for contraception information
79228615|NCT02234271|Other|Health Educator Counseling|Counseling via health educator
79228616|NCT03307850|Other|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
79371200|NCT00953290|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
79371201|NCT03024190|Other|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
79371202|NCT03024190|Other|stretching exercise|15- min stretching exercise for upper extremity twice daily
79371203|NCT03024190|Other|OT rehabilitation program|regular rehabilitation program for 3 weeks
79371204|NCT03024268|Device|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
79371205|NCT03034408|Drug|Nalmefene|
79371206|NCT03034408|Drug|Baclofen|
79524930|NCT05622877|Other|Basic treatment|Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.
79547150|NCT01551667|Biological|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
79228617|NCT02264769|Drug|Carbetocin|
79998623|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
79998624|NCT05184517|Drug|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
79998625|NCT05184517|Drug|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
79228618|NCT05162040|Device|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
79228619|NCT03307772|Dietary Supplement|Probiotics|
79228620|NCT03307772|Dietary Supplement|Prebiotics|
79228621|NCT03307772|Dietary Supplement|Prebiotics and Probiotics|
79228622|NCT03307772|Dietary Supplement|Placebo|
79371207|NCT03034408|Drug|Placebo Oral Capsule|
79371208|NCT03034252|Procedure|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
79371209|NCT03017092|Behavioral|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
79371210|NCT03016858|Procedure|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
79371211|NCT03023020|Drug|Aspirin|Dosing per current guidelines and local practice
79371212|NCT03023020|Drug|P2Y12 inhibitor|Dosing per current guidelines and local practice
79371213|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
79228623|NCT02264847|Drug|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
79228624|NCT02264847|Drug|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
79228625|NCT05156190|Other|bright classrooms with light level over 1000 lux|Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
79998626|NCT05207475|Device|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
79228626|NCT02262195|Other|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
79228627|NCT05161962|Combination Product|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
79680184|NCT00525239|Drug|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
79228628|NCT05161962|Combination Product|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
79228629|NCT05726552|Other|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
79228630|NCT03469128|Behavioral|Cognitive processing therapy|Psychological treatment for patients suffering from PTSD and SUD symptoms.
79228631|NCT03469128|Drug|Sertraline|Sertraline for the treatment of post-traumatic stress and SU disorders
79228632|NCT03469128|Other|Placebo Control|Placebo Control
79228633|NCT02542215|Drug|Cobiprostone|Cobiprostone 30 mcg oral spray
79228634|NCT02542215|Drug|Placebo|Matching placebo oral spray
79228635|NCT02542215|Drug|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
79228636|NCT02542215|Radiation|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
79228637|NCT05270174|Other|no intervention|no intervention
79228638|NCT03299582|Device|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
79228639|NCT03299582|Device|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
79228640|NCT02264925|Device|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
79228641|NCT03299504|Other|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
79228642|NCT05161572|Drug|Oxaliplatin|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
79680185|NCT02929758|Behavioral|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
79680186|NCT02947139|Drug|Co-administration of DWC20155/DWC20156|
79680187|NCT02947139|Drug|DWC20161|
79228643|NCT05161572|Drug|Tegafur-Gimeracil-Oteracil|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
79228644|NCT05161572|Drug|Sintilimab|The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
79228645|NCT05161572|Radiation|Concurrent chemoradiation|The radiotherapy (RT) consists of 45 Gy delivered in 25 fractions every five days per week for five weeks. The dose of concurrent ChT is 60 mg/m2 S-1 orally, oral tablets twice daily, days 1-5 of each week.
79228646|NCT05161572|Procedure|D2/R0 gastrectomy|Gastrectomy with standard D2 lymphadenectomy is recommended. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle third tumors, the gastric margin is recommended to be more than 5 cm, and a total gastrectomy is performed. For lower third tumors, a 2 cm duodenal margin is recommended, and a subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
79228647|NCT02524197|Drug|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
79228648|NCT02524197|Drug|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
79998627|NCT03644628|Procedure|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
79998628|NCT01336153|Drug|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
79228649|NCT02524197|Drug|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
79228650|NCT02524197|Drug|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
79228651|NCT05161416|Behavioral|Bubble Blowing|Active Distraction Methods
79228652|NCT05161416|Behavioral|Cartoon Watching|Passive Distraction Methods
79228653|NCT02262273|Other|Data Collection|Colleciton of data from medical records only
79228654|NCT02722928|Other|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
79228655|NCT03470844|Behavioral|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
79228656|NCT03470844|Behavioral|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
79228657|NCT03470844|Other|fMRI|Brain volume, chemical markers, functional outcome
79371214|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
79371215|NCT00087555|Drug|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
79371216|NCT03016780|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
79371217|NCT03016780|Other|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
79371218|NCT03022318|Drug|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
79371219|NCT01677897|Drug|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
79371220|NCT03033940|Radiation|Observational use of fluoroscopy|
79371221|NCT03483363|Drug|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure.
79371222|NCT03483363|Drug|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
79371223|NCT03483363|Drug|intravenous (IV) prophylactic antibiotic|All groups with receive standard parenteral (IV) prophylactic antibiotic.
79371224|NCT03033628|Device|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
79371225|NCT03033628|Device|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
79371226|NCT01677975|Procedure|FNA (fine needle aspiration)|
79371227|NCT03016702|Other|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
79998629|NCT01336153|Drug|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
79998630|NCT03629067|Drug|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
79371228|NCT03016702|Other|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
79371229|NCT00956020|Biological|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
79371230|NCT03086733|Drug|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
79371231|NCT03017170|Drug|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
79371232|NCT03017170|Drug|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
79371233|NCT03033862|Device|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
79371234|NCT03033862|Device|Drug Eluting Stent|Drug Eluting Stent
79998631|NCT03629067|Drug|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
79998632|NCT05182333|Other|Examination|History taking, examination of upper limb
79228658|NCT03470844|Behavioral|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
79228659|NCT03472170|Dietary Supplement|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
79228660|NCT03472170|Other|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
79228661|NCT04156698|Drug|Docetaxel|Docetaxel is a chemotherapy drug.
79371235|NCT00086619|Drug|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
79371236|NCT00945958|Drug|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
79998633|NCT03644082|Behavioral|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
79228662|NCT04156698|Drug|Cisplatin|Cisplatin is a chemotherapy drug.
79524931|NCT05605704|Drug|atherolive|In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
79524932|NCT05604599|Drug|Intranasal dexmedetomidine|45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
79371237|NCT00085917|Drug|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
79228663|NCT04156698|Drug|Capecitabine|Capecitabine is a chemotherapy drug.
79524933|NCT05604599|Drug|Intravenous dexmedetomidine|patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
79371238|NCT00085917|Drug|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
79371239|NCT03416283|Behavioral|Remote Monitoring|Remote BP monitoring and medication adherence
79524934|NCT05603793|Behavioral|Knowledge, Attitude & Practices|The objective the of the KAP intervention is to explore key aspects related to child health and nutrition to better understand the community's knowledge, perception and practices. In addition to child health, we are also tracking the transition of health from urban to rural areas in terms of the prevalence of adult non-communicable diseases.
79680188|NCT02929836|Procedure|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
79998634|NCT03644082|Behavioral|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
79228664|NCT04156698|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
79228665|NCT03108326|Biological|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
79371240|NCT03416283|Behavioral|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
79524935|NCT05599646|Behavioral|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
79680189|NCT02929836|Procedure|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
79680190|NCT02929836|Procedure|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
79228666|NCT03307694|Diagnostic Test|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
79228667|NCT03307694|Diagnostic Test|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
79371241|NCT03416049|Device|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
79371242|NCT03416049|Device|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
79371243|NCT03416049|Device|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
79371244|NCT03416049|Device|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
79371245|NCT00084747|Drug|bortezomib|
79524936|NCT05599646|Behavioral|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
79680191|NCT02929836|Procedure|linear ablation|Right atrial CTI ablation was performed during SR.
79680192|NCT02929836|Device|CARTO|3 dimensional mapping system
79680193|NCT04693052|Other|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
79680194|NCT02929914|Procedure|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
79998635|NCT03644082|Behavioral|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
79998636|NCT03644082|Behavioral|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
79998637|NCT03644082|Behavioral|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
79998638|NCT03644082|Behavioral|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
79524937|NCT05594511|Procedure|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
79680195|NCT02929914|Procedure|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
79998639|NCT03644082|Behavioral|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
79371246|NCT04402671|Other|non-cross-linked porcine skin collagen membrane|non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
79680196|NCT02929914|Procedure|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
79371247|NCT04402671|Other|glutaraldehyde cross-linked bovine collagen membrane|glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
79371248|NCT01678287|Drug|ASP1941|oral
79371249|NCT01678287|Drug|Placebo|oral
79680197|NCT02929914|Procedure|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
79680198|NCT02929914|Procedure|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
79823884|NCT00783315|Behavioral|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
79998640|NCT03644082|Behavioral|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
79228668|NCT03307694|Diagnostic Test|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
79524938|NCT05594511|Procedure|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
79524939|NCT05576220|Device|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
79823885|NCT00783315|Behavioral|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
79998641|NCT03644082|Behavioral|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
79228669|NCT01439919|Drug|SSR411298|"Form: tablet~Route: oral administration with food"
79228670|NCT01439919|Drug|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
79371250|NCT01678365|Drug|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
79371251|NCT00946270|Drug|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
79371252|NCT00946270|Drug|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
79371253|NCT00946270|Drug|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
79371254|NCT03478293|Device|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
79524940|NCT05572840|Other|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
79524941|NCT05554874|Other|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
79524942|NCT05554874|Other|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
79524943|NCT05543837|Drug|Capsaicin|Patients will receive a fixed dose of capsaicin
79524944|NCT05534867|Other|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
79524945|NCT05519982|Behavioral|Sleep Treatment Education Program (STEP-1)|Video conference instruction on behavioral changes to improve sleep.
79680199|NCT02947334|Biological|Bococizumab|Bococizumab PFS
79680200|NCT02947334|Drug|Placebo|Placebo
79680201|NCT00525278|Drug|Levocetirizine dihydrochloride|
79680202|NCT00525317|Drug|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
79680203|NCT02929719|Drug|Test.|gel
79998642|NCT03644082|Behavioral|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
79998643|NCT03644082|Behavioral|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
79998644|NCT01340287|Dietary Supplement|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
79680204|NCT02929719|Drug|Aczone Gel 5%|gel
79998645|NCT01340287|Dietary Supplement|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
79680205|NCT02929719|Drug|Placebo|gel
79680206|NCT00525980|Behavioral|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
79680207|NCT00525980|Behavioral|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
79680208|NCT00525980|Other|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
79680209|NCT00525980|Behavioral|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
79680210|NCT02929875|Behavioral|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
79823886|NCT04073940|Behavioral|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
79823887|NCT00783393|Drug|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
79371255|NCT03021850|Procedure|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
79371256|NCT03475641|Drug|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
79371257|NCT03475641|Procedure|The current standard treatment|Tumescent anesthesia.
79371258|NCT01678521|Procedure|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
79823888|NCT00783471|Drug|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
79998646|NCT05207319|Other|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
79998647|NCT01341691|Other|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
79998648|NCT05213403|Diagnostic Test|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
79998649|NCT05213325|Diagnostic Test|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
79228671|NCT03470766|Device|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
79228672|NCT02262351|Other|30 Second Pulse Check|To detect atrial fibrillation
79228673|NCT02262351|Device|Watch BP Home A|Blood pressure device that detects atrial fibrillation
79228674|NCT02262351|Device|HeartCheck Hand-held ECG device|To detect atrial fibrillation
79228675|NCT04034082|Device|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
79371259|NCT03021616|Other|energy drink|32oz of commercially available energy drink
79371260|NCT03021616|Other|Moxifloxacin 400mg|400mg moxifloxacin active control drink
79371261|NCT03021616|Other|Placebo|Placebo drink
79371262|NCT03021694|Dietary Supplement|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
79680211|NCT00525356|Device|Medtronic Talent Stent-Graft-System|
79680212|NCT04689672|Diagnostic Test|Lung ultrasound|Bedside lung ultrasound
79680213|NCT00525395|Genetic|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
79680214|NCT00525395|Procedure|Continuous phototherapy|Group B: 6 months non-stop treatment.
79680215|NCT04693559|Procedure|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
79680216|NCT04693559|Procedure|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
79823889|NCT00783471|Drug|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
79228676|NCT04034082|Other|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
79371263|NCT03086187|Device|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
79371264|NCT02245828|Drug|QCC374|Single and multiple ascending doses of QCC374
79371265|NCT02245828|Drug|Placebo|Placebo comparator
79823890|NCT00792051|Biological|Inactivated influenza vaccine|0.5ml intramuscular single dose
79228677|NCT03307538|Radiation|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
79823891|NCT00792051|Biological|Saline|0.5ml intramuscular, one dose
79823892|NCT00787215|Other|observational: no treatment involved|observational: no treatment involved
79823893|NCT00792129|Device|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
79823894|NCT00792207|Other|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
79823895|NCT00792207|Other|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
79823896|NCT00787293|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
79823897|NCT02460900|Drug|Varenicline|
79228678|NCT05131464|Drug|CM310|CM310, 300 mg/2 mL, SC, every 2 weeks
79228679|NCT04964024|Diagnostic Test|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
79228680|NCT03810144|Genetic|Vectra MBDA Test|Vectra Guided versus Usual Care
79371266|NCT00956254|Drug|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
79228681|NCT03299270|Other|Questionnaires|Quality of Life and Functional recovery questionnaires
79371267|NCT03021148|Other|Questionnaire|Administration of questionnaire.
79823898|NCT02460900|Behavioral|Positively Smoke Free|
79823899|NCT02460900|Drug|Placebo|
79228682|NCT03470688|Biological|Originator|Originator anti-TNF agents
79228683|NCT03470688|Biological|Biosimilar|Biosimilar anti-TNF agents
79228684|NCT02262429|Other|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
79228685|NCT02262429|Other|ONS Standard Feeding|Standard of care
79228686|NCT03307460|Drug|68Ga-NOTA-AE105|PET/MRI scan
79228687|NCT05072886|Drug|AT193|Topical applied to affected areas daily
79228688|NCT02466542|Drug|Placebo group|Patients will receive regular general anesthesia
79228689|NCT02466542|Drug|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
79228690|NCT05067270|Drug|Sodium Citrate|Administered SC infusion.
79371268|NCT03085953|Behavioral|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
79371269|NCT03085953|Other|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
79371270|NCT03020680|Dietary Supplement|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
79371271|NCT03086109|Other|Risk factors|Risk factors associated bone degenerative diseases
79524946|NCT05519982|Behavioral|Enhanced Usual Care|Video conference instruction on relaxation techniques to improve sleep.
79524947|NCT05514769|Procedure|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty|The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
79823900|NCT02460900|Behavioral|Standard of Care|
79823901|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
79823902|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
79823903|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
79823904|NCT00783549|Drug|an undetermined dose of GSK1292263|GSK investigational product or placebo
79823905|NCT00783549|Drug|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
79823906|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
79823907|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposures.
79823908|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
79823909|NCT00783627|Procedure|Angiography|Angiography done at the J1 visit
79823910|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
79228691|NCT05067270|Drug|Treprostinil|Administered SC infusion.
79228692|NCT05067270|Drug|Humalog diluent|Administered SC infusion.
79823911|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
79228693|NCT05067270|Drug|Magnesium Chloride|Administered SC infusion.
79228694|NCT01437735|Drug|QAW039|QAW039 po
79228695|NCT01437735|Drug|Montelukast|Montelukast 10 mg po
79228696|NCT01437735|Drug|Placebo|Placebo
79228697|NCT02722304|Biological|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
79228698|NCT02722304|Biological|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
79228699|NCT02722304|Biological|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
79228700|NCT02722304|Biological|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
79228701|NCT02722304|Biological|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
79228702|NCT04984902|Device|Extracorporal therapy|Extracorporal therapy
79228703|NCT01437657|Drug|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
79680217|NCT04693559|Procedure|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
79371272|NCT03020212|Drug|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
79524948|NCT05514561|Diagnostic Test|Fecal calprotectin|To calculate the diagnostic accuracy of fecal calprotectin in the diagnosis of significant ileocolonic lesions
79823912|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
79823913|NCT00430495|Drug|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
79228704|NCT01437657|Drug|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
79228705|NCT01437657|Drug|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
79228706|NCT03299192|Behavioral|Tai Chi|Yang Style Tai Chi
79228707|NCT03299192|Behavioral|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
79228708|NCT03299192|Other|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
79228709|NCT05728112|Other|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
79524949|NCT05514561|Diagnostic Test|Fecal immunochemical test|To calculate the diagnostic accuracy of the fecal immunochemical test in the diagnosis of significant ileocolonic lesions
79524950|NCT05512000|Behavioral|Feedback with massed trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
79524951|NCT05512000|Behavioral|Feedback with spaced trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
79524952|NCT05512000|Behavioral|No feedback with massed trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
79524953|NCT05512000|Behavioral|No feedback with spaced trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
79680218|NCT04323150|Device|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
79680219|NCT04323150|Device|Conventional suction system|The using of open (conventional) suctioning
79680220|NCT00525434|Device|Seraffix LTB|wounds closure by using laser and albumin
79680221|NCT02929524|Drug|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
79823914|NCT02554695|Drug|placebo|subcutaneous saline injection
79228710|NCT05728112|Other|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
79228711|NCT03470610|Drug|Progesterone|6 mg estradiol and vaginal and rectal progesterone
79228712|NCT01436487|Biological|MultiStem|single infusion 1-2 days following ischemic stroke
79228713|NCT01436487|Biological|Placebo|single infusion 1-2 days following ischemic stroke
79228714|NCT04653714|Procedure|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
79524954|NCT05512000|Behavioral|No teaching control|The words in this set are not taught, only assessed.
79823915|NCT02554695|Drug|denosumab|single subcutaneous injection of denosumab 60 mg
79823916|NCT00792285|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
79998650|NCT03166371|Dietary Supplement|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
79228715|NCT04653714|Device|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
79371273|NCT01678599|Drug|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
79823917|NCT00792363|Drug|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
79228716|NCT02509845|Drug|C16G2|Antimicrobial peptide
79228717|NCT02509845|Other|Placebo|Placebo
79228718|NCT04628754|Other|Exercise and protein|Home based exercise regime and dietary protein guidance
79228719|NCT03307148|Drug|ATRA|Administered orally on D1-15 of each 28 day cycle.
79228720|NCT03307148|Drug|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
79228721|NCT03307148|Drug|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
79228722|NCT03984591|Drug|Eplerenone|Eplerenone according to guidelines
79228723|NCT03984591|Drug|Spironolactone|Spironolactone according to guidelines
79371274|NCT03445221|Dietary Supplement|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
79371275|NCT03445221|Dietary Supplement|Conventional Diet|patients will continue preoperative oral conventional diet.
79371276|NCT03019822|Drug|LSD|100ug per os, single dose
79371277|NCT03019822|Drug|MDMA|125mg per os, single dose
79371278|NCT03019822|Drug|Amphetamine|40.3mg per os, single dose
79371279|NCT03019822|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs
79371280|NCT01678677|Biological|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371281|NCT01678677|Biological|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371282|NCT01678677|Biological|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371283|NCT01678677|Biological|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371284|NCT01678677|Biological|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371285|NCT01678677|Biological|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371286|NCT01678677|Biological|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371287|NCT01678677|Biological|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371288|NCT01678677|Drug|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79371289|NCT03019978|Other|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
79371290|NCT03443193|Other|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
79371291|NCT03019900|Procedure|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
79524955|NCT05497999|Other|Proactive Outreach|"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
79823918|NCT00792363|Drug|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
79371292|NCT03019432|Behavioral|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
79228724|NCT04568538|Other|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~What is shaken baby syndrome and what is its cause?~What are the harms caused by shaken baby syndrome?~How is shaken baby syndrome understood?~What problems can shaken baby syndrome cause?~What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
79998651|NCT03166371|Other|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
79228725|NCT04816058|Behavioral|Determining the level of ankle instability|Ankle instability
79228726|NCT02503137|Drug|Topical SM04554 solution|
79228727|NCT02503137|Drug|Topical Vehicle solution|
79228728|NCT03470532|Drug|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
79228729|NCT03470532|Drug|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
79228730|NCT02468336|Device|AngioDefender|
79228731|NCT02468336|Device|Ultrasound|
79228732|NCT02502669|Drug|Finasteride 23.5 mg tablets|
79371293|NCT00946348|Drug|Dronabinol|Dronabinol 10 mg or 15 mg
79371294|NCT00946348|Drug|Cannabis|Cannabis cigarette
79371295|NCT00081159|Drug|Doxorubicin hydrochloride|Doxorubicin 20 mg/m^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
80016581|NCT05120674|Behavioral|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
79371296|NCT00081159|Drug|Goserelin acetate|
79371297|NCT00081159|Drug|Leuprolide acetate|
79228733|NCT02502669|Drug|Finasteride 33.5 mg tablets|
79371298|NCT00081159|Drug|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
79371299|NCT00081159|Procedure|orchiectomy|
79371300|NCT00081159|Radiation|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
79371301|NCT03033550|Behavioral|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
79371302|NCT03033706|Procedure|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
79371303|NCT03033706|Procedure|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
79371304|NCT03033706|Procedure|Brain tumor excision|Brain tumor excision under general anesthesia
79371305|NCT03033472|Drug|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
79371306|NCT03033472|Drug|Oral Placebo|Oral Placebo 30 minutes before treatment
79371307|NCT01679067|Procedure|colonoscopy with endoscopic biopsies|
79371308|NCT02981836|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
79371309|NCT02981836|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
79371310|NCT03033004|Device|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
79371311|NCT03033004|Device|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
79371312|NCT03033004|Device|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
79371313|NCT03085641|Device|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
79524956|NCT05497999|Other|No Proactive Outreach|Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
79228734|NCT02502669|Drug|Placebo tablets|
79228735|NCT04839510|Drug|MRG002|Administrated intravenously
79228736|NCT03306914|Other|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
79228737|NCT03306914|Other|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
79228738|NCT03306914|Drug|Albumin 5%|Infusion of Albumin 5% intra-operatively
79228739|NCT03306914|Drug|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
79228740|NCT03135093|Other|No intervention|No Intervention
79228741|NCT03306836|Drug|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
79228742|NCT03306836|Drug|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
79228743|NCT04487145|Drug|Dihydroartemisinin-piperaquine|It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
79228744|NCT02265081|Procedure|ultrasound|pelvic floor ultrasound
79228745|NCT02265081|Procedure|uroflow-meter|uroflow meter: measurement of passed urine volume
79228746|NCT01252641|Biological|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
79228747|NCT00709956|Drug|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
79228748|NCT00709956|Drug|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
79228749|NCT03306758|Drug|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
79228750|NCT02268201|Drug|Advagraf|oral
79228751|NCT02268201|Drug|Prograf|oral
79371314|NCT03033082|Other|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
79371315|NCT03033160|Drug|Estradiol Ring|
79524957|NCT05496647|Other|Virtual Reality|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Preferred video will be watched with Virtual Reality Glasses for approximately 20 minutes during the process, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form, Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; At the 1st hour after the procedure, Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale and Satisfaction Evaluation Form will be filled."
79823919|NCT00787683|Device|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
79228752|NCT03306602|Device|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
79371316|NCT03019354|Device|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
79524958|NCT05496647|Other|Music Therapy|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; During the procedure, the preferred music for Music Therapy will be played for approximately 20 minutes, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
79680222|NCT02929524|Drug|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
79680223|NCT00525473|Drug|Azathioprine|azathioprine usual dosage 100mg per day
79680224|NCT04310475|Other|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
79680225|NCT00526136|Drug|Placebo|
79680226|NCT00526136|Drug|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
79680227|NCT02929446|Procedure|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
79823920|NCT00425113|Drug|Metronidazole|
79823921|NCT00425113|Procedure|Blood Draw|
79823922|NCT00425113|Procedure|CT Scan|
79823923|NCT00425113|Procedure|PET Scan|
79823924|NCT00792441|Device|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
79823925|NCT01034293|Dietary Supplement|low feeding frequency (3x)|3 meals a day
79823926|NCT01034293|Dietary Supplement|High feeding frequency (14x)|14 meals a day
79228753|NCT03306602|Device|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
79371317|NCT03019354|Device|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
79371318|NCT04348539|Other|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
79371319|NCT00958282|Drug|lisdexamfetamine/Behavior Therapy|
79371320|NCT00958282|Other|placebo|
79823927|NCT03919032|Other|This is an observational study without intervention|This is an observational study without intervention
79823928|NCT00792519|Behavioral|HIV support group|group support
79823929|NCT00792519|Behavioral|CBT|group cognitive behavioral treatment
79823930|NCT03994783|Drug|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
79823931|NCT03994783|Drug|Methylprednisolone|Intravenous infusion of methylprednisolone
79823932|NCT03994783|Drug|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
80016582|NCT05120674|Behavioral|CPT|Cognitive Therapy for PTSD
80016583|NCT05120674|Behavioral|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
79228754|NCT02265159|Procedure|Focal Therapy Using High Intensity Focused Ultrasound|
79228755|NCT05722574|Behavioral|Romantic Competence Intervention|Online, 30-minute self-administered relationship competence program for youth ages 16-20
79228756|NCT05722574|Behavioral|Information Only Control Condition|Online, 30-minute self-administered relationship education activity for youth ages 16-20
79228757|NCT02265315|Other|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
79680228|NCT02929446|Procedure|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
79680229|NCT00526175|Drug|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
79823933|NCT03994783|Procedure|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
79823934|NCT04072536|Device|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
79228758|NCT02265315|Behavioral|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
79228759|NCT02268279|Drug|solithromycin|
79371321|NCT03019276|Drug|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
79371322|NCT03032926|Behavioral|Open Trial|Behavioral Intervention
79371323|NCT03033316|Drug|Dexamethasone|
79524959|NCT05496647|Other|Stress Ball Application|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Stress ball will be played for approximately 20 minutes during the process.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
79680230|NCT00526175|Drug|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
79680231|NCT00526175|Drug|Daunorubicin|30 mg/m2, i.v., days 8 and 15
79823935|NCT04072536|Device|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
79823936|NCT00440011|Drug|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
79823937|NCT00440011|Drug|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
79228760|NCT03306524|Device|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
79228761|NCT03306524|Device|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
79228762|NCT03306524|Device|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
79228763|NCT03306524|Device|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
79228764|NCT03306524|Device|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
79228765|NCT03306524|Device|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
79228766|NCT03306524|Device|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
79228767|NCT03306524|Device|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
79228768|NCT03306524|Device|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
79228769|NCT03306524|Device|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
79228770|NCT04425096|Other|Skin to skin contact|Skin to skin contact
79228771|NCT02268357|Drug|Propranolol|Oral propranolol capsules
79371324|NCT03032848|Drug|Conjugated Estrogen|use of 1 gram per day
79371325|NCT03032848|Drug|Promestriene|use of 1 gram per day
79371326|NCT03032848|Drug|Estriol|use of 1 gram per day
79371327|NCT03032848|Drug|Vaginal Moisturizer - Cream|use of 1 gram per day
79371328|NCT00080223|Drug|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
79680232|NCT00526175|Drug|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
79680233|NCT00526175|Drug|Cyclophosphamide|1000 mg/m2, i.v., day 22.
79680234|NCT00526175|Drug|Methotrexate|Age <1 year 1-2 years 2-3 years > 3 years MTX 5 mg 8 mg 10 mg 12 mg
79680235|NCT00526175|Drug|Cytosine Arabinoside|Edad <1 year 1-2 years 2-3 years > 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
79680236|NCT00526175|Drug|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
79680237|NCT00526175|Drug|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
79680238|NCT02930031|Dietary Supplement|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
79680239|NCT02930031|Dietary Supplement|Placebo|500 mL orally, daily for eight days following exercise
79680240|NCT02929563|Drug|Pantoprazole|
79823938|NCT03105102|Drug|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
79823939|NCT03105102|Drug|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
79823940|NCT03105102|Drug|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
79823941|NCT03105102|Drug|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
79228772|NCT05430386|Drug|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
79228773|NCT04416906|Drug|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
79680241|NCT02929563|Drug|Placebo (for pantoprazole)|
79823942|NCT03105102|Drug|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
79823943|NCT00877448|Biological|Adjuvanted Multimeric-001 250 Mcg|
79228774|NCT02268435|Drug|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
79228775|NCT02466464|Device|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
79228776|NCT02466464|Device|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
79228777|NCT04402944|Drug|Pulmozyme|Pulmozyme 2.5 mg BID
79371329|NCT03472443|Other|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
79371330|NCT04402359|Drug|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
79371331|NCT04402359|Drug|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
79371332|NCT04402359|Device|ventilator|all patients selected to be ventilated for 14 days
79371333|NCT00088179|Drug|pexelizumab in conjunction with CABG|
79371334|NCT00959764|Drug|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
79680242|NCT00525551|Drug|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
79371335|NCT00959764|Drug|Intranasal Calcitonin|Intranasal Calcitonin Spray
79371336|NCT00959764|Drug|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
79680243|NCT00525551|Drug|Placebo (NaCl)|300 mL 0.9% NaCl
79680244|NCT04689399|Diagnostic Test|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
79823944|NCT00877448|Biological|Multimeric-001 250 Mcg|
79823945|NCT00877448|Biological|Phosphate Buffered saline|
79823946|NCT00877448|Biological|Adjuvanted PBS|
79371337|NCT01005706|Drug|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
79823947|NCT00877448|Biological|Adjuvanted Multimeric-001 500 Mcg|
79823948|NCT00877448|Biological|Multimeric-001 500 Mcg|
79823949|NCT00877448|Biological|Multimeric-001 125 Mcg|
79823950|NCT00783861|Drug|Lactic Acid|Lactic Acid (Dermacyd Femina)
79823951|NCT01034371|Procedure|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
79228778|NCT04402944|Drug|Placebo|Saline 2.5 mL BID
79228779|NCT01423149|Drug|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
79228780|NCT01235559|Drug|Placebo|Oral doses, once a day for 52 weeks
79228781|NCT01235559|Drug|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
79228782|NCT01235559|Drug|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
79371338|NCT01005706|Drug|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
79371339|NCT05346471|Device|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
79371340|NCT01679379|Procedure|Absorbable suture group|Skin is closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture]
79823952|NCT01034371|Procedure|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
79371341|NCT01679379|Procedure|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
79524960|NCT05496647|Other|Control|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; Women in the control group will not undergo any intervention other than routine surgery.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure, the Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
79524961|NCT05486026|Drug|Duloxetine 30 MG|patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks
79371342|NCT03085251|Device|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~Subjects will be asked to wash and dry their hands before the measurements.~The measurement procedure for each reagent system lot of a BGMS will be as follows:~Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
79680245|NCT04288323|Drug|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
79680246|NCT02946359|Drug|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
79680247|NCT02929173|Other|Allceram|Pressed E-max coping veneered with E-max veneering system
79680248|NCT02929173|Other|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
79680249|NCT02946437|Drug|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
79228783|NCT04207476|Device|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
79228784|NCT04207476|Device|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
79371343|NCT03085407|Procedure|early cholecystectomy|cholecystectomy was done within 48 after admission
79371344|NCT03085407|Procedure|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
79371345|NCT01679691|Other|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
79371346|NCT03470805|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
79371347|NCT03084549|Drug|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
79371348|NCT03084549|Drug|Administration of placebo|Administration of placebo in the margins of the episiotomy
79371349|NCT03082521|Behavioral|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
79371350|NCT03080259|Behavioral|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
79524962|NCT05486026|Drug|Nonsteroidal Antiinflammatory Drug|patient in this second group will receive NSAID for 3 weeks
79524963|NCT05468099|Other|Chlorhexidine mouthwash and Povidone-Iodine|Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils
79524964|NCT05468099|Device|High volume evacuator|High volume evacuator held by assistant to capture dental spray
79524965|NCT05468099|Device|High volume evactuator and saliva ejector|High volume evacuator and saliva ejector held by assistant to capture dental spray
79524966|NCT05468099|Device|Local Exhaust System|Local exhaust system hovers above patient head to capture dental spray
79524967|NCT05463549|Other|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
79524968|NCT05449587|Other|MRI and PRO|MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
79228785|NCT03470454|Drug|Linagliptin Oral Tablet|Linagliptin for blood glucose control
79228786|NCT04490252|Dietary Supplement|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
79228787|NCT03130842|Drug|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
79680250|NCT02946437|Drug|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
79680251|NCT02946437|Drug|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
79680252|NCT02946437|Device|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
79228788|NCT03130842|Drug|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
79228789|NCT03130764|Drug|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
79228790|NCT03130764|Drug|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
79371351|NCT03081351|Procedure|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
79823953|NCT01034371|Procedure|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
79371352|NCT03081351|Procedure|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
79371353|NCT03084861|Drug|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
80016584|NCT05120674|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
79371354|NCT03084861|Drug|Conventional treatment|"Artificial tears: Lubristil ®~Therapeutic Contact lens: Air Optix Night&Day"
79228791|NCT01234779|Drug|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
79228792|NCT01234779|Drug|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
79228793|NCT01234779|Drug|olanzapine|15 mg orally daily, 4 weeks
79228794|NCT01234779|Drug|placebo|orally daily, 4 weeks
79228795|NCT01234311|Drug|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
79228796|NCT01234311|Drug|Placebo|
79371355|NCT01006252|Drug|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
79228797|NCT03223350|Drug|Capsaicin 0.1% Cream|Topical application
79228798|NCT03223350|Drug|Placebos|placebo cream
79371356|NCT01006252|Drug|Paclitaxel|80 mg/m^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
79371357|NCT03081897|Drug|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
79371358|NCT03081897|Drug|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
79371359|NCT03089931|Procedure|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
79371360|NCT03084705|Device|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
79524969|NCT05445596|Behavioral|Functional communication training|Functional communication training (FCT) is a behavioral approach to treating problem behavior. During FCT, children learn to use communication to access reinforcers, instead of using problem behavior.
79524970|NCT05438654|Diagnostic Test|Point of care ultrasound|"Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel"
79524971|NCT05438251|Drug|Fespixon Cream|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (approximately 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 12 weeks"
79680253|NCT02946632|Drug|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
79680254|NCT02946632|Drug|Stepwise add-on therapy|metformin -> glimepirde -> sitagliptin
79680255|NCT02929134|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
79680256|NCT02929134|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
79823954|NCT04971213|Device|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
79823955|NCT04971213|Device|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
79823956|NCT00783939|Drug|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
80016585|NCT01346059|Drug|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
79228799|NCT04581642|Device|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
79228800|NCT03306368|Behavioral|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
79228801|NCT02840136|Drug|Piperacillin-tazobactam combination product|
79228802|NCT02840136|Drug|Meropenem|
79228803|NCT02840136|Drug|Ceftazidime|
79228804|NCT04491188|Dietary Supplement|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
79228805|NCT04491188|Dietary Supplement|Placebo|Maltodextrin placebo
79680257|NCT04693091|Device|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
79998652|NCT05207241|Other|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
79228806|NCT02468258|Procedure|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
79228807|NCT04015050|Other|milk based infant formula|Cows milk ased infant formula
79228808|NCT02263287|Other|LeSCoD scale|LeSCoD is a clinical scale
79228809|NCT03306290|Drug|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (~30 min), 1 tube (5 ml) of blood will be withdrawn~Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
79228810|NCT01616199|Drug|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
79228811|NCT01616199|Drug|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
79228812|NCT03306212|Drug|Botulinum toxin A|
79371361|NCT02245906|Dietary Supplement|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79371362|NCT02245906|Dietary Supplement|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79371363|NCT02245906|Dietary Supplement|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79680258|NCT02929212|Other|Solid Meal|Subjects will receive solid meals during meal study
79998653|NCT02962908|Biological|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
79371364|NCT03080649|Device|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
79371365|NCT03080649|Device|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
79371366|NCT00959842|Drug|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
79371367|NCT03080805|Drug|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)
79371368|NCT03080805|Drug|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
79371369|NCT00959920|Procedure|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
79371370|NCT00959920|Procedure|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
79524972|NCT05432570|Procedure|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
79998654|NCT02962908|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
79998655|NCT02962908|Biological|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
79228813|NCT03306212|Other|Occupational Therapy|
79228814|NCT03306212|Other|Intermittent serial casting|
79228815|NCT04506138|Drug|Camrelizumab|Camrelizumab 200mg D1, D22
79228816|NCT04506138|Drug|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound) 100mg/m^2 D1, D8, D22, D29
79228817|NCT04506138|Drug|Carboplatin|Carboplatin AUC5 D1, D22
79371371|NCT03018964|Procedure|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
79228818|NCT03306134|Diagnostic Test|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
79371372|NCT03018964|Procedure|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
79228819|NCT04456452|Biological|Ampion|Ampion, administered by intravenous infusion
79524973|NCT05432570|Procedure|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
79371373|NCT03089775|Drug|BBI-2000|Experimental
79524974|NCT05406830|Device|verum acupuncture|The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
79524975|NCT05406830|Behavioral|health education|According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
79524976|NCT05406830|Device|sham acupuncture|We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
79524977|NCT05390645|Drug|MFA-370|MFA-370 is a treatment with a combination of two approved pharmaceuticals
79998656|NCT02962908|Biological|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
79228820|NCT04456452|Other|Standard of Care|Standard of Care
79371374|NCT03089775|Drug|Vehicle|Vehicle Comparator
79371375|NCT03089775|Other|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
79371376|NCT04401735|Drug|Polydeoxyribonucleotides|PDRN injection to epidural space
79371377|NCT04401735|Drug|Normal saline|Normal saline
79371378|NCT01007110|Dietary Supplement|DHA|Docosahexaenoic Acid (DHA) from algal oil
79524978|NCT05384964|Other|Questionnaire|Questionnaire completed by ICU nurses
79524979|NCT05380401|Dietary Supplement|Enfamil® DHA & ARA Supplement for Special Dietary Use|Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
79680259|NCT02929212|Other|Liquid Meal|Subjects will receive liquid meals, during meal study
79680260|NCT02929212|Drug|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
79228821|NCT01598103|Drug|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
79228822|NCT01598103|Drug|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
79228823|NCT04456530|Drug|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
79228824|NCT04456530|Other|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
79371379|NCT01007110|Other|Placebo|Placebo capsule
79371380|NCT03019120|Drug|Vitamin D|"Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
79371381|NCT03080337|Other|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
79371382|NCT00960622|Drug|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
79371383|NCT00960622|Drug|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
79371384|NCT00960622|Drug|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
79371385|NCT03430947|Drug|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
79680261|NCT02929212|Other|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
79371386|NCT03430947|Drug|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
79680262|NCT02929212|Other|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
79998657|NCT03642756|Device|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
79998658|NCT02962284|Drug|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
79998659|NCT03642600|Dietary Supplement|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
79228825|NCT05395754|Device|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
79680263|NCT02947373|Drug|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
79998660|NCT03642600|Drug|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
79371387|NCT00960778|Drug|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
79524980|NCT05366582|Device|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
79371388|NCT00960778|Other|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
79371389|NCT03392649|Device|Parasym|Tragus stimulation was done using the Parasym device.
79524981|NCT05366582|Device|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
79524982|NCT05352386|Diagnostic Test|Coronary computed tomography angiography (CCTA)|Participants undergo coronary computed tomography angiography (CCTA)
79524983|NCT05333926|Device|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
79524984|NCT05332067|Drug|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
79524985|NCT05332067|Drug|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
79524986|NCT05323890|Drug|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
79524987|NCT05323318|Other|Neuropsychological Sequelae|Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
79680264|NCT02929251|Drug|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
80016586|NCT01346059|Drug|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
79228826|NCT02268591|Device|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
79228827|NCT04456374|Other|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
79228828|NCT03471936|Diagnostic Test|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
79371390|NCT03019042|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
79371391|NCT03019042|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
79371392|NCT03080571|Biological|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
79371393|NCT03080571|Other|standard care|
79371394|NCT00961402|Behavioral|Wellness Control|6-month wellness control
79371395|NCT00961402|Behavioral|Exercise Intervention|6 month exercise intervention
79228829|NCT02268669|Other|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
79371396|NCT03080181|Drug|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
79524988|NCT05312554|Device|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
79680265|NCT02929251|Drug|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
79680266|NCT02929251|Drug|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
79680267|NCT02929368|Device|PICC implantation under fluoroscopy|PICC Catheter implantation
79680268|NCT02929368|Device|PICC Implantation under Sherlock System|PICC Catheter implantation
79680269|NCT02946281|Behavioral|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
79680270|NCT02929290|Drug|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
79680271|NCT02947451|Other|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
79524989|NCT05312437|Other|Interruptive Alert, CDS|"Experimental: CDS Intervention Adult patients in the highest predicted risk tier (>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~Disagree with alert and provide a rationale for disagreement (CDS complete)~Indicate suicide risk face-to-face screening has already occurred (CDS complete)~Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)"
79998661|NCT03642522|Device|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
79524990|NCT05312437|Other|Passive Prompt, CDS|"Adult patients in the highest predicted risk tier (>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
79524991|NCT05308199|Other|thoracic manipulation|thoracic manipulation for unlocking of facet joints
79228830|NCT01407003|Drug|LIK066|Participants will receive a single or multiple doses of LIK066
79228831|NCT01407003|Drug|Placebo|Participants will receive a single or multiple doses of a matching placebo
79371397|NCT03018886|Other|GHRH plus arginine test|One ug/kg GHRH [GHRH(1-29), GEREF Serono, Italy] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
79371398|NCT03080025|Behavioral|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches & techniques, which contains a resource- & solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
79371399|NCT01007656|Dietary Supplement|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
79524992|NCT05308199|Other|muscle enegy technique|to release muscle spasm of cervical musces
79524993|NCT05303233|Procedure|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
79680272|NCT02947451|Other|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
79998662|NCT03642444|Device|Cane|Assistive walking device
79998663|NCT03642444|Device|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
79228832|NCT02724774|Behavioral|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
79371400|NCT03089385|Other|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
79371401|NCT03089229|Drug|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
79371402|NCT03089229|Drug|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
79680273|NCT02929095|Drug|dexmedetomidine|
79680274|NCT02929095|Drug|midazolam|
79680275|NCT02929095|Drug|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
79998664|NCT03642288|Drug|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
79680276|NCT02946554|Biological|HepaStem|
79228833|NCT05359952|Behavioral|Starting the Conversation|The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
79680277|NCT02928861|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
79680278|NCT02946476|Other|prognostic impact of non cardiac comorbidities|
79680279|NCT02928900|Behavioral|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
79680280|NCT00525668|Drug|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
79680281|NCT00525668|Drug|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
79680282|NCT02928783|Behavioral|Home-based cardiac rehabilitation|
79228834|NCT05359952|Behavioral|Sexual and Menopausal Health Resources Only|A list of resources on sexual/menopausal health both within and outside the institution, including websites.
79371403|NCT03089307|Device|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
79680283|NCT02946593|Behavioral|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 & 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
79680284|NCT02946593|Behavioral|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
79680285|NCT02928822|Behavioral|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
79371404|NCT03088293|Drug|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
79371405|NCT03088293|Drug|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
79371406|NCT03089151|Behavioral|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~A garden plot in a Denver Urban Garden~Seeds and plant starts~Introductory gardening workshop~Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
79371407|NCT03084003|Dietary Supplement|Almonds|
79371408|NCT03084003|Dietary Supplement|Graham crackers|
79371409|NCT03703401|Diagnostic Test|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
79371410|NCT01008280|Drug|baclofen|baclofen 10 mg tid
79371411|NCT01008280|Drug|placebo|placebo pill tid
79371412|NCT03084159|Behavioral|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
79371413|NCT04279665|Device|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
79371414|NCT03088995|Diagnostic Test|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
79371415|NCT03089073|Drug|Desmopressin|60μg or 120μg once daily at bedtime
79680286|NCT02928822|Behavioral|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
79680287|NCT00525707|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
79680288|NCT02929017|Other|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
79680289|NCT02929017|Other|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
79680290|NCT00526214|Drug|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
79680291|NCT02928744|Other|COPD|Plethysmography
79228835|NCT01233375|Drug|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
79998665|NCT03641352|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
79228836|NCT05346302|Drug|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
79228837|NCT05346302|Drug|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
79371416|NCT00963430|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
79524994|NCT05303233|Procedure|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
79524995|NCT05301179|Other|Protein quantity and quality|Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
79228838|NCT05346302|Other|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
79371417|NCT03083925|Device|TIPS|Transjugular Intrahepatic Portosystemic Shunt
79524996|NCT05295992|Device|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
79228839|NCT01232595|Drug|LFF571|
79371418|NCT03426423|Other|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
79524997|NCT05293223|Biological|Ad5-nCov|Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
79524998|NCT05284019|Drug|Eptinezumab|Concentrate for solution for IV infusion
79524999|NCT05284019|Drug|Erenumab|Solution for SC Injection
79525000|NCT05284019|Drug|Onabotulinumtoxin-A|Solution for IM Injection
79525001|NCT05284019|Drug|Fremanezumab|Solution for SC Injection
79525002|NCT05284019|Drug|Galcanezumab|Solution for SC Injection
79680292|NCT02928744|Other|COPD|Forced oscillations
79709674|NCT01605929|Procedure|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
79998666|NCT03641352|Drug|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
79525003|NCT05263336|Drug|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
79228840|NCT01232595|Drug|Vancomycin (POC)|
79228841|NCT02721498|Procedure|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
79228842|NCT02721498|Other|Rest period|A 30-60 minute of resting
79228843|NCT04472676|Drug|LY3473329|Administered orally.
79228844|NCT04472676|Drug|Placebo|Administered orally.
79228845|NCT01231347|Drug|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
79228846|NCT01231347|Drug|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
79228847|NCT01231347|Drug|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
79228848|NCT01231347|Drug|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
79228849|NCT02466152|Drug|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram [mg/g]) and 1.0% (10 mg/g)
79525004|NCT05250804|Other|Helfer Skin Tap Technique|Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
79525005|NCT05249634|Drug|Jatenzo Pill|oral tablet daily
79525006|NCT05244980|Drug|TDM-105795|TDM-105795 topical solution
79525007|NCT05244980|Drug|Placebo|Placebo for TDM-105795 topical solution
79228850|NCT03470376|Dietary Supplement|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
79371419|NCT03426423|Other|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
79525008|NCT05232604|Other|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
79371420|NCT01009762|Biological|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
79371421|NCT05688813|Procedure|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
79525009|NCT05232604|Other|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
79525010|NCT05228366|Other|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
79525011|NCT05228366|Other|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
79525012|NCT05228366|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
79525013|NCT05222581|Device|Prototypes of breast shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump.
79525014|NCT05217342|Drug|Diuretic therapy|Standard diuretic therapy according to the current guidelines
79525015|NCT05211245|Device|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain & muscle spasm by altering nerve conduction velocity & changes in cell membrane permeability along with increased rate of tissue repair & wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization.
79525016|NCT05194618|Dietary Supplement|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
80016587|NCT03661281|Diagnostic Test|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
79525017|NCT05194618|Dietary Supplement|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
79525018|NCT05193370|Drug|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
79709675|NCT00594594|Other|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
80016588|NCT03661281|Diagnostic Test|Pinch strength|Measured in every splint position using a standard dynamometer
80016589|NCT03661281|Diagnostic Test|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
80016590|NCT03202030|Procedure|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
79228851|NCT03470376|Behavioral|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
79228852|NCT02719028|Drug|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
79228853|NCT02719028|Drug|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
79228854|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
79228855|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
79228856|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
79228857|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
79228858|NCT01230957|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
79228859|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
79228860|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
79228861|NCT03306056|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
79823957|NCT04739930|Procedure|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
79823958|NCT04739930|Procedure|Control group incision|0.5cm sham incision over the iliac crest
79823959|NCT00788229|Drug|AT01|eye drop for 12 weeks
80016591|NCT03202030|Procedure|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
79371422|NCT01009918|Drug|Coreg CR®|Given orally
79823960|NCT00788229|Drug|AT02|eye drop for 12 weeks
79525019|NCT05193370|Drug|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
79525020|NCT05172947|Drug|Resveratrol|This group received resveratrol with the conventional therapy
79525021|NCT05172947|Drug|Placebo|This group received placebo with the conventional therapy
79371423|NCT01009918|Drug|lisinopril|Given orally
79371424|NCT01009918|Other|placebo|Given orally
79525022|NCT05172947|Other|Resveratrol plus Pharmaceutical care|This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
79228862|NCT03306056|Other|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~5 strength training exercises (chest, upper/lower back, abdominals, legs)~3 sets per exercise~time-effort per session: ~90 min~2 training sessions per week~duration of exercise intervention: 12 weeks"
79525023|NCT05172947|Other|Placebo+Pharmaceutical care|This group received placebo with Pharmaceutical care in addition to the conventional therapy
79525024|NCT05170607|Diagnostic Test|Proteomic analysis by antibody microarrays|Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
79680293|NCT02928705|Procedure|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
79680294|NCT02928705|Procedure|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
79823961|NCT00788229|Drug|AT03|eye drop for 12 weeks
80016592|NCT02284724|Procedure|Dry Needling|
79228863|NCT03306056|Other|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~5 strength training exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week~duration of exercise intervention: 12 weeks"
79371425|NCT03088683|Device|Nathanson Retractor|Liver will be retracted with Nathanson retractor
79371426|NCT03088683|Device|Reveel Retractor|Liver will be retracted with Reveel retractor
79371427|NCT04401657|Diagnostic Test|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
79525025|NCT05167591|Diagnostic Test|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
79525026|NCT05151367|Behavioral|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
79680295|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
79371428|NCT03019198|Drug|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
79371429|NCT03019198|Drug|Placebo - Concentrate|
79371430|NCT04401501|Other|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
79371431|NCT04401501|Other|Exercise|Exercises for cervicogenic headache
79680296|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
79823962|NCT00788229|Drug|AT04|eye drop for 12 weeks
79823963|NCT00663117|Drug|Naltrexone-HCl|naltrexone 4.5 mg
79823964|NCT00663117|Drug|Placebo|Placebo
79823965|NCT02578628|Other|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
79823966|NCT04072328|Drug|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
80016593|NCT02284724|Procedure|Sham Needling|
80016594|NCT05204069|Drug|Instillation of cyclopentolate|Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
79998667|NCT03641274|Other|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
79228864|NCT03306056|Other|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~time-effort per session: ~20 min~duration of exercise intervention: 12 weeks"
79525027|NCT05127902|Diagnostic Test|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System."
79228865|NCT01228383|Biological|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
79228866|NCT01228383|Biological|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
79680297|NCT00526253|Procedure|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
79680298|NCT02928939|Other|drug-drug or drug-disease interaction|
79680299|NCT03457584|Procedure|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
79680300|NCT03457584|Procedure|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
79371432|NCT03018808|Other|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
79371433|NCT03018808|Other|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
79680301|NCT02928666|Other|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
79680302|NCT02947256|Procedure|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
79680303|NCT02947256|Procedure|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
79680304|NCT02928510|Procedure|Biospecimen Collection|Undergo biospecimen collection
79680305|NCT02928510|Procedure|Colonoscopy|Undergo colonoscopy
79680306|NCT02928510|Procedure|Colposcopic Biopsy|Undergo colposcopic biopsy
79680307|NCT02928510|Drug|Idelalisib|Given PO
79680308|NCT02928510|Other|Laboratory Biomarker Analysis|Correlative studies
79228867|NCT01228383|Biological|Placebo|Placebo intramuscularly on Day 0.
79228868|NCT01228383|Biological|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
79371434|NCT03018808|Other|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
79371435|NCT03018808|Procedure|Blood test|Blood samples will be collected at indicated time points
79371436|NCT03018808|Other|anthropometric measures|Anthropologic measures will be performed.
79680309|NCT02928510|Other|Pharmacological Study|Correlative studies
79680310|NCT02928510|Procedure|Physical Examination|Undergo physical examination
79680311|NCT02928510|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
79680312|NCT04692974|Device|Mobile phone application and smart watch|Mobile phone application prompts
79228869|NCT01228383|Biological|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
79228870|NCT03305978|Device|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
79228871|NCT03305978|Device|Low dose chest CT|standard diagnostic low dose chest CT
79228872|NCT01594983|Drug|LCQ908|
79228873|NCT01594983|Drug|Fenofibrate|Fenofibrate once daily 12 weeks
79228874|NCT01594983|Drug|Fish Oil|Fish Oil once daily for 12 weeks
79228875|NCT01594983|Drug|Placebo of LCQ908|Matching placebo of LCQ908
79228876|NCT01594983|Drug|Placebo of fenofibrate|Matching placebo of fenofibrate
79228877|NCT01594983|Drug|Placebo of fish oil|Matching placebo of fish oil capsule
79228878|NCT03305900|Other|No Intervention|Cross-sectional study requiring a single serum sample
79228879|NCT01404585|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
79680313|NCT02928393|Drug|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
79680314|NCT02928393|Drug|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
79680315|NCT02947412|Other|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
79680316|NCT02928354|Drug|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
79680317|NCT02928354|Drug|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
79228880|NCT01404585|Drug|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
79371437|NCT03018808|Other|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
79228881|NCT01404585|Drug|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
79371438|NCT03083613|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
79371439|NCT03083613|Drug|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
79371440|NCT00963508|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
80016595|NCT03661203|Behavioral|Focus group|Focus group for qualitative group only
79228882|NCT03305510|Diagnostic Test|vitamin D is below 20ng/ml|
79371441|NCT00963508|Drug|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
79371442|NCT03088371|Drug|Bupivacaine 0.25%|For psoas sciatic block.
79371443|NCT03088371|Other|Pajunk Needle|For local anaesthesia application in psoas sciatic block
79371444|NCT03088371|Other|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
79371445|NCT03088371|Drug|Lidocaine 1%|For psoas sciatic block.
79371446|NCT03088371|Drug|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
79371447|NCT03088371|Drug|Lidocaine 2 %|For psoas sciatic block in the post-operative period
79371448|NCT03088371|Drug|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
79371449|NCT01010854|Drug|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
79525028|NCT05122832|Diagnostic Test|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
79680318|NCT02928354|Drug|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
79228883|NCT01224795|Drug|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
79228884|NCT01224795|Drug|Placebo Comparator|Placebo Peramivir, administered intravenously.
79228885|NCT02263443|Procedure|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
79371450|NCT05685537|Drug|Levosimendan|Initiation of levosimendan 48 hours before surgery
79371451|NCT04279509|Procedure|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
79371452|NCT04279509|Procedure|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
79371453|NCT00964444|Device|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
79371454|NCT05685459|Other|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
79371455|NCT04400721|Drug|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
79371456|NCT01010932|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
79371457|NCT01010932|Other|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
79371458|NCT03018652|Drug|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
79371459|NCT03018652|Drug|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
79371460|NCT04353700|Behavioral|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
79371461|NCT04353466|Procedure|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
79371462|NCT04353466|Drug|Elelyso|intravenous (IV) infusions of Elelyso
79371463|NCT03018496|Dietary Supplement|Beta-Hydroxy-Beta-Methylbutyrate|
79371464|NCT03018496|Other|Placebo|
79371465|NCT00966238|Biological|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
79709676|NCT02270606|Radiation|intensity-modulated radiation therapy|Undergo IMRT
79709677|NCT02270606|Drug|fluorouracil|Given IV
79709678|NCT02270606|Drug|oxaliplatin|Given IV
79709679|NCT02270606|Drug|leucovorin calcium|Given IV
80016596|NCT03661203|Behavioral|Individual interview|Individual interview for qualitative group only
80016597|NCT03661203|Behavioral|online self questionnaire|online self questionnaire
79371466|NCT01012336|Drug|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
79709680|NCT02270606|Procedure|therapeutic conventional surgery|Undergo total mesorectal excision
79823967|NCT04072328|Drug|Midazolam|midazolam with propofol
80016598|NCT03661203|Behavioral|self questionnaire|online self questionnaire following focus group or individual interview For qualitative group only
79228886|NCT02263443|Procedure|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
79228887|NCT02263443|Procedure|No enema|Patients NPO groups will NPO and no bowel preparation.
79371467|NCT00966550|Other|Tomato|Tomato with high carb/fat meal
79371468|NCT00966550|Other|Non-tomato|Non-tomato with high carb/fat meal
79371469|NCT03387501|Drug|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
79371470|NCT01012492|Drug|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
79371471|NCT03016624|Device|OCT guided PCI|oct guided
79371472|NCT03016624|Device|Angiography guided PCI|angio guided
79371473|NCT03083457|Drug|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
79371474|NCT03083457|Drug|General anesthetic|Total intravenous anesthesia with a standard protocol
79371475|NCT03083457|Drug|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
79371476|NCT03083457|Procedure|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
79371477|NCT03083457|Procedure|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
79371478|NCT04348227|Behavioral|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
79371479|NCT00967486|Procedure|Carotid endarterectomy with routine shount|
79371480|NCT00967486|Procedure|Carotid endarterectomy with selective shunt|
79525029|NCT05122832|Diagnostic Test|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
79525030|NCT05122832|Diagnostic Test|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
79823968|NCT00792753|Device|Medtronic Endeavor Coronary Stent System|coronary stent implantation
80016599|NCT04548973|Drug|Esketamine|Esketamine
80016600|NCT04548973|Drug|Normal saline|2ml normal saline
79228888|NCT02265627|Drug|BIIL 284 BS|
79228889|NCT01402401|Drug|AUY922|
79371481|NCT04348461|Drug|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
79371482|NCT04348617|Other|Moderate exercise|50 minutes of moderate exercise on treadmill
79228890|NCT01402401|Drug|Trastuzumab|
79228891|NCT02720510|Drug|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
79228892|NCT02720510|Drug|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
79228893|NCT02720510|Drug|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
79228894|NCT02720510|Drug|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
79228895|NCT02263521|Other|No intervention employed. Study is based on a cross-sectional observational design.|
79228896|NCT01220271|Drug|LY2157299|Administered orally
79228897|NCT01220271|Drug|Radiation|Administered as approved
79228898|NCT01220271|Drug|Temozolomide|Administered orally
79228899|NCT03305432|Combination Product|sleeve + preoperative PPI|sleeve + preoperative PPI
79228900|NCT03305432|Combination Product|sleeve + preoperative Placebo|sleeve + preoperative Placebo
79228901|NCT01396785|Drug|33525|Daily for 14 days
79371483|NCT04348617|Other|Rest|50 minutes of rest or sedentary activity
79525031|NCT05121415|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
79525032|NCT05118997|Device|IRRAflow|IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.
79823969|NCT00792753|Device|DESyne BD Novolimus Stent System|coronary stent implantation
79371484|NCT01013194|Other|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2."
79371485|NCT04761237|Drug|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV < 13%.The infusion was stopped when the SVV < 10%.If the increase of SV was less than 10% or CI < 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
79525033|NCT05118997|Device|EVD|An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
79998668|NCT03644004|Other|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
79525034|NCT05095181|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
79525035|NCT05095155|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
79680319|NCT02946944|Drug|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \ g + 10 mg apixaban 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
79998669|NCT03643926|Procedure|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
79228902|NCT01396785|Drug|Placebo|Daily for 14 days
79525036|NCT05095142|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
79525037|NCT05095129|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
79525038|NCT05090644|Genetic|DNA analysis|GWAS
79680320|NCT02946944|Drug|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
79525039|NCT05090631|Genetic|DNA analysis|GWAS
79998670|NCT03643926|Procedure|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
79998671|NCT03640884|Drug|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
79998672|NCT03641040|Diagnostic Test|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
79998673|NCT03641040|Diagnostic Test|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
79302882|NCT05713019|Diagnostic Test|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
79525040|NCT05090618|Genetic|DNA analysis|GWAS
79525041|NCT05090605|Genetic|DNA analysis|GWAS
79525042|NCT05090436|Other|Schroth Exercise|two month (three session per week)
79525043|NCT05090436|Other|Functional Electrical Stimulation (physiotherapy techniques)|two month (three session per week)
79525044|NCT05088512|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
79998674|NCT03641976|Drug|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
79228903|NCT02468102|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban [od], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
79680321|NCT02928471|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
79228904|NCT02468102|Drug|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
79228905|NCT04491266|Dietary Supplement|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
79228906|NCT04491266|Dietary Supplement|placebo|maltodextrins
79228907|NCT01204749|Drug|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
79228908|NCT01204749|Drug|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
79228909|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
79525045|NCT05088499|Genetic|DNA analysis|GWAS
79680322|NCT02946983|Other|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
79680323|NCT02946983|Other|Control|Intragastric administration of distilled water
79680324|NCT02928432|Drug|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
79998675|NCT03641976|Drug|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
79998676|NCT01069692|Drug|SBR759A|SBR759A 6g daily
79998677|NCT01069692|Drug|SBR759A|Placebo Comparator 0g daily
79228910|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
79228911|NCT02466698|Procedure|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
79228912|NCT02466698|Drug|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
79228913|NCT02466698|Drug|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
79998678|NCT01069692|Drug|SBR759A|SBR759A 3g daily
79998679|NCT01069692|Drug|SBR759A|9g daily
79998680|NCT01069692|Drug|SBR759A|12g daily
80016601|NCT02277938|Drug|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
79228914|NCT02466698|Drug|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
79525046|NCT05088486|Genetic|DNA analysis|GWAS
79525047|NCT05078827|Drug|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
79680325|NCT02928549|Behavioral|semi-structured interviews|
79680326|NCT02947061|Drug|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
79680327|NCT02947061|Drug|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
79680328|NCT02928276|Other|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
79823970|NCT00792753|Device|DESyne Novolimus Stent System|coronary stent implantation
79680329|NCT02946320|Device|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
79823971|NCT00495716|Drug|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
79228915|NCT05244590|Other|Consultation model for patients with palliative care needs|"Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care."
79228916|NCT02720198|Drug|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
79228917|NCT02720198|Drug|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
79371486|NCT05684835|Procedure|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
79371487|NCT03018184|Other|MRI and Muscle Dynamometer|
79680330|NCT02946320|Device|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
79680331|NCT02946320|Device|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
79680332|NCT02928627|Other|Analysis of microRNA expression|sample analysis
79680333|NCT02928315|Drug|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
79680334|NCT02928315|Other|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
79680335|NCT00525746|Behavioral|Interview|Interview lasting about 50 minutes.
79680336|NCT04692090|Other|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
79680337|NCT00526409|Drug|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
79823972|NCT00495716|Drug|acyclovir|400 mg acyclovir orally twice daily for 1 year
79823973|NCT00793065|Other|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
79228918|NCT05212467|Behavioral|AIR-program|This is a guided self management program that is added on the treatment as usual.
79371488|NCT00968032|Device|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
79371489|NCT04401345|Drug|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
79371490|NCT04401345|Drug|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
79371491|NCT00968344|Dietary Supplement|Leucine|3-4g Leucine added to daily meals
79371492|NCT00968344|Dietary Supplement|Alanine|Powered amino acid
79371493|NCT03083301|Other|Medical Files data extraction|Medical Files data extraction
79371494|NCT05684679|Other|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
79371495|NCT05684679|Other|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
79371496|NCT04761003|Device|Thoracoscopy forceps|take pleural biopsy
79371497|NCT01015534|Drug|Temozolomide|
79371498|NCT01015534|Radiation|Whole brain irradiation|
79680338|NCT00526409|Drug|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
79680339|NCT00526409|Drug|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
79823974|NCT00793065|Other|Medical Home redesign|Implementation of NCQA Level III Medical Home
79823975|NCT00788385|Device|ShuntCheck test|
79823976|NCT00784017|Drug|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
79823977|NCT00784017|Drug|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
79823978|NCT04074122|Diagnostic Test|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
80016602|NCT04056585|Procedure|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
79525048|NCT05078827|Drug|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
79228919|NCT05212467|Behavioral|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
79371499|NCT05688033|Radiation|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
79680340|NCT00526409|Drug|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
79680341|NCT00526409|Drug|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
79680342|NCT00526409|Drug|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
79680343|NCT00526409|Drug|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
79680344|NCT02928237|Device|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
79680345|NCT00526448|Drug|ribavirin|2000 mg/day
79680346|NCT00526448|Drug|ribavirin|1000-1200 mg/day
79680347|NCT00526448|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
79680348|NCT00526448|Drug|epoetin beta|epoetin beta 450 UI/week
79823979|NCT04073342|Genetic|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
79228920|NCT05212467|Behavioral|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
79228921|NCT05231876|Other|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
79228922|NCT01194375|Drug|Low Strength IDP-107|Once a day for 16 weeks
79228923|NCT01194375|Drug|High Strength IDP-107|Once a day for 16 weeks
79371500|NCT03083145|Dietary Supplement|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
79823980|NCT00570141|Device|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
79823981|NCT02579694|Device|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
79228924|NCT01194375|Drug|Placebo|Once a day for 16 weeks
79228925|NCT01193361|Drug|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
79228926|NCT01193361|Drug|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
79228927|NCT01193361|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
79525049|NCT05078827|Drug|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
79371501|NCT03083145|Dietary Supplement|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
79371502|NCT03083145|Behavioral|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
79371503|NCT05683353|Other|None intervention|None intervention.
79371504|NCT00968890|Biological|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
79371505|NCT00968890|Biological|Fluarix™|Intramuscular injection, 1 dose
79371506|NCT00968890|Biological|Placebo|Intramuscular injection, 1 dose
79525050|NCT05076981|Drug|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
79525051|NCT05076422|Drug|BI 3006337|BI 3006337
79525052|NCT05076422|Drug|Placebo|Placebo
79680349|NCT02928159|Device|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
79680350|NCT05647629|Procedure|Total hip arthroplasty|hip prosthesis surgery
79680351|NCT00525863|Drug|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to ~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
79680352|NCT02928198|Device|ABSORB BVS|
79680353|NCT04692545|Dietary Supplement|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
79680354|NCT04692506|Other|Probiotic|The study product is probiotic
79680355|NCT00527865|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
79680356|NCT00527865|Drug|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
79823982|NCT02578550|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
79823983|NCT02578550|Drug|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
79680357|NCT00526487|Device|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
79680358|NCT00526487|Device|Endovascular Repair|Endovascular Repair
79680359|NCT02928081|Procedure|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
79680360|NCT02928081|Procedure|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
79680361|NCT00526565|Behavioral|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
79709681|NCT00594633|Other|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
79709682|NCT02270762|Other|Rest in bed|
79228928|NCT01193361|Drug|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
79709683|NCT02270762|Other|Passive verticalization|
79823984|NCT02578550|Drug|Darunavir|A single tablet containing darunavir 800 mg will be administered.
79823985|NCT02578550|Drug|Cobicistat|A single table containing cobistat 150 mg will be administered.
79823986|NCT00788463|Drug|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
79998681|NCT03621228|Device|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
80016603|NCT04056585|Procedure|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
79228929|NCT01193361|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
79228930|NCT03305354|Behavioral|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
79228931|NCT03305354|Behavioral|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
79371507|NCT03082833|Drug|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
79371508|NCT03082989|Device|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
79371509|NCT03082989|Other|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
79371510|NCT00970216|Drug|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
79371511|NCT03017950|Drug|CKD-330|
79371512|NCT03017950|Drug|D086|
79371513|NCT03017950|Drug|CKD-330 + D086|
79371514|NCT00971620|Biological|Botulinum toxin type A|Given as an intralesional injection.
79371515|NCT00971620|Other|Placebo|Given as an intralesional injection
79371516|NCT05687565|Dietary Supplement|Control group placebo|Dietary suplementation
79371517|NCT05687565|Dietary Supplement|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
79371518|NCT05687565|Dietary Supplement|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
79371519|NCT01884922|Drug|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
79525053|NCT05074979|Other|telerehabilitation|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
79525054|NCT05074979|Other|home exercise program|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
79525055|NCT05074979|Other|informed program|will informed after COVID 19
79525056|NCT05065164|Drug|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
79525057|NCT05062122|Other|vibration group|Hand skills were evaluated before and after 10 minutes of vibration application.
79998682|NCT03641898|Procedure|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or >90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR >0.80 are defined as FNLs and should result in deferral of PCI.
79680362|NCT00526565|Behavioral|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
80016604|NCT05120518|Other|Collection of post mortem tissue donation|Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
79525058|NCT05062122|Other|kinesiology tape group|Dexterity was assessed before and after kinesiology tape application.
79228932|NCT02263677|Drug|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
79228933|NCT01390545|Drug|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
79228934|NCT01591473|Drug|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
79525059|NCT05062122|Other|control group|Manual dexterity was assessed before and after traditional physiotherapy.
79525060|NCT05057819|Drug|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
79525061|NCT05057819|Drug|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
79680363|NCT02928003|Procedure|Lung surgery|Genetic analysis and questionnaires
79228935|NCT01591473|Drug|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
79228936|NCT01591473|Drug|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
79228937|NCT01591473|Drug|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
79228938|NCT01591473|Drug|Placebo|Placebo; 3 doses; nasal administration every 28 days
79228939|NCT01591473|Drug|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
79228940|NCT02265861|Drug|HCG|
79228941|NCT01192035|Drug|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
79228942|NCT01192035|Drug|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
79228943|NCT02268747|Drug|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
79228944|NCT01590459|Drug|VX-509|50 mg oral tablet
79525062|NCT05046834|Other|cold application|Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.
79525063|NCT05046834|Other|cold application until 13.6 C|After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
79525064|NCT05035693|Device|MOVE®-C|Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
79680364|NCT02946827|Dietary Supplement|Balanced low FODMAPs /gluten free diet|
79680365|NCT02946827|Dietary Supplement|Balanced gluten free diet|
79680366|NCT02928042|Other|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
79680367|NCT02946671|Biological|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
79709684|NCT02270762|Other|Rest in bed|
79228945|NCT01590459|Drug|VX-509 matching placebo|0 mg oral tablet
80016605|NCT04710875|Drug|Na-lactate|intravenous
80016606|NCT04710875|Drug|Sodium chloride|Intravenous
79525065|NCT05029375|Behavioral|PEERS® for Preschoolers|P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
79680368|NCT02946671|Biological|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
79680369|NCT02927886|Procedure|Per-oral endoscopy pyloromyotomy|
80016607|NCT04055805|Behavioral|Observational Analysis|Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
79371520|NCT01884922|Drug|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
79371521|NCT03083223|Other|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
79371522|NCT01610908|Other|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
79228946|NCT01384383|Drug|GS-5885|GS-5885 30 mg tablet administered orally once daily
79228947|NCT01384383|Drug|GS-9451|GS-9451 200 mg tablet administered orally once daily
79228948|NCT01384383|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79371523|NCT01610908|Other|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
79371524|NCT05687409|Drug|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
79371525|NCT05687409|Drug|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
79371526|NCT05687409|Dietary Supplement|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
79371527|NCT05679063|Other|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
79371528|NCT05679063|Other|Sham, Control|Talks about healthy habits
79371529|NCT02162680|Drug|1% lidocaine|
79371530|NCT02162680|Drug|bacteriostatic normal saline (BNS)|
79371531|NCT02162992|Other|No intervention|Observational
79371532|NCT05687331|Procedure|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
79371533|NCT05687331|Procedure|venipuncture|Peripheral venipuncture to gather a blood sample
79371534|NCT05687331|Diagnostic Test|MRI-scan|MRI-scan of the knee
79371535|NCT05687331|Diagnostic Test|Physical examination|Physical examination of the injured knee
79371536|NCT05687331|Other|KOOS questionnaire|KOOS questionnaire of the injured knee
79371537|NCT00972088|Device|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
79525066|NCT05027074|Drug|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
79680370|NCT02927886|Procedure|Intrapyloric injection of Botulinum toxin|
79709685|NCT01605968|Device|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
79823987|NCT00788463|Drug|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
80016608|NCT00415142|Drug|saredutant (SR48968)|oral administration (capsules)
80016609|NCT00415142|Drug|placebo|oral administration (capsules)
79228949|NCT01384383|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
79228950|NCT01557777|Drug|Navitoclax|QD
79228951|NCT02268825|Drug|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
79228952|NCT01381731|Drug|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
79998683|NCT03641898|Diagnostic Test|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
79371538|NCT05677815|Procedure|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
79525067|NCT05027074|Drug|Placebo|Normal saline administered via IV infusion
79998684|NCT01344876|Drug|OPB-51602|once daily during the treatment period
79525068|NCT05024487|Diagnostic Test|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
79525069|NCT05022095|Other|Questionnaires|Diverse questionnaires have to be filled in.
79525070|NCT05011006|Diagnostic Test|NT3 blood draw|blood draw
79525071|NCT05004389|Diagnostic Test|MRI|white matter integrity and brain structural connectivity metrics
79371539|NCT01017250|Radiation|Stereotactic Radiosurgery (SRS)|Tumor Volume < 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
79525072|NCT05004389|Diagnostic Test|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
79525073|NCT05004389|Other|Clinical assessments|measures of strength, balance, and mobility
79525074|NCT04981821|Behavioral|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
79525075|NCT04981821|Behavioral|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
79525076|NCT04975763|Other|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
79525077|NCT04975763|Other|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
79525078|NCT04962165|Device|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
79525079|NCT04947033|Drug|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
79525080|NCT04934124|Drug|ITI-333|ITI-333 oral solution
79680371|NCT00526604|Behavioral|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
79709686|NCT01605968|Device|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
79998685|NCT03641586|Drug|BGB-283|
79998686|NCT05183178|Drug|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient >75 years of age or <60 kg will receive 5 mg prasugrel OD.
79998687|NCT05183178|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
79998688|NCT03640806|Other|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
79998689|NCT03572426|Other|genotyping all subjects|genotyping using SNaPshot genotyping method.
79228953|NCT01381731|Drug|placebo|opthalmic solution 2 drops in each eye QID
79525081|NCT04934124|Other|Placebo|Matching placebo
79525082|NCT04928196|Other|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
79228954|NCT02268903|Drug|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
79525083|NCT04924920|Diagnostic Test|SIGH|To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV [SIMV (PC) + PS mode], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
79525084|NCT04924920|Diagnostic Test|EEOT|• The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
79525085|NCT04924010|Behavioral|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format [Connolly KS et al] AND an evidence-based CBT manual specifically designed to treat chronic pain [Murphy JL et al].
79709687|NCT04355013|Device|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
79998690|NCT02846324|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
79371540|NCT01017250|Drug|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
79228955|NCT02268903|Drug|Placebo|Placebo in one single direct intra venous injection
79228956|NCT01381107|Drug|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
79228957|NCT01381107|Drug|Placebo|Sublingual administration once daily for 7 consecutive days.
79228958|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
79228959|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
79228960|NCT02268981|Device|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
79228961|NCT02269059|Drug|MK-7680|MK-7680 10 mg and 100 mg capsules
79228962|NCT03135405|Behavioral|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
79228963|NCT03135405|Behavioral|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
79228964|NCT03135405|Behavioral|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
79228965|NCT01369095|Drug|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C&D)
79228966|NCT01369095|Drug|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C&D)
79228967|NCT01369095|Drug|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B&C)
79228968|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
79228969|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
79228970|NCT01369095|Drug|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
79228971|NCT01369095|Drug|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
79228972|NCT03135561|Behavioral|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
79228973|NCT03135561|Behavioral|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
79228974|NCT02269215|Drug|BIII 890 CL|
79228975|NCT02269215|Drug|Placebo|
79228976|NCT02266095|Device|Oval-8 Splint|Splinting with Oval-8
79228977|NCT02266095|Device|Tee Pee Splint|Splinting with Tee Pee
79228978|NCT02266095|Device|Forearm Based Splint|Splinting with Forearm based
79709688|NCT01606046|Device|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
79709689|NCT01606046|Drug|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
79228979|NCT02266173|Drug|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
79228980|NCT01168713|Drug|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
79228981|NCT01168713|Drug|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
79228982|NCT02269293|Drug|Paclitaxel|
79228983|NCT02269293|Drug|Carboplatin|
79228984|NCT02269293|Drug|Selinexor|
79228985|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
79228986|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
79228987|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
79228988|NCT01545453|Drug|placebo|subcutaneous dose every 4 weeks
79228989|NCT04476303|Drug|BEY2153|Capsule
79228990|NCT04476381|Procedure|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
79228991|NCT01161615|Drug|MRX-7EAT|Application of up to two patches for up to 7 days.
79228992|NCT01161615|Drug|Placebo|Application of up to two patches for up to 7 days.
79228993|NCT01366131|Drug|MEGF0444A|Intravenous repeating dose
79228994|NCT01366131|Drug|bevacizumab|Intravenous repeating dose
79228995|NCT01366131|Drug|carboplatin|Intravenous repeating dose
79228996|NCT01366131|Drug|paclitaxel|Intravenous repeating dose
79228997|NCT01366131|Drug|placebo|Intravenous repeating dose
79228998|NCT01365195|Drug|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
79228999|NCT01365195|Drug|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
79229000|NCT01365195|Drug|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
79229001|NCT02269371|Other|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
79229002|NCT02269371|Other|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
79229003|NCT02269449|Device|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
79229004|NCT02269449|Device|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
79229005|NCT02269449|Procedure|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
79229006|NCT02269449|Procedure|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
79709690|NCT02892630|Other|No intervention|
79709691|NCT01606085|Behavioral|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
79998691|NCT02846324|Drug|Placebo|Placebo capsules
80016610|NCT00415142|Drug|escitalopram|oral administration (capsules)
79680372|NCT02946164|Behavioral|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
79680373|NCT02946710|Biological|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
79229007|NCT01359969|Drug|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
79229008|NCT01160601|Drug|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
79680374|NCT02927730|Other|no interventions|no interventions
79680375|NCT04692402|Device|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
79998692|NCT02240342|Drug|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
79998693|NCT03576092|Diagnostic Test|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
79998694|NCT03161093|Drug|Fasinumab|Solution for injection in pre-filled syringe
79998695|NCT03161093|Drug|Naproxen|Pharmaceutical form: Capsule
79998696|NCT03161093|Drug|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
79229009|NCT01160601|Drug|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
79229010|NCT01529853|Drug|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79229011|NCT01529853|Drug|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79229012|NCT01357395|Drug|Amuvatinib|Amuvatinib 300 mg PO TID
79229013|NCT02269605|Other|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
79229014|NCT02269605|Drug|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
79229015|NCT02269605|Drug|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
79229016|NCT02269683|Procedure|Robot-assisted distal pancreatectomy|
79229017|NCT02269683|Procedure|Laparoscopic distal pancreatectomy|
79229018|NCT01356849|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
79229019|NCT01356849|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
79229020|NCT02266407|Procedure|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
79229021|NCT01521663|Drug|IPX159|
79229022|NCT01521663|Drug|Placebo|
79229023|NCT02266485|Drug|BIBB 515 BS|
79229024|NCT02266485|Drug|Pravastatin|
79229025|NCT02266485|Drug|Placebo|
79229026|NCT01344993|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
79229027|NCT02269839|Device|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
79229028|NCT02263989|Drug|Telmisartan film coated tablet|
79229029|NCT02263989|Drug|Telmisartan conventional tablet|
79229030|NCT02266563|Drug|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
79229031|NCT02266563|Drug|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
79680376|NCT02927808|Behavioral|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
79998697|NCT03161093|Drug|Naproxen-matching placebo|Capsule
79998698|NCT02847650|Drug|Placebo|
79998699|NCT02847650|Drug|PF-06649751|
80016611|NCT03661125|Drug|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
79823988|NCT00579254|Drug|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
79371541|NCT03082443|Other|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
79371542|NCT00812032|Drug|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
79371543|NCT00812032|Drug|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
79371544|NCT04352764|Diagnostic Test|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
79371545|NCT05687175|Other|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
79371546|NCT04746651|Other|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
79371547|NCT02159872|Drug|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
79371548|NCT00417664|Drug|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
79371549|NCT00417664|Drug|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
79371550|NCT00417664|Drug|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
79371551|NCT05687019|Combination Product|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
79371552|NCT03400059|Device|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
79525086|NCT04924010|Behavioral|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
79525087|NCT04905979|Drug|AD113|Two oral capsules administered before bed
79823989|NCT02574806|Procedure|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
79823990|NCT00793221|Device|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
79823991|NCT00793221|Device|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
79229032|NCT02264067|Drug|Talsaclidine|
79229033|NCT02264067|Drug|Placebo|
79371553|NCT03400059|Device|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
79371554|NCT01021306|Device|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
79371555|NCT01021306|Device|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
79229034|NCT02269995|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
79229035|NCT02270073|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
79229036|NCT02270151|Device|MyDiagnostick|Diagnostick strategy with MyDiagnostick
79229037|NCT02266641|Behavioral|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
79229038|NCT02266641|Dietary Supplement|multivitamin supplement|
79525088|NCT04905979|Drug|Atomoxetine|Two oral capsules administered before bed
79525089|NCT04889859|Procedure|long Roux limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
79371556|NCT01021306|Other|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
79371557|NCT01021306|Other|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
79371558|NCT03082287|Device|Fecal Calprotectin Level|Measurement of calprotectin in feces
79371559|NCT01021618|Drug|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
79371560|NCT01021618|Other|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
79371561|NCT03082053|Drug|varlitinib|IMP
79371562|NCT03082053|Drug|capecitabine|Companion Medication
79525090|NCT04889859|Procedure|long biliopancreatic limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
79525091|NCT04885400|Behavioral|iJobs|During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
79525092|NCT04880590|Other|Sex intercourse|A heterosexual sexual relationship
79525093|NCT04870827|Drug|13N Amonia|Administered during PET/CT scans
79525094|NCT04860765|Device|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
79525095|NCT04854512|Drug|Metformin DR|Delay-Release Metformin
79371563|NCT01022242|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
79371564|NCT01022242|Drug|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
79525096|NCT04854512|Drug|Metformin IR|Immediate Release Metformin
79525097|NCT04854512|Drug|Metformin DR Placebo|Metformin DR Placebo
79525098|NCT04854512|Drug|Metformin IR placebo|Metformin IR placebo
79371565|NCT03358563|Drug|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
79525099|NCT04804072|Drug|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
79525100|NCT04804072|Diagnostic Test|HIV testing|HIV testing
79680377|NCT02927652|Other|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
79823992|NCT02578134|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
79998700|NCT03573440|Other|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
80016612|NCT03661125|Drug|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
79525101|NCT04804072|Drug|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
79229039|NCT02270853|Device|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
79229040|NCT02271633|Dietary Supplement|Sodium nitrate|
79229041|NCT02271633|Dietary Supplement|Beetroot juice|
79229042|NCT02271633|Dietary Supplement|Spinach|
79229043|NCT02271633|Dietary Supplement|Rocket salad|
79229044|NCT04475601|Drug|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
79525102|NCT04804072|Drug|PrEP for participants without HIV|PrEP for participants without HIV
79525103|NCT04804072|Diagnostic Test|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
79525104|NCT04804072|Diagnostic Test|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
79525105|NCT04804072|Diagnostic Test|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
79525106|NCT04804072|Other|Primary care|Primary care
79525107|NCT04804072|Behavioral|Harm reduction services|Harm reduction services
79525108|NCT04804072|Behavioral|Peer navigation|Peer navigation
79525109|NCT04804072|Diagnostic Test|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
79229045|NCT01516203|Drug|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
79525110|NCT04798365|Behavioral|Intervention group|medical education and distribution of educations materials
79680378|NCT02946086|Behavioral|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
79680379|NCT02946086|Behavioral|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
79680380|NCT00526643|Drug|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
79680381|NCT00526643|Drug|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
79680382|NCT02945163|Drug|Tenofovir|Tenofovir Disoproxil Fumarate
79998701|NCT03573284|Diagnostic Test|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
79229046|NCT01516203|Drug|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
79229047|NCT01321359|Drug|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
79229048|NCT00703118|Drug|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
79371566|NCT03358563|Drug|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
79229049|NCT00703118|Drug|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
79525111|NCT04795089|Procedure|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
79229050|NCT00703118|Drug|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
79229051|NCT00703118|Drug|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
79229052|NCT01510119|Drug|Hydroxychloroquine|
79525112|NCT04778670|Diagnostic Test|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
79229053|NCT01510119|Drug|RAD001|
79229054|NCT01501383|Drug|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
79229055|NCT01501383|Drug|Placebo|Matching placebo
79229056|NCT01501383|Drug|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
79229057|NCT04475367|Other|App hypercross group|hypertensive patients using HyperCrossApp
79525113|NCT04778670|Diagnostic Test|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
79525114|NCT04774445|Behavioral|MyCancerGene|Interactive Health Communication Application
79680383|NCT02945163|Drug|Lamivudine|Lamivudine
79680384|NCT02945163|Drug|Efavirenz|Efavirenz
79680385|NCT00526682|Dietary Supplement|Irvingia/cissus combo|
79680386|NCT02927574|Device|DCB|
79680387|NCT02927574|Device|POBA|
79680388|NCT02927418|Behavioral|Strength & Conditioning|
79680389|NCT02927418|Behavioral|Control|
79680390|NCT00526760|Drug|Dexmedetomidine|
79680391|NCT00526838|Drug|XL228|1-hour IV infusion
79680392|NCT02927379|Drug|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
79680393|NCT02927379|Drug|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
79680394|NCT02927379|Drug|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
79680395|NCT00526877|Drug|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
79680396|NCT02927496|Drug|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)"
79680397|NCT02927496|Drug|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
79680398|NCT00526916|Drug|[C-11]PBR28|
79680399|NCT02927535|Drug|TNF blockers monotherapy|
79680400|NCT00527969|Drug|HT1001 extract of Panax quinquefolius L|
79680401|NCT00527033|Drug|YM178|Oral
79680402|NCT00527033|Drug|Placebo|Oral
79709692|NCT01606085|Behavioral|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
79525115|NCT04772664|Dietary Supplement|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
79680403|NCT02945891|Device|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
79680404|NCT02945072|Procedure|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
79229058|NCT04475367|Other|without App hypercross group|Interdisciplinary health care
79371567|NCT03358563|Drug|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
79680405|NCT02945072|Procedure|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
79680406|NCT02924922|Procedure|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
79680407|NCT02924922|Procedure|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
79680408|NCT02924922|Device|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
79680409|NCT02924922|Device|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
79680410|NCT02924922|Drug|Mannitol|
79680411|NCT04692896|Drug|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
79680412|NCT02927340|Drug|Lorlatinib|
79680413|NCT00528008|Other|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
79680414|NCT00528008|Other|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
79680415|NCT02925039|Other|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
79680416|NCT02925039|Other|Treatment as usual|Treatment as usual
79680417|NCT02946203|Other|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
79680418|NCT02946203|Other|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
79680419|NCT02924961|Device|Triathlon PS total knee system with mobile-bearing|
79998702|NCT03573284|Diagnostic Test|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
79229059|NCT01150695|Other|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
79229060|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine [approximately 1x10^9 colony forming units (cfu)/mL] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
79371568|NCT03358563|Radiation|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
79371569|NCT01018420|Drug|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
79371570|NCT01018420|Drug|Moxifloxacin|400 mg capsule at the 6 hour point
79371571|NCT04401033|Behavioral|Telephonic medical visit|The patient will receive a telephonic call passing a medical visit
79680420|NCT02924961|Device|Triathlon PS total knee system with fixed-bearing|
80016613|NCT00413114|Drug|Obatoclax mesylate (GX15-070MS)|
79525116|NCT04772664|Dietary Supplement|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
79525117|NCT04772651|Other|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
79525118|NCT04772651|Other|Normal hospital diet|Normal hospital diet
79371572|NCT04401033|Procedure|Gastrointestinal endoscopy|Upper or lower GI endoscopy according to clinical practice and current guidelines
79680421|NCT04692740|Drug|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
79680422|NCT02925000|Drug|TLC178|TLC178
79823993|NCT02578134|Other|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
79525119|NCT04772651|Other|dietary coaching|dietary coaching
79525120|NCT04772651|Other|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
79525121|NCT04759144|Device|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
79823994|NCT04072562|Drug|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
79998703|NCT03576014|Biological|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2~4 weeks after the transplant.
79229061|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
79371573|NCT04401033|Procedure|Abdominal ultrasound|Diagnostic abdominal ultrasound according to the current guidelines
79229062|NCT02272023|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
79823995|NCT00784329|Device|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
79823996|NCT04072484|Other|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
79823997|NCT00793299|Behavioral|Video Illness Narrative|video
79998704|NCT03575858|Device|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
79998705|NCT03575858|Device|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
79998706|NCT03575780|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
79229063|NCT02272023|Behavioral|Single session of Motivational Interviewing|
79371574|NCT03081975|Device|HD white light or NBI|Use of NBI or HD white light
79371575|NCT03082131|Dietary Supplement|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
79371576|NCT03081819|Drug|SH003|Herbal medicine for cancer treatment
79371577|NCT00974350|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
79525122|NCT04759144|Device|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
79525123|NCT04757701|Other|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
79525124|NCT04737200|Dietary Supplement|Time-of-day of enteral nutrition provision (daytime first)|Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.
79525125|NCT04737200|Dietary Supplement|Time-of-day of enteral nutrition provision (nighttime first)|Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
79525126|NCT04734847|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
79525127|NCT04734847|Device|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
79680423|NCT04692857|Procedure|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
79680424|NCT00528047|Drug|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
79998707|NCT01334255|Drug|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
80016614|NCT03660579|Other|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
80016615|NCT03660579|Other|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
79371578|NCT00974350|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
79371579|NCT00974350|Drug|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
79525128|NCT04731870|Other|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
79998708|NCT03575624|Behavioral|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
79229064|NCT02272179|Behavioral|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
79680425|NCT01580462|Other|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
79680426|NCT02926989|Drug|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
79680427|NCT02926989|Drug|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
79680428|NCT04692272|Behavioral|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
79680429|NCT02924805|Other|Telemedical care|Telemedically guided care based on a standard operating procedure
79680430|NCT02924649|Procedure|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
79680431|NCT00528125|Procedure|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
79680432|NCT00528125|Procedure|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
80016616|NCT03660579|Other|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
79229065|NCT02272179|Behavioral|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
79229066|NCT02272179|Behavioral|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
79229067|NCT05205044|Diagnostic Test|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
79229068|NCT01302249|Drug|Latanoprost 0.005%|q.d.
79680433|NCT02945696|Procedure|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
79371580|NCT05633901|Other|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
79371581|NCT05633901|Other|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
79371582|NCT05633511|Procedure|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
79371583|NCT05395702|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
79525130|NCT04724031|Drug|PARP inhibitor|use at any line of treatment in patients with advanced ovarian cancer
79229069|NCT01302249|Drug|AR-12286 Ophthalmic Solution 0.5%|
79525133|NCT04687969|Drug|[18F]DCFPyL|will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
79525134|NCT04687969|Radiation|PET/MRI scanner|PET/MRI Scan with [18F]DCFPyL as directed by protocol
79525135|NCT04679376|Drug|Atorvastatin|40 mg daily administered orally in tablet or capsule form
79525136|NCT04679376|Drug|Placebo|Administered daily orally in tablet or capsule form, contains no active medicine
79229070|NCT01302249|Drug|Timolol maleate ophthalmic solution 0.5%|
79229071|NCT02261636|Drug|mesalazine|
79229072|NCT02272257|Behavioral|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
79525137|NCT04678999|Behavioral|Mind-body exercise and education|The intervention will delivered via a secure Zoom video platform.
79680434|NCT02945696|Drug|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
79680435|NCT02926872|Other|There is no intervention in the study|
79680436|NCT02926794|Behavioral|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
79525138|NCT04677959|Drug|Fluticasone propionate/salmeterol (FS)|FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
79680437|NCT02926794|Behavioral|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
79680438|NCT02926794|Behavioral|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
79680439|NCT02926794|Behavioral|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
79680440|NCT00528164|Behavioral|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
79680441|NCT02924766|Drug|Niraparib|Participants will start with niraparib 200 mg once daily.
79680442|NCT02924766|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4*60 mg) once daily orally.
79680443|NCT02924766|Drug|Abiraterone Acetate|Participants will receive 1000 mg (4*250mg) once daily.
79680444|NCT02924766|Drug|Prednisone|Participants will receive 10 mg (1*5 mg twice daily).
79680445|NCT02926755|Procedure|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
79229073|NCT02272257|Behavioral|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
79680446|NCT00528281|Drug|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
79680447|NCT00528281|Drug|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
79371584|NCT03016546|Behavioral|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
79525139|NCT04677959|Drug|Albuterol|Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
79525140|NCT04677959|Drug|Standard of Care Asthma Medication|Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
79525141|NCT04677959|Drug|Standard of Care Rescue Medication|Current rescue medication
79680448|NCT00528320|Device|Ovatio CRT|
79680449|NCT02926599|Behavioral|Personal Optimization Training|
79680450|NCT01580501|Drug|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
79680451|NCT02924532|Biological|immediate post operative bioassay of Parathyroid Hormone|
79998709|NCT03573128|Behavioral|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
79998710|NCT03573128|Other|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
79998711|NCT01334333|Drug|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
79680452|NCT00528359|Drug|quetiapine or olanzapine or risperidone or aripiprazole|
79680453|NCT02946008|Radiation|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
79998712|NCT01334333|Drug|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
79229074|NCT03305198|Biological|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
79525142|NCT04671043|Dietary Supplement|Caffeine and glucose|Caffeine and glucose powder dissolved in water
79525143|NCT04671043|Dietary Supplement|Glucose alone|Glucose powder dissolved in water
79525144|NCT04671043|Dietary Supplement|Placebo|Artificial sweetener dissolved in water
79823998|NCT04072406|Other|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
79371585|NCT03016546|Behavioral|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
79525145|NCT04656899|Behavioral|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
79680454|NCT02946008|Procedure|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
79680455|NCT02944721|Genetic|Genetical analyses|
79680456|NCT02944721|Other|Chronic pain identification questionnaires|
79229075|NCT05628519|Behavioral|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
79229076|NCT05628519|Behavioral|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
79371586|NCT01023178|Drug|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
79229077|NCT03305120|Other|pain VAS evaluation|each patient has to answer to a questionnaire about pain
79229078|NCT05628441|Other|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
79371587|NCT01023178|Drug|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
79371588|NCT01023178|Drug|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
79229079|NCT01493505|Drug|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
79371589|NCT01023178|Drug|Progesterone, micronized|Given starting at 18 months
79525146|NCT04645342|Device|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
79998713|NCT03573050|Drug|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
79998714|NCT03573050|Drug|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
79229080|NCT01493505|Drug|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
79229081|NCT01493505|Drug|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
79229082|NCT01493505|Drug|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
79229083|NCT02464748|Other|TiM telehealth arm|
79229084|NCT02464592|Procedure|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
79229085|NCT04813718|Dietary Supplement|Omni-Biotic Pro Vi 5|Pre- and probiotic
79229086|NCT04813718|Dietary Supplement|Placebo|Placebo
79525147|NCT04645342|Device|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
79525148|NCT04642586|Diagnostic Test|multimodal magnetic resonance imaging|Brain MRI exam (without contrast injection)
79525149|NCT04642586|Diagnostic Test|blood test|Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
79680457|NCT02944721|Other|Neurophysiological and psychophysical evaluations|
79680458|NCT02944721|Other|Quality of life questionnaires|
79680459|NCT02924493|Other|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
79680460|NCT00527150|Drug|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
79680461|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
79823999|NCT04072406|Other|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
79824000|NCT00788619|Procedure|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
79824001|NCT00788619|Procedure|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
79525150|NCT04642586|Diagnostic Test|neuropsychological assessment|neuropsychological assessment
79229087|NCT01493271|Drug|Placebo|Placebo to RO5093151
79525151|NCT04639297|Device|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
79525152|NCT04639297|Device|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
79229088|NCT01493271|Drug|RO5093151|oral doses twice daily for up to 28 days
79229089|NCT01301781|Drug|BLI801|BLI801 laxative - oral solution
79371590|NCT03373851|Device|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
79525153|NCT04637035|Other|Supportive Oncology Care at Home|Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
79525154|NCT04633590|Behavioral|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
79525155|NCT04618198|Other|Immediate anti-TB therapy|Study participants will receive immediate empiric anti-TB therapy
79525156|NCT04618198|Other|Sepsis-specific dose anti-TB therapy|Study participants will receive conventional WHO weight-based dose anti-TB therapy
79525157|NCT04617925|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
79525158|NCT04612920|Drug|Ibuprofen, acetaminophen, oxycodone|The timing of medications is the intervention.
79525159|NCT04581135|Other|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
79525160|NCT04570293|Drug|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
79680462|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
79680463|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
79680464|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
79680465|NCT00527189|Behavioral|Balance Exercises|Home based balance exercises based on Otago Exercise programme
79824002|NCT00661089|Drug|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
79998715|NCT03572894|Device|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~T1 : Vt 8 mL/Kg of PBW during 5 minutes~T2 : Vt 10 mL/kg of PBW during 5 minutes~T3 : Vt 6 mL/kg of PBW during 5 minutes~T4 : A single recruitment maneuver~Data will be recorded at each step."
79229090|NCT01301781|Drug|Placebo|BLI801 placebo - oral solution
79229091|NCT02466308|Device|SAM Ultrasound Diathermy Device|
79229092|NCT01301157|Drug|M518101|Proper quantity twice a day
79229093|NCT01301157|Drug|placebo|Proper quantity twice a day
79229094|NCT01301157|Drug|Dovonex|Proper quantity twice a day
79229095|NCT02465996|Device|pCLE examination|All FD patients received pCLE examination.
79229096|NCT02465996|Drug|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
79229097|NCT01296087|Drug|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
79709693|NCT00594828|Device|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
79824003|NCT00661089|Drug|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
79824004|NCT03098082|Device|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
79998716|NCT03575312|Drug|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
79229098|NCT01296087|Drug|Placebo|Matching placebo capsule given once daily on Days 1 to 28
79229099|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - low|
79229100|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - medium|
79229101|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - high|
79229102|NCT02264145|Drug|Ethanolic Solution From Respimat®|
79824005|NCT01773278|Drug|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
79824006|NCT01773278|Drug|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels > 100 mg/dl if possible
79824007|NCT00788853|Other|No treatment given|No treatment is given
79824008|NCT04071002|Other|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
79998717|NCT05186441|Other|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
79998718|NCT05186441|Other|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
79998719|NCT03572816|Device|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
79229103|NCT02266953|Behavioral|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
79525161|NCT04570293|Drug|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
79680466|NCT00527228|Drug|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
79680467|NCT00527228|Drug|placebo|
79680468|NCT02926482|Behavioral|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
79680469|NCT00527267|Drug|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
79824009|NCT00788931|Drug|IV LBH589|
79998720|NCT02847494|Drug|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
79998721|NCT02847494|Drug|Dexamethasone|dexamethasone 10mg intramuscular injection
79998722|NCT02847494|Drug|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
79229104|NCT02266953|Behavioral|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
79371591|NCT03373773|Procedure|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
79371592|NCT01023568|Device|Macintosh blade|Intubation with Macintosh blade laryngoscope
79525162|NCT04565275|Drug|Drug ICP-192|"Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the 3+3 dose escalation scheme~Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase."
79824010|NCT00788931|Drug|Oral LBH589|
79824011|NCT00788931|Drug|trastuzumab|
79371593|NCT01023568|Device|Glidescope|Intubation with Glidescope laryngoscope.
79371594|NCT01023568|Device|Truview PCD|Intubation with Truview PCD laryngoscope.
79525163|NCT04543045|Other|not an intervention|not an intervention
79525164|NCT04531462|Drug|Empagliflozin|Empagliflozin
79525165|NCT04531462|Drug|Placebo|Placebo
79824012|NCT00788931|Drug|paclitaxel|
79824013|NCT00709514|Drug|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
79998723|NCT02559401|Other|MRI|
79998724|NCT02559401|Other|Neurocognitive battery|
79998725|NCT03572270|Diagnostic Test|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
79998726|NCT03572270|Diagnostic Test|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
79998727|NCT02554253|Drug|Ketamine|Ketamine used for induction
79998728|NCT02554253|Drug|Propofol|Propofol for induction
79998729|NCT02239484|Drug|Tadalafil|
79824014|NCT00709514|Drug|Placebo|Placebo
79824015|NCT00709670|Procedure|MSCT and stress echocardiography|tests MSCT and stress echocardiography
79824016|NCT00709748|Device|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
79824017|NCT00709748|Device|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
79371595|NCT01023724|Drug|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
79371596|NCT01023724|Drug|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
79525166|NCT04527016|Procedure|Microbiota and eosinophils based therapy|"Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~Blood eosinophils<3%+ Moraxella species>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~Blood eosinophils ≥3%+ Moraxella species>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~Blood eosinophils<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
79680470|NCT00527267|Drug|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
79525167|NCT04527016|Drug|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~regular inhaled FP 50 ug twice daily via spacer for 3 months;~montelukast(4mg od for 3 months)~intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
79680471|NCT02924298|Behavioral|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
79680472|NCT02924415|Behavioral|Tele-care support|Psychoeducation treatment based on telemedicine
79998730|NCT02239484|Drug|Tamsulosin|
79680473|NCT02924415|Other|Control group|Standard care
79680474|NCT02944994|Other|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
79998731|NCT02239484|Drug|Tadalafil + Tamsulosin|
79998732|NCT01331759|Device|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
79371597|NCT00974818|Drug|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
79998733|NCT03575234|Drug|Cyclophosphamide|Given IV
79998734|NCT03575234|Biological|IRX-2|Given SC
79998735|NCT03575234|Biological|Nivolumab|Given IV
79998736|NCT03575234|Procedure|Surgery|Undergo surgery
79998737|NCT01337531|Drug|Gonal-F, Fostimon|dosage form
79371598|NCT00974818|Biological|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
79371599|NCT05395546|Other|dCBT-I|"Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~Scale assessment needs to be completed at the end of treatment~One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
79371600|NCT00977704|Device|Restylane and Perlane|
79371601|NCT05395390|Behavioral|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
79525170|NCT04511442|Other|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~high / low in fat (HF / LF)~high / low in carbohydrates (HC / LC)~high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
79525171|NCT04507815|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
79525172|NCT04507815|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
79680475|NCT02944994|Other|Routine Care|This arm will reflect typical care received in routine mental health care
79680476|NCT02924181|Device|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
79680477|NCT00527306|Dietary Supplement|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
79680478|NCT02926287|Other|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
79371602|NCT05395234|Behavioral|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura & McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction & flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
79371603|NCT03371667|Drug|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
79824018|NCT02574650|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
79371604|NCT03371667|Drug|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
79371605|NCT01024738|Drug|Fluoride|Brush half mouth twice daily for four days.
79371606|NCT01024738|Drug|Triclosan, fluoride|Brush twice daily
79371607|NCT01024738|Drug|Chlorhexidine Gluconate|Rinse mouth twice a day
79371608|NCT04279041|Procedure|root canal preparation|root canal preparation
79525173|NCT04501120|Drug|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
79525174|NCT04501120|Drug|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
79525175|NCT04501120|Drug|standard-dose HHT|2mg/m^2 IV QD on Days 1-7 (28-day cycle).
79525176|NCT04501120|Drug|Azacitidine|75 mg/m^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
79525177|NCT04501120|Drug|APG-2575|APG-2575 orally once daily for 14 days, every 28 days as a cycle.
79371609|NCT01024972|Drug|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
79371610|NCT01024972|Drug|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
79371611|NCT03370809|Radiation|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
79371612|NCT05686395|Procedure|Ultrasound-guided Interscalene Block group|ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
79525178|NCT04477317|Drug|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
79525179|NCT04477317|Drug|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
79525180|NCT04434196|Drug|CC-99282|CC-99282
79680479|NCT02924259|Device|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
79998738|NCT01337531|Drug|Gonal-F, Fostimon|injection, daily, 10-15 days
80016617|NCT03660579|Other|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
79525181|NCT04434196|Drug|Obinutuzumab|Obinutuzumab
79525182|NCT04426461|Behavioral|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
79525183|NCT04426461|Behavioral|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
79525184|NCT04426461|Behavioral|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
79525185|NCT04416191|Other|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
79680480|NCT02944916|Device|IryPump R Set|
79680481|NCT02924454|Drug|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
79680482|NCT02924454|Drug|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
79824019|NCT04072094|Procedure|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
79824020|NCT04072094|Procedure|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
79525186|NCT04415931|Procedure|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
79998739|NCT03572114|Diagnostic Test|3Tesla MRI|"A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~conventional FLAIR sequence"
79371613|NCT05686395|Procedure|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
79371614|NCT05686395|Drug|Bupivacaine|bupivacaine 0.25%.
79371615|NCT01025830|Drug|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
79371616|NCT01025830|Drug|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
79371617|NCT03081039|Drug|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
79525187|NCT04415931|Procedure|Interscalene block|Standard interscalene brachial plexus regional block
79525188|NCT04410380|Behavioral|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
79525189|NCT04395430|Behavioral|Usual Care|"Participants will receive standard care which consist of the following:~a lifestyle counseling visit~educational materials~goal-setting by a healthcare professional, and~information about general weight management resources.~weighing scale and measuring tape with instructions to use~fitness tracker"
79680483|NCT02924454|Drug|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
79680484|NCT02924454|Drug|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
79680485|NCT04692038|Device|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
79680486|NCT02924337|Drug|Placebo|
79680487|NCT02924337|Drug|Imeglimin|
79680488|NCT02924337|Drug|Moxifloxacin|
79680489|NCT00528515|Drug|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
79680490|NCT00528515|Drug|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
79680491|NCT02923986|Drug|BP1001 (varying dose)|BP1001 (varying dose)
79680492|NCT02923986|Drug|BP1001 (fixed dose)|BP1001 (fixed dose)
79371618|NCT03081039|Drug|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
79371619|NCT03081039|Drug|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
79371620|NCT01026844|Drug|erlotinib|Taken orally once a day
79824021|NCT02577848|Drug|GLP-1|GLP-1 were taken daily for 7 days
79371621|NCT01026844|Drug|hydroxychloroquine|Taken orally once a day
79998740|NCT03572114|Behavioral|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
79998741|NCT03572114|Behavioral|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
79371622|NCT04278963|Drug|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
79371623|NCT04278963|Drug|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
79680493|NCT02923986|Drug|Dasatinib|Dasatinib
79680494|NCT00528554|Procedure|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
79680495|NCT00528554|Procedure|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
79680496|NCT02926248|Drug|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
79680497|NCT02926248|Other|Placebo|
79680498|NCT02945735|Behavioral|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
79680499|NCT02924025|Behavioral|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
79680500|NCT00528593|Drug|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
79824022|NCT02577848|Drug|Placebo|Placebo were taken daily for 7 days
79824023|NCT00582426|Drug|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
79998742|NCT03572114|Behavioral|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
79229105|NCT02267031|Procedure|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
79229106|NCT02264301|Drug|Puerarin injection 400 mg|
79229107|NCT02264301|Drug|Qingkailing injection 40 ml|
79525190|NCT04395430|Behavioral|online KKH Sports Singapore Program with Usual Care|"Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes)."
79525191|NCT04333875|Device|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
79525192|NCT04330638|Other|Usual Care|Usual Care
79525193|NCT04330638|Drug|Anakinra|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
79525194|NCT04330638|Drug|Siltuximab|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
79525195|NCT04330638|Drug|Tocilizumab|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
79525196|NCT04325321|Other|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
79680501|NCT00528632|Other|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
79680502|NCT02926326|Drug|BCT197|A single dose of BCT197
79680503|NCT02926326|Drug|Azithromycin|3 daily doses of Azithromycin
79680504|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
79371624|NCT04278963|Other|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
79371625|NCT04278963|Other|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
79525197|NCT04322006|Drug|TJ004309|Antibody to CD73
79998743|NCT03572114|Behavioral|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
79525198|NCT04322006|Drug|Toripalimab|Humanized monoclonal antibody to PD-1
80016618|NCT01318915|Drug|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
79229108|NCT02267109|Biological|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
79229109|NCT02267109|Biological|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
79229110|NCT05596838|Procedure|Intracorneal rings placement|Intracorneal rings placement in keratoconus using laser
79229111|NCT01487109|Drug|CTP-499|600 mg tablet twice daily
79229112|NCT01487109|Drug|Placebo|Matching placebo tablet
79229113|NCT02465918|Device|motor cortex stimulation (Change of Stimulation Timing)|
79371626|NCT00979732|Dietary Supplement|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
79371627|NCT00979732|Dietary Supplement|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
79371628|NCT03368781|Device|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
79680505|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
79680506|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
79680507|NCT02924103|Device|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
79680508|NCT00528710|Dietary Supplement|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
79229114|NCT04476069|Drug|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
79229115|NCT04475913|Other|DIG Axial|patients received 4 axial implants and digital impression
79229116|NCT04475913|Other|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
79371629|NCT03353181|Device|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
79371630|NCT03353181|Device|Biliary stent|Standard placement of biliary stent
79229117|NCT04475913|Other|CIG Axial|patients received 4 axial implants and conventional impression
79371631|NCT05686239|Drug|RL-007|investigational study drug
79229118|NCT04475913|Other|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
80016619|NCT01318915|Drug|Rituximab|375 mg/m^2 IV infusion on day -6 before transplant and on day 1 after transplant.
79229119|NCT05627973|Device|Aortic Valve Replacement|Surgical replacement of aortic valves
79229120|NCT02464826|Drug|Nailprotex|Nailprotex apply to the abnormal nail twice daily
79371632|NCT05686239|Drug|Placebo|placebo capsules matching the appearance and size of the active drug
79371633|NCT05686161|Biological|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
79371634|NCT05686161|Biological|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
79371635|NCT05686161|Biological|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
79371636|NCT03368313|Device|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
79371637|NCT04279743|Dietary Supplement|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
79371638|NCT04279743|Dietary Supplement|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
79371639|NCT03345615|Diagnostic Test|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
79371640|NCT03345537|Other|Non interventional study|Non interventional study - only data collected and one blood sample additional
79371641|NCT03344913|Behavioral|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
79371642|NCT03321981|Drug|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
79371643|NCT03321981|Drug|Trastuzumab|humanised IgG1 monoclonal antibody
79371644|NCT03321981|Drug|Vinorelbine|antineoplastic drug of vinca alkaloid family
79229121|NCT02464670|Biological|INO-4201|INO-4201 delivered IM followed by Electroporation
79229122|NCT02464670|Biological|INO-4202|INO-4202 delivered IM followed by Electroporation
79229123|NCT02464670|Biological|INO-4201|INO-4201 delivered ID followed by Electroporation
79229124|NCT02464670|Biological|INO-4212|INO-4212 delivered IM followed by Electroporation
79229125|NCT02464670|Biological|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
79229126|NCT02464670|Biological|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
79229127|NCT02267265|Other|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
79229128|NCT02267265|Other|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
79229129|NCT01481571|Device|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
79998744|NCT04563611|Other|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
79525199|NCT04315610|Other|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
79680509|NCT02926443|Other|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
79371645|NCT03321981|Drug|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
79525200|NCT04315610|Other|Treatment as usual|Active comparator group, based on traditional information and follow-up.
79525201|NCT04304131|Diagnostic Test|Earlytect Colon Cancer|A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
79525202|NCT04298879|Drug|IBI376|IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
79525203|NCT04298554|Other|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
79998745|NCT04563611|Other|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
79229130|NCT05529758|Behavioral|Internalized Weight Bias Intervention|ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, & Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, & Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
79229131|NCT01124565|Drug|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
79371646|NCT05685693|Procedure|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
79525204|NCT04298554|Other|Hemp Oil|CBD PURE HEMP OIL
79525205|NCT04291521|Drug|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
79525206|NCT04291521|Drug|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
79525207|NCT04291521|Drug|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
79525208|NCT04280601|Dietary Supplement|vitamin D|Patients with insufficient and/or deficient vitamin D status (<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
79525209|NCT04271501|Procedure|Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)|Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
79525210|NCT04271501|Device|RECELL 1:5 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
79525211|NCT04271501|Device|RECELL 1:10 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
79525212|NCT04271501|Device|RECELL 1:20 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
79525213|NCT04266964|Procedure|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
79525214|NCT04264013|Behavioral|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
79525215|NCT04264013|Behavioral|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
79525216|NCT04263064|Drug|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
79525217|NCT04263064|Drug|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
79680510|NCT02926443|Other|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
79998746|NCT04563611|Other|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
79998747|NCT04563611|Other|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
79525218|NCT04261751|Other|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
79680511|NCT00528749|Other|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
79824024|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
79229132|NCT02465840|Procedure|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
79680512|NCT02924142|Device|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
79229133|NCT02465840|Procedure|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
79229134|NCT02465840|Other|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
79371647|NCT05685693|Procedure|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
79371648|NCT01027468|Drug|Bevacizumab|intraocular bevacizumab injection
79525219|NCT04258449|Device|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
79680513|NCT02945462|Biological|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
79680514|NCT00528827|Drug|Cardene® I.V.|"5 mcg/kg/min Cardene I.V.~2.5 mcg/kg/min Cardene I.V.~0.5 mcg/kg/min Cardene I.V."
79680515|NCT02926170|Drug|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
79680516|NCT02926170|Drug|acenocumarol|Doses will be adjusted according to INR
79680517|NCT04691765|Drug|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
80016620|NCT01318915|Drug|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
79229135|NCT01123785|Drug|INO-8875|eye drops for 14 days in one eye
79229136|NCT01123785|Drug|Placebo|Matched vehicle-control
79229137|NCT01293669|Drug|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
79525220|NCT04249466|Other|Questionnaire|"During this consult, several parameters will be measured :~nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
79525221|NCT04248764|Other|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
79525222|NCT04248764|Other|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
79680518|NCT04689204|Drug|CTA30X|CTA30X cell injection by intravenous infusion
79680519|NCT04691687|Drug|Furosemide|IV loop diuretic therapy
79680520|NCT04691687|Drug|IV Solution|IV Placebo comparator
79680521|NCT02923908|Other|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
79680522|NCT02923908|Other|Voice Recording|A voice recording will be made for the duration of the tasting period.
79680523|NCT02923908|Other|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
79680524|NCT02923908|Other|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
79680525|NCT04110327|Device|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Perihperal Vascular Stent System
79680526|NCT04049175|Drug|Treatment A|Tablet of CHF 6532
79680527|NCT04049175|Drug|Treatment B|Tablet of CHF 6532
79680528|NCT04049175|Drug|Treatment C|Tablet of CHF 6532
79680529|NCT04049175|Drug|Treatment D|Tablet of CHF 6532 placebo
79680530|NCT02926131|Other|Blood sampling|"One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
79824025|NCT02574572|Biological|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
79824026|NCT02575898|Other|First Session|Creative Practice and Positive Re-enforcement
79229138|NCT01293669|Drug|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
79680531|NCT04692311|Device|an intelligent client-centred task-oriented training|3 x 45min of training with i-ACT system
79680532|NCT04692311|Other|Semi-structured interview|Participants, patients and therapists, were invited to a semi-structured interview after training period.
79680533|NCT02923869|Drug|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
79680534|NCT02923869|Drug|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
79824027|NCT02575898|Other|Second Session|Disease Related
79824028|NCT02575898|Behavioral|Third through Sixth Sessions|Life Review and Legacy
79824029|NCT04019184|Drug|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
79998748|NCT02240420|Behavioral|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
79998749|NCT04508855|Drug|Low molecular weight heparin|Switch from direct oral anticoagulants to low molecular weight heparin
79229139|NCT02465762|Device|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
79229140|NCT02465684|Procedure|unicondylar knee arthroplasty|
79371649|NCT01027780|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
79371650|NCT05102799|Other|No intervention|No intervention
79371651|NCT05395156|Device|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
79525223|NCT04231669|Behavioral|Anzansi Family Program|"the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention."
79525224|NCT04228107|Device|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
79680535|NCT00528905|Drug|AZD3480|oral capsule
79680536|NCT02923791|Biological|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
79680537|NCT02923791|Biological|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
79680538|NCT02926092|Diagnostic Test|Observation|Observation of progression of disease over time
79680539|NCT00527462|Procedure|Bronchoscopy|bronchoscopy with segmental allergen challenge
79824030|NCT04019184|Drug|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
79824031|NCT00709982|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
79998750|NCT03575078|Drug|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
79998751|NCT02259842|Drug|BI 34021 FU2 solution|
79998752|NCT02259842|Drug|BI 34021 FU2 tablet|dose group 4 only
79998753|NCT02259842|Drug|Placebo|
79998754|NCT02259842|Other|High fat, high calorie breakfast|only for dose groups 3 and 5
79998755|NCT03377036|Diagnostic Test|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
79998756|NCT03377036|Diagnostic Test|2D-FFDM|2D full-field digital mammography
79229141|NCT01480479|Drug|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
79229142|NCT01480479|Drug|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
79680540|NCT00527462|Other|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
79680541|NCT04689243|Procedure|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
79680542|NCT04689243|Procedure|red light|red light, 3 times a week.
79229143|NCT01480479|Drug|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
79680543|NCT00527540|Drug|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
79680544|NCT02926053|Procedure|Surgical removal of tumor tissue for T cell production|Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
79680545|NCT02926053|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
79680546|NCT02926053|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
79680547|NCT02926053|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
79680548|NCT02926053|Drug|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
79680549|NCT00527579|Drug|[F-18]FBR|
79680550|NCT00527657|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
79680551|NCT00527657|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
79680552|NCT00527657|Drug|Thalidomide|200 mg/m^2 by mouth daily.
79824032|NCT02387970|Procedure|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
79824033|NCT02387970|Procedure|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
79998757|NCT03572504|Other|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
79680553|NCT02925897|Behavioral|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
79229144|NCT01116141|Drug|CH-4051|Different doses CH-4051 to be compared
79229145|NCT01116141|Drug|Methotrexate (MTX)|20 mg MTX weekly
79371652|NCT03320343|Other|MRI|3D morphological MRI and diffusion tensor imaging
79371653|NCT05395000|Behavioral|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
79371654|NCT05395000|Behavioral|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
79998758|NCT03157583|Other|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
79525225|NCT04215692|Diagnostic Test|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
79998759|NCT03157583|Other|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
79371655|NCT05395000|Behavioral|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
79525226|NCT04210778|Behavioral|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
79525227|NCT04210778|Behavioral|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
79525228|NCT04208048|Device|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
79824034|NCT02387970|Device|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
79824035|NCT02387970|Device|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
79998760|NCT03157583|Other|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
79229146|NCT01116141|Drug|Folic Acid|1 mg folic acid daily
79229147|NCT01287585|Drug|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
79824036|NCT00710060|Behavioral|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
79824037|NCT00710060|Behavioral|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
79824038|NCT04070690|Procedure|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
79229148|NCT01287585|Drug|Placebo|weekly, intramuscular, until disease progression or toxicity.
79229149|NCT01287585|Other|Best Supportive Care|treatment of disease-related symptoms throughout the study.
79229150|NCT01284387|Biological|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
79525229|NCT04204135|Procedure|LLIF or ALIF procedures|LLIF or ALIF procedures
79525230|NCT04194541|Device|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
79680554|NCT00528983|Drug|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
79680555|NCT00528983|Drug|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
79680556|NCT00528983|Drug|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
79680557|NCT02923752|Device|MRI|Contrast-enhanced MRI
79371656|NCT04278807|Procedure|Regional Anesthesia - Nerve Blocks|Regional Anesthesia and ultrasound-guided nerve blocks
79371657|NCT00980278|Procedure|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
79525231|NCT04194541|Device|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
79680558|NCT00529022|Drug|Azacitidine|75 mg/m^2 Subcutaneous Injection or by vein Daily for 5 Days.
79680559|NCT00529022|Drug|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
79680560|NCT00529022|Drug|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
79680561|NCT02923596|Procedure|History of prior Surgery|History of prior Surgery will be reviewed
79680562|NCT02923596|Radiation|History of Radiation Therapy|History of prior radiation therapy will be reviewed
79680563|NCT00527696|Procedure|transvaginal obturator tape|
79680564|NCT02923557|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
79680565|NCT02923635|Procedure|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
79680566|NCT02923635|Procedure|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
79680567|NCT00529139|Device|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
79229151|NCT02264457|Device|T-flex Aspheric Toric IOL|
79229152|NCT02264457|Device|AT TORBI toric IOL|
79229153|NCT01280565|Drug|Masitinib|Masitinib 7.5 mg/kg/day
79229154|NCT01280565|Drug|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
79229155|NCT04476147|Other|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
79680568|NCT00529139|Device|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. <90 mg/dL (<15 mmol/L)
79680569|NCT02925975|Drug|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
79229156|NCT01113957|Drug|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
79229157|NCT01113957|Drug|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
79229158|NCT01113957|Drug|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
79229159|NCT01111773|Drug|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
79371658|NCT00980278|Biological|Aastrom BRCs|sinus augmentation, BRC application, dental implant
79371659|NCT03344211|Drug|Enzalutamide|Given PO
79371660|NCT03344211|Other|Laboratory Biomarker Analysis|Correlative studies
79371661|NCT03344211|Radiation|Radium Ra 223 Dichloride|Given IV
79525232|NCT04194541|Device|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
79525233|NCT04190706|Other|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
79525234|NCT04190706|Other|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
79525235|NCT04185532|Other|Rebound ACL brace and physioterapy|Usage of rebound ACL brace and physioterapy supervised by physioterapist
79525236|NCT04185532|Other|Physioterapy|Physioterapy supervised by physioterapist
79680570|NCT02925975|Device|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
79680571|NCT02925975|Procedure|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
79680572|NCT00527813|Procedure|prone position|prone position for at least 16 hours per day
79680573|NCT02925936|Other|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
79680574|NCT02925936|Other|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
79680575|NCT00527852|Device|Flocked swab|
79680576|NCT04692428|Procedure|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
79680577|NCT04259892|Biological|2019-nCoV PCR|Nasopharyngeal swabs
79680578|NCT02945033|Drug|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
79680579|NCT02945033|Drug|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
79680580|NCT02945033|Procedure|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
79680581|NCT02945033|Biological|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
79680582|NCT02945033|Biological|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
79680583|NCT02945111|Behavioral|Real-time view|
79680584|NCT02945111|Behavioral|No visual support|
79680585|NCT04256967|Other|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
79229160|NCT04339959|Other|Remote Assessment of Physical Function with Direct Observation|An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up & Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
79229161|NCT04339959|Other|Remote Assessment of Physical Function|An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up & Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
79525237|NCT04153396|Drug|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
79229162|NCT01103037|Drug|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
79998761|NCT03157583|Other|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
79229163|NCT01103037|Drug|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
79680586|NCT02944760|Other|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
79998762|NCT03157583|Other|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
79680587|NCT02923518|Other|Questionnaire|Observational study without any intervention described under intervention type
79680588|NCT02923479|Device|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
79680589|NCT02923479|Other|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
79371662|NCT05394454|Procedure|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
79680590|NCT02923479|Other|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
79680591|NCT02923479|Device|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
79680592|NCT02923479|Device|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
79680593|NCT02944838|Behavioral|Senior Change Makers Advocacy Program|see description
79680594|NCT02944838|Behavioral|Senior Change Makers Physical Activity Program|see description
79371663|NCT03274401|Device|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
79371664|NCT03274401|Device|5 day ECG patch|Selection of device for monitoring clinicians' choice
79371665|NCT05086107|Drug|BV100|Rifabutin for infusion
79680595|NCT00529256|Behavioral|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
79998763|NCT03157583|Other|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
79998764|NCT03157583|Other|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
79371666|NCT05085015|Other|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
79229164|NCT01280331|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
79229165|NCT01280331|Drug|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
79229166|NCT01280331|Drug|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
79229167|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
79525238|NCT04153396|Drug|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
79998765|NCT03570710|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
79371667|NCT05085015|Other|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
79525239|NCT04148521|Behavioral|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
79525240|NCT04131309|Drug|Daratumumab|As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
79525241|NCT04131309|Drug|Bortezomib Injection|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
79525242|NCT04131309|Drug|Dexamethasone oral tablet|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
80016621|NCT01318915|Drug|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
79371668|NCT05075109|Device|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
79525243|NCT04119778|Behavioral|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
79525244|NCT04108767|Behavioral|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
80016622|NCT01318915|Drug|MMF|1 g twice daily on days 0 through 12
79229168|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
79229169|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
79229170|NCT01474083|Drug|Placebo|Dose-matched placebo. Oral administration.
79229171|NCT01266525|Drug|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
79229172|NCT01266525|Drug|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
79229173|NCT01266525|Drug|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
79229174|NCT01472991|Drug|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
79229175|NCT01472991|Drug|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
79229176|NCT01472991|Drug|Placebo|Placebo capsules will be taken once daily for 4 weeks
79229177|NCT01266135|Drug|QAX576|QAX576 10 mg/kg intravenous infusion
79371669|NCT05075109|Device|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
79998766|NCT03570710|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
79229178|NCT01266135|Drug|Placebo|Placebo to QAX576 intravenous infusion
79525245|NCT04100486|Other|Standing-Squatting-Standing Test|The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
79525246|NCT04100486|Other|Deep Breathing Test|The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
79525247|NCT04100486|Other|Cold Pressor Test|The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
79525248|NCT04100486|Other|Cold Face Test|The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
79680596|NCT00529295|Drug|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
79229179|NCT01265901|Drug|Sunitinib|As per label.
79525249|NCT04100486|Other|Valsalva Maneuver|The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
79525250|NCT04100486|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
79525251|NCT04078594|Other|sepsis e-alert|At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
79525252|NCT04077970|Biological|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
79525253|NCT04067427|Other|Mental training|App-based mental training
79525254|NCT04056221|Other|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
79525255|NCT04056221|Other|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
79525256|NCT04040959|Drug|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
79525257|NCT04035031|Drug|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
79525258|NCT04035031|Drug|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
79525259|NCT04018638|Other|B-FREE|Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
79525260|NCT04014907|Procedure|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
79525261|NCT04006392|Device|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
79525262|NCT04006392|Device|Placebo Laser|Non-therapeutic output.
79680597|NCT00529334|Radiation|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
79680598|NCT04218903|Behavioral|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
79229180|NCT01265901|Biological|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
79229181|NCT01265901|Drug|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
79229182|NCT01265901|Drug|IMA901|Intradermal vaccinations with IMA901 vaccine.
79229183|NCT02267499|Other|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
79229184|NCT05627505|Diagnostic Test|metagenomic next-generation sequencing|Collection of bronchoalveolar lavage fluid
79525263|NCT04000568|Other|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
79824039|NCT03086850|Behavioral|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~<6000 steps/day: increase by 3000 steps/day~6000 - 10000 steps/day: reach 10000 steps/day~> 10000 steps/day: maintain or increase steps"
79371670|NCT05075109|Other|Task Related Training|"Each session of TRT would include:~1. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~Reaching activities~Forward supported reach with cane on tabletop~Reaching against gravity~Reaching overhead with active wrist/hand movements~Dynamic reaching to target e.g. catch a ball~Grasping, holding and release~Grasp, hold and release objects with gravity minimized~Pick up and move/release small objects on table~Pick up and move/release large objects without proximal support~Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~Upper limb ADL~Brushing hair, putting on scarf~Opening bottles, turning off water tap~Writing, drawing~Folding of towels, hanging towels and setting table~Self-feeding"
79824040|NCT03086850|Other|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
79824041|NCT00710138|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
79824042|NCT04072172|Device|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
79824043|NCT00580034|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
79229185|NCT05627427|Drug|Surufatinib|250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
79229186|NCT05627427|Drug|Sintilimab|200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
79229187|NCT02267733|Drug|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
79229188|NCT02264535|Drug|0.1mg/ml Ginkgolides Meglumine Injection|
79229189|NCT02264535|Drug|1mg/ml Ginkgolides Meglumine Injection|
79229190|NCT02264535|Drug|5mg/ml Ginkgolides Meglumine Injection|
79229191|NCT02264613|Drug|ALRN-6924|ALRN-6924 will be administered as an IV infusion
79229192|NCT02267889|Procedure|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
79229193|NCT02267889|Device|D-SPECT dedicated cardiac nuclear camera|
79229194|NCT01850082|Procedure|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
79229195|NCT01463397|Drug|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
79229196|NCT01463397|Drug|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
79525264|NCT03997617|Diagnostic Test|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
79998767|NCT03570710|Drug|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
79229197|NCT05231382|Procedure|Raltitrexed, oxaliplatin (SALOX) treatment|Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment
79229198|NCT05231382|Procedure|Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment|Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
79229199|NCT05627037|Device|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
79371671|NCT01029730|Drug|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
79998768|NCT01315379|Behavioral|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
79525265|NCT03959423|Device|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
79525266|NCT03934697|Behavioral|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
79525267|NCT03907462|Behavioral|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
79229200|NCT05627037|Device|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
79824044|NCT00580034|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
79824045|NCT00710216|Drug|Lamivudine|100 mg/day
79824046|NCT00710216|Drug|Telbivudine|600 mg/day
79229201|NCT03949140|Procedure|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
79229202|NCT02267967|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
79229203|NCT01262235|Drug|TKM-080301|Repeat dose IV infusion.
79998769|NCT01337765|Drug|BEZ235 + MEK162|
79229204|NCT01262001|Drug|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
79229205|NCT01262001|Drug|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
79229206|NCT05161026|Other|Bone osteodensitometry|Evaluation of bone osteodensitometry
79229207|NCT01100151|Drug|RDC-1036 (ALKS 37)|Capsules for oral administration
79229208|NCT01100151|Drug|Placebo|Capsules for oral administration
79229209|NCT01460511|Drug|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
79229210|NCT01460511|Drug|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
79525268|NCT03900910|Other|Gastric cancer prevention|Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
79525269|NCT03900910|Other|Execution of the program|Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
79525270|NCT03879304|Other|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
79525271|NCT03879304|Other|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
79680599|NCT04218903|Behavioral|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
79680600|NCT02945306|Procedure|Adenotonsillectomy|
79680601|NCT02945306|Drug|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
79525272|NCT03869957|Dietary Supplement|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
79525273|NCT03860285|Other|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
79680602|NCT02945618|Device|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
79680603|NCT02945618|Other|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
79680604|NCT02922933|Drug|entinostat|HDAC (histone deacetylase inhibitor)
79680605|NCT02922933|Dietary Supplement|Omeprazole|Proton pump inhibitor
79680606|NCT02922933|Dietary Supplement|Famotidine|Histamine-2 blocker
79229211|NCT01458405|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
79525274|NCT03852147|Procedure|: hemodynamic management|"Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.~Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine."
79824047|NCT02575820|Procedure|Old red blood cells transfusion|Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
79824048|NCT02575820|Procedure|New red blood cells transfusion|Red blood cells (shelf life =< 14 days) transfusion during the operation (total hip replacement arthroplasty)
79824049|NCT02577692|Other|Oxygen|breathing oxygen
79824050|NCT02577692|Other|Ambient|breathing ambient air
79824051|NCT03913598|Other|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
79824052|NCT00710294|Device|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
79824053|NCT00710372|Biological|CYT006-AngQb|s.c. injection
79824054|NCT00773513|Drug|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
79998770|NCT01334489|Device|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
79998771|NCT02842736|Device|Cerene(R) Cryotherapy Device|
79371672|NCT01029730|Drug|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
79229212|NCT01458405|Drug|Placebo|Single, blinded, intracoronary infusion of a placebo solution
79371673|NCT01029730|Drug|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
79371674|NCT05552235|Device|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
79525275|NCT03844607|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
79525276|NCT03844607|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
79680607|NCT00529412|Other|Seprafilm|two sheets per body
79680608|NCT00529490|Drug|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
79998772|NCT01307033|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
79680609|NCT00529490|Drug|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
79680610|NCT02923089|Other|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79680611|NCT02923089|Other|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79998773|NCT01307033|Drug|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
79998774|NCT01307033|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
79229213|NCT03135171|Drug|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
79229214|NCT03135171|Drug|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
79525277|NCT03835065|Procedure|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
79525278|NCT03835065|Other|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
79680612|NCT02923089|Other|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79998775|NCT01307033|Drug|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
79998776|NCT02844920|Device|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
79998777|NCT04446143|Behavioral|Mindfulness meditation|Mindfulness meditation
79998778|NCT02244398|Other|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
79998779|NCT02244398|Other|FP services|VHTs in the control arm only provide family planning services
79998780|NCT04475705|Drug|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
79998781|NCT04475705|Drug|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
79229215|NCT03135171|Drug|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
79229216|NCT01449591|Drug|BFH772 1% ointment|
79229217|NCT01449591|Drug|Vehicle ointment|
79229218|NCT01449591|Drug|Noritate® 1% cream|
79229219|NCT04475445|Other|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
79229220|NCT04475445|Other|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
79371675|NCT05552235|Other|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
79371676|NCT05066997|Drug|Active treatment arm: OCS-01 (dexamethasone)|The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit
79371677|NCT05066997|Drug|Vehicle|The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit
79525279|NCT03835065|Other|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
79824055|NCT00773513|Drug|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
80016623|NCT04508842|Biological|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
80016624|NCT04688177|Device|Body Composition|The subjects should lie in the supine position on a non-conducting surface for 5 min. 4 surface electrodes with cables will be attached to the right hand and ankle of subjects.
79229221|NCT00909753|Drug|Ursodiol|Ursodiol Tablets, 500 mg
79229222|NCT00909753|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
79371678|NCT05345535|Other|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
79371679|NCT05345535|Other|Walking|45 minutes of moderate tempo walking
79998782|NCT03569150|Other|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
79998783|NCT03158311|Drug|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
79998784|NCT03158311|Drug|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
79998785|NCT01331915|Biological|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
79371680|NCT03273621|Procedure|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
79371681|NCT05025033|Drug|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
79525280|NCT03801837|Dietary Supplement|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts [15% of daily calories or 30-45 grams based on kcal requirement of the individual]
79525281|NCT03801837|Dietary Supplement|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
79525282|NCT03790150|Other|Evidence-based practices|Implementation of evidence-based practices
79525283|NCT03786783|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79525284|NCT03786783|Drug|Carboplatin|Given IV
79680613|NCT02923089|Other|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79680614|NCT02923089|Other|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79680615|NCT02923089|Other|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79680616|NCT02923089|Other|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79824056|NCT00773513|Drug|Epoetin Beta|Epoetin beta will be administered as per approved label.
79998786|NCT02244866|Drug|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
79998787|NCT02244866|Drug|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
79371682|NCT00980746|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
79371683|NCT00980746|Drug|Placebo|oral route
79229223|NCT01444365|Drug|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
79229224|NCT01444365|Drug|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
79371684|NCT05424783|Other|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
79371685|NCT02984631|Procedure|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
79525285|NCT03786783|Drug|Cisplatin|Given IV
79525286|NCT03786783|Drug|Cyclophosphamide|Given IV
79525287|NCT03786783|Drug|Dexrazoxane|Given IV
79525288|NCT03786783|Biological|Dinutuximab|Given IV
79525289|NCT03786783|Drug|Doxorubicin|Given IV
79525290|NCT03786783|Drug|Etoposide|Given IV
79525291|NCT03786783|Radiation|External Beam Radiation Therapy|Undergo EBRT
79525292|NCT03786783|Drug|Isotretinoin|Given PO
79525293|NCT03786783|Drug|Melphalan|Given IV
79680617|NCT02923089|Other|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79680618|NCT02923089|Other|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
79824057|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
79525294|NCT03786783|Biological|Sargramostim|Given SC
79525295|NCT03786783|Drug|Thiotepa|Given IV
79525296|NCT03786783|Drug|Topotecan|Given IV
79525297|NCT03786783|Drug|Vincristine|Given IV
79525298|NCT03785587|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
79525299|NCT03761680|Dietary Supplement|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
79525300|NCT03761680|Dietary Supplement|Control Intervention|Patients receive ONS between meals or at their request as usual
79680619|NCT00527891|Procedure|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
79824058|NCT00710528|Drug|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
79824059|NCT04070612|Other|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
79824060|NCT00711074|Drug|AZD5672|single dose 200mg aqueous solution
79824061|NCT02574416|Other|There is no intervention|The study is observational and there is no intervention
79824062|NCT00711152|Other|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
79824063|NCT00711152|Other|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
79824064|NCT00711230|Biological|DermaVir|
79824065|NCT00711230|Biological|Placebo|glucose/dextrose
79824066|NCT00711308|Drug|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
79824067|NCT00711308|Drug|acenocoumarol|acenocoumarol for 6 months
79998788|NCT01334567|Drug|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
79229225|NCT03991377|Behavioral|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history.~Patient preparation.~Patient assessment.~Memory desensitization.~Installing the positive cognition.~Body scan.~Closure.~Reevaluation."
79229226|NCT03991377|Drug|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
79680620|NCT02923050|Behavioral|Simple Suppers|Theory-based 10-week family meals program
79680621|NCT02945267|Drug|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
79680622|NCT02945267|Drug|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
79998789|NCT03570398|Other|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
79998790|NCT03570398|Other|abdominal ultrasound|abdominal ultrasound
79229227|NCT01442337|Drug|ASP8597|one time IV dose
79998791|NCT01337843|Other|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
79998792|NCT01337843|Other|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
79998793|NCT04398329|Drug|HTX-034|HTX-034, low dose
79998794|NCT04398329|Drug|HTX-034|HTX-034, high dose
79229228|NCT01442337|Drug|Placebo|one time IV dose
79229229|NCT01098435|Drug|RDC-0313 (ALKS 33)|Capsules for daily oral administration
79229230|NCT01098435|Drug|Placebo|Capsules containing lactose and no active drug for daily oral administration
79229231|NCT05626959|Drug|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
79229232|NCT00909597|Drug|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
79229233|NCT00909597|Drug|taspoglutide|10mg sc once weekly
79229234|NCT00909597|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
79680623|NCT02926014|Device|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
79824068|NCT02601911|Drug|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
79998795|NCT04398329|Device|Luer lock applicator|Applicator for instillation
79824069|NCT02601911|Drug|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
79824070|NCT02601911|Other|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
79824071|NCT00711386|Drug|GSK706769|50mg, 100mg, 200mg, or 400mg
79824072|NCT00711386|Other|Placebo|Placebo
79824073|NCT04101773|Procedure|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
79824074|NCT00711542|Biological|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
79824075|NCT00711542|Biological|placebo medium|intracoronary infusion of placebo medium
79998796|NCT04398329|Drug|Bupivacaine HCl|Bupivacaine HCl, 50 mg
79998797|NCT00449111|Drug|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
79998798|NCT03568916|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
80016625|NCT04688177|Device|Heart rate variability|After supine quietly for 20 min, a lead I electrocardiogram will be taken for 5 min.
79824076|NCT04104347|Other|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz & Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
79229235|NCT05626881|Drug|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
79229236|NCT05626881|Drug|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
79229237|NCT01094067|Drug|ACT-050089|5 mg/h intravenously, Tezosentan
79824077|NCT04104347|Other|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
79824078|NCT00711620|Drug|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
79998799|NCT03568916|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
79998800|NCT03568916|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
79525301|NCT03720080|Device|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
79229238|NCT01094067|Other|Placebo|Matching placebo
79229239|NCT01077297|Drug|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
79680624|NCT02926014|Other|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
79709694|NCT00594828|Device|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
79824079|NCT02577380|Behavioral|IPV/GBV HTC|Participants will be interviewed after receiving their services.
79824080|NCT02577614|Drug|FEIBA|Administration of FEIBA after cardiopulmonary bypass
80016626|NCT04688177|Device|Grip Strength|The participants will squeeze the hand dynamometer as hard as possible with the dominant hand. 3 successive measurements will be taken.
79229240|NCT05653245|Drug|RGD Peptide|adhesion molecules
79229241|NCT04766931|Drug|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
79229242|NCT04766931|Drug|FB2001 Placebo|Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
79229243|NCT00905385|Biological|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
79229244|NCT05379855|Drug|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
79229245|NCT05379855|Drug|placebo eye drops (0.9% preservative free sodium chloride)|placebo eye drops (0.9% preservative free sodium chloride)
79229246|NCT03731910|Diagnostic Test|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
79229247|NCT01070433|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
79229248|NCT01070433|Other|Standard of Care|Topical application twice a day
79229249|NCT03715764|Other|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
79525302|NCT03661073|Behavioral|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
79824081|NCT02577614|Drug|Normal Saline|Administration of placebo after cardiopulmonary bypass
79824082|NCT02577458|Drug|CM082|CM082 tablets taken orally once a day on 28-day cycles
79525303|NCT03661073|Behavioral|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
79525304|NCT03654833|Drug|Rucaparib|PARP inhibitor
79824083|NCT02577458|Drug|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
79824084|NCT00767039|Drug|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
79824085|NCT00767039|Drug|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
79824086|NCT01640522|Other|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
79824087|NCT01640522|Other|Enhanced usual Care|
79824088|NCT04071938|Other|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
79824089|NCT04071938|Other|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
79998801|NCT01334645|Other|Copeptin|"Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
79824090|NCT00662649|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
79229250|NCT03715764|Other|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
79229251|NCT00904683|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
79525305|NCT03654833|Drug|Abemaciclib|CDK4/6 inhibitor
79824091|NCT00662649|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
79998802|NCT03571880|Device|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
79998803|NCT03635593|Drug|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
79525306|NCT03654833|Drug|pembrolizumab & bemcentinib|PD1 checkpoint inhibitor, AXL inhibitor
79998804|NCT03635593|Drug|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
80016627|NCT04688177|Device|Exhale Carbon Monoxide Concentration|Subjects in sitting position, performing 1 inspiration, then exhale to carbon monoxide meter.
79525307|NCT03654833|Drug|Atezolizumab & Bevacizumab|PDL1 checkpoint inhibitor, VEGF inhibitor
79525308|NCT03654833|Drug|Dostarlimab and Niraparib|IG Antibody, PARP Inhibitor
79525309|NCT03653455|Behavioral|Email reminders|Patients will receive email reminders until their PROs are completed.
79525310|NCT03653455|Behavioral|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
79525311|NCT03653455|Behavioral|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
79229252|NCT00904683|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
79229253|NCT02718326|Drug|Intravitreal aflibercept injection [IAI]|
79229254|NCT02718326|Drug|Sham|
79229255|NCT03691584|Drug|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
79229256|NCT03691584|Procedure|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
79229257|NCT03683628|Procedure|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
79229258|NCT03683628|Drug|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
79525312|NCT03520751|Drug|scAAV1.tMCK.NTF3|gene vector
79525313|NCT03519451|Other|Internet-Based Intervention|Given KickAsh smartphone mobile application
79525314|NCT03519451|Other|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
79525315|NCT03519451|Other|Questionnaire Administration|Ancillary studies
79525316|NCT03432494|Device|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
79824092|NCT02577770|Device|acupuncture|therapeutic acupuncture treatment with actual needles
79824093|NCT02577770|Dietary Supplement|200mg caffeine|8g coffee, po
79824094|NCT02577770|Dietary Supplement|400mg caffeine|16g coffee, po
79824095|NCT02577770|Dietary Supplement|Decaffeinated|decaffeinated coffee, po
79824096|NCT00766493|Device|GORE® Embolic Filter|Embolic protection during carotid stenting
79824097|NCT00129896|Drug|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
79824098|NCT00129896|Drug|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
79824099|NCT00129896|Drug|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
79824100|NCT02602535|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
79824101|NCT02602535|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
79824102|NCT02574338|Device|Foley's Catheter|intracervical extraamniotic Foley's catheter
79824103|NCT02574338|Drug|prostaglandin E1 analogue|intravaginal misoprostol
79824104|NCT03070392|Biological|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
79824105|NCT03070392|Drug|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
79229259|NCT05160792|Device|Pressure monitoring system under compression bandages on index leg|Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
79525317|NCT03426904|Drug|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
79525318|NCT03426904|Drug|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
79525319|NCT03420482|Drug|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
79824106|NCT03070392|Biological|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
79824107|NCT03070392|Biological|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
79824108|NCT00711698|Procedure|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
79824109|NCT00711698|Drug|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
79824110|NCT00784043|Device|Cochlear Implant|Bilateral Implantation in children
79229260|NCT03470298|Procedure|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
79229261|NCT04009512|Device|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
79998805|NCT03635593|Other|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
79229262|NCT05527262|Behavioral|Queen Square Upper Limb Neurorehabilitation Programme|A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
79709695|NCT02270801|Drug|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
79709696|NCT04327713|Dietary Supplement|fish oil supplement|daily fish oil supplement vs. placebo
79709697|NCT01606163|Biological|GC1102|"Description: GC1102 IV bolus injection during 10~ 30 seconds.~Amount: group1-3ml, group2-5ml, group3-8ml~Subject number: group1-8, group2-8, group3-8~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
79824111|NCT02555241|Behavioral|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
79998806|NCT05213247|Device|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
79525320|NCT03420482|Drug|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
79525321|NCT03375827|Other|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
79709698|NCT01606163|Other|JW normal saline|"Description: Normal saline IV bolus injection through 10~ 30 seconds.~Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~Subject number: 9~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
79709699|NCT02892942|Drug|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
79709700|NCT02892942|Drug|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
79709701|NCT02892942|Drug|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
79229263|NCT05527262|Device|Immersive gaming therapy|The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
79680625|NCT02926014|Other|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
79824112|NCT02555241|Behavioral|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
79824113|NCT02555241|Behavioral|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
79824114|NCT04071548|Other|HIIT Exercise|"HIIT exercise bike protocol~3 minute warm up~Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~10x60 second Recovery period~5 minute cool-down"
79824115|NCT00789087|Procedure|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
79824116|NCT00789087|Procedure|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
79824117|NCT00711776|Drug|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
79824118|NCT00711776|Drug|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
79824119|NCT00795171|Drug|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
79824120|NCT00795171|Drug|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
79998807|NCT04373915|Behavioral|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
79998808|NCT03571490|Drug|Ropivacaine|Single shot of ropivacaine 0.325%
79824121|NCT00795171|Drug|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
79229264|NCT03891888|Procedure|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
79229265|NCT05160402|Drug|IGM-6268|Active comparator
79229266|NCT05160402|Drug|Placebo|Placebo comparator
79824122|NCT00711854|Drug|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
79824123|NCT00711854|Drug|Linezolid|Linezolid (600 mg IV or PO twice daily)
79824124|NCT00711854|Drug|Rifampicin|Rifampicin (600 mg IV or PO once daily)
79824125|NCT00795249|Behavioral|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
79824126|NCT00795327|Device|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
79229267|NCT05052086|Diagnostic Test|Magnetomotoric ultrasound|Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
79229268|NCT03468972|Drug|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria < 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
79824127|NCT00773279|Device|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
79824128|NCT00773279|Device|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
79824129|NCT05003882|Other|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
79824130|NCT00795405|Behavioral|Exposure to sporting events|Exposure to sporting events
79824131|NCT00795405|Behavioral|No exposure to sporting events|No exposure to sporting events
79824132|NCT02579304|Procedure|transbronchial lung cryobiopsy|bronchoscopic sampling
79824133|NCT04046211|Drug|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
79824134|NCT00712088|Behavioral|Project ICARE|Group-level intervention (Project ICARE)
79824135|NCT00712088|Behavioral|HCT|Offer of HIV counseling and testing
79824136|NCT02579226|Drug|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
79824137|NCT00795483|Drug|Zoledronic acid|Zoledronic Acid 5mg/year
79824138|NCT00795483|Behavioral|Lifestyle modifications|Lifestyle modifications
79998809|NCT03571490|Drug|Saline|Single shot of saline 0.9%
79998810|NCT05754801|Drug|Yunzhi Essence|Yunzhi Essence capsule
79998811|NCT05754801|Other|Placebo|Placebo capsules
79229269|NCT03468972|Other|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of <130/80 mmHg, and protein restriction diet. If proteinuria does not decrease < 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
79229270|NCT03468894|Behavioral|Treadmill desk walking|See intervention arm description
79371686|NCT05201157|Other|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
79371687|NCT05201157|Other|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
79371688|NCT00981214|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
79371689|NCT03308565|Biological|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
79824139|NCT00795483|Drug|Zoledronic acid|Zoledronic acid (5mg/2years)
79824140|NCT00712400|Drug|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
79824141|NCT00712400|Drug|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
79824142|NCT00766415|Drug|AZD1981|Oral tablet, twice daily, 4 weeks treatment
79824143|NCT00766415|Drug|Placebo|Placebo
79824144|NCT04071834|Diagnostic Test|ELISA|Detection of blood orphanin and norepinephrine in patients
79371690|NCT01031134|Behavioral|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
79680626|NCT00529607|Drug|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
79824145|NCT03015792|Drug|Dexamethasone|Given PO
79229271|NCT03471858|Device|Cervical balloon|To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
79229272|NCT03471858|Drug|Prostaglandins|Prostin will be used in the control arm.
79229273|NCT03600714|Drug|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
79229274|NCT03600714|Drug|Lonafarnib|Oral prenylation inhibitor
79371691|NCT01031134|Other|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
79371692|NCT05415657|Drug|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
79680627|NCT00529607|Procedure|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
79680628|NCT00529607|Procedure|cardiac MRI|before discharge and after 6 months
79680629|NCT00529607|Procedure|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
79680630|NCT02922972|Device|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
79680631|NCT00529646|Drug|APD791|
79824146|NCT03015792|Drug|Ibrutinib|Given PO
79824147|NCT03015792|Other|Laboratory Biomarker Analysis|Correlative studies
79824148|NCT03015792|Drug|Lenalidomide|Given PO
79824149|NCT03015792|Other|Pharmacological Study|Correlative studies
79824150|NCT03015792|Other|Quality-of-Life Assessment|Ancillary studies
79824151|NCT00789165|Drug|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
79824152|NCT00789165|Drug|no therapy|No therapy; this is not a placebo-controlled trial
79824153|NCT00712556|Radiation|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
79824154|NCT00795561|Procedure|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
79824155|NCT00795561|Procedure|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
79998812|NCT01331993|Drug|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
79824156|NCT00772967|Drug|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
79680632|NCT02922855|Behavioral|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
79998813|NCT01331993|Drug|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
79998814|NCT01331993|Drug|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
79998815|NCT03424694|Radiation|HDR brachytherapy as monotherapy|
79229275|NCT03600714|Drug|Ritonavir|Booster of lonafarnib action
79371693|NCT05415657|Drug|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
79371694|NCT03016234|Drug|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
79680633|NCT02922855|Behavioral|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
79680634|NCT02922855|Behavioral|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
79824157|NCT00772967|Drug|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
79824158|NCT00772967|Drug|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
79998816|NCT01340365|Behavioral|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
79998817|NCT01340365|Behavioral|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
79998818|NCT01337999|Other|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
79998819|NCT03571412|Device|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
79998820|NCT01341769|Other|Dietary Intervention|
79998821|NCT01341769|Other|Dietary Intervention|
79998822|NCT01341769|Other|Dietary Intervention|
79229276|NCT05493488|Biological|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
79680635|NCT04689321|Other|No intervention|This is not an interventional study.
79680636|NCT00527930|Drug|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
79998823|NCT01341769|Other|Dietary Intervention|
79998824|NCT04344431|Combination Product|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
79998825|NCT05709080|Other|family-professional collaboration practice model|Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
79998826|NCT05184127|Drug|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
79229277|NCT05493488|Biological|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
79229278|NCT05493488|Biological|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
79229279|NCT03112902|Device|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
79229280|NCT02720042|Device|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
79229281|NCT03471780|Diagnostic Test|ultrasound|Transperineal us are made to pregnant ladies in labour
79229282|NCT01352793|Biological|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
79680637|NCT00529841|Drug|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
79680638|NCT00529880|Drug|Fludarabine , cytarabine|
79680639|NCT02922504|Behavioral|Music intervention group|
79680640|NCT02922504|Behavioral|Controlled group|
79680641|NCT02944643|Other|Mindfulness and Support Groups|
79680642|NCT02925702|Drug|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
79680643|NCT00531089|Drug|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
79680644|NCT02922699|Drug|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
79680645|NCT02922699|Drug|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
79680646|NCT02944604|Drug|PEG-rhG-CSF|
79824159|NCT02363010|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
79229283|NCT01352793|Biological|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
79525322|NCT03362372|Behavioral|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
79680647|NCT02922660|Drug|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
79229284|NCT03470142|Procedure|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
79229285|NCT03470142|Procedure|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
79824160|NCT02363010|Behavioral|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
79998827|NCT05184127|Combination Product|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
79998828|NCT01338077|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
79371695|NCT03016234|Drug|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
79525323|NCT03361072|Dietary Supplement|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
79998829|NCT01338077|Drug|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
79680648|NCT02922660|Procedure|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
79680649|NCT02922660|Procedure|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
79998830|NCT03570320|Other|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
79998831|NCT01315561|Other|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
79998832|NCT04328129|Procedure|Human biological samples|"Blood sample~Nasopharyngeal swab."
79998833|NCT01336309|Behavioral|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
79680650|NCT02922660|Drug|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
79998834|NCT03571178|Other|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
79998835|NCT04266665|Drug|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
79229286|NCT03471702|Device|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
79229287|NCT03468738|Other|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
79229288|NCT04590014|Device|Control HVNI Device|During this session, patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
79680651|NCT02922660|Drug|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
79680652|NCT02276924|Device|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
79680653|NCT02922465|Drug|K-877|
79680654|NCT02922465|Drug|Clopidogrel|
79680655|NCT02944292|Procedure|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
79998836|NCT04266665|Other|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
79998837|NCT03571100|Drug|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
79680656|NCT02944292|Drug|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
79680657|NCT02922426|Drug|ALKS 3831|Daily dosing for 21 consecutive days
79824161|NCT02363010|Behavioral|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
79824162|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
79824163|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
79824164|NCT01419704|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
79824165|NCT00789243|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
79824166|NCT00712634|Biological|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
79824167|NCT00662259|Drug|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
79998838|NCT03571100|Drug|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
79998839|NCT01338311|Drug|salbutamol|200mcg twice daily for a total of 7 doses
79998840|NCT01338311|Drug|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
79824168|NCT00662259|Drug|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
79824169|NCT04070222|Other|Hysteroscopy|"Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~ART will be carried out with standard protocol and the clinical outcome will be recorded;~The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
79824170|NCT00712790|Drug|Sorafenib|Tablet, 400mg orally, twice daily
79998841|NCT01336387|Drug|retinoid 9cUAB30|Given PO
79998842|NCT01336387|Other|placebo|Given PO
79998843|NCT01336387|Other|pharmacological study|Correlative studies
79371696|NCT03695679|Behavioral|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~Perceived Susceptibility and Perceived Severity~Perceived Benefits and Perceived Barriers~Cue to Action~Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
79371697|NCT04353388|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
79680658|NCT02922426|Drug|Olanzapine|Daily dosing for 21 consecutive days
79680659|NCT02922426|Drug|Placebo|Daily dosing for 21 consecutive days
79680660|NCT04691921|Behavioral|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
79824171|NCT00712790|Radiation|SIR-Spheres|one time treatment and capped at 3.0 Gbq
79998844|NCT01336387|Other|laboratory biomarker analysis|Correlative studies
79998845|NCT01336387|Other|cancer prevention|Disease prevention
79998846|NCT01334879|Drug|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
79998847|NCT05354492|Other|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
79998848|NCT03570242|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
79998849|NCT01315795|Drug|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
79998850|NCT03570164|Drug|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
79998851|NCT03570164|Drug|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
79824172|NCT02574104|Other|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
79680661|NCT00529919|Dietary Supplement|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
79824173|NCT02577744|Other|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
79998852|NCT05181943|Device|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
79998853|NCT05181943|Drug|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
79680662|NCT02922114|Other|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
79680663|NCT02925663|Behavioral|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
79998854|NCT01315951|Biological|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
79998855|NCT01391234|Radiation|STAT RT planning and delivery workflow|"Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
79680664|NCT02943629|Device|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
79998856|NCT05184049|Drug|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
79998857|NCT05184049|Drug|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
79229289|NCT04590014|Device|Test HVNI Device|During this session, patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
79998858|NCT01336543|Drug|Chemotherapy following concurrent Chemoradiotherapy|"NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
79998859|NCT03570086|Diagnostic Test|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
79998860|NCT01341847|Procedure|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
79371698|NCT01031914|Device|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
79680665|NCT02943629|Device|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
79680666|NCT02943629|Device|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
79680667|NCT02925624|Procedure|Pulmonary vein isolation|
79680668|NCT00531128|Behavioral|High/Low Sitosterol|
79680669|NCT02925351|Procedure|Computed Tomography|Undergo PET/CT scan
79680670|NCT02925351|Radiation|Fluorine F 18 Clofarabine|Given IV
79680671|NCT02925351|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79680672|NCT02944409|Device|total knee prothesis VEGA System|total knee replacement
79680673|NCT00531167|Drug|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
79680674|NCT02944214|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
79824174|NCT02577744|Other|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
79824175|NCT00712868|Drug|Lactic acid|Once a day
79998861|NCT01341847|Procedure|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
79824176|NCT00660699|Drug|Gemcitabine|
79824177|NCT00660699|Drug|Docetaxel|
79824178|NCT00660699|Radiation|Radiation|
79824179|NCT02577068|Drug|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
79680675|NCT02944214|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
79525324|NCT03303963|Diagnostic Test|Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
79680676|NCT02925546|Drug|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
79824180|NCT02577068|Drug|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
79824181|NCT02576834|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
79824182|NCT02576834|Other|Services as Usual|Services as usually provided in the community
79824183|NCT00582114|Drug|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
79824184|NCT00582114|Drug|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
79824185|NCT04071080|Drug|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
79824186|NCT04071080|Drug|Placebo|500mL Gatorade
79998862|NCT03568370|Other|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
79680677|NCT02925546|Drug|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
79680678|NCT02925546|Drug|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
79680679|NCT02944331|Procedure|Endovenous steam ablation|
79680680|NCT02922075|Biological|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
79680681|NCT02922075|Biological|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
79680682|NCT02922075|Device|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
79824187|NCT01719666|Procedure|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
79824188|NCT01719666|Procedure|conventional surgery|conventional surgery: MPFL reconstruction
79824189|NCT00582036|Drug|Regular Insulin|Use of sliding scale insulin as per Appendix 1
79824190|NCT00582036|Device|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
79824191|NCT00581360|Drug|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
79998863|NCT03568214|Other|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
79998864|NCT03568136|Drug|Secukinumab 300 mg|Solution for injection in pre-filled syringe
79998865|NCT03568136|Drug|Placebo|Solution for injection in pre-filled syringe
79998866|NCT01336621|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
79998867|NCT05187481|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
79998868|NCT05187481|Drug|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
79998869|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
79680683|NCT02922075|Procedure|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
79680684|NCT02922075|Device|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
79680685|NCT02922075|Biological|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
79680686|NCT02922075|Drug|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
79680687|NCT02922075|Device|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
79680688|NCT02922075|Other|No soft tissue graft|No soft tissue graft was used
79680689|NCT02944487|Drug|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
79680690|NCT02944487|Drug|Placebo|Matching placebo capsules
79680691|NCT00531245|Drug|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
79680692|NCT00529997|Device|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
79680693|NCT03458585|Other|Self-administered questionnaire|Self-administered questionnaire
79680694|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
79680695|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
79680696|NCT02922348|Drug|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
79680697|NCT02922348|Drug|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
79680698|NCT02922270|Other|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
79998870|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
79371699|NCT05404893|Diagnostic Test|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
79371700|NCT02167204|Procedure|Computed Tomography|Undergo 18F-FLT PET/CT
79371701|NCT02167204|Radiation|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
79371702|NCT02167204|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET/CT
79371703|NCT05404737|Other|transthoracic echocardiography (TTE)|In order to evaluate the interchangeability of RV-LSF, a TTE will be performed just after the placement of general anesthesia, when the patient is under mechanical ventilation
79371704|NCT05404737|Other|transoesophageal echocardiography (TEE).|During cardiopulmonary bypass surgery patients is monitored by a TEE as recommended.
79371705|NCT04992429|Procedure|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
79371706|NCT05538585|Drug|Galicaftor|Oral
79371707|NCT05538585|Drug|Navocaftor|Oral
79371708|NCT00982072|Drug|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
79371709|NCT00982072|Drug|prednisolone|Prednisolone 1mg/kg maximum 60mg od
79371710|NCT05343195|Other|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
79371711|NCT05343195|Other|Control|Control intervention: conventional physiotherapy after hip replacement
79680699|NCT00527501|Drug|Travoprost/brinzolamide|
79680700|NCT02943512|Other|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
79680701|NCT02925468|Device|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
79680702|NCT02922387|Drug|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
79680703|NCT02922387|Behavioral|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
79680704|NCT00530153|Behavioral|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
79998871|NCT00383435|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
79998872|NCT00383435|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
79998873|NCT00383435|Drug|Placebo|Placebo MDI twice a day for 26 weeks
79998874|NCT01336699|Other|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
79998875|NCT01336699|Biological|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
79998876|NCT01336699|Biological|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
79229290|NCT04489862|Biological|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10^5 CAR+ T cells/kg will be infused on day 0.
79229291|NCT05163366|Drug|GROUP A|Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
79525325|NCT03303963|Diagnostic Test|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~FDA microscopy~Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~Measurement of pre-rRNA synthesis"
79525326|NCT03302611|Behavioral|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
79680705|NCT00530153|Dietary Supplement|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
79371712|NCT01899053|Drug|TAK-228|TAK-228 Capsules
79371713|NCT01899053|Drug|TAK-117|TAK-117 Capsules
79680706|NCT02922309|Behavioral|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
79680707|NCT02922309|Behavioral|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
79680708|NCT00530192|Other|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
79680709|NCT02922231|Biological|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
79680710|NCT02921724|Device|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
79680711|NCT04691882|Behavioral|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
79998877|NCT01340521|Drug|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
79998878|NCT03698123|Other|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
79371714|NCT05396235|Biological|MT-3921|Solution for infusion; Intravenous (IV)
79371715|NCT05396235|Biological|Placebo|Solution for infusion; Intravenous (IV)
79371716|NCT05532423|Drug|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
79371717|NCT05532423|Drug|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
79371718|NCT01032694|Drug|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
79371719|NCT01032694|Drug|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
79525327|NCT03292315|Drug|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
79525328|NCT03292315|Other|No Intervention|No injection will be administered
79371720|NCT01032850|Drug|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
79525329|NCT03287830|Behavioral|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
79525330|NCT03287778|Dietary Supplement|Pyridoxine|Max dose of 400 mg QD PO
79525331|NCT03287778|Dietary Supplement|Placebo|Matching placebos will be administered.
79525332|NCT03273413|Drug|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
79680712|NCT04691882|Behavioral|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
79680713|NCT02925507|Other|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
79680714|NCT00531323|Drug|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
79371721|NCT04399707|Device|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
79371722|NCT04399707|Device|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
79371723|NCT05390944|Drug|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
79680715|NCT00531323|Drug|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
79371724|NCT05390944|Drug|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
79371725|NCT04911309|Other|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
79371726|NCT04911309|Other|standard therapy / treatment|12 weeks standard therapy / treatment
79371727|NCT04909437|Dietary Supplement|Mycobiotic|2 sachet/day, 21 days, oral
79998879|NCT01340599|Dietary Supplement|defined green tea catechin extract|Given PO
79998880|NCT01340599|Other|placebo|Given PO
79680716|NCT02921880|Other|Cardiac Rehabilitation|
79680717|NCT02921958|Behavioral|occupational therapy|Family-centered occupational therapy services
79998881|NCT01340599|Other|immunohistochemistry staining method|Correlative studies
79998882|NCT01340599|Other|immunoenzyme technique|Correlative studies
79998883|NCT01340599|Other|questionnaire administration|Ancillary studies
79998884|NCT01340599|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
79998885|NCT01340599|Other|high performance liquid chromatography|Correlative studies
79998886|NCT01340599|Other|mass spectrometry|Correlative studies
79998887|NCT01335035|Drug|deferasirox|
79998888|NCT01340677|Drug|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
79998889|NCT01340677|Drug|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
79371728|NCT04909437|Dietary Supplement|Placebo|2 sachet/day, 21 days, oral
79371729|NCT01032928|Behavioral|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
79371730|NCT04278261|Procedure|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
79371731|NCT04278261|Procedure|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
79371732|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
79371733|NCT00983242|Drug|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
79371734|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
79371735|NCT04278105|Device|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
79525333|NCT03273413|Drug|Placebo|Inactive tablet
79525334|NCT03266484|Dietary Supplement|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
79525335|NCT03266484|Dietary Supplement|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
79525336|NCT03242824|Drug|Fluorine F 18 Fluorodopa|Contrast used in PET
79525337|NCT03242824|Radiation|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
79525338|NCT03242824|Procedure|Positron Emission Tomography|imaging test
79525339|NCT03233750|Behavioral|Stress Inoculation Training|see description in arm/group descriptions
79525340|NCT03233750|Behavioral|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
79525341|NCT03227458|Other|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
79525342|NCT03227458|Other|Placebo|Participants will take placebo daily for 36 weeks.
79525343|NCT03227458|Behavioral|Exercise|bone-loading exercise on 3 days per week for 38 weeks
79525344|NCT03181633|Drug|ACH-0144471|ACH-0144471 will be administered to all participants enrolled in the study.
79680718|NCT04689126|Procedure|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
79998890|NCT01340677|Drug|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
79998891|NCT05164315|Procedure|Tailored surgery|Procedure: Tailored surgery based on intraoperative local excision/biopsy
79998892|NCT05164315|Procedure|Total mesorectal excision (TME)|Procedure: Total mesorectal excision for all allocated patients
79998893|NCT01335269|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
79680719|NCT00531362|Drug|Plain aspirin|Plain aspirin 75 mg or 150 mg
79680720|NCT02925585|Other|Pre/post imaging|
79680721|NCT00531401|Drug|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
79680722|NCT02925273|Other|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~Flexion at the distal interphalangeal joint of the hand~Flexion at the proximal interphalangeal joint of the hand~Flexion at the metacarpal-phalangeal joint of the hand"
79998894|NCT05183815|Other|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
79998895|NCT01335347|Biological|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
79998896|NCT01335347|Biological|Placebo control|Capsules of the same size and shape as experimental groups
79998897|NCT05164003|Drug|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
79229292|NCT05163366|Drug|GROUP B|The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
79998898|NCT05164003|Drug|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
79998899|NCT05163535|Drug|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
79229293|NCT04489784|Device|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
79229294|NCT05004428|Other|No intervention|Retrospective population-based study utilizing administrative data without any intervention.
79229295|NCT01038843|Drug|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
79371736|NCT04278105|Device|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
79371737|NCT04278105|Other|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
79371738|NCT04278027|Behavioral|Cognitive Remediation Therapy|"CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)"
79371739|NCT00984334|Drug|Naloxone SR 5 mg capsules|
79525345|NCT03141983|Drug|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
79525346|NCT03141983|Drug|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
79680723|NCT02925273|Other|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
79229296|NCT02462954|Device|ContraGel|
79998900|NCT05163535|Other|ELPIDA®|Elsulfavirine capsules
79998901|NCT01338467|Device|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
79998902|NCT01340755|Procedure|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
79998903|NCT04434209|Device|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
79229297|NCT02462954|Device|HEC Universal Placebo gel|
79229298|NCT05159232|Procedure|hospital stay|hospital stay in in inguinal hernia repair
79680724|NCT00531440|Drug|Everolimus (RAD001)|
79998904|NCT04434209|Other|Standard of Care|Standard of Care patient management
79998905|NCT01341925|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
79229299|NCT02462408|Procedure|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
79229300|NCT02462408|Procedure|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
79680725|NCT04015011|Combination Product|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
79680726|NCT02944526|Drug|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
79680727|NCT02944526|Drug|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
79824192|NCT05673564|Procedure|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
79824193|NCT02574182|Radiation|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
79525347|NCT03122223|Biological|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10^6 cell culture infectious dose (CCID)50 and less than 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
79371740|NCT00984334|Drug|Placebo|
79371741|NCT00984334|Drug|Naloxone SR 10 mg capsules|
79229301|NCT00900783|Drug|valacyclovir|1 gram, three times a day for seven days
79229302|NCT00900783|Drug|FV-100|400 mg, once daily, for seven days
79229303|NCT00900783|Drug|FV-100|200 mg, once daily, for seven days
79229304|NCT00900783|Drug|Valacyclovir placebo|three times a day, for seven days
79229305|NCT00900783|Drug|FV-100 placebo|once daily, for seven days
79371742|NCT00984334|Drug|Naloxone SR 20mg capsules|
79371743|NCT00984334|Drug|Naloxone SR 2.5 mg capsules|
79371744|NCT02168062|Behavioral|Behavioral Dietary Intervention|Receive individualized nutrition counseling
79824194|NCT01650792|Drug|Aspirin|
79824195|NCT00713180|Procedure|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
79824196|NCT03918018|Device|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
79824197|NCT05673122|Device|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
79824198|NCT00660387|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
79824199|NCT00660387|Drug|Placebo Gel|
79824200|NCT00660387|Drug|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
79824201|NCT00660387|Drug|Placebo (PBO) oral capsules|
79824202|NCT00660387|Device|CADD-Legacy® 1400 ambulatory infusion pump|
79229306|NCT05139576|Diagnostic Test|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels >150 ng/ml were contacted via telephone.
79229307|NCT04993196|Diagnostic Test|T1rho imaging|Magnetic Resonance Imaging using T1rho
79229308|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
79229309|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
79371745|NCT02168062|Other|Counseling|Receive individualized symptom management service counseling
79371746|NCT02168062|Other|Educational Intervention|Review educational modules
79371747|NCT02168062|Behavioral|Exercise Intervention|Receive individualized exercise counseling
79371748|NCT02168062|Drug|Goserelin Acetate|Given SC
79229310|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
79229311|NCT01035879|Drug|Sitagliptin|tablets and capsule once daily
79229312|NCT01035879|Drug|placebo|tablets and capsule once daily
79229313|NCT05164536|Drug|Amyvid|All participants will undergo a single β-amyloid PET scan with Amyvid.
79229314|NCT01029873|Drug|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
79229315|NCT01029873|Biological|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
79371749|NCT02168062|Other|Laboratory Biomarker Analysis|Correlative studies
79371750|NCT02168062|Drug|Leuprolide Acetate|Given SC or IM
79371751|NCT02168062|Other|Quality-of-Life Assessment|Ancillary studies
79371752|NCT02168062|Drug|Triptorelin Pamoate|Given IM
79371753|NCT05334459|Radiation|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~o ER / PR /Her2 /Ki67 study)~Collection of CTC.~Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~o Denosumab, Biphosphonate for bone metastasis~RT to metastatic side (if visible). Continue Systemic therapy~12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~ST will be continued until progression and/or unmanageable toxicity.~Radiologic evaluation every 3-6-month based on institutional practice."
79229316|NCT05164380|Other|Picture naming tasks|PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
79229317|NCT01026051|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
79371755|NCT03304587|Diagnostic Test|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
79525348|NCT03122223|Biological|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
79525349|NCT03122223|Biological|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
79525350|NCT03122223|Biological|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
79525351|NCT03077087|Device|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
79525352|NCT03074539|Drug|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
79525353|NCT03074539|Procedure|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
79525354|NCT03074539|Procedure|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
79525355|NCT03030131|Drug|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
79525356|NCT03011021|Drug|Liraglutide|Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
79525357|NCT03011021|Biological|UCB-Treg|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml normal saline
79525358|NCT03011021|Drug|Insulin|Receive insulin following clinician's instruction.
79998906|NCT01341925|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
79229318|NCT02462642|Dietary Supplement|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
79525359|NCT02995252|Other|Blood draws|
79229319|NCT02462642|Other|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
79525360|NCT02995252|Drug|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
79525361|NCT02995252|Other|Knowledge Index Questionnaire|
79525362|NCT02995252|Other|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
79525363|NCT02995252|Procedure|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
79525364|NCT02970513|Other|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
79525365|NCT02932826|Biological|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml NS
79525366|NCT02932826|Drug|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
79525367|NCT02874131|Behavioral|Behavioral Activation|Behavioral activation
79680728|NCT04013763|Other|wheat containing skin care products|stop or continue using wheat containing skin care products
79229320|NCT02462642|Dietary Supplement|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
79229321|NCT02462642|Other|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
79229322|NCT01024101|Drug|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
79525368|NCT02874131|Behavioral|Cognitive Processing Therapy|Cognitive processing therapy
79525369|NCT02853604|Drug|ADXS11-001|
79525370|NCT02853604|Drug|Placebo|
79525371|NCT02843191|Drug|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
79680729|NCT00530309|Drug|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
79680730|NCT00530309|Drug|Placebo|Subjects will also receive placebo.
79680731|NCT02917785|Device|Karman curettage|
79824203|NCT00660387|Device|PEG tube|percutaneous endoscopic gastrostomy tube
79680732|NCT04000854|Drug|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
79229323|NCT04489706|Drug|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
79229324|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
79680733|NCT03994614|Other|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
79229325|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
79229326|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
79229327|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
79229328|NCT05118516|Drug|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
79229329|NCT00818493|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
79371756|NCT03304587|Diagnostic Test|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
79371757|NCT03304587|Other|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
79525372|NCT02817360|Drug|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
79371758|NCT03304587|Other|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
79525373|NCT02817360|Other|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
79525374|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 8 Gy|
79525375|NCT02811250|Radiation|Stereotactic radiotherapy 5 x 8 Gy|
79525376|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 10 Gy|
79525377|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 12 Gy|
79525378|NCT02799706|Drug|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
79525379|NCT02799706|Drug|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
79525380|NCT02799706|Radiation|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
79525381|NCT02770599|Other|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
79525382|NCT02759458|Device|Smith & Nephew Healicoil Anchor|
79680734|NCT00530387|Drug|19 organic sunscreen filters and 5 topical NSAIDs|
79680735|NCT04689165|Biological|Experimental Group A meningococcal polysaccharide vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
79680736|NCT04689165|Biological|Control Group A meningococcal polysaccharide vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
79680737|NCT04689087|Combination Product|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
79680738|NCT00530543|Procedure|Robot-assisted gait training|
79680739|NCT00530582|Drug|progesterone|300mg progesterone /placebo each for 21 days
79229330|NCT00818493|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
79229331|NCT00818493|Drug|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
79229332|NCT05164068|Behavioral|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
79229333|NCT02717546|Device|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
79229334|NCT04455126|Drug|Preservative-free tafluprost eye drops|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
79229335|NCT03134469|Dietary Supplement|Probiotic supplement|Probiotic supplement
79229336|NCT03134469|Dietary Supplement|Placebo supplement|Placebo supplement
79525383|NCT02759458|Device|Smith & Nephew Twinfix Anchor|
79998907|NCT01341925|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
79998908|NCT01338623|Drug|Tansulosine|capsule 0,4 mg
79998909|NCT01340833|Drug|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK2118436, starting 1.75 hours after the oral dose
79229337|NCT05119062|Other|Usual care|Families in the control group will be provided with routine care, including regular antenatal check ups, one bed side education (within 24 hours after delivery), one group session with discharge precautions (3rd to 5th day postpartum), two home visits (first week and second week after discharge respectively), and two physical body check at hospital on the 30th and 42nd day postpartum. Contents of the bed side education, pre-discharge education and home visits focuses on health related information, such as postpartum care, infant care and breastfeeding, etc.
79229338|NCT05119062|Other|an online intergenerational co-parenting programme+usual care|The program is proposed to include five sessions, with three antenatal sessions to be offered weekly during the 34-36 weeks gestation and two postnatal sessions weekly starting from the first week after discharge from hospital. The intervention will be delivered online.The program is designed for the intergenerational co-parenting families to undertake with parents together with grandmothers. The online courses will be delivered by an online platform in the study hospital. The first session will be pushed to participants in the intervention group within 2 days (around 34 weeks gestation) after recruitment. The second and third session will be pushed around 35 and 36 weeks gestation separately. The first postnatal session will be provided around the first to second week postpartum; and second postnatal session will be provided around the third to fourth week postpartum.
79680740|NCT00530660|Biological|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
79680741|NCT02917863|Drug|L-Thyroxine (tablet, per os)|
79680742|NCT02917863|Drug|L-Thyroxine (oral drops, solution)|
79998910|NCT01332383|Drug|Naratriptan|
79680743|NCT00530699|Drug|AZD1152|intravenous
79998911|NCT01338701|Procedure|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
79680744|NCT02917824|Device|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
79680745|NCT02917824|Device|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
79680746|NCT00530738|Drug|Lipoplus|i.v. fat emulsion for parenteral nutrition
79680747|NCT00530738|Drug|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
79680748|NCT02921685|Drug|Monalizumab|Four dose levels will be tested.
79680749|NCT02944175|Drug|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
79998912|NCT01338701|Procedure|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
79998913|NCT01338701|Other|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
79998914|NCT01340911|Drug|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
79998915|NCT01340911|Drug|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
79525384|NCT02689778|Drug|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
79525385|NCT02689778|Drug|Placebo|Identical tablets without active substance
79525386|NCT02678377|Drug|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
79525387|NCT02678377|Drug|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
79525388|NCT02659384|Drug|Bevacizumab|
79525389|NCT02659384|Drug|atezolizumab|
79525390|NCT02659384|Drug|acetylsalicylic acid|
79525391|NCT02659384|Drug|placebo|
79680750|NCT02944175|Drug|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
79680751|NCT02917746|Drug|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
79680752|NCT02917746|Procedure|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
79680753|NCT04688892|Device|Cupping|dynamic cupping
79680754|NCT02944370|Behavioral|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
79680755|NCT00531557|Drug|Darunavir ritonavir|
79680756|NCT02921568|Device|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
79998916|NCT01340989|Procedure|alteration of the insufflation gas|addition of 4% oxygen
79998917|NCT01340989|Procedure|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~humidification~set temperature of 32°C"
79998918|NCT01340989|Procedure|standard pneumoperitoneum|no intervention besides the use of CO2
79998919|NCT01337011|Other|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
79229339|NCT05622903|Other|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
79371759|NCT03304587|Diagnostic Test|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
79371760|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
79371761|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
79525392|NCT02659306|Drug|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
79680757|NCT02921568|Device|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
79680758|NCT02944097|Dietary Supplement|Vineatrol 30 native powder|
79229340|NCT05622903|Other|No Cash Benefit|No monthly cash benefit.
79229341|NCT00893139|Drug|AL-38583 ophthalmic solution 0.05%|
79680759|NCT02944097|Dietary Supplement|Vineatrol 30 micelles|
79680760|NCT02917902|Other|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
79680761|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
79680762|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
79680763|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
79680764|NCT02921646|Other|Measure of resting energetic expenditure|measure of resting energetic expenditure
79680765|NCT02943707|Procedure|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
79680766|NCT02943707|Drug|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
79998920|NCT05162209|Dietary Supplement|Synbiotic|Oral sachet, for 12 weeks
79525393|NCT02632552|Behavioral|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
79525394|NCT02632552|Behavioral|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
79680767|NCT00531635|Drug|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
79680768|NCT02917551|Other|7 days of adequate antibiotic treatment|
79998921|NCT01342159|Procedure|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
79680769|NCT02917551|Other|14 days of adequate antibiotic treatment|
79229342|NCT00893139|Drug|AL-38583 ophthalmic solution 0.10%|
79229343|NCT00893139|Drug|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
79229344|NCT01378962|Drug|erlotinib|150 mg orally once a day for 12 months
79229345|NCT00892203|Drug|BGG492|
79229346|NCT00892203|Drug|Sumatriptan|
79229347|NCT00892203|Drug|Placebo|
79680770|NCT00531674|Dietary Supplement|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
79680771|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
79680772|NCT00531674|Dietary Supplement|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
79680773|NCT00531674|Dietary Supplement|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
79680774|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
79680775|NCT00531674|Dietary Supplement|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
79680776|NCT02921529|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
79680777|NCT02921529|Other|false stimulation|Electrodes were attached to specific acupoints without electric current
79680778|NCT02943824|Other|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
79229348|NCT05377983|Other|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
79229349|NCT05113524|Other|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
79229350|NCT05113524|Other|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
79371762|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
79371763|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
79371764|NCT03304587|Other|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
79525395|NCT02591147|Device|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
79525396|NCT02591147|Device|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
79824204|NCT00660387|Device|J-tube|jejunal tube
79680779|NCT02943824|Other|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
79824205|NCT00582738|Drug|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
79824206|NCT00582738|Drug|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
79824207|NCT00713336|Drug|ZD4054|ZD4054 10mg Tablet
79525397|NCT02588872|Biological|Platelet-rich Plasma (PRP)|
79525398|NCT02588872|Biological|Hyaluronic Acid|
79525399|NCT02456233|Procedure|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
79525400|NCT02456233|Procedure|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
79525401|NCT02448485|Procedure|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
79525402|NCT02387203|Drug|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
79680780|NCT02921607|Other|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
79680781|NCT00530933|Procedure|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
79680782|NCT00530933|Procedure|Transcutaneous tibial nerve stimulation|30 minutes once weekly
79680783|NCT00530933|Procedure|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
79824208|NCT00713336|Drug|Moxifloxacin|400 mg capsule
79824209|NCT00713336|Drug|ZD4054 Placebo|3 tablets
79824210|NCT00713336|Drug|Moxifloxacin placebo|1 capsule
79680784|NCT02917668|Other|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
79824211|NCT00713336|Drug|ZD4054 Placebo|2 tablets
79525403|NCT02381353|Drug|Bupivacaine|Intraoperative orbital injection of local pain medication
79680785|NCT02917668|Other|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %
79680786|NCT00531713|Drug|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
79824212|NCT00713336|Drug|ZD4054|30mg tablet
79824213|NCT00713336|Drug|ZD4054|10mg tablet
79824214|NCT00789711|Drug|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
79824215|NCT00789711|Drug|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
79824216|NCT00713726|Drug|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
79824217|NCT00713726|Drug|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
79824218|NCT00772889|Biological|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
79824219|NCT00772889|Biological|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
79229351|NCT05342922|Procedure|Ultrasound group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
79229352|NCT05342922|Procedure|Landmark group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
79229353|NCT00890409|Device|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
79229354|NCT05163756|Drug|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
79229355|NCT05163756|Drug|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
79229356|NCT00889473|Drug|Larazotide acetate|gelatin capsule
79229357|NCT00889473|Drug|Placebo|gelatin capsule
79229358|NCT00889473|Dietary Supplement|Gluten 900 mg|gelatin capsule
79229359|NCT05391204|Other|Functional Tests|Various physical exercices of inferior members
79229360|NCT00810147|Drug|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
79229361|NCT00810147|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
79229362|NCT00810147|Drug|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
79229363|NCT00810147|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
79229364|NCT00810147|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
79525404|NCT02310061|Procedure|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
79525405|NCT02310061|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
79525406|NCT02305537|Behavioral|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
79525407|NCT02296307|Other|Blood test: CA-125 biomarker|"CA-125 biomarker blood test at visit 1, day 1.~CA-125 biomarker blood test at visit 2, week 6."
79525408|NCT02296307|Other|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
79824220|NCT00795795|Procedure|Preimplantation Genetic Screening|Preimplantation Genetic Screening
79824221|NCT00795795|Procedure|IVF without PGS|IVF without PGS
79229365|NCT04375956|Drug|Pembrolizumab|Experimental
79229366|NCT04495478|Drug|Ramucirumab - IV|Administered IV.
79229367|NCT04495478|Drug|Placebo - IV|Administered IV.
79229368|NCT04495478|Drug|Ramucirumab - SC|Administered SC.
79229369|NCT04495478|Drug|Placebo - SC|Administered SC.
79229370|NCT04308564|Diagnostic Test|Blood test|Blood test for the identification of biomarkers
79229371|NCT04487444|Drug|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
79229372|NCT00152763|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
79229373|NCT00152763|Other|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
79229374|NCT03181542|Device|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
79229375|NCT00809679|Drug|T-62 Dose 1|Capsule dosage form 100 mg bid
79525409|NCT02296307|Other|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
79525410|NCT01992653|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
79525411|NCT01992653|Drug|Doxorubicin|Doxorubicin will be administered at 50 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
79998922|NCT01342237|Drug|HDCT 1(TTC), HDCT2(MEC)|"TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
79525412|NCT01992653|Drug|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
79525413|NCT01992653|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
79998923|NCT01337323|Drug|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
79229376|NCT00809679|Drug|T-62 Dose 2|Capsule dosage form 200 mg bid
79229377|NCT00809679|Other|Placebo|Capsule dosage form placebo bid
79229378|NCT00884715|Drug|Octreotide|short acting octreotide
79229379|NCT03603080|Drug|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
79371765|NCT03304587|Other|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
79371766|NCT03304587|Other|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
79371767|NCT03304587|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
79371768|NCT03304587|Other|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue & sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
79371769|NCT04352920|Other|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
79680787|NCT02921334|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
79680788|NCT00530972|Drug|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg <75 kg, 1200 mg >75 kg)
79824222|NCT05325983|Other|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
79998924|NCT03157037|Biological|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
79525414|NCT01992653|Drug|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
79525415|NCT01992653|Drug|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
79229380|NCT03126552|Biological|Necator americanus L3 larvae|50 Necator americanus L3 larvae
79525416|NCT01992653|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
79680789|NCT02943863|Device|HFNC followed by conventional nasal cannula|
79680790|NCT02943863|Device|Conventional nasal cannula followed by HFNC|
79680791|NCT02943278|Behavioral|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
79680792|NCT02943278|Behavioral|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
79680793|NCT02943434|Other|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
79998925|NCT04830943|Drug|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
79998926|NCT01341145|Behavioral|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
79229381|NCT01019187|Procedure|Quality-of-Life Assessment|Ancillary Studies
79229382|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
79229383|NCT01019187|Other|Placebo|Given orally
79680794|NCT02917707|Other|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
79680795|NCT02921451|Device|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
79229384|NCT01019187|Procedure|Fatigue Assessment and Management|
79229385|NCT01019187|Procedure|Sleep Disorder Therapy|
79229386|NCT01019187|Drug|Armodafinil|Given orally
79229387|NCT01019187|Procedure|Quality-of-life assessment|Ancillary studies
79229388|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
79229389|NCT01019187|Procedure|Fatigue Assessment and Management|
79229390|NCT01019187|Procedure|Management of Therapy|
79229391|NCT01019187|Procedure|Sleep disorder therapy|
79824223|NCT05325983|Other|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
79824224|NCT00800553|Drug|donepezil|5mg o.m. p.o. for approx. 2 weeks
79371770|NCT05387356|Other|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 <150 despite a PEEP >10 cmH2O.
79525417|NCT01924247|Behavioral|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
79680796|NCT02943317|Drug|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
79680797|NCT02943317|Drug|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
79680798|NCT02917590|Other|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
79824225|NCT00800553|Drug|Placebo|5mg of placebo for approx. 2 weeks
79824226|NCT04103801|Dietary Supplement|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
79824227|NCT00793767|Drug|erythropoietin|bolus of 400 IU/kg
79824228|NCT00793767|Drug|placebo (saline)|i.v
79824229|NCT04103723|Procedure|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
79824230|NCT00796029|Drug|14C-paliperidone|
79998927|NCT01341145|Behavioral|Relaxation|12-week progressive muscle relaxation program (active control)
79229392|NCT01019187|Procedure|cognitive assessment|
79229393|NCT01019187|Procedure|Quality of Life assessment|Ancillary Studies
79229394|NCT01019187|Other|Questionnaire Administration|Ancillary studies
79229395|NCT01019187|Other|Placebo|Given orally
79371771|NCT01888367|Drug|DFA-02 Antibiotic Gel|
79371772|NCT01888367|Drug|DFA-02 Placebo Gel|
79525418|NCT01924247|Behavioral|Standard treatment by family physician|Standard treatment by family physician.
79525419|NCT01881659|Other|HPV screening|Women who signed informed consent will be screened with HPV testing.
79525420|NCT01850303|Drug|Pemetrexed|
79824231|NCT00793845|Drug|Cyclophosphamide|First HDCT
79824232|NCT00793845|Drug|Etoposide|First HDCT
79824233|NCT00793845|Drug|Carboplatin|First HDCT
79998928|NCT03067610|Radiation|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
79998929|NCT03067610|Drug|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
80016628|NCT04688177|Device|Pulmonary Function Test|Subjects should be in a sitting position with a nose clip, then perform pulmonary function test. Participants should perform at least 3 acceptable attempts, but no more than 8 attempts in total.
79229396|NCT01019187|Procedure|Fatigue assessment and management|
79229397|NCT01019187|Procedure|Management of therapy and complications|
79229398|NCT01019187|Procedure|Sleep disorder therapy|
79229399|NCT01019187|Drug|Armodafinil|Given orally
79229400|NCT01019187|Procedure|Cognitive Assessment|
79229401|NCT01019187|Procedure|Quality of Life Assessment|Quality of Life Assessment
79229402|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
79525421|NCT01850303|Drug|Gemcitabine|
79525422|NCT01850303|Drug|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
79680799|NCT02917590|Other|Single-task obstacle crossing training|Obstacle crossing training
79680800|NCT02943356|Drug|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
79680801|NCT02921373|Biological|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
79680802|NCT02921373|Device|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
79680803|NCT02943239|Drug|REGN1033|REGN1033
79680804|NCT02943239|Drug|REGN2477|REGN2477
79680805|NCT02943239|Other|Placebo|Placebo
79680806|NCT02917512|Drug|HU00701|Cyclosporine 0.01% + 3% trehalose
79824234|NCT00793845|Drug|Thiotepa|Second HDCT
79824235|NCT00793845|Drug|Melphalan|Second HDCT
79824236|NCT00793845|Radiation|Total body irradiation|Second HDCT
79998930|NCT01338935|Drug|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage *.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
79371773|NCT05386732|Device|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
80016629|NCT04688177|Device|Respiratory Muscle Function|Subject will perform both maximal inspiratory pressure and maximal expiratory pressure for 3 times in sitting position with the nose clip.
80016630|NCT04688177|Behavioral|Fagerström Test for Nicotine Dependence|Fagerström Test for Nicotine Dependence Traditional Chinese version will be adopted. It is a 6-item questionnaire that could help quantify the smoking frequency, amounts, and level of dependence.
80016631|NCT04688177|Behavioral|Seven-Day Physical Activity Recall Questionnaire|Physical activity will be measured by the Chinese Version of the Seven-Day Physical Activity Recall Questionnaire. Participants will need to recall the time (hours) they spent in various leisure activities in the past 7 days.
79229403|NCT01019187|Procedure|Fatifue assessment and management|
79229404|NCT02464514|Other|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
79229405|NCT02464514|Other|High fat meal|58% fat, 17% protein, and 25% carbohydrate
79229406|NCT01018875|Drug|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
79680807|NCT02917512|Drug|HU007|Cyclosporine 0.02% + 3% trehalose
79229407|NCT01018875|Drug|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
79229408|NCT01018875|Drug|placebo|Subjects will take 4 capsules once daily for 12 weeks.
79525423|NCT01763671|Drug|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
79229409|NCT01018173|Drug|placebo|sc weekly
79229410|NCT01018173|Drug|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
79229411|NCT04453956|Diagnostic Test|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
79229412|NCT04453956|Diagnostic Test|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
79229413|NCT04453956|Diagnostic Test|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
79229414|NCT03271190|Behavioral|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
79371774|NCT00988000|Other|telephone consultation|alternative to face to face consultation for new referrals
79371775|NCT00988000|Other|No intervention|no alternative to face to face consultation
79525424|NCT01763671|Drug|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
79525425|NCT01763671|Drug|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
79525426|NCT01696435|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
79680808|NCT02917512|Drug|Restasis|Cyclosporine 0.05%
79680809|NCT02917512|Drug|Placebo|Vehicle
79680810|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks & 9 months
79680811|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks & 9 months
79680812|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6&14 weeks & 9 months
79680813|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks & 9 months
79680814|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks & 9 months
79680815|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6&14 weeks & 9 months
79680816|NCT00531908|Drug|furosemide|furosemide
79824237|NCT04099745|Device|CGM|Continuous Glucose Monitoring System
79824238|NCT04099745|Device|FGM|Flash glucose monitoring System
79824239|NCT00800709|Drug|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
79824240|NCT00916331|Procedure|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
79824241|NCT00916331|Procedure|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
79824242|NCT00793923|Drug|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
79824243|NCT00793923|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
79824244|NCT01247324|Drug|Interferon beta-1a|
79824245|NCT01247324|Drug|Ocrelizumab-matching placebo|
79824246|NCT01247324|Drug|Ocrelizumab|
79824247|NCT01247324|Drug|Interferon beta-1a-matching placebo|
79371776|NCT05343117|Drug|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
79824248|NCT00772577|Drug|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
79680817|NCT03403569|Drug|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
79824249|NCT00772577|Drug|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
80016632|NCT04688177|Device|Cardiopulmonary exercise testing|Bruce protocol as the treadmill evaluation protocol will be adopted for cardiopulmonary exercise testing.
79371777|NCT05343117|Drug|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
79371778|NCT01898195|Drug|Varenicline|Varenicline will be provided for three months.
79525427|NCT01696435|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79824250|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
80016633|NCT02278796|Drug|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
79680818|NCT03403569|Drug|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
79680819|NCT00531791|Drug|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
79525428|NCT01696435|Dietary Supplement|Fish oil placebo|Fish oil placebo
79525429|NCT01696435|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
79680820|NCT00531791|Drug|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
79824251|NCT02345850|Procedure|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
80016634|NCT02278796|Drug|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
80016635|NCT02987205|Device|Revanesse Ultra|NLF correction
79229415|NCT03271190|Behavioral|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
79229416|NCT04155450|Other|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~Flexing one upper extremity~Extending one lower extremity with a leg slide~Extending one lower extremity by lifting it off the mat~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~Progress to prone position:~Extending one lower extremity~Extending both lower extremity"
79371779|NCT01898195|Behavioral|Text Message|Text messages will be developed twice daily for three months
79371780|NCT01898195|Behavioral|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
79371781|NCT04348071|Drug|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
79371782|NCT05242666|Diagnostic Test|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
79371783|NCT05242666|Other|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a [11C]PIB radiotracer
79371784|NCT05242666|Other|3T MR Imaging of the Brain|3T MR Imaging of the Brain
79371785|NCT05242666|Other|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
79525430|NCT01681264|Drug|Morphine|
79680821|NCT02943551|Other|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
79525431|NCT01681264|Drug|Guanfacine 1mg|
79525432|NCT01681264|Drug|Guanfacine 2mg|
79525433|NCT01681264|Drug|Placebo|
79525434|NCT01654276|Drug|Febuxostat|One 40 mg tablet once a day for 6 months
79525435|NCT01527591|Biological|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
79525436|NCT01399658|Procedure|Image-guided brachytherapy|MRI-guided application of brachytherapy
79525437|NCT01399658|Drug|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
79824252|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
79229417|NCT04155450|Other|McKenzie Extension Exercise Protocol|"Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
79229418|NCT04155450|Other|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
79998931|NCT01338935|Drug|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
79229419|NCT04455204|Diagnostic Test|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
79229420|NCT04455204|Diagnostic Test|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
79229421|NCT04455204|Diagnostic Test|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
79229422|NCT04455204|Diagnostic Test|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
79229423|NCT00806403|Drug|reteplase 10+10 U|comparison to primary PCI
79371786|NCT03696927|Device|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
79371787|NCT01897727|Drug|Spironolactone|
79371788|NCT01897727|Drug|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
79371789|NCT04352998|Dietary Supplement|One dose pre-workout condition|one dose of a multi-ingredient pre-workout supplement
79525438|NCT01296113|Drug|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
79680822|NCT02943551|Other|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
79680823|NCT02943551|Other|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
79824253|NCT02345850|Drug|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
80016636|NCT02987205|Device|Restylane|NLF Correction
80016637|NCT00411242|Drug|agomelatine|
80016638|NCT00411242|Drug|placebo|
80016639|NCT04530643|Drug|HY209 0.3%|25 subjects will be assigned to drug (HY209 0.3% gel).
79229424|NCT00806403|Procedure|primary PCI|comparison to thrombolysis
79229425|NCT04852874|Procedure|Ultrasound-guided Quadratus Lumborum Block|"Low dose spinal anesthesia will be done at L3-4 lumbar vertebrae with bupivacaine 2.5 mg (0.5 ml Marcaine 0.5%) and fentanyl 25 µgm (0.5 ml) of fentanyl amp (100 µgm/ 2ml) to be added to 1.5 - 2 ml of free water to form total volume of 2.5- 3ml according to the patient height aiming level of T6 sensory level.~Quadratus lumorum block:~After 4 to 5 minutes, ultrasound guided quadratus lumborum block (QL 1,2,3) will be done unilaterally, using low-frequency convex probe, taking into consideration the total volume of injectate not exceeding 0.4 ml /kg of (bupivacaine 0.5%) to avoid local anesthesia systemic toxicity. This is equal to 0.8 ml/kg of (bupivacaine 0.25%).~After confirming the correct position of the needle, 0.2-3 ml/kg of 0.25% bupivacaine plus 1.5 mg dexamethasone and magnesium sulphate of 100 mg will be injected in each site of the QL 1,2,3 using the lean body weight. The lean body weight will be calculated by omni lean body mass online calculator."
79229426|NCT04076280|Behavioral|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education [4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
79229427|NCT04076280|Behavioral|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
79229428|NCT05399940|Diagnostic Test|Serum PSA,Delta Neutrophil Index(DNI),WBC|Urine culture, prostate volume
79371790|NCT04352998|Dietary Supplement|Two dose pre-workout condition|two doses of a multi-ingredient pre-workout supplement
79525439|NCT00690196|Behavioral|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
79229429|NCT02465294|Dietary Supplement|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
79229430|NCT02465294|Behavioral|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
79680824|NCT02943551|Other|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
79680825|NCT02943551|Other|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
79680826|NCT02921178|Other|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
79680827|NCT03279276|Procedure|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
79680828|NCT02943044|Device|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
79680829|NCT02921217|Dietary Supplement|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
80016640|NCT04530643|Drug|HY209 0.5%|25 subjects will be assigned to drug (HY209 0.5% gel).
80016641|NCT04530643|Drug|Placebo|25 subjects will be assigned to drug (Placebo).
79229431|NCT02465294|Other|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
79229432|NCT02465294|Other|Blood Test|All subjects will have blood tests performed.
79229433|NCT02465294|Dietary Supplement|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
79229434|NCT05390658|Other|Not application|Not application
79229435|NCT00883311|Device|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
79229436|NCT02464982|Procedure|Tattoo|tattoo device with EC standards, and sterile single-use only needle
79229437|NCT05390424|Diagnostic Test|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
79680830|NCT02921217|Dietary Supplement|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
79229438|NCT00802425|Drug|AM-111|single intratympanic injection
79229439|NCT00802425|Drug|placebo|single intratympanic injection
79371791|NCT04352998|Dietary Supplement|Placebo condition|one dose of a placebo
79371792|NCT05593744|Other|no intervention|This is an observational study so not involved intervention
79371793|NCT01897493|Drug|Evacetrapib|Administered orally
79371794|NCT01897493|Drug|Digoxin|Administered orally
79371795|NCT04353076|Other|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
79371796|NCT04353076|Other|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
79371797|NCT03264027|Drug|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
79998932|NCT01338935|Drug|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
79998933|NCT04455295|Device|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
79371798|NCT03264027|Drug|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
79525440|NCT00690196|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
79525441|NCT00590122|Drug|Parcopa|at subjects current stable dose of comparator
79525442|NCT00590122|Drug|carbidopa-levodopa (Sinemet)|at subjects current stable dose
79525443|NCT00309192|Drug|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
79525444|NCT00309192|Procedure|Grid laser|Grid laser as specified in ETDRS
79680831|NCT02921217|Dietary Supplement|Control|Placebo: 300 mg maltodextrin.
79680832|NCT02943122|Device|Ambulatory blood pressure monitor|
79680833|NCT00531986|Drug|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
79998934|NCT03567902|Device|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
79998935|NCT03567902|Device|Direct laryngoscope intubation|Direct laryngoscope intubation
79998936|NCT05186701|Other|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
79998937|NCT05186701|Other|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
79680834|NCT00531986|Drug|HAART|Patients will continued their current HAART
79680835|NCT00531869|Behavioral|biases towards products|
79680836|NCT02917434|Dietary Supplement|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
79680837|NCT02920827|Combination Product|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
79371799|NCT03264027|Drug|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
79371800|NCT04415411|Other|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
79371801|NCT01887353|Drug|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
79680838|NCT02920827|Combination Product|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
79680839|NCT05319743|Other|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
79680840|NCT02921100|Procedure|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
79680841|NCT02921100|Procedure|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
79680842|NCT02921100|Procedure|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
79680843|NCT02921100|Device|EUS-guided fine needle|
79680844|NCT02943005|Procedure|Rotator cuff repair|
79680845|NCT02943161|Dietary Supplement|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
79709702|NCT02270879|Procedure|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
79998938|NCT03570008|Behavioral|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
79824254|NCT02345850|Drug|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
79525445|NCT00309192|Procedure|Sham Injection|Simulation procedure for triamcinolone injection
79525446|NCT00110591|Drug|PRO 140|Monoclonal antibody to CCR5
79525447|NCT01689246|Drug|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
79998939|NCT03570008|Behavioral|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
79371802|NCT01887353|Drug|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
79371803|NCT00988156|Drug|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
79525448|NCT01689246|Drug|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
79525449|NCT01689246|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
79525450|NCT01685268|Drug|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
79525451|NCT01685268|Drug|abiraterone acetate|1000 mg PO daily.
79525452|NCT01685268|Drug|Prednisone|5 mg PO twice daily.
79525453|NCT01683786|Drug|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day
79525454|NCT01684956|Procedure|Intradermal injection|
79525455|NCT01684956|Procedure|Subcutaneous injection|
79525456|NCT01683084|Drug|Telmisartan|
79680846|NCT02921139|Radiation|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
79371804|NCT00988156|Drug|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
79680847|NCT02921139|Procedure|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
79680848|NCT05319704|Other|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
79680849|NCT05319704|Other|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
79680850|NCT05318456|Dietary Supplement|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
79371805|NCT02160730|Drug|R-roscovitine|See Arm Description
79371806|NCT01896869|Drug|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
79371807|NCT01896869|Biological|Vaccine|5x10^8 cells administered in 6 intradermal injections
79525457|NCT01683084|Drug|Placebo|
79525458|NCT04823442|Drug|Mirabegron|Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
79525459|NCT04823442|Drug|Bisoprolol Fumarate|a single dose of 10 mg (2 tablets of 5 mg)
79525460|NCT04827108|Other|PeNAT validation|Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)
79525461|NCT04820244|Other|No intervention|No intervention
79525462|NCT04820634|Other|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills & concepts of job interviews. Sessions are approximately 90 minutes long.
79525463|NCT04820634|Other|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
79525464|NCT04825470|Procedure|Liver Transplantation|Liver Transplantation
79824255|NCT02345850|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
79998940|NCT02246426|Other|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
79680851|NCT05318456|Dietary Supplement|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
79998941|NCT02246426|Other|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
79998942|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
79998943|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
79680852|NCT05318456|Other|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
79998944|NCT00381485|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
79229440|NCT02464358|Behavioral|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
79229441|NCT02464358|Behavioral|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
79229442|NCT05399862|Dietary Supplement|Lactobacillus reuteri DSM 17648 probiotic|Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection
79229443|NCT05399862|Other|Placebo|Placebo capsule with no microbial cell preparation
79229444|NCT00802347|Drug|I5NP|"Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
79998945|NCT05183269|Device|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
79229445|NCT00802347|Drug|Saline|"Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
79229446|NCT02464280|Other|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
79371808|NCT01896869|Drug|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
79998946|NCT01335503|Dietary Supplement|AN-PEP|Endoprotease enzyme (AN-PEP)
79371809|NCT03329001|Drug|Niraparib Tablet|Niraparib tablet formulation
79371810|NCT03329001|Drug|Niraparib Capsule|Niraparib capsule formulation
79371811|NCT04872465|Device|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
79371812|NCT04872465|Device|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
79371813|NCT01896557|Drug|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
79371814|NCT01896557|Drug|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
79998947|NCT01341379|Drug|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
79229447|NCT02464280|Other|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
79229448|NCT02464280|Other|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
79229449|NCT04253444|Behavioral|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
79680853|NCT02920905|Drug|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
79824256|NCT00800787|Biological|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly"
79371815|NCT01896557|Drug|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
79371816|NCT02160808|Drug|Secretin|Drug to stimulate pancreatic secretion
79371817|NCT02160808|Drug|Placebo|
79998948|NCT01332539|Other|no intervention|non-interventional study
79998949|NCT01335659|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
79998950|NCT01335659|Device|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
79824257|NCT04099433|Dietary Supplement|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
79824258|NCT04099433|Other|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
79824259|NCT04045977|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
79824260|NCT04045977|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
79998951|NCT05182957|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
79998952|NCT05182957|Drug|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
79229450|NCT04253444|Behavioral|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
79229451|NCT01912950|Device|Prowave LX IPL|
79229452|NCT03134391|Drug|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
79229453|NCT02463968|Procedure|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
79371818|NCT01886105|Drug|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
79371819|NCT01886105|Other|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
79824261|NCT04045977|Behavioral|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
79998953|NCT05182957|Drug|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
79229454|NCT02463968|Procedure|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
79229455|NCT05399394|Drug|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
79998954|NCT02840474|Biological|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
79998955|NCT02840474|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
79998956|NCT00092651|Drug|MK0653A, ezetimibe (+) simvastatin|
79998957|NCT00092651|Drug|Comparators: simvastatin and ezetimibe|
79998958|NCT04777981|Dietary Supplement|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans [15, 16]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
79229456|NCT05399394|Radiation|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
79229457|NCT05399316|Dietary Supplement|Inulin|Natural fiber supplement extracted from chicory
79229458|NCT05399316|Dietary Supplement|Maltodextrin|Natural non-fermentable sugar
79371820|NCT01886105|Radiation|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
79371821|NCT03327909|Behavioral|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
79371822|NCT00989014|Drug|CD07805/47|0.5% Topical Gel
79371823|NCT00989014|Drug|CD07805/47|0.18% Topical Gel
79371824|NCT00989014|Drug|CD07805/47|0.07% Topical Gel
79998959|NCT04777981|Dietary Supplement|Placebo|Placebo
79998960|NCT01335737|Behavioral|aerobic training|12 weeks of aerobic training, 4 times/week
79998961|NCT01335737|Behavioral|Wait list|wait list control condition
79998962|NCT04889599|Drug|BH009 (Docetaxel injection)|75mg/m2
79998963|NCT04889599|Drug|Docetaxel injection|75mg/m2
79824262|NCT04021667|Other|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
79998964|NCT03476213|Procedure|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
79998965|NCT03476213|Procedure|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
79998966|NCT03567746|Procedure|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
79709703|NCT00594867|Drug|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
79824263|NCT04101305|Diagnostic Test|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
79824264|NCT04100993|Other|No intervention used|No intervention used
79229459|NCT05399238|Device|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
79824265|NCT04099043|Device|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
79998967|NCT03567746|Procedure|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
79229460|NCT01007721|Drug|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
79229461|NCT01007721|Drug|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
79229462|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
79229463|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
79371825|NCT00989014|Drug|CD07805/47 placebo|Vehicle Topical Gel
79709704|NCT00594867|Drug|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
79709705|NCT00594867|Drug|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
79371826|NCT05095012|Other|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
79371827|NCT03262779|Biological|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
79371828|NCT05593120|Diagnostic Test|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
79525465|NCT04821648|Drug|RJV001|Subcutaneous injection in the abdomen
79229464|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
79229465|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
79229466|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
79229467|NCT01007721|Drug|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
79229468|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
79525466|NCT04821648|Drug|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
79525467|NCT04829682|Behavioral|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
79709706|NCT01606241|Drug|Cyclophosphamide|Given PO
79709707|NCT01606241|Other|Laboratory Biomarker Analysis|Correlative studies
79709708|NCT01606241|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
79998968|NCT01342627|Drug|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
79998969|NCT04384393|Biological|ThisCART19 cells|0.2-60 x 10^6 CAR T cells per kg body weight.
79998970|NCT03570944|Procedure|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
79229469|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
79824266|NCT04073550|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
79229470|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
79824267|NCT04073550|Drug|Placebos|Anlotinib blank analog capsule.
79824268|NCT04073550|Drug|Topotecan|A topoisomerase I inhibitor.
79229471|NCT01007721|Drug|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
79229472|NCT01007721|Drug|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
79824269|NCT02576600|Device|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
79824270|NCT02576600|Other|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
79824271|NCT02576600|Drug|Propofol|TCI
79824272|NCT02576600|Drug|Remifentanil|TCI
79824273|NCT02863770|Other|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
79824274|NCT00713804|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
79824275|NCT00713804|Behavioral|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
79371829|NCT05593120|Diagnostic Test|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
79371831|NCT00990964|Device|Attain Success Lead|Attain Success Lead
79371832|NCT03299751|Biological|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
79371833|NCT05022394|Biological|Nivolumab|Given IV
79371834|NCT05022394|Drug|Sapanisertib|Given PO
79371835|NCT01895777|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
79371836|NCT01895777|Drug|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
79371837|NCT05005936|Procedure|Ultrasonography|Undergo ABUS
79371838|NCT05005936|Procedure|Ultrasonography|Undergo WBUS
79824276|NCT02329470|Procedure|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
79229473|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
79229474|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
79525468|NCT04829682|Behavioral|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
79525469|NCT02270892|Device|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
79525470|NCT01384396|Drug|KW-3357|Intravenous infusion once a day
79824277|NCT00796185|Drug|Paliperidone ER|
79998971|NCT01343641|Drug|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
79229475|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
79229476|NCT01007721|Drug|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
79998972|NCT01343641|Drug|Placebo|Inactive Pill used as a comparator
79998973|NCT03155945|Drug|Olorinab|Olorinab active treatment for 8 weeks.
79229477|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
79229478|NCT01007721|Drug|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
79525471|NCT01384409|Drug|KW-3357|Intravenous infusion once a day
79229479|NCT01007721|Drug|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
79998974|NCT03570866|Diagnostic Test|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
79998975|NCT03570866|Procedure|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
79229480|NCT00701558|Drug|Erlotinib|150 mg po daily
79998976|NCT01342705|Procedure|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
79229481|NCT00701558|Drug|Gemcitabine|1000 mg/m^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
79229482|NCT03233828|Biological|Aldesleukin|500,000 IU in 0.1mL
79229483|NCT03233828|Other|Saline|0.1 mL of sterile saline solution (0.9% m/v)
79371839|NCT03291951|Behavioral|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
79371840|NCT00992602|Drug|methotrexate|Given IV
79229484|NCT04454814|Other|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
79229485|NCT04454814|Other|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
79229486|NCT03882177|Drug|Pravastatin|Tablets, administered orally
79229487|NCT03882177|Drug|Rifafour|Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
79371841|NCT00992602|Drug|liposomal cytarabine|Given IT or via LP
79525472|NCT01384422|Drug|GLPG0634|
79525473|NCT01384435|Drug|KPS-0373|
79525474|NCT01384435|Drug|KPS-0373|
79525475|NCT01384435|Drug|KPS-0373|
79525476|NCT01384435|Drug|KPS-0373|
79998977|NCT03570788|Procedure|Amputation|Major amputation defined as at or above ankle
79998978|NCT01342783|Genetic|DNA analysis|
79229488|NCT03882177|Dietary Supplement|Vitamin B6|Administered orally.
79229489|NCT01007097|Drug|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
79371842|NCT00992602|Other|quality-of-life assessment|Ancillary studies
79371843|NCT00992602|Other|laboratory biomarker analysis|Correlative studies
79371844|NCT00993226|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
79371845|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
79371846|NCT00993226|Drug|Bupivacaine HCl Treatment 1c|40 ml
79371847|NCT00993226|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
79525477|NCT01384435|Drug|Placebo|
79525478|NCT01384448|Procedure|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
79525479|NCT01384448|Procedure|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
79229490|NCT01007097|Drug|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
79229491|NCT01007097|Drug|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
79229492|NCT01007097|Drug|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
79229493|NCT01007097|Drug|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
79229494|NCT01007097|Drug|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
79371848|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
79371849|NCT00993226|Drug|Bupivacaine HCl Treatment 2c|40 ml
79680854|NCT02920905|Drug|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
79998979|NCT01342783|Genetic|RNA analysis|
79998980|NCT01342783|Genetic|mutation analysis|
79998981|NCT01342783|Genetic|nucleic acid sequencing|
79998982|NCT01342783|Other|laboratory biomarker analysis|
79998983|NCT03569930|Drug|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
79998984|NCT03569930|Drug|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
79998985|NCT03569930|Behavioral|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
79824278|NCT02848092|Behavioral|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
79824279|NCT02848092|Other|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
79998986|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
79998987|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
79998988|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
79998989|NCT01343719|Drug|BI 661051|low dose solution for oral administration
79229495|NCT01007097|Drug|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
79229496|NCT02461082|Device|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
79229497|NCT02461082|Other|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
79525480|NCT01384474|Other|Diffusion of a surgical safety checklist|"Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
79525481|NCT01384500|Other|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
79525482|NCT01384552|Other|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
79680855|NCT02920905|Drug|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
79680856|NCT02920944|Device|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
79680857|NCT02920944|Device|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
79680858|NCT02917395|Device|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
79680859|NCT05319392|Diagnostic Test|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
79680860|NCT02917200|Drug|Moxifloxacin|Oral route
79680861|NCT02917200|Device|DAV132|Oral route
79998990|NCT01343719|Drug|BI 661051|low dose solution for oral administration
79998991|NCT01343719|Drug|BI 661051|low dose solution for oral administration
79998992|NCT01343719|Drug|BI 661051|high dose solution for oral administration
79998993|NCT01343719|Drug|BI 661051|high dose solution for oral administration
79998994|NCT01343719|Drug|BI 661051|low dose tablet
79229498|NCT01663402|Drug|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
79680862|NCT02917200|Other|Negative control|Oral route
79680863|NCT05318144|Other||
79680864|NCT05319275|Drug|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
79680865|NCT05319275|Drug|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
79998995|NCT01343719|Drug|Placebo|solution for administration
79998996|NCT01343719|Drug|BI 661051|medium dose tablet
79998997|NCT03569852|Behavioral|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
79998998|NCT03569852|Behavioral|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
79998999|NCT01316731|Other|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
79229499|NCT01663402|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
79824280|NCT04070066|Other|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
79824281|NCT04070066|Other|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
79824282|NCT00660309|Drug|Aliskiren|Aliskiren 300 mg tablets
79525483|NCT01384552|Other|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
79525484|NCT01384565|Drug|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
79229500|NCT01663402|Drug|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
79525485|NCT01384565|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
79680866|NCT02920515|Drug|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
79680867|NCT02920515|Drug|Zhibo dihuang pills|Traditional Chinese Medicine
79824283|NCT00660309|Drug|Irbesartan|Irbesartan 300 mg tablets
79824284|NCT00660309|Drug|Captopril|Captopril 25 mg tablet
79824285|NCT04578002|Other|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
79824286|NCT02845518|Procedure|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
79229501|NCT04454892|Other|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
79229502|NCT03223298|Drug|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
79680868|NCT02920515|Drug|Dabu ying pills|Traditional Chinese Medicine
79999000|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
79680869|NCT02942069|Behavioral|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
79229503|NCT03223298|Drug|0.9% Sodium Chloride Injection|1cc syringe
79680870|NCT02917356|Other|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
79824287|NCT04925388|Other|rapid molecular diagnosis|peritoneal samples will be analysed using Unyvero IAI test
79824288|NCT04925388|Other|conventional method analysis|peritoneal samples will be analysed using conventional method
79999001|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
79229504|NCT05399160|Behavioral|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
79525486|NCT01384578|Drug|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
79680871|NCT02917356|Other|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
79680872|NCT02917356|Other|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
79680873|NCT02920554|Procedure|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
79824289|NCT04046133|Drug|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
79824290|NCT02257554|Behavioral|education|Discussion of surgical expectations with patients
79824291|NCT00794079|Dietary Supplement|omega-3 fatty acids|4 grams per day for 8 weeks
79824292|NCT00794079|Dietary Supplement|corn oil|4 grams per day for 8 weeks
79824293|NCT02573714|Drug|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
79525487|NCT01384578|Drug|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
79824294|NCT02573714|Drug|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
79229505|NCT05390346|Behavioral|Nutrition education|The intervention programs consist of nutrition monitoring and diet intervention.
79229506|NCT03297086|Procedure|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
79229507|NCT00869661|Drug|Copegus|1000/1200mg po daily for 24 or 48 weeks
79229508|NCT00869661|Drug|Copegus|1000/1200mg po daily for 48 weeks
79525488|NCT01384617|Procedure|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
79525489|NCT01384617|Procedure|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
79525490|NCT01384643|Drug|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
79824295|NCT02573714|Other|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
79824296|NCT02573714|Other|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
79824297|NCT02573714|Other|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
79824298|NCT00794235|Drug|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
79824299|NCT00800943|Biological|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
79824300|NCT00714116|Drug|SBI-087|Single IV or SC dose of SBI-087
79229509|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
79229510|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 48 weeks
79229511|NCT00869661|Drug|RO5024048|1000mg bid for 24 weeks
79229512|NCT00869661|Drug|RO5024048|500mg bid for 12 weeks
79229513|NCT00869661|Drug|RO5024048|1000mg bid for 8 weeks
79229514|NCT00869661|Drug|RO5024048|1000mg bid for 12 weeks
79229515|NCT03192566|Drug|Tylenol|Dosing of Tylenol for post operative pain control
79229516|NCT04455984|Other|Date collection|Retrospective data analysis
79229517|NCT03297008|Other|No internvetion|No intervention, this is an observational study
79229518|NCT03296930|Drug|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
79824301|NCT00801021|Drug|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
79824302|NCT00796341|Procedure|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
79824303|NCT02575664|Drug|Buprenorphine|Buprenorphine 5 microg/h/7 days
79824304|NCT02575664|Drug|Placebo|Placebo patch
79824305|NCT02554539|Procedure|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
79824306|NCT02576522|Radiation|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
79229519|NCT03296930|Drug|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
79229520|NCT04605510|Other|Passive Cervical Joint Mobilization|It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
79229521|NCT05563545|Biological|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5~D-3), determined by tumor burden at baseline.
79371850|NCT04889248|Other|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
79824307|NCT00796497|Drug|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
79824308|NCT00714194|Procedure|Normal continuous sedation|Normal continuous sedation.
79824309|NCT00714194|Other|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
79229522|NCT04607772|Drug|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
79229523|NCT04607772|Drug|Rituximab|Dose: 375 mg/m^2
79371851|NCT01885559|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
79824310|NCT00796575|Drug|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
79824311|NCT00796575|Drug|placebo tablets|placebo tablets matching active
79824312|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
79824313|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
79824314|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
79824315|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
79229524|NCT04607772|Drug|Bendamustine|Dose: 90 mg/m^2
79229525|NCT04607772|Drug|Polatuzumab Vedotin|Dose: 1.8 mg/kg
79229526|NCT04607772|Drug|Ibrutinib|Dose: 420, 560 mg
79229527|NCT04607772|Drug|Lenalidomide|Dose: 20, 25 mg
79229528|NCT04607772|Drug|Tafasitamab|Dose: 12 mg/kg
79229529|NCT04607772|Drug|Venetoclax|Dose: 200, 400, 600, 800 mg
79229530|NCT04607772|Drug|Gemcitabine|Dose: 1000 mg/m^2
79229531|NCT04607772|Drug|Oxaliplatin|Dose: 100 mg/m^2
79229532|NCT03296852|Diagnostic Test|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
79371852|NCT01885559|Drug|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
79371853|NCT01885559|Drug|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
79824316|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
79371854|NCT01884545|Behavioral|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
79371855|NCT01884545|Genetic|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
79824317|NCT00801177|Biological|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
79824318|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
79824319|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
79824320|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
79824321|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
79824322|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
79824323|NCT00801177|Biological|IMC-11F8|"Cohort 4~600 mg I.V."
79824324|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
79824325|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
79824326|NCT00581100|Drug|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
79824327|NCT02554461|Other|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
79824328|NCT00579098|Drug|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
79824329|NCT00579098|Drug|Placebo|Placebo tablet taken by mouth once daily for 90 days
79824330|NCT00794391|Behavioral|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
79824331|NCT00794391|Behavioral|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
79824332|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
79824333|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
79680874|NCT02920554|Procedure|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
79229533|NCT03296852|Drug|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
79824334|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
79999002|NCT03160703|Other|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
79229534|NCT02464124|Drug|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
79371856|NCT01884545|Behavioral|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
79371857|NCT01895543|Drug|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
79824335|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
79229535|NCT02464124|Drug|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
79371858|NCT00994318|Drug|FCM (Ferric carboxymaltose) high ferritin target|
79525491|NCT01384656|Drug|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
79680875|NCT02942849|Drug|r-hFSH|As per standard clinical practice
79680876|NCT02917005|Drug|Palbociclib|CDK 4/6 inhibitor
79680877|NCT02917005|Drug|Exemestane|Aromatase inhibitor
79824336|NCT00801255|Drug|RO5024048|500mg po bid/100mg po q8h for 7 days
79824337|NCT00801255|Drug|danoprevir|500mg po bid/100mg po q8h for 14 days
79824338|NCT00801255|Drug|danoprevir|1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days
79824339|NCT00801255|Drug|danoprevir|1000mg po bid/200mg po q8h for 14 days
79680878|NCT02917005|Drug|Goserelin|LHRH agonist
79824340|NCT00801255|Drug|danoprevir|1000mg/600mg po twice daily for 14 days
79999003|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
79999004|NCT03569774|Procedure|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
79999005|NCT03569774|Procedure|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
79229536|NCT00859521|Drug|Levetiracetam|1000 mg Tablet
79229537|NCT00859521|Drug|Keppra®|1000 mg Tablet
79371859|NCT00994318|Drug|FCM (Ferric carboxymaltose) low ferritin target|
79371860|NCT00994318|Drug|Oral Iron (Ferrous sulphate)|
79371861|NCT04695808|Behavioral|yoga|Yoga practice will be done two days a week for 10 weeks.
79371862|NCT04525456|Dietary Supplement|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
79680879|NCT02920632|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
79680880|NCT02920632|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
79680881|NCT02942810|Drug|WCK 5222|IV infusion over a period of 60 minutes
79680882|NCT02920710|Drug|Repository Corticotropin Injection|"Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
79680883|NCT02941913|Drug|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
79824341|NCT00801255|Drug|danoprevir|1000mg/900mg po twice daily for 14 days
79824342|NCT04893590|Behavioral|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
79824343|NCT02577588|Biological|re-activated T cells|autologous reactivated T cells against p53
79824344|NCT02554305|Device|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
79824345|NCT02554305|Device|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
79680884|NCT05319002|Behavioral|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure & future template: Strong closure with artwork. 8. Re-evaluation: if possible.
79824346|NCT04069988|Behavioral|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
79824347|NCT02577666|Behavioral|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
79824348|NCT02577666|Behavioral|Housing Only|receives 3 months of project supported rental assistance
79229538|NCT04455672|Device|splints|"Scaning of the maxillary and mandibular cast in the centric relation.~The CAD/ CAM splints will be designed using Exocad s.~The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~All patient will be asked to wear their spints during sleeping only.~In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
79824349|NCT02577666|Behavioral|Treatment as Usual|receives services as normally offered within the community
79824350|NCT00796731|Drug|SAR3419|administered by intravenous infusion
79999006|NCT01342861|Dietary Supplement|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
79229539|NCT02463890|Other|Training|
79371863|NCT00995722|Drug|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
79999007|NCT03567668|Procedure|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
79371864|NCT00995722|Drug|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
79371865|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
79229540|NCT02463890|Other|Control|
79371866|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
79371867|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
79371868|NCT03016468|Drug|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
79525492|NCT01384682|Drug|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
79525493|NCT01384695|Drug|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
79824351|NCT04891328|Other|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
79824352|NCT00794625|Drug|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
79824353|NCT00794625|Drug|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
79824354|NCT00794625|Drug|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
79824355|NCT00794625|Drug|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
79824356|NCT00794625|Behavioral|Behavioral family counseling|Weekly behavioral counseling with a therapist
79824357|NCT00714350|Behavioral|New ICU Display Visualization|
79824358|NCT02577432|Drug|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
79525494|NCT01384695|Drug|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
79229541|NCT05398770|Dietary Supplement|Vitamin D supplementation (30 µg/d)|The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
79229542|NCT04649775|Device|AirFLO2|Mask device
79229543|NCT05398692|Other|Virtual vs On Site Pulmonary Rehabilitation|As part of the on site or virtual visits, the subject will receive standard pulmonary rehabilitation educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques. If post exertional malaise is present, the patient will only receive the educational sessions, no aerobic training.
79229544|NCT03130374|Biological|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
79999008|NCT01316965|Behavioral|Multifaceted prevention program HELP(Hospital Elder Life Program)|"A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
79229545|NCT04159454|Device|PITA|Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate ~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
79229546|NCT00843687|Drug|Risperidone long-acting injectable|
79371869|NCT03016468|Drug|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
79371870|NCT00997204|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
79371871|NCT00997516|Procedure|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
79371872|NCT00997516|Procedure|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
79371873|NCT04263610|Drug|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
79525495|NCT01384708|Drug|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
79371874|NCT04263610|Drug|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (>=) 30% at Week 8, no dose increase will be done and if PASI is less than (<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
79680885|NCT02917161|Device|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
79680886|NCT02941952|Device|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
79371875|NCT04263610|Drug|Tildrakizumab|Participants who achieve PASI less than (<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg [(as per the Summary of Product Characteristics (SmPC)] at Weeks 16, 20 and 32 up to Week 40.
79680887|NCT02917044|Procedure|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
79229547|NCT03176004|Other|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
79229548|NCT04642131|Dietary Supplement|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
79229549|NCT04642131|Device|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
79525496|NCT01384747|Drug|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
79824359|NCT02577432|Drug|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
79824360|NCT02577432|Drug|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
79525497|NCT01384747|Drug|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
79229550|NCT04642131|Other|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
79229551|NCT05390190|Device|Non ablative radiofrequency|Device
79229552|NCT02866526|Other|Patient questionnaire|quantitative and qualitative data collection will be proposed.
79525498|NCT01384799|Drug|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
79525499|NCT01384799|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
79525500|NCT01384799|Radiation|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
79229553|NCT05398614|Biological|SENL101|Patients will be treated with CD7 CAR-T cells
79229554|NCT05398458|Procedure|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
79824361|NCT02577432|Drug|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
79824362|NCT02577276|Device|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
79824363|NCT00794703|Drug|micafungin (Mycamine)|Intravenous
79824364|NCT00794703|Drug|itraconazole|oral
79824365|NCT02575430|Other|No treatment: retrospective chart review|
79824366|NCT00772031|Drug|propranolol LA|Propranolol LA up to 240 mg/day
79824367|NCT00772031|Drug|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
79824368|NCT00772031|Drug|placebo|an inactive substance
79824369|NCT02576262|Procedure|TCT，HPV，colposcopic inspection|
79824370|NCT00801411|Drug|cyclophosphamide|Given IV
79229555|NCT01001715|Drug|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
79824371|NCT00801411|Drug|docetaxel|Given IV
79824372|NCT00801411|Drug|doxorubicin hydrochloride|Given IV
79824373|NCT02579148|Biological|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
79824374|NCT02579148|Biological|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
79824375|NCT04577066|Other|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
79824376|NCT04577066|Other|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
79824377|NCT04577066|Other|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
79824378|NCT00794859|Drug|Sorafenib|400mg twice daily
79824379|NCT00714506|Behavioral|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
79824380|NCT00714506|Other|Physical activity control|physical activity plus successful aging health education
79229556|NCT01001715|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
79229557|NCT04473729|Other|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
79229558|NCT02463812|Drug|Intralipid|
79229559|NCT02463812|Drug|Saline|
79229560|NCT00789633|Drug|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
79229561|NCT00789633|Drug|Placebo|Matching placebo given orally twice daily
79229562|NCT00789633|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
79525501|NCT01384812|Drug|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
79525502|NCT01384812|Drug|isoton sodium chloride|intravenous injection for 25 min
79525503|NCT01384838|Behavioral|Counseling|Nutritional, lifestyle and sports counseling
79525504|NCT01384838|Behavioral|physical activity|counseling and controlled physical activity
79525505|NCT01384851|Drug|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
79525506|NCT01384851|Drug|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
79525507|NCT01384851|Drug|Refresh Contacts|One drop both eyes four times daily for two weeks
79824381|NCT00580866|Device|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
79824382|NCT00801567|Device|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
79824383|NCT00771953|Drug|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
79824384|NCT00771953|Drug|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
79824385|NCT00771953|Drug|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
79824386|NCT02576028|Other|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
79824387|NCT02576028|Other|standard active exercises|two sessions of 45 minutes of active exercises
79824388|NCT00714584|Drug|Naltrexone HCl.|
79824389|NCT02554227|Other|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
79824390|NCT03988127|Diagnostic Test|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
79824391|NCT00714662|Device|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
79824392|NCT02553837|Biological|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
79824393|NCT00621244|Drug|LBH589|
79824394|NCT02553759|Other|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
79525508|NCT01384864|Drug|proflavine|2-6 ml of 0.01% proflavine
79680888|NCT02917044|Device|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
79824395|NCT04021901|Device|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
79824396|NCT00801645|Behavioral|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
79824397|NCT00916409|Device|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
79824398|NCT00916409|Drug|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
79824399|NCT00714740|Drug|acetazolamide|acetazolamide 2 times 250mg per day
79824400|NCT00659529|Drug|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
79824401|NCT02575508|Drug|Fluorouracil|Given IV
79824402|NCT02575508|Drug|Irinotecan Hydrochloride|Given IV
79229563|NCT02463188|Behavioral|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
79229564|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
79229565|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
79229566|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
79824403|NCT02575508|Other|Laboratory Biomarker Analysis|Correlative studies
79824404|NCT02575508|Drug|Oxaliplatin|Given IV
79824405|NCT02575508|Drug|pan FGFR Kinase Inhibitor BGJ398|Given IV
79824406|NCT02575508|Other|Pharmacological Study|Correlative studies
79824407|NCT00795015|Drug|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
79229567|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
79229568|NCT00788541|Other|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
79229569|NCT03296618|Drug|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
79229570|NCT03296540|Drug|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
79229571|NCT03296540|Drug|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
79525509|NCT01384890|Radiation|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
79680889|NCT02917044|Procedure|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
79680890|NCT02917044|Device|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
79999009|NCT01332617|Drug|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"Simvastatin 80 mg PO daily starting day -2 through day 10.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
79229572|NCT00787059|Drug|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10^9 vp to 10^12 vp in 5 dose groups
79229573|NCT00787059|Drug|Sucrose (3%)|
79229574|NCT04489160|Drug|C1 Inhibitor, Human|6000 IU C1-INH
79525510|NCT01384890|Radiation|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
79525511|NCT01384903|Drug|KW-3357|Intravenous infusion once a day
79525512|NCT01384903|Drug|Plasma-derived antithrombin|Intravenous infusion once a day
79525513|NCT01384916|Behavioral|Yoga|2x weekly
79525514|NCT01384916|Behavioral|Healthy Living Workshop|2x weekly
79525515|NCT01384942|Behavioral|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
79525516|NCT01384942|Behavioral|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
79824408|NCT00795015|Drug|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
79824409|NCT04045899|Device|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
79824410|NCT04045899|Device|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
79229575|NCT04489160|Drug|Placebo|0.9% saline
79229576|NCT00786201|Drug|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
79229577|NCT00786201|Drug|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
79229578|NCT00786201|Drug|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
79229579|NCT00786201|Drug|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
79229580|NCT05536557|Other|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
79229581|NCT05536557|Other|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
79371876|NCT00997594|Procedure|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
79525517|NCT01384968|Dietary Supplement|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
79229582|NCT03296384|Other|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
79229583|NCT00841815|Drug|Amlodipine Besylate|10 mg Tablet
79229584|NCT00841815|Drug|Norvasc®|10 mg Tablet
79229585|NCT03296306|Drug|Treatment duration of cisplatin based chemotherapy|"GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
79229586|NCT04440280|Drug|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
79525518|NCT01384981|Procedure|pulmonary rehabilitation|
79229587|NCT04440280|Drug|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
79229588|NCT04440280|Drug|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
79229589|NCT03296228|Radiation|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
79229590|NCT03296228|Radiation|Flexibility Radiographs (awake traction)|awake traction
79371877|NCT04225390|Drug|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
79525519|NCT01384994|Drug|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
79525520|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
79525521|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
79525522|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
79525523|NCT01384994|Drug|Panitumumab|6 mg/kg BW every 2 weeks
79525524|NCT01384994|Drug|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
79229591|NCT03296228|Radiation|Flexibility Radiographs (STUGA)|supine traction under GA
79371878|NCT00997672|Drug|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
79680891|NCT02942693|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
79680892|NCT02942693|Radiation|Particle Therapy|Same total dose and fractionation will be used in both arms.
79680893|NCT02916888|Other|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
79680894|NCT02916888|Other|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
79680895|NCT02941874|Other|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
79824411|NCT04045899|Device|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
79824412|NCT02575586|Device|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
79371879|NCT00997672|Drug|Placebo|
79525525|NCT01384994|Drug|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
79525526|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
79525527|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
79525528|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
79680896|NCT02941835|Radiation|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
79680897|NCT02920593|Drug|Vitamin D3|Vitamin D prophylaxis
79680898|NCT02942732|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
79680899|NCT02942459|Other|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
79680900|NCT02942459|Other|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
79229592|NCT04572412|Radiation|Low dose Radiotherapy|"External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved."
79525529|NCT01385007|Behavioral|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
79680901|NCT02920437|Behavioral|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
79229593|NCT03295916|Radiation|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
79371880|NCT04160650|Behavioral|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
79680902|NCT02920437|Other|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
79371881|NCT04828161|Drug|ensovibep|IV on day 1 only.
79371882|NCT04828161|Drug|Placebo|IV on day 1 only.
79680903|NCT02942420|Drug|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
79680904|NCT02920359|Drug|LEUPRORELIN ACETATE|
79680905|NCT02916849|Other|Safe Step|Strength and balance exercise-digital version
79680906|NCT02916849|Other|OEP|Strength and balance exercise -paper version
79824413|NCT02575586|Device|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
79824414|NCT00714818|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
79229594|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
79824415|NCT00714818|Behavioral|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
79999010|NCT03569696|Biological|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
79229595|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
79229596|NCT00782535|Drug|Placebo|Inhaled solution, single dose of placebo
79229597|NCT00841659|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
79229598|NCT00841659|Drug|Paxil®|40 mg Film-Coated Tablet
79229599|NCT04061252|Drug|KHK4827|brodalumab 210mg Q2W, SC
79229600|NCT04061252|Drug|Placebo|Q2W, SC
79229601|NCT05503654|Behavioral|Nutrition education|Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
79229602|NCT04057586|Procedure|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
79229603|NCT04057586|Procedure|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
79229604|NCT05079243|Biological|Scaffold and adipose-derived stromal cell enriched fat grafts|eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
79371883|NCT01000324|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
79371884|NCT01000324|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
79371885|NCT01000324|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
79371886|NCT04399629|Behavioral|PCIT-ED|12 sessions of PCIT-ED therapy
79680907|NCT02941796|Drug|HCP1105|
79680908|NCT02941796|Drug|HCP0918|
79680909|NCT02941796|Drug|HCP0816|
79680910|NCT02916654|Dietary Supplement|sucrosomial iron|administration of sucrosomial iron
79229605|NCT04473417|Drug|Forxiga|single dose administration after 10hr fasting
79824416|NCT00843700|Behavioral|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
79824417|NCT00843700|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
79999011|NCT01343797|Other|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
79371887|NCT04399629|Behavioral|Parenting Wisely|Teaches parents how to set more effective limits
79371888|NCT04606797|Drug|Nicotine patch|Nicotine transdermal patches as per product monograph
79371889|NCT02164240|Drug|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
79371890|NCT02164240|Drug|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
79371891|NCT02164396|Device|Spectacle Lens|Spectacle Lens Only
79371892|NCT02164396|Device|Habitual Soft Contact Lens|subject's own contact lens
79371893|NCT02164396|Device|Test Lens|senofilcon A or narafilcon A
79371894|NCT02169466|Drug|BIA 9-1067|OPC, Opicapone
79371895|NCT02169466|Drug|Placebo|PLC, Placebo
79371896|NCT02169466|Drug|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
79371897|NCT05440396|Diagnostic Test|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
79371898|NCT01001806|Drug|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
79371899|NCT01001806|Drug|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
79525530|NCT01385020|Drug|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
79680911|NCT02916654|Drug|Sulphate iron|administration of sulphate iron
79680912|NCT02916576|Device|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
79680913|NCT02941562|Radiation|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
79680914|NCT02941562|Drug|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
79680915|NCT02941562|Radiation|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
79999012|NCT00092573|Drug|MK0653, ezetimibe|
79229606|NCT04473417|Drug|DA-2811|single dose administration after 10hr fasting
79229607|NCT04473417|Drug|DA-2811|single dose administration after 10hr fasting
79525531|NCT01385046|Behavioral|Project Fit|physical activity and nutrition education
79680916|NCT02941562|Drug|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
79680917|NCT02941562|Procedure|Radical rectal cancer resection|Radical rectal cancer resection
79824418|NCT00796887|Drug|Extended-Release Niacin|500mg tablet once daily
79824419|NCT00796887|Drug|Extended-Release Niacin|1000mg tablet once daily
79824420|NCT00796887|Drug|Placebo|Placebo tablet once daily
79999013|NCT00092573|Drug|Comparator: fenofibrate monotherapy|
79229608|NCT04473417|Drug|DA-2811|single dose administration after high fat and calorie fed diet
79229609|NCT05503576|Device|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
79229610|NCT01001091|Drug|AL-38583 ophthalmic solution|
79371900|NCT01001806|Drug|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
79999014|NCT01342939|Other|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
79525532|NCT01385072|Biological|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
79525533|NCT01385111|Procedure|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
79229611|NCT01001091|Drug|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
79229612|NCT01001091|Drug|Dexamethasone ophthalmic suspension, 0.1%|
79371901|NCT04021264|Drug|Ropivacaine-Sufentanil|Local anesthetic injection
79371902|NCT04021264|Drug|Dextrose 5|Sham injection
79525534|NCT01385111|Procedure|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
79525535|NCT01385124|Drug|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
79525536|NCT01385150|Genetic|mutation analysis|
79525537|NCT01385150|Genetic|protein analysis|
79525538|NCT01385150|Other|laboratory biomarker analysis|
79525539|NCT01385150|Other|liquid chromatography|
79525540|NCT01385150|Other|mass spectrometry|
79525541|NCT01385215|Drug|Fluzone|0.5 ml/15 micrograms
79525542|NCT01385215|Drug|Fluzone|0.5 ml/60 micrograms
79371903|NCT01002118|Drug|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
79229613|NCT05076045|Device|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
79229614|NCT02716298|Device|fanfilcon A|contact lens
79371904|NCT01002118|Drug|Placebo|4 capsules each day for 16 weeks
79371905|NCT05322369|Other|periodontal charting only|Periodontal charting only
79525543|NCT01385228|Drug|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
79525544|NCT01385228|Drug|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
79525545|NCT01385228|Drug|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
79680918|NCT02941562|Drug|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
79680919|NCT02942888|Dietary Supplement|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
79680920|NCT02942888|Dietary Supplement|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
79680921|NCT02916420|Drug|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
79680922|NCT02916420|Drug|Dexamethasone|≤70 years,40mg/day; >70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
79680923|NCT05318924|Drug|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
79680924|NCT05318924|Other|Placebo|Participants will receive a saline infusion as the placebo control condition.
79229615|NCT02716298|Device|lotrafilcon B|contact lens
79229616|NCT05076682|Drug|Choline|Choline 300mg tid or 500mg bid, p.o
79229617|NCT05076682|Drug|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
79229618|NCT05076682|Drug|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
79229619|NCT05076682|Drug|Efavirenz|Efavirenz 600mg qd, p.o
79371906|NCT05311839|Other|Exercise|Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
79371907|NCT05311839|Other|Thera band|graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
79371908|NCT01003288|Biological|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
79371909|NCT04759365|Drug|ASN51|ASN51 formulation for oral capsule
79371910|NCT04759365|Drug|Placebo|Placebo formulation for oral capsule
79371911|NCT05364112|Device|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
79525546|NCT01385228|Drug|Prednisone|5mg Prednisone given twice daily days 1-21.
79525547|NCT01385228|Drug|Pegfilgrastim|
79525548|NCT01385241|Behavioral|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
79525549|NCT01385267|Procedure|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
79525550|NCT01385319|Device|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
79229620|NCT05066139|Other|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
79229621|NCT00840879|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
79371912|NCT03232593|Drug|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
79680925|NCT02920398|Drug|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
79824421|NCT00578942|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
79229622|NCT00840879|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
79229623|NCT05503498|Other|DATA RECORDING|RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
79824422|NCT00835822|Drug|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
79824423|NCT00835822|Drug|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
79824424|NCT02553213|Other|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
79824425|NCT02553213|Other|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
79824426|NCT02553213|Other|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
79824427|NCT02553213|Other|easy digestible diet|
79824428|NCT02575274|Procedure|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
79229624|NCT02163434|Drug|Gabapentin|
79371913|NCT02162446|Drug|satoreotide trizoxetan|
79371914|NCT01895309|Drug|Enbrel (etanercept)|
79680926|NCT05318885|Other|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
79680927|NCT02916342|Procedure|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
79680928|NCT02916342|Procedure|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
79824429|NCT00843934|Drug|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
79229625|NCT02163434|Drug|Metoclopramide|
79305571|NCT03241667|Device|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
79371915|NCT01895309|Drug|SB4 (proposed biosimilar to etanercept)|
79371916|NCT04738071|Device|PFO closure|PFO closure after stroke or transient ischemic attack
79371917|NCT01884311|Biological|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
79680929|NCT05318846|Drug|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
79680930|NCT05318846|Drug|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
79680931|NCT02920203|Genetic|Heart and spleen tissue|genetic sequencing
79824430|NCT00843934|Drug|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
79824431|NCT00805701|Drug|avodart|0.5 avodart once daily for 13 weeks
79824432|NCT00805701|Drug|Placebo|placebo
79824433|NCT02547610|Device|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
79229626|NCT04638946|Behavioral|Titration to high intensity exercise (T-HIE)|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Participants will begin at low intensity with the goal of titrating to high intensity by 2 weeks prior to the end of trial (Week 6). If a participant achieves at least 70% of the duration goal at the target heart rate, he/she will be titrated to the next dose level (moderate intensity). This will continue until high intensity exercise is achieved. Prescription is based on heart rate reserve((maximum heart rate [220-age] - resting heart rate)*intensity percent - resting heart rate. Intensity percent lower/upper limits for moderate intensity are 40-59% and for high intensity are 60-84%.
79371918|NCT01004770|Drug|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
79371919|NCT01004770|Drug|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
79229627|NCT04638946|Behavioral|Low intensity exercise prescription|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Prescription is based on heart rate reserve ((maximum heart rate [220-age] - resting heart rate)*30-39% (lower/upper limit of zone) - resting heart rate.
79229628|NCT05563324|Genetic|DNA extraction and genotyping of candidate genetic polymorphisms|
79229629|NCT05563324|Other|self-assessment questionnaires|
79229630|NCT00840411|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
79229631|NCT00840411|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
79371920|NCT04399317|Device|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
79371921|NCT03230877|Device|Toffee full face mask with 'Improved Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.
79371922|NCT03230877|Device|Toffee full face mask with 'Normal Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
79680932|NCT02942381|Drug|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
79371923|NCT04469374|Other|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
79525551|NCT01385319|Device|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
79680933|NCT02942381|Drug|Placebo|
79680934|NCT02920281|Other|Polysomnography|
79824434|NCT00805779|Device|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
79824435|NCT00714896|Behavioral|Stepped-Care|"stage-based expert system written intervention at baseline and 3 months~in-person stage appropriate counseling at baseline and 3 months~telephone counseling sessions at weeks 2,4 and 8,~as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
79229632|NCT00840099|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
79229633|NCT00840099|Drug|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
79305572|NCT00700739|Device|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
79371924|NCT04469374|Other|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
79371925|NCT01884077|Device|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
79371926|NCT01884077|Device|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
79680935|NCT02941718|Behavioral|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
79680936|NCT02941718|Behavioral|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
79680937|NCT02920320|Other|Internet-based self-help program|
79680938|NCT03458468|Drug|Tranexamic Acid|1g Tranexamic acid prior to skin incision
79680939|NCT03458468|Drug|Saline|Equivalent volume of saline prior to skin incision
79824436|NCT00714896|Behavioral|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
79824437|NCT04042948|Drug|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
79824438|NCT00796965|Drug|AZD7268|Solution/Capsule, Oral, once daily
79824439|NCT00796965|Drug|Placebo|
79824440|NCT00765245|Drug|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
79824441|NCT00765245|Drug|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
79824442|NCT00765245|Drug|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
79824443|NCT02546518|Device|Moniri Otovent|Please see Arm Description.
79824444|NCT02546518|Device|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
79824445|NCT00801879|Drug|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
79824446|NCT00801879|Drug|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
79824447|NCT00718484|Drug|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
79525552|NCT01385332|Procedure|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
79824448|NCT00718484|Drug|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
79824449|NCT00841126|Drug|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
79824450|NCT00841126|Drug|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
79824451|NCT00841126|Drug|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
79229634|NCT03108248|Drug|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
79229635|NCT03108248|Device|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
79229636|NCT04634890|Behavioral|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
79229637|NCT00836901|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
79824452|NCT02553369|Other|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
79824453|NCT03987113|Other|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
79229638|NCT00836901|Drug|Augmentin®|400 mg-57 mg chewable tablet
79525553|NCT01385332|Procedure|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
79680940|NCT02919891|Other|Questionnaire|Questionnaires
79680941|NCT02941679|Drug|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
79680942|NCT02941679|Drug|HGP1011|Boehringer Ingelheim
79680943|NCT02941679|Drug|HCP0910|GlaxoSmithKline
79680944|NCT02919930|Device|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
79680945|NCT02919930|Device|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
79680946|NCT02942537|Device|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
79824454|NCT02575040|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
79824455|NCT03987347|Other|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
79824456|NCT00805857|Drug|Tipranavir|
79824457|NCT00718562|Drug|AMN107|
79824458|NCT00801957|Drug|tacrolimus ointment 0.03%|topical application
79824459|NCT00801957|Drug|hydrocortisone acetate ointment 1%|topical application
79824460|NCT00801957|Drug|hydrocortisone butyrate ointment 0.1%|topical application
79824461|NCT00801957|Biological|Meningitec|im injection
79824462|NCT00801957|Biological|AC VAX|im injection
79824463|NCT02572544|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
79824464|NCT02547688|Device|Nasal High Flow|
79371927|NCT04614311|Drug|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
79824465|NCT00714974|Device|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
79824466|NCT00836134|Procedure|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
79824467|NCT00836134|Procedure|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
79824468|NCT00715052|Procedure|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
79229639|NCT04466384|Device|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
79229640|NCT05503420|Device|Masticatory muscle training exerciser|In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
79229641|NCT04444466|Drug|UCB8600|Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
79229642|NCT04444466|Other|Placebo|Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
79525554|NCT01385345|Drug|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
79525555|NCT01385358|Procedure|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
79680947|NCT02942537|Procedure|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
79371928|NCT03922204|Drug|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
79371929|NCT04717791|Device|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
79680948|NCT02916537|Drug|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
79824469|NCT00782795|Drug|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
79999015|NCT01342939|Other|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
79371930|NCT04713579|Other|No intervention - observational study|There is no intervention in this study as it is purely observational.
79525556|NCT01385358|Procedure|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
79680949|NCT02916537|Procedure|Prostatectomy|Radical prostatectomy with lymph node dissection
79680950|NCT02916615|Other|High nitrate vegetables|vegetables naturally high in nitrate
79680951|NCT02916615|Dietary Supplement|Low nitrate vegetables + nitrate|pill containing KNO3
79824470|NCT00782795|Drug|Placebo|
79680952|NCT02916615|Other|Low nitrate vegetables|vegetables naturally low in nitrate
79680953|NCT02942342|Procedure|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
79680954|NCT02916459|Device|21G EBUS-TBNA needle|
79680955|NCT02916459|Device|Flexible 19G EBUS-TBNA needle|
79680956|NCT02942303|Drug|Dysport|
79680957|NCT02942303|Procedure|lateral orbicularis injection|
79680958|NCT02942303|Procedure|Lateral orbicularis + corrugator injection|
79824471|NCT00841282|Procedure|Colonoscopy for colorectal cancer screening|
79824472|NCT00841282|Procedure|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
79824473|NCT00841282|Procedure|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
79824474|NCT00715130|Behavioral|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
79824475|NCT00841360|Other|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
79824476|NCT00841360|Other|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
79824477|NCT02573558|Drug|Dexmedetomidine|
79824478|NCT02573558|Drug|Propofol|
79824479|NCT00656799|Drug|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
79824480|NCT00656799|Drug|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
79824481|NCT00764699|Drug|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
79999016|NCT01342939|Dietary Supplement|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
79999017|NCT01342939|Other|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
79680959|NCT02920086|Behavioral|Nutrition Education Program|"The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~Nutritional education will be provided to ICU patents' families by a dietitian~Tracking of nutritional information by family~Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
79680960|NCT02920086|Other|Decision Support Program|"Families will be provided with a web-based decision support tool (My ICU Guide)~Families will meet with the ICU medical team early in ICU stay to review goals of care"
79824482|NCT02547142|Other|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
79824483|NCT00715286|Other|timing of surgery|Surgery is followed by chemotherapy
79824484|NCT00715286|Other|timing of surgery|Chemotherapy is followed by surgery
79824485|NCT00844012|Drug|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
79824486|NCT00844012|Drug|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
79680961|NCT02942147|Device|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
79824487|NCT02574962|Drug|H.P. Acthar® Gel|
79824488|NCT00802035|Drug|Baclofen IR|30 mg; single dose
79824489|NCT00802035|Drug|Baclofen ER|30 mg; single dose
79999018|NCT01342939|Other|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
79229643|NCT04460560|Drug|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
79229644|NCT03295838|Behavioral|Mentalization-based treatment|See Arm description
79229645|NCT04288804|Device|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
79680962|NCT02942147|Procedure|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
79229646|NCT04288804|Device|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
79680963|NCT02916381|Procedure|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
79824490|NCT00836212|Drug|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
79824491|NCT00836212|Drug|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
79824492|NCT04069676|Other|EEG|EEG, ECG and EDR record during a behavioral task
79824493|NCT00782717|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
79680964|NCT02916381|Procedure|General anaesthesia|
79824494|NCT00782717|Other|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
79824495|NCT00782717|Drug|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
79824496|NCT00656175|Drug|raltegravir|raltegravir
79999019|NCT03392090|Other|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
79229647|NCT04537689|Biological|Ixekizumab|Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.
79680965|NCT02920047|Drug|Fimasartan/Amlodipine|Treatment B
79680966|NCT02920047|Drug|Fimasartan + Amlodipine|Treatment A
79680967|NCT02920125|Drug|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
79680968|NCT02920125|Combination Product|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
79999020|NCT04376983|Behavioral|Telerehabilitation for patients with a cardiac resynchronisation device|Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
79999021|NCT01332695|Drug|ST101|tablets for oral administration
79999022|NCT01332695|Drug|Placebo|placebo to match
79999023|NCT03569540|Drug|Glibenclamide|Placebo-controlled; Double blind test
79999024|NCT03569540|Other|Placebo|Amylum
79999025|NCT04376437|Drug|medical cannabis|inhalation by using a Portable Metered-Dose Cannabis Inhaler
79680969|NCT02920125|Other|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
79680970|NCT02942030|Other|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
79229648|NCT04537689|Drug|Methotrexate|Oral tablet up to 15mg per week
79680971|NCT02916264|Procedure|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
79824497|NCT02572622|Other|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
79824498|NCT02572622|Other|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
79824499|NCT02572622|Other|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
79824500|NCT02572622|Other|exercise|special lumbar stabilization exercises were applied in advanced protocol.
79824501|NCT02601599|Behavioral|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
79824502|NCT02572466|Other|Hemodialysis|ESRD group received long-term hemodialysis
79999026|NCT01335893|Drug|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
79999027|NCT03567278|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
79999028|NCT01339169|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
79229649|NCT04537689|Drug|Cyclosporin A|Oral capsule up to 200mg per day
79229650|NCT04537689|Drug|Acitretin|Oral capsule up to 25mg per day
79371931|NCT04579029|Procedure|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
79680972|NCT02941991|Biological|hESC-RPE|sub-retinal injection
79999029|NCT05251441|Dietary Supplement|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
79229651|NCT02462096|Device|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
79371932|NCT04705545|Device|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
79371933|NCT04705545|Device|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
79229652|NCT03295760|Drug|Q10 Coenzyme|
79229653|NCT05563012|Drug|Sintilimal Injection|Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
79680973|NCT02915952|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
79680974|NCT02915952|Other|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
79229654|NCT03295604|Procedure|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
79229655|NCT03295604|Procedure|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
79229656|NCT04501653|Drug|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
79680975|NCT05318495|Device|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
79680976|NCT05318495|Device|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
79680977|NCT05318495|Device|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
79680978|NCT02920164|Device|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
79999030|NCT03567200|Behavioral|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
79999031|NCT01332773|Procedure|Artery first procedure|early identification of SMA to evaluate infiltration
79999032|NCT01332773|Procedure|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
79999033|NCT04371679|Other|No interventions planned|No interventions planned. Observational.
79229657|NCT04501653|Drug|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
79525557|NCT01385384|Device|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
79229658|NCT04730206|Drug|Camostat|100 milligram tablets
79229659|NCT04730206|Drug|Placebo|oral tablets, identical in size and shape
79229660|NCT04730206|Drug|Molnupiravir|200 milligram tablets
79229661|NCT02463344|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
79371934|NCT05066698|Biological|ST266|Topical ocular application: one drop four times a day for eight weeks
79525558|NCT01385397|Other|Preceptorship and virtual community|
79525559|NCT01385410|Behavioral|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
79525560|NCT01385423|Drug|Preparative Regimen|Fludarabine 25 mg/m^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (*if < 4 months from prior transplant, omit day -4 dose)
79525561|NCT01385423|Biological|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
79680979|NCT02920164|Device|Placebo acupuncture|Placebo acupuncture with placebo needles
79680980|NCT02940938|Other|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
79680981|NCT02941055|Other|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
79680982|NCT02941055|Other|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
79680983|NCT02919852|Procedure|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
79371935|NCT05066698|Other|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
79371936|NCT05066698|Biological|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
79371937|NCT04277793|Behavioral|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
79371938|NCT05058742|Device|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
79371939|NCT03832101|Behavioral|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
79371940|NCT03685318|Device|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
79371941|NCT03685318|Device|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
79680984|NCT02941094|Device|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
79680985|NCT02941094|Device|Ultrasound|Xario, Toshiba Tokyo Japan
79680986|NCT02941133|Other|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
79680987|NCT02941133|Other|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
79229662|NCT00781443|Drug|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
79371942|NCT03617302|Drug|Experimental: Nitrate-containing|Experimental
79525562|NCT01385449|Procedure|interscalene catheter|interscalene catheter
79525563|NCT01385449|Procedure|interscalene block|interscalene block
79999034|NCT03567512|Behavioral|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
79999035|NCT03567512|Behavioral|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes)."
79371943|NCT03617302|Drug|Placebo: Nitrate-depleted|Placebo
79229663|NCT00781443|Drug|placebo|Repeating subcutaneous injection
79371944|NCT04334980|Biological|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
79371945|NCT05003908|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79371946|NCT04323748|Drug|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
79371947|NCT03015298|Device|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
79371948|NCT03015298|Device|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
79371949|NCT04296838|Drug|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
79371950|NCT03228459|Diagnostic Test|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
79371951|NCT03228459|Diagnostic Test|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
79371952|NCT03228459|Diagnostic Test|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
79824503|NCT00797121|Procedure|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
79229664|NCT03134937|Device|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
79229665|NCT05503342|Other|Mobile Application|Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
79229666|NCT05503342|Other|Asthma control assessment|Asthma control assessment questionnaire application in paper format
79229667|NCT04473027|Diagnostic Test|Blood sample collection|Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
79371953|NCT03228459|Diagnostic Test|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
79371954|NCT03228459|Diagnostic Test|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
79371955|NCT03228459|Diagnostic Test|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
79371956|NCT03228459|Diagnostic Test|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
79525564|NCT01385475|Behavioral|RT|8 week RT Intervention
79525565|NCT01385488|Behavioral|self-monitor arm volume|bioelectrical impedance
79680988|NCT02916069|Device|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
79229668|NCT04432480|Procedure|NIPE (Newborn Infant Parasympathetic Evaluation) monitoring|Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
79999036|NCT01339325|Procedure|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
79999037|NCT03569462|Behavioral|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
79999038|NCT03569462|Behavioral|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
79525566|NCT01385501|Other|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
79229669|NCT00990327|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
79229670|NCT00990327|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
79229671|NCT03050814|Drug|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
79680989|NCT02916069|Device|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
79229672|NCT03050814|Biological|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
79229673|NCT03050814|Drug|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
79229674|NCT03050814|Drug|5-Fluorouracil (FU)|400mg/m^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
79229675|NCT03050814|Drug|Leucovorin|400mg/m^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
79371957|NCT03228459|Other|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
79371958|NCT03228459|Other|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
79525567|NCT01385527|Behavioral|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
79371959|NCT03228459|Diagnostic Test|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
79371960|NCT03258177|Other|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
79525568|NCT01385527|Drug|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
79680990|NCT02916069|Device|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
79371961|NCT03015064|Other|Myocardial Infarction|Observational study of myocardial Infarction patients
79229676|NCT03050814|Drug|Oxaliplatin|85mg/m^2 (Arm A) or 68mg/m^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
79680991|NCT02941016|Drug|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
79680992|NCT02941172|Other|Cold exposure|Controlled cold exposure is performed before and during PET scan
79680993|NCT02941172|Other|[18F]FMPEP-d2|PET radiotracer used in imaging
79680994|NCT02941172|Other|[18F]FDG|PET radiotracer used in imaging
79680995|NCT02916225|Behavioral|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
79824504|NCT00715364|Drug|NTx™-265: rhCG, then rEPO|"rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
79229677|NCT03050814|Drug|Capecitabine|625 mg/m^2 twice a day by mouth. Part of the standard of care therapy.
79229678|NCT03050814|Drug|5-Fluorouracil (FU)|2400 mg/m^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
79229679|NCT04430218|Device|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
79229680|NCT04429750|Procedure|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
79229681|NCT04429750|Procedure|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
79229682|NCT05390112|Biological|DNA|ctDNA; cfDNA
79229683|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
79229684|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
79371962|NCT03187054|Procedure|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
79371963|NCT04760457|Procedure|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
79371964|NCT04760457|Procedure|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
79371965|NCT04760457|Procedure|Implant immediate loading|Four mini implants will be immediately loaded.
79999039|NCT05708690|Drug|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
79999040|NCT05708690|Drug|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
79999041|NCT01343875|Procedure|tear of the distal tendon in the biceps muscle|
79999042|NCT04851821|Drug|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
79229685|NCT02462174|Drug|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
79229686|NCT02462174|Drug|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
79305573|NCT00700739|Device|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
79371966|NCT04760457|Procedure|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
79371967|NCT02991586|Behavioral|Dialectical Behaviour Therapy|Group of families
79371968|NCT04898296|Other|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
79525569|NCT01385540|Behavioral|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
79680996|NCT02916225|Behavioral|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
79680997|NCT02916186|Biological|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
79371969|NCT04898296|Other|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
79371970|NCT04550013|Other|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
79999043|NCT03567122|Other|Internal Focus of Attention|Information already included in arm/group descriptions.
79999044|NCT03567122|Other|External Focus of Attention|Information already included in arm/group descriptions.
79999045|NCT03567122|Other|Control|Information already included in arm/group descriptions.
79999046|NCT03569384|Combination Product|Tele Rehab|The intervention group will obtain telerehabilitation
79824505|NCT00715364|Drug|Saline Placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then~Saline IV, on Day 7, 8, and 9 of study participation"
79680998|NCT02916186|Procedure|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
79371971|NCT04550013|Other|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
79680999|NCT03200379|Other|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
79371972|NCT04894162|Other|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
79525570|NCT01385553|Behavioral|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
79824506|NCT02601677|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
79824507|NCT02601677|Drug|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
79824508|NCT00620776|Behavioral|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
79824509|NCT00620776|Drug|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
79824510|NCT00656019|Drug|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
79824511|NCT04282226|Device|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
79824512|NCT04282226|Device|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
79824513|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
79824514|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
79999047|NCT01343953|Procedure|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
79229687|NCT02564146|Drug|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
79229688|NCT02564146|Drug|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
79229689|NCT03747276|Other|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
79229690|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
79371973|NCT04134520|Device|ProLung System|Non-invasive bioconductance measurements
79681000|NCT02941484|Procedure|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
79681001|NCT02941484|Procedure|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
79681002|NCT02915913|Behavioral|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
79824515|NCT04046367|Behavioral|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
79824516|NCT04046367|Behavioral|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
79999048|NCT05140291|Other|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
79681003|NCT02915913|Behavioral|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
79525571|NCT01385553|Behavioral|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
79229691|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
79229692|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
79229693|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
79229694|NCT02462252|Drug|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
79371974|NCT02808364|Biological|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
79371975|NCT02709616|Biological|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
79525572|NCT01385631|Drug|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
79371976|NCT02468752|Drug|Oxygen|
79999049|NCT05140291|Other|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
79525573|NCT01385631|Drug|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
79681004|NCT02915913|Behavioral|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
79681005|NCT02915913|Other|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
79999050|NCT03567044|Diagnostic Test|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
79681006|NCT02277002|Device|Cabin Air Filtration|
79525574|NCT01385657|Drug|Placebo|A total of 4 doses were administered.
79681007|NCT02277002|Other|Placebo|No Cabin Air Filtration
79999051|NCT02247128|Drug|Aspirin + clopidogrel|
79999052|NCT02247128|Drug|Aspirin monotherapy|
79999053|NCT02247128|Drug|OAC + clopicogrel|
79229695|NCT02462252|Drug|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
79229696|NCT02462252|Drug|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
79229697|NCT02462252|Drug|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
79229698|NCT04613362|Behavioral|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Clinical health psychology therapy delivered via telehealth
79229699|NCT04613362|Behavioral|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
79229700|NCT03130452|Drug|Lansoprazole 30mg|lansoprazole 30 mg tablet
79371977|NCT02468752|Other|Air|
79371978|NCT04817956|Drug|Atezolizumab|drugs used outside indication, based on biomarker
79525575|NCT01385657|Drug|Dupilumab|A total of 4 doses were administered.
79525576|NCT01385657|Other|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
79525577|NCT01385670|Device|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
79525578|NCT01385683|Drug|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
79525579|NCT01385683|Drug|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
79681008|NCT04688619|Behavioral|"Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
79681009|NCT04688619|Behavioral|"Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
79681010|NCT02919735|Drug|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
79681011|NCT02919735|Drug|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
79681012|NCT02941250|Device|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
79999054|NCT02247128|Drug|OAC monotherapy|
79999055|NCT01339481|Drug|abatacept|Intravenous Infusion
79371979|NCT04672239|Behavioral|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
79681013|NCT02919774|Drug|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
79824517|NCT00782483|Device|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
79824518|NCT00782483|Device|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
79371980|NCT04672239|Behavioral|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
79229701|NCT03130452|Drug|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
79229702|NCT03130452|Drug|Clarithromycin 500mg|Clarithromycin 500mg tablet
79371981|NCT04672239|Behavioral|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
79371982|NCT01894919|Biological|Bexsero® vaccine (1 dose at study month zero)|
79229703|NCT03130452|Drug|Metronidazole 500 mg|Metronidazole 500 mg tablet
79229704|NCT04473495|Device|educational video|educational video before intervention
79229705|NCT00979251|Drug|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
79229706|NCT00979251|Drug|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
79371983|NCT01894919|Biological|Bexsero® vaccine (2 doses 1 month apart)|
79371984|NCT04418206|Other|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
79681014|NCT02919774|Drug|placebo|matching placebo tablets
79371985|NCT04130698|Behavioral|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
79371986|NCT04130698|Drug|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
79371987|NCT04130698|Behavioral|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
79371988|NCT05306223|Drug|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
79371989|NCT05306223|Drug|Levofloxacin|Levofloxacin filmcoated will be administered orally
79371990|NCT05306223|Drug|Linezolid|Linezolid tablets will be administered orally
79371991|NCT05306223|Drug|Cycloserine|Cycloserine capsules will be administered orally.
79371992|NCT05306223|Drug|Clofazimine|Clofazimine capsules will be administered orally.
79371993|NCT05306223|Drug|Pyrazinamide|Pyrazinamide tablets will be administered orally.
79229707|NCT03108170|Other|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
79229708|NCT03108170|Other|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
79371994|NCT05306223|Drug|Protionamide|Protionamide enteric-coated tablets will be administered orally.
79371995|NCT03016000|Drug|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
79371996|NCT03016000|Other|Observation|Just observation
79371997|NCT04130152|Drug|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
79371998|NCT04130152|Drug|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
79371999|NCT03224481|Other|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
79372000|NCT01894841|Behavioral|Coping Long Term with Active Suicide (CLASP)|6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
79681015|NCT02941445|Drug|sitagliptin and metformin|
79681016|NCT02941445|Drug|Metformin|
79824519|NCT00782483|Device|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
79824520|NCT02573090|Procedure|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
79824521|NCT02573090|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
79999056|NCT01344031|Drug|Akt Inhibitor MK2206|Given PO
79999057|NCT01344031|Drug|Anastrozole|Given PO
79999058|NCT01344031|Drug|Fulvestrant|Given IM
79999059|NCT01344031|Other|Laboratory Biomarker Analysis|Correlative studies
79999060|NCT01332929|Drug|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
79824522|NCT04798521|Other|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
79824523|NCT04798521|Other|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
79824524|NCT05505227|Behavioral|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
79824525|NCT05505227|Behavioral|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
79824526|NCT02546830|Device|FreeO2 v2.2 active|"Automatic adjustment of oxygen through the Free O2 device.~FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
79824527|NCT02546830|Device|FreeO2 v2.2 with manual oxygenation|"Manual adjustment of oxygen without the assistance of the FreeO2 device.~Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
79525580|NCT01385735|Drug|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
79372001|NCT01894841|Other|Safety Assessment and Follow Up Evaluation|enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
79372002|NCT04106674|Procedure|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
79999061|NCT04660279|Diagnostic Test|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
79372003|NCT03254589|Drug|Methotrexate|See arm descriptions
79372004|NCT03254589|Drug|Sulfasalazine|See arm description
79525581|NCT01385735|Drug|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
79372005|NCT03254589|Drug|Other DMARDs|See arm
79525582|NCT01385761|Device|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
79681017|NCT02941757|Behavioral|Mediterranean diet Intervention|"Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~Peer-education and support~Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~Email or text message encouragement and reminders during the intervention."
79372006|NCT01894607|Procedure|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
79372007|NCT01894607|Drug|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
79372008|NCT01894607|Behavioral|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
79525583|NCT01385761|Device|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
79525584|NCT01385774|Procedure|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
79681018|NCT02919501|Drug|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
79681019|NCT02919501|Other|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
79681020|NCT02919501|Drug|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
79824528|NCT00802269|Procedure|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
79824529|NCT02601443|Device|Cervical Pessary|
79999062|NCT01316029|Procedure|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
79999063|NCT05185193|Device|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
79999064|NCT05185193|Device|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
79999065|NCT02247986|Drug|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
79229709|NCT03108170|Other|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
79229710|NCT04551352|Drug|RO7293583|RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
79372009|NCT04399395|Drug|Naltrexone/bupropion|Approved drug for obesity treatment
79525585|NCT01385774|Other|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
79525586|NCT01385800|Biological|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
79525587|NCT01385800|Biological|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
79525588|NCT01385826|Drug|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
79681021|NCT02940782|Procedure|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
79681022|NCT02940782|Procedure|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
79681023|NCT02940782|Device|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
79681024|NCT02919579|Drug|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
79681025|NCT02919579|Drug|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
79681026|NCT02919579|Other|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
79681027|NCT02919579|Drug|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
79681028|NCT04688697|Procedure|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
79999066|NCT04580953|Device|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
79229711|NCT04551352|Drug|Tocilizumab|Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
79372010|NCT04399395|Other|Lifestyle|Lifestyle
79372011|NCT01883453|Device|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
79372012|NCT01883453|Device|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
79372013|NCT02000596|Drug|Trastuzumab plus Pertuzumab|
79372014|NCT02000596|Drug|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
79372015|NCT02000596|Drug|Chemotherapy with Eribulin|
79681029|NCT04688697|Procedure|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
79681030|NCT02940821|Other|Toothbrushing|Mechanical plaque removal
79681031|NCT02940821|Other|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
79681032|NCT02940821|Other|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
79681033|NCT02940821|Other|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
79229712|NCT04551352|Drug|Obinutuzumab|If implemented, it will be given either on D-7 or D-7 and D-6.
79229713|NCT04551352|Drug|Adalimumab|If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
79229714|NCT02462798|Other|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
79229715|NCT02462798|Other|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
79305574|NCT04486703|Other|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
79372016|NCT03223779|Drug|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
79372017|NCT03223779|Radiation|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
79372018|NCT04613297|Other|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~at day 3~day 5 and~In case of aggravation~At the discharge from hospital"
79999067|NCT03569306|Device|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
79999068|NCT03569306|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
79372019|NCT04613297|Other|Baseline blood sample|Blood sample will be performed at the inclusion visit only
79681034|NCT02940821|Other|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
79681035|NCT02941601|Drug|Necitumumab|Administered IV
79681036|NCT02941601|Drug|Gemcitabine|Administered IV
79681037|NCT02941601|Drug|Carboplatin|Administered IV
79681038|NCT02940899|Other|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
79229716|NCT05398224|Drug|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients >65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
79999069|NCT03566888|Device|Blood pressure assessment|Validation of an automated blood pressure device
79229717|NCT04496271|Device|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
79229718|NCT04542304|Drug|Metolazone|Participants will be given a metolazone for the 1-week study period.
79229719|NCT04542304|Drug|Placebo|Participants will be given a placebo for the 1-week study period.
79229720|NCT02463110|Drug|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
79229721|NCT02463110|Drug|No treatment|
79229722|NCT02463110|Drug|Placebo|
79229723|NCT05398146|Behavioral|mathematical operations|Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
79229724|NCT05398146|Behavioral|ball squeezing|For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
79229725|NCT05398146|Behavioral|listening to music|Children were allowed to listen to music with headphones during dressing changes.
79229726|NCT05398146|Other|kontrol grubu|No application was made during dressing change in children. Routine dressing change of the clinic was applied.
79229727|NCT05241314|Behavioral|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
79229728|NCT05241314|Behavioral|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
79229729|NCT04473573|Device|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the *2, *3 and *17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
79229730|NCT04535908|Radiation|Hypofractionated radiotherapy|Hypofractionated radiotherapy in prostate cancer patients
79229731|NCT04438629|Drug|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
79229732|NCT05502952|Drug|Pentoxifylline|Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
79229733|NCT05498194|Diagnostic Test|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (~ 1cm3 ) are collected during surgery
79229734|NCT05389059|Procedure|CAF+CM|Periodontal surgery including CAF+CM application
79229735|NCT05389059|Procedure|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
79229736|NCT04414449|Other|ICT-enabled Social-emotional Learning|ICT-enabled Social-emotional Learning
79372020|NCT02165722|Behavioral|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit [chronic and acute] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
79372021|NCT04654143|Drug|BVL-GSK098 capsule, placebo|Oral QD
79372022|NCT01882985|Drug|Docetaxel|Given IV
79525589|NCT01385826|Drug|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
79681039|NCT03631719|Biological|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
79681040|NCT04691453|Procedure|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
79999070|NCT05708534|Drug|Belatacept|Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
79999071|NCT03159611|Drug|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
79824530|NCT02573480|Behavioral|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
79999072|NCT03159611|Drug|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
79999073|NCT03000374|Drug|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
79229737|NCT04441658|Biological|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
79229738|NCT04441658|Biological|saline|saline containing human albumin will be infused to the control group
79824531|NCT00841516|Other|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
79229740|NCT03295526|Procedure|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
79229741|NCT03295448|Other|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
79229742|NCT03295448|Other|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
79229743|NCT03295448|Other|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
79229744|NCT00835575|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
79229745|NCT00835575|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
79229746|NCT03295370|Procedure|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
79372023|NCT01882985|Dietary Supplement|Lycopene|Given PO
79229747|NCT03295292|Biological|Stem cells|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
79525590|NCT01385839|Procedure|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
79229748|NCT03295292|Other|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
79229749|NCT00777309|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
79229750|NCT00777309|Drug|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
79681041|NCT04691453|Procedure|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
79824532|NCT00841516|Biological|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
79824533|NCT04069832|Behavioral|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
79229751|NCT00777309|Drug|Placebo|The placebo is provided as a capsule
79229752|NCT03295214|Drug|Acetaminophen|Acetaminophen given for pain relief
79229753|NCT04604704|Drug|Naltrexone|Naltrexone at 4.5 mg/day
79372024|NCT04648761|Biological|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
79372025|NCT04277481|Other|10 minute cold pack|10 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
79999074|NCT03000374|Drug|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
79999075|NCT03000374|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
79999076|NCT03000374|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
79229754|NCT04604704|Dietary Supplement|NAD+|NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
79372026|NCT04277481|Other|12 minute cold pack|12 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
79372027|NCT04277481|Other|15 minute cold pack|15, min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
79824534|NCT00841594|Drug|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
79824535|NCT00841594|Drug|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
79229755|NCT03295058|Drug|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
79229756|NCT03295058|Drug|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
79229757|NCT03295058|Procedure|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
79525591|NCT01385839|Procedure|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
79681042|NCT02940743|Behavioral|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
79681043|NCT02940743|Behavioral|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
79681044|NCT02940743|Behavioral|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
79681045|NCT03458390|Device|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
79681046|NCT03160638|Drug|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
79824536|NCT04068974|Drug|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 [PD-1]). Monoclonal antibodies like SHR-1210 that can block this pathway.
79824537|NCT04068974|Drug|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
79229758|NCT03295058|Drug|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
79229759|NCT00777231|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
79229760|NCT02462018|Device|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
79372028|NCT04277481|Other|20 minute cold pack|20 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
79372029|NCT02166346|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
79372030|NCT02166346|Drug|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
79372031|NCT01893905|Drug|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
79372032|NCT01893905|Drug|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
79372033|NCT04460235|Drug|Prevenar13 Pneumo-23|Vaccination according national guidelines
79525592|NCT01385852|Procedure|microcoaxial phacoemulsification|conventional longitudinal ultrasound
79525593|NCT01385865|Dietary Supplement|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
79525594|NCT01385865|Dietary Supplement|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
79525595|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
79681047|NCT02940704|Procedure|Reciproc|"Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~Reciproc file selection: R40 (40/0.06) is to be used."
79824538|NCT00836290|Behavioral|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
79824539|NCT00836290|Behavioral|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
79525596|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
79525597|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
79229761|NCT00776373|Drug|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
79229762|NCT04601194|Behavioral|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
79229763|NCT04373577|Procedure|erector spinae plane block|the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.
79229764|NCT04373577|Procedure|pericapsular nerve group block|the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
79229765|NCT04065802|Radiation|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
79525598|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
79525599|NCT01385891|Drug|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
79525600|NCT01385930|Behavioral|Lifestyle counseling|Lifestyle counseling
79525601|NCT01385956|Drug|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
79525602|NCT01385956|Drug|Gemcitabine|Fixed dose: 1000mg/m^2 weekly x3 then 1 week off
79681048|NCT02940704|Procedure|One Shape|"Coronal preflaring will be performed using Gates Glidden drill.~Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
79681049|NCT02940587|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
79681050|NCT02919540|Other|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
79681051|NCT02919462|Drug|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
79681052|NCT02919462|Drug|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
79681053|NCT02919462|Drug|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
79824540|NCT00782171|Device|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
79824541|NCT02572700|Other|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
79824542|NCT00836368|Dietary Supplement|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
79681054|NCT02919462|Drug|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
79681055|NCT02919462|Drug|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
79681056|NCT02919462|Drug|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
79824543|NCT00718796|Other|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
79525603|NCT01385969|Device|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
79525604|NCT01385969|Device|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
79525605|NCT01385969|Device|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
79681057|NCT02941367|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79681058|NCT02941367|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
79681059|NCT02941367|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79681060|NCT02941367|Drug|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79681061|NCT03153150|Drug|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79681062|NCT03153150|Drug|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79681063|NCT03153150|Drug|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79999077|NCT04323943|Device|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~6MWT where energy cost will be measured~5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
79229766|NCT00772785|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
79229767|NCT02461706|Drug|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
79229768|NCT02461706|Other|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
79229769|NCT05497648|Behavioral|Choose to Move|"CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions."
79229770|NCT04474665|Device|Reverse shoulder arthroplasty utilizing Blueprint Software|Reverse shoulder arthroplasty utilizing Blueprint Software
79229771|NCT02460848|Other|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
79229772|NCT02460848|Other|Outpatient therapeutic program and counseling|
79229773|NCT04474431|Other|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
79681064|NCT03153150|Drug|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79681065|NCT03153150|Drug|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79681066|NCT03153150|Drug|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79681067|NCT03153150|Drug|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
79681068|NCT02940431|Other|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
79681069|NCT02940431|Other|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
79681070|NCT05317598|Other|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
79681071|NCT02916147|Drug|Sevoflurane|
79681072|NCT02916147|Drug|Propofol|
79999078|NCT03566654|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
79305575|NCT04930497|Procedure|vestibular socket technique with bone grafting|a vestibular horizontal incision was made then a subperiosteal tunnel was created and a facial bone membrane was placed. The facial gap was filled with a mixture of autogenous bone and deproteinized bovine bone mineral
79305576|NCT04930497|Procedure|vestibular socket technique without bone grafting|the vestibular incision was done horizontally about 3 to 4 mm apical to the mucogingival junction and extending 5 to 10 mm horizontally. A submucoperiosteal tunnel was created labially from the socket orifice till the vestibular access incision
79305577|NCT03241277|Procedure|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
79681073|NCT04688970|Other|no intervention|no intervention
79999079|NCT03566654|Device|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
79229774|NCT03294902|Device|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
79229775|NCT05497570|Drug|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
79372034|NCT01050946|Biological|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
79372035|NCT03677661|Other|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
79372036|NCT03677661|Other|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
79372037|NCT03015922|Drug|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
79372038|NCT03015922|Biological|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
79372039|NCT01893827|Drug|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
79372040|NCT01893827|Drug|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
79824544|NCT00718796|Other|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
79824545|NCT00844168|Drug|sorafenib tosylate|Given orally
79525606|NCT01385982|Other|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
79525607|NCT01386034|Drug|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-[1-13C]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
79681074|NCT05317559|Behavioral|room light|The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
79681075|NCT02915562|Other|exercise|
79681076|NCT02915718|Procedure|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
79681077|NCT03458351|Device|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
79681078|NCT03458351|Device|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
79681079|NCT02915757|Device|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
79681080|NCT02919384|Other|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
79824546|NCT00844168|Other|laboratory biomarker analysis|Correlative studies
79824547|NCT02573168|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
79824548|NCT02573168|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
79824549|NCT02573168|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
79824550|NCT00836446|Other|physical activity|physical activity routines 5 times a weeks for 12 weeks.
79229776|NCT00963885|Drug|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
79372041|NCT03015766|Other|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
79372042|NCT03015766|Other|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
79372043|NCT03222843|Drug|Hetrombopag Olamine|once daily
79372044|NCT03222843|Drug|matching placebo|once daily
79372045|NCT03015688|Radiation|x-ray images|
79372046|NCT01882907|Drug|vildagliptin|vildagliptin 50mg bid for 16 weeks
79372047|NCT01882907|Drug|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
79372048|NCT04073823|Device|Flexitouch Plus|Flexitouch Plus full arm and core treatment
79372049|NCT04073823|Device|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
79525608|NCT01386047|Other|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
79525609|NCT01386060|Other|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
79525610|NCT01386073|Drug|FreshKote|Three times a day for three months
79525611|NCT01386073|Drug|Systane|three times a day for three months
79681081|NCT05296616|Behavioral|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
79681082|NCT02915640|Other|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
79525612|NCT01386086|Drug|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
79525613|NCT01386099|Drug|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
79525614|NCT01386099|Drug|Placebo|Placebo twice a day for 12 weeks.
79525615|NCT01386112|Drug|EUR-1100|Active oral medication
79525616|NCT01386112|Drug|placebo|matching placebo
79525617|NCT01386138|Behavioral|Psycho-education|Receive RBT education and peer-support in a group format.
79681083|NCT06026189|Diagnostic Test|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
79229777|NCT00963885|Drug|Pegasys|180micrograms sc weekly for 24 or 48 weeks
79229778|NCT00963885|Drug|Placebo|po for 12 weeks
79229779|NCT00963885|Drug|Placebo|po for 24 weeks
79229780|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
79229781|NCT00963885|Drug|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
79229782|NCT00963885|Drug|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
79229783|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
79229784|NCT02461862|Behavioral|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
79229785|NCT02461862|Procedure|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
79229786|NCT02461862|Procedure|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
79525618|NCT01386138|Behavioral|Experimental|Receive RBT education and a pro-active counseling method
79525619|NCT01386151|Drug|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
79525620|NCT01386151|Drug|Saline placebo|Normal (0.9%) saline will be used as a placebo.
79525621|NCT01386164|Biological|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
79525622|NCT01386164|Biological|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
79229787|NCT02461940|Behavioral|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
79372050|NCT04049955|Procedure|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
79372051|NCT01051570|Drug|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
79999080|NCT03566654|Device|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
79229788|NCT00958971|Drug|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
79525623|NCT01386177|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
79372052|NCT01051570|Drug|RAD 001|5 mg orally starting on Day 2 then continuous
79372053|NCT01051570|Drug|prednisone|5 mg orally twice a day starting on Day 1 then continuous
79372054|NCT01051570|Other|laboratory biomarker analysis|Samples will be collected from archival tissue.
79372055|NCT01051570|Other|pharmacological study|Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
79525624|NCT01386177|Drug|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
79525625|NCT01386177|Drug|placebo|capsules identical to MDMA or doxazosin
79525626|NCT01386190|Other|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
79525627|NCT01386216|Device|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
79681084|NCT06026163|Drug|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
79681085|NCT06026163|Other|Placebo|Equivalent volume of saline
79681086|NCT06026150|Other|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
79681087|NCT06026137|Procedure|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
79681088|NCT06026137|Procedure|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
79709709|NCT04353453|Device|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
79824551|NCT00841750|Procedure|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
79229789|NCT03294824|Other|blood sample|peripheral blood samples are collected
79372056|NCT04046601|Device|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
79525628|NCT01386229|Drug|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
79999081|NCT03635359|Diagnostic Test|blood test|analysis of cell-free DNA in maternal plasma
79229790|NCT05497414|Behavioral|Sleep deprivation|Overnight sleep deprivation.
79372057|NCT01893281|Drug|Topical Testosterone Solution|Administered topically to axillae.
79372058|NCT02981446|Drug|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
79525629|NCT01386229|Drug|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
79525630|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
79525631|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
79525632|NCT01386242|Other|Saline Injection|Saline Injection, 1mL, im,three times per week
79824552|NCT00841750|Procedure|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
79824553|NCT02574884|Procedure|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
79824554|NCT00836524|Procedure|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
79824555|NCT00764465|Drug|Maraviroc|300 mg BID
79372059|NCT02981446|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
79525633|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
79525634|NCT01386255|Drug|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
79681089|NCT06026124|Behavioral|Retrieval-based word learning|"Learning sessions: Children will practice novel nouns in the context of a story book on Day 1. They will learn 4 words in each of the two conditions. Study only condition: they will simply hear the information (word & meaning) as part of the story. Spaced retrieval condition: they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. In the study only practice condition, children will simply continue to hear the information. This practice schedule is repeated the next day (Day 2) using the same story book.~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and meaning twice. One week after Day 1, this recall test is completed again. The child will also complete a recognition test: the child will hear a novel noun and point to its referent in an array of 3."
79824556|NCT00764465|Drug|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
79824557|NCT00764465|Drug|Ritonavir|100 mg BID, 100 mg QD
79824558|NCT02546752|Other|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
79229791|NCT00835497|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
79525635|NCT01386255|Drug|placebo|placebo. No other names
79681090|NCT06026085|Other|Skinceuticals skin care product(CE)|Skinceuticals skin care product(CE FERULIC)+routine sun protection
79824559|NCT00715832|Biological|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
79824560|NCT04069598|Diagnostic Test|Statin intolerance test|Statin intolerance test
79824561|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
79824562|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
79824563|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, <= 4 mg, Once daily, 7 days
79824564|NCT00836602|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
79229792|NCT00835497|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
79229793|NCT05491564|Device|SoftStitch™|The SoftStitch™ meniscal repair system includes a unique knotless all-inside meniscal repair implant with all suture fixation, eliminating the traditional hard plastic PEEK anchors used in the previous devices.
79229794|NCT00763503|Drug|CD 2027|3µg/g Oily Spray
79229795|NCT00761709|Drug|AL-39256 Ophthalmic Suspension, 1%|
79525636|NCT01386268|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
79525637|NCT01386281|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
79824565|NCT00655863|Drug|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
79824566|NCT00655863|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
79824567|NCT00655863|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
79824568|NCT00718874|Other|Dietary|modification of macronutrient content
79824569|NCT05672030|Other|Non-Interventional|No intervention.
79824570|NCT02572310|Device|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
79229796|NCT00761709|Drug|Latanoprost Ophthalmic Solution, 0.005%|
79229797|NCT00761709|Drug|Vehicle|Inactive ingredients used as a placebo comparator
79229798|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
79229799|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
79229800|NCT04976049|Procedure|Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery|Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
79229801|NCT00759135|Drug|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
79229802|NCT00759135|Drug|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
79229803|NCT00759135|Drug|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
79229804|NCT05439447|Diagnostic Test|Patients scheduled for VFSS testing group|Patients scheduled for VFSS testing, patient with voice.
79372060|NCT01893203|Drug|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
79824571|NCT00836680|Device|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
79824572|NCT00718952|Drug|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
79824573|NCT00718952|Drug|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
79999082|NCT03566576|Drug|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
79999083|NCT03566576|Drug|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
79229805|NCT04474041|Device|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
79372061|NCT01893203|Drug|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
79372062|NCT04023435|Other|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
79372063|NCT05263947|Drug|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
79229806|NCT00835263|Drug|Lamotrigine|200 mg Tablet
79229807|NCT00835263|Drug|Lamictal®|200 mg Tablet
79229808|NCT04946019|Combination Product|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
79229809|NCT02639910|Biological|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
79229810|NCT02639910|Drug|Idelalisib|idelalisib dose: 150 mg twice daily orally
79372064|NCT04415567|Drug|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW <60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
79525638|NCT01386294|Drug|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
79525639|NCT01386294|Drug|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
79525640|NCT01386320|Procedure|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
79525641|NCT01386320|Procedure|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
79229811|NCT02639910|Drug|Venetoclax|venetoclax dose: 400 mg once daily orally
79229812|NCT04892667|Other|intervention|The patient participating in the study needs to respect a minimum of 12-hour fasting period, a high protein and a low-carbohydrate diet prior to performing PET/CT in order to limit physiological 18F-FDG myocardial fixation.
79525642|NCT01386333|Drug|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
79824574|NCT00718952|Drug|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
79824575|NCT00719030|Dietary Supplement|Pomegranate pill|Pomegranate extract pill
79824576|NCT00719030|Dietary Supplement|Pomegranate pill placebo|Pomegranate pill placebo
79999084|NCT03566576|Drug|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
79229813|NCT00954057|Drug|LIPO-102|intraorbital injection
79229814|NCT00954057|Drug|Placebo|intraorbital injection
79229815|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
79229816|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
79229817|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
79229818|NCT05397990|Behavioral|Exercise|12 weeks of moderate intensity exercise, three times a week.
79999085|NCT04377997|Drug|Enoxaparin|Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
79681091|NCT06026085|Other|fraxel laser therapy|Fraxel DUAL 1550/1927 Laser System
79999086|NCT03566498|Dietary Supplement|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
79372065|NCT04723576|Behavioral|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
79372066|NCT03280251|Drug|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
79999087|NCT03566498|Dietary Supplement|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
79229819|NCT04454502|Other|Oral colostrum administration|In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
79229820|NCT04454580|Drug|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
79229821|NCT05389878|Other|rehabilitation|All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
79372067|NCT03280251|Drug|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
79372068|NCT03280251|Other|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
79372069|NCT03280251|Other|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
79681092|NCT06026085|Other|0.9% normal saline|0.9% normal saline+routine sun protection
79681093|NCT06026072|Other|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
79681094|NCT06026020|Other|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
79681095|NCT06026007|Other|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
79681096|NCT06026007|Other|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
79525643|NCT01386333|Drug|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
79681097|NCT06026007|Other|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
79229822|NCT00948909|Drug|Placebo|Placebo intervention
79229823|NCT00948909|Drug|ABT-126|Experimental intervention
79229824|NCT00948909|Drug|donepezil|Active comparator intervention
79229825|NCT03735576|Behavioral|Psychotherapy|15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity
79372070|NCT01882829|Drug|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
79372071|NCT04399005|Other|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
79372072|NCT04399005|Other|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
79372073|NCT04760301|Drug|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
79372074|NCT04760301|Other|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
79525644|NCT01386346|Drug|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
79525645|NCT01386346|Drug|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
79525646|NCT01386346|Drug|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
79525647|NCT01386346|Drug|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
79999088|NCT01336049|Drug|Nimotuzumab|Nimotuzumab 200mg/week
79999089|NCT04758949|Drug|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
79999090|NCT04758949|Drug|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
79681098|NCT06025981|Other|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
79229826|NCT03735576|Diagnostic Test|Questionnaires|There will be a total of four assessments (see primary & secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.
79229827|NCT03735576|Other|Magnetic Resonance Imaging|Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.
79372075|NCT04760301|Drug|IV 1 g tranexamic acid|IV 1 g tranexamic acid diluted in 100 ml saline
79229828|NCT03735576|Other|Blood analysis|Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.
79229829|NCT04419090|Other|web-based centralized service and message|Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
79229830|NCT02522910|Drug|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
79229831|NCT00948753|Drug|Maraviroc 150 MG|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
79372076|NCT04760301|Other|IV 1 g normal saline|IV 100 ml normal saline
79372077|NCT02170870|Drug|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
79525648|NCT01386372|Drug|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
79681099|NCT06025981|Other|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
79681100|NCT06025981|Other|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
79372078|NCT02170870|Drug|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
79372079|NCT02170870|Drug|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
79372080|NCT04400097|Procedure|suture|suture methods of autograft conjunctival transplantation
79372081|NCT04678648|Drug|RSC-1255 Dose Escalation|Phase 1a will enroll 24-34 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
79372082|NCT04678648|Drug|RSC-1255 Dose Expansion|Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
79372083|NCT03015454|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
79525649|NCT01386372|Other|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
79525650|NCT01386398|Drug|bortezomib|
79525651|NCT01386398|Drug|vorinostat|
79525652|NCT01386398|Other|laboratory biomarker analysis|
79999091|NCT04758949|Drug|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
79229832|NCT00948753|Drug|Maraviroc 300 mg|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
79229833|NCT00948753|Drug|Maraviroc 300 mg Phase II|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
79999092|NCT04320979|Radiation|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
79229834|NCT05397834|Drug|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
79229835|NCT05397834|Drug|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
79372084|NCT03015454|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
79372085|NCT04760379|Other|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
79372086|NCT04760379|Other|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
79525653|NCT01386411|Genetic|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
79525654|NCT01386489|Biological|VRC-HIVDNA016-00-VP|
79525655|NCT01386489|Biological|VRC-HIVADV014-00-VP|
79372087|NCT03014908|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
79525656|NCT01386502|Biological|p53: 264-272 peptide|
79525657|NCT01386502|Drug|CT-011|
79681101|NCT06025968|Behavioral|i-CBT|The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..
79372088|NCT01054768|Drug|alpha-lipoic acid and acetyl-L-carnitine|none to report
79372089|NCT01054768|Drug|Control|none to report
79372090|NCT04387617|Drug|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
79372091|NCT04387617|Drug|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
79372092|NCT03014830|Drug|Alirocumab|150 mg SQ every 2 weeks
79372093|NCT03014830|Drug|Placebos|Placebo injections SQ every 2 weeks
79372094|NCT05237193|Diagnostic Test|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
79525658|NCT01386541|Drug|BYK324677|capsules, administered orally
79525659|NCT01386567|Drug|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
79525660|NCT01386567|Drug|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
79229836|NCT03991650|Behavioral|Monitoring with a device|Participants will be monitored by an App.
79525661|NCT01386580|Drug|2B3-101|IV every 21 days
79681102|NCT06025968|Behavioral|Applied relaxation|Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
79681103|NCT06025955|Procedure|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
79681104|NCT06025955|Procedure|open flap debridement|flap surgery will be done
79681105|NCT02916030|Dietary Supplement|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
79681106|NCT06025916|Drug|Tranexamic acid|20 ml of oral solution TA (100mg/ml)
79999093|NCT04320979|Radiation|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
79999094|NCT03564860|Procedure|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
79999095|NCT03565016|Other|no interventional study|no interventional study
79229837|NCT03134547|Drug|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
79229838|NCT03134547|Drug|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
79229839|NCT02522676|Procedure|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
79229840|NCT02522676|Procedure|Endoscopic kidney stone surgery|Mini PCNL will be performed.
79229841|NCT02522676|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
79229842|NCT02522676|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
79229843|NCT02522676|Procedure|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
79525662|NCT01386580|Drug|Trastuzumab|IV every 21 days
79525663|NCT01386580|Drug|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
79525664|NCT01386580|Drug|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
79525665|NCT01386593|Drug|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
79525666|NCT01386593|Drug|"Basel Cocktail"|
79525667|NCT01386593|Drug|Basel cocktail + Rifampicin|
79372095|NCT03984669|Diagnostic Test|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
79372096|NCT03984669|Biological|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
79229844|NCT02522676|Procedure|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
79824577|NCT00844246|Other|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
79372097|NCT04277403|Radiation|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
79999096|NCT05708456|Other|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
79999097|NCT01344343|Other|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
79372098|NCT04277403|Radiation|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
79372099|NCT03014596|Other|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
79372100|NCT04365465|Device|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
79709710|NCT04353453|Device|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
79999098|NCT03566186|Other|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
79999099|NCT03566186|Other|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
79525668|NCT01386619|Biological|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing >1 10e7 NK cells/kg bodyweight (BW) and < 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
79525669|NCT01386658|Drug|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
79525670|NCT01386671|Drug|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
79999100|NCT03566186|Other|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
79999101|NCT01344421|Procedure|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
79229845|NCT05397756|Other|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
79229846|NCT01963208|Drug|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
79229847|NCT01963208|Drug|Placebo|placebo
79229848|NCT00834873|Drug|Carvedilol 25 mg tablets|1 x 25 mg
79229849|NCT00834873|Drug|COREG® 25 mg tablets|1 x 25 mg
79525671|NCT01386671|Drug|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
79525672|NCT01386723|Drug|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
79525673|NCT01386736|Drug|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
79525674|NCT01386736|Drug|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
79525675|NCT01386749|Procedure|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
79999102|NCT03566030|Drug|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
79999103|NCT03566030|Drug|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
79824578|NCT00844246|Other|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
79229850|NCT03294746|Other|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
79999104|NCT04312711|Diagnostic Test|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
79709711|NCT00595023|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
79229851|NCT03294746|Other|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
79824579|NCT00781937|Drug|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
79824580|NCT00781937|Drug|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
79824581|NCT00802581|Procedure|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
79999105|NCT03565952|Other|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
79999106|NCT03565952|Other|Control group|The control group does not receive treatment
79525676|NCT01386762|Other|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
79824582|NCT00802581|Procedure|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
79824583|NCT00842062|Device|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
79824584|NCT00836836|Other|Modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
79824585|NCT00797589|Drug|HES|20ml/kg as prime fluid
79229852|NCT01377480|Drug|Posaconazole|POS 40 mg/mL oral suspension
79525677|NCT01386827|Biological|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml > 2 years later
79525678|NCT01386827|Biological|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml > 2 years later
79525679|NCT01386827|Biological|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
79824586|NCT00797589|Drug|Ringer lactate|
79824587|NCT00719108|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
79824588|NCT00719108|Biological|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
79999107|NCT03565796|Behavioral|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
79229853|NCT01377480|Drug|Placebo for posaconazole|Placebo oral suspension
79229854|NCT01377480|Drug|Benznidazole|BNZ 100 mg oral tablet
79229855|NCT04263909|Drug|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
79229856|NCT04488848|Other|bolus glucose|bolus Glucose
79229857|NCT04488848|Other|continuous clucose|continuous clucose
79229858|NCT00754455|Biological|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
79229859|NCT00754455|Biological|Placebo|Placebo as a single injection of 0.5 mL.
79229860|NCT01421264|Drug|Gabapentin|300mg capsules by mouth
79229861|NCT04415840|Diagnostic Test|acetic acid test|using acetic acid to unmask dysplastic lesions on the cervix uteri
79229862|NCT04415840|Diagnostic Test|Lugol's solution test|using Lugol's solution after acetic acid test to unmask dysplastic lesions on the cervix uteri
79525680|NCT01386827|Biological|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
79229863|NCT05397522|Other|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
79525681|NCT01386840|Other|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
79525682|NCT01386853|Drug|Pitavastatin|2 mg QD
79525683|NCT01386853|Drug|Atorvastatin|10 mg QD
79824589|NCT00842140|Drug|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
79824590|NCT00842140|Drug|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
79824591|NCT00842140|Drug|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
79824592|NCT00806169|Drug|triamcinolone and bevacizumab|
79229864|NCT05397522|Other|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
79372101|NCT04365465|Device|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
79681107|NCT06025890|Other|Functional Training.|"Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children."
79824593|NCT02572232|Device|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
79229865|NCT00946569|Drug|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
79824594|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
79824595|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
79229866|NCT00946569|Drug|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
79229867|NCT04488614|Procedure|Breast Concervative or Meastectomy|National treatment guidelines in Norway
79229868|NCT05397444|Other|No intervention|This is an observational study with no intervention.
79229869|NCT03134859|Behavioral|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
79229870|NCT04293159|Dietary Supplement|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
79229871|NCT00834795|Drug|Carvedilol 25 mg tablets|1 x 25 mg
79229872|NCT00834795|Drug|COREG® 25 mg tablets|1 x 25 mg
79525684|NCT01386866|Drug|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of [14C]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
79525685|NCT01386879|Drug|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
79525686|NCT01386892|Other|No intervention|There is no intervention for this study
79525687|NCT01386905|Device|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
79824596|NCT02572154|Other|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
79824597|NCT00802815|Drug|Etanercept|50 milligrams subcutaneously every week
79824598|NCT04100759|Drug|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
79824599|NCT00836914|Drug|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
79824600|NCT00836914|Drug|Placebo|Placebo capsules administered orally BID for 7 days
79824601|NCT04124042|Biological|XT-150|plasmid DNA
79824602|NCT04124042|Drug|Placebo|Placebo is a sterile phosphate-buffered saline
79824603|NCT05180175|Drug|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
79229873|NCT00834717|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
79372102|NCT04365465|Other|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
79372103|NCT04398615|Device|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
79372104|NCT01055704|Drug|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
79824604|NCT00844402|Drug|Atorvastatin|oral, 10 mg, daily, 48 weeks
79229874|NCT00834717|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
79229875|NCT00834639|Drug|divalproex sodium|delayed-release 500 mg tablet
79824605|NCT04117412|Other|Exercise|Same participants will undergo different one bout of exercise protocols
79824606|NCT00802971|Dietary Supplement|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
79372105|NCT01055704|Drug|Codeine only|30 mg taken orally four times daily for 5 days
79372106|NCT01055704|Drug|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
79372107|NCT01055704|Drug|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
79525688|NCT01386918|Device|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
79999108|NCT03565796|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
79999109|NCT03565796|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
79229876|NCT00834639|Drug|Depakote®|delayed-release 500 mg tablet
79681108|NCT06025890|Other|Observe.|Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
79681109|NCT06025864|Other|Breastfeeding|"Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months."
79824607|NCT02546908|Other|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
79229877|NCT00940095|Drug|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
79229878|NCT00940095|Drug|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
79229879|NCT00940095|Drug|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
79229880|NCT00834561|Drug|Lamotrigine|200 mg Tablet
79229881|NCT00834561|Drug|Lamictal®|200 mg Tablet
79229882|NCT00939237|Drug|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
79229883|NCT00939237|Drug|Placebo|
79229884|NCT00754221|Drug|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
79372108|NCT03280017|Drug|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
79372109|NCT03280017|Drug|Normal saline|normal saline infusion
79372110|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
79824608|NCT04115852|Behavioral|fmri|functional magnetic resonance imaging
79824609|NCT00806247|Drug|tapentadol HCl|
79229885|NCT00753285|Device|Renal Denervation|
79229886|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
79229887|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
79229888|NCT00834405|Drug|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
79229889|NCT00834405|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
79229890|NCT00834249|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
79229891|NCT00834249|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
79229892|NCT00751803|Drug|BI 44370 TA Low Dose|
79229893|NCT00751803|Drug|Eletriptan|
79229894|NCT00751803|Drug|Placebo|
79229895|NCT00751803|Drug|BI 44370 TA Medium Dose|
79372111|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 6 months
79372112|NCT01882439|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
79372113|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
79372114|NCT01882439|Other|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
79372115|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 3 months
79372116|NCT05236491|Biological|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
79372117|NCT02246686|Drug|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
79372118|NCT02246686|Drug|Placebo|Application over 12 weeks 20 drops three time daily
79372119|NCT04400019|Drug|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
79372120|NCT01055782|Device|Endoguide|Use of endoguide to facilitate completion of endoscopy
79372121|NCT05225805|Drug|Lefamulin|Antibiotic
79525689|NCT01386931|Procedure|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
79824610|NCT00803127|Device|vs-sense|detection swab
79681110|NCT06025851|Drug|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
79824611|NCT00797745|Biological|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
79824612|NCT00797745|Drug|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
79824613|NCT00797745|Drug|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
79824614|NCT00797745|Drug|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
79824615|NCT04070846|Drug|[14C] LC350189|Carbon-14 labelded LC350189
79824616|NCT00659373|Drug|Tamoxifen|
79229896|NCT05420961|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
79229897|NCT05420961|Biological|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile solution
79229898|NCT05420961|Biological|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
79229899|NCT05402397|Drug|Losartan Potassium|Patients will receive losartan potassium for 30 days.
79229900|NCT00833937|Drug|Zolpidem 10 mg tablets|1 x 10 mg
79229901|NCT00833937|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
79229902|NCT04245111|Other|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
79229903|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
79372122|NCT01056016|Other|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
79372123|NCT01056328|Device|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
79824617|NCT00659373|Drug|triptorelin|
79824618|NCT00659373|Drug|Exemestane|
79372124|NCT01056328|Device|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
79372125|NCT04358913|Device|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
79229904|NCT00831051|Drug|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
79229905|NCT00831051|Drug|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
79372126|NCT01892657|Drug|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
79372127|NCT04351581|Other|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
79372128|NCT04351581|Other|Continuation of ACEi/ARB|Continuation of ACEi/ARB
79372129|NCT01057888|Other|Autodialer|Autodialer telephone calls
79372130|NCT01057888|Other|Letters|Mailed reminder letters
79681111|NCT06025851|Drug|Placebo|Placebo Comparator
79681112|NCT06025825|Drug|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
79681113|NCT06025825|Drug|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
79229906|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
79681114|NCT06025812|Biological|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
79824619|NCT00837070|Procedure|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
79824620|NCT00716378|Behavioral|Teen Passenger Presence|
79824621|NCT00719342|Drug|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
79824622|NCT00719342|Other|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
79824623|NCT00842452|Drug|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
79824624|NCT00842452|Other|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
79824625|NCT02552745|Drug|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
79525690|NCT01386931|Procedure|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
79229907|NCT00831051|Drug|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
79999110|NCT03565796|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
79999111|NCT03565796|Behavioral|COSH booklet|A general smoking cessation self-help booklet
79372131|NCT01881737|Drug|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
79372132|NCT01109056|Drug|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
79999112|NCT04256005|Other|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
79999113|NCT05353946|Device|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
79999114|NCT03565718|Behavioral|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
79372133|NCT01109056|Drug|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
79372134|NCT04760145|Other|Multicomponent Exercise with Blood Flow Restriction|"10 minutes of initial warm-up.~20 minutes of strength exercises.~10 minutes of resistance exercises.~10 minutes of coordination and balance exercises.~5 minutes of flexibility.~5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction."
79525691|NCT01386996|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
79525692|NCT01386996|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
79525693|NCT01387048|Drug|skinoren|gel 15%, twice daily, 36 weeks
79999115|NCT03565718|Behavioral|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
79999116|NCT01344499|Procedure|Carbon dioxide|standard pneumoperitoneum with 100% CO2
79999117|NCT01344499|Procedure|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
79999118|NCT01344499|Drug|Adept|instillation of 1 liter of fluid at the end of laparoscopy
79999119|NCT01344499|Drug|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
79999120|NCT03565562|Other|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
79999121|NCT03565562|Other|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
79525694|NCT01387048|Drug|differin|0.1% gel, once daily in the evening
79525695|NCT01387048|Drug|skinoren|12 weeks treatment, the following 24 months only observation
79525696|NCT01387061|Procedure|hepatic resection|surgical resection of the liver for multiple HCC
79525697|NCT01387087|Drug|ASP015K|oral
79525698|NCT01387087|Drug|Placebo|oral
79525699|NCT01387100|Behavioral|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
79525700|NCT01387126|Dietary Supplement|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
79525701|NCT01387165|Drug|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
79999122|NCT05065879|Biological|COVAX|2 doses of Covid-19 vaccine
79999123|NCT01339715|Procedure|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
79999124|NCT01333085|Drug|carboplatin|
79999125|NCT01333085|Drug|RAD001|
79999126|NCT01333085|Drug|paclitaxel|
79999127|NCT01344655|Drug|Atimos®|Formoterol 12 μg pMDI
79999128|NCT01344655|Drug|Serevent™|Salmeterol 25 µg pMDI
79229908|NCT00831051|Drug|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
79229909|NCT00750633|Drug|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
79229910|NCT00750633|Drug|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
79229911|NCT00750633|Drug|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
79229912|NCT00750633|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
79525702|NCT01387191|Drug|Epoprostenol|
79525703|NCT01387204|Drug|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
79999129|NCT01344655|Drug|Placebo|placebo
79372135|NCT04760145|Other|Multicomponent Exercise without Blood Flow Restriction|"10 minutes of initial warm-up.~20 minutes of strength exercises.~10 minutes of resistance exercises.~10 minutes of coordination and balance exercises.~5 minutes of flexibility.~5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction."
79372136|NCT03870399|Drug|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
79525704|NCT01387217|Drug|GSK2018682|GSK2018682
79525705|NCT01387217|Drug|Placebo|Matched Placebo
79824626|NCT02547844|Drug|efavirenz + emtricitabina + tenofovir|
79824627|NCT02547844|Drug|rilpivirina + emtricitabina + tenofovir|
79525706|NCT01387243|Drug|Orlistat|60 mg
79824628|NCT00439777|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
79525707|NCT01387256|Drug|medical abortion|pregnancy termination with drugs
79525708|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
79229913|NCT00750243|Drug|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
79525709|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 3, single dose
79525710|NCT01387308|Drug|Fostamatinib|Oral tablets, 100 mg, single dose
79229914|NCT00750243|Drug|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
79681115|NCT06025812|Biological|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
79681116|NCT06025786|Combination Product|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
79681117|NCT06025773|Drug|Lansoprazole 15 mg|AD-2121 (Lansoprazole 15 mg), Oral, Capsule
79824629|NCT00439777|Drug|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
79229915|NCT05380011|Other|Constraint Induced Movement Therapy and Bimanual Task Training|Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
79229916|NCT05380011|Other|Bimanual Task Training|Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
79229917|NCT04438707|Other|Pilates Method combined with Therapeutic exercice.|Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
79229918|NCT04438707|Other|Therapeutic exercise|Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
79824630|NCT00842686|Drug|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
79824631|NCT04045821|Drug|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
79824632|NCT04045821|Drug|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
79824633|NCT04045821|Procedure|dilation and curettage|all participants will undergo routine D&C procedure
79824634|NCT04068584|Other|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
79824635|NCT00842842|Procedure|tack fixation of mesh|tack fixation of mesh
79229919|NCT00748605|Drug|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
79525711|NCT01387308|Drug|Fostamatinib|Oral tablets, 150 mg, single dose
79525712|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
79525713|NCT01387321|Drug|BYL719|
79525714|NCT01387334|Behavioral|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
79525715|NCT01387360|Device|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
79525716|NCT01387373|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
79525717|NCT01387399|Procedure|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
79525718|NCT01387425|Drug|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
79372137|NCT01109602|Other|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
79824636|NCT00842842|Procedure|glue fixation of mesh|glue fixation of mesh
79999130|NCT03565484|Drug|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
79229920|NCT00748605|Drug|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
79372138|NCT02175472|Device|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
79372139|NCT02175472|Device|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
79229921|NCT00748605|Drug|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
79229922|NCT00748605|Other|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
79372140|NCT03014752|Other|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
79372141|NCT03014752|Other|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
79525719|NCT01387425|Drug|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
79525720|NCT01387477|Drug|Lactate|Infusion of 66 mmol of lactate
79229923|NCT00748605|Other|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
79229924|NCT00924170|Drug|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
79229925|NCT00924170|Drug|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and >18:25mg/m^2/day Patients 8 - 9:30 mg/m^2/day Patients 15- 17:20 mg/m^2/day"
79681118|NCT06025773|Drug|Lansoprazole 15mg/Calcium carbonate 600mg|AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
79681119|NCT06025630|Drug|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
79681120|NCT06025630|Drug|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
79681121|NCT06025617|Other|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
79681122|NCT06025617|Other|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
79681123|NCT06025552|Drug|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1~4 PK, PD, safety, and exploratory efficacy data.
79681124|NCT06025552|Drug|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
79824637|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
79824638|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
79229926|NCT00924170|Drug|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and >18:250 mg/m^2/day Patients 8 - 9:300 mg/m^2/day Patients 15-17:200 mg/m^2/day"
79229927|NCT00747123|Biological|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
79229928|NCT00747123|Biological|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
79229929|NCT03294512|Behavioral|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
79305578|NCT02623335|Other|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
79305579|NCT03241199|Drug|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
79525721|NCT01387477|Drug|Glucose|Infusion of 33 mmol of glucose
79525722|NCT01387490|Behavioral|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
79824639|NCT00844636|Device|Sharp needle|
79824640|NCT00844636|Device|Blunt needles|
79229930|NCT04809285|Device|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
79525723|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
79525724|NCT01387503|Procedure|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
79681125|NCT06025539|Behavioral|Animal-assisted resilience training|Participants take part in 12 sessions (120 minutes each), each session focuses on a topic that is related to resilience. The intervention takes part outdoors on a farm, and includes interactions with several different animals. The training takes place in small groups, and includes exercises, observations, and discussions.
79681126|NCT06025487|Biological|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
79681127|NCT06025474|Drug|Vortioxetine 20Mg Tab|Encapsulated vortioxetine immediate release tablets, once daily
79229931|NCT00920985|Drug|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
79525725|NCT01387555|Biological|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
79681128|NCT06025474|Drug|Paroxetine 20 Mg Oral Tablet|Encapsulated paroxetine tablets, once daily
79999131|NCT03565484|Drug|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
79999132|NCT03565484|Drug|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
79229932|NCT00920985|Drug|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
79229933|NCT04808349|Other|no intervention|no intervention
79229934|NCT05388747|Drug|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
79229935|NCT00828321|Drug|Ramipril 10 mg capsule|1 x 10 mg
79229936|NCT00828321|Drug|Altace® 10 mg capsule|1 x 10 mg
79229937|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
79229938|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
79229939|NCT01352715|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
79372142|NCT01892501|Procedure|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
79372143|NCT01892501|Device|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
79372144|NCT04333407|Drug|Aspirin 75mg|• If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
79372145|NCT04333407|Drug|Clopidogrel 75mg|• If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
79372146|NCT04333407|Drug|Rivaroxaban 2.5 MG|"If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated"
79525726|NCT01387555|Other|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
79525727|NCT01387568|Drug|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
79525728|NCT01387568|Drug|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
79525729|NCT01387620|Drug|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
79681129|NCT06025474|Drug|Sertraline 50 MG|Encapsulated sertraline tablets, once daily
79681130|NCT06025474|Drug|Citalopram 20mg|Encapsulated citalopram tablets, once daily
79681131|NCT06025474|Drug|Escitalopram 10mg|Encapsulated escitalopram tablets, once daily
79681132|NCT06025474|Drug|Duloxetine 60 MG|Encapsulated duloxetine tablets, once daily
79681133|NCT06025474|Drug|Pregabalin 75mg|Encapsulated pregabalin tablets, once daily
79681134|NCT06025461|Other|no intervention|no intervention
79681135|NCT06025409|Drug|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
79681136|NCT06025383|Dietary Supplement|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
79681137|NCT06025383|Dietary Supplement|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
79681138|NCT06025357|Dietary Supplement|L-Citrulline supplementation|4 weeks of L-Citrulline supplementation (10 grams/day).
79681139|NCT06025357|Dietary Supplement|Placebo|4 weeks of microcrystalline Cellulose supplementation.
79681140|NCT06025279|Other|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
79681141|NCT06025266|Device|Evaluation of Viscoelastic and mechanical properties with MyotonPRO|MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.
79824641|NCT02575196|Device|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
79824642|NCT00806481|Drug|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
79999133|NCT01336127|Behavioral|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
79999134|NCT03565406|Drug|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
79229940|NCT01352715|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
79229941|NCT01352715|Drug|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
79681142|NCT06025240|Diagnostic Test|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is >20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
79372147|NCT04333407|Drug|Atorvastatin 40mg|• If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
79372148|NCT04333407|Drug|Omeprazole 20mg|• If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
79372149|NCT04398225|Drug|Centanafadine|Extended release capsule
79824643|NCT00806481|Drug|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
79824644|NCT02546596|Device|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
79372150|NCT04398147|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
79372151|NCT04398147|Biological|Placebo|Intramuscular administration
79372152|NCT04398927|Drug|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
79372153|NCT04398927|Drug|Sintilimab|Sintilimab
79372154|NCT03203889|Behavioral|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
79824645|NCT00709436|Drug|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
79999135|NCT03565406|Drug|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
79999136|NCT01333163|Biological|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
79999137|NCT01333163|Biological|Isotone NaCl|2 hours IV infusion.
79999138|NCT04734379|Drug|Fasudil|Oral fasudil 180 mg/day
79372155|NCT03203889|Behavioral|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
79372156|NCT03203187|Other|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
79999139|NCT03565250|Other|self understanding interview|semi-structured interview designed for assessment of identity according to Damon & Hart's 7-dimension develomental model
79229942|NCT01352715|Drug|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
79229943|NCT01352715|Drug|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
79824646|NCT00709436|Drug|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
79824647|NCT00803673|Drug|100mcg|100mcg '719
79824648|NCT00803673|Drug|500mcg|500mcg '719
79824649|NCT00803673|Drug|1000mcg|1000mcg '719
79305580|NCT03241355|Dietary Supplement|prebiotic inulin-type fructan|
79824650|NCT00803673|Drug|Placebo|Placebo '719
79824651|NCT00844792|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
79999140|NCT05352620|Other|Implant assisted maxillary overdenture|For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
79824652|NCT00844792|Drug|Placebo|Twice a day with meals.
79824653|NCT04017195|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
79824654|NCT04017195|Drug|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
79824655|NCT00719420|Drug|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
79229944|NCT01352715|Drug|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
79372157|NCT03203187|Other|No intervention|No mango intake for two weeks.
79824656|NCT00719420|Drug|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
79824657|NCT00797901|Other|Collaborative Care|
79999141|NCT04163887|Procedure|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
79999142|NCT01333241|Behavioral|Lifestyle behavior interventon grop|
79999143|NCT01333241|Other|Placebo Comparator: Control group|
79999144|NCT03565094|Drug|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
79525730|NCT01387633|Other|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
79681143|NCT06025240|Diagnostic Test|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the <60 and >60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
79681144|NCT06025240|Other|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
79681145|NCT06025214|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
79681146|NCT06025214|Drug|ADVAIR DISKUS® 500/50|2 inhalations in one study period
79681147|NCT06025201|Behavioral|Resting State EEG|During this intervention, participants will be asked to not think about anything in particular while EEG is recorded. Resting state will be conducted with either the participants having their eyes open, or eyes closed.
79681148|NCT06025201|Behavioral|Picture Viewing EEG|During this intervention, participants will view emotionally charged pictures for a short period of time. Afterwards, participants will be asked to rate their emotional reactions to the pictures. EEG will be recorded during this intervention.
79999145|NCT03565094|Drug|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
79999146|NCT01339871|Drug|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
79229945|NCT01352715|Drug|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
79229946|NCT01352715|Drug|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
79229947|NCT00743925|Drug|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
79229948|NCT00740727|Drug|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
79305581|NCT03241355|Dietary Supplement|Placebo maltodextrin|
79372158|NCT05194059|Behavioral|Home-based physical activity|Participants will follow a personalized activity pacing program
79372159|NCT01059682|Drug|Dalcetrapib|Dalcetrapib 600 mg orally once daily
79372160|NCT01059682|Drug|Placebo|Placebo orally once daily
79824658|NCT00844870|Behavioral|stabilization training|training of arm function with the trunk stabilized
79824659|NCT00844870|Behavioral|auditory training group|response to an auditory signal
79824660|NCT00719498|Drug|Epo-alpha|
79824661|NCT00803829|Other|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
79824662|NCT00716612|Drug|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
79824663|NCT00716612|Drug|Placebo control|po Placebo QD
79824664|NCT00842920|Drug|Simvastatin 60 mg|60 mg once daily
79824665|NCT00842920|Drug|Placebo|one tablet once daily
79824666|NCT00842920|Drug|Simvastatin 20 mg|20 mg once daily
79824667|NCT00806559|Other|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
79824668|NCT00806559|Other|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
79824669|NCT00716690|Procedure|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
79824670|NCT02552979|Other|atopic patch test|
79999147|NCT01339871|Drug|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
79229949|NCT00740727|Procedure|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
79229950|NCT00826059|Device|Active Sphenopalatine Ganglion (SPG) Stimulation|SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
79681149|NCT06025201|Behavioral|Stop Signal EEG|During this intervention, participants will be asked to respond quickly to a visual stimulus with a button press. At times, participants will be asked to inhibit their responses. EEG will be recorded during this intervention.
79372161|NCT04398693|Dietary Supplement|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
79525731|NCT01387633|Other|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
79525732|NCT01387646|Behavioral|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
79525733|NCT01387659|Procedure|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
79525734|NCT01387711|Drug|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
79681150|NCT06025188|Other|training set|LASSO regression analysis, Logistic regression analysis, Nomogram
79681151|NCT06025175|Radiation|Low level Lazer therapy|30 patients will receive low level lazer therapy 3 times a week for 12 weeks.
79681152|NCT06025175|Other|Routine exercises|30 patients will receive only routine exercises 3 times a week for 12 weeks.
79681153|NCT06025162|Drug|enoxaparin|dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
79824671|NCT00722774|Biological|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
79824672|NCT03118063|Diagnostic Test|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
79999148|NCT01339949|Device|IRay|low voltage external beam radiosurgery
79999149|NCT01339949|Device|IRay|low voltage external beam radiosurgery
79525735|NCT01387724|Genetic|RNA analysis|
79525736|NCT01387724|Genetic|polymerase chain reaction|
79525737|NCT01387724|Genetic|protein expression analysis|
79525738|NCT01387724|Genetic|proteomic profiling|
79681154|NCT06025084|Drug|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
79681155|NCT06025071|Drug|colchicine|Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
79681156|NCT06025058|Device|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
79681157|NCT06025019|Behavioral|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
79824673|NCT00842998|Drug|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
79999150|NCT04693429|Drug|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
79999151|NCT05353712|Other|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
79999152|NCT05353712|Other|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
79229951|NCT00826059|Device|Sham Sphenopalatine Ganglion (SPG) Stimulation|Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
79229952|NCT00825513|Device|Akreos Toric IOL|Lens implant following cataract surgery
79681158|NCT06025006|Other|alternative to incarceration|place of respite with housing plus intensive follow-up
79372162|NCT04399083|Dietary Supplement|Caffeine|"Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL."
79824674|NCT00806637|Procedure|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
79372163|NCT01892345|Drug|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
79824675|NCT00806637|Procedure|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
79525739|NCT01387724|Genetic|western blotting|
79525740|NCT01387724|Other|enzyme-linked immunosorbent assay|
79824676|NCT00716768|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
79681161|NCT06024967|Drug|PEG-somatropin|PEG-somatropin
79229953|NCT00825513|Device|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
79681162|NCT06024954|Other|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
79681163|NCT06024954|Other|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
79681164|NCT06024954|Other|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
79824677|NCT00716768|Procedure|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
79229954|NCT00919893|Drug|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
79229955|NCT00919893|Drug|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
79525741|NCT01387724|Other|immunohistochemistry staining method|
79824678|NCT01034449|Other|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
79824679|NCT00716846|Drug|simvastatin|10mg, 2 weeks
79525742|NCT01387724|Other|laboratory biomarker analysis|
79525743|NCT01387724|Other|liquid chromatography|
79525744|NCT01387724|Other|mass spectrometry|
79525745|NCT01387750|Other|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
79525746|NCT01387750|Other|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
79525747|NCT01387828|Procedure|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
79525748|NCT01387828|Procedure|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
79525749|NCT01387841|Behavioral|yoga|Postures,relaxation techniques
79681165|NCT06024915|Drug|TQ05105 tablets|TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
79681166|NCT06024915|Drug|Itraconazole capsule|Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
79824680|NCT00716846|Drug|atorvastatin|10mg
79824681|NCT00716846|Drug|pitavastatin|2mg
79372164|NCT01892345|Drug|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
79824682|NCT00797979|Device|Skull Grip bone fixation|Skull Grip bone fixation
79372165|NCT01059760|Behavioral|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
79372166|NCT01059760|Behavioral|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
79372167|NCT05179551|Procedure|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
79372168|NCT04399785|Other|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
79372169|NCT01059994|Drug|Placebo sildenafil|Oral, daily, 1 week.
79525750|NCT01387841|Behavioral|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
79525751|NCT01387867|Procedure|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
79681167|NCT06024915|Drug|Rifampicin Capsule|Rifampicin is a strong inducer of CYP3A.
79681168|NCT06024850|Other|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
79681169|NCT06024837|Other|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
79824683|NCT00797979|Device|sutures|Standard skull bon flap fixation, sutures
79372170|NCT01059994|Drug|Sildenafil|oral, 25mg, daily for 1 week
79372171|NCT01061476|Device|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
79372172|NCT01061476|Other|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
79372173|NCT01061476|Other|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
79372174|NCT01111162|Biological|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
79372175|NCT04398303|Biological|ACT-20-MSC|1 million cells / kg body weight in 100 ml in conditioned media
79372176|NCT04398303|Biological|ACT-20-CM|100 ml of conditioned media only
79372177|NCT04398303|Biological|Placebo|100 ml of MEM-α
79681170|NCT06024811|Behavioral|supporting nursing care|Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
79681171|NCT06024798|Diagnostic Test|Photon-Counting-Computed-Tomography|Initial and follow up (after 4 weeks) PCCT acquisition of the affected area of the lower extremity. Image acquisition will be performed on the PCCT
79681172|NCT06024746|Drug|Finerenone|Oral finerenone.
79681173|NCT06024746|Drug|Empagliflozin|Oral empagliflozin.
79681174|NCT06024681|Other|Faecal microbiota transplant|Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
79681175|NCT06024616|Behavioral|TARANG|"TARANG is structured to be interactive to empower young women to navigate newly formed relationships, improve women's awareness on sexual reproductive health and challenge inequitable gender norms with an aim to reduce unintended pregnancies. TARANG will also provide women with life skills education to improve mobility and agency. Each TARANG intervention women's group will have ~6-7 members and may meet up to twice a month for 8 months.~Vikalp's moderators will also conduct light touch sessions for mothers-in-law and husbands of newly married women. In conjunction with Vikalp, the research team from NEERMAN will recruit mothers-in-law of soon-to-be-married women to participate in 4 group sessions provided weekly for 1 month before the start of the intervention for newly married women. Husbands will be provided 4 group sessions spaced roughly 2 months apart throughout the course of the 8 months the newly married women are engaged in the intervention."
79681176|NCT06024577|Behavioral|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
79681177|NCT06024577|Behavioral|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
79372178|NCT03784287|Drug|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
79372179|NCT03772743|Other|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
79525752|NCT01387867|Procedure|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
79525753|NCT01387867|Procedure|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
79824684|NCT00620854|Drug|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
79824685|NCT00620854|Drug|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
79824686|NCT00620854|Drug|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
79229956|NCT04789863|Device|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring & follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
79824687|NCT00620854|Drug|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
79824688|NCT05672966|Biological|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
79372180|NCT03772743|Other|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
79372181|NCT01111318|Drug|BI 10773|2 tablets BI 10773 25 mg single dose
79372182|NCT04760067|Other|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
79372183|NCT03571048|Behavioral|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
79525754|NCT01387880|Drug|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
79525755|NCT01387880|Drug|Everolimus|1.66 mg per day up to 7½ mg per day
79525756|NCT01387893|Behavioral|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
79525757|NCT01387906|Drug|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
79525758|NCT01387919|Behavioral|Prolonged fasting|48 hours of fasting
79525759|NCT01387945|Behavioral|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
79681178|NCT06024577|Behavioral|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
79681179|NCT06024564|Device|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
79681180|NCT06024525|Device|Paclitaxel-Coated Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
79372184|NCT03571048|Behavioral|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
79681181|NCT06024525|Device|Paclitaxel-Releasing Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
79681182|NCT06024499|Drug|HY209GEL Active|Selected two among three doses (HY209GEL 0.5% or 1% or 2%) in PART1
79681183|NCT06024499|Other|Placebo|Placebo
79824689|NCT05672966|Biological|Placebo|0.5mL, Intramuscular
79372185|NCT01892189|Drug|Ketamine|Ketamine intravenous administration.
79372186|NCT01892189|Drug|TAK-063|TAK-063 tablets
79372187|NCT01892189|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
79525760|NCT01387958|Drug|LCQ908|
79525761|NCT01387958|Drug|Placebo|
79681184|NCT06024473|Device|rTMS|Transcranial Magnetic Stimulation
79681185|NCT06024473|Device|rTMS+iVCT|Transcranial Magnetic Stimulation and immersive virtual reality
79681186|NCT06024460|Procedure|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
79681187|NCT06024460|Procedure|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
79824690|NCT00716924|Drug|Clopidogrel|300 mg
79824691|NCT00716924|Drug|Clopidogrel|600 mg
79824692|NCT00430027|Drug|Capecitabine|Given 650 mg/m^2 BID on days of ration therapy, 825 mg/m^2 day 1-14, day 15-20 off x 4
79824693|NCT00430027|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2, 130mg/m2 IV Q 21 days x 4
79824694|NCT00430027|Drug|Cetuximab|Initial Cetuximab 400 mg/m^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
79824695|NCT04043182|Procedure|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
79824696|NCT04043260|Device|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
79824697|NCT00717080|Procedure|IOL surgery|IOL surgery using capsular tension ring (AURORING)
79229957|NCT04789863|Other|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
79372188|NCT03750201|Device|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
79372189|NCT03750201|Device|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
79372190|NCT01062568|Drug|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
79372191|NCT01062568|Drug|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
79372192|NCT03739281|Diagnostic Test|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
79372193|NCT03739281|Diagnostic Test|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
79681188|NCT06024447|Procedure|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
79681189|NCT06024421|Drug|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
79824698|NCT00717080|Procedure|IOL surgery|IOL surgery without CTR
79824699|NCT04766229|Combination Product|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
79824700|NCT04068506|Drug|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
79999153|NCT05353712|Other|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
79372194|NCT03014518|Other|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
79372195|NCT03014518|Other|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
79525762|NCT01387997|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
79525763|NCT01388010|Other|1-Fermented Probiotic Dairy Product (test)|
79525764|NCT01388010|Other|2-Milk-based non-fermented dairy product(control)|
79999154|NCT05353712|Other|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
79999155|NCT05353712|Other|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
79681190|NCT06024421|Drug|Placebo|Light yellow, film-coated tablet
79681191|NCT06024395|Behavioral|Dental FearLess|Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.
79681192|NCT06024382|Other|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
79681193|NCT06024382|Other|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
79681194|NCT06024356|Drug|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
79372196|NCT05155137|Drug|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
79525765|NCT01388023|Dietary Supplement|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
79824701|NCT03871335|Diagnostic Test|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
79372197|NCT05155137|Behavioral|Stroke Riskometer|the primary care units will be randomized to use Stroke Riskometer App together with health community workers to help in the lifestyle modifications
79824702|NCT00851188|Behavioral|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
79824703|NCT00851188|Behavioral|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
79999156|NCT05353712|Other|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
79372198|NCT01881425|Procedure|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
79372199|NCT01881425|Device|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
79525766|NCT01388036|Drug|esmolol|consecutive infusions of esmolol and normal saline (placebo)
79525767|NCT01388049|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
79525768|NCT01388062|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
79681195|NCT06024343|Procedure|MPD Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is damaged due to its proximity or encasement by the tumor, MPD repair or reconstruction is performed.
79824704|NCT00851188|Other|Waiting list|Waiting list
79824705|NCT04068740|Procedure|Surgical treatment of valvular heart disease|Valve replacement or repair
79824706|NCT04068740|Diagnostic Test|Virtual treatment|Virtual valve replacement or repair surgery
79824707|NCT00803907|Drug|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
79824708|NCT00843154|Drug|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
79681196|NCT06024317|Behavioral|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
79681197|NCT06024317|Behavioral|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
79681198|NCT06024317|Behavioral|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
79999157|NCT01336283|Other|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
79999158|NCT01336283|Other|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
79999159|NCT01336283|Other|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
79824709|NCT00843154|Drug|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
79681199|NCT06024317|Behavioral|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
79681200|NCT06024304|Device|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
79681201|NCT06024304|Device|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
79681202|NCT06024278|Behavioral|Caregiver educational videos|The intervention will be culturally tailored education videos for caregivers receiving hospice services.
79681203|NCT06024265|Drug|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
79824710|NCT00803985|Procedure|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
79824711|NCT00803985|Procedure|Lichtenstein|Operation for primary inguinal hernias i men
79229958|NCT04472871|Device|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
79390860|NCT03189342|Behavioral|exercise-cognitive activity combined training|The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
79525769|NCT01388075|Drug|Rifampicin|oral, 450 mg/day , 7 days
79525770|NCT01388088|Drug|Spironolactone|25 mg twice a day
79525771|NCT01388088|Drug|Amiloride|5 mg twice a day
79525772|NCT01388088|Drug|Placebo|twice a day
79681204|NCT06024252|Drug|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
79229959|NCT00738387|Drug|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
79229960|NCT00738387|Drug|Placebo|Placebo i.v. on day 1 of each 21 day cycle
79229961|NCT00738387|Drug|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
79229962|NCT04472715|Procedure|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
79229963|NCT00645177|Drug|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
79525773|NCT01388101|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
79681205|NCT06024213|Procedure|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
79229964|NCT00645177|Drug|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
79229965|NCT00645177|Drug|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
79824712|NCT00429793|Drug|temsirolimus|Given IV
79824713|NCT00851266|Biological|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
79229966|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
79229967|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
79824714|NCT00851266|Biological|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
79229968|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
79229969|NCT00643383|Drug|Combination drug (Acetaminophen + Tramadol)|
79229970|NCT00643383|Drug|Placebo|
79229971|NCT02559622|Drug|Secukinumab|300 mg secukinumab
79229972|NCT02559622|Other|Placebo|Placebo followed by 300 mg secukinumab
79229973|NCT02559622|Other|Placebo|Placebo followed by 150 mg secukinumab
79681206|NCT06024213|Drug|indocyanine green|Intervention description: indocyanine green (5 to 10 mg [ie, 2 to 4 mL of a 2.5 mg/mL solution]) administered by periareolar or peritumoural route
79681207|NCT06024213|Drug|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
79681208|NCT06024213|Drug|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
79229974|NCT02559622|Drug|Secukinumab|150 mg secukinumab
79372200|NCT04165473|Behavioral|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
79229975|NCT05491486|Behavioral|Mindfulness-based Group Therapy|see above
79824715|NCT04067570|Radiation|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
79229976|NCT05491408|Device|Cough assist device|A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure [4,5].
79229977|NCT04285450|Dietary Supplement|Vitamin K|1mg
79229978|NCT04285450|Other|Placebo|Lactose
79229979|NCT05497102|Drug|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
79229980|NCT05496946|Other|Head bathing skill|A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
79372201|NCT01064284|Drug|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
79372202|NCT01064284|Drug|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
79372203|NCT04611815|Procedure|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
79372204|NCT04611815|Diagnostic Test|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
79372205|NCT04611815|Diagnostic Test|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
79372206|NCT01891721|Behavioral|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
79390861|NCT03797170|Other|Gut microbiota samples|Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy
79390862|NCT00361348|Drug|Palifermin|
79390863|NCT00361348|Drug|Heparin|
79390864|NCT02431884|Procedure|collect body fluids/tissues & med history|collect tissues/fluids & history
79390865|NCT02431728|Dietary Supplement|Melatonin|5 mg capsule p.o. at bedtime daily
79390866|NCT02431728|Dietary Supplement|Matched Placebo|5 mg capsule p.o. at bedtime daily
79525774|NCT01388114|Device|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
79525775|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
79525776|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
79525777|NCT01388153|Drug|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
79525778|NCT01388179|Device|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
79525779|NCT01388205|Behavioral|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
79229981|NCT03998254|Drug|V503|9vHPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
79229982|NCT03998254|Drug|Gardasil|qHPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
79229983|NCT03994978|Procedure|elective sigmoidectomy|elective sigmoidectomy
79229984|NCT05496400|Radiation|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~Cardiac output:~Cerebral, intestinal and renal blood flow velocities:"
79999160|NCT03916549|Device|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
79999161|NCT05353634|Diagnostic Test|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
79999162|NCT03564704|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
79229985|NCT05490628|Other|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
79372207|NCT01891721|Behavioral|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
79372208|NCT01891721|Behavioral|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
79372209|NCT01064362|Drug|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
79525780|NCT01388231|Behavioral|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
79681209|NCT06024200|Other|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
79372210|NCT01064362|Drug|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
79229986|NCT05490628|Other|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
79229987|NCT05496088|Procedure|Re-PVI only|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
79229988|NCT05496088|Procedure|Re-PVI + substrate ablation|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
79372211|NCT03646461|Drug|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
79372212|NCT03646461|Drug|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
79372213|NCT03646461|Drug|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
79372214|NCT03013738|Behavioral|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
79372215|NCT03013738|Other|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
79372216|NCT01880957|Drug|Lithium|
79372217|NCT01880957|Drug|Lamotrigine|
79525781|NCT01388231|Behavioral|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
79525782|NCT01388257|Procedure|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
79525783|NCT01388257|Procedure|Simple seton drain removal|Patients are simply followed after seton drain removal.
79525784|NCT01388270|Device|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
79525785|NCT01388322|Drug|Enoxaparin|40 mg (4000 IU) women <80 kg at the time of randomization or 60 mg (6000 IU) women> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
79824716|NCT00806871|Drug|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
79999163|NCT03564704|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
79372218|NCT04152837|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
79372219|NCT01064830|Drug|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
79229989|NCT04175938|Device|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
79229990|NCT05490160|Drug|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
79372220|NCT01064830|Drug|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
79824717|NCT00806871|Drug|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
79824718|NCT00806871|Drug|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
79824719|NCT00717158|Behavioral|Usual medical care|
79372221|NCT01879553|Biological|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
79372222|NCT01115452|Drug|5% Potassium nitrate|5% potassium nitrate solution
79372223|NCT01115452|Drug|2.5% Potassium nitrate|2.5% potassium nitrate solution
79372224|NCT01115452|Other|Sterile water|Sterile water
79824720|NCT00717158|Behavioral|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
79824721|NCT00855400|Procedure|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
79824722|NCT00855400|Procedure|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
79824723|NCT00798213|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
79229991|NCT05495620|Drug|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
79229992|NCT05495620|Drug|Lenalidomide|Oral
79229993|NCT05495620|Drug|Dexamethasone|Oral or intravenous
79525786|NCT01388348|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
79229994|NCT05490082|Drug|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
79372225|NCT04126551|Other|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
79824724|NCT00798213|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
79229995|NCT02559310|Drug|lefamulin|antibacterial agent
79229996|NCT02559310|Drug|Moxifloxacin|antibacterial agent
79372226|NCT01890785|Drug|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
79372227|NCT03571971|Other|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
79372228|NCT03571971|Other|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
79372229|NCT03564015|Other|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
79824725|NCT04069208|Drug|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
79824726|NCT04042246|Behavioral|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
79824727|NCT04067258|Diagnostic Test|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
79999164|NCT03564704|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
79999165|NCT03564704|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
79999166|NCT03564704|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
79229997|NCT02559310|Drug|Linezolid|antibacterial agent
79229998|NCT05495542|Other|ShotBlocker|ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects [5]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered [6]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory [7]
79372230|NCT03564015|Other|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
79372231|NCT04616651|Behavioral|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
79390867|NCT03188640|Procedure|Laparoscopic gastric-bypass surgery|Female participants with BMI >30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
79525787|NCT01388374|Other|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
79525788|NCT01388400|Other|conventional occupational therapy|upper limb exercises
79525789|NCT01388400|Device|video capture virtual reality|virtual reality delivered uppe limb exercises
79525790|NCT01388413|Drug|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
79525791|NCT01388426|Device|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
79229999|NCT05490004|Other|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
79230000|NCT04150276|Procedure|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
79372232|NCT04616651|Behavioral|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
79525792|NCT01388439|Drug|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants < 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants > 38 weeks PMA. Dosing in infants < 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants > 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants > 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
79525793|NCT01388452|Device|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
79525794|NCT01388465|Behavioral|Mobile phone text messaging|Daily assessment followed by feedback
79681210|NCT06024200|Other|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
79681211|NCT06024187|Procedure|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
79681212|NCT06024187|Procedure|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
79681213|NCT06024161|Other|Weight gain|≥5% weight gain
79681214|NCT06024161|Other|Weight loss|≥5% weight loss after arthroplasty
79681215|NCT06024161|Other|Weight unchanged|<5% weight change after arthroplasty
79681216|NCT06024148|Other|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
79681217|NCT06024135|Device|NeoKidney|Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
79681218|NCT06024122|Other|IRM exam|A non-sedated MRI scan will be performed to assess the structure and function of the children's brains
79681219|NCT06023511|Device|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
79681220|NCT06023459|Drug|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.
79681221|NCT06023459|Drug|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.
79681222|NCT06023394|Device|Laryngeal Mask Airway|Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
79681223|NCT06023394|Device|Endotracheal Tube Device|Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
79681224|NCT06023277|Biological|ConvitVax|ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
79999167|NCT03564704|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79230001|NCT04150276|Procedure|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
79230002|NCT05495308|Procedure|neoadjuvant treatment|We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
79824728|NCT00807027|Drug|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
79824729|NCT00424645|Drug|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
79824730|NCT00424645|Drug|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
79824731|NCT00845104|Drug|fludarabine phosphate|Given IV
79824732|NCT00845104|Biological|rituximab|Given IV
79824733|NCT00845104|Biological|bevacizumab|Given IV
79999168|NCT03564704|Drug|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79999169|NCT03564704|Drug|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
79999170|NCT03564704|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79999171|NCT03564704|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79999172|NCT03564704|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
79999173|NCT03564704|Procedure|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
79999174|NCT03564704|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
79230003|NCT04149808|Device|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
79230004|NCT04149808|Device|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
79681225|NCT06023251|Other|Clinical Nutrition|"Nutritional care plan implementation, including~A step-up and step-down nutritional protocol guided by caloric and protein ratio~Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~Dedicated and specialized dietician and nurse involvement~Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition."
79681226|NCT06023238|Procedure|Treatment of Chronic TKA PJI|Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
79681227|NCT06023225|Behavioral|Pain|Postoperative pain levels
79999175|NCT03564704|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
79230005|NCT05495152|Drug|Sintilimab|Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
79681228|NCT06023225|Behavioral|Opioid use|Postoperative opioid use
79681229|NCT06023186|Drug|mavacamten|Study participants will receive mavacamten under the standard of care
79824734|NCT00845104|Other|laboratory biomarker analysis|Correlative studies
79824735|NCT00845104|Other|flow cytometry|Correlative studies
79999176|NCT03564704|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
79999177|NCT03564704|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
79230006|NCT04147624|Drug|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
79230007|NCT04147624|Other|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
79230008|NCT05489848|Drug|Paclitaxel|Paclitaxel: paclitaxel dose of 135~175mg / m2, about 3 hours after the infusion, the use of pretreatment drugs before the infusion according to the drug instructions. Every 21 days is one session.
79230009|NCT05489848|Drug|Carboplatin|Carboplatin: Doses were given at AUC=5 - 6 and used after paclitaxel. Based on the calculated amount, the maximum dose of carboplatin per chemotherapy does not exceed 750mg.
79824736|NCT00845104|Genetic|polymerase chain reaction|Correlative studies
79824737|NCT00845104|Genetic|fluorescence in situ hybridization|Correlative studies
79824738|NCT00804063|Procedure|drawing blood sample|fasting blood sample
79824739|NCT02553681|Device|roflufocon D contact lenses|HPT treated rigid contact lenses
79824740|NCT02553681|Device|RGP contact lenses made from roflufocon D|
79824741|NCT01034605|Dietary Supplement|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
79824742|NCT03994939|Behavioral|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
79824743|NCT00763451|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
79824744|NCT00763451|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
79824745|NCT00763451|Device|Pen auto-injector|
79824746|NCT00763451|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
79824747|NCT00762762|Drug|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
79824748|NCT00762762|Drug|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
79824749|NCT00424489|Biological|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
79824750|NCT00424489|Drug|Cyclophosphamide|
79824751|NCT00424489|Drug|ATG (rabbit)|
79824752|NCT00424489|Drug|Mesna|
79681230|NCT06023134|Diagnostic Test|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
79372233|NCT04616651|Behavioral|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
79372234|NCT01066624|Drug|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
79824753|NCT00424489|Drug|Methylprednisolone|
79824754|NCT00424489|Drug|G-CSF|
79230010|NCT05489848|Drug|Cisplatin|Concurrent cisplatin intravenous chemotherapy on radiotherapy days 1 and 29,50mg / m2, a total of 2 times.
79372235|NCT01066624|Other|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
79372236|NCT01066624|Device|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
79681231|NCT06023134|Diagnostic Test|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
79824755|NCT00578864|Drug|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~Hour 0: Etoposide 50 mg/m2 po daily~Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~Etoposide 50 mg/m2 po once daily"
79525795|NCT01388504|Drug|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
79525796|NCT01388504|Other|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
79824756|NCT00578864|Drug|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if < 12 kg) with Mesna 400 mg/m2 (13 mg/kg if < 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if < 12 kg) IV over 15 minutes"
79824757|NCT00578864|Drug|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
79824758|NCT00578864|Drug|Cisplatin|Cycle 1, 2, and 4
79824759|NCT00578864|Drug|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
79230011|NCT05489848|Radiation|EBRT|50.4Gy/28 / 6 weeks; common iliac node positive or paraaortic node positive plus extended field.The radiation extension field should include the entire pelvic cavity, the common iliac vessels and the paraaortic lymph node area.The range above the extension field is determined based on the clinical status, but at least 1-2cm above the renal vascular level.
79230012|NCT05489848|Radiation|VBT|Subnormal vaginal mucosa was 0.5cm, 30Gy / 5times /5weeks.
79372237|NCT01878383|Device|Genexpert assay|
79372238|NCT04123197|Other|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
79372239|NCT05132907|Biological|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
79372240|NCT04398771|Drug|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
79525797|NCT01388517|Drug|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
79230013|NCT05489770|Dietary Supplement|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid has been used as a supplement since 1991 with no reports of adverse effects received by the Manufacturer.
79372241|NCT01067716|Device|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
79372242|NCT01863953|Drug|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
79372243|NCT01863953|Drug|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
79525798|NCT01388517|Drug|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
79525799|NCT01388517|Drug|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
79525800|NCT01388556|Behavioral|Tango dancing|Twice weekly tango dance classes
79525801|NCT01388569|Other|flow cytometry|
79525802|NCT01388569|Other|immunologic technique|
79525803|NCT01388569|Other|laboratory biomarker analysis|
79525804|NCT01388582|Device|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
79525805|NCT01388582|Device|Implanon|60 mcg/day contraceptive implant
79525806|NCT01388582|Drug|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
79824760|NCT00578864|Drug|Mesna|Standard weight-based dosing with cyclophosphamide
79824761|NCT00578864|Drug|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
79824762|NCT00578864|Procedure|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
79230014|NCT05489770|Dietary Supplement|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra)|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom
79824763|NCT01034683|Drug|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
79824764|NCT02579070|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
79824765|NCT00717470|Drug|Prograf®|oral
79824766|NCT00717470|Drug|Advagraf®|oral
79824767|NCT00717470|Drug|Mycophenolate Mofetil|oral
79824768|NCT00717470|Drug|Simulect|oral
79824769|NCT00717470|Drug|methylprednisolone / prednisone|oral
79824770|NCT02577198|Other|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
79824771|NCT00631566|Drug|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
79824772|NCT00631566|Drug|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
79824773|NCT04067414|Biological|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10^6/kg CAR+ cells; Dose 2: 3×10^6/kg CAR+ cells; Dose 3: 6×10^6/kg CAR+ cells."
79824774|NCT00717548|Behavioral|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
79824775|NCT00722852|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
79824776|NCT00722852|Drug|Placebo|100 mg (b.i.d.)
79824777|NCT04838418|Procedure|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
79230015|NCT05489692|Procedure|hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
79999178|NCT03564704|Diagnostic Test|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
79230016|NCT05494684|Other|Multisensoral Nature-based Intervention|The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
79372244|NCT01863953|Drug|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
79372245|NCT01863953|Drug|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
79372246|NCT01068964|Drug|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
79525807|NCT01388582|Device|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
79525808|NCT01388582|Device|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
79681232|NCT06023121|Diagnostic Test|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
79681233|NCT06023082|Dietary Supplement|Colon Broom Premium supplement|"The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron"
79824778|NCT00770315|Biological|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
79824779|NCT00770315|Biological|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
79824780|NCT04071600|Drug|Neuropeptide Y|Intranasal
79824781|NCT04071600|Other|Placebo|intranasal
79824782|NCT05657444|Drug|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
79681234|NCT06023043|Drug|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
79681235|NCT06023017|Behavioral|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
79824783|NCT04072302|Drug|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
79999179|NCT03564704|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
79999180|NCT03564704|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
79999181|NCT03564704|Drug|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
79999182|NCT03564704|Diagnostic Test|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
79999183|NCT03564548|Drug|PPP001|Group assigned to PPP001
79999184|NCT03564548|Drug|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
79999185|NCT03159455|Drug|BI 1467335|Duration - 28 days
79230017|NCT05489536|Behavioral|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
79824784|NCT04072302|Drug|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
79681236|NCT06023017|Behavioral|standard perioperative care without any prone position training|Patients in the control group (C group) received standard perioperative care without any prone position training.
79824785|NCT04103411|Other|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
79824786|NCT00525720|Drug|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
79824787|NCT00525720|Behavioral|Questionnaire|Questionnaires taking 30 total minutes.
79824788|NCT00587171|Device|Patching|2 hours daily patching
79824789|NCT00587171|Procedure|Near activities|30 minutes daily near activities at home
79824790|NCT00587171|Procedure|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
79824791|NCT00587171|Procedure|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
79824792|NCT04833426|Drug|Testosterone gel|Topical gel containing testosterone
79372247|NCT01068964|Drug|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
79525809|NCT01388595|Drug|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
79525810|NCT01388595|Drug|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
79525811|NCT01388595|Drug|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported & QP release tested in UK : DHP Clinical supplies, Powys, UK
79681237|NCT06022978|Procedure|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
79824793|NCT04833426|Drug|Placebo|Topical gel without active substance
79824794|NCT02576964|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
79824795|NCT02576964|Drug|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
79824796|NCT00763139|Drug|Pioglitazone|45 mg by mouth once a day for 8 weeks
79999186|NCT03159455|Drug|Placebo|Duration - 28 days
79372248|NCT03217162|Drug|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
79372249|NCT03217162|Drug|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
79372250|NCT00768274|Drug|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
79372251|NCT00768274|Drug|Placebo|Placebo twice daily (b.i.d.) for 28 days
79681238|NCT06022978|Procedure|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
79824797|NCT00763139|Drug|Placebo|By mouth once a day for 8 weeks
79824798|NCT04074408|Procedure|stereotactic surgery|stereotactic aspiration surgery
79824799|NCT04074408|Biological|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
79824800|NCT04074408|Biological|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
79824801|NCT00781859|Drug|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
79824802|NCT00781859|Drug|Placebo|Placebo intravitreal injection
79824803|NCT02576886|Device|Gamma Camera|All images acquired with the General Electric Discovery 530c
79824804|NCT02576886|Procedure|Prone Imaging|
79824805|NCT04100915|Other|No Intervention|There is no intervention for this study
79824806|NCT01344252|Drug|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
79824807|NCT04101383|Drug|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
79824808|NCT04101383|Drug|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
79824809|NCT02576808|Drug|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
79824810|NCT02576808|Drug|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
79824811|NCT04100681|Device|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
79824812|NCT04100681|Device|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
79824813|NCT04098965|Other|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
79999187|NCT05353010|Drug|Tacrolimus|Tacrolimus 5mg (1 mg * 5 capsules)
79681239|NCT06022965|Other|Best Practice|Receive SOC
79681240|NCT06022965|Other|Comprehensive Geriatric Assessment|Complete CARG-GA
79681241|NCT06022965|Other|Electronic Health Record Review|Ancillary studies
79681242|NCT06022965|Other|Questionnaire Administration|Ancillary studies
79681243|NCT06022965|Other|Supportive Care|Receive GA-based interventions
79372252|NCT01116466|Device|ActiGait|ActiGait - implantable drop foot stimulator
79681244|NCT06022965|Other|Telemedicine|Receive GA-based interventions via telemedicine
79681245|NCT06022952|Other|Stone MD stent radar|Mobile app
79230018|NCT05489458|Procedure|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
79681246|NCT06022939|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Given IV
79824814|NCT04098965|Other|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
79824815|NCT02576730|Procedure|ORIF|surgery for foot and ankle fractures
79824816|NCT04098887|Radiation|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
79824817|NCT04100603|Other|No Intervention|There is no intervention for this study
79230019|NCT05489458|Procedure|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
79230020|NCT00640419|Drug|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
79230021|NCT00640419|Drug|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
79230022|NCT00640185|Drug|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
79230023|NCT00640185|Drug|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
79230024|NCT00721695|Drug|OMS302|OMS302 Irrigation Solution
79230025|NCT00721695|Drug|OMS302-PE|OMS302-PE HCI Irrigation Solution
79230026|NCT00721695|Drug|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
79372253|NCT04352842|Other|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
79372254|NCT02984475|Drug|Metformin|
79372255|NCT01069354|Device|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
79525812|NCT01388621|Drug|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
79525813|NCT01388621|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
79525814|NCT01388621|Drug|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
79525815|NCT01388621|Drug|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
79525816|NCT01388621|Drug|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
79681247|NCT06022939|Procedure|Biopsy|Undergo fat pad biopsy
79681248|NCT06022939|Procedure|Biospecimen Collection|Undergo blood and urine specimen collection
79681249|NCT06022939|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79681250|NCT06022939|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79681251|NCT06022939|Drug|Bortezomib|Given SC
79681252|NCT06022939|Procedure|Computed Tomography|Undergo CT scan
79681253|NCT06022939|Drug|Cyclophosphamide|Given PO or IV
79681254|NCT06022939|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
79681255|NCT06022939|Drug|Dexamethasone|Given PO or IV
79681256|NCT06022939|Procedure|Echocardiography|Undergo echocardiography
79681257|NCT06022939|Procedure|Magnetic Resonance Imaging|Undergo MRI
79681258|NCT06022939|Drug|Melphalan|Given IV
79681259|NCT06022939|Procedure|Positron Emission Tomography|Undergo PET-CT
79681260|NCT06022939|Procedure|Stem Cell Isolation|Undergo stem cell collection
79681261|NCT06022939|Other|Survey Administration|Ancillary study
79681262|NCT06022900|Behavioral|Online training group|online health education with video call
79681263|NCT06022900|Behavioral|Face-to-face training group|Face-to-face health education with home visit
79824818|NCT00580788|Drug|PTHrP (1-36)|IND # 49,175
79824819|NCT02576106|Device|Cryoablation|
79824820|NCT02575872|Behavioral|Exercise Intervention|Participate in physical activity behavioral intervention
79824821|NCT04071678|Behavioral|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
79824822|NCT04073160|Drug|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
79824823|NCT04073160|Drug|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
79999188|NCT05353010|Drug|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg* 1 tablet)
79372256|NCT01069354|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
79372257|NCT03517917|Other|Tumour tissue collection|Collection of tumour tissue and blood
79525817|NCT01388621|Drug|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
79372258|NCT01069510|Drug|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
79372259|NCT01069510|Other|Placebo|Placebo daily for 12 months
79824824|NCT04073160|Radiation|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
79999189|NCT05353010|Drug|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg*1 tablet) and Tacrolimus 5mg(1mg * 5capsules)
79230027|NCT00625833|Drug|Placebo|Oral tablet once a day dosing for 10 weeks.
79230028|NCT00625833|Drug|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
79230029|NCT00735267|Drug|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
79372260|NCT04398069|Procedure|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
79372261|NCT03013660|Other|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
79372262|NCT04746261|Behavioral|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
79525818|NCT01388660|Drug|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I & II Day 1 (crossover manner)
79525819|NCT01388660|Drug|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I & II Day 1 (crossover manner)
79230030|NCT03299114|Other|Whirlpool|
79230031|NCT03294356|Other|FT210771|An electronic cigarette
79525820|NCT01388673|Procedure|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
79525821|NCT01388712|Dietary Supplement|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
79525822|NCT01388712|Dietary Supplement|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
79525823|NCT01388738|Drug|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg*3 times per day) per os
79681264|NCT06022874|Other|Phoilex Releaf Gel|"Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks.~The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised.~The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study.~The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day."
79824825|NCT04073160|Drug|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
79824826|NCT00417079|Drug|cabazitaxel (XRP6258) (RPR116258)|25 mg/m^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
79230032|NCT03294356|Other|FT210751|An electronic cigarette
79230033|NCT03294356|Other|6T30134157764|An electronic cigarette
79230034|NCT03294356|Other|G41A7C071|An electronic cigarette
79230035|NCT03294356|Other|M011161212|An electronic cigarette
79525824|NCT01388738|Drug|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
79525825|NCT01388738|Drug|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
79525826|NCT01388751|Procedure|night splinting|splint finger at night for 4 weeks
79525827|NCT01388764|Drug|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
79824827|NCT00417079|Drug|mitoxantrone|12 mg/m^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
79824828|NCT00417079|Drug|prednisone|10 mg daily administered by oral route
79999190|NCT05352854|Drug|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
79230036|NCT03294356|Other|FT21002|A combustible cigarette
79230037|NCT00718965|Drug|AVE5530|one tablet in the evening with dinner
79230038|NCT00718965|Drug|Placebo|one tablet in the evening with dinner
79681265|NCT06022861|Drug|LY01015|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
79681266|NCT06022861|Drug|Fluorouracil|Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
79681267|NCT06022861|Drug|Cisplatin|Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
79681268|NCT06022861|Drug|Opdivo®|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
79681269|NCT06022848|Procedure|occipital nerve stimulator|Quantitative sensory testing
79372263|NCT04746261|Other|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
79681270|NCT06022835|Other|Chlorhexidine Gluconate-gel (CHG) Dressing|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
79681271|NCT06022796|Other|Healthy Ketogenic Ready-to-Eat Meals|Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.
79525828|NCT01388829|Drug|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
79681272|NCT06022796|Other|Healthy Ketogenic Diet|Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
79681273|NCT06022783|Other|Virtual reality intervention|Watching a relaxing video with using VR-G for 20 minutes
79681274|NCT06022770|Dietary Supplement|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
79681275|NCT06022744|Drug|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
79681276|NCT06022731|Diagnostic Test|Panoramic Radiography|this retrospective study includes analysis of radiographs previously taken from patients for various purposes
79372264|NCT04278495|Drug|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
79681277|NCT06022718|Other|Taping|Kinesio taping and Rigid taping was applied.
79525829|NCT01388829|Drug|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
79230039|NCT03294200|Device|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
79681278|NCT06022692|Device|Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
79681279|NCT06022692|Drug|tislelizumab (BeiGene, China) combined with PD-1 inhibitor|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
79230040|NCT03108404|Other|Validation of a diagnostic test|Validation of a diagnostic test
79230041|NCT03290924|Behavioral|Low dose high frequency health worker training approach|"Two 4-day training sessions for skilled birth attendants~1-day peer practice coordinator training after first training session~Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models~SMS reminder messages and quizzes~Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors~Health information officer training~Data collection and use training~Supply of simulators, newborn resuscitation equipment, and delivery sets"
79230042|NCT03290924|Behavioral|Active Comparison|Training on data collection and reporting
79230043|NCT03299036|Device|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
79230044|NCT03290846|Drug|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
79372265|NCT04278495|Drug|Placebo|Placebo
79372266|NCT04276545|Drug|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
79525830|NCT01388842|Drug|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
79681280|NCT06022679|Other|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
79681281|NCT06022666|Other|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
79681282|NCT06022653|Other|Treatment|EVAR,TEVAR,PTA
79681283|NCT06022640|Behavioral|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
79824829|NCT00429169|Drug|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
79681284|NCT06022627|Behavioral|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
79681285|NCT06022601|Device|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
79824830|NCT00429169|Drug|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
79372267|NCT04276545|Drug|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
79372268|NCT01117948|Drug|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
79372269|NCT01117948|Drug|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
79372270|NCT02445027|Device|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
79372271|NCT01118338|Device|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
79372272|NCT01118338|Device|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
79824831|NCT02575716|Device|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
79824832|NCT01034761|Behavioral|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
79824833|NCT01037491|Drug|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
79824834|NCT02578836|Procedure|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
79372273|NCT03014440|Drug|Cannabidiol|
79372274|NCT03013036|Device|Ultrasonography|
79372275|NCT03013036|Drug|Sevoflurane|
79372276|NCT03013036|Drug|intravenous midazolam|
79372277|NCT03013036|Drug|Propofol|
79372278|NCT03013036|Drug|fentanyl and rocuronium|
79824835|NCT03994237|Other|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
79230045|NCT03290846|Drug|Saline Solution|Randomized, single-blinded saline infusion.
79230046|NCT03290846|Other|Cold exposure|All subjects will undergo a cold exposure PET scan.
79372279|NCT01071538|Drug|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
79824836|NCT01033201|Other|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
79230047|NCT03298958|Drug|Rapamycin|Subject will be randomized to one of the 2 arms
79230048|NCT03298958|Drug|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
79230049|NCT03294122|Radiation|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
79372280|NCT03346395|Behavioral|Problem solving based intervention|Problem solving based intervention
79372281|NCT03346395|Behavioral|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
79372282|NCT04352686|Drug|Buspirone|Administration of buspirone to assess esophageal sensitivity
79372283|NCT04352686|Drug|Placebo|Administration of placebo to assess differences in esophageal sensitivity
79372284|NCT03146091|Other|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
79372285|NCT03146091|Other|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
79390868|NCT04343326|Procedure|perform corneal collagen cross linking accelerated and delivery of systemic oxygen|CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
79390869|NCT04343326|Procedure|perform corneal collagen cross linking accelerated and without additional oxygen therapy|corneal collagen cross linking with accelerated protocol without additional oxygen therapy
79681286|NCT06022588|Drug|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
79681287|NCT06022588|Drug|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
79230050|NCT03294122|Radiation|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
79230051|NCT02461394|Device|Blood glucose monitoring systems for self-testing|
79230052|NCT03294044|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
79372286|NCT01119040|Procedure|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
79824837|NCT01033279|Other|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
79824838|NCT02046330|Device|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
79999191|NCT01841177|Drug|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
79372287|NCT04275687|Radiation|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost."
79525831|NCT01388842|Drug|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
79372288|NCT04275687|Drug|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
79824839|NCT00194298|Procedure|FDG-PET Imaging|
79372289|NCT02172742|Drug|BIA 2-093|BIA 2-093 1200 mg once-daily
79372290|NCT02172742|Drug|Placebo|matching placebo
79525832|NCT01388855|Drug|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
79824840|NCT04071522|Other|no intervention|no intervention
79824841|NCT02576418|Other|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
79824842|NCT02576340|Drug|otilonium bromide|otilonium bromide was administered before the procedure
79824843|NCT02578602|Drug|Gadoxetate Disodium|Given IV
79372291|NCT02172742|Drug|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
79525833|NCT01388855|Drug|Placebo|Pills made to look like vitamin D but have no medication in them
79525834|NCT01388868|Other|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
79525835|NCT01388868|Other|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
79824844|NCT02578602|Device|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
79824845|NCT02574702|Procedure|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
79824846|NCT04071444|Other|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
79824847|NCT00128856|Drug|Gemcitabine|
79824848|NCT00128856|Drug|Adriamycine|
79824849|NCT00128856|Drug|Paclitaxel|
79999192|NCT01336361|Other|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
79999193|NCT02838134|Other|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
79824850|NCT00128778|Drug|Pegylated liposomal doxorubicin|
79824851|NCT05673252|Diagnostic Test|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
79824852|NCT05673252|Procedure|biopsy|histopathology findings
79824853|NCT04901910|Behavioral|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
79824854|NCT04901910|Behavioral|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
79372292|NCT03831633|Drug|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
79372293|NCT03831633|Drug|Standard of Care|"oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~IV ondansetron 8 mg on Day 1~Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
79824855|NCT00709488|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
79372294|NCT04396509|Behavioral|Maternal Attachment Inventory Score|three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
79824856|NCT00709488|Procedure|Placement of device in prostate urethra|Placement of device in prostate urethra
79525836|NCT01388868|Other|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
79824857|NCT00709488|Device|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
79824858|NCT00714246|Drug|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
79525837|NCT01388881|Other|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
79525838|NCT01388959|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
79999194|NCT02838134|Other|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
79230053|NCT03294044|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
79230054|NCT02460770|Drug|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
79230055|NCT03298724|Behavioral|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
79230056|NCT03290456|Drug|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
79230057|NCT03290456|Drug|Placebo 5mg/day extended of 12 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
79230058|NCT02555878|Drug|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
79230059|NCT02555878|Drug|Placebo|Placebo tablet will be administered orally once daily for 180 days.
79230060|NCT02460536|Behavioral|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
79230061|NCT02460536|Behavioral|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
79372295|NCT02216175|Other|SLIT to cow's milk|Sublingual immunotherapy
79525839|NCT01388998|Other|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
79824859|NCT00714246|Drug|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
79824860|NCT00714246|Drug|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
79824861|NCT04071288|Procedure|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
79824862|NCT02574546|Procedure|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
79824863|NCT00416455|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
79824864|NCT00416455|Procedure|positron emission tomography|Undergo FDG PET/CT
79824865|NCT00416455|Procedure|computed tomography|Undergo FDG PET/CT
79824866|NCT00416455|Drug|ferumoxtran-10|Undergo femoxtran-10 MRI
79681288|NCT06022588|Diagnostic Test|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
79681289|NCT06022588|Diagnostic Test|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
79824867|NCT00416455|Procedure|magnetic resonance imaging|Undergo femoxtran-10 MRI
79824868|NCT00416455|Procedure|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
79230062|NCT02460536|Behavioral|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
79824869|NCT00416455|Procedure|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
79372296|NCT02216175|Other|Low dose OIT|Oral Immunotherapy (low dose)
79372297|NCT02216175|Other|Conventional OIT to cow's milk|Oral Immunotherapy
79824870|NCT04071210|Dietary Supplement|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
79824871|NCT04071210|Dietary Supplement|Placebo tablet|Placebo tablet twice a day for 12 weeks
79372298|NCT03145857|Drug|[68]Ga-HA-DOTATATE|All participants will be injected with [68]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
79372299|NCT02172820|Behavioral|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
79372300|NCT03086889|Other|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
79999195|NCT03150589|Drug|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
79999196|NCT03150589|Drug|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
79999197|NCT05708378|Other|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
79999198|NCT05708378|Other|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
79372301|NCT03086889|Other|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
79525840|NCT01389037|Behavioral|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
79525841|NCT01389037|Behavioral|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
79681290|NCT06022575|Procedure|Telehealth integrated care|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
79681291|NCT06022575|Procedure|Conventional health care|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
79824872|NCT00415909|Drug|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
79230063|NCT02460536|Behavioral|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
79230064|NCT03298646|Drug|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
79230065|NCT03298646|Drug|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
79230066|NCT03298568|Dietary Supplement|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
79230067|NCT05494372|Other|safety precautions|Nursing safety precautions on CPB
79372302|NCT02393079|Device|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
79372303|NCT02393079|Device|Sham|A SHAM identical helmet will be used in the control group.
79372304|NCT01074034|Device|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
79372305|NCT02173522|Device|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
79372306|NCT01075204|Drug|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
79390870|NCT04343326|Procedure|perform Conventiona corneal collagen cross linking|Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
79525842|NCT01389063|Drug|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
79824873|NCT00415909|Drug|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
79230068|NCT05489224|Biological|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
79681292|NCT06022536|Drug|SSS40|Subjects injected with SSS40
79230069|NCT05489224|Biological|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
79372307|NCT01120834|Drug|azacytidine|"Dose level 1: azacitidine 55 mg/m2 on days 1-5~Dose level 2: azacitidine 75 mg/m2 on days 1-5~Dose level 3: azacitidine 55 mg/m2 on days 1-5~Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
79525843|NCT01389154|Procedure|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
79372308|NCT01120834|Drug|vorinostat|"Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
79372309|NCT01120990|Other|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
79390871|NCT03183960|Behavioral|Mentor|Traditional rehabilitation.
79525844|NCT01389167|Drug|Vivitrol|An extended release naltrexone formulation for intramuscular injection
79525845|NCT01389167|Drug|Naltrexone (oral)|Naltrexone 50 mg pills, daily
79525846|NCT01389167|Behavioral|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
79525847|NCT01389167|Behavioral|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
79681293|NCT06022536|Drug|Placebo|Subjects injected with Placebo
79999199|NCT05340452|Drug|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
79230070|NCT02460614|Procedure|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
79230071|NCT02460614|Procedure|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
79390872|NCT04536376|Behavioral|Resilience Program|Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.
79390873|NCT03183882|Behavioral|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
79681294|NCT06022523|Diagnostic Test|Data acquisition using DT-400 pulse oximetry system|Acquisition of photopleth data during profound hypoxia using a Consolidated Research DT-400 pulse oximetry system.
79681295|NCT06022471|Procedure|Stapes surgery|Stapedectomy operation
79681296|NCT06022224|Biological|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10^11 viral particles/mL.
79681297|NCT06022224|Biological|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
79681298|NCT06021561|Diagnostic Test|Diagnosis of pain|Pain will be investigated - type, origin, level
79681299|NCT06020755|Drug|Toripalimab|200mg q2w intravenous
79681300|NCT06020755|Drug|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
79681301|NCT06020521|Other|Three spectrometry differents technics|"Collection of expired air as follows:~For online mass spectrometry techniques (PTR-MS and SICRIT)~For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
79681302|NCT06020430|Radiation|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
79681303|NCT06020248|Other|Wear clothing that has been exposed to cigarette smoke for 3 hours.|Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
79999200|NCT05340452|Drug|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
79999201|NCT02835092|Other|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 & 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
79230072|NCT02460614|Other|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
79230073|NCT03293732|Biological|DCB07010|A protein based adjuvant originated from prokaryotic organism.
79681304|NCT06020027|Behavioral|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
79999202|NCT02835092|Other|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 & 2 & 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
79999203|NCT02835092|Other|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
79999204|NCT03564392|Behavioral|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
79999205|NCT03145207|Drug|Lidocaine patch|lidocaine patch
79999206|NCT02836652|Device|HeartMate II (HMII)|Left Ventricular Assist Device
79999207|NCT02836652|Drug|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
79824874|NCT00709566|Behavioral|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
79824875|NCT00709566|Behavioral|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
79824876|NCT02573688|Behavioral|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
79999208|NCT02836652|Drug|acetylsalicylic acid (ASA) therapy|(81mg/day)
79372310|NCT04346836|Behavioral|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
79681305|NCT06019962|Device|digital pelvic inclinometer|It is a reliable and valid instrument for measuring pelvic tilt angle
79681306|NCT06019754|Procedure|combined Lumbar and sacral plexus block|performing an ultrasound-guided combined Lumbar and sacral plexus block using one-point puncture
79824877|NCT00709644|Drug|Norgestimate; Ethinyl Estradiol; Folic acid.|
79824878|NCT00415597|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
79824879|NCT04071054|Diagnostic Test|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
79999209|NCT04335175|Other|None - observational study|None - observational study
79372311|NCT04346836|Behavioral|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
79372312|NCT02798224|Behavioral|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
79824880|NCT00714480|Drug|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
79824881|NCT00714480|Drug|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
79824882|NCT00714480|Drug|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
79824883|NCT00714558|Drug|Fentanyl citrate; Naltrexone; Naloxone|
79824884|NCT00709800|Biological|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
79824885|NCT00709800|Biological|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
79824886|NCT00709800|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
79824887|NCT00709800|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
79230074|NCT03293732|Biological|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
79824888|NCT00709800|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
79230075|NCT04139980|Other|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
79230076|NCT03290222|Other|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
79230077|NCT05494294|Procedure|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
79681307|NCT06019741|Drug|Rivaroxaban and aspirin 80|rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
79230078|NCT05494294|Procedure|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
79305582|NCT04930419|Device|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
79372313|NCT02798224|Behavioral|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
79372314|NCT01122160|Drug|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
79525848|NCT01389180|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
79824889|NCT02574624|Procedure|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
79824890|NCT02575638|Drug|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
79372315|NCT01122160|Drug|placebo|Placebo with berries (blackberries + strawberries)
79372316|NCT02623816|Drug|Optimal Dosing of Omeprazole|Omeprazole 20 mg
79372317|NCT02180230|Device|Shorty implants|Dental implant insertion to maxilla or mandible
79390874|NCT03183882|Behavioral|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
79525849|NCT01389180|Behavioral|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
79525850|NCT01389180|Behavioral|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
79681308|NCT06019741|Drug|Aspirin 80|aspirin 80 mg orally post coronary bypass surgery
79525851|NCT01389193|Drug|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
79525852|NCT01389193|Drug|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
79681309|NCT06019468|Other|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
79824891|NCT02573610|Drug|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
79824892|NCT02573610|Drug|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
79824893|NCT02575560|Other|history data|history data of PFS after 1st line or second line theray
79525853|NCT01389206|Drug|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
79681310|NCT06018701|Device|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
79824894|NCT00710190|Device|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
79681311|NCT06018389|Behavioral|Structural only|"A shared list of school policies for or related to, school-based social events at school premises. The policy initiatives include (but are not limited to): increasing the number of social events without alcohol; promoting non-alcoholic beverages at parties; working with student associations regarding their roles and responsibilities; encouraging parental involvement at school events and disseminating the schools' alcohol policy among students and parents. The school principal and management will be responsible for the implementation and enforcement of the policies.~The Information-based interactive parent meetings will be 45 minutes and will take place at the schools. Parents will be offered concrete, research-informed advice about how they can reduce risk of hazardous substance use and promote well-being among their adolescents. Following a 15-minute presentation, the group leader facilitates a discussion and exchange of experience between parents."
79681312|NCT06018389|Behavioral|Structural+Group MI|"Within school classes, students are divided into groups of 5-8 students and each group will be assigned a group leader from the research team. The group-based Motivational Interviewing (group MI) is manualized and consists of two one-hour group sessions administered over two consecutive weeks. The first session is focused on Tell your story, Gains from not drinking, and Social norms. In the second session, the focus is on Personal values, Linking values with behavior and Planning/choices regarding alcohol. Both group MI sessions will take place at the schools during the school day."
79824895|NCT00715182|Drug|TKI258|
79824896|NCT04070586|Device|4DCBCT images|Images are acquired and assessed offline
79824897|NCT02574468|Drug|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
79824898|NCT02574468|Procedure|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
79999210|NCT01344811|Procedure|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
79525854|NCT01389219|Other|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron & vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
79681313|NCT06018298|Other|Treatment as usual (TAU)|the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.
79824899|NCT00710268|Drug|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
79824900|NCT00710268|Drug|Bevacizumab|IV administration10 mg/kg every 14 days
79824901|NCT02575482|Drug|SUVN-D4010|
79230079|NCT05489068|Behavioral|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
79230080|NCT05489068|Behavioral|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
79824902|NCT02575482|Drug|Placebo|
79824903|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
79824904|NCT02575326|Behavioral|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
79824905|NCT02575248|Drug|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
79824906|NCT02575248|Drug|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
79824907|NCT02575170|Drug|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
79824908|NCT02575170|Drug|Ringer's lactate solution|200 ml of Ringer's lactate solution
79824909|NCT00710502|Procedure|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
79681314|NCT06017843|Other|Camps site selection for active case finding for TB using MATCH-AI|The primary intervention in this study is the roll-out of MATCH-AI, an artificial intelligence software that models sub-district TB prevalence, to guide site selection of ACF camps. The MATCH-AI tool uses a Bayesian modelling approach to predict TB prevalence to a resolution of 10,000 population that are mapped as polygons. The model integrates data from a range of sources including historical TB facility notification data, previous ACF data as well as contextual factors such as demographics, income, population density, health indicators such as vaccination coverage and climate related variables to predict localized TB prevalence. In the intervention arm, camps will be conducted primarily in locations guided by MATCH-AI.
79681315|NCT06017804|Other|Muscle energy technique|Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.
79681316|NCT06017804|Other|Self-myofascial release technique|A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
79681317|NCT06017544|Procedure|PCI|The T2DM affected by AMI will be referred for receiving PCI.
79681318|NCT06017362|Drug|Insulin|Topical insulin 1UI/ml 4 times a day
79681319|NCT06017362|Drug|Artificial tear|Artificial tears 4 times a day
79681320|NCT06016218|Drug|Simvastatin|Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
79824910|NCT00710502|Procedure|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
79824911|NCT02573454|Behavioral|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
79824912|NCT00710658|Behavioral|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
79824913|NCT00710736|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
79230081|NCT03290066|Device|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
79681321|NCT06013618|Drug|Naxitamab monotherapy|Naxitamab is administered on days 1, 3, and 5
79372318|NCT03012958|Other|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
79824914|NCT00710736|Drug|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
79824915|NCT00715416|Device|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
79824916|NCT00715416|Procedure|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
79824917|NCT00715494|Behavioral|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
79824918|NCT00620542|Drug|Rosuvastatin|capsule, oral, once daily
79824919|NCT00620542|Drug|Atorvastatin|capsule, oral, one daily
79824920|NCT00711048|Drug|AZD1386|oral, single dose
79824921|NCT00711048|Drug|Placebo|Oral solution, single dose
79824922|NCT04070742|Drug|FMX101|
79824923|NCT04269876|Dietary Supplement|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
79999211|NCT01344811|Other|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
79230082|NCT03290066|Other|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
79230083|NCT03289988|Other|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
79230084|NCT05488990|Drug|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
79230085|NCT05488990|Drug|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
79824924|NCT04269876|Dietary Supplement|Dietary Supplement|Dietary Supplement capsules
79824925|NCT04269876|Dietary Supplement|Placebo|Placebo softgels
79824926|NCT04269876|Dietary Supplement|Placebo|Placebo capsules
79681322|NCT06013618|Drug|GM-CSF|Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
79230086|NCT05488990|Drug|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
79824927|NCT04069806|Dietary Supplement|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
79681323|NCT06013618|Drug|Irinotecan|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
79824928|NCT00851344|Drug|GSK835726 (10mg)|GSK835726 (10mg) tablet
79824929|NCT00851344|Drug|GSK835726 (50mg)|GSK835726 (50mg) tablet
79824930|NCT00851344|Drug|GSK835726 (100mg)|GSK835726 (100mg) tablet
79824931|NCT00851344|Drug|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
79824932|NCT00851344|Other|Placebo|Placebo to match active
79824933|NCT00855478|Device|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
79824934|NCT00855556|Genetic|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~No fasting, activity or medication restrictions are required prior to or following blood collection.~Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
79230087|NCT05488990|Drug|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
79824935|NCT00711126|Drug|GW642444|2.5mcg IV
79999212|NCT02836496|Drug|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
79999213|NCT02836496|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
79230088|NCT05488990|Drug|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
79230089|NCT05488990|Drug|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
79372319|NCT01122238|Drug|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
79372320|NCT01122238|Drug|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
79525855|NCT01389271|Drug|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
79525856|NCT01389297|Behavioral|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
79525857|NCT01389297|Behavioral|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
79525858|NCT01389349|Other|Acupuncture|Battlefield acupuncture protocol
79525859|NCT01389349|Other|Sham Control|Sham control acupuncture
79525860|NCT01389362|Drug|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
79525861|NCT01389362|Drug|Placebo comparator|2 sachets to be taken daily
79525862|NCT01389375|Device|FemoSeal®|Closure device for femoral artery access closure
79525863|NCT01389375|Device|ExoSeal®|Closure device for femoral artery access closure
79525864|NCT01389375|Other|Manual compression|Conventional manual compression
79681324|NCT06013618|Drug|Temozolomide|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
79824936|NCT00711126|Drug|GW642444|5mcg IV
79824937|NCT00711126|Drug|GW642444|10mcg IV
79824938|NCT00711126|Drug|GW642444|100mcg inhaled
79824939|NCT00711126|Drug|GW642444|20mcg IV
79824940|NCT00711126|Drug|GW642444|500mcg oral
79824941|NCT02545036|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
79824942|NCT02544958|Device|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
79824943|NCT00715572|Drug|thyroxine|monotherapy with thyroxine
79824944|NCT00715572|Drug|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
79824945|NCT02573298|Device|ice|local ice application for 30 minutes
79824946|NCT02573298|Device|cold gas|local cold gas application for 2 minutes
79824947|NCT00845260|Behavioral|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
79824948|NCT00845260|Behavioral|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
79824949|NCT00715806|Device|Open MRI scanner.|Imaging in an Open MRI scanner.
79824950|NCT00715806|Device|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
79824951|NCT00851500|Drug|K-604|K-604 is given for 26 weeks
79824952|NCT00851500|Other|Placebo|placebo tablets are given for 26 weeks
79824953|NCT00711204|Drug|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
79999214|NCT02836496|Drug|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
79525865|NCT01389388|Drug|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
79525866|NCT01389401|Drug|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
79372321|NCT01122238|Behavioral|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
79525867|NCT01389414|Drug|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
79525868|NCT01389414|Drug|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
79525869|NCT01389427|Drug|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525870|NCT01389427|Drug|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525871|NCT01389427|Drug|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525872|NCT01389427|Drug|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525873|NCT01389427|Drug|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525874|NCT01389427|Drug|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525875|NCT01389427|Drug|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525876|NCT01389427|Drug|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525877|NCT01389427|Drug|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525878|NCT01389427|Drug|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525879|NCT01389427|Drug|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525880|NCT01389427|Drug|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
79525881|NCT01389440|Drug|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
79681325|NCT06013618|Drug|Naxitamab in combination therapy|Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
79681326|NCT06013618|Drug|GM-CSF with combination regimen|GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
79681327|NCT06013618|Drug|Sintilimab|Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
79681328|NCT06012734|Drug|LB-100|IV on day 1 and day 3
79681329|NCT06012734|Drug|Atezolizumab|IV on day 1
79681330|NCT06012539|Other|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
79681331|NCT06012461|Other|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
79681332|NCT06012461|Other|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
79681333|NCT06012461|Other|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
79681334|NCT06012461|Other|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
79824954|NCT04042870|Behavioral|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
79824955|NCT05810857|Diagnostic Test|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
79230090|NCT03293576|Behavioral|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
79824956|NCT05810857|Diagnostic Test|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
79824957|NCT05810844|Diagnostic Test|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
79824958|NCT05810844|Diagnostic Test|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
79824959|NCT05810831|Diagnostic Test|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
79824960|NCT05810831|Diagnostic Test|Massage|conservative physiotherapy protocol including massage
79824961|NCT05810818|Diagnostic Test|Dry Needling|Dry needling treatment will be consisting of two treatments per week
79525882|NCT01389453|Procedure|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
79525883|NCT01389466|Biological|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
79681335|NCT06011551|Device|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
79824962|NCT05810818|Diagnostic Test|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
79525884|NCT01389466|Biological|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
79681336|NCT06011551|Other|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
79681337|NCT06011369|Procedure|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
79681338|NCT06011278|Other|Community Supported Videos|"Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research."
79681339|NCT06010797|Device|Showing Pre-treatment photographs of the patient|Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
79681340|NCT06010576|Procedure|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
79824963|NCT05810805|Other|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
79824964|NCT05810779|Other|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
79824965|NCT05810779|Other|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
79824966|NCT05810740|Drug|Binimetinib Oral Tablet|Two-period Crossover study
79230091|NCT03289832|Dietary Supplement|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
79230092|NCT03289832|Dietary Supplement|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
79230093|NCT02461472|Other|not intervention|This is a cross-sectional study, no intervention was performed.
79230094|NCT02555722|Device|fanfilcon A (test)|silicone hydrogel lens
79230095|NCT02555722|Device|enfilcon A (control)|silicone hydrogel lens
79230096|NCT05493748|Other|Bladder training|Bladder training for overactive bladder syndrome.
79230097|NCT04119388|Other|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
79525885|NCT01389479|Biological|Fluviral™|Intramuscular, single dose
79525886|NCT01389479|Biological|Fluzone®|Intramuscular, single dose
79525887|NCT01389492|Other|frozen meat cutlets meal|250 g of meat cutlets
79525888|NCT01389492|Other|meat meals|250 g of meat meal for 4 days
79525889|NCT01389505|Procedure|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
79525890|NCT01389505|Procedure|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
79681341|NCT06010576|Procedure|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
79681342|NCT06009991|Drug|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
79681343|NCT06009991|Drug|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
79681344|NCT06009120|Other|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
79230098|NCT03289598|Behavioral|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
79230099|NCT03293342|Behavioral|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~Psychoeducation about anxiety~Exploration of the individual anxiety~Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
79525891|NCT01389518|Drug|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
79525892|NCT01389518|Drug|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
79525893|NCT01389531|Procedure|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
79525894|NCT01389544|Drug|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
79525895|NCT01389544|Drug|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
79525896|NCT01389544|Drug|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
79525897|NCT01389557|Drug|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.~P. vivax: DHP (3 days) + primaquine (14 days)"
79525898|NCT01389570|Procedure|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
79525899|NCT01389583|Drug|AUY922|70 mg/m2 60-min i.v. infusion weekly
79525900|NCT01389609|Drug|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
79525901|NCT01389609|Drug|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
79372322|NCT01122238|Behavioral|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
79525902|NCT01389609|Drug|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
79525903|NCT01389622|Other|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
79824967|NCT05810701|Other|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
79230100|NCT03293342|Combination Product|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
79230101|NCT03293186|Combination Product|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
79372323|NCT01122238|Other|No Intervention|No Intervention
79372324|NCT01122238|Drug|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
79525904|NCT01389622|Other|acupuncture|random points + digital pressure
79681345|NCT06008639|Device|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
79230102|NCT02461316|Other|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
79681346|NCT06008639|Device|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
79525905|NCT01389648|Other|Pre Operative|Pre operative chest physiotherapy treatment
79999215|NCT02836496|Drug|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
79372325|NCT01122316|Drug|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
79372326|NCT01076452|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
79372327|NCT01076686|Drug|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
79372328|NCT03049449|Biological|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
79525906|NCT01389661|Biological|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
79525907|NCT01389674|Procedure|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
79525908|NCT01389687|Biological|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
79525909|NCT01389713|Drug|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
79525910|NCT01389713|Drug|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
79525911|NCT01389726|Behavioral|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
79230103|NCT03289520|Drug|Clopidogrel|
79230104|NCT03289520|Drug|Placebo|
79230105|NCT03298100|Other|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
79230106|NCT03289442|Procedure|supine position|patients were positioned on their supine position to receive colonoscopy insertion
79525912|NCT01389726|Behavioral|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
79525913|NCT01389726|Behavioral|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader & 1 peer leader over the course of 11 weeks.
79525914|NCT01389739|Other|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
79525915|NCT01389778|Drug|Metformin ER|Metformin ER 1500 mg for 12 weeks
79525916|NCT01389778|Drug|Metformin|
79525917|NCT01389791|Drug|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
79525918|NCT01389791|Drug|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
79525919|NCT01389791|Drug|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
79999216|NCT04213807|Biological|MAA868 Cohort 1|Subcutaneous injection: low dose
79230107|NCT03289364|Device|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
79230108|NCT03289286|Other|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:~Completion of questionnaires using an electronic tool,~Telephone follow-up if necessary between the nurse and the patient."
79230109|NCT03293108|Drug|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
79230110|NCT03293108|Dietary Supplement|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
79372329|NCT03049449|Drug|Cyclophosphamide|300 or 500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
79372330|NCT03049449|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
79390875|NCT03183726|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention."
79525920|NCT01389830|Behavioral|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
79525921|NCT01389869|Biological|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
79525922|NCT01389869|Biological|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
79525923|NCT01389869|Biological|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
79681347|NCT06008405|Drug|TQB2928 Injection + Azacitidine for injection|"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
79999217|NCT04213807|Biological|MAA868 Cohort 2|Subcutaneous injection: high dose
79230111|NCT03293108|Dietary Supplement|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
79230112|NCT03292796|Drug|Prostaglandins|
79390876|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
79525924|NCT01389869|Biological|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
79525925|NCT01389895|Drug|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
79999218|NCT04213807|Biological|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
79525926|NCT01389895|Drug|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
79999219|NCT04213807|Other|Placebo|Subcutaneous injection: Placebo
79999220|NCT05065099|Device|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
79230113|NCT03292718|Device|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
79305583|NCT04930419|Device|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
79390877|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
79525927|NCT01389908|Drug|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
79999221|NCT01344967|Drug|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
79999222|NCT05250661|Other|Aqueous propolis extract|The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
79999223|NCT04176913|Drug|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
79999224|NCT04172467|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
79824968|NCT05810688|Other|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
79681348|NCT06008184|Other|24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)|"24 hours sampling of 4 biological fluids:~blood: sampling every 20 minutes (through a venous catheter)~ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~Sweat : collection of 1 to 3 samples at 4 differents timepoints~Saliva : sampling every hour (except during the night)"
79681349|NCT06008184|Other|24 hours sampling of ISF or sweat (after validating the correlation with blood)|24 hours sampling in an ambulatory setting
79999225|NCT03268213|Biological|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
79999226|NCT05050279|Drug|Delgocitinib capsule|oral capsule
79999227|NCT05050279|Drug|Placebo capsule|oral capsule
79999228|NCT03074227|Other|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
79999229|NCT03074227|Other|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
79999230|NCT01345201|Biological|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
79999231|NCT04072861|Drug|RBT-9|intravenous administration
79999232|NCT05250349|Diagnostic Test|Echocardiography|Transthoracic echocardiography with standard measurements
79999233|NCT05250349|Diagnostic Test|Doppler sonography|Transcarotid and transcranial Doppler sonography
79999234|NCT05250349|Diagnostic Test|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
79390878|NCT00362206|Drug|Pravastatin|Pravastatin 40 mg
79681350|NCT06006975|Radiation|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
79824969|NCT05810675|Behavioral|Telehealth Early Intervention Program (TEIP)|The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
79824970|NCT05810662|Other|Lactated ringer and dextrose 5%|Fluid use perioperative
79999235|NCT04044781|Drug|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
79999236|NCT04044469|Behavioral|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
79999237|NCT04044469|Behavioral|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
79999238|NCT04044469|Behavioral|Control group|This group receives no further information after watching the videotaped doctor's report.
79999239|NCT04634383|Device|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
79999240|NCT01345279|Drug|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
79999241|NCT01345279|Drug|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
79999242|NCT01345279|Drug|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
79999243|NCT00577577|Drug|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
79999244|NCT00577577|Drug|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
79999245|NCT02833844|Drug|Evolocumab|Dose of subcutaneous evolocumab QM
79305584|NCT02349893|Device|RFA treatment|RFA treatment using CelonProSleep plus system
79305585|NCT04935333|Procedure|Collection of Leiomyoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
79390879|NCT03185442|Device|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
79824971|NCT05810636|Device|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
79824972|NCT05810623|Drug|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
79999246|NCT02833844|Drug|Placebo|Dose of matching placebo QM
79681351|NCT06006975|Diagnostic Test|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
79824973|NCT05810584|Device|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
79824974|NCT05810571|Procedure|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
79824975|NCT05810571|Procedure|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
79824976|NCT05810558|Procedure|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
79824977|NCT05810558|Procedure|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
79230114|NCT03288896|Behavioral|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
79230115|NCT03288818|Drug|Mechlorethamine Hydrochloride Gel|Given topically
79230116|NCT03288818|Procedure|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
79230117|NCT03288740|Drug|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
79525928|NCT01389921|Other|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
79681352|NCT05998382|Behavioral|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
79824978|NCT05810532|Other|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water
79824979|NCT05810532|Other|1 hour of fasting time|Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
79230118|NCT03288740|Drug|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
79230119|NCT03288740|Drug|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
79372331|NCT04396431|Behavioral|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
79681353|NCT05993390|Drug|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
79681354|NCT05993390|Drug|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
79824980|NCT05810506|Other|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
79824981|NCT05810454|Device|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
79372332|NCT02399943|Drug|Trametinib|
79525929|NCT01389986|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
79525930|NCT01389999|Other|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
79525931|NCT01390012|Drug|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
79824982|NCT05810454|Device|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
79824983|NCT05810441|Other|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
79824984|NCT05810389|Combination Product|Fluoride|Application methods of delivery of topical fluoride
79824985|NCT05810376|Behavioral|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
79824986|NCT05810376|Other|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
79824987|NCT05810337|Dietary Supplement|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
79999247|NCT01345357|Drug|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
79824988|NCT05810337|Dietary Supplement|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
79999248|NCT01345357|Drug|Gemcitabine|Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
79999249|NCT01345357|Drug|Cisplatin|Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
79681355|NCT05990790|Drug|Desflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
79999250|NCT01333631|Drug|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
79525932|NCT01390012|Drug|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
79681356|NCT05990790|Drug|Sevoflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
79824989|NCT05810337|Dietary Supplement|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
79824990|NCT05810324|Drug|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
79999251|NCT05014789|Device|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
79230120|NCT03288740|Drug|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
79230121|NCT03297632|Behavioral|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
79230122|NCT03288662|Other|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
79372333|NCT02399943|Drug|Panitumumab|
79372334|NCT03186027|Dietary Supplement|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
79372335|NCT03186027|Dietary Supplement|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
79372336|NCT04397913|Drug|Paracetamol|15 mg/kg, q6h
79372337|NCT04397913|Drug|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
79372338|NCT04397523|Biological|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
79390880|NCT03748186|Drug|STRO-002|intravenous antibody drug conjugate
79390881|NCT02314468|Procedure|Negative pressure wound therapy|NPWT changed twice a week.
79390882|NCT02314468|Procedure|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
79390883|NCT01704287|Biological|Pembrolizumab|IV infusion
79681357|NCT05990790|Drug|Propofol|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
79525933|NCT01390025|Biological|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
79525934|NCT01390025|Biological|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
79525935|NCT01390051|Drug|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
79525936|NCT01390051|Drug|tinzaparin|Dose 4,500 IE daily
79525937|NCT01390103|Other|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
79681358|NCT05990504|Device|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
79681359|NCT05990504|Device|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
79681360|NCT05990244|Diagnostic Test|Magnetic Resonance Elastography|Undergo MRE and routine MRI
79681361|NCT05990244|Procedure|Assessment and Recording|Undergo recording of tumor stiffness during surgery and molecular pathological classification through genetic analysis
79681362|NCT05986136|Drug|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
79681363|NCT05986136|Drug|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
79681364|NCT05983016|Device|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
79681365|NCT05982392|Drug|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
79681366|NCT05982392|Drug|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
79372339|NCT02176408|Behavioral|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
79999252|NCT01345435|Procedure|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
79681367|NCT05982392|Drug|Placebo|Placebo will be given 60 minutes before start of procedure.
79681368|NCT05975619|Device|HyperSight imaging|Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.
79824991|NCT05810298|Other|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
79824992|NCT05810298|Other|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
79999253|NCT01345435|Procedure|Telemonitoring & Telemedicine|The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
79390884|NCT01704287|Drug|Carboplatin|Carboplatin per institutional standard
79390885|NCT01704287|Drug|Paclitaxel|Paclitaxel per institutional standard
79390886|NCT01704287|Drug|Dacarbazine|Dacarbazine per institutional standard
79230123|NCT03108092|Other|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
79525938|NCT01390116|Dietary Supplement|Aged garlic extract|2 aged garlic extract capsules taken twice daily
79525939|NCT01390116|Dietary Supplement|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
79525940|NCT01390129|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
79525941|NCT01390129|Procedure|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
79525942|NCT01390142|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
79681369|NCT05973162|Other|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
79681370|NCT05973162|Other|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
79824993|NCT05810298|Behavioral|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
79824994|NCT05810207|Procedure|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
79824995|NCT05810142|Drug|furquimatinib and sintilimab|furquimatinib and sintilimab
79824996|NCT05810129|Other|Cross-education training|Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
79824997|NCT05810129|Other|Cross-education training|Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
79824998|NCT05810103|Drug|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
79824999|NCT05810090|Procedure|Total knee arthroplasty|patient who received a TKA in our hospital
79825000|NCT05810012|Drug|PENG block|10ml of 0.125% isobaric bupivacaine injected
79681371|NCT05972031|Behavioral|Person-centred integrated care intervention|See arm description.
79825001|NCT05810012|Drug|FICB Block|20ml of 0.125% isobaric bupivacaine injected
79825002|NCT05809999|Procedure|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
79372340|NCT02176408|Behavioral|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
79825003|NCT05809973|Diagnostic Test|VISA tool|Validation of VISA
79825004|NCT05809960|Other|Nursing support program|It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
79825005|NCT05809960|Other|Routine nursing care|Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
79825006|NCT05809882|Device|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
79230124|NCT03108092|Other|Control|Standard care in the department where the trial is conducted
79230125|NCT03292328|Other|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
79825007|NCT05809882|Device|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
79230126|NCT03292328|Other|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
79390887|NCT01704287|Drug|Temozolomide|Temozolomide per institutional standard
79390888|NCT00362752|Drug|Norfloxacin|400 mg po bid
79825008|NCT05809869|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
79825009|NCT05809869|Drug|Tremelimumab|Tremelimumab 300mg intravenous infusion on week 1 only.
79825010|NCT05809869|Radiation|Yttrium-90 radioembolisation|Yttrium-90 radioembolisation on week 2 only.
79825011|NCT05809843|Device|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
79525943|NCT01390142|Procedure|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
79825012|NCT05809817|Procedure|Periodontal treatment|Scaling and root planing
79825013|NCT05809804|Drug|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
79525944|NCT01390142|Procedure|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
79681372|NCT05971966|Other|Virtual Reality technique|"They would be receiving treatment as follow:~Specific exercises by using virtual reality with conventional treatment. The VR game included holopoint,hot squat and portal stories that will target the hamstring, quadriceps and gluteas muscles.Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: virtual reality gaming exercises Conventional PT including patellar mobilization+ ultrasound on anterior knee in supine lying + stretching of ITB . Frequency: 10 reps with 5 sec hold for 3 times/week for 4 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
79825014|NCT05809765|Other|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
79825015|NCT05809726|Other|Manual lymph drainage|one session 20 minutes
79825016|NCT05809674|Device|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
79525945|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
79825017|NCT05809661|Behavioral|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
79825018|NCT05809635|Other|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
79825019|NCT05809544|Device|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
79825020|NCT05809544|Device|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
79825021|NCT05809518|Drug|Propofol injection|sedation after cardiac surgery
79825022|NCT05809518|Drug|Dexmedetomidine injection|sedation after cardiac surgery
79230127|NCT03292172|Drug|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
79372341|NCT02176408|Behavioral|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
79372342|NCT02176486|Drug|Ixazomib|Ixazomib capsules.
79372343|NCT02176486|Drug|Placebo|Ixazomib placebo-matching capsules.
79525946|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
79825023|NCT05809518|Drug|Dexmedetomidine and Propofol|sedation after cardiac surgery
79230128|NCT03292172|Drug|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
79230129|NCT02460926|Procedure|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
79230130|NCT03291938|Drug|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
79230131|NCT03291938|Other|Pharmacodynamic Study|Correlative studies
79230132|NCT03291938|Other|Pharmacokinetic Study|Correlative studies
79230133|NCT03288584|Drug|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
79681373|NCT05971966|Other|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of quadriceps and hamstring muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Muscle energy technique to improve range of motion.~Conventional PT including patellar mobilization + ultrasound on anterior knee in supine lying + stretching of ITB. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
79825024|NCT05809492|Other|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
79372344|NCT01124188|Drug|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
79825025|NCT05809479|Other|No intervention|No intervention
79825026|NCT05809440|Other|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
79825027|NCT05809401|Behavioral|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
79825028|NCT05809401|Behavioral|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
79825029|NCT05809336|Drug|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
79999254|NCT01345435|Other|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
79999255|NCT04611763|Drug|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
79999256|NCT04611763|Drug|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
79230134|NCT03288584|Drug|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
79372345|NCT01124188|Behavioral|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
79681374|NCT05971953|Other|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
79825030|NCT05809336|Drug|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
79825031|NCT05809245|Procedure|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
79999257|NCT05329064|Biological|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
79230135|NCT03288584|Drug|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
79372346|NCT01124188|Behavioral|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
79372347|NCT02220478|Device|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
79372348|NCT01125202|Behavioral|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
79372349|NCT01125202|Behavioral|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
79372350|NCT03013114|Drug|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
79230136|NCT02461004|Drug|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
79230137|NCT02461004|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
79230138|NCT03288428|Drug|Nalbuphine|patient controlled analgesia with Nalbuphine
79230139|NCT03288428|Drug|Morphine|patient controlled analgesia with Morphine
79230140|NCT03288350|Drug|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
79999258|NCT05186935|Device|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
79999259|NCT04568629|Other|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
79999260|NCT04568629|Other|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
79230141|NCT04488380|Other|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
79372351|NCT01077310|Drug|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
79372352|NCT01077310|Drug|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
79372353|NCT02989857|Drug|AG-120|Tablet administered orally
79372354|NCT02989857|Drug|Placebo|Tablet administered orally
79372355|NCT02393937|Drug|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
79525947|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
79525948|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
79681375|NCT05971953|Other|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
79681376|NCT05971810|Dietary Supplement|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
79825032|NCT05809232|Other|CARES-guided Group|Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
79999261|NCT04973917|Procedure|respiratory support|respirators for invasive mechanical ventilation
79999262|NCT03985033|Other|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
79999263|NCT01341782|Drug|paricalcitol|
79999264|NCT01341782|Drug|maxacalcitol|
79999265|NCT01341782|Drug|paricalcitol placebo|
79999266|NCT01341782|Drug|maxacalcitol placebo|
79999267|NCT01345747|Device|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
79230142|NCT03291860|Procedure|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
79230143|NCT02461238|Other|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
79230144|NCT02461238|Other|Nutrition education|Nutrition education workshops taught by a dietician
79230145|NCT03291782|Drug|D-0120|oral, single dose
79372356|NCT02393937|Drug|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
79681377|NCT05971810|Other|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
79681378|NCT05970146|Drug|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
79681379|NCT05970146|Drug|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
79681380|NCT05969912|Other|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
79999268|NCT05150509|Diagnostic Test|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
79999269|NCT02250157|Drug|Oratecan|
79999270|NCT03952429|Behavioral|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
79999271|NCT03952429|Behavioral|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
79999272|NCT01345825|Other|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
79999273|NCT01345903|Procedure|therapeutic conventional surgery|Undergo robotic-assisted surgery
79372357|NCT02393937|Drug|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
79999274|NCT05063149|Drug|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
79999275|NCT05063149|Other|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
79681381|NCT05969912|Other|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
79681382|NCT05964881|Procedure|sacrospinous hysteropexy|sacrospinous hysteropexy
79999276|NCT01341470|Drug|LY2495655|administered intravenously or subcutaneously
79372358|NCT01877915|Drug|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
79372359|NCT01877915|Drug|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
79848930|NCT05837533|Other|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
79999277|NCT01341470|Drug|Placebo|administered intravenously or subcutaneously
79999278|NCT03564158|Drug|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
79999279|NCT03564158|Drug|Placebo|Placebo
79999280|NCT03564158|Drug|Moxifloxacin|Active Comparator
79999281|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
79999282|NCT02677298|Drug|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
79999283|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
79999284|NCT03143101|Biological|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
79999285|NCT03143101|Biological|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
79999286|NCT03143101|Biological|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
79999287|NCT01345981|Drug|Lidocaine|dosage 20 mg and 40 mg
79999288|NCT00871351|Drug|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
79372360|NCT01877915|Other|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
79372361|NCT01876979|Device|IMF Screws|stainless steel screws placed in bone
79372362|NCT01876979|Device|Erich Arch Bars|Surgical braces wired around teeth
79390889|NCT00362752|Drug|Placebo|Placebo 400 mg po bid
79390890|NCT00118209|Biological|rituximab|IV
79390891|NCT00118209|Drug|cyclophosphamide|IV
79999289|NCT00871351|Drug|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
79999290|NCT00871351|Drug|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
79999291|NCT00871351|Drug|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
79999292|NCT04920331|Biological|Erenumab|140mg single intravenous administration (60 minutes)
79230146|NCT03291704|Device|Thermal therapy device|Thermal therapy of blocked Meibomian glands
79230147|NCT03288272|Radiation|Whole Brain Radiotherapy|Radiotherapy of the whole brain
79372363|NCT04397601|Drug|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
79372364|NCT04397601|Drug|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
79372365|NCT01860989|Drug|KAE609|KAE609 75mg single dose
79372366|NCT01860989|Drug|KAE609|KAE609 150mg single dose
79525949|NCT01390168|Behavioral|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
79525950|NCT01390168|Behavioral|Waitlist|active waitlist
79525951|NCT01390207|Other|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
79525952|NCT01390285|Device|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
79525953|NCT01390285|Device|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
79525954|NCT01390311|Drug|Azacitidine|
79525955|NCT01390311|Drug|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
79525956|NCT01390311|Biological|Donor Leukocyte Infusion (DLI)|
79525957|NCT01390324|Drug|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
79525958|NCT01390324|Drug|Naratriptan|Tablets containing naratriptan 2,5 mg
79681383|NCT05961540|Other|Conventional care|"Instruct parents to follow up with the baby at the doctor's appointment.~Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight)."
79681384|NCT05961540|Behavioral|Breastfeeding behavioural intervention for mothers of infants with CHD|"Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~Evaluate signs of hunger and satiety in infants.~Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~Training methods for promoting breast milk secretion.~To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~Establish a breastfeeding promotion alliance.~Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~Assess and guide the growth and development of infants with CHD."
79999293|NCT02745080|Biological|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
79372367|NCT01860989|Drug|KAE609|KAE609 225mg single dose
79681385|NCT05961462|Behavioral|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
79230148|NCT03288272|Other|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
79230149|NCT03297320|Other|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
79230150|NCT03288116|Diagnostic Test|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
79230151|NCT00003224|Biological|QS21|vaccine adjuvant
79230152|NCT00003224|Biological|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
79230153|NCT00003224|Biological|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
79372368|NCT01860989|Drug|KAE609|KAE609 300mg single dose
79372369|NCT02906241|Behavioral|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
79390892|NCT00118209|Drug|doxorubicin|IV or CIVI
79390893|NCT00118209|Drug|vincristine|IV or CIVI
79525959|NCT01390324|Drug|Naproxen|Tablets containing naproxen 500 mg
79230154|NCT00003224|Biological|p946/tet-p|This peptide is a longer version of p946 (gp100 [280-288]) sythesized colinearly with the tetanus helper peptide (Tet-p)
79230155|NCT00003224|Biological|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
79525960|NCT01390337|Drug|AC220|Oral Liquid
79525961|NCT01390337|Drug|daunorubicin|Intravenous Infusion
79525962|NCT01390337|Drug|cytarabine|Intravenous Infusion
79525963|NCT01390350|Drug|Canakinumab|150mg subcutaneous injections on day 0
79525964|NCT01390350|Drug|Placebo|150mg subcutaneous injections on day 0
79525965|NCT01390363|Other|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
79999294|NCT02745080|Biological|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
79681386|NCT05960695|Other|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
79681387|NCT05960695|Other|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
79681388|NCT05956184|Device|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
79681389|NCT05952544|Drug|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
79999295|NCT01346137|Drug|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
79999296|NCT04537507|Procedure|Coronary angiography|
79999297|NCT00521599|Drug|Mometasone furoate dry powder inhaler|
79999298|NCT00521599|Drug|Placebo|
79681390|NCT05952544|Other|low protein diet|patients were on low protein diet only
79999299|NCT00442897|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
79999300|NCT00442897|Drug|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
79681391|NCT05949749|Diagnostic Test|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
79681392|NCT05949073|Procedure|Non-impregnated retraction cords/ less than 10 minutes|lower first molar will be prepared for full coverage restoration, plain retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
79999301|NCT01346215|Biological|heparin sodium|5000 UI/mL
79230156|NCT03291548|Dietary Supplement|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
79230157|NCT03291548|Dietary Supplement|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
79230158|NCT04489316|Other|Narrative medicine curriculum|The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
79825033|NCT05809206|Other|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
79999302|NCT01346215|Biological|heparin sodium|5000 UI/mL
79999303|NCT02834390|Drug|Quizartinib|"[Induction period, Cycle 1] Once-daily repeated oral administration Day 8 to Day 21.~[Induction period, Cycle 2] Once-daily repeated oral administration Day 6 to Day 19.~[Consolidation period] Once-daily repeated oral administration Day 6 to Day 19."
79230159|NCT03288038|Drug|Rosuvastatin|
79230160|NCT03288038|Drug|Ezetimibe|
79230161|NCT03283358|Behavioral|Person-centered follow up|
79230162|NCT03287960|Drug|Setmelanotide|Once daily subcutaneous injection
79230163|NCT03287960|Drug|Placebo|Once daily subcutaneous injection
79230164|NCT03287882|Dietary Supplement|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
79230165|NCT03287882|Behavioral|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
79390894|NCT00118209|Drug|prednisone|oral
79390895|NCT00118209|Drug|etoposide|CIVI
79999304|NCT02834390|Drug|Cytarabine|"[Induction period, Cycle 1] Once-daily intravenous injection of 100 mg/m^2 cytarabine on Day 1 to 7.~[Induction period, Cycle 2] Once-daily intravenous injection of 100 mg/m^2 cytarabine on Day 1 to 5.~[Consolidation period] Twice-daily intravenous injection of 3.0 g/m^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
79999305|NCT02834390|Drug|Idarubicin|"Either Idarubicin or Daunorubicin will be used [Induction period, Cycle 1] Once-daily intravenous injection of 12 mg/m^2 idarubicin on Day 1 to 3.~[Induction period, Cycle 2] Once-daily intravenous injection of 12 mg/m^2 idarubicin on Day 1 and 2."
79390896|NCT00118209|Drug|filgrastim|IV
79390897|NCT00118209|Drug|pegfilgrastim|IV
79999306|NCT02834390|Drug|Daunorubicin|"Either Idarubicin or Daunorubicin will be used [Induction period, Cycle 1] Once-daily intravenous injection of 60mg/m^2 daunorubicin on Day 1 to 3.~[Induction period, Cycle 2] Once-daily intravenous injection of 60mg/m^2 daunorubicin on Day 1 and 2."
79230166|NCT03287726|Dietary Supplement|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
79372370|NCT02906241|Behavioral|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
79681393|NCT05949073|Procedure|Non-impregnated retraction cords/ more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then a plain retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
79372371|NCT01860677|Device|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
79372372|NCT02870829|Drug|menaquinone-7|Oral supplement given post dialysis 3x/week
79372373|NCT02861391|Device|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
79681394|NCT05949073|Drug|impregnated gingival retraction cord - less than 10 minutes|lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
79372374|NCT02861391|Device|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
79681395|NCT05949073|Drug|impregnated gingival retraction cord - more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
79681396|NCT05944913|Device|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
79681397|NCT05942820|Drug|BWC0977|SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
79230167|NCT03287726|Dietary Supplement|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
79230168|NCT03291314|Drug|Axitinib|1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) [7].
79390898|NCT02276326|Dietary Supplement|VSL#3 sachets|4 sachets a day for 4 months
79681398|NCT05942820|Drug|Placebo|"SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977"
79681399|NCT05942313|Drug|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
79681400|NCT05934981|Procedure|Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation|low pressure pneumoperitoneum (5-7mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.
79681401|NCT05934981|Procedure|Laparoscopic surgery under low pressure and conventional Insufflation|low pressure pneumoperitoneum (5-7mmHg), and use standard room temperature with dry insufflation.
79681402|NCT05933044|Drug|Durvalumab|Chemoradiotherapy plus durvalumab
79681403|NCT05930119|Drug|HMPL-453|300 mg HMPL-453
79999307|NCT03141151|Behavioral|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
79999308|NCT03141151|Behavioral|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
79999309|NCT01317433|Drug|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
79999310|NCT01317433|Drug|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
79999311|NCT01358708|Drug|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
79999312|NCT01358708|Drug|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
79390899|NCT01897779|Drug|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
79681404|NCT05930119|Drug|Rabeprazole|20 mg of rabeprazole will be administered by mouth once daily.
79825034|NCT05809206|Other|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
79999313|NCT01346449|Behavioral|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
79999314|NCT01346449|Behavioral|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
79230169|NCT03291314|Drug|Avelumab|2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
79372375|NCT02843529|Other|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
79999315|NCT01346449|Behavioral|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
79999316|NCT01346449|Behavioral|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
79372376|NCT01876901|Procedure|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
79372377|NCT01876901|Procedure|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
79372378|NCT01876823|Drug|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
79372379|NCT01876823|Drug|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
79372380|NCT01876511|Drug|MK-3475|MK-3475 10 mg/kg every 14 days
79372381|NCT01993719|Drug|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
79372382|NCT01993719|Drug|Fludarabine|25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days
79372383|NCT01993719|Drug|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
79681405|NCT05929131|Other|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
79681406|NCT05929131|Other|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
79825035|NCT05809206|Other|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
79999317|NCT03563768|Procedure|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
79999318|NCT01317511|Dietary Supplement|Protein|Protein drink
79999319|NCT03563924|Other|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
79999320|NCT03563846|Drug|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
79230170|NCT03291236|Other|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
79230171|NCT03283280|Other|Ever X Posterior|Resin composite restoration can be made as a direct onlay
79230172|NCT03287648|Diagnostic Test|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
79230173|NCT03287570|Device|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
79372384|NCT01993719|Drug|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
79999321|NCT03635281|Procedure|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
79999322|NCT03635281|Procedure|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
79372385|NCT01993719|Drug|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
79372386|NCT01993719|Drug|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m^2 IV over 60 minutes.
79372387|NCT01993719|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV)
79525966|NCT01390363|Other|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
79372388|NCT01993719|Drug|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
79525967|NCT01390376|Drug|DAAOI-1|DAAOI-1 1g
79525968|NCT01390376|Drug|DAAOI-1|DAAOI-1 2g
79525969|NCT01390376|Drug|placebo|starch pill
79525970|NCT01390454|Procedure|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
79525971|NCT01390454|Procedure|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
79525972|NCT01390454|Procedure|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
79372389|NCT00638235|Device|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
79372390|NCT00638235|Device|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
79525973|NCT01390467|Drug|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
79525974|NCT01390480|Drug|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
79525975|NCT01390493|Behavioral|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
79372391|NCT00638235|Device|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
79525976|NCT01390506|Drug|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
79525977|NCT01390506|Drug|Placebo|0,9% sodium chloride is administered intravenously
79525978|NCT01390519|Other|everolimis|
79525979|NCT01390532|Device|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
79372392|NCT00638235|Device|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
79525980|NCT01390558|Procedure|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
79525981|NCT01390571|Drug|olaparib|
79999323|NCT01346761|Behavioral|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
79372393|NCT00638235|Device|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
79372394|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
79372395|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
79372396|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
79525982|NCT01390571|Drug|temozolomide|
79525983|NCT01390571|Genetic|gene expression analysis|
79525984|NCT01390571|Genetic|protein expression analysis|
79372397|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
79372398|NCT01848171|Drug|L-thyroxine|
79372399|NCT02758665|Drug|ibrutinib|
79372400|NCT02758665|Drug|obinutuzumab|
79372401|NCT02758665|Drug|venetoclax|
79525985|NCT01390571|Other|laboratory biomarker analysis|
79525986|NCT01390571|Other|pharmacological study|
79525987|NCT01390571|Procedure|diffusion-weighted magnetic resonance imaging|
79525988|NCT01390571|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79525989|NCT01390571|Procedure|therapeutic conventional surgery|
79525990|NCT01390597|Genetic|DNA analysis|
79525991|NCT01390597|Genetic|cytogenetic analysis|
79525992|NCT01390597|Genetic|gene mapping|
79525993|NCT01390597|Genetic|mutation analysis|
79681407|NCT05929131|Other|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
79681408|NCT05926427|Drug|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
79825036|NCT05809206|Device|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
79825037|NCT05809167|Drug|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day*7days."
79825038|NCT05809154|Diagnostic Test|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
79230174|NCT03287570|Procedure|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
79825039|NCT05809141|Diagnostic Test|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
79825040|NCT05809128|Other|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
79825041|NCT05809102|Procedure|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
79230175|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
79372402|NCT03182673|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
79230176|NCT03283202|Drug|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
79681409|NCT05926427|Drug|Rituximab|375 mg/m^2 ivgtt, D0 of each 28-day cycle
79681410|NCT05926427|Drug|Chemotherapy|Not specified, recommended regimen according to histopathologic type
79825042|NCT05809076|Device|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
79999324|NCT01346761|Behavioral|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
79999325|NCT01356602|Drug|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
79372403|NCT03182673|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
79372404|NCT03182673|Drug|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
79372405|NCT00638157|Drug|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
79525994|NCT01390597|Genetic|polymerase chain reaction|
79681411|NCT05925777|Device|THEAL (Mectronic, Bergamo)|laser therapy high intensity
79681412|NCT05925270|Behavioral|mhGAP-Remote|One in-person session followed by standardized SMSs to reinforce the concepts learned in the first session. The intervention follows principles of the World Health Organization's Mental Health Gap Action Programme (mhGAP). Study interventionists can provide telephonic support to participants to implement the skills.
79681413|NCT05925270|Behavioral|mhGAP-Standard|Four in-person sessions with up to two booster sessions following the principles of World Health Organization's Mental Health Gap Action Programme (mhGAP).
79525995|NCT01390597|Other|laboratory biomarker analysis|
79525996|NCT01390623|Drug|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
79525997|NCT01390662|Dietary Supplement|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
79525998|NCT01390662|Dietary Supplement|placebo|one tablet of sugar pill pr. day, for 24 weeks.
79525999|NCT01390701|Device|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
79526000|NCT01390701|Drug|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
79526001|NCT01390714|Drug|E3710|"Arm A:~E3710 40 mg→RPZ 10 mg→E3710 20 mg~RPZ 10 mg→E3710 20 mg→E3710 40 mg~E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
79230177|NCT03283202|Drug|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
79230178|NCT03283202|Drug|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
79372406|NCT00638157|Drug|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
79372407|NCT00637377|Drug|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
79372408|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
79372409|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
79372410|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
79372411|NCT00636987|Device|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
79372412|NCT01475110|Drug|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
79526002|NCT01390714|Drug|E3710|"Arm B:~E3710 40 mg→E3710 80 mg→EPZ 40 mg~E3710 80 mg→EPZ 40 mg →E3710 40 mg~EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
79526003|NCT01390727|Device|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
79526004|NCT01390727|Other|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
79526005|NCT01390753|Dietary Supplement|Human donor milk|
79526006|NCT01390766|Drug|Azathioprine|
79526007|NCT01390792|Drug|Zanamivir hydrate|
79230179|NCT03283202|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
79526008|NCT01390805|Drug|Valaciclovir Hydrochloride.|
79526009|NCT01390831|Device|THERMOCOOL® Catheter|Catheter-based renal denervation
79526010|NCT01390883|Drug|Fondaparinux Sodium|
79526011|NCT01390896|Drug|Fondaparinux Sodium|
79372413|NCT01080118|Device|Airtraq|Subjects were taught with the Airtraq video laryngoscope
79372414|NCT01080118|Other|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
79825043|NCT05809076|Device|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
79999326|NCT01356602|Drug|Canakinumab lyophilized powder|Canakinumab lyophilized powder
79230180|NCT03283202|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
79230181|NCT04570358|Other|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
79372415|NCT03013582|Biological|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
79526012|NCT01390922|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
79526013|NCT01390935|Other|guideline adherence|guideline adherence of physician
79526014|NCT01390961|Drug|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
79526015|NCT01391039|Drug|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
79526016|NCT01391052|Drug|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
79526017|NCT01391052|Other|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
79526018|NCT01391065|Radiation|MR PET Guided Brachytherapy|
79526019|NCT01391078|Device|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
79526020|NCT01391078|Device|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
79526021|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
79526022|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
79526023|NCT01391104|Drug|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
79526024|NCT01391104|Drug|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
79526025|NCT01391117|Drug|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
79526026|NCT01391117|Drug|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
79999327|NCT01356602|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide
79999328|NCT01356602|Drug|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
79526027|NCT01391117|Drug|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
79230182|NCT04570358|Other|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
79230183|NCT03283124|Procedure|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
79825044|NCT05809063|Other|observational|document the number , disease pattern& outcome of neonates admitted to the neonatal intensive care units
79999329|NCT01347775|Device|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
79230184|NCT03283046|Drug|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
79230185|NCT03283046|Drug|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
79526028|NCT01391117|Drug|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
79230186|NCT03283046|Drug|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
79526029|NCT01391117|Drug|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
79526030|NCT01391117|Drug|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
79526031|NCT01391117|Drug|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
79526032|NCT01391117|Drug|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
79526033|NCT01391117|Drug|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
79825045|NCT05809050|Diagnostic Test|BM aspirate|Bone Marrow aspiration & Examination
79230187|NCT03283046|Drug|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
79372416|NCT03013582|Procedure|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
79372417|NCT05307796|Behavioral|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
79372418|NCT05307718|Drug|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
79372419|NCT05307562|Other|Interval training + analytical strength|Patients will receive a training program
79372420|NCT05307562|Other|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
79999330|NCT01347775|Device|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
79526034|NCT01391117|Drug|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
79526035|NCT01391156|Drug|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
79372421|NCT05307484|Other|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
79372422|NCT05307484|Other|Dengue prevention website|This is a website containing information regarding dengue prevention.
79526036|NCT01391156|Drug|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
79526037|NCT01391169|Other|seromuscular flap enforcement|seromuscular flap enforcement
79526038|NCT01391182|Other|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
79526039|NCT01391182|Other|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
79526040|NCT01391195|Device|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
79825046|NCT05809037|Device|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
79825047|NCT05809037|Device|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
79825048|NCT05809024|Drug|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
79999331|NCT01347853|Drug|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
79372423|NCT01376596|Behavioral|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
79526041|NCT01391208|Drug|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
79681414|NCT05924386|Procedure|patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments|Multiunit abutments is considered a gold standard screw retained abutments. Multi-unit abutments are used to correct for varying heights among the implants, to establish a level restorative platform for the prosthesis, as well as to situate the implant connection even with or just below the gingival surface. Also they are used to correct the angulation of implants, helping to keep the screw access holes away from the facial surfaces of the restoration, and facilitate the path of insertion of prosthesis.
79681415|NCT05924386|Procedure|all on 4 fixed mandibular prosthesis using OTbridge attachment system|"The OT bridge attachment system introduced by (Rhein 83) is a global, well-established system used in the removable prosthetic protocols, the presence of seeger acetal ring placed between the sub-equatorial area of the OT Equator and the cylindrical Extragrade abutment compensates the space between the extragrade abutment and the OT equator attachment correcting the minor misalignments that produced during the prosthetic procedure and resulting in more passive fit."
79681416|NCT05924321|Drug|Carbetocin|Single infusion of Carbetocin
79681417|NCT05924321|Drug|Placebo|Single IV infusion of matching placebo
79681418|NCT05924321|Drug|Placebo and Moxifloxacin|Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
79681419|NCT05922280|Other|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
79825049|NCT05808998|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
79825050|NCT05808985|Drug|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
79825051|NCT05808946|Drug|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
79372424|NCT01376596|Behavioral|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
79372425|NCT01033864|Drug|MMF|1 g per day b.i.d. p.o. for at least 1 month
79230188|NCT03287258|Other|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
79526042|NCT01391221|Drug|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
79526043|NCT01391260|Other|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
79526044|NCT01391338|Drug|ASP3652|Oral
79372426|NCT01033864|Drug|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
79526045|NCT01391338|Drug|Placebo|Oral
79825052|NCT05808946|Drug|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
79825053|NCT05808907|Other|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
79825054|NCT05808894|Procedure|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
79825055|NCT05808868|Other|Screening|"The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph."
79999332|NCT01347853|Drug|Placebo|Intranasal post-surgery for up to 5 days total
79230189|NCT03287258|Other|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
79372427|NCT01033864|Drug|Prednisone|5 mg per day p.o.
79372428|NCT03012568|Device|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
79999333|NCT01346917|Drug|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
79390900|NCT01897779|Drug|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
79526046|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~On Day 1 of the first course of chemotherapy~On Day 1 of the second course of chemotherapy~Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~At the end of chemotherapy"
79526047|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~On Day 1 of the first course of chemotherapy~On Day 1 of the second course of chemotherapy~Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~At the end of chemotherapy"
79526048|NCT01391377|Drug|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
79681420|NCT05922280|Other|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
79825056|NCT05808855|Procedure|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
79825057|NCT05808855|Procedure|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
79825058|NCT05808361|Other|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
79825059|NCT05808361|Other|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
79825060|NCT05808283|Other|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
79825061|NCT05808140|Drug|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
79825062|NCT05808140|Device|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
79825063|NCT05807698|Behavioral|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
79825064|NCT05806073|Procedure|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
79999334|NCT01346917|Drug|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
79825065|NCT05806073|Procedure|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
79825066|NCT05802420|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
79999335|NCT01343017|Other|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
79230190|NCT03287180|Behavioral|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
79390901|NCT01897779|Drug|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
79390902|NCT01897779|Drug|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
79390903|NCT04342156|Drug|Hydroxychloroquine Sulfate 200 milligram (mg) Tab|Oral tablet of Hydroxychloroquine sulfate
79526049|NCT01391377|Drug|Sugar pill|Placebo
79526050|NCT01391390|Drug|Melatonin|10mg/day, 12-week treatment
79526051|NCT01391390|Drug|Placebo|10mg/day, 12-week treatment for TD
79526052|NCT01391403|Drug|Artemisinin|400 mg/day
79526053|NCT01391403|Other|Placebo|400mg/day
79825067|NCT05802407|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
79372429|NCT05307016|Diagnostic Test|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
79825068|NCT05802394|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
79999336|NCT03563612|Device|cpap|application of cpap to the non-dependent lung, during one lung ventilation
79825069|NCT05797272|Procedure|in-utero HSCT|Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
79230191|NCT03287180|Other|Combination of buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
79230192|NCT03287102|Procedure|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
79526054|NCT01391429|Behavioral|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
79825070|NCT05783050|Device|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
79526055|NCT01391442|Biological|blood and urine samples|58 ml of blood 120 ml of urine
79526056|NCT01391442|Genetic|blood sample|11 ml of blood
79825071|NCT05783050|Device|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
79825072|NCT05778786|Device|Acuvue Oasys 1 Day for Astigmatism|CONTROL
79825073|NCT05778786|Device|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
79825074|NCT05773456|Other|Sushi and wakame salad|One serving of mixed sushi and wakame salad
79526057|NCT01391442|Other|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
79825075|NCT05770349|Procedure|coronary artery bypass grafting|Coronary artery bypass grafting
79825076|NCT05767840|Other|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~Khushi Aur Khatoon - for the treatment of depression and anxiety~Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
79999337|NCT01348009|Drug|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
79999338|NCT03620305|Other|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
79999339|NCT01343173|Drug|Imatinib stop|To stop imatinib after inclusion.
79230193|NCT03287024|Device|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
79372430|NCT01082380|Drug|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066
79999340|NCT01346995|Other|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
79999341|NCT01346995|Other|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
79372431|NCT01083628|Behavioral|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
79526058|NCT01391442|Other|Stanislas ancillary study : MRI examination with GRICS technique|
79526059|NCT01391455|Procedure|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
79526060|NCT01391481|Drug|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
79526061|NCT01391481|Drug|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
79526062|NCT01389934|Drug|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
79526063|NCT01389934|Drug|Placebo|Women of this group be infused saline 2 ml / h for 48h.
79681421|NCT05919628|Other|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
79526064|NCT01391494|Biological|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
79230194|NCT03286946|Procedure|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
79372432|NCT01083628|Behavioral|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
79681422|NCT05917275|Drug|Amlodipine|4 weeks of Amlodipine
79681423|NCT05917275|Drug|Olmesartan|4 weeks of Olmesartan
79681424|NCT05917275|Drug|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
79526065|NCT01391494|Biological|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
79825077|NCT05809375|Other|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
79825078|NCT05766163|Device|DaVinci RARP|Assisted-robotic radical prostatectomy.
79999342|NCT02830880|Drug|FACBC PET-CT|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
79999343|NCT02830880|Other|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
79999344|NCT03141307|Behavioral|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
79681425|NCT05917275|Drug|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
79230195|NCT03286946|Procedure|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
79230196|NCT03286868|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
79681426|NCT05914870|Other|Multi-component training|"The multicomponent training group will perform 60 minutes of training per session:~10 minutes of joint mobility exercises and dynamic stretching.~20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~10 minutes of cool down and static stretching."
79681427|NCT05914870|Other|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching."
79681428|NCT05911321|Drug|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
79230197|NCT03286868|Device|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
79372433|NCT01083706|Drug|azacitidine|Given SC or IV
79372434|NCT01083706|Other|laboratory biomarker analysis|Correlative studies
79372435|NCT03014128|Other|Clinical examination and data processing of questionnaires|xy
79372436|NCT01035346|Drug|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
79372437|NCT01035346|Drug|Placebo|Single dose of a placebo
79372438|NCT03186729|Drug|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
79372439|NCT03012802|Procedure|Colorectal Surgery|Postoperative Audit
79526066|NCT01391494|Biological|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
79372440|NCT05306392|Device|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
79526067|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
79526068|NCT01391494|Biological|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
79526069|NCT01391494|Biological|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
79825079|NCT05766163|Device|Hugo RARP|Assisted-robotic radical prostatectomy.
79999345|NCT03141307|Behavioral|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
79999346|NCT03141307|Behavioral|Control|Standard of care, paper-based brochure
79825080|NCT05766163|Device|Versius RARP|Assisted-robotic radical prostatectomy.
79681429|NCT05911321|Drug|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
79825081|NCT05764876|Drug|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
79230198|NCT03974204|Procedure|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
79230199|NCT03974204|Procedure|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~When suspected metastatic meningitis symptoms arise and~at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
79230200|NCT03974204|Procedure|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~1 month after the beginning of the specific treatment,~3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
79230201|NCT03921320|Procedure|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
79372441|NCT05306392|Device|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
79372442|NCT05306314|Dietary Supplement|TREATAPROST|oral administration before meals 30 minutes
79372443|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
79372444|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
79526070|NCT01391494|Biological|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
79681430|NCT05911321|Drug|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
79681431|NCT05910996|Procedure|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
79681432|NCT05910658|Behavioral|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
79825082|NCT05764876|Drug|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
79372445|NCT01085500|Behavioral|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
79372446|NCT01085500|Procedure|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
79372447|NCT01035658|Drug|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
79372448|NCT01035658|Drug|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
79372449|NCT05306236|Other|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
79372450|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
79372451|NCT01037452|Drug|Lansoprazole|Tablet
79372452|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide|Tablet
79372453|NCT01037452|Drug|Placebo|Tablet
79372454|NCT03012646|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
79372455|NCT05289856|Drug|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
79372456|NCT01085968|Behavioral|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
79681433|NCT05907668|Drug|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
79825083|NCT05753904|Procedure|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
79999347|NCT01347151|Device|The glidescope video laryngoscopy|
79999348|NCT01347151|Device|The Pentax airwayscope|
79526071|NCT01391494|Biological|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
79526072|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
79526073|NCT01391494|Biological|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
79526074|NCT01391494|Biological|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
79526075|NCT01391494|Biological|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
79825085|NCT05748678|Device|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
79681434|NCT05903417|Drug|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
79825086|NCT05747118|Behavioral|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
79999349|NCT01348243|Drug|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
79999350|NCT01348243|Drug|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
79999351|NCT01347229|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
79999352|NCT01348321|Drug|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
79999353|NCT03772951|Other|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
79999354|NCT03772951|Drug|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
79526076|NCT01391494|Biological|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
79526077|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
79372457|NCT01087918|Device|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
79372458|NCT01087918|Other|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
79372459|NCT00636441|Drug|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
79390904|NCT01682837|Drug|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
79390905|NCT01682837|Drug|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
79526078|NCT01391494|Biological|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
79526079|NCT01391520|Drug|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
79825087|NCT05741190|Device|Pentacam Imaging|Imaging of the corneal surface
79526080|NCT01391520|Drug|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
79825088|NCT05723458|Combination Product|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
79825089|NCT05723458|Drug|Placebo|Placebo cream containing vaseline
79825090|NCT05722535|Behavioral|Media Discussion and Planning Tool (MDPT)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
79825091|NCT05721651|Drug|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
79825092|NCT05720988|Drug|Azacitidine|Given SC
79825093|NCT05720988|Biological|Tagraxofusp-erzs|Given IV
79230202|NCT03921320|Procedure|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
79230203|NCT03921320|Procedure|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
79230204|NCT03282734|Other|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
79230205|NCT03282734|Other|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
79230206|NCT03918980|Drug|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
79526081|NCT01391533|Drug|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
79230207|NCT03918980|Drug|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
79526082|NCT01391572|Radiation|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
79230208|NCT03286790|Other|Data collection on pneumonia events|
79230209|NCT03282578|Device|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
79372460|NCT01087996|Biological|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
79372461|NCT01087996|Biological|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
79372462|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
79372463|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
79372464|NCT00636363|Device|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
79372465|NCT02984397|Drug|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
79372466|NCT02984397|Drug|Placebo|
79372467|NCT02984397|Other|Standard of Care|
79526083|NCT01391572|Radiation|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
79372468|NCT01922427|Drug|RNS60|
79390906|NCT01682837|Drug|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
79526084|NCT01391572|Drug|cisplatin|
79526085|NCT01391572|Drug|fluorouracil|
79681435|NCT05903417|Other|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
79681436|NCT05901311|Drug|LY3537982|Administered orally.
79681437|NCT05901311|Drug|[¹⁴C]-LY3537982|Administered orally.
79681438|NCT05901311|Drug|[¹⁴C]-LY3537982|Administered IV.
79681439|NCT05898555|Device|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
79681440|NCT05896007|Drug|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
79681441|NCT05896007|Drug|Rituximab|375 mg/m^2 ivgtt, D0 of each 28-day cycle
79681442|NCT05896007|Drug|Methotrexate|3.5 g/m^2 ivgtt, D1 of each 28-day cycle
79681443|NCT05896007|Drug|Temozolomide|150 mg/m^2 ivgtt, D1-D5 of each 28-day cycle
79709712|NCT04352985|Device|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
79825094|NCT05717478|Combination Product|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
79825095|NCT05717478|Device|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
79825096|NCT05716763|Drug|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
79825097|NCT05716763|Drug|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
79825098|NCT05716503|Device|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
79230210|NCT03282578|Device|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
79526086|NCT01391585|Other|Text Message prompts|In this single armed intervention, patients will receive text message prompts
79825099|NCT05716503|Other|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
79230211|NCT02460146|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
79230212|NCT02460146|Other|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
79825100|NCT05703841|Drug|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
79825101|NCT05700942|Device|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
79825102|NCT05700942|Device|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
79825103|NCT05697718|Biological|MSC|a single injection dose i.v.
79825104|NCT05691062|Device|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
79526087|NCT01391598|Drug|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
79825105|NCT05691062|Device|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
79825106|NCT05682092|Dietary Supplement|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
79825107|NCT05682092|Dietary Supplement|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
79825108|NCT05679648|Diagnostic Test|ultrasonography|studying degree of steatosis
79230213|NCT02460302|Drug|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
79372469|NCT01600131|Behavioral|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
79372470|NCT01600131|Other|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
79372471|NCT01088464|Biological|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
79681444|NCT05893433|Device|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
79681445|NCT05893433|Other|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
79230214|NCT02460302|Drug|Placebo|Placebo suppository inserted vaginally
79372472|NCT01088464|Biological|IMC-11F8|800 mg intravenously, every 2 weeks
79681446|NCT05891132|Drug|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
79709713|NCT02270918|Drug|Kcentra|IV infusion
79709714|NCT02270918|Drug|Apixaban|
79709715|NCT02270918|Drug|Placebo|
79825109|NCT05678465|Procedure|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
79825110|NCT05678465|Procedure|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
79825111|NCT05678088|Behavioral|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
79825112|NCT05678088|Behavioral|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
79230215|NCT03282500|Behavioral|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
79372473|NCT01088464|Biological|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
79372474|NCT01090180|Drug|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
79372475|NCT01090180|Drug|Placebo (sugar pill)|inactive
79372476|NCT00636207|Drug|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
79372477|NCT00636207|Drug|Placebo|Placebo dry powder inhaler
79372478|NCT01922505|Drug|PPI triple therapy|
79390907|NCT01682837|Drug|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
79390908|NCT02213068|Drug|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
79825113|NCT05676177|Diagnostic Test|Ultra Low Dose CT|"Two immediately consecutive scans with either one or two breath-holds~First scan (ULD_DECT_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)>30), that is 5 or 10 mAs~Second scan (ULD_DECT_2) 80 kVp - fixed current 20 or 40 mA (if BMI>30), that is 10 or 20 mAs"
79825114|NCT05676177|Diagnostic Test|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
79825115|NCT05657665|Other|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
79825116|NCT05655052|Device|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~An introductory information form will be filled in for women in all three groups.~While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~The Control Group will be given routine IUD application and care."
79825117|NCT05655052|Device|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~An introductory information form will be filled in for women in all three groups.~While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~The Control Group will be given routine IUD application and care."
79230216|NCT04264910|Behavioral|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
79230217|NCT03680846|Device|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
79372479|NCT04395885|Other|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
79526088|NCT01391598|Drug|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
79526089|NCT01391624|Drug|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
79526090|NCT01391624|Drug|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
79999355|NCT01343329|Drug|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
79999356|NCT01343329|Drug|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
79999357|NCT01317589|Drug|fentanyl|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
79230218|NCT03680846|Other|CMM|Conventional Medical Management
79526091|NCT01391637|Biological|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
79230219|NCT03650816|Other|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
79230220|NCT03650816|Other|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
79372480|NCT01091116|Drug|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
79372481|NCT01091116|Drug|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
79372482|NCT01091116|Drug|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
79372483|NCT01091116|Drug|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
79372484|NCT01091116|Drug|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
79372485|NCT03013426|Drug|NVX-508|Administration of NVX-508 emulsion intravenously
79526092|NCT01391650|Procedure|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
79526093|NCT01391676|Procedure|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
79526094|NCT01391689|Dietary Supplement|diindolylmethane|Given PO
79230221|NCT03107936|Behavioral|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
79526095|NCT01391689|Dietary Supplement|placebo|Given PO
79526096|NCT01391715|Drug|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
79526097|NCT01391715|Drug|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
79526098|NCT01391728|Behavioral|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
79230222|NCT04255550|Diagnostic Test|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
79526099|NCT01391741|Other|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
79230223|NCT03282422|Device|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
79372486|NCT01092364|Behavioral|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
79230224|NCT03282422|Device|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
79230225|NCT03286712|Drug|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
79230226|NCT03286478|Behavioral|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
79372487|NCT01092442|Procedure|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
79681447|NCT05891132|Drug|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
79999358|NCT01317589|Drug|methadone|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
79372488|NCT01092676|Drug|Ibuprofen Regular Dosing|Regular dosing
79372489|NCT01092676|Drug|PRN dosing Ibuprofen|PRN dosing Ibupofen
79372490|NCT01092910|Device|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
79372491|NCT05289622|Device|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
79372492|NCT05271994|Procedure|endoscopic biliary drainage|endoscopic biliary drainage
79372493|NCT05190640|Dietary Supplement|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
79372494|NCT05106244|Other|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
79372495|NCT05088148|Other|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
79372496|NCT01039792|Drug|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
79372497|NCT01039792|Dietary Supplement|Placebo|placebo
79526100|NCT01391741|Other|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
79372498|NCT03013816|Behavioral|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
79372499|NCT03013816|Behavioral|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
79526101|NCT01391754|Behavioral|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
79526102|NCT01391754|Other|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
79230227|NCT03286478|Behavioral|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
79526103|NCT01391754|Behavioral|Services As Usual|Home based services not using the SafeCare model
79526104|NCT01391754|Other|Uncoached|No in vivo coached quality control or fidelity monitoring
79230228|NCT03286478|Behavioral|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
79230229|NCT02458586|Dietary Supplement|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
79372500|NCT03013816|Behavioral|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
79526105|NCT01391767|Device|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
79526106|NCT01391845|Drug|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
79526107|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
79681448|NCT05890924|Other|WAST questionnaire|"WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)"
79681449|NCT05890638|Drug|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
79681450|NCT05890638|Drug|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
79681451|NCT05887440|Behavioral|isokinetic strength training of knee extensor and flexor muscles|"Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)"
79681452|NCT05885867|Behavioral|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
79681453|NCT05885503|Biological|RC-28E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
79230230|NCT03417674|Combination Product|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
79372501|NCT03012724|Device|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
79372502|NCT03012724|Device|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
79372503|NCT05023720|Other|nonintervention|
79372504|NCT01041274|Drug|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
79372505|NCT01041274|Drug|Placebo|Placebo by mouth daily for 12 months.
79372506|NCT01041274|Behavioral|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
79372507|NCT01041274|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
79526108|NCT01391845|Drug|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
79526109|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
79526110|NCT01391871|Device|OCT|Optical coherence tomography
79526111|NCT01391871|Device|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
79526112|NCT01391897|Behavioral|psychotherapy|"multimodal complex psychotherapy"
79526113|NCT01391923|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79526114|NCT01391936|Procedure|Tension Band Wiring|AO technique of TBW for fixation of fracture.
79526115|NCT01391936|Procedure|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
79526116|NCT01391975|Procedure|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
79526117|NCT01392014|Drug|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
79681454|NCT05885503|Biological|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
79681455|NCT05884788|Other|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~An attachment questionnaire: Relationship Scales Questionnaire~A questionnaire on symptoms: Distress thermometer"
79709716|NCT02270996|Other|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
79999359|NCT01347385|Procedure|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
79999360|NCT01347385|Procedure|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
79999361|NCT01348477|Procedure|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
79372508|NCT01041274|Radiation|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
79372509|NCT00635427|Biological|VPRIV®|Intravenous infusion, every other week (EOW)
79372510|NCT00635349|Drug|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
79526118|NCT01392014|Drug|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
79526119|NCT01392027|Procedure|Blood Draw|Blood draw for research specimens only
79526120|NCT01392066|Behavioral|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
79526121|NCT01392079|Drug|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
79681456|NCT05884190|Other|Remote Medical Model (RMM)|Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
79681457|NCT05884190|Other|Community Health Model (CHM)|Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
79526122|NCT01392105|Drug|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
79681458|NCT05884190|Other|SoC|SoC for Postpartum Hypertension
79372511|NCT00635349|Drug|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
79372512|NCT00635349|Drug|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
79681459|NCT05882929|Other|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
79999362|NCT02825420|Drug|trabectedin|
79999363|NCT01347463|Procedure|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
79999364|NCT01347619|Other|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
79372513|NCT00634803|Behavioral|CBT|Cognitive behavioral therapy
79372514|NCT00634803|Drug|Buprenorphine|buprenorphine/naloxone
79372515|NCT00634803|Other|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
79372516|NCT00634803|Other|Physician Management|Brief physician counseling
79526123|NCT01392105|Drug|Control group|No additional treatment of mesenchymal stem cells
79681460|NCT05882929|Other|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
79825118|NCT05651321|Other|Samples materials of basic taste stimuli and enteral nutrition preparations|Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
79526124|NCT01392131|Dietary Supplement|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
79825119|NCT05648435|Diagnostic Test|Lithium measures|Measurements of lithium levels in blood and urine
79526125|NCT01392131|Other|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
79526126|NCT01392144|Procedure|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
79526127|NCT01392144|Behavioral|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
79526128|NCT01392157|Device|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
79526129|NCT01392157|Device|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
79526130|NCT01392157|Device|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
79526131|NCT01392157|Device|LNG-IUS|100 women will receive an LNG-IUS
79526132|NCT01392209|Other|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
79526133|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues~Perceptions of thyroid cancer and disease status~Sources of information used in papillary microcarcinoma treatment decision-making~Treatment decision-making processes and influential factors~Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~Views about how to improve acceptability of active surveillance as a disease management option"
79526134|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues:~Perceptions of thyroid cancer and disease status~Sources of information used in papillary microcarcinoma treatment decision-making~Treatment decision-making processes and influential factors~Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~Views about how to improve acceptability of active surveillance as a disease management option"
79526135|NCT01392235|Drug|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
79681463|NCT05880238|Behavioral|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
79681464|NCT05880238|Other|Control group|The control group will continue their education according to the preschool education curriculum.
79681465|NCT05876949|Biological|Denosumab|AVT03 (denosumab) or Xgeva (denosumab) will be given as 1 time subcutaneous injection)
79681466|NCT05869812|Drug|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
79681467|NCT05869812|Dietary Supplement|CaLa|Comparative placebo
79825120|NCT05645497|Procedure|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
79825121|NCT05645497|Procedure|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
79825122|NCT05642767|Diagnostic Test|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
79825123|NCT05642767|Diagnostic Test|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
79825124|NCT05642767|Diagnostic Test|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
79372517|NCT01401699|Device|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
79372518|NCT01042288|Drug|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
79372519|NCT01042288|Drug|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
79372520|NCT01042288|Drug|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
79372521|NCT01217385|Procedure|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
79526136|NCT01392287|Drug|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
79825125|NCT05642767|Diagnostic Test|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
79681468|NCT05869019|Other|education|Premature baby care training will be provided.
79825126|NCT05639829|Behavioral|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
79230231|NCT03282188|Biological|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
79825127|NCT05635656|Device|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
79825128|NCT05633823|Other|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~A user account will be created after the application is downloaded to the mobile phone/tablet.~After logging into the application, the map of the game will be displayed.~The game will start with the first level of the game consisting of 5 levels.~At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~After watching the videos, interactive games will be played.~Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
79526137|NCT01392313|Dietary Supplement|Carnitine|Carnitine Ingestion
79825129|NCT05626166|Drug|Placebo|placebo tablets twice daily
79825130|NCT05626166|Drug|Diosmin|diosmin 600 mg twice daily
79825131|NCT05624138|Drug|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
79230232|NCT03282188|Drug|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
79825132|NCT05624138|Drug|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
79230233|NCT03384212|Drug|Cladribine|
79230234|NCT03384212|Drug|Fludarabine|
79230235|NCT03384212|Drug|Busulfan|
79681469|NCT05868824|Other|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
79709717|NCT00595062|Radiation|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
79709718|NCT01580189|Dietary Supplement|Whey protein|18g protein, immediately after training, 9 weeks
79825133|NCT05610800|Drug|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
79825134|NCT05610800|Drug|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
79825135|NCT05610800|Drug|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke >10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
79526138|NCT01392313|Dietary Supplement|Placebo|Carnitine placebo
79825136|NCT05610800|Behavioral|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
79825137|NCT05597930|Device|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
79526139|NCT01392339|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
79709719|NCT01580189|Dietary Supplement|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
79825138|NCT05596383|Dietary Supplement|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
79825139|NCT05596383|Dietary Supplement|Placebo|Placebo
79825140|NCT05594745|Drug|Lifitegrast Ophthalmic|eyedrop
79230236|NCT03384212|Drug|Cytarabine|
79526140|NCT01392352|Drug|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
79526141|NCT01392391|Procedure|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
79681470|NCT05862636|Behavioral|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
79681471|NCT05860231|Device|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
79709720|NCT01580189|Dietary Supplement|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
79709721|NCT00595140|Drug|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
79709722|NCT00595140|Drug|combination with somatostatin analogue octreotide|s.c., 100µg, one time
79709723|NCT00595140|Drug|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
79825141|NCT05594745|Drug|Systane Free|eyedrop
79825142|NCT05594745|Device|Lipiflow|thermal pulsation
79825143|NCT05592717|Drug|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
79825144|NCT05592561|Other|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was ~10 min.
79825145|NCT05592548|Device|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
79825146|NCT05580159|Biological|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
79825147|NCT05580159|Biological|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
79825148|NCT05579938|Dietary Supplement|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
79825149|NCT05579938|Dietary Supplement|Placebo lozenge|Identical placebo lozenge
79825150|NCT05568953|Biological|Stamaril|Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
79230237|NCT03272516|Behavioral|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
79230238|NCT03272516|Other|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
79526142|NCT01392391|Procedure|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
79230239|NCT03271658|Behavioral|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
79230240|NCT03271658|Behavioral|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
79526143|NCT01392430|Other|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
79526144|NCT01392456|Procedure|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
79526145|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
79230241|NCT02460068|Drug|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
79230242|NCT02460068|Drug|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
79999365|NCT01347619|Other|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
79372522|NCT01042366|Biological|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
79999366|NCT01347619|Other|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
79372523|NCT01043146|Drug|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
79999367|NCT01343563|Procedure|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
79999368|NCT01348555|Drug|Bronchodilatator|
79709724|NCT02271035|Drug|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
79999369|NCT01348555|Drug|Bronchodilatator|
79825151|NCT05568953|Biological|Imojev|Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
79825152|NCT05568953|Biological|Ixiaro|Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
79825153|NCT05563896|Other|No intervention|No intervention
79825154|NCT05563233|Other|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
79999370|NCT04437277|Diagnostic Test|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
79230243|NCT02460068|Drug|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
79230244|NCT03286322|Other|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
79230245|NCT03286322|Other|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
79825155|NCT05563233|Device|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
79372524|NCT01043146|Drug|placebo|intravenous 0.9 % NaCl
79372525|NCT04906018|Device|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
79372526|NCT04880668|Device|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
79372527|NCT01043926|Drug|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
79372528|NCT04801810|Other|Normobaric hypoxia|Low oxygen exposure to mimic ~8500 feet elevation (experimental).
79372529|NCT04801810|Other|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
79372530|NCT01044706|Drug|Bicalutamide|50 mg Oral Tablet
79372531|NCT04447534|Drug|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
79372532|NCT04447534|Drug|zinc|Zinc tablets
79709725|NCT02271035|Drug|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
79709726|NCT01606358|Drug|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
79709727|NCT04352517|Other|Online Survey|Online survey completion through google app.
79825156|NCT05558085|Behavioral|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
79825157|NCT05556200|Drug|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight <50 kg)
79825158|NCT05556200|Drug|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
79825159|NCT05553080|Genetic|Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.
79230246|NCT03286244|Drug|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
79825160|NCT05549622|Other|Low-soluble fiber diet|12 older adults (>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
79825161|NCT05549622|Other|High-soluble fiber diet|12 older adults (>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
79825162|NCT05542212|Device|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
79825163|NCT05542212|Device|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
79825164|NCT05540080|Device|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
79230247|NCT03282110|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
79230248|NCT03282110|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
79372533|NCT03014050|Device|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
79372534|NCT01044862|Drug|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
79825165|NCT05532215|Drug|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
79825166|NCT05532215|Drug|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
79372535|NCT01044862|Drug|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
79825167|NCT05528497|Other|VR+|Use of a virtual reality helmet during ovocyte retrieval
79825168|NCT05525026|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
79825169|NCT05524766|Device|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
79230249|NCT03282110|Drug|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
79230250|NCT03282032|Other|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
79372536|NCT01044862|Drug|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
79372537|NCT01045174|Device|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
79390909|NCT02213068|Drug|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
79825170|NCT05524740|Device|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
79825171|NCT05524662|Device|BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
79825172|NCT05520502|Other|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
79825173|NCT05519423|Behavioral|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
79825174|NCT05516654|Diagnostic Test|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
79825175|NCT05516654|Diagnostic Test|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
79825176|NCT05516654|Diagnostic Test|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
79825177|NCT05516654|Diagnostic Test|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
79825178|NCT05509322|Other|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
79825179|NCT05509322|Other|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
79999371|NCT00687986|Radiation|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
79999372|NCT00687986|Procedure|primary surgery|an anatomical surgical resection with lymph node dissection
79681472|NCT05860231|Device|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
79999373|NCT04422925|Procedure|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
79372538|NCT04365478|Procedure|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
79372539|NCT04365478|Procedure|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
79681473|NCT05858736|Drug|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
79999374|NCT03563378|Drug|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
79230251|NCT03270878|Drug|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
79230252|NCT03270878|Drug|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
79372540|NCT04361656|Drug|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
79372541|NCT04361656|Drug|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
79372542|NCT04242394|Procedure|ERCP|Routine ERCP procedures with gallbladder in situ patient
79825180|NCT05505240|Other|Respiratory analysis at cold temperature|Respiratory analysis at an ambient temperature of 18°C
79825181|NCT05505240|Other|Respiratory analysis at room temperature|Respiratory analysis at an ambient temperature of 22°C
79825182|NCT05505240|Other|Respiratory analysis at thermoneutral temperature|Respiratory analysis at an ambient temperature of 28°C
79999375|NCT03563378|Drug|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
79230253|NCT02459522|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
79230254|NCT03269942|Procedure|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
79230255|NCT03269942|Procedure|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
79230256|NCT03269786|Diagnostic Test|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
79999376|NCT01352455|Procedure|Hemodialysis|5 days per week hemodialysis
79230257|NCT03269786|Device|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
79230258|NCT03269864|Procedure|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
79372543|NCT04238338|Other|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
79372544|NCT01047358|Drug|Aromasin|25 mg table QD
79681474|NCT05856708|Other|DISEASE|
79825183|NCT05505240|Other|Respiratory analysis at hot temperature|Respiratory analysis at an ambient temperature of 38°C
79825184|NCT05500014|Other|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
79999377|NCT02829944|Drug|Ropivacaine|
79999378|NCT02829944|Drug|Ketorolac|
79999379|NCT02829944|Drug|Placebo|
79999380|NCT03563300|Other|Wheat flour|Wheat flour will be administered once daily for 7 days
79999381|NCT03563300|Other|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
79999382|NCT04014842|Device|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
79999383|NCT04014530|Drug|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
79999384|NCT03563534|Drug|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
79230259|NCT03285932|Radiation|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
79372545|NCT01047358|Drug|Aromasin|25 mg table QD
79526146|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
79681475|NCT05856669|Device|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
79681476|NCT05851430|Device|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
79681477|NCT05847829|Device|T-REEX algorithm|Phase locked transcranial stimulation.
79681478|NCT05839899|Drug|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
79681479|NCT05839899|Drug|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
79681480|NCT05839860|Other|Salt 3 g|Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours
79681481|NCT05839860|Other|Salt 6 g|Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours
79681482|NCT05839860|Other|Salt 9 g|Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
79681483|NCT05838560|Drug|Dasatinib + quercetin|dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
79709728|NCT02271074|Other|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
79825185|NCT05492630|Drug|HEC73077 tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
79825186|NCT05492630|Drug|HEC73077 placebo tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
79999385|NCT03563534|Drug|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
79372546|NCT01048606|Behavioral|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
79372547|NCT01048606|Dietary Supplement|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
79390910|NCT02213068|Drug|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
79390911|NCT00702234|Biological|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
79526147|NCT01392534|Drug|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
79526148|NCT01392586|Procedure|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
79825187|NCT05492383|Device|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
79230260|NCT03285932|Radiation|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
79825188|NCT05486975|Biological|CT0591CP Cells|CT0591CP cells
79230261|NCT03285698|Device|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
79230262|NCT03285698|Device|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
79230263|NCT03285620|Drug|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
79230264|NCT03285620|Drug|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
79230265|NCT02459600|Other|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
79230266|NCT03285464|Other|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
79230267|NCT03269708|Behavioral|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
79526149|NCT01392586|Other|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
79681484|NCT05835882|Biological|Red Blood Cell concentrates from organ donor|"Intervention is a 3-step procedure consisting of 1) recovering blood from the donor during organ procurement; 2) processing donor blood to RBC units; 3) transfusing donor blood to recipients, if necessary during surgery.~Donor blood recovery. A: Donor evaluation. During the donor workup, the donor coordinator team gathers additional information from the donor relatives. If no contraindication to blood collection exists, the donor-recipient ABO-crossmatch is performed, and if negative the donor is considered eligible. B: Donor blood collection. It is carried out by a trained investigator, through the continuous autotransfusion system CATSmart (Fresenius Kabi) in the surgery room.~Donor blood processing, carried out using the continuous flow CATSmart device. About 4 RBC units are collected.~Donor RBC unit transfusion to recipients according to procedures usually adopted at our hospital (final hb level 8-9 g/dL)."
79681485|NCT05835011|Drug|Decitabine/Cedazuridine|Oral FDC tablets administration
79681486|NCT05835011|Drug|Magrolimab|IV administration
79681487|NCT05834569|Drug|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
79681488|NCT05834569|Drug|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
79681489|NCT05832164|Other|Multifactorial intervention|"Adherence to a Mediterranean diet.~Progressive aerobic and anaerobic exercise program.~Review of polypharmacy~Group socialization activities"
79825189|NCT05478915|Procedure|discectomy of the TMJ disc|removal of the TMJ disc
79825190|NCT05478915|Procedure|TMJ discopexy|fixation of the TMJ disc
79825191|NCT05471947|Drug|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
79825192|NCT05468567|Diagnostic Test|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
79230268|NCT02459912|Procedure|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
79230269|NCT02459912|Device|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
79230270|NCT03269630|Other|No intervention. Biospecimen collection only|Biospecimen collection
79230271|NCT03281642|Other|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
79230272|NCT03285386|Behavioral|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
79230273|NCT03285386|Behavioral|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
79230274|NCT03285074|Other|No intervention|No intervention
79526150|NCT01392599|Procedure|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
79825193|NCT05468567|Diagnostic Test|French Matrix Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
79526151|NCT01392612|Drug|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
79825194|NCT05468567|Behavioral|SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
79681490|NCT05831683|Other|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
79825195|NCT05468502|Drug|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
79999386|NCT02824562|Behavioral|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
79999387|NCT02824562|Behavioral|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
79999388|NCT02744066|Device|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
79230275|NCT03284996|Device|Doppler ultrasonography|Examination of the whole cases & controls by doppler ultrasound to measure renal resistive index.
79230276|NCT03269240|Behavioral|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
79230277|NCT03269240|Other|Onsite training|Participants are training at their health facilities
79372548|NCT01048606|Other|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
79372549|NCT04224766|Procedure|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
79526152|NCT01392638|Other|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
79526153|NCT01392638|Drug|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
79681491|NCT05825040|Behavioral|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
79825196|NCT05466032|Other|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
79230278|NCT03269240|Other|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
79230279|NCT03281486|Device|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
79526154|NCT01392690|Behavioral|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
79526155|NCT01392716|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
79825197|NCT05465681|Drug|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
79825198|NCT05463601|Drug|Mecapegfilgrastim|Mecapegfilgrastim
79230280|NCT03281486|Device|Placebo|Placebo formulation without the active ingredients
79230281|NCT03269318|Drug|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
79230282|NCT03268928|Behavioral|Story Starters Intervention|Shared reading intervention
79230283|NCT03268928|Behavioral|Wait-list Control|Wait-list control
79825199|NCT05463601|Drug|dalpiciclib|dalpiciclib
79526156|NCT01392755|Drug|danoprevir|oral doses of danoprevir
79526157|NCT01392755|Drug|omeprazole|oral doses of omeprazole
79526158|NCT01392755|Drug|ranitidine|oral dose of ranitidine
79526159|NCT01392755|Drug|ritonavir|oral doses of ritonavir
79526160|NCT01392768|Drug|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
79526161|NCT01392768|Drug|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
79825200|NCT05463601|Drug|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
79825201|NCT05462015|Behavioral|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
79825202|NCT05462015|Behavioral|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
79526162|NCT01392794|Drug|YM060|oral, without water
79825203|NCT05438082|Drug|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if < 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
79999389|NCT03563456|Behavioral|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
79999390|NCT03563456|Behavioral|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
79999391|NCT03563144|Drug|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
79999392|NCT03563144|Drug|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
79999393|NCT03563144|Drug|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
79999394|NCT03563144|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79230284|NCT03268850|Other|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
79230285|NCT03268850|Behavioral|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
79999395|NCT03563144|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79999396|NCT03563144|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
79999397|NCT03563144|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79526163|NCT01392807|Drug|NKTR-118|25 mg Oral tablets, single dose
79526164|NCT01392820|Drug|TC-5214|Tablet, Oral, twice daily
79526165|NCT01392820|Drug|Placebo|Tablet, Oral, twice daily
79526166|NCT01392833|Drug|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
79526167|NCT01392833|Drug|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
79526168|NCT01392833|Drug|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
79681492|NCT05825040|Behavioral|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
79681493|NCT05825040|Behavioral|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
79999398|NCT03563144|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
79999399|NCT03563144|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79526169|NCT01392872|Other|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
79526170|NCT01392898|Drug|liraglutide|liraglutide 1.8 mg q.d.
79681494|NCT05820347|Device|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
79681495|NCT05819710|Drug|TS-142|Single dose of 5 mg of TS-142
79681496|NCT05819710|Drug|TS-142|Single-dose of 10 mg of TS-142
79681497|NCT05819710|Drug|Zopiclone|Single-dose of 7.5 mg of zopiclone
79681498|NCT05819710|Drug|Placebo|Single-dose of placebo
79681499|NCT05816551|Other|Controlled hyperthermia|Individuals will be exposed to a control trial (no hyperthermia) and a controlled hyperthermia trial.
79681500|NCT05815875|Combination Product|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
79999400|NCT03563144|Biological|GI-6207|CEA yeast vaccine
79825204|NCT05438082|Other|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
79825205|NCT05432245|Device|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
79825206|NCT05418283|Behavioral|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
79825207|NCT05414448|Device|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
79825208|NCT05410561|Behavioral|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
79999401|NCT03563144|Biological|GI-6301|Brachyury yeast vaccine
79230286|NCT03268850|Behavioral|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
79230287|NCT03284918|Dietary Supplement|Plant stanol ester|
79230288|NCT03284918|Dietary Supplement|Placebo|
79230289|NCT03284840|Diagnostic Test|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
79230290|NCT03284840|Diagnostic Test|Thyroid size|Thyroid size by ultrasound.
79526171|NCT01392898|Drug|Insulin|insulin dosed according titration scheme
79681501|NCT05815875|Other|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
79681502|NCT05811403|Other|Epigallocatechin gallate (EGCG)|Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.
79230291|NCT03284762|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
79230292|NCT03284684|Other|Blood test|plasma concentration of circulating DNA of specific genes
79372550|NCT04224766|Procedure|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
79526172|NCT01392911|Drug|Rifampicin|High dose rifampicin
79526173|NCT01392924|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
79526174|NCT01392937|Device|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
79681503|NCT05811403|Other|Sodium hypochlorite (NaOCl)|Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.
79681504|NCT05811403|Other|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.
79681505|NCT05811403|Other|Premixed bioceramic putty|Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
79825209|NCT05410561|Behavioral|TeleTx intervention|TeleTx will consist of an initial session and then 8 ~counseling sessions.
79825210|NCT05410249|Diagnostic Test|Serum IL10 By ELISA|measurement Of IL10 by ELISA
79825211|NCT05410249|Diagnostic Test|SNP -3279 A/C of FOXP3|Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.
79825212|NCT05410249|Diagnostic Test|SNP-924 A/G Of FOXP3|Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
79825213|NCT05397379|Drug|HEC96719|Oral tablets
79825214|NCT05397379|Drug|Placebo|Comparator
79825215|NCT05395416|Drug|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
79825216|NCT05395416|Drug|Placebo|administered orally once daily for 12 weeks
79825217|NCT05395195|Drug|Erythropoietin|Erythropoietin injections (500u/kg) x 9 doses
79825218|NCT05395195|Other|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
79825219|NCT05394207|Dietary Supplement|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
79825220|NCT05394207|Other|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
79825221|NCT05391360|Drug|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
79825222|NCT05391360|Drug|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
79999402|NCT03563144|Biological|haNK|NK-92 [CD16.158V, ER IL-2]
79999403|NCT03563144|Drug|Avelumab|Avelumab
79999404|NCT03563144|Drug|Bevacizumab|Bevacizumab
79999405|NCT03563144|Drug|Capecitabine|Capecitabine
79999406|NCT03563144|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79999407|NCT03563144|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79999408|NCT03563144|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79526175|NCT01392937|Device|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
79681506|NCT05805735|Other|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
79526176|NCT01392950|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
79681507|NCT05804318|Device|Daily adaptive SBRT with urethral sparing|The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
79526177|NCT01392950|Device|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
79526178|NCT01392976|Drug|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
79526179|NCT01392976|Drug|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
79526180|NCT01393015|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
79681508|NCT05799287|Biological|Telitacicept|Telitacicept 240 mg SC
79681509|NCT05799287|Drug|Placebo|Placebo to Telitacicept
79681510|NCT05789134|Other|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
79681511|NCT05789043|Drug|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
79681512|NCT05789043|Drug|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
79230293|NCT03268694|Behavioral|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
79230294|NCT03268694|Behavioral|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
79526181|NCT01393015|Device|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
79681513|NCT05789043|Drug|camrelizumab|camrelizumab 200mg，q2w
79681514|NCT05784051|Drug|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain >10% after 2 lines of AAD treatment).
79681515|NCT05784051|Drug|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
79681516|NCT05783791|Diagnostic Test|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~Is noninvasive~Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~Does not by design or intention introduce energy into a subject, and~Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
79681517|NCT05781334|Other|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
79681518|NCT05775926|Other|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
79681519|NCT05764720|Radiation|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
79681520|NCT05760937|Drug|BMS-986447|Specified dose on specified days
79681521|NCT05760937|Drug|Placebo|Specified dose on specified days
79681522|NCT05758805|Device|mini-invasive esophagoscopy|mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter
79681523|NCT05758805|Device|HP-SD AF ablation by a CF sensing catheter|AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
79681524|NCT05758766|Dietary Supplement|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
79681525|NCT05757973|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
79681526|NCT05755308|Procedure|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
79681527|NCT05755308|Procedure|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
79681528|NCT05743010|Drug|APL-1401|APL-1401 capsules orally once daily
79681529|NCT05743010|Drug|Placebo|Placebo capsules orally once daily
79825223|NCT05391360|Drug|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
79825224|NCT05391360|Drug|entecavir tablets|once daily for consecutive 28 days
79681530|NCT05742633|Other|Active release technique|"Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)"
79526182|NCT01393028|Other|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
79526183|NCT01393028|Other|Standard care|Standard care according to international guidelines
79681531|NCT05742633|Other|Self-myofascial release|"Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)"
79526184|NCT01393041|Device|Angio-Seal VIP|Vascular Closure Device
79526185|NCT01393054|Drug|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
79526186|NCT01393067|Device|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
79681532|NCT05741138|Other|Core strengthening|"Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time."
79681533|NCT05741138|Other|Conventional treatment|Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
79681534|NCT05739201|Procedure|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
79681535|NCT05739201|Procedure|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
79681536|NCT05739201|Procedure|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
79681537|NCT05735327|Drug|No intervention|As this is an observational study, no intervention will be administered.
79681538|NCT05731063|Procedure|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
79681539|NCT05730946|Diagnostic Test|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
79681540|NCT05726786|Drug|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
79681541|NCT05720416|Dietary Supplement|protein supplementation|protein supplementation for 16 weeks
79825225|NCT05386407|Diagnostic Test|telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)|"After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP."
79230295|NCT03268694|Behavioral|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
79230296|NCT02458664|Genetic|Genetic analysis on tumor kept in tumor bank|
79230297|NCT03269006|Device|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
79230298|NCT03269006|Device|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
79230299|NCT03269006|Device|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
79526187|NCT01393067|Device|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
79526188|NCT01393080|Drug|Nimotuzumab and TP regimen|"TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
79526189|NCT01393080|Drug|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
79999409|NCT03563144|Drug|Oxaliplatin|Oxaliplatin
79526190|NCT01393093|Procedure|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
79230300|NCT03269006|Device|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
79372551|NCT04224766|Procedure|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
79372552|NCT04210882|Behavioral|Moderate-Intensity Exercise|See description of study arm.
79372553|NCT03012256|Other|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
79372554|NCT04128514|Device|Panoptix Toric|Cataract surgery and IOL implantation
79681542|NCT05720416|Behavioral|muscle strength training|muscle strength training for 16 weeks
79999410|NCT04835636|Behavioral|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
79230301|NCT04172558|Biological|OnabotulinumtoxinA|a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
79681543|NCT05720416|Other|usual care|no intervention
79681544|NCT05718648|Drug|BI 1015550|BI 1015550
79681545|NCT05712239|Other|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
79681546|NCT05712239|Other|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
79230302|NCT04172558|Drug|Trimix|on demand ICI of Trimix
79230303|NCT03107858|Drug|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
79372555|NCT01049776|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
79372556|NCT01772004|Drug|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
79526191|NCT01393119|Drug|GTx-758|
79825226|NCT05374993|Device|3TBA|Induce third molar tooth bud agenesis
79825227|NCT05374980|Dietary Supplement|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
79825228|NCT05374980|Dietary Supplement|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
79999411|NCT03831074|Device|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
79999412|NCT03825224|Procedure|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
79999413|NCT03824600|Diagnostic Test|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
79999414|NCT04705766|Other|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
79230304|NCT03107858|Drug|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
79230305|NCT03281330|Behavioral|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
79230306|NCT03284528|Other|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
79230307|NCT03269162|Drug|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
79372557|NCT02930044|Other|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
79526192|NCT01393119|Drug|GTx-758|
79526193|NCT01393119|Drug|GTx-758|
79526194|NCT01393119|Drug|GTx-758|
79526195|NCT01391988|Procedure|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
79526196|NCT01391988|Procedure|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
79372558|NCT02930044|Other|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
79681547|NCT05712239|Other|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
79681548|NCT05711927|Device|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
79825229|NCT05372523|Diagnostic Test|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
79825230|NCT05372523|Diagnostic Test|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
79230308|NCT03269162|Drug|Docetaxel|75mg/m2,ivgtt 30mins, d1
79230309|NCT03269162|Drug|Pemetrexed|500mg/m2, ivgtt 30mins, d1
79230310|NCT03269162|Drug|Cisplatin|75mg/m2, ivgtt >2h, d1
79230311|NCT03268772|Drug|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
79372559|NCT02930044|Drug|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
79526197|NCT01393145|Drug|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
79526198|NCT01393145|Drug|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
79681549|NCT05711927|Device|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
79681550|NCT05708040|Device|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
79681551|NCT05708040|Device|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
79230312|NCT03268616|Device|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
79230313|NCT03268304|Other|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
79681552|NCT05703334|Other|Kinesio tap|Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
79681553|NCT05702255|Other|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
79681554|NCT05702255|Other|Sham acuptressure|The same protocol as the active acupressure group.
79681555|NCT05701657|Other|Diet A|This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, fish, nuts/seeds, and vegetable oils, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
79230314|NCT03268460|Diagnostic Test|Arterial blood gases|blood PH, HCO3
79390912|NCT00702234|Biological|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
79390913|NCT00702234|Biological|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
79526199|NCT01393184|Drug|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
79526200|NCT01393197|Other|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
79681556|NCT05701657|Other|Diet B|This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, sweets, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
79681557|NCT05701657|Other|Diet C|This diet has moderate-high amounts of vegetables, meat/poultry/egg, fish, nuts/seeds, and fats/oils, low amounts of fruits and dairy, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
79681558|NCT05701657|Other|Liquid Mixed Meal Tolerance Test|A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
79825231|NCT05371743|Diagnostic Test|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆_Ct) method
79825232|NCT05371743|Diagnostic Test|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
79825233|NCT05371743|Diagnostic Test|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
79999415|NCT04784624|Behavioral|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
79999416|NCT04763720|Behavioral|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
79230315|NCT03268460|Diagnostic Test|Blood anion gap|(Na+) - (Cl- + HCO3-)
79372560|NCT02181400|Device|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
79526201|NCT01393210|Dietary Supplement|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
79526202|NCT01393210|Other|low-calorie diet|low-calorie diet only for 12 weeks.
79681559|NCT05701657|Other|Diet-Specific Mixed Meal Tolerance Test|The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
79825234|NCT05366764|Drug|SAR443765|solution for injection
79825235|NCT05366764|Drug|Placebo|solution for injection
79825236|NCT05366764|Drug|Salbutamol or levosalbutamol|metered dose inhaler
79230316|NCT03268460|Diagnostic Test|serum electrolytes|Na+ , K+ , Cl- and calcium
79230317|NCT03268460|Diagnostic Test|renal function test|blood urea and serum creatinine
79230318|NCT03268460|Diagnostic Test|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
79230319|NCT03284450|Other|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
79372561|NCT04352218|Device|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
79372562|NCT04352218|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
79372563|NCT03012178|Procedure|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
79526203|NCT01393223|Drug|LP-08 80mg|Intravesical instillation of 80mg LP08
79526204|NCT01393223|Drug|Normal saline|Intravesical instillation of normal saline
79526205|NCT01393223|Drug|LP-08 20mg|Intravesical instillation of 20mg LP08
79681560|NCT05701215|Drug|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
79526206|NCT01393275|Other|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
79230320|NCT03284450|Other|SSRS|The SSRS (Howatson & Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
79825237|NCT05357378|Device|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
79230321|NCT03284372|Behavioral|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
79230322|NCT03284372|Behavioral|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
79372564|NCT03012412|Behavioral|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
79372565|NCT02666638|Other|Control Volunteers|MRI on up to a 7T scanner without contrast.
79372566|NCT02666638|Other|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
79372567|NCT03683524|Drug|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
79372568|NCT03683524|Drug|Current ART|To continue with their current ART
79372569|NCT02246842|Biological|D-Gam® (human anti-D immunoglobulin)|
79526207|NCT01393275|Other|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
79526208|NCT01393288|Drug|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
79372570|NCT02246842|Biological|Rhophylac® (human anti-D immunoglobulin)|
79825238|NCT05357378|Device|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~Smith & Nephew Anthology® Total Hip System in combination with R3® Acetabular System."
79825239|NCT05355207|Drug|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
79372571|NCT02617342|Behavioral|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
79372572|NCT02550886|Other|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
79372573|NCT02249650|Drug|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
79372574|NCT02182492|Drug|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
79372575|NCT02182492|Drug|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
79372576|NCT02182804|Device|Olympus|narrow band imaging with magnification
79372577|NCT02182804|Device|Cellvizio|probe-based confocal laser endomicroscopy
79372578|NCT01668082|Procedure|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
79372579|NCT03010306|Other|CASITA|
79372580|NCT03010384|Other|Rehabilitation program|
79372581|NCT01163656|Device|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
79372582|NCT01163656|Device|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
79526209|NCT01393288|Drug|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
79526210|NCT01393288|Drug|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
79526211|NCT01393327|Behavioral|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
79681561|NCT05700422|Drug|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
79681562|NCT05694247|Device|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
79681563|NCT05687526|Biological|Telitacicept 2.5 mg/kg|Subjects will be given Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.
79681564|NCT05687318|Device|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
79999417|NCT01338818|Drug|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
79526212|NCT01393340|Drug|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
79999418|NCT02823470|Drug|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
79526213|NCT01393340|Drug|Placebo|Placebo
79999419|NCT02823470|Device|activated smart device|
79999420|NCT02823470|Device|de-activated smart device|
79999421|NCT04748510|Procedure|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
79372583|NCT01129804|Behavioral|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
79372584|NCT01165840|Drug|Dapsone|100 mg PO x 1 dose
79681565|NCT05681377|Drug|Flumazenil|After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
79230323|NCT03284294|Drug|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
79230324|NCT03284294|Drug|Placebo|Oral placebo daily for 8 weeks
79372585|NCT04351854|Other|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
79390914|NCT00702234|Biological|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
79390915|NCT00702234|Drug|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
79681566|NCT05681026|Behavioral|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week, over the first 30 days of your hospitalization.
79681567|NCT05681026|Behavioral|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
79681568|NCT05681026|Behavioral|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
79681569|NCT05680818|Drug|Encaleret|Administered as film-coated tablet for oral use
79526214|NCT01393353|Other|Cognitive Training|
79526215|NCT01393353|Other|computer game|
79526216|NCT01393366|Other|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
79681570|NCT05680818|Dietary Supplement|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
79526217|NCT01393366|Other|Usual Practice|None, only usual practice.
79825240|NCT05337280|Device|Imagio OA/US|Imagio optoacoustic/ultrasound
79825241|NCT05319041|Drug|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
79825242|NCT05319041|Drug|Placebo|0.5g maltodextrin without any herbs medicine
79230325|NCT03284216|Procedure|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
79825243|NCT05314335|Other|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
79230326|NCT03284216|Procedure|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
79230327|NCT03284216|Behavioral|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
79526218|NCT01393418|Other|Cardiac Surgery|
79526219|NCT01392196|Procedure|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
79526220|NCT01393470|Procedure|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
79681571|NCT05677984|Procedure|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
79681572|NCT05674942|Other|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
79372586|NCT00952692|Biological|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
79999422|NCT04748510|Procedure|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
79999423|NCT05238584|Procedure|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at >2 cm from the gastroepiploic arcade.
79681573|NCT05668559|Procedure|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
79681574|NCT05668559|Procedure|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
79681575|NCT05668416|Other|education|The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
79999424|NCT04645862|Diagnostic Test|CT scans|4D CTA imaging
79230328|NCT03281018|Behavioral|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
79372587|NCT00952692|Drug|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
79372588|NCT01168024|Device|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
79372589|NCT01168024|Other|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
79372590|NCT05389566|Diagnostic Test|Quantative Sensory Testing|Evaluation of small fiber neuropathy
79372591|NCT05389566|Diagnostic Test|NCStat-DPN-Check|Evaluation of large fiber neuropathy
79372592|NCT05389566|Diagnostic Test|Composite Autonomic Symptom Score 31|Evaluation of autonomic neuropathy
79372593|NCT05389566|Diagnostic Test|Computerized dynamic posturography|Evaluation of dynamic postural control
79372594|NCT05389566|Diagnostic Test|Video Head Impulse Test|Evaluation of vertigo and the vestibular organ
79372595|NCT05389566|Diagnostic Test|Accelerometer|Evaluation of gait pattern
79372596|NCT05389566|Diagnostic Test|Handgrip strength|Evaluation of muscle strength
79372597|NCT05389566|Diagnostic Test|Dual Energy X-ray Absorbtimetry scan|Evaluation of body composition
79372598|NCT05389566|Diagnostic Test|Force Plate Platform|Evaluation of balance while standing still
79681576|NCT05661279|Procedure|general anesthesia|general anesthesia
79681577|NCT05661279|Procedure|general anesthesia plus Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia
79999425|NCT03562910|Other|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
79372599|NCT01168726|Behavioral|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
79372600|NCT01168726|Behavioral|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
79372601|NCT01168726|Behavioral|Alcohol Education|Educational information about harms associated with heavy drinking.
79372602|NCT01170754|Drug|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
79999426|NCT03562754|Procedure|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
79999427|NCT03562754|Procedure|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
79999428|NCT02259920|Drug|KUC 7483 CL, immediate release tablet|
79372603|NCT01170754|Drug|Golytely 4 liters|Golytely 4 liters
79526221|NCT01393496|Other|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
79681578|NCT05661279|Procedure|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
79999429|NCT02259920|Drug|KUC 7483 CL, particulate formulation|
79999430|NCT02259920|Drug|KUC 7483 CL, solution formulation|
79372604|NCT02522832|Other|Titre 1|Virus infection
79230329|NCT03284060|Behavioral|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~pen and paper tasks focusing on specific emotion recognition component (20 min),~computerized tasks focusing on the same process (20 min),~a proposal of a home-based task (during 20 min)."
79230330|NCT03283904|Other|Multicomponent physical activity intervention|School-based multicomponent intervention
79681579|NCT05660681|Drug|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
79999431|NCT02259920|Device|Enterion™ capsule|
79999432|NCT04353674|Device|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
79999433|NCT04353674|Device|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
79230331|NCT02558296|Drug|Bexagliflozin|20 mg, tablet
79230332|NCT02558296|Drug|Placebo|20 mg tablet to match active comparator
79372605|NCT02522832|Other|Titre 2|Virus infection
79230333|NCT03268226|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
79372606|NCT02522832|Other|Titre 3|Virus infection
79372607|NCT05166330|Drug|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
79372608|NCT05166330|Drug|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
79999434|NCT01371656|Drug|levofloxacin|Given PO or IV
79681580|NCT05660681|Drug|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
79681581|NCT05660239|Other|Community Intervention|To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
79709729|NCT02271074|Behavioral|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
79999435|NCT01354106|Device|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
79999436|NCT01354028|Other|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
79999437|NCT03065582|Other|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
79999438|NCT03065582|Other|Topical Product B|topical application of product A without topical antioxidants
79999439|NCT03065582|Other|Topical Product C|Topical application of antioxidants only
79999440|NCT03065582|Other|Control|No product applied
79372609|NCT01378104|Drug|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
79372610|NCT01378104|Drug|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
79526222|NCT01393496|Other|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
79526223|NCT01393548|Drug|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
79526224|NCT01393548|Drug|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
79681582|NCT05648292|Behavioral|Neuropsychological tests and psychological questionnaires|"The clinical group will complete:~the BCcogSEP: a comprehensive neuropsychological examination~the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~The control group will complete:~the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
79230334|NCT03283748|Device|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
79372611|NCT03344250|Drug|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
79999441|NCT04541888|Drug|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
79999442|NCT04541888|Drug|Placebo|Placebo
79999443|NCT04541888|Drug|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
79681583|NCT05647005|Other|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
79230335|NCT05234996|Device|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
79372612|NCT03344250|Drug|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
79372613|NCT01130740|Behavioral|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
79999444|NCT01354964|Drug|Vitamin D|
79999445|NCT01354964|Drug|Placebo|
79999446|NCT03562676|Other|weightlessness|parabolic flight
79999447|NCT02673476|Drug|ALS-008176|ALS-008176 tablets
79230336|NCT03268148|Device|LaserPen|low level laser is used before heel-lancing for newborn screening
79230337|NCT03283592|Other|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
79230338|NCT03283592|Other|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
79372614|NCT05397288|Behavioral|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~1st month: group practice (1 time/week), home visits (2 times/week)~2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~3rd month: group practice (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
79390916|NCT00421876|Behavioral|multifactorial continued educational - behavioural programme|
79390917|NCT04483284|Drug|TACE combined with Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
79390918|NCT04483284|Procedure|TACE plus Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
79526225|NCT01393561|Drug|Group 1|Brompheniramine + phenylephrine
79526226|NCT01393561|Drug|Group 2|Placebo
79526227|NCT01393574|Drug|Melatonin|3 mg for body weight <40kg, 6 mg for body weight >40kg, once a day 30-60 minutes before sleep
79999448|NCT02673476|Drug|Placebo|Identical placebo tablets
79526228|NCT01393574|Drug|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
79526229|NCT01393587|Procedure|Taking blood samples|
79526230|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
79999449|NCT01354496|Drug|LY2409021 Reference Form|Administered orally
79999450|NCT01354496|Drug|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
79999451|NCT01354496|Drug|LY2409021 Test-High Formulation (high particle size)|Administered orally
79230339|NCT03283514|Other|Complete denture|questionnaire
79230340|NCT02737475|Drug|BMS-986178|Specified dose on specified days
79230341|NCT02737475|Drug|Nivolumab|Specified dose on specified days
79230342|NCT02737475|Drug|Ipilimumab|Specified dose on specified days
79999452|NCT01354496|Drug|LY2409021 Test-Low Formulation (low particle size)|Administered orally
79999453|NCT04164134|Other|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
79999454|NCT02259998|Drug|Persantin® new formulation|
79999455|NCT02259998|Drug|Persantin® commercial formulation|
79230343|NCT02737475|Biological|Tetanus vaccine|Specified dose on specified days
79230344|NCT02737475|Biological|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
79230345|NCT02737475|Drug|Cyclophosphamide|Specified dose on specified days
79230346|NCT03265262|Diagnostic Test|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
79825244|NCT05314335|Other|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
79825245|NCT05308225|Biological|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
79230347|NCT02459834|Other|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
79230348|NCT02459834|Other|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
79230349|NCT02459834|Other|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
79230350|NCT05488834|Other|Critical-Care Pain Observation Tool|"The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness."
79230351|NCT03280706|Dietary Supplement|Maltodextrin|Maltodextrin 50g in water 500ml
79372615|NCT05397288|Behavioral|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~1st month: group practice (1 time/week), home visits (2 times/week)~2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~3rd month: group practice (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
79372616|NCT05397288|Behavioral|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~1st month: group talk (1 time/week), individual consultation (2 times/week)~2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~3rd month: group talk (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
79372617|NCT04453644|Other|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
79372618|NCT05166174|Procedure|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
79526231|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
79526232|NCT01393652|Drug|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
79526233|NCT01393665|Drug|PENNEL capsule|"hard capsule DDB 25mg & GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
79681584|NCT05647005|Other|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
79681585|NCT05644067|Biological|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
79681586|NCT05644067|Biological|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
79681587|NCT05644067|Biological|CHMI|Controlled Human Malaria Infection (CHMI)- challenge with Plasmodium falciparum sporozoites in a sub-group of participants who received SumayaVac-1(SUM-101) or Verorab
79681588|NCT05643144|Device|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
79681589|NCT05642923|Drug|Synthetic Vitamin B1|Synthetic Vitamin B1 400 mg per day
79526234|NCT01393665|Drug|Placebo|Placebo
79526235|NCT01393678|Drug|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
79825246|NCT05303844|Drug|H101|H101 intratumorally injection starts at day 0.
79825247|NCT05303844|Drug|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79825248|NCT05297019|Procedure|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
79825249|NCT05280574|Device|GE Portrait Monitor|All patients will be monitored
79825250|NCT05280574|Device|GE Portrait Monitoring with intervened by clinician|Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
79825251|NCT05280574|Device|GE Portrait Monitoring randomized to blinded or unblinded|Without intervention
79825252|NCT05279313|Drug|Centanafadine Hydrochloride|Capsule
79825253|NCT05278364|Drug|SY-5007|a RET selective Inhibitor
79825254|NCT05277844|Radiation|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
79825255|NCT05277844|Drug|TKI|TKI
79825256|NCT05274659|Drug|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
79825257|NCT05274659|Drug|Placebo|Placebo
79230352|NCT03280706|Dietary Supplement|Orange Juice|Orange juice 480ml + 20ml of water
79230353|NCT03280706|Dietary Supplement|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
79230354|NCT05493592|Biological|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|"Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health."
79825258|NCT05274061|Behavioral|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
79230355|NCT02457806|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
79230356|NCT02457806|Drug|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
79526236|NCT01393678|Drug|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg & garlic oil 50mg ............. 1cap
79230357|NCT05493514|Device|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
79372619|NCT05396976|Behavioral|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
79372620|NCT01131052|Drug|Insulin Glargine|glargine once a day
79372621|NCT01131052|Drug|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
79372622|NCT01131052|Drug|Insulin glulisine|glulisine given as needed before meals
79526237|NCT01393691|Behavioral|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
79681590|NCT05641363|Drug|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
79681591|NCT05638139|Biological|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
79681592|NCT05636241|Other|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
79681593|NCT05636241|Other|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
79681594|NCT05636228|Drug|INV-102|INV-102 Ophthalmic Solution
79681595|NCT05636228|Drug|Vehicle|Vehicle Ophthalmic Solution
79825259|NCT05272137|Device|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
79825260|NCT05263739|Drug|ESG206|Administered via intravenous (IV) infusion
79526238|NCT01393691|Behavioral|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
79526239|NCT01393769|Drug|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
79681596|NCT05634889|Radiation|De-escalation|No regional radiotherapy. Radiotherapy towards the remaining breast after breast conserving surgery, but no radiotherapy at all after mastectomy.
79681597|NCT05624710|Drug|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
79230358|NCT02457572|Procedure|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
79230359|NCT02457572|Other|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
79230360|NCT02459756|Other|Beverage: Spray dried blackcurrant powder dissolved in water|
79230361|NCT02459756|Other|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
79230362|NCT02557672|Drug|Prothrombin complex concentrate (Human)|PCC (Kcentra)
79372623|NCT03687138|Other|24h urin sample|The samples will analyzed by proteomic techniques
79390919|NCT00235833|Biological|adalimumab|40 mg every other week (eow), subcutaneous (sc)
79390920|NCT03188952|Diagnostic Test|International Caries Classification and Management System|Caries assessment and management system
79681598|NCT05623072|Device|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
79825261|NCT05262621|Other|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
79825262|NCT05262621|Other|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
79825263|NCT05260606|Diagnostic Test|F-18 FDG PET/CT|"1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2nd scan: interim~Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3rd scan: optional (3rd scan can be performed when disease progression is suspected)~Imaging~Fasting: at least 6 hours~Blood glucose level: < 200 mg/dL~F-18 FDG 0.14 mCi/kg (IV)~Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~First and second scans have to be performed with same scan."
79825264|NCT05260164|Device|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
79825265|NCT05257538|Other|FMT|Fecal microbiota transfer from a healthy and tested volunteer
79526240|NCT01393782|Drug|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
79825266|NCT05257538|Other|placebo enema|colored water enema
79825267|NCT05249998|Other|Program combing APA, Nutrition, and Therapeutic Education|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
79825268|NCT05248672|Drug|CT1812|Study Drug
79825269|NCT05236946|Radiation|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
79825270|NCT05236946|Drug|Tyrosine kinase inhibitor|TKI
79825271|NCT05234424|Other|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
79825272|NCT05222932|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
79230363|NCT02557672|Biological|Fresh frozen plasma (FFP)|FFP
79372624|NCT01132144|Procedure|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
79825273|NCT05222932|Drug|Avelumab|Anti-PDL1 antibody
79825274|NCT05216419|Drug|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
79372625|NCT01132144|Procedure|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
79526241|NCT01393808|Drug|Paricalcitol|1-month Paricalcitol 2mcg/day
79526242|NCT01393808|Other|placebo|1-month Placebo Treatment
79526243|NCT01393834|Procedure|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
79681599|NCT05623072|Device|Sham tDCS|20 min, vmPFC Sham tDCS
79681600|NCT05618691|Drug|GFH312|Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
79999456|NCT04009460|Drug|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
79681601|NCT05618691|Other|Placebo|Placebo will be administered to subjects in the placebo group
79681602|NCT05614557|Device|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
79230364|NCT02459678|Behavioral|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
79230365|NCT02459678|Other|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
79230366|NCT03280472|Behavioral|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
79999457|NCT02035826|Behavioral|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
79230367|NCT03280472|Behavioral|Symptom tracking|Participants will track their symptoms
79372626|NCT01379274|Drug|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
79372627|NCT05389410|Device|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
79372628|NCT05389410|Device|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
79372629|NCT01171690|Drug|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
79526244|NCT01393834|Procedure|Milking of the cord|Milking of the cord 4 times in 10 seconds
79372630|NCT03153384|Procedure|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
79526245|NCT01393886|Procedure|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
79526246|NCT01393912|Drug|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
79526247|NCT01393925|Drug|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
79526248|NCT01393938|Other|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
79526249|NCT01393951|Biological|ASP7374|subcutaneous and intramuscular
79681603|NCT05614557|Device|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
79230368|NCT03267602|Device|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~older than 18 years, AHI> 15 and present obvious symptoms or~less than 18 years, AHI still> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
79230369|NCT03267446|Device|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
79230370|NCT03267992|Behavioral|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
79230371|NCT02458196|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
79230372|NCT02458196|Drug|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
79230373|NCT02502071|Drug|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
79230374|NCT03265184|Dietary Supplement|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
79526250|NCT01393977|Procedure|rehabilitation of limb function|only receive rehabilitation of limb function
79526251|NCT01393977|Procedure|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
79526252|NCT01394029|Drug|deferasirox|
79526253|NCT01394042|Device|Proxiscan device|All patients will be imaged with the device
79526254|NCT01394055|Drug|RM-131|100 μg subcutaneously once
79526255|NCT01394055|Drug|Placebo|Matching placebo volume subcutaneously once
79526256|NCT01394094|Behavioral|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
79526257|NCT01394120|Drug|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
79526258|NCT01394120|Drug|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
79526259|NCT01394133|Drug|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
79681604|NCT05607511|Other|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
79999458|NCT02035904|Drug|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
79230375|NCT05207735|Drug|Sintilimab|"Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
79825275|NCT05212714|Device|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
79825276|NCT05205863|Biological|Cofact|Human prothrombin complex concentrate
79825277|NCT05196529|Other|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
79372631|NCT02522988|Behavioral|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
79825278|NCT05196464|Behavioral|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
79825279|NCT05196464|Behavioral|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
79999459|NCT02035904|Drug|saline|patient controlled infusion from the 2nd day after surgery
79372632|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
79372633|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
79999460|NCT02035904|Drug|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
79526260|NCT01394146|Other|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
79999461|NCT02035904|Device|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
79999462|NCT02035904|Drug|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
79999463|NCT02035904|Drug|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
79999464|NCT04110080|Procedure|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
79999465|NCT04110080|Other|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
79999466|NCT04110080|Other|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
79999467|NCT04110080|Procedure|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
79230376|NCT03264950|Diagnostic Test|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
79230377|NCT03264638|Drug|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
79230378|NCT03264638|Drug|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
79526261|NCT01394224|Drug|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
79526262|NCT01394224|Drug|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
79526263|NCT01394237|Other|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
79526264|NCT01394289|Biological|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
79372634|NCT05396664|Behavioral|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
79825280|NCT05195866|Diagnostic Test|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
79999468|NCT04110080|Procedure|regional anesthesia|transabdominal plane and rectus sheath nerve block
79999469|NCT03562520|Behavioral|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
79999470|NCT02035982|Drug|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
79526265|NCT01394341|Drug|Liraglutide|Daily sc. injection, individual dosage
79526266|NCT01394354|Drug|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
79230379|NCT03264638|Drug|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
79526267|NCT01394354|Drug|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
79681605|NCT05606874|Other|Pre-heating of flowable resin composite used as a pit and fissure sealant.|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
79681606|NCT05606874|Other|Conventional resin fissure sealant|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
79230380|NCT05741801|Other|interviews|observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
79372635|NCT05389254|Device|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
79372636|NCT05389254|Device|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
79681607|NCT05602389|Other|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
79372637|NCT01132378|Procedure|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
79372638|NCT05389176|Drug|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
79372639|NCT05396508|Procedure|interfacial injection|10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
79526268|NCT01394354|Drug|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
79526269|NCT01394354|Drug|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
79526270|NCT01394367|Other|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
79681608|NCT05602389|Other|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
79999471|NCT02035982|Drug|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
79230381|NCT02714426|Behavioral|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
79372640|NCT05396508|Procedure|physical therapy|protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
79372641|NCT01132690|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
79526271|NCT01394380|Other|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
79526272|NCT01394393|Behavioral|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, & Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
79681609|NCT05602389|Other|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
79681610|NCT05601596|Diagnostic Test|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
79681611|NCT05600244|Procedure|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
79825281|NCT05192226|Behavioral|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
79999472|NCT05707832|Drug|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
79526273|NCT01394393|Behavioral|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper & Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
79372642|NCT05380830|Other|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
79999473|NCT02822222|Drug|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
79372643|NCT05396274|Device|High Flow Nasal Cannula|high flow nasale cannula
79372644|NCT04454034|Procedure|arthroscopic synovectomy|arthroscopic synovectomy
79372645|NCT01132846|Other|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
79681612|NCT05600244|Procedure|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
79681613|NCT05600244|Procedure|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
79999474|NCT02822222|Drug|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
79999475|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
79999476|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
79372646|NCT01132846|Drug|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
79999477|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
79999478|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
79999479|NCT02821910|Drug|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
79372647|NCT01132846|Drug|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
79372648|NCT03130608|Other|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
79526274|NCT01394393|Dietary Supplement|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
79526275|NCT01394406|Drug|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
79681614|NCT05596916|Other|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
79681615|NCT05596916|Other|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
79681616|NCT05595083|Drug|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
79681617|NCT05595083|Drug|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
79681618|NCT05594043|Drug|MK-6598|Oral tablet
79681619|NCT05594043|Biological|Pembrolizumab|Intravenous (IV) infusion
79681620|NCT05591703|Behavioral|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
79999480|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
79999481|NCT03819452|Diagnostic Test|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
79999482|NCT05707910|Biological|EBV immunological agent|Low-dose group:2*10^7 Medium-dose group:5*10^7 High-dose group:2*10^8
79999483|NCT05707676|Drug|LB4330|LB4330
79999484|NCT03972956|Other|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
79230382|NCT02714426|Other|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
79526276|NCT01394406|Drug|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
79526277|NCT01394419|Drug|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
79681621|NCT05588427|Dietary Supplement|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
79681622|NCT05588427|Dietary Supplement|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
79681623|NCT05585710|Other|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
79681624|NCT05585710|Procedure|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
79230383|NCT04500821|Device|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
79230384|NCT03264794|Drug|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
79230385|NCT03264794|Drug|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
79230386|NCT03264794|Drug|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
79372649|NCT05396196|Device|Kinesio® Tape|Manual Fascial Glide Application
79372650|NCT01173016|Drug|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
79372651|NCT05165784|Procedure|femoral vein identification|Femoral vein identification using V technique
79372652|NCT05165784|Procedure|femoral vein identification|Femoral vein identification using palpation technique
79526278|NCT01394419|Drug|Saline|Equal volume of normal saline
79681625|NCT05585710|Procedure|Bilateral or unilateral mastectomy|Standard of care
79999485|NCT02817776|Device|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
79999486|NCT03138655|Drug|Vedolizumab|Vedolizumab IV infusion.
79999487|NCT02036138|Procedure|Laparoscopic Sleeve Gastrectomy|
79999488|NCT02036138|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
79999489|NCT02036138|Drug|Advanced Medical Therapy|
79999490|NCT03562442|Behavioral|Smoking cessation|Smoking cessation with or without professional / medical support
79999491|NCT05707520|Drug|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
79999492|NCT05707520|Drug|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
79999493|NCT04412785|Drug|Cyclosporine|• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
79999494|NCT03689101|Procedure|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
79999495|NCT02820038|Behavioral|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
79230387|NCT02925923|Drug|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
79230388|NCT02925923|Drug|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
79526279|NCT01394432|Procedure|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
79526280|NCT01394445|Drug|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
79372653|NCT04215900|Behavioral|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
79526281|NCT01394445|Drug|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
79526282|NCT01394458|Other|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
79999496|NCT02820038|Behavioral|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
79999497|NCT02820038|Behavioral|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
79526283|NCT01394458|Drug|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
79526284|NCT01394471|Drug|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
79999498|NCT01348867|Other|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
79999499|NCT01352611|Drug|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
79999500|NCT01352689|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
79999501|NCT01352689|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
79999502|NCT03688399|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
79999503|NCT03688399|Device|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
79999504|NCT01357213|Drug|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
79230389|NCT02925923|Drug|Clopidogrel|
79230390|NCT03267368|Behavioral|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
79999505|NCT01357213|Other|Placebo|Normal saline 100 ml
79999506|NCT01348945|Other|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
79999507|NCT01357291|Behavioral|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
79526285|NCT01394484|Other|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
79999508|NCT01357291|Behavioral|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
79372654|NCT01133158|Drug|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
79372655|NCT03109626|Dietary Supplement|DHA|
79372656|NCT01133860|Drug|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
79372657|NCT04455516|Procedure|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
79372658|NCT05372406|Other|• no intervention|• no intervention
79372659|NCT01134016|Drug|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
79372660|NCT04819074|Procedure|Microsurgery|Microsurgery for unruptured intracranial aneurysm
79372661|NCT01173874|Drug|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
79526286|NCT01394484|Dietary Supplement|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
79526287|NCT01394497|Drug|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
79526288|NCT01394536|Device|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
79526289|NCT01394536|Device|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
79526290|NCT01394562|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
79526291|NCT01394562|Other|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
79526292|NCT01394575|Radiation|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
79526293|NCT01394588|Device|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
79526294|NCT01394653|Drug|YM060|oral, with water
79526295|NCT01394679|Drug|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
79526296|NCT01394679|Drug|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
79526297|NCT01394731|Drug|Acetaminophen|
79230391|NCT03267290|Diagnostic Test|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
79230392|NCT03280316|Procedure|surgery|patients with SVMs receive surgery
79526298|NCT01394731|Drug|Meperidine|
79999509|NCT01352767|Device|InsuPad|Heating pad
79999510|NCT02819804|Drug|Dasatinib|Given PO
79999511|NCT02819804|Other|Laboratory Biomarker Analysis|Correlative studies
79999512|NCT02819804|Biological|Nivolumab|Given IV
79999513|NCT02819804|Other|Pharmacological Study|Correlative studies
79230393|NCT03280316|Procedure|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
79230394|NCT03280316|Procedure|botulinum toxin A injection|BOTOX
79230395|NCT03280316|Drug|M receptor antagonist|Tolterodine
79230396|NCT02410343|Drug|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
79230397|NCT02410343|Drug|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
79825283|NCT05187195|Other|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
79825284|NCT05187195|Other|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
79825285|NCT05177770|Drug|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
79825286|NCT05177770|Drug|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
79372662|NCT04815798|Combination Product|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
79372663|NCT04815798|Combination Product|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
79372664|NCT04815798|Procedure|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
79372665|NCT05391282|Other|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
79372666|NCT05337384|Diagnostic Test|Sonography|Sonographic Venous Doppler Imaging
79825287|NCT05177770|Drug|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
79372667|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
79372668|NCT01174030|Drug|Vehicle Gel|Vehicle Gel QD
79526299|NCT01394757|Drug|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
79825288|NCT05175313|Radiation|transthoracic ultrasonography|"lung ultrasonography~Diaphragm and respiratory muscle ultrasound~inferior vena cava ultrasound"
79825289|NCT05175313|Device|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
79372669|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
79372670|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
79372671|NCT01174030|Drug|Vehicle Gel|Vehicle Gel BID
79372672|NCT01174576|Other|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
79526300|NCT01394770|Drug|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
79526301|NCT01394783|Device|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
79825290|NCT05175053|Other|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
79230398|NCT03267056|Device|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
79230399|NCT03264872|Behavioral|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
79372673|NCT04641936|Other|No intervention required|No intervention required
79372674|NCT01134328|Drug|AC-150 Combo|1 drop in each eye for up to 14 days
79681626|NCT05585710|Device|Tissue expander|Standard of care
79999514|NCT02819726|Biological|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
79372675|NCT01134328|Drug|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
79372676|NCT01134328|Drug|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
79372677|NCT01134328|Drug|Vehicle|1 drop in each eye once per day for up to 14 days
79372678|NCT04636554|Other|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
79681627|NCT05585710|Other|Acellular dermal matrix|Standard of care
79681628|NCT05581173|Device|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
79681629|NCT05570630|Behavioral|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
79681630|NCT05570630|Other|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
79825291|NCT05175053|Other|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
79825292|NCT05150626|Drug|DBPR108 tablets|Drug: DBPR108, tablets, oral
79825293|NCT05149625|Device|Dexcom G6|continuous glucose monitoring device
79372679|NCT05165004|Behavioral|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
79681631|NCT05566262|Drug|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
79681632|NCT05565443|Device|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
79825294|NCT05144737|Behavioral|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
79825295|NCT05138250|Drug|Mepolizumab 100 MG|participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
79372680|NCT05165004|Behavioral|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
79825296|NCT05128409|Drug|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
79372681|NCT05165004|Behavioral|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
79372682|NCT04622124|Drug|Placebo|
79372683|NCT04622124|Dietary Supplement|fasted vs. high-fat meal|
79372684|NCT04622124|Drug|Placebo|
79372685|NCT01134952|Drug|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
79526302|NCT01394783|Device|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
79526303|NCT01394796|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
79825297|NCT05128409|Drug|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
79825298|NCT05126927|Biological|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
79372686|NCT03130686|Device|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
79372687|NCT04590222|Other|blood sample|One blood sample of 60 mL (EDTA)
79526304|NCT01394796|Drug|Placebo|No active treatment is given.
79526305|NCT01394809|Behavioral|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
79825299|NCT05126524|Other|NO INTERVENTION|Observational study, no intervention performed
79825300|NCT05121454|Device|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
79825301|NCT05118568|Device|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
79825302|NCT05117034|Drug|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
79230400|NCT03264872|Other|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
79230401|NCT03264716|Device|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
79230402|NCT03064841|Drug|No Treatment|No treatment
79230403|NCT02457416|Other|Peanut|Treatment with peanut in increasing doses until a maintenance dose
79230404|NCT03280238|Diagnostic Test|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
79526306|NCT01394835|Drug|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
79526307|NCT01394835|Drug|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
79526308|NCT01394835|Drug|AAT|Inhalation twice daily' 160mg
79526309|NCT01394848|Device|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
79526310|NCT01394848|Device|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
79526311|NCT01394848|Drug|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
79526312|NCT01394848|Drug|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
79681633|NCT05563155|Drug|Dexamethasone 24 mg|Dexamethasone 24 mg on day 1 after surgery.
79681634|NCT05563155|Drug|Placebo|Placebo tablet given on day 1 after surgery.
79681635|NCT05556655|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
79681636|NCT05552859|Drug|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
79681637|NCT05552859|Drug|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
79825303|NCT05117034|Drug|Nacl 0.9%|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
79999515|NCT02819726|Biological|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
79372688|NCT01175434|Other|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
79372689|NCT01175902|Drug|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
79372690|NCT01175902|Drug|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
79372691|NCT05384730|Other|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
79372692|NCT01135186|Drug|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
79999516|NCT02819726|Biological|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
79372693|NCT05379114|Other|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
79372694|NCT05379114|Other|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
79372695|NCT05376228|Drug|Oral Vancomycin|As part of standard of care
79526313|NCT01394861|Device|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
79526314|NCT01394874|Behavioral|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
79999517|NCT02816138|Drug|Nicotine|Open-label transdermal nicotine patch
79526315|NCT01394887|Drug|Metformin|850 mg of metformin twice daily over 12 weeks
79526316|NCT01394887|Drug|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
79526317|NCT01394913|Drug|Reumatocept (etanercept)|50mg each week for 30 weeks
79526318|NCT01394913|Drug|Enbrel (etanercept)|50mg each week for 30 weeks
79526319|NCT01394965|Procedure|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
79526320|NCT01395069|Drug|Nepafenac 0.1%|1 drop QID for 1 month
79526321|NCT01395069|Drug|Ketorolac 0.5%|1 drop QID for 1 month
79681638|NCT05544240|Drug|SV-101|SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
79681639|NCT05544227|Drug|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
79681640|NCT05754710|Drug|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
79999518|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
79999519|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
79999520|NCT02815670|Drug|Idarucizumab|
79372696|NCT05164848|Drug|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
79372697|NCT05164848|Drug|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
79526322|NCT01395069|Other|Placebo (sterile saline drops)|1 drop QID for 1 month
79526323|NCT01395095|Other|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
79526324|NCT01395095|Other|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
79526325|NCT01395095|Other|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
79526326|NCT01395108|Drug|Nemonoxacin|oral once daily
79526327|NCT01395121|Drug|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
79526328|NCT01395134|Device|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
79681641|NCT05540353|Device|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
79681642|NCT05540353|Device|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
79681643|NCT05535153|Other|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
79372698|NCT05164770|Drug|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX|"Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
79372699|NCT05164770|Drug|R-CHOP; R-DA-EPOCH; R-HD MTX|"R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
79372700|NCT05374668|Behavioral|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
79526329|NCT01395147|Drug|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
79526330|NCT01395173|Procedure|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
79681644|NCT05534152|Other|sumac|1% iranian brown sumac
79681645|NCT05532397|Drug|QPOP category 1|combination regimens with published data in the setting of gliomas
79681646|NCT05532397|Drug|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
79372701|NCT05164692|Combination Product|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
79372702|NCT05164692|Drug|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
79372703|NCT01922583|Drug|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
79372704|NCT01922661|Drug|REGN1908-1909|
79681647|NCT05529459|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
79681648|NCT05527769|Procedure|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
79825304|NCT05110105|Behavioral|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2~6 individuals) for 40 minutes.
79825305|NCT05110105|Behavioral|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
79825306|NCT05109078|Drug|[14C]- Rongliflozin|Patients will receive single dose of orally [14C]- Rongliflozin on Day 1
79372705|NCT01922661|Other|placebo|
79825307|NCT05108766|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
79825308|NCT05108766|Drug|Placebo|Matching placebo to tildrakizumab administered SC
79825309|NCT05106777|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
79372706|NCT05090982|Other|Audio recordings during the consultations|50 patients with audio recordings of the consultation
79372707|NCT05090982|Other|Audio recordings during the consultations and test of the shared medical decision-making tool for modification|50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
79372708|NCT05090982|Other|Audio recordings during the consultations and test of the shared medical decision-making tool for validation|50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
79526331|NCT01395173|Procedure|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
79526332|NCT01395186|Procedure|varicocelectomy|varicocelectomy for painful varicocele
79825310|NCT05096208|Biological|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
79825311|NCT05096208|Biological|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
79825312|NCT05096208|Biological|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
79825313|NCT05096208|Biological|Placebo|Placebo
79825314|NCT05093920|Drug|Doxorubicin-Eluting Beads|"The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
79526333|NCT01395199|Drug|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
79681649|NCT05526586|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
79681650|NCT05526586|Other|Zero Alcohol Gum Prototype|Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
79681651|NCT05526586|Other|Alcohol Gum Prototype|Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
79681652|NCT05526586|Other|Listerine Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
79681653|NCT05526586|Other|5% Hydroalcohol|Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
79681654|NCT05525741|Other|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~Inform the subject of the goals, constraints and risks of the study and obtain written consent.~Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
79825315|NCT05089318|Dietary Supplement|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
79825316|NCT05077982|Diagnostic Test|Spirometry|Spirometry to assess lung function
79526334|NCT01395238|Behavioral|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
79681655|NCT05525741|Other|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~Inform the subject of the goals, constraints and risks of the study and obtain written consent.~Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
79681656|NCT05524545|Drug|Evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
79681657|NCT05524545|Drug|Enfortumab Vedotin|Nectin-4 directed antibody and microtubule inhibitor conjugate
79681658|NCT05524454|Device|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
79681659|NCT05516888|Procedure|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
79681660|NCT05516888|Procedure|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
79825317|NCT05077982|Diagnostic Test|6-minute walk|Exercise tolerance
79825318|NCT05069727|Procedure|Regular Protocol with advanced carbohydrate counting|"Review 3 Days CGM data in Manual Mode~Carb Ratio by formula 360 / TDD~Finetune ICR~Target 100 or 110 mg/dl~AIT: 2-3 hour~Insulin Bolus for meal (advanced carb counting)~The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
79825319|NCT05069727|Procedure|Simplified Protocol with fixed carbohydrate content|"Review 3 Days CGM data in Manual Mode~Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD >60)~Target 100 mg/dl~AIT: 2 hours~Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
79825320|NCT05064358|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered.
79825321|NCT05060471|Drug|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
79825322|NCT05052879|Drug|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
79825323|NCT05052879|Drug|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
79825324|NCT05052879|Other|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
79526335|NCT01395251|Drug|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
79526336|NCT01395290|Drug|cholecalciferol|20.000 IU per week, oral
79526337|NCT01395342|Other|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
79999521|NCT02037152|Behavioral|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
79681661|NCT05509608|Device|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
79999522|NCT02036918|Drug|Sipuleucel-T|
79999523|NCT02036918|Procedure|Lymph Node Biopsy|
79230405|NCT03280082|Other|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
79230406|NCT03280082|Other|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
79372709|NCT05370222|Behavioral|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
79372710|NCT00634569|Biological|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
79526338|NCT01395355|Behavioral|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
79526339|NCT01395355|Behavioral|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
79526340|NCT01395381|Drug|Placebo|placebo given once
79681662|NCT05509608|Device|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
79681663|NCT05497843|Drug|Chiauranib|50mg, orally once daily
79681664|NCT05496673|Diagnostic Test|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
79681665|NCT05496673|Diagnostic Test|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
79681666|NCT05496673|Diagnostic Test|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
79999524|NCT02809976|Drug|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
79230407|NCT02045303|Device|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
79230408|NCT02045303|Device|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
79230409|NCT05234840|Drug|platelet rich plasma|1. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
79230410|NCT05234840|Drug|Triamcinolone|40 mg triamcinolone with 1% lidocaine, total of 2 ml
79526341|NCT01395381|Drug|Albendazole|single dose albendazole given at the time of enrollment
79526342|NCT01395407|Radiation|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~21 18 15~23 20 17~25 22 19"
79999525|NCT02036528|Drug|Gentamicin Topical Gel|
79999526|NCT02036528|Drug|Ciprofloxacin|
79999527|NCT02036528|Drug|Doxycycline|
79526343|NCT01395420|Drug|CAZ104|IV Infusion
79681667|NCT05488626|Device|Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
79681668|NCT05488626|Device|Non-Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
79681669|NCT05488626|Drug|Chemotherapy|Concomitant chemotherapy per NCCN or other national guidelines.
79681670|NCT05488626|Drug|Immunotherapy|Adjuvant immunotherapy per national or institutional guidelines.
79230411|NCT03264482|Procedure|M-TURP|endoscopic resection of the prostatic adenoma
79526344|NCT01395420|Drug|CAZ104|IV Infusion
79526345|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
79526346|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
79999528|NCT02047682|Behavioral|Biopsychosocial|
79999529|NCT02047682|Behavioral|Reference|
79999530|NCT02880865|Biological|Live attenuated SA 14-14-2 Japanese Encephalitis vaccine|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
79999531|NCT02880865|Biological|Measles, mumps, rubella vaccine|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
79825325|NCT05052879|Other|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
79999532|NCT01352923|Other|blood test|preparation of blood platelets
79999533|NCT03635125|Drug|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
79999534|NCT03635125|Drug|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
79999535|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
79999536|NCT01854385|Drug|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
79999537|NCT02809118|Drug|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
79999538|NCT02809118|Drug|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
79230412|NCT03264482|Procedure|THUVAP|vaporization of prostatic adenoma via THULIUM laser
79230413|NCT03266744|Diagnostic Test|Computerised Tomography|
79372711|NCT04396353|Other|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
79372712|NCT01175980|Other|Laboratory Biomarker Analysis|Correlative studies
79372713|NCT01175980|Drug|Vorinostat|Given PO
79372714|NCT04246554|Drug|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
79372715|NCT04246554|Drug|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
79372716|NCT01922817|Drug|Saxagliptin|5mg saxagliptin
79372717|NCT04275765|Behavioral|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
79372718|NCT04275765|Other|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
79681671|NCT05486338|Device|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
79825326|NCT05049707|Drug|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
79825327|NCT05049707|Other|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
79825328|NCT05043805|Drug|Dextromethorphan|add on therapy
79825329|NCT05043805|Other|placebo|add on therapy
79825330|NCT05033483|Dietary Supplement|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
79825331|NCT05033483|Dietary Supplement|Placebo|Gelatin capsule containing microcrystalline cellulose
79825332|NCT05026047|Other|HPV self-sampling|HPV self-sampling in HIV-positive women
79825333|NCT05013918|Other|Observational study|No intervention
79999539|NCT02809118|Other|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
79999540|NCT01353001|Behavioral|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
79999541|NCT01353001|Behavioral|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
79999542|NCT01353001|Behavioral|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
79230414|NCT03266744|Diagnostic Test|Whole Body Magnetic Resonance Imaging|
79230415|NCT03266744|Diagnostic Test|Bone scan|
79230416|NCT05740163|Dietary Supplement|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
79230417|NCT03266822|Other|No intervention|Observational study
79230418|NCT03280004|Drug|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
79372719|NCT05697432|Diagnostic Test|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
79681672|NCT05485415|Behavioral|Multimodal intervention|Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
79681673|NCT05485415|Behavioral|Control|General sleep advice
79681674|NCT05484258|Behavioral|Shared Medical Visit|Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
79230419|NCT05759585|Behavioral|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
79825334|NCT05008185|Procedure|Regenerative Peripheral Nerve Interface (RPNI) surgery|Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision
79999543|NCT01349023|Other|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
79372720|NCT05697432|Diagnostic Test|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
79825335|NCT05008185|Procedure|Traction Neurectomy|Surgeons will perform neuroma resection and traction neurectomy,
79825336|NCT05007964|Device|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
79999544|NCT02036606|Behavioral|questionary|
79681675|NCT05482919|Behavioral|Baseline Survey|The baseline survey, initial PHQ-9 and GAD-7, could be collected prior to surgery after consent, or on the day of surgery, for participants who are undergoing elective surgery or urgent procedures and did not attend pre-operative clinic. Demographic information such as race and ethnicity, pain medications and pain history and baseline self-reported health information will be collected. It will take about 15 minutes to complete.
79230420|NCT03279068|Other|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
79230421|NCT03628937|Dietary Supplement|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
79999545|NCT02047838|Other|Anti-mullerian hormone (AMH) level dosage.|
79999546|NCT02047838|Other|Follicle-stimulating hormone (FSH) level dosage.|
79372721|NCT05697432|Diagnostic Test|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
79372722|NCT05697432|Diagnostic Test|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
79372723|NCT05697432|Behavioral|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
79372724|NCT01176448|Device|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
79681676|NCT05482919|Behavioral|Post Operative Surveys|Post operative surveys will be collected at one week, two weeks, one month, then monthly up to 6 months after surgery with total of 7 post-op surveys. Refer to Table 1 for visit windows. The study survey could be collected by phone, REDCap texting or email per the subject's preference. Survey content will also include: daily average and maximum self-reported pain scores on a 0-10 Numeric Rating Scale (NRS) pain scale, average hours of sleep, anxiety and depression screens using the PHQ-9 and GAD-7 questionnaires (Months 1, 3, and 5), pain location and quality, percentage of day spent in pain, satisfaction with recovery using a five-point Likert scale, and type, quantity and timing of any medications used for pain (including opioid alternatives).
79825337|NCT04997187|Dietary Supplement|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
79825338|NCT04997187|Dietary Supplement|Control group|Placebo 400 mg/day for 12 weeks
79999547|NCT02047838|Other|Antral follicle count (AFC).|
79999548|NCT01318681|Drug|cetirizine 10 mg|cetirizine 10 mg over encapsulated
79999549|NCT01318681|Drug|fluticasone furoate|nasal spray 25ug per dose
79999550|NCT01318681|Drug|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
79999551|NCT02036684|Behavioral|Prehabilitation (PREHAB)|
79230422|NCT03628937|Other|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
79999552|NCT03562286|Procedure|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
79999553|NCT03604159|Drug|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
79999554|NCT03604159|Drug|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
79999555|NCT03686930|Drug|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
79230423|NCT03266666|Behavioral|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
79372725|NCT01176448|Device|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
79372726|NCT04275609|Other|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
79825339|NCT04992247|Biological|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
79825340|NCT04992247|Biological|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
79825341|NCT04986501|Device|MucoPEG|Experimental
79825342|NCT04986501|Device|Biotene|Active Comparator
79825343|NCT04982913|Drug|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
79825344|NCT04981899|Drug|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
79825345|NCT04981899|Drug|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
79825346|NCT04981899|Drug|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
79825347|NCT04981899|Drug|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
79825348|NCT04967872|Other|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
79825349|NCT04960059|Other|No intervention|This is an observational study
79825350|NCT04956887|Behavioral|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
79825351|NCT04956887|Other|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
79230424|NCT03266666|Other|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
79230425|NCT03266510|Other|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
79709730|NCT02271074|Other|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
79825352|NCT04956081|Device|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
79825353|NCT04955600|Other|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
79825354|NCT04929600|Drug|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
79825355|NCT04929600|Drug|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
79825356|NCT04925648|Drug|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
79230426|NCT03266510|Other|Sham training|Subjects will perform sham training for 6 weeks.
79230427|NCT05214521|Device|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
79825357|NCT04925648|Drug|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
79825358|NCT04910295|Drug|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
79825359|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
79230428|NCT03264326|Other|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
79230429|NCT03264326|Other|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
79230430|NCT03264326|Other|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
79230431|NCT05189951|Other|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
79230432|NCT05189951|Other|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
79230433|NCT05189951|Other|circular+vertical motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
79230434|NCT02459444|Device|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
79230435|NCT02459444|Other|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
79526347|NCT01395433|Drug|Escitalopram|1 x 20 mg, single dose
79526348|NCT01395459|Behavioral|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
79526349|NCT01395459|Behavioral|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
79526350|NCT01395472|Behavioral|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
79526351|NCT01395472|Behavioral|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
79526352|NCT01395485|Drug|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
79681677|NCT05482919|Behavioral|Qualitative Interviews|Using sampling to identify adolescents who exhibit higher pain scores or prolonged opioid use compared to peers after completion of the first three surveys (pre-operative, Week 1, Week 2), the study will also select a representative sample of adolescents who are recovering as anticipated. Examples of delayed recovery include a higher proportion of moderate to severe pain scores, dissatisfaction with recovery and prolonged opioid use compared to peers. As a balancing measure, the upper limit of adolescents who are perceived to exhibit delayed recovery that are approached for interviews will be capped at a 3:1 ratio compared to those who are recovering as anticipated, and Investigators will prioritize an equal demographic distribution among the two groups. Interviews will take place over the phone or through a CHOP approved vendor at 1 and 3 months after surgery; audio will be recorded with participant consent.
79999556|NCT03686930|Drug|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
79999557|NCT03686930|Drug|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
79999558|NCT03686930|Drug|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
79999559|NCT01353235|Drug|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
79372727|NCT04275609|Other|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
79526353|NCT01395498|Other|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
79372728|NCT04275921|Diagnostic Test|MRI scan|MRI analysis using TWIST and HASTE
79372729|NCT04275921|Diagnostic Test|4D MRI|4D MRI alongside 4D CT in lung cancer
79526354|NCT01395511|Device|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 * 40 (mm) / SJ 0.18 * 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
79526355|NCT01395563|Behavioral|strength training|strength training, high intensity, twice up to 3 times per week
79372730|NCT05350644|Other|Primary exposure variable|"Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
79372731|NCT05350644|Other|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
79372732|NCT04397289|Drug|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
79526356|NCT01395576|Device|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
79526357|NCT01395589|Drug|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
79526358|NCT01395602|Drug|Cabergoline|cabergoline 0.5 mg twice weekly
79825360|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
79999560|NCT01353235|Drug|usual care|no drug administered
79999561|NCT02048228|Drug|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
79999562|NCT02048228|Drug|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
79526359|NCT01395602|Other|placebo|1 pill twice weekly
79526360|NCT01395628|Drug|in vitro sensitivity-directed chemotherapy|
79526361|NCT01395628|Other|cell proliferation assay|
79526362|NCT01395628|Other|fluorescence activated cell sorting|
79526363|NCT01395628|Other|laboratory biomarker analysis|
79526364|NCT01395628|Other|microscopy|
79526365|NCT01395654|Drug|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
79526366|NCT01395667|Other|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
79681678|NCT05477888|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
79681679|NCT05477381|Diagnostic Test|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
79681680|NCT05474846|Drug|Melatonin|Given by PO
79681681|NCT05474846|Other|Placebo for Melatonin|Given by PO
79681682|NCT05474846|Drug|Melatonin|Given by PO
79681683|NCT05474846|Drug|Methylphenidate|Given by PO
79681684|NCT05474586|Other|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
79709731|NCT00595218|Behavioral|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
79999563|NCT01349179|Device|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
79230436|NCT03264170|Diagnostic Test|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
79681685|NCT05474586|Other|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
79999564|NCT05701046|Procedure|Interbody fusion surgery|Interbody fusion surgery
79999565|NCT03046927|Drug|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
79999566|NCT03046927|Other|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
79230437|NCT03277976|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
79230438|NCT03277976|Device|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
79526367|NCT01395693|Device|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
79230439|NCT03266120|Other|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
79372733|NCT01135420|Behavioral|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
79372734|NCT01135420|Other|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
79526368|NCT01395706|Procedure|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
79681686|NCT05474586|Other|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
79372735|NCT04396275|Other|Food-1|Cooked whole navy beans (300 kcal)
79372736|NCT04396275|Other|Food-2|Cooked whole yellow split peas (300 kcal)
79372737|NCT04396275|Other|Food-3|Cooked rice considered as control (300 kcal)
79372738|NCT05697354|Procedure|Cognitive rehabilitation using interactive tablet|the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
79526369|NCT01395719|Other|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
79526370|NCT01395732|Drug|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
79681687|NCT05473039|Dietary Supplement|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
79681688|NCT05473039|Other|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
79999567|NCT02036762|Other|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
79999568|NCT01357369|Procedure|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
79999569|NCT02037308|Dietary Supplement|Bread|
79999570|NCT01349257|Drug|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
79526371|NCT01395745|Drug|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
79526372|NCT01395745|Drug|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
79681689|NCT05472090|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
79681690|NCT05472090|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
79681691|NCT05470504|Drug|Pegvisomant|30 mg subcutaneously every day for 4 weeks.
79681692|NCT05470413|Drug|SHR0302|SHR0302 4 mg
79681693|NCT05470413|Drug|SHR0302|SHR0302 8 mg
79681694|NCT05470413|Drug|Placebo|Placebo
79825361|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
79681695|NCT05467488|Procedure|photofunctionalization|UVA and UVC photofunctionalization of dental implants
79825362|NCT04906174|Other|Electronic Health Record Review|Medical records are reviewed
79825363|NCT04899479|Drug|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
79999571|NCT03813446|Device|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
79999572|NCT03589105|Drug|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
79999573|NCT03589105|Drug|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
79999574|NCT03813368|Procedure|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
79230440|NCT03266120|Other|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
79230441|NCT01841333|Drug|PF-04449913|100mg given orally
79230442|NCT03277742|Behavioral|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
79230443|NCT03277742|Drug|Standard of care|DOTS plus standard DM2 care
79230444|NCT03266354|Procedure|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
79230445|NCT03619967|Device|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
79230446|NCT03266432|Other|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
79526373|NCT01395771|Behavioral|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
79681696|NCT05461352|Drug|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
79230447|NCT05234918|Device|Pediatric Rotary File Systems|"Kedo S plus (p1 molar file ) (A1 anterior file)~Kidzo-file system 25/4 30/4 30/6"
79230448|NCT02459288|Drug|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
79526374|NCT01395849|Drug|Salmeterol and Fluticasone|
79681697|NCT05461352|Drug|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
79681698|NCT05457985|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
79681699|NCT05457985|Behavioral|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
79230449|NCT02459288|Drug|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
79526375|NCT01395862|Drug|Salmeterol and Fluticasone|
79526376|NCT01395875|Drug|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
79526377|NCT01395875|Drug|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium [IPR]).
79681700|NCT05457985|Behavioral|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
79825364|NCT04899479|Other|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
79825365|NCT04895293|Drug|RBM-007 Injectable Solution|Sterile solution
79825366|NCT04861844|Behavioral|mindfulness training|phone based mindfulness training on 4 consecutive days
79825367|NCT04861844|Behavioral|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
79526378|NCT01395927|Drug|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
79681701|NCT05450133|Other|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
79681702|NCT05450133|Other|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
79681703|NCT05450133|Other|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
79681704|NCT05450133|Other|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
79681705|NCT05450133|Other|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
79825368|NCT04861415|Radiation|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
79999575|NCT02048306|Behavioral|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
79999576|NCT02048306|Behavioral|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
79999577|NCT01357447|Drug|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
79230450|NCT03064451|Procedure|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
79230451|NCT00734253|Drug|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
79230452|NCT00734253|Drug|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
79681706|NCT05447221|Diagnostic Test|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
79681707|NCT05444361|Device|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
79681708|NCT05444361|Device|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
79681709|NCT05437679|Other|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
79709732|NCT00595218|Other|Patient Preference Results|Knowledge of Patient Preference Results
79709733|NCT01606397|Drug|Placebo|Administered orally (capsule)
79709734|NCT01606397|Drug|LY2409021|Administered orally (capsule)
79825369|NCT04861415|Radiation|Conventionally Fractionated Radiation|External beam radiation therapy treatment
79825370|NCT04859426|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
79825371|NCT04852367|Device|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
79230453|NCT00734253|Drug|Placebo|Placebo capsules taken twice a day for 1-year
79230454|NCT00730665|Drug|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
79230455|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
79230456|NCT00730665|Drug|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
79230457|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
79825372|NCT04852367|Drug|Doxorubicin|Doxorubicin infusion
79825373|NCT04852367|Drug|ThermoDox|ThermoDox infusion
79825374|NCT04850703|Device|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
79825375|NCT04850703|Drug|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
79999578|NCT01357447|Drug|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
79999579|NCT02048384|Drug|metformin alone (Arm A)|metformin alone
79999580|NCT02048384|Drug|metformin (Arm B)|rapamycin + metformin
79999581|NCT02048384|Drug|rapamycin (Arm B)|rapamycin + metformin
79999582|NCT01353391|Drug|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
79999583|NCT01353391|Drug|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
79999584|NCT01349335|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
79999585|NCT01349335|Drug|Tolvaptan|tablet, 30 mg, Qd, 7 days
79230458|NCT00730665|Drug|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
79526379|NCT01395927|Drug|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
79681710|NCT05434117|Behavioral|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
79681711|NCT05434117|Behavioral|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
79825376|NCT04850703|Combination Product|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
79526380|NCT01395940|Drug|KLH-2109|
79681712|NCT05419284|Other|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~+ 3 extra exercise sessions led by a caregiver (+Care)"
79681713|NCT05419284|Other|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
79999586|NCT01349335|Drug|placebo|tablet, 30 mg, Qd, 7days.
79526381|NCT01395940|Drug|KLH-2109|
79526382|NCT01395953|Drug|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
79999587|NCT03040921|Procedure|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
79999588|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
79999589|NCT03009487|Drug|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
79999590|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
79681714|NCT05419284|Other|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
79999591|NCT02048540|Biological|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
79999592|NCT02048540|Drug|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
79999593|NCT02048540|Procedure|Gastrectomy|
79999594|NCT01353469|Drug|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
79681715|NCT05411718|Drug|Naproxen|Given by PO
79681716|NCT05411718|Drug|Aspirin|Given by PO
79681717|NCT05408572|Biological|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
79825377|NCT04850703|Diagnostic Test|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
79825378|NCT04843787|Drug|SLV213|SLV213 oral capsule (200mg) BID
79825379|NCT04843787|Drug|SLV213|SLV213 oral capsule (400mg) BID
79825380|NCT04843787|Drug|SLV213|SLV213 oral capsule (800mg) QD
79825381|NCT04843787|Drug|Placebo|Placebo oral capsule (200mg) BID
79999595|NCT01353469|Drug|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
79999596|NCT03562208|Biological|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
79825382|NCT04843787|Drug|Placebo|Placebo oral capsule (400mg) BID
79825383|NCT04843787|Drug|Placebo|Placebo oral capsule (800mg) QD
79825384|NCT04836520|Drug|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
79825385|NCT04807231|Biological|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
79999597|NCT03562130|Drug|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
79999598|NCT02050178|Drug|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
79999599|NCT02050256|Other|continuing medical education and electronic decision support|
79999600|NCT02050256|Other|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
79681718|NCT05404230|Dietary Supplement|Fish oil|Fish oil containing poly unsaturated fatty acids.
79999601|NCT02037074|Drug|Drug: EVP-6308|Arms 1, 2, 3
79999602|NCT02037074|Drug|Placebo|Arm 4
79999603|NCT02048618|Drug|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
79999604|NCT02048618|Drug|Placebo|placebo oral tablets, intake once daily for 20 weeks
79825386|NCT04806399|Other|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
79825387|NCT04802070|Drug|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
79825388|NCT04797143|Device|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
79825389|NCT04791956|Dietary Supplement|Prebiotic|Daily intake of Inulin-type fructans from chicory
79825390|NCT04791956|Dietary Supplement|Placebo|Daily intake of maltodextrin
79825391|NCT04788940|Procedure|Percutaneous Coronary Intervention|Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
79825392|NCT04782531|Other|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
79230459|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
79825393|NCT04782531|Other|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
79526383|NCT01395953|Drug|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
79526384|NCT01395979|Behavioral|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
79999605|NCT02047448|Procedure|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
79999606|NCT02050412|Other|Cat fur scratch test|
79230460|NCT00730665|Drug|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
79230461|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
79230462|NCT00730665|Other|Placebo|Capsule, Placebo, every 12 hours (twice a day)
79230463|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
79230464|NCT03263858|Device|Stent|Implantation of coronary stent in de novo coronary artery lesions
79372739|NCT05697354|Procedure|Cognitive rehabilitation using smartphone App Medico Amico|the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
79372740|NCT00634179|Drug|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
79372741|NCT00634179|Biological|Rituximab|Rituximab 375 mg/m²
79372742|NCT00634179|Drug|Doxorubicin|Doxorubicin 50 mg/m²
79372743|NCT00634179|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m²
79526385|NCT01395979|Behavioral|Supportive Psychotherapy|Eight weekly sessions
79526386|NCT01395979|Behavioral|Sexual Risk Reduction Intervention|Two weekly sessions.
79526387|NCT01395992|Drug|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
79526388|NCT01395992|Drug|asenapine|asenapine 10 mg tablet, SL BID for 182 days
79999607|NCT02048696|Other|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
79999608|NCT02048774|Behavioral|Designation of Social Positioning|
79526389|NCT01396031|Behavioral|Physical Therapy|Standard of care
79526390|NCT01396109|Procedure|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
79526391|NCT01396109|Procedure|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
79526392|NCT01396122|Procedure|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
79825394|NCT04777877|Other|Pain Neuroscience Education delivered via a Virtual Reality Headset|Pain educational videos (5) and guided imagery 360 degree nature videos (5)
79825395|NCT04771091|Diagnostic Test|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
79681719|NCT05404230|Dietary Supplement|Corn oil|Corn oil
79825396|NCT04765150|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
79825397|NCT04765150|Other|Electronic Health Record Review|Medical charts are reviewed
79526393|NCT01396135|Drug|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
79526394|NCT01396135|Drug|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
79526395|NCT01396135|Drug|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
79526396|NCT01396135|Drug|Placebo|Single dose of placebo given as a matching number of oral tablets
79526397|NCT01396135|Drug|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
79526398|NCT01396135|Drug|Placebo|Multiple doses of placebo given as a matching number of oral tablets
79526399|NCT01396174|Behavioral|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
79526400|NCT01396174|Behavioral|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
79526401|NCT01396200|Drug|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
79825398|NCT04753021|Other|Exercise|Progressively increasing training load
79825399|NCT04751422|Other|Electronic Health Record Review|Medical data is collected
79825400|NCT04727996|Drug|Sitravatinib|120 mg will be administered orally once daily
79825401|NCT04727996|Drug|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
79825402|NCT04921059|Diagnostic Test|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
79825403|NCT04704700|Device|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
79825404|NCT04704700|Device|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
79825405|NCT04695327|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
79825406|NCT04692623|Drug|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
79526402|NCT01396200|Drug|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
79681720|NCT05402813|Other|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
79681721|NCT05402813|Other|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
79526403|NCT01396252|Drug|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
79526404|NCT01396252|Drug|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
79526405|NCT01396252|Drug|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
79526406|NCT01396252|Drug|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
79526407|NCT01396252|Drug|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
79526408|NCT01396291|Drug|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
79526409|NCT01396291|Drug|placebo|asenapine-matched placebo, sublingual tablets, BID
79526410|NCT01396304|Device|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
79681722|NCT05399433|Other|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
79681723|NCT05397457|Device|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
79681724|NCT05396703|Procedure|TOETVA|Completed procedure.
79709735|NCT00595257|Device|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
79709736|NCT02271113|Drug|GMI-1271|
79825407|NCT04692623|Drug|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
79825408|NCT04690608|Drug|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
79709737|NCT02271113|Drug|Placebo|
79825409|NCT04684238|Drug|Midazolam|Solution for Injection/Infusion
79825410|NCT04684238|Drug|Isoflurane|Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
79825411|NCT04638543|Drug|ABP-671|ABP-671 Tablet
79825412|NCT04638543|Drug|Placebo|Placebo
79999609|NCT02048852|Other|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
79999610|NCT02048852|Other|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
79526411|NCT01396304|Device|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
79526412|NCT01396330|Behavioral|stress|3 professional safe drive training courses each lasting 30 minutes
79526413|NCT01396356|Procedure|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
79526414|NCT01396369|Drug|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
79526415|NCT01396369|Drug|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
79526416|NCT01396460|Other|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
79526417|NCT01396473|Behavioral|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
79526418|NCT01396499|Drug|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
79681725|NCT05395312|Other|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~Topic-based personal growth articles, exercises, and chatbots~Webinars and talks on varied mental health related topics~Virtual support community~Level 3 (mild to moderate)~Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
79681726|NCT05394987|Device|Spectacles|"Prescription of refractive error correction in spectacles.~Refractive error will be determined as part of a standard optometric eye exam (performed by a registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group [PEDIG] amblyopia clinical trial protocols): Hypermetropia - not under-corrected by more than +1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia - full correction of the anisometropic difference. Astigmatism - full cylinder power prescribed.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., more than 50% of waking hours) for the duration of the study."
79681727|NCT05391516|Diagnostic Test|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
79681728|NCT05388890|Drug|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
79709738|NCT02271113|Drug|Enoxaparin Sodium (Lovenox®)|
79999611|NCT02048852|Other|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
79999612|NCT02048852|Other|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
79999613|NCT03561974|Device|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
79999614|NCT02048930|Device|Budesonide Easyhaler|
79999615|NCT02048930|Device|Budesonide dry powder inhaler|
79526419|NCT01396564|Drug|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
79230465|NCT03277508|Device|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
79230466|NCT03277508|Device|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
79526420|NCT01396564|Drug|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
79526421|NCT01396577|Drug|perampanel|3 x 2 mg perampanel once per day
79372744|NCT00634179|Drug|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
79681729|NCT05388890|Drug|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
79999616|NCT02049008|Other|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
79999617|NCT02049008|Other|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
79372745|NCT00634179|Drug|Prednisone|Prednisone 100 mg/day given orally on days 1-5
79372746|NCT01178944|Other|Laboratory Biomarker Analysis|Correlative studies
79372747|NCT01178944|Drug|Oxaliplatin|Given IV
79526422|NCT01396577|Drug|perampanel|6 mg perampanel once per day
79526423|NCT01396590|Drug|Perampanel|6 x 2 mg perampanel once per day
79526424|NCT01396590|Drug|Perampanel|12 mg perampanel once per day
79526425|NCT01396616|Device|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
79526426|NCT01396629|Procedure|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
79681730|NCT05385432|Drug|Rabbit Anti thymocyte globulin (rATG)|The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
79372748|NCT01178944|Drug|Pralatrexate|Given IV
79372749|NCT03011788|Drug|Golytely Oral Solution|Bowel purge prior to,colonoscopy
79372750|NCT01179490|Drug|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
79372751|NCT01179490|Drug|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
79372752|NCT01179568|Drug|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
79372753|NCT01179568|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
79526427|NCT01396642|Other|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
79526428|NCT01396655|Drug|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
79681731|NCT05385432|Drug|Basiliximab|Simulect® IV 40mg D0 and D4
79681732|NCT05385211|Other|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
79681733|NCT05379907|Other|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
79681734|NCT05379270|Other|Diet soda|Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
79681735|NCT05376579|Other|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
79681736|NCT05367037|Device|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
79681737|NCT05367037|Device|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
79230467|NCT02280681|Other|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
79230468|NCT03058679|Other|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
79230469|NCT02280759|Drug|Gelatin Tannate|
79230470|NCT02280759|Drug|Placebo|Placebo consists of an identical formulation, except active substance
79372754|NCT01179568|Other|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
79372755|NCT01180036|Drug|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
79526429|NCT01396668|Drug|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
79526430|NCT01396681|Drug|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
79526431|NCT01396694|Other|Questionnaire|Questionnaire
79681738|NCT05364905|Drug|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
79681739|NCT05360212|Procedure|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
79681740|NCT05360212|Procedure|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
79681741|NCT05360212|Procedure|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
79681742|NCT05355428|Other|offering of breast milk feed 3 hours prior to p lanned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
79681743|NCT05352750|Biological|SON-1010|SON-1010 multiple ascending dose
79681744|NCT05338528|Behavioral|BE-FIT exercise program|BE-FIT is an evidence-based exercise program that focuses on early mobilization and recovery by minimizing bed rest, promoting functional tasks, and encouraging self-management. The intervention ist based on the Mobilization of Vulnerable Elders (MOVE) program and consists of a bedside exercise plan, done independently by the patient without the need for additional rehabilitation or healthcare staff.
79681745|NCT05324982|Drug|Oral Placebo|Placebo will be orally self-administered by study participants.
79681746|NCT05324982|Drug|Oral CBG Cannabis|CBG cannabis oil will be orally self-administered by study participants.
79681747|NCT05324345|Behavioral|Prehabilitation group|All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
79230471|NCT03275948|Other|whole grain|whole grain rye
79230472|NCT03275948|Other|reference|white wheat bread
79230473|NCT00714597|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
79230474|NCT00714597|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
79230475|NCT02457104|Procedure|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
79230476|NCT02457104|Behavioral|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
79230477|NCT02280837|Other|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
79372756|NCT01180036|Drug|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
79372757|NCT01180894|Drug|Iron sucrose|100 mg IV TIW
79372758|NCT01180894|Drug|Placebo|
79825413|NCT04628377|Device|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
79999618|NCT02808338|Device|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
79681748|NCT05319678|Other|evaluation with Meludia music software|"Measurement instruments:~- MuMu Questionnaire~MuRQoL Questionnaire~Questionnaire for subjects aged 6-17 years~Music tool Meludia (www.meludia.com)~Acoustic analysis of the voice: the Praat programme~Audiological tests"
79230478|NCT00729027|Drug|25 mg/day AVE5530|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
79230479|NCT00729027|Drug|50 mg/day AVE5530|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
79526432|NCT01396707|Drug|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~Oxaliplatin 130 mg/m2 i.v. on day 1"
79372759|NCT01181050|Drug|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
79526433|NCT01396720|Drug|fluvoxamine|Fluvoxamine 100mg daily, 7 days
79372760|NCT01181050|Drug|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
79681749|NCT05319158|Other|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
79681750|NCT05318638|Device|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
79681751|NCT05315674|Diagnostic Test|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
79681752|NCT05313724|Other|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
79681753|NCT05313464|Other|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
79825414|NCT04621019|Device|BTL-785F|Treatment with study device.
79825415|NCT04592094|Device|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
79372761|NCT03011944|Other|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
79372762|NCT03877926|Biological|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
79372763|NCT03877926|Biological|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
79526434|NCT01396720|Drug|citalopharm|Citalopharm 20mg daily, 7 days
79526435|NCT01396733|Drug|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
79526436|NCT01396759|Procedure|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
79526437|NCT01396759|Procedure|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
79681754|NCT05313464|Other|syringe-push enteral feeding|skin to skin nutrition with syringe pump
79230480|NCT00729027|Drug|placebo|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
79825416|NCT04586348|Combination Product|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
79999619|NCT02808338|Device|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
79999620|NCT02808338|Device|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
79230481|NCT03265886|Drug|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
79825417|NCT04586348|Combination Product|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
79825418|NCT04577001|Drug|Letrozole|2.5 mg orally daily for 6 months
79681755|NCT05311761|Other|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
79825419|NCT04577001|Drug|Placebo|No active ingredient taken orally daily for 6 months
79999621|NCT02808338|Device|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
79999622|NCT02050646|Other|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
79999623|NCT02050646|Other|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
79999624|NCT02037386|Device|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
79230482|NCT03265886|Drug|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
79230483|NCT00728091|Drug|Satavaptan|tablets
79230484|NCT00728091|Drug|placebo|tablets
79230485|NCT03275792|Drug|D5-0.9%NS|Admission for intravascular volume expansion
79230486|NCT03275792|Drug|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
79230487|NCT03275090|Drug|Smoflipid ®|
79230488|NCT03382821|Procedure|Transforaminal ESI with dexamethasone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
79230489|NCT03382821|Procedure|Transforaminal catheter-targeted ESI with triamcinolone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
79230490|NCT03382821|Drug|Dexamethasone Sodium Phosphate 10 MG/ML|Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
79230491|NCT03382821|Drug|Lidocaine|1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
79681756|NCT05311215|Drug|SL-1002|SL-1002 injectable solution
79825420|NCT04576078|Drug|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
79825421|NCT04576078|Drug|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
79825422|NCT04561557|Biological|CT103A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×106 CAR+ T cells/kg will be infused on day 0.
79372764|NCT01181674|Drug|insulin glargine|sc injection
79681757|NCT05311215|Drug|Placebo|Matching placebo injectable solution
79825423|NCT04561557|Drug|Cyclophosphamide and fludarabine|"Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
79825424|NCT04561258|Biological|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
79825425|NCT04560127|Drug|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
79999625|NCT02049086|Behavioral|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
79372765|NCT01181674|Drug|metformin|oral administration
79372766|NCT01181674|Drug|acarbose|oral administration
79372767|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
79230492|NCT03382821|Drug|Triamcinolone Acetonide 40mg/mL|Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
79372768|NCT01181674|Drug|insulin glargine|sc injection
79681758|NCT05310227|Device|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
79681759|NCT05310175|Device|Electroacupuncture|Filiform needles (0.30×50mm, Hanyi brand, Beijing Medical Appliance, China) and the SDZ-V electric acupuncture (Suzhou Medical Appliance) apparatus will be used. After acupuncture at the acupoints group, the needle handle will be connected with the electrode of the electric acupuncture apparatus.
79681760|NCT05310175|Device|Sham acupuncture|Shallow needle insertion of 2-3 mm at sham acupoints without manipulation.
79372769|NCT01181674|Drug|metformin|oral administration
79372770|NCT01181674|Drug|acarbose|oral administration
79372771|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
79372772|NCT01181674|Other|Standard glycemic care|as informed by the current clinical practice guidelines
79372773|NCT01182376|Drug|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
79372774|NCT01182376|Drug|Placebo|Placebo will be administered by the patient's team according to established guidelines.
79372775|NCT01183312|Drug|Flumazenil|Sublingual flumazenil
79709739|NCT04349904|Diagnostic Test|Near-Focus Narrow Band Imaging|High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)
79825426|NCT04555616|Behavioral|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
79825427|NCT04555616|Behavioral|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
79825428|NCT04555616|Behavioral|Placebo|Participants' caregivers will receive a set script of placebo modifications.
79825429|NCT04549337|Behavioral|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate >85% of HR max will be evaluated to determine the intensity."
79825430|NCT04541914|Diagnostic Test|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
79999626|NCT02049086|Behavioral|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
79999627|NCT02049242|Procedure|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
79230493|NCT02557516|Drug|monalizumab|"During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks."
79372776|NCT05219136|Other|Modified Fasting Group|a new fasting protocol is applied to subjects.
79681761|NCT05309772|Diagnostic Test|Basophil activation test (BAT)|"Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils."
79681762|NCT05309772|Diagnostic Test|Oral food challenge (OFC)|Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
79681763|NCT05307289|Other|Biposy|Biopsy at inclusion visit and at disease progression if applicable
79709740|NCT02271152|Procedure|FAST mapping and ablation|
79709741|NCT02271152|Procedure|PVI|
79709742|NCT01606514|Behavioral|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
79230494|NCT03263624|Device|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
79230495|NCT03263624|Drug|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
79230496|NCT01976247|Device|High Intensity Focused Ultrasound Device|
79230497|NCT01976247|Device|Noninvasive Cryolipolysis Device|
79372777|NCT05219136|Other|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
79372778|NCT03188172|Drug|Cyclophosphamide|Chemotherapy
79372779|NCT03188172|Drug|Bortezomib|Chemotherapy
79372780|NCT03188172|Drug|Lenalidomide|Chemotherapy
79372781|NCT03188172|Drug|Daratumumab|Chemotherapy
79372782|NCT03188172|Drug|Dexamethasone|Chemotherapy
79372783|NCT03188172|Drug|Melphalan|Chemotherapy
79372784|NCT03188172|Drug|Filgrastim|Haematopoietic agent for the stem cell harvest
79372785|NCT05340036|Procedure|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
79526438|NCT01396759|Procedure|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
79825431|NCT04536532|Drug|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
79825432|NCT04536532|Drug|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
79825433|NCT04536532|Drug|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
79825434|NCT04536532|Drug|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
79999628|NCT02049242|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
79999629|NCT02049320|Drug|Remifentanil|
79999630|NCT02050724|Drug|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
79999631|NCT02050724|Device|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
79230498|NCT03274544|Other|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~Huang Qi (Radix Astragali Membranaceus): 2 g~Dan Shen (Radix Salviae Miltiorrhizae): 1 g~Jiang Huang (Rhizoma Curcumae Longae): 1 g~Yin Xing (Semen Gingko Bilobae): 1 g~Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~Bai He (Bulbus Lilii): 1g~Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~Zi Su Ye (Folium Perillae Frutescentis): 1 g~Yin Yang Huo (Herba Epimedii): 1g"
79230499|NCT02280915|Other|Savoury food product|
79372786|NCT05340036|Procedure|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
79372787|NCT01184014|Drug|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
79372788|NCT01184014|Drug|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
79526439|NCT01396772|Behavioral|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
79526440|NCT01396772|Other|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
79526441|NCT01396824|Other|No intervention|No intervention
79999632|NCT02050724|Device|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
79999633|NCT02260076|Drug|PEG 400|
79999634|NCT02260076|Drug|Placebo|
79999635|NCT02807948|Device|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
79999636|NCT02050802|Drug|Moxifloxacin 400 mg|
79999637|NCT02050802|Drug|Macitentan 10 mg|
79999638|NCT02050802|Drug|Macitentan 30 mg|
79999639|NCT02050802|Other|Placebo|
79999640|NCT02051504|Behavioral|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
79230500|NCT05493436|Diagnostic Test|MII pH-meter|using multichannel impedance pH-meter
79230501|NCT00711555|Drug|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
79526442|NCT01396863|Procedure|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
79681764|NCT05305443|Behavioral|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
79681765|NCT05305443|Behavioral|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
79825435|NCT04526158|Behavioral|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
79372789|NCT03130140|Procedure|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
79372790|NCT03130140|Other|Control|Conventional EUS-FNA
79999641|NCT02051504|Dietary Supplement|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
79999642|NCT02051504|Procedure|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
79999643|NCT02051504|Procedure|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
79999644|NCT02051504|Procedure|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
79526443|NCT01396863|Procedure|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
79825436|NCT04526158|Behavioral|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
79999645|NCT02051504|Procedure|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
79999646|NCT02051504|Other|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
79999647|NCT02051582|Procedure|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
79999648|NCT02051582|Procedure|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
79230502|NCT05488756|Other|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
79230503|NCT05488756|Other|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
79372791|NCT01185028|Drug|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
79372792|NCT03011866|Drug|Wound topically irrigated with 500mg TXA|
79372793|NCT03011866|Drug|1mg/kg/hr TXA intravenous infusion till the last suture|
79526444|NCT01396876|Behavioral|clown|a distraction technique is performed by a clown during venipuncture
79526445|NCT01396889|Drug|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
79526446|NCT01396889|Drug|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
79681766|NCT05305443|Behavioral|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
79825437|NCT04518566|Behavioral|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
79372794|NCT05263596|Diagnostic Test|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~Mini Mental State Exam (MMSE)~Clock-drawing test (CDT)~Geriatric depression scale (GDS)~Functional independence measure (FIM) at admission~Timed up and go Test (TUG)~Gait speed~Hand grip strength (HGS)~Nutritional risk screening (NRS)~Additional measurements:~Chair-stand-test~Clinical frailty scale (CFS)~Calf circumference and mid-arm circumference~Body impedance analysis (BIA)~US~DXA"
79825438|NCT04508634|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
79825439|NCT04508634|Drug|Metformin Pill|Metformin 1000mg bid
79526447|NCT01396902|Behavioral|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
79681767|NCT05305443|Behavioral|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
79999649|NCT02051660|Behavioral|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
79999650|NCT02051660|Behavioral|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
79999651|NCT02051738|Drug|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
79372795|NCT05199168|Procedure|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
79999652|NCT02051738|Drug|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
79999653|NCT02050958|Drug|OXP001|
79999654|NCT02050958|Drug|Ibuprofen|
79681768|NCT05304351|Biological|CRV-101 Vaccine Antigen High Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
79999655|NCT02037464|Dietary Supplement|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
79526448|NCT01396902|Behavioral|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
79999656|NCT02049554|Other|Preconception Care Screener|
79999657|NCT02049710|Behavioral|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
79999658|NCT02049710|Behavioral|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
79999659|NCT01353625|Drug|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
79999660|NCT01357603|Biological|Glargine|dosage form: Subcutaneous injection
79999661|NCT02051894|Drug|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
79999662|NCT01357681|Drug|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
79999663|NCT01357681|Drug|Placebo|Placebo
79999664|NCT02049788|Behavioral|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
79526449|NCT01396915|Dietary Supplement|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
79526450|NCT01396928|Procedure|Colonic reservoir|Type of reservoir to be performed
79526451|NCT01396941|Behavioral|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
79526452|NCT01396967|Device|surgery|cataract surgery
79825440|NCT04490512|Biological|FluBHPVE6E7|Multiple subcutaneous, intradermal or intramuscular administrations
79825441|NCT04484194|Behavioral|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
79825442|NCT04480502|Biological|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
79825443|NCT04480502|Drug|Ipilimumab|CTLA-4 monoclonal antibody
79825444|NCT04468334|Device|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
79681769|NCT05304351|Biological|CRV-101 Vaccine Antigen Low Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
79230504|NCT05488756|Other|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
79230505|NCT00701181|Procedure|Laser Treatment|Necessity of laser treatment is assessed every three months.
79230506|NCT00701181|Drug|PF-04523655 high|3 mg intravitreal injection
79230507|NCT00701181|Drug|PF-04523655 middle|1 mg intravitreal injection
79372796|NCT01143142|Behavioral|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
79372797|NCT02186938|Device|FloTrac|
79999665|NCT02049788|Behavioral|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
79681770|NCT05304351|Biological|Shingrix|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
79681771|NCT05304351|Biological|CRV-101 Vaccine Adjuvant High Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
79681772|NCT05304351|Biological|CRV-101 Vaccine Adjuvant Middle Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
79230508|NCT00701181|Drug|PF-04523655 low|0.4 mg intravitreal injection
79230509|NCT03263390|Procedure|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
79230510|NCT03263390|Drug|Anti Obesity Drugs|Response to FDA approved anti obesity medications
79372798|NCT05190822|Other|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
79372799|NCT02187016|Device|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
79372800|NCT02187016|Device|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
79372801|NCT02187016|Device|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
79372802|NCT02187016|Device|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
79372803|NCT05439798|Drug|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
79526453|NCT01396993|Procedure|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
79526454|NCT01396993|Procedure|Breast Surgery|Breast conserving therapy without defect correction
79526455|NCT01397006|Drug|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
79526456|NCT01397019|Drug|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
79681773|NCT05304351|Biological|CRV-101 Vaccine Adjuvant Low Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
79526457|NCT01397032|Behavioral|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
79526458|NCT01397032|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
79526459|NCT01397045|Other|VATS|Video-assisted lung segmentectomy
79681774|NCT05304273|Drug|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
79825445|NCT04455867|Behavioral|Diabetes Exercise and Healthy Lifestyle Program|The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
79825446|NCT04455867|Other|Outpatient care|Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
79681775|NCT05304273|Drug|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
79681776|NCT05303805|Drug|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
79681777|NCT05303805|Combination Product|Cyteal|Rinsing and cleaning of ulcer.
79681778|NCT05302921|Procedure|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
79681779|NCT05302921|Drug|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
79709743|NCT00595296|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
79825447|NCT04453072|Other|Interview|Participate in interviews
79825448|NCT04453072|Other|Media Intervention|Receive iPhone with W8Loss2Go app
79230511|NCT04277182|Biological|burn wound dressing|"st. group: It will be considered as a control group and rats will not be treated.~nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days."
79230512|NCT03273920|Procedure|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
79372804|NCT05439798|Drug|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
79372805|NCT05439798|Drug|Dexamethasone|Dexamethasone
79372806|NCT02188576|Drug|high dose TXA|
79526460|NCT01397045|Procedure|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
79230513|NCT03273920|Procedure|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
79230514|NCT02280993|Drug|DHAP|DHAP
79526461|NCT01397097|Drug|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
79526462|NCT01397097|Drug|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
79526463|NCT01397123|Other|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
79526464|NCT01397149|Drug|Placebo|Dosage form, frequency and duration exactly as experimental arm.
79825449|NCT04453072|Other|Questionnaire Administration|Complete questionnaires
79825450|NCT04453072|Other|Scale Device|Receive body scale and food scale
79825451|NCT04453072|Behavioral|Telephone-Based Intervention|Receive telephone calls
79825452|NCT04453072|Other|Text Message|Receive text message
79825453|NCT04447092|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
79825454|NCT04447092|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
79230515|NCT02280993|Drug|Brentuximab Vedotin|Brentuximab Vedotin
79372807|NCT02188576|Drug|Low dose TXA|
79372808|NCT05439720|Dietary Supplement|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
79825455|NCT04447092|Drug|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
79825456|NCT04447092|Drug|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
79825457|NCT04447092|Drug|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
79372809|NCT05439720|Dietary Supplement|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
79372810|NCT05439720|Behavioral|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
79825458|NCT04447092|Drug|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
79825459|NCT04447092|Drug|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
79825460|NCT04437134|Other|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
79848931|NCT05837169|Other|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
79848932|NCT05834946|Other|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
79848933|NCT05834946|Other|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
79999666|NCT02037932|Device|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
79999667|NCT01543633|Drug|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
79999668|NCT03561740|Drug|capecitabine|additional metronomic chemotherapy of capecitabine
79230516|NCT02280993|Other|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
79230517|NCT02459210|Behavioral|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
79999669|NCT03494647|Device|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
79999670|NCT03494647|Device|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
79999671|NCT02037698|Device|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
79999672|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
79230518|NCT02459210|Behavioral|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
79372811|NCT05439642|Other|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
79372812|NCT02189122|Drug|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
79372813|NCT02189122|Drug|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
79372814|NCT02189122|Drug|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
79681780|NCT05302921|Drug|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation [CD]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
79681781|NCT05302609|Biological|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
79999673|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
79999674|NCT02053454|Drug|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
79230519|NCT05493202|Device|Mira Fertility Tracker|Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
79230520|NCT02459132|Behavioral|High-intensity aerobic interval exercise|See arm/group description
79230521|NCT05493124|Drug|Manpixiao|A traditional Chinese medicine composition
79230522|NCT05493124|Drug|Active comparator|Other drugs that may have therapeutic effects
79230523|NCT03263312|Behavioral|Exercise|Exercise training all patients enrolled.
79230524|NCT05493046|Behavioral|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
79230525|NCT05493046|Behavioral|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
79230526|NCT03263468|Procedure|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
79372815|NCT02189122|Drug|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
79372816|NCT02189122|Drug|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
79372817|NCT02189122|Drug|Placebo|Subjects will take matching placebo for five days.
79372818|NCT05309460|Drug|Labetalol Oral Tablet|See Labetalol arm.
79372819|NCT05309460|Drug|NIFEdipine ER|See Nifedipine arm.
79999675|NCT02053454|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79681782|NCT05300503|Behavioral|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
79999676|NCT02052050|Other|core stability|
79999677|NCT02931097|Device|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
79999678|NCT02931097|Device|Sham stimulation|
79999679|NCT02052128|Drug|onapristone|
79999680|NCT01349413|Drug|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
79999681|NCT01349413|Other|Placebo|Identical looking placebo
79999682|NCT01349647|Biological|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
79999683|NCT01349647|Biological|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
79999684|NCT06273735|Diagnostic Test|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
79372820|NCT03261804|Behavioral|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
79372821|NCT01093690|Drug|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
79681783|NCT05299112|Dietary Supplement|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
79230527|NCT03263468|Procedure|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting >48 hours to 45 days post primary PCI
79230528|NCT05492968|Drug|Epinephrin|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
79230529|NCT05492968|Drug|Norepinephrine|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
79372822|NCT01093690|Drug|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
79372823|NCT05301426|Other|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
79372824|NCT05301426|Other|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
79372825|NCT05301426|Other|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
79372826|NCT04455360|Other|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
79372827|NCT01143610|Procedure|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
79372828|NCT01143610|Other|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
79372829|NCT05439486|Device|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
79372830|NCT01143688|Drug|albuterol|
79372831|NCT01143688|Drug|placebo inhaler|
79372832|NCT01143688|Procedure|placebo acupuncture|
79681784|NCT05296772|Biological|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
79681785|NCT05296772|Biological|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
79681786|NCT05289271|Biological|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
79709744|NCT02271191|Drug|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
79848934|NCT05829824|Behavioral|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
79848935|NCT05829824|Other|AutoReach|Phone call / SMS Text
79848936|NCT05829824|Procedure|Biospecimen samples|Saliva and breath sample
79848937|NCT05826496|Other|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
79848938|NCT05816070|Drug|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
79848939|NCT05816070|Drug|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
79848940|NCT05795413|Procedure|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
79681787|NCT05287620|Device|Emerald device|The Emerald device is a wireless sensor that can track the motion, breathing, and sleep of participants without touching or requiring any interaction with the participants, allowing them to go about their normal lives. The Emerald device operates by transmitting and receiving low power radio signals that reflect off of the participant and return back to the device. The power of these signals is 1,000 times lower than what a typical Wi-Fi device transmits. The ability of the device to monitor gait, breathing, sleep, and other metrics has been validated and documented. Studies of the Emerald device in individuals with Parkinson's disease, Alzheimer's disease, and rare diseases have demonstrated the feasibility of monitoring at home and the ability to characterize gait, breathing, and sleep in these populations specifically. In this study, the Emerald device will be used to characterize the mobility, breathing and sleep of the participant.
79230530|NCT05492968|Drug|Phenylephrine|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
79230531|NCT02457026|Drug|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
79230532|NCT02457026|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
79230533|NCT02457026|Drug|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
79230534|NCT05488210|Dietary Supplement|FontActiv DiaBest HP/HC|Daily intake of two FontActiv DiaBest HP/HC during 2 months
79230535|NCT02458898|Behavioral|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
79372833|NCT04455594|Drug|Almonertinib|Oral, 110mg QD
79681788|NCT05284903|Other|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
79681789|NCT05284903|Other|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
79526465|NCT01397149|Drug|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to > 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
79526466|NCT01397175|Device|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
79681790|NCT05284903|Other|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
79681791|NCT05284903|Other|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
79681792|NCT05278104|Drug|Zentiva®|Zentiva®
79372834|NCT04455594|Drug|Erlotinib|Oral, 150mg QD
79372835|NCT04455594|Drug|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
79372836|NCT04455594|Drug|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
79372837|NCT04455594|Drug|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
79372838|NCT05439408|Drug|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
79372839|NCT05439408|Drug|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
79372840|NCT05261880|Other|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
79230536|NCT05488132|Drug|anti-siglec-6 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
79372841|NCT05261880|Other|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
79230537|NCT02456870|Other|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
79230538|NCT05492890|Device|Dexcom G6|Continuous glucose monitoring
79372842|NCT04453800|Drug|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
79372843|NCT04453800|Drug|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
79230539|NCT03273842|Biological|PF-06881894|pre-filled syringe 6 mg
79230540|NCT03273842|Biological|US-approved Neulasta|pre-filled syringe 6 mg
79526467|NCT01397175|Device|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
79681793|NCT05278104|Drug|Placebo|Placebo
79681794|NCT05266963|Drug|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
79681795|NCT05266963|Drug|Placebo|Placebo
79681796|NCT05260658|Drug|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
79681797|NCT05260658|Drug|Placebo|CFTX-1554 matching placebo
79526468|NCT01397175|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
79526469|NCT01397188|Device|PiCCO|transpulmonary thermodilution technique
79526470|NCT01397188|Other|sham, no intervention|no intervention
79526471|NCT01397214|Drug|Megace F|Megace F oral suspension
79526472|NCT01397214|Drug|Megace OS|Megace oral suspension
79681798|NCT05255289|Procedure|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
79681799|NCT05255289|Procedure|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
79681800|NCT05255289|Procedure|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
79681801|NCT05255289|Procedure|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
79681802|NCT05254587|Device|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
79681803|NCT05250024|Device|UHMWP Cranioplasty|patient specific cranial implant
79681804|NCT05250024|Device|PEEK Cranioplasty|patient specific cranial implant
79825461|NCT04437134|Other|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
79526473|NCT01397240|Drug|Albis Tab|2 Tab, twice a day, 12 weeks
79681805|NCT05248399|Behavioral|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a ~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe & Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
79681806|NCT05248399|Behavioral|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
79681807|NCT05245916|Drug|IBI397|IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
79230541|NCT05492812|Other|Sedation and Nursing Management in EEG Recording in Children|Evaluation of the effect of sedative agents applied during EEG recording in children
79230542|NCT05492812|Drug|Chloral Hydrate|Chloral Hydrate
79526474|NCT01397240|Drug|Placebo|2 Tab, twice a day, 12 weeks
79526475|NCT01397266|Procedure|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
79230543|NCT05492812|Drug|Hydroxyzine|Hydroxyzine
79230544|NCT05492812|Drug|Melatonin|Melatonin
79230545|NCT05492734|Drug|EDG-5506|single oral dose
79372844|NCT04453800|Drug|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
79372845|NCT04453800|Other|placebo|Saline was administered intravenously
79372846|NCT01188460|Behavioral|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
79372847|NCT01188460|Behavioral|Sleep diary|
79526476|NCT01397266|Procedure|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
79526477|NCT01397305|Drug|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
79526478|NCT01397305|Drug|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
79681808|NCT05245916|Drug|IBI397+Sintilimab|IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
79230546|NCT03265418|Device|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
79230547|NCT03265418|Other|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
79372848|NCT03011476|Drug|Donepezil|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
79372849|NCT03011476|Drug|Placebos|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
79372850|NCT05438784|Procedure|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
79230548|NCT03265418|Procedure|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
79526479|NCT01397331|Drug|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
79526480|NCT01397331|Drug|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
79681809|NCT05245916|Drug|IBI397+Rituximab|IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
79681810|NCT05240846|Procedure|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
79681811|NCT05240846|Procedure|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
79681812|NCT05237947|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
79681813|NCT05237947|Other|Questionnaire Administration|Ancillary studies
79681814|NCT05237947|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
79681815|NCT05237947|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
79681816|NCT05233488|Device|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
79681817|NCT05230368|Drug|Decitabine cycle 1|Decitabine administration (5mg/m²) at days 1, 2, 3
79825462|NCT04414813|Biological|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
79848941|NCT05795413|Drug|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
79230549|NCT05487976|Drug|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
79230550|NCT05487898|Device|Cycling wheelchair|Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
79230551|NCT03265652|Device|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
79372851|NCT05438784|Procedure|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
79372852|NCT02522754|Biological|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
79372853|NCT02522754|Biological|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
79372854|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
79526481|NCT01397357|Other|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
79526482|NCT01397370|Drug|GLPG0492|Oral solution
79526483|NCT01397370|Drug|Placebo|Oral solution
79526484|NCT01397396|Procedure|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
79526485|NCT01397474|Other|PPTFM|Peripheral Perfusion Targeted Fluid Management
79230552|NCT03265652|Device|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
79230553|NCT03265028|Behavioral|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
79526486|NCT05269290|Drug|Ingavirin®, syrup, 30 mg/5 ml|A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
79526487|NCT05269290|Drug|Placebo|Placebo will be administered once a day on top of standard therapy.
79526488|NCT05269251|Device|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
79526489|NCT05268952|Other|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
79526490|NCT05268952|Other|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
79526491|NCT05268913|Diagnostic Test|MRI scan|Participants will undertake a magnetic resonance imaging scan.
79526492|NCT05268913|Biological|Blood test|Participants will undertake a fasting blood test.
79526493|NCT05268900|Device|Volume control ventilation group|Volume control ventilation mode
79526494|NCT05268900|Device|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
79681818|NCT05230368|Drug|Romidepsin cycle 1|Romidepsin administration (5mg/m²) at days 4, 11, 18
79681819|NCT05230368|Drug|Decitabine cycle 2|Decitabine administration (5mg/m²) at days 35, 36, 37
79681820|NCT05230368|Drug|Romidepsin cycle 2|Romidepsin administration (5mg/m²) at days 38, 45, 52
79681821|NCT05230368|Drug|Decitabine cycle 3|Decitabine administration (5mg/m²) at days 70, 71, 72
79681822|NCT05230368|Drug|Romidepsin cycle 3|Romidepsin administration (5mg/m²) at days 73, 80, 87
79681823|NCT05230368|Drug|Decitabine cycle 4|Decitabine administration (5mg/m²) at days 105, 106, 107
79681824|NCT05230368|Drug|Romidepsin cycle 4|Romidepsin administration (5mg/m²) at days 108, 115, 122
79681825|NCT05223478|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
79681826|NCT05223478|Drug|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
79230554|NCT02458118|Drug|Secretin|Secretin 1 IU/kg over 3 min
79230555|NCT05487742|Drug|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
79230556|NCT05487742|Drug|placebo salin infusion|salin infused as aplacebo for 72 hours
79230557|NCT02457650|Drug|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
79230558|NCT02457650|Drug|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
79681827|NCT05219565|Device|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
79681828|NCT05212298|Dietary Supplement|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
79681829|NCT05212298|Dietary Supplement|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
79681830|NCT05212298|Dietary Supplement|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
79681831|NCT05206084|Device|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Subjects in this arm will be treated with IBS
79681832|NCT05206084|Device|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|Subjects in this arm will be treated with XIENCE
79681833|NCT05205499|Device|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
79230559|NCT02457650|Biological|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
79230560|NCT02456948|Drug|Minocycline|6 weeks 200mg/day Minocycline add-on
79230561|NCT02456948|Drug|Placebo|6 weeks Placebo add-on
79230562|NCT05487508|Drug|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
79230563|NCT05487508|Drug|Normal saline|Placebo (NaCl 0.9%)
79230564|NCT04185142|Combination Product|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
79372855|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
79372856|NCT01188694|Drug|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
79372857|NCT01188694|Behavioral|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
79681834|NCT05205161|Drug|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
79681835|NCT05193526|Other|No intervention|No intervention
79681836|NCT05192421|Behavioral|Wellness Education|Receive wellness education through a weekly email and web portal content.
79681837|NCT05192421|Behavioral|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
79681838|NCT05192421|Behavioral|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
79681839|NCT05188222|Drug|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
79848942|NCT05795192|Drug|SB17170|Taking SB17170 orally once a day
79526495|NCT05268861|Behavioral|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
79526496|NCT05268861|Behavioral|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
79526497|NCT05268848|Other|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
79681840|NCT05188222|Drug|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
79681841|NCT05182242|Other|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
79681842|NCT05182242|Biological|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
79681843|NCT05182242|Other|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
79681844|NCT05182242|Other|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
79681845|NCT05182242|Other|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
79681846|NCT05181137|Drug|SHR0302|Oral tablets taken once daily (QD)
79681847|NCT05181137|Drug|Placebo|Oral tablets taken once daily (QD)
79681848|NCT05177510|Drug|Mifepristone|Progestin Antagonist
79681849|NCT05177510|Drug|Placebo|Placebo
79681850|NCT05176860|Device|CBCT Imaging|Two research CBCT images will be acquired per subject.
79681851|NCT05174338|Other|Registry|Observational, data collection
79681852|NCT05174286|Behavioral|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
79681853|NCT05174286|Behavioral|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
79709745|NCT02271269|Behavioral|Value Pricing Subsidies|"Usual care for glaucoma~Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
79709746|NCT00595374|Drug|insulin detemir|
79709747|NCT00595374|Drug|insulin NPH|
79709748|NCT00595374|Drug|insulin aspart|
79825463|NCT04379921|Device|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
79825464|NCT04375826|Device|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
79709749|NCT01606553|Device|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
79825465|NCT04375826|Device|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
79825466|NCT04371224|Drug|Irinotecan Liposomal Injection [Onivyde]|both arm
79230565|NCT04175704|Drug|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
79230566|NCT02713490|Drug|EXPAREL|EXPAREL and bupivacaine HCl
79230567|NCT02713490|Drug|Bupivacaine|Single dose of bupivacaine HCl 0.5%
79230568|NCT05491954|Device|Dexcom G6|Continuous glucose monitoring
79230569|NCT03263234|Other|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
79825467|NCT04371224|Drug|Capecitabine|NaliCap
79681854|NCT05170165|Other|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
79681855|NCT05168475|Biological|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
79825468|NCT04371224|Drug|5-fluorouracil|NAPOLI
79681856|NCT05168475|Biological|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
79825469|NCT04371224|Drug|Leucovorin|NAPOLI
79825470|NCT04368455|Behavioral|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
79825471|NCT04368455|Behavioral|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
79825472|NCT04363242|Biological|SYN125|Administered by IV infusion
79372858|NCT01188694|Behavioral|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
79526498|NCT05268835|Drug|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
79681857|NCT05168475|Biological|Tocilizumab|Hospital-supplied stock.
79526499|NCT05268718|Drug|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
79526500|NCT05268718|Drug|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
79681858|NCT05164861|Dietary Supplement|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%*), vitamin B1 - 0.4 mg (29%*), B2 - 0.21 mg (13%*), B6 - 0.48 mg (24%*), niacin - 2.74 mg (15%*), folic acid - 24.0 mcg (12%*). Energy value/Caloric content - 54 kilojoules/13 kcal (* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries & juniper berries, or strawberries & lime leaves, or passion fruit & mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
79825473|NCT04363242|Biological|SYN004|Administered by IV infusion
79825474|NCT04343183|Device|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
79825475|NCT04329364|Combination Product|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
79305586|NCT04935333|Procedure|Collection of Leiomyosarcoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
79526501|NCT05268718|Other|Normal saline|To be placebo, normal saline were administrated to infectious eye
79825476|NCT04329364|Procedure|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
79825477|NCT04327336|Device|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
79825478|NCT04327336|Device|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
79848943|NCT05795192|Drug|Placebo|Taking Placebo orally once a day
79372859|NCT04453566|Other|Online Survey|Online Survey
79372860|NCT04454112|Device|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
79372861|NCT04454268|Procedure|cyst extirpation|complete removal of the cyst without rupture
79372862|NCT01188928|Drug|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
79372863|NCT01188928|Drug|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
79372864|NCT01188928|Drug|Calcipotriene|Topical suspension once daily for up to 8 weeks.
79848944|NCT05788081|Drug|BMS-986369|BMS-986369 is an orally administered Cereblon-modulating compound
79848945|NCT05788081|Drug|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
79848946|NCT05788081|Drug|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
79999685|NCT06273722|Device|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution <7.5 µm lateral, <5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
79305587|NCT04935333|Procedure|Collection of control samples|Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
79305588|NCT03241043|Drug|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
79305589|NCT03241043|Drug|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
79681859|NCT05164523|Diagnostic Test|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
79372865|NCT01188928|Drug|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
79372866|NCT05438706|Drug|chidamide|Chidamide, an HDAC inhibitor
79372867|NCT05438706|Drug|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
79681860|NCT05164523|Diagnostic Test|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
79681861|NCT05159453|Biological|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
79526502|NCT05268692|Drug|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (< 1.25 m2, 60 mg/d; ≥ 1.25 to < 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
79526503|NCT05268692|Drug|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
79526504|NCT05268627|Drug|Liraglutide|endoscopy
79681862|NCT05159453|Device|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
79681863|NCT05149287|Drug|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
79681864|NCT05149287|Other|Placebo|1% lidocaine and saline
79681865|NCT05144854|Drug|ONO-4538|Specified dose on specified days
79681866|NCT05144854|Drug|Ipilimumab|Specified dose on specified days
79681867|NCT05144854|Drug|Oxaliplatin|Specified dose on specified days
79681868|NCT05144854|Drug|Capecitabine|Specified dose on specified days
79681869|NCT05144854|Drug|S-1|Specified dose on specified days
79681870|NCT05142293|Other|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
79681871|NCT05138809|Behavioral|Exercise|Use online exercise platform
79681872|NCT05136456|Drug|SHR1459 Low Dose|SHR1459 oral tablets taken once daily (QD) for 24weeks
79681873|NCT05136456|Drug|SHR1459 High Dose|SHR1459 oral tablets taken once daily (QD) for 24 weeks
79681874|NCT05136456|Drug|Placebo|Placebo oral tablets taken once daily (QD) for 24 weeks
79230570|NCT05487430|Behavioral|Positive Self-Affirmation|Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
79681875|NCT05136443|Drug|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
79681876|NCT05133297|Drug|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
79230571|NCT02459054|Device|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
79230572|NCT05487352|Other|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
79372868|NCT05438706|Drug|carboplatin|Carboplatin [diammine(1,1-cyclobutanedicarboxylato)platinum(II)] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
79526505|NCT05268601|Drug|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
79681877|NCT05133297|Drug|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
79681878|NCT05133297|Drug|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
79681879|NCT05133297|Drug|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
79681880|NCT05132088|Drug|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
79681881|NCT05132088|Drug|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
79681882|NCT05131685|Procedure|Reduction|closed reduction under conscious sedation followed by casting
79681883|NCT05131685|Procedure|Immobilization|immobilization in cast without reduction
79681884|NCT05131659|Behavioral|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
79681885|NCT05127291|Other|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
79709750|NCT01606553|Device|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
79709751|NCT04328025|Other|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
79372869|NCT05438706|Drug|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
79681886|NCT05122676|Behavioral|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
79526506|NCT05268601|Drug|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
79390921|NCT03648268|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
79681887|NCT05117398|Drug|Dalbavancin administration|"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance < 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
79681888|NCT05117398|Drug|Standard antibiotic therapy|Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
79681889|NCT05115461|Device|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
79681890|NCT05115461|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
79681891|NCT05110781|Biological|Atezolizumab|Given IV
79681892|NCT05110781|Radiation|Radiation Therapy|Undergo radiation therapy
79681893|NCT05110781|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79681894|NCT05110508|Behavioral|Text Based Behavioral Intervention for Physical Activity|Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
79681895|NCT05110196|Drug|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
79825479|NCT04318964|Biological|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
79825480|NCT04306900|Combination Product|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
79230573|NCT03263156|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
79526507|NCT05268601|Drug|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
79526508|NCT05268601|Drug|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
79526509|NCT05268536|Other|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
79526510|NCT05268536|Other|resistance exercise|resistance exercise
79526511|NCT05268523|Behavioral|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
79825481|NCT04306900|Combination Product|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
79825482|NCT04306900|Combination Product|TTX-030 and mFOLFOX6|Dose and schedule per protocol
79825483|NCT04306900|Combination Product|TTX-030 and budigalimab|Dose and schedule per protocol
79681896|NCT05110196|Drug|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
79825484|NCT04306900|Combination Product|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
79825485|NCT04306900|Combination Product|TTX-030 and pembrolizumab|Dose and schedule per protocol
79825486|NCT04306900|Combination Product|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
79825487|NCT04306900|Combination Product|Budigalimab and mFOLFOX6|Dose and schedule per protocol
79230574|NCT04057144|Behavioral|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
79230575|NCT04057144|Behavioral|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
79390922|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
79390923|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
79390924|NCT01703819|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
79390925|NCT01703819|Other|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
79390926|NCT01898715|Drug|ATR-101|
79681897|NCT05100355|Procedure|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
79681898|NCT05100355|Procedure|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
79825488|NCT04296604|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
79825489|NCT04288687|Drug|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
79681899|NCT05100134|Drug|ceritinib|Patients receive ceritinib
79681900|NCT05085860|Behavioral|Moderate-intensity continuous training (MICT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
79681901|NCT05085860|Behavioral|High-intensity interval training (HIIT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
79825490|NCT04278235|Drug|Elezanumab|Solution for intravenous (IV) infusion
79825491|NCT04271579|Procedure|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
79681902|NCT05084222|Drug|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
79681903|NCT05084222|Drug|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
79681904|NCT05084222|Drug|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
79681905|NCT05082129|Device|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
79681906|NCT05080660|Drug|LY3526318|Administered orally.
79230576|NCT04057144|Behavioral|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
79230577|NCT05487118|Device|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
79681907|NCT05080660|Drug|Placebo|Administered orally.
79681908|NCT05080322|Drug|Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray|on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
79681909|NCT05080322|Drug|Fluticasone Nasal 50 Mcg/Inh Nasal Spray|on-demand or maintenance
79681910|NCT05079269|Other|Crystalloid Solutions|As above
79681911|NCT05065190|Drug|nintedanib|nintedanib
79681912|NCT05065190|Drug|Placebo|Placebo
79681913|NCT05057975|Device|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
79825492|NCT04269512|Procedure|lymph node dissection|At least 10 lymph nodes must be removed.
79825493|NCT04269161|Device|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
79825494|NCT04259047|Behavioral|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
79825495|NCT04259047|Behavioral|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
79825496|NCT04257994|Diagnostic Test|obtaining a buccal smear sample|A sample will be taken from the inside of the participants' cheeks using a soft brush
79825497|NCT04245228|Behavioral|Wellness Coach|Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
79230578|NCT05487118|Device|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
79390927|NCT02425410|Other|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
79825498|NCT04231708|Drug|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
79681914|NCT05057975|Device|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
79825499|NCT04231708|Device|Active rTMS|10Hz rTMS over the left dlPFC
79825500|NCT04231708|Drug|Placebo|lactose (inside capsule)
79230579|NCT03262844|Behavioral|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
79230580|NCT03262844|Procedure|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
79230581|NCT03265106|Biological|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
79230582|NCT03265340|Device|dTMS|
79230583|NCT02457884|Other|Temporal Group|Visual Processing Training
79390928|NCT02425410|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
79526512|NCT05268523|Behavioral|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
79526513|NCT05268484|Device|Perturbation-based Training with visual cues using Neurocom|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
79681915|NCT05054920|Other|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
79681916|NCT05054920|Other|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
79825501|NCT04231708|Device|Sham rTMS|inactive stimulation over the left dlPFC
79230584|NCT02457884|Other|Spatial Group|Spatial visual span training
79390929|NCT00255801|Drug|Targretin® (bexarotene)|
79390930|NCT00255801|Drug|pegylated liposomal doxorubicin hydrochloride|
79526514|NCT05268354|Other|6-week neuromuscular training program|Training program consisting of three neuromuscular training sessions per week
79681917|NCT05054920|Other|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
79681918|NCT05054153|Other|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
79825502|NCT04229992|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
79825503|NCT04229992|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
79825504|NCT04229472|Diagnostic Test|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
79825505|NCT04229472|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
79825506|NCT04221230|Drug|BTRX-335140|Active Drug
79825507|NCT04221230|Drug|Placebo|Placebo
79825508|NCT04218786|Drug|Colchicine|The tablet will be given once daily for the span of the study
79825509|NCT04218786|Drug|Placebo oral tablet|The tablet will be given once daily for the span of the study
79825510|NCT04202692|Device|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
79825511|NCT04202692|Device|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
79230585|NCT02457884|Other|Combined Group|Visual processing speed and spatial visual span training
79230586|NCT02457884|Other|Control Group|Leisure reading activities
79825512|NCT04201119|Device|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
79999686|NCT06273709|Device|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|(Michelson Diagnostics Maidstone, Kent, UK; resolution <7.5 µm lateral, <5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
79999687|NCT06273696|Device|ShangRing|The ShangRing is a sterile, single use, disposable male circumcision (MC) device that consists of two concentric plastic rings, the inner of which is lined by a silicone pad, which provides a smooth and non-bio reactive surface against the surgical wound. The outer ring consists of 2 halves which are hinged together at the same end. On each side of the halves there is a locking clasp which allows for locking itself with inner ring. The ShangRing device is removed seven days after placement.
79681919|NCT05054153|Other|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
79999688|NCT06273683|Other|Hand-held bipolar energy instrument|A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
79999689|NCT06273683|Other|Traditional suture ligation|Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
79999690|NCT06273670|Other|screening and data collection|"Structured questionnaire prepared in English and translated to local language (Arabic). The questionnaire is then linguistically validated by two forwards translations and one backward translation. Data was collected by the investigators who were not participating in the study.~Personal or telephone interview will be conducted with clients and service providers conducted to collect the data."
79999691|NCT06273657|Other|Medisinstart|Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
79999692|NCT06273644|Other|Carbohydrates|Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
79999693|NCT06273631|Other|multiple-diverse carbohydrate diet|"Carbohydrate provides 50~55% of total dietary energy, protein 10~15%, and fat 20 ~30%. Among them, 45~50% of carbohydrate supply sources are refined grains, 45~50% of carbohydrate supply sources are whole grains, beans or potatoes.~The total energy is divided into 6 meals per day. The breakfast provides 15~20% of total energy, lunch 20~25%，dinner 15~20%，and each of 3 extra meals provides 10~15% of total energy."
79372870|NCT05438472|Other|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT > 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
79526515|NCT05268211|Diagnostic Test|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
79999694|NCT06273631|Other|middle carbohydrate diet|"Carbohydrate provides 50~55% of total dietary energy, protein 10~15%, and fat 20 ~30%. Among them, 90~95% of carbohydrate supply sources are refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25~30% of total energy, lunch 30~40%，and dinner 30~35%."
79999695|NCT06273618|Other|Micro-Learning|Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.
79230587|NCT05387954|Procedure|Transcatheter PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
79230588|NCT05387954|Drug|Oral Anticoagulant, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
79230589|NCT05387954|Drug|Antiplatelet therapy|Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
79526516|NCT05268068|Drug|Risankizumab|Intravenous (IV) Infusion
79526517|NCT05268068|Drug|Risankizumab|Subcutaneous (SC) Injection
79681920|NCT05054153|Other|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
79526518|NCT05267977|Drug|Cephalosporin 1St Generation|
79526519|NCT05267977|Drug|Aminoglycosides|
79526520|NCT05267964|Procedure|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
79526521|NCT05267964|Procedure|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
79526522|NCT05246891|Other|rehabilitation nursing|Functional respiratory rehabilitation and motor exercise plan.
79825513|NCT04198831|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
79999696|NCT06273605|Other|Egg Ladder|12 month protocol of graded and gradual egg introduction
79999697|NCT06273592|Other|Animal-based meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
79999698|NCT06273592|Other|Plant-based meat meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
79526523|NCT05246748|Other|Human Caring Theory based Education|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
79526524|NCT05246748|Other|Standard Education|The control group received solely standard education program for one sessions in prenatal period.
79681921|NCT05050643|Other|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
79999699|NCT06273579|Behavioral|Experimental Group - Verbal expert instructor feedback in AI's words|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. They will also be provided with a list of commands that the ICEMS uses. When the system detects an error in a student's performance for a given metric, the expert instructor must deliver this command in the same words as the ICEMS.
79999700|NCT06273579|Behavioral|Experimental Group - Verbal expert instructor feedback in expert's own words|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. When the system detects an error in a student's performance for a given metric, the expert will deliver feedback in their own words.
79999701|NCT06273566|Other|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
79999702|NCT06273553|Biological|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
79230590|NCT05074784|Device|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
79230591|NCT05074784|Device|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
79230592|NCT03944018|Behavioral|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
79230593|NCT03262688|Drug|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
79681922|NCT05050643|Other|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
79230594|NCT03262688|Drug|Bupivacaine HCl infiltration|Infiltration of the surgical site
79681923|NCT05039866|Biological|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
79230595|NCT05486884|Procedure|Maintain MAP ≥ 90 mmHg|Maintain MAP ≥ 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
79681924|NCT05039203|Device|Indwelling urinary catheter|Removal of indwelling urinary catheter
79681925|NCT05038098|Procedure|Gastrectomy|Undergo surgery
79681926|NCT05038098|Drug|Indocyanine Green|Given peritumorally
79681927|NCT05038098|Other|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
79681928|NCT05031832|Diagnostic Test|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
79681929|NCT05027048|Drug|Calcium chloride|See arm description above
79681930|NCT05027048|Drug|Saline placebo|see arm description above
79681931|NCT05025059|Procedure|Discussion|Participate in coaching sessions
79681932|NCT05025059|Other|Exercise Intervention|Perform walking exercise
79681933|NCT05025059|Other|Exercise Intervention|Perform strength exercises
79681934|NCT05025059|Other|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
79681935|NCT05025059|Other|Informational Intervention|Maintain exercise log
79681936|NCT05025059|Other|Medical Device Usage and Evaluation|Wear fitness tracker
79681937|NCT05025059|Other|Quality-of-Life Assessment|Complete questionnaires
79681938|NCT05025059|Other|Questionnaire Administration|Complete questionnaires
79681939|NCT05025020|Other|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
79681940|NCT05025020|Other|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
79681941|NCT05025020|Other|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
79681942|NCT05025020|Other|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
79999703|NCT06273540|Drug|STP7 (mavoglurant) or Placebo|"STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline."
79372871|NCT05167344|Behavioral|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
79999704|NCT06273527|Behavioral|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
79526525|NCT05238090|Other|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
79526526|NCT05238090|Other|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
79526527|NCT05207696|Other|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
79681943|NCT05021133|Behavioral|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
79681944|NCT05020678|Biological|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10^8 NK cells (6 × 10^6/kg for patients < 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
79681945|NCT05018130|Procedure|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
79681946|NCT05018130|Procedure|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
79681947|NCT05017727|Device|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
79681948|NCT05014776|Drug|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
79681949|NCT05014776|Drug|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
79999705|NCT06273527|Other|Sham Program|The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
79230596|NCT05486884|Procedure|Maintain MAP ≥ 65 mmHg|Maintain MAP ≥ 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine
79230597|NCT02458820|Procedure|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
79230598|NCT03262532|Other|Web-base simulator|Training manipulation of TEE using a Web-based simulator
79230599|NCT03262532|Other|No web-base simulator|Training manipulation of TEE with out a web-base simulator
79230600|NCT05485792|Diagnostic Test|18F-FAPI PET/CT and 18F-FDG PET/CT|Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
79372872|NCT01189240|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
79372873|NCT01189240|Biological|bevacizumab|Given IV
79372874|NCT01189240|Other|laboratory biomarker analysis|Correlative studies
79372875|NCT01189240|Other|pharmacological study|Correlative studies
79390931|NCT02427048|Behavioral|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
79825514|NCT04198831|Other|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
79825515|NCT04198818|Drug|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
79825516|NCT04195542|Other|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
79825517|NCT04192825|Procedure|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
79230601|NCT03870464|Diagnostic Test|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
79230602|NCT03870464|Diagnostic Test|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
79372876|NCT03467490|Behavioral|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
79825518|NCT04177758|Drug|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
79825519|NCT04177758|Drug|Control|Patients randomized to the control will receive a placebo
79230603|NCT03870464|Other|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
79230604|NCT03870464|Behavioral|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
79230605|NCT05485402|Dietary Supplement|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
79372877|NCT03462264|Device|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
79372878|NCT03462264|Other|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
79526528|NCT05186558|Drug|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~lenalidomide: 10 mg, po, for 18 months."
79526529|NCT05175456|Other|Bedjet|Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
79526530|NCT05175456|Device|FitBit|Each participant will receive a FitBit device to track sleep quality and related information.
79681950|NCT05014776|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
79681951|NCT05014776|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 [1 × 109 colony forming units (CFU) in 100ml NS] will be administered IV on Day 2 of Cycles 1-6.
79681952|NCT05013216|Drug|KRAS peptide vaccine|"KRAS peptide vaccine will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13.~Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
79230606|NCT05485402|Dietary Supplement|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
79372879|NCT03013348|Device|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography [EEG] recordings) that are pathognomonic for PNES activity.
79372880|NCT03467334|Dietary Supplement|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
79372881|NCT03467334|Dietary Supplement|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
79526531|NCT05113810|Drug|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
79526532|NCT05113810|Other|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
79526533|NCT05101135|Drug|JT-001|Subjects take the investigational products once a day for 24 weeks.
79681953|NCT05011162|Device|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
79372882|NCT03467334|Drug|Simethicone 20 MG|Standard treatment for infant colic
79372883|NCT02880384|Other|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
79372884|NCT03462186|Other|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
79825520|NCT04172805|Drug|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
79825521|NCT04159909|Device|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
79825522|NCT04159909|Device|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
79825523|NCT04150458|Drug|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
79230607|NCT05485402|Dietary Supplement|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
79372885|NCT02874144|Drug|AZ compound|40 mg three times daily po for 12 weeks
79681954|NCT05007275|Biological|1x10^9 vp AZD1222|A single dose of 1x 10^9 vp AZD1222
79681955|NCT05007275|Biological|5x10^9 vp AZD1222|A single dose of 5x 10^9 vp AZD1222
79825524|NCT04147208|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
79825525|NCT04147208|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
79825526|NCT04147208|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
79825527|NCT04137510|Device|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
79825528|NCT04120688|Device|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
79825529|NCT04085991|Drug|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
79825530|NCT04072991|Other|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
79825531|NCT04047771|Drug|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
79230608|NCT05485402|Dietary Supplement|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
79230609|NCT05485402|Other|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
79230610|NCT05485324|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
79372886|NCT02874144|Other|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
79526534|NCT05101135|Drug|JT-001 Placebo|Subjects take the investigational products once a day for 24 weeks.
79825532|NCT04025931|Drug|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
79825533|NCT04003103|Drug|Islatravir|Islatravir 30 mg capsules taken by mouth.
79825534|NCT04003103|Drug|Placebo|Placebo capsules taken by mouth.
79230611|NCT03797924|Drug|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
79230612|NCT03797924|Behavioral|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
79230613|NCT02456792|Procedure|IVF|Women will undergo one IVF cycle
79372887|NCT02874144|Drug|Intranasal corticosteroid|QD Nasal Spray
79372888|NCT02874144|Drug|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
79372889|NCT03467178|Drug|Decitabine|Nucleic Acid Synthesis Inhibitor
79372890|NCT03467178|Drug|Carboplatin|Chemotherapy medication
79526535|NCT05092698|Dietary Supplement|Vitamin D (cholecalciferol)|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
79681956|NCT05007275|Biological|1x10^10 vp AZD1222|A single dose of 1x10^10 vp AZD1222
79681957|NCT05005312|Drug|PF-07321332|Tablet
79681958|NCT05005312|Drug|Ritonavir|PK Boosting agent
79681959|NCT05004220|Procedure|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
79372891|NCT03467178|Drug|Pegylated Liposomal Doxorubicin|Chemotherapy medication
79372892|NCT03467178|Drug|Gemcitabine|Chemotherapy medication
79372893|NCT03467178|Drug|Paclitaxel|Chemotherapy medication
79681960|NCT05001984|Drug|Alirocumab|Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
79681961|NCT04999046|Device|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
79681962|NCT04995328|Other|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
79526536|NCT05092698|Dietary Supplement|Herbal oil|Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
79825535|NCT03999216|Drug|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
79825536|NCT03989401|Other|Multimedia video health education|The experimental group conducted multimedia video education while admission.
79825537|NCT03971617|Drug|Hydrogen|each hydrogen tablet contains 80mg magnesium
79825538|NCT03971617|Drug|Placebo oral tablet|matching placebo tablet
79825539|NCT03965585|Procedure|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
79825540|NCT03964909|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI
79999706|NCT06273514|Other|TECAR|"TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM."
79230614|NCT02456792|Procedure|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
79372894|NCT03462108|Biological|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
79999707|NCT06273514|Other|Dry needling|"Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe."
79681963|NCT04994483|Drug|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
79681964|NCT04994483|Drug|Placebo|Matching placebo given b.i.d. for 52 weeks.
79681965|NCT04988945|Procedure|TACE|Procedure of TACE will be standardized.
79825541|NCT03964909|Procedure|Magnetic Resonance Imaging|Undergo CVR MRI
79372895|NCT03462108|Other|Placebo|Placebo contains 30% sucrose in DMEM
79372896|NCT03467100|Drug|XEN901|Capsule filled with XEN901
79372897|NCT03467100|Drug|Inert Ingredients Oral Product|Placebo capsule
79372898|NCT05434182|Procedure|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
79526537|NCT05051254|Other|Esogastric pressure measurement|"Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function."
79825542|NCT03964909|Procedure|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
79825543|NCT03959683|Device|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
79825544|NCT03959683|Device|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
79230616|NCT02458976|Device|PDL|
79230617|NCT05074628|Drug|Nitrofurantoin capsules|methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
79526538|NCT05009355|Drug|Vitamin C|antioxidant
79526539|NCT05003661|Behavioral|Parents' Voice|the intervention is recording of parents voice of reading children's book.
79681966|NCT04988945|Radiation|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
79230618|NCT02458742|Drug|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
79681967|NCT04988945|Drug|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
79681968|NCT04988945|Drug|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
79681969|NCT04988750|Device|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
79681970|NCT04985565|Other|Dietary Intervention|Participate in Mediterranean diet
79230619|NCT02458742|Drug|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
79372899|NCT05434182|Procedure|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
79825545|NCT03958929|Other|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
79230620|NCT03237910|Diagnostic Test|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
79230621|NCT03237910|Procedure|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
79230622|NCT03237910|Procedure|CPR|chest compressions and ventilations at a rate of 30:2
79230623|NCT03262766|Other|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
79230624|NCT03262766|Behavioral|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
79230625|NCT03262766|Other|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
79230626|NCT05486494|Other|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
79230627|NCT02403310|Drug|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~Dose Level 2: 80 mg twice weekly.~Dose Level 1 (starting dose): 60 mg twice weekly.~Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
79230628|NCT02403310|Drug|Daunorubicin|"Induction: Daunorubicin 60 mg/m^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m^2/day (days 1-2)."
79230629|NCT02403310|Drug|Cytarabine|"Induction: Cytarabine 100 mg/m^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m^2/day (continuous infusion on days 1-5)."
79230630|NCT03258944|Other|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
79372900|NCT02847078|Device|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
79372901|NCT02847078|Device|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
79372902|NCT02835534|Drug|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
79526540|NCT04986449|Behavioral|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
79526541|NCT04981587|Procedure|Strength exercise|Strength exercise protocol for upper and lower limbs, using weights and elastic bands
79681971|NCT04985565|Procedure|Radical Prostatectomy|Undergo standard of care radical prostatectomy
79681972|NCT04982731|Other|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
79681973|NCT04979455|Other|Core temperature monitoring|Core temperature will be monitored on the day of exercise
79681974|NCT04979455|Behavioral|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
79681975|NCT04979455|Other|Heart rate monitoring|Heart rate will be monitored on the day of exercise
79681976|NCT04979455|Other|Urine collection|Urine samples will be collected at baseline and on the day of exercise
79681977|NCT04979455|Other|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
79681978|NCT04979455|Other|Blood collection|Blood samples will be completed at baseline
79681979|NCT04979455|Other|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
79681980|NCT04979455|Other|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
79681981|NCT04979455|Other|Stool collection|Stool samples will be collected at baseline and on the day of exercise
79825546|NCT03945448|Drug|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
79681982|NCT04968990|Device|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
79681983|NCT04968990|Drug|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
79230631|NCT01665274|Drug|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
79230632|NCT01665274|Drug|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
79230633|NCT01665274|Procedure|D2 resection|D2 resection
79230634|NCT03259256|Procedure|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
79372903|NCT02835534|Drug|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
79526542|NCT04981587|Other|Usual treatment|The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
79526543|NCT04980014|Drug|NesinaAct® Tablet|NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
79526544|NCT04975204|Drug|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
79526545|NCT04965870|Drug|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
79526546|NCT04954807|Dietary Supplement|human milk fortified|HMF will be given 6 scoops a day
79526547|NCT04954807|Dietary Supplement|placebo|Placebo will be given six scoops a day
79526548|NCT04944745|Other|Myofascial Release|Moderate pressure manual treatment to the pectoral fascia.
79526549|NCT04944745|Other|Soft-touch Control|No pressure manual treatment to the pectoral fascia.
79526550|NCT04856436|Drug|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
79230635|NCT03262064|Combination Product|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
79230636|NCT03262298|Biological|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
79230637|NCT05484856|Biological|Autologous adipose tissue derived stromal cells|autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
79230638|NCT05387876|Dietary Supplement|Vitamin D intervention|Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
79372904|NCT02722200|Drug|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
79372905|NCT02722200|Other|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
79390932|NCT01898871|Dietary Supplement|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
79526551|NCT04853212|Procedure|Biopsy|Biopsy during recto-coloscopy
79526552|NCT04685902|Device|One-way speaking valve|One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
79526553|NCT04641091|Device|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
79526554|NCT04600674|Procedure|Delayed cord clamping|DCC performed at 60 sec after birth
79526555|NCT04600674|Procedure|Early cord clamping|ECC performed at 15 sec after birth
79526556|NCT04598087|Behavioral|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically ~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
79526557|NCT04593784|Drug|Ciraparantag|Ciraparantag: 180 mg, intravenous
79526558|NCT04593784|Drug|Placebo|Placebo: 0.9% sodium chloride, intravenous
79681984|NCT04968990|Procedure|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
79681985|NCT04968990|Procedure|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
79681986|NCT04968990|Procedure|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
79681987|NCT04965727|Procedure|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
79526559|NCT04593784|Device|Point-of-Care Coagulometer (investigational device)|Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
79526560|NCT04576910|Biological|vaccinated with Sabin IPV|the 4th dose of polio vaccination
79681988|NCT04965688|Drug|Drug determined by treating oncologist based on recommendation from systems biology analysis.|All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
79825547|NCT03945448|Drug|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
79825548|NCT03941873|Drug|Sitravatinib|Study participants will receive sitravatinib capsule once daily
79526561|NCT04576910|Biological|vaccinated with bOPV|the 4th dose of polio vaccination
79372906|NCT04066218|Other|Interviews|"Participation will serve as verbal consent.~Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~REDCap link will be sent for PROMIS SexFS Brief.~PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
79372907|NCT04453176|Other|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
79372908|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
79372909|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
79526562|NCT04503603|Drug|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
79526563|NCT04503603|Other|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
79526564|NCT04500366|Behavioral|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
79526565|NCT04500366|Behavioral|Virtual Group Exercise|Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
79526566|NCT04500366|Combination Product|Nutrition Consult and Protein Supplementation|"Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days."
79526567|NCT04500366|Behavioral|Medication Review|A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
79681989|NCT04964895|Other|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
79681990|NCT04959279|Other|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
79825549|NCT03941873|Drug|Sitravatinib plus Tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
79825550|NCT03941873|Drug|Sitravatinib|Study participants will receive sitravatinib capsule once daily.
79825551|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
79825552|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
79825553|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
79825554|NCT03941587|Drug|Aflibercept + reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
79825555|NCT03941587|Drug|Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
79825556|NCT03941171|Procedure|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
79825557|NCT03941171|Other|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
79999708|NCT06273501|Drug|Magtrace|Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
79372910|NCT01094548|Drug|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
79372911|NCT01094548|Drug|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
79526568|NCT04466540|Drug|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
79681991|NCT04957173|Other|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~A maintenance phase of weight loss for 16 weeks.~An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
79681992|NCT04956770|Procedure|Implantation surgery|"The intervention involves the implantation of:~a neurostimulator: the Activa® RC from Medtronic~a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
79825558|NCT03941171|Other|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
79681993|NCT04956692|Biological|Pembrolizumab SC|SC injection
79825559|NCT03935763|Other|observational disease study|observation of routine clinical practices in mCRC
79848947|NCT05786222|Behavioral|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator [a trained CSH employee] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
79230639|NCT05387876|Dietary Supplement|Placebo intervention|Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
79372912|NCT01094704|Drug|sodium chloride (7%)|4mL nebulized 7% sodium chloride
79372913|NCT02611830|Drug|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
79372914|NCT02611830|Drug|Placebo IV|Vedolizumab intravenous infusion placebo
79681994|NCT04956692|Biological|Pembrolizumab IV|IV injection
79681995|NCT04956692|Drug|Paclitaxel|IV injection
79681996|NCT04956692|Drug|Nab-Paclitaxel|IV infusion
79681997|NCT04956692|Drug|Carboplatin|IV infusion
79230640|NCT02456402|Device|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
79230641|NCT02456402|Device|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
79230642|NCT05074004|Other|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
79230643|NCT03262220|Radiation|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
79372915|NCT02611830|Drug|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
79372916|NCT02611830|Drug|Placebo SC|Vedolizumab subcutaneous injection placebo
79390933|NCT02431416|Drug|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
79681998|NCT04956692|Drug|Cisplatin|IV infusion
79681999|NCT04956692|Drug|Pemetrexed|IV infusion
79682000|NCT04955444|Other|Quality improvement bundle|The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
79390934|NCT02431416|Drug|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
79526569|NCT04466540|Drug|Placebo|Hydroxychloroquine placebo
79526570|NCT04454918|Drug|TAK-906 Oral Capsule|TAK-906 capsule.
79526571|NCT04454918|Drug|[14C]-TAK-906 Intravenous Infusion|[14C]-TAK-906 intravenous infusion.
79526572|NCT04454918|Drug|[14C]-TAK-906 Oral Solution|[14C]-TAK-906 oral solution.
79526573|NCT06105541|Device|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
79526574|NCT06105515|Procedure|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
79825560|NCT03930524|Behavioral|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
79825561|NCT03930524|Behavioral|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
79825562|NCT03930524|Behavioral|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
79825563|NCT03930524|Behavioral|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
79825564|NCT03930524|Behavioral|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
79230644|NCT04560166|Drug|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"Irinotecan, solution for infusion (20 mg/mL)~Temozolomide, capsules (5 mg, 20 mg and 100 mg)~The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"
79230645|NCT03262376|Dietary Supplement|Minerals + Vitamins|A mineral and vitamin tablet
79230646|NCT03262376|Dietary Supplement|Botanical A|Botanical extract administered in capsule form
79526575|NCT06105502|Behavioral|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
79526576|NCT06105489|Procedure|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~The door will be removed.~The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~The flaps will be meticulously sutured."
79682001|NCT04950439|Other|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
79682002|NCT04947449|Device|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
79230647|NCT03262376|Dietary Supplement|Botanical B|Botanical extract administered in capsule form
79230648|NCT03262376|Other|Placebo|Cellulose crystalline tablet
79230649|NCT03259100|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
79230650|NCT03261986|Radiation|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
79230651|NCT03261986|Procedure|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
79230652|NCT04344340|Diagnostic Test|clinical examination|clinical examination
79230653|NCT02456714|Drug|FOLFIRINOX|
79390935|NCT01899183|Procedure|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
79390936|NCT02425332|Device|Lokomat gait trainer|
79390937|NCT01898949|Other|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
79390938|NCT02431338|Procedure|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
79390939|NCT00708084|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
79682003|NCT04946305|Other|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
79682004|NCT04943588|Diagnostic Test|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
79825565|NCT03923322|Drug|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
79825566|NCT03923322|Other|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
79682005|NCT04943588|Diagnostic Test|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
79825567|NCT03921528|Biological|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
79230654|NCT05480020|Other|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
79825568|NCT03917420|Drug|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
79825569|NCT03917420|Drug|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
79825570|NCT03917147|Procedure|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
79230655|NCT05480020|Other|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
79825571|NCT03902067|Biological|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU， at the concentration of 2x10(7) cells/ml.
79825572|NCT03902067|Biological|Control Group|Routine treatment without catheter infusion
79230656|NCT05480020|Other|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
79230657|NCT03259646|Behavioral|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
79230658|NCT03258866|Drug|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
79230659|NCT03258866|Drug|Rituximab|given with a single dose of 375mg/m2
79682006|NCT04943588|Diagnostic Test|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
79825573|NCT03892720|Other|Quality-of-Life Assessment|Ancillary studies
79230660|NCT02456324|Device|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
79230661|NCT02456324|Device|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
79230662|NCT05484232|Procedure|Laparoscopic Cholecystectomy|Early laparoscopic cholecystectomy in patients with acute calcular cholecystitis
79230663|NCT03258476|Drug|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
79682007|NCT04922281|Device|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
79682008|NCT04917107|Behavioral|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
79682009|NCT04912466|Drug|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
79682010|NCT04910022|Drug|NMS-03305293|Route of administration: Oral
79682011|NCT04910022|Drug|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
79682012|NCT04902248|Device|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
79682013|NCT04902248|Procedure|angiographic embolization|Transcatheter selective embolization to bleeding arteries
79682014|NCT04894773|Other|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
79682015|NCT04894773|Other|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
79825574|NCT03892720|Other|Questionnaire Administration|Ancillary studies
79825575|NCT03892720|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79682016|NCT04891692|Device|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
79825576|NCT03886077|Drug|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
79825577|NCT03870815|Procedure|CABG|Patients who undergoing CABG
79825578|NCT03870815|Procedure|PCI|Patients who undergoing PCI with DES
79825579|NCT03853473|Procedure|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
79825580|NCT03845244|Device|Flow reduction first|-10L/min q 1hr
79825581|NCT03845244|Device|FiO2 reduction first|- 0.1 q 1hr
79825582|NCT03845244|Device|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
79825583|NCT03844568|Device|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
79825584|NCT03841760|Diagnostic Test|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
79825585|NCT03833102|Other|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
79825586|NCT03832322|Procedure|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
79682017|NCT04889066|Radiation|Stereotactic Radiation Therapy|"24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm."
79682018|NCT04889066|Drug|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
79825587|NCT03832322|Procedure|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
79825588|NCT03828968|Diagnostic Test|bladder scan|Measurement of vesical volume by bladder scan
79825589|NCT03802656|Device|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
79230664|NCT03258476|Behavioral|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
79230665|NCT03258476|Drug|Placebo|Placebo oral capsule
79526577|NCT06105489|Procedure|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~The door will be removed.~The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~The flaps will be meticulously sutured."
79372917|NCT03461874|Behavioral|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
79390940|NCT00708084|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
79230666|NCT03258398|Drug|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
79230667|NCT03258398|Drug|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
79825590|NCT03797482|Procedure|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
79825591|NCT03781973|Behavioral|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
79825592|NCT03773003|Dietary Supplement|Probiotics|"The administered probiotics are readily available on the market and contain~Bifidobacterium breve, B. infantis, B. lactis, B. longum~Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~Streptococcus thermophilus"
79825593|NCT03773003|Dietary Supplement|Placebo|Identically looking to verum, containing corn starch.
79825594|NCT03766438|Behavioral|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
79825595|NCT03755154|Drug|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
79825596|NCT03755154|Drug|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
79825597|NCT03720119|Drug|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
79825598|NCT03713528|Drug|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
79825599|NCT03709511|Other|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
79230668|NCT05479942|Other|Graded motor imagery training paradigm|"Graded motor imagery is the psychological representation of attention doing movement of a part of body, without actually moving that part, it broken down into three unique stages of treatment techniques:~Left/right discrimination (Implicit motor imagery):~Explicit motor imagery~Mirror Therapy"
79372918|NCT03461874|Behavioral|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
79390941|NCT01682759|Drug|Omarigliptin|
79390942|NCT01682759|Drug|Placebo to Omarigliptin|
79526578|NCT06105437|Other|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
79526579|NCT06105424|Procedure|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
79526580|NCT06105398|Other|clinical evaluation|clinical evaluation tests
79682019|NCT04883528|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
79682020|NCT04883528|Drug|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
79682021|NCT04870645|Procedure|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
79682022|NCT04870645|Procedure|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
79682023|NCT04870645|Drug|Gadolinium-Chelate|Contrast agent
79682024|NCT04870645|Drug|Iopamidol|Contrast agent
79682025|NCT04868149|Procedure|Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)|Surgery procedure
79825600|NCT03708562|Device|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
79825601|NCT03705845|Drug|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
79230669|NCT05479942|Other|conventional therapy (task-oriented active/passive range of motion training)|"Patient will do 3 tasks as: drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, and combing their hairs.~Practice shoulder flexion and abduction active ROM, and passive ROM training"
79825602|NCT03705845|Drug|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
79230670|NCT03261752|Diagnostic Test|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.
79230671|NCT03261596|Drug|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
79372919|NCT03461874|Drug|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
79825603|NCT03669718|Biological|ISA101b|Every 3 weeks for a total of 3 times
79825604|NCT03669718|Drug|Cemiplimab|Every 3 weeks for up to 24 months
79825605|NCT03669718|Other|Placebo|Every 3 weeks for a total of 3 times
79682026|NCT04867902|Behavioral|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
79825606|NCT03668457|Behavioral|Intervention to Patients|"Multifaceted intervention consisting of:~A collaborative care management intervention, including depression education, medication management and behavioral activation.~Use of a medication reminder mobile app."
79230672|NCT04072588|Procedure|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
79372920|NCT03461718|Drug|Ketamine|Experimental arm for sedation.
79825607|NCT03668457|Behavioral|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
79825608|NCT03668457|Other|Control|Other: Usual care Usual care for depressive disorder received in mental health units
79825609|NCT03668197|Biological|microbiological analysis|microbiological analysis of the peritoneal fluid
79825610|NCT03668184|Other|preeclampsia|occurrence of pre-eclampsia
79825611|NCT03649555|Drug|[18F]-FTC-146|Two 5 mCi [18F]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
79825612|NCT03644966|Dietary Supplement|Bifidobacterium infantis|Probiotics
79825613|NCT03644966|Other|Placebo|Sugar pill manufactured to mimic probiotic tablet
79825614|NCT03644966|Drug|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
79825615|NCT03642990|Drug|Nicotinamide Riboside|Capsule
79825616|NCT03639311|Drug|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
79825617|NCT03639311|Drug|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
79230673|NCT04488458|Diagnostic Test|MIC or MBEC+MIC based treatment algorithm|"i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks."
79230674|NCT05479864|Procedure|anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
79230675|NCT03261908|Genetic|detection of genotype|detection of genotype by next generation sequencing
79230676|NCT03825874|Other|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
79372921|NCT03461718|Drug|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
79372922|NCT03461718|Drug|Fentanyl|Part of standard sedation regimen
79372923|NCT03467022|Drug|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
79372924|NCT02522364|Device|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
79372925|NCT02522364|Other|Standard|Clinical and intermittent electrocardiographic follow-up of patients
79372926|NCT03129594|Diagnostic Test|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
79682027|NCT04864392|Drug|LNA043 Dosing Regimen A|Injection to the knee
79682028|NCT04864392|Drug|LNA043 Dosing Regimen B|Injection to the knee
79682029|NCT04864392|Drug|LNA043 Dosing Regimen C|Injection to the knee
79825618|NCT03639311|Drug|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
79825619|NCT03639311|Drug|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
79825620|NCT03633825|Behavioral|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
79825621|NCT03630146|Behavioral|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
79825622|NCT03630146|Other|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
79825623|NCT03608410|Other|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
79825624|NCT03582475|Drug|Carboplatin|Given IV
79825625|NCT03582475|Drug|Cisplatin|Given IV
79825626|NCT03582475|Drug|Docetaxel|Given IV
79825627|NCT03582475|Drug|Etoposide|Given IV
79825628|NCT03582475|Biological|Pembrolizumab|Given IV
79825629|NCT03579784|Drug|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
79825630|NCT03579784|Drug|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
79230677|NCT03825874|Other|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
79372927|NCT03461640|Other|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
79372928|NCT03461640|Behavioral|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
79825631|NCT03579784|Drug|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
79825632|NCT03571984|Behavioral|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
79372929|NCT03466788|Other|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
79390943|NCT01682759|Drug|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
79825633|NCT03564171|Combination Product|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
79825634|NCT03553563|Drug|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
79825635|NCT03553563|Drug|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
79825636|NCT06063733|Other|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
79825637|NCT06063694|Device|Synthetic electrospun fiber matrix|Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation with primary closure.
79825638|NCT06063655|Dietary Supplement|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
79825639|NCT06063655|Dietary Supplement|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
79230678|NCT03772574|Device|Facemask preoxygenation|Standard facemask preoxygenation
79230679|NCT03772574|Device|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
79230680|NCT05483842|Other|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
79682030|NCT04864392|Drug|LNA043 Dosing Regimen D|Injection to the knee
79999709|NCT06273488|Other|Auriculotherapy|Treatment of pain, drug addictions, or other ailments by stimulating the various points on the external ear (EAR AURICLES). It is based on the ancient Chinese practices of EAR ACUPUNCTURE, but sometimes magnets and other modes of stimulation are used.
79526581|NCT06105385|Other|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
79526582|NCT06105333|Procedure|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was <10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained >10th centile for >60 seconds or if rSO2 was >90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
79372930|NCT03466710|Procedure|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
79999710|NCT06273475|Other|Robot-assisted Training|Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.
79999711|NCT06273475|Other|Standard Training|Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.
79372931|NCT03466710|Other|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or >LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is >/=CIN II. Results of </=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
79372932|NCT03466710|Diagnostic Test|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
79390944|NCT01682759|Drug|Glimepiride Placebo|
79526583|NCT06105320|Other|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
79682031|NCT04864392|Drug|Placebo|Injection to the knee
79682032|NCT04863443|Device|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
79682033|NCT04854980|Other|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
79709752|NCT02271308|Behavioral|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
79709753|NCT04349670|Procedure|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
79999712|NCT06273462|Drug|Palmitoylethanolamide 600mg twice a day|600mg palmitoylethanolamide twice a day
79999713|NCT06273462|Other|placebo|visually identical placebo capsule
79999714|NCT06273449|Device|Group 3 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Intraoral scan RPD Design Method: Based on intraoral scan, using design software RPD Fabrication Method: Additive manufacturing
79999715|NCT06273449|Device|Group 2 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using design software RPD Fabrication Method: Additive manufacturing
79999716|NCT06273436|Other|Listening to Women and Pregnant and Postpartum People (LTWP)|LTWP is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
79682034|NCT04843059|Other|The resident memory T-cell infiltrate in perilesional vitiligo skin|"The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24."
79682035|NCT04839952|Behavioral|Healthy Lifestyles|12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
79372933|NCT03466632|Drug|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
79825640|NCT06063655|Dietary Supplement|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
79825641|NCT06063616|Other|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
79999717|NCT06273423|Other|OULA, Mind-body Physical Activity|Group dance fitness program with focus on the mind-body connection
79682036|NCT04839952|Behavioral|Education-Only Control|This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
79682037|NCT04837937|Behavioral|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' [Beginner] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
79372934|NCT03466632|Drug|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
79526584|NCT06105320|Other|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
79682038|NCT04837937|Behavioral|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
79682039|NCT04837937|Behavioral|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
79682040|NCT04837937|Behavioral|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient [Difficult]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
79999718|NCT06273410|Other|Cention N|Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
79999719|NCT06273410|Other|Cention N + Adhesive|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel & dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
79526585|NCT06105294|Behavioral|time-restricted eating|Restrict eating to a 10-hour window.
79526586|NCT06105281|Behavioral|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
79526587|NCT06105268|Other|flipped learning training group|flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
79682041|NCT04835597|Behavioral|Behavioral Assessment|Complete movement assessment
79682042|NCT04835597|Other|Electronic Health Record Review|SAE data is collected
79999720|NCT06273410|Other|Bulk Fill Composite|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel & dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
79372935|NCT03466554|Device|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
79372936|NCT03461562|Other|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
79372937|NCT05348928|Device|Continuous glucose monitoring device|Continuous glucose monitoring device
79372938|NCT05348928|Other|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
79372939|NCT01144624|Drug|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
79372940|NCT01144624|Drug|Placebo|Intravenous infusion of a saline solution
79372941|NCT05339334|Drug|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
79526588|NCT06105255|Drug|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
79526589|NCT06105203|Procedure|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
79526590|NCT06105203|Procedure|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
79709754|NCT01606592|Behavioral|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
79825642|NCT06063616|Other|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
79526591|NCT06105164|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
79825643|NCT06063603|Procedure|Acupuncture Therapy|Undergo acupuncture therapy
79825644|NCT06063603|Behavioral|Cancer Pain Management|Receive pain clinic referral
79825645|NCT06063603|Behavioral|Cognitive Behavior Therapy|Undergo CBT
79230681|NCT05483842|Other|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
79526592|NCT06105164|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
79682043|NCT04825587|Procedure|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
79682044|NCT04824911|Drug|Clopidogrel|300mg loading and 75mg/day from day 2
79682045|NCT04824911|Drug|Aspirin|Aspirin(100-300mg/day)
79682046|NCT04824911|Drug|Atorvastatin|Atorvastatin 40-80mg/day
79230682|NCT05479786|Other|Expectant management|Follow-up with beta-HCG dosages and transvaginal ultrasound scans
79372942|NCT01096810|Drug|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
79372943|NCT03461328|Drug|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
79372944|NCT02455284|Device|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
79372945|NCT03466398|Behavioral|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
79372946|NCT04453254|Other|Whole Food Meal|Isocaloric/ macronutrient whole food meal
79682047|NCT04824911|Drug|Rosuvastatin|Rosuvastatin 20 mg/day.
79825646|NCT06063603|Procedure|Discussion|Participate in focus group
79825647|NCT06063603|Other|Educational Intervention|Receive self-guided pain management education materials
79230683|NCT05479786|Procedure|Salpingectomy|Removal of the affected Fallopian tube by laparoscopy
79230684|NCT05479786|Procedure|Salpingostomy|Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
79372947|NCT04453254|Other|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
79372948|NCT01145638|Drug|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
79372949|NCT01145638|Drug|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
79372950|NCT03466320|Biological|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
79372951|NCT03466242|Drug|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
79372952|NCT03466242|Drug|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
79682048|NCT04821544|Behavioral|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
79230685|NCT05499208|Other|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
79230686|NCT04319380|Biological|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
79230687|NCT04319380|Drug|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
79825648|NCT06063603|Other|Exercise|Participate in exercise
79825649|NCT06063603|Other|Interview|Complete interview
79825650|NCT06063603|Procedure|Massage Therapy|Receive massage
79825651|NCT06063603|Behavioral|Mindfulness Relaxation|Practice mindfulness
79825652|NCT06063603|Procedure|Pain Therapy|Receive pain treatment/medicine
79230688|NCT04319380|Biological|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
79825653|NCT06063603|Other|Palliative Therapy|Receive palliative care referral
79825654|NCT06063603|Behavioral|Patient Navigation|Undergo visits with PCM and CHW for pain management
79825655|NCT06063603|Other|Referral|Receive pain management referrals
79230689|NCT04319380|Drug|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
79230690|NCT05479708|Device|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
79372953|NCT03013270|Other|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
79372954|NCT03013270|Other|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
79682049|NCT04818489|Drug|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
79682050|NCT04818489|Other|the standard protocol only|the local standard protocol for COVID19
79372955|NCT03013270|Other|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
79372956|NCT03013270|Other|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
79526593|NCT06105112|Device|Hyaluronic acid|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
79526594|NCT06105112|Device|Enamel matrix derivatives|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
79682051|NCT04810806|Procedure|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
79682052|NCT04810806|Procedure|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
79825656|NCT06063603|Procedure|Spiritual Therapy|Receive spiritual support
79825657|NCT06063603|Procedure|Spiritual Care Referral|Receive spiritual care referral
79230691|NCT02456558|Drug|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
79230692|NCT02456558|Drug|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
79230693|NCT03798080|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79682053|NCT04803474|Diagnostic Test|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
79709755|NCT01606592|Behavioral|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
79709756|NCT01606592|Other|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
79825658|NCT06063603|Other|Survey Administration|Ancillary studies
79825659|NCT06063564|Behavioral|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
79825660|NCT06063564|Behavioral|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
79682054|NCT04781504|Behavioral|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
79825661|NCT06063551|Procedure|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
79825662|NCT06063525|Other|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
79682055|NCT04780659|Biological|Comirnaty (COVID-19, mRNA vaccine)|Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
79825663|NCT06063512|Other|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
79390945|NCT01682759|Drug|Metformin|Participants will continue on their stable dose (>=1500 mg/day) of open-label metformin throughout the trial.
79682056|NCT04768023|Drug|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
79682057|NCT04768023|Drug|Placebo|Matching amount of vegetable oil to the vitamin D3.
79682058|NCT04758403|Radiation|Navigation Bronchoscopy|Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
79682059|NCT04758403|Radiation|Cone beam computed tomography (CBCT)|Per Protocol
79682060|NCT04753879|Drug|Nab-paclitaxel|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: Abraxane"
79682061|NCT04753879|Drug|Gemcitabine|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: Gemzar"
79682062|NCT04753879|Drug|Cisplatin|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: N/A"
79682063|NCT04753879|Drug|Irinotecan|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: N/A"
79682064|NCT04753879|Drug|Capecitabine|"Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~Other Name: Xeloda"
79682065|NCT04753879|Drug|Pembrolizumab|"Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~Other Name: MK-3475; Keytruda"
79682066|NCT04753879|Drug|Olaparib|"Patients will receive treatment on Days 1-21 during the maintenance phase.~Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~Other Name: Lynparza"
79709757|NCT00595569|Behavioral|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
79825664|NCT06063473|Drug|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
79825665|NCT06063473|Drug|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
79230694|NCT03798080|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79390946|NCT01682759|Drug|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
79390947|NCT00239733|Drug|Anti-D|30-minute infusion administered in an outpatient setting
79390948|NCT03185754|Procedure|Sublobar resection|Sublobar resection
79390949|NCT03185754|Procedure|lobectomy|lobectomy
79709758|NCT02271347|Drug|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
79825666|NCT06063473|Drug|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
79825667|NCT06063447|Other|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
79230695|NCT03798080|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79230696|NCT05498974|Other|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
79230697|NCT03258242|Drug|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
79390950|NCT02431182|Behavioral|Memory Training Workshop|"Presentation of the workshop: Objectives and Methodology~Explanation of the different types of memory and its implication in normal life~Strategies for gathering and codification of the information~Strategies for selection and storage the information~Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~Strategies for recuperation according to the individual profile. Improving self-esteem~Strategies for recuperation Social skills.~Personal and social skills~New contexts and opportunities~Evaluation of the workshop"
79390951|NCT01682681|Drug|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
79682067|NCT04751812|Procedure|High-pain multimodal anesthesia with opioids|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
79682068|NCT04751812|Procedure|Low-pain opioid free|"Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated."
79825668|NCT06063421|Device|Electronic Cigarette (EC)|The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
79825669|NCT06063421|Drug|Nicotine Replacement Therapy|NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
79682069|NCT04751812|Procedure|Standard of care|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
79230698|NCT03258242|Drug|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
79526595|NCT06105099|Behavioral|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
79999721|NCT06273397|Drug|Acetazolamide 250 MG|Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
79682070|NCT04750226|Drug|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
79682071|NCT04742634|Drug|DEC-C|"DEC-C will be provided by Taiho Pharmaceuticals.~Cycle 1 Day 1 may take place between Day 42 & Day 100 post-transplant."
79848948|NCT05776966|Behavioral|Gender-specific digital intervention (GSDI)|The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.
79848949|NCT05776966|Other|Treatment as usual|Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
79999722|NCT06273397|Drug|Metolazone 2.5 MG|Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
79230699|NCT03258086|Diagnostic Test|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
79230700|NCT03257930|Drug|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
79230701|NCT03257852|Drug|ASP5094|intravenously administration
79682072|NCT04742634|Device|MyeloSeq-HD|-Laboratory test developed at Washington University School of Medicine
79682073|NCT04742309|Drug|Pecs-2 block (single injection)|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
79230702|NCT03257852|Drug|Placebo|intravenously administration
79230703|NCT03257852|Other|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
79230704|NCT05498896|Drug|Atezolizumab|IV infusion
79230705|NCT05498896|Drug|Ipatasertib|Oral
79230706|NCT05498896|Drug|Paclitaxel|IV infusion
79230707|NCT05498896|Drug|Doxorubicin|IV infusion
79230708|NCT05498896|Drug|Cyclophosphamide|IV infusion
79230709|NCT04765358|Other|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
79682074|NCT04742309|Drug|Paravertebral block (single injection)|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
79999723|NCT06273397|Drug|Furosemide Injection|Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
79682075|NCT04736966|Drug|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
79682076|NCT04736966|Drug|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
79682077|NCT04736966|Drug|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
79682078|NCT04729751|Drug|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
79682079|NCT04727593|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
79682080|NCT04727593|Other|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
79682081|NCT04726501|Other|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
79682082|NCT04720534|Drug|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
79999724|NCT06273371|Other|Damira 2000 Infant formula|100% extensive casein hydrolysate Infant formula
79999725|NCT06273332|Other|AI-assisted registration|We will use artificial intelligence to register 3d model on intra-oral scan
79682083|NCT04720534|Drug|Placebo|calculated volume to match active treatment by sc injection
79682084|NCT04720274|Device|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
79682085|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
79682086|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
79999726|NCT06273332|Other|Point-based registration|We will use five references points or more to perform model registration
79999727|NCT06273319|Drug|OXYGEN THERAPY|15 AND 30 LT OXYGEN TREATMENT
79999728|NCT06273306|Device|IMIDOC|Patient´s Mobile App for recording clinical data
79999729|NCT06273293|Diagnostic Test|Fractional Flow Reserve|"Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~Determination of the diastolic dPR index: the average value (2-3 determinations).~Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center."
79682087|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
79682088|NCT04717310|Drug|Vehicle|Twice a day (BID)
79682089|NCT04707469|Drug|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
79682090|NCT04700540|Device|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
79230710|NCT03257774|Other|Adhesive strip A|Strip consisting of a newly developed adhesive
79682091|NCT04699149|Other|Transcranial magnetic stimulation|Non-invasive brain stimulation
79682092|NCT04699149|Other|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
79682093|NCT04693598|Biological|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
79230711|NCT03257774|Other|Adhesive strip B|Strip consisting of a newly developed adhesive
79230712|NCT03257774|Other|Adhesive strip C|Strip consisting of a newly developed adhesive
79230713|NCT04779476|Other|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
79230714|NCT04667156|Drug|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
79682094|NCT04677179|Drug|LY3471851|administered SC
79682095|NCT04677179|Drug|Placebo|administered SC
79682096|NCT04675827|Drug|Pertuzumab and tratuzumab fixed dose combination|Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
79682097|NCT04675827|Drug|Trastuzumab emtansine|Treatment administration: adjuvant T-DM1 for 14 cycles.
79682098|NCT04675034|Biological|MEDI7352|Dose A: MEDI7352 Q2W
79999730|NCT06273280|Procedure|SOC|Physician-guided GDMT up-titration
79999731|NCT06273280|Procedure|Protocolized up-titration|Renal-based protocolized GDMT up-titration
79999732|NCT06273267|Other|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
79999733|NCT06273254|Drug|Sacubitril and Valsartan Tablets 49mg/51mg|Each tablet contains Sacubitril 49 mg and Valsartan 51 mg
79682099|NCT04675034|Biological|MEDI7352|Dose B: MEDI7352 Q2W
79999734|NCT06273254|Drug|Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)|Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
79999735|NCT06273241|Other|food intake|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics..
79999736|NCT06273228|Behavioral|Family Check-Up Online|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
79682100|NCT04675034|Biological|MEDI7352|Dose C: MEDI7352 Q2W
79682101|NCT04675034|Biological|MEDI7352|Dose D: MEDI7352 Q2W
79999737|NCT06273215|Drug|The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
79372957|NCT03461250|Diagnostic Test|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
79372958|NCT03461172|Procedure|Surgery of breast cancer|Surgery of breast cancer
79372959|NCT03461172|Other|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
79682102|NCT04675034|Biological|Placebo|Placebo to match MEDI7352 Q2W
79682103|NCT04671095|Device|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
79682104|NCT04662151|Biological|AT-100|reconstituted AT-100 for intratracheal administration
79999738|NCT06273202|Other|Infant Massage|Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
79999739|NCT06273189|Device|Conventional|In conventional group, contralateral side mandibular osteotomies were performed with Lindeman and round bur (Karl Storz, Tuttlingen, Germany)
79999740|NCT06273189|Device|Bone Scalpel|In ultrasonic device group, osteotomies one side of the mandible were performed unilaterally using an ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY) with a serrated standard blade
79230715|NCT03257540|Device|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
79230716|NCT02455700|Device|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
79230717|NCT03257306|Procedure|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
79230718|NCT03257306|Procedure|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
79230719|NCT03252704|Other|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
79682105|NCT04662151|Procedure|Air-sham|room air for intratracheal administration
79682106|NCT04658641|Device|Boston Scientific: Study tool computer|Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
79682107|NCT04651816|Behavioral|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
79682108|NCT04651816|Behavioral|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
79682109|NCT04651816|Behavioral|DPP Program|All Participants will be enrolled in the DPP program.
79682110|NCT04644471|Diagnostic Test|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
79682111|NCT04644471|Diagnostic Test|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
79682112|NCT04639141|Combination Product|Synbiotic|Prebiotic + Probiotic
79848952|NCT05772533|Procedure|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
79682113|NCT04639141|Behavioral|Gut-directed Hypnotherapy|Psychotherapy sessions
79999741|NCT06273176|Procedure|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
79999742|NCT06273176|Procedure|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
79230720|NCT03252704|Other|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
79999743|NCT06273176|Procedure|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
79230721|NCT03257462|Drug|SPR001|SPR001 Capsules
79230722|NCT03257228|Genetic|comparative semiquantitative immunohistochemistry|
79372960|NCT03466164|Behavioral|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
79372961|NCT02980120|Other|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig & Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
79372962|NCT02980120|Other|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner & Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
79372963|NCT02980120|Other|EDI-2|The Eating Disorder Inventory 2 (Paul & Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
79372964|NCT02980120|Other|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig & Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
79682114|NCT04636814|Drug|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
79682115|NCT04636814|Drug|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
79682116|NCT04636814|Drug|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
79999744|NCT06273150|Other|Positive genetic test for pathological expansion in ATN1|Positive genetic test for pathological expansion in ATN1
79230723|NCT03257072|Biological|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
79230724|NCT03257072|Biological|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
79230725|NCT03257072|Biological|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
79230726|NCT03252470|Procedure|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
79230727|NCT03261518|Procedure|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
79390952|NCT03183804|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
79682117|NCT04636814|Drug|Roflumilast|- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
79682118|NCT04634279|Behavioral|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
79682119|NCT04623944|Biological|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
79682120|NCT04598919|Drug|Saracatinab|125 mg once daily by mouth for 24 weeks
79682121|NCT04598919|Drug|Placebo|once daily by mouth for 24 weeks
79682122|NCT04590937|Drug|BI 730357|Film-coated tablet
79682123|NCT04590937|Drug|CRESTOR®|Film-coated tablet
79682124|NCT04590937|Drug|Lenoxin®|Tablet
79526596|NCT06105099|Behavioral|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
79682125|NCT04590937|Drug|MetfoLiquid GeriaSan®|Oral solution
79230728|NCT03256604|Diagnostic Test|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
79999745|NCT06273137|Behavioral|Positive affect treatment|PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
79682126|NCT04590937|Drug|Lasix®|Oral solution
79682127|NCT04576897|Diagnostic Test|Velacur|Ultrasound elasticity imaging
79999746|NCT06273124|Device|SteadiSet Extended Wear Infusion Set|Each participant will be given 12 Extended Wear Infusion Sets to wear over 12 wear periods up to 168 hours each.
79999747|NCT06273111|Drug|5% simvastatin ointment|5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
79999748|NCT06273098|Behavioral|Bladder Health Education|This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).
79230729|NCT03256838|Drug|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
79372965|NCT02980120|Other|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke & Krischer, 2011).
79390953|NCT03183804|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
79682128|NCT04571749|Behavioral|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
79682129|NCT04565691|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 50% of the cases.
79230730|NCT02743221|Drug|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
79230731|NCT02743221|Drug|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
79682130|NCT04563923|Drug|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
79682131|NCT04563923|Other|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
79230732|NCT03256682|Behavioral|Stress management counseling|stress management counseling based on CBT and relaxation
79230733|NCT03261128|Other|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
79305590|NCT03240497|Behavioral|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol [7]."
79682132|NCT04562558|Drug|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
79682133|NCT04562558|Drug|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
79682134|NCT04562558|Drug|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
79682135|NCT04560673|Drug|Duloxetine|Given PO
79682136|NCT04560673|Behavioral|Neurofeedback|Receive neurofeedback training
79682137|NCT04560673|Other|Quality-of-Life Assessment|Ancillary studies
79682138|NCT04560673|Other|Questionnaire Administration|Ancillary studies
79682139|NCT04545723|Device|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
79230734|NCT03252158|Behavioral|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2&3 and 5&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
79825670|NCT06063408|Behavioral|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
79682140|NCT04542356|Drug|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
79999749|NCT06273046|Behavioral|Biofeedback|Four visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 1:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A reinforcement phone call will be performed 2 months or 7 days later (incontinence and dyssinergic defecation, respectively) and a final visit will be performed at the end of the study.
79230735|NCT03260972|Drug|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
79230736|NCT03260972|Drug|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
79230737|NCT03370263|Drug|Benlysta|Benlysta will be administered intravenously or subcutaneously.
79230738|NCT03260816|Behavioral|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
79230739|NCT03260816|Other|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
79230740|NCT00692445|Drug|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
79372966|NCT02980120|Other|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann & Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
79390954|NCT03182712|Dietary Supplement|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
79526597|NCT06105099|Behavioral|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
79682141|NCT04542356|Drug|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
79682142|NCT04530409|Drug|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
79682143|NCT04528329|Drug|Early-Dexamethasone|early use of dexamethasone as early as laboratory evidence of high inflammatory markers
79682144|NCT04528329|Drug|Late dexamethazone|Use of dexamethasone on deterioration of the cases with increased severity
79709759|NCT04348734|Diagnostic Test|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
79825671|NCT06063408|Behavioral|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
79825672|NCT06063395|Procedure|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
79390955|NCT03182712|Dietary Supplement|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
79526598|NCT06105086|Other|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
79682145|NCT04527406|Procedure|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
79825673|NCT06063369|Drug|Palmitoylethanolamide|"Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
79825674|NCT06063291|Drug|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
79825675|NCT06063291|Drug|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
79825676|NCT06063278|Behavioral|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
79825677|NCT06063265|Behavioral|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
79999750|NCT06273046|Behavioral|Placebo|Four visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions, by means of commercial videos on alternative exercises to be performed daily at home. A reinforcement phone call will be performed 2 months or 7 days later (incontinence and dyssinergic defecation, respectively) and a final visit will be performed at the end of the study.
79999751|NCT06273020|Drug|Cerebrolysin|Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
79230741|NCT00692445|Drug|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
79230742|NCT03256370|Procedure|milk collection|"Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~After completed informed consent, demographic data was collected and filled in case record form~Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
79390956|NCT01682603|Drug|Botulinum toxin A|BoNT-A (BOTOX 300U)
79526599|NCT06104995|Other|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
79390957|NCT03183024|Biological|benralizumab|open-label treatment
79390958|NCT03183024|Biological|placebo|sterile water to mimic benralizumab
79390959|NCT00240981|Drug|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
79390960|NCT00240981|Drug|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
79709760|NCT01172938|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
79709761|NCT01172938|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
79709762|NCT01172938|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
79999752|NCT06273020|Procedure|Brain-MRI with contrast after 10-14 days of cerebrolysin|Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
79999753|NCT06273007|Other|PartoMa intervention(Locally achievable intrapartum care guideline), in house LDHF trainings|We will implement PartoMa interventions: seminars, LDHF training, and supportive supervision
79682146|NCT04527406|Procedure|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
79999754|NCT06272994|Diagnostic Test|MRSA Nasal Swab PCR|For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
79999755|NCT06272981|Device|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
79999756|NCT06272968|Diagnostic Test|Neuropsychological Testing|Neuropsychological Testing via Cambridge CANTAB Connect
79999757|NCT06272955|Device|Spinal Cord Stimulator (SCS)|"Patients are already implanted with device from the H-49023 study.~The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
79999758|NCT06272942|Other|An ICU admission and a temporally related ARDS diagnosis|"This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis.~ARDS stands for acute respiratory distress syndrome."
79372967|NCT02980120|Device|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
79372968|NCT03466008|Behavioral|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
79526600|NCT06104995|Other|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
79526601|NCT06104982|Device|NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices|Neuromuscular electrical stimulation (NMES) is applied to intact second motor neurons and target muscles of patients with SCI and provides functional and therapeutic benefits in neurological rehabilitation. Functional electrical stimulation (FES) is a type of NMES that is used for electrical stimulation during exercises such as crunches. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device.
79682147|NCT04526288|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
79682148|NCT04526288|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79682149|NCT04524572|Behavioral|Motion sensor|To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
79999759|NCT06272929|Device|doppler ultrasound|doppler US
79999760|NCT06272916|Drug|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
79372969|NCT05324280|Procedure|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
79372970|NCT02522052|Other|Blue mussel diet|5 meals a week containing blue mussels
79372971|NCT02522052|Other|Meat/Control diet|5 meals a week containing meat
79372972|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed QD
79709763|NCT01172938|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
79999761|NCT06272903|Drug|20% benzocaine, topical anesthetic|"Indicated as a topical anesthetic for use on oral mucosa prior to local anesthetic injections, scaling and prophylaxis. Also useful to relieve discomfort associated with taking impressions and intra- oral radiographs.~The benzocaine topical anesthetic will be applied according to standard clinical practice, aiming to provide local anesthesia to the treatment site and minimize discomfort during the procedure (placing elastomeric orthodontic separators)."
79999762|NCT06272903|Other|Children's Toothpaste|Strawberry-flavored children's toothpaste available in Dubai, UAE.
79372973|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed BID
79526602|NCT06104982|Other|Isometric strengthening exercises|Isometric abdominal strengthening exercises are part of the standard rehabilitation program for individuals with spinal cord injuries.
79372974|NCT01190878|Drug|DuraSite Vehicle|Vehicle dosed BID
79999763|NCT06272890|Behavioral|motivational interviewing|motivational interviewing
79999764|NCT06272877|Other|Fluidotherapy|Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
79372975|NCT01190878|Drug|Xibrom™|0.09% bromfenac dosed BID
79230743|NCT03256058|Procedure|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
79372976|NCT03465930|Procedure|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
79372977|NCT01146496|Device|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
79372978|NCT03461094|Device|Preload assessment and volume expansion|Fluid therapy perform
79372979|NCT01146808|Drug|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
79372980|NCT02522130|Drug|Lidocaine|intracervical injection
79372981|NCT02522130|Drug|oral misoprostol|oral treatment
79999765|NCT06272877|Other|conventional rehabilitation program|The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
79682150|NCT04505371|Behavioral|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
79682151|NCT04505163|Procedure|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
79682152|NCT04505163|Device|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
79372982|NCT02522130|Drug|naproxen|oral treatment
79372983|NCT02522130|Other|placebo|oral treatment
79999766|NCT06272851|Device|optical coherence tomography|measuring choroidal thickness using optical coherence tomography
79526605|NCT06104943|Other|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
79526606|NCT06104943|Other|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
79526607|NCT06104943|Other|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
79682153|NCT04505020|Other|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
79682154|NCT04505020|Other|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
79999767|NCT06272838|Other|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
79999768|NCT06272838|Other|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
79230744|NCT03256058|Procedure|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
79230745|NCT03836625|Other|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
79230746|NCT03252236|Behavioral|Tai Chi|Modified 12-form Yang style Tai Chi.
79372984|NCT03461016|Behavioral|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure [is] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
79372985|NCT01148524|Biological|No Vaccine|
79372986|NCT01148524|Biological|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
79526608|NCT06104943|Other|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
79526609|NCT06104852|Other|Survey|Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
79526610|NCT06104852|Other|Optional Medication Washout|Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
79526611|NCT06104839|Drug|NXC736|oral administration
79526612|NCT06104839|Drug|Placebo|oral administration
79526613|NCT06104813|Other|Interviews|Interview with volunteer, to ask them a series of open questions about sexual health in the deaf male population.
79825678|NCT06063252|Behavioral|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
79372987|NCT03460938|Procedure|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
79825679|NCT06063200|Drug|Methylphenidate Pill|Single encapsulated pill
79230747|NCT03252236|Behavioral|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
79230748|NCT03256292|Drug|Testosterone replacement|Testosterone replacement therapy
79526614|NCT06104800|Other|Calorie-restricted diet with red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
79526615|NCT06104800|Other|Calorie-restricted diet without red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
79372988|NCT03460860|Dietary Supplement|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
79526616|NCT06104774|Behavioral|Tai Chi Exercise|The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge.
79526617|NCT06104761|Other|Release group|i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
79526618|NCT06104761|Other|strength exercises and stretching for upper crossed syndrome|I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
79526619|NCT06104722|Other|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
79682155|NCT04495608|Drug|Fluconazole|"Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~From W0 to W2 : 1 caps/ day~From W2 to W4 : 1 or 2 caps/day~From W4 to W6 : 1, 2 or 3 caps/day~From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is > 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period)."
79682156|NCT04495608|Drug|Placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
79825680|NCT06063174|Behavioral|Education Program|12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.
79825681|NCT06063174|Behavioral|Think Well Program|12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.
79526620|NCT06104722|Other|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
79526621|NCT06104696|Procedure|Functional geriatric assessment|Examination of physical and mental status using standardized tests.
79526622|NCT06104644|Drug|Deucravacitinib|Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
79230749|NCT03256292|Behavioral|lifestyle|lifestyle intervention consisting of diet and increased physical activity
79230750|NCT04473261|Drug|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
79230751|NCT04473261|Drug|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
79230752|NCT04473261|Drug|Placebo|Empty capsule will be given as placebo
79230753|NCT04473261|Drug|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
79230754|NCT01358968|Drug|LY2603618|Administered intravenously as a 1-hour infusion.
79230755|NCT01358968|Drug|Desipramine|Administered orally
79230756|NCT01358968|Drug|Pemetrexed|Administered intravenously as a 10-minute infusion.
79230757|NCT01358968|Drug|Gemcitabine|Administered intravenously as a 30-minute infusion.
79372989|NCT03460860|Dietary Supplement|Placebo|The intervention is to be taken once daily, for 12 weeks.
79372990|NCT01191736|Behavioral|No training, assessed within 60 mins|Subjects receive no training in resuscitation
79372991|NCT01191736|Behavioral|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
79372992|NCT01191736|Behavioral|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
79372993|NCT01191736|Behavioral|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
79372994|NCT01191736|Behavioral|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
79999769|NCT06272825|Other|Virtual reality|VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.
79999770|NCT06272825|Other|conventional rehabilitation|The conventional exercise program will include 20 minutes TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
79999771|NCT06272812|Biological|MTBVAC|Vaccine Dose: MTBVAC 5x10^5 Formulation (approximately, per standard dose): 3 - 17x10^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
79999772|NCT06272812|Biological|Placebo|0.9% saline Volume: 0.1 mL/dose Intradermal
79999773|NCT06272799|Drug|T-DM1 adjuvant|Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events
79999774|NCT06272786|Other|conventional physiotherapy program.|It will be applied to a rehabilitation program including joint range of motion exercises and physical therapy modalities by a physiotherapist at the Physical Therapy Hospital.
79526623|NCT06104631|Other|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
79999775|NCT06272786|Other|Suprascapular nerve block|Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
79526624|NCT06104631|Other|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
79526625|NCT06104592|Radiation|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
79526626|NCT06104592|Biological|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
79526627|NCT06104501|Device|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
79526628|NCT06104488|Drug|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
79526629|NCT06104475|Other|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
79682157|NCT04493892|Behavioral|Educational Intervention|Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
79682158|NCT04478838|Drug|Risperidone|0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets
79682159|NCT04478838|Drug|Olanzapine|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
79999776|NCT06272773|Device|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
79999777|NCT06272760|Other|Home-based hand-arm bimanual intensive training (Tele-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training. HABIT has been adapted into a home-based format by ZOOM, referred to as Home-Based HABIT (H-HABIT).
79999778|NCT06272760|Other|Hand-arm bimanual intensive training (In-clinic-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training.
79999779|NCT06272747|Drug|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
79999780|NCT06272747|Drug|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
79230758|NCT03256214|Procedure|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
79230759|NCT03256214|Procedure|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
79230760|NCT04473339|Procedure|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
79372995|NCT01191736|Behavioral|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
79372996|NCT01191736|Behavioral|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
79372997|NCT03460782|Biological|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
79825682|NCT06063174|Behavioral|Be Well Program|12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.
79825683|NCT06063174|Behavioral|Eat Well Program|12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.
79825684|NCT06063174|Behavioral|Sleep Well Program|12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
79999781|NCT06272734|Device|Reprieve System|The Reprieve System is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
79526630|NCT06104462|Device|Intermittent theta burst stimulation (iTBS)|"The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10*3*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 * (Dsitex - Dm1). Therefore, 2.8 * 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies."
79999782|NCT06272721|Diagnostic Test|Griffiths Scale|The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
79372998|NCT01192282|Procedure|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
79999783|NCT06272695|Biological|Volagidemab|Administered by SC injection once weekly for 6 weeks
79999784|NCT06272682|Procedure|Systemic bethametasone injection|betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
79999785|NCT06272682|Procedure|Local bethametasone injection|Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
79230761|NCT04473339|Procedure|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
79230762|NCT03260738|Device|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
79230763|NCT03260738|Other|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
79372999|NCT04607382|Drug|LEP|LEP dosage up to the discretion of the treating gynecologists.
79373000|NCT04607382|Drug|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
79373001|NCT01192828|Drug|taurine|Take Taurine for 4 1/2 days, two doses per day
79373002|NCT01099618|Drug|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
79373003|NCT01099618|Drug|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
79373004|NCT01099618|Drug|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
79373005|NCT01099774|Drug|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
79373006|NCT01099774|Drug|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
79373007|NCT03013192|Other|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
79373008|NCT01328574|Drug|TRC105|15 mg/kg intravenously
79526634|NCT06104423|Drug|Nebivolol 5 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
79682160|NCT04463316|Diagnostic Test|Retrospective file studies|No intevention, retrospective file study: medical history, laboratory values, additional tests, physical and psychological complaints.
79682161|NCT04460638|Biological|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
79682162|NCT04460638|Other|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
79526635|NCT06104423|Drug|Ramipril 2.5/5/10 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
79825685|NCT06063174|Behavioral|Move Well Program|12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
79999786|NCT06272669|Device|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
79999787|NCT06272669|Device|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
79999788|NCT06272643|Diagnostic Test|IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)|OCT and IVUS in Patients with LMCA lesion (25-60%)
79999789|NCT06272630|Drug|DWJ1464|DWJ1464, TID, Duration of administaration: 8 weeks, Visit: every 4 week
79999790|NCT06272630|Drug|Placebo of DWJ1464|Placebo of DWJ1464, TID, Duration of administaration: 8 weeks, Visit: every 4 week
79999791|NCT06272617|Device|verum acupuncture|a type of acupuncture which is useful
79825686|NCT06063148|Device|Enrolled Participant|Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
79526638|NCT06104384|Behavioral|Behavioral and supportive therapy|Behavioral and supportive therapy
79526639|NCT06104267|Behavioral|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
79526640|NCT06104241|Biological|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10^7 cells,1.0 ×10^8 cells, 3.0× 10^8 cells,1.0 × 10^9 cells,3.0 ×10^9 cells.
79526641|NCT06104215|Biological|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10^8 cells,5.0 ×10^8 cells, 1.0× 10^9 cells,3.0 × 10^9 cells,6.0 ×10^9 cells.
79526642|NCT06104189|Diagnostic Test|MRI|MRI based classification of breast cancer histological factors and subtypes
79526643|NCT06104150|Other|Intervallic submaximal exercise test|Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
79709764|NCT02271464|Drug|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
79825687|NCT06063122|Device|smallTalk NICU Active|The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
79825688|NCT06063096|Dietary Supplement|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
79825689|NCT06063096|Dietary Supplement|Placebo|Fruit-flavoured drink with high fructose corn syrup
79825690|NCT06063070|Drug|Fluzoparib Capsules|oral
79999792|NCT06272617|Device|sham acupuncture|a type of acupuncture which is useless
79999793|NCT06272604|Behavioral|Personalized Exercise Rehabilitation|The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
79999794|NCT06272591|Other|Preliminary search in the patient's file|"Details of the information previously sought in the patient's file :~age profession gender/parity physiological or pathological pregnancy indication for induction of labour gestational age at time of induction"
79999795|NCT06272591|Other|A posteriori research in the patient's file|Data on maternal and foetal morbidity and mortality following childbirth will be collected.
79825691|NCT06063070|Drug|Bevacizumab|Injectable solution
79373009|NCT03460626|Drug|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
79373010|NCT03460626|Other|Placebo|an odorless oil without any therapeutic effect
79373011|NCT04453488|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
79373012|NCT04453488|Biological|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
79682163|NCT04450628|Procedure|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
79825692|NCT06063057|Biological|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
79825693|NCT06063057|Biological|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
79825694|NCT06063057|Biological|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
79825695|NCT06063057|Biological|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
79825696|NCT06063018|Drug|RC48 + Tislelizumab|RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
79825697|NCT06062953|Drug|Melatonin|3-9 mg flexible dosing before bed time
79825698|NCT06062953|Drug|Quetiapine|50-150 mg flexible dosing before bed time
79526644|NCT06104137|Other|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
79526645|NCT06104137|Other|standard patient consent process|standard consenting and shared decision making in the clinic
79373013|NCT01100242|Drug|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
79526646|NCT06104111|Dietary Supplement|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
79526647|NCT06104085|Diagnostic Test|99mTc-MY6349 SPECT/CT scan|Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
79825699|NCT06062953|Drug|Placebo|1-3 capsules flexible dosing before bed time
79825700|NCT06062940|Behavioral|SHARE Approach|The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
79825701|NCT06062901|Other|Educational Intervention|Receive educational intervention
79825702|NCT06062901|Other|Interview|Participate in one-on-one interview
79825703|NCT06062901|Other|Survey Administration|Ancillary studies
79825704|NCT06062875|Drug|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
79373014|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
79373015|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
79373016|NCT03460548|Device|Remogen|instil 1 drop of the product in each eye, 4 times per day
79373017|NCT03460548|Device|Cationorm|instil 1 drop of the product in each eye, 4 times per day
79825705|NCT06062862|Device|The Incentive Spirometer|Tri-flow device flow-oriented incentive spirometer .
79825706|NCT06062862|Device|The breather respiratory muscle training device|The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
79825707|NCT06062823|Drug|Afatinib 40 MG|Afatinib 40mg administered orally daily.
79825708|NCT06062797|Device|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
79825709|NCT06062797|Device|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
79825710|NCT06062771|Device|FIDIAL PLUS|1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
79825711|NCT06062771|Device|IAL®-F|Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS
79999796|NCT06272591|Other|First questionnaire : choice of induction method reason for choice|Given on arrival at the maternity unit to begin induction.
79999797|NCT06272591|Other|Second questionnaire : experience of induction|Given post-partum in the maternity unit.
79999798|NCT06272552|Other|PROMs and PREMs|"Participants are administered PROMs and PREMs at a given timeline adequate to each participant conditions for a duration of 2 years. The administration of PROMs is done by email using the REDCap platform. The research team and health care professionals have access to their patient&amp;amp;#39;s results to aid in the patients clinical care.~Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
79230764|NCT02281071|Procedure|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
79526648|NCT06104072|Device|REHACOM Software|"It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning & executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel & printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~For each Cognitive training domain there is one hundred levels of difficulty.~Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level."
79373018|NCT01149616|Drug|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
79373019|NCT01149616|Drug|placebo|2 ml normal saline IV x1
79373020|NCT03465462|Dietary Supplement|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
79709765|NCT02271464|Drug|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~CAPECITABINE 500 mg/tid orally, continuously,~CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
79373021|NCT03465462|Dietary Supplement|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
79825712|NCT06062758|Behavioral|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
79373022|NCT03465462|Dietary Supplement|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
79373023|NCT03460470|Drug|Sildenafil|PDE5 Inhibitor
79526649|NCT06104072|Other|Designed Physical Therapy Program|a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises.
79526650|NCT06104059|Device|Nociception level index (NOL™)|If a NOL value >25 persists for >1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
79526651|NCT06104059|Other|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
79526652|NCT06104033|Device|drug-coated balloon|For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
79709766|NCT00595608|Drug|Sterimar Spray|Post-op nasal spray, three times a day
79825713|NCT06062745|Drug|18F-fluciclovine|18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
79825714|NCT06062745|Device|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
79825715|NCT06062732|Behavioral|Face It|School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.
79825716|NCT06062732|Behavioral|Control|Services as usual
79825717|NCT06062719|Drug|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
79825718|NCT06062719|Drug|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
79373024|NCT03460470|Drug|Placebo oral capsule|Placebo for Sildenafil
79373025|NCT03465306|Behavioral|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
79373026|NCT03465306|Device|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
79373027|NCT01101100|Drug|AMG 827|210 mg SC or 140 mg SC
79373028|NCT03460392|Drug|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
79709767|NCT00595608|Drug|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
79999799|NCT06272552|Other|PREMs|"Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
79999800|NCT06272552|Other|Control|At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
79373029|NCT01149772|Behavioral|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
79373030|NCT05201118|Drug|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
79373031|NCT05201118|Drug|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
79373032|NCT05012436|Drug|YHD1119 75mg|A single oral dose
79373033|NCT01101880|Biological|filgrastim|Given SC
79373034|NCT01101880|Drug|clofarabine|Given IV
79373035|NCT01101880|Drug|cytarabine|Given IV
79373036|NCT03460080|Diagnostic Test|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
79373037|NCT04989972|Drug|PSIL428|1 mg of psilocybin
79373038|NCT04989972|Dietary Supplement|Oyster mushroom|1 mg of oyster mushroom
79373039|NCT04989972|Drug|PSIL428|1 mg psilocybin
79373040|NCT01101958|Device|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
79373041|NCT01101958|Device|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
79373042|NCT04978038|Drug|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
79526653|NCT06104033|Device|drug-eluting stent|When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
79526654|NCT06104020|Other|Intraoperative fluid management stratigies.|"Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr."
79526655|NCT06104007|Device|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
79526656|NCT06103981|Other|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
79526657|NCT06103942|Diagnostic Test|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
79526658|NCT06103916|Other|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
79526659|NCT06103903|Behavioral|Questionnaire|Questionnaire according to age (6-13;14-17); the parents for minors and adults
79526660|NCT06103825|Drug|Solriamfetol|solriamfetol : QD，PO，Day 1-Day 84；
79526661|NCT06103825|Drug|Placebo|Placebo :QD，PO，Day 1-Day 84
79526662|NCT06103812|Device|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
79526663|NCT06103799|Behavioral|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
79526664|NCT06103773|Drug|TollB-001 tablets|TollB-001 treatment
79526665|NCT06103773|Drug|TollB-001 placebo|TollB-001 Placebo
79526666|NCT06103747|Drug|Metformin / Vildagliptin Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of test drug
79709768|NCT04326894|Drug|25 mg/week oral methotrexate tablets|
79709769|NCT04326894|Drug|25mg/week oral placebo tablets|
79999801|NCT06272552|Other|Healthcare professionals|Healthcare professionals participating in the study answer an evaluation questionnaire before the implementation starts at their service and two years later to measure their perceptions about the implementation.
79999802|NCT06272539|Procedure|Exercise|The exercise The exercise will be adapted according to the phases based on the results already published, limiting in each phase the degrees of flexion and extension of the spine in order to avoid the risk of electrode migration.
79373043|NCT04978038|Drug|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
79825719|NCT06062706|Procedure|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
79825720|NCT06062693|Device|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
79999803|NCT06272539|Procedure|Spinal Cord Stimulation|Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
79999804|NCT06272526|Other|Internet Based Intervention - GUIDED|The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
79373044|NCT01194466|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
79682164|NCT04450628|Device|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
79373045|NCT03011632|Drug|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
79373046|NCT03011632|Drug|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
79373047|NCT01102270|Drug|Eszopiclone|3mg tablet once prior to sleep
79373048|NCT01102270|Drug|Placebo|1 placebo capsule prior to sleep
79373049|NCT01102894|Device|SmartPill|SmartPill
79373050|NCT01103440|Drug|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
79526667|NCT06103747|Drug|Galvumet® Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of reference drug
79526668|NCT06103695|Drug|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
79526669|NCT06103669|Device|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
79373051|NCT01103440|Drug|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
79526670|NCT06103630|Other|Oropharyngeal Exercises|Oropharyngeal Exercises
79682165|NCT04446416|Device|NaviFUS System|Open the BBB using focused ultrasound and contrast agent SonoVue®
79682166|NCT04446416|Drug|Bevacizumab|An anti-angiogenic agent to block tumor growth
79682167|NCT04440930|Other|White tea|Mouthwash with white tea five to six times a day for nine weeks
79682168|NCT04440930|Other|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
79682169|NCT04435496|Device|GYN-CS|placement of the GYN-CS device
79682170|NCT04421378|Drug|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
79526671|NCT06103630|Other|Mandibular advancement device|Mandibular advancement device
79526672|NCT06103578|Diagnostic Test|GCF and saliva analysis|ELISA
79526673|NCT06103565|Other|Clinical Decision Support Tool|Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
79825721|NCT06062680|Drug|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
79825722|NCT06062615|Procedure|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
79825723|NCT06062615|Procedure|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
79825724|NCT06062615|Device|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
79526674|NCT06103188|Drug|Placebo|The placebo pill will be given to the patients 1 hour prior to their planned surgery.
79682171|NCT04421378|Drug|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
79682172|NCT04421378|Drug|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
79682173|NCT04421378|Radiation|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
79682174|NCT04421378|Drug|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
79373052|NCT03011554|Device|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
79373053|NCT01152112|Device|Myomectomy|Removal of fibroids and / or polyps
79526675|NCT06103188|Drug|Diazepam|Diazepam will be given to the patients 1 hour prior to their planned surgery.
79526676|NCT06103188|Drug|Melatonin|Melatonin will be given to the patients 1 hour prior to their planned surgery.
79526677|NCT06103006|Other|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to >1 set).
79526678|NCT06102889|Diagnostic Test|liquid biopsy|Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics
79682175|NCT04421378|Device|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
79682176|NCT04421378|Drug|Carmustine|Dose and Formulation: 150 or 200 mg/m^2; Route of Administration: Intravenous
79682177|NCT04419077|Behavioral|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
79682178|NCT04409600|Behavioral|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
79682179|NCT04409600|Behavioral|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
79682180|NCT04409600|Drug|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
79682181|NCT04409600|Drug|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
79682182|NCT04396522|Device|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
79999805|NCT06272500|Other|oral administration of a compound digestive enzyme capsule|receives only oral administration of a compound digestive enzyme capsule, with one capsule taken three times a day.
79999806|NCT06272500|Other|oral administration of apple cider vinegar|receives only oral administration of apple cider vinegar, with 15ml of apple cider vinegar with an acidity of ≥3.5g/100ml consumed after each meal.
79999807|NCT06272500|Other|oral administration of both the compound digestive enzyme capsule and apple cider vinegar|receives oral administration of both the compound digestive enzyme capsule and apple cider vinegar simultaneously.
79999808|NCT06272487|Drug|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
79373054|NCT04352374|Other|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
79373055|NCT04352374|Device|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
79999809|NCT06272487|Drug|Placebo|Placebo administered by SC injection
79999810|NCT06272474|Other|CAD-CAM zirconia crowns using buccal interocclusal record.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal interocclusal record.~First, scanning the buccal interocclusal record for each patient with the two arches in maximum intercuspation position (MIP) will be performed. The IOS will immediately reproduce the occlusal state of the digital casts; this method is called the buccal bite registration method (BBR)."
79999811|NCT06272474|Other|CAD-CAM zirconia crowns using lateral interocclusal records.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using lateral interocclusal record.~A second scan will be performed for each patient to record lateral mandibular excursion. Then, three STL files will be exported; maxillary arch, mandibular arch at MIP and lateral mandibular excursion"
79373056|NCT01105312|Drug|letrozole|
79373057|NCT01105312|Drug|panobinostat|
79373058|NCT01105312|Genetic|RNA analysis|
79373059|NCT01105312|Genetic|microarray analysis|
79373060|NCT01105312|Genetic|reverse transcriptase-polymerase chain reaction|
79373061|NCT01105312|Other|enzyme-linked immunosorbent assay|
79373062|NCT01105312|Other|immunohistochemistry staining method|
79526679|NCT06102408|Other|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
79526680|NCT06101979|Device|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
79526681|NCT06101160|Drug|onaBoNT-A|injection under ultrasonography
79526682|NCT06100887|Drug|EDG-5506 Dose 1|EDG-5506 is administered orally once per day
79526683|NCT06100887|Drug|EDG-5506 Dose 2|EDG-5506 is administered orally once per day
79526684|NCT06100887|Drug|Placebo|Placebo is administered orally once per day
79526685|NCT06100497|Drug|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
79526686|NCT06100497|Drug|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
79526687|NCT06100497|Drug|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
79682183|NCT04384198|Procedure|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
79682184|NCT04373512|Drug|Culturelle 10 Billion CFU Capsule (2 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
79682185|NCT04373512|Drug|Culturelle 10 Billion CFU Capsule (4 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
79825725|NCT06062589|Radiation|Iodine-125 particle brachytherapy|All enrolled patients' relapsed or metastatic lesions underwent image-guided radiation I-125 particle implantation brachytherapy (single implantation, half-life of 60 days, 99% of total dose given after 90 days). The prescribed dose is above 130Gy. Technical process: positioning and preoperative planning design; Template reset and particle implantation under the guidance of image system; Rapid and real-time intraoperative optimization; Postoperative dose validation.
79999812|NCT06272448|Other|Telerehabilitation|The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation…), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
79682186|NCT04324892|Drug|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
79999813|NCT06272435|Dietary Supplement|Multiplier|Subjects will consume 1 Liter (2 servings) of commercially available Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
79682187|NCT04322305|Drug|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
79682188|NCT04322305|Other|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
79682189|NCT04307992|Device|Prophylactic sac filling with AneuFix|ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
79825726|NCT06062589|Drug|AK104|AK104 treatment (6mg/kg Q2W) starting within 1 week of particle implantation, for a total of 6 cycles or until disease progression, intolerable toxicity, investigator decision, withdrawal of informed consent, death, or other reasons as specified in the protocol.
79999814|NCT06272435|Dietary Supplement|Sugar Free|Subjects will consume 1 Liter (2 servings) of experimental Sugar Free Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
79373063|NCT01105312|Other|laboratory biomarker analysis|
79682190|NCT04305158|Drug|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
79682191|NCT04301778|Drug|Durvalumab|"Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~Drug - 1500mg IV"
79682192|NCT04301778|Drug|SNDX-6352|"SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~Drug - 3mg/kg IV"
79682193|NCT04291209|Drug|N-Acetyl Cysteine|One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
79682194|NCT04285827|Biological|CSL889|Administered as an IV infusion
79682195|NCT04270266|Other|Educational Intervention|Attend educational sessions
79230765|NCT05498740|Device|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
79373064|NCT01328496|Drug|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
79373065|NCT04488978|Drug|Irbesartan/Amlodipine|QID
79682196|NCT04270266|Other|Meditation Therapy|Attend meditation sessions
79682197|NCT04270266|Other|Questionnaire Administration|Ancillary studies
79230766|NCT03260660|Device|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
79682198|NCT04267796|Other|Aerobic Exercise|Complete aerobic training
79682199|NCT04267796|Other|Dietary Intervention|Receive diet recommendations from health coach or registered dietitian
79682200|NCT04267796|Other|Quality-of-Life Assessment|Ancillary studies
79682201|NCT04267796|Other|Questionnaire Administration|Ancillary studies
79682202|NCT04267796|Other|Resistance Training|Complete high-resistance circuit training sessions
79682203|NCT04266912|Drug|Avelumab|Given IV
79682204|NCT04266912|Drug|Berzosertib|Given IV
79682205|NCT04256824|Drug|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
79682206|NCT04256824|Drug|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
79682207|NCT04256213|Drug|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
79682208|NCT04254237|Procedure|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
79682209|NCT04254237|Procedure|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
79682210|NCT04248829|Drug|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
79825727|NCT06062563|Drug|Anlotinib Hydrochloride Capsule and Penpulimab|"Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC."
79526688|NCT06097195|Device|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
79825728|NCT06062524|Device|Aorta Vascular Plug System|The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
79825729|NCT06062498|Drug|elacestrant, palbociclib, abemaciclib, ribociclib|Given orally
79825730|NCT06062485|Drug|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
79526689|NCT06096727|Behavioral|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
79825731|NCT06062459|Other|Motor Control Exercise|Motor control exercises focusing on the activation and control of deep spinal muscles
79825732|NCT06062459|Other|Balance Training|Balance training exercises on to enhance proprioception and stability
79999815|NCT06272435|Dietary Supplement|Sugar Free with Amino Acids|Subjects will consume 1 Liter (2 servings) of commercially available Sugar Free Hydration Multiplier product that contains amino acids at a rate of 250 milliliters per 7.5 minutes.
79230767|NCT02281227|Procedure|skin compression|skin compression with an indicator for determination of needle entry point
79390961|NCT03182790|Behavioral|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
79526690|NCT06096584|Procedure|Triple Injection Perisartorius block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone.~Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata"
79682211|NCT04248829|Drug|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
79682212|NCT04248829|Drug|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
79682213|NCT04248829|Drug|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
79682214|NCT04248751|Device|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
79825733|NCT06062459|Other|Control Group|Participants received hot pack and stretching exercise
79999816|NCT06272435|Dietary Supplement|Water|Subjects will consume 1 Liter of water at a rate of 250 milliliters per 7.5 minutes.
79999817|NCT06272422|Procedure|hip arthroplasty|resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
79999818|NCT06272409|Drug|DEP114|DEP114 oral solution
79682215|NCT04248751|Procedure|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
79999819|NCT06272409|Drug|Desloratadine 0.5 MG/ML|Desloratadine oral solution
79999820|NCT06272396|Device|Smart watch|ECG 1D/6D
79230768|NCT03252080|Behavioral|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
79230769|NCT03252080|Behavioral|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
79230770|NCT02281305|Drug|Colchicine|
79825734|NCT06062355|Drug|HRS-9815 injection|HRS-9815 injection
79373066|NCT04464486|Other|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
79825735|NCT06062277|Drug|Colchicine 0.5 MG|one oral tablet daily for 30 days
79825736|NCT06062264|Behavioral|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
79373067|NCT03465228|Device|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
79230771|NCT03251846|Device|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
79230772|NCT00624351|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
79526691|NCT06096584|Procedure|Dual sub sartorial block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone~Patients will receive a combination of femoral triangle block and distal ACB."
79526692|NCT06096584|Procedure|Femoral triangle block|Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.
79526693|NCT06096584|Procedure|Distal adductor canal block|Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.
79526694|NCT06096584|Procedure|Suprasartorial plane block|Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata
79682216|NCT04248322|Behavioral|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
79682217|NCT04247763|Other|Saturated Fat Meal|
79682218|NCT04247763|Other|Oleic Sunflower Oil Meal|
79682219|NCT04247074|Biological|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
79682220|NCT04247074|Biological|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
79682221|NCT04231448|Drug|R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)|R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV [maximum total 2 mg], and prednisone [or equivalent] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
79682222|NCT04231448|Drug|Tucidinostat|Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
79682223|NCT04231448|Drug|Placebo|Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
79682224|NCT04224051|Drug|Metformin|Metformin target dose 2 g daily
79825737|NCT06062264|Behavioral|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
79825738|NCT06062238|Biological|M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
79682225|NCT04224051|Other|Standard care|Abdominal aortic aneurysm surveillance
79825739|NCT06062238|Biological|Placebo|Participants will receive an intramuscular dose of normal saline (0.9 percent [%] sodium chloride [NaCl]), on Day 1 and Day 29.
79825740|NCT06062212|Procedure|Transpulmonary pressure|Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
79825741|NCT06062186|Dietary Supplement|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
79825742|NCT06062186|Dietary Supplement|AmaTea Guayusa Extract|650 mg of AmaTea Guayusa Extract, given as two capsules
79825743|NCT06062186|Dietary Supplement|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
79825744|NCT06062160|Other|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
79999821|NCT06272383|Drug|0.15 mg/kg dexamethasone|25% less than the standard practice of dexamethasone at 0.6mg/kg
79230773|NCT00624351|Other|Placebo|Phosphate-buffered Saline (PBS) infusion.
79230774|NCT03251690|Drug|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
79230775|NCT03251690|Drug|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
79230776|NCT00620685|Drug|Placebo|Tablet, once daily for 4 weeks
79230777|NCT00620685|Drug|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
79825745|NCT06062147|Behavioral|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
79230778|NCT00620685|Drug|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
79230779|NCT03260582|Other|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
79682226|NCT04216823|Device|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
79682227|NCT04216641|Dietary Supplement|Adapted food intervention|Adapted food intervention
79682228|NCT04209686|Drug|Paclitaxel|"Patients will receive treatment on Day 1 and 8 starting with cycle 2.~Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~Drug - Paclitaxel - 80mg IV"
79825746|NCT06062121|Device|Motor-cable-driven Rehabilitation Robotic System|Subjects will wear the motor-cable-driven system and receive 30 minutes (including preparation time) wrist and forearm robot-assisting exercise
79682229|NCT04209686|Drug|Olaparib|"Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~Drug - 100 mg or 300mg"
79682230|NCT04209686|Drug|Pembrolizumab|"Patients will receive treatment every 21 days.~Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~Drug - 200mg IV"
79682231|NCT04209114|Biological|Nivolumab|Specified dose on specified days
79682232|NCT04209114|Procedure|Radical cystectomy (RC)|Surgical removal of the bladder
79682233|NCT04209114|Biological|Bempegaldesleukin|Specified dose on specified days
79825747|NCT06062082|Procedure|adrenalectomy|laparoscopic exeresis of the adrenal gland
79682234|NCT04203797|Drug|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
79682235|NCT04203797|Drug|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
79682236|NCT04197479|Drug|Placebo|Matching tablets
79682237|NCT04197479|Drug|Resmetirom|Tablet
79682238|NCT04191590|Procedure|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
79682239|NCT04190212|Behavioral|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
79682240|NCT04176978|Drug|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
79682241|NCT04176978|Other|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
79682242|NCT04176965|Device|FINEVISION HP IOL|Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
79682243|NCT04176965|Device|Alcon AcrySof SN60AT|Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
79230780|NCT05498584|Behavioral|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
79682244|NCT04175639|Behavioral|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
79682245|NCT04173728|Other|Standard mixed macronutrients tolerance test|Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
79825748|NCT06062030|Drug|DWJ1609|Drug of test group
79825749|NCT06062030|Drug|DWC202304|Drug of control group
79825750|NCT06062004|Procedure|Small Incision Lenticule Extraction (SMILE)|"All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~Cap thickness of 120 μm~Cap diameter of 1 mm larger than the lenticule diameter~Cap side cut angle 70°~3 mm incision positioned at 100° and angled at 45°~Transition zone of 0.1 mm and clearance of 0.5 mm~Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm"
79230781|NCT03252002|Drug|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
79230782|NCT03252002|Drug|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
79682246|NCT04166435|Drug|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
79682247|NCT04156945|Behavioral|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
79825751|NCT06060522|Diagnostic Test|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
79825752|NCT06060353|Behavioral|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, & Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
79999822|NCT06272370|Other|Asthma Symptom Monitoring online tools|All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above
79526695|NCT06094075|Other|Resistance training based on DSI value|The intervention consist of modifying the ongoing resistance exercises. Those with low DSI values will perform ballistics, explosive exercises. Those with high DSI will perform heavy-load training. The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
79373068|NCT03465228|Device|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
79526696|NCT06094075|Other|Normal training group|The participants will do a general training program (not based on DSI values). The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
79526697|NCT06093256|Device|Fixed orthodontic appliances|Taste sensation will be checked before and after fixed orthodontic therapy.
79526698|NCT06092411|Behavioral|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
79526699|NCT06092411|Device|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
79526700|NCT06090071|Device|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
79526701|NCT06090071|Device|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
79230783|NCT05478928|Other|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
79230784|NCT05478928|Device|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
79230785|NCT05478928|Other|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
79230786|NCT05478928|Device|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
79682248|NCT04156945|Diagnostic Test|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
79999823|NCT06272370|Drug|Inhaled Steroids|participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy
79999824|NCT06272370|Drug|Azithromycin Pill|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
79682249|NCT04152941|Drug|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
79682250|NCT04150900|Drug|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
79682251|NCT04150900|Drug|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
79682252|NCT04131036|Other|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
79682253|NCT04126798|Other|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
79682254|NCT04124965|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
79682255|NCT04121754|Device|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
79682256|NCT04121754|Other|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
79999825|NCT06272357|Other|Antiarrhythmic drugs|Antiarrhythmic drugs in pediatrics
79526702|NCT06090071|Drug|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
79230787|NCT05478928|Device|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
79230788|NCT05478928|Other|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
79526703|NCT06089057|Behavioral|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
79526704|NCT06089057|Behavioral|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
79682260|NCT04116073|Drug|INCMGA00012 (PD-1 antibody)|"Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)"
79999826|NCT06272344|Other|Teleconsultation|Teleconsultation at 6 months
79230789|NCT00620451|Drug|larazotide acetate|gelatin capsule
79230790|NCT00620451|Drug|placebo|gelatin capsule
79230791|NCT03255278|Biological|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
79526705|NCT06088563|Other|Vaccine injection|Injection of the vaccine in renal transplant patients.
79709770|NCT02271542|Drug|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
79999827|NCT06272331|Other|Low-protein plant-based drink|Ingestion of a low-protein plant-based drink
79999828|NCT06272331|Other|High-protein plant-based drink|Ingestion of a high-protein plant-based drink
79999829|NCT06272331|Other|Cow's milk|Ingestion of cow's milk
79999830|NCT06272318|Other|Blood Pressure Cuff, EKG, PPG|A blood pressure cuff, an EKG, and a PPG will be utilized to collect subject vitals.
79682261|NCT04098133|Other|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
79526706|NCT06087991|Behavioral|Implementation of the BINDeR-Tx service model|ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
79682262|NCT04098133|Other|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
79682263|NCT04098133|Other|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
79682264|NCT04098133|Other|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
79999831|NCT06272305|Procedure|This research does not require any specific investigation and does not imply any modification of treatment.|Collection of data from the medical record for patients with a non specific carotid endarterectomy
79999832|NCT06272292|Diagnostic Test|EOS|Every subject in this study will undergo a radiographic analysis of the hip and spine using a low-dose, full-body biplanar X-ray acquisition (in standing, sitting and squatting position, EOS imaging).
79999833|NCT06272292|Diagnostic Test|3D motion lab analysis|"A hip-specific 3D motion analysis will be performed. The 3D motion protocol will be divided into 2 main sections.~First section: Consist of movements categorized within the activities of daily living (walking at self-selected speed, uphill walking, standardized deep squat and non-standardized deep squat)~Second section: Consists of movements that are categorized within athletic training and have been specifically chosen to induce large hip ranges of motion (Sumo squats, dead lifts, forward lunges, running uphill and downhill)~Each movements will be repeated 6 times. Three times with the dominant foot/opposite leg on the force plate to collect kinetic data. All data will be captured using two 10-15 camera 3D motion capture systems and one capturing an instrumented treadmill (M-gait)"
79682265|NCT04081493|Other|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
79682266|NCT04067596|Procedure|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
79682267|NCT04059640|Device|LiquiBand FIX8 Open Hernia Mesh Fixation Device|"Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant."
79682268|NCT04058639|Procedure|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
79999834|NCT06272279|Device|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
79999835|NCT06272279|Other|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
79999836|NCT06272279|Other|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
79999837|NCT06272279|Other|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
79526707|NCT06087484|Behavioral|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
79682269|NCT04058639|Procedure|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
79682270|NCT04049981|Device|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
79682271|NCT04022967|Drug|dolutegravir|One daily tablet (50mg) during 96 weeks
79526708|NCT06087107|Other|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
79526709|NCT06087107|Other|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
79682272|NCT04022967|Drug|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
79709771|NCT00595647|Device|Drug eluting stent|Implantation of stent
79709772|NCT00595647|Device|Bare metal stent|Implantation of stent
79825753|NCT06060353|Behavioral|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs & rights, child temperament, praise & acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play & relationship skills, empathy & praise, anger management.
79825754|NCT06060236|Drug|Ibuprofen 800 mg|Ibuprofen 800 Mg İv
79825755|NCT06060236|Drug|Dexketoprofen|Dexketoprofen 50 Mg İV
79999838|NCT06272266|Device|Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)|"For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group."
79373069|NCT03465228|Other|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
79373070|NCT03460002|Biological|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
79373071|NCT03460002|Biological|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
79526710|NCT06086717|Other|Kinesio Taping|"One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis"
79526711|NCT06086717|Other|Dry Needling|"Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle)."
79526712|NCT06085885|Device|Cochlear implant|Cochlear implant
79682273|NCT04022967|Drug|tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
79682274|NCT04022967|Drug|Lamivudine|One daily tablet (300mg) during 96 weeks
79682275|NCT04021862|Drug|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
79682276|NCT04021862|Drug|Placebo|Placebo will be administered subcutaneously.
79825756|NCT06059820|Other|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
79825757|NCT06059820|Procedure|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
79373072|NCT01105702|Drug|Temozolomide|
79373073|NCT01105702|Drug|Bevacizumab|
79526713|NCT06085534|Drug|LNK01001|Capsules for oral use
79526714|NCT06085534|Drug|Placebo|Capsules for oral use
79526715|NCT06085521|Drug|LNK01001 Dose A|Capsules taken orally
79526716|NCT06085521|Drug|LNK01001 Dose B|Capsules taken orally
79526717|NCT06085521|Drug|placebo|Capsules taken orally
79526718|NCT06079931|Drug|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
79526719|NCT06074055|Other|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
79526720|NCT06073184|Drug|Ozempic|Semaglutide injection, 2mg once weekly.
79526721|NCT06073184|Drug|Mirena|Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
79526722|NCT06071845|Device|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
79682277|NCT04003155|Drug|fezolinetant|Oral Tablet
79682278|NCT04003155|Drug|placebo|Oral Tablet
79682279|NCT04003142|Drug|Fezolinetant|Oral tablet
79682280|NCT04003142|Drug|placebo|Oral Tablet
79825758|NCT06059378|Device|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
79825759|NCT06059274|Other|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
79825760|NCT06058975|Other|Observational|Review the management of duodenal trauma in France
79526723|NCT06071845|Diagnostic Test|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
79825761|NCT06058169|Device|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
79999839|NCT06272266|Device|Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).|Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
79999840|NCT06272266|Device|Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
79999841|NCT06272266|Device|Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
79526724|NCT06067516|Other|Fluid resuscitations|In line with the recommendations in the Surviving Sepsis Guide, fingertip capillary refill time (CRT) will be measured by applying pressure to the index finger for 15 seconds in the T1 time period after 30 mL/kg/3 hours crystalloid infusion.
79373074|NCT01105702|Drug|Lithium Carbonate|
79373075|NCT01105702|Radiation|Radiation|
79373076|NCT03465150|Other|acne|Patient with acne
79682281|NCT03998813|Drug|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
79682282|NCT03998813|Drug|Ropivacaine|Tissue infiltration
79825762|NCT06057311|Other|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
79373077|NCT01197898|Biological|Collagenase Santyl Ointment|Topical daily application
79373078|NCT01197898|Other|Placebo Comparator|Topical daily application
79526725|NCT06066905|Drug|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
79526726|NCT06049576|Procedure|Biospecimen Collection|Undergo blood and stool sample collection
79526727|NCT06049576|Procedure|Bone Scan|Undergo bone scan
79526728|NCT06049576|Procedure|Computed Tomography|Undergo CT
79526729|NCT06049576|Biological|Ipilimumab|Given IV
79526730|NCT06049576|Procedure|Magnetic Resonance Imaging|Undergo MRI
79526731|NCT06049576|Drug|Myrciaria dubia Prebiotic Supplement|Given PO
79526732|NCT06049576|Biological|Nivolumab|Given IV
79682283|NCT03991221|Other|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
79682284|NCT03991221|Other|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
79682285|NCT03991221|Other|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
79373079|NCT03129750|Device|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
79373080|NCT03468582|Combination Product|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
79373081|NCT04453332|Drug|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
79373082|NCT04453332|Drug|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
79682286|NCT03991091|Drug|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
79682287|NCT03991091|Drug|continuation of oxytocin administration|continuation of oxytocin administration
79682288|NCT03971422|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
79682289|NCT03971422|Other|Placebo|Subjects will receive placebo at pre-specified time points.
79682290|NCT03952754|Behavioral|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
79682291|NCT03952754|Behavioral|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
79682292|NCT03945656|Drug|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
79682293|NCT03945656|Drug|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
79825763|NCT06057311|Other|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
79682294|NCT03927079|Biological|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
79825764|NCT06057311|Other|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
79825765|NCT06056843|Other|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.|Women screened for breast cancer by clinical breast examination (CBE). Those with positive CBE will be triaged by portable ultrasound device by non-radiologists. All recruited women will receive a diagnostic mammography and, if necessary, an ultrasound performed by a radiologist. The radiologist will be blinded to the portable ultrasound device findings. Those with suspected lesions either on mammography or ultrasound will have fine needle aspiration cytology (FNAC) or core biopsy. The women with confirmed diagnosis of breast cancer will be staged and appropriately treated as per the policy of the hospital.
79825766|NCT06055530|Diagnostic Test|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
79825767|NCT06055049|Other|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
79825768|NCT06054217|Drug|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
79825769|NCT06049927|Biological|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
79999842|NCT06272253|Biological|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|Dose : 1 dose 0.5 ml containing 5 μg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
79526733|NCT06048809|Other|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
79825770|NCT06049927|Biological|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
79999843|NCT06272240|Other|Ovarian Cancer Organoids|To characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)
79999844|NCT06272227|Drug|alfacalcidol|Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
79999845|NCT06272227|Drug|placebo|Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
79999846|NCT06272227|Drug|Denosumab|denosumab
79230792|NCT03255278|Biological|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
79526734|NCT06048809|Other|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
79526735|NCT06044896|Procedure|Supine Positioning|The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
79682295|NCT03927079|Procedure|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
79682296|NCT03927079|Biological|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
79682297|NCT03903211|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
79682298|NCT03874416|Other|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
79682299|NCT03874416|Other|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
79682300|NCT03866499|Drug|BPI-7711|180 mg, oral, QD
79682301|NCT03866499|Drug|Gefitinib|250 mg, oral, QD
79682302|NCT03866499|Drug|Placebo Tablet|250 mg gefitinib placebo tablet, QD
79825771|NCT06049927|Biological|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
79999847|NCT06272214|Radiation|Adjuvant radiotherapy|"The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area."
79230793|NCT03255278|Biological|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
79373083|NCT03464994|Diagnostic Test|ophthalmological examination|"Refraction~Best corrected visual acuity~Intraocular pressure~Slit lamp examination with vital dye (Oxford grading)~Tear break-up time (TBUT)~Schirmer I testing~Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch & Lomb) corneal videotopographies~Pachymetry~Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~questionnaire about ichthyosis severity~questionnaire about life quality specifically for patient presenting ichthyosis"
79999848|NCT06272214|Other|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
79999849|NCT06272201|Device|POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
79526736|NCT06044896|Procedure|Body Lateral Positioning|The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
79526737|NCT06044623|Drug|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
79999850|NCT06272188|Other|web-based online preconceptional counselling|web-based online preconceptional counselling
79526738|NCT06044623|Drug|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
79526739|NCT06044142|Drug|Curcumin|Curcumin and low laser therapy will be used on patients undergoing chemotherapy
79230794|NCT03255278|Biological|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
79526740|NCT06044142|Device|Laser|Low level laser therapy
79682303|NCT03866499|Drug|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
79682304|NCT03861208|Other|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
79682305|NCT03861208|Other|usual diet|foods representing the usually provided foods at childcare are offered
79230795|NCT03255278|Biological|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
79230796|NCT03251768|Drug|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
79230797|NCT03251768|Drug|GCSF|GCSF 5 mcg/kg/day
79390962|NCT03182790|Behavioral|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
79682306|NCT03848728|Other|SEARCH Youth combination intervention|"Administration of life-stage assessment tool~Structured choice clinic access~Rapid feedback of VL results~Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
79682307|NCT03848364|Behavioral|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
79682308|NCT03843775|Drug|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
79682309|NCT03843775|Drug|Encorafenib|encorafenib 450 mg oral QD
79682310|NCT03831477|Device|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
79682311|NCT03822962|Drug|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
79682312|NCT03822962|Other|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
79682313|NCT03806387|Drug|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
79682314|NCT03770260|Drug|Ixazomib Citrate|Given PO
79682315|NCT03770260|Drug|Pevonedistat|Given IV
79682316|NCT03762850|Drug|sparsentan|Target dose of 400 mg daily
79682317|NCT03762850|Drug|irbesartan|Target dose of 300 mg daily
79682318|NCT03762850|Drug|Dapagliflozin|Target dose of 10 mg daily
79682319|NCT03759093|Drug|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
79825772|NCT06049927|Biological|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
79682320|NCT03759093|Drug|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
79682321|NCT03759093|Drug|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
79825773|NCT06047951|Procedure|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~Only one aneurysm will be treated per patient~The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~A prescription dose of 25 Gy at the margin of the target will be used~The maximal dose on optic pathways will be kept below 10 Gy~The brainstem 12-Gy volume will be kept below 1cc"
79825774|NCT06033820|Drug|ZR2-ICE|"Drug: zanubrutinib Oral Capsule~Drug: lenalidomide Oral Capsule~Drug: R-ICE chemotherapy"
79682322|NCT03759093|Other|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
79682323|NCT03759093|Drug|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
79999851|NCT06272175|Other|Open Kinetic Chain Activity|PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
79825775|NCT06027905|Other|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
79526741|NCT06043986|Device|novel nurse call system|"Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money."
79682324|NCT03759093|Drug|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
79682325|NCT03759093|Drug|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
79682326|NCT03759093|Drug|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
79682327|NCT03759093|Drug|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
79682328|NCT03759093|Drug|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
79825776|NCT06019325|Procedure|RIB|After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
79825777|NCT06018467|Drug|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
79825778|NCT06018467|Dietary Supplement|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
79682329|NCT03759093|Drug|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
79682330|NCT03756961|Drug|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
79230798|NCT00617331|Biological|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
79230799|NCT05483374|Other|observation|Not applicable, it is an observational registry
79526742|NCT06043011|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
79682331|NCT03756961|Behavioral|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
79230800|NCT02455778|Dietary Supplement|Cinnamon|
79230801|NCT02455778|Dietary Supplement|Placebo|
79825779|NCT06018467|Dietary Supplement|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
79825780|NCT06018311|Behavioral|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
79825781|NCT06010836|Behavioral|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
79825782|NCT05997368|Other|Survey1|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
79230802|NCT03260270|Diagnostic Test|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
79825783|NCT05997368|Other|Survey2|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
79230803|NCT00687687|Drug|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
79230804|NCT00687687|Drug|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
79230805|NCT00687687|Drug|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
79230806|NCT04268758|Device|tulipon|Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.
79682332|NCT03756961|Drug|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
79373084|NCT03458286|Device|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
79373085|NCT03468504|Device|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
79373086|NCT03468504|Device|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
79526743|NCT06038487|Procedure|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
79682333|NCT03756961|Drug|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
79709773|NCT04315402|Other|prospective, descriptive study via survey|"Survey administered at check out.~Patient's rate of follow-up data gathered via chart review."
79230807|NCT03251534|Procedure|Centromedullary nailing|
79230808|NCT03952312|Behavioral|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
79230809|NCT03952312|Behavioral|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
79230810|NCT00685113|Drug|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
79230811|NCT00685113|Drug|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
79230812|NCT00685113|Drug|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
79230813|NCT03260114|Other|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
79230814|NCT05498350|Procedure|Ovulatory trigger timing|Timing of medication to induce final oocyte maturation
79373087|NCT03468504|Device|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
79999852|NCT06272175|Other|Closed Kinetic Chain Activity|Weight-bearing on the hemiplegic hand with extended elbow in standing position
79999853|NCT06272162|Radiation|MR guided radiotherapy|5 fractions of 10 Gray MRgRT in addition to standard of care
79230815|NCT04267900|Drug|99mTc-HPArk2|99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
79230816|NCT02978859|Drug|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
79230817|NCT04267588|Other|Navio Mobile App|Participants will use the Navio Mobile App to track participants' pain and pain treatment
79230818|NCT00615693|Drug|AEB071|
79230819|NCT00701090|Drug|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
79230820|NCT00701090|Drug|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
79373088|NCT04906434|Drug|60mg ABSK-011capsule|Three 20mg capsules,QD for oral administration
79373089|NCT04906434|Drug|120mg ABSK-011capsule|One 20mg capsule and one 100mg capsule,QD for oral administration
79373090|NCT04906434|Drug|180mg ABSK-011capsule|One 100mg capsule and four 20mg capsules,QD for oral administration
79373091|NCT04906434|Drug|240mg ABSK-011capsule|Two 100mg capsules and two 20mg capsules,QD for oral administration
79373092|NCT04906434|Drug|320 mg ABSK-011capsule|Three 100mg capsule and one 20mg capsule,QD for oral administration
79526744|NCT06038487|Procedure|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
79526745|NCT06037876|Drug|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
79526746|NCT06037876|Drug|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
79526747|NCT06037590|Combination Product|Levodopa Cyclops™|Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler
79526748|NCT06037590|Combination Product|INBRIJA®|Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
79682334|NCT03756961|Device|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
79682335|NCT03756961|Drug|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
79682336|NCT03756961|Drug|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
79999854|NCT06272149|Drug|VGN-R08b|VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
79682337|NCT03756961|Drug|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
79230821|NCT00701090|Drug|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
79230822|NCT00614601|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
79230823|NCT03255356|Other|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
79373093|NCT04906434|Drug|400mg ABSK-011capsule|Four 100mg capsules,QD for oral administration
79373094|NCT04904250|Device|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
79373095|NCT04904250|Device|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
79373096|NCT04348422|Diagnostic Test|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
79373097|NCT04348422|Diagnostic Test|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
79373098|NCT04348422|Other|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
79373099|NCT04453098|Behavioral|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
79373100|NCT03456570|Drug|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
79373101|NCT03456570|Drug|Placebo Oral Tablet|oral tablets twice daily
79373102|NCT05203224|Drug|Dornase Alfa|Intravenous Dornase alfa
79526749|NCT06035601|Device|EHR-integrated texting platform|"An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~Evidence-based prevention education material on recurrent UTIs~5 standing orders for urinalysis and urine culture in the EHR upon enrollment~Standard-of-care management for recurrent UTI"
79682338|NCT03756961|Drug|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
79230824|NCT02283489|Drug|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
79682339|NCT03749148|Drug|Dupilumab|anti-IL4-Receptor alpha
79682340|NCT03749148|Drug|Placebo|Placebo
79999855|NCT06272136|Device|Clinical Demo 2.0|During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
79999856|NCT06272123|Other|no intervention|no intervention
79373103|NCT03464838|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
79373104|NCT03464838|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
79230825|NCT02283489|Drug|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
79230826|NCT02283489|Drug|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
79230827|NCT02455232|Procedure|upper limb muscle block|
79230828|NCT02455232|Drug|4cc of lidocaïne®|
79230829|NCT03259958|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
79373105|NCT04870554|Behavioral|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
79373106|NCT03456180|Device|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
79526750|NCT06035601|Other|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms, and 3 to 6 month in-person visits for check-ins and prevention treatment discussion)
79526751|NCT06032247|Behavioral|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
79682341|NCT03737110|Drug|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and <18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and <18 years old) injections once weekly
79682342|NCT03737110|Drug|Placebo|Placebo SC injections once weekly
79682343|NCT03735901|Drug|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
79682344|NCT03735901|Drug|Matching placebo|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
79682345|NCT03723590|Device|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
79682346|NCT03710122|Drug|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
79682347|NCT03710122|Other|Placebo|Placebo for Vancomycin
79682348|NCT03705741|Behavioral|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
79709774|NCT01109992|Drug|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
79709775|NCT01109992|Drug|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
79709776|NCT02892357|Drug|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
79999857|NCT06272110|Other|System level Language Access (LA) intervention|Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
79999858|NCT06272097|Behavioral|Intervention program based on TIME-CDST tool led by wound specialist nurses|Based on the TIME CDST tool led by wound specialist nurses, which includes the following four areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment.
79999859|NCT06272097|Behavioral|A routine wound care program|A routine wound care program of wound cleaning and dressing changes
79999860|NCT06272084|Device|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
79999861|NCT06272058|Drug|Avenciguat (BI 685509)|Avenciguat (BI 685509)
79230830|NCT03259958|Drug|Aricept|Aricept Tablet
79682349|NCT03698669|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS involves an initial face-to-face meeting followed by regular phone meetings. In preliminary research, patients found this format to be convenient. The initial meeting includes the patient, the BHS and the PCP; the PCP then regularly receives treatment notes from the BHS. Also, the PCP, who has a longitudinal relationship with the patient, is encouraged to further reinforce TOPPS goals. After each TOPPS session, the BHS also mails a copy of the clinical note to the patient. Additionally, each participant is provided with a workbook that reviews the key elements of each treatment session and provides exercises for at-home practice of skills.
79825784|NCT05997368|Other|Survey3|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
79825785|NCT05992896|Drug|Bupivacaine liposome|Injection into pelvic area and into the edges of wound at the end of the procedure.
79825786|NCT05992896|Drug|Placebo|Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
79825787|NCT05953207|Other|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
79825788|NCT05953207|Other|Standard Of Care|Sleep hygiene and safety education session
79825789|NCT05937386|Drug|AGMB-129|Oral capsule
79825790|NCT05937386|Drug|MDZ|Pre-filled oral syringes
79999862|NCT06272045|Behavioral|Enriched home visiting|Enriched home visiting with cardiovascular health promotion content
79230831|NCT03251456|Other|Tertiary care|"Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
79230832|NCT03251456|Other|Usual Care|"Inform the parents that there are abnormalities after eye disease screening of their children~Inform the parents that they should take their children to the hospital for further consultation~Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
79230833|NCT00679731|Drug|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
79373107|NCT03468348|Drug|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
79373108|NCT03464682|Drug|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
79526752|NCT06032247|Behavioral|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
79526753|NCT06028802|Diagnostic Test|CT Clock Tool measurement|Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
79230834|NCT00679731|Drug|Methotrexate|5.0 to 25 mg weekly
79230835|NCT00605553|Drug|Placebo|"Placebo oral capsules~Placebo for 7 days"
79230836|NCT00605553|Drug|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
79373109|NCT03464682|Drug|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
79373110|NCT03464682|Drug|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
79373111|NCT03464682|Drug|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
79526754|NCT06026436|Biological|Blood samples|12-24 hours after P2Y12 ADP receptor loading dose (LD)
79526755|NCT06026436|Biological|Blood samples|1 month after Percutaneous Coronary Intervention (PCI)
79526756|NCT06017882|Other|Partial sleep deprivation|
79526757|NCT06011798|Drug|Aflibercept|Anti-VEGF control
79526758|NCT06011798|Drug|foselutoclax|Experimental drug
79373112|NCT03464682|Drug|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
79373113|NCT03464682|Drug|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
79373114|NCT03464526|Drug|Orvepitant|Tablet, once daily, oral
79526759|NCT06011291|Drug|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
79526760|NCT06011291|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
79526761|NCT06008613|Device|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
79526762|NCT06008158|Radiation|Accelerated Partial Breast Irradiation|Undergo APBI
79526763|NCT05988710|Drug|Buccal Buprenorphine 300 mcg|buprenorphine for 300mcg buccal administration
79526764|NCT05988710|Drug|Buccal Buprenorphine 600 mcg|buprenorphine for 600mcg buccal administration
79526765|NCT05988710|Drug|Buccal Buprenorphine 900 mcg|buprenorphine for 900mcg buccal administration
79526766|NCT05988710|Drug|Buccal Placebo|Placebo for buccal administration
79526767|NCT05988710|Drug|Oral Placebo|Placebo for oral administration
79825791|NCT05922865|Device|KNEESUP smart knee assistive device + KNEESUP care APP|In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.
79373115|NCT03464526|Drug|Placebo|Tablet, once daily, oral
79526768|NCT05988710|Drug|Oral immediate-release oxycodone 10mg|Immediate-release oxycodone for 10 mg oral administration
79526769|NCT05969808|Other|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
79825792|NCT05922865|Device|KNEESUP care APP|In KNEESUP care APP group, the participants only used the KNEESUP care APP which was installed in the mobile phone. The APP was designed with an individualized exercise program. Participants could follow the APP to do the exercise program according to their own conditions.
79825793|NCT05922865|Behavioral|Healthy consulation|In Healthy consulation group, participants received routine outpatient health education.
79526770|NCT05969808|Other|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
79230837|NCT00678171|Device|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
79373116|NCT03468192|Other|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
79526771|NCT05965258|Diagnostic Test|Cardiac magnetic resonance (CMR)|Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
79526772|NCT05952271|Other|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
79526773|NCT05950594|Radiation|Radiotherapy|Standard of care pre-operative radiotherapy
79709777|NCT02892357|Drug|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
79825794|NCT05920798|Procedure|Biopsy|Undergo biopsy
79825795|NCT05920798|Procedure|Biospecimen Collection|Undergo blood sample collection
79526774|NCT05950594|Other|Surgery|Standard of care definitive surgery
79526775|NCT05944770|Other|DIY portable air cleaner with a highly effective filter|"A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater."
79825796|NCT05920798|Procedure|Computed Tomography|Undergo CT
79825797|NCT05920798|Procedure|Magnetic Resonance Imaging|Undergo MRI
79825798|NCT05920798|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
79825799|NCT05920798|Biological|Pembrolizumab|Given IV
79825800|NCT05920798|Procedure|Pheresis|Undergo apheresis
79825801|NCT05919082|Drug|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
79230838|NCT02455934|Dietary Supplement|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and <12 days apart.
79526776|NCT05944770|Other|DIY portable air cleaner with sham filtration|"A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke."
79526777|NCT05936255|Behavioral|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
79825802|NCT05919082|Drug|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
79825803|NCT05914311|Device|Suture|secures SCS trial leads with a suture
79825804|NCT05914311|Device|Dermabond|secures SCS trial leads with dermabond
79825805|NCT05907980|Drug|ROSE12|ROSE12 as a IV infusion
79373117|NCT02522598|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
79373118|NCT02522598|Drug|Placebo|water for injection
79373119|NCT03464370|Other|Measure of emotional stressors|"For the Epileptic Group~Rapid interrogation, completing the clinical data~A scale of impact of the precipitating factors of crises~An emotional Stroop~A task of detecting emotional targets against threatening information~A measure of the perception of emotions using film clips~A scale of measurement of perceived stress~The transfer of psychiatric scales~For the healthy volunteers group :~A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~An emotional Stroop~A task of detecting emotional targets against threatening information~A scale of measurement of perceived stress~A measure of the perception of emotions using film clips~A rapid neuropsychological assessment"
79709778|NCT00595686|Drug|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
79709779|NCT02271620|Procedure|nasal allergen provocation test|nasal allergen provocation test
79709780|NCT00595725|Other|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
79825806|NCT05907980|Drug|Atezolizumab|Atezolizumab as a IV infusion
79682350|NCT03698669|Behavioral|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity. This control condition was accepted by our participants in preliminary studies; it does not directly target functional impairment, and participants do not set tailored goals relating to their own values. The BHS will communicate with the PCP only if a participant shows signs of clinical deterioration.
79999863|NCT06272045|Behavioral|Routine home visiting|Home visiting without cardiovascular health promotion content
79230839|NCT00507741|Drug|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
79230840|NCT00507741|Drug|Ertafolide|
79230841|NCT03251066|Other|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
79230842|NCT00677313|Drug|metreleptin|metreleptin injection
79230843|NCT02455856|Drug|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6.
79230844|NCT02455856|Drug|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
79373120|NCT04862052|Procedure|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
79526778|NCT05916885|Other|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
79526779|NCT05916885|Other|conventional therapy alone|a control group receiving conventional therapy alone.
79526780|NCT05916872|Other|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
79230845|NCT02283645|Drug|3 % minoxidil lotion|
79230846|NCT02283645|Drug|Placebo|
79373121|NCT03453918|Dietary Supplement|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
79390963|NCT03182790|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
79390964|NCT03182790|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
79390965|NCT03182790|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
79526781|NCT05916872|Other|control group|Patients will receive conventional therapy.
79526782|NCT05915247|Drug|HER-096|Administered as a single dose via s.c. injection
79682351|NCT03697304|Drug|BI 754091|Solution for infusion
79230847|NCT02283723|Other|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
79230848|NCT02283723|Other|Usual care|While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
79230849|NCT03259412|Dietary Supplement|Fish Oil|Fish Oil Capsule
79230850|NCT03259412|Dietary Supplement|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
79230851|NCT00602745|Drug|S-1|oral administration
79230852|NCT00602745|Drug|5-Fluorouracil|intravenous bolus
79526783|NCT05915247|Drug|Placebo|Administered as a single dose via s.c. injection
79526784|NCT05902546|Other|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
79526785|NCT05902546|Other|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
79526786|NCT05896423|Behavioral|PrEP awareness materials|Community-designed PrEP awareness materials - developed in the formative portion of this study
79526787|NCT05888662|Procedure|Endo-epicardial ablation|Endo-epicardial ablation of ventricular tachycardia
79682352|NCT03697304|Drug|BI 754111|Solution for infusion
79682353|NCT03697304|Drug|BI 836880|Solution for infusion
79230853|NCT03251222|Drug|Dexmedetomidine|Intranasal aplication of dexmedetomidine
79373122|NCT03453918|Other|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
79373123|NCT03468114|Behavioral|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
79230854|NCT03251222|Other|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
79230855|NCT04487912|Drug|Tilmanocept|Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
79230856|NCT04487912|Drug|Nanocolloid|Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
79230857|NCT04471857|Behavioral|Hypnosis|
79230858|NCT04471389|Other|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
79230859|NCT02281461|Device|Male circumcision using a non-surgical device|Male Circumcision
79373124|NCT03468114|Behavioral|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
79373125|NCT03452982|Other|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
79526788|NCT05888662|Procedure|endocardial ablation only|endocardial-only catheter ablation of ventricular tachycardia
79526789|NCT05882357|Drug|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
79526790|NCT05882357|Drug|IVA|Granules for oral administration
79526791|NCT05879653|Drug|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
79526792|NCT05879653|Drug|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
79526793|NCT05879653|Procedure|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
79526794|NCT05879653|Radiation|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
79526795|NCT05878288|Drug|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
79682354|NCT03691077|Drug|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
79682355|NCT03682887|Procedure|Cryoballoon PV isolation group|"Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~Target number of subjects: 278 (138 per group)~Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
79230860|NCT04487600|Other|Active voiding trial|
79230861|NCT02281539|Device|Neuromotus|
79230862|NCT03250910|Drug|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
79230863|NCT03250910|Drug|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
79230864|NCT02283801|Drug|Eslicarbazepine acetate|
79230865|NCT02283801|Drug|Lamotrigine|
79230866|NCT02455154|Drug|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
79230867|NCT02455154|Drug|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
79230868|NCT02455154|Drug|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
79230869|NCT00502515|Drug|SSR180575|Oral, once daily dosing
79230870|NCT00502515|Drug|Placebo|Oral, once daily dosing
79230871|NCT03254810|Biological|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
79230872|NCT03254810|Biological|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
79230873|NCT03254810|Biological|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
79682356|NCT03682887|Procedure|Cryoballoon PV isolation with Additional RA linear ablation group|"Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~Target number of subjects: 278 (138 per group)~Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
79682357|NCT03669926|Radiation|Digital Breast Tomosynthesis+synthetic mammography|Two-view tomosynthesis performed with GE Senographe Pristina.
79682358|NCT03662776|Behavioral|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
79682359|NCT03662776|Behavioral|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
79682360|NCT03625648|Drug|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
79682361|NCT03625648|Drug|Placebo|placebo
79682362|NCT03624933|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
79682363|NCT03624933|Behavioral|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
79848953|NCT05772533|Procedure|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
79230874|NCT00501735|Drug|Forodesine 200 mg|2 x 100mg tablets once daily
79230875|NCT03255122|Behavioral|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, & Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
79230876|NCT03255122|Behavioral|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
79230877|NCT03255044|Drug|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
79230878|NCT03255044|Drug|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
79230879|NCT03255044|Other|guideline directed therapy|standard heart failure therapy
79230880|NCT00499239|Drug|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
79230881|NCT03246464|Device|Orthokeratology lenses|Rigid gas permeable contact lenses
79682364|NCT03623867|Drug|Secukinumab|Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
79682365|NCT03623867|Drug|Placebo|Subject will take placebo once weekly in week 0-4, and once monthly till week 48
79230882|NCT03246464|Device|Single-vision spectacles|Regular single vision spectacles
79230883|NCT02281617|Behavioral|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
79230884|NCT02454998|Other|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
79230885|NCT00677079|Drug|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
79373126|NCT03468036|Other|none, does not apply|none: does not apply
79390966|NCT03182790|Behavioral|COSH booklet|A general smoking cessation self-help booklet
79390967|NCT03182790|Behavioral|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
79682366|NCT03616535|Other|Cognitive training|The investigators will provide participants with tablets to play brain games.
79682367|NCT03616535|Other|Exercise training|The investigators will provide participants with foot peddlers.
79682368|NCT03616535|Other|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
79682369|NCT03602157|Biological|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10^7, 5x10^7, 1x10^8
79682370|NCT03602157|Biological|ALTCAR.CD30 cells|Fixed dose level of 1x10^8
79682371|NCT03602157|Drug|Bendamustine|70 mg/m^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
79682372|NCT03602157|Drug|Fludarabine|30 mg/m^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
79682373|NCT03601442|Biological|CTL019|CTL019
79825807|NCT05906615|Drug|Lidocaine IV|Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
79682374|NCT03595098|Behavioral|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
79682375|NCT03595098|Behavioral|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
79682376|NCT03594630|Drug|Chemotherapy|Receive chemotherapy
79825808|NCT05901493|Behavioral|Perceptual category training|Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
79825809|NCT05889013|Device|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
79825810|NCT05884853|Behavioral|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
79825811|NCT05880355|Drug|Dapansutrile|Oral inhibitor of NLRP3
79230886|NCT03250988|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
79230887|NCT03245996|Device|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
79230888|NCT03245996|Device|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
79682377|NCT03594630|Other|Patient Observation|Receive active surveillance
79230889|NCT03245996|Device|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
79230890|NCT03245996|Drug|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
79373127|NCT04803786|Drug|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
79682378|NCT03594630|Other|Questionnaire Administration|Ancillary studies
79682379|NCT03594630|Procedure|Resection of Rectum|Undergo surgical resection
79682380|NCT03592771|Behavioral|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
79373128|NCT03464214|Device|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
79682381|NCT03592771|Behavioral|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
79682382|NCT03587740|Drug|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
79682383|NCT03586999|Drug|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
79682384|NCT03586999|Drug|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
79825812|NCT05880355|Other|Placebo|Non-active placebo
79230891|NCT03245996|Drug|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
79373129|NCT03464214|Behavioral|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
79373130|NCT03464058|Drug|BOS172767 tablets|Oral tablets
79373131|NCT03464058|Drug|BOS172767 liquid capsules|Oral capsules
79373132|NCT03464058|Drug|BOS172767 micronized capsules|Oral capsules
79682385|NCT03586999|Drug|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
79682386|NCT03586999|Drug|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
79682387|NCT03586999|Drug|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
79230892|NCT03245996|Drug|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
79682388|NCT03586999|Drug|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21-day cycles of the medications.
79825813|NCT05879367|Drug|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
79682389|NCT03575390|Dietary Supplement|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
79825814|NCT05879367|Drug|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
79825815|NCT05879367|Drug|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
79825816|NCT05879367|Drug|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
79825817|NCT05863507|Dietary Supplement|Grape powder supplementation|The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
79825818|NCT05863507|Dietary Supplement|Placebo|The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
79825819|NCT05853367|Drug|MK-0472|Oral Administration
79825820|NCT05853367|Biological|Pembrolizumab|IV infusion
79825821|NCT05849493|Behavioral|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
79682390|NCT03575390|Dietary Supplement|Pomegranate|Pomegranate extract 500mg
79682391|NCT03564522|Procedure|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
79682392|NCT03564522|Radiation|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
79682393|NCT03537495|Drug|Linezolid|"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."
79682394|NCT03534518|Other|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
79230893|NCT05209503|Other|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio > 0.80, then no PCI revascularization of target blood vessels will be carried out.
79682395|NCT03534518|Other|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
79825822|NCT05849493|Behavioral|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
79825823|NCT05847439|Drug|[14C]BMS-986419|Specified dose on specified days
79230894|NCT05209503|Other|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
79825824|NCT05846022|Other|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
79230895|NCT03254966|Drug|SHR0302|Oral tablets
79230896|NCT03254966|Drug|Placebo|Oral tablets
79230897|NCT03786484|Drug|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
79230898|NCT02281929|Drug|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
79230899|NCT02281929|Drug|Placebo|Placebo in three daily doses during 30 days
79373133|NCT03464058|Drug|BOS172767 immediate release capsules|Oral capsules
79373134|NCT03464058|Drug|BOS172767 matching placebo capsules|Oral capsules
79825825|NCT05846022|Other|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
79825826|NCT05825092|Drug|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
79230900|NCT02281929|Drug|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
79682396|NCT03525288|Radiation|PSMA -PET/CT simulation|"PET/CT simulation.~If no additional lesions detected: RT as planned per standard care.~If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~If PSMA-PET/CT imaging consistent with widely metastatic disease (>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
79682397|NCT03525288|Radiation|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
79682398|NCT03519269|Device|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
79682399|NCT03518606|Drug|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
79682400|NCT03506971|Other|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
79682401|NCT03506971|Other|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~1 every month from birth to 1 year~1 every 2 months from 1 year to 2 years~1 every 3 months from 2 years to 4 years"
79682402|NCT03506971|Other|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~1 at 4 months~1 at 24 months"
79682403|NCT03497299|Device|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
79230901|NCT03254498|Device|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
79230902|NCT03254498|Device|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
79526796|NCT05877586|Other|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
79682404|NCT03497299|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
79682405|NCT03495154|Device|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
79682406|NCT03486340|Procedure|Cardiologic assessment|Aggressive ischemic risk factor management
79682407|NCT03480672|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
79682408|NCT03480672|Other|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
79682409|NCT03479255|Behavioral|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight, and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call in order to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patient from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent issues related to their care.
79230903|NCT02283879|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
79230904|NCT04424056|Drug|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
79526797|NCT05876273|Device|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
79526798|NCT05876273|Device|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
79526799|NCT05874713|Biological|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
79230905|NCT04424056|Drug|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
79230906|NCT04424056|Drug|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
79230907|NCT04424056|Drug|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
79230908|NCT04424056|Other|Standard of care|Treatment with drugs or procedures in routine clinical practice
79682410|NCT03479255|Behavioral|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
79682411|NCT03466918|Device|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
79682412|NCT03454295|Behavioral|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
79682413|NCT03454295|Behavioral|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
79230909|NCT02454374|Procedure|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
79373135|NCT03464058|Drug|BOS172767 matching placebo tablets|Oral tablets
79230910|NCT02454374|Procedure|Routine Physiotherapy Care|Routine Physiotherapy Care
79825827|NCT05825092|Drug|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
79825828|NCT05825092|Diagnostic Test|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery < 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
79825829|NCT05825092|Diagnostic Test|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
79825830|NCT05825092|Diagnostic Test|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
79825831|NCT05825092|Diagnostic Test|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
79825832|NCT05825092|Diagnostic Test|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
79825833|NCT05824702|Behavioral|Peer education & communications|The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.
79825834|NCT05824702|Behavioral|Standard of care educational|This is an educational equal attention control group
79825835|NCT05820568|Behavioral|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
79825836|NCT05819749|Behavioral|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
79825837|NCT05818709|Device|HAC 22L|Subcutaneous and/or Supraperiosteal injection
79825838|NCT05805397|Behavioral|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
79825839|NCT05805397|Behavioral|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
79230911|NCT03250442|Device|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
79373136|NCT03464058|Drug|Rabeprazole|Oral tablets
79373137|NCT03463902|Device|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
79825840|NCT05802615|Behavioral|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
79373138|NCT03463902|Device|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
79373139|NCT03463902|Device|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
79526800|NCT05874713|Biological|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
79526801|NCT05874713|Biological|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
79230912|NCT03250442|Other|Standard Dry Dressing|These are customary dry dressings.
79825841|NCT05802615|Other|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
79230913|NCT00497757|Biological|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
79230914|NCT05478772|Drug|CTP-543|12 mg on Day 1 and Day 7
79709781|NCT02271659|Radiation|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
79230915|NCT05478772|Drug|Fluconazole|200 mg once daily on Days 3 through to Day 8
79526802|NCT05874713|Biological|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
79825842|NCT05795101|Drug|Trastuzumab deruxtecan|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
79825843|NCT05795101|Drug|Durvalumab|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
79825844|NCT05794789|Behavioral|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
79825845|NCT05767970|Behavioral|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
79526803|NCT05874713|Biological|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
79526804|NCT05864950|Device|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
79526805|NCT05864001|Behavioral|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
79709782|NCT02271659|Radiation|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
79825846|NCT05765578|Biological|Moderna COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
79825847|NCT05765578|Biological|Moderna mRNA1273.222 Booster|Sterile liquid for injection. Intervention not administered through this study.
79825848|NCT05765578|Biological|Pfizer COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
79825849|NCT05765578|Biological|Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
79825850|NCT05765578|Biological|Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
79825851|NCT05732740|Behavioral|Empower@Home:Connected|Cognitive behavioral therapy
79825852|NCT05722769|Behavioral|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
79848954|NCT05772078|Other|Assess compliance rate and demographics|Records to evaluate attendance rate
79526806|NCT05859152|Other|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
79230916|NCT02945852|Drug|apatinib|apatinib 500mg/d until progressive Disease
79230917|NCT03245684|Diagnostic Test|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
79230918|NCT00672009|Drug|Ixabepilone|Ixabepilone 35 mg/m^2 intravenously over 3 hours every 21 days for 4 cycles.
79230919|NCT03245528|Drug|LJPC-501|angiotensin II
79230920|NCT00495885|Drug|volinanserin (M100907)|oral, one tablet taken around bedtime
79230921|NCT00495885|Drug|Placebo|oral, one tablet taken around bedtime
79230922|NCT03245606|Procedure|Liver biopsy|Measurement of liver fibrosis
79230923|NCT03245606|Device|Abdominal MRI|Measurement of liver fibrosis
79230924|NCT03245606|Device|Transient elastography|Measurement of liver fibrosis
79230925|NCT00592995|Drug|Creatine monohydrate|10 to 30 grams daily
79230926|NCT00592995|Drug|Placebo|10 to 30 grams daily
79230927|NCT03254030|Other|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
79230928|NCT03254186|Drug|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
79709783|NCT01109524|Drug|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
79825853|NCT05722769|Behavioral|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
79825854|NCT05719350|Other|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
79526807|NCT05859152|Other|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
79526808|NCT05845541|Behavioral|Technology Supported Meditation and Biofeedback|"Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.~During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed."
79526809|NCT05845541|Other|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
79526810|NCT05838183|Diagnostic Test|The relationship between imaging and ROSE and NGS|The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
79825855|NCT05714007|Drug|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
79825856|NCT05714007|Drug|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
79825857|NCT05713838|Drug|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
79825858|NCT05713838|Drug|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
79825859|NCT05713838|Drug|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
79825860|NCT05713838|Radiation|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
79825861|NCT05712512|Behavioral|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
79999864|NCT06272032|Procedure|High-intensity focused ultrasound (HIFU)|Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
79230929|NCT03254186|Drug|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
79230930|NCT04272424|Procedure|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
79230931|NCT03250598|Drug|AG-348|50 mg single-dose
79230932|NCT03250598|Drug|AG-348|5 mg single-dose
79230933|NCT03250598|Drug|AG-348|200 mg single-dose
79230934|NCT02282085|Drug|Aripiprazole Once-Monthly|
79230935|NCT02282085|Drug|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
79305591|NCT03240497|Behavioral|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
79709784|NCT01109524|Drug|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
79709785|NCT01109524|Drug|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
79305592|NCT02453945|Device|Adjustable Support Bra|A ClearPoint Medical support bra
79709786|NCT02271737|Behavioral|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
79825862|NCT05712512|Other|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
79825863|NCT05712187|Drug|ALTO-100|ALTO-100 tablet BID
79825864|NCT05712187|Drug|Placebo|Placebo tablet BID
79825865|NCT05711290|Dietary Supplement|Oxygen Nanobubble|This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
79999865|NCT06272032|Drug|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
79999866|NCT06272019|Other|Iodine gargle|Iodine gargle 0.2 %
79305593|NCT04956315|Diagnostic Test|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
79825866|NCT05711290|Other|Placebo|The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
79825867|NCT05705544|Device|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
79825868|NCT05705544|Device|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
79825869|NCT05669859|Procedure|Exercise|"The rehabilitation program designed in our study was based on the development of core muscle control and dynamic stabilization of the spine, which is generally required by patients. All exercises were combined with controlled breathing, focusing on the mobility of the extremities and the activity of multiple muscle groups.~Our program created in this direction will start with face-to-face patient education; For 8 weeks, will be carried out remotely online under the supervision of a physiotherapist.On non-telerehabilitation days, they will be asked to keep an exercise diary, instructed to practice the exercise approach presented in sessions at home daily in 20-minute periods. The exercise diary will be checked during online sessions."
79526811|NCT05835856|Device|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
79825870|NCT05655520|Drug|SAGE-718|Oral softgel lipid capsules
79825871|NCT05651295|Behavioral|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
79825872|NCT05651295|Behavioral|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
79825873|NCT05651295|Behavioral|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
79825874|NCT05639894|Biological|RSV mRNA LNP CL-0059 Low dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
79825875|NCT05639894|Biological|RSV mRNA LNP CL-0137 Low dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
79825876|NCT05639894|Biological|RSV mRNA LNP CL-0059 Medium Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
79825877|NCT05639894|Biological|RSV mRNA LNP CL-0137 Medium Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
79825878|NCT05639894|Biological|RSV mRNA LNP CL-0059 High Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
79825879|NCT05639894|Biological|RSV mRNA LNP CL-0137 High RSV mRNA LNP CL-0137 High Dose Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
79825880|NCT05639894|Other|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
79825881|NCT05628675|Other|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
79999867|NCT06272006|Procedure|Coronally Positioned Flap with Connective Tissue Graft|his intervention involves surgically repositioning the gum tissue over the exposed tooth root and adding a connective tissue graft. The graft is obtained from the patient's palate and placed in the area of gingival recession to promote tissue regeneration and enhance root coverage. The procedure aims to reduce gingival recession and improve periodontal health.
79999868|NCT06272006|Procedure|Modified Coronally Advanced Tunnel with Connective Tissue Graft|This intervention utilizes a minimally invasive technique to create a tunnel beneath the gum tissue, through which a connective tissue graft is placed. The graft, sourced from the patient's palate, is used to encourage the growth of new gum tissue over the exposed root. This method is designed to minimize trauma and promote faster recovery, aiming to improve root coverage and periodontal outcomes.
79526812|NCT05835856|Device|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
79526813|NCT05835856|Device|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
79682414|NCT03454295|Behavioral|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. [79]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) [63]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
79682415|NCT03421691|Device|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
79682416|NCT03406572|Device|HFHO Group|"Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~Brand name: Airvo 2"
79825882|NCT05621096|Radiation|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
79825883|NCT05621096|Biological|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
79825884|NCT05621096|Radiation|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
79825885|NCT05611957|Drug|LY3437943|Administered SC.
79825886|NCT05601024|Behavioral|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
79825887|NCT05592132|Other|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
79230936|NCT05482984|Other|video-recorded role-play and guided reflection|The experimental group was divided into 6 teams. Before the course, the teacher in charge and each group developed six scenarios: restraint, suicidal intent, respiratory distress, chronic heart failure, medication refusal, and accidental amputation. The researcher guided each group to write scripts about the clinical situations (30 minutes), create role-play videos (50 minutes), and share literature that was helpful in understanding this context (30 minutes). Each student played a role in the filming process. The final film was viewed by all the students during class. Each live class session was 50 minutes in length, with one session per week for 6 weeks. All students were asked to attend six video-viewing sessions and participate in a reflective discussion.
79230937|NCT05475496|Other|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
79230938|NCT00671073|Drug|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
79230939|NCT00671073|Drug|Placebo|Placebo, oral administration, once daily for 12 weeks
79373140|NCT03463902|Device|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
79825888|NCT05581212|Other|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
79825889|NCT05579431|Drug|VX-634|Suspension for oral administration.
79825890|NCT05579431|Drug|Placebo|Suspension for oral administration.
79825891|NCT05577559|Procedure|intermediate cervical plexus block|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
79230940|NCT00671073|Drug|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
79373141|NCT03463902|Device|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
79825892|NCT05577559|Procedure|Cervical Erector spinae block|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
79825893|NCT05555875|Behavioral|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
79825894|NCT05544357|Other|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
79848955|NCT05770869|Device|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
79230941|NCT00671073|Drug|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
79230942|NCT03245216|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
79230943|NCT03245216|Behavioral|rest|Seated rest before motor learning
79230944|NCT03245216|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
79230945|NCT03245294|Procedure|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
79230946|NCT04471467|Procedure|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
79373142|NCT05163444|Device|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
79373143|NCT05163444|Device|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
79373144|NCT03451734|Drug|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
79390968|NCT03182790|Behavioral|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
79373145|NCT03451734|Drug|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
79825895|NCT05544357|Other|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
79999869|NCT06271941|Procedure|Hybrid Argon Plasma Coagulation (h-APC)|The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
79230947|NCT03250754|Device|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
79230948|NCT03245060|Behavioral|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
79230949|NCT03250364|Device|Multilayer bandage|See arm/group descriptions
79230950|NCT03250364|Device|Double compression bandage|See arm/group descriptions
79230951|NCT03250364|Device|Cohesive bandage|See arm/group descriptions
79230952|NCT03250364|Device|Adhesive compression bandage|See arm/group descriptions
79230953|NCT03250364|Device|Kinesiotaping bandage|See arm/group descriptions
79230954|NCT03250364|Other|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
79305594|NCT04956315|Diagnostic Test|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
79373146|NCT03451734|Drug|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
79373147|NCT03129984|Device|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
79373148|NCT03467880|Other|Clinical Observation|No treatment given but observation with IOS
79373149|NCT03451344|Other|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
79526814|NCT05835856|Device|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
79526815|NCT05835856|Other|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
79526816|NCT05831046|Other|ED management software|Patients utilize software after being screened, but prior to being re-evaluated by physician
79305595|NCT04956315|Diagnostic Test|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
79373150|NCT03451344|Other|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
79526817|NCT05816330|Biological|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
79526818|NCT05816330|Other|Normal Saline|Administered one time via subcutaneous route.
79682417|NCT03406572|Device|Standard O2|Standard oxygen therapy
79682418|NCT03397602|Behavioral|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
79682419|NCT03397602|Behavioral|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
79682420|NCT03390296|Biological|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
79682421|NCT03390296|Drug|Avelumab|Given IV
79682422|NCT03390296|Drug|Azacitidine|Given IV or SC
79682423|NCT03390296|Drug|Gemtuzumab Ozogamicin|Given IV
79682424|NCT03390296|Drug|Glasdegib|Given PO
79682425|NCT03390296|Drug|Glasdegib Maleate|Given PO
79682426|NCT03390296|Drug|Venetoclax|Given PO
79682427|NCT03390296|Drug|Azacitidine|Given IV or SC
79848956|NCT05765448|Other|Soy control|Soy isolate control meal
79999870|NCT06271941|Procedure|Snare tip soft coagulation (STSC)|The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
79230955|NCT03250364|Other|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
79825896|NCT05534022|Device|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
79825897|NCT05531812|Other|G2R with individual coaching|"Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~A one-time asset transfer of US$300 delivered ~7 months into the program;~Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
79230956|NCT03250364|Behavioral|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
79230957|NCT03245138|Procedure|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
79848957|NCT05765448|Other|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
79230958|NCT03245138|Procedure|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
79230959|NCT03244982|Drug|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
79230960|NCT03244982|Drug|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
79230961|NCT03250286|Device|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed."
79230962|NCT03250286|Device|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
79230963|NCT03244748|Procedure|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
79230964|NCT04487366|Other|reaching targeted area on the phantom model|resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
79682428|NCT03386240|Drug|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
79848958|NCT05765448|Other|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
79848959|NCT05765448|Other|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
79848960|NCT05765448|Other|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
79999871|NCT06271928|Drug|Yijing Keli|Once enrolled, participants will be administrated Yijing Keli
79230965|NCT03253640|Other|Exposure|Healthcare associated infection (HAI)
79230966|NCT03250208|Dietary Supplement|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
79230967|NCT03250208|Other|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
79373151|NCT03467802|Biological|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
79526819|NCT05802927|Other|DSF|Diabetes-specific formula
79526820|NCT05802927|Other|Breakfast 1|Noodle Soup
79230968|NCT03253484|Radiation|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
79390969|NCT02431026|Device|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
79526821|NCT05802927|Other|Breakfast 2|Glutinous rice
79526822|NCT05795647|Drug|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
79682429|NCT03386240|Other|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
79682430|NCT03362801|Diagnostic Test|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
79230969|NCT03244670|Other|Observation study only, no specific intervention|Observation study only, no specific intervention
79526823|NCT05784194|Procedure|Intervention for correct discharge medication list|As above
79682431|NCT03338387|Drug|Acipimox|Acipimox
79682432|NCT03338387|Drug|Placebo|Placebo Other Names: Placebo (for Olbetam)
79682433|NCT03334253|Drug|Atropine|Daily 0.01% atropine eyedrops
79682434|NCT03334253|Other|Placebo Eyedrops|Daily placebo eyedrops
79682435|NCT03314857|Device|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
79682436|NCT03306264|Drug|ASTX727|ASTX727 is a tablet for oral administration, containing the fixed-dose combination of 100 mg cedazuridine (a cytidine deaminase inhibitor) and 35 mg decitabine, given by mouth Dailyx5 in 28-day cycles (in Cycle 1 or Cycle 2, then in Cycle 3 and beyond).
79682437|NCT03306264|Drug|Dacogen|Decitabine 20 mg/m^2 one-hour IV infusion Dailyx5 (in one 28-day cycle: either Cycle 1 or Cycle 2).
79682438|NCT03304080|Drug|Anastrozole|1 mg orally daily, day 1 to day 28
79373152|NCT03467802|Device|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
79373153|NCT01198366|Biological|AERAS-402 1.5 x 10^10 vp|
79825898|NCT05531812|Other|G2R with group coaching|"Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~A one-time asset transfer of US$300 delivered ~7 months into the program;~Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
79230970|NCT03250130|Behavioral|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
79230971|NCT03249974|Device|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
79230972|NCT03244592|Drug|Minocycline|200 mg/day
79373154|NCT01198366|Biological|AERAS-402 3.0 x 10^10 vp|
79373155|NCT01198366|Biological|AERAS-402 1.0 x 10^11 vp|
79825899|NCT05521113|Behavioral|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
79373156|NCT01198366|Biological|Placebo|
79682439|NCT03304080|Drug|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
79682440|NCT03304080|Drug|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
79682441|NCT03304080|Drug|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
79682442|NCT03302156|Drug|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
79825900|NCT05521113|Behavioral|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
79230973|NCT03244592|Drug|Sugar pill|Matched placebo
79682443|NCT03275506|Drug|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
79825901|NCT05515198|Other|Patient Education|Patients will be provided educational opportunities.
79230974|NCT03244514|Other|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
79230975|NCT03253328|Drug|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
79230976|NCT03253328|Drug|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
79230977|NCT03253874|Behavioral|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
79230978|NCT03253406|Behavioral|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
79230979|NCT03253406|Behavioral|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
79230980|NCT03253250|Drug|ETV；TDF；ADV|NAs
79373157|NCT03130218|Other|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
79373158|NCT03129906|Dietary Supplement|Gluten|
79373159|NCT03129906|Dietary Supplement|Rice protein|
79373160|NCT03011320|Drug|EC1456|intravenous (IV) bolus dose
79390970|NCT01682213|Drug|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
79682444|NCT03275506|Drug|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
79682445|NCT03267680|Drug|Cyclophosphamide|Given IV
79682446|NCT03267680|Drug|Indomethacin|Given PO
79682447|NCT03267680|Biological|IRX-2|Given via submucosal injection or SC
79682448|NCT03267680|Other|Laboratory Biomarker Analysis|Correlative studies
79682449|NCT03267680|Dietary Supplement|Multivitamin|Given zinc-containing multivitamin PO
79682450|NCT03267680|Drug|Omeprazole|Given PO
79682451|NCT03267680|Other|Placebo|Given via submucosal injections or SC
79682452|NCT03267680|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79682453|NCT03256656|Other|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
79682454|NCT03249870|Drug|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
79825902|NCT05515198|Other|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
79230981|NCT03253250|Drug|Peginterferon Alfa-2a|peginterferon
79230982|NCT03253562|Drug|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
79230983|NCT03253562|Drug|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
79230984|NCT03244280|Drug|MOB015B|Topical formulation
79230985|NCT03244436|Procedure|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
79230986|NCT03249818|Device|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
79230987|NCT03249896|Behavioral|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
79373161|NCT03011320|Drug|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
79373162|NCT03463746|Device|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
79373163|NCT03463746|Device|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
79373164|NCT03451266|Drug|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
79373165|NCT03451266|Drug|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
79526824|NCT05775809|Drug|selective serotonin reuptake inhibitors|"Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded."
79682455|NCT03244722|Dietary Supplement|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
79682456|NCT03244722|Other|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
79526825|NCT05775809|Device|TMS|TMS are allowed. The method, frequency, and duration of therapy should be recorded.
79526826|NCT05770804|Behavioral|Face to face education|Face-to-face training was provided and supported by booklets.
79682457|NCT03240731|Biological|bone marrow transplant|haploidentical bone marrow transplant
79825903|NCT05515198|Other|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
79230988|NCT03253016|Diagnostic Test|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
79230989|NCT03250052|Drug|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
79373166|NCT05322486|Procedure|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
79373167|NCT05322486|Drug|chemotherapy|Chemotherapy with or without biological drugs.
79373168|NCT03463668|Device|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
79526827|NCT05769855|Drug|HR18034|HR18034 380mg
79825904|NCT05513560|Drug|Ibudilast|10mg pills, 2 pills twice per day
79825905|NCT05513560|Drug|Pentoxifylline|400mg pill 3 times per day
79848961|NCT05762536|Drug|Darolutamide|Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
79373169|NCT03467646|Procedure|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
79526828|NCT05769855|Drug|ropivacaine HCl|ropivacaine HCl 75mg.
79526829|NCT05769855|Drug|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
79682458|NCT03235739|Drug|Naloxegol 25 MG|Oral Naloxegol 25 MG
79682459|NCT03235739|Drug|Placebo|matching oral placebo
79682460|NCT03224312|Other|no intervention|no intervention
79682461|NCT03210688|Drug|Prednisolone|Tablet prednisolone
79682462|NCT03210688|Drug|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
79999872|NCT06271915|Procedure|SNAGs - eccentric exercise|The Mulligan's (SNAGS) procedure will be applied to the cervical region by a physical therapist. As the participant will be in a seated position, therapist's stands over right side of the participant, while placing middle and ring finger of the right hand over C4-C5-C6-C7, applying gentle pressure on spinous process in ventral and upward direction with 45-degree angle by the lateral border of the left hand over the middle and ring finger, as the force applied over the spinous process done by left hand. SNAGS techniques will be applied three times per second with ten repetitions over the vertebrae mentioned above. As the therapist applying the glides, we ask the participant move their head towards the affected limb. Moreover, other study showed a significant improvement with using of upper cervical manual technique on headache symptoms, central sensitization and disability. The study will be single-blinded to the participants while examine and apply the procedure to them.
79999873|NCT06271902|Other|Singapore Youth Shoulder Overuse Injury Prevention Program|A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
79999874|NCT06271902|Other|Lower body stretching program|A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
79999875|NCT06271889|Device|Non-stress test|It will be performed with the HUNTLEIGH brand BD4000XS-2 model NST device located at the maternity clinic to listen to the fetal heart sound, approximately min 3 max 5 min will be listened to. According to the studies conducted in the literature, the half-life of adrenaline in plasma is 3 minutes when an invasive/noninvasive intervention is performed on an adult individual. Therefore, the fetal heart rate will be listened to for 3 minutes (Dalal & Grujic; 2021; https://www.medicines.org.uk/emc/product/6284/smpc#gref https://www.ncbi.nlm.nih.gov/books/NBK482160 / )
79999876|NCT06271876|Other|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
79999877|NCT06271837|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
79999878|NCT06271824|Behavioral|Self-Compassion Based Resilient Caregiving Course|The Resilient Caregiving Course is a live, online, weekly 6 session program lasting 1.25 hours per session. The structure contains didactics, group discussions, guided exercises, and practices facilitated by a certified self-compassion instructor. Topics covered include: (1) noticing and accepting emotions (including conflicting emotions); (2) cultivating curiosity and self-compassion; (3) relating skillfully to difficult thoughts; (4) savoring and gratitude practices.
79230990|NCT03250052|Drug|(fimasartan and linagliptin) x 7days|Part A & Part B: Co-administration of fimasartan and linagliptin
79373170|NCT03467646|Procedure|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
79373171|NCT03467646|Procedure|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
79373172|NCT01199146|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
79373173|NCT01199848|Dietary Supplement|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
79373174|NCT01199848|Dietary Supplement|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
79373175|NCT01199848|Dietary Supplement|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
79682463|NCT03189810|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
79682464|NCT03189810|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
79709787|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
79373176|NCT01199848|Dietary Supplement|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
79373177|NCT01199848|Dietary Supplement|Placebonofiber|Placebo without Fiber
79373178|NCT03467568|Dietary Supplement|Sodium Chloride|300mg sodium chloride will be provided in a capsule
79230991|NCT02455310|Behavioral|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
79230992|NCT05478382|Drug|Pregabalin 25 MG|Patients are given 0 to 3 capsules per administration according to their allocated group.
79230993|NCT05478382|Drug|Placebo|Patients are given 0 to 3 capsules per administration according to their allocated group.
79230994|NCT03244358|Drug|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
79373179|NCT03467568|Other|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
79373180|NCT03467568|Dietary Supplement|Water|Twice during the morning a drink of 150ml of water will be consumed
79373181|NCT03467568|Biological|No water consumed|No water will be consumed during the monring
79373182|NCT01199926|Dietary Supplement|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
79373183|NCT01199926|Drug|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
79373184|NCT03463590|Device|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
79526830|NCT05759221|Procedure|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
79682465|NCT03189810|Behavioral|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
79999879|NCT06271798|Other|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as Deep Vein Thrombosis (DVT) and improving overall circulatory health.
79999880|NCT06271798|Other|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
79373185|NCT01106326|Behavioral|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
79373186|NCT03463434|Device|Air Fluidized Therapy|AFT bed used for pressure injury treatment
79373187|NCT03463434|Device|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
79373188|NCT03463356|Behavioral|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
79999881|NCT06271798|Other|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
79373189|NCT03463278|Diagnostic Test|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
79230995|NCT05482750|Other|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
79373190|NCT03463200|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
79305596|NCT02453867|Other|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels > 5ng/ml) Stop mycophenolate at month 6
79305597|NCT02453867|Drug|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
79373191|NCT03463200|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
79373192|NCT03463200|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
79373193|NCT04212780|Device|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
79373194|NCT04212780|Procedure|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
79373195|NCT04212780|Procedure|standard ET DBS|Single Lead VIM
79373196|NCT04212780|Procedure|ipsilateral VO|second lead in the ipsilateral VO
79373197|NCT01106950|Biological|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
79373198|NCT01106950|Drug|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
79373199|NCT01106950|Drug|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
79682466|NCT03176771|Drug|MT-5199|MT-5199 40 mg capsules
79682467|NCT03176771|Drug|Placebo|MT-5199 placebo capsules
79709788|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
79825906|NCT05513560|Other|Placebo|Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
79373200|NCT01106950|Drug|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
79373201|NCT01106950|Procedure|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
79373202|NCT01106950|Drug|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
79373203|NCT01107730|Drug|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
79373204|NCT01107730|Drug|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
79682468|NCT03140748|Other|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
79682469|NCT03115788|Other|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
79682470|NCT03115788|Other|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
79825907|NCT05502913|Drug|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
79825908|NCT05502913|Other|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
79302630|NCT03202771|Device|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
79373205|NCT01107730|Drug|Placebo|Placebo
79373206|NCT03463122|Device|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
79373207|NCT03463122|Other|conventional therapy|conventional therapy for stroke rehabilitation
79373208|NCT03011164|Procedure|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
79373209|NCT03463044|Drug|nangibotide|Continous i.v. infusion
79373210|NCT03463044|Drug|Placebo|Placebo
79682471|NCT03115788|Device|iPad|
79682472|NCT03109795|Drug|Clonidine Pill|sympathetic nerve activity blockade
79682473|NCT03109795|Drug|Hydrochlorothiazide|Blood pressure-lowering control condition
79682474|NCT03012399|Behavioral|Hypnosedation|Undergo hypnosedation
79682475|NCT03012399|Other|Questionnaire Administration|Ancillary studies
79682476|NCT03012399|Behavioral|Verbal Support|Speak with min-body specialist
79373211|NCT02522208|Drug|BiDil XR|fixed combination capsule
79825909|NCT05497401|Biological|MesenCure|Enhanced mesenchymal cell-based product
79825910|NCT05497401|Other|Placebo|Saline
79825911|NCT05497024|Behavioral|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
79825912|NCT05497024|Behavioral|Surveys|Participants may answer questions that are sensitive in nature.
79825913|NCT05486312|Device|CT-155 smartphone app|The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
79373212|NCT02522208|Drug|BiDil Immediate Release (IR)|fixed combination tablet
79825914|NCT05481502|Procedure|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
79825915|NCT05481502|Procedure|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
79825916|NCT05481502|Procedure|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
79848962|NCT05762536|Drug|Docetaxel or cabazitaxel|Docetaxel or cabazitaxel Q3W
79373213|NCT01107964|Drug|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
79373214|NCT01107964|Drug|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
79526831|NCT05733091|Behavioral|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
79526832|NCT05727059|Device|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
79526833|NCT05714514|Drug|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
79526834|NCT05714514|Other|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
79682477|NCT03004144|Other|FLOAT|
79682478|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
79682479|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
79682480|NCT02971956|Drug|Pembrolizumab|Immune checkpoint inhibitor
79682481|NCT02968823|Other|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
79825917|NCT05476224|Biological|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
79825918|NCT05452122|Other|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
79230996|NCT05482750|Other|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
79230997|NCT03249740|Drug|GB-102|Intravitreal injection of GB-102
79825919|NCT05432258|Device|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
79230998|NCT03249740|Drug|Aflibercept|Intravitreal injection of Aflibercept.
79230999|NCT05478226|Other|drugs or BPA|PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
79231000|NCT03057977|Drug|Empagliflozin|once daily
79231001|NCT03057977|Drug|Placebo|once daily
79825920|NCT05432258|Device|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
79825921|NCT05427539|Device|TEST LENS|AO1DfA manufactured with PG hydration
79999882|NCT06271785|Diagnostic Test|HR-EEG recording|All participants will have a HR-EEG recordings. It will be made at rest. Nap-like sleep is encouraged, but no sedatives will be given. Recording time will not exceed two hours.
79231002|NCT03244046|Behavioral|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
79999883|NCT06271772|Drug|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
79231003|NCT03244046|Behavioral|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
79231004|NCT05482594|Diagnostic Test|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
79373215|NCT05684172|Drug|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
79682482|NCT02968823|Other|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
79682483|NCT02967289|Drug|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
79682484|NCT02967289|Drug|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
79825922|NCT05427539|Device|CONTROL LENS|AO1DfA manufactured with IPA hydration
79825923|NCT05417581|Procedure|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
79825924|NCT05412953|Other|Questionnaire Administration|Complete questionnaire
79825925|NCT05412953|Behavioral|Tonation Breathing Technique|Participate in tonation breathing techniques
79825926|NCT05412082|Radiation|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
79825927|NCT05412082|Drug|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
79999884|NCT06271772|Drug|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 3-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
79999885|NCT06271772|Drug|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
79999886|NCT06271759|Other|Fragrance inhalation|Inhalation of fragranced essential oils
79999887|NCT06271746|Device|FibroNova (Active mode)|FibroNova neurostimulator of conditional pain modulation (CPM)
79999888|NCT06271746|Device|FibroNova (Sham mode)|FibroNova neurostimulator with an electrical output not intended for neurostimulation
79231005|NCT05482594|Diagnostic Test|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
79682485|NCT02956473|Device|Supine MRI|
79373216|NCT05684172|Other|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
79682486|NCT02956473|Other|Neoadjuvant Therapy (NAT)|
79682487|NCT02956473|Device|Ultrasound|
79682488|NCT02956473|Device|Mammography|
79999889|NCT06271733|Device|TMS|2 sessions of iTBS per day for 5 days
79999890|NCT06271733|Device|Sham|2 sessions per day for 5 days of sham condition
79231006|NCT03252782|Device|Herbst Appliance|Acrylic Splint Herbst Appliance
79231007|NCT03252782|Device|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
79231008|NCT03249506|Drug|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
79231009|NCT03249506|Drug|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
79231010|NCT03249506|Drug|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
79231011|NCT03249506|Drug|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
79231012|NCT03249506|Drug|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
79231013|NCT03249506|Drug|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
79231014|NCT03249506|Drug|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
79682489|NCT02956473|Procedure|Standard of Care|
79999891|NCT06271720|Other|visceral manipulation|"visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius"
79231015|NCT03249506|Drug|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
79231016|NCT03252860|Other|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
79999892|NCT06271720|Other|integrated neuromuscular inhibition|It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
79231017|NCT03244202|Other|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
79231018|NCT03244202|Other|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
79373217|NCT01200160|Drug|Niacin|
79373218|NCT04452786|Procedure|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
79373219|NCT04452786|Procedure|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
79373220|NCT01153672|Drug|vorinostat|Given PO
79373221|NCT01153672|Other|laboratory biomarker analysis|Correlative studies
79373222|NCT01153672|Procedure|biopsy|Optional correlative studies
79373223|NCT01153672|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
79373224|NCT01153672|Procedure|positron emission tomography|Correlative studies
79373225|NCT01153672|Drug|anastrozole|Given PO
79373226|NCT01153672|Drug|letrozole|Given PO
79373227|NCT01153672|Drug|exemestane|Given PO
79373228|NCT01153672|Genetic|gene expression analysis|Correlative studies
79373229|NCT03010072|Drug|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
79373230|NCT03010072|Drug|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
79682490|NCT02956473|Device|Standard MRI|
79682491|NCT02953301|Drug|resminostat|
79682492|NCT02953301|Drug|Placebo|
79999893|NCT06271707|Drug|0.5% bupivacaine|an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine
79999894|NCT06271707|Other|Saline|an ultrasound guided left stellate ganglion block with 5 mL of saline
79999895|NCT06271694|Other|Vestibular Rehabilitation|Standard vestibular rehabilitation
79999896|NCT06271681|Drug|15-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
79999897|NCT06271681|Drug|23-valent pneumococcal polysaccharide vaccine|23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
79999898|NCT06271668|Other|Naloxone Co-prescribing CDS|Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
79825928|NCT05412082|Drug|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
79999899|NCT06271655|Device|SPOTFIRE R Panel|The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
79231019|NCT03249662|Procedure|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
79231020|NCT03249662|Drug|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
79231021|NCT02454062|Drug|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
79231022|NCT02454062|Drug|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
79373231|NCT02734212|Behavioral|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
79231023|NCT03239444|Device|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
79231024|NCT03239366|Other|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
79231025|NCT03239366|Other|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
79373232|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
79373233|NCT01202578|Device|tympanostomy tube|tympanostomy tube delivery system
79373234|NCT03462810|Drug|cabotegravir, CAB|open label investigational product
79373235|NCT01202656|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
79373236|NCT01202656|Drug|Saline|intrauterine saline infusion 1 cc
79373237|NCT03462732|Device|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
79373238|NCT03462732|Device|Nelaton catheter|plus nelaton catheter
79825929|NCT05412082|Drug|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
79825930|NCT05412082|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
79825931|NCT05412082|Radiation|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~Dose level -1: 10 Gy delivered in 4 fractions~Dose level 0: 12 Gy delivered in 4 fractions~Dose level 1: 14 Gy delivered in 4 fractions~Dose level 2: 16 Gy in delivered 4 fractions"
79231026|NCT03239288|Other|Control digestible carbohydrate|Single serving of control product
79231027|NCT03239288|Other|Test resistant starch type 4|Single serving of test product
79373239|NCT01219738|Drug|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
79373240|NCT01219738|Drug|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
79373241|NCT01219738|Drug|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
79373242|NCT01219738|Drug|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
79373243|NCT01219738|Drug|Placebo|A single inhaled dose of placebo from a DPI.
79373244|NCT04639752|Behavioral|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
79373245|NCT04639752|Behavioral|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
79526836|NCT05711420|Behavioral|Gamification method group|Gamification method group
79526837|NCT05711420|Behavioral|Flipped learning group|Flipped learning group
79231028|NCT03249428|Device|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
79231029|NCT05213975|Device|Kinesio tape|Kinesio taping
79231030|NCT03243812|Biological|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
79231031|NCT03243812|Other|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
79231032|NCT03243812|Other|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
79231033|NCT03243812|Other|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
79231034|NCT05751161|Other|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
79526838|NCT05703113|Behavioral|Web 2.0 tools|Education with Web 2.0 tools
79231035|NCT03243500|Drug|Atracurium|5mg in 1 ml normal saline
79231036|NCT03243500|Drug|Lidocaine 2%|
79825932|NCT05408715|Other|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
79682493|NCT02941705|Biological|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
79825933|NCT05402943|Behavioral|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
79825934|NCT05402943|Behavioral|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
79999900|NCT06271642|Behavioral|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with experimental Frequency placed on their arm and randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
79999901|NCT06271642|Behavioral|Bluetooth Haptic Device (Control Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with control frequency placed on their arm. They will be randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
79231037|NCT03243500|Drug|Bupivacaine 0.5%|
79825935|NCT05402943|Behavioral|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
79373246|NCT03848754|Drug|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
79231038|NCT03243500|Drug|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
79373247|NCT03848754|Drug|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m^2 on Day 1 of a 28-day cycle.
79373248|NCT03848754|Drug|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
79231039|NCT03243500|Procedure|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
79231040|NCT00941915|Radiation|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
79305598|NCT02453867|Drug|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
79373249|NCT03848754|Drug|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
79682494|NCT02941705|Biological|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
79682495|NCT02939742|Drug|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
79373250|NCT01155154|Drug|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
79373251|NCT01155154|Drug|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
79373252|NCT01155154|Drug|placebo|Two placebo capsules every 6 hours for 7 days
79373253|NCT02521896|Device|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
79373254|NCT03786432|Device|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
79373255|NCT04614714|Drug|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
79682496|NCT02939742|Drug|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
79682497|NCT02916966|Other|Patient Registry|Patient Registry
79682498|NCT02902484|Drug|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
79709789|NCT01109173|Other|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
79231041|NCT02454218|Device|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
79231042|NCT03243578|Other|None as this is an observational study|
79231043|NCT05213819|Other|Carpal Tunnel Syndrome|
79373256|NCT04614714|Drug|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
79682499|NCT02891811|Drug|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
79682500|NCT02891811|Drug|Thalidomide|100mg orally on days 1-28 in patients <75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
79825936|NCT05402943|Behavioral|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
79373257|NCT01221298|Drug|ABT-450|tablets
79373258|NCT01221298|Drug|ABT-072|tablets
79373259|NCT01221298|Drug|Ribavirin|tablets
79231044|NCT03238898|Drug|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
79231045|NCT03238898|Other|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
79305599|NCT02453867|Drug|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
79373260|NCT01221298|Drug|Ritonavir|capsules
79373261|NCT05321004|Other|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
79373262|NCT01222234|Drug|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
79373263|NCT01222234|Device|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
79373264|NCT01222234|Drug|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
79373265|NCT01203046|Drug|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
79373266|NCT04604184|Drug|BI 764198|BI 764198
79373267|NCT04604184|Drug|Placebo|Placebo
79373268|NCT04604106|Diagnostic Test|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
79373269|NCT04604106|Diagnostic Test|Ages & Stages questionnaire|The Ages & Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
79373270|NCT04604106|Diagnostic Test|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
79373271|NCT04549272|Other|No interventions|No interventions - observational study
79373272|NCT04542720|Procedure|Randomized: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
79373273|NCT04542720|Procedure|Randomized: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
79373274|NCT04542720|Procedure|Observational: Decompression|This intervention is identical to the Randomized: Decompression intervention. Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
79526839|NCT05692635|Diagnostic Test|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
79526840|NCT05692635|Other|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
79526841|NCT05692635|Other|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
79526842|NCT05692635|Drug|Gadolinium|Given intravenously
79526843|NCT05686122|Behavioral|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
79526844|NCT05673005|Device|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
79682501|NCT02891811|Drug|Lenalidomide|25mg p.o. on days 1-21 of each cycle
79682502|NCT02891811|Drug|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients <75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
79682503|NCT02798042|Other|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
79231046|NCT03249194|Drug|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
79825937|NCT05386017|Other|Anthropometric measurements and sociodemographic and health data collection|"Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat.~Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression"
79825938|NCT05320835|Behavioral|HIV, HCV and overdose prevention|HIV, HCV and overdose prevention
79825939|NCT05312983|Other|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~Session A : objective audiological tests~Session B ; subjective audiological tests~Session C : balance tests."
79825940|NCT05312983|Other|Blood sampling|A 10 mL blood sample will be collected during the study.
79825941|NCT05312983|Other|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
79825942|NCT05307068|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
79825943|NCT05302154|Behavioral|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
79825944|NCT05302154|Behavioral|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
79825945|NCT05302154|Behavioral|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
79373275|NCT04542720|Procedure|Observational: Extension Fusion|This intervention is identical to the Randomized: Extension Fusion intervention. Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
79231047|NCT03062891|Procedure|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
79231048|NCT04486508|Drug|intermediate dose Enoxaparin/ unfractionated heparin|Intermediate dose anticoagulation according to creatinine clearance and weight
79231049|NCT04486508|Drug|standard prophylactic dose Enoxaparin/ unfractionated heparin|Standard prophylaxis anticoagulation according to creatinine clearance and weight
79231050|NCT04486508|Drug|Atorvastatin 20mg|Statin
79231051|NCT04486508|Drug|Matched placebo|Matched placebo to atorvastatin 20 mg
79231052|NCT03243266|Diagnostic Test|CBC/Diff Reference Interval|Results will not be used to manage patients
79231053|NCT02552212|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringe~Concentration: 200 mg / ml~Route of Administration: Subcutaneous injection"
79231054|NCT02552212|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
79231055|NCT02454764|Drug|Tenofovir + Interferon alpha 2b|
79373276|NCT04504266|Behavioral|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
79231056|NCT02454764|Drug|Tenofovir disoproxil Fumarate|
79373277|NCT03462420|Other|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
79373278|NCT03449394|Other|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
79373279|NCT05320848|Behavioral|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
79373280|NCT03449316|Behavioral|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
79682504|NCT02789020|Drug|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
79682505|NCT02789020|Other|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
79682506|NCT02789020|Device|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
79682507|NCT02789020|Device|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
79231057|NCT03243188|Other|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
79682508|NCT02789020|Other|Physical Function Performance Test|This test will be performed at baseline and one year.
79231058|NCT00685919|Drug|Carbidopa|200 mg every 6 hours for 5 doses given orally
79682509|NCT02785848|Other|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
79682510|NCT02756273|Device|bridge device|
79682511|NCT02756273|Device|no bridge device|
79682512|NCT02719314|Drug|Glucocorticoid treatment|Glucocorticoid treatment
79682513|NCT02602769|Diagnostic Test|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
79682514|NCT02598362|Drug|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
79682515|NCT02585388|Drug|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
79825946|NCT05293951|Device|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
79825947|NCT05293951|Device|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
79999902|NCT06271629|Diagnostic Test|Insomnia severity index|"The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties."
79373281|NCT05320536|Drug|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
79231059|NCT00685919|Drug|Placebo|every 6 hours for 5 doses, given orally, and matching Carbidopa
79231060|NCT03243344|Device|Surgiflo|using device during the endonasal surgery.
79231061|NCT03243344|Device|Floseal|using device during the endonasal surgery.
79231062|NCT03243344|Device|Algosteril|using device during the endonasal surgery.
79231063|NCT03243110|Diagnostic Test|breathing test|Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
79373282|NCT05320536|Drug|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
79682516|NCT02585388|Drug|Letrozole|Lestrozole at 2,5 mg every day , per oral
79682517|NCT02585388|Drug|Anastrozole|Anastrozole at 1 mg every day, per oral
79682518|NCT02584465|Drug|Tamoxifen|Tamoxifen: 40 mg/day
79682519|NCT02584465|Drug|Regorafenib|Stivarga; 120mg/day
79682520|NCT02579278|Other|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
79682521|NCT02579278|Other|Blood sample (mrEMVI negative patient)|
79682522|NCT02579161|Drug|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
79682523|NCT02579161|Drug|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
79682524|NCT02579161|Drug|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
79682525|NCT02579161|Drug|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
79682526|NCT02568124|Drug|Tranexamic Acid|
79682527|NCT02568124|Drug|Placebo|
79825948|NCT05286034|Behavioral|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
79825949|NCT05273918|Other|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
79682528|NCT02536170|Drug|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
79825950|NCT05273918|Other|body mediation|15 workshops once a week during 90 minutes
79825951|NCT05257772|Device|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
79825952|NCT05254730|Device|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
79825953|NCT05236790|Diagnostic Test|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
79825954|NCT05228860|Behavioral|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~Months 1-4: 1 family-wide orientation + 12 weekly sessions~Months 5-6: 4 bimonthly group sessions~Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
79825955|NCT05228860|Behavioral|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
79999903|NCT06271616|Procedure|Biospecimen Collection|Undergo blood sample collection
79373283|NCT02460588|Drug|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
79682529|NCT02536170|Drug|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
79999904|NCT06271616|Procedure|Echocardiography|Undergo echocardiography
79999905|NCT06271616|Drug|Ibrutinib|Given PO
79999906|NCT06271603|Diagnostic Test|diagnosis based on deepLive™ LC-OCT device|Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.
79999907|NCT06271603|Diagnostic Test|diagnosis based on skin biopsy|Control Arm: Standard management with an initial diagnosis based on skin biopsy
79999908|NCT06271590|Device|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
79999909|NCT06271590|Device|Drug eluting stents (DES)|For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
79999910|NCT06271577|Device|AliveCor 12-lead ECG|The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
79231064|NCT03238820|Procedure|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
79231065|NCT03239054|Behavioral|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
79231066|NCT03239054|Behavioral|Control group|Information will be given as part of standard care
79373284|NCT02460588|Drug|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
79526847|NCT05645523|Drug|Indocyanine Green|Given in to the vein (IV)
79682530|NCT02536170|Other|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
79682531|NCT02535533|Drug|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
79682532|NCT02535533|Drug|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
79231067|NCT03238742|Drug|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
79231068|NCT03238742|Drug|normal saline|200ml normal saline every 12 hours for 5 days
79825956|NCT05214664|Procedure|Anesthesia|"Once the anesthesia is performed by the Anesthesia practitioner either with the EZ-Block® device or by the conventional freehand technique, the surgical procedure will be performed in the same way in both arms, and for each tooth, by the Surgery practitioner:~The Surgery practitioner takes charge of the patient after a post-anesthesia time of 10 minutes and performs a new antisepsis then completes the anesthesia by anesthetizing the buccal and lingual nerve with a carpule of 1.8ml of articaine + adrenaline at 1/200000.~The Surgery practitioner starts the surgical procedure.~In the absence of pain, the practitioner Surgery carries out the surgical act in its totality (situation of success for the principal criterion of the study) then records the EVA at the end of the intervention."
79825957|NCT05214573|Drug|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
79231069|NCT05478148|Device|Gingival thickness|After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
79231070|NCT03243032|Drug|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
79231071|NCT03243032|Drug|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
79231072|NCT03243032|Drug|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
79373285|NCT02460588|Drug|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
79373286|NCT03641430|Other|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
79373287|NCT04369638|Device|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
79373288|NCT04369638|Device|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
79373289|NCT05320458|Other|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
79682533|NCT02535533|Drug|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
79231073|NCT03243032|Drug|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
79373290|NCT05320224|Other|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
79526848|NCT05635032|Other|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
79682534|NCT02535533|Drug|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
79682535|NCT02535533|Drug|Selenomethionine (SLM)|Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
79231074|NCT05478070|Device|Dexcom G6|Continuous glucose monitor
79709790|NCT01109173|Other|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
79231075|NCT03249038|Other|Measurement of external blood loss|
79231076|NCT03249038|Diagnostic Test|Serum Hemoglobin concentration|
79825958|NCT05214573|Drug|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
79825959|NCT05214573|Drug|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
79373291|NCT03449160|Device|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
79825960|NCT05214573|Drug|Sulfonylurea|Patients in the data who filled a sulfonylurea
79373292|NCT03449160|Other|physical therapy|routine physical therapy
79373293|NCT03449082|Biological|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
79825961|NCT05211271|Device|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
79825962|NCT05205668|Biological|F-652|IL-22 fusion protein administered intravenously
79825963|NCT05205668|Biological|Placebo|Placebo administered intravenously
79825964|NCT05204641|Biological|Fecal Microbiota Transfer provided by Human Biome Institute|Fecal Microbiota Transfer with colonoscopy
79825965|NCT05186974|Drug|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
79231077|NCT05473546|Other|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
79231078|NCT03061331|Drug|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
79231079|NCT03061331|Drug|Placebo|No Active Drug
79373294|NCT03449082|Biological|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
79825966|NCT05186974|Drug|Pembrolizumab|Administered intravenously
79825967|NCT05186974|Drug|Carboplatin|Administered intravenously
79373295|NCT03449082|Drug|Fibrin glue|Fibrin glue 0.5cc
79373296|NCT03449082|Drug|Normal saline|Normal saline 0.5cc
79373297|NCT05308134|Other|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
79373298|NCT05308134|Other|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
79373299|NCT05308134|Other|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
79825968|NCT05186974|Drug|Cisplatin|Administered intravenously
79373300|NCT03449004|Other|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
79373301|NCT03129672|Procedure|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
79373302|NCT03130062|Other|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
79373303|NCT03413202|Drug|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
79825969|NCT05182840|Drug|BI 690517|BI 690517
79825970|NCT05182840|Drug|Placebo to BI 690517|Placebo to BI 690517
79526849|NCT05621733|Other|ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
79526850|NCT05619991|Other|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
79825971|NCT05182840|Drug|Empagliflozin|Empagliflozin
79825972|NCT05182840|Drug|Placebo to empagliflozin|Placebo to empagliflozin
79825973|NCT05146908|Biological|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
79825974|NCT05146908|Other|Echography|"In 3 steps:~before initiation of enteral nutrition~4h after initiation of enteral nutrition~After 24 hours of enteral nutrition"
79231080|NCT05482438|Device|Polyethylene|Wear measurement
79231081|NCT03242876|Other|Control|Control will be 109 g white bread to be consumed together with 200 mL water
79231082|NCT03242876|Other|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
79231083|NCT00700778|Biological|recombinant human chorionic gonadotropin|
79526851|NCT05619991|Other|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
79682536|NCT02530983|Other|Mayo Clinic Upper Digestive Disease Survey on Paper|Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
79709791|NCT02271776|Dietary Supplement|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
79709792|NCT02271776|Dietary Supplement|maltodextrin|
79231084|NCT00700778|Genetic|microarray analysis|
79373304|NCT03413202|Drug|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
79231085|NCT00700778|Other|immunohistochemistry staining method|
79373305|NCT02521818|Other|Modified Atkins Diet|
79825975|NCT05146908|Other|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~echographic parameters at H0, H4 and H24~venous congestion parameters~biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~the occurrence or not of the primary endpoint (and time to occurrence).~symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~organ failure and replacement over the period, and mortality.~the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
79825976|NCT05144945|Biological|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
79231086|NCT00700778|Other|laboratory biomarker analysis|
79373306|NCT02521818|Other|NIA Diet for Seniors|
79825977|NCT05144945|Biological|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
79373307|NCT04169100|Drug|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
79373308|NCT03698448|Drug|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
79682537|NCT02530983|Other|Upper Digestive Disease (UDD Monitor) App|"Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile&pli=1"
79682538|NCT02524483|Behavioral|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
79682539|NCT02524483|Behavioral|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
79682540|NCT02523443|Other|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
79682541|NCT02523443|Other|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
79682542|NCT02498912|Procedure|Production of Genetically-modified T cells|
79682543|NCT02498912|Drug|Cyclophosphamide|
79231087|NCT00700778|Procedure|needle biopsy|
79231088|NCT05213585|Drug|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
79231089|NCT03238664|Procedure|Biopsy|Undergo biopsy of bladder tumor
79231090|NCT03238664|Device|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
79231091|NCT03238664|Other|Laboratory Biomarker Analysis|Correlative studies
79231092|NCT03238664|Procedure|Radical Cystectomy|Undergo RARC
79373309|NCT04155996|Device|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
79373310|NCT05239806|Biological|SCTV01C|Day 0; intramuscular injection
79682544|NCT02498912|Device|IP Catheter Insertion|
79682545|NCT02498912|Genetic|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
79373311|NCT05239806|Biological|SCTV01E|Day 0; intramuscular injection
79373312|NCT05239806|Biological|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
79373313|NCT05239806|Biological|Comirnaty|Day 0; intramuscular injection
79373314|NCT05239806|Biological|SCTV01E|Day 180; intramuscular injection
79231093|NCT03238664|Device|Ultrasonography|Undergo CEUS
79231094|NCT03238508|Procedure|Deferred stenting|Previously described
79231095|NCT05213429|Other|non interventional study|non interventional
79231096|NCT03238586|Behavioral|WELL Program|
79231097|NCT05209607|Other|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
79231098|NCT05209607|Other|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
79231099|NCT03683680|Other|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
79373315|NCT01155778|Biological|Recombinant human heparan N-sulfatase (rhHNS)|
79373316|NCT04155840|Drug|Copanlisib|Given IV
79373317|NCT04155840|Biological|Rituximab|Given IV
79373318|NCT04155840|Drug|Bendamustine|Given IV
79682546|NCT02498912|Drug|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
79373319|NCT03448848|Drug|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
79825978|NCT05141370|Device|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
79526852|NCT05619874|Behavioral|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
79682547|NCT02431897|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
79825979|NCT05139303|Device|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: > 50% reduction of AHI/RDI. Criterion II: AHI/RDI < 5 events/hour or <15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI >5 events/hour with OSA associates symptoms.
79825980|NCT05135767|Behavioral|Brief Motivational Interviewing with Personalized Feedback|A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
79825981|NCT05135351|Dietary Supplement|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
79825982|NCT05135351|Dietary Supplement|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
79825983|NCT05130996|Device|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
79825984|NCT05126485|Device|Haptic Biofeedback from SageMotion Biofeedback System|"Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied"
79999911|NCT06271564|Drug|Magnetite ZnO Composite Nanoparticles|Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
79999912|NCT06271564|Drug|Topical Placebo Gel|Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
79999913|NCT06271434|Dietary Supplement|THYROX (Atlantic krill oil|The daily content of krill oil is 1500 mg, including omega-3 fatty acids 262.5 mg, EPA - 180 mg, DHA- 82.5 mg, phospholipids - 600 mg, astaxanthin 150 mg.
79373320|NCT03448848|Drug|sterile normal saline|sterile normal saline in a volume equal to the study drug
79526853|NCT05619874|Behavioral|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
79526854|NCT05605379|Biological|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
79526855|NCT05597878|Drug|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
79999914|NCT06271434|Dietary Supplement|Placebo|The control capsules will be made of olive oil of equal size and color.
79999915|NCT06271278|Behavioral|Emotional Freedom Technique|Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
79526856|NCT05597878|Drug|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
79682548|NCT02431897|Drug|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
79682549|NCT02427841|Drug|Fluorouracil|Given IV
79682550|NCT02427841|Drug|Gemcitabine|Given IV
79682551|NCT02427841|Radiation|Image Guided Radiation Therapy|Undergo IG-IMRT
79682552|NCT02427841|Radiation|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
79682553|NCT02427841|Other|Laboratory Biomarker Analysis|Correlative studies
79682554|NCT02427841|Drug|Nab-paclitaxel|Given IV
79825985|NCT05123027|Behavioral|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
79825986|NCT05123027|Behavioral|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
79825987|NCT05119621|Device|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
79825988|NCT05117489|Drug|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
79231100|NCT03683680|Other|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
79231101|NCT02453828|Procedure|Non-cardiac surgery|patients having non-cardiac surgery
79825989|NCT05117489|Drug|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
79825990|NCT05117489|Drug|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
79373321|NCT05086770|Device|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
80016642|NCT03238053|Procedure|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
79373322|NCT05086770|Device|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
79825991|NCT05117489|Drug|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
79231102|NCT05482282|Biological|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
79373323|NCT03448770|Drug|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
79825992|NCT05116722|Device|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
79373324|NCT03448770|Drug|Lactulose : 20-30gm|Lactulose : 20-30gm
79825993|NCT05101070|Drug|S-531011|Administered by intravenous infusion
79373325|NCT03443778|Drug|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
79373326|NCT03443778|Drug|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
79373327|NCT03443778|Drug|Nacl 0,9 %|Injectable Solution
79373328|NCT03443622|Drug|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-[4-chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
79825994|NCT05101070|Drug|Pembrolizumab|Administered by intravenous infusion
79825995|NCT05064332|Drug|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
79526857|NCT05597878|Drug|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
79825996|NCT05064332|Drug|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
79825997|NCT05057780|Other|Communication Skills Curriculum|Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
79825998|NCT05055141|Other|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
79825999|NCT05051345|Other|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
79826000|NCT05051345|Other|Informational Intervention|Receive tobacco cessation self-help materials
79826001|NCT05051345|Other|Informational Intervention|Receive Smoke-Free Homes mailings
79826002|NCT05051345|Other|Media Intervention|Download and use the Wellness app
79826003|NCT05051345|Other|Questionnaire Administration|Ancillary studies
79231103|NCT05482282|Biological|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
79373329|NCT01872312|Device|treatment with valves (The Spiration® IBV Valve System)|treat BPF
79826004|NCT05051345|Behavioral|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
79826005|NCT05051345|Other|Survey Administration|Ancillary studies
79373330|NCT03443544|Procedure|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
79526858|NCT05597878|Drug|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
79826006|NCT05051345|Behavioral|Telephone-Based Intervention|Receive telephone counseling sessions
79373331|NCT02948712|Behavioral|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
79373332|NCT02948712|Behavioral|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
79682555|NCT02427841|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79682556|NCT02425566|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
79682557|NCT02425566|Drug|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
79682558|NCT02413788|Other|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
79682559|NCT02413788|Other|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
79682560|NCT02413788|Device|treadmill|
79682561|NCT02386735|Drug|Placebo|Three days prednisone 40mg, two days placebo
79682562|NCT02386735|Drug|Prednisone|Five days prednisone 40mg.
79682563|NCT02383251|Drug|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
79682564|NCT02383251|Drug|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
79682565|NCT02348216|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.
79682566|NCT02348216|Drug|Fludarabine|Administered according to package insert
79373333|NCT03129516|Behavioral|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
79373334|NCT03443466|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
79373335|NCT03443466|Device|Loss of resistance (LOR)|Using loss of resistance technique only
79999916|NCT06270641|Other|ExerciseRx intervention|ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
79373336|NCT03448380|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
79526859|NCT05597878|Drug|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
79526860|NCT05594589|Drug|Lemborexant|Lemborexant oral tablet.
79526861|NCT05594589|Other|PBO|Lemborexant-matched PBO tablet.
79682567|NCT02348216|Drug|Cyclophosphamide|Administered according to package insert
79999917|NCT06270277|Diagnostic Test|Pediatric Quality of Life Inventory (PedsQL)|Questionnaire
79373337|NCT03443388|Device|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
79526862|NCT05591846|Behavioral|Face-to-face training|Face-to-face training
79526863|NCT05591846|Behavioral|web-based training|web-based training
79682568|NCT02337647|Other|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
79826007|NCT05051345|Behavioral|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
79526864|NCT05589701|Radiation|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
79526865|NCT05589363|Drug|ABC block with bupivacaine/liposomal bupivacaine|Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
79526866|NCT05589363|Drug|ABC block with saline|Patients will be randomized to receive an ABC block using normal saline
79526867|NCT05584657|Drug|Sulopenem etzadroxil/probenecid|Oral sulopenem twice daily for 5 days
79526868|NCT05584657|Drug|Amoxicillin/clavulanate|Oral Augmentin twice daily for 5 days
79526869|NCT05580770|Drug|Mirdametinib|Mirdametinib administered orally
79682569|NCT02307331|Device|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
79682570|NCT02307331|Device|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
79682571|NCT02307331|Device|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
79682572|NCT02307331|Device|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
79682573|NCT02307331|Device|Sirius stem|A polished tapered stem
79826008|NCT05051345|Other|Tobacco Cessation Counseling|Receive telephone counseling sessions
79826009|NCT05036330|Other|Clinical Evaluation|Undergo speech and swallow evaluation
79826010|NCT05036330|Procedure|Physical Examination|Undergo examination of TEP and laryngectomy stoma
79682574|NCT02292641|Procedure|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
79682575|NCT02272309|Procedure|EEG and EP measurement|
79682576|NCT02204683|Drug|Aflibercept|Intravitreal aflibercept
79682577|NCT02157532|Procedure|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
79682578|NCT02157532|Drug|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
79682579|NCT02134301|Drug|Oritavancin|
79682580|NCT02037529|Drug|Eribulin Mesylate|Given IV
79999918|NCT06270277|Diagnostic Test|Strengths and Difficulties Questionnaire (SDQ)|Questionnaire
79999919|NCT06269783|Behavioral|sipIT|Automated and manual fluid tracking system with just-in-time reminder messages to support fluid intake habit formation.
79999920|NCT06269770|Drug|Tapentadol|Add tapentadol, for effective pain management in a multimodal setting during TKR.
79231104|NCT05482282|Biological|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
79231105|NCT05482282|Biological|Pentabio|3 doses of Pentabio
79231106|NCT03238274|Device|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
79231107|NCT05209529|Drug|olaparib|olaparib 300 mg per os BID
79231108|NCT05209529|Drug|Durvalumab|durvalumab 1500 mg IV Q4 weeks
79231109|NCT04424134|Drug|Bromhexine and Spironolactone|Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
79231110|NCT04424134|Drug|Base therapy|Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
79231111|NCT04486430|Drug|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
79231112|NCT04486430|Drug|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
79231113|NCT04486430|Drug|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
79231114|NCT04486430|Drug|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
79231115|NCT05213117|Behavioral|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
79231116|NCT05482204|Other|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
79373338|NCT03448302|Radiation|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time & permeability surface measurements will be obtained.
79526870|NCT05580770|Drug|BGB-3245|BGB-3245 administered orally
79526871|NCT05568615|Drug|MT-1186|Suspension
79526872|NCT05547425|Device|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
79526873|NCT05547425|Device|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
79526874|NCT05547425|Device|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
79526875|NCT05547425|Device|Raw images|No editing is performed on images.
79682581|NCT02037529|Other|Laboratory Biomarker Analysis|Correlative studies
79682582|NCT02037529|Drug|Paclitaxel|Given IV
79682583|NCT02037529|Other|Quality-of-Life Assessment|Ancillary studies
79231117|NCT05482204|Other|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
79231118|NCT05209373|Behavioral|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
79231119|NCT05209373|Behavioral|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
79231120|NCT03248726|Drug|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
79682584|NCT02030028|Drug|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
79682585|NCT01956123|Drug|Follitropin Delta (FE 999049)|
79682586|NCT01956123|Drug|Follitropin Alfa (GONAL-F)|
79999921|NCT06269770|Drug|Tramadol|Add tramadol, for effective pain management in a multimodal setting during TKR.
80016643|NCT03238053|Device|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
79999922|NCT06269224|Other|Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners.|The Myoton device was used over the Latissimus Dorsi (LD) muscle on both dominant and nondominant sides to measure muscle tone (Hz), elasticity, and stiffness (N/m) values. Trunk flexibility and flexibility of lumbar extensor muscles were measured with tape measurement (cm). The trunk range of motion (ROM, ˚) was measured using goniometer. Thoracolumbar Fascia Length Test and Modified Schober Test were used for thoracolumbar (TLF) fascia flexibility. The weekly training distance (km), duration (h) and daily water consumption (lt) rates were recorded. The percentage of individuals experiencing lower extremity injuries and lower back pain within the RSM group was calculated.
79231121|NCT03248726|Drug|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
79682587|NCT01906814|Drug|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
79231122|NCT04486274|Other|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
79231123|NCT04486196|Device|Medency Primo Diode Laser Device (Medency, Vicenza, Italy)|Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
79231124|NCT04486196|Procedure|2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),|Final conventional irrigation
79231125|NCT03248804|Behavioral|Soy group|
79231126|NCT03248804|Behavioral|Non-soy group|
79231127|NCT04557280|Combination Product|Selatogrel|A single subcutaneous injection of 16 mg.
79231128|NCT04557280|Drug|Selatogrel|A single subcutaneous injection of 16 mg.
79231129|NCT03242330|Device|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
79231130|NCT05477992|Procedure|Endovascular embolization|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
79231131|NCT03248414|Dietary Supplement|Lactobacillus sakei|1 pack contained 5 x 109 cfu
79231132|NCT04961021|Procedure|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
79231133|NCT05208827|Drug|Vitamin D3|Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
79231134|NCT05208827|Drug|The placebo(not contain vitamin D)|Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
79231135|NCT03242564|Device|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
79231136|NCT03242486|Device|toric intraocular lens|
79231137|NCT04947059|Drug|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
79373339|NCT03443310|Procedure|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
79373340|NCT03955614|Other|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
79373341|NCT03955614|Other|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
79373342|NCT03955614|Other|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
79373343|NCT01203826|Biological|Asfotase Alfa|
79373344|NCT03943836|Behavioral|Music|Patients in the music group will listen to classical music during their dental procedure.
79373345|NCT03448146|Drug|Para-Toluenesulfonamide|
79373346|NCT03011008|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
79373347|NCT03011008|Drug|Insulin|Receive insulin following clinician's instruction.
79526876|NCT05529511|Other|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
79526877|NCT05529511|Other|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
79826011|NCT05036330|Other|Quality-of-Life Assessment|Complete questionnaires
79826012|NCT05036330|Other|Questionnaire Administration|Complete questionnaires
79231138|NCT04947059|Drug|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
79373348|NCT03443232|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
79682588|NCT01906814|Drug|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
79826013|NCT05027308|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection
79826014|NCT05022823|Device|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
79826015|NCT05022823|Device|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
79231139|NCT03237962|Device|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
79826016|NCT05022823|Device|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
79231140|NCT03237962|Device|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
79373349|NCT03443232|Procedure|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
79373350|NCT04983732|Drug|FL-101-Intravenous|150 mg administered via the IV route
79231141|NCT04945967|Procedure|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
79231142|NCT04945967|Procedure|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
79526878|NCT05528692|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
79682589|NCT01894308|Drug|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
79682590|NCT01894308|Device|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
79373351|NCT04983732|Drug|FL-101-Subcutaneous|150 mg administered via the SC route
79526879|NCT05509634|Drug|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
79682591|NCT01764399|Behavioral|Care4U|
79682592|NCT01762176|Procedure|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
79682593|NCT01762176|Procedure|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
79682594|NCT01705158|Drug|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
79826017|NCT05022823|Behavioral|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
79826018|NCT05022823|Behavioral|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
79826019|NCT05016531|Device|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
79826020|NCT05016531|Device|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
79231143|NCT05477914|Other|questionnaire|questionnare about nutritional knowledge of pregnant women
79305600|NCT04956471|Other|interview|A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
79373352|NCT04452552|Other|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
79373353|NCT01157416|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
79826021|NCT04997681|Behavioral|Combined Aerobic Exercise and Resistance Training (AE + RT)|AE + RT will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. AE + RT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 strength training exercises (that progressively increase in resistance intensity over time) will be completed followed by a break. Aerobic exercises that safely increase the participant's heart rate will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the AE + RT exercise session is approximately 65 minutes.
79826022|NCT04997681|Behavioral|Cognitive Training (NeuropeakTM)|NeuropeakTM is a program which will be completed by participants remotely using a tablet or computer. It consists of cognitive training including dual-task training that requires participants to maintain and prepare for many response alternatives (working memory) and to share attention between two concurrent tasks (divided attention). Difficulty of cognitive training is tailored to their individual functioning level. During each session, participants perform one of two different visuo-motor tasks, which include sets of visual stimuli (e.g., letters, numbers, animals, vehicles, fruits, celestial bodies) and respective hand-button correspondences (i.e., keys that are to be tapped on either the right or the left side of the screen). Participants are instructed to perform these tasks as fast as possible, while maintaining accuracy. Training also includes online feedback and a histogram of daily performance to encourage improvement. NeuropeakTM takes approximately 30 minutes to complete.
79526880|NCT05509634|Drug|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
79826023|NCT04997681|Behavioral|Control Cognitive Training of Website Searching and Video Watching (WS+V)|During the WS + V task, participants alternate between 2 different tasks (touristic searching using internet and video watching). For the touristic searching using internet, participants are required to find 3 hotels, 3 touristic places, and 3 restaurants of their own preference in a city assigned by the instructor (a new city will be selected each session). They will also need to include the respective addresses of those places on their log sheet. For the video watching task, participants watch a National Geographic video on YouTube selected by the instructor with a different video selected for each session. They will watch the video for 20 minutes and during the remaining 5 minutes they will answer the following questions on their log sheet: 1) What is the video about? 2) What is the most important information in your opinion? 3) Create a question based on the video and answer your own question. WS + V sessions take approximately 30 minutes to complete.
79826024|NCT04997681|Behavioral|Control Balance and Toning Exercise Training (BAT)|BAT exercises will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. BAT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 balance and toning exercises will be completed followed by a break. Stretching exercises will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the BAT exercise session is approximately 65 minutes.
79231144|NCT03238118|Other|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
79305601|NCT04935645|Behavioral|Progressive Muscle Relaxation|PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
79373354|NCT01157416|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
79305602|NCT02453789|Drug|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
79373355|NCT01157416|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
79682595|NCT01700543|Procedure|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
79682596|NCT01673100|Behavioral|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
79682597|NCT01583322|Drug|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
79305603|NCT02453789|Drug|Placebo|
79305604|NCT03240185|Behavioral|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
79373356|NCT03443154|Diagnostic Test|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
79373357|NCT01206478|Drug|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
79373358|NCT01206478|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
79682598|NCT01583322|Drug|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
79682599|NCT01571037|Drug|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
79682600|NCT01571037|Drug|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
79682601|NCT01558427|Procedure|Surveillance|Active clinical surveillance
79682602|NCT01558427|Procedure|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
79682603|NCT01535248|Other|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
79682604|NCT01487538|Behavioral|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
79682605|NCT01487538|Behavioral|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
79682606|NCT01487538|Behavioral|Discussion Boards|forum to exchange information and experiences
79682607|NCT01487538|Behavioral|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
79682608|NCT01469650|Dietary Supplement|cholecalciferal|400 IU/day
79682609|NCT01469650|Dietary Supplement|cholecalciferol|800 IU/day D3
79682610|NCT01452269|Behavioral|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
79682611|NCT01431326|Drug|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
79373359|NCT01206478|Drug|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
79373360|NCT04963530|Procedure|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
79682612|NCT01397877|Drug|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
79682613|NCT01307644|Behavioral|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
79682614|NCT01307644|Behavioral|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
79826025|NCT04990349|Drug|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
79231145|NCT03238118|Other|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
79373361|NCT04963530|Procedure|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
79373362|NCT04963530|Procedure|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
79682615|NCT01307644|Behavioral|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
79826026|NCT04987216|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
79373363|NCT04963530|Procedure|No intervention|No intervention.
79682616|NCT01303679|Drug|Paclitaxel|IV, 80mg/m² at d1, d8, d15
79999923|NCT06268782|Behavioral|Rehabilitate your core|The intervention was an online exercise program &#34;Rehabilitate your core,&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
79826027|NCT04976088|Drug|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
79826028|NCT04976088|Drug|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
79826029|NCT04976088|Drug|Placebo|Placebo: Placebo plaster, topical application once a day.
79826030|NCT04920318|Combination Product|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
79373364|NCT01158820|Drug|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
79682617|NCT01303679|Drug|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
79682618|NCT01303679|Drug|Exemestane|daily 25 mg (1 pill) oral intake
79231146|NCT03238118|Other|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
79231147|NCT04935905|Device|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
79231148|NCT04934657|Other|no intervention|no intervention
79231149|NCT05212805|Behavioral|Aerobic exercise|Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.
79682619|NCT01298713|Drug|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
79826031|NCT04920318|Combination Product|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
79999924|NCT06268054|Drug|DEH113|Tablets
79999925|NCT06268054|Drug|Placebo Comparator|Tablets
79999926|NCT06268015|Drug|Botensilimab|75 mg IV every 6 weeks for up to 4 doses
79231150|NCT05212805|Behavioral|Task-oriented upper-limb training|The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
79373365|NCT01158820|Drug|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
79373366|NCT01158820|Drug|Midazolam load|2 mg bolus prior to bronchoscopy
79373367|NCT01158820|Drug|Fentanyl load|50 µg bolus prior to bronchoscopy
79373368|NCT01158820|Drug|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
79682620|NCT01298713|Drug|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
79682621|NCT01191697|Drug|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
79682622|NCT01191697|Drug|trastuzumab|Given intravenously on day 1 of each treatment cycle
79826032|NCT04912323|Device|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
79373369|NCT01158820|Drug|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
79373370|NCT01158820|Drug|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
79373371|NCT01158820|Drug|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
79373372|NCT01158820|Drug|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
79373373|NCT03707028|Drug|Rivoceranib|Film-coated tablet
79373374|NCT03707028|Drug|Paclitaxel|Solution administered intravenously
79373375|NCT03447756|Drug|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
79373376|NCT03447756|Drug|Placebo oral capsule|placebo to match
79682623|NCT01191697|Drug|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
79682624|NCT01191697|Drug|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
79826033|NCT04874038|Drug|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
79826034|NCT04874038|Drug|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
79231151|NCT05212805|Behavioral|Sport events participation|A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.
79231152|NCT03248960|Diagnostic Test|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
79231153|NCT03248960|Diagnostic Test|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
79526881|NCT05505760|Behavioral|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
79526882|NCT05503095|Genetic|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
79526883|NCT05499000|Behavioral|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
79526884|NCT05489718|Biological|IBI324|Dose 2 IBI324 of multiple IVT injection
79682625|NCT01189643|Drug|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
79682626|NCT01186042|Other|Observational|No intervention
79682627|NCT01182506|Behavioral|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
79682628|NCT01092884|Dietary Supplement|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
79826035|NCT04866719|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
79826036|NCT04828148|Behavioral|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
79826037|NCT04799535|Procedure|Ultrasound|Undergo breast ultrasound
79826038|NCT04771481|Drug|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
79826039|NCT04771481|Drug|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
79826040|NCT04769700|Behavioral|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
79826041|NCT04769700|Behavioral|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
79526885|NCT05489718|Biological|IBI324|Dose 2 IBI324 of single IVT injection
79826042|NCT04769700|Behavioral|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
79826043|NCT04757038|Device|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
79526886|NCT05489718|Biological|IBI324|Dose 1 IBI324 of single IVT injection
79682629|NCT01092884|Other|Placebo|This placebo capsule will be taken orally three times daily
79682630|NCT01044745|Drug|rituximab|Given IV
79826044|NCT04720196|Device|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
79826045|NCT04720196|Device|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
79826046|NCT04696198|Other|Manual Therapy Intervention|Manual Therapy Interventions to improve range of motion and decrease pain
79826047|NCT04696198|Other|Standard care|standard care
79231154|NCT03248960|Diagnostic Test|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
79373377|NCT01207570|Procedure|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
79373378|NCT01207570|Procedure|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
79826048|NCT04667312|Drug|Durvalumab|Durvalumab
79526887|NCT05489718|Biological|IBI324|Dose 3 IBI324 of single IVT injection
79526888|NCT05489718|Biological|IBI324|Dose 3 IBI324 of multiple IVT injection
79526889|NCT05475925|Drug|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
79526890|NCT05470218|Other|Meal|Liquid mixed meal with different amounts of protein and leucine
79826049|NCT04651582|Behavioral|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
79826050|NCT04651582|Behavioral|Cognitive Stimulating Activities|20 hours of traditional computer games
79826051|NCT04650893|Drug|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
79826052|NCT04650893|Drug|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
79526891|NCT05469464|Drug|Orismilast modified release tablets|"Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~UNI50001~LEO32731"
79526892|NCT05469464|Drug|Placebo|Placebo matching tablets
79826053|NCT04650893|Drug|Placebo|Control
79826054|NCT04611152|Drug|KSI-301|Intravitreal Injection
79999927|NCT06268015|Drug|Balstilimab|240 mg IV every 2 weeks
79231155|NCT03248960|Diagnostic Test|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
79231156|NCT03248648|Drug|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
79231157|NCT03248648|Drug|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
79373379|NCT03447678|Drug|Pembrolizumab|humanized antibody used in cancer immunotherapy
79526893|NCT05464524|Other|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
79526894|NCT05464524|Other|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
79526895|NCT05464498|Device|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
79526896|NCT05464498|Other|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
79682631|NCT01044745|Drug|mycophenolate mofetil|Given IV or PO
79682632|NCT01044745|Drug|tacrolimus|Given IV
79682633|NCT01044745|Drug|anti-thymocyte globulin|Given IV
79682634|NCT01044745|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
79682635|NCT01044745|Other|laboratory biomarker analysis|Correlative studies
79682636|NCT01044745|Biological|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
79682637|NCT01044745|Drug|cyclophosphamide|Given PO or IV
79682638|NCT01044745|Drug|fludarabine phosphate|Given IV
79826055|NCT04611152|Drug|Aflibercept|Intravitreal Injection
79826056|NCT04611152|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
79826057|NCT04604041|Diagnostic Test|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
79826058|NCT04603937|Drug|KSI-301|Intravitreal Injection
79826059|NCT04603937|Drug|Aflibercept|Intravitreal Injection
79682639|NCT01044745|Drug|busulfan|Given IV
79682640|NCT01044745|Radiation|total-body irradiation|Undergo TBI
79826060|NCT04603937|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
79826061|NCT04603651|Drug|Bamlanivimab|Administered intravenously (IV).
79826062|NCT04602975|Biological|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
79999928|NCT06268015|Drug|Oxaliplatin|85 mg/m2 IV every 2 weeks
79999929|NCT06268015|Drug|Leucovorin|400 mg/m2 IV every 2 weeks
79682641|NCT01044745|Biological|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
79682642|NCT01044745|Biological|immunosuppressive therapy|Undergo immunosuppressive therapy
79999930|NCT06268015|Drug|Fluorouracil|400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
79231158|NCT01563575|Other|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
79231159|NCT03237806|Drug|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
79231160|NCT03237806|Drug|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
79231161|NCT03237728|Drug|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
79373380|NCT01207648|Drug|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
79373381|NCT01225354|Drug|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
79526897|NCT05438225|Behavioral|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
79526898|NCT05432167|Drug|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
79682643|NCT00990275|Other|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
79682644|NCT00661882|Other|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
79682645|NCT00661882|Other|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
79826063|NCT04602975|Biological|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
79826064|NCT04602975|Biological|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
79826065|NCT04602975|Biological|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
79231162|NCT03237728|Drug|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
79231163|NCT03237728|Drug|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
79231164|NCT03237728|Drug|Placebos|Placebos,Q8h,Day1-Day7
79231165|NCT03241784|Biological|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
79526899|NCT05432167|Drug|Placebo|Patients will take placebo tablets by mouth once daily.
79526900|NCT05430230|Drug|Naproxen 500 Mg|naproxen tablets
79526901|NCT05430230|Drug|Placebo|lactose NF
79682646|NCT00661882|Other|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
79826066|NCT04602975|Biological|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
79826067|NCT04602975|Biological|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
79826068|NCT04600934|Device|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
79826069|NCT04600934|Device|Plain old balloon angioplasty|POBA
79826070|NCT04595890|Device|Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC)|Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).
79999931|NCT06268015|Drug|Bevacizumab|5 mg/kg IV every 2 weeks
79999932|NCT06268015|Drug|Panitumumab|6 mg/kg IV every 2 weeks
79231166|NCT03241784|Biological|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
79231167|NCT03242096|Combination Product|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
79231168|NCT03242096|Combination Product|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
79526902|NCT05405569|Other|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
79526903|NCT05405569|Other|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
79526904|NCT05400655|Drug|L9LS|Administered subcutaneously.
79526905|NCT05400655|Other|Normal Saline|Administered subcutaneously.
79526906|NCT05397912|Diagnostic Test|Uterine Elastography|Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
79682647|NCT00661882|Procedure|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
79682648|NCT00580385|Other|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
79682649|NCT00570791|Device|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
79682650|NCT00566826|Behavioral|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
79526907|NCT05390398|Behavioral|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
79682651|NCT00566826|Behavioral|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
79682652|NCT00264511|Other|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
79682653|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
79999933|NCT06267911|Other|Cognitive stimulation and psychological support (RGS-ICU)|The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
79231169|NCT05211557|Biological|fhB7H3.CAR-Ts|"Three dose levels will be evaluated: Dose Level 1 (1×10^6/kg), dose Level 2 (3×10^6/kg) and dose Level 3 (5×10^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10^6/kg /infusion) will be evaluated.~Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan"
79231170|NCT03248336|Procedure|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
79526908|NCT05383079|Drug|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
79526909|NCT05383079|Drug|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
79999934|NCT06267456|Diagnostic Test|Upper Limb Rotation Test|The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.
79682654|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
79682655|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
79682656|NCT05291078|Device|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
79682657|NCT02941328|Drug|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
79682658|NCT02941328|Drug|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
79709793|NCT04327596|Procedure|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
79709794|NCT02271971|Dietary Supplement|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
79709795|NCT02271971|Dietary Supplement|Placebo|A daily placebo capsule during 6 weeks.
79231171|NCT04716803|Biological|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
79231172|NCT04716803|Device|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
79231173|NCT03241472|Drug|Letrozole|oral tablets 5 mg
79231174|NCT03241472|Drug|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
79682659|NCT02915796|Biological|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
79826071|NCT04595890|Other|Saline injection|Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).
79826072|NCT04564885|Device|BAGUERA®C Cervical Disc Prosthesis|surgery
79231175|NCT03241628|Device|Dressing Glove|Viscose dressing glove
79231176|NCT04313075|Drug|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
79231177|NCT02551666|Other|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
79231178|NCT02551666|Other|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
79231179|NCT04306523|Other|Observation|4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
79373382|NCT04937790|Behavioral|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
79526910|NCT05381155|Behavioral|A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay|"The intervention is composed of two tasks:~The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room."
79526911|NCT05370820|Drug|Tranexamic acid|IV 2 minutes, IV 10 minutes, IM
79826073|NCT04564885|Device|Mobi-C Cervical Disc|surgery
79826074|NCT04551547|Biological|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 300SU/0.5ml
79826075|NCT04551547|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 600SU/0.5ml
79826076|NCT04551547|Other|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research & Development Co., Ltd.
79826077|NCT04539236|Drug|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
79231180|NCT03241550|Drug|isavuconazonium sulfate - intravenous|IV infusion
79826078|NCT04539236|Drug|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
79231181|NCT03241550|Drug|isavuconazonium sulfate - oral|Oral
79231182|NCT05481580|Diagnostic Test|Periodontal probing|"The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment"
79231183|NCT05211167|Drug|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
79231184|NCT05211167|Drug|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
79682660|NCT02915796|Biological|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
79682661|NCT02915796|Procedure|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
79682662|NCT02915796|Biological|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
79682663|NCT02941289|Procedure|visual search performance of everyday objects in realistic scenes|
79682664|NCT02919228|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
79682665|NCT02941211|Device|Aqueduct -100|
79682666|NCT02915484|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
79682667|NCT02940977|Other|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
79231192|NCT05477446|Biological|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
79231193|NCT05211089|Other|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
79231194|NCT03248102|Diagnostic Test|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
79390971|NCT04483128|Device|Electrical stimulation: Interferential Current (IFC): Experimental Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~Carrier frequency of 4000 Hz~Amplitude modulated frequency of 65 Hz (AMF)~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~Session duration: 25 minutes"
79390972|NCT04483128|Device|Electrical stimulation: Interferential Current (IFC): Control Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~Carrier frequency of 4000 Hz~Amplitude modulated frequency of 65 Hz (AMF)~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~NO intensity (0 mA)~Session duration: 25 minutes"
79390973|NCT03183336|Procedure|ridge split interpositional block graft|
79526912|NCT05367544|Behavioral|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
79526913|NCT05367544|Behavioral|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
79682668|NCT02915328|Device|Filterwire EZ™|
79682669|NCT02915328|Device|MO.MA Ultra|
79682670|NCT02915328|Device|Stent Roadsaver®|
79682671|NCT02915328|Device|Carotid Wallstent|
79682672|NCT05238545|Other|gluten-free diet|Diet excluding foods containing gluten.
79682673|NCT02915133|Procedure|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
79231195|NCT03903562|Biological|V503|0.5 mL 9vHPV VLP Vaccine
79231196|NCT03237416|Drug|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
79682674|NCT04691336|Behavioral|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
79682675|NCT02915250|Drug|BioChaperone® Combo|Injection of BioChaperone® Combo
79682676|NCT02915250|Drug|Humalog® Mix25|Injection of Humalog® Mix25
79682677|NCT02915250|Drug|Humalog®|Injection of Humalog®
79682678|NCT02915250|Drug|Lantus®|Injection of Lantus®
79682679|NCT02915250|Drug|Placebo|Injection of 0.9% NaCl
79682680|NCT02277041|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
79682681|NCT02277041|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
79231197|NCT03237416|Drug|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
79231198|NCT03237416|Drug|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
79231199|NCT05211011|Drug|Fosfomycin|Infectofos 5 g
79390974|NCT03183336|Procedure|decortication Onlay block graft|
79682682|NCT02915289|Procedure|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
79682683|NCT02915289|Procedure|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
79231200|NCT05481346|Procedure|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
79231201|NCT03247946|Behavioral|upright head position|Bottle feeding of infants with their head in upward and not supine head position
79231202|NCT05470894|Biological|Approved COVID-19 vaccine|Vaccination for COVI9-19
79231203|NCT04534049|Other|Intensive Strength Training (IST)|
79231204|NCT04534049|Other|Strength Endurance Training (SET)|
79231205|NCT04534049|Other|Flexibility Training (FT)|
79231206|NCT03237338|Procedure|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
79526914|NCT05367544|Behavioral|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
79526915|NCT05341011|Behavioral|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
79526916|NCT05329220|Biological|ABNCoV2|ABNCoV2 100μg single dose
79231207|NCT03237338|Procedure|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
79826081|NCT04509102|Drug|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
79231208|NCT04243343|Device|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
79231209|NCT04243343|Other|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
79231210|NCT03237104|Other|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
79231211|NCT04486820|Other|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
79231212|NCT05210855|Diagnostic Test|CT scan|Scan with classic dose followed by ultra-low dose
79390975|NCT02430792|Behavioral|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
79390976|NCT02126553|Other|Laboratory Biomarker Analysis|Correlative studies
79390977|NCT02126553|Drug|Lenalidomide|Given PO
79390978|NCT02425020|Dietary Supplement|Meat Protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
79526917|NCT05329220|Biological|Comirnaty|Comirnaty
79682684|NCT02939378|Dietary Supplement|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
79682685|NCT02939378|Dietary Supplement|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
79682686|NCT02915406|Device|CliniMACs|
79682687|NCT02939339|Device|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
79682688|NCT02939339|Device|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
79682689|NCT02918916|Other|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
79231213|NCT05481268|Other|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
79231214|NCT05481268|Other|Stretching Group|In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
79231215|NCT05481268|Other|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
79231216|NCT04103333|Procedure|Lumbar Puncture|Administered as specified in the treatment arm.
79231217|NCT04103333|Procedure|Blood Collection|Administered as specified in the treatment arm.
79826082|NCT04509102|Drug|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
79682690|NCT02918916|Other|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
79826083|NCT04502186|Behavioral|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
79826084|NCT04502186|Other|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
79231218|NCT04486664|Behavioral|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
79826085|NCT04470518|Other|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
79373383|NCT04937790|Behavioral|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
79826086|NCT04428060|Other|PERSEUS CPR|Resuscitation based on patient physiology
79373384|NCT02521662|Drug|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
79682691|NCT02939417|Other|Grape seed extract|Grape seed extract - collagen cross-linking agent
79682692|NCT02919033|Other|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
79682693|NCT02919033|Device|Self-management|"Usual care~Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~All patients receive proficiency training in using the BP tele-monitor, and mobile App."
79231219|NCT03247868|Combination Product|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
79231220|NCT04207229|Device|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
79682694|NCT02919033|Other|PCTM intervention|"Usual care~Self-management~PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~PCPs and cardiologists receive training of the CareLinker website."
79999935|NCT06267456|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Athletes were placed in a push-up position with a distance of 91.44 centimeters (cm) (3 feet) between their hands for the test position. Subsequently, they were instructed to touch one hand to the other as quickly as possible. The total number of touches within a 15-second period was recorded. Modified push-up position was used for women, and regular push-up position for men during this time. Prior to the test, a familiarization trial consisting of 5 repetitions was performed. The test was then repeated 3 times, and the average of these repetitions was recorded as the score. Individuals were given a 45-second rest period between repetitions. The normalized score, representing the touch count per individual's height, was calculated. The power score was obtained by multiplying the touch count by 68% of the individual's body weight in kilograms.
79999936|NCT06267456|Diagnostic Test|Upper Quarter Y Balance Test|The Upper Extremity Y Balance Test was created using three rulers placed on the ground in the medial, inferolateral, and superolateral directions. The rulers in the superolateral and inferolateral directions were positioned at a 90° angle to each other, while the ruler in the medial direction was placed at a 135° angle with respect to these two directions. In this test, both arms started in a push-up position with shoulder-width apart. The athlete was then instructed to touch, using their non-dominant hand, the maximum reachable point in the medial, inferolateral, and superolateral directions.
79682695|NCT02939456|Other|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
79231221|NCT04487288|Diagnostic Test|SONAZOID|CEUS using SONAZOID with fusion technique
79682696|NCT02918799|Behavioral|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
79682697|NCT02939261|Behavioral|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
79682698|NCT02939261|Behavioral|Control|monthly emails with general health information
79682699|NCT02918682|Other|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
79826087|NCT04428060|Other|Standard CPR|Resuscitation based on current guidelines
79826088|NCT04409340|Device|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
79826089|NCT04409340|Device|QUS|QUS
79999937|NCT06267404|Other|Iliopsoas Positional release therapy|Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
79373385|NCT02521662|Device|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
79999938|NCT06267404|Other|Conventional exercises|Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
79373386|NCT02521662|Drug|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
79373387|NCT02521662|Behavioral|Behavioural support|Withdrawal-oriented behavioural support
79373388|NCT01226914|Drug|EVICEL|EVICEL
79373389|NCT01158976|Dietary Supplement|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
79231222|NCT04094519|Drug|enzalutamide|oral
79231223|NCT04094519|Drug|enzalutamide Placebo|oral
79231224|NCT04094519|Drug|digoxin|oral
79231225|NCT04094519|Drug|rosuvastatin|oral
79231226|NCT03241238|Other|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
79373390|NCT01158976|Other|Placebo|soybean oils with strawberry flavoring
79373391|NCT04937556|Dietary Supplement|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
79682700|NCT02918682|Other|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
79999939|NCT06266182|Behavioral|Acceptance and Commitment Therapy|ACT intervention will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive a web-based intervention consisting of educational and practical tasks/activities. Participants will learn to recognize moments of choice (actions that lead towards values or away from them) and to use attention flexibly to free themselves from the power of thoughts, to open up and accept emotions, and to be able to determine what is important and take action in line with values. All of the tasks will be available in written form and audio. The ACT intervention is built from standard ACT exercises.
79999940|NCT06266182|Behavioral|Education|Education will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive information about post-transplant prescriptions along with exercises to support the implementation. Participants will learn about nutrition, personal hygiene, preventing infections, coping with fatigue, resuming activity, rest and sleep, engaging in social interactions, and sexual health. The content is prepared based on available guides for HCT recipients.
79999941|NCT06265233|Other|Group Improv sessions|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
79999942|NCT06265233|Behavioral|Group Exposure and Response Prevention (ERP) Therapy|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
79999943|NCT06265012|Biological|PHV01|Marburg virus vaccine
79999944|NCT06265012|Biological|Placebo|Lactated Ringer's Solution
79999945|NCT06264713|Device|Immersive Virtual Reality|Patients wear a head-mounted-display and will be immersed in a virtual environment. The stimuli will be provided in the left, center and right visual fields. Eye-tracking biofeedback will be provided about the real-time performance during each exercise.
79999946|NCT06264713|Device|Sham Immersive Virtual Reality|The patients performed the same protocol of the experimental group, differently to the immersive virtual reality group, from session 2 to session 8 (7 sessions), the stimuli will be provided in the center and right visual fields.
79999947|NCT06264596|Drug|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
79999948|NCT06264596|Procedure|Normal Saline irrigation fluid|The control group will have two 3-L normal saline solution bags prepared with no additive
79999949|NCT06264531|Drug|Bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
79231227|NCT03307564|Device|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
79231228|NCT02454452|Procedure|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
79231229|NCT02454452|Procedure|Saphenous vein stripping|Saphenous vein stripping
79231230|NCT02454452|Procedure|CHIVA|conservative hemodynamic treatment venous insufficiency
79231231|NCT03061175|Other|Internet-Based Intervention|Receive web-based CPM-DA
79373392|NCT04937556|Dietary Supplement|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
79373393|NCT01227382|Procedure|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
79373394|NCT05183880|Dietary Supplement|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
79999950|NCT06264531|Drug|Placebo|NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
79999951|NCT06261775|Other|Red meat-based meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
79999952|NCT06261775|Other|Lacto-ovo-vegetarian meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
79999953|NCT06260709|Drug|NNC6019-0001|Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
79999954|NCT06258811|Drug|albumin paclitaxel, cispatin, tislelizumab|Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
79231232|NCT03061175|Other|Survey Administration|Ancillary studies
79231233|NCT02359838|Other|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
79231234|NCT02359838|Other|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
79373395|NCT05183880|Dietary Supplement|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
79373396|NCT01159054|Drug|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
79999955|NCT06257563|Other|Isle of TEND Intervention|"The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers."
79999956|NCT06256692|Other|Pulse oximeter|No real intervention, but all study participants will have an additional pulse oximeter attached, to measure oxygen saturation.
79999957|NCT06255093|Behavioral|Community-based recreation program referral|Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.
79999958|NCT06255093|Behavioral|Pre-surveys only|Receive online wellness education and anxiety treatment options information
79231235|NCT02189798|Device|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
79231236|NCT02189798|Device|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
79231237|NCT03061097|Biological|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
79231238|NCT03061097|Other|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
79231239|NCT03107702|Diagnostic Test|melatonin|the relationship between melatonin level and analgesia requirement.
79231240|NCT02554318|Drug|Rifampicin|
79373397|NCT04451694|Other|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
79373398|NCT01209442|Drug|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
79373399|NCT01209442|Drug|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
79373400|NCT01209442|Radiation|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
79373401|NCT04451928|Diagnostic Test|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
79526918|NCT05328258|Drug|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
79709796|NCT04344639|Other|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
79999959|NCT06254898|Behavioral|Child life standard of care|Standard preparation and support provided to the participant by a Certified Child Life Specialist.
79999960|NCT06254898|Behavioral|Child life standard of care + incentives provided with conditional agreement.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. Before the procedure the child life specialist discusses earning a prize with the patient if they demonstrate the agreed upon coping goal (i.e. holding arm still, taking deep breaths, engaging in distraction.) At the end of the procedure the patient is provided with the prize if they earn the prize based on the agreed upon coping plan.
79231241|NCT02554318|Drug|Isoniazid|
79373402|NCT04452006|Drug|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
79373403|NCT04452006|Drug|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
79373404|NCT04452006|Drug|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
79999961|NCT06254898|Behavioral|Child life standard of care + incentive provided unconditionally.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. After the procedure is complete the patient is provided with a prize. The patient does not need to do anything to earn the prize.
79231242|NCT02554318|Drug|Pyrazinamide|
79231243|NCT02554318|Drug|Ethambutol|
79231244|NCT02554318|Dietary Supplement|Fermented soybean|
79373405|NCT04452006|Drug|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
79373406|NCT04452006|Drug|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
79526919|NCT05328258|Drug|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
79526920|NCT05324358|Drug|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (~0.9% NaCl) adjusted to a pH of ~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
79526921|NCT05324358|Drug|Morphine Sulfate|Morphine single use vials at 4 mg/mL, filled with 1 mL.
79526922|NCT05324358|Other|Intravenous Placebo for NTM-001|Placebo alcohol free saline solution (~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
79231245|NCT04487054|Other|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
79999962|NCT06253520|Drug|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
79999963|NCT06253520|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
79373407|NCT04452006|Drug|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
79373408|NCT04452006|Drug|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
79373409|NCT04452006|Drug|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
79373410|NCT01160380|Drug|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
79373411|NCT01160380|Drug|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
79373412|NCT03071328|Drug|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
79682701|NCT02918682|Other|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
79682702|NCT02918682|Other|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
79231246|NCT03628157|Other|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
79231247|NCT03241160|Other|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
79526923|NCT05324358|Other|IV Placebo for Morphine|Placebo single use vials with saline (matching active morphine).
79682703|NCT05034536|Drug|Pembrolizumab|Intravenous infusion
79682704|NCT05034536|Drug|Infliximab|Intravenous infusion
79682705|NCT05034536|Drug|Placebo|Intravenous infusion
79682706|NCT05018351|Behavioral|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
79709797|NCT02273024|Behavioral|Exercise|
79231248|NCT04487132|Behavioral|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.
79231249|NCT04487132|Behavioral|Recess or lunch time activities|group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
79231250|NCT03976973|Drug|Bromelain|Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
79373413|NCT03447600|Behavioral|Alternate Day Fasting|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
79373414|NCT03447600|Behavioral|Continuous dietary restriction|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
79526924|NCT05311969|Other|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~Mini Mental State Examination~Stroop Victoria Test~Hayling test~Frontal Assessment Battery test mental flexibility:~Trial Making Test (TMT) A and B~Connection test~Alphaflex test~Verbal and visuospatial working memory~Wechsler Adult Intelligence Scale (WAIS) span~Visuo-spatial span~Visuo-spatial span simplified version~Month Of the Year Backwards (MOTYB) Planning~Tinker Toy test~Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
79999964|NCT06253520|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
79231251|NCT03976973|Drug|Acetylcysteine|Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
79999965|NCT06253520|Biological|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).
79999966|NCT06253520|Biological|GRT-C903/GRT-R904|Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
79526925|NCT05301556|Other|Experimental Product|"Before the surgery: FSMP provides daily target energy needed by participants~1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
79526926|NCT05301556|Other|Control Product|"Before surgery: TPF-T provides daily target energy needed by participants~1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
79526927|NCT05301322|Biological|RSVpreF Vaccine|RSV Vaccine
79526928|NCT05301322|Other|Placebo|Placebo
79526929|NCT05301322|Biological|Seasonal Inactivated Influenza Vaccine|SIIV
79999967|NCT06251193|Behavioral|E-CBSST|E-CBSST is a blended intervention that combines Cognitive Behavioral Social Skills Training and Executive Function Training.
79999968|NCT06250855|Device|Mini Toric IOL|Adults (males and females) ≥18 years with cataract and pre-existing corneal astigmatism who have undergone monocular or binocular Mini Toric Ready implantation after cataract surgery in which the cataract lens was removed by phacoemulsification, with circular capsulorhexis, leaving the posterior capsule intact.
79231252|NCT03976973|Procedure|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
79231253|NCT03241316|Behavioral|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
79231254|NCT05476978|Diagnostic Test|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
79231255|NCT04066751|Drug|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
79373415|NCT03447444|Other|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
79373416|NCT04956042|Drug|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
79373417|NCT04956042|Drug|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
79373418|NCT03442998|Other|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
79526930|NCT05286528|Drug|Bosutinib|Bosutinib as prescribed in real world
79526931|NCT05286528|Drug|Imatinib|Imatinib as prescribed in real world
79526932|NCT05286528|Drug|Nilotinib|Nilotinib as prescribed in real world
79526933|NCT05286528|Drug|Dasatinib|Dasatinib as prescribed in real world
79999969|NCT06249048|Biological|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
79999970|NCT06249048|Biological|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
79999971|NCT06248515|Drug|Sacituzumab govitecan-hziy|10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
79231256|NCT03241004|Other|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
79231257|NCT03240770|Device|VPro5 device|Use of the VPro5 device for 5 minutes a day
79231258|NCT03240770|Other|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
79526934|NCT05286528|Drug|Ponatinib|Ponatinib as prescribed in real world
79526935|NCT05265026|Behavioral|High Intensity Interval Training|A training session consists of 40 minutes as follows: 4x4 minutes at > 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at ~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: >85% of HRmax).
79526936|NCT05256537|Other|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
79682707|NCT05018351|Behavioral|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
79682708|NCT02915094|Drug|Anakinra|
79826090|NCT04367922|Behavioral|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
79999972|NCT06248437|Other|innovative nutraceutical-type food product that we designed called HIC1® from coffee mucilage|All participants completed a survey on sociodemographic data (age, sex, respiratory problems, smoking, among others). Weight, height, skin folds, and a blood sample were taken to quantify the Oxygen Radical Absorption Capacity (ORAC) units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and lipid profile. At that time, they were explained how they should eat the nutraceutical food, starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant
79999973|NCT06248008|Drug|ASC40|ASC40 tablets orally once daily
79373419|NCT03442998|Other|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
79373420|NCT01228084|Drug|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
79682709|NCT02918643|Other|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
79826091|NCT04349709|Behavioral|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus & Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
79373421|NCT01228084|Other|Laboratory biomarker analysis|Correlative studies
79682710|NCT05012891|Other|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
79682711|NCT02939027|Device|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
79682712|NCT02939027|Device|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
79826092|NCT04325308|Procedure|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
79826093|NCT04325308|Procedure|Usual human milk diet|Human-based protein will not be added to the human milk administered.
79826094|NCT04294745|Procedure|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
79999974|NCT06245395|Device|Virtual Reality|Meta Quest 2 Headset
79999975|NCT06244992|Drug|PTT-936|Eligible patients will receive single-agent PTT-936 administered per orally (PO).
79999976|NCT06244992|Drug|Combination of PTT-936 and anti-PD-1/L1 therapy|Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
79999977|NCT06244264|Procedure|Autoblood transfusion|Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
79373422|NCT01228084|Other|Pharmacological study|Correlative studies
79231259|NCT02550106|Drug|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
79231260|NCT05209919|Diagnostic Test|Transthoracic Echocardiography|All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
79231261|NCT03237260|Drug|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
79231262|NCT03237026|Other|No intervention required|No intervention required
79231263|NCT03247400|Drug|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
79231264|NCT03247400|Drug|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
79373423|NCT03009994|Procedure|Repair of uterine incision|
79373424|NCT03009994|Procedure|Exteriorization of the uterus|
79373425|NCT03009994|Procedure|Non exteriorization of the uterus|
79682713|NCT02915172|Drug|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
79682714|NCT02915172|Drug|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
79682715|NCT02938988|Procedure|Antimicrobial photodynamic therapy|Described in arm/group
79682716|NCT02938988|Procedure|Scaling and root planning|Described in arm/group
79682717|NCT02938988|Device|red laser|658nm; 0.1W; 2229J/cm², 10s per point
79999978|NCT06242925|Device|AbCLO (Abdominal Wall Closure) Device|They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
79682718|NCT02938988|Drug|methylene blue dye|
79682719|NCT02918994|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
79682720|NCT02939144|Dietary Supplement|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
79682721|NCT02915055|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
79682722|NCT02915055|Drug|standard oxycodone/acetaminophen|
79682723|NCT02939222|Device|Implant placement|Routine implant placement in the ideal three dimensional implant position
79682724|NCT02938910|Other|non interventional study|Non invasive imaging study without interventional procedures
79682725|NCT04690790|Procedure|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
79231265|NCT03060551|Procedure|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
79231266|NCT03236948|Behavioral|Women for Women International Intervention|
79526937|NCT05253573|Drug|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
79526938|NCT05253573|Behavioral|Self-help materials (to support smoking cessation)|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."
79682726|NCT01295827|Biological|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
79682727|NCT02918838|Behavioral|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
79682728|NCT02918838|Behavioral|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
79999979|NCT06241560|Drug|BI 1015550|BI 1015550
79999980|NCT06241560|Drug|Pirfenidone|Pirfenidone
79231267|NCT02453516|Procedure|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
79231268|NCT02453516|Procedure|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
79682729|NCT02918838|Behavioral|Control Group|
79682730|NCT02918760|Drug|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
79682731|NCT02918760|Other|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
79682732|NCT02914743|Behavioral|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
79682733|NCT02914743|Procedure|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
79682734|NCT04983368|Drug|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
79682735|NCT04983368|Drug|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
79682736|NCT04983368|Drug|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
79231269|NCT02453516|Drug|ropivacaine|Drug indicated for regional anesthesia
79231270|NCT02453516|Drug|epinephrine|Drug indicated to prolong the action of regional anesthesia
79231271|NCT02453516|Other|sterile saline|Neutral injection (no drug involved)
79826095|NCT04294745|Procedure|Inferior alveolar nerve block|Standard technique of mandibular nerve block
79682737|NCT02918604|Device|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
79231272|NCT03716609|Dietary Supplement|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
79682738|NCT01295671|Behavioral|Provision of beverages|Home delivery of specified beverage type
79373426|NCT03442920|Other|Exercise|This group made exercise for 12 week/3 times a week.
79682739|NCT02918526|Device|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
79682740|NCT02938871|Dietary Supplement|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
79682741|NCT02938871|Dietary Supplement|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
79826096|NCT04283734|Device|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
79231273|NCT03716609|Other|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
79231274|NCT03716609|Other|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
79231275|NCT02453438|Other|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
79231276|NCT03709355|Drug|Elpida®|Elpida® capsules, 20mg
79526939|NCT05253573|Behavioral|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
79526940|NCT05252845|Biological|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
79682742|NCT01295320|Procedure|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
79682743|NCT02918448|Other|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
79682744|NCT04690517|Procedure|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
79682745|NCT01295281|Device|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
79682746|NCT01295281|Device|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
79826097|NCT04278001|Device|Dual 24-hour ABPM|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
79826098|NCT04256317|Drug|Azacitidine|Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
79231277|NCT03709355|Drug|Rifampin|Rifampin capsules, 150mg
79231278|NCT03709355|Drug|Rifabutin|Rifabutin capsules, 150mg
79682747|NCT02914821|Behavioral|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
79709798|NCT02272088|Behavioral|physical activity-moderate|cross -over of moderate and intense physical activity
79231279|NCT03709355|Drug|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
79231280|NCT03709355|Drug|Omeprazole|Omeprazole Film-coated tablets 20mg
79231281|NCT03709355|Drug|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
79231282|NCT03709355|Drug|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
79373427|NCT03010696|Other|No interventions, questionnaire, collect specimen|
79373428|NCT04923984|Procedure|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
79373429|NCT03447366|Diagnostic Test|mitral doppler|Mitral doppler before and after vascular filling
79373430|NCT01229410|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
79373431|NCT01229410|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
79709799|NCT02272088|Behavioral|Intense physical activity|cross -over of moderate and intense physical activity
79709800|NCT01172821|Drug|placebo|Placebo that represents BI drug
79709801|NCT01172821|Drug|placebo|Placebo that represents comparator
79826099|NCT04256317|Drug|ASTX030 (cedazuridine + azacitidine)|Tablets/Capsules for oral administration
79231283|NCT03240848|Procedure|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
79231284|NCT03240848|Procedure|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
79231285|NCT03240848|Procedure|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
79231286|NCT05209217|Drug|Ketamine|Intranasal administration of their customary prescribed dose
79231287|NCT03240926|Device|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
79231288|NCT03247244|Drug|Cannabis|THC 10%, CBD <0.5%
79231289|NCT03247244|Drug|Cannabis|THC 8.6%, CBD 8.6%
79526941|NCT05252845|Drug|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
79231290|NCT03247244|Drug|Cannabis|THC 0.6%, CBD 14%
79231291|NCT03988829|Behavioral|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
79231292|NCT03988829|Behavioral|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
79231293|NCT03988829|Behavioral|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
79373432|NCT02521740|Other|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
79373433|NCT01212172|Device|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
79231294|NCT03240458|Device|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
79682748|NCT04690712|Behavioral|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
79826100|NCT04256317|Drug|Cedazuridine|Tablets for oral administration
79826101|NCT04249492|Device|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
79826102|NCT04249492|Device|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
79231295|NCT02453906|Other|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
79231296|NCT02453906|Other|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
79231297|NCT02453906|Other|Control 2|stimulation at 5 control points
79231298|NCT02453906|Other|Control 3|no stimulation at 5 control points
79231299|NCT01662310|Drug|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
79526942|NCT05252845|Drug|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
79682749|NCT01294696|Drug|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
79826103|NCT04249245|Other|Nasal Swab|All
79231300|NCT01662310|Drug|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
79682750|NCT02914704|Device|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
79826104|NCT04229680|Other|High Salt|Consumption of pills containing table salt for 10 days.
79826105|NCT04229680|Other|Recommended Salt|Consumption of pills containing dextrose for 10 days.
79826106|NCT04228380|Other|No intervention|No intervention
79231301|NCT03973853|Behavioral|Virtual reality driving stimulation program|This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
79373434|NCT01212172|Device|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
79682751|NCT04324255|Procedure|LT|Liver transplantation
79682752|NCT04690751|Drug|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
79682753|NCT04326361|Procedure|Neonatal surgeries|Current practices of neonatal surgeries in India
79682754|NCT02918487|Drug|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
79709802|NCT01172821|Drug|placebo|Placebo that represents comparator
79826107|NCT04221594|Procedure|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
79826108|NCT04221594|Procedure|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate ~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
79999981|NCT06239376|Procedure|GnRHa+AI - AC|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
79999982|NCT06239376|Procedure|Artificial cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
79999983|NCT06232252|Drug|BI 765423|BI 765423
79231302|NCT03973853|Behavioral|TAU|This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
79231303|NCT00700622|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
79373435|NCT03442686|Behavioral|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
79373436|NCT03447054|Behavioral|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
79231304|NCT00700622|Drug|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
79231305|NCT00700622|Drug|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
79231306|NCT05480410|Device|Repetitive transcranial magnetic stimulation|rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
79373437|NCT03447054|Behavioral|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
79231307|NCT03236636|Drug|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
79231308|NCT03236636|Drug|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
79373438|NCT03447054|Behavioral|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
79231309|NCT03628625|Drug|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
79373439|NCT03447054|Behavioral|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
79373440|NCT01160458|Drug|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
79709803|NCT01172821|Drug|tiotropium Respimat® low dose|IMP
79709804|NCT01172821|Drug|placebo|Placebo that represents BI drug
79709805|NCT01172821|Drug|tiotropium Respimat® high dose|IMP
79709806|NCT01172821|Drug|50 mcg salmeterol HFA MDI|Active comparator
79709807|NCT01172821|Drug|placebo|Placebo that represents comparator
79709808|NCT02272127|Drug|icotinib|
79709809|NCT02272205|Other|Retrospective analysis of records|
79709810|NCT01172275|Drug|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
79826109|NCT04221594|Procedure|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
79826110|NCT04217447|Drug|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
79999984|NCT06232252|Drug|Placebo matching BI 765423|Placebo matching BI 765423
79999985|NCT06231264|Device|transcutaneous electrical acustimulation at treatment sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
79999986|NCT06231264|Device|transcutaneous electrical acustimulation at sham sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
79999987|NCT06230484|Device|Invisalign first palatal expander|Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
79231310|NCT03628625|Drug|Placebo|Folic acid for 3 days
79231311|NCT03628625|Drug|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
79231312|NCT03359993|Procedure|Premedication of intubation|The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
79390979|NCT02425020|Dietary Supplement|Whey protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
79526943|NCT05242380|Other|Kettlebell Exercise|"The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row."
79526944|NCT05235464|Other|Standard meal|Standard meal
79526945|NCT05235464|Other|High animal protein meal|Meal with high animal protein content
79526946|NCT05235464|Other|High plant protein meal|Meal with high plant protein content
79526947|NCT05235464|Other|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
79231313|NCT04468594|Other|rigid tapping|Taping techniques We will use rigid tape and apply it bilaterally. In the rigid tape application, a combination pack of zinc oxide tape and the protective tape will be used. The protective tape will be applied first with no tension. To apply the rigid tape, subjects will be instructed to place their thoracic spine in a neutral position, the rigid tape will be applied bilaterally from the first to the twelfth thoracic vertebra. Subjects will be asked to retract and depress the scapula. The rigid tape will be applied diagonally from the middle of the scapular spine to the twelfth thoracic vertebra; this technique will be applied bilaterally. The rigid tape will be applied 3 times per week and will be applied for 6 weeks.
79231314|NCT04468594|Other|scapular stabilizing excercise|"consisted of:~wall slides with squat,~wall push-ups plus ipsilateral leg extension,~lawnmower with diagonal squat,~resisted scapular retraction with contralateral leg squat and robbery with squat.~Robbery with squat~Resisted shoulder internal rotation with step~Resisted shoulder external rotation with step~Resisted full can with step All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands The patient will perform 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly."
79390980|NCT02425020|Dietary Supplement|Carbohydrate|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
79526948|NCT05201898|Other|control:usual medical management|with regular doctor visits every 3 months
79999988|NCT06230484|Device|Conventional rapid maxillary expansion|Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
79390981|NCT01703741|Drug|Testosterone Gel (FE 999093)|
79390982|NCT02430948|Other|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
79390983|NCT02430948|Other|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
79390984|NCT02430948|Other|Standard support|Screening recommendations presented in standard format
79999989|NCT06230224|Drug|Odronextamab|Administered by intravenous (IV) infusion
79999990|NCT06230224|Drug|Ifosfamide|Administered by IV infusion, as part of the ICE ± R salvage therapy
79373441|NCT03109704|Procedure|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
79373442|NCT03109704|Procedure|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
79373443|NCT03109704|Procedure|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
79373444|NCT01212484|Drug|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
79231315|NCT04468594|Other|therapeutic exercises|"Pectoralis minor stretching~Posterior shoulder stretching~Levator scapula stretching~Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~Resisted shoulder internal rotation~Resisted shoulder external rotation~Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets."
79526949|NCT05201898|Behavioral|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
79231316|NCT03238235|Drug|givinostat|suspension of givinostat (10 mg/mL)
79526950|NCT05201898|Behavioral|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
79682755|NCT02918487|Drug|Placebo|Inactive compound that is similar looking as the intervention
79682756|NCT04207606|Behavioral|Post Epidural Steroid Injection Follow-up|All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
79682757|NCT03458078|Drug|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
79682758|NCT03458078|Drug|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
79682759|NCT03458078|Drug|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
79682760|NCT02914860|Device|Cardiac CT|"Cardiac CT - contract enhanced cardiac CT according to standard protocol~D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~Merge CT and D-SPECT image data to generate SUMO map."
79999991|NCT06230224|Drug|Carboplatin|Administered by IV infusion, as part of the ICE ± R salvage therapy
79999992|NCT06230224|Drug|Etoposide|Administered by IV infusion, as part of the ICE ± R salvage therapy
79231317|NCT03238235|Drug|placebo|suspension manufactured to mimic givinostat
79231318|NCT03247166|Device|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
79231319|NCT05187923|Diagnostic Test|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
79231320|NCT02553928|Drug|Memantine (once daily)|
79231321|NCT02553928|Drug|Memantine (twice daily)|
79231322|NCT04486976|Device|Cornea/Anterior Segment OCT CASIA2|Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
79231323|NCT04486976|Device|Optovue RTVue XR Avanti|Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
79231324|NCT03247010|Other|Blood sampling|Blood samples are taken before each cycle of Radium 223
79526951|NCT05201248|Drug|Epcoritamab|Subcutaneous Injection (SC)
79526952|NCT05201248|Drug|Cyclophosphamide|IV Injection
79526953|NCT05201248|Drug|Rituximab|Intravenous (IV) Infusion
79526954|NCT05201248|Drug|Doxorubicin|IV Infusion
79526955|NCT05201248|Drug|Vincristine|IV Infusion
79526956|NCT05201248|Drug|Prednisone|Oral; Tablet
79526957|NCT05201248|Drug|Lenalidomide|Oral; Capsule
79526958|NCT05179954|Other|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
79526959|NCT05166785|Other|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
79682761|NCT02914860|Procedure|Ablation Procedure|"CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~Control HFS~At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~Exit and entrance block confirmation~Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
79826111|NCT04217447|Drug|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
79826112|NCT04210349|Biological|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
79826113|NCT04210349|Biological|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
79826114|NCT04210349|Biological|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
79826115|NCT04203901|Biological|CMN-001|Autologous Dendritic Cell Therapy
79826116|NCT04203901|Biological|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
79826117|NCT04203901|Drug|Lenvatinib+Everolimus|TKI+mTOR inhibitors
79231325|NCT03240380|Behavioral|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
79231326|NCT03240380|Behavioral|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
79231327|NCT03908255|Drug|Branch Chain Amino Acid|Nutritional supplementation
79231328|NCT03908255|Other|maltodextrin|Placebo
79231329|NCT03246854|Drug|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
79373445|NCT01212484|Drug|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
79373446|NCT03446976|Biological|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
79231330|NCT04527718|Drug|Placebo|placebo as a single SC injection on Day 1;
79373447|NCT03446976|Biological|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
79231331|NCT04527718|Drug|611|611 as a single SC injection on Day 1;
79231332|NCT03246776|Drug|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
79373448|NCT03109548|Other|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
79373449|NCT01212874|Drug|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
79373450|NCT01212874|Drug|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
79373451|NCT03446898|Other|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
79682762|NCT02914860|Device|D-SPECT|
79526960|NCT05166785|Other|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
79826118|NCT04198766|Drug|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
79826119|NCT04198766|Drug|Pembrolizumab 200 mg|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
79826120|NCT04198766|Drug|Pembrolizumab 400 mg|Pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
79826121|NCT04197648|Device|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
79999993|NCT06230224|Drug|Rituximab|Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
79999994|NCT06230224|Drug|Dexamethasone|Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
79999995|NCT06230224|Drug|Cisplatin|Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
79999996|NCT06230224|Drug|Cytarabine|Administered by IV infusion, as part of the DHAP ± R salvage therapy.
79231333|NCT03972826|Other|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
79826122|NCT04196777|Behavioral|Audit-and-feedback|We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
79826123|NCT04171700|Drug|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
79231334|NCT03246542|Diagnostic Test|shistocytes percentage|
79231335|NCT05480332|Device|EndoPAT|"We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point."
79231336|NCT03240146|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
79231337|NCT03076775|Other|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
79231338|NCT05480254|Other|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
79231339|NCT03240224|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
79231340|NCT03240224|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
79231341|NCT03240302|Device|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
79373452|NCT03442608|Procedure|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
79373453|NCT03446820|Other|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
79826124|NCT04168684|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
79826125|NCT04168684|Behavioral|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
79826126|NCT04128137|Drug|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
79373454|NCT03446742|Other|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
79373455|NCT03129438|Diagnostic Test|continuous EEG (cEEG)|differential use of continuous versus routine EEG
79682763|NCT04690556|Drug|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
79682764|NCT04690556|Drug|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
79373456|NCT03129438|Diagnostic Test|routine EEG (rEEG)|differential use of continuous versus routine EEG
79373457|NCT03442530|Behavioral|ToPIC|Expanded tobacco cessation counseling for pregnant women.
79373458|NCT03442530|Behavioral|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
79390985|NCT02430948|Other|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
79682765|NCT01294579|Biological|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
79682766|NCT01294579|Drug|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
79709811|NCT01172275|Other|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
79709812|NCT02272283|Device|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
79231342|NCT03240302|Device|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
79682767|NCT03554655|Device|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
79682768|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
79682769|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
79682770|NCT04972331|Procedure|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
79709813|NCT05036356|Other|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
79709814|NCT05034952|Drug|VX-548|Tablets for oral administration.
79709815|NCT05034952|Drug|HB/APAP|Capsules for oral administration.
79709816|NCT05034952|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
79231343|NCT05480176|Other|Comprehensive intervention and management Ⅰ|Mainly health advisory.
79231344|NCT05480176|Other|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
79373459|NCT03442452|Other|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
79373460|NCT04900584|Other|Checklist|Checklist of guideline-based treatment before discharge
79826127|NCT04128137|Other|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
79826128|NCT04112355|Other|Blood Collection|Blood draw
79826129|NCT04096066|Drug|Carfilzomib|"20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
79826130|NCT04096066|Drug|Lenalidomide|- 25 mg orally on days 1-21 of each cycle.
79999997|NCT06230224|Drug|Gemcitabine|Administered by IV infusion, as part of the GDP ± R salvage therapy.
79373461|NCT04900584|Other|Education|Heart failure education before discharge
79231345|NCT05480176|Other|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
79231346|NCT03067493|Biological|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
79231347|NCT03239912|Device|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
79373462|NCT04900584|Other|Telephone monitoring|Telephone monitoring after discharge
79373463|NCT03442218|Drug|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
79373464|NCT03442218|Drug|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
79373465|NCT01859741|Drug|OMP-59R5|OMP-59R5 administered intravenously
79373466|NCT01859741|Drug|Etoposide|administered intravenously
79373467|NCT01859741|Drug|Placebo|administered IV
79231348|NCT03239912|Other|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
79231349|NCT05476666|Procedure|Peripherial and central venous access|Passing a peripherial and a central venous catheter/cannula
79231350|NCT03875495|Drug|Temferon|Genetically modified autologous HSPCs
79373468|NCT01859741|Drug|Cisplatin or Carboplatin|administered intravenously
79373469|NCT01212952|Drug|pomalidomide|Given orally
79373470|NCT01212952|Drug|bortezomib|Given IV
79373471|NCT01212952|Drug|dexamethasone|Given orally
79373472|NCT01212952|Other|laboratory biomarker analysis|Optional correlative studies
79373473|NCT01212952|Other|gene expression analysis|Optional correlative studies
79231351|NCT03236558|Procedure|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
79373474|NCT05161182|Other|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
79373475|NCT05161182|Other|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
79826131|NCT04096066|Drug|Dexamethasone|"- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
79826132|NCT04085731|Procedure|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
79526961|NCT05154058|Procedure|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
79526962|NCT05154058|Procedure|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
79682771|NCT04972331|Procedure|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have < 1% blood cells and <1% white cells in the injection.
79682772|NCT04972331|Other|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
79682773|NCT02914665|Drug|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
79682774|NCT02914665|Drug|Placebo|Placebo administered intravenously once daily for 7 consecutive days
79826133|NCT04057352|Device|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
79999998|NCT06229223|Behavioral|PALOMA|Partnering with Parents of Adolescent Latinos on Mental Health Assistance
79999999|NCT06228703|Device|High-flow nasal cannula device with flow setting at 40 L/min or higher|Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
79373476|NCT04609865|Drug|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
79373477|NCT04609865|Drug|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
79526963|NCT05140551|Device|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
79526964|NCT05129098|Device|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath
79231352|NCT05160467|Diagnostic Test|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
79526965|NCT05129098|Device|Right ventricular active fixation lead|Active fixation lead (standard)
79526966|NCT05082649|Other|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
79682775|NCT04927169|Drug|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
79682776|NCT04927169|Drug|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
79682777|NCT02914626|Drug|Intravitreal ranibizumab|Intravitreal ranibizumab injection
79682778|NCT02918331|Drug|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
79709817|NCT05034952|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
80000000|NCT06228560|Biological|LP-003|Liquid in vial
80000001|NCT06228560|Biological|Placebo|Liquid in vial
79231353|NCT02453204|Behavioral|Sitting|
79231354|NCT02453204|Behavioral|Standing|
79231355|NCT02453204|Behavioral|Walking|
79231356|NCT05160389|Drug|PBI-200|Single dose of PBI-200
79231357|NCT03246386|Drug|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
79231358|NCT03246386|Drug|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
79231359|NCT03851081|Biological|Inotuzumab Ozogamicin|Given IV
80000002|NCT06228560|Biological|Omalizumab|Liquid in vial
79231360|NCT03851081|Other|Quality-of-Life Assessment|Ancillary studies
79231361|NCT03851081|Drug|Vincristine Sulfate Liposome|Given IV
79526967|NCT05082649|Other|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
79682779|NCT02918331|Drug|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
79373478|NCT04608695|Procedure|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
79373479|NCT01229722|Device|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
80000003|NCT06228248|Other|metagenomics|Feces used for metagenomic testing
79231362|NCT03239756|Biological|TK006|Subcutaneous injection
79231363|NCT05156645|Drug|SCTA01 and SCTA01C|Diluted by 0.9% normal saline
79231364|NCT05156645|Drug|Placebo|Diluted by 0.9% normal saline
79231365|NCT03239834|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
79231366|NCT05130671|Drug|Standard of care|Standard of care treatment as per the hospital guidelines
79231367|NCT05130671|Dietary Supplement|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
79231368|NCT05112419|Drug|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
79231369|NCT03246308|Radiation|Phototherapy|Taking blood sample.
79231370|NCT03235388|Other|Audit filters|Institutional implementation of audit filters
79231371|NCT03239600|Drug|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
79231372|NCT03239600|Drug|Placebo|Placebo solution will be administered by IV infusion.
79231373|NCT03239600|Drug|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
79373480|NCT01229722|Device|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
79390986|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
79526968|NCT05073809|Diagnostic Test|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
79682780|NCT02918331|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
79682781|NCT02918058|Other|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
79682782|NCT03457961|Drug|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
79682783|NCT02914587|Device|ARTAS System|
79682784|NCT02914587|Other|Manual Implantation|
80000004|NCT06228157|Behavioral|Routine therapy|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
80000005|NCT06228157|Procedure|Stellate ganglion block|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
80000006|NCT06227780|Other|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
80000007|NCT06227780|Other|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
80000008|NCT06226818|Other|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
79682785|NCT02938715|Other|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
79682786|NCT02914431|Device|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
79682787|NCT02918136|Biological|Adipose derived regenerative cells|
79682788|NCT02918136|Drug|Cortisone Injectable|
79231374|NCT03234998|Device|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
79231375|NCT03234998|Device|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
79373481|NCT01859507|Drug|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
79526969|NCT05066347|Device|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
79682789|NCT01294462|Drug|Ticagrelor|90 mg, oral dose twice daily
79682790|NCT01294462|Drug|Clopidogrel|75 mg, oral dose once daily
79682791|NCT01294462|Drug|Acetylsalicylic acid ASA|Low Dose ASA
79682792|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
79682793|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
80000009|NCT06225713|Device|focused power ultrasound mediated inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
80000010|NCT06225713|Device|sham-control group|Participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
80000011|NCT06225648|Other|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
79373482|NCT01140594|Procedure|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
79682794|NCT01294423|Drug|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
79682795|NCT02918175|Behavioral|mHealth|Personalized step count feedback and medication teaching tool.
79682796|NCT02914353|Drug|EP=7041|Factor X!a Inhibitor
79682797|NCT02914353|Drug|Placebo|Normal Saline
79682798|NCT02938598|Behavioral|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
79682799|NCT02914197|Other|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
79682800|NCT02938832|Behavioral|Advice on what food to choose and eat|Dietary advice
79682801|NCT02910570|Drug|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
79709818|NCT00596037|Drug|Growth hormone - LB03002|
79709819|NCT02272322|Device|cystocele repair with biomesh soft prolaps and endofast reliant|
79373483|NCT01140594|Procedure|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
79373484|NCT03442140|Other|Harmonica playing|Patients will play the harmonica for up to 6 months
79526970|NCT05062343|Device|Dilapan-S|Osmotic dilator
79526971|NCT05062343|Device|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
79526972|NCT05048212|Drug|Nivolumab|Given by IV
79526973|NCT05048212|Drug|Ipilimumab|Given by IV
79526974|NCT05048212|Drug|Cabozantinib|Given by IV
80000012|NCT06225115|Drug|KYN-5356|KYN-5356, oral tablet
79305605|NCT03240107|Procedure|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
79826134|NCT04037787|Procedure|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
79826135|NCT04022590|Device|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
80000013|NCT06225115|Drug|placebo|placebo, oral tablet
79826136|NCT04022590|Behavioral|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
79373485|NCT04608227|Device|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
79373486|NCT03442062|Other|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
79526975|NCT05046964|Device|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
79526976|NCT05025280|Other|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
79526977|NCT05020821|Procedure|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
79526978|NCT05020821|Procedure|Continuous superior trunk block|During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
80000014|NCT06223971|Drug|[11C]CPPC Injection|"A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide]"
80000015|NCT06223971|Drug|[11C]CPPC Injection|"A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide]"
80000016|NCT06223360|Drug|Low Dose Benfotiamine|300mg benfotiamine capsules (BID, twice a day)
80000017|NCT06223360|Drug|High Dose Benfotiamine|600mg benfotiamine capsules (BID, twice a day)
80000018|NCT06223360|Drug|Placebo|Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
80000019|NCT06222099|Device|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
79305606|NCT03240107|Procedure|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
79526984|NCT05010265|Other|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
79682802|NCT02910570|Drug|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
79682803|NCT02910453|Procedure|Pulmonary lobectomy|
79682804|NCT02938754|Behavioral|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
79682805|NCT02938754|Behavioral|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
79682806|NCT02938364|Other|Earplugs|Plastic earplugs on both ears
79826137|NCT04018391|Behavioral|Stepped care for nonadherence and depression|"Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
80000020|NCT06222099|Other|Standard care|Remote patient monitoring companies in regular contact with patients as per their standard operating procedures. (RPMC do not receive measurement data from the Heartfelt device, but will get any other data they collect via their usual methods e.g. remotely monitored weight data)
79373487|NCT03442062|Other|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
79526985|NCT05010265|Other|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
79526986|NCT05007873|Drug|Dasatinib|Given PO
79526987|NCT05007873|Drug|Decitabine and Cedazuridine|Given PO
79682807|NCT02938364|Other|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
79682808|NCT02938364|Other|Placebo|Non pressure bands put on the wrists of the participant
79682809|NCT01294150|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
79826138|NCT04018391|Other|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
79826139|NCT04016870|Device|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
79826140|NCT04016870|Device|New Pacemaker|Devices from the four manufacturers below will be used.
80000021|NCT06222099|Device|Direct-to-patient alerts|The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts).
80000022|NCT06222099|Device|RPMC care|The RPMC receives measurement data and alert data from the device.
80000023|NCT06222099|Other|Questionnaires|Patients were presented with one or more optional questionnaires (some validated, some bespoke)
80000024|NCT06220864|Drug|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
80000025|NCT06218823|Drug|Transdermal Nicotine Patch|a stop smoking aid, 21 milligrams(mg), 14mg, or 7mg of nicotine delivered over 24 hours
80000026|NCT06218823|Behavioral|Standard Telephone Counseling|3 brief telephone-based smoking cessation counseling sessions
80000027|NCT06218823|Drug|Varenicline|12 weeks of an oral smoking cessation medication
80000028|NCT06218823|Behavioral|Cancer-Targeted Telephone Counseling|7 telephone-based smoking cessation counseling sessions adapted for cancer patients
80000029|NCT06218823|Other|Mailed Information about Standard Care Resources|Publicly funded treatment resources including the SmokefreeTXT program sponsored by the National Cancer Institute and the Wisconsin Tobacco Quit Line.
80000030|NCT06210035|Behavioral|Belly-focus meditation|Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
79231376|NCT03628547|Behavioral|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
79231377|NCT02966093|Drug|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
79526988|NCT05005910|Drug|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
79373488|NCT03442062|Other|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
79390987|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
79526989|NCT05005910|Drug|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
79526990|NCT05004285|Drug|[F-18]Florastamin|A single dose of [F-18]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and [F-18]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
79526991|NCT04983901|Drug|Cefepime|Given IV
79526992|NCT04983901|Drug|Imipenem/cilastatin-relebactam|Given IV
79526993|NCT04983901|Drug|Daptomycin|Given IV
79682810|NCT01294150|Other|Cystoscopy|The Control Group will undergo cystoscopy.
79682811|NCT01294150|Device|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
79826141|NCT04010357|Drug|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
79373489|NCT01876043|Drug|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~Stage 1(17 participants): if <=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~Stage 2 (37 participants): if >= 11 non-progressions, Aplidin was considered promising."
79526994|NCT04983901|Drug|Linezolid|Given IV or PO
79373490|NCT01875731|Behavioral|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
79373491|NCT01875731|Behavioral|Guideline|Strategy based on enforced guideline guided antibiotic use
79826142|NCT03990610|Procedure|Mammoplasty|Undergo standard of care breast reconstructive surgery
79826143|NCT03990610|Procedure|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
79826144|NCT03985527|Device|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
79826145|NCT03976258|Drug|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
80000031|NCT06210035|Behavioral|Belly-focus meditation with slow breathing|Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
79682812|NCT04324216|Other|3D virtual reality and hands-on aromatherapy|Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
79682813|NCT02938208|Device|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
79682814|NCT04832516|Other|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
80000032|NCT06204302|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using Komodo Research Database (KRD)
80000033|NCT06204302|Drug|Enzalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
80000034|NCT06204302|Drug|Apalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
79373492|NCT03129204|Behavioral|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
79373493|NCT03441828|Procedure|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
79373494|NCT03441828|Drug|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
79526995|NCT04983901|Drug|Meropenem|Given IV
79526996|NCT04983901|Drug|Piperacillin-Tazobactam|Given IV
79682815|NCT04832516|Other|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
79682816|NCT02910141|Device|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
79682817|NCT04817072|Other|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
79682818|NCT02910336|Other|Quantitative Sensory Testing|sensory testing profile
79682819|NCT04817033|Procedure|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
79526997|NCT04983901|Drug|Vancomycin|Given IV
79526998|NCT04983199|Device|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
79526999|NCT04980404|Drug|Inqovi|Tablet combination of drugs decitabine and cedazuridine, given orally.
79527000|NCT04957992|Other|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
79527001|NCT04957992|Other|Control Toddler Drink|~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
79682820|NCT04817033|Procedure|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
79682821|NCT04817033|Drug|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
79682822|NCT04817033|Drug|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
79231378|NCT02966093|Drug|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
79373495|NCT03441828|Drug|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
79373496|NCT03446430|Device|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
79373497|NCT04891614|Device|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
79527002|NCT04957992|Other|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
79682823|NCT01292473|Drug|Placebo|Placebo was supplied lyophilized in vials.
79682824|NCT01292473|Drug|Omalizumab|Omalizumab was supplied lyophilized in vials.
79231379|NCT03229616|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
79231380|NCT03229616|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79231381|NCT03229616|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
79231382|NCT03058991|Behavioral|Distress Tolerance Intervention|See arm/group description.
79373498|NCT01873859|Drug|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
79527003|NCT04957992|Other|Experimental Toddler Drink|~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
79682825|NCT03026049|Device|deep venous stenting|Deep venous stent
79682826|NCT03457883|Device|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
79826146|NCT03976258|Drug|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
79826147|NCT03976258|Drug|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
79527004|NCT04957992|Other|Human Milk|Ad libitum or as instructed by HCP
79527005|NCT04957992|Other|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
79527006|NCT04957992|Other|Human Milk Toddler Drink|~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
79527007|NCT04956575|Biological|mRNA-1010|Sterile liquid for injection
79527008|NCT04956575|Biological|Placebo|0.9% sodium chloride solution for injection
79527009|NCT04956575|Biological|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
80000035|NCT06201754|Other|Measure air quality|Measure air quality, including PM2.5、PM10
79373499|NCT03446274|Drug|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
79373500|NCT00493896|Drug|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
79373501|NCT00493896|Drug|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
79373502|NCT00388908|Behavioral|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
79527010|NCT04949087|Procedure|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
79682827|NCT03457883|Device|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
79826148|NCT03976258|Drug|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
79826149|NCT03953690|Other|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
79826150|NCT03909165|Drug|Sugammadex 2 mg/kg|For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.
79231383|NCT03058991|Behavioral|Working Memory Intervention|See arm/group description.
79231384|NCT03058991|Behavioral|Control Informational Intervention|See arm/group description.
79231385|NCT03234920|Dietary Supplement|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
79231386|NCT03234920|Other|Placebo|The placebo will be 200 ml of fruit juice given twice daily
79231387|NCT03236090|Dietary Supplement|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
79373503|NCT00388908|Other|Usual Care|
79527011|NCT04948294|Device|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
79527012|NCT04948294|Device|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
79527013|NCT04942379|Other|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
79527014|NCT04942379|Other|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
79682828|NCT02938247|Dietary Supplement|High caloric, high protein ONS|
79709820|NCT04310371|Behavioral|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
79826151|NCT03909165|Drug|Sugammadex 4 mg/kg|For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
79231388|NCT03229460|Other|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
79682829|NCT02914002|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
79682830|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
79826152|NCT03909165|Drug|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
79231389|NCT03229460|Device|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
79231390|NCT03229460|Device|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
79231391|NCT02744651|Device|EUS-FNA|"Please note the text in section Arm description"
79527017|NCT04925414|Drug|oxygenotherapy|High concentration mask delivering 15L/min of oxygen
79527018|NCT04925414|Drug|placebo air aerosol|High concentration mask delivering 15L/min of air
79527019|NCT04920708|Drug|Ipatasertib 300mg|Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
79527020|NCT04920708|Drug|Fulvestrant 500g|Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
79527021|NCT04920708|Drug|Palbociclib 75mg-125mg|Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
79682831|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
79682832|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
79682833|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
79682834|NCT02938286|Device|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
79682835|NCT02938286|Drug|AHES|Topical application at test region I-IV under occlusion for 15 minutes
79826153|NCT03909165|Drug|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
79826154|NCT03906331|Drug|Selpercatinib|Open-label expanded access
79231392|NCT02744651|Device|EUS-Endodrill biopsy|"Please note the text in section Arm description"
79682836|NCT02913963|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
79231393|NCT03229304|Other||
79231394|NCT03234764|Other|Immunotherapy|
79231395|NCT03234842|Radiation|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
79231396|NCT03234842|Radiation|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
79527022|NCT04920708|Drug|CDK4/6 Inhibitor|CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
79527023|NCT04904796|Other|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
79527024|NCT04904796|Other|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
79527025|NCT04895111|Diagnostic Test|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
79527026|NCT04889274|Biological|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
79527027|NCT04889274|Biological|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
79527028|NCT04889274|Biological|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
79826155|NCT03876808|Device|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
79682837|NCT02913963|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
79527029|NCT04843683|Radiation|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
79682838|NCT01292239|Drug|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
79682839|NCT01292239|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
79826156|NCT03876808|Device|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
79527030|NCT04832698|Other|Survey Administration|Complete survey
79231397|NCT03234842|Drug|Chemotherapy|Concurrent weekly chemotherapy at standard doses
79231398|NCT03229070|Other|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
79231399|NCT03229070|Other|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
79231400|NCT03229226|Other|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
79527031|NCT04812015|Device|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
79527032|NCT04812015|Device|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
79527033|NCT04812015|Device|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
79527034|NCT04812015|Device|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
79826157|NCT03858205|Other|Quality-of-Life Assessment|Ancillary studies
79231401|NCT03229148|Procedure|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
79231402|NCT03229148|Procedure|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
79305607|NCT03057561|Drug|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
79527035|NCT04812015|Device|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
79527036|NCT04812015|Device|taVNS 0 minutes|Sham taVNS 75 minutes
79682840|NCT01292239|Drug|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
79682841|NCT01292239|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
79682842|NCT02938091|Other|High-fat diet|Typical Western diet
79682843|NCT02938091|Other|Low-fat diet|Traditional Caribbean Hispanic diet
79682844|NCT01291225|Other|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
79826158|NCT03858205|Other|Questionnaire Administration|Ancillary studies
79826159|NCT03858205|Radiation|Radiation Therapy|Receive low-dose radiation therapy
79826160|NCT03844828|Device|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
79527037|NCT04811040|Drug|Oral Lenacapavir|Tablets administered without regard to food
79527038|NCT04811040|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
79527039|NCT04811040|Drug|Teropavimab|Administered intravenously
79527040|NCT04811040|Drug|Zinlirvimab|Administered intravenously
79527041|NCT04808479|Behavioral|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
79527042|NCT04808479|Behavioral|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
79527043|NCT04803006|Biological|TCD601|Investigational Product
79527044|NCT04799587|Other|Magnet at P6|Magnet applied at P6 and attached with adhesive tape. The P6 pressure point is 2 inches proximal to the flexor retinaculum, between the flexor carpi radialis and palmaras longus.
79826161|NCT03826030|Device|Sham|sham group receives no active current stimulation except 15 seconds of current ramp up in the beginning and 15 seconds of current ramp up in the end of the 30-minute session to create a scalp perception to blind the subject.
79826162|NCT03826030|Device|Low dose tDCS|The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
79826163|NCT03826030|Device|High dose tDCS|The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
79826164|NCT03826030|Behavioral|mCIMT|All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
79826165|NCT03808454|Drug|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
79826166|NCT03808454|Other|Rehabilitation|strengthening ex, posture training,...
79826167|NCT03808454|Combination Product|PRP+Rehabilitation|combine PRP and Rehabilitation
79826168|NCT03784443|Drug|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
79826169|NCT03784443|Drug|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
79231403|NCT04485962|Biological|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
79231404|NCT03228992|Drug|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
79231405|NCT03228992|Other|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
79231406|NCT03234452|Dietary Supplement|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
79231407|NCT03234452|Dietary Supplement|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
79231408|NCT00700310|Drug|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
79231409|NCT00700310|Drug|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
79373504|NCT04288674|Other|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
79527045|NCT04799587|Other|Magnet applied to arm not at P6 pressure point.|Magnet applied to arm not at P6 pressure point and affixed with adhesive tape.
79527046|NCT04796896|Biological|mRNA-1273|Sterile liquid for injection
79682845|NCT01291225|Behavioral|Educational campaign|Educational materials will be developed and distributed in Ross County.
79682846|NCT02909985|Other|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
79682847|NCT02909985|Other|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
79682848|NCT02909985|Other|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
79682849|NCT02937974|Drug|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
79682850|NCT02937974|Drug|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
79682851|NCT05600179|Drug|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
79709821|NCT02881372|Other|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
79826170|NCT03784443|Procedure|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
79231410|NCT00700310|Drug|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
79231411|NCT00700310|Drug|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
79231412|NCT02452502|Device|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
79231413|NCT03228524|Drug|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
79231414|NCT03228524|Behavioral|Therapeutic exercise|Standard physiotherapy
79231415|NCT03228524|Drug|Placebo Oral Tablet|Placebo
79231416|NCT03234296|Drug|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
79231417|NCT03234296|Other|Placebo|Intravenous placebo followed by per oral placebo
79373505|NCT04288674|Other|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
79373506|NCT04288674|Other|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
79390988|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
79390989|NCT02430714|Drug|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
79527047|NCT04796896|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79527048|NCT04796896|Biological|mRNA-1273.214|Sterile liquid for injection
79231418|NCT03234140|Genetic|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
79373507|NCT04884438|Behavioral|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~Psychoeducation about gratitude and its effects on health (both physical and psychological).~Gratitude towards life:~Gratitude walk~Three positive things~Sharing gratitude~Social gratitude:~Daily thanks to others~Gratitude letter~Proof of gratitude~Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~Gratitude for the things I do to take care of my physical health.~Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~Gratitude for what I do to take care of others."
79527049|NCT04789720|Behavioral|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
79527050|NCT04777305|Other|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
79527051|NCT04774471|Diagnostic Test|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
79527052|NCT04732065|Drug|ONC206|Given orally (PO)
79527053|NCT04732065|Radiation|Standard of Care Radiation Therapy|Undergo RT
79527054|NCT04723862|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
79527055|NCT04723862|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
79682852|NCT01290796|Device|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
79682853|NCT02937662|Drug|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
79682854|NCT02937662|Drug|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
79682855|NCT02937662|Drug|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
79682856|NCT02937662|Drug|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
79682857|NCT02909946|Behavioral|Multi-modal Infection Control Program|"Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~Hand hygiene education to residents and families (resident-level intervention).~Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
79682858|NCT01290757|Drug|Dabigatran etexilate|150 mg Capsugel (T)
79682859|NCT01290757|Drug|Dabigatran etexilate|150 mg Qualicaps (R)
79231419|NCT03234140|Genetic|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
79231420|NCT02509325|Device|Parkinson's Kinetigraph|
79231421|NCT03228368|Drug|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
79231422|NCT05095805|Behavioral|additional weight-bearing exercise|Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
79231423|NCT05095805|Behavioral|standard weight-bearing exercise|conventional training for fitting of initial prosthesis
79231424|NCT03228758|Procedure|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
79373508|NCT03450486|Other|exercise|one 30 minute bout of mild exercise
79527056|NCT04720105|Drug|Duobrii®|Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
79527057|NCT04693234|Drug|Tislelizumab|Administered as specified in the treatment arm
79231425|NCT03228446|Behavioral|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
79231426|NCT03228446|Behavioral|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
79231427|NCT03228446|Other|no training (control)|no training applied
79231428|NCT05042765|Other|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
79231429|NCT03235466|Behavioral|Voice Therapy|See Arm 1 & 2
79231430|NCT03235466|Behavioral|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 & 3
79682860|NCT02937857|Drug|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
79826171|NCT03777709|Behavioral|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
79826172|NCT03768336|Other|Waitlist control|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
79826173|NCT03768336|Other|3RP-AYA|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
79826174|NCT03742141|Device|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
79826175|NCT03742141|Drug|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
79527058|NCT04693234|Drug|Ociperlimab|Administered as specified in the treatment arm
79231431|NCT03235466|Behavioral|Heart Rate Variability Biofeedback|See Arm 2 & 3
79231432|NCT03665129|Biological|IPH5401 and Durvalumab|IPH5401 and durvalumab
79231433|NCT03235622|Diagnostic Test|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
79373509|NCT03441672|Behavioral|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
79373510|NCT03449940|Procedure|Immediate repair|
79527059|NCT04664179|Biological|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10^7 cells/m2
79527060|NCT04664179|Biological|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10^7 cells/m2
79527061|NCT04664179|Biological|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10^7 cells/m2
79682861|NCT02937857|Drug|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
79682862|NCT04324060|Drug|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased >50×10e9/L, total course is 6 months
79682863|NCT04324060|Drug|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
79682864|NCT01290718|Drug|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
79682865|NCT01290718|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
79682866|NCT02937935|Biological|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
79231434|NCT03235700|Other|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
79231435|NCT03235700|Other|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
79231436|NCT03234062|Other|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
79231437|NCT03234062|Other|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
79305608|NCT03057561|Drug|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
79373511|NCT03449940|Procedure|Delayed repair|
79373512|NCT03449940|Drug|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
79373513|NCT03449940|Drug|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
79373514|NCT03449940|Drug|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
79373515|NCT03449862|Other|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
79373516|NCT04452240|Device|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
79527062|NCT04664179|Biological|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10^8 cells/m2
79527063|NCT04664179|Biological|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10^8 cells/m2
79527064|NCT04649177|Device|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
79527065|NCT04594278|Behavioral|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
79527066|NCT04585542|Drug|Polyethylene Glycol 3350|Nonspecific laxative comparison group.
79527067|NCT04585542|Drug|Sodium Polystyrene Sulfonate Oral Suspension [SPS]|Potassium binder to treat hyperkalemia.
79527068|NCT04585542|Drug|Patiromer|Potassium binder to treat hyperkalemia.
79527069|NCT04585542|Drug|Sodium zirconium cyclosilicate|Potassium binder to treat hyperkalemia.
79682867|NCT02937935|Biological|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
79682868|NCT04688424|Device|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
79826176|NCT03687060|Behavioral|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
79826177|NCT03687060|Behavioral|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
79373517|NCT03446196|Device|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
79826178|NCT03687060|Behavioral|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
79826179|NCT03663777|Other|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
79826180|NCT03663777|Other|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
79373518|NCT03441516|Drug|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
79373519|NCT03441516|Drug|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
79373520|NCT03445962|Diagnostic Test|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~Anthropometric evaluation~biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~rest electrocardiogram~motor assessment (strenght, flexibility and balance)~actigraphy~Autonomic nervous system assessment during sleep~Autonomic nervous system assessment during head up tilt test before and after physical exercise~maximal treadmill test (VO2 max measure)~polysomnography~seismocardiography~questionnaires :sleep and physical activity"
79373521|NCT03445884|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV.
79373522|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
79373523|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
79373524|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
79373525|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
79373526|NCT03441438|Dietary Supplement|Water|Serum and urine markers will be obtained after drinking 5 oz of water
79373527|NCT03441438|Dietary Supplement|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
79231438|NCT03234062|Other|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
79373528|NCT03441438|Dietary Supplement|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
79231439|NCT03233984|Behavioral|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
79231440|NCT04882631|Drug|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
79231441|NCT04882631|Drug|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
79231442|NCT04882631|Other|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
79231443|NCT04882631|Other|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
79231444|NCT03235778|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
79231445|NCT03235778|Drug|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
79231446|NCT04439513|Device|Hemostasis|Compression device to achieve hemostasis.
79231447|NCT03233906|Dietary Supplement|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
79682869|NCT04688424|Other|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
79231448|NCT02452970|Drug|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
79373529|NCT01857869|Biological|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
79682870|NCT02937896|Drug|Desmopressin|40 micrograms Nasal Desmopressin.
79682871|NCT02937896|Drug|Ketorolac|30mg intravenous Ketorolac.
79527070|NCT04585334|Drug|Tricortin 1000|Tricortin 1000 [2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
79527071|NCT04585334|Drug|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
79682872|NCT02937896|Drug|Normal Saline|1cc intravenous Normal Saline.
80000036|NCT06199349|Drug|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
79231449|NCT02452970|Drug|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
79231450|NCT04302077|Other|virtual doctor visit|interactive live-video feed at home through EPIC
79682873|NCT02937896|Drug|Normal Saline|4 puffs nasal Normal Saline.
79682874|NCT02937779|Drug|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
79682875|NCT02937779|Device|Rapid tests HBe Ag|For all HBs Ag positive women
79709822|NCT04326855|Other|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
79231451|NCT04302077|Other|Standard care doctor's visit|In person visit as per standard of care
79231452|NCT03233672|Radiation|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
79231453|NCT04854941|Other|Probiotics|Probiotics (10^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
79231454|NCT03227900|Drug|Lidocaine|Intragastric infusion of lidocain
79231455|NCT03227900|Drug|Placebos|Intragastric infusion of water for injections
79231456|NCT03227978|Combination Product|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
79231457|NCT03227744|Behavioral|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
79231458|NCT03227744|Other|Surveys|MAX-PC, GAD and FACT-P
79231459|NCT03227822|Procedure|Short spot stenting|
79231460|NCT03227822|Procedure|Long lesion stenting|
79231461|NCT02452736|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
79231462|NCT03120104|Other|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
79231463|NCT03120104|Other|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just two weeks after the stoma closure
79231464|NCT03120182|Drug|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
79231465|NCT03120182|Drug|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
79373530|NCT01857869|Biological|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
79390990|NCT02425254|Drug|Intravenous paracetamol|1000mg intravenous solution for infusion
79390991|NCT02425254|Drug|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
79390992|NCT02424942|Drug|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
79390993|NCT02424942|Drug|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
79390994|NCT02426736|Drug|Dexamethasone|
79826181|NCT03583073|Behavioral|Enhanced Referral/Linkage to Care|"The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment."
79826182|NCT03583073|Behavioral|Standard Care|Referral to the Coordinated Specialty Care (CSC) clinic
79826183|NCT03531814|Behavioral|Medication Event Monitoring System (MEMS)|A computerized method of tracking the dates and times of a pill bottle being opened.
79826184|NCT03512223|Drug|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
79826185|NCT03502668|Drug|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
79826186|NCT03502668|Drug|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
79826187|NCT03481075|Other|Biomechanical computer program|Fusion assisting software for image-guided intervention
79826188|NCT03474458|Drug|Doxycycline|Doxycycline
80000037|NCT06199349|Other|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
80000038|NCT06197243|Other|Acupuncture|Patients will receive acupuncture for 12 weeks.
79527072|NCT04585334|Drug|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
79826189|NCT03474458|Drug|Standard of care therapy|Standard of care therapy
79826190|NCT03452319|Other|Pretraining|Increased physical activity, and daily strength training and breathing exercises.
79231466|NCT02074436|Drug|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
80000039|NCT06197243|Other|Yoga|Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.
79231467|NCT02074436|Other|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
79231468|NCT01575548|Drug|Pazopanib|Given PO
79231469|NCT01575548|Other|Placebo Administration|Given PO
79527073|NCT04574960|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
79527074|NCT04574960|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
79527075|NCT04574960|Drug|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
79826191|NCT03452319|Other|Usual care|Preoperative information
79826192|NCT03386500|Drug|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
79527076|NCT04574947|Drug|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
79826193|NCT03369405|Other|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
80000040|NCT06197243|Other|Deprescribing|Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.
80000041|NCT06196528|Device|WristArt implant|implantation of the WristArt implant
80000042|NCT06194318|Biological|Candidate vaccine, SCB-1019|The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
80000043|NCT06194318|Biological|placebo|placebo
80000044|NCT06190093|Biological|bevacizumab|1.25 mg, intravitreal injection
80000045|NCT06190093|Biological|ranibizumab|0.5mg, intravitreal injection
80000046|NCT06184126|Device|Virtual Reality Headset and Hand-Held Controllers|Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.
79231470|NCT03233282|Other|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
79390995|NCT02426736|Drug|Bupivacaine|
79390996|NCT02426736|Procedure|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
79390997|NCT03183180|Diagnostic Test|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
79390998|NCT03182634|Drug|Fulvestrant|
79390999|NCT03182634|Drug|Neratinib|
79391000|NCT03182634|Drug|AZD5363|
79391001|NCT03182634|Drug|Olaparib|
79391002|NCT03182634|Drug|AZD6738|
79391003|NCT03185676|Other|Bilberry|A bilberry based probiotic beverage
79391004|NCT03185676|Other|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
79527077|NCT04574947|Drug|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
79527078|NCT04574947|Procedure|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
79826194|NCT03329976|Other|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
79826195|NCT03301363|Device|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
79826196|NCT03226418|Drug|Cytarabine|Given IV
79231471|NCT03233282|Other|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
79373531|NCT01857869|Procedure|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
79373532|NCT01230424|Drug|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
79373533|NCT01230424|Drug|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
79373534|NCT02521428|Other|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
79373535|NCT01230502|Drug|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
79826197|NCT03226418|Drug|Decitabine|Given IV
79527079|NCT04574947|Procedure|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
79527080|NCT04573309|Drug|ALXN1840|Administered orally as tablets.
79826198|NCT03226418|Drug|Idarubicin|Given IV
79826199|NCT03226418|Other|Laboratory Biomarker Analysis|Correlative studies
79826200|NCT03226418|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79826201|NCT03226418|Other|Quality-of-Life Assessment|Ancillary studies
79231472|NCT03233282|Other|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
79231473|NCT03233282|Other|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
79527081|NCT04571541|Device|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
79527082|NCT04554693|Drug|Metronidazole Oral|250 mg oral three times a day for 14 days
79527083|NCT04554693|Drug|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
79826202|NCT03226418|Other|Questionnaire Administration|Ancillary studies
79826203|NCT03226418|Drug|Azacitidine|Given by infusion
79826204|NCT03226418|Drug|Venetoclax|oral tablet
79231474|NCT03233282|Other|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
79527084|NCT04511845|Drug|SPYK04|SPYK04 capsule
79527085|NCT04507568|Other|Quality of Life Questionnaires|Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.
79826205|NCT03226418|Drug|glasdegib|oral tablet
79826206|NCT03169010|Other|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
79826207|NCT03169010|Genetic|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
79826208|NCT03165136|Drug|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
79826209|NCT03165136|Drug|Placebo|placebo of hydroxychloroquine
79826210|NCT03141437|Other|Best Practice|Receive standard of care
79826211|NCT03141437|Other|Educational Intervention|Receive educational materials
79826212|NCT03141437|Other|Internet-Based Intervention|Use decision-making website
79826213|NCT03141437|Other|Questionnaire Administration|Ancillary studies
79826214|NCT03115086|Drug|Cholbam|Cholbam prescribed according to the approved label.
79826215|NCT03106701|Procedure|Ablation|Epicardial Radiofrequency ablation
79826216|NCT03089268|Procedure|Colonoscopy|A colonoscopy will be performed to all individuals.
79826217|NCT03089268|Procedure|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
79826218|NCT03089268|Genetic|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
79826219|NCT03073785|Drug|Capecitabine|Given PO
79826220|NCT03073785|Drug|Fluorouracil|Given IV
79826221|NCT03073785|Other|Laboratory Biomarker Analysis|Correlative studies
79826222|NCT03073785|Other|Pharmacological Study|Correlative studies
79826223|NCT03073785|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
79826224|NCT03073785|Drug|Zoledronic Acid|Given IV
79826225|NCT03066648|Drug|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
79826226|NCT03066648|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
79826227|NCT03066648|Drug|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
79682876|NCT04688229|Device|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
80000047|NCT06184126|Other|Blindfolding and Noise Cancelling|Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
79231475|NCT03233282|Other|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
80000048|NCT06181123|Other|Cardiorespiratory Assesments|The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
79373536|NCT01230502|Other|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
79373537|NCT01230502|Other|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
79527086|NCT04488198|Other|Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
79527087|NCT04488198|Other|Placebo-Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
79826228|NCT03066648|Drug|Azacitidine|Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
79826229|NCT02968849|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose > 10^6 cell culture infectious dose 50% (CCIDv50) and < 1 × 10^8 CCIDv50 (nominal dose of 10^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
79826230|NCT02968849|Biological|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
79231476|NCT03233282|Other|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
79231477|NCT03233282|Other|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
79231478|NCT03233282|Other|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
79527088|NCT04475523|Drug|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
80000049|NCT06178588|Procedure|Biopsy|Undergo tumor biopsy
80000050|NCT06178588|Procedure|Biospecimen Collection|Undergo blood sample collection
80000051|NCT06178588|Procedure|Computed Tomography|Undergo PET/CT scan
80000052|NCT06178588|Procedure|Magnetic Resonance Imaging|Undergo MRI
80000053|NCT06178588|Procedure|Positron Emission Tomography|Undergo PET/CT
79231479|NCT03233282|Other|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
79305609|NCT03240029|Other|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
79527089|NCT04474925|Procedure|Brain Surgery|Surgery to remove brain metastases
79527090|NCT04474925|Radiation|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
79527091|NCT04473911|Drug|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
79527092|NCT04473911|Drug|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
79527093|NCT04473911|Radiation|TBI|Total body irradiation (TBI) once per cycle.
79527094|NCT04473911|Drug|Melphalan|Melphalan, infusion, determined dosage, once per cycle
79527095|NCT04473911|Drug|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
79373538|NCT03438240|Drug|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
79527096|NCT04473911|Drug|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
79527097|NCT04473911|Drug|RGI-2001|IV, predetermined dose, weekly to 6 total doses
79373539|NCT03438240|Drug|Fentanyl|Plus 50 µg fentanyl
79527098|NCT04473911|Drug|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
79527099|NCT04446312|Drug|Bowel Prep|Orally ingested liquid bowel preparation
79527100|NCT04439409|Device|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
79527101|NCT04410406|Drug|Ivermectin|Ivermectin (IVM) 200 µg/kg
80000054|NCT06178588|Biological|Sacituzumab Govitecan|Given IV
79527102|NCT04410406|Drug|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
79527103|NCT04410406|Drug|Albendazole|Albendazole (ABZ) 400 mg
79527104|NCT04410406|Drug|Moxidectin|Moxidectin (Mox) 8 mg
79527105|NCT04403074|Procedure|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
79527106|NCT04359888|Other|Multi-Component Exercise Training (MCET)|Three one-hour training sessions per week for six weeks in Multi-Component Exercise Training (MCET). (See Study Design)
79527107|NCT04359888|Other|Balanced Reach Training (BRT)|Three one-hour training sessions per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
79231480|NCT03233282|Other|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
79527108|NCT04350125|Biological|Autologous Platelet Rich Plasma|One 4-5mL platelet rich plasma injection administered to each side of the intracavernosal space on the right and left side of the corpus cavernosum at the base of the penis, every two weeks for 6 weeks.
79527109|NCT04342546|Device|NovaGray RILA Breast® test|The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
79231481|NCT02451722|Device|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
79231482|NCT02451644|Device|pedometer|patient will cary pedometer
79231483|NCT03222908|Behavioral|Intervention1: Contract Agreement|Smoking Cessation Contract
79231484|NCT03222908|Behavioral|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
79231485|NCT03228056|Diagnostic Test|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
79231486|NCT02452658|Other|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
79373540|NCT03438240|Drug|Dexmedetomidine|Plus 50 µg dexmedetomidine
79373541|NCT01160848|Drug|Area cleaned with saline water and occluded with Tegaderm|
79527112|NCT04323189|Drug|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
79231487|NCT03227666|Behavioral|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
79231488|NCT04486040|Procedure|Drainage|Use of the suction drainage after hip revision arthroplasty
79231489|NCT04486040|Procedure|No-drainage|Patients without drainage after surgery
79231490|NCT04485884|Drug|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
79231491|NCT04485884|Drug|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
79373542|NCT01160848|Drug|Area cleaned with saline water|
79373543|NCT01160848|Drug|Area cleaned with Ethyl alcohol solution|
79373544|NCT01160848|Drug|Visonac left on the skin for 24 hours in facial area one|
79373545|NCT01160848|Drug|Visonac wiped off after one hour|
79373546|NCT01160848|Drug|Visonac left on the skin 24 hours in facial area two|
79373547|NCT03445572|Other|Best Practice|Receive standard supportive care
79373548|NCT03445572|Procedure|Meditation Therapy|Perform MSB
79373549|NCT03445572|Procedure|Meditation Therapy|Perform IK meditation
79373550|NCT03445572|Other|Questionnaire Administration|Ancillary studies
79373551|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
79527113|NCT04323189|Drug|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
79527114|NCT04321330|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
79527115|NCT04287985|Drug|Dose-Placebo|Unit Dose Strength - 0.9%.
79527116|NCT04287985|Drug|Low Dose-VIS649|Dose Level = Low
79527117|NCT04287985|Drug|Medium Dose-VIS649|Dose Level = Medium
79527118|NCT04287985|Drug|High Dose-VIS649|Dose Level = High
79527119|NCT04270149|Biological|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
80000055|NCT06177912|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
79682877|NCT04688229|Other|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
79682878|NCT04688073|Behavioral|Exercise|Running
79682879|NCT04688073|Behavioral|Rest|sit and rest
79682880|NCT02937428|Behavioral|Look away from the needle|Participant looks away from the needle during vaccination
79682881|NCT02937428|Behavioral|Look at the needle|Participant looks at the needle during vaccination
79682882|NCT02909790|Device|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
79682883|NCT01290679|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
79682884|NCT01290679|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
79682885|NCT01290679|Drug|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
79682886|NCT01290679|Drug|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
80000056|NCT06177912|Biological|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
79682887|NCT03457389|Drug|Cabergoline|Cabergoline tablet
80000057|NCT06176196|Drug|VX-548|Tablets for oral administration.
79231492|NCT04485884|Drug|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
79231493|NCT04485884|Drug|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
79231494|NCT04485884|Drug|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
79373552|NCT01213576|Drug|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
80000058|NCT06176196|Drug|Placebo|Tablets for oral administration.
80000059|NCT06175312|Other|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
79231495|NCT04485884|Drug|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
79231496|NCT03227432|Drug|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
79231497|NCT03227432|Drug|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
79231498|NCT03227432|Drug|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
79231499|NCT03227432|Drug|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
79231500|NCT03222596|Behavioral|Exercise training|Exercise programme includes breathing and upper limbs exercises.
79373553|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
79373554|NCT01213576|Drug|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
79373555|NCT03445416|Behavioral|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
79373556|NCT03445416|Behavioral|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
79682888|NCT02937467|Device|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
79682889|NCT02937311|Other|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
79682890|NCT02937311|Other|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
79826231|NCT02968849|Biological|Placebo|Sodium Chloride for injection, 0.9% delivered IM
79826232|NCT02877394|Device|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
80000060|NCT06175312|Other|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
80000061|NCT06174220|Drug|Tideglusib|Tideglusib 1g po daily
80000062|NCT06174220|Drug|Placebo|Matching placebo 1g po daily
80000063|NCT06173323|Behavioral|ImPart - Improving Chronic Kidney Disease Decisional Partnerships|ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
79826233|NCT02877394|Device|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
79826234|NCT02796313|Behavioral|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
79826235|NCT02796313|Behavioral|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
79826236|NCT02795104|Behavioral|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
79527120|NCT04268914|Device|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
79527121|NCT04268914|Device|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
79682891|NCT02937311|Other|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
79231501|NCT03222674|Biological|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
79682892|NCT02890186|Device|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
79682893|NCT02890186|Other|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
79826237|NCT02795104|Behavioral|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
79826238|NCT02795104|Behavioral|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
79826239|NCT02766465|Drug|Busulfan|"A:~Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics."
79682894|NCT02909673|Behavioral|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
79682895|NCT02937233|Biological|Zika Virus Purified Inactivated Vaccine|
79826240|NCT02766465|Drug|Fludarabine|"A:~Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).~C:~Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4"
79826241|NCT02766465|Drug|r-ATG|"A:~r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg)."
79826242|NCT02766465|Procedure|Hematopoietic Cell Transplant|"A,B,C:~Day 0 is the day of transplantation."
79231502|NCT04485572|Diagnostic Test|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
79231503|NCT04485572|Diagnostic Test|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
79682896|NCT02937233|Other|Placebo|
79682897|NCT02909751|Drug|Epirubicin 90 mg/m2 iv|Max. 3 months
79826243|NCT02766465|Drug|Tacrolimus|"A:~Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.~C:~Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines"
79826244|NCT02766465|Drug|Methotrexate|"A:~Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant"
79826245|NCT02766465|Procedure|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
80000064|NCT06171178|Drug|ASP1012|Intravenous (IV) infusion
79231504|NCT04485572|Diagnostic Test|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
79682898|NCT02909751|Drug|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
80000065|NCT06171178|Drug|Pembrolizumab|IV infusion
80000066|NCT06166017|Other|Exposure to minimal amount of lingual keratinized tissue width|measurement of clinical parameters
80000067|NCT06161116|Biological|MK-6194|SC Injection
79682899|NCT02909751|Drug|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
79682900|NCT02909751|Drug|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
79682901|NCT02909751|Drug|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
79682902|NCT02909751|Dietary Supplement|Tocotrienol 300 mg x 3 daily|Max. 6 months
79682903|NCT02909829|Device|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
79682904|NCT02909829|Device|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
79682905|NCT02909829|Device|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
79826246|NCT02766465|Drug|Alemtuzumab|"B:~Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3~C:~Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days."
79826247|NCT02766465|Drug|Total Body Irradiation (TBI)|Total Body Irradiation 300 cGY on Day -2
79826248|NCT02766465|Drug|Sirolimus|Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ >50%
79826249|NCT02766465|Drug|Melphalan|"C:~Melphalan 140 mg/m2 IV dose will be given on Day -3"
79231505|NCT04485572|Diagnostic Test|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
80000068|NCT06161116|Biological|Placebo|SC Injection
80000069|NCT06159621|Drug|PD-1inhibitor - LVGN 3616|Administration of one dose of LVGN 3616 - 300mg
80000070|NCT06159621|Drug|CD 40 Agonist - LVGN 7409|Administration of one dose of LVGN 7409 - 1mg/kg
79682906|NCT02909712|Drug|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
80000071|NCT06157151|Biological|PRGN-2009 plus Pembrolizumab|Subjects randomized will receive PRGN-2009 (5 x 10^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
79682907|NCT02909712|Drug|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
80000072|NCT06157151|Drug|Pembrolizumab alone|Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
80000073|NCT06157008|Drug|General Anesthetics|General anesthetics used in spinal cord electrical stimulator insertion surgery
80000074|NCT06156072|Diagnostic Test|Ultrasound-guided venipuncture|Venipuncture will be performed using ultrasound to identify the most appropriate vessel and guide the puncture
80000075|NCT06155721|Device|Virtual Reality Cognitive Stimulation Program|Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
79231506|NCT04485572|Diagnostic Test|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
79231507|NCT03222518|Drug|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
79231508|NCT03222518|Drug|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
79682908|NCT02913885|Drug|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
79682909|NCT02913885|Drug|fluoride varnish|fluoride inhibit the progression of white spot lesion
79682910|NCT01290601|Drug|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
79682911|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
79826250|NCT02766465|Drug|G-CSF|G-CSF 5 μg/kg/day continue until neutrophil engraftment.
79231509|NCT03222518|Drug|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
79231510|NCT03222440|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
79682912|NCT01290601|Drug|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
79373557|NCT05088408|Dietary Supplement|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
79373558|NCT05088408|Other|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
79682913|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
79682914|NCT02978391|Device|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
79682915|NCT02978391|Drug|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
79682916|NCT01290523|Device|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
79682917|NCT02936882|Procedure|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
79682918|NCT01290094|Drug|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
79682919|NCT04324957|Other|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
79682920|NCT04688346|Drug|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
79682921|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
79682922|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
79682923|NCT04324333|Behavioral|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
79682924|NCT04688268|Drug|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
79682925|NCT02936726|Behavioral|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
79682926|NCT02936726|Behavioral|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
79682927|NCT02913846|Other|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
79682928|NCT02913846|Other|Muscular assessment|An assessment of muscular force will be performed once a week.
79682929|NCT02913846|Other|Pre-albumine dosage|Dosage performed once a month.
79682930|NCT04762589|Drug|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
79682931|NCT04762589|Drug|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
79682932|NCT01289821|Drug|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
79682933|NCT01289821|Drug|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m^2 oxaliplatin as a 2 hour i.v. infusion.
79231511|NCT03222206|Drug|Salsalate|"Medicate salsalate 2g/day after run-in period~Check side effect after 1 month and Control dosage (2g/day or 3g/day)~Check side effect after 2 month"
79682934|NCT01289821|Drug|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2 hour i.v. infusion.
79682935|NCT01289821|Drug|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m^2 5 FU 46 hour i.v. infusion.
79682936|NCT02913768|Drug|Ondansetron|
79231512|NCT03222206|Other|Placebo|"Medicate placebo 2g/day after run-in period~Check side effect after 1 month and Control dosage (2g/day or 3g/day)~Check side effect after 2 month"
79231513|NCT04484714|Behavioral|Exercise|Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
79231514|NCT03227588|Diagnostic Test|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
79231515|NCT03227276|Dietary Supplement|Litramine|2 tablets to be taken 3 times a day after meals
79682937|NCT02913768|Drug|Normal saline|
79682938|NCT03457844|Drug|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
79826251|NCT02749422|Diagnostic Test|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
79231516|NCT03227276|Dietary Supplement|Placebo tablet|2 tablets to be taken 3 times a day after meals
79231517|NCT03227354|Device|Vittamed 205|non-invasive Intracranial Pressure measurement
79231518|NCT04485650|Other|music therapy|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.
79373559|NCT03010774|Behavioral|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
79527122|NCT04268901|Device|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
79682939|NCT03457805|Device|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
79682940|NCT04690283|Drug|Mimetic granules of Yiqi-Wenjing prescriptions|The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
79682941|NCT04690283|Drug|Huangqi-Guizhi-Wuwu granules|The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
79682942|NCT04690283|Drug|Danggui-Sini granules|The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
79682943|NCT02913534|Radiation|whole brain radiotherapy|
79682944|NCT02936804|Device|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
79682945|NCT02913807|Procedure|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
79682946|NCT02913807|Procedure|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
79682947|NCT02936570|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
79682948|NCT01289782|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
79682949|NCT01289782|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
79682950|NCT01289782|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
79682951|NCT01289782|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
79231519|NCT04485650|Other|sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
79231520|NCT04485650|Other|non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
79231521|NCT03227120|Other|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
79231522|NCT03227198|Biological|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
79231523|NCT03227198|Biological|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
79231524|NCT03222284|Device|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
79231525|NCT03222362|Other|Surgery|
79231526|NCT02451566|Device|Ovation Prime Abdominal Stent Graft System|
79373560|NCT03010774|Behavioral|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
79527123|NCT04268901|Device|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
79682952|NCT02913417|Device|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
79231527|NCT03232970|Other|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
79373561|NCT04452630|Other|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
80000076|NCT06155149|Other|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
79231528|NCT04484792|Other|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
79231529|NCT04484792|Other|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
79373562|NCT04452318|Drug|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
79682953|NCT02913417|Drug|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
79826252|NCT02743455|Drug|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
79826253|NCT02743455|Biological|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
79373563|NCT04452318|Drug|Placebo|SC or IM injections
79373564|NCT01161160|Biological|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
79826254|NCT02743455|Biological|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
79231530|NCT04484792|Other|placebo|Plain water
79231531|NCT03222050|Other|Distraction technique|
79231532|NCT03221816|Drug|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
79231533|NCT03221816|Drug|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
79231534|NCT03221894|Dietary Supplement|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
79373565|NCT01161160|Biological|GSK Biologicals' - GSK2340272A|Intramuscular injection
79373566|NCT04621578|Device|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
79373567|NCT04573764|Dietary Supplement|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
79373568|NCT04573764|Dietary Supplement|Placebo|Taste-matched water
79373569|NCT04571190|Behavioral|Prenatal MBSR|Prenatal MBSR is an adaptation to the original MBSR program. The essential program elements characterizing MBSR is maintained and integrated with the particular context and specific needs of this group of pregnant women. Adaptations to the MBSR program draw upon both empirical data as well as existing research and theory.
79682954|NCT02913417|Drug|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
79682955|NCT02936492|Drug|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
79682956|NCT02936492|Drug|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
79682957|NCT02936492|Drug|BAY1003803 0.01% ointment|Topical administration for 22 h per day
79682958|NCT02936492|Drug|BAY1003803 0.1% ointment|Topical administration for 22 h per day
79826255|NCT02743455|Other|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
79682959|NCT02936492|Drug|Lipophilic cream vehicle|Topical administration for 22 h per day
79682960|NCT02936492|Drug|Ointment vehicle|Topical administration for 22 h per day
79826256|NCT02743455|Other|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
79826257|NCT02743455|Biological|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
79826258|NCT02716753|Biological|seminal plasma|
79826259|NCT02716753|Biological|Physiological NaCL solution|
79826260|NCT02675244|Procedure|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
79826261|NCT02675244|Procedure|MVS|MVS will be performed using standard surgical techniques
79826262|NCT02654210|Other|No Intervention|No Intervention
79373570|NCT03010618|Other|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
79373571|NCT03438162|Behavioral|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
79373572|NCT03010852|Behavioral|Focused incentive spirometer education and monitoring|
79682961|NCT02936492|Drug|Clobetasol propionate|Topical administration for 22 h per day
79682962|NCT02913573|Device|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
79682963|NCT02913573|Drug|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
79682964|NCT01289353|Drug|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
79682965|NCT01289353|Radiation|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
79682966|NCT02913651|Device|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
79682967|NCT02936414|Drug|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
79682968|NCT02936414|Drug|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
79826263|NCT02553447|Dietary Supplement|Cholecalciferol|Given PO
79826264|NCT02553447|Other|Laboratory Biomarker Analysis|Optional correlative studies
79826265|NCT02424188|Other|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
79826266|NCT02351791|Other|Patch 1|Patch 1:standard adhesive with own feces in sleeve
79826267|NCT02351791|Other|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
79826268|NCT02351791|Other|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
79826269|NCT02351791|Other|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
79826270|NCT02351791|Other|Patch 5|Patch 5:standard adhesive with buffer in sleeve
79826271|NCT02351791|Other|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
79826272|NCT02306174|Behavioral|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~A group agreement and a confidentiality contract~Homework assignments~Viewing informational videos about hoarding~Behavioral experiments including sorting and discarding exercises~Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
79826273|NCT02020707|Biological|Bevacizumab|Given IV
79826274|NCT02020707|Other|Laboratory Biomarker Analysis|Correlative studies
79826275|NCT02020707|Drug|Nab-paclitaxel|Given IV
79826276|NCT02020707|Other|Pharmacological Study|Correlative studies
79826277|NCT01814358|Dietary Supplement|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
79826278|NCT01814358|Dietary Supplement|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
79826279|NCT01714271|Behavioral|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
79826280|NCT01714271|Behavioral|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
79826281|NCT01683877|Procedure|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
79373573|NCT03438084|Dietary Supplement|Interesterified fat|50 g fat provided as commercially available interesterified fat.
79682969|NCT02913300|Drug|Lignocaine 1% concentration solution|
79682970|NCT02913300|Drug|Lignocaine 2% concentration solution|
79682971|NCT02936375|Drug|Iguratimod|25mg twice a day, orally administrated
79682972|NCT02936375|Drug|Cyclophosphamide|1g/m², every 4 weeks, intravenous
79682973|NCT02936375|Drug|Azathioprine|2mg/kg·d, once a day, orally administrated
79527124|NCT04268901|Device|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
79826282|NCT01683877|Procedure|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
79826283|NCT01632436|Drug|Pixantrone|Experimental Drug
79826284|NCT01594047|Drug|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
79682974|NCT02936375|Drug|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
79826285|NCT01594047|Drug|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
79826286|NCT01532609|Behavioral|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
79826287|NCT01519349|Biological|rAAV1.CMV.huFollistatin344|"First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
80000077|NCT06155149|Other|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
80000078|NCT06154265|Device|TEE probe|Transesophageal echocardiography, ultrasound probe
80000079|NCT06153290|Procedure|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
80000080|NCT06153290|Procedure|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
80000081|NCT06153199|Behavioral|Video training - Self-management|Short video modules on self-management of back pain without medication
80000082|NCT06153199|Behavioral|Video training - Ergonomics|Short video module on ergonomic adjustment for limiting back pain in nursery and landscape work
79682975|NCT02913690|Dietary Supplement|Placebo|2 x 150mg capsules daily
79231535|NCT03226964|Device|high flow nasal oxygen|humidified high flow nasal oxygen
79231536|NCT03119870|Other|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
79826288|NCT01496313|Drug|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
79305610|NCT04935567|Other|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
79682976|NCT02913690|Dietary Supplement|TRF|2 x 150mg capsules daily
79682977|NCT01289119|Drug|Alogliptin|Alogliptin tablets
80000083|NCT06153199|Behavioral|Supervisor training|In person discussion of work processes and support for workers to implement self-management and ergonomic modifications
80000084|NCT06153199|Behavioral|Guided choice of ergonomic options matched to most difficult tasks|Survey based guidance on ergonomic choices appropriate for work tasks that are the most difficult due to back pain
80000085|NCT06153199|Behavioral|Prioritized lists of self management options|Survey based guidance for prioritized choices of self-management
80000086|NCT06153199|Behavioral|Text reminders|Reminders to implement choices
79682978|NCT01289119|Drug|Placebo to alogliptin|Alogliptin placebo-matching tablets.
79682979|NCT01289119|Drug|Metformin|Stable metformin dose
79682980|NCT01289119|Drug|Pioglitazone|Stable pioglitazone dose
79682981|NCT02936336|Other|exercise|circuit exercise, aerobic dance and Tai Chi exercise
79682982|NCT02913378|Procedure|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
79682983|NCT02913378|Procedure|Sling|Conservative treatment with sling and rehabilitation
79682984|NCT02936141|Behavioral|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
80000087|NCT06146504|Dietary Supplement|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial & anti-parasite formula.
80000088|NCT06146504|Other|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
80000089|NCT06146452|Other|Not|Not
80000090|NCT06144710|Drug|SG301 SC Injection|"This Study consists of Parts A and B. Part A ：SG301 SC Injection In healthy volunteers at 1 mg/kg dose group (n=4) and 2 mg/kg dose group(n=4) ; all 4 participants in each group will receive a single dose of SG301 SC Injection by abdominal subcutaneous injection.~Part B：SG301 SC Injection/SG301 SC placebo MAD will be performed for SLE participants in 4 dose groups (n=10/group), namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups.~2 mg/kg dose groups:SG301 SC Injection (n=8) or SG301 SC placebo (n=2); 4 mg/kg, 8 mg/kg and 12 mg/kg dose groups, the first 2 participants in each group will receive the investigational drug SG301 SC Injection , and the remaining 8 participants will be randomized in a 6:2 ratio to receive multiple doses of SG301 SC Injection (n=6) or SG301 SC placebo will be subcutaneously injected every 2 weeks [Q2W] in a 2-week cycle for a total of 6 doses in the MAD study."
80000091|NCT06144294|Other|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
80000092|NCT06144294|Diagnostic Test|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
79527125|NCT04221724|Other|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
79373574|NCT03438084|Dietary Supplement|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
79527126|NCT04220866|Drug|Ulevostinag|IT injection
79231537|NCT03119870|Other|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
79231538|NCT03119870|Other|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
79373575|NCT03438084|Dietary Supplement|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
79373576|NCT03438084|Dietary Supplement|Butter|50g fat provided as commercially available spreadable butter
79373577|NCT01161862|Device|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
79373578|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
79682985|NCT02913339|Other|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
79682986|NCT02936180|Biological|HD-TIV|
79682987|NCT02936180|Biological|SD-QIV|
79682988|NCT01289041|Drug|BKM120|
79682989|NCT02913183|Drug|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
79682990|NCT02913183|Drug|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
79682991|NCT01288729|Device|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
79682992|NCT01288729|Device|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
79373579|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
79527127|NCT04220866|Biological|Pembrolizumab|IV infusion
79682993|NCT02936258|Procedure|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
79682994|NCT02936258|Procedure|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
79682995|NCT02936258|Procedure|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
79682996|NCT01288612|Device|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
79682997|NCT01288612|Device|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
79527128|NCT04197297|Diagnostic Test|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
79373580|NCT01214824|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
79231539|NCT03120026|Dietary Supplement|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
79231540|NCT03120026|Dietary Supplement|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
79231541|NCT03107468|Other|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
79373581|NCT03437850|Other|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
79373582|NCT03437772|Behavioral|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
79373583|NCT01214980|Device|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
79373584|NCT01214980|Other|Standard of care|Standard of care provided per site-specific protocol
79527129|NCT04179136|Dietary Supplement|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
79527130|NCT04179136|Dietary Supplement|Placebo treatment matching intervention|Placebo treatment matching intervention
79527131|NCT04170946|Other|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
79527132|NCT04170283|Drug|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.
79527133|NCT04170283|Drug|Tislelizumab|Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
79682998|NCT02913027|Other|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
79682999|NCT02913027|Other|Bimanual Exam|
79683000|NCT02913027|Other|Speculum Exam|
79683001|NCT04323982|Procedure|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
79373585|NCT03445338|Drug|K0706|Study
79373586|NCT03445338|Drug|K0706|Study
79373587|NCT03445338|Drug|K0706|Study
79373588|NCT03445260|Other|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
79683002|NCT04323982|Procedure|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
79683003|NCT02936297|Dietary Supplement|High dose Gluten|
79683004|NCT02936297|Dietary Supplement|Low dose Gluten|
79683005|NCT02936297|Dietary Supplement|Lactose free placebo|
79683006|NCT01287832|Drug|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
79683007|NCT01287832|Drug|Daptomycin|
79373589|NCT03445260|Other|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
79373590|NCT01232920|Drug|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
79373591|NCT01232920|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
79373592|NCT03445182|Procedure|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
79527134|NCT04160052|Drug|Azacitidine|Given SC or IV
79527135|NCT04160052|Drug|Venetoclax|Given PO
79527136|NCT04152018|Drug|PF-06940434|PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
79527137|NCT04152018|Drug|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
79826289|NCT01496313|Drug|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
79826290|NCT01298323|Behavioral|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
79826291|NCT01298323|Drug|Vandetanib|Treatment 300mg vandetanib opel label.
79826292|NCT01268579|Drug|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
79826293|NCT01165632|Procedure|biopsy|Correlative studies
79826294|NCT01165632|Procedure|computed tomography|Undergo computed tomography
79826295|NCT01165632|Procedure|therapeutic conventional surgery|Undergo stereotactic craniotomy
79826296|NCT01165632|Radiation|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
79826297|NCT01165632|Radiation|radiation therapy|Undergo radiation therapy
79231542|NCT03107468|Other|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
79231543|NCT03226574|Drug|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
79527138|NCT04149574|Drug|nivolumab|Specified Dose on Specified Days
79231544|NCT03119636|Biological|NPC transplantation|The cells are stereotactically implanted in the striatum.
79527139|NCT04149574|Other|Placebo|Specified Dose on Specified Days
79527140|NCT04149574|Biological|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
79231545|NCT03119636|Drug|Levodopa|Levodopa is used depending on the patient's condition
79231546|NCT03107234|Other|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
79527141|NCT04147559|Device|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
79527142|NCT04139577|Biological|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
79683008|NCT02913066|Other|S-1 concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle.
79527143|NCT04121325|Device|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
79683009|NCT02913066|Other|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.
79683010|NCT00623701|Biological|Allerslit forte|sublingual placebo preparation, daily
79527144|NCT04115384|Drug|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
79683011|NCT00623701|Biological|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
79683012|NCT02936063|Procedure|Surgical staples|Closure of surgical wound at skin level with surgical staples
79683013|NCT02936063|Procedure|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
79683014|NCT01287754|Drug|erlotinib [Tarceva]|150 mg daily orally
79527145|NCT04113733|Other|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
79826298|NCT01165632|Procedure|magnetic resonance imaging|Undergo magnetic resonance imaging
79826299|NCT01165632|Procedure|positron emission tomography|Undergo positron emission tomography
79826300|NCT01165632|Drug|fluorine F 18 fluorodopa|Given IV
79826301|NCT01056523|Drug|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
79826302|NCT01056523|Drug|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
79826303|NCT00579878|Drug|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
79373593|NCT03445182|Device|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
79826304|NCT00579878|Drug|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
80000093|NCT06143033|Other|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
80000094|NCT06140563|Other|anticoagulation dosing|In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
80000095|NCT06136897|Procedure|Biopsy|Undergo biopsy
79683015|NCT02912832|Device|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
80000096|NCT06136897|Procedure|Biospecimen Collection|Undergo collection of blood samples
80000097|NCT06136897|Procedure|Echocardiography|Undergo ECHO
80000098|NCT06136897|Biological|Pertuzumab|Given IV
79373594|NCT03010540|Drug|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
79373595|NCT03010540|Drug|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
79373596|NCT03445104|Other|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
79527146|NCT04075149|Drug|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if > 60 kg, 100 mg twice daily.
79527147|NCT04060199|Drug|Viltolarsen|IV infusion
79527148|NCT04060199|Drug|Placebo|IV infusion
79527149|NCT04028570|Radiation|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
79683016|NCT02912793|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
79683017|NCT02935751|Other|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
79683018|NCT02912871|Other|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
79683019|NCT02935790|Drug|ACY-241|tablet
79683020|NCT02935790|Drug|nivolumab|infusion
79683021|NCT02935790|Drug|ipilimumab|infusion
80000099|NCT06136897|Procedure|Radiologic Examination|Undergo radiologic evaluation
80000100|NCT06136897|Biological|Trastuzumab|Given IV
79373597|NCT03445104|Other|Placebo|During one of the two experimental sessions, participants will be given a placebo.
79527150|NCT04025554|Drug|Anakinra|100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
79527151|NCT04025372|Drug|Bicalutamide|Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
79527152|NCT04025372|Drug|GnRH Agonist|In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
79527153|NCT04025372|Radiation|Radiation Therapy|Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
79683022|NCT02912637|Other|Hyperpolarized Xenon MRI|MRI & MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
79683023|NCT02912910|Other|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
79683024|NCT02912910|Other|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
79683025|NCT02935829|Other|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79683026|NCT02935829|Other|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79683027|NCT02935829|Other|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79683028|NCT02935829|Other|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79683029|NCT02935829|Other|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
79826305|NCT00579878|Drug|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
79826306|NCT00554788|Procedure|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
79826307|NCT00554788|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
79826308|NCT00554788|Drug|Carboplatin|Given IV
79826309|NCT00554788|Drug|Cisplatin|Given IV
79826310|NCT00554788|Drug|Cyclophosphamide|Given IV
79826311|NCT00554788|Drug|Etoposide|Given IV
79231547|NCT03232814|Behavioral|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
79373598|NCT03445026|Diagnostic Test|dental panorama|radiographic examination
79373599|NCT01234714|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
79373600|NCT01234714|Procedure|Major liver resection|Hepatectomy of >= 3 liver segments
79527154|NCT04025372|Drug|Darolutamide|Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
79826312|NCT00554788|Biological|Filgrastim|Given SC
79826313|NCT00554788|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
79826314|NCT00554788|Radiation|Radiation Therapy|Undergo radiotherapy
80000101|NCT06134466|Dietary Supplement|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
79231548|NCT03226496|Behavioral|motivational interviewing|
79231549|NCT03232502|Diagnostic Test|Pharmacogenetic testing|Basic pharmacogenetic panel
79305611|NCT03239795|Other|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
79305612|NCT03057093|Other|Non interventional study|retrospective noninterventional study
79373601|NCT03440580|Device|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
79373602|NCT03440502|Procedure|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
79373603|NCT01162096|Device|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
79305613|NCT03239951|Device|iTind|temporary implant
79305614|NCT04935099|Dietary Supplement|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
79373604|NCT03437538|Device|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
79373605|NCT03437538|Device|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
79527155|NCT04019002|Drug|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
79527156|NCT04017351|Other|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
79527157|NCT04004611|Drug|Mirikizumab|Administered IV and SC
79527158|NCT04004364|Other|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
79826315|NCT00554788|Drug|Thiotepa|Given IV
79373606|NCT04801290|Procedure|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
79826316|NCT00554788|Drug|Vincristine Sulfate|Given IV
79826317|NCT00431288|Behavioral|diet high in fruits, vegetables, and dairy|
79826318|NCT00431288|Other|Routine nutrition care|
80000102|NCT06125912|Other|Dime Beauty TBT Cream|Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
80000103|NCT06125912|Other|Positive Control|Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
79527159|NCT03994770|Diagnostic Test|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
79231550|NCT03226262|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
79231551|NCT03226340|Drug|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
79527160|NCT03951259|Drug|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
79373607|NCT01234870|Drug|Gadolinium|
79527161|NCT03951259|Drug|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
79231552|NCT03226340|Drug|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
79231553|NCT03221504|Other|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
79373608|NCT01234870|Drug|Adenosine|
79373609|NCT05665686|Device|Relaxation training with device|Relaxation training will be applied with the device.
79527162|NCT03949660|Device|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
79683030|NCT02935829|Other|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
79683031|NCT02912598|Device|Mallinckrodt™ Endobronchial Tube|
79826319|NCT00410761|Drug|ZD6474 (Vandetanib)|once daily oral tablet
79826320|NCT00138216|Drug|irinotecan hydrochloride|
79826321|NCT00138216|Drug|temozolomide|
79826322|NCT00138216|Drug|vincristine sulfate|
79373610|NCT05665686|Other|Home Exercise|An exercise application including home exercise programs will be performed for six weeks.
79373611|NCT03437460|Drug|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
79683032|NCT02912598|Device|Fuji Uniblocker™|
79683033|NCT02912598|Device|ETView VivaSight™-SL+EB|
79683034|NCT02912598|Device|COOK© Arndt Endobronchial Blocker|
79826323|NCT03548103|Dietary Supplement|Green tea extract|Green tea extract 500 mg tid for 16 weeks
79826324|NCT03548103|Dietary Supplement|Placebo|Placebo tid for 16 weeks
79826325|NCT03542760|Drug|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
79826326|NCT03513653|Diagnostic Test|Echocardiography with speckle-tracking imaging|"Measurement of left ventricular ejection fraction and global longitudinal strain~Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~Measurement of right ventricular global longitudinal strain"
79826327|NCT03503643|Device|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
79826328|NCT03496792|Other|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
79826329|NCT03496792|Other|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
79231554|NCT03221504|Other|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
79683035|NCT02935712|Drug|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
79231555|NCT03221582|Drug|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
79231556|NCT03232268|Biological|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
79683036|NCT02935712|Drug|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
79231557|NCT03221348|Biological|CHO-H01|Glyco-engineered anti-CD20 antibody
79231558|NCT03221114|Behavioral|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
79826330|NCT03496792|Other|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
79826331|NCT03496792|Other|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
79373612|NCT03437460|Dietary Supplement|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
79826332|NCT03487224|Device|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
79231559|NCT03232034|Dietary Supplement|Calcium Citrate|1000 mg calcium as calcium citrate
79527163|NCT03949660|Device|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
79826333|NCT03477292|Drug|Duration of antibiotic|Duration of antibiotic for treatment of VAP
79231560|NCT03232034|Dietary Supplement|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
79231561|NCT03232034|Dietary Supplement|Whey Protein Hydrolysate|50 g whey protein hydrolysate
79231562|NCT03225950|Other|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
79231563|NCT03225950|Diagnostic Test|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
79373613|NCT03444792|Procedure|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~- If failed the surgeon will use artery forceps to dilate cervix"
79683037|NCT02935712|Drug|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
79683038|NCT02912754|Drug|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
79373614|NCT03444636|Drug|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
79826334|NCT03471650|Drug|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
79826335|NCT03465540|Drug|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
79826336|NCT03465540|Drug|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
79231564|NCT03225950|Genetic|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
79231565|NCT03225950|Diagnostic Test|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
79231566|NCT03119948|Drug|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
79373615|NCT03444636|Drug|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
79373616|NCT01215292|Drug|Acyline|300 mcg/kg on Day 1
79373617|NCT01215292|Drug|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
79373618|NCT01215292|Drug|ketoconazole 400|400 mg PO daily, Days 3-10
79373619|NCT01215292|Drug|Ketoconazole 800|800 mg PO daily, Day 3-10
79373620|NCT01215292|Drug|Dutasteride|2.5 mg PO daily, Day 3-10
79373621|NCT01215292|Drug|Anastrozole|1 mg PO daily, Day 3-10
79373622|NCT01215292|Drug|Placebo ketoconazole|placebo to mimic ketoconazole
79683039|NCT02912754|Drug|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
79683040|NCT02912676|Drug|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
80000104|NCT06125730|Other|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
79231567|NCT03119948|Drug|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
80000105|NCT06124482|Device|Total Knee arthroplasty|The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
80000106|NCT06123130|Device|Vectorcardiography (VECG)|Patients enrolled will undergo diagnostic ECG recording: three sets of simultaneous 30s recordings with the investigational device AIMIGo and a standard 12L ECG.
80000107|NCT06121661|Device|APPRAISE Trauma Clinical Decision Support System|Real-time bedside decision-support system for trauma patient management
80000108|NCT06118723|Procedure|Supramaximal resection|Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
79231568|NCT03119948|Drug|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
79231569|NCT03221270|Device|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
79231570|NCT03221270|Device|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
79231571|NCT03221270|Device|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
79826337|NCT03465540|Drug|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
80000109|NCT06118723|Procedure|Maximal safe resection|Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
79527164|NCT03949660|Device|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
79373623|NCT04796454|Drug|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
80000110|NCT06114784|Diagnostic Test|metagenomics|Perform metagenomic analysis on balf, feces, and blood
79373624|NCT04796454|Drug|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
79373625|NCT04796454|Drug|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
79527165|NCT03949660|Device|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
79527166|NCT03948061|Other|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
79527167|NCT03948061|Other|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
79527168|NCT03939767|Drug|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
79527169|NCT03918382|Other|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
79683041|NCT02912481|Procedure|posterior tibial artery|
79683042|NCT02912481|Procedure|radial artery|
79683043|NCT02912481|Procedure|dorsalis pedis artery|
79826338|NCT03462316|Biological|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
79826339|NCT03437798|Other|Disease status|Women who reported periodontal disease diagnosis/condition
80000111|NCT06113003|Dietary Supplement|Prebiotic|Wheat dextrin fiber
79373626|NCT04796454|Drug|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
79683044|NCT02935985|Other|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
79683045|NCT02935439|Other|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
80000112|NCT06113003|Dietary Supplement|Probiotic|Probiotic packet
80000113|NCT06110780|Other|acupuncture|"The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
80000114|NCT06107387|Behavioral|Binge Eating Self-help for Teens|Guided self-help intervention
79683046|NCT02912169|Procedure|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
79683047|NCT02912169|Biological|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
79826340|NCT03420404|Other|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
79826341|NCT03368547|Procedure|Computed Tomography|Undergo PET/CT scan
80000115|NCT06101641|Other|Shellac nail polish application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
80000116|NCT06097481|Behavioral|Narrative Intervention for Chronic Illness-Heart Failure|The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
79231572|NCT03221270|Device|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
79231573|NCT03232112|Drug|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
79231574|NCT03232112|Drug|BD PosiFlush (saline)|Subcutaneous injection once-weekly
79231575|NCT04485806|Other|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
79527170|NCT03914820|Procedure|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
79527171|NCT03914820|Procedure|Standard surgery|Standard surgery without HIPEC CO2
79527172|NCT03914820|Drug|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
79826342|NCT03368547|Radiation|Gallium Ga 68 Gozetotide|Given IV
79826343|NCT03368547|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79826344|NCT03338309|Other|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
79231576|NCT04485806|Other|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
79231577|NCT04485806|Other|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
79231578|NCT04485806|Other|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
79231579|NCT03119558|Drug|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
79231580|NCT03119480|Device|electronic alerts|electronic alerts for AKI
79231581|NCT03231956|Device|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
79231582|NCT02554786|Drug|Indacaterol acetate/Mometasone furoate|
79231583|NCT02554786|Drug|Mometasone furoate|
79231584|NCT02554786|Drug|Salmeterol xinafoate/fluticasone propionate|
79231585|NCT03232190|Other|Web Application|Parents receive a web application that offers information and support until the age of 2.
79231586|NCT05202314|Drug|Immunotherapy (Camrelizumab)|After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
79527173|NCT03907046|Drug|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
79527174|NCT03907046|Drug|Aspirin|Aspirin is an oral antiplatelet drug.
79527175|NCT03895359|Radiation|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
79527176|NCT03895359|Drug|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
79527177|NCT03891966|Procedure|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
79527178|NCT03891966|Procedure|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
79683048|NCT02912520|Drug|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
79683049|NCT02935166|Other|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
79683050|NCT02935959|Drug|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
79683051|NCT02935959|Drug|nebulized Dexmedetomidine|
79683052|NCT02935959|Drug|nebulized midazolam|
79683053|NCT02935127|Procedure|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
79683054|NCT02935127|Procedure|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
79683055|NCT02912286|Device|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
79683056|NCT02912286|Device|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
79683057|NCT02912286|Device|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
80000117|NCT06097481|Other|Attention Control|Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
80000118|NCT06083753|Drug|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
80000119|NCT06083753|Drug|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
79231587|NCT03225638|Combination Product|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
79373627|NCT04796454|Drug|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
79527179|NCT03884439|Drug|Infliximab [infliximab biosimilar 3]|<Crohn's disease> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. <Ulcerative colitis> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
79527180|NCT03859427|Drug|Carfilzomib|Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
79527181|NCT03859427|Drug|Carfilzomib|Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
80000120|NCT06083753|Drug|Placebo|Subjects will receive daily oral matching dose of Placebo
79527182|NCT03859427|Drug|Lenalidomide|Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
80000121|NCT06083259|Device|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
80000122|NCT06083259|Procedure|Gelatin sponge stabilization with cyanoacrylate|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
79231588|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
79231589|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
79231590|NCT03225326|Drug|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
79231591|NCT03225326|Drug|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
79373628|NCT03437382|Device|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
79373629|NCT05113680|Behavioral|compassion focused group|Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
79373630|NCT05113680|Behavioral|emotional competencies|Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
79373631|NCT02521506|Device|Verio Pattern Alert® activated|
79683058|NCT02912325|Dietary Supplement|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
79683059|NCT02935322|Drug|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
79683060|NCT02935322|Drug|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
79683061|NCT02935322|Drug|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
79683062|NCT02935322|Other|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
80000123|NCT06082895|Behavioral|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
80000124|NCT06079476|Drug|Romosozumab|Single-use prefilled syringe for SC injection.
80000125|NCT06078501|Drug|Misoprostol 400mcg buccal|Misoprostol 400mcg buccal administration 2-3 hours prior to procedure
80000126|NCT06078501|Drug|Placebo|Placebo buccal administration 2-3 hours prior to procedure
79826345|NCT03336931|Diagnostic Test|Molecular profiling and drug testing|"Laboratory analysis including:~A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~Multi-disciplinary Tumour Board case discussion~Recommendation of personalised therapy"
79826346|NCT03319407|Device|EPAD monitoring system|EPAD system will be used as part of routine care
79231592|NCT03119792|Other|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
79373632|NCT02521506|Device|Verio Pattern Alert® deactivated|
79373633|NCT02189668|Drug|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
79373634|NCT03437304|Biological|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
79683063|NCT02912130|Dietary Supplement|Protein Supplementation|1.2-1.5g/kg/body weight per day
79683064|NCT02912130|Other|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
79231593|NCT03119792|Other|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
79373635|NCT03437304|Biological|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
79527183|NCT03859427|Drug|Dexamethasone|Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
79527184|NCT03832855|Biological|pING-hHER3FL|Plasmid vaccine containing HER3
79683065|NCT02912130|Other|Resistance Exercise|60 minutes per week of progressive resistance training
79683066|NCT02935049|Procedure|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
79683067|NCT02934893|Other|Medication Management Clinic|referral to medication management clinic from primary care
79683068|NCT02934893|Other|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
79683069|NCT02935647|Drug|Diprivan|
79683070|NCT02934815|Other|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
79305615|NCT04935099|Dietary Supplement|Placebo powder|22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
79527185|NCT03824938|Drug|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
79527186|NCT03824938|Drug|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
79683071|NCT02912247|Drug|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
79683072|NCT02912247|Drug|adalimumab|adalimumab, 40mg,subcutaneous injection,once
79826347|NCT03270150|Device|BTL-899|BTL-899
79826348|NCT03262155|Biological|Blood test|
79826349|NCT03217227|Other|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
79305616|NCT03239717|Other|Whey protein powder|Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
79305617|NCT03239717|Other|BCAD2|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
79373636|NCT03437304|Biological|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
79373637|NCT03437304|Biological|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
79373638|NCT03437304|Drug|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
79373639|NCT03437304|Biological|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
79373640|NCT02981290|Drug|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
79527187|NCT03824938|Other|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
79527188|NCT03766425|Drug|Aflibercept|subconjunctival injection
79527189|NCT03766425|Drug|Mitomycin|subconjunctival injection
80000127|NCT06078397|Device|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
79683073|NCT02935491|Device|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
79231594|NCT03225014|Device|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
79373641|NCT02981290|Drug|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
79305618|NCT03056781|Behavioral|social interaction|Participants will engage in a social interaction with another person
79373642|NCT02981290|Drug|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
79373643|NCT02981290|Drug|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
79373644|NCT03437226|Drug|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
79683074|NCT02935010|Drug|Esomeprazole|proton pump inhibitor
79683075|NCT02935010|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
79683076|NCT02935010|Drug|Amoxicillin|antibiotic for H. pylori eradication
79683077|NCT02935010|Drug|Clarithromycin|antibiotic for H. pylori eradication
79305619|NCT03056781|Behavioral|food consumption|Participants will be offered food stuffs to eat/drink
79305620|NCT03239327|Drug|Misoprostol|
79373645|NCT03437226|Drug|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
79373646|NCT03444558|Dietary Supplement|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
79683078|NCT02935010|Drug|Metronidazole|antibiotic for H. pylori eradication
79683079|NCT02935010|Drug|Levofloxacin|antibiotic for H. pylori eradication
79683080|NCT02912013|Device|Me Mini|Home use hair removal device
79373647|NCT03444558|Other|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
79373648|NCT01236196|Behavioral|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
79373649|NCT01236196|Behavioral|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
80000128|NCT06078397|Device|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
79373650|NCT03444480|Drug|Remimazolam Tosylate|Initial dose plus supplemental doses
79373651|NCT04793412|Device|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
79373652|NCT01236742|Device|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
79373653|NCT01236742|Device|single-vision glasses|daily wear of spectacle glasses to correct vision
79373654|NCT04788420|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
79373655|NCT01282138|Drug|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
79373656|NCT01282138|Other|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
79683081|NCT02934776|Device|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
79683082|NCT02911974|Device|Acquire EUS Biopsy Device|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
79683083|NCT02911974|Device|Expect EUS Aspiration Needle|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
79683084|NCT04690244|Other|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
80000129|NCT06077227|Behavioral|virtual reality therapy|4 weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
79826350|NCT03217227|Procedure|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
79683085|NCT02935569|Device|Compression HeadBand|"commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
80000130|NCT06077227|Other|matched control group|taking the same surveys as the VR intervention group on a weekly basis for 4 weeks
80000131|NCT06071715|Device|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
79231595|NCT03225014|Diagnostic Test|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
79231596|NCT03225248|Drug|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
79231597|NCT03225248|Drug|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
79231598|NCT03225092|Biological|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
79231599|NCT03224936|Device|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
79683086|NCT04690166|Other|The speech records related to the reading document|"The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer."
79683087|NCT02935530|Drug|s-LMWH|2125KU, subcutaneous injection of 5-10 days
79683088|NCT02935530|Drug|LMWH|4250KU, subcutaneous injection of 5-10 days
79231600|NCT04791137|Behavioral|Imagery cognitive bias modification|The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell & Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. It is hypothesised that via repeatedly practising imagining positive resolutions for ambiguous situations in the training sessions, a bias is trained to automatically imagine positive resolutions for ambiguous situations encountered in daily life.
79231601|NCT03220880|Drug|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
79231602|NCT02949479|Behavioral|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
79231603|NCT05700539|Behavioral|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
79231604|NCT04787549|Device|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
79683089|NCT02935530|Drug|Argatroban|20mg, injection for 5-10 days
79683090|NCT02934737|Other|Progression of diabetes|
79683091|NCT02935608|Drug|BIIB074|Administered as specified in the treatment arm
79683092|NCT02935608|Drug|Placebo|Matched placebo
79683093|NCT02935803|Procedure|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
79683094|NCT02934386|Device|WinMedical WinPack device|
79683095|NCT02912052|Drug|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
79683096|NCT02912052|Drug|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
79231605|NCT02929589|Drug|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
79231606|NCT02929589|Drug|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
80000132|NCT06071715|Device|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
79683097|NCT02934620|Device|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
79683098|NCT02934620|Device|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
79231607|NCT02929589|Drug|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
79231608|NCT02929589|Drug|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
79231609|NCT02910635|Drug|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
79231610|NCT02910635|Drug|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
79683099|NCT02934620|Behavioral|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
79683100|NCT02935881|Device|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
79683101|NCT02935881|Procedure|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
79683102|NCT02934464|Drug|RAMUCIRUMAB|
79683103|NCT02934464|Drug|Paclitaxel|Paclitaxel
79683104|NCT02934464|Drug|FOLFOX 4|
79683105|NCT02934464|Drug|mFOLFOX 6|
79683106|NCT02934464|Drug|XELOX|
79683107|NCT02934542|Device|AutoLap system|
79683108|NCT02935413|Device|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
80016644|NCT03238053|Device|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
79231611|NCT02910635|Drug|Placebo|
79231612|NCT04769531|Other|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
79683109|NCT02935413|Behavioral|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
79231613|NCT04769531|Other|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
79231614|NCT04769531|Other|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
79231615|NCT04721951|Procedure|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
79231616|NCT03628469|Behavioral|Proactive Health Support|Active listening, coaching and counselling
79373657|NCT01922973|Other|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
79373658|NCT03440346|Other|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
79373659|NCT03444402|Drug|CKD-381(formulation I)|1 tablet administered before the breakfast during 7 days
79373660|NCT03444402|Drug|CKD-381(formulation II)|1 tablet administered before the breakfast during 7 days
79373661|NCT03444402|Drug|D026(Nexium 40mg)|1 tablet administered before the breakfast during 7 days
79683110|NCT02934425|Other|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
79683111|NCT02934425|Other|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
79683112|NCT02935218|Behavioral|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
79683113|NCT02934308|Device|Skin Conductance Monitor|
79683114|NCT02934269|Drug|Placebo|
79683115|NCT02934269|Drug|CC-90006|
79683116|NCT02788461|Radiation|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
79683117|NCT02788461|Radiation|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
79683118|NCT02934035|Drug|Antidepressant|
79826351|NCT03217227|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
79826352|NCT03217227|Diagnostic Test|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
79826353|NCT03216798|Other|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
79826354|NCT03185455|Other|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
80000133|NCT06071221|Behavioral|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
80000134|NCT06071221|Behavioral|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
80000135|NCT06068894|Dietary Supplement|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
80016645|NCT05230420|Other|Clamping|Clamping of chest tube
79231617|NCT01347645|Drug|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
79231618|NCT01347645|Drug|E7820|"Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
79231619|NCT02614547|Drug|SAGE-547|Administered as intravenous infusion.
79231620|NCT02614547|Drug|Placebo|Administered as intravenous infusion.
79231621|NCT04472481|Drug|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
79231622|NCT04472247|Diagnostic Test|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
79231623|NCT00581997|Drug|QAX576|
79231624|NCT00581997|Drug|Placebo|
79683119|NCT02911740|Other|Urine LAM Ag test|TB diagnostic assay
79683120|NCT02934152|Drug|H pylori eradication|H pylori eradication
79683121|NCT02934152|Other|H pylori eradication timing|Early or late eradication
79683122|NCT02935296|Behavioral|Integrated Intervention|systems navigation, psychosocial counseling
79683123|NCT02934074|Other|No intervention|
79683124|NCT02911779|Procedure|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
79683125|NCT02934113|Behavioral|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
79683126|NCT02934113|Behavioral|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
79683127|NCT02935335|Drug|Menotrophin|
79683128|NCT02933996|Device|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
79826355|NCT03182075|Behavioral|Computerized Training|OCD participants will receive 14 sessions of training via computer within 3 weeks.
79826356|NCT03179969|Other|paravalvular leak|Observational study on patients with paravalvular leak
79683129|NCT02933996|Device|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
79683130|NCT02934230|Behavioral|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
79683131|NCT02933840|Device|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
79683132|NCT02911662|Drug|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
79683133|NCT02911662|Drug|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
79683134|NCT02933723|Procedure|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
79683135|NCT02911623|Device|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
79683136|NCT02935101|Drug|Prednisolone|formulated for oral administration. encapsulated.
79683137|NCT02935101|Drug|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
80000136|NCT06068894|Dietary Supplement|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
80000137|NCT06068894|Other|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
80016646|NCT05230420|Other|Urine bag|Attachment of a urine bag to chest tube
79527190|NCT03705806|Radiation|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
79527191|NCT03674047|Drug|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
79527192|NCT03638167|Biological|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
79527193|NCT03636373|Drug|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
79527194|NCT03636373|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
79826357|NCT03177044|Behavioral|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
79683138|NCT04689971|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
79683139|NCT04689971|Drug|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
79683140|NCT02934945|Drug|budesonide 160μg/formoterol 4.5μg|SMART regimen
79683141|NCT02933762|Drug|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
79683142|NCT02933762|Drug|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
79683143|NCT02933645|Drug|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
79683144|NCT02933645|Drug|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
79826358|NCT03159923|Other|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
80016647|NCT03622671|Procedure|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
79826359|NCT03152903|Biological|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
79826360|NCT03152903|Other|Placebo|Single dose of Placebo is administered intradermally.
79826361|NCT03152890|Drug|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
79683145|NCT02933645|Radiation|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq [18F]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
79683146|NCT02933645|Drug|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
79826362|NCT03148600|Behavioral|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
80000138|NCT06068036|Behavioral|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
79826363|NCT03148600|Other|Standard arm|Standard medical and nursing care
79683147|NCT02933567|Other|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
80000139|NCT06068036|Behavioral|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
79683148|NCT02933684|Drug|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
80000140|NCT06066619|Dietary Supplement|100% Cranberry Juice|100% Cranberry juice will be provided from Ocean Spray Company.
80000141|NCT06066619|Dietary Supplement|100% Cranberry Juice + 200 mg L-theanine|100% Cranberry Juice + 200 mg L-theanine will be provided from Ocean Spray Company.
79231625|NCT02478983|Device|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
79527197|NCT03560310|Drug|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
79527198|NCT03560310|Drug|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
79527199|NCT03470675|Drug|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
79527200|NCT03470675|Drug|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
79527201|NCT03470675|Drug|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
79527202|NCT03456063|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
79527203|NCT03456063|Drug|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
79683149|NCT02933684|Behavioral|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
79683150|NCT02933684|Drug|Placebo|Administered in pill form.
79826364|NCT03141255|Device|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
79826365|NCT03141255|Device|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
79826366|NCT03139162|Other|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
79826367|NCT03123029|Drug|Venetoclax|Venetoclax will be administered orally.
79826368|NCT03091231|Diagnostic Test|mpUS multiparametric Ultrasound|compare the mpUS to other methods
79683151|NCT02934867|Other|Protocol phone advice|Protocol phone advice
79683152|NCT02934867|Other|Usual phone advice|Usual phone advice
79826369|NCT03088579|Device|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
79826370|NCT03088553|Drug|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
79826371|NCT03062085|Other|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
79826372|NCT03055897|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
80000142|NCT06066619|Dietary Supplement|Placebo Juice|Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry juice.
80000143|NCT06061809|Drug|Bevacizumab|Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
80000144|NCT06061809|Drug|PD-L1 t-haNK|Participants will receive PD-L1 t-haNK (~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
80000145|NCT06061809|Drug|N-803|Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
80000146|NCT06055855|Procedure|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
80000147|NCT06055855|Procedure|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
80016648|NCT03622671|Procedure|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
80016649|NCT05230264|Other|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
79231626|NCT02478983|Device|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
79373662|NCT01238536|Procedure|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
79373663|NCT01238536|Procedure|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
79373664|NCT01238536|Drug|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
79373665|NCT01238536|Drug|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
79373666|NCT03437070|Drug|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
79373667|NCT03437070|Drug|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
79373668|NCT03437070|Drug|Olaratumab|Administered intravenously per protocol
79373669|NCT04346446|Drug|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
79683153|NCT02933333|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
79373670|NCT04346446|Other|Supportive Care|Supportive Care
79527204|NCT03456063|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
79527205|NCT03456063|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
79527206|NCT03456063|Drug|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
79683154|NCT02933333|Biological|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
79683155|NCT02933333|Biological|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
79231627|NCT04702763|Other|Eye-Tracker®T2 + e-VOG|"1st step: eyes movements assessed with standard video-oculography device~2° step: eyes movements assessed with e-VOG digital application~Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
79373671|NCT04346446|Drug|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
79373672|NCT00634101|Device|nelfilcon A|contact lens
79373673|NCT00634101|Device|narafilcon A|contact lens
79527207|NCT03456063|Drug|Cisplatin|Cisplatin 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
79231628|NCT04702763|Other|e-VOG + Eye-Tracker®T2|"1st step: eyes movements assessed with e-VOG digital application~2° step: eyes movements assessed with standard video-oculography device~Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
79683156|NCT02911584|Procedure|Laparoscopic procedure|
79683157|NCT02933294|Procedure|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
79683158|NCT02933294|Procedure|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
79683159|NCT02934828|Drug|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
79683160|NCT02934828|Drug|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
79683161|NCT02670252|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
79373674|NCT04478058|Behavioral|Live CBT|Weekly in-person Cognitive Behavioural Therapy
79373675|NCT04478058|Behavioral|e-CBT|Weekly online Cognitive Behavioural Therapy
79527208|NCT03456063|Drug|Gemcitabine|Gemcitabine 1250 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
79527209|NCT03448796|Procedure|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
79683162|NCT02670252|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79683163|NCT02670252|Radiation|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
79826373|NCT03055832|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
79826374|NCT03055832|Device|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
79826375|NCT03052595|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
79826376|NCT03052595|Diagnostic Test|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
79826377|NCT03052595|Diagnostic Test|Stroop test|Stroop test will be used to test cognitive function
80016650|NCT02279810|Behavioral|survey|Survey
80016651|NCT01658293|Behavioral|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
79527210|NCT03448796|Other|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
79527211|NCT03418818|Drug|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
79527212|NCT03418818|Drug|Pimonidazole|Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
79527213|NCT03417284|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
79527214|NCT03417284|Biological|Filgrastim-sndz|Given SC
79527215|NCT03417284|Drug|Melphalan Hydrochloride|Given IV
79683164|NCT02933177|Behavioral|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
79683165|NCT02933177|Behavioral|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
79683166|NCT02911467|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
79683167|NCT02911467|Device|MRI|MRI scan following the Pyruvate injection
79683168|NCT02934789|Procedure|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
79231629|NCT04681079|Drug|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
79231630|NCT04681079|Drug|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
79231631|NCT00580125|Drug|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
79231632|NCT00580125|Other|Placebo|Placebo, oral capsule, once daily for 21 days
79231633|NCT00580125|Drug|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
79683169|NCT02934789|Drug|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
79683170|NCT02933099|Drug|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
79683171|NCT02933099|Drug|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
79683172|NCT02935023|Radiation|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
79683173|NCT02911506|Other|Polysomnography|
79231634|NCT00580125|Drug|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
79231635|NCT00580125|Drug|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
79527216|NCT03383133|Drug|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
79231636|NCT04423900|Diagnostic Test|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
79231637|NCT00579189|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79231638|NCT00579189|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79527217|NCT03350607|Other|Non interventional study|Non interventional study (collect of data)
79527218|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
79527219|NCT03281369|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
79527220|NCT03281369|Drug|Oxaliplatin|Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
79527221|NCT03281369|Drug|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
79527222|NCT03281369|Drug|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
79527223|NCT03281369|Biological|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
79527224|NCT03281369|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
79527225|NCT03281369|Biological|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
79527226|NCT03281369|Drug|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
79683174|NCT02934906|Procedure|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
79683175|NCT02911350|Drug|Hormone Suppressors|
79683176|NCT02911350|Drug|Paclitaxel|
79683177|NCT02911350|Radiation|Radiation Therapy|
79683178|NCT04623983|Device|bonding tray|Orthodontic bonding tray
79683179|NCT02911428|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
79683180|NCT02911389|Other|Home PT via web-based platform|
79683181|NCT02911389|Other|Home PT via paper manual|
79683182|NCT02911389|Other|outpatient PT|
79683183|NCT02933021|Other|Blood sample taken|
79231639|NCT00579189|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
79231640|NCT00667953|Drug|Gleevec|Gleevec (600 mg) daily.
79231641|NCT00667953|Drug|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
79231642|NCT00578955|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
79231643|NCT00578955|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
79683184|NCT02933021|Other|Answering a lifestyle questionnaire|
79683185|NCT02933021|Other|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
79826378|NCT03048877|Drug|Apatinib Oral Tablet|Apatinib Mesylate Tablets
79826379|NCT03048877|Drug|Placebo Oral Tablet|Placebo Oral Tablet
79826380|NCT03032575|Behavioral|SEARCH010/RV254|
79683186|NCT02934750|Behavioral|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~Breathe in through your nose (as if you are smelling something) for about 2 seconds.~Pucker your lips like you're getting ready to blow out candles on a birthday cake.~Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~Repeat."
79683187|NCT02932709|Behavioral|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
80000148|NCT06054282|Behavioral|"Ready for Tonsillectomy educational mobile application"|"The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions."
80000149|NCT06052059|Drug|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
80000150|NCT06052059|Drug|IV Placebo|Placebo matching IV tulisokibart
80000151|NCT06052059|Drug|SC Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
80000152|NCT06052059|Drug|SC Placebo|Placebo matching SC tulisokibart
80000153|NCT06049589|Dietary Supplement|Coconut Oil|Coconut oil rinsing
80000154|NCT06049589|Drug|Chlorhexidine mouthwash|Chlorhexidine rinsing
79231644|NCT00578955|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
79231645|NCT00576537|Biological|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
79683188|NCT02911233|Biological|Thromboelastograpgy|
79683189|NCT02932748|Dietary Supplement|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
79683190|NCT02932748|Behavioral|Group Phone (GP)|Weight management program delivered via group conference call.
79683191|NCT02932748|Dietary Supplement|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
79683192|NCT02932748|Behavioral|Individual Phone (IP)|Weight management program delivered via individual phone call.
79826381|NCT02951351|Drug|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
80000155|NCT06049589|Other|Water mouthwash|Control with water rinsing
80000156|NCT06047171|Biological|ALE.F02|ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
80000157|NCT06047171|Drug|Rituximab|Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
80000158|NCT06047171|Drug|GlucoCorticoid|Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
80000159|NCT06047171|Drug|Cyclophosphamid|Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
80000160|NCT06047171|Drug|Placebo|Drug product that will contain no active ingredient
80000161|NCT06047171|Drug|Immunosuppressive Agents|Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
79231646|NCT00575055|Drug|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
79231647|NCT00575055|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
79231648|NCT00575055|Drug|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
79231649|NCT02282241|Drug|Melatonin|
79231650|NCT02282241|Other|Placebo|
79231651|NCT02424851|Drug|Bortezomib|"1.3 mg/m2 subcutaneously* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
79231652|NCT02424851|Drug|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
79231653|NCT02424851|Drug|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
79231654|NCT02424851|Drug|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
79231655|NCT02284035|Drug|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
79683193|NCT02932748|Behavioral|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
79826382|NCT02951351|Procedure|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
79826383|NCT02940925|Other|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
79231656|NCT02284035|Drug|EFV/TDF/FTC|standard combination therapy
79231657|NCT02284035|Drug|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
79231658|NCT02284035|Drug|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
79231659|NCT02284035|Drug|EFV plus ABC/3TC or RPV/TDF/FTC|
79826384|NCT02940925|Other|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
79231660|NCT02284035|Drug|ATV/r plus ABC/3TC|
79231661|NCT02284035|Drug|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
79231662|NCT02284035|Drug|RAL plus ABC/3TC|
79373676|NCT01284244|Device|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
79527227|NCT03281369|Drug|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
79683194|NCT02932514|Device|Eversense (Senseonics) Continuous Glucose Monitoring System|"Evaluate accuracy of Eversense CGM System to SMBG Meter.~Compare performance between abdomen and arm insertion sites.~Determine the usability of the Eversense System in a home-use setting for 180 days."
79683195|NCT02911311|Drug|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
79527228|NCT03281369|Drug|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
79683196|NCT02911311|Device|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
79527229|NCT03281369|Drug|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
79231663|NCT02284035|Drug|Other ART regimens|
79527230|NCT03281369|Drug|Cisplatin|Cisplatin: 80 mg/m^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
79527231|NCT03281369|Drug|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
79231664|NCT00484419|Drug|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
79231665|NCT00484419|Drug|rosiglitazone maleate|rosiglitazone tablets 4mg
79231666|NCT00484419|Drug|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
79231667|NCT02422355|Device|FNS|Surgical intervention using the FNS
79231668|NCT02162615|Device|Restorelle Direct Fix A|
79231669|NCT02162615|Device|Restorelle Direct Fix P|
79231670|NCT02162615|Procedure|Native Tissue Repair Anterior|
79231671|NCT02162615|Procedure|Native Tissue Repair Posterior|
79709823|NCT04326855|Other|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
79826385|NCT02915705|Biological|burosumab|solution for subcutaneous (SC) injection
79826386|NCT02915705|Drug|Oral Phosphate Supplement|oral tablet; oral solution; oral powder
79826387|NCT02915705|Drug|active vitamin D|tablet, oral solution
80016652|NCT01658293|Behavioral|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
80016653|NCT05203913|Drug|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
79231672|NCT03220724|Biological|CH505TF|Administered by intramuscular (IM) injection in the thigh
79231673|NCT03220724|Biological|CH505w53|Administered by IM injection in the thigh
79231674|NCT03220724|Biological|CH505w78|Administered by IM injection in the thigh
79231675|NCT03220724|Biological|CH505 M5|Administered by IM injection in the thigh
79231676|NCT03220724|Biological|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
79231677|NCT03220724|Biological|Placebo|Administered by IM injection in the thigh
79231678|NCT00484029|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
79231679|NCT00484029|Other|Air|Air (Medical Grade)
79231680|NCT00483171|Drug|CP-945,598|CP-945,598
79231681|NCT00483171|Behavioral|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
79231682|NCT00483171|Behavioral|Low Calorie Diet|Low calorie diet
79231683|NCT02273895|Drug|Scopolamine|0.3 mg/mL, intravenously, once
79231684|NCT00480831|Drug|bevacizumab|Intravenous repeating dose
79231685|NCT00480831|Drug|carboplatin|Intravenous repeating dose
79231686|NCT00480831|Drug|paclitaxel|Intravenous repeating dose
79231687|NCT00480831|Drug|placebo|Intravenous repeating dose
79231688|NCT00480831|Drug|PRO95780|Intravenous repeating dose
79231689|NCT03220568|Other|Fatty acids present in adipose tissue samples|
79231690|NCT00667173|Drug|IDP-115|Topical application for 12 weeks
79231691|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
79527232|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 800 mg/m^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
79527233|NCT03263130|Other|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
79527234|NCT03262974|Diagnostic Test|PCR|PCR
79527235|NCT03262974|Diagnostic Test|HPLC-UV|HPLC-UV
79527236|NCT03195478|Drug|Nivolumab|Specified dose on specified days
79527237|NCT03195478|Drug|Ipilimumab|Specified dose on specified days
79527238|NCT03042156|Radiation|Palliative Radiation Therapy|
79826388|NCT02891278|Drug|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
79826389|NCT02891278|Drug|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
79826390|NCT02891278|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
79826391|NCT02843308|Behavioral|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
79826392|NCT02807181|Drug|Cisplatin-gemcitabine|Systemic chemotherapy
79826393|NCT02807181|Device|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
79826394|NCT02768870|Device|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
79826395|NCT02750618|Biological|Burosumab|solution for subcutaneous injection
80000162|NCT06045572|Device|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
79231692|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
79373677|NCT01284244|Device|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
79826396|NCT02616432|Device|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
79231693|NCT03220334|Drug|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
79373678|NCT04469088|Other|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
79373679|NCT04469088|Other|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
79527239|NCT03016871|Drug|Carboplatin|Given IV
79826397|NCT02537431|Biological|burosumab|solution for subcutaneous injection
79826398|NCT02526160|Biological|burosumab|solution for SC injection
80000163|NCT06043440|Drug|Oxygen|Active nocturnal oxygen concentrator
79826399|NCT02526160|Other|Placebo|saline solution for SC injection
79826400|NCT02454543|Procedure|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
80000164|NCT06040190|Drug|topical placebo tablet|Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
79527240|NCT03016871|Drug|Etoposide|Given IV
79527241|NCT03016871|Drug|Ifosfamide|Given IV
79527242|NCT03016871|Other|Laboratory Biomarker Analysis|Correlative studies
79527243|NCT03016871|Biological|Nivolumab|Given IV
79527244|NCT03004443|Drug|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
79231694|NCT03220334|Drug|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
79527245|NCT03004443|Drug|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
79527246|NCT02869841|Drug|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
79527247|NCT02869841|Drug|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
79527248|NCT02869841|Drug|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
79527249|NCT02869841|Other|Placebo|No rectus sheath analgesia
79231695|NCT03220256|Drug|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
79826401|NCT02454543|Drug|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
79826402|NCT02430740|Drug|recFSH|
79826403|NCT02384512|Drug|Azilect®|AZILECT® 1mg Tablets
79826404|NCT02366494|Drug|Bicalutamide|ANDROGEN BLOCKADE
79826405|NCT02366494|Drug|Leuprolide|ANDROGEN BLOCKADE
79683197|NCT02932631|Other|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
79826406|NCT02366494|Drug|Goserelin|ANDROGEN BLOCKADE
79826407|NCT02366494|Drug|Triptorelin|ANDROGEN BLOCKADE
79826408|NCT02366494|Drug|Docetaxel|Chemo hormonal therapy
79231696|NCT00479505|Drug|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
79231697|NCT00479505|Drug|Placebo|Placebo
79231698|NCT02451410|Other|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
79231699|NCT02451332|Biological|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
79231700|NCT00566397|Drug|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
79373680|NCT03129048|Behavioral|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
79231701|NCT00566397|Drug|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
79231702|NCT00566397|Drug|Placebo|Placebo
79231703|NCT03220490|Behavioral|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
79826409|NCT02366494|Drug|Abiraterone|Chemo hormonal therapy
79826410|NCT02366494|Drug|Apalutamide|Nonsteroidal antiandrogen medication
79231704|NCT03220490|Behavioral|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
79826411|NCT02366494|Drug|Enzalutamide|Nonsteroidal antiandrogen medication
79826412|NCT02333136|Device|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
79826413|NCT02257229|Procedure|Surgical|Surgery only
79373681|NCT04450290|Device|CIDEXEL implant|The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
80000165|NCT06040190|Drug|topical clonazepam tablet|Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.
79373682|NCT00633477|Drug|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
79373683|NCT00633477|Drug|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
79373684|NCT03128970|Other|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
79373685|NCT03128736|Drug|Esomeprazole group|Esomeprazole 40mg qd
79373686|NCT03128736|Drug|Dexlansoprazole group|Dexlansoprazole 60mg qd
79373687|NCT01923207|Drug|DX-2930|
79826414|NCT02257229|Procedure|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
79826415|NCT02257229|Procedure|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
79826416|NCT02244788|Device|SR™ PIP|
79826417|NCT02163577|Biological|burosumab|solution for SC injection
79826418|NCT02157610|Behavioral|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
79527250|NCT02861755|Behavioral|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
79231705|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
79683198|NCT04690101|Other|none, this is an observational study|none, this is an observational study
79683199|NCT02932358|Other|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
79527251|NCT02861755|Behavioral|5-week Emotion Reporting|
79683200|NCT02932358|Other|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
79683201|NCT04689906|Other|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
79683202|NCT04690257|Other|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
79683203|NCT02932397|Drug|Intravenous dose of 0.5 mg/kg of propofol|
79826419|NCT02157610|Drug|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke <10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
79231706|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
79231707|NCT03056573|Device|Transaortic TAVR Implant|Transaortic TAVR implant
79231708|NCT03056573|Device|Subclavian /Axillary TAVR implant|Subclavian /Axillary TAVR implant
79231709|NCT03220100|Other|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
79231710|NCT02553772|Drug|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
79527252|NCT02798029|Radiation|Frameless Fractionated Stereotactic Radiation Therapy|
79683204|NCT02932397|Drug|Intravenous dose of 0.05 mL/kg of saline solution|
79683205|NCT02932319|Device|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
79683206|NCT02932319|Other|expectative|expectative until the next day befor starting the induction
79683207|NCT02911272|Device|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
79826420|NCT02157610|Behavioral|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
79826421|NCT02157610|Procedure|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
79826422|NCT02157610|Behavioral|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
79373688|NCT01923207|Drug|Placebo|placebo, subcutaneous administration
79373689|NCT01218958|Drug|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
79373690|NCT01218958|Drug|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
79373691|NCT01218958|Drug|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
79373692|NCT01218958|Drug|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
79527253|NCT02793492|Device|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
79527254|NCT02701699|Biological|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
79527255|NCT02629692|Drug|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
79527256|NCT02596490|Behavioral|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
79683208|NCT02911272|Drug|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
79683209|NCT02911272|Procedure|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
79683210|NCT02911272|Device|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
79683211|NCT02932241|Behavioral|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
79683212|NCT02911194|Dietary Supplement|a2 milk|replace all milk with a2 milk
79826423|NCT02157610|Drug|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
79826424|NCT02078869|Drug|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
80000166|NCT06040190|Dietary Supplement|oral alpha-lipoic acid capsule|Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.
79683213|NCT02911194|Dietary Supplement|a1 containing milk|use a1 containing milk
79826425|NCT02078869|Drug|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
80000167|NCT06040190|Other|topical phytotherapic capsaicin gel|Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.
79231711|NCT02553772|Drug|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
79231712|NCT00665145|Drug|SB-509|Active drug
79231713|NCT00665145|Drug|SB-509|Active drug
79527257|NCT02596490|Behavioral|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
79527258|NCT02596490|Behavioral|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
79527259|NCT02402920|Drug|Carboplatin|Given IV
79826426|NCT01946815|Drug|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
79231714|NCT00665145|Drug|Placebo|Placebo
79231715|NCT00665145|Drug|SB-509|Active drug
79527260|NCT02402920|Drug|Cisplatin|Given IV
79527261|NCT02402920|Drug|Etoposide|Given IV
79527262|NCT02402920|Other|Laboratory Biomarker Analysis|Correlative studies
79527263|NCT02402920|Biological|Pembrolizumab|Given IV
79683214|NCT02932436|Drug|Empagliflozin|10 mg per os daily for 12 weeks
79683215|NCT02932436|Drug|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
79683216|NCT02932670|Other|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
79683217|NCT02910960|Device|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
79826427|NCT01943318|Procedure|Liver biopsy|Histologic evaluation
80000168|NCT06040190|Radiation|local photobiomodulation|Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
80000169|NCT06040086|Drug|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
79231716|NCT03119714|Drug|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
79231717|NCT03119714|Drug|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
79231718|NCT02274597|Device|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
79231719|NCT04617977|Behavioral|I-BMS for families with children suffering from eczema|It is a strength-based, family system approach to aid empowerment of individuals. It focuses on the interplay between physical and emotional well-being, the spiritual transformation of adverse life experiences, and the acceptance of adversity through reflection on the philosophical concepts of forgiveness and letting go. It integrates Western therapeutic techniques and Eastern philosophies to develop spiritual transformation through suffering and pain under a meaning-oriented framework. It consists of six three-hour consecutive weekly sessions: (1) awareness of body-mind connection; (2) regulation of emotion; (3) acknowledgement of the gains and losses in the caregiving or illness experience; (4) appreciation of self and others; (5) cultivation of acceptance; and (6) meaning reconstruction of caregiving or illness experience.
79231720|NCT04617977|Behavioral|Health education for parents whose children have eczema|It focuses on practical eczema management. It serves as a control for group effect between conditions. It consists of six three-hour sessions: (1) information about the physiology of eczema and its health impact; (2) recognition and avoidance of trigger factors and daily skin care; (3) dealing with itching and scratching; (4) stage-related treatment of symptoms and unconventional therapies; (5) general child nutrition, food allergies in eczema, and different forms of diets; and (6) self-management plan and problems in integrating into daily routine.
79527264|NCT02402920|Procedure|Radiation Therapy|Undergo radiation therapy
79527265|NCT02315521|Procedure|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
79527266|NCT02277028|Behavioral|priming and task specific training|This task specific training protocol has been used in several clinical trials.
79527267|NCT02273375|Drug|MEDI4736|
79527268|NCT02273375|Drug|Placebo|
79826428|NCT01943318|Device|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
79826429|NCT01937156|Drug|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
79826430|NCT01937156|Drug|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
79683218|NCT02910960|Device|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
80000170|NCT06040086|Drug|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study.
79683219|NCT02932124|Device|mechanical chest compression device|
80000171|NCT06039410|Device|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
80000172|NCT06038474|Drug|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
79527269|NCT02266212|Procedure|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
79231721|NCT00562887|Biological|Placebo|every 4 weeks, IV
79231722|NCT00562887|Biological|ABT-874|400 mg IV every 4 weeks
79231723|NCT00562887|Biological|ABT-874|700 mg IV every 4 weeks
79231724|NCT05468554|Drug|metformin|Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
79231725|NCT05468554|Radiation|Radioactive iodine (I-131)|Patients qualified to receive 131I treatment
79527270|NCT02117063|Behavioral|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
79683220|NCT02932007|Drug|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
80000173|NCT06036784|Drug|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
79683221|NCT02932085|Device|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
79527271|NCT02113202|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
80000174|NCT06036784|Drug|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
79527272|NCT02113202|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
79683222|NCT02910882|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
79683223|NCT02910882|Drug|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
80000175|NCT06036784|Drug|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
80000176|NCT06036784|Drug|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
80000177|NCT06035848|Procedure|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~Components of metabolic derangement~Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
80000178|NCT06035848|Procedure|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
79527273|NCT01999062|Other|IMRT + CT + MR scan|
79527274|NCT01811043|Behavioral|Guided Meditation|
79527275|NCT01811043|Behavioral|Music|
79231726|NCT04617821|Drug|Nab paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.
79231727|NCT04617821|Drug|mFOLFIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
79231728|NCT03219632|Drug|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
79231729|NCT03219008|Drug|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
79527276|NCT01811043|Behavioral|Supportive Dialogue|
79683224|NCT02910882|Radiation|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
79683225|NCT02931968|Device|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
80016654|NCT05203913|Drug|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
79683226|NCT02934438|Dietary Supplement|Neo40|
79231730|NCT03219008|Combination Product|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
79231731|NCT03219008|Drug|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
79373693|NCT03444246|Dietary Supplement|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
79231732|NCT03219008|Combination Product|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
79231733|NCT03219008|Drug|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
79231734|NCT03219008|Drug|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
79373694|NCT03444246|Dietary Supplement|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
79373695|NCT01240330|Device|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
79527277|NCT01803542|Radiation|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
79231735|NCT03219008|Combination Product|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
79527278|NCT01781468|Drug|armodafinil 150 mg|given orally
79527279|NCT01781468|Other|Placebo|given orally
79683227|NCT02934438|Dietary Supplement|Placebo|
79231736|NCT03219008|Combination Product|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
79231737|NCT03219008|Drug|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
80016655|NCT05203913|Drug|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
80016656|NCT05203913|Radiation|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
79527280|NCT01781468|Drug|armodafinil 250 mg|given orally
79527281|NCT01709045|Other|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
79231738|NCT03219008|Combination Product|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
79231739|NCT03219008|Drug|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
79373696|NCT04377360|Radiation|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
79527282|NCT01709045|Radiation|Dual-Energy Computed Tomography (DECT)|
79527283|NCT01709045|Other|Ultrasound|
79527284|NCT01709045|Other|Transcranial doppler|
79527285|NCT01545141|Drug|Chemokin Modulatory Regimen (5 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
79826431|NCT01805804|Drug|placebo/valsartan|
79826432|NCT01718873|Drug|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
79826433|NCT01718873|Drug|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
79826434|NCT01718873|Drug|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
79527286|NCT01545141|Drug|Chemokin Modulatory Regimen (10 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
79527287|NCT01545141|Drug|Chemokin Modulatory Regimen (20 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
79683228|NCT02932046|Dietary Supplement|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
79709824|NCT04326855|Other|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
79683229|NCT02934516|Procedure|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
79683230|NCT02932202|Other|Longitudinal Nutritional Counseling|
79373697|NCT04752228|Other|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
79527288|NCT01500798|Drug|20 mg bardoxolone methyl|20 mg, oral, once daily
79683231|NCT02932202|Other|Standard Care|
79683232|NCT02934594|Other|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
79683233|NCT02931929|Drug|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
79683234|NCT02910804|Drug|68Ga-BBN-IRDye800CW|
79826435|NCT01718873|Drug|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
79826436|NCT01718873|Drug|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
79231740|NCT03219008|Combination Product|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
79231741|NCT03219008|Other|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
79826437|NCT01511250|Biological|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
79231742|NCT02553538|Behavioral|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
79231743|NCT03218930|Behavioral|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
79231744|NCT03218930|Behavioral|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
79373698|NCT04752228|Other|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
79527289|NCT01500798|Drug|Placebo|Oral, once daily
79527290|NCT01428895|Procedure|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
79826438|NCT01511250|Biological|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
79826439|NCT01424566|Drug|Nabiximols|
79826440|NCT01424566|Drug|Placebo (GA-0034)|
79826441|NCT01367561|Drug|Naloxone|
79527291|NCT01428895|Other|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
79826442|NCT01367561|Drug|IV Methylnaltrexone (MNTX)|
79826443|NCT01367561|Drug|Placebo|
79231745|NCT03218930|Behavioral|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
79373699|NCT03440268|Drug|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
79826444|NCT01361607|Drug|Nabiximols|
79231746|NCT03218930|Behavioral|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
79231747|NCT00562497|Drug|Prochymal®|Prochymal® intravenous infusion.
79683235|NCT02910804|Device|PET/NIRF|
79231748|NCT00562497|Other|Placebo|Placebo-matching Prochymal® intravenous infusion.
79231749|NCT00562497|Other|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
79683236|NCT02910804|Procedure|PET/NIR fluorescent imaging-guided surgery|
79683237|NCT02931734|Drug|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
79683238|NCT02931734|Drug|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
79683239|NCT02931734|Procedure|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
79826445|NCT01361607|Drug|Placebo (GA-0034)|
79826446|NCT01337089|Drug|Nabiximols|
79826447|NCT01276587|Drug|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
79826448|NCT01217580|Drug|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
79826449|NCT01217580|Drug|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
79826450|NCT00981396|Behavioral|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
79826451|NCT00981396|Behavioral|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
79826452|NCT00802646|Drug|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
79826453|NCT00802646|Drug|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
79826454|NCT00473707|Procedure|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
79826455|NCT00473707|Procedure|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
79826456|NCT00473707|Drug|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
79826457|NCT00473707|Drug|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
79826458|NCT00279500|Device|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
79826459|NCT00233675|Drug|GABITRIL (tiagabine hydrochloride; CEP-6671)|
79826460|NCT00202774|Drug|(capecitabine, oxaliplatin, 5-fluorouracil)|
79231750|NCT03218540|Procedure|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV > 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP < 8 mmHg
79231751|NCT02548156|Other|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
79826461|NCT00114530|Biological|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
79826462|NCT00114530|Drug|cyclophosphamide|An initial intravenous dose of 500 mg/m^2 was followed by 11 infusions of 750 mg/m^2 with mesna given for bladder protection.
79826463|NCT00107744|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
79826464|NCT00107744|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
79826465|NCT00107744|Dietary Supplement|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
79826466|NCT00845338|Drug|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
79826467|NCT00711360|Device|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
79231752|NCT02548156|Other|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
79231753|NCT02548156|Other|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
79231754|NCT02548156|Other|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
79231755|NCT02548156|Other|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
79527292|NCT01422759|Drug|Spironolactone|50-100 mg PO BID (X 12 weeks)
79527293|NCT01421797|Drug|Dexamethasone|1 mg PO
79527294|NCT01421797|Drug|Cortrosyn|single IV bolus of 0.25 mg will be administered
79527295|NCT01404741|Procedure|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
79527296|NCT01404741|Procedure|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
79527297|NCT01335022|Behavioral|lecture|6 lectures on cardiovascular disease covering obesity, diet & exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
79527298|NCT01279408|Other|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
79527299|NCT00944528|Radiation|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
79527300|NCT00937248|Device|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
79826468|NCT00855634|Procedure|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
79826469|NCT00855634|Procedure|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
79231756|NCT03217994|Drug|gel HP|gel of hygrogen peroxide for teeth bleaching
79231757|NCT00468975|Drug|PF-610,355|
79231758|NCT00468975|Drug|Salmeterol|
79231759|NCT01503515|Drug|Caspofungin Acetate|Given IV
79683240|NCT02934672|Other|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
79683241|NCT02931656|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
79683242|NCT02910765|Drug|methylene blue|
79683243|NCT02910765|Drug|ozone|
79826470|NCT05673174|Diagnostic Test|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
79826471|NCT00923962|Drug|Glucagon like peptide-1|0,1 pmol/kg/min
80000179|NCT06035445|Behavioral|In-person adolescent-friendly service (iPAS) intervention|Monthly visits take place in a group setting with sessions led by peer educators. Clinical staff and peer educators are trained in care of adolescents using the Right to Care training materials. During their clinic visit, adolescents are evaluated individually by a healthcare provider and receive their supply of ART. In addition, adolescents participate in scheduled group team-building activities including dancing, sports, music and receive group counseling facilitated by peer educators. Nine group counseling sessions will discuss the topics of: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. The half-day sessions will end with the provision of a meal. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
80016657|NCT03660501|Device|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
79231760|NCT01503515|Drug|Fluconazole|Given IV or PO
79231761|NCT01503515|Other|Laboratory Biomarker Analysis|Optional correlative studies
79826472|NCT00923962|Drug|Adenosine|20-40 microgram/minute
79231762|NCT01503515|Drug|Voriconazole|Given IV or PO
79373700|NCT03440268|Drug|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
79527301|NCT00937248|Device|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
79231763|NCT03231566|Behavioral|Pain Neuroscience Education|See arm/group description
79231764|NCT00468273|Drug|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
79231765|NCT03217916|Diagnostic Test|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
79373701|NCT04369014|Drug|etomidate anesthesia|etomidate is used for induction and maintenance of general anesthesia
79527302|NCT00881660|Device|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
79527303|NCT00857662|Device|Onyx|Embolization
79527304|NCT00857662|Device|TRUFILL|Embolization
79683244|NCT02910765|Other|saline infusion|
79231766|NCT00468117|Procedure|Islet transplantation|
79231767|NCT00468117|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
79231768|NCT00468117|Biological|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
79231769|NCT00468117|Biological|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
79231770|NCT00468117|Biological|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
79231771|NCT03231488|Other|Mindfulness intervention|A 10 minute mindfulness of breath exercise
79231772|NCT03231488|Other|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
79231773|NCT03217604|Drug|Placebo|Treatment with placebo
79373702|NCT04369014|Drug|propofol anesthesia|propofol is used for induction and maintenance of general anesthesia
79373703|NCT03436914|Drug|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
79683245|NCT02910765|Other|oxygen|
79683246|NCT02931773|Device|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
79709825|NCT04326855|Other|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
79826473|NCT00711438|Behavioral|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
79826474|NCT00711438|Behavioral|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
79826475|NCT02575092|Drug|Enalapril Maleate Tablets(as the program-based antihypertension)|
79826476|NCT02575092|Drug|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
79826477|NCT02575092|Drug|Placebo|
79826478|NCT00851578|Device|WATCHMAN|WATCHMAN LAA Closure Device
79826479|NCT04097470|Drug|Decitabine|Decitabine dosage 20mg/m2 i.v.
79231774|NCT03217604|Drug|PF-06852231|Treatment with PF-06852231
79231775|NCT03231254|Device|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
79683247|NCT02934633|Behavioral|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
79231776|NCT02276079|Behavioral|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
79683248|NCT02934633|Behavioral|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
79826480|NCT04097470|Drug|Midostaurin|Midostaurin 50 mg b.i.d.
79826481|NCT02575014|Drug|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
79826482|NCT04041934|Dietary Supplement|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
79826483|NCT02573142|Behavioral|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
79826484|NCT02573142|Behavioral|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
79231777|NCT02276079|Behavioral|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
79373704|NCT03436836|Drug|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
79683249|NCT02931617|Other|Chest Physiotherapy|
79683250|NCT02931617|Device|Post-therapy lung volume measurements|In both intervention groups.
79683251|NCT02925026|Dietary Supplement|Lactoferrin|
79683252|NCT02925026|Dietary Supplement|Lysozyme|
79683253|NCT02925026|Dietary Supplement|Placebo|
79683254|NCT02925065|Other|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
79683255|NCT02925182|Device|Er,Cr:YSGG Laser|
79683256|NCT02924987|Drug|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
79683257|NCT04687995|Procedure|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
79683258|NCT02925104|Drug|INC280|
79683259|NCT02910687|Other|This is an observational study|
79683260|NCT02924909|Drug|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
79683261|NCT02934360|Device|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
79683262|NCT02924948|Procedure|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
79683263|NCT02934321|Dietary Supplement|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
79683264|NCT02934321|Dietary Supplement|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
79683265|NCT02924831|Other|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
79683266|NCT02924831|Other|moxibustion|Stimulating acupoints by using burned moxa
79683267|NCT02924831|Other|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
79826490|NCT00845494|Behavioral|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
79231778|NCT03216824|Other|Dressing|A dressing is maintained on the CVAD exit site.
79231779|NCT03216824|Other|No-Dressing|The CVAD exit site is not covered with a dressing.
79683268|NCT02934126|Other|breast cancer patients|semi structured face to face interviews
79683269|NCT02924753|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
79826491|NCT00855790|Other|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
79826492|NCT04042090|Device|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
79826493|NCT04069650|Procedure|Free flap|Free flap reconstruction of the oral cavity
79231780|NCT00468039|Drug|vildagliptin + metformin|
79231781|NCT02451254|Procedure|circumferential ablation|circumferential ablation of the pulmonary veins
79231782|NCT02451254|Device|SVT ablation|SVT ablation
79683270|NCT02924753|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
79826494|NCT00851734|Drug|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
79826495|NCT00716040|Behavioral|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
79826496|NCT00716040|Other|Usual care|The control group will be submitted to the usual care of the health service
79826497|NCT04019028|Device|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
79231783|NCT02451020|Other|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
79231784|NCT03224702|Drug|M6495|Subjects will receive M6495 on Day 1
79231785|NCT03224702|Drug|Placebo|Subjects will receive placebo matched to M6495 on Day 1
79231786|NCT02742519|Drug|ivacaftor|
79231787|NCT02742519|Drug|Placebo|
79231788|NCT01375010|Drug|Vitamin D3|2000 mg QD
79231789|NCT01375010|Other|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
79231790|NCT01375010|Drug|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
79231791|NCT03231332|Other|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
79231792|NCT00548925|Drug|ABT-894|6 mg BID tablets, 8 weeks of treatment
79683271|NCT02924753|Biological|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
79683272|NCT04673136|Device|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
79683273|NCT04673136|Other|Colonoscopy|Standard colonoscopy
79683274|NCT02924792|Device|Reinfusion - Sternal IO needle|
79683275|NCT02924792|Device|Reinfusion - Intravenous needle|
79683276|NCT02910375|Other|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
79683277|NCT02910375|Other|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
79683278|NCT02924675|Drug|Pregabalin|150mg daily in three doses during three weeks
79683279|NCT02924675|Drug|Placebo|Three doses daily with lactose
79231793|NCT00548925|Drug|placebo|BID tablets, 8 weeks of treatment
79683280|NCT02910609|Device|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
79683281|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic RFA assisted TE|
79683282|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic partial nephrectomy|
79826498|NCT04019028|Device|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
79826499|NCT04019028|Device|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
79826500|NCT00845572|Behavioral|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
79373705|NCT03436836|Drug|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
79826501|NCT00851812|Behavioral|Exercise|Standard care monitoring
79826502|NCT00851812|Behavioral|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
79373706|NCT03436836|Drug|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
79826503|NCT00711906|Drug|Cotrimoxazole|Cotrimoxazole
79826504|NCT00711906|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
79826505|NCT00851968|Procedure|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
79826506|NCT00851968|Procedure|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
79826507|NCT00851968|Procedure|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
79826508|NCT04018950|Drug|ETX2514|intravenous infusion
79826509|NCT04018950|Drug|14C-ETX2514|intravenous infusion
79231794|NCT03231176|Drug|Varlitinib|oral tablets, twice daily
79231795|NCT03231176|Drug|Capecitabine|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
79231796|NCT02276235|Device|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
79826510|NCT00845806|Other|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
80016658|NCT05230108|Procedure|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
79231797|NCT02276235|Device|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
79231798|NCT02450942|Drug|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
79231799|NCT00467025|Drug|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
79373707|NCT03444012|Drug|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
79373708|NCT04729452|Other|blood test|blood test to test immune response to SARS-CoV-2
79373709|NCT00331773|Radiation|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
79373710|NCT00331773|Radiation|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
79373711|NCT03440034|Drug|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
79373712|NCT04708938|Other|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
79373713|NCT04708938|Other|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
79826511|NCT00709410|Biological|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
79683283|NCT02924558|Other|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
79683284|NCT02924558|Other|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
79683285|NCT03847545|Drug|Fampridine|sustained-release tablet 10 mg morning and evening.
79826512|NCT02545972|Drug|tacrolimus extended release|daily dosing of tacrolimus
79231800|NCT00467025|Drug|Sorafenib|400 mg PO BID
79231801|NCT00467025|Drug|AMG 386 placebo IV|AMG 386 placebo IV
79231802|NCT02276469|Behavioral|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
79231803|NCT03231020|Other|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
79231804|NCT02277795|Device|AccuCirc|Circumcision with the use of the AccuCirc device.
79231805|NCT00546585|Biological|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
79231806|NCT00546585|Drug|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
79231807|NCT03230786|Drug|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
79231808|NCT02282397|Device|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
79683286|NCT02924285|Procedure|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
79231809|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
79231810|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
79373714|NCT03433326|Drug|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
79373715|NCT03436446|Other|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
79683287|NCT02924285|Drug|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
79683288|NCT02924363|Diagnostic Test|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
79683289|NCT02924363|Diagnostic Test|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
79683290|NCT02934048|Other|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
79826513|NCT02574780|Other|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
79826514|NCT02574780|Other|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
79826515|NCT00852046|Drug|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
79826516|NCT02573064|Drug|Colistin|
79231811|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
79231812|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
79231813|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
79231814|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
79231815|NCT00546273|Biological|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
79231816|NCT00546273|Biological|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
79231817|NCT00546273|Biological|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
79231818|NCT00546273|Biological|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
79231819|NCT00546273|Biological|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
79231820|NCT02452112|Drug|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
79373716|NCT03439956|Procedure|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
79373717|NCT03439878|Dietary Supplement|Galactose|Co-ingestion of d-galactose with a high-fat meal
79373718|NCT03439878|Dietary Supplement|Glucose|Co-ingestion of d-glucose with a high-fat meal
79373719|NCT04327518|Device|TECNIS® Toric II|Toric Intraocular Lens
80000180|NCT06035445|Behavioral|mHealth (InTSHA) intervention|The InTSHA intervention is based on Got Transition elements (two-way messaging between adolescents and healthcare providers) and the SMART model. The SMART model focuses on modifiable factors of transition preparation through content delivery, facilitated discussions, online meet ups and consultation with the healthcare team. The intervention consists of 9 modules delivered monthly by group chat. The topics of the modules are: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. Outside of scheduled group chat sessions, adolescents have access to the chat group to check in with members, review content of the sessions, or to comment or ask additional questions. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
80000181|NCT06035445|Behavioral|Standard of Care|Adolescents in standard of care are seen every three months by clinicians and collect medication monthly at an on-site pharmacy during regular weekdays. Individual counseling delivered by counselors or social workers is available when necessary. Staff at all clinics receive training in adolescent-friendly services (AFS) through the Right to Care training materials.
79826517|NCT02573064|Drug|Tigecycline|
79826518|NCT02573064|Drug|Vancomycin|
80000182|NCT06027840|Drug|Varenicline|Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
79683291|NCT02934048|Other|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
80000183|NCT06027840|Behavioral|Counseling|Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
79231821|NCT02452112|Drug|Placebo|Placebo patch to be placed on the site of pain
79683292|NCT02934048|Other|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
79231822|NCT00659061|Dietary Supplement|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
79231823|NCT00659061|Behavioral|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
79683293|NCT02924207|Other|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
79683294|NCT02934087|Procedure|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
79826519|NCT00845884|Drug|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
79826520|NCT02574936|Procedure|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
79826521|NCT00923806|Biological|PG13-CEA_TCR (Anti-CEA TCR PBL)|
79826522|NCT00923806|Drug|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
79826523|NCT00848068|Other|FID 114657|artificial tears
79527305|NCT00777998|Procedure|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> 2 months later: Melphalan plus allogeneic PBSCT~-> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~-> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10^6 (MRD) or 5 x 10^5 (MUD) CD3+ cells per kg BW)~-> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Further DLI depending on MRD-measurement"
79826524|NCT00848068|Other|OPTIVE Lubricant Eye Drops|artificial tears
79826525|NCT00711984|Device|Herkulink renal artery Stent|renal artery stent
79231824|NCT02451956|Drug|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
80000184|NCT06027840|Behavioral|Guided Self-Change Booklets|The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
80000185|NCT06025097|Drug|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
79373720|NCT03439800|Other|Mental and Physical Practice|"Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~From 9th to final training session: both mental and physical practice of the dual task gait."
79683295|NCT01287520|Drug|LY2090314|Administered intravenously
79683296|NCT01287520|Drug|pemetrexed|Administered intravenously
80000186|NCT06018402|Other|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
80000187|NCT06018402|Other|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
80000188|NCT06018168|Other|Skincare Routine|"Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~VITAMINSCRUB - Wet your face with lukewarm water & apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
79683297|NCT01287520|Drug|Carboplatin|Administered intravenously
79683298|NCT01287520|Other|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
79826526|NCT00711984|Other|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
79683299|NCT02924246|Biological|cholera vaccination|Oral cholera vaccination on day 0 and day 14
79826527|NCT00856102|Behavioral|Exercise|Home-base walking program
79826528|NCT00856102|Behavioral|Control|Usual care
79826529|NCT00718536|Drug|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
79826530|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
79683300|NCT02924246|Other|raw milk|raw milk
79683301|NCT02924246|Other|pasteurized milk|pasteurized milk
80016659|NCT00402428|Drug|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
80016660|NCT00402428|Drug|peginterferon alfa-2a|180 mcg once a week for 48 weeks
80016661|NCT00402428|Drug|Ribavirin|"1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects~=,> 75kg)"
79231825|NCT02451956|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
79231826|NCT02725372|Drug|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
79231827|NCT02725372|Drug|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
79231828|NCT00542685|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
79683302|NCT02924246|Other|UHT milk|UHT milk
79683303|NCT04323865|Diagnostic Test|fetal heart rate variability|No direct intervention, as the study is observational.
79683304|NCT00623740|Drug|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
79683305|NCT00623740|Drug|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
79683306|NCT01287403|Other|Refined wheat flour|A treated cereal flour mixed with milk.
79231829|NCT00542685|Drug|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
79683307|NCT01287403|Other|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
79683308|NCT01287403|Other|Wholegrain wheat flour|A treated cereal flour mixed with milk.
79683309|NCT01287403|Other|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
79683310|NCT01287403|Other|Wholegrain barley flour|A treated cereal flour mixed with milk.
79683311|NCT01287403|Other|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
79683312|NCT02924168|Device|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
79683313|NCT02924168|Device|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
79683314|NCT02889913|Other|No intervention only description|No intervention only description
79826531|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
79826532|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
79683315|NCT01287364|Drug|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
79231830|NCT00542685|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
80000189|NCT06018168|Dietary Supplement|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
79527306|NCT00777998|Procedure|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~-> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
79683316|NCT01287364|Drug|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
79826533|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
79826534|NCT02572674|Other|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
79826535|NCT02572674|Genetic|Genetic sample|Blood samples
79826536|NCT00856336|Drug|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
79826537|NCT00712062|Drug|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
79527307|NCT00188539|Procedure|Pre-treatment tumour oxygen measurements (under anesthesia)|
80000190|NCT06016634|Drug|Alendronate Sodium|Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
80000191|NCT06015282|Biological|Investigational aQIVc|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79231831|NCT00542685|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
79231832|NCT02450786|Drug|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
79231833|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
79231834|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
79231835|NCT00539721|Drug|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
79231836|NCT00539721|Drug|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
79231837|NCT00539721|Drug|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
79231838|NCT00539721|Drug|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
79231839|NCT00539721|Drug|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
79231840|NCT00539721|Drug|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
79231841|NCT03224780|Diagnostic Test|maternal serum creatine kinase|Biochemical marker
79527308|NCT04453449|Drug|Midazolam|Midazolam given as a sedative during diagnostic lumbar medial branch block
79527309|NCT04366336|Procedure|Blood Flow Restriction Training|Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
79683317|NCT02924012|Other|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
79683318|NCT02924012|Other|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
79683319|NCT02924012|Other|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
79683320|NCT02889757|Drug|Acteylcysteine|randomized into three arms
79683321|NCT02889952|Device|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
79683322|NCT02889835|Device|Supreme Universal Restorative|
79683323|NCT02889835|Device|Supreme Flowable Restorative|
79683324|NCT02889835|Device|Bulk Fill Flowable Restorative|
79683325|NCT02923973|Other|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
79231842|NCT03224780|Diagnostic Test|3D Doppler ultrasound|Doppler for placental vessels
79231843|NCT00464061|Drug|Volinanserin|oral administration
79683326|NCT01287013|Device|Cone-beam computed tomography (CT)|Imaging
80000192|NCT06015282|Biological|licensed QIV1|Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
80000193|NCT06015282|Biological|licensed QIV2|Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
80000194|NCT06012851|Behavioral|Mobile behavioral parent training (mBPT) and prompts|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access. In-the-moment feedback will include parenting feedback and parenting strategies.
80000195|NCT06011265|Drug|Myrbetriq 25Mg Extended-Release Tablet|Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
80000196|NCT06011265|Drug|Placebo|Participants take empty capsule orally
80000197|NCT06006559|Drug|EYU688|EYU688 administered by oral route
80000198|NCT06006559|Drug|Placebo|Matching placebo administered orally as capsules
80000199|NCT06005025|Other|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
79373721|NCT03439800|Other|Physical Practice|"Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
79683327|NCT01287013|Device|Conventional Computed Tomography (CT)|Imaging
80000200|NCT05997693|Drug|Ticagrelor 90 MG|Ticagrelor 90 mg bd taken orally
80000201|NCT05997693|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally
80000202|NCT05995353|Drug|Risankizumab|Intravenous (IV) Infusion
80000203|NCT05995353|Drug|Risankizumab|Subcutaneous (SC) Injection
80000204|NCT05995340|Device|ELAPR002f Injectable Gel|Intradermal Injections
80000205|NCT05995340|Other|Saline Control|Intradermal Injections
80000206|NCT05992454|Device|EOLIFE|Measurement of ventilatory parameters during manual ventilation by professional rescuers during out-of-hospital cardiac arrest
80000207|NCT05990348|Other|difficult weaning patients|intercostal thickening fraction values during PSV and NAVA modalities in patients with difficult weaning from MV admitted in ICU.
79231844|NCT00464061|Drug|Placebo|oral administration
79231845|NCT03230630|Diagnostic Test|plasma melatonin levels|
79231846|NCT00460941|Drug|Placebo|sc weekly
79231847|NCT00460941|Drug|Taspoglutide 20mg|sc weekly
79231848|NCT00460941|Drug|Taspoglutide 20mg-30mg|sc weekly
79231849|NCT00460941|Drug|Taspoglutide 20mg-40mg|sc weekly
80000208|NCT05986786|Device|Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule|Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
80000209|NCT05985538|Behavioral|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
80016662|NCT05120206|Procedure|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
79231850|NCT03224078|Other|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
79231851|NCT03213782|Other|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
79231852|NCT00460317|Drug|AMG 706|125 mg QD orally every day
79231853|NCT00460317|Drug|placebo|125 mg QD orally every day
79231854|NCT00460317|Drug|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
79231855|NCT00460317|Drug|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
79373722|NCT04760223|Behavioral|Video intervention|a 100-second video, presenting a personal story of a boy/girl dealing with depression
79683328|NCT02934243|Device|laryngeal mask insertion|airway management with laryngeal mask
79683329|NCT02924090|Drug|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
79683330|NCT02924090|Drug|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
79683331|NCT02924090|Procedure|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
79683332|NCT02924090|Procedure|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
79826538|NCT00848146|Procedure|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
79826539|NCT02545816|Device|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
79231856|NCT03230552|Other|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
79231857|NCT03213548|Procedure|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
79826540|NCT00712140|Biological|trastuzumab|Given IV
79527310|NCT04366336|Procedure|Standard Physical Therapy|Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
79527311|NCT04364867|Drug|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
79826541|NCT00712140|Drug|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
80000210|NCT05985538|Behavioral|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
79527312|NCT04364867|Drug|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
79527313|NCT04347343|Procedure|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
79527314|NCT04340739|Other|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
79527315|NCT04333888|Behavioral|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
79527316|NCT04283071|Device|Boxed infrared gross kinematic assessment tool|An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
79527317|NCT04233814|Drug|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
79826542|NCT02546206|Dietary Supplement|Probiotic Yoghurt|Probiotic yoghurt consumption
79826543|NCT02546206|Dietary Supplement|Natural Yoghurt|Natural yoghurt consumption
79826544|NCT02545738|Drug|Liraglutide|active treatment
79231858|NCT03213548|Procedure|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
79231859|NCT00534027|Drug|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
79826545|NCT02545738|Drug|placebo|placebo
79826546|NCT00712218|Procedure|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
79826547|NCT00712218|Procedure|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions [24, ].
79231860|NCT00534027|Other|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
79231861|NCT00459693|Drug|[11C]PBR28|
80000211|NCT05983822|Device|Technological Group|Specific rehabilitation for the recovery of hand function using the end-effector robot
80000212|NCT05983822|Other|Conventional Treatment|Conventional rehabilitation
79231862|NCT02450864|Other|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
80000213|NCT05981131|Drug|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
80000214|NCT05980442|Device|Navigated total knee arthroplasty|Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system
80000215|NCT05980442|Device|Robot assisted total knee arthroplasty|Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
80000216|NCT05978063|Drug|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
80000217|NCT05978063|Drug|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
80000218|NCT05978063|Drug|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
79231863|NCT02451878|Behavioral|E-Couch|e-couch is an online CBT based intervention
79231864|NCT03230942|Other|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
79231865|NCT03230942|Other|Pos-operative rehabilitation|Physical therapy treatment
79231866|NCT02284191|Radiation|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
79373723|NCT03439722|Other|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
80000219|NCT05978063|Drug|Placebo tablets|Oral Placebo administered twice daily
79373724|NCT00244101|Drug|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
79373725|NCT00244101|Device|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
79527318|NCT04233814|Drug|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
79527319|NCT04232059|Device|cerebral oximetry|evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
79373726|NCT00244101|Drug|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
79527320|NCT04212286|Diagnostic Test|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
79527321|NCT04155216|Behavioral|Relaxation and guided imagery program|Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
79527322|NCT04023162|Behavioral|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
80000220|NCT05968755|Device|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
79373727|NCT04959708|Other|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
79373728|NCT03436212|Device|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
79527323|NCT04023162|Behavioral|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
80000221|NCT05968755|Other|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
80000222|NCT05967351|Genetic|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
80000223|NCT05963997|Drug|Samuraciclib|Samuraciclib capsules by mouth once a day
79373729|NCT02337465|Device|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
80000224|NCT05963997|Drug|Elacestrant Dihydrochloride|Elacestrant tablets by mouth once a day
80000225|NCT05963581|Behavioral|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
80000226|NCT05959434|Behavioral|Cognitive Processing Therapy + Relapse Prevention|Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol use disorder
79826548|NCT00848224|Behavioral|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
79826549|NCT00848302|Drug|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
79826550|NCT02572596|Drug|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
80000227|NCT05959434|Behavioral|Relapse Prevention|Cognitive-Behavioral Therapy that targets alcohol use, specifically
80000228|NCT05957510|Drug|Serplulimab|serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
79231867|NCT03212846|Other|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
79231868|NCT02548078|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
79231869|NCT02548078|Biological|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
79373730|NCT02337465|Radiation|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
79373731|NCT03436134|Other|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
79373732|NCT03436134|Other|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
79373733|NCT03439644|Other|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
79373734|NCT00633243|Procedure|Modified Directly Observed Therapy (mDOT)|
79683333|NCT01286779|Biological|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
79373735|NCT00633243|Procedure|Self-Administered Therapy (SAT)|
79826551|NCT02572596|Drug|CTX|CTX 2.5/m2 for 2 days.
79826552|NCT02572596|Drug|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
79826553|NCT00718614|Procedure|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
79826554|NCT04069728|Other|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
80000229|NCT05957510|Drug|SOC|the treatment recommended by the investigator
80000230|NCT05948618|Behavioral|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
80000231|NCT05948618|Behavioral|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
80000232|NCT05947981|Dietary Supplement|Dextrose 5%, normal saline|Decrease fasting hours
80000233|NCT05945147|Drug|Ketamine|An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
80000234|NCT05945147|Drug|Midazolam|A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
79683334|NCT02934165|Behavioral|Family Safety 123|Theoretically-based injury prevention videos for families
80000235|NCT05945147|Drug|Normal Saline|An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
80000236|NCT05944952|Drug|buprenorphine/naloxone|Participants will be dosed with buprenorphine/ naloxone strips
80000237|NCT05943535|Drug|Placebo|Placebo administered QID
80000238|NCT05943535|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
79683335|NCT02934165|Behavioral|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
79683336|NCT04137770|Other|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
80000239|NCT05943535|Device|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
80000240|NCT05936203|Other|Insulin therapy adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
80000241|NCT05936203|Other|Nutritional adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
79373736|NCT04759677|Other|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
79231870|NCT00532311|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
79683337|NCT05594797|Drug|Human BCMA Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
79231871|NCT00532311|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
79373737|NCT04451382|Biological|OnabotulinumtoxinA (BoNTA)|
79373738|NCT04451382|Procedure|Percutaneous tibial nerve stimulation (PTNS)|
79373739|NCT04276389|Device|OCT-guided paclitaxel drug-coated balloon angioplasty|OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
79527324|NCT04023162|Behavioral|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
79826555|NCT04069728|Other|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
79527325|NCT04002388|Behavioral|activity monitor group|will receive a FitBit and will be asked to wear this for one year
80000242|NCT05936203|Other|Combination of strategies|Strategies used to manage glucose control during a prolonged aerobic exercise
79527326|NCT04002388|Behavioral|usual care group|will NOT receive a FitBit
79527327|NCT03993821|Drug|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
79527328|NCT03964545|Behavioral|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
79527329|NCT03871751|Behavioral|Safe and Sound Protocol|The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
79527330|NCT03735849|Biological|VRC07-523LS|Administered by intravenous (IV) infusion
79683338|NCT01286740|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
79683339|NCT02934009|Device|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
79826556|NCT00712374|Drug|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
80000243|NCT05933057|Drug|Givinostat|Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
80000244|NCT05933057|Drug|Placebo|Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
80000245|NCT05929911|Behavioral|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
79231872|NCT03224156|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
79231873|NCT03230708|Other|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
79683340|NCT01286311|Behavioral|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
79231874|NCT03230708|Drug|convention drugs|according to usage method of drugs
79231875|NCT03230474|Drug|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
79231876|NCT03230474|Drug|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
79231877|NCT00532233|Drug|QAX576|
79231878|NCT00532077|Drug|rhPTH(1-34)|
79231879|NCT00532077|Drug|SB-751689 100 mg|
79231880|NCT00532077|Drug|SB-751689 400 mg|
79231881|NCT03212924|Behavioral|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
79683341|NCT02923856|Device|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
79683342|NCT02923856|Device|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
79826557|NCT02573220|Biological|Cetuximab|Given IV
79826558|NCT02573220|Drug|Fluorouracil|Given IV
79826559|NCT02573220|Drug|Irinotecan Hydrochloride|Given IV
79826560|NCT02573220|Drug|Leucovorin Calcium|Given IV
79826561|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
79826562|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
79826563|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
79826564|NCT04070274|Procedure|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
79231882|NCT03212924|Behavioral|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
79231883|NCT03212924|Behavioral|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
79826565|NCT02572440|Procedure|Sorin XTRA/Sorin Group,|
79826566|NCT00718848|Procedure|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
79826567|NCT00718848|Procedure|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
79826568|NCT00618982|Drug|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
79826569|NCT00716352|Behavioral|Educational intervention programme|
79231884|NCT03212924|Behavioral|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
79373740|NCT04276389|Device|Angiography-guided paclitaxel drug-coated balloon angioplasty|Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
79373741|NCT03128658|Diagnostic Test|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
80000246|NCT05927610|Diagnostic Test|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
79373742|NCT03128658|Diagnostic Test|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
79373743|NCT03128619|Procedure|Biopsy of Breast|Undergo biopsy
79373744|NCT03128619|Drug|Copanlisib|Given IV
79527331|NCT03691857|Procedure|Ultrasound algorithm (EMERALD-US)|Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
79527332|NCT03663361|Other|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
79373745|NCT03128619|Other|Laboratory Biomarker Analysis|Correlative studies
79527333|NCT03663361|Other|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
79683343|NCT02923856|Device|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
79683344|NCT02934204|Drug|methotrexate|
79683345|NCT02934204|Drug|temozolomide|
79683346|NCT01286077|Drug|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
79683347|NCT04689152|Biological|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
79231885|NCT03212924|Behavioral|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
79527334|NCT03572621|Other|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
79826570|NCT02544880|Drug|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
79231886|NCT03212924|Behavioral|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
79683348|NCT03749655|Behavioral|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
79527335|NCT03572621|Other|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
79826571|NCT02544880|Biological|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
79826572|NCT02544880|Biological|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
79826573|NCT02544880|Other|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
79826574|NCT02544880|Other|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
79231887|NCT02282553|Device|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
79373746|NCT03128619|Drug|Letrozole|Given PO
79373747|NCT03128619|Drug|Palbociclib|Given PO
79527336|NCT03572621|Other|Participation|Participation in a therapeutic education day.
79527337|NCT03552393|Drug|Mircera|The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
79527338|NCT03524170|Drug|Bintrafusp Alfa|Given IV
79683349|NCT05590936|Drug|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
79826575|NCT02544880|Other|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
80000247|NCT05921448|Biological|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
79373748|NCT03128619|Other|Pharmacological Study|Correlative studies
79373749|NCT04451616|Diagnostic Test|Blood sample collection|Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
79373750|NCT04451616|Diagnostic Test|Hair sample collection|Hair sample collection will be performed. Hair mineral analysis will be performed.
79527339|NCT03524170|Radiation|Radiation Therapy|Undergo radiation therapy
79683350|NCT05590936|Drug|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
79826576|NCT02544880|Other|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
79826577|NCT00856570|Drug|warfarin|Oral
79826578|NCT00856570|Drug|YM178|Oral
79826579|NCT04068870|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
80000248|NCT05921448|Biological|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
80000249|NCT05917938|Drug|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
80000250|NCT05914233|Device|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
80000251|NCT05908357|Other|Exergaming|Use of the exergame XboX 360 series with kinect sensor
79231888|NCT02282553|Device|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
79373751|NCT04451616|Diagnostic Test|Urine sample collection|Urine sample collection will be performed. Urine mineral analysis will be performed.
79373752|NCT04451616|Diagnostic Test|Body composition analysis|Body composition analysis with the use of electric bioimpedance will be performed.
79373753|NCT04451616|Diagnostic Test|Questionnaires|Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
79373754|NCT04451616|Diagnostic Test|Blood pressure, pulse and blood oxygen saturation measurement|Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
79373755|NCT04395573|Device|Accuro|ultrasound device (Accuro, Rivanna Medical, Charlottesville, VA) with automated pattern recognition software programmed (SpineNav3DTM technology) to calculate the depth to epidural space and identify bony landmarks
79527340|NCT03490331|Other|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
79527341|NCT03336983|Drug|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
79527342|NCT03336983|Drug|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
79527343|NCT03333382|Device|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
79527344|NCT03333382|Device|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
79683351|NCT01285960|Device|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
80000252|NCT05908357|Other|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
80000253|NCT05908331|Device|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
80000254|NCT05908331|Device|Plan balloon Angioplasty (POBA)|Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
80000255|NCT05906602|Device|Real Ischemic Conditioning|10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5 minutes), repeated 5 times for a total of 50 minutes.
79373756|NCT04395573|Device|standard ultrasound device|standard ultrasound device (o calculate the depth to epidural space and identify bony landmarks
79373757|NCT03433092|Other|serum carotenoids|In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
79527345|NCT03301493|Other|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
79683352|NCT02933814|Drug|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
79683353|NCT04323826|Other|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
79683354|NCT04323826|Other|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
79683355|NCT04323826|Other|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
79683356|NCT04323826|Other|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
79683357|NCT04690140|Procedure|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
79683358|NCT04690140|Procedure|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
79683359|NCT05578183|Device|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
79683360|NCT05578183|Device|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
79683361|NCT02923817|Biological|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
79826580|NCT00852280|Device|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
79826581|NCT00719004|Procedure|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
79826582|NCT00856648|Device|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
79373758|NCT04451538|Dietary Supplement|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoons, 440 kcal]/day, twice a day).
79527346|NCT03283813|Dietary Supplement|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
79527347|NCT03283813|Drug|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
79683362|NCT02933775|Genetic|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
79683363|NCT02933775|Drug|Fludarabine|30 mg/m^2/day×4 days
79683364|NCT02933775|Drug|Cyclophosphamide|500 mg/m^2/day×2 days
79683365|NCT02923700|Biological|Leukocyte-rich PRP intra-articular injections|
79683366|NCT02923700|Biological|Leukocyte-poor PRP intra-articular injections|
79683367|NCT02923622|Other|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
80000256|NCT05906602|Device|Sham Ischemic Conditioning|Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely in cuff pressure during blood flow restriction to replicate to replicate perceived tightness without arterial blood flow restriction.
79373759|NCT04451538|Dietary Supplement|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
79527348|NCT03283813|Drug|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
79527349|NCT03283657|Behavioral|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
79527350|NCT03283657|Behavioral|Usual care (UC)|Standard care with routine medical care.
79527351|NCT03262519|Diagnostic Test|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
79527352|NCT03245827|Drug|Clomiphene|clomiphene capsule 25mg twice a week
79527353|NCT03245827|Drug|Placebo|placebo capsule 25mg twice a week
79527354|NCT03169231|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
79683368|NCT02923622|Other|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
79683369|NCT02923622|Other|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
79683370|NCT02923583|Biological|M834|
79683371|NCT02923583|Biological|US-Sourced Orencia®|
79683372|NCT02923583|Biological|EU-Sourced Orencia®|
79826583|NCT00856804|Drug|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
79826584|NCT00712608|Other|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
79826585|NCT00712608|Other|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
79826586|NCT00712608|Other|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
79826587|NCT00856882|Dietary Supplement|soy protein|
79826588|NCT00856882|Dietary Supplement|isoflavones|
79826589|NCT00856882|Dietary Supplement|milk protein|
79826590|NCT00712686|Drug|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
79826591|NCT00712686|Drug|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
79826592|NCT04041856|Drug|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
79826593|NCT00856960|Drug|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
79826594|NCT00856960|Drug|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
79826595|NCT00856960|Drug|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
79826596|NCT00856960|Drug|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
79826597|NCT00856960|Drug|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
79826598|NCT00712764|Drug|Adenosine|
79826599|NCT00712764|Drug|Placebo|
79826600|NCT03911622|Device|MRI|medical device that is used as an imaging tool for soft tissues
79527355|NCT03169231|Other|Placebo|Intravenously delivered
79683373|NCT02933580|Drug|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
79683374|NCT02933580|Other|Placebo|Participants will receive matching placebo tablets on Day 1.
79826601|NCT00848458|Other|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
79683375|NCT02923388|Drug|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
79683376|NCT02923388|Drug|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
79683377|NCT02923388|Drug|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
79683378|NCT02923388|Drug|Placebo pill|Placebo pill orally thrice daily for 5 weeks
79683379|NCT02933658|Drug|Telmisartan|
79683380|NCT02933658|Drug|Amlodipine|
79683381|NCT02933658|Drug|Rosuvastatin|
79826602|NCT00848458|Other|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
79826603|NCT00578786|Drug|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
79826604|NCT00424255|Drug|Lapatinib|Dual ErbB1/2 inhibitor
79826605|NCT00424255|Radiation|Chemoradiation|Radiation plus platinum based chemotherapy
79527356|NCT03129321|Drug|Econazole Nitrate Cream, 1%|
79527357|NCT03129321|Drug|Placebo|
79527358|NCT03107611|Drug|Pimecrolimus Cream, 1%|
79826606|NCT00424255|Other|Placebo|Placebo
79826607|NCT03910764|Other|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
79826608|NCT00852358|Drug|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
79826609|NCT02574156|Drug|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
79826610|NCT00848692|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
79826611|NCT00848692|Drug|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
79826612|NCT00712842|Other|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
80000257|NCT05906602|Other|Aerobic Exercise|Thirty minutes of moderate intensity continuous aerobic exercise using a recumbent stepper.
79527359|NCT03107611|Drug|Placebo Cream|
79527360|NCT03107611|Drug|Pimecrolimus Cream, 1%|
79527361|NCT02988544|Procedure|Artificial shrinkage|Artificial shrinkage of blastocyst
79527362|NCT02880774|Other|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
79527363|NCT02880774|Other|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
79683382|NCT02923661|Device|CM LOC|
79683383|NCT02923661|Device|ball attachment|
79683384|NCT02933853|Drug|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
79683385|NCT02933853|Drug|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
79683386|NCT02923505|Procedure|polygraphy or polysomnography|
79683387|NCT02923310|Biological|Platelets Rich Plasma|
79683388|NCT02923310|Biological|Leucocyte - Platelets Rich Plasma|
79683389|NCT02923310|Drug|Hialuronic Acid|
79683390|NCT00532194|Drug|cediranib|Once-daily oral tablet starting dose 20mg
79683391|NCT02933268|Dietary Supplement|High water intake|High water intake aimed at achieving an urine osmolality < 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
79826613|NCT00848770|Drug|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
79683392|NCT02933268|Other|Ad libitum water intake|Water intake guided by thirst
79826614|NCT00848770|Drug|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
79826615|NCT00848770|Drug|manipulation of SAP|Esmolol or NPS or NOR
79826616|NCT04070118|Procedure|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
79231892|NCT02279901|Behavioral|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~OSA program~CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
79373760|NCT03433014|Procedure|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
79373761|NCT03433014|Other|Control|No infiltration
79373762|NCT01872689|Drug|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
79527364|NCT02801136|Behavioral|ReACT|
79527365|NCT02801136|Behavioral|Supportive Therapy|
79527366|NCT02798588|Radiation|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)->8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
79527367|NCT02720016|Behavioral|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
79527368|NCT02720016|Behavioral|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
79826617|NCT00717704|Drug|ixabepilone|by vein once every 3 weeks
79683393|NCT02923154|Drug|MT-3995|
79683394|NCT02923154|Drug|Placebo|
79683395|NCT02665143|Drug|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
79826618|NCT00717704|Drug|Dasatinib|by mouth once daily
79826619|NCT00713076|Other|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
79683396|NCT00532272|Drug|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
79826620|NCT00713154|Drug|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
79683397|NCT02922920|Other|Tart cherry juice|16 fl. oz of tart cherry juice
79826621|NCT00713154|Drug|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
80000258|NCT05897099|Behavioral|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
80000259|NCT05897099|Behavioral|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
80000260|NCT05896800|Device|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
80000261|NCT05896384|Drug|BI 456906|BI 456906
80000262|NCT05896384|Drug|Microgynon®|Ethinylestradiol (EE) and Levonorgestrel (LNG)
80000263|NCT05893537|Drug|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
80000264|NCT05893537|Drug|Placebo Comparator|123 participants will receive a single daily dose of placebo
80000265|NCT05888493|Biological|Tisagenlecleucel|Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10^8 CAR-positive viable T-cells taken intravenously (i.v.).
80000266|NCT05888493|Drug|Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
79826622|NCT00620074|Drug|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
79373763|NCT01872689|Drug|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
79527369|NCT02720016|Behavioral|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
79527370|NCT02607956|Drug|DTG|50 mg tablets administered orally, once daily
79527371|NCT02607956|Drug|F/TAF|200/25 mg tablets administered orally, once daily
80000267|NCT05888493|Drug|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
79527372|NCT02607956|Drug|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
79527373|NCT02607956|Drug|DTG Placebo|Tablets administered orally, once daily
79527374|NCT02607956|Drug|F/TAF Placebo|Tablets administered orally, once daily
79683398|NCT02922920|Other|Placebo|16 fl. oz of placebo
79826623|NCT00620074|Drug|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
80000268|NCT05888493|Drug|Lymphodepleting chemotherapy|"Fludarabine (25 mg/m^2 intravenously [i.v.] daily for 3 doses) OR Cyclophosphamide (250 mg/m^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)"
80000269|NCT05888493|Other|Corticosteroids and/or Radiation (Bridging therapy)|Corticosteroids and/or Radiation
80000270|NCT05885373|Dietary Supplement|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
80000271|NCT05883748|Drug|DISC-1459|DISC-1459 dose level 1
80000272|NCT05883748|Drug|DISC-1459|DISC-1459 dose level 2
80000273|NCT05877898|Behavioral|CHW Education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life.
79527375|NCT02607956|Drug|B/F/TAF Placebo|Tablets administered orally, once daily
79527376|NCT02564523|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)
79683399|NCT03292419|Procedure|Topography-guided LASIK|LASIK surgery
79683400|NCT02933385|Behavioral|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
79683401|NCT02933385|Behavioral|Web-based health discussions|Create interactions between the employees.
79683402|NCT02933385|Behavioral|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
79373764|NCT01872689|Drug|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
79373765|NCT04678908|Drug|HB0025|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
79527377|NCT02564523|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units)
79527378|NCT02564523|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline
79683403|NCT02933385|Behavioral|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
79683404|NCT02933385|Behavioral|Closing events|these aim to motivate the employees to continue into the program.
79683405|NCT02933385|Behavioral|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
79683406|NCT02933385|Behavioral|Social Health platform|
79683407|NCT02933385|Behavioral|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
79527379|NCT02560961|Other|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
79683408|NCT02922842|Device|Transcutaneous Electrical Nerve Stimulation|
79373766|NCT03999606|Behavioral|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
79373767|NCT03435978|Behavioral|MetS+|
79373768|NCT03435978|Other|MetS-|Data processing from Patient Medical Files
79373769|NCT03435900|Drug|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
79826624|NCT01033435|Other|No intervention|
79527380|NCT02560961|Other|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
79527381|NCT02499666|Procedure|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
79683409|NCT02933190|Procedure|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
79683410|NCT02923076|Other|CCR5 delta32/delta32 cord blood transplantation|
79826625|NCT04069130|Drug|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
79826626|NCT04042012|Other|Eccentric exercise|soleus eccentric exercise
79826627|NCT04042012|Other|PNE|the application of galvanic current
79826628|NCT04042012|Other|Combined|soleus eccentric exercise and PNE
80000274|NCT05877898|Behavioral|CHW Education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
79373770|NCT03435900|Drug|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
79373771|NCT00632931|Drug|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
79373772|NCT00632931|Drug|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
79683411|NCT02923037|Procedure|Yoga|Complete guided and home yoga sessions
79683412|NCT02923037|Other|tape measurement of arm|Ancillary studies
79683413|NCT02923037|Other|Quality-of-Life Assessment|Ancillary studies
79683414|NCT02923037|Other|ldex measurement of arms|
79683415|NCT02933229|Device|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
79683416|NCT02933229|Drug|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
79683417|NCT02922803|Drug|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
79826629|NCT00719238|Behavioral|Nutrition plus education|Nutritional instruction in small groups plus education
79826630|NCT00719238|Behavioral|Education only|Educational video and pamphlets
79826631|NCT02571296|Drug|micronized progesterone|Oral
79826632|NCT02571296|Drug|Placebo|Oral
80000275|NCT05867927|Device|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
80000276|NCT05867927|Device|Non-da Vinci Surgery|Non-da Vinci Surgery
79373773|NCT04666974|Behavioral|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
79373774|NCT04666974|Behavioral|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
79683418|NCT02922803|Drug|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
79683419|NCT02933424|Dietary Supplement|Protein Powder|
79826633|NCT00857038|Drug|Doxycycline|Doxycycline tablets, 100mg daily
79826634|NCT00857038|Drug|Placebo|Placebo tablets 100mg
79527382|NCT02499666|Device|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
79527383|NCT02499666|Drug|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
79683420|NCT03194568|Device|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
79683421|NCT02922569|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
79683422|NCT02922569|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
79231893|NCT02279901|Behavioral|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
79683423|NCT02922569|Other|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
79826635|NCT00719316|Drug|Aliskiren|Aliskiren 300mg per day for 6 weeks
79826636|NCT00720200|Behavioral|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
79231894|NCT03230396|Dietary Supplement|Vitamingum Sport|Vitamin -supplemented chewing gum
79231895|NCT03230396|Dietary Supplement|Vitamingum Immunity|Vitamin -supplemented chewing gum
79373775|NCT01857323|Drug|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
79231896|NCT03230396|Dietary Supplement|Placebo|Control chewing gum. No vitamin content.
79373776|NCT03439488|Drug|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
79527384|NCT02474017|Drug|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
79527385|NCT02474017|Device|CRC749 inhaler|
79683424|NCT02922569|Other|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
79683425|NCT02834559|Drug|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
79826637|NCT00720200|Behavioral|Usual Care|Family Members receiving usual care/clinical interaction
79683426|NCT02834559|Drug|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
79683427|NCT02922608|Other|simulation practice|simulation session
79683428|NCT02933307|Device|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
79826638|NCT03926988|Device|NeVa Stent Retriever|mechanical neurothrombectomy
79826639|NCT00857116|Drug|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
79826640|NCT00857116|Drug|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
79826641|NCT00717782|Procedure|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
79826642|NCT00717782|Procedure|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
79826643|NCT00719394|Drug|GSI 136|
79826644|NCT00719394|Drug|placebo|
79826645|NCT00857194|Procedure|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
79826646|NCT00857194|Procedure|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
79373777|NCT03439488|Drug|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
79373778|NCT03435822|Other|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
79373779|NCT03435822|Other|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
79373780|NCT03104439|Drug|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
79373781|NCT03104439|Drug|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
79373782|NCT03104439|Radiation|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
79373783|NCT03432780|Drug|Docetaxel|
79527386|NCT02420912|Drug|Ibrutinib|Given PO
79527387|NCT02420912|Other|Laboratory Biomarker Analysis|Correlative studies
79527388|NCT02420912|Biological|Nivolumab|Given IV
79527389|NCT02094716|Drug|Permethrin Foam 4%|Topical application, whole-body treatment
79527390|NCT02094716|Drug|Permethrin Foam 5%|Topical application, whole-body treatment
79527391|NCT02094716|Drug|Vehicle Foam|Topical application, whole-body treatment
79683429|NCT02933307|Device|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
79683430|NCT02922686|Drug|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
79826647|NCT03847870|Diagnostic Test|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
79826648|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
79826649|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
80000277|NCT05867407|Device|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
80000278|NCT05867407|Other|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
79231897|NCT03210194|Behavioral|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
79231898|NCT03210194|Behavioral|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
79373784|NCT03432780|Biological|Hormone and radiation therapy|
79373785|NCT03432780|Radiation|Radiation therapy|
79373786|NCT00055731|Drug|bicalutamide|
79373787|NCT00055731|Drug|Goserelin Acetate|
79373788|NCT00055731|Drug|docetaxel|
79527392|NCT01868139|Device|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
79527393|NCT01762605|Other|Supportive Care|
79527394|NCT01762605|Procedure|Cast|
79527395|NCT01620658|Device|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
79527396|NCT01620658|Device|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
79683431|NCT02922686|Drug|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
79683432|NCT02922686|Drug|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
79683433|NCT02922530|Other|Computerized Plasticity-based Adaptive Cognitive Training|
79231899|NCT00529503|Drug|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
79231900|NCT00529503|Drug|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
79231901|NCT00529503|Drug|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
79231902|NCT00529503|Drug|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
79373789|NCT00055731|Drug|Estramustine phosphate sodium|
79683434|NCT02922530|Other|Commercially available computerized training|
79683435|NCT02922452|Drug|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
79683436|NCT02922452|Drug|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
79683437|NCT02922374|Drug|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
79373790|NCT00055731|Drug|acetylsalicylic acid|
79373791|NCT00055731|Procedure|conventional surgery|
79373792|NCT00055731|Radiation|radiation therapy|
79373793|NCT03432702|Procedure|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
79373794|NCT03435744|Drug|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
79373795|NCT03435744|Other|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
79527397|NCT01620658|Device|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
79527398|NCT01460810|Other|1000CsK Silicon Oil Tamponade|Details covered in arm description
79527399|NCT01447628|Drug|Saline|intravenous, no active drug
79527400|NCT01447628|Drug|Ferinject or CosmoFer|Intravenous, 1000 mg iron
79527401|NCT00744484|Behavioral|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
79683438|NCT02933151|Dietary Supplement|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
79527402|NCT00744484|Behavioral|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
79527403|NCT00667329|Drug|2CdA|1.5 mg/m^2 subcutaneous injection three times daily x 7 days.
79527404|NCT00667329|Drug|Cyclophosphamide|40 mg/m^2 PO twice daily x 7 days.
79826650|NCT04068558|Device|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
79826651|NCT04068558|Device|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
79826652|NCT04068090|Other|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
79826653|NCT04068090|Other|Blood Collection|biomarker analysis
79373796|NCT03975504|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
79826654|NCT00857428|Drug|oxymorphone|Tablets
79826655|NCT00857428|Drug|Oxymorphone|40 mg tablets
79826656|NCT02572778|Procedure|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
79826657|NCT04069494|Other|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
79826658|NCT04018768|Other|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
79826659|NCT04018768|Other|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
80000279|NCT05862324|Biological|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
79826660|NCT00719784|Device|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
79826661|NCT00848848|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
79826662|NCT00848848|Biological|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
79826663|NCT00848848|Biological|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
80000280|NCT05861999|Drug|risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
80000281|NCT05861453|Drug|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
80000282|NCT05851872|Procedure|Coronary angiogram|Being done per standard of care
80000283|NCT05851872|Procedure|Right heart catheterization|Being done per standard of care
79373797|NCT03975504|Device|artificial intelligence (AI)|AI was performed in high-risk individuals recruitment and lung nodules management
79683439|NCT02922491|Dietary Supplement|vitamin E|daily intake of vitamin E
79683440|NCT02922491|Dietary Supplement|starch|daily intake of starch (control)
79683441|NCT04687722|Other|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
80000284|NCT05851573|Behavioral|Psychosocial intervention|an SLP-administered 5-week treatment focused on psychological well-being
80000285|NCT05849298|Drug|AAA617|Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
80000286|NCT05849298|Drug|AAA517|Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans
80000287|NCT05849298|Drug|Piflufolastat F 18|Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
79373798|NCT03975504|Diagnostic Test|autofluorescence imaging (AFI)|AFI applied in screening of centrally located SCC.
79373799|NCT03439410|Other|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
79373800|NCT03435666|Drug|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
79373801|NCT03435666|Drug|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
79373802|NCT00632541|Drug|Sorafenib|Sorafenib 200mg po daily
79527405|NCT00667329|Drug|Rituximab|375 mg/m^2 IV once weekly x 4 weeks.
79527406|NCT00515853|Behavioral|Biofeedback|Biofeedback sessions or biofeedback exercises
79527407|NCT00492167|Biological|beta-glucan|
79527408|NCT00492167|Biological|monoclonal antibody 3F8|
79527409|NCT00492167|Other|immunohistochemistry staining method|
79527410|NCT00492167|Other|laboratory biomarker analysis|
79527411|NCT00003458|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
79683442|NCT04687722|Other|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
79683443|NCT03457454|Other|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
79683444|NCT03457454|Other|Patient Participant Interview|-Approximately 45-60 minute interview
79683445|NCT03457454|Other|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
79683446|NCT03457454|Other|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
79826664|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
79683447|NCT02933112|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
79683448|NCT02922140|Behavioral|pharmaceutical care service|
79826665|NCT00848848|Biological|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
79826666|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
79826667|NCT00848848|Biological|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
79826668|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
79231903|NCT00529503|Drug|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
79527412|NCT05274724|Diagnostic Test|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
79683449|NCT02932917|Device|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
79683450|NCT02922179|Drug|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
79683451|NCT05467644|Procedure|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
79826669|NCT00848848|Biological|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
79826670|NCT00848848|Biological|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
79826671|NCT04069364|Behavioral|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
79826672|NCT02573922|Drug|oxycodone-naloxone|
80000288|NCT05849298|Drug|ARPI|Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
80000289|NCT05849298|Drug|ADT|as prescribed by the local investigator
80000290|NCT05849298|Other|Best supportive care|as prescribed by the local investigator
80000291|NCT05848687|Drug|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
80000292|NCT05848687|Drug|Mitoxantrone|Given IV
80000293|NCT05848687|Drug|PEG asparaginase|Given IV
80000294|NCT05848687|Drug|Bortezomib|Given IV
79231904|NCT00529503|Drug|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
79231905|NCT05459350|Diagnostic Test|Safe Discharge Classification|Safe Discharge Classification
79373803|NCT00632541|Drug|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
79373804|NCT00632541|Other|Imaging|Imaging every third cycle
79231906|NCT05459194|Device|RP - TA|randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
79231907|NCT03230240|Drug|HIPEC|heated intraIP chemotherapy
79231908|NCT05476198|Procedure|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
79373805|NCT01872611|Drug|Nepafenac Ophthalmic Suspension, 0.3%|
79373806|NCT01872611|Other|Vehicle|Inactive ingredients used as placebo comparator
79373807|NCT01872611|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
79373808|NCT04451148|Other|Obese with or without metabolic syndromesubjects|Children with obesity and with or without metabolic syndrome
79373809|NCT03432624|Diagnostic Test|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.*all arms are given the same intervention.
79826673|NCT02573922|Drug|Oxycodone|
79826674|NCT00852436|Drug|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
79826675|NCT00852436|Drug|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
80000295|NCT05848687|Drug|Vorinostat|Taken PO or NG
80000296|NCT05848687|Drug|Mercaptopurine|Given PO or NG.
80000297|NCT05848687|Drug|Methotrexate|Given IV, IM or PO
80000298|NCT05848687|Drug|Blinatumomab|Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
79373810|NCT04607681|Behavioral|EDUCATION|WEB BASED EDUCATION
80000299|NCT05848687|Drug|Ziftomenib|3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
79527413|NCT05274724|Diagnostic Test|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
79527414|NCT05274685|Procedure|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
79683452|NCT02922062|Other|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
79527415|NCT05274594|Radiation|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
79683453|NCT02922062|Other|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
79683454|NCT02922062|Other|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
79683455|NCT02922101|Behavioral|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
79683456|NCT02922101|Behavioral|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
79683457|NCT02932839|Device|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
79527416|NCT05274568|Drug|[18F]UCB-2897|"Investigational Agent:~[18F]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product [18F]UCB2897is delivered in normal saline (0.9 % sodium chloride [NaCl]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. [18F]UCB2897 will be stored at ambient temperature in its original container."
79683458|NCT02932800|Procedure|"Fixation with ballerina technique and flip"|
79826676|NCT02574000|Other|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
79826677|NCT02574000|Other|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
79231909|NCT05476198|Procedure|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
79683459|NCT02932800|Procedure|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
79826678|NCT04068350|Other|Pain questionnaire|Pain questionnaire, 3 months after surgery
79683460|NCT02932800|Other|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
79683461|NCT02921984|Drug|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
79683462|NCT02921984|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
79683463|NCT02921984|Drug|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
79683464|NCT02921984|Drug|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
79683465|NCT02921867|Other|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
79683466|NCT05467566|Device|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
79826679|NCT02573844|Drug|Proklama|
79826680|NCT02573844|Drug|Placebo|
79231910|NCT02280057|Drug|Metformin|Metformin 1500 mg (=2 pills) per day in six months
79231911|NCT02280057|Drug|Placebo|2 pills per day in six months; pills look like metformin pills
79231912|NCT03209960|Diagnostic Test|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
79683467|NCT05467566|Device|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
79826681|NCT02545894|Behavioral|Cognitive therapy|"The tasks are:~visually tracking a picture as it moves across the computer screen~pressing a button every time a picture is seen on the screen~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
79826682|NCT00424177|Drug|eltrombopag|experimental
79826683|NCT04068116|Procedure|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty & coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion & reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
79826684|NCT00716430|Behavioral|Quality Improvement Programme|Quality Improvement training programme
79826685|NCT00720512|Biological|bevacizumab|Given IV
80000300|NCT05847166|Radiation|[99mTc]Tc-PSMA-T4|[99mTc]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The [99mTc]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product [99mTc]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
80000301|NCT05840224|Biological|GS-4528|Administered intravenously
80000302|NCT05840224|Drug|Zimberelimab|Administered intravenously.
80000303|NCT05836571|Procedure|Biopsy|Undergo biopsy
80000304|NCT05836571|Procedure|Biospecimen Collection|Undergo collection of blood
80000305|NCT05836571|Drug|Cabozantinib|Given PO
80000306|NCT05836571|Procedure|Computed Tomography|Undergo CT
79373811|NCT03089853|Device|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
79373812|NCT03439176|Other|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
79373813|NCT03439176|Other|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
79373814|NCT03439176|Other|PL4|This strip contains a new adhesive
79826686|NCT00720512|Drug|fluorouracil|Given IV
79373815|NCT03439176|Other|PL16-L|This strip contains a new adhesive
79826687|NCT00720512|Drug|irinotecan hydrochloride|Given IV
79826688|NCT00720512|Drug|leucovorin calcium|Given IV
79826689|NCT00720512|Drug|oxaliplatin|Given IV
79826690|NCT04069286|Drug|Oral Aroeira/ Amoxicillin/ Claritromycin|Oral Aroeira (Schinus terebinthifolius Raddi, 640mg/tablet) 1 tablet, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
79826691|NCT04069286|Drug|Omeprazole/ Amoxicillin/ Claritromycin|Omeprazole 1 tablet of 20mg, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
79373816|NCT03432468|Drug|Valsartan 1|the high dose of valsartan
79373817|NCT03432468|Drug|Valsartan 80 mg|a single dose of valsartan
79373818|NCT03086967|Device|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
79527417|NCT05274490|Procedure|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
79683468|NCT02921945|Biological|SCT800|recombinant human coagulation factor VIII
79683469|NCT04689230|Procedure|upper eyelid blepharoplasty|upper eyelid blepharoplasty
79826692|NCT00716508|Procedure|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
80000307|NCT05836571|Biological|Ipilimumab|Given IV
80000308|NCT05836571|Procedure|Magnetic Resonance Imaging|Undergo MRI
80000309|NCT05836571|Biological|Nivolumab|Given IV
80000310|NCT05836012|Biological|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
80000311|NCT05836012|Biological|Placebo|2 injections - given at 4 months and the second at 6 months of age.
80000312|NCT05832632|Behavioral|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
79683470|NCT04647825|Other|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
80000313|NCT05832632|Behavioral|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
79683471|NCT04689269|Other|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
79683472|NCT04689269|Other|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
79826693|NCT00716508|Procedure|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
79683473|NCT04689269|Device|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
79683474|NCT04689269|Device|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
79826694|NCT04069442|Other|This is a non-interventional study|This is a non-interventional study
79373819|NCT03435588|Procedure|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
79373820|NCT03435588|Procedure|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
79683475|NCT01285609|Drug|Ipilimumab|
79373821|NCT03435588|Procedure|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
79373822|NCT01856543|Other|Eucerin|
79373823|NCT01856543|Other|Mometasone Furoate 0.1%|
79683476|NCT01285609|Drug|Placebo|
79826695|NCT03992846|Drug|75 mg linzagolix tablet|For oral administration once daily
79373824|NCT03435432|Dietary Supplement|Glucose|Glucose drink
79683477|NCT01285609|Drug|Paclitaxel|
79683478|NCT01285609|Drug|Carboplatin|
79683479|NCT02921672|Other|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
79826696|NCT03992846|Drug|200 mg linzagolix tablet|For oral administration once daily
79826697|NCT03992846|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
79826698|NCT03992846|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
79826699|NCT03992846|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
79826700|NCT03992846|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
80000314|NCT05832632|Behavioral|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
80000315|NCT05832632|Behavioral|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
79683480|NCT04689984|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
79683481|NCT04689984|Drug|Astaxanthin|Astaxanthin 6 mg tablet once daily
80000316|NCT05832177|Behavioral|Cancer CientoUno (101) program|The Spanish version of Cancer 101 consists of several modules that address cancer control and prevention, risk factors, early detection and screening guidelines, cancer diagnosis and stages, cancer treatment, cancer and genetics, cancer and chronic disease, patient and caregiver support, HPV, biobanking, and clinical trials. All modules contain a written summary with learning objectives, a PowerPoint presentation, pre- and post-module evaluations with an answer sheet, a glossary, references, and supplemental resources. This program will occur on an ongoing basis.
79373825|NCT03435432|Dietary Supplement|Water|Control
79683482|NCT02921711|Device|LVIS®|Low-profile Visualized Intraluminal Support device
79683483|NCT05467254|Biological|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
79683484|NCT03981341|Drug|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
79683485|NCT04620057|Dietary Supplement|butyrate|sodium butyrate (20 mg/kg body weight/day)
79683486|NCT04620057|Other|placebo|cornstarch
79683487|NCT03924440|Diagnostic Test|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
79683488|NCT01285492|Drug|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
79683489|NCT01285492|Drug|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
79683490|NCT02889991|Other|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
79683491|NCT02889991|Other|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
79683492|NCT02889991|Other|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
79826701|NCT00713622|Drug|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
80000317|NCT05832177|Behavioral|Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)|This is a biennial cancer symposium focused on cancer topics important to Hispanic/Latinos. This day-long event includes a plenary session and concurrent sessions where healthcare professionals present educational information about cancer, cancer prevention, early detection methods, and other related topics.
79373826|NCT03439098|Dietary Supplement|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
79373827|NCT03439098|Dietary Supplement|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
79683493|NCT02889991|Other|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~Monitor longitudinally taut band, with index and middle fingers.~Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~Remove the bridles and perform hemostasis with cotton.~We will give end to the technique placebo of dry needling."
79683494|NCT04615143|Drug|Tislelizumab|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
79231913|NCT03209960|Other|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
79373828|NCT03439098|Dietary Supplement|Placebo|Placebo daily for 8 weeks
79373829|NCT03439020|Procedure|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
79373830|NCT03439020|Procedure|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
79373831|NCT03432312|Drug|Nicotine lozenge|Nicotine mint lozenge, 4 mg
79683495|NCT04615143|Drug|Tislelizumab combined with Levatinib|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
79683496|NCT02921594|Device|Total knee arthroplasty with Vanguard XP|
79373832|NCT03432312|Drug|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
79373833|NCT03438942|Dietary Supplement|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
79373834|NCT03438942|Dietary Supplement|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
79373835|NCT03438864|Device|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
79373836|NCT03438864|Other|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
79373837|NCT03432234|Other|Biomarkers|This is an observational study, there is no intervention
79373838|NCT03432156|Biological|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
79373839|NCT04451070|Other|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
79683497|NCT02921594|Device|Total knee arthroplasty with Vanguard CR|
79683498|NCT05467137|Device|MSOT|MSOT imaging (after ICG injection)
79683499|NCT02933463|Other|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
79683500|NCT02933463|Other|Clinpro sealant|
79683501|NCT02921633|Other|Intervention letter|
79826702|NCT00713622|Drug|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
79826703|NCT00719940|Behavioral|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
79826704|NCT00719940|Other|Waiting group|No intervention
79826705|NCT00718172|Procedure|Liver Biopsy|
79826706|NCT00718172|Drug|Peginterferon &amp; Ribavirin for Hepatitis C|
79826707|NCT00718172|Drug|Pre-treatment Ribavirin|
79683502|NCT01284634|Drug|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
79683503|NCT01284634|Drug|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
79373840|NCT04450680|Other|Beta-lactam Therapeutic Drug Monitoring|Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment
79683504|NCT01284634|Drug|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
79826708|NCT00720018|Drug|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
79683505|NCT01284634|Drug|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
79826709|NCT00716664|Other|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
80000318|NCT05832177|Behavioral|¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)|This is an educational and community outreach effort comprised of local charlas (talks) led by Hispanic/Latino healthcare professionals (e.g., the partnership Community Health Educator [CHE], topic experts) who provide education and answer questions about specific cancer topics. The charlas may be conducted in multiple modalities (in person, virtual, hybrid) and may be conducted in English and/or Spanish. At least three events will be held each year in the partnership locations.
80000319|NCT05832177|Behavioral|Community/Researcher Forum: El Puente (Translation in English: The Bridge).|The main goal of the El Puente annual event is to generate dialogue between community members and researchers about cancer treatment and cancer-focused research topics. During El Puente's presentations, researchers present their projects and data results to community members, allowing community members to react to the research, make suggestions, and express concerns.
80000320|NCT05832177|Behavioral|Lunch and Learn Updated Recommendations Series.|This is a virtual podcast that will discuss cancer-related recommendations and guidelines from the United States Preventive Services Task Force (USPSTF). The podcasts are pre-recorded, 30 minute long, and will be in English and/or Spanish. This podcast will be hosted by the Outreach Core (OC) CHE, and feature experts who will explain the updated recommendations and active steps that community members and providers can take to facilitate adherence. This activity will begin according to the project timeline
79683506|NCT02932722|Other|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
79683507|NCT02932722|Drug|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
79683508|NCT02932722|Drug|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
79826710|NCT00716664|Other|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
79826711|NCT00618826|Drug|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
79231914|NCT05459116|Device|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients >40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients <40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
79373841|NCT03438786|Procedure|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
79683509|NCT02921516|Behavioral|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
79683510|NCT02921516|Behavioral|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
79683511|NCT02921516|Behavioral|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
79683512|NCT01284361|Device|30 cm Intermittent Catheter|Randomized cross-over
79683513|NCT01284361|Device|40 cm Intermittent Catheter|randomized cross-over
79683514|NCT02921438|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
79683515|NCT02932761|Drug|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
79683516|NCT02932761|Procedure|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
79826712|NCT00618826|Drug|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
79826713|NCT00618826|Drug|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
79683517|NCT01283971|Drug|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
79683518|NCT01283971|Drug|adalimumab|Adalimumab 40 mg SC every 2 weeks.
79527418|NCT05274438|Drug|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
79527419|NCT05274386|Device|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
79527420|NCT05274386|Device|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours.
79527421|NCT05274386|Device|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours.
79826714|NCT02572362|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
79826715|NCT00718250|Biological|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
79826716|NCT00718250|Biological|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
79826717|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
79683519|NCT01283971|Drug|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
79683520|NCT01283971|Drug|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
79683521|NCT01283971|Drug|methotrexate|Methotrexate 10-25 mg weekly.
79683522|NCT01283971|Drug|folate|Folate at least 5 mg weekly.
79683523|NCT05466981|Behavioral|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
79826718|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
80000321|NCT05832177|Behavioral|Community Engagement (CE) Training Program for U54 Partnership Investigators|This is a series of 2 1/2-day CE workshops designed and delivered up to 20 partnership researchers (including faculty and junior investigators) delivered across four sessions per year (6 to 10 researchers per year). Each session includes two hours of lectures (didactic material) and one hour of practice activities (practical application of the theoretical content). Session topics will include CE: concepts and principles, theoretical roots, levels, and ethics. The OC team will provide educational materials and additional references in each session.
79683524|NCT02921282|Genetic|Genotype dopamine|Laboratory investigations of nicotine reinforcement
79683525|NCT02921282|Genetic|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
79683526|NCT02921360|Drug|acetylsalicylic acid|
79826719|NCT00720174|Biological|Cixutumumab|Given IV
79826720|NCT00720174|Drug|Doxorubicin Hydrochloride|Given IV
79826721|NCT00720174|Other|Laboratory Biomarker Analysis|Correlative studies
79826722|NCT00857740|Behavioral|Education|Education about the neurophysiology of pain
79826723|NCT04041544|Drug|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
79826724|NCT04041544|Drug|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
79826725|NCT00722930|Drug|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
79826726|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
79826727|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
79826728|NCT00713778|Procedure|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
79683527|NCT02932605|Drug|Placebo|Placebo
79826729|NCT00849004|Other|silicone gel|silicone gel
79826730|NCT00849004|Other|silicone sheet|silicone sheet
79683528|NCT02932605|Drug|Cannabidiol|Cannabidiol
79683529|NCT02921204|Other|Vitamin D status|There is no intervention in this study
79683530|NCT01283581|Drug|Delafloxacin|300mg IV every 12 hours for 5-14 days
79683531|NCT01283581|Drug|Linezolid|600mg IV every 12 hours for 5-14 days
79683532|NCT01283581|Drug|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
79683533|NCT05466903|Dietary Supplement|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
79683534|NCT01283542|Drug|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
79826731|NCT00849004|Other|paper tape|paper tape
79826732|NCT03834740|Drug|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
79683535|NCT05466864|Device|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
79683536|NCT02921048|Dietary Supplement|omega-3 fatty acids|
79683537|NCT02932488|Drug|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
79683538|NCT02921165|Drug|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
80000322|NCT05832177|Behavioral|Community Advisory Panels (CAP)|These CAPs work closely with the (CHE) to oversee the identification, development, and coordination of the outreach activities; provide advice on the development and implementation of community needs and assessments; provide guidance for recruitment and retention of research participants; and assist in the recruitment for educational events and research and vetting community educational materials and the content of protocols for research projects.
79826733|NCT03834740|Drug|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
79826734|NCT00849082|Drug|cyproterone acetate|
80000323|NCT05832177|Behavioral|Research Corner|The goal is to provide bidirectional communication between the community and researchers to increase CE strategies into cancer disparities research through periodic meetings between community members and researchers to discuss CE strategies, research recruitment strategies, dissemination strategies, among others.
80000324|NCT05832177|Behavioral|Community-based Training Program (CBTP) for Community Leaders and Stakeholders.|The CBTP provides the opportunity to acquire knowledge to impart cancer prevention education (Cancer 101) and skills necessary to disseminate educational information (hands-on experiences through OC educational activities). This training will be provided in-person and remotely to increase participation. This activity will begin according to the project timeline.
79231915|NCT02280135|Biological|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
79373842|NCT03438786|Procedure|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
79373843|NCT03438708|Drug|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
79373844|NCT00632463|Biological|RI-001|Dose 1
79373845|NCT00632463|Biological|RI-001|Dose 2
79527422|NCT05274360|Behavioral|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
79826735|NCT00849082|Drug|goserelin acetate|
79527423|NCT05274360|Behavioral|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
79527424|NCT05274256|Procedure|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
80000325|NCT05832177|Behavioral|Integrate Cancer 101 into the Stakeholders Programs|This program will offer stakeholders a no-cost workshop of three credit hours to increase cancer prevention education among Hispanic/Latinos. CMEs will be provided virtually to increase participation. This activity will begin according to the project timeline.
79527425|NCT05274191|Drug|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
79527426|NCT05274191|Other|standard regimen|standard regimen
79683539|NCT02921165|Drug|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
79683540|NCT01283386|Drug|Chlorambucil|10 mg/m^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
79683541|NCT01283386|Drug|Cyclophosphamide|150 mg/m^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
79826736|NCT00849082|Radiation|radiation therapy|
79826737|NCT00713856|Procedure|Custom PRK with iris registration|PRK
79826738|NCT00713856|Procedure|Conventional PRK|PRK
79683542|NCT01283386|Drug|Fludarabine|20 mg/m^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
79683543|NCT01283386|Drug|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
79683544|NCT05466786|Other|Standard Management|Standard Management
79683545|NCT02920931|Drug|Tenofovir disoproxil|
79826739|NCT02545582|Device|VITARIA System|Implantable vagus nerve stimulator
79683546|NCT01283152|Drug|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
79683547|NCT01283152|Drug|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
79231916|NCT02280135|Other|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
79826740|NCT00713934|Biological|CD133|portal vein infusion of CD133+ cells
79826741|NCT00713934|Biological|BM-MNC|portal vein infusion of BM-MNC
79826742|NCT00849160|Drug|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
79826743|NCT00714012|Other|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
79231917|NCT02279589|Biological|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
79826744|NCT00857974|Other|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
79231918|NCT02279589|Biological|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
79231919|NCT02279589|Biological|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
79527427|NCT05274139|Drug|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
79527428|NCT05274139|Drug|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
79527429|NCT05274113|Drug|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
79527430|NCT05274113|Drug|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
79373846|NCT00632463|Biological|RI-001|Placebo
79373847|NCT03435276|Drug|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
79373848|NCT03435276|Other|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
79373849|NCT01923597|Drug|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
79373850|NCT03435198|Diagnostic Test|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
79373851|NCT00632229|Drug|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
79373852|NCT00632229|Drug|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
79527431|NCT05274100|Drug|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
79527432|NCT05274100|Drug|Risankizumab|Intravenous Infusion
79527433|NCT05274100|Drug|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
79527434|NCT05274087|Drug|Risankizumab|Subcutaneous autoinjector
79527435|NCT05273957|Other|Case Manager|Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
79527436|NCT05273957|Other|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
79683548|NCT02932527|Behavioral|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
79683549|NCT02932527|Procedure|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
79683550|NCT02932527|Procedure|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
79683551|NCT01283035|Drug|Akt Inhibitor MK2206|Given PO
79683552|NCT01283035|Other|Laboratory Biomarker Analysis|Correlative studies
79683553|NCT02920853|Behavioral|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
79683554|NCT02920853|Behavioral|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
79683555|NCT02932371|Device|ECOM™.|
79683556|NCT02932371|Device|Trans-esophageal echography|
79683557|NCT01283464|Drug|Retinol|1.0% cream
79683558|NCT01283464|Drug|Tretinoin|0.02% cream
79683559|NCT01282801|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
79683560|NCT01282801|Drug|Effexor® XR|150 mg Extended-Release Capsule
79231920|NCT03209804|Procedure|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
79683561|NCT02920814|Other|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
79683562|NCT00532350|Drug|QAT370|
79826745|NCT00720252|Device|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
79826746|NCT00720590|Drug|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
79231921|NCT02282709|Drug|Daclatasvir|60 mg once daily
79231922|NCT02282709|Drug|asunaprevir|100 mg BID
79231923|NCT03119402|Behavioral|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
79231924|NCT03119402|Device|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
79527437|NCT05273944|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
79527438|NCT05273866|Other|Virtual reality|Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
79826747|NCT00720590|Drug|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
79231925|NCT02282787|Drug|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
79373853|NCT03435120|Other|No intervention|No intervention
79373854|NCT01923675|Other|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
79373855|NCT01923675|Other|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
79826748|NCT00720590|Drug|Placebo|Daily dose of placebo for 4 weeks
79373856|NCT01923675|Other|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
79527439|NCT05273853|Procedure|Partial Adenoidectomy|Partial removal of adenoid
79527440|NCT05273801|Device|Heart Rate Recording from Multiple Participants, No visual feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
79826749|NCT00852514|Device|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
79826750|NCT00718406|Drug|Metoprolol|
79826751|NCT00718406|Drug|metoprolol plus morphine|
80000326|NCT05832177|Behavioral|Community Engagement (CE) Training Program for Lay Community Members|A series of two-day CE workshops designed and delivered to 30 lay community members over a four-year period (6 to 10 participants per year). The proposed CE workshops includes: 1) CE principles, 2) cancer prevention education principles, and 3) community-based promotion strategies for cancer prevention. This activity will begin according to the project timeline.
79527441|NCT05273801|Device|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
79683563|NCT00532350|Drug|Placebo|
79683564|NCT00532350|Drug|Tiotropium|
79683565|NCT02920775|Other|Non-interventional study - retrospective database review|
79683566|NCT02932566|Drug|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
79683567|NCT02932566|Drug|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
79683568|NCT00532389|Drug|LBH589|
79683569|NCT02920580|Procedure|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
79826752|NCT02572206|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
79826753|NCT02572206|Device|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
79826754|NCT00849238|Drug|mycophenolate mofetil|
79683570|NCT02920580|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
79527442|NCT05273593|Device|Confocal Laser Endomicroscopy (CLE)|Administration of fluorescein, intravesically and intravenously. CLE measurements with flexible and rigid probe of papillary bladder tumour and rigid probe-measurement of resection bed.
79826755|NCT05374070|Dietary Supplement|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79683571|NCT02932644|Other|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
79826756|NCT05374070|Dietary Supplement|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79826757|NCT05374070|Dietary Supplement|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79826758|NCT05374070|Dietary Supplement|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79826759|NCT00720408|Drug|Prograf-XL|oral
79826760|NCT00720408|Drug|Prograf|oral
79826761|NCT00720408|Drug|MMF|oral
79373857|NCT01923675|Other|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
79683572|NCT02932644|Other|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
79683573|NCT02920697|Drug|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
79826762|NCT00852670|Drug|ACT-128800|ACT-128800 administered orally once daily
79826763|NCT00852670|Drug|Placebo|Matching placebo capsules administered orally once daily
79826764|NCT00717210|Drug|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
79231926|NCT03223844|Drug|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
79231927|NCT00458601|Drug|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
79231928|NCT00458601|Drug|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
79373858|NCT03434964|Diagnostic Test|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
79373859|NCT03431922|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
79373860|NCT01923753|Device|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
79373861|NCT01923753|Device|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
79527443|NCT05273528|Biological|Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
79527444|NCT05273489|Procedure|Hepatectomy|Neoadjuvant treatment
79527445|NCT05273398|Drug|nasal diazepam|Nasal administration of diazepam
79527446|NCT05273372|Other|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
79527447|NCT05273372|Other|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
79826765|NCT00717210|Radiation|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
79826766|NCT00723086|Drug|docetaxel (XRP6976)|combined treatment with prednisolone
79826767|NCT00720486|Behavioral|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
79826768|NCT00720486|Behavioral|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
79826769|NCT00858286|Other|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
79826770|NCT04018378|Drug|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
79683574|NCT05466708|Drug|Esketamine combined with dexmedetomidine|"Asic ketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature."
79683575|NCT05466708|Drug|Dexmedetomidine|Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
79683576|NCT02920541|Drug|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
79373862|NCT01923753|Device|Sham Aerosure|Deactivated but identical Aerosure HFAO device
79231929|NCT03223688|Behavioral|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
79231930|NCT03223688|Behavioral|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
79231931|NCT03223688|Behavioral|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
79527448|NCT05273333|Device|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
79373863|NCT00631137|Drug|testosterone gel applied to skin|Application of testosterone gel
79527449|NCT05273294|Device|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
79683577|NCT01282294|Device|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
79683578|NCT02932293|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
79683579|NCT02920502|Dietary Supplement|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
79683580|NCT02920502|Dietary Supplement|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
79231932|NCT00658047|Drug|CH-1504|Comparison of different doses of CH-1504
79231933|NCT00658047|Drug|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
79231934|NCT03230162|Drug|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
79231935|NCT03230162|Drug|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
79231936|NCT03223532|Device|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
79231937|NCT03223532|Device|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
79231938|NCT00455559|Drug|Perifosine|
79231939|NCT00455559|Drug|Imatinib Mesylate|
79373864|NCT00631137|Dietary Supplement|whey powder protein|
79373865|NCT03428880|Drug|Morphine|spinal morphine is done before cesarean section
79373866|NCT03428880|Drug|Quadratus lumborum block|a US Block QLB is done after surgery
79373867|NCT01923831|Drug|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
79527450|NCT05273229|Other|Virtual Gait|Virtual Gait: the patient will be placed in a standing position (with an ad-hoc designed help system) in front of a mirror (from the waist up) and a screen (from the waist down) where a video of legs walking on a treadmill will be projected and overcoming obstacles. Projected legs will be customized based on height, using the tibia length method.
79527451|NCT05273229|Other|Physical exercise|"PE: it will be divided into two parts: in the first one, a gait technique training will be carried out and, in the second, a leg strength training, for 30 min. Exercises:~Coordination exercises: normal and lateral parallel walking and walking with obstacles.~Functional exercises such as climbing stairs, etc.~Lower limb strength exercises. Strength exercises will be prescribed according to the guidelines of the American College of Sports Medicine (ACSM). Progression will be customized based on individual abilities."
79527452|NCT05273229|Other|Sham Virtual Gait|only the placebo virtual gait.
79683581|NCT02920502|Dietary Supplement|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
79683582|NCT02920502|Other|Arm 1: Placebo|One time dose of Placebo
79683583|NCT01282216|Biological|Havrix|1440 ELISA units, or 1 mL, IM
79683584|NCT01282216|Biological|PCV13|0.5 mL IM
79709826|NCT04326855|Other|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
79683585|NCT04323709|Other|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
79683586|NCT04323709|Other|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
79683587|NCT01281865|Other|diagnostic laboratory biomarker analysis|Correlative studies
79231940|NCT03230084|Device|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
79231941|NCT02916433|Drug|Octreotide|
79826771|NCT04018378|Drug|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
79826772|NCT05373602|Diagnostic Test|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
79826773|NCT05373524|Biological|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
79826774|NCT00849550|Drug|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
79231942|NCT02284269|Drug|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
79826775|NCT04018976|Device|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
79826776|NCT04018976|Device|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
79826777|NCT04018976|Device|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
79231943|NCT02451800|Other|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
79231944|NCT02451800|Other|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
79527453|NCT05273073|Dietary Supplement|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
79231945|NCT02451800|Other|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
79527454|NCT05273073|Dietary Supplement|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
79231946|NCT04059523|Drug|S6G5T-3|once daily
79826778|NCT05373368|Behavioral|multi purpose activities|
79826779|NCT03816488|Drug|Metformin|Metformin (usual dose) administered 2 h before surgery
79826780|NCT03816488|Drug|Salsalate|Salsalate 1.5 g administered 2 h before surgery
79826781|NCT00858676|Drug|acarbose|50mg acarbose 3 times a day PO. duration: one year
79231947|NCT04059523|Drug|Retin-A® 0.1% Cream|once daily
79231948|NCT02282943|Device|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
79231949|NCT02282943|Device|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
79373868|NCT01923831|Drug|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
79373869|NCT01923909|Drug|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
79527455|NCT05273021|Diagnostic Test|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
79826782|NCT00720668|Procedure|radiofrequency ablation|radiofrequency ablation for HCC
79826783|NCT00858754|Drug|methylnaltrexone|
79826784|NCT00858754|Drug|placebo|
79826785|NCT00723164|Drug|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
79826786|NCT00723164|Drug|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
79826787|NCT00849706|Other|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
79826788|NCT00858910|Other|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
79826789|NCT00858910|Other|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~the disease (stroke),~therapy options,~self-help groups and their offers for support,~helping aids for independent living at home."
79373870|NCT01923909|Drug|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
80000327|NCT05831579|Radiation|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
79231950|NCT03223454|Biological|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
79527456|NCT05272982|Diagnostic Test|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
79683588|NCT01281865|Drug|everolimus|Given PO
79683589|NCT01281865|Drug|imatinib mesylate|Given PO
79683590|NCT02932683|Device|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
79683591|NCT02920658|Drug|NAVS Naphthalan|
79683592|NCT02920658|Drug|0.05% Betamethasone dipropionate|
79683593|NCT02889679|Procedure|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
79683594|NCT02889679|Procedure|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
79683595|NCT02889679|Procedure|Standard polypectomy|Standard polypectomy will be performed for diminutive (<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
79683596|NCT02890030|Behavioral|Questionnaire|"Neurotoxicity~Medications of interest~General health~Family history"
79231951|NCT03223454|Biological|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
79231952|NCT04059133|Device|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
79231953|NCT04059133|Device|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
79231954|NCT00657501|Drug|testosterone gel|once daily transdermal gel, 300 mcg
79231955|NCT00657501|Drug|placebo gel|once daily transdermal placebo gel
79373871|NCT03434886|Other|CFView|Registry patient portal
79373872|NCT03434886|Other|CF educational videos|CF educational videos
79373873|NCT03434808|Other|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
79373874|NCT03428724|Drug|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
79373875|NCT03428724|Drug|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age>65, neurologic comorbidities)
79373876|NCT04450602|Dietary Supplement|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
79373877|NCT04450602|Other|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
79826790|NCT00852826|Procedure|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
80000328|NCT05830110|Device|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
80000329|NCT05830110|Device|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
79373878|NCT04450602|Other|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
79231956|NCT02452580|Other|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
79231957|NCT03675841|Drug|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
80000330|NCT05829174|Behavioral|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
80000331|NCT05829174|Behavioral|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
79527457|NCT05272982|Diagnostic Test|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
79527458|NCT05272904|Procedure|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
79527459|NCT05272904|Procedure|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
79826791|NCT00852826|Procedure|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
79826792|NCT00723242|Drug|Viraferon-peg and Rebetol|
79373879|NCT04450602|Other|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
79373880|NCT04450602|Dietary Supplement|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
79826793|NCT02545426|Other|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
79826794|NCT00720824|Behavioral|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
79826795|NCT00720824|Behavioral|Office routine|Standard vaccine administration
79826796|NCT05373290|Other|there is no intervention in the study|there is no intervention in the study
80000332|NCT05829174|Behavioral|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
79231958|NCT03229694|Drug|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
79826797|NCT05373134|Drug|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
79826798|NCT05373134|Other|Placebo|Placebo
79826799|NCT00723320|Drug|Atorvastatin|atorvastatin 10mg/d
80000333|NCT05829174|Behavioral|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
79231959|NCT03229694|Drug|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
79231960|NCT03223142|Device|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
79231961|NCT03675607|Other|Complementary feeding behaviours|Any kind of complementary feeding practice
79231962|NCT00452127|Drug|PRO131921|Escalating doses by IV infusion
79231963|NCT03223064|Diagnostic Test|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
79231964|NCT03223064|Diagnostic Test|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
79826800|NCT00723320|Behavioral|Aggressive lifestyle intervention|aggressive lifestyle intervention
79826801|NCT00578448|Drug|Belatacept|IV infusion
80000334|NCT05827081|Drug|Ribociclib|Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
80000335|NCT05827081|Drug|Letrozole|Letrozole 2.5 mg orally once daily continuously
80000336|NCT05827081|Drug|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
80000337|NCT05827081|Drug|Goserelin|Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
79826802|NCT05373056|Behavioral|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
79826803|NCT05373056|Behavioral|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
79826804|NCT05372978|Behavioral|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
79826805|NCT02571764|Other|Nutritional Oats Cookie|
79826806|NCT02572128|Other|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
79826808|NCT02572050|Procedure|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
79826809|NCT00720564|Drug|arsenic trioxide|
79826810|NCT00720564|Drug|temozolomide|
79826811|NCT00720564|Procedure|adjuvant therapy|
79527460|NCT05272839|Dietary Supplement|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
79683597|NCT02920619|Device|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
79683598|NCT01281202|Drug|Vigabatrin|Tablets
79683599|NCT01281202|Drug|Matching Placebo|Tablets
79826812|NCT00720564|Radiation|intensity-modulated radiation therapy|
79826813|NCT00720564|Radiation|radiation therapy|
79527461|NCT05272839|Dietary Supplement|Control group|The control group will receive only lifestyle and dietary recommendations.
79527462|NCT05272449|Device|Sleep apnea diagnosis|Split-night
79527463|NCT05272436|Device|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
79527464|NCT05272371|Combination Product|Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)|Dinutuximab beta in combination with chemotherapy.
79527465|NCT05272358|Other|NETSARC network|MDTB and/or surgery in NETSARC network
79683600|NCT02889718|Device|CONCERT-CL® station|"During cancer surgery (surgery > 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~Port B = open loop: Analgesic~Port A = closed loop: Hypnotic~Port C = closed loop: Curare"
79683601|NCT02889718|Other|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
79683602|NCT02932215|Drug|lorcaserin|Open label
79683603|NCT02932215|Other|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
79683604|NCT01281124|Drug|Azacitidine|Given subcutaneously
79826814|NCT04070430|Other|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
79826815|NCT04070430|Other|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
79826816|NCT00578318|Behavioral|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
79826817|NCT00714090|Other|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
79826818|NCT00714090|Other|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
79826819|NCT00714090|Other|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
79826820|NCT04067024|Procedure|Local anesthesia made by surgeon|infiltration with local anesthetics
79826821|NCT04067024|Procedure|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
79826822|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
79826823|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
79826824|NCT05364710|Dietary Supplement|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
79826825|NCT00618748|Drug|Olanzapine|5-20 mg/day, oral, daily
79826826|NCT04067544|Device|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
79826827|NCT00723476|Behavioral|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
79826828|NCT00723476|Behavioral|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
79826829|NCT02570906|Device|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
79826830|NCT00717600|Dietary Supplement|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
79826831|NCT00721058|Other|CT-scan|A pre-operative CT-scan will be made
80000338|NCT05827081|Drug|Leuprolide|Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
80000339|NCT05827081|Drug|Exemestane|Exemestane 25 mg once daily continuously
80000340|NCT05822583|Drug|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of >175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
79231965|NCT03675529|Behavioral|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
79527466|NCT05272215|Procedure|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
80000341|NCT05822583|Drug|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
79231966|NCT02280213|Device|MIL|Direct laryngoscopy 1
79231967|NCT02280213|Device|MAC|Direct laryngoscopy 2
79231968|NCT02280213|Device|WIS|Direct laryngoscopy 3
79527467|NCT05272215|Procedure|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
79527468|NCT05272189|Behavioral|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
79527469|NCT05272189|Behavioral|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
79527470|NCT05272163|Behavioral|Stimulus Type|Targets can be specific or categorical
79527471|NCT05272163|Behavioral|Target Presence|There is or is not a target present on each trial
79527472|NCT05272163|Behavioral|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
79683605|NCT01281124|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79683606|NCT01281124|Other|Pharmacological Study|Correlative studies
79683607|NCT00623857|Dietary Supplement|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
79683608|NCT00623857|Dietary Supplement|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
79683609|NCT00623857|Dietary Supplement|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
79683610|NCT00623857|Dietary Supplement|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
80000342|NCT05820711|Drug|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~Dose -1: 5 (4 - 6) x10^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~Dose 0: 10 (8 - 12) x10^6 MSCs per gland (1 ml)~Dose 1: 20 (16 - 24) x10^6 MSCs per gland (2 ml)"
80000343|NCT05815927|Drug|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
79231969|NCT02280213|Device|PHIL|Direct laryngoscopy 4
79231970|NCT03209648|Drug|Debio 1450|Debio 1450, 40 mg capsule.
79231971|NCT03209648|Drug|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
79683611|NCT05466435|Other|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
79527473|NCT05272124|Other|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
79683612|NCT05466435|Other|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
79683613|NCT02920424|Drug|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
79683614|NCT02920424|Drug|Placebo|Subjects will receive matching placebo.
79826832|NCT00850018|Procedure|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
79826833|NCT00850018|Behavioral|Usual care|Participants will receive usual care for the treatment of SCD.
79826834|NCT00721370|Device|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
79373881|NCT04450602|Other|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
79826835|NCT03566160|Device|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
79826836|NCT04067102|Drug|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
79527474|NCT05272124|Other|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
79527475|NCT05272020|Diagnostic Test|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
79683615|NCT01280968|Biological|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
79683616|NCT01280968|Biological|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
79826837|NCT04067102|Drug|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
79826838|NCT00859144|Behavioral|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
79826839|NCT00859144|Behavioral|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
79231972|NCT04058899|Drug|Dexmedetomidine|sedative and might be analgesic drug
79231973|NCT04058899|Drug|Nalbuphine|agonist antagonist narcotic
79231974|NCT04058899|Device|infusion pump|infusion pump for titration of fluid containing drug infusion
79231975|NCT00657189|Drug|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
79527476|NCT05271968|Procedure|Global management of scabies|"For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes"
79527477|NCT05271942|Procedure|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
79683617|NCT02889445|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
79231976|NCT00657189|Drug|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
79231977|NCT00657189|Drug|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
79683618|NCT02920385|Drug|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
79683619|NCT02920385|Drug|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
79683620|NCT02920385|Drug|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
79231978|NCT00657189|Drug|MEDI-545|100 mg every week × 13 doses
79231979|NCT00657189|Drug|Placebo|SC Placebo every week × 13 doses
79373882|NCT04450602|Other|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
79527478|NCT05271942|Procedure|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
79683621|NCT02920385|Drug|Placebo|Oral administration once daily together with semaglutide
79683622|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
79527479|NCT05271877|Procedure|Laparoscopy|Diagnostic/operative laparoscopic procedure
79527480|NCT05271838|Dietary Supplement|Magnesium acetate mixture (30 mmol/ml)|Patients with a magnesium retention test >25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
79527481|NCT05271838|Dietary Supplement|High-protein diet (2 g/kg/day)|Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
79527482|NCT05271786|Other|Decannulation|retrospective evaluation of decannulation
79683623|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
79683624|NCT01280812|Behavioral|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
79683625|NCT02932020|Drug|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
79683626|NCT02932020|Drug|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
79683627|NCT02932020|Device|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
80000344|NCT05815927|Radiation|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
80000345|NCT05814432|Drug|Single high dose of liposomal amphotericin B|Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
80000346|NCT05814432|Drug|L-AmB standard dose|Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
79231980|NCT03670459|Other|Cawthorne Cooksey exercises|Eye movements and head movements
79231981|NCT03670459|Other|Vestibular habituation exercises|Move from a sitting position to flat on the back
79231982|NCT03670459|Other|Balance exercises|Weight Shift Forward and Back
79231983|NCT00656097|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
79527483|NCT05271539|Drug|Lucentis alone group|The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
79527484|NCT05271539|Drug|Lucentis dexamethasone group|Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
79527485|NCT05271500|Device|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
79683628|NCT02932020|Drug|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
79231984|NCT00656097|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
79231985|NCT00656097|Biological|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
79683629|NCT02932098|Behavioral|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
79683630|NCT02932098|Behavioral|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
80000347|NCT05811156|Behavioral|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
80000348|NCT05790954|Other|Guided imagery|Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
80000349|NCT05789082|Drug|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
80000350|NCT05789082|Drug|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
80000351|NCT05789082|Drug|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
80000352|NCT05789082|Drug|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
80000353|NCT05789082|Drug|Pemetrexed|Participants will receive IV pemetrexed Q3W.
80000354|NCT05788432|Device|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
80000355|NCT05787613|Drug|HLX26|Anti-LAG-3 monoclonal Antibody Injection
80000356|NCT05787613|Drug|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
80000357|NCT05787613|Drug|Chemotherapy drug|non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
80000358|NCT05787613|Drug|Placebo|placebo
79683631|NCT02932098|Behavioral|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
79527486|NCT05271487|Other|Multi-Step Botanical Skin Care Regimen|"The intervention includes 7 different topical products:~Cleanser~Toner~Oil Control Cream~Exfoliating Facial Scrub~Clay Mask~Acne Spot Treatment~Body Scrub"
79683632|NCT05466396|Behavioral|smoking|Smoking history and spirometry are used to define groups
79231986|NCT03670381|Other|Psychiatric diagnosis|
79231987|NCT03209180|Drug|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
79231988|NCT03209180|Drug|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
79231989|NCT02280369|Device|Automated abdominal binder|Inflatable abdominal binder
79683633|NCT02920307|Procedure|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
79231990|NCT03215017|Device|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
79527487|NCT05271461|Radiation|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
79527488|NCT05271461|Other|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
79683634|NCT02920307|Procedure|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
79231991|NCT03215017|Drug|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
79231992|NCT00447993|Drug|NT-501|High Dose
79231993|NCT00447993|Drug|NT-501|Low Dose
79231994|NCT03229928|Device|MOCHA|"MOCHA phone-based application~Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~Wrist based sensor (applicable only to sensor wearing participants)."
79231995|NCT03675373|Behavioral|Mobile chat-based instant messages|"Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques."
79231996|NCT03675373|Behavioral|Alcohol brief intervention|Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
79683635|NCT02920307|Procedure|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
79683636|NCT02920307|Procedure|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
80000359|NCT05785429|Drug|Colchicine 0.5 MG|Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
80000360|NCT05785429|Drug|Placebo|Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
80000361|NCT05783622|Drug|JANX008|JANX008 is dosed via IV weekly in a 21-day cycle
80000362|NCT05782907|Drug|Upadacitinib|Oral Solution/ Tablets
80000363|NCT05771428|Drug|ABBV-552|Oral Capsule
79231997|NCT02283021|Other|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
79231998|NCT03229772|Device|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
80000364|NCT05771428|Drug|Placebo for ABBV-552|Oral Capsule
80000365|NCT05769595|Biological|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
80000366|NCT05769595|Drug|Placebo|IV infusion
80000367|NCT05766306|Dietary Supplement|Probiotic Blend|Participants will be taking 1 sachet a day, 3 billion CFU.
80000368|NCT05766306|Dietary Supplement|Placebo|Participants will be taking 1 sachet a day.
80000369|NCT05759533|Procedure|Corrected carotid flow time, IVC diameter|Corrected carotid flow time correction: is the carotid systole time, with heart rate correction applied IVC Collapsibility Index measurement is a reliable predictor of intraoperative hypotension within 30 minutes of spinal anesthetic administration
80000370|NCT05757557|Drug|Sham treatment|Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
79826840|NCT00859144|Behavioral|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
80000371|NCT05757557|Drug|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperatively after trachea intubation, during CPB, and for six hours after surgery.
79527489|NCT05271422|Device|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
79527490|NCT05271422|Device|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
79527491|NCT05271396|Other|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
79527492|NCT05271370|Drug|PRO 140 350|Pro140 SC injection 350 mg
79826841|NCT04067154|Diagnostic Test|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
80000372|NCT05756920|Drug|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
80000373|NCT05756920|Drug|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
80000374|NCT05756166|Procedure|Biopsy|Undergo tumor biopsy
80000375|NCT05756166|Procedure|Biospecimen Collection|Undergo blood sample collection
80000376|NCT05756166|Drug|Celecoxib|Given PO
80000377|NCT05756166|Procedure|Computed Tomography|Undergo CT scan
80000378|NCT05756166|Biological|Interferon Alpha-2|Given IV
80000379|NCT05756166|Procedure|Magnetic Resonance Imaging|Undergo MRI
80000380|NCT05756166|Biological|Pembrolizumab|Given IV
80000381|NCT05756166|Drug|Rintatolimod|Given IV
79527493|NCT05271370|Drug|PRO 140 525|525 mg
79527494|NCT05271370|Drug|PRO 140 700|700 mg
79527495|NCT05271253|Drug|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
79527496|NCT05271253|Drug|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
79527497|NCT05271253|Drug|normal Saline|injection of normal Saline
79826842|NCT05311202|Behavioral|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
80000382|NCT05750628|Drug|INE963|oral INE963
80000383|NCT05750628|Drug|KAE609 (Cipargamin)|oral KAE609 (Cipargamin)
80000384|NCT05750628|Drug|SoC (Coartem)|SoC (Coartem)
80000385|NCT05750628|Drug|KLU156|oral sachet KLU156 (KAF156 + lumefantrine)
80000386|NCT05747261|Genetic|ANB-004, dose 1|Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
80000387|NCT05747261|Genetic|ANB-004, dose 2|Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
80000388|NCT05747261|Genetic|ANB-004, dose 3|Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
79683637|NCT01280656|Drug|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
79683638|NCT01280656|Drug|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
79683639|NCT01280656|Drug|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
79683640|NCT01280656|Drug|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
80000389|NCT05747222|Other|Action Observation Tharapy|Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.
80000390|NCT05747222|Other|Conventional Therapy|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
79527498|NCT05271227|Other|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
79683641|NCT05466162|Other|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
79683642|NCT05466162|Other|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
79527499|NCT05271201|Other|treadmill exercise (mild)|mild intensity treadmill training.
79527500|NCT05271201|Other|treadmill exercise (moderate)|moderate-intensity treadmill training
79683643|NCT03741530|Drug|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
79683644|NCT03741530|Other|Standard management for ICH|Usual care and drug in hospital
79683645|NCT01280617|Drug|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
79683646|NCT01280617|Drug|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
79683647|NCT02920268|Other|Dance and yoga intervention|
79683648|NCT02932137|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
79683649|NCT02889484|Procedure|Lumbar disc hernia surgery|
79683650|NCT02889328|Drug|Regorafenib|Regorafenib 100mg continuous dosing arm
79683651|NCT02932059|Behavioral|Metamemory|Metamemory evaluation using a sentence construction strategy
79683652|NCT01280266|Drug|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
80016663|NCT03108339|Other|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
79231999|NCT03670303|Behavioral|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~Lectures on importance of spectacles use including visual materials such as pictures and videos.~An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~Posters~Brochures"
79683653|NCT01279447|Drug|0.25% Bupivacaine|10cc, single dose, US guided injection
79683654|NCT01279447|Drug|Normal Saline|10cc, single dose, US guided injection
79683655|NCT05466045|Other|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
79683656|NCT05466045|Other|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
79683657|NCT02920034|Device|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
79683658|NCT02920034|Device|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
79683659|NCT02920034|Device|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
79683660|NCT02931981|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
79683661|NCT02920151|Other|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
79826843|NCT05311202|Behavioral|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
79373883|NCT04450602|Other|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
79527501|NCT05271188|Procedure|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function [8]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity [9, 10]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) [11]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
79527502|NCT05271149|Other|Routine Physical Therapy|Routine physical therapy and orthosis
79683662|NCT02932254|Drug|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
79683663|NCT02932254|Drug|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
79826844|NCT05311202|Behavioral|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
79683664|NCT02920112|Behavioral|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
79683665|NCT02920190|Drug|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
79527503|NCT05271136|Other|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
79527504|NCT05271136|Other|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
79527505|NCT05271136|Other|Cleansing Lotion|Facial cleansing lotion to be used by study participants
79527506|NCT05271136|Other|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
79683666|NCT05465850|Diagnostic Test|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
79683667|NCT02919878|Drug|Gemcitabine|Nucleoside analog- Chemotherapy
79826845|NCT05311202|Behavioral|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
79683668|NCT02919878|Radiation|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
79683669|NCT02919878|Drug|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
79683670|NCT02931786|Drug|propofol|propofol, midazolam and atropine administration via intravenous cannula.
79683671|NCT02931786|Drug|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
79683672|NCT02931747|Dietary Supplement|Placebo|Subjects are received Placebo once daily for 16 weeks.
79683673|NCT02931747|Dietary Supplement|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
79683674|NCT02931747|Dietary Supplement|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
79683675|NCT02919605|Drug|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
79683676|NCT02919605|Drug|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
79683677|NCT02919605|Drug|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
79683678|NCT02931708|Other|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
79683679|NCT02919800|Biological|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
79683680|NCT02919800|Other|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
79683681|NCT04687605|Procedure|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
79683682|NCT02931630|Other|Whey protein powder|60 g of whey protein powder
79683683|NCT02931630|Other|Maltodextrin powder|60 g of Maltodextrin powder
79826846|NCT05311202|Behavioral|Control group|Reading a book related to cognitive function & exercise for 40 minutes
79826847|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
79826848|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
79527507|NCT05271136|Other|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
79826849|NCT05659290|Drug|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
79232000|NCT03209336|Radiation|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
79373884|NCT04892940|Device|Virtual Reality (VR) technique|"The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group."
79527508|NCT05271123|Diagnostic Test|Assessment of respiratory function and growth motor function classiffication level|Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
79527509|NCT05271110|Procedure|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
79683684|NCT02931630|Other|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
79683685|NCT02931630|Other|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
79683686|NCT02931669|Other|Qualitative Descriptive Study|
79683687|NCT02919722|Behavioral|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
79683688|NCT02931864|Other|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
79683689|NCT02931864|Other|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
79826850|NCT05659290|Drug|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
79527510|NCT05271058|Other|Control group|23 eyes that didn't receive any intraoperative steroids
79527511|NCT05271058|Drug|Dexamethasone group|23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
79826851|NCT00852982|Behavioral|Exercise|Nordic walking, with walking poles, five hours per week during four months
79232001|NCT05208021|Behavioral|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
79232002|NCT03209102|Other|Clinical assessment|"Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
79232003|NCT03209102|Behavioral|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
79527512|NCT05271058|Drug|Triamcinolone (TA) group|23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
79527513|NCT05271045|Dietary Supplement|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
79683690|NCT00532428|Drug|Raloxifene|60 mg QD
79683691|NCT00532428|Drug|Raloxifene|120 mg QD
79826852|NCT02571504|Behavioral|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
79527514|NCT05271045|Dietary Supplement|Active comparator|30 g fortified canola oil with vitamins A and D
79527515|NCT05271045|Dietary Supplement|Placebo|30 g fortified sunflower oil with vitamins A and D
79683692|NCT00532428|Drug|Placebo|Placebo
80000391|NCT05747170|Other|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
80000392|NCT05746325|Other|Digital Photography|Digital photographs taken of array placement
79232004|NCT03209102|Other|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
79232005|NCT03209102|Biological|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
79232006|NCT02283099|Biological|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5)
79232007|NCT03670225|Device|Invia Motion Endure|NPWT Invia Motion Endure
79232008|NCT03208400|Behavioral|virtual reality exposure|one-session exposure conveyed via virtual reality technology
79232009|NCT02280447|Biological|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
79232010|NCT02280447|Biological|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
79373885|NCT04892940|Drug|Analgesic protocol|"Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively."
79373886|NCT03305250|Device|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
79527516|NCT05270967|Diagnostic Test|F-18 FDG PET/CT imaging|Oncological imaging
79683693|NCT02919839|Other|non-Interventional|
79527517|NCT05270967|Biological|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
80000393|NCT05746325|Procedure|Lumbar Puncture|Undergo LP
79527518|NCT05270954|Biological|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
79527519|NCT05270954|Drug|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
79527520|NCT05270941|Procedure|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
79527521|NCT05270915|Behavioral|Family supportive care in EOLC|The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
79232011|NCT02280447|Biological|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
79232012|NCT02280447|Biological|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
79232013|NCT03675295|Drug|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
79232014|NCT03675295|Drug|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
79232015|NCT00528333|Drug|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
79232016|NCT00528333|Drug|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
79683694|NCT00532467|Drug|SRX251|
79683695|NCT02919527|Other|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
79683696|NCT02919527|Other|Stretching|Static Stretching performed at the anterior thigh
79683697|NCT00532506|Drug|SK-0403|
79683698|NCT02919644|Biological|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
79683699|NCT02919644|Drug|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
80000394|NCT05746325|Procedure|Magnetic Resonance Imaging|Undergo MRI
79232017|NCT00528333|Drug|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
79232018|NCT03675217|Other|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
79232019|NCT03675217|Other|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
79232020|NCT00526227|Device|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
79232021|NCT02284425|Drug|REGN1193|
79232022|NCT02284425|Drug|Placebo|
79232023|NCT03134157|Drug|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
79232024|NCT03134157|Drug|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
79232025|NCT03134157|Drug|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
79373887|NCT03085563|Drug|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
79373888|NCT03085563|Drug|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
79373889|NCT03431766|Device|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
79527522|NCT05270889|Drug|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~Subjects with body weight <70 kg: 1800 mg IV on Day 1 of each 21-day cycle~Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
79527523|NCT05270824|Combination Product|radical surgery after neoadjuvant immunotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
79527524|NCT05270824|Combination Product|radical surgery after neoadjuvant chemotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
80000395|NCT05746325|Device|Medical Device Usage and Evaluation|Transducer arrays applied and wear NovoTTF-200T
79232026|NCT02280603|Drug|DA-4001C|1ml by topical application twice a day
79232027|NCT02280603|Drug|5% minoxidil|1ml by topical application twice a day
79232028|NCT03134235|Other|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
79232029|NCT00524277|Biological|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
79232030|NCT00524277|Biological|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
79232031|NCT00524277|Biological|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
79232032|NCT00524277|Biological|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
79527525|NCT05270772|Biological|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10^6/kg,1.5×10^6/kg, 5.0×10^6/kg CAR+ cells.
79527526|NCT05270720|Biological|dendritic cell|"Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107."
80000396|NCT05745883|Drug|DISC-0974|DISC-0974 is administered subcutaneously
80000397|NCT05745883|Drug|Placebo|Placebo is administered subcutaneously
80000398|NCT05743985|Other|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
80000399|NCT05740566|Drug|Tarlatamab|Tarlatamab will be administered as an IV infusion.
79232033|NCT02284503|Drug|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
80000400|NCT05740566|Drug|Lurbinectedin|Lurbinectedin will be administered per local SOC.
79232034|NCT00650949|Drug|CYT997|Escalating doses (100mg/m^2 to 150mg/m^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
79232035|NCT00650949|Drug|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
79232036|NCT00520923|Drug|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
79232037|NCT00520923|Drug|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
79232038|NCT00520923|Drug|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
79232039|NCT00520923|Drug|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
79232040|NCT00520923|Drug|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
79232041|NCT00520923|Drug|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
79232042|NCT00520923|Drug|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
79373890|NCT03431766|Device|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
79826853|NCT05304494|Other|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
79683700|NCT05465733|Drug|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
79683701|NCT02919488|Other|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
79826854|NCT00859378|Device|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith & Nephew)
79826855|NCT00859378|Device|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
79232043|NCT02547922|Biological|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
79232044|NCT02547922|Drug|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
79232045|NCT02286375|Behavioral|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
79232046|NCT00514371|Drug|tanespimycin|High dose
79373891|NCT04450446|Drug|Low molecular weight heparin|Anticoagulation therapy
79527527|NCT05270681|Other|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
79527528|NCT05270642|Procedure|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
79683702|NCT02919488|Other|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
79232047|NCT00514371|Drug|Bortezomib|Mid dose, and low dose
79373892|NCT03274752|Drug|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
79373893|NCT03274752|Drug|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
79527529|NCT05270629|Other|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
79527530|NCT05270629|Other|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
79527531|NCT05270616|Procedure|robotic surgery|minimally invasive surgery using the Davinci robotic system
79527532|NCT05270616|Procedure|uniport surgery|VATS minimally invasive surgery under the uniportal status
79683703|NCT00533286|Drug|benzodiacepine|diazepam (2 x 5 mg/ die)
79232048|NCT04471077|Procedure|bariatric surgery|(Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
79232049|NCT04470765|Device|Zida|Transcutaneous Tibial Nerve Stimulation
79373894|NCT03256734|Other|Policy intervention|Incentive payment for physicians
79373895|NCT03902418|Drug|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
79373896|NCT03428568|Other|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
79373897|NCT03428568|Drug|Nexium|omeprazole
79373898|NCT03428568|Drug|Amoxil|Antibiotic
79683704|NCT03680456|Drug|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
79683705|NCT03680456|Drug|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
79683706|NCT03673787|Drug|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
79683707|NCT03673787|Drug|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
79826856|NCT00717678|Drug|Prograf-XL|oral
79826857|NCT00717678|Drug|Prograf|oral
79826858|NCT00717678|Drug|MMF|oral
79826859|NCT00859534|Drug|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
79826860|NCT05050682|Drug|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
80000401|NCT05740566|Drug|Topotecan|Topotecan will be administered per local SOC.
80000402|NCT05740566|Drug|Amrubicin|Amrubicin will be administered per local SOC.
80000403|NCT05740007|Drug|IW-3300 rectal foam|IW-3300 rectal foam administered daily for 12 weeks
80000404|NCT05740007|Drug|Placebo|Placebo rectal foam administered daily for 12 weeks
80000405|NCT05739448|Other|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
79683708|NCT05465694|Procedure|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
79683709|NCT05465694|Procedure|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
79683710|NCT03615248|Device|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~the dose was given,~the metered dose inhaler was properly shaken,~the metered dose inhaler is properly aligned,~the flow of medication is appropriate and~there is no accidental exhalation into the inhaler."
80000406|NCT05739448|Other|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
79232050|NCT02547766|Drug|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
79232051|NCT04470531|Drug|oral co-trimoxazole|oral co-trimoxazole + standard therapy
79373899|NCT03428568|Drug|Clarithromycin|Antibiotic
79373900|NCT03431688|Drug|PAM|treatment with PPI, metonidazole, amoxicillin
79373901|NCT03431688|Drug|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
79373902|NCT00630825|Drug|LY2189265|
79373903|NCT00630825|Drug|Placebo|
79373904|NCT03431610|Drug|SB414 2%|Twice daily
79527533|NCT05270616|Procedure|multiple- port surgery|VATS minimally invasive surgery under the multiple- port status
79527534|NCT05270590|Procedure|minimally invasive rheumatic mitral valve surgery|First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
79527535|NCT05270577|Other|Prehabilitation|prehabilitation
79232052|NCT02286453|Drug|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
79527536|NCT05270577|Other|Standard care|No intervention
79527537|NCT05270564|Procedure|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
79527538|NCT05270564|Procedure|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
79527539|NCT05270551|Procedure|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
79527540|NCT05270538|Device|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
79232053|NCT02286453|Drug|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
79232054|NCT02286531|Drug|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
79232055|NCT04470999|Other|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
79232056|NCT00385515|Drug|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
79232057|NCT00385515|Drug|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
79373905|NCT03431610|Drug|SB414 6%|Twice daily
79373906|NCT03431610|Drug|Vehicle|Placebo comparator
79373907|NCT04257474|Behavioral|Self-Report Survey|The self-report survey will be created using the Health Services Utilization Model (HSUM)
79373908|NCT04257474|Behavioral|Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
79373909|NCT03434574|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
79373910|NCT03434574|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
79373911|NCT03434496|Device|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
79373912|NCT03434340|Biological|Peppermint essential oil|2 drops applied on a nasal strip
79373913|NCT03434340|Drug|Granisetron|1mg intravenous injection
79373914|NCT03434340|Drug|Dexamethasone|4mg intravenous injection
79232058|NCT04471155|Procedure|Holep|laser enucleation of the gland versus open enucleation
79373915|NCT03431454|Procedure|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
79683711|NCT04805112|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
79373916|NCT03431454|Procedure|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
79373917|NCT03431454|Procedure|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
79232059|NCT00443391|Drug|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
79232060|NCT02286609|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
79683712|NCT03571802|Drug|Simvastatin|"The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
79683713|NCT04799652|Other|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
79683714|NCT02919332|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
79527541|NCT05270486|Procedure|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
79683715|NCT02919332|Radiation|Fludeoxyglucose F-18|Given IV
79683716|NCT02919332|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
79527542|NCT05270447|Other|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
79683717|NCT05465577|Other|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
79683718|NCT02919254|Dietary Supplement|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
79683719|NCT02919254|Other|Placebo|Fruit juice cordial containing negligible nitrate
79683720|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
79683721|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
79683722|NCT05463315|Device|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
79683723|NCT02919371|Drug|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
79683724|NCT02919371|Drug|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
79683725|NCT05460819|Other|Acupuncture treatment|"Acupoint selection: Hegu-Yinxi acupoint group (clearing heat and relieving sweat), Sanyinjiao-Fuliu acupoint group (nourishing yin and tonifying kidney), Tianshu-uteri acupoint group (special effect points) (12 acupoints on both sides).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
79709827|NCT02272400|Other|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
79232061|NCT00511485|Drug|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
79232062|NCT00511485|Drug|Etarfolatide|
79232063|NCT00508989|Drug|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
79232064|NCT00508989|Drug|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
79232065|NCT00508989|Drug|L-NMMA|
79232066|NCT00508989|Drug|Acetylcholine|
79232067|NCT02742441|Drug|122-0551 Foam|Topical Foam containing active drug
79232068|NCT02742441|Drug|Vehicle Foam|Topical Foam containing no active drug
79232069|NCT05457166|Device|KASPARD system for fall prevention in nursing homes|"All subjects will be monitored for 2 periods of 100 nights each. Recordings will be made continuously at night for the duration of the study Period 0: set-up, adjustment, recording (without alarm); This is a preparatory phase which is part of the usual use of the device.~Duration: 10 days Before period: The BEFORE period runs for 100 nights during which the device alarm is not activated, but the device records events.~After period: The AFTER period is 100 nights during which the device alarm is activated: Monitoring with recording + alarm activated (usual care + action if alarm is triggered)"
79683726|NCT05460819|Other|Sham Acupuncture treatment|"Selecting acupoints: Select the side opening positions of the 6 acupuncture points in the real acupuncture group, and select non-meridian and non-points (points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
79683727|NCT02919410|Device|iodophor-impregnated adhesive drapes|
79683728|NCT02919410|Other|No adhesive drapes|
79683729|NCT02919215|Behavioral|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
79232070|NCT04470141|Drug|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
79232071|NCT03981328|Device|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
79373918|NCT01923987|Radiation|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
79527543|NCT05270447|Behavioral|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
79527544|NCT05270434|Procedure|time interval between ESWL and ERCP is 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
79527545|NCT05270434|Procedure|time interval between ESWL and ERCP is 12-36h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12-36h.
79527546|NCT05270434|Procedure|time interval between ESWL and ERCP is greater than 36h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP >36h.
79232072|NCT03981328|Device|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
79527547|NCT05270434|Drug|morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
79527548|NCT05270421|Drug|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
79683730|NCT04748016|Other|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
79683731|NCT04748016|Other|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
79527549|NCT05270421|Other|Conventional Treatment|Standard ESWL
79683732|NCT04736901|Drug|Enoxaparin|0.5 mg/kg every 12 hours
79683733|NCT04736901|Drug|Enoxaparin|40 mg/day
79683734|NCT04736901|Drug|Rivaroxaban|10 mg once daily
79683735|NCT04736901|Drug|Rivaroxaban|20 mg once daily
79232073|NCT04470297|Drug|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
79232074|NCT03104842|Drug|Isatuximab|Antibody Intravenous
79232075|NCT03104842|Drug|Carfilzomib|Intravenous
79232076|NCT03104842|Drug|Lenalidomide|Capsel
79232077|NCT03104842|Drug|Dexamethasone|Capsel
79232078|NCT00436683|Drug|Fermagate|Film coated tablet 500mg
79232079|NCT00436683|Drug|Sevelamer HCl|tablet 800mg
79232080|NCT02286999|Drug|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
79232081|NCT02286999|Drug|Placebo|
79232082|NCT00434811|Biological|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
79232083|NCT00434811|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
79232084|NCT00434811|Drug|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
79683736|NCT04736901|Drug|Apixaban|2.5 mg twice daily
79232085|NCT00434811|Drug|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
79232086|NCT00434811|Biological|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
79683737|NCT04736901|Drug|Apixaban|5 mg twice daily
79232087|NCT00434811|Procedure|Islet Transplantation|Transplantation of pancreatic islet cell
79373919|NCT01923987|Drug|Chemotherapy|"Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~Bevacizumab 5 mg/kg IV over 90 mins on Day 1~Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
79826861|NCT00853138|Behavioral|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
79826862|NCT04067466|Dietary Supplement|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
79826863|NCT04067466|Dietary Supplement|Control product|Placebo product with maltodextrin and plum powder
79826864|NCT02571842|Drug|Intravenous Rituximab|- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
79826865|NCT02571842|Drug|ACEI/ARB and corticosteroids|"ACEI or ARB will be prescribed as high as tolerable dose.~Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
79232088|NCT00434811|Biological|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
79373920|NCT01923987|Procedure|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
79373921|NCT03101163|Biological|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
79826866|NCT02546284|Drug|lenzilumab|
79527550|NCT05270343|Drug|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml[125-200nmol/L], ≤100ng/ml[≤250nmol/L]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
79683738|NCT02919176|Drug|Mirabegron|Mirabegron 50 mg/day
79826867|NCT02572830|Behavioral|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
79826868|NCT02572830|Behavioral|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
79826869|NCT00721448|Drug|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
79826870|NCT00721448|Drug|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
79826871|NCT00720954|Procedure|Ct-guided pleural needle biopsy|Biopsy of pleura
79232089|NCT02284659|Device|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
79232090|NCT02284659|Device|FES- Sham|
79826872|NCT00720954|Procedure|Thoracoscopy|Biopsy of pleura
79232091|NCT03133845|Procedure|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
79826873|NCT02570828|Device|Thermal Imaging|FLIR ONE attachment to an iPhone
79826874|NCT00853216|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
79373922|NCT03101163|Other|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
79527551|NCT05270330|Other|This is an observational study, we don't have any interventions.|No intervention
79683739|NCT02919176|Drug|Pioglitazone|Pioglitazone 30 mg/day
79683740|NCT02919176|Drug|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
79683741|NCT04734678|Drug|Tocilizumab|400 mg IV only once
79683742|NCT04734678|Drug|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
79826875|NCT00853216|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
79826876|NCT02571062|Drug|Fexinidazole|
80000407|NCT05735795|Other|Carbon Black Tattoo|SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
79232092|NCT03133845|Procedure|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
79232093|NCT03133845|Procedure|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
79232094|NCT03133845|Procedure|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
79232095|NCT03133845|Procedure|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
79683743|NCT02919059|Drug|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
79373923|NCT02521194|Behavioral|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
79373924|NCT01924065|Procedure|Cardioversion|Electrical cardioversion
79826877|NCT00859768|Other|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
80000408|NCT05734183|Other|MIME|Multisensorial IMmersive Experiences
79683744|NCT02919059|Drug|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
79683745|NCT05421507|Radiation|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
79683746|NCT00533364|Drug|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
79683747|NCT02918786|Device|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
79683748|NCT02918786|Device|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
79683749|NCT04731753|Device|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
79683750|NCT02918981|Behavioral|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
79683751|NCT02918981|Dietary Supplement|14 g Whey protein|
79683752|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine|
79683753|NCT02918981|Dietary Supplement|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
79683754|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
79683755|NCT02918981|Other|Water control|
79683756|NCT04727775|Drug|Favipiravir|Antiviral drugs
79683757|NCT04727775|Drug|Remdesivir|Antiviral drugs
79232096|NCT03133845|Procedure|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
79232097|NCT03133845|Procedure|Spinal Anesthesia|Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.
79683758|NCT02918825|Drug|Olanzapine|Olanzapine
79683759|NCT02918825|Drug|Paliperidone|Paliperidone
79683760|NCT05420376|Procedure|Split Mesh|TEP repair of inguinal hernias using either split or whole mesh
79683761|NCT02919020|Other|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
79232098|NCT03133845|Procedure|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
79232099|NCT03133845|Procedure|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.
79232100|NCT03133845|Procedure|Administration of intrathecal morphine|Patient may receive intrathecal morphine for post-operative pain control.
79232101|NCT04441671|Drug|Disodium Pyrophosphate|Absorption trial
79232102|NCT03209024|Other|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
79373925|NCT01924065|Drug|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
79683762|NCT02919020|Other|Resistance exercise|resistance exercise to strengthen lower limbs
79683763|NCT04724070|Genetic|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
79683764|NCT02918903|Procedure|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
79683765|NCT02918903|Procedure|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
79232103|NCT03209024|Device|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
79527552|NCT05270252|Other|Learning and Care|"The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright & Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care."
79683766|NCT05407935|Behavioral|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
79683767|NCT05407935|Behavioral|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
79683768|NCT02918747|Drug|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
79373926|NCT03428412|Drug|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
79373927|NCT03428412|Drug|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
79683769|NCT02918747|Drug|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
79683770|NCT02918747|Drug|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
79683771|NCT02918747|Drug|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
79683772|NCT02918747|Drug|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
79683773|NCT02918747|Drug|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
79683774|NCT02918747|Drug|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
79683775|NCT02918747|Drug|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
79683776|NCT02918747|Radiation|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
79683777|NCT02918708|Biological|Synflorix|10-valent pneumococcal conjugate vaccine
79683778|NCT02918708|Biological|Prevenar13|13-valent pneumococcal conjugate vaccine
79683779|NCT02918591|Drug|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
79683780|NCT02918513|Behavioral|Wellness Element 1 - Exercise|1. Daily wellness element focusing on Exercise; adherence documented online daily
79683781|NCT02918513|Behavioral|Wellness Element 2 - Mindfulness|2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
79683782|NCT02918513|Behavioral|Wellness Element 3 - Sleep Hygiene|3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
79683783|NCT02918513|Behavioral|Wellness Element 4 - Social Connectedness|4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
79683784|NCT02918513|Behavioral|Wellness Element 5 - Nutrition|5. Daily wellness element focusing on Nutrition; adherence documented online daily
79683785|NCT02918513|Behavioral|Wellness Element 6 - Wellness Exercises|6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
79683786|NCT02918513|Behavioral|Wellness Element 7 - Motivational Messages|7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
79232104|NCT00120393|Drug|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
79232105|NCT00120393|Drug|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
79683787|NCT02918240|Procedure|Appointment intervals|
79683788|NCT02918240|Device|fixed orthodontic braces|
79232106|NCT05476120|Behavioral|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
79232107|NCT03201224|Device|"After Group"|
79232108|NCT00117819|Drug|[123I]ß CIT and SPECT imaging|To assess [123I]ß CIT and SPECT imaging
79683789|NCT04680039|Device|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
79683790|NCT02918045|Device|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
79683791|NCT02918045|Device|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
79527553|NCT05270226|Behavioral|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
79826878|NCT04961528|Drug|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 5 days"
79826879|NCT04961528|Drug|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 5 days"
79527554|NCT05270187|Other|Photobiomodulation therapy (laser therapy)|The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
79826880|NCT04961528|Drug|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 5 days."
79683792|NCT02918123|Biological|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
79683793|NCT05400096|Other|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
79826881|NCT00721032|Procedure|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
79232109|NCT03208946|Other|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
79826882|NCT00721032|Drug|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -> new dose 100 once daily (QD) -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD"
79826883|NCT00859846|Procedure|Arterial line placement|"The following measures will be collected and compared.~Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~number of attempts, defined as forward advancements of needle, required to cannulate the artery.~number of separate skin punctures.~number of arteries into which entry is attempted."
79683794|NCT02917850|Procedure|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
79683795|NCT02917850|Procedure|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
79232110|NCT03208946|Other|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
79232111|NCT05726019|Drug|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
79683796|NCT03825575|Device|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
79826884|NCT00723866|Other|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
79683797|NCT00532545|Drug|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
79683798|NCT03819062|Device|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
79683799|NCT04674111|Device|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is indicated to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
79709828|NCT02273102|Drug|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
79826885|NCT00723866|Other|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
80000409|NCT05734183|Other|MIME + tDCS|Multisensorial IMmersive Experiences plus transcranial direct current stimulation
80000410|NCT05734105|Drug|Ripretinib|50 mg tablets
80000411|NCT05734105|Drug|Sunitinib|12.5 mg tablets
80000412|NCT05729165|Device|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
79826886|NCT04069182|Behavioral|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
79826887|NCT00850252|Device|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
79826888|NCT00853294|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
79232112|NCT03208790|Drug|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
79232113|NCT03208790|Drug|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
79373928|NCT03431298|Behavioral|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~First, lumbo-pelvic and hip dynamic direction control.~Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~Third, trunk muscle groups and hip muscle groups through range control.~Fourth, functional movement control training"
79373929|NCT03431298|Behavioral|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~10 min Warm up~40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~10 min Cool down"
79373930|NCT00638703|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU Oxalobacter formigenes twice daily for 24 weeks
79826889|NCT00853294|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
79826890|NCT00717834|Biological|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
79826891|NCT00658359|Drug|Cyclosporine|Standard of care
79826892|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
79826893|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
79232114|NCT03208790|Drug|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
79232115|NCT00116415|Drug|efavirenz; didanosine EC; lamivudine|
79232116|NCT03207698|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
79232117|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
79373931|NCT00638703|Drug|Placebo|placebo
79527555|NCT05270187|Other|Facial massage and facial expression exercises|Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
79232118|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
79527556|NCT05270161|Procedure|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
79527557|NCT05270161|Procedure|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
79709829|NCT02273102|Drug|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
79709830|NCT02272478|Drug|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
79709831|NCT02272478|Drug|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
79527558|NCT05270161|Procedure|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
79373932|NCT03431220|Device|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
79373933|NCT01924143|Drug|TD-9855|radiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)
79373934|NCT03434106|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
79527559|NCT05270161|Procedure|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
79527560|NCT05270135|Behavioral|ASAP|ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
79683800|NCT03792737|Device|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
79683801|NCT03792737|Device|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
79683802|NCT03792737|Device|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
79683803|NCT03792737|Device|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
79683804|NCT03792737|Device|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
79683805|NCT04686942|Diagnostic Test|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
79683806|NCT03782519|Other|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
79683807|NCT03782519|Other|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
79373935|NCT03434106|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
79373936|NCT01924377|Procedure|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance >5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
79527561|NCT05270070|Other|Appointment booking system|Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
79527562|NCT05270018|Drug|Bacterial Lysates|14mg once a day
79527563|NCT05270018|Other|normal saline|14.0ml once a day
79683808|NCT00533403|Drug|MK0686|
79683809|NCT05381883|Other|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
79683810|NCT00533481|Drug|MK0557|
79683811|NCT03756155|Procedure|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
79683812|NCT00533520|Drug|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
79683813|NCT00533559|Drug|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
79683814|NCT00533559|Drug|Placebo|Placebo comparator
80000413|NCT05729165|Other|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
79232119|NCT02287077|Procedure|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
79232120|NCT03201302|Other|School physical education class|Children participated only in school physical education classes only.
79527564|NCT05270005|Diagnostic Test|Ultrasound-based flow imaging|Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
79527565|NCT05270005|Diagnostic Test|Ultrasound-based strain imaging|Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
80000414|NCT05727969|Drug|Dexmedetomidine|Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
79373937|NCT01924377|Procedure|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
79373938|NCT03428334|Drug|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
79373939|NCT01924611|Procedure|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
80000415|NCT05727969|Drug|Lactated Ringer|Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
80000416|NCT05727969|Procedure|Hypospadias|Children who will undergone hypospadias surgery
79232121|NCT03201302|Other|Taekwondo|Children participated only in taekwondo training only.
79232122|NCT03201302|Other|Martial arts|Children participated only in martial arts training only.
79232123|NCT03201302|Other|Climbing|Children participated only in climbing training only.
79232124|NCT03201302|Other|Volleyball|Children participated only in volleyball training only.
79232125|NCT03201302|Other|Artistic gymnastics|Children participated only in artistic gymnastics training only.
79232126|NCT03201302|Other|Swimming|Children participated only in swimming training only.
79232127|NCT03201302|Other|Dance|Children participated only in dance training only.
79373940|NCT01924611|Procedure|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
79373941|NCT01241344|Drug|Brincidofovir|"Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
79373942|NCT01241344|Other|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
79373943|NCT01925001|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
79373944|NCT01925001|Drug|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
79373945|NCT03009682|Drug|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
79373946|NCT03431142|Drug|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
79373947|NCT03431142|Drug|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
79373948|NCT02521272|Other|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
79373949|NCT02521272|Device|air pocket|Zero air pocket or one-liter air pocket in the snow.
79373950|NCT03831321|Drug|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
79373951|NCT03831321|Device|Cystoscopy|Diagnostic cystoscopy
79373952|NCT03831321|Drug|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
79527566|NCT05270005|Diagnostic Test|Conventional duplex|Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
79683815|NCT03685253|Drug|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
79683816|NCT03685253|Drug|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
79683817|NCT04673604|Diagnostic Test|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
79683818|NCT04673604|Drug|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
80000417|NCT05727969|Device|Surgical pleth index|The SPI value will be measured using Datex-Ohmeda (GE Healthcare,Madison,WI 53707-7550 USA) monitoring system.
80000418|NCT05724602|Drug|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
80000419|NCT05724602|Drug|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
79826894|NCT00721266|Drug|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
79826895|NCT00853450|Drug|AZD6482|Single intravenous infusion during a maximum of 5 hours
79826896|NCT00853450|Drug|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
79826897|NCT00853450|Drug|ASA|75 mg orally once daily during 7 days in each treatment arm
79232128|NCT03201302|Other|Basketball|Children participated only in basketball training only.
79527567|NCT05269979|Behavioral|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
79826898|NCT04066790|Drug|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
79826899|NCT04066790|Drug|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
79232129|NCT03201302|Other|Wrestling|Children participated only in wrestling training only.
79826900|NCT04066790|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
79232130|NCT03201302|Other|Football (soccer)|Children participated only in football (soccer) training only.
79527568|NCT05269940|Drug|ZX-101A|oral dosing, once daily
79527569|NCT05269927|Diagnostic Test|EEG|resting state EEG
79527570|NCT05269927|Diagnostic Test|DNA samples|genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
79683819|NCT03663608|Procedure|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
79826901|NCT04066790|Drug|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
79826902|NCT04066790|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
79826903|NCT03477552|Device|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
80000420|NCT05719311|Drug|adrulipase|Enteric microgranule formulation of adrulipase.
79232131|NCT03201302|Other|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
79232132|NCT03201302|Other|Track and field|Children participated only in track and field training only.
79232133|NCT03201302|Other|Tennis|Children participated only in tennis training only.
79232134|NCT03201302|Other|Combination of activities 1|Children participated in two weight-bearing activities.
79232135|NCT03201302|Other|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
79373953|NCT01285024|Device|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
79527571|NCT05269927|Diagnostic Test|clinical data|"standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT)."
79527572|NCT05269927|Other|environmental data|questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
79683820|NCT04602819|Device|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
79683821|NCT04602819|Device|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
79826904|NCT03477552|Other|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
80000421|NCT05711394|Drug|Atogepant|Oral Tablet
79232136|NCT02287155|Behavioral|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
79232137|NCT03208712|Drug|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
79232138|NCT03208712|Drug|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
79232139|NCT00099879|Drug|BMS-275183|
79232140|NCT03201380|Other|TEP scanner with choline|
79826905|NCT00860080|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
79826906|NCT00860080|Drug|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
79826907|NCT00721604|Drug|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
80000422|NCT05711394|Drug|Placebo-Matching Atogepant|Oral Tablet
80000423|NCT05704738|Drug|Rocatinlimab|Subcutaneous (SC) injection
80000424|NCT05704738|Drug|Placebo|SC injection
79232141|NCT05725941|Device|TogRite stretch Strapping|it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.
80000425|NCT05704166|Drug|Pirfenidone/Placebo|Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
79683822|NCT04602819|Device|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
79683823|NCT04602819|Device|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
79683824|NCT05348109|Other|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
80000426|NCT05703373|Dietary Supplement|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
80000427|NCT05699863|Behavioral|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
80000428|NCT05696613|Drug|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
79683825|NCT00532181|Behavioral|Savings Behavior and Consumer's Approach to Risk|
80000429|NCT05696613|Drug|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
79683826|NCT00532220|Drug|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
79683827|NCT00532220|Drug|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
80000430|NCT05695924|Device|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
80000431|NCT05695924|Procedure|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
80000432|NCT05689164|Biological|fordadistrogene movaparvovec|gene therapy administered in a previous study.
80000433|NCT05686941|Other|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
80000434|NCT05686941|Other|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
79232142|NCT05725941|Other|Traditional upper limb functional exercise training|The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm &hand activities, and daily living functions of the affected upper limbs.
79232143|NCT03208556|Biological|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10^5 /kg，1×10^6 /kg，3×10^6 /kg，and 6×10^6 CAR T cells/kg"
79232144|NCT03208556|Drug|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
79232145|NCT00429429|Procedure|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
79391005|NCT03182556|Behavioral|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
79683828|NCT00532584|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
79683829|NCT03457259|Device|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
79683830|NCT03457259|Device|Midline|Pt. will receive midline
79683831|NCT04687332|Other|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
79683832|NCT05467709|Drug|Midazolam|2 mg Day 1 and Day 16
79683833|NCT05467709|Drug|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
79232146|NCT03201146|Drug|Apatinib|Doses to be determined following the completion of Phase I of the study.
79232147|NCT03201146|Drug|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
79232148|NCT03201146|Drug|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
79232149|NCT03201146|Drug|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
79232150|NCT03201146|Drug|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
79232151|NCT00370383|Drug|Erlotinib|erlotinib 150 mg/day once daily
79683834|NCT00532623|Drug|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
79826908|NCT00850330|Other|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
79373954|NCT03430908|Other|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
79683835|NCT00532623|Drug|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
79683836|NCT04687488|Other|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
79683837|NCT04687488|Other|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
79683838|NCT00533598|Drug|MK0557|
79826909|NCT02571192|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
79826910|NCT02571192|Radiation|5.95 μCi RAD|
80000435|NCT05685849|Device|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
79232152|NCT00370383|Drug|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
79232153|NCT03107312|Procedure|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
79232154|NCT02450630|Behavioral|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated & severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
79232155|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
79232156|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
79232157|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
79683839|NCT05467592|Other|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
79683840|NCT00532662|Drug|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
79683841|NCT00532337|Drug|ONO-5334|Placebo - 24/mos.
79232158|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
79232159|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
79683842|NCT00532337|Drug|ONO-5334|100mg QD /24 months
79683843|NCT00532337|Drug|ONO-5334|50mg BID /24 mos.
79826911|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
79232160|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
79683844|NCT00532337|Drug|ONO-5334|300mg QD /24 mos.
79683845|NCT00532337|Drug|ONO-5334|Alendronate 70mg once weekly / 24 mos
79683846|NCT05467436|Drug|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
79683847|NCT00533676|Drug|MK0524A, /Duration of Treatment : 8 Weeks|
79683848|NCT00533676|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
79826912|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
80000436|NCT05683262|Procedure|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
79683849|NCT05467319|Drug|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
79232161|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
79232162|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
79232163|NCT03207932|Procedure|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
79232164|NCT02547220|Biological|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
79232165|NCT02547220|Drug|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
79373955|NCT01925079|Behavioral|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~Routine education at discharge.~4 education brochures will be delivered to patients.~Calendar with healthy tips will be delivered to patients before discharge.~A follow-up brochure with medical expert letter.~A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
79373956|NCT01925079|Other|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~Routine education at discharge.~A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
79373957|NCT03156582|Other|Data collecting|
79373958|NCT04450134|Other|Lactose|Placebo: Lactose capsules
79373959|NCT04450134|Drug|Fexofenadine Hydrochloride|H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
79373960|NCT04450134|Drug|Famotidine|H2 receptor antagonist: 40 mg Famotidine
79232166|NCT03207308|Dietary Supplement|Vitamin A supplementation|200,000 IU of preformed vitamin A
79683850|NCT05467319|Drug|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
79826913|NCT00724022|Drug|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
79826914|NCT00850408|Procedure|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
79826915|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
79826916|NCT00721344|Drug|Moxifloxacin|Tablets 400mg
79232167|NCT00366795|Drug|Satavaptan|oral administration once daily
79232168|NCT00366795|Drug|placebo|oral administration once daily
79232169|NCT04484870|Drug|oral Danshu capsule|Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
79232170|NCT00366327|Drug|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
79232171|NCT03207464|Drug|[C-11]Methylreboxetine|8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a [C-11]MRB PET scan and a MRI scan.
79232172|NCT03207230|Device|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
79373961|NCT04450134|Other|High-intensity interval training (HIIT)|6 weeks HIIT
79373962|NCT01286818|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
79373963|NCT01286818|Drug|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
79373964|NCT01286818|Drug|levofolinate|IV infusion, 200 mg/m² every 2 weeks
79683851|NCT04590300|Other|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
79683852|NCT05467241|Behavioral|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
79683853|NCT05467202|Drug|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
79826917|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
79826918|NCT00721344|Drug|Placebo|Placebo cartridges
79826919|NCT00717990|Drug|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
79826920|NCT00717990|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
79232173|NCT03207230|Device|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
79232174|NCT03207230|Device|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
79373965|NCT01286818|Drug|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
79373966|NCT03113292|Other|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
79527573|NCT05269914|Other|Autologous anti-CD19 CAR-T cell injection|"According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed."
79527574|NCT05269719|Procedure|Suture of digital nerve|The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
79527575|NCT05269693|Other|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
79527576|NCT05269654|Device|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
79527577|NCT05269654|Other|Normal Saline|Sham Comparator
79527578|NCT05269641|Other|Food: whole almonds|60g of whole almonds will be consumed daily.
79683854|NCT05338788|Other|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
79683855|NCT05466968|Drug|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
79683856|NCT05466968|Drug|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
79683857|NCT05466812|Drug|Sr-89|"strontium-89 chloride treatment~periodical evaluation and follow-up"
79683858|NCT00533754|Procedure|drawing blood|
79683859|NCT05466773|Behavioral|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
79826921|NCT00717990|Drug|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
79232175|NCT02542072|Device|comfilcon A|contact lens
79232176|NCT02542072|Device|samfilcon A|contact lens
79232177|NCT03207152|Biological|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
79232178|NCT00422019|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
79232179|NCT00422019|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
79232180|NCT03207542|Drug|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
79683860|NCT00533793|Procedure|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
79826922|NCT00853528|Other|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
79826923|NCT00853528|Procedure|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
79826924|NCT00853528|Procedure|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
79826925|NCT00853528|Radiation|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
79826926|NCT00853528|Radiation|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
79826927|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
79826928|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
79826929|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
79826930|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
79826931|NCT04878302|Behavioral|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
79826932|NCT00850486|Device|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
79826933|NCT02572986|Drug|Permethrin|
79826934|NCT00853684|Drug|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
79826935|NCT00853684|Drug|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
79527579|NCT05269641|Other|Food: non-nut snack|A non-nut snack will be consumed daily.
79826936|NCT00853918|Other|$20 cash|$20 cash incentive mailed with survey
79826937|NCT00853918|Other|$50 cash|$50 cash incentive mailed with survey
79826938|NCT00853918|Other|$50 check|$50 check incentive mailed with survey
79232181|NCT00360867|Drug|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
79232182|NCT03208634|Device|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
79232183|NCT03481114|Combination Product|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
79232184|NCT03481114|Combination Product|Standard chemoradiotherapy|Patients in this arm will receive a standard radiotherapy course.
79232185|NCT02450474|Device|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
79527580|NCT05269524|Behavioral|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
79527581|NCT05269485|Radiation|High-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
79683861|NCT00533832|Device|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
79826939|NCT00853918|Other|$100 check|$100 check incentive mailed with survey
79232186|NCT02450474|Device|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
79232187|NCT00074997|Other|Placebo|Single intravenous infusion of placebo.
79232188|NCT00074997|Genetic|OZ1|Single intravenous infusion of OZ1.
79683862|NCT05466617|Behavioral|Mobile Health for Physical Activity Behavior Change|All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
79826940|NCT02570360|Behavioral|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
79826941|NCT02570360|Behavioral|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
79826942|NCT00723060|Drug|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
79826943|NCT00860236|Other|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
79232189|NCT00074997|Genetic|CD34+ cells|Autologous CD34+ cells.
79232190|NCT03200990|Device|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
79527582|NCT05269485|Radiation|Low-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
79527583|NCT05269420|Procedure|SAS-J|Single Anastomosis Sleeve Jejunal Bypass
79527584|NCT05269342|Behavioral|nurse-led counseling and after intervention|the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
79527585|NCT05269329|Drug|XC8, film-coated tablets, 20 mg/day|20 mg/day (1 tablet twice a day)
79527586|NCT05269329|Drug|XC8, film-coated tablets, 40 mg/day|40 mg/day (2 tablets twice a day)
79527587|NCT05269329|Drug|XC8, film-coated tablets, 80 mg/day|80 mg/day (4 tablets twice a day)
79826944|NCT00860236|Behavioral|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
79826945|NCT00724100|Drug|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
79826946|NCT04069416|Procedure|living donor liver transplantation|liver graft from a living donor
79826947|NCT00860392|Drug|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
79826948|NCT02571816|Drug|ASP2215|oral
79232191|NCT02287389|Device|balloon dilation|
79826949|NCT00850798|Drug|Intensive glycemic control|Intensive glycemic control
79232192|NCT02287389|Procedure|cryotherapy|
79826950|NCT00850798|Drug|Conservative glycemic control|OADs and insulin
79826951|NCT02572908|Other|Sourdough wheat bread|
80000437|NCT05683262|Procedure|Ultrasound-guided coccygeal nerve block|Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
80000438|NCT05683262|Procedure|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block|After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
80000439|NCT05681182|Combination Product|CardiaMend with the Addition of Amiodarone|The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
80000440|NCT05668949|Drug|TTI-101|Given by PO
79373967|NCT03113292|Other|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
80000441|NCT05668949|Drug|Pembrolizumab|Given by IV (vein)
79683863|NCT04484610|Drug|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
79232193|NCT02287389|Procedure|spiculiform electrosurgery|
79373968|NCT04450056|Other|No intervention|No intervention
79373969|NCT01925157|Biological|LY3090106 - SQ|Administered SQ.
79373970|NCT01925157|Biological|LY3090106 - IV|Administered IV.
79683864|NCT04687670|Diagnostic Test|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
79826952|NCT02572908|Other|Regular yeast baked toast bread|
79373971|NCT01925157|Biological|Placebo - SQ|Administered SQ.
79373972|NCT01243294|Device|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
79373973|NCT01243294|Device|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
79373974|NCT03428256|Device|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
79826953|NCT02572908|Other|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
79232194|NCT02287389|Drug|mitomycin C|
79232195|NCT00057993|Biological|trastuzumab|
79232196|NCT00057993|Drug|exemestane|
79232197|NCT03200756|Behavioral|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
79232198|NCT03200756|Behavioral|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
79232199|NCT02448290|Drug|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
79232200|NCT00357279|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
79232201|NCT00357279|Drug|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
79232202|NCT02448134|Behavioral|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
79232203|NCT02284815|Dietary Supplement|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
79232204|NCT04484558|Drug|Actilyse|Infusion
79232205|NCT00055575|Drug|Scopolamine Nasal Spray|
79373975|NCT03428256|Device|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
79373976|NCT00635505|Drug|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
79373977|NCT00635505|Drug|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
79373978|NCT00635505|Drug|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
79373979|NCT03428178|Drug|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
79373980|NCT01243450|Drug|Tretinoin|Treatment of acne
79373981|NCT01243450|Drug|placebo|treatment of acne
79373982|NCT01925313|Drug|CJ-30044|20.51mg a day,PO,QD
79826954|NCT02571140|Drug|Teriparatide|subcutaneous standard injection
79826955|NCT02571140|Drug|Oral PTH (1-34)|Different optimization of API
79826956|NCT00854074|Device|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
79826957|NCT04068324|Dietary Supplement|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
79826958|NCT02570204|Behavioral|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
79826959|NCT00721656|Drug|Placebo|
79826960|NCT00721656|Drug|KLS-0611|
79683865|NCT04687670|Diagnostic Test|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
79683866|NCT05466266|Device|ICE|All patients received ICE examination.
79826961|NCT04066712|Drug|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
79373983|NCT01925313|Drug|TALION TAB. 10mg|10mg a day,PO,BID
79527588|NCT05269329|Drug|Placebo|1, 2, or 4 tablets twice a day
79826962|NCT02571686|Device|Surveyor S4|
79826963|NCT00723216|Drug|enoxaparin|20 mg twice a day
79826964|NCT00723216|Other|Physical prophylaxis|
79826965|NCT00619918|Drug|Nebulized 3% saline|4 ml inhaled q8h
79826966|NCT00619918|Drug|Placebo|normal saline
79826967|NCT00724178|Dietary Supplement|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
79232206|NCT03206996|Behavioral|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
79527589|NCT05262673|Biological|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
79232207|NCT03206996|Behavioral|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
79373984|NCT03433872|Other|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
79373985|NCT05249751|Diagnostic Test|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
79373986|NCT03430830|Drug|Ravidasvir 50mg|50mg, Tablet
79527590|NCT05254392|Device|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
79683867|NCT05466266|Device|TEE|All patients received TEE examination.
79683868|NCT05307354|Other|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
79826968|NCT02571270|Other|Combined aerobic and resistance physical training program|
79826969|NCT04800536|Other|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
79826970|NCT04800536|Other|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
79826971|NCT02546050|Drug|Metformin|
79826972|NCT00721812|Drug|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
79826973|NCT04800224|Drug|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
79826974|NCT04800224|Drug|Placebo|900mg/day of Placebo for 10 days.
79826975|NCT00860548|Drug|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
80000442|NCT05663567|Behavioral|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
79232208|NCT03206996|Behavioral|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
79232209|NCT00051129|Drug|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
79826976|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
79826977|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
79826978|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
79826979|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
79826980|NCT00860626|Drug|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
79826981|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
80000443|NCT05659368|Drug|Tirzepatide|tirzepatide once weekly
80000444|NCT05649956|Drug|Letrozole|Letrozole 2.5 mg PO daily
80000445|NCT05644184|Biological|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
79683869|NCT05307354|Other|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
79232210|NCT00051129|Other|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
79373987|NCT03430830|Drug|Ravidasvir 200mg|200mg, Tablet
79373988|NCT00635193|Drug|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
79683870|NCT05466227|Other|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~Patient is attached to 12-lead ECG monitoring~The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~Patient's legs are elevated (45°) for 15 seconds~Afterwards, the patient is placed back in an upright position~If not efficient, this maneuver can be repeated up to two times"
79683871|NCT04472793|Diagnostic Test|SARS-CoV-2|"Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~Testing monthly serum samples to document post-viral infection."
79826982|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
79232211|NCT03200600|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
79373989|NCT00635193|Drug|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
79373990|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
79826983|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
79826984|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
79826985|NCT04041466|Diagnostic Test|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
79232212|NCT03200600|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
79373991|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
79373992|NCT01925391|Drug|Tono-pen XL Applanation tonometer + Ocu-film +|
79373993|NCT00633789|Drug|brivanib|Tablets, Oral, 800 mg, once daily, until progression
79373994|NCT00633789|Drug|Placebo|Tablets, Oral, 0 mg, once daily, until progression
79373995|NCT01287208|Device|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
79373996|NCT01287208|Device|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
79826986|NCT04067934|Behavioral|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
79826987|NCT00860704|Drug|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
79826988|NCT04742660|Drug|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
80000446|NCT05644184|Biological|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
80000447|NCT05638607|Behavioral|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
80000448|NCT05636943|Behavioral|Adapted Intimacy Enhancement|Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
79373997|NCT00630201|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
79527591|NCT05253625|Other|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
79826989|NCT00860782|Behavioral|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
79826990|NCT04069260|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
79826991|NCT04734938|Dietary Supplement|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
79826992|NCT00860860|Drug|TF2|TF2: 75-300 mg
79826993|NCT00860860|Drug|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
80000449|NCT05636943|Behavioral|Intimacy Facts and Resources|Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
80000450|NCT05634486|Behavioral|Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)|Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
80000451|NCT05634486|Other|Psychoeducation (Sham intervention)|Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
80000452|NCT05633355|Drug|Rocatinlimab|Subcutaneous (SC) injection
79232213|NCT03200600|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
79232214|NCT03200600|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
79232215|NCT02547454|Drug|Methoxy polyethylene glycol-epoetin beta|
79232216|NCT05725785|Behavioral|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
79373998|NCT04396197|Other|Physiotherapy|Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
79373999|NCT05241483|Diagnostic Test|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
79232217|NCT00049959|Drug|verteporfin PDT|
79232218|NCT00040677|Drug|Low Dose ICA-17043|Low dose arm
79374000|NCT01288534|Radiation|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
79374001|NCT01925547|Dietary Supplement|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
79826994|NCT02571894|Other|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
79826995|NCT01089296|Other|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
79826996|NCT04041388|Other|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
79826997|NCT00854152|Drug|GDC-0980|Escalating repeating dose
79826998|NCT00721890|Dietary Supplement|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
79826999|NCT01005914|Drug|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
80000453|NCT05624749|Drug|ianalumab|ianalumab s.c. monthly
79232219|NCT00040677|Drug|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
79232220|NCT00040677|Drug|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
79232221|NCT03206840|Behavioral|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
79374002|NCT01925547|Dietary Supplement|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
80000454|NCT05624749|Drug|placebo|placebo s.c. monthly
80000455|NCT05615636|Drug|Mosunetuzumab|Given by IV (vein)
80000456|NCT05615636|Drug|Polatuzumab vedotin|Given by IV (vein)
80000457|NCT05615636|Drug|Tafasitamab|Given by IV (vein)
80000458|NCT05615636|Drug|Lenalidomide|Given by PO
80000459|NCT05614739|Drug|LOXO-435|Oral
80000460|NCT05614739|Drug|Pembrolizumab|IV
79827000|NCT01005914|Drug|cytarabine|Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
80000461|NCT05611931|Drug|Selinexor|Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
80000462|NCT05611931|Drug|Matching Placebo for selinexor|Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
80000463|NCT05605899|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
80000464|NCT05605899|Drug|Cyclophosphamide|Administered intravenously
79305621|NCT04930185|Behavioral|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
79374003|NCT04395807|Device|Helmet CPAP|Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
79527592|NCT05252897|Procedure|Endoscopic necrosectomy with step up approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
79527593|NCT05252897|Procedure|Endoscopic necrosectomy with direct approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
79527594|NCT05252468|Device|TaffiX™|Personal nasal powder spray.
79683872|NCT05466149|Drug|Furmonertinib|240mg QD on a continuous dosing schedule.
79683873|NCT00532701|Drug|Peg-IFN + WB RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16"
79683874|NCT00532701|Drug|Peg-IFN + LD RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
79683875|NCT00532701|Drug|Peg-IFN + WB RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
79374004|NCT04395807|Device|HFNC|Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
79827001|NCT01005914|Drug|dexamethasone|Day 1-4; 11-14: 40 mg daily
79827002|NCT01005914|Drug|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
79827003|NCT01005914|Drug|imatinib mesylate|600 mg/day
80000465|NCT05605899|Drug|Fludarabine|Administered intravenously
79374005|NCT03122301|Drug|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
79374006|NCT03122301|Drug|Saline|sham injection with saline
79527595|NCT05251961|Procedure|operative deformity correction|"The participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities.~Procedure will be done under anaesethia~Osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod"
79527596|NCT05250739|Other|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
79827004|NCT01005914|Drug|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
79827005|NCT01005914|Drug|methylprednisolone|Day 1-3: 50mg IV BID
79827006|NCT01005914|Drug|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
79827007|NCT01005914|Drug|vincristine sulfate|Day 4 & 11: 2 mg IV
79827008|NCT00854230|Drug|Naltrexone|Naltrexone dose 25-100mg
79827009|NCT04067076|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
80000466|NCT05605899|Drug|Etoposide|Administered intravenously
80000467|NCT05605899|Drug|Rituximab|Administered intravenously
80000468|NCT05605899|Drug|Doxorubicin|Administered intravenously
80000469|NCT05605899|Drug|Vincristine|Administered intravenously
80000470|NCT05605899|Drug|Prednisone|Administered orally
80000471|NCT05601440|Drug|RP-6306|Dose and schedule will be assigned at enrolment
80000472|NCT05601440|Drug|Gemcitabine|Dose and schedule will be assigned at enrolment
80000473|NCT05601440|Other|Observation|Monitoring arm
80000474|NCT05601440|Drug|Niraparib|Dose and schedule will be assigned at enrolment
80000475|NCT05601440|Drug|Fulvestrant|Dose and schedule will be assigned at enrolment
80000476|NCT05599945|Drug|NNC0581-0001|Participants will receive up to four single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
80000477|NCT05599945|Drug|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
79683876|NCT00532701|Drug|Peg-IFN + WB RBV for 48 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
79683877|NCT00532701|Drug|Peg-IFN + LD RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
79827010|NCT00861016|Drug|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
79827011|NCT04018144|Diagnostic Test|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
79827012|NCT04697966|Behavioral|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
80000478|NCT05595837|Other|Standard organ transplant|Standard organ transplant procedures and follow up care
80000479|NCT05590923|Drug|OLA group: Olanzapine|"OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)."
79527597|NCT05250739|Other|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
80000480|NCT05590923|Drug|DEX group: Dexamethasone|"DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC)."
80000481|NCT05587296|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
80000482|NCT05587296|Drug|Placebo|Matching placebo orally once daily.
79527598|NCT05250583|Biological|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
79527599|NCT05250193|Device|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
79527600|NCT05250193|Device|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
79683878|NCT01276639|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
80000483|NCT05562466|Drug|QMF149|QMF149 75/40 μg o.d via Breezhaler
80000484|NCT05562466|Drug|Budesonide|Budesonide 200 μg o.d via Breezhaler
80000485|NCT05561673|Combination Product|GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide|Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
80000486|NCT05561673|Biological|GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system|Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
80000487|NCT05561673|Biological|GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system|Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
80000488|NCT05561673|Biological|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
80000489|NCT05561673|Biological|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
80000490|NCT05558696|Drug|bomedemstat|Oral tablet
80000491|NCT05554458|Behavioral|ChildTaks+ intervention|The ChildTalks+ Intervention ChildTalks+ is a preventive intervention originally developed in the Netherlands, targeting children up to 18 years of age. It has been implemented in Norway, Italy, and Portugal. It has a clear and well-described theoretical basis focusing on psychoeducation. Its key strategy is to provide feasible and replicable interventions to improve the quality of life of families where parents are affected by a mental disorder.
80000492|NCT05553834|Combination Product|Alirocumab and Cemiplimab|Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
79232222|NCT05725707|Behavioral|Friendship Group|Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
79232223|NCT03206684|Drug|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
79527601|NCT05250141|Drug|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
79683879|NCT01276639|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
79683880|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
79683881|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
79683882|NCT05465915|Device|Electroconvulsive therapy|Patients are treated with ECT.
79683883|NCT05465837|Procedure|Tracheostomy|Early and Late Tracheostomy (</= 10 days: Early and >10 days: Late)
79683884|NCT05465759|Other|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
79683885|NCT00532415|Drug|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
79683886|NCT00532454|Drug|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
79683887|NCT01275625|Drug|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
80000493|NCT05547061|Drug|Lu-177-DGUL|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
79232224|NCT03206684|Drug|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
79232225|NCT05219123|Other|ERCP with no PD cannulation|ERCP with no PD cannulation
79232226|NCT05219123|Other|ERCP with single PD cannulation|ERCP with single PD cannulation
80000494|NCT05547061|Drug|Ga-68-NGUL|Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
79527602|NCT05250141|Drug|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
79527603|NCT05254769|Device|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
79683888|NCT05465720|Behavioral|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
80000495|NCT05542511|Diagnostic Test|NanoString nCounter assay|The NanoString nCounter assay by NanoString Technologies will be used to measure blood transcriptional signatures in presumptive TBs. Non-TB participants with elevated transcriptional signature readouts will be investigated for respiratory infections other than Mycobacterium tuberculosis using a next-generation sequencing (NGS)-based respiratory pathogen panel.
79232227|NCT00036621|Drug|BMS-275291|
79683889|NCT05463458|Other|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
79232228|NCT03200444|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
79232229|NCT03200444|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
79232230|NCT03200444|Other|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
79232231|NCT03200444|Other|P-4|Newly developed adhesive P-4
79232232|NCT03200444|Other|P-15|Newly developed adhesive P-14
79232233|NCT03200444|Other|P-16|Newly developed adhesive P-8
79232234|NCT04588337|Drug|rhTNK-tPA|Thrombolysis
79232235|NCT03119324|Device|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
79232236|NCT03119324|Device|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
79232237|NCT03119324|Drug|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
79232238|NCT00415623|Drug|Amlodipine|Amlodipine 5mg/ day
79232239|NCT00415623|Drug|Amlodipine|Amlodipine 10mg/ day
79374007|NCT01920087|Drug|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
79374008|NCT01920087|Drug|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
79391006|NCT03182556|Behavioral|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
79683890|NCT05459792|Procedure|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
79683891|NCT05459792|Procedure|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
79683892|NCT05459792|Procedure|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
79683893|NCT04686825|Drug|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
79527604|NCT05248724|Combination Product|periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
79527605|NCT05248724|Drug|placebo|50 ml of 0.9 saline
79527606|NCT05246241|Device|magnetic resonance imaging|Preoperative magnetic resonance imaging
79527607|NCT05237310|Device|Standard Colonoscopy|Standard Colonoscopy using a standard Fujifilm colonoscope
80000496|NCT05537220|Drug|N-acetylcysteine|After randomization, participants will be given about 10-months supply of study drug (intervention), with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, drug reconciliation will occur. At each visit at Baseline, M9, M18, M27, M36, that is, every 9 months, participants will be given another 10-month supply of study drug.
79527608|NCT05237310|Device|G-EYE Colonoscopy|G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
80000497|NCT05537220|Drug|Placebo|After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
79232240|NCT05219045|Other|Ohio RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
79527609|NCT05237310|Device|CAD-EYE|Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
80000498|NCT05536141|Drug|AB521|Administered as specified in the treatment arm
80000499|NCT05534724|Other|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks
80000500|NCT05534724|Other|Complete weight-bearing|Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
80000501|NCT05529992|Drug|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
80000502|NCT05521880|Drug|Oritavancin|Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
80000503|NCT05519254|Dietary Supplement|Lactoferrin|Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
79232241|NCT03206606|Device|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
79374009|NCT01920243|Behavioral|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
80000504|NCT05519254|Dietary Supplement|Lysozyme|Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
79232242|NCT02287545|Procedure|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
79374010|NCT01925859|Drug|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
79527610|NCT05235893|Procedure|Reflexology|Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.
79527611|NCT05235893|Procedure|Sucrose %24|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
79527612|NCT05235893|Procedure|Kangaroo care|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
79527613|NCT05235893|Procedure|Music|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
79527614|NCT05232006|Drug|Niraparib|Niraparib, once daily
79374011|NCT04347837|Device|Titan SGS stapler|Stapler for the longitudinal resection of the stomach
79374012|NCT01920321|Procedure|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
79374013|NCT03435627|Drug|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
79683894|NCT04686825|Drug|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
79683895|NCT04686825|Drug|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
79683896|NCT04686825|Drug|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
80000505|NCT05519254|Combination Product|Lactoferrin + Lysozyme|Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
79527615|NCT05231447|Other|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
79527616|NCT05228548|Other|Perioperative blood transfusion|Perioperative blood transfusion
79527617|NCT05225051|Other|skin biopsy|skin biopsy
79232243|NCT03195608|Device|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
79527618|NCT05224583|Procedure|Simultaneous Liver-Kidney Transplant|Simultaneous Liver-Kidney Transplant
79527619|NCT05224297|Radiation|external beam photon therapy|Patients receive external beam photon therapy for different tumor locations (groups).
79527620|NCT05214885|Diagnostic Test|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
79827013|NCT04697966|Behavioral|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
80000506|NCT05519254|Other|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
79527621|NCT05211362|Biological|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
80000507|NCT05517902|Biological|StrataGraft|StrataGraft® Construct
79232244|NCT03195608|Behavioral|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
79527622|NCT05211362|Biological|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
79527623|NCT05209841|Drug|Low dose heparin|Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
79527624|NCT05209841|Drug|Normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
79527625|NCT05203978|Procedure|colonoscopy|Colonoscopy
79527626|NCT05202899|Drug|sugammadex|The use of sugammadex
79527627|NCT05191537|Other|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
79527628|NCT05191537|Other|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
79232245|NCT03134001|Device|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
79232246|NCT03118544|Device|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
79232247|NCT01969409|Drug|Rituximab|i.v. rituximab given on two occasions 14 days apart.
79527630|NCT05186922|Biological|CM326|CM326 injection
79527631|NCT05186922|Other|Placebo|Placebo
80000508|NCT05513625|Drug|Pritelivir|oral administration
80000509|NCT05513625|Drug|ESO and pritelivir|oral administration
80000510|NCT05507515|Drug|ONO-2020|ONO-2020 tablets
80000511|NCT05507515|Drug|Placebo|Placebo tablets matching ONO-2020 tablets
80000512|NCT05504421|Other|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
79374014|NCT01920399|Drug|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
79374015|NCT01920399|Drug|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
79374016|NCT01926171|Drug|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
79527632|NCT05182827|Other|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
79527633|NCT05182346|Procedure|Manual therapy|"Acupressure of acupoints is manipulation of classic acupoints by pressure.~Ischemic compression release is applying pressure to the myofascial trigger points until release of these points."
79527634|NCT05175911|Other|golden hour : an initial standardized stabilization|"This is a quality improvement project to evaluate the implementation of Golden hour, a standardized stabilization during the first hour of life in inborn preterm infants younger than 31 weeks of gestational age or weighting less than 1300 g in the NICU of the University of Liege.~There is no comparative arm."
79527635|NCT05173142|Drug|HMPL-453|HMPL-453 administered orally.
79527636|NCT05173142|Drug|gemcitabine and cisplatin|Gemcitabine and Cisplatin administered intravenously.
79527637|NCT05173142|Drug|toripalimab|Toripalimab administered intravenously.
79527638|NCT05173142|Drug|Docetaxel|Docetaxel administered intravenously.
79374017|NCT01926327|Biological|PRP injection|Injection of PRP in patients with knee osteoarthritis.
79683897|NCT05455892|Other|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
80000513|NCT05502237|Drug|Zimberelimab|Administered intravenously
79683898|NCT05454800|Other|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
80000514|NCT05502237|Drug|Domvanalimab|Administered intravenously
80000515|NCT05502237|Drug|Pembrolizumab|Administered intravenously
80000516|NCT05502237|Drug|Carboplatin|Administered intravenously
79232248|NCT01969409|Drug|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
79232249|NCT00413205|Drug|Placebo|po daily
79232250|NCT00413205|Drug|RAR Gamma|5mg po daily
79374018|NCT01926327|Biological|Placebo|
79374019|NCT03092037|Procedure|Blood draw|The Investigators will collect serum and whole blood from participants.
79374020|NCT05247723|Device|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
79374021|NCT05247723|Procedure|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
79374022|NCT01926405|Procedure|saliva collection|collection of saliva
79374023|NCT01920945|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
79374024|NCT01926483|Other|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
79527639|NCT05167929|Behavioral|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
80000517|NCT05502237|Drug|Cisplatin|Administered intravenously
80000518|NCT05502237|Drug|Paclitaxel|Administered intravenously
80000519|NCT05502237|Drug|Nab-paclitaxel|Administered intravenously
80000520|NCT05502237|Drug|Pemetrexed|Administered intravenously
79232251|NCT03118856|Diagnostic Test|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
79232252|NCT02448212|Drug|TS-121|Oral
79232253|NCT02448212|Drug|[11C]TASP0410699|Intravenous radiotracer
79232254|NCT02448212|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
79374025|NCT01926639|Biological|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
79374026|NCT01921413|Device|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
79827014|NCT00718380|Drug|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
79527640|NCT05167929|Behavioral|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
79827015|NCT02553291|Behavioral|SystemCHANGE|
79232255|NCT05218577|Other|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
79232256|NCT05218577|Dietary Supplement|selenium supplement|20 microgram/day selenium suppplement powder.
79527641|NCT05167929|Behavioral|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
79683899|NCT05454800|Other|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
79683900|NCT04686552|Dietary Supplement|cinnamon|6 g of ground cinnamon
79527642|NCT05167435|Other|Myofascial Release Experimental|Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
79683901|NCT00533988|Device|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
79232257|NCT05218577|Other|Placebo|the placebo mocaf powder
79683902|NCT05285748|Behavioral|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
79683903|NCT05285748|Behavioral|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
79683904|NCT05424887|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
79827016|NCT02553291|Behavioral|Control|
79827017|NCT04683068|Behavioral|Message comparison|Message comparison
80000521|NCT05495646|Procedure|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
80000522|NCT05487599|Genetic|LY3884961|• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
80000523|NCT05486416|Drug|HSK3486|HSK3486 for induction of general anesthesia
79232258|NCT03134079|Other|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
79232259|NCT03134079|Other|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
79527643|NCT05167435|Other|Posterior-Anterior Glide|Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
79527644|NCT05165875|Drug|Hydrocortisone-Lidocaine|"Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
79683905|NCT05424887|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
79683906|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
79683907|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
79683908|NCT00533637|Drug|Placebo|Citrate buffer with preservatives
79683909|NCT05466695|Drug|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
79827018|NCT00851032|Other|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
79827019|NCT05632250|Device|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
79827020|NCT00807105|Device|H-coil dTMS|treatment with deep TMS stimulation.
80000524|NCT05486416|Drug|Propofol|Propofol for induction of general anesthesia
80000525|NCT05483907|Drug|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
80000526|NCT05483907|Drug|Placebo|Placebo 24 weeks + Follow-up 4 weeks
79683910|NCT05284500|Procedure|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
79683911|NCT05423639|Device|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
79683912|NCT05423639|Device|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
79232260|NCT03134079|Other|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
79232261|NCT02447978|Biological|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
79683913|NCT05281185|Drug|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
79683914|NCT05281185|Drug|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
79683915|NCT00532532|Drug|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
79683916|NCT00532532|Drug|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
79683917|NCT00532532|Drug|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
79683918|NCT04393935|Behavioral|Pharmacy delivered PrEP Intervention|Men who are eligible and agree to the clinical screener will be provided with a pre-packaged kit of self-administered tests for HIV, rectal chlamydia, syphilis and gonorrhea and creatinine and directed back to the private area of the pharmacy to perform their screenings. Participants will be asked to return the screening tests to the pharmacy technician. The pharmacy technician will process/ interpret the results of the rapid HIV test first in case a treatment referral needs to be set up. Then s/he will process/interpret the results of a rapid rectal chlamydia, syphilis, gonorrhea and rapid finger prick creatinine test. HIV negative customers will be provided with their results and be given a 7-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Participants will be contacted after 3 months to determine whether they continued PrEP use.
80000527|NCT05480800|Biological|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
80000528|NCT05480800|Biological|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
80000529|NCT05480800|Biological|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
79374027|NCT01926795|Procedure|Short leg cast|
79527645|NCT05165875|Other|Splint|"Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
79527646|NCT05163860|Other|Survey|Participants will complete an online survey.
79527647|NCT05163457|Other|Data collection|frailty evaluation
79232262|NCT02447978|Biological|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
79232263|NCT02447978|Biological|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
79232264|NCT03962231|Other|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
79374028|NCT01926795|Procedure|No Immobilization|
79374029|NCT02199496|Biological|Stelara (ustekinumab)|"In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40"
79374030|NCT04395417|Drug|Hyaluronic Acid|Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.
79527648|NCT05162313|Device|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
79827021|NCT00854386|Drug|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
79827022|NCT00854386|Drug|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
79527649|NCT05162118|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab|Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
79827023|NCT00804219|Biological|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
79827024|NCT00723684|Other|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
79827025|NCT00723684|Other|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
79683919|NCT05405036|Other|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
79683920|NCT05354297|Device|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
79683921|NCT05354297|Device|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
79683922|NCT05354297|Device|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
79683923|NCT05354297|Device|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
79683924|NCT05276544|Behavioral|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
79683925|NCT00532571|Drug|CoQ10|
79827026|NCT00851110|Procedure|stem cell reinfusion|hematopoietic stem cell reinfusion
79232265|NCT03962231|Other|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
79232266|NCT01909895|Other|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
79827027|NCT00851110|Drug|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
80000530|NCT05480800|Biological|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).
80000531|NCT05480800|Biological|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
79232267|NCT01909895|Other|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
79232268|NCT01909895|Other|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
79232269|NCT01909895|Other|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
79683926|NCT05346614|Behavioral|Lifestyle intervention|Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
79827028|NCT00798291|Other|Ad lib diet and Control placebo|one packet with water two times a day
79827029|NCT00798291|Other|Ad lib diet and An 777|one packet with water two times a day
79827030|NCT00798291|Other|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
79827031|NCT00798291|Other|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
80000532|NCT05480800|Biological|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
79683927|NCT00532610|Drug|GSK189075|
79683928|NCT04322565|Drug|Colchicine|Cochicine 1mg/day
79527650|NCT05159310|Procedure|Cast vs Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
79527651|NCT05158556|Other|Myofascial Release Technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. Deep pressure will be applied and glided medially towards the thoraco-lumbar region.
79683929|NCT04687826|Other|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
79374031|NCT04395417|Biological|Prolotherapy|Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
79683930|NCT04687826|Other|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
79683931|NCT05267691|Procedure|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
79683932|NCT05342285|Diagnostic Test|Flow mediated dilation|flow mediated dilation in brachial artery
79683933|NCT05259189|Drug|NBL-012 Injection|a single subcutaneous injection
79683934|NCT05259189|Drug|Placebo|a single subcutaneous injection
79683935|NCT05333354|Other|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
79683936|NCT00532688|Drug|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
79683937|NCT00534144|Drug|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
79827032|NCT03650088|Behavioral|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
79232270|NCT00150813|Drug|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
79232271|NCT02712788|Drug|Milrinone|
79232272|NCT02712788|Drug|Placebo|
79232273|NCT05218421|Diagnostic Test|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
79374032|NCT02199574|Drug|EXPAREL|133 mg EXPAREL in 10 mL.
79374033|NCT03088527|Drug|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
79683938|NCT00534144|Drug|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
79827033|NCT00721916|Drug|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
79232274|NCT05218421|Other|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
79232275|NCT05218421|Other|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
79374034|NCT01926951|Device|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
79374035|NCT02199652|Drug|Prazosin|
79374036|NCT02199652|Drug|Placebo|
79374037|NCT05241561|Drug|Cabozantinib|"Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile."
79683939|NCT00534183|Drug|Olanzapine|Olanzapine in dose range of 10-20mg
79683940|NCT00534183|Drug|Risperidone|Risperidone 1-6mg
79683941|NCT00534183|Drug|Haloperidol|Haloperidol 10-20mg
79709832|NCT02272478|Drug|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
79709833|NCT02272478|Drug|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
79683942|NCT05303714|Combination Product|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
79683943|NCT05296928|Procedure|laparoscopic incision|laparoscopic umbilical trocar entry pathways
79232276|NCT00035529|Drug|Placebo|Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months.
79232277|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months.
79683944|NCT05223387|Device|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
79683945|NCT05223387|Device|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
79683946|NCT00532727|Drug|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
79683947|NCT00532727|Drug|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
80000533|NCT05480800|Biological|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
79232278|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.
79232279|NCT03195686|Device|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
79232280|NCT03206528|Device|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
79374038|NCT05241561|Biological|Blood sample|biomonitoring and pharmacokinetics
79374039|NCT05241561|Other|Questionnaires of quality of life|FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
79374040|NCT03009916|Drug|"cholestagel® (Colesevelam)"|3750mg
79374041|NCT03009916|Drug|Placebos|3750mg
79374042|NCT01921491|Procedure|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
79527652|NCT05158556|Other|Instrument Assisted Soft tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
79527653|NCT05155917|Drug|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
79527654|NCT05153291|Procedure|Bachmann's bundle lead placement|Atrial lead placement at Bachmann's bundle area
79527655|NCT05153291|Procedure|Right atrial appendage lead placement|Atrial lead placement in the right atrial appendage
79683948|NCT04261218|Drug|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
79683949|NCT04261218|Drug|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
79232281|NCT02449928|Drug|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
79683950|NCT05274620|Behavioral|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
79232282|NCT02449928|Drug|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
79232283|NCT00356109|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
79374043|NCT01921491|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
79374044|NCT01921569|Behavioral|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
79374045|NCT01921569|Other|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
79374046|NCT01921569|Other|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
79374047|NCT01289080|Drug|OPC-34712|administered orally
79374048|NCT01927029|Drug|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
79374049|NCT01927029|Drug|Placebo|
79374050|NCT01921647|Drug|YH4808|
79374051|NCT01921647|Drug|Nexium|
79374052|NCT01921647|Drug|Amoxicillin|
79374053|NCT01921647|Drug|clarithromycin|
79374054|NCT01246258|Other|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
79374055|NCT01246258|Other|Utricular centrifugation test|Standard test of balance function
79527656|NCT05150041|Device|Guardian connect|"Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
79827034|NCT00721916|Drug|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
79232284|NCT00356109|Drug|Injectable insulin|patient specific dose, injected, before meals, 6 months
79527657|NCT05150041|Device|iPro2|"Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
79527658|NCT05138029|Drug|Ranibizumab Injection [Lucentis]|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
79683951|NCT05262998|Procedure|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
79683952|NCT05262998|Procedure|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
79683953|NCT04687410|Device|ProControl, MediGlobe|standard 22G FNA needle
79683954|NCT04687410|Device|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
79232285|NCT00356109|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
79374056|NCT01927107|Dietary Supplement|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
79374057|NCT03087591|Other|Laboratory Biomarker Analysis|Correlative studies
79374058|NCT03087591|Biological|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|Given IV
79232286|NCT02308111|Drug|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
79527659|NCT05138029|Procedure|Inner limiting membrane stripping|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
79683955|NCT00532766|Drug|Jusline|
79827035|NCT02552901|Drug|0.1 mg/kg ICG Dose|least efficacious dose
79827036|NCT02552901|Drug|0.5 mg/kg ICG dose|per package insert
80000534|NCT05480800|Combination Product|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
80000535|NCT05480800|Combination Product|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
80000536|NCT05480800|Drug|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).
79232287|NCT02308111|Drug|Placebo|One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
79232288|NCT03206138|Biological|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
79232289|NCT03206138|Biological|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
79232290|NCT03195842|Other|Recordable card|
79232291|NCT00006225|Biological|filgrastim|
79232292|NCT00006225|Biological|recombinant flt3 ligand|
79232293|NCT00006225|Biological|recombinant human thrombopoietin|
79527660|NCT05138029|Drug|Dexamethasone intravitreal implant|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
79527661|NCT05135039|Drug|Canagliflozin|Canagliflozin 100mg/day/patient
79527662|NCT05135039|Drug|Placebo|Placebo 100mg/day/patient
79232294|NCT00006225|Biological|recombinant interleukin-3|
79232295|NCT00006225|Procedure|in vitro-treated peripheral blood stem cell transplantation|
79232296|NCT02447900|Device|BioXmark|
79374059|NCT03087357|Other|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
79527663|NCT05128591|Drug|Rivaroxaban 18mg Oral Tablet|AD-109 (Rivaroxaban 18mg) Oral Tablet
79232297|NCT00005595|Drug|arsenic trioxide|
79527664|NCT05128591|Drug|Rivaroxaban 20 MG Oral Tablet|AD-1091 (Rivaroxaban 20mg) Oral Tablet
79527665|NCT05127408|Procedure|Interventional Endoscopy|correct defects of the gastrointestinal tract.
79232298|NCT02447822|Drug|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
79232299|NCT04481945|Drug|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
79232300|NCT00411801|Biological|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
79527666|NCT05123560|Other|Anonymous online questionnaire|A QR code qill be provided to access the online questionnaire
79827037|NCT00861172|Procedure|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
80000537|NCT05480800|Other|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).
79527667|NCT05121701|Device|Videolaryngoscope|C-MAC PM-Karl Storz
79527668|NCT05121701|Device|Macintosh Laryngoscope|Laryngoscope
79527669|NCT05111327|Other|Structured guideline|Students in the intervention group will receive more learning materials before study. The structured guideline will be used to facilitate students' learning in simulation by the facilitator.
79527670|NCT05109806|Behavioral|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
79527671|NCT05096052|Drug|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
79527672|NCT05096052|Drug|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
80000538|NCT05479097|Drug|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
79232301|NCT00411801|Biological|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
79232302|NCT03200522|Other|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
79232303|NCT03200522|Other|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
79232304|NCT04477265|Drug|Solifenacin Succinate 5mg/tab daily|participants will be taking oral medication for 3 months
79232305|NCT04477265|Behavioral|biofeedback-assisted pelvic floor muscle training|participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
79232306|NCT00353457|Drug|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
79232307|NCT00353457|Radiation|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
79232308|NCT03206294|Other|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
79232309|NCT02287701|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
79232310|NCT02449850|Other|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
79232311|NCT02449850|Other|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
79527673|NCT05093595|Device|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
79527674|NCT05088928|Drug|Apixaban|Direct Acting Oral Anti coagulant
79527675|NCT05088928|Drug|Rivaroxaban|Direct Acting Oral Anti coagulant
79527676|NCT05078762|Other|Immersive Virtual Reality|Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
79232312|NCT01346189|Behavioral|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
79232313|NCT00411099|Drug|agomelatine|
79232314|NCT00411099|Drug|placebo|
79232315|NCT03206372|Other|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
79232316|NCT03206372|Other|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
79527677|NCT05075122|Biological|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
79527678|NCT05075122|Drug|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
79527679|NCT05075122|Drug|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
79527680|NCT05067439|Drug|Abrocitinib|200 mg once daily (QD)
79527681|NCT05067439|Drug|Omeprazole|single doses of 10 mg
79527682|NCT05067439|Drug|Caffeine|single dose of 100 mg
79527683|NCT05067439|Drug|Efavirenz|single doses of 50 mg
79232317|NCT05218031|Behavioral|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
79827038|NCT00721994|Device|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
79827039|NCT04068714|Procedure|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
79232318|NCT03195530|Drug|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
79374060|NCT01339858|Drug|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
79374061|NCT01339858|Other|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
79527684|NCT05064176|Other|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~week 3-4: start physical therapy, 2 days/ week: exercises, skin care & manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care & MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
79683956|NCT04687449|Dietary Supplement|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
79527685|NCT05064176|Procedure|Reconstructive lymphatic surgery|"For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~Placed lymph nodes induce lymphangiogenesis"
79527686|NCT05064137|Drug|Monomeric self - assembling peptide P11-4|Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
79232319|NCT03195452|Drug|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
79527687|NCT05064137|Drug|Tricalcium phosphate fluoride varnish, 5% F-|Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
79527688|NCT05064137|Drug|fluoride varnish (5% sodium fluoride)|fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
79527689|NCT05059743|Drug|[14C]-Larotinib|Patients will receive single dose of orally [14C]-Larotinib on Day 1.
79683957|NCT04687449|Other|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
79683958|NCT04687449|Other|Standard care|The standard of care for COPD.
79683959|NCT04221009|Behavioral|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
79683960|NCT04200924|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
79683961|NCT04200924|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
79709834|NCT02272478|Drug|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
79232320|NCT00406809|Drug|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
79232321|NCT02449772|Other|No intervention|No intervention
79527690|NCT05057364|Other|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
79232322|NCT00004911|Procedure|bowel obstruction management|
79232323|NCT00004911|Procedure|quality-of-life assessment|
79232324|NCT03200210|Drug|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
79232325|NCT03200210|Drug|Placebo|Pills manufactured to mimic Febuxostat tablets
79232326|NCT00004899|Biological|filgrastim|
79827040|NCT00861250|Drug|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
79232327|NCT00004899|Drug|busulfan|
79232328|NCT00004899|Drug|etoposide|
79232329|NCT00004899|Procedure|autologous bone marrow transplantation|
79527691|NCT05055986|Device|Semiautomatic segmentation of open-source software|Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
79527692|NCT05052528|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
79527693|NCT05052528|Drug|Cyclophosphamide|Given IV
79232330|NCT00333411|Drug|BIRT 2584 XX|
79683962|NCT05230979|Other|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
79709835|NCT02272478|Drug|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
79709836|NCT02272517|Drug|Vortioxetine 10-20 mg|
79232331|NCT00333411|Drug|Placebo|
79709837|NCT02272517|Drug|Escitalopram 10-20 mg|
79232332|NCT03199976|Drug|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
79232333|NCT03199976|Drug|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
79232334|NCT03199976|Drug|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
79232335|NCT03675061|Other|Current care|Tocolysis and a complete corticosteroid treatment.
79232336|NCT03675061|Device|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
79827041|NCT00807183|Other|woodstove|installation of new EPA-certified woodstove
79232337|NCT03675061|Device|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
79232338|NCT00369317|Drug|asparaginase|Given IM
79232339|NCT00369317|Drug|daunorubicin hydrochloride|Given IV
79232340|NCT00369317|Drug|cytarabine|Given IV or IT
79232341|NCT00369317|Drug|thioguanine|Given orally
79232342|NCT00369317|Drug|etoposide|Given IV
79232343|NCT00369317|Other|laboratory biomarker analysis|Correlative studies
79232344|NCT03205670|Procedure|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
79232345|NCT05725551|Device|ShotBlocker|"Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer."
79232346|NCT05725551|Other|Finger Puppet group|"During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
79527694|NCT05052528|Drug|Fludarabine Phosphate|Given IV
79527695|NCT05052528|Biological|Rituximab|Given IV
79527696|NCT05051150|Drug|Epinephrin 0.03|epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
79827042|NCT00807183|Other|inactive air filter|air filter units without filter in place
79827043|NCT00807183|Other|Active air filter|air filter units correctly operating
79527697|NCT05051150|Drug|Epinephrin 0.05|epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
79527698|NCT05051150|Drug|Epinephrin 0.07|epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
79527699|NCT05045313|Drug|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
79527700|NCT05045313|Drug|Digoxin tablet|Drug: Digoxin, tablet, oral
79527701|NCT05045313|Drug|Probenecid tablets|Drug: Probenecid, tablet, oral
79527702|NCT05045313|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
79827044|NCT00722150|Drug|Artesunate|2 mg/kg/day x 7 days
79827045|NCT00722150|Drug|Artesunate|4 mg/kg/day x 7 days
79232347|NCT05725551|Other|Balloon group|"An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
79527703|NCT05044572|Other|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
79683963|NCT05230979|Other|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
79709838|NCT02272673|Dietary Supplement|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
79527704|NCT05044572|Other|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
79527705|NCT05044156|Other|salivary sample|salivary sample
79527706|NCT05032872|Behavioral|Social Exergame Treatment Group|"Physical activity tracking, walk to grow flowers and plant their own garden~Follow workout tutorials~Daily steps tracked by Fitbit and workout log tracked by the app~Daily reminders to wear Fitbit, use the app, and share stories to unlock new flowers to grow~Includes social features: like, reply, and see other's stories, and share their stories; Access to other people's gardens~In-app rewards (unlock new flowers to grow each week) if participants post stories"
79527707|NCT05032872|Behavioral|Control Group|"Physical activity tracking, walk to grow flowers and plant their own garden~Follow workout tutorials~Daily steps tracked by Fitbit and workout log tracked by the app~Daily reminders to wear Fitbit and use the app"
79827046|NCT00722150|Drug|Artesunate|6 mg/kg/day x 7 days
79827047|NCT02571738|Biological|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
79827048|NCT02571738|Other|Control|Standard of Care
80000539|NCT05478538|Procedure|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
79232348|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
79232349|NCT04470219|Other|Cognitive support by RemindMe|
79232350|NCT02447666|Drug|Azacitidine|
79232351|NCT04469751|Diagnostic Test|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
79232352|NCT03193021|Device|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
79232353|NCT03193021|Other|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
79232354|NCT04469829|Drug|Secukinumab|standard doses of secukinumab for psoriasis
79232355|NCT04469829|Drug|Methotrexate|Methotrexate 15 mg/week
79527708|NCT05007561|Drug|Naltrexone Hydrochloride|oral naltrexone
79527709|NCT05007561|Drug|Placebo|oral sugar pill
79527710|NCT04983394|Other|Virtual Realty Exercises|motion-controlled video game
79527711|NCT04983394|Other|Aerobic exercises|cycling activity
79527712|NCT04983394|Other|conventional exercises|stretching, strengthening and endurance exercises
79527713|NCT04981002|Other|Telemedicine Consultation with self orthopedic exam|Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.
79527714|NCT04981002|Other|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
79527715|NCT04970914|Drug|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
79527716|NCT04970914|Drug|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
79527717|NCT04968418|Device|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
79527718|NCT04965402|Drug|BMS-986166|Specified dose on specified days
79527719|NCT04965402|Other|Placebo|Specified dose on specified days
79527720|NCT04961801|Drug|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
79827049|NCT00861094|Drug|cisplatin|
79827050|NCT00861094|Drug|5-FU|
79827051|NCT00861094|Drug|oxaliplatin|
79827052|NCT00861094|Radiation|radiation therapy|
79827053|NCT00861094|Drug|Folinic Acid|
79827054|NCT02554149|Radiation|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
79827055|NCT00722228|Biological|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
80000540|NCT05476770|Drug|Tagraxofusp|Dose will be assigned at study entry. Give IV over 15 minutes.
79232356|NCT05217719|Drug|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
79232357|NCT05217719|Drug|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
79232358|NCT04469673|Biological|Biological：JS002|Administered by subcutaneous injection
80000541|NCT05476770|Drug|Fludarabine|"30 mg/m^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5."
79527721|NCT04954131|Biological|Candidate Vaccine, SCB-2019|30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
79683964|NCT05230979|Other|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
79709839|NCT02272712|Behavioral|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
79709840|NCT02272751|Behavioral|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
80000542|NCT05476770|Drug|Cytarabine|2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
80000543|NCT05476770|Drug|Dexamethasone|"20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~Any oral formulation of dexamethasone is acceptable.~IV may be given if oral formulation is not tolerated"
80000544|NCT05476770|Drug|Vincristine|"1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~Infusion will start 30 minutes after start of tagraxofusp on day 8."
79232359|NCT04469673|Biological|Placebo|Administered by subcutaneous injection
79232360|NCT03195296|Other|No intervention|No intervention related to the study is foreseen
79232361|NCT03674905|Procedure|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
79527722|NCT04954131|Other|Placebo|Saline solution (0.9%)
79527723|NCT04938388|Drug|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
79527724|NCT04938388|Dietary Supplement|Fresh organic vegetables|Prescriptions of organic vegetables
79527725|NCT04935723|Other|Reiki|The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
79527726|NCT04935008|Diagnostic Test|The recruitment maneuver|In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
79527727|NCT04931264|Diagnostic Test|YuWell YE660D Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
79527728|NCT04910932|Other|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
79232362|NCT03674905|Procedure|Peripheral nerve block|Pre-operative peripheral nerve block.
79232363|NCT05217485|Device|Zio 14-day cardiac patch|A wearble adhesive cardiac patch (14-day) called Zio
79232364|NCT00405951|Drug|Obatoclax mesylate 250 ml|
79232365|NCT00405951|Drug|Docetaxel|
79232366|NCT03194984|Drug|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
79232367|NCT03194984|Drug|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
79232368|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
79232369|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
79232370|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
79232371|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
79232372|NCT03669757|Drug|LEO 134310 vehicle|Active substance: none
79232373|NCT03669757|Drug|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
80000545|NCT05476770|Drug|Azacitidine|"75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion."
79232374|NCT00405327|Biological|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
79232375|NCT00405327|Other|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
79232376|NCT03199898|Diagnostic Test|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
79232377|NCT03913091|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
79527729|NCT04910932|Other|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
79232378|NCT03913091|Drug|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
79232379|NCT00330369|Drug|Darusentan|Darusentan administered orally once daily
80000546|NCT05476770|Drug|Methotrexate|"Give intrathecally:~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients ≥9 years of age"
79232380|NCT00330369|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
79232381|NCT03199664|Radiation|NB-UVB|NB-UVB given twice weekly for 6 months
79232382|NCT03199664|Combination Product|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
79232383|NCT02447588|Other|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
80000547|NCT05476770|Drug|Cytarabine IT|"Give intrathecally:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg"
79374062|NCT03831555|Behavioral|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~Information: knowledge about HCV treatment and one's own HCV disease status~Medication Adherence: current prescribed medications and adherence to them in the prior month~Self-efficacy: self-confidence about adhering to HCV treatment~Social Support and Stability: stability of financial, housing, and social support resources~Alcohol and substance use: alcohol and substance use behaviors and current treatment~Psychiatric Stability: current psychiatric status, previous and current treatment~Energy Level: sleep and fatigue~Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
80000548|NCT05476770|Drug|Hydrocortisone|"Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg"
79374063|NCT03087123|Behavioral|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
79232384|NCT02447588|Other|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
79232385|NCT02447510|Procedure|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
79232386|NCT02447510|Procedure|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
80000549|NCT05471245|Device|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
79232387|NCT02447510|Procedure|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
79232388|NCT03205592|Diagnostic Test|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
80000550|NCT05464160|Device|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
79232389|NCT05216471|Radiation|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
79232390|NCT02149537|Drug|hydroxyurea|
79232391|NCT03205982|Device|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
79232392|NCT03205982|Device|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
79232393|NCT05216237|Drug|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
79232394|NCT03205904|Dietary Supplement|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
79232395|NCT04058977|Other|Power training|Progressive exercise protocol with focus on velocity of movement
79232396|NCT03205514|Diagnostic Test|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
79232397|NCT03674749|Other|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
79232398|NCT02284971|Biological|CDX1127|
79232399|NCT02284971|Radiation|SBRT|
80000551|NCT05464160|Other|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
79527730|NCT04909372|Behavioral|Labelling|"Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact."
80000552|NCT05461131|Biological|BPZE1|Live attenuated vaccine
79232400|NCT05217329|Other|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
79683965|NCT05230979|Other|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
79232401|NCT05217329|Other|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
79232402|NCT03205202|Dietary Supplement|Cocoa extract|
79232403|NCT03205202|Dietary Supplement|Multivitamin|
79374064|NCT04275453|Drug|FDG|FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
79374065|NCT04275453|Dietary Supplement|Ketone Drink|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
79374066|NCT04275453|Other|Ketogenetic Diet|Subjects needs to be on Ketogenetic diet
79683966|NCT05230979|Other|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
79709841|NCT02272751|Behavioral|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
80000553|NCT05461131|Biological|Placebo|Placebo
80000554|NCT05461131|Drug|Azithromycin|Antibiotic
80000555|NCT05461131|Other|Bordetella Pertussis Challenge Strain|Challenge Strain
80000556|NCT05459129|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
80000557|NCT05459129|Drug|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
79232404|NCT03205202|Dietary Supplement|Cocoa extract placebo|
79232405|NCT03205202|Dietary Supplement|Multivitamin placebo|
79232406|NCT00322257|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
79232407|NCT00322257|Drug|insulin detemir|Injection s.c., 50% of daily dose
79232408|NCT00322257|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
79232409|NCT03199742|Behavioral|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress & use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
79232410|NCT03199742|Behavioral|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
79305622|NCT04930185|Behavioral|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
79374067|NCT01339936|Device|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
80000558|NCT05459129|Drug|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
80000559|NCT05459129|Drug|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
80000560|NCT05449171|Other|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
80000561|NCT05419050|Drug|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
79232411|NCT05216939|Other|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
79232412|NCT05216939|Other|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
79683967|NCT05230979|Other|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
80000562|NCT05419024|Other|Acute Treatment Interruption|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
79232413|NCT05216939|Other|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
79374068|NCT05246865|Drug|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
79374069|NCT01289392|Device|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
79374070|NCT01289392|Device|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
79374071|NCT01289392|Behavioral|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
79683968|NCT00532818|Drug|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
79683969|NCT00532818|Drug|Placebo|Cisplatin + Topotecan plus placebo
79683970|NCT04687397|Behavioral|Rehabilitation|Multidisciplinary rehabilitation
79683971|NCT05209035|Drug|Trazodone|Trazodone 50mg daily
79683972|NCT05209035|Other|Placebo|Starch 50mg
79683973|NCT04687202|Other|follow up and record|None additional intervention was applied to the subjects.
79683974|NCT00534261|Drug|Interferon beta-1a|IM injection
79683975|NCT04687319|Biological|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
79683976|NCT04687280|Other|non interventional|non interventional, study on data
79683977|NCT04686708|Other|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
79683978|NCT00534300|Drug|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
79683979|NCT00534300|Drug|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
79683980|NCT05202405|Drug|AD-221|AD-221 Oral Tablet
79683981|NCT05202405|Drug|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
79683982|NCT00532857|Drug|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
79683983|NCT05200377|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
79683984|NCT05190458|Other|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
79709842|NCT04344132|Procedure|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
79683985|NCT05190458|Other|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
79683986|NCT04169334|Behavioral|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
79683987|NCT05180903|Other|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
79683988|NCT05191251|Diagnostic Test|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
79683989|NCT04686513|Other|Observation|observational study
79827056|NCT00807261|Drug|Gemcitabine and Docetaxel|"Drug and schedule~Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~Treatment should be delayed if the ANC<1,500/ mm3, or if the platelet count <75,000/mm3 on the first day of the next cycle.~Gemcitabine & docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
79232414|NCT05216939|Other|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
79232415|NCT03195218|Device|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
79232416|NCT05216783|Behavioral|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
79683990|NCT05152004|Drug|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
79683991|NCT05152004|Drug|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
79232417|NCT03627845|Drug|PHP-303|Investigational drug
79232418|NCT03627845|Other|Placebo|Matching placebo
79374072|NCT01921725|Device|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
79374073|NCT03111537|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
79374074|NCT03111537|Other|E-Cigarette|Use of E-cigarette: multiple flavors offered.
79374075|NCT03111537|Other|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
79374076|NCT01289548|Device|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
79683992|NCT05152004|Drug|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
79374077|NCT01927263|Biological|NI-071|100mg/vial
79374078|NCT01927263|Biological|Infliximab|100mg/vial
79683993|NCT05152004|Drug|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
79683994|NCT00534339|Device|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
79683995|NCT05132153|Drug|Milrinone|will be given by nebulization
79683996|NCT05132153|Drug|Normal saline|will be given by nebuliztion
79683997|NCT00534378|Drug|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
79683998|NCT05131997|Drug|AD-221|PO, Once daily(QD), 8 weeks
79683999|NCT05131997|Drug|AD-221A|PO, Once daily(QD), 8 weeks
79684000|NCT05131997|Drug|AD-221B|PO, Once daily(QD), 8 weeks
79684001|NCT05131997|Drug|AD-221C|PO, Once daily(QD), 8 weeks
79684002|NCT00534456|Drug|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
79827057|NCT04019106|Drug|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
80000563|NCT05407324|Drug|Dazucorilant 300 mg|300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
79374079|NCT01921881|Other|St John's wort|
79527731|NCT04908826|Procedure|Indocyanine Green (ICG) administration|Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
79527732|NCT04897425|Device|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics"
79374080|NCT01341730|Drug|Atorvastatin 20mg|20 mg QD for 3 months
79374081|NCT01341730|Drug|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
79827058|NCT02571608|Drug|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
79374082|NCT01921959|Behavioral|Intervention|Postpartum women are randomized to intervention or control group
79232419|NCT03199586|Drug|NP-G2-044|capsule
79527733|NCT04894786|Other|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
79527734|NCT04894786|Other|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
79527735|NCT04891835|Other|Data extraction from medical files|Data extraction from medical files
79527736|NCT04886908|Other|Data extraction from medical files|Data extraction from medical files
79527737|NCT04886817|Behavioral|Pilot Intervention to reduce SSB consumption in children and families|"A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors"
79527738|NCT04886284|Drug|Ertapenem|Adjunctive ertapenem
79527739|NCT04886284|Drug|Placebo|Saline placebo
79232420|NCT01918345|Behavioral|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
79527740|NCT04876703|Device|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
79527741|NCT04876703|Other|Standard motor training|Standard motor training is the conventional rehabilitation treatment
79684003|NCT00534456|Drug|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
79684004|NCT05167773|Device|tonometer|A subject undergoes intraocular pressure measurement with tonometer
80000564|NCT05407324|Drug|Dazucorilant 150 mg|Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
80000565|NCT05407324|Other|Placebo|Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.
79374083|NCT01247272|Drug|Fluoxetine Hydrochloride|90 mg Capsules
79374084|NCT01247272|Drug|PROZAC WEEKLY®|90 mg Capsules
79374085|NCT03430089|Biological|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
79374086|NCT03430089|Biological|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
79374087|NCT03430089|Biological|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
79374088|NCT01290484|Drug|Sildenafil|Sildenafil oral tablet three times daily
79374089|NCT01247428|Device|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
79374090|NCT04397055|Dietary Supplement|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
79684005|NCT05163990|Other|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
79527742|NCT04871815|Drug|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
79684006|NCT05077631|Drug|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
79827059|NCT02571608|Drug|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
79232421|NCT01918345|Behavioral|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
79232422|NCT05234138|Other|Blood Sample|Blood Sample
79527743|NCT04870333|Drug|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
79527744|NCT04870333|Drug|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
79527745|NCT04870333|Drug|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
79527746|NCT04870333|Drug|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
79527747|NCT04870333|Drug|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter."
79684007|NCT05077631|Drug|Placebo|Placebo oral solution
79684008|NCT05077631|Drug|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
79684009|NCT00532961|Drug|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
79684010|NCT00532961|Drug|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
79684011|NCT04138524|Other|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
79684012|NCT05121792|Behavioral|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
79827060|NCT00865072|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
79827061|NCT00865072|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
79827062|NCT00798447|Drug|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
79374091|NCT04397055|Dietary Supplement|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
79374092|NCT04396743|Procedure|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
79374093|NCT04396743|Procedure|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
79374094|NCT03518619|Behavioral|PFIcope+EMI|The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
79374095|NCT01928043|Drug|Curcumin|
79827063|NCT00798447|Drug|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
79827064|NCT02571660|Drug|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
79827065|NCT02571660|Drug|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
79374096|NCT01342666|Dietary Supplement|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
79232423|NCT02285049|Other|Urticaria Control Test|"The patients get the 1st UAS28 form and four-week appointment to follow up.~Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~Then patients fill the 1st UCT and DLQI questionnaire by themselves.~The patients get the 2nd UAS28 form and four-week appointment to follow up.~At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
79527748|NCT04870333|Drug|Placebo|There will be a single infusion placebo, in the form of 50mL 0.9% sodium chloride, administered at the beginning of the study.
79527749|NCT04861610|Behavioral|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
79684013|NCT00534534|Behavioral|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
79684014|NCT05062070|Drug|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
79527750|NCT04861610|Behavioral|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
79527751|NCT04860271|Procedure|Manual Acupuncture|Manual acupuncture treatment using different types of needle
79527752|NCT04857099|Other|Data extraction from medical files|Data extraction from medical files
79527753|NCT04856696|Diagnostic Test|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
79684015|NCT05062070|Drug|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
80000566|NCT05387707|Drug|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
80000567|NCT05387707|Drug|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
79232424|NCT03674515|Device|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
79232425|NCT03674515|Device|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
79374097|NCT01342666|Dietary Supplement|Cucumber consumption|Daily consumption of 300g of cucumber.
79374098|NCT02979886|Drug|GnRH-a|the hormone reaction to the down regulation of the patients
79374099|NCT02979886|Drug|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
79374100|NCT01928121|Other|Care provided by AF expert program|
79527754|NCT04856696|Diagnostic Test|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
79527755|NCT04853459|Procedure|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
79527756|NCT04851847|Device|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
79527757|NCT04839172|Diagnostic Test|Dual-energy X-ray Absorptiometry (DXA) scan|Longitudinal changes in body composition are examined over four consecutive seasons (2017-2018, 2018-2019, 2019-2020, 2020-2021), four times per season in the following stages: start-preseason, start-season, mid-season and end-season.
79527758|NCT04837534|Behavioral|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
79684016|NCT00534573|Drug|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
79684017|NCT04686890|Procedure|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
79827066|NCT00722306|Drug|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
80000568|NCT05387707|Drug|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
79374101|NCT01290640|Device|DePuy fixed-bearing Total Condylar III (TC3) TKA|
80000569|NCT05387707|Drug|Placebo|Oral Placebo tablets administered twice daily
79374102|NCT01290640|Device|DePuy PFC Rotating Platform TC3 TKA|
79374103|NCT01928511|Drug|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
79374104|NCT01928511|Drug|Nucleos(t)ide analogue therapy|
79684018|NCT04686890|Procedure|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
79684019|NCT00533000|Procedure|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
79684020|NCT00534612|Procedure|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
79684021|NCT00533039|Drug|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
79827067|NCT00804297|Drug|Octreotide (drug)|
79827068|NCT00722384|Drug|bevasiranib|
80000570|NCT05387707|Drug|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
80000571|NCT05384951|Dietary Supplement|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
80000572|NCT05382286|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
80000573|NCT05382286|Drug|Pembrolizumab|Administered intravenously
80000574|NCT05382286|Drug|Paclitaxel|Administered intravenously
80000575|NCT05382286|Drug|nab-Paclitaxel|Administered intravenously
80000576|NCT05382286|Drug|Gemcitabine|Administered intravenously
79232426|NCT03205436|Other|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
79527759|NCT04837534|Behavioral|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
79684022|NCT00533039|Drug|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
79827069|NCT00722384|Drug|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
79827070|NCT00804375|Drug|2PX|cutaneous solution to be applied twice daily for 84 days
80000577|NCT05382286|Drug|Carboplatin|Administered intravenously
79827071|NCT00804375|Drug|Placebo|cutaneous solution to be applied twice daily for 84 days
80000578|NCT05382091|Drug|naltrexone implant|3.6 g per implant set each containing 60% naltrexone
79232427|NCT03674359|Diagnostic Test|BDG analysis|BDG analysis
79232428|NCT00312975|Drug|CP-675,206|Given intravenously every 3 months
79232429|NCT00312975|Drug|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
79232430|NCT03425435|Other|QoL and developed questionnaires for healthcare research|Questionnaires
79684023|NCT05103306|Drug|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
79684024|NCT05103306|Drug|INS|Basal insulin add on the background OADs
80000579|NCT05381948|Drug|Eyp-1901|Intravitreal Injection
80000580|NCT05381948|Drug|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
79684025|NCT05042999|Device|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
79684026|NCT05102097|Behavioral|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
79684027|NCT05102097|Behavioral|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
79527760|NCT04835402|Drug|Pembrolizumab|400mg every 6 weeks
79527761|NCT04835402|Device|Irreversible electroporation|Percutaneous ablation of one liver metastasis
79827072|NCT04067700|Procedure|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
80000581|NCT05373823|Other|MySmartSkin enhancement|Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
80000582|NCT05373823|Other|Educational webpage on Skin Self-Examination|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
80000583|NCT05373823|Other|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
80000584|NCT05362409|Drug|5 Aminolevulinic Acid|5-aminolevulinic acid [5-ALA] administered orally 20 mg/kg every 4 weeks
79232431|NCT03199508|Diagnostic Test|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
79232432|NCT03199508|Diagnostic Test|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
79232433|NCT05215301|Diagnostic Test|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
79232434|NCT02285205|Drug|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
79684028|NCT05102097|Behavioral|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
79374105|NCT05241327|Dietary Supplement|Beetroot Juice|Inorganic Nitrate
79527762|NCT04834648|Behavioral|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
79827073|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
80000585|NCT05362409|Device|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
80000586|NCT05358886|Drug|BPN14770/ zatolmilast|25mg BID BPN14770
80000587|NCT05358886|Drug|Placebo|Placebo
80000588|NCT05353257|Drug|HLX10|"Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
79527763|NCT04831762|Behavioral|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
79684029|NCT05102097|Behavioral|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
79684030|NCT05007002|Device|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
79232435|NCT03199820|Device|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
79684031|NCT04106037|Other|Data extraction from medical files|Data extraction from medical files
79684032|NCT04980443|Diagnostic Test|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
79684033|NCT00534651|Drug|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
79684034|NCT04971980|Drug|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10^6 cells/kg body weight, 1.0x10^6 cells/kg body weight, 1.5x10^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
79684035|NCT04965779|Device|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
79684036|NCT04965779|Other|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
79684037|NCT04960241|Procedure|Homebased telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
79827074|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
79232436|NCT03199820|Drug|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
80000589|NCT05353257|Drug|carboplatin/cisplatin-etoposide|"Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice."
79232437|NCT03532659|Other|Active video game|Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
79374106|NCT05241249|Drug|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at our research pharmacy.
79374107|NCT05241249|Drug|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
79827075|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
79827076|NCT00865228|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
79827077|NCT00724412|Other|Systane|Dry Eye relief eye drops
79827078|NCT00724412|Other|Optive|Dry Eye relief eye drops
79232438|NCT03243071|Behavioral|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
79374108|NCT05241249|Drug|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
79827079|NCT00722202|Drug|ERB-257|
79374109|NCT05241171|Device|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
79374110|NCT03430752|Other|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
79527764|NCT04831762|Behavioral|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
79527765|NCT04831762|Behavioral|Laby 5-12|Test of motor planning using labyrinths
79527766|NCT04831762|Behavioral|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
79527767|NCT04831762|Behavioral|Stroop animals|Stroop test for preK children using animals instead of words
79232439|NCT03243071|Behavioral|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
79527768|NCT04817579|Device|Digital photography combined with eLABor_aid shade analyzing software|ELABor_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
79527769|NCT04817579|Device|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
79684038|NCT04960241|Procedure|Homebased rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
79232440|NCT03199430|Dietary Supplement|Epigallocatechin gallate|
79232441|NCT03199430|Dietary Supplement|Placebo|1450mg Corn Flour
79527770|NCT04817579|Device|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
79232442|NCT05725473|Device|Eso-Flip|Dilatation with Eso-FLIP
79232443|NCT03195062|Other|Test meal|Liquid test meal (fructose+glucose)
79232444|NCT03532503|Device|Foley catheter|Transcervical foley catheter will be applied
79684039|NCT04960241|Procedure|No physical rehabilitation|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
79684040|NCT05080959|Drug|CPL-01|Subjects will receive a single dose
79684041|NCT05080959|Drug|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
79684042|NCT05080959|Drug|Placebo|Subjects will receive a single dose
79684043|NCT00533078|Dietary Supplement|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
79684044|NCT05064267|Diagnostic Test|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
79684045|NCT04942730|Drug|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
79827080|NCT00722202|Other|placebo|
79232445|NCT03118388|Behavioral|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
79827081|NCT00724490|Procedure|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
79232446|NCT03118388|Behavioral|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
79232447|NCT02287857|Drug|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
79232448|NCT02287857|Drug|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
79374111|NCT01928667|Other|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
79374112|NCT03433716|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
79527771|NCT04805255|Radiation|Hypofractionated Stereotactic Radiotherapy|A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
80000590|NCT05353257|Radiation|Thoracic radiotherapy|Standard Thoracic Radiotherapy
80000591|NCT05353257|Drug|Placebo|Placebo Q3W
79232449|NCT05214677|Drug|DW1809|pelubiprofen 30mg
79232450|NCT05214677|Drug|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
79232451|NCT03532347|Device|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
79232452|NCT03204968|Device|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
79374113|NCT01928823|Behavioral|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
79374114|NCT01928823|Drug|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
79374115|NCT01290874|Drug|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
79374116|NCT01290874|Drug|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
79232453|NCT03532269|Device|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
79232454|NCT03204890|Other|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
79527772|NCT04800718|Other|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
79232455|NCT00399789|Drug|Perifosine|Perifosine will be tested in 3 dose forms
79232456|NCT03118310|Behavioral|5:2 diet|Dietary intervention according to 5:2 diet during three months.
79374117|NCT01290874|Drug|Formoterol|Formoterol 12 mcg twice daily for one year
79374118|NCT02977494|Drug|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
79527773|NCT04800276|Other|muscle strengthening targeted on ischemic areas|muscle strengthening targeted on ischemic areas
79527774|NCT04800276|Other|global muscle strenghtening|global muscle strenghtening
79527775|NCT04791813|Other|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
79527776|NCT04783376|Drug|: Insulin, lispro and regular insulin|"A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
79527777|NCT04783285|Behavioral|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
79527778|NCT04772560|Device|Precision1 for Astigmatism|Daily disposable soft toric contact lens
79527779|NCT04772560|Device|Precision1 Sphere|Daily disposable soft spherical contact lens
79527780|NCT04768829|Drug|Moringa oleifera leaf 10mg/100ml|ear drops
79527781|NCT04768829|Drug|Ear Drop|plain ear drop formulation without moringa
79527782|NCT04760912|Drug|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
79527783|NCT04760912|Procedure|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
79527784|NCT04758208|Diagnostic Test|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
79527785|NCT04738448|Behavioral|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
79527786|NCT04738201|Other|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
79527787|NCT04734613|Behavioral|Tai Chi exercise|Yang style Tai Chi 16 movements
79527788|NCT04734613|Behavioral|self management|health education and dietary counseling
79527789|NCT04732481|Procedure|passive leg lift test|passive leg lift test
79684046|NCT04942730|Drug|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
79684047|NCT04942730|Drug|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
79232457|NCT03118310|Behavioral|LCHF|Dietary intervention according to LCHF diet during three months.
79684048|NCT04942730|Drug|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
79684049|NCT04942730|Drug|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
79684050|NCT04942730|Drug|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
79374119|NCT02977494|Drug|Bortezomib|
79374120|NCT02977494|Drug|Dexamethasone|
79374121|NCT01929603|Procedure|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
79374122|NCT01929603|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
79374123|NCT01929603|Drug|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
79374124|NCT04217850|Other|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
79232458|NCT03118310|Behavioral|Placebo diet|Placebo diet: normal dietary advice
79374125|NCT04217850|Other|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
79232459|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
79374126|NCT04178460|Drug|Niraparib combined with MGD013|"The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation)."
79374127|NCT01344616|Behavioral|lifestyle support|computer-based lifestyle improvement support and clinician support
79527790|NCT04729816|Other|Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.|"Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63"
79527791|NCT04717401|Procedure|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
79684051|NCT04068402|Device|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
79684052|NCT04909190|Procedure|Increased saline flush volume|Additional flushing of the stentgraft delivery system.
79374128|NCT01929837|Device|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
79684053|NCT04034901|Device|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~Activity~Step count~Heart rate~Respiratory rate~Skin temperature~SpO2"
79827082|NCT00723762|Procedure|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
80000592|NCT05353257|Radiation|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
80000593|NCT05352672|Drug|Fianlimab|Intravenous (IV) infusion
79527792|NCT04717401|Procedure|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
79684054|NCT04903964|Other|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
79684055|NCT00534690|Procedure|One-Lung ventilation|Low Vt, High PEP
79684056|NCT00534690|Procedure|One-Llung ventilation|High Vt, low PEP
79684057|NCT04901936|Drug|Pegcetacoplan|Complement (C3) inhibitor
80000594|NCT05352672|Drug|Cemiplimab|IV infusion
80000595|NCT05352672|Drug|Pembrolizumab|IV infusion
80000596|NCT05352672|Drug|Placebo|IV infusion
79232460|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
79232461|NCT01318499|Other|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
79232462|NCT00397293|Drug|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
79232463|NCT00397293|Drug|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
79232464|NCT03628079|Drug|ReposMBZ|Capsules 50mg, 100mg, 200mg
80000597|NCT05339438|Radiation|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
80000598|NCT05337306|Other|GogyUp Reader|Participants will have unlimited access to the assistive-reading technologies available in the GogyUp Reader app for help understanding post-visit educational documents on type 2 diabetes mellitus disease management.
80000599|NCT05327010|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
80000600|NCT05327010|Procedure|Biopsy|Undergo tumor biopsy
80000601|NCT05327010|Procedure|Biospecimen Collection|Undergo blood sample collection
79684058|NCT01272193|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
79684059|NCT01272193|Drug|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
79684060|NCT04899206|Drug|With an Antidepressant Drug|Current users of an antidepressant drug.
80000602|NCT05327010|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
79232465|NCT03118154|Other|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
79232466|NCT03204734|Drug|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
79232467|NCT03204734|Drug|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
79374129|NCT01929837|Device|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
79374130|NCT01929837|Device|sham E-field navigated rTMS|
79374131|NCT01929837|Device|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
79374132|NCT01928901|Drug|administration of Sinupret|
79374133|NCT01928901|Drug|administration of Bronchipret|
79374134|NCT01928901|Drug|administration of Sinupret Placebo|
79374135|NCT01928901|Drug|administration of Bronchipret Placebo|
79374136|NCT01290952|Procedure|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
79374137|NCT01290952|Procedure|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
79684061|NCT04899206|Drug|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
79684062|NCT04019613|Diagnostic Test|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
79684063|NCT04687163|Drug|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
79684064|NCT04687163|Drug|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
79684065|NCT04687163|Drug|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight <60 kg)
79684066|NCT04017117|Procedure|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
79684067|NCT00533156|Device|Vascular access site closure (7F Ensure)|
79684068|NCT04686812|Behavioral|Worksite health promotion program|Physical activity, nutrition, and stress management programs
79684069|NCT01270828|Drug|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
79684070|NCT01270828|Drug|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
79684071|NCT00533195|Drug|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
79684072|NCT00533195|Device|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
79684073|NCT03987165|Other|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
79684074|NCT03982407|Drug|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
79684075|NCT00533234|Device|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
79684076|NCT04687124|Dietary Supplement|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
79684077|NCT04687124|Other|standard care|No specified intervention
79684078|NCT01269385|Biological|alemtuzumab|Given subcutaneously
79684079|NCT01269385|Biological|rituximab|Given IV
79684080|NCT01269385|Drug|PGG beta-glucan|Given IV
79684081|NCT01269385|Other|flow cytometry|Correlative studies
79684082|NCT01269385|Other|laboratory biomarker analysis|Correlative studies
79684083|NCT01269385|Genetic|DNA analysis|Correlative studies
79684084|NCT01269385|Genetic|fluorescence in situ hybridization|Correlative studies
79684085|NCT01269385|Genetic|polymerase chain reaction|Correlative studies
79684086|NCT01269385|Genetic|polymorphism analysis|Correlative studies
79684087|NCT01269385|Genetic|mutation analysis|Correlative studies
79684088|NCT02715635|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
79684089|NCT02715635|Dietary Supplement|Concentrate beetroot Juice|140 ml containing ~8 mmol of inorganic nitrate
79684090|NCT02715635|Dietary Supplement|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
79684091|NCT04685954|Device|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
80000603|NCT05327010|Drug|Talazoparib|Given PO
80000604|NCT05321069|Drug|BI 1015550|BI 1015550
80000605|NCT05321069|Drug|Placebo|Placebo
79391007|NCT03182478|Behavioral|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
79684092|NCT04685954|Device|Filtek Ultimate Universal|Incremental restorative composite
79684093|NCT00532974|Biological|EP1090|Low dose
79684094|NCT00532974|Biological|EP1090|High dose
79684095|NCT00533013|Other|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
79527793|NCT04715516|Behavioral|alcohol brief intervention|Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
79684096|NCT00533013|Other|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
79684097|NCT02071862|Drug|CB-839|CB-839 monotherapy
79684098|NCT02071862|Drug|Pac-CB|CB-839 in combination with standard dose paclitaxel
79527794|NCT04715516|Behavioral|lifestyle health promotion|Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
79527795|NCT04712604|Behavioral|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
79684099|NCT02071862|Drug|CBE|CB-839 in combination with standard dose everolimus
79684100|NCT02071862|Drug|CB-Erl|CB-839 in combination with standard dose erlotnib
79684101|NCT02071862|Drug|CBD|CB-839 in combination with standard dose docetaxel
79684102|NCT02071862|Drug|CB-Cabo|CB-839 in combination with standard dose cabozantinib
79232468|NCT02287935|Procedure|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
79232469|NCT02287935|Procedure|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
79232470|NCT03627689|Other|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
79684103|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
79232471|NCT03627689|Other|Sham air purifier|control arm
79232472|NCT00300027|Drug|BMS-582664|
79232473|NCT00396357|Drug|Vildagliptin|
79232474|NCT00396357|Drug|metformin|
79232475|NCT03627611|Drug|Levothyroxin|3 months
79232476|NCT03627611|Drug|Liothyronine|3 months
79684104|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
79684105|NCT05051085|Behavioral|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
79684106|NCT01268683|Drug|Glyburide for Injection|Administered as specified in the treatment arm.
79232477|NCT02447042|Procedure|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
79684107|NCT05037201|Behavioral|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
79684108|NCT02021474|Drug|AGX-201|Subcutaneous injection
79684109|NCT02021474|Drug|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
79684110|NCT01268566|Drug|MEDI-575|MEDI-575 as an IV infusion.
79684111|NCT05010291|Behavioral|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
79684112|NCT05010291|Behavioral|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
79232478|NCT02447042|Device|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
79684113|NCT05010291|Behavioral|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
79232479|NCT00394563|Drug|RN624 (PF-04383119)|10 mcg/kg
79232480|NCT00394563|Drug|RN624 (PF-04383119)|25 mcg/kg
79527796|NCT04706767|Drug|Co-administration Lidocaine and Dexmedetomidine|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.
79527797|NCT04706767|Drug|Dexmedetomidine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.
79527798|NCT04706767|Drug|Lidocaine infusion|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.
79684114|NCT05010291|Behavioral|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
79684115|NCT01268488|Device|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
79232481|NCT00394563|Drug|RN624 (PF-04383119)|50 mcg/kg
79232482|NCT00394563|Drug|RN624 (PF-04383119)|100 mcg/kg
79232483|NCT00394563|Drug|RN624 (PF-04383119)|200 mcg/kg
79232484|NCT00394563|Drug|placebo|
79232485|NCT05194319|Other|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
79232486|NCT02449538|Drug|everolimus|everolimus 10 mg qd daily one cycle is 28days.
79232487|NCT04469361|Other|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
79232488|NCT04469361|Other|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
79232489|NCT04469361|Other|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
79232490|NCT04469361|Other|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
79374138|NCT03008902|Procedure|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
79232491|NCT02446652|Drug|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
79374139|NCT01928979|Other|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
79527799|NCT04706767|Drug|Saline infusion|Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.
79527800|NCT04706468|Drug|TG-1000|Capsules taken orally
79527801|NCT04705298|Dietary Supplement|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
79232492|NCT02446652|Drug|Placebo|Placebo (orally) starting 1 week before the first day of the QT
79232493|NCT02446652|Drug|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
79374140|NCT04075734|Behavioral|Managing Your Health: Self-Management + Peer Mentoring|"The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call."
79374141|NCT05240859|Drug|Geleli|Adalimumab Biosimilar
80000606|NCT05320822|Other|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
79527802|NCT04705298|Dietary Supplement|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
79527803|NCT04700215|Device|BiPAP|To give bilevel positive airway pressure to the lungs
79527804|NCT04700215|Device|Incentive spirometry|IS for 15 minutes after every 4 hours
79684116|NCT04686071|Other|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
79374142|NCT04395105|Drug|High-Dose Dexamethasone|IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
79374143|NCT04072770|Dietary Supplement|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
80000607|NCT05320822|Other|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
80000608|NCT05320432|Device|Transcutaneous electrical nerve stimulation (TENS)|A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.
80000609|NCT05320432|Device|Sham|No current applied through pads.
80000610|NCT05320198|Drug|DISC-0974|DISC-0974 is administered subcutaneously.
80000611|NCT05318573|Drug|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
80000612|NCT05318573|Drug|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
80000613|NCT05316935|Drug|GnRHa|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
80000614|NCT05316935|Drug|Letrozole 2.5mg|2.5mg po qd and no more than 24 weeks
79527805|NCT04699656|Drug|Plazomicin Injection|single dose of plazomicin
79527806|NCT04698304|Procedure|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
79527807|NCT04693364|Other|Decision Aid|Use 3D printed breast model
79527808|NCT04693364|Procedure|Discussion|Participate in consultation
80000615|NCT05316935|Drug|Diane-35|Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
80000616|NCT05316935|Drug|MET|500mg po tid
80000617|NCT05312645|Drug|Diclofenac 1% Topical|2 grams topically four times daily for 2 weeks to posterior cervical spine
80000618|NCT05312645|Other|Petroleum Jelly|2 grams topically four times daily for 2 weeks to posterior cervical spine
80000619|NCT05306041|Drug|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
80000620|NCT05306041|Drug|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
79374144|NCT04072770|Dietary Supplement|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
79527809|NCT04693364|Other|Questionnaire Administration|Complete questionnaires
79527810|NCT04690686|Device|LW-02 device immunopheresis combined with atezolizumab|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
79232494|NCT02446652|Drug|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
79232495|NCT05068427|Drug|Chidamide|20mg or 30mg orally twice per week(BIW)
79232496|NCT05068427|Drug|Envafolimab|400mg subcutaneous infusions every 4 weeks
79232497|NCT00299715|Drug|Paliperidone extended-release|
79232498|NCT05193695|Other|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
79232499|NCT00299325|Drug|Rimonabant|Tablet, oral administration
79374145|NCT01291108|Drug|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
79374146|NCT01291108|Drug|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
79374147|NCT01291108|Drug|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
79374148|NCT01920789|Radiation|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
80000621|NCT05306041|Drug|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
79527811|NCT04690686|Device|LW-02 device immunopheresis combined with weekly paclitaxel|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
79527812|NCT04690686|Device|LW-02 device immunopheresis|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
79684117|NCT04686071|Other|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
79684118|NCT01268098|Drug|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
79684119|NCT00533052|Behavioral|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
80000622|NCT05301842|Drug|Tremelimumab|Tremelimumab IV (intravenous)
79232500|NCT00299325|Drug|Placebo (for Rimonabant)|Tablet, oral administration
79232501|NCT00299325|Other|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
79232502|NCT02446808|Device|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
79374149|NCT01920789|Radiation|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
79374150|NCT01929213|Drug|Udenafil|Udenafil is administered
79374151|NCT01929213|Drug|Bosentan|Bosentan is administered
79527813|NCT04685369|Other|Medical Data extraction|Medical Data extraction
79684120|NCT01674803|Device|Orsiro|biodegradable polymer sirolimus eluting stent
79684121|NCT01674803|Device|Synergy|biodegradable polymer everolimus eluting stent
79232503|NCT00391209|Drug|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
79232504|NCT00391209|Drug|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
79684122|NCT01674803|Device|Resolute Integrity|durable polymer zotarolimus-eluting stent
79684123|NCT04959825|Drug|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
79684124|NCT04959825|Drug|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
79232505|NCT02446574|Drug|Paclitaxel|starting dose 20mg/m2 qw
79684125|NCT04955184|Device|non-invasive monitoring|non-invasive measurements of cardiac output
79684126|NCT05471453|Dietary Supplement|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
79232506|NCT02446574|Drug|Cisplatin|dose 25mg/m2 qw
79232507|NCT02446574|Radiation|Radiation|60Gy/2Gy/30f
79374152|NCT01929213|Drug|Udenafil/Bosentan|Udenafil and Bosentan are administered
79374153|NCT01291498|Device|High Intensity Focused Ultrasound|One or two HIFU sessions
80000623|NCT05301842|Drug|Durvalumab|Durvalumab IV (intravenous)
80000624|NCT05301842|Procedure|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
80000625|NCT05301842|Drug|Lenvatinib|Lenvatinib (oral)
80000626|NCT05300711|Procedure|Bilateral salpingectomy|Removal of both fallopian tubes.
80000627|NCT05300711|Procedure|Colorectal surgery|Colorectal surgery as indicated by attending surgeon.
79527814|NCT04682977|Other|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
79527815|NCT04682977|Other|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
79527816|NCT04682626|Dietary Supplement|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
79684127|NCT05471453|Dietary Supplement|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
80000628|NCT05289193|Diagnostic Test|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
80000629|NCT05289193|Drug|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
79527817|NCT04665622|Other|Eye-Tracking / Neuropsychological evaluations|Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
79527818|NCT04656236|Biological|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
79232508|NCT01775813|Drug|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
79232509|NCT01775813|Drug|Placebo|Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
79232510|NCT00287547|Drug|CTLA4Ig / Abatacept|
79232511|NCT03204344|Dietary Supplement|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
79374154|NCT02984085|Drug|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
79374155|NCT03726060|Other|control group|In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months
79374156|NCT03726060|Other|test group|In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
79374157|NCT05604651|Other|no intervention|no intervention
80000630|NCT05289193|Drug|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
80000631|NCT05289193|Procedure|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
80000632|NCT05285891|Drug|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
80000633|NCT05285891|Drug|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 18 through Month 48.
80000634|NCT05283720|Drug|Epcoritamab|Subcutaneous Injection (SC)
80000635|NCT05283720|Drug|Lenalidomide|Oral; Capsule
79374158|NCT03430518|Drug|Durvalumab|1.12g given IV on day 1 every 21 day cycle
79374159|NCT03430518|Drug|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
79374160|NCT02938806|Other|No intervention|No intervention
79684128|NCT04949607|Dietary Supplement|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
79684129|NCT03457233|Drug|Gonadotropins|1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
80000636|NCT05283720|Drug|Ibrutinib|Oral; Capsule
80000637|NCT05283720|Drug|Rituximab|Intravenous (IV); Injection
80000638|NCT05283720|Drug|Cyclophosphamide|IV; Injection
80000639|NCT05283720|Drug|Doxorubicin Hydrochloride [HCl]|IV; Injection
80000640|NCT05283720|Drug|Prednisone|Oral; Tablet
79827083|NCT00861328|Drug|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
79684130|NCT03457233|Drug|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
79684131|NCT03457233|Drug|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
80000641|NCT05283720|Drug|Polatuzumab Vedotin|IV; Injection
80000642|NCT05283720|Drug|Venetoclax|Oral; Tablet
80000643|NCT05283720|Drug|CC-99282|Oral; Capsule
80000644|NCT05282823|Device|Boston Scientific Cardiac Cryoablation System|is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
80000645|NCT05280132|Procedure|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
80000646|NCT05280132|Other|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
79232512|NCT03204344|Other|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
80000647|NCT05279287|Other|Video and kinematic data recording of minimally invasive surgical procedure|Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
79232513|NCT02285517|Procedure|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
79232514|NCT02285517|Procedure|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
79374161|NCT05240157|Drug|Corticosteroid Derivatives|observational
79374162|NCT03430440|Device|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
79374163|NCT03430440|Device|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
79374164|NCT01920867|Procedure|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
79374165|NCT01920867|Procedure|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
79374166|NCT01920867|Procedure|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
79684132|NCT03457233|Drug|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
79684133|NCT00535808|Drug|nitroprusside|Administration of nitroprusside
79684134|NCT00535808|Drug|nitroglycerine|Administration of nitroglycerine
79684135|NCT00535808|Drug|sevoflurane|Administration of Sevoflurane
79684136|NCT04920903|Drug|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
79684137|NCT04920903|Drug|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
79684138|NCT05471063|Drug|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
80000648|NCT05276297|Drug|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
80000649|NCT05276297|Biological|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
80000650|NCT05276297|Drug|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
80000651|NCT05275998|Drug|TMB-365/TMB-380|Monoclonal antibodies to be given intravenously
80000652|NCT05270382|Other|cetylpyridinium chloride|The mouthwash is used to see the effects on wound healing and the oral microbiome.
80000653|NCT05269394|Drug|E2814|Administered intravenously in a blinded fashion
80000654|NCT05269394|Drug|Lecanemab|Administered intravenously
80000655|NCT05269394|Drug|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
79827084|NCT00861328|Drug|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
79684139|NCT05471063|Drug|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
80000656|NCT05269121|Biological|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
80000657|NCT05266495|Other|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
80000658|NCT05265325|Drug|AND017 TIW|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 4 mg and 2-weeks interval according to Hb levels
79232515|NCT03204578|Drug|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
79374167|NCT01920867|Procedure|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
79374168|NCT01920867|Procedure|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
79374169|NCT03128424|Device|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
79374170|NCT01925937|Drug|Atorvastatin|
79527819|NCT04647513|Device|Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)|The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process. These fillers (also known as soft tissue augmentation medical devices) can correct the skin depressions/wrinkles, balance the disproportions or correct topographical anomalies.
79527820|NCT04645576|Device|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
79527821|NCT04623372|Procedure|suture|suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
79527822|NCT04623372|Procedure|directed wound healing|application of a dry dressing without any prior suture after the skin biopsy.
79527823|NCT04621682|Other|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
79684140|NCT05471063|Drug|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
79684141|NCT04920396|Device|E>Eye IRPL|Regulated intense pulsed light therapy
79684142|NCT04920396|Device|Warm compress|Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
79827085|NCT00722462|Procedure|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
79827086|NCT00722462|Procedure|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
80000659|NCT05265325|Drug|AND017 QW|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg and 2-weeks interval according to Hb levels
79232516|NCT03204578|Drug|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
79232517|NCT02285595|Device|Sonendo GentleWave™ System|
79232518|NCT01694069|Drug|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
79232519|NCT03204500|Combination Product|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
79232520|NCT03204500|Drug|Placebos|Administered orally under the same conditions
79232521|NCT02449616|Drug|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
79232522|NCT02285673|Biological|Umbilical Cord Mesenchymal Stem Cell|
79232523|NCT03204032|Drug|Tegafur|Tegafur 40-60mg po bid(d1-d14);
79527824|NCT04621682|Other|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
79527825|NCT04616846|Diagnostic Test|Peripheral venous ultrasound|Screening for VTE from D7 to 42
80000660|NCT05265325|Drug|epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
80000661|NCT05259735|Combination Product|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
80000662|NCT05259735|Other|Comparator|In this arm usual management of T2DM without any clinical guideline
80000663|NCT05257629|Combination Product|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
80000664|NCT05257629|Other|Varenicline Plus Counseling|Varenicline plus counseling
80000665|NCT05257408|Drug|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
80000666|NCT05257408|Drug|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing.
80000667|NCT05257408|Drug|Nab-paclitaxel 100 mg/m^2|Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
80000668|NCT05241015|Other|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
79374171|NCT01925937|Drug|Coenzyme Q10|
79374172|NCT01925937|Drug|placebo for coenzyme Q10|
79527826|NCT04614597|Biological|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
79374173|NCT03430362|Drug|Hyoscine N Butylbromide|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
79527827|NCT04614142|Drug|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
79527828|NCT04613739|Behavioral|insurance navigation|Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
79527829|NCT04609124|Diagnostic Test|Abdominal ultrasound evaluation of antral area|ultrasound assessment of antral cross sectional area
79527830|NCT04605172|Other|hospitalization for premature birth|Number of inborn and outborn infants prematurely born during a specific period of time
79684143|NCT05471024|Procedure|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
80000669|NCT05241015|Other|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
79374174|NCT03430362|Drug|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
79527831|NCT04604691|Drug|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
79527832|NCT04594525|Other|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
79527833|NCT04580381|Drug|Natalizumab Injection [Tysabri]|Natalizumab infusion interval according to local practice defining the patient's group
79527834|NCT04575792|Behavioral|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
79527835|NCT04575649|Other|Gastrointestinal anomalies|Infants born late preterm (at or above 35 weeks gestation) and term infants admitted to the NICU with congenital gastrointestinal anomalies, including gastroschisis, omphalocele, esophageal and bowel artesias, tracheoesophageal fistulas, Hirschsprung's disease, or congenital diaphragmatic hernias.
79527836|NCT04561154|Other|questionnaire|three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
79684144|NCT05471024|Procedure|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
79684145|NCT05471024|Procedure|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
79684146|NCT04912206|Diagnostic Test|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
79827087|NCT02570880|Other|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
79374175|NCT05240079|Device|Heart rate measurement with Caducy system (twice). SpO2 measurement with Caducy system (Twice).|Heart rate and SpO2 measurement with Caducy (the visage of the subject is filmed 30 seconds and 1 minute with a camera) and heart rate and SpO2 measurement with gold standard (heart rate monitor and oximeter pod linked to an acquisition station). The procedure is repeated twice.
79374176|NCT03430284|Behavioral|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
79684147|NCT05470946|Device|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
79684148|NCT04910100|Drug|Nebivolol Ophthalmic Suspension 1 Percent|1 drop instilled into each eye twice daily
79684149|NCT04910100|Drug|Nebivolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
79684150|NCT04910100|Drug|Timolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
79374177|NCT03430284|Drug|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~GLP-1 receptor agonist~Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
80000670|NCT05237531|Behavioral|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
79374178|NCT03430284|Other|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
80000671|NCT05237531|Behavioral|Standard of care|Education per provider preference (no standardization, current standard of care)
80000672|NCT05237531|Behavioral|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
79374179|NCT03430284|Other|General treatment|General treatment is carried out based on the device from the general practitioners at present.
79374180|NCT03057639|Other|Quality-of-Life Assessment|Ancillary studies
79527837|NCT04561050|Other|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
79527838|NCT04548245|Device|EEG|EEG
79827088|NCT00724646|Other|Survey|3 individual surveys
79527839|NCT04542564|Device|telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
79527840|NCT04542564|Other|usual care|These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
79527841|NCT04537884|Drug|UBX1325|Investigational drug intravitreal injection
79527842|NCT04535349|Diagnostic Test|Whole-body & CZT bone tracer imaging (SPECT)|Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
79684151|NCT04910100|Drug|Timolol Ophthalmic Solution 0.5 Percent|1 drop instilled into each eye twice daily
79232524|NCT03204032|Drug|Temozolomide|200mg po qd(d10-d14)
79232525|NCT03204032|Drug|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
79827089|NCT00724646|Other|Focus group|Focus group discussions facilitated by a psychologist
79684152|NCT01268059|Drug|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
79232526|NCT01445327|Other|Specimen collection|
79232527|NCT02285751|Drug|acetylsalicylic acid|
79684153|NCT01268059|Drug|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
79684154|NCT01268059|Drug|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
79827090|NCT00618514|Device|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
79827091|NCT00618514|Device|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
79232528|NCT02285751|Drug|clopidogrel|
79232529|NCT02285751|Drug|prasugrel|
79232530|NCT02285751|Drug|ticagrelor|
79374181|NCT03057639|Other|Questionnaire Administration|Ancillary studies
79527843|NCT04534686|Behavioral|CogXergaming|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
79827092|NCT04067804|Behavioral|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
79827093|NCT00854542|Behavioral|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
79684155|NCT04901598|Other|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
79684156|NCT00535886|Dietary Supplement|Man-made Trans FA|EA as 6% of total energy
79827094|NCT00722540|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
80000673|NCT05235282|Device|IQoro|An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.
79232531|NCT02446184|Procedure|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
79232532|NCT02446184|Procedure|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
79232533|NCT03532113|Behavioral|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
79374182|NCT03428022|Drug|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
79374183|NCT05076396|Drug|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
79527844|NCT04534686|Behavioral|Matter of Balance Training|The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
79684157|NCT00535886|Dietary Supplement|Natural Trans FA|VA as 6% of total energy
79827095|NCT00722540|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79827096|NCT00722540|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79684158|NCT00535886|Dietary Supplement|Oleic Acid|OA as 6% of total energy
79684159|NCT01267825|Drug|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
79827097|NCT00722540|Drug|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79827098|NCT00722540|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79827099|NCT00722540|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79827100|NCT00722540|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79684160|NCT01267825|Drug|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
79827101|NCT00722540|Drug|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
80000674|NCT05235282|Other|Usual care for swallowing function|Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
80000675|NCT05234112|Behavioral|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
79232534|NCT03532113|Behavioral|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
79374184|NCT00986661|Drug|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
79827102|NCT00722540|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
79827103|NCT00722540|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
79827104|NCT00861406|Drug|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
79232535|NCT03532113|Behavioral|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
79527845|NCT04526925|Device|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
79232536|NCT02449694|Device|OCS Liver|OCS Liver will be used to preserve the donor liver
79232537|NCT02446730|Device|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
79527846|NCT04526925|Other|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
79527847|NCT04496245|Drug|Broncho-Vaxom®|Broncho-Vaxom adult capsules® (OM85)
80000676|NCT05234112|Diagnostic Test|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
79527848|NCT04492410|Other|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
79684161|NCT02889406|Behavioral|Motivational intervention|motivational interviewing schema
79684162|NCT00593242|Biological|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
79684163|NCT00593242|Other|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
79684164|NCT05470829|Drug|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28"
80000677|NCT05234112|Behavioral|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
79374185|NCT03128112|Other|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
79374186|NCT00989781|Radiation|3-D Ultrasound|One time pelvic ultrasound
79684165|NCT05470829|Other|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28"
80000678|NCT05234112|Diagnostic Test|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
80000679|NCT05234112|Procedure|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
79232538|NCT02446730|Drug|Prasugel|
79232539|NCT02446730|Drug|Clopidogrel|
79374187|NCT00989781|Drug|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
79527849|NCT04476745|Dietary Supplement|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
79527850|NCT04471545|Procedure|Pectoral nerve block type II|A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided
79684166|NCT00593281|Drug|Hylenex|Add Hylenex to SC injection of Morphine
80000680|NCT05234112|Diagnostic Test|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
80000681|NCT05233098|Device|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
79232540|NCT03198806|Other|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
79232541|NCT03198806|Other|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
79374188|NCT00989781|Drug|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
79527851|NCT04469140|Device|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
79527852|NCT04468971|Biological|CK0802|Cryopreserved, off the shelf, cord blood derived T regulatory cells
79527853|NCT04468971|Drug|Placebo|Expicient
79527854|NCT04466449|Diagnostic Test|stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba
80000682|NCT05221580|Drug|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
79827105|NCT00861406|Drug|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
79827106|NCT00861484|Drug|GSK958108|Coated Tablets 1 mg
79374189|NCT00989781|Drug|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
79827107|NCT00861484|Drug|Placebo|Coated tablets
79827108|NCT04018742|Other|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
79684167|NCT04327102|Behavioral|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
79684168|NCT00536003|Drug|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
79684169|NCT00536003|Drug|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
79827109|NCT00865384|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
79684170|NCT00593476|Other|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
79827110|NCT00865384|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
79827111|NCT00724724|Drug|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
79827112|NCT00724724|Drug|Aspirin|Aspirin 100mg Qd for 1 year
79684171|NCT00593476|Other|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
79684172|NCT00593515|Behavioral|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
79684173|NCT00593515|Behavioral|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
79684174|NCT00533091|Biological|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
79684175|NCT00533091|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
79684176|NCT00536042|Drug|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
79684177|NCT01606384|Drug|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
79684178|NCT01606384|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
79684179|NCT01606423|Drug|Placebo|Administered orally, single dose
80000683|NCT05218967|Other|Virtual Reality Headset|A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
80000684|NCT05207813|Device|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
79374190|NCT00989781|Drug|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
79684180|NCT01606423|Drug|LY2409021|Administered orally, single dose
79684181|NCT01606462|Drug|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
79684182|NCT00533130|Procedure|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
79684183|NCT00533130|Procedure|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
79684184|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
79684185|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
79684186|NCT01606579|Drug|PRI-724|PRI-724
79684187|NCT01606579|Drug|PRI-724|PRI-724 in combination with dasatinib
79684188|NCT01606579|Drug|PRI-724|PRI-724 in combination with low dose ara-C therapy
79827113|NCT00865462|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
79827114|NCT00865462|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
79827115|NCT04130204|Drug|DYV700|Proprietary transdermal delivery platform
79827116|NCT04130204|Drug|Placebo|Vehicle transdermal delivery platform
79827117|NCT04130204|Drug|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
79827118|NCT00723918|Drug|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
79827119|NCT00723918|Drug|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
79827120|NCT00723918|Drug|SAB placebo|an inactive substance
79827121|NCT00723918|Drug|Methadone placebo|Methadone placebo
79827122|NCT00722618|Behavioral|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
79827123|NCT00722618|Other|Written materials|2 written materials available on public website
79827124|NCT05373888|Device|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~Closed (flat and convex)~Drainable with Roll'Up (flat and convex)~High flow with tape outlet (flat)"
79684189|NCT00533169|Drug|ZD6474|Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.
79684190|NCT00533169|Drug|Retinoic Acid|Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
79374191|NCT00989781|Drug|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
79374192|NCT01292746|Device|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
79684191|NCT01606696|Behavioral|HIIT|Higher intensity interval training.
79232542|NCT03198806|Other|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
79232543|NCT03198806|Other|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
79232544|NCT03194828|Behavioral|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
79232545|NCT03194828|Behavioral|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
79232546|NCT05114915|Drug|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion
79374193|NCT03430128|Dietary Supplement|IMPACT immunotherapy|Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.
79374194|NCT03430128|Dietary Supplement|ENSURE|Liquid milk formula available over the counter
79374195|NCT03427944|Drug|Calcium Dobesilate group|Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
79374196|NCT03427944|Drug|Conventional Treatment group|Conventional treatment were used to treat patients with chronic renal failure.
79374197|NCT03050463|Procedure|Biospecimen Collection|Undergo blood and saliva sample collection
79374198|NCT03050463|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
79374199|NCT03050463|Other|Questionnaire Administration|Ancillary studies
79374200|NCT01922193|Drug|Highly Purified Urofollitropin|for injection
79527855|NCT04458805|Drug|NX-13 250 mg|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
79684192|NCT01606696|Behavioral|Standard intensity non-interval training|Standard intensity non-interval training.
79684193|NCT00593632|Dietary Supplement|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
79232547|NCT03532035|Drug|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
79232548|NCT03532035|Drug|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
79374201|NCT01922193|Drug|Recombinant Human Follitropin Alfa|for injection
79374202|NCT03427788|Drug|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
79374203|NCT03427788|Drug|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
79374204|NCT03429972|Device|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
79374205|NCT03429972|Drug|Paclitaxel|80mg/m^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
79374206|NCT05601999|Biological|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
79374207|NCT05601999|Biological|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
79374208|NCT03423576|Behavioral|comprehensive patient-centered outpatient health service with multiple components|Individualized multi-component education and counselling program coordinated by a case Manager.
79684194|NCT00533208|Drug|MK0524|
79684195|NCT00593671|Procedure|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
79684196|NCT02892721|Other|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
79684197|NCT00593710|Drug|Losartan|Losartan (25mg OD)
79684198|NCT00593710|Drug|Atenolol|Atenolol (25-50mg OD)
79684199|NCT04885686|Device|Endomethasone N RCS|Root canal sealer
79684200|NCT04885686|Device|Endomethasone SP RCS|Root canal sealer
79684201|NCT00593749|Behavioral|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
79684202|NCT00593749|Behavioral|Control|control group in study
79374209|NCT01347034|Procedure|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
79374210|NCT01347034|Biological|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
79374211|NCT03423498|Other|toe-spread-out exercise|The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
79374212|NCT04351282|Radiation|SBRT|SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
79232549|NCT04950257|Device|digital CBT self-help including specific intervention elements to target worry and rumination.|The self-help app includes self-monitoring, psychoeducation and active self-help exercises. The self-monitoring includes daily mood ratings and an ecological momentary assessment option (MoodTracker) for more detailed analysis of mood, worry, activity and situational context. The digital self-help provides psychoeducation, tips, advice, exercises and training for each individual focused on reducing worry and rumination, using strategies from the proven rumination-focused CBT intervention. The app includes text, pictures, audio-recordings, animations, audio-exercises to practice (e.g., self-compassion, relaxation, concreteness exercises), and questionnaires with tailored feedback. The app is designed for iOS and Android use.
79232550|NCT03531801|Other|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
79232551|NCT03198182|Drug|Placebo|Specified dose on specified days
79232552|NCT03198182|Drug|BMS-986036|Specified dose on specified days
79374213|NCT03427710|Drug|CiVi007|cholesterol lowering drug
79374214|NCT03427710|Other|Placebo|matching placebo to CiVi007
79374215|NCT01349140|Drug|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
79684203|NCT00536081|Drug|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
79684204|NCT02892643|Procedure|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
79684205|NCT02892643|Procedure|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
79684206|NCT00593944|Biological|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
79527856|NCT04458805|Drug|Placebo|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
79527857|NCT04458753|Other|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
79527858|NCT04458753|Other|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
79527859|NCT04458441|Other|warm group/cold group|sequential randomization
79527860|NCT04450888|Other|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
79684207|NCT00536159|Other|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
79827125|NCT00865540|Drug|prednisolone acetate 1%|1 drop every 8h two days before surgery
79527861|NCT04445207|Biological|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
79527862|NCT04433390|Drug|Naloxegol|one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
79527863|NCT04433390|Drug|inert tablet|one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
79827126|NCT00865540|Drug|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
79684208|NCT00536159|Other|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
79684209|NCT00594139|Biological|Autologous neobladder construct|provision of an autologous neo-bladder construct
79827127|NCT00865540|Drug|nepafenac 0.1%|1 drop every 8h two days before surgery
79827128|NCT00865540|Drug|methylcellulose 0.5%|1 drop every 8h two days before surgery
79232553|NCT03531723|Other|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
79232554|NCT05037071|Device|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
79232555|NCT03203798|Procedure|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
79232556|NCT03203798|Procedure|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
79527864|NCT04432272|Biological|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
79527865|NCT04408222|Other|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
79527866|NCT04407806|Device|Continous Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization
79527867|NCT04407806|Device|Intermittent Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
79527868|NCT04399746|Drug|Ivermectin|6mg once daily in day 0,1,7 and 8
79527869|NCT04399746|Drug|Azithromycin|500mg once daily for 4 days
79527870|NCT04399746|Drug|Cholecalciferol|400 IU twice daily for 30 days
79684210|NCT04882449|Device|Bodyport Scale|The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
79827129|NCT00723996|Behavioral|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
79827130|NCT04066556|Other|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~Cut-off values in areas of irreversible changes according to non-contrast CT images~Cut-off values in occlusion sites and collateral scores according to CT angiographies~Cut-off values of consolidated CT imaging index including clot, core, and collateral score~Cut-off values of comorbidity index~Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
79827131|NCT00865618|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
79684211|NCT00594217|Drug|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
79684212|NCT00594217|Other|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
79827132|NCT00865618|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
79827133|NCT02570594|Other|questionary|
79827134|NCT00722280|Procedure|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
79232557|NCT05724927|Behavioral|Animal assisted activity|The interviews consist of a total of six interviews, including an introduction, four studies, and a termination. Interviews will be held individually in each person's own room in the nursing home. Materials such as plastic aquarium, fish, fish food, fish food scales that will be given to the individuals during the interviews will be taken to the institution by the researchers before and will be given to the elderly individuals in the second interview.
79374216|NCT05248113|Device|Electrical stimulation of cochlear nerve|Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
79527871|NCT04391608|Drug|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
79527872|NCT04383756|Biological|Donor Blood|Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
79527873|NCT04383756|Biological|Banked Blood|Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
79527874|NCT04368299|Other|Telemedicine|Videoconferencing for follow-up
79527875|NCT04368299|Other|Standard care|Standard in-person outpatient follow-up
79527876|NCT04368091|Device|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
79527877|NCT04362436|Radiation|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
79684213|NCT01606774|Other|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
79684214|NCT00536237|Drug|Comparator: niacin / Duration of Treatment: 17 Weeks|
79684215|NCT00536237|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
79684216|NCT00536237|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
79684217|NCT01606813|Other|Usual Care|Standard care
79684218|NCT01606813|Behavioral|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
79684219|NCT01606813|Behavioral|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
79374217|NCT03079167|Drug|Epoetin Alfa|
79684220|NCT01606813|Behavioral|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
80000685|NCT05205577|Device|Tens Eco Plus|30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
79232558|NCT02446340|Drug|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
79374218|NCT03079167|Drug|Normal saline|
79232559|NCT02446340|Drug|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
79232560|NCT04669379|Behavioral|EXPECT: Preoperative optimization of patient's expectations|Patients work through an online-tool (around 30 minutes). This preoperative intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the surgery-benefits and recovery process, giving information, and giving advice for coping resources.
79232561|NCT03531567|Behavioral|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
79374219|NCT04449900|Other|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
79374220|NCT03427632|Drug|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
79374221|NCT03427554|Drug|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
79374222|NCT03427554|Drug|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
79527879|NCT04331379|Device|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
79527880|NCT04331379|Device|Taping Alone|Horizontal tape alone.
79527881|NCT04329715|Behavioral|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
79527882|NCT04329715|Behavioral|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
79684221|NCT04874376|Device|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
79684222|NCT00533247|Drug|Celecoxib|
80000686|NCT05204329|Biological|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
79374223|NCT03427554|Drug|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
79374224|NCT03128190|Other|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
79527883|NCT04328090|Other|Computer based Antimicrobial stewardship (AMS) intervention system|"Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~Re-evaluation alerts and decision support for the choice of antimicrobial.~Quality control audit and feedback."
79684223|NCT01260181|Drug|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
79684224|NCT00536276|Dietary Supplement|Vitamin D2|Daily enteral dose of 100IU/kg
79684225|NCT00536276|Dietary Supplement|Vitamin D3|Daily enteral dose of 100IU/kg
79684226|NCT02892565|Other|Blood sample|
79684227|NCT00594373|Drug|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
79527884|NCT04325919|Other|No intervention|No intervention
79527885|NCT04324021|Biological|Emapalumab|I.v. infusion every third day
79827135|NCT00655629|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
80000687|NCT05201495|Device|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
79232562|NCT03531567|Behavioral|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
79527886|NCT04324021|Biological|Anakinra|Daily i.v. infusion
79232563|NCT04797065|Procedure|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes."
79374225|NCT01349920|Drug|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
79374226|NCT03128346|Procedure|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
79527887|NCT04322487|Diagnostic Test|Lung ultrasound|A proposal of a standardized approach in order to optimize the use of lung ultrasound in COVID-19 patients. We focus on equipment, procedure, classification and data-sharing.
79374227|NCT03128346|Drug|Hydromorphone Hydrochloride|IV, Hydromorphone
79527888|NCT04320797|Diagnostic Test|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
79527889|NCT04318821|Procedure|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
79527890|NCT04318808|Procedure|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
79527891|NCT04311437|Procedure|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
79527892|NCT04311437|Procedure|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
79527893|NCT04310956|Device|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
79527894|NCT04310956|Device|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
79527895|NCT04309513|Behavioral|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.
79527896|NCT04309513|Behavioral|Step Counter to motivate physical activity|Step Counter to motivate physical activity
79527897|NCT04300738|Device|CCS wit CT Scann measurement|Measurement with 2 devices
79527898|NCT04265365|Device|rTMS+rPMS_iTBS_R|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79527899|NCT04265365|Device|rTMS+rPMS_cTBS_R|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79684228|NCT00594373|Drug|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
79684229|NCT00594412|Procedure|Diagnostic Radiology: 1H-MRS of the liver|
79684230|NCT02892799|Other|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
79684231|NCT02892799|Other|Standard of Care|
79684232|NCT05470166|Drug|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
79684233|NCT05470166|Other|saline IV|saline infusion same volume as lidocaine
79684234|NCT00594529|Procedure|Surgery|Liver resection for metastatic liver lesions
79684235|NCT05470127|Device|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
79684236|NCT05470049|Drug|SHR8554 Injection and SHR0410 Injection|Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
79684237|NCT05470049|Drug|SHR8554 Injection and SHR0410 Injection|Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
79827136|NCT00655629|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
79374228|NCT03128346|Drug|Aspirin|Oral Aspirin
79374229|NCT03128346|Drug|Acetaminophen|Oral acetaminophen
79374230|NCT03128346|Drug|Fentanyl|IV, fentanyl
79684238|NCT05470049|Drug|SHR8554 Injection and Placebo for SHR0410 Injection|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
79684239|NCT02412579|Other|None - Standard of Care|
79232564|NCT04797065|Procedure|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes."
79684240|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
79232565|NCT03531489|Device|AIR-AD|Non-significant risk medical device as decided by institutional review board
79232566|NCT02712398|Device|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
79232567|NCT05222945|Other|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
79232568|NCT02288013|Procedure|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
79374231|NCT03423108|Behavioral|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
79374232|NCT03423108|Behavioral|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
79374233|NCT02521116|Other|Dynamic Vessel Analyzer|
79374234|NCT02521116|Other|Oxymap T1|
79527900|NCT04265365|Device|rTMS +sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at radial nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79827137|NCT00865696|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
79827138|NCT00865696|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
79827139|NCT00724802|Dietary Supplement|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
79374235|NCT03427476|Drug|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
79374236|NCT03423030|Drug|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
79527901|NCT04265365|Device|rTMS+rPMS_iTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79527902|NCT04265365|Device|rTMS+rPMS_cTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79827140|NCT00724802|Drug|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
80000688|NCT05192798|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
80000689|NCT05192798|Drug|Apatinib Mesylate|Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
79374237|NCT03423030|Drug|Placebo|matching placebo supplied as powder for oral solution
79374238|NCT03423030|Drug|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
79374239|NCT03427242|Drug|Apatinib|oral apatinib 750mg qd
79684241|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
79684242|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
79684243|NCT01259869|Drug|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
79827141|NCT05373732|Behavioral|meditation|meditation practice 20 minutes twice a day at home and attending classes at the clinic.
80000690|NCT05192798|Drug|Bevacizumab|Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
79374240|NCT01252732|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
79374241|NCT01252732|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
79374242|NCT02854644|Other|additional blood sample|
79374243|NCT00989235|Drug|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
79374244|NCT00989235|Drug|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
79527903|NCT04265365|Device|sham-rTMS+sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve/nervus ulnaris on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
79232569|NCT05222867|Procedure|lower back massage|Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
79232570|NCT00282867|Drug|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
79684244|NCT05469932|Device|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
79684245|NCT00594607|Device|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
79232571|NCT00282867|Other|standard care|usual care
79232572|NCT03203720|Behavioral|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
79232573|NCT05222711|Device|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
79232574|NCT03198338|Drug|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
79232575|NCT03198338|Drug|Normal Saline|0.9% Normal Saline
79232576|NCT03198338|Device|Ultrasound|Ultrasound guided TAP block
79374245|NCT06154122|Device|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
79374246|NCT06154122|Other|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
79374247|NCT06154109|Drug|Xiaopi granules|Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
79374248|NCT06154109|Drug|Xiaopi decoction|Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
79374249|NCT06154109|Drug|Placebo|The placebo does not contain any active pharmaceutical ingredients .
79684246|NCT00594607|Device|Fx8 (Fresenius)|Polysulphone dialysis membrane
79684247|NCT05469776|Procedure|bicruciate-retaining total knee arthroplasty|
79684248|NCT05469776|Procedure|posterior-stabilized total knee arthroplasty|
79232577|NCT05222633|Drug|Ranibizumab|Ranibizumab 0.5mg/0.05ml intravitreal injection
79232578|NCT05222633|Drug|Aflibercept|Aflibercept 2.0mg/0.05ml intravitreal injection
79527904|NCT04265365|Device|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
79232579|NCT05222633|Drug|Conbercept|Conbercept 0.5mg/0.05ml intravitreal injection
79232580|NCT03198260|Other|Fascial manipulation|Deep frictional massage
79527905|NCT04265365|Device|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
79527906|NCT04261153|Other|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
79684249|NCT05469659|Drug|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
79684250|NCT05469659|Drug|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
79684251|NCT04686006|Drug|Potassium Iodide|
79684252|NCT05469620|Dietary Supplement|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
80000691|NCT05191706|Drug|Dexamethasone|single anterior chamber injection
79232581|NCT03198104|Device|MRI|
79232582|NCT05222243|Drug|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
79232583|NCT05222243|Drug|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
79232584|NCT05222243|Drug|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
79232585|NCT03203252|Other|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
79232586|NCT03203252|Other|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
79374250|NCT06154096|Other|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
79374251|NCT06154070|Drug|DaxibotulinumtoxinA|"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
79232587|NCT03203252|Other|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
79232588|NCT04469283|Other|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
79374252|NCT06154044|Biological|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
79374253|NCT06154031|Behavioral|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
79374254|NCT06154018|Drug|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
79527907|NCT04260945|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
79684253|NCT05469620|Other|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
79684254|NCT00535704|Behavioral|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
79684255|NCT00535704|Behavioral|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
79684256|NCT05469542|Device|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
79684257|NCT01808820|Biological|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
79684258|NCT01808820|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
79684259|NCT01808820|Drug|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
79684260|NCT01808820|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
79232589|NCT02285829|Drug|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
79232590|NCT03203408|Device|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
79684261|NCT05469386|Drug|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
79684262|NCT05469386|Behavioral|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
79684263|NCT05469386|Drug|Placebo|Placebo capsule
79684264|NCT05469386|Behavioral|General Classroom|General education classroom procedures
79684265|NCT05469386|Behavioral|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
80000692|NCT05191706|Drug|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
79232591|NCT03203408|Device|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
79232592|NCT02285985|Drug|Saxagliptin|Tablets: 5 mg
79232593|NCT02285985|Drug|Placebo|Tablets: 5mg
79232594|NCT02445950|Behavioral|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
79232595|NCT02445950|Behavioral|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
79374255|NCT06153992|Device|Intelligent portable isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using intelligent portable isokinetic muscle strength test training system
79374256|NCT06153992|Device|isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using isokinetic muscle strength test training system
79527908|NCT04260932|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
79527909|NCT04246008|Other|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
79232596|NCT05222009|Drug|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
79684266|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
79684267|NCT01462890|Drug|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
79684268|NCT01462890|Drug|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
79684269|NCT01462890|Other|specialized pathology review (Germany only)|before randomization
79684270|NCT05469152|Diagnostic Test|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
79232597|NCT05222009|Drug|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
79232598|NCT02445872|Drug|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
79374257|NCT06153992|Other|without test training|Treatment was performed without using any isokinetic muscle strength test training system
79374258|NCT06153979|Biological|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
79684271|NCT05469113|Drug|Repaglinide|Administered orally.
79374259|NCT06153953|Device|vacuum device|use of vacuum device in dressing of diabetic wounds
79684272|NCT05469113|Drug|Selpercatinib|Administered orally.
79374260|NCT06153953|Other|conventional dressing therapy|us of conventional dressing with betadine and iruxol in diabetic wounds
79684273|NCT01259713|Drug|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
79684274|NCT01259713|Drug|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
79527910|NCT04246008|Other|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
79684275|NCT00594724|Procedure|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
79527911|NCT04245644|Behavioral|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
79527912|NCT04238845|Drug|AQSP Administration|Three days treatment of all children with AQSP for SMC
79527913|NCT04238845|Dietary Supplement|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
79684276|NCT00622882|Other|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
79684277|NCT01052727|Procedure|Laparoscopic Cholecystectomy|
80000693|NCT05183867|Device|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
80000694|NCT05183763|Behavioral|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
79232599|NCT02445872|Drug|Palonosetron|
79232600|NCT02445872|Drug|Dexamethasone|
79232601|NCT02286063|Drug|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
79527914|NCT04238845|Dietary Supplement|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
79527915|NCT04238845|Dietary Supplement|Supplementation with Zinc|Daily supplementation with Zinc
79684278|NCT00622921|Behavioral|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
79684279|NCT05469035|Other|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
79684280|NCT05469035|Other|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
79684281|NCT02892526|Other|Abdominoplasty with exeresis of cutaneous tissue|
79684282|NCT02892526|Other|Collection of cutaneous tissue|
79684283|NCT01259401|Behavioral|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
79684284|NCT01259401|Behavioral|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
79684285|NCT05471466|Procedure|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
79827142|NCT05373732|Behavioral|Health education control|didactic based classes in CVD risk factor reduction and prevention
79827143|NCT02545114|Drug|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
80000695|NCT05183763|Behavioral|Medication reminder tools|Medication-taking reminder app and pillbox
79684286|NCT00594841|Procedure|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~Anatomic reduction of the AC joint~Definitive fixation with a hook plate and screws"
79374261|NCT06153940|Device|Treatment|"The Everglade™ Stem, is a second generation cementless blade style hip stem Forged in Titanium and proximally Antero-Posterior (AP) flared with Titanium Plasma Spray + Hydroxyapatite (TPS + HA) coated for bone on-growth.~The stem has distal geometry and a polished anodized surface finish to minimize the stem hanging in Dorr A femurs.~The World Acetabular Cup is a porous coated and mated with the Cross-linked polyethylene World Liner"
79374262|NCT06153927|Diagnostic Test|CT-FFR|CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
79684287|NCT00594841|Other|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
79684288|NCT05468879|Drug|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
79684289|NCT05468879|Drug|Amaryl®|Amaryl®
79684290|NCT05471427|Drug|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
79684291|NCT04130074|Device|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
79684292|NCT00536354|Other|Postural Orientation|
79684293|NCT04320433|Diagnostic Test|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
79684294|NCT05471388|Diagnostic Test|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
79374263|NCT06153914|Procedure|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
79684295|NCT05558449|Device|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
79684296|NCT05558449|Drug|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
79684297|NCT05558449|Device|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
79527916|NCT04232202|Device|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
79684298|NCT04326907|Procedure|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
79684299|NCT05468801|Other|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
79684300|NCT05468801|Other|Placebo|Placebo plus Standard Pharmacologic Treatment
79684301|NCT04326946|Device|Alfapump|alfapump implementation
79684302|NCT04326985|Biological|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
79232602|NCT02446106|Dietary Supplement|Soup with MSG|0.5% MSG + 0.48% salt
79232603|NCT02446106|Dietary Supplement|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
79232604|NCT02288169|Behavioral|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
79527917|NCT04232202|Procedure|Standard extraction|Standard extraction procedure
79527918|NCT04228822|Other|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
79527919|NCT04223037|Biological|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
79527920|NCT04223037|Biological|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
79527921|NCT04213365|Other|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
79527922|NCT04211753|Behavioral|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
79527923|NCT04211753|Device|Mobile app|Medical device for crisis intervention
79684303|NCT04326985|Drug|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
79684304|NCT00536393|Drug|Doxorubicin|
79684305|NCT00536393|Drug|Doxorubicin pegylated|
79684306|NCT00595387|Other|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
79827144|NCT00722696|Other|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
80000696|NCT05180097|Drug|Gemcitabine|1000mg/m2 IV, 30 mins D1, D8
80000697|NCT05180097|Drug|Dexamethasone|40mg daily PO, D1-D4
79232605|NCT02288169|Behavioral|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
79374264|NCT06153901|Procedure|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
79374265|NCT06153862|Diagnostic Test|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
79374266|NCT06153849|Diagnostic Test|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
79374267|NCT06153823|Other|virtual reality glasses|child behavior management will be done by using VR glasses distraction
79374268|NCT06153823|Other|Tell Show and Do|child behavior management will be done by using tell show and do technique
79374269|NCT06153784|Drug|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
79374270|NCT06153771|Other|Collection of brain and kidney NIRS measurements|(recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed
79374271|NCT06153771|Other|echocardiography|on day 2, day 4 and day 7 of life
79374272|NCT06153745|Device|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, CA USA)|pediatric cataract surgery
79374273|NCT06153706|Drug|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
79374274|NCT06153706|Other|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
79374275|NCT06153680|Device|Insoles|"Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14."
79374276|NCT06153667|Device|Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.
79374277|NCT06153641|Other|N/A-Observational Study|N/A-Observational Study
79374278|NCT06153628|Other|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
79374279|NCT06153615|Other|EEG (64 electrodes)|EEG recording while awake, at rest then during an attentional cognitive test
79374280|NCT06153615|Other|Cognitive task (SART)|Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)
79374281|NCT06153615|Other|Pupillometry and eye tracking|Study of pupil size and gaze path during the cognitive test (correlated with alertness)
79374282|NCT06153615|Other|Thoracoabdominal belts|Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
79374283|NCT06153602|Drug|Nalbuphine Hydrochloride 10 MG/ML|Nalbuphine(10mg/ml) 0.08 ml intrathecal
79374284|NCT06153602|Drug|Sodium Chloride 0.9 % in 5 ML Injection|0.9% Sodium Chloride 0.08 ml intrathecal
79527924|NCT04210661|Other|prediction software with spell checker|test with prediction software with spell checker
79527925|NCT04209621|Drug|Duvelisib|twice daily as tolerated until disease progression
79527926|NCT04209621|Drug|Ibrutinib|daily for the first six 28-day cycles
79527927|NCT04207983|Combination Product|EYS606|EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
79527928|NCT04205175|Drug|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
79527929|NCT04186663|Drug|Silver Diamine Fluoride|38% aqueous silver diamine fluoride [Ag(NH3)]2F, CAS RN 33040-28-7
79527930|NCT04180267|Device|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
79527931|NCT04179734|Drug|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
80000698|NCT05180097|Drug|Cisplatin|75mg/m2 IV, 1 hour, D1
80000699|NCT05180097|Drug|Brentuximab vedotin|1.8 mg/kg IV, 30 mins, Q21 days
80000700|NCT05180097|Drug|Pembrolizumab|200mg IV, 30 mins, Q 21 days
80000701|NCT05178043|Drug|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
80000702|NCT05178043|Drug|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
80000703|NCT05172999|Device|levonorgestrel-releasing intrauterine system|Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
80000704|NCT05172999|Drug|Polyethylene Glycol Loxenatide|Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
79527932|NCT04179734|Drug|Placebo|Placebo subcutaenous injection.
79684307|NCT00595387|Other|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
79827145|NCT02570568|Device|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
79827146|NCT02570568|Device|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
79827147|NCT02570568|Procedure|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
79827148|NCT00861562|Drug|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
79684308|NCT00595543|Drug|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
79374285|NCT06153589|Other|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
80000705|NCT05172245|Procedure|Biopsy|Undergo tumor biopsy
79374286|NCT06153524|Behavioral|Physical activity|12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.
79684309|NCT00595543|Drug|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
79827149|NCT00861562|Drug|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
79827150|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
80000706|NCT05172245|Procedure|Biospecimen Collection|Undergo blood sample collection
80000707|NCT05172245|Drug|Cisplatin|Given IV
80000708|NCT05172245|Procedure|Computed Tomography|Undergo CT or PET/CT
80000709|NCT05172245|Drug|Ipatasertib|Given PO
79374287|NCT06153524|Behavioral|Smartphone time|12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
80000710|NCT05172245|Procedure|Magnetic Resonance Imaging|Undergo MRI
80000711|NCT05172245|Procedure|Positron Emission Tomography|Undergo PET/CT
80000712|NCT05172245|Radiation|Radiation Therapy|Undergo radiation therapy
80000713|NCT05167903|Other|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
79527933|NCT04176302|Device|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
79527934|NCT04176302|Diagnostic Test|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
80000714|NCT05167903|Behavioral|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
80000715|NCT05163808|Drug|zatolmilast|Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
79527935|NCT04176302|Other|Traditional clinical practice|The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
79684310|NCT00595543|Drug|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
79684311|NCT05519098|Device|COLO-SW-1|Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
79684312|NCT00595660|Procedure|FNA - fine needle aspiration|Fine Needle aspiration
79684313|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
79684314|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
79827151|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
79827152|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
79827153|NCT02571348|Procedure|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
79827154|NCT00854698|Other|exercise training|subjects are asked to exercise 20 or 30 minutes.
79827155|NCT00854698|Other|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
79827156|NCT00804453|Device|Cartridge blood set|Once a week
79827157|NCT00804453|Device|Standard blood line|Once a week
80000716|NCT05163808|Drug|Placebo|Placebo
80000717|NCT05155293|Drug|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
80000718|NCT05155293|Drug|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
80000719|NCT05144555|Other|Fixed orthodontic treatment with stainless steel brackets|"Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
79527936|NCT04158219|Behavioral|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
79684315|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
79684316|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
79684317|NCT05504746|Drug|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
79684318|NCT05504746|Drug|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
79684319|NCT05504746|Drug|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
79527937|NCT04156217|Biological|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
79527938|NCT04155853|Procedure|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
79527939|NCT04155853|Procedure|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
79684320|NCT05504746|Drug|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
79684321|NCT02892370|Drug|SHR0302|SHR0302 tablets (10 mg)
79684322|NCT04326868|Drug|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
79684323|NCT05468762|Procedure|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
79684324|NCT00595738|Other|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
79232606|NCT03203486|Other|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
79684325|NCT00595777|Behavioral|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
79684326|NCT00595816|Other|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
79232607|NCT05724537|Procedure|Quadrangular resection and annular plication|Mitral regurgitation is treated removing the redundant tissue of the posterior leaflet, which is then reconstructed by sutures and plicating the posterior annulus
79827158|NCT00724074|Device|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
79827159|NCT00724074|Device|Usual Care|Usual Care
79827160|NCT00854776|Drug|lansoprazole|30 mg once daily
79827161|NCT00854776|Drug|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
79232608|NCT05221775|Drug|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
79684327|NCT05468723|Device|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses [which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
79827162|NCT00798525|Drug|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of > 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
79684328|NCT00595855|Procedure|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
79684329|NCT00595855|Procedure|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
79684330|NCT00595972|Drug|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
79827163|NCT00798525|Drug|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine < 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
80000720|NCT05144555|Other|Fixed orthodontic treatment with ceramic brackets|"Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
80000721|NCT05141006|Drug|BOTOX|Injection into the bladder
80000722|NCT05141006|Drug|Placebo for BOTOX|Injection into the bladder
79232609|NCT02288403|Behavioral|Aerobic interval training|
79232610|NCT02288403|Behavioral|Continuous training|
79232611|NCT03197792|Other|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
79232612|NCT05221541|Procedure|vibration|whole-body vibration and soleus tendon vibration will be applied to participants
79374288|NCT06153511|Procedure|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
80000723|NCT05133128|Other|blood samples|blood samples
79527940|NCT04155437|Behavioral|Health Facility Level Interventions|"Intensified counseling on maternal dietary diversity and quality using job aids~Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~Distribution/prescription of IFA tablets at each ANC visit~Use of pill card/reminders for pregnant women and their spouses~Monthly IFA tablet stock monitoring to assure sufficient supplies~Measurement of weight gain during each ANC visit and advise on healthy weight gain~Checks for functioning scales and use of monitoring sheets~Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~Reminder on importance of early ANC attendance and 4+ visits"
79684331|NCT00596050|Drug|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
79684332|NCT00596050|Drug|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
79827164|NCT02571374|Dietary Supplement|symbiotic group|this group received sachets of symbiotic
79827165|NCT02571374|Dietary Supplement|placebo group|this group received placebo
79232613|NCT05724459|Other|Peer education|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
79827166|NCT00861640|Drug|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
79827167|NCT00861640|Drug|Oral Rabeprazole|Oral Rabeprazole 1 bid
79827168|NCT00724230|Drug|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
80000724|NCT05132842|Other|Survey Administration|Complete a Survey
80000725|NCT05126277|Drug|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
79374289|NCT06153472|Device|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
80000726|NCT05126277|Drug|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
80000727|NCT05126277|Drug|placebo s.c.|placebo s.c. q4w in addition to SoC
79527941|NCT04155437|Behavioral|Community Level Interventions|"Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~Early identification of pregnant women~Support women's group discussions~2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
79684333|NCT05468684|Other|no intervention|there are no interventions planned, we observe the patients in a cohort study which is named inception cohort study because we test participants before the condition develops.
79684334|NCT02888899|Behavioral|Biofeedback|
79527942|NCT04155437|Behavioral|Health System Level Interventions|"Training on nutrition interventions during ANC for all ANC providers and community health workers~Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~Quarterly supportive supervision of health facility staff by the health district management team~Monthly supportive supervision of ASBCs~Monthly review between health facilities and ASBCs~Training and use of data registers~Training and use of mother's cards to record up to 8 ANC visits and nutrition services~Training on data utilization to improve coverage and quality"
80000728|NCT05124821|Device|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
80000729|NCT05112198|Device|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
80000730|NCT05111626|Drug|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
80000731|NCT05111626|Drug|Nivolumab|Nivolumab will be administered as IV infusion.
79232614|NCT02445560|Dietary Supplement|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
79374290|NCT06153433|Drug|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
79374291|NCT06153433|Drug|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
79374292|NCT06153342|Drug|TL-925|TL-925 is an eye drop.
79374293|NCT06153342|Drug|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
79374294|NCT06153329|Drug|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
79684335|NCT02888899|Drug|Loperamide|
79232615|NCT02445560|Dietary Supplement|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
79374295|NCT06153329|Drug|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
79374296|NCT06153329|Drug|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
79374297|NCT06153316|Other|School shooting incident|The school has experienced a gun shooting incident within the past 2 years of the study (for 3 case schools) and prior to 2 years (for 3 case schools). Incidents where a gun was displayed but no shot was fired, or where a shot was fired by police or security officer will not be included.
79374298|NCT06153238|Drug|GME751|400 mg Q6W, i.v. infusion, over 24 weeks period
79374299|NCT06153238|Drug|Keytruda - EU|400 mg Q6W, i.v. infusion, over 24 weeks period
79527943|NCT04154423|Other|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
79684336|NCT02888899|Drug|Stool bulking agent (sterculia or ispaghula husk)|
79684337|NCT02888899|Other|PTNS|
79684338|NCT05470959|Other|ACTIVA bioactive|bioactive ionic resin composite
79684339|NCT05470959|Other|Riva LC|resin-modified glass ionomer
79684340|NCT00624091|Procedure|Cardiac surgery|Cardiac surgery within 48 hours of randomization
79684341|NCT00624091|Procedure|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
80000732|NCT05111626|Drug|Chemotherapy|"mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally."
80000733|NCT05111626|Other|Placebo|Placebo will be administered as IV infusion.
80000734|NCT05104463|Drug|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
80000735|NCT05102682|Other|Balance exercise program using exoskeleton device|Exercise program focused on strengthening core body muscles and balance supported by Rex exoskeleton device
80000736|NCT05099003|Procedure|Biopsy|Undergo a biopsy
80000737|NCT05099003|Procedure|Magnetic Resonance Imaging|Undergo a MRI
80000738|NCT05099003|Radiation|Radiation Therapy|Undergo radiation therapy
80000739|NCT05099003|Drug|Selinexor|Given orally
80000740|NCT05089656|Genetic|OAV101|Gene therapy
79232616|NCT02445560|Dietary Supplement|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
79827169|NCT00724230|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
80000741|NCT05089656|Procedure|Sham control|The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
79684342|NCT05468645|Drug|[14C]Hemay005|Name: [14C]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
79232617|NCT02445560|Dietary Supplement|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
79232618|NCT02445638|Other|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
79232619|NCT02445638|Other|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
79527944|NCT04154423|Other|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
79232620|NCT04700423|Drug|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
79527945|NCT04154371|Device|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
79527946|NCT04152824|Behavioral|Resilience-Supportive Leadership Training (RESULT)|Leaders will receive a training addressing supportive supervisor behaviors and resilience
79527947|NCT04131959|Device|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
79827170|NCT04066322|Procedure|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
80000742|NCT05089630|Biological|Pentamer (low)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
80000743|NCT05089630|Biological|Pentamer (med)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
80000744|NCT05089630|Biological|Pentamer (med)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
79527948|NCT04121559|Behavioral|School Interventions|"Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing."
79527949|NCT04121559|Behavioral|Community Interventions|"Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing."
79527950|NCT04121559|Behavioral|School System Interventions|"Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office."
79527951|NCT04112654|Procedure|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
79684343|NCT00596128|Behavioral|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
79684344|NCT00596206|Drug|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
79684345|NCT00596245|Drug|MT400|MT 400, naproxen sodium 550mg
79827171|NCT04066322|Other|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
79827172|NCT00861718|Drug|AZD7268|Capsule, Oral, QD
79827173|NCT00861718|Drug|AZD7268|Capsule, Oral, BID
79827174|NCT00861718|Drug|Placebo|Capsule, Oral BID
79827175|NCT00725036|Drug|inhaled human insulin|
79827176|NCT00725036|Drug|insulin aspart|
79827177|NCT00725036|Drug|insulin NPH|
79827178|NCT00865774|Behavioral|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
79827179|NCT00865774|Behavioral|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
80000745|NCT05089630|Biological|Pentamer (high)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
80000746|NCT05089630|Combination Product|Placebo (saline)|Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
80000747|NCT05087329|Behavioral|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
79684346|NCT00596284|Behavioral|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
79684347|NCT00596284|Behavioral|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
79684348|NCT05468528|Procedure|catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)|individualized stepwise linear ablation without pulmonary vein isolation
79684349|NCT05468528|Procedure|catheter radiofrequency ablation(PVI)|pulmonary vein isolation
79684350|NCT05427448|Diagnostic Test|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
79684351|NCT00624130|Drug|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
79684352|NCT00624130|Drug|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
79684353|NCT05468450|Drug|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
79684354|NCT05468450|Device|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
79827180|NCT00724386|Drug|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
79827181|NCT00724386|Drug|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
80000748|NCT05084508|Biological|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm
80000749|NCT05084508|Biological|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm
79232621|NCT04700423|Drug|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
79232622|NCT04700423|Drug|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
79232623|NCT04700423|Drug|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
79527952|NCT04112654|Procedure|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
79527953|NCT04098406|Drug|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
79527954|NCT04098406|Drug|Placebo|Placebo is liquid with identical color and taste
79827182|NCT00724386|Drug|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
79827183|NCT00724386|Radiation|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
79827184|NCT00865852|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
80000750|NCT05084508|Biological|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm
80000751|NCT05084508|Biological|Marketed varicella vaccine Lot 1|1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm
79232624|NCT04700423|Drug|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
79232625|NCT02286219|Drug|FS102|Experimental
79232626|NCT03197948|Other|Internet-Based Intervention|Complete questionnaire via a smartphone application
79527955|NCT04095104|Drug|Phentermine|Phentermine tablet
79527956|NCT04095104|Drug|Immediate Release Topiramate|Topiramate tablet
79827185|NCT00865852|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
79827186|NCT02571114|Dietary Supplement|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
79827187|NCT02571114|Dietary Supplement|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
79827188|NCT02571114|Dietary Supplement|Control 1|White bread (serving size = 25 g available carbohydrate)
79827189|NCT02571114|Dietary Supplement|Control 2|White bread (serving size = 25 g available carbohydrate)
79827190|NCT00725114|Biological|Tetrodotoxin|30 µg twice daily for 4 days
79827191|NCT00725114|Biological|Placebo|2 mL subcutaneous injection twice daily for 4 days
80000752|NCT05084508|Biological|Marketed varicella vaccine Lot 2|1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm
79232627|NCT04653467|Drug|GLPG4399 oral suspension|GLPG4399 for oral administration
79827192|NCT02545192|Device|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
79827193|NCT00724542|Drug|Voglibose tablets|0.2mg Tid
80000753|NCT05084508|Biological|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
80000754|NCT05084508|Biological|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
79527957|NCT04095104|Drug|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
79374300|NCT06153238|Drug|Keytruda - US|400 mg Q6W, i.v. infusion, over 24 weeks period
79232628|NCT04653467|Drug|GLPG4399 capsules|GLPG4399 for oral administration
79232629|NCT04653467|Drug|Placebo|Placebo oral suspension
79232630|NCT00273351|Drug|[123I]B-CIT|Subjects will receive up to 6 mCi of [123I] B-CIT injected intravenously
79374301|NCT06153186|Drug|Flunarizine Hydrochloride|Flunarizine tablet
79374302|NCT06153160|Device|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
79232631|NCT02445716|Drug|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
79232632|NCT02445716|Drug|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
79374303|NCT06153134|Drug|10% Curcuma xanthorriza Roxb.|Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
79374304|NCT06153134|Drug|2% Kojic Acid|Patients in experimental arms will receive 2% Kojic Acid cream for 2 months
79684355|NCT04686123|Other|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
79374305|NCT06153108|Device|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
79684356|NCT04686123|Other|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
79684357|NCT04320355|Other|Soft tissue manual therapy|The intervention is a type of massage.
79684358|NCT00535860|Drug|Teriparatide|Daily for 96 days
79374306|NCT06153095|Biological|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
79374307|NCT06153095|Biological|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
79374308|NCT06153095|Biological|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
79684359|NCT05388721|Other|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
79684360|NCT02892331|Behavioral|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
79374309|NCT06153082|Diagnostic Test|ROTEM|In ROTEM group if CT EXTEM >80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM <35 and MCF FIBTEM <8 CRYO or Fibrinogen concentrate, if MCF EXTEM<35 and MCF FIBTEM >8 Platelet, CL LY>50 Trenaxemic acid
79527958|NCT04095104|Drug|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
79527959|NCT04086966|Drug|[68Ga]PSMA-PET/MRI or PET/CT|[68Ga]PSMA-PET/MRI or PET/CT
79527960|NCT04084990|Device|S9 VPAP Adapt|Auto-titrated positive airway pressure
79527961|NCT04067622|Device|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
79827194|NCT00724620|Biological|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
79232633|NCT04607369|Device|EyeCTester|Smartphone app that allows vision testing
80000755|NCT05084508|Biological|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh
79527962|NCT04067284|Behavioral|Nutrition education|"Nutrition Education on~Continued breastfeeding until two years of age~Food groups~Balanced diet~Introduction to locally available nutritious and low-cost foods~Amount and frequency of complementary feeding~Safe water, and~Handwashing with soap before feeding"
79527963|NCT04067284|Dietary Supplement|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
79527964|NCT04067284|Other|Usual care|No intervention/ control group
79527965|NCT04061564|Device|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
79527966|NCT04045405|Drug|CDR132L|i.v. administration
79527967|NCT04044729|Drug|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
79527968|NCT04044729|Drug|Placebo|Placebo
79527969|NCT04009356|Procedure|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
79527970|NCT04008082|Drug|Lenvatinib|Lenvatinib capsule.
79527971|NCT03997526|Device|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
79527972|NCT03995589|Other|Walking|Technology-guided semi-supervised walking therapy
79527973|NCT03995589|Other|Control|Go Home and Walk advice
79527974|NCT03979937|Procedure|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
79527975|NCT03979547|Behavioral|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
80000756|NCT05078775|Other|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
80000757|NCT05075603|Drug|Efineptakin alfa|NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
79232634|NCT02286297|Device|McGRATH® MAC|video-laryngoscopy-1
79232635|NCT02286297|Device|AirTraq|video-laryngoscopy-2
79232636|NCT02286297|Device|GlideScope|video-laryngoscopy-3
79232637|NCT02286297|Device|Miller|Direct laryngoscopy
79232638|NCT03197636|Drug|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
79374310|NCT06153082|Diagnostic Test|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
79374311|NCT06153056|Diagnostic Test|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
79527976|NCT03979534|Other|low protein diet|Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
79527977|NCT03978000|Drug|IBP-9414|Oral suspension
79527978|NCT03978000|Drug|Placebo|Sterile water
79527979|NCT03977779|Device|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
79527980|NCT03974243|Drug|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
79527981|NCT03974243|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
80000758|NCT05075603|Drug|Tisagenlecleucel|Administered as standard of care as described in the package insert on Day 0.
80000759|NCT05075603|Drug|Axicabtagene ciloleucel|Administered as standard of care as described in the package insert on Day 0.
80000760|NCT05075603|Drug|Lisocabtagene Maraleucel|Administered as standard of care as described in the package insert on Day 0.
79232639|NCT04597151|Dietary Supplement|Dietary Intervention|Attend diet education sessions
79232640|NCT03194438|Behavioral|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
79232641|NCT05724381|Diagnostic Test|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
79232642|NCT03194594|Drug|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
79527982|NCT03970109|Drug|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
79827195|NCT00724620|Drug|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
80000761|NCT05074810|Drug|avutometinib and sotorasib|The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
80000762|NCT05074810|Drug|avutometinib and sotorasib and defactinib|The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
80000763|NCT05073003|Drug|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
80000764|NCT05073003|Biological|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1_Adults_Dose C_GR1 and ST2_Adults_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2_Children_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1_Adults_Dose C_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose C_Safety and ST2_Infants_Dose C_Dose find groups in Stage 2 (Africa).
79232643|NCT04469049|Behavioral|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
79684361|NCT02892331|Behavioral|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
79684362|NCT00536549|Device|Guardian RT|
79684363|NCT00536549|Behavioral|Education about the self monitoring blood glucose|
79527983|NCT03970109|Drug|Placebo oral tablet|Placebo oral tablet
79527984|NCT03967925|Drug|Belimumab|Sub-cutaneous injection
79527985|NCT03967925|Drug|Rituximab|IV infusion 1g x 2
79527986|NCT03967925|Drug|Prednisolone|20mg prednisolone tapering dose
79527987|NCT03954743|Biological|PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
79527988|NCT03954743|Biological|Lyophilized formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
79684364|NCT04208074|Other|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
79684365|NCT00596479|Drug|Filgrastim (rG-CSF)|
79684366|NCT05387668|Drug|BGB-23339|Administered orally as a tablet.
79684367|NCT05387668|Drug|Placebo|Administered orally as a tablet.
79684368|NCT04207957|Drug|Olorofim|150 mg
79684369|NCT05383339|Other|Blood collection|- 56mL blood collected additionally to routine care
79684370|NCT00535977|Dietary Supplement|Broccoli|400g ITC-enriched broccoli per week for 12 months
80000765|NCT05073003|Biological|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2_Children_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose B_Safety and ST2_Infants_Dose B_Dose find groups in Stage 2 (Africa).
80000766|NCT05073003|Biological|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose A_Safety and ST2_Infants_Dose A_Dose find groups in Stage 2 (Africa).
79232644|NCT03133533|Procedure|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
79232645|NCT03133533|Procedure|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
79232646|NCT02450240|Behavioral|standardized diagnostic assessment|
79232647|NCT02450240|Behavioral|self-report questionnaires|
79684371|NCT00535977|Dietary Supplement|Peas|400g frozen garden peas per week for 12 months
79684372|NCT00596518|Drug|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
79684373|NCT00536016|Drug|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
79684374|NCT00596557|Drug|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
79232648|NCT02450240|Behavioral|behavioral tasks|
79232649|NCT02450240|Other|physiological measurements|
79232650|NCT02450240|Other|structural and functional magnetic resonance imaging and EEG|
79232651|NCT02450240|Other|biomarker and microbiome assessments|
79232652|NCT02450240|Other|blood to derive induced pluripotent stem cells|
79232653|NCT02450240|Other|genetic and epigenetic assessments|
79684375|NCT04326556|Other|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
79684376|NCT00596596|Drug|prucalopride|0,5 mg once daily
79684377|NCT00596596|Drug|prucalopride|1 mg once daily
79527989|NCT03954223|Behavioral|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
79527990|NCT03954223|Behavioral|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
79527991|NCT03954223|Device|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
79527992|NCT03952663|Procedure|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
79232654|NCT03133455|Other|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
79684378|NCT00596596|Drug|2 mg prucalopride|2 mg once daily
79527993|NCT03952663|Procedure|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
79527994|NCT03925584|Other|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
79527995|NCT03920969|Behavioral|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
79527996|NCT03915327|Drug|Intravenous iron isomaltose anhydride|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
79684379|NCT00596596|Drug|4 mg prucalopride|4 mg once daily
79232655|NCT04407377|Drug|Tolperisone Hydrochloride|Study Drug
79232656|NCT04407377|Drug|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
79684380|NCT00596596|Other|Placebo|placebo once daily
79527997|NCT03911830|Other|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
79684381|NCT05468294|Drug|F16IL2|F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
79232657|NCT04407377|Other|Placebo|Placebo Comparator
79232658|NCT00272649|Biological|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
79232659|NCT04375085|Device|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
79232660|NCT03203174|Device|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
79232661|NCT03203174|Device|Sham Microneedle|Flat roller with no needles on the roller
79232662|NCT03203174|Drug|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
79232663|NCT03203174|Other|Saline|Saline applied to the palm
79374313|NCT06153030|Other|no intervention|No intervention
79374314|NCT06152991|Drug|GODEX|"The amount of active ingredient per dose (1 capsule)~Carnitine Orotate 150mg~liver extract antitoxic fraction 12.5㎎~Adenine Hydrochloride 2.5mg~Pyridoxine Hydrochloride 25mg~Riboflavin 0.5mg~Cyanocobalamin 0.125mg~Biphenyl Dimethyl Dicarboxylate 25mg"
79374315|NCT06152991|Drug|Placebo|"Anhydrous lactose 50mg.~Colloidal silicon dioxide 12mg.~Amorphous cellulose 50mg.~Lactose monohydrate 215.625mg.~Magnesium stearate 7mg.~Upper and lower brown opaque capsules 77mg."
79374316|NCT06152978|Drug|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
79374317|NCT06152978|Drug|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
79374318|NCT06152939|Other|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
79374319|NCT06152926|Other|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
79527998|NCT03883594|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
79527999|NCT03880565|Device|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation|Early use of ECMO
79528000|NCT03880565|Device|Standard Advanced Cardiac Life Support (ACLS) Resuscitation|Standard life support resuscitation
79528001|NCT03876652|Device|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
79528002|NCT03876080|Other|Dry needling|The use of a solid filiform needle to treat trigger points
79528003|NCT03876080|Other|Sham needling|Simulated needling
79528004|NCT03874988|Behavioral|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
79684382|NCT05468294|Drug|Nivolumab, fixed dose|Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
79684383|NCT00596674|Behavioral|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
79684384|NCT00596674|Other|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
79528005|NCT03874988|Behavioral|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
79232664|NCT03531333|Procedure|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
79232665|NCT04484480|Procedure|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
79684385|NCT02892175|Procedure|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
79232666|NCT02450162|Procedure|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
79232667|NCT04612283|Other|NGA-01 gel|NGA-01 is a gel formulation with mostly herbal active ingredients
79232668|NCT04612283|Other|Placebo|A Placebo with no active ingredients
79684386|NCT00536588|Genetic|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
79684387|NCT00596791|Drug|tafluprost|prostaglandine analoque
79232669|NCT04484402|Biological|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
79232670|NCT04484402|Biological|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
79684388|NCT05312866|Procedure|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
79528006|NCT03874988|Behavioral|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
79684389|NCT05312866|Procedure|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
79684390|NCT05470803|Biological|AstraZeneca/Fiocruz|4th dose of SARS-CoV-2 vaccine
79684391|NCT05470803|Biological|Pfizer/Wyeth|4th dose of SARS-CoV-2 vaccine
79684392|NCT05470803|Biological|Clover SCB-2019|4th dose of SARS-CoV-2 vaccine
79684393|NCT00622960|Other|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
79232671|NCT04484402|Other|standard treatment|Standard treatment according to the Clinical protocols
79232672|NCT05220995|Genetic|protocol|ovarian stimulation protocols on euploid rates were compared.
79232673|NCT00257205|Drug|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
79528007|NCT03874988|Behavioral|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
79684394|NCT00622960|Other|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
79827196|NCT00866008|Drug|Ovarian stimulation|"Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
79232674|NCT00257205|Drug|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
79232675|NCT00257205|Drug|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
79528008|NCT03873467|Behavioral|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
79528009|NCT03873467|Other|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
79528010|NCT03867643|Biological|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (<10mIU/mL and [10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
79528011|NCT03861533|Other|survey|Cross-Reference
79528012|NCT03858621|Drug|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
79684395|NCT05468255|Other|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
79684396|NCT04326790|Drug|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
79684397|NCT04326790|Drug|Standard treatment|Standard treatment
79827197|NCT00722514|Behavioral|patient education|"complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~Patient education 6 x 90 Minutes"
79827198|NCT00722514|Behavioral|Standard Care|"complex individual antiinflammatory rehabilitation program during inpatient~complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
79827199|NCT00866086|Other|questionnaire administration|
79827200|NCT00866086|Procedure|computed tomography|
79232676|NCT05052749|Other|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
79232677|NCT05052749|Other|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
79232678|NCT03194516|Other|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
79232679|NCT03627533|Procedure|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
79827201|NCT00866086|Radiation|radiation therapy treatment planning/simulation|
79374320|NCT06152900|Device|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
79374321|NCT06152887|Device|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
79528013|NCT03857984|Other|Blood sampling|blood sample before and after a single HD
79528014|NCT03857074|Device|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
79528015|NCT03815370|Device|Experimental: ABRO™ Binder Arm|ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
79528016|NCT03815370|Device|Placebo Comparator: Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
79827202|NCT02571426|Drug|Sevoflurane|anesthetic agent
79528017|NCT03799588|Device|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
79528018|NCT03788993|Other|Blue-depleted evening light condition|"A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin."
79528019|NCT03788993|Other|Normal light condition|"The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h."
79528020|NCT03788421|Device|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
79528021|NCT03788421|Procedure|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
79528022|NCT03782792|Drug|Spesolimab|Solution for infusion
79528023|NCT03782792|Drug|Placebo|Solution for infusion
79528024|NCT03762161|Drug|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
79528025|NCT03758170|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
79827203|NCT02571426|Drug|propofol|anesthetic agent
79827204|NCT00861796|Drug|CYR-101|Experimental arm
79827205|NCT00861796|Drug|Placebo|Placebo comparator
79827206|NCT00722670|Behavioral|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
79827207|NCT00722670|Behavioral|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
79232680|NCT03197714|Drug|OPB-111077|"Two dose schemas will be employed:~Level 1: 200 mg daily~Level 2: 250 mg daily"
79232681|NCT05220761|Diagnostic Test|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
79374322|NCT06152887|Device|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
79374323|NCT06152848|Other|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
79374324|NCT06152822|Drug|pyrotinib+capecitabine+bevacizumab|pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
79374325|NCT06152796|Drug|Paracetamol|Anti_inflammatory drug
79684398|NCT05468177|Combination Product|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
79374326|NCT06152796|Drug|Ibuprofen|Non steroidal anti_inflammatory drug
79374327|NCT06152757|Biological|First dose|1.0×10^8cells,Intravenous infusion，1 subject is planned to be enrolled
79374328|NCT06152757|Biological|Second dose|3.0×10^8cells,Intravenous infusion，3 subject is planned to be enrolled
79374329|NCT06152757|Biological|The third dose|1.0×10^9cells,Intravenous infusion，3 subject is planned to be enrolled
79374330|NCT06152757|Biological|The fourth dose|3.0×10^9cells,Intravenous infusion，3 subject is planned to be enrolled
79374331|NCT06152705|Device|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
79528026|NCT03752762|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
79528027|NCT03752762|Behavioral|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
79684399|NCT00596986|Drug|Duloxetine|Duloxetine 30mg up to 120mg per day.
79684400|NCT00596986|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
79232682|NCT05220683|Device|digital marking system|Verion or Callisto, digital marking system
79684401|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
79374332|NCT06152692|Device|SHAM Continuous positive airway pressure|Placebo treatment
79684402|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
79684403|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
79684404|NCT04326517|Procedure|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
79684405|NCT00597064|Drug|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
79684406|NCT00536627|Biological|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
79232683|NCT03194282|Other|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
79232684|NCT04089527|Drug|CC-95775|CC-95775
79374333|NCT06152692|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
79374334|NCT06152679|Other|None - qualitative interviews|Qualitative interviews with patients asking about their experience of day-case endourology.
79374335|NCT06152666|Other|None - qualitative interviews|These are qualitative interviews and involve no intervention
79232685|NCT05724303|Other|8-week neuromuscular training program|Training program consisting of two neuromuscular training sessions per week
79374336|NCT06152640|Device|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling was used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: the intervention targets were at the left and right ACC, 5 times per week (Monday through Friday), for 6 weeks, a total of 30 treatments were given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
79232686|NCT03194204|Drug|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
79232687|NCT04441359|Other|Supplemented formula|standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
79232688|NCT04441359|Other|Standard formula|standard infant formula not supplemented with prebiotic inulin-type fructans
79232689|NCT05052047|Other|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
79827208|NCT00854854|Biological|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
79232690|NCT05052047|Other|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
79374337|NCT06152640|Device|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets were at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), 5 times per week (Monday through Friday), for 6 weeks, a total of 30 treatments were given."
79374338|NCT06152640|Other|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
79374339|NCT06150794|Device|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
79374340|NCT06150794|Drug|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
79528028|NCT03746756|Behavioral|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
79528029|NCT03746756|Behavioral|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
79528030|NCT03740035|Device|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
79827209|NCT05373030|Biological|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
79232691|NCT03203018|Behavioral|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
79232692|NCT05013359|Other|No treatment given|No treatment given
79232693|NCT03197480|Drug|Aflibercept Injection [Eylea]|All subjects will receive 4 monthly intravitreal injections of aflibercept
79684407|NCT00597103|Other|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
79684408|NCT00597103|Other|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
79684409|NCT00597103|Other|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
79684410|NCT00597142|Device|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~Lesion length ≤15mm~Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~RVD 4.0-7.0mm"
79684411|NCT02909595|Device|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter [Extractor Pro RX [M00547000, M00547010, or M00547020]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
79827210|NCT00854932|Other|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
79827211|NCT02570802|Procedure|Ultrasonographic examination|
79684412|NCT02909595|Device|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V [FG-V435P or FG-V425PR]; Olympus Corp., Shang hai,China).
79232694|NCT00151281|Drug|PEPC|"Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC < 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis"
79374341|NCT06150222|Other|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
79684413|NCT04326712|Other|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
79684414|NCT04326712|Other|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
79684415|NCT04326595|Procedure|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
79232695|NCT00151281|Drug|Thalidomide|"Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)"
79232696|NCT00151281|Drug|Rituximab|"Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
79232697|NCT03202862|Drug|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
79232698|NCT03627455|Other|Percutaneous coronary intervention|Percutaneous coronary intervention
79232699|NCT03202940|Drug|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
79232700|NCT03202940|Drug|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
79232701|NCT00255099|Drug|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
79374342|NCT06150040|Drug|NP137|IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
79528031|NCT03739034|Behavioral|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
79684416|NCT00597181|Procedure|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
79528032|NCT03736954|Behavioral|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
79528033|NCT03733119|Drug|Akt/ERK Inhibitor ONC201|Given PO
79528034|NCT03733119|Dietary Supplement|Methionine-Restricted Diet|Given PO
79827212|NCT00578292|Drug|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
79232702|NCT00255099|Drug|Placebo|2 tablets b.i.d. / 96 weeks
79232703|NCT02445482|Procedure|Biopsy|archival tissue or fresh biospsy
79232704|NCT02288481|Drug|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
79232705|NCT02288481|Other|Placebo|Placebo Suspension
79374343|NCT06150040|Drug|Azacitidine Injection|Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
79374344|NCT06150040|Drug|Venetoclax|Orally, 70 mg, every day on Days 1-28
79528035|NCT03724669|Behavioral|waiting list|After the study ends, they will have access to receive the educational texts and view the online lectures.
79528036|NCT03724669|Behavioral|benzodiazepines related knowledge intervention|participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
79684417|NCT00597181|Procedure|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
79684418|NCT00597220|Dietary Supplement|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
79684419|NCT00597220|Drug|Placebo|Placebo
79684420|NCT02892097|Device|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
79684421|NCT02892097|Device|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
79684422|NCT02892097|Behavioral|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
79684423|NCT00597259|Drug|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
79827213|NCT00578292|Drug|Fludarabine|30mg/m2 Day -5 through Day -2
79232706|NCT03197246|Device|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
79232707|NCT03197246|Device|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
79374345|NCT06149208|Behavioral|Interview|Families will complete interviews about their experiences with the new treatment standard and managing pain at home
79374346|NCT06145776|Other|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
79684424|NCT00597259|Drug|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
79827214|NCT00578292|Drug|Campath 1H|Per institutional guidelines Days -5 through -2
79827215|NCT00578292|Drug|Cyclophosphamide|50 mg/kg Days -5 through -2
80000767|NCT05073003|Biological|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2_Adults_Control C group and children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
79232708|NCT05724147|Behavioral|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
79374347|NCT06145776|Other|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
79374348|NCT06145594|Other|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
79374349|NCT06145594|Other|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
79374350|NCT06143371|Biological|CAN10|Single dose intravenous or Multiple doses subcutaneously
79374351|NCT06143371|Biological|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
79374352|NCT06141317|Biological|PASC transplantation (25 million PASCs/patient)|3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
79374353|NCT06141317|Biological|Control|0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
79528037|NCT03719183|Diagnostic Test|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
79684425|NCT05468060|Drug|PA1010|Placebo as control
79528038|NCT03719183|Diagnostic Test|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~t(8;21) (RUNX1-RUNX1T1).~inv(16), t(16;16) (CBFB-MYH11).~t(9;22) (BCR-ABL).~11q23 KMT2A rearrangements.~inv(3) MECOM rearrangements.~DEK-NUP214 rearrangements.~Del(5q) Deletion~Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~t(15;17) (PML-RARA).~17q RARA rearrangements"
79528039|NCT03719183|Diagnostic Test|Multiplex FISH (M-FISH)|24-color karyotyping
79528040|NCT03717935|Dietary Supplement|Essential Amino Acid (EAA) Supplement|Powder supplement
79528041|NCT03717935|Other|Placebo|Powder that will be similar to the essential amino acid supplement
79528042|NCT03715751|Other|ASV|Adaptive Support Ventilation
79528043|NCT03715751|Other|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
79528044|NCT03709368|Other|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
79684426|NCT02892253|Device|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
79684427|NCT05470764|Drug|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
79827216|NCT00578292|Drug|MESNA|10 mg/kg x 5 Days -5 through -2
79827217|NCT00861874|Drug|Decitabine|20 mg/m2 IV, Days 1-5
79827218|NCT00861874|Drug|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
79827219|NCT03765242|Other|Non-Interventional|Non-Interventional
79827220|NCT05372874|Drug|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
80000768|NCT05073003|Combination Product|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2_Adults_Control C group in Stage 2 (Africa).
79374354|NCT06140901|Diagnostic Test|Study morphological and functional of respiratory epithelium|The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
79827221|NCT02544646|Other|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
79684428|NCT05470764|Drug|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
79684429|NCT00597298|Device|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
79827222|NCT00725192|Behavioral|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
79827223|NCT00725192|Behavioral|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
79232709|NCT03203096|Dietary Supplement|Magnesium|Magnesium citrate / Magnesium oxide
79684430|NCT00597298|Device|sham threshold|non-training physical activity
79827224|NCT04067856|Drug|Bevacizumab Injection|Intravitreal injection
79684431|NCT04320550|Diagnostic Test|abdominal ultra sound|non invasive tests to exclude pathological causes
79684432|NCT05271019|Device|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
79827225|NCT00866164|Device|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
79827226|NCT00570063|Drug|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
79827227|NCT00570063|Drug|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
79827228|NCT05372796|Other|IASTM|instrument-assisted soft tissue mobilization
79827229|NCT05372796|Other|home exercise|home exercise
79827230|NCT05372796|Device|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
79374355|NCT06139874|Behavioral|THRIVE|Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
79374356|NCT06139874|Behavioral|Parenting Wisely|Online asynchronous parenting program.
79827231|NCT04042714|Drug|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
80000769|NCT05073003|Combination Product|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
80000770|NCT05073003|Combination Product|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa).
80000771|NCT05073003|Biological|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
80000772|NCT05071235|Device|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
79232710|NCT03203096|Dietary Supplement|Placebo|
79232711|NCT00231153|Drug|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
79232712|NCT00231153|Drug|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
79232713|NCT03202784|Drug|BCX7353|BCX7353
79232714|NCT05220527|Drug|Triamcinolone plus hyruan|triamcinolone plus hyruan injections, one time per week, for 3 weeks
79232715|NCT05220527|Drug|vitagen plus hyruan|vitagen plus hyruan injections, one time per week, for 3 weeks
79374357|NCT06137911|Drug|JYP0061|JYP0061 orally administered
79374358|NCT06137911|Drug|placebo|Placebo orally administered
79391008|NCT03182478|Behavioral|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
79827232|NCT03401918|Diagnostic Test|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
80000773|NCT05071235|Device|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
79232716|NCT05220527|Drug|normal saline plus hyruan|normal saline plus hyruan injections, one time per week, for 3 weeks
79528045|NCT03709368|Behavioral|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch & smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
79528046|NCT03709368|Behavioral|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
79684433|NCT04326634|Other|controlled exercises|controlled exercises
79684434|NCT04326634|Other|non controlled exercises group|non controlled exercises
80000774|NCT05071235|Device|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
79232717|NCT03197402|Dietary Supplement|Leucine-enriched protein gel delivery system|Leucine enriched
79232718|NCT03197402|Dietary Supplement|Milk protein gel delivery system|Non-leucine enriched
79684435|NCT00597337|Behavioral|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
79684436|NCT00597415|Drug|celecoxib|celecoxib 200mg
79684437|NCT00597415|Drug|placebo|placebo
79684438|NCT00597454|Other|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
79684439|NCT04686110|Other|angiographic optical coherence tomography|angiographic optical coherence tomography
79684440|NCT00597532|Dietary Supplement|Soy|soy (soy protein supplementation 50 grams/day)
79684441|NCT00597532|Dietary Supplement|Milk|placebo (milk protein supplementation 50 grams/day)
79684442|NCT00597610|Other|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
79684443|NCT00597649|Drug|Bicifadine|SR dosage form of 400 mg bid or tid for one year
79232719|NCT05220449|Other|Cross-frequency dual-site tACS|Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)
79232720|NCT05724069|Drug|Velusetrag|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
79684444|NCT04686032|Other|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS* for incisional pain (30min)
79232721|NCT05724069|Drug|Placebo|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
80000775|NCT05071235|Device|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
79374360|NCT06128291|Procedure|posterior colporrhaphy|posterior colporrhaphy for rectocele.
79374361|NCT06122610|Device|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
80000776|NCT05071235|Procedure|Dressing|Application of Helianthus annuus oil dressing.
80000777|NCT05065047|Drug|Belantamab mafodotin|Given by IV
80000778|NCT05053087|Drug|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
80000779|NCT05053087|Drug|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
80000780|NCT05053087|Drug|Placebo|Saline filled catheter
80000781|NCT05052801|Drug|Bemarituzumab|Intravenous (IV) infusion
80000782|NCT05052801|Drug|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
79374362|NCT06122610|Device|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
79827233|NCT03401918|Drug|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
79827234|NCT05227378|Biological|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
79827235|NCT02570646|Behavioral|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
79827236|NCT00725348|Drug|Talarozole|1.0 mg oral dose per day
79827237|NCT02545348|Procedure|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
80000783|NCT05052801|Drug|Placebo|IV infusion
79528047|NCT03709368|Behavioral|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
79528048|NCT03709368|Behavioral|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
79528049|NCT03709368|Other|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
79684445|NCT04686032|Other|Early ambulation|Patient education & Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
79827238|NCT00724776|Biological|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
80000784|NCT05049057|Drug|Erenumab 140 Mg/mL Subcutaneous Solution|Active erenumab delivered via subcutaneous injection.
79827239|NCT05325216|Procedure|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
79232722|NCT05723991|Drug|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
79528050|NCT03705338|Device|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
79528051|NCT03705338|Drug|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
79684446|NCT00597688|Drug|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
79684447|NCT00597688|Drug|Placebo gel|Oral mucosal application of placebo gel
79374363|NCT06122610|Drug|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
79374364|NCT06122610|Drug|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
79374365|NCT06122103|Device|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
79374366|NCT06122103|Device|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
79684448|NCT00597844|Other|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
79684449|NCT00597844|Other|undergo voice evaluation and fMRI prior|in approximately one month and six months
79684450|NCT05467982|Behavioral|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
80000785|NCT05049057|Drug|Placebo|Placebo delivered via subcutaneous injection.
80000786|NCT05047757|Dietary Supplement|Test meal with 15N labeled favabean|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
80000787|NCT05039281|Biological|Atezolizumab|Given IV
80000788|NCT05039281|Drug|Cabozantinib|Given PO
80000789|NCT05016882|Drug|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
80000790|NCT05016882|Drug|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
80000791|NCT05016882|Drug|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
80000792|NCT05016882|Drug|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
79391009|NCT03183258|Other|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
79391010|NCT02426424|Device|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
79232723|NCT05220215|Other|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
79232724|NCT05220215|Other|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
79684451|NCT05467982|Behavioral|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
79684452|NCT05470530|Drug|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
79684453|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
79684454|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
79684455|NCT02909517|Other|cSLO imaging|
79684456|NCT02891902|Other|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
79232725|NCT03531177|Behavioral|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
79232726|NCT03531177|Behavioral|Control|Participants receive usual care from their healthcare team.
79232727|NCT05682599|Drug|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
79232728|NCT05682599|Drug|Placebo|Placebo
79232729|NCT03531021|Behavioral|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
79528052|NCT03704285|Drug|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
79528053|NCT03704285|Device|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
79528054|NCT03697395|Diagnostic Test|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
79528055|NCT03697395|Drug|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
79232730|NCT03530553|Other|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
79528056|NCT03696537|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
79528057|NCT03696537|Radiation|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
79684457|NCT00598117|Behavioral|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~Initial QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS"
79684458|NCT02891980|Biological|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
79684459|NCT02891980|Biological|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
79684460|NCT00536666|Drug|Iron oligosaccharide|
79684461|NCT04207762|Diagnostic Test|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
79528058|NCT03688243|Device|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
79528059|NCT03682250|Device|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
79827240|NCT05325216|Procedure|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
79827241|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
79827242|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
79232731|NCT05722509|Procedure|"Distal Flap Reduction Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
79528060|NCT03682250|Device|Holter monitor|A Holter monitor will be used to measure heart's activity
79528061|NCT03664765|Other|UA and RMT|daily oropharyngeal and respiratory muscle exercises
79827243|NCT00577772|Drug|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
79684462|NCT04207762|Diagnostic Test|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after [18F]AmBF3-TATE administration.
79684463|NCT04128943|Other|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
79684464|NCT04128943|Other|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
79684465|NCT04128943|Other|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
79684466|NCT04128943|Other|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
79684467|NCT05467826|Drug|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
79684468|NCT05467826|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
79684469|NCT04127734|Procedure|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
79684470|NCT00598156|Drug|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
79684471|NCT00598156|Drug|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
79684472|NCT00598195|Drug|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
79684473|NCT00598234|Drug|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
79827244|NCT00577772|Device|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
80000793|NCT05016882|Drug|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
79232732|NCT05722509|Procedure|"Only Exodontia Group"|Third molar exodontia without associated surgery.
79528062|NCT03664765|Other|Sham exercise|Daily sham exercises
79528063|NCT03663829|Other|Non-Interventional|Non-Interventional
79684474|NCT00598390|Drug|[11C]MePPEP|
79827245|NCT00577772|Procedure|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
79827246|NCT00578136|Drug|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
79827247|NCT00861952|Other|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
79528064|NCT03663829|Other|Non-Interventional|Non-Interventional
79528065|NCT03662672|Procedure|Rib raising and lumbar release|Rib raising per protocol described in arm description.
79528066|NCT03662672|Procedure|Sham procedure|Sham procedure per protocol described in arm description
80000794|NCT05016882|Drug|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
79232733|NCT05219747|Other|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
79528067|NCT03661996|Drug|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
79528068|NCT03661996|Drug|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
79684475|NCT04326205|Device|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
79684476|NCT04326205|Device|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
79827248|NCT00861952|Other|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
79827249|NCT04065698|Drug|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
79232734|NCT05219747|Other|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
79232735|NCT02288715|Other|no interventions|
79232736|NCT05219357|Other|Ayu-Care|Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.
79232737|NCT05219357|Drug|Usual-Care|Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
79232738|NCT04873739|Diagnostic Test|Anterior Segment OCT|AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
79684477|NCT04326205|Other|no stimulation|Both tDCS and FES will not be used in this section.
79827250|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
79827251|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
79232739|NCT05723757|Diagnostic Test|blood sampling|Draw a 8.5mL blood sample for detection of SNPs of genomic origin
79232740|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
79528069|NCT03661996|Device|ElastoGel|Cooling Device
79528070|NCT03661996|Device|Breg Ice Water Pump|Cooling Device
79827252|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
79827253|NCT00855088|Drug|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
79827254|NCT00855088|Drug|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
79827255|NCT00855088|Drug|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
79827256|NCT00725426|Drug|Bosutinib|
79827257|NCT02553603|Drug|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
79827258|NCT02553603|Drug|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
79827259|NCT00730184|Dietary Supplement|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
79827260|NCT00730184|Dietary Supplement|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
79232741|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
79232742|NCT01318109|Drug|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
79232743|NCT05722197|Behavioral|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
79374367|NCT06121024|Procedure|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
79391011|NCT02426424|Device|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
79528071|NCT03645759|Behavioral|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
79528072|NCT03645759|Other|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
79528073|NCT03639064|Drug|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
79684478|NCT00598429|Drug|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
79684479|NCT05470452|Other|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
79684480|NCT05470452|Other|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
79684481|NCT00598546|Behavioral|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
79684482|NCT00598624|Drug|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
79232744|NCT03530475|Diagnostic Test|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
79827261|NCT03846622|Other|Calculation of scoring systems for bleeding|
79374368|NCT06115525|Other|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
79374369|NCT06115525|Other|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
79528074|NCT03633461|Drug|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
79528075|NCT03633461|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
79528076|NCT03628560|Device|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
79528077|NCT03628560|Device|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
79684483|NCT02891785|Behavioral|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
79684484|NCT00536094|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
79684485|NCT00536094|Behavioral|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
79827262|NCT00807339|Radiation|Stereotactic radiation|Dose escalation three consecutive treatments
79827263|NCT00807339|Device|CyberKnife Robotic Radiosurgery System|
79827264|NCT03314766|Device|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
79528078|NCT03628560|Device|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
79528079|NCT03628560|Device|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
79684486|NCT05466344|Device|Herbst Group|"Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~When reactivation of the telescopic piston is needed, extension rings are used."
79827265|NCT00730262|Drug|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
79827266|NCT00862030|Procedure|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
79232745|NCT05720871|Device|rTMS + capsaicin 150μM (natural TRPV1 agonist)|"Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days."
79684487|NCT05466344|Device|TFBC Group|"The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~Finally follow finishing steps for each patient."
79684488|NCT02891746|Other|non invasive sampling|
79684489|NCT00598741|Other|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
79684490|NCT00598858|Drug|Docetaxel|Given IV
79684491|NCT00598858|Drug|Prednisone|Given PO
79232746|NCT05720871|Device|tDCS + capsaicin 150μM (natural TRPV1 agonist)|"Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days."
79374370|NCT06110637|Other|"hard shoes runners evaluation"|"The hard shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
79374371|NCT06110637|Other|"Soft shoes runners evaluation"|"The soft shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
79374372|NCT06108375|Other|music therapy|music played live by a music therapist
79528080|NCT03628560|Device|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
79528081|NCT03622658|Biological|Placebo|Placebo solution for subcutaneous injection.
79684492|NCT02909166|Drug|aliskiren|
79684493|NCT05466305|Device|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
79232747|NCT05198453|Biological|vaccination|patients who received COVID-19 vaccine
79232748|NCT02288793|Other|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
79374373|NCT06108375|Other|recording|a recording of the same music played by the music therapist
79374374|NCT06105996|Behavioral|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
79374375|NCT06105788|Other|Exercise|"Arm exercise will be an arm ergometer for 20 minutes, preceded by a 5-minute warm-up.~Leg exercise will be a cycling ergometer for 20 minutes, preceded by a 5-minute warm-up.~The exercise intensity will be set at 70% of the heart rate reserve (HRR) for each type of exercise."
79374376|NCT06100120|Procedure|Implant placement|Placement of osteointegrated implants
79528082|NCT03622658|Biological|Namilumab|Namilumab solution for subcutaneous injection
79528083|NCT03621475|Device|Novel restraint|Use of a novel arm restraint
79528084|NCT03620968|Other|cognitive training|15 minutes day of brain training by an APP
79528085|NCT03615521|Other|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
79528086|NCT03615521|Other|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
79684494|NCT04207684|Drug|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
79684495|NCT02909400|Drug|KH176|
79684496|NCT02909400|Drug|placebo|
79684497|NCT05604950|Diagnostic Test|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
79684498|NCT03135067|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
79684499|NCT00536133|Drug|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
79684500|NCT00536133|Other|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
79684501|NCT05603858|Procedure|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
79684502|NCT02909478|Drug|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
79684503|NCT02909478|Drug|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
79684504|NCT03005626|Other|Therapeutic education|
79684505|NCT03005626|Other|Standard follow-up|
79684506|NCT00536211|Behavioral|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
79684507|NCT00536211|Drug|Metformin|oral tablet, 1000 mg daily for 17 days
79684508|NCT02914873|Procedure|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
79684509|NCT00536705|Drug|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
79827267|NCT00804531|Drug|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
79827268|NCT00804531|Drug|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
79684510|NCT00624208|Drug|droperidol and saline|droperidol 20 mcg.kg-1 and saline
80000795|NCT05006833|Behavioral|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
79232749|NCT05720481|Other|Full mouth Scaling and root planing|patients were treated with full mouth Scaling and root planing
79684511|NCT00624208|Drug|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
79684512|NCT00624208|Drug|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
79684513|NCT00624208|Drug|saline and saline|saline and saline
80000796|NCT05006833|Behavioral|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
79232750|NCT05720481|Other|Quadrant Scaling and root planing|patients were treated with quadrant Scaling and root planing
79232751|NCT05636267|Drug|AK119|AK119 IV every 3 weeks.
79827269|NCT00725088|Behavioral|Exercise training|Exercise training
79827270|NCT00866710|Other|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
80000797|NCT05006833|Behavioral|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
80000798|NCT05006833|Behavioral|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
79232752|NCT05636267|Drug|AK112|AK112 IV every 3 weeks.
79232753|NCT05636267|Drug|Pemetrexed|Pemetrexed IV every 3 weeks.
79232754|NCT05636267|Drug|Carboplatin|Carboplatin IV every 3 weeks.
79232755|NCT02288871|Radiation|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
79232756|NCT05635175|Other|hip abductors physiotherapy self training|hip abductors self training program during 7 to 10 weeks associate with a PFMT
79232757|NCT05635175|Other|Standard pelvic floor muscle training|Standard pelvic floor muscle training
79232758|NCT05635175|Other|Standard pelvic floor muscle training self training|Standard pelvic floor muscle training self training
79232759|NCT02288949|Other|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
79374377|NCT06090344|Other|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
79528087|NCT03615521|Other|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
79528088|NCT03615521|Other|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
79528089|NCT03615521|Other|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
79684514|NCT00624247|Other|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
79374378|NCT06090344|Other|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
79684515|NCT00536783|Drug|Quetiapine|
80000799|NCT05005182|Procedure|Biospecimen Collection|Undergo blood sample collection
80000800|NCT05005182|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
80000801|NCT05005182|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
80000802|NCT05005182|Drug|Hydroxyurea|Given PO
80000803|NCT05005182|Biological|Luspatercept|Given SC
80000804|NCT05005182|Other|Questionnaire Administration|Ancillary studies
80000805|NCT04998773|Device|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
79684516|NCT00536289|Device|Blunt needle|Blunt tipped suture needle
79684517|NCT05601791|Procedure|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
79684518|NCT05601791|Procedure|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
79374379|NCT06084429|Other|pre and post test (health educational intervention)|"The health education will be provided the following sessions.~Introduction to Global and Bangladesh Health, Health Information access (Validity), Critical Values (Vital signs, BMI, RBS etc.), Emergency Management (burn, chocking, knife cut, fainting etc.), Food (classification, healthy food, unhealthy, food label, salt intake) (NCDs from unhealthy diet), Smoking and Alcohol (NCD related, substance abuse, secondhand smoking), Physical activity (Benefits, sedentary lifestyle, NCD related), Women's health (menstruation, menstrual cycle, hygiene, STD, contraception), Hygiene (water, food, brushing, bath, toileting, healthy habits), Environmental Sanitation and Communicable disease (clean, effects on health), and Women's health and societal contribution"
79374380|NCT06082882|Behavioral|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a ~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
79684519|NCT05470062|Device|arch support insoles (FootDisc)|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
79684520|NCT04685642|Drug|Aspirin|Aspirin (100mg/day)
80000806|NCT04998773|Device|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
79684521|NCT04685642|Drug|Atorvastatin|Atorvastatin (20mg/day)
79232760|NCT05194709|Biological|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10^9 cells.
79232761|NCT03530943|Behavioral|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
79684522|NCT02909244|Biological|Biological sampling|Biological sampling
79232762|NCT03530943|Behavioral|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
79232763|NCT03530787|Other|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
79374381|NCT06082882|Behavioral|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
79374382|NCT06082505|Behavioral|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
79528090|NCT03600142|Behavioral|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
79232764|NCT03530787|Other|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
79232765|NCT03873311|Drug|Azacytidine, HAG Regimen|Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
79232766|NCT03873311|Drug|Azacytidine|Azacytidine 75mg/m2 QD for 7 days.
79232767|NCT00162279|Drug|Abatacept|
79232768|NCT02712554|Drug|CL-108|7.5 mg/325 mg/12.5 mg tablet
79528091|NCT03526510|Radiation|Conventionally Fractionated versus Hypofractionated Boost|
79684523|NCT04685564|Drug|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
79684524|NCT04685564|Drug|Placebo|the same as RBD1016
79684525|NCT02909283|Procedure|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
80000807|NCT04998773|Device|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
79232769|NCT02712554|Drug|M366|7.5 mg/325 mg tablet
80000808|NCT04998136|Drug|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
79684526|NCT02908932|Dietary Supplement|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
79528092|NCT03517098|Procedure|The ERAS group|"ERAS pathway for orthopedic surgeons:~Shortened preoperative fasting from intake.~Preoperative tranexamic acid administration.~No indwelling catheters.~No tourniquet used for TKA.~No drainage tube.~Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~Intravenous 20 mg of dexamethasone before anesthetic induction.~Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~Laryngeal mask for airway.~Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
79232770|NCT02712554|Drug|Placebo|
79528093|NCT03517098|Procedure|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
79528094|NCT03499314|Device|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
79528095|NCT03499314|Device|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
79528096|NCT03499314|Other|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
79827271|NCT00807729|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
80000809|NCT04998136|Drug|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
79232771|NCT03527901|Diagnostic Test|GCF collection with aMMP-8 chair side test|
79232772|NCT03527901|Other|Saliva collection|
79684527|NCT02908932|Dietary Supplement|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
79684528|NCT05595785|Behavioral|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
79528097|NCT03496597|Procedure|Retinal imaging assessment|"OCT-angiography~Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~Eye fundus photography: macular image~Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
79528098|NCT03496597|Procedure|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
79528099|NCT03478215|Biological|Mesenchymal Stromal Stem Cells (MSCs) Infusion|"Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion."
79528100|NCT03478215|Other|Normal Saline (Placebo) Infusion|"Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion."
79528101|NCT03477084|Biological|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
80000810|NCT04997499|Behavioral|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
80000811|NCT04995575|Procedure|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
79232773|NCT00145431|Drug|torcetrapib/atorvastatin|
79232774|NCT00145431|Drug|atorvastatin|
79232775|NCT00145431|Drug|fenofibrate|
79232776|NCT05370261|Dietary Supplement|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
79232777|NCT05370261|Dietary Supplement|Regular Berberine hard-gels|Total dose of 500 mg of berberine
79232778|NCT00135369|Drug|stavudine extended-release, lamivudine, efavirenz|
79232779|NCT03530319|Drug|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
79232780|NCT03530319|Drug|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
79305623|NCT04930185|Behavioral|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
80000812|NCT04994717|Drug|Blinatumomab|Continuous intravenous (cIV) infusion
80000813|NCT04994717|Drug|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
79684529|NCT05595785|Behavioral|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
80000814|NCT04994717|Drug|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
80000815|NCT04987307|Drug|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
79232781|NCT05234372|Behavioral|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites & resources.
79232784|NCT00133497|Biological|MF-59|Microfluoridized adjuvant 59 (MF59).
79232785|NCT00133497|Drug|Placebo|0.5 mL of saline placebo.
79374383|NCT06082505|Behavioral|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
79684530|NCT02909205|Other|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
79374384|NCT06082154|Device|ultrasound|Patient will undergo multiorgan ultrasonography
79374385|NCT06080217|Device|study group|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
79374386|NCT06080217|Device|placebo (sham control)|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, but without any energy transferred through the probe,"
79684531|NCT02909205|Other|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
79684532|NCT05579795|Procedure|Detethering of the spinal cord|Release of the tethered spinal cord
80000816|NCT04987307|Drug|Placebo|Placebo will be administered by SC injection.
79232786|NCT00133497|Biological|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
79232787|NCT02445170|Procedure|Amputation|Transmetatarsal or below-knee amputation
79232788|NCT02445404|Drug|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
79374387|NCT06058936|Other|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
79528102|NCT03468556|Drug|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
79528103|NCT03468556|Drug|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
79528104|NCT03465384|Behavioral|Comet|The intervention is a behaviorally based and manualized parent training program.
79528105|NCT03416088|Behavioral|Beverage consumption|The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
80000817|NCT04985942|Drug|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
79528106|NCT03416088|Behavioral|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
79528107|NCT03416088|Behavioral|Body motion|Exercise or body postural changes
79528108|NCT03410355|Procedure|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
80000818|NCT04985942|Drug|Placebo|Matching capsules administered orally, once daily.
80000819|NCT04977453|Drug|GI-101|Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
80000820|NCT04977453|Drug|Pembrolizumab (KEYTRUDA®)|Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
80000821|NCT04977453|Drug|Lenvatinib|Lenvatinib will be administered at an approved dose orally.
79528109|NCT03410355|Procedure|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
79232789|NCT02445404|Drug|fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
79374388|NCT06054061|Behavioral|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
79827272|NCT00807729|Procedure|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
79827273|NCT00866866|Drug|N-Acetyl Cysteine|600 mg PO BID
79528110|NCT03399617|Dietary Supplement|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
79684533|NCT05312346|Diagnostic Test|seum zinic,vit B12, parathyriod function|seum zinic,vit B12, parathyriod function
79684534|NCT05568563|Drug|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
79528111|NCT03399617|Behavioral|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
79684535|NCT05568563|Other|Honey|Honey is a natural dietary product
79374389|NCT06054061|Behavioral|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
79827274|NCT00866866|Drug|Placebo|1 tab PO BID
79528112|NCT03399617|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
79684536|NCT00536861|Drug|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
79827275|NCT00804765|Other|Therapeutic education|Intensive training individual and collective teaching
79827276|NCT00804765|Other|Follow-up|classical follow-up with two individual consultations
79374390|NCT06051188|Device|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
79684537|NCT05469984|Drug|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
79827277|NCT00855244|Other|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
79827278|NCT00312728|Drug|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
79232790|NCT05346315|Other|RDN Medical Nutrition Therapy|The RDNs will provide bi-monthly nutrition care, counseling, and dietary recommendations for a 6-month intervention, delivered either in-person or via telehealth, to the grocery store patrons during the study intervention. The RDN will provided care to the participant based upon the participant's unique dietary and nutritional needs. The RDN will provide nutrition recommendations and create meal plans via NutriStyle for the participants to follow. The meal plans will be uploaded into the grocery store's E-commerce shopping platform, which the participant can utilize to purchase foods that are needed to follow the RDNs nutrition recommendations for an individual person.
79305624|NCT03239639|Behavioral|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
79305625|NCT03239639|Other|Wait list control|No intervention
79374391|NCT06045793|Drug|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
79374392|NCT06045793|Drug|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
79684538|NCT05469984|Drug|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
79684539|NCT00536900|Behavioral|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
79684540|NCT00536900|Behavioral|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
80000822|NCT04977453|Radiation|Local Radiotherapy|Patients will receive SBRT prior to the first dose of GI-101
79528113|NCT03395366|Other|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts & worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
79232791|NCT04468269|Other|Task oriented balance training with sensory integration group|"Sitting position:~Sit in a chair without backrest while keeping the feet on floor.~Sit on a ball while keeping the feet on the floor.~Sit to stand:~Sit in a chair without a backrest~Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~Walk forward~Walk forward cross an obstacle, and then continue to walk.~Walk Lateral~Walk Backward~Tandem walk"
79305626|NCT03239171|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
79374393|NCT06036446|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
79374394|NCT06036446|Drug|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
79374395|NCT06031623|Device|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
79374396|NCT06029049|Drug|Modified Time Principle Induction (MTPI) with rocuronium|Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
79528114|NCT03386162|Drug|Alpelisib|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
79528115|NCT03386162|Drug|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
79528116|NCT03373071|Biological|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
79684541|NCT05312190|Drug|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
79684542|NCT05312190|Drug|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
79684543|NCT00537173|Procedure|Core Biopsy|biopsy
79684544|NCT00537173|Procedure|Blood Collection|Blood/serum sample
79684545|NCT00537173|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
79684546|NCT00537173|Drug|Avastin|Avastin 10 mg/kg IV, day 1 and 15
79684547|NCT00537212|Other|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
79684548|NCT00537212|Other|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
79684549|NCT00537212|Other|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
79374397|NCT06029049|Drug|RSI succinylcholine|Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
79374398|NCT06028620|Behavioral|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
79528117|NCT03369431|Dietary Supplement|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
79305627|NCT03239171|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
79528118|NCT03369431|Dietary Supplement|Placebo|4.4 grams of maltose and silicon dioxide per sachet
79528119|NCT03360214|Drug|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
79684550|NCT02503839|Drug|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
79684551|NCT02503839|Biological|H56:IC31|Therapeutic and prophylactic TB vaccine
79684552|NCT05469750|Drug|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
79305628|NCT02314559|Drug|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
79684553|NCT05530109|Other|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
79827279|NCT00312728|Drug|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
79827280|NCT00312728|Drug|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
79827281|NCT00804921|Drug|bevacizumab|
79827282|NCT00804921|Procedure|anterior chamber paracentesis|
79827283|NCT00804921|Drug|acetazolamide|
79827284|NCT00804921|Drug|brimonidine|
79827285|NCT00866944|Drug|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
79827286|NCT00866944|Drug|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
79827287|NCT00866944|Drug|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
79827288|NCT00922155|Device|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
79827289|NCT00798681|Dietary Supplement|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
79232792|NCT04468269|Other|Task oriented balance training without sensory integration group|"Sitting position:~Sit in a chair without a backrest while keeping the feet on a firm surface.~Sit on a ball while keeping the feet on the firm surface~Sit to stand:~Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing on a firm surface.~Perform a semi-tandem stance on the firm surface~Walking:~Walk forward on a firm surface.~Walk forward on the firm surface, cross an obstacle, and then continue to walk.~Walk sideways~Walk Backward~Tandem walk"
79232793|NCT02445092|Other|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
79827290|NCT00798681|Other|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
79374399|NCT06023290|Diagnostic Test|Heart rhythm measurements with Preventicus®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
79374400|NCT06023290|Diagnostic Test|Heart rhythm measurements with FibriCheck®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
79528120|NCT03360214|Other|Placebo Drug|For sham drug, 0.9% saline, will be used.
79528121|NCT03360214|Device|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
79528122|NCT03360214|Other|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
79528123|NCT03360214|Drug|Ropivacaine Hydrochloride|For active drug, 0.25% naropin, will be used.
79528124|NCT03359239|Drug|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 [+/-2] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
79684554|NCT05469516|Device|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis"
79684555|NCT05469516|Device|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
79684556|NCT03457181|Other|music|effect of music on anxiety scores
79684557|NCT03457181|Other|operating room noise|effect of operating room noise on anxiety scores
79684558|NCT00537251|Drug|Insulin glargine|
79684559|NCT05311410|Other|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
79827291|NCT00798681|Other|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
79827292|NCT00577824|Drug|exenatide|subcutaneous injection, 5mcg, twice a day
79528125|NCT03359239|Biological|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
79684560|NCT05311410|Procedure|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
79684561|NCT05469399|Other|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
79684562|NCT05469399|Other|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
79528126|NCT03359239|Drug|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
79684563|NCT03457064|Behavioral|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
79374401|NCT06023290|Diagnostic Test|Heart rhythm measurements with Apple Watch®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
79528127|NCT03359239|Drug|Normal saline|0.19 mL
79684564|NCT05433740|Device|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
79684565|NCT05294133|Behavioral|physical activity|physical activity
79684566|NCT00537368|Drug|CNTO 888|
79684567|NCT05399342|Other|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
79684568|NCT05285709|Diagnostic Test|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
79684569|NCT05285709|Diagnostic Test|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
79684570|NCT05282238|Diagnostic Test|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
79684571|NCT00536367|Other|No intervention - observational study only|
79684572|NCT05468775|Behavioral|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
79684573|NCT05384717|Other|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
79684574|NCT05384717|Other|Control group|No intervention
79684575|NCT02399839|Drug|lomitapide|As prescribed by Physician.
79684576|NCT04321486|Other|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
79684577|NCT05468658|Other|Designing the birthing unit according to the philosophy of Feng Shui|"The cabinets will be painted using salmon and pastel green.~It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~Live nature videos and sounds will be projected onto the wall.~Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~Natural plants will be placed.~Lighting will be used.~Bed linen will be designed according to the Feng Shui.~Wooden bell will be used.~Turtle, elephant and Wu Lou objects will be placed.~The Bagua mirror will be placed.~Crystals will be placed.~Natural stones will be placed.~The fountain will be placed in the east compass direction of the unit.~Straw bamboo separator will be used."
79684578|NCT04319926|Drug|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
79684579|NCT04319926|Drug|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
79684580|NCT04320043|Procedure|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
79374402|NCT06023290|Diagnostic Test|Heart rhythm measurements with 6L Kardia Mobile®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
79374403|NCT06020937|Diagnostic Test|TDI|Sniffin' Sticks Threshold and Identification Test
79374404|NCT06020937|Diagnostic Test|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
79528128|NCT03350594|Behavioral|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
79528129|NCT03350594|Behavioral|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
79528130|NCT03336866|Drug|Placebo|Normal saline
79528131|NCT03336866|Drug|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
79684581|NCT05382416|Behavioral|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
79684582|NCT05194579|Combination Product|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
79827293|NCT00577824|Drug|exenatide|subcutaneous injection, 10mcg, twice a day
79232794|NCT05726175|Drug|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
79827294|NCT00577824|Drug|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
80000823|NCT04977453|Drug|GI-101A|Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
79232795|NCT05726175|Drug|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
79232796|NCT02444858|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10^5/kg) ，once a day,a total of three times.
80000824|NCT04975152|Drug|Cemiplimab-Rwlc|Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
79374405|NCT06020937|Diagnostic Test|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
79528132|NCT03336411|Behavioral|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
79232797|NCT02444858|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
79232798|NCT02444780|Procedure|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
79232799|NCT04484246|Other|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
79232800|NCT05319327|Other|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
79232801|NCT05319327|Other|Control|General counseling to adhere to a healthy Mediterranean diet
79374406|NCT06020937|Diagnostic Test|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
79528133|NCT03336411|Behavioral|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
79528134|NCT03335345|Other|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
79528135|NCT03335345|Other|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
79528136|NCT03332173|Drug|Zanubrutinib|Oral administration using 80 mg capsules
79827295|NCT04046289|Dietary Supplement|Low Calcium Milk|50 mg calcium/day
79827296|NCT04046289|Dietary Supplement|Regular Calcium Milk|400 mg/day
79827297|NCT04046289|Dietary Supplement|Probiotic 1|regular calcium milk + probiotic
79827298|NCT04046289|Dietary Supplement|Probiotic 2|regular calcium milk + probiotic
79374407|NCT06020937|Diagnostic Test|Visual Analogue Scale Ratings|"Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
79374408|NCT06020937|Diagnostic Test|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
79827299|NCT02554071|Other|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
79827300|NCT00855322|Other|Gym exercise group intervention|Gym based circuit class
79827301|NCT00855322|Other|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
79827302|NCT00855322|Other|Control group|No intervention
79827303|NCT00807807|Dietary Supplement|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
79827304|NCT00807807|Drug|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
80000825|NCT04968964|Device|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
80000826|NCT04968964|Other|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
80000827|NCT04943497|Other|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
80000828|NCT04943497|Other|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
80000829|NCT04943497|Other|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
80000830|NCT04943497|Other|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
79528137|NCT03328676|Drug|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
79684583|NCT05194579|Combination Product|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
79684584|NCT04320472|Other|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
79684585|NCT05378594|Diagnostic Test|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
79684586|NCT05468580|Procedure|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
79684587|NCT05468580|Procedure|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
79374409|NCT06018493|Device|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
79528138|NCT03328676|Drug|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
79827305|NCT05333406|Drug|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10^5 cells/kg"
79827306|NCT05333406|Drug|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10^6 cells/kg"
79232802|NCT03197168|Behavioral|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
79232803|NCT03197168|Behavioral|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
79232804|NCT04441515|Device|Ipod with music|music of patient's preference provided 2 hours daily
79827307|NCT00867256|Device|Large Diameter Metal on Metal|
79232805|NCT04441515|Device|ipod with books to listen|2 hours of daily listening to books
79232806|NCT04441515|Device|ipod only with usual care|participants given device only
79305629|NCT02314559|Drug|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
79374410|NCT06018493|Device|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
79374411|NCT06002191|Behavioral|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
79528139|NCT03324711|Diagnostic Test|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
79528140|NCT03322293|Drug|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
79528141|NCT03322293|Device|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
79528142|NCT03322033|Device|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
79528143|NCT03315039|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
79528144|NCT03308045|Biological|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
79528145|NCT03295773|Diagnostic Test|3DRA|
79528146|NCT03291652|Diagnostic Test|DSA/3DRA|DSA/3DRA
79827308|NCT00805077|Procedure|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
79827309|NCT00805077|Other|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
79827310|NCT00870298|Drug|Trimethoprim/Sulfamethoxazole and Warfarin|
79827311|NCT00730340|Procedure|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
79827312|NCT00730340|Procedure|Tonsillectomy with open fossa|SOP for a tonsillectomy.
79827313|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
79827314|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
79827315|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
79827316|NCT04016350|Behavioral|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
79827317|NCT04016350|Behavioral|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
79232807|NCT03107156|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
79232808|NCT03530085|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
79232809|NCT03530085|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
79827318|NCT00725166|Other|Skeletal muscle aging|"W1 - Blood test~Maximal voluntary contraction of quadriceps~Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
79232810|NCT03530085|Drug|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
79232811|NCT03107390|Other|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
79232812|NCT03525639|Diagnostic Test|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
79232813|NCT02712320|Drug|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
79232814|NCT03527667|Behavioral|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
79374412|NCT06002191|Behavioral|Questionnaires of Online Experiences|Adolescents will receive brief questionnaires related to their online experiences and the impact those experiences have had on their stress level.
79374413|NCT06001853|Drug|BM-MSC injection|BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
79232815|NCT03197012|Drug|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
79232816|NCT03197012|Drug|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
79232817|NCT02449304|Device|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
79232818|NCT03196856|Behavioral|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
79232819|NCT03196856|Dietary Supplement|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
79232820|NCT03196856|Dietary Supplement|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
79374414|NCT06001853|Drug|DSMO Injection|After 12 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
79374415|NCT05999812|Drug|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
79528147|NCT03276533|Drug|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
79528148|NCT03276533|Drug|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
79528149|NCT03276533|Drug|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
79827319|NCT02575742|Device|3D-Transit system|
79827320|NCT00807963|Drug|rHuPH20|recombinant human hyaluronidase PH20 injection
79827321|NCT00807963|Drug|zoledronic acid|subcutaneous injection
79827322|NCT05227066|Other|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
79827323|NCT05227066|Other|traditional physical therapy group|traditional physical therapy group
79232821|NCT03530007|Drug|Normal saline|normal saline used for prevention of spinal shivering
79232822|NCT03530007|Drug|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
79232823|NCT03530007|Drug|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
79374416|NCT05999812|Drug|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
79374417|NCT05999812|Drug|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
79374419|NCT05998837|Drug|Dapagliflozin 10mg Tab|"Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
80000831|NCT04941456|Other|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
79232824|NCT03194048|Other|Functional Chewing Training|"FuCT;~Family training~Providing optimal sitting posture for children to support oral sensorimotor functions~Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~Massage of the upper and lower gums through the front teeth to molar area~Chewing training to stimulate lateral and rotational tongue movements~Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
79528150|NCT03276533|Drug|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
79528151|NCT03258996|Procedure|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
79528152|NCT03258996|Procedure|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
79528153|NCT03254394|Drug|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
79528154|NCT03254394|Drug|Placebo|Dextrose 5% in water will be administered as active comparator.
79684588|NCT04206943|Biological|Car-T Cell Therapy|"Lymphodepletion Protocol:~-6. Day: Cyclophosphamide 300 mg / m^2 i.v.~-5. -4. and -3. Days: Fludarabine 30 mg / m^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
79827324|NCT05210634|Dietary Supplement|THCv|THCv in MCT oil
79827325|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
79827326|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
79827327|NCT00805233|Drug|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
79827328|NCT00805233|Drug|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
79827329|NCT00725244|Device|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
80000832|NCT04941456|Device|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
79528155|NCT03254394|Drug|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
80000833|NCT04936542|Biological|AboBoNT-A|AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)
80000834|NCT04936542|Biological|OnaBoNT-A|OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
80000835|NCT04933851|Behavioral|ACT1VATE|ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.
80000836|NCT04933851|Behavioral|DSME/S|Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
80000837|NCT04931563|Biological|Anifrolumab|Intravenous infusion (IV)
80000838|NCT04931563|Drug|placebo|Intravenous infusion (IV)
79232825|NCT03194048|Other|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~Family training~passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
79232826|NCT03202238|Other|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
79232827|NCT03202238|Device|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
79232828|NCT03202238|Device|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
79232829|NCT03529929|Drug|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
79827330|NCT00725244|Device|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
80000839|NCT04905407|Drug|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
80000840|NCT04905407|Drug|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
80000841|NCT04905407|Drug|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
79528156|NCT03253809|Device|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
80016664|NCT05120050|Device|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H&E staining etc.
79232830|NCT03202394|Drug|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
79232831|NCT03202394|Drug|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
79232832|NCT03052751|Drug|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
79232833|NCT03052751|Other|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
79232834|NCT03525561|Drug|Acetazolamide Pill|Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
79528157|NCT03252314|Device|Second-generation hydrogel coils|Hydrogel coils 90% by length
79684589|NCT01313923|Drug|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
79684590|NCT01313884|Drug|Irinotecan|50 mg/m2/day x 5 days
79827331|NCT02569502|Drug|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
79827332|NCT00798837|Radiation|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions~A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
79827333|NCT02569580|Device|Topically|"use the No More medical device as anti lice treatment"
79232835|NCT03525561|Drug|Placebo pill|Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
79232836|NCT03202004|Drug|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
79374420|NCT05998837|Drug|Placebo|"Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
79528158|NCT03247205|Behavioral|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
79528159|NCT03227081|Behavioral|Sleep Deprivation|Sleep Deprivation
79528160|NCT03203876|Biological|Lirilumab|Specified dose on specified days
79684591|NCT01313884|Drug|Vincristine|2 mg/m2 to a maximum of 2 mg
79232837|NCT03202004|Drug|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
79232838|NCT05270265|Biological|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
79305630|NCT04934709|Device|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
79374421|NCT05992571|Other|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
79374422|NCT05992571|Dietary Supplement|β-OHB|Ingestion of a high dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
79232839|NCT03118700|Other|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
79827334|NCT00725400|Other|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
79528161|NCT03203876|Biological|Nivolumab|Specified dose on specified days
79827335|NCT00725400|Procedure|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
79827336|NCT00798915|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
79827337|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
79827338|NCT00798915|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
79232840|NCT03118700|Other|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
79827339|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
79827340|NCT00730496|Procedure|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
79827341|NCT00798993|Other|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
79528162|NCT03203876|Biological|Ipilimumab|Specified dose on specified days
79684592|NCT01313884|Drug|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
79827342|NCT00798993|Drug|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
79827343|NCT00798993|Other|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
79827344|NCT00725582|Drug|IMA-026|
79827345|NCT00725582|Other|Placebo|
79827346|NCT00862108|Drug|Methylphenidate|mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
79827347|NCT04041154|Behavioral|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
79827348|NCT04041154|Behavioral|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
80016665|NCT03953599|Biological|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
79232846|NCT03527511|Other|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
79305631|NCT04934709|Device|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
79528163|NCT03191240|Drug|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
79528164|NCT03191240|Drug|Normal saline|Placebo
79528165|NCT03180294|Drug|Bupropion 150 mg XL|By mouth
79528166|NCT03180294|Drug|Placebo|By mouth
79684593|NCT01313884|Drug|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
79684594|NCT01313884|Drug|Cytoxan|1200 mg/m2
79684595|NCT01313884|Drug|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
79684596|NCT05352659|Behavioral|Face-to-face and online LGBTQ+ training|The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.
79684597|NCT05352659|Behavioral|On-line training|This study arm receives only links to publicly available on-line LGBTQ training.
79684598|NCT01158664|Device|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
79684599|NCT01158664|Device|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
79232847|NCT05696691|Drug|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
80000842|NCT04896736|Other|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase >/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
79305632|NCT04955535|Procedure|Arthroscopic synovectomy|Arthroscopic synovectomy
79684600|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
79827349|NCT04041154|Behavioral|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
79827350|NCT00862264|Drug|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
80000843|NCT04896736|Other|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
79374423|NCT05989100|Behavioral|Favourate taste stimulation|The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.
79374424|NCT05989100|Behavioral|Sour taste stimulation|Using sour swab to brush oral cavity and tounge.
79374425|NCT05989100|Behavioral|Thermal stimulation group|Only ice-water swab to brush oral cavity and tounge.
79374426|NCT05985395|Behavioral|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
79374427|NCT05982665|Other|Molecular hydrogen|Hydrogen gas, purity >99.9%, flow rate 300 ml/min.
79684601|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
79374428|NCT05982665|Other|Placebo|Ambient air, flow rate 300 ml/min.
79827351|NCT02569424|Behavioral|Patient's position|Supine or Trendelenburg strict -20°)
79827352|NCT00870376|Other|biomarkers|To define a biomarker or combination of overactive bladder syndrome
79827353|NCT02844660|Biological|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
79827354|NCT02844660|Other|Standard of Care|moist wound therapy and offloading
80000844|NCT04880863|Drug|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP will be administered in a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1.
79374429|NCT05977530|Behavioral|self-rescue training|children will receive training for self-rescue if they are alone in water
79374430|NCT05972265|Behavioral|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
79374431|NCT05972265|Behavioral|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
79374432|NCT05972265|Behavioral|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
79528167|NCT03147222|Behavioral|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
79528168|NCT03122743|Procedure|Biospecimen Collection|Undergo collection of serum samples
79528169|NCT03122743|Other|Laboratory Biomarker Analysis|Correlative studies
79528170|NCT03122743|Other|Questionnaire Administration|Ancillary studies
79305633|NCT03239093|Other|No intervention|Observational study using official data from the Federal Office of Statistics
79305634|NCT04934631|Other|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
79684602|NCT05193240|Diagnostic Test|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
79684603|NCT00537563|Drug|Telithromycin|
79684604|NCT00536406|Behavioral|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
79684605|NCT00536406|Behavioral|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
79374433|NCT05972265|Other|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
80000845|NCT04880863|Drug|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel will be administered in combination with the study drug, NAP, on Day 2.
79684606|NCT01135459|Drug|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
79684607|NCT01135459|Drug|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
79684608|NCT00537602|Drug|miglustat|
79684609|NCT00537602|Drug|placebo|
79684610|NCT05178667|Dietary Supplement|High dose|Food supplements are consumed during 3 months by healthy volunteers.
79684611|NCT05178667|Dietary Supplement|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
80000846|NCT04880863|Drug|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
79232848|NCT05696691|Behavioral|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
79684612|NCT05178667|Dietary Supplement|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
79684613|NCT00221572|Procedure|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
79684614|NCT00536445|Device|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
79374434|NCT05972265|Other|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
79374435|NCT05972265|Other|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
79684615|NCT01259284|Drug|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
79684616|NCT01259284|Dietary Supplement|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
80000847|NCT04871282|Drug|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
80000848|NCT04871282|Other|Placebo|Placebo to match AL102
80000849|NCT04865770|Drug|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
79232849|NCT04760483|Device|SoracteLite(TM) TPLA for BPH|see prior section
79305635|NCT04934631|Other|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
79305636|NCT03238937|Device|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
79684617|NCT01259284|Other|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
79684618|NCT03457025|Drug|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
79684619|NCT03457025|Drug|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
79684620|NCT03457025|Device|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
79684621|NCT01259245|Other|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
79684622|NCT01259245|Other|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
79684623|NCT00537719|Drug|GSK716155|albiglutide subcutaneous injection
79684624|NCT00537719|Drug|Placebo|placebo injection
80000850|NCT04865770|Drug|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
80000851|NCT04859946|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
80000852|NCT04859946|Drug|Busulfan|Given IV
80000853|NCT04859946|Drug|Cyclophosphamide|Given IV
80000854|NCT04859946|Drug|Fludarabine|Given IV
79232850|NCT03525483|Diagnostic Test|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
79232851|NCT03529851|Other|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
79374436|NCT05972265|Other|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
80000855|NCT04859946|Drug|Itacitinib|Given PO
80000856|NCT04859946|Drug|Tacrolimus|Given IV or PO
79528171|NCT03111030|Behavioral|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~An assessment of motivated the participant is to be physically active~A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~Progress and barriers will be reassessed and discussed."
79684625|NCT04685603|Biological|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
79684626|NCT04685837|Other|therapeutic exercise|"As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants."
79827355|NCT00730574|Dietary Supplement|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
80000857|NCT04859946|Drug|Thiotepa|Given IV
79232852|NCT03527355|Biological|Vi-DT|Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
79232853|NCT03527355|Biological|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
79528172|NCT03098797|Drug|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
80000858|NCT04855734|Behavioral|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach [Sessions 1 & 2] and Respecting Choices [Session 3].
80000859|NCT04852328|Drug|CUE-101|CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
80000860|NCT04848961|Behavioral|LungTalk|MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
79232854|NCT03527355|Other|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
79232855|NCT01317797|Drug|namilumab (MT203)|administered three times, subcutaneous in the abdomen
79232856|NCT01317797|Drug|Placebo|administered three times, subcutaneous in the abdomen
79232857|NCT05595395|Drug|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
79232858|NCT05595395|Drug|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
79232859|NCT03529617|Other|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
79528173|NCT03096067|Other|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
79528174|NCT03096067|Other|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
80000861|NCT04847466|Drug|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
80000862|NCT04847466|Drug|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
80000863|NCT04847466|Biological|PD-L1 t-haNK|PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
80000864|NCT04845035|Drug|Dasatinib|By mouth
80000865|NCT04845035|Drug|Ponatinib|By mouth
80000866|NCT04845035|Drug|Berlin-Frankfurt-Münster Chemotherapy|with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
79528175|NCT03095313|Other|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol [Omnipaque™]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
79684627|NCT00536562|Behavioral|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition & psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
79684628|NCT04685174|Device|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
79827356|NCT02570048|Device|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
79827357|NCT00870532|Drug|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
79827358|NCT00870532|Drug|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
79827359|NCT02771496|Other|Other: observational only- no intervention|Other: observational only- no intervention
79827360|NCT05121402|Drug|TLL018|a TYK2/JAK1 inhibitor
79827361|NCT05121402|Other|Placebo|a TLL018 Placebo
79232860|NCT05707169|Procedure|Saphenous Ablation|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
79232861|NCT05707169|Device|Endogenous Laser Ablation (EVLA)|Endogenous Laser Ablation (EVLA)
79528176|NCT03090295|Device|Palpation and Accuro|Identify placement for spinal
79827362|NCT00867724|Device|Aer-O-Scope Colonoscopy|Screening Colonoscopy
79827363|NCT02570516|Procedure|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
79827364|NCT00725478|Drug|Piribedil|
79528177|NCT03071601|Drug|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
79528178|NCT03071601|Drug|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
79684629|NCT00537758|Behavioral|Cognitive Behavior Therapy|
79684630|NCT00537758|Behavioral|CBT and BWL|
79684631|NCT00537758|Behavioral|Behavioral Weight Loss Treatment|
79684632|NCT04685096|Other|Test product creme|twice daily application of creme containing 2% NMN
79684633|NCT04685096|Other|Reference creme|twice daily application of reference creme
79684634|NCT05121090|Behavioral|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
79827365|NCT00730652|Biological|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
79827366|NCT01951274|Drug|VPD-737|NK1 Receptor Antagonist
79827367|NCT01951274|Drug|Placebo|
79827368|NCT00725556|Other|Speech Therapy|Speech Therapy
79827369|NCT03355794|Drug|ribociclib|Oral capsule or liquid formula
79827370|NCT03355794|Drug|Everolimus|Oral tablets or dispersible tablets
79827371|NCT01487174|Drug|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
79827372|NCT01487174|Drug|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
79684635|NCT00537797|Other|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
79684636|NCT00537836|Drug|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
79684637|NCT00537836|Drug|Placebo|Placebo, once daily p.o. over 8 weeks
79684638|NCT00537836|Drug|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
79684639|NCT05468268|Device|20 Hz rTMS|rTMS stimulation
79827373|NCT00725634|Biological|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
79827374|NCT00725634|Biological|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
80000867|NCT04845035|Drug|Methotrexate and Cytarabine|Intrathecal
79232862|NCT05707169|Drug|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
80000868|NCT04840862|Drug|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
80000869|NCT04840862|Drug|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
80000870|NCT04838626|Drug|[18F]CTT1057|PET/CT imaging with [18F]CTT1057
79374437|NCT05972265|Other|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
80000871|NCT04826341|Drug|Berzosertib|Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.
79528179|NCT03061903|Device|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
79528180|NCT03061903|Device|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
80000872|NCT04826341|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
80000873|NCT04823663|Device|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
80000874|NCT04823663|Procedure|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
79528181|NCT03061643|Drug|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
79528182|NCT03061643|Other|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
79684640|NCT05468268|Device|Sham rTMS|Sham stimulation
79684641|NCT02277171|Device|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
79684642|NCT00537875|Dietary Supplement|Ginger|Capsule, 1000 mg, BID, 3 days
80000875|NCT04821622|Drug|talazoparib plus enzalutamide|experimental arm
79528183|NCT03061630|Drug|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
80000876|NCT04821622|Drug|Placebo plus enzalutamide|Active comparator arm
80000877|NCT04817644|Drug|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
80000878|NCT04816708|Behavioral|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
79232863|NCT05707091|Other|Low level laser therapy and conventional therapy|One group treated with low level laser therapy along with conventional therapy
79232864|NCT05707091|Procedure|Conventional therapy|Group B treated with ems and exercises
79528184|NCT03061630|Drug|Cisplatin|D1: CISPLATIN 60G/M2
79528185|NCT03055390|Drug|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
79528186|NCT03055390|Drug|placebo|2ml of saline intravenous
79528187|NCT03039140|Other|Educational Intervention|Attend weekly educational sessions
79528188|NCT03039140|Behavioral|Exercise Intervention|Participate in CR program
79528189|NCT03039140|Other|Quality-of-Life Assessment|Ancillary studies
79528190|NCT03039140|Other|Questionnaire Administration|Ancillary studies
79684643|NCT00537875|Dietary Supplement|Placebo|Capsule, 1000 mg, BID, 3 days
80000879|NCT04789291|Drug|BI 1595043|Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
80000880|NCT04784715|Drug|Trastuzumab deruxtecan|Administered by intravenous infusion
80000881|NCT04784715|Drug|Placebo|Administered by intravenous infusion
79684644|NCT00551564|Drug|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
79684645|NCT05105061|Drug|Ketamine (Ketalar)|0.5 mg/kg of body weight
79684646|NCT05105061|Drug|Placebo|IM injection of matching placebo
79684647|NCT04870463|Procedure|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
79232865|NCT03525249|Dietary Supplement|nutraceutical|Subjects will consume a capsule for eight weeks
79232866|NCT03529539|Drug|PSV|
79232867|NCT03627221|Behavioral|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
79232868|NCT02712008|Drug|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
79684648|NCT00551603|Drug|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
80000882|NCT04784715|Drug|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
80000883|NCT04784715|Drug|Pertuzumab|Administered by intravenous infusion
80000884|NCT04784715|Drug|Trastuzumab|Administered by intravenous infusion
80000885|NCT04781387|Drug|CRS3123|Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days
79232869|NCT02712008|Drug|Intravitreal Aflibercept Injection (IAI)|
79827375|NCT01248806|Radiation|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
79827376|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
79827377|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
80000886|NCT04781387|Drug|Active Comparator|Active comparator is administered 125 mg PO QID
79232870|NCT03527121|Other|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
79232871|NCT03527121|Other|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
79232872|NCT05130515|Drug|Niraparib|Niraparib 200mg po QD, day1~21
79232873|NCT05130515|Drug|Anlotinib|Anlotinib 10mg po QD, day1~14, 3 weeks/cycle
79232874|NCT03525171|Diagnostic Test|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
79528191|NCT03033056|Behavioral|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
79684649|NCT00551603|Drug|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
79684650|NCT05093712|Other|Educational Intervention|Watch educational video
79827378|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
79827379|NCT02570724|Drug|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
79827380|NCT02570724|Biological|blood patch|
79827381|NCT00725738|Genetic|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
80000887|NCT04780464|Drug|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
80000888|NCT04780464|Drug|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
79232875|NCT04484324|Other|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
79232876|NCT04483934|Biological|Dermal fibroblasts|"Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
79232877|NCT04483934|Device|LED phototherapy|LED phototherapy
79232878|NCT03626987|Diagnostic Test|mass spectrometry (MALDI-TOF)|The determination of the protein composition of the bacterial spectrum
79528192|NCT03015142|Device|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
79528193|NCT03012672|Drug|Cladribine|Given IV
79528194|NCT03012672|Drug|Cytarabine|Given IV
79528195|NCT03012672|Biological|Granulocyte Colony-Stimulating Factor|Given SC
79528196|NCT03012672|Drug|Mitoxantrone Hydrochloride|Given IV
79528197|NCT03012672|Other|Quality-of-Life Assessment|Ancillary studies
79528198|NCT03012672|Other|Questionnaire Administration|Ancillary studies
79684651|NCT05093712|Other|Survey Administration|Complete surveys
79827382|NCT00862342|Drug|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
79232879|NCT03201926|Dietary Supplement|mealworms|10g , 3 times a day , po, 2 months
79827383|NCT00870610|Procedure|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
79827384|NCT00730808|Dietary Supplement|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
79827385|NCT02544724|Biological|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
79827386|NCT00867880|Drug|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
79827387|NCT04040374|Diagnostic Test|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
80000889|NCT04780464|Drug|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
79232880|NCT03201926|Dietary Supplement|grain powder|grain powder, 10g ,3times one day,2months
79305637|NCT03056859|Device|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
79305638|NCT03238859|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
80000890|NCT04780464|Drug|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
80000891|NCT04780464|Drug|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
80000892|NCT04777396|Drug|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
80000893|NCT04777396|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
80000894|NCT04772807|Device|Kinocardiograph|Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone
79684652|NCT04864262|Other|Photovoice|Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
79684653|NCT04853264|Device|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
79684654|NCT04853264|Device|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
79827388|NCT04040374|Diagnostic Test|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
79827389|NCT00862420|Drug|clopidogrel (SR25990)|oral administration (tablets)
79827390|NCT00862420|Drug|ticlopidine|oral administration (tablets)
79827391|NCT00321698|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
79827392|NCT00321698|Drug|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
80000895|NCT04765202|Procedure|AG Tx|The control treatment is meshed autograft applied to a FT burn area
79232881|NCT03626909|Other|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
79305639|NCT03238859|Device|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
79374438|NCT05970406|Other|high intensity dysphagia therapy|Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
79528199|NCT03011775|Drug|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
79528200|NCT03011775|Drug|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
80000896|NCT04765202|Biological|SOMA Tx|The experimental treatment is more widely meshed autograft than the AG Tx site applied to a FT burn area and covered with SOMA
80000897|NCT04761198|Drug|Etigilimab dosing|IV infusion of IV etigilimab every 2 weeks
79528201|NCT03011775|Drug|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
79528202|NCT03011775|Drug|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
80000898|NCT04761198|Drug|Nivolumab|IV infusion of nivolumab every 2 weeks
80000899|NCT04759911|Other|Quality-of-Life Assessment|Ancillary studies
80000900|NCT04759911|Other|Questionnaire Administration|Ancillary studies
80000901|NCT04759911|Drug|Selpercatinib|Given PO
80000902|NCT04759911|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
80000903|NCT04754711|Dietary Supplement|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
80000904|NCT04745559|Biological|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
79374439|NCT05970224|Drug|Ir-CPI|Participants receive a single intravenous dose of Ir-CPI during 48 hours
79374440|NCT05968170|Device|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
79374441|NCT05961215|Device|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
79528203|NCT03011775|Drug|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
79528204|NCT03011775|Drug|Ramipril 5 MG|1 tablet per a day
79528205|NCT03011346|Device|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
79528206|NCT03011346|Device|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
79232882|NCT03626909|Other|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
79232883|NCT03626909|Other|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
79528207|NCT03007485|Other|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
79374442|NCT05954741|Other|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
79374443|NCT05954741|Other|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
80000905|NCT04745559|Biological|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
80000906|NCT04738838|Drug|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
80000907|NCT04738838|Drug|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
79232884|NCT03626909|Other|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
79374444|NCT05954741|Other|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
79374445|NCT05941416|Diagnostic Test|Nordic Orofacial test- screening arabic modified version|Nordic Orofacial Test- screening is an instrument that can be used for the identification of orofacial myofunctional disorders in children aged three years or older, in youths and in adults. It is divided into two sections, interview and examination. The screening can be directed by dental or health care professional personnel.
79374446|NCT05934994|Other|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
79528208|NCT02998476|Drug|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
79684655|NCT05075811|Drug|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
80000908|NCT04736121|Device|Resin microspheres containing yttrium-90 (Y-90)|Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
79528209|NCT02960997|Drug|Sirolimus, 2%|
79684656|NCT05075811|Other|Placebo|Normal Saline
79684657|NCT04806191|Other|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
79232885|NCT03202082|Behavioral|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
79528210|NCT02960997|Drug|Vehicle|
79528211|NCT02951104|Device|Ultrasonic Cardiac Output Monitor (USCOM) system|
79528212|NCT02947217|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
79684658|NCT04806191|Other|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
79684659|NCT04806191|Other|Treatment as usual (TAU)|Usual care as provided by the GP
79684660|NCT00551681|Device|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
79684661|NCT00551681|Device|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
79684662|NCT04686045|Other|observational study|observational study
79684663|NCT00551720|Behavioral|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
79684664|NCT00551720|Behavioral|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
79684665|NCT04686201|Device|Diabetes Mobile Application|incorporating mobile application usage in managing diabetes mellitus patient in health clinics
79232886|NCT03201692|Device|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
79827393|NCT02569944|Procedure|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
79827394|NCT02569944|Procedure|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
79827395|NCT00725894|Device|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
79232887|NCT03201692|Device|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
79232888|NCT02450084|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
79232889|NCT02450084|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
79374447|NCT05930756|Procedure|Radiofrequency ablation|Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
79374448|NCT05925868|Behavioral|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
79374449|NCT05925634|Behavioral|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
79374450|NCT05925634|Behavioral|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
79684666|NCT00551798|Procedure|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
79232890|NCT02450084|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
79232891|NCT02450084|Drug|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
79232892|NCT04467177|Other|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
79232893|NCT04467177|Other|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
79232894|NCT03196622|Device|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
79232895|NCT05706467|Device|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
79232896|NCT05706467|Device|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
79232897|NCT03201770|Drug|pyronaridine artesunate|Antimalarial treatment
79391012|NCT03183648|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
79528213|NCT02947217|Other|Sterile Saline|0.5 mL of sterile Saline administered im
79528214|NCT02924480|Procedure|Cystectomy|
79528215|NCT02924480|Drug|Lidocaine|Patients will receive lidocaine infusion during surgery
79528216|NCT02924480|Drug|Saline|Patients will receive saline infusion during surgery
79684667|NCT05056584|Biological|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
79684668|NCT05056584|Biological|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
79232898|NCT03529305|Device|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
79232899|NCT03529305|Other|Physical therapy|Receive physical therapy
79232900|NCT02444468|Device|Flowtron ACS800|Flowtron ACS800 and bandage
79232901|NCT02444468|Other|Bandage|Bandage only
79232902|NCT03196700|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
79528217|NCT02924064|Drug|Teneligliptin 20mg|
79528218|NCT02924064|Drug|Placebo|
79528219|NCT02924064|Drug|Metformin ≥ 1000 mg|
79528220|NCT02916706|Drug|Teneligliptin 20mg|
79528221|NCT02916706|Drug|Placebo|
79684669|NCT05467995|Biological|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
79684670|NCT05467995|Biological|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
79528222|NCT02889900|Drug|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
79684671|NCT00551915|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
79684672|NCT00551915|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
79684673|NCT00551915|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
79684674|NCT00551915|Biological|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
79684675|NCT00551915|Biological|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
79684676|NCT00551954|Drug|acarbose|100 mg (tablets) t.i.d.
79684677|NCT00551954|Drug|placebo|one tablet t.i.d.
79684678|NCT05467956|Other|Covid-19|Covid-19 disease
79684679|NCT00551993|Procedure|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
79684680|NCT00551993|Procedure|Laparoscopic Sacral Colpopexy|Standard laparoscopy
79374451|NCT05918952|Diagnostic Test|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
79827396|NCT02544568|Other|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
79827397|NCT02569970|Drug|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
79827398|NCT02569970|Drug|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
79827399|NCT00867958|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
79827400|NCT04066998|Other|Tears sampling|Tears sampling
79827401|NCT04066998|Other|Lashes sampling|Lashes sampling
79827402|NCT00868036|Procedure|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
79827403|NCT00725972|Other|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
79827404|NCT00725972|Procedure|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
79827405|NCT00725790|Drug|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
79827406|NCT00725790|Drug|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
79374452|NCT05918952|Other|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
79528223|NCT02882022|Device|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
79528224|NCT02879942|Other|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
79528225|NCT02879942|Other|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
79528226|NCT02873819|Drug|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
79528227|NCT02873819|Drug|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
79684681|NCT00552149|Drug|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
79684682|NCT05467878|Other|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
79684683|NCT03455699|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
79684684|NCT03455699|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
79528228|NCT02873819|Drug|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
79528229|NCT02873819|Drug|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
80000909|NCT04734652|Combination Product|Biktarvy®|"Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose."
79374453|NCT05917626|Behavioral|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
79374454|NCT05909553|Drug|Venetoclax|Oral; Tablet
79684685|NCT03455699|Device|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
80000910|NCT04734652|Combination Product|TLD- fixed-drug combination single tablet|Standard of care Dolutegravir-based regimen
80000911|NCT04732247|Drug|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
80000912|NCT04732247|Drug|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
80000913|NCT04710940|Behavioral|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
80000914|NCT04710940|Behavioral|Usual Care|Participants will receive usual care for DSMT.
79528230|NCT02873819|Drug|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
79528231|NCT02866695|Drug|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
79528232|NCT02862964|Other|identify L4/L5|"For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
79232903|NCT03196544|Behavioral|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
79528233|NCT02834793|Drug|Placebo|Participants will receive matching placebo in Randomization phase.
79684686|NCT00536640|Drug|Erlotinib|150 mg per os, given daily until tumor progression
79684687|NCT00536640|Drug|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
79232904|NCT03196544|Behavioral|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
79232905|NCT04205799|Drug|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
79232906|NCT03201614|Device|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
79232907|NCT03201614|Device|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
79374455|NCT05896436|Behavioral|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
79684688|NCT00536640|Drug|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
79684689|NCT00536640|Drug|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
79684690|NCT00552227|Drug|ruboxistaurin|oral 32 mg daily
79684691|NCT00552227|Other|placebo|placebo
80000915|NCT04706689|Behavioral|SWADOC tool|"The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items."
80000916|NCT04706689|Behavioral|FOTT-SAS|"Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required"
80000917|NCT04697719|Drug|Aspirin 81mg|81mg oral capsule
80000918|NCT04697719|Drug|Aspirin 325mg|325mg oral capsule
80000919|NCT04682483|Drug|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
80000920|NCT04682483|Drug|Inotrope|Inotropes include dobutamine and milrinone.
80000921|NCT04682483|Device|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
79528234|NCT02834793|Drug|Perampanel|Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
79827407|NCT00862498|Other|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
79528235|NCT02810457|Drug|FKB238 (bevacizumab)|
79528236|NCT02810457|Drug|Avastin (bevacizumab)|
79528237|NCT02810457|Drug|Paclitaxel|
79528238|NCT02810457|Drug|Carboplatin|
79528239|NCT02803242|Other|Patient Reported Outcomes|
79684692|NCT00536679|Drug|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
79684693|NCT00536679|Drug|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
79684694|NCT00536679|Drug|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
79684695|NCT04793477|Device|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
79684696|NCT04974801|Device|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
79684697|NCT04974801|Device|Usual Care|Continued Usual Care routines.
79684698|NCT04967430|Drug|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
79528240|NCT02745535|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|
80000922|NCT04681066|Drug|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
80000923|NCT04681066|Other|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
80000924|NCT04670822|Behavioral|Breastfeeding promotion|The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
80000925|NCT04670822|Behavioral|Attention placebo control|The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
80000926|NCT04669600|Drug|SAR445088 (BIVV020)|Pharmaceutical form:solution for injection
79827408|NCT00731276|Drug|irinotecan hydrochloride|
79827409|NCT00731276|Other|pharmacogenomic studies|
79827410|NCT00731276|Other|pharmacological study|
79232908|NCT03201614|Drug|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
79232909|NCT03201536|Device|conventional Suture|Sutures
79232910|NCT03201536|Device|Zip3|wound closure device
79528241|NCT02730312|Biological|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
79528242|NCT02729701|Drug|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
79528243|NCT02723305|Other|No intervention|
79528244|NCT02684253|Drug|Nivolumab|
79528245|NCT02684253|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
79528246|NCT02683356|Other|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
79528247|NCT02683356|Other|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
79528248|NCT02681406|Behavioral|ACHESS|Smartphone based additions focused application, encouraging social support
79528249|NCT02681406|Behavioral|TMC|Brief telephone monitoring and counseling
79528250|NCT02666794|Drug|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
79528251|NCT02666794|Drug|Epidural sufentanil|20 mcg
79528252|NCT02666794|Procedure|Placement of the epidural catheter|Placement of the epidural catheter
79528253|NCT02666794|Drug|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
79528254|NCT02666794|Drug|Intrathecal morphine|60 mcg
79528255|NCT02666794|Procedure|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
79528256|NCT02666794|Drug|Intrathecal sufentanil|5 mcg
80000927|NCT04660955|Other|No Intervention - Observational study with MRI|90 minute MRI of the knees
80000928|NCT04652154|Other|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
80000929|NCT04648904|Radiation|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
80000930|NCT04631406|Biological|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
80000931|NCT04630496|Behavioral|Fitbit|Electronic activity tracker
80000932|NCT04619251|Drug|BI 1323495|BI 1323495
80000933|NCT04619251|Drug|Placebo|Placebo
80000934|NCT04619251|Drug|Itraconazole|Itraconazole
79684699|NCT04967430|Other|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
80000935|NCT04600466|Other|Molecular testing for all participants.|Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
79684700|NCT04783103|Device|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
79684701|NCT01259089|Drug|erlotinib hydrochloride|Given orally
80000936|NCT04600466|Other|Germline Testing|Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
80000937|NCT04600466|Other|Survey|Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
79232911|NCT03856190|Other|Fasting and plant-based nutrition|The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
79232912|NCT03856190|Other|Standard Nutrition Counselling|The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
79232913|NCT04176393|Drug|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
79374456|NCT05891158|Drug|Fazirsiran|Fazirsiran SC injection.
79374457|NCT05890794|Biological|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
79374458|NCT05890794|Biological|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
79374459|NCT05889221|Other|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
79374460|NCT05886816|Drug|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
79374461|NCT05886816|Other|Placebo|Placebo pills
79528257|NCT02656550|Procedure|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
79528258|NCT02655055|Procedure|high frequency voluntary apheresis blood donation|
79528259|NCT02625090|Drug|UCB0942|"Active Substance: UCB0942~Pharmaceutical form: Film-coated tablet~Concentration: 25 mg, 100 mg or 200 mg~Route of Administration: oral"
79528260|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
79684702|NCT01259089|Drug|Hsp90 inhibitor AUY922|Given IV
79684703|NCT01259089|Other|laboratory biomarker analysis|Correlative studies
79684704|NCT01259089|Procedure|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
79684705|NCT01259089|Genetic|mutation analysis|Correlative studies
79684706|NCT01259089|Other|pharmacological study|Correlative studies
80000938|NCT04591743|Device|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
80000939|NCT04591743|Device|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
80000940|NCT04591743|Drug|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
80000941|NCT04591743|Other|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
80000942|NCT04564898|Drug|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
80000943|NCT04564898|Drug|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
80000944|NCT04564898|Drug|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
79374462|NCT05873556|Behavioral|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
79827411|NCT00725868|Other|Data private hospitals, angioplasty, sampling of blood|"Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~coronary angioplasty~Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
79374463|NCT05872789|Drug|Diazepam 1% oral gel|Diazepam 1% used with topic oral gel on tongue and palate twice daily.
79827412|NCT00868114|Biological|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
79827413|NCT00731354|Device|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
79827414|NCT00731354|Device|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
79827415|NCT00725946|Drug|Iodine-124|
80000945|NCT04559334|Device|Tetrasodium EDTA Catheter Lock Solution|KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
80000946|NCT04552769|Drug|Abemaciclib|200 mg orally
80000947|NCT04550832|Drug|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
79374464|NCT05872789|Drug|Placebo|Placebo oral gel used on tongue and palate twice daily.
79374465|NCT05870033|Device|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
79374466|NCT05856513|Drug|ZSP1273|Participants receive ZSP1273 orally.
79528261|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
79684707|NCT05467839|Device|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
79684708|NCT05142436|Other|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
79684709|NCT05142436|Other|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
79684710|NCT05142436|Other|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
79684711|NCT05142436|Other|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
79684712|NCT05142436|Other|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
79684713|NCT04960176|Procedure|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
79684714|NCT04960176|Procedure|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
79684715|NCT05466513|Other|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
79827416|NCT00725946|Radiation|PET/CT with Iodine-124|
79827417|NCT02569346|Drug|Triumeq|Single-dose Triumeq as a whole tablet
79827418|NCT02569346|Drug|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
80000948|NCT04550832|Drug|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
79374467|NCT05856513|Drug|ZSP1273|Participants receive ZSP1273 orally.
79374468|NCT05856513|Drug|ZSP1273|Participants receive ZSP1273 orally.
79374469|NCT05852717|Procedure|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
79374470|NCT05852717|Drug|GDP|Gemcitabine Cisplatin Dexamethasone
79374471|NCT05852717|Drug|Epcoritamab|Epcoritamab
79528262|NCT02619552|Drug|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
79528263|NCT02612038|Device|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
79827419|NCT02569346|Drug|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
79827420|NCT04066842|Other|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
79528264|NCT02612038|Device|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
79232914|NCT03525093|Behavioral|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
80000949|NCT04548596|Diagnostic Test|Transcranial Doppler|"In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP) data will be collected in the following four scenarios. Each recording is up to 60 minutes in length:~External ventricular drain (EVD) closed to drainage for a 24 hour period as part of the EVD weaning protocol per standard of care (SOC): The Initial reading will be done within 4 hours of EVD closing. The second reading will be done within 4 hours of anticipated removal of EVD.~EVD closed most of the time and opened to drainage when the ICP becomes elevated per SOC~EVD with Intra-Parenchymal fiber optical ICP sensor per SOC~Intra-Parenchymal fiber optical ICP sensor per SOC"
80000950|NCT04515407|Other|PAS at Rest|Paired Associative Stimulation will be delivered while the participant is seated and resting.
80000951|NCT04515407|Other|PAS - Active|Paired Associative Stimulation will be delivered while the participant is seated and producing submaximal background activity in the plantarflexor muscles.
80000952|NCT04515407|Other|PAS - Walking|Paired Associative Stimulation will be delivered while the participant is walking, during the late stance phase of the gait cycle.
80000953|NCT04515186|Drug|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
80000954|NCT04515186|Drug|Miltefosine|50 mg capsule
79528265|NCT02598492|Other|arterial blood gas|Just record clinical lab data
80000955|NCT04515186|Device|Thermotherapy machine|Localized Current Field radio-frequency generating device
79528266|NCT02573376|Behavioral|Directly Observed Therapy|
79528267|NCT02573376|Behavioral|Wirelessly Observed Therapy|
79528268|NCT02566018|Procedure|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
79528269|NCT02566018|Procedure|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
79528270|NCT02563691|Radiation|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
79232915|NCT03525093|Behavioral|Health education|Participants receive a health education booklet on improving coping with stress.
79232916|NCT03193658|Procedure|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
79232917|NCT03193658|Drug|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
79232918|NCT03119246|Other|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
79232919|NCT03525015|Other|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
79528271|NCT02556450|Drug|Spironolacton|Administration of Spironolacton 25 mg per day
79528272|NCT02539225|Drug|Ramucirumab|Administered IV
79528273|NCT02539225|Drug|Placebo|Administered IV
79528274|NCT02539225|Drug|S-1|Administered PO
79528275|NCT02539225|Drug|Oxaliplatin|Administered IV
79528276|NCT02539225|Drug|Paclitaxel|Administered IV
79528277|NCT02535650|Drug|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
79528278|NCT02526017|Biological|Cabiralizumab|Solution for IV administration
79528279|NCT02526017|Biological|Nivolumab|Solution for IV administration
79528280|NCT02516657|Drug|Liraglutide|Liraglutide 0.6 mg
79528281|NCT02479919|Device|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
79528282|NCT02479919|Device|Magstim® Sham TBS|Sham stimulation
79528283|NCT02459067|Biological|ImmuniCell®|Autologous γδ T Lymphocytes
79528284|NCT02427581|Biological|Personalized synthetic long peptide vaccine (Poly ICLC)|
79827421|NCT00731432|Drug|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
79827422|NCT00731432|Drug|Placebo Patch|Identical in shape and texture to treatment patch
79827423|NCT00726102|Other|Meat|2 0z of locally available meat per day
79827424|NCT00726102|Other|Cereal|Daily provision of cereal to infants from 6-18 mos
79827425|NCT00726102|Other|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
79232920|NCT03525015|Other|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
79232921|NCT02449070|Drug|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
79827426|NCT00731510|Dietary Supplement|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
79827427|NCT00731510|Dietary Supplement|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
79827428|NCT00726804|Drug|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
79827429|NCT00726908|Dietary Supplement|Low carbohydrate|43% CHO
79827430|NCT00726960|Drug|aprepitant|Oral, 125 mg once daily for one week
79827431|NCT00726960|Drug|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
79827432|NCT00726128|Device|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
79827433|NCT02570958|Drug|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
79827434|NCT00731744|Procedure|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
79827435|NCT02570412|Drug|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
80000956|NCT04505579|Device|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
80000957|NCT04504435|Drug|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
79528285|NCT02427581|Drug|Poly ICLC|
79528286|NCT02423525|Drug|Afatinib|
79528287|NCT02417415|Other|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at ~44ºC continuously for 2 hr.
79528288|NCT02417415|Other|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
79528289|NCT02369653|Drug|Apixaban|
79827436|NCT00726206|Other|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
80000958|NCT04504435|Drug|Placebo|Matching placebo capsules will be provided
80000959|NCT04499248|Drug|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
80000960|NCT04499248|Other|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
80000961|NCT04499248|Other|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
80000962|NCT04499248|Other|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
80000963|NCT04499248|Drug|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant behind the study eye.
80000964|NCT04499248|Other|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
79528290|NCT02369653|Other|No systemic anticoagulant prophylaxis|
79528291|NCT02356861|Device|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
79528292|NCT02333708|Other|Blood sample|
79528293|NCT02293109|Drug|carfilzomib|Given IV
80000965|NCT04499248|Other|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
80000966|NCT04481061|Genetic|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
80000967|NCT04477330|Other|Transcranial direct current stimulation (tDCS)|1 mA tDCS
79528294|NCT02293109|Drug|cyclophosphamide|Given IV
79528295|NCT02293109|Drug|vincristine sulfate|Given IV
79528296|NCT02293109|Drug|doxorubicin hydrochloride|Given IV
79528297|NCT02293109|Drug|dexamethasone|Given PO
79827437|NCT02202590|Device|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
79827438|NCT00727038|Drug|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
79827439|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
80000968|NCT04477330|Other|Ankle motor training|Visuomotor target tracking task
80000969|NCT04477330|Behavioral|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
80000970|NCT04472351|Behavioral|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
80000971|NCT04464707|Drug|Fremanezumab|Dose A or Dose B subcutaneous
80000972|NCT04464707|Drug|Placebo|Matching placebo
80000973|NCT04464668|Behavioral|Provider Tools|Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
80000974|NCT04464668|Behavioral|Provider surveys|Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
79232922|NCT03529149|Combination Product|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV>37cm/s of （middle cerebral artery)MCA, PI < 1.34cm/s, aMFV>40cm/s of (basilar artery)BA, PI < 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
80000975|NCT04460586|Drug|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
80000976|NCT04460586|Drug|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
80000977|NCT04460040|Behavioral|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
80000978|NCT04453033|Device|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
80000979|NCT04447222|Other|Quality-of-Life Assessment|Ancillary studies
80000980|NCT04447222|Other|Questionnaire Administration|Ancillary studies
79232923|NCT03618056|Biological|AIDSVAX® B/E|Administered by intramuscular injection
79232924|NCT03526809|Diagnostic Test|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
79374472|NCT05849077|Other|Sat75|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
79528298|NCT02293109|Drug|methotrexate|Given IV
79528299|NCT02293109|Drug|cytarabine|Given IV
79528300|NCT02293109|Drug|leucovorin calcium|Given IV or PO
79528301|NCT02293109|Drug|methylprednisolone|Given IV
79827440|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
80000981|NCT04447222|Other|Survey Administration|Complete survey
79528302|NCT02293109|Biological|rituximab|
79528303|NCT02293109|Other|laboratory biomarker analysis|Correlative studies
80000982|NCT04436835|Behavioral|Psychotherapy|Undergo ART
79528304|NCT02284568|Drug|Placebo|Placebo
79528305|NCT02284568|Drug|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
79528306|NCT02284568|Drug|Placebo|Placebo capsules
79528307|NCT02228525|Drug|selinexor (KPT-330)|
80000983|NCT04436835|Other|Questionnaire Administration|Ancillary studies
79528308|NCT02195986|Drug|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
79232925|NCT04101045|Diagnostic Test|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
79528309|NCT02195986|Drug|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
80000984|NCT04434092|Drug|Crovalimab|Crovalimab will be administered as specified in the respective arms.
80000985|NCT04434092|Drug|Eculizumab|Eculizumab will be administered as specified in the respective arm.
80000986|NCT04432506|Biological|Anakinra|Given SC
79374473|NCT05849077|Other|Sat50|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
79528310|NCT02195986|Drug|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
79528311|NCT02078206|Other|Neurocognitive stimulation|
79528312|NCT02061319|Behavioral|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
79684716|NCT00552266|Drug|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
80000987|NCT04432506|Biological|Axicabtagene Ciloleucel|Given IV
79684717|NCT04943757|Drug|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
79684718|NCT04943757|Drug|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
79684719|NCT00552383|Procedure|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff [this includes 3 of the investigators], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
79684720|NCT04942704|Other|Non interventional Imaging - MRI|MRI Scanning using short protocols
79232926|NCT02449382|Procedure|continuous venovenous hemofiltration|If the serum sodium concentration >150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
79232927|NCT02449382|Drug|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
79684721|NCT00552500|Drug|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
80000988|NCT04432506|Drug|Cyclophosphamide|Given IV
79232928|NCT03193268|Other|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
79684722|NCT05465265|Behavioral|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
80000989|NCT04432506|Drug|Fludarabine|Given IV
79232929|NCT03193268|Other|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
80000990|NCT04430075|Device|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
80000991|NCT04408820|Drug|Roxadustat|Oral
80000992|NCT04388891|Device|Minimally supervised therapy with the ReHapticKnob|The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
80000993|NCT04384978|Behavioral|Play Serious Games with a Social Robot (Ryan)|Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
80000994|NCT04384978|Behavioral|Play Solitary Games Without a Social Robot|Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
80016666|NCT03660267|Other|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
79232930|NCT03196388|Drug|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
79232931|NCT03526731|Other|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
79232932|NCT03193502|Drug|rivaroxaban|rivaroxaban
79528313|NCT02027948|Other|nutritional and functional assessments|"Patients will undergo nutritional & functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, & baseline weight loss. Patients will receive chemotherapy & radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) & radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, & post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, & Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished & receive the appropriate intervention."
79232933|NCT03526965|Other|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
80000995|NCT04372498|Drug|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
79232934|NCT03526965|Drug|Usual care|Intervention included pain medications and exercise movements for neck.
79232935|NCT03193580|Device|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
79528314|NCT02013297|Radiation|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
79528315|NCT02000635|Other|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
79232936|NCT03193580|Device|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
79232937|NCT03193580|Device|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
79232938|NCT05616429|Dietary Supplement|Alcat based personal diet|Alcat based personalized diet with dietician supervision and follow-up + usual care
79232939|NCT05616429|Dietary Supplement|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
79232940|NCT05616429|Other|usual care|usual care
79374474|NCT05847322|Biological|Bordetella pertussis B1917|The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
79374475|NCT05847322|Drug|Azithromycin Pill|A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
79374476|NCT05844280|Procedure|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
79374477|NCT05844280|Procedure|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
79528316|NCT01987973|Procedure|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
79528317|NCT01987973|Procedure|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
79528318|NCT01982630|Drug|MK-8521|
79374478|NCT05838131|Drug|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
79374479|NCT05833880|Behavioral|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
79374480|NCT05829031|Behavioral|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
80000996|NCT04369976|Device|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
80000997|NCT04369053|Diagnostic Test|Freenome test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.
80000998|NCT04333745|Other|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
80000999|NCT04333745|Dietary Supplement|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
80001000|NCT04302025|Drug|Alectinib|Participants will receive oral alectinib twice per day (BID)
80001001|NCT04302025|Drug|Entrectinib|Participants will receive oral entrectinib daily
80001002|NCT04302025|Drug|Vemurafenib|Participants will receive oral vemurafenib BID
80001003|NCT04302025|Drug|Cobimetinib|Participants will receive oral cobimetinib daily
80001004|NCT04302025|Drug|Pralsetinib|Participants will receive oral pralsetinib daily
80001005|NCT04302025|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
80001006|NCT04302025|Drug|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
79374481|NCT05826951|Drug|Alcohol|Alcohol (0.8g/kg)
80001007|NCT04302025|Procedure|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
80001008|NCT04302025|Drug|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
80001009|NCT04302025|Drug|Divarasib|Participants in the KRAS G12C cohort will receive GDC-6036 for approximately 8 weeks until the day before surgery.
80001010|NCT04284436|Behavioral|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
79232941|NCT04013217|Combination Product|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
79232942|NCT03193034|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
79232943|NCT05603949|Device|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
79232944|NCT02711306|Dietary Supplement|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
79374482|NCT05826951|Drug|Placebo|Placebo
79528319|NCT01982630|Drug|Liraglutide|
79528320|NCT01982630|Drug|Placebo|
79528321|NCT01951469|Drug|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
80001011|NCT04272619|Behavioral|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
80001012|NCT04270955|Procedure|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
80001013|NCT04270955|Procedure|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
80001014|NCT04268979|Behavioral|eSNAP|eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.
79528322|NCT01951469|Drug|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
79528323|NCT01940809|Drug|Dabrafenib|Given PO
79528324|NCT01940809|Biological|Ipilimumab|Given IV
79528325|NCT01940809|Other|Laboratory Biomarker Analysis|Correlative studies
79528326|NCT01940809|Biological|Nivolumab|Given IV
79528327|NCT01940809|Drug|Trametinib|Given PO
79528328|NCT01937247|Procedure|Patients will be inducted in the induction room|The patients will be inducted in the induction room
79528329|NCT01937247|Procedure|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
79684723|NCT00552539|Other|'educational video'|'educational video'
79827441|NCT04018586|Device|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
79232945|NCT02711306|Dietary Supplement|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
79232946|NCT03528993|Other|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
79232947|NCT03528993|Other|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
79827442|NCT04018586|Device|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
79827443|NCT04018586|Device|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
79827444|NCT00726258|Drug|ketamine|ketamine with various concentrations
80001015|NCT04268979|Behavioral|Caregiver Navigator|The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
79232948|NCT03528993|Other|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
79232949|NCT03193112|Drug|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
79684724|NCT04917783|Behavioral|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
79528330|NCT01937247|Drug|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
79528331|NCT01937247|Procedure|STANDARD PROCESS|standard process
79528332|NCT01879228|Drug|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
79684725|NCT04917783|Behavioral|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
79827445|NCT00726258|Drug|placebo|physiological serum
79827446|NCT00727142|Procedure|Surgical treatment|Insertion of a functioning shunt
79827447|NCT04793802|Other|PHYSIO|session of physiotherapy
79827448|NCT02569814|Drug|Fimasartan/Amlodipine/Rosuvastatin|
79827449|NCT02569814|Drug|Fimasartan/Amlodipine|
79827450|NCT02569814|Drug|Rosuvastatin|
79827451|NCT00726492|Other|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
79827452|NCT00726492|Other|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
79827453|NCT00726570|Device|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
79827454|NCT00726570|Drug|Dalteparin|"2500 UI qd if ≤ 50 kg body weight~5000 UI qd if > 50 kg"
79827455|NCT00726570|Procedure|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~Patient admission (before SCD start)~40-60 min after admission~Morning after surgery"
79827456|NCT00726726|Drug|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
79827457|NCT00726726|Drug|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
79827458|NCT00726726|Drug|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
79374490|NCT05806177|Drug|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
79827459|NCT00731978|Procedure|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
80001016|NCT04259138|Biological|Treatment Algorithm A|Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
80016667|NCT03660267|Other|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
79827460|NCT00727350|Radiation|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
79827461|NCT00732056|Drug|GRN163L|25% dose escalation infused over 2 hours weekly
79827462|NCT00654381|Drug|BI 1356|5 mg/daily
80001017|NCT04259138|Biological|Treatment Algorithm B|"Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
80001018|NCT04259138|Biological|Treatment Algorithm C|"Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
79232950|NCT03196154|Diagnostic Test|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
80001019|NCT04258943|Drug|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
80001020|NCT04246814|Device|LG1|Application of LASER AsGa 904nm 10 J/cm².
79232951|NCT03196154|Diagnostic Test|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
79232952|NCT03996525|Device|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
79374491|NCT05806177|Drug|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
79374492|NCT05802056|Biological|Aldesleukin|Given IP
79374493|NCT05802056|Procedure|Biopsy|Undergo biopsy
79374494|NCT05802056|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79827463|NCT00654381|Drug|BI 1356|10 mg/daily
80001021|NCT04246814|Device|LG2|Application of LASER AsGa 904nm 8 J/cm².
80001022|NCT04246814|Device|LG3|Application of LASER AsGa 904nm 4 J/cm².
80001023|NCT04246814|Device|CC|Application of placebo LASER.
80001024|NCT04246814|Procedure|Dressing|Application of Helianthus annuus oil dressing.
80001025|NCT04243538|Behavioral|I-HoME|I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
80001026|NCT04240002|Drug|gilteritinib|Administered orally.
80001027|NCT04240002|Drug|fludarabine|Administered by intravenous (IV) infusion
79232953|NCT03996525|Device|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
79374495|NCT05802056|Procedure|Computed Tomography|Undergo PET/CT
79374496|NCT05802056|Procedure|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
80001028|NCT04240002|Drug|cytarabine|Administered by intravenous (IV) infusion
79374497|NCT05802056|Drug|Fluorouracil|Given IV
79374498|NCT05802056|Drug|Leucovorin Calcium|Given IV
79528333|NCT01879228|Drug|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
79827464|NCT00654381|Drug|voglibose placebo|three times daily
79827465|NCT00654381|Drug|BI 1356 placebo|once daily
79827466|NCT00654381|Drug|voglibose|0.6 mg/daily
79827467|NCT00727428|Biological|FluLaval® TF|One IM injection.
80001029|NCT04240002|Drug|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
80001030|NCT04221581|Device|Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis|FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
80001031|NCT04216563|Drug|Asciminib|Given PO
80001032|NCT04208490|Other|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
80001033|NCT04203082|Behavioral|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
79374499|NCT05802056|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79374500|NCT05802056|Biological|Nivolumab|Given IV
79374501|NCT05802056|Drug|Oxaliplatin|Given IV
79374502|NCT05802056|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
80001034|NCT04203082|Other|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
80001035|NCT04185883|Drug|Sotorasib|Sotorasib administered orally as a tablet.
80001036|NCT04185883|Drug|Trametinib|Trametinib administered orally as a tablet.
80001037|NCT04185883|Drug|RMC-4630|RMC-4630 administered orally as a capsule.
80001038|NCT04185883|Drug|Afatinib|afatinib administered orally as a tablet.
80001039|NCT04185883|Drug|Pembrolizumab|pembrolizumab administered as an intravenous (IV) infusion.
80001040|NCT04185883|Drug|Panitumumab|Panitumumab administered as an intravenous (IV) infusion.
79827468|NCT02089880|Device|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
80001041|NCT04185883|Drug|Carboplatin, pemetrexed, docetaxel, paclitaxel|Carboplatin, pemetrexed, docetaxel administered as an intravenous (IV) infusion.
79827469|NCT02089880|Device|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
79827470|NCT00727584|Radiation|radiation therapy|Patients undergo external beam radiotherapy
80001042|NCT04185883|Drug|Atezolizumab|Atezolizumab administered as an intravenous (IV) injection.
79684726|NCT02277314|Procedure|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
79684727|NCT04756388|Other|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
79232954|NCT03994497|Other|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
79232955|NCT03193424|Drug|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
79232956|NCT03526653|Other|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
79374503|NCT05797831|Drug|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
79684728|NCT04756388|Other|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
79684729|NCT01258738|Biological|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
79827471|NCT04018482|Other|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
79827472|NCT04018482|Other|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
80001043|NCT04185883|Drug|Palbociclib|Palbociclib administered orally as a tablet.
79232957|NCT03526653|Other|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
79232958|NCT03526653|Other|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
79374504|NCT05797831|Drug|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
79374505|NCT05795842|Device|wearable wristband model|MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
80001044|NCT04185883|Drug|MVASI® (bevacizumab-awwb)|MVASI® (bevacizumab-awwb) administered as an intravenous (IV) infusion.
80001045|NCT04185883|Drug|TNO155|TNO155 administered orally as a capsule.
80001046|NCT04185883|Drug|Intravenous (IV) Chemotherapy (Regimen 1)|Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
80001047|NCT04185883|Drug|IV Chemotherapy (Regimen 2)|IV chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
80001048|NCT04185883|Drug|BI 1701963|BI 1701963 administered orally
80001049|NCT04185883|Drug|AMG 404|AMG 404 administered as an intravenous (IV) infusion.
80001050|NCT04185883|Drug|Everolimus|Everolimus administered orally.
80016668|NCT03660267|Other|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
80016669|NCT03950245|Other|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
80016670|NCT03950245|Other|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
79232959|NCT03193346|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
79232960|NCT03193346|Drug|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® [Sodium chloride 0.9 mg] IM injections in head/neck areas.
79232961|NCT03118622|Device|Pentax|Intubation using Pentax video laryngoscope in Pentax group
79232962|NCT02448836|Device|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
79232963|NCT02448836|Device|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
79232964|NCT03118076|Drug|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
79374506|NCT05795842|Device|Standard of care extended ECG monitoring|Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
79374507|NCT05792787|Diagnostic Test|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~The number of decayed, missing and filled teeth (DMFT index)~The number of teeth with AP~Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
79528334|NCT01813370|Other|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
79684730|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
79374509|NCT05791695|Other|Non Applicable|No study-specific interventions for this observational study.
79827473|NCT00808041|Device|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
79374510|NCT05787743|Other|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
79232965|NCT03118076|Drug|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
79232966|NCT03117764|Device|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
79305640|NCT04929873|Behavioral|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure < 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
79374511|NCT05787743|Other|Base cream|Apply on the face twice a day
79374512|NCT05787041|Other|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
79374513|NCT05787041|Other|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
79528335|NCT01779557|Drug|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
79528336|NCT01779557|Drug|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
79684731|NCT01258738|Other|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
79528337|NCT01738009|Other|Induction of flow limitation|
79528338|NCT01729754|Drug|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
79684732|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
79827474|NCT00727454|Device|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
79827475|NCT00727454|Device|No treatment|No treatment
79827476|NCT00727662|Other|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
80016671|NCT03950245|Other|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
80016672|NCT03950245|Other|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
80016673|NCT02937077|Device|Medtronic Reveal LINQ|
79827477|NCT00727662|Other|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
79827478|NCT00805311|Procedure|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
79827479|NCT00805311|Drug|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
79232967|NCT03117764|Behavioral|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
79374514|NCT05787028|Drug|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
79374515|NCT05787028|Drug|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
79528339|NCT01729754|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
79305641|NCT04929873|Behavioral|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
79305642|NCT04486547|Behavioral|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
79374516|NCT05785806|Behavioral|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
79374517|NCT05785806|Behavioral|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
79528340|NCT01729754|Drug|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
79528341|NCT01729754|Drug|Etanercept Placebo|Matching placebo to etanercept administered SC
79528342|NCT01729754|Drug|Etanercept 50 mg|Etanercept 50 mg administered SC
79528343|NCT01658683|Behavioral|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
79684733|NCT04900077|Device|Carriere® Motion™ Appliance|class II malocclusion corrector
79684734|NCT00552656|Device|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
79528344|NCT01622998|Drug|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
79684735|NCT05604456|Procedure|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
79684736|NCT01824537|Biological|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
79528345|NCT01622998|Drug|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
79528346|NCT01599741|Radiation|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
79827480|NCT00726440|Device|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
79528347|NCT01599741|Radiation|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
79684737|NCT01824537|Biological|Hepatitis A vaccine|Provided by Sanofi Pasteur.
79827481|NCT00726440|Device|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
79684738|NCT04863339|Drug|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
79684739|NCT04863339|Drug|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
79684740|NCT04684277|Drug|antidepressant treatment|depression recieve antidepressant treatment
79684741|NCT04684277|Other|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
79827482|NCT00726440|Device|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
79827483|NCT04474314|Drug|IMR-687|Oral administration of once daily IMR-687
79827484|NCT04474314|Drug|Placebo|Oral administration of once daily Placebo
79827485|NCT00808119|Drug|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
79232968|NCT03117764|Device|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
79827486|NCT00732290|Drug|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
79684742|NCT05604183|Procedure|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
79827487|NCT00732290|Drug|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
79827488|NCT02569788|Radiation|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
79232969|NCT03528915|Other|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
79232970|NCT03528915|Other|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
79232971|NCT03192878|Drug|Infliximab|infliximab biosimilar
79232972|NCT03524703|Other|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
79232973|NCT03195920|Device|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
79528348|NCT01597583|Behavioral|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
79827489|NCT03906344|Drug|INCB052793|
79827490|NCT00730002|Procedure|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
79827491|NCT00730002|Procedure|Magnetic resonance imaging|MR spectroscopy
79827492|NCT00730002|Procedure|MRA|MRA of the brain
79827493|NCT00730002|Procedure|MRA|
79827494|NCT00730002|Procedure|diffusion Imaging|MRA of the Brain
79827495|NCT00730002|Procedure|perfusion imaging.|MRA of the brain
79232974|NCT04467099|Other|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
79232975|NCT04467099|Radiation|X-ray|Standard x-ray of the foot.
79232976|NCT04467099|Other|Questionnaire|All participants will complete a questionnaire.
79827496|NCT04460664|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79232977|NCT00294320|Drug|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
79232978|NCT00294320|Other|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
79232979|NCT03526575|Drug|Zolpidem|
79232980|NCT00189254|Drug|Imiquimod|No defined treatments were given during this study.
79232981|NCT03526419|Drug|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
79232982|NCT04978857|Other|autobiographic movie|viewing an autobiographic film through a virtual reality headset
79528349|NCT01595620|Other|Thermal|Thermal sensation/pain testing
79528350|NCT01595620|Other|Electrical|Electrical sensation/pain testing
79528351|NCT01595620|Other|Capsaicin|Intradermal Capsaicin
79528352|NCT01595620|Drug|THC|Active THC (0.01 mg/kg) administered over 10 minutes
79528353|NCT01595620|Drug|THC|Active THC (0.03 mg/kg) administered over 10 minutes
79528354|NCT01595620|Drug|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
79684743|NCT05604183|Procedure|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
79684744|NCT05604183|Diagnostic Test|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
79827497|NCT02570334|Other|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
80016674|NCT03660111|Diagnostic Test|spirometry|only measurement of spirometry
79305643|NCT03239405|Device|Suction callibrated system|One-step suction callibrated SG system
79305644|NCT03238703|Drug|Anastrozole|Given PO
79305645|NCT03238703|Drug|Exemestane|Given PO
79528355|NCT01593852|Radiation|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
79528356|NCT01593852|Radiation|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
79827498|NCT00732446|Drug|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
79684745|NCT05603871|Procedure|ligamentoplasty of ligamentum teres|"An addition to the steps of the open reduction, the following were done:~Identification of ligamentum teres~Ligamentoplasty of ligamentum teres"
79684746|NCT04651985|Other|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
79827499|NCT00732446|Drug|Moxifloxacin|moxifloxacin 0,5% qid and
79827500|NCT00732446|Drug|Dexamethasone|dexamethasone 0,1% qid
79827501|NCT04065672|Drug|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
79827502|NCT00732524|Drug|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
79827503|NCT00732524|Drug|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
79232983|NCT02448524|Device|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
79232984|NCT02448524|Device|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
79684747|NCT04853940|Other|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
79684748|NCT04647968|Procedure|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
79684749|NCT04647968|Procedure|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
79684750|NCT04630184|Behavioral|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
79827504|NCT00657267|Drug|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
79232985|NCT02710292|Device|Delefilcon A contact lenses|
79232986|NCT02710292|Device|Narafilcon A contact lenses|
79232987|NCT03192644|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
79232988|NCT03192644|Procedure|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
79232989|NCT03192644|Drug|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
79374518|NCT05785806|Behavioral|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
79827505|NCT00733850|Drug|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
79232990|NCT03192644|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
79232991|NCT03110055|Drug|Grazoprevir/Elbasvir|anti-viral treatment for HCV
79232992|NCT03110055|Other|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
79305646|NCT03238703|Other|Laboratory Biomarker Analysis|Correlative studies
79305647|NCT03238703|Drug|Letrozole|Given PO
79528357|NCT01591629|Drug|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
79528358|NCT01591629|Drug|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
79827506|NCT00733850|Drug|Gemcitabine|Intravenous repeating dose
79827507|NCT00727818|Device|guided bone regeneration|
79305648|NCT03238703|Other|Quality-of-Life Assessment|Ancillary studies
79305649|NCT03238703|Other|Questionnaire Administration|Ancillary studies
79528359|NCT01591629|Drug|Placebo|Placebo
79528360|NCT01515306|Biological|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
79528361|NCT01515306|Drug|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
79528362|NCT01515098|Dietary Supplement|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
79528363|NCT01515098|Dietary Supplement|Dextrose Placebo|Placebo developed to closely match blueberry powder.
79827508|NCT04016961|Other|AAT - Dog|therapy dog added to inpatient PT and OT session
79827509|NCT04016961|Other|TAU - No Dog|PT and OT as usual without the addition of therapy dog
79827510|NCT00732602|Other|GIP-infusion|
79827511|NCT00732602|Other|Sodium-chloride|
79827512|NCT00732602|Other|GLP-2 infusion|
79827513|NCT00808197|Procedure|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
79827514|NCT00727896|Behavioral|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
79827515|NCT00727896|Drug|Diabetes Treatment|Life style modification and drug therapy
79827516|NCT00727766|Drug|Clofarabine|
79827517|NCT00799071|Drug|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
79827518|NCT00730080|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
79827519|NCT02569268|Other|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
79827520|NCT04066920|Drug|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) [ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 ], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
79827521|NCT00732836|Drug|HAI Abraxane|Escalating doses (beginning dose 180 mg/m^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
79827522|NCT00732836|Procedure|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
79827523|NCT00732836|Drug|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
80016675|NCT05208515|Other|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
80016676|NCT05208515|Other|general operating center|send emergency cesarean section needing women from labor room to general operating center
80016677|NCT04211818|Behavioral|Eating Behavior|A dietary book will be given to the patient and will be filled by this one during 14 days
79232993|NCT03110055|Procedure|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
79232994|NCT02448602|Other|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
79232995|NCT02448602|Other|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
79684751|NCT04630184|Behavioral|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
79684752|NCT04630184|Behavioral|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
79827524|NCT00799149|Drug|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
79827525|NCT00733928|Device|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
79232996|NCT02448602|Other|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
79827526|NCT00733928|Device|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
79827527|NCT00805623|Dietary Supplement|sucrose|1 cc of sucrose 33.5% with or without pacifier
79827528|NCT04280172|Other|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
79827529|NCT04280172|Other|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
79305650|NCT03238703|Drug|Tamoxifen Citrate|Given PO
79305651|NCT03238703|Drug|Toremifene Citrate|Given PO
79374519|NCT05785806|Behavioral|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
79374520|NCT05785806|Behavioral|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
79374521|NCT05778994|Device|INTORUS|Exercise protocol with intorus
79374522|NCT05777174|Drug|MB-102|130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.
79528364|NCT01513187|Drug|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
79528365|NCT01433965|Drug|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
79528366|NCT01431157|Procedure|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
79528367|NCT01431157|Other|No nasal oxygen|Patients will have no intervention for sleep apnea
79528368|NCT01423851|Drug|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
79684753|NCT00552734|Device|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
79684754|NCT00552773|Drug|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
79684755|NCT00536718|Genetic|gene expression analysis|
79827530|NCT00732914|Drug|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
79232997|NCT03195998|Diagnostic Test|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
79827531|NCT00732914|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
79827532|NCT00728052|Drug|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
79827533|NCT00728052|Drug|Placebo|Placebo capsules will be administered orally with water.
79827534|NCT00808275|Dietary Supplement|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
79827535|NCT00727922|Drug|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
79827536|NCT00809289|Drug|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
79827537|NCT00809289|Drug|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
79232998|NCT03528759|Diagnostic Test||phenotypic and genotypic Method
79232999|NCT01190852|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
79233000|NCT01190852|Drug|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
79827538|NCT00809289|Drug|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
79233001|NCT01190852|Drug|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
79233002|NCT02444312|Behavioral|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
79374523|NCT05777174|Device|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.
79528369|NCT01360593|Drug|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
79528370|NCT01360593|Drug|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
79528371|NCT01360593|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
79528372|NCT01354977|Drug|Resveratrol|1,000mg twice daily for 28 days
79827539|NCT02570256|Behavioral|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
80016678|NCT04211818|Biological|Blood glucose records|A glycemic sensor will be placed at the back of the patient's arm
80016679|NCT03660033|Diagnostic Test|ECG in delivery room|See arm/group discussions
79233003|NCT02444312|Behavioral|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
79233004|NCT02444156|Other|Indoor rowing|
79684756|NCT00536718|Genetic|molecular diagnostic method|
79684757|NCT00536718|Genetic|polymorphism analysis|
79684758|NCT00536718|Genetic|protein expression analysis|
79233005|NCT04917159|Behavioral|ACT (Acceptance and Commitment Therapy) plus brief CHF education|The participants will identify their values and clarify their alternative behavior, exploring their thoughts and feelings, and finding ways to meet their own and their family member's needs. The rational bond between the patient and his/her family caregiver will be emphasized. In addtion, the contents of brief CHF education are based on the latest national clinical practice guideline for CHF, including symptoms monitoring, medication adherence, fluid and salt restriction, smoking cessation, alcohol consumption, and physical activity maintenance.
79374524|NCT05777031|Drug|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
79827540|NCT02570256|Behavioral|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
80001051|NCT04183010|Behavioral|Physical activity coaching|"Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~A low intensity activity from one of the categories they selected upon start of coaching~A moderate-to-vigorous endurance activity~The participant will be linked to video content with exercise tutorials/video coaching~Option to skip exercise that day~Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~Yes~No~Give me a different exercise"
79528373|NCT01334606|Device|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
79684759|NCT00536718|Other|medical chart review|
79684760|NCT00536718|Other|questionnaire administration|
79528374|NCT01334606|Device|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
80001052|NCT04182334|Other|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
80001053|NCT04182334|Other|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
80001054|NCT04169763|Drug|Cisplatin|Given IV
80001055|NCT04169763|Radiation|External Beam Radiation Therapy|Undergo EBRT
80001056|NCT04169763|Drug|Nelfinavir|Given PO
79684761|NCT04831164|Other|NA (not an interventional study)|(not an interventional study)
79684762|NCT04816617|Behavioral|Aerobic exercise intervention|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
79684763|NCT04816617|Behavioral|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
80001057|NCT04162015|Drug|Nivolumab|nivolumab 360 mg
80001058|NCT04162015|Drug|Pemetrexed|500 mg/m^2
79233006|NCT04917159|Behavioral|HE (Health Education)|The educational contents are based on the latest national clinical practice guideline for CHF. Besides the basic information on CHF education provided in intervention group, the contents of CHF education also include definition of CHF, epidemiology, diagnosis, comorbidity, and CHF treatment. ACT components are not covered.
79305652|NCT03238547|Diagnostic Test|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
79374525|NCT05768841|Behavioral|mental health issues|survey on mental health issues in endurance athletes
79374526|NCT05768087|Radiation|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
79374527|NCT05761860|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
79528375|NCT01317875|Drug|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
79684764|NCT04543682|Drug|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
79374528|NCT05761860|Drug|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
79528376|NCT01226732|Drug|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
79528377|NCT01226732|Drug|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
79528378|NCT01003496|Behavioral|Treatment as Usual (TAU)|Outpatient substance abuse treatment
80001059|NCT04162015|Drug|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
80001060|NCT04145115|Biological|Ipilimumab|Given IV
79374529|NCT05761860|Other|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
79233007|NCT04915677|Procedure|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
79233008|NCT04915677|Procedure|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
79233009|NCT02710214|Drug|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
79233010|NCT02710214|Drug|Placebo|Once-daily dosing of placebo for 8 weeks
79374530|NCT05761860|Drug|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
80001061|NCT04145115|Procedure|Magnetic Resonance Imaging|Undergo MRI
80001062|NCT04145115|Biological|Nivolumab|Given IV
80001063|NCT04126395|Diagnostic Test|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
79374531|NCT05761860|Other|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
79374532|NCT05759299|Procedure|Tracheal intubation|Advanced airway management with tracheal intubation performed after induction with hypnotic and/or opioid drugs and laryngoscopy
80001064|NCT04126395|Diagnostic Test|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
80001065|NCT04126395|Diagnostic Test|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
79233011|NCT03524547|Device|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
79233012|NCT03524547|Device|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
79233013|NCT05189990|Diagnostic Test|Electrical impedance tomography|Fatty liver patients will be recruited from the Department of Medicine at Queen Mary Hospital. Gender- and age- matched control subjects will be publicly recruited. Subjects will undergo the EIT-liver scan and FibroScan®. Selected subgroups will also undergo MRI-PDFF scan. The performance characteristics of the device and with respect to Fibroscan/ MRI-PDFF for liver fat quantification will be assessed.
80001066|NCT04126395|Other|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
79528379|NCT01003496|Behavioral|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
79528380|NCT00962988|Drug|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
79684765|NCT04543682|Drug|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
79684766|NCT04543682|Procedure|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
80001067|NCT04123756|Behavioral|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
79374533|NCT05759052|Behavioral|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
79374534|NCT05753800|Device|INTORUS|Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
80001068|NCT04120974|Behavioral|Optimal insulin injection|subjects receive training in optimal injection technique.
80001069|NCT04115371|Behavioral|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
79233014|NCT05561205|Device|rTMS|repetitive transcranial magnetic stimulation
80001070|NCT04107805|Drug|BI 1323495|Tablet
80001071|NCT04107805|Drug|Placebo|Tablet
80001072|NCT04107805|Drug|Midazolam|Oral administration
80016680|NCT00401570|Drug|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
79374535|NCT05744323|Other|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
79827541|NCT02570256|Behavioral|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
80001073|NCT04085887|Drug|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
80001074|NCT04085887|Device|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
80001075|NCT04085887|Device|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
80001076|NCT04085887|Device|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
79233015|NCT05561205|Drug|methylphenidate|methylphenidate
79233016|NCT03052517|Drug|QAW039 150 mg|One tablet of QAW039 150 mg once daily
80001077|NCT04075461|Procedure|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
80001078|NCT04075461|Procedure|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
80001079|NCT04069468|Device|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
79233017|NCT03052517|Drug|QAW039 450 mg|One tablet of QAW039 450 mg once daily
79233018|NCT03052517|Drug|Placebo|One tablet of Placebo once daily
79684767|NCT05603676|Other|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
79827542|NCT02569034|Other|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
79374536|NCT05743582|Procedure|Bronchoscopy for sample collection|Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
79374537|NCT05743582|Procedure|Blood donation|Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
79827543|NCT02569034|Other|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
80001080|NCT04043442|Device|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
80001081|NCT04042025|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
80001082|NCT04039113|Biological|Tezepelumab|Tezepelumab subcutaneous injection
80001083|NCT04039113|Other|Placebo|Placebo subcutaneous injection
79305653|NCT03238547|Diagnostic Test|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
79528381|NCT00962988|Other|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
80001084|NCT04031508|Combination Product|lipid injectable emulsion with Fish oil|TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
80001085|NCT04018755|Biological|anakinra|anakinra single-use prefilled glass syringes
80001086|NCT04011579|Other|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
80001087|NCT04011241|Drug|BI 1323495|Tablet
80001088|NCT04011241|Drug|Itraconazole|Oral solution
80001089|NCT03997383|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
79305654|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
79305655|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
79305656|NCT03238625|Drug|Lidocaine|Lidocaine injection
79305657|NCT03238625|Drug|Sodium cloride 0.9%|Placebo
79305658|NCT03238391|Procedure|Ischemic preconditioning|It is mentioned before in arm/group descriptions
79374538|NCT05741034|Device|JUVÉDERM® VOLITE™|Injection, subdermal and/or intradermal
79374539|NCT05741034|Other|Control|No-treatment control
79374540|NCT05740046|Device|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
80001090|NCT03997383|Drug|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
80001091|NCT03988751|Behavioral|Ambulation|Variation in ambulatory intensity.
80001092|NCT03986268|Drug|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
79233019|NCT02708498|Behavioral|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
79233020|NCT03766659|Diagnostic Test|MOSE|EUS-FNB with MOSE
80001093|NCT03983954|Combination Product|Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|"Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion.~NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days."
80001094|NCT03983954|Combination Product|Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
79233021|NCT03766659|Diagnostic Test|ROSE|EUS-FNA with ROSE
79233022|NCT03524391|Behavioral|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
79233023|NCT03524391|Drug|Chemotherapy|Usual Care group had standard chemotherapy regimens
79233024|NCT02710136|Biological|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
79684768|NCT05603676|Other|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
79233025|NCT04441437|Behavioral|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
79374541|NCT05733377|Diagnostic Test|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
79528382|NCT00949312|Genetic|RNA marker analysis of lymph node and primary tumors|
79528383|NCT00949312|Genetic|microarray profiling of primary tumors|
79305659|NCT03238469|Device|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
79528384|NCT00949312|Genetic|reverse transcriptase-polymerase chain reaction of lymph node specimens|
79528385|NCT00949312|Other|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
79528386|NCT00949312|Procedure|regional lymph node dissection|
80001095|NCT03982888|Procedure|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
79528387|NCT00949312|Other|lymph node staining for H&E and pancytokeratin IHC|
79528388|NCT00828308|Drug|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
79528389|NCT00828308|Procedure|Prostatectomy|Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study**
80001096|NCT03982888|Device|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
79374542|NCT05733377|Diagnostic Test|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
79374543|NCT05726539|Behavioral|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
79528390|NCT00824252|Behavioral|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
79233026|NCT04441437|Behavioral|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
79374544|NCT05724784|Behavioral|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
79528391|NCT00768820|Drug|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
80001097|NCT03970447|Drug|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
80001098|NCT03970447|Drug|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
80001099|NCT03970447|Drug|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
80001100|NCT03970447|Radiation|Radiation|60 Gy
80001101|NCT03970447|Drug|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
80001102|NCT03970447|Drug|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
80001103|NCT03970447|Drug|VT1021|"Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
80001104|NCT03970447|Drug|Troriluzole|Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
80001105|NCT03970447|Biological|ADI-PEG 20|Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
80001106|NCT03968406|Other|Quality-of-Life Assessment|Ancillary studies
80001107|NCT03968406|Radiation|Radiation Therapy|Undergo radiation therapy
79233027|NCT03526341|Device|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
79233028|NCT04467645|Other|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
79233029|NCT02443844|Procedure|Transurethral Resection|Endoscopic treatment of bladder cancer
79233030|NCT02443844|Drug|Tamsulosin|Medical treatment for benign prostate hyperplasia
79374545|NCT05714527|Device|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
80001108|NCT03968406|Drug|Talazoparib|Given PO
79374546|NCT05714527|Device|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
79374547|NCT05709002|Behavioral|MASP+|mHealth (mobile app) for smoking cessation
79374548|NCT05709002|Behavioral|Control|A mobile app designed to assist the general population with smoking cessation.
79528392|NCT00678730|Drug|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
79528393|NCT00654264|Procedure|Water immersion|Subjects will sit in tub for four hours.
79528394|NCT00600015|Drug|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
80001109|NCT03957577|Other|Prospective observational cohort study|Prospective observational cohort study
80001110|NCT03945552|Behavioral|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
80001111|NCT03937154|Drug|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
80001112|NCT03937154|Drug|Placebo|Placebo comparator
80001113|NCT03922724|Drug|ATL-RIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
79374549|NCT05698940|Procedure|Infundibultomy|Infundibultomy on one side of patient
79374550|NCT05694312|Drug|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
79374551|NCT05693545|Drug|phenoxymethyl penicillin|Prophylaxis
79374552|NCT05693545|Drug|intramuscular benzathine penicillin G (BPG) prophylaxis|Prophylaxis
79528395|NCT00600015|Drug|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
79528396|NCT00500071|Drug|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
79374553|NCT05687305|Other|White Noise|White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 1st and 2nd postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
79684769|NCT04802616|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
79684770|NCT04802616|Drug|Placebo|Matched tablets without any active substance.
80001114|NCT03922724|Drug|mRIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
79684771|NCT04473092|Device|TMVR|Patients who undergo TMVR for MR at the PI´s site
79684772|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
80001115|NCT03922724|Procedure|allo HCT|Stem cell transplant
80001116|NCT03922724|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
79233031|NCT03754335|Procedure|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
79374554|NCT05685316|Device|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
80001117|NCT03922724|Drug|GVHD prophylaxis|"High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25."
79528397|NCT00447122|Drug|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
79233032|NCT02440100|Drug|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
79233033|NCT02440100|Drug|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
79233034|NCT02440100|Drug|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
79233035|NCT03524313|Diagnostic Test|End tidal carbon monoxide|"Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~Evaluation of femoral veinous velocity"
79233036|NCT02439944|Drug|Nicotine patch|
79233037|NCT02439944|Drug|Nicotine mouthspray|
79374555|NCT05682339|Other|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
79374556|NCT05682339|Other|L-isoleucine|L-isoleucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
79374557|NCT05682339|Other|Combination of quinine and L-isoleucine|In this condition, both quinine and L-isoleucine will be administered as 'active'.
79528398|NCT00447122|Drug|Lapatinib 1000mg/d|1000mg/d
79528399|NCT00447122|Drug|Lapatinib 1500mg/d|1500mg/d
79374558|NCT05682339|Other|Control|"In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered."
79528400|NCT00447122|Drug|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
79528401|NCT00447122|Drug|Oxaliplatin 100mg/m2|100mg/m2
79528402|NCT00430040|Drug|carvedilol|carvedilol
79528403|NCT00430040|Drug|lisinopril|lisinopril
79528404|NCT00382252|Procedure|computed tomography|
79528405|NCT00382252|Procedure|positron emission tomography|
80001118|NCT03922724|Drug|IOC|e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
79528406|NCT00382252|Procedure|radiofrequency ablation|
80001119|NCT03922035|Other|Best Practice|Receive standard peri-/post-transplant supportive care
80001120|NCT03922035|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
79233038|NCT03133065|Drug|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
79233039|NCT02434250|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
79233040|NCT03803111|Behavioral|Initial exercise training|Initial exercise training program
79233041|NCT03803111|Drug|Initial FCM|Initial intravenous iron supplementation (FCM)
79233042|NCT03803111|Drug|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
79233043|NCT03803111|Behavioral|Subsequent exercise training|Subsequent exercise training program after 2 months
79233044|NCT03190616|Drug|apatinib|apatinib 500mg/qd, 28d/cycle
79233045|NCT03190538|Other|No intervention|There will be no specific intervention to these paediatric NASH patient
79233046|NCT03702231|Biological|Zoster Vaccine Recombinant, Adjuvanted|A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.
79233047|NCT04484090|Device|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
79528407|NCT00290251|Drug|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
79528408|NCT00290251|Drug|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
79528409|NCT00290251|Drug|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
79684773|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
79684774|NCT04772274|Drug|Ustekinumab|45 mg, single-dose
79684775|NCT04398797|Other|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
79684776|NCT03457311|Drug|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
79684777|NCT04370327|Other|Pain Free Exercise (PF)|Patients will exercise until the onset on claudication (1 on the rating scale)
79684778|NCT04370327|Other|Moderate Claudication Pain Exercise (MOD-P)|Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
79684779|NCT04370327|Other|Maximal Claudication Pain Exercise (MAX-P)|Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
79684780|NCT00536835|Drug|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
79684781|NCT04362527|Drug|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
79684782|NCT04362527|Drug|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
79233048|NCT02443922|Drug|Glimepiride|Glimepiride 2mg qam
79233049|NCT02443922|Drug|Sitagliptin|Sitagliptin 100mg qam
79233050|NCT02443922|Drug|Metformin|Metformin as prescribed
79233051|NCT04799847|Drug|Catumaxomab|This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
79233052|NCT02434562|Other|Serum (with or without urine) samples|
79233053|NCT02439866|Drug|placebo|gelatinous capsules filled with sugar as placebo
79233054|NCT02439866|Drug|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
79233055|NCT02439866|Drug|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
79233056|NCT02439788|Drug|cyclophosphamide|500 mg/m2/day x 2 days; for patients <12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
79233057|NCT02439788|Drug|Fludarabine|30 mg/m2/day x 3 days; for patients <12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
79374559|NCT05676502|Device|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
79528410|NCT00133835|Procedure|Extracorporeal shock wave lithotripsy|
79528411|NCT00133835|Procedure|Endoscopic drainage of the main pancreatic duct|
79528412|NCT00066963|Device|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
79528413|NCT01397487|Procedure|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
79233058|NCT02439788|Genetic|GINAKIT Cells|"Dose Level 1 = 3 x 10^6~Dose Level 2 = 1 x 10^7~Dose Level 3 = 3 x 10^7~Dose Level 4 = 1 x 10^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
79233059|NCT02434796|Behavioral|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
79684783|NCT05579145|Other|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
80001121|NCT03901573|Drug|NT-I7|"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"
79233060|NCT02434796|Behavioral|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
79233061|NCT04483388|Other|Training with Virtual Reality|Computed virtual reality therapy was performed using the Nintendo Wii® console equipment. This system allows interaction with the player by means of a movement detection system and the representation of his avatar graphical representation of a user in virtual reality. It has a remote control with a wireless system, responsible for capturing the speed, direction , acceleration and deceleration of movement. The movements performed by the player are captured and reproduced on a screen via an infrared light sensor, positioned above the TV. The feedback given by the TV provides the movement itself observing opportunity in real time, generating positive reinforcement and facilitating training and improved task. The software used in this study was the Nintendo Wii Sports.
79233062|NCT04483388|Other|Conventional Training|"It was done five types of exercises following to the protocol:~Exercise 1 (shoulder abduction); Exercise 2 (external rotation of the shoulder); Exercise 3 (elbow extension); Exercise 4 (weight transfer in upper limbs: a sitting position); Exercise 5 (function: task-oriented training)."
80001122|NCT03901573|Drug|atezolizumab|"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"
79233063|NCT02443532|Behavioral|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
79233064|NCT02443532|Behavioral|Individual education|Usual care (individual consultations as routinely performed)
79374560|NCT05676463|Procedure|MRI-guided Intensity-Modulated Radiation Therapy|Undergo MRI-guided IMRT
79374561|NCT05676463|Drug|Antiandrogen Therapy|Receive SOC ADT
79374562|NCT05676463|Procedure|PSMA PET Scan|Undergo PSMA PET scan
79374563|NCT05676463|Procedure|Computed Tomography|Undergo CT
79374564|NCT05676463|Procedure|Magnetic Resonance Imaging|Undergo MRI
80001123|NCT03899792|Drug|LOXO-292|Oral LOXO-292
80001124|NCT03886519|Procedure|BRAP (Bevel/rotate/advance procedure)|Trichiasis surgery using the BRAP procedure
79374565|NCT05676463|Procedure|Bone Scan|Undergo bone scan
80001125|NCT03886519|Procedure|Trabut|Trichiasis surgery using the Trabut procedure
79374566|NCT05676463|Procedure|Biospecimen Collection|Undergo blood sample collection
79374567|NCT05676463|Other|Quality-of-Life Assessment|Ancillary studies
79374568|NCT05665491|Behavioral|HabitWorks|Smartphone app-delivered interpretation bias intervention
79528414|NCT01397500|Drug|Genotropin|Genotropin administered sc once a day by patient or caregiver.
79528415|NCT01397500|Drug|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
79528416|NCT01397513|Drug|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
79528417|NCT01397539|Drug|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
80001126|NCT03864146|Behavioral|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
80001127|NCT03842358|Device|Hand-held hybrid probe|Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
80001128|NCT03834818|Behavioral|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~Download the Medable App~Register to the study~Validated Questionnaires~Active Task~Every Day~9:00 a.m. Daily Questions~9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~Day 1 Pre-Surgery~1-Week Post Operation~2-Weeks Post Operation~1-Month Post Operation~3-Months Post Operation~6-Months Post Operation"
79528418|NCT01397539|Other|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
79684784|NCT05579145|Other|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
79684785|NCT04755114|Other|Turkish Music|Turkish Music;In choosing the music, patients will be asked about their favorite vocalist and music pieces before the procedure. The researcher will then download these music pieces from YouTube and create a 30-minute list and listen to patients.
79827544|NCT05623722|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
79827545|NCT02552667|Drug|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
79827546|NCT02552667|Drug|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
79827547|NCT00728000|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
79827548|NCT00728000|Drug|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
79827549|NCT00728000|Drug|Erlotinib|100mg/day PO on days 1-14 and 15-28
79827550|NCT04066530|Drug|AD-203|AD-203 administered two times daily for two weeks
79827551|NCT04066530|Drug|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
80001129|NCT03819153|Drug|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
80001130|NCT03819153|Drug|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
80001131|NCT03817320|Drug|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
79233065|NCT02443454|Device|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
79233066|NCT02443454|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
79233067|NCT03188198|Drug|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
79374569|NCT05665491|Behavioral|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
79827552|NCT00808431|Behavioral|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
79233068|NCT03188276|Drug|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
79374570|NCT05662592|Device|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
79374571|NCT05660109|Drug|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
79374572|NCT05660109|Other|Placebo|Placebo
79374573|NCT05659160|Procedure|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
79233069|NCT03188276|Drug|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
79233070|NCT03192410|Behavioral|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
79233071|NCT03192410|Behavioral|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
79374574|NCT05652270|Behavioral|Goal Attainment|Development of an attainable goal
79528419|NCT01397565|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
79528420|NCT01397565|Procedure|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
79528421|NCT01397604|Drug|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
79827553|NCT02569190|Device|Walkbot|Robot assisted gait training
79827554|NCT04235556|Behavioral|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
79827555|NCT00809367|Other|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
79827556|NCT00728208|Drug|GSK372475|1.5mg for 28 days
79827557|NCT02552433|Dietary Supplement|protein intake assessment and optimisation|
79827558|NCT00733070|Device|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
80001132|NCT03817320|Drug|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and < 1 year: 1.2mg/m2/dose~< 6 months: 1mg/m2/dose"
79374575|NCT05652270|Behavioral|Goal Development|"A Systematic process to help patients create SMaRT  goals"
80001133|NCT03817320|Drug|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and < 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
79528422|NCT01397604|Drug|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
80001134|NCT03817320|Drug|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and < 1 year: 2,000 IU/m2/dose~< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~1 year: 25,000 IU/m2/dose~6 months and < 1 year: 20,000 IU/m2/dose~< 6 months: 17,500 IU/m2/dose"
80001135|NCT03817320|Drug|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and < 1 year: 48 mg/m2/dose~< 6 months: 42mg/m2/dose"
80001136|NCT03817320|Drug|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
80001137|NCT03817320|Drug|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
80001138|NCT03817320|Drug|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
80001139|NCT03802331|Drug|BI 1323495,|single oral doses
79374576|NCT05652270|Behavioral|Goal Tracking|Setting milestones to allow patients to track their progress towards their developed goal
79374577|NCT05636397|Dietary Supplement|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
79374578|NCT05635344|Drug|Pembrolizumab|Single dose 200mg dose of Pembrolizumab given intravenously
79528423|NCT01397604|Other|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
79684786|NCT04755114|Other|comedy movie|Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. In the selection of comedy films, the opinions of two experts from Mimar Sinan University, Faculty of Fine Arts, Department of Cinema and Television and İnönü University will be preferred, and the films Kemal Sunal and Şener Şen, one of the actors that Turkish people know closely, laugh most and have settled into their culture, will be preferred.
79684787|NCT04748952|Device|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
80001140|NCT03799445|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
80001141|NCT03799445|Biological|Ipilimumab|Given IV
80001142|NCT03799445|Biological|Nivolumab|Given IV
80001143|NCT03799445|Other|Quality-of-Life Assessment|Ancillary studies
80001144|NCT03799445|Other|Questionnaire Administration|Ancillary studies
80001145|NCT03782376|Drug|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
80001146|NCT03782376|Drug|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
79233072|NCT03192410|Biological|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
79233073|NCT03192410|Biological|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
79233074|NCT03192410|Genetic|DNA|SNPs (GWAS)
79233075|NCT03192410|Biological|Mental well-being|Cognitive function; dispositional optimism; depression.
79233076|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
79233077|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
80001147|NCT03782376|Drug|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
80001148|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
80001149|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
80001150|NCT03774082|Drug|INC424|Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
80001151|NCT03760523|Drug|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
79233078|NCT02443376|Device|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
79233079|NCT02443376|Device|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
79233080|NCT03190304|Drug|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
79233081|NCT03190304|Drug|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
79233082|NCT03190148|Other|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
79233083|NCT03190148|Other|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
79528424|NCT01397630|Drug|Oxytocin|Accelerated Oxytocin Titration
80001152|NCT03752827|Device|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
79233084|NCT03190148|Other|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
79233085|NCT03189992|Drug|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
79233086|NCT03189992|Drug|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
79233087|NCT02439632|Drug|prulifloxacin|
79233088|NCT02439632|Drug|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
79528425|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
79684788|NCT00552851|Drug|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
79233089|NCT02439632|Drug|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
79233090|NCT02439632|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
79233091|NCT02434172|Other|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
79374579|NCT05630521|Behavioral|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
79374580|NCT05630183|Drug|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
79528426|NCT01397643|Other|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
79528427|NCT01397708|Biological|INXN-2001|"approximately 1.0 x 1012 viral particles (vp) per injection~one intratumoral injection of INXN-2001 per study cycle~maximum of 6 study cycles"
79528428|NCT01397708|Drug|INXN-1001|"4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~7 oral daily doses of INXN-1001 per study cycle~maximum of 6 study cycles~1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
79684789|NCT01614171|Biological|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
79684790|NCT05567367|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
79684791|NCT05567367|Drug|Vardenafil Oral Tablet|20 mg oral vardenafil tablet.
79684792|NCT05562024|Biological|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
80001153|NCT03752827|Drug|Corticosteroid|Corticosteroid injection into subacrominal space
79233092|NCT02434874|Device|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
79233093|NCT02434094|Behavioral|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
79233094|NCT03133611|Other|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
79233095|NCT03133611|Other|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
79374581|NCT05630183|Drug|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
79374582|NCT05630183|Drug|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
79374583|NCT05619458|Behavioral|Mindfulness Intervention|6-week mindfulness intervention
79684793|NCT00536952|Drug|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
79684794|NCT00536952|Drug|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
79684795|NCT00536952|Radiation|Radiation Therapy|5 days per week for 4 weeks
79684796|NCT04684004|Other|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
80001154|NCT03752723|Drug|GX-I7|i.m.
80001155|NCT03752723|Drug|Pembrolizumab|i.v.
80001156|NCT03752723|Drug|cyclophosphamide|i.v.
80001157|NCT03712605|Other|Best Practice|Receive standard of care observation
80001158|NCT03712605|Procedure|Biospecimen Collection|Undergo blood sample collection
80001159|NCT03712605|Procedure|Computed Tomography|Undergo PET-CT or CT
80001160|NCT03712605|Procedure|Magnetic Resonance Imaging|Undergo MRI
80001161|NCT03712605|Biological|Pembrolizumab|Given IV
80001162|NCT03712605|Procedure|Positron Emission Tomography|Undergo PET-CT
80001163|NCT03712605|Radiation|Radiation Therapy|Undergo radiation therapy
80001164|NCT03697278|Device|Smith medical CADDsolis|This group will be monitoring from a network.
79374584|NCT05606276|Other|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
80001165|NCT03689543|Drug|ER beta agonist|We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.
79827559|NCT04065620|Diagnostic Test|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration <24 hours, those without one good reading per hour and those with <70% of satisfactory readings will be excluded
79827560|NCT00730314|Procedure|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
79827561|NCT02553993|Device|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
80001166|NCT03689543|Other|Placebo|Placebo
80001167|NCT03683433|Drug|Azacitidine|Given SC or IV
79233096|NCT02439398|Biological|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
79684797|NCT04675632|Procedure|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
79684798|NCT04282616|Other|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
80001168|NCT03683433|Drug|Enasidenib Mesylate|Given PO
79233097|NCT02439398|Other|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
79233098|NCT03187808|Other|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
79374585|NCT05606276|Other|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
79374586|NCT05599750|Procedure|Incisional hernia repair|Participants will undergo incisional hernia repair
79528429|NCT01397734|Drug|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
79528430|NCT01397799|Drug|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
79528431|NCT01397812|Device|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
79684799|NCT04282616|Other|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
79684800|NCT04282616|Other|In-hospital structured supervised physical activity program|Supervised exercise training program
79374587|NCT05595694|Other|No intervention|This is a retrospective review of 1320 patients in our database who underwent elective primary and revision TJA in Queen Mary Hospital, Hong Kong from from January 2018 to December 2021. No intervention was involved.
79528432|NCT01397812|Device|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
79528433|NCT01397838|Drug|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
80001169|NCT03682081|Device|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
80001170|NCT03682081|Device|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
79684801|NCT00537147|Biological|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
80016681|NCT00401570|Drug|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
79684802|NCT00537147|Biological|Placebo|Placebo for WN/DEN4delta30 vaccine
79684803|NCT04656951|Drug|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
79684804|NCT00537186|Drug|Iron oligosaccharide|
80001171|NCT03674372|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E < 25%; O/E LHR < 30 %) and right CDH (O/E LHR < 45%).
80001172|NCT03664830|Drug|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
80001173|NCT03634241|Biological|Pembrolizumab|Given IV
80001174|NCT03634241|Other|Quality-of-Life Assessment|Ancillary studies
80001175|NCT03634241|Procedure|Computed Tomography|Undergo CT
80001176|NCT03634241|Procedure|Biospecimen Collection|Undergo collection of blood samples
80001177|NCT03588390|Drug|BI 1323495|Low strength tablet
79528434|NCT01397942|Other|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
79684805|NCT04251260|Other|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
79684806|NCT04244786|Device|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
79684807|NCT04642014|Biological|COVID-19 convalescent plasma treatment|"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."
80001178|NCT03588390|Drug|BI 1323495|Middle strength tablet
80001179|NCT03588390|Drug|BI 1323495|High strength tablet
80001180|NCT03588390|Drug|Placebo|Placebo to low strength tablet
79233099|NCT03187808|Other|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
79528435|NCT01397955|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
80001181|NCT03588390|Drug|Placebo|Placebo to middle strength tablet
80001182|NCT03588390|Drug|Placebo|Placebo to high strength tablet
79233100|NCT02443064|Drug|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
80001183|NCT03581942|Drug|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
80001184|NCT03581942|Drug|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
80001185|NCT03573544|Drug|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
79233101|NCT02433938|Procedure|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
79233102|NCT02433938|Procedure|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
79233103|NCT02741271|Drug|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
79233104|NCT02741271|Drug|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
79528436|NCT01397981|Behavioral|Gait retraining|Changing the kinematics of walking
79528437|NCT01397994|Drug|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
79528438|NCT01397994|Drug|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
79528439|NCT01398007|Procedure|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
79528440|NCT01398020|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
80001186|NCT03573544|Drug|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
80001187|NCT03573544|Device|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
80001188|NCT03547973|Drug|Sacituzumab Govitecan-hziy|Administered intravenously.
80001189|NCT03547973|Drug|Pembrolizumab|Administered per package insert
80001190|NCT03547973|Drug|Cisplatin|Administered per package insert
80001191|NCT03547973|Drug|Avelumab|Administered per package insert
80001192|NCT03547973|Drug|Zimberelimab|Administered intravenously
80001193|NCT03547973|Drug|Carboplatin|Administered per package insert
80001194|NCT03547973|Drug|Gemcitabine|Administered per package insert
80001195|NCT03547973|Drug|Domvanalimab|Administered intravenously
80001196|NCT03543189|Drug|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
80016682|NCT02284958|Behavioral|Standard|Back care advice
80001197|NCT03543189|Radiation|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
80001198|NCT03543189|Radiation|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
80001199|NCT03543189|Drug|Androgen Deprivation Therapy|Standard of care.
80001200|NCT03512249|Biological|H56:IC31|5ug H56/500 nmol IC31
80001201|NCT03512249|Biological|Placebo|Sterile saline for injection
80001202|NCT03511092|Dietary Supplement|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
80001203|NCT03511092|Dietary Supplement|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
80001204|NCT03511092|Dietary Supplement|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
80001205|NCT03511092|Other|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
79233105|NCT02741271|Drug|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
79233106|NCT02741271|Drug|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
79233107|NCT02741271|Drug|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
79233108|NCT02443142|Drug|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
79528441|NCT01398020|Drug|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
79528442|NCT01398033|Device|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
80001206|NCT03504800|Device|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B & C.
80001207|NCT03494569|Drug|Fludarabine|Given IV
79528443|NCT01398033|Device|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
79528444|NCT01398046|Drug|Dasatinib|dasatinib (100mg) PO x1
79528445|NCT01398046|Drug|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
79684808|NCT04234334|Other|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
79684809|NCT04234334|Other|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
80001208|NCT03494569|Other|Laboratory Biomarker Analysis|Correlative studies
80001209|NCT03494569|Drug|Melphalan|Given as per City of Hope Standard Operating Procedure
80001210|NCT03494569|Radiation|Total Marrow Irradiation|Undergo TMLI
79233109|NCT02443142|Drug|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
79233110|NCT02442908|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
79233111|NCT02442908|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
79233112|NCT02439242|Drug|fluid challenge of saline|250 ml of saline
79233113|NCT02439008|Procedure|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
79233114|NCT02439008|Procedure|Blood samples collection during radiotherapy|"Sample T1: within 15 minutes after the administration of the first fraction,~Sample T2: within 15 minutes after the administration of the second fraction,~Sample T3: within 15 minutes after the administration of the third fraction"
79528446|NCT01398046|Drug|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
79528447|NCT01398072|Drug|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
79528448|NCT01398072|Drug|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
79684810|NCT00552890|Other|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
79374592|NCT05586360|Drug|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
79374593|NCT05584397|Procedure|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
79528449|NCT01398072|Drug|Doxycycline|An oral dose of 100 mg once daily.
79528450|NCT01398072|Drug|Placebo|Oral dose of one table once daily.
79528451|NCT01398098|Drug|Sodium phosphate|32 tablets
79528452|NCT01398111|Drug|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
79684811|NCT00552890|Other|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
79684812|NCT04200755|Drug|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
79684813|NCT04200755|Other|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
79684814|NCT04173533|Drug|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
80001211|NCT03472300|Other|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
79233115|NCT02439008|Procedure|Blood samples collection after radiotherapy|"Sample T4: one week after the end of the radiotherapy,~Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
79528453|NCT01398111|Drug|Glycopyrrolate|glycopyrrolate pMDI
79684815|NCT04173533|Drug|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
79233116|NCT02439008|Radiation|Radiotherapy|
79233117|NCT03524079|Drug|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
79233118|NCT03528525|Other||observation
80001212|NCT03455985|Other|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
79374594|NCT05584397|Procedure|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
79528454|NCT01398111|Drug|Formoterol|formoterol pMDI
79528455|NCT01398111|Drug|Placebo|placebo pMDI
79528456|NCT01398124|Biological|Cyclin B1 Peptide|vaccine
79528457|NCT01398150|Dietary Supplement|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
79684816|NCT05544591|Drug|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
79684817|NCT05544591|Drug|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
79684818|NCT05544591|Drug|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
79233119|NCT02439086|Device|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
79233120|NCT04694547|Other|There is no intervention, as this is a survey study|Survey
79233121|NCT02438774|Behavioral|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
79233122|NCT02438774|Behavioral|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
79233123|NCT02438930|Behavioral|Motivational interviewing intervention during HIV testing|
79233124|NCT02438930|Behavioral|Standard-of-care counseling during HIV testing|
79684819|NCT01534065|Device|Barricaid|Implanted intra-operatively during discectomy
79684820|NCT05539794|Behavioral|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
80001213|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
80001214|NCT03449537|Dietary Supplement|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
79233125|NCT03526263|Procedure|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
79233126|NCT02438852|Other|Placebo|Given IV
79233127|NCT02438852|Other|Questionnaire Administration|Ancillary studies
79233128|NCT02438852|Drug|Ropivacaine Hydrochloride|Given IV
79374595|NCT05584397|Procedure|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
79528458|NCT01398150|Dietary Supplement|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
79528459|NCT01398163|Other|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
79528460|NCT01398163|Other|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
79528461|NCT01398189|Drug|clozapine|C-11 clozapine
80001215|NCT03449537|Dietary Supplement|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
79528462|NCT01398202|Dietary Supplement|vitamin D3|20 micrograms per day for 10 weeks
79528463|NCT01398202|Dietary Supplement|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
79528464|NCT01398202|Dietary Supplement|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
79528465|NCT01398202|Dietary Supplement|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
79528466|NCT01398215|Procedure|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
80001216|NCT03436992|Dietary Supplement|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
79827562|NCT02553993|Device|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
79528467|NCT01398228|Behavioral|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
79528468|NCT01398241|Drug|RO5267683|Multiple ascending doses
79528469|NCT01398241|Drug|placebo|Multiple ascending doses
79528470|NCT01398254|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
80001217|NCT03436992|Dietary Supplement|Resveratrol|1500 mg trans-resveratrol
80001218|NCT03436992|Other|Placebo|placebo
79528471|NCT01398267|Drug|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
79827563|NCT02553993|Other|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
79374596|NCT05584397|Procedure|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
79528472|NCT01398267|Drug|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
79528473|NCT01398267|Drug|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
79684821|NCT01258348|Drug|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
79684822|NCT01258348|Drug|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
79233129|NCT03523845|Other|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
79233130|NCT02438618|Procedure|Surgery for Ponto bone anchored hearing aids|
79233131|NCT02438696|Drug|BI 1060469, iFF, Test|
79233132|NCT02438696|Drug|BI 1060469, iFF, Test|
79374597|NCT05584397|Procedure|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
79528474|NCT01398293|Drug|danoprevir|100 mg single dose orally
79528475|NCT01398293|Drug|danoprevir|400 mg single dose orally
79684823|NCT01258075|Drug|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
79684824|NCT01258075|Drug|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
79233133|NCT02438696|Drug|BI 1060469, TF1, Reference|
79233134|NCT02438696|Drug|BI 1060469, TF2, Test|
79233135|NCT02438696|Drug|BI 1060469, TF2, Test|
79528476|NCT01398293|Drug|danoprevir placebo|single oral dose
79528477|NCT01398293|Drug|moxifloxacin|400 mg single dose orally
79528478|NCT01398293|Drug|moxifloxacin placebo|single oral dose
79528479|NCT01398293|Drug|ritonavir|100 mg single dose orally
79528480|NCT01398293|Drug|ritonavir placebo|single oral dose
79528481|NCT01398306|Other|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
79233136|NCT02438696|Drug|BI 1060469, iFF, Test|
79233137|NCT02438696|Drug|BI 1060469, TF1, Reference|
79233138|NCT02438696|Drug|BI 1060469, iFF, Test|
79233139|NCT02438696|Drug|BI 1060469, iFF, Test|
79233140|NCT02438696|Drug|BI 1060469, TF1, Reference|
79233141|NCT02438696|Drug|BI 1060469, TF2, Test|
79233142|NCT02438696|Drug|BI 1060469, TF1, Reference|
79233143|NCT02438696|Drug|BI 1060469, TF1, Reference|
79233144|NCT02438696|Drug|BI 1060469, TF2, Test|
79233145|NCT02438696|Drug|BI 1060469, TF2, Test|
79233146|NCT02438696|Drug|BI 1060469, iFF, Test|
79233147|NCT02438696|Drug|BI 1060469, TF2, Test|
79233148|NCT02438696|Drug|BI 1060469, TF1, Reference|
79528482|NCT01398345|Behavioral|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
79528483|NCT01398371|Drug|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
79684825|NCT01257568|Device|Rejuvenate Modular Hip|Rejuvenate Modular Hip
79827564|NCT04065230|Drug|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
79827565|NCT00728078|Drug|thalidomide|thalidomide 50mg tid for 6 months
79827566|NCT00653991|Behavioral|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
80001219|NCT03417011|Device|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
80001220|NCT03412565|Drug|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
80001221|NCT03412565|Drug|Bortezomib|Bortezomib will be administered as 1.3 mg/m^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
79528484|NCT01398371|Drug|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
79684826|NCT04687878|Drug|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
79827567|NCT02561988|Drug|Avapritinib|
80001222|NCT03412565|Drug|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
80001223|NCT03412565|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
80001224|NCT03412565|Drug|Melphalan|Melphalan will be administered as 9 mg/m^2 orally in Cycles 1 to 9.
80001225|NCT03412565|Drug|Prednisone|Prednisone will be administered as 60 mg/m^2 orally in cycles 1 to 9.
80001226|NCT03412565|Drug|Carfilzomib|Carfilzomib will be administered as 20 mg/m^2 IV on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
80001227|NCT03357224|Drug|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
80001228|NCT03336255|Behavioral|South Asian Healthy Lifestyle Initiative (SAHELI)|Culturally tailored lifestyle intervention for South Asians.
80001229|NCT03335267|Drug|CPX-351|Cytarabine:Daunorubicin Liposome Injection
79233149|NCT03523767|Biological|S.typhi Injection|0.5 ml of S.typhi injection
79233150|NCT03523767|Biological|Normal Saline Injection|0.5 ml of normal saline injection
79233151|NCT05509803|Behavioral|PE Audit and Feedback Tool|The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
79233152|NCT02442674|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
79528485|NCT01398384|Drug|Nitric Oxide|MI size at 48-72 hours
79233153|NCT02442674|Other|Placebo|Placebo tablet matching active drug
79528486|NCT01398384|Drug|MI size at 48-72 hours|Placebo gas
79528487|NCT01398423|Drug|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
79684827|NCT04687878|Drug|Normal saline|twice a day, intranasally, every day for 12 weeks
79528488|NCT01398423|Drug|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
79827568|NCT04066088|Other|Placebo|Placebo will be administered same times as GXR
79827569|NCT04066088|Drug|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
79827570|NCT00799461|Other|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
79233154|NCT02442752|Drug|Dexlansoprazole|Dexlansoprazole capsules
79233155|NCT03523689|Procedure|Bronchoscopy|Undergo bronchoscopy
79233156|NCT03523689|Procedure|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
79528489|NCT01398436|Procedure|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
79528490|NCT01398449|Radiation|Elective nodal irradiation (ENI)|
79528491|NCT01398449|Other|Adjuvant chemotherapy only|
79684828|NCT04687839|Procedure|Induction of suction blister|For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
79684829|NCT04687839|Other|Transepidermal water loss (TEWL)|"At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~For subsequent visits, before product application"
79827571|NCT00799461|Other|questionnaire administration|Completion of questions in an online format
79827572|NCT00799461|Procedure|psychosocial assessment and care|Assessment and care of psychosocial aspects
80001230|NCT03333915|Drug|Pamiparib|Pamiparib is provided as oral capsules
80001231|NCT03274869|Other|No intervention|No intervention
79233157|NCT02442518|Procedure|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
79233158|NCT03523611|Procedure|Lung Resection|Lung resection surgery
79233159|NCT02442362|Drug|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
79233160|NCT02442362|Drug|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area < 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
79528492|NCT01398462|Drug|CWP232291|IV Infusion
79684830|NCT04687839|Other|Macrophotography|"At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~For subsequent visits, before product application"
79827573|NCT00799461|Procedure|assessment of therapy complications|Evaluation of complications of treatment
80001232|NCT03269669|Drug|Bendamustine Hydrochloride|Given IV
80001233|NCT03269669|Procedure|Biopsy|Undergo biopsy
80001234|NCT03269669|Procedure|Biospecimen Collection|Undergo collection of blood
80001235|NCT03269669|Procedure|Computed Tomography|Undergo PET/CT scans
80001236|NCT03269669|Drug|Cyclophosphamide|Given IV
79684831|NCT04687839|Device|Wound healing medical device|Twice daily application on superficial wounds
79374598|NCT05573178|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
79374599|NCT05572879|Biological|EuCorVac-19|COVID-19 vaccine
79374600|NCT05572879|Biological|ChAdOx1 nCoV-19|COVID-19 vaccine
79827574|NCT00799461|Procedure|management of therapy complications|Managing therapy complications
79827575|NCT00799461|Procedure|fatigue assessment and management|Assessing and managing fatigue
79827576|NCT00799461|Other|counseling intervention|Counseling provided via telephone
79374601|NCT05570812|Drug|Placebo|(4-week ramp, 4-week steady dosing)
79827577|NCT02570178|Other|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
79374602|NCT05570812|Drug|Pregnenolone|(4-week ramp, 4-week steady dosing)
79374603|NCT05568056|Behavioral|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
79374604|NCT05555173|Device|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
79374605|NCT05555056|Device|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
80001237|NCT03269669|Drug|Doxorubicin Hydrochloride|Given IV
79827578|NCT00733148|Drug|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
79827579|NCT00730392|Drug|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
79827580|NCT00730392|Drug|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
79374606|NCT05555056|Device|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
79528493|NCT01398488|Behavioral|Patient education|Patient education by health care professional compared to education via tablet PC
79684832|NCT01256788|Device|Euflexxa|4 injections of 2ml of Euflexxa
79684833|NCT01256788|Other|Saline|4 injections of 3 ml of sterile saline
79374607|NCT05552716|Other|School safety tactics and policies|A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
79528494|NCT01398501|Drug|Sorafenib|Oral, 200 to 400 mg QD or BID
79528495|NCT01398527|Other|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
79528496|NCT01398540|Biological|IXIARO|2 immunizations (0,5ml) with a 28 day interval
79684834|NCT01256671|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
79684835|NCT04687566|Drug|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
80001238|NCT03269669|Procedure|Echocardiography|Undergo ECHO
80001239|NCT03269669|Drug|Lenalidomide|Given PO
79684836|NCT04687566|Drug|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
80001240|NCT03269669|Procedure|Multigated Acquisition Scan|Undergo MUGA
80001241|NCT03269669|Biological|Obinutuzumab|Given IV
80001242|NCT03269669|Procedure|Positron Emission Tomography|Undergo PET/CT scans
80001243|NCT03269669|Drug|Prednisone|Given PO
80001244|NCT03269669|Drug|Umbralisib|Given PO
80001245|NCT03269669|Drug|Vincristine Sulfate|Given IV
80001246|NCT03215420|Diagnostic Test|MRI 3T|
80001247|NCT03208062|Other|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
80001248|NCT03202706|Procedure|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
80001249|NCT03194607|Other|Functional walk tests|
80001250|NCT03194607|Other|3D analysis of locomotion and posture|
80001251|NCT03194607|Other|questionnaires|
79233161|NCT04440488|Biological|ARALAST NP|Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.
79233162|NCT03187574|Device|Elevate Ant™|Surgery with Elevate Ant™
79233163|NCT03187574|Device|Perigee™|Surgery with Perigee™
79233164|NCT04468581|Behavioral|Use of mobile application|Use of the TraceTogether mobile application during the COVID-19 period
79233165|NCT02433860|Behavioral|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately > 36 weeks gestation or at delivery."
79233166|NCT04468503|Other|Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional|In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.
79233167|NCT03523455|Dietary Supplement|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
79233168|NCT03523455|Other|Sugar Pill|Taken orally in capsule form
79233169|NCT03189836|Biological|ACTR707|autologous T cell product
79827581|NCT00809601|Device|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
79233170|NCT03189836|Biological|rituximab|CD20-directed cytolytic antibody
79233171|NCT03523299|Procedure|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
79233172|NCT03190226|Procedure|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
79233173|NCT03190226|Procedure|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
79233174|NCT05490927|Behavioral|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
79233175|NCT03525717|Dietary Supplement|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
79233176|NCT03525717|Dietary Supplement|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
79233177|NCT03187184|Device|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
79528497|NCT01398553|Device|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
79233178|NCT04466943|Device|Neuromuscular transmission monitoring (NMT)|NMT is to monitor the depth of neuromuscular blockade intensity
79233179|NCT02438462|Other|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
79374608|NCT05551936|Drug|Bendamustine|90 mg/m^2 IV Days 1-2, Cycles 1-3
79374609|NCT05551936|Drug|Rituximab|375 mg/m^2 IV Day 1 Cycles 1-6
79374610|NCT05551936|Drug|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
79374611|NCT05550675|Other|Questionnaires|Disease specific questionnaires
79528498|NCT01398553|Other|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
79374612|NCT05540613|Behavioral|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
79374613|NCT05540613|Behavioral|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
79374614|NCT05540613|Behavioral|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
79391013|NCT01681511|Device|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
79528499|NCT01398579|Procedure|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
79528500|NCT01398592|Drug|Vildagliptin|50mg vildagliptin bid
79684837|NCT04687566|Drug|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
79374615|NCT05537389|Device|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
79684838|NCT04687566|Drug|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
79684839|NCT04683809|Other|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
79233180|NCT04466397|Device|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
79233181|NCT02438150|Behavioral|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
79233182|NCT02438150|Behavioral|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
79233183|NCT03212469|Drug|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
79233184|NCT03212469|Drug|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
79233185|NCT03212469|Radiation|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
79233186|NCT02438228|Other|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
79233187|NCT02442440|Drug|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
79233188|NCT03187496|Drug|Midazolam|Each subject will receive midazolam on Days 1 and 12.
79233189|NCT03187496|Drug|Caffeine|Each subject will receive caffeine on Days 1 and 12.
79684840|NCT01256476|Drug|pitavastatin|pitavastatin 4 mg once daily (QD)
79684841|NCT01256476|Drug|pravastatin|Pravastatin 40 mg once daily (QD)
79684842|NCT05507892|Drug|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
79684843|NCT05507892|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
79827582|NCT00730470|Drug|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
79233190|NCT03187496|Drug|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
79233191|NCT03187496|Drug|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
79374616|NCT05535075|Device|Vancomycin model-informed precision dosing|A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg*h/L
79374617|NCT05535075|Drug|Vancomycin|Vancomycin treatment
79528501|NCT01398592|Drug|Sitagliptin|100mg sitagliptin po qd
79528502|NCT01398605|Other|Exercise training|Different dose of exercise training
79528503|NCT01398618|Drug|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
79528504|NCT01398644|Other|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
79528505|NCT01398657|Drug|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
79528506|NCT01398670|Biological|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
79684844|NCT04128371|Biological|Nucala (mepolizumab)|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials will be reconstituted with 1.2 ml sterile water for injection (according to the product labeling) and secondarily diluted in 100-250 ml of 0.9% normal saline (NaCl) for infusion (to a final concentration of 0.3-7.5 mg/ml).
79684845|NCT04684043|Device|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
79684846|NCT04684082|Device|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
79684847|NCT04683887|Device|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
80001252|NCT03191149|Procedure|Biospecimen Collection|Undergo collection of blood samples
79233192|NCT04440969|Behavioral|Multi-domain intervention|"Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app."
79233193|NCT03186950|Procedure|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
79233194|NCT03186950|Procedure|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
79233195|NCT02438072|Drug|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
79233196|NCT03184311|Other|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
79233197|NCT03184311|Other|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
79233198|NCT02437994|Behavioral|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
79233199|NCT02437838|Other|No Intervention|No Intervention
79233200|NCT03522987|Drug|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
79233201|NCT02437760|Other|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~at time of diagnosis~every 3 month during treatment~stop at the progression or after 12 months"
79827583|NCT00734084|Device|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
79233202|NCT03186872|Behavioral|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
79827584|NCT01528046|Drug|Vincristine|Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
79827585|NCT01528046|Drug|Irinotecan|Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
79827586|NCT01528046|Drug|Temozolomide|Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
79827587|NCT01528046|Drug|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
80001253|NCT03191149|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
80001254|NCT03191149|Procedure|Magnetic Resonance Imaging|Undergo MRI
80001255|NCT03191149|Drug|Osimertinib|Given PO
79233203|NCT03522909|Other|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~Primary outcome variable.~- Hospital length of stay~Secondary outcome variables.~Number of admissions from outside hospitals~Adverse outcomes~Intensive Care Unit admissions~Opioid use~NICU admissions~Patient satisfaction~Cost of inpatient admission~Cost of outpatient care~Hospital readmissions rate"
79233204|NCT02433626|Drug|COTI2|COTI-2 is a third generation thiosemicarbazone.
79233205|NCT02433626|Drug|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
79374618|NCT05532891|Other|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
79374619|NCT05524493|Diagnostic Test|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2*-weighted sequences
79374620|NCT05524493|Diagnostic Test|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
79528507|NCT01398670|Biological|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
79528508|NCT01398696|Procedure|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
79528509|NCT01398696|Procedure|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
79528510|NCT01398709|Other|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
79528511|NCT01398709|Other|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
80001256|NCT03177291|Drug|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
80001257|NCT03177291|Drug|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
80001258|NCT03177291|Drug|Paclitaxel|200 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
80001259|NCT03177291|Drug|Pemetrexed|500 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
80001260|NCT03142568|Drug|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
80001261|NCT03142568|Other|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
79684848|NCT05506956|Drug|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
80001262|NCT03142321|Drug|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
80001263|NCT03128866|Procedure|Hemipelvectomy|Undergo hemipelvectomy
79827588|NCT00652899|Biological|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
79827589|NCT00652899|Drug|Cyclophosphamide|60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.
80001264|NCT03128866|Drug|Tranexamic Acid|Given IV
80001265|NCT03078543|Device|ANTHEM™ PS Total Knee System implant|"The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~Titanium primary tibial components~Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
79827590|NCT00652899|Drug|Fludarabine phosphate|25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.
79827591|NCT00652899|Radiation|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
79374621|NCT05524493|Diagnostic Test|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
80001266|NCT03075254|Device|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
80001267|NCT03075254|Device|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
80001268|NCT03075254|Device|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
80001269|NCT03072927|Device|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
79233206|NCT03392415|Procedure|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
79528512|NCT01398722|Other|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
79528513|NCT01398722|Other|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
80001270|NCT03070236|Other|Survey|Select questions will be ask in the survey
79528514|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
79827592|NCT00652899|Biological|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 * 10^7/kg
79827593|NCT00652899|Biological|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
79233207|NCT04466709|Other|none intervention type|This is an observational study, no intervention
79233208|NCT02437448|Other|No intervention|
79233209|NCT02290041|Drug|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
79528515|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
79528516|NCT01398748|Drug|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
79528517|NCT01398761|Other|Signout tool|Electronic signout tool
79827594|NCT04147962|Device|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
79827595|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, single dose
79827596|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
79827597|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, single dose
79827598|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
79827599|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
79827600|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, single dose
79827601|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, single dose
79827602|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, single dose
79827603|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, single-dose
79233210|NCT02290041|Drug|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
79374622|NCT05524493|Diagnostic Test|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
79374623|NCT05524493|Diagnostic Test|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
79827604|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
80001271|NCT03063918|Other|Informational Intervention|Receive a workbook
79684849|NCT05506722|Device|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
79684850|NCT05504616|Other|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
80001272|NCT03063918|Other|Quality-of-Life Assessment|Ancillary studies
80001273|NCT03063918|Other|Questionnaire Administration|Ancillary studies
79374624|NCT05524480|Behavioral|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
79374625|NCT05524480|Behavioral|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
79374626|NCT05523609|Drug|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
79827605|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
79827606|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
79827607|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
79827608|NCT00734240|Drug|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
79827609|NCT00734240|Drug|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
79827610|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
79827611|NCT04066452|Diagnostic Test|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
79827612|NCT04066452|Diagnostic Test|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
79827613|NCT00733382|Drug|dexamethazone|injection form, 8 miligram, injected once
79827614|NCT00728442|Device|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
80001274|NCT03063918|Other|Survey Administration|Ancillary studies
79374627|NCT05523609|Drug|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
79374628|NCT05518435|Other|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
79374629|NCT05509751|Behavioral|GAM, exercise, health education|geriatric assessment, exercise and health education
79827615|NCT00733460|Drug|BFPET|
79827616|NCT00728520|Drug|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
80001275|NCT03063918|Behavioral|Telephone-Based Intervention|Receive personalized dietary intervention
80001276|NCT03063619|Drug|Afimoxifene|Applied topically
79374630|NCT05505344|Device|VentriJect Seismofit validation|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
80001277|NCT03063619|Other|Laboratory Biomarker Analysis|Correlative studies
79374631|NCT05493033|Procedure|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
79391014|NCT01681511|Device|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®* silver alloy coating and BARD® hydrogel.
79684851|NCT04108364|Behavioral|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
79684852|NCT05502276|Procedure|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
79684853|NCT05502276|Procedure|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
79684854|NCT04106999|Drug|Dexmedetomidine|Drug infusion will be delivered intra-operatively
79684855|NCT04106999|Drug|Placebos|Normal Saline will be infused as a control drug
79684856|NCT04105049|Other|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
80001278|NCT03063619|Other|Placebo|Applied topically
80001279|NCT03063619|Other|Questionnaire Administration|Ancillary studies
80001280|NCT03058861|Behavioral|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
80001281|NCT03037385|Drug|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
80016683|NCT02284958|Behavioral|Walking|Back care advice, individualized 12 week pedometer-driven walking program
80016684|NCT05193565|Drug|Sirolimus|Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~8ng/mL
80016685|NCT05193565|Drug|Mycophenolate mofetil|Up to 1g BID(total 2g daily), PO
79827617|NCT04065308|Drug|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
79233211|NCT02442128|Drug|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
79233212|NCT02442128|Drug|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
79684857|NCT05003089|Drug|BAY1834845|Tablet, oral.
79374632|NCT05493033|Procedure|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
79374633|NCT05489237|Drug|IDRX-42|IDRX-42 will be administered at assigned doses and schedules once daily in continuous cycles of 28 days each.
79374634|NCT05489237|Drug|IDRX-42|IDRX-42 will be administered at RP2DS once daily in continuous cycles of 28 days each.
79684858|NCT05003089|Drug|BAY1830839|Tablet, oral.
79233213|NCT04465773|Procedure|general anesthesia for scheduled gynecological surgery|
79233214|NCT04465773|Drug|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
79374635|NCT05487846|Behavioral|Patient Navigation|Receive peer navigation services
79374636|NCT05487846|Other|Genetic Counseling|Receive genetic counseling
79374637|NCT05487846|Other|Survey Administration|Ancillary studies
79528518|NCT01398865|Procedure|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
79528519|NCT01398878|Behavioral|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
79684859|NCT05003089|Drug|Prednisolone|Tablet, oral.
79684860|NCT05003089|Drug|Placebo|Tablet, oral.
79684861|NCT01256008|Behavioral|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
79827618|NCT00733538|Drug|zometa|patients receiving treatment during their follow-up
79827619|NCT00730548|Behavioral|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
79827620|NCT00728156|Drug|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
79233215|NCT04465773|Drug|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
79233216|NCT04465773|Procedure|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
79374638|NCT05487846|Other|Best Practice|Receive standard care
79374639|NCT05487846|Other|Genetic Counseling|Receive genetic counseling
79827621|NCT00728156|Drug|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
79233217|NCT04465773|Device|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
79233218|NCT02441972|Drug|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
79374640|NCT05487846|Other|Survey Administration|Ancillary studies
79374641|NCT05482646|Behavioral|Tai Chi|The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.
79374642|NCT05482646|Behavioral|Conventional exercise|The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.
79374643|NCT05482646|Behavioral|Health Education Control|Participants in the control group will participate in a health education program delivered by research personnel.
79374644|NCT05481437|Drug|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
79374645|NCT05481359|Device|Ablamap Software|Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation.
79374646|NCT05475678|Drug|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
79374647|NCT05475678|Drug|TCb regimen|docetaxel + carboplatin regimen
79233219|NCT04468191|Device|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
79374648|NCT05470036|Behavioral|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
79374649|NCT05468203|Drug|Dapagliflozin 10mg Tab|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
79827622|NCT02569554|Drug|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
79374650|NCT05468203|Drug|Placebo|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
79374651|NCT05466331|Other|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
79374652|NCT05466331|Other|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
79374653|NCT05458934|Other|No intervention|no intervention
79374654|NCT05450770|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
79374655|NCT05446324|Drug|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
79528520|NCT01398891|Other|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
79528521|NCT01398917|Procedure|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
79684862|NCT01256008|Behavioral|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
79684863|NCT04066127|Device|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
79684864|NCT04066127|Device|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
79684865|NCT04976101|Device|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
79827623|NCT02569554|Drug|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
79827624|NCT00728234|Device|aEEG recording|weekly recordings with aEEG
79374656|NCT05442437|Biological|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
79827625|NCT00734318|Drug|Flutiform 250/10 micrograms|
79374657|NCT05440890|Other|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
79374658|NCT05440890|Other|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
79374659|NCT05415488|Other|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
79827626|NCT00734318|Drug|Flutiform 50/5 micrograms|
79827627|NCT00734318|Drug|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
79827628|NCT00734318|Drug|Flixotide pMDI 250 micrograms|
80016686|NCT03214887|Biological|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
79233220|NCT04468191|Device|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
79233221|NCT02290197|Procedure|Surgery|Surgical reconstruction of all injured ligaments.
79233222|NCT02290197|Device|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
79233223|NCT02290197|Device|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
79233224|NCT02290275|Dietary Supplement|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
79528522|NCT01398917|Procedure|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
79233225|NCT02290275|Other|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
79233226|NCT02290275|Dietary Supplement|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
79528523|NCT01398930|Other|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
79528524|NCT01398969|Biological|Fresh FMT|Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
79233227|NCT02709746|Drug|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
79233228|NCT02709746|Drug|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
79233229|NCT02709746|Drug|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
79233230|NCT02709746|Other|Placebo|Encapsulated tablet
79233231|NCT02441894|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
79374660|NCT05406635|Diagnostic Test|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
79374661|NCT05405881|Other|Proprioception measurement tool|No intervention, as it is a psychometric properties study
79374662|NCT05403359|Drug|Steroids|"Description of the intervention in each of the work packages:~WP1A admission: Steroid dose >6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~WP2 ICU admission: High-dose steroids (dexamethasone >6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone >6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
79528525|NCT01398969|Biological|Frozen-and-Thawed FMT|Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
79684866|NCT04976101|Device|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
79684867|NCT04206826|Device|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
79684868|NCT04206826|Device|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
79684869|NCT04207021|Dietary Supplement|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
79827629|NCT04052412|Drug|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
79827630|NCT00733616|Drug|DOX: Docetaxel, oxaliplatin, Capecitabine|"Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~Capecitabine 625 mg/m2, bid, oral, continuous~6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
79827631|NCT00728832|Drug|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
79233232|NCT02441894|Drug|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
79233233|NCT02441894|Drug|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
79233234|NCT02441894|Drug|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
79233235|NCT02441894|Drug|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
79233236|NCT02441894|Drug|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
79233237|NCT02441894|Drug|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
79233238|NCT01317641|Drug|ODM-201|ODM-201 administered orally daily
79233239|NCT02433548|Procedure|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
79233240|NCT02433548|Procedure|Sham injection|subcutaneous of 5 cc of normal saline
79233241|NCT02433704|Device|New Intraosseous|Intraosseous administration of prophylactic antibiotics
79233242|NCT02433704|Drug|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
79528526|NCT01398995|Other|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
79528527|NCT01399021|Other|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
79528528|NCT01399021|Other|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
79827632|NCT00734396|Procedure|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
79827633|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
79528529|NCT01399073|Behavioral|virtual reality setup|testing for neglect in a virtual reality setup
79233243|NCT02437292|Other|Ischemic compression with stretching|
79374663|NCT05402566|Diagnostic Test|Deuterium metabolic imaging|MRI after oral administration of 75g of [6,6'-2H2]glucose.
79374664|NCT05398354|Behavioral|Active retirement|"During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants."
79374665|NCT05397600|Drug|Bimatoprost Ophthalmic|Eyedrops
79374666|NCT05390567|Behavioral|Participant Choice of HPV Self-Test|Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
79374667|NCT05390567|Behavioral|Survey: Participant cancer history and cervical cancer prevention/screening knowledge|Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
79374668|NCT05390567|Behavioral|Participant Choice of Standard of Care in-clinic Pap-test|Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
79374669|NCT05362968|Drug|Freeze-dried strawberry powder|Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
79374670|NCT05359185|Behavioral|Family Wellness|https://familywellness.com/
79374671|NCT05359185|Behavioral|Career Coaching|Individualized career coaching and employment services.
79233244|NCT02433470|Device|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
79233245|NCT05453825|Biological|navicixizumab+paclitaxel|navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
79233246|NCT05453825|Biological|navicixizumab+irinotecan|navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
79233247|NCT05453825|Biological|navicixizumab monotherapy|navicixizumab 3 mg/kg Q2W
79233248|NCT03186794|Other|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
79233249|NCT02437058|Other|preidictive model|
79233250|NCT03189680|Other|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
79528530|NCT01399073|Behavioral|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
79528531|NCT01399073|Other|c-mri|structural and functional (resting state) imaging
79374672|NCT05359185|Behavioral|Financial Planning|Individualized financial planning services.
79827634|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
79233251|NCT05024279|Device|Left bundle branch area pacing|"Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.~In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed."
79233252|NCT05024279|Device|Right ventricular pacing|Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
79233253|NCT02441738|Procedure|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
79528532|NCT01399086|Drug|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
79684870|NCT04207021|Dietary Supplement|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
79827635|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
79827636|NCT00733694|Device|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
79233254|NCT02441738|Procedure|Catheter Ablation|The procedure will be performed following standard of care guidelines.
79233255|NCT02441504|Other|Low intensity Exercise|aerobic exercise training using walking and running
79374673|NCT05352958|Procedure|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
79374674|NCT05352958|Other|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
79374675|NCT05350462|Behavioral|Community pilot L-PZQ distribution - intervention is NOT part of this observational study|Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
79528533|NCT01399112|Behavioral|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
79528534|NCT01399151|Dietary Supplement|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
79528535|NCT01399151|Dietary Supplement|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
79528536|NCT01399151|Dietary Supplement|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
79528537|NCT01399164|Other|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
79528538|NCT01399216|Dietary Supplement|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
79528539|NCT01399216|Dietary Supplement|Placebo|for 8 weeks
79233256|NCT02290353|Device|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer [2]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
79233257|NCT02441816|Drug|Aflibercept|
79233258|NCT02441816|Other|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
79233259|NCT02433392|Procedure|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
79233260|NCT02441582|Other|Telemetry|
79233261|NCT02441582|Other|Non-telemetry|
79374676|NCT05330780|Other|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
79233262|NCT02433782|Other|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
79233263|NCT02433314|Drug|SAGE-547|
79374677|NCT05313516|Device|OKKO Health app|Use of OKKO Health app for home monitoring.
79528540|NCT01399242|Drug|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
79528541|NCT01399255|Biological|Insulin lispro|Dosage form- Subcutaneous Injection
79684871|NCT03457272|Other|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
79233264|NCT02290431|Drug|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
79233265|NCT02290431|Drug|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) & treatment phase 2 (42 days).
79233266|NCT02290431|Drug|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days & treatment phase 2 (42 days)
79233267|NCT03189758|Other|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
79233268|NCT03189758|Other|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
79233269|NCT02433236|Drug|Fostamatinib Disodium tablet 100 mg|
79233270|NCT02433236|Drug|Fostamatinib Disodium tablet 150 mg|
79391015|NCT02426190|Other|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
79827637|NCT00733772|Dietary Supplement|flaxseed|30 grams/day of flaxseed for 12 weeks
79827638|NCT00733772|Behavioral|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
79827639|NCT00728312|Drug|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
79827640|NCT00728312|Drug|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
79391016|NCT02426190|Other|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
79528542|NCT01399307|Procedure|Liposuction|Elective Liposuction
79528543|NCT01399320|Procedure|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
79827641|NCT00728390|Drug|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
79233271|NCT02290587|Other|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~Questionnaire for depression and anxiety~Evaluation of executive functions~Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~morphological MRI~functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
79827642|NCT00734552|Dietary Supplement|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
79233272|NCT02290587|Device|MRI|
79827643|NCT00734552|Dietary Supplement|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
79827644|NCT00728546|Drug|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
79233273|NCT02432924|Behavioral|Instant + Multidimensional Physical Activity Feedback|
79233274|NCT02888535|Other|Internal Medicine consultation|
79233275|NCT02441270|Drug|Cyclophosphamide|
79233276|NCT02441270|Radiation|Stereotactic body radiotherapy|
79233277|NCT03528135|Behavioral|Project PRIDE|See arms section.
79374678|NCT05304052|Behavioral|Mindfulness Meditation classes|The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
79374679|NCT05289076|Drug|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
79374680|NCT05282485|Dietary Supplement|Synbiotic|Synbiotic (2'-FL HMO + B. infantis probiotics)
79374681|NCT05282485|Dietary Supplement|Maltodextrin|Maltodextrin
79528544|NCT01399333|Dietary Supplement|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
79827645|NCT02568722|Other|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization."
79827646|NCT02568722|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
79827647|NCT00738686|Device|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
79827648|NCT04064216|Procedure|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
79827649|NCT00617890|Biological|robatumumab|Robatumumab IV every two weeks until disease progression.
79827650|NCT04066010|Other|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
79827651|NCT00730626|Dietary Supplement|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
79827652|NCT00730626|Dietary Supplement|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
79233278|NCT02441192|Other|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
79233279|NCT02441192|Other|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
79233280|NCT02441192|Other|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
79528545|NCT01399333|Dietary Supplement|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
79233281|NCT02441348|Behavioral|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
79233282|NCT02290665|Other|Thermosensitive gel rectal formulation|
79233283|NCT02290665|Other|Saline enema|
79233284|NCT02436980|Drug|Tramadol|GROUP T
79233285|NCT02436980|Drug|Midazolam|GROUP M
79233286|NCT02436902|Procedure|TACE|TACE is performed one month after resection.
79233287|NCT02436902|Drug|Sorafenib|Sorafenib is submitted one month after resection.
79233288|NCT02436902|Drug|TACE plus sorafenib|TACE plus sorafenib will be submitted one month after resection.
79233289|NCT02436902|Other|empty control|This group will not receive adjuvant therapy.
79684872|NCT05467683|Behavioral|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
80001282|NCT03025412|Procedure|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
79684873|NCT01255423|Drug|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
79374682|NCT05280275|Drug|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
79684874|NCT01255423|Drug|Placebo|Placebo, 4 times daily
79684875|NCT01255306|Other|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~On 7th postoperative day~On 30th postoperative day~On 90th postoperative day~On 180th postoperative day"
79528546|NCT01399333|Dietary Supplement|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
79528547|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
79528548|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
79528549|NCT01399359|Behavioral|Counseling session|
79528550|NCT01399359|Other|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
79528551|NCT01399359|Other|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
79528552|NCT01399359|Other|online questionnaire|
79684876|NCT01255306|Drug|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
79684877|NCT04006964|Device|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
79684878|NCT01254721|Drug|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
79684879|NCT01254721|Drug|lithium|300mg tablet, oral
79827653|NCT00730626|Dietary Supplement|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
79827654|NCT00870766|Procedure|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
79827655|NCT00728780|Drug|ABT-143|once
79374683|NCT05280275|Drug|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
79374684|NCT05280275|Drug|Lenalidomide|Lenalidomide will be administered per os.
79374685|NCT05280275|Drug|Dexamethasone|Dexamethasone will be administered intravenously or per os.
79374686|NCT05278065|Other|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
79374687|NCT05244226|Drug|Fentanyl/Hydromorphone|Per routine care
79374688|NCT05244226|Drug|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
79528553|NCT01399398|Procedure|Brain Scan-PET|
79528554|NCT01399398|Procedure|Brain Scan-MRI|
79528555|NCT01399398|Procedure|Arterial Line|
79528556|NCT01399398|Procedure|Venous Line|
79827656|NCT00728780|Drug|ABT-335 and rosuvastatin|once
79827657|NCT00870844|Drug|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
79827658|NCT00870844|Drug|Placebo|Vials with solution for IV infusion
79528557|NCT01399398|Procedure|Blood Sampling|
79827659|NCT00734708|Drug|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
79827660|NCT00734708|Drug|Placebo|Control
79528558|NCT01399424|Drug|CP|Immunization
79528559|NCT01399450|Drug|paliperidone|paliperidone augmenting on ongoing medication
79528560|NCT01399463|Device|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
79528561|NCT01399463|Device|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
79827661|NCT04066296|Drug|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
79827662|NCT02341014|Drug|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient regardless of dose level must be 20mg/m2 . All subsequent doses of carfilzomib will be based on the patient's dose level.
79827663|NCT02341014|Drug|Romidepsin|
80001283|NCT03025412|Behavioral|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
80001284|NCT03013933|Drug|Brentuximab Vedotin|Given IV
80001285|NCT03013933|Drug|Cyclosporine|Given PO
80001286|NCT03013933|Other|Pharmacokinetic Study|Correlative studies
79233290|NCT04009863|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
79528562|NCT01399476|Procedure|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
79827664|NCT02341014|Drug|Lenalidomide|
79827665|NCT00738764|Biological|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
79827666|NCT00730782|Biological|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
79827667|NCT00868426|Drug|Budesonide/Formoterol Batch 1|Single, inhaled dose
79827668|NCT00868426|Drug|Budesonide/Formoterol Batch 2|Single, inhaled dose
80001287|NCT03013933|Drug|Verapamil|Given PO
80001288|NCT03013933|Drug|Verapamil Hydrochloride|Given PO
80001289|NCT02996825|Drug|Gemcitabine|Given IV
80001290|NCT02996825|Drug|Gemcitabine Hydrochloride|Given IV
79827669|NCT00868426|Drug|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
79827670|NCT03872856|Device|BP-ICAN|"One of two home blood pressure monitor devices will be used.~Omron 7 Series Wrist cuff~Omron 10 Series Upper Arm cuff"
79374691|NCT05237869|Device|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
79528563|NCT01399476|Procedure|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
79827671|NCT00870922|Procedure|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
79827672|NCT00868504|Other|no intervention|no intervention
79827673|NCT03853746|Drug|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
79827674|NCT00868582|Other|PET scanning in cancer|Collection of institutional practice PET imaging data
79827675|NCT03037242|Procedure|Transtibial pullout technique|Evaluating radographs
79827676|NCT00868660|Drug|ZP1848|sc. bolus
79827677|NCT00712166|Drug|AZLI 75 mg three times daily (TID)|
79827678|NCT00712166|Drug|Placebo three times daily (TID)|
79827679|NCT00868738|Dietary Supplement|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
79827680|NCT00652743|Biological|Pandemic influenza vaccine GSK1562902A|IM administration
80001291|NCT02996825|Other|Laboratory Biomarker Analysis|Correlative studies
80001292|NCT02996825|Biological|Mirvetuximab Soravtansine|Given IV
79233291|NCT04009863|Radiation|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
79233292|NCT02436590|Device|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
79233293|NCT02290743|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
79827681|NCT00730860|Procedure|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
79827682|NCT00730860|Procedure|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
79827683|NCT00868816|Drug|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
79827684|NCT00868816|Drug|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
79827685|NCT02569866|Drug|Cephalexin|Capsules containing cephalexin/500mg
79827686|NCT02569866|Drug|Placebo|Capsules containing placebo/500mg
79827687|NCT00868894|Drug|DE-104 medium concentration|Topical ocular application
79827688|NCT00868894|Drug|DE-104 high concentration|Topical ocular application
79827689|NCT00868894|Drug|Placebo|Topical ocular application
80001293|NCT02996825|Other|Pharmacological Study|Correlative studies
80001294|NCT02994160|Other|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
80001295|NCT02993146|Other|Laboratory Biomarker Analysis|Correlative studies
80001296|NCT02993146|Other|Pharmacological Study|Correlative studies
80001297|NCT02993146|Other|Quality-of-Life Assessment|Ancillary studies
80001298|NCT02993146|Drug|Ropidoxuridine|Given PO
80001299|NCT02993146|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
80001300|NCT02976337|Drug|Naloxone|active drug infusion
80001301|NCT02976337|Drug|Normal Saline|placebo comparator
80001302|NCT02967744|Drug|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
80001303|NCT02964078|Drug|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
80001304|NCT02964078|Drug|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
80001305|NCT02946697|Behavioral|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
79233294|NCT02436512|Drug|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~(Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~(Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
79233295|NCT02432768|Drug|Triheptanoin|Anaplerotic dietary oil
79233296|NCT02432768|Other|Placebo oil|Safflower oil
79233297|NCT03186716|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
80001306|NCT02945800|Drug|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m^2 intravenously (IV)
80001307|NCT02945800|Drug|Gemcitabine|Gemcitabine: 1000 mg/m^2 intravenously (IV)
79233298|NCT03186716|Dietary Supplement|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
79233299|NCT02436434|Device|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
79827690|NCT00868894|Drug|0.005% latanoprost|Topical ocular application
80001308|NCT02923726|Device|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
79233300|NCT04466241|Drug|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
79233301|NCT04466241|Drug|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
79233302|NCT04466241|Drug|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
79233303|NCT02440880|Drug|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
79233304|NCT02440880|Drug|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
79233305|NCT02440880|Drug|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
80001309|NCT02923726|Device|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
80001310|NCT02905643|Other|Study subjects|This study does not include an intervention it is only observational.
80001311|NCT02892591|Drug|Cannabis|vaporized plant material
80001312|NCT02892591|Drug|Oxycodone|oral capsule
79374692|NCT05237869|Other|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
79684880|NCT04519671|Drug|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
80001313|NCT02892591|Drug|Placebo for Cannabis|vaporized placebo plant material
79233306|NCT02440880|Drug|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
79233307|NCT02440880|Other|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
79374693|NCT05224986|Behavioral|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
79374694|NCT05213273|Behavioral|nutritional guidelines to promote healthy diet and increase fish intake|"Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish."
79374695|NCT05194124|Drug|Setmelanotide 20mg weekly|1:1 randomization in the double blind period, followed by open label
79827691|NCT00730938|Drug|cefuroxime|intracameral cefuroxime 0.1 ml
79827692|NCT00730938|Drug|Saline placebo|0.1 ml of Ringers lactate
79827693|NCT00712010|Other|Whey protein native|Whey protein native against the 6 other arms
79827694|NCT00712010|Other|Whey protein microgels|Whey protein microgels versus the six other arms
79827695|NCT00712010|Other|Hydrolyzed whey protein|versus the six other arms
80001314|NCT02892591|Drug|Placebo for Oxycodone|oral placebo capsule
80001315|NCT02872831|Device|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
80001316|NCT02872831|Device|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
79233308|NCT04466319|Other|Rocking Chair|Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
79233309|NCT03192098|Device|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
79233310|NCT02290977|Radiation|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
79233311|NCT03186482|Drug|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
79827696|NCT00712010|Other|Casein native|versus the six other arms
79827697|NCT00712010|Other|Hydrolyzed casein|versus the six other arms
80001317|NCT02865928|Drug|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
80001318|NCT02865928|Drug|Normal Saline|Same injection technique as intervention arm with normal saline
79233312|NCT03186482|Drug|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
79233313|NCT03186482|Drug|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
79233314|NCT03522363|Other|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
79233315|NCT03186092|Other|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
79233316|NCT03186092|Other|sham muscle training|sham comparator
79374696|NCT05194124|Drug|Placebo daily|1:1 randomization in the double blind period
79684881|NCT04519671|Other|Placebo|Normal saline
79684882|NCT04207099|Device|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
79374697|NCT05194124|Drug|Setmelanotide 30mg weekly|1:1 randomization in the double blind period, followed by open label
79684883|NCT05575258|Other|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
79684884|NCT05575258|Other|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
79827698|NCT00712010|Other|Total milk protein native|versus the six other arms
79827699|NCT00712010|Other|Hydrolyzed milk protein|versus the six other arms
80001319|NCT02859675|Other|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
80001320|NCT02859675|Biological|blood sampling|sampling of 2 mL
80001321|NCT02859675|Other|Questionnaires|Stunkard, PrefQuest
79374698|NCT05194124|Drug|Setmelanotide 2mg daily|1:1 randomization in the double blind period
79374699|NCT05194124|Drug|Setmelanotide 3mg daily|1:1 randomization in the double blind period
79684885|NCT04862533|Drug|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
79684886|NCT04862533|Drug|Placebo|Participants will receive matching placebo three times a day
79684887|NCT04862533|Procedure|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
79684888|NCT05570656|Device|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
79827700|NCT00731016|Drug|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~injection 1, S1: 0.0125 mg/kg of zoledronic acid~injection 2, S6: 0.025 mg/kg of zoledronic acid~injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
79827701|NCT00868972|Procedure|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
80001322|NCT02859506|Other|Respiratory quotient|
80001323|NCT02859506|Other|Olfactory liking|
79374700|NCT05194124|Drug|Placebo weekly|1:1 randomization in the double blind period
79827702|NCT00868972|Device|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
80001324|NCT02803905|Biological|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
79528564|NCT01399489|Behavioral|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
79684889|NCT04853095|Procedure|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
79827703|NCT00799539|Drug|bortezomib|From cycles 1-4, 1.3mg/m^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
79827704|NCT00799539|Drug|bortezomib|From cycles 5-9, 1.3mg/m^2 on days 1, 8, 22, and 29 of each 6-week cycle
79827705|NCT00799539|Drug|melphalan|9 mg/m^2 once daily on days 1-4 of each 6-week cycle
79827706|NCT00799539|Drug|prednisone|60 mg/m^2 once daily on days 1-4 of each 6-week cycle
79827707|NCT00731172|Drug|glatiramer acetate|20 mg daily subcutaneous injection through week 12
79827708|NCT00731172|Drug|placebo|subcutaneous daiky injection through week 12
80001325|NCT02793375|Drug|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
79233317|NCT03522285|Other|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
79374701|NCT05175469|Diagnostic Test|Flow cytometric analysis of neutrophil myeloperoxidase expression|"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."
79374702|NCT05157464|Drug|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
79827709|NCT00799695|Behavioral|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
79827710|NCT00869284|Drug|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
79528565|NCT01399502|Behavioral|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
79684890|NCT04853095|Procedure|Standard of care|ePLND without peritoneal flap fixation
80001326|NCT02793375|Drug|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
80001327|NCT02770326|Biological|Fecal Microbiota Transplantation (FMT)|
80001328|NCT02734290|Drug|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
80001329|NCT02734290|Drug|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
80001330|NCT02734290|Drug|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
79233318|NCT02436278|Other|4MGS|Usual walking speed measured over 4 metres
79233319|NCT03522207|Diagnostic Test|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
79528566|NCT01399515|Drug|Valproic Acid|One 500mg tablet by mouth daily
79528567|NCT01399554|Behavioral|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
79684891|NCT04785469|Other|Low-load eccentric training|"Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
80001331|NCT02721888|Drug|Liraglutide|
80001332|NCT02721888|Drug|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
80001333|NCT02721888|Biological|Blood sample|
80001334|NCT02721888|Other|Kinetic substudy (10 patients)|
80001335|NCT02656654|Other|Whole-body compression|
80001336|NCT02653287|Behavioral|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
80001337|NCT02653287|Other|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
79827711|NCT00869284|Procedure|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
80001338|NCT02652260|Drug|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
79233320|NCT03522207|Drug|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
79233321|NCT03522207|Drug|Placebos|placebo per os 30 minutes prior to 2nd PSG
79233322|NCT03522207|Diagnostic Test|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
79233323|NCT03522207|Drug|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
79233324|NCT03522207|Drug|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
79233325|NCT03522207|Diagnostic Test|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
79528568|NCT01399567|Behavioral|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
79233326|NCT03186248|Procedure|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
79528569|NCT01399606|Drug|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
79528570|NCT01399632|Behavioral|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
80001339|NCT02652260|Drug|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
79528571|NCT01399632|Behavioral|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
80001340|NCT02652260|Drug|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
79233327|NCT03528057|Device|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
79233328|NCT03527979|Procedure|IVF/ICSI|IVF/ICSI
79233329|NCT03627377|Behavioral|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
79233330|NCT02707952|Drug|ABT-493/ABT-530|Co-formulated tablet
79233331|NCT02707952|Drug|OBV/PTV/r|Co-formulated tablet
79374703|NCT05155605|Device|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
79374704|NCT05154318|Procedure|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
79374705|NCT05154318|Procedure|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
79374706|NCT05153863|Device|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
79528572|NCT01399645|Drug|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
79827712|NCT00738842|Drug|AZD6140|Oral tablets taken bid for 5 days
79827713|NCT00738842|Drug|Placebo to match AZD6140|Oral tablets taken bid for 5 days
79374707|NCT05133245|Other|Diagnostic study only|Diagnostic study only
79374708|NCT05130229|Behavioral|Sleep Well Bee Well|Sleep program to help toddlers sleep better
80001341|NCT02652260|Drug|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
80001342|NCT02652260|Drug|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
80001343|NCT02569879|Other|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
80001344|NCT02539992|Device|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
80001345|NCT02539992|Device|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
80001346|NCT02539992|Device|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
79233332|NCT05706155|Behavioral|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
79233333|NCT05706155|Behavioral|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
79233334|NCT05552573|Biological|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
79233335|NCT05552573|Biological|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
79233336|NCT05552573|Biological|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
79233337|NCT03189056|Diagnostic Test|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
79233338|NCT03189056|Biological|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
79528573|NCT01399671|Other|vestibular stimulation|vestibular stimulation
79528574|NCT01399710|Procedure|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
79827714|NCT00809913|Drug|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
80001347|NCT02535741|Device|Triathlon CR Total Knee System|Primary total knee replacement
80001348|NCT02525627|Device|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
79374709|NCT05126862|Behavioral|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
79374710|NCT05117632|Drug|ALTO-100 PO tablet|one tablet twice daily
79374711|NCT05116241|Biological|BPZE1 pertussis vaccine and placebo|Live attenuated pertussis vaccine and placebo
79827715|NCT00729222|Drug|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
79827716|NCT00729222|Drug|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
80001349|NCT02525627|Device|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
80001350|NCT02525627|Device|Symax stem|Orthopaedic implant
79374712|NCT05116241|Biological|BPZE1 pertussis vaccine and Boostrix|Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine
79374713|NCT05116241|Biological|Placebo and Boostrix|Tetanus, diphtheria, and aP vaccine and placebo
80001351|NCT02525627|Device|Accolade TMZF stem|Orthopaedic implant
80001352|NCT02525588|Device|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
80001353|NCT02525562|Device|Triathlon Total Knee System with X3 insert|Total knee replacement
80001354|NCT02525562|Device|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
80001355|NCT02525562|Device|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
80001356|NCT02525562|Procedure|Total Knee Replacement|Total Knee Replacement
80001357|NCT02525562|Procedure|Partial Knee Resurfacing|Partial Knee Resurfacing
80001358|NCT02524730|Device|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
80001359|NCT02522728|Device|Triathlon CR|Implantation of Knee Prosthesis
80001360|NCT02522728|Device|Triathlon PS|Implantation of Knee Prosthesis
80001361|NCT02520531|Device|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
80001362|NCT02520531|Device|Scorpio NRG PS|Implantation of total knee prosthesis
80001363|NCT02505893|Biological|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
80001364|NCT02505893|Drug|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
80001365|NCT02505893|Drug|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
80001366|NCT02505893|Drug|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
80001367|NCT02505126|Device|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
80001368|NCT02505126|Device|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
80001369|NCT02446236|Drug|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
79233339|NCT03189056|Procedure|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
79233340|NCT03189368|Device|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used)~Nearly simultaneous (Δt=5msec) second left ventricular pulse and~Threshold of ≤3.5V@0.5msec"
79528575|NCT01399710|Procedure|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
79528576|NCT01399710|Device|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
80001370|NCT02446236|Drug|Ibrutinib|560 mg PO daily
79528577|NCT01399749|Other|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
79528578|NCT01399762|Device|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
79528579|NCT01399775|Procedure|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
79528580|NCT01399775|Procedure|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
80001371|NCT02446236|Drug|Rituximab|375 mg/m2 IV Day 1
79528581|NCT01399814|Behavioral|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000~1500ml crystalloid was administered on the days following operation
79528582|NCT01399814|Behavioral|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000~2500ml crystalloid was administered on the days following operation
79528583|NCT01399840|Drug|BMN 673|Oral capsule with multiple dosage forms given once daily
80001372|NCT02441803|Drug|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
80001373|NCT02441803|Drug|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
80001374|NCT02441803|Drug|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
80001375|NCT02441803|Radiation|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
80001376|NCT02441803|Drug|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
79233341|NCT02291211|Drug|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
79233342|NCT03189290|Procedure|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
79528584|NCT01399853|Biological|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
79528585|NCT01399853|Biological|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
80001377|NCT02441803|Biological|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
80001378|NCT02441803|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
80001379|NCT02441803|Drug|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
80001380|NCT02441803|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
80001381|NCT02441803|Drug|Decitabine|20 mg/m2 by vein on Days 1 - 5.
80001382|NCT02441803|Drug|Cytarabine|1 g/m2 by vein on Days 6 - 10.
80001383|NCT02441803|Drug|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
80001384|NCT02421939|Drug|gilteritinib|tablet, oral
80001385|NCT02421939|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
80001386|NCT02421939|Drug|Azacitidine|SC or IV injection
80001387|NCT02421939|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
80001388|NCT02421939|Drug|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
80001389|NCT02337829|Drug|Acalabrutinib (Arm A)|"A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
79684892|NCT04785469|Other|Usual care|"Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + [0.002x6-Minute walk work (6MWW)]. [Sex: female = 0; male:1] [6MWW = 6-Minute walk distance x weight in kg].~Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
80001390|NCT02337829|Drug|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
79233343|NCT03627143|Other|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~Selection of one or more local physician champions from both the ED as well as the cardiology group;~Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~Development of local action plan addressing local barriers to implementation;~Provision of the free Smartphone App to be developed for the guidelines;~Regular reminders provided by the local research staff;~Audit and feedback charts of site compliance"
79827717|NCT03896386|Other|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
79233344|NCT05392101|Drug|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
80001391|NCT02310321|Drug|gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
80001392|NCT02310321|Drug|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m^2 idarubicin on 3 consecutive days.
79684893|NCT03989102|Biological|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
79374714|NCT05113641|Dietary Supplement|Alkalizing Fruit and Vegetables|The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values < 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
80001393|NCT02310321|Drug|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m^2 cytarabine on Days 1, 3, and 5."
79374715|NCT05113641|Drug|Sodium bicarbonate|Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the Seven Oaks Hospital pharmacy.
79528586|NCT01399853|Biological|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
79528587|NCT01399853|Biological|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
79374716|NCT05098444|Behavioral|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
79528588|NCT01399853|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
79528589|NCT01399879|Other|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
79528590|NCT01399892|Dietary Supplement|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
79528591|NCT01399970|Other|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
79684894|NCT03989102|Other|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
79684895|NCT01254643|Biological|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
79684896|NCT04491825|Diagnostic Test|Skin suction blistering and skin biopsies|Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
79827718|NCT00734786|Other|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
79827719|NCT00808743|Drug|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
79827720|NCT00808743|Drug|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
79827721|NCT00808743|Drug|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
80001394|NCT02120352|Drug|GSK744|White to almost white oval shaped film coated 30 mg tablets for oral administration.
80001395|NCT02120352|Drug|GSK744 LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
80001396|NCT02120352|Drug|TMC278 LA|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
79684897|NCT01254604|Drug|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
80001397|NCT02120352|Drug|ABC/3TC|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
80001398|NCT02120352|Drug|RPV|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
80001399|NCT02091141|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
80001400|NCT02091141|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
79233345|NCT04951739|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
79233346|NCT03191708|Diagnostic Test|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
79374717|NCT05098444|Other|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
79374718|NCT05090865|Dietary Supplement|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
79374719|NCT05090865|Dietary Supplement|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake < 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
79374720|NCT05079620|Drug|Ceftriaxone|If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
79374721|NCT05079620|Drug|Amoxicillin clavulanic acid|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
79684898|NCT01254604|Drug|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
79684899|NCT03980093|Behavioral|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
79827722|NCT00869596|Drug|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
79827723|NCT00869596|Drug|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
80001401|NCT02091141|Drug|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
80001402|NCT02091141|Drug|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
80001403|NCT02091141|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
80001404|NCT02091141|Drug|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
80001405|NCT02091141|Drug|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
80001406|NCT02091141|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
79233347|NCT02291367|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
79233348|NCT02291367|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
79374722|NCT05079620|Drug|Cefepime|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
79684900|NCT03980093|Behavioral|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
79827724|NCT00869596|Drug|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
79827725|NCT00869596|Drug|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
79827726|NCT03743376|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
79827727|NCT03743376|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
79827728|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
79827729|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
79827730|NCT00869674|Procedure|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
79827731|NCT03728478|Drug|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
79827732|NCT03728478|Drug|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
79827733|NCT03728478|Drug|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
79827734|NCT00738998|Behavioral|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
79827735|NCT00738998|Other|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
79827736|NCT00653523|Drug|Ezetimibe|Ezetimibe 10 mg once daily
79827737|NCT00653523|Drug|Simvastatin|Simvastatin 20 mg daily
79827738|NCT00739076|Behavioral|Virtual Reality|Using Virtual Reality for pain control
79827739|NCT00869830|Other|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
79827740|NCT00799851|Device|Variceal band ligation|
79233349|NCT03191474|Behavioral|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
79827741|NCT00799851|Drug|cyanoacrylate injection|cyanoacrylate injection
79827742|NCT02544412|Behavioral|novel mindfulness-based well-being training|
79827743|NCT02717442|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
79827744|NCT02717442|Drug|Placebo|Single intratympanic injection of placebo
79374723|NCT05079620|Drug|Vancomycin|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
79374724|NCT05079620|Drug|Levofloxacin|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
79374725|NCT05079321|Device|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
79374726|NCT05079321|Device|Uncoated|Zen™ RC scleral lenses (non-coated)
79827745|NCT00799929|Other|in vitro fertilization (IVF/ICSI)|
79827746|NCT00734942|Other|support service|"professional partners for communication~befriending with other families concerned~information and education (about illness, symptoms, first aid, caring)~free-time activities and time out~homework assistance~administrative advise~support for everyday life"
80001407|NCT02083692|Drug|Metformin|
80001408|NCT02040857|Drug|Palbociclib|CDK 4/6 inhibitor
79827747|NCT00862732|Behavioral|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
80001409|NCT02040857|Drug|Aromatase Inhibitor|Endocrine Therapy
80001410|NCT01992146|Drug|Target-controlled naloxone-infusion|
79827748|NCT00862732|Other|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
79827749|NCT00808977|Drug|Dersalazine sodium|Dersalazine sodium 2400 mg daily
79827750|NCT00808977|Drug|Mesalazine|Mesalazine 2400 mg daily
79827751|NCT00808977|Drug|Placebo|Placebo matching active and experimental treatments
79827752|NCT04065854|Behavioral|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
79827753|NCT02544334|Procedure|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
79827754|NCT02544334|Other|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
79827755|NCT02544334|Other|Saliva Collection|All participants will have a saliva collection.
79827756|NCT00800007|Drug|ANZ-521|3x10^7 cfu or 3x10^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
80001411|NCT01992146|Drug|Placebo|
80001412|NCT01961063|Drug|busulfan|Given IV
80001413|NCT01961063|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
80001414|NCT01961063|Other|pharmacological study|Correlative studies
80001415|NCT01961063|Other|laboratory biomarker analysis|Correlative studies
79827757|NCT00800007|Drug|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
79827758|NCT00739232|Drug|HSD-016|
80001416|NCT01909245|Biological|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
80001417|NCT01909245|Drug|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
79528592|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
79528593|NCT01400009|Drug|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
79827759|NCT00739232|Other|placebo|
79374727|NCT05068869|Other|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
79374728|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
79827760|NCT02569008|Drug|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
79827761|NCT00735020|Biological|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
79528594|NCT01400009|Drug|Placebo|Standard Placebo made of Lactose 100 mg
79528595|NCT01400022|Other|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
79528596|NCT01400022|Other|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
79528597|NCT01400048|Dietary Supplement|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
79827762|NCT00735020|Biological|Influenza Vaccine|1 dose of Influenza Vaccine
79528598|NCT01400048|Dietary Supplement|Placebo control|60mg Ascorbic acid
79528599|NCT01400074|Drug|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
79684901|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
79827763|NCT03869151|Diagnostic Test|CBC|lymphocyte and monocyte count
79528600|NCT01400087|Device|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
80001418|NCT01909245|Drug|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
80001419|NCT01842386|Drug|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
79528601|NCT01400100|Drug|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
80001420|NCT01813695|Procedure|Preemptive genotyping in medical record|
80001421|NCT01813695|Procedure|Genotyping not included in electronic medical record|
79684902|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
79827764|NCT04065906|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
79827765|NCT04065906|Drug|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
79827766|NCT02544256|Procedure|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
79827767|NCT00739388|Drug|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
80001422|NCT01673334|Device|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
79528602|NCT01400100|Drug|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
79528603|NCT01400152|Device|Additional active warming|Chemical heat pad applied to the upper torso
79528604|NCT01400165|Drug|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
79528605|NCT01400165|Drug|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
79827768|NCT00809211|Drug|nilotinib|
79827769|NCT00809211|Genetic|cytogenetic analysis|
79827770|NCT00809211|Genetic|mutation analysis|
79827771|NCT00809211|Genetic|polymerase chain reaction|
79827772|NCT00809211|Other|pharmacological study|
79827773|NCT00862888|Drug|PF-00446687|Single 200mg dose as an oral solution
79827774|NCT00862888|Drug|Placebo|Placebo for oral solution
79827775|NCT00862888|Drug|Placebo|Placebo for tablet
79827776|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
79827777|NCT00862888|Drug|PF-00446687|Single 125 mg dose as an oral solution
80001423|NCT01629498|Radiation|Image Guided Radiation Therapy|Undergo image-guided IMRT
80001424|NCT01629498|Radiation|Image Guided Radiation Therapy|Undergo image-guided IMPT
80001425|NCT01629498|Radiation|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
80001426|NCT01629498|Radiation|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
80001427|NCT01629498|Other|Laboratory Biomarker Analysis|Optional correlative studies
79827778|NCT00862888|Drug|PF-00446687|Single 175 mg dose as an oral solution
80001428|NCT01629498|Radiation|Photon Beam Radiation Therapy|Undergo image-guided IMRT
79374729|NCT05049850|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
79827779|NCT00862888|Drug|PF-00446687|Single 20 mg dose as an oral solution
79528606|NCT01400165|Drug|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
79528607|NCT01400165|Procedure|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
79827780|NCT00862888|Drug|Placebo|Placebo for oral solution
80001429|NCT01629498|Radiation|Proton Beam Radiation Therapy|Undergo image-guided IMPT
79827781|NCT00862888|Drug|Placebo|Placebo for tablet
80001430|NCT01629498|Other|Questionnaire Administration|Ancillary studies
80001431|NCT01610258|Other|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
80001432|NCT01485601|Biological|MT10109|Single dose intramuscular injection MT10109 vs Botox®
79233354|NCT02440958|Drug|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
79233355|NCT05587283|Drug|Experimental: Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule, 0.2 x 10^9 CFU/capsule with excipients.
79233356|NCT05587283|Drug|Experimental: Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule, 1 x 10^9 CFU/capsule with excipients.
79528608|NCT01400191|Drug|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
79233357|NCT05587283|Drug|Experimental: High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule, 5 x 10^9 CFU/capsule with excipients.
79233358|NCT05587283|Other|Placebo Comparator: Low dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
79233359|NCT05587283|Other|Placebo Comparator: Medium dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
79233360|NCT05587283|Other|Placebo Comparator: High dose Placebo capsule|High dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
79374730|NCT05037461|Radiation|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
79391017|NCT02426190|Other|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
79528609|NCT01400217|Drug|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
79528610|NCT01400217|Drug|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
79827782|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
79827783|NCT00729456|Other|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
79827784|NCT00800085|Drug|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
79827785|NCT00731250|Drug|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
79827786|NCT00731250|Drug|Placebo|Subjects will be administered SB-705498 matching placebo tablets
79827787|NCT00731250|Other|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
79827788|NCT04041076|Procedure|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
79827789|NCT00735098|Other|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
79827790|NCT00735098|Other|strength training exercise|strength training exercise, 3 times per week for 8 weeks
79827791|NCT00735098|Other|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
79827792|NCT00735098|Other|Control group|8 week control group
80001433|NCT01236287|Drug|Voclosporin|Subjects will receive voclosporin capsules, twice daily
80001434|NCT01202500|Procedure|reducing treatment to 3 months|The treatment will be stopped after 3 months
80001435|NCT01202500|Procedure|registered length of treatment|The treatment procedure will follow the actual recommandation
80001436|NCT01093612|Procedure|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
80001437|NCT01093612|Radiation|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
80001438|NCT01093612|Procedure|Biopsy|Correlative Studies
80001439|NCT01093612|Other|Immunohistochemistry staining method|Correlative studies
80001440|NCT01093612|Other|laboratory biomarker analysis|Correlative studies
80001441|NCT01093612|Genetic|mutation analysis|Correlative studies
80001442|NCT01051635|Drug|LMP400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
80001443|NCT01051635|Drug|LMP776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
80001444|NCT00676715|Drug|Placebo|Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
80001445|NCT00676715|Drug|Ocrelizumab|Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
80001446|NCT00676715|Drug|Avonex|Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
80001447|NCT00641381|Drug|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
79528611|NCT01400230|Procedure|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
80001448|NCT00641381|Drug|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
80001449|NCT00641381|Drug|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
80001450|NCT00641381|Other|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
80001451|NCT00641381|Procedure|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
79233361|NCT03186170|Other|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
79528612|NCT01400256|Drug|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
79528613|NCT01400282|Device|High frequency spinal cord stimulation|
79528614|NCT01400308|Drug|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
79528615|NCT01400308|Device|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
79528616|NCT01400334|Radiation|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine [HED, 20 mCi (740 MBq)] to quantify sympathetic nerve function, b) 13N-ammonia [NH3, 20 mCi (740 MBq)] for regional perfusion, and c) 18F-2-deoxyglucose [FDG; 6.5 mCi (241 MBq)] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
79528617|NCT01400360|Other|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
79528618|NCT01400373|Device|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
79233362|NCT02291757|Dietary Supplement|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
79233363|NCT02291757|Dietary Supplement|Placebo|Placebo, 500 mg, once daily, p.o.
79233364|NCT02440802|Genetic|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
79528619|NCT01400386|Other|Coffee bioavailability trial|Coffee bioavailability trial
79528620|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
80001452|NCT00641381|Procedure|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
80001453|NCT00639301|Behavioral|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
79233365|NCT05581277|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.
79528621|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
79827793|NCT00800163|Other|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
80001454|NCT00516373|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
80001455|NCT00436982|Device|Cemented Triathlon total knee system|Orthopaedic implant
80001456|NCT00436982|Device|Duracon total knee system|Orthopaedic implant
80001457|NCT00379041|Biological|bleomycin sulfate|
80001458|NCT00379041|Drug|doxorubicin hydrochloride|
80001459|NCT00379041|Drug|mechlorethamine hydrochloride|
80001460|NCT00379041|Drug|prednisone|
80001461|NCT00379041|Drug|procarbazine hydrochloride|
80001462|NCT00379041|Drug|vinblastine sulfate|
79528622|NCT01400464|Drug|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
80001463|NCT00379041|Drug|vincristine sulfate|
80001464|NCT00379041|Radiation|radiation therapy|
79233366|NCT02440724|Device|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
79528623|NCT01400490|Dietary Supplement|EPA-DHA Study|6 weeks of dietary supplementation
79233367|NCT02440724|Device|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
79233368|NCT03117608|Biological|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
79233369|NCT03117608|Biological|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
79528624|NCT01400542|Device|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
79528625|NCT01400542|Device|No treatment|no treatment
79233370|NCT02432534|Drug|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
79233371|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
79233372|NCT04919447|Procedure|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
79233373|NCT02432612|Drug|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
79233374|NCT02432222|Behavioral|Visual Arts Training|Visual arts training
79233375|NCT02432222|Behavioral|Music Training|Music training
79233376|NCT05705843|Drug|Intraosseous Vancomycin Injection|• IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).
79233377|NCT05705843|Drug|Intravenous Vancomycin|IV Vancomycin will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS).
79528626|NCT01400555|Drug|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
79528627|NCT01400555|Drug|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
79528628|NCT01400555|Drug|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
79233378|NCT02436044|Procedure|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
79528629|NCT01400555|Drug|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
79528630|NCT01400568|Drug|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
79827794|NCT00731328|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
80001465|NCT00378105|Drug|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
80001466|NCT00378105|Drug|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
80001467|NCT00378105|Drug|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
80001468|NCT00005584|Biological|bleomycin sulfate|
80001469|NCT00005584|Drug|ABVD regimen|
79233379|NCT02436044|Drug|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
79233380|NCT02436044|Drug|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
80001470|NCT00005584|Drug|BEACOPP regimen|
80001471|NCT00005584|Drug|epirubicin hydrochloride|
80001472|NCT00005584|Drug|prednisone|
80001473|NCT00005584|Drug|vinblastine sulfate|
80001474|NCT00005584|Radiation|radiation therapy|
80001475|NCT00002462|Biological|bleomycin sulfate|
80001476|NCT00002462|Drug|doxorubicin hydrochloride|
80001477|NCT00002462|Drug|mechlorethamine hydrochloride|
80001478|NCT00002462|Drug|prednisone|
80001479|NCT00002462|Drug|procarbazine hydrochloride|
80001480|NCT00002462|Drug|vinblastine sulfate|
80001481|NCT00002462|Drug|vincristine sulfate|
80001482|NCT00002462|Radiation|low-LET cobalt-60 gamma ray therapy|
80001483|NCT00002462|Radiation|low-LET photon therapy|
80001484|NCT00002462|Radiation|radiation therapy|
80001485|NCT00000538|Behavioral|diet, fat-restricted|
80001486|NCT02806232|Drug|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
79528631|NCT01400568|Drug|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
79233381|NCT02436044|Drug|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
79528632|NCT01400581|Behavioral|Collaborative Care Intervention|See description of Intervention arm
79233382|NCT02435732|Drug|Placebo saline solution|saline solution
79528633|NCT01400607|Biological|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
80001487|NCT02806232|Drug|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
79528634|NCT01400607|Other|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
80001488|NCT02806232|Drug|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
80001489|NCT02908087|Drug|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
80001490|NCT02908087|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
79233383|NCT02435732|Drug|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
79233384|NCT02435732|Drug|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
79827795|NCT00729170|Dietary Supplement|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
79233385|NCT02435654|Drug|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
79233386|NCT02435498|Other|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
79233387|NCT02435498|Other|Video|The online video will contain the same information within the website.
79233388|NCT02435498|Other|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
79233389|NCT02440490|Behavioral|Computerised cognitive training|
79233390|NCT02440490|Behavioral|Video watching|
79233391|NCT03186014|Device|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
79233392|NCT02440412|Other|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
79233393|NCT02440412|Other|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
79233394|NCT05293535|Other|Prognostic study|No intervention... as it is a prognostic study and no intervention done on patients.
79233395|NCT02435420|Device|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
79233396|NCT02435342|Drug|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
79233397|NCT02435342|Drug|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
79827796|NCT00871078|Device|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
80001491|NCT01357837|Drug|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
79233398|NCT05571527|Biological|Platelet Rich Plasma treatment|Patients receive platelet-rich plasma via injection into the vaginal area.
79528635|NCT01400620|Drug|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
79528636|NCT01400633|Drug|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
79528637|NCT01400646|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
79528638|NCT01400646|Drug|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
79528639|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
79528640|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
79528641|NCT01400646|Drug|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
80001492|NCT01357837|Drug|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
80001493|NCT01357837|Drug|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
80001494|NCT01357837|Drug|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
80001495|NCT02053532|Procedure|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
80001496|NCT02053688|Device|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
80001497|NCT02053688|Device|Toric Soft Contact Lenses|astigmatism correction using toric optics
80001498|NCT01349725|Drug|ARRY-502|Oral; multiple dose, escalating
80001499|NCT01349725|Drug|Placebo|Oral; matching placebo
80001500|NCT02037854|Other|Nutrient formulation|
80001501|NCT01353781|Drug|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
79374731|NCT05036655|Procedure|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
80001502|NCT03805880|Diagnostic Test|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
79233399|NCT05571527|Drug|Vaginal Hyaluronic Acid supplement|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
79233400|NCT03185858|Behavioral|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
79233401|NCT02432066|Drug|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
79374732|NCT05033002|Behavioral|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
79374733|NCT05026827|Other|Iyengar Yoga|Participation in Iyengar Yoga classes
79528642|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
80001503|NCT03561662|Dietary Supplement|Alpro soya drinks|12 weeks
79528643|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
79528644|NCT01400659|Procedure|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
79528645|NCT01400659|Procedure|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
79233402|NCT02432066|Drug|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
79233403|NCT03050801|Device|rTMS|Altering the connectivity of trans-synaptic pathways
79233404|NCT03191318|Other|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
79233405|NCT03191318|Other|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
79374734|NCT05026827|Other|Socialization Control|Participation in socialization control group sessions
79528646|NCT01400672|Biological|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
79528647|NCT01400672|Drug|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
79528648|NCT01400672|Radiation|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
79233406|NCT03190850|Other|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
79233407|NCT03190850|Other|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
79374735|NCT05019170|Behavioral|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
80001504|NCT02051036|Procedure|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
80001505|NCT02053766|Drug|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
80001506|NCT02053766|Drug|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
80001507|NCT02053766|Drug|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
79233408|NCT03191006|Device|MEI BIN insoles|insoles
79233409|NCT02431910|Other|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
79233410|NCT02431910|Other|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
79233411|NCT05233514|Other|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
80001508|NCT02053844|Other|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
80001509|NCT02053844|Other|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
80001510|NCT02053922|Drug|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
79233412|NCT02431832|Drug|Augmentin tab|
79233413|NCT02435186|Drug|p53 gene|p53 gene will be given intraperitoneally.
79233414|NCT02435186|Drug|Cisplatin|150 mg/m^2 cisplatin will be given intraperitoneally.
80001511|NCT02053922|Drug|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . [Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
79233415|NCT02435186|Drug|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
79233416|NCT03842657|Combination Product|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
79233417|NCT02435108|Drug|crizotinib|crizotinib 250mg bid daily
80001512|NCT02053922|Drug|Misoprostol|Misoprostol (200 mcg Tablet) [Misotac, Sigma Pharmaceutical Industries, SAE, Egypt] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
79233418|NCT02434952|Drug|Dihydroartemisinin piperaquine (DHA PP)|
79233419|NCT02434952|Drug|Primaquine|
79233420|NCT03117842|Other|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
79374736|NCT05019170|Behavioral|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
79391018|NCT02426190|Other|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
79391019|NCT03117270|Drug|filgotinib|one filgotinib oral tablet q.d.
79528649|NCT01400685|Drug|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
80001513|NCT02052206|Procedure|Shoulder replacement surgery|
79528650|NCT01400685|Drug|Bendamustine|90 mg/m^2 IV days 1-2 of each cycle for 6 cycles
79528651|NCT01400685|Drug|Rituximab|375 mg/m^2 IV day 1 (cycle 1), 500 mg/m^2 day 1 (cycles 2-6)
79528652|NCT01400711|Other|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
80001514|NCT02054000|Drug|Tirofiban|Intracoronary administering of Tirofiban
80001515|NCT02054000|Other|Placebo|Intracoronary serum physiologic
80001516|NCT02054078|Drug|Bevacizumab|Bevacizumab200mg by intrapleural administration
80001517|NCT02054078|Drug|Pulvis talci|Pulvis talci 4g by intrapleural administration
80001518|NCT02052284|Other|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
80001519|NCT02051192|Behavioral|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
79391020|NCT03117270|Drug|Placebo Oral Tablet|one placebo oral tablet q.d.
79528653|NCT01400711|Other|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
80001520|NCT02051192|Other|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
79233421|NCT03626753|Drug|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
79233422|NCT03626753|Drug|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
79233423|NCT03626753|Drug|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
79233424|NCT03626753|Drug|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
79374740|NCT05003518|Behavioral|ParentText|ParentText delivers content, aligning with children's developmental stages (0-23 months, 2-9 years, 10-17 years). ParentText content is delivered through text messages, images, audio and video for parents/ caregivers and their children. Parents receive parenting content surrounding three themes: 1) relationship building by spending time together, 2) positive reinforcement, 3) stress reduction for parents and caregivers. Further supportive content is available for parents of children living with disabilities, child development, online child safety, talking about COVID-19 with children, family budgeting, family harmony, helping with schoolwork and sexual violence prevention.
79233425|NCT03626753|Drug|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
79528654|NCT01400724|Dietary Supplement|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
79528655|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
79528656|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
79827797|NCT00871078|Device|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
79827798|NCT04065594|Procedure|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
80001521|NCT02052362|Drug|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
80001522|NCT03561506|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
80001523|NCT03561506|Drug|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
79233426|NCT03626753|Drug|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
79233427|NCT03117686|Diagnostic Test|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
79233428|NCT02431520|Procedure|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
79233429|NCT02431520|Procedure|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
79233430|NCT03626675|Procedure|phaco- trabeculectomy|combined phaco-trabeculectomy surgery
79233431|NCT02440256|Other|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
79233432|NCT05272085|Procedure|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
79233433|NCT05272085|Procedure|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
79233434|NCT02431442|Drug|RM-493|
79233435|NCT02431442|Drug|Placebo|
79374741|NCT05001282|Drug|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
79374742|NCT04986241|Drug|Statin|Chronic use of statin prescribed previously by the assistant physician.
79374743|NCT04986241|Other|Physical activity|Physically active participants
79374744|NCT04986241|Other|Sedentary|Physically inactive or sedentary participants.
79391021|NCT03117504|Other|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
79391022|NCT03182322|Drug|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
79374745|NCT04982497|Behavioral|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker & Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
79233436|NCT04717271|Other|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
79233437|NCT04717271|Other|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
79233438|NCT04921865|Device|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
79233439|NCT02434640|Drug|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
79233440|NCT02434640|Drug|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
79233441|NCT02434640|Drug|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
79233442|NCT03185780|Other|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
79528657|NCT01400750|Drug|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
79374746|NCT04982497|Other|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
79374747|NCT04977999|Other|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
79374748|NCT04969198|Drug|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
79684903|NCT03945734|Behavioral|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
79233443|NCT03185936|Procedure|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
79374749|NCT04968847|Device|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
79528658|NCT01400750|Drug|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
79528659|NCT01400763|Dietary Supplement|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
79528660|NCT01400763|Dietary Supplement|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
79528661|NCT01400763|Dietary Supplement|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
79528662|NCT01400763|Dietary Supplement|Placebo beverage|Placebo beverage
79528663|NCT01400789|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
79528664|NCT01400802|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
79528665|NCT01400828|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
79528666|NCT01400828|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
79528667|NCT01400828|Drug|Placebo|(encapsulated) Tablets QD/14 days
79528668|NCT01400854|Drug|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
79827799|NCT04065594|Procedure|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
79827800|NCT00735176|Procedure|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
79233444|NCT03185624|Drug|Rifaximin|Antibiotics
79233445|NCT02434718|Drug|Aducanumab|As described in the treatment arm
79233446|NCT02434718|Drug|Placebo|IV administration of 0.9% sodium chloride
79233447|NCT03190772|Other|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
79233448|NCT03190772|Other|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
79233449|NCT02707640|Drug|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
80001524|NCT01336439|Drug|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
80001525|NCT01336595|Device|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
80001526|NCT01336595|Device|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
80001527|NCT01336751|Drug|Insulin glargine|solution for subcutaneous injection
79233450|NCT02707640|Drug|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
79233451|NCT02707640|Drug|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
79233452|NCT03190694|Drug|Dapagliflozin 10mg|Tablet
79233453|NCT02430272|Drug|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
79233454|NCT02430506|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
79827801|NCT00735176|Procedure|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
80001528|NCT01336751|Drug|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
79528669|NCT01399996|Dietary Supplement|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
79374750|NCT04968405|Device|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
79374751|NCT04965012|Behavioral|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
79528670|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
79528671|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
79528672|NCT01399996|Dietary Supplement|A capsule containing the probiotic|A capsule taken daily will provide between 10x^y9 and 10x^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
79528673|NCT01400867|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects < 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
79528674|NCT01400867|Drug|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
79391023|NCT03182322|Other|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
79391024|NCT03185364|Drug|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
79391025|NCT03185364|Drug|Placebo Oral Tablet|placebos treatment for 12 weeks
79391026|NCT02424864|Other|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
79528675|NCT01400867|Drug|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
79528676|NCT01400945|Drug|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
79528677|NCT01400984|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
79528678|NCT01400997|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
79528679|NCT01401036|Device|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
79827802|NCT00862966|Other|citrate|comparison of different catheter lock solutions
79827803|NCT00862966|Other|heparin|comparison of different lock solutions
79827804|NCT02569320|Drug|Dexamethasone|Given PO
79827805|NCT02569320|Drug|HDAC Inhibitor AR-42|Given PO
79827806|NCT02569320|Other|Laboratory Biomarker Analysis|Correlative studies
79827807|NCT02569320|Drug|Pomalidomide|Given PO
79827808|NCT00739466|Drug|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
79233455|NCT02430506|Biological|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
79233456|NCT04586855|Diagnostic Test|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
79233457|NCT04586855|Diagnostic Test|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
80001529|NCT01336829|Drug|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
79233458|NCT03626597|Diagnostic Test|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
79528680|NCT01401036|Procedure|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
79233459|NCT03626597|Behavioral|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling & referral to care
79374752|NCT04965012|Behavioral|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
79374753|NCT04960605|Procedure|Dental implants|Treatment of the toothless regions with dental implants
79374754|NCT04948853|Behavioral|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
79374755|NCT04943900|Drug|BMS-986416|Specified dose on specified days
79528681|NCT01401075|Drug|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
79528682|NCT01401075|Drug|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
79233460|NCT03626597|Behavioral|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling & referral to care
79233461|NCT03188978|Drug|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
79233462|NCT03188978|Other|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
79374756|NCT04943900|Drug|Nivolumab|Specified dose on specified days
79374757|NCT04943861|Behavioral|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
79528683|NCT01401088|Device|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
79528684|NCT01401114|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
79528685|NCT01401140|Drug|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
79528686|NCT01401140|Drug|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
79528687|NCT01401179|Drug|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
79528688|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
79528689|NCT01401192|Drug|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 & cisplatin 70mg/m2 D1 every 3 weeks
79528690|NCT01401192|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 & cisplatin 70mg/m2 every 3 weeks
79528691|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
79528692|NCT01401205|Other|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
79528693|NCT01401218|Other|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
79528694|NCT01401231|Behavioral|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
79528695|NCT01401231|Other|Usual care|Continued usual care (could include referral for medication or psychotherapy)
79528696|NCT01401270|Behavioral|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
79528697|NCT01401296|Behavioral|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
80001530|NCT01336829|Drug|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
79233463|NCT02431286|Drug|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
79374758|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
79391027|NCT02424786|Other|STOPP/START criteria|Evaluation of medication lists
79827809|NCT00739466|Drug|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
80001531|NCT01336829|Drug|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
79233464|NCT02431286|Drug|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
79233465|NCT02431286|Drug|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
79233466|NCT02431208|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
79233467|NCT02431208|Drug|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
79233468|NCT02431208|Drug|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
79374759|NCT04941300|Other|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
79233469|NCT02431208|Drug|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
79233470|NCT02431208|Drug|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
79233471|NCT03107078|Drug|Glucocorticoids|Intravenous Glucocorticoids (GCs)
79374760|NCT04941300|Other|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~Identification of individuals with abnormal FIT~Results review and colonoscopy order by provider~Results reporting to patient~Insurance approval for colonoscopy~Colonoscopy scheduling~Bowel preparation & colonoscopy completion~Colonoscopy results provided to patient and CHC~Referral-to-Care for patients with CRC (if necessary)"
79528698|NCT01401296|Behavioral|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
79528699|NCT01401335|Behavioral|Questionnaires|questionnaires at entry, month 4, 8 and 12
79528700|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
79528701|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
79528702|NCT01401413|Drug|ramelteon|8 mg nightly for 30 nights
79528703|NCT01401413|Drug|placebo|placebo control i pill nightly for 30 nights
79528704|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
79528705|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
79528706|NCT01401491|Drug|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
79528707|NCT01401491|Drug|clozapine plus placebo|clozapine 300 mg/day plus placebo
79528708|NCT01401504|Drug|ASP3026|oral
80001532|NCT01336829|Drug|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
80001533|NCT01340183|Drug|AZD5099|IV Dose
80001534|NCT01340183|Drug|Placebo|IV Dose
80001535|NCT02960490|Drug|E6011|subcutaneous administration
80001536|NCT02960490|Drug|Placebo|subcutaneous administration
79528709|NCT01401569|Behavioral|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
79827810|NCT00739466|Drug|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
79827811|NCT02544178|Radiation|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
79827812|NCT00863044|Procedure|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
79827813|NCT00863044|Procedure|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
80001537|NCT02804750|Drug|CORT125134|
80001538|NCT05184491|Drug|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
80001539|NCT05184491|Drug|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
80001540|NCT05184491|Drug|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
80001541|NCT05184491|Drug|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
79374761|NCT04939402|Diagnostic Test|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
79374762|NCT04939220|Procedure|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
79233472|NCT03188900|Biological|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
79233473|NCT05693597|Drug|Imtenan Oil|Cold Press Oil
79528710|NCT01401608|Device|RF Ablation|Ablation of arrhythmogenic ventricular tissue
79528711|NCT01401621|Behavioral|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
79233474|NCT05693597|Drug|Baraka Capsules|Soft Gelatin Capsules
79827814|NCT00739544|Other|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
79233475|NCT02430350|Drug|Compound Edaravone Injection|
79233476|NCT02430350|Drug|Edaravone Injection|
79528712|NCT01401621|Behavioral|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
79528713|NCT01401621|Behavioral|Control|No scratch-off element
79528714|NCT01401634|Other|Oral water|2 Liters of water given orally
79528715|NCT01401634|Other|Intravenous normal saline|2 Liters Intravenous normal saline
79684904|NCT03939065|Device|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
79684905|NCT03939065|Device|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
79684906|NCT01254565|Drug|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
79684907|NCT01254565|Drug|Placebo|Administered intravenously at the end of hemodialysis
79684908|NCT04772053|Procedure|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
79827815|NCT00735332|Drug|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
79827816|NCT00869908|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79827817|NCT00869908|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79827818|NCT00869908|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79233477|NCT02430974|Drug|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
79233478|NCT02430116|Procedure|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
79233479|NCT02429960|Device|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
79233480|NCT02429960|Device|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
79233481|NCT02429960|Device|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
79233482|NCT02429960|Drug|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
79233483|NCT02429804|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
79528716|NCT01401660|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
79528717|NCT01401673|Drug|Indantadol|Titration
79684909|NCT02889055|Device|patient requiring the MIRUS (mechanical ventilation)|
79684910|NCT01254409|Biological|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
79684911|NCT01254409|Other|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
79684912|NCT04324177|Other|Demographic data, morbidity data|To detect association between the demographic data of pediatric patients including age ,sex,hospital stay and clinical data including the diagnosis and co morbidity with the outcome of pediatric patients admitted to ICU of Assiut University children hospital
79684913|NCT04684160|Device|Fixed-bearing TKA|
79684914|NCT04684160|Device|Mobile-bearing TKA|
79684915|NCT04390698|Procedure|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
79233484|NCT02429804|Drug|Fludeoxyglucose F-18|Given IV
79233485|NCT02429804|Drug|Fluorine F 18 Sodium Fluoride|Given IV
79233486|NCT02429804|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79233487|NCT02429804|Procedure|Positron Emission Tomography|Undergo PET/MRI
79233488|NCT03185156|Drug|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
79233489|NCT03185156|Drug|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
79233490|NCT03188744|Other|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
79233491|NCT03188744|Other|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
79374763|NCT04939220|Procedure|TEE with Deep Sedation|Deep sedation with propofol and natural airway
79374764|NCT04935138|Genetic|cfDNA analysis|sequencing data from cfDNA analysis
79374765|NCT04935034|Dietary Supplement|Vitamin D supplement|This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
80001542|NCT05184491|Drug|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
80001543|NCT01340339|Device|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
80001544|NCT01340339|Device|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
80001545|NCT05184179|Drug|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
80001546|NCT02051270|Other|Descriptive study|More than 65 years old elders
80001547|NCT05187299|Other|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
80001548|NCT02054312|Behavioral|Family Based Interpersonal Psychotherapy (FB-IPT)|
80001549|NCT02054312|Behavioral|Client Centered Therapy (CCT)|
79233492|NCT04483700|Drug|Filgotinib|Tablets administered orally once daily
79233493|NCT04483700|Drug|Placebo to Match Filgotinib|Tablets administered orally once daily
79374766|NCT04928664|Drug|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
79374767|NCT04928664|Drug|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
79684916|NCT04390698|Drug|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
79374768|NCT04928261|Drug|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
79374769|NCT04916392|Drug|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
79374770|NCT04908384|Behavioral|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
79374771|NCT04902352|Procedure|No Periadventitial dissection of the SMA|lymphoneural tissue around SMA left intact
79391028|NCT02424552|Drug|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
80001550|NCT01341509|Procedure|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
80001551|NCT01341509|Procedure|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
79233494|NCT02434406|Behavioral|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
79233495|NCT02708966|Drug|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
79391029|NCT02424552|Drug|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
79233496|NCT02708966|Drug|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
79233497|NCT02429726|Drug|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
79233498|NCT02429726|Drug|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
80001552|NCT01341509|Procedure|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
80001553|NCT02051348|Biological|Pylopass|Pylopass
80001554|NCT02051348|Biological|Placebo|Placebo
80001555|NCT02052518|Behavioral|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
80001556|NCT03640962|Other|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
79233499|NCT02429726|Drug|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
79233500|NCT02429882|Drug|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
79233501|NCT02429882|Drug|Placebo|Placebo will be administered subcutaneously
79233502|NCT02429648|Procedure|DCC first then PVI|DCC performed prior to PVI
79233503|NCT02429648|Procedure|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
80001557|NCT02052674|Device|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
79374772|NCT04902352|Procedure|Periadventitial dissection of the SMA|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well."
80001558|NCT02052674|Device|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
79684917|NCT04390698|Procedure|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
79827819|NCT00734058|Device|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
79233504|NCT02425358|Other|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
79528718|NCT01401712|Procedure|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
79233505|NCT02425358|Other|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
79374773|NCT04897568|Other|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
79684918|NCT04390698|Procedure|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
79684919|NCT01254331|Drug|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
79684920|NCT04673578|Drug|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
79684921|NCT04673578|Other|Placebo|Microcrystalline cellulose
79827820|NCT00739622|Drug|TMC278|
79233506|NCT02425358|Other|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
79528719|NCT01401712|Procedure|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
79528720|NCT01401725|Behavioral|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
79528721|NCT01401725|Behavioral|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
79528722|NCT01401725|Other|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
79684922|NCT05414058|Drug|Apo-Methylphenidate ER|The study medication will be administered by a clinical registered nurse (RN), alongside their other medications. Patients will continue their regular medications as per standard of care.
79233507|NCT02425358|Other|PCI only|The saline was intracoronary infusion with the use of microtubular.
79233508|NCT02425436|Drug|Ginkgo Biloba Extract|
79233509|NCT02425436|Other|Placebo|
79233510|NCT03183050|Behavioral|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
79233511|NCT02429492|Device|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
79684923|NCT03757403|Drug|RDD1609|RDD1609 to be applied on the perianal area BID
79684924|NCT03757403|Drug|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
79684925|NCT04381923|Device|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of < 60%. If oxygen saturation (Sp02) remains < 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
79684926|NCT04381923|Device|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of < 60%. If oxygen saturation (SpO2) remains < 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
79827821|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
80001559|NCT05163834|Biological|Efgartigimod|intravenous infusion of efgartigimod
80001560|NCT05163834|Other|Placebo|intravenous infusion of placebo
80001561|NCT05163834|Biological|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
80001562|NCT05182619|Procedure|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
79827822|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
80001563|NCT01065012|Drug|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
80001564|NCT01065012|Drug|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
79233512|NCT02429180|Other|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
79233513|NCT03117452|Behavioral|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
79374774|NCT04887454|Behavioral|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
79374775|NCT04887454|Behavioral|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
79374776|NCT04887454|Other|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
79374777|NCT04884334|Device|VAC-Stent®|treatment with the VAC-Stent®
79374778|NCT04879706|Other|None planned|No intervention planned
79528723|NCT01401751|Device|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
79528724|NCT01401764|Other|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
79528725|NCT01401790|Device|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~Automatic download of blood glucose levels~Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~Changes in treatment plan by the diabetes professionals~E mail exchanges between families and health care professionals~Reinforcement of teaching program"
79528726|NCT01401790|Other|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
79528727|NCT01401803|Drug|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
79528728|NCT01401816|Other|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
79374779|NCT04868695|Procedure|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
79374780|NCT04866251|Diagnostic Test|Gag reflex test; assessment of Mallampati Score|Testing of gag reflex Assessment of Mallampati Score
79827823|NCT00870064|Procedure|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
79827824|NCT00870064|Procedure|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
80001565|NCT01065012|Drug|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
80001566|NCT01065012|Drug|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
80001567|NCT01065012|Drug|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
80001568|NCT01065012|Drug|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
79374781|NCT04859725|Device|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
79374782|NCT04854668|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
79374783|NCT04854668|Drug|Bevacizumab|Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
79233514|NCT03182816|Biological|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
79233515|NCT03117374|Behavioral|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
79233516|NCT02430896|Drug|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
79233517|NCT02430896|Drug|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
79233518|NCT02425280|Behavioral|Narrative Exposure Therapy|
79233519|NCT02425280|Behavioral|Treatment as Usual|
79233520|NCT03184844|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
79233521|NCT02429102|Drug|MT-8554|
79233522|NCT02429102|Drug|Placebo|
79374784|NCT04854668|Drug|Oxaliplatin|Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
79374785|NCT04854668|Drug|Capecitabine|Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
79374786|NCT04842084|Biological|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
79374787|NCT04837521|Behavioral|Unified Protocol|Five session psychotherapy
79374788|NCT04836312|Behavioral|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
79374789|NCT04830488|Behavioral|e-learning didactic module|Participants utilize e-learning
79374790|NCT04830488|Behavioral|Personal reflection activities|Participants complete questionnaires
79528729|NCT01401829|Behavioral|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
79528730|NCT01401829|Behavioral|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
79528731|NCT01401829|Behavioral|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
79233523|NCT03185390|Procedure|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
79233524|NCT03185312|Diagnostic Test|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
79233525|NCT02425202|Drug|Ketamine|Post-operative continuous infusion until 0600 the next day
79233526|NCT02425202|Other|Saline infusion|Post-operative continuous infusion until 0600 the next day
79233527|NCT02425124|Behavioral|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
79233528|NCT03185468|Genetic|4SCAR-PSMA|PSMA-specific 4th Generation CART
79233529|NCT03185468|Genetic|4SCAR-FRa|FRa-specific 4th Generation CART
79233530|NCT02430662|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
79233531|NCT02430662|Device|NanoKnife|
79233532|NCT02706938|Other|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
79233533|NCT02706938|Other|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
79233534|NCT02430584|Other|Observational - no intervention|
79528732|NCT01401868|Drug|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
79233535|NCT03182504|Drug|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
79233536|NCT03182504|Drug|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
79233537|NCT02430428|Device|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
79528733|NCT01401920|Other|leg elevation|bilateral passive leg elevation for 30 seconds
79528734|NCT01401920|Other|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
79528735|NCT01401920|Other|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
79684927|NCT00537342|Biological|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
79684928|NCT04338516|Device|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
79827825|NCT00734136|Procedure|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
79233538|NCT03182348|Procedure|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
79233539|NCT02429024|Device|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
79233540|NCT02429024|Device|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
79233541|NCT02421458|Radiation|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
79233542|NCT02421458|Radiation|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
79233543|NCT04483310|Behavioral|MR therapy.|MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
79233544|NCT04483310|Behavioral|breathing-distraction exercise|The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
79233545|NCT02428946|Drug|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
79233546|NCT03182036|Device|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
79233547|NCT02422004|Other|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
79233548|NCT02422004|Other|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
79233549|NCT02428634|Behavioral|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
79233550|NCT02428634|Behavioral|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
79233551|NCT02421302|Dietary Supplement|RUTF|This is ready-to-use-therapeutic-food
79374791|NCT04830410|Dietary Supplement|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
79374792|NCT04830410|Dietary Supplement|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
79374793|NCT04820933|Drug|Doravirine 100 Mg|Doravirine 100 Mg orally dail
79374794|NCT04804605|Drug|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream
79374795|NCT04788264|Other|Medical Device Usage and Evaluation|Receive Fitbit
79374796|NCT04788264|Other|Consultation|Receive consultation from a physical therapist
79374797|NCT04788264|Other|Exercise Intervention|Attend exercise training sessions
79374798|NCT04788264|Behavioral|Behavioral Intervention|Attend sessions with a behavioral therapist
79374799|NCT04788264|Other|Questionnaire Administration|Ancillary studies
79374800|NCT04788264|Other|Quality of Life Assessment|Ancillary studies
79528736|NCT01401920|Other|control group|supine position without passive leg elevation or trendelenburg position
79528737|NCT01401933|Drug|Linifanib|QD on Days 1 and 13
79528738|NCT01401933|Drug|Rifampin|QD on Days 5-16
79528739|NCT01401946|Drug|soy isoflavones|
79528740|NCT01401946|Drug|Placebo|
79684929|NCT04338516|Device|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
79684930|NCT00537420|Drug|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
79684931|NCT00537420|Drug|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
79684932|NCT00537420|Drug|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
79684933|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
79684934|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
79684935|NCT00537420|Drug|Sibutramine|Sibutramine will be taken once daily with or without food
80001569|NCT01315691|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
80001570|NCT01315691|Drug|Placebo for liposomal amikacin for inhalation|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are the same as for Arikace™.~Placebo will be administered for 28 days."
80001571|NCT02038244|Other|Multimodal integrative medicine inpatient treatment program|
80001572|NCT05654090|Drug|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
79528741|NCT01402024|Drug|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
80001573|NCT01340729|Drug|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
80001574|NCT02052830|Behavioral|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
80001575|NCT02959866|Other|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
79233552|NCT02428868|Drug|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
79374801|NCT04786093|Radiation|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
79374802|NCT04786093|Drug|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
79684936|NCT04295889|Diagnostic Test|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
79684937|NCT04295889|Diagnostic Test|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR | EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
79528742|NCT01402024|Drug|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
79528743|NCT01402037|Drug|Glucose|Glucose 20% intravenous
79684938|NCT00537459|Drug|16448|
79684939|NCT03504215|Other|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
80001576|NCT05183711|Behavioral|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
80001577|NCT02054468|Drug|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
79233553|NCT02428868|Drug|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
80001578|NCT02054468|Drug|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
80001579|NCT02054468|Drug|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
80001580|NCT02054468|Drug|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
80001581|NCT02054468|Drug|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
80001582|NCT02054468|Drug|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
80001583|NCT02054468|Drug|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
80001584|NCT02054468|Drug|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
80001585|NCT02054468|Drug|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
79233554|NCT02428868|Other|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
79233555|NCT02428400|Biological|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
79233556|NCT02428400|Biological|Placebo|Placebo: adenovirus reference material (ARM) buffer
79233557|NCT02424890|Other|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
79684940|NCT03457038|Biological|Blood Test|"Addition to the current care but during the normal follow-up visit :~At the entrance to the service: search for bacterial 16S RNA in the blood~Additional blood tests (4) at T6-12-18 and 36h~At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~1 time per day: Assay of CRP and PCT from samples taken in common practice~J30: Assessment of the vital status of the patient"
79233558|NCT03181880|Drug|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
79233559|NCT03181880|Drug|Standard of Care|Brochodilators
79233560|NCT02428556|Other|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
79233561|NCT02428556|Other|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
79233562|NCT02428556|Other|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
79374803|NCT04785976|Procedure|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
79374804|NCT04779684|Other|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
79374805|NCT04778709|Device|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
79374806|NCT04778059|Drug|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
79684941|NCT04218279|Other|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
79827826|NCT00734136|Procedure|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
79233563|NCT02428556|Other|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
79233564|NCT02428556|Other|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
79233565|NCT03178994|Drug|2% ketoconazole cream|2% ketoconazole cream applies twice daily
79374807|NCT04778059|Drug|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
79374808|NCT04773470|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
79374809|NCT04765033|Drug|Nebulized 5% Hypertonic saline|nebulized 0.9% saline
79374810|NCT04726150|Other|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
79374811|NCT04723784|Other|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
79374812|NCT04723784|Other|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
79374813|NCT04723784|Other|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
79391030|NCT02424708|Drug|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
79684942|NCT04183374|Other|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
79684943|NCT01254292|Drug|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
79827827|NCT00739778|Other|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
79528744|NCT01402037|Device|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
79233566|NCT03178994|Drug|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
79374814|NCT04690049|Other|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
79528745|NCT01402076|Drug|Tasimelteon|20mg daily dosing, Days 4-20
79528746|NCT01402076|Drug|Rosiglitazone|4mg, single dose, Days 3 and 20
79374815|NCT04690049|Other|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
79827828|NCT00739778|Other|food vehicle blank|water blank
79684944|NCT01254292|Drug|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
79684945|NCT04178538|Procedure|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
79684946|NCT04178538|Procedure|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
79827829|NCT00739778|Other|food - sweetener, positive control|4.7% sucrose in water
80001586|NCT01340807|Other|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
80001587|NCT03640650|Combination Product|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
80001588|NCT03640650|Drug|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
79233567|NCT03182114|Other|supine position|the patient will be placed in regular supine position after spinal anesthesia
79233568|NCT03182114|Other|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
79374817|NCT04621266|Behavioral|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
79374818|NCT04621227|Drug|PF-06882961|120 mg and 200 mg BID
79233569|NCT03182114|Drug|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
79233570|NCT03182270|Diagnostic Test|nCLE|Procedure: EUS-FNA Device: nCLE
79233571|NCT02424812|Behavioral|Lifebuoy School of Five Handwashing Intervention|
79233572|NCT02428322|Dietary Supplement|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
79374819|NCT04621227|Drug|Rosuvastatin|10 mg single dose
79528747|NCT01402076|Drug|Midazolam|10mg, single dose, Days 1 and 18
79528748|NCT01402089|Drug|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
79684947|NCT00553007|Procedure|Periodontal therapy|Normal periodontal therapy is performed.
79827830|NCT00739778|Other|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
79827831|NCT00731718|Device|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
79827832|NCT04695392|Other|R2 Bundle|"During the intervention phase subjects will receive R2.~Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~Cycled day-night lighting and modulation of sound to match the child's routine,~Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~Night fasting with bolus enteral daytime feedings,~Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~Continuity in nursing care, and~Parent diaries."
79233573|NCT02428322|Dietary Supplement|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
79233574|NCT02428244|Behavioral|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
79233575|NCT02428244|Behavioral|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
79827833|NCT00870142|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
79827834|NCT00870142|Drug|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
80001589|NCT05183555|Drug|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
79528749|NCT01402089|Drug|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
79684948|NCT04075383|Procedure|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
79684949|NCT04075383|Procedure|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
79233576|NCT03185078|Device|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
79374820|NCT04621227|Drug|Midazolam|2mg single dose
79374821|NCT04597918|Drug|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
79374822|NCT04592549|Drug|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
79827835|NCT00731796|Device|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
79233577|NCT03185078|Other|Placebo ESWT|In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
79233578|NCT03184532|Diagnostic Test|ultrasound|ultrasound examination of pyloric antrum
79233579|NCT02424500|Device|d-Nav|Insulin dosage is adjusted as required
79374823|NCT04592549|Other|Placebo|Placebo
79374824|NCT04591990|Drug|Administration of AVP|Administration of AVP
79684950|NCT00537498|Drug|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is < 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is < 1,6g/l treatment must be stopped and continued after rising up to >2g/l"
79684951|NCT01254019|Drug|GSK2402968 6mg/kg/week|subcutaneous
79827836|NCT00870220|Drug|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
79233580|NCT02424500|Device|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
79233581|NCT03106766|Drug|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
79233582|NCT03106766|Drug|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
79374825|NCT04591990|Drug|Administration of placebo AVP|Administration of placebo AVP
79374826|NCT04591990|Drug|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
79374827|NCT04591990|Drug|Administration of hydrocortisone|Administration of hydrocortisone
79374828|NCT04586023|Drug|Fenebrutinib|Participants will receive fenebrutinib.
79374829|NCT04586023|Drug|Teriflunomide|Participants will receive teriflunomide.
79528750|NCT01402089|Drug|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
79528751|NCT01402089|Drug|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
79528752|NCT01402154|Biological|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
79233583|NCT04483154|Device|Coala Heart Monitor|The Coala Heart Monitor (Coala Life AB, Sweden) is a CE and FDA-cleared device for real-time, remote monitoring of 2-lead ECG as well as heart and lung sounds. The Coala Heart Monitor automatically detects for 9 of the most common arrhythmias and has an integrated stethoscope for remote auscultation. It is paired wirelessly with the patient's smartphone and results are provided instantly both to patient and to connected provider in the cloud-based Coala Care portal.
79233584|NCT02424266|Device|None invasive imaging of the tear film (AdOM)|White light tomography imaging
79233585|NCT03053063|Drug|SEL|Tablets administered orally once daily
79374830|NCT04586023|Drug|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
79374831|NCT04583033|Behavioral|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
79391031|NCT02424708|Drug|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
79391032|NCT02424708|Drug|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
79528753|NCT01402154|Biological|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
79528754|NCT01402167|Procedure|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
79528755|NCT01402167|Procedure|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
79528756|NCT01402180|Biological|Nimotuzumab|
79827837|NCT00735410|Biological|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
79528757|NCT01402180|Radiation|Radiation therapy|
79233586|NCT03053063|Drug|Placebo to match SEL 6 mg|Tablets administered orally once daily
79233587|NCT03053063|Drug|Placebo to match SEL 18 mg|Tablets administered orally once daily
79233588|NCT03117218|Diagnostic Test|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
79233589|NCT03116906|Drug|BI 685509|to be given for a total of up to 15 days
79528758|NCT01402180|Radiation|radiation therapy|
79827838|NCT00729768|Drug|basiliximab|2 intravenous doses
79827839|NCT00729768|Drug|efalizumab|Subcutaneous repeating dose
79233590|NCT03116906|Drug|Placebo|to be given for a total of up to 15 days
79233591|NCT00702338|Drug|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
79233592|NCT00702338|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
79233593|NCT00702338|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
79233594|NCT00702338|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
79233595|NCT03184688|Procedure|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
79233596|NCT03184688|Drug|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
79233597|NCT02428010|Device|TMVR Implant|Implantation of the Twelve TMVR System
79233598|NCT02427932|Drug|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
79233599|NCT02427932|Drug|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
79233600|NCT02427932|Drug|Gentamicin|Prescribed to non-pregnant participants
79233601|NCT04678193|Drug|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
79233602|NCT03626519|Other|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
79391033|NCT03182088|Drug|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
79391034|NCT03182088|Drug|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
79528759|NCT01402180|Drug|chemotherapy|
79827840|NCT00729768|Drug|mycophenolate mofetil|Oral repeating dose
79233603|NCT03626519|Other|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
79233604|NCT02427776|Biological|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
79233605|NCT03178760|Diagnostic Test|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~Age~Gender~Weight~Length~Waist Circumference~Body mass index"
79233606|NCT04576247|Behavioral|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
79233607|NCT03184610|Device|OCT-scanning|All participants will be scanned with a OCT-device
79233608|NCT03184766|Drug|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
79233609|NCT03184766|Drug|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
79233610|NCT03184766|Drug|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
79528760|NCT01402180|Drug|chemotherapy|
79528761|NCT01402193|Drug|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
79528762|NCT01402193|Drug|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
79684952|NCT04687644|Behavioral|Online education|Education group
79827841|NCT00729768|Drug|corticosteroids|Repeating doses
79827842|NCT00729768|Drug|cyclosporine|Oral repeating dose
80001590|NCT03618966|Device|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
79684953|NCT03055871|Behavioral|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
79684954|NCT03055871|Behavioral|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
79827843|NCT00739856|Procedure|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
80001591|NCT05187143|Device|DENTAL IMPLANT|The study implants were 3.5, 3.75 or 4.5 mm implant diameter, Straumann® BLX implant SLActive® Roxolid® (Institut Straumann AG, Basel, Switzerland) and the abutment was a 0 °, 2.5 mm of height Straumann® Screw-retained Abutment. The length of the implants was 6, 8 and 10 mm. The 6 mm implant is only commercially available in 3.75 and 4.5 diameter.
79374832|NCT04553185|Other|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
79528763|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
80001592|NCT02052908|Other|Laboratory Biomarker Analysis|Correlative studies
80001593|NCT02052908|Drug|Naproxen|Given PO
80001594|NCT02052908|Other|Placebo Administration|Given PO
79374833|NCT04547634|Other|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
79374834|NCT04546126|Drug|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
79374835|NCT04546126|Drug|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
79374836|NCT04546126|Combination Product|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
79528764|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
79684955|NCT04683458|Device|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
79684956|NCT04319497|Device|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
80001595|NCT03640572|Diagnostic Test|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
80001596|NCT01336985|Drug|Irinotecan|
80001597|NCT01336985|Procedure|Chemoembolization|
80001598|NCT01336985|Device|Drug-Eluting Beads|
80001599|NCT01336985|Procedure|Biopsy|
79374841|NCT04534413|Device|composite optical fiberscope (COF)|Fiber Technology
79684957|NCT04319497|Device|Autorefraction|Five autorefraction measurements will be performed for all the patients included
79684958|NCT04319497|Device|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
79684959|NCT01253317|Drug|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
79233611|NCT03184376|Dietary Supplement|Prebiotic oligofructose|Powder format
79684960|NCT00537537|Drug|Telbivudine|
79684961|NCT02863874|Device|VicrylPlus®|Suture
79684962|NCT02863874|Device|Vicryl®|Suture
79684963|NCT04319770|Device|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
79233612|NCT03184376|Dietary Supplement|Placebo maltodextrin|Powder format
79684964|NCT04319770|Device|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
79684965|NCT04073472|Drug|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
79233613|NCT03181568|Device|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
79528765|NCT01402206|Behavioral|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
79684966|NCT01253200|Device|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
79684967|NCT01253200|Device|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
79684968|NCT00553046|Other|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
79684969|NCT04515901|Drug|2% lidocaine|Viscous lidocaine
79684970|NCT04515901|Other|Placebo|Methylcellulose and cherry flavouring
79528766|NCT01402219|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
79528767|NCT01402219|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
79528768|NCT01402245|Biological|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
79233614|NCT03181568|Procedure|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
79233615|NCT03181646|Drug|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
79233616|NCT04482998|Other|No intervention - retrospective study|No intervention - retrospective study
79528769|NCT01402245|Biological|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
79684971|NCT01253044|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
79233617|NCT02420834|Other|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
79684972|NCT01253044|Behavioral|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
79684973|NCT02646527|Behavioral|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
79684974|NCT04685889|Procedure|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
79684975|NCT04206514|Behavioral|Person Centered Care - Post Abortion Support|Post abortion phone based support
79684977|NCT04001556|Diagnostic Test|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
79684978|NCT04001556|Diagnostic Test|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
79233618|NCT02420834|Other|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
79374842|NCT04533672|Diagnostic Test|MRI Sequences|New multiparametric MRI techniques
79374843|NCT04531917|Other|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
79528770|NCT01402297|Drug|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
79827844|NCT00734370|Behavioral|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Virtual reality Exposure to agoraphobic situations and interoceptive exposure~Relapse prevention"
79827845|NCT00734370|Behavioral|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Standard exposure in vivo to agoraphobic situations and interoceptive exposure~Relapse prevention (according to the protocol of Craske & Barlow)"
79528771|NCT01402310|Other|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
79374844|NCT04531917|Other|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
79827846|NCT00871156|Drug|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
79233619|NCT02420834|Other|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
79374845|NCT04531917|Other|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
79528772|NCT01402323|Other|time point of tooth extraction|
79827847|NCT00871156|Drug|Placebo|Placebo
79528773|NCT01402336|Drug|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
79827848|NCT00734448|Dietary Supplement|myo-inositol|2 g twice a day until delivery
79233620|NCT02420834|Other|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
79528774|NCT01402336|Drug|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
79528775|NCT01402388|Behavioral|Group lifestyle programme|
79528776|NCT01402414|Radiation|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
79684979|NCT04001556|Diagnostic Test|MSG US|Ultrasonography of Major Salivary Glands
79684980|NCT04320589|Drug|Dexmedetomidine|which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
79827849|NCT00735488|Other|Observational|Summary of data
79827850|NCT04039906|Device|Removal of needle with using ANDYs|"ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~Identify the number of syringes processed by ANDY.~After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
79827851|NCT04064372|Behavioral|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
79233621|NCT03184298|Other|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
79233622|NCT03184298|Other|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
79233623|NCT03184298|Other|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
79233624|NCT03184142|Behavioral|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
79233625|NCT03184142|Behavioral|Video|Student watch a 15-minute intimidation video (see arm description).
79233626|NCT03184142|Behavioral|Control group|No intervention. The students suture for 70 minutes
79233627|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams once daily
79233628|NCT01316939|Drug|Placebo|Placebo
80001600|NCT03640494|Device|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
80001601|NCT01337063|Other|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
80001602|NCT03640416|Device|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
80001603|NCT01337141|Other|Control|7 face-to-face visits.
79684981|NCT04320589|Drug|General anesthetic|1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, ACI & ACRB e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
79684982|NCT04319458|Behavioral|Fotonovela|Secret Feelings/Sentimientos Secretos
79827852|NCT04064372|Behavioral|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
79827853|NCT00734526|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
80001604|NCT01337141|Device|Telecare system|5 telematic visits and 2 face-to-face visits.
79233629|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams twice daily
79528777|NCT01402414|Radiation|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
79528778|NCT01402414|Radiation|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
79528779|NCT01402440|Drug|AEB071|
79684983|NCT04319458|Behavioral|Control|NIH Brochure: Depression: What You Need to Know
79684984|NCT01252966|Behavioral|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
79684985|NCT01252966|Behavioral|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
79684986|NCT00537615|Drug|PD 0332334|
79684987|NCT02582957|Other|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
79827854|NCT00734526|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
79233630|NCT03183986|Device|Phototherapy|Phototherapy for 24 hours.
79233631|NCT03184220|Procedure|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~Suboccipital induction~Posterior elongation of the cervical fascia in Supine position~Assisted cervical fascia~Myofascial induction of sternocleidomastoid"
79374849|NCT04484142|Drug|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
79374850|NCT04466683|Radiation|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
79374851|NCT04466683|Radiation|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
79374852|NCT04459806|Procedure|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
79374853|NCT04451863|Drug|Low THC|Vaporized THC (5 mg)
79374854|NCT04451863|Drug|High THC|Vaporized THC (15 mg)
79374855|NCT04451863|Drug|Low Myrcene|Vaporized Myrcene (0.5 mg)
79374856|NCT04451863|Drug|High Myrcene|Vaporized Myrcene (12.0 mg)
79233632|NCT03184220|Procedure|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
79233633|NCT02424110|Procedure|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
79233634|NCT02424110|Procedure|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
79233635|NCT02424110|Device|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
79374857|NCT04451863|Drug|Low Beta-Caryophyllene|Vaporized Beta-Caryophyllene (0.5 mg)
79374858|NCT04451863|Drug|High Beta-Caryophyllene|Vaporized Beta-Caryophyllene (7.5 mg)
79374859|NCT04451863|Drug|Placebo|Vaporized Placebo
79528780|NCT01402453|Behavioral|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
79528781|NCT01402453|Behavioral|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
79528782|NCT01402466|Behavioral|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
80001605|NCT03640338|Device|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
79233636|NCT02424110|Device|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
79374860|NCT04398706|Biological|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
79374861|NCT04398706|Biological|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
79374862|NCT04398706|Biological|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
79374863|NCT04398706|Biological|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
79374864|NCT04398706|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
79374865|NCT04398706|Biological|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
79528783|NCT01402466|Behavioral|Project Bridge|Arm 2
79528784|NCT01402479|Drug|Ramipril|ramipril 2.5mg twice a day
79374866|NCT04398706|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
79528785|NCT01402505|Procedure|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
79528786|NCT01402518|Procedure|Per-oral enodscopic myotomy|
79233637|NCT02424032|Behavioral|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
79233638|NCT02424032|Behavioral|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
79233639|NCT02420756|Device|PET Scan|
79374867|NCT04398706|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
79374868|NCT04398706|Biological|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
79374869|NCT04381260|Other|No intervention|There is no intervention for patients included in this group as this is a retrospective data registry only.
79374870|NCT04381260|Other|Interview|Key Informant Interview
79374871|NCT04381260|Other|Survey|Stakeholder survey
79374872|NCT04353739|Behavioral|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
79374873|NCT04351906|Device|ECCO2R|ECCO2R integrated into the multiFiltrate device
79374874|NCT04334759|Drug|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
79374875|NCT04334759|Drug|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
79233640|NCT02423954|Drug|Temsirolimus|
79233641|NCT02423954|Drug|Irinotecan|
79374876|NCT04334759|Drug|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
80001606|NCT05186831|Behavioral|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
80001607|NCT05186831|Behavioral|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
79528787|NCT01402557|Behavioral|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
79528788|NCT01402557|Behavioral|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
79528789|NCT01402557|Behavioral|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
80001608|NCT01337375|Drug|peginterferon alfa 2a [Pegasys]|sc weekly
80001609|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv weekly
80001610|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|sc twice weekly
80001611|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv twice weekly
80001612|NCT03635411|Dietary Supplement|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
79233642|NCT02423954|Drug|Irinotecan + capecitabine|
79827855|NCT00734526|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
80001613|NCT03635411|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Basis supplement.
80001614|NCT02748512|Drug|FAI Insert administered using the Mk II inserter|
80001615|NCT02748512|Drug|FAI Insert administered using the Mk I inserter|
79233643|NCT02423954|Drug|nivolumab|
79233644|NCT03626441|Dietary Supplement|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
79374877|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
80001616|NCT04816799|Behavioral|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
80001617|NCT04875455|Device|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
80001618|NCT02748356|Drug|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
80001619|NCT02052986|Other|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
79233645|NCT03626441|Dietary Supplement|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
79233646|NCT02427542|Other|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
79233647|NCT02427542|Other|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
79233648|NCT03178682|Diagnostic Test|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
79233649|NCT03181334|Behavioral|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
79233650|NCT03181334|Behavioral|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
79233651|NCT03181334|Behavioral|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
79374878|NCT04317586|Device|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
79391035|NCT03182088|Drug|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
79391036|NCT03182088|Drug|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
79827856|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
79233652|NCT03181334|Behavioral|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
79827857|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
79827858|NCT00876304|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
79374879|NCT04270123|Other|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
79827859|NCT00876304|Drug|Placebo|Placebo capsules every 12 hours for 10 days
79374880|NCT04267874|Procedure|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
79827860|NCT00735722|Device|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
79233653|NCT03181334|Behavioral|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
79233654|NCT03178604|Other|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
79233655|NCT03178604|Other|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
79233656|NCT03044249|Drug|MP-101|Capsules
79233657|NCT03044249|Drug|Placebo|Capsules
79827861|NCT00731952|Drug|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
79827862|NCT04065932|Drug|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
79827863|NCT04065932|Drug|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
79233658|NCT02427308|Drug|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
79233659|NCT03178292|Drug|Levofloxacin|Levofloxacin 500Mg daily for 5 days
79233660|NCT03178292|Drug|Placebo|Placebo Oral Tablet daily for 5 days
79374881|NCT04267874|Dietary Supplement|Nutritional Supplementation|Given black raspberry nectar PO
79374882|NCT04267874|Drug|Placebo Administration|Given PO
79374883|NCT04267874|Other|Questionnaire Administration|Ancillary studies
79374884|NCT04219020|Other|Co-created intervention|
79374885|NCT04214184|Behavioral|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
79374886|NCT04210713|Drug|Minocycline|200 mg/day
79374887|NCT04210713|Drug|Sugar pill|Matched placebo
79374888|NCT04198779|Device|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
79374889|NCT04192071|Other|virtual technology - high interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer and dietary intake. Interactive nutrition risk feedback will be customized based on user input.
79374890|NCT04192071|Other|virtual technology - low interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer. Minimally interactive risk feedback will be delivered.
79374891|NCT04192071|Other|non-colorectal cancer related module|Participants engage with web-based content not related to colorectal cancer or nutrition.
79374892|NCT04185415|Drug|bepranemab|"bepranemab will be administered in a predefined dosage.~Pharmaceutical Form: Solution for infusion~Route of Administration: Intravenous"
79374893|NCT04185415|Drug|Placebo|"Pharmaceutical Form: Solution for infusion~Concentration: 0.9% w/v sodium chloride aqueous solution~Route of Administration: Intravenous"
79374894|NCT04151264|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
79374895|NCT04149314|Other|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
79827864|NCT04065932|Drug|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
79233661|NCT02427386|Drug|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
79233662|NCT02427386|Drug|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
79233663|NCT05520827|Drug|BI 1584862|BI 1584862
79233664|NCT05520827|Drug|Placebo|Placebo
79233665|NCT03181802|Drug|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
79374896|NCT04141839|Behavioral|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
79374897|NCT04133376|Other|Electronic hookah vaping with nicotine|Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
79374898|NCT04133376|Other|Electronic hookah vaping without nicotine|Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
79374899|NCT04127214|Other|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
79374900|NCT04121221|Drug|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
79374901|NCT04121221|Other|Placebo|IM injection once every 4 weeks
79374902|NCT04117334|Other|Bracing|
79374903|NCT04116658|Biological|Multiple dose of EO2401|Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
79374904|NCT04102098|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
79374905|NCT04102098|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
79827865|NCT06147674|Device|VQm Pulmonary Health Monitor™|"The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~Pulmonary Blood Flow (PBF)~Shunt Fraction (Qsi)~Dead space (VD):~Functional Residual Capacity (FRC)"
79528790|NCT01402583|Drug|PEG IFN/Ribavirin|PEG IFN/Ribavirin
79528791|NCT01402596|Drug|Midazolam|0,4 mg per kg - intranasal midazolam - once
79528792|NCT01402596|Drug|Chloral Hydrate|50 mg per kg, rectal
79827866|NCT06147648|Drug|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
79827867|NCT06147635|Dietary Supplement|Micro-encapsulated granules of tributyrin (intervention)|Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
79233666|NCT03181802|Drug|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
79233667|NCT04518137|Drug|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
79374906|NCT04083170|Drug|Fludarabine|Given IV
79528793|NCT01402609|Device|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
79528794|NCT01402609|Device|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
79233668|NCT03181178|Dietary Supplement|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
79233669|NCT03181178|Dietary Supplement|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
79233670|NCT03181178|Behavioral|Nutrition education|This intervention provided nutrition education sessions
79233671|NCT04541537|Diagnostic Test|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
79374907|NCT04083170|Drug|Cyclophosphamide|Given IV
79374908|NCT04083170|Drug|Thiotepa|Given IV
79374909|NCT04083170|Radiation|Total-Body Irradiation|Undergo TBI
79374910|NCT04083170|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
79374911|NCT04083170|Biological|Dilanubicel|Given IV
79374912|NCT04056910|Drug|ivosidenib and nivolumab|"Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days."
79374913|NCT04048278|Drug|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
79374914|NCT04048278|Drug|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
79374915|NCT04047368|Procedure|Rotablation|Percutaneous Coronary Intervention using Rotablation
79374916|NCT04047368|Procedure|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
79391037|NCT02426346|Behavioral|Behavioral weight control|Prescription of diet & physical activity and behavioral strategies for weight control
79827868|NCT06147635|Dietary Supplement|Micro-encapsulated granules of sunflower oil (placebo)|Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
80001620|NCT02054624|Behavioral|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
79827869|NCT06147570|Drug|HS-10365 capsules|HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
79233672|NCT04541537|Diagnostic Test|Dog Detection|Analysed by the dogs of Curie Institute at the training centers
79827870|NCT06147557|Procedure|Heat therapy|14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
79374917|NCT04045717|Radiation|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
79827871|NCT06147544|Drug|PB-718|Administered subcutaneously once a week
79827872|NCT06147544|Drug|Placebo|Administered subcutaneously once a week
79827873|NCT06147531|Biological|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
79233673|NCT02420522|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
79374918|NCT04024020|Other|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
79374919|NCT04008121|Combination Product|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
79374920|NCT04008121|Combination Product|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
79233674|NCT02420522|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
79233675|NCT04540757|Procedure|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
79233676|NCT04540757|Procedure|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
79233677|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
79374921|NCT04008121|Combination Product|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
79374922|NCT04008121|Combination Product|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
79374923|NCT04004065|Drug|Vesleteplirsen|Vesleteplirsen injection, for IV use
79374924|NCT04003506|Drug|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
79374925|NCT04003506|Drug|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
79374926|NCT03998501|Behavioral|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
79374927|NCT03980457|Device|Indego Exoskeleton|Powered generated orthosis
79374928|NCT03980457|Other|Standard Rehabilitation|Standard Rehabilitation
79374929|NCT03974711|Other|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
79374930|NCT03965299|Device|VERUM TTNS|"Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
79374931|NCT03965299|Device|SHAM TTNS|"Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
79374932|NCT03964493|Drug|TNP-2092|TNP-2092 100mg/vial
79374933|NCT03964493|Drug|Vancomycin|Vancomycin 1g/vial
79391038|NCT02426346|Behavioral|Group-based physical activity|Teens exercise for 60 minutes with their group
79391039|NCT02426346|Behavioral|Group-based incentives|Adolescents earn reinforcements within group
80001621|NCT02054624|Behavioral|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
80001622|NCT02054624|Behavioral|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
80001623|NCT02054624|Behavioral|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
80001624|NCT01341041|Biological|chlorine dioxide|one time wash with 50ppm CD solution
80001625|NCT01341041|Biological|saline|one time wash with 50-100 cc normal saline
80001626|NCT02053064|Genetic|SAF-301|
80001627|NCT04805021|Other|no intervention|no intervention
80001628|NCT02053142|Drug|Acyclovir|Single dose of acyclovir 200mg was given for pk study
80001629|NCT02053142|Drug|Placebo|
79233678|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
79233679|NCT02427230|Drug|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
79374934|NCT03951909|Behavioral|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
79233680|NCT05478551|Drug|Botulinum Toxin|We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.
79233681|NCT05478551|Drug|Normal saline|Normal saline will serve as the placebo control on the contralateral side of the back.
79374935|NCT03951909|Behavioral|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
79233682|NCT03180788|Procedure|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
79233683|NCT03180788|Procedure|Traditional ESD|Endoscopic submucosa dissection
79233684|NCT02420444|Biological|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
79374936|NCT03939026|Genetic|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
79528795|NCT01402622|Drug|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
79528796|NCT01402635|Device|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
80001630|NCT01316471|Behavioral|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
80001631|NCT01316471|Other|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
79233685|NCT02420444|Biological|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
79528797|NCT01402648|Dietary Supplement|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
79528798|NCT01402648|Dietary Supplement|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
79233686|NCT02420444|Biological|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
79233687|NCT04328909|Device|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
79233688|NCT04328909|Other|Control Group|Usual care - No E-Care app will be provided
79233689|NCT03180866|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
79827874|NCT06147531|Biological|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
79233690|NCT03181022|Behavioral|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
79827875|NCT06147492|Procedure|transanal total mesorectal excision|a transanal bottom-up approach was employed for the TME procedure
79827876|NCT06147492|Procedure|Laparoscopic Total Mesorectal Excision|Laparoscopic Total Mesorectal Excision
80001632|NCT01316549|Drug|Fludarabine|Given as injection
79233691|NCT03181490|Diagnostic Test|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
79233692|NCT03180944|Drug|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
79233693|NCT03180944|Drug|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
79233694|NCT03180944|Drug|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
79233695|NCT03180944|Drug|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
79233696|NCT03180944|Drug|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
79233697|NCT03184064|Dietary Supplement|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
79374937|NCT03939026|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
79374938|NCT03939026|Drug|Fludarabine|Chemotherapy for lymphodepletion
79374939|NCT03939026|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
79374940|NCT03926767|Other|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
79374941|NCT03926767|Other|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
79374942|NCT03926767|Other|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
79528799|NCT01402674|Drug|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
79528800|NCT01402713|Biological|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
79528801|NCT01402713|Biological|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
79528802|NCT01402726|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
79528803|NCT01402739|Other|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
79528804|NCT01402739|Other|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
79528805|NCT01402752|Biological|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
79233698|NCT03184064|Dietary Supplement|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
79374943|NCT03926767|Other|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
79233699|NCT03184064|Dietary Supplement|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
79233700|NCT03184064|Dietary Supplement|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
79827877|NCT06147466|Device|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
79233701|NCT03184064|Dietary Supplement|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
79374944|NCT03925389|Procedure|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
79374945|NCT03915574|Device|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
79374946|NCT03915574|Device|Standard Epidural|Control group - standard epidural (no dural puncture)
79374947|NCT03914196|Diagnostic Test|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
79374948|NCT03912272|Behavioral|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
79374949|NCT03912272|Behavioral|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
79374950|NCT03902912|Drug|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
79684988|NCT03990909|Dietary Supplement|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
79827878|NCT06147453|Device|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
79233702|NCT02420288|Behavioral|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
79233703|NCT03975491|Behavioral|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50-70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
79233704|NCT03975491|Behavioral|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
79233705|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
79391040|NCT02426346|Behavioral|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
79391041|NCT02425878|Drug|Ulipristal Acetate|
79391042|NCT02425878|Drug|Placebo|
79684989|NCT03990909|Dietary Supplement|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
79684990|NCT03990909|Dietary Supplement|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
79684991|NCT01252810|Drug|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
79684992|NCT04206709|Procedure|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
79684993|NCT04206709|Other|passive pedaling|20 minutes passive pedaling by upper limbs.
79684994|NCT00537654|Drug|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
79827879|NCT06147440|Other|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
79827880|NCT06147401|Procedure|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
79827881|NCT06147401|Procedure|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
79827882|NCT06147388|Diagnostic Test|Colposcopy|No surgery, observation
79233706|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
79233707|NCT03180710|Drug|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
79233708|NCT03180710|Drug|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
79233709|NCT04322669|Drug|Pidotimod|Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
79233710|NCT04322669|Drug|Placebo|Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
79374951|NCT03887481|Device|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS & Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
79528806|NCT01402765|Device|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
79684995|NCT00537654|Drug|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
79827883|NCT06147375|Drug|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
79827884|NCT06147362|Drug|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
79528807|NCT01402765|Device|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
80001633|NCT02054780|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
79684996|NCT00537654|Drug|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
79827885|NCT06147349|Procedure|Radical or partial nephrectomy|Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
79233711|NCT03180476|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
79528808|NCT01402791|Other|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
79528809|NCT01402830|Other|Visual analogue scales (EVAs)|This scale measures the pain intensity.
79528810|NCT01402843|Drug|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
79684997|NCT00537654|Drug|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
79684998|NCT04397692|Device|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
79233712|NCT03180632|Drug|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
79233713|NCT03180632|Other|Placebo|Patient receive one of two tablet of Placebo according to body weight
79233714|NCT03943277|Other|No intervention, observational study|No intervention observational study
79233715|NCT04483232|Biological|Ear canal swab|Ear canal swab
79233716|NCT04295057|Other|Non-intervention|Non-intervention
79233717|NCT02420132|Other|Ranibizumab|Ranibizumab administered as part of standard-of-care
79233718|NCT03183752|Drug|Metformin|500 mg metformin three times daily
79233719|NCT03183752|Drug|Placebo|500 mg placebo three times daily
79233720|NCT02420054|Behavioral|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
79233721|NCT02420054|Other|Time control|Time control period with no change in eating habits.
79233722|NCT04287179|Drug|Semaglutide|Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
79233723|NCT03183674|Drug|Oxytocin|Single dose oxytocin 45 minutes before the test
79233724|NCT03183674|Other|placebo|saline solution 0,9% spray nasal
79374952|NCT03887481|Device|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
79374953|NCT03879096|Other|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
79528811|NCT01402856|Other|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long & utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, & interactive games simulating distracted driving.
79528812|NCT01402882|Drug|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
79528813|NCT01402895|Other|Exercise|Transversus abdominus exercise
79528814|NCT01402895|Other|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
79528815|NCT01402921|Device|V0322 BC|"Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~3 months duration daily treatment"
79684999|NCT01252186|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
79827886|NCT06147297|Behavioral|Tuned In|The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
79827887|NCT06147271|Drug|SGLT2i|A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
79827888|NCT06147232|Drug|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
79233725|NCT03117530|Drug|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
79233726|NCT03180320|Behavioral|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~Baduanjin exercise;~evaluations of exercise capacity and clinical conditions;~consultations on exercise prescription and management of symptoms/signs during exercise;~education covering topics related to the CHF and exercise; and~a series of adherence strategies."
79233727|NCT03180320|Drug|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
79233728|NCT03889925|Drug|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
79528816|NCT01402934|Procedure|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
79685000|NCT01252186|Drug|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
79233729|NCT03889925|Biological|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
79233730|NCT05103254|Drug|Bempedoic Acid|Bempedoic Acid 180 MG
79233731|NCT05103254|Drug|Bempedoic Acid / Ezetimibe|Bempedoic Acid 180 MG / Ezetimibe 10 MG
79374954|NCT03877744|Behavioral|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
79374955|NCT03877744|Behavioral|live technician|parents will install car seat through guidance from a live certified technician who is present
79374956|NCT03864406|Drug|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
79374957|NCT03864406|Drug|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
79374958|NCT03864406|Drug|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
79685001|NCT01252186|Drug|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
79685002|NCT03988335|Drug|RIST4721|RIST4721 oral solution
79685003|NCT03988335|Drug|Placebo|Placebo oral solution
79685004|NCT00537693|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
79685005|NCT04320316|Drug|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
80001634|NCT02054780|Behavioral|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
79233732|NCT02426840|Dietary Supplement|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
79233733|NCT02426840|Dietary Supplement|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
79233734|NCT02427074|Procedure|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
79685006|NCT01731782|Drug|bupivacaine|
79233735|NCT02427074|Procedure|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
79233736|NCT03178526|Drug|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
79685007|NCT01731782|Drug|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
79233737|NCT03178526|Drug|Placebo|placebo gel
79685008|NCT02889211|Behavioral|Gambling Task|
79685009|NCT01251952|Drug|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
79233738|NCT02426996|Procedure|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
79233739|NCT02423486|Device|Electromagnetic stimulation therapy (BIOCON-2000)|
79233740|NCT02423486|Device|Electromagnetic stimulation therapy with biofeedback|
79233741|NCT04256369|Combination Product|Parenteral Nutrition (PN) Premixed Olimel N9E|Parenteral nutrition
79233742|NCT02423564|Dietary Supplement|Digesta Lac|
79233743|NCT02423564|Other|Placebo|
79233744|NCT03180164|Other|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
79374959|NCT03853122|Other|Best current practice exercise programme|"Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy).~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads"
79374960|NCT03853122|Other|Experimental exercise programme|Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
79685010|NCT04356430|Drug|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
79685011|NCT04356430|Drug|Prednisone|5 mg oral low dose prednisone, once daily
79685012|NCT04356430|Drug|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
79685013|NCT01352195|Behavioral|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
79685014|NCT04321135|Behavioral|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
79685015|NCT04321135|Behavioral|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
79685016|NCT04320238|Drug|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
79685017|NCT04320238|Drug|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
79685018|NCT04320121|Dietary Supplement|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
79528817|NCT01402960|Device|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
79528818|NCT01402973|Other|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
79685019|NCT04320121|Dietary Supplement|Placebo group|Placebo 2,000 mg/day for 12 weeks
79827889|NCT06147232|Drug|Placebo|Placebo tablet
79233745|NCT02423642|Procedure|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
79233746|NCT02423642|Procedure|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
79827890|NCT06147219|Procedure|interlocking intramedullary tibial nail|primary dynamization versus standard interlocking intramedullary tibial nail
79827891|NCT06147141|Behavioral|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
79827892|NCT06147141|Behavioral|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
79827893|NCT06147115|Other|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
79374961|NCT03846804|Diagnostic Test|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
79827894|NCT06147089|Behavioral|Sleep Intervention|Participants in the sleep intervention receive advice on: sleep hygiene/environment, sleep timing, naps, and exposure to light. These advices will be tailored to the personal situation of the participant, as measured during the run-in period.
79827895|NCT06147089|Behavioral|Nutritional intervention|Participants in the nutritional intervention receive personalised advice on the distribution of calories and nutrients over 24 hrs, and on specific food products based on the outcomes of the continuous glucose measurements (CGM) during the run-in period. The guidelines will include room for personal dietary preferences.
79374962|NCT03832686|Other|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
79233747|NCT03180242|Biological|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
79528819|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
79528820|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
79528821|NCT01402999|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
79685020|NCT04320004|Behavioral|Education|Subject receives education
79233748|NCT03180242|Biological|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
79233749|NCT03180242|Biological|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
79233750|NCT00709904|Drug|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
79233751|NCT00709904|Drug|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
79685021|NCT04320004|Behavioral|Education with Reminder|Subject receives education with reminder
79685022|NCT04320004|Behavioral|Education + Disposal Bag|Subject receives education and disposal bag
79685023|NCT04320004|Behavioral|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
79685024|NCT01229072|Biological|Heparin sodic|Heparin sodic 150UI/kg
79685025|NCT01229072|Biological|heparin liquemine|Heparin sodic 150UI/kg
79827896|NCT06147050|Drug|Metformin|Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.
79827897|NCT06147050|Other|Placebo|Patients will receive matching placebo control twice daily.
79233752|NCT00709904|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
79233753|NCT02426606|Other|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~white rice or white rice combined with 1 of 3 different lentil varieties or~white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
79233754|NCT03183596|Drug|Bupivacaine|20-60cc of 0.25% Bupivacaine
79233755|NCT03183596|Drug|Dexamethasone|2-4mg of Dexamethasone
79233756|NCT03178214|Drug|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
79233757|NCT03626051|Device|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
79233758|NCT03626051|Device|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
79233759|NCT03183362|Device|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
79233760|NCT03183362|Device|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
79233761|NCT03117062|Other|occlusal reduction|relief of occlusion following endodontic treatment
79233762|NCT02704130|Device|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
79374963|NCT03826199|Drug|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
79374964|NCT03826199|Behavioral|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
79374965|NCT03823534|Drug|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
79685026|NCT04685733|Device|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
79685027|NCT01228643|Biological|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
79374966|NCT03823534|Drug|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
79233763|NCT02704130|Procedure|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
79233764|NCT03180008|Behavioral|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
79374967|NCT03823534|Drug|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
79374968|NCT03823534|Drug|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
79374969|NCT03823534|Drug|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
79685028|NCT01228643|Device|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
79685029|NCT04685460|Other|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
79685030|NCT01199978|Radiation|Fractionated proton radiation|Given daily for approximately 5.5 weeks
79685031|NCT01199978|Drug|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
79685032|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
79685033|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
79685034|NCT04283513|Drug|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
79827898|NCT06147024|Other|historical control|Received a conventional preoperative assessment
79827899|NCT06147024|Other|3D printed lesion model|Received 3D printed lesion models for preoperative planning
80001635|NCT01316627|Behavioral|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
79685035|NCT01251367|Biological|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
79685036|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
79685037|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
79685038|NCT04685148|Drug|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
79827900|NCT06146998|Other|3D health education model|explanation combined with 3D health education model
79233765|NCT03180008|Behavioral|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
79233766|NCT03594305|Behavioral|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
79827901|NCT06146998|Other|Verbal explanation|Regular explanation
79827902|NCT06146972|Drug|Iguratimod|Iguratimod 25mg bid + tofacitinib 5mg bid
79827903|NCT06146933|Diagnostic Test|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
79827904|NCT06146933|Diagnostic Test|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
79233767|NCT02426762|Procedure|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~4-5 trocar-produced incisions (5/10mm, minor incision)~1 sample-retrieval incision (4-5cm, small incision)"
79528822|NCT01403012|Other|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
79528823|NCT01403025|Drug|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
79528824|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 1 for 84 days
79528825|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 2 for 84 days
79528826|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 3 for 84 days
79528827|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
79827905|NCT06146920|Other|Evaluation of ctDNA using the F1T after 1 year of immunotherapy|"Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study."
79233768|NCT02426762|Device|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
79233769|NCT04325243|Drug|Sildenafil 50 mg|50 mg oral Sildenafil tablet
79233770|NCT04325243|Drug|Placebo oral tablet|placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
79374970|NCT03823534|Drug|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
79374971|NCT03823534|Drug|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
79374972|NCT03807440|Drug|Empagliflozin|Empagliflozin
79374973|NCT03807440|Drug|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
79374974|NCT03807440|Drug|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
79374975|NCT03807440|Drug|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
79528828|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 5 for 84 days
79528829|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 6 for 84 days
79528830|NCT01403038|Drug|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
79528831|NCT01403077|Device|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
79685039|NCT04685148|Drug|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
79685040|NCT04258358|Other|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
79685041|NCT02888548|Procedure|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
79685042|NCT02888548|Procedure|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
79827906|NCT06146907|Other|cognitive motor dual task exercises|exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
79827907|NCT06146907|Other|exergaming|Nintendo switch games that involve physical activity by participants to complete
79827908|NCT06146881|Drug|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
79827909|NCT06146881|Drug|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
79827910|NCT06146842|Drug|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
79827911|NCT06146829|Other|no intervention|no intervention
79233771|NCT03179774|Device|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
79233772|NCT02419586|Other|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
79233773|NCT02419820|Drug|APD791|Temanogrel
79233774|NCT02419820|Drug|Clopidogrel|Clopidogrel
79827912|NCT06146751|Drug|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
79233775|NCT02419820|Drug|Aspirin|Aspirin
79233776|NCT02419820|Drug|Placebo for APD791|Placebo for APD791
79233777|NCT05464511|Other|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
79233778|NCT03179852|Behavioral|nutrition education|nutrition education
79374976|NCT03799874|Drug|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
79374977|NCT03799874|Other|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
79827913|NCT06146738|Behavioral|Palliative Care|Best supportive care without surgical intervention
79827914|NCT06146738|Procedure|Tumor biopsy|Tumor biopsy
79827915|NCT06146738|Procedure|Tumor resection|Maximal safe resection of the tumor
79827916|NCT06146725|Procedure|Tumor resection|Maximal safe resection of the tumor
79827917|NCT06146725|Procedure|Tumor biopsy|Biopsy of the tumor
79827918|NCT06146712|Other|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
79827919|NCT06146660|Drug|Mavacamten|According to approved product label
79374978|NCT03796884|Drug|Linaclotide|Given PO
79374979|NCT03796884|Other|Placebo|Given PO
79685043|NCT03888222|Drug|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
79827920|NCT06146569|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
79827921|NCT06146569|Device|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
79827922|NCT06146556|Procedure|catheter based ablation|electrophysiological catheter based ablation of ventricular arrhythmia
79827923|NCT06146543|Other|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
79827924|NCT06146517|Other|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
79685044|NCT03888222|Drug|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
79827925|NCT06146517|Other|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
79827926|NCT06146517|Other|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
79827927|NCT06146491|Drug|Oral tablet and transdermal patch|oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
79827928|NCT06146478|Drug|Thalidomide|Thalidomide given at an average dose of 1.5mg/kg/day
79827929|NCT06146426|Dietary Supplement|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
80001636|NCT01316627|Behavioral|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
79374980|NCT03783403|Drug|CC-95251|Specified dose on specified days
80001637|NCT03439657|Biological|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
79528832|NCT01403103|Dietary Supplement|cholecalciferol|Given PO
80001638|NCT03439657|Biological|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
80001639|NCT02053220|Biological|Colo-Ad1|Oncolytic virus
80001640|NCT02056028|Procedure|Hepatic resection|
79374981|NCT03783403|Drug|Rituximab|Specified dose on specified days
79374982|NCT03783403|Drug|Cetuximab|Specified dose on specified days
79374983|NCT03774849|Device|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
79374984|NCT03774849|Device|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
79374985|NCT03774849|Device|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
79528833|NCT01403103|Procedure|biopsy|Correlative studies
79528834|NCT01403103|Genetic|protein expression analysis|Correlative studies
79528835|NCT01403103|Other|enzyme-linked immunosorbent assay|Correlative studies
79528836|NCT01403103|Other|laboratory biomarker analysis|Correlative studies
79685045|NCT01250509|Behavioral|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
79827930|NCT06146387|Dietary Supplement|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
79374986|NCT03770338|Drug|Teriparatide|20ug dosage daily injection, 1-month preoperative
79528837|NCT01403103|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
79528838|NCT01403129|Procedure|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
79528839|NCT01403129|Procedure|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
79685046|NCT04239638|Diagnostic Test|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
79685047|NCT03883893|Drug|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
79827931|NCT06146387|Dietary Supplement|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
79374987|NCT03767231|Diagnostic Test|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
79374988|NCT03761706|Behavioral|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
79528840|NCT01403155|Biological|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
79528841|NCT01403168|Other|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
79528842|NCT01403168|Other|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
79685048|NCT03883893|Other|Normal saline|Normal saline will given if randomized to this group.
80001641|NCT01341743|Drug|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
80001642|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
80001643|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
79685049|NCT04319575|Drug|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
79685050|NCT00537732|Drug|omeprazole|20 mg daily
79827932|NCT06146387|Dietary Supplement|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
79685051|NCT00537732|Drug|omeprazole|20 vs. 60 mg daily, genotype dependent
79685052|NCT04180436|Drug|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
79685053|NCT00537927|Procedure|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
79528843|NCT01403181|Drug|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
79685054|NCT01250119|Drug|erlotinib [Tarceva]|150 mg daily, orally
79685055|NCT04682444|Drug|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
80001644|NCT02054858|Procedure|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
79685056|NCT04682444|Drug|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
79827933|NCT06146361|Behavioral|COVID-19 Group Problem Solving|"This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods."
80001645|NCT01341197|Other|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
80001646|NCT01341275|Biological|hepatitis B vaccine|10 ug dose, one-time administration
80001647|NCT01341275|Biological|hepatitis B vaccine|20 ug dose, one-time administration
80001648|NCT02852161|Device|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
80001649|NCT01353937|Drug|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
80001650|NCT04720001|Drug|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
80001651|NCT04720001|Device|PET|PET Scan for brain imaging
80001652|NCT02878213|Device|D700 System|Atrial Fibrillation Ablation Procedure
80001653|NCT04705883|Drug|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
79528844|NCT01403207|Other|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
79528845|NCT01403220|Procedure|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
79685057|NCT04320277|Drug|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
79685058|NCT05300529|Other|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
80001654|NCT04677491|Drug|Ospemifene 60 mg|Ospemifene vs placebo
80001655|NCT04677491|Behavioral|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
79685059|NCT05300529|Other|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
80001656|NCT02053298|Drug|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
80001657|NCT04653545|Diagnostic Test|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
79685060|NCT04163549|Behavioral|Safe at Home|Discussion-based intervention
79685061|NCT01250002|Drug|Placebo|Placebo will receive the same volume of saline infusion.
80001658|NCT02054936|Drug|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
79374989|NCT03761706|Other|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
80001659|NCT02054936|Drug|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
79233779|NCT02419430|Behavioral|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
79374990|NCT03746522|Drug|Setmelanotide|SC injection of setmelanotide
79685062|NCT01250002|Drug|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
80001660|NCT02802878|Device|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
80001661|NCT02802878|Device|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
80001662|NCT04782791|Drug|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA<1.25 m2, 40mg; 1.25<BSA<1.50 m2, 50mg; BSA>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
80001663|NCT04782791|Drug|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
80001664|NCT04782791|Procedure|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
79685063|NCT05491876|Other|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
79233780|NCT02419430|Behavioral|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~Joys of Life~Count your blessings~Think differenc, feel better~Exercising --> Happier~+ Exercising --> Sleep~Pre-Sleep routine~Eat that frog~Mindful Meditation"
79374991|NCT03746522|Drug|Placebo|SC injection of placebo
79374992|NCT03715712|Other|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure > 65mmHg and a systolic blood pressure of < 160mmHg using norepinephrine continuous infusion
79374993|NCT03715712|Other|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
79685064|NCT05491876|Other|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
79528846|NCT01403220|Procedure|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
79528847|NCT01403233|Dietary Supplement|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
79528848|NCT01403233|Dietary Supplement|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
79374994|NCT03710161|Drug|Vitamin D|Vitamin D taken in two different dosages daily for six months.
79528849|NCT01403233|Dietary Supplement|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
79528850|NCT01403259|Drug|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
79528851|NCT01403272|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
79528852|NCT01403285|Drug|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
79233781|NCT02419430|Behavioral|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
79233782|NCT05692739|Drug|Insulin|see arm description
79528853|NCT01403285|Biological|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
79685065|NCT04157153|Device|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
79685066|NCT04119596|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
79233783|NCT05692739|Drug|Cyclosporins|see arm description
80001665|NCT04773197|Behavioral|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
79233784|NCT05692739|Drug|Artificial tears|see arm description
79233785|NCT03116984|Procedure|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
79233786|NCT03116984|Radiation|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
79233787|NCT02426528|Other|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
80001666|NCT04773197|Behavioral|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
80001667|NCT04773197|Behavioral|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
79685067|NCT04119596|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
80001668|NCT01341353|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
79827934|NCT06146361|Behavioral|Standard of Care|This group will receive a COVID-19 prevention flyer and social resources list only
80001669|NCT01341353|Drug|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
79685068|NCT04107389|Behavioral|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
79685069|NCT04107389|Behavioral|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
79827935|NCT06146361|Behavioral|Booster session|"Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention."
79233788|NCT03380351|Behavioral|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
79827937|NCT06146322|Other|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
80001670|NCT02056106|Drug|antidepressant therapy|
80001671|NCT05183087|Diagnostic Test|3T Connectome MRI|MRI scan of structural connectivity
80001672|NCT05183087|Diagnostic Test|7 Tesla MRI|MRI scan of functional connectivity
79233789|NCT03380351|Behavioral|SCDIC control groups|The research team will characterize the control settings, including patients, providers and organization.
79233790|NCT02419352|Drug|Sugammadex|
79374995|NCT03709667|Behavioral|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
79528854|NCT01403285|Biological|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
79233791|NCT02419352|Drug|Neostigmine/atropine|
79233792|NCT02423720|Behavioral|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
79528855|NCT01403285|Drug|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
79528856|NCT01403298|Behavioral|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
80001673|NCT05183087|Diagnostic Test|TSPO PET|PET scan of neuroinflammation
80001674|NCT05183087|Diagnostic Test|Tau PET|PET scan of tau deposition
80001675|NCT05183087|Diagnostic Test|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
80001676|NCT05183087|Diagnostic Test|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
80001677|NCT02056184|Drug|Adalimumab|
80001678|NCT01341431|Drug|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
79233793|NCT03365687|Dietary Supplement|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
79233794|NCT03365687|Dietary Supplement|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
79233795|NCT02419118|Drug|Daratumumab|Treatment of myeloma patients with Daratumumab
79233796|NCT02419118|Drug|Lenalidomide|Treatment of myeloma patients
79233797|NCT02419118|Drug|Dexamethasone|Treatment of myeloma patients
79233798|NCT05515289|Drug|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
79374996|NCT03709667|Behavioral|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
79374997|NCT03709277|Behavioral|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
79528857|NCT01403298|Other|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
79528858|NCT01403311|Drug|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
79528859|NCT01403324|Drug|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
79528860|NCT01403337|Other|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
79528861|NCT01403337|Other|Control|A Blood Pressure cuff inflated to 40-50 mmHg
79528862|NCT01403363|Drug|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
79528863|NCT01403389|Drug|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
79528864|NCT01403389|Drug|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
79528865|NCT01403415|Drug|Dexamethasone|Given PO or IV
79528866|NCT01403415|Other|Laboratory Biomarker Analysis|Correlative studies
79528867|NCT01403415|Drug|Methotrexate|Given IT
80001679|NCT02056262|Other|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
80001680|NCT02056262|Biological|Saliva sampling|A saliva sample will be harvested.
79233799|NCT02426294|Drug|Pioglitazone|
79233800|NCT02426294|Drug|Glimepiride|
79233801|NCT05692661|Radiation|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels [10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx ].
79233802|NCT02426450|Procedure|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
79374998|NCT03692494|Other|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
80001681|NCT02056262|Biological|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
80001682|NCT02801396|Device|Etafilcon A Design 1 (Test 1)|
80001683|NCT02801396|Device|Etafilcon A Design 2 (Test 2)|
80001684|NCT02801396|Device|Etafilcon A (Control)|
80001685|NCT02800928|Drug|CERC-501|CERC-501
80001686|NCT02800928|Drug|Placebo|Placebo
80001687|NCT02056418|Dietary Supplement|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
80001688|NCT02056418|Drug|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
80001689|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
80001690|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
80001691|NCT02056574|Drug|NA-1|
80001692|NCT02056574|Drug|Placebo|
79528868|NCT01403415|Drug|Mitoxantrone Hydrochloride|Given IV
80001693|NCT02058680|Biological|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
80001694|NCT02058758|Device|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
79233803|NCT02426450|Drug|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
79528869|NCT01403415|Drug|Pegaspargase|Given IV
79528870|NCT01403415|Other|Pharmacological Study|Correlative studies
79528871|NCT01403415|Drug|Temsirolimus|Given IV
80001695|NCT02058914|Dietary Supplement|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
80001696|NCT02058914|Dietary Supplement|High Glucose sweetened beverage|HG-sweetened beverage
80001697|NCT02055014|Drug|Liraglutide|
80001698|NCT02055014|Device|Duodenal-jejunal bypass liner - Endobarrier device|
80001699|NCT03148691|Drug|A-101|Topical Solution
79233804|NCT02426450|Drug|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
79233805|NCT02423330|Device|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
79528872|NCT01403415|Drug|Vincristine Sulfate|Given IV
79685070|NCT05329116|Drug|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
79685071|NCT05329116|Biological|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
79685072|NCT04107116|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
79685073|NCT04107116|Other|Usual Care|Usual care as provided by local oncologists
79685074|NCT04105595|Device|Septal defect closure|Device closure of atrial septal defect
79685075|NCT04069637|Combination Product|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
79685076|NCT00537849|Device|Sonablate 500(SB-500)|
79685077|NCT03995771|Other|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
79685078|NCT00537888|Drug|fluconazole|Intravenous or oral 400 md/d
79685079|NCT05307510|Device|Prefabricated splint|Subjects will be provided either a prefabricated splint
79685080|NCT05307510|Device|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
79827938|NCT06146322|Other|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, ~4 g β-glucan
79233806|NCT02419196|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
79233807|NCT02426372|Biological|QBECO SSI|QBECO Site Specific Immunomodulators
79233808|NCT02426060|Drug|Imrecoxib|
79233809|NCT02426060|Drug|Warfarin|
79233810|NCT03761069|Drug|PTC299|PTC299 will be administered per the treatment arm description
79233811|NCT02423174|Procedure|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
79233812|NCT02423174|Device|FMwand Surgical System|
79528873|NCT01403428|Other|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
79528874|NCT01403454|Behavioral|Interactive Health Communication Application|web-based application
79528875|NCT01403467|Device|Continuous positive airway pressure|CPAP 8 cmH2O
80001700|NCT02059226|Behavioral|cognitive behavioural therapy|Internet-based CBT
80001701|NCT02059226|Other|Internet-based resource page|Static webpage
80001702|NCT02059304|Device|Measurement of cervical length with embryo transfer catheter|
80001703|NCT03148067|Procedure|Intramedullary nailing for fracture fixation|
80001704|NCT02059382|Behavioral|ChiRunning training|
79528876|NCT01403493|Behavioral|Patient education|
79528877|NCT01403506|Drug|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
80001705|NCT02059382|Behavioral|unblinded accelerometer|
80001706|NCT02059382|Behavioral|participation in online social network|
80001707|NCT02059382|Behavioral|participation in study website|
80001708|NCT02059382|Behavioral|Technology support for behavior change|
80001709|NCT02055170|Drug|finasteride 5mg oral daily|
80001710|NCT04552925|Other|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
80001711|NCT02055326|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
80001712|NCT02055326|Behavioral|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
80001713|NCT02055326|Behavioral|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
80001714|NCT03561116|Dietary Supplement|XAN|Daily intake of a sachet containing 12 mg of XAN
79374999|NCT03692494|Other|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
79528878|NCT01403532|Drug|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
79233813|NCT02423252|Behavioral|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
79233814|NCT02423252|Other|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
79233815|NCT05692583|Diagnostic Test|ultrasound examination of wrist|musculoskeletal ultrasound examination of affected wrist
79375000|NCT03689049|Procedure|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
79375001|NCT03689049|Procedure|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
79528879|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
79375002|NCT03682536|Drug|Luspatercept|Specified dose on specified days
79528880|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
79528881|NCT01403545|Drug|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
79528882|NCT01403545|Other|Placebo|5% glucose infusion over 120 minutes
79528883|NCT01403558|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
79528884|NCT01403571|Dietary Supplement|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
79528885|NCT01403571|Dietary Supplement|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
79528886|NCT01403597|Device|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
79685081|NCT05264142|Drug|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
79685082|NCT05264142|Drug|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
79685083|NCT05264142|Drug|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
79685084|NCT01246960|Biological|Ramucirumab|Administered intravenously
79685085|NCT01246960|Drug|Placebo|Administered intravenously
79685086|NCT01246960|Drug|Oxaliplatin|Administered intravenously
79685087|NCT01246960|Drug|Leucovorin|Administered intravenously
79685088|NCT01246960|Drug|5-Fluorouracil|Administered intravenously
79685089|NCT03870269|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
79685090|NCT00544986|Drug|Anastrozole|
80001715|NCT03561116|Dietary Supplement|Placebo|Daily intake of a sachet containing excipient
80001716|NCT04490993|Drug|APL-1202 in combination with Epirubicin|"Induction period: APL-1202 is administered for 12 consecutive weeks~Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
80001717|NCT04490993|Drug|Placebo in combination with Epirubicin|"Induction period: placebo is administered for 12 consecutive weeks~Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
80001718|NCT02055482|Drug|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
80001719|NCT02055482|Biological|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
79685091|NCT01244620|Drug|sitaxentan|sitaxsentan 100 mg QD for 6 days
79528887|NCT01403623|Procedure|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
79827939|NCT06146322|Other|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, ~5 g β-glucan
79375003|NCT03682536|Drug|Epoetin alfa|Specified dose on specified days
79827940|NCT06146322|Other|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, ~6 g β-glucan
79528888|NCT01403623|Procedure|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
79827941|NCT06146322|Other|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
79827942|NCT06146322|Other|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, ~4 g β-glucan
79827943|NCT06146322|Other|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, ~5 g β-glucan
80001720|NCT04465565|Procedure|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
79233816|NCT04051697|Behavioral|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
79233817|NCT02425982|Procedure|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
79528889|NCT01403649|Behavioral|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
79528890|NCT01403649|Other|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
79528891|NCT01403662|Drug|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
79685092|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
79827944|NCT06146322|Other|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, ~6 g β-glucan
79827945|NCT06146309|Drug|aflibercept (2mg/0.05ml)|Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
79827946|NCT06146296|Biological|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
79827947|NCT06146296|Biological|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
80001721|NCT04395755|Behavioral|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
80001722|NCT04395755|Behavioral|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
80001723|NCT04743947|Other|No intervention; observational study|no intervention
80001724|NCT02059460|Drug|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
80001725|NCT02059460|Drug|placebo|
79375004|NCT03670316|Drug|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
79685093|NCT01244620|Drug|sitaxsentan|sitaxsentan 100 mg QD for 6 days
79685094|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
79685095|NCT01244620|Drug|sitaxsentan|sitaxentan 100 mg QD for 6 days
79685096|NCT01244620|Drug|sildenafil|sildenafil 20 mg TID for 6 days
80001726|NCT02055716|Drug|Sulforadex|
80001727|NCT02055716|Drug|alpha-cyclodextrin|
79233818|NCT02425982|Procedure|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
79233819|NCT03749135|Drug|Dupilumab|anti-IL4-Receptor alpha
79375005|NCT03670316|Other|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
79528892|NCT01403675|Procedure|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
79375006|NCT03596801|Biological|RSV 6120/∆NS1|Delivered as nose drops
79685097|NCT04682717|Device|perfusion index monitoring for postinduction hypotension|Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to <30% of baseline or absolute MAP <60 mmHg. MAP <55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR <50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
79827948|NCT06146283|Combination Product|Jamar Hydraulic Hand Dynamometer|"This device measures hand grip strength. The individual should be in an upright sitting position. There should be no arm support on the sitting surface. ...~The knee angle should be 90 degrees. Elbow angle should be 90 degrees. The wrist should be held without deviation. The measurement should be performed 3 times with an interval of 10 seconds."
80001728|NCT04739735|Procedure|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
79685098|NCT04319692|Dietary Supplement|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks
79233820|NCT03749135|Drug|Placebo|Placebo
79233821|NCT02418962|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
79375007|NCT03596801|Biological|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
79375008|NCT03596801|Biological|Placebo|Delivered as nose drops
79375009|NCT03570892|Drug|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
79375010|NCT03570892|Drug|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
79375011|NCT03498378|Drug|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
79685099|NCT04319692|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks.
79685100|NCT05238480|Device|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
79685101|NCT05238480|Device|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
79375012|NCT03498378|Drug|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
79685102|NCT04682327|Other|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
79685103|NCT04682327|Other|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
79685104|NCT02889640|Other|SAGA Innovations|An intensive math tutoring program
79375013|NCT03498378|Drug|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
79375014|NCT03493165|Drug|Everolimus|mTOR inhibitor
79685105|NCT02889640|Other|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
79827949|NCT06146244|Procedure|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
80001729|NCT02059538|Other|Adipose tissue biopsies (omental and subcutaneous) liver|
80001730|NCT02059538|Radiation|CT-scan|
79233822|NCT02418962|Other|Normal Saline|0.9% Sodium chloride solution for injection
79233823|NCT02422784|Dietary Supplement|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
79233824|NCT02422784|Dietary Supplement|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
80001731|NCT02059538|Other|Stools sampling|
80001732|NCT02059538|Other|DNA sampling|
79233825|NCT02422784|Dietary Supplement|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
79375015|NCT03478956|Drug|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
79375016|NCT03477110|Drug|Temozolomide|Given PO
79375017|NCT03477110|Radiation|Radiation Therapy|Undergo radiation therapy
79375018|NCT03477110|Device|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
79375019|NCT03477110|Procedure|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
79375020|NCT03475043|Behavioral|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
80001733|NCT02059538|Other|Blood sampling|
80001734|NCT02059538|Other|Urine sampling|
79233826|NCT03740009|Drug|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
79233827|NCT02418806|Behavioral|Psychotherapy groups|
79375021|NCT03467113|Drug|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
79375022|NCT03467113|Drug|Cannabidiol|Cannabidiol
79375023|NCT03415828|Device|Ethanol gel|Intradiscal injection of ethanol gel
79375024|NCT03415828|Drug|Prednisolone acetate|Intradiscal infiltration of steroids
79375025|NCT03356886|Procedure|Spinal Manipulative Technique|1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
79375026|NCT03356886|Behavioral|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
79375027|NCT03347110|Drug|Bimekizumab|Bimekizumab at a prespecified dose.
79375028|NCT03343236|Radiation|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
79375029|NCT03332303|Drug|Estrace® Cream|Estrace® Cream
79375030|NCT03332303|Drug|Estradiol Vaginal Cream|Estradiol Vaginal Cream
79375031|NCT03332303|Drug|Vehicle Cream|Vehicle Cream
79375032|NCT03306615|Drug|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
79375033|NCT03306615|Drug|Placebo|0.9% Sodium Chloride Injection
79685106|NCT02889640|Other|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
79685107|NCT00545142|Drug|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
79233828|NCT02418806|Behavioral|Self-help groups|
79233829|NCT03183440|Dietary Supplement|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
79233830|NCT03183440|Other|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
79233831|NCT05692505|Diagnostic Test|QuadQuik|Invitro diagnostic device
79233832|NCT02425670|Other|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
79233833|NCT03710525|Other|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
79375034|NCT03283878|Drug|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
79375035|NCT03278730|Drug|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
79375036|NCT03278730|Drug|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
79375037|NCT03277729|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
79375038|NCT03277729|Drug|Cyclophosphamide|Given IV
79375039|NCT03277729|Other|Laboratory Biomarker Analysis|Correlative studies
79375040|NCT03277729|Procedure|Leukapheresis|Undergo leukapheresis
79375041|NCT03277729|Drug|Fludarabine Phosphate|Given IV
79375042|NCT03261505|Device|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
79685108|NCT00545142|Drug|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
80001735|NCT02059538|Radiation|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
80001736|NCT01341899|Procedure|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
80001737|NCT02059616|Drug|Amlodipine 5mg|Daily oral administration for 8 weeks
80001738|NCT02059616|Drug|Amlodipine 10mg|Daily oral administration for 8 weeks
80001739|NCT02059616|Drug|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
80001740|NCT02059616|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
79233834|NCT03710525|Other|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
80001741|NCT04724681|Device|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
80001742|NCT02055794|Procedure|Suturing of the perineal skin|
79233835|NCT05692427|Device|Cryopen - Cryotherapy|Cryotherapy with N20
79375043|NCT03240965|Diagnostic Test|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
79375044|NCT03240965|Other|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
79375045|NCT03240965|Diagnostic Test|Taste-/smell-test|Taste-/smell-test
79827950|NCT06146244|Device|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
79827951|NCT06146205|Procedure|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
79827952|NCT06146205|Procedure|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
79827953|NCT06146192|Drug|Colchicine|colchicine 1-2 mg/day
79827954|NCT06146166|Dietary Supplement|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
80001743|NCT02055794|Procedure|Closing perineal skin with surgical glue|
79528893|NCT01403688|Procedure|RPFNA|"Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
79685109|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
80001744|NCT02055794|Procedure|No suturing of the perineal skin|
79375046|NCT03240965|Diagnostic Test|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
79685110|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
80001745|NCT02059694|Drug|Hyaluronidase|
80001746|NCT02059694|Other|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
79233836|NCT03183206|Procedure|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
79233837|NCT03183206|Biological|γδ T cells|γδ T cells will be used against
79233838|NCT03183206|Other|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
79233839|NCT05692349|Device|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
79233840|NCT03179696|Behavioral|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
79233841|NCT03179618|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
79233842|NCT03179618|Drug|Lipid Regulating Drugs|Mainly including statins
79233843|NCT03179618|Drug|Coronary Vasodilator|Mainly including nitrates
79233844|NCT03179618|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
79233845|NCT03182894|Drug|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
79375047|NCT03206801|Procedure|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
79375048|NCT03093909|Drug|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
79528894|NCT01403701|Behavioral|Physical therapy|pelvic floor physical therapy
79528895|NCT01403714|Procedure|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
79685111|NCT01267201|Drug|methylprednisolone|tablet 32 mg single dose
79685112|NCT04323514|Dietary Supplement|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
79685113|NCT00545220|Behavioral|problem-solving training|
79685114|NCT00545220|Behavioral|sham intervention|
79685115|NCT03755492|Other|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
79685116|NCT05175573|Device|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
79685117|NCT05175573|Device|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
79685118|NCT03736616|Drug|Carboplatin|Chemotherapy
79685119|NCT03736616|Drug|Ifosfamide|Chemotherapy
79827955|NCT06146166|Dietary Supplement|Oral placebo supplement|Oral placebo supplement taken once daily
79827956|NCT06146140|Dietary Supplement|Oral herbal supplement|Take one capsule daily
79827957|NCT06146140|Dietary Supplement|Oral placebo supplement|Take one capsule daily
80001747|NCT02055872|Drug|Intravenous albumin|
80001748|NCT02055872|Drug|Normal saline|
80001749|NCT03146741|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
79233846|NCT03649217|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
79685120|NCT03736616|Drug|Etoposide|Chemotherapy
79233847|NCT02418650|Drug|ODM-201 300 mg tablet|
79233848|NCT02418650|Drug|intravenous14C-ODM-201|
79375049|NCT03089320|Behavioral|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
79375050|NCT03089320|Behavioral|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
79375051|NCT03089320|Behavioral|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
79528896|NCT01403740|Drug|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
79685121|NCT03736616|Biological|Rituximab|Anti-CD20 mAb
79685122|NCT03736616|Drug|Carmustine|Chemotherapy
79827958|NCT06146127|Other|phenotyping|Large scale molecular phenotyping
79233849|NCT02418650|Drug|300 mg 14C-ODM-201 oral solution|
79233850|NCT02418728|Other|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
79233851|NCT02418884|Drug|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
79375052|NCT03083431|Drug|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
79375053|NCT03083431|Drug|Placebo|Oral solution containing the same excipients as propranolol solution
79375054|NCT03077399|Device|SCALA|All items of SCALA are applied
79375055|NCT03050931|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
79375056|NCT03025334|Device|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
79375057|NCT02974881|Device|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
79528897|NCT01403779|Radiation|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
79685123|NCT03736616|Drug|Cytarabine|Chemotherapy
79685124|NCT03736616|Drug|Melphalan|Chemotherapy
79685125|NCT03736616|Other|Autologous HSCT|Cellular Therapy
79685126|NCT03736616|Drug|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
79685127|NCT04684680|Dietary Supplement|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
79233852|NCT05511935|Other|professional development training for CHWs on dental health (GRIN)|multi module online training
79233853|NCT03106922|Drug|PMF104|"Powder for oral solution:~Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
79528898|NCT01403792|Drug|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
79528899|NCT01403818|Drug|ASP1941|oral
79528900|NCT01403818|Drug|Mitiglinide calcium hydrate|oral
79528901|NCT01403831|Other|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
79528902|NCT01403844|Other|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
79233854|NCT03106922|Drug|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
79233855|NCT05692193|Behavioral|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
79685128|NCT04684680|Dietary Supplement|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
79685129|NCT03718403|Drug|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
79685130|NCT00545259|Drug|AEB071|
79685131|NCT00537966|Drug|Dolutegravir|In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)
79685132|NCT00537966|Drug|Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate|standard dosage
79685133|NCT00537966|Drug|Raltegravir|standard dosage
79685134|NCT00537966|Drug|Darunavir|standard dosage
79233856|NCT02423096|Drug|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
79233857|NCT03629951|Drug|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
79233858|NCT02423018|Drug|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
79233859|NCT02423018|Drug|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
79233860|NCT03622385|Other|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
79233861|NCT04483076|Drug|Chemotherapy drug|The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA < 1.25 m2; 50mg BID for 1.25 m2 < BSA <1.5 m2; 60mg BID for BSA > 1.5 m2. Day 15 to day 21 is the rest period.
79233862|NCT04483076|Procedure|Gastrectomy|Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
79685135|NCT00537966|Drug|Ritonavir|used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting
79233863|NCT04483076|Procedure|Laparoscopic exploration|Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
79233864|NCT05692115|Diagnostic Test|stress ECG|stress ECG to patients suspected to be ischemic patients .
79375058|NCT02972788|Drug|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
79375059|NCT02972788|Other|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
79375060|NCT02927769|Biological|Nivolumab|Specified Dose on Specified Days
79375061|NCT02927769|Biological|brentuximab vedotin|Specified Dose on Specified Days
79375062|NCT02927769|Biological|bendamustine|Specified Dose on Specified Days
79685136|NCT00537966|Drug|Rilpivirine|standard dosage
79528903|NCT01403844|Other|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
79685137|NCT00537966|Drug|Lamivudine|standard dosage
79233865|NCT02422862|Other|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
79233866|NCT03564353|Device|tDCS|tDCS
79375063|NCT02878174|Procedure|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
79375064|NCT02874040|Procedure|Endoresection|Endoresection of the tumor scar
79827959|NCT06146114|Diagnostic Test|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
79685138|NCT00537966|Drug|tenofovir|standard dosage
79827960|NCT06146062|Drug|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
79685139|NCT00537966|Drug|Emtricitabine|standard dosage
79685140|NCT00537966|Drug|Abacavir|standard dosage
79375065|NCT02874040|Procedure|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
79375066|NCT02864563|Procedure|Blood sampling|"Blood sample at diagnosis to evaluate MYCN amplification in plasma.~In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
79375067|NCT02851992|Device|GTS cementless stem|Total Hip Arthroplasty
79375068|NCT02827435|Drug|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
79375069|NCT02824991|Procedure|detection of local twitch response intensities during dry needling|
79528904|NCT01403844|Other|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
79528905|NCT01403844|Other|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
79528906|NCT01403857|Other|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
79685141|NCT03456492|Diagnostic Test|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
79827961|NCT06146062|Drug|placebo|3 injections one week apart
79528907|NCT01403857|Other|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
80001750|NCT03561038|Device|Franseen Needle|Comparing 2 needles designed for tissue acquisition
79233867|NCT05691959|Drug|Placebo|Patients randomized to placebo group will receive Normal Saline 50ml IV.
79233868|NCT05691959|Drug|Calcium|Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
79233869|NCT02418338|Other|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
79528908|NCT01403870|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
79685142|NCT01266967|Drug|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
79233870|NCT02422706|Drug|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
79528909|NCT01403883|Behavioral|Standard Care|Psychological & enterostomal therapy clinics on demand only
79528910|NCT01403883|Behavioral|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
79685143|NCT03456414|Other|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
79685144|NCT00538005|Biological|bevacizumab|
79685145|NCT00538005|Drug|oxaliplatin|
79685146|NCT00538005|Drug|sorafenib tosylate|
79685147|NCT03610412|Other|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
80001751|NCT03561038|Device|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
80001752|NCT02056730|Drug|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
80001753|NCT05162573|Drug|177Lu-PSMA-617|Dose-escalation of 177Lu-PSMA-617 (3, 6 or 9 GBq) combined with external beam radiotherapy (EBRT)
80001754|NCT05162573|Radiation|EBRT|External Beam Radiotherapy
80001755|NCT02056808|Drug|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
80001756|NCT02055950|Procedure|Storage of kidney in refrigerated solution|
80001757|NCT02055950|Procedure|Kidney perfused by pulsatile machine|
80001758|NCT01337219|Drug|Tobramycin|
79233871|NCT02422706|Drug|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
79233872|NCT02422706|Drug|Omeprazole|Omeprazole 20 twice daily
79233873|NCT02422706|Drug|Clarithromycin|KLacid twice daily
79233874|NCT02422706|Drug|Levofloxacin|Tavanic. Tavacin
79528911|NCT01403896|Drug|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
79528912|NCT01403896|Drug|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
79233875|NCT02422706|Drug|Doxicycline|Vibramycin 100 mg twice daily
79233876|NCT03058757|Drug|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~one day before surgery~four hours before surgery"
79233877|NCT02418260|Procedure|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
79233878|NCT02418260|Procedure|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
79233879|NCT02418260|Procedure|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
79528913|NCT01403909|Device|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
79528914|NCT01403909|Procedure|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
79685148|NCT03610412|Other|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
79685149|NCT00538044|Drug|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
79685150|NCT00538083|Other|Chocolate|74 grams of single dose solid dark chocolate versus placebo
79685151|NCT00538083|Other|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
79528915|NCT01403922|Drug|TC-5214|Tablet oral bid days 1 to 7
79685152|NCT00538083|Other|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, & placebo given for six weeks
80001759|NCT03560804|Drug|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
80001760|NCT03560804|Drug|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
80001761|NCT02056886|Procedure|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
79233880|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
79375080|NCT02788773|Drug|Durvalumab|
79375081|NCT02788773|Drug|Tremelimumab|
79375082|NCT02754544|Procedure|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
79375083|NCT02754544|Other|Electrocorticography|Undergo electrocorticography
79375084|NCT02688400|Drug|Diacerein|
79375085|NCT02688400|Drug|Celecoxib|
79375086|NCT02688400|Drug|Placebo|
79375087|NCT02637583|Drug|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
79528916|NCT01403922|Drug|TC-5214|Tablet oral bid days 8 to 14
79528917|NCT01403948|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
79685153|NCT00545337|Drug|Insuline glulisine|
79685154|NCT01266850|Biological|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
80001762|NCT03150719|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
80001763|NCT03150719|Drug|Ivacaftor|IVA 150 mg tablet.
80001764|NCT03150719|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
80001765|NCT03150719|Drug|Placebo|Placebo matched to IVA tablet.
80001766|NCT02038400|Device|KINETUBE medical Device|
80001767|NCT02038400|Device|insertion of tympanic ventilation tubes (tympanostomy)|
80001768|NCT01343927|Behavioral|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
80001769|NCT01343927|Behavioral|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
79233881|NCT03138889|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
79233882|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
79233883|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
79233884|NCT03138889|Drug|Cisplatin|Cisplatin will be dosed per the pharmacy manual
79233885|NCT03138889|Drug|Carboplatin|Carboplatin will be dosed per the pharmacy manual
79233886|NCT03138889|Drug|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
79233887|NCT03138889|Drug|Paclitaxel|Paclitaxel will be dosed per local practice and label
79233888|NCT03138889|Drug|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
79233889|NCT03138889|Drug|Atezolizumab|Atezolizumab will be dosed per current label indication
79233890|NCT02422472|Device|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
79233891|NCT02425514|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
79233892|NCT02425514|Device|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
79233893|NCT02425748|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
79375088|NCT02637583|Drug|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
79528918|NCT01403974|Drug|BI 836845|Intravenous infusion once every week
79528919|NCT01404000|Drug|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
79528920|NCT01404013|Drug|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
79528921|NCT01404013|Drug|Montelukast|Montelukast 10mg ,every night, for 8 weeks
79528922|NCT01404013|Drug|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
79827962|NCT06146036|Behavioral|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
79827963|NCT06146036|Behavioral|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
79375089|NCT02626455|Drug|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
79528923|NCT01404026|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
80001770|NCT01343927|Behavioral|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
79233894|NCT02425748|Biological|γδ T Cell|γδ T cells will be used against non small lung tumor.
79685155|NCT01266850|Biological|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
79827964|NCT06146036|Other|Control|No exercise, sedentary.
79827965|NCT06146023|Device|Robotic anastomosis (Symani surgical system and RoboticScope)|Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
79827966|NCT06146023|Procedure|Conventional anastomosis|Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
80001771|NCT02057120|Procedure|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
80001772|NCT02057120|Device|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
80001773|NCT02057354|Behavioral|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
80001774|NCT02057354|Behavioral|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
79528924|NCT01404052|Device|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
79528925|NCT01404065|Procedure|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
80001775|NCT04828187|Diagnostic Test|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
80001776|NCT02057432|Device|intra-operative MRI|Patients will undergo an MRI during surgery.
79528926|NCT01404091|Drug|LY2940094|Administered orally
79528927|NCT01404104|Drug|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
79528928|NCT01404117|Drug|Laquinimod 0.6|Laquinimod 0.6 capsule
80001777|NCT01344005|Other|caregiver-related intervention or procedure|
80001778|NCT01344005|Other|questionnaire administration|
79528929|NCT01404117|Drug|Laquinimod 1.2|Placebo
80001779|NCT01344005|Procedure|quality-of-life assessment|
80001780|NCT01344005|Procedure|radiography|
79233895|NCT02425748|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
79233896|NCT03669679|Procedure|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
79233897|NCT02422394|Drug|Eltrombopag|
79233898|NCT02418494|Other|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
79233899|NCT02418494|Other|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
79528930|NCT01404117|Other|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
79528931|NCT01404130|Drug|Isotretinoin|0.5-1mg/kg daily for 4-6 months
79375090|NCT02626455|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
80001781|NCT02059772|Drug|ranibizumab|
79375091|NCT02626455|Drug|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
80001782|NCT02059772|Procedure|micropulse diode laser|
80001783|NCT01344083|Drug|T1210|2 drops T1210 once a day
80001784|NCT01344083|Drug|Olopatadine hydrochloride|2 drops once a day Olopatadine
80001785|NCT04039217|Drug|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
80001786|NCT02059850|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
80001787|NCT02059850|Drug|Cyclophosphamide|Given IV
80001788|NCT02059850|Other|Laboratory Biomarker Analysis|Correlative studies
80001789|NCT01342055|Drug|Apetrol ES|sequences of administered drugs
80001790|NCT02038478|Biological|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
79528932|NCT01404143|Procedure|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
80001791|NCT00982111|Drug|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
80001792|NCT00982111|Drug|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
80001793|NCT00982111|Biological|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
79375092|NCT02626455|Drug|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
79375093|NCT02626455|Drug|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
79375094|NCT02626455|Drug|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
79528933|NCT01404143|Procedure|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
80001794|NCT05615090|Procedure|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
80001795|NCT05615090|Procedure|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
80001796|NCT02957682|Drug|Praluent (Alirocumab)|
80001797|NCT02957682|Drug|Placebo|
80001798|NCT02057822|Procedure|Cytokins assay in tears|
80001799|NCT03057951|Drug|Empagliflozin|once daily
80001800|NCT03057951|Drug|Placebo|once daily
79233900|NCT01881763|Drug|Ketamine|Ketamine 1-2 mgr/ kg IV
79233901|NCT01881763|Drug|Methohexital|Methohexital 0.5-1mg/kg IV
79233902|NCT03178058|Other|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
79375095|NCT02626455|Drug|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
79375096|NCT02626455|Drug|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
79375097|NCT02492932|Device|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
80001801|NCT02060240|Behavioral|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
80001802|NCT02038556|Behavioral|cognitive behaviorial therapy -Insomnia|
80001803|NCT02057900|Biological|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
80001804|NCT02060318|Drug|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
80001805|NCT01318837|Drug|solifenacin|oral
80001806|NCT03146663|Drug|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
80001807|NCT03146663|Drug|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
80001808|NCT01350037|Drug|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
79233903|NCT03137095|Other|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 & 5.
79233904|NCT03137095|Other|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
79233905|NCT02418416|Other|Oocyte double chemical activation|Oocyte double chemical activation
79233906|NCT02422316|Other|Non-contrast Cardiac CT scan|
79233907|NCT03674203|Biological|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
79528934|NCT01404156|Drug|(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)"
79685156|NCT00538122|Device|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
79685157|NCT03431480|Biological|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
79685158|NCT00545376|Procedure|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
79685159|NCT00545376|Procedure|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
79233908|NCT03674125|Biological|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
79233909|NCT03669601|Drug|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
79233910|NCT03669601|Drug|Gemcitabine|Nucleoside metabolic inhibitor.
79233911|NCT03541499|Biological|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10^7 colony forming units (CFU) or 10^9 CFU.
79233912|NCT03541499|Other|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
79233913|NCT05691881|Drug|68Ga-NY105|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
79233914|NCT02706392|Other|Laboratory Biomarker Analysis|Correlative studies
79375098|NCT02433197|Device|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
79375099|NCT02352896|Drug|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
79685160|NCT00545376|Other|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
79685161|NCT00538161|Other|Ventilation strategy|
79233915|NCT02706392|Biological|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
79233916|NCT02416388|Drug|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
79233917|NCT02416388|Drug|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
80001809|NCT01350037|Drug|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
80001810|NCT02060006|Drug|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
80001811|NCT01350193|Device|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
79375100|NCT02320136|Behavioral|cognitive testing|patients perform simple tasks like watching a video or memorizing items
79528935|NCT01404156|Other|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1. Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
79685162|NCT00545415|Dietary Supplement|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
79827967|NCT06146010|Other|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
80001812|NCT01350193|Other|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
80001813|NCT03640182|Other|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
79375101|NCT02242266|Drug|Tiotropium low dose|inhalation powder, hard PE capsule
79375102|NCT02242266|Drug|Tiotropium medium dose|inhalation powder, hard PE capsule
79375103|NCT02242266|Drug|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
79375104|NCT02242266|Drug|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
79685163|NCT00545415|Dietary Supplement|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
79375105|NCT02242266|Drug|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
79528936|NCT01404169|Drug|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
79685164|NCT00545415|Dietary Supplement|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
79685165|NCT00545415|Dietary Supplement|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
80001814|NCT03620435|Drug|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
80001815|NCT01357993|Drug|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
80001816|NCT03618888|Other|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
80001817|NCT03618888|Other|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
79375106|NCT02193347|Biological|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
80001818|NCT01317017|Drug|Actimmune|"All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~Patients will return at one to two weeks for suture removal.~Clinical assessments done at every visit.~Patients will also be evaluated at each visit for any adverse events."
80001819|NCT05637554|Procedure|Laparoscopic appendectomy using clipping.|Laparoscopic appendectomy using clipping to secure the base of the appendix.
80001820|NCT05637554|Procedure|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
80001821|NCT03640104|Behavioral|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
80001822|NCT03640104|Behavioral|Nutrition guidelines|Nutritional recommendations based on international guidelines
80001823|NCT04686773|Biological|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
80001824|NCT04686773|Biological|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
80001825|NCT02058056|Radiation|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
80001826|NCT05162495|Device|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
80001827|NCT02956278|Drug|Allopurinol|
80001828|NCT02956278|Other|Placebo|lactose placebo pill
79375107|NCT02193347|Biological|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
79375108|NCT02193347|Drug|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
79685166|NCT00545415|Dietary Supplement|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
79375109|NCT02176434|Procedure|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
79375110|NCT02176434|Biological|hematopoietic stem cell|
79528937|NCT01404169|Drug|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
80001829|NCT02058134|Device|cardioPAT cell saver|
80001830|NCT02060396|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
80001831|NCT01358071|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
80001832|NCT01358071|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
80001833|NCT01358071|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
80001834|NCT04827719|Drug|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
80001835|NCT02058212|Drug|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
79375111|NCT02045381|Procedure|MRI Group|A single research MRI
79375112|NCT02039843|Other|Emotional Support Dogs|Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized.
79375113|NCT02039843|Other|Service Dogs|Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, & behind).
79375114|NCT02004275|Drug|pomalidomide|given PO
79375115|NCT02004275|Drug|ixazomib|given PO
79375116|NCT02004275|Drug|dexamethasone|given PO
79528938|NCT01404182|Biological|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
79528939|NCT01404195|Dietary Supplement|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
80001836|NCT02957136|Device|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
80001837|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
80001838|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
79233918|NCT02416388|Drug|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
79233919|NCT02416388|Drug|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
79233920|NCT02416388|Drug|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
79233921|NCT02416388|Drug|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~720 mg BID from D0 to D+28 for HLA-identical siblings~720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
80001839|NCT02060474|Drug|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
79528940|NCT01404247|Other|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
79528941|NCT01404247|Procedure|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
79528942|NCT01404273|Behavioral|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
80001840|NCT03561272|Other|Smart Phone Application|Oral medication adherence phone application.
80001841|NCT03561272|Other|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
80001842|NCT03640260|Behavioral|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
80001843|NCT01354171|Device|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
80001844|NCT04668443|Other|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
79233922|NCT02416388|Drug|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
79233923|NCT02416388|Drug|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
79233924|NCT02416388|Drug|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
79233925|NCT02416388|Drug|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~100 mg/d on D1 to D8 (selection phase dose level 1)~or 200 mg/d on D1 to D8 (selection phase dose level 2)~or 400 mg/d on D1 to D8 (selection phase dose level 3)~or 400 mg/d on D1 to D14 (selection phase dose level 4)"
79375120|NCT01911013|Procedure|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
79375121|NCT01911013|Device|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
79375122|NCT01911013|Device|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
79528943|NCT01404286|Behavioral|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
79375123|NCT01731444|Drug|Phenylephrine|
79375124|NCT01630785|Device|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
79375125|NCT01559129|Drug|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
79375126|NCT01559129|Drug|Placebo|Matching placebo capsules taken orally once a day
79375127|NCT01488240|Procedure|pulsed dye laser|laser energy
79233926|NCT02417948|Other|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
79233927|NCT02417948|Other|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
79827968|NCT06145984|Behavioral|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
79827969|NCT06145984|Behavioral|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
79827970|NCT06145971|Behavioral|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
79233928|NCT02418104|Drug|CHS-1701|
79233929|NCT02418104|Drug|Pegfilgrastim (Neulasta)|
79233930|NCT02886065|Drug|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
79233931|NCT02886065|Drug|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
79233932|NCT02886065|Drug|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
79528944|NCT01404299|Dietary Supplement|Nutritional Supplementation|- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
79528945|NCT01404299|Other|Control|- No intervention, except monthly home visits
79233933|NCT02886065|Biological|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
79233934|NCT02416466|Biological|anti-CEA CAR-T cells|Gene modified patient T cells.
79233935|NCT02416466|Device|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
79233936|NCT03496259|Device|On-Q pump|Type of pain control device used
79233937|NCT03496259|Device|Epidural catheter|Type of pain control device used
79233938|NCT05454215|Device|Mechanical insufflation/exsufflation conventional|Conventional settings in a commercially available chest physiotherapy device
79375128|NCT01210781|Procedure|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
79375129|NCT01005303|Drug|Placebo|1 Tablet Daily
79375130|NCT01005303|Drug|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
79233939|NCT05454215|Device|Mechanical insufflation/exsufflation modified|Modified settings in a commercially available chest physiotherapy device
79233940|NCT02416310|Device|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
79233941|NCT03392441|Other|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
79233942|NCT03177824|Drug|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
79233943|NCT03177824|Drug|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
79233944|NCT02416544|Other|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
79375131|NCT01003028|Drug|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
79375132|NCT01003028|Drug|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
79375133|NCT00388882|Drug|tiotropium|
79375134|NCT00388882|Drug|ipratropium bromide / albuterol|
79375135|NCT00355238|Drug|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
79375136|NCT00303303|Biological|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
80001845|NCT03561194|Dietary Supplement|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
79528946|NCT01404312|Drug|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
79375137|NCT00303303|Biological|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
79375138|NCT00303303|Biological|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
79233945|NCT02416232|Drug|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
79233946|NCT02416232|Drug|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
79233947|NCT04482842|Device|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
79375139|NCT00275444|Drug|Tipranavir|
79375140|NCT00274560|Drug|Tiotropium|
79375141|NCT00274560|Drug|Salmeterol|
79375142|NCT00274508|Drug|tiotropium bromide|
79528947|NCT01404312|Drug|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
79528948|NCT01404312|Dietary Supplement|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
79528949|NCT01404338|Drug|Halobetasol 0.05% ointment|
79528950|NCT01404338|Drug|Placebo Ointment|
79528951|NCT01404351|Device|PEAK PlasmaBlade|
79528952|NCT01404351|Procedure|Scalpel and Traditional Electrosurgery|
79685167|NCT00545415|Dietary Supplement|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
79233948|NCT04482842|Drug|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
79233949|NCT02415920|Drug|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
79375143|NCT00239447|Drug|Tiotropium|
79375144|NCT00239447|Device|HandiHaler|
79375145|NCT00239447|Device|Respimat SMI|
79375146|NCT00144248|Drug|nevirapine|
79375147|NCT00056641|Drug|tipranavir|
79375148|NCT00056641|Drug|ritonavir|
79375149|NCT00056641|Drug|saquinavir|
79375150|NCT00056641|Drug|amprenavir|
79375151|NCT00056641|Drug|lopinavir|
79375152|NCT03422874|Drug|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
79375153|NCT03422874|Drug|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
79375154|NCT01253824|Drug|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
79375155|NCT01253824|Drug|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
79528953|NCT01404364|Drug|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
79528954|NCT01404364|Drug|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
79528955|NCT01404377|Procedure|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
79685168|NCT00545493|Drug|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
79827971|NCT06145958|Drug|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
79528956|NCT01404390|Drug|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
79528957|NCT01404390|Drug|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
79528958|NCT01404403|Device|Rapid System|
79528959|NCT01404442|Drug|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
80001846|NCT03618810|Drug|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
79233950|NCT02415920|Drug|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
79233951|NCT02415764|Behavioral|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
79528960|NCT01404442|Drug|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
79528961|NCT01404442|Drug|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
79375156|NCT03422796|Drug|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79375157|NCT03422796|Drug|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79528962|NCT01404455|Other|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
79528963|NCT01404468|Device|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
79375158|NCT03422796|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79528964|NCT01404468|Other|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
79528965|NCT01404468|Device|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
79528966|NCT01404481|Device|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
79528967|NCT01404507|Drug|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
79528968|NCT01404507|Device|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
79685169|NCT00545493|Drug|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
79685170|NCT01266460|Biological|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
80001847|NCT03618810|Drug|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
79375159|NCT04396977|Procedure|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
79375160|NCT04396977|Procedure|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
79375161|NCT03429738|Drug|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
79375162|NCT03429738|Drug|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
79391043|NCT02146144|Procedure|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~Central and peripheral 25 Gauge vitrectomy~dissection of the epimacular membrane~injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~Intraoperative picture to see the possible spontaneous ILM peeling~If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~Arm 1: no peeling, where the ILM peeling will not be made~Arm 2: active peeling, where the ILM peeling will be made"
79528969|NCT01404507|Other|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
79528970|NCT01404520|Other|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
79528971|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg Ferrous sulfate
79528972|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg ferrous sulfate
79528973|NCT01404533|Dietary Supplement|Ferrous sulfate|6 mg ferrous sulfate
79528974|NCT01404546|Other|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
79528975|NCT01404546|Other|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
79528976|NCT01404598|Drug|naproxcinod 750 bid|naproxcinod 750 bid
79528977|NCT01404598|Drug|naproxcinod 3000 mg od|naproxcinod 3000 mg od
79528978|NCT01404598|Drug|naproxen 500 mg bid|naproxen 500 mg bid
79528979|NCT01404637|Drug|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
79528980|NCT01404637|Drug|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
80001848|NCT01354249|Dietary Supplement|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
80001849|NCT02058446|Drug|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
79685171|NCT01266460|Other|Laboratory Biomarker Analysis|Correlative studies
79685172|NCT05119257|Biological|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
80001850|NCT02236650|Behavioral|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
80001851|NCT02236650|Other|Treatment as Usual|Treatment as Usual for 4 weeks
80001852|NCT01354327|Dietary Supplement|Limicol|3 tablets / day during 4 months
80001853|NCT01354327|Dietary Supplement|Placebo|3 tablets / day during 4 months
80001854|NCT05160311|Drug|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
79391044|NCT02425722|Drug|ASP0456|oral
80001855|NCT05160311|Device|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
79685173|NCT01266265|Drug|inhaled prostacyclin|Tyvaso
80001856|NCT02058524|Biological|fecal microbiota transplantation|
80001857|NCT02058602|Other|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
80001858|NCT02715141|Behavioral|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
80001859|NCT02031666|Drug|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
80001860|NCT02031666|Drug|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
79391045|NCT02425722|Drug|Placebo|oral
79685174|NCT01266265|Drug|inhaled prostacyclin|As prescribed by the physician
79233952|NCT02422082|Dietary Supplement|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
79233953|NCT02422082|Dietary Supplement|Placebo|Dietary supplementation with placebo twice daily for 12 months
79233954|NCT03389243|Drug|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
79391046|NCT02070328|Other|Registry|
79391047|NCT03185286|Device|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
80001861|NCT01354405|Drug|Lanreotide|120 mg every 28 days intramuscular
80001862|NCT03363035|Drug|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
80001863|NCT03363035|Drug|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
79391048|NCT02061514|Procedure|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
79391049|NCT02061514|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
80001864|NCT03363035|Drug|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
80001865|NCT02060084|Drug|a control group|the same dose of luke warm water
80001866|NCT02060084|Drug|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks
80001867|NCT05211843|Other|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
80001868|NCT05211843|Other|Apple juice|apple juice
80001869|NCT03619122|Procedure|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
80001870|NCT01350349|Behavioral|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
80001871|NCT01350349|Behavioral|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
80001872|NCT03618732|Other|Bilateral movement-based computer training|
79233955|NCT03389243|Drug|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
79233956|NCT03389243|Drug|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
79233957|NCT03179150|Diagnostic Test|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
79391050|NCT02425800|Other|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
79685175|NCT01266265|Drug|prostacyclin|As prescribed by the physician
79685176|NCT01266265|Drug|subcutaneous and intravenous prostacyclin|As prescribed by physician
79685177|NCT01266265|Drug|oral ERA|As prescribed by physician
79685178|NCT01266265|Drug|oral PDE5 inhibitors|As prescribed by physician
79685179|NCT00538200|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
79685180|NCT00538200|Other|Dietary Advice|Standard dietary advice
80001873|NCT03618732|Other|Video-directed conventional training|
80001874|NCT03150485|Device|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
80001875|NCT02060552|Drug|Diacerein|oral administration of IL-1βinhibitory
80001876|NCT02060552|Drug|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
79233958|NCT03179228|Device|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
79233959|NCT03042767|Biological|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
79233960|NCT03042767|Other|Placebo|Matched Placebo
79375163|NCT05242185|Other|Observational study|- Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
79375164|NCT03429660|Other|Medical information|"The information collected are about :~Introduction or non-introduction of treatment~Cumulative dose of treatment~Drug dispensation and withdrawal~Hospitalization reason~Safety information~Demographic data (date of death)"
79375165|NCT01253902|Drug|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
79375166|NCT01253902|Drug|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
79685181|NCT00545649|Behavioral|Exercise and education|
79685182|NCT00545649|Behavioral|Education|
79375167|NCT01253902|Drug|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
79233961|NCT02421770|Other|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
79233962|NCT02421770|Other|placebo|
79375168|NCT02843100|Other|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
79233963|NCT02421692|Other|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
79233964|NCT02421926|Drug|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
79375169|NCT02843100|Other|Crohn's Disease Exclusion Diet|a limited whole food diet
79375170|NCT02843100|Other|Partial Enteral Nutrition|25-50% of Energy from formula
79375171|NCT02843100|Other|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
79685183|NCT03268382|Drug|APR-246|Intravenous infusion
79685184|NCT03268382|Drug|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
79685185|NCT01266148|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
79685186|NCT01266148|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
79233965|NCT02421614|Other|high-protein low-carbohydrate diet with high olive oil|
79685187|NCT01266148|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
80001877|NCT02060552|Drug|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
80001878|NCT01358149|Other|cocoa-based food|single intake of cocoa-based food
80001879|NCT01358149|Other|cocoa-based food|Single intake of cocoa-based food
80001880|NCT05384886|Diagnostic Test|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
80001881|NCT01350427|Dietary Supplement|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
80001882|NCT01350427|Dietary Supplement|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
80001883|NCT01350427|Dietary Supplement|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
79685188|NCT01266148|Drug|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
79827972|NCT06145932|Device|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
79685189|NCT01266148|Drug|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
79827973|NCT06145932|Device|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
79827974|NCT06145880|Diagnostic Test|Artificial intelligence tool for transthoracic echocardiography|Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
80001884|NCT05211765|Diagnostic Test|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
80001885|NCT05384574|Dietary Supplement|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
80001886|NCT04355585|Drug|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
80001887|NCT04355585|Drug|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
79375172|NCT01253980|Drug|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
79375173|NCT01253980|Drug|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days"
79375174|NCT04449354|Device|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
79375175|NCT00988533|Drug|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
79375176|NCT01254214|Behavioral|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
79375177|NCT01254214|Behavioral|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
79375178|NCT03048669|Other|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
79375179|NCT01254760|Device|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
79375180|NCT01254760|Device|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
79685190|NCT00538239|Drug|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
79685191|NCT00538239|Drug|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
79685192|NCT03263897|Device|insufflation|mobile interface driven insufflation of the ear canal
79685193|NCT03263897|Device|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
79685194|NCT00545727|Behavioral|Diet|Whole-foods, low glycemic index diet
79685195|NCT00545727|Other|Standard diet|Standard diet meeting American Diabetes Association guidelines
79685196|NCT01266070|Drug|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
79827975|NCT06145841|Diagnostic Test|Pathogen metagenomic next-generation sequencing|In diagnosing patients with AIDS combined with severe pneumonia and/or sepsis, use pathogen metagenomics technology to detect peripheral blood specimens
79827976|NCT06145828|Device|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
79827977|NCT06145802|Biological|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
79827978|NCT06145711|Other|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
79827979|NCT06145685|Procedure|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
79827980|NCT06145685|Procedure|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
79827981|NCT06145672|Procedure|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
80001888|NCT05189743|Procedure|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
79528981|NCT01404663|Biological|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
79685197|NCT05270148|Other|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
79685198|NCT05270148|Other|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
79827982|NCT06145659|Behavioral|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
79233966|NCT02421614|Other|high-protein low-carbohydrate diet with high sunflower oil|
79233967|NCT03312881|Diagnostic Test|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
79233968|NCT03312881|Diagnostic Test|neuroimaging|magnetic resonance imaging (MRI)
79233969|NCT03312881|Other|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
79375181|NCT05601375|Other|Echocardiography|Fetal echocardiography (ultrasound)
79233970|NCT02410616|Behavioral|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
79685199|NCT00538278|Other|Database|database
79685200|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
79375182|NCT02984007|Behavioral|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
79685201|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
79685202|NCT03228563|Other|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5*10^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
79233971|NCT02410616|Behavioral|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
79375183|NCT02984007|Other|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
79375184|NCT01350388|Drug|Febuxostat|80 mg/day of febuxostat for 24 weeks
79375185|NCT01350388|Drug|Placebo|1 placebo tablet per day for 24 weeks
79375186|NCT03154749|Drug|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
79391051|NCT02425800|Other|Laboratory Biomarker Analysis|Correlative studies
79528982|NCT01404676|Drug|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
79528983|NCT01404676|Drug|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
79528984|NCT01404689|Drug|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
79528985|NCT01404689|Other|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
79528986|NCT01404702|Drug|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
79685203|NCT01265953|Drug|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
79685204|NCT01265953|Dietary Supplement|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
79685205|NCT01265875|Drug|Human Secretin|Dose Escalation
79685206|NCT00545805|Procedure|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
79685207|NCT00545805|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
79685208|NCT01265797|Device|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
79827983|NCT06145633|Procedure|Biopsy|Undergo biopsy
79827984|NCT06145633|Procedure|Biospecimen Collection|Undergo blood sample colleciton
79827985|NCT06145633|Procedure|Bone Scan|Undergo bone scan
79827986|NCT06145633|Procedure|Computed Tomography|Undergo CT, SPECT/CT, PET/CT
79827987|NCT06145633|Other|Fludeoxyglucose F-18|Undergo FDG PET/CT
80001889|NCT02061020|Drug|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
80001890|NCT02031744|Drug|erlotinib [Tarceva]|150 mg oral administration once daily
79528987|NCT01404702|Biological|Aldesleukin|"Dose Level 1: 3 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
80001891|NCT02031744|Drug|Placebo|15 mg/kg intravenous administration every 3 weeks
80001892|NCT02031744|Drug|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
80001893|NCT04653389|Drug|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
80001894|NCT04653389|Drug|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
80001895|NCT04653389|Radiation|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
80001896|NCT05211687|Other|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
80001897|NCT03134911|Drug|DOAC or VKA|6 months - 2 years
80001898|NCT03134911|Drug|VKA|6 months - 2 years
79528988|NCT01404715|Drug|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
79528989|NCT01404715|Drug|Imatinib|A single oral dose of 600 mg of imatinib
79528990|NCT01404767|Drug|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
80001899|NCT05182593|Other|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
80001900|NCT05182593|Other|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (<5 grams/day)
80001901|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
79233972|NCT05691257|Drug|Roxadustat|"The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019."
79233973|NCT05691257|Drug|Recombinant human eythropoietin and/or Iron agents|Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
79528991|NCT01404767|Drug|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
79528992|NCT01404780|Device|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
79528993|NCT01404780|Device|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
79528994|NCT01404793|Drug|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
79685209|NCT01265797|Device|Sham Device|participant wears sham device for 20 minutes daily for 28 days
79233974|NCT02410460|Drug|clonidine|
79233975|NCT02410460|Drug|glycopyrrolate|
79685210|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
79685211|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
79827988|NCT06145633|Other|Gallium Ga 68 Gozetotide|Given IV
79827989|NCT06145633|Drug|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
79827990|NCT06145633|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
80001902|NCT02061098|Dietary Supplement|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
80001903|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
80001904|NCT02061098|Dietary Supplement|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
80001905|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
80001906|NCT02061098|Dietary Supplement|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
80001907|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
79528995|NCT01404806|Drug|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
79827991|NCT06145633|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
79827992|NCT06145633|Drug|Vorinostat|Given IV
79827993|NCT06145568|Other|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
79827994|NCT06145542|Behavioral|AR group: aerobic training before resistance training|"Exercise are performed 3 times/wk for 8 wks.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively.~Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time."
79827995|NCT06145542|Behavioral|RA group: resistance exercise before aerobic exercise|"Exercise are performed 3 times/wk for 8 wks.~Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session."
80001908|NCT02061098|Dietary Supplement|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
79375187|NCT03633396|Biological|Imsidolimab|Administered by subcutaneous injection once a month
79375188|NCT03633396|Drug|Placebo|Administered by subcutaneous injection once a month
79528996|NCT01404819|Drug|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
79528997|NCT01404819|Drug|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
79528998|NCT01404845|Dietary Supplement|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
79528999|NCT01404845|Dietary Supplement|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
79685212|NCT01265719|Other|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
79685213|NCT01265719|Other|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
79685214|NCT03148496|Device|Biologic Mesh|Biologic mesh placed during surgery
79685215|NCT03148496|Procedure|Small Bites|0.5 cm x 0.5 cm sutures used
79685216|NCT03148496|Procedure|Large Bites|1.0 x 1.0 sutures used
79685217|NCT00538395|Drug|Adriamycin, Taxol and Cytoxan|Chemotherapy
79375189|NCT03422718|Behavioral|Healthy Behavior Texts|Participants receive motivational health behavior texts
79375190|NCT03422718|Behavioral|No healthy behavior texts|Participants do not receive healthy behavior texts
79375191|NCT03422718|Behavioral|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
79233976|NCT02410460|Drug|propofol|
79375192|NCT03422718|Behavioral|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
79529000|NCT01404858|Behavioral|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
79529001|NCT01404871|Drug|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
79529002|NCT01404871|Drug|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
79529003|NCT01404871|Drug|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily
79685218|NCT01265563|Drug|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
79685219|NCT01265563|Drug|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
79685220|NCT01265563|Drug|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
79685221|NCT01265563|Drug|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
79233977|NCT02410460|Drug|ketamine|
79233978|NCT02410460|Drug|marcaine|
79233979|NCT02410460|Drug|scopolamine|
79233980|NCT02410460|Drug|midazolam|
79233981|NCT02410460|Device|ondansetron|
79233982|NCT02410460|Drug|metoclopramide|
79233983|NCT02410460|Drug|glycopyrrolate|
79233984|NCT02410460|Drug|lidocaine|
79233985|NCT02410460|Drug|famotidine|
79233986|NCT02410460|Drug|desflurane|
79233987|NCT02410460|Drug|sevoflurane|
79827996|NCT06145529|Other|RT Functional HIIT circuit program (15 minutes) with or without gamification approach|"EG1 (RT Functional HIIT circuit program): This intervention involves a 15-minute Resistance Training (RT) Functional High-Intensity Interval Training (HIIT) circuit program. The focus is on functional movements performed at a high intensity within intervals.~EG2 (RT Functional HIIT circuit program with gamification): This intervention replicates the RT Functional HIIT circuit program from EG1 but incorporates gamification strategies. Gamification involves the application of game-like elements, such as points, rewards, and competition, to make the exercise routine more engaging and enjoyable for the participants.~Control Group (CG): Children in the control group continue with their regular Physical Education (PE) sessions, maintaining their usual routine"
79827997|NCT06145516|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
79827998|NCT06145516|Behavioral|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
79827999|NCT06145490|Dietary Supplement|Caffeine|Caffeine capsule 250 mg, oral intake
79828000|NCT06145490|Drug|Placebo|Placebo capsule, oral intake
80001909|NCT01344239|Procedure|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
80001910|NCT03618576|Procedure|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
80001911|NCT02061176|Procedure|Transanal Haemorrhoidal Dearterialization|
80001912|NCT02061176|Procedure|Open Haemorrhoidectomy|
80001913|NCT02061254|Device|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
80001914|NCT02061254|Device|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
80001915|NCT02061254|Device|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
80001916|NCT02061254|Procedure|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
79375193|NCT03422718|Behavioral|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
79375194|NCT03422718|Behavioral|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
79233988|NCT02410226|Procedure|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
79375195|NCT00988065|Drug|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
79233989|NCT02410226|Radiation|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
79375196|NCT00988065|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
79375197|NCT00988065|Drug|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
79529004|NCT01404884|Procedure|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
79529005|NCT01404897|Other|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
79685222|NCT01265563|Drug|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
79685223|NCT03025139|Other|Educational Intervention|Attend survivorship education
79685224|NCT03025139|Other|Laboratory Biomarker Analysis|Correlative studies
79685225|NCT03025139|Procedure|Meditation Therapy|Attend mindfulness meditation
79233990|NCT02410226|Radiation|Sham ultrasound procedure|Applying the ultrasound probe on the patient's back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
79375198|NCT00988065|Drug|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
79529006|NCT01404897|Other|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
79685226|NCT03025139|Other|Questionnaire Administration|Ancillary studies
79685227|NCT00545922|Behavioral|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
79685228|NCT00545922|Behavioral|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
79685229|NCT01265056|Drug|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg* daily.~Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]~Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]~* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
79529007|NCT01404897|Other|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
79529008|NCT01404910|Device|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
80001917|NCT05189665|Procedure|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
80001918|NCT05189665|Procedure|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
80001919|NCT01344395|Drug|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
79233991|NCT02410070|Procedure|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
80001920|NCT01344395|Drug|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
80001921|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
79375199|NCT03422640|Drug|Apremilast|Open label treatment with apremilast
79375200|NCT03427164|Procedure|Transjugular Intrahepatic Portosystemic Shunt|The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
79529009|NCT01404962|Biological|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
79529010|NCT01404975|Other|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
79529011|NCT01405014|Behavioral|Hold Me Tight|Relationship enhancement group
79685230|NCT01265056|Drug|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
80001922|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
79375201|NCT05601297|Other|questationair|acceptability of women to partner violance
79375202|NCT01351090|Drug|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
79375203|NCT01351090|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
79233992|NCT03116672|Drug|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
79375204|NCT01351090|Drug|Placebo|Intranasal
79375205|NCT01918644|Radiation|stereotactic body radiation therapy|Undergo SBRT
79375206|NCT01918644|Drug|capecitabine|Given PO
79375207|NCT01918644|Procedure|therapeutic conventional surgery|Undergo definitive surgery
79685231|NCT05656651|Behavioral|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
79233993|NCT03116672|Drug|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
79233994|NCT03116672|Drug|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
79375208|NCT01918644|Procedure|magnetic resonance imaging|Optional correlative studies
79375209|NCT01918644|Other|laboratory biomarker analysis|Optional correlative studies
79375210|NCT00987831|Other|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
79375211|NCT00987831|Other|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
79391052|NCT02430636|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
79391053|NCT02430636|Device|NanoKnife|
79529012|NCT01405079|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
79529013|NCT01405079|Drug|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
79529014|NCT01405092|Device|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
79529015|NCT01405092|Device|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
79529016|NCT01405118|Drug|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
79529017|NCT01405131|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
79685232|NCT02942498|Drug|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
79685233|NCT02942498|Drug|Placebo|Placebo
79375212|NCT00987831|Drug|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
79685234|NCT00545961|Drug|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
79233995|NCT02417636|Other|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
79233996|NCT03175094|Behavioral|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
79375213|NCT03608358|Drug|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
79375214|NCT03608358|Drug|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
79233997|NCT03174860|Drug|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
79233998|NCT03174860|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
79375215|NCT03608358|Drug|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
79375216|NCT03608358|Drug|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
79375217|NCT03608358|Drug|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
79828001|NCT06145451|Behavioral|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
79828002|NCT06145438|Drug|Dienogest|Drug is administered orally at the same time every day
79828003|NCT06145438|Drug|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
79828004|NCT06145438|Drug|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
79828005|NCT06145438|Drug|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
79828006|NCT06145425|Other|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
79828007|NCT06145412|Drug|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
79233999|NCT02417480|Behavioral|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
79234000|NCT02417480|Behavioral|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
79375218|NCT03608358|Drug|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
79375219|NCT04274907|Drug|Venetoclax|Tablet: Oral
79375220|NCT04274907|Drug|Pembrolizumab|Intravenous (IV) Infusion
79375221|NCT01256164|Device|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
79375222|NCT01256164|Device|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
79375223|NCT03422484|Other|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
79685235|NCT00545961|Drug|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
79234001|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79375224|NCT03427086|Drug|Biotin|High dose biotin
79375225|NCT03427086|Drug|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
79375226|NCT03148665|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
79685236|NCT02935517|Biological|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
79685237|NCT00538551|Other|Database|Database
79685238|NCT01264939|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
79685239|NCT01264939|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
79828008|NCT06145412|Drug|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
79828009|NCT06145412|Radiation|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
79828010|NCT06145399|Diagnostic Test|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
79828011|NCT06145399|Diagnostic Test|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
79828012|NCT06145399|Drug|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
80001923|NCT02062112|Other|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
80001924|NCT01342289|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
80001925|NCT01342289|Drug|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m^2/day IV.
80001926|NCT01342289|Radiation|Total body irradiation|Day -1: 200 centigray in one fraction.
79234002|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
79375227|NCT03427008|Other|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
80001927|NCT01342289|Drug|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
79529018|NCT01405131|Drug|methylprednisolone|tablets 32 mg single dose
79529019|NCT01405144|Drug|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
79685240|NCT01264939|Drug|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
79234003|NCT02417558|Behavioral|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
79234004|NCT02417558|Behavioral|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
79234005|NCT02410148|Device|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
79234006|NCT03174470|Device|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
79685241|NCT01264939|Drug|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
79828013|NCT06145308|Drug|Vedolizumab|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (HER2 expression group) : Vedicetumab (2.5mg/kg, Q2w) alone or combined with platinum-based chemotherapy drugs (carboplatin 200-250mg/m2, Q2w or cisplatin 50mg/m2, Q2w) Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (HER2 expression group) : Vedicetumab monotherapy (2mg/kg, IV, Q2w) or vedicetumab (2mg/kg, IV, Q2w) combined with immune checkpoint inhibitors (triprilizumab 3mg/kg, IV, Q2w, etc.) or vedicetumab (2mg/kg, IV, Q2W, etc.) Q2w) in combination with oral HER2 TKI (pyrrotinib 400mg po qd and other drugs) or Vedicetsol in combination with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w).
80001928|NCT01342289|Drug|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
79391054|NCT03183492|Biological|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
80001929|NCT01342289|Drug|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
80001930|NCT01342289|Drug|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
80001931|NCT01342289|Biological|Bone marrow transplant|Donor stem cells infused IV on Day 0.
80001932|NCT03134599|Device|etafilcon A|contact lens
80001933|NCT03134599|Device|methafilcon A - Interozzo|contact lens
80001934|NCT03134599|Device|methafilcon A - CVI (CooperVision)|contact lens
79391055|NCT03183414|Other|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
79529020|NCT01405144|Procedure|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
79529021|NCT01405157|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
79529022|NCT01405157|Drug|methylprednisolone|tablets 16 mg single dose
79529023|NCT01405170|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
79529024|NCT01405170|Drug|methylprednisolone|tablets 32 mg single dose
80001935|NCT02062190|Drug|resveratrol|"100mg 2x/day~1 month"
79529025|NCT01405183|Other|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
79828014|NCT06145308|Drug|larotinib or enttraitinib|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po;
79685242|NCT00538668|Drug|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
79828015|NCT06145308|Drug|antiandrogen drug treatment|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment;
79828016|NCT06145308|Drug|SHR-A1921|"Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(TROP-2 positive group) : Goxatuzumab 10mg/kg, D1 and D8, Q3w or SHR-A1921 anti-TROP-2 therapy.~Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(TROP-2 positive group) : Goxatuzumab 10mg/kg, D1 and D8, Q3w or SHR-A1921 anti-TROP-2 therapy."
79375228|NCT00986973|Drug|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
79375229|NCT01887522|Drug|Vinblastine + Nilotinib|"Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
79234007|NCT02417402|Other|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
79234008|NCT02417402|Other|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
79234009|NCT02409992|Behavioral|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
79234010|NCT02409992|Behavioral|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
79234011|NCT02417090|Drug|Insulin|Pregnant women who used insulin to treat gestational diabetes
79375230|NCT01887522|Drug|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
79529026|NCT01405235|Drug|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
79529027|NCT01405235|Drug|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
79529028|NCT01405248|Drug|Butylphthalide|20 mg/time per os three times a day. 180days
79685243|NCT02889367|Drug|Odalasvir 100 mg|Participants will receive odalasvir 2*50 mg tablet, orally once on Day 1.
79529029|NCT01405248|Drug|Placebo|20 mg/time per os three times a day. 180days
79529030|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
79529031|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
79529032|NCT01405261|Drug|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
79529033|NCT01405261|Drug|oral placebo|Subjects will be randomised to receive a single dose of placebo.
79529034|NCT01405274|Other|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
79685244|NCT02889367|Drug|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
79685245|NCT02889367|Drug|Odalasvir 500 mg|Participants will receive odalasvir 10*50 mg tablet, orally once on Day 1.
79529035|NCT01405287|Device|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
79529036|NCT01405300|Dietary Supplement|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver ~1200 kcal.
80001936|NCT05128539|Drug|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
79529037|NCT01405300|Dietary Supplement|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver ~1200 kcal.
79529038|NCT01405326|Biological|adalimumab|40mg sc. every two weeks for six months
79529039|NCT01405339|Device|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
79529040|NCT01405339|Device|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
79375231|NCT03422406|Other|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
80001937|NCT01319071|Other|Blood sample|Extraction of blood sample from top-level athletes
80001938|NCT03618498|Procedure|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
80001939|NCT05109273|Procedure|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
80001940|NCT02060708|Device|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
79375232|NCT03426930|Other|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
79375233|NCT03426930|Other|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
79375234|NCT00986427|Drug|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
79375235|NCT00986427|Drug|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
79529041|NCT01405352|Dietary Supplement|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
79529042|NCT01405365|Drug|Metronidazole|Metronidazole 400mg TID for 10 days
79685246|NCT02889367|Drug|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20*50 mg tablet, orally once on Day 1.
79685247|NCT02922647|Device|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
79234012|NCT02417090|Drug|Metformin|Pregnant women who used metformin to treat gestational diabetes
79234013|NCT00703820|Drug|Cytarabine|See Detailed Description
79234014|NCT00703820|Drug|Daunorubicin|See Detailed Description
79234015|NCT00703820|Drug|Etoposide|See Detailed Description
79234016|NCT00703820|Drug|Clofarabine|See Detailed Description
79529043|NCT01405365|Drug|Placebo|Placebo pill TID for 10 days
79529044|NCT01405365|Procedure|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
79529045|NCT01405378|Device|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
79234017|NCT00703820|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79234018|NCT03177980|Drug|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
79375236|NCT05245461|Other|Assessments|Muscle Strength, Proprioception, Kinesiophobia
79375237|NCT03426852|Other|No intervention|No intervention
79375238|NCT05601063|Behavioral|Winterlight Speech Assessment|Digital assessment of speech and language abilities
79529046|NCT01405391|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
79685248|NCT02922647|Device|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
79529047|NCT01405404|Behavioral|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
79685249|NCT05543356|Biological|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
80001941|NCT04194606|Procedure|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
80001942|NCT05211531|Other|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
79529048|NCT01405404|Other|Parent Training|12-session group on parenting skills and child behavior management
79529049|NCT01405417|Procedure|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
80001943|NCT01354483|Biological|Umbilical Cord Blood Mononuclear Cell|
79685250|NCT05543356|Biological|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
79685251|NCT05543356|Biological|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
79685252|NCT05543356|Biological|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
79685253|NCT05543356|Biological|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
80001944|NCT01354483|Biological|Methylprednisolone|30mg/kg i.v. methylprednisolone
79685254|NCT05543356|Biological|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
79685255|NCT05543356|Biological|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
79685256|NCT05543356|Biological|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
79685257|NCT00546039|Drug|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
80001945|NCT01354483|Drug|Lithium Carbonate Tablet|6 weeks
79234019|NCT03177980|Drug|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
79685258|NCT00546039|Drug|Placebo|Capsule
79234020|NCT02409836|Drug|Marketed Dentifrice|Marketed Dentifrice
79234021|NCT02409836|Drug|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
79234022|NCT02409836|Drug|Marketed Flavored Dentifrice|Bubble Gum Flavored
79234023|NCT03174626|Behavioral|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
80001946|NCT02061410|Device|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
80001947|NCT05211453|Procedure|atrioventricular node ablation|atrioventricular node ablation
80001948|NCT03560726|Behavioral|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
80001949|NCT05211375|Procedure|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
79234024|NCT03174626|Other|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
79234025|NCT02417012|Behavioral|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
79234026|NCT02417012|Behavioral|Standard care|Standard individual diabetes support
79234027|NCT02409758|Behavioral|Voice therapy|Voice therapy applied during 6 weeks.
79234028|NCT02409602|Other|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
79234029|NCT03177668|Drug|YS110|Intravenous administration
79234030|NCT03177902|Drug|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
79685259|NCT02916719|Device|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
79685260|NCT01264081|Drug|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
79685261|NCT00538707|Behavioral|2-minute Bondet test|2-minute Bondet test
79685262|NCT00538746|Device|BIPAP|
79685263|NCT00538746|Device|PSV|
79685264|NCT00538746|Device|PSV + CPAP|
79529050|NCT01405430|Biological|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
79685265|NCT05042778|Other|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
79685266|NCT02711969|Drug|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
80001950|NCT05211375|Procedure|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
79685267|NCT00538941|Dietary Supplement|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
80001951|NCT03618264|Drug|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
80001952|NCT03618264|Drug|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
80001953|NCT05089617|Drug|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
79234031|NCT03177590|Other|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
79234032|NCT03177434|Drug|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
79234033|NCT03177434|Drug|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
79234034|NCT02415530|Behavioral|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3~6 months
79234035|NCT02415530|Other|No intervention|No intervention
79234036|NCT03045887|Drug|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
79375239|NCT03426774|Device|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
79375240|NCT03426774|Device|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
79375241|NCT02842320|Other|biological samples|bone marrow and blood
79375242|NCT00986349|Device|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
79375243|NCT03426696|Behavioral|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
79375244|NCT03426618|Other|Non-interventional|Non-interventional
79375245|NCT03429192|Procedure|Surgery|Surgeries plus dissection of lymph nodes
79529051|NCT01405482|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
79685268|NCT00538941|Dietary Supplement|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
79375246|NCT03426540|Drug|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
79375247|NCT03426462|Drug|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
79375248|NCT03421938|Other|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
79375249|NCT03421860|Drug|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
79529052|NCT01405482|Other|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
80001954|NCT03628911|Device|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
80001955|NCT03617016|Drug|Domperidone|Participants will receive domperidone tablets orally.
80001956|NCT03617016|Drug|Placebo|Participants will receive matching placebo to domperidone tablets orally.
79529053|NCT01405495|Procedure|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
79234037|NCT03045887|Drug|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
79234038|NCT03045887|Drug|Placebo|Lactose as powder for inhalation
79234039|NCT02415374|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
79234040|NCT02415296|Other|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
79234041|NCT02415296|Other|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
79234042|NCT02415296|Other|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
79234043|NCT02415452|Procedure|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
79234044|NCT02409524|Biological|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
79375250|NCT03421860|Drug|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
80001957|NCT03798938|Other|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
79234045|NCT02409524|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
79234046|NCT02409524|Biological|CRCL|Autologous tumor-derived chaperone protein mixture
79234047|NCT03177278|Drug|[14C]-plazomicin|single intravenous dose
79234048|NCT02587325|Drug|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|ABI-009
79234049|NCT02409446|Dietary Supplement|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
79234050|NCT02409056|Behavioral|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
79234051|NCT02409056|Behavioral|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
79234052|NCT02415218|Biological|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
79375251|NCT03421860|Drug|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
79529054|NCT01405573|Other|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
79234053|NCT02415140|Other|Rate of depression|
79234054|NCT02414906|Other|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
79234055|NCT03177356|Procedure|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
79234056|NCT03177356|Procedure|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
79234057|NCT02414984|Biological|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
79529055|NCT01405573|Drug|sorafenib|400 mg twice a day
79529056|NCT01405599|Drug|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
79529057|NCT01405612|Drug|Midazolam|Single oral administration on Day 1 or Day 5
79529058|NCT01405612|Drug|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
79529059|NCT01405625|Other|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
80001958|NCT05210829|Diagnostic Test|stationary and trait anxiety scale|survey
80001959|NCT02062268|Behavioral|health education & law enforcement|
80001960|NCT02031822|Procedure|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
80001961|NCT02060786|Drug|generic clopidogrel (Plavitor® )|
80001962|NCT02060786|Drug|original clopidogrel (Plavix® )|
80001963|NCT03628833|Device|Incontinence Management System|Incontinence detection device
80001964|NCT03616938|Procedure|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
80001965|NCT02060864|Dietary Supplement|AN-PEP|Two pills are consumed in the morning with a breakfast
80001966|NCT02060864|Dietary Supplement|Placebo|
80001967|NCT03560414|Procedure|simple plasma exchange|simple plasma exchange treatment
80001968|NCT03560414|Procedure|conventional PDF treatment group|conventional PDF treatment group
80001969|NCT03560414|Procedure|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
80001970|NCT02062424|Other|DIPI|
79234058|NCT02415062|Drug|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
79828017|NCT06145308|Drug|small molecule multi-target tyrosine kinase inhibitors|"Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(ACC group): Adenoid cystadenocarcinoma given acitinib (5mg bid po) or apatinib (500mg qd po) or Renvastinib (24mg qd po) or sorafenib (400mg bid po) or anrotinib (12mg qd) po) or other small molecule multi-target tyrosine kinase inhibitors.~Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(ACC group): Adenoid cystadenocarcinoma given acitinib (5mg bid po) or apatinib (500mg qd po) or Renvastinib (24mg qd po) or sorafenib (400mg bid po) or anrotinib (12mg qd) po) or other small molecule multi-target tyrosine kinase inhibitors."
80001971|NCT03798704|Diagnostic Test|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
80001972|NCT05384418|Radiation|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
80001973|NCT03153137|Drug|Macitentan 10 mg|film-coated tablet; oral use
80001974|NCT03153137|Drug|Placebo|film-coated tablet; oral use
79234059|NCT02409212|Behavioral|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
79234060|NCT02409212|Behavioral|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
79375252|NCT03421860|Drug|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
79375253|NCT03426384|Behavioral|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
79375254|NCT04448730|Diagnostic Test|serum marker levels|two groups comparisons
79375255|NCT03421626|Device|Xpert BCR-ABL Ultra|Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
79529060|NCT01405625|Other|AAAAI standard of care written action plan|
79529061|NCT01405638|Behavioral|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
79529062|NCT01405638|Behavioral|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
79529063|NCT01405651|Drug|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
79529064|NCT01405651|Drug|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
79529065|NCT01405664|Other|Weight-Bearing as Tolerated|WBAT immediately after surgery
79529066|NCT01405677|Biological|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
79529067|NCT01405677|Biological|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
79234061|NCT02416700|Procedure|immediate implant surgery|Surgery of dental implants in one side of the mouth.
79234062|NCT02416700|Device|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
79234063|NCT02408978|Drug|OXP005|
79234064|NCT02408978|Drug|Naproxen|
79234065|NCT02408822|Device|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
79234066|NCT02408822|Device|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
79234067|NCT02414672|Behavioral|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
79234068|NCT03176576|Behavioral|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
79234069|NCT03176576|Other|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
79234070|NCT03176576|Other|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
79234071|NCT03176576|Other|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
79234072|NCT02408744|Drug|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
79234073|NCT03176888|Behavioral|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
79234074|NCT03176888|Behavioral|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey & Greer (2012)
79234075|NCT02414594|Drug|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
79529068|NCT01405677|Biological|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
79529069|NCT01405703|Other|xrays|xrays from 2 week postop to 5 year postop
79529070|NCT01405716|Behavioral|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
79529071|NCT01405716|Behavioral|Health Education|8-week health education program
79685269|NCT01263925|Drug|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
79234076|NCT02414594|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79685270|NCT01263925|Drug|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
79685271|NCT01263925|Drug|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
79685272|NCT01263925|Drug|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
79685273|NCT04323631|Drug|Hydroxychloroquine|Oral
79828018|NCT06145308|Drug|albumin paclitaxel with platinum|Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(no target and other groups) : albumin paclitaxel 160mg/m2 combined with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w); Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(no target and other groups) : albumin paclitaxel 160mg/m2 combined with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w);
79828019|NCT06145295|Behavioral|mobile online support group (experiment group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
79685274|NCT04323631|Other|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
79828020|NCT06145295|Behavioral|offline support group (control group)|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
79375256|NCT04449120|Behavioral|Mediterranean diet-based culinary intervention|The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.
79375257|NCT04449120|Behavioral|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
79685275|NCT00546234|Drug|tiotropium|18 mcg daily via Handihaler
79685276|NCT00546234|Drug|long acting beta agonist|Turbohaler, 6 & 12 mcg
79685277|NCT03455348|Other|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
79828021|NCT06145269|Drug|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
79234077|NCT03176810|Device|OCT|OCT is used to guide PCI.
79234078|NCT03176810|Device|Angiography|Angiography is used to guide PCI.
79234079|NCT02416778|Drug|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
79234080|NCT02408666|Other|Interview|
79234081|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
79234082|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
79234083|NCT02414516|Drug|OBP-801|OBP-801 will be administered IV
79685278|NCT00539019|Other|calories measured 5x following wound healing|measure REE at various time points postburn
79685279|NCT00539097|Dietary Supplement|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
79685280|NCT02664506|Behavioral|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
79685281|NCT05042037|Dietary Supplement|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
79685282|NCT05042037|Other|Placebo|Placebo sachet with no microbial cell preparation
79685283|NCT02664038|Behavioral|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
79685284|NCT02623439|Drug|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
79685285|NCT00546312|Device|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
79375258|NCT03421548|Device|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
79685286|NCT02599922|Biological|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
79685287|NCT00539175|Device|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
79685288|NCT00539175|Device|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
79828022|NCT06145243|Other|Home based exercise|Patients will be given a visual brochure with pictures explaining the exercises. Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the home exercise group will be checked by phone every week.
79828023|NCT06145243|Other|Video-based resistive exercise|A video recording of the exercises will be taken and given to the patients as a video recording.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the video-based exercise group will be checked by phone every week.
79828024|NCT06145243|Other|Supervised resistive exercise|Patients will perform their exercises under the supervision of a physiotherapist.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.
79828025|NCT06145230|Other||
79828026|NCT06145217|Drug|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
80001975|NCT05654558|Device|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
80001976|NCT05654558|Device|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
79234084|NCT03176342|Other|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
79234085|NCT03174080|Radiation|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
79234086|NCT02414360|Other|Shortened Format|Shortened format of a systematic review
79234087|NCT02414360|Other|Full Length|Full length systematic review
79375259|NCT04448652|Drug|NSAID|no other intervention than described in the groups.
79529072|NCT01405755|Behavioral|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
79685289|NCT02277353|Other|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
79375260|NCT03483324|Biological|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
79375261|NCT03483324|Biological|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
79685290|NCT00539292|Procedure|Primary placement of a spring-loaded silo|
79685291|NCT00539292|Procedure|Primary Closure|primary closure of abdomen
79828027|NCT06145204|Other|questionnaire|anamnesis, OMSPQ, DN4, Brief Pain Inventory-short form, lymph-ICF-LL
79828028|NCT06145178|Biological|SPYVAC01|Novel vaccine SPYVLP01
79234088|NCT03171896|Other|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
79234089|NCT03171896|Other|Sham|No clown will be present in the room during labor
79234090|NCT04482452|Procedure|Colonoscopy|Diagnostic colonoscopy will be performed
79234091|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
79375262|NCT03426150|Drug|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
79529073|NCT01405807|Drug|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
79529074|NCT01405833|Drug|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
79529075|NCT01405833|Drug|Placebo|Single dose IV matched placebo
79529076|NCT01405846|Drug|Gefitinib|250mg od for 6 months
79529077|NCT01405872|Other|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
79685292|NCT00539331|Drug|AZD2171|oral tablet
79685293|NCT00539331|Drug|Paclitaxel|intravenous infusion
79685294|NCT00539331|Drug|Carboplatin|intravenous injection
80001977|NCT03616626|Radiation|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
79234092|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
79685295|NCT00546468|Procedure|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
79685296|NCT00546468|Procedure|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
79685297|NCT02236013|Drug|Gilteritinib|Oral
79685298|NCT02236013|Drug|Idarubicin|lyophilized powder administered intravenously
80001978|NCT03616626|Radiation|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
79234093|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
79234094|NCT02414126|Device|CPAP|
79375263|NCT03426150|Drug|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
80001979|NCT03616626|Radiation|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
80001980|NCT03617484|Drug|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle.
80001981|NCT03617484|Drug|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
79234095|NCT02414282|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
79234096|NCT03116204|Other|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
79234097|NCT03116516|Drug|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
79234098|NCT03116516|Drug|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
79375264|NCT02053584|Device|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
79375265|NCT02053584|Device|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
79234099|NCT01564537|Drug|Ixazomib|Ixazomib capsules
79234100|NCT01564537|Drug|Lenalidomide|Lenalidomide capsules
79234101|NCT01564537|Drug|Dexamethasone|Dexamethasone tablets
79234102|NCT01564537|Drug|Placebo|Ixazomib placebo-matching capsules
79375266|NCT03127878|Other|Exercise|
79375267|NCT03421314|Dietary Supplement|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
79375268|NCT03421236|Biological|Ty21a|intravesical administration of Ty21a
79375269|NCT03425994|Drug|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
79375270|NCT03421158|Behavioral|breastfeeding|Newborns were breastfed during the procedure
79529078|NCT01405885|Biological|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529079|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529080|NCT01405885|Biological|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529081|NCT01405885|Biological|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529082|NCT01405885|Biological|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529083|NCT01405885|Biological|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529084|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
79529085|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
79529086|NCT01405885|Biological|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
79529087|NCT01405885|Biological|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
79529088|NCT01405976|Device|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
79529089|NCT01405989|Drug|darexaban|oral
79685299|NCT02236013|Drug|Cytarabine|solution administered intravenously
79685300|NCT02236013|Drug|Daunorubicin|solution administered intravenously
79685301|NCT03456999|Biological|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
79685302|NCT03456999|Biological|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
79234103|NCT03116360|Diagnostic Test|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
79375271|NCT03421158|Dietary Supplement|oral sucrose|Newborns were given oral sucrose during the procedure
80001982|NCT01344473|Device|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
79234104|NCT03174236|Drug|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
79685303|NCT00539409|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
79234105|NCT03174236|Drug|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
79234106|NCT03174236|Drug|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
79234107|NCT03174236|Other|Placebo|Suspension manufactured to match metronidazole
79234108|NCT03174236|Drug|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
79234109|NCT03202043|Other|High dose vegetable juice|High dose (13 fl oz) vegetable juice
79234110|NCT03202043|Other|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
79234111|NCT03202043|Other|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
79529090|NCT01405989|Drug|ketoconazole|oral
79234112|NCT03202043|Other|Control bottled water|Control (12 fl oz) bottled water
79234113|NCT03172052|Drug|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
79234114|NCT03172052|Drug|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
79529091|NCT01406002|Drug|darexaban|oral
79234115|NCT03172052|Device|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
79234116|NCT03172052|Device|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
79234117|NCT03673969|Procedure|Gastric bypass|Surgical method of gastric bypass
79234118|NCT03673891|Device|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
79375272|NCT03421158|Behavioral|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
79375273|NCT03421158|Behavioral|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
79375274|NCT03421080|Behavioral|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
79529092|NCT01406002|Drug|Rifampicin|oral
79529093|NCT01406028|Behavioral|Phone calls|Phone calls to offer emotional support
79529094|NCT01406041|Biological|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
79529095|NCT01406054|Other|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
79529096|NCT01406067|Behavioral|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
79685304|NCT01263691|Biological|BioThrax|BioThrax
79685305|NCT01263691|Biological|AV7909 Formulation 1|AV7909 Formulation 1
79685306|NCT01263691|Biological|AV7909 Formulation 2|AV7909 Formulation 2
79685307|NCT01263691|Biological|AV7909 Formulation 3|AV7909 Formulation 3
79685308|NCT01263691|Biological|AV7909 Formulation 4|AV7909 Formulation 4
79685309|NCT01263691|Drug|Control|Saline control
80001983|NCT02063204|Drug|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
80001984|NCT03617406|Diagnostic Test|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
80001985|NCT01344551|Dietary Supplement|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
80001986|NCT03618108|Drug|Doxycycline Capsule|doxycycline capsule
79828029|NCT06145165|Other|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
80001987|NCT03618108|Drug|Azithromycin Capsule|azithromycin capsule
80001988|NCT03618108|Drug|Rifabutin Oral Capsule|rifabutin capsule
80001989|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
80001990|NCT03618108|Drug|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
80001991|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
79234119|NCT03174392|Other|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
79375275|NCT03421080|Behavioral|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
79375276|NCT03416712|Other|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
79375277|NCT03425916|Other|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
79375278|NCT03416634|Behavioral|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
79529097|NCT01406067|Behavioral|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
79529098|NCT01406080|Drug|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
79529099|NCT01406080|Drug|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
79529100|NCT01406106|Dietary Supplement|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
79529101|NCT01406119|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
79685310|NCT02178410|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
80001992|NCT03138473|Diagnostic Test|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
79529102|NCT01406132|Drug|ASP015K|oral
79685311|NCT02178410|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79685312|NCT02178410|Dietary Supplement|Fish oil placebo|Fish oil placebo
79685313|NCT02178410|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
79685314|NCT00539448|Drug|insulin glargine|in combination with insulin Glulisine as bolus regimen
79685315|NCT00539448|Drug|insulin glulisine|in combination with insulin Glargine as bolus regimen
79685316|NCT02100254|Behavioral|behavioral intervention|View personal narrative informational video
80001993|NCT03138473|Diagnostic Test|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-[rSS/bSS]) ×100.
80001994|NCT02031900|Device|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
79685317|NCT02100254|Behavioral|behavioral intervention|View fact-based informational video
79828030|NCT06145165|Combination Product|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
80001995|NCT04903704|Diagnostic Test|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
80001996|NCT01342601|Device|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
80001997|NCT01342601|Device|Placebo products|Nasal Spray and Eye drops without Ectoin
80001998|NCT03616548|Diagnostic Test|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
80001999|NCT04349657|Device|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
80002000|NCT04349657|Procedure|Endarterectomy treatment group|Surgical treatment through endarterectomy
79234120|NCT03174392|Other|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
79234121|NCT02414048|Drug|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
79234122|NCT03171662|Other|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
79234123|NCT03064217|Procedure|CLP and 12 weeks waiting|Restorative treatments will be initiated 12 weeks after clinical crown lengthenings (CLPs).
79234124|NCT03064217|Procedure|Digital impression taken at surgery|The final impression will be made at surgery.
79234125|NCT02413814|Behavioral|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
79234126|NCT02413814|Behavioral|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
79234127|NCT02408354|Drug|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
79529103|NCT01406145|Drug|ASP0777|oral tablet
79529104|NCT01406145|Drug|Placebo|oral tablet
79375279|NCT03416634|Behavioral|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
79375280|NCT03416634|Behavioral|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
79529105|NCT01406158|Drug|Solifenacin Succinate Formulation A|oral suspension
79529106|NCT01406158|Drug|Solifenacin Succinate Formulation B|oral suspension
79685318|NCT04323358|Diagnostic Test|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
79685319|NCT04323358|Diagnostic Test|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
79529107|NCT01406158|Drug|Solifenacin Succinate|oral tablet
79529108|NCT01406171|Drug|Isavuconazole|oral
79685320|NCT05539846|Procedure|modified blood collection method|The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
79529109|NCT01406171|Drug|Midazolam|Oral
79529110|NCT01406236|Procedure|Transradial PCI|Transradial PCI
79685321|NCT01808456|Biological|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
79685322|NCT01808456|Biological|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
79828031|NCT06145165|Other|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
80002001|NCT03616392|Drug|D308, CKD-501|"D308~CKD-501: Lobeglitazone sulfate 0.5mg"
80016687|NCT05189587|Device|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
79529111|NCT01406236|Procedure|Transfemoral PCI|Transfemoral PCI
80002002|NCT04894968|Diagnostic Test|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~Symptoms of heart failure (e.g. dyspnea on extertion)~Preserved ejection fraction (Left ventricular ejection fraction ≥50%~NT-proBNP ≥125 pg/mL~Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~Left atrial volume index >34 mL/m²~Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~E/e' ≥13~Septal e' <9 cm/s"
79828032|NCT06144216|Other|CLOE Outreach Intervention|The CLOE outreach intervention is a community-led, strengths-based, and trauma-informed program to support self-identifying women and youth who experience interpersonal and structural gender-based violence. Outreach services are designed to mitigate the effects of gender-based violence, build trusting relationships with service providers, and improve safety, well-being and engagement with health and social care.
79828033|NCT06144021|Dietary Supplement|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
79828034|NCT06144021|Dietary Supplement|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
79828035|NCT06143566|Drug|Polypill|A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
79828036|NCT06143358|Drug|Qingkepingchuan Granules|Qingkepingchuan Granules,Take it three times a day with water after meals.
79828037|NCT06143358|Other|conventional treatment|Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
80002003|NCT03615378|Dietary Supplement|5000 IU D3|Daily
79529112|NCT01406249|Drug|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
79529113|NCT01406249|Drug|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
79529114|NCT01406262|Biological|Albiglutide|once weekly subcutaneous injection
79529115|NCT01406262|Drug|Moxifloxacin|oral tablet
79685323|NCT01781741|Combination Product|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
79685324|NCT01781741|Other|quality-of-life assessment|Ancillary studies
79685325|NCT01715714|Drug|Statin Recapture Therapy|Given 12h and 2h before CABG
79828038|NCT06142942|Other|Exercise Intervention|Participants will complete an exercise intervention where they will exercise 2, 3, or 4 days per week for 4 weeks.
79685326|NCT01715714|Drug|Placebo|Given 12h and 2h before CABG.
79828039|NCT06142110|Other|Funcional movement screen|FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.
79828040|NCT06142110|Diagnostic Test|Respiratory muscle strength|Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
80002004|NCT03615378|Dietary Supplement|1000 IU D3|Daily
80002005|NCT03615378|Dietary Supplement|Placebo|lactose/sugar tablet
80002006|NCT03616314|Device|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
80002007|NCT03616314|Device|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
80002008|NCT03616314|Other|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
80002009|NCT02236728|Drug|Pramipexole|
79375281|NCT03416634|Behavioral|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
79375282|NCT03421002|Drug|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
79375283|NCT03420924|Device|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
79685327|NCT01540253|Drug|PI3K inhibitor BKM120|Given PO
79375284|NCT03420924|Device|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
79375285|NCT03420846|Other|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
79375286|NCT02521038|Drug|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
79391056|NCT03182010|Device|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
79529116|NCT01406275|Drug|Amoxicillin and clavulanate|
79529117|NCT01406288|Other|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
79685328|NCT01540253|Drug|docetaxel|Given IV
79685329|NCT01540253|Other|pharmacological study|Correlative studies
79685330|NCT01540253|Other|questionnaire administration|Ancillary studies
79685331|NCT01540253|Other|laboratory biomarker analysis|Correlative studies
80002010|NCT01344707|Drug|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
79828041|NCT06141681|Other|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
79234128|NCT02408354|Drug|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
79234129|NCT02406404|Behavioral|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
79375287|NCT03416556|Procedure|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
79375288|NCT03416556|Procedure|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
79529118|NCT01406301|Drug|fondaparinux|fondaparinux
79529119|NCT01406314|Drug|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
79529120|NCT01406327|Drug|Ambrisentan|Ambrisentan
79529121|NCT01406340|Drug|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
79375289|NCT03416556|Other|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
79375290|NCT03416478|Diagnostic Test|ctDNA test|ctDNA test to find some possible mutation.
79685332|NCT01497392|Drug|dovitinib lactate|Given PO
79685333|NCT01497392|Drug|gemcitabine hydrochloride|Given IV
79828042|NCT06141512|Behavioral|Reduced-exertion high-intensity interval training (REHIT)|Description same as Arm description.
79375291|NCT03416400|Other|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
79375292|NCT00985959|Drug|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
79529122|NCT01406353|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
79685334|NCT01497392|Drug|capecitabine|Given PO
79685335|NCT01497392|Other|laboratory biomarker analysis|Correlative studies
79685336|NCT01497392|Other|enzyme-linked immunosorbent assay|Correlative studies
79685337|NCT01497392|Other|pharmacological study|Correlative studies
79685338|NCT01310192|Device|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
79685339|NCT05106855|Radiation|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
79234130|NCT03176264|Drug|PDR001|400 mg every 4 weeks
79234131|NCT03176264|Drug|bevacizumab|5 mg/kg every 2 weeks
79234132|NCT03176264|Drug|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
79685340|NCT05106855|Other|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
79685341|NCT05106855|Radiation|Low Laser Radiation off|This group will receive laser application off.
79685342|NCT05106855|Procedure|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
79685343|NCT05106855|Procedure|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
79685344|NCT00539565|Drug|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
79685345|NCT00539565|Drug|placebo|
79685346|NCT00539604|Procedure|MDCT and Coronary Angiography|
79685347|NCT00539760|Drug|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
79685348|NCT00539760|Drug|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
79375293|NCT00985959|Drug|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
80002011|NCT03615300|Diagnostic Test|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
80002012|NCT04254653|Behavioral|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 ~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
79234133|NCT02406170|Drug|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
79234134|NCT02406170|Drug|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
79375294|NCT00985959|Drug|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
79375295|NCT00985959|Drug|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
79375296|NCT00985959|Drug|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
79375297|NCT05607849|Other|"Leaflet decidons ensemble (making a decision together)"|"At the beginning of the intervention, material i) informing women of the existence of the DA for participation or not in breast cancer screening and (ii) aiming to promote the implementation of shared medical decision will be sent or not sent to women and their GPs according to their allocation arm. This material will be sent at the same time as the breast cancer screening invitation letter.~For the secondary outcomes, questionnaires will be sent to a sample of women in each arm."
79375298|NCT00985725|Drug|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
79375299|NCT00985725|Drug|Matching placebo|oral, once daily
79375300|NCT01294306|Drug|Akt Inhibitor MK2206|Given PO
79375301|NCT01294306|Drug|Erlotinib Hydrochloride|Given PO
79375302|NCT01294306|Other|Laboratory Biomarker Analysis|Correlative studies
79375303|NCT01294306|Other|Pharmacological Study|Correlative studies
79375304|NCT00985491|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
79375305|NCT05602701|Other|Preoperative assessment|Preoperative assessment of physical fitness
79685349|NCT00539799|Drug|prednisolone|5 - 7.5 mg/day
79685350|NCT00539799|Drug|Placebo|Matched placebo to prednisolone
79685351|NCT00945152|Drug|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
79685352|NCT00945152|Drug|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
79685353|NCT00546507|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
79685354|NCT00546507|Drug|celecoxib|
79685355|NCT00546507|Other|placebo|
79685356|NCT00546546|Drug|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
80002013|NCT01344785|Procedure|Intramedullary nailing|All patients will be treated with Intramedullary nailing
80002014|NCT03136861|Biological|AIN457|anti IL-17a monoclonal antibody
80002015|NCT03136861|Drug|AIN457 Placebo|Placebo matching AIN457
79375306|NCT01351480|Biological|abatacept|Abatacept administered SC weekly at 125 mg dose
79375307|NCT03416829|Behavioral|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
79375308|NCT04348149|Dietary Supplement|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
79375309|NCT05607693|Drug|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
79375310|NCT01352182|Drug|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
79375311|NCT00984867|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
79375312|NCT00984867|Drug|Placebo|Matching placebo tablet
79685357|NCT00659711|Drug|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
79685358|NCT00659711|Drug|Placebo|will be placed on a placebo for 12 weeks.
79685359|NCT00546624|Drug|MK0777|
79685360|NCT00580346|Device|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
79828043|NCT06140823|Other|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
79828044|NCT06140823|Other|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
80016688|NCT04471922|Drug|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
79375313|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
80002016|NCT03482856|Behavioral|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
80002017|NCT03482856|Behavioral|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
80002018|NCT01342679|Drug|dasatinib|100mg QD
79234135|NCT03173768|Procedure|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
79234136|NCT02413658|Drug|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
80002019|NCT04852926|Other|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~T0 (at inclusion) : before disease + since diagnosis~C4 (chemotherapy course n°4)~C6 (chemotherapy course n°6)~M3 (3 months after chemotherapy)~M6 (6 months after chemotherapy)~A1 (1 year after chemotherapy)~A2 (2 years after chemotherapy)"
79529123|NCT01406366|Behavioral|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
79234137|NCT02413658|Drug|Sugar solution|
79234138|NCT02406014|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
79375314|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
79375315|NCT01294384|Drug|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
80002020|NCT03616080|Behavioral|soccer play program|once a week for an hour of a soccer program for 8 weeks
80002021|NCT01342835|Drug|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
79375316|NCT01257802|Drug|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
79375317|NCT01257802|Drug|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
79529124|NCT01406366|Behavioral|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
79529125|NCT01406379|Procedure|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
79529126|NCT01406379|Procedure|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
79529127|NCT01406392|Drug|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
79828045|NCT06140823|Other|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
79828046|NCT06140602|Other|Intervention shake|The pecan shake contains 69g of pecans
79375318|NCT05607303|Other|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
79375319|NCT02979964|Behavioral|Audit and Feedback|
79375320|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
79375321|NCT00984009|Other|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
79375322|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
79529128|NCT01406392|Drug|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
79529129|NCT01406405|Procedure|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
79828047|NCT06140342|Behavioral|Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.
79375323|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
80002022|NCT03616002|Other|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
80002023|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
80002024|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
80002025|NCT01354561|Procedure|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
79375324|NCT00983931|Drug|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
79375325|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
80002026|NCT02666183|Behavioral|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
80002027|NCT02666183|Behavioral|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
80002028|NCT02666183|Behavioral|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
80002029|NCT03316950|Device|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
80002030|NCT03316950|Device|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
79375326|NCT05606211|Other|No intervention|Observational, no intervention
79375327|NCT03075111|Diagnostic Test|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
80002031|NCT03316950|Device|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
80002032|NCT03139279|Drug|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
79529130|NCT01406418|Biological|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
79529131|NCT01406418|Biological|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
79685361|NCT00546663|Drug|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
80002033|NCT03139279|Other|Saline placebo|Intravenous saline/placebo
80002034|NCT03139279|Drug|Propofol|Propofol titrated intravenous boluses
80002035|NCT02562599|Drug|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
80002036|NCT02562599|Radiation|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
79375328|NCT05604573|Diagnostic Test|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
79375329|NCT02984319|Dietary Supplement|Cherry versus placebo concentrate|Acute cherry concentrate
79375330|NCT05604495|Diagnostic Test|Sweat Test|In people with cystic fibrosis (CF), there is a problem in the transport of chloride across cell membranes. This results in higher concentrations of chloride (as salt) in sweat compared to those who do not have cystic fibrosis. So, if there is a family history or a possibility of CF, the sweat test is part of the special tests to help make, or exclude, a diagnosis of cystic fibrosis.
79375331|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
79375332|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
79375333|NCT00983853|Biological|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
79375334|NCT00983853|Drug|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
79529132|NCT01406418|Biological|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
79529133|NCT01406418|Biological|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
79685362|NCT00300599|Device|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
79685363|NCT00300599|Other|Placebo|Placebo
79685364|NCT00546702|Drug|Insuline Glulisine|
79685365|NCT02581007|Drug|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
79685366|NCT02581007|Drug|Melphalan|
79685367|NCT02581007|Drug|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
79685368|NCT02581007|Procedure|peripheral blood stem cell transplant|
79685369|NCT00546741|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
79685370|NCT00546741|Drug|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
79685371|NCT00546741|Drug|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
79234139|NCT02406014|Drug|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
79375335|NCT00983853|Drug|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
80002037|NCT01358227|Drug|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
80002038|NCT03311958|Drug|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
80002039|NCT01370642|Drug|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
79234140|NCT02406092|Drug|Rituximab|Rituximab SC 1400 mg
79234141|NCT02406092|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
79375336|NCT05604261|Drug|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
79529134|NCT01406418|Biological|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
79529135|NCT01406418|Biological|Placebo|Administered as a single 2-hour intravenous infusion
79375337|NCT05604261|Drug|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
79375338|NCT05604261|Drug|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
79391057|NCT03182010|Device|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
79529136|NCT01406431|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
79529137|NCT01406431|Drug|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
80002040|NCT01370642|Drug|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
79391058|NCT03181854|Behavioral|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
79234142|NCT02406092|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice.
79529138|NCT01406470|Drug|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
79529139|NCT01406483|Other|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
79234143|NCT02406092|Drug|Vincristine|Vincristine will be administered as per standard local practice.
79234144|NCT02406092|Drug|Prednisone|Prednisone will be administered as per standard local practice.
79234145|NCT02406092|Drug|Fludarabine|Fludarabine will be administered as per standard local practice.
79234146|NCT02413268|Drug|Nitroglycerin|
79234147|NCT03173690|Other|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
79234148|NCT03173690|Other|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
79234149|NCT02405936|Procedure|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
79391059|NCT03181854|Behavioral|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
79529140|NCT01406496|Drug|insulin|Three different timings of insulin delivered by a pump
79529141|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
79529142|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
79529143|NCT01406522|Drug|Oral tacrine|Tacrine, 160 mg per day, four times daily
79529144|NCT01406522|Drug|Oral placebo|Microcrystalline cellulose
79529145|NCT01406535|Drug|Vardenafil|5 mg vardenafil per os twice daily
80002041|NCT01370642|Biological|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
80002042|NCT01370642|Drug|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
80002043|NCT02873208|Drug|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
80002044|NCT03138967|Drug|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
79234150|NCT02413502|Biological|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10^8 CFUs.
79234151|NCT02405858|Drug|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
79234152|NCT02405858|Drug|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
79234153|NCT03171740|Drug|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
79234154|NCT03171740|Drug|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
79234155|NCT03171740|Drug|Oral saline|Oral saline, 0.25ml/kg
79234156|NCT03171740|Drug|Nasal saline|Nasal saline 0.01ml/kg
80002045|NCT03138967|Drug|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
80002046|NCT03138967|Drug|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
79529146|NCT01406535|Other|Placebo|5 mg placebo per os twice daily
80002047|NCT03138967|Drug|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
80002048|NCT01358305|Other|Protein Blend|Single intake of approximately 20 grams of total protein
80002049|NCT01547117|Radiation|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
79234157|NCT03176186|Combination Product|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
79375339|NCT03032601|Dietary Supplement|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
79529147|NCT01406587|Drug|PP4001|50 mg, 1 dose every 12 hours x 4 doses
79234158|NCT03175952|Diagnostic Test|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
79375340|NCT05604105|Other|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
79234159|NCT02413424|Dietary Supplement|Sucralose|60 ml of 2mM sucralose
79529148|NCT01406587|Drug|PP4001|100 mg, 1 dose every 12 hours x 4 doses
79234160|NCT02413424|Other|Water|60 ml of water
79234161|NCT02413424|Dietary Supplement|glucose load|
79234162|NCT02413112|Behavioral|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
79234163|NCT04482764|Drug|Valproic Acid|Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
79391060|NCT02430402|Other|Rehabilitation in warm climate|
79529149|NCT01406587|Drug|PP4001|200 mg, 1 dose every 12 hours x 4 doses
79529150|NCT01406587|Drug|Placebo|Placebo, 1 dose every 12 hours x 4 doses
79529151|NCT01406600|Drug|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24~48 hours from optimal ovarian stimulation status.
79529152|NCT01406613|Other|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
79685372|NCT02540330|Drug|Fulvestrant|
79529153|NCT01406626|Behavioral|Peer Navigator|Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
79529154|NCT01406639|Drug|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
80002050|NCT01547117|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
80002051|NCT01547117|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
80002052|NCT01547117|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
80002053|NCT01358383|Drug|naproxen|250mg, oral dose
80002054|NCT01358383|Drug|esomeprazole|20mg, oral dose
80002055|NCT03560336|Drug|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
79234164|NCT03173378|Other|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
79234165|NCT02408042|Drug|Pembrolizumab|
79529155|NCT01406704|Drug|Rosiglitazone|Rosiglitazone (8 mg/day)
79529156|NCT01406704|Drug|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
79685373|NCT00546858|Other|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
79685374|NCT00546936|Drug|ranibizumab|0.5mg ranibizumab
79685375|NCT00546936|Drug|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
79529157|NCT01406704|Drug|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
79529158|NCT01406730|Other|exercise|16 week of periodized progressive running exercise 2-4 times/week
79529159|NCT01406743|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
79529160|NCT01406769|Procedure|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
79234166|NCT02408042|Drug|Etoposide|
79828048|NCT06139432|Device|Active tDCS|"Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~Cathode opposite the left temporoparietal junction (between T3 and P3).~The stimulation level is 2mA for 20 minutes.~Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
79828049|NCT06139432|Device|Sham tDCS|"Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~Cathode opposite the left temporoparietal junction (between T3 and P3).~Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
79529161|NCT01406769|Procedure|Lymphadenectomy|Undergo lymphadenectomy
79529162|NCT01406769|Procedure|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
79685376|NCT02438891|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
79529163|NCT01406782|Biological|rituximab|
79685377|NCT00546975|Dietary Supplement|Resource Support®|
79234167|NCT02408042|Drug|Ifosfamide|
79529164|NCT01406782|Genetic|DNA analysis|
79685378|NCT00546975|Dietary Supplement|Resource Protein®|
79685379|NCT00546975|Dietary Supplement|Placebo|
79234168|NCT02408042|Drug|Mesna|
79375341|NCT04759287|Device|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
79685380|NCT05006313|Device|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
79685381|NCT01263496|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
79685382|NCT01263496|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
79234169|NCT02408042|Drug|Carboplatin|
79375342|NCT04759287|Device|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
79375343|NCT05603013|Drug|Vinorelbine|Vinorelbine Tartrate Oral
79375344|NCT05603013|Radiation|Radiotherapy|hypofractionated radiotherapy
79375345|NCT05603013|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
79529165|NCT01406782|Genetic|gene expression analysis|
79375346|NCT05603013|Drug|GM-CSF|GM-CSF subcutaneous injection
79375347|NCT05603013|Drug|IL-2|IL-2 subcutaneous injection
79529166|NCT01406782|Genetic|polymerase chain reaction|
79685383|NCT01263496|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
79685384|NCT01263496|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
79685385|NCT01263496|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
79828050|NCT06137131|Behavioral|Straw phonation in air|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in air
79828051|NCT06137131|Behavioral|straw phonation in water|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in 2 cm or 5 cm water
79375348|NCT00983073|Drug|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
79391061|NCT02424318|Drug|Topiramate|topiramate 25mg twice 1 week -> topiramate 50mg twice 7 weeks
79828052|NCT06137131|Behavioral|/u/ phonation|/u/ phonation without a straw, control condition
79234170|NCT02408042|Drug|Brentuximab vedotin|
79234171|NCT02408042|Drug|Rituximab|
79234172|NCT03173222|Procedure|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
79234173|NCT03172988|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
79234174|NCT03172988|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
79529167|NCT01406782|Other|laboratory biomarker analysis|
79529168|NCT01406808|Behavioral|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
79529169|NCT01406821|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
79529170|NCT01406821|Procedure|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
79529171|NCT01406834|Behavioral|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
79685386|NCT00547014|Drug|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
79685387|NCT00547014|Drug|52364 3 mg|3 mg capsule single dose administered orally as a single dose
79828053|NCT06134167|Device|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
79685388|NCT00547014|Drug|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
79685389|NCT00547014|Drug|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
79685390|NCT00547014|Drug|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
79685391|NCT00547014|Drug|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
79685392|NCT00547014|Drug|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
79685393|NCT04681937|Combination Product|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
79685394|NCT04681937|Combination Product|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
79685395|NCT04681937|Combination Product|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
79685396|NCT04681937|Combination Product|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
79685397|NCT00547053|Drug|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
79685398|NCT02131649|Device|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
79685399|NCT00547092|Drug|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
79685400|NCT00547092|Drug|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
79685401|NCT00547131|Drug|temozolomide|
79685402|NCT00547131|Other|laboratory biomarker analysis|
79685403|NCT00547131|Other|liquid chromatography|
79685404|NCT00547131|Other|mass spectrometry|
79685405|NCT00547131|Other|pharmacological study|
79828054|NCT06132841|Drug|AZD6234|Participants will receive repeated doses of AZD6234 as a solution via SC
79828055|NCT06132841|Drug|Placebo|Participants will receive matching volumes of the placebo as a solution via SC
79828056|NCT06132698|Drug|Tislelizumab, pemetrexed|Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
79828057|NCT06129643|Drug|Conventional group|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
79828058|NCT06129643|Device|Dual laser group|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
80002056|NCT04847388|Drug|Substance like alcohol, marijuana, etc.|Cohort study
79685406|NCT00547131|Procedure|conventional surgery|
79685407|NCT00547131|Radiation|stereotactic radiosurgery|
79685408|NCT01964495|Drug|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
79375349|NCT05602857|Other|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
79685409|NCT01964495|Drug|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
79685410|NCT01964495|Drug|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
79685411|NCT00547170|Drug|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
79685412|NCT00547170|Drug|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
79828059|NCT06129643|Combination Product|Combined group|17% EDTA was used to remove smear layer followed by diode laser for disinfection
79828060|NCT06128096|Drug|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|"Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention."
79828061|NCT06127017|Procedure|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
80016689|NCT04471922|Drug|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
79529172|NCT01406847|Other|Spinal Manipulation|High velocity low amplitude joint-biased intervention
80002057|NCT03136159|Device|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
79234175|NCT03172988|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
79234176|NCT03172988|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
79828062|NCT06127017|Procedure|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
80002058|NCT03615768|Combination Product|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
79234177|NCT03042611|Drug|Rivoceranib|Oral tablet
79234178|NCT03042611|Drug|Placebo|Oral tablet
79234179|NCT03171350|Diagnostic Test|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
79375350|NCT05602857|Other|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
79685413|NCT00900809|Biological|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
79234180|NCT03171584|Drug|Terbinafine|oral antifungal drugs
79234181|NCT02988245|Drug|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
79234182|NCT02988245|Drug|JNC-8|Using JNC-8 guidelines to guide therapy
79375351|NCT05604027|Diagnostic Test|Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects
79375352|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
79529173|NCT01406847|Other|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
79529174|NCT01406847|Other|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
79685414|NCT01263223|Drug|LY2216684|Administered orally
79828063|NCT06125210|Behavioral|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
79828064|NCT06125210|Dietary Supplement|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
79234183|NCT02388659|Device|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
79375353|NCT00982137|Biological|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
79529175|NCT01406886|Behavioral|Eating rate|
79529176|NCT01406899|Behavioral|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
79685415|NCT01263223|Drug|Placebo|Administered orally
79685416|NCT00547209|Drug|air|60% air combined with 40% oxygen for ventilation
79234184|NCT02879825|Device|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
79234185|NCT02349815|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
79234186|NCT03171506|Other|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that ~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
79234187|NCT03171506|Other|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
79234188|NCT02818517|Other|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
80002059|NCT03615768|Drug|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
79685417|NCT00547209|Drug|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
79828065|NCT06125210|Procedure|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
79828066|NCT06122064|Other|Best Practice|Receive standard of care
79234189|NCT02818517|Other|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
79529177|NCT01406912|Other|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
79529178|NCT01406912|Other|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
79685418|NCT00547287|Drug|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
79828067|NCT06122064|Other|Communication Intervention|Use shared decision-making conversation tool
79828068|NCT06122064|Other|Electronic Health Record Review|Ancillary studies
79828069|NCT06122064|Other|Survey Administration|Ancillary studies
79828070|NCT06122064|Other|Video Recording|Ancillary studies
79828071|NCT06117839|Procedure|using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.|-There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .
79828072|NCT06116409|Drug|Bupivacain|Bupivacaine was used for postoperative analgesia block.
79828073|NCT06113029|Diagnostic Test|The Hamilton Rating Scale for Anxiety|The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).
79828074|NCT06113029|Diagnostic Test|The Beck Depression inventory|one of the most widely used instruments for measuring the severity of depression
80002060|NCT03615768|Drug|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
80002061|NCT02061644|Other|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
80002062|NCT04178135|Drug|rLH|rLH supplement from day 1 of stimulation
80002063|NCT04178135|Drug|rLH|rLH supplement from day 6 of stimulation
80002064|NCT04958070|Other|MPS I|MPS I, symptoms of disease onset , ERT
80002065|NCT01318291|Behavioral|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
79234190|NCT02405702|Other|restrospective study|
79529179|NCT01406925|Drug|Placebo control|Placebo cream
79529180|NCT01406925|Drug|NRL001 cream|Cream for single-dose intra-anal application
79529181|NCT01406964|Other|CAT test|A CAT test is performed in order to diagnose tubal factor causes
80002066|NCT01318291|Behavioral|Control|Medical treatment alone
79529182|NCT01406964|Other|Histerosalpingography|A Histerosalpingography is performed.
79529183|NCT01407016|Drug|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
79685419|NCT00547287|Drug|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
79685420|NCT02908958|Biological|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
79685421|NCT02908958|Biological|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
79685422|NCT01263106|Drug|LY2216684|18-mg LY2216684 oral dose
80002067|NCT03793400|Drug|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
80002068|NCT03614988|Other|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
80002069|NCT03614988|Other|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
80002070|NCT01318369|Drug|Namisol|Single dose delta-9-tetrahydrocannabinol
79234191|NCT02699957|Procedure|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
79685423|NCT01263106|Drug|Theophylline|200-mg theophylline oral dose
79828075|NCT06113029|Diagnostic Test|Rand SF-36 Questionnaire|The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). Component analyses showed that there are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS). All scales do contribute in different proportions to the scoring of both PCS and MCS measures
79828076|NCT06107621|Behavioral|iCBT for Gambling Disorder and psychiatric comorbidities|The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
79828077|NCT06105697|Device|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to ~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
80002071|NCT01318369|Drug|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
80016690|NCT04471922|Drug|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
80016691|NCT04368364|Drug|Intrathecal morphine sulfate (ITM)|Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
79685424|NCT00547326|Procedure|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
79685425|NCT00547326|Procedure|Treatment with placebo|Treatment with placebo
79685426|NCT01263028|Drug|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
79685427|NCT00547404|Drug|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
79828078|NCT06105697|Other|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
79828079|NCT06104904|Behavioral|MAPP|Behavioral intervention based on exposure therapy strategies.
80002072|NCT02061722|Radiation|PET Imaging with [18F]MNI-659|"The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
79375354|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
79375355|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
80002073|NCT01345097|Device|Total Hip Arthroplasty|Total Hip Arthroplasty
79375356|NCT05603715|Drug|Pyridostigmine Bromide|Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
79529184|NCT01407042|Procedure|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
79529185|NCT01407055|Behavioral|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
79529186|NCT01407055|Behavioral|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
79529187|NCT01407120|Behavioral|New Beginnings Program|A preventive intervention for divorced families.
79529188|NCT01407133|Device|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
79529189|NCT01407133|Device|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
79529190|NCT01407185|Other|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
79529191|NCT01407211|Dietary Supplement|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
79529192|NCT01407224|Behavioral|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
79685428|NCT02908919|Procedure|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
79685429|NCT04323319|Device|ESWT, Graston Technique|"The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week."
79685430|NCT01262989|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
79828080|NCT06104293|Other|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
79828081|NCT06102057|Radiation|standard Radiotherapy|standard FDG-PET-based radiotherapy
80002074|NCT01350739|Procedure|intraumbilical incision|vertical, intraumbilical incision
80002075|NCT01350739|Procedure|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
80002076|NCT03479684|Other|Gene-directed dosage of warfarin|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
79375357|NCT04394793|Radiation|Low dose radiation therapy|Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
79375358|NCT00981747|Drug|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
80002077|NCT03479684|Other|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
80002078|NCT01316003|Other|Optical coherence tomography|Optical coherence tomography
80002079|NCT01318447|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
80002080|NCT01986933|Drug|nemolizumab (CIM331)|
80002081|NCT01986933|Other|Placebo|
79685431|NCT01262989|Drug|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
79685432|NCT00547443|Drug|carboplatin|Given IV
79685433|NCT00547443|Drug|paclitaxel|Given IV
79685434|NCT00547443|Drug|sorafenib tosylate|Given orally
79685435|NCT00547443|Radiation|radiation therapy|Given 5 days a week for 7.5 weeks
79828082|NCT06102057|Drug|Chemotherapy|concurrent standard of care chemotherapy
79828083|NCT06102057|Drug|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
79828084|NCT06102057|Radiation|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
79828085|NCT06101498|Diagnostic Test|Akut kidnet injury(AKI)|postoperative 24 hours
79828086|NCT06100198|Other|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
79828087|NCT06091904|Drug|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
79828088|NCT06091904|Drug|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
79828089|NCT06090175|Other|Projector colleyscope group|Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.
79828090|NCT06090175|Other|Matching card group|Matching card will be used in children aged 3-6 who are administered inhaler medication.
79828091|NCT06088992|Genetic|HG004|Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
79828092|NCT06087757|Drug|Open Label Clemastine with a blinded randomize withdrawal|Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
80002082|NCT05251103|Other|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
80002083|NCT03614052|Drug|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
80002084|NCT03614052|Drug|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
80002085|NCT01318525|Drug|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
80002086|NCT01318525|Drug|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
79375359|NCT00981747|Drug|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
79375360|NCT00981747|Drug|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
79375361|NCT00981747|Drug|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
79685436|NCT02908997|Other|MindMate|A dementia-specific mobile reminding application
79685437|NCT00547482|Device|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
79685438|NCT02909075|Device|PET/CT scans|
79685439|NCT02909075|Device|MRI|
79685440|NCT03456258|Diagnostic Test|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
79685441|NCT02909114|Radiation|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
79685442|NCT02277210|Other|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
79685443|NCT04682171|Other|Low level laser therapy|"Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
79828093|NCT06086795|Other|Whole eggs|3 large whole eggs per day for 4 weeks
79828094|NCT06086795|Other|Egg yolks|3 large egg equivalent of egg yolks per day for 4 weeks
79828095|NCT06086795|Other|Egg whites|3 large egg equivalent of egg whites per day for 4 weeks
79828096|NCT06083012|Device|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1 software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~3D mapping of the atria and location of areas of interest;~Catheter ablation at the operator's discretion."
79828097|NCT06080191|Drug|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR_Lenti_ALLO~A single infusion of CD19-CAR_Lenti_ALLO on Day 0"
79828098|NCT06079060|Device|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
79375362|NCT05602545|Other|food consumption in periodontal health and disease|To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
79685444|NCT04682171|Other|Conventional Exercise Therapy|"Quadriceps isometric strengthening exercises.~Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~Hamstring muscle isometric exercises~Active ankle pump.~Short arc terminal extension exercises for the knee joint.~Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
79685445|NCT02277288|Other|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
79828099|NCT06079060|Device|Control Latex Condom|61mm width Natural Rubber Latex Condom
79375363|NCT04394403|Behavioral|Internet-based guided self-help based on CBT principles|Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
79375364|NCT03030183|Drug|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
79375365|NCT03029169|Drug|Propafenone i.v.|Treatment
79375366|NCT03029169|Drug|Amiodarone i.v.|Treatment
79828100|NCT06078813|Radiation|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
79375367|NCT04759209|Diagnostic Test|Biopsies|
79375368|NCT04275219|Drug|Tongfu capsules|Tongfu capsules include 5 herbals
79375369|NCT04275219|Drug|The Placebo of Tongfu capsules|The Placebo of Tongfu capsules are made from dextrin, starch and so on.
79375370|NCT05609955|Drug|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
79828101|NCT06075836|Other|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A."
79828102|NCT06075836|Other|Ground truthing|Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
79828103|NCT06075511|Diagnostic Test|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
79828104|NCT06075511|Behavioral|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
79828105|NCT06075511|Behavioral|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
79828106|NCT06075511|Behavioral|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
79828107|NCT06075511|Diagnostic Test|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
79828108|NCT06075511|Diagnostic Test|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
79375371|NCT04129905|Biological|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
79375372|NCT04129905|Diagnostic Test|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
79685446|NCT00547560|Drug|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
79375373|NCT04129905|Diagnostic Test|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
79375374|NCT04129905|Diagnostic Test|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
79375375|NCT04129905|Diagnostic Test|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
79375376|NCT04129905|Diagnostic Test|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
79375377|NCT04129905|Biological|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
79234192|NCT02405546|Other|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
79234193|NCT02405546|Other|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
79828109|NCT06075511|Diagnostic Test|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
79529193|NCT01407237|Drug|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
79529194|NCT01407289|Drug|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
79234194|NCT02407652|Behavioral|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
79375378|NCT01295710|Biological|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
79529195|NCT01407302|Other|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
79529196|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
79828110|NCT06075511|Diagnostic Test|Quality of Life|Subject will complete Quality of Life Questionnaire
79529197|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
79529198|NCT01407341|Procedure|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
79529199|NCT01407341|Procedure|bone graft|Receive beta tricalcium-phosphate bone graft
79685447|NCT02908607|Device|Thermal imaging|Examination of the cervix by thermal imaging camera
79685448|NCT00547599|Drug|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
79685449|NCT02908451|Biological|AbGn-107|Antibody Drug Conjugate
79685450|NCT00547677|Radiation|stereotactic radiosurgery|
79685451|NCT02908763|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
79685452|NCT00547716|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
79828111|NCT06066736|Other|observational|No intervention, observational group
79828112|NCT06066099|Drug|AP31969|Oral tablets
79828113|NCT06066099|Drug|Placebo|Oral tablets
80016692|NCT04368364|Drug|Bupivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
79234195|NCT02407652|Behavioral|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
79234196|NCT02407574|Device|External Pacing Box|Atrial pacing using an external pacing box
79375379|NCT01295710|Biological|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
79375380|NCT01258504|Drug|St. Johns Wort|"Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
79375381|NCT01258582|Procedure|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
79234197|NCT02407496|Other|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
79234198|NCT02407418|Other|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
79234199|NCT02407418|Other|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
79234200|NCT02412410|Behavioral|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
79234201|NCT04481984|Other|Home-based Hand exercise|"Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day."
79234202|NCT04481984|Other|Care advice|Patients received care advice including avoiding cold exposure and trauma.
79234203|NCT02405624|Procedure|continuous positive airway pressure|CPAP training for muscle strength
79375382|NCT01258582|Procedure|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
79375383|NCT04351828|Procedure|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
79375384|NCT01259128|Drug|SER120 Nasal Spray 500 ng/day|SER120 Level 1
79375385|NCT01259128|Drug|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
79375386|NCT01353976|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
79685453|NCT00547716|Drug|Placebo comparator|
79234204|NCT02407340|Drug|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
79375387|NCT01353976|Other|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
79375388|NCT01354444|Drug|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
79375389|NCT01354444|Drug|Placebo|a pill that will look like the active drug but will not contain any carvedilol
79529200|NCT01407341|Procedure|quality-of-life assessment|Ancillary studies
79529201|NCT01407341|Other|questionnaire administration|Ancillary studies
79529202|NCT01407380|Drug|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
79529203|NCT01407393|Device|Glucosanol|2 tablets 3x daily for 12 weeks
79685454|NCT02908802|Dietary Supplement|Probiotic|Probiotic
79828114|NCT06065475|Behavioral|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided in-plane or out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, inject 3ml of 2% lidocaine on the surface of the thyroid cartilage plate.
79828115|NCT06065189|Biological|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
79685455|NCT02908802|Dietary Supplement|Placebo|Probiotics capsules without the active ingredient
79828116|NCT06064903|Biological|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
79828117|NCT06061510|Dietary Supplement|omega-3 polyunsaturated fatty acids|Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
79828118|NCT06061510|Dietary Supplement|corn oil|Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
79828119|NCT06060509|Dietary Supplement|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
79828120|NCT06060509|Dietary Supplement|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
79828121|NCT06060210|Drug|normal Saline|50-ml Saline
79828122|NCT06060210|Drug|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
79529204|NCT01407393|Device|Placebo|2 tablets 3x daily for 12 weeks
79828123|NCT06059586|Behavioral|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
79828124|NCT06059586|Device|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
79685456|NCT02908646|Procedure|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
79685457|NCT02908646|Procedure|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
79685458|NCT02908568|Device|Spring device|Brisk dilatation of fhe mouth.
79828126|NCT06051396|Procedure|Right sided heart catheterization|Hemodynamic evaluation was performed in the supine position. RHC was performed using the modified Seldinger technique with an 8F sheath inserted in the jugular, basilic or cephalic vein . The Swan-Ganz catheter was a 7F, two-lumen, fluid filled, and pressure-measuring tipped catheter (Corodyn TD; Braun Medical, Bethlehem, PA, USA). The zero-level reference was determined at midthoracic line.(9)
79234205|NCT02407340|Drug|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
79234206|NCT02701634|Drug|ENTO|Tablets administered orally
79234207|NCT02701634|Drug|Placebo|Tablets administered orally
79234208|NCT02407262|Dietary Supplement|Black seed oil|
79234209|NCT02407262|Other|Placebo|vegetable oil
79375390|NCT01259440|Behavioral|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
79685459|NCT02908568|Device|Mandible stimulator|Stimulation of fhe mouth.
79685460|NCT02908412|Drug|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
79685461|NCT04686474|Drug|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
79234210|NCT02407184|Other|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
79234211|NCT02412332|Procedure|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
79375391|NCT01259440|Behavioral|Usual Care|Consists of one week telephone call and one month clinic visit
79375392|NCT03009526|Drug|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
79375393|NCT03009526|Drug|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
79375394|NCT01259596|Behavioral|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
79375395|NCT01259596|Behavioral|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
79375396|NCT01354990|Drug|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
79529205|NCT01407406|Drug|BIIB023 - low dose IV Dose|
79529206|NCT01407406|Drug|BIIB023 - high dose IV Dose|
80002087|NCT02062892|Drug|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
80002088|NCT02062892|Drug|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
80002089|NCT02063360|Drug|BMS-663068|BMS-663068
80002090|NCT02063360|Drug|Darunavir (DRV)|Darunavir (DRV)
80002091|NCT02063360|Drug|Ritonavir (RTV)|Ritonavir (RTV)
80002092|NCT02063360|Drug|Etravirine (ETR)|Etravirine (ETR)
79685462|NCT04686630|Other|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
80002093|NCT01358461|Biological|Blood sampling|Blood sampling
80002094|NCT01358461|Other|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
80002095|NCT03614832|Drug|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
80002096|NCT03614832|Drug|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
80002097|NCT05210595|Drug|Clopidogrel 75 mg|75 mg/day as maintenance dose.
79234212|NCT02412332|Procedure|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
80002098|NCT05210595|Drug|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
80002099|NCT05210595|Drug|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
80002100|NCT01358539|Behavioral|Pain education|Patients receiving pain education
80002101|NCT03560570|Biological|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
80002102|NCT03560570|Other|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
80002103|NCT03614754|Diagnostic Test|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
80002104|NCT02061800|Device|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
80002105|NCT02061800|Drug|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
80002106|NCT02061800|Drug|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
79234213|NCT02405156|Drug|Letrozole|
79234214|NCT02405156|Drug|Placebo|
79234215|NCT02405156|Drug|Misoprostol|
79375397|NCT01355224|Genetic|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
79375398|NCT01355224|Behavioral|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
79828127|NCT06049043|Other|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
79828128|NCT06049043|Other|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
80002107|NCT02061800|Drug|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
80002108|NCT02061800|Drug|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
79234216|NCT02412254|Other|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
79234217|NCT02412254|Other|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
79234218|NCT02407106|Dietary Supplement|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
79375399|NCT01260454|Drug|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
79375400|NCT01296646|Drug|Naltrexone|50 mg oral naltrexone once/day
79828129|NCT06047470|Behavioral|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
79828130|NCT06047470|Behavioral|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
79828131|NCT06043700|Other|No Intervention|No treatment intervention will be administered.
79234219|NCT02405312|Behavioral|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
79828132|NCT06041880|Device|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
79828133|NCT06039852|Other|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~Safe and comfortable position to enable sleep~Positioning to enable UAD overnight~Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
79234220|NCT02412020|Drug|PA101|
80002109|NCT02061800|Drug|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
79234221|NCT02412020|Drug|Placebo|
79234222|NCT03171428|Procedure|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
79375401|NCT01296646|Behavioral|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
79375402|NCT01296646|Drug|Placebo|An inactive pill to control for non-pharmacological responses.
79375403|NCT01297348|Drug|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
79375404|NCT01297348|Drug|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
79375405|NCT01856309|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
79828134|NCT06038331|Biological|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
79828135|NCT06034262|Biological|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
79828136|NCT06033027|Device|Carbonhand|During this phase, participants use the Carbonhand soft-robotic glove system in daily life for 6 weeks to support the performance of daily activities with their affected hand in the home environment. The participants are free to choose for which activities, when and for how long they use the Carbonhand. However, it is recommended to use the Carbonhand at least 180 minutes a week during the most common ADL, such as household activities, dressing/undressing, eating/drinking/cooking, and/or leisure activities.
80002110|NCT02061800|Drug|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
79234223|NCT02412176|Procedure|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
79234224|NCT02412176|Procedure|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
79234225|NCT02411942|Drug|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
79234226|NCT02411942|Drug|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
79234227|NCT02411942|Drug|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
79234228|NCT02406950|Drug|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
79234229|NCT02406872|Drug|Remimazolam Tosilate|IV pumping for anesthesia
79234230|NCT02406872|Drug|Propofol|IV bolus for anesthesia
79375406|NCT01856309|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
79375407|NCT01856309|Drug|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
79375408|NCT01260688|Drug|cediranib maleate|Given orally
79375409|NCT01260688|Drug|dasatinib|Given orally
79375410|NCT01355458|Drug|CD07805/47 gel|applied topically once daily
79375411|NCT01355458|Drug|Placebo|applied topically once daily
79375412|NCT01298128|Drug|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
79375413|NCT01298128|Drug|marvelon|marvelon 21 daily
79375414|NCT01298752|Drug|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
79375415|NCT01298752|Drug|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
79375416|NCT02199964|Drug|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
79375417|NCT02199964|Drug|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
79391062|NCT03179280|Drug|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
79375418|NCT01299454|Drug|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
79828137|NCT06030999|Dietary Supplement|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
80002111|NCT02061800|Drug|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
80002112|NCT02061800|Drug|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
80002113|NCT01354795|Procedure|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
80002114|NCT01354795|Procedure|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
80002115|NCT01350817|Drug|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
80002116|NCT01350817|Drug|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
79234231|NCT03171272|Other|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
79234232|NCT02404922|Drug|CTP-730|
79375419|NCT02323048|Drug|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
79234233|NCT02404922|Drug|Placebo for CTP-730|
79234234|NCT02406716|Other|Biospecimen retention|
79828138|NCT06030999|Dietary Supplement|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
79828139|NCT06030999|Dietary Supplement|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
79234235|NCT03172832|Procedure|PTBD|Percutaneous access and tube placement into the bile duct
79234236|NCT03172832|Procedure|ERC|Endoscopic access and stent placement in the bile duct
79375420|NCT02323048|Drug|placebo|Placebo (sugar pill)
79375421|NCT01265446|Drug|Lidocaine 8mg + CPC 2mg|one single dose
79375422|NCT01265446|Drug|Lidocaine 1mg + CPC 2mg|one single dose
79375423|NCT01265524|Drug|CLP|Oral administration
79375424|NCT01265524|Drug|Placebo|Oral administration
79529207|NCT01407419|Other|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
79828140|NCT06030882|Other|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
80002117|NCT02063438|Procedure|Pericostal suture technique|
80002118|NCT02063438|Procedure|Intracostal suture technique|
79375425|NCT01299610|Drug|GW870086 2.0%|White to slightly colored opaque cream
79375426|NCT01299610|Drug|GW870086 0.2%|White to slightly colored opaque cream
79375427|NCT01299610|Drug|FP 0.05%|White cream
79529208|NCT01407419|Other|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
79529209|NCT01407432|Drug|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
80002119|NCT01986075|Behavioral|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
80002120|NCT01986075|Drug|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
80002121|NCT01986075|Drug|Placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
80002122|NCT04753710|Drug|Ocular gel|Instillation
80002123|NCT02061878|Drug|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
80002124|NCT02061878|Drug|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
80002125|NCT01358617|Other|diagnostic laboratory biomarker analysis|Correlative studies
80002126|NCT00394355|Drug|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
79234237|NCT03173144|Other|Primary exposure variable|"Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~Low intake of red and processed meat (defined as below the lower tertile [33.3% of the total sample]) and high intake of dietary fibres (defined as those above the upper tertile [33.3% of the total sample]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
79685463|NCT02908256|Drug|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
79685464|NCT02908256|Drug|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
79685465|NCT00547872|Procedure|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
80002127|NCT00394355|Drug|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
79234238|NCT03173144|Other|Other (exploratory) exposure variables|"Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~Pretreatment lifestyle-associated biomarkers~Combinations of lifestyle factors and lifestyle-associated biomarkers~Gene-environment interaction analyses~Pretreatment levels of inflammatory molecules"
79234239|NCT03172676|Drug|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
79529210|NCT01407432|Drug|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
79234240|NCT03172676|Drug|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
79234241|NCT03172676|Drug|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
79234242|NCT03176030|Dietary Supplement|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
79529211|NCT01407445|Drug|Placebo|1 tablet/ oral/ 3 times a day for 90 days
79529212|NCT01407445|Drug|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
79529213|NCT01407458|Other|Upper Limb Exercises|Upper limb exercises
79529214|NCT01407458|Other|Normal physical exercises|Exercises usually done by children in physical education classes
79529215|NCT01407471|Drug|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
79685466|NCT02908295|Drug|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
80002128|NCT00394355|Drug|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
79234243|NCT02404844|Drug|BKM120|daily oral
79234244|NCT02404844|Drug|Tamoxifen|daily oral
79234245|NCT02404766|Other|C0-C1 dorsal glide manual mobilization|
79234246|NCT02404766|Other|C7-T1 ventral cranial glide manual mobilization|
79234247|NCT03116594|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
79234248|NCT03116594|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
79234249|NCT03175640|Behavioral|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
79529216|NCT01407471|Drug|Clobetasol + Placebo|One application 6 days a week during 4 weeks
79529217|NCT01407471|Drug|Placebo + Spironolactone|One application 6 days a week during 7 weeks
79529218|NCT01407471|Drug|Placebo + Placebo|One application 6 days a week during 7 weeks
79529219|NCT01407484|Drug|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
79529220|NCT01407484|Drug|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
79529221|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
79529222|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
79529223|NCT01407497|Biological|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
79685467|NCT02908295|Drug|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
79685468|NCT03809442|Drug|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
80002129|NCT00394355|Drug|montelukast|10 mg given once daily in the evening by mouth for 1 year.
80002130|NCT01822743|Procedure|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
80002131|NCT01822743|Procedure|sham comparator|
80002132|NCT02797808|Drug|Sertraline|Impact of sertraline on functional brain connectivity
79234250|NCT03175406|Diagnostic Test|Manipal cervical scoring system|
79529224|NCT01407497|Biological|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
79685469|NCT03809442|Drug|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
79685470|NCT03809442|Drug|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
79685471|NCT03809442|Drug|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
79685472|NCT03809442|Drug|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
79828141|NCT06025136|Other|Using a gel pillow|Within the scope of the study, gel pillows with a cold surface were used in the patients in the study group. It is produced by combining the obtained special liquid with elastic material with NASA approved molecule exchange technology and is made of OEKO-TEX CLASS 1 certified material.Thanks to the gel material on the pillow surface, the surface temperature is reduced from 37°C to 24°C in about 10 seconds. It gives a feeling of coolness with its thermal conductivity feature.
79828142|NCT06019988|Other|Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening|All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)
79529225|NCT01407536|Device|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
79685473|NCT03809442|Drug|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
79685474|NCT02908217|Drug|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
79685475|NCT02908217|Drug|Placebo|6 Intravenous infusions of placebo every 4 weeks.
79685476|NCT00547950|Drug|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid*1year.
79685477|NCT02908373|Other|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
79685478|NCT00534729|Drug|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
79685479|NCT02908139|Device|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
80002133|NCT02797808|Other|No Intervention|Healthy control non-intervention
80002134|NCT01800669|Other|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
79234251|NCT04482296|Drug|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
79234252|NCT03116282|Behavioral|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
79234253|NCT04481906|Procedure|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
79234254|NCT02405000|Other|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
79234255|NCT02406482|Behavioral|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
79234256|NCT02406482|Behavioral|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
79234257|NCT03171194|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
79234258|NCT02442765|Drug|AVP-786|
79234259|NCT02442765|Drug|Placebo|
79234260|NCT02404454|Procedure|Hysteroscopic metroplasty|
79375428|NCT01299610|Drug|Placebo|White to slightly colored opaque cream
79375429|NCT01300624|Behavioral|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
79375430|NCT04352062|Drug|Melatonin|
79375431|NCT04352062|Other|placebo|
79375432|NCT04352062|Drug|Pantoprazole 40mg|pantoprazole 2 x 40mg
79375433|NCT04352062|Drug|Amoxicillin|Amoxicillin 2 x 1000mg
79375434|NCT04352062|Drug|Levofloxacin 500mg|Levofloxacin 2 x 500mg
79375435|NCT01302808|Combination Product|Erlotinib plus Romidepsin (8 mg/m^2)|
79375436|NCT01302808|Combination Product|Erlotinib plus Romidepsin (10 mg/m^2)|
79375437|NCT01302808|Combination Product|Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|
79685480|NCT02908139|Device|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
79828143|NCT06019767|Behavioral|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
79375438|NCT01302808|Combination Product|(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis|
79375439|NCT01267240|Drug|Capecitabine|Given PO
80002135|NCT01800669|Other|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
80002136|NCT05251025|Other|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
80002137|NCT05251025|Other|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
80016693|NCT04368364|Drug|ropivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
79529226|NCT01407549|Behavioral|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
79234261|NCT02404454|Device|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
79234262|NCT02404454|Procedure|Office second look hysteroscopy|Second-look hysteroscopy after three months
79529227|NCT01407588|Procedure|Magnetic navigation|Ablation with use of the magnetic navigation system
79685481|NCT00534768|Procedure|active debridement|debridement on 1st, 3-5th and 7th postoperative days
79685482|NCT00534768|Procedure|control group|Postoperative debridement on 7th postoperative day
79234263|NCT04964258|Drug|TAK-105-a|TAK-105-a subcutaneous solution.
79234264|NCT04964258|Drug|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
79375440|NCT01267240|Drug|Vorinostat|Given PO
79375441|NCT01357564|Other|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
79375442|NCT01357564|Other|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
79529228|NCT01407588|Procedure|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
79685483|NCT00547989|Drug|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
79828144|NCT06018935|Other|No intervention|No intervention
79828145|NCT06017284|Drug|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
79234265|NCT04964258|Drug|TAK-105-b|TAK-105-b subcutaneous solution.
79234266|NCT04964258|Drug|TAK-105-b Placebo|TAK-105-b placebo-matching solution.
79234267|NCT03115892|Drug|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
79234268|NCT03115892|Drug|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
79234269|NCT03116048|Other|Chronic pain evaluation|Chronic pain assessment with study questionnaire
79685484|NCT00547989|Drug|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
79828146|NCT06017284|Drug|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
79828147|NCT06017284|Drug|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
79828148|NCT06017284|Drug|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
79828149|NCT06016439|Procedure|Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT|Residual rotator cuff defect will be reconstructed using LHBBT.
79828150|NCT06016439|Procedure|Arthroscopic rotator cuff partial repair|Rotator cuff will be repaired with remaining residual defect.
79828151|NCT06016439|Procedure|Arthroscopic complete rotator cuff repair|Arthroscopic complete repair as a standard procedure.
80002138|NCT02796560|Drug|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
80002139|NCT02796560|Drug|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
79234270|NCT02406794|Drug|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
79375443|NCT01855919|Drug|Duloxetine|Administered orally
79375444|NCT01855919|Drug|Placebo|Administered orally
79375445|NCT01357720|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
79375446|NCT01357720|Biological|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), inactive pertussis bacteria (>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
79375447|NCT01871519|Device|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
79375448|NCT01871285|Drug|Buprenorphine|
79375449|NCT01871285|Drug|Placebo film|Matching placebo buccal film
79375450|NCT01871285|Drug|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
79375451|NCT01871285|Drug|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
79375452|NCT01871285|Drug|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
79375453|NCT01358266|Drug|DE-109 44 ug|Low dose
79375454|NCT01358266|Drug|DE-109 440 ug|Medium dose
79375455|NCT01358266|Drug|DE-109 880 ug|High dose
79375456|NCT01870973|Procedure|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
79529229|NCT01407601|Dietary Supplement|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
79828152|NCT06016439|Device|Suture anchor(s)|Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
80002140|NCT01316081|Dietary Supplement|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
79234271|NCT02411786|Biological|pTVG-AR|Given ID
79234272|NCT02411786|Biological|gm-csf|Given ID
79234273|NCT02411708|Drug|SANGUINATE|Single two-hour infusion of SANGUINATE
79234274|NCT02411708|Drug|Placebo|Single two-hour infusion of placebo
79375457|NCT01870973|Procedure|no root canal treatment, anesthesia, pain medications, and antibiotic|
79375458|NCT01267864|Drug|Metoclopramide|10mg IVSS
79375459|NCT01267864|Drug|Ketorolac|30g IVSS
79375460|NCT01267864|Drug|Valproate|1gm IVSS
79375461|NCT01854827|Drug|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
79375462|NCT04415255|Other|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, ~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
79375463|NCT04415255|Other|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
79375464|NCT04414709|Other|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
79375465|NCT04414709|Other|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
79375466|NCT02196688|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
79375467|NCT02196688|Drug|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
79375468|NCT01359748|Device|Reference sphygmomanometer|* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
79234275|NCT02411864|Other|different low b-values distribution|
79828153|NCT06014424|Drug|JZP541|Participants in this arm will receive ZP541 for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
79529230|NCT01407614|Procedure|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
79234276|NCT02411552|Behavioral|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
79529231|NCT01407640|Procedure|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
79828154|NCT06014424|Other|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
79375469|NCT01359748|Device|Sphygmomanometer under test|Electronic Oscillometric method.
79685485|NCT00547989|Drug|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
79685486|NCT00534807|Drug|Vinflunine|
79828155|NCT06008236|Behavioral|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
79234277|NCT03172442|Device|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
79375470|NCT03009448|Other|Interview|Each subject will be interviewed using a semi constructed interview.
79375471|NCT01360450|Drug|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between < 9.
79375472|NCT01360450|Drug|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
79529232|NCT01407653|Procedure|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
79529233|NCT01407653|Procedure|Usual care|Classical care
79685487|NCT00534807|Drug|Rifampin|
79828156|NCT06007209|Other|Manual Pressure Point|Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
79828157|NCT06005428|Drug|CRD-4730|Oral CRD-4730 in capsule form
79828158|NCT06005428|Drug|Placebo|Placebo to match CRD-4730 in capsule form
80016694|NCT02285036|Biological|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
79234278|NCT03172442|Device|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
79234279|NCT03172442|Device|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
79234280|NCT03524001|Device|Compare VVi mode versus DDD bifocal stimulation through crossover randomization|All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
79234281|NCT02404376|Drug|Exenatide|Intravenous administration of Exenatide
79234282|NCT02404376|Other|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
79375473|NCT03009214|Drug|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
79375474|NCT01268644|Drug|Leptin|weight based sub-cutaneous injection twice daily of Leptin
79529234|NCT01407666|Procedure|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
79234283|NCT02404376|Drug|Placebo|Intrevenous administration of Placebo
79234284|NCT02406560|Drug|tafamidis|fasted
79234285|NCT02406560|Drug|tafamidis|high fat meal
79234286|NCT02406560|Drug|tafamidis|
79234287|NCT04466085|Biological|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79234288|NCT04466085|Biological|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79234289|NCT04466085|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79234290|NCT02404298|Drug|IVIg|
79529235|NCT01407679|Drug|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
79529236|NCT01407731|Genetic|protein expression analysis|
79234291|NCT02217891|Behavioral|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, & qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits & harms of tumor genomic profiling; 2) interest in & perceived benefits & harms of incidental findings arising from tumor genomic profiling; 3) anticipated process & needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, & those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; & 6) implications of & concerns about incidental findings for family.
79529237|NCT01407731|Genetic|western blotting|
80016695|NCT02285036|Biological|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
79234292|NCT02406638|Other|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
79234293|NCT03517995|Drug|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
79234294|NCT03517995|Other|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
79529238|NCT01407731|Other|laboratory biomarker analysis|
79529239|NCT01407744|Other|laboratory biomarker analysis|Correlative studies
79529240|NCT01407757|Genetic|DNA analysis|
79529241|NCT01407757|Genetic|gene expression analysis|
79234295|NCT03517995|Procedure|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
79234296|NCT03115658|Behavioral|Physical Activity|12 week print based intervention
79234297|NCT02411240|Device|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
79234298|NCT03132987|Other|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
79234299|NCT02411630|Drug|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
79234300|NCT02411318|Behavioral|Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
79234301|NCT02411318|Drug|ProLab 200mg caffeine capsule|Participants will swallow one ProLab caffeine 200mg tablet.
79234302|NCT02411318|Other|Ethanol ingestion|Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
79234303|NCT02411318|Drug|Glucose Tolerance Drink|Participants will consume 100 grams of glucose
79234304|NCT03133299|Drug|Glucocorticoids|Oral prednisolone for four months
79234305|NCT03133299|Drug|Vitamin D|Oral vitamin D for two months
79234306|NCT03172598|Drug|MT-8554 low dose|Capsule
79234307|NCT03172598|Drug|MT-8554 middle dose|Capsule
79234308|NCT03172598|Drug|MT-8554 high dose|Capsule
79234309|NCT03172598|Drug|Placebo|Capsule
79234310|NCT04465695|Drug|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
79234311|NCT04465695|Drug|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
79234312|NCT03115736|Drug|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
79234313|NCT03172286|Device|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
79234314|NCT04465851|Dietary Supplement|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
79234315|NCT04465851|Dietary Supplement|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
79529242|NCT01407757|Other|laboratory biomarker analysis|
79529243|NCT01407757|Other|pharmacogenomic studies|
79529244|NCT01407783|Behavioral|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
79529245|NCT01407796|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|
79529246|NCT01407796|Drug|[18F](+/-)NOS|
79529247|NCT01407809|Device|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
80016696|NCT03659877|Behavioral|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
79234316|NCT04465851|Other|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
79685488|NCT02908022|Device|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
79234317|NCT04465851|Other|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
79685489|NCT02908022|Device|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
79529248|NCT01407822|Drug|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
79685490|NCT00534846|Drug|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
80002141|NCT05735301|Procedure|Endovascular therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
80002142|NCT05735301|Drug|Drug|Drug conservative therapy could be uesd in patients who with no indication of surgery
80002143|NCT02062970|Biological|blood draw|
80002144|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
79234318|NCT04465851|Dietary Supplement|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
79234319|NCT04465539|Drug|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
79529249|NCT01407822|Drug|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
79529250|NCT01407835|Biological|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
79234320|NCT04465539|Drug|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
79234321|NCT04465539|Drug|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
79234322|NCT02404142|Drug|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
79234323|NCT02404142|Drug|saline isotonic solution|
79234324|NCT03172208|Biological|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
79234325|NCT03172208|Biological|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
79234326|NCT03172208|Biological|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
79234327|NCT03172208|Biological|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
79234328|NCT03172208|Other|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
79234329|NCT03172208|Other|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
79234330|NCT03172208|Other|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
79375475|NCT01303744|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
79375476|NCT01303744|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
79375477|NCT01303744|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
79375478|NCT01303744|Drug|Placebo|oral tablet, once a day in the morning for 12 weeks
79375479|NCT01361620|Drug|aspirin|aspirin 81mg, 7-10 days
79529251|NCT01407848|Drug|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
79529252|NCT01407848|Drug|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
79685491|NCT00534846|Drug|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
79828159|NCT06000436|Other|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
79685492|NCT00548067|Drug|Valsartan/hydrochlorothiazide (HCTZ)|
79685493|NCT00548067|Drug|Valsartan/amlodipine|
79685494|NCT00548067|Drug|Amlodipine/hydrochlorothiazide(HCTZ)|
79234331|NCT02294565|Drug|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
79685495|NCT00548067|Drug|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
80002145|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
80002146|NCT02063048|Behavioral|Text Message Based Weight Loss Support|
80002147|NCT05007405|Other|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
79685496|NCT02907827|Other|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
79685497|NCT00534885|Biological|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
80002148|NCT01343069|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
80002149|NCT03560492|Other|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
80002150|NCT03560492|Device|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
79234332|NCT02294565|Drug|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
79234333|NCT02410928|Device|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
79234334|NCT02410928|Device|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
79375480|NCT01361854|Device|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
79375481|NCT01269736|Behavioral|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
79234335|NCT02410928|Device|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
79234336|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
79234337|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
79375482|NCT01305772|Drug|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 & 4 of RT alone or weeks 1 & 4 of cisplatin/RT if they tolerated first dose of panitumumab.
79375483|NCT01305772|Procedure|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
79375484|NCT01305772|Procedure|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
79685498|NCT00534885|Biological|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
79685499|NCT00534885|Biological|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
79685500|NCT00534885|Biological|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
79685501|NCT02907671|Procedure|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
79685502|NCT00548106|Dietary Supplement|partially hydrolyzed whey|Total infant feeding by study formula.
79685503|NCT00548106|Dietary Supplement|Nan HA|Total infant diet by study formula.
79685504|NCT02907749|Drug|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
79685505|NCT02907749|Drug|Carvedilol|Patients are treated with carvedilol only.
79685506|NCT00534924|Drug|Vit C|
79685507|NCT00534924|Procedure|Postconditioning|
79685508|NCT00534924|Other|no intervention|
79685509|NCT00548223|Drug|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid*1year
79685510|NCT00548223|Drug|placebo|Capsule, 0.18g, 2#, Bid*1year
79685511|NCT02907593|Drug|Budesonide in Calfactant|Budesonide in Calfactant
79685512|NCT00548301|Drug|cyclosporine|
79685513|NCT02907710|Drug|Endostar|intravenous infusion
79685514|NCT02907710|Drug|DDP|
79685515|NCT03781362|Drug|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
79234338|NCT02411162|Drug|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm^2 of skin.
79529253|NCT01407861|Other|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
79529254|NCT01407861|Other|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
79685516|NCT03781362|Drug|Capecitabine|Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
80002151|NCT01343147|Other|Microwave diathermy|Deep tissue heating via microwave diathermy
80002152|NCT01343147|Other|Superficial hyperthermia|Superficial heating via hot pack application
80002153|NCT05210127|Procedure|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
79234339|NCT02411162|Drug|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
79234340|NCT03522051|Other|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
79234341|NCT02411006|Behavioral|Prediction mailing|Ask people to predict their upcoming medication adherence
79234342|NCT02411006|Behavioral|Commitment mailing|Ask people to commit to their upcoming medication adherence
79234343|NCT02411006|Behavioral|Reminder|Remind people to take their medicine
79529255|NCT01407887|Drug|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
79529256|NCT01407900|Drug|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
79685517|NCT02907515|Device|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
79685518|NCT02907515|Device|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
79685519|NCT03767907|Behavioral|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
79685520|NCT03767907|Behavioral|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
79685521|NCT04682249|Drug|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
79685522|NCT04682249|Drug|Sintilimab|Sintilimab
79234344|NCT02411006|Behavioral|Anonymity|Keep patient predictions and commitment anonymous
79234345|NCT02411006|Behavioral|Identification|Ask patients to report their predictions and commitments
79234346|NCT03521973|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
79234347|NCT03521973|Other|Normal Saline|0.9% Sodium chloride
79234348|NCT03171974|Drug|Dexamethasone|dexamethasone will be injected intracapsular under US
79685523|NCT04682249|Drug|Apatinib|Apatinib
79685524|NCT00548379|Drug|vitamin D|vitamin D 100,000 units once in 3 months
79685525|NCT00548379|Drug|placebo|olive oil 1ml
79685526|NCT04682054|Procedure|ocular surgery|surgery to remove the pathological eye tissue
79685527|NCT04972617|Diagnostic Test|albumin function analysis (ABIC)|After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
79685528|NCT04682210|Drug|Sintilimab|Sintilimab 200mg IV Q3W
79685529|NCT04682210|Drug|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
80002154|NCT01345331|Behavioral|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
80002155|NCT02062034|Drug|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
80002156|NCT02062034|Drug|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
80002157|NCT02062034|Drug|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
79234349|NCT03171974|Device|US|dexamethasone will be injected intracapsular under US
79234350|NCT02292069|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
79234351|NCT02404064|Drug|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
79234352|NCT02404064|Drug|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
79529257|NCT01407900|Drug|5% Dextrose in Water|four hour infusion IV
79529258|NCT01407913|Procedure|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
79529259|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
80002158|NCT03620357|Device|CGM|CGM Group: Dexcom G6 CGM
80002159|NCT03620357|Device|SMBG|SMBG Group: Blood Glucose Meter
80002160|NCT02063594|Drug|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
80002161|NCT02063594|Drug|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
80002162|NCT00344487|Drug|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
80002163|NCT03789968|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
79234353|NCT02404064|Drug|Placebo|No perioperative antibiotics
79234354|NCT03171038|Other|Telemonitoring|
79375485|NCT01270126|Device|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
79529260|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
79529261|NCT01407978|Biological|Vaccination with Fluval P monovalent influenza vaccine|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
79529262|NCT01407978|Biological|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
79529263|NCT01407978|Biological|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
79529264|NCT01407991|Other|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
79529265|NCT01407991|Other|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
79529266|NCT01408004|Drug|Pazopanib|Tablet 800mg qd til progression
79529267|NCT01408004|Drug|Everolimus|tablet 10 mg qd til progression
79529268|NCT01408004|Drug|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
79529269|NCT01408004|Drug|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
79529270|NCT01408004|Drug|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
79529271|NCT01408004|Drug|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
79529272|NCT01408056|Drug|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
79529273|NCT01408056|Drug|Mupirocin 2% Ointment|Topical application twice per day for 60 days
79529274|NCT01408069|Drug|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
80002164|NCT05089643|Drug|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
80002165|NCT05089643|Drug|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
80002166|NCT02871492|Drug|Pritelivir 5% w/w ointment|
80002167|NCT02871492|Drug|Pritelivir ointment matching placebo|
79234355|NCT02294643|Drug|Sarpogrelate|
79234356|NCT02294643|Drug|Aspirin|
79234357|NCT02294643|Drug|Clopidogrel|
79234358|NCT02294643|Drug|Placebo (for Sarpogrelate)|
79234359|NCT02401958|Other|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
79234360|NCT03520803|Other|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
79234361|NCT02410694|Drug|Ixazomib|
79234362|NCT02410694|Drug|Thalidomide|
79234363|NCT02410694|Drug|Dexamethasone|
79234364|NCT02410538|Other|"list of FAQ"|
79375486|NCT01270516|Drug|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
79375487|NCT01270516|Drug|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
79375488|NCT01270516|Drug|Saline|Control
79529275|NCT01408069|Drug|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
79685530|NCT04682015|Other|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
79234365|NCT03521895|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
79828160|NCT06000436|Other|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
79828161|NCT06000436|Other|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume <5 g less per day to prevent cardiovascular diseases."
79828162|NCT06000436|Other|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
79828163|NCT05997680|Behavioral|Parent-child yoga|The 45-minute yoga sessions are structured to include an opening and a closing ritual that remain the same throughout the 8 weeks, between which an active and a calming parts are scheduled. The active and calming parts are embedded in stories that align with the developmental level and interests typical of 4-to-6-year-olds. Each session is clearly structured with each exercise and transition well described in the Yoga for Little Hearts Yoga Program Manual. In addition to the yoga sessions, at-home exercises (5 min) including breathing, meditation and mindfulness activities will be explained to participants. We will ask them to practice them at home at least 3 times every week, for the 8-week duration of the intervention. Including the yoga session and home exercises, the 8-week intervention thus includes at least 60 minutes of yoga per week. Parents will be encouraged to pursue the at-home exercises after the end of the 8-week yoga program, up to the 6-month follow-up.
79828164|NCT05996809|Device|Coseal|Adhesion reduction
79828165|NCT05992168|Device|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
79828166|NCT05991453|Other|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
79828167|NCT05991453|Other|Anesthetic technique inhaled agent|Must administer inhaled agent.
79828168|NCT05990166|Other|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
79828169|NCT05990166|Other|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
80002168|NCT02871492|Drug|Zovirax® cream|
80002169|NCT01345487|Other|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
79529276|NCT01408095|Drug|LY2608204|Administered orally
79529277|NCT01408095|Drug|Glimepiride|Administered orally
80002170|NCT01345487|Other|Animal protein|Protein in the form of minced pork/beef
79234366|NCT03171116|Other|none intervention|it is not an interventional study; it is an observational study
79234367|NCT02401880|Drug|Linagliptin|22 subjects will receive Linagliptin for 30 days
79234368|NCT02401880|Other|Placebo|22 subjects will receive Placebo for 30 days
79234369|NCT02401880|Drug|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
79234370|NCT03517839|Other|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
79234371|NCT03170726|Drug|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
79375489|NCT01271452|Biological|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
79375490|NCT01271452|Biological|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
79375491|NCT01271686|Drug|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
79375492|NCT01362946|Behavioral|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
79375493|NCT01362946|Behavioral|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
79529278|NCT01408108|Procedure|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
79234372|NCT03170726|Drug|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
79234373|NCT03170726|Other|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
79529279|NCT01408108|Procedure|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
79685531|NCT03664089|Behavioral|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
79828170|NCT05988996|Behavioral|Participant guided peer support gathering|This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
79828171|NCT05988541|Diagnostic Test|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
80002171|NCT02063126|Dietary Supplement|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
80002172|NCT02063126|Dietary Supplement|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
80002173|NCT04959435|Other|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
80002174|NCT02032056|Dietary Supplement|Probiotic (10^9 CFU/day)|
80002175|NCT02032056|Dietary Supplement|Probiotic (10^8 CFU/day)|
80002176|NCT02032056|Other|Placebo|
79234374|NCT03520725|Other|No Intervention|This gruop did not have an intervention
79234375|NCT03520725|Dietary Supplement|Pineapple snack bar|30 g daily of pineapple snack bar
79234376|NCT03520725|Dietary Supplement|Mango snack bar|30 g daily of mango snack bar
79234377|NCT02401802|Dietary Supplement|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
79234378|NCT02401802|Dietary Supplement|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
79375494|NCT01854047|Drug|Dupilumab|Solution for injection, Subcutaneous injection
79375495|NCT01854047|Drug|placebo|Solution for injection, Subcutaneous injection
79685532|NCT03664089|Behavioral|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
79685533|NCT04682132|Diagnostic Test|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
79234379|NCT02401724|Other|Transcranial direct current stimulation|
79375496|NCT01854047|Drug|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
79375497|NCT01854047|Drug|Salbutamol/albuterol|Oral inhalation as needed
79375498|NCT01854047|Drug|Levosalbutamol/levalbuterol|Oral inhalation as needed
79375499|NCT01363258|Behavioral|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
79375500|NCT01363258|Procedure|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
79375501|NCT01363492|Biological|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
79375502|NCT01307098|Drug|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
79375503|NCT01307098|Drug|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
79375504|NCT01307098|Drug|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
79375505|NCT01870739|Drug|sacubitril/valsartan (LCZ696)|200 mg tablets
80002177|NCT05591300|Diagnostic Test|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
80002178|NCT03615612|Other|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
80002179|NCT02063750|Other|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
79375506|NCT01870739|Drug|olmesartan|
79375507|NCT01870739|Other|placebo to sacubitril/valsartan (LCZ696)|placebo
79375508|NCT01870739|Other|placebo to olmesartan|placebo
79529280|NCT01408121|Other|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
80002180|NCT02063750|Other|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
80002181|NCT05209113|Other|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
80002182|NCT03143855|Drug|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
80002183|NCT03143855|Drug|Placebo|Placebo will be administered twice daily for for 5 days
80002184|NCT03615456|Procedure|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
80002185|NCT03615456|Procedure|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
80002186|NCT02878603|Biological|Caplacizumab|
80002187|NCT02878603|Other|Standard of Care|• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
79234380|NCT02401724|Other|Action Training|
79234381|NCT02401490|Drug|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
79234382|NCT02401490|Drug|Placebo|
79234383|NCT02401646|Dietary Supplement|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
79234384|NCT02401646|Dietary Supplement|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
79234385|NCT04481438|Other|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
79234386|NCT02294721|Device|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
79375509|NCT01870739|Drug|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
79375510|NCT01272388|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
79529281|NCT01408134|Other|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
79529282|NCT01408160|Drug|Cytarabine|Given IV
80002188|NCT03613974|Drug|Lidocaine|patients will receive different lidocaine concentrations
80002189|NCT01343225|Drug|atripla|once a day
79234387|NCT02294721|Device|The CPREazy|feedback device-1
79234388|NCT02294721|Device|TrueCPR|feedback device -2
79234389|NCT02294721|Device|The CPR PRO APP|feedback device -3
79234390|NCT02294721|Device|The CardioPump|feedback device- 4
79685534|NCT00548496|Drug|SB-751689|SB-751689
79234391|NCT03175016|Procedure|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
79234392|NCT03175016|Drug|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
79234393|NCT03175016|Device|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
79391063|NCT02424396|Drug|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
79685535|NCT00548496|Other|Placebo|Placebo to match
79234394|NCT03175250|Behavioral|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
79234395|NCT03175250|Behavioral|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
79234396|NCT03175250|Behavioral|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
79529283|NCT01408160|Biological|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
79529284|NCT01408160|Other|Laboratory Biomarker Analysis|Correlative studies
79529285|NCT01408160|Other|Pharmacological Study|Correlative studies
79529286|NCT01408173|Drug|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
79529287|NCT01408186|Drug|Rabeprazole|Rabeprazole 20 mg daily
79529288|NCT01408186|Drug|Famotidine|Famotidine 40mg daily
79529289|NCT01408199|Drug|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
79685536|NCT02907476|Behavioral|Iyengar Yoga|
79685537|NCT02907476|Behavioral|Walking|
79685538|NCT04971876|Device|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
80002190|NCT01343225|Drug|darunavir ritonavir raltegravir|as directed
80002191|NCT01317251|Other|Dietary intervention (without dairy products)|Control diet without dairy products
80002192|NCT01317251|Other|Dietary intervention (high milk content)|Diet with a high content of milk (~1200 mg Ca/d from milk)
80002193|NCT01317251|Other|Dietary intervention (high cheese content)|Diet with a high content of cheese (~1200 mg Ca/d from cheese)
80002194|NCT05078333|Other|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
79529290|NCT01408212|Procedure|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
79828172|NCT05988541|Diagnostic Test|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
79828173|NCT05988541|Diagnostic Test|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
79828174|NCT05988541|Diagnostic Test|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
79828175|NCT05987657|Diagnostic Test|Salivary and blood progesterone dosage|"Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval."
79828176|NCT05986487|Device|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
79828177|NCT05986487|Device|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
79828178|NCT05983588|Drug|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
79529291|NCT01408238|Biological|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
79529292|NCT01408264|Device|Conventional 0.035 guidewire|0.035 guidewire
79529293|NCT01408264|Device|Olympus Visiglide 0.025 guidewire|0.025 guidewire
79529294|NCT01408290|Biological|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
79529295|NCT01408290|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
79685539|NCT04971876|Device|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
79685540|NCT04971876|Device|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
79685541|NCT02907554|Drug|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
79685542|NCT02907554|Drug|Placebo|control group receives a placebo
79375511|NCT01272388|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
79375512|NCT01613417|Drug|gadoteridol|ProHance 0.1 mmol/kg
79685543|NCT03657303|Device|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
79685544|NCT02907632|Drug|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
79685545|NCT02907632|Drug|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
79375513|NCT01613417|Drug|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
79375514|NCT01364740|Device|PMP-300E|Data collected from Level 3 device
79375515|NCT01364740|Device|In-lab PSG|Data collected from Type I In-Lab Polysomnography
79375516|NCT04414865|Device|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
79391064|NCT02424396|Drug|Placebo|
79391065|NCT02424240|Other|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 & IGFBP-3 combination
79391066|NCT02424474|Device|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
79375517|NCT01364896|Procedure|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~Anal cytology testing"
79828179|NCT05983588|Drug|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
79828180|NCT05983380|Other|Hand Mobility and Grip Strengthening Exercises|Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.
79828181|NCT05983380|Other|Usual Care|Manual lymphatic drainage, compression, exercise, skin hygiene.
80002195|NCT05078333|Device|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
79234397|NCT03520257|Drug|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
79234398|NCT03520257|Device|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
79234399|NCT02292303|Dietary Supplement|zinc-enriched yeast|
79234400|NCT02292303|Dietary Supplement|Zinc references|
79234401|NCT02397044|Procedure|Implant surgery|Compare surgical protocols
79234402|NCT03170570|Device|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
79234403|NCT02294955|Device|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
79234404|NCT02294955|Drug|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
79375518|NCT01870583|Drug|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
79375519|NCT01870583|Drug|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
79375520|NCT01870583|Drug|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
79375521|NCT04351594|Drug|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
79529296|NCT01408290|Biological|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
79685546|NCT02907437|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
79685547|NCT02907437|Drug|Placebo|(200 mg/day)
79234405|NCT02294955|Drug|Sotalol|Dosage orally 80-160 mg twice daily
79234406|NCT02294955|Drug|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
79234407|NCT02294955|Drug|Propafenone|Dosage orally 300 mg twice daily
79234408|NCT02294955|Drug|Disopyramide|Dosage orally 250-375 mg twice Daily
79375522|NCT04351594|Other|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
79375523|NCT04603469|Other|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
79391067|NCT02424474|Biological|Regular serum screening|
79529297|NCT01408290|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
79685548|NCT02907437|Other|Probiotics|(450 mg/day)
79685549|NCT00548535|Procedure|Reliability of complication assessment|
79685550|NCT02907047|Other|tourniquet inflated|
79685551|NCT02907047|Other|tourniquet not inflated|
79685552|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
79685553|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
79685554|NCT01262872|Biological|Synflorix™|Intramuscular injection
79685555|NCT01262872|Biological|Prevnar13™|Intramuscular injection
79685556|NCT01262872|Biological|Tritanrix™-HepB/Hib|Intramuscular injection
79685557|NCT01262872|Biological|Polio Sabin™|Orally
79685558|NCT01262872|Biological|M-Vac™|Intramuscular injection
79685559|NCT01262872|Biological|Stamaril™|Intramuscular injection
79529298|NCT01408316|Drug|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
79828182|NCT05981664|Device|One Handed Video Game Controller Adapter|The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
79234409|NCT02294955|Drug|Dronedarone|Dosage orally 400 mg twice daily
79234410|NCT03619733|Other|no intervention|this is an observational study. no intervention is planned
79234411|NCT04481594|Drug|HPN-01|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
79234412|NCT04481594|Drug|Placebo|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
79234413|NCT05416697|Drug|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
79375524|NCT01308814|Drug|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
79529299|NCT01408342|Drug|Alemtuzumab and Rituximab|"Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~Cyclosporine 3 mg/kg starting day 21"
79529300|NCT01408355|Drug|PF-06273588|Intravenous, 50 microgram, single dose
79685560|NCT03622320|Other|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
79375525|NCT01308814|Drug|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
79375526|NCT03009760|Drug|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
79828183|NCT05979506|Procedure|Cutaneous wraps|"The topical treatment that will be used in this study are:~For the body, an emollient cream with a high lipid content: Cold cream~For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~Occlusion by wrapping the patient in a plastic film, then covering with a blanket~After 1 hour, the unabsorbed excess cream is removed with a towel"
79234414|NCT05416697|Drug|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
79234415|NCT02396888|Drug|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
79234416|NCT02396888|Drug|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
79234417|NCT02295033|Radiation|Boost irradiation|
79234418|NCT04480580|Diagnostic Test|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
79375527|NCT03009760|Drug|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
79685561|NCT00534963|Procedure|cervical vs. uterine placement of balloon catheter|
79685562|NCT02907125|Behavioral|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
79828184|NCT05977673|Drug|Tislelizumab|Tislelizumab 200mg IV day1
79828185|NCT05977465|Drug|Empagliflozin 25 MG|treatment
79234419|NCT03517683|Other|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
79375528|NCT03009760|Drug|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
79375529|NCT03009760|Drug|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
79375530|NCT03009604|Drug|Simethicone|Simethicone 40mg oral tablets
79375531|NCT03009604|Drug|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram & disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
79375532|NCT01275586|Drug|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
79375533|NCT01275664|Procedure|Adjuvant Therapy|Ancillary studies
79234420|NCT03517683|Other|High speed|speed of intrathecal injection will be 1ml in 5 seconds
79234421|NCT02401334|Device|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
79375534|NCT01275664|Drug|Aprepitant|Given IV and PO
79375535|NCT01275664|Drug|Carboplatin|Given IP
79375536|NCT01275664|Drug|Cisplatin|Given IP
79375537|NCT01275664|Drug|Dexamethasone|Given PO
79375538|NCT01275664|Drug|Granisetron Transdermal Patch|Apply one patch to upper arm
79375539|NCT01275664|Procedure|Management of Therapy Complications|Ancillary studies
79529301|NCT01408355|Drug|PF-06273588|Oral solution, 50 microgram, single dose
79529302|NCT01408368|Procedure|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
79529303|NCT01408368|Procedure|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
79828186|NCT05975554|Drug|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
80002196|NCT04736511|Other|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
80002197|NCT04736511|Other|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
79234422|NCT02401568|Device|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
80016697|NCT05180851|Drug|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
79234423|NCT02401568|Procedure|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
79234424|NCT02245763|Device|Leaflet Clip|
79234425|NCT02396498|Drug|HIPEC|Using cisplatin in HIPEC plus oral S-1
79234426|NCT02164643|Drug|Flutemetamol (18F)|
79234427|NCT02164643|Drug|Florbetapir (18F)|
79234428|NCT02403908|Device|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery <2 mm proximal from both ostia of right and left pulmonary arteries.
79234429|NCT02292459|Drug|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
79234430|NCT02292459|Drug|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
79234431|NCT02396576|Behavioral|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
79234432|NCT03520023|Other|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
79234433|NCT02396654|Other|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
79375540|NCT01275664|Other|Questionnaire Administration|Ancillary studies
79375541|NCT02193490|Drug|DNase|DNase 0.1% eye drops four times a day for 8 weeks
79375542|NCT02193490|Drug|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
79529304|NCT01408381|Other|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
79529305|NCT01408394|Drug|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
79529306|NCT01408394|Drug|90 mg controlled release form|This is the 90 mg controlled release form
79234434|NCT03170336|Drug|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
79234435|NCT03170336|Drug|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
79234436|NCT02295111|Device|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
79234437|NCT02295111|Behavioral|TCM health consult|Traditional Chinese Medicine Health Consult without needling
79234438|NCT02295111|Other|Usual Care|Standard NHS care
79234439|NCT03170102|Other|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
79234440|NCT04465305|Procedure|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
79234441|NCT04465305|Procedure|plasty treatment|patients with tarlov cysts treated by plasty nerve root
79234442|NCT03169946|Procedure|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
79234443|NCT03169946|Procedure|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
79234444|NCT02396186|Device|PTCA Balloon Angioplasty|
79375543|NCT01367080|Drug|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
79375544|NCT01367080|Drug|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
79375545|NCT01367860|Procedure|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
79529307|NCT01408394|Drug|180 mg controlled release form|This is the 180 mg controlled release capsule
79529308|NCT01408407|Other|Aveeno cream|Apply cream on irradiated area twice a day
79529309|NCT01408407|Other|Alkagin paste|Apply Alkagin paste three times a day.
79529310|NCT01408420|Procedure|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
79828187|NCT05975554|Procedure|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
79529311|NCT01408433|Other|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
79685563|NCT02907125|Behavioral|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
79685564|NCT02907125|Behavioral|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
79685565|NCT02907320|Drug|CYCLO 3 ® FORT|
79685566|NCT02907320|Drug|MPFF|
79685567|NCT02907320|Drug|placebo CYCLO 3 ® FORT|
80002198|NCT04736511|Other|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
80002199|NCT04736511|Other|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
80002200|NCT05250635|Device|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
80002201|NCT01370408|Drug|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
80016698|NCT00543374|Drug|Placebo|Placebo
79375546|NCT01367860|Procedure|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
79529312|NCT01408433|Other|Double embryo transfer|two (2) embryo transfer of untested embryos
79529313|NCT01408446|Drug|Menthol|Capsule 48mg three times a day after meals 8 weeks
79529314|NCT01408446|Drug|Placebo|Capsule 48mg three times a day after meals 8 weeks
79529315|NCT01408472|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
79529316|NCT01408498|Drug|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
79529317|NCT01408524|Drug|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
79529318|NCT01408524|Drug|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
79529319|NCT01408550|Drug|NPB-01|Intravenous immunoglobulin
79685568|NCT02907320|Drug|placebo MPFF|
79685569|NCT02907164|Behavioral|Email invitation|Receive emails encouraging them to sign up
79685570|NCT02907164|Behavioral|Social norm|Receive information about how many people have signed up
79375547|NCT01869959|Drug|LY2405319|Administered SC
79375548|NCT01869959|Drug|Placebo|Administered SC
79529320|NCT01408550|Drug|Placebo|Physiological saline
79529321|NCT01408589|Drug|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
79529322|NCT01408602|Drug|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
79529323|NCT01408602|Drug|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
79529324|NCT01408602|Drug|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
79685571|NCT02907164|Behavioral|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
79685572|NCT02907164|Behavioral|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
79375549|NCT01368874|Device|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
79375550|NCT01369030|Other|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
79529325|NCT01408654|Behavioral|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
79529326|NCT01408667|Drug|TRC150094|50 mg Tablets once a day
79529327|NCT01408667|Other|Placebo|Tablets once daily
79529328|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
79529329|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
79685573|NCT04323085|Behavioral|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
79685574|NCT04323085|Behavioral|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
80002202|NCT01370408|Drug|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
80002203|NCT01370408|Drug|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
80002204|NCT04769388|Drug|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
79529330|NCT01408680|Dietary Supplement|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
80002205|NCT04769388|Drug|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
80002206|NCT01345565|Drug|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
80002207|NCT03294109|Drug|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
80002208|NCT01345643|Other|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
80002209|NCT01345643|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
80002210|NCT03517488|Biological|XmAb20717|Monoclonal bispecific antibody
80002211|NCT04727931|Behavioral|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
80002212|NCT02065466|Drug|nab-paclitaxel|
80002213|NCT02065466|Drug|Temozolomide|
80002214|NCT02065466|Drug|Bevacizumab|
79234445|NCT03517605|Other|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
79375551|NCT01613027|Biological|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
79234446|NCT03517527|Behavioral|Exercise|
79234447|NCT02699684|Device|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
79234448|NCT02699684|Device|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
79234449|NCT02699684|Device|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
79234450|NCT02699684|Device|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
79234451|NCT02699684|Device|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
79234452|NCT03169868|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
79375552|NCT01369108|Device|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
79529331|NCT01408693|Procedure|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
79529332|NCT01408693|Procedure|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
79529333|NCT01408745|Device|Sternumfix|sternotomy closure with Sternumfix
79375553|NCT01369108|Device|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
79375554|NCT04595045|Drug|Botulinum toxin type A infiltrations|Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
79375555|NCT01369732|Drug|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
79375556|NCT01369732|Drug|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
79375557|NCT01869725|Drug|gallium Ga 68-edotreotide|Given IV
79529334|NCT01408745|Procedure|steel wire|sternotomy closure with steel wire
79828188|NCT05972993|Biological|mRNA-CR-04 vaccine 10μg|mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
80002215|NCT01358773|Other|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
80002216|NCT03970811|Procedure|Immediate Implants|dental implants are immediately placed after tooth extraction
79529335|NCT01408758|Other|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
80002217|NCT03970811|Procedure|temporary restoration|temporary restoration will be placed immediately after implant placement
79685575|NCT05519488|Behavioral|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
79234453|NCT03169400|Device|Theranova dialyzer|Hemoadialysis
79685576|NCT05519488|Behavioral|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
80002218|NCT03970811|Procedure|final restoration|final restoration (loading) will be placed 3 months postsurgical
79234454|NCT02292615|Other|Medical Imaging|
79234455|NCT03169478|Procedure|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
79234456|NCT02295189|Drug|Ketorolac Tromethamine|anti-inflammatory injection
79529336|NCT01408758|Other|No VCRT, only physician counseling at visits|No intervention
79529337|NCT01408797|Procedure|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
79529338|NCT01408797|Drug|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
79685577|NCT02907281|Other|Observational|Observational
79685578|NCT04323241|Other|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
79685579|NCT02899637|Device|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
79685580|NCT02899637|Device|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
80002219|NCT02064062|Biological|Autologous Mesenchymal Stem Cells|
80002220|NCT03963869|Other|Malaria Camps|The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
80002221|NCT05208801|Drug|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
80002222|NCT05208801|Drug|Morphine|Intrathecal injection of morphine 400mcg
80002223|NCT05208801|Drug|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
79234457|NCT02295189|Drug|Triamcinolone Acetonide|corticosteroid injection
79234458|NCT03169322|Procedure|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
79234459|NCT02292693|Device|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
79234460|NCT02292693|Device|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
79234461|NCT02292693|Device|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
79234462|NCT03169556|Device|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
79375558|NCT01869725|Procedure|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
79375559|NCT01869725|Radiation|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
79375560|NCT01869725|Procedure|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
79685583|NCT02899676|Other|neuropsychological testing|
80002224|NCT03614598|Procedure|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
80002225|NCT03614598|Procedure|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
80002226|NCT03614598|Procedure|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
79375561|NCT01869725|Procedure|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
79375562|NCT01309360|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
79685584|NCT02899676|Other|functional magnetic resonance imaging|
79685585|NCT02899676|Other|simple arithmetic operations|
80002227|NCT02064140|Drug|Rocuronium|
80002228|NCT03963011|Diagnostic Test|Bowel Ultrasound|Ultrasound imaging of the bowel
80002229|NCT03628755|Behavioral|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
80002230|NCT03628755|Behavioral|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
80002231|NCT03628755|Behavioral|combination Group|combination group intervention of DMT + FST
80002232|NCT01355029|Behavioral|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
80002233|NCT02065544|Behavioral|behavioral weight loss and exercise|Weight loss and exercise counseling
79685586|NCT00548574|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
79685587|NCT00548574|Drug|Mesalazine|
80002234|NCT05190627|Drug|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
80002235|NCT05190627|Drug|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
80002236|NCT02064218|Drug|Anti-hypertensive drugs|
80002237|NCT01345799|Drug|TRK-170|
80002238|NCT01345799|Drug|Placebo|
80002239|NCT03614520|Other|Administration of olive oil|25 mL of extra virgin olive oil
80002240|NCT03614520|Other|Administration of red wine|150 mL or Red Wine
79234463|NCT03169556|Device|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
79685588|NCT02899559|Behavioral|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
79685589|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
80002241|NCT03614520|Other|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
80002242|NCT03614520|Other|Water|Mineral water will be given as placebo
80002243|NCT03614520|Other|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
80002244|NCT03614520|Other|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
80002245|NCT03614520|Other|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
80002246|NCT01358851|Procedure|Cryotherapy|1-2 times during the treatment time
79685590|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
79685591|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
79685592|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
80002247|NCT01358851|Drug|LAS41005|once daily
80002248|NCT02065778|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
80002249|NCT03619941|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
80002250|NCT03619941|Dietary Supplement|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
80002251|NCT01343303|Drug|Placebo|Placebo tablet/capsule every 12 hours for 21 days
80002252|NCT01343303|Drug|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
80002253|NCT01343303|Drug|Naproxen|500 mg capsule every 12 hours for 21 days
80002254|NCT01343303|Drug|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
79234464|NCT02295267|Other|walnut allergy provocation|double blind placebo controlled food challenge
79234465|NCT02396264|Other|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
79234466|NCT02396264|Other|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
79234467|NCT03519633|Drug|Sugammadex|Reversal of deep NMB
79234468|NCT03519633|Drug|Neostigmine|Reversal of moderate NMB
79234469|NCT02289027|Biological|cAd3-EBOZ vaccine|
80002255|NCT03614442|Other|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
80002256|NCT04418115|Other|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
79234470|NCT02289027|Biological|Placebo (for cAd3-EBOZ vaccine)|Diluent
79375563|NCT01309360|Drug|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
79375564|NCT01309360|Drug|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
79375565|NCT01309360|Drug|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
79375566|NCT01851863|Drug|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
79391068|NCT01681433|Drug|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
79685593|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
79375567|NCT01851863|Drug|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
79375568|NCT01851863|Drug|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
79685594|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
79685595|NCT01262677|Drug|placebo|matched to the active drug
79685596|NCT02899442|Other|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
79685597|NCT00535041|Drug|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
79685598|NCT02899364|Drug|Sodium thiosulfate|see description under experimental arm
79685599|NCT02899364|Drug|Sodium chloride 0.9%|see description under placebo comparator arm
79685600|NCT02899364|Procedure|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
79375569|NCT01851863|Drug|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
79828189|NCT05972993|Biological|mRNA-CR-04 vaccine 30μg|mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
79685601|NCT02899364|Other|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
79685602|NCT00548613|Biological|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
79685603|NCT00548613|Biological|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
79685604|NCT04206865|Drug|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
79828190|NCT05972993|Biological|mRNA-CR-04 vaccine 100μg|mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
79685605|NCT04206865|Drug|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
79828191|NCT05972993|Drug|Placebo|Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
80002257|NCT01343381|Drug|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
79828192|NCT05969574|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
79828193|NCT05969574|Diagnostic Test|Blood test AMH|Measurement of AMH performed on the day of first consultation
80002258|NCT01343381|Drug|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
80002259|NCT03620149|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
80002260|NCT02064686|Other|Exhaled breath temperature|
79375570|NCT01369888|Drug|Cyclophosphamide|60 mg/m^2, intravenous (IV) (in the vein) x 2 days
79375571|NCT01369888|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
79375572|NCT01369888|Biological|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
79375573|NCT01369888|Drug|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
79375574|NCT01850615|Drug|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
79375575|NCT01850615|Drug|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
79375576|NCT02196766|Other|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
80016699|NCT00543374|Drug|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
80016700|NCT04056195|Drug|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
80016701|NCT04056195|Drug|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
80016702|NCT02926937|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet;~Route of administration: oral"
79234471|NCT02396030|Drug|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
79375577|NCT02196766|Other|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
80002261|NCT03614286|Diagnostic Test|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
79529339|NCT01408797|Procedure|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
79234472|NCT02396030|Drug|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
79375578|NCT04602221|Drug|Lamotrigine|Tablet
79375579|NCT04602221|Drug|BI 409306|Film-coated tablet
79234473|NCT02289183|Procedure|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
79375580|NCT04602221|Drug|Placebo|Tablet, Film-coated tablet
79375581|NCT04602221|Drug|BI 425809|Film-coated tablet
79234474|NCT02289183|Procedure|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
79234475|NCT03168152|Radiation|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
79375582|NCT01309906|Device|Investigational lens|Bausch & Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
79375583|NCT01309906|Device|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
79375584|NCT04415099|Other|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~Unilateral heel raise exercise~Close chain resisted foot adduction exercise"
79375585|NCT01372462|Device|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
79375586|NCT01372462|Device|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
79375587|NCT01372462|Device|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
79375588|NCT01373242|Drug|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
79375589|NCT01279564|Device|ETview TVT endotracheal tube|intubation
79375590|NCT01279564|Device|Endotracheal tube|Intubation
79529340|NCT01408810|Drug|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
79529341|NCT01408836|Procedure|Plasma exchange|Plasma exchange
79529342|NCT01408836|Drug|Intravenous methyl prednisolone|Intravenous methyl prednisolone
79529343|NCT01408836|Drug|Methyl prednisolone|methyl prednisolone
79234476|NCT03168152|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
79529344|NCT01408849|Drug|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
79529345|NCT01408849|Drug|Omeprazole|Standard therapy
79529346|NCT01408875|Device|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
79529347|NCT01408927|Other|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
79375591|NCT01280110|Drug|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
79375592|NCT01280110|Drug|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
79375593|NCT03009136|Drug|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
79375594|NCT03009136|Drug|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
79375595|NCT01403584|Device|AutoVPAP with addition of AutoEPAP|Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
79375596|NCT01403584|Device|AutoVPAP with EPAP manually selected|Conventionally applied Expiratory Positive Airway Pressure (EPAP)
79375597|NCT01374490|Drug|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
79529348|NCT01408927|Other|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
79529349|NCT01408927|Other|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
79529350|NCT01408953|Biological|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
79529351|NCT01408966|Dietary Supplement|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
80002262|NCT04369755|Other|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
80002263|NCT01343537|Other|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
79529352|NCT01408966|Dietary Supplement|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
79685606|NCT02899247|Procedure|Surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
79375598|NCT01374802|Drug|Darunavir|400 mg tablet for oral administration
79375599|NCT01374802|Drug|Ritonavir|tablet for oral administration
79375600|NCT01374802|Drug|BI 201335|
79375601|NCT01375660|Drug|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
79375602|NCT01375660|Drug|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
79375603|NCT01868477|Drug|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
79685607|NCT02899247|Procedure|No surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
79234477|NCT03168230|Procedure|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
79375604|NCT01868477|Drug|Erythropoietin alpha|
79375605|NCT01868477|Drug|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
79375606|NCT01849289|Drug|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
79375607|NCT01849289|Drug|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
79375608|NCT01868243|Drug|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
79375609|NCT01868243|Drug|Warfarin|Warfarin adjusted-dose
79375610|NCT01611935|Drug|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
79375611|NCT02201056|Drug|TAK-935|TAK-935 oral solution
79375612|NCT02201056|Drug|Placebo|TAK-935 placebo-matching oral solution
79375613|NCT01868009|Device|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
79529353|NCT01408979|Drug|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
79685608|NCT00535080|Drug|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
79685609|NCT02899403|Other|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
79685610|NCT01262638|Drug|ETC-1002|ETC-1002 daily for 12 weeks
79685611|NCT01262638|Drug|Placebo|Placebo daily for 12 weeks
79375614|NCT01868009|Device|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
79375615|NCT02201212|Drug|Everolimus|
79375616|NCT01376050|Device|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
79375617|NCT01376050|Device|Placebo Laser|Placebo Laser has no therapeutic output emitted.
79375618|NCT01376362|Drug|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
79375619|NCT03009292|Drug|lenvatinib|once daily continuous dosing
79391069|NCT01681433|Drug|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
79391070|NCT01681433|Drug|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
79529354|NCT01408979|Drug|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
79529355|NCT01409005|Drug|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1~21~Interval: every 4 weeks"
79529356|NCT01409018|Drug|Itraconazole|pharmacokinetics
80002264|NCT02064374|Drug|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
79685612|NCT02899520|Other|Reference method|Electrostimulation associated to perineal training
80002265|NCT02064374|Drug|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
79234478|NCT02289261|Drug|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
79375620|NCT01312948|Device|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
80002266|NCT02064374|Drug|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
79234479|NCT02289261|Drug|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
79234480|NCT03168074|Drug|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
79685613|NCT02899520|Other|CMP ® method|Method based on Knowledge and Control of Perineum
79234481|NCT02295345|Other|Cognitive Behavioural Therapy for Insomnia|
79234482|NCT02403752|Behavioral|Paired PLIE Program|Integrative exercise as described above
79234483|NCT03517215|Behavioral|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
79234484|NCT03517215|Behavioral|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
79234485|NCT02396108|Drug|Paclitaxel + Carboplatin + ASLAN001|"Phase I~IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
79375621|NCT04346680|Procedure|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
79375622|NCT01962792|Drug|Ibrutinib|
79234486|NCT02293083|Drug|trigger point injection|
79234487|NCT03519477|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
79375623|NCT01962792|Drug|Carfilzomib|
79375624|NCT01962792|Drug|Dexamethasone|
79375625|NCT01849055|Drug|Placebo|Administered orally
79685614|NCT00535119|Drug|Carboplatin|Given IV
79234488|NCT03521661|Procedure|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
79375626|NCT01849055|Drug|LY3023703|Administered orally
79375627|NCT01849055|Drug|Celecoxib|Administered orally
79375628|NCT01404832|Drug|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
79375629|NCT03420690|Other|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (>1) and the death of patients (> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
79375630|NCT01848353|Behavioral|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
79375631|NCT02418390|Procedure|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
79685615|NCT00535119|Other|Laboratory Biomarker Analysis|Correlative studies
79685616|NCT00535119|Drug|Paclitaxel|Given IV
79685617|NCT00535119|Other|Pharmacological Study|Correlative studies
79685618|NCT00535119|Drug|Veliparib|Given PO
79685619|NCT00535158|Drug|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
79685620|NCT00535197|Biological|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
79685621|NCT04684407|Procedure|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
79685622|NCT04942080|Biological|CALR allele burden quantification|"DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~at diagnosis and follow-up (inclusion period: 3 years)~max 1 sample/year~secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
79685623|NCT00548769|Drug|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
79529357|NCT01409044|Other|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
79685624|NCT00548769|Drug|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
79234489|NCT02395718|Other|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
79375632|NCT03420534|Drug|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
79685625|NCT00548769|Drug|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
79529358|NCT01409083|Device|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
79685626|NCT00548769|Drug|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
79828194|NCT05968274|Device|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
80002267|NCT03614208|Behavioral|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
79375633|NCT03420534|Drug|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
79375634|NCT03420534|Dietary Supplement|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
80002268|NCT05188365|Other|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
79375635|NCT03420534|Dietary Supplement|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
79529359|NCT01409122|Drug|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
80016703|NCT02926937|Drug|Placebo|"Pharmaceutical form: tablet;~Route of administration: oral"
79529360|NCT01409122|Drug|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
79234490|NCT02395718|Other|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
79234491|NCT02289339|Device|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
79529361|NCT01409122|Drug|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
79529362|NCT01409122|Drug|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
79685627|NCT01262560|Drug|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
79685628|NCT01262560|Drug|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
79529363|NCT01409122|Drug|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
79529364|NCT01409135|Drug|AGS-22M6E|IV Infusion
79234492|NCT02403518|Device|Freedom Spinal Cord Stimulator System|
79234493|NCT03519399|Device|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
79234494|NCT02403596|Drug|Exacyl®|
79234495|NCT02403596|Other|Placebo of Exacyl®|
79375636|NCT03416322|Other|Water exchange|Infusion and remove water during inertion and withdrawal of colonoscope
79375637|NCT01313494|Drug|Roflumilast|Roflumilast tablets
79375638|NCT01313494|Drug|Placebo|Placebo tablets
79529365|NCT01409135|Drug|ASG-22CE|IV Infusion
79234496|NCT02293161|Drug|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
79234497|NCT02293161|Drug|Placebo|It is Sodium Chloride Intravenous Infusion
79234498|NCT04480112|Behavioral|Technology based social interactions|Participants will be socially interacting using any available technology with members of the research team.
79234499|NCT04480112|Other|No research related technology based social interactions|No technology based social interactions with the research team.
79529366|NCT01409148|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
79828195|NCT05968274|Device|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
79828196|NCT05965167|Drug|EBP05|Oral tablets
79828197|NCT05965167|Drug|Forteo 20 mg|Subcutaneous injection
80016704|NCT05174533|Other|Data collection|electrocardiogram
79234500|NCT03167762|Device|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
79529367|NCT01409174|Drug|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
79529368|NCT01409174|Drug|Temozolomide|200 mg/m^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
79529369|NCT01409174|Drug|Cisplatin|25 mg/m^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
79685629|NCT01262560|Drug|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
79685630|NCT03429894|Device|Percutaneous Coronary Intervention|Drug eluting stent implant
79685631|NCT04686669|Drug|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
79685632|NCT04686669|Drug|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
79685633|NCT04207450|Other|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
79685634|NCT04207450|Other|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
79828198|NCT05965167|Drug|EBP11|Oral tablets
79828199|NCT05965167|Drug|EBP22|Oral tablets
79828200|NCT05964998|Device|transcranial direct current stimulation|Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
79234501|NCT03519321|Device|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
79234502|NCT03169088|Other|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~survey like FFQ, IPAQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
79234503|NCT04464681|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
79234504|NCT04464681|Drug|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
79234505|NCT02289495|Drug|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
79234506|NCT02289495|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
79234507|NCT02289495|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
79234508|NCT03168776|Device|BuMA Supreme DES|Implant BuMA Supreme stent only
79234509|NCT03168776|Device|Xience or Promus DES|Implant XIENCE family or Promus family only
79234510|NCT03519165|Device|EV1000(FloTrac System 4.0)|
79375639|NCT01313494|Drug|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
79375640|NCT01847885|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
79391071|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
79391072|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
79529370|NCT01409174|Drug|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
79529371|NCT01409174|Drug|Interleukin-2|9 million IU/m^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
79828201|NCT05964998|Device|Sham transcranial direct current stimulation|Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
79234511|NCT01774721|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
79529372|NCT01409187|Drug|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
79529373|NCT01409187|Drug|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
79529374|NCT01409187|Drug|Interleukin-2 (Aldesleukin)|9 million IU/m^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
79685635|NCT04207450|Other|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
79828202|NCT05964725|Device|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
79828203|NCT05964725|Device|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
79828204|NCT05960032|Drug|Zavegepant|Participants receiving single dose of Zavegepant 10 mg
79828205|NCT05957952|Procedure|Motor control exercise with dynamic taping|Subjects will learn how to control their scapula during motor control exercise with application of dynamic tape
79234512|NCT01774721|Drug|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
80016705|NCT05229796|Drug|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
79375641|NCT01314742|Drug|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
79529375|NCT01409226|Device|3.0-T MRI|Participants undergo MRI prior to biopsy.
79375642|NCT01314742|Other|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
79529376|NCT01409226|Procedure|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
79529377|NCT01409278|Procedure|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
79375643|NCT01407094|Drug|Sertraline|50-200mg/day
79828206|NCT05957952|Procedure|Motor control exercise|Subjects will learn how to control their scapula during motor control exercise without taping
79375644|NCT01407094|Drug|Placebo|1-4 pills per day
79375645|NCT01407094|Drug|BupropionXL|150-450 mg/day
79234513|NCT02293239|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
79375646|NCT01867307|Drug|Empagliflozin|
79375647|NCT01867307|Drug|BI 10773|open label
79529378|NCT01409278|Procedure|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
79529379|NCT01409278|Procedure|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
79529380|NCT01409304|Device|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
79529381|NCT01409317|Device|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
79685636|NCT04686396|Device|Demineralized bone matrix|Demineralized bone matrix
79375648|NCT01845077|Drug|2x500 mg Metformin (Glumetza)|2 tablets
79685637|NCT04322773|Drug|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
79685638|NCT04322773|Drug|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
79685639|NCT04322773|Drug|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
79828207|NCT05950646|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
79375649|NCT01845077|Drug|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
79375650|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
79375651|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
79375652|NCT01845077|Drug|3x500 mg Metformin (Glumetza)|3 tablets
79375653|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
79375654|NCT01845077|Drug|2 x 500 mg Metformin (Glumetza)|2 tablets
79375655|NCT01845077|Drug|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
79375656|NCT01845077|Drug|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
79529382|NCT01409317|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
79529383|NCT01409343|Drug|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
79685640|NCT04322773|Other|Standard medical care|management as usual
79828208|NCT05950646|Drug|Esketamine|Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
79234514|NCT02395796|Procedure|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
79234515|NCT02289573|Device|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
79375657|NCT01866917|Drug|Ropivacaine 0.5% 20cc injectate bilaterally|
79375658|NCT01866917|Drug|Placebo|
79375659|NCT01407952|Device|HydroCoil Embolic System|HydroCoil Embolic System
79375660|NCT01407952|Device|Control (bare platinum coils)|bare platinum coils
79375661|NCT01316302|Drug|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
79375662|NCT01316302|Drug|Placebo|Matching placebo, taken QD for 12 weeks.
79375663|NCT01410058|Dietary Supplement|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
79685641|NCT04322812|Device|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index [WPI] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
79685642|NCT04322812|Device|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
79685643|NCT02888782|Other|Pharmacist Consultation|
79828209|NCT05950646|Drug|Normal saline|Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
79828210|NCT05949008|Drug|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
79828211|NCT05949008|Drug|Placebo|Matching placebo will be provided as 1000 mg capsules
79828212|NCT05944926|Behavioral|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
79234516|NCT03170492|Other|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
79375664|NCT01410058|Drug|Efavirenz 600mg|Efavirenz 600mg based regimen
79375665|NCT01410058|Drug|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
79375666|NCT01380106|Drug|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
79375667|NCT01380106|Drug|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
79375668|NCT01381120|Drug|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
79375669|NCT01381120|Drug|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
79375670|NCT01316770|Drug|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
79375671|NCT01316770|Drug|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
79375672|NCT01316926|Drug|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
79375673|NCT01316926|Drug|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
79391073|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
79391074|NCT01681277|Drug|Placebo to BI 113608 PIB qd|powder for oral solution
79391075|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
79375674|NCT01318408|Drug|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
79685644|NCT04686591|Drug|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
79685645|NCT04686591|Drug|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
79234517|NCT03170492|Other|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
79529384|NCT01409356|Behavioral|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
79529385|NCT01409369|Drug|RO4995819|single oral dose
79828213|NCT05944926|Drug|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit.
79529386|NCT01409369|Drug|activated charcoal|orally 3 times daily, Days 1-7
79828214|NCT05944562|Drug|Tulmimetostat|Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
79529387|NCT01409395|Drug|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
79234518|NCT03518931|Diagnostic Test|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
79234519|NCT02395952|Drug|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
79685646|NCT04686591|Drug|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
79234520|NCT02395952|Device|Acuvue Oasys Bandage Contact Lens|
79685647|NCT04043494|Drug|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
79234521|NCT02395952|Device|Ambiodisk|
79375675|NCT01319110|Drug|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
79375676|NCT01319110|Dietary Supplement|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
79685648|NCT04043494|Drug|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
79828215|NCT05942911|Drug|IHL-675A|Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
79828216|NCT05942911|Drug|Cannabidiol|Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
79828217|NCT05942911|Drug|Hydroxychloroquine|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
79828218|NCT05942911|Drug|Placebo|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
79391076|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
79391077|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
79391078|NCT01681277|Drug|BI 113608 PIB qd|powder for oral solution
79529388|NCT01409395|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
79529389|NCT01409408|Drug|Aliskiren|300 mg of aliskiren daily for 8 weeks.
79529390|NCT01409408|Drug|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
79529391|NCT01409421|Behavioral|motivational interviewing|counseling intervention
79685649|NCT04043494|Drug|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
79234522|NCT02395952|Device|Prokera|
79234523|NCT03516903|Drug|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
79234524|NCT03516903|Drug|Placebo|Placebo-LDE (Lipid nanoemulsion)
79234525|NCT03516903|Drug|Folic Acid|Folic acid pill
79391079|NCT01703117|Drug|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
79391080|NCT01703117|Drug|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
80002269|NCT05188365|Other|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
79234526|NCT05693285|Other|No intervention|No intervention
79685650|NCT04043494|Drug|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
79828219|NCT05942716|Drug|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
79234527|NCT02292381|Other|Isometric exercise|
79375677|NCT01383616|Device|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
79375678|NCT03008512|Drug|Genexol-PM|
79685651|NCT04043494|Drug|Doxorubicin|Part of standard chemotherapy
79685652|NCT04043494|Drug|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
79828220|NCT05942105|Procedure|Breast conservative surgery|Breast conservative surgery after non-palpable lesion localization
79375679|NCT04351516|Drug|Hydroxychloroquine|dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
79375680|NCT04351516|Other|Placebo|Placebo: Film Coated Tablette
79375681|NCT01411696|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
79375682|NCT01412086|Drug|No Intervention|No Intervention.
79375683|NCT01844765|Drug|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
79375684|NCT01412164|Device|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
79375685|NCT04346758|Procedure|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
79375686|NCT01866293|Drug|Cabozantinib (XL184)|
79375687|NCT01844687|Drug|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
79375688|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
79375689|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
79529392|NCT01409421|Behavioral|three phone calls to remind patients to take their eye drops|reminder phone calls
80002270|NCT05061251|Drug|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
79234528|NCT05693207|Device|EMG|wearables EMG
79234529|NCT02289651|Device|Venner|Video-laryngoscopy
79234530|NCT02289651|Device|Miller|Direct-Laryngoscopy
79529393|NCT01409447|Device|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
79234531|NCT02293317|Biological|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
79529394|NCT01409460|Procedure|Oburator Nerve block|Use of selective pain block.
79685653|NCT04043494|Drug|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
79234532|NCT02293317|Drug|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
79234533|NCT02293317|Other|Saline|Placebo
79234534|NCT03516825|Other|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
79529395|NCT01409460|Procedure|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
79685654|NCT04043494|Drug|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
79685655|NCT04043494|Drug|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib* (Randomization R2)
79234535|NCT02295501|Biological|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
79234536|NCT02295579|Other|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
79234537|NCT02295657|Device|standard double-lumen tube|intubation using standard double-lumen tube
79375690|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
79685656|NCT04043494|Drug|Prednisone|Part of standard chemotherapy
79234538|NCT02295657|Device|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
79234539|NCT03516747|Diagnostic Test|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
79828221|NCT05942092|Procedure|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
79234540|NCT03516747|Diagnostic Test|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
79234541|NCT03516747|Diagnostic Test|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
79234542|NCT03516747|Diagnostic Test|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
79234543|NCT03516669|Drug|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
79234544|NCT03516669|Drug|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
79234545|NCT03521427|Other|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
79234546|NCT03521427|Other|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
79375691|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
79529396|NCT01409473|Radiation|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
79529397|NCT01409486|Other|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
79529398|NCT01409512|Procedure|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
79685657|NCT04043494|Drug|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
79685658|NCT04043494|Drug|Thioguanine|Part of standard chemotherapy
79685659|NCT04043494|Drug|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
79685660|NCT04043494|Drug|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
79685661|NCT04686357|Diagnostic Test|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~Normal result~Ultralow or Dysbiotic result~Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
79685662|NCT04686357|Diagnostic Test|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
79828222|NCT05940896|Drug|Disitamab vedotin|Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
79234547|NCT02289807|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
79234548|NCT02289807|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
80002271|NCT01351129|Drug|Formulation 1|150-mg immediate release tablet (single dose)
79234549|NCT03521349|Other|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
79234550|NCT03521349|Other|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
79234551|NCT02289885|Device|SonoScape|Ultrasonography device
79234552|NCT02298153|Drug|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
79234553|NCT02298153|Drug|epacadostat|epacadostat: Oral daily dosing
79234554|NCT03514797|Drug|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
79234555|NCT03514797|Drug|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
79375692|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
79375693|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
79375694|NCT01844375|Dietary Supplement|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
79375695|NCT01844375|Other|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
79529399|NCT01409538|Other|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
79529400|NCT01409538|Other|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
79685663|NCT02899481|Other|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
79685664|NCT02899286|Biological|PEG-BCT-100|PEGylated recombinant human arginase
79685665|NCT00535275|Drug|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
79685666|NCT00535275|Drug|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
80002272|NCT01351129|Drug|Formulation 2|150-mg modified release capsule, short duration (single dose)
79828223|NCT05939648|Biological|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
80002273|NCT01351129|Drug|Formulation 3|150-mg modified release capsule, long duration (single dose)
80002274|NCT02064452|Other|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
80002275|NCT02064452|Behavioral|Placebo Comparator|Enhanced Usual Community Care-Waitlist
80002276|NCT02236884|Procedure|no-scar transanal total mesorectal excision(TME)|
80002277|NCT01355263|Drug|iron and vitamin a|
80002278|NCT04415177|Device|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
79234556|NCT02298231|Other|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
80002279|NCT04415177|Device|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
79234557|NCT02298231|Other|Mystic Isle Balance Intervention|Balance therapy using virtual reality
79375696|NCT02367456|Drug|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
79685667|NCT04322344|Drug|Escin|treatment with escin or escinate sodium
80002280|NCT02065856|Biological|AVANZ Salsola|AVANZ Salsola
79685668|NCT04322344|Drug|standard therapy|antiviral drugs
79685669|NCT04322422|Drug|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
79234558|NCT02298231|Other|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
79828224|NCT05939648|Other|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
79234559|NCT03518775|Device|Biometry|Measurement of Cornea
79234560|NCT03518697|Behavioral|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
79234561|NCT02293473|Device|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
79234562|NCT02293473|Device|BIS-Bispectral Index Monitor|Depth of anaesthesia
79234563|NCT02293473|Device|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
79234564|NCT02293473|Other|Standard of care|Using standard of care
79234565|NCT02298309|Other|Test-and-Treat TB|
79375697|NCT02367456|Drug|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
79375698|NCT03416166|Device|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
79375699|NCT03420456|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
79375700|NCT03420378|Dietary Supplement|vitamin D|Vitamin D replacement
79375701|NCT03425682|Other|ViBone|Viable Bone Allograft
79375702|NCT03415932|Behavioral|health education|Health information by a multimodal team
79375703|NCT03425604|Procedure|Intrauterine insemination|
79529401|NCT01409551|Procedure|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
80002281|NCT03613428|Drug|Ruxolitinib|Dose escalation up to 80 mg administered orally
80002282|NCT03613428|Drug|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
80002283|NCT03613428|Drug|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
80002284|NCT03290521|Procedure|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
80002285|NCT03290521|Procedure|No washing|no washing
80002286|NCT02065934|Other|cardio-pulmonary resuscitation|
80002287|NCT01343615|Procedure|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
80002288|NCT01343615|Procedure|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
79529402|NCT01409551|Procedure|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
79529403|NCT01409590|Behavioral|Exercise program|Homogenous exercise program in local fitness centers
79685670|NCT04322422|Drug|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
79375704|NCT03425448|Drug|Heparin|Heparin hemodialysis catheter lock solution
80002289|NCT03613350|Diagnostic Test|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
79685671|NCT02899169|Drug|Realgar-Indigo naturalis formula|
79234566|NCT02298387|Drug|OMP-305B83|intravenous (in the vein) infusions
79375705|NCT03425448|Device|Neutrolin|Neutrolin hemodialysis catheter lock
79685672|NCT02899169|Drug|all-trans retinoic acid|
80002290|NCT02064530|Drug|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
79375706|NCT03419988|Behavioral|Exercise Intervention|24 sessions of aerobic exercise
79529404|NCT01409590|Behavioral|Diet|Weigh loss diet program prescribed by a professional nutritionist
79529405|NCT01409603|Drug|darexaban|oral
79234567|NCT02295813|Biological|FBF001|
79375707|NCT03425370|Procedure|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
79375708|NCT03415698|Drug|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
79375709|NCT03415698|Drug|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
79529406|NCT01409603|Drug|Naproxen|oral
79685673|NCT02899169|Drug|Arsenic trioxide|
79685674|NCT02899169|Drug|Hydroxyurea|
79234568|NCT02295813|Drug|Placebo|
79234569|NCT02293551|Drug|Lispro|Administered SC
79685675|NCT05517031|Other|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
79685676|NCT04322188|Other||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
79685677|NCT02899130|Drug|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
79685678|NCT02899130|Drug|Placebo|Inactive compound that is similar looking as the intervention
80002291|NCT02064530|Drug|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
80002292|NCT02064530|Drug|serum physiologic|21 ml serum physiologic is applied interfasially
80002293|NCT01358929|Drug|Placebo|Placebo to RO6807952
79375710|NCT03425214|Other|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
79375711|NCT03425214|Other|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
80002294|NCT01358929|Drug|RO6807952|Escalating subcutaneous dose
79234570|NCT03518541|Procedure|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
79234571|NCT02298543|Other|coronary spasm|
79234572|NCT03518463|Combination Product|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
79375712|NCT03425214|Other|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
79234573|NCT02298621|Other|pomegranate juice|Randomized clinical trial or RCT
79234574|NCT02298621|Other|placebo|Randomized clinical trial or RCT
79234575|NCT02293629|Drug|BMS-986147|
79234576|NCT02293629|Drug|Placebo matching BMS-986147|
79375713|NCT03419910|Drug|BMS-986165|Specified dose on specified days
79234577|NCT04465149|Procedure|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
79234578|NCT02295969|Drug|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
79375714|NCT03419910|Drug|Cyclosporine|Specified dose on specified days
79375715|NCT03419754|Dietary Supplement|Glucose|Glucose
79375716|NCT03419754|Behavioral|Fidgetting|low intensity physical activity (fidgetting)
79375717|NCT03415542|Behavioral|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
79529407|NCT01409616|Drug|darexaban|oral
79529408|NCT01409616|Drug|darexaban (double dose)|oral
79529409|NCT01409616|Drug|Acetyl Salicylic Acid|oral
79529410|NCT01409616|Drug|clopidogrel|oral
79529411|NCT01409642|Behavioral|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
79529412|NCT01409642|Behavioral|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
79529413|NCT01409642|Behavioral|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
79685679|NCT00548964|Drug|Lithium|600-900mg of Li carbonate
79685680|NCT00548964|Drug|Ketamine|0.5mg/kg of ketamine
79685681|NCT04322227|Drug|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
79685682|NCT04322227|Drug|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
79685683|NCT04322227|Drug|Placebo (treatment C)|Placebo, BID capsules, orally
79685684|NCT02889601|Other|Psycho-behavioural assessment|DAPHNE Scale
79529414|NCT01409655|Behavioral|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
79529415|NCT01409668|Dietary Supplement|L. Amylovorus|L. Amylovorus
79529416|NCT01409668|Dietary Supplement|L. Fermentum|L. Fermentum
79685685|NCT02898896|Biological|blood test|Additional 21 ml of blood will be collected
79685686|NCT02899013|Other|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
80002295|NCT01345877|Procedure|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
79529417|NCT01409694|Drug|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
79685687|NCT02899091|Biological|CB-AC-02|"Stage1:~① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0~② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)"
79685688|NCT02899091|Biological|Placebo|"Stage2:~Placebo on day 0 and on week 4 (repeated injection)"
80002296|NCT01568229|Drug|AMG 747|Three dose levels once-daily oral administration
79234579|NCT03516435|Device|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
79375718|NCT04801602|Diagnostic Test|Rapid diagnostic tests|To evaluate different RDTs that are commercially available internationally for detecting antigens or antibodies to Salmonella Typhi and use blood culture as standard for comparison.
79375719|NCT03425136|Other|Systems Analysis and Improvement Approach (SAIA)|Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
79685689|NCT04323007|Diagnostic Test|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
79234580|NCT03516435|Device|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
79234581|NCT02298855|Behavioral|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
79234582|NCT04464837|Device|Cold Snare Polypectomy of intermediate sized polyps (10-15 mm)|If an eligible polyp (10-15mm) is found, cold snare polypectomy is performed with the Olympus SnareMaster® Plus Snare
79234583|NCT03518385|Diagnostic Test|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
79234584|NCT02299011|Device|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
79234585|NCT02299011|Drug|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
79234586|NCT02296047|Drug|Placebo|physiological saline
79375720|NCT01319812|Device|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
79685690|NCT04684290|Procedure|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
79685691|NCT04684290|Procedure|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
79685692|NCT00549003|Device|Rapid Diagnostic Test for P. falciparum malaria|
79685693|NCT02898857|Other|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
79685694|NCT00549081|Dietary Supplement|DHEA|oral DHEA tablets 75 mg daily
79828225|NCT05939063|Procedure|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
80002297|NCT01568229|Drug|Placebo|Once-daily oral administration
80002298|NCT03613896|Procedure|conventional dentures|conventional dentures
80002299|NCT03613896|Procedure|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
80002300|NCT02066012|Other|dysmetabolic iron overload syndrome|
80002301|NCT05384028|Other|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
79375721|NCT01319812|Device|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
79529418|NCT01409694|Drug|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
79685695|NCT02898779|Drug|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
79529419|NCT01409694|Drug|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
79828226|NCT05939063|Procedure|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
79828227|NCT05937165|Other|Freeze-dried Blueberry Powder|Three day consumption of two doses of freeze-dried blueberry powder
79828228|NCT05936736|Radiation|prostate SBRT|Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
79828229|NCT05933187|Drug|Treatment A: Emraclidine 30mg IR tablets (reference)|IR oral tablets
79234587|NCT02296047|Drug|ipratropium bromide|80 µg inhalation once
79234588|NCT02296047|Drug|salbutamol|400 µg inhalation once
79234589|NCT02293707|Biological|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
79375722|NCT03415386|Drug|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
79375723|NCT03415230|Other|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
79375724|NCT03415230|Other|Sham massage|Sham massage involves only light touch massage in a non systematic way
79529420|NCT01409720|Other|exercise|tailored isometric physical exercise
79828230|NCT05933187|Drug|Treatment B: Emraclidine 30mg IR test tablets 1|IR oral tablets
79828231|NCT05933187|Drug|Treatment C: Emraclidine 30mg IR test tablets 2|IR oral tablets
79828232|NCT05933187|Drug|Treatment D: Emraclidine 30mg IR test tablets 3|IR oral tablets
79828233|NCT05930535|Behavioral|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
79828234|NCT05930210|Drug|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
79828235|NCT05930210|Drug|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
79828236|NCT05927012|Drug|KER-047|Oral tablet, daily (or every other day) administration
79828237|NCT05925712|Device|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
79828238|NCT05925712|Device|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
79828239|NCT05915546|Drug|Emraclidine|Tablets
79828240|NCT05912283|Device|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
79828241|NCT05912283|Device|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
79828242|NCT05912283|Device|Control Latex Condom|Commercial natural rubber latex condom
79828243|NCT05905705|Diagnostic Test|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
79529421|NCT01409733|Device|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
79685696|NCT00535431|Drug|AER 001|60 mg (in nebuliser), twice daily for 28 days
79685697|NCT00535431|Drug|placebo|Sterile saline nebulised, twice daily for 28 days
79234590|NCT03514407|Drug|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
79375725|NCT01865747|Drug|Cabozantinib tablets|
79375726|NCT01865747|Drug|Everolimus (Afinitor) tablets|
79234591|NCT02293785|Drug|Oxycodone-Naloxone|
79234592|NCT01162109|Dietary Supplement|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
79529422|NCT01409759|Procedure|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
79529423|NCT01409499|Procedure|hepatic resection|palliative hepatectomy followed by sorafenib
79685698|NCT02898701|Behavioral|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
79375727|NCT03424980|Combination Product|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
79529424|NCT01409499|Procedure|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
79529425|NCT01409499|Drug|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
79529426|NCT01409824|Other|CDSS|Clinical Decision Support System
79529427|NCT01409850|Device|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
79529428|NCT01409850|Device|Soft splint|
79685699|NCT00549120|Drug|Propranolol|40 mg tablets
79234593|NCT02296203|Drug|cetuximab|
79234594|NCT02296203|Drug|irinotecan|
79529429|NCT01409876|Radiation|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
79529430|NCT01409889|Behavioral|Diabetes Prevention Program|
79529431|NCT01409889|Behavioral|Healthy Living Program|
79529432|NCT01410019|Other|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
79529433|NCT01410032|Procedure|Plate fixation|Reconstruction plate
79234595|NCT03514251|Procedure|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
79234596|NCT03518229|Device|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
79234597|NCT03518229|Device|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
79234598|NCT05504525|Procedure|Fascia Iliaca block|Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.
79375728|NCT03424902|Diagnostic Test|cardiac computed tomography and cardiac catheterization|assesment of certain predictors with CT and fluroscopy for paravalvular leakage
79375729|NCT03415074|Behavioral|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
79375730|NCT01385644|Other|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
79529434|NCT01410032|Procedure|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
79529435|NCT01410045|Procedure|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
79529436|NCT01410136|Procedure|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
79529437|NCT01410149|Other|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
79529438|NCT01410149|Other|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
79529439|NCT01410149|Other|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
79529440|NCT01410162|Drug|Tacrolimus|tacrolimus extended release capsules vs Prograf
79529441|NCT01410175|Device|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
79685700|NCT00549120|Drug|Salbutamol|Metered dose inhaler (600 μg)
79685701|NCT00549120|Drug|Ipratropium|Metered dose inhaler (40 μg)
79685702|NCT00549120|Drug|Placebo|Placebo for propranolol tablets
79529442|NCT01410201|Drug|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
79234599|NCT05504525|Procedure|Quadratus lumborum block|The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
79375731|NCT03424746|Drug|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
79529443|NCT01410214|Drug|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
79685703|NCT04680884|Drug|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
80002302|NCT05384028|Other|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
80002303|NCT01355341|Drug|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
80002304|NCT02066090|Device|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
80002305|NCT02066090|Device|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
80002306|NCT01351207|Other|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
79375732|NCT03414918|Drug|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
79375733|NCT04448496|Drug|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
79375734|NCT01387672|Drug|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
79375735|NCT01387672|Other|Placebo|Placebo ointment
79375736|NCT03419520|Behavioral|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
79529444|NCT01410214|Drug|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
79375737|NCT01843673|Procedure|computed tomography|Undergo FBCT
79375738|NCT01843673|Procedure|cone-beam computed tomography|Undergo dual CBCT
79375739|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian kV OBI
79375740|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
79529445|NCT01410253|Other|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
79685704|NCT04680884|Drug|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
79375741|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian MV OBI
79375742|NCT01843673|Procedure|electronic portal imaging|Undergo EPID imaging
79375743|NCT01843673|Radiation|image-guided adaptive radiation therapy|Undergo IGART
79375744|NCT03419442|Drug|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
79375745|NCT03419442|Drug|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
79529446|NCT01410253|Other|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
79529447|NCT01410253|Other|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
79529448|NCT01410253|Other|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
79529449|NCT01410266|Other|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
79529450|NCT01410279|Other|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
79685705|NCT04680884|Drug|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
79685706|NCT04680884|Other|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
79685707|NCT03318588|Procedure|Vitrectomy|Pars plana vitrectomy
79375746|NCT03419442|Drug|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
80002307|NCT05250557|Diagnostic Test|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
80002308|NCT03613194|Procedure|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
80002309|NCT04519437|Drug|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
79234600|NCT03518151|Other|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
79529451|NCT01410292|Other|GI and fiber meals|meals with different fiber content and glycemic index
79529452|NCT01410292|Other|meals|four different meal regarding GI and fiber content
79529453|NCT01410331|Biological|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
80002310|NCT04519437|Drug|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
80002311|NCT02064608|Drug|AZD2014|mTOR inhibitor
80002312|NCT04299997|Other|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"Ass of targeted suspect lesions~On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~Max diameter~Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
80002313|NCT03613584|Drug|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
80002314|NCT03613584|Drug|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
80002315|NCT03907943|Procedure|carotid endarterectomy|Surgical treatment of ICA stenosis.
80002316|NCT02066246|Device|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
79234601|NCT03518151|Other|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
79375747|NCT01412710|Drug|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
79375748|NCT03424668|Behavioral|diet|lifestyle factors
79375749|NCT01843205|Drug|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
79685708|NCT02898428|Device|Continuous glucose monitoring (CGM)|
79685709|NCT00549159|Device|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
80002317|NCT02066246|Device|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
79375750|NCT01843205|Drug|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
79529454|NCT01410331|Biological|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
79529455|NCT01410331|Biological|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
79375751|NCT01412866|Behavioral|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
79375752|NCT01412866|Behavioral|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
79391081|NCT01702961|Drug|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
79391082|NCT01702961|Drug|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
79391083|NCT01702961|Drug|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
79529456|NCT01410331|Biological|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
79529457|NCT01410370|Radiation|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
79529458|NCT01410370|Drug|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
79529459|NCT01410383|Drug|Placebo|Tablets taken daily
79529460|NCT01410383|Drug|Eprotirome|Tablets taken daily
79529461|NCT01410383|Drug|Eprotirome|Tablets taken daily
79529462|NCT01410435|Drug|Monofer|Infusion according to current HB level
79685710|NCT00549159|Device|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
79685711|NCT02898311|Device|immediate loading of posterior implants with chairside CAD-CAM composite crown|
79685712|NCT00549237|Dietary Supplement|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
79685713|NCT00549237|Other|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
79828244|NCT05905705|Diagnostic Test|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
79828245|NCT05900752|Dietary Supplement|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
79828246|NCT05900752|Dietary Supplement|Placebo product|consume one sachet of the assigned product, once a day after meals.
79828247|NCT05900362|Device|VitalCare Platform|All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
79391084|NCT01702961|Drug|BCNU|BCNU 300 mg/m2 IV given on Day -6
79391085|NCT01702961|Drug|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
79828248|NCT05896033|Behavioral|Non-Menthol Cigarettes|Ppts will be randomly assigned to a group that receives non-menthol cigarettes
79828249|NCT05896033|Behavioral|Tobacco Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes
80002318|NCT01359085|Drug|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
79828250|NCT05896033|Behavioral|Menthol Cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored cigarettes
79685714|NCT02898545|Device|SEEQ monitor|An external cardiac rhythm monitor
79828251|NCT05896033|Behavioral|Menthol Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
79828252|NCT05895773|Drug|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
79828253|NCT05895773|Drug|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
79828254|NCT05894785|Procedure|External cephalic version|An ECV attempt is made on the study group
79828255|NCT05894005|Other|Immersive 360 (3D) video|"Group A VR - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of Route 1.~Traditional - Route 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Group B Traditional - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1. Then the students will be assessed with an observed walkthrough of Route 1.~VR - Route 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2."
79828256|NCT05891743|Diagnostic Test|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
79828257|NCT05891470|Device|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
79828258|NCT05891470|Device|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
79828259|NCT05884580|Device|Neuflo BPH Treatment System|The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
80002319|NCT01359085|Procedure|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
80002320|NCT05384184|Procedure|Tumor /metastases removal|Tumor /metastases removal
79234602|NCT03514095|Other|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
79234603|NCT02294097|Procedure|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
79685715|NCT00535470|Drug|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
79685716|NCT02898467|Other|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
79685717|NCT02898467|Other|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
79234604|NCT02302443|Biological|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
79391086|NCT01702961|Drug|Stem Cells|Stem cells given on Day 0
79391087|NCT01593917|Device|Trifecta™ Valve|Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
79391088|NCT01593761|Drug|CG400549|960mg QD at fed state approx 1 hour after meal
79391089|NCT02706834|Drug|TAK-828|TAK-828 oral solution
79391090|NCT02706834|Drug|Placebo|TAK-828 placebo-matching oral solution
80002321|NCT01351285|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
80002322|NCT05189041|Other|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
80002323|NCT02032290|Procedure|Assessment of Coronary Flow Reserve|
79234605|NCT02302443|Biological|Active comparator|Single dose subcutaneous administration of active comparator
80002324|NCT02032290|Procedure|Percutaneous coronary intervention|
79234606|NCT03516123|Drug|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
79685718|NCT03284112|Behavioral|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
79685719|NCT03284112|Behavioral|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
79685720|NCT02898584|Other|BP Track|
80002325|NCT02032290|Drug|ticagrelor loading|
80002326|NCT02032290|Drug|Clopidogrel loading|
79685721|NCT03455309|Biological|NDV-3A|Single dose administered by intramuscular injection
79685722|NCT03455309|Biological|Placebo|Single dose administered by intramuscular injection
80002327|NCT01317329|Other|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
80002328|NCT03560180|Diagnostic Test|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
80002329|NCT03560180|Diagnostic Test|Serum C-reactive Protein|see study protocol
79234607|NCT03132597|Behavioral|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
79234608|NCT02296281|Drug|Pirfenidone|
79234609|NCT03513861|Other|FASTER Assessment tool|The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
79234610|NCT02299245|Drug|rosuvastatin|different dose of rosuvastatin treatment
79234611|NCT02302521|Device|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
79234612|NCT02299323|Device|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
79234613|NCT02296359|Biological|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
79234614|NCT02302599|Biological|Umbilical cord mesenchymal stem cells|Infusion treatment
79234615|NCT02302599|Biological|Controlled suspension liquid|Infusion treatment
79375753|NCT03419208|Other|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
79375754|NCT03419130|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
79375755|NCT03419130|Other|Laboratory Biomarker Analysis|Correlative studies
80002330|NCT03560180|Diagnostic Test|serum Procalcitonin|see study protocol
80002331|NCT01351363|Device|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
80002332|NCT01351363|Device|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
80002333|NCT05384106|Dietary Supplement|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
80002334|NCT05050565|Behavioral|Experiences of stigma and psychological flexibility in chronic pain participants|Chronic pain participants will answer questionnaires at two points in time, two weeks apart. These questionnaires ask about stigma and psychological flexibility, as well as depression, catastrophizing, pain interference, and social adjustment. The data collected is only observational and does not include any intervention.
80002335|NCT03379428|Drug|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
80002336|NCT03379428|Drug|Ibrutinib 560 mg|560 mg by mouth daily
80002337|NCT03379428|Drug|Ibrutinib 840 mg|840 mg by mouth daily
79234616|NCT03513627|Procedure|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
79685723|NCT00549315|Device|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
80002338|NCT03379428|Drug|Ibrutinib 420 mg|420 mg by mouth daily
80002339|NCT03132805|Behavioral|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
80002340|NCT03132805|Behavioral|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
80002341|NCT03628131|Drug|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
79234617|NCT03513549|Drug|Loxapine 10 MG|
79375756|NCT03419130|Biological|Pembrolizumab|Given IV
79375757|NCT03419130|Radiation|Radiation Therapy|Undergo conventionally fractionated RT
79375758|NCT01320826|Procedure|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
79375759|NCT03414840|Drug|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
80002342|NCT03628131|Drug|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
79685724|NCT00535509|Radiation|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
79685725|NCT00535509|Other|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
79234618|NCT03513471|Biological|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
79234619|NCT03513471|Other|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
79234620|NCT03513471|Drug|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
79234621|NCT02296437|Other|Transcranial direct current stimulation combined with cognitive training|
79234622|NCT03516045|Drug|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
79234623|NCT03515967|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
79375760|NCT01414036|Other|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
79685726|NCT00535509|Drug|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
79685727|NCT02898350|Device|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
79685728|NCT02898350|Device|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
79685729|NCT02898350|Device|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
80002343|NCT03628131|Drug|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
80002344|NCT03628131|Drug|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
80002345|NCT02067884|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
80002346|NCT02067884|Procedure|shear wave elastography|Undergo SWE
79234624|NCT02302755|Drug|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
79234625|NCT03513393|Drug|velpatasvir|Test 1
79234626|NCT03513393|Drug|velpatasvir|Test 2
79234627|NCT03513393|Drug|velpatasvir|Reference
79234628|NCT02302911|Behavioral|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
79234629|NCT02302911|Behavioral|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
79375761|NCT01414036|Behavioral|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
79375762|NCT03414762|Device|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
79375763|NCT03414762|Device|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
79685730|NCT02898350|Device|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
79685731|NCT00549354|Device|Endoluminal Graft|
80002347|NCT02067884|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
80002348|NCT02067884|Device|Philips Shear Wave Elastography|Equipment used for SWE
80002349|NCT01317485|Procedure|Laparoscopic lavage and drainage|"[CLOSED] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~***This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
79234630|NCT02302911|Other|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
79234631|NCT02299401|Drug|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
79234632|NCT02299401|Device|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
79234633|NCT03513315|Behavioral|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
79828260|NCT05884359|Diagnostic Test|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
80002350|NCT01317485|Procedure|Sigmoidectomy with primary anastomosis|[OPEN] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
80002351|NCT01317485|Procedure|Sigmoidectomy with end-colostomy|[OPEN] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
80002352|NCT03612882|Other|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
80002353|NCT03560024|Other|PACAP27|PACAP27 is vasodilator of cerebral vessels
80002354|NCT03560024|Other|Placebo|Saline
80002355|NCT05102643|Biological|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
79234634|NCT03513315|Behavioral|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
79234635|NCT02296515|Procedure|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
79234636|NCT02296593|Device|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
79234637|NCT02699450|Drug|Faricimab|Faricimab will be administered by IVT injection in the study eye.
79234638|NCT02699450|Drug|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
79375764|NCT03424590|Device|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
79375765|NCT04351672|Behavioral|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
79375766|NCT04351672|Behavioral|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
79375767|NCT03424434|Other|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
79375768|NCT01414426|Drug|vandetanib|Given PO
79375769|NCT01414426|Other|placebo|Given PO
79375770|NCT01414426|Other|immunohistochemistry staining method|Correlative studies
79375771|NCT01414426|Other|laboratory biomarker analysis|Correlative studies
79375772|NCT01414426|Procedure|biopsy|Correlative studies
79375773|NCT01414426|Other|pharmacological study|Correlative studies
79375774|NCT03418974|Drug|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
79529463|NCT01410461|Device|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
79529464|NCT01410461|Device|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
79234639|NCT02299557|Drug|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
79234640|NCT02299557|Drug|Placebo gel|Placebo gel applied intra-anally once daily
79375775|NCT03418974|Drug|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
79375776|NCT03418974|Drug|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
79375777|NCT03424356|Drug|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
79375778|NCT03424356|Drug|Saline Solution|1-2 ml saline solution
79375779|NCT03424356|Drug|Fentanyl|1mcg/kg for induction
79375780|NCT03424356|Drug|Propofol|2-3mg/kg for anaesthetic induction
79375781|NCT03424356|Procedure|cystoscopy|patients will treated with this surgical procedure
80002356|NCT05102643|Biological|Matching placebo|Solution for intramuscular injection
80002357|NCT01351441|Behavioral|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
80002358|NCT01351441|Other|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
80002359|NCT01351441|Other|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
80002360|NCT01351441|Behavioral|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
80002361|NCT02260232|Other|exercise training|
80002362|NCT01319227|Procedure|Hip replacement|Hip arthroplasty with uncemented components
80002363|NCT02067962|Biological|Blood sample|Blood sample
80002364|NCT03613272|Procedure|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
80002365|NCT03613272|Procedure|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
80002366|NCT05250479|Behavioral|Mindfulness education|44 primiparous pregnant women will receive mindfulness education
79234641|NCT02302989|Drug|Ranibizumab 0.5mg|
79234642|NCT02299713|Device|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
79375782|NCT03127410|Other|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
79234643|NCT02296671|Drug|Pemetrexed|
80002367|NCT01355653|Device|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
80002368|NCT01355653|Device|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
79234644|NCT02296671|Drug|Oxaliplatin|
79234645|NCT02296671|Drug|Leucovorin|
79234646|NCT02296671|Drug|Fluorouracil|
80002369|NCT05033223|Other|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
79234647|NCT02296671|Genetic|Germline genotyping analyses for TSER|
79234648|NCT02296749|Drug|Sirolimus|Sirolimus tablets 2 mg
79375783|NCT03414528|Diagnostic Test|Diagnostic Test|Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
79234649|NCT04481750|Drug|MT-1186|Solution or suspension
79234650|NCT04481750|Drug|MT-1186-matching placebo|Solution or suspension
79375784|NCT03414450|Drug|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
79685732|NCT02898038|Dietary Supplement|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
79685733|NCT00535548|Biological|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
80002370|NCT02032368|Procedure|transarterial chemoembolization (TACE)|
80002371|NCT01351519|Drug|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
80002372|NCT03612492|Drug|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
80002373|NCT03612492|Drug|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
80002374|NCT04970199|Device|laser application on acupoints|laser acupuncture
80002375|NCT05250401|Diagnostic Test|liver functions and thyroid functions|laboratory tests
80002376|NCT03612414|Dietary Supplement|Aqualief|Three tablets/day
80002377|NCT03612414|Dietary Supplement|Placebo|Three tablets/day
80002378|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
79234651|NCT02303223|Drug|Propofol|
79234652|NCT03168620|Procedure|Restoration|
79375785|NCT03414450|Drug|dasatinib|dasatinib tablets at 140 mg will be dosed every day
79375786|NCT03414294|Drug|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
79375787|NCT03414294|Drug|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
80002379|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
80002380|NCT04952493|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
80002381|NCT04952493|Drug|Sodium Iodide I 131|RAI treatment may shrink the tumor
79305660|NCT04486469|Other|Physical Therapy Group|"Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~Connective Tissue Massage or Dicke~Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)"
80002382|NCT04952493|Drug|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
80002383|NCT01351597|Drug|docetaxel/ oxaliplatin|"docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
79375788|NCT03414294|Drug|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
80016706|NCT04426981|Behavioral|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
79234653|NCT03515889|Behavioral|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
79234654|NCT03515889|Behavioral|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
80016707|NCT03627481|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
79234655|NCT02395874|Procedure|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
79234656|NCT02299947|Drug|Haemocomplettan P|
79234657|NCT02299947|Drug|Placebo|
79375789|NCT03414294|Drug|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
79375790|NCT03414294|Drug|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
79375791|NCT03414294|Drug|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
79234658|NCT05692817|Device|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
79529465|NCT01410500|Drug|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
79375792|NCT03414294|Drug|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
79529466|NCT01410513|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
79529467|NCT01410539|Device|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
79375793|NCT03414294|Drug|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
79375794|NCT01389076|Drug|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
79529468|NCT01410539|Drug|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
79529469|NCT01410591|Device|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
80016708|NCT00151892|Drug|SPD476|2.4 g/day Once Daily (QD)
79234659|NCT03510585|Other|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
79234660|NCT03510585|Other|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
79685734|NCT02897999|Biological|QBKPN|QBKPN Site Specific Immunomodulators
79375795|NCT01389076|Drug|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
79375796|NCT02948478|Other|Exposed|Precarious patients
79375797|NCT02948478|Other|Non exposed|Non precarious patients
80002384|NCT04951245|Procedure|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
79529470|NCT01410591|Device|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
79529471|NCT01410617|Procedure|hemodialysis|3 sessions hemodialysis before CABG
79529472|NCT01410630|Diagnostic Test|FLT-PET/CT|Standard of Care
79529473|NCT01410630|Diagnostic Test|FDG-PET/CT|Standard of Care
79529474|NCT01410630|Drug|FLT|5 mCi IV
79529475|NCT01410643|Other|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
79685735|NCT02897999|Other|Placebo|Placebo
79685736|NCT01262365|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
79685737|NCT01262365|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
80016709|NCT00151892|Drug|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
79234661|NCT05364983|Device|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
79234662|NCT05364983|Device|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
79234663|NCT03168854|Biological|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
79375798|NCT02813226|Other|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
79375799|NCT03414216|Procedure|Group 1 early offloading surgery|As above.
79375800|NCT03414216|Procedure|Group 2 - off-loading in fiberglass cast|As above.
79375801|NCT03127800|Drug|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
79375802|NCT01389856|Drug|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
79375803|NCT01389856|Drug|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
79685738|NCT01262365|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
79685739|NCT03244176|Drug|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
79685740|NCT02898155|Other|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
79685741|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
79375804|NCT04448964|Drug|JNJ-70033093|JNJ-70033093 will be administered orally as per assigned treatment sequence.
79529476|NCT01410656|Behavioral|Telephone Implementation Intention|Telephone implementation intention counseling
79529477|NCT01410656|Behavioral|Self-completed implementation intention|Self-administered implementation intention intervention
79529478|NCT01410669|Behavioral|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
79685742|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
80002385|NCT04951245|Procedure|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
80002386|NCT01347749|Behavioral|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
80002387|NCT01347749|Behavioral|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
80002388|NCT02793128|Drug|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
80002389|NCT03612180|Drug|Metoprolol Succinate|Pharmacokinetics
80002390|NCT04400799|Drug|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
79234664|NCT03168854|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
79234665|NCT02300181|Dietary Supplement|Placebo|
79234666|NCT02300181|Dietary Supplement|Bacillus subtilis var natto DC-15|
79375805|NCT03423966|Device|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
79375806|NCT03418896|Drug|human chorionic gonadotropin|a single injection of a standard dose
79375807|NCT03414138|Behavioral|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen [four sessions; 20 min/session] will be used to teach patients to independently practice mindfulness meditation.
80002391|NCT01359241|Procedure|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
79375808|NCT03414138|Behavioral|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
79375809|NCT01323010|Drug|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
80002392|NCT01359241|Drug|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
79234667|NCT02699996|Other|Questionnaire Administration|Complete interview
79234668|NCT02699996|Behavioral|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
79375810|NCT01323010|Drug|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg)
79375811|NCT03127176|Other|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
79375812|NCT03423810|Drug|Hydralazine|Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
79375813|NCT01835015|Drug|CLG561|Administered by intravitreal injection, Day 1
79375814|NCT03414060|Device|Menstrual Cup|
79375815|NCT03413904|Procedure|transanal TME|transanal approach to TME in rectal cancer
79375816|NCT03413904|Procedure|laparoscopic TME|laparoscopic approach to TME in rectal cancer
79529479|NCT01410682|Other|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
79685743|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
79685744|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
79685745|NCT03971110|Drug|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
79234669|NCT03510429|Dietary Supplement|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
79234670|NCT03510429|Other|Routine post-op care|Routine post-operative care
79375817|NCT01390246|Drug|Bupropion SR|Bupropion SR 150 mg tablet
79375818|NCT01390246|Behavioral|Smoking Cessation Counseling|35-min counseling by trained research nurse
79234671|NCT02403362|Drug|EPO-018B|
79234672|NCT03513159|Behavioral|Pathfinder support|A pathfinder will support the patient with structured activities.
79234673|NCT03168698|Drug|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
79234674|NCT03168698|Drug|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
79234675|NCT02303301|Dietary Supplement|Probiotics|Cultures from the oropharynx
79375819|NCT01390246|Drug|Placebo|Matching Bupropion SR placebo tablet
79375820|NCT03418584|Device|HybridAPC|HybridAPC is a device which combines submucosal fluid injection with APC
79375821|NCT01390870|Drug|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
79529480|NCT01410682|Other|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
79234676|NCT02303301|Dietary Supplement|Placebo|Cultures from the oropharynx
79529481|NCT01410708|Drug|Dasatinib|
79828261|NCT05878665|Diagnostic Test|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
79234677|NCT02395406|Device|Orotracheal intubation with Totaltrack|
79234678|NCT02395406|Device|Orotracheal intubation with Airtraq|
79529482|NCT01410721|Behavioral|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
79529483|NCT01410721|Behavioral|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
79828262|NCT05871060|Dietary Supplement|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
80002393|NCT05250323|Other|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
80002394|NCT04697238|Device|Weight vest|A vest weighing up to a maximum of 15 kg.
79685746|NCT00549432|Device|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
80016710|NCT05093491|Diagnostic Test|Spirometry and ultrasonography in stroke group|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed
79234679|NCT02296905|Drug|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
79234680|NCT02296905|Drug|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
79234681|NCT04464447|Behavioral|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
79234682|NCT04464135|Other|acetic acid staining|The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
79529484|NCT01410734|Drug|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
79234683|NCT04464135|Other|Water exchange colonoscopy|The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
79529485|NCT01410747|Drug|Tacrolimus|oral
79529486|NCT01410760|Other|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
79234684|NCT02403440|Drug|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
79234685|NCT02395328|Behavioral|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
79234686|NCT03513003|Device|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
79234687|NCT03513003|Behavioral|Stop habit|Children stop the use of their pacifier and/or baby bottle
79234688|NCT03510351|Drug|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
79234689|NCT02400632|Device|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
79234690|NCT03512925|Other|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
79234691|NCT02395250|Biological|anti-GPC3 CAR T|
79529487|NCT01410786|Procedure|Conventional Instrumentation|Standard Oxford surgical instruments
79529488|NCT01410786|Procedure|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
79529489|NCT01410838|Other|Broth|200 mL of sodium chloride containing broth, consumed three times per day
79529490|NCT01410838|Other|Broth|200 mL of MSG containing broth consumed three times per day
79529491|NCT01410851|Other|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
79685747|NCT02897882|Other|Lung transplant|Pain evaluation
79685748|NCT03932812|Behavioral|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
79685749|NCT03456024|Other|Questinnaire|
79685750|NCT04322266|Drug|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
79685751|NCT04322266|Drug|HCP1306|Ezetimibe /Rosuvastatin
79685752|NCT04322266|Drug|HGP0904|Amlodipine
79685753|NCT04322266|Drug|HGP0608|Losartan potassium
79685754|NCT02897726|Drug|NVP-1402|Oral
79685755|NCT02897726|Drug|NVP-1402R|Oral
79685756|NCT03208959|Drug|HTI-1090|IDO/TDO inhibitor
80002395|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
80002396|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
80002397|NCT05383794|Other|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
80002398|NCT02068040|Dietary Supplement|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
80002399|NCT02068196|Procedure|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
80002400|NCT02068196|Drug|Ipilimumab|
80002401|NCT03612570|Device|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
80002402|NCT03142451|Drug|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
80002403|NCT03142451|Drug|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
80002404|NCT04065789|Drug|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
80002405|NCT04065789|Drug|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
79234692|NCT02296983|Biological|VSV-ZEBOV|VSV-ZEBOV
79529492|NCT01410864|Device|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
79828263|NCT05871060|Dietary Supplement|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
79234693|NCT02403284|Drug|Liraglutide|Subcutaneous injection by patient
79685757|NCT04322110|Other|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
79685758|NCT04322110|Other|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
79685759|NCT02897804|Behavioral|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
79375822|NCT03127254|Behavioral|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
79234694|NCT02403284|Drug|Sugar Pill|Subcutaneous injection daily
79234695|NCT02400866|Drug|Olanzapine|
79375823|NCT03127254|Behavioral|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
79375824|NCT03127254|Behavioral|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
79234696|NCT03132909|Other|Feelings Determination|Determine the feelings of doctors caring for their colleagues
79234697|NCT02400788|Drug|Resminostat|
79234698|NCT02400788|Drug|Sorafenib|
79529493|NCT01410864|Other|Control|Devices or drugs used to seal the dura (other than DuraSeal)
79234699|NCT02297061|Biological|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
79529494|NCT01410903|Device|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
79529495|NCT01410916|Drug|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
79529496|NCT01410929|Procedure|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
79685760|NCT02897804|Behavioral|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685761|NCT02897804|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
79828264|NCT05871060|Dietary Supplement|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
79828265|NCT05866354|Drug|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
79234700|NCT02403128|Drug|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
79234701|NCT02297217|Drug|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
79234702|NCT02297217|Radiation|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
79234703|NCT03512769|Device|Restful Jaw Device|The Restful Jaw device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. If needed, the dental assistant also holds the jaw in a slightly forward position to maintain an open airway. This device replicates the dental assistant in holding the jaw during dental procedures.
79234704|NCT03512691|Behavioral|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
79305661|NCT04486079|Dietary Supplement|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
79305662|NCT03238313|Behavioral|Plan A|
79305663|NCT03238313|Behavioral|Toxic Life Cycle of a Cigarette|Video
79529497|NCT01410955|Dietary Supplement|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
79529498|NCT01410955|Dietary Supplement|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
79529499|NCT01410968|Drug|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
79529500|NCT01411020|Procedure|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
79529501|NCT01411046|Diagnostic Test|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
79529502|NCT01411059|Behavioral|yoga|yoga classes 2 times per week for 32 weeks
79828266|NCT05865457|Device|BUFY02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
79828267|NCT05865457|Device|TRB02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
79529503|NCT01411072|Drug|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
79529504|NCT01411072|Drug|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
79529505|NCT01411098|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
79529506|NCT01411098|Radiation|intensity-modulated radiation therapy|Undergo IMRT
79529507|NCT01411098|Drug|cisplatin|Given IV
79828268|NCT05865379|Device|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
79529508|NCT01411098|Drug|etoposide|Given IV
79529509|NCT01411111|Drug|Rosuvastatin 10 mg|days 1-14
79529510|NCT01411111|Drug|GSK2190915 30mg|1x30mg tablet, days 8-14
79529511|NCT01411111|Drug|GSK2190915 100mg|1x100mg tablet, days 8-14
79529512|NCT01411124|Drug|gabapentin enacarbil|600 mg investigational compound
79529513|NCT01411124|Drug|diphenhydramine|50 mg active comparator
79529514|NCT01411124|Drug|placebo|placebo
79529515|NCT01411176|Drug|Menthol|20 mL NPO-11 in a prefilled plastic syringe
79529516|NCT01411176|Drug|Placebo|The placebo is included same additives as active comparator.
79529517|NCT01411189|Drug|Menthol|20 mL NPO-11 in prefilled syringe
79828269|NCT05865379|Device|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
79828270|NCT05863442|Drug|Soliris 300 MG in 30 ML Injection|Active Comparator
79828271|NCT05863442|Drug|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
79828272|NCT05858541|Behavioral|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
80002406|NCT04065789|Drug|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
79828273|NCT05858541|Behavioral|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
80002407|NCT04065789|Drug|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
80002408|NCT03611478|Dietary Supplement|Probiotic formulation|Probiotic capsule
80002409|NCT03611478|Dietary Supplement|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
79234705|NCT03512691|Behavioral|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
80002410|NCT02066558|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
80002411|NCT02066558|Other|Placebo|
80002412|NCT04933773|Other|Movement artifact - knocking|60 seconds motion artifact simulation - knocking with sensors
80002413|NCT04933773|Other|Movement artifact - tremor|60 seconds motion artifact simulation - tremor with sensors
80002414|NCT04933773|Other|Artifact - ambient light|60 seconds artifact simulation - ambient light using sensor opening
80002415|NCT04933773|Other|Artifact - low perfusion|60 seconds artifact simulation - reduced perfusion using a cuff
80002416|NCT04933773|Other|SpO2 measurement|Two SpO2 measuring devices are active simultaneously on one hand during measurement.
79234706|NCT02300337|Device|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
79234707|NCT02300415|Biological|blood sample|Dosage of presepsine
79234708|NCT03510039|Behavioral|Early device / Follow up|"Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call"
79234709|NCT03510039|Other|Usual care|"Group Before : usual care by nurses"
79234710|NCT03515577|Procedure|Computed Tomography|Undergo PET/CT
79234711|NCT03515577|Drug|Fluciclovine F18|Given fluciclovine F18
79234712|NCT03515577|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
79234713|NCT03515577|Other|Laboratory Biomarker Analysis|Correlative studies
79234714|NCT03515577|Procedure|Positron Emission Tomography|Undergo PET/CT
79234715|NCT02303379|Other|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
79234716|NCT02303379|Other|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
79529518|NCT01411202|Drug|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
79529519|NCT01411202|Other|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
79529520|NCT01411254|Drug|Betamethasone Microsphere (DE-102） Low Dose|
79529521|NCT01411254|Drug|Betamethasone Microsphere (DE-102） High Dose|
79529522|NCT01411254|Drug|Sham|
79529523|NCT01411280|Drug|methylphenidate|Ritalin 10mg, Ritalin 20mg
79685762|NCT02897804|Behavioral|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79529524|NCT01411293|Other|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
79529525|NCT01411293|Other|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
79685763|NCT02897804|Behavioral|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
79685764|NCT02897804|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
80002417|NCT01351831|Other|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
79529526|NCT01411306|Other|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
80002418|NCT01351831|Other|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
80002419|NCT03611634|Other|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
79828274|NCT05858112|Diagnostic Test|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
79828275|NCT05855746|Drug|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF < 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
80002420|NCT02064842|Drug|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
80002421|NCT02064842|Drug|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
80002422|NCT02064842|Drug|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
80002423|NCT02064842|Drug|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV [80 mg/mL strength]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
79529527|NCT01411306|Procedure|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
80002424|NCT04924881|Drug|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
80002425|NCT04924881|Other|Placebo granules|Placebo granules once daily for 8 weeks
79529528|NCT01411358|Biological|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
80002426|NCT01355809|Drug|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
80002427|NCT01355809|Drug|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
80002428|NCT01355809|Drug|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
80002429|NCT03612102|Behavioral|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
80002430|NCT04013139|Diagnostic Test|CPET|CPET
80002431|NCT03141905|Other|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
79234717|NCT02303379|Other|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
80002432|NCT03141905|Other|Usual Care|Standard clinical care
79234718|NCT03509961|Diagnostic Test|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
79234719|NCT03509961|Drug|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
79234720|NCT03515499|Behavioral|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
79234721|NCT03515499|Behavioral|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
79305664|NCT03238079|Biological|10% IGIV|300-900 mg/kg
79529529|NCT01411358|Biological|elderly aged over 60|one dose of 0.5mL AdimFlu-S
79685765|NCT02897804|Behavioral|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685766|NCT02897804|Behavioral|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
80002433|NCT05383638|Other|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
80002434|NCT04917315|Drug|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
80002435|NCT04917315|Drug|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
80002436|NCT03612024|Behavioral|questionnaire|a standardized questionnaire was sent to all participants
79529530|NCT01411371|Procedure|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
80002437|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
80002438|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
79685767|NCT02897804|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
80002439|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
80002440|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
80002441|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
80002442|NCT04887597|Drug|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
79234722|NCT03512613|Device|c-FLOW 3310-P|"c-FLOW 3310-P is a continuous, non-invasive monitor of cerebral deep tissue blood flow used to measure relative changes in blood flow.~The device monitors regional micro circulatory blood flow in tissues, by using sensors placed near the area of interest."
79234723|NCT03509805|Diagnostic Test|polysomnography|
79234724|NCT02297295|Other|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
79234725|NCT02303457|Procedure|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
79234726|NCT02303457|Procedure|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
79234727|NCT02300649|Drug|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
79234728|NCT02300649|Drug|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
79234729|NCT03512379|Device|TIANJI Robot|A robotic system for spinal surgery
79234730|NCT03512379|Device|Fluoroscopy|For fluoroscopy-based free hand surgery
79234731|NCT03512379|Device|Navigation|For navigation-assisted spinal surgery
79234732|NCT02297451|Procedure|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
79234733|NCT02303535|Procedure|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
79234734|NCT02303535|Procedure|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
79234735|NCT02303613|Other|Mapping|Mapping of current triage situation regarding 30 days mortality
79234736|NCT02739321|Device|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
79685768|NCT02897804|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685769|NCT02897804|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
80002443|NCT01347905|Other|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
79234737|NCT02449161|Drug|MPA|
79234738|NCT02449161|Drug|placebo|
79234739|NCT02303691|Behavioral|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
79685770|NCT02897804|Behavioral|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79234740|NCT02303691|Behavioral|Neutral Training|A control version of computerized attention training.
79529531|NCT01411371|Drug|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
79529532|NCT01411384|Procedure|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
79529533|NCT01411384|Device|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
80002444|NCT04192266|Drug|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
80002445|NCT04192266|Drug|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
80002446|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
80002447|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
79234741|NCT03515421|Device|Frazier 3 Verio|In vitro diagnostic device (IVDD)
79234742|NCT03515421|Device|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
79529534|NCT01411397|Other|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
79529535|NCT01411397|Other|mesh repair|mesh repair of strangulated hernia without resection
79685771|NCT02897804|Behavioral|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
79685772|NCT02897804|Behavioral|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685773|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
79828276|NCT05855746|Drug|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF < 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
80002448|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
79234743|NCT02297529|Drug|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
80002449|NCT05250245|Drug|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
79234744|NCT02303769|Drug|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
79234745|NCT02303769|Drug|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
79234746|NCT04464525|Drug|Omecamtiv mecarbil|Film-coated tablet administered orally.
79234747|NCT03509649|Procedure|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
79234748|NCT02303847|Drug|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
79234749|NCT03509493|Diagnostic Test|FibriCheck|Digital health application
79234750|NCT03512145|Device|VIPUN Balloon Catheter|Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
79234751|NCT02297607|Dietary Supplement|Tube Feeding|
79234752|NCT03509415|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
79305665|NCT05387681|Drug|Envafolimab|short course radiotherapy ：5*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
79828277|NCT05855447|Other|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
79529536|NCT01411410|Drug|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
79529537|NCT01411410|Drug|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
79685774|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
80002450|NCT05250245|Other|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
80002451|NCT01347983|Drug|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
80002452|NCT02068664|Behavioral|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
80002453|NCT01359475|Procedure|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
79234753|NCT02297685|Device|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
79529538|NCT01411423|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
79529539|NCT01411436|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
79685775|NCT02897804|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
79685776|NCT02897804|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685777|NCT02897804|Behavioral|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
79529540|NCT01411449|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
79685778|NCT02897804|Behavioral|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685779|NCT02897804|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
80002454|NCT03611400|Dietary Supplement|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
80002455|NCT03611400|Dietary Supplement|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
80002456|NCT05249933|Drug|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
80002457|NCT02064998|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
79305666|NCT03238157|Drug|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
79529541|NCT01411462|Device|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
79529542|NCT01411475|Other|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
79529543|NCT01411514|Drug|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
79529544|NCT01411514|Drug|Placebo|Placebo tablets. They will be administered during 25 days
79828278|NCT05855447|Other|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
79234754|NCT02297685|Device|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
79234755|NCT02297685|Device|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
79234756|NCT02297763|Drug|quetiapine|"patient body weight <50kg : quetiapine 12.5mg patient body weight >=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
79234757|NCT02297763|Drug|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
79828279|NCT05855447|Other|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
79234758|NCT03511989|Device|Bone borne distractor|Bone borne distraction device
79234759|NCT03511989|Device|Tooth borne distractor|Tooth borne distraction device
79828280|NCT05850884|Diagnostic Test|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
79828281|NCT05845307|Drug|Control Group|Given by PO
79828282|NCT05845307|Drug|TTI-101|Given by PO
79828283|NCT05845073|Dietary Supplement|Probiotic|Participants in this arm will receive a daily dose of 2x10^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
79234760|NCT03511989|Procedure|Segmental LF1 Osteotomy group 1|
79234761|NCT03511989|Procedure|Segmental LF1 Osteotomy group 2|
79234762|NCT03511989|Procedure|Segmental LF1 Osteotomy group 3|
79529545|NCT01411540|Dietary Supplement|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
79529546|NCT01411553|Other|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
79828284|NCT05845073|Dietary Supplement|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
79529547|NCT01411566|Behavioral|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
79828286|NCT05838170|Drug|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
79828287|NCT05838170|Other|Vehicle control gel|Aqueous gel
79828288|NCT05836064|Device|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
79828289|NCT05836064|Other|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
80002458|NCT02064998|Behavioral|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
80002459|NCT02064998|Behavioral|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
80002460|NCT02032602|Other|Deep Dry Needling|
80002461|NCT01359553|Other|Intra-articular ultrasound imaging of knee joint during arthroscopy|
80002462|NCT01359553|Other|Non-invasive ultrasound imaging of knee|
79529548|NCT01411566|Behavioral|regular treatment|regular treatment
79529549|NCT01411605|Behavioral|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
79529550|NCT01411618|Other|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
79529551|NCT01411631|Dietary Supplement|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
79529552|NCT01411657|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
79529553|NCT01411670|Drug|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
80002463|NCT01359553|Other|Quantitative MRI imaging of knee|
80002464|NCT01359553|Other|Contrast-enhanced CT imaging of knee|
80002465|NCT02068742|Other|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
80002466|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
80002467|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
80002468|NCT01348217|Radiation|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
79234763|NCT03511911|Diagnostic Test|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
79234764|NCT03511911|Diagnostic Test|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
79685780|NCT02897804|Behavioral|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79828290|NCT05830578|Device|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
79828291|NCT05830526|Other|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
80002469|NCT01348217|Radiation|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
79529554|NCT01411670|Drug|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
79685781|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
79685782|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685783|NCT02897804|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
79529555|NCT01411670|Drug|Placebo comparator|Standard treatment
79529556|NCT01411683|Device|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
80002470|NCT01348217|Radiation|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
80002471|NCT01348217|Drug|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
80002472|NCT02065076|Drug|Sodium polystyrene sulfonate|
79529557|NCT01411709|Drug|Vitano|two 200mg tablets per day for 14 days
79529558|NCT01411722|Device|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
79529559|NCT01411735|Drug|Enalapril|2.5mg titrated up to 10mg twice daily
79529560|NCT01411735|Drug|placebo|2.5mg titrated up to 10mg twice daily.
79529561|NCT01411748|Dietary Supplement|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
80002473|NCT02065076|Drug|Lactose with carob gum|
80002474|NCT02465593|Drug|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
80002475|NCT02465593|Drug|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
80002476|NCT02465593|Drug|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
79234765|NCT02303925|Device|NESTER COILS|
79234766|NCT02304003|Other|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
79234767|NCT02304003|Other|Standard Care|Standard follow up in primary care.
79375825|NCT03127254|Behavioral|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
79685784|NCT02897804|Behavioral|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685785|NCT02897804|Behavioral|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
79234768|NCT03511833|Drug|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----> 0.1 ml/kg
79685786|NCT02897804|Behavioral|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79828292|NCT05827952|Behavioral|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
79828293|NCT05827068|Biological|mRNA-1011.1|Sterile liquid for injection
79828294|NCT05827068|Biological|mRNA-1011.2|Sterile liquid for injection
79828295|NCT05827068|Biological|mRNA-1012.1|Sterile liquid for injection
80002477|NCT02465593|Procedure|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
80002478|NCT02465593|Radiation|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
80002479|NCT02068898|Drug|XS003|
79375826|NCT03127254|Behavioral|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
79375827|NCT03008668|Other|acupuncture|a stimulation of the body or auricular points
79375828|NCT03423732|Drug|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
79529562|NCT01411748|Drug|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
79529563|NCT01411761|Dietary Supplement|Reflor|5 million unit/day, first 15 day of life
79529564|NCT01411761|Other|serum physiologic|1 cc added to one feeding in a day
79529565|NCT01411787|Behavioral|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
79529566|NCT01411800|Drug|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
79529567|NCT01411800|Drug|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
79828296|NCT05827068|Biological|mRNA-1010|Sterile liquid for injection
79828297|NCT05827068|Biological|mRNA-1010.2|Sterile liquid for injection
79828298|NCT05827068|Biological|mRNA-1010.3|Sterile liquid for injection
79828299|NCT05825261|Other|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
80002480|NCT02068898|Drug|Tasigna|
80002481|NCT03611322|Drug|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
79234769|NCT03511833|Drug|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---> 0.02ml/kg
79234770|NCT03515343|Diagnostic Test|Screening colonoscopy according to resect-and-discard strategy|This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
79234771|NCT03509337|Diagnostic Test|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
79305667|NCT03237923|Device|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
79375829|NCT03423732|Drug|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
79375830|NCT04631952|Behavioral|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
79375831|NCT04631952|Behavioral|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
79529568|NCT01411826|Behavioral|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
79828300|NCT05825261|Other|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
80002482|NCT03611322|Drug|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
79685787|NCT02897804|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
79234772|NCT03511755|Device|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
79375832|NCT02231814|Dietary Supplement|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
79375833|NCT02231814|Other|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
79375834|NCT03413826|Behavioral|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
79375835|NCT03413748|Procedure|Elective Cesarean Section|lower segment cesarean section
79375836|NCT03413748|Other|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
79375837|NCT03418506|Behavioral|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
79375838|NCT01842581|Drug|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
79375839|NCT01842581|Drug|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
79375840|NCT04448028|Drug|Placebo|Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
79375841|NCT04448028|Drug|Esomeprazole 20mg|Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
79529569|NCT01411826|Behavioral|Information Only|Information from CDC website on colon cancer screening.
80002483|NCT03611322|Drug|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
79375842|NCT04447950|Procedure|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
79375843|NCT04447950|Procedure|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
79375844|NCT05169996|Other|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
79529570|NCT01411865|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
80002484|NCT03611322|Device|DV3372|DV3372 device will be used for administration of semaglutide
79234773|NCT02696798|Drug|Ixekizumab|Administered SC
79234774|NCT02696798|Drug|Placebo|Administered SC
79234775|NCT02304081|Drug|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
79375845|NCT05169996|Other|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
79828301|NCT05822557|Other|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
80002485|NCT03611322|Device|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
79529571|NCT01411865|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
80002486|NCT02424019|Drug|ILUVIEN 0.19 MG|
80002487|NCT01346423|Behavioral|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
79234776|NCT02304081|Drug|Placebo for Saxagliptin|
79234777|NCT03511677|Device|Insole|Customized insole
79234778|NCT03511677|Device|Placebo Insole|Placebo flat insole
79828302|NCT05822128|Other|Test of an alternative Epworth Sleepiness Scale ESS-ALT in French|Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
79375846|NCT05169996|Other|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
79375847|NCT05169996|Other|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
79375848|NCT05169996|Other|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
79828303|NCT05821933|Drug|RC108|RC108 plus Furmonertinib and/or Toripalimab
79828304|NCT05819853|Drug|Wegovy Injectable Product|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
79828305|NCT05819853|Drug|Metformin and Wegovy|Participants already on Metformin as part of their clinical care, and still having irregular periods will be enrolled in the Metformin and Semaglutide arm. Semaglutide will be added in addition to the Metformin they are currently taking. 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
79234779|NCT03515265|Other|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
79375849|NCT03418194|Procedure|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
79375850|NCT03418194|Procedure|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
79234780|NCT03515265|Other|Microhybrid resin composite restoration|a type of conventional resin composite
79234781|NCT02304237|Drug|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
79234782|NCT02304237|Drug|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
79234783|NCT03515187|Drug|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
79375851|NCT03413514|Drug|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0<n<8)
79375852|NCT03413514|Procedure|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
79375853|NCT03413514|Procedure|Surgery|Radical surgery with D2 lymph node dissection
79529572|NCT01411878|Behavioral|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
79685788|NCT02897804|Behavioral|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685789|NCT02897804|Behavioral|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
79828306|NCT05819541|Drug|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
79828307|NCT05819541|Drug|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
79828308|NCT05819541|Drug|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
79828309|NCT05819359|Drug|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
79828310|NCT05819359|Drug|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
79828311|NCT05819359|Drug|Placebo|Placebo, once daily, oral administration.
80016711|NCT05093491|Diagnostic Test|Spirometry and ultrasonography in healthy group|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
79234784|NCT03515187|Drug|0.1% sodium bromide solution|one to two drops in eye, twice per day
79234785|NCT03515187|Other|Meibomian gland massage|Physiotherapy
79234786|NCT03515187|Other|Placebo|Vehicle
79234787|NCT02301117|Drug|TAS-102|
80002488|NCT01346423|Behavioral|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
79234788|NCT02394938|Other|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
79234789|NCT02301195|Other|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
79234790|NCT02301195|Other|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
79685790|NCT02897804|Behavioral|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
79685791|NCT02889250|Device|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
79375854|NCT03413514|Drug|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0<n<8)
79375855|NCT03413514|Other|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
79375856|NCT01833533|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
79375857|NCT01833533|Drug|Ribavirin|Capsule
79375858|NCT01833533|Drug|Placebo for Ribavirin|Capsule
79375859|NCT03413436|Drug|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
79375860|NCT03413436|Drug|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
79375861|NCT01833455|Drug|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
79375862|NCT01833455|Drug|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
79685792|NCT02889094|Other|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
79685793|NCT02897687|Behavioral|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
79685794|NCT02897687|Behavioral|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
79685795|NCT01262287|Drug|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
79685796|NCT01262287|Drug|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
79685797|NCT01262092|Drug|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
79685798|NCT04322071|Other|Interview|Qualitative interviews only
79685799|NCT03455946|Behavioral|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
80002489|NCT03610776|Device|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
79685800|NCT03165279|Procedure|Zenith Alpha Abdominal stentgraft|
79685801|NCT04680962|Biological|MabionCD20 (candidate biosimilar to rituximab)|Intravenous infusion, 10 mg/ml concentrate, 500 ml
79685802|NCT04680962|Biological|MabThera®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
80002490|NCT03610776|Device|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
80002491|NCT01346579|Other|laboratory biomarker analysis|Correlative sciences
79234791|NCT02395094|Behavioral|Child Life|"Child Life preparation in surgical daycare can include:~role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~the use of books/storyboards that show pictures of operating room and daycare routines~teaching & rehearsing coping and relaxation skills such as deep breathing and guided imagery~age-appropriate explanation of what to expect throughout the day in SDCU"
79234792|NCT02304315|Biological|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
79234793|NCT02304315|Biological|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
79234794|NCT02400320|Drug|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
79375863|NCT03418116|Device|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
80002492|NCT03611088|Other|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
80002493|NCT02066870|Drug|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
79234795|NCT02400320|Drug|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
79234796|NCT02400320|Other|Saline|Saline
79375864|NCT03413358|Drug|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
79375865|NCT03413358|Drug|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
79375866|NCT01833143|Drug|Bortezomib|
79234797|NCT03511443|Diagnostic Test|hsRDT|Testing highly sensitive RDT detection for low parasitemia
79375867|NCT01833143|Drug|Acyclovir|
79234798|NCT03511365|Biological|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
79234799|NCT02297919|Behavioral|Effectiveness of Internet Based Obesity Control Programme|
79375868|NCT03127332|Other|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
79375869|NCT05169528|Other|Colorectal Cancer Prehabilitation Programme|Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
79375870|NCT01841567|Device|Mepilex border post. op|
79375871|NCT01841567|Device|Mepilex border post op|
79375872|NCT03413280|Drug|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
79529573|NCT01411878|Behavioral|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
79529574|NCT01411904|Device|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
79529575|NCT01411930|Drug|Intramuscular olanzapine, aripiprazole|"1st clamp: single intramuscular 10.0 mg dose of olanzapine~2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
79529576|NCT01411930|Drug|Intramuscular aripiprazole, olanzapine|"1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
79685803|NCT04680962|Biological|Rituxan®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
79234800|NCT02297997|Drug|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
79234801|NCT02297997|Drug|Placebo|Control group takes the placebo for the same period.
79234802|NCT03511287|Other|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
79305668|NCT04485845|Drug|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
79305669|NCT04485845|Drug|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
79375873|NCT03413280|Drug|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
79375874|NCT05169450|Drug|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
79375875|NCT05169450|Drug|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
79375876|NCT03411174|Radiation|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
79375877|NCT04448340|Diagnostic Test|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
79375878|NCT03417648|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
79375879|NCT03417648|Other|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
79375880|NCT03411018|Other|Mechanical ventilation exposure|
79685804|NCT01261975|Procedure|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
79685805|NCT01261975|Procedure|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
79305670|NCT04485845|Drug|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
79685806|NCT02897531|Procedure|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
79234803|NCT03509103|Other|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
79234804|NCT02301273|Other|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
79685807|NCT02897531|Procedure|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
79234805|NCT02301273|Other|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
79234806|NCT02395016|Drug|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
79375881|NCT01833065|Drug|Elobixibat 10 mg/day|Elobixibat 10 mg/day
79828312|NCT05817825|Behavioral|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
79375882|NCT01833065|Drug|Elobixibat 5 mg/day|Elobixibat 5 mg/day
79375883|NCT01833065|Drug|Placebo|Placebo
79529577|NCT01411956|Other|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
79375884|NCT03413124|Drug|MGL-3196 Tablet|MGL-3196 in Tablet form
79529578|NCT01411956|Other|Placebo video|The control group watched a 25-minute patient education video on depression.
79529579|NCT01411969|Drug|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
79685808|NCT00549471|Other|physiotherapy|CG children will undergo a program of intensive physiotherapy
79685809|NCT00549471|Other|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
79685810|NCT01261780|Device|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
79828313|NCT05817825|Behavioral|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
80002494|NCT02066870|Drug|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
79375885|NCT03413124|Drug|MGL-3196 Capsule|MGL-3196 in Capsule form
79685811|NCT01261780|Drug|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
79685812|NCT02897843|Device|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
79685813|NCT02897843|Device|sham tDCS|sham tDCS
79685814|NCT03088410|Drug|Zidovudine|neonatal 4 weeks prophylactic
79375886|NCT03410940|Device|CLS Brevius stem with Kinectiv technology|
79375887|NCT04860102|Procedure|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
79375888|NCT03413046|Diagnostic Test|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
79375889|NCT02520804|Drug|sterofundin|sterofundin for shock patients in the first 72 hours
79375890|NCT02520804|Drug|normal saline|Normal saline for shock patients in the first 72 hours
79685815|NCT03088410|Drug|Nevirapine|neonatal 4 weeks prophylactic
79685816|NCT02897765|Biological|NEO-PV-01|Personal cancer vaccine
79685817|NCT02897765|Biological|Nivolumab|monoclonal antibody against PD1
79685818|NCT02897765|Other|Adjuvant|immune adjuvant
79234807|NCT02395016|Drug|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
79234808|NCT02395016|Other|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
79529580|NCT01412008|Drug|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
79685819|NCT02897570|Dietary Supplement|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
79685820|NCT02897570|Dietary Supplement|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
79685821|NCT02897570|Dietary Supplement|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
80002495|NCT05030363|Drug|ALDH enzyme supplementation|ALDH enzyme (PICOZYMEQ™)
79234809|NCT02298075|Drug|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
79234810|NCT02298075|Drug|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
79234811|NCT03515109|Procedure|Altis tape|placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
79234812|NCT03515109|Procedure|TVTO|placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
79234813|NCT02403050|Device|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
79234814|NCT03508947|Drug|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
79234815|NCT03508947|Drug|Placebo|Sodium Chloride
79234816|NCT02394782|Device|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
79234817|NCT02394782|Device|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
79234818|NCT04480268|Drug|PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy|"The PAXG regimen includes:~nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity."
79234819|NCT03515031|Device|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
79234820|NCT03515031|Device|Venturi Mask Oxygenation|delivery of high flow oxygen
79234821|NCT03514953|Behavioral|Reduced Physical Activity|"Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns."
79234822|NCT02400398|Other|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
79234823|NCT02301351|Other|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
79234824|NCT02301351|Other|Text Warning Label|All packs provided will include standard text warning labels
79234825|NCT02400164|Device|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
79529581|NCT01412073|Drug|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
79529582|NCT01412073|Drug|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby & the placenta
79529583|NCT01412099|Behavioral|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
79529584|NCT01412099|Behavioral|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
79529585|NCT01412125|Other|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
79529586|NCT01412125|Other|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
79529587|NCT01412138|Other|genetic analysis|"To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~In vitro culture conditions for cell proliferation.~To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
79685822|NCT02897570|Dietary Supplement|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
80002496|NCT03635203|Device|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
79234826|NCT03510975|Drug|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
79375891|NCT03412968|Procedure|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
79685823|NCT02897570|Device|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
79685824|NCT02897570|Device|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
79234827|NCT03510975|Behavioral|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
79234828|NCT03510975|Behavioral|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
79685825|NCT04686162|Other|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
79234829|NCT02301507|Behavioral|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
79234830|NCT03169790|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79234831|NCT03169790|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
79234832|NCT03169790|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79375892|NCT03412968|Procedure|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
79375893|NCT02520882|Drug|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
79529588|NCT01412203|Behavioral|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
79529589|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
79375894|NCT02520882|Device|PET/CT|
79529590|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|
79529591|NCT01412242|Other|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
79529592|NCT01412294|Drug|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
79529593|NCT01412307|Drug|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
79529594|NCT01412307|Drug|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
79529595|NCT01412307|Other|Bio-specimen Retention|Samples with DNA and without DNA
79529596|NCT01412320|Other|Cocoa|dissolved in water twice daily
79529597|NCT01412320|Other|Cocoa|dissolved in water twice daily
79529598|NCT01412346|Other|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
79529599|NCT01412359|Drug|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
79529600|NCT01412385|Biological|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
79529601|NCT01412385|Biological|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
79529602|NCT01412385|Biological|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
79529603|NCT01412398|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
79529604|NCT01412411|Behavioral|Nutritionl Education|to assess the change in behaviour
79529605|NCT01412411|Dietary Supplement|Oral Iron Supplementation along with Nturition Eductaion|
79529606|NCT01412411|Dietary Supplement|Multiple micronutrient fortification plus Nutrition Education|
80002497|NCT03611244|Device|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
79234833|NCT03169790|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79234834|NCT03169790|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
80002498|NCT04034355|Drug|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
79234835|NCT03169790|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79234836|NCT03169790|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79529607|NCT01412437|Dietary Supplement|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
79234837|NCT03169790|Drug|Lovaza|Omega-3-acid ethyl esters
79375895|NCT01831817|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
79685826|NCT02897492|Other|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
79375896|NCT01831817|Drug|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
79375897|NCT01831817|Drug|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
79685827|NCT02897180|Biological|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
79685828|NCT02897180|Biological|Placebo|Capsules containin Placebo
79685829|NCT00549588|Other|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
79234838|NCT03169790|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79234839|NCT03169790|Drug|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
79234840|NCT03169790|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
79234841|NCT03169790|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
79375898|NCT01831817|Drug|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
79375899|NCT04839744|Drug|TG103 produced by the modified manufacturing process|Drug: TG103 (a modified manufacturing process), 15mg, SC
79529608|NCT01412437|Drug|sapropterin dihydrochloride|20 mg/kg for 4 months
79529609|NCT01412437|Drug|sapropterin dihydrochloride|
79529610|NCT01412450|Device|nitinol stent|implantation of one Protégé EverFlex stent
79529611|NCT01412463|Device|stent placement|"pre-dilation of the study lesion is mandatory~stent placement with 1 Protégé Everflex+ stent~only 1 stent is allowed within the study protocol~post-dilation may be performed but is not mandatory"
79529612|NCT01412489|Device|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
80002499|NCT04034355|Other|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
80002500|NCT05210699|Other|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
80002501|NCT05210699|Other|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
80002502|NCT05210699|Other|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
79234842|NCT03169790|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
79234843|NCT03169790|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
79234844|NCT02301585|Procedure|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
79375900|NCT04839744|Drug|TG103 produced by the original manufacturing process|Drug: TG103 (the original manufacturing process), 15mg, SC
79375901|NCT03397836|Other|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
79375902|NCT03397836|Other|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
79375903|NCT03397758|Device|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
79391091|NCT03117348|Other|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
79529613|NCT01412502|Other|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
79529614|NCT01412515|Drug|everolimus|everolimus per os 10mg per day
79529615|NCT01412528|Other|Allergen extracts|
79375904|NCT05169294|Other|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
79234845|NCT02301585|Procedure|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
79391092|NCT01702025|Drug|Placebo|Yellow corn meal in gel capsules
79234846|NCT02304393|Drug|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
79234847|NCT02304393|Drug|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
79234848|NCT02402972|Drug|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
79234849|NCT02402972|Drug|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
79234850|NCT04464369|Drug|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
79234851|NCT04464369|Drug|Placebo|placebo pills matching the look and weight of the itopride tablets
79234852|NCT02402816|Device|MultiPoint Pacing ON|MultiPoint Pacing ON
79234853|NCT02402816|Device|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
79234854|NCT02394470|Other|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
79234855|NCT02394470|Other|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
79391093|NCT01702025|Drug|Aminophylline|National Drug Code (NDC) 0143-1020-01
79234856|NCT02394470|Other|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
79391094|NCT01702025|Drug|Methazolamide|NDC 0781-1072-01
79529616|NCT01412567|Drug|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
79529617|NCT01412567|Drug|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
79529618|NCT01412580|Other|observational follow-up|observational follow-up
79529619|NCT01412593|Biological|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
79529620|NCT01412606|Procedure|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
80002503|NCT05210699|Other|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
79234857|NCT02394236|Other|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
79234858|NCT02304627|Drug|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
79234859|NCT02402738|Behavioral|Interpersonal and Social Rhythm Therapy|
79234860|NCT02402738|Behavioral|Enhanced Treatment as Usual|
79234861|NCT02301741|Behavioral|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
79234862|NCT02399930|Other|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
79391095|NCT01702025|Drug|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
79529621|NCT01412632|Drug|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
79529622|NCT01412645|Dietary Supplement|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
79685830|NCT00549588|Other|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
79685831|NCT00549588|Other|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
79685832|NCT00549588|Other|Intervention: none (only UV)|
79685833|NCT02897102|Behavioral|Training|Training program based on abacus and other activities
79685834|NCT02897102|Other|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
80002504|NCT05210699|Other|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
79529623|NCT01412658|Dietary Supplement|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
79828314|NCT05815264|Biological|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
80002505|NCT05210699|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
79234863|NCT03508791|Other|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
79234864|NCT03508791|Other|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
79234865|NCT03508791|Other|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
79234866|NCT02306421|Procedure|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
80002506|NCT02066948|Other|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
79234867|NCT02306421|Procedure|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
79375905|NCT05169294|Other|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
79375906|NCT02520648|Other|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
79375907|NCT02520648|Other|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
79529624|NCT01412658|Dietary Supplement|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
79685835|NCT01261624|Drug|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
79685836|NCT02888938|Other|pelvic radiography|
79529625|NCT01412671|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
79529626|NCT01412684|Procedure|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
79529627|NCT01412697|Behavioral|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
79529628|NCT01412723|Other|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
79529629|NCT01412723|Other|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
79685837|NCT02888938|Other|pelvic MRI|
79685838|NCT02888938|Other|pelvic CT-scan|
79685839|NCT04322032|Drug|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
79685840|NCT04322032|Drug|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
80002507|NCT02066948|Other|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
80002508|NCT02066948|Other|meal pattern|skew or even
80002509|NCT02066948|Dietary Supplement|even|even amount of protein distributed between each meal
80002510|NCT02066948|Dietary Supplement|skew|a skewed amount of protein is distributed between each meal
80002511|NCT01317745|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
80002512|NCT01317745|Drug|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
80002513|NCT01317745|Biological|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
80002514|NCT03610932|Dietary Supplement|Vitamin C|Taken as 3 500mg capsules.
80002515|NCT03610932|Other|Placebo|Taken as 3 500mg capsules.
80002516|NCT01355965|Biological|Autologous T cells|
80002517|NCT03610620|Procedure|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
79234868|NCT02306421|Procedure|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
79828315|NCT05815264|Biological|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp & Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
79828316|NCT05813834|Procedure|Genicular Nerves Block|US guided genicular nerves block
79234869|NCT02306421|Procedure|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
79234870|NCT02306421|Procedure|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
79234871|NCT02400008|Procedure|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
79375908|NCT02520648|Other|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
79685841|NCT03711331|Other|FilmArray® Pneumonia panel plus|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
79234872|NCT02394314|Drug|MEDI0382|MEDI0382 administered subcutaneously
79234873|NCT02394314|Drug|Placebo|Placebo administered subcutaneously
79234874|NCT03508713|Drug|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
79375909|NCT03410550|Device|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
79375910|NCT03412656|Device|SoftHand Pro with CUFF force feedback device|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
79375911|NCT03412500|Drug|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
79234875|NCT04481828|Procedure|gastrectomy|gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
79234876|NCT03510897|Drug|teprasiran|IV injection
79234877|NCT03510897|Drug|Placebo|isotonic saline
79375912|NCT03412500|Drug|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
79234878|NCT02394158|Drug|Metformin|
79234879|NCT02394158|Drug|placebo|
79375913|NCT01417780|Drug|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
79375914|NCT01417780|Drug|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
79375915|NCT01840943|Drug|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
79529630|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
79529631|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
79529632|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
79529633|NCT01412736|Drug|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
79685842|NCT03711331|Other|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
79685843|NCT02887053|Device|MRI|
79685844|NCT04321798|Behavioral|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
79685845|NCT05532982|Other|Interviews and Surveys|Qualitative interviews and surveys
79685846|NCT02897336|Procedure|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
79685847|NCT02897336|Procedure|interlaminar|interlaminar epidural corticosteroid injection
79685848|NCT04321642|Drug|Entonox|Entonox gas with mouth piece
79685849|NCT04321642|Drug|Not receive Entonox|Not receive any gas
79828317|NCT05812963|Diagnostic Test|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
80002518|NCT01346657|Drug|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
79529634|NCT01412775|Behavioral|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
79234880|NCT02698826|Other|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas [ABG] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value <100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
79828318|NCT05812963|Diagnostic Test|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis >90%, we will judge FFR value of ≤0.80.
79828319|NCT05808413|Behavioral|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
79828320|NCT05808413|Behavioral|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
79828321|NCT05808413|Behavioral|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
79828322|NCT05807841|Procedure|percutaneous coronary intervention|IVUS-guided stent implantation
80002519|NCT01359709|Drug|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
80002520|NCT02067026|Dietary Supplement|Aleurone|
79234881|NCT03508635|Drug|CORT125134|Oral capsules
79234882|NCT03508635|Drug|Matching Placebo of CORT125134|Placebo
79234883|NCT03508635|Drug|Mifepristone|Active comparator
79234884|NCT03508635|Drug|Prednisone|Challenge agent
79234885|NCT03508635|Drug|Glucose|
79234886|NCT02399852|Drug|Lomitapide|
79375916|NCT01840943|Drug|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
79375917|NCT03397524|Other|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
79529635|NCT01412788|Procedure|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
79529636|NCT01412788|Procedure|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
79685850|NCT04321681|Other|no intervention|no intervention
79685851|NCT02897219|Drug|ipragliflozin|Oral administration once daily
80002521|NCT02067026|Dietary Supplement|Placebo|
80002522|NCT04158336|Drug|ZN-c3|ZN-c3 is a study drug
80002523|NCT01346735|Other|No intervention|
79529637|NCT01412814|Device|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
79529638|NCT01412814|Other|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
79685852|NCT02897219|Drug|Placebo|Oral administration once daily
80002524|NCT03940365|Device|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
79685853|NCT02897219|Other|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
80002525|NCT01317823|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
80002526|NCT05539898|Device|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
80002527|NCT02826486|Drug|BL-8040|BL-8040 subcutaneous(SC) injections
80002528|NCT02826486|Drug|Pembrolizumab|pembrolizumab will be given as a 30-minute IV infusion
80002529|NCT02826486|Drug|Chemotherapy of Onivyde|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
79375918|NCT03127020|Drug|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
79391096|NCT03117426|Device|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
79391097|NCT03117426|Device|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
79685854|NCT04321603|Behavioral|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
79685855|NCT02882685|Procedure|Roux-en-y gastric bypass|
79685856|NCT02882685|Procedure|Single anastomosis gastric bypass|
79685857|NCT04321720|Other|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
79828323|NCT05803694|Device|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
79685858|NCT04321720|Other|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
79685859|NCT04321720|Other|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
79685860|NCT04321720|Other|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
79375919|NCT03412422|Diagnostic Test|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
79828324|NCT05792475|Diagnostic Test|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
79375920|NCT01840163|Other|Static version of CanSORT tool|
79375921|NCT01840163|Other|CanSORT Online Tool|
79375922|NCT05171400|Procedure|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
79375923|NCT05171400|Device|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
79529639|NCT01412827|Radiation|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
80002530|NCT01359787|Drug|Mapracorat|Daily topical application
80002531|NCT01359787|Drug|Vehicle without active|Daily topical application
80002532|NCT02067260|Device|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
80002533|NCT02067260|Device|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
80002534|NCT02825940|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
80002535|NCT02825940|Drug|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m^2 on Days 1 and 8.
80002536|NCT02825940|Drug|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m^2 on Day 1.
80002537|NCT02065232|Drug|Tilmanocept|
80002538|NCT02065232|Drug|Sulfur Colloid|
80002539|NCT02304991|Drug|Liquid Peanut Extract|5000mcg/ml peanut protein
80002540|NCT02304991|Drug|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
80002541|NCT04870281|Device|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
80002542|NCT01348295|Other|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
80002543|NCT02069132|Drug|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
80002544|NCT03715985|Drug|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
79375924|NCT05171400|Device|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
79375925|NCT02203630|Drug|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
79685861|NCT04321837|Dietary Supplement|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
79685862|NCT04321837|Drug|Ibandronate|Bisphosphonate
79685863|NCT04321837|Dietary Supplement|Vitamin D3|Oral vitamin D3
79685864|NCT02897414|Other|Surveillance of state medical examiner databases|
80002545|NCT04852029|Other|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
80002546|NCT01352065|Drug|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
80002547|NCT01352065|Drug|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
80002548|NCT01352065|Drug|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
80002549|NCT02065310|Other|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 & 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
79685865|NCT02858934|Radiation|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
79685866|NCT02897453|Device|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
79685867|NCT00549627|Device|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
79685868|NCT02896829|Behavioral|Interruption of the treatment by Imatinib|
79828325|NCT05788458|Drug|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
79828326|NCT05788237|Biological|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
79828327|NCT05788237|Biological|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
79828328|NCT05788237|Biological|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
79828329|NCT05788237|Drug|Placebo|0.9% saline for injection
80002550|NCT03610854|Device|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
79685869|NCT02854566|Device|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
80002551|NCT01356043|Drug|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
80002552|NCT01356043|Drug|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
80002553|NCT02065388|Behavioral|Standard of care dosing for warfarin|
80002554|NCT02065388|Genetic|Genotype-guided dosingTaiwan algorithm for warfarin|
79375926|NCT02203630|Drug|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
79375927|NCT05169138|Other|Aromatherapy application /massage with lavender oil|The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.
79375928|NCT05169138|Other|Aromatherapy application / inhalation with lavender oil|The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
79375929|NCT03397446|Drug|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
79375930|NCT04447482|Device|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
79375931|NCT04447482|Procedure|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
79685870|NCT00549666|Drug|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
79685871|NCT00549666|Drug|Placebo 40 mg|Placebo 40 mg once daily during treatment period
79828330|NCT05788237|Biological|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
79828331|NCT05788237|Biological|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
80002555|NCT02065388|Genetic|Genotype-guided dosing IWPC algorithm for warfarin|
79375932|NCT02196922|Device|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
79685872|NCT00549666|Drug|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
79685873|NCT04680806|Device|Er,Cr:YSGG laser 2780 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
79685874|NCT04680806|Device|Diode laser 940 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
79828332|NCT05779761|Behavioral|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
79234887|NCT02399774|Device|Leboride|"Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control~Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
79685875|NCT04680767|Drug|LY3502970|Administered orally.
79234888|NCT04481282|Drug|Terbutaline|2.5mg po tid for 12 weeks
79234889|NCT04481282|Drug|Danazol|200mg po bid for 12 weeks
79234890|NCT02541604|Drug|Atezolizumab|Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
79234891|NCT02302053|Dietary Supplement|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
79234892|NCT02302053|Dietary Supplement|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
79234893|NCT02399540|Device|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
79234894|NCT02399540|Device|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
79234895|NCT02399540|Device|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
79375933|NCT02196922|Other|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
79685876|NCT04680767|Drug|[¹⁴C]-LY3502970|Administered orally.
79685877|NCT00551538|Drug|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
79685878|NCT00551538|Drug|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
79685879|NCT04680494|Other|moderate intensity physical exercise|
79685880|NCT04680494|Other|high intensity physical exercise|
79685881|NCT04680494|Other|rest|
79234896|NCT02399540|Device|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
79234897|NCT02304861|Procedure|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
79375934|NCT03127098|Biological|ETBX-011|ETBX-011 immunization will be administered by subcutaneous (SC) injection.
79375935|NCT03127098|Biological|ALT-803|ALT-803 will be administered by SC injection.
79375936|NCT03410472|Behavioral|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
79685885|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
79685886|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
79375937|NCT03397368|Diagnostic Test|Transperineal Ultrasound -|Every women with stress incontinence witll be subjected to urodynamics to confirm genuine stress incontinence then will be subjected Transperineal US
79685887|NCT04931901|Device|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
79828333|NCT05779761|Behavioral|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
79828334|NCT05779761|Behavioral|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
79828335|NCT05778279|Diagnostic Test|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
79375938|NCT04681794|Other|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
79375939|NCT04667442|Diagnostic Test|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
79529640|NCT01412840|Other|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
79828336|NCT05777720|Device|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
79828337|NCT05777720|Behavioral|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
80002556|NCT04835415|Procedure|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
79234898|NCT02304861|Procedure|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
79234899|NCT02302131|Other|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
79685888|NCT04207645|Diagnostic Test|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
79529641|NCT01412840|Other|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
79685889|NCT05512585|Other|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
79685890|NCT02896790|Other|Interviews with 2 oncologists and 10 patients|
79685891|NCT02896790|Other|Interviews with 15 patients|
79529642|NCT01412853|Other|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
79234900|NCT02393846|Drug|Ketoprofen gel|Topical ketoprofen as used in gel form.
79234901|NCT02393846|Drug|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
79234902|NCT02302209|Drug|Oxytocin|
79234903|NCT02302209|Other|Placebo Comparator|
79375940|NCT03410316|Other|No intervention|
79375941|NCT03397290|Device|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
79391098|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
79391099|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
79391100|NCT01592747|Drug|Placebo capsules|Once daily, oral administration.
79529643|NCT01412892|Drug|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
79828338|NCT05777720|Behavioral|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
79828339|NCT05775341|Other|No Intervention|This is purely an observational study.
79828340|NCT05771922|Diagnostic Test|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
79828341|NCT05768620|Other|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
79828342|NCT05768620|Other|TAU|This is the usual care used to train visuospatial processes
79234904|NCT02302287|Dietary Supplement|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
79828343|NCT05764616|Procedure|PARASTERNAL BLOCK|After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.
79828344|NCT05764616|Procedure|LOCAL INFILTRATION OF DRAINAGE EXIT SITES|At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side
79828345|NCT05764616|Procedure|RECTUS SHEATH BLOCK|At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
79828346|NCT05764343|Other|Immediate smoking cessation support|Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
79828347|NCT05756569|Procedure|Biospecimen Collection|Undergo collection of blood
79828348|NCT05756569|Procedure|Computed Tomography|Undergo CT
79828349|NCT05756569|Drug|Enfortumab Vedotin|Given IV
79828350|NCT05756569|Procedure|Magnetic Resonance Imaging|Undergo MRI
79828351|NCT05756569|Biological|Pembrolizumab|Given IV
79828352|NCT05756569|Other|Questionnaire Administration|Ancillary studies
79828353|NCT05753215|Drug|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
80002557|NCT04835415|Procedure|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
79375942|NCT03410238|Behavioral|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
79391101|NCT03106974|Device|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
79828354|NCT05753215|Drug|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
79234905|NCT02302287|Other|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
79234906|NCT02302287|Other|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
79391102|NCT03106974|Device|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
79529644|NCT01412996|Procedure|surgery|single ACCESS laparoscopic cholecystectomy
79529645|NCT01412996|Other|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
79529646|NCT01413022|Drug|Oxaliplatin|
79529647|NCT01413022|Drug|Irinotecan|
79529648|NCT01413022|Drug|Leucovorin|
79828355|NCT05750342|Dietary Supplement|Experimental Product Caqui|Supplement extracted from persimmon
79529649|NCT01413022|Drug|Fluorouracil|
79828356|NCT05750342|Dietary Supplement|Control product placebo|Product with identical characteristics to the experimental product.
79828357|NCT05749055|Drug|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
79828358|NCT05749055|Drug|Placebo|Placebo
79828359|NCT05748028|Other|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
79828360|NCT05748028|Other|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
79828361|NCT05739435|Drug|ESK-001|Oral tablet
80002558|NCT01317563|Dietary Supplement|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
80002559|NCT01317563|Dietary Supplement|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
79828364|NCT05734287|Diagnostic Test|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
79529650|NCT01413022|Other|laboratory biomarker analysis|Correlative studies
79529651|NCT01413022|Other|flow cytometry|Correlative studies
79529652|NCT01413022|Other|immunohistochemistry staining method|Correlative studies
80002560|NCT01359865|Procedure|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at <0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
80002561|NCT02067338|Drug|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
79234907|NCT04481360|Device|CT of the chest|Degree of affection on the lung infected by COVID19
79529653|NCT01413022|Other|pharmacological study|Correlative studies
79234908|NCT02399618|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
79234909|NCT02306499|Procedure|ICSI|Intracytoplasmic Sperm Injection
79234910|NCT02394002|Drug|Propofol|
79234911|NCT02306577|Drug|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
79234912|NCT05454982|Device|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
79234913|NCT02402348|Drug|Metformin|
79234914|NCT02304939|Procedure|changeover|
79234915|NCT02304939|Device|use of automatic infusion pump|
79234916|NCT02304939|Behavioral|datas collection|
79234917|NCT04423666|Behavioral|Walking using a wireless pedometer|See arm/group
79234918|NCT02399696|Behavioral|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
79234919|NCT02399696|Behavioral|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
79375943|NCT04656522|Behavioral|Participatory Comic Intervention|This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
79375944|NCT03397212|Other|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
79375945|NCT03397212|Other|Sham acupuncture|Ear acupuncture using inactive sham points
79375946|NCT01417936|Drug|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
79529654|NCT01413022|Drug|PF-04136309|
79529655|NCT01413035|Biological|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
79529656|NCT01413048|Drug|Carvedilol 25mg|Tablet, q.d.
79529657|NCT01413048|Drug|AGSCT101 12.5mg|Tablet, q.d.
79529658|NCT01413061|Procedure|Subtalar Arthrodesis|
79529659|NCT01413074|Other|Peritoneal Dialysis treatment|PD treatment
79529660|NCT01413074|Other|Hemodialysis treatment|HD treatment
79529661|NCT01413113|Drug|pazopanib hydrochloride|Given PO
79529662|NCT01413113|Radiation|iodine I 131|Given IM
79685892|NCT04207528|Behavioral|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
79685893|NCT04319848|Other|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
79685894|NCT02897024|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
79828365|NCT05732883|Drug|Dexamethasone|Dexamethasone injection
79828366|NCT05732883|Drug|Normal saline|Placebo
79529663|NCT01413126|Dietary Supplement|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
79529664|NCT01413139|Device|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
79828367|NCT05729958|Diagnostic Test|CT scan|CT scan of the involved ankle
80002562|NCT02067338|Drug|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
79234920|NCT02399462|Drug|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly* Weeks 27 through 28~*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
79685895|NCT04207489|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
79234921|NCT03505047|Device|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
79234922|NCT02402114|Drug|Hydrocortisone|120 mg Hydrocortisone given orally one time.
79685896|NCT04320160|Procedure|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
79234923|NCT02311413|Drug|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
79375947|NCT05171010|Other|no study-based therapeutic interventions|no study-based therapeutic interventions
79234924|NCT02311413|Drug|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
79375948|NCT05170932|Procedure|CHX gel 2 % + 24% EDTA|The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
79375949|NCT01418482|Device|Mepilex Border Ag|a silver dressing
79685897|NCT04320160|Procedure|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
79828368|NCT05727735|Device|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
79828369|NCT05727735|Drug|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
79828370|NCT05727189|Drug|TR-01-XRR (1)|Extended-release form
80002563|NCT01336764|Behavioral|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
80002564|NCT01336764|Behavioral|Control|Unguided listening to radio/music.
79234925|NCT02311491|Device|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
79234926|NCT05745896|Other|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
79234927|NCT05745896|Other|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
79375950|NCT05168358|Procedure|Overnight Bladder Drainage|Parents or caregivers of the patients will be taught to place an indwelling catheter in the bladder at bedtime for about 8-12 h under a clean technique every night for one year. The catheter will then be allowed to drain freely into a gravity drainage collecting bag or in the diapers. On the next morning, the catheter will be removed and the timed voiding regimen will be resumed.
79529665|NCT01413152|Biological|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
79529666|NCT01413230|Drug|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
79828371|NCT05727189|Drug|TR-01-XRR (2)|Extended-release form
79828372|NCT05727189|Drug|TR-01-XRR (3)|Extended-release form
79828373|NCT05727189|Drug|TR-01-XRS|Extended-release form
79828374|NCT05727189|Drug|TR-01-XR|Extended-release form
79828375|NCT05727189|Drug|TR-01-IR|Active comparator
80002565|NCT04801173|Combination Product|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
80002566|NCT04801173|Behavioral|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
80002567|NCT01348451|Device|surgical implantation|human spinal cord stem cell implantation in ALS patients
80002568|NCT03423290|Device|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
80002569|NCT01352143|Drug|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
79234928|NCT02394080|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
79529667|NCT01413243|Drug|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
79828376|NCT05727189|Drug|Placebo|Placebo comparator
80002570|NCT01352143|Drug|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
80002571|NCT02260310|Other|Weizhong and Huantiao|
80002572|NCT02260310|Other|A-shi point|
79234929|NCT02546674|Drug|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
79529668|NCT01413269|Radiation|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
80002573|NCT05188651|Behavioral|face masks|wearing face masks
80002574|NCT01352299|Device|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
79529669|NCT01413282|Radiation|Cardiac CT|Calcium scan and CT coronary angiography
79828377|NCT05725226|Device|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
80002575|NCT01352299|Device|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
80002576|NCT01352299|Device|Miller|Laryngoscopy performed with Miller Laryngoscope
80002577|NCT01352299|Device|TrueView|Laryngoscopy performed with TrueView laryngoscope
80002578|NCT01348529|Behavioral|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
80002579|NCT02069210|Other|Blood transfusion|Intraoperative blood transfusion
79234930|NCT02305251|Other|Survey|Standard Gamble Survey
79234931|NCT02393534|Other|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
79234932|NCT04463355|Behavioral|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
79234933|NCT02399150|Other|No intervention as observational study|
79234934|NCT02305407|Procedure|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
79234935|NCT02305407|Other|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
79234936|NCT03507543|Drug|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
79234937|NCT04487782|Other|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
79234938|NCT03167684|Device|Oral appliance therapy|Fitted oral appliance
79234939|NCT05454904|Behavioral|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) <3 teaspoons/day of olive or Canola oil and <3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
79375951|NCT03410160|Diagnostic Test|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
79375952|NCT01393132|Drug|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
79375953|NCT01393132|Drug|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
79375954|NCT03412110|Other|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
79375955|NCT05170620|Procedure|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
79375956|NCT01324882|Device|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
79529670|NCT01413295|Drug|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
79529671|NCT01413295|Other|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
79529672|NCT01413347|Procedure|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
79529673|NCT01413347|Procedure|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
79828378|NCT05725226|Device|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
79828379|NCT05710055|Dietary Supplement|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
79828380|NCT05710055|Dietary Supplement|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
80002580|NCT05188573|Device|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
80002581|NCT05188573|Device|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
80002582|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg lorlatinib
79234940|NCT05454904|Behavioral|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or >3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) >2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) <1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and <4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
79529674|NCT01413373|Radiation|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
79234941|NCT05454904|Behavioral|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
79529675|NCT01413373|Radiation|computer tomography|One cone beam computer tomography examination before surgery
79529676|NCT01413386|Device|biliary stent|palliative treatment for malignant patients
79529677|NCT01413412|Procedure|Ventral hernia repair using full thickness skin graft|25 patients
79529678|NCT01413412|Procedure|Ventral hernia repair using mesh|25 patients
79685898|NCT03678493|Biological|Fecal Microbiota Transplant (FMT)|Oral Capsule
80002583|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
80002584|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg QD lorlatinib
79685899|NCT03678493|Other|Placebo|Oral Capsule
80002585|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
80002586|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
80002587|NCT01347125|Device|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
79234942|NCT02305485|Device|NeoVas BCS|Subjects receiving NeoVas BCS
79234943|NCT02305485|Device|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
79234944|NCT02399072|Other|No intervention|No intervention administered in this study
79234945|NCT04480762|Drug|SHR-1703|SHR-1703
79234946|NCT04480762|Drug|Placebo|Placebo of the SHR-1703
79234947|NCT02311569|Drug|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
79234948|NCT02399306|Drug|Enteral nutrition|Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
79375957|NCT01324882|Device|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
79375958|NCT03397056|Other|Questionnaire|The Questionnaire is provided in the links at the end of the declaration.
79375959|NCT02520570|Drug|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
79375960|NCT03396978|Other|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
79375961|NCT04632966|Biological|Biological: PTP-001|allogeneic placental tissue particulate
79375962|NCT03396900|Drug|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
79375963|NCT03396900|Other|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
79685900|NCT02896946|Radiation|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
80002588|NCT05188495|Drug|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
80002589|NCT02069288|Drug|Fludrocortisone|50 µg of fludrocortisone per os
80002590|NCT02069288|Drug|Placebo|1 tablet of placebo per os
79375964|NCT03412032|Other|assessment|different assessments in both arms
79375965|NCT03410082|Device|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
79529679|NCT01413438|Procedure|Craniotomy|
79529680|NCT01413451|Drug|Amatuximab (MORab-009)|
79685901|NCT04321447|Other|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
79828381|NCT05710055|Dietary Supplement|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
79828382|NCT05710055|Dietary Supplement|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
79828383|NCT05709873|Behavioral|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
79828384|NCT05709873|Behavioral|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
79685902|NCT00624169|Procedure|An optimized perioperative course|A number of interventions before, during and after surgery
79828385|NCT05709288|Drug|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
79828386|NCT05704036|Drug|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
79375966|NCT03410082|Diagnostic Test|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
79828387|NCT05704036|Drug|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
79828388|NCT05703048|Drug|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
79828389|NCT05703048|Drug|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
79828390|NCT05700721|Drug|Niraparib|Given by PO
79375967|NCT03411876|Device|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
79685903|NCT03627130|Drug|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
79828391|NCT05700721|Drug|Dostarlimab|Given by IV (vein)
79828392|NCT05697848|Other|Physiotherapy combined with Pain Education|Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
79828393|NCT05697848|Other|Physiotherapy|Patients with chronic low back pain receive manual therapy treatment
79828394|NCT05697601|Diagnostic Test|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
79828395|NCT05697601|Diagnostic Test|Pathology analysis|Pathology assessment of cells and tissues from respective organs
79375968|NCT03411876|Device|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
79375969|NCT03410004|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
79375970|NCT03396744|Device|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
79375971|NCT03411798|Drug|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
79685904|NCT03627130|Drug|Potassium Chloride|Potassium Chloride capsules for 5 days
79828396|NCT05696938|Dietary Supplement|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
79828397|NCT05696938|Dietary Supplement|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
79828398|NCT05690464|Dietary Supplement|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
79828399|NCT05690464|Dietary Supplement|placebo|placebo
79828400|NCT05690243|Behavioral|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
79828401|NCT05689307|Device|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
79828402|NCT05683171|Drug|Rituximab|Given by IV (vein)
79828403|NCT05683171|Drug|Lenalidomide|Given by PO
79375972|NCT03409536|Device|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
79375973|NCT03408756|Drug|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
79685905|NCT02896868|Drug|LY3041658|Administered IV.
79685906|NCT02896868|Drug|Placebo|Administered IV.
79685907|NCT04321096|Drug|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
79685908|NCT04321096|Drug|Placebo oral tablet|Placebo
79685909|NCT00549861|Procedure|Cardiac Magnetic Resonance study|Cardiac MRI study
79685910|NCT04321018|Dietary Supplement|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
79685911|NCT04321018|Dietary Supplement|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
79234949|NCT02399306|Radiation|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
79828404|NCT05683171|Drug|Valemetostat|Given by PO
79375974|NCT03406806|Other|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
79234950|NCT02393456|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
79828406|NCT05675579|Drug|Sacituzumab Govitecan|Given by IV (vein)
79828407|NCT05675579|Drug|Pembrolizumab|Given by IV (vein)
79828408|NCT05656040|Biological|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
79828409|NCT05656040|Drug|Placebo|Normal saline administered subcutaneously
79828410|NCT05651282|Drug|Provera|Progesterone Challenge Test
79828411|NCT05650008|Drug|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
79828412|NCT05646719|Drug|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
80002591|NCT01356121|Drug|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
79234951|NCT02393456|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
79375975|NCT03406806|Other|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
79375976|NCT03406806|Other|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
79375977|NCT03411720|Other|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
79685912|NCT04320784|Other|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
79685913|NCT04320784|Other|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
80002592|NCT01356121|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
80002593|NCT05725161|Behavioral|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
80002594|NCT05725161|Behavioral|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
79685914|NCT03556696|Device|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
79685915|NCT03556696|Device|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
79685916|NCT03556696|Drug|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the [50-70] range.
79234952|NCT02393612|Drug|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
79234953|NCT02393612|Drug|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
79685917|NCT03556696|Drug|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in [40-60] range
79828413|NCT05646719|Other|Placebo|Vehicle for Phentolamine Ophthalmic Solution
79828414|NCT05646719|Drug|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
79828415|NCT05646719|Other|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
80002595|NCT01336608|Drug|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
80002596|NCT01336608|Drug|Vilanterol|Inhaled long acting beta-agonist
79685918|NCT03556696|Device|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target"
79234954|NCT02311803|Procedure|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
79234955|NCT02311803|Procedure|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
79685919|NCT04320706|Drug|Oral Oxytocin|Administration of oxytocin (24 international units) orally
79685920|NCT04320706|Drug|Oral Placebo|Administration of placebo orally
79828416|NCT05644522|Device|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
79375978|NCT03411564|Other|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
79685921|NCT03523819|Drug|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
79828417|NCT05641922|Device|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
79234956|NCT02546362|Device|Cefaly|
79828418|NCT05632809|Drug|NKTR-255|Given by IV (vein)
79234957|NCT03167840|Behavioral|Physical and Cognitive Training|Physical Exercise and Cognitive Training
79234958|NCT03167840|Behavioral|Physical Training|Physical training alone
79375979|NCT01394614|Biological|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
79375980|NCT04588818|Drug|Adalimumab plus Methotrexate|"Adalimumab 40 mg (≥30kg weight) or 20mg (<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) ."
79529681|NCT01413477|Drug|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
79828419|NCT05632809|Drug|Durvalumab|Given by IV (vein)
79234959|NCT03167840|Behavioral|Cognitive training|Cognitive training alone
79234960|NCT03504891|Diagnostic Test|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
79234961|NCT03504891|Diagnostic Test|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
79234962|NCT02306733|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
79234963|NCT02306733|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
79234964|NCT05454436|Procedure|sinus tract healing in single or multi visit with single cone technique with bioceramic sealer|Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
79529682|NCT01413490|Drug|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
79529683|NCT01413555|Other|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
79529684|NCT01413568|Drug|POL6326|
79529685|NCT01413568|Procedure|Leukapheresis|
79529686|NCT01413568|Procedure|PBSC Transplant|
79685922|NCT03523819|Drug|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
79685923|NCT04207567|Behavioral|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
79685924|NCT02896673|Procedure|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
79685925|NCT02888704|Drug|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
79234965|NCT02698436|Device|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
79234966|NCT02698436|Drug|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
79685926|NCT03512158|Other|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
79234967|NCT03507465|Drug|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
79375981|NCT03406494|Other|Early multicomponent physical therapy program|"Positioning (upright bed standing; turning, moving on bed).~Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~Respiratory muscle training (supine abdominal breathing training).~Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage)."
79375982|NCT01394692|Procedure|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
79375983|NCT01394692|Procedure|standard microsurgery|microsurgical tumor resection
79375984|NCT01422226|Drug|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
79375985|NCT01422226|Other|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
79375986|NCT01423162|Other|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
79375987|NCT01423162|Other|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
79529687|NCT01413581|Drug|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
79529688|NCT01413581|Drug|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
79685927|NCT02896439|Device|Neurophysiological MONITORING|"The neurophysiology team perform:~Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~Establishment of a spacer or forceps in the greater or lesser sciatic notch~Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~At the end of the incision~On the establishment of a spacer or forceps in the greater or lesser sciatic notch~When towing layout~At the end of the intervention"
79685928|NCT02896478|Other|No intervention. Only observational study|
79685929|NCT02896322|Radiation|Partial breast irradiation with cyberknife|
79375988|NCT05170542|Drug|Camrelizumab+S-1|Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
79375989|NCT01328782|Drug|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
79529689|NCT01413594|Behavioral|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
79529690|NCT01413607|Device|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
79529691|NCT01413607|Device|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
79529692|NCT01413620|Drug|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
79529693|NCT01413633|Procedure|cholecystectomy|single incision laparoscopic cholecystectomy
79529694|NCT01413646|Dietary Supplement|Walnut Supplementation|Eight weeks of walnut supplementation
79529695|NCT01413646|Dietary Supplement|No walnut supplementation|Eight weeks without walnut supplementation
79529696|NCT01413659|Biological|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
79685930|NCT02896166|Other|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
79685931|NCT00553709|Drug|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
79685932|NCT02896244|Other|no intervention|
79828420|NCT05629754|Diagnostic Test|MRI, radiological assessment|MRI and radiological assessment of the involved knee
79828421|NCT05621460|Other|500mL carbonated water|Drink 500mL carbonated water immediately prior to head-up tilt test
79828422|NCT05621460|Other|500mL still water|Drink 500mL still water immediately prior to head-up tilt test
80002597|NCT01336608|Drug|Placebo|Placebo
79234968|NCT03507465|Drug|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
79234969|NCT05476042|Drug|Prescription of placebo|Normal saline
79234970|NCT05476042|Drug|Erythropoietin prescription|Erythropoietin 3000 units in normal saline
79234971|NCT05476042|Drug|Erythropoietin prescription|Erythropoietin 6000 units in normal saline
79234972|NCT03507387|Drug|Phenylephrine|5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
79234973|NCT03507387|Drug|Normal saline|1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
79234974|NCT03507387|Drug|Bupivacaine|All patients will receive spinal anesthesia with bupivacaine.
79828423|NCT05621460|Other|50mL still water|Drink 50mL still water immediately prior to head-up tilt test
79828424|NCT05621252|Drug|PLN-74809|160 mg PLN-74809
79828425|NCT05621252|Drug|Placebo|Matching placebo
79685933|NCT00551694|Drug|GSK256073A tablets|
79375990|NCT01328782|Drug|Bupivacaine 0.25%|"Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
79375991|NCT01328782|Drug|Ropivacaine 0.20%|"Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
79375992|NCT04447326|Drug|Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy|Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
79375993|NCT04447326|Drug|IC＋CCRT|IC＋CCRT
79375994|NCT01426360|Other|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
79375995|NCT01426360|Other|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
79375996|NCT03411330|Drug|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
79375997|NCT03411330|Drug|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
79375998|NCT03411330|Drug|Bupivacaine|bupivacaine (0.5%)
79375999|NCT05167890|Dietary Supplement|Coffee|Coffee 3 times per day
79529697|NCT01413672|Device|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
79529698|NCT01413685|Other|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
79529699|NCT01413711|Drug|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
79529700|NCT01413763|Drug|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
79685934|NCT00551733|Drug|carboplatin|Given IV
79685935|NCT00551733|Drug|paclitaxel|Given IV
79828426|NCT05613322|Diagnostic Test|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
79828427|NCT05607758|Behavioral|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
79828428|NCT05605912|Other|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
79828429|NCT05605912|Device|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
79828430|NCT05604833|Behavioral|Progressive Muscle Relaxation Exercises|"In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects."
79529701|NCT01413763|Drug|Placebo cream|placebo cream applied daily for 2 weeks
79529702|NCT01413776|Dietary Supplement|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
79529703|NCT01413789|Drug|Dermatix|1 application of Dermatix
79529704|NCT01413789|Drug|Kelocote|1 application of Kelocote
79529705|NCT01413789|Drug|BAP scar gel|1 application of BAP scar gel
79529706|NCT01413789|Drug|Alhydran|1 application of Alhydran
79234975|NCT03508401|Other|Passive leg raising (PLR)|"PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs"
79376000|NCT05167890|Dietary Supplement|Orange juice|Orange juice 3 times per day
79376001|NCT03411252|Drug|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
79529707|NCT01413789|Drug|Bap Scar Care T|1 application of BAP Scar Care T
79529708|NCT01413789|Drug|Bap Scar Care S|1 Application of Bap Scar Care S
79685936|NCT00551733|Drug|paclitaxel poliglumex|Given IV
79685937|NCT02896283|Radiation|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
79529709|NCT01413789|Drug|Mepiform|1 application of Mepiform
79529710|NCT01413789|Drug|Scar Ban Elastic|1 application of Scar Ban Elastic
79685938|NCT02896283|Radiation|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
79685939|NCT00551772|Drug|SB-742457|
79685940|NCT02896205|Drug|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
79828431|NCT05604807|Other|Dementia course with virtual reality|dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
80002598|NCT02069444|Procedure|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
80002599|NCT02069444|Procedure|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
80002600|NCT03872999|Other|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
80002601|NCT03628521|Drug|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
79376002|NCT03411252|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron
80002602|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
80002603|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
80002604|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
79234976|NCT03508401|Device|Echo-Doppler measurements|"Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin))."
79234977|NCT03504813|Other|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
79685941|NCT02896205|Drug|Placebo|Subjects will be given matching placebo for 6 months
79685942|NCT04922424|Drug|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
79685943|NCT04922424|Other|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
79685944|NCT00550056|Behavioral|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
79685945|NCT00550056|Behavioral|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
79685946|NCT02896634|Biological|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
79685947|NCT00551811|Drug|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
80002605|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
79685948|NCT00551811|Drug|Placebo|Placebo tablets will be intended to be administered orally.
79685949|NCT00553748|Drug|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
79685950|NCT00551850|Drug|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
80002606|NCT02067494|Other|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
80002607|NCT02067494|Other|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
79234978|NCT03504813|Other|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
79376003|NCT03394170|Other|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
79376004|NCT03396354|Procedure|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
79376005|NCT03396354|Procedure|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
79685951|NCT02896049|Device|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
79685952|NCT00550095|Drug|valsartan|
79685953|NCT02895893|Behavioral|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
80002608|NCT01361347|Dietary Supplement|milk|milk for milk allergic children (1:25 dilution, whole milk)
80002609|NCT05697003|Drug|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
80002610|NCT05697003|Drug|ADVAIR DISKUS 100/50|2 inhalations in one study period
80002611|NCT01356199|Dietary Supplement|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
80002612|NCT01356199|Dietary Supplement|PLACEBO|PLACEBO. 6 per day for 8 months.
80002613|NCT02067572|Other|Saline mouthwash|
80002614|NCT02067572|Other|Salvia mouthwash|
80002615|NCT03775473|Diagnostic Test|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
80002616|NCT02069522|Other|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
79376006|NCT05167812|Other|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
79376007|NCT04390620|Device|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
79529711|NCT01413828|Drug|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
79529712|NCT01413828|Drug|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
79376008|NCT01831427|Drug|Andecaliximab|Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
79529713|NCT01413841|Drug|Nasal oxygen|3 l oxygen
79529714|NCT01413841|Drug|Regular nasal air|3 l nasal air
79529715|NCT01413854|Drug|sugar pill|One tablet two times daily during four weeks
79529716|NCT01413854|Drug|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
79529717|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
79376009|NCT01831427|Drug|Placebo to match Andecaliximab|Placebo to match andecaliximab administered by IV infusion
79376010|NCT01426828|Biological|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
79376011|NCT03396120|Diagnostic Test|Pulmonary function test|forced vital capacity and diffusing capacity
79529718|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
79529719|NCT01413893|Drug|linifanib|QD daily
79234979|NCT03504813|Other|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
80002617|NCT02069522|Other|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
79234980|NCT03504813|Behavioral|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
79234981|NCT02694536|Drug|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
79376012|NCT01830881|Drug|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
79376013|NCT01830881|Drug|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
79376014|NCT01830881|Other|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
79376015|NCT01830881|Drug|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
79376016|NCT03404700|Behavioral|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
79376017|NCT03404700|Behavioral|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
79376018|NCT03404700|Behavioral|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
79376019|NCT03404700|Behavioral|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
79529720|NCT01413906|Drug|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
79529721|NCT01413984|Behavioral|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
80002618|NCT02033148|Drug|icotinib hydrochloride|Given PO
80002619|NCT02033148|Other|laboratory biomarker analysis|Correlative studies
80002620|NCT02033148|Other|pharmacological study|Correlative studies
80002621|NCT01361425|Drug|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
80002622|NCT01361425|Drug|placebo|placebo 500mg 8/8h, orally
80002623|NCT02033226|Device|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
80002624|NCT02033226|Device|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
80002625|NCT01356355|Drug|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
80002626|NCT01356355|Drug|Placebo|One capsule twice a day daily till ureteral stent in situ
80002627|NCT01356355|Drug|Tolterodine|One capsule twice a day daily till ureteral stent in situ
79685954|NCT00551889|Drug|celecoxib|
79234982|NCT02694536|Drug|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
79234983|NCT01661686|Device|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
79234984|NCT01661686|Device|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
79234985|NCT02312037|Biological|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~Mylotarg <=9 mg/m2 as a single agent on Day 1 & 14 of a 28-day cycle for a total of two cycles~Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
79234986|NCT03167918|Drug|Calcium Dobesilate|gave each patient 0.5 g bid，
79529722|NCT01414023|Behavioral|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
79685955|NCT00551889|Drug|cyclophosphamide|
79234987|NCT03167918|Drug|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
79376020|NCT01396486|Drug|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
79828432|NCT05604807|Other|Dementia course with no virtual reality|dementia course, intergenerational learning, world café teaching method and community practice
79529723|NCT01414023|Behavioral|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
79828433|NCT05603442|Procedure|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
79828434|NCT05601232|Radiation|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
79529724|NCT01414049|Procedure|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
79529725|NCT01414049|Procedure|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
79828435|NCT05601206|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
79234988|NCT03167918|Drug|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
79234989|NCT03167918|Drug|metformin|gave each patient 1000 mg, bid, PO
79376021|NCT01396486|Drug|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
79685956|NCT00551889|Other|laboratory biomarker analysis|
79685957|NCT00550212|Drug|neratinib|HKI-272, Single-dose capsule and solution
79685958|NCT02895932|Radiation|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
79685959|NCT00551967|Procedure|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
79685960|NCT02896010|Other|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
79234990|NCT03167918|Drug|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
79685961|NCT02896010|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
79685962|NCT00552006|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
79828436|NCT05601206|Behavioral|Enhanced Usual Care|Usual care from health providers
79234991|NCT05745818|Drug|Colchicine Pill|oral pills
79828437|NCT05601102|Behavioral|danceSing Care|- Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
79234992|NCT05475964|Device|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
79234993|NCT02393300|Drug|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
79234994|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
79529726|NCT01414062|Behavioral|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
79529727|NCT01414062|Behavioral|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the NYC-based not-for-profit, God's Love We Deliver
79828438|NCT05600803|Procedure|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
79234995|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
79234996|NCT02305875|Other|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
79234997|NCT03106610|Drug|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
79234998|NCT03106610|Behavioral|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
79828439|NCT05597189|Dietary Supplement|Experimental product|Botanical extract
79376022|NCT05215002|Other|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
79376023|NCT05215002|Other|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
79376024|NCT03395964|Procedure|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
79376025|NCT03395964|Procedure|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
79828440|NCT05597189|Other|Control product consumption|Product with identical characteristics to the experimental product.
79376026|NCT03397680|Diagnostic Test|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
79376027|NCT01397656|Procedure|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
79529728|NCT01414088|Other|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
79529729|NCT01414088|Other|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
79529730|NCT01414088|Other|glucose 5%|infusion, 23 ml/kg, during 50 minutes
79529731|NCT01414101|Drug|ISIS CRP Rx or Placebo|
79529732|NCT01414140|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
79828441|NCT05592249|Other|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.
79234999|NCT02678884|Drug|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
79529733|NCT01414218|Behavioral|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
79529734|NCT01414231|Drug|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
79828442|NCT05592249|Other|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
79529735|NCT01414283|Drug|PSMA ADC|PSMA ADC administered IV
79529736|NCT01414296|Drug|PSMA ADC|PSMA ADC administered IV
79529737|NCT01414335|Dietary Supplement|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
79529738|NCT01414335|Other|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
79529739|NCT01414348|Behavioral|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
79529740|NCT01414348|Behavioral|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
79828443|NCT05588219|Drug|Tislelizumab|Tislelizumab injection[10ml:100mg] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
79828444|NCT05588219|Drug|DDP synchronous with radiotherapy|DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
79828445|NCT05585346|Device|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
79376028|NCT01397656|Procedure|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
80002628|NCT02069600|Device|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
79828446|NCT05585346|Drug|Oral vitamin B1|Oral vitamin B1 10mg, times/day
79828447|NCT05585021|Dietary Supplement|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
79376029|NCT01330420|Behavioral|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~Examination and reversal of negative thought patterns.~Physical movement, including stretching and yoga.~Healthy eating and other positive lifestyle behaviors.~Goal setting."
79376030|NCT03126942|Device|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
79376031|NCT03126942|Device|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
79376032|NCT01838681|Drug|Placebo|Once daily, tablets, orally
79376033|NCT01838681|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
79828448|NCT05585021|Dietary Supplement|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
80002629|NCT03610542|Behavioral|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
79376034|NCT01838681|Drug|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
80002630|NCT03610542|Behavioral|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
79376035|NCT03404544|Drug|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
79376036|NCT03404544|Drug|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
79376037|NCT01398280|Drug|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
79376038|NCT01398280|Drug|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
79376039|NCT03403842|Device|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
79376040|NCT03403842|Device|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
79376041|NCT03403842|Drug|PCA Morphine|Administration of endovenous morphine with a PCA
79529741|NCT01414374|Drug|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
79529742|NCT01414374|Drug|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
79529743|NCT01414387|Procedure|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
79828449|NCT05584098|Other|qSOFA and MEWS|qSOFA and MEWS used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
80002631|NCT03610542|Behavioral|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
80002632|NCT03610542|Behavioral|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
79235000|NCT03504735|Behavioral|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
79235001|NCT03504735|Drug|Caduet Pill|Take once daily.
79235002|NCT03504735|Drug|Placebo|Take once daily.
79235003|NCT02312115|Drug|Furosemide|Diuretic
79235004|NCT02312115|Drug|Placebo|Saline
79235005|NCT03106532|Drug|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
79235006|NCT03106532|Drug|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
79235007|NCT03106532|Drug|Placebo ophthalmic solution|3 drops daily, 28 days
79235008|NCT03504657|Device|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
79391103|NCT02425488|Behavioral|Nursing therapeutics education|"Educational intervention will focus on~Appropriate lifestyles~Early recognition of signs/prodromal symptoms of HF~Early recognition of signs of inflammation of the ICD-pocket~Good management of the device~1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
79235009|NCT03504657|Device|stenting angioplasty|Angioplasty with a stenting
79235010|NCT03026140|Drug|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
79376042|NCT01398982|Drug|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
79376043|NCT01398982|Drug|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
79376044|NCT03394092|Diagnostic Test|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
79376045|NCT02203162|Device|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
79376046|NCT04589897|Device|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
79376047|NCT04589897|Device|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
79828450|NCT05575908|Procedure|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
80002633|NCT03610542|Behavioral|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
79376048|NCT04290000|Other|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~Apheresis sampling~CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
79376049|NCT05167188|Other|no intervention|no intervention
79376050|NCT04447560|Procedure|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
79376051|NCT03394014|Procedure|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
79391104|NCT02426112|Drug|Azithromycin|
79529744|NCT01414387|Procedure|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
79828451|NCT05575102|Other|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
79828452|NCT05574296|Drug|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
80002634|NCT03634969|Drug|BMS-986224|Specified dose on specified days
79235011|NCT03026140|Drug|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
79235012|NCT03026140|Drug|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
79391105|NCT02426112|Drug|Placebo|
79391106|NCT03117192|Drug|Zinc Sulfate|Zinc supplementation in syrup form
79529745|NCT01414400|Other|Blood draw for culture|Blood will be drawn and sent for culture.
80002635|NCT01356433|Drug|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
80002636|NCT01356433|Drug|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
79235013|NCT03026140|Drug|BMS-986253|BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
79235014|NCT03026140|Drug|BMS-986016|Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29
79235015|NCT02398994|Drug|Intravenous Methylprednisolone|
79235016|NCT02398994|Drug|Intravenous Immunoglobulin|
79235017|NCT02306889|Drug|Fenofibrate|130mg Capsules
79235018|NCT02306889|Drug|ANTARA® (fenofibrate)|130mg Capsules
79235019|NCT02393144|Device|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
79685963|NCT00552006|Behavioral|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
80002637|NCT02033460|Other|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
79235020|NCT02393144|Device|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
79376052|NCT03401970|Behavioral|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
79529746|NCT01414439|Behavioral|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
79529747|NCT01414465|Drug|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
79235021|NCT02393144|Other|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
79376053|NCT03401970|Behavioral|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
79391107|NCT03117192|Drug|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
79529748|NCT01414478|Other|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
79529749|NCT01414504|Biological|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
79529750|NCT01414504|Biological|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
79685964|NCT02895854|Radiation|Hypofractionated RT 5 x 7,25 Gy|
79685965|NCT02895854|Radiation|LDR-brachytherapy with I125 seeds|
79685966|NCT00550251|Device|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
79685967|NCT00550251|Device|Placebo wristbands|Elasticated wrist bands without active bead.
79685968|NCT01261390|Behavioral|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
79529751|NCT01414504|Biological|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
79529752|NCT01414504|Biological|Control|control, 0.1mL Pneumovax at 3-5yrs
79529753|NCT01414517|Dietary Supplement|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
79529754|NCT01414517|Dietary Supplement|Maltodextrin|a non-prebiotic carbohydrate
79529755|NCT01414530|Drug|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
79529756|NCT01414530|Drug|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
79235022|NCT02393144|Drug|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
79235023|NCT02393144|Drug|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
79235024|NCT02393144|Drug|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
79235025|NCT02393144|Drug|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
79235026|NCT05465200|Procedure|Structured treatment of cardiogenic shock patients|"Creation of hub&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
79235027|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected.
79235028|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected
79235029|NCT02393222|Other|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
79235030|NCT02306031|Drug|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
79376054|NCT03401970|Behavioral|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
79376055|NCT01427296|Drug|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
79376056|NCT01427296|Drug|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
79685969|NCT01261390|Device|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
79685970|NCT01261390|Device|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
79376057|NCT03126162|Procedure|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
79828453|NCT05574296|Other|Usual care|Usual care post-ECPR event, including targeted temperature management.
79376058|NCT03126162|Procedure|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
79828454|NCT05573906|Combination Product|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
79235031|NCT02306031|Drug|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
79529757|NCT01414543|Other|Information Sheet|Providing the Participant with information regarding the aim of the experiment
79529758|NCT01414543|Other|Consent|Providing a consent form for participants. The participant is aware of his or her rights
79235032|NCT02392910|Drug|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
79529759|NCT01414543|Other|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
79529760|NCT01414543|Other|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
79529761|NCT01414556|Other|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
79235033|NCT02392910|Drug|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
79529762|NCT01414556|Other|saline|
79529763|NCT01414569|Drug|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
79529764|NCT01414582|Device|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
79529765|NCT01414582|Other|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
79529766|NCT01414595|Genetic|DNA analysis|
79529767|NCT01414595|Genetic|DNA methylation analysis|
79376059|NCT03401736|Device|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
79376060|NCT03401736|Drug|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
79529768|NCT01414595|Genetic|RNA analysis|
79529769|NCT01414595|Genetic|gene expression analysis|
79529770|NCT01414595|Genetic|polymorphism analysis|
79529771|NCT01414595|Other|laboratory biomarker analysis|
79529772|NCT01414595|Other|medical chart review|
79529773|NCT01414608|Radiation|Brachytherapy|Undergo brachytherapy
79529774|NCT01414608|Drug|Carboplatin|Given IV
79529775|NCT01414608|Drug|Cisplatin|Given IV
79529776|NCT01414608|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
79529777|NCT01414608|Drug|Paclitaxel|Given IV
80002638|NCT02033460|Other|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
80002639|NCT02033460|Other|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
80002640|NCT03691727|Drug|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
80002641|NCT03691727|Diagnostic Test|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
80002642|NCT03691727|Diagnostic Test|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
80002643|NCT03691727|Behavioral|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
80002644|NCT03691727|Diagnostic Test|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
79529778|NCT01414608|Other|Quality-of-Life Assessment|Ancillary studies
80002645|NCT03691727|Other|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
80002646|NCT02069834|Drug|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
80002647|NCT02069834|Drug|Arm 2 (control)|Continuation of existing HAART at the time of randomization
80002648|NCT01360177|Procedure|124 PET/CT imaging|Standard of Care
79235034|NCT02307045|Drug|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
79235035|NCT02307045|Drug|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
79235036|NCT02398604|Drug|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
79235037|NCT02398604|Drug|Placebo|Placebo
79235038|NCT04464291|Other|Detection of Streptococcus pneumoniae strains|There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
79235039|NCT03167372|Other|Litebook® Advantage|Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
79376061|NCT03401736|Drug|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
79529779|NCT01414621|Other|atrial tissue sample|atrial tissue sample from CABG patient
79376062|NCT02203786|Drug|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
79376063|NCT02203786|Drug|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
79529780|NCT01414647|Dietary Supplement|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
79529781|NCT01414647|Dietary Supplement|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
79529782|NCT01414647|Other|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
79828455|NCT05573906|Combination Product|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
79828456|NCT05567406|Drug|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
80002649|NCT01360177|Drug|Na134I|25 to 150 mCi
80002650|NCT01360177|Drug|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
80002651|NCT01360177|Drug|Tri-iodothyronine|20 mg/day x 2
80002652|NCT02071940|Drug|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
80002653|NCT01348685|Other|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
80002654|NCT01348685|Other|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
80002655|NCT01348685|Other|The effect of solid vs. liquid forms of whey protein on food intake|
80002656|NCT01346371|Drug|Refresh Tears 0.5% Lubricant Eye Drops|
80002657|NCT01346371|Drug|Bepreve 1.5% Ophthalmic Solution|
80002658|NCT01348841|Other|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
80002659|NCT02069912|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
80002660|NCT01356511|Drug|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
79529783|NCT01414660|Procedure|transplantation|transplantation of islet, kidney or liver
79376064|NCT02203786|Drug|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
79529784|NCT01414673|Drug|HCG|5000 IU
79529785|NCT01414686|Other|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
79235040|NCT03167372|Other|Fitbit Flex2 TM|Standard system activity and sleep tracker
79235041|NCT02312271|Other|enteral formula|standard tube feeding formulas
79685971|NCT01261390|Device|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
79685972|NCT02895815|Combination Product|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit [SRAK-02 kit] and third arm accessory).
79685973|NCT02895815|Combination Product|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
79685974|NCT02895503|Behavioral|Yoga|Participate in yoga
79685975|NCT02895503|Behavioral|Support Group Therapy|Participate in emotional support group therapy
79685976|NCT02895503|Other|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, & Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
80002661|NCT01356511|Drug|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
80002662|NCT03685487|Procedure|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
80002663|NCT03685487|Other|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
80002664|NCT02069990|Drug|Cholecalciferol|
80002665|NCT01347281|Procedure|Injection of [18F]HX4|"Injection of [18F]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~[18F]HX4 PET scans; 444 MBq (12 mCi) [18F]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of [18F]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): [18F]FDG PET in treatment position"
79235042|NCT02306109|Procedure|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
79391108|NCT02421198|Behavioral|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
79391109|NCT04768439|Drug|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
79529786|NCT01414699|Behavioral|Variety|These conditions will have snack served with an increase of fruit variety.
79529787|NCT01414699|Behavioral|Non-Variety|These conditions will receive a snack without a variety of fruit.
79529788|NCT01414712|Other|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
79529789|NCT01414725|Other|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al [2009]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
79685977|NCT02895503|Other|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
79685978|NCT03455764|Drug|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
79828457|NCT05555771|Behavioral|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
80002666|NCT02072018|Drug|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
80002667|NCT02072018|Drug|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
80002668|NCT01347359|Behavioral|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
79235043|NCT02306109|Procedure|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
79235044|NCT03167294|Device|AquaBeam System|Aquablation
79376065|NCT02203786|Drug|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
79376066|NCT02203786|Behavioral|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
79376067|NCT03009058|Biological|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
79376068|NCT03009058|Drug|Gemcitabine|Standard of Care chemotherapy
79376069|NCT03009058|Drug|Nabpaclitaxel|Standard of Care chemotherapy
79529790|NCT01414725|Other|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
79529791|NCT01414725|Other|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
80002669|NCT01347359|Behavioral|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
80002670|NCT02076308|Other|Electroacupuncture and physical therapy|real electroacupuncture
80002671|NCT02076308|Other|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
80002672|NCT02070068|Device|PINPOINT System|
79235045|NCT03504345|Drug|Prometrium|The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
79376070|NCT03009058|Drug|Capecitabine|Standard of Care chemotherapy
79376071|NCT03009058|Drug|Folinic Acid|Standard of Care chemotherapy
79376072|NCT03009058|Drug|Fluorouracil|Standard of Care chemotherapy
79376073|NCT03009058|Drug|Irinotecan|Standard of Care chemotherapy
79376074|NCT03009058|Drug|Oxaliplatin|Standard of Care chemotherapy
79376075|NCT03009058|Biological|cetuximab|Standard of Care immunotherapy
79376076|NCT03009058|Biological|Anti-PD1|Standard of Care immunotherapy
79376077|NCT03009058|Biological|Ipilimumab|Standard of Care immunotherapy
79376078|NCT03009058|Drug|Cyclophosphamide|Standard of Care chemotherapy
79376079|NCT01611857|Drug|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
79376080|NCT01611857|Drug|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m^2, 5-FU continuous IV 2400 mg/m^2 over 46 hours, leucovorin 400 mg/m^2 IV, and oxaliplatin 85 mg/m^2.
79376081|NCT03393702|Drug|Gabapentin|"Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
79376082|NCT03393702|Drug|Placebo|"Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~Patients after surgery receive identical placebo capsules 2 times per day."
79376083|NCT02204176|Other|Exercise info|"Discussion:~benefits of exercise~types of exercise~exercise guidelines~components of an exercise session~how to reduce risk of injuries"
79529792|NCT01414751|Behavioral|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
80002673|NCT01347437|Behavioral|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
80002674|NCT05076409|Drug|BI 425809|Period 1 and period 2
79235046|NCT02398760|Other|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
79376084|NCT02204176|Other|Implementation intentions|"Discussion of:~barriers to exercise and how to address/overcome barriers~how to create detailed exercise plans"
79376085|NCT02204176|Other|Industriousness|"Discussion of:~realistic monitoring of efforts related to exercise~reaching and pushing past thresholds for sustained effort for exercise"
79376086|NCT02204176|Device|pedometer|
79685979|NCT03455764|Drug|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
79376087|NCT03399864|Behavioral|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
79376088|NCT03399864|Other|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
79376089|NCT01829477|Drug|TAK-875|TAK-875 50 mg tablets
79376090|NCT01829477|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
79376091|NCT01829477|Drug|Glimepiride|Glimepiride tablet.
79376092|NCT02204566|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
79529793|NCT01414751|Behavioral|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
79529794|NCT01414764|Other|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
79685980|NCT03455764|Drug|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
80002675|NCT05076409|Drug|fluconazole|Period 2
80002676|NCT02076386|Drug|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
79529795|NCT01414764|Drug|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
79529796|NCT01414790|Procedure|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
79235047|NCT02392988|Other|acupuncture treatment|acupuncture treatment
79235048|NCT02392988|Other|Placebo Comparator|Placebo Comparator
79529797|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
79529798|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg per day
79685981|NCT04902495|Other|MTA Pro Root|pulp therapy
79685982|NCT04902495|Other|MTA HP Repair|pulp therapy
79685983|NCT04902495|Other|Biodentine|pulp therapy
79685984|NCT00552162|Procedure|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
79685985|NCT00552162|Procedure|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
79685986|NCT02895659|Procedure|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
79685987|NCT00552201|Drug|Tacrolimus|Administration Twice a day after adjustment to blood level
79235049|NCT02307201|Drug|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
79235050|NCT03167528|Behavioral|Relaxation|Relaxation
79235051|NCT03167528|Behavioral|Hypnosis|Hypnosis
79376093|NCT03126864|Procedure|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10^9 (expected range 5 x 10^8 - 5 x 10^10), for up to two days.
79376094|NCT03126864|Drug|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
79376095|NCT03126864|Drug|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
79529799|NCT01414816|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
79529800|NCT01414829|Procedure|Gastroscopy|The reason for gastroscopy will be not related to the study
79529801|NCT01414842|Device|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
79529802|NCT01414842|Device|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
79685988|NCT02895464|Other|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
79828458|NCT05555771|Behavioral|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
79828459|NCT05555758|Drug|Adamgammadex Sodium|Aom0319 will be administered intravenously with water for injection.
79828460|NCT05555758|Drug|0.9% Sodium Chloride Injection|0.9% Sodium Chloride will be administered intravenously.
79828461|NCT05555706|Drug|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
79828462|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
79529803|NCT01414868|Drug|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
79529804|NCT01414881|Drug|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
79529805|NCT01414881|Drug|Placebo|Placebo administered subcutaneously (SC) once weekly
79685989|NCT03391882|Drug|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
79828463|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
79828464|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
79235052|NCT03167528|Behavioral|Holistic gymnastics|holistic gymnastics
79828465|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359.
79828466|NCT05545514|Drug|One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,|To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
79828467|NCT05545384|Drug|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
79828468|NCT05545384|Drug|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
79828469|NCT05545384|Drug|Standard of care|Patients in this group will be treated according to standard care
79828470|NCT05540054|Other|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
79828471|NCT05540054|Other|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
79828472|NCT05538715|Procedure|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
79828473|NCT05538715|Procedure|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
79235053|NCT03167528|Device|Transcutaneous electrical nerve stimulation (TENS)|TENS
79828474|NCT05538702|Device|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
79235054|NCT03167528|Behavioral|Sophrology|Sophrology
79235055|NCT02306187|Drug|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
79235056|NCT03167216|Drug|Cromolyn Sodium|Mast cell stabilizer
79235057|NCT03167216|Drug|Cetirizine Hydrochloride|Histamine receptor antagonist
79235058|NCT03508167|Device|Thermal Band|Thermal Band used 8 hours per day
79529806|NCT01414894|Other|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
79529807|NCT01414894|Other|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
79529808|NCT01414907|Behavioral|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
79529809|NCT01414933|Other|Biopsy|Breast metastases biopsy
80002677|NCT01347515|Other|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
79685990|NCT03391882|Drug|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
79235059|NCT03508167|Drug|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
79376096|NCT03126864|Biological|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is > 1.5 x 105/kg but ≤ 4.5 x 105/kg.
80002678|NCT05033353|Diagnostic Test|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
79235060|NCT03508167|Drug|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
79235061|NCT03507231|Behavioral|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
79235062|NCT03507231|Behavioral|Incentive for Vaccination|$5 gift card offered for vaccination
79235063|NCT03507231|Behavioral|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
79529810|NCT01414946|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
79685991|NCT00550329|Drug|Glipizide GITS|
79235064|NCT02392832|Biological|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
79235065|NCT03507153|Procedure|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
79235066|NCT03507153|Procedure|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
79235067|NCT02393066|Drug|Propofol|Sedation
79376097|NCT03399708|Drug|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
79376098|NCT03399630|Other|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
79376099|NCT03399630|Other|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
79529811|NCT01414946|Other|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
79529812|NCT01414972|Drug|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
79529813|NCT01414972|Drug|placebo|1 cap placebo/day for 3 month
79529814|NCT01414985|Biological|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
79529815|NCT01414998|Behavioral|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
79529816|NCT01414998|Behavioral|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
79529817|NCT01415011|Drug|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
79685992|NCT02895620|Biological|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
79685993|NCT00550485|Drug|escitalopram|escitalopram 4 mg
79685994|NCT01261000|Drug|Pegvisomant|Pegvisomant used as indicated
79828475|NCT05538702|Device|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
79828476|NCT05538702|Device|Marlboro Gold (Conventional cigarette)|Conventional cigarette
79828477|NCT05538702|Device|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
80002679|NCT01347593|Drug|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
80002680|NCT02076464|Behavioral|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
80002681|NCT01360333|Other|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
80002682|NCT02072252|Behavioral|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
80002683|NCT03672227|Behavioral|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
80002684|NCT01347671|Drug|GRT6005|25µg/day once daily
79235068|NCT02393066|Drug|Dexmedetomidine|Sedation
79235069|NCT03504267|Other|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
79376100|NCT03395730|Drug|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
79529818|NCT01415024|Procedure|second LV lead in CRT|second LV lead in CRT
79529819|NCT01415037|Procedure|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
79529820|NCT01415050|Device|Whole body vibration|15 times WBV
79529821|NCT01415063|Procedure|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
79529822|NCT01415063|Procedure|TACE-RFA|TACE first, then RFA within 2 weeks
79529823|NCT01415076|Procedure|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
79529824|NCT01415089|Behavioral|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
79529825|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 1: 50 ug
79828478|NCT05529732|Other|e-Mobile Application Patient Education for Patients with Thyroidectomy|"Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery."
79828479|NCT05525871|Dietary Supplement|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
79828480|NCT05525871|Dietary Supplement|Control product|Fruit puree
79828481|NCT05525429|Behavioral|Nutrition Education|Multidimensional nutrition education will be provided.
80002685|NCT01347671|Drug|GRT6005|75 µg/day once daily
80002686|NCT01347671|Drug|GRT6005|200 µg/day once daily
80002687|NCT01347671|Drug|Matching Placebo|Once daily
80002688|NCT01361659|Procedure|shockwave treatment|9 treatments in 3 months
80002689|NCT03671603|Drug|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
80002690|NCT02072330|Drug|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
80002691|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
80002692|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
80002693|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
79235070|NCT02392754|Device|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
79376101|NCT03395730|Procedure|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
79376102|NCT03395730|Procedure|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
79376103|NCT01334086|Drug|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
79376104|NCT03399474|Drug|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
79376105|NCT03399474|Drug|Dexmedetomidine 0.5 ug/kg|pecedex
79529826|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
79828482|NCT05520203|Other|Care provided by the Nurse Practitioner|Introduction of a Nurse Practitioner in the interdisciplinary care team
80002694|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
79235071|NCT03504111|Procedure|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
79376106|NCT03399474|Drug|Dexmedetomidine Injection 0.25 ug/kg|pecedex
79376107|NCT01611155|Drug|venlafaxine|Given PO
79828483|NCT05519800|Dietary Supplement|Isomaltulose|Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
79828484|NCT05519800|Dietary Supplement|Maltodextrin|Diet will be supplemented using a beverage containing Maltodextrin.
80002695|NCT05128643|Biological|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
79376108|NCT01611155|Drug|placebo|Given PO
80002696|NCT02070224|Other|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
80002697|NCT02070224|Other|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
79376109|NCT01611155|Other|questionnaire administration|Ancillary studies
79828485|NCT05514873|Drug|zilucoplan (RA101495)|Subcutaneous injection
79376110|NCT01611155|Other|quality-of-life assessment|Ancillary studies
79529827|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
79529828|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
79529829|NCT01415102|Drug|Placebo|Inhaled
79685995|NCT00550524|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
79828486|NCT05503810|Behavioral|Social support|Contact ones a week with Informal caregiver or peer support
79828487|NCT05501132|Device|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
79828488|NCT05499780|Device|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
79828489|NCT05498155|Drug|Neoadjuvant Olaparib monotherapy group|Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
79828490|NCT05498155|Combination Product|Neoadjuvant combination therapy with olaparib plus durvalumab|Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
80002698|NCT03660215|Other|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
80002699|NCT02072408|Drug|aflibercept|"Three monthly intravitreal aflibercept (2mg) injections~Five bimonthly intravitreal aflibercept (2mg) injections~Rescue treatment: Verteporfin photodynamic therapy~Loss of five ETDRS letters or one Snellen line of vision from baseline~Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~Presence of active polyp on indocyanine green angiography"
80002700|NCT02076542|Behavioral|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
80002701|NCT03644849|Device|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
80002702|NCT03644849|Other|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
80002703|NCT02070458|Drug|ixazomib|Given PO
79376111|NCT01430182|Drug|Methadone|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
79376112|NCT01430182|Drug|Morphine|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
79685996|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
79376113|NCT05166408|Procedure|Buccinator myomucosal flap|Buccinator myomucosal flap for primary cleft palate palatoplasty
79376114|NCT05166408|Procedure|Bardach two flap palatoplasty|Bardach two flap palatoplasty
79529830|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
79529831|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
79529832|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
79529833|NCT01415102|Drug|Placebo|Inhaled
79828491|NCT05495230|Behavioral|Person-centred integrated care intervention|See arm description.
80002704|NCT02070458|Drug|mitoxantrone hydrochloride|Given IV
80002705|NCT02070458|Drug|etoposide|Given IV
79376115|NCT05097768|Drug|Dexamethasone 0.5mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
79376116|NCT05097768|Drug|Ketorolac 10 Mg Oral Tablet|The patients will be randomly given the medication by mouth 60 min before administering IANB.
80002706|NCT02070458|Drug|cytarabine|Given IV
80002707|NCT03131479|Drug|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
80002708|NCT02076854|Behavioral|Text-Message Intervention|
80002709|NCT01348997|Behavioral|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
80002710|NCT01348997|Behavioral|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
79235072|NCT03504111|Procedure|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
80002711|NCT03620227|Other|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
80002712|NCT03620227|Dietary Supplement|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
79235073|NCT02398838|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
79235074|NCT02398838|Drug|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
79235075|NCT02398682|Other|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1) Rapidly establish a credible diagnosis of the cause of AKI including:~Improved assessment of volume status~Standardised use of urine dipstick .~Appropriate sepsis investigations.~Urgent ultrasound with suspected obstruction."
80002713|NCT03620227|Dietary Supplement|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
79235076|NCT02398682|Other|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
79235077|NCT02398682|Other|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
79376117|NCT05097768|Drug|Meloxicam 7.5 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
79529834|NCT01415128|Drug|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
79376118|NCT05097768|Drug|Ibuprofen 600 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
79376119|NCT05097768|Drug|Placebo|The patients will be randomly given the medication by mouth 60 min before administering IANB.
79376120|NCT01829243|Drug|Milnacipran|
79376121|NCT01829243|Drug|Placebo|
79685997|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
80002714|NCT02072564|Other|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
80002715|NCT02076932|Behavioral|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
79376122|NCT03393312|Device|Transcranial direct current stimulation (tDCS)|Electric current
79828492|NCT05495230|Other|Usual care|See arm description.
80002716|NCT02077010|Drug|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
80002717|NCT01319461|Device|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
80002718|NCT01319461|Device|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
80002719|NCT02070536|Other|sRAGE|
80002720|NCT03180749|Other|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
79376123|NCT01838447|Dietary Supplement|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
79376124|NCT03395574|Drug|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
79376125|NCT03395574|Drug|Normal saline|drug will be given after 30 minutes as placebo in control group
79376126|NCT03395496|Drug|Biodentine|Biodentine pulpotomy agent
79376127|NCT03395496|Drug|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
79376128|NCT03399240|Device|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
79376129|NCT01829165|Device|rTMS Treatment|MRI-compatible TMS stimulator
79376130|NCT01829165|Device|Sham rTMS Treatment|
79376131|NCT04982172|Drug|Infliximab|Infliximab (Inflectra® [Pfizer]), dosage determined using model-informed precision dosing, intravenously administered
79529835|NCT01415128|Drug|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
79529836|NCT01415128|Drug|Desipramine|Single dose of Desipramine (50 mg) for 1 day
79529837|NCT01415141|Drug|Peginterferon alfa-2a|180ug subcutaneously, weekly
79685998|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
79828493|NCT05490290|Other|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
79235078|NCT02398682|Other|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
79235079|NCT02398682|Other|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
79235080|NCT02398682|Other|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
79235081|NCT03508089|Other|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
79235082|NCT03508089|Other|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
79235083|NCT02312427|Drug|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
79376132|NCT04982172|Drug|Infliximab|Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
79376133|NCT04592471|Device|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
79376134|NCT04944186|Other|Structured Pressure Injury Patient Education (mySPIPE)|It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
79376135|NCT04944186|Other|Standard Patient Education|No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
79376136|NCT03393234|Radiation|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
79376137|NCT01837823|Drug|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
79376138|NCT03393156|Behavioral|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
79376139|NCT03395262|Dietary Supplement|Active with caffeine|Novel formula with caffeine
79376140|NCT03395262|Dietary Supplement|Active without caffeine|Novel formula without caffeine
79376141|NCT03395262|Dietary Supplement|Placebo|Dextrose placebo
79391110|NCT04768439|Drug|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
79529838|NCT01415141|Drug|Ribavirin|"Administered orally twice a day as follows:~weight < 75kg - 1000mg weight ≥ 75kg - 1200mg"
79529839|NCT01415141|Drug|telaprevir|750mg every 8 hours, orally
79529840|NCT01415154|Device|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
79685999|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
79686000|NCT02895425|Other|Registry (No intervention)|
79686001|NCT00550563|Dietary Supplement|cholecalciferol|Oral
79235084|NCT02312427|Drug|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
79529841|NCT01415193|Procedure|Selective Tibial Nerve block|Use of selective pain block.
79529842|NCT01415193|Procedure|Sciatic Nerve Block|Use of Sciatic Nerve Block
79686002|NCT00550563|Genetic|polymerase chain reaction|companion study
79686003|NCT00550563|Genetic|polymorphism analysis|companion study
79686004|NCT00550563|Genetic|protein expression analysis|companion study
79686005|NCT00550563|Genetic|reverse transcriptase-polymerase chain reaction|companion study
79686006|NCT00550563|Genetic|western blotting|companion study
79686007|NCT00550563|Other|high performance liquid chromatography|companion study
79686008|NCT00550563|Other|laboratory biomarker analysis|companion study
79686009|NCT00550563|Other|pharmacological study|companion study
79686010|NCT00550563|Procedure|adjuvant therapy|Additional therapy
79686011|NCT00550563|Procedure|immunoscintigraphy|additional testing
79828494|NCT05488808|Device|repetitive Transcranial Magnetic Stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
79828495|NCT05488054|Procedure|Physical Therapy|Patients will undergo physical therapy following surgical intervention
79828496|NCT05488054|Procedure|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
79828497|NCT05488054|Device|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
79828498|NCT05485584|Drug|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
80002721|NCT02077088|Other|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
80002722|NCT01361815|Device|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
80002723|NCT01349075|Radiation|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
80002724|NCT02072720|Drug|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
80002725|NCT05077007|Procedure|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
79235085|NCT02312427|Drug|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
79235086|NCT02398916|Behavioral|Music listening|
79235087|NCT02312505|Device|COPFX|cardiac Output by semi-invasive pulse contour analysis
79235088|NCT03115346|Other|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
80002726|NCT05077007|Procedure|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
79235089|NCT03504033|Drug|Xenon|inhalation to maintain anesthesia
79686012|NCT02895698|Device|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
80002727|NCT01356745|Drug|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
79235090|NCT03504033|Drug|Desflurane|inhalation to maintain anesthesia
80002728|NCT01356745|Drug|medical air|inhalation gas for inhalation use
79235091|NCT03132519|Drug|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
79235092|NCT03115970|Procedure|capillary and venous lactate level measurement|capillary and venous lactate level measurement
80002729|NCT02072798|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
79235093|NCT02306343|Device|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
79235094|NCT02398448|Drug|Zyloprim® 300 mg|
79529843|NCT01415206|Behavioral|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
79686013|NCT02895698|Other|Stretching exercises|"The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~Standing self-stretching of the calf muscles.~Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~All stretches were done six times and the duration of each stretch is 30 seconds."
79235095|NCT02398448|Drug|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
79235096|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
79235097|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 3|
79235098|NCT03508011|Drug|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
79235099|NCT02398370|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
79235100|NCT03503955|Other|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
79529844|NCT01415206|Behavioral|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
79529845|NCT01415219|Other|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
80002730|NCT01361893|Other|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
80002731|NCT03602885|Behavioral|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
80002732|NCT03602885|Behavioral|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
80002733|NCT01360567|Dietary Supplement|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
80002734|NCT01360567|Dietary Supplement|Placebo|500 mg . one capsule of placebo, 3 times per day
80002735|NCT02077244|Behavioral|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
80002736|NCT01361971|Procedure|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
80002737|NCT02880761|Procedure|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
80002738|NCT01356823|Biological|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
80002739|NCT01356823|Biological|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
79235101|NCT03503955|Other|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
79235102|NCT02392520|Drug|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
79376142|NCT03852888|Biological|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
79529846|NCT01415245|Device|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
79235103|NCT02392520|Drug|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
79376143|NCT03399162|Behavioral|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
79686014|NCT02895191|Drug|ulinastatin|Patients will receive the study drugs for 7 to 14 days
79686015|NCT02895191|Drug|placebo|Patients will receive the placebo for 7 to 14 days
79376144|NCT03399162|Behavioral|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
79376145|NCT04755972|Other|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
79376146|NCT04755972|Other|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
79529847|NCT01415271|Other|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
80002740|NCT01356823|Biological|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
80002741|NCT01356823|Biological|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
80002742|NCT02070770|Dietary Supplement|Very low calorie diet|
80002743|NCT02070770|Other|Standard weight loss diet|
80002744|NCT01349153|Behavioral|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
80002745|NCT01349153|Behavioral|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
80002746|NCT03635047|Biological|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
80002747|NCT03635047|Other|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
80002748|NCT02073032|Other|No intervention, only observation|
79376147|NCT04755972|Other|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
79529848|NCT01415284|Drug|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
79529849|NCT01415297|Drug|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
79529850|NCT01415336|Drug|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
79529851|NCT01415336|Drug|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
79686016|NCT02895269|Behavioral|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
79686017|NCT04765020|Behavioral|Experimental: moderate to high-intensity exercise|"Four parts:~Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~Activity trackers with individual movement goals that will be adjusted every two weeks"
79686018|NCT00550641|Other|physical therapy|physical therapy in warm pool performing stretching
79686019|NCT00550641|Other|physical therapy|physical therapy in warm pool performing Ai Chi
79376148|NCT01828073|Drug|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
79376149|NCT04697693|Drug|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD >7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
79828499|NCT05485584|Drug|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
79529852|NCT01415362|Device|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
79529853|NCT01415375|Behavioral|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
79828500|NCT05485584|Drug|Placebo Nasal Spray|Once daily
79828501|NCT05485584|Drug|Placebo Nasal Spray|Twice daily
79828502|NCT05482048|Other|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue."
79686020|NCT04680650|Drug|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
79376150|NCT04697693|Drug|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
79828503|NCT05477784|Other|Educational Intervention|Receive EC-PC program
79828504|NCT05477784|Other|Informational Intervention|Receive education booklet
79529854|NCT01415375|Behavioral|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
79376151|NCT03819114|Drug|Levonorgestrel (LNG)|LNG tablet(s) were administered by mouth in a directly observed manner.
79376152|NCT01827839|Biological|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
79686021|NCT04680650|Drug|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
79828505|NCT05477784|Other|Questionnaire Administration|Ancillary studies
79828506|NCT05477199|Other|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
79828507|NCT05477199|Other|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
79828508|NCT05468372|Drug|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
79376153|NCT03399084|Drug|Ferric carboxymaltose|750 mg/15 mL
79376154|NCT05239416|Procedure|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
79376155|NCT04722120|Radiation|Low radiation dose CT|Underwent liver CT with 30% lower radiation dose
79529855|NCT01415388|Dietary Supplement|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
79686022|NCT00550758|Drug|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
79686023|NCT00550758|Device|spirometry|spirometry
79686024|NCT04680572|Procedure|arthroplasty|arthroplasty for fracture neck of femur
79686025|NCT00552435|Device|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
79376156|NCT04722120|Radiation|Conventional CT (radiation)|Underwent liver CT without change of radiation.
79376157|NCT04722120|Drug|Low contrast dose CT|Underwent liver CT 20% lower dose contrast media.
79376158|NCT04722120|Drug|Conventional CT (contrast agent)|Underwent liver CT without change of contrast media doses.
79376159|NCT04722120|Other|Deep-learning based contrast boosting algorithms|Applied deep-learning based contrast boosting algorithms on acquired CT images
79529856|NCT01415414|Drug|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
79529857|NCT01415466|Drug|Cresto|tablet, 20mg
79529858|NCT01415466|Drug|Olmetec|tablet, 40mg
79529859|NCT01415466|Drug|Cresto, Olmetec|tablet, 20mg and 40mg
80016712|NCT04914091|Other|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
79235104|NCT02312583|Behavioral|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
79235105|NCT02312583|Behavioral|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
79376160|NCT04709250|Procedure|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
79376161|NCT04709250|Procedure|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
79376162|NCT04709250|Drug|bupivacaine|bupivacaine
79376163|NCT01827371|Biological|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
79376164|NCT05239260|Diagnostic Test|CMR|CMR
79376165|NCT03399006|Device|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position & carried out for measurement of fetal CRL and diagnosis of any major fetal defects
79376166|NCT03399006|Device|Doppler Ultrasound|"measurement of UtA-PI & UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
79376167|NCT03399006|Device|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
79376168|NCT03392922|Device|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
79686026|NCT02895308|Behavioral|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
79828509|NCT05468372|Drug|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B [5 mg/kg/day infusion in 5% dextrose solution] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
79235106|NCT02316249|Drug|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
79235107|NCT02316249|Other|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
79235108|NCT03115268|Behavioral|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
79235109|NCT02307357|Behavioral|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
79376169|NCT03392922|Device|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
80002749|NCT04943549|Drug|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
80002750|NCT02070848|Other|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
80002751|NCT02070848|Other|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
80002752|NCT02070848|Other|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
80002753|NCT04790695|Drug|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
80002754|NCT02073110|Device|Percutaneous Optical Biopsy (OCT and DRS)|
80002755|NCT01356979|Procedure|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
80002756|NCT02073188|Device|iBGStar|
80002757|NCT02073188|Device|Traditional Glucometer|
80002758|NCT01319305|Device|FinESS Sinus Treatment|balloon sinuplasty
80002759|NCT02073266|Procedure|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
80002760|NCT02073344|Procedure|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
79235110|NCT02307435|Biological|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
79235111|NCT02696096|Other|FMRI|all participants will complete 2 FMRIs
79376170|NCT05056116|Drug|Surufatinib Toripalimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
79376171|NCT03126318|Drug|COR-001|Anti-inflammatory therapy
79376172|NCT03126318|Drug|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
79376173|NCT02520258|Other|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
79376174|NCT02520258|Other|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
79376175|NCT03392844|Other|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
80002761|NCT02073344|Other|no intervention|no renal replacement therapy
80002762|NCT04252105|Dietary Supplement|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
80002763|NCT02073422|Device|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
80002764|NCT02073422|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
80002765|NCT02073500|Other|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
80002766|NCT02073578|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
80002767|NCT02077322|Device|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
79235112|NCT02696096|Drug|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
79235113|NCT02316327|Drug|gemcitabine, cisplatin and bevacizumab|Therapeutic
80002768|NCT02077322|Device|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
80002769|NCT02077400|Drug|Cephazolin|Cephazolin
80002770|NCT01362283|Other|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
79235114|NCT04480346|Behavioral|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
79235115|NCT03132441|Other|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
79235116|NCT03503721|Procedure|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
79235117|NCT03503721|Procedure|bipolarTURP|the prostate will transurethrally resected using a bipolar current
79235118|NCT02316405|Other|Arm and Leg Cycling Exercise for Walking after Stroke|
79235119|NCT02392364|Drug|Intravitreal Aflibercept Injection|
79391111|NCT02421042|Drug|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
79391112|NCT02986295|Device|BioMimeTM Stent, Ultimaster® Stent|
80002771|NCT02077478|Device|Remifentanil and propofol administration using TCI|
80002772|NCT02077478|Device|Remifentanil and propofol administration using MCI|
80002773|NCT02077556|Drug|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
80002774|NCT02077556|Drug|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)
80002775|NCT02077556|Drug|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
80002776|NCT02077556|Drug|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
80002777|NCT02077556|Drug|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
80002778|NCT02930941|Drug|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
80002779|NCT02930941|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
80002780|NCT02077634|Drug|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
80002781|NCT02077634|Drug|abiraterone acetate + prednisone|ormon therapy will be stopped
80002782|NCT01349309|Behavioral|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
80002783|NCT01365403|Drug|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
79235120|NCT02392676|Drug|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
79235121|NCT02392676|Drug|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
79235122|NCT03503487|Other|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
79376176|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
79376177|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
79376178|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
79376179|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
80002784|NCT01365403|Drug|carbamazepine|multiple oral doses, Days 1-24 of study period 2
80002785|NCT01352663|Biological|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
80002786|NCT01352663|Biological|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
80002787|NCT01362361|Drug|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
80002788|NCT01362361|Drug|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
80002789|NCT02077712|Drug|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
80002790|NCT04949789|Other|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
80002791|NCT04949789|Other|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
80002792|NCT04949789|Other|IP I|2 Capsules to be taken 30 minutes before breakfast.
80002793|NCT04949789|Other|IP II|2 Capsules to be taken 30 minutes before breakfast.
80002794|NCT04949789|Other|IP III|2 Capsules to be taken 30 minutes before breakfast.
80002795|NCT05191771|Device|Neovis Total Multi|1 drop in each eye, 4 times per day
80002796|NCT05191771|Device|Systane Balance|1 drop in each eye, 4 times per day
80002797|NCT02073734|Drug|Dexamethasone|Dexamethasone 8mg/IV
80002798|NCT02073734|Drug|Placebo|Placebo given IV
80002799|NCT01365559|Drug|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
79686027|NCT02895308|Behavioral|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
80002800|NCT01365559|Drug|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
80002801|NCT03137537|Drug|Ivabradine|lower heart rate in heart failure patients.
80002802|NCT03137537|Drug|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
80002803|NCT02071004|Drug|DS-1040b|IV of 6 mg given once over 30 minutes
80002804|NCT02071004|Drug|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
80002805|NCT02077790|Device|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
80002806|NCT05187559|Other|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
80002807|NCT05187559|Device|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
80002808|NCT03137459|Behavioral|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
79235123|NCT03167996|Behavioral|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
79235124|NCT03507075|Behavioral|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
79235125|NCT03507075|Behavioral|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
79235126|NCT03106298|Drug|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
79376180|NCT05238402|Drug|Statin|Statin on COVID 19 patienst
79376181|NCT03395106|Behavioral|Parent source|Having a parent feature prominently in a news story
79376182|NCT03395106|Behavioral|Doctor source|Having a doctor feature prominently in a news story
79376183|NCT03395106|Behavioral|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
79376184|NCT03395106|Behavioral|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
79376185|NCT03395028|Drug|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
79686028|NCT00550797|Biological|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
79686029|NCT00550797|Biological|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
79686030|NCT02895113|Drug|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
80002809|NCT03137459|Other|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
80002810|NCT02071160|Drug|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
80002811|NCT01362673|Drug|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
80002812|NCT01362673|Drug|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
79235127|NCT02316561|Radiation|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
79828510|NCT05468281|Other|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
80002813|NCT01362673|Drug|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
79828511|NCT05465083|Device|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
80002814|NCT01362673|Drug|Placebo|Oral single dose as matching placebo
80002815|NCT01362673|Drug|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
79828512|NCT05462873|Biological|QEQ278|Intravenous dosing of QEQ278
80002816|NCT01362673|Drug|Placebo|Oral multiple doses as matching placebo for 12 days
80002817|NCT02077868|Other|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
80002818|NCT02077868|Drug|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
80002819|NCT01360957|Dietary Supplement|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
80002820|NCT04912583|Device|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
80002821|NCT04912583|Device|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
80002822|NCT03131713|Drug|Acetaminophen|Acetaminophen 1000mg
80002823|NCT03534011|Procedure|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
79235128|NCT02398292|Other|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
79376186|NCT03394950|Drug|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
79235129|NCT02398292|Other|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
79376187|NCT03394950|Drug|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
79376188|NCT01473160|Device|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
79376189|NCT01473160|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
79376190|NCT03394872|Procedure|Drainage of the pleural effusion|
79828513|NCT05461859|Procedure|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
80002824|NCT03534011|Device|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
80002825|NCT01361035|Other|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
79376191|NCT03392766|Device|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
79376192|NCT03392766|Device|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
79376193|NCT03392688|Other|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
79686031|NCT02895113|Other|Placebo|Patients in this arm will be treated with placebo
79686032|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
79686033|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
79686034|NCT02895386|Device|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
79686035|NCT02895386|Other|Sham procedure|Sham procedure + continuing current antihypertensive medications.
79686036|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
79376194|NCT03392688|Diagnostic Test|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
79376195|NCT03392688|Other|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
79376196|NCT04586634|Device|Peristeen cone catheter|The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
79686037|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
79686038|NCT00550875|Biological|placebo|Sublingual. 2 drops/daily 2 years
79828514|NCT05453682|Radiation|hypo-IMRT|Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
80002826|NCT04894799|Other|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
79302631|NCT03202771|Other|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
80002827|NCT04894799|Other|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
80002828|NCT05191693|Procedure|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
80002829|NCT02073812|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
80002830|NCT03514121|Biological|FPA150|A monoclonal antibody against B7-H4
79376197|NCT04567992|Procedure|superficial cervical plexus block|ultrasound guided injection of local anaesthesia in the superficial cervical plexus
79376198|NCT01335724|Drug|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
79376199|NCT01335724|Drug|Placebo gel|Placebo gel
79376200|NCT01476202|Drug|nicotine|nicotine in the form of a mouth strip, lozenge and gum
79376201|NCT01539694|Device|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
79529860|NCT01415479|Behavioral|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
79828515|NCT05453084|Behavioral|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
79828516|NCT05452720|Device|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
80002831|NCT03514121|Biological|Pembrolizumab|An anti-PD1 antibody
80002832|NCT02930005|Drug|Meclofenamic acid|
80002833|NCT02930005|Drug|Pentosan polysulfate sodium|
80002834|NCT02074046|Biological|cancer stem cell vaccine|
80002835|NCT02071238|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
80002836|NCT02071238|Behavioral|Group Consultation|Informed consent discussion in group-format
80002837|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
80002838|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
79376202|NCT01539694|Device|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
79376203|NCT01476748|Device|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
79376204|NCT01477450|Device|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
79376205|NCT01477450|Device|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
79686039|NCT02894996|Drug|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
79686040|NCT00552630|Device|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
79686041|NCT00552630|Drug|placebo|placebo with same characteristics as drug
79376206|NCT01477762|Drug|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
79376207|NCT01477762|Drug|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
79529861|NCT01415479|Behavioral|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
80002839|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
80002840|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
80002841|NCT01349387|Drug|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
79235130|NCT02307591|Drug|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
79235131|NCT02307591|Drug|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~Children < 29 kg: 5 mg/kg 3 times a day"
80002842|NCT01365715|Procedure|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
80002843|NCT01365715|Procedure|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
79235132|NCT02316639|Other|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
79235133|NCT02397980|Behavioral|Behavioral intervention|"What the dementia is~How to deal with behavioral problems in patients with dementia~How to manage caregiver's stress~How to care dementic patients as well as caregivers themselves"
80002844|NCT04913441|Other|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
79235134|NCT03506997|Drug|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
80002845|NCT04913441|Other|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
79391113|NCT02416596|Procedure|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
79686042|NCT02894957|Drug|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
80002846|NCT04913441|Other|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
80002847|NCT01361191|Drug|R-MEGACHOP|"If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
79686043|NCT02894879|Device|BreatheMAX®|"Modify chest physical therapy~oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
80016713|NCT02740127|Procedure|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
80016714|NCT02740127|Drug|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
80016715|NCT02740127|Drug|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
79686044|NCT02894879|Other|Routine treatment|"Routine chest physical therapy~Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
79828517|NCT05451784|Drug|PD1+ TILs (NUMARZU-001) product infusion|"The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction)."
79828518|NCT05444270|Other|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
80002848|NCT03499613|Other|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
80002849|NCT04905173|Other|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
80002850|NCT04905173|Drug|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
80002851|NCT04905173|Other|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
80002852|NCT01362751|Other|No intervention|This study is an observational cohort study > no interventions
80002853|NCT01361269|Drug|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
80002854|NCT01357187|Other|Scheduled removal of posterior instrumentation with AmnioFix|
80002855|NCT01357187|Other|Scheduled removal of posterior instrumentation without AmnioFix|
79235135|NCT02398136|Drug|Ketamine|
79235136|NCT02398136|Drug|Midazolam|
80002856|NCT01362829|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
79686045|NCT00550992|Biological|anti-thymocyte globulin|
79235137|NCT03503253|Device|Interlock-35 Fibered IDC Occlusion System|Use of detachable coil for LAA leak closure
79235138|NCT03503253|Device|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
79235139|NCT03503253|Device|Azur Peripheral Coil System|Use of detachable coil for LAA leak closure
79686046|NCT00550992|Drug|asparaginase|
79686047|NCT00550992|Drug|busulfan|
79686048|NCT00550992|Drug|cyclophosphamide|
79686049|NCT00550992|Drug|cyclosporine|
79686050|NCT00550992|Drug|cytarabine|
79686051|NCT00550992|Drug|daunorubicin hydrochloride|
79686052|NCT00550992|Drug|etoposide|
79686053|NCT00550992|Drug|leucovorin calcium|
80002857|NCT01349543|Biological|RSV A Memphis 37|Intranasal administration
80002858|NCT01353209|Drug|Letrozole|2.5 mg daily for twelve months
80002859|NCT01353209|Drug|Placebo|sugar pill given daily for twelve months
80002860|NCT03637491|Drug|Avelumab|IV treatment
80002861|NCT03637491|Drug|Binimetinib|Oral treatment
80002862|NCT03637491|Drug|Talazoparib|Oral treatment
80002863|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
80002864|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
79235140|NCT05745584|Drug|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
79686054|NCT00550992|Drug|melphalan|
79686055|NCT00550992|Drug|mercaptopurine|
79686056|NCT00550992|Drug|methotrexate|
79686057|NCT00550992|Drug|mitoxantrone hydrochloride|
79686058|NCT00550992|Drug|pegaspargase|
79686059|NCT00550992|Drug|prednisolone|
79686060|NCT00550992|Drug|prednisone|
79686061|NCT00550992|Drug|therapeutic hydrocortisone|
79686062|NCT00550992|Drug|thioguanine|
79686063|NCT00550992|Drug|vincristine sulfate|
79686064|NCT00550992|Procedure|allogeneic bone marrow transplantation|
79686065|NCT00550992|Procedure|allogeneic hematopoietic stem cell transplantation|
79686066|NCT00550992|Procedure|umbilical cord blood transplantation|
79235141|NCT02312661|Drug|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
79235142|NCT02312661|Drug|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
79235143|NCT02312661|Drug|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
79235144|NCT05745506|Other||Not applicable, there is no intervention description in this study.
79235145|NCT03501771|Other|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
79828519|NCT05444270|Radiation|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
79828520|NCT05443529|Other|Adaptive sports|Participation in community adaptive sports programs
79828521|NCT05443061|Drug|Nitroglycerin|Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
80002865|NCT01357265|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
79235146|NCT02397902|Dietary Supplement|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
79235147|NCT02397902|Dietary Supplement|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
79235148|NCT02307669|Behavioral|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
79529862|NCT01415479|Behavioral|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
79235149|NCT02307669|Behavioral|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
79529863|NCT01415492|Behavioral|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
79529864|NCT01415492|Behavioral|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
79529865|NCT01415505|Drug|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
80002866|NCT04550455|Drug|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
80002867|NCT03713463|Other|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
80002868|NCT01363141|Other|Regular AGE Diet|Regular AGE Diet
80002869|NCT01363141|Other|Low AGE Diet|One year reduction in dietary AGE intake.
79235150|NCT02398058|Drug|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
79529866|NCT01415557|Other|Non-Fortified Control Product|Non-Fortified Control Beverage
79529867|NCT01415557|Other|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
79529868|NCT01415596|Drug|salbutamol|
79686067|NCT02895074|Procedure|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
79686068|NCT02895074|Procedure|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
79686069|NCT02895074|Drug|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
79828522|NCT05443061|Drug|Normal saline|Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
79828523|NCT05440149|Radiation|No PMRT for mastectomy / No regional RT for BCS|"Regional RT includes high-tangent field, and can include undissected axilla.~The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
80002870|NCT03675243|Diagnostic Test|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
79235151|NCT02398058|Drug|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
79529869|NCT01415596|Drug|Placebo|
79529870|NCT01415622|Device|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
80002871|NCT01349699|Drug|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
80002872|NCT01349699|Drug|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
79828524|NCT05440149|Radiation|PMRT for mastectomy / WBI + Regional RT for BCS|"Regional RT includes high-tangent field, and can include undissected axilla.~The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
79828525|NCT05439564|Drug|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
79828526|NCT05439564|Drug|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
79828527|NCT05439564|Drug|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
79828528|NCT05438875|Drug|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
79828529|NCT05438875|Drug|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
79828530|NCT05435833|Procedure|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
80002873|NCT01349699|Drug|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
80002874|NCT01349699|Drug|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
79235152|NCT03503175|Device|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
79235153|NCT03503175|Device|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
79235154|NCT03501615|Drug|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
79376208|NCT01478854|Radiation|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
79376209|NCT01478854|Drug|Chemotherapy|Temozolomide
79529871|NCT01415622|Procedure|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
79529872|NCT01415635|Dietary Supplement|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
79529873|NCT01415661|Other|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
79686070|NCT02895074|Drug|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
80016716|NCT02740127|Drug|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
79302632|NCT02483741|Biological|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
79376210|NCT01434472|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
79376211|NCT01434472|Drug|Cyclosporine|Given PO
79376212|NCT01434472|Drug|Fludarabine Phosphate|Given IV
79376213|NCT01434472|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
79686071|NCT02894918|Drug|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
79686072|NCT00551109|Drug|placebo|placebo, oral administration, once daily for 8 weeks
79686073|NCT00551109|Drug|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
79686074|NCT00551109|Drug|SA4503 High|High dose, oral administration, once daily for 8 weeks
79686075|NCT02894723|Dietary Supplement|L-arginine|30 ml arginoline contains 5 gr l-arginine
79686076|NCT02894723|Dietary Supplement|syrup|The same bottle of the experimental group, but without l-arginine
79686077|NCT00551187|Biological|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
79686078|NCT00551187|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
79686079|NCT00551187|Biological|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
79686080|NCT02894528|Drug|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
80016717|NCT02740127|Drug|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
80016718|NCT02740127|Drug|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
79376214|NCT01434472|Drug|Mycophenolate Mofetil|Given PO
79686081|NCT02894528|Drug|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
79686082|NCT02894450|Other|blood test|bioassay xaban
79686083|NCT00551265|Drug|Cyclophosphamide|Given IV
79235155|NCT02312817|Other|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
80002875|NCT01370161|Procedure|TIPS treatment|"A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
80002876|NCT01370161|Drug|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
80002877|NCT01370239|Biological|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
80002878|NCT01801709|Genetic|intracerebral administration of AAVrh.10cuARSA|
80002879|NCT03628443|Diagnostic Test|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
79235156|NCT02312817|Other|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
79376215|NCT01434472|Other|Pharmacological Study|Correlative studies
79376216|NCT01434472|Biological|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
80002880|NCT05191069|Other|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
80002881|NCT05191069|Other|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
80002882|NCT01353443|Procedure|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
80002883|NCT03628365|Dietary Supplement|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
79686084|NCT00551265|Procedure|Laboratory Biomarker Analysis|Correlative studies
79686085|NCT00551265|Biological|Oregovomab|Given IV
79686086|NCT02894489|Device|corneal lenses|wear corneal lenses on daily basis
79686087|NCT02894489|Device|large diameter lenses|
79686088|NCT00551304|Device|Ardian Catheter|
80002884|NCT01365871|Procedure|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
79376217|NCT01434472|Radiation|Total-Body Irradiation|Undergo TBI
79376218|NCT01434472|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
79376219|NCT01434472|Drug|Fludarabine|Given IV
79376220|NCT01435174|Drug|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
79376221|NCT01435174|Procedure|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
80002885|NCT03040661|Procedure|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
80002886|NCT05683587|Other|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
79376222|NCT01435174|Procedure|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
79686089|NCT02894606|Drug|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
79686090|NCT02894606|Drug|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
80002887|NCT01349777|Drug|Pregrel®|Pregrel® 75mg daily for 12 months
80002888|NCT01349777|Drug|Plavix®|Plavix® 75mg daily for 12 months
80002889|NCT04240925|Device|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
79376223|NCT01436266|Drug|Misoprostol|400 mcg buccally 2 hours prior to procedure
79376224|NCT01436266|Other|Folic acid|2mg buccally 2 hours prior to procedure
79376225|NCT01542502|Drug|Anakinra|Anakinra 100 mg daily subcutaneous injection
79376226|NCT01542502|Drug|Placebo|Placebo daily subcutaneous injection
79376227|NCT01439620|Device|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
79376228|NCT01439854|Drug|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
80002890|NCT04240925|Device|Standard NIMV|Will be treated by standard NIMV with no sigh
80002891|NCT04700007|Drug|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
80002892|NCT04700007|Drug|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
80002893|NCT04700007|Drug|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
80002894|NCT04700007|Drug|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
80002895|NCT04700007|Drug|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
79235157|NCT02693834|Device|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
79235158|NCT02693834|Device|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
79376229|NCT01439854|Drug|Placebo|Patients are treated with placebo
80002896|NCT01349855|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
80002897|NCT01318655|Drug|NKTR-118|Tablet, Oral, Once daily
79235159|NCT02312895|Other|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
79376230|NCT01479478|Drug|Placebo|One placebo capsule daily.
79376231|NCT01479478|Dietary Supplement|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
79376232|NCT04409262|Drug|Remdesivir|Participants will receive intravenous (IV) RDV
80002898|NCT01318655|Drug|Placebo|Tablet, Oral, Once daily
79235160|NCT02312895|Other|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
79376233|NCT04409262|Drug|Tocilizumab|Participants will receive IV TCZ
79376234|NCT04409262|Drug|Placebo|Participants will receive IV placebo matched to TCZ
79376235|NCT01481740|Drug|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
79686091|NCT02894567|Device|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
79686092|NCT00551343|Drug|Exenatide|10ug Exenatide single s.c. injection
79235161|NCT02312895|Other|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
80002899|NCT04654533|Other|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, & Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
80002900|NCT04317521|Device|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
79235162|NCT02312973|Drug|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
79376236|NCT01481740|Drug|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
79376237|NCT01544062|Drug|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
79376238|NCT01544062|Drug|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
79235163|NCT02312973|Drug|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
79376239|NCT04331964|Procedure|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
79376240|NCT03392454|Procedure|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
79376241|NCT03392454|Procedure|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
79828531|NCT05427123|Other|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
79828532|NCT05425485|Behavioral|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
80002901|NCT03430869|Drug|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
80002902|NCT03430869|Drug|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
80002903|NCT01350011|Behavioral|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
80002904|NCT01350011|Behavioral|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
80002905|NCT01357343|Other|Chiropractic|Spinal manipulation and active and passive therapy.
79529874|NCT01415687|Drug|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
79529875|NCT01415687|Drug|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
79828533|NCT05424237|Behavioral|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
80002906|NCT01357343|Other|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
80002907|NCT01353599|Drug|Mometasone furoate|220mcg once daily, for eight weeks
80002908|NCT01733147|Drug|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
80002909|NCT01733147|Drug|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
80002910|NCT03334539|Biological|HL036 ophthalmic solution|HL036 ophthalmic solution
80002911|NCT03334539|Other|Placebo vehicle solution|Placebo vehicle solution
80002912|NCT04308707|Other|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
79235164|NCT03506919|Drug|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
79376242|NCT03126084|Drug|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
80002913|NCT01350089|Drug|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
79376243|NCT03126084|Drug|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
79376244|NCT03126084|Drug|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
79376245|NCT03126084|Drug|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
79376246|NCT03126084|Procedure|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
79376247|NCT03126084|Drug|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
79376248|NCT03126396|Device|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
80002914|NCT01350089|Drug|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
80002915|NCT01350089|Drug|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
80002916|NCT01350089|Drug|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
79828534|NCT05422820|Diagnostic Test|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (>150-400 or >400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
79828535|NCT05421858|Drug|PF-07842805|PF-07842805 (IV infusion)
80002917|NCT01357421|Drug|TT301|Single iv dose of TT301
80002918|NCT01357421|Drug|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
80002919|NCT01350167|Procedure|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
79376249|NCT03126006|Procedure|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
79235165|NCT04871048|Device|Transcranial direct current stimulation (tDCS) active|Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.
79376250|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
79376251|NCT01483378|Other|Choosing to receive the vaccine|
79376252|NCT03392298|Drug|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
79376253|NCT01440634|Other|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
79529876|NCT01415700|Device|Functional electrical stimulator|The stimulator is surgically implanted
79529877|NCT01415700|Device|feet orthosis|feet orthosis specifically mold
80002920|NCT03296553|Drug|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
80002921|NCT03296553|Drug|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
80002922|NCT03131167|Drug|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
80002923|NCT03131167|Drug|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
80002924|NCT01365949|Genetic|microarray analysis|
80002925|NCT01365949|Genetic|protein analysis|
80002926|NCT01365949|Other|immunohistochemistry staining method|
80002927|NCT01365949|Other|laboratory biomarker analysis|
80002928|NCT01370551|Drug|Gynoflor|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
80002929|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
80002930|NCT01363375|Procedure|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
80002931|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
80002932|NCT01370707|Drug|Metformin|1000~1500mg/day, 24weeks
79235166|NCT04871048|Device|Transcranial direct current stimulation (tDCS) non active|The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
79235167|NCT02545504|Drug|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
79376254|NCT03392220|Procedure|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
79376255|NCT03392220|Procedure|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
79376256|NCT03008356|Dietary Supplement|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
79376257|NCT03008356|Behavioral|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
79529878|NCT01415713|Drug|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
79828536|NCT05421858|Drug|Caspofungin|Caspofungin (IV infusion)
79828537|NCT05421858|Drug|PF-07842805|PF-07842805 oral tablet
79828538|NCT05421858|Drug|Fluconazole|Fluconazole oral capsule
80002933|NCT01370707|Drug|CJ-30001/CJ-30002|0.6/1500mg~0.9/1500mg/day, 24weeks
80002934|NCT04336735|Other|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
80002935|NCT01363531|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
79828539|NCT05421858|Drug|Placebo|Matching placebo (IV infusion)
79828540|NCT05421858|Drug|Placebo|Matching placebo (tablet or capsule)
79828541|NCT05421611|Biological|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
79828542|NCT05421611|Biological|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
79828543|NCT05418816|Device|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
79828544|NCT05417711|Device|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
79828545|NCT05417711|Device|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
80002936|NCT01366105|Device|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
80002937|NCT01363609|Drug|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
80002938|NCT01363609|Drug|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
80002939|NCT01363609|Drug|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
79235168|NCT02545504|Drug|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
80002940|NCT01363687|Device|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
80002941|NCT03060447|Drug|Vesatolimod|Tablets Administered orally
80002942|NCT03060447|Drug|Placebo|Tablets Administered orally
80002943|NCT03060447|Drug|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
79235169|NCT02545504|Drug|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
79235170|NCT02545504|Drug|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
79235171|NCT02545504|Drug|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
79235172|NCT03506841|Drug|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
79235173|NCT02316795|Procedure|Sentinel lymph node biopsy|
79235174|NCT02316795|Device|Goggle-based device with light-emitting diodes (LED)|
79235175|NCT02316795|Drug|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
79376258|NCT03008356|Dietary Supplement|Placebo capsules|
79376259|NCT04305912|Device|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses.
79235176|NCT02397512|Drug|application of lactulose|Subjects will ingest 50g of lactulose once
79376260|NCT04305912|Device|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses.
79376261|NCT01544998|Drug|Nesiritide|10 ug/kg
79376262|NCT01544998|Drug|Tadalafil|5 mg
79376263|NCT01544998|Drug|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
79376264|NCT01544998|Drug|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
80002944|NCT04623567|Drug|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
80002945|NCT04623567|Drug|Metformin|The metformin tablets (500mg) will be administrated.
80002946|NCT01712789|Drug|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
80002947|NCT01712789|Drug|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
80002948|NCT01357499|Device|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
79376265|NCT03391830|Drug|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
79376266|NCT03391830|Drug|Placebo|Placebo
79235177|NCT02397512|Other|application of sucrose|Subjects will ingest 50g of sucrose once
79235178|NCT02313051|Drug|Everolimus|mTOR inhibitor
79376267|NCT04033770|Other|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
79376268|NCT04033770|Other|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
79376269|NCT01441492|Procedure|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
79376270|NCT01441492|Procedure|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
79529879|NCT01415726|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 ~ 7 hrs.
79529880|NCT01415739|Other|laboratory biomarker analysis|Correlative studies
79529881|NCT01415765|Drug|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
79529882|NCT01415765|Drug|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
79686093|NCT00551382|Drug|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
79686094|NCT00551382|Drug|Placebo|Look alike tablets or granules 1 per day for 12 weeks
79686095|NCT02894684|Drug|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
80002949|NCT01357499|Device|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
80002950|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
80002951|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
80002952|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
80002953|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)
80002954|NCT03387449|Device|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
79686096|NCT02894684|Drug|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
79235179|NCT02313051|Drug|Goserelin|
79235180|NCT02313051|Drug|Letrozole|
79235181|NCT03501537|Procedure|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
79235182|NCT02397590|Drug|Fimasartan|
79235183|NCT02397590|Drug|Atorvastatin|
79302633|NCT03072303|Other|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
79376271|NCT01441570|Drug|Nebivolol|Subject will take nebivolol daily for 12 weeks.
79376272|NCT01441570|Drug|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
79376273|NCT03394794|Device|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
79376274|NCT05238012|Drug|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
79376275|NCT05238012|Drug|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
79376276|NCT01441882|Drug|Dasatinib|Given PO
79376277|NCT01441882|Other|Laboratory Biomarker Analysis|Correlative studies
79376278|NCT01441882|Other|Pharmacological Study|Correlative studies
79376279|NCT03394716|Radiation|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
79529883|NCT01415765|Drug|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
79376280|NCT05237856|Device|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
79235184|NCT05745116|Device|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
79235185|NCT02545270|Procedure|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
79235186|NCT02545270|Procedure|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
80002955|NCT01350557|Other|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
79235187|NCT02545270|Procedure|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
79235188|NCT02397356|Drug|Ketamine first AB|Nebulised ketamine 1mg/kg
79235189|NCT02397356|Drug|Placebo first BA|Nebulised saline 1-2ml
79235190|NCT02316873|Behavioral|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
79235191|NCT02316873|Behavioral|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
79235192|NCT05453344|Device|DexCom one|Provision of DexCom One for glucose monitoring
79376281|NCT01484626|Drug|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
80002956|NCT01350557|Other|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
80002957|NCT04565379|Drug|NuSepin® 0.1 mg|NuSepin® 0.1 mg
79302634|NCT05714111|Other|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
79376282|NCT04446936|Procedure|Flap covering for pressure ulcer|Flap covering for pressure ulcer
79376283|NCT03394638|Other|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
79376284|NCT03394638|Other|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
79529884|NCT01415765|Drug|Vincristine|CIV on days 1-4 of every 21 day cycle
79686097|NCT02894645|Drug|Prednisolone|Oral
79686098|NCT02894645|Drug|Dexamethasone|Oral
79686099|NCT02894645|Drug|L-Asparaginase|Intramuscular injection
79686100|NCT02894645|Drug|Vincristine|Intravenous
79686101|NCT02894645|Drug|Methotrexate|Intrathecal/ Intravenous/ Oral
80002958|NCT04565379|Drug|NuSepin® 0.2 mg|NuSepin® 0.2 mg
79686102|NCT02894645|Drug|Daunorubicin|Intravenous
79686103|NCT02894645|Drug|Doxorubicin|Intravenous
80002959|NCT04565379|Drug|Placebo|Normal Saline
80002960|NCT03074318|Drug|Avelumab|Given IV
80002961|NCT03074318|Drug|Trabectedin|Given IV
79376285|NCT03394638|Procedure|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
79391114|NCT02416596|Device|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
79391115|NCT04767815|Drug|Diet A group|Fasting + DWN12088 200 mg
79391116|NCT04767815|Drug|Diet B group|30 minutes after a high-fat meal + DWN12088 200 mg
79529885|NCT01415765|Drug|Cyclophosphamide|IV on day 5 of each 21 day cycle
79529886|NCT01415765|Drug|Doxorubicin|CIV on days 1-4 of each 21 day cycle
79529887|NCT01415765|Drug|Rituximab|IV on day 1 of each 21 day cycle
79529888|NCT01415765|Drug|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
79529889|NCT01415778|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
79686104|NCT02894645|Drug|Cyclophosphamide|Intravenous
79686105|NCT02894645|Drug|Cytarabine|Intravenous/ Subcutaneous injection
79686106|NCT02894645|Drug|6-Mercaptopurine|Oral
79686107|NCT02894645|Drug|Thioguanine|Oral
79686108|NCT02894645|Drug|Fludarabine|Intravenous
80002962|NCT02071316|Drug|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
79235193|NCT02317029|Device|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
79529890|NCT01415778|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
79686109|NCT02894645|Drug|Imatinib|Oral (For BCR-ABL ALL only)
79828546|NCT05417360|Dietary Supplement|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
80002963|NCT02071316|Drug|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
80002964|NCT03318224|Other|none (observational study)|only assessments via questionnaires, no interventions
80002965|NCT02071472|Other|DP medication reconciliation|
80002966|NCT02071550|Device|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
80002967|NCT02071550|Device|FORESIGHT and INVOS monitor|
80002968|NCT02074202|Drug|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
80002969|NCT02074202|Drug|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
80002970|NCT02074280|Drug|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
79235194|NCT02317029|Procedure|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
79302635|NCT01374919|Drug|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
79376286|NCT03394560|Device|High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
79391117|NCT04767815|Drug|Diet C group|2 hours after a high-fat meal + DWN12088 200 mg
79391118|NCT03181776|Other|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
79391119|NCT03181776|Other|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
79391120|NCT03181776|Other|supine position|The mother will be placed in standard supine position
79529891|NCT01415791|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
79529892|NCT01415804|Device|endoprosthesis|Thoracic aortic stentgraft
79529893|NCT01415830|Biological|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
79529894|NCT01415830|Biological|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
79686110|NCT02894372|Device|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
79686111|NCT02894372|Device|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
79686112|NCT00552747|Drug|fenofibrate|fenofibrate 160 mg capsules qd
79686113|NCT00552747|Drug|placebo|capsules placebo
79686114|NCT00004553|Procedure|Electromyography|
79828547|NCT05417360|Dietary Supplement|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
79828548|NCT05416385|Other|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
80002971|NCT02074592|Behavioral|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
80002972|NCT02074592|Behavioral|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
80002973|NCT02074670|Other|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
80002974|NCT02077946|Drug|liraglutide|No treatment given.
79529895|NCT01415856|Device|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
79529896|NCT01415856|Device|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
79529897|NCT01415895|Drug|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
79529898|NCT01415895|Drug|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
80002975|NCT02077946|Drug|sitagliptin|No treatment given.
80002976|NCT02078024|Drug|IVM plus ALB|
80002977|NCT02078024|Drug|IVM|
80002978|NCT03559790|Drug|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
80002979|NCT02079896|Drug|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
80002980|NCT02079896|Drug|Placebo|
79686115|NCT00551499|Device|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
79828549|NCT05403944|Behavioral|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
80002981|NCT02079974|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months
80002982|NCT03559556|Other|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
79828550|NCT05403944|Behavioral|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
80002983|NCT01353755|Drug|Grass pollen specific immunotherapy|"Strength 1 (0.78μg/mL)~Strength 2 (6.25μg/mL)~Strength 3 (50μg/mL)~Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
80002984|NCT01353755|Drug|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
79235195|NCT02317029|Device|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
79235196|NCT02317029|Procedure|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
79235197|NCT05453110|Behavioral|Deadlift Form Education|The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
79235198|NCT02307825|Drug|Azithromycin|The drug will be taken three times a week for four months.
79529899|NCT01415947|Device|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
79529900|NCT01415973|Dietary Supplement|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
79529901|NCT01415973|Dietary Supplement|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
79529902|NCT01416012|Behavioral|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
79686116|NCT02277327|Behavioral|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
79686117|NCT02277327|Behavioral|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
79686118|NCT05428124|Other|In vitro fertilisation|In vitro fertilisation
80002985|NCT02080052|Device|Robot-assisted prostate biopsy|
79686119|NCT05427851|Procedure|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
79686120|NCT05427851|Device|Diode laser - fonalaser|diode laser beam application
80002986|NCT03135119|Behavioral|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
80002987|NCT03135119|Behavioral|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
80002988|NCT02078258|Behavioral|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
80002989|NCT01317953|Dietary Supplement|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
80002990|NCT02078336|Drug|Midazolam Mylan|
80002991|NCT02078336|Drug|Lorazepam Mylan|
79235199|NCT02307825|Drug|Placebo|The placebo will be taken three times a week for four months.
79235200|NCT02540668|Drug|Lanabecestat|Administered orally
79235201|NCT02540668|Drug|Warfarin|Administered orally
79235202|NCT03506763|Drug|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
79235203|NCT03506763|Drug|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
79235204|NCT03506763|Drug|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
79235205|NCT02441439|Dietary Supplement|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
79235206|NCT02441439|Dietary Supplement|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
79235207|NCT02669992|Procedure|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
80002992|NCT02078336|Drug|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
79235208|NCT02669992|Procedure|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
79235209|NCT05475652|Other|Manual therapy|The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
80002993|NCT01353833|Drug|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
79302636|NCT03072381|Biological|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
79376287|NCT03394560|Device|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
79376288|NCT03394482|Drug|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
79376289|NCT03394482|Drug|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
79529903|NCT01416012|Behavioral|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
80002994|NCT01350635|Biological|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
80002995|NCT02080130|Dietary Supplement|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
80002996|NCT02080130|Dietary Supplement|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
80002997|NCT02080130|Other|Placebo|Placebo
80002998|NCT03366779|Device|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
80002999|NCT03559478|Procedure|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
79376290|NCT03394482|Drug|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
79529904|NCT01416012|Behavioral|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
80003000|NCT03559478|Procedure|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
80003001|NCT03355001|Device|Monosyn® Quick|"Mucosal sutures in the facial and oral~Dermal sutures, particularly in pediatrics~Episiotomy~Circumcision"
80003002|NCT03353675|Biological|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
80003003|NCT03353675|Drug|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
80003004|NCT03353675|Drug|Nivolumab|360 mg IV administration every 3 weeks
80003005|NCT02075060|Procedure|IPOI (pre-operative)|
80003006|NCT02075060|Procedure|IPOP (post-operative)|
80003007|NCT01350713|Drug|povidone iodine|one local application of 10% povidone iodine ointment
79376291|NCT03394482|Drug|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
79376292|NCT03394482|Drug|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
79376293|NCT03394482|Drug|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
79376294|NCT01545232|Biological|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
79529905|NCT01416012|Behavioral|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
79529906|NCT01416038|Biological|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
79529907|NCT01416038|Drug|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
80003008|NCT02075216|Procedure|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
80003009|NCT02075216|Biological|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
80003010|NCT01318889|Drug|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
79686121|NCT04584333|Behavioral|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
80003011|NCT02075294|Drug|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
80003012|NCT02080208|Device|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
80003013|NCT01357967|Drug|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
79235210|NCT05475652|Other|Placebo intervention|"The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group"
79235211|NCT04463199|Other|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
79235212|NCT02307981|Other|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
79376295|NCT01545232|Biological|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
79376296|NCT03394404|Device|ECG-I mapping and PVI|ECG-I mapping and PVI
79376297|NCT05237778|Behavioral|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
79376298|NCT05237778|Behavioral|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
79376299|NCT05237700|Other|Patient positioning on operating table|The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
79376300|NCT01545700|Drug|Control-saline|Patients are randomized to receive saline 2 cc
79376301|NCT01545700|Drug|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
79529908|NCT01416051|Dietary Supplement|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
80003014|NCT01357967|Drug|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime"
80003015|NCT02075372|Other|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
80003016|NCT02870855|Drug|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
80003017|NCT02075450|Device|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
79235213|NCT02317185|Device|genex bone graft with bone graft|
79235214|NCT02317185|Other|autogenous bone graft|
79235215|NCT02308059|Other|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
79376302|NCT01545700|Drug|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
79376303|NCT01545700|Drug|Control saline|Patients are randomized to receive saline 2 cc
79376304|NCT01545700|Drug|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
79376305|NCT01545700|Drug|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
79376306|NCT02520336|Behavioral|Reminder|
79529909|NCT01416051|Other|Placebo|100% milk fat
79529910|NCT01416103|Other|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
79529911|NCT01416103|Other|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
79529912|NCT01416116|Drug|QUTENZA|topical
79529913|NCT01416116|Drug|Lidocaine|topical
79529914|NCT01416116|Drug|Tramadol|oral
79235216|NCT02308059|Other|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
79235217|NCT02308137|Drug|Domperidone|Simon-2-stage design for domperidone futility
79376307|NCT04006002|Other|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
79529915|NCT01416168|Other|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
79686122|NCT03455790|Diagnostic Test|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
79686123|NCT05427617|Drug|Control group|Physician chosen treatment
79376308|NCT01486810|Drug|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
80003018|NCT02075450|Other|Just in Time Video|CPR Just in Time training video administered before the simulation case
80003019|NCT02075528|Drug|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
80003020|NCT02075684|Procedure|Renal Biopsy|
80003021|NCT02075762|Procedure|Transbronchial biopsy|
80003022|NCT02075762|Procedure|Cryoprobe biopsy|
80003023|NCT02075762|Procedure|VATS biopsy|
80003024|NCT02078804|Procedure|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
80003025|NCT02080286|Behavioral|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
79376309|NCT01486810|Behavioral|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
79376310|NCT04446780|Procedure|Mediolateral episiotomy|Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
79376311|NCT04446546|Procedure|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
79376312|NCT01487668|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
79376313|NCT03398772|Behavioral|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
79235218|NCT02313363|Device|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
79235219|NCT03502863|Device|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
79376314|NCT04446624|Other|Music therapy intervention|Group psychotherapy with music intervention
79376315|NCT01443442|Drug|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
79529916|NCT01416207|Drug|Avonex|4 weekly injections of Avonex (IM)
79686124|NCT05427617|Drug|Case group|Druggable ctDNA alterations-guided therapy
79686125|NCT04581018|Other|Health supplements|28 days of health supplements (synbiotic), 4g daily
80003026|NCT02080286|Device|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
79235220|NCT03502863|Other|Manual Refraction|Manual refraction and ETDRS chart
79235221|NCT02397824|Other|Salivary and blood samples|
79235222|NCT03501459|Drug|Rituximab|
79235223|NCT02308293|Behavioral|High intensity exercise|3x30 seconds 'all out' sprints
79235224|NCT02308293|Behavioral|Lay down comfortably|rest
79235225|NCT02317263|Drug|testosterone|
79235226|NCT02317263|Drug|placebo gel|
79235227|NCT03506685|Other|Dry needling and STM|dry needling and soft tissue mobilization
79235228|NCT03502629|Biological|GB226|3mg/kg treat every 2 weeks
79376316|NCT01443442|Drug|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
79686126|NCT05427500|Drug|5 mL of 0.5% preservative-free bupivacaine|IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
79235229|NCT02317341|Drug|Ketamine|Single intravenous dose
79235230|NCT02317341|Drug|Placebo (saline)|Given intravenously over 40 minutes
79235231|NCT02317341|Drug|Ketamine|Single intravenous dose given over 40 minutes
79686127|NCT04564482|Radiation|CRT|50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
79686128|NCT04564482|Radiation|SCPRT|25 Gy in 5 Gy fractions over 5 working days
79686129|NCT04564482|Radiation|CROSS Protocol|41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
79686130|NCT04564482|Diagnostic Test|PD-L1 PET|10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
79686131|NCT04564404|Other|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
80003027|NCT02080286|Device|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
80003028|NCT02080442|Other|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
79235232|NCT02317341|Drug|Midazolam|Given intravenously over 40 minutes
79235233|NCT02317341|Drug|Midazolam(placebo)|Given intravenously over 40 minutes
80003029|NCT03137069|Drug|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
79235234|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
79235235|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
79686132|NCT03455751|Genetic|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
79235236|NCT02317419|Drug|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
79235237|NCT02317419|Drug|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
79235238|NCT02313441|Other|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
79235239|NCT02313519|Dietary Supplement|Probiotics|Probiotics are prepared in capsule form
79235240|NCT02313519|Dietary Supplement|Placebo|Glucose powder
79235241|NCT02308605|Device|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
80003030|NCT03137069|Drug|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
80003031|NCT02080520|Dietary Supplement|Nattokinase|
80003032|NCT02080520|Dietary Supplement|Placebo|
79235242|NCT03501225|Procedure|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
79235243|NCT03501225|Procedure|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
79235244|NCT02313753|Behavioral|CLASP|
79235245|NCT02313753|Behavioral|SAFE|
79235246|NCT05452330|Other|Connective tissue massage|Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
79235247|NCT05452330|Other|Classical massage|Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
79235248|NCT02317497|Other|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
80003033|NCT02080598|Behavioral|2 cigarettes in 15 minutes|
80003034|NCT01350869|Device|Xience|Patients with Xience
79235249|NCT02317497|Drug|Vasopressors to maintain normal blood pressure values, if needed|
79686133|NCT03455712|Behavioral|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
80003035|NCT01358045|Drug|Diclofenac|Application on the lesion 2 times a day 8 weeks.
80003036|NCT01358045|Drug|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
79235250|NCT02317497|Drug|Osmotherapeutics to lowr intracranial pressure, if needed|
80003037|NCT01358045|Drug|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
79376317|NCT03389646|Device|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
80003038|NCT02076230|Drug|[14C] TH-302 (Label 1)|[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
80003039|NCT02076230|Drug|[14C] TH-302 (Label 2)|[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
79235251|NCT02317497|Procedure|Endovascular stroke care to treat brain vessel occlusions, if needed|
79235252|NCT02317497|Procedure|Decompressive neurosurgery, if needed|
79235253|NCT02313831|Other|Interval training|Patients of this group will be submitted to an interval training program
79235254|NCT03501147|Other|Resistance training|15 minutes of resistance training during work every day
79376318|NCT01444924|Drug|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
79686134|NCT05427305|Drug|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
79686135|NCT05427305|Drug|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
79686136|NCT05427188|Behavioral|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
80003040|NCT02076230|Drug|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
79235255|NCT02314065|Behavioral|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
79235256|NCT02314065|Behavioral|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
79235257|NCT02314221|Device|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
79235258|NCT02308683|Dietary Supplement|Moringa oleifera|12 weeks supplementation
79235259|NCT03943888|Drug|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
79376319|NCT01444924|Drug|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
79391121|NCT03179046|Diagnostic Test|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
79391122|NCT03181464|Drug|Lidocaine 4%|lidocaine solution
79391123|NCT03181464|Drug|Placebo|saline .9% injection
80003041|NCT03559712|Other|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
80003042|NCT02080754|Other|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
80003043|NCT02080754|Other|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
80003044|NCT01354067|Behavioral|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
79235260|NCT03943888|Drug|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
79235261|NCT03943888|Drug|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
79235262|NCT03943888|Drug|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
79686137|NCT05427188|Behavioral|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
79828551|NCT05400603|Combination Product|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10^7 and then 3 x 10^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
79828552|NCT05397496|Biological|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
79376320|NCT03389568|Behavioral|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
79235263|NCT02308761|Drug|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
79376321|NCT01546402|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
79828553|NCT05391841|Drug|NOVOCART Inject|Autologous Chondrocyte Implantation
79828554|NCT05389553|Other|Ultrasound exam|We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
79376322|NCT01546402|Procedure|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
79828555|NCT05381441|Behavioral|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
79376323|NCT03389490|Drug|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
79828556|NCT05379725|Other|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
79828557|NCT05379725|Other|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
79235264|NCT03506607|Other|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
79235265|NCT03506607|Other|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
79376324|NCT03389490|Drug|Neutral protamine hagedorn insulin|Self titration of NPH insulin
79686138|NCT01099449|Drug|calcium gluconate|Given IV
79686139|NCT01099449|Drug|magnesium sulfate|Given IV
79686140|NCT01099449|Other|placebo|Given IV
79686141|NCT01099449|Drug|oxaliplatin|
79686142|NCT05427071|Device|Magnetic seed localization|Magnetic seed guided localization
79686143|NCT04471740|Procedure|CSF shunt diversion|Clinical response to a CSF shunt insertion
80003045|NCT01354067|Behavioral|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
79686144|NCT04680143|Drug|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
79686145|NCT05426798|Drug|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
79686146|NCT01234402|Biological|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
79686147|NCT01234402|Biological|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
79686148|NCT01234402|Drug|Capecitabine|"1000 mg/m^2 orally~Twice a day for 14 days"
79235266|NCT03506607|Other|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
79529917|NCT01416220|Drug|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
80003046|NCT01357811|Drug|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
79235267|NCT03942718|Other|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
79235268|NCT03506529|Other|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
79529918|NCT01416220|Drug|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
79529919|NCT01416233|Procedure|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
79686149|NCT05464017|Device|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
79235269|NCT02317731|Other|Straw|Bowel preparation ingestion with a straw
79235270|NCT03502551|Drug|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
79686150|NCT05426720|Other|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
79686151|NCT01260922|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
79686152|NCT01260922|Drug|Aricept®|10 mg Orally Disintegrating Tablet
79686153|NCT05426642|Other|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
79686154|NCT05426642|Other|Brochure|The brochure contain the information regarding cervical cancer and its screening
79686155|NCT01233817|Other|Progressive strength training|the systematic increase in resistance weights
80003047|NCT01357811|Drug|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
80003048|NCT02079116|Other|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~60 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
79235271|NCT02314377|Drug|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
80016719|NCT02740127|Behavioral|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
79235272|NCT03502473|Device|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~The Main console~Transducer"
79235273|NCT02398214|Behavioral|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to < 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
79235274|NCT02314455|Other|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
79235275|NCT02535364|Biological|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
79235276|NCT05464576|Diagnostic Test|MRI|Using the MRI in the diagnosis of the bladder cancer (invasive or not)
80003049|NCT02079116|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
79376325|NCT01546636|Other|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
79376326|NCT01546636|Other|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
79686156|NCT04206748|Device|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
79376327|NCT03391752|Combination Product|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
79686157|NCT04206748|Device|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
79686158|NCT05426603|Procedure|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
79686159|NCT05426603|Procedure|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
79686160|NCT01233232|Drug|Placebo|Oral dose bid
79686161|NCT01233232|Drug|AZD5069 50mg|Oral dose bid
79686162|NCT01233232|Drug|AZD5069 80mg|Oral dose bid
79686163|NCT01233076|Device|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
79235277|NCT02942290|Drug|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 & Days 1-2 of Week 2 of 28 day cycle.
79686164|NCT01233076|Device|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
79235278|NCT02942290|Drug|Venetoclax|Oral; Tablet
79235279|NCT02540356|Biological|BAX69 Single-Route Arm|Intraperitoneal (IP) only
79235280|NCT02540356|Biological|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
79376328|NCT03391674|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
79376329|NCT01547806|Drug|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
79686165|NCT04389879|Other|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
80003050|NCT01351181|Behavioral|Leaflet|Advice Leaflet
80003051|NCT01351181|Behavioral|Exercise Advice|Leaflet
80003052|NCT01351181|Behavioral|Normal Care|Normal Care
80003053|NCT02080910|Behavioral|Psychoeducation|
80003054|NCT04300985|Drug|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
79376330|NCT01547806|Drug|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
79376331|NCT01547806|Procedure|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
79376332|NCT03391596|Behavioral|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
79376333|NCT03391596|Behavioral|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
79376334|NCT03391596|Behavioral|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
79376335|NCT01445626|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
80003055|NCT04300985|Drug|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
80003056|NCT04300985|Drug|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
80003057|NCT02079194|Drug|P2Y12 antagonist monotherapy|
80003058|NCT02079194|Drug|aspirin plus P2Y12 antagonist|
80003059|NCT01358279|Procedure|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
79235281|NCT05433064|Device|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
79686166|NCT05426018|Drug|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
79235282|NCT05431816|Dietary Supplement|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
79235283|NCT05463094|Drug|Test Glucophage® XR|Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
79235284|NCT05463094|Drug|Reference Glucophage® XR|Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
79376336|NCT03398460|Diagnostic Test|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
79376337|NCT02744742|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
79686167|NCT01212094|Drug|Rituximab|
79686168|NCT01212094|Other|normal saline|normal saline
79686169|NCT05425706|Other|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
79686170|NCT05425628|Device|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
79686171|NCT05457426|Procedure|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
79828558|NCT05378776|Dietary Supplement|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
79828559|NCT05378776|Dietary Supplement|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
80003060|NCT01351259|Device|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
79235285|NCT05463016|Device|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
79235286|NCT05463016|Device|Placebo Group 1: Placebo Lenses|Placebo Lenses
79235287|NCT05463016|Device|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
79235288|NCT05463016|Device|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
79235289|NCT05463016|Device|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
79376338|NCT02744742|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
79529920|NCT01416246|Procedure|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is < or = to 50 and/or age > 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
79529921|NCT01416259|Drug|Withdraw treatment|
79235290|NCT05431660|Other|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
79235291|NCT05431660|Other|control group|diabetic foot school information booklet and weekly video conference meeting
79235292|NCT05431348|Device|Smartwatch|Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
79235293|NCT05431348|Diagnostic Test|Serum Cortisol|Level of cortisol in serum will be determined
79235294|NCT05431348|Other|Questionnaires|Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
79235295|NCT05450068|Other|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
79376339|NCT02744742|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79376340|NCT02744742|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
79235296|NCT05450068|Other|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
79686172|NCT05425589|Procedure|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
79828560|NCT05373095|Behavioral|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically <$1.
79828561|NCT05372016|Biological|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
79376341|NCT01548040|Device|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
79529922|NCT01416298|Other|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and > 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching >10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after >10% is achieved is acceptable and now will be put into standard clinical practice.
79529923|NCT01416311|Drug|Eltrombopag|
79529924|NCT01416324|Drug|placebo|Vehicle used to dilute the powder for oral administration.
79686173|NCT05425394|Behavioral|Delay first bath|Newborns delay first bath to 8 hours after birth
79686174|NCT05425316|Behavioral|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
79828562|NCT05372016|Biological|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
80003061|NCT01351493|Drug|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
79235297|NCT05450068|Other|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
79686175|NCT05425316|Behavioral|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
80003062|NCT01351493|Drug|placebo|placebo Gel, once or twice per day, 12weeks
80003063|NCT02829671|Other|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
79235298|NCT05449678|Behavioral|Low-carb diet|A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet. This is not a strict diet to follow or a ketogenic diet. Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
79235299|NCT05449600|Device|Thermotape|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
79376342|NCT01548040|Device|Quadriceps TENS|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
79376343|NCT03389334|Other|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
79376344|NCT01548742|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
79376345|NCT01548742|Behavioral|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
79391124|NCT02416362|Other|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
79529925|NCT01416324|Drug|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
79686176|NCT05425316|Behavioral|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
79686177|NCT05425316|Behavioral|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
79529926|NCT01416324|Drug|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
80003064|NCT01354379|Biological|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
80003065|NCT01354379|Biological|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
79529927|NCT01416324|Drug|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
79686178|NCT05425316|Behavioral|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
79529928|NCT01416324|Drug|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
79529929|NCT01416324|Drug|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
79529930|NCT01416324|Drug|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
79686179|NCT05419401|Drug|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
79686180|NCT05419401|Drug|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
79686181|NCT04436393|Diagnostic Test|Guardant360 test|tumor cfDNA testing
79686182|NCT04330560|Device|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
79828563|NCT05366556|Behavioral|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
79828564|NCT05359068|Drug|SPH3127 tablet|1 tablet
79686183|NCT04330560|Device|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
79686184|NCT04330560|Device|Exercise teleconsultation|Conducted through smartphone video call app.
79686185|NCT04330560|Procedure|Other CR components|Including dietary, psychology, education conducted at the center.
79686186|NCT04330560|Procedure|Standard care|Undergoing standard care by cardiac rehabilitation at the center
79686187|NCT05409885|Other|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
79686188|NCT05409885|Other|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
79235300|NCT05449600|Device|Tegaderm|Tegaderm™will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
79235301|NCT05449600|Device|Kind|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
79235302|NCT05430724|Procedure|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
79235303|NCT02534896|Drug|Treatment I|Sunpharma1505 and Placebo
79235304|NCT02534896|Drug|Treatment II|Sunpharma1505 and Placebo
79376346|NCT03125772|Device|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
79376347|NCT03125772|Device|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
79376348|NCT03391518|Procedure|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
79529931|NCT01416324|Drug|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
79686189|NCT04327479|Diagnostic Test|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
79686190|NCT01232569|Drug|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
79235305|NCT02534896|Drug|Treatment III|Reference1505 and Placebo
79235306|NCT02697734|Drug|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
79235307|NCT02697734|Drug|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration
79235308|NCT05447494|Drug|Low-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
79391125|NCT02416362|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
79391126|NCT02416440|Other|blood sample|blood sample
79391127|NCT02424162|Device|+2.75 diopters multifocal intraocular lens|
79529932|NCT01416337|Drug|GSK1120212|2 mg single dose tablet on Day 1 of study
79235309|NCT05447494|Drug|High-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
79235310|NCT05411536|Other|Walking trials|"All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus [EF], internal focus [IF], and no specific focus [NF]) in the GW and FW in a randomised order."
79376349|NCT03391440|Drug|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
79376350|NCT01447888|Drug|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
79529933|NCT01416337|Drug|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
79686191|NCT01232569|Drug|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
79686192|NCT00552864|Drug|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
79686193|NCT00552864|Drug|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
79686194|NCT04419584|Drug|Modified Qing-Ying Decoction|Herbal granules
79686195|NCT04419584|Drug|Identical looking placebo|Placebo granules
79828565|NCT05359068|Drug|SPH3127 tablet|2 tablets
79828566|NCT05359068|Drug|SPH3127 tablet|4 tablets
79235311|NCT02392130|Drug|Clobetasol propionate 0.05% ointment|
79828567|NCT05359068|Drug|Valsartan|1 valsartan capsule
79235312|NCT02392130|Drug|LEO 130852A gel 1%|
79235313|NCT02392130|Drug|LEO 130852A placebo gel|
79235314|NCT02392052|Behavioral|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
79235315|NCT02392052|Behavioral|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
79235316|NCT02391974|Device|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
79235317|NCT02692586|Device|FlowTriever System|
79235318|NCT02391896|Device|Dual energy and tomosynthesis xray|
79828568|NCT05359068|Drug|SPH3127 tablet|2 tablets
79235319|NCT05744882|Procedure|coronectony|root canal treatment
79828569|NCT05359068|Drug|Valsartan|1 valsartan capsule
79235320|NCT05744882|Procedure|root canal treatment|root canal treatment
79235321|NCT02534350|Drug|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
79235322|NCT02534350|Drug|Placebo|Tablets administered orally or via NG tube once daily
79235323|NCT03165422|Other|Non-Interventional|Non-Interventional
79376351|NCT01447888|Other|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
79376352|NCT03398382|Dietary Supplement|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
79391128|NCT02424162|Device|+3.25 diopters multifocal intraocular lens|
79529934|NCT01416350|Drug|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
79529935|NCT01416350|Drug|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
79529936|NCT01416350|Drug|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
79529937|NCT01416363|Drug|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
79529938|NCT01416363|Drug|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
79529939|NCT01416363|Drug|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
79529940|NCT01416376|Drug|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
79529941|NCT01416376|Drug|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
79529942|NCT01416415|Other|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
79828570|NCT05358418|Other|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
79529943|NCT01416415|Other|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
79235324|NCT03166904|Drug|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
79529944|NCT01416480|Drug|Theobromine 300mg|Capsule, b.i.d.
79235325|NCT05385497|Other|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
79235326|NCT05385497|Device|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
79529945|NCT01416480|Drug|Levodropropizine 10mg|Syrup, t.i.d.
79529946|NCT01416493|Drug|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
79686196|NCT04416542|Diagnostic Test|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
79686197|NCT01211665|Drug|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
79686198|NCT01211665|Drug|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
79686199|NCT04401176|Drug|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
79235327|NCT05356091|Drug|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
79686200|NCT04401176|Drug|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
79828571|NCT05357027|Biological|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
79828572|NCT05357027|Drug|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
79828573|NCT05357027|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
79828574|NCT05357027|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
79235328|NCT05356091|Drug|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
79235329|NCT05196971|Drug|HS-10345 84mg|6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
79235330|NCT05196971|Drug|Placebo|6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
79235331|NCT05351021|Drug|Metformin|cidophage 850 gm twice daily
79235332|NCT05351021|Drug|Placebo|placebo twice daily for treatment period
79235333|NCT05309291|Device|Theranova 400 Dialyzer|Dialysis performed in HD mode.
79235334|NCT05309291|Device|FX 800 Dialyzer|Dialysis performed in HDF mode.
79302637|NCT03072381|Drug|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
79529947|NCT01416506|Other|No Drug|It's a surveillance
79529948|NCT01416519|Procedure|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
79529949|NCT01416519|Procedure|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
79529950|NCT01416545|Behavioral|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
79529951|NCT01416545|Behavioral|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
79235335|NCT03625817|Behavioral|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having >800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
79235336|NCT02688764|Drug|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
79686201|NCT02887612|Other|ctDNA test|
79235337|NCT02688764|Drug|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
79235338|NCT02688608|Drug|Pembrolizumab|200 mg IV once every 3 weeks
79686202|NCT04393922|Behavioral|Acoustic stimuli (Startle)|A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
79686203|NCT04389905|Behavioral|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
79686204|NCT01232491|Drug|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
79235339|NCT02688530|Drug|IV Saline|
79235340|NCT02688530|Drug|IV Dexamethasone 4mg|
79235341|NCT02688530|Drug|IV Dexamethasone 6mg|
79235342|NCT02688530|Drug|IV Dexamethasone 8mg|
79529952|NCT01416558|Drug|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
79529953|NCT01416597|Biological|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
79529954|NCT01416623|Drug|henatinib|Henatinib Maleate Tablets
79686205|NCT01232491|Dietary Supplement|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
79686206|NCT05388591|Other|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
79686207|NCT04355234|Diagnostic Test|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
79235343|NCT03167060|Device|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
79235344|NCT03167060|Device|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
79235345|NCT03166826|Other|Modified Apgar Scoring System|Modified APGAR scoring system
79235346|NCT05744804|Drug|-group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg|receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
79235347|NCT05744804|Drug|(acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
79529955|NCT01416649|Drug|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
79686208|NCT04355234|Biological|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
79686209|NCT04335305|Drug|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
79686210|NCT04335305|Biological|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
79686211|NCT04253951|Diagnostic Test|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
80003066|NCT02079272|Other|Helical tomotherapy for breast cancer|"At baseline, before helical tomotherapy is performed, for each included woman will have:~measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~cardiologic examination including echocardiography for measurement of strain and strain rate~a CT coronary angiogram for measurement of coronary plaque indexes~Helical tomotherapy will be performed for all women included in the cohort.~At the end of tomotherapy, follow-up will include:~measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~A CT coronary angiogram 24 months after radiotherapy"
79235348|NCT03166748|Combination Product|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
79235349|NCT05744726|Biological|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
79235350|NCT05744726|Combination Product|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
79235351|NCT03166670|Diagnostic Test|stool examination|collection of stool specimen and microscopic examination for parasites
80003067|NCT03558698|Other|Good ventilation|Good ventilation with a low concentration of CO2
80003068|NCT03558698|Other|Ventilation CO2|CO2 High and Good ventilation
79235352|NCT03166670|Diagnostic Test|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
79235353|NCT05083559|Device|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
79235354|NCT05083559|Device|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
79235355|NCT03166982|Procedure|transvaginal approach|
79235356|NCT03166982|Procedure|laparoscopic approach|
79376353|NCT03398382|Dietary Supplement|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
79529956|NCT01416662|Drug|gemcitabine hydrochloride|
79529957|NCT01416701|Dietary Supplement|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
79529958|NCT01416701|Dietary Supplement|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
80003069|NCT03558698|Other|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
80003070|NCT01318187|Drug|paracetamol|1 gr
79529959|NCT01416727|Other|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
79529960|NCT01416727|Other|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
79529961|NCT01416740|Procedure|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
79529962|NCT01416740|Drug|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
79529963|NCT01416753|Device|UCR|BVM-based regulation of ultrafiltration and conductivity
79529964|NCT01416753|Device|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
80003071|NCT01318187|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
80003072|NCT01318187|Drug|Paracetamol|1 gr intravenous
80003073|NCT01318187|Drug|Paracetamol|intravenous 1 gr
80003074|NCT01318187|Drug|Morphine|0.1 mg/kg intravenous
80003075|NCT01358435|Biological|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
80003076|NCT01358435|Biological|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
80003077|NCT03558620|Procedure|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
80003078|NCT01318265|Drug|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
80003079|NCT01354457|Drug|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
80003080|NCT02079350|Drug|%6 HES and %4 Gelofusine|
80003081|NCT02081066|Other|cardiovascular risk factors|
80003082|NCT01351649|Behavioral|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
80003083|NCT02079428|Other|No interventions|
80003084|NCT03062540|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
80003085|NCT03062540|Drug|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
80003086|NCT01351883|Dietary Supplement|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
80003087|NCT03060980|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
79235357|NCT05150795|Drug|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
79235358|NCT05150795|Drug|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
80003088|NCT03060980|Drug|Empagliflozin (oral)|10 mg/day and 25 mg/day
80003089|NCT03060980|Drug|Glimepiride (oral)|1-6 mg/day
80003090|NCT01358591|Dietary Supplement|High calcium milk|High calcium milk (9 mg/kgBM)
79376354|NCT03398382|Dietary Supplement|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
79686212|NCT04248530|Device|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
79686213|NCT04255212|Other|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
80003091|NCT01358591|Dietary Supplement|Control|Regular Milk
80003092|NCT01358747|Drug|BEACOPPesc|
80003093|NCT01358747|Drug|BEACOPPesc - ABVD - PET2|
80003094|NCT03124459|Drug|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
80003095|NCT03124459|Drug|Placebo|Recombinant fusion protein or buffer solution
80003096|NCT02081144|Other|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of ~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
80003097|NCT02081144|Drug|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
80003098|NCT02081144|Drug|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
80003099|NCT02081144|Behavioral|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
80003100|NCT01351961|Biological|blood sampling|take a sample of blood, 46 ml
80003101|NCT01351961|Procedure|brain MRI and TEP cerebral|magnetic resonance imaging
80003102|NCT01351961|Other|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
80003103|NCT01351961|Other|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
79235359|NCT02400658|Device|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
80003104|NCT01351961|Procedure|Vascular explorations|Pulse wave velocity, VWF, IMT
80003105|NCT01351961|Biological|Urine sample|
80003106|NCT02083328|Dietary Supplement|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
80003107|NCT02083328|Dietary Supplement|Placebo (Mannitol)|Mannitol filled in gelatine capsules
80003108|NCT01354535|Procedure|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
79235360|NCT03167138|Biological|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
79376355|NCT03398382|Dietary Supplement|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
79376356|NCT03391206|Diagnostic Test|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
79376357|NCT03389256|Drug|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
79376358|NCT03389256|Drug|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
79376359|NCT01490788|Drug|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
79376360|NCT01490788|Drug|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
79376361|NCT01490788|Drug|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
79529965|NCT01416766|Other|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
79376362|NCT03389178|Diagnostic Test|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control
79235361|NCT03167138|Device|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
79376363|NCT02559726|Procedure|Echocardiography (TEE)|
80003109|NCT01354535|Procedure|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
80003110|NCT02079506|Drug|Candesartan|
80003111|NCT02079506|Drug|Rosuvastatin|
79235362|NCT05027087|Dietary Supplement|Blueberry gummy|Gummy bear containing blueberry powder
79235363|NCT05027087|Dietary Supplement|Placebo gummy|Gummy bear with no active ingredients
79235364|NCT05446636|Device|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
79235365|NCT03166280|Drug|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
79235366|NCT03166280|Drug|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
79376364|NCT02559726|Device|Magnetic resonance imaging (MRI) with gadolinium enhancement|
79376365|NCT02559726|Device|Magnetic resonance imaging (MRI) without gadolinium enhancement|
79376366|NCT02559726|Procedure|3D electrocardiographic mapping (ECM)|
79376367|NCT02559024|Drug|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
79376368|NCT03391050|Drug|APR-246|Intravenous infusion
79376369|NCT03391050|Drug|Dabrafenib|Oral administration
79376370|NCT03397992|Other|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
79376371|NCT03390972|Drug|Placebo|Placebo (NaCl 0.9%) TCI infusion
79376372|NCT03390972|Drug|Dexmedetomidine|Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
79376373|NCT01550224|Drug|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
79376374|NCT01550224|Drug|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
79376375|NCT01254474|Device|Cardiac chambers mapping with MAP 4|
79376376|NCT01491022|Drug|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
79376377|NCT01491022|Drug|placebo first, then Ampyra|placebo
79376378|NCT00782184|Drug|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
79376379|NCT00782184|Drug|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
79376380|NCT00782184|Drug|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
79376381|NCT02979808|Device|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
79529966|NCT01416779|Behavioral|Writing Intervention|Finding Balance Writing Intervention
79529967|NCT01416792|Procedure|Centrifugation|
79529968|NCT01416792|Procedure|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
79529969|NCT01416818|Drug|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
79529970|NCT01416818|Drug|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
79686214|NCT04255212|Other|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
79828575|NCT05352074|Procedure|subtotal colectomy with cecal-rectal anastomosis|The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
79235367|NCT05427994|Other|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
80003112|NCT01370941|Dietary Supplement|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
80003113|NCT01370941|Dietary Supplement|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
80003114|NCT02081222|Procedure|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
80003115|NCT02940548|Drug|Nifedipine GITS|Nifedipine GITS 30~60mg/day for 8 weeks
80003116|NCT02940548|Drug|Amlodipine besylate|Amlodipine besylate 5~10mg/day for 8 weeks
80003117|NCT01366183|Procedure|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
79376382|NCT01448356|Procedure|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
79376383|NCT03390816|Other|Nutritional assessment|Observational
79376384|NCT03397914|Drug|Colistimethate Sodium|Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
79376385|NCT02214238|Device|PAP device|
79529971|NCT01416818|Drug|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
79529972|NCT01416844|Biological|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
79529973|NCT01416857|Other|RDDT|
80003118|NCT01366183|Drug|Carboplatin|Undergo chemotherapy
80003119|NCT01366183|Biological|Filgrastim|Undergo chemotherapy
80003120|NCT01366183|Drug|Paclitaxel|Undergo chemotherapy
79235368|NCT04440254|Diagnostic Test|Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device|Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
79686215|NCT04255212|Other|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
80003121|NCT01366183|Other|Pharmacological Study|Correlative studies
80003122|NCT01366183|Other|Quality-of-Life Assessment|Ancillary studies
80003123|NCT01366183|Other|Questionnaire Administration|Ancillary studies
80003124|NCT03134183|Drug|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D&E
80003125|NCT03134183|Drug|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D&E
80003126|NCT02083484|Biological|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
79376386|NCT01450306|Drug|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
79376387|NCT01450306|Behavioral|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
80003127|NCT01354613|Drug|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
79235369|NCT03037307|Other|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
79235370|NCT03037307|Other|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
79235371|NCT03037307|Other|Negative Control|No adhesive
79376388|NCT01450306|Drug|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
79376389|NCT03126708|Drug|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
79376390|NCT03126708|Drug|cisplatin plus paclitaxel|Chemotherapy
79529974|NCT01416870|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
79529975|NCT01416870|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
79529976|NCT01416883|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
79529977|NCT01416896|Procedure|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
79529978|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
79686216|NCT04255212|Other|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
79686217|NCT04207268|Behavioral|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
79686218|NCT04207268|Behavioral|Nutrition Advice|Participate in only nutrition advice
79686219|NCT05353803|Other|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
79686220|NCT00552903|Behavioral|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
79686221|NCT04176029|Device|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
80003128|NCT01354613|Drug|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
79686222|NCT04152980|Drug|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
80003129|NCT01317719|Procedure|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
79529979|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
79686223|NCT01232452|Drug|Pemetrexed|Administered intravenously (IV)
80003130|NCT05189405|Device|INVOcell IVC|Embryo development in intravaginal incubation
79686224|NCT01232452|Drug|Cisplatin|Administered IV
80003131|NCT02083640|Drug|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
80003132|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
80003133|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
80003134|NCT01352039|Biological|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
80003135|NCT01352039|Biological|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
80003136|NCT02083718|Biological|PBSC|
80003137|NCT02083718|Biological|MSCs|
80003138|NCT05189327|Other|No intervention|Non-interventional study
79235372|NCT05746052|Procedure|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
79235373|NCT02428049|Radiation|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
79235374|NCT05427526|Procedure|intraocular lens implantation|Lens surgery during or before vitrectomy surgery.
79235375|NCT05410054|Other|no intervention|observational research
79302638|NCT02483507|Other|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
79828576|NCT05352074|Procedure|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
79828577|NCT05350878|Other|Implementation Intervention|Virtual and in-person implementation support
80003139|NCT02083796|Procedure|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
80003140|NCT02083796|Procedure|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
80003141|NCT02083796|Procedure|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
80003142|NCT02083796|Procedure|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
80003143|NCT01363921|Device|HCO 1100|Dialysis treatment with HCO1100
79529980|NCT01416896|Procedure|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
79529981|NCT01416909|Other|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
79686225|NCT01232452|Drug|Cixutumumab|Administered IV
79686226|NCT01211197|Drug|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
79686227|NCT01211197|Drug|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
79686228|NCT01211197|Drug|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
79686229|NCT04679519|Other|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
79828578|NCT05347199|Drug|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
79828579|NCT05347199|Drug|Placebo|two doses, orally
79828580|NCT05346588|Other|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
79828581|NCT05346588|Other|Anesthetic technique inhaled agent|must administer inhaled agent.
79828582|NCT05340374|Drug|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
80003144|NCT02079818|Device|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
80003145|NCT01358903|Drug|RO5429083|Cohorts receiving multiple escalating doses iv
79235376|NCT03669887|Behavioral|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
79235377|NCT02538094|Device|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
79235378|NCT02538094|Device|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
79235379|NCT02686034|Device|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
79376391|NCT03390738|Drug|Nivolumab|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
79376392|NCT03390660|Other|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
79376393|NCT03389100|Drug|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
79529982|NCT01416909|Other|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
79529983|NCT01416909|Other|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
79529984|NCT01416948|Drug|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
79828583|NCT05340374|Drug|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
80003146|NCT01358903|Drug|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
80003147|NCT01366261|Device|semirigid thoracoscopy|thoracoscopy with semirigid instrument
79828584|NCT05335356|Biological|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara
79828585|NCT05335356|Biological|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
80003148|NCT01366261|Device|rigid thoracoscopy|thoracoscopy with rigid instrument
79302639|NCT05003193|Device|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
79376394|NCT03385434|Device|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
79376395|NCT03390582|Drug|Methimazole Pill|Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
79529985|NCT01416948|Drug|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
80003149|NCT03136367|Other|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
79686230|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
79235380|NCT02686034|Device|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
79235381|NCT02685488|Device|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
79376396|NCT03385356|Drug|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
80003150|NCT03136367|Other|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
80003151|NCT04419337|Drug|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
80003152|NCT03124381|Device|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
79376397|NCT03385278|Other|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
79376398|NCT01913574|Device|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
79376399|NCT01913574|Procedure|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
79376400|NCT03125850|Other|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
79376401|NCT03125850|Other|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
79376402|NCT03388866|Drug|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
79529986|NCT01416948|Drug|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
79828586|NCT05329025|Drug|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
80003153|NCT03124381|Device|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
79235382|NCT02685488|Device|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
79235383|NCT03166592|Device|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
79235384|NCT03166514|Dietary Supplement|Commercially Available Food Bar|
79235385|NCT03166514|Dietary Supplement|Placebo|
79235386|NCT04479800|Drug|ASTX660|Form: capsule; Route of administration: oral
79235387|NCT02533570|Drug|Brentuximab vedotin|
79235388|NCT02533570|Drug|Placebo|
79235389|NCT03106220|Behavioral|exercise|home exercise program
79376403|NCT03388866|Other|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
79376404|NCT01873170|Drug|levonorgestrel exposure|
79376405|NCT01873170|Drug|DMPA exposure|
79376406|NCT01873170|Drug|etonogestrel exposure|
79376407|NCT01873170|Device|IUD insertion|
79376408|NCT01873170|Device|subdermal contraceptive implant insertion|
79376409|NCT03390348|Device|LENA Recorder|Use of the LENA recorder to document crying and fussing
79376410|NCT01856868|Drug|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
79376411|NCT03390270|Other|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
79376412|NCT03125694|Drug|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
79376413|NCT03125694|Drug|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
79376414|NCT03385200|Drug|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
79529987|NCT01416961|Radiation|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
79529988|NCT01416961|Drug|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
79529989|NCT01416961|Drug|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
79529990|NCT01416974|Drug|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
79529991|NCT01416974|Biological|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
79529992|NCT01417013|Other|Systane Ultra|Lubricant Eye Drops
79529993|NCT01417013|Other|Optive|Lubricant eye drops
79686231|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
79235390|NCT03106220|Other|placebo|encourage walking and physical therapy per standard care.
79686232|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
79828587|NCT05326568|Other|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
79828588|NCT05322096|Drug|RGH-706|"Capsules~Oral administration"
79828589|NCT05322096|Drug|Placebo|"Capsules~Oral administration"
79828590|NCT05320796|Diagnostic Test|upper endoscopy|A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
79828591|NCT05310487|Biological|162|The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
79235391|NCT02268448|Drug|Clonidine|
79235392|NCT02268448|Drug|Naltrexone|
79376415|NCT02731638|Drug|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
79376416|NCT02731638|Drug|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
79376417|NCT01451632|Drug|MM-121|escalating doses MM-121 IV QW
79376418|NCT01451632|Drug|Irinotecan|180 mg/m2 IV Q2W
79376419|NCT01451632|Drug|Cetuximab|escalating doses cetuximab IV QW
79235393|NCT05744570|Procedure|Epidural anesthesia|Regional anesthesia for labor pain
79235394|NCT03106064|Behavioral|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
79235395|NCT03106064|Other|Usual Care|Usual hospital care
79376420|NCT03388710|Radiation|XRay|Xray to confirm the location of the endotracheal tube
79529994|NCT01417052|Drug|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
79529995|NCT01417052|Drug|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
79529996|NCT01417052|Drug|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
79529997|NCT01417052|Drug|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
79529998|NCT01417052|Drug|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
79529999|NCT01417052|Drug|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
79530000|NCT01417052|Drug|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
79530001|NCT01417052|Drug|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
79530002|NCT01417052|Drug|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
79530003|NCT01417052|Drug|Placebo|Matching placebo dosing in capsule form
79530004|NCT01417065|Drug|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
79530005|NCT01417143|Drug|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
79828592|NCT05310487|Other|Placebo|an intervention that appearance is the same as 162, but contains no active ingredients
79530006|NCT01417169|Drug|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting <50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
79235396|NCT03106142|Procedure|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
80003154|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
79686233|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
80003155|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
79686234|NCT04679792|Diagnostic Test|Dynamic posturography|Balance evaluation
79828593|NCT05295758|Behavioral|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
79828594|NCT05294120|Device|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
79828595|NCT05294120|Radiation|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
80003156|NCT01354769|Device|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
80003157|NCT01352273|Drug|MEK162 + RAF265|
80003158|NCT01352351|Behavioral|Breastfeeding promotion intervention|"Breastfeeding counseling during monthly microcredit meetings~Weekly cell phone messages about breastfeeding"
80003159|NCT05189093|Drug|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|"In the phase I dose escalation part:it is planned to recruit patients with relapsed/refractory advanced lymphoma, and 4 doses will be explored: 7.5mg/kg, 15mg/kg, 22.5mg/kg and 30mg/kg dose groups. once every two weeks (Q2W), every 14 days is a dosing cycle.~Recommend Phase II dose based on the results of Phase I dose escalation part."
80003160|NCT03620279|Behavioral|Magic camp intervention|Hand-arm bimanual motor skills training
79235397|NCT03105908|Behavioral|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
79235398|NCT03105908|Behavioral|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
79235399|NCT03036839|Drug|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
79530007|NCT01417182|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
79530008|NCT01417221|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
80003161|NCT04006717|Device|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
79530009|NCT01417247|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
79235400|NCT04977791|Drug|Anti-PD-1/PD-L1 monoclonal antibody|Observe a situation before and after immunotherapy
79235401|NCT03619421|Dietary Supplement|Zinc supplement|25 mg
79235402|NCT03625739|Drug|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
79235403|NCT05123885|Other|Study on Data|Study on Data
79235404|NCT04030871|Device|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
79530010|NCT01417273|Dietary Supplement|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
79530011|NCT01417273|Drug|Drug: placebo|1 cap placebo/day for 12 month
79530012|NCT01417299|Dietary Supplement|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
79530013|NCT01417299|Dietary Supplement|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
79828596|NCT05294107|Procedure|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~6 biopsies are taken on average in clinical routine~4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
79530014|NCT01417312|Dietary Supplement|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
79828597|NCT05292404|Drug|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
79828598|NCT05292404|Other|conventional treatment|conventional treatment were given according to international uniformguidelines
80003162|NCT04006717|Procedure|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
80003163|NCT01371097|Other|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
79235405|NCT04030871|Device|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
79235406|NCT03904199|Drug|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
79376421|NCT03390192|Device|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
79530015|NCT01417312|Dietary Supplement|Placebo|Daily intake of placebo capsules for 3 months
79235407|NCT05022173|Device|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
79828599|NCT05292209|Drug|Riluzole 50 MG|Riluzole 50mg tablets
79828600|NCT05281796|Diagnostic Test|GCF obtaining|GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
79235408|NCT05022173|Device|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
79828601|NCT05281796|Diagnostic Test|saliva obtaining|Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
79828602|NCT05281237|Device|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
79235409|NCT01286207|Drug|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
79235410|NCT01286207|Drug|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
79235411|NCT01286207|Drug|Standard Care|Active standard care
79376422|NCT03390192|Device|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
79530016|NCT01417351|Dietary Supplement|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
79828603|NCT05275894|Behavioral|Implant hygiene instructions and removal of the prosthesis|Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis
79828604|NCT05275894|Procedure|Non-surgical peri-implantitis treatment /microsurgery|Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia
80003164|NCT01371175|Biological|DNA.HIVA|0.5mg DNA.HIVA or placebo
80003165|NCT01371175|Biological|MVA.HIVA|5x10^6 pfu MVA or placebo
80003166|NCT01371175|Biological|MVA.HIVA|5x10^7 pfu MVA or placebo
80003167|NCT01371175|Biological|MVA.HIVA|2.5x10^8 pfu MVA or placebo
79376423|NCT01491490|Drug|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
79376424|NCT01491490|Drug|Placebo|Capsules taken once a day for 6 weeks
79376425|NCT03008200|Device|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
79376426|NCT03812016|Device|Magnetic device|The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and one sensor (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the magnetic device.
79376427|NCT02520492|Device|noninvasive method of ICP measurements (Elios)|
79530017|NCT01417351|Dietary Supplement|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
79530018|NCT01417364|Drug|Testosterone enanthate|100 mg. IM weekly throughout study
79530019|NCT01417364|Drug|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
79530020|NCT01417364|Drug|Placebo|Injected IM weekly throughout study
79530021|NCT01417390|Drug|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
80003168|NCT04208815|Other|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
80003169|NCT04208815|Other|Milk Fat|Effects of the addition of 20 g milk fat.
79235412|NCT02236000|Drug|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
79235413|NCT02236000|Drug|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
79235414|NCT04460014|Behavioral|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
79235415|NCT04460014|Behavioral|Attention Placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
79376428|NCT01491958|Drug|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
79530022|NCT01417390|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
79530023|NCT01417403|Drug|hydroxychloroquine|Given PO
79530024|NCT01417403|Radiation|radiation therapy|Undergo radiotherapy
79530025|NCT01417429|Drug|Galantamine|8mg/a day or placebo
79530026|NCT01417429|Drug|IV Nicotine|1.0 mg/70 kg of nicotine against saline
79530027|NCT01417442|Genetic|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
79530028|NCT01417468|Behavioral|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
79530029|NCT01417468|Behavioral|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
79530030|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
79686235|NCT04679363|Other|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
79686236|NCT04679363|Other|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
79686237|NCT00553137|Drug|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
79686238|NCT00553137|Drug|fluconazole|150 mg fluconazole tablets once daily for 14 days
79828605|NCT05275894|Procedure|Implant surface decontamination 1(ultrasonic device)|Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).
80003170|NCT01371253|Other|Nintendo wii balance training|
80003171|NCT01371253|Other|EVA-soles|
79376429|NCT01491958|Drug|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
79376430|NCT01491958|Drug|methotrexate|Day +1, +3, and +6 and +11
79376431|NCT01492582|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
79376432|NCT01492582|Other|laboratory biomarker analysis|Correlative studies
79376433|NCT01492582|Other|survey administration|Ancillary studies
80003172|NCT01371331|Drug|Tacrolimus granules|oral
79376434|NCT01492582|Other|medical chart review|Ancillary studies
79302640|NCT03202615|Dietary Supplement|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
79376435|NCT01493596|Drug|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
79530031|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
79530032|NCT01417507|Procedure|cognitive assessment|Undergo neurocognitive assessment
79530033|NCT01417507|Procedure|magnetic resonance imaging|Undergo MRI
79530034|NCT01417507|Other|laboratory biomarker analysis|Correlative studies
79530035|NCT01417507|Other|questionnaire administration|Ancillary studies
79530036|NCT01417507|Procedure|quality-of-life assessment|Ancillary studies
79530037|NCT01417546|Drug|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
79530038|NCT01417572|Drug|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
79530039|NCT01417585|Behavioral|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
79530040|NCT01417585|Behavioral|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
80003173|NCT03972865|Other|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
80003174|NCT01366339|Drug|Oral methylnaltrexone|
80003175|NCT01366339|Drug|Oral placebo|
79530041|NCT01417598|Other|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
79686239|NCT04679246|Behavioral|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
79376436|NCT01493596|Drug|Placebo|An equal volume of water mixed with juice will be administered.
79828606|NCT05275894|Procedure|Implant surface decontamination 2 (air polishing)|Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).
79376437|NCT01552876|Device|etafilcon A|A daily wear contact lens
79376438|NCT01552876|Device|nelfilcon A|A daily wear contact lens
79686240|NCT04090775|Drug|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
79686241|NCT04090775|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
80003176|NCT03133793|Drug|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
80003177|NCT03133793|Drug|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
79686242|NCT04090775|Drug|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
79686243|NCT04090775|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
79686244|NCT00553176|Other|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
79828607|NCT05275894|Procedure|Implant surface decontamination 3 (electrolytic cleaning)|Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.
79828608|NCT05275894|Drug|Antibiotic treatment (Metronidazole)|Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
79828609|NCT05275894|Procedure|Modification and polishing of the prosthesis|If necessary, modification and polishing of the prosthesis to make it cleanable.
80003178|NCT03133793|Other|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
80003179|NCT03133793|Other|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
79235416|NCT05408026|Drug|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
79235417|NCT05408026|Drug|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
80003180|NCT05190601|Device|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
79235418|NCT04423510|Procedure|Crystallized phenol treatment|
80003181|NCT01318421|Drug|ELND002|
79235419|NCT00968201|Drug|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
79376439|NCT01552876|Device|Filcon II 3|a daily disposable
79376440|NCT01495858|Drug|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
79376441|NCT01495858|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
79235420|NCT00968201|Drug|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
80003182|NCT02747238|Device|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
80003183|NCT02747238|Procedure|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
80003184|NCT02747238|Procedure|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
79235421|NCT00967577|Drug|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
79235422|NCT00943397|Drug|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
79376442|NCT01495858|Drug|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
79530042|NCT01417598|Other|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
79686245|NCT04166136|Other|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
79686246|NCT04166136|Other|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
79828610|NCT05273697|Procedure|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~Complete suction of air from the intestinal tract~Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~Complete immersion of the lesion in water~Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
79828611|NCT05273697|Procedure|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
80003185|NCT03133481|Procedure|Adductor Canal Nerve Block|Adductor Canal never technique
79235423|NCT00943397|Drug|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
79235424|NCT00935519|Device|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
79235425|NCT00817817|Device|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
79235426|NCT00817817|Device|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
79376443|NCT01496248|Dietary Supplement|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
79376444|NCT01497496|Drug|High Dose Methylprednisolone (HDMP)|1000 mg/m^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
79828612|NCT05269992|Other|Real food products|As per arm/group descriptions.
79235427|NCT05303675|Other|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
79235428|NCT03628859|Biological|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib [in France only], as per product SmPC or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab)
79376445|NCT01497496|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
79376446|NCT01497496|Drug|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
79376447|NCT02208310|Drug|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
79376448|NCT02208310|Drug|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
80003186|NCT03133481|Drug|Femoral Nerve Block|Traditional technique
79235429|NCT00702845|Drug|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
79376449|NCT01453894|Behavioral|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
80003187|NCT01366573|Drug|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
80003188|NCT01366573|Other|Placebo|Placebo
80003189|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age.
80003190|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.
79235430|NCT00702845|Drug|recFSH (follitropin beta)|150 IU recFSH SC injection
79376450|NCT01454362|Drug|Nicotine|Inhalation of nicotine.
79530043|NCT01417611|Procedure|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
79686247|NCT04166136|Other|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
79235431|NCT00702845|Drug|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
79235432|NCT00702845|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
79686248|NCT04089839|Other|Non-Interventional|Non-Interventional
79686249|NCT04045145|Drug|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
79530044|NCT01417624|Other|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
79530045|NCT01417637|Radiation|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
79686250|NCT01232296|Drug|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
79686251|NCT01232296|Drug|sorafenib|400 mg p.o. b.i.d.
79686252|NCT04041011|Drug|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
79686253|NCT04041011|Drug|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
79686254|NCT04041011|Drug|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
80003191|NCT05190289|Other|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
79235433|NCT00702845|Biological|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
79235434|NCT00702845|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
79235435|NCT00702845|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
79235436|NCT00702845|Biological|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
79235437|NCT00647933|Drug|Org 36286|Subcutaneous Org 36286
79376451|NCT01455064|Device|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
79376452|NCT01456000|Device|EAS-AC (HeartLight)|Pulmonary vien isolation
79686255|NCT02888236|Drug|LEO 32731|
79686256|NCT02888236|Drug|LEO 32731 Placebo|
80003192|NCT05124509|Biological|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
80003193|NCT05124509|Biological|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
80003194|NCT02864316|Drug|Nivolumab|
80003195|NCT03941509|Behavioral|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
80003196|NCT01364077|Drug|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
80003197|NCT01364077|Drug|Placebo|Matched placebo
79235438|NCT00647933|Drug|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
79235439|NCT00641771|Drug|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
79235440|NCT00641771|Drug|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
79235441|NCT05008445|Biological|LM-102 Injection|LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
79235442|NCT05008445|Combination Product|LM-102 Injection combined with SOC|LM-102 Injection with appropriate dose level(s), combined with SOC.
79376453|NCT01456000|Procedure|Control Arm Ablation|Treatment with standard ablation.
79376454|NCT01554982|Drug|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
79376455|NCT01497808|Drug|Ipilimumab|
79376456|NCT01497808|Radiation|Stereotactic Body Radiation Therapy|
79376457|NCT01498588|Drug|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
79376458|NCT01498588|Drug|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
79376459|NCT01498588|Drug|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
79376460|NCT01498588|Drug|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
79376461|NCT01498744|Drug|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
79530046|NCT01417637|Radiation|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
79530047|NCT01417650|Radiation|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
79530048|NCT01417650|Radiation|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
79686257|NCT04136379|Diagnostic Test|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
79686258|NCT01231984|Device|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
79686259|NCT01231984|Device|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
79828613|NCT05265065|Biological|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
79235443|NCT03821831|Device|Continuous Positive Airway Pressure|CPAP machine
79235444|NCT03821831|Device|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
79235445|NCT05096585|Behavioral|Delayed bedtime sleep restriction|bedtime 2 hr later than their normal bedtime
79235446|NCT05096585|Behavioral|Early wake sleep restriction|wake time 2 hr earlier than their normal wake time
79235447|NCT00519857|Drug|Tibolone|1.25 mg p.o, once daily for 3 years
79235448|NCT00519857|Drug|Placebo|Tablet p.o, once daily for 3 years
79235449|NCT00431093|Drug|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
79376462|NCT01498978|Biological|ipilimumab|Given IV
79376463|NCT01498978|Other|laboratory biomarker analysis|Correlative studies
79376464|NCT01458418|Drug|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
79376465|NCT01458418|Other|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
79376466|NCT01458418|Drug|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
79376467|NCT01557322|Biological|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
79376468|NCT01557322|Drug|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
79376469|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
79376470|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
79235450|NCT00431093|Drug|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
79235451|NCT04051385|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
80003198|NCT05190133|Drug|UIC201602 and co-administration of UIC201601 and UIC201602|"UIC201602 4 Cap/day for 14 days~Wash out 21 days~UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
80003199|NCT05190133|Drug|UIC201601 and co-administration of UIC201601 and UIC201602|"UIC201601 4 Tab/day for 7 days~Wash out 14 days~UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
79235452|NCT04051385|Other|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
79686260|NCT01231984|Device|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
79686261|NCT04684095|Behavioral|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
79235453|NCT05283941|Dietary Supplement|Pistachio Group|Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
79376471|NCT01459588|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
79376472|NCT01459588|Drug|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
79530049|NCT01417663|Drug|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
79530050|NCT01417663|Behavioral|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
79376473|NCT01501162|Drug|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
79530051|NCT01417676|Radiation|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
80003200|NCT02862600|Drug|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
80003201|NCT02862600|Device|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
79235454|NCT01302847|Drug|DTG film-coated tablets|DTG film-coated tablets initial starting dose at ~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
79235455|NCT01302847|Drug|DTG granules for suspension|DTG granules for suspension initial starting dose at ~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
79235456|NCT01302847|Drug|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of ~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to <6 kg: 5 mg DTG dispersible tablets; Weight band 6 to <10 kg: 15 mg DTG dispersible tablets; Weight band 10 to <14 kg: 20 mg DTG dispersible tablets; Weight band 14 to <20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
79235457|NCT01302847|Drug|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of ~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to <6 kg: 5 mg DTG dispersible tablets; Weight band 6 to <10 kg: 15 mg DTG dispersible tablets; Weight band 10 to <14 kg: 20 mg DTG dispersible tablets; Weight band 14 to <20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
79302641|NCT03202615|Drug|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
79376474|NCT01501162|Drug|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
79530052|NCT01417689|Other|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
79530053|NCT01417702|Device|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
79530054|NCT01417715|Device|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
79828614|NCT05265065|Biological|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
80003202|NCT01359137|Behavioral|Probation as usual|Routine probation with do deferred jail condition.
80003203|NCT01359137|Behavioral|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
80003204|NCT01359137|Behavioral|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
80003205|NCT01364155|Drug|LIM-0705|
80003206|NCT01364155|Drug|Placebo capsules|
80003207|NCT05189899|Device|Virtual reality|One hemodialysis session with virtual reality and one other without it
80003208|NCT01354847|Device|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
79235458|NCT01302847|Drug|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of ~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to <6 kg: 5 mg DTG dispersible tablets; Weight band 6 to <10 kg: 15 mg DTG dispersible tablets."
79235459|NCT03619577|Behavioral|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
79235460|NCT00092963|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
79235461|NCT00092963|Drug|Comparator: placebo / Duration of Treatment: 1 day|
79235462|NCT00092885|Drug|MK0476, montelukast sodium|
79376475|NCT01502332|Other|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
79235463|NCT00092885|Drug|Comparator: placebo|
79235464|NCT03039569|Behavioral|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
79376476|NCT01502332|Other|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
79376477|NCT01504672|Other|Medication review|"In the intervention, the pharmacist will evaluate:~Is there an indication for the drug?~Has the drug desired effect?~Is the dose correct and dosing scheme correct?~Side effects, contraindications, inappropriate drugs~Interactions~Treatment time~Cost effectiveness~Adherence to recommendation list~Problems with handling the drugs (for example crushing of the tablets)~Untreated indication~Double medications~Administration of drugs"
79376478|NCT01557790|Radiation|Proton Radiation Therapy|
79376479|NCT01557868|Device|hylan G-F 20|Three 2 cc injections at weekly intervals
79376480|NCT01557868|Device|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
79376481|NCT01559506|Device|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
79530055|NCT01417754|Drug|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
79530056|NCT01417767|Drug|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
79530057|NCT01417767|Drug|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
79530058|NCT01417806|Drug|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
79828615|NCT05264480|Procedure|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
79235465|NCT03673735|Drug|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
79235466|NCT03673735|Radiation|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
79235467|NCT03673735|Drug|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
79235468|NCT03673735|Drug|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
79235469|NCT02738775|Biological|Ublituximab|Administered as an IV infusion.
79376482|NCT02208466|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
79376483|NCT02208466|Drug|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
79376484|NCT02208466|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
79376485|NCT02208466|Drug|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
79376486|NCT02209948|Drug|Temozolomide|
79376487|NCT02981212|Drug|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
79376488|NCT02981212|Drug|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
79376489|NCT02981212|Drug|Corticosteroid|combination with Mycophenolate Mofetil
79376490|NCT02981212|Drug|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
79376491|NCT01560286|Biological|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
79235470|NCT02738775|Drug|Placebo|
79235471|NCT00092105|Drug|MK0476, montelukast sodium|
79235472|NCT00092105|Drug|Comparator: placebo|
79235473|NCT00092027|Drug|MK0217, alendronate sodium/Duration of Treatment: 6 months|
79235474|NCT00092027|Drug|Comparator: placebo / Duration of Treatment: 6 months|
79235475|NCT00076973|Drug|montelukast sodium|Duration of Treatment: 6 months
80003209|NCT03767101|Behavioral|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
80003210|NCT01359527|Device|Hip Resurfacing|
80003211|NCT01359527|Device|Total Hip Arthroplasty|
80003212|NCT01354925|Drug|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
80003213|NCT01354925|Drug|Standard of care|Standard of care during Ramadan according to physicians decision
80003214|NCT03812107|Other|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
80003215|NCT03812107|Other|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
80003216|NCT02864082|Drug|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
79235476|NCT00076973|Drug|Comparator: placebo|Duration of Treatment: 6 months
79235477|NCT02314533|Drug|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
79235478|NCT02317965|Other|Maternal Blood Draw|Maternal Blood Draw
79235479|NCT03502395|Drug|Lidocaine|): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
79376492|NCT01505764|Drug|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
79376493|NCT01505764|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
79376494|NCT01464190|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
79530059|NCT01417819|Other|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
80003217|NCT02864082|Drug|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
80003218|NCT02864082|Drug|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
80003219|NCT02864082|Drug|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
80003220|NCT05091281|Device|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
80003221|NCT05091281|Device|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
80003222|NCT05091281|Device|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
80003223|NCT03556345|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
79530060|NCT01417832|Drug|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
80003224|NCT03610230|Drug|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
79530061|NCT01417832|Drug|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
79235480|NCT03502395|Drug|Normal saline|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
79376495|NCT01464190|Drug|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
79376496|NCT01466764|Drug|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
79530062|NCT01417845|Behavioral|High Intensity Exercise Training|"High intensity resistance and aerobic training~Resistance training is performed 2 days per week for 3 months~Aerobic training is performed on the same days as resistance training and 1 additional day per week."
79686262|NCT01210807|Device|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
79686263|NCT01210807|Device|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
79376497|NCT01466764|Other|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
79376498|NCT01563406|Other|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
79376499|NCT01563406|Other|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
79376500|NCT01563406|Drug|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
79686264|NCT00552942|Procedure|laparoscopic gastric bypass plus omentectomy|
80003225|NCT03610230|Drug|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
79235481|NCT02308995|Procedure|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
80003226|NCT01359605|Drug|varespladib methyl|500 mg oral suspension
79235482|NCT02308995|Procedure|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
80003227|NCT01366963|Behavioral|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 & 7 (visual search and attention processes) Trails A & B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
79376501|NCT01563406|Drug|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
79376502|NCT01468012|Drug|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
80003228|NCT01366963|Behavioral|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
79235483|NCT02308995|Device|V-Loc (Covidien, Mansfield, MA)|
79235484|NCT02308995|Device|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
79235485|NCT02318043|Drug|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
79376503|NCT01468012|Drug|Placebo|matched placebo for LCE condition dosed twice daily
79376504|NCT01468558|Drug|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
79376505|NCT01468558|Drug|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
80003229|NCT01366963|Behavioral|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
79376506|NCT01468558|Drug|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
80003230|NCT03609684|Other|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
80003231|NCT03609684|Other|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
80003232|NCT03609684|Other|Sedentary Group|People who are not interested in any sports and don't do any exercises
79235486|NCT05277545|Behavioral|Technology addiction education|Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
79235487|NCT03502317|Behavioral|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
79376507|NCT03730662|Drug|Tirzepatide|Administered SC.
79376508|NCT03730662|Drug|Insulin Glargine|Administered SC
79376509|NCT01509040|Other|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
79530063|NCT01417845|Behavioral|Moderate Intensity Exercise Training|"Moderate intensity resistance and aerobic training~Resistance training is performed on 2 days per week for 3 months.~Aerobic training is performed on the same days as resistance training and 1 additional day per week."
79530064|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
79530065|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
80003233|NCT05188859|Drug|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
80003234|NCT01367041|Procedure|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
80003235|NCT02033538|Drug|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
79376510|NCT01509040|Device|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
79376511|NCT01509040|Device|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
79376512|NCT01470118|Drug|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
79376513|NCT01470118|Drug|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
80003236|NCT01364311|Dietary Supplement|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
80003237|NCT01319513|Other|whey protein bolus|single dose of 25 g whey protein
79530066|NCT01417897|Drug|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
79530067|NCT01417897|Drug|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
79530068|NCT01417897|Drug|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
80003238|NCT01319513|Other|whey protein pulses|10 2.5 g pulses of whey protein
80003239|NCT02792192|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
80003240|NCT02792192|Biological|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
80003241|NCT01359683|Device|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
80003242|NCT05187949|Other|Mixed-method approach|Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
80003243|NCT03609996|Device|Panretinal Photocoagulation|Laser treatment for PDR
80003244|NCT03609996|Drug|Lucentis|Intraviteral injection
80003245|NCT05178199|Behavioral|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
79376514|NCT01470118|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
79376515|NCT03388554|Device|tDCS|
79376516|NCT03388320|Device|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
80003246|NCT05178199|Behavioral|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
80003247|NCT02088008|Drug|cinidipine, valsartan|
80003248|NCT02033772|Procedure|Thoracoscopic surgery|
79376517|NCT01470196|Drug|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
79376518|NCT01470196|Drug|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
79376519|NCT01470196|Drug|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
79530069|NCT01417923|Drug|vitamin D|P.O.4000 units Vit D per day for 6 weeks
79530070|NCT01417949|Other|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
79530071|NCT01417975|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
79530072|NCT01417975|Behavioral|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
79530073|NCT01417988|Drug|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
79530074|NCT01417988|Drug|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
79530075|NCT01418027|Other|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
79530076|NCT01418027|Other|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
79530077|NCT01418053|Drug|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
79686265|NCT03969095|Behavioral|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
79686266|NCT05302479|Other|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
79686267|NCT00554138|Drug|placebo|1 dd for 7-10 days
79235488|NCT03502317|Behavioral|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
79235489|NCT03433313|Drug|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
79235490|NCT03433313|Drug|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
79235491|NCT02314767|Behavioral|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
79686268|NCT00554138|Drug|rosuvastatin|1 dd 20 mg for 7-10 days
79235492|NCT02314767|Behavioral|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
79686269|NCT03455595|Procedure|Endoscopic exams|Coloscopy
79828616|NCT05264480|Procedure|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
79828617|NCT05261828|Behavioral|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
79828618|NCT05261828|Behavioral|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
79235493|NCT02318121|Procedure|Amniotomy first|rupture of membranes to augment labor
79828619|NCT05260333|Device|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
79828620|NCT05259813|Genetic|JWCAR029 (Relmacabtagene Autoleucel)|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
79828621|NCT05255159|Diagnostic Test|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
79828622|NCT05253560|Diagnostic Test|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
79828623|NCT05253534|Device|GlaucoT Glaucoma Treatment Device|"In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow."
79376520|NCT03389958|Other|Counseling and provision of contraception|Provider training, availability of contraceptive methods
79376521|NCT03389880|Procedure|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
79686270|NCT03923387|Device|MynxGrip|Vascular Closure
79828624|NCT05241730|Other|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
79828625|NCT05241730|Other|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
79828626|NCT05241730|Other|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
79828627|NCT05241730|Other|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
79828628|NCT05239403|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
79828629|NCT05239403|Other|Questionnaire Administration|Complete questionnaires
79828630|NCT05236374|Other|Beef protein|Animal protein source
79828631|NCT05235633|Diagnostic Test|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
79828632|NCT05234983|Behavioral|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
79828633|NCT05233085|Drug|AZD4041|Participants will receive oral solution of AZD4041 as stated in arm description.
79686271|NCT03923387|Other|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
79686272|NCT01231555|Drug|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
79686273|NCT01231555|Drug|GSK2248761 200 mg once daily|2x100 mg capsules
79686274|NCT01231555|Drug|Efavirenz 600 mg once daily|1x600mg tablet
79686275|NCT05288907|Drug|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
79686276|NCT04683861|Procedure|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
79828634|NCT05233085|Other|Placebo|Participants will receive oral solution of placebo as stated in arm description.
80003249|NCT01361789|Drug|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
80003250|NCT01361789|Drug|Dexamethasone|8 mg IV
80003251|NCT01361789|Drug|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
80003252|NCT05168761|Procedure|partial nephrectomy|
80003253|NCT02081612|Behavioral|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
80003254|NCT02081612|Procedure|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
79235494|NCT02318121|Procedure|Oxytocin first|Administration of oxytocin to augment labor
79235495|NCT02318121|Procedure|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
79235496|NCT02318121|Drug|Oxytocin|
79235497|NCT02318199|Procedure|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
79235498|NCT05225597|Procedure|Intracameral administration of epinephrine and carbachol during cataract surgery|All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
79235499|NCT02314845|Other|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
79235500|NCT02314845|Other|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
79376522|NCT03389880|Procedure|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
79376523|NCT01565356|Drug|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
79376524|NCT04446234|Drug|Risperidone|Use medicine according to patients condition
79530078|NCT01418053|Drug|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
79530079|NCT01418066|Drug|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
79828635|NCT05230550|Drug|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
80003255|NCT02964507|Drug|GSK525762|GSK525762 will be administered.
80003256|NCT02964507|Drug|Placebo|Placebo will be administered.
79235501|NCT05225519|Device|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
79235502|NCT05225519|Device|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
79235503|NCT04051307|Drug|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
79235504|NCT04051307|Drug|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
79376525|NCT04446234|Drug|Aripiprazole|Use medicine according to patients condition
79376526|NCT04446234|Drug|Ziprasidone|Use medicine according to patients condition
79376527|NCT04446234|Drug|Amisulpride|Use medicine according to patients condition
79530080|NCT01418066|Drug|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
80003257|NCT02964507|Drug|Fulvestrant|Fulvestrant will be administered.
80003258|NCT01359761|Behavioral|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
79235505|NCT05225285|Biological|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
79235506|NCT05225285|Biological|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
80003259|NCT02083874|Drug|CBD|
80003260|NCT01367197|Behavioral|exercise training|group based exercise training
79376528|NCT04446234|Drug|Quetiapine|Use medicine according to patients condition
79376529|NCT01510834|Behavioral|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
80003261|NCT05188781|Drug|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
80003262|NCT02083952|Other|Swaddle Blanket|Two arms involve varying time spent in blanket
80003263|NCT01367353|Procedure|surgery or debulking surgery|surgery or debulking surgery
80003264|NCT01359839|Behavioral|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
80003265|NCT03634735|Drug|Thiamine|Vitamine B1
80003266|NCT03634735|Other|Placebo|Placebo tablets
80003267|NCT03559322|Device|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
80003268|NCT03634657|Radiation|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
79828636|NCT05229393|Other|Cervical plus Diaphragmatic Manual Therapy plus Breathing Reeducation Exercises|"Diaphragmatic Manual Therapy consists of techniques intended to indirectly stretch and mobilize the diaphragmatic muscle fibers. This will help to improve muscle contraction and decrease tension. The experimental maneuvers include the Doming Diaphragmatic Technique as described by Leon Chaitow, Lewit, and the Manual Diaphragmatic Release Technique as described by Leon Chaitow. Both maneuvers are performed in two sets of 10 repetitions, within a 1-minute interval.~Cervical Manual Therapy consists of vertebral mobilization techniques according to the Mulligan technique.~Breathing Reeducation Exercises consist of i) recognition of the abnormal breathing pattern, ii) relaxation techniques for all the primary and accessory respiratory muscles, iii) diaphragm breathing reeducation iv) pursed lips exercise v) reeducation of the normal breathing rate"
79828637|NCT05229393|Other|Cervical Manual Therapy plus sham Diaphragmatic Manual Therapy|"Ultrasound sham as Diaphragmatic Manual techniques. Disconnected ultrasound will be applied in the same position as for the experimental group for 15 min as a placebo treatment.~Cervical Manual Therapy: will consist of vertebral mobilization techniques according to Mulligan -"
79235507|NCT03673579|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
79376530|NCT03385044|Procedure|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
80003269|NCT03634657|Radiation|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield & X-ray protective strips
79235508|NCT03070327|Biological|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10^6, 3x10^6, and 1x10^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
79376531|NCT03385044|Procedure|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
79376532|NCT03388086|Drug|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
79376533|NCT03613506|Drug|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
79376534|NCT01565902|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
79828638|NCT05229393|Other|Conventional Physiotherapy Program|Conventional Physiotherapy Program consists of TENS for 15min, Microwave pulsed Diathermy for 10min, soft tissue techniques for 15min
79828639|NCT05222555|Drug|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
79828640|NCT05222555|Drug|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
79828641|NCT05221762|Diagnostic Test|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) at 3 Tesla
79828642|NCT05218694|Diagnostic Test|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
80003270|NCT03634657|Radiation|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield & X-ray protective strips & X-ray protection patient cut-outs
80003271|NCT04563195|Drug|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
79235509|NCT03070327|Drug|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
80003272|NCT02084108|Other|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
79235510|NCT03070327|Drug|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
79235511|NCT00543127|Drug|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
79235512|NCT00543127|Drug|Anastrozole|1 mg oral Anastrozole per day during 5 years.
79376535|NCT01566448|Drug|Ketamine|20mg/5ml swish and spit four times daily
79376536|NCT05565976|Drug|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
79376537|NCT05565976|Drug|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
79376538|NCT05565976|Drug|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
79530081|NCT01418079|Device|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
79530082|NCT01418105|Procedure|Videofluroscopic swallow study (VFSS)|Barium, radiation
79530083|NCT01418105|Procedure|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
80003273|NCT01371409|Other|continuous theta burst stimulation|80% active motor threshold, 600 pulses
79376539|NCT05565976|Drug|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
79376540|NCT01566526|Drug|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
79530084|NCT01418105|Procedure|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
80003274|NCT02084186|Other|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
80003275|NCT02084186|Other|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
80003276|NCT03170869|Device|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
79828645|NCT05209685|Other|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
79828646|NCT05209685|Other|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
80003277|NCT02084342|Drug|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
80003278|NCT02084342|Drug|normal saline|100ml, IV for 30min,before incision.
80003279|NCT02084342|Drug|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
80003280|NCT03558542|Other|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
80003281|NCT01371487|Drug|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
80003282|NCT02084420|Drug|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
80003283|NCT02084420|Drug|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
80003284|NCT01367431|Dietary Supplement|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
79235513|NCT02314923|Biological|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.
79376541|NCT03185832|Device|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
79376542|NCT03185832|Device|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
80003285|NCT01367509|Drug|Methylnaltrexone (MNTX)|
80003286|NCT02084498|Device|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
80003287|NCT02084498|Behavioral|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
80003288|NCT01364545|Dietary Supplement|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
80003289|NCT01364545|Dietary Supplement|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
80003290|NCT02088086|Behavioral|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
80003291|NCT02088086|Behavioral|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
79376543|NCT03185832|Device|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
79530085|NCT01418118|Drug|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
79530086|NCT01418118|Drug|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
79530087|NCT01418118|Drug|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
79530088|NCT01418118|Drug|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
80003292|NCT02088086|Behavioral|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
80003293|NCT01364701|Drug|Sildenafil 100 mg|4 tablets for on demand use
80003294|NCT01364701|Drug|Tadalafil 20 mg|4 tablets on demand
80003295|NCT01364701|Drug|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
80003296|NCT02088242|Drug|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
80003297|NCT02088242|Drug|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
79235514|NCT02314923|Other|Placebo|0.9% Saline
79235515|NCT00409435|Drug|pyridostigmine|one 180 mg capsule per day for 3 days
79235516|NCT00409435|Drug|Placebo|one capsule per day for 3 days
79235517|NCT02309307|Device|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
79235518|NCT03500601|Other|Nut components|nut components consumed daily for a period of 28 days
79235519|NCT03500601|Other|Placebo|Placebo consumed daily for a period of 28 days
79235520|NCT02309385|Drug|8% Dexamethasone Sodium Phosphate - Visulex|
79235521|NCT02309385|Drug|15% Dexamethasone Sodium Phosphate - Visulex|
79235522|NCT02309385|Drug|Prednisolone Acetate (1%) Eye Drops|
79530089|NCT01418131|Drug|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
79530090|NCT01418131|Drug|Placebo|Placebo
79376544|NCT03185832|Other|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
79376545|NCT01566838|Drug|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
79391129|NCT02424006|Device|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
79530091|NCT01418144|Procedure|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
79530092|NCT01418144|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
79530093|NCT01418157|Drug|Acetazolamide|125 mg twice daily until 4380 meters altitude
79530094|NCT01418157|Drug|Placebo|Twice daily
79530095|NCT01418170|Other|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
79686277|NCT01210651|Behavioral|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
79828647|NCT05208411|Behavioral|Project ImPACT: Improving Parents As Communication Teachers|"Project ImPACT (Improving Parents As Communication Teachers, Ingersoll & Dvortcsak, 2019) is a promising evidence-based parent-mediated intervention that is part of a class of naturalistic, developmental, behavioral interventions (NBDIs). NBDIs involve the use of behavioral principles of learning to teach skills chosen from a developmental sequence in naturalistic play-setting and using natural rewards. Skills selected as relevant for intervention are those that allow the child to participate more fully within reciprocal interactions with the adult. In recent years the program has been adapted for use with infants and toddlers at elevated likelihood of ASD. These adaptations have made this program appropriate for younger children and children who are experiencing social communication delays but do not have an ASD diagnosis."
79828648|NCT05202080|Other|Opioid Counseling and Pain Coping Skills Video|The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
79686278|NCT01210651|Behavioral|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
79828649|NCT05199324|Drug|Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the intervention arm will be switched early to oral antibiotics (within 72 hours from index blood culture collection)
80003298|NCT02440464|Procedure|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
79530096|NCT01418183|Procedure|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
79530097|NCT01418183|Procedure|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
79530098|NCT01418183|Procedure|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
79530099|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
80003299|NCT02440464|Drug|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
80003300|NCT02440464|Drug|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
80003301|NCT02440464|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
79686279|NCT03911336|Drug|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
79828650|NCT05199324|Drug|Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 24 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
79376546|NCT01566838|Drug|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
80003302|NCT02440464|Drug|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
80003303|NCT02440464|Drug|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
80003304|NCT01367587|Drug|IV Methylnaltrexone|
79828651|NCT05198310|Drug|KPL-404|Humanized monoclonal antibody
79376549|NCT02930538|Other|Survey|Completing a survey on RedCap
80003305|NCT02088398|Drug|ACY-1215|
80003306|NCT02084576|Drug|Nepafenac|One drop in the study eye 3 times daily for 30 days
80003307|NCT02084576|Drug|Ketorolac|One drop in the study eye 4 times daily for 30 days
80003308|NCT03131453|Drug|CNP520 50mg|50 mg capsule
80003309|NCT03131453|Drug|CNP520 15mg|15 mg capsule
80003310|NCT03131453|Other|Matching placebo|Matching placebo for 15 and 50 mg capsules
80003311|NCT02084654|Drug|Exenatide 5 and 10 mcg 2 times a day|
80003312|NCT02084654|Drug|placebo|
79376550|NCT03384888|Device|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
79530100|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
79530101|NCT01418235|Biological|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
80003313|NCT01367743|Drug|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
80003314|NCT01367743|Drug|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
80003315|NCT02084732|Drug|Sorafenib|drug
80003316|NCT02084810|Drug|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
79376551|NCT03384888|Device|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
79376552|NCT01567150|Device|Novel Dressing|Topical wound dressing
79686280|NCT03911336|Drug|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
79686281|NCT03911336|Drug|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
79686282|NCT04683822|Other|Telerehabilitation|Patients will attend telerehabilitation sessions
79828652|NCT05198310|Drug|Placebo|Matching placebo
80003317|NCT02084810|Drug|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
80003318|NCT02780401|Other|Laboratory Biomarker Analysis|Correlative studies
80003319|NCT02780401|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
80003320|NCT02780401|Biological|Sargramostim|Given ID
80003321|NCT02533232|Drug|Minocycline|Minocycline 200mg per day
80003322|NCT01371799|Drug|Drug|Placebo
80003323|NCT01371799|Drug|Drug|4mg and 8mg Study drug
79235523|NCT03463785|Other|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
79376553|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
79686283|NCT03850535|Drug|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
79530102|NCT01418235|Biological|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
79530103|NCT01418274|Drug|danoprevir|oral doses of danoprevir
79530104|NCT01418274|Drug|escitalopram|oral doses of escitalopram
79530105|NCT01418274|Drug|ritonavir|oral doses of ritonavir
79686284|NCT03850535|Drug|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
80003324|NCT02686814|Device|17mm MDT-2215 aortic valve bioprosthesis|
79686285|NCT03850535|Drug|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m^2 QD as IV infusion.
80003325|NCT03779828|Device|HOME LINK|Telemonitoring system which include web platform and connected devices.
80003326|NCT02673151|Procedure|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
79376554|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
79376555|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
80003327|NCT02673151|Drug|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
80003328|NCT02673151|Procedure|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
80003329|NCT02436655|Procedure|surgical aortic valve replacement|open heart aortic valve replacement
80003330|NCT02082080|Other|Education|
80003331|NCT02082080|Other|Social support|
79376556|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
79530106|NCT01418300|Drug|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
80003332|NCT02084966|Procedure|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
80003333|NCT02942277|Biological|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
80003334|NCT02942277|Biological|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
79376557|NCT01568008|Drug|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
79376558|NCT05565508|Procedure|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
79376559|NCT05565508|Procedure|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
79376560|NCT05658120|Drug|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
79376561|NCT01514734|Drug|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
79376562|NCT03380754|Dietary Supplement|Nutricia preOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
79530107|NCT01418391|Procedure|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12~18 hours upon to the regional anesthetics choose"
79530108|NCT01418404|Other|Noxious TS|hot, cold alternately, noxious TS in study A
79530109|NCT01418404|Other|Innocuous TS|warm, cool alternately, Innocuious TS in study A
79530110|NCT01418404|Other|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
79530111|NCT01418404|Other|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
80003335|NCT02942277|Other|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
80003336|NCT02942277|Biological|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
80003337|NCT02942277|Biological|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
79376563|NCT03380754|Other|Nestle Splash Lemon Flavor Water (Placebo)|Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
79376564|NCT01515046|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
79686286|NCT03850535|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
80003338|NCT02942277|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
80003339|NCT02942277|Drug|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
80003340|NCT05042947|Device|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
80003341|NCT05042947|Device|Titanium Clip|the Titanium Clip
80003342|NCT01365013|Behavioral|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
79376565|NCT03384576|Other|Music intervention|Classical music to be played in the Emergency waiting room
79686287|NCT05285436|Device|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
79686288|NCT05263089|Other|PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)|"Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s."
79686289|NCT05263089|Other|ESTELITE® Alpha; Tokuyama, Tokyo, Japan|The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
79686290|NCT03850301|Drug|XBD173|7 days treatment
80003343|NCT01365013|Behavioral|Control group|Standard advice for lifestyle change
80003344|NCT02085044|Dietary Supplement|Ready-to-Used Supplement Food administration|
80003345|NCT02835963|Other|Data collection|Usual data collection
80003346|NCT03559244|Other|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
80003347|NCT03559244|Other|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
80003348|NCT04548375|Device|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
80003349|NCT02082236|Drug|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
80003350|NCT02082236|Drug|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
80003351|NCT02082236|Drug|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
79376566|NCT03384576|Other|No music|No music played in emergency waiting room
79376567|NCT01568944|Drug|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
79376568|NCT01568944|Procedure|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
79376569|NCT03380598|Behavioral|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
79376570|NCT03380598|Behavioral|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
79376571|NCT05565274|Drug|Pentazocine plus placebo|30mg of pentazocine and 2milliLitre of injection water
79376572|NCT03380520|Drug|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
79376573|NCT03380520|Drug|Placebo|IV nacl 0.9%
79376574|NCT03387540|Drug|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
79376575|NCT05173662|Procedure|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
79376576|NCT03387384|Other|Non-interventional study|Non-interventional study
79376577|NCT05173584|Drug|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
79376578|NCT05173584|Drug|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
79376579|NCT04671030|Drug|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
80003352|NCT02082236|Drug|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
80003353|NCT02085122|Other|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
80003354|NCT02082314|Procedure|RFA Vertebroplasty|
79235524|NCT03023137|Behavioral|Walking & dietary modification|"Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
79235525|NCT03502239|Other|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
79235526|NCT02315001|Drug|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
79235527|NCT02315001|Other|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
80003355|NCT02085200|Other|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
80003356|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
80003357|NCT03557996|Drug|Silver Diamine Fluoride|SDF will be applied with a brush
79235528|NCT03049813|Behavioral|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
79235529|NCT03049813|Other|Supported Employment (Services as Usual)|Standard supported employment services.
79235530|NCT03502161|Device|QuantiFERON CMV Assay|Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
79235531|NCT02445885|Procedure|PCI|Guideline directed Percutaneous Coronary Intervention
79235532|NCT03673267|Behavioral|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
80003358|NCT03557996|Drug|Sodium Fluoride Varnish|NaF will be applied with a brush
80003359|NCT03559166|Drug|BLD-2660|Randomized to active product or placebo
80003360|NCT02088710|Behavioral|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
79235533|NCT03669913|Other|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
79235534|NCT02315079|Other|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
80003361|NCT02085278|Device|Apollo Micro Catheter device|Detachable Tip Micro catheter
79376580|NCT04671030|Device|Iontophoresis|Application of direct current to skin using an FDA-approved device
80003362|NCT03559088|Other|Migraine App|Smart phone app used to report migraine burden to the EHR.
80003363|NCT02296801|Drug|Letrozole|
80003364|NCT02296801|Drug|palbociclib|
80003365|NCT02082470|Other|follow-up care|Undergo survivorship care planning
80003366|NCT02082470|Other|active surveillance|Undergo cancer surveillance
79235535|NCT02315079|Other|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
79235536|NCT03500523|Diagnostic Test|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
79235537|NCT03673111|Drug|Y14|Gut hormone analogue
79235538|NCT03673111|Drug|Placebo|0.9% saline
79235539|NCT03673033|Procedure|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
79235540|NCT04463277|Behavioral|Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
79376581|NCT04660890|Drug|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
79376582|NCT04660890|Drug|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
79376583|NCT04660890|Drug|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
80003367|NCT02082470|Other|questionnaire administration|Ancillary studies
80003368|NCT02085434|Behavioral|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
80003369|NCT02859324|Drug|CC-122|
80003370|NCT02859324|Drug|Nivolumab|
79235541|NCT04463277|Behavioral|Time Restricted Feeding|Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
80003371|NCT02085512|Procedure|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
80003372|NCT02085512|Other|Control, web-based tasks|No training modules
79235542|NCT04463277|Behavioral|Time Restricted Feeding with Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
79235543|NCT03506217|Device|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
79235544|NCT02309463|Drug|Endothelin receptor antagonist therapy|
79235545|NCT03502083|Drug|GLP-1 (7-36)Amide|IV infusion
79235546|NCT03500367|Drug|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
79235547|NCT02318433|Drug|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
79235548|NCT02318433|Drug|Saline|
79235549|NCT02315235|Biological|Normal saline|Normal saline is injected in one leg of patient.
79376584|NCT04660890|Drug|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
79376585|NCT04632264|Other|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
79530112|NCT01418404|Other|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
79530113|NCT01418404|Other|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
80003373|NCT01365247|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
80003374|NCT01365247|Behavioral|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
80003375|NCT01365247|Behavioral|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
80003376|NCT02085590|Biological|BCG vaccine|
80003377|NCT02085590|Biological|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
80003378|NCT02143063|Behavioral|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
80003379|NCT02143063|Behavioral|prize contingency management on a variable interval schedule for cocaine abstinence|
80003380|NCT02143063|Behavioral|standard care|
80003381|NCT02088866|Drug|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
80003382|NCT02859246|Drug|Mucinex®|Mucinex®
80003383|NCT02088944|Drug|Infliximab|
79235550|NCT02315235|Biological|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
79235551|NCT03506139|Radiation|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
79235552|NCT02318511|Procedure|Knee injection|Injection into knee for the treatment of Osteoarthritis
79235553|NCT02318511|Other|ReNu amniotic allograft|
79235554|NCT02318511|Device|placebo saline|
79235555|NCT02318511|Device|Hyaluronic Acid|
79235556|NCT02315391|Dietary Supplement|isolated whey protein|isolated whey protein
79235557|NCT02315391|Dietary Supplement|micellar whey protein|micellar whey protein
79235558|NCT02315391|Dietary Supplement|glycine|glycine
79235559|NCT02315391|Dietary Supplement|citrulline|citrulline
79235560|NCT02318745|Behavioral|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
79235561|NCT02318745|Behavioral|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
79376586|NCT04632264|Other|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
79376587|NCT04632264|Other|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
79376588|NCT04632264|Other|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
79530114|NCT01418417|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
79530115|NCT01418430|Drug|CHOP-daclizumab|
79530116|NCT01418443|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
79530117|NCT01418456|Drug|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
79530118|NCT01418469|Dietary Supplement|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
79530119|NCT01418469|Dietary Supplement|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
79235562|NCT03022981|Drug|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
79376589|NCT04607928|Drug|Pirfenidone|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
79376590|NCT04607928|Drug|Placebo|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
79376591|NCT03610386|Other|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will receive menthoxypropanediol topically.
79376592|NCT03610386|Other|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will not receive menthoxypropanediol.
79376593|NCT03384420|Biological|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
79376594|NCT03387228|Other|Pain education|"Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes."
79376595|NCT03387228|Other|Control group|"The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking."
79376596|NCT04569786|Biological|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10^5 pfu/mL (Panels A, E), 2.40x10^6 pfu/mL (Panels B,F), 1.15x10^7 pfu/mL (Panels C, G), 5.55x10^7 pfu/mL (Panels D, H, I).
79376597|NCT04569786|Other|Placebo|Placebo administered via IM injection.
79376598|NCT04485624|Other|No intervention|Observational study
79376599|NCT04447170|Procedure|Simple repair or Graham technique|Simple suture with or without omental protective patch
79530120|NCT01418469|Dietary Supplement|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
79530121|NCT01418469|Dietary Supplement|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
79530122|NCT01418495|Other|Cytology Specimen Collection Procedure|Correlative studies
79530123|NCT01418495|Other|Pharmacological Study|Correlative studies
79530124|NCT01418508|Behavioral|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
79235563|NCT03022981|Drug|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
79235564|NCT03164967|Biological|Bivigam|
79235565|NCT03502005|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
79235566|NCT03501927|Diagnostic Test|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~Left ventricular systolic function~Left ventricular diastolic function~Right ventricular systolic function~Right ventricular pressure overload~Biventricular sizes~Pathology of the mitral- and aortic valves~Pericardial fluid~Gross fluid status~Pleural effusion"
79235567|NCT04058821|Diagnostic Test|Novel MRI scan - 7 days post injury|"A turbo spin-echo localiser (20 seconds)~Single-shot echo planar diffusion tensor imaging (7 minutes)~3D constructive interference in steady state (CISS, 6 minutes)~Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
79376600|NCT05172804|Behavioral|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement [11].
79391130|NCT02424006|Device|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
79530125|NCT01418508|Behavioral|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
79530126|NCT01418521|Drug|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
79530127|NCT01418521|Drug|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
79530128|NCT01418534|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
79530129|NCT01418547|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
79530130|NCT01418560|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
79686291|NCT03850301|Drug|Etifoxine|7 days treatment
80003384|NCT03609606|Drug|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
80003385|NCT03609606|Drug|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
80003386|NCT03609606|Drug|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
80003387|NCT02073097|Drug|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
80003388|NCT02073097|Biological|Rituximab|Given IV (375mg/m^2)
80003389|NCT02073097|Drug|Cyclophosphamide|Given IV (750mg/m^2)
79235568|NCT04058821|Diagnostic Test|Novel MRI scan - 14 days post injury|"A turbo spin-echo localiser (20 seconds)~Single-shot echo planar diffusion tensor imaging (7 minutes)~3D constructive interference in steady state (CISS, 6 minutes)~Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
79235569|NCT04058821|Diagnostic Test|Functional MRI scan - 6 months post brachial plexus exploration|"Continuous whole brain echo-planar imaging~High-resolution T1-weighted imaging of the brain~Bilateral magnetic resonance spectroscopy (12 minutes)"
79376601|NCT05172804|Behavioral|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin [11].
79530131|NCT01418573|Other|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
79530132|NCT01418573|Other|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
79686292|NCT04114929|Other|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
79686293|NCT04114929|Other|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
79686294|NCT03792932|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
79686295|NCT03792932|Procedure|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
79235570|NCT04058821|Diagnostic Test|Functional MRI scan - 12 months post brachial plexus exploration|"Continuous whole brain echo-planar imaging~High-resolution T1-weighted imaging of the brain~Bilateral magnetic resonance spectroscopy (12 minutes)"
80003390|NCT02073097|Drug|Doxorubicin hydrochloride|Given IV (50mg/m^2)
79302642|NCT05455853|Other|Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices|"• First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices."
80003391|NCT02073097|Drug|Vincristine sulfate|Given IV (1.4mg/m^2)
79302643|NCT03202459|Drug|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
79530133|NCT01418573|Other|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
80003392|NCT02073097|Drug|Prednisone|Given PO (100mg)
79530134|NCT01418586|Drug|Torrent's Alfuzosin Extended Release Tablet|
80003393|NCT02073097|Drug|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
80003394|NCT02073097|Drug|Acyclovir|PO (400mg)
79530135|NCT01418599|Drug|Torrent's Alfuzosin Extended Release Tablet|
79530136|NCT01418612|Drug|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
79530137|NCT01418625|Drug|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
79530138|NCT01418651|Drug|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
79530139|NCT01418664|Dietary Supplement|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
80003395|NCT02082548|Other|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
79376602|NCT05172804|Behavioral|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) [11]."
79376603|NCT05172804|Other|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
79530140|NCT01418677|Drug|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
79530141|NCT01418677|Drug|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
79530142|NCT01418677|Drug|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
79530143|NCT01418716|Other|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
79686296|NCT05255367|Combination Product|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
79686297|NCT03753620|Device|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
79686298|NCT03753620|Device|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
79828653|NCT05198258|Other|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
79828654|NCT05198258|Other|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
79828655|NCT05174975|Behavioral|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
79828656|NCT05172271|Device|MagPro TMS Stimulator and coil|TMS measurements of cortical excitability pre and post study intervention
79686299|NCT04095156|Diagnostic Test|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
79828657|NCT05172271|Device|Thymatron System IV|The Thymatron System IV (Somatics LLC, Venice, FL, USA)is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.
79235571|NCT02315547|Drug|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
79302644|NCT03202459|Drug|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
79376604|NCT03380442|Drug|Psilocybin|Psilocybin ingested orally
79530144|NCT01418716|Other|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
79530145|NCT01418729|Drug|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
79686300|NCT03750266|Other|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
79686301|NCT04679129|Drug|ASC42|Oral tablets
79376605|NCT03380442|Drug|Ketamine (Ketalar)|Ketamine administered intranasally
79235572|NCT02309541|Device|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
79828658|NCT05172271|Device|Magnetic Resonance Imaging Scanner|Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.
79686302|NCT04679129|Drug|Placebo|Oral tablets
79686303|NCT05236452|Other|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
79828659|NCT05172271|Other|ECT device without stimulation|Anesthesia alone
79828660|NCT05169866|Drug|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
79235573|NCT03669445|Drug|Ixazomib|21-day cycles induction and 28-day cycles consolidation
79235574|NCT03669445|Drug|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
79235575|NCT03669445|Drug|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
79235576|NCT03669445|Drug|Daratumumab|21-day cycles induction and 28-day cycles consolidation
79235577|NCT02309619|Procedure|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
79828661|NCT05169866|Drug|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
79828662|NCT05169840|Other|Genetic Risk Score for Coronary Artery Disease|Blood samples will be genotyped for million of genetic risk variants for Coronary Artery Disease (CAD)
79828663|NCT05153239|Drug|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 & 8 q3wk
79235578|NCT03669835|Dietary Supplement|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
79235579|NCT03669835|Drug|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
79235580|NCT03501849|Device|Polypectomy using a cold snare|Polypectomy by cold-snare technique
79235581|NCT03500133|Radiation|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
79235582|NCT03500133|Drug|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
79376606|NCT03380364|Device|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
79376607|NCT03558360|Diagnostic Test|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
79376608|NCT03387072|Other|Non interventional study|mental stress test and Blood (or salivary) sample
79686304|NCT04678934|Procedure|TAVR|Transcatheter aortic valve replacement
79686305|NCT04679090|Other|Exercise Program|Participants will exercise twice a week for twelve weeks total.
79686306|NCT05228535|Dietary Supplement|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
79828664|NCT05153239|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
79686307|NCT03689660|Other|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
79828665|NCT05153239|Drug|Irinotecan|Irinotecan 350 mg/m² intravenously Day 1 q3wk
80003396|NCT04523298|Procedure|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
80003397|NCT04523298|Other|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
79376609|NCT05172570|Drug|Gabapentin|Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
79376610|NCT03386916|Procedure|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
79235583|NCT03500133|Drug|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
79235584|NCT03500133|Radiation|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
79828666|NCT05153239|Drug|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
79828667|NCT05153239|Drug|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
79828668|NCT05148052|Device|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
79235585|NCT03500133|Drug|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
79828669|NCT05148052|Behavioral|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
79828670|NCT05144191|Device|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
79828671|NCT05131919|Drug|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
79235586|NCT03500133|Drug|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
79376611|NCT03380286|Device|Firehawk|Firehawk stent
80003398|NCT02089022|Other|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
80003399|NCT03609528|Device|CamPROBE|To be completed
80003400|NCT02082626|Drug|Eribulin mesylate|
79376612|NCT02519868|Device|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
79376613|NCT02519868|Device|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
79376614|NCT05172414|Other|No intervention|The single group had no intervention. All followed the same procedures of different collection methods.
79376615|NCT03380130|Drug|Nivolumab|An anti-programmed death 1 monoclonal antibody
79376616|NCT03380130|Device|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
79828672|NCT05127434|Drug|Placebo|0.9% sodium chloride (normal saline) injection
79828673|NCT05127434|Drug|mRNA-1345|Sterile liquid for injection
79376617|NCT03386838|Biological|Nivolumab|Specified dose on specified days
79376618|NCT03386838|Drug|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
79530146|NCT01418742|Drug|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
79530147|NCT01418742|Drug|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
79828674|NCT05126888|Drug|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
79828675|NCT05126888|Other|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
79828676|NCT05126849|Other|Allogenic transplantation|"Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~Stem cell source Bone Marrow~GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
79828677|NCT05123482|Drug|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers
79235587|NCT03500133|Drug|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
79828678|NCT05121597|Device|HugeMed Videolaryngoscope|Macintosh laryngoscope
79376619|NCT03386838|Biological|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
79828679|NCT05120856|Behavioral|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
79828680|NCT05120856|Behavioral|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
79376620|NCT03386838|Drug|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
79828681|NCT05117294|Drug|Bocidelpar|Oral
79376621|NCT03386838|Drug|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
79376622|NCT03386838|Drug|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
79686308|NCT03689660|Other|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
79828682|NCT05115838|Drug|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
79828683|NCT05115838|Drug|Placebo|Placebo implantable rod placed subdermally on the upper arm.
79828684|NCT05105100|Procedure|Biopsy|Tumor tissue collection
79828685|NCT05105100|Procedure|Biospecimen Collection|Intravenously Blood draw
79828686|NCT05101265|Drug|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
79828687|NCT05101265|Drug|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
79828688|NCT05101174|Behavioral|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation."
79828689|NCT05101174|Behavioral|Control Group|The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
79235588|NCT03500133|Drug|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
79302645|NCT03202459|Drug|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
79376623|NCT03386760|Device|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
79376624|NCT03386760|Device|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
79376625|NCT03384342|Device|Narrow-band UV-B therapy|"Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
79376626|NCT03386682|Device|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
79376627|NCT03384264|Other|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
79376628|NCT03384186|Drug|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams [mg]) oral tablet.
79686309|NCT03689660|Other|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
79686310|NCT05209893|Other|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
79686311|NCT05209893|Other|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
79235589|NCT03500133|Drug|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
79235590|NCT02315781|Device|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
80003401|NCT03610152|Behavioral|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
79235591|NCT02315781|Device|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
79376629|NCT03384186|Drug|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
79376630|NCT03384186|Drug|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
79376631|NCT03379974|Drug|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
79376632|NCT03379974|Behavioral|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
79376633|NCT03384030|Other|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
79376634|NCT03379896|Other|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
79376635|NCT03379818|Behavioral|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
79530148|NCT01418755|Biological|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
79530149|NCT01417793|Behavioral|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
79686312|NCT03688100|Behavioral|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
80003402|NCT02921997|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
80003403|NCT02921997|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
80003404|NCT02921997|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
80003405|NCT02089100|Radiation|stereotactic body radiation therapy|
80003406|NCT02089100|Radiation|Systemic treatment|
79235592|NCT02315937|Procedure|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
79235593|NCT02316015|Dietary Supplement|Infatrini® or Infatrini Peptisorb®|
79235594|NCT02316093|Other|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
79235595|NCT04462653|Device|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
79530150|NCT01418768|Other|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
79530151|NCT01418794|Device|High dose rapamycin stent|Concentration of rapamycin is 2.5%
79530152|NCT01418794|Device|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
79530153|NCT01418807|Procedure|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
79530154|NCT01418807|Procedure|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
79530155|NCT01418820|Device|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
79530156|NCT01418820|Device|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
79828690|NCT05096767|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
79530157|NCT01418872|Other|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
79530158|NCT01418898|Other|Dietary Intervention|Nutrient fortified oat beverage
79235596|NCT04462653|Device|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
79235597|NCT04462809|Drug|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
79530159|NCT01418911|Other|questionnaire|questionnaire only
79530160|NCT01418950|Other|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
79828691|NCT05091957|Other|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
79828692|NCT05091957|Other|Usual Care|Participants in both groups will receive a written summary of available resources
79828693|NCT05083754|Drug|Retifanlimab|Anti-PD-1 Therapy
79376636|NCT03379818|Behavioral|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
79376637|NCT03386370|Device|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
79376638|NCT03383952|Biological|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
79376639|NCT03383796|Procedure|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
79828694|NCT05083754|Drug|Temozolomide|Anti-PD-1 Therapy
79376640|NCT03383796|Procedure|Open resection for pCCA|Open resection for pCCA
79828695|NCT05083754|Radiation|Radiation Therapy|Standard of Care
79828696|NCT05075759|Behavioral|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
79530161|NCT01418963|Drug|RO5285119|single and multiple ascending oral doses
79530162|NCT01418963|Drug|placebo|single and multiple oral doses
79530163|NCT01418976|Behavioral|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
79530164|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
79828697|NCT05075759|Behavioral|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
79828698|NCT05075759|Behavioral|Behavioral Intervention|Remote sessions with a health coach
79828699|NCT05075759|Other|Survey Administration|Ancillary studies
79530165|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
79530166|NCT01419002|Radiation|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
79530167|NCT01419002|Procedure|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
79828700|NCT05074849|Behavioral|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
79828701|NCT05074238|Other|Zinc containing suncreen|"The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study."
79828702|NCT05073692|Drug|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
79235598|NCT04462575|Procedure|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
79235599|NCT04462575|Procedure|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
79235600|NCT02320773|Drug|Betmiga®|Oral
79530168|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =>90 mL/min)
79530169|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr <30 mL/min)
79530170|NCT01419093|Other|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on [feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
79530171|NCT01419106|Device|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
79530172|NCT01419119|Drug|Cholecalciferol|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
79828703|NCT05073692|Drug|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
79235601|NCT03498651|Behavioral|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
79235602|NCT03498651|Behavioral|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
79530173|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
79376641|NCT01570036|Drug|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
79235603|NCT03498651|Behavioral|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
79235604|NCT02320851|Behavioral|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
79235605|NCT02320851|Behavioral|Self-help group (SHG)|(see description of corresponding study arm)
79376642|NCT01570036|Drug|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
79376643|NCT01570036|Drug|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
79376644|NCT03386136|Drug|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
79376645|NCT03379584|Drug|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
79376646|NCT03386058|Device|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
79686313|NCT03688100|Drug|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
79686314|NCT04000503|Behavioral|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
79686315|NCT03653117|Device|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
79686316|NCT03653000|Procedure|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
79828704|NCT05073692|Drug|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
79235606|NCT02309775|Other|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
79235607|NCT03377699|Drug|Insulin degludec|Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
79235608|NCT03377699|Drug|Insulin Aspart|Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
79828705|NCT05073692|Drug|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
79828706|NCT05073692|Drug|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
79828707|NCT05073692|Drug|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
79828708|NCT05073692|Drug|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
79828709|NCT05073692|Drug|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
79828710|NCT05073692|Drug|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
80003407|NCT01083433|Behavioral|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
80003408|NCT01083433|Device|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
80003409|NCT02082704|Behavioral|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
80003410|NCT02082704|Behavioral|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
80003411|NCT02791490|Drug|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
80003412|NCT02791490|Drug|Placebo|Oral tablet, once daily at approximately the same time each day
80003413|NCT02791490|Drug|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
80003414|NCT02821143|Other|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
80003415|NCT02821143|Other|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
80003416|NCT02660775|Behavioral|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task (TREF)~for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~for self assessment : Self - assessment of social cognition (ACSo)"
79686317|NCT03653000|Drug|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
79686318|NCT03963687|Other|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
79686319|NCT03963687|Other|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
79235609|NCT03377699|Drug|Insulin detemir|Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
79235610|NCT04463901|Procedure|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
79235611|NCT04463901|Procedure|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
79235612|NCT04463901|Procedure|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
79235613|NCT04463901|Procedure|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
79686320|NCT03639389|Drug|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
79686321|NCT03639389|Drug|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
79686322|NCT05174091|Other|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
79828711|NCT05073692|Drug|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
79828712|NCT05073692|Drug|Glipizide (SU)|Exposure to Glimepiride (SU)
79235614|NCT02309853|Other|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~Visual or tactile scanning in the personal space~Visual or tactile scanning and trunk rotation in the peripersonal space~Visual scanning and trunk rotation in the extrapersonal space"
79235615|NCT02309853|Other|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
79302646|NCT04991181|Drug|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
79828713|NCT05073692|Drug|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
79828714|NCT05073692|Drug|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
79686323|NCT03603665|Biological|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
79828715|NCT05073692|Drug|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
79376647|NCT05564962|Diagnostic Test|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
79828716|NCT05071222|Genetic|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
79828717|NCT05068271|Behavioral|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
79828718|NCT05068271|Behavioral|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
79828719|NCT05067335|Drug|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
79376648|NCT03383718|Procedure|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
79376649|NCT03383718|Other|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
79376650|NCT01516684|Drug|placebo administration|Given topically
79530174|NCT01419119|Drug|Cholecalciferol|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
79530175|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
79376651|NCT01516684|Drug|EMLA|Given topically
79686324|NCT03603665|Other|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
79686325|NCT03943641|Other|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
79686326|NCT03579173|Diagnostic Test|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
79686327|NCT03579173|Diagnostic Test|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
79686328|NCT03579173|Diagnostic Test|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
79376652|NCT01516684|Drug|propofol|Given IV
79376653|NCT01516684|Drug|fentanyl citrate|Given IV
79530176|NCT01419132|Drug|Furosemide|125-250 mg furosemide bid
79530177|NCT01419132|Drug|Furosemide|125-250 mf furosemide bid
79530178|NCT01419145|Other|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
79530179|NCT01419145|Other|Standard care|Standard cancer care
79686329|NCT05172531|Drug|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
79686330|NCT05172531|Drug|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
79828720|NCT05067335|Drug|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
79828721|NCT05066789|Device|Type of stent|1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)
79828722|NCT05066789|Drug|Duration of DAPT|1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
79828723|NCT05062226|Dietary Supplement|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
79828724|NCT05061706|Drug|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
79686331|NCT03570983|Drug|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
79376654|NCT03383640|Other|Active exercises|Active flexion movements every waking hour of the replanted digits
79828725|NCT05061706|Drug|Placebo|Matching capsules administered orally, once daily.
80003417|NCT02660775|Behavioral|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy : Empathy quotient (EQ)~for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
80003418|NCT02660775|Behavioral|Healthy controls|only social cognitive measures
80003419|NCT01365325|Other|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
80003420|NCT01365325|Other|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
79235616|NCT03505827|Diagnostic Test|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
79376655|NCT04316754|Other|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
79376656|NCT03383562|Procedure|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
79376657|NCT01517074|Drug|Sirolimus|Subconjunctival injection
79376658|NCT03379350|Procedure|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
79376659|NCT01570348|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
79376660|NCT01570348|Drug|Cyclophosphamide|Given IV
79828726|NCT05060562|Other|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
79828727|NCT05060562|Other|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
79828728|NCT05058664|Behavioral|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
79235617|NCT03500055|Procedure|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
79235618|NCT04752449|Behavioral|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
79235619|NCT02318823|Other|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
79235620|NCT02318823|Other|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
79235621|NCT05224817|Other|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
79376661|NCT01570348|Drug|Fludarabine Phosphate|Given IV
79376662|NCT01570348|Other|Laboratory Biomarker Analysis|Correlative studies
79376663|NCT01570348|Drug|Mycophenolate Mofetil|Given PO
79376664|NCT01570348|Drug|Mycophenolic Acid|Given PO
79376665|NCT01570348|Other|Quality-of-Life Assessment|Ancillary studies
79376666|NCT01570348|Drug|Tacrolimus|Given IV or PO
79376667|NCT01570348|Radiation|Total-Body Irradiation|Undergo TBI
79376668|NCT03383484|Other|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
79376669|NCT03383484|Other|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
79376670|NCT03383406|Drug|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1~Day3 by Intravenous infusion."
79376671|NCT05564884|Other|no intervantion|no intervention
79828729|NCT05058664|Behavioral|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
79530180|NCT01419210|Other|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
79686332|NCT03570983|Drug|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
79686333|NCT03570983|Drug|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
79376672|NCT04445922|Drug|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
79530181|NCT01419210|Other|Educational Presentations|Attend a two-hour presentation each week for four weeks
79686334|NCT03570983|Drug|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
79828730|NCT05052580|Other|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
80003421|NCT01368367|Other|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
80003422|NCT02833935|Behavioral|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
80003423|NCT02085746|Other|Defining Sexual Activity Questionnaire|
80003424|NCT02085824|Drug|Enoxaparin|
79376673|NCT04445922|Drug|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
79235622|NCT02319057|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
79235623|NCT02319057|Drug|ORM-12741 IR|Immediate release formulation of ORM-12741
79235624|NCT02319057|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
79235625|NCT01314443|Other|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
79376674|NCT01572298|Device|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
79530182|NCT01419210|Other|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
79530183|NCT01419210|Other|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
80003425|NCT02085824|Drug|rivaroxaban|
80003426|NCT02085824|Drug|dabigatran|
80003427|NCT01368445|Drug|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM & PM)
80003428|NCT01368445|Drug|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
80003429|NCT01368445|Drug|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM)
80003430|NCT02085902|Drug|Ropivacaine|
80003431|NCT02654223|Biological|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
80003432|NCT02654223|Biological|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
79530184|NCT01419262|Drug|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
79530185|NCT01419262|Drug|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
79530186|NCT01419288|Other|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
79686335|NCT03570983|Drug|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
79686336|NCT05170815|Procedure|Spine surgery|Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
79828731|NCT05046418|Other|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
79828732|NCT05046314|Biological|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m^2 and 1.5mg/m^2 from the second cycle，every 28 days is a study cycle.
79235626|NCT01314443|Dietary Supplement|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
79235627|NCT01314443|Other|Placebo|Participants will take placebo for 7 days
79235628|NCT01314443|Behavioral|Smoking cessation|Participants will quit smoking without any pharmacological aids
79235629|NCT02310009|Drug|Anakinra (AN)|
79235630|NCT02310009|Behavioral|Exercise (EX)|
79530187|NCT01419301|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
79235631|NCT02310009|Behavioral|Control (CON)|
79235632|NCT03498573|Other|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
79530188|NCT01419327|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
79828733|NCT05043337|Behavioral|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
79686337|NCT03540758|Drug|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
79235633|NCT05655065|Procedure|increase of mean arterial pressure at 65-70 mmHg|Increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion at the discretion of the clinician)
79376675|NCT01572298|Device|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
79376676|NCT03379116|Other|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
79828734|NCT05043337|Behavioral|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
79376677|NCT01518868|Device|Investigational contact lens|Worn on a daily wear basis for one week.
79376678|NCT01518868|Device|PureVision contact lens|Worn on a daily wear basis for one week
79376679|NCT04287348|Drug|Brolucizumab 6 mg solution for intravitreal injection|All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
79376680|NCT03383328|Drug|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
79376681|NCT03383328|Drug|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
79376682|NCT03383328|Drug|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
79686338|NCT03540758|Drug|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
79686339|NCT03540758|Drug|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
79530189|NCT01419340|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
79376683|NCT03383328|Drug|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
79530190|NCT01419353|Drug|estradiol valerate|2 mg P.O / day for 1-6 days.
79530191|NCT01419366|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
79530192|NCT01419392|Drug|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
79530193|NCT01419392|Drug|matching placebo|orally, 4 times per day for 21 days
79530194|NCT01419405|Drug|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
79235634|NCT05655065|Procedure|increase of mean arterial pressure at 80-85 mmHg|Increase of mean arterial pressure at 80-85mmHg (with catecholamines or volemic expansion at the discretion of the clinician).
79530195|NCT01419405|Drug|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
79235635|NCT03498417|Diagnostic Test|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
79235636|NCT03212651|Drug|Pembrolizumab|Pembrolizumab 200mg IV infusion
79235637|NCT03499977|Behavioral|Sitting|10 min bouts
79235638|NCT03499977|Behavioral|Light-Intensity Cycling|10min bout
79235639|NCT03499977|Behavioral|Moderate-Intensity Cycling|10 min bout
79235640|NCT03499977|Behavioral|High-Intensity Cycling|10 min bout
79235641|NCT02319135|Drug|Azacitadine|
79235642|NCT02319135|Drug|Fludarabine|
79235643|NCT02319135|Drug|Cytarabine|
79235644|NCT02319135|Drug|Lenograstim|
79235645|NCT02319135|Drug|Filgastrim|
79376684|NCT03383328|Drug|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
79376685|NCT04445376|Other|Physical Exercises|Aerobic Training and Breathing Exercises.
79530196|NCT01419405|Drug|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
80003433|NCT02654223|Biological|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
80003434|NCT02654223|Biological|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
80003435|NCT02654223|Biological|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
80003436|NCT02654223|Biological|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
80003437|NCT02654223|Biological|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
80003438|NCT02654223|Biological|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
80003439|NCT02654223|Biological|Subcutaneous placebo|Comparison between placebo and active group
79376686|NCT01573702|Procedure|Stereotactic Radiosurgery|21 Gy daily for 5 days
80003440|NCT02654223|Biological|Sublingual placebo|Comparison between placebo and active group
80003441|NCT01368523|Drug|nilotinib|
80003442|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
80003443|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
80003444|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
80003445|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
80003446|NCT01368601|Procedure|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
79235646|NCT05242991|Device|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
80003447|NCT01368679|Procedure|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
80003448|NCT02507973|Other|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
80003449|NCT02507973|Other|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
80003450|NCT03558386|Behavioral|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
80003451|NCT02086214|Device|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
79235647|NCT02319213|Other|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
79376687|NCT01573702|Drug|Erlotinib|150mg once daily
79376688|NCT04445298|Diagnostic Test|Transepidermal water loss|We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
80003452|NCT02086214|Device|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
80003453|NCT01368757|Drug|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
80003454|NCT02082938|Device|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
80003455|NCT04893187|Drug|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
80003456|NCT04893187|Drug|Placebo|Matched placebo.
79235648|NCT02319213|Other|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
79235649|NCT02319213|Other|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
79235650|NCT03498183|Drug|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
79235651|NCT03499743|Drug|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
79235652|NCT03499743|Drug|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
79235653|NCT03499743|Drug|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
79530197|NCT01419431|Procedure|Laparoscopic resection|Inflammatory response in laparoscopic surgery
79686340|NCT05154045|Other|Experimental Formula|Diabetes-specific study formula
79686341|NCT05154045|Other|Test Meal|Instant oatmeal
79235654|NCT03498027|Device|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
79530198|NCT01419444|Behavioral|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
79235655|NCT02310087|Dietary Supplement|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
79235656|NCT02310087|Other|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
79530199|NCT01419457|Drug|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
79530200|NCT01419457|Drug|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
79530201|NCT01419457|Drug|Favipiravir|800 mg Single Dose
79376689|NCT04445298|Diagnostic Test|Skin tape stripping|Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
79235657|NCT02310165|Procedure|Z-tract Insertion Technique|
79376690|NCT04445298|Diagnostic Test|Blood draw|We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
79235658|NCT02310165|Procedure|Coaxial Insertion Technique|
79376691|NCT04445298|Diagnostic Test|Bacterial PCR swab|Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
79376692|NCT03379038|Other|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
79686342|NCT05135481|Procedure|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
79686343|NCT05135481|Other|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
79686344|NCT04678778|Behavioral|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
79686345|NCT03787797|Diagnostic Test|Echocardiography|Assessment of epicardial adipose tissue thickness
79686346|NCT03187379|Drug|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
79686347|NCT03187379|Drug|Bupivacaine|60cc Bupivacaine
79686348|NCT03182231|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
79686349|NCT05124288|Other|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
79686350|NCT03077360|Behavioral|Lifestyle|Lifestyle changes to lose weight or become more fit
79828735|NCT05043337|Behavioral|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
79235659|NCT02923921|Biological|Pegilodecakin|Pegilodecakin plus FOLFOX
79235660|NCT02923921|Drug|FOLFOX|FOLFOX Alone
79235661|NCT02310243|Drug|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
79235662|NCT05223569|Device|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
79235663|NCT05223569|Device|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
79235664|NCT02989571|Drug|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
79376693|NCT03379038|Other|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
79376694|NCT03093246|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
79376695|NCT03093246|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
79235665|NCT02989571|Drug|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
79376696|NCT03093246|Other|Placebo|Placebo pills over a period of 180 days
79530202|NCT01419470|Drug|dapoxetine|"multiple dosing~12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
79530203|NCT01419483|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
79530204|NCT01419496|Genetic|protein expression analysis|
79530205|NCT01419496|Other|flow cytometry|
79530206|NCT01419496|Other|laboratory biomarker analysis|
79530207|NCT01419509|Genetic|DNA methylation analysis|
79530208|NCT01419509|Genetic|microarray analysis|
79530209|NCT01419509|Genetic|polymerase chain reaction|
79530210|NCT01419509|Other|laboratory biomarker analysis|
79530211|NCT01419548|Drug|ABT-888|
79530212|NCT01419548|Drug|Carboplatin|
79530213|NCT01419548|Drug|Paclitaxel|
79530214|NCT01419587|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
79686351|NCT03722511|Dietary Supplement|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
79686352|NCT02964884|Drug|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
79686353|NCT02964884|Behavioral|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
79686354|NCT02964884|Drug|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
79686355|NCT02964884|Behavioral|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
80003457|NCT03558308|Behavioral|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
80003458|NCT03558308|Other|Sham computerized gaming|Sham training with generally stimulating computer-games
79235666|NCT03497793|Other|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
79235667|NCT02319447|Behavioral|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
79235668|NCT02321085|Procedure|Sinus Rhythm control|
79235669|NCT02321085|Procedure|Pulse Rate control|
79235670|NCT03625661|Drug|Ferinject|Ferinject 50mg/ml, one injection
79235671|NCT03497715|Drug|Ibuprofen lysine|Test 1
79235672|NCT03497715|Drug|Ibuprofen Sodium|Test 2
79235673|NCT03497715|Drug|Ibuprofen|Test 3
79235674|NCT03497715|Drug|Ibuprofen (Nurofen)|Reference 1
79235675|NCT03497715|Drug|Ibuprofen (Wockhardt)|Reference 2
79235676|NCT02321163|Device|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
79235677|NCT02321163|Device|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
79235678|NCT02321163|Device|NMES no stimulation|Placebo, electrode pad on, no stimulation
79376697|NCT03093246|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
79376698|NCT03000426|Procedure|Free gingival graft|Free gingival graft removal from palate for socket preservation
79376699|NCT03000426|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
79376700|NCT05171634|Device|DiscoveryTM|Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).
79376701|NCT05171634|Device|iSCAN|Virtual colonoscopy assisted by iSCAN
79376702|NCT03125460|Device|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
79376703|NCT02969928|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
79376704|NCT02969928|Drug|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
79376705|NCT02969928|Drug|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
79376706|NCT02969928|Drug|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
79376707|NCT05171556|Other|Cosmetic product|RV4942A is a face balm product
79235679|NCT04462887|Behavioral|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
79376708|NCT02968446|Dietary Supplement|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
79530215|NCT01419600|Drug|AZD8683|Single Dose Inhaled IMP via Turbuhaler
79530216|NCT01419600|Drug|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
79530217|NCT01419613|Behavioral|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
79530218|NCT01419613|Behavioral|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
79530219|NCT01419652|Other|hold hypoglycemic meds|continue versus hold hypoglycemic medications
79828736|NCT05042895|Procedure|Group A|"Office diagnostic hysteroscopy for assessment of the following:~cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone [FSH], LH, thyroid-stimulating hormone [TSH], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
79828737|NCT05042895|Procedure|Group B|"Office diagnostic hysteroscopy for assessment of the following:~cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone [FSH], LH, thyroid-stimulating hormone [TSH], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
79828738|NCT05038527|Device|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
79686356|NCT04683705|Diagnostic Test|Ultrasound|"High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
79828739|NCT05030441|Drug|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
79828740|NCT05026749|Drug|AZM Group|AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
79686357|NCT02837042|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
79686358|NCT04683744|Other|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
79235680|NCT02321241|Drug|Aflibercept (EYLEA, BAY-86-5321)|"st year: 3 monthly injections followed by 1 injection every two months~nd year and following: injection according the visual and anatomical results observed the 1st year"
79686359|NCT04683744|Other|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
79376709|NCT02968446|Dietary Supplement|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
79376710|NCT02968446|Drug|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
79376711|NCT03125382|Device|Carelink System|Patients start to perform device data transmission through Carelink system
79686360|NCT05098470|Drug|Metformin|1500-2000 mg per day for 8 weeks
79686361|NCT05098470|Drug|Insulin Glargine|Long-acting insulin for 8 weeks
79235681|NCT03583307|Drug|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
79235682|NCT02310477|Drug|regorafenib|regorafenib for all groups
79235683|NCT02449551|Drug|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
79376712|NCT03125382|Device|In office standard visit|Patients start or maintain in office standard visits
79376713|NCT03383250|Dietary Supplement|Normal meal|
79376714|NCT03378960|Drug|Omeprazole 20mg|
79376715|NCT02907996|Drug|Sofosbuvir|400 mg tablet administered orally once daily
79376716|NCT03378882|Biological|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
79686362|NCT05098470|Drug|Dorzagliatin|Oral Glucokinase Activator 75 mg twice daily for 8 weeks
79530220|NCT01419678|Other|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
79530221|NCT01419691|Drug|auranofin|6 mg twice a day for a total of 12 mg total daily dose
79530222|NCT01419730|Drug|Vitamin D3|Vitamin D3 50,000 IU
79530223|NCT01419730|Behavioral|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
79530224|NCT01419756|Device|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
79530225|NCT01419782|Other|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
79828741|NCT05026749|Other|Control Group|Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
80003459|NCT02086292|Procedure|2 ml 1% Lidocaine|
80003460|NCT02086292|Procedure|1 ml 2% Lidocaine|
79686363|NCT02710643|Drug|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
80003461|NCT03558932|Diagnostic Test|pleural biopsy|diagnostic sampling
80003462|NCT02769273|Device|Percutaneous Transluminal Angioplasty|
79376717|NCT03378882|Procedure|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
80003463|NCT02083016|Device|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
79235684|NCT03499665|Behavioral|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
79235685|NCT03499665|Behavioral|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
79235686|NCT03499665|Behavioral|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
79235687|NCT03039023|Dietary Supplement|Choline Bitartrate|500mg choline bitartrate tablets
79376718|NCT03383172|Behavioral|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
79828742|NCT05009992|Drug|ONC201|Given orally (PO)
79235688|NCT03039023|Other|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
79235689|NCT03039023|Other|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
79235690|NCT03039023|Dietary Supplement|Phosphatidylcholine capsules|420 mg phosphatidylcholine capsules obtained from a commercial source.
79235691|NCT02310555|Procedure|Gastric bypass|
79235692|NCT02310555|Procedure|Modified gastric bypass.|
79235693|NCT02310555|Procedure|Slevee Gastrectomy|
79235694|NCT03499431|Device|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
79235695|NCT03708263|Device|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
79828743|NCT05009992|Radiation|Radiation Therapy|Undergo radiation therapy
79828744|NCT05009992|Drug|Paxalisib|Given PO
79828745|NCT05002374|Other|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
80003464|NCT02083016|Device|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
80003465|NCT02086370|Procedure|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
80003466|NCT02086370|Procedure|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
80003467|NCT02083172|Device|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
80003468|NCT02425644|Drug|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
80003469|NCT02425644|Drug|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
80003470|NCT02184741|Drug|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
79235696|NCT03708263|Device|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
79235697|NCT02310711|Other|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
79235698|NCT03022045|Drug|risankizumab|risankizumab administered by subcutaneous injection
79235699|NCT02736695|Drug|F-18 AV 1451|Tau binding agent
79235700|NCT04462263|Drug|HTL0014242|Solid suspension capsule
79235701|NCT04462341|Device|Water Flosser|Device that uses water under pressure to clean around teeth and under the gums
79376719|NCT03378804|Procedure|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
79376720|NCT03378804|Procedure|Continous epidural analgesia|
79686364|NCT05093205|Drug|PF-06882961|Tablets
79686365|NCT05093205|Drug|Atorvastatin|Tablets
79686366|NCT05093205|Drug|Midazolam|Syrup
79686367|NCT05093205|Drug|Levonorgestrel & Ethinyl Estradiol|Tablet
79686368|NCT00552981|Procedure|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
79686369|NCT00552981|Procedure|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
79530226|NCT01419808|Procedure|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
79530227|NCT01419808|Procedure|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
79686370|NCT02623751|Drug|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
79828746|NCT05002374|Other|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
79828747|NCT05001555|Drug|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
79828748|NCT05001555|Drug|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
80003471|NCT02184741|Drug|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
80003472|NCT02086526|Drug|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
80003473|NCT04180995|Drug|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
79828749|NCT04999345|Other|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
80003474|NCT02627690|Other|islet transplanted|islet transplantation
79235702|NCT04462341|Device|Manual Toothbrush|Plastic handle with nylon bristles to clean teeth
79235703|NCT02321397|Drug|Oxycodone|
79376721|NCT03385824|Behavioral|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
79828750|NCT04999345|Other|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
80003475|NCT02627690|Other|non islet transplanted|no islet transplantation (for a non nephrologic reason)
79376722|NCT03385746|Other|polyamide|metal reinforced polyamide denture base material
79376723|NCT03385746|Other|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
79530228|NCT01419821|Drug|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
80003476|NCT03558776|Dietary Supplement|linseed oil|linseed oil and defined background diet
80003477|NCT02089178|Procedure|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
80003478|NCT02089178|Procedure|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
80003479|NCT02089178|Drug|propofol-remifentanil|
79686371|NCT02623751|Drug|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
79686372|NCT00553215|Procedure|quality-of-life assessment|
79686373|NCT00553215|Procedure|questionnaire administration|
79828751|NCT04995172|Procedure|Computed Tomography|Undergo mobile CT-assisted bronchoscopy
80003480|NCT02089178|Drug|sevoflurane-remifentanil|
80003481|NCT02089256|Drug|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
79828752|NCT04995172|Other|Electronic Health Record Review|Patients' medical records are reviewed
79828753|NCT04995172|Procedure|Endobronchial Ultrasound Bronchoscopy|Undergo radial probe EBUS
79828754|NCT04990596|Biological|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
80003482|NCT02090816|Procedure|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
79235704|NCT02321397|Drug|Naloxone|Prolonged Release Tablets
79235705|NCT02319603|Drug|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
79235706|NCT02319603|Drug|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
79235707|NCT02673671|Device|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
79235708|NCT03499275|Device|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
79376724|NCT03378726|Dietary Supplement|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
79376725|NCT03378726|Behavioral|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
79376726|NCT03378726|Behavioral|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
79530229|NCT01419821|Other|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
79530230|NCT01419847|Drug|Ciclopirox|
79530231|NCT01419847|Drug|Placebo|
79530232|NCT01419873|Drug|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
79686374|NCT02469155|Drug|ITI-007|
79686375|NCT02469155|Drug|Risperidone|
79686376|NCT02469155|Drug|Placebo|
79686377|NCT02465606|Drug|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
79686378|NCT02465606|Drug|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
79828755|NCT04984356|Biological|WU-CART-007|A single IV infusion of WU-CART-007 Cells on Day 1
80003483|NCT04099329|Behavioral|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
79376727|NCT03378726|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
79828756|NCT04978584|Drug|Acalabrutinib|Given PO
79828757|NCT04978584|Drug|Cyclophosphamide|Given IV
79828758|NCT04978584|Drug|Doxorubicin Hydrochloride|Given IV
79828759|NCT04978584|Drug|Lenalidomide|Given PO
80003484|NCT02086760|Other|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
80003485|NCT02086760|Radiation|Scintigraphy|
80003486|NCT02861664|Other|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
80003487|NCT02861664|Other|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
80003488|NCT02086838|Drug|Theragran Hematinic|
80003489|NCT02086838|Drug|low molecular weight iron dextran|
80003490|NCT02236962|Drug|Placebo|
80003491|NCT02236962|Drug|Ephedrine, pioglitazone|
79235709|NCT03499275|Device|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
80003492|NCT04431375|Biological|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
79235710|NCT03499275|Other|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
79235711|NCT03499275|Other|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
79376728|NCT03378726|Behavioral|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
80003493|NCT04431375|Drug|Tenofovir|Tenofovir [antiviral] 300mg PO once a day .
79530233|NCT01419899|Behavioral|Brief motivational intervention|A 20-30 minute motivational based discussion
80003494|NCT04431375|Other|Fecal Mircobiota Transplantation|FMT for 7 days
80003495|NCT02086994|Drug|misoprostol|given after the delivery of the anterior shoulder of the baby.
80003496|NCT02086994|Drug|carbetocin|given after delivery of anterior shoulder
80003497|NCT01307787|Other|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
80003498|NCT01307787|Other|no intervention|waiting list control group with no intervention
79686379|NCT05080530|Drug|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
79686380|NCT00554177|Drug|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
79686381|NCT00554177|Drug|Placebo|2 doses of 1200mg, administered 2-3 days apart
80003499|NCT02089412|Drug|E2006|
79235712|NCT03497559|Other|Music|Classical music
79235713|NCT02310945|Other|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
79530234|NCT01419912|Dietary Supplement|soy milk|
79530235|NCT01419912|Dietary Supplement|cow's milk|
79828760|NCT04978584|Drug|Prednisone|Given PO
79828761|NCT04978584|Biological|Rituximab|Given IV
79828762|NCT04978584|Biological|Tafasitamab|Given IV
79828763|NCT04978584|Drug|Vincristine|Given IV
79828764|NCT04973163|Drug|BI 1823911|BI 1823911
79828765|NCT04973163|Drug|BI 1701963|BI 1701963
79828766|NCT04973163|Drug|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
79828771|NCT04970576|Drug|Rivaroxaban|Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
79828772|NCT04970576|Drug|Warfarin|Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
79828773|NCT04964739|Behavioral|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
79828774|NCT04961112|Device|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
79828775|NCT04961112|Device|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
79235714|NCT05209451|Behavioral|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
80003500|NCT03557606|Procedure|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
80003501|NCT02091050|Other|2D HDR planning|HDR planning using simple radiograph (2D)
79828776|NCT04948554|Biological|MK-2225|Administered Subcutaneously (SC)
79828777|NCT04948554|Biological|Placebo|Administered SC
79828778|NCT04943744|Device|Entero-tracker|Esophageal STRING test (Entero-tracker)
80003502|NCT02091050|Other|3D HDR planning|HDR planning using computed tomography (3D)
80003503|NCT02087228|Device|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
79530236|NCT01419925|Biological|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
79686382|NCT03487692|Other|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
80003504|NCT02087228|Device|radiofrequency energy ablation device|
79235715|NCT05209451|Other|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
79530237|NCT01419925|Biological|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
79686383|NCT03487692|Other|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
79828779|NCT04941716|Drug|Acalabrutinib|Given PO
79828780|NCT04941716|Drug|Venetoclax|Given PO
79828781|NCT04940780|Other|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
79828782|NCT04940780|Other|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
79828783|NCT04933331|Drug|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
80003505|NCT02089490|Device|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
80003506|NCT02089568|Drug|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
79235716|NCT05209451|Behavioral|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
79376729|NCT03378648|Drug|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
79376730|NCT03378648|Drug|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
79530238|NCT01419925|Biological|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
79530239|NCT01419925|Biological|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
79530240|NCT01419938|Device|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
80003507|NCT02089568|Drug|Normal Saline|Placebo - 0.9% saline
79530241|NCT01419938|Device|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
79828784|NCT04933331|Device|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
79828785|NCT04933331|Device|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
79828786|NCT04933331|Device|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
80003508|NCT03284853|Drug|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
80003509|NCT03284853|Drug|GANFORT®|Topical sterile ophthalmic solution
80003510|NCT02091596|Drug|PluroGel N|Study Drug
80003511|NCT02091596|Drug|PluroGel|PluroGel Vehicle Placebo Comparator
79376731|NCT03378648|Drug|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
79686384|NCT02456675|Drug|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
79686385|NCT02456675|Drug|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
80003512|NCT03557528|Procedure|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
79376732|NCT04063488|Drug|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
79376733|NCT04039542|Other|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
79376734|NCT01519414|Other|Laboratory Biomarker Analysis|Optional correlative studies
80003513|NCT03557450|Device|PET/CT Scan|PET/CT scanning with sodium fluoride
80003514|NCT02087384|Biological|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
79376735|NCT01519414|Other|Placebo|Given PO
79686386|NCT02456675|Drug|itacitinib|The dose of itacitinib will be given orally once daily (QD).
79686387|NCT02456480|Drug|CLS001|topical gel
79686388|NCT02456480|Drug|Vehicle|topical gel
79828787|NCT04933331|Drug|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
79828788|NCT04906746|Drug|Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.|There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
80003515|NCT02087384|Drug|Placebo|injection of 0.9% saline
80003516|NCT02087462|Other|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
80003517|NCT02087462|Other|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
79376736|NCT01519414|Drug|Tivantinib|Given PO
79530242|NCT01419951|Behavioral|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
79302647|NCT03215641|Device|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
79302648|NCT02483663|Device|Functional Magnetic Resonance Imaging|Measure brain activity.
79302649|NCT02483663|Radiation|Dual Energy X-ray absorptiometry|Body composition measurements.
79302650|NCT02483663|Other|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
79530243|NCT01419951|Other|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
79530244|NCT01419951|Behavioral|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
79530245|NCT01419964|Drug|Group 01|ACH24
79302651|NCT02483663|Other|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
79302652|NCT02483663|Other|Test Meals|Breakfast, a snack, and lunch provided during study visit.
79530246|NCT01419964|Drug|Group 02|Placebo
79530247|NCT01419990|Drug|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
79530248|NCT01419990|Drug|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
79530249|NCT01419990|Drug|Placebo|Placebo oral capsules, qd, 10 days
79530250|NCT01420003|Procedure|Bone Marrow Aspiration|3 per study
79530251|NCT01420003|Procedure|Tonsil Biopsy|Optional upon completion of study
79530252|NCT01420042|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
79530253|NCT01420042|Drug|Placebo|Lemon flavoured cordial and Water for Injection
79530254|NCT01420055|Drug|fingolimod|
79686389|NCT03425565|Drug|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
79686390|NCT04678700|Other|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~Directed abdominal-diaphragmatic ventilation (10 times).~Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
79530255|NCT01420094|Drug|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.
79530256|NCT01420094|Drug|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
79376737|NCT01519570|Other|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
79530257|NCT01420094|Drug|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
79828791|NCT04903561|Device|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
79828792|NCT04900155|Drug|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
80003518|NCT02087462|Drug|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
80003519|NCT02087462|Drug|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
80003520|NCT02087540|Drug|Telmisartan 80mg|
80003521|NCT02087540|Drug|Rosuvastatin 20mg|
80003522|NCT02087540|Drug|Rosuvastatin 10mg|
80003523|NCT02087540|Drug|Placebo(for Telmisartan 80mg)|
79530258|NCT01420133|Other|Regimen|regimen normal in salt and sugar
79235717|NCT02319681|Behavioral|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
79235718|NCT02319681|Behavioral|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
79235719|NCT02321475|Drug|EGb761®|
79235720|NCT02321553|Other|Brown rice|brown rice cake
79235721|NCT02321553|Other|White rice|white rice cake
79530259|NCT01420133|Other|Standard regimen|with diet low in salt and sugar
79530260|NCT01420159|Drug|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
79530261|NCT01420172|Other|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
79828793|NCT04900155|Drug|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
79828794|NCT04899076|Device|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
79828795|NCT04897893|Other|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
79828796|NCT04896164|Drug|Curcumin Lozenges|Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
79235722|NCT05155631|Behavioral|COGNITIVE BEHAVIORAL THERAPY|8-10 week self directed on line CBT program approved by FDA
79302653|NCT02483663|Other|Computer Tests|Perform a series of computer tests to determine reaction time.
79376738|NCT01575106|Device|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
79530262|NCT01420185|Genetic|RNA analysis|
79828797|NCT04896164|Other|Placebo Lozenges|Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
80003524|NCT02087540|Drug|Placebo(for Rosuvastatin 20mg)|
79530263|NCT01420185|Genetic|gene expression analysis|
79530264|NCT01420185|Genetic|microarray analysis|
79530265|NCT01420185|Genetic|reverse transcriptase-polymerase chain reaction|
79530266|NCT01420185|Other|laboratory biomarker analysis|
79530267|NCT01420198|Behavioral|Lifestyle intervention|Increased physical activity and improved food habits
79530268|NCT01420211|Drug|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
80003525|NCT02087540|Drug|Placebo(for Rosuvastatin 10mg)|
80003526|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
80003527|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
80003528|NCT03952923|Biological|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
80003529|NCT03206463|Drug|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
79530269|NCT01420211|Device|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
79828798|NCT04894825|Drug|M108|Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)
80003530|NCT03206463|Drug|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
79235723|NCT02321631|Dietary Supplement|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
79235724|NCT02321631|Dietary Supplement|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
79235725|NCT03499197|Diagnostic Test|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
80003531|NCT03206463|Drug|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
79235726|NCT02321709|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79235727|NCT02321709|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79235728|NCT03037619|Behavioral|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
79235729|NCT03037619|Behavioral|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
79530270|NCT01420224|Other|Commercial airline flight|Normal scheduled passenger flight
79530271|NCT01420263|Procedure|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
79828799|NCT04894825|Drug|M108|IV infusion Q3W. (21-day cycles)
79530272|NCT01420263|Procedure|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
79530273|NCT01420302|Procedure|Nurse directed insulin titration|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
79686391|NCT05073627|Drug|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
79235730|NCT03497403|Procedure|Socket preservation control|After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
79235731|NCT03497403|Procedure|Socket preservation experimental|After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
79828800|NCT04893226|Behavioral|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
79828801|NCT04890730|Other|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
79828802|NCT04885036|Behavioral|EFST intervention|EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.
80003532|NCT02091674|Device|Hyaluronic acid|Injected gel
80003533|NCT02087618|Other|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
80003534|NCT02087618|Other|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
79530274|NCT01420302|Procedure|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
79530275|NCT01420328|Drug|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin
79686392|NCT04678739|Drug|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
79686393|NCT04678739|Drug|Tocilizumab|Actemra IV Infusion
79686394|NCT00554255|Drug|SB751689|
79686395|NCT00554333|Biological|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
79530276|NCT01420341|Drug|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
79530277|NCT01420341|Drug|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
79686396|NCT00554333|Biological|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
80003535|NCT04610827|Drug|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
79376739|NCT01519882|Other|Placebo|"Placebo patches size equivalent to 4, 6 & 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
79235732|NCT04463433|Behavioral|Cognitive and behavioral intervention.|Two hours group sessions including mindfulness and emotion regulation. The practice of mindfulness is taught to parents to become aware of their thoughts and emotion on the present moment. The behavioral intervention has parents develop an Positive Time-out for dealing with conflict and negativity, using strategies to down-regulate their own negative emotions.
79376740|NCT01519882|Other|Rotigotine|"Rotigotine patches of 4,6 & 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
79376741|NCT05562856|Combination Product|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
79376742|NCT01576120|Other|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
79235733|NCT04463433|Behavioral|Problem-solving and relationship improvement intervention.|Two hours group sessions including problem-solving and improving marital relationship . In the problem-solving part, the knowledge and techniques of problem-solving are taught to couple. relationship improvement part which promote the couple relationship by being aware of their own and their partner's deep-seated needs and communicating in a congruent way.
79235734|NCT02319915|Drug|Tranexamic Acid|
79376743|NCT01576120|Other|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
79235735|NCT02319915|Drug|Adrenalin|
79376744|NCT01520038|Radiation|Proton therapy|
79376745|NCT01520038|Radiation|IMRT|
79376746|NCT03008044|Device|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
79235736|NCT04898309|Drug|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
79376747|NCT01576276|Radiation|Integrated MR-PET scan|Integrated MR-PET scan using [11C]diprenorphine
79376748|NCT01576276|Drug|Ketorolac|3 administrations of ketorolac over course of study
79235737|NCT04898309|Drug|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
79235738|NCT04898309|Drug|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
79530278|NCT01420367|Drug|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
80003536|NCT01218555|Drug|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
79376749|NCT01576588|Drug|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
79376750|NCT01576588|Drug|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
79376751|NCT01826981|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
79376752|NCT01826981|Drug|SOF|SOF 400 mg tablet administered orally once daily
79530279|NCT01420393|Procedure|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
79530280|NCT01420393|Other|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
79530281|NCT01420406|Other|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
80003537|NCT01218555|Drug|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
80003538|NCT04503733|Drug|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
80003539|NCT04503733|Drug|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
79235739|NCT04898309|Drug|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
79530282|NCT01420406|Other|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
79530283|NCT01420406|Other|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
80003540|NCT04503733|Drug|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
80003541|NCT04503733|Drug|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
80003542|NCT04503733|Other|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
80003543|NCT03557060|Drug|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
79235740|NCT04898309|Drug|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
79235741|NCT04898309|Drug|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
79376753|NCT01826981|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
80003544|NCT01368991|Device|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
79686397|NCT03418701|Behavioral|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
79686398|NCT03368196|Drug|DS-8201a|An antibody drug conjugate
79376754|NCT01826981|Drug|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
80003545|NCT01368991|Procedure|Conventional closure|conventional closure, no kryptonite applied
80003546|NCT02091830|Drug|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
80003547|NCT02091830|Other|Physiotherapy|
80003548|NCT02091830|Drug|Cortisone Injection|
79376755|NCT01826981|Drug|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
80003549|NCT02091830|Other|Others|
79235742|NCT02311023|Other|Intermittent fasting|
79235743|NCT03694457|Procedure|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
80003550|NCT01111305|Drug|Reslizumab|
79376756|NCT01826981|Drug|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
79376757|NCT02247154|Biological|Vigam® (Human Normal Immunoglobulin)|
80003551|NCT01111305|Drug|Diethylcarbamazine|
80003552|NCT01111305|Other|Placebo|
80003553|NCT05191927|Other|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
79235744|NCT03694457|Procedure|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
79235745|NCT03505437|Other|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
79376758|NCT01522924|Other|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
79530284|NCT01420406|Other|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
79530285|NCT01420419|Other|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
79530286|NCT01420419|Other|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
79530287|NCT01420432|Biological|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
79530288|NCT01420445|Drug|YHD001 dose level 1|three times daily / 7 days
79235746|NCT03505437|Other|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
79235747|NCT03497325|Drug|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
79235748|NCT03497325|Drug|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
79235749|NCT02321787|Procedure|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
79235750|NCT03497247|Behavioral|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
79235751|NCT03499041|Drug|LY3314814|Administered orally
79376759|NCT01523704|Device|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
79376760|NCT01523704|Device|BIOTRONIK Home Monitoring System with In-office Follow-up|
79376761|NCT02728752|Drug|Octagam 10%|Patients to be treated with Octagam 10%
79530289|NCT01420445|Drug|YHD001 dose level 2|three times daily / 7 days
79530290|NCT01420445|Drug|Pelargonium sidoides extract|6-9mL three times daily / 7 days
79530291|NCT01420445|Drug|placebo|three times daily / 7 days
79530292|NCT01420458|Drug|Experimental|Bioequivalence of two drug formulations
79530293|NCT01419522|Other|Gait Training Method|Treadmill training at constant velocity
79530294|NCT01420471|Drug|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
79235752|NCT03498963|Procedure|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
79376762|NCT02728752|Other|Placebo|Patients to be treated with a Placebo
79376763|NCT03007810|Drug|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
79376764|NCT03007810|Drug|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
79376765|NCT01578772|Drug|Telmisartan|80mg tablets po daily for 6 weeks
79530295|NCT01420471|Other|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
79530296|NCT01420484|Other|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
79828803|NCT04885036|Behavioral|Treatment As Usual|In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
79828804|NCT04882514|Biological|p*17-K4S2|Administer p*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
80003554|NCT02089802|Drug|Pazopanib|
79235753|NCT02321865|Drug|NPC-02|
79530297|NCT01420497|Drug|intra-articular infiltration|intra articular infiltration
79686399|NCT02436824|Drug|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
79686400|NCT02436824|Other|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
79235754|NCT03505359|Other|partial knee immobilization protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
79686401|NCT02433158|Drug|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
79686402|NCT05029479|Other|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
79686403|NCT02428088|Drug|Dasotraline|Dasotraline 2 mg once daily
80003555|NCT04497415|Other|Video-Based intervention|Three minutes video of a nurse that shares her personal story
79235755|NCT03505359|Other|standard ACL reconstruction rehabilitation protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
79530298|NCT01420497|Drug|epidural infiltration|epidural infiltration
80003556|NCT02087696|Drug|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
79235756|NCT03498885|Procedure|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
79235757|NCT03498885|Procedure|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
79376766|NCT03007576|Biological|RegStem|RegStem, 1.5 ml, one injection
79376767|NCT01804049|Drug|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
79376768|NCT01804049|Drug|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
79376769|NCT02383992|Drug|3% H2O2 solution|
79376770|NCT02383992|Drug|0.9% normal saline|
79376771|NCT02346630|Drug|Placebo|Placebo capsules daily for 3 weeks.
79376772|NCT02346630|Drug|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
79376773|NCT02346630|Device|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
79376774|NCT01826825|Behavioral|Cognitive Screen|Cognitive Screen
79530299|NCT01420510|Drug|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
79530300|NCT01420510|Drug|Placebo vaginal gel|Application of a placebo vaginal gel
79686404|NCT02428088|Drug|Dasotraline|Dasotraline 4 mg once daily
79686405|NCT02428088|Drug|Placebo Comparator|Placebo once daily
79376775|NCT01826825|Behavioral|Mini-Cog|Cognitive Screen
79376776|NCT03385668|Drug|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
79376777|NCT01803737|Behavioral|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
79530301|NCT01420523|Drug|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
79530302|NCT01420562|Procedure|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
79686406|NCT03261609|Other|preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)
79686407|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
79686408|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
79828805|NCT04882514|Biological|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
79530303|NCT01420575|Behavioral|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
79686409|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
79686410|NCT02422979|Combination Product|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
79235758|NCT05027399|Behavioral|Nursing teleconsultation for lifestyle changes|Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
79235759|NCT02311101|Drug|Mitomycin C|Given intravesically
79828806|NCT04882514|Biological|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
79530304|NCT01420575|Behavioral|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
79235760|NCT03619499|Device|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
79235761|NCT04058119|Behavioral|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
79235762|NCT04925765|Device|Flowly (TMC-CP01)|The Flowly (TMC-CP01) treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression.
79235763|NCT04058275|Other|Draw blood (phlebotomy, 83 ml)|Draw 83 ml of blood
79235764|NCT03498807|Device|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
79235765|NCT03498807|Device|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
79235766|NCT03668899|Procedure|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
79686411|NCT02422979|Combination Product|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
79686412|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
79235767|NCT02319993|Drug|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
79686413|NCT03230565|Drug|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
79686414|NCT03230565|Drug|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
79828807|NCT04881825|Drug|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
79235768|NCT02319993|Drug|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
79235769|NCT02319993|Drug|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
79235770|NCT03669211|Diagnostic Test|Cardiac stress test|In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
79235771|NCT04771013|Biological|Thymic peptides|250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
79235772|NCT02320071|Other|Examination of abdominal wall strength changes over time|
79235773|NCT03623191|Other|Clinical examination|
79235774|NCT04760561|Procedure|prone position group|Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
79235775|NCT04620187|Drug|Ado-trastuzumab (T) emtansine (T-DM1)|Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
79828808|NCT04867616|Other|Placebo|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
79235776|NCT04620187|Radiation|Standard of Care Radiotherapy|Radiotherapy to shrink or kill tumors
79235777|NCT04620187|Drug|Standard of Care Chemotherapy|Intravenous injection
79235778|NCT04637321|Procedure|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
79235779|NCT02320305|Biological|MART-1 Antigen|Given IM
79235780|NCT02320305|Drug|TLR4 Agonist GLA-SE|Given IM
79235781|NCT02320305|Other|Laboratory Biomarker Analysis|Correlative studies
79235782|NCT04599725|Drug|medical abortion|medical abortion
79530305|NCT01420614|Procedure|Femoral approach|diagnostic and interventional procedures by femoral artery access
80003557|NCT03634423|Behavioral|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
79686415|NCT02416076|Device|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
80003558|NCT03634423|Behavioral|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
79530306|NCT01420614|Procedure|Radial approach|diagnostic and interventional procedures by radial artery access
80003559|NCT03634423|Behavioral|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003560|NCT03634423|Behavioral|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003561|NCT03634423|Behavioral|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003562|NCT03634423|Behavioral|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
79530307|NCT01420640|Behavioral|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
80003563|NCT03634423|Behavioral|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003564|NCT03634423|Behavioral|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003565|NCT03634423|Behavioral|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
79235783|NCT03625271|Device|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
79235784|NCT03497091|Other|Enteral Formula|Enteral Feeding with an amino acid-based formula
80003566|NCT03634423|Behavioral|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003567|NCT03634423|Behavioral|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
79376778|NCT01803737|Behavioral|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
79530308|NCT01420640|Behavioral|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
79530309|NCT01420640|Behavioral|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
79530310|NCT01420640|Behavioral|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
79530311|NCT01420640|Behavioral|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
79530312|NCT01420666|Drug|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
79376779|NCT03994848|Behavioral|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
79530313|NCT01420666|Drug|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
79686416|NCT02416076|Device|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
79686417|NCT02389985|Drug|CRLX101|
79686418|NCT02389985|Drug|Paclitaxel|
79686419|NCT02377895|Drug|Nasapaque Nasal Solution|
79686420|NCT02377895|Drug|Placebo Saline Nasal Solution|
79530314|NCT01420666|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
79530315|NCT01420666|Drug|Placebo|placebo, three tablets four times a day, orally, with food
79530316|NCT01420692|Drug|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
79530317|NCT01420692|Drug|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
79530318|NCT01420718|Drug|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
79530319|NCT01420718|Drug|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
80003568|NCT03634423|Behavioral|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
80003569|NCT00792831|Drug|ITF2357|Histone-Deacetylase Inhibitor
80003570|NCT00496431|Drug|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
80003571|NCT03634501|Biological|Activated NK|Cell suspension
80003572|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
80003573|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
79828809|NCT04867616|Biological|Bepranemab|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
79235785|NCT03668665|Drug|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
79828810|NCT04865302|Procedure|SSC|"Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes.~SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes.~Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed."
79828811|NCT04862975|Drug|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
79686421|NCT05018832|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79686422|NCT03455075|Drug|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
79530320|NCT01420744|Drug|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
79686423|NCT03455075|Drug|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
79686424|NCT03455075|Drug|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
79828812|NCT04862975|Drug|Efavirenz|Efavirenz will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
79828813|NCT04862975|Drug|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
79530321|NCT01420744|Drug|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
79530322|NCT01420757|Procedure|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
79530323|NCT01420796|Other|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
79686425|NCT04684017|Drug|Anlotinib hydrochloride|anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
79686426|NCT04684017|Drug|Etoposide|100mg/m2 iv on days 1-3 every 21 days for 4 cycles
79686427|NCT04684017|Drug|Carboplatin|AUC 5 iv on day 1 every 21 days for 4 cycles
79828814|NCT04862975|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
80003574|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
80003575|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
79530324|NCT01420796|Other|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
80003576|NCT03627897|Drug|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
80003577|NCT03627897|Drug|saline|No drugs or interventions were administered to the control group.
79686428|NCT00554450|Drug|Dapagliflozin|Tablets, Oral, once daily
80003578|NCT01372111|Drug|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
80003579|NCT01372111|Radiation|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
79235786|NCT03668665|Device|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
79686429|NCT04683666|Procedure|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. ^Postoperative complications were assessed.
79686430|NCT00554489|Behavioral|exercise intervention|participation in physical activity intervention program weeks 2 through 5
79828815|NCT04854863|Diagnostic Test|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
79235787|NCT02322489|Device|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
79235788|NCT02322489|Device|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
79235789|NCT04058509|Combination Product|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
79530325|NCT01420796|Other|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
79235790|NCT02320383|Biological|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
79235791|NCT02320383|Drug|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
79376780|NCT03378492|Device|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
79530326|NCT01420822|Drug|Fluticasone|Collection of safety data
79530327|NCT01420835|Other|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
79530328|NCT01420835|Other|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
79530329|NCT01420861|Drug|GTx-758|two GTx 758 tablets per day
79530330|NCT01420887|Procedure|Continuous Passive Motion|Continuous passive motion.
79530331|NCT01420887|Procedure|Physical Therapy|Physical therapy.
79530332|NCT01420900|Device|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
79530333|NCT01420900|Device|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
79686431|NCT00553020|Drug|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
79686432|NCT00554528|Device|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
79686433|NCT00554528|Procedure|arthrodesis - cervical disk surgery|discectomy and arthrodesis
79686434|NCT04683198|Drug|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
79235792|NCT03668509|Drug|SHR1459|oral adminstration, single dose
79530334|NCT01420913|Drug|Pregabalin|Pregabalin 300mg a day
79530335|NCT01420952|Drug|[11C]LY2428703|
79235793|NCT03494595|Procedure|Pediatric Liver transplantation|Pediatric Liver transplantation
79235794|NCT03021265|Drug|T80/A5/H12.5 FDC|Drug
79235795|NCT02322567|Other|medical records|review of medical records
79235796|NCT03704987|Diagnostic Test|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
79235797|NCT03669289|Other|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
79530336|NCT01420978|Procedure|CSF Diversion|CSF drainage
79530337|NCT01421004|Drug|TKI258|
79530338|NCT01421030|Procedure|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
79530339|NCT01421043|Drug|triazolam liquid oral drops|0.25 mg single dose oral drops
79530340|NCT01421043|Drug|triazolam tablets|0.25 mg single oral dose
79530341|NCT01421082|Device|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
79235798|NCT04461951|Other|Lifestyles (exposure)|no intervention
79376781|NCT03378492|Procedure|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
79530342|NCT01421108|Behavioral|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
79530343|NCT01421108|Behavioral|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
79530344|NCT01421121|Biological|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
79530345|NCT01421121|Biological|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
79530346|NCT01421121|Biological|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
79530347|NCT01421121|Biological|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
79828816|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
79828817|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
79828818|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program|Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
79235799|NCT03668353|Biological|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
79235800|NCT03704909|Drug|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
79530348|NCT01421121|Biological|Placebo|0.5ml placebo, two doses, 28 days interval
79235801|NCT03704909|Drug|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
79376782|NCT03378024|Device|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
79376783|NCT01826201|Drug|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
79530349|NCT01421160|Drug|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
79530350|NCT01421173|Drug|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
79530351|NCT01421173|Drug|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
79530352|NCT01421173|Drug|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
79686435|NCT04683198|Drug|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
79686436|NCT04683198|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
79686437|NCT04683198|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
79686438|NCT00554567|Behavioral|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
79686439|NCT02346422|Genetic|MYDICAR Phase 1|Single dose of MYDICAR
79530353|NCT01421173|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
79530354|NCT01421173|Procedure|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
79686440|NCT02346422|Genetic|MYDICAR Phase 2|Single dose of MYDICAR
79686441|NCT02346422|Genetic|Placebo Phase 2 only|Single dose of placebo
79235802|NCT03704831|Other|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
79235803|NCT03704831|Other|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
79235804|NCT04462029|Drug|BR4002|"Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
79235805|NCT04462029|Drug|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
79828819|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program|Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
79376784|NCT01826201|Drug|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
79376785|NCT03385590|Dietary Supplement|Soy-fiber-maize|Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.
79376786|NCT03385590|Dietary Supplement|Maize|Two servings of maize porridge will be consumed by the children each day for a period of six months.
79530355|NCT01421173|Drug|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
79828820|NCT04840927|Drug|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
79530356|NCT01421173|Drug|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
79828821|NCT04839406|Behavioral|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
79235806|NCT03669055|Other|Magnetic Resonance Imaging|Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
79376787|NCT04947072|Procedure|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
79235807|NCT03704675|Drug|TEW-7197|Administered orally
79376788|NCT04947072|Procedure|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
79376789|NCT04942158|Procedure|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
79530357|NCT01421173|Drug|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
79530358|NCT01421173|Drug|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
79530359|NCT01421199|Procedure|Myringotomy|tube placement for children with multiple ear infections
79530360|NCT01421212|Biological|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).~Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
79530361|NCT01421238|Behavioral|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
79530362|NCT01421316|Radiation|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
79530363|NCT01421368|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
79530364|NCT01421368|Drug|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
79686442|NCT03048552|Behavioral|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
79686443|NCT02342249|Drug|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
79686444|NCT02342249|Drug|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2*300 mg tablets) will be administered over 5-6 days.
79686445|NCT02342249|Drug|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
79686446|NCT02342249|Drug|Placebo|Subjects will receive matching placebo of Oseltamivir
79686447|NCT04683276|Procedure|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and >2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
79686448|NCT02933970|Other|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
79686449|NCT02339129|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
79235808|NCT03494517|Drug|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
79828822|NCT04839081|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
79530365|NCT01421368|Drug|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
80003580|NCT02248532|Biological|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening <6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
79530366|NCT01421407|Device|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
79686450|NCT02339129|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
79828823|NCT04835987|Diagnostic Test|Holter ECG|Measurement of the modification of the sympathomimetic balance
79828824|NCT04835987|Behavioral|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
80003581|NCT05191849|Diagnostic Test|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2~4 cycles of chemotherapy, or at the time of disease progression.
79235809|NCT04461873|Other|Reiki|Reiki by touching
79235810|NCT04461873|Other|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
79376790|NCT04942158|Procedure|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
79376791|NCT03382704|Diagnostic Test|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
79376792|NCT03382626|Device|anodal tDCS|Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
79376793|NCT03382626|Device|Computer-assisted training|The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
79376794|NCT03382626|Device|sham tDCS|Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
79376795|NCT03375450|Other|Standard of Care|Participants will be followed as per local routine primary healthcare practice
79530367|NCT01421433|Drug|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
79530368|NCT01421433|Drug|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
79530369|NCT01421485|Behavioral|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
79828825|NCT04835987|Diagnostic Test|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
79530370|NCT01421485|Behavioral|Treatment as Usual|Treatment in community, case management
79530371|NCT01421550|Procedure|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
79530372|NCT01421550|Procedure|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
79686451|NCT04678622|Device|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
79235811|NCT04177901|Device|Near infrared spectroscopy|It is used for detection of tissue oxygenation
79235812|NCT02320617|Procedure|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
79686452|NCT04971798|Biological|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
79686453|NCT04678388|Drug|Reference drug|1 Cap., single oral administration under fasting condition
79686454|NCT04678388|Drug|Test drug 1|1 Tab., single oral administration under fasting condition
79686455|NCT04678388|Drug|Test drug 2|1 Tab., single oral administration under fasting condition
79686456|NCT02884206|Drug|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
79686457|NCT02884206|Drug|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
79686458|NCT02884206|Drug|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
79686459|NCT02884206|Drug|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
79828826|NCT04835766|Diagnostic Test|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
79828827|NCT04829448|Dietary Supplement|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
80003582|NCT02250404|Other|cytology specimen collection procedure|Correlative studies
80003583|NCT02250404|Other|laboratory biomarker analysis|Correlative studies
80003584|NCT03125941|Drug|Dexamethasone|pre-operative intravenous administration
80003585|NCT02092142|Biological|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
80003586|NCT02774889|Behavioral|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~Fall prevention tips~Fall prevention exercise videos with narrations for proper technique and safety precautions~Guest expert videos with online access to the guest expert to ask questions~Tools to set exercise goals, get reminders and track progress~Access to a fall prevention specialist for personal feedback and suggested group homework~Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~Fall prevention resources"
80003587|NCT02095886|Drug|BMS-955176|BMS-955176
80003588|NCT01372579|Drug|eribulin mesylate|Given IV
79235813|NCT03491865|Behavioral|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
80003589|NCT01372579|Drug|carboplatin|Given IV
80003590|NCT01372579|Procedure|biopsy|Correlative studies
80003591|NCT02089958|Procedure|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
80003592|NCT02090036|Drug|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
80003593|NCT02090036|Drug|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
79235814|NCT03496935|Device|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
79235815|NCT04050839|Other|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
79235816|NCT04050839|Drug|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
79235817|NCT02322645|Drug|Eszopiclone Tablets 3 mg|
80003594|NCT03125629|Drug|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
79235818|NCT04050761|Biological|Nivolumab|Specified dose on Specific Days
79376796|NCT03375372|Procedure|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
79376797|NCT03377946|Biological|probiotics|the probiotics group was taking probiotics 4 packets a day
79530373|NCT01421563|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
79530374|NCT01421576|Dietary Supplement|High fat meal|offer high fat-meal in the morning before drug intake.
79530375|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
79828828|NCT04825834|Other|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.
79828829|NCT04822064|Drug|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
79828830|NCT04822064|Drug|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
80003595|NCT03125629|Drug|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
80003596|NCT03125629|Device|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
80003597|NCT03125629|Device|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
80003598|NCT02092376|Drug|Cholecalciferol|
80003599|NCT02092376|Drug|Placebo|
80003600|NCT02090192|Procedure|WBV training|
80003601|NCT02090192|Procedure|PRT training|
79376798|NCT03377946|Biological|placebo|the placebo group was taking placebo 4 packets a day
79530376|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
79530377|NCT01421628|Other|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
79530378|NCT01421680|Dietary Supplement|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
80003602|NCT05452928|Drug|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
79530379|NCT01421693|Drug|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days~Intravenous infusion. Vials of crystalline powder."
79686460|NCT04678973|Behavioral|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
79686461|NCT04961541|Biological|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
79686462|NCT04961541|Biological|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
79235819|NCT03496857|Device|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
79235820|NCT03496857|Other|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
79376799|NCT03125538|Other|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
79530380|NCT01421693|Drug|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
79530381|NCT01421706|Drug|Sibutramine-clopidogrel|Sibutramine-clopidogrel
79828831|NCT04821843|Drug|Platinum based chemotherapy|q1-3W according to physician's preference
79235821|NCT05130021|Drug|MAX-40279-01|MAX-40279-01 50mg/70mg
79530382|NCT01421706|Drug|sibutramine-Clarithromycin|sibutramine-Clarithromycin
79235822|NCT05130021|Drug|regorafenib|regorafenib
79235823|NCT02324595|Procedure|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
79530383|NCT01421745|Other|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
79530384|NCT01421758|Behavioral|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
79530385|NCT01421758|Behavioral|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
79530386|NCT01421784|Other|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
79530387|NCT01421823|Drug|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
79530388|NCT01421823|Drug|Placebo|2 weeks local treatment with placebo ointment
79530389|NCT01421836|Procedure|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
79530390|NCT01421836|Procedure|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
79530391|NCT01421862|Genetic|DNA methylation analysis|
79530392|NCT01421862|Genetic|RNA analysis|
79530393|NCT01421862|Genetic|gene expression analysis|
79530394|NCT01421862|Genetic|microarray analysis|
79530395|NCT01421862|Genetic|mutation analysis|
79530396|NCT01421862|Genetic|nucleic acid sequencing|
79530397|NCT01421862|Other|laboratory biomarker analysis|
79530398|NCT01421875|Genetic|DNA methylation analysis|
79530399|NCT01421875|Genetic|RNA analysis|
79530400|NCT01421875|Genetic|gene expression analysis|
79530401|NCT01421875|Genetic|microarray analysis|
79530402|NCT01421875|Genetic|nucleic acid sequencing|
79530403|NCT01421875|Other|laboratory biomarker analysis|
79530404|NCT01421901|Drug|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
79530405|NCT01421901|Procedure|appendectomy|
79828832|NCT04821843|Drug|Paclitaxel based chemotherapy|q1-3W according to physician's preference
79530406|NCT01421914|Other|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
79828833|NCT04821843|Radiation|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
79828834|NCT04821843|Procedure|Surgery|Radical esophagectomy
80003603|NCT05452928|Drug|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
80003604|NCT03125395|Drug|LUM/IVA|Participants received LUM/IVA every q12h.
80003605|NCT00264602|Drug|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
80003606|NCT03557138|Behavioral|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG)
80003607|NCT01369303|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
80003608|NCT03556436|Drug|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
79686463|NCT04961541|Biological|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
80003609|NCT02092532|Drug|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
80003610|NCT02092532|Procedure|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
80003611|NCT02092688|Device|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
80003612|NCT02092766|Drug|artesunate|
80003613|NCT02092766|Drug|quinine|
80003614|NCT02090348|Drug|dimethyl fumarate|Administered as specified in the treatment arm
80003615|NCT02721069|Drug|NRL-1|
79376800|NCT03125538|Other|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
79686464|NCT02326454|Drug|talaporfin sodium|1 mg/kg
79686465|NCT02326454|Drug|Saline|
79686466|NCT02326454|Device|Drug Activator 100 J/cm|Light Dose: 100 J/cm
79686467|NCT02326454|Device|Drug Activator 200 J/cm|Light Dose: 200 J/cm
79235824|NCT03491787|Device|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
79235825|NCT05099757|Biological|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
79235826|NCT03494283|Behavioral|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
79235827|NCT02322957|Drug|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
79235828|NCT04785261|Drug|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
79235829|NCT04785261|Drug|Carbomer|1 drip each time, at bedtime, for 12 weeks.
79376801|NCT03377868|Diagnostic Test|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
79376802|NCT03377868|Diagnostic Test|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
79376803|NCT03382470|Other|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
79686468|NCT02324309|Drug|BIOD-531|
79686469|NCT02324309|Drug|Humalog Mix 75/25|
79686470|NCT02324309|Drug|Humulin R U-500|
79686471|NCT02324309|Drug|BIOD-531|
79686472|NCT02307851|Biological|Quadrivalent VLP Vaccine|
79828835|NCT04821843|Drug|Immunotherapy|Anti-PD-1/PD-L1 Antibody
79828836|NCT04821843|Drug|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
79828837|NCT04821843|Drug|Nimotuzumab|200-400mg, d1,qW
79828838|NCT04821817|Drug|Normal saline|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
79828839|NCT04821817|Drug|Rocuronium|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
79828840|NCT04816955|Behavioral|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
79828841|NCT04815304|Diagnostic Test|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
79828842|NCT04811716|Drug|Pozelimab|Administered Sub-cutaneous (SC) per protocol
79686473|NCT02307851|Biological|Comparator TIV|
79828843|NCT04811716|Drug|Cemdisiran|Administered SC per protocol
79828844|NCT04810611|Drug|MBG453|Anti-TIM3 monoclonal antibody
79828845|NCT04810611|Drug|NIS793|Anti-TGF-β monoclonal antibody
79828846|NCT04810611|Drug|canakinumab|Anti-IL-1β monoclonal antibody
79828847|NCT04809324|Procedure|Gross examination of the resection specimen|measurement of the surgical margin by the operating surgeon using sterile scale, margins <7mm will be revised on table
79828848|NCT04809324|Procedure|Frozen section|frozen section evaluation of the specimen by the pathologist
79828849|NCT04809168|Other|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
79828850|NCT04797481|Procedure|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
79828851|NCT04797481|Procedure|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
79235830|NCT04785261|Drug|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
79530407|NCT01421927|Drug|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia < 75000/mm3 or neutropenia < 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~- Duration~until persistent stringent complete response for 3 months~or progression defined by IMWG criteria12~or unacceptable toxicity~or one year after transplant"
79530408|NCT01421940|Drug|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
79530409|NCT01421940|Drug|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
79828852|NCT04796324|Drug|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
79828853|NCT04787341|Drug|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~RAS and BRAF wt ct-DNA at the time of screening."
79686474|NCT02826213|Device|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
80003616|NCT02092844|Behavioral|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
79235831|NCT04611789|Drug|LY3832479|Administered subcutaneously
79235832|NCT04611789|Drug|Placebo|Administered subcutaneously
79235833|NCT03496389|Drug|Gabapentin|Gabapentin 300mg daily
79235834|NCT03496389|Drug|Tramadol|Tramadol 50mg QID
79235835|NCT03496389|Drug|Panadol|Panadol 500mg QID
79530410|NCT01421953|Device|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
79686475|NCT02826213|Device|Waves perfusion device|Renal Perfusion with Waves perfusion device
79686476|NCT02306291|Drug|GMI-1271|E-selectin antagonist
79686477|NCT02306291|Drug|Mitoxantrone|induction chemotherapy
79686478|NCT02306291|Drug|Etoposide|induction chemotherapy
79686479|NCT02306291|Drug|Cytarabine|induction chemotherapy
79686480|NCT02306291|Drug|Idarubicin|induction chemotherapy
79686481|NCT02302079|Drug|ASP8232|oral capsule
79686482|NCT02302079|Drug|ranibizumab|intravitreal (IVT) injection
79686483|NCT02302079|Drug|Placebo|oral capsule
79686484|NCT02302079|Other|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
79686485|NCT01210495|Drug|Axitinib (AG-013736)|Axitinib [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
79686486|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
79235836|NCT03496311|Diagnostic Test|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
79828854|NCT04787341|Drug|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~RAS and BRAF wt ct-DNA at the time of screening."
79828855|NCT04786275|Drug|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
80003617|NCT00390741|Behavioral|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
80003618|NCT02093000|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
80003619|NCT00261807|Drug|Daptomycin 6mg/kg/day|
80003620|NCT02093078|Behavioral|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
79376804|NCT03377712|Device|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
80003621|NCT02090504|Drug|Sodium Oxybate (SMO)|
79235837|NCT02323035|Device|Headgear|Investigative Headgear with CPAP Mask.
79235838|NCT03496155|Behavioral|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
79376805|NCT03377712|Device|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
79376806|NCT03377712|Device|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
79686487|NCT01210495|Drug|Placebo|Placebo [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
79686488|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
79686489|NCT02289716|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
79686490|NCT02289716|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
79686491|NCT02289716|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
79235839|NCT04414527|Behavioral|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~national nutrition and health care including IFA supplementation,~treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
79376807|NCT03377712|Device|Pain evaluation|by means of questionnaires
79376808|NCT03377712|Device|Evaluation of the function|through questionnaires
79376809|NCT03377712|Device|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
79376810|NCT03377712|Device|Quality of life assessment|through questionnaire
79376811|NCT03947112|Behavioral|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
79686492|NCT04922697|Other|Educational Intervention|Watch educational videos and use wearable air pollution sensor
79686493|NCT04922697|Other|Questionnaire Administration|Complete questionnaires
79828856|NCT04786275|Other|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
80003622|NCT02090504|Drug|Oxazepam|
80003623|NCT01567059|Drug|tosedostat|Given PO
80003624|NCT01567059|Drug|cytarabine|Given IV
80003625|NCT01567059|Drug|decitabine|Given IV
80003626|NCT02090582|Other|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
80003627|NCT02090582|Other|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
80003628|NCT02093156|Other|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
80003629|NCT03556982|Biological|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
80003630|NCT02090660|Other|ICG Localization with Spy thoracoscope localization|
80003631|NCT00073671|Behavioral|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
80003632|NCT00073671|Other|Usual care|Participants receive usual care
79235840|NCT04414527|Behavioral|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~National nutrition and health care including IFA supplementation~treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
79235841|NCT03491709|Drug|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
80003633|NCT02090738|Drug|Acetazolamide group|
79235842|NCT03491709|Drug|Cetuximab injection|Cetuximab injection
79376812|NCT03396666|Other|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
79376813|NCT03387774|Drug|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
79235843|NCT02325063|Drug|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
79530411|NCT01421966|Biological|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
79530412|NCT01421966|Biological|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
79530413|NCT01421979|Dietary Supplement|Energy Drink, Taurine, Caffeine|
79686494|NCT02289092|Behavioral|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
79686495|NCT04918095|Device|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
79530414|NCT01421992|Drug|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
79686496|NCT02267642|Biological|AbGn-168H|monoclonal antibody
79686497|NCT04917822|Behavioral|Emotion regulation|Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
79686498|NCT04917822|Behavioral|Information provision|Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
79686499|NCT02267525|Drug|Velusetrag|
79686500|NCT02267525|Drug|Placebo|
79828857|NCT04782284|Other|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
79235844|NCT02325063|Drug|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
79235845|NCT02325063|Drug|Corticoid injection|Patients will be treated with an injection of Corticoids.
79235846|NCT04086693|Device|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
79235847|NCT04086693|Device|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
79235848|NCT02325141|Procedure|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
79235849|NCT03495999|Diagnostic Test|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
79235850|NCT02323191|Drug|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
79235851|NCT02323191|Drug|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
79235852|NCT02323269|Drug|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
79235853|NCT02323347|Other|Progesterone|Progesterone level
79530415|NCT01421992|Drug|Placebo|one tablet placebo per day during 3 weeks
79530416|NCT01422005|Other|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
79235854|NCT03495843|Diagnostic Test|Spinal stiffness|Spinal stiffness will be assessed with a device, which measures tissue compliance according to the concept of impulse-response
79235855|NCT04070313|Drug|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
79235856|NCT03763149|Biological|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
79235857|NCT03495765|Drug|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
79235858|NCT03495531|Device|Virtual Reality|Virtual Reality headset with calming scenery
79235859|NCT02325297|Other|Letter of condolence|
79235860|NCT02325375|Procedure|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
79235861|NCT03491475|Drug|Ajmaline test|Administration of Ajmaline
79686501|NCT04678076|Drug|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
79235862|NCT02325453|Procedure|Robotic Surgery|Surgical procedure performed with a robotic system.
79235863|NCT02325453|Procedure|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
79235864|NCT02325453|Procedure|Open Surgery|Traditional approach for gastric cancer.
79235865|NCT03561597|Behavioral|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
79235866|NCT02323425|Device|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
79235867|NCT02323503|Device|CRT-D device replacement|
79235868|NCT03499119|Drug|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
79235869|NCT03499119|Drug|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
79235870|NCT03499119|Drug|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
79235871|NCT03132207|Other|Non interventionel study|Only one questionnaire will be done for women and professional
79235872|NCT03328845|Drug|Toujeo SoloStar|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
79235873|NCT03328845|Drug|Tresiba|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
79235874|NCT03328845|Drug|Humalog Kwikpen|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels < 150 mg/dl
79235875|NCT03328845|Drug|NovoRapid|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels < 150 mg/dl
79235876|NCT03328845|Drug|Apidra|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels < 150 mg/dl
79235877|NCT03495297|Procedure|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
79235878|NCT03291171|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
79235879|NCT02323737|Drug|Irinotecan and cisplatin|
79235880|NCT02323737|Drug|Etoposide and cisplatin|
79235881|NCT03491319|Procedure|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
79235882|NCT03491319|Procedure|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
79235883|NCT03491319|Procedure|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
79376814|NCT03387774|Radiation|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
80003634|NCT02090738|Drug|Standard regimen group|
79235884|NCT03037359|Biological|Bivigam|Human immune globulin
79235885|NCT03037359|Biological|Other|Human immune globulin
79235886|NCT03491241|Dietary Supplement|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (<50%) overload.
79302654|NCT02483663|Procedure|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
80003635|NCT02096510|Drug|Solu-Cortef|administration by pump for minimum 2 weeks
79376815|NCT03387774|Drug|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
80003636|NCT02096510|Drug|Cortef|tablet treatment 2 ro 3 times per day for 14 days
80003637|NCT05218317|Diagnostic Test|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
80003638|NCT03556280|Device|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
80003639|NCT03556280|Device|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
79235887|NCT03495219|Procedure|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
79235888|NCT03491163|Diagnostic Test|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
79530417|NCT01422005|Other|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
80003640|NCT03555656|Behavioral|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
79686502|NCT04678076|Drug|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
79828858|NCT04782284|Other|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
80003641|NCT03555656|Behavioral|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
80003642|NCT02093468|Drug|MST-188|
79235889|NCT02323815|Dietary Supplement|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
79235890|NCT02323815|Behavioral|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
79235891|NCT03491085|Drug|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
79235892|NCT02323893|Drug|[18F]F-AraG|
79235893|NCT02323971|Drug|Ticagrelor|
79235894|NCT03490851|Other|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
79235895|NCT03490851|Other|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
79235896|NCT03490851|Other|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
79302655|NCT03118609|Other|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
79376816|NCT04377594|Procedure|Radio frequency ablation|Two different radio frequency ablation procedures
79686503|NCT00554645|Behavioral|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
79686504|NCT00554645|Other|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
79828859|NCT04748874|Procedure|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
79828860|NCT04741009|Device|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
79530418|NCT01422018|Drug|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
79530419|NCT01422096|Drug|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if > 37.5 kg im once
79530420|NCT01422109|Drug|YH14659|YH14659 capsule by oral
79530421|NCT01422109|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
80003643|NCT02093468|Drug|Saline|
79530422|NCT01422122|Drug|Vitamin D3|4000 mg per day, one tablespoon syrup per day
79530423|NCT01422122|Drug|Placebo|one table spoon Syrup per day
80003644|NCT02093546|Procedure|Biospecimen Collection|Undergo collection of blood and tumor
80003645|NCT03441555|Drug|Venetoclax|tablet, oral
80003646|NCT03441555|Drug|Alvocidib|Intravenous
80003647|NCT02098772|Drug|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
80003648|NCT02098772|Drug|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
80003649|NCT03357081|Drug|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
80003650|NCT02093780|Behavioral|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
79530424|NCT01422174|Procedure|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
79530425|NCT01422252|Device|Vigi'Fall®|Precocious fall detection device
79530426|NCT01422278|Other|Rehabilitation|Three weeks of rehabilitation in Hospital.
79530427|NCT01422291|Drug|paracetamol|1 gr
79530428|NCT01422291|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
80003651|NCT02093780|Behavioral|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
79235897|NCT03490851|Other|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
79530429|NCT01422291|Drug|Dexketoprofen|50 mg
79530430|NCT01422291|Drug|Paracetamole|1 gr
79686505|NCT02257619|Drug|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
79235898|NCT04461717|Device|MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation|Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
79235899|NCT03148899|Drug|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
79235900|NCT03148899|Drug|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
79235901|NCT03493893|Device|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
79686506|NCT02257619|Drug|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m^2 Q3W for Part 1 of the study.
79235902|NCT03495141|Behavioral|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
79235903|NCT03495063|Dietary Supplement|Natural Caffeine|Consumption of 400mg of natural caffeine
79235904|NCT03495063|Dietary Supplement|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
79235905|NCT02324127|Device|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
79235906|NCT03036267|Behavioral|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
79235907|NCT03036267|Other|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
79530431|NCT01422317|Drug|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
79530432|NCT01422317|Drug|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
79530433|NCT01422330|Drug|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
79530434|NCT01422343|Procedure|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
79530435|NCT01422395|Procedure|Freezing|Vitrification
79530436|NCT01422447|Other|regular intervention|the subjects in the control group live in the used model
79235908|NCT03132285|Device|PrePex|Prepex is a non surgical male circumcision device
79235909|NCT02325843|Other|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
79530437|NCT01422447|Other|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
79530438|NCT01422460|Biological|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
79530439|NCT01422473|Device|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
79530440|NCT01422486|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
79530441|NCT01422499|Drug|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
79530442|NCT01422512|Biological|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
79686507|NCT04683471|Device|Stimulator|Neuromodulation
79686508|NCT04683471|Device|Sham|Sham
79686509|NCT02235272|Drug|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
79686510|NCT02235272|Drug|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
80003652|NCT03346239|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
80003653|NCT03346239|Drug|Escitalopram|10-20 mg of Escitalopram
80003654|NCT03346239|Behavioral|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
79530443|NCT01422525|Procedure|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
79530444|NCT01422551|Behavioral|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
80003655|NCT05216289|Dietary Supplement|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
80003656|NCT05216289|Other|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
80003657|NCT02098928|Behavioral|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
80003658|NCT02098928|Device|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
80003659|NCT02995551|Procedure|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
80003660|NCT02995551|Behavioral|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
80003661|NCT03556124|Device|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
79235910|NCT02325921|Device|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
79235911|NCT03490617|Drug|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
79235912|NCT03494907|Drug|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
79235913|NCT03494907|Other|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
79235914|NCT03494907|Other|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
79235915|NCT03494907|Drug|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
79235916|NCT03490539|Drug|Mycophenolate Mofetil|oral tablets
79376817|NCT03382392|Other|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
79376818|NCT03124290|Other|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
79376819|NCT03382314|Combination Product|HDDO-1614|"Combination drug (Bazedoxifene + Cholecalciferol)~Incrementally modified drug~Not market authorized product"
79376820|NCT03382314|Drug|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
80003662|NCT03556124|Device|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
80003663|NCT03556124|Device|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
80003664|NCT03556124|Device|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
80003665|NCT02820753|Behavioral|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
80003666|NCT03556046|Diagnostic Test|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
79235917|NCT03490539|Drug|Azathioprine|oral tablet
79235918|NCT03494751|Device|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
79376821|NCT01523782|Drug|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
79376822|NCT03124524|Drug|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
79376823|NCT03124524|Drug|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
79376824|NCT03377400|Drug|Durvalumab|concurrent radiotherapy
79376825|NCT01525420|Behavioral|Acceptance Therapy (ACT)|ACT
79376826|NCT01525420|Other|Cognitive Behavioral Therapy (CBT)|CBT
79376827|NCT03377322|Drug|Probiotic Capsule|Probiotic - one capsule a day for four weeks
79376828|NCT03377322|Drug|Placebo Capsule|Placebo - one capsule a day for four weeks
79376829|NCT03382236|Other|osteopathy|osteopathic techniques
79376830|NCT01803269|Drug|topotecan hydrochloride|Given IV
79376831|NCT01803269|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
79376832|NCT03382080|Other|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
79530445|NCT01422551|Behavioral|a psycho-educational control|a single-day psycho-educational seminar
79530446|NCT01422564|Device|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
79530447|NCT01422564|Device|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
79530448|NCT01422577|Device|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
79530449|NCT01422577|Device|White light Endoscopy|White light Endoscopy
79530450|NCT01422590|Drug|Sitagliptin|Single oral administration of sitagliptin 100 mg
79530451|NCT01422590|Drug|Mitiglinide|Single oral administration of mitiglinide 10 mg
79686511|NCT04891302|Drug|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
80003667|NCT05218161|Drug|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
80003668|NCT02861586|Biological|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
80003669|NCT02861586|Biological|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
80003670|NCT02861586|Biological|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
80003671|NCT02861586|Biological|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
80003672|NCT02096822|Behavioral|Facilitated tucking + non-nutritive sucking|
79235919|NCT03494751|Device|No heart monitor|Standard monitoring by nurses.
79235920|NCT03494673|Diagnostic Test|BOLD MRI|"Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~BOLD MR images will be obtained by using a T2*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
79235921|NCT03490461|Drug|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
79235922|NCT03489135|Device|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
79235923|NCT03493737|Behavioral|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
79235924|NCT03490305|Procedure|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
79235925|NCT03493659|Behavioral|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
79235926|NCT03493659|Behavioral|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
79235927|NCT03493659|Behavioral|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
79235928|NCT03496077|Other|Flavored and unflavored little cigars/cigarillos (LCCs)|Flavored and unflavored LCCs that are currently available for purchase
79235929|NCT02586519|Device|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
79235930|NCT02516553|Drug|BI 894999|day 1 to day 21 in 3-week cycles
79235931|NCT02516553|Drug|BI 894999|day 1 to day 14 followed by a week off in 3-week cycles in schedule B
79235932|NCT02516553|Drug|BI 894999|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
79235933|NCT03034967|Drug|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
79235934|NCT03034967|Drug|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
79235935|NCT03034967|Drug|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
79376833|NCT03382080|Other|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
79376834|NCT03377166|Diagnostic Test|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
79376835|NCT01802879|Drug|Panobinostat|Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
79376836|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
79376837|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
79376838|NCT03145038|Drug|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
79376839|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
79530452|NCT01422590|Drug|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
79530453|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
79686512|NCT04891302|Drug|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
80003673|NCT02096822|Other|non-nutritive sucking|
80003674|NCT05217771|Other|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
79530454|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
79828861|NCT04738786|Procedure|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
79828862|NCT04738786|Procedure|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
79828863|NCT04738734|Device|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
79235936|NCT03034967|Drug|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
79828864|NCT04738734|Device|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
79828865|NCT04738695|Diagnostic Test|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
79235937|NCT03021187|Drug|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
79376840|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
79686513|NCT02229929|Drug|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
79235938|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
79235939|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
79235940|NCT03021187|Drug|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
79235941|NCT03493503|Drug|Salbutamol|Intravenous Salbutamol loading dose
79235942|NCT03493503|Drug|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
79235943|NCT03490149|Device|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
79235944|NCT03490149|Drug|Medication - Treatment as usual|Medication only sample - Treatment as usual
79235945|NCT02366559|Device|Hyfrecator|
79530455|NCT01422616|Drug|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus [maximum bolus dose of 9mg] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
79376841|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
79376842|NCT01825577|Drug|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
79376843|NCT03382002|Diagnostic Test|TCL|evaluation of oxidative status
79376844|NCT03375138|Drug|belatacept|Specified dose on specified days
79376845|NCT03124914|Other|Neuromuscular tests|Neuromuscular tests
79376846|NCT03381924|Other|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
79376847|NCT03381924|Other|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
79376848|NCT03124680|Combination Product|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
79686514|NCT02229929|Drug|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
79686515|NCT02229929|Drug|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
79686516|NCT02229929|Drug|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
79686517|NCT02229929|Drug|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
79686518|NCT02229929|Drug|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
79828866|NCT04733768|Diagnostic Test|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
79828867|NCT04728932|Drug|Levosimendan|A continuous infusion of Levosimendan over 24h
79828868|NCT04728932|Drug|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
79828869|NCT04718883|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10^8 CAR+T cells
79828870|NCT04718129|Behavioral|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
79235946|NCT02366559|Device|532 nm Q-switched Nd:YAG laser|
79235947|NCT05150145|Radiation|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
79235948|NCT03493347|Behavioral|Equine-assisted Occupational Therapy|Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
79530456|NCT01422616|Drug|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
79235949|NCT03668275|Procedure|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
79235950|NCT03489915|Device|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
79686519|NCT02224235|Drug|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
79686520|NCT02224235|Device|Resolute Integrity DES|Resolute Integrity DES
79235951|NCT03667963|Other|Glucose|50g glucose dissolved in 250ml water
79686521|NCT02224235|Device|COBRA PzF|
79686522|NCT02224235|Drug|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
79235952|NCT03667963|Other|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
79235953|NCT03667963|Other|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
79530457|NCT01422616|Other|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
79530458|NCT01422616|Other|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
79530459|NCT01422629|Device|Ultrasonic ablation device|High Intensity focused ultrasound treatment
79686523|NCT02529852|Drug|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
79686524|NCT02529852|Drug|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
79686525|NCT02529852|Drug|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
79686526|NCT02529852|Drug|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
79686527|NCT02529852|Drug|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
79828871|NCT04716400|Behavioral|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
79828872|NCT04712643|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
79235954|NCT03667963|Other|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
79235955|NCT03488901|Other|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
79235956|NCT03667885|Diagnostic Test|Blood sample|basic blood sample
79376849|NCT03124680|Combination Product|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
79530460|NCT01422642|Device|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
79235957|NCT03667885|Diagnostic Test|urine sample|basic urine sample
79235958|NCT03667885|Diagnostic Test|Multi planar MRI|T1 (with reduced affinity for fatty tissue) +/- contrast, diffusion weighted sequences and wash in/wash out
79686528|NCT02529852|Drug|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
79686529|NCT02223182|Biological|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
79686530|NCT02223182|Biological|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
79686531|NCT02223182|Biological|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
79686532|NCT02223182|Biological|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
79686533|NCT02222948|Drug|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79686534|NCT02222948|Drug|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79686535|NCT02221232|Drug|Chloraprep|Apply topically.
79235959|NCT03704597|Other|cryotherapy|Cooling of oral mucosa
79235960|NCT05149521|Other|None - this is a consensus group study to develop an intervention|None - this is a consensus group study to develop an intervention
79235961|NCT03489837|Drug|Levotuss|oral taken
79235962|NCT03488823|Dietary Supplement|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
79235963|NCT03488823|Dietary Supplement|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
79235964|NCT03488745|Behavioral|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
80003675|NCT02094014|Behavioral|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
79235965|NCT03625505|Drug|Venetoclax|tablet, oral
79235966|NCT03625505|Drug|Gilteritinib|tablet, oral
79235967|NCT03493269|Drug|BAY1834845|Orally administered.
79235968|NCT03493269|Other|Matching Placebo|Orally administered.
79235969|NCT03493269|Drug|Midazolam|Part 1: Orally administered 1mg as a single dose.
79235970|NCT04257682|Drug|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
79530461|NCT01422642|Device|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
79530462|NCT01422668|Other|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
79530463|NCT01422681|Device|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
79530464|NCT01422707|Drug|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
79530465|NCT01422733|Drug|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
79828873|NCT04712643|Drug|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
79828874|NCT04712643|Device|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
79235971|NCT04257682|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
79235972|NCT04257682|Drug|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
80003676|NCT02094014|Behavioral|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
79235973|NCT03704519|Drug|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
79235974|NCT03704519|Drug|Enzalutamide|4 x 40 mg capsules, once orally
79376850|NCT03124446|Behavioral|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
79235975|NCT03704519|Other|Placebo|4 placebo tablets, once orally
79235976|NCT01735929|Procedure|Neck Liposuction and Ultrasound Treatment|
79235977|NCT01735929|Procedure|Sham Treatment|
79235978|NCT03489759|Device|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
79530466|NCT01422733|Drug|dexamethasone|1 mg PO twice
79530467|NCT01422733|Drug|Cosyntropin|250 micrograms IV twice
79530468|NCT01422733|Drug|rhCG|25 mcg IV twice
79530469|NCT01422772|Biological|VM202RY|0.5mg intramuscular injection
79530470|NCT01422772|Biological|VM202RY|1mg intramuscular injection
79828875|NCT04710641|Drug|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
79235979|NCT03489759|Device|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
79235980|NCT03667183|Other|Pilates|Specific postures in movement according to Pilates guidelines.
79235981|NCT05424952|Other|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
79235982|NCT04766333|Behavioral|Healthcare Worker Focused Outreach|This a focused outreach intervention strategy specifically designed for healthcare workers.
79235983|NCT04766333|Behavioral|Community Organization Led Outreach|This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
79235984|NCT05405530|Device|nasal mask oxygen kit|Using the nasal mask oxygen kit for oxygenation.
79235985|NCT05405530|Device|regular nasal cannula|Using nasal cannula for oxygenation.
79235986|NCT03020641|Procedure|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
79235987|NCT03020641|Procedure|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
79828876|NCT04710641|Drug|Sorafenib|Oral adminstration twice a day
80003677|NCT02094014|Behavioral|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
79686536|NCT02221232|Drug|ZuraPrep|Apply topically.
79686537|NCT02221232|Drug|ZuraPrep Vehicle|Apply topically.
79530471|NCT01422772|Biological|VM202RY|2mg intramuscular injection
79686538|NCT02206100|Drug|PER977|reversal of edoxaban-induced anticoagulation
79686539|NCT02206100|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
79686540|NCT02206100|Drug|enoxaparin|
79686541|NCT02421159|Behavioral|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
80003678|NCT02099162|Device|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
79686542|NCT02421159|Behavioral|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
79686543|NCT02409303|Behavioral|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
79686544|NCT00554723|Drug|NeuroAid|4 capsules 3 times daily, for three months
80003679|NCT02099240|Drug|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
80003680|NCT02099240|Procedure|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
79235988|NCT05405140|Other|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
79235989|NCT05405140|Other|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
79376851|NCT03124446|Behavioral|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
79376852|NCT01802411|Drug|EXPAREL 266 mg|
79530472|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
79376853|NCT01802411|Drug|Placebo|
79235990|NCT05404906|Drug|Azacitidine|Given SC
79530473|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
79686545|NCT00554723|Drug|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
79686546|NCT00554762|Drug|GW842166X|Administer
79686547|NCT01231516|Drug|GSK1349572|50mg once daily
79686548|NCT01231516|Drug|Raltegravir|400mg twice daily
79686549|NCT01231516|Drug|GSK1349572 Placebo|Inactive placebo tablet once daily
79686550|NCT01231516|Drug|Raltegravir Placebo|Inactive placebo tablet twice daily
79686551|NCT04668911|Other|Swab|PCR test for SARS-CoV2, oral and nasal swab
79686552|NCT04669106|Other|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
79686553|NCT04668755|Device|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
79828877|NCT04707599|Other|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
80003681|NCT02384421|Device|Adaptive DBS (Activa PC+S Neurostimulator)|
79828878|NCT04707196|Drug|Abemaciclib|Administered orally
80003682|NCT02384421|Device|Continuous DBS (Activa PC+S Neurostimulator)|
80003683|NCT03610074|Other|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
80003684|NCT03610074|Procedure|Blood test|Additional blood test 5 min after mint ice cubes application
79235991|NCT05404906|Drug|Venetoclax|Given PO
79828879|NCT04707196|Drug|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole or anastrozole administered orally (physician choice)
80003685|NCT03610074|Other|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
80003686|NCT02034084|Procedure|left radial approach|Coronary diagnostic procedures performed through left radial approach
79530474|NCT01422811|Behavioral|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
79235992|NCT05404906|Other|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
79376854|NCT03381846|Procedure|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
79376855|NCT03381846|Procedure|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
79530475|NCT01422811|Other|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
79530476|NCT01422863|Behavioral|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
79828880|NCT04707196|Drug|Fulvestrant|Administered intramuscularly
80003687|NCT02034084|Procedure|Right radial approach|coronary diagnostic procedures performed through right radial approach
79235993|NCT03020407|Procedure|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
79235994|NCT03020407|Drug|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
79235995|NCT03020407|Drug|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
80003688|NCT05215899|Other|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
79235996|NCT03667729|Behavioral|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
79235997|NCT03624959|Drug|Ozanimod|ozanimod
79235998|NCT03624959|Drug|Gemfibrozil|Gemfibrozil
79235999|NCT03624959|Drug|Itraconazole|Itraconazole
79236000|NCT03624959|Drug|Rifampin|Rifampin
79236001|NCT03667105|Procedure|CAF|Periodontal surgical technique to treat gingival recessions.
79236002|NCT03667105|Other|MC|Xenogenous graft placed in the surgical site.
79236003|NCT03667105|Other|XDM|Xenogenous dermal collagen graft placed in the surgical site.
79236004|NCT04888637|Diagnostic Test|Baseline MEG Test|Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.
79236005|NCT04888637|Behavioral|Receptive Language Task|"The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break."
79236006|NCT04888637|Behavioral|Memory Task|"The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes."
79236007|NCT04579315|Other|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
79236008|NCT02536846|Drug|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
79302656|NCT03118999|Dietary Supplement|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
79302657|NCT03118999|Dietary Supplement|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
79376856|NCT03374904|Behavioral|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
79376857|NCT03374904|Behavioral|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
79236009|NCT03554057|Diagnostic Test|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
79236010|NCT03014011|Other|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
79530477|NCT01422902|Other|Plasticity-based Cognitive Training|
79236011|NCT03014011|Other|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
79236012|NCT03012841|Device|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
79236013|NCT03704129|Other|Tutor|The participants will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself.
79530478|NCT01422902|Other|Non-plasticity-based Training|Computer games
79530479|NCT01422928|Procedure|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~GV.14~LI.11 (bilateral)~SP.6 (bilateral)~SP.10 (bilateral)~ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
79530480|NCT01422941|Device|CAVU Attune Device|The CAVU Attune device is used with LAGB.
79530481|NCT01422954|Drug|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
79686554|NCT04668755|Device|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
79686555|NCT01231321|Drug|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
79686556|NCT04668677|Other|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
79686557|NCT04668482|Device|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
79686558|NCT04668482|Device|SCS is switched on|Spinal cord stimulator is functioning
79686559|NCT04668560|Behavioral|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
79686560|NCT01627548|Behavioral|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
79686561|NCT04668404|Diagnostic Test|Sonoclot|Sonoclot machine
79686562|NCT01210222|Biological|Trebananib|Given IV
79236014|NCT02359864|Radiation|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
79530482|NCT01422954|Drug|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
79530483|NCT01422954|Biological|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
79236015|NCT02359864|Radiation|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
79302658|NCT03118999|Dietary Supplement|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
79530484|NCT01422954|Biological|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
79530485|NCT01422954|Drug|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
79530486|NCT01422967|Behavioral|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
79530487|NCT01422980|Other|1- Test dairy product containing specific ingredients|
79530488|NCT01422980|Other|2- Control dairy product without specific ingredients|
80003689|NCT03609450|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
80003690|NCT03609450|Behavioral|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
80003691|NCT05383248|Behavioral|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
80003692|NCT05383248|Behavioral|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
80003693|NCT05215743|Drug|Antioxidant therapy|Active therapy
80003694|NCT05215743|Drug|NaCl 0.9%|Placebo
80003695|NCT02099396|Drug|Docetaxel+lobaplatin|
80003696|NCT02099396|Drug|Gemcitabine+lobaplatin|
80003697|NCT05215665|Drug|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
80003698|NCT05215665|Drug|Lenvatinib|8/12mg PO QD continuously
80003699|NCT05215665|Drug|Toripalimab|240mg IV d1 Q3W
79236016|NCT03703973|Diagnostic Test|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
79236017|NCT01764191|Other|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
79236018|NCT03703739|Dietary Supplement|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
79236019|NCT03703739|Dietary Supplement|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
79236020|NCT03703739|Dietary Supplement|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
79236021|NCT03703739|Dietary Supplement|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
79236022|NCT03703739|Dietary Supplement|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
79236023|NCT03703739|Dietary Supplement|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
80003700|NCT02094092|Other|ProTectis drops (five drops per day) for 21 days|
80003701|NCT02094092|Other|Placebo drops (five drops per day) for 21 days|
79236024|NCT03703739|Dietary Supplement|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
79530489|NCT01422993|Other|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
80003702|NCT03627663|Behavioral|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
80003703|NCT02099474|Other|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
80003704|NCT02250638|Other|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
80003705|NCT02250716|Procedure|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
80003706|NCT03555500|Other|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
80003707|NCT05217069|Drug|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
79236025|NCT05441176|Other|Questionnaires|Scoring of the DASH is performed according to references.
79236026|NCT05402254|Other|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
79530490|NCT01423006|Procedure|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
79530491|NCT01423019|Dietary Supplement|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
79376858|NCT03381768|Biological|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
80003708|NCT05217069|Drug|Folinic Acid|400mg/m2
80003709|NCT05217069|Drug|Irinotecan|180 mg/m2
79236027|NCT04423042|Biological|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
79236028|NCT05440006|Drug|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
79236029|NCT05439460|Drug|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
79236030|NCT05439460|Drug|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
79236031|NCT05439460|Drug|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
79376859|NCT03381768|Biological|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
79236032|NCT03019627|Drug|NGF|Eye Drop 20 μg/mL
79236033|NCT03019627|Other|Vehicle|Vehicle Eye Drop
79236034|NCT01661140|Drug|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
79376860|NCT03377010|Other|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
79686563|NCT04668287|Behavioral|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
80003710|NCT05217069|Drug|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
80003711|NCT05217069|Drug|Avelumab|10mg/kg IV (day 1 q2w)
80003712|NCT02096978|Procedure|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
80003713|NCT02250170|Drug|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
79530492|NCT01423019|Dietary Supplement|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
79686564|NCT01210144|Drug|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
80003714|NCT02065635|Procedure|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
80003715|NCT02065635|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
80003716|NCT02097368|Procedure|tongue strength measurement|tongue strength measurement
80003717|NCT02097368|Procedure|respiratory function measurement|respiratory function measurement
80003718|NCT02097368|Procedure|swallowing tests|swallowing tests
80003719|NCT02097368|Other|Magnetic resonance imaging|Magnetic resonance imaging
79236035|NCT01661140|Drug|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
79236036|NCT01661140|Drug|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
79236037|NCT03019549|Drug|Lanabecestat|Administered orally
79530493|NCT01423019|Other|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
79530494|NCT01423032|Drug|bendamustine|100 mg/m² iv, day 1+2, q4w
79530495|NCT01423032|Drug|Fludarabine|25 mg/m² iv, days 1-5, q4w
79530496|NCT01423123|Drug|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
79236038|NCT03019549|Drug|Rosuvastatin|Administered orally
79236039|NCT05400850|Other|YOGA|Five different YOGA Asana's will made randomly
79236040|NCT05423314|Procedure|knee brace cold therapy|"receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
79302659|NCT04456959|Drug|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
79302660|NCT03202693|Drug|PA-824|
79376861|NCT03377010|Other|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
79376862|NCT02976948|Other|No intervention|
79530497|NCT01423123|Biological|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
79530498|NCT01423123|Drug|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
79530499|NCT01423136|Device|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
79530500|NCT01423175|Drug|Clofarabine, ara-C|
79828881|NCT04693858|Behavioral|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
80003720|NCT03556748|Other|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
80003721|NCT02094248|Drug|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
80003722|NCT02094248|Drug|control|Normal saline，1ml/day, s.c injection
79376863|NCT03381690|Procedure|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
79236041|NCT01661062|Other|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
79530501|NCT01423175|Drug|FLAMSA|
79236042|NCT04260958|Other|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
79236043|NCT05436886|Drug|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
79376864|NCT03374748|Other|N/A - observational study|N/A - observational study
79376865|NCT01579084|Drug|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
79686565|NCT01210144|Drug|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
80003723|NCT02250248|Biological|AttraX Putty|
79376866|NCT01579084|Drug|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
79376867|NCT01579084|Drug|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
79376868|NCT01579084|Drug|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
79530502|NCT01423188|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
79530503|NCT01423188|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
79530504|NCT01423214|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
79530505|NCT01423214|Procedure|Laparoscopic surgery|Conventional laparoscopic procedures
79530506|NCT01423227|Behavioral|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
79530507|NCT01423227|Behavioral|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
79530508|NCT01423240|Drug|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
79530509|NCT01423240|Drug|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
79686566|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
79686567|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
79686568|NCT05423470|Behavioral|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
80003724|NCT02250248|Other|Iliac Crest Bone Graft (ICBG)|
80003725|NCT02099942|Device|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~as stand-alone intervention~as a bridge to transcatheter aortic valve replacement (TAVR)~as a bridge to surgical aortic valve replacement (SAVR)~as an intraprocedural predilatation prior to TAVR"
80003726|NCT02100020|Other|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
80003727|NCT02097446|Device|Guardix-FL|
80003728|NCT02097446|Device|Interceed|
80003729|NCT02097524|Drug|Sarilumab|
80003730|NCT02097524|Drug|Tocilizumab|
79530510|NCT01423240|Drug|Placebo|Placebo once daily orally in the evening
79828882|NCT04693858|Behavioral|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
79828883|NCT04691518|Other|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
79686569|NCT05423470|Behavioral|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
79686570|NCT04668053|Other|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
79828884|NCT04691518|Other|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
79828885|NCT04691206|Other|briefing objectives, intraoperative teaching, and debriefing feedback|A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
79828886|NCT04675164|Device|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
79828887|NCT04675164|Procedure|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
79828888|NCT04667663|Drug|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
79828889|NCT04667663|Drug|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
79828890|NCT04667663|Drug|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
79828891|NCT04667663|Drug|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
79376869|NCT02963610|Drug|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
79828892|NCT04659863|Drug|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
79530511|NCT01423266|Procedure|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
79236044|NCT05436886|Drug|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
79530512|NCT01423292|Procedure|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
79828893|NCT04659863|Drug|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
79828894|NCT04657354|Procedure|Assessment|Early surgical assessment
79828895|NCT04655573|Procedure|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
79236045|NCT01373151|Drug|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
79530513|NCT01423292|Drug|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
79530514|NCT01423292|Drug|Placebo|placebo
79530515|NCT01423305|Drug|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
79530516|NCT01423305|Drug|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
79828896|NCT04652076|Drug|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
79828897|NCT04652076|Drug|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
79828898|NCT04652076|Drug|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
79236046|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
79530517|NCT01423318|Drug|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
79530518|NCT01423318|Drug|placebo|single dose subcutaneously
79236047|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
79376870|NCT02963610|Drug|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
79828899|NCT04652076|Drug|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
80003731|NCT03628053|Biological|Tisagenlecleucel|autologous cellular immunotherapy product
79376871|NCT03376932|Drug|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
79376872|NCT03376932|Drug|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
79828900|NCT04640480|Drug|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
80003732|NCT03628053|Drug|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
79236048|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
79236049|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
79236050|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
79376873|NCT03376932|Drug|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
79236051|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
79236052|NCT01373151|Drug|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
79236053|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
79236054|NCT01373151|Drug|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
79236055|NCT01373151|Drug|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
79236056|NCT05435716|Device|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
79236057|NCT05435716|Device|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
79236058|NCT05148897|Other|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
79236059|NCT03488589|Diagnostic Test|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
79236060|NCT03488511|Other|FoodforCare at home|Six small protein rich meals that will be delivered twice a week for 3 weeks.
79236061|NCT01660906|Drug|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
79530519|NCT01423357|Other|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
79530520|NCT01423370|Drug|YHD1023|5g oral once daily
79530521|NCT01423370|Drug|YHD1023|5g oral twice a day
79236062|NCT03488979|Other|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
79376874|NCT03376932|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
79376875|NCT03376932|Device|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
79530522|NCT01423370|Drug|YHD1023|10g oral once daily
79530523|NCT01423370|Drug|Cialis|5mg oral once daily
79530524|NCT01423370|Drug|Placebo|Oral
79530525|NCT01423409|Device|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
79530526|NCT01423409|Device|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
79530527|NCT01423435|Drug|TRK-100STP|oral
79530528|NCT01423448|Other|bulletin board|An asynchronous online bulletin board for people with experience of depression
79530529|NCT01423487|Drug|Metformin|0.5g bid 26 weeks
79530530|NCT01423487|Other|Starch tablets|0.5g bid 26 weeks
79530531|NCT01423500|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
79530532|NCT01423500|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
79828901|NCT04637698|Biological|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
79828902|NCT04632758|Drug|WX-0593 Tablets|tablets, 60 mg→180mg, QD
79828903|NCT04632758|Drug|crizotinib|Capsules, 250mg, BID
79828904|NCT04629209|Drug|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
80003733|NCT03628053|Drug|Inotuzumab|CD22-directed antibody-drug conjugate
79530533|NCT01423500|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
79530534|NCT01423500|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
80003734|NCT02100176|Other|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
80003735|NCT02100176|Drug|Rotigotine|Rotigotine 2-8 mg/24 h
80003736|NCT02250482|Biological|Optivate® (Human Coagulation Factor VIII)|
80003737|NCT01377753|Device|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
79530535|NCT01423500|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
79530536|NCT01423500|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
79236063|NCT01285947|Device|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
79236064|NCT01285947|Other|Needle Application|30-gauge needle insertion into skin
79686571|NCT04668053|Other|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
79236065|NCT01285947|Device|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
79686572|NCT01209949|Drug|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
80003738|NCT03556670|Behavioral|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
79376876|NCT03376932|Device|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
79686573|NCT04667936|Other|Treatment group|None, solely treatment documentation
79686574|NCT04667975|Drug|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
79686575|NCT04831593|Other|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
79686576|NCT04831593|Other|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
79530537|NCT01423500|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
79530538|NCT01423513|Other|Fibular Taping|Tape with be applied with tension.
79530539|NCT01423513|Other|Sham Taping|Tape will be applied without tension
79686577|NCT04667858|Device|Home Ovulation Test|Visual read home ovulation test
79828905|NCT04627285|Drug|Lacosamide|"Pharmaceutical form: Oral-solution~Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
80003739|NCT03556670|Other|Control|Usual practice control
79828906|NCT04618315|Device|Hearing Aids|Receiver-in-the-ear hearing aids.
80003740|NCT02250560|Biological|Replenine®-VF (High Purity Factor IX)|
79236066|NCT01285947|Device|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
79236067|NCT03015181|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
79376877|NCT03376932|Device|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
79376878|NCT03376932|Device|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
79530540|NCT01423526|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
79530541|NCT01423526|Drug|Placebo|Placebo tablets, oral administration, single administrations
79530542|NCT01423539|Drug|bendamustine|Intravenous repeating dose\n
79236068|NCT03493191|Drug|0.5μg/kg SHR0410|a single dose of 0.5μg/kg SHR0410
79236069|NCT03493191|Drug|1μg/kg SHR0410|a single dose of 2μg/kg SHR0410
79530543|NCT01423539|Drug|navitoclax|Oral repeating dose\n
79236070|NCT03493191|Drug|2μg/kg SHR0410|a single dose of 2μg/kg SHR0410
79530544|NCT01423539|Drug|rituximab|Intravenous repeating dose\n
79236071|NCT03493191|Drug|5μg/kg SHR0410|a single dose of 5μg/kg SHR0410
79236072|NCT03493191|Drug|10μg/kg SHR0410|a single dose of 10μg/kg SHR0410
79236073|NCT03493191|Drug|20μg/kg SHR0410|a single dose of 20μg/kg SHR0410
79530545|NCT01423565|Device|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
79530546|NCT01423578|Behavioral|Hatha Yoga (HY)|3 Sessions of yoga instruction
79530547|NCT01423578|Behavioral|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
79828907|NCT04600362|Drug|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
79236074|NCT05435014|Drug|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
79828908|NCT04597658|Behavioral|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
79828909|NCT04597658|Behavioral|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
79236075|NCT05435014|Drug|Lipiodol|TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
79236076|NCT03666949|Drug|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
79530548|NCT01423578|Behavioral|Smoking Cessation Counseling|4 smoking cessation counseling visits.
79686578|NCT04825509|Device|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
79686579|NCT04667897|Drug|601 1.25mg|Solution for injection (intravitreal use)
79686580|NCT04667897|Drug|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
79828910|NCT04596384|Other|Best Practice|Participate in a surgeon-only perioperative care program
79236077|NCT03666949|Drug|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
79236078|NCT00886691|Biological|Bevacizumab|Given IV
79236079|NCT00886691|Drug|Everolimus|Given PO
79236080|NCT00886691|Other|Laboratory Biomarker Analysis|Correlative studies
79236081|NCT00886691|Other|Placebo|Given PO
79236082|NCT03667417|Other|Questionnaires|standardized data collection and 10-year prospective follow-up
79236083|NCT00960297|Drug|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
79236084|NCT00960297|Drug|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
79236085|NCT00960297|Drug|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
79236086|NCT03488433|Device|Abduction brace|Donjoy Ultrasling IV
79236087|NCT03488433|Device|Antirotation sling|Donjoy shoulder immobilizer
79236088|NCT00518037|Behavioral|surveys|anxiety surveys
79236089|NCT04423354|Procedure|Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
79236090|NCT03018691|Drug|OPA-15406|
79236091|NCT03018691|Drug|Placebos|
79236092|NCT03493113|Diagnostic Test|EEG|
79686581|NCT04683081|Device|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
79686582|NCT01209832|Drug|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
79686583|NCT01209832|Drug|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
79686584|NCT04667819|Drug|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
79236093|NCT05112861|Biological|bevacizumab|1.25 mg, intravitreal injection
79236094|NCT04052035|Procedure|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
79236095|NCT04423198|Behavioral|Cognitive Assessment|Self administered cognitive battery
79236096|NCT04423198|Behavioral|Patient Reported Neurological Outcome Assessments|Standard neurocognitive and neuropsychological tests
79236097|NCT04423198|Procedure|Blood Draw|Specimen collection of whole blood, serum, RNA
79530549|NCT01423591|Drug|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
79530550|NCT01423591|Drug|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
79530551|NCT01423656|Drug|LEO 29102|
79530552|NCT01423656|Drug|Placebo|Placebo Comparator: LEO 29102 vehicle
79530553|NCT01423695|Drug|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
80003741|NCT02094482|Device|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
80003742|NCT05194761|Drug|Normal saline|Using normal saline nebulization in neonates postextubation
80003743|NCT02094560|Drug|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
80003744|NCT03627975|Procedure|Conservative treatment|"The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
79530554|NCT01423708|Drug|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of >5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels <5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
80003745|NCT05194605|Other|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
79236098|NCT03667261|Device|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
79236099|NCT03667261|Device|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
79236100|NCT03493035|Diagnostic Test|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
79686585|NCT04683159|Drug|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (~0.05mL) 15 minutes prior to surgery
79236101|NCT03493035|Diagnostic Test|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
79236102|NCT05418400|Other|sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X|dental filling materials
79376879|NCT03376932|Device|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
79376880|NCT03007342|Drug|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
79376881|NCT03007342|Drug|Placebo|
79236103|NCT01790776|Radiation|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
79236104|NCT01790776|Radiation|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
79686586|NCT04683159|Drug|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (~0.05mL) 15 minutes prior to surgery
79686587|NCT01230892|Drug|Nebivolol|10 mg PO qday
79686588|NCT01230892|Drug|Atenolol|100 mg PO qday
79686589|NCT04667624|Drug|Twynsta|Manufactured by Boehringer Ingelheim
79686590|NCT04667624|Drug|LodineT|•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
79236105|NCT05148585|Other|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
79376882|NCT03376854|Device|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
79376883|NCT03376854|Drug|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
79376884|NCT03376854|Device|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature >38°C will receive 650 mg acetaminophen and, if temperature remains >38°C, surface cooling will be initiated to return core temperature to 37-38°C.
79376885|NCT01579162|Device|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
79530555|NCT01423721|Drug|Bromihexine hydrochloride syrup|syrup
79530556|NCT01423721|Drug|Bromihexine hydrochloride granules|granules
79530557|NCT01423747|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
79530558|NCT01423747|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
79828911|NCT04596384|Procedure|Functional Assessment|Complete a functional assessment
79236106|NCT05148585|Other|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
79236107|NCT05130333|Other|No intervention|No intervention
79236108|NCT04746911|Drug|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
79376886|NCT01580098|Other|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
79376887|NCT01580098|Other|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
79530559|NCT01423747|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
79530560|NCT01423747|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
79686591|NCT03455400|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
79686592|NCT04667351|Drug|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
79828912|NCT04596384|Other|Medical Device Usage and Evaluation|Wear an actigraph
79686593|NCT04667351|Drug|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
79686594|NCT01230814|Drug|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
79686595|NCT01230814|Drug|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
79376888|NCT03376776|Procedure|Vitrectomy|
79376889|NCT03381534|Device|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
79828913|NCT04596384|Procedure|Nutritional Assessment|Complete a nutritional assessment
79828914|NCT04596384|Other|Quality-of-Life Assessment|Ancillary studies
79828915|NCT04596384|Other|Questionnaire Administration|Ancillary studies
79828916|NCT04596384|Other|TapCloud|Use TapCloud app
79828917|NCT04587531|Device|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
79530561|NCT01423747|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
79530562|NCT01423747|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
79530563|NCT01423747|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
79530564|NCT01423786|Dietary Supplement|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
79828918|NCT04586257|Procedure|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
80003746|NCT02097836|Device|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
80003747|NCT03555812|Other|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
79236109|NCT04460859|Other|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
79236110|NCT03012061|Drug|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
79530565|NCT01423799|Dietary Supplement|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
79530566|NCT01423799|Dietary Supplement|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
79686596|NCT01230307|Drug|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
79686597|NCT01230307|Drug|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
80003748|NCT05423366|Device|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
80003749|NCT05186571|Biological|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
79236111|NCT03012061|Drug|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
79236112|NCT03012061|Drug|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
79236113|NCT03012061|Drug|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
79236114|NCT04953065|Other|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
79236115|NCT00408863|Drug|tibolone|tibolone 2.5 mg/day
79236116|NCT00408863|Drug|placebo|
79236117|NCT05085327|Drug|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
79236118|NCT05085327|Drug|ChapStick Lip Moisturizer Mint Flavour|Sunscreen lip balm.
79686598|NCT04810377|Procedure|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
80003750|NCT05223309|Other|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
80003751|NCT02097914|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
79236119|NCT05085327|Drug|ChapStick Lip Moisturizer Black Cherry Flavour|Sunscreen lip balm.
79236120|NCT05085327|Drug|SPF Standard Sunscreen|SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)
79236121|NCT05378074|Drug|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
79236122|NCT05378074|Drug|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
79236123|NCT05113719|Other|Exercise|Both groups will perform bridge exercise
79236124|NCT03666793|Other|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
79236125|NCT03488277|Other|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
79236126|NCT03665389|Device|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
79236127|NCT03703661|Procedure|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
79236128|NCT03703661|Procedure|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
79236129|NCT04941339|Drug|MRG002|Administrated intravenously
79236130|NCT03666715|Drug|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
79236131|NCT03666715|Drug|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
79236132|NCT03665311|Biological|25% Albumin fluid|25% Albumin fluid (100 mL)
79236133|NCT03665311|Other|Normal Saline|0.9% Normal Saline (100 mL)
79236134|NCT04830033|Other|ENO Breathe group|Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
79236135|NCT03666637|Procedure|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
79828919|NCT04586257|Procedure|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
79828920|NCT04573738|Procedure|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
79828921|NCT04573738|Procedure|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
79828922|NCT04571281|Diagnostic Test|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
79828923|NCT04570709|Other|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
79828924|NCT04568369|Device|rTMS|See treatment arm description.
79236136|NCT03488199|Device|Stent Acculink ™|Carotid Artery Revascularization using Stents
79236137|NCT03488199|Device|CGuardTM™|Carotid Artery Revascularization using Stents
79236138|NCT03010501|Other|Food Energy Density|Food Energy density manipulated
79236139|NCT03489681|Device|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
79376890|NCT03381534|Device|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
79376891|NCT03007654|Device|Mediclore|apply medical device fully around intrauterine surgery area
79530567|NCT01423825|Biological|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
79530568|NCT01423825|Biological|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
79530569|NCT01423825|Other|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
79686599|NCT00556595|Procedure|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
79686600|NCT00556595|Procedure|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
79686601|NCT01209598|Drug|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
79236140|NCT03666481|Behavioral|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
79236141|NCT03131973|Drug|BMS-986195|Specified dose on specified days
79236142|NCT03131973|Drug|Methotrexate|Specified dose on specified days
79530570|NCT01423838|Drug|Solifenacin|5 mg, oral, once in a day
79236143|NCT03131973|Drug|Leucovorin|Specified dose on specified days
79236144|NCT03131973|Drug|Caffeine|Specified dose on specified days
79236145|NCT03131973|Drug|Montelukast|Specified dose on specified days
79236146|NCT03131973|Drug|Flurbiprofen|Specified dose on specified days
79376892|NCT03007654|Device|Adept|apply medical device fully around intrauterine surgery area
79376893|NCT03007264|Device|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
79376894|NCT03376620|Drug|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
79376895|NCT03376620|Drug|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
79376896|NCT03374514|Drug|Dexamethasone|instilation of the solution in the middle ear
79530571|NCT01423838|Drug|Oxybutynin|5 mg, oral, three times in a day
80003752|NCT05150847|Other|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
80003753|NCT02094950|Procedure|Acupuncture|
80003754|NCT04967079|Drug|Trametinib|Trametinib 2 mg given orally, once daily
79686602|NCT01209598|Drug|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
79686603|NCT04809090|Behavioral|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
79686604|NCT04809090|Device|App CA|An APP together a CA (Conversational Agent).
79686605|NCT00556634|Drug|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
79236147|NCT03131973|Drug|Omeprazole|Specified dose on specified days
79236148|NCT03131973|Drug|Midazolam|Specified dose on specified days
79236149|NCT03131973|Drug|Digoxin|Specified dose on specified days
79236150|NCT03131973|Drug|Pravastatin|Specified dose on specified days
79236151|NCT03665233|Device|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
79236152|NCT05078931|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
79530572|NCT01423864|Drug|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
79236153|NCT05078931|Drug|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
79236154|NCT05579873|Procedure|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
79530573|NCT01423864|Drug|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
79530574|NCT01423890|Genetic|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
79686606|NCT01209520|Drug|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
79686607|NCT01209520|Drug|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
79686608|NCT01209520|Drug|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
79686609|NCT01209520|Drug|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
79686610|NCT01209520|Procedure|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
79686611|NCT01209520|Procedure|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
79686612|NCT01209520|Drug|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
79686613|NCT01209520|Drug|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
79686614|NCT01209520|Drug|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
80003755|NCT04967079|Drug|Anlotinib|Anlotinib capsules given orally, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). The initial dose is 8 mg, QD, PO, taken for the first 14 days of each 21-day cycle. If no patients developed DLT in the first treatment cycle, the 10 mg dose was explored. If 1 of 3 patients had a DLT, 3 more patients would need to be included for evaluation at this dose. If >1 out of 3 patients in a given dose group develops DLT, it is suggested that a lower dose group can be explored. If no DLT occurred at the 10 mg dose, the 12 mg dose was explored.
79236155|NCT03492957|Other|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
79236156|NCT03002623|Drug|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
79236157|NCT04825197|Drug|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
79236158|NCT04728191|Other|Physiotherapy|physiotherapeutical instructions and training as described.
79530575|NCT01423903|Drug|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
80003756|NCT03555734|Other|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
80003757|NCT03890601|Biological|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
79686615|NCT01209325|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
79686616|NCT01209325|Other|laboratory biomarker analysis|
80003758|NCT03556592|Drug|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
80003759|NCT03556592|Drug|Caffeine|1x 100 mg tablet
80003760|NCT03556592|Drug|Warfarin|2x 5 mg tablets
80003761|NCT03556592|Drug|Omeprazole|1x 20 mg capsule
79236159|NCT04728191|Other|standard care|Standard care as described.
80003762|NCT03556592|Drug|Metoprolol|1x 100 mg tablet
79686617|NCT04805541|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
79236160|NCT04737135|Other|Non intervention|Patients without intervention
79236161|NCT03665857|Behavioral|a multicomponent intervention|"School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~Monitoring of students' weight and height Students will be monitored their weight and height monthly.~Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
79236162|NCT04703361|Biological|Placebo NaCl|Placebo
79236163|NCT04703361|Biological|Niacin|B3 vitamin, Niacin
79236164|NCT04703361|Biological|Na-3-OHB|Na-3-OHB
79236165|NCT03010423|Drug|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
79236166|NCT05576597|Drug|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
79376897|NCT03374514|Drug|Sterile isotonic saline solution|Sterile isotonic saline solution
79686618|NCT04805541|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
79686619|NCT04805541|Device|Diabetic retinopathy screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
79686620|NCT04667273|Procedure|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
79828925|NCT04567368|Diagnostic Test|Xpert MTB/XDR|Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID
80003763|NCT03556592|Drug|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
80003764|NCT05070117|Behavioral|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
80003765|NCT02095028|Behavioral|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
80003766|NCT04964193|Drug|Elzsa film-coated tablet|Administered with 240 mL of water
80003767|NCT04964193|Drug|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
80003768|NCT02095262|Other|reactive auditory training|
80003769|NCT02095262|Other|Interactive auditory training|
80003770|NCT04814199|Other|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
79376898|NCT03381456|Other|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
79376899|NCT03374436|Behavioral|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
79376900|NCT03374436|Behavioral|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
79530576|NCT01423929|Drug|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
79530577|NCT01423929|Device|Room air|Fitting of Oxymask TM
79530578|NCT01423955|Drug|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
79530579|NCT01423955|Drug|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
80003771|NCT02100488|Device|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
80003772|NCT02100488|Other|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
80003773|NCT03627819|Dietary Supplement|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
79236167|NCT04727099|Device|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
79376901|NCT03374436|Behavioral|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
79376902|NCT01526356|Drug|Placebo|Study cream is applied nightly to the affected areas on the face.
79376903|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
79376904|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
79530580|NCT01423968|Biological|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
79530581|NCT01423968|Other|saline|
79530582|NCT01423994|Procedure|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
79236168|NCT03492879|Device|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
79236169|NCT03002311|Device|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
79530583|NCT01423994|Procedure|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate <50 bpm, High Heart Rate >165 bpm, and Pause > 3 seconds.
79530584|NCT01424007|Behavioral|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
79376905|NCT03812094|Device|Enurad 400|Alarm treatment
79376906|NCT03812094|Behavioral|Basic Bladder advice|Pre-specified Basic bladder advice
79376907|NCT04838964|Drug|MRG003|Administrated intravenously
79376908|NCT01526902|Device|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
79376909|NCT01526902|Device|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
79376910|NCT03376542|Diagnostic Test|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
79530585|NCT01424020|Other|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
79376911|NCT02519946|Other|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
79376912|NCT03376464|Device|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
79530586|NCT01424046|Drug|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
79530587|NCT01424046|Drug|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
79530588|NCT01424059|Other|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
79828926|NCT04564339|Drug|Ravulizumab|Dosages (loading and maintenance) will be based on the participant's body weight.
79828927|NCT04564339|Drug|Placebo|Dosages (loading and maintenance) will be based on the participant's body weight.
80003774|NCT03627819|Dietary Supplement|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
80003775|NCT03627819|Dietary Supplement|Control margarine|Margarine without any addition
80003776|NCT02100566|Behavioral|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
80003777|NCT02100566|Behavioral|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
80003778|NCT05655819|Drug|Glutamine|5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
80003779|NCT05655819|Drug|Placebo|Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
79686621|NCT04667273|Procedure|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
79686622|NCT04798677|Dietary Supplement|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
80003780|NCT02095418|Drug|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
80003781|NCT02095418|Drug|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
80003782|NCT03627585|Device|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
80003783|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
80003784|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
80003785|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
80003786|NCT04865497|Biological|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
79236170|NCT05034471|Device|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
79236171|NCT03488043|Procedure|Needle lung biopsy|Needle lung biopsy
79236172|NCT03002077|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
79236173|NCT03487965|Dietary Supplement|Low dose Polyphenol|botanical supplement with 25 mg polyphenol
79236174|NCT03487965|Dietary Supplement|High dose Polyphenol|botanical supplement with 13 mg polyphenol
79686623|NCT04798677|Dietary Supplement|Placebo|Powder for dissolution in water, excipents. Lemon flavor
79828928|NCT04564339|Other|Background Therapy|Participants will receive background therapy consistent with the standard of care.
80003787|NCT05665725|Procedure|Biospecimen Collection|Undergo blood sample collection
80003788|NCT05665725|Procedure|Computed Tomography|Undergo CT scan
80003789|NCT05665725|Procedure|Positron Emission Tomography|Undergo PET scan
80003790|NCT05665725|Biological|Siltuximab|Given IV
80003791|NCT02098148|Drug|Xenon|
80003792|NCT02098148|Drug|Placebo|
79236175|NCT03487965|Dietary Supplement|Placebo Control|inert tablet made to mimic the experimental tablets
79376913|NCT01528228|Device|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
79376914|NCT03381222|Diagnostic Test|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
79376915|NCT03376386|Radiation|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
79376916|NCT03376308|Diagnostic Test|Pain Score|"Four poin scala 0=No Pain~mild~intermediate~severe"
80003793|NCT01369381|Procedure|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
79236176|NCT04209153|Other|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
79376917|NCT03376308|Diagnostic Test|Withdrawal movement score|"Withdrawal movements~no movement response~movement limited to the wrist~movement limited to the elbow/shoulder,~generalized movement response."
80003794|NCT02098382|Device|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
80003795|NCT05168527|Drug|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
79530589|NCT01424111|Drug|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
79530590|NCT01424111|Other|Healthy Control|No Treatment
79236177|NCT03665779|Drug|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
79236178|NCT03665779|Drug|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
80003796|NCT02095496|Device|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
79686624|NCT04667429|Other|Food|HEC83518 40mg will be taken orally fasted or with food
79236179|NCT03664999|Diagnostic Test|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
79376918|NCT03376308|Diagnostic Test|hemodynamic response|Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
80003797|NCT02095496|Device|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
79376919|NCT03381144|Drug|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
79530591|NCT01424124|Drug|YHD001 dose level 1|Tablet, three times daily / 8 weeks
79236180|NCT03703505|Drug|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled [14C]AG-348.
79530592|NCT01424124|Drug|YHD001 dose level 2|Tablet, three times daily / 8 weeks
79686625|NCT04667429|Drug|HEC83518|HEC83518 will be taken orally before sleep for 15 days
79686626|NCT04667429|Drug|placebo|The placebo will be administered before sleep for 15 days.
79686627|NCT04667546|Other|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
79686628|NCT04784754|Drug|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
79686629|NCT04784754|Drug|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
79686630|NCT04666883|Other|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
79236181|NCT03703505|Drug|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
79236182|NCT04947293|Other|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
79236183|NCT04946435|Combination Product|Antibiotic Irrigation|The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation
79530593|NCT01424124|Drug|Singulair|Tablet, one times daily / 8 weeks
79530594|NCT01424124|Drug|Placebo|Tablet, one times daily / 7 days
79530595|NCT01424137|Device|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
79530596|NCT01424137|Device|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
79686631|NCT04666805|Drug|Tamoxifen|20 mg/d, oral administration
79686632|NCT04666805|Drug|Toremifene|60 mg/d, oral administration
79686633|NCT04666805|Drug|Anastrozole|1 tablet (1 mg) per day, oral administration
79686634|NCT04666805|Drug|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
80003798|NCT01372657|Other|biometry calculation|
79530597|NCT01424137|Device|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
79530598|NCT01424150|Other|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
79530599|NCT01424150|Other|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
79530600|NCT01424163|Drug|Single dose reduced|Treatment 1 (Part A)
79530601|NCT01424163|Drug|Single dose standard|Treatment 2 (Part A)
79530602|NCT01424163|Drug|Multiple Dose|Treatment 3 (Part A)
79530603|NCT01424163|Drug|Multiple Dose|Part B
79686635|NCT04666805|Drug|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
79686636|NCT04666376|Other|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
79686637|NCT04666337|Procedure|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
79686638|NCT00556790|Procedure|Standard Care|standard fluid regime, delayed feeding
79686639|NCT00556790|Procedure|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
80003799|NCT02098460|Drug|Atorvastatin, Probucol, Cilostazol|
80003800|NCT05166031|Biological|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
79376920|NCT03381144|Drug|Placebo|Participants will receive GDC-0334-matching placebo.
79376921|NCT03374280|Drug|pemetrexed/cisplatin intercalating gefitinib|
80003801|NCT02095574|Drug|[14C]ABT-199 (GDC-0199)|[14C]ABT-199 will be administered as a single oral administration
79376922|NCT03374280|Drug|pemetrexed/cisplatin|
80003802|NCT03555344|Other|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
79236184|NCT03666403|Procedure|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
79236185|NCT03666403|Procedure|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
79376923|NCT03376230|Other|Collect of blood, urines, and intestinal biopsies|
79376924|NCT03381066|Drug|gefitinib, pemetrexed,cisplatin|"Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
79376925|NCT03381066|Drug|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
79376926|NCT03374124|Diagnostic Test|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
80003803|NCT05150119|Diagnostic Test|Evaluation of Synovial IL-6 in diabetic patients with gonarthrosis|To evaluate if there is a linear positive correlation between plasma glycated hemoglobin concentration HbA1c and synovial IL-6 in diabetic patients
79376927|NCT03380988|Other|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
79376928|NCT03380988|Other|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
79376929|NCT03374046|Procedure|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
79530604|NCT01424176|Drug|Dexpramipexole (dose 1)|
79530605|NCT01424176|Drug|Dexpramipexole (dose 2)|
79530606|NCT01424202|Device|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
79530607|NCT01424241|Drug|Sandostatin LAR|This will be a open label dose escalation study of Sandostatin LAR 10 Mg, 20Mg, 30 Mg up to 40 mg if necessary.
79530608|NCT01424254|Device|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
79530609|NCT01424254|Procedure|Push-Enteroscopy|currently recommended standard
79236186|NCT03666403|Procedure|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
79376930|NCT03380910|Behavioral|Pharmacy and Behavioral Health Team|An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
79376931|NCT03380910|Behavioral|Motivational Interviewing|Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
79376932|NCT02814786|Radiation|MRI scanner|"This examination is divided in 2 parts:~Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
79376933|NCT02814786|Other|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
79376934|NCT04764552|Dietary Supplement|Yeahhh Baby Ointment|The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.
79376935|NCT04764552|Other|Coconut oil ointment|Coconut oil ointment with a little olive oil.
79530610|NCT01424267|Device|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
79236187|NCT03686891|Other|Skin prick tests with four native legumes|Skin prick tests with four native legumes
79530611|NCT01424280|Drug|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
79530612|NCT01424280|Drug|Placebo|Single dose of matching placebo tablets
79530613|NCT01424319|Drug|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
79530614|NCT01424319|Drug|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
79530615|NCT01424319|Drug|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
79236188|NCT03703427|Drug|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
79530616|NCT01424332|Drug|Darexaban|oral
79530617|NCT01424332|Drug|Acetyl Salicylic Acid (ASA)|oral
79530618|NCT01424345|Drug|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
79686640|NCT04738461|Other|Telerehabilitation|The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
79686641|NCT04738461|Other|Standard Physiotherapy|Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
79686642|NCT04738461|Other|Home Exercise Group|The same exercise program applied to telerehabilitation group.
79686643|NCT00556868|Other|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
79686644|NCT00556907|Radiation|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
79686645|NCT00556907|Device|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
79686646|NCT04721457|Drug|Distilled Water|Control group
79686647|NCT04721457|Drug|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
79236189|NCT03703427|Drug|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
79236190|NCT03703349|Drug|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
79236191|NCT03703349|Drug|Placebo Oral Tablet|Placebo for Magnesium
79686648|NCT04721457|Drug|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
79236192|NCT03008005|Drug|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
79236193|NCT03008005|Drug|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
79236194|NCT03008005|Drug|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
79530619|NCT01424345|Drug|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
79376936|NCT02647242|Behavioral|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
80003804|NCT02095730|Drug|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
79376937|NCT03376074|Device|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
79530620|NCT01424358|Other|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
79376938|NCT03376074|Other|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
79376939|NCT02520024|Behavioral|self-directed care|
79376940|NCT03370146|Behavioral|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
80003805|NCT02095730|Drug|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
80003806|NCT02095730|Device|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
79530621|NCT01424384|Drug|Citalopram|Neurophysiological testing.
80003807|NCT02095730|Device|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
79236195|NCT03666325|Drug|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
79686649|NCT04721457|Drug|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
79686650|NCT04721457|Drug|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
79686651|NCT04721457|Other|No rinse group|second control group
79686652|NCT04666415|Other|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
79236196|NCT03666325|Drug|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
79236197|NCT03394781|Drug|DUR-928|oral suspension daily for 28 days
79236198|NCT03666247|Behavioral|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
79376941|NCT03370146|Behavioral|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
79686653|NCT00557024|Procedure|RFA|radiofrequency ablation
79686654|NCT00557024|Procedure|radiotherapy after RFA|radiotherapy after RFA
79686655|NCT04666493|Other|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
79376942|NCT03370146|Behavioral|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
79376943|NCT03375996|Drug|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
79376944|NCT01580410|Drug|mitomycin C|Given by HIPEC
79530622|NCT01424384|Drug|GSK424887|Neurophysiological testing
79530623|NCT01424384|Drug|Plactebo To Match|Neurophysiological testing
79530624|NCT01424423|Drug|Placebo|Placebo
79530625|NCT01424423|Drug|GSK1223249|I.V. Infusion
79530626|NCT01424436|Biological|GSK933776|1mg/kg dose group
79530627|NCT01424436|Biological|GSK933776|3mg/kg dose group
79530628|NCT01424436|Biological|GSK933776|6mg/kg dose group
79530629|NCT01424449|Radiation|[11C]PHNO|examine the effects of [11C]PHNO mass carry-over and displaceable binding
79530630|NCT01424449|Drug|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
79530631|NCT01424462|Drug|A|Single dose treatment IR formulation
79530632|NCT01424462|Drug|B|Low Extended release single dose
79828929|NCT04559932|Other|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
79828930|NCT04558073|Behavioral|Body Project (BP)|"The BP intervention offers discussions and exercises to make participants realize the cost of pursuing social ideals valuing thinness. This produces cognitive dissonance, a cognitive discomfort due to a contradiction between speech and beliefs, which motivates to modify one's beliefs. The curriculum includes discussions on techniques of the advertising industry and the unique ideal of beauty promoted worldwide, as well as on the costs of pursuing the thin-ideal. Participants are also challenged to try behaviours they avoid because their appearance bother them. Societal activism actions are also discussed."
80003808|NCT04781283|Device|measurement of endothelial cell density by specular microscopy|"During this first appointment (T0), in addition to the usual treatment, measurement of the endothelial cell density by specular microscopy will be carried out on the affected eye (basal cell density). To overcome the variability linked to the machine, three consecutive measurements will be taken; the average of the three measurements will be used.~As part of his post-operative follow-up, the patient will be reviewed at one month, one year, two years, three years, four years and five years after the operation. During these consultations and as part of the research, a new determination of the cell density (3 consecutive measurements) by specular microscopy of the operated eye and an evaluation of the position of the XEN implant will be carried out each time. ® by OCT scan for patients having undergone this surgery."
80003809|NCT05138731|Other|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
79686656|NCT04711785|Behavioral|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
80003810|NCT05406284|Procedure|double kissing nano culotte stenting|patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
79236199|NCT03666247|Behavioral|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
79376945|NCT01580410|Drug|oxaliplatin|Given by HIPEC
79376946|NCT01580410|Procedure|therapeutic conventional surgery|Undergo surgery
79686657|NCT04666220|Other|VETC evaluation|We will evaluate VETC presence on tissue specimens
79686658|NCT04684758|Other|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
79686659|NCT04666142|Other|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
79686660|NCT04666142|Other|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
79686661|NCT04650126|Biological|ATM001|monovalent anti-TNF-receptor 1 antibody format
79686662|NCT04650126|Biological|ATM001 Placebo|ATM001 Placebo
79686663|NCT04665908|Other|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
79236200|NCT03703193|Other|Dry Needling|A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
79236201|NCT03703193|Other|Physical Therapy|A single session of modulatory interventions targeting modulation of central nervous system.
79236202|NCT03665701|Procedure|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
79376947|NCT01580410|Other|quality-of-life assessment|Ancillary studies
79376948|NCT01580410|Drug|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
79376949|NCT03373812|Procedure|Blepharoptosis repair|levator advancement or mullerectomy
79376950|NCT03373734|Device|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
79376951|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
79376952|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
79376953|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
79686664|NCT04644744|Device|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
79376954|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
80003811|NCT01369459|Behavioral|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
79530633|NCT01424462|Drug|C|Medium extended release formulation
79686665|NCT04644744|Device|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
80003812|NCT02102438|Drug|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
80003813|NCT02102438|Drug|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
79686666|NCT04665986|Drug|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
79686667|NCT04665986|Drug|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
79686668|NCT04638309|Drug|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
79236203|NCT03255863|Other|Questionnaire|Patient Self reported questionnaire filled in.
80003814|NCT02102438|Drug|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
80003815|NCT05222217|Device|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
80003816|NCT04156789|Diagnostic Test|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
80003817|NCT05222061|Device|Drug coated balloon for the side brunch|Intervention is explained in group description
79686669|NCT04666103|Procedure|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
80003818|NCT05222061|Device|Conventional balloon for the side brunch|Intervention is explained in group description
80003819|NCT02098616|Drug|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
80003820|NCT02098616|Drug|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
80003821|NCT05108077|Biological|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
80003822|NCT05108077|Other|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
79236204|NCT02440425|Drug|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
79236205|NCT02440425|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
79236206|NCT04054141|Device|Mag Stim|rTMS
79236207|NCT03199079|Other|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
79376955|NCT03370068|Other|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
79376956|NCT03370068|Other|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
79376957|NCT01530178|Drug|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
79376958|NCT01530178|Drug|Placebo Oral Tablet|
79376959|NCT03369990|Drug|Botulinum toxin type A|Botulinum toxin type A(DWP450)
79376960|NCT03369990|Drug|Placebos|Normal Saline
79686670|NCT04633473|Behavioral|SIB-Time Web-Application Tool|Parent-child dyads will use the SIBTime app in a 4-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
79686671|NCT04666064|Diagnostic Test|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
79376961|NCT03375840|Behavioral|Text-only PWL|Control condition
79376962|NCT03375840|Behavioral|Low-emot PWL|Pictorial warning
79530634|NCT01424462|Drug|D|High extended release rate single dose
79530635|NCT01424475|Genetic|Healthy|Healthy Volunteers
79530636|NCT01424475|Genetic|PKD Patients|PKS Patients
79530637|NCT01424488|Drug|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
79530638|NCT01424488|Drug|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
79236208|NCT04050917|Device|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
79530639|NCT01424540|Drug|GSK2336805 150mg|Single Dose
79686672|NCT04666064|Other|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
79828931|NCT04558073|Behavioral|Healthy Weight Program (HW)|The HW intervention allows participants to make personalized changes in their diet and physical activity each week gradually, to aim for a health-ideal rather than a thin-ideal. The intervention is based on small changes, based on behavioural change techniques. Advice is given on what types of changes introduce to promote health, and how to implement changes sustainably. Difficulties are discussed in the group with a problem-solving approach. The last session introduces a long-term view of lifestyle change.
79828932|NCT04554368|Procedure|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
79236209|NCT04050917|Device|no stimulation|The smartwatch generates no stimulation.
79236210|NCT03109743|Behavioral|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
79236211|NCT03109743|Behavioral|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
79530640|NCT01424540|Other|Placebo|Single Dose
79686673|NCT04665830|Drug|Evolocumab|treated patients with evolocumab for high cholesterol
79686674|NCT04631133|Device|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
79828933|NCT04553497|Device|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
80003823|NCT04952805|Drug|MAD0004J08|MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
79686675|NCT04665791|Biological|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
79686676|NCT04665674|Other|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
79686677|NCT04683237|Drug|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
79686678|NCT04683237|Drug|Megestrol Acetate 160 MG|160mg po qd
79236212|NCT04182321|Drug|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
79530641|NCT01424553|Other|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
79686679|NCT04665518|Other|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
79686680|NCT04568694|Procedure|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
79686681|NCT04568694|Procedure|Conventional Lung Transplantation|Reference Therapy
79686682|NCT04549701|Other|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
79686683|NCT04549701|Other|Standard of care|Standard of care will be provided.
79828934|NCT04553497|Other|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
80003824|NCT04952805|Other|Placebo|Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
79686684|NCT04665362|Drug|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
79686685|NCT04683120|Diagnostic Test|Zenith FLIM Diagnostics|In-vitro
80003825|NCT01372267|Behavioral|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
80003826|NCT01372267|Behavioral|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
79236213|NCT04182321|Drug|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
79236214|NCT03703037|Diagnostic Test|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
79236215|NCT04461405|Behavioral|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
79236216|NCT03702959|Drug|Betamethasone|Corticosteroids
79686686|NCT04665401|Behavioral|Tailored MERIT|see arm description
79686687|NCT04665401|Behavioral|Standard MERIT|see arm description
79530642|NCT01424579|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
79530643|NCT01424579|Other|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
79828935|NCT04552288|Drug|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
79828936|NCT04551963|Drug|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
80003827|NCT02098694|Other|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
79530644|NCT01424579|Other|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
79302661|NCT05374187|Device|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
79376963|NCT03375840|Behavioral|High-emot PWL|Pictorial warning
79376964|NCT03375840|Behavioral|Immediate posttest|
79376965|NCT03375840|Behavioral|delay posttest|
79376966|NCT03006874|Drug|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
79376967|NCT03006874|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
79686688|NCT04503291|Procedure|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
79686689|NCT04498182|Drug|AR15512|Administered via topical ocular instillation, one drop per eye, twice daily for 84 days. Both eyes will be treated.
79686690|NCT04498182|Drug|Vehicle|Administered via topical ocular instillation, one drop per eye, twice daily for 84 days. Both eyes will be treated.
79686691|NCT04494555|Device|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
79686692|NCT04494555|Device|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
79828937|NCT04551963|Drug|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
80003828|NCT04134013|Dietary Supplement|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
80003829|NCT04134013|Other|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
80003830|NCT02102516|Drug|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing >=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
80003831|NCT04952467|Drug|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
80003832|NCT02106182|Drug|Silodosin|
79376968|NCT03006874|Drug|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
79376969|NCT03369912|Biological|CSJ148|Active
79376970|NCT03369912|Other|Placebo|No Drug
79376971|NCT03375684|Other|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
79376972|NCT03375684|Other|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
79530645|NCT01424592|Device|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
79530646|NCT01424605|Procedure|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
79530647|NCT01424618|Drug|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
79530648|NCT01424618|Drug|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
79530649|NCT01424631|Procedure|single incision laparoscopic appendectomy|
79530650|NCT01424631|Procedure|conventional laparoscopic appendectomy|
79530651|NCT01424657|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography
79530652|NCT01424657|Procedure|MRCP|magnetic resonance cholangiopancreatography
79686693|NCT04494555|Device|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
79686694|NCT04665167|Behavioral|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
79686695|NCT04665167|Behavioral|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
79686696|NCT04459884|Procedure|mechanical ventilation|mechanical ventilation > 48h
79686697|NCT04665011|Device|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
79686698|NCT04665011|Device|Caretaker|non-invasive blood pressure monitor
79686699|NCT04665284|Drug|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
79686700|NCT04665284|Drug|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
79686701|NCT04432974|Device|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
79828938|NCT04551963|Drug|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
79828939|NCT04551963|Drug|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
79828940|NCT04551963|Drug|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
79828941|NCT04527107|Drug|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
79828942|NCT04527107|Drug|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
79828943|NCT04527107|Drug|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
79686702|NCT04664894|Drug|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
80003833|NCT02106182|Other|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
79686703|NCT04424394|Device|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
79686704|NCT04424394|Biological|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
79828944|NCT04527107|Drug|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
80003834|NCT02106182|Other|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
80003835|NCT02106182|Other|12 weeks|
80003836|NCT01369693|Procedure|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
80003837|NCT03554642|Device|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
80003838|NCT03554642|Behavioral|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
80003839|NCT04663503|Other|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
80003840|NCT02102594|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
80003841|NCT03124537|Behavioral|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
80003842|NCT03124537|Behavioral|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
79686705|NCT04424394|Other|Saline|2 intracavernosal injections over a period of 7 weeks.
80003843|NCT04946877|Diagnostic Test|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
79686706|NCT04664660|Other|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
80003844|NCT02102672|Drug|Trimetazidine|
79686707|NCT04664699|Device|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI < 13% indicates adequate volume"
79686708|NCT04664699|Device|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
79686709|NCT04664504|Combination Product|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
79686710|NCT04664504|Radiation|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
79686711|NCT04664504|Radiation|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
79686712|NCT04664504|Drug|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses*3 weeks per course.
79686713|NCT04664504|Drug|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses*3 weeks per course
79686714|NCT04664504|Procedure|TME|Total mesorectal excision
79686715|NCT04415073|Drug|SNDX-6352|SNDX-6352
79828945|NCT04527107|Drug|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
79236217|NCT03702881|Device|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
79828946|NCT04527107|Drug|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
79236218|NCT03702881|Device|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
79828947|NCT04527107|Drug|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
79828948|NCT04515342|Diagnostic Test|DXA|Each participant will undergo one DXA scan
79686716|NCT04415073|Drug|Placebo|Placebo comparator
79236219|NCT03001219|Drug|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
79236220|NCT03001219|Drug|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
79686717|NCT00557102|Biological|cetuximab|
79828949|NCT04515342|Other|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
79828950|NCT04515342|Other|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
79828951|NCT04512287|Drug|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
79828952|NCT04512287|Other|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
79686718|NCT00557102|Biological|filgrastim|
79236221|NCT03001219|Drug|Placebo|Participants will receive intravenous infusion of placebo.
79686719|NCT00557102|Drug|fluorouracil|
79686720|NCT00557102|Drug|irinotecan hydrochloride|
79828953|NCT04502381|Drug|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
79828954|NCT04502381|Drug|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
79828955|NCT04489719|Procedure|Biospecimen Collection|Undergo collection of blood samples
79828956|NCT04489719|Other|Questionnaire Administration|Ancillary studies
79828957|NCT04489719|Drug|Radium Ra 223 Dichloride|Given IV
79828958|NCT04472910|Drug|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
79236222|NCT03001219|Drug|RO7123520|Participants will receive intravenous infusion of RO7123520.
79236223|NCT03492723|Dietary Supplement|Aged Garlic Extract|NR
79236224|NCT05477849|Drug|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"Dose level 1~Dose level 2~Dose level 3~Dose level 4~Dose level 5"
79686721|NCT00557102|Drug|leucovorin calcium|
79686722|NCT04682808|Drug|FCN-338|FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
79686723|NCT04664543|Other|Free diet|To follow the regular dietary habits with no restriction nor modification.
79686724|NCT04664543|Other|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
79686725|NCT04682613|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active teachers"|"Prevention program: young In Favor of Myself, with teacher participation"
79686726|NCT04682613|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no teacher involvement"|"Prevention program: young In Favor of Myself, without teacher participation"
79686727|NCT04664816|Drug|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
79686728|NCT04664816|Drug|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
79828959|NCT04468113|Device|Tumark® Vision clip|Suspicious intramammary lesion is marked with clip
79828960|NCT04466566|Other|Saline|Saline will serve as the control
79828961|NCT04466566|Biological|Exendin-9,39|Exendin-9,39 will block the GLP-1 receptor
79828962|NCT04454697|Device|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
79686729|NCT04682691|Drug|Erythromycin (400mg)|parturients will receive oral Erythromycin (400mg)
79686730|NCT04682691|Drug|metoclopramide (10mg)|will be receive oral metoclopramide (10mg)
79686731|NCT04682691|Dietary Supplement|naturally flavored water|will be receive naturally flavored water
79828963|NCT04451135|Diagnostic Test|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
79828964|NCT04451135|Diagnostic Test|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
79828965|NCT04451135|Diagnostic Test|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
79828966|NCT04451135|Diagnostic Test|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
79530653|NCT01424709|Drug|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
79828967|NCT04451135|Diagnostic Test|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
79686732|NCT04664348|Other|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
79828968|NCT04451135|Diagnostic Test|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
79236225|NCT04461093|Other|Acupressure wristband and Palanosetron|"Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction."
79236226|NCT03702803|Dietary Supplement|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
79236227|NCT03702803|Drug|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
79302662|NCT05374187|Device|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
79828969|NCT04432597|Biological|PRGN-2009 (Phase I)|On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29.
79828970|NCT04432597|Biological|PRGN-2009 (Phase II)|On the phase II portion of the protocol PRGN-2009 will be administered on just Day (D)1 and D15.
79828971|NCT04432597|Biological|M7824|"Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
79828972|NCT04432597|Diagnostic Test|MRI|MRI (with gadolinium) of the neck, chest, skull, and/or sinonasal, if indicated, will be used when computed tomography (CT) scan is not an option to follow the disease.
79828973|NCT04432597|Diagnostic Test|Bone scan|Bone scans and other imaging assessments may also be performed as clinically indicated.
79828974|NCT04432597|Diagnostic Test|CT scan|Imaging of the neck, chest, skull, and/or sinonasal, if indicated, will be performed every 8 weeks. In the event of a partial response (PR) or complete response (CR) tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator.
79828975|NCT04432597|Diagnostic Test|Brain CT|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
79376973|NCT03373578|Device|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
79530654|NCT01424709|Drug|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
79530655|NCT01424735|Drug|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
79530656|NCT01424748|Dietary Supplement|Tahitian Noni Juice|noni fruit juice
79530657|NCT01424748|Dietary Supplement|Placebo|Placebo juice
80003845|NCT01369771|Drug|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
79236228|NCT03543943|Procedure|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon [1]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
80003846|NCT03554564|Behavioral|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
80003847|NCT03554564|Other|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
79530658|NCT01424761|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
80003848|NCT02106260|Drug|CLS003|
80003849|NCT02106338|Other|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
79236229|NCT03543943|Procedure|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
79236230|NCT03543943|Procedure|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
79236231|NCT03702647|Drug|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
79236232|NCT03702647|Drug|Normal saline|30mL of normal saline placed in the POEM tunnel
79828976|NCT04432597|Diagnostic Test|Brain MRI|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
79236233|NCT03489447|Other|ICU care|exposure to ICU treatment with or without diagnosed sepsis
79236234|NCT04583787|Diagnostic Test|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
79686733|NCT04664348|Other|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
79530659|NCT01424761|Other|Placebo|Placebo :starch
79686734|NCT04682886|Diagnostic Test|diagnosis|there is no intervention diagnosis or treatment for patients
79686735|NCT04664114|Behavioral|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
79686736|NCT04682418|Device|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
80003850|NCT02106338|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
79236235|NCT04583787|Diagnostic Test|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
80003851|NCT04806217|Other|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
80003852|NCT02101346|Dietary Supplement|Mixed High Fat Diet|Healthy, Round 1
80003853|NCT02101346|Dietary Supplement|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
80003854|NCT02101346|Dietary Supplement|Monounsaturated fat diet|Healthy, Round 1
80003855|NCT02101346|Dietary Supplement|Polyunsaturated fat diet|Healthy, Round 1
79236236|NCT03000673|Drug|Enoxaparin|Specified dose of Enoxaparin on specified days
79236237|NCT03000673|Drug|unfractionated heparin (UFH)|Specified dose of UFH on specified days
79236238|NCT03000673|Drug|BMS-986177|Specified dose of BMS-986177 on specified day
79236239|NCT03487731|Biological|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
79530660|NCT01424774|Drug|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
80003856|NCT02101346|Dietary Supplement|Triolein 13C|Healthy, Round 2
80003857|NCT02101346|Dietary Supplement|Low fat|Healthy, Round 1
80003858|NCT04728139|Diagnostic Test|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
80003859|NCT05221671|Other|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
80003860|NCT05221515|Behavioral|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
80003861|NCT05221515|Behavioral|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
79828977|NCT04432597|Procedure|Biopsy (Phase I)|"Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants)."
79828978|NCT04432597|Procedure|Biopsy (Phase II)|"Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants)."
80003862|NCT01369927|Biological|Shigella Sonnei O-SPC/rBRU|
79236240|NCT03487731|Drug|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
80003863|NCT02101502|Other|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
79828979|NCT04416555|Device|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
79236241|NCT03487653|Biological|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
79236242|NCT05423249|Drug|Ferrous sulfate|Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
80003864|NCT02101580|Drug|ADI-PEG 20|
79686737|NCT04664036|Diagnostic Test|ultrasound|ultrasound to check for NAFLD according to Saverymuttu criteria
79828980|NCT04416555|Device|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
79828981|NCT04408612|Diagnostic Test|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
80003865|NCT05648019|Biological|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
80003866|NCT02106416|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
80003867|NCT05365087|Procedure|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
80003868|NCT05365087|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
79236243|NCT05423249|Drug|Prenatal|Oral prenatal vitamin once daily for both groups
79236244|NCT05423249|Drug|Docusate Sodium|Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
79236245|NCT05423249|Drug|Ascorbic Acid 500Mg Tab|Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
79236246|NCT05423249|Drug|Placebo|Oral placebo pill once daily
79236247|NCT04334577|Biological|live attenuated zoster vaccine|subcutaneous injection
79236248|NCT04334577|Biological|placebo|subcutaneous injection
79236249|NCT02912455|Drug|canagliflozin|encapsulated (gelatin capsule).
79236250|NCT02912455|Drug|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
79686738|NCT04664036|Diagnostic Test|elastography|elastography to compare liver stiffness indices
79686739|NCT04664036|Diagnostic Test|controlled attenuation parameter (CAP)|CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
79686740|NCT04664036|Diagnostic Test|FLI|the FLI is a score panel designed to screen for NAFLD
79686741|NCT04664036|Diagnostic Test|FIB-4|the FIB-4 is a score panel designed to screen for significant fibrosis
79686742|NCT04664036|Diagnostic Test|NFS|the NFS is a score panel designed to screen for significant fibrosis
79686743|NCT01209286|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
79686744|NCT05423080|Drug|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
79236251|NCT03492645|Behavioral|Telephone-and technology-facilitated treatment protocol|"8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
79530661|NCT01424800|Device|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
79236252|NCT03492645|Behavioral|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
79236253|NCT03492567|Biological|Blood test|Blood draw (max 15 ml)
79236254|NCT03666169|Other|Survey|Survey
79236255|NCT03702491|Drug|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
79376974|NCT01581970|Drug|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
79376975|NCT01581970|Drug|Cetuximab|The initial dose of cetuximab 400 mg/m^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m^2 intravenously (IV) over 60 minutes.
79828982|NCT04400708|Procedure|adductor canal block|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
79828983|NCT04400708|Procedure|control group|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
79530662|NCT01424826|Drug|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
79530663|NCT01424826|Drug|Rifampicin|< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days > 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
79530664|NCT01424826|Drug|Raltegravir|800 mg bd for 4 days
79686745|NCT05423080|Drug|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
79686746|NCT04663763|Drug|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
79686747|NCT04663763|Drug|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
79236256|NCT03702491|Drug|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
79376976|NCT01583452|Other|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
79376977|NCT01583686|Drug|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
79686748|NCT04663763|Drug|Oxaliplatin|Usage: 130mg/m2 d1 q3w
79236257|NCT04056481|Drug|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
79376978|NCT01583686|Biological|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
79376979|NCT01583686|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
79530665|NCT01424839|Radiation|craniospinal irradiation|"Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
79686749|NCT04663880|Other|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
79686750|NCT04663880|Other|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
79686751|NCT04663880|Other|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
79236258|NCT03663751|Drug|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
79828984|NCT04398992|Other|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
80003869|NCT01372345|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
79236259|NCT04054687|Drug|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
79236260|NCT04054687|Other|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
79530666|NCT01424839|Drug|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
79530667|NCT01424839|Radiation|ventricular irradiation|"Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
79236261|NCT04524507|Biological|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
79376980|NCT01583686|Drug|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
79376981|NCT01532128|Drug|rasagiline|1 mg rasagiline (single-dose)
80003870|NCT04249323|Drug|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
79376982|NCT01532128|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
79376983|NCT01584388|Drug|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
79376984|NCT03007108|Other|blood withdrawal|
79530668|NCT01424839|Drug|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
79686752|NCT04663919|Procedure|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
79376985|NCT01584544|Drug|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
79376986|NCT01584544|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
79686753|NCT04663919|Behavioral|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
79686754|NCT04353102|Drug|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
79686755|NCT04663958|Diagnostic Test|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
79686756|NCT04351737|Drug|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
79686757|NCT04351737|Drug|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
79686758|NCT04347915|Drug|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
79686759|NCT04347915|Drug|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
79686760|NCT03455361|Procedure|Stark Implant with low primary stability|
79686761|NCT04663685|Other|Exercise program|Participants will start with receiving two 1-on-1 exercise sessions per week. Each session is anticipated to last 30 minutes. As progress is made, participants will be encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises are aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift & carry and calf raise.
79686762|NCT04663685|Other|Nutrition education|Participants will receive a nutrition education booklet and have access to 5 online videos that correspond to key topics in the booklet, including: reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day. Participants will attend three 60-minute nutrition seminars led by a dietitian, where the group will review content from the booklet and videos, and discuss personalized strategies for protein intake.
79686763|NCT04663451|Radiation|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
79686764|NCT04185051|Drug|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
79686765|NCT04185051|Drug|Placebo|Participants will receive matching placebo oral capsules.
79828985|NCT04397874|Diagnostic Test|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
79828986|NCT04396483|Procedure|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
79828987|NCT04396483|Procedure|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
79828988|NCT04390971|Biological|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
79828989|NCT04390308|Procedure|Ovarian puncture|Egg collection
80003871|NCT04249323|Drug|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
79828990|NCT04390308|Other|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
79828991|NCT04390308|Diagnostic Test|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
79530669|NCT01424839|Drug|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
80003872|NCT04249323|Drug|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
80003873|NCT02102750|Drug|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
80003874|NCT01372735|Radiation|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
80003875|NCT01372735|Radiation|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
80003876|NCT04227327|Drug|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
79828992|NCT04389203|Procedure|Unilateral tubal disconnection + Spontaneous follow up for pregnancy|Unilateral tubal disconnection + Spontaneous follow up for pregnancy
79236262|NCT04524507|Biological|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
79828993|NCT04389203|Procedure|Unilateral tubal disconnection + ICSI|Unilateral tubal disconnection + ICSI
80003877|NCT04227327|Drug|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
79828994|NCT04379765|Behavioral|Exercise and physical therapy|Decompression operation
80003878|NCT02102828|Device|extended compression|Home use of extended compression therapy and aspirin
80003879|NCT02102828|Other|Aspirin|standard therapy of aspirin
80003880|NCT05228119|Biological|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
80003881|NCT02101658|Other|clinic-based weight measurements|
79236263|NCT02999191|Drug|BI 1467335 (Treatment A)|
79236264|NCT02999191|Drug|BI 1467335 (Treatment B)|
79236265|NCT02999191|Drug|BI 1467335 (Treatment C)|
79236266|NCT03837639|Other|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
79236267|NCT03837639|Other|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
79302663|NCT03202381|Drug|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
79530670|NCT01424839|Radiation|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
79530671|NCT01424852|Dietary Supplement|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
80003882|NCT01372423|Drug|Lubiprostone|24 mcg capsules
80003883|NCT01372423|Drug|Placebo|24 mcg capsules
80003884|NCT02102906|Procedure|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
80003885|NCT02102984|Device|covered biliary stents|endoscopic placement of covered biliary stents
80003886|NCT02102984|Device|uncovered biliary stents|endoscopic placement of uncovered biliary stents
80003887|NCT02101814|Procedure|Roux-en-Y gastric bypass (bariatric surgery)|
80003888|NCT01375933|Biological|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
80003889|NCT02106650|Drug|Folotyn and Leucovorin|
80003890|NCT02106650|Drug|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
79530672|NCT01424865|Genetic|fluorescence in situ hybridization|
79530673|NCT01424865|Other|immunohistochemistry staining method|
79828997|NCT04372914|Dietary Supplement|BRB Lozenges|Each lozenge is made from 1 gram of freeze-dried black raspberry powder (equivalent to ~5 black raspberries) in the form of a dissolvable slow-release lozenge.
79828998|NCT04370704|Drug|INCAGN02385|INCAGN02385 administered intravenously
79828999|NCT04370704|Drug|INCAGN02390|INCAGN02390 administered intravenously
79829000|NCT04370704|Drug|INCMGA00012.|INCMGA00012 administered intravenously
79829001|NCT04356638|Drug|Midazolam|Oral Midazolam and intranasal placebo
79829002|NCT04356638|Drug|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
79829003|NCT04356638|Other|Placebo|Placebo orally and intranasally
79829004|NCT04347434|Drug|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
79829005|NCT04343170|Drug|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
79829006|NCT04343170|Drug|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
79829007|NCT04342026|Other|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
79829008|NCT04338152|Behavioral|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
79829009|NCT04338152|Behavioral|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
79686766|NCT04663412|Other|Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)|Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
79829010|NCT04337242|Behavioral|B-DIT|Blended Dynamic Interpersonal Therapy
79829011|NCT04337242|Behavioral|B-CBT|Blended Cognitive Behavioral Therapy
79829012|NCT04337242|Behavioral|DIT|Dynamic Interpersonal Therapy
79376987|NCT01584544|Drug|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
79829013|NCT04337242|Behavioral|Cognitive Behavioral Therapy|CBT
79829014|NCT04336111|Procedure|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
79376988|NCT01584544|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
79376989|NCT01584544|Drug|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
79376990|NCT03006952|Drug|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
79686767|NCT04175028|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
79829015|NCT04336046|Procedure|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
79530674|NCT01424865|Other|immunologic technique|
79530675|NCT01424865|Other|laboratory biomarker analysis|
79829016|NCT04336046|Procedure|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
79829017|NCT04336046|Drug|normal saline|using 1 mg /kg normal saline
79829018|NCT04336046|Drug|Bupivacaine|bupivacaine
79829019|NCT04335994|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
79376991|NCT03006952|Drug|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
79376992|NCT01532830|Device|n-VNS|
79376993|NCT01802333|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
79376994|NCT01802333|Drug|Cytarabine|Given IV
79376995|NCT01802333|Drug|Daunorubicin Hydrochloride|Given IV
79376996|NCT01802333|Drug|Idarubicin|Given IV
79530676|NCT01424891|Drug|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
79530677|NCT01424891|Drug|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
79530678|NCT01424891|Drug|Placebo|treatment with placebo over 8 weeks
79686768|NCT04663490|Diagnostic Test|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
79686769|NCT04662983|Device|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
79829020|NCT04335994|Device|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
79829021|NCT04331418|Drug|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
79829022|NCT04331418|Procedure|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
79829023|NCT04317859|Behavioral|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
79829024|NCT04307511|Drug|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
79236268|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
79829025|NCT04307511|Drug|Aspirin|Aspirin
79829026|NCT04304183|Procedure|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
79236269|NCT03492489|Drug|cemiplimab|Intravenous (IV) administration
79236270|NCT04050397|Other|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
79376997|NCT01802333|Other|Laboratory Biomarker Analysis|Correlative studies
79686770|NCT04119765|Biological|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
79686771|NCT04119765|Biological|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
79686772|NCT04119765|Procedure|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
79686773|NCT04119765|Procedure|central pressure measurement|central pressure will be measured thank to the Complior® device
79686774|NCT04663139|Drug|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
79686775|NCT04663139|Drug|Placebo|Matching placebo
79829027|NCT04301011|Biological|TBio-6517|Engineered Oncolytic Vaccinia Virus
79829028|NCT04301011|Biological|Pembrolizumab|Immune checkpoint inhibitor.
79829030|NCT04261192|Other|Constitution of tumor and blood samples|Constitution of tumor and blood samples
79829031|NCT04227483|Drug|Deflazacort|Deflazacort for 4 months
79236271|NCT04050397|Other|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
79829032|NCT04227483|Drug|Prednisolone|Prednisolone for 4 months
79236272|NCT03492411|Other|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
79236273|NCT02531698|Biological|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
79376998|NCT01802333|Drug|Vorinostat|Given PO
79376999|NCT01585324|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
79377000|NCT01585324|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
79377001|NCT03006484|Other|No intervention|No intervention will be needed.
79377002|NCT03006640|Drug|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
79377003|NCT03006640|Drug|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
79236274|NCT02531698|Biological|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
80003891|NCT02106650|Drug|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
79686776|NCT04095780|Other|Advanced oral hygiene care programme|"Brush teeth with standardized power tooth brush twice a day.~Rinse mouth with chlorhexidine twice a day.~Oral hygiene education"
79829033|NCT04219254|Drug|BI1206|"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"
80003892|NCT05221437|Other|antibiotic prescription|
79236275|NCT02531698|Other|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
79236276|NCT04308837|Drug|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
79236277|NCT04308837|Drug|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
79377004|NCT01586962|Drug|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
79377005|NCT01588444|Device|cortical FDBA|cortical mineralized freeze-dried bone allograft
79686777|NCT04095780|Other|Oral hygiene instruction|Oral hygiene education
79686778|NCT04662788|Drug|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
79236278|NCT04308837|Drug|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
79236279|NCT04308837|Drug|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
79236280|NCT04308837|Drug|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
79686779|NCT04088994|Other|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
79686780|NCT04088994|Other|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
80003893|NCT01376011|Dietary Supplement|quercetin/placebo|Quercetin 500mg once per day versus placebo
79829034|NCT04200534|Other|Best Practice|Receive usual care counseling
80003894|NCT02106806|Dietary Supplement|Zinc|35 mg of elemental zinc twice daily for 16 weeks
80003895|NCT02106806|Other|Placebo|One capsule, twice daily for 16 weeks
80003896|NCT02966119|Drug|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
79236281|NCT04308837|Drug|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
79236282|NCT04308837|Radiation|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams >6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
79377006|NCT01588444|Device|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
79377007|NCT03006250|Drug|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
79829035|NCT04200534|Drug|Nicotine Patch|Given nicotine patches
79829036|NCT04200534|Other|Quality-of-Life Assessment|Ancillary studies
79377008|NCT03006250|Drug|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
79377009|NCT03006406|Drug|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
79377010|NCT00980655|Biological|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
79377011|NCT00980655|Biological|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
79377012|NCT04129437|Drug|Ibuprofen|Weight based ibuprofen dosing
79829037|NCT04200534|Other|Questionnaire Administration|Ancillary studies
79829038|NCT04200534|Other|Tobacco Cessation Counseling|Receive counseling over the phone
79829039|NCT04195633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
79829040|NCT04195633|Drug|Cyclophosphamide|Given IV
79829041|NCT04195633|Drug|Cyclosporine|Given IV or PO
79829042|NCT04195633|Biological|Filgrastim|Given IV
79829043|NCT04195633|Drug|Fludarabine|Given IV
79829044|NCT04195633|Drug|Mycophenolate Mofetil|Given IV or PO
79829045|NCT04195633|Drug|Mycophenolate Sodium|Given PO
79829046|NCT04195633|Radiation|Total-Body Irradiation|Undergo total-body irradiation
80003897|NCT05707299|Procedure|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
79829047|NCT04195633|Drug|Treosulfan|Given IV
79686781|NCT04065516|Procedure|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
80003898|NCT02103296|Procedure|Drawing admission labs from cord blood|
79686782|NCT04037007|Procedure|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
79686783|NCT04037007|Procedure|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
79236283|NCT04308837|Procedure|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
80003899|NCT02103296|Procedure|Drawing admission labs from infant blood|
79686784|NCT04037007|Procedure|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
79686785|NCT04037007|Procedure|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
79686786|NCT04010253|Device|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
79686787|NCT04010253|Other|Autogenic drainage|Manual aiway clearance by autogenic drainage
79236284|NCT04308837|Radiation|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
79236285|NCT02998021|Device|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
79686788|NCT04662866|Drug|Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg|Comparison of 4 different antihyperglycemic drugs
79236286|NCT02998021|Device|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training."
79686789|NCT04662476|Dietary Supplement|Vitamin D3|Vitamin D3 supplement
79686790|NCT04008927|Diagnostic Test|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
79686791|NCT04008927|Diagnostic Test|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL). In addition a measure of the liver stiffness will be performed.
79686792|NCT04008927|Drug|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
79686793|NCT04662437|Diagnostic Test|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
79686794|NCT03986424|Drug|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
79686795|NCT03986424|Drug|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
79686796|NCT04662593|Behavioral|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
79686797|NCT03974451|Device|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
79829048|NCT04190823|Drug|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
79236287|NCT03487497|Procedure|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
79686798|NCT03974451|Device|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
80003900|NCT02956759|Procedure|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
80003901|NCT02101892|Drug|Amitriptyline|per os, daily, evening
79686799|NCT04661969|Procedure|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
80003902|NCT02101892|Drug|placebo|per os, daily, evening
79686800|NCT03943368|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
79236288|NCT03664375|Other|Botulinum toxin type A|All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
79236289|NCT03664375|Other|Task Specific Training|Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
79236290|NCT03731247|Device|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
79236291|NCT03731247|Device|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
79377013|NCT04129437|Procedure|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
79377014|NCT05609799|Other|Blood sample|Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
79377015|NCT01535014|Drug|Dietressa|Comparison of different dosages (frequency) of drug
79686801|NCT03899181|Device|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
79686802|NCT03899181|Other|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
79829049|NCT04189783|Drug|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
80003903|NCT03634111|Procedure|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
80003904|NCT03634111|Drug|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
79377016|NCT01535014|Drug|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
80003905|NCT03634111|Drug|Ropivacaine|Ropivacaine 0.25% 20 ml each side
80003906|NCT02102048|Drug|Atazanavir|
80003907|NCT02102126|Procedure|Renal denervation|
80003908|NCT03118297|Drug|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
79377017|NCT05609721|Other|no intervention, only observational study|no intervention, only observational study
79377018|NCT04588259|Drug|Faster aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
79377019|NCT04588259|Drug|Insulin aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
79377020|NCT04588259|Drug|Insulin degludec|Administered s.c. (subcutaneously, under the skin) for 16 weeks
79377021|NCT01535326|Procedure|air insufflation|insufflate air during the insertion of colonoscopy
79377022|NCT01535326|Procedure|water immersion|infuse water during insertion, aspirate water during withdrawal
79377023|NCT01535326|Procedure|water exchange|infuse and remove water during insertion phase of colonoscopy
79377024|NCT01801865|Device|GE OPTIMA MR430s with HDX/GE Electronics|
80003909|NCT03118297|Drug|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
80003910|NCT02250794|Drug|metformin and sitagliptin|metformin 750 mg PO twice daily
80003911|NCT02250794|Drug|insulin glargine and insulin lispro|insulin glargine given once daily
80003912|NCT02250794|Drug|metformin and sitagliptin|sitagliptin 100 mg PO once daily
80003913|NCT02250794|Drug|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
80003914|NCT02103374|Drug|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
80003915|NCT02103374|Drug|Placebo|1 capsule lactose during 48 weeks
80003916|NCT01374061|Device|Classical intubation|Classical intubation
80003917|NCT01374061|Device|GLIDESCOPE|GLIDESCOPE intubation
80003918|NCT05658783|Other|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
79236292|NCT03434301|Device|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
79236293|NCT03434301|Device|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
79236294|NCT03492333|Other|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
79236295|NCT00403793|Drug|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
79236296|NCT00403793|Drug|Placebo|42 or 44 weeks with placebo implant and placebo injections
79829050|NCT04189783|Drug|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
79829051|NCT04189783|Other|Questionnaire Administration|Ancillary studies
79236297|NCT03419871|Other|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
79236298|NCT03419871|Other|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
79236299|NCT03702335|Behavioral|Dietary Counselling|Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
79236300|NCT03489213|Other|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
79236301|NCT03489213|Behavioral|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
79829052|NCT04188600|Dietary Supplement|Libicare|"The main ingredients of Libicare® are:~Trigonella Foenum-graecum (Trigonella)~Tribulus Terrestris (Tribulus)~Turnera Diffusa (Damiana)"
79829053|NCT04188600|Dietary Supplement|active control|Selenium and vitamins B complex
79829054|NCT04188327|Procedure|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~Acyclovir 800 mg orally every 5 times per day 7 days.~Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
79530679|NCT01424904|Dietary Supplement|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
79686803|NCT03883230|Diagnostic Test|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
79686804|NCT00557180|Drug|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
79829055|NCT04188327|Procedure|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~Acyclovir 800 mg orally every 5 times per day for 7 days.~Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
79829056|NCT04187352|Drug|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
79829057|NCT04187352|Drug|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
79236302|NCT03489213|Other|Laboratory Biomarker Analysis|Correlative studies
79236303|NCT03489213|Dietary Supplement|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
79829058|NCT04186208|Drug|NOVOCART 3D|Autologous Chondrocyte Implantation
79236304|NCT03489213|Other|Questionnaire Administration|Ancillary studies
79530680|NCT01424956|Device|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
79686805|NCT00557180|Drug|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
79829059|NCT04185701|Other|SiVIEW software|Eye examination by a technician with the SiVIEW software
79686806|NCT00557180|Drug|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
79686807|NCT03818724|Device|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
79829060|NCT04185701|Other|Expert|Eye examination by an expert including optimal correction in distance and near vision
79236305|NCT04387773|Drug|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
79829061|NCT04164940|Other|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
79829063|NCT04135300|Genetic|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
79829064|NCT04122469|Radiation|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
79829065|NCT04120636|Drug|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
79530681|NCT01425008|Drug|MLN2480|Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
79530682|NCT01425034|Other|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
79829066|NCT04120311|Drug|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
79829067|NCT04116528|Drug|Ketamine|0.5mg/kg
79829068|NCT04116528|Drug|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
79829069|NCT04116528|Drug|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
79530683|NCT01425034|Other|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
79686808|NCT00557219|Drug|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
79377025|NCT01590238|Biological|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
79686809|NCT00557219|Drug|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
79377026|NCT00980343|Drug|vismodegib|Given orally
79377027|NCT00980343|Procedure|therapeutic conventional surgery|undergo surgery
79686810|NCT00557219|Drug|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
79686811|NCT00539877|Drug|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
79686812|NCT03798405|Behavioral|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
79829070|NCT04107883|Biological|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
79829071|NCT04107883|Diagnostic Test|blood sample|get blood samples at several specific points in time during perioperation
79829072|NCT04103476|Combination Product|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
79829073|NCT04103476|Other|Placebo|Placebo
79829074|NCT04102007|Drug|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
79829075|NCT04100213|Behavioral|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
79829076|NCT04089215|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10^8 CAR+T cells and 1.5 x 10^8 CAR+T cells
79829077|NCT04072978|Device|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
79377028|NCT00980343|Other|laboratory biomarker analysis|correlative studies
79377029|NCT00980343|Other|pharmacological study|correlative studies
79377030|NCT01801475|Drug|Ondansetron|Pregnant & non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
79530684|NCT01425060|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
79530685|NCT01425060|Other|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
79829078|NCT04054401|Device|DRG Neurostimulation with Spinal Fusion|Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
79236306|NCT03034577|Drug|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
79236307|NCT03034577|Drug|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
79377031|NCT01536184|Behavioral|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
79530686|NCT01425073|Other|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
80003919|NCT02103452|Procedure|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
79377032|NCT03063021|Drug|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
79530687|NCT01425086|Device|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
79530688|NCT01425099|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
79530689|NCT01425099|Drug|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
79530690|NCT01425125|Drug|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
79530691|NCT01425151|Device|i-Gel|Oropharyngeal leak pressure Insertion success
79530692|NCT01425151|Device|ProSeal|Oropharyngeal leak pressure Insertion success
79686813|NCT03796338|Device|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
79686814|NCT00557336|Drug|somatropin|
79686815|NCT00539916|Behavioral|Regular orange juice consumption|600 mL /day.
79686816|NCT04661618|Device|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
79686817|NCT00539955|Behavioral|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
79686818|NCT00539955|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
79377033|NCT01536496|Biological|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
79377034|NCT01536496|Biological|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
79377035|NCT02337933|Drug|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
79530693|NCT01425164|Drug|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
79530694|NCT01425164|Drug|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
79530695|NCT01425177|Procedure|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
79829079|NCT04052555|Drug|Berzosertib|Given IV
79829080|NCT04052555|Procedure|Biospecimen Collection|Correlative studies
79829081|NCT04052555|Other|Quality-of-Life Assessment|Ancillary studies
79829082|NCT04052555|Other|Questionnaire Administration|Ancillary studies
79829083|NCT04052555|Radiation|Radiation Therapy|Undergo RT
79829084|NCT04045301|Biological|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
80003920|NCT03967587|Device|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
80003921|NCT02250950|Behavioral|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
79236308|NCT03487341|Other|Cord drainage|Cord drainage
79236309|NCT03487341|Other|Cord clamping|Cord clamping
79236310|NCT05377060|Behavioral|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
79236311|NCT05377060|Behavioral|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
79236312|NCT04384497|Biological|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
79530696|NCT01425216|Drug|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
79829085|NCT04045301|Biological|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
79236313|NCT03705455|Behavioral|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
79686819|NCT04661696|Drug|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
80003922|NCT02250950|Behavioral|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
80003923|NCT05707221|Other|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
80003924|NCT05707221|Other|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
80003925|NCT05707221|Other|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
80003926|NCT02103530|Other|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
80003927|NCT05220969|Genetic|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
80003928|NCT02251028|Behavioral|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
80003929|NCT03117361|Drug|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
80003930|NCT03117361|Drug|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
80003931|NCT03117361|Drug|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
80003932|NCT01368614|Device|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
79236314|NCT03092427|Dietary Supplement|VSL#3|Dietary Supplement
79236315|NCT03092427|Other|Placebo|Placebo
80003933|NCT01368614|Device|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
79236316|NCT04364997|Drug|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
79530697|NCT01425242|Drug|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
79377036|NCT02337933|Drug|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
79530698|NCT01425242|Drug|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
79530699|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
79686820|NCT04661462|Other|online survey|We invite volunteers after COVID-19 to participate in an online survey.
79686821|NCT03766191|Behavioral|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
79236317|NCT04364997|Drug|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
79377037|NCT03062943|Drug|Nintedanib|
79377038|NCT01536886|Drug|LEO 90100|
79377039|NCT01536886|Drug|Betamethasone plus calcipotriol|
79377040|NCT01536886|Drug|Ointment vehicle|
79377041|NCT01536886|Drug|LEO 90100 vehicle|
79377042|NCT01822925|Drug|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
79377043|NCT01822925|Drug|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
79377044|NCT01822925|Drug|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
79686822|NCT03766191|Other|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
79686823|NCT04661228|Diagnostic Test|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
79686824|NCT06087536|Drug|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
79686825|NCT06087536|Drug|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
79829086|NCT04045301|Biological|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
80003934|NCT01368614|Device|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
79530700|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
79236318|NCT04364997|Drug|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
79236319|NCT04364997|Drug|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
79236320|NCT05376982|Diagnostic Test|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
79236321|NCT05376982|Diagnostic Test|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
79236322|NCT04820075|Behavioral|improvement of preoperative shower|Process about preoperative shower
79236323|NCT03034629|Behavioral|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
79236324|NCT01717924|Procedure|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
79236325|NCT01717924|Procedure|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
79236326|NCT04289493|Other|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
79236327|NCT03701867|Other|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
79236328|NCT03750279|Other|Exercise therapy|"5 min. warm up with light exercises for the lower limb prior to strength/endurance exercise therapy.~Strength/endurance exercise therapy including level 1 or 2 per session:~Level 1: Pelvic lifts (2x15 rep.), one-legged knee bends (2x10 rep. per leg), hip abductions (2x10 rep. per leg). The participants may progress from level 1 to level 2.~Level 2: Pelvic lifts (3x15 rep.), one-legged knee bends (3x10 rep. per leg), hip abductions (2x10 rep. per leg), sideways slide (2x10 rep. per leg), and backwards slide (2x10 rep. per leg). The participants may regress from level 2 to level 1."
79236329|NCT03750279|Other|LLLT|- LLLT (60 mW mean output per probe, 904 nm wavelength) applied to the knee in adherence with the recommendations by World Association for Laser Therapy, in terms of dosage per treatment spot.
79236330|NCT03750279|Other|Sham LLLT|- Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
79236331|NCT03701789|Drug|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
79686826|NCT06087523|Other|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~Systemic Lupus Activity Questionnaire~Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
79686827|NCT06087471|Dietary Supplement|Intervention snack|The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
79236332|NCT05417386|Drug|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
79686828|NCT06087471|Dietary Supplement|Control Snack|The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
79829087|NCT04045301|Other|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
80003935|NCT05220891|Other|Paracentesis|Paracentesis from ascitic patient
80003936|NCT05219305|Device|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
79236333|NCT05417386|Drug|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79236334|NCT05417386|Drug|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79236335|NCT05417386|Drug|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79236336|NCT05417386|Drug|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79236337|NCT05417386|Drug|NIS793|Given by intravenous infusion
79236338|NCT05417386|Radiation|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
79236339|NCT05417386|Drug|Capecitabine|Taken Orally as part of Chemoradiation
79236340|NCT05417386|Radiation|Radiation Therapy|Radiation Therapy as part of Chemoradiation
79236341|NCT05417386|Procedure|Surgery|Surgical removal of tumor
79236342|NCT03487263|Biological|IC14|chimeric monoclonal antibody against human IC14
79236343|NCT03702101|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
79530701|NCT01425320|Drug|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
79530702|NCT01425320|Drug|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
79530703|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
79530704|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
79530705|NCT01425385|Other|Near infrared spectroscopy monitoring|This is an observational study without interventions
79829088|NCT04044404|Diagnostic Test|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
79530706|NCT01425385|Other|Autoregulation monitoring|There are no interventions in this observational study
79530707|NCT01425398|Drug|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
79686829|NCT06087289|Drug|KAND567|"KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression)."
79686830|NCT06087289|Drug|Carboplatin|Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
79686831|NCT06087263|Drug|Regorafenib|Given by PO
79686832|NCT06087224|Other|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
79686833|NCT06087211|Drug|Duloxetine and magnesium sulphate|this group will receive Duloxetine 30 mg orally and an intravenous (IV) infusion of magnesium sulphate 50mg/kg mixed with 200ml normal saline (NS) 1 hour before surgery
79829089|NCT04017650|Biological|Cetuximab|Given IV
80003937|NCT05707065|Other|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
79829090|NCT04017650|Drug|Encorafenib|Given PO
79829091|NCT04017650|Biological|Nivolumab|Given IV
80003938|NCT05707065|Other|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
80003939|NCT02102360|Device|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
79236344|NCT04005729|Drug|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
79236345|NCT03486015|Drug|Sterile water|2 ml of sterile water
79236346|NCT03486015|Drug|30% glucose|2 ml of 30% glucose
79236347|NCT04599023|Device|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
79236348|NCT01659736|Device|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
79236349|NCT03487107|Drug|SOF|400 mg tablet administered orally once daily
79236350|NCT03487107|Drug|DAG181|100 mg capsule administered orally once daily
79530708|NCT01425398|Drug|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
79530709|NCT01425411|Drug|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
79530710|NCT01425424|Other|Vitamin D supplementation|Vitamin D
79829092|NCT04005430|Drug|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
80003940|NCT02102360|Device|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
80003941|NCT03555110|Behavioral|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
80003942|NCT03555110|Behavioral|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
79236351|NCT03705299|Device|Non-Invasive CVP vs Standard CVP|
79236352|NCT03705221|Behavioral|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
79530711|NCT01425450|Drug|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
79530712|NCT01425450|Drug|HF1020 placebo|Single dose: HF1020 placebo capsule
79530713|NCT01425476|Drug|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
79530714|NCT01425476|Drug|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
79530715|NCT01425476|Drug|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
79530716|NCT01425502|Behavioral|DQIP Intervention|"The DQIP intervention comprises of:~Educational outreach~Information technology application~Financial incentives"
79530717|NCT01425515|Behavioral|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
79530718|NCT01425554|Other|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
79530719|NCT01425554|Other|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
79530720|NCT01425554|Other|Air-plethysmography of the neck|Air-plethysmography of the neck
79530721|NCT01425554|Other|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
79530722|NCT01425567|Drug|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
79530723|NCT01425580|Drug|liraglutide|1.8 mg s.c. (QD)
79377045|NCT01822925|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
79377046|NCT02247310|Drug|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
79377047|NCT02247310|Device|BETACONNECT|Auto-injector device to support the injection of Betaferon
79377048|NCT03041415|Behavioral|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
79686834|NCT06087211|Drug|Duloxetine|this group will receive Duloxetine 30 mg orally and 200ml NS infusion 1 hour before surgery
79829093|NCT04002830|Drug|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
80003943|NCT05083273|Other|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
80003944|NCT02110004|Procedure|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
79686835|NCT06087211|Drug|placebo|will receive placebo capsule and an IV infusion of 200ml NS 1 hour before surgery
79236353|NCT03705221|Behavioral|Healthy Parent Carers online resources|Online resources related to health and wellbeing
79236354|NCT03485937|Behavioral|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
79686836|NCT06087185|Behavioral|Mindful Eating|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
79829094|NCT03978507|Behavioral|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
79236355|NCT03485937|Behavioral|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
79236356|NCT03485937|Behavioral|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
79377049|NCT03041415|Behavioral|ALED + Our Voice PA Program|"12-week class focused on teaching self-regulatory skills to increase regular PA~Neighborhood assessment, consensus-building, & advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
79829095|NCT03978507|Behavioral|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
79829096|NCT03967379|Behavioral|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
79829097|NCT03967379|Other|Enhanced Standard Care|Standard of care administered by the institution
80003945|NCT02110004|Device|Picasso NAV Catheter|
79377050|NCT00989001|Drug|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
79377051|NCT00989001|Drug|Placebo|Injection
79530724|NCT01425580|Drug|glimepiride|4 mg p.o. (QD)
79530725|NCT01425580|Drug|Metformin|500 mg p.o. (BID)
79530726|NCT01425606|Other|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
79530727|NCT01425619|Biological|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
79530728|NCT01425619|Drug|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
79530729|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
79530730|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
79530731|NCT01425645|Other|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
80003946|NCT05082337|Device|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
80003947|NCT03053427|Drug|Placebo|Oral administration
80003948|NCT03053427|Drug|Gabapentin enacarbil|Oral administration
79377052|NCT03061539|Drug|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
79377053|NCT01590550|Procedure|Use of citrate based dialysate|Use of heparin free citrate based dialysate
79377054|NCT05609253|Drug|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
79829098|NCT03958721|Drug|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
79377055|NCT05609253|Drug|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
80003949|NCT02107118|Biological|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
80003950|NCT02107118|Other|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
79236357|NCT05591716|Procedure|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
79302664|NCT05713721|Device|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
79302665|NCT05713721|Other|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
79377056|NCT01591018|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
79377057|NCT01591018|Procedure|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
79377058|NCT05609097|Other|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
79530732|NCT01425658|Drug|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
79686837|NCT06087185|Behavioral|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
79686838|NCT06087172|Diagnostic Test|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
79829099|NCT03958721|Radiation|Radiotherapy|Once daily (Monday through Friday) for six weeks
80003951|NCT05081089|Drug|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
80003952|NCT05081089|Drug|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
80003953|NCT05081089|Drug|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
80003954|NCT05081089|Drug|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
79829100|NCT03938649|Radiation|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
79829101|NCT03938649|Drug|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
80003955|NCT03555032|Drug|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
79530733|NCT01425658|Drug|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
79530734|NCT01425658|Drug|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
79530735|NCT01425697|Other|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
80003956|NCT03554408|Drug|10-1074-LS|Subcutaneous injection of 10-1074-LS
80003957|NCT03554408|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS
80003958|NCT03554408|Drug|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
80003959|NCT03554408|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
80003960|NCT05220579|Device|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
80003961|NCT05220579|Device|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
79236358|NCT05591716|Procedure|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
79829102|NCT03937700|Device|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
79829103|NCT03930056|Device|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
79236359|NCT03485859|Device|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
79530736|NCT01425697|Other|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
79530737|NCT01425736|Drug|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
79829104|NCT03930056|Device|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
79829105|NCT03906877|Procedure|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
80003962|NCT02103686|Drug|Lyrica|
80003963|NCT02103686|Drug|Experimental drug|sustained release formulation of pregabalin
80003964|NCT02103686|Dietary Supplement|High fat meal|
80003965|NCT02103686|Dietary Supplement|fasted|
80003966|NCT01372969|Drug|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
80003967|NCT02110082|Biological|Urelumab|
80003968|NCT02110082|Biological|Cetuximab|
80003969|NCT05706831|Other|Combinatory effect of music stimulation and neurostimulation|music
79236360|NCT03485859|Device|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
80003970|NCT02103764|Drug|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
79377059|NCT05609097|Other|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
79377060|NCT01801007|Device|Flow Re-Direction Endoluminal Device (FRED)|
79377061|NCT05609019|Drug|SYHX2005|Tablets. Take orally.
79530738|NCT01425736|Drug|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
79530739|NCT01425762|Other|Drug Dose|100 versus 200 mcg IT morphine
79530740|NCT01425775|Drug|vitamin D 25(OH)D|2000IU/day for 12 months
79530741|NCT01425775|Other|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
79530742|NCT01425788|Biological|Osiris Phleum pratense|
79530743|NCT01425788|Biological|Osiris Phleum pratense|
79530744|NCT01425788|Biological|Osiris Phleum pratense|
79530745|NCT05386940|Other|PKN1 level|different PKN1 level after on-pump cardiac surgery
79236361|NCT03705143|Behavioral|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
79829106|NCT03906877|Behavioral|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
80003971|NCT02103764|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
79236362|NCT03705143|Behavioral|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
79377062|NCT04120545|Device|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
79530746|NCT05386862|Behavioral|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
79236363|NCT05375890|Other|no intervention|Narcolepsy patients in Russia gathered according to criteria.
79236364|NCT02997163|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
79530747|NCT05386823|Drug|HF1K16|A range of doses of HF1K16 will be tested based on the assessment of safety, tolerability and pharmacokinetics.
79377063|NCT04120545|Device|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
79377064|NCT01822691|Drug|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
79377065|NCT01822535|Drug|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
79377066|NCT01537666|Drug|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
79530748|NCT05386823|Drug|Placebo|Placebo
79530749|NCT05386667|Drug|Majezik %0.25 oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
79530750|NCT05386667|Other|Aftamed oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
79686839|NCT06087159|Behavioral|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
79686840|NCT06087094|Drug|HRS-7450 ；Placebo|HRS-7450 or Placebo
79686841|NCT06087068|Drug|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
79829107|NCT03906877|Other|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
79377067|NCT01537666|Drug|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
79377068|NCT01537900|Drug|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
79530751|NCT05386667|Other|Crystalin oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
79530752|NCT05386667|Procedure|Free gingival graft harvesting|Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
79530753|NCT05386498|Procedure|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
79530754|NCT05386498|Procedure|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
79829108|NCT03906877|Other|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
79829109|NCT03905707|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
79530755|NCT05386498|Procedure|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
79829110|NCT03904043|Radiation|Radiation therapy|-Monday-Friday treatment is strongly recommended
79236365|NCT03705065|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
79530756|NCT05386446|Drug|Interferon gamma human recombinant (IFN-G)|nasal form
79530757|NCT01425112|Procedure|Phacoemulsification|Surgery for complications of trabeculectomy
79530758|NCT05386433|Drug|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir [PF-07321332] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
79829111|NCT03904043|Drug|FOLFOX regimen|-CAPOX can be given as alternative
79829112|NCT03904043|Other|Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire|-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy
79829113|NCT03904043|Procedure|Rectal biopsy samples|-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.
79829114|NCT03904043|Procedure|Blood for ctDNA|-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after RT (if this visit aligns with a follow-up time point, one draw can be used to satisfy both time points), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)
79829115|NCT03901001|Drug|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
79236366|NCT03702023|Drug|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
79829116|NCT03901001|Drug|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
79829117|NCT03900988|Drug|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
79829118|NCT03900988|Drug|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
79236367|NCT03702023|Drug|Placebo Oral Tablet|Control group will be given a placebo capsule.
79236368|NCT05391880|Drug|BEBT-503 20mg|BEBT-503 capsule
79829119|NCT03900377|Drug|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
79236369|NCT05391880|Drug|BEBT-503 40mg|BEBT-503 capsule
79829120|NCT03898960|Device|NIMBUS Device|NIMBUS Geometric Clot Extractor
79829121|NCT03895489|Device|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
79829122|NCT03895489|Device|Stryker|Stryker Triathlon Total Knee prosthesis
79236370|NCT05391880|Drug|BEBT-503 80mg|BEBT-503 capsule
79377069|NCT03005938|Procedure|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
79530759|NCT05386433|Drug|standard-of-care|standard-of-care of COVID-19
79530760|NCT05386316|Other|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
79236371|NCT05391880|Drug|BEBT-503 120mg|BEBT-503 capsule
79236372|NCT05391880|Drug|BEBT-503 180mg|BEBT-503 capsule
79236373|NCT05391880|Drug|placebo 20mg|placebo capsule
79236374|NCT05391880|Drug|placebo 40mg|placebo capsule
79236375|NCT05391880|Drug|placebo 80mg|placebo capsule
79236376|NCT05391880|Drug|placebo 120mg|placebo capsule
79236377|NCT05391880|Drug|placebo 180mg|placebo capsule
79236378|NCT04649255|Device|Liquid Embolic|Lava Liquid Embolic System (LES)
79302666|NCT05713721|Other|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
79236379|NCT04532827|Behavioral|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
79236380|NCT05390086|Other|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
79236381|NCT03698513|Drug|BMS-986177|BMS-986177 capsule
79236382|NCT03698513|Other|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
79236383|NCT03698513|Drug|Clopidogrel|Clopidogrel tablet
79530761|NCT05386316|Other|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
79530762|NCT05386290|Drug|Infliximab|A TNFα inhibitor in UC and CD treatment
79530763|NCT05386290|Drug|Vedolizumab|An integrin receptor antagonist in UC and CD treatment
79530764|NCT05386290|Drug|Ustekinumab|An IL-12/IL-23 inhibitor in CD treatment
79686842|NCT06087055|Drug|GST-HG171/Ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
79686843|NCT06087055|Drug|Itraconazole|Administered orally once daily for 9 days from Days 8 through 16
79686844|NCT06087055|Drug|GST-HG171/Ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
79829123|NCT03895489|Device|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
79236384|NCT03698513|Drug|Aspirin|Aspirin tablet
79236385|NCT05416294|Device|Primary Relief|The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
79236386|NCT05416294|Device|Inactive Primary Relief|The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
79236387|NCT03698435|Drug|Ganciclovir|Intravenous ganciclovir + TDM
79236388|NCT03698435|Drug|Valganciclovir|Oral valganciclovir + TDM
79236389|NCT03698357|Behavioral|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
79236390|NCT03698357|Behavioral|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
79236391|NCT05389072|Device|control contact lens|control CRT lens
79236392|NCT03701633|Diagnostic Test|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
79377070|NCT03005938|Procedure|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
79377071|NCT01591408|Device|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
79391131|NCT03181698|Diagnostic Test|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
79829124|NCT03874104|Dietary Supplement|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
79829125|NCT03863093|Device|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
79829126|NCT03863093|Device|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
79829127|NCT03853616|Biological|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
79686845|NCT06087042|Diagnostic Test|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
80003972|NCT05011201|Device|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
79236393|NCT04641065|Other|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
79236394|NCT03701945|Other|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
79236395|NCT03698045|Drug|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
79236396|NCT04547075|Other|Turkish validity and reliability|"Contact with developers and formation of steering committee~Translation from English to Turkish~Back translation from Turkish to English~Comparison of translation~Review of translated versions.~Reaching consensus and development of pilot version~Testing in clinical setting~Revision of pilot version~Testing of final version"
79829128|NCT03843385|Drug|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
79377072|NCT01539070|Behavioral|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
79829129|NCT03843385|Drug|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
79236397|NCT03701477|Behavioral|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
79236398|NCT03701477|Behavioral|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
79236399|NCT03697889|Drug|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
79829130|NCT03843385|Drug|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
79829131|NCT03824327|Procedure|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
79236400|NCT03697889|Drug|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
79236401|NCT03692819|Drug|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
79829132|NCT03824327|Drug|Papaverine Hydrochloride|Given IV
79829133|NCT03824327|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79236402|NCT03692819|Drug|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
79377073|NCT01592500|Drug|MOD-4023|Once weekly subcutaneous injection
79377074|NCT01592500|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
79391132|NCT03116724|Procedure|central venous catheterization through Rt. IJV|"insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~measurement of the depth of the catheter at insertion point"
79686846|NCT06087016|Other|Urine vibrational analysis|Urine vibrational analysis
79686847|NCT06087003|Drug|Basiliximab Injection|As an induction treatment for kidney transplantation
79829134|NCT03822728|Diagnostic Test|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
79829135|NCT03815825|Drug|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
79829136|NCT03815825|Drug|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
79829137|NCT03809013|Drug|RC48-ADC|2.0mg/kg IV every 2 weeks
79829138|NCT03802240|Drug|Sintilimab|200mg IV Q3W
79829139|NCT03802240|Drug|IBI305|15mg/kg IV Q3W
79829140|NCT03802240|Drug|Pemetrexed|500mg/m2 IV Q3W
79829141|NCT03802240|Drug|Cisplatin|75mg/m2 IV Q3W
79829142|NCT03802240|Drug|Placebo1|Placebo1 IV Q3W
79829143|NCT03802240|Drug|Placebo2|Placebo2 IV Q3W
79829144|NCT03799328|Other|multi-OIT|low dose OIT to multiple foods
79236403|NCT03692819|Drug|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
79686848|NCT06087003|Drug|rabbit ATG|As an induction treatment for kidney transplantation
79686849|NCT06086990|Device|Contigo Application|Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.
79686850|NCT06086925|Drug|Black Raspberry|Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.
79686851|NCT06086886|Drug|BMS-986454|Specified dose on specified days
79686852|NCT06086886|Other|Placebo|Specified dose on specified days
79686853|NCT06086860|Other|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
79686854|NCT06086847|Other|progressive resistant exercises|"Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3. Progressive Resistance exercises:~Leg press :( dual leg press): Leg press target the~Quadriceps or quads .but they also work your Hamstrings.~Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~Rectus femoris~Vastus lateralis~Vastus medialis~Vastus intermedius~4. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
79829145|NCT03796572|Drug|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
79829146|NCT03796572|Other|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
79829147|NCT03787693|Behavioral|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
79236404|NCT00458536|Biological|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
79686855|NCT06086808|Other|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
80003973|NCT05011201|Device|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
80003974|NCT02110316|Other|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
80003975|NCT02103842|Drug|Omega-3 fatty acids|
80003976|NCT05220267|Drug|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
79236405|NCT00458536|Drug|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
79236406|NCT03697733|Procedure|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
79236407|NCT05373394|Other|Test battery|motor and neuropsychological test battery
79236408|NCT03697655|Drug|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
80003977|NCT02110394|Other|bendamustine|Routine practice
80003978|NCT02110394|Other|rituximab|Routine practice
80003979|NCT02373241|Drug|Losartan|Standard dosing
80003980|NCT02373241|Drug|Losartan|Experimental dosing
79236409|NCT05373160|Other|Assessment study|Assessment of functional tests with and without dual tasks
79236410|NCT02526550|Biological|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
79236411|NCT02526550|Biological|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
79302667|NCT05713721|Other|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
79302668|NCT05002647|Other|NO intervention|There is no intervention
79302669|NCT03200509|Other|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
80003981|NCT03052959|Behavioral|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
80003982|NCT03052959|Other|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
79530765|NCT05386290|Drug|conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)|Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
79686856|NCT06086808|Other|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
80003983|NCT02107430|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
80003984|NCT02107430|Radiation|Standard radiotherapy|radiotherapy
80003985|NCT05706675|Procedure|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
79686857|NCT06086782|Other|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
80003986|NCT03120013|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
79236412|NCT05565352|Drug|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
80003987|NCT03120013|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
79377075|NCT03002116|Other|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
80003988|NCT05656131|Drug|Fluzoparib|Arms A will be treated with fluzoparib alone
80003989|NCT05656131|Drug|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
80003990|NCT02110472|Device|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
80003991|NCT01373047|Biological|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
79236413|NCT04423276|Drug|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
79530766|NCT05386251|Behavioral|BPT/OST|See Arm description.
80003992|NCT02103998|Drug|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
80003993|NCT02103998|Drug|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
79236414|NCT04423276|Drug|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
79236415|NCT03701243|Procedure|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
80003994|NCT05220111|Procedure|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
80003995|NCT01941589|Drug|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
79302670|NCT03200509|Other|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
79530767|NCT05386251|Behavioral|Peer Support|See Arm description
79530768|NCT05386212|Device|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
80003996|NCT01941589|Drug|corticosteroids only|IV corticosteroids only
80003997|NCT02110550|Other|IPS.emmax endocrown|
80003998|NCT02110628|Procedure|Roux-en-Y anastomosis|Roux-en-Y anastomosis
80003999|NCT02110628|Procedure|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
80004000|NCT02107664|Radiation|Palliative RT for bone cancer pain|
80004001|NCT01845649|Drug|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
80004002|NCT01845649|Drug|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
80004003|NCT03554252|Other|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
80004004|NCT03554252|Other|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
79236416|NCT03701243|Procedure|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
79236417|NCT03697499|Combination Product|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
79236418|NCT03697499|Combination Product|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
79530769|NCT05386186|Drug|Glimepiride|Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
79686858|NCT06086782|Other|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
79236419|NCT03697499|Combination Product|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
79236420|NCT03697499|Combination Product|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
79686859|NCT06086769|Device|High flow nasal canula|Measurement of diaphragm thickening fraction, respiratory rate and esophageal pressure swing with calculation of diaphragmatic pressure-time product without the use of HFNC and with the use of HFNC at 20 and 40 Liters per minute
79829148|NCT03786237|Drug|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
79829149|NCT03780322|Device|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
80004005|NCT01345929|Drug|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
80004006|NCT01345929|Drug|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
79236421|NCT05371210|Other|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
79236422|NCT04423432|Other|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
79236423|NCT04423432|Other|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion~Isometric isolated knee extension and knee flexion~Isometric terminal knee extension~Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
79236424|NCT04423432|Device|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
79236425|NCT04423432|Procedure|Joint Mobilization|"Tibio-femoral Anterior Glide~Tibio-femoral Posterior Glide~Patellofemoral Joint Mobilization"
79236426|NCT04423432|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
79236427|NCT04423432|Dietary Supplement|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
79236428|NCT05370586|Other|Pericapsular nerve Group Block|Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
79236429|NCT05370586|Other|Infrainguinal Fascia Iliaca Block|Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
79236430|NCT03701087|Drug|Vitamin D|2800 IU daily till 26 weeks of pregnancy
79236431|NCT03701009|Procedure|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
79236432|NCT03701009|Procedure|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
79302671|NCT03315611|Drug|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
79530770|NCT05386186|Drug|Sitagliptin|Add sitagliptin 100mg once daily in all patients randomized to this arm.
79530771|NCT05386160|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
80004007|NCT02107742|Procedure|Normal speed lidocaine injection|30 seconds
80004008|NCT02107742|Procedure|Slow lidocaine injection|speed 45 seconds
80004009|NCT02107742|Procedure|Fast lidocaine injection|speed 15 seconds
80004010|NCT01825291|Procedure|CPAP treatment|
80004011|NCT02250872|Drug|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
80004012|NCT02250872|Drug|Placebo|100mg in 2 divided doses plus cisplatin
79530772|NCT05386160|Device|Phacoemulsification|Phacoemulsification
79829150|NCT03780322|Other|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~Upper extremity weight bearing exercises.~Approximation techniques on wrist, elbow and shoulder.~Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~Scapulothoracic joint mobilization.~Stretching of shoulder abductors and external rotators.~Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
79236433|NCT03701009|Procedure|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
79829151|NCT03779217|Other|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
79829152|NCT03779217|Procedure|mastoplasty and breast fat excission|As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
80004013|NCT02250872|Drug|Cisplatin|All patients will receive intravenous cisplatin
80004014|NCT01374139|Drug|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
79236434|NCT03697265|Drug|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
79377076|NCT01799993|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
79377077|NCT01799993|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
79377078|NCT01593592|Dietary Supplement|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
79530773|NCT05386121|Procedure|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
79377079|NCT01593592|Dietary Supplement|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
79829153|NCT03776552|Other|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
79829154|NCT03776552|Other|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
79829155|NCT03760328|Device|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
79829156|NCT03758118|Dietary Supplement|Citicoline|Citicoline administered in oral solution
79829157|NCT03740490|Combination Product|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
79236435|NCT03697265|Drug|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
79236436|NCT03697265|Drug|Placebo|Subcutaneous (SC) adminstration
79236437|NCT05415046|Procedure|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
79829158|NCT03740490|Combination Product|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
79829159|NCT03734237|Biological|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
79829160|NCT03734237|Biological|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
80004015|NCT01374139|Drug|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
80004016|NCT03817983|Diagnostic Test|MRE review for axSpA|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease followed by clinical and MRI assessment
80004017|NCT02107820|Behavioral|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
79236438|NCT03697187|Drug|rhC1INH|Recombinant human C1 inhibitor
79236439|NCT03692507|Dietary Supplement|HMB|Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 5 days prior to surgery.
79236440|NCT03692507|Dietary Supplement|Protein and HMB|Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 5 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.
79302672|NCT03315611|Other|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
79302673|NCT05002725|Drug|Lidocain|300mg (20ml) will be injected
79377080|NCT01593592|Drug|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
79377081|NCT01593592|Drug|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
79686860|NCT06086743|Other|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
80004018|NCT02107820|Device|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
80004019|NCT02110784|Drug|Eurartesim tablets|dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
80004020|NCT04988425|Drug|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
80004021|NCT04988425|Drug|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
80004022|NCT04988425|Drug|Saline|Injection of the same volume of saline immediately after admission before surgery
80004023|NCT03553784|Other|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
79236441|NCT03692507|Dietary Supplement|ERAS|Patients in the third group (High protein) will drink 2- 8oz bottles of Ensure surgery daily (morning and night) for 5 days prior to surgery. Each bottle contains 18g of protein. and a clear 50g Pre-surgery drink on the day of surgery
79377082|NCT01593592|Drug|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
79829161|NCT03734237|Biological|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
79829162|NCT03733990|Biological|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
79829163|NCT03729765|Device|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
79829164|NCT03693872|Drug|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
79829165|NCT03693872|Drug|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
79829166|NCT03686696|Drug|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
80004024|NCT03554096|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
80004025|NCT02104154|Device|Samsung LABGEO PT10 Hepatic Panel|
80004026|NCT02110862|Other|Transittime. Defecography|
79236442|NCT05610748|Procedure|Sub-Periosteal Peri-implant Augmented Layer technique|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
79236443|NCT05610748|Procedure|Soft tissue augmentation|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
79377083|NCT03001960|Drug|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
79377084|NCT03001960|Drug|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
80004027|NCT01343901|Drug|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
80004028|NCT02110940|Other|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
80004029|NCT02110940|Other|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
80004030|NCT02104232|Behavioral|THPP-I|
80004031|NCT02104232|Behavioral|EUC|
79236444|NCT05369338|Device|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
79236445|NCT05369338|Device|Sham Controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
79686861|NCT06086743|Other|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
79686862|NCT06086678|Other|Conventional physical therapy|"Deep breathing exercise.~Diaphragmatic breathing exercise.~Pursed lip breathing exercise."
79686863|NCT06086678|Other|Hydrotherapy|"Water walking exercise.~Forward lunges exercise.~Single leg balance exercise.~Side stepping exercise.~Push ups exercise.~Standing knee lifts exercise."
79686864|NCT06086678|Other|Aerobic exercise|Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
79686865|NCT06086665|Drug|Niraparib|Niraparib
79302674|NCT03200041|Procedure|Blood sample|20 ml blood sample taken from vein in arm
79377085|NCT01822223|Device|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a & 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b & 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
79377086|NCT01593670|Drug|Decitabine|administered intravenous (IV), 10 mg/m^2/day over 1 hour on days 1-5.
79377087|NCT01593670|Drug|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
79686866|NCT06086652|Diagnostic Test|PET/CT|detection of possible primary tumor
79377088|NCT01593670|Biological|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
79686867|NCT06086639|Other|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
79377089|NCT01593670|Other|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
79686868|NCT06086613|Drug|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.~In Part C, participants will receive AGA2115 in multiple doses administered as a SC injection."
79829167|NCT03686696|Drug|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
79829168|NCT03686696|Drug|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
79829169|NCT03679650|Drug|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
79829170|NCT03679650|Biological|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
80004032|NCT02104466|Procedure|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
79829171|NCT03679078|Dietary Supplement|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
80004033|NCT05617521|Device|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
79829172|NCT03654898|Behavioral|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q & A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
80004034|NCT05617521|Device|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
80004035|NCT04862858|Other|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
79829173|NCT03654898|Behavioral|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
80004036|NCT02104622|Device|ReWalk Rehabilitation 2.0|
80004037|NCT05219643|Device|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
79236446|NCT03696875|Other|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
79377090|NCT01593748|Drug|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
79377091|NCT01593748|Drug|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
79377092|NCT01594294|Device|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
79377093|NCT01594294|Device|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
79686869|NCT06086613|Drug|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection.~In Part C, up to 2 cohorts will receive multiple doses of placebo administered as a SC injection."
79686870|NCT06086600|Other|Instrument Assisted Soft Tissue Mobilization|"give gentle strokes from proximal to distal to check for trigger point or taut band. After knowing the exact location, give gentle strokes with minimal pressure in all directions by keeping the instrument in 30 to 60 degree angle. Application time will be between 40- 120 seconds.~Conventional treatment will include~Hot pack for 10-15 min (calf muscles)~Stretching exercises of gastro-soleus (10reps x 2Sets).~Post session : Cold pack for 5 minutes (calf muscles)"
79829174|NCT03654742|Procedure|tonsillectomy|removal of tonsil tissue as described in the study arms
79829175|NCT03651648|Device|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
79236447|NCT03696875|Other|Standard of care|Standard of care
79236448|NCT03692429|Drug|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
79236449|NCT03692429|Drug|FOLFOX|5-FU, leucovorin and oxaliplatin
79236450|NCT03692429|Drug|FOLFIRI|5-FU, leucovorin and irinotecan
79377094|NCT01594294|Device|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
79377095|NCT01594294|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
79236451|NCT03700853|Diagnostic Test|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
79236452|NCT04523129|Drug|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
79236453|NCT04523129|Drug|Vehicle topical ocular, eye drops|Vehicle
80004038|NCT05219643|Device|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
80004039|NCT02108132|Biological|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
79686871|NCT06086600|Other|Dynamic oscillatory stretch technique|"Passively dorsiflexe the ankle to a point of the first stretch sensation. The next component to DOS, 2- second, passive stretch with slow oscillations at end range was applied. This procedure is repeated 10 times in each set with total of 3 sets .Therefore,10reps x2 second hold oscillation x 3 sets are given.Conventional treatment will include~Hot pack for 10-15 min (calf muscles)~Stretching exercises of gastro-soleus (10reps x 2Sets).~Post session : Cold pack for 5 minutes (calf muscles"
79686872|NCT06086548|Other|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
79686873|NCT06086509|Other|Music|Children were played music during computerized tomography.
80004040|NCT02108132|Biological|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
79302675|NCT03075345|Behavioral|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
79377096|NCT01594294|Device|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
79377097|NCT01594528|Other|pain tests|pain induction with pressure application or ischemia on the arm
79377098|NCT03005704|Drug|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
79377099|NCT03001648|Procedure|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
79377100|NCT01595386|Drug|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
79686874|NCT06086496|Device|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79686875|NCT06086483|Drug|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
79377101|NCT01595386|Drug|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
79377102|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
79377103|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
79686876|NCT06086483|Drug|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
79686877|NCT06086405|Device|Patients underwent cardiorespiratory support|Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator
79686878|NCT06086366|Other|[11C]DTBZ PET scan|One [11C]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
79686879|NCT06086366|Other|[18F]SDM8 PET scan|One [18F]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
79686880|NCT06086366|Other|MRI scan|One MRI scan
79686881|NCT06086353|Drug|Tafamidis|Patients on tafamidis will be observed
79686882|NCT06086327|Drug|68Ga-Pentixafor|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
79377104|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
79686883|NCT06086314|Other|reactive exercise training in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
79686884|NCT06086314|Other|reactive exercise training with co-contraction in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
79686885|NCT06086314|Other|neurorehabilitation program with functional reaching training|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
79686886|NCT06086288|Drug|Pembrolizumab, Etoposide, Cisplatin or Carboplatin|Induction Phase (4 cycles, 1Cycle=3W): Pembrolizumab 200 mg + Etoposide + Cisplatin or Carboplatin; Maintenance Phase (16 Cycles, 1Cycle=6W): Pembrolizumab 400 mg
79686887|NCT06086262|Device|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
80004041|NCT02108210|Drug|Anakinra|
80004042|NCT02108210|Drug|Placebo|
79302676|NCT03075345|Behavioral|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
79377105|NCT01595854|Drug|dabigatran etexilate|low dose dabigatran
79377106|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
79377107|NCT01596088|Drug|Dexrazoxane|
80004043|NCT03053271|Drug|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
80004044|NCT03053271|Drug|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
80004045|NCT02104700|Drug|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
80004046|NCT02104778|Drug|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
80004047|NCT02104778|Drug|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
80004048|NCT05205681|Diagnostic Test|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
79686888|NCT06086236|Device|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
80004049|NCT02104856|Device|Alair System (Bronchial Thermoplasty)|
80004050|NCT02108366|Drug|Celecoxib|Celecoxib 200mg daily
79686889|NCT06086223|Procedure|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
80004051|NCT02108366|Drug|Oseltamivir|Oseltamivir 75mg bid
79686890|NCT06086223|Procedure|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
79686891|NCT06086210|Other|Low-level laser therapy|Low-level laser therapy was applied to each area for 1 minute, with a wavelength of 808 nm and a dose of 2j/cm2 for a total of 5 minutes,10j/cm2 in continuous mode. A total of 15 sessions were applied 5 days a week for 3 weeks.
79686892|NCT06086210|Other|Sham|Sham therapy was applied to each area for 1 minute, with a wavelength of 0 nm and a dose of 0j/cm2 for a total of 5 minutes, 0j/cm2. A total of 15 sessions were applied 5 days a week for 3 weeks.
79686893|NCT06086158|Procedure|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
79686894|NCT06086119|Diagnostic Test|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
79686895|NCT06086106|Procedure|caudal block|The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
79686896|NCT06086106|Procedure|Dorsal Penile Nerve Block DPNB|DPNB is A type of pain control post-operative, often performed as a circumferential infiltration of the root of the penis (ring block). Two skin wheals are raised at the dorsal base of the penis, one on each side just below and medial to the pubic spine. A 25-gauge, 37.5-mm needle is introduced on each side, and the bupivacaine (1 to 1.5 mL) maximum dose 2 ml concentration 0.25% for infants is injected superficially and deep along the lower border of the pubic ramus to anesthetize the dorsal nerve. For a complete ring of infiltration,
79686897|NCT06086106|Drug|Systemic opioids|Systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
79686898|NCT06086041|Procedure|cochlear implant|cochlear implant
79686899|NCT06086002|Device|Microwave ablation|Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.
79686900|NCT06085989|Behavioral|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
79686901|NCT06085989|Behavioral|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
79686902|NCT06085976|Drug|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
79686903|NCT06085976|Other|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
79686904|NCT06085950|Device|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
79686905|NCT06085937|Drug|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
79829176|NCT03651648|Device|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
80004052|NCT02108366|Drug|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
80004053|NCT05602233|Other|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
80004054|NCT05602233|Other|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
79686906|NCT06085898|Drug|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
79829177|NCT03644277|Other|Acute Intermitted Hypoxia|Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
80004055|NCT02104934|Procedure|Adductor Canal Block|
79686907|NCT06085846|Device|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
79686908|NCT06085820|Behavioral|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
79686909|NCT06085820|Behavioral|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
79686910|NCT06085794|Procedure|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
79236454|NCT03700775|Other|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal <130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
79686911|NCT06085794|Procedure|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
79829178|NCT03644277|Procedure|Massed Practise|"Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve >100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded."
80004056|NCT05706207|Drug|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
80004057|NCT05706207|Drug|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
80004058|NCT05706207|Drug|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
80004059|NCT05706207|Drug|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
79236455|NCT03692351|Device|Uncemented acetabular cup with screw holes|
80004060|NCT05706207|Drug|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
79236456|NCT03692351|Device|Uncemented acetabular cup without screw holes|
80004061|NCT05706207|Drug|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
79236457|NCT03700697|Behavioral|Family Stress Module Intervention|as above
79377108|NCT02228382|Drug|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
79377109|NCT02216422|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
79377110|NCT02216422|Drug|Dasabuvir|Tablet
79377111|NCT02216422|Drug|Ribavirin (RBV)|Tablet
79377112|NCT03001570|Drug|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
79377113|NCT03005548|Device|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
80004062|NCT05706207|Drug|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
80004063|NCT05706207|Drug|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
80004064|NCT02105090|Drug|Anesthetics, Local|
80004065|NCT02105090|Drug|Sodium Chloride 0.9%|
80004066|NCT03627273|Diagnostic Test|6 minutes walking test with walker|to walk during 6 minutes with walker
80004067|NCT03627273|Diagnostic Test|6 minutes walking test|to walk during 6 minutes with walker
80004068|NCT02111330|Drug|PBF-509|
79236458|NCT03700619|Other|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
80004069|NCT02111330|Drug|Placebo|
80004070|NCT02105168|Procedure|Blood sample|Optional
80004071|NCT02105168|Procedure|Tumorous biopsy|Optional
79530774|NCT05386121|Procedure|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
79530775|NCT05386121|Device|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
79530776|NCT05386121|Device|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
79530777|NCT05386121|Drug|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
79530778|NCT05386121|Drug|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
79530779|NCT05386056|Drug|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
79530780|NCT05386056|Drug|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
79530781|NCT05386056|Procedure|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
79530782|NCT05386004|Other|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
79530783|NCT05385939|Other|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
79530784|NCT05385900|Drug|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
79686912|NCT06085768|Behavioral|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
79686913|NCT06085716|Behavioral|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
79686914|NCT06085716|Drug|Open Label Placebo|This group will only take placebo capsules every day.
79686915|NCT06085716|Behavioral|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
80004072|NCT02105168|Procedure|Healthy material sample|Optional
80004073|NCT03553628|Other|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
80004074|NCT03553628|Other|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
80004075|NCT02111486|Other|breakfast|
80004076|NCT02111720|Behavioral|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
79530785|NCT05385861|Drug|nanoliposomal irinotecan plus carboplatin|"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= [(140-age) x weight x 0.85 (if female)] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
80004077|NCT02111720|Behavioral|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
80004078|NCT02111954|Diagnostic Test|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
80004079|NCT03553550|Other|biospecimen collection|Peripheral blood collection Archival tissue collection
80004080|NCT02112032|Drug|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
80004081|NCT02112032|Drug|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
80004082|NCT01343823|Drug|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
80004083|NCT01343823|Drug|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
80004084|NCT01343823|Drug|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
80004085|NCT01343823|Drug|placebo|Administered as two SC 3 mL injections
80004086|NCT01343823|Drug|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
80004087|NCT01343823|Drug|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
80004088|NCT02108678|Behavioral|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
80004089|NCT02108678|Behavioral|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
80004090|NCT02251184|Drug|Aggrenox|
80004091|NCT02251184|Drug|Dipyridamole|
80004092|NCT02251184|Drug|Aspirin|
80004093|NCT02251184|Drug|Lansoprazole|
80004094|NCT05706051|Other|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
80004095|NCT02108756|Drug|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
80004096|NCT02108756|Drug|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
79686916|NCT06085703|Drug|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
79686917|NCT06085703|Drug|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
79686919|NCT06085625|Behavioral|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
79686920|NCT06085625|Behavioral|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
79686921|NCT06085586|Other|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
79686922|NCT06085586|Other|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
79686923|NCT06085560|Behavioral|Usual Care Message|Usual care is provided by the FQHC for the screening option chosen.
79686924|NCT06085560|Behavioral|Implementation Intention Intervention: Standard Message|Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.
79686925|NCT06085560|Behavioral|Implementation Intention Intervention: Culturally-Targeted Message|Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
79829179|NCT03644277|Other|Rapael Glove|The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
79829180|NCT03643770|Combination Product|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
79829181|NCT03631173|Procedure|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
79829182|NCT03598894|Other|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
79829183|NCT03584464|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
79236459|NCT04519229|Behavioral|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
79829184|NCT03573882|Drug|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
79829185|NCT03567824|Drug|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
79829186|NCT03567824|Drug|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
79829187|NCT03565159|Biological|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
80004097|NCT05596461|Device|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
79530786|NCT05385848|Procedure|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
79530787|NCT05385835|Other|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
79530788|NCT05385822|Behavioral|Pelvic Floor Muscle Training|"Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~Constant tension for 30 seconds twice, with a 30-second pause~Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
79686926|NCT06085547|Behavioral|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
79530789|NCT05385744|Biological|BCD-132|anti-CD20 monoclonal antibody
79530790|NCT05385744|Drug|Teriflunomide|Teriflunomide 14 mg
79686927|NCT06085547|Behavioral|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
79686928|NCT06085469|Behavioral|Temporal Adaptation Approach|the temporal adaptation: It includes giving importance to the use of time, choosing meaningful activities, adjusting the time used during these activities and improving it. Such adaptation serves to improve an individual's quality of life, health, and occupational participation.
79686929|NCT06085456|Diagnostic Test|Hematologic features|Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
79829188|NCT03565159|Other|Sodium Chloride 0.9%|Placebo
79829189|NCT03550040|Procedure|Radical prostatectomy|Surgical removal of the prostate
79829190|NCT03541291|Device|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
79829191|NCT03531320|Drug|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
79829192|NCT03529201|Procedure|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
79829193|NCT03529201|Device|PCA|Patient-controlled analgesia
79829194|NCT03529201|Procedure|GA|General anesthesia
79829195|NCT03529201|Drug|Oxycodone|administered by PCA
79829196|NCT03529201|Drug|Sevoflurane|Inhalational anesthetic during GA
79236460|NCT04346849|Procedure|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
79829197|NCT03529201|Drug|Fentanyl|painkiller during GA
79829198|NCT03529201|Drug|Rocuronium|muscle relaxant during GA
79829199|NCT03510208|Procedure|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
80004098|NCT05596461|Device|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
80004099|NCT02108834|Procedure|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
80004100|NCT02108834|Procedure|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
79829200|NCT03510208|Biological|Panitumumab|Given IV
80004101|NCT05547399|Drug|Zanubrutinib|Administered orally as a tablet or capsule
80004102|NCT02109068|Behavioral|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
80004103|NCT02109068|Behavioral|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
80004104|NCT02109146|Drug|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization should be used in the experimental group
80004105|NCT02109146|Other|No intervention No Transcatheter Arterial Chemoembolization|
80004106|NCT03553862|Behavioral|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
80004107|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
80004108|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
80004109|NCT01318083|Drug|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
79530791|NCT05385731|Other|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
79829201|NCT03510208|Drug|Panitumumab-IRDye800|Given IV
79829202|NCT03510208|Device|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
80004110|NCT02109224|Drug|Ibrutinib|Given PO
80004111|NCT02109224|Other|Laboratory Biomarker Analysis|Correlative studies
80004112|NCT02109224|Other|Pharmacological Study|Correlative studies
79530792|NCT05385731|Other|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
79530793|NCT05385731|Other|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
79530794|NCT05385627|Procedure|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
79530795|NCT05385614|Behavioral|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
79530796|NCT05385445|Behavioral|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit & Feedback interventions to change prescribing and laboratory ordering.
79686930|NCT06085443|Device|Ear Hygiene|2 sprays in each ear, every 3 days at home
79829203|NCT03496623|Drug|Inhaled treprostinil solution|Treprostinil inhalation solution
79829204|NCT03496623|Drug|Placebo solution|Placebo solution
79829205|NCT03473561|Drug|Racecadotril plus ORS|"1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to < 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily."
79530797|NCT05385419|Diagnostic Test|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
79530798|NCT05385276|Procedure|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
79686931|NCT06085430|Device|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
79236461|NCT03696719|Device|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
79377114|NCT03005548|Drug|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
79530799|NCT05385276|Procedure|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
79530800|NCT05385250|Other|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
79686932|NCT06085417|Drug|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
79686933|NCT06085417|Drug|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
79686934|NCT06085417|Drug|bupivacaine|bupivacaine
79686935|NCT06085404|Procedure|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
79686936|NCT06084520|Diagnostic Test|Current Opioid Misuse Measure (COMM)-SWE|Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
79686937|NCT06084520|Diagnostic Test|Oral fluid drug test|Oral fluid sampling to detect drugs. Analysis with LC-HRMS
79686938|NCT06084520|Diagnostic Test|PETh|Alcohol use detection
79686939|NCT06084520|Diagnostic Test|ASI-SR|Cross-validation form
79686940|NCT06084520|Diagnostic Test|AUDIT|Cross-validation form
79686941|NCT06084520|Diagnostic Test|DUDIT|Cross-validation form
79686942|NCT06084520|Diagnostic Test|Brief Pain Inventory - BPI|Cross-validation form
79686943|NCT06084520|Diagnostic Test|Patient Global Impression of Change PGIC|Cross-validation form
79377115|NCT03373500|Other|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
79377116|NCT03005392|Other|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
79377117|NCT03369834|Device|Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
79829206|NCT03471260|Drug|Azacitidine|Given IV or SC
79236462|NCT03696719|Biological|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
79530801|NCT05385198|Behavioral|VOICE care|"I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed."
79236463|NCT04336943|Biological|Durvalumab|Given IV
79236464|NCT04336943|Drug|Olaparib|Given PO
79377118|NCT03369834|Device|Infrared Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
79530802|NCT05385185|Drug|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
79530803|NCT05385172|Other|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
79686944|NCT06084520|Diagnostic Test|GAD-7|Cross-validation form
79530804|NCT05385146|Other|qigong|Chan-Chuang qigong with breathing meditation for 15 weeks
79530805|NCT05385133|Procedure|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
79686945|NCT06084520|Diagnostic Test|Patient Health questionnaire (PHQ9)|Cross-validation form
79686946|NCT06084520|Diagnostic Test|DBS - cannabis test|cross-validation form
79829207|NCT03471260|Drug|Ivosidenib|Given PO
79686947|NCT06084520|Other|Sample of Blood for later DNA and immunological analysis in future studies|sample collection for future studies
79829208|NCT03471260|Drug|Venetoclax|Given PO
79829209|NCT03466450|Drug|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
80004113|NCT03554876|Device|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
80004114|NCT03554876|Device|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
80004115|NCT03554876|Device|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
80004116|NCT02109302|Procedure|Blood sample|
80004117|NCT02109302|Procedure|Skin biopsy|
79530806|NCT05385133|Procedure|Manual condylar position|post-osteotomy condylar position was performed using the conventional manual method
79686948|NCT06084416|Drug|Sovilnesib|Sovilnesib tablets will be given orally.
79686949|NCT06084000|Device|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
79829210|NCT03466450|Drug|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
79829211|NCT03459820|Diagnostic Test|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
79829212|NCT03455517|Drug|Venetoclax|Venetoclax and rituximab association
79829213|NCT03455517|Drug|Rituximab|Venetoclax and rituximab association
80004118|NCT02109302|Other|Questionnaire|
79236465|NCT04336943|Other|Quality-of-Life Assessment|Ancillary studies
79236466|NCT04336943|Other|Questionnaire Administration|Ancillary studies
79236467|NCT03030989|Drug|Chlorhexidine Gluconate 2% Wipe|
79236468|NCT03030989|Drug|Placebo Wipe|
79236469|NCT03030599|Drug|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
79236470|NCT03030599|Other|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial [United States Pharmacopeia/ National Formulary])
79236471|NCT04512521|Drug|Mepolizumab|Mepolizumab therapy
79829214|NCT03431168|Drug|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
79829215|NCT03431168|Drug|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
79530807|NCT05385120|Procedure|Temporary Portocaval Shunt|In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
79530808|NCT05385107|Diagnostic Test|Serum procalcitonin concentration|
79530809|NCT05385094|Diagnostic Test|S Creatinine concentration|
79530810|NCT05385094|Diagnostic Test|Serum Cystatin C concentration|
79530811|NCT05385094|Diagnostic Test|Urinary Creatinine Clearance|
79530812|NCT05385081|Other|genomic profiling|next generation sequencing
79686950|NCT06084000|Device|Drug-eluting stent|"Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~Special consideration:~Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
79829216|NCT03419481|Drug|pembrolizumab|200mg every 3 weeks infusion
79829217|NCT03412630|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
79829218|NCT03404908|Procedure|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
79829219|NCT03404908|Procedure|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
79829220|NCT03404908|Drug|Ropivacaine|In both groups (TAP&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
79530813|NCT05385068|Drug|Niraparib|"Niraparib 200 or 300mg* QD PO continually;~*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight <77 kg or platelets count <150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle"
79530814|NCT05385029|Drug|Thyroxine|treatment for hypothyroidism or hyperthyroidism
79829221|NCT03404908|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
79829222|NCT03404908|Drug|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
79236472|NCT03692195|Device|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
79236473|NCT03692195|Other|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
79530815|NCT05385003|Dietary Supplement|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
79530816|NCT05385003|Dietary Supplement|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
79530817|NCT05385003|Dietary Supplement|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
79829223|NCT03404908|Drug|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
79829224|NCT03404908|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
79829225|NCT03404908|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
79829226|NCT03399032|Drug|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
79829227|NCT03386617|Drug|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
79236474|NCT04499807|Other|AFib detection with wearable smart watch|Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
79236475|NCT03700463|Other|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
79236476|NCT03696641|Other|glazed lithium disilicate crowns|glazing of IPS e.max crowns
79236477|NCT03696641|Other|polished lithium disilicate crowns|polishing of IPS e.max crowns
79236478|NCT03696563|Device|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
79236479|NCT03696563|Other|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
79236480|NCT03624647|Device|Power toothbrush|Experimental power toothbrush
79530818|NCT05384990|Device|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
79530819|NCT05384977|Drug|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
79530820|NCT05384639|Device|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
79829228|NCT03383354|Other|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
79829229|NCT03366272|Drug|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
79236481|NCT03624647|Device|Manual toothbrush|Marketed manual toothbrush
79236482|NCT03624257|Device|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
79236483|NCT03624257|Procedure|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
79377119|NCT03369834|Device|Infrared and Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
79236484|NCT03624569|Other|Bagel|A bagel will be consumed daily for 2 weeks.
79236485|NCT03624569|Other|Potato|A potato will be consumed daily for 2 weeks.
79236486|NCT03700307|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
79236487|NCT03696329|Drug|Tetrabenazine Tablets 25 mg|
79377120|NCT03369834|Device|Sham|LED device off.
79530821|NCT05384639|Device|Cycling Group|Participant will cycle only.
79530822|NCT05384639|Device|Cognitive Group|Participant will perform cognitive training only.
79530823|NCT05383755|Behavioral|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
79530824|NCT05379413|Drug|Botulinum toxin type A|Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
79686951|NCT06083831|Other|feeding type|In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
79686952|NCT06083467|Diagnostic Test|Amyloid PET scan|Positron Emission Tomography (PET) scan using either Florbetaben F18 or 11C-PiB radiotracer
79686953|NCT06083467|Diagnostic Test|Brain MRI Scan|MRI scan of the brain
79686954|NCT06083467|Behavioral|Neurologic exam|Neurologic exam and assessments, including video interview
79686955|NCT06083376|Other|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
79686956|NCT06083376|Other|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
79686957|NCT06083233|Diagnostic Test|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
79686958|NCT06083233|Diagnostic Test|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
79686959|NCT06083233|Procedure|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
79686960|NCT06083233|Procedure|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
79686961|NCT06083233|Procedure|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
79829230|NCT03366272|Drug|Rituximab|eight cycles of R-GemOx in 2-wk intervals
79829231|NCT03366272|Drug|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
79236488|NCT03696173|Other|Non-Interventional|Non-Interventional
79829232|NCT03366272|Device|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
79829233|NCT03363217|Drug|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
79829234|NCT03334708|Diagnostic Test|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~For draw amounts up to 50mL, there is no required hemoglobin threshold.~For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing < 50kg~For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
79236489|NCT03696173|Other|Non-Interventional|Non-Interventional
79829235|NCT03334708|Diagnostic Test|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
79829236|NCT03334708|Diagnostic Test|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
79829237|NCT03330418|Biological|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
79829238|NCT03330418|Biological|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
79829239|NCT03319797|Drug|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
79829240|NCT03314805|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
79829241|NCT03314805|Drug|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
79829242|NCT03314805|Procedure|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
79236490|NCT03696095|Drug|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
79236491|NCT03696095|Drug|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
79236492|NCT03700229|Drug|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
79236493|NCT03700229|Drug|Rituximab|rituximab intravenously 500 mg for one dose
79236494|NCT03700151|Behavioral|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
79530825|NCT05379374|Combination Product|bupivacaine and morphine|Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
79530826|NCT05375708|Radiation|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
79686962|NCT06083233|Procedure|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
79686963|NCT06083233|Procedure|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
79686964|NCT06083233|Procedure|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
79686965|NCT06083038|Drug|Alpelisib|Patients will receive standard of care alpelisib
79686966|NCT06083038|Device|FreeStyle Libre 2 Continuous Glucose Monitor|All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.
79829243|NCT03313804|Drug|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
79829244|NCT03313804|Radiation|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
79829245|NCT03293810|Other|Observational study|Post-Authorization Safety Study
79829246|NCT03283033|Behavioral|New salad bar|New salad bar placed in school
79829247|NCT03283033|Behavioral|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
79829248|NCT03269981|Radiation|Whole breast irradiation|Radiotherapy to the whole breast alone.
79829249|NCT03269981|Radiation|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
79829250|NCT03241537|Radiation|Intensity modulated radiotherapy|
79829251|NCT03239626|Radiation|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
79829252|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
79829253|NCT03229200|Drug|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
79236495|NCT03619343|Procedure|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
79236496|NCT03692117|Device|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
79530827|NCT05375708|Drug|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is <70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
79686967|NCT06081452|Behavioral|Survey|Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
79686968|NCT06081088|Other|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
79236497|NCT03700073|Other|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
79829254|NCT03224507|Drug|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
79829255|NCT03224507|Drug|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
79829256|NCT03215030|Drug|Modakafusp alfa|Modakafusp alfa intravenous infusion.
79829257|NCT03215030|Drug|Dexamethasone|Dexamethasone.
80016720|NCT05119504|Behavioral|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
79236498|NCT03700073|Other|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
79236499|NCT03692039|Procedure|M-pro files in rotating motion|An endodontic file that has controlled memory properties
79236500|NCT03692039|Procedure|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
79236501|NCT03695861|Diagnostic Test|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
79377121|NCT03005470|Device|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
79377122|NCT03005470|Device|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
79377123|NCT03005470|Device|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
79530828|NCT05375279|Procedure|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
79377124|NCT03005470|Other|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
79530829|NCT05373810|Other|Surgery|all interventions are allowed
79236502|NCT04311749|Genetic|Expanded panel cell free DNA testing (non-invasive prenatal testing)|Maternal blood sampling
79236503|NCT04311749|Genetic|Placental biopsy|Post-delivery placental sampling
79236504|NCT04311749|Genetic|Umbilical cord blood|Post-delivery umbilical cord blood sampling
79377125|NCT03373422|Drug|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
79377126|NCT03373422|Drug|Placebo|Matching placebo tablets
79377127|NCT03375606|Biological|CSL730|Solution for IV infusion
79686969|NCT06081088|Other|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
79829258|NCT03193190|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
79829259|NCT03193190|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
79829260|NCT03193190|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
79829261|NCT03193190|Drug|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
79829262|NCT03193190|Drug|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
79377128|NCT03375606|Other|Placebo|Saline solution for IV infusion
80004119|NCT05705895|Procedure|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~Vein valve/needleless connector will be used.~Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~Needle-free connectors will be replaced every 96 hours at the latest.~If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~Pulsatile give stop give stop technique will be used in the washing process."
79377129|NCT03375528|Device|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
79377130|NCT03363750|Behavioral|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
79377131|NCT03373344|Behavioral|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
79829263|NCT03193190|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
80004120|NCT05192187|Other|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~perceived harmfulness of activities (selection of PHODA-SeV)~cognitions about lifting and pain~reasons for avoidance behaviour (lifting)~Standardised questionnaires include~NRS for pain~TSK-11~FABQ~RMDQ"
79829264|NCT03193190|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
79829265|NCT03193190|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
79829266|NCT03193190|Drug|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
80004121|NCT02105402|Behavioral|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
80004122|NCT02112110|Drug|BMS-791325|
80004123|NCT02112110|Drug|[13C]-BMS-791325|
80004124|NCT02105480|Device|Computer aided auscultation (CAA)|
79377132|NCT03373344|Behavioral|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
79377133|NCT03373266|Drug|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
79377134|NCT03373266|Drug|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
79377135|NCT03369366|Device|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
79829267|NCT03193190|Drug|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
79829268|NCT03193190|Drug|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
79829269|NCT03193190|Drug|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
79829270|NCT03193190|Drug|AB928|AB928 will be administered as per the schedule specified in the respective arm.
79829271|NCT03193190|Drug|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
79829272|NCT03193190|Drug|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
79829273|NCT03169985|Drug|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
80004125|NCT02105714|Procedure|Stool culturing for pathogenic bacteria|
79236505|NCT03695705|Drug|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
79236506|NCT03695627|Behavioral|Meditation|10 minute a day, 8 week digital meditation
79236507|NCT03699839|Biological|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
79829274|NCT03169985|Drug|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
80004126|NCT02105714|Procedure|Kato-Katz technique|
79686970|NCT06081088|Other|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
79377136|NCT03369366|Device|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
79686971|NCT06080347|Other|Anti-inflammatory Diet|Dietary intervention
79686972|NCT06080347|Other|Healthy Diet|Dietary intervention
79686973|NCT06080126|Other|Control: per usual practice|160 patients were included as per usual practice.
80004127|NCT02105714|Procedure|Baermann technique|
80004128|NCT02105714|Device|Mini-FLOTAC|
79236508|NCT03699839|Biological|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
80004129|NCT02105714|Device|Crypto/Giardia Duo Strip|
80004130|NCT02105714|Procedure|Formalin-ether concentration technique|
80004131|NCT02105714|Device|CCA RDT|
80004132|NCT02105714|Procedure|Koga agar plate culture|
79236509|NCT03699839|Biological|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
79236510|NCT04050215|Procedure|Computed Tomography|Undergo PET/CT
79236511|NCT04050215|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
79236512|NCT04050215|Procedure|Positron Emission Tomography|Undergo PET/CT
79377137|NCT02217904|Drug|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
79377138|NCT02217904|Drug|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
79530830|NCT05372965|Other|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 4 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
79686974|NCT06080126|Other|Intervention MAF|160 patients were included with MAF intervention.
79686975|NCT06079801|Device|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
79686976|NCT06079801|Drug|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
79686977|NCT06079541|Drug|JMKX003142 will be administered orally|oral once
79829275|NCT03153527|Drug|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
79829276|NCT03153527|Other|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
79829277|NCT03151278|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
80004133|NCT02105714|Procedure|Kinyoun staining|
80004134|NCT02105714|Device|Multiplex PCR|
80004135|NCT02105714|Procedure|Metagenomics analysis|
79236513|NCT04050215|Other|Questionnaire Administration|Ancillary studies
79236514|NCT03699683|Other|Combined aerobic and resistance training program|
79377139|NCT02217904|Drug|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
79377140|NCT02217904|Drug|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
79236515|NCT03691805|Device|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
79530831|NCT05372965|Other|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
79377141|NCT02217904|Drug|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
80004136|NCT05540067|Behavioral|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
80004137|NCT05540067|Other|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
79236516|NCT03691805|Device|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
79236517|NCT03699605|Other|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
79236518|NCT03699605|Other|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
79236519|NCT03695549|Procedure|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
79236520|NCT03695549|Procedure|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
79236521|NCT03699527|Behavioral|Multiple questionnaires administered|This is an observational trial
79236522|NCT03699449|Drug|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
79236523|NCT03699449|Drug|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
79236524|NCT03699449|Drug|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
79236525|NCT03699449|Drug|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
79377142|NCT02217904|Drug|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
79377143|NCT02981134|Procedure|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
79377144|NCT03363516|Diagnostic Test|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
79377145|NCT03363438|Other|no intervention survey|there was no intervention this was a survey
79530832|NCT05339633|Drug|[14C]-D-0502|Drug: [14C]-D-0502 and D-0502
79236526|NCT03699449|Drug|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
79530833|NCT05335174|Device|Device: HemoSphere monitor and Acumen IQ sensor.|Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
79377146|NCT02980900|Dietary Supplement|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
79530834|NCT05312060|Device|PC Pneumatic compression|Pneumatic compression of the operated limb
79530835|NCT05312060|Other|AE Antithromboembolic exercises|Exercises for the edema
79686978|NCT06079541|Drug|JMKX003142 will be administered orally|oral once
79686979|NCT06079541|Drug|JMKX003142 will be administered orally|oral once
79686980|NCT06079541|Drug|Placebo in Cohorts 1 to 7|oral once
79686981|NCT06079541|Drug|Placebo in 3 Cohorts|oral once
79686982|NCT06078969|Drug|Prednisone|For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
79686983|NCT06078306|Drug|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
79686984|NCT06078306|Drug|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
79686985|NCT06078306|Drug|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
79236527|NCT03699449|Drug|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
79829278|NCT03151278|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
79829279|NCT03148054|Device|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
79829280|NCT03119012|Drug|Clopidogrel|75mg/day
79236528|NCT03028415|Device|AMPLEX|A bone graft substitute
79236529|NCT03028415|Procedure|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
79236530|NCT04477577|Behavioral|New Parent Intervention|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
79236531|NCT04477577|Behavioral|Safety Control|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
79236532|NCT03699371|Procedure|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
79377147|NCT02980900|Dietary Supplement|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
79829281|NCT03119012|Drug|Ticagrelor|120mg/day
79829282|NCT03119012|Drug|Aspirin|100mg/day
79377148|NCT02980900|Dietary Supplement|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
79377149|NCT02980900|Dietary Supplement|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
79236533|NCT04475081|Biological|MMR vaccine|Merck MMR-II vaccine
79236534|NCT03699293|Drug|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
79530836|NCT05299697|Drug|TG103 15 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
79530837|NCT05299697|Drug|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
79530838|NCT05299697|Drug|Placebo|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
79686986|NCT06078228|Drug|Propfol - Fentanyl- Atracurium|investigate the reliability of preanesthetic ultrasound measurements of the carotid artery FTc and the internal jugular vein collapsibility index in predicting hypotension during the induction of general anesthesia.
79829283|NCT03117036|Drug|Chemotherapy|Systemic chemotherapy with curative intent
79236535|NCT03699293|Drug|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
79236536|NCT03699293|Drug|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
79236537|NCT03695003|Dietary Supplement|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
79236538|NCT03695003|Dietary Supplement|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
79686987|NCT06077981|Procedure|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
79829284|NCT03117010|Drug|Steroids|High dose dexamethasone 20 mg PO or IV
79829285|NCT03117010|Drug|Etoposide|Etoposide 150mg/BSA
79829286|NCT03116763|Behavioral|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
79829287|NCT03116763|Other|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
79236539|NCT02692040|Drug|G3215|Gut hormone analogue
79236540|NCT02692040|Drug|Placebo|0.9% saline
79236541|NCT05610670|Other|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
79530839|NCT05296655|Other|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
80004138|NCT02112266|Other|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
79686988|NCT06077981|Procedure|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
79686989|NCT06077955|Procedure|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
80004139|NCT02112266|Other|no mail support|follow-up without mail support
80004140|NCT05538039|Other|Distract with play dough|Distract with play dough
80004141|NCT05538039|Other|Distract with play kaleidoscope|Distract with play kaleidoscope
80004142|NCT05538039|Other|Control group|Routine nursing care
80004143|NCT02109380|Behavioral|Bed rest|
80004144|NCT02109536|Device|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
80004145|NCT02105792|Drug|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
80004146|NCT03817515|Drug|ABI-009|Sirolimus Albumin-bound Nanoparticles
79236542|NCT03029819|Behavioral|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
80004147|NCT02112344|Radiation|IMRT|
80004148|NCT02105870|Drug|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
80004149|NCT02112422|Drug|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
80004150|NCT02112422|Drug|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
79236543|NCT03029819|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
79236544|NCT03029819|Behavioral|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
79236545|NCT03029819|Drug|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
80004151|NCT02251340|Behavioral|Eczema Care Plan|
79236546|NCT03105830|Drug|iv paracetamol|iv paracetamol
80004152|NCT05646147|Device|Maximal Systolic Acceleration|Reliability of the maximal systolic acceleration
80004153|NCT02109692|Other|blood sample|dosage of miRNA
80004154|NCT05705583|Other|Other: Blood and Urine Collection|Blood and Urine Collection
79377150|NCT03372876|Dietary Supplement|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
79377151|NCT03369288|Diagnostic Test|PET MRI|18F-fluoride PET-MRI
79377152|NCT03372798|Procedure|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
79377153|NCT03369132|Device|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
79236547|NCT03694769|Other|Semi-structured interview|One-hour interview with researcher
79236548|NCT03694769|Other|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
79236549|NCT03162380|Other|Date collection|Date collection
79377154|NCT03369132|Device|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
79377155|NCT05488600|Behavioral|Executive Function Assessment|Digit Span (Forward and Backward) Test, Stroop Test, Trail Making Test A and B forms, Tower of London Test were used to evaluate executive functions.
79377156|NCT03005158|Other|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
79377157|NCT03005158|Other|Randomization Phase|Standard care or HighSTEACS pathway.
79377158|NCT03005158|Other|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are <5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
79377159|NCT01900002|Other|Laboratory Biomarker Analysis|Correlative studies
79530840|NCT05296655|Other|Reflux finding score|laryngoscopy with a score RFS
79829288|NCT03085147|Drug|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
79530841|NCT05286918|Procedure|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to <5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
79530842|NCT05259254|Other|Mobile Application|the mobile application will be consist of 4 modules which are: video observed therapy, health education, reminder system, and feedback.
79686990|NCT06077955|Procedure|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
79686991|NCT06076668|Drug|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
79829289|NCT03074305|Device|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~DEB strategy~DES strategy"
79829290|NCT03046862|Drug|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
79829291|NCT03046862|Drug|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
79829292|NCT03046862|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1& D8 every 3 weeks
79829293|NCT03046862|Drug|Cisplatin|Cisplatin 25 mg/m2 iv on D1& D8 every 3 weeks
79829294|NCT03042078|Device|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
79829295|NCT03042078|Device|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
79377160|NCT01900002|Other|Quality-of-Life Assessment|Ancillary studies
79686992|NCT06076668|Drug|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
79686993|NCT06076668|Drug|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
79829296|NCT03031626|Biological|Medical Air vs Oxygen|Medical Air/Oxygen will be given
79377161|NCT01900002|Drug|Sorafenib|Given PO
79829297|NCT03031210|Drug|Amoxicillin|(90 mg/kg/day) twice daily
79829298|NCT03025984|Behavioral|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
79829299|NCT03025932|Procedure|repair of giant hiatal hernia with mesh and anterior fundoplication|
79829300|NCT03018262|Device|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
79829301|NCT03018262|Device|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
79829302|NCT03018262|Device|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
79377162|NCT01900002|Drug|Sorafenib Tosylate|Given PO
80004155|NCT02106026|Other|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
80004156|NCT05159115|Other|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
80004157|NCT05159115|Other|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
79236550|NCT04465409|Device|Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.|Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
79236551|NCT04440020|Other|Beverage of Olive Oil Leaves|Beverage of Olive Oil Leaves,Oleuropein
79377163|NCT01900002|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
79377164|NCT03005314|Procedure|chemotherapy|chemotherapy before surgery
79377165|NCT03005314|Procedure|Surgery|chemotherapy after surgery
79377166|NCT03005002|Biological|Durvalumab|Given IV
79377167|NCT03005002|Other|Laboratory Biomarker Analysis|Correlative studies
79377168|NCT03005002|Biological|Tremelimumab|Given IV
79377169|NCT03001336|Other|no intervention|This is a cross-sectional study
79377170|NCT03123510|Dietary Supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
79377171|NCT03123510|Dietary Supplement|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
80004158|NCT02251418|Device|Extracorporeal shockwave therapy|
79236552|NCT04440020|Other|Mediterranean Diet|Mediterranean Diet ,for a personal nutrition with the same dietary habits
79686994|NCT06076005|Other|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
79686995|NCT06075368|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79829303|NCT03017586|Device|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
79829304|NCT03001869|Drug|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
79829305|NCT02988921|Device|MRI and CT|
79236553|NCT03691415|Drug|BELKYRA Inj.|Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
79377172|NCT02247856|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
79377173|NCT02247856|Device|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
79530843|NCT05259254|Other|Direct Observed Therapy|it is a specific strategy that require identification, training, and supervision by various parties such as healthcare worker, community volunteer, or family members to directly monitor the ingestion of anti-TB medication. DOT was aimed to improve medication adherence by active monitoring and documenting the consumption of each dose taken. Conducting DOT is not only limited to directly observe the treatment, but also can assess medication side effects as well as to document the visit and information regarding medications (e.g., frequency and timing of taking medication).
79530844|NCT05252624|Drug|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
79236554|NCT03699215|Drug|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension <90 mmHg.
79236555|NCT03699215|Drug|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
79530845|NCT05252624|Drug|Henagliflozin 5Mg Tab|Single oral tablet
79686996|NCT06074211|Behavioral|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
79686997|NCT06074211|Behavioral|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
79686998|NCT06073041|Other|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then recieve an in-depth standardized onboard training.
79686999|NCT06072521|Drug|Lactoferrin Bovine|Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
79687000|NCT06068881|Drug|Tazverik (Tazemetostat)|Oral Tablet
79687001|NCT06065241|Dietary Supplement|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
79829306|NCT02988921|Radiation|Ratiotherapy|
79829307|NCT02988921|Drug|Paclitaxel, platinum-based drug|
79687002|NCT06065241|Other|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
79829308|NCT02986672|Dietary Supplement|Calanus oil|Omega-3 oil in form of calanus oil
79829309|NCT02986672|Other|Medical Paraffin|2ml per day
79829310|NCT02983565|Device|Intelligent oxygen therapy system (iO2Ts)|
79829311|NCT02981615|Drug|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
79829312|NCT02981615|Drug|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
79236556|NCT03166436|Procedure|Radiofrequency ablation|radiofrequency ablation
79530846|NCT05237622|Device|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
79530847|NCT05234411|Other|Evaluation of ketogenic diet impact on ketonemia|Ketonemia and glycemia levels monitoring during different phases of menstrual cycles
79530848|NCT05216484|Biological|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
79530849|NCT05167656|Other|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
79829313|NCT02963363|Other|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
79829314|NCT02944799|Drug|Placebo|Discontinuation of alendronate treatment
79829315|NCT02944799|Drug|Alendronate|
79829316|NCT02944799|Drug|Calcium|Daily dietary supplement of 800mg calcium
79829317|NCT02944799|Drug|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
80004159|NCT02112500|Biological|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
79530850|NCT05167656|Other|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
79829318|NCT02940951|Other|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
79530851|NCT05167656|Other|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
79530852|NCT05122715|Device|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
79530853|NCT05115422|Behavioral|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
79530854|NCT05113615|Drug|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
79530855|NCT05113615|Drug|Matching placebo|matching placebo Respimat inhaler
79530856|NCT05047432|Other|Non-interventional trial|Non-interventional trial
79530857|NCT05041504|Behavioral|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
79829319|NCT02940951|Other|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
79829320|NCT02931279|Device|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
79829321|NCT02923947|Drug|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
79829322|NCT02914535|Drug|Filgotinib|Tablet(s) administered orally once daily
79829323|NCT02914535|Drug|Placebo|Tablet(s) administered orally once daily
79829324|NCT02903680|Drug|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
79829325|NCT02903680|Drug|Placebo group|Normal Saline 0,9% same volume
79829326|NCT02864004|Drug|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
79829327|NCT02864004|Other|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
79829328|NCT02842424|Drug|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
79829329|NCT02834364|Drug|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
79829330|NCT02834364|Drug|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
79829331|NCT02823041|Behavioral|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
79829332|NCT02823041|Behavioral|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
79829333|NCT02823041|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
79829334|NCT02823041|Behavioral|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
79829335|NCT02810743|Drug|ddAC-CP-Olaparib|ddAC-CP-Olaparib
79829336|NCT02810743|Drug|ddAC-mini CTC|ddAC - mini CTC
79829337|NCT02759835|Drug|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
79530858|NCT05041504|Other|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
79530859|NCT05037630|Behavioral|Self-guided Digital Tool for Problematic Alcohol Use|See arm/group-description
79829338|NCT02759835|Other|Local Ablative Therapy (LAT)|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
80004160|NCT05644899|Procedure|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
79236557|NCT03166436|Procedure|Biliary stenting|biliary stenting
80016721|NCT05119504|Behavioral|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
79377174|NCT02247856|Device|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
79377175|NCT04526964|Behavioral|Self-management curriculum|The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
79530860|NCT05030233|Behavioral|Nurse-Administered Touch Intervention|The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
79530861|NCT05013957|Diagnostic Test|Methylation analysis|Methylation analysis
79530862|NCT04981977|Behavioral|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
79377176|NCT03001102|Device|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
79236558|NCT03699137|Other|No interventions|No interventions
79236559|NCT03166358|Behavioral|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
79377177|NCT03001102|Device|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
79687003|NCT06064812|Drug|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
79687004|NCT06064812|Drug|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
79829339|NCT02720302|Behavioral|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
79377178|NCT03001102|Device|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
79236560|NCT04479956|Procedure|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
79236561|NCT04457843|Other|usual medical care|Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
79236562|NCT03699059|Other|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
79530863|NCT04981977|Behavioral|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
79829340|NCT02720302|Behavioral|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
79829341|NCT02720094|Drug|Cabotegravir Oral Tablet|30 mg tablet
79530864|NCT04981977|Other|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
79829342|NCT02720094|Drug|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
79829343|NCT02720094|Drug|Placebo for TDF/FTC tablets|
79829344|NCT02720094|Drug|Placebo for cabotegravir oral tablet|
80004161|NCT05644899|Procedure|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
79236563|NCT03694535|Drug|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
79236564|NCT03694379|Other|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
79236565|NCT03115034|Drug|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
79687005|NCT06060028|Device|Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences|The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.
79687006|NCT06060028|Device|Sham treatment|In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
79829345|NCT02720094|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
79829346|NCT02720094|Drug|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
79829347|NCT02716012|Drug|MTL-CEBPA|Intravenous administration
79829348|NCT02716012|Drug|Sorafenib 200mg|Sorafenib tablets
79829349|NCT02715518|Device|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~FFR-guided strategy arm~Angiography-guided strategy arm"
79236566|NCT03115034|Drug|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
79236567|NCT03115034|Other|blank|Patients under CEA without taking melatonin or placebo
79829350|NCT02695498|Other|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class [9 total classes.] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
79377179|NCT02519556|Drug|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
79377180|NCT02519556|Drug|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
79377181|NCT03000946|Drug|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
79236568|NCT03161990|Procedure|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
79377182|NCT03000946|Drug|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
79377183|NCT03363282|Procedure|Pterygium Excision|Pterygium excision is the first step for repair
79391133|NCT02416284|Other|NFBDG|"Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
80004162|NCT02106104|Drug|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
79236569|NCT03161990|Procedure|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
80004163|NCT02106104|Drug|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
79236570|NCT03694223|Other|Health education delivery methods|
80004164|NCT02113670|Other|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
79236571|NCT03691259|Other|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
79236572|NCT02678390|Dietary Supplement|MCT|A 5 day consecutive MCT intake of 30 g/day.
79829351|NCT02695498|Other|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
80004165|NCT02109926|Other|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
80004166|NCT02113748|Other|Downhill walking training|Walk on a treadmill with a negative inclination.
80004167|NCT02113748|Other|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
80004168|NCT05703867|Device|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
79687007|NCT06055751|Device|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
79687008|NCT06053983|Device|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
79687009|NCT06053983|Drug|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
80004169|NCT02113826|Drug|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
80004170|NCT02118974|Procedure|Hysterectomy|Hysterectomy
79236573|NCT02678390|Dietary Supplement|MCT+ aerobic exercise|A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
79687010|NCT06053983|Drug|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
79829352|NCT02688777|Behavioral|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
79829353|NCT02648334|Device|IN.PACT drug coated balloon|
79829354|NCT02648334|Device|Lutonix drug coated balloon|
79829355|NCT02646618|Behavioral|Get Social|Online-delivered weight loss intervention
80004171|NCT02112656|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
80004172|NCT02112656|Drug|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
80004173|NCT01376323|Drug|GSK256073 1mg|GSK256073 1mg capsule
80004174|NCT01376323|Drug|GSK256073 5mg|GSK256073 5mg capsule
80004175|NCT01376323|Drug|GSK256073 10mg|GSK256073 10mg capsule
79236574|NCT02678390|Dietary Supplement|Aerobic exercise|A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
79236575|NCT02678390|Dietary Supplement|Control day|No MCT or aerobic exercise
79236576|NCT03694067|Other|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
79236577|NCT05553236|Diagnostic Test|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
79236578|NCT03698981|Behavioral|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
79236579|NCT03027557|Drug|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
79829356|NCT02646618|Behavioral|Traditional|Group-delivered weight loss intervention
79530865|NCT04883944|Other|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~swaddling;~non-nutritive sucking with pacifier in infants with PMA < 32 weeks;~nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~holding;~exposure to maternal voice."
79236580|NCT03027557|Drug|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
79236581|NCT03027557|Other|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
79236582|NCT03027557|Other|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
79236583|NCT03162068|Other|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
79236584|NCT03162146|Other|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
79236585|NCT03698903|Behavioral|Take a STAND 4 Health|The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
79530866|NCT04883944|Other|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~swaddling;~non-nutritive sucking with pacifier in infants with PMA < 32 weeks;~nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~holding."
79687011|NCT06053840|Drug|Chloral Hydrate|Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
79687012|NCT06051968|Behavioral|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
79687013|NCT06051968|Behavioral|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
79687014|NCT06049160|Drug|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
79829357|NCT02646618|Device|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
79829358|NCT02617186|Procedure|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
79829359|NCT02617186|Procedure|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
79829360|NCT02609425|Device|Stratafix PGA Suture|Subject leak Stricture rates post procedure
79829361|NCT02607722|Drug|Nintedanib|
79829362|NCT02567253|Procedure|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
79829363|NCT02567253|Drug|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
79829364|NCT02567253|Drug|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
79829365|NCT02567253|Drug|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
79829366|NCT02567253|Drug|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
79829367|NCT02564068|Drug|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
79829368|NCT02563600|Behavioral|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
79829369|NCT02563600|Behavioral|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
79829370|NCT02549157|Procedure|Pelvic Floor Muscle Training|
80004176|NCT01376323|Drug|GSK256073 25mg|GSK256073 25mg capsule
79236587|NCT03698825|Drug|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
79236588|NCT03691181|Device|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
79236589|NCT03029585|Drug|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
79236590|NCT03029585|Drug|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
79530867|NCT04850378|Drug|Dalteparin|Drug: Dalteparin 200 units/kg once a day for 4-7 days.
79530868|NCT04850378|Drug|Apixaban|Drug: Apixaban 5 mg twice a day for 4-7 days.
79530869|NCT04834882|Other|Data collection (|online survey
80004177|NCT01376323|Drug|Placebo|placebo capsule
80004178|NCT01376323|Drug|Sitagliptin 100mg|Sitagliptin 100mg capsule
80004179|NCT02113904|Drug|Adalimumab|6 injections (one every 15 days during 3 months)
79687015|NCT06047834|Drug|Standard of Care with Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 escalating dose levels (in terms of lofexidine base): low dose, mid dose, or high dose.
79236591|NCT03029585|Drug|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
79236592|NCT03029585|Drug|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
79236593|NCT03029585|Drug|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
79236594|NCT04295135|Behavioral|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. The OneSheet works by aggregating and structuring information that is already collected, that providers often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of the OneSheet is to make the information that is important in clinical decisionmaking more readily available, and to reduce the amount of time that providers need to spend locating this information.
79687016|NCT06047834|Other|Standard of Care without Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
79687017|NCT06046937|Drug|Monolaurin|applied thinly twice a day
79687018|NCT06046937|Drug|Mupirocin ointment|applied thinly twice a day
79687019|NCT06046443|Drug|LB54640|Oral daily administration
79377184|NCT03006718|Other|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
79687020|NCT06046443|Drug|Placebo|Placebo matched to LB54640
79377185|NCT03004768|Drug|BMS-986165|Oral solution dose of 24 mg [14C] BMS-986165 containing approximately 100 micro Ci of TRA
79687021|NCT06042088|Other|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
79687022|NCT06041620|Biological|VGB-Ex01|CRISPR-Cas12b editing hematopoietic stem cells
79687023|NCT06038851|Procedure|Para-Sartorial Compartments (PACS) Block|"This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment)."
80004180|NCT05703633|Other|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
80004181|NCT02119052|Drug|octeotride|
80004182|NCT02119052|Drug|placebo|
80004183|NCT02119130|Device|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
79236595|NCT03698747|Device|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
79236596|NCT02678000|Drug|LHW090|LHW090 is orally administered
79236597|NCT02678000|Drug|Placebo|Matching placebo of LHW090
79236598|NCT05495438|Other|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
79391134|NCT03116802|Drug|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
79391135|NCT03116646|Diagnostic Test|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
79687024|NCT06038851|Procedure|Femoral Triangle Block (FTB)|"The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~The needle will be inserted with a latero-medial orientation in the plane.~The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle."
80004184|NCT05459805|Drug|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
80004185|NCT05459805|Drug|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
80004186|NCT02119208|Behavioral|Intensity and timing of exercise|
80004187|NCT02113982|Drug|SL-401|
79236599|NCT02691572|Procedure|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
79236600|NCT02691572|Drug|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
79236601|NCT02691572|Drug|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
79236602|NCT02691572|Procedure|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
79687025|NCT06038851|Procedure|Infiltration between popliteal artery and capsule of the knee (IPACK) block|It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
79687026|NCT06036108|Drug|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
80004188|NCT02112812|Drug|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
80004189|NCT02112812|Drug|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
80004190|NCT02112812|Drug|Eradication therapy for Helicobacter pylori|
79236603|NCT02691572|Procedure|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
80004191|NCT05432115|Drug|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
80004192|NCT02114528|Drug|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
79236604|NCT02691572|Procedure|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.
79236605|NCT02691572|Procedure|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
79236606|NCT02691572|Drug|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
79377186|NCT03369054|Behavioral|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
79377187|NCT03369054|Behavioral|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
79377188|NCT03005236|Drug|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
79236607|NCT02691572|Drug|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
79236608|NCT02691572|Procedure|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
79377189|NCT03005236|Drug|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
79377190|NCT03363204|Device|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
79377191|NCT03004690|Device|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
79377192|NCT03004690|Device|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
79377193|NCT02519010|Drug|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
79377194|NCT02519010|Drug|Exforge|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
79377195|NCT03372642|Device|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
79377196|NCT03004456|Other|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
79377197|NCT03363126|Procedure|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
79377198|NCT03004612|Combination Product|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
79377199|NCT03004612|Drug|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
79377200|NCT04525560|Other|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
79377201|NCT04525560|Other|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
79377202|NCT03363048|Behavioral|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
79377203|NCT03363048|Behavioral|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
79687027|NCT06036108|Drug|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
79687028|NCT06035211|Other|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
79829371|NCT02546895|Other|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
79829372|NCT02521493|Drug|Asparaginase|Given IM or IV
79377204|NCT03000868|Procedure|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
79530870|NCT04809103|Drug|cis-diamminedichloroplatinum|Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
79829373|NCT02521493|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
79236609|NCT03688217|Behavioral|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
79236610|NCT03688217|Behavioral|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
79829374|NCT02521493|Drug|Cytarabine|Given IT and IV
79829375|NCT02521493|Drug|Daunorubicin Hydrochloride|Given IV
79829376|NCT02521493|Drug|Etoposide|Given IV
79829377|NCT02521493|Other|Laboratory Biomarker Analysis|Correlative studies
79829378|NCT02521493|Drug|Mitoxantrone Hydrochloride|Given IV
79829379|NCT02521493|Drug|Thioguanine|Given PO
79236611|NCT05320172|Drug|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
79829380|NCT02517749|Device|Chest Drain Insertion and Talc Pleurodesis|
79829381|NCT02517749|Device|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
79377205|NCT03000868|Procedure|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
79377206|NCT04527042|Drug|Rivaroxaban|It is determined by the clinician's routine clinical prescription.
79391136|NCT02423928|Biological|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
79391137|NCT02423928|Drug|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
79530871|NCT04804371|Drug|F18-FDG|Evaluate FDG uptake
79530872|NCT04797234|Other|Control|There will be no intervention to the control group.
79829382|NCT02514395|Other|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2[32] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
79829383|NCT02419495|Drug|Capecitabine|Given PO
79829384|NCT02419495|Drug|Carboplatin|Given IV
79829385|NCT02419495|Drug|Cyclophosphamide|Given IV
79829386|NCT02419495|Drug|Doxorubicin|Given IV
79829387|NCT02419495|Drug|Eribulin|Given IV
79829388|NCT02419495|Drug|Fluorouracil|Given IV
79829389|NCT02419495|Biological|Ipilimumab|Given IV
79829390|NCT02419495|Drug|Irinotecan Hydrochloride|Given IV
79829391|NCT02419495|Drug|Leucovorin Calcium|Given IV
79829392|NCT02419495|Biological|Nivolumab|Given IV
79530873|NCT04797234|Other|Experiment|The experimental group will be trained for 6 weeks.
79530874|NCT04830527|Behavioral|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
79530875|NCT04830527|Behavioral|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
79530876|NCT04776031|Device|R:GEN Laser System|Laser Treatment
79530877|NCT04771052|Other|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
79530878|NCT04765371|Drug|DEXAMETHASONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
79530879|NCT04765371|Drug|PREDNISOLONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
79530880|NCT04744363|Drug|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
79530881|NCT04727541|Drug|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
79530882|NCT04700735|Device|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
79530883|NCT04673162|Drug|Methylprednisolone, Placebo|iv administration
79530884|NCT04665375|Drug|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
79530885|NCT04658082|Device|H.G.R (GWave) non-invasive glucometer|Glucose tolerance test
79530886|NCT04647071|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
79530887|NCT04647071|Dietary Supplement|Control|Microcrystalline cellulose
79687029|NCT06027034|Behavioral|Online program for psoriasis (GAIA-PSO-01)|The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
79687030|NCT06026826|Device|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
79687031|NCT06026826|Device|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
79829393|NCT02419495|Drug|Olaparib|Given PO
79829394|NCT02419495|Drug|Oxaliplatin|Given IV
80004193|NCT02114528|Procedure|Catheter ablation|Ventricular tachycardia catheter ablation.
79236612|NCT03693911|Behavioral|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
79829395|NCT02419495|Drug|Paclitaxel|Given IV
79829396|NCT02419495|Biological|Pembrolizumab|Given IV
79829397|NCT02419495|Drug|Pemetrexed|Given IV
80004194|NCT04975321|Device|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
80004195|NCT04975321|Device|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
80004196|NCT04975321|Device|Composite strip crown|Placement of an anterior primary crown restoration
80004197|NCT02112890|Other|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
79236613|NCT03693833|Drug|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
79236614|NCT03693833|Drug|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
79236615|NCT03693755|Procedure|In-plane Group|Placement of femoral nerve catheter under ultrasound control
79530888|NCT04638244|Behavioral|Music|Brief Online Music
79530889|NCT04638244|Behavioral|Reading messages|Reading psychoeducational messages
79530890|NCT04572568|Other|Multi-disciplinary assessment|"Comprehensive evaluation by multidisciplinary experts;~Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics."
79530891|NCT04566081|Other|iTALKbetter: deterministic|A word retrieval therapy application
79530892|NCT04566081|Other|iTALKbetter: reactive|A word retrieval therapy application
79530893|NCT04560556|Diagnostic Test|Point-of-Care (POC) Rapid HIV Test|Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
79829398|NCT02419495|Drug|Selinexor|Given PO
79829399|NCT02419495|Drug|Topotecan|Given IV
79829400|NCT02400216|Drug|dual cholate|test for defining disease severity
79829401|NCT02386917|Procedure|Gastric bypass|Weight loss surgery
79829402|NCT02386917|Behavioral|Very low calorie diet|Non-surgical weight loss procedure
79236616|NCT03693755|Procedure|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
79236617|NCT03693599|Drug|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
79829403|NCT02385617|Drug|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
79829404|NCT02385617|Drug|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
79829405|NCT02381249|Drug|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
79829406|NCT02381249|Drug|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
79829408|NCT02347930|Other|kidney ultrasound|kidney ultrasound
79829409|NCT02339922|Drug|Ixazomib Citrate|Given PO
79829410|NCT02339922|Other|Laboratory Biomarker Analysis|Correlative studies
79829411|NCT02339922|Biological|Rituximab|Given IV
80004198|NCT05410587|Device|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
79236618|NCT03693599|Drug|Syntometrine|one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
79236619|NCT04277663|Drug|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
79236620|NCT04277663|Drug|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
79236621|NCT04277663|Drug|High-dose recombinant interferon a-2B|In this group, subjects will be given 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
79377207|NCT03000790|Device|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
79530894|NCT04560556|Diagnostic Test|Fourth Generation Antigen/antibody (Ag/Ab) HIV Test|Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
79829412|NCT02332356|Drug|azathioprine or adalimumab and infliximab|
79829413|NCT02299596|Other|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
79829414|NCT02285114|Drug|F/TAF|F/TAF tablets administered orally once daily
79829415|NCT02285114|Drug|3rd ARV agent|A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).
79829416|NCT02285114|Drug|Boosted PIs|Boosted PIs of the participant's pre-existing regimen may include one of the following: ATV, LPV, or DRV.
79829417|NCT02252250|Procedure|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
79829418|NCT02252250|Procedure|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
79829419|NCT02250131|Procedure|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery > 280 mL/min/m2
80004199|NCT02112968|Procedure|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
80004200|NCT02112968|Procedure|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
80004201|NCT02112968|Procedure|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
79530895|NCT04531566|Dietary Supplement|Oral Feed|Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.
79530896|NCT04531566|Dietary Supplement|Usual care|Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
79530897|NCT04524221|Drug|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
79530898|NCT04524221|Drug|Placebo|Placebo taken twice daily in capsule form for 42 days
79530899|NCT04500951|Other|Optimized resting environment|"Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient."
79829420|NCT02193620|Drug|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
79236622|NCT03693443|Behavioral|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
79236623|NCT03693209|Behavioral|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
79236624|NCT03693209|Behavioral|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
79236625|NCT04270643|Dietary Supplement|Vitamin D3|ATC code A11CC05 (cholecalciferol)
79236626|NCT04270643|Dietary Supplement|Placebo|Ethyl oleate
79236627|NCT03693131|Drug|Icosapent (MND-2119)|Icosapent (MND-2119) capsules.
79236628|NCT03693131|Drug|Icosapent (EPADEL CAPSULES 300)|Icosapent (EPADEL CAPSULES 300) capsules.
79530900|NCT04500951|Other|Standard resting environment|The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
79530901|NCT04452175|Other|JUUL E-CIGARETTE|JUUL E-CIGARETTE USAGE FOR 24 WEEKS
79829421|NCT02193620|Drug|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
79829422|NCT02193620|Drug|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
80004202|NCT03627117|Drug|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
79236629|NCT03687983|Device|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
79829423|NCT02187848|Drug|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
79236630|NCT02677844|Drug|Abemaciclib|Administered orally
79236631|NCT02677844|Drug|Placebo|Administered orally
79236632|NCT02677844|Drug|Loperamide|Administered orally
79236633|NCT03687905|Drug|Chloroquine|group1 received chloroquine .
79530902|NCT04444687|Diagnostic Test|Test for SARS-CoV-2|"As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~After intubation samples are acquired in the OR~tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~blood sample (as part of standard operation procedures for CoVID-19 patients)~fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR."
79687032|NCT06017180|Other|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
79829424|NCT02183168|Drug|Meloxicam suppository|
79829425|NCT02183168|Drug|Meloxicam tablet|
79829426|NCT02183168|Drug|Indomethacin|
79829427|NCT02183129|Drug|Diclofenac|
79829428|NCT02183129|Drug|Meloxicam|
79829429|NCT02176967|Procedure|Biopsy|Undergo biopsy
79829430|NCT02176967|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79829431|NCT02176967|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79829432|NCT02176967|Drug|Carboplatin|Given IV
79829433|NCT02176967|Other|Clinical Observation|Undergo clinical observation
79829434|NCT02176967|Procedure|Computed Tomography|Undergo CT
80004203|NCT03627117|Drug|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
80004204|NCT02113046|Procedure|pancreatico-jejunal anastomosis|
79829435|NCT02176967|Drug|Cyclophosphamide|Given IV
79829436|NCT02176967|Drug|Doxorubicin Hydrochloride|Given IV
80004205|NCT02113046|Procedure|traditional anastomosis|
79236634|NCT03687905|Drug|Hydroxychloroquine|Group 2 received hydroxychloroquine
79829437|NCT02176967|Drug|Etoposide|Given IV
79829438|NCT02176967|Procedure|Magnetic Resonance Imaging|Undergo MRI
79829439|NCT02176967|Procedure|Ultrasound|Undergo ultrasound
79829440|NCT02137850|Drug|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
80004206|NCT05074641|Other|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
80004207|NCT05074641|Other|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
80004208|NCT01376401|Drug|Bendamustine|
80004209|NCT01376401|Drug|Velcade|
80004210|NCT01376401|Drug|Prednisone|
79236635|NCT03687515|Drug|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
79236636|NCT03687515|Drug|budesonide|nasal spray 256μg BID
79236637|NCT03687515|Drug|Prednisone|oral prednisone 24mg QD
79829441|NCT02077621|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
79829442|NCT02077621|Drug|Placebo|500 mL normal saline
79829443|NCT02065011|Drug|Blood draw for the laboratory assessment|
79829444|NCT01994499|Device|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
79829445|NCT01994499|Drug|Medical drainage|Medical pleural drainage
79829446|NCT01843530|Drug|Berinert|
79829447|NCT01843530|Drug|Clemastin|
79829448|NCT01843530|Drug|Cortisone acetate|
79829449|NCT01843530|Drug|NaCl|
79829450|NCT01720563|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
79829451|NCT01720563|Drug|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
79829452|NCT01720563|Procedure|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
79829453|NCT01720550|Drug|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
79829454|NCT01720550|Drug|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
79687033|NCT06017180|Other|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
79687034|NCT06014047|Procedure|No-touch vein graft|Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
79687035|NCT06014047|Procedure|Radial artery graft|One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
79687036|NCT06009523|Device|Transcranial direct current stimulation|1 stimulation per day during 15 days.
79687037|NCT06007677|Drug|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
79687038|NCT05988151|Other|New surgical approach|Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
79687039|NCT05986266|Drug|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
79687040|NCT05982132|Other|anthropometric measurement|Measurement of weight and other anthropometrics data
79236638|NCT03164876|Drug|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
79236639|NCT03164876|Drug|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
80004211|NCT02119364|Other|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
79530903|NCT04431622|Device|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
79530904|NCT04421677|Drug|Phenylbutyrate Oral Tablet|Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
79687041|NCT05980728|Other|No Intervention|No Intervention
80004212|NCT05611983|Behavioral|sensory relearning|feasibility of early sensory relearning
80004213|NCT02119520|Drug|Platelet rich fibrin +Atorvastatin|
79305671|NCT03237767|Other|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
79377208|NCT03372486|Drug|Bupivacaine plus naloxone|Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
79377209|NCT03372486|Drug|Bupivacaine|Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
79377210|NCT05064670|Behavioral|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
79687042|NCT05979779|Drug|HU6|HU6 is being evaluated for its efficacy in improving liver fat content in obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis (NASH)
79687043|NCT05979779|Other|Placebo|Placebo
79829455|NCT01696565|Drug|PG2|Injectable
79829456|NCT01656902|Drug|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
79829457|NCT01656902|Procedure|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
79829458|NCT01626079|Device|MitraClip System|Percutaneous mitral valve repair using MitraClip System
79829459|NCT01560182|Genetic|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
79829460|NCT01502280|Drug|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
80004214|NCT02119520|Drug|Platelet rich fibrin|
79530905|NCT04413240|Device|Telerehabilitation|"VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
79530906|NCT04413240|Other|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
79530907|NCT04399200|Device|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
79530908|NCT04347538|Other|Saline Nasal Irrigation|Saline nasal irrigation BID
80004215|NCT02119520|Procedure|open flap debridement|
79236640|NCT03690713|Diagnostic Test|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × ([1.35 × Pd/Pa] - 0.32).
79236641|NCT03687437|Diagnostic Test|Blood sample|Complete blood count
79236642|NCT03687281|Other|Survey|"The questionnaire consists of three parts:~knowledge assessment;~socio-demographic, medical and lifestyle data;~use of Chemsex."
79377211|NCT03372330|Drug|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
79236643|NCT03687203|Diagnostic Test|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
79377212|NCT03372330|Drug|Standard care for sepsis|The standard care for the patient with sepsis.
79530909|NCT04347538|Other|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
79530910|NCT04340206|Behavioral|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
80004216|NCT02114762|Procedure|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
80004217|NCT00263731|Other|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
79687044|NCT05978687|Drug|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
79236644|NCT03682913|Behavioral|P-CIT protocol|Personalized inhibitory control training for one week.
79829461|NCT01502280|Drug|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
79829462|NCT01485809|Drug|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
79829463|NCT01420237|Device|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
79829464|NCT01413100|Biological|Anti-Thymocyte Globulin|Given IV
79236645|NCT03682913|Behavioral|Placebo|without personalized inhibitory control training for one week.
79236646|NCT03682835|Dietary Supplement|FDGard|capsule containing peppermint oil and caraway oil
79236647|NCT03682835|Other|Placebo|Placebo capsule containing cellulose
79377213|NCT04525482|Other|Early goal-directed sedation programs|A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
79829465|NCT01413100|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
79829466|NCT01413100|Drug|Cyclophosphamide|Given IV
79236648|NCT02691494|Drug|Elagolix|Film-coated tablets
79829467|NCT01413100|Biological|Filgrastim|Given SC
79829468|NCT01413100|Other|Laboratory Biomarker Analysis|Correlative studies
79829469|NCT01413100|Drug|Mycophenolate Mofetil|Given PO
79829470|NCT01413100|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
79829471|NCT01413100|Drug|Plerixafor|Given SC
79829472|NCT01413100|Other|Quality-of-Life Assessment|Ancillary studies
79829473|NCT01413100|Other|Questionnaire Administration|Ancillary studies
79829474|NCT01349959|Drug|Azacitidine|Given SC
79829475|NCT01349959|Drug|Entinostat|Given PO
80004218|NCT05609877|Procedure|NONA-LISA|The staff will perform Less Invasive Surfactant Administration using the standard pre- and post-procedure care including non-pharmacological treatment. The patients will not receive pharmacological analgesic treatment routinely.
80004219|NCT02119754|Drug|Plurogel PN|
80004220|NCT03961789|Other|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
80004221|NCT02119832|Device|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
80004222|NCT01376479|Biological|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
80004223|NCT01376479|Biological|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
79377214|NCT05035888|Drug|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to < 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
79377215|NCT05035888|Drug|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
79377216|NCT03368820|Other|No intervention|Treatment left at the discretion of the participant
79236649|NCT02691494|Drug|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
79829476|NCT01349959|Other|Laboratory Biomarker Analysis|Correlative studies
80004224|NCT01376479|Biological|Placebo|Phosphate Buffered Saline (PBS)
80004225|NCT03552614|Device|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
79236650|NCT02691494|Drug|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
79236651|NCT02691494|Drug|Placebo for Elagolix|Film-coated placebo tablets
79829477|NCT01349959|Other|Pharmacological Study|Correlative studies
79829478|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
79829479|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
79829480|NCT01331681|Procedure|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
79829481|NCT01325233|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
79829482|NCT01325233|Drug|Placebo|500 ml normal saline, tiw, 2 weeks
79829483|NCT01286272|Drug|Bendamustine Hydrochloride|Given IV
79829484|NCT01286272|Drug|Bortezomib|Given IV or SC
79829485|NCT01286272|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET
79236652|NCT03682679|Diagnostic Test|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
79236653|NCT03164798|Procedure|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
79829486|NCT01286272|Other|Laboratory Biomarker Analysis|Correlative studies
79829487|NCT01286272|Biological|Ofatumumab|Given IV
79829488|NCT01286272|Procedure|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
79829489|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
79829490|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
79829491|NCT01215136|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
79829492|NCT01142401|Drug|Bortezomib|Given IV
79829493|NCT01142401|Drug|Fulvestrant|Given IM
79829494|NCT01142401|Other|Laboratory Biomarker Analysis|Correlative studies
80004226|NCT03552614|Other|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
80004227|NCT04854343|Diagnostic Test|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
80004228|NCT04854343|Diagnostic Test|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
80004229|NCT04854343|Diagnostic Test|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
80004230|NCT05695053|Device|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
79236654|NCT03624335|Procedure|ECC|Early clamping of the umbilical cord
79829495|NCT01111617|Procedure|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
80004231|NCT05695053|Other|Placebo|Placebo
79377217|NCT03000712|Biological|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml drug: saline solution
79377218|NCT03372252|Device|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
80004232|NCT02119910|Behavioral|Technology Supported Manual|
80004233|NCT05693337|Device|Forward Looking Infrared Radar (FLIR) thermal imaging|The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
80004234|NCT02113280|Procedure|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
79236655|NCT03624335|Procedure|DCC|Delayed clamping of the umbilical cord
79236656|NCT03624335|Procedure|Blood Test 6hours|Blood Test 6hours
79377219|NCT03000478|Behavioral|Prolonged Exposure|
79377220|NCT03000478|Behavioral|Virtual Reality Exposure Therapy|
79377221|NCT03372018|Behavioral|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
79377222|NCT03372018|Behavioral|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
79377223|NCT03004300|Procedure|Rapid maxillary expansion|Device
79377224|NCT03004300|Procedure|Adenotonsillectomy|Surgery
79377225|NCT03362814|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
79377226|NCT03362814|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
79377227|NCT03362814|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
79377228|NCT03362814|Drug|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(<75kg = 1000mg and ≥75kg = 1200mg)
79829496|NCT00870636|Drug|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
79829497|NCT00860600|Drug|PG2|500mg/vial, iv infusion, 3 ~ 5 times/week, 2.5 ~ 3.5 hr/time
79829498|NCT00633828|Behavioral|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
79236657|NCT03624335|Procedure|Blood Test 24hours|Blood Test 24hours
79236658|NCT03624335|Procedure|Blood Test 48hours|Blood Test 48hours
79236659|NCT03624335|Procedure|Blood Test 28days|Blood Test 28days
79236660|NCT02677220|Device|CI532 cochlear implant|
79236661|NCT05277116|Other|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
79377229|NCT03362814|Drug|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
79377230|NCT03362814|Drug|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
79377231|NCT03362814|Drug|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
79377232|NCT03362814|Drug|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(<75kg = 5 tablets and ≥75kg = 6 tablets)
79377233|NCT03004066|Drug|Daptomycin|standard care
79377234|NCT05004454|Dietary Supplement|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
79829499|NCT00584532|Drug|Placebo|10 Placebo Capsules taken orally every day.
79829500|NCT00584532|Drug|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
80004235|NCT02113280|Procedure|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
80004236|NCT05522127|Other|Colonoscopy|Colonoscopy
79236662|NCT03972449|Behavioral|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
79377235|NCT05004454|Dietary Supplement|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
79377236|NCT03362736|Drug|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to [<=] 55 kilogram [kg] will receive 260 milligram [mg] ustekinumab; > 55 kg to <= 85 kg will receive 390 mg ustekinumab; and > 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
79829501|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
79829502|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
79530911|NCT04340206|Behavioral|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
79236663|NCT03972449|Behavioral|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
79377237|NCT03004222|Drug|Bupivacaine|20 ml of 0.5% Bupivacaine
79829503|NCT00523107|Drug|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
79829504|NCT00523107|Drug|Placebo|500 ml normal saline t.i.w. per week
79829505|NCT00482807|Drug|bicalutamide|
79829506|NCT00482807|Drug|docetaxel|
79236664|NCT03962309|Other|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
79377238|NCT03004222|Drug|Placebos|
79377239|NCT03368586|Device|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (<4.0 mmol/L) or high (>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
79530912|NCT04340206|Behavioral|Control group, no intervention|Behavioral: No intervention
79829507|NCT00482807|Drug|goserelin|
79829508|NCT00482807|Radiation|intensity-modulated radiation therapy|
79829509|NCT00474604|Procedure|diffusion-weighted magnetic resonance imaging|A scan will be performed.
79829510|NCT00474604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
79829511|NCT00474604|Procedure|magnetic resonance spectroscopic imaging|A scan will be performed.
79236665|NCT02682602|Device|DePuy Synthes total hip arthroplasty|
79236666|NCT02682602|Radiation|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
79829512|NCT00202371|Procedure|Red Blood Cell transfusion|
79829513|NCT00871312|Device|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
79829514|NCT00871312|Device|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
79829515|NCT00740012|Other|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
79829516|NCT00740012|Other|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
79829517|NCT00740012|Other|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
80004237|NCT05522127|Other|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
80004238|NCT02113358|Drug|Intravenous colloid bolus with Voluven|
79829518|NCT00740012|Other|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
79829519|NCT00740012|Other|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
79829520|NCT00740012|Other|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
79829521|NCT04064268|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
80004239|NCT04854187|Device|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
79236667|NCT02682602|Radiation|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
79236668|NCT03959111|Other|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
79236669|NCT03959111|Other|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
79236670|NCT03803657|Device|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
79236671|NCT03690635|Procedure|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
79236672|NCT03691337|Drug|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
79829522|NCT04064268|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
80004240|NCT03769142|Procedure|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
80004241|NCT02114840|Procedure|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
79236673|NCT03691337|Drug|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
79236674|NCT03691337|Drug|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
80004242|NCT02114840|Procedure|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
80004243|NCT02114840|Procedure|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
80004244|NCT04878055|Drug|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
79377240|NCT03000634|Drug|Elotuzumab|Administered through a small tube that goes directly into the vein
79377241|NCT03000634|Drug|Bortezomib|Administered as a subcutaneous injection under the skin
79530913|NCT04334031|Genetic|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
79530914|NCT04334031|Other|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
79530915|NCT04333953|Other|No intervention|No intervention, observational study
79829523|NCT00740090|Drug|AMA1-C1/Alhydrogel plus CPG 7909|
79829524|NCT00738660|Drug|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
79829525|NCT00740168|Drug|bevacizumab treatment|single infusion 10 mg/kg
80004245|NCT04878055|Other|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
79377242|NCT03000634|Drug|Lenalidomide|Capsule taken by mouth
79829526|NCT05225974|Drug|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
80004246|NCT01376713|Biological|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
80004247|NCT01376713|Biological|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
80004248|NCT05286567|Drug|RGRN-305|Heat shock protein 90 inhibitor
79377243|NCT03000634|Drug|Dexamethasone|Taken by mouth
79377244|NCT02518776|Behavioral|Neuropsychological tests|Neuropsychological tests
79377245|NCT03000400|Behavioral|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
79377246|NCT03000400|Behavioral|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
79377247|NCT02520102|Drug|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
79377248|NCT03000556|Drug|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
79377249|NCT03371940|Behavioral|Program ACTIVE Exercise|Please see the Exercise arm description above.
79829527|NCT05225974|Drug|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
79829528|NCT00740246|Drug|VIT-45|
79829529|NCT00729638|Drug|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
79829530|NCT00729638|Drug|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
80004249|NCT05286567|Drug|Placebo|Placebo (blinded)
79530916|NCT04323501|Other|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
79236675|NCT03682445|Other|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
80004250|NCT02114918|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
79236676|NCT03164642|Behavioral|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
79530917|NCT04323501|Other|Control group|Usual care
79687045|NCT05978687|Drug|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
79687046|NCT05971082|Other|Follow-up|Follow-up study of progression/remission of liver disease
79687047|NCT05967598|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
79687048|NCT05967598|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
79829531|NCT00734682|Drug|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
79829532|NCT00876538|Drug|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
79236677|NCT03164642|Behavioral|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
79236678|NCT03690479|Device|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
79530918|NCT04318951|Behavioral|Intensive communicative-pragmatic social interaction.|"ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the […]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks."
79530919|NCT04318951|Behavioral|Standard care.|Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
79829533|NCT00876538|Drug|Placebo Control|Placebo Control 2 capsules once day with the noon meal
79530920|NCT04311762|Drug|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
79687049|NCT05967598|Device|Sham cyma conchae stimulation|The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
79687050|NCT05961332|Device|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
79829534|NCT00732108|Drug|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
79829535|NCT00732108|Drug|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
79829536|NCT00735800|Behavioral|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
80004251|NCT02114918|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
79236679|NCT03690479|Device|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
79236680|NCT02681510|Drug|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
79236681|NCT02681510|Drug|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
79829537|NCT00735800|Behavioral|Telephone Support|Supportive telephone counseling about caregiving
79377250|NCT03371940|Behavioral|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
79829538|NCT00876616|Drug|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
79530921|NCT04293601|Other|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~NCPAP duration < 48 hours (h)~Gestational Age (GA) > 32 weeks (wks)~Current weight > 1500 g~Interventions:~alternating mask or nasal prongs once per shift~skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~NCPAP duration from 48 to 72 h~GA from 32 to 28 wks~Current weight from 1500 to 1000 g~Interventions:~alternating mask or nasal prongs twice per shift~skin assessment (excoriation, erythema or skin breakdown) twice per shift~repositioning of device once per shift~High:~NCPAP duration > 72 h~GA < 28 wks~Current weight < 1000 g~Interventions:~alternating mask or nasal prongs twice per shift~skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~repositioning of device every 3 h per shift"
79530922|NCT04293601|Other|Standard nursing care|"Use of hydrocolloid as nasal barrier dressing~Appropriate size of headbands, indicated by production company~Appropriate size of mask or binasal prongs, indicated by production company~Frequently assess skin integrity, every 4 hours~Replace hydrocolloid if it's dirty or displaced~Humidity and heat gases"
79530923|NCT04257565|Device|Wheeled Knee Walker|The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
79530924|NCT04257565|Other|Usual and Customary Care|This group will receive usual and customary care for treatment of their diabetic foot ulcer
79687051|NCT05961332|Device|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
79829539|NCT00876616|Drug|Cyclophosphamide|CTX 0.75g/m2 BSA
79829540|NCT04064502|Diagnostic Test|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
79829541|NCT00729716|Biological|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
80004252|NCT03626961|Other|readmission|Readmission after 48 hours
79236682|NCT02681510|Drug|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
79236683|NCT03690323|Procedure|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
79236684|NCT03690323|Drug|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
79236685|NCT03690323|Drug|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
79236686|NCT03690323|Drug|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
79377251|NCT03371940|Behavioral|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
79377252|NCT03371940|Behavioral|Usual Care - No intervention|Please see the Usual Care arm description above.
79377253|NCT03368508|Behavioral|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
79377254|NCT03368508|Behavioral|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
79377255|NCT03000322|Device|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
79377256|NCT03371862|Drug|Liraglutide Pen Injector [Victoza]|Pilot study of liraglutide in patients with short bowel.
80004253|NCT03626961|Other|discharge|Discharge
79829542|NCT00729716|Procedure|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
79829543|NCT00863200|Behavioral|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
79530925|NCT04223362|Other|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
79236687|NCT03682211|Drug|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
79687052|NCT05961332|Device|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
79687053|NCT05961059|Biological|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
79236688|NCT03682211|Drug|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
79236689|NCT03161834|Other|Observational|
79236690|NCT03161600|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
79236691|NCT03690245|Procedure|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
79377257|NCT03362580|Device|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
79377258|NCT03362580|Device|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
79377259|NCT03362580|Device|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
79377260|NCT03362580|Device|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
79377261|NCT03368430|Dietary Supplement|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
79530926|NCT04223362|Other|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
79530927|NCT04203472|Device|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
79530928|NCT04203472|Device|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
79687054|NCT05961059|Biological|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
79687055|NCT05961059|Biological|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
79687056|NCT05961059|Biological|Placebo|Placebo vaccination with commercially available saline solution.
79687057|NCT05960994|Other|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
79687058|NCT05948813|Drug|TY-9591|The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
79236692|NCT03686735|Other|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
79687059|NCT05948813|Drug|Osimertinib|The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
79687060|NCT05948267|Drug|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
79829544|NCT00863200|Behavioral|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
79829545|NCT00734760|Behavioral|education|face-to-face education and counseling intervention
80004254|NCT05108493|Other|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
80004255|NCT05108493|Other|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
79377262|NCT03368430|Drug|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
79829546|NCT00740324|Drug|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
79377263|NCT03371784|Drug|Hydrocortisone|I.V. administration
79829547|NCT00740324|Drug|NPO-11|NPO-11 after administration of NPO-11
79377264|NCT03371784|Drug|Placebo|I.V. administration
79829548|NCT00740324|Drug|NPO-11|1 mg glucagons after administration of NPO-11
80004256|NCT03725293|Device|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
80004257|NCT03725293|Device|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
79377265|NCT03003832|Other|Change in electronic health record default for new opioid analgesic prescriptions|
79377266|NCT03368352|Dietary Supplement|Melatonin|Dietary supplement melatonin
79687061|NCT05948267|Drug|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
80004258|NCT01368536|Drug|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
79687062|NCT05945303|Procedure|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
80004259|NCT01368536|Drug|Amlodipine|Amlodipine 5 mg and 10 mg capsule
80004260|NCT01368536|Drug|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
79236693|NCT03686735|Other|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
79236694|NCT03686735|Other|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
79829549|NCT00871468|Procedure|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
79829550|NCT00871468|Procedure|anterior-inferior plate|ORIF clavicle with anterior inferior plate
80004261|NCT01368536|Drug|Placebo of Valturna Tablet|Matching placebo of valturna tablet
80004262|NCT01368536|Drug|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
79236695|NCT03686735|Other|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
79377267|NCT03368352|Other|Hypoxia|Sleep in a hypoxic tent simulating high altitude
79377268|NCT02248012|Drug|Everolimus , temozolomide|
79377269|NCT03371628|Device|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
79377270|NCT03003988|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
79377271|NCT03003988|Dietary Supplement|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
79829551|NCT00738738|Drug|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
79829552|NCT00735956|Behavioral|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
79305672|NCT03237767|Other|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
79377272|NCT03003988|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
79687063|NCT05944965|Drug|Atomoxetine 80 mg plus Oxybutynin 5 mg|80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed
79687064|NCT05944965|Drug|Atomoxetine 80 MG|80mg Atomoxetine administered 30 mins prior to bed
79687065|NCT05944965|Drug|Placebo|Placebo and placebo (sugar pill) administered 30 mins prior to bed
79687066|NCT05935085|Drug|ANB032|BTLA agonist antibody
79829553|NCT04040998|Behavioral|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
79829554|NCT05575440|Procedure|Computed Tomography|Undergo a PET/CT scan
79829555|NCT05575440|Radiation|Fluorine F 18 Tetrafluoroborate|Given IV
79829556|NCT05575440|Procedure|Positron Emission Tomography|Undergo a PET/CT scan
80004263|NCT05103735|Drug|Propofol|awake neurosurgery under propofol-remifentanil sedation
79530929|NCT04168814|Other|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
79236696|NCT03681899|Other|Questionnaires|"Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~Medical and surgical history (Charlson Comorbidity Scale);~Assessment of oral/dental condition~Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~Autonomy evaluation (Lawton and Katz scales);~Mobility assessment (anamnestic evaluation);~Evaluation of Thyme (GDS 4 items);~Psycho-behavioral disorders,~Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
79829557|NCT05575440|Other|Survey Administration|Ancillary studies
79829558|NCT00863278|Procedure|pulsed dye laser treatment|On one side of the face according to Arm placement.
79687067|NCT05935085|Drug|Placebo|Placebo
79236697|NCT02690714|Biological|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
79687068|NCT05921149|Dietary Supplement|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
79829559|NCT00863278|Drug|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
79236698|NCT04769726|Dietary Supplement|almonds|almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
79305673|NCT00700427|Drug|atomoxetine hydrochloride|Oral 40-100 mg/day
79377273|NCT03003910|Behavioral|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
79377274|NCT03003910|Behavioral|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
79377275|NCT03362346|Device|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
79377276|NCT03362268|Drug|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
79530930|NCT04134871|Behavioral|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
79687069|NCT05921149|Drug|Carboplatin|Given IV
79530931|NCT04072146|Drug|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
79530932|NCT04072146|Drug|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
79530933|NCT04058847|Other|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
79687070|NCT05921149|Drug|Paclitaxel|Given IV
79687071|NCT05921149|Dietary Supplement|Standard diet|Normal diet
79829560|NCT00740558|Procedure|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
79829561|NCT00740558|Procedure|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
79829562|NCT00729794|Drug|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
79305674|NCT00700427|Drug|Placebo|Oral delivery of matching placebo
79829563|NCT00729794|Drug|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
79829564|NCT00871546|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
79829565|NCT00871546|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
79829566|NCT00871546|Biological|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
79829567|NCT00732186|Biological|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
80004264|NCT03051165|Device|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
80004265|NCT01319929|Drug|LY2828360|Administered orally
80004266|NCT01319929|Drug|Placebo|Administered orally
79305675|NCT03237533|Drug|Dexamethasone|Dexamethasone will be applied locally on the lesion
79305676|NCT03107663|Drug|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
79305677|NCT03237221|Drug|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
79530934|NCT04040153|Behavioral|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
79530935|NCT04001972|Behavioral|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
79377277|NCT03362268|Drug|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
79530936|NCT04001972|Drug|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette <30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette >30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
79530937|NCT04001972|Behavioral|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
79530938|NCT04001972|Behavioral|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
79377278|NCT04901962|Device|JOBST® Confidence compression garments|JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
79530939|NCT03987906|Behavioral|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
79687073|NCT05910502|Behavioral|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
79687074|NCT05908253|Behavioral|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
80004267|NCT03553316|Drug|PK101-002|-(Single) PK101-002
80004268|NCT03553316|Combination Product|PK101|-(Combination) PK101-001, PK101-002
80004269|NCT04194099|Device|20 Hz rTMS (Brain)|Higher frequency (>5 Hz) trains increase cortical excitability.
80004270|NCT04194099|Device|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
79236699|NCT03165812|Procedure|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
79236700|NCT03165812|Procedure|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
79377279|NCT04523844|Drug|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
79377280|NCT02248090|Drug|AZD9496|AZD9496
80004271|NCT04194099|Device|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
80004272|NCT04194099|Device|20 Hz current square-wave pulses (Spinal)|Higher frequency (>5 Hz) of current increase cortical excitability.
80004273|NCT04194099|Device|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
80004274|NCT04194099|Device|sham|with sham stimulation on brain and spinal.
80004275|NCT03552458|Drug|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
79236701|NCT03690167|Other|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
79236702|NCT03690167|Other|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
79236703|NCT03690167|Other|Control|Nothing applied after extraction
79236704|NCT03686579|Radiation|chest trauma|clinical and radiological study
79530940|NCT03963570|Behavioral|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
79530941|NCT03963570|Behavioral|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
79530942|NCT03945084|Drug|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily <77 kg or <150,000 µL: 200 mg (2 X 100 mg capsules) daily*~* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
79530943|NCT03945084|Other|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
79530944|NCT03920241|Behavioral|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
79687075|NCT05908253|Behavioral|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
80004276|NCT03552458|Drug|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
80004277|NCT03633565|Drug|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
80004278|NCT03633565|Drug|Prednisolone (Steroids)|tablet 20 mg
80004279|NCT03633565|Procedure|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
80004280|NCT02120066|Procedure|Vitrectomy for submacular hemorrhage|
80004281|NCT02120066|Drug|subretinal injection of tissue-plasminogen activator|
80004282|NCT02120144|Other|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
80004283|NCT02120144|Other|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
80004284|NCT01373359|Drug|Misoprostol|400 µg sublingual misoprostol
80004285|NCT01373359|Drug|Oxytocin|10 IU IM
79377281|NCT02248090|Drug|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
79377282|NCT03362034|Device|double transfer trays|double trays one soft and one hard
79377283|NCT03362034|Device|single transfer tray|single soft tray
79377284|NCT03003754|Behavioral|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
79377285|NCT03003754|Behavioral|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
79377286|NCT03361878|Drug|Metformin Hydrochloride|Single dose of 500mg oral metformin
79377287|NCT03361800|Drug|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
79377288|NCT04523532|Other|Dietary folate and hazelnut oil|Intervention with folate-rich diet and hazelnut oil supplement in capsule
79377289|NCT02995642|Drug|18F-FPPRGD2|One single intravenous injection.
79236705|NCT03164954|Diagnostic Test|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
79236706|NCT03686501|Drug|PF-06412562|Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two [18F]MNI-968 injections
79829568|NCT04064996|Other|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
79530945|NCT03920241|Behavioral|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
79530946|NCT03920241|Other|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
79530947|NCT03896191|Procedure|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
79687076|NCT05908253|Behavioral|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
79236707|NCT03165968|Device|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
79236708|NCT03681821|Behavioral|Transtheoretical Model (TTM)-based Intervention|Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
79236709|NCT03164408|Procedure|Orthopaedic Implant Removal|
79236710|NCT03164330|Behavioral|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
79236711|NCT03164330|Behavioral|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
79687077|NCT05908058|Other|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
79236712|NCT03164330|Behavioral|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, & waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); & (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
79530948|NCT03896191|Other|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
79530949|NCT03894657|Diagnostic Test|Nasal brushing|Nasal scrapping at visit V0
79687078|NCT05903547|Device|Dermabond Prineo|For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.
79687079|NCT05903547|Other|Suture|For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
80004286|NCT02123186|Other|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
80004287|NCT03110185|Device|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
80004288|NCT03110185|Device|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
79530950|NCT03894657|Other|Sputum sample|"Visit V0 : 1 Aliquot for Sputum biobank~Visit V1 : 2 Aliquots~for Sputum biobank~for pharmacokinetic (PK) study~Visit V2 : 2 Aliquots~for Sputum biobank~for pharmacokinetic (PK) study"
79236713|NCT03164330|Behavioral|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
79236714|NCT03164330|Behavioral|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
79236715|NCT03164330|Behavioral|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
79530951|NCT03894657|Other|blood sample|"Visit V0 : Additional 14 mL~5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis~3 mL in Dry tube for Serum biobank~6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank~Visit V1 : Additional 9 mL~2x3 mL in dry tube for pharmacokinetic (PK) study~3 mL in Dry tube for Serum biobank~Visit V2 : Additional 6 mL~3 mL in dry tube for pharmacokinetic (PK) study~3 mL in Dry tube for Serum biobank"
79530952|NCT03894657|Drug|Orkambi|"Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.~Orkambi treatment is part of usual care."
79530953|NCT03886467|Other|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
79687080|NCT05898529|Diagnostic Test|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
79687081|NCT05895006|Device|alpha-frequency tACS|The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
79687082|NCT05895006|Device|Random noise stimulation|The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
79687083|NCT05894655|Behavioral|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
80004289|NCT03110185|Device|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
79236716|NCT03681743|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
79236717|NCT03681665|Other|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80~90% reduced radiation dose compared to standard dose CT.
79236718|NCT03165890|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79236719|NCT03165890|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79236720|NCT03689933|Device|Root analog implant|a custom made root analogue implant made from milled titanium
80004290|NCT02123264|Drug|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
80016722|NCT05119426|Biological|Vi-TT|Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and <16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
79377290|NCT02995642|Device|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
79377291|NCT02995642|Procedure|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
79377292|NCT02995642|Device|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
79377293|NCT02518932|Drug|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
79377294|NCT02518932|Drug|placebo saline|
79377295|NCT02998606|Drug|Naloxegol|MOVANTIK™ 25 mg, daily
79377296|NCT02998606|Drug|Placebo Oral Capsule|Placebo 25 mg, daily
79377297|NCT04636528|Device|Digital rehabilitation|"Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist."
79391138|NCT02423928|Drug|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
79391139|NCT02051608|Drug|Placebo|Participants received Placebo SC injection Q4W.
79530954|NCT03882463|Device|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
79236721|NCT05228990|Device|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
79236722|NCT03115190|Diagnostic Test|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
79236723|NCT03114800|Device|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
79236724|NCT03114956|Procedure|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
79236725|NCT03114956|Procedure|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
79236726|NCT03114956|Procedure|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
79377298|NCT04636528|Device|Conventional rehabilitation|"Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, PTs will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week)."
79377299|NCT05365438|Drug|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
79377300|NCT05365438|Drug|Omega 3-Atorvastatin|Atmeg 2 capsules
79530955|NCT03881228|Behavioral|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
79530956|NCT03861481|Drug|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
79530957|NCT03861481|Other|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
79530958|NCT03853941|Behavioral|Intervention|Theory-based communication training programme delivered to healthcare professionals
80016723|NCT04590833|Behavioral|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
79377301|NCT05365438|Drug|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
79377302|NCT05290558|Drug|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
79377303|NCT05290558|Drug|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
79530959|NCT03821649|Behavioral|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
79530960|NCT03821649|Behavioral|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
79530961|NCT03811262|Procedure|ESP BLOCK|local anesthetic will be injected between transverous process and erector spinae muscle
79530962|NCT03811262|Procedure|PECS BLOCK|local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
79530963|NCT03758833|Diagnostic Test|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
79530964|NCT03758833|Procedure|Single embryo transfer|Transfer of single embryo
79530965|NCT03758833|Procedure|Double embryo tranfer|Transfer of two embryos
79530966|NCT03730974|Device|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
79530967|NCT03716466|Other|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
79530968|NCT03716466|Other|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
79530969|NCT03708198|Drug|Liposomal Bupivacaine|intercostal block
79687084|NCT05894655|Behavioral|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
79829569|NCT04064996|Other|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
79829570|NCT00729872|Biological|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
79829571|NCT00729872|Other|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
79829572|NCT04039828|Drug|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for > 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
79236727|NCT03114956|Procedure|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
79236728|NCT03166046|Device|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
79236729|NCT03166046|Device|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
79236730|NCT03681587|Other|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
79829573|NCT00729950|Biological|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
79829574|NCT00616018|Drug|acetaminophen|4 g/day for 10 consecutive days
79829575|NCT04064970|Behavioral|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
79236731|NCT03681587|Other|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
79829576|NCT00740948|Drug|Rituximab (mabthera) Injection|2 * 1g of Rituximab at the 1st day and at the 14th day.
79829577|NCT00740948|Drug|Placebo: NaCl 0.9% or Glucose 5%|2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
79829578|NCT00871702|Genetic|CD34-TK75 transduced donor lymphocytes|
79236732|NCT03161366|Biological|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
79236733|NCT03161288|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
79377304|NCT02997670|Other|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
79236734|NCT03161288|Drug|Placebo|Matched placebo
79236735|NCT03681509|Drug|Pramipexole|Pramipexole
79236736|NCT03681509|Drug|Placebo|Lactose placebo capsule
79377305|NCT05132998|Other|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
79530970|NCT03706729|Device|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
79530971|NCT03695068|Behavioral|RISE Intervention|Described in Arms description.
79530972|NCT03683498|Biological|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
79236737|NCT03686267|Other|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
79236738|NCT03686267|Other|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
79236739|NCT03686267|Other|titanium abutment with no color masking|color masking methods are avoided in this arm
79236740|NCT03686189|Device|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
79236741|NCT03686111|Diagnostic Test|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
79829579|NCT00871702|Radiation|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
79530973|NCT03654599|Behavioral|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
79530974|NCT03654599|Behavioral|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
79530975|NCT03654599|Behavioral|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
79236742|NCT03685955|Biological|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
79530976|NCT03648476|Behavioral|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
79236743|NCT03164252|Radiation|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
79236744|NCT03164252|Radiation|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
79236745|NCT03164252|Radiation|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
79236746|NCT03161210|Other|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
79530977|NCT03641196|Device|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
79530978|NCT03641196|Procedure|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
79530979|NCT03608982|Other|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
79829580|NCT00732342|Behavioral|Contingency Management|Prizes given for targeted behavior of abstinence
80004291|NCT04132869|Behavioral|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
79377306|NCT05132998|Other|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
80004292|NCT02251964|Drug|Rituximab|2 times 1000mg dose at 14 days interval treatment
79377307|NCT05672914|Behavioral|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
79377308|NCT03003364|Drug|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
80004293|NCT02251964|Radiation|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
80004294|NCT04739995|Drug|Low-dose naltrexone|4.5 mg LDN/day for 1 year
80004295|NCT02120612|Other|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
79236747|NCT03161210|Other|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
79236748|NCT03161210|Other|Saline|Saline is a control group
79377309|NCT03003364|Drug|Placebo|Placebo in a blinded syringe
79530980|NCT03608982|Other|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
79829581|NCT00876850|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
80004296|NCT01374295|Other|video|watch a 3 minute video
79377310|NCT03003598|Other|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
79377311|NCT03003598|Other|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
79530981|NCT03578393|Device|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
79530982|NCT03562806|Diagnostic Test|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
79530983|NCT03559426|Drug|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
79530984|NCT03559426|Drug|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
79530985|NCT03557762|Behavioral|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
79530986|NCT03537937|Other|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
80004297|NCT01374295|Other|standard education|Receives standard verbal education from healthcare provider
80004298|NCT02115152|Drug|fluorouracil|
79530987|NCT03537937|Other|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
79530988|NCT03537937|Other|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
79530989|NCT03491280|Genetic|NGS Diagnostic|Blood take for genetic diagnostic.
79530990|NCT03484000|Behavioral|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
79530991|NCT03444753|Drug|BMS-986299|Specified dose on specified day
79530992|NCT03444753|Biological|Nivolumab|Specified dose on specified day
80004299|NCT02115152|Drug|capecitabine|
79236749|NCT03160976|Other|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
79236750|NCT03164096|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
79377312|NCT02981056|Other|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
79391140|NCT02051608|Drug|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
79530993|NCT03444753|Biological|Ipilimumab|Specified dose on specified day
79530994|NCT03413982|Other|Registry|Patient registry
79687085|NCT05894655|Behavioral|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
79687086|NCT05867030|Drug|lenalidomide|lenalidomide is administered orally
79687087|NCT05867030|Drug|rituximab|rituximab is administered intravenously
79687088|NCT05867030|Drug|parsaclisib|parsaclisib is administered orally
79687089|NCT05863351|Procedure|Computed Tomography|Undergo CT
79687090|NCT05863351|Procedure|Magnetic Resonance Imaging|Undergo MRI
79687091|NCT05863351|Other|Questionnaire Administration|Ancillary studies
79687092|NCT05863351|Procedure|Stereotactic Ablative Radiotherapy|Undergo SAbR
79687093|NCT05863351|Procedure|Systemic Therapy|Given standard of care systemic therapy
80004300|NCT02115152|Drug|cyclophosphamide|
80004301|NCT02115152|Drug|Epirubicin|
80004302|NCT04680871|Device|In-Ear Sensor|The device will passively monitor participants' biometrics
80004303|NCT02115230|Procedure|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
80004304|NCT04657861|Drug|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
80004305|NCT02115464|Drug|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
80004306|NCT02115464|Radiation|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
80004307|NCT02858076|Drug|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
80004308|NCT02858076|Procedure|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
79530995|NCT03360838|Other|CogCheck|Performance of study participants in the application
79687094|NCT05862051|Procedure|Local Ablative Therapy|LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation [radiofrequency ablation (RFA) or microwave ablation (MWA)]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
79687095|NCT05862051|Procedure|Standard first-line systemic treatment|Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
79687096|NCT05829785|Device|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vascular occlusion test
79829582|NCT00876850|Drug|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
79829583|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
79829584|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
80004309|NCT02115620|Other|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
80004310|NCT01319695|Drug|corifollitropin alfa|100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg
79829585|NCT00734916|Dietary Supplement|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
79829586|NCT00872092|Other|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
79829587|NCT00738816|Other|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
79829588|NCT00877084|Other|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
79829589|NCT00877084|Other|Usual care|usual care according to clinical pathway for COPD, No training
79829590|NCT00735150|Behavioral|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
80004311|NCT01319695|Drug|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
80004312|NCT01373437|Device|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
79829591|NCT05157412|Drug|Doxycycline 100 mg Oral Tablet|Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
80004313|NCT02123342|Behavioral|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
80004314|NCT04594759|Drug|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
79377313|NCT02981056|Other|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
79377314|NCT02981056|Other|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
79391141|NCT02705586|Behavioral|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
79530996|NCT03337945|Drug|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
79530997|NCT03314480|Diagnostic Test|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
79530998|NCT03286309|Device|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
79687097|NCT05825170|Device|FASY L|Subjects will receive FASY L in lips at level of their scar.
79236751|NCT04480034|Procedure|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
79236752|NCT03164018|Drug|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
79687098|NCT05801510|Behavioral|Cognitive Muscular Therapy for knee pain|Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
79687099|NCT05801198|Dietary Supplement|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
79829592|NCT05157412|Drug|Prednisolone 20 mg|Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
79829593|NCT00732420|Drug|topotecan|Topoisomerase I inhibition.
79829594|NCT00732420|Drug|pazopanib|Tyrosine kinase inhibitor
79377315|NCT03003286|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
79829595|NCT00877162|Behavioral|Controlled crying and routines|Behavioural (teaching and support)
79829596|NCT00877240|Behavioral|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
79829597|NCT00863590|Drug|odanacatib|[Intervention Name: odanacatib (Panel A)] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
79391142|NCT02423850|Device|3D Wound Assessment Monitor (WAM) camera|Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
79391143|NCT03106740|Drug|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
79236753|NCT03689777|Procedure|sleeve gastrectomy|sleeve gastrectomy
79236754|NCT03689777|Procedure|gastric bypass|gastric bypass
79236755|NCT03163784|Biological|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
79236756|NCT03163784|Biological|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
79391144|NCT03106740|Diagnostic Test|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of [11C]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
79530999|NCT03242070|Other|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
79531000|NCT03203694|Behavioral|Walking|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
79531001|NCT03203694|Behavioral|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
79531002|NCT03170700|Behavioral|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
79531003|NCT03170700|Behavioral|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
79531004|NCT03142035|Drug|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
79531005|NCT03142035|Drug|gonapeptyl|gonadotropic releasing hormone agonist
79531006|NCT03142035|Procedure|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
79531007|NCT03076723|Other|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
79531008|NCT03076723|Other|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
79236757|NCT03163784|Drug|Antibiotic|Antibiotic pre-treatment
79687100|NCT05795621|Biological|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
79687101|NCT05795621|Biological|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
79687102|NCT05788094|Drug|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~Tafenoquine KOZENIS® 150 mg film-coated tablets will be purchased from GSK (Glaxo Smith Kline Pharmaceutical industry), 450 mg (3 tablets) will be given."
79829598|NCT00863590|Drug|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
79236758|NCT03163784|Drug|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
79236759|NCT01791543|Device|Intramural Needle Ablation Catheter|
79236760|NCT03681431|Drug|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
79236761|NCT03681431|Drug|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
79236762|NCT03744741|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
79236763|NCT02925455|Device|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
79236764|NCT02925455|Device|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
79377316|NCT03003286|Behavioral|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
79531009|NCT03057652|Device|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
79531010|NCT03057652|Device|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
79687103|NCT05788094|Drug|Chloroquine plus Tafenoquine (450 mg adult dose)|"Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~Tafenoquine KOZENIS® 150 mg film-coated tablets will be purchased from GSK (Glaxo Smith Kline Pharmaceutical industry), 450 mg (3 tablets) will be given."
79687104|NCT05786482|Behavioral|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
79687105|NCT05786482|Behavioral|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
79687106|NCT05783908|Combination Product|With non-magnetic screen|Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing
79687107|NCT05779618|Other|no intervention|observational study, all data collected are binary
79829599|NCT00863590|Drug|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
79236765|NCT01563783|Procedure|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
79236766|NCT01563783|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
79236767|NCT01563783|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
79236768|NCT03689621|Device|Transcutaneous vagus nerve stimulation (tVNS)|
79236769|NCT03681197|Drug|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
79377317|NCT03003442|Dietary Supplement|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
79377318|NCT03003442|Dietary Supplement|Placebo|Placebo
79377319|NCT03003208|Other|Pulmonary rehabilitation|An exercise and education program
79829600|NCT00863590|Drug|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
79829601|NCT00735228|Device|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
79236770|NCT03681197|Drug|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
79236771|NCT03681197|Drug|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
79687108|NCT05776602|Diagnostic Test|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
79829602|NCT03843892|Drug|OFEV|twice daily
79829603|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
79377320|NCT05437354|Other|survey|Oncology medical staff should respond to a survey
79377321|NCT05431036|Device|transthoracic ultrasonography|"The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
79687112|NCT05756673|Drug|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
79829604|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
79829605|NCT00863668|Drug|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
79829606|NCT00863668|Drug|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
79236772|NCT03485703|Drug|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
79236773|NCT03485703|Drug|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
79531011|NCT03057652|Device|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
79829607|NCT00863668|Procedure|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
79829608|NCT00863668|Procedure|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
79829609|NCT00739206|Drug|SAR97276A|Dose based on body weight
79829610|NCT00735540|Other|Observational|Data summary only
79829611|NCT00739284|Device|nephrostomy tube and ureteral stent|
79829612|NCT00872248|Procedure|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
79236774|NCT03165344|Other|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
79236775|NCT03165344|Other|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
79236776|NCT03165344|Other|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
79236777|NCT03487029|Other|Short duration|exercise Short duration high intensity training
79236778|NCT03487029|Other|Long duration|exercise Long duration high intensity training
79377322|NCT03002896|Behavioral|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
79377323|NCT03002896|Other|Treatment as Usual|
79829613|NCT00872248|Procedure|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
79829614|NCT00732576|Dietary Supplement|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
79829615|NCT00732576|Dietary Supplement|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
79829616|NCT00732576|Dietary Supplement|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
79829617|NCT00863902|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
79377324|NCT02248168|Drug|Pramipexole|
79377325|NCT02248402|Biological|Vax-DC/MM|
79829618|NCT00863902|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
79829619|NCT00732732|Dietary Supplement|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
79829620|NCT00732732|Other|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
79531012|NCT03053713|Behavioral|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
79531013|NCT03053713|Behavioral|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
79687113|NCT05756673|Drug|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
79829621|NCT00732810|Drug|SCH 727965|SCH 727965 50 mg/m^2 IV on Day 1 of each 21 day cycle until disease progression.
79531014|NCT03008746|Other|water used for oral wash|
79377326|NCT05672446|Other|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
79531015|NCT03008746|Other|sputum|
79531016|NCT03008746|Other|oral wash|
79531017|NCT02980003|Drug|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
79531018|NCT02980003|Drug|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
79531019|NCT02980003|Drug|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
79531020|NCT02884323|Device|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
79236779|NCT03165578|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
79687114|NCT05756673|Drug|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
79687115|NCT05756673|Device|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
79236780|NCT03165578|Other|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
79687116|NCT05745935|Drug|Oxytocin|This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
79236781|NCT03486951|Procedure|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
79531021|NCT02786875|Other|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
79377327|NCT05672290|Other|Electrical stimulation 1|External electrical stimulation will be applied for 30 minutes 3 days a week during 6 weeks. Electrodes were placed around the pelvis.
79531022|NCT02786875|Other|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
79531023|NCT02786875|Behavioral|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
79687117|NCT05740813|Drug|ABBV-CLS-7262 Dose 1|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
79531024|NCT02786875|Behavioral|Basic physical activity|General recommendations for physical activity
79687118|NCT05740813|Drug|ABBV-CLS-7262 Dose 2|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
79687119|NCT05740813|Drug|Matching Placebo|Matching placebo is administered orally once per day for 24 weeks.
79829622|NCT00732810|Drug|Capecitabine|Capecitabine 1250 mg/m^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
79829623|NCT00732810|Drug|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
79829624|NCT00732888|Drug|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
79829625|NCT00732888|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
79829626|NCT00732966|Drug|losartan|with losartan 50 mg once daily for one month
79829627|NCT00732966|Drug|valsartan|valsartan 160 mg once daily
79236782|NCT03114878|Other|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
79377328|NCT05672290|Other|Electrical stimulation 2|External electrical stimulation will be applied for 30 minutes one day a week during 6 weeks. Electrodes were placed around the pelvis.
79531025|NCT02786875|Drug|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
79531026|NCT02786875|Drug|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
79531027|NCT02778256|Device|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
79531028|NCT02778256|Device|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
79531029|NCT02767882|Drug|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
80004315|NCT02123420|Device|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, St-Stevens-Woluwe, Belgium)."
79531030|NCT02767882|Drug|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
79531031|NCT02420184|Device|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
79531032|NCT02420184|Other|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
79531033|NCT02319408|Radiation|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
80004316|NCT02123498|Drug|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
80004317|NCT02123498|Drug|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
79531034|NCT02264223|Dietary Supplement|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
79531035|NCT02264223|Dietary Supplement|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
79531036|NCT02246257|Other|Simvastatin|LDL > 2.5 is treated with 40 mg
79531037|NCT02246257|Other|Losartan|BT > 140/90 mmHg treated with 50 mg OD
79531038|NCT02246257|Other|Losartan|DM BT > 130/80 mmHg treated with 50 mg OD
79531039|NCT02246257|Other|Losartan|Microalbuminuria (urinary albumin creatinin ratio > 30 mg) treated with 100 mg OD
79531040|NCT02246257|Other|Metformin|HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
79531041|NCT02246257|Other|Outpatient rheumatology department|(4 times yearly)
80004318|NCT02123498|Drug|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
80004319|NCT02123498|Procedure|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
79531042|NCT02246257|Other|Refered to general practice|
79531043|NCT02197221|Drug|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
79531044|NCT02197221|Drug|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
79531045|NCT02131779|Behavioral|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
79531046|NCT02131779|Behavioral|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
79531047|NCT02076958|Behavioral|Community Health Advisor education|
79531048|NCT02010385|Drug|Octreotide|
80004320|NCT02123498|Procedure|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
79531049|NCT02010385|Drug|Saline|
79531050|NCT01989299|Device|ILR implantation|
79531051|NCT01949714|Procedure|Removal of adrenal tumor|
79531052|NCT01079325|Drug|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
79531053|NCT01079325|Other|Saline|
79531054|NCT00704561|Device|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
79531055|NCT00704561|Device|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
79531056|NCT00704561|Device|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
79531057|NCT00704561|Device|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
79531058|NCT00223145|Radiation|Radiotherapy 70 Gy|Radiotherapy to the prostate
79531059|NCT00223145|Radiation|Radiotherapy 76 Gy|Radiotherapy to the prostate
79531060|NCT00223145|Drug|Androgen blockade|Duration : 6 months
79531061|NCT01425827|Drug|duloxetine HCL|60 mg/day duloxetine for 16 weeks
79531062|NCT01425827|Drug|placebo|similar looking tablets to the active agent for 16 weeks
79531063|NCT01425840|Drug|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
79531064|NCT01425905|Other|The Blues Program|
79531065|NCT01425905|Other|Hey Durham|
79531066|NCT01425918|Behavioral|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
79531067|NCT01425918|Behavioral|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
79377329|NCT02997124|Procedure|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
79531068|NCT01425931|Procedure|Heart Lung machine|measurement of microcirculation with O2C device
79687120|NCT05720000|Device|Photobiomodulation|Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
79687121|NCT05720000|Procedure|PDO thread|The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
79687122|NCT05718089|Other|Continuous aerobic exercise|"The Continuous aerobic exercise session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The  Continuous aerobic exercise intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
79829628|NCT00739440|Biological|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
80004321|NCT02237040|Procedure|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
79829629|NCT00735774|Drug|11C-ORM-13070|Single dose of i.v. solution
80004322|NCT02115776|Drug|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
79236783|NCT03114878|Behavioral|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
79236784|NCT03689465|Drug|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
79829630|NCT03901560|Other|Music Therapy|
79377330|NCT02997124|Procedure|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
79377331|NCT03002428|Drug|Teriparatide (PF708)|Subcutaneous injection
79377332|NCT03002428|Drug|Teriparatide (Forteo)|Subcutaneous injection
79829631|NCT00735852|Drug|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
79236785|NCT03689465|Drug|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
79377333|NCT03002584|Other|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
79377334|NCT03002662|Other|colonoscopy|
79377335|NCT02224612|Device|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
79377336|NCT02224612|Device|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
79377337|NCT02225860|Behavioral|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
79531069|NCT01425957|Procedure|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
79687123|NCT05718089|Other|High intensity interval training|"The High intensity interval training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The High intensity interval training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
79829632|NCT00739518|Procedure|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
79236786|NCT03689465|Drug|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
79236787|NCT03689465|Drug|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
79829633|NCT00424021|Drug|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
79236788|NCT03689465|Drug|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
79236789|NCT03485625|Drug|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
79531070|NCT01425983|Dietary Supplement|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
79687124|NCT05718089|Other|Resistance training|"The Resistance training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The Resistance training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
79687125|NCT05702515|Other|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
79687126|NCT05693077|Biological|10E4 NTCD spores|in capsule for oral ingestion.
79377338|NCT01377012|Biological|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
79377339|NCT01377012|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
79377340|NCT05672056|Procedure|Computer guided placement of a stock plate pre-bent on a 3D printed model|We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
79377341|NCT03371550|Drug|Docetaxel|Induction chemotherapy
79377342|NCT03371550|Radiation|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
79531071|NCT01425983|Other|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
79829634|NCT00733044|Behavioral|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
79829635|NCT00733044|Other|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
79829636|NCT00735930|Drug|Alvocidib Hydrochloride|Given IV
79829637|NCT00735930|Drug|Lenalidomide|Given PO
79829638|NCT00735930|Other|Pharmacological Study|Correlative studies
79829639|NCT00735930|Other|Laboratory Biomarker Analysis|Correlative studies
79377343|NCT03371550|Drug|Cisplatin|Induction chemotherapy
79829640|NCT03902262|Procedure|appendicectomy|
79829641|NCT00736008|Other|Observational|Data summary only
79829642|NCT00736086|Device|Vessel Closure (StarClose™)|
80004323|NCT02115776|Drug|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
79377344|NCT05671744|Other|Cell-based non-invasive prenatal testing|Blood sampling
79391145|NCT03106740|Other|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
79236790|NCT03485625|Drug|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
79531072|NCT01425996|Drug|Lipotecan® (TLC388)|"Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
79531073|NCT01426022|Other|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
79531074|NCT01426022|Behavioral|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
79531075|NCT01426048|Other|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
79236791|NCT03485625|Drug|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
79236792|NCT03685799|Diagnostic Test|Pathological revision|Pathological revision
79236793|NCT03114332|Procedure|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
79236794|NCT03680885|Drug|Lidocaine gel|Lidocaine gel 5%, PEG with FD&C Blue No.1 (Brilliant Blue FCF)
79377345|NCT03371472|Device|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
79236795|NCT03680885|Drug|Placebo|PEG with FD&C Blue No.1 (Brilliant Blue FCF)
80004324|NCT02115776|Drug|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
79236796|NCT03680885|Drug|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
79236797|NCT03114566|Other|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
79236798|NCT03689309|Procedure|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
79531076|NCT01426061|Other|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
79687127|NCT05693077|Biological|10E7 NTCD spores|in capsule for oral ingestion.
79377346|NCT03371394|Other|no intervention|no intervention
79377347|NCT02324920|Device|DDD-CLS|
79377348|NCT02324920|Device|ODO|
79377349|NCT03371316|Biological|ViaShield|Anti-adhesion scores using amnion patch
79377350|NCT03371238|Behavioral|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
79377351|NCT05671666|Diagnostic Test|Urea cycle flux study|Quantification of ureagenesis
79531077|NCT01426061|Other|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
79531078|NCT01426061|Other|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
79531079|NCT01426074|Drug|Bevacizumab 5 mg/kg|Intravenously every two weeks
79531080|NCT01426087|Drug|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
79531081|NCT01426087|Procedure|endoscopic therapy|gastroscope plus EIS/EVL/HI
79531082|NCT01426100|Drug|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
79531083|NCT01426100|Drug|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
79531084|NCT01426100|Drug|Telmisartan 80mg|Telmisartan 80mg monotherapy
79687128|NCT05693077|Other|placebo|in capsule for oral ingestion.
79687129|NCT05693077|Drug|Vancomycin Oral Capsule|4 times a day 250mg
79687130|NCT05692271|Drug|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
79687131|NCT05692271|Drug|Placebo|Matching placebo
80004325|NCT02856282|Drug|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
80004326|NCT02115854|Other|labial biopsy|
80004327|NCT02115932|Other|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
79531085|NCT01426126|Drug|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
79531086|NCT01426139|Device|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
79531087|NCT01426165|Drug|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
79531088|NCT01426178|Device|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
79236799|NCT03680807|Diagnostic Test|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
79236800|NCT03163862|Procedure|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
79687132|NCT05683925|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
79377352|NCT04527120|Other|indigenously developed ultrasound phantom (IDUP)|Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
79687133|NCT05683925|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
80004328|NCT03959319|Other|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
80004329|NCT03959319|Other|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
80004330|NCT02123654|Drug|Daclatasvir|
80004331|NCT02123654|Drug|Asunaprevir|
80004332|NCT02123654|Drug|DCV 3DAA|
80004333|NCT02123654|Other|Placebo for DCV 3DAA|
80004334|NCT02123654|Other|Placebo for Daclatasvir|
80004335|NCT02123654|Other|Placebo for Asunaprevir|
80004336|NCT03609138|Device|Spinal Hardware|Pedicle screws and patient specific rods
80004337|NCT02116010|Drug|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
80004338|NCT02116010|Drug|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
80004339|NCT02116010|Drug|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
80004340|NCT03609294|Drug|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
79236801|NCT03163862|Drug|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
79377353|NCT05670028|Drug|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
79377354|NCT03004378|Behavioral|Activity Tracker|Fitbit Alta
79377355|NCT03123900|Behavioral|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
79531089|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
79531090|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
79531091|NCT01426256|Dietary Supplement|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
79531092|NCT01426282|Other|no intervention|no intervention
80004341|NCT03609294|Drug|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
80004342|NCT05214495|Drug|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
80004343|NCT05214495|Drug|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
80004344|NCT03608904|Other|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
80004345|NCT03608904|Other|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
79531093|NCT01426282|Other|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
79687134|NCT05683925|Device|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
79687135|NCT05679726|Behavioral|massage|reflexology foot massage
79236802|NCT03163862|Drug|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
79687136|NCT05664711|Drug|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
79687137|NCT05652933|Diagnostic Test|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
79687138|NCT05651360|Diagnostic Test|low-dose CT|Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
79687139|NCT05648045|Behavioral|Behaviour intervention targeted for Lifestyle modification|An intervention to strengthen resilience that controls self-efficacy, self-esteem and optimism.
79687140|NCT05647889|Drug|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
79687141|NCT05647889|Combination Product|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
79687142|NCT05647889|Other|Standard PVC procedure|Standard PVC procedure will be applied
79687143|NCT05645341|Diagnostic Test|screening system for ocular surface malignant tumors|Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
79687144|NCT05634044|Device|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
79687145|NCT05631756|Other|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
79687146|NCT05622279|Procedure|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
79687147|NCT05606237|Device|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
79236803|NCT03685565|Procedure|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
79377356|NCT03123900|Behavioral|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
79377357|NCT03123900|Behavioral|Combined training|Subjects included in this group receive both types of intervention.
79687148|NCT05597345|Drug|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
79687149|NCT05576974|Drug|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
79687150|NCT05576129|Device|TGP-tACS|"38 min and 20s of 4mA peak-to-peak theta-gamma stimulation with 75 Hz-gamma coupled to the peak of 6Hz-theta waves. 3s ramp-up at the beginning of stimulation and 3s ramp-down at the end of stimulation.~Administered using a Starstim® device and 5 gel electrodes with a πcm² area."
79687151|NCT05576129|Device|Sham-tACS|38 min and 20s of alternation between 10s of 4mA peak-to-peak TGP- tACS and a 6 min 30s stimulation-free interval. Each stimulation consists of 3s ramp-up, 4s TGP stimulation and 3s ramp-down. Administered using a Starstim® device and 5 gel electrodes with a πcm² area.
79687152|NCT05551455|Other|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
79687153|NCT05551455|Other|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
79236804|NCT03685565|Procedure|Dermabond|Laceration repaired with Dermabond
79236805|NCT03163706|Behavioral|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
79236806|NCT03033069|Drug|Brexpiprazole|Brexpiprazole oral tablets.
79377358|NCT05669872|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
79377359|NCT05669872|Drug|RBC|pack RBC transfusion
79377360|NCT03124056|Device|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
79377361|NCT04861948|Drug|IBI188|intravenous
79377362|NCT04861948|Drug|GM-CSF|subcutaneous injection
79236807|NCT03033069|Drug|Sertraline|Sertraline oral capsules.
79236808|NCT03033069|Drug|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
79236809|NCT03033069|Drug|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
79377363|NCT04861948|Drug|Cisplatin/Carboplatin|intravenous
79377364|NCT04861948|Drug|Bevacizumab|intravenous
79829643|NCT00617734|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
79531094|NCT01426295|Device|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0."
79531095|NCT01426295|Drug|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
79531096|NCT01426321|Other|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
79531097|NCT01426334|Drug|dasatinib|Given PO
79531098|NCT01426334|Other|diagnostic laboratory biomarker analysis|Correlative studies
79687154|NCT05535361|Device|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
79687155|NCT05530863|Behavioral|Assisted Therapy|The participant will receive coaching calls and support
79687156|NCT05530863|Behavioral|Sleep Hygiene|Standard Sleep Hygiene instructions.
79687157|NCT05526469|Procedure|Serratus anterior plane block|patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
80004346|NCT03551990|Procedure|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
79377365|NCT04861948|Drug|Sintilimab|intravenous
79829644|NCT00617734|Biological|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
79687158|NCT05526469|Procedure|erector spinae plane blocks|patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
79687159|NCT05526469|Drug|Bupivacaine 0.25% Injectable Solution|Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
79687160|NCT05521568|Diagnostic Test|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
79829645|NCT00733122|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
79829646|NCT00733200|Procedure|Minor or Major Liver Resection|
79829647|NCT00877318|Device|SCAD information system|Cardiac rehabilitation at home by telemedicine
79377366|NCT04861948|Drug|Pemetrexed|intravenous
79377367|NCT04526496|Drug|FTP-198, single dose|Single dose of FTP-198, 6 dose levels, oral suspension
79377368|NCT04526496|Drug|Placebo, single dose|Placebo matched to FTP-198, oral suspension
79377369|NCT04526496|Drug|FTP-198, multiple doses|Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
79377370|NCT04526496|Drug|Placebo, multiple doses|Placebo matched to FTP-198, oral suspension, 7 days
79377371|NCT04856956|Other|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
79377372|NCT04526184|Procedure|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
79377373|NCT04856332|Other|Telepresence robot installed at child's home during parent's hospitalisation|Telepresence robot installed at child's home during parent's hospitalisation in long term protective isolation for maintaining parent-child ink (only children aged 15 years or less are concerned)
79377374|NCT04526262|Device|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
79531099|NCT01426334|Other|pharmacological study|Correlative studies
79531100|NCT01426334|Drug|cyclosporine|Given PO
79531101|NCT01426399|Drug|LC15-0444|LC15-0444 50mg qd (8 days once daily)
79531102|NCT01426399|Drug|Metformin|Metformin 1000 mg bid (8 days twice daily)
79531103|NCT01426399|Drug|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
79531104|NCT01426451|Other|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
79687161|NCT05521568|Diagnostic Test|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~Swab #1 will be used to perform the rapid antigen detection test (see below)~Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
79829648|NCT00577460|Drug|Pramipexole|Pramipexole ER 0.375 -4.5 mg
79829649|NCT00577460|Drug|Placebo|Placebo tablets identical to Pramipexole ER tablets
79829650|NCT00877396|Biological|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
79531105|NCT01426451|Other|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
79377375|NCT04526028|Drug|Fulvestrant Injectable Product|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
79377376|NCT04526028|Drug|Palbociclib|Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
79829651|NCT00877396|Biological|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
79829652|NCT00877474|Drug|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
79829653|NCT00872326|Procedure|Autologous Bone Marrow Mononuclear Cells|Infusion > 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
79377377|NCT04812184|Device|Tape Face Mask|Adding tape to face mask
79377378|NCT02518698|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
79377379|NCT04143490|Other|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
79377380|NCT03368274|Drug|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
79829654|NCT00736112|Other|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
79829655|NCT00736112|Procedure|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
79829656|NCT00736112|Procedure|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
79377381|NCT03361644|Behavioral|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
79531106|NCT01426464|Drug|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
79531107|NCT01426490|Dietary Supplement|Vitamin C|Vitamin C, 100 mg/d
79829657|NCT00863980|Drug|Micardis (Telmisartan)|40-80 mg/day oral administration
79829658|NCT00863980|Drug|Blopress (Candesartan)|8-12 mg/day oral administration
79829659|NCT00415519|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
79829660|NCT00415519|Drug|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
80004347|NCT03907917|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
79377382|NCT03361644|Behavioral|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
79391146|NCT02415972|Other|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
79531108|NCT01426490|Dietary Supplement|Vitamin B6|Vitamin B6, 50mg/d
79531109|NCT01426490|Dietary Supplement|Folic acid|Folic acid 400 microgram/d
79531110|NCT01426490|Dietary Supplement|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
79531111|NCT01426542|Drug|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
79531112|NCT01426542|Other|No medication, but routine heart surgery|No medication, but routine heart surgery
79531113|NCT01426568|Behavioral|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
79377383|NCT04765462|Biological|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10^6/kg, 1 x10^7/kg to 5x10^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
79531114|NCT01426607|Device|AMO|
79302677|NCT03215251|Other|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
79377384|NCT03361566|Behavioral|physical activity|3 different levels of physical activity
79377385|NCT03361566|Behavioral|energy intake|4 different types of energy intake
80004348|NCT01917552|Drug|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
79377386|NCT04666558|Other|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
79531115|NCT01426620|Dietary Supplement|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
79531116|NCT01426633|Drug|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
79531117|NCT01426646|Drug|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
80004349|NCT02120690|Device|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
79377387|NCT04666558|Other|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
79377388|NCT03361488|Other|Trained anesthesiogist|
79377389|NCT02247544|Drug|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
79377390|NCT03368040|Device|Tcore|Monitoring system to measure body temperature based on heat-flux technology
79531118|NCT01426646|Drug|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
79531119|NCT01426659|Behavioral|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
79687162|NCT05521568|Diagnostic Test|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
79377391|NCT03370848|Dietary Supplement|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
79377392|NCT03370848|Drug|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
79377393|NCT03367884|Procedure|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
79531120|NCT01426672|Other|Monovision Correction (with the help of glasses or contact lenses)|
79531121|NCT01426698|Procedure|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
79531122|NCT01426724|Drug|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
79531123|NCT01426737|Drug|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
79531124|NCT01426750|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
79687163|NCT05520034|Behavioral|Health Education|The participants will receive a 45mins, face-to-face group health education before discharge and during the 6th month by a nurse and a physiotherapist. Participants will be received refresher health education over the phone call , if the patient and family caregiver cannot come for any reason. They will also receive a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
79687164|NCT05517083|Diagnostic Test|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
79236810|NCT03689231|Other|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
79829661|NCT00736268|Behavioral|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
79829662|NCT00736268|Other|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
79829663|NCT01323907|Drug|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
79302678|NCT03315533|Drug|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
79829664|NCT01323985|Drug|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
79829665|NCT01323985|Drug|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
79829666|NCT02568176|Drug|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
79829667|NCT02568176|Drug|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
79302679|NCT03315533|Drug|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
79302680|NCT03315533|Drug|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
79829668|NCT02568176|Drug|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
79829669|NCT01033591|Behavioral|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
79829670|NCT01033591|Behavioral|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
79377394|NCT03367884|Radiation|Definitive radiotherapy|Definitive radiotherapy (70Gy)
80004350|NCT02120768|Procedure|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
80004351|NCT02120846|Other|Flywheel leg-press resistance exercise|
80004352|NCT03833817|Behavioral|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
80004353|NCT02116088|Behavioral|Teacher Coaching|
79377395|NCT03123432|Dietary Supplement|immunomodulating nutrients enriched diet|
79377396|NCT03123432|Dietary Supplement|standard diet|
79377397|NCT02248792|Drug|Methotrexate|
79377398|NCT03367728|Drug|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
79377399|NCT03367728|Drug|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
79391147|NCT03106818|Drug|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
79391148|NCT03106818|Drug|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
79687165|NCT05514340|Drug|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
79236811|NCT03163628|Biological|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
80004354|NCT05022771|Drug|PMG1015 Dose 1|Dose level 1 of PMG1015
79236812|NCT03685409|Drug|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
79236813|NCT03685409|Drug|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
79236814|NCT05147948|Behavioral|iACT for PTSD and Chronic Pain|The participants will go through internet-based Acceptance and Commitment Therapy which mainly involves: 1) Exercises focused on developing acceptance, defusion, and mindfulness skills; 2) Identification of personal values as well as valued steps and feared situations to approach during the program 3) Written exposure exercises focusing on the traumatic memory adapted from Written exposure therapy (WET) using an ACT-based framework. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
80004355|NCT05022771|Drug|PMG1015 Dose 2|Dose level 2 of PMG1015
79377400|NCT03361332|Other|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
79377401|NCT03370692|Other|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
79687166|NCT05514340|Drug|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
79687167|NCT05490511|Drug|Tacrolimus single dose|5 mg once
79687168|NCT05490511|Drug|Epidiolex single dose|Epidiolex 5 mg/kg
79687169|NCT05490511|Drug|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
79302681|NCT05002491|Other|High protein diet|Normal vs high protein dietary feeding
79377402|NCT02519634|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
79377403|NCT02519634|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
79687170|NCT05488067|Drug|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
80004356|NCT05022771|Drug|PMG1015 Dose 3|Dose level 3 of PMG1015
80004357|NCT05022771|Drug|PMG1015 Dose 4|Dose level 4 of PMG1015
80004358|NCT05022771|Drug|PMG1015 Dose 5|Dose level 5 of PMG1015
79377404|NCT02248870|Drug|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
79377405|NCT02248870|Drug|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
79377406|NCT03367650|Dietary Supplement|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
79391149|NCT03106818|Drug|conventional|only conventional post operative analgesics will be used
79531125|NCT01426776|Procedure|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
79531126|NCT01426802|Drug|vildagliptin|Drug 50mg vildagliptin bid
79531127|NCT01426815|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
79531128|NCT01426815|Drug|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
79531129|NCT01426841|Radiation|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
79531130|NCT01426880|Drug|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
79531131|NCT01426880|Drug|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
79687171|NCT05465434|Drug|Zinc Supplement|Zinc sulphate 50 mg
79687172|NCT05461326|Procedure|Quad tendon|quadriceps tendon autograft
79687173|NCT05461326|Procedure|BTB|patellar tendon autograft
79236815|NCT05146544|Other|Heart Rate Recording|During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
79236816|NCT03486795|Device|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
79531132|NCT01426906|Drug|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
79531133|NCT01426906|Drug|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
79531134|NCT01426919|Other|Head CT scan and blood draw within 12 hours of injury|
79687174|NCT05453227|Drug|Zinc|To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
79687175|NCT05451836|Other|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
79687176|NCT05451836|Other|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
79377407|NCT02993380|Dietary Supplement|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
80004359|NCT05022771|Drug|PMG1015 Dose 6|Dose level 6 of PMG1015
79377408|NCT02993380|Dietary Supplement|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
80004360|NCT05022771|Drug|Placebo|Placebo to match
79236817|NCT03486795|Device|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
80004361|NCT05022771|Drug|PMG1015 Dose 7|Dose level 7 of PMG1015
79236818|NCT03486795|Device|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
79236819|NCT02917265|Device|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
79377409|NCT03361254|Biological|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
79531135|NCT01426932|Other|Video recording of Head Impulse Test|Video recording of Head Impulse Test
79531136|NCT01426945|Genetic|protein expression analysis|
79531137|NCT01426945|Other|immunohistochemistry staining method|
79531138|NCT01426945|Other|laboratory biomarker analysis|
79531139|NCT01426971|Drug|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
80004362|NCT02116400|Other|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
79236820|NCT02917265|Device|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
79236821|NCT03486717|Device|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
79236822|NCT03163940|Behavioral|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
79377410|NCT04073056|Drug|Bupivacaine|Bupivacaine Hcl 0.25% Inj
79377411|NCT03361098|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
79531140|NCT01426971|Drug|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
79531141|NCT01426035|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
79531142|NCT01426984|Drug|methylphenidate|a capsule containing 20 mg
79531143|NCT01427010|Radiation|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography ([18F]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
79531144|NCT01427023|Device|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
79687179|NCT05437250|Drug|Non interventional study|CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
79687180|NCT05433688|Device|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
79687181|NCT05425251|Diagnostic Test|GFAP and UCH-L1|2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
79687182|NCT05423210|Combination Product|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
79687183|NCT05419362|Drug|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10^11 colony-forming units (CFU)
79687184|NCT05419362|Drug|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
80004363|NCT02116400|Other|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
79236823|NCT03486639|Other|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
79531145|NCT01427036|Procedure|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
80004364|NCT02116400|Biological|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
79687185|NCT05414812|Behavioral|Multi-component oncofertility care intervention|"The intervention includes:~Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
79687186|NCT05408780|Drug|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
79687187|NCT05374174|Diagnostic Test|Tardieu Scale for Spasticity|The clinician will rotate the elbow joint at various speeds while the participant sits relaxed.
79687188|NCT05365919|Other|Family Talk Intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
79687189|NCT05359731|Drug|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
79687190|NCT05359731|Drug|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
79236824|NCT03165500|Drug|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
79687191|NCT05355337|Drug|Pramipexole|9 weeks of treatment with Pramipexole
79687192|NCT05355337|Drug|Placebo|9 weeks of treatment with Placebo
80004365|NCT02732184|Drug|Co-ArgI-PEG modified human arginase I|
80004366|NCT02121080|Drug|REGN2222(SAR438584)|
80004367|NCT02121080|Drug|placebo|
80004368|NCT03608592|Biological|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
80004369|NCT03608592|Biological|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
79236825|NCT03165500|Drug|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
79236826|NCT03165500|Drug|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
79236827|NCT03165500|Procedure|Third molar extraction|Anxious patients in need of third molar extraction
79377412|NCT03361098|Drug|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
79377413|NCT03361098|Other|placebo exenatide|placebo b.i.d. exenatide
79377414|NCT03361098|Other|placebo dapagliflozin|placebo tablets dapagliflozin
79377415|NCT03367494|Diagnostic Test|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
79391150|NCT03181620|Other|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
79236828|NCT03163238|Drug|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
79236829|NCT03163238|Drug|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
79829671|NCT03899870|Procedure|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
80004370|NCT03552302|Behavioral|Yoga|"Yoga stretch warm-up exercise for 15 minutes.~Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~Great rest for 15 minutes"
79236830|NCT05150379|Other|Different exercises with their shoulders|"Y Balance Test~Shoulder rotator muscle isometric maximum strength~One handed medicine ball throw~Modified Closed Kinetic Chain Upper Extremity Stability Test"
79531146|NCT01427036|Procedure|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
80004371|NCT03827265|Device|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
80004372|NCT02720718|Device|Stratafix|
80004373|NCT02720718|Device|Vicryl|
80004374|NCT02123732|Dietary Supplement|DbXell|
79531147|NCT01427049|Device|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
79531148|NCT01427062|Other|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
79531149|NCT01427062|Other|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
79531150|NCT01427075|Procedure|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
79687193|NCT05348083|Procedure|ESPB|Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
79829672|NCT03899870|Drug|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil [5-FU] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
79236831|NCT05150379|Behavioral|SI-RSI questionnaire|French version of Shoulder Instability Return-to-Sport after Injury
79377416|NCT03370458|Dietary Supplement|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
79531151|NCT01427088|Device|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
79687194|NCT05341817|Drug|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
79687195|NCT05341817|Drug|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
80004375|NCT02123732|Dietary Supplement|Placebo|
79377417|NCT03370458|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
79687196|NCT05341232|Behavioral|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
80004376|NCT04059588|Drug|2141 V-11|intratumoral injection of 2141-V11
80004377|NCT02123810|Other|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
80004378|NCT03119701|Drug|Interferon Beta-1A|Lyophilisate for solution for injection.
79377418|NCT02519478|Behavioral|Helmetless Tackling Training (HuTT)|see previous sections
79531152|NCT01427114|Drug|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
79531153|NCT01427140|Other|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
79687197|NCT05341232|Behavioral|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
79687198|NCT05341232|Behavioral|Board Games|Participants will play board games with each other.
79687199|NCT05336435|Diagnostic Test|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
79829673|NCT03899870|Drug|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
79829674|NCT00741182|Drug|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
79829675|NCT00872404|Drug|CP-751,871|20mg/kg/3 weeks
79829676|NCT00423943|Drug|modafinil|200 milligrams daily dose
79829677|NCT00423943|Drug|Placebos|capsule containing placebo
79829678|NCT00736346|Behavioral|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
79829679|NCT00736346|Behavioral|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
79829680|NCT00736346|Drug|paroxetine|40 mg die, for 6 months
80004379|NCT03119701|Drug|Placebo|Lyophilisate for solution for injection as placebo.
80004380|NCT03717129|Drug|Genvoya Oral dose|Single Genvoya oral dose directly observed
79236832|NCT04461561|Genetic|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
79236833|NCT04059341|Device|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
79236834|NCT03486561|Drug|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
80004381|NCT03717129|Drug|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
80004382|NCT03551912|Procedure|Surgery|All patients coming for elective surgery
79531154|NCT01427140|Other|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
79531155|NCT01427153|Procedure|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
79531156|NCT01427153|Procedure|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
80004383|NCT02116478|Procedure|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
79531157|NCT01427166|Other|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
79531158|NCT01427192|Drug|acetazolamide|250 mg bid
79531159|NCT01427192|Other|Supplemental oxygen|Oxygen deliverded by nasal cannula
79531160|NCT01427192|Procedure|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
79829681|NCT00864058|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
79829682|NCT00864058|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
79829683|NCT00864136|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
79829684|NCT00864136|Drug|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
79829685|NCT00864136|Drug|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
79829686|NCT05742308|Behavioral|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
79829687|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
79829688|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
79829689|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
80004384|NCT02123888|Radiation|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
80004385|NCT03627039|Drug|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
80004386|NCT03627039|Drug|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
79687200|NCT05334173|Procedure|Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb|The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
79829690|NCT00864214|Drug|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
79236835|NCT03689153|Drug|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
79829691|NCT05742230|Drug|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
79829692|NCT05742230|Drug|blank control|standard treatment
79236836|NCT03689153|Drug|Placebo|Participants will receive matching placebo intravenously.
79829693|NCT00872482|Drug|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
79829694|NCT00428389|Drug|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
79829695|NCT00428389|Drug|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
79377419|NCT05594290|Drug|Retifanlimab|Retifanlimab i.v. 500 mg day 1
79377420|NCT05594290|Drug|Cisplatin|Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
79377421|NCT05594290|Drug|Etoposide|Etoposide 100 mg/sqm iv. day 1, 2, 3
79377422|NCT03370380|Drug|Aflibercept|Patients are treated according to authorization of Aflibercept
79377423|NCT03360864|Other|Education program|Patient will participate to a education program.
79377424|NCT03367416|Behavioral|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~educating executives on how to promote effective process change techniques~training staff teams in the theory and practice of organizational change techniques~training staff to develop and implement a process improvement intervention~implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
79377425|NCT04525170|Device|HPT treatment|
79377426|NCT04525170|Device|untreated|
79377427|NCT03360786|Other|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
79377428|NCT03360786|Other|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
79377429|NCT03367338|Other|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
79391151|NCT01592045|Biological|ch14.18 -NCI|25 mg/m^2/day IV for four consecutive days
79687201|NCT05301543|Behavioral|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
79687202|NCT05301543|Behavioral|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
79687203|NCT05296473|Device|ADHD Therapy|investigational game-play therapy
79829696|NCT00736424|Device|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
79829697|NCT00616642|Drug|rosiglitazone maleate|Given orally
79829698|NCT02568488|Drug|Metformin|850 mg orally twice daily for 6 months
79829699|NCT01324063|Biological|sargramostim|
79829700|NCT01324063|Drug|amsacrine|
79829701|NCT01324063|Drug|cytarabine|
79829702|NCT01324063|Drug|daunorubicin hydrochloride|
79829703|NCT01324063|Procedure|quality-of-life assessment|
79829704|NCT00923624|Other|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
79829705|NCT00923624|Behavioral|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
79829706|NCT03994549|Drug|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
79829707|NCT00736658|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
79829708|NCT00736658|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
79829709|NCT05225896|Genetic|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
79829710|NCT00872560|Device|NovoFine® needle 6 mm|
79829711|NCT00872560|Device|NovoFine® needle 8 mm|
79829712|NCT04645394|Dietary Supplement|Aronia melanocarpa|Administered once (acute study)
79829713|NCT04645394|Dietary Supplement|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
79829714|NCT04645394|Dietary Supplement|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
79829715|NCT04645394|Dietary Supplement|Placebo|Administered once (acute study)
79829716|NCT01589029|Drug|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
79829717|NCT00877786|Behavioral|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
79236837|NCT05123144|Behavioral|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
79531161|NCT01427192|Other|Room air|Room air applied via sham oxygen concentrator
79377430|NCT04523610|Behavioral|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
79531162|NCT01427192|Drug|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
79687204|NCT05296473|Device|Control Therapy|control game-play therapy
79829718|NCT02568332|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
79829719|NCT02568332|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
79829720|NCT01033669|Device|CRC-749|There is no drug being used. This is a device.
79829721|NCT01033669|Device|Diskus|There is no drug being used. This is a device.
79829722|NCT01033669|Device|Twisthaler|There is no drug being used. This is a device.
79829723|NCT01033669|Device|Miat Monohaler|There is no drug being used. This is a device.
79829724|NCT00872638|Procedure|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
79829725|NCT00872638|Procedure|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
79829726|NCT00877864|Behavioral|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
79829727|NCT00877864|Behavioral|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
79829728|NCT00877864|Behavioral|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
79377431|NCT04523610|Other|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
79377432|NCT04523610|Other|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
79391152|NCT01592045|Biological|ch14.18-UTC|17.5 mg/m^2/day IV for four consecutive days
79531163|NCT01427205|Drug|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
79531164|NCT01427205|Drug|OSI-906|150 mg by mouth twice a day.
79531165|NCT01427205|Other|Placebo|Placebo taken by mouth twice daily.
79829729|NCT00877864|Behavioral|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
79829730|NCT00877864|Behavioral|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
79829731|NCT00877864|Behavioral|Control|No exercise program provided by the study
79829732|NCT00736736|Other|Additional Hip Muscle Strengthening to Leg Press Exercise|
79829733|NCT00736736|Other|Leg Press Exercise|
79829734|NCT00864448|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
79829735|NCT00864448|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
79829736|NCT00406315|Drug|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
79829737|NCT05740904|Other|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
79829738|NCT05740904|Other|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
79687205|NCT05296317|Drug|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
79687206|NCT05296317|Drug|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
79829739|NCT00872716|Drug|Quetiapine XR|100 mg single-dose Quetiapine XR
79829740|NCT00872716|Other|Placebo|Placebo
79829741|NCT05740826|Device|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
79829742|NCT00864526|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
79829743|NCT00864526|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
79236838|NCT03685097|Diagnostic Test|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
79531166|NCT01427218|Other|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
79531167|NCT01427218|Behavioral|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
79829744|NCT02568410|Procedure|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
79531168|NCT01427218|Behavioral|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
79829745|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
79236839|NCT03165266|Diagnostic Test|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~. Right Ventricle fractional area change.~. Tricuspid annular plane systolic excursion .~. Tissue Doppler derived tricuspid annular systolic velocity.~. Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~Right ventricular basal, mid ,and longitudinal dimensions.~Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
79829746|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
79236840|NCT02533713|Device|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
79236841|NCT03680573|Drug|Control: Lacated Ringers|This site will serve as the control site
79236842|NCT03680573|Drug|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
79236843|NCT03680573|Drug|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
80004387|NCT01374373|Biological|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
80004388|NCT02116556|Drug|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
79236844|NCT03680573|Drug|BH4|This site will be use to locally supplement BH4.
79531169|NCT01427218|Other|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
79531170|NCT01427231|Dietary Supplement|glucose|The effect of a glucose solution on cognitive performance will be measured.
79236845|NCT03680573|Drug|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
79236846|NCT03680573|Drug|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
79377433|NCT02995174|Device|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
79377434|NCT02995174|Device|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
79377435|NCT03965104|Behavioral|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
79391153|NCT01592045|Biological|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m^2/day for 14 days during Courses 1, 3, and 5.
79531171|NCT01427231|Dietary Supplement|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
79531172|NCT01427231|Dietary Supplement|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
79687207|NCT05290090|Drug|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
79687208|NCT05279534|Dietary Supplement|Probiotic|Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
80004389|NCT02116556|Drug|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
80004390|NCT03634345|Drug|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
80004391|NCT03634345|Drug|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
80004392|NCT03634345|Drug|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
80004393|NCT02116634|Biological|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
79236847|NCT03680573|Drug|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
79531173|NCT01427244|Drug|trastuzumab|monoclonal antibody
79531174|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation A
79531175|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
79531176|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
79829747|NCT04064138|Procedure|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
79829748|NCT04064138|Procedure|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
79687209|NCT05279534|Other|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
79829749|NCT04064138|Other|General anesthesia|General anesthesia
79829750|NCT01323751|Drug|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
80004394|NCT02906137|Other|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
79236848|NCT05130645|Diagnostic Test|Mental Angle|In order to standardize and measure the mental angle, the projection of the mental will be accepted as the midline, the jaw structure will be transferred to the paper using the profile contour meter, and the angle between the angulus mandible and the mental will be measured and recorded with a digital protractor.
79531177|NCT01427270|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
79236849|NCT03689075|Drug|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
79377436|NCT03358446|Other|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
79377437|NCT03358446|Other|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
80004395|NCT02121314|Drug|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
79236850|NCT05015127|Drug|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
79687210|NCT05278741|Procedure|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months and six months : 2 questionnaires + two tests will be perfomed"
79687211|NCT05278260|Dietary Supplement|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
79687212|NCT05278260|Dietary Supplement|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
79829751|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose, 1 day
79829752|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
79829753|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
79829754|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
79377440|NCT03358368|Device|Vitalscan|Vitalscan is a magnetocardiograph device
79377441|NCT03367260|Other|Preference Elicitation|Survey of patient preferences for treatment
79377442|NCT03360552|Other|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
79377443|NCT03360552|Other|Usual care|Usual clinical evaluation
79531178|NCT01427270|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
79531179|NCT01427270|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
79531180|NCT01427283|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
79829755|NCT05741996|Behavioral|Taping|Taping types and brace acute effects for knee osteoartritis
80004396|NCT05760859|Other|Initial cue|"Symptom volunteered by the patient"
80004397|NCT03553238|Drug|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
80004398|NCT03553238|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
79531181|NCT01427283|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
80004399|NCT03553238|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
80004400|NCT03553238|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
79236851|NCT05015127|Drug|Placebo|Placebo
79236852|NCT05015127|Drug|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
79236853|NCT05015127|Drug|Placebo|Placebo qw by HBM9161 680mg qw from week 12
79829756|NCT00872794|Device|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
79687213|NCT05275725|Drug|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
79829757|NCT00878176|Procedure|First stage tined lead procedure|bilateral first stage tined lead placement
79829758|NCT00711594|Drug|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
80004401|NCT03553238|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
80004402|NCT03553238|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
80004403|NCT03553238|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
80004404|NCT03553238|Drug|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
79236854|NCT03680495|Drug|Methylprednisolone|1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
79236855|NCT02328885|Drug|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
79236856|NCT02178345|Procedure|diffusion weighted (DW) MRI|
79236857|NCT02178345|Procedure|dynamic contrast agent (DCE) MRI|
79236858|NCT03685019|Radiation|Valgus Stress|Valgus stress radiograph
79236859|NCT03685019|Radiation|Varus stress|Varus stress radiograph
79236860|NCT03685019|Radiation|0 degree flexion radiograph|0 degree flexion radiograph
79236861|NCT03685019|Radiation|20 degree flexion radiograph|20 degree flexion radiograph
79377444|NCT04525248|Procedure|Laparoscopic total colectomy + low resection of rectum|Laparoscopic total colectomy + low resection of rectum
79377445|NCT04525248|Procedure|Laparoscopic total colectomy + High resection of rectum|Laparoscopic total colectomy + High resection of rectum
79377446|NCT03367182|Drug|Weekly paclitaxel|Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
79377447|NCT03367182|Drug|Topotecan|Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
79377448|NCT03367182|Drug|Pegylated liposomal doxorubicin|Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks
79687214|NCT05266313|Behavioral|Oncosexology program|Thematic workshops throughout the year
79236862|NCT03685019|Radiation|45 degree flexion radiograph|45 degree flexion radiograph
79687215|NCT05260021|Drug|Tirzepatide Dose 1|Administered SC
79236863|NCT01997697|Other|behavior change program|behavior change program among patients with obesity
79377449|NCT03367182|Drug|Bevacizumab|Drug: bevacizumab [Avastin] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
79687216|NCT05260021|Drug|Tirzepatide Dose 2|Administered SC
79687217|NCT05260021|Drug|Placebo|Administered SC
79687218|NCT05259319|Drug|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
79687219|NCT05259319|Drug|Tiragolumab|Treatment given every 21 days during 24 months or until progression
79829759|NCT00711594|Drug|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
79829760|NCT00711594|Drug|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
79829761|NCT00711594|Drug|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
79829762|NCT02543866|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
79829763|NCT00872872|Drug|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
79829764|NCT00864760|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
79829765|NCT00864760|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
79829766|NCT00710762|Drug|BIBF1120|
80004405|NCT03553238|Drug|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
80004406|NCT03553238|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
80004407|NCT03553238|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
79236864|NCT03688997|Other|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
79236865|NCT03492255|Drug|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
79531182|NCT01427283|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
79531183|NCT01427322|Drug|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
79531184|NCT01427322|Radiation|Radiation therapy|Standard radiation therapy
79531185|NCT01427335|Drug|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
79531186|NCT01427335|Drug|0.9 % saline|0.9 % saline intravenous infusion
79531187|NCT01427348|Procedure|with assistant|head extension by an assistant during direct laryngoscopy
79531188|NCT01427348|Procedure|without assistant|without head extension by an assistant during direct laryngoscopy
79531189|NCT01427387|Drug|ASP0456|oral
79531190|NCT01427387|Drug|Placebo|oral
80004408|NCT03553238|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
80004409|NCT03553238|Procedure|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
80004410|NCT03553238|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
79377450|NCT03360474|Behavioral|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
79377451|NCT05561764|Drug|Imipenem/Cilastatin/Relebactam|Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
79377452|NCT03358212|Drug|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
79236866|NCT03492255|Drug|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone [750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
79236867|NCT03492255|Drug|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
79377453|NCT04521816|Behavioral|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~Improve Veteran and staff satisfaction~Objectives:~Maintain the patient in the home setting as much as possible~Secure appropriate home environment to facilitate health and well-being~Utilize comprehensive team-based care~Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
79377454|NCT03358134|Drug|Secukinumab|anti IL17 therapy (subcutaneous)
79377455|NCT04334668|Dietary Supplement|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
79377456|NCT04334668|Other|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
79377457|NCT03360318|Device|elbow cast|elbow cast
79377458|NCT03360318|Device|Removable elbow brace|Removable elbow brace
79377459|NCT03124134|Device|Gelesis200|Encapsulated hydrogel
79377460|NCT03124134|Other|Water, only (placebo)|300 mL of water
79531191|NCT01427400|Drug|Botulinum Toxin-A|100 Units diluted in 25cc saline
79531192|NCT01427400|Drug|Saline|Dispensed in a 25cc syringe
79531193|NCT01427426|Dietary Supplement|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
79531194|NCT01427426|Other|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
79829767|NCT00710762|Drug|Placebo|
79829768|NCT05137912|Biological|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
79531195|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Consult
79531196|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Control - Standard of Care
79531197|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Newsletter
79829769|NCT00736814|Drug|carboplatin|Given intravenously
80004411|NCT03553238|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
80004412|NCT03553238|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
80004413|NCT03553238|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
79236868|NCT03492255|Drug|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
79236869|NCT03684941|Device|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
79236870|NCT03684941|Device|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
79236871|NCT03684863|Drug|Capecitabine|observation
79377461|NCT04256980|Drug|Pemigatinib|Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
79377462|NCT04222270|Behavioral|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
79391154|NCT01592045|Biological|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m^2/day for the first week and at a dose of 4.5 MIU/m^2/day for the second week during Courses 2 and 4.
79531198|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Parent Letter
79531199|NCT01427478|Drug|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
79531200|NCT01427478|Drug|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
79531201|NCT01427491|Device|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
79829770|NCT00736814|Drug|docetaxel|Given intravenously
79829771|NCT00736814|Drug|gemcitabine hydrochloride|Given intravenously
79829772|NCT00736814|Drug|vinorelbine tartrate|Given intravenously
79829773|NCT04063904|Drug|Mifepristone|One 200 mg pill (oral)
79829774|NCT04063904|Drug|Misoprostol|Two 400 mcg pills (sublingual)
79829775|NCT00573430|Drug|Candesartan Cilexetil|8 mg oral once daily dose
80004414|NCT03553238|Diagnostic Test|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
79377463|NCT04522128|Behavioral|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
79236872|NCT04715997|Drug|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
79236873|NCT04715997|Drug|Placebo|Normal saline
79236874|NCT03680417|Biological|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
79236875|NCT05388513|Procedure|Surgical Resection|Surgically treated patients included
79236876|NCT03680339|Procedure|cesarean section|CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
79829776|NCT00573430|Drug|Candesartan Cilexetil|16 mg oral once daily dose
79829777|NCT00573430|Drug|Candesartan Cilexetil 32mg|32 mg oral once daily dose
79829778|NCT00711516|Drug|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
79829779|NCT00711516|Drug|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
79531202|NCT01427491|Device|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
79829780|NCT05741762|Other|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
79236877|NCT03680339|Drug|Misoprostol|The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
79829781|NCT00864838|Drug|Acetazolamide|250 mg 1 hour before intravitreal injection
79829782|NCT00864838|Drug|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
79531203|NCT01427530|Device|Deep Brain Stimulation|Deep Brain Stimulation
79236878|NCT03680339|Drug|Oxytocin|10 IU of oxytocin with fetal delivery
79236879|NCT04100057|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
79377464|NCT04193410|Behavioral|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
79531204|NCT01427543|Behavioral|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
79531205|NCT01427569|Drug|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
79531206|NCT01427569|Other|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
79687220|NCT05259319|Radiation|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
79687221|NCT05254886|Other|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~Report the presence of pre-existing comorbidities/EIMs~Detect the presence of risk factors~Implement recommendations for the detection and/or management of comorbidities/EIMs."
79687222|NCT05247853|Procedure|Blood collection|Blood collection at enrollment visit
79687223|NCT05247853|Procedure|Oral, cervicovaginal and anal specimen collection|Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits
79531207|NCT01427582|Drug|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
79531208|NCT01427621|Procedure|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
79531209|NCT01427634|Behavioral|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
79531210|NCT01427634|Other|Usual Care|Receive usual care as provided by the VAD clinical team.
79531211|NCT01427647|Procedure|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
79687224|NCT05247853|Procedure|Anoscopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH
79829783|NCT00864838|Procedure|Anterior chamber paracentesis|Immediately after bevacizumab injection
79531212|NCT01427660|Behavioral|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
79531213|NCT01427660|Behavioral|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
80004415|NCT03553238|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
79531214|NCT01427673|Procedure|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
79531215|NCT01427686|Drug|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
79531216|NCT01427686|Drug|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
79687225|NCT05247853|Procedure|Colposcopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV
79531217|NCT01427699|Drug|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
79687226|NCT05247853|Procedure|Ablative Treatment|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy
79687227|NCT05247853|Procedure|LEEP (Loop Electrosurgical Excision Procedure)|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
79829784|NCT05740748|Drug|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
79829785|NCT05740748|Drug|Placebo|placebo sc q4wks for 20 weeks
79829786|NCT00873028|Other|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
80004416|NCT03553238|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
80004417|NCT04980027|Drug|Insulin glargine (U300)|Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
80004418|NCT01373593|Drug|lidocaine|
80004419|NCT01373593|Drug|Placebo|
80004420|NCT04611477|Other|Rice Hulk|Placebo
80004421|NCT04611477|Other|Synbiotic365 Ver 5|Active Comparator
79302682|NCT03214861|Other|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
79302683|NCT02483351|Other|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
79302684|NCT02483351|Other|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of <=80g/L
79377465|NCT04190680|Behavioral|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
79687228|NCT05243966|Device|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
79687229|NCT05243680|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
79829787|NCT04039516|Drug|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
79829788|NCT00873106|Device|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
80004422|NCT04611477|Other|Synbiotic365 Ver 7|Active Comparator
80004423|NCT02116712|Drug|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
80004424|NCT02116790|Drug|Naproxen|Subjects will take one 250mg Naproxen capsule
80004425|NCT02116790|Drug|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
80004426|NCT02116790|Drug|Sinemet|Subjects will take one 25mg/100mg Sinemet.
80004427|NCT02116790|Drug|Placebo|Subjects will take two placebos.
80004428|NCT04675489|Other|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
80004429|NCT04935021|Drug|ATTR-CM|Current treatment
80004430|NCT02859961|Drug|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
80004431|NCT02859961|Drug|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
80004432|NCT02859961|Drug|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
79829789|NCT05741684|Behavioral|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
80004433|NCT02124200|Device|EGO/CE4, 9mg nicotine|
80004434|NCT02124278|Drug|PUL-042 Inhalation Solution|
80004435|NCT04503993|Other|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
80004436|NCT02116868|Device|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
80004437|NCT02116868|Drug|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
80004438|NCT02116868|Drug|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
80004439|NCT02679781|Drug|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
80004440|NCT02679781|Drug|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
80004441|NCT03551834|Other|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
79531218|NCT01427764|Device|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
79531219|NCT01427816|Drug|KCT-0809|
79531220|NCT01427816|Drug|KCT-0809|
79687230|NCT05242848|Behavioral|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is >13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
80004442|NCT03551834|Other|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
80004443|NCT03633877|Device|DuraporeTM and Hy-Tape®|Medical tapes
80004444|NCT02124356|Other|Evaluation of functional performance|
80004445|NCT04475133|Other|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
80004446|NCT02251730|Behavioral|Smoking cessation|Refer for smoking cessation
80004447|NCT02121548|Behavioral|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
80004448|NCT02121548|Behavioral|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
80004449|NCT02121704|Device|Magnetic Endoscope Imaging (Scope Guide)|
80004450|NCT04373031|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
80004451|NCT04373031|Drug|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
79305678|NCT02453633|Other|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
79531221|NCT01427816|Drug|Placebo|
79531222|NCT01427829|Behavioral|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
80004452|NCT02116946|Biological|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
79302685|NCT03075189|Dietary Supplement|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
79829790|NCT05741684|Behavioral|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
79687231|NCT05231915|Genetic|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
79687232|NCT05229770|Dietary Supplement|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
79829791|NCT00615550|Drug|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
79829792|NCT00615550|Drug|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
79829793|NCT04039594|Device|VA ECMO|VA ECMO for cardiopulmonary support
80004453|NCT02116946|Other|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
80004454|NCT03553160|Other|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
80004455|NCT02121782|Biological|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
80004456|NCT02121782|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
79302686|NCT05437835|Drug|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
79377466|NCT03358056|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
79377467|NCT02993458|Other|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
79377468|NCT02993458|Other|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
79531223|NCT01427842|Drug|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
79531224|NCT01427855|Other|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
79687233|NCT05215223|Device|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
80004457|NCT02117102|Other|Bladder and lumbar stimulation technic|
79377469|NCT02993458|Other|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
79236880|NCT04100057|Behavioral|Desensitization Therapy for insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
79531225|NCT01427855|Other|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
79531226|NCT01427855|Other|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
79531227|NCT01427855|Other|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
79531228|NCT01427855|Other|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
79531229|NCT01427855|Other|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
79687234|NCT05215223|Device|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
80004458|NCT04656847|Drug|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
79687235|NCT05214430|Other|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
79687236|NCT05206409|Diagnostic Test|Ultrasound|Fetal head position determination using ultrasound
79236881|NCT03680261|Radiation|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
79531230|NCT01427868|Drug|LB80380 maleate salt|183 mg (150 mg as a free base)
79531231|NCT01427868|Drug|LB80380 free base|150 mg
79687237|NCT05204290|Drug|Pembrolizumab|Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
79687238|NCT05204290|Radiation|Stereotactic Body Radiation Therapy|patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).
79687239|NCT05204290|Other|Blood draws|Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
80004459|NCT03553082|Drug|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
80004460|NCT03553082|Drug|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
80004461|NCT03318393|Drug|Bivalirudin|Continuous infusion
80004462|NCT03318393|Drug|Unfractionated heparin|Continuous infusion
80004463|NCT02117180|Other|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
79531232|NCT01427894|Other|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
79531233|NCT01427946|Drug|IPI-504|
79531234|NCT01427946|Drug|Everolimus|
79531235|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg~Mivacurium 200µg/kg immediately followed by~Fentanyl 2µg/kg"
79531236|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg~Fentanyl 2µg/kg, repeat max. two times~Mivacurium 200µg/kg"
79531237|NCT01427998|Dietary Supplement|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
79531238|NCT01427998|Other|placebo|placebo
79531239|NCT01428037|Drug|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
79531240|NCT01428037|Drug|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
79531241|NCT01427127|Drug|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
79531242|NCT01428050|Drug|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
79531243|NCT01428050|Drug|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
79531244|NCT01428154|Drug|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
79531245|NCT01428180|Drug|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
79531246|NCT01428180|Procedure|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
79531247|NCT01428180|Drug|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
79531248|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
79531249|NCT01428232|Other|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
79236882|NCT03680261|Drug|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
79236883|NCT03680183|Drug|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
79531250|NCT01428232|Other|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
79531251|NCT01428271|Other|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
79531252|NCT01428284|Drug|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
79531253|NCT01428297|Drug|BPR277 ointment (controlled application)|
79531254|NCT01428297|Drug|Placebo (Vehicle)|
79531255|NCT01428297|Drug|BPR277 ointment|
79531256|NCT01428297|Drug|Placebo (Vehicle)|
79531257|NCT01428297|Drug|BPR277|
79531258|NCT01428297|Drug|Placebo (Vehicle)|
79531259|NCT01428310|Dietary Supplement|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
79531260|NCT01428310|Dietary Supplement|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
79687240|NCT05202626|Diagnostic Test|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
80004464|NCT02117258|Drug|Z-360|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
80004465|NCT02117258|Drug|Placebo|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
80004466|NCT03110029|Drug|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
80004467|NCT03110029|Other|Application of Nail Polish|Application of Nail Polish
80004468|NCT04051749|Procedure|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
79236884|NCT02136069|Drug|Etrolizumab|105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
79236885|NCT02136069|Drug|Infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
79236886|NCT02136069|Other|Placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
79531261|NCT01428323|Device|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
79531262|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
79531263|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
79531264|NCT01428375|Drug|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
79531265|NCT01428375|Other|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
79531266|NCT01428388|Drug|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
79531267|NCT01428388|Drug|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
79531268|NCT01428401|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
79531269|NCT01428401|Other|Placebo|at a rate of 3 g three times per day
79236887|NCT02136069|Other|Placebo (Injection)|Administered by SC injection Q4W until Week 52
79236888|NCT02917031|Drug|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
79531270|NCT01428414|Drug|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
79531271|NCT01428414|Drug|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
79531272|NCT01428414|Drug|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
79531273|NCT01428414|Drug|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
79531274|NCT01428427|Drug|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
79531275|NCT01428427|Drug|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
79531276|NCT01428440|Radiation|18FML10|apoptosis imaging radio ligand
79531277|NCT01428466|Drug|GSK2585823|CLDM1%/BPO3%
79531278|NCT01428466|Drug|Benzoyl peroxide 3%|Benzoyl peroxide 3%
79531279|NCT01428466|Drug|Benzoyl peroxide 5%|Benzoyl peroxide 5%
79531280|NCT01428466|Other|Vehicle|placebo
80004469|NCT02122016|Device|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
80004470|NCT02122016|Other|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
79531281|NCT01428479|Drug|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
79687241|NCT05197426|Drug|Oral Azacitidine|Specified dose on specified days
80004471|NCT04858815|Behavioral|yogic breathing|participation in yogic breathing
80004472|NCT02122094|Behavioral|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
80004473|NCT02117336|Drug|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
80004474|NCT03552146|Drug|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
79687242|NCT05197426|Other|Placebo|Specified dose of specified days
79687243|NCT05193227|Drug|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
80004475|NCT03552146|Drug|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
80004476|NCT01374763|Drug|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
79687244|NCT05193227|Drug|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
79829794|NCT00873184|Behavioral|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
79377470|NCT02993458|Other|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
80004477|NCT01374763|Drug|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
80004478|NCT02117492|Procedure|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
79531282|NCT01428479|Drug|Placebo|Placebo solution will be administered intravenously.
79531283|NCT01428492|Drug|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
79531284|NCT01428492|Drug|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
79531285|NCT01428492|Drug|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
79531286|NCT01428505|Radiation|[18F]PBR111|radioligand to assess binding to TSPO
79531287|NCT01428518|Drug|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
79687245|NCT05188404|Behavioral|Choice of cannabis product|Participants choose and purchase their own cannabis product
79687246|NCT05158764|Device|Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification|Etiological treatment of venous disease of the lower limbs stage C6 / C6r
79687247|NCT05126082|Behavioral|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
79687248|NCT05125328|Drug|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate>100bpm and arterial blood pressure>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR<50bpm and ABP<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
80004479|NCT02340403|Procedure|NMR Spectroscopy|
80004480|NCT02122250|Behavioral|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
79236889|NCT02917031|Drug|Sitagliptin|50 mg or 100 mg, gray capsule
79377471|NCT03360084|Procedure|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
79377472|NCT03123666|Drug|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
79377473|NCT03123666|Other|Placebo|Placebo identical to GMCSF will be given
79531288|NCT01428531|Drug|Fondaparinux Sodium|
80004481|NCT02122250|Behavioral|Static web-based materials|Static web-based materials
79687249|NCT05124184|Device|GORE® PROPATEN® Vascular Graft|Patients that have had treatment with GORE® PROPATEN® Vascular Graft
79377474|NCT04160806|Device|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
80004482|NCT03608514|Drug|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
80004483|NCT03551756|Other|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
80004484|NCT04207749|Device|LID015385 contact lenses|Investigational soft contact lenses
80004485|NCT04207749|Device|Comfilcon A contact lenses|Commercially available soft contact lenses
80004486|NCT04207749|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
79829795|NCT05127538|Diagnostic Test|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
79377475|NCT03357978|Diagnostic Test|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
79377476|NCT03357978|Diagnostic Test|blood draw|Blood samples are taken from sober patients
79377477|NCT03357978|Diagnostic Test|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
79377478|NCT03357978|Diagnostic Test|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
79531289|NCT01428544|Drug|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
80004487|NCT02237274|Other|High altitude exposition|High altitude exposition
80004488|NCT02117726|Drug|Dexmedetomidine,midazolam|
79531290|NCT01428570|Device|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
79531291|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ lower dose (10^8 TU) at weeks 0, 8 and 16.
79531292|NCT01428596|Biological|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
79531293|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ higher dose (10^9 TU) at weeks 0, 8 and 16.
79531294|NCT01428609|Procedure|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
79531295|NCT01428622|Device|Respimat|aqueous and ethanolic solution
79531296|NCT01428622|Device|Respimat|aqueous and ethanolic solution
79531297|NCT01428622|Device|Respimat|aqueous and ethanolic solution
80004489|NCT02117726|Drug|Propofol,midazolam|
80004490|NCT04125342|Device|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
79531298|NCT01428622|Device|Respimat|aqueous and ethanolic solution
80004491|NCT04125342|Device|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
80004492|NCT03551678|Device|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
80004493|NCT02733432|Drug|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
80004494|NCT02733432|Drug|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
80004495|NCT02733432|Drug|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
80004496|NCT02733432|Drug|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
79236890|NCT02917031|Drug|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
79236891|NCT02917031|Drug|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
79236892|NCT03485235|Procedure|D&C|Dilatation and curettage
79236893|NCT03485235|Procedure|ICSI|Intra Cytoplasmic Sperm Injection
79236894|NCT04654455|Other|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
79236895|NCT04460547|Drug|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
79531299|NCT01428622|Device|Respimat|aqueous and ethanolic solution
79531300|NCT01428622|Device|Respimat|aqueous and ethanolic solution
79531301|NCT01428622|Device|Respimat|aqueous and ethanolic solution
79531302|NCT01428622|Drug|Olodaterol|aqueous solution
79531303|NCT01428622|Drug|Olodaterol|aqueous solution
79531304|NCT01428622|Drug|Olodaterol|aqueous solution
79531305|NCT01428622|Drug|Olodaterol|aqueous solution
79531306|NCT01428622|Drug|Olodaterol|aqueous solution
79531307|NCT01428622|Drug|Olodaterol|aqueous solution
79687250|NCT05124184|Device|GORE-TEX® Vascular Grafts|Patients that have had treatment with GORE-TEX® Vascular Grafts
79687251|NCT05112900|Behavioral|Text Messaging (TM)|[see arm/group descriptions]
79687252|NCT05112900|Behavioral|Text Messaging + Health Navigation (TM+HN)|[see arm/group descriptions]
79687253|NCT05097599|Drug|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
79236896|NCT04460547|Drug|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
79687254|NCT05097599|Drug|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
79687255|NCT05097599|Drug|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
79377479|NCT03357978|Diagnostic Test|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
79377480|NCT03109392|Drug|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
79377481|NCT03109392|Drug|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
79687256|NCT05097599|Drug|fam-trastuzumab deruxtecan-nxki|This arm of the Strata PATH trial will assess the clinical benefit of Enhertu® (fam-trastuzumab deruxtecan-nxki) in patients with advanced solid tumors harboring HER2 over-expression, as detected by Strata testing (HER2 Expression Score positive [HER2 ES-positive]), excluding breast cancer, gastric cancer, or gastroesophageal junction (GEJ) cancer.
79236897|NCT04460547|Drug|DAS181|DAS181 administration to COVID-19 infected patients.
79687257|NCT05097599|Drug|enfortumab vedotin|This arm of the Strata PATH trial will assess the clinical benefit of Padcev® (enfortumab-vedotin) in patients with advanced solid tumors and are Nectin-4 Expression Score High (Nectin-4 ES-H), as detected by Strata testing, excluding urothelial cancer.
79829796|NCT05127538|Diagnostic Test|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
79236898|NCT04460547|Drug|Ivermectin|Ivermectin administration to COVID-19 infected patients.
79377482|NCT03109392|Drug|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
79531308|NCT01428622|Drug|Olodaterol|aqueous solution
79531309|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79531310|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79531311|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79531312|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79687258|NCT05097599|Drug|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
79829797|NCT00736164|Dietary Supplement|selenomethionine|Given orally
79829798|NCT00736164|Other|placebo|Given orally
79829799|NCT00739830|Drug|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
79829800|NCT00739830|Drug|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
80004497|NCT02733432|Drug|Fluconazole|oral fluconazole (150mg) on Day 1
79236899|NCT04460547|Drug|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
79236900|NCT03132051|Drug|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
79236901|NCT03684707|Drug|Metformin Hcl 500Mg 24Hr Sa Tab|Glucophage 500 mg once daily
79236902|NCT03684707|Other|starch tablet|starch tablets
79377483|NCT03357900|Device|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
79377484|NCT03360006|Drug|ABBV-744|Tablet, oral
79377485|NCT04525326|Drug|Cetuximab|mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
79377486|NCT04525326|Drug|Bevacizumab|mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
79377487|NCT04525326|Drug|mFOLFOX/FOLFIRI ( Standard Chemotherapy)|Standard Chemotherapy
79377488|NCT03367104|Device|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
79377489|NCT03359928|Behavioral|Boxing|as already discussed
79377490|NCT03359928|Behavioral|Stair stepping|as already discussed
79377491|NCT03359928|Behavioral|Stair climbing|as already discussed
79377492|NCT03357822|Drug|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
79377493|NCT03357822|Drug|Entecavir|0.5mg entecavir is orally taken every day
79531313|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79531314|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79531315|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
79531316|NCT01428622|Drug|BI54903|ethanolic solution
79531317|NCT01428622|Drug|BI54903|ethanolic solution
79531318|NCT01428622|Drug|BI54903|ethanolic solution
79531319|NCT01428622|Drug|BI54903|ethanolic solution
79531320|NCT01428622|Drug|BI54903|ethanolic solution
79531321|NCT01428622|Drug|BI54903|ethanolic solution
79531322|NCT01428622|Drug|BI54903|ethanolic solution
79531323|NCT01428648|Behavioral|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
79829801|NCT00739830|Drug|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
79687259|NCT05097599|Drug|pembrolizumab|This arm of the Strata PATH trial will assess the clinical benefit of pembrolizumab in patients with advanced solid tumors and are Immunotherapy Response Score High (IRS-H), as detected by Strata testing, excluding approved pembrolizumab indications.
79687260|NCT05097599|Drug|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
79829802|NCT05111782|Other|Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach|Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
79829803|NCT00577382|Drug|Sunitinib|
79829804|NCT00733434|Drug|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
79829805|NCT00733434|Other|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
79829806|NCT04039282|Device|myfood24|online website for dietary analysis
79829807|NCT00736320|Drug|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
79377494|NCT03357822|Drug|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
79531324|NCT01428141|Drug|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
79377495|NCT03367026|Drug|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
79377496|NCT05445934|Drug|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
79531325|NCT01428687|Behavioral|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
79531326|NCT01428687|Behavioral|No change in sleep|This group is taught to maintain their current sleep habits.
79531327|NCT01428726|Drug|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
79531328|NCT01428739|Device|MRS|Procedure
79531329|NCT01428804|Device|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
79687261|NCT05097144|Device|Lens A (fanfilcon A)|Daily wear for one month
79687262|NCT05097144|Device|Lens B (asmofilcon A)|Daily wear for one month
79687263|NCT05068947|Drug|GV101|GV101 administered once orally.
79829808|NCT00736320|Radiation|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
79829809|NCT00878566|Other|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
79377497|NCT05445934|Drug|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
79377498|NCT03366948|Other|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
79377499|NCT03357744|Other|distress barometer|not applicable, observational study
79377500|NCT03359772|Other|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
79377501|NCT03542500|Behavioral|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
79531330|NCT01428817|Drug|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
79531331|NCT01428817|Drug|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
79531332|NCT01428817|Drug|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
79687264|NCT05068947|Drug|Placebo|Matched placebo
79687265|NCT05058196|Radiation|Whole breast radiotherapy|Whole breast radiotherapy after surgery
79687266|NCT05058196|Radiation|Intra Operative Radiotherapy|Intra Operative Radiotherapy
79687267|NCT05058157|Dietary Supplement|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
79687268|NCT05048719|Drug|LY3502970|Administered orally
79687269|NCT05048719|Drug|Dulaglutide|Administered subcutaneously
79687270|NCT05048719|Drug|Placebo|Administered orally
79829810|NCT00878566|Other|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
79829811|NCT04065282|Drug|Sintilimab|3 cycles before radical surgery
79829812|NCT04065282|Drug|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
79829813|NCT04065282|Drug|Capecitabine|1000mg/m2 bid po D1~14 Q3W, 3 cycles perioperation
79829814|NCT00873262|Drug|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
79829815|NCT00873262|Drug|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
79236903|NCT03688841|Device|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
79236904|NCT03688841|Device|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
79236905|NCT03684551|Other|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
79377502|NCT03542500|Behavioral|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
79829816|NCT00736970|Drug|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
79829817|NCT00736970|Drug|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
79829818|NCT00879736|Behavioral|THT PACE Training|Patient training
79829819|NCT00879736|Behavioral|THT PACE Training|Patient training
79829820|NCT00879736|Other|placebo|
79829821|NCT00873340|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
79377503|NCT03366870|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
79829822|NCT00740064|Drug|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
79377504|NCT03366870|Behavioral|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
79531333|NCT01428817|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
79531334|NCT01428817|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
79829823|NCT00736398|Procedure|Spinal fusion|Spinal fusion
79531335|NCT01428830|Procedure|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
79687271|NCT05048719|Drug|Placebo|Administered subcutaneously
79687272|NCT05048498|Drug|NEX-18a injection|"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."
79687273|NCT05048498|Drug|Azacitidine Injection|In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
79829824|NCT00614926|Drug|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
80004498|NCT03634189|Drug|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
79829825|NCT00614926|Drug|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
79829826|NCT00873418|Behavioral|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
79829827|NCT00873496|Drug|Hydroxychloroquine|
80004499|NCT02117804|Other|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
80004500|NCT03043365|Drug|control fish oil|4 capsules, 3 times a day after meals
80004501|NCT03043365|Drug|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
79377505|NCT02248948|Dietary Supplement|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
79236906|NCT03684551|Other|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
79236907|NCT03684551|Other|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
79377506|NCT02248948|Dietary Supplement|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
79531336|NCT01428830|Procedure|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
79377507|NCT03359694|Drug|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
79531337|NCT01428843|Drug|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
80004502|NCT03608046|Drug|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
79377508|NCT03359694|Drug|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
79377509|NCT03359694|Drug|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
79377510|NCT03407716|Drug|American Ginseng|Given PO
79377511|NCT03407716|Other|Laboratory Biomarker Analysis|Correlative studies
79377512|NCT03407716|Other|Placebo|Given PO
79377513|NCT03407716|Other|Questionnaire Administration|Correlative studies
79531338|NCT01428843|Drug|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
79531339|NCT01428908|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
79829828|NCT04040140|Other|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
80004503|NCT03608046|Drug|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
80004504|NCT03608046|Drug|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
79377514|NCT03359616|Procedure|Transanally curable surgical resection|Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
79377515|NCT03359616|Procedure|Laparoscopic total mesorectal excision|Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
79377516|NCT02227810|Other|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
79531340|NCT01428908|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
79531341|NCT01428908|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
79531342|NCT01428908|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
79829829|NCT00879892|Drug|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
79829830|NCT00879892|Other|Hypothermia|24 hour, target core temperature 33
79829831|NCT00873574|Biological|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
80004505|NCT02122484|Drug|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
80004506|NCT04051515|Other|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
80004507|NCT04051515|Other|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
80004508|NCT02251574|Other|Low Calorie Diet|Weight management program designed around a low calorie diet.
80004509|NCT02251574|Other|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
79531343|NCT01428921|Behavioral|Theory based education and brief motivation interview|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
79829832|NCT00878956|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
80004510|NCT02251574|Other|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
80004511|NCT03108157|Procedure|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
80004512|NCT03608124|Behavioral|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
79236908|NCT03680027|Dietary Supplement|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
79236909|NCT01018563|Drug|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
79531344|NCT01428947|Procedure|Arterial approach|Randomization to right radial or femoral approach
79687274|NCT05030207|Diagnostic Test|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
79687275|NCT05030207|Diagnostic Test|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
79687276|NCT05028114|Drug|AC-1202|Tricaprilin formulated as AC-1202
79236910|NCT03679871|Other|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
79236911|NCT02528188|Drug|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
79236912|NCT02528188|Biological|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
79236913|NCT02528188|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
79236914|NCT03684395|Drug|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
79377517|NCT02227810|Other|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
79377518|NCT02227810|Other|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
79377519|NCT03357666|Drug|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
79377520|NCT03357666|Drug|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
79377521|NCT03357666|Drug|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
79377522|NCT03357666|Drug|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
79687277|NCT05028114|Drug|AC-OLE-01|Tricaprilin Formulation
79687278|NCT05028114|Drug|AC-OLE-02|Tricaprilin Formulation
79687279|NCT05028114|Drug|AC-OLE-03|Tricaprilin Formulation
79687280|NCT05028114|Drug|AC-OLE-04|Tricaprilin Formulation
79829833|NCT00878956|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
79829834|NCT00740142|Drug|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
79829835|NCT00740142|Drug|placebo and lactulose|placebo 3 times a day for 7 days
79829836|NCT00873652|Biological|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
80004513|NCT04051437|Procedure|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
80004514|NCT04051437|Drug|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
79236915|NCT03684395|Drug|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
79302687|NCT03075033|Device|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
79687281|NCT05028114|Drug|AC-OLE-05|Tricaprilin Formulation
79687282|NCT05028114|Drug|AC-OLE-06|Tricaprilin Formulation
79687283|NCT05028114|Drug|AC-OLE-07|Tricaprilin Formulation
79531345|NCT01428960|Dietary Supplement|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
79687284|NCT05028114|Drug|AC-OLE-08|Tricaprilin Formulation
79687285|NCT05028114|Drug|AC-OLE-09|Tricaprilin Formulation
79829837|NCT02568774|Other|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
79829838|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
79236916|NCT04050137|Other|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
79236917|NCT04460391|Behavioral|Intensive rehabilitation|Early standing training and routine rehabilitation
79829839|NCT04039048|Device|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
79829840|NCT04039048|Device|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
79829841|NCT04039048|Other|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
79829842|NCT00423319|Drug|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
79829843|NCT00423319|Drug|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
79829844|NCT00423319|Drug|Enoxaparin-matching placebo|Administered as injection
79829845|NCT00423319|Drug|Apixaban-matching placebo|Administered as oral tablets
79377523|NCT03357666|Drug|Placebo|Vaginal administration, two tablets once a day for 7 days
79377524|NCT03366714|Device|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
79377525|NCT03366714|Device|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
79531346|NCT01428986|Drug|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
79531347|NCT01428999|Dietary Supplement|probiotics|probiotics 1 pack (2g) bid for three weeks
79531348|NCT01429012|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
79531349|NCT01429012|Other|Culture medium without MSC.|2 ml of culture medium.
79531350|NCT01429025|Biological|rituximab|IV
79531351|NCT01429025|Drug|bendamustine|IV
79531352|NCT01429025|Drug|lenalidomide|PO
79531353|NCT01429090|Procedure|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
79829846|NCT05224492|Drug|Sulforaphane|40 mg of Sulforaphane powder once daily.
79302688|NCT03075033|Device|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
79391155|NCT01592045|Drug|Isotretinoin|"Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight > 12 kg: 80 mg/m^2/dose twice daily (total daily dose is 160 mg/m^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily)."
79391156|NCT03181230|Other|No intervention|No intervention
79391157|NCT03178968|Other|Orange juice|3 immersion times in orange juice were investigated
79531354|NCT01429090|Drug|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
79531355|NCT01429090|Drug|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
79687286|NCT05028114|Drug|AC-OLE-010|Tricaprilin Formulation
79687287|NCT05028114|Drug|AC-OLE-P|Placebo to tricaprilin formulation
79687288|NCT05020197|Diagnostic Test|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
79829847|NCT05224492|Other|Placebo|Placebo
79829848|NCT00733668|Drug|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
79829849|NCT00879112|Drug|MB07811|Oral
79829850|NCT00879112|Drug|Placebo|Oral
80004515|NCT02122874|Device|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
80004516|NCT02122874|Other|1200 Kcal diet|
80004517|NCT03619993|Device|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
80004518|NCT03619993|Device|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
79531356|NCT01429090|Procedure|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
79687289|NCT05017779|Behavioral|Unstuck & On Target: High School|Unstuck & On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
79829851|NCT00736710|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
79829852|NCT00736710|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
80004519|NCT02124590|Other|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
79377526|NCT03357432|Other|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
80004520|NCT02124590|Other|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
80004521|NCT02124668|Drug|Enzalutamide|oral
79236918|NCT04059497|Behavioral|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
79236919|NCT04059497|Behavioral|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
79236920|NCT04460001|Drug|Ranibizumab|Intravitreal
79236921|NCT04460001|Drug|Ranibizumab|Intravitreal
79236922|NCT04460001|Drug|triamcinolone acetate|intravitreal
79377527|NCT03357354|Behavioral|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
79377528|NCT03350620|Drug|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
79377529|NCT03350620|Drug|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
79377530|NCT03350620|Drug|Placebo|Vehicle (placebo) will be administered, once daily (QD)
79377531|NCT03123276|Drug|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
79377532|NCT03123276|Drug|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
79377533|NCT03366558|Diagnostic Test|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
79531357|NCT01429090|Procedure|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
79531358|NCT01429090|Procedure|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
79531359|NCT01429116|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
79531360|NCT01429129|Drug|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
79531361|NCT01429142|Behavioral|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
79236923|NCT03486483|Other|Exercise|Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
79302689|NCT03107143|Device|Q2 System|
79829853|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
79687290|NCT05017779|Other|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
79236924|NCT03896165|Other|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
79531362|NCT01429142|Behavioral|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
79829854|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
79829855|NCT00880126|Behavioral|Community Development Teams|CDTs bring together counties who are implementing a new practice
79687291|NCT05009862|Drug|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
79687292|NCT05009862|Drug|Placebo|placebo
79687293|NCT05009862|Drug|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
79531363|NCT01429155|Genetic|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
79531364|NCT01429181|Drug|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
79531365|NCT01429194|Procedure|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
80004522|NCT02117960|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
79687294|NCT05003180|Procedure|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
79829856|NCT00880204|Behavioral|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
79829857|NCT00873808|Drug|clodronate disodium|
79829858|NCT00873808|Drug|demeclocycline hydrochloride|
79829859|NCT00873808|Drug|ibandronate sodium|
79531366|NCT01429246|Dietary Supplement|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
79829860|NCT00873808|Drug|tetracycline hydrochloride|
79531367|NCT01429246|Dietary Supplement|Salt Substitute|Estimated 30 grams per day per household member
79687295|NCT04994886|Procedure|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
79687296|NCT04972227|Drug|CY6463|oral tablets
79687297|NCT04972227|Drug|Placebo|oral tablets
79829861|NCT00873808|Drug|zoledronic acid|
79829862|NCT00873808|Other|laboratory biomarker analysis|
79829863|NCT00873808|Procedure|adjuvant therapy|
79829864|NCT00873808|Procedure|computed tomography|
79829865|NCT00873808|Procedure|dual x-ray absorptiometry|
79829866|NCT04064190|Drug|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
79829867|NCT00873886|Drug|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
79829868|NCT00873886|Procedure|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
79829869|NCT00736788|Drug|AZD1704|single dose oral suspension, 4 different dose levels
79829870|NCT00736788|Drug|Placebo|single dose oral suspension
79829871|NCT00740454|Other|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
80004523|NCT02117960|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
80004524|NCT03606018|Drug|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
79531368|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
79531369|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
79687298|NCT04962997|Other|Data collection|"Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient."
79236925|NCT04459923|Procedure|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
79687299|NCT04954001|Drug|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
79687300|NCT04949802|Device|ViaLase Laser|ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
79829872|NCT00880282|Biological|cixutumumab|Given IV
79687301|NCT04945915|Other|blood sampling|There was no intervention because this reasearch is observational study.
79236926|NCT04459923|Procedure|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
79236927|NCT03679793|Procedure|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
79236928|NCT03679793|Procedure|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
79377534|NCT03366558|Diagnostic Test|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
79687302|NCT04938583|Biological|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
79687303|NCT04938583|Drug|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
79377535|NCT03359382|Other|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
79531370|NCT01429363|Procedure|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
79687304|NCT04938583|Drug|Paclitaxel|175 mg/m^2, Day 1 x 6 cycles (every 21 days)
79687305|NCT04938583|Drug|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
79687306|NCT04925856|Other|blood sample|"•Blood sample:~1 heparinized tube (4 mL) for collection of plasma and storage~1 heparinized tube (4 mL) for immunophenotyping,~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
79687307|NCT04918082|Other|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
79829873|NCT00880282|Drug|temsirolimus|Given IV
79829874|NCT00880282|Other|pharmacological study|Correlative studies
79829875|NCT00880282|Other|laboratory biomarker analysis|Correlative studies
79829876|NCT00740532|Genetic|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
79687308|NCT04913142|Other|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
79236929|NCT03679715|Other|participatory art-based activity|"The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work.~In Montreal, Canada, participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops.~In Tokyo, Japan, participants will meet once per week for a 2h workshop at the Tokyo Fuji Museum in a dedicated room during a three month-period defining a session. The session will be composed of 12 consecutive workshops."
79829877|NCT00879268|Device|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
80004525|NCT03606018|Drug|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
79236930|NCT03486405|Other|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
79305679|NCT02453633|Other|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
79531371|NCT01429376|Other|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
79687309|NCT04888416|Behavioral|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
79687310|NCT04878575|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
79829878|NCT05741268|Behavioral|Dialectical behavior therapy|14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
79829879|NCT00879346|Drug|AZD8931|160mg oral single dose (4 x 40mg tablets)
79829880|NCT00874042|Drug|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
79687311|NCT04878575|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
79829881|NCT00736866|Drug|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
79829882|NCT00736866|Drug|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
79829883|NCT00879424|Dietary Supplement|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
79829884|NCT00879424|Dietary Supplement|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
79377536|NCT03855904|Device|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
79377537|NCT03357276|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
79829885|NCT00710684|Drug|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
80004526|NCT01373749|Drug|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
79531372|NCT01429376|Other|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
79531373|NCT01429376|Other|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
79531374|NCT01429376|Other|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
79829886|NCT00710684|Drug|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
79829887|NCT00710684|Drug|Placebo|Placebo added to existing donepezil
79829888|NCT00710684|Drug|donepezil 5-10mg|existing donepezil treatment
79829889|NCT00874198|Procedure|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
79829890|NCT00740688|Procedure|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
79829891|NCT00740688|Procedure|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
79829892|NCT00710606|Drug|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
79829893|NCT00710606|Drug|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
79829894|NCT00713544|Drug|AZD5672|20 mg oral, once daily
80004527|NCT01373749|Drug|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
80004528|NCT02035254|Other|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
79377538|NCT04524936|Diagnostic Test|blood sample|
79829895|NCT00713544|Drug|Etanercept|50 mg, subcutaneous injection, weekly
80004529|NCT03551600|Procedure|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
80004530|NCT04505605|Other|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
79377539|NCT04524780|Device|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
79377540|NCT03359226|Procedure|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
79377541|NCT03359148|Device|Disposable ventilator system|
79377542|NCT03359148|Device|Conventional reused ventilator system|
79829896|NCT00713544|Drug|Placebo|placebo, oral, once daily
80004531|NCT02118116|Other|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
79236931|NCT03486405|Other|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
79236932|NCT03679637|Behavioral|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
79377543|NCT04521660|Device|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
79377544|NCT02249026|Drug|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
79531375|NCT01429402|Drug|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
79531376|NCT01429402|Drug|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
79531377|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
79531378|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
79531379|NCT01429415|Drug|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
79829897|NCT00713544|Drug|AZD5672|50 mg oral, once daily
79829898|NCT00713544|Drug|AZD5672|100 mg oral, once daily
79829899|NCT00713544|Drug|AZD5672|150 mg oral, once daily
79829900|NCT00737126|Drug|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
79829901|NCT00737126|Drug|Placebo|Administration of an oral placebo pill
79829902|NCT04063436|Device|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
79829903|NCT00740766|Behavioral|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
79829904|NCT00415363|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
79829905|NCT00415363|Drug|placebo|oral, daily
80004532|NCT03607968|Procedure|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
80004533|NCT05760625|Diagnostic Test|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
79236933|NCT03485001|Other|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
79236934|NCT03485001|Procedure|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
79236935|NCT03484845|Drug|Lactoferrin and ferrous fumarate|"Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
79236936|NCT03688607|Procedure|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
79687312|NCT04876989|Procedure|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
79687313|NCT04876989|Procedure|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
79236937|NCT03679481|Drug|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
79236938|NCT03679481|Drug|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
79236939|NCT03679403|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
79236940|NCT05151783|Other|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
79377545|NCT02249026|Drug|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
79687314|NCT04873674|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
79377546|NCT04521504|Device|Kinematic biofeedback with ISEO motion analysis system|Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
79829906|NCT04063046|Drug|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 ~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
79829907|NCT04063046|Drug|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
79531380|NCT01429415|Drug|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
79829908|NCT00740844|Device|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
79531381|NCT01429428|Other|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
79531382|NCT01429428|Other|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
79829909|NCT05529056|Drug|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
79829910|NCT05529056|Drug|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
79687315|NCT04873674|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
79687316|NCT04871672|Other|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
79687317|NCT04871672|Other|Home Exercise program|home exercise
79687318|NCT04858269|Drug|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
79829911|NCT05529056|Drug|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
79687319|NCT04858269|Drug|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
79829912|NCT05529056|Drug|Placebo|Placebo ophthalmic solution
79829913|NCT00740922|Drug|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
79829914|NCT00741000|Procedure|Cervical Stairstep|Cervical low force mobilization procedure.
79829915|NCT05740436|Other|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
79829916|NCT00741078|Drug|statin, amlodipine|
79829917|NCT02568800|Drug|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
79829918|NCT02568800|Drug|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
79305680|NCT02453399|Device|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
79687320|NCT04858269|Drug|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
79687321|NCT04797442|Drug|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5*10^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
79531383|NCT01429467|Device|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
79531384|NCT01429480|Procedure|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
79236941|NCT05151783|Other|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) & repeated contractions will be used in all patterns
79687322|NCT04797442|Drug|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
79687323|NCT04768153|Biological|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
79829919|NCT00415051|Biological|RVF MP-12|Administer 1 ml SQ
79829920|NCT00741234|Drug|SB939|SB939 taken orally in a 4-week cycle.
79829921|NCT00741234|Drug|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
79236942|NCT03484689|Behavioral|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
79687324|NCT04763564|Drug|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
79829922|NCT00741312|Behavioral|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
79829923|NCT00741312|Behavioral|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
79829924|NCT02568228|Dietary Supplement|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
79236943|NCT05151705|Drug|HR17031 injection|Treatment group A:HR17031 injection; 10U/0.024mg
79377547|NCT03366402|Diagnostic Test|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
79531385|NCT01429480|Procedure|Preoperative Ultrasound Guided Posterior TAP Block|
79829925|NCT02568228|Other|Lean and fatty fish|The fish group will be open labeled.
79829926|NCT02568228|Dietary Supplement|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
79829927|NCT02568306|Drug|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
79829928|NCT02568306|Drug|placebo|Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
79829929|NCT00713258|Drug|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
79829930|NCT00713258|Drug|Alendronate|70 mg alendronate weekly
79829931|NCT00710034|Other|Oral tobacco|Snus
79829932|NCT00710034|Drug|Nicotine Gum|4 mg Nicotine gum
79829933|NCT02567942|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation
79829934|NCT02567942|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
79829935|NCT00414973|Drug|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
79236944|NCT05151705|Drug|HR17031 injection|Treatment group B: HR17031 injection; 10U/0.024mg
79531386|NCT01429480|Drug|Patient controlled analgesia|
79531387|NCT01429506|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
79236945|NCT05151705|Drug|HR17031 injection|Treatment group C: HR17031 injection; 10U/0.024mg
79531388|NCT01429506|Drug|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
79236946|NCT05151627|Procedure|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
79377548|NCT03366324|Genetic|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
79377549|NCT03366324|Procedure|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
79377550|NCT03133156|Other|Exercise Intervention|10-Week Aerobic Exercise Training
79687325|NCT04763564|Drug|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
79687326|NCT04743505|Drug|APL-101|-Provided by Apollomics
79687327|NCT04743505|Drug|Osimertinib|-Given standard of care
79687328|NCT04742504|Biological|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
79687329|NCT04730154|Behavioral|Pain Neuroscience Education (PNE)|PNE is a cognitive behavioural intervention, including educating patients that pain is an output product of the brain resulting from input from multiple central and peripheral nervous system processes and leading to threat perception. Transferring that knowledge to patients, allows them to understand, accept and effectively cope with their pain. In order to obtain the targeted behavioural change, motivational interviewing is used as the communication process throughout PNE.
79236947|NCT05151627|Device|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
79687330|NCT04730154|Behavioral|Motivational Interviewing (MI)|Motivational interviewing is a directive, collaborative, patient-centered communication approach for eliciting and enhancing motivation for behaviour change by helping clients to resolve ambivalence and uncertainty.
79377551|NCT04521192|Drug|Fluzoparib|the first period: test preparation; the second period: reference preparation
80004534|NCT02034786|Procedure|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
79531389|NCT01429519|Drug|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
79687331|NCT04730154|Behavioral|Biomedically-focused education|The traditional biomedical-focused education programme explains patient's pain experience from a tissue (injured versus healthy tissue) and biomechanical perspective.
79687332|NCT04719832|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
79687333|NCT04719832|Drug|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
79687334|NCT04718870|Drug|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
79687335|NCT04718103|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
79687336|NCT04718103|Biological|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
79377552|NCT04521192|Drug|Fluzoparib|the first period: reference preparation the second period: test preparation
79377553|NCT02995876|Procedure|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
79377554|NCT02995876|Procedure|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
79377555|NCT03359070|Drug|Dapaconazole|Application of 1 gram on the lesion.
79377556|NCT03359070|Drug|Miconazole Nitrate|Application of 1 gram on the lesion.
79377557|NCT03366246|Drug|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
79377558|NCT03366246|Drug|placebo|according randomized this side received placebo or active product
79531390|NCT01429545|Drug|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
79531391|NCT01429545|Drug|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
79531392|NCT01429571|Other|No intervention|No intervention
79687337|NCT04708860|Behavioral|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
80004535|NCT02034786|Biological|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
80004536|NCT02034786|Procedure|Transdermal injection|Transdermal injection of hyaluronic acid only.
79687338|NCT04708860|Behavioral|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
79687339|NCT04705220|Dietary Supplement|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
79829936|NCT00414973|Drug|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
80004537|NCT03605940|Combination Product|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
80004538|NCT03605940|Drug|Corticosteroids|2 mg/kg/day
80004539|NCT02124980|Behavioral|Recovery Line|
79377559|NCT01623466|Drug|levonorgestrel|transdermal contraceptive delivery system
79377560|NCT04521036|Biological|Convalescent Plasma as Therapy for Covid-19 patients|Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
79377561|NCT04524624|Device|AI-based CDSS|"Automatically identifying acute ischemic stroke lesions on DWI.~Classification of stroke subtypes and mechanisms.~Evidence-based alerts and guidelines for early stroke management.~Guideline-recommended secondary stroke prevention strategies."
79377562|NCT03366090|Procedure|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
80004540|NCT03605472|Other|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
79236948|NCT04461249|Drug|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
79829937|NCT00423085|Drug|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
79236949|NCT04461249|Drug|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
79687340|NCT04705220|Other|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
79687341|NCT04696887|Behavioral|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
79829938|NCT00423085|Drug|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
79829939|NCT00414661|Drug|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
79829940|NCT01608451|Drug|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
79236950|NCT04461249|Drug|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
79236951|NCT04611633|Combination Product|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
79236952|NCT05151549|Drug|Camrelizumab|200mg/3weeks
79236953|NCT05151549|Drug|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
79236954|NCT05151393|Diagnostic Test|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
79236955|NCT03484611|Drug|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
79236956|NCT03484611|Drug|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
79377563|NCT01624168|Behavioral|Anxiety Management Education|written materials on management of anxiety for self-study
79377564|NCT01624168|Behavioral|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
79377565|NCT01624168|Behavioral|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
79236957|NCT03484611|Drug|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
79236958|NCT03484611|Procedure|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
79377566|NCT03358914|Other|No intervention|Completion of surveys
79377567|NCT03365856|Other|observational study|as clinical practice
79687342|NCT04691557|Other|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
79687343|NCT04691557|Other|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
79829941|NCT01608451|Drug|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
79829942|NCT00405067|Drug|BMS-201038 (AEGR-733)|
79829943|NCT00405067|Drug|Ezetimibe|
79829944|NCT00708708|Drug|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
80004541|NCT02125058|Procedure|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
79829945|NCT00404755|Drug|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
79829946|NCT00404755|Drug|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
80004542|NCT02125058|Procedure|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
79236959|NCT03484611|Drug|Progesterone|vaginal prontogest 400 mg twice daily
79236960|NCT05151081|Other|basicly|Do not repeat information already included in arm/group descriptions.
79236961|NCT03486249|Other|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
79377568|NCT03642574|Procedure|CNV|Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
79377569|NCT03358680|Device|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
79687344|NCT04691232|Biological|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
79236962|NCT03491943|Procedure|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
79829947|NCT00404755|Drug|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
79236963|NCT03491943|Procedure|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
79377570|NCT04520958|Behavioral|Mindfulness of Breath|Mindfulness of Breath consisted of instruction in focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
79377571|NCT04520958|Behavioral|Mindfulness of Pain|Mindfulness of Pain consisted of instruction in how to (1) zoom in to deconstruct pain into its constituent physical sensations and precisely map each sensation's spatial location, (2) use mindful breathing to zoom out and broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that were absent of sensation and pleasant sensations), and (3) shift attention from unpleasant sensations to neutral/pleasant sensations or experiences.
79687345|NCT04683315|Drug|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
79687346|NCT04683315|Drug|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
79687347|NCT04683315|Radiation|Chemoradiation|50.4 Gy in 28 fractions.
79687348|NCT04677790|Behavioral|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
79687349|NCT04649229|Drug|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
79829948|NCT03742453|Diagnostic Test|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
79829949|NCT03742453|Diagnostic Test|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
79829950|NCT03904381|Drug|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
79829951|NCT03904381|Procedure|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
79829952|NCT03904381|Procedure|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
79829953|NCT02568150|Biological|Single group, open-label|
79829954|NCT01535911|Other|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
79829955|NCT00737256|Drug|Aripiprazole|15-30 mg
79829956|NCT00737256|Drug|Perphenazine|8-16 mg
79829957|NCT00614614|Biological|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
79829958|NCT00614614|Biological|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
79829959|NCT00614614|Biological|Infanrix®|One dose as intramuscular injection
79829960|NCT00614614|Biological|ActHIB®|Three doses in the priming phase as intramuscular injection
79829961|NCT00614614|Biological|Pediarix®|Three doses in the priming phase as intramuscular injection
79829962|NCT00713310|Drug|Asacol 400 mg|"High dose:~17-<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
79829963|NCT00713310|Drug|Asacol 400 mg|"Low dose:~17-<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
79236964|NCT02447133|Device|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
79236965|NCT03679325|Dietary Supplement|vitamine D|a dose once a week
79236966|NCT03679325|Other|whole body vibration (WBV)|03 months of WBV training three times per week
79236967|NCT03684239|Behavioral|G-CBT|CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.
79236968|NCT03684239|Other|Conventional treatment|Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
79236969|NCT03684161|Diagnostic Test|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
79687350|NCT04649229|Drug|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
79531393|NCT01429610|Drug|Rituximab+mVPDL|"Induction:~Dauno 90 mg/m2/d by civ (d1-3)~Vinc 2 mg iv (d1, 8)~Pred 60 mg/m2/d po (d1-14)~for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~Rituximab 375mg/m2/d (d8)~Consolidation A (cycle1)~D 45 mg/m2/day by continuous iv (d1, 2)~V 2 mg iv (d1, 8)~P 60 mg/m2/day po (d1-14)~for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~Rituximab 375mg/m2/d (d8)~Consolidation B (cycles2&4)~Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~Eto 150 mg/m2/d iv over 3 hr (d1-4)~Rituximab 375mg/m2/d d8~Consolidation C (cycles 3&5)~Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~Rituximab 375mg/m2/d (d8&22)~Maintenance (for 2 years)~- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~Consider alloHCT"
79531394|NCT01429636|Behavioral|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
79687351|NCT04649229|Drug|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
79687352|NCT04649229|Drug|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
79687353|NCT04649229|Drug|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
79687354|NCT04645732|Behavioral|Personalized exercise therapy and self-management support program|See description under Arms
79687355|NCT04645732|Other|Usual care|See description under Arms
79829964|NCT00737334|Device|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
79829965|NCT05740488|Drug|Apalutamide|240mg, po, qd
79829966|NCT05740488|Drug|89Sr|100~150MBq(based on weight), iv, q90d
79687356|NCT04645667|Drug|Tacrolimus|Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
79687357|NCT04644029|Drug|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
79687358|NCT04644029|Drug|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
79687359|NCT04644029|Drug|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
79687360|NCT04644029|Drug|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
79687361|NCT04640077|Other|No Intervention|No intervention
79687362|NCT04640077|Drug|donanemab|Administered IV
79687363|NCT04626297|Drug|Lebrikizumab|Given SC
79687364|NCT04626297|Drug|Placebo|Given SC
79687365|NCT04621526|Drug|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
79687366|NCT04621526|Drug|dexmedetomidine- propofol|patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
79687367|NCT04592809|Drug|Ketamine Hydrochloride|infused over a 40 minute period
79687368|NCT04592809|Drug|Midazolam Hydrochloride|infused over a 40 minute period
80004543|NCT04421131|Device|Pocket colposcope/Mobile phone camera|The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
79687369|NCT04584255|Drug|Niraparib|Predetermined dosage PO Daily
79687370|NCT04584255|Drug|Dostarlimab|Predetermined Dosage, IV,q3 weeks
79687371|NCT04567407|Drug|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
79687372|NCT04566978|Drug|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
79687373|NCT04566978|Diagnostic Test|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~Within one to four hours following injection of tracer on Day 1~24-72 hours post-injection (Day 2-4)~20-168 hours post-injection (once during days 5-7)"
79687374|NCT04533165|Behavioral|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
79687375|NCT04532177|Radiation|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
80004544|NCT04421131|Other|mIVAA|A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
79236970|NCT03684083|Procedure|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
79829967|NCT05740488|Drug|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
79687376|NCT04529408|Device|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
79687377|NCT04500964|Device|TAVR|Trancatheter aortic valve replacement
79377572|NCT04520958|Behavioral|Cognitive-Behaviorally Based Pain Psychoeducation|Cognitive-Behaviorally Based Pain Psychoeducation consisted of psychoeducation about the link between thoughts, emotions, and behavior and provided instruction in the use logic to dispute maladaptive thoughts about pain that might otherwise exacerbate pain and distress.
79531395|NCT01429636|Behavioral|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
79687378|NCT04465097|Drug|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
79829968|NCT05740410|Device|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
79829969|NCT00874354|Drug|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
79829970|NCT05742126|Drug|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
79829971|NCT05742126|Drug|Placebo|Matching placebo
79829972|NCT05742126|Drug|Heparin sodium injection|Matching positive control
79829973|NCT00737412|Other|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
79829974|NCT00737412|Other|Placebo|Matching capsules devoid of microorganisms
79829975|NCT00882856|Drug|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
79829976|NCT00882856|Drug|Placebo|placebo
79829977|NCT02568462|Device|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
79377573|NCT04520646|Drug|Empagliflozin|empagliflozin of 10mg/day is added on the basis of primary care
79377574|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
79687379|NCT04465097|Drug|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
79829978|NCT00882934|Other|Induction to efficient treatment|Informative letters.
79829979|NCT00882934|Other|Doubt to the efficacy of treatment|Informative letters.
79829980|NCT00882934|Other|Induction to ineffective treatment|Informative letters
79687380|NCT04465097|Drug|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
79829981|NCT00874588|Biological|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
79829982|NCT04064658|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
79531396|NCT01429649|Procedure|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
79531397|NCT01429662|Behavioral|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
79687381|NCT04462588|Drug|Cipro 400 MG in 200 ML Injection|medical tratment group
79687382|NCT04462588|Drug|Flagyl I.V. RTU|medical tratment group
79687383|NCT04462588|Procedure|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
79687384|NCT04440150|Procedure|Appendectomy|Open or Laparascopic Surgery
79829983|NCT04064658|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
79829984|NCT04064658|Procedure|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
79829985|NCT00883012|Biological|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms**, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms**, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms** Two doses, one month apart"
79829986|NCT00883012|Biological|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
79829987|NCT00737490|Other|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
79531398|NCT01429662|Behavioral|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
79829988|NCT00737490|Other|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
79829989|NCT00737646|Behavioral|Usual care|No intervention will be conducted in this arm of the study.
79829990|NCT00737646|Behavioral|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
79531399|NCT01429675|Drug|bonviva|150mg Ibandronate once a month
79531400|NCT01429688|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
79829991|NCT00737646|Behavioral|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
79531401|NCT01429701|Drug|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
79687385|NCT04437823|Biological|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
79829992|NCT00880672|Drug|dutasteride|5mg, oral, daily, 2-4 weeks
79829993|NCT04064034|Other|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
79687386|NCT04433065|Device|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
79829994|NCT00874666|Other|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
79687387|NCT04429243|Device|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
79829995|NCT00874666|Dietary Supplement|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
79829996|NCT03900546|Device|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
79829997|NCT00737724|Drug|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
79829998|NCT00737724|Drug|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
79377575|NCT03365700|Procedure|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
79377576|NCT03365700|Procedure|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
79829999|NCT00880828|Other|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
79830000|NCT00880828|Other|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
79830001|NCT00880828|Drug|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
79830002|NCT05741970|Procedure|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
79830003|NCT00883402|Procedure|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
79830004|NCT00422461|Drug|placebo|placebo, oral, tablets, once daily, for 28 days
79830005|NCT00422461|Drug|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
79830006|NCT00422461|Drug|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
79830007|NCT00422461|Drug|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
79531402|NCT01429701|Drug|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
79531403|NCT01429714|Device|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
79531404|NCT01429714|Device|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
79830008|NCT04346134|Procedure|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
79830009|NCT04346134|Procedure|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
79830010|NCT00712920|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
79830011|NCT00712920|Drug|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
79830012|NCT00712920|Drug|Placebo|Placebo
79377577|NCT01624948|Drug|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
79531405|NCT01429740|Drug|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
79531406|NCT01429740|Drug|Placebo|Placebo oral solution or capsules
79531407|NCT01429753|Other|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
79531408|NCT01429753|Device|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
79531409|NCT01429766|Other|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~st visit Within one day of the date of simulation~nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
79687388|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
79687389|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
79687390|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
79830013|NCT01037647|Other|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
79830014|NCT00874744|Drug|Bevacizumab|1.25mg bevacizumab (0.05ml)
79830015|NCT00874744|Drug|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
79377578|NCT01624948|Drug|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
79830016|NCT03993769|Other|A19010-F|A snus product
79830017|NCT03993769|Other|B19010-F|A snus product
79377579|NCT03357042|Other|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
79531410|NCT01429779|Drug|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
79830018|NCT04038658|Behavioral|Move-It|
79830019|NCT05736744|Drug|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
79830020|NCT05736744|Drug|Rocuronium Bromide|Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval
79830021|NCT05736744|Drug|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
79830022|NCT04270084|Behavioral|Alive-Family|All participants receive lifestyle modification through use of m-health app
79830023|NCT00920868|Drug|dasatinib|dasatinib at 50 mg PO BID)
79830024|NCT00920868|Drug|bevacizumab|7.5 mg/kg IV day 1
80004545|NCT03607734|Drug|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
80016724|NCT04590833|Behavioral|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
80016725|NCT04539431|Genetic|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
80016726|NCT04472234|Other|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
79377580|NCT03357042|Other|Standard of care|Normal concussion treatment; physical and cognitive rest
79377581|NCT03259204|Device|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
79830025|NCT00920868|Drug|Oxaliplatin|130 mg/m2 IV day 1
79830026|NCT00920868|Drug|Capecitabine|850 mg/m2 PO BID on days 1-14
79377582|NCT04520568|Combination Product|High flow nasal cannula|using sedation with the HFNC F&P AIRVOTM 2 to maintain oxygenation
80004546|NCT02118272|Device|Physica KR|
80004547|NCT04167345|Drug|VX-814|Tablet for oral administration.
80004548|NCT04167345|Drug|Placebo|Placebo matched to VX-814 for oral administration.
80004549|NCT03605316|Procedure|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
79830027|NCT00880984|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
79830028|NCT00874900|Other|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
79830029|NCT00874900|Other|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
80004550|NCT01375153|Drug|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
80004551|NCT01375153|Drug|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
80004552|NCT02035488|Drug|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
80004553|NCT05196997|Other|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
79531411|NCT01429805|Device|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
80004554|NCT03602430|Drug|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
80004555|NCT03602430|Drug|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
80004556|NCT02126852|Device|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
80004557|NCT02126852|Device|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
79236971|NCT03878927|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
79236972|NCT03878927|Drug|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
79236973|NCT03684005|Other|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
79531412|NCT01429818|Drug|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
79531413|NCT01429818|Drug|Metformin|1000 mg tablets once daily for eight weeks
79531414|NCT01429831|Drug|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
79531415|NCT01429844|Drug|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
79531416|NCT01429844|Drug|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
79531417|NCT01429870|Drug|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
79687391|NCT04409119|Device|HIS/LBB pacing|3830 lead to HIS or LBB
79687392|NCT04409119|Device|LV pacing|LV lead in a CS branch
79687393|NCT04404140|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.
79687394|NCT04404140|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.
79687395|NCT04404140|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m^2, as per the dosing schedule described above.
79687396|NCT04349358|Other|FDG and FCH PET/CT|"during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
79687397|NCT04346654|Drug|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
79687398|NCT04346654|Drug|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
80004558|NCT02126852|Device|Electromyography (EMG)|Neuromuscular monitoring
80004559|NCT03605238|Biological|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
80004560|NCT02252120|Device|Supreme|
80004561|NCT02252120|Device|Laryngeal Tube|
79687399|NCT04319094|Behavioral|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
79687400|NCT04319094|Other|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
79830030|NCT00874900|Other|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
79830031|NCT00881062|Drug|Proellex|A single oral dose administered after at least a 10 hour fast
79830032|NCT05741814|Drug|Propofol|Gynecologist guided individualised propofol only sedation
79830033|NCT04721626|Drug|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
79830034|NCT04721626|Drug|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
79687401|NCT04291508|Drug|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs < 50 kg) every six hours for 5 days (20 doses)
79830035|NCT04721626|Drug|Tetracycline Ointment|Postoperative: ~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
79377583|NCT04520568|Combination Product|CONTROL|using general anaesthesia with one lung ventilation (OLV) technique
79830036|NCT04064892|Behavioral|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, & Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
79830037|NCT00881140|Drug|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
79830038|NCT05741736|Behavioral|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
79830039|NCT00883636|Other|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
79687402|NCT04291508|Drug|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
79687403|NCT04291508|Drug|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
79687404|NCT04291508|Drug|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
79687405|NCT04256759|Drug|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
79830040|NCT00883636|Other|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
79830041|NCT00883636|Other|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
79830042|NCT00883714|Other|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
79830043|NCT00883714|Other|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
79830044|NCT05733078|Drug|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
79830045|NCT05733078|Drug|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
79830046|NCT00883792|Procedure|Colonoscopy|Once-only colonoscopy screening
79377584|NCT03358602|Radiation|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
79377585|NCT03358602|Procedure|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
79687406|NCT04255823|Other|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
79687407|NCT04255823|Other|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
79531418|NCT01429896|Other|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
79531419|NCT01429909|Device|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2*.
79830047|NCT00874978|Drug|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
79531420|NCT01429935|Drug|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
79830048|NCT04063254|Radiation|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
79830049|NCT00737880|Other|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
79531421|NCT01429935|Drug|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
79830050|NCT05728632|Drug|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
79531422|NCT01429935|Other|placebo|capsules contain starch
79531423|NCT01429961|Drug|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1~14
79687408|NCT04242498|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
79687409|NCT04242498|Other|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
79687410|NCT04240158|Drug|IW-6463|IW-6463 Tablet
79531424|NCT01429974|Other|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
79830051|NCT05728632|Drug|Placebo|Placebo, capsule, once daily, for 12 months
79830052|NCT04180540|Device|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
79687411|NCT04240158|Drug|Matching Placebo|Matching Placebo Tablet
79687412|NCT04169191|Drug|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
79531425|NCT01430000|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
79830053|NCT04180540|Other|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
79830054|NCT05741580|Procedure|Evolution of symptoms|percentage of patients with improvement in their symptoms
79830055|NCT05577936|Device|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
79830056|NCT05577936|Other|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
79531426|NCT01430013|Drug|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
79830057|NCT00612586|Drug|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
79830058|NCT00612586|Drug|Placebo|oral, daily (up to 1 yr or until progressive disease)
79377586|NCT01625104|Other|Non Intervention|Business as usual
79377587|NCT01625104|Other|Agressive Intervention Process Improvement Strategies|
79377588|NCT04445142|Procedure|fovea-sparing internal limiting membrane peeling|fovea-sparing internal limiting membrane peeling surgery
79377589|NCT03365544|Other|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
79531427|NCT01430039|Procedure|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
79687413|NCT04160325|Dietary Supplement|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
79687414|NCT04160325|Drug|azathioprine|azathioprine
79687415|NCT04160325|Other|normal diet|normal diet
79830059|NCT00612586|Drug|Leucovorin (LV)|400 milligram per meter squared (mg/m^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
79531428|NCT01430039|Procedure|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
79531429|NCT01430052|Drug|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
79531430|NCT01430052|Drug|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
79531431|NCT01430065|Drug|ASP015K|oral
79531432|NCT01430065|Drug|Tacrolimus|oral
79531433|NCT01430078|Drug|ASP015K|oral tablet
79531434|NCT01430078|Drug|ASP015K|solution via oral capsule
79687416|NCT04154189|Drug|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
79687417|NCT04154189|Drug|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
79531435|NCT01430117|Biological|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
80004562|NCT03605160|Procedure|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
79236974|NCT03867539|Other|Differing pain management strategy|"The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated."
79236975|NCT03679169|Procedure|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
79687418|NCT04154189|Drug|Etoposide|Etoposide 100 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
79236976|NCT03623555|Behavioral|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
79531436|NCT01430143|Behavioral|Exercise|Daily exercise for 12 weeks.
79830060|NCT00612586|Drug|5-fluorouracil (5-FU)|400 mg/m^2 bolus then 2400 mg/m^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
79236977|NCT03623555|Biological|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
79531437|NCT01430156|Drug|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
79531438|NCT01430156|Drug|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
80004563|NCT03605160|Procedure|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
79531439|NCT01430195|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
79531440|NCT01430195|Procedure|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
79531441|NCT01430208|Procedure|resectoscopy|hysteroscopy for myomas G0 and/or polyps
79531442|NCT01430221|Behavioral|Mindfulness-based Personalized Health Planning|
79531443|NCT01430221|Other|Structured & Guided Education|
79531444|NCT01430234|Drug|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
79531445|NCT01430247|Other|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
79687419|NCT04154189|Drug|Lenvatinib|Lenvatinib 14 mg/m^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors [RECIST] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
79236978|NCT03842267|Drug|Gemigliptin 50mg|"The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~Dapagliflozin 10 mg / day~Metformin ≥ 1,000 mg / day"
79531446|NCT01430260|Drug|Ciclesonide|200 ㎍ once daily
79531447|NCT01430260|Drug|Levocetirizine|5mg once daily
79531448|NCT01430260|Drug|Ciclesonide & Levocetirizine|"Omnaris (ciclesonide) 200 ㎍ once daily~Levocetirizine 5mg once daily"
79531449|NCT01430286|Behavioral|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
79531450|NCT01430286|Behavioral|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
79687420|NCT04115527|Procedure|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
79687421|NCT04115527|Procedure|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
79687422|NCT04108481|Drug|Durvalumab|Immunotherapy
79687423|NCT04108481|Radiation|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
79687424|NCT04083859|Other|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
79687425|NCT04083859|Other|Lung health video|Web-based video about guideline recommended exercise for lung health
79687426|NCT04073303|Biological|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
79377590|NCT01625416|Behavioral|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
79531451|NCT01430312|Drug|azelaic acid pre-foam formulation|
79830061|NCT00612586|Drug|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
79531452|NCT01430312|Drug|Vehicle pre-foam formulation|
79830062|NCT05741424|Diagnostic Test|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
79236979|NCT03842267|Drug|Gemigliptin Placebo|"The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~Dapagliflozin 10 mg / day~Metformin ≥ 1,000 mg / day"
79531453|NCT01430312|Drug|Water|
79830063|NCT05741424|Diagnostic Test|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
79830064|NCT00883870|Drug|mesenchymal stem cells|Intramuscular injection
79830065|NCT00883870|Drug|Plasmalyte A|Intramuscular injection
79531454|NCT01430312|Drug|Sodium lauryl sulfate|
79531455|NCT01430364|Device|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
79531456|NCT01430364|Device|BIOSS Lim|
79302690|NCT03200197|Other|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
79531457|NCT01430364|Device|CarloS|
79531458|NCT01430377|Procedure|SB predilatation|Initial SB [predilatation.
79531459|NCT01430377|Procedure|No SB predilatation|Without SB predilatation
79531460|NCT01430416|Drug|AEB071|
79531461|NCT01430429|Drug|NI-0801|
79687427|NCT04073303|Other|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
79687428|NCT04068441|Other|no intervention|No intervention
79687429|NCT04048161|Drug|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is < 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
79687430|NCT04048161|Drug|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20~30mg/kg/day，BID. The concentration for MPA-AUC is 30~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
79687431|NCT04032964|Drug|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
79531462|NCT01430481|Dietary Supplement|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
79687432|NCT04032964|Drug|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
79830066|NCT04038892|Other|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
79830067|NCT04038892|Other|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
79531463|NCT01428674|Other|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
79531464|NCT01428674|Other|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
79531465|NCT01430507|Drug|Revamilast|Tablet, Low dose, Once daily for 12 weeks
79531466|NCT01430507|Drug|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
79531467|NCT01430507|Drug|Revamilast|Tablet, High dose, Once daily for 12 weeks
79531468|NCT01430507|Drug|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
79531469|NCT01430520|Drug|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
79531470|NCT01430520|Drug|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
79531471|NCT01430533|Drug|azelaic acid pre foam formulation|
79531472|NCT01430533|Drug|Vehicle pre foam formulation|
79236980|NCT03688373|Behavioral|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
79687433|NCT03976193|Behavioral|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
79236981|NCT04060511|Drug|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
79830068|NCT04038892|Other|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
79830069|NCT00614380|Drug|telmisartan/amlodipine 40/5 mg fixed combination|
79830070|NCT00614380|Drug|telmisartan/amlodipine 80/5 mg fixed combination|
79830071|NCT05525130|Dietary Supplement|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
79377591|NCT04520880|Diagnostic Test|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
79830072|NCT05525130|Dietary Supplement|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
79236982|NCT03623711|Drug|Escitalopram|participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
79236983|NCT03623711|Drug|Duloxetine|participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
79391158|NCT04767659|Device|MAMMOT2|Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
79391159|NCT02415582|Other|Aerobic exercise|Aerobic exercise on treadmill
79391160|NCT02415582|Other|Combined exercises|Combined resistance and aerobic exercise
79531473|NCT01430533|Drug|Water|
79687434|NCT03976193|Behavioral|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
79531474|NCT01430598|Procedure|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
79531475|NCT01430598|Other|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
79531476|NCT01430637|Genetic|DNA analysis|
79830073|NCT05507190|Other|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
79236984|NCT03623711|Drug|Bupropion|participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
79236985|NCT03623711|Other|Healthy control|Healthy control take placebo tablets
79236986|NCT03677609|Behavioral|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
79531477|NCT01430637|Genetic|RNA analysis|
79531478|NCT01430637|Genetic|gene expression analysis|
79531479|NCT01430637|Genetic|mutation analysis|
79531480|NCT01430637|Genetic|nucleic acid sequencing|
79531481|NCT01430637|Genetic|polymerase chain reaction|
79687435|NCT03964233|Drug|BI 907828|Film-coated tablets
79687436|NCT03964233|Drug|ezabenlimab|Solution for infusion
79531482|NCT01430637|Other|laboratory biomarker analysis|
79531483|NCT01430637|Other|pharmacogenomic studies|
79236987|NCT03683927|Combination Product|Bacillus clausii|The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
80004564|NCT02260544|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
80004565|NCT05470647|Biological|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously.
80004566|NCT05470647|Biological|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously.
80004567|NCT05470647|Biological|Placebo|Placebo was injected subcutaneously.
80004568|NCT03552848|Biological|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
80004569|NCT04409665|Drug|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
80004570|NCT04409665|Drug|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
80004571|NCT02854800|Drug|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
79236988|NCT03683927|Other|Sterile water|The placebo group will receive sterile water 4 times a week
79236989|NCT03683849|Other|Training|One hour of training, twice a week, for six months.
79531484|NCT01430650|Drug|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
79236990|NCT03563261|Dietary Supplement|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
79236991|NCT03563261|Dietary Supplement|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
79236992|NCT03677531|Other|Quality-of-Life Assessment|Ancillary studies
79377592|NCT04520880|Diagnostic Test|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
79531485|NCT01430650|Drug|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
79531486|NCT01430676|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
79687437|NCT03964233|Drug|BI 754111|Solution for infusion
79687438|NCT03949673|Drug|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
79687439|NCT03949673|Drug|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
79687440|NCT03949673|Drug|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
79687441|NCT03949673|Drug|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
80004572|NCT03552770|Drug|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
80004573|NCT01373827|Device|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
80004574|NCT02118350|Behavioral|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
80004575|NCT05196139|Other|retrospective study|vitrectomy performed in case of submacular bleeding
80004576|NCT02125214|Device|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
80004577|NCT01375231|Procedure|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
79236993|NCT03677531|Other|Questionnaire Administration|Ancillary studies
79236994|NCT03677531|Radiation|Radiation Therapy|Undergo RT
79236995|NCT03677531|Other|Video|Watch video of choice during RT
79236996|NCT05610592|Procedure|total mesorectal exicision|
79302691|NCT03200197|Other|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
79531487|NCT01430689|Biological|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~Home visits weekly until the infant is born and reaches 6 months of age~If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
80004578|NCT01375231|Procedure|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
80004579|NCT02035098|Other|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
80004580|NCT04394923|Procedure|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
80004581|NCT04394923|Procedure|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
80004582|NCT02125370|Other|Qualitative and survey|
80004583|NCT03605082|Drug|UCB0107|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
79531488|NCT01430689|Biological|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~Home visits weekly until the infant is born and reaches 6 months of age~If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
79687442|NCT03949673|Drug|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
79236997|NCT03678857|Dietary Supplement|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
79236998|NCT03683771|Diagnostic Test|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
79302692|NCT05002179|Drug|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
79830074|NCT02567994|Drug|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
80004584|NCT03605082|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
79830075|NCT00738192|Drug|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
80004585|NCT02126930|Other|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
79302693|NCT03107299|Other|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
79377593|NCT04520724|Dietary Supplement|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
79377594|NCT04520724|Dietary Supplement|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
79377595|NCT03477604|Device|MicroStent and Standard PTA|Self-expanding stent and standard PTA balloon
79377596|NCT03477604|Device|Standard PTA|Standard PTA balloon
80004586|NCT02126930|Other|Routine care|Patients randomized to this arm will receive care in the habitual manner.
80004587|NCT03602274|Diagnostic Test|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
80004588|NCT03602274|Diagnostic Test|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
80004589|NCT03602274|Other|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
80004590|NCT02118506|Other|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
79830076|NCT00738192|Drug|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
79687443|NCT03922529|Behavioral|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format [site transitioning to home]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
79830077|NCT00738192|Drug|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
79377597|NCT04520802|Diagnostic Test|18F-DPA-714 PET/CT neuroimaging|"Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~Longitudinal neuropsychological examinations (up to 6 months postoperatively)~Blood samples are drawn to assess the severity of the systemic inflammatory response"
79377598|NCT03365466|Drug|Low dose aspirin|LDA 25mg tid
79531489|NCT01430702|Device|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
79531490|NCT01430715|Other|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, > 5th % to < 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
79531491|NCT01430780|Drug|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
79531492|NCT01430780|Drug|control group|placebo
79531493|NCT01430793|Drug|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
79531494|NCT01430793|Drug|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
79531495|NCT01430793|Drug|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
79687444|NCT03922529|Other|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
79687445|NCT03919955|Drug|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed
79377599|NCT03365466|Drug|Low molecular weight heparin|LMWH 5000u IH qd
79687446|NCT03919955|Drug|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed
79687447|NCT03919955|Drug|Placebo|Placebo, per mouth, before bed
79687448|NCT03909919|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
79687449|NCT03905512|Drug|SEL-212|Administered as specified in the treatment arm
79377600|NCT03365466|Drug|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
79531496|NCT01430793|Drug|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
79531497|NCT01430806|Drug|Dronedarone arm|PO Dronedarone 400 mg BID
79531498|NCT01430806|Drug|Dronedarone|Dronedarone PO 400 MG BID
79687450|NCT03905512|Drug|KRYSTEXXA®|Administered as specified in the treatment arm
79687451|NCT03891875|Combination Product|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
79687452|NCT03891875|Combination Product|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
79687453|NCT03856827|Drug|IW-6463|IW-6463 Tablet
79687454|NCT03856827|Drug|Matching Placebo|Matching Placebo Tablet
79377601|NCT03365466|Drug|no treatment|Patients who did not receive any treatment.
79377602|NCT03833284|Behavioral|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
79377603|NCT03833284|Behavioral|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
79391161|NCT02415582|Other|Control|45 minutes resting sitting
79687455|NCT03849898|Procedure|Surgery|Surgical fracture treatment
79830078|NCT00875134|Other|Verbal prompt|Patient hears a voice recording
79830079|NCT00875134|Other|Skin Stimulus|Patient receives either a skin stimulus
79830080|NCT05697978|Device|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
79830081|NCT04681534|Device|AlphaDBS System|AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
80004591|NCT02118506|Other|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
80004592|NCT05376384|Diagnostic Test|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
80004593|NCT05376384|Procedure|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
80004594|NCT02127008|Procedure|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
79531499|NCT01430858|Device|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
80004595|NCT02127008|Procedure|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
79687456|NCT03849898|Other|Non-Surgical fracture treatment|Non-Surgical fracture treatment
80004596|NCT02931539|Drug|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
79236999|NCT03683693|Diagnostic Test|Procalcitonin group|"The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT < 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT < 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion."
79377604|NCT03356964|Drug|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
79377605|NCT03346252|Drug|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
79377606|NCT04522752|Other|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
79531500|NCT01430858|Other|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion & strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion & strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low & high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion & strain gauge readings will be captured."
79687457|NCT03847051|Diagnostic Test|MRI|Brain MRI without intravenous contrast
79687458|NCT03834064|Behavioral|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
79687459|NCT03830164|Drug|Atorvastatin|Given PO
79687460|NCT03830164|Drug|Pentoxifylline|Given PO
79687461|NCT03830164|Dietary Supplement|Vitamin E Compound|Given PO
79830082|NCT00883948|Behavioral|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
79830083|NCT00883948|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
79830084|NCT05695326|Behavioral|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
79830085|NCT00738348|Drug|sivelstat|sivelstat sodiumhydrate
79830086|NCT00738348|Drug|glucose|glucose
80004597|NCT02931539|Drug|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
79237000|NCT04994080|Drug|Paricalcitol|Paricalcitol QD Treatment
79237001|NCT04994080|Drug|Placebo|Placebo QD or TIW
79237002|NCT05412316|Other|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
79830087|NCT00884026|Device|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
79237003|NCT05363878|Behavioral|Native HEALTH|This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
79531501|NCT01430884|Other|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
79531502|NCT01430910|Drug|CAZ104|IV infusion
79237004|NCT05363800|Drug|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
79237005|NCT05550220|Diagnostic Test|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
79531503|NCT01430910|Drug|Avibactam|IV infusion
79237006|NCT05362474|Drug|Montelukast|10mg orally once a day
79237007|NCT05542342|Drug|Tislelizumab|200 mg IV once every 3 weeks
79237008|NCT05542342|Drug|Sitravatinib Malate|100 mg orally once daily
79687462|NCT03795311|Drug|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
79687463|NCT03776136|Drug|lenvatinib|Administered orally once a day during each 21-day cycle.
79687464|NCT03776136|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
79687465|NCT03769181|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79237009|NCT05362396|Other|Inspiratory Muscle Training with Powerbreath IMT device.|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
79237010|NCT05610202|Drug|TQB3702 tablets|TQB3702 tablets are selective BTK inhibitors.
79377607|NCT04522830|Drug|BTL-TML-COVID|"Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
79531504|NCT01430910|Drug|Ceftazidime|IV infusion
79531505|NCT01430923|Drug|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
79531506|NCT01430923|Drug|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
79531507|NCT01430949|Procedure|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
79531508|NCT01430975|Drug|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
79531509|NCT01430975|Drug|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
79531510|NCT01431001|Device|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
79531511|NCT01431040|Other|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
79531512|NCT01431040|Other|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
79687466|NCT03769181|Drug|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79531513|NCT01431053|Drug|aspirin|Aspirin 50mg po daily
79531514|NCT01431053|Drug|Exemestane|Exemestane 25mg po daily
79531515|NCT01431066|Device|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
79531516|NCT01431066|Device|ActiPatch PRFE Device|Actipatch PRFE device
79830088|NCT00884026|Device|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
79531517|NCT01431092|Drug|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
79830089|NCT05678946|Other|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
79830090|NCT05678946|Other|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
80004598|NCT02931539|Drug|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
79830091|NCT05678946|Other|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
79237011|NCT05361304|Device|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
79830092|NCT00875290|Device|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
79830093|NCT00884104|Drug|Solifenacin|Oral
79830094|NCT04140214|Drug|Hypertonic saline|Nebulized hypertonic saline solution (6%)
79237012|NCT05361304|Device|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
79377608|NCT04522830|Drug|Placebo|"Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
79531518|NCT01431092|Drug|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
79687467|NCT03766672|Diagnostic Test|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
79830095|NCT04140214|Drug|Carbocysteine 750 MG|Carbocisteine tablet
79830096|NCT00612508|Drug|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
79830097|NCT00612508|Drug|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
79237014|NCT05540002|Device|High Intensity Quell|Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.
79237015|NCT05540002|Device|Low Intensity Quell|Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
79377609|NCT03365388|Drug|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
79531519|NCT01431118|Other|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
80004599|NCT02931539|Drug|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
80004600|NCT02931539|Drug|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
79377610|NCT03365388|Drug|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
79377611|NCT03365310|Drug|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
79531520|NCT01431118|Other|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
79531521|NCT01431183|Behavioral|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
79531522|NCT01431196|Biological|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
79687468|NCT03722407|Drug|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
79531523|NCT01431222|Device|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
79830098|NCT00881218|Drug|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
80004601|NCT03602196|Other|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
80004602|NCT03602196|Other|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
80004603|NCT03602196|Other|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
80004604|NCT02125448|Device|MRI and PET-CT|
79531524|NCT01431235|Behavioral|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
79687469|NCT03676478|Other|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
79687470|NCT03657628|Other|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
79830099|NCT00613834|Drug|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
79237016|NCT05359510|Procedure|prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing|before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
79237017|NCT05601622|Procedure|Fluid loading|Intravenous administration of 10ml/kg of crystalloids over 10 minutes
79377612|NCT03365310|Other|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
79377613|NCT03356808|Biological|Lung cancer-specific T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
79377614|NCT04522986|Biological|Mesenchymal stem cell|1*10^8 cells are administered once a week, total four times intravenously.
79377615|NCT03123744|Drug|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
79377616|NCT04522362|Other|Control task and Trier Social Stress Task|Same as Arm
79377617|NCT03358524|Drug|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
79531525|NCT01431261|Other|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
79830100|NCT00613834|Drug|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
79830101|NCT00875368|Drug|maraviroc|maraviroc dose dependent on co-medication
79531526|NCT01431261|Behavioral|Pain management|Educational sessions in pain management 4 times
79531527|NCT01431352|Drug|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
79531528|NCT01431352|Drug|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
79830102|NCT00875368|Drug|Placebo|Placebo drug
79830103|NCT00884182|Biological|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
79830104|NCT00875446|Drug|PLACEBO|Placebo
79830105|NCT00875446|Drug|GSK1223249|I.V Infusion
79237018|NCT05601622|Diagnostic Test|Transthoracic echocardiography|Transthoracic echocardiographic measurement of stroke volume index
79237019|NCT05601622|Diagnostic Test|PVI, RPVI|Continuous measurement of pleth variability index and Rainbow pleth variability index
79237020|NCT05601622|Procedure|Tidal volume change|Changing tidal volume for mechanical ventilation as 6, 8, 10 ml/kg
79237021|NCT05599516|Biological|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
79237022|NCT05599516|Biological|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
79237023|NCT05599516|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
79237024|NCT05598970|Other|Digital application supported CHW Parenting Intervention|"All pregnant women served by the trained CHW will be invited to participate in the Parenting program, from when the mother is at least 20 weeks pregnant and less than 32 weeks pregnant with the target child for a period of 15 months. CHWs will visit pregnant women at least 3 times during their pregnancy and at least 16 times following delivery. In addition to the individual home visits, the CHWs will organise bi-weekly in-community group sessions for children aged 6-12 months and their primary caregivers, focusing on caregiver-child interaction and stimulation activities.~The immediate supervisors Health Care Workers (HCWs) of the CHWs will be trained to closely monitor CHWs activities and progress made. HCWs and CHWs will in turn be supervised and supported by district level Council Health Management Team (CHMT).~Parenting services will be provided to all target children of these eligible caregivers, irrespective of their learning or physical abilities."
79830106|NCT03920098|Other|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level >100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels > 92 mg/dL and/or plasma glucose levels > 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose >100 mg/dL and/or > 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
79830107|NCT03912298|Other|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
79237025|NCT05598970|Other|Unconditional Cash Transfer only Intervention fixed amount|The fixed cost for delivering the Parenting only Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer fixed amount' treatment arm, the transfer will be 109,000 TZS (32,000 TZS + 77,000 TZS).
79830108|NCT02543710|Procedure|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
79830109|NCT02543710|Drug|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
79237026|NCT05598970|Other|Unconditional Cash Transfer Intervention|Families will receive from 5-7 months pregnancy over a period of 15 months a bi-monthly unconditional cash transfer, which equals the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under Tanzania Social Action Fund (TASAF), i.e., Tanzania's National Cash Transfer program.
79305681|NCT03236831|Other|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~Avoidance of potentially nephrotoxic medications.~Optimizing volume status (avoidance of volume overload or depletion)~Optimizing electrolytes and acid-base status~Minimizing IV contrast exposure when appropriate~Treating severe anemia~Optimization of hemodynamics (Mean arterial BP>65mmHg)"
79531529|NCT01431365|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
79830110|NCT00884260|Drug|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
79531530|NCT01431365|Behavioral|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
79687471|NCT03638297|Drug|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
80004605|NCT05195671|Other|Review|Reviewing all protocols
79687472|NCT03623490|Other|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
79687473|NCT03621696|Drug|Cisplatin|-100 mg/m^2 intravenous push bolus (IVPB)
79531531|NCT01431404|Biological|Etanercept (Enbrel)|prefilled syringe, SC
79531532|NCT01431404|Biological|HD203|HD203, prefilled syringe, SC injection
79531533|NCT01431430|Drug|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
79531534|NCT01431430|Drug|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
79687474|NCT03621696|Radiation|Intensity modulated radiation therapy|-IMRT or IMPT can be used
79687475|NCT03621696|Radiation|Intensity modulated proton therapy|-IMRT or IMPT can be used
79687476|NCT03621696|Procedure|Surgery|-Standard of care
79237027|NCT05598970|Other|Unconditional Cash Transfer only Intervention vary amount|The rationale for the levels of the varying UCT amounts is to keep them comparable with i) the bi-monthly cost of the parenting program per family, ii) the bi-monthly cash transfers disbursed under TASAF, and iii) the sum of the bi-monthly cost of the parenting program and the bi-monthly cash transfer disbursed under TASAF. The fixed cost for delivering the Parenting Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer only vary amount' group, each of the amounts vary individually (32,000 TZS; 77,000 TZS; 109,000 TZS).
79687477|NCT03621696|Other|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
79531535|NCT01431443|Other|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
79830111|NCT04038814|Procedure|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) < 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
79830112|NCT04038814|Procedure|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~Automatic continuous subglottic secretion drainage"
79830113|NCT00881296|Drug|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
79830114|NCT00881296|Drug|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
79830115|NCT02543788|Procedure|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
79830116|NCT02543632|Device|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
79830117|NCT00884338|Other|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
79237028|NCT05380024|Drug|Ensartinib|Ensartinib 225mg QD 8 weeks
79531536|NCT01431443|Other|Placebo Chocolate|Placebo intervention
79531537|NCT01431456|Drug|Dabigatran|Dabigatran
79531538|NCT01431456|Drug|Rivaroxaban|Rivaroxaban
79531539|NCT01431456|Drug|Nadroparin|Nadroparin
79531540|NCT01431469|Dietary Supplement|Cow's milk|Powdered Whole Cow's Milk
79830118|NCT00884338|Other|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
79830119|NCT00881374|Drug|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
79830120|NCT00613366|Drug|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
79830121|NCT00613366|Dietary Supplement|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
79237029|NCT05343598|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
79531541|NCT01431469|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
79531542|NCT01431495|Drug|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
79531543|NCT01431495|Drug|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
79687478|NCT03621696|Other|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
79377618|NCT03358524|Drug|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
79377619|NCT03365232|Device|non custom base attachment|non custom base attachment
79377620|NCT03365232|Device|custom base attachment|custom base attachment
79377621|NCT04444986|Drug|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
79377622|NCT04444986|Drug|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
79377623|NCT04444596|Diagnostic Test|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
79687479|NCT03621696|Other|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
79830122|NCT00875602|Device|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
79830123|NCT00875680|Device|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
79830124|NCT00612352|Drug|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
79830125|NCT00884416|Drug|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
79830126|NCT00875758|Procedure|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
79830127|NCT00875758|Procedure|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
79237030|NCT05343598|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
79830128|NCT04018300|Dietary Supplement|Ferrous sulfate|65 mg Fe as ferrous sulfate
79830129|NCT04018300|Dietary Supplement|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
79830130|NCT04018300|Other|Placebo|Contains maltodextrin.
79830131|NCT00875914|Procedure|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
79830132|NCT02543164|Other|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
79830133|NCT02543164|Other|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
79830134|NCT00884494|Drug|Ghrelin infusion to assess effects on insulin sensitivity|
79830135|NCT00875992|Device|ETN with ASLS|Angle stable locking of ETN using ASLS
79237031|NCT05342740|Other|collect whole blood, urine and stool samples|collect whole blood, urine and stool samples
79237032|NCT05342194|Drug|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
79377624|NCT04444674|Biological|ChAdOx1 nCoV-19|Dose of 5-7.5x10^10vp of ChAdOx1 nCoV-19
79377625|NCT04444674|Biological|Normal saline 0.9%|Normal saline 0.9% as placebo
79377626|NCT03365076|Other|Physical activity|Aerobic physical activity as stated in Arm A
79377627|NCT03356574|Procedure|Single-ventricle palliation surgery|Single-ventricle palliation surgery
79377628|NCT02519166|Biological|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
79377629|NCT03356730|Drug|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
79687480|NCT03621696|Other|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
79830136|NCT00875992|Device|ETN locked with conventional locking bolts|Conventional surgical procedure
79830137|NCT00881686|Drug|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
79830138|NCT00885508|Drug|Lenalidomide|"Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
79830139|NCT02543086|Drug|KAE609|Study drug
79830140|NCT02543086|Drug|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
79377630|NCT03356730|Other|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
79830141|NCT00885586|Device|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
79830142|NCT00885586|Drug|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
79830143|NCT00885586|Procedure|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
79830144|NCT02543242|Device|InToneTM (InControl Medical, LLC) - Medical Device|
79830145|NCT02543008|Procedure|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
79830146|NCT02543008|Procedure|Physical activity|Information already included in arm/group descriptions.
80004606|NCT02125526|Device|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
80004607|NCT05195593|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
79237033|NCT05342194|Drug|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
79377631|NCT03354702|Other|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
79377632|NCT03354702|Other|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
79377633|NCT03364998|Drug|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
79237034|NCT05342194|Drug|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
79830147|NCT02543008|Procedure|Placebo|Information already included in arm/group descriptions.
79830148|NCT02542930|Radiation|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
79830149|NCT02542930|Drug|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
79830150|NCT00704730|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
79377634|NCT03364998|Drug|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
79377635|NCT03356418|Other|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
79830151|NCT00704730|Drug|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
79830152|NCT00881764|Procedure|Inguinal hernia surgery|Non-experimental procedure
79830153|NCT00881764|Procedure|General anesthesia|Non-experimental procedure/treatment
79830154|NCT04038034|Dietary Supplement|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
79830155|NCT04038034|Dietary Supplement|Placebo|Placebo
79830156|NCT04037878|Procedure|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
79237035|NCT05342194|Drug|Oral placebo|Oral placebo po QD continuously
79237036|NCT05342194|Drug|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
79237037|NCT05342194|Drug|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
79237038|NCT05342194|Drug|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
79237039|NCT04422496|Drug|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
79237040|NCT05341804|Behavioral|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
79377636|NCT03356418|Other|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
79377637|NCT04520022|Drug|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
79391162|NCT01591499|Device|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
79830157|NCT04037878|Procedure|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
79830158|NCT04037878|Drug|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
79830159|NCT00881842|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
79830160|NCT00651261|Drug|cytarabine|Given IV
79830161|NCT00651261|Drug|daunorubicin|Given IV
79830162|NCT00651261|Drug|midostaurin|Given orally
80004608|NCT03602118|Drug|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
80004609|NCT02131142|Device|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
79830163|NCT00651261|Other|placebo|Given orally
79830164|NCT00651261|Drug|dexamethasone acetate|ocular medication administration
80004610|NCT01375309|Dietary Supplement|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5*10to9th bacteria per day
80004611|NCT01375309|Dietary Supplement|Placebo contains dextrin|0.5 of dextrin
80004612|NCT03604848|Drug|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
80004613|NCT03604848|Drug|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
80004614|NCT03604848|Drug|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
79391163|NCT01591499|Device|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
79391164|NCT03178656|Drug|Sorafenib|continuous application of the drugs
80004615|NCT03604848|Drug|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, >70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, >70kg 1200 mg daily;"
79391165|NCT03178656|Procedure|surgery|curative resection
79531544|NCT01431547|Drug|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m^2, and escalated for successive cohorts of participants until MTD is found
79531545|NCT01431547|Drug|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
79687481|NCT03621696|Other|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
79687482|NCT03594747|Drug|Tislelizumab|Administered intravenously as described
79687483|NCT03594747|Drug|Paclitaxel|Administered intravenously as described
79687484|NCT03594747|Drug|Nab-paclitaxel|Administered intravenously as described
79687485|NCT03594747|Drug|Carboplatin|Administered intravenously as described
79687486|NCT03592641|Drug|Savolitinib|Given PO
79687487|NCT03565783|Biological|Cemiplimab|Given IV
79687488|NCT03538119|Other|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
79830165|NCT00885820|Drug|Tacrolimus|Oral
79830166|NCT00885820|Drug|MMF|Oral
79830167|NCT00885820|Drug|Corticosteroids (Prednisone)|Oral
79830168|NCT02542618|Behavioral|Inquiry Based Stress Reduction (IBSR)|
80004616|NCT02125682|Drug|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
80004617|NCT02125682|Drug|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
79237041|NCT05341804|Behavioral|balance training|Includes static balance, dynamic balance and strength training
79237042|NCT05341258|Diagnostic Test|EtCO2|EtCO2
79237043|NCT05341258|Diagnostic Test|PaCO2|PaCO2
79237044|NCT03623789|Drug|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
79237045|NCT03623789|Drug|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
79237046|NCT03623789|Drug|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
79237047|NCT05307406|Biological|Experimental|Participants will receive a single IV infusion in a double blind manner
79302694|NCT04997967|Drug|Ketamine/Propofol|The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 [19]. Time taken to achieve this score was also recorded.
79531546|NCT01431547|Drug|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
79531547|NCT01431560|Device|fixation of the ankle fracture (Solco )|fixation with metallic implant
79377638|NCT04520334|Other|Zhineng Qigong intervention|"The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD."
79531548|NCT01431560|Device|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
79531549|NCT01431586|Drug|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
80004618|NCT03602040|Behavioral|PISICC|"PISICC consists of:~Standard disease-specific information leaflet~Personalised lifestyle consideration form~1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
79237048|NCT05341024|Other|Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
79237049|NCT05306470|Procedure|Ethyl chloride|Application of ethyl chloride for a cooling effect to numb the area for oral infiltration anesthetic
79531550|NCT01431599|Radiation|short-course radiation|33Gy/10 fractions
79830169|NCT02542618|Behavioral|Cognitive Behavioral Therapy (CBT)|
79830170|NCT02542774|Other|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
79237050|NCT05306470|Procedure|5% lidocaine gel|Application of 5% lidocaine gel to numb the area for oral infiltration anesthetic
79377639|NCT04508946|Drug|vitamin c - thiamine- hydrocortisone|Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
79377640|NCT03364842|Drug|Furosemide|Administering furosemide
79377641|NCT04443972|Other|PD VitalOs cement®|PD VitalOs cement®* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
79531551|NCT01431612|Drug|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
79531552|NCT01431612|Drug|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
79687489|NCT03538119|Other|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
79830171|NCT02567838|Drug|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
79830172|NCT02567838|Drug|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
79237051|NCT05340010|Drug|Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU|From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
79377642|NCT04443972|Other|Hydroxyapatite bone graft|a bioceramic bone substitute, providing a scaffold for bone deposition
79531553|NCT01431612|Drug|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
79830173|NCT00885898|Procedure|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
79830174|NCT00885898|Procedure|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
79237052|NCT05339386|Drug|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
80004619|NCT03551444|Drug|Administration of DAA-based treatment|"Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~Virological failures and early discontinuations of therapy due to adverse events will be also registered."
79237053|NCT05339074|Drug|Ketamine Hydrochloride|60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
79237054|NCT05338996|Behavioral|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
79531554|NCT01431625|Other|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~.- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
79531555|NCT01431651|Dietary Supplement|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
79237055|NCT05352490|Diagnostic Test|calculate LUS score|calculate LUS score
79237056|NCT05560282|Drug|Fenfluramine|"FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5."
79237057|NCT03683615|Procedure|repair of orbital floor fractures using resorbable plates|
79377643|NCT04443972|Other|biodegardable collagen membrane|provide efficacious barriers that were interposed between the flap and root surface.
80004620|NCT03604770|Other|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
80004621|NCT02125760|Other|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
79377644|NCT03356184|Device|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
79377645|NCT03356184|Device|The Earlysense System Device Group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
79377646|NCT03364764|Drug|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
79531556|NCT01431664|Drug|multikinase inhibitor AT9283|
79377647|NCT02519400|Drug|Amitriptyline|Single oral dosing
79377648|NCT02518542|Procedure|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
79377649|NCT02518542|Procedure|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
79377650|NCT02518542|Procedure|Endoscopic intervention C|Endoscopic balloon dilatation
79687495|NCT03468985|Drug|Cabozantinib|Given PO
79377651|NCT02518542|Procedure|Laparoscopic Surgery|Laparoscopic Heller myotomy
79531557|NCT01431664|Other|laboratory biomarker analysis|
79531558|NCT01431664|Other|pharmacological study|
79531559|NCT01431677|Procedure|Muscle Biopsy|
79687496|NCT03468985|Biological|Ipilimumab|Given IV
79687497|NCT03468985|Biological|Nivolumab|Given IV
79830175|NCT05462574|Other|No Intervention|No Intervention
79830176|NCT00651183|Drug|Pramipexole immediate release|
80004622|NCT02125760|Other|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
80004623|NCT05760391|Radiation|Radiotherapy|IMRT or SABR for patients with ESCC.
80004624|NCT03604614|Drug|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
79830177|NCT00810381|Drug|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
79830178|NCT00810381|Drug|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
79830179|NCT00810381|Drug|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
79830180|NCT00810381|Drug|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
79830181|NCT02553057|Device|mechanical ventilation|
79830182|NCT00800319|Drug|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
80004625|NCT03604614|Drug|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
80004626|NCT01361945|Drug|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
79830183|NCT00800319|Drug|Placebo|Volume matched placebo; oral solution; single dose
79830184|NCT00813501|Biological|immunosuppressive therapy|
79237058|NCT03678779|Behavioral|Incentive|$5 grocery gift card
79237059|NCT03678779|Behavioral|Education|Video-based brief nutrition education
79531560|NCT01431690|Drug|warfarin|A single 25 mg dose of warfarin
79687498|NCT03447912|Behavioral|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
79687499|NCT03434418|Drug|osimertinib|80 mg oral administration daily
79687500|NCT03417336|Radiation|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
80004627|NCT03601962|Dietary Supplement|Aqualief|400mg oral mucoadesive tablets
80004628|NCT03601962|Other|Placebo|400mg Placebo oral mucoadesive tablets
80004629|NCT02127242|Procedure|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
79237060|NCT03678779|Behavioral|Combined|Both Incentive and Education interventions received
79531561|NCT01431690|Drug|omefas|4 x 1 g capsule dose of Epanova®
79687501|NCT03386539|Drug|Everolimus|Everolimus tablet
79687502|NCT03386539|Drug|Tacrolimus|Tacrolimus capsule or liquid suspension
79687503|NCT03386539|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
79687504|NCT03366103|Biological|Navitoclax|Given PO
79687505|NCT03366103|Drug|Vistusertib|Given PO
79687506|NCT03314337|Device|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
79830185|NCT00813501|Other|immunological diagnostic method|
79830186|NCT00813501|Procedure|allogeneic hematopoietic stem cell transplantation|
79237061|NCT03677453|Other|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
79237062|NCT03678701|Dietary Supplement|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
79237063|NCT05338450|Drug|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
79237064|NCT05338450|Drug|Placebo|Placebo equivalent to experimental arm
79531562|NCT01431690|Drug|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
79531563|NCT01431729|Other|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
79830187|NCT00699972|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
79830188|NCT00699972|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
79830189|NCT00699972|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
79830190|NCT00800475|Drug|Gemfibrozil Tablets|
79830191|NCT00810849|Drug|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
80004630|NCT02237430|Device|MynxGrip|Closure device for femoral artery access closure
80004631|NCT02237430|Other|Manual compression|Conventional manual compression
80004632|NCT02546999|Drug|botox|The agent will be given only once at point zero in the time scheme for the project.
80004633|NCT02546999|Drug|placebo|The agent will be given only once at point zero in the time scheme for the project.
80004634|NCT02131220|Drug|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
80004635|NCT02131220|Drug|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
80004636|NCT02131220|Drug|normal saline|intracoronary bolus infusion using selective catheter during PCI
79830192|NCT00810849|Biological|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
79687507|NCT03307109|Other|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
79687508|NCT03304821|Drug|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
79687509|NCT03304821|Drug|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
79830193|NCT00922311|Drug|Aliskiren|Titrate from 150 mg daily to 300 mg daily
79830194|NCT00810927|Procedure|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
79830195|NCT00810927|Procedure|Laser Doppler flowmetry|Measurement of choroidal blood flow
79830196|NCT00810927|Procedure|Measurement of intraocular pressure|
79830197|NCT00813657|Behavioral|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, ~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (~8 minutes), followed by toning and very light resistance exercises (~20 minutes) and a light intensity cool-down (~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
79830198|NCT00811005|Radiation|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
80004637|NCT03601884|Behavioral|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication & Metabolic Monitoring, Collaborative & Strategies, Change enhancement, Visioning & Goal Setting and Maintain Well-being.
80004638|NCT03601884|Other|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
79377652|NCT04518696|Procedure|suprachoroidal buckling|"Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures."
79531564|NCT01431742|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
79687510|NCT03267121|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
79687511|NCT03267121|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
79687512|NCT03253679|Drug|Adavosertib|Given PO
79687513|NCT03208010|Behavioral|Diabetes Prevention Intervention|"Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~Specific goals set for weight loss and physical activities~Fitbits provided for monitoring physical activity goals~Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes."
79531565|NCT01431768|Device|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
80004639|NCT03550664|Device|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
80004640|NCT04042077|Drug|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
79531566|NCT01431781|Drug|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
79377653|NCT04509258|Drug|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
79687514|NCT03208010|Other|Enhanced Usual Care|"Monitoring by existing personal physicians~Feedback on lab results~Referrals to physicians or clinics, if needed~Diabetes prevention educational materials"
79687515|NCT03187340|Behavioral|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
79830199|NCT00811005|Radiation|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
79830200|NCT00813735|Drug|Eszopiclone|Eszopiclone 2mg daily at bedtime
79830201|NCT00813735|Drug|Placebo|Placebo daily at bedtime
79830202|NCT00813735|Drug|Escitalopram|Escitalopram 10mg or 20mg
79830203|NCT00811083|Drug|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
79830204|NCT00642759|Drug|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
79830205|NCT00642759|Drug|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
79830206|NCT00642759|Drug|Bevacizumab|IV infusion
79377654|NCT04509258|Dietary Supplement|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
79830207|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
79531567|NCT01431781|Other|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
79687516|NCT03187340|Behavioral|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
79687517|NCT03181477|Device|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
79830208|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
79830209|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
79830210|NCT00817557|Drug|Loteprednol|Anti-inflammatory
79830211|NCT00817557|Other|Rewetter|
79830212|NCT00811161|Device|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
79830213|NCT00611026|Drug|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
79830214|NCT00611026|Drug|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
79830215|NCT00611026|Drug|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
79830216|NCT00813969|Biological|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
79531568|NCT01431833|Drug|TR-701 FA|Oral single dose 200 mg
79531569|NCT01431859|Biological|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
79531570|NCT01431859|Other|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
79830217|NCT02552589|Other|Amine fluoride|toothpaste
79830218|NCT02552589|Other|Placebo|toothpaste
79830219|NCT00811239|Drug|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
79830220|NCT00811239|Other|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
79302695|NCT04997967|Drug|Propofol|Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
79302696|NCT02479607|Device|Smartphone or tablet|
79302697|NCT03202225|Device|constrained polyethylene|constrained polyethylene insert
79302698|NCT03200275|Diagnostic Test|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
79302699|NCT02479295|Device|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
79302700|NCT04991415|Other|Manual Therapy|
79531571|NCT01431885|Procedure|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
79830221|NCT00814047|Drug|Yohimbine hydrochloride|
79377655|NCT04509258|Drug|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
79377656|NCT04509258|Drug|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
79830222|NCT00646113|Device|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
79830223|NCT00814125|Drug|Anastrozole (Arimidex)|1mg, orally, once daily
79830224|NCT00814125|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
79830225|NCT00814125|Drug|Nolvadex placebo|
79830226|NCT00814125|Drug|Arimidex placebo|
80004641|NCT04042077|Drug|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
80004642|NCT04042077|Drug|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
80004643|NCT04042077|Drug|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
80004644|NCT04042077|Drug|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
80004645|NCT03557359|Drug|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
79237065|NCT03683537|Diagnostic Test|Glial fibrillary acidic protein|3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
79237066|NCT03677297|Drug|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
79302701|NCT03214471|Behavioral|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
79531572|NCT01431885|Procedure|Cervical change|Diagnosis will be made by digital examination of cervical change
79687518|NCT03155906|Other|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
79302702|NCT04990947|Other|lifestyle / RYGB|No intervention, just 2 different groups will be included
79377657|NCT03354624|Drug|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
79531573|NCT01431898|Drug|GS-9669 tablets|
79531574|NCT01431898|Drug|Placebo to Match GS-9669 tablet|
79531575|NCT01431911|Drug|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
79531576|NCT01431911|Drug|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
79531577|NCT01431924|Drug|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
79687519|NCT03099148|Drug|Reference Formulation (R)|Administered PO
79830227|NCT04016883|Other|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
79830228|NCT04016883|Other|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
79830229|NCT00817713|Drug|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~Praziquantel 2400mg single dose~Ivermectin 12 mg, single dose~Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
79830230|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
79830231|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
79830232|NCT00422383|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
79830233|NCT00814281|Other|placebo|Placebo
79830234|NCT00814281|Drug|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
79830235|NCT00817791|Device|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
80004646|NCT03550586|Other|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
80004647|NCT03626025|Other|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
80004648|NCT02127320|Drug|Rosuvastatin 20mg|
80004649|NCT02127320|Drug|Ezetimibe 10mg|
80004650|NCT02127320|Drug|Rosuvastatin 20mg + Ezetimibe 10mg|
79830236|NCT00811551|Device|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
80004651|NCT03604380|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
79687520|NCT03099148|Drug|LY3337641 (T1)|20 mg PO
79687521|NCT03099148|Drug|LY3337641 (T2)|20 mg PO
79687522|NCT03099109|Drug|LY3321367|Administered IV
79830237|NCT02542540|Other|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
79830238|NCT00811629|Other|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
79830239|NCT02542228|Other|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
80004652|NCT03604380|Other|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
80004653|NCT02125916|Other|oxygen therapy|
80004654|NCT03522415|Drug|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
80004655|NCT03522415|Drug|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
80004656|NCT02125994|Procedure|Interscalene nerve block|
79237067|NCT03683459|Device|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
79377658|NCT03354546|Diagnostic Test|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
79377659|NCT03354468|Behavioral|fall prevention program|fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
79531578|NCT01431924|Drug|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
80004657|NCT04226833|Drug|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
80004658|NCT02131298|Drug|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
80004659|NCT02131298|Drug|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
80004660|NCT01375387|Drug|Lacosamide|100 mg oral tablet, single dose
79302703|NCT02483195|Drug|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
79531579|NCT01431937|Drug|GSK2018682|Active Drug
79531580|NCT01431937|Drug|Placebo|Placebo
79531581|NCT01432028|Drug|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
79531582|NCT01432028|Drug|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
79531583|NCT01432067|Other|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
79531584|NCT01432067|Other|Classic physical activities|Daily physical activities based on a standard guide
79531585|NCT01432080|Drug|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
79531586|NCT01432080|Drug|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
79687523|NCT03099109|Drug|LY3300054|Administered IV
79687524|NCT03095352|Biological|Pembrolizumab|200 mg Given IV
79687525|NCT03095352|Drug|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
79687526|NCT03095352|Biological|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
79687527|NCT03088813|Drug|Irinotecan liposome injection|IV
79687528|NCT03088813|Drug|Topotecan|IV
79687529|NCT03061474|Drug|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
79687530|NCT03061474|Drug|Placebo Comparator|Oral Tablet
79687531|NCT03040726|Drug|Netupitant|Given PO
79687532|NCT03040726|Drug|Palonosetron|Given PO
79687533|NCT03040726|Drug|Palonosetron Hydrochloride|Given PO
79687534|NCT03040726|Other|Placebo|Given PO
79687535|NCT03040726|Other|Questionnaire Administration|Ancillary studies
79687536|NCT02936453|Procedure|Device implantation|"Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~Implantation of Activa RC neurostimulator"
80004661|NCT01375387|Drug|Lacosamide|Lacosamide 2 X 100 mg tablet
80004662|NCT01375387|Drug|Lacosamide|Lacosamide 4 X 100mg tablet
80004663|NCT01375387|Other|Placebo 3|Placebo - 3 tablets
80004664|NCT01375387|Other|Placebo 4|Placebo - 4 tablets
80004665|NCT01375387|Other|Placebo 2|Placebo - 2 tablets
79237068|NCT05303584|Biological|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
79377660|NCT03355950|Procedure|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
79377661|NCT03355950|Procedure|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
79377662|NCT03364374|Behavioral|Postural counseling|A therapist will provide verbal/physical cues to improve the participants posture
79830240|NCT00814359|Drug|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
79830241|NCT00814359|Drug|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
79531587|NCT01432080|Drug|Montelukast|Montelukast 10 mg PO qhs for 3 months
79531588|NCT01432080|Drug|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
79687537|NCT02932501|Procedure|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
79830242|NCT00817869|Other|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
79830243|NCT00612040|Drug|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
79830244|NCT00612040|Drug|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
79830245|NCT00612040|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
79830246|NCT00612040|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
79830247|NCT00422227|Drug|Etanercept , Methotrexate|"Etanercept: 25 mg twice weekly over 16 weeks, SC~Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO"
79377663|NCT03364218|Drug|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
79687538|NCT02932501|Procedure|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
79237069|NCT05303584|Biological|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
79302704|NCT02483195|Drug|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
79377664|NCT04444284|Biological|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
79377665|NCT04444284|Biological|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
79531589|NCT01432093|Other|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
79531590|NCT01432093|Other|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
79687539|NCT02932501|Procedure|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
79687540|NCT02899728|Drug|Carboplatin|Given IV
79687541|NCT02899728|Drug|Cediranib|Given PO
79687542|NCT02899728|Drug|Cediranib Maleate|Given PO
79687543|NCT02899728|Drug|Cisplatin|Given IV
79687544|NCT02899728|Drug|Etoposide|Given IV
79687545|NCT02899728|Drug|Olaparib|Given PO
79687546|NCT02899065|Diagnostic Test|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
79830248|NCT00422227|Drug|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
79830249|NCT02551497|Drug|CNV1014802|
79830250|NCT00811785|Drug|Copper Histidine|Daily subcutaneous injections for three years
79830251|NCT00814515|Drug|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
79830252|NCT00814515|Drug|NOVA22007|Vehicle
79830253|NCT00814593|Biological|lymphokine-activated killer cells|Instilled into the tumor bed cavity
79830254|NCT00814593|Drug|polifeprosan 20 with carmustine implant|Intracranial placement
79830255|NCT02542306|Drug|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
79830256|NCT00817947|Device|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
79830257|NCT00421993|Drug|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
79830258|NCT00421993|Drug|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
79830259|NCT00421993|Drug|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
79830260|NCT00421993|Drug|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
79531591|NCT01432106|Drug|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of < 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
79531592|NCT01432119|Device|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
79531593|NCT01432119|Drug|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
79531594|NCT01432119|Drug|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
79237070|NCT05303584|Biological|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
79531595|NCT01432119|Procedure|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
79531596|NCT01432132|Behavioral|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
79830261|NCT00884884|Drug|Double Placebo|1 capsule daily
80004666|NCT03936699|Device|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet & Exercise Subjects to be instructed on a healthy 1200 calorie diet."
80004667|NCT03936699|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
79237071|NCT03677219|Other|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
79237072|NCT03683303|Behavioral|mobile applications (APP)|"the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses."
79237073|NCT03683303|Behavioral|oral education|"the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
79237074|NCT03676985|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
79237075|NCT03676985|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
79237076|NCT03676985|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
79237077|NCT05348824|Dietary Supplement|Moringa oleifera leaf|Leaf extract preparation
79377666|NCT04444284|Other|Placebo|Single dose administered intranasally on Day 1
80004668|NCT02126072|Dietary Supplement|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
80004669|NCT02126072|Dietary Supplement|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
80004670|NCT05194813|Other|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
79237078|NCT05348824|Drug|Sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
79237079|NCT03678155|Other|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
79237080|NCT03678077|Other|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
79377667|NCT04444284|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3)|Single dose administered intranasally on Day 1
79377668|NCT03354312|Drug|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
79377669|NCT03354312|Drug|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
79377670|NCT03354234|Other|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
79531597|NCT01432132|Behavioral|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
79531598|NCT01432158|Biological|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
79531599|NCT01432158|Biological|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
79830262|NCT00884884|Drug|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
80004671|NCT05194813|Other|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
80004672|NCT02853318|Biological|Bevacizumab|Given IV
80004673|NCT02853318|Drug|Cyclophosphamide|Given PO
80004674|NCT02853318|Other|Laboratory Biomarker Analysis|Correlative studies
79830263|NCT00884884|Drug|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
79830264|NCT00884884|Drug|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
79830265|NCT00884884|Drug|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
79830266|NCT00884884|Drug|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
79830267|NCT00884884|Drug|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
79830268|NCT00884884|Drug|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
79830269|NCT00884884|Drug|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
79830270|NCT00884884|Drug|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
79830271|NCT00884962|Device|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
79830272|NCT00814749|Procedure|midureteral sling|midureteral sling
79830273|NCT00814749|Other|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
79830274|NCT01037725|Drug|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
79830275|NCT01037725|Drug|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
79531600|NCT01432184|Procedure|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
79830276|NCT02551029|Other|Capsaicin|
79830277|NCT02551029|Other|Placebo|
79830278|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
79830279|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
79237081|NCT05301088|Other|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
79377671|NCT03354234|Other|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
79377672|NCT03354234|Other|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
79377673|NCT03354234|Device|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
79531601|NCT01432197|Other|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
79830280|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
79830281|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
79377674|NCT03354234|Device|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
79377675|NCT03364062|Procedure|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
79377676|NCT03363984|Drug|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
79377677|NCT03363984|Drug|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
79377678|NCT03363828|Drug|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
79391166|NCT03177096|Behavioral|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
79531602|NCT01432210|Other|Post-prandial Feeding Study|
79830282|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
79830283|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
79830284|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
79830285|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
79830286|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
79237082|NCT02988401|Drug|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
79237083|NCT02988401|Drug|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
79531603|NCT01432223|Drug|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
79531604|NCT01432249|Drug|Enbrel group|will be decided by treating physicians
79830287|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
79830288|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
79830289|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
80004675|NCT02853318|Biological|Pembrolizumab|Given IV
80004676|NCT02127476|Drug|KHK6640|Single ascending dose and multiple ascending doses administration
80004677|NCT02127476|Drug|Matching Placebo|Single ascending dose and multiple ascending doses administration
80004678|NCT03918213|Diagnostic Test|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
80004679|NCT03431545|Behavioral|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
79830290|NCT00413959|Drug|VELCADE®|1.6 mg/m^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
79531605|NCT01432301|Drug|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
79531606|NCT01432314|Other|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
79830291|NCT00413959|Drug|Rituximab|375 mg/m^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
79237084|NCT05299060|Procedure|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
79830292|NCT00413959|Drug|Cyclophosphamide|400 mg/m^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
79830293|NCT00413959|Drug|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
79830294|NCT00814905|Drug|saline|A saline infusion after delivery (one dose)
79237085|NCT05299060|Procedure|standard cure|"The standard cure consists of:~Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
79237086|NCT05268874|Other|Clavipectoral block|Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
79237087|NCT04246528|Behavioral|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
79237088|NCT05330962|Other|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
79237089|NCT05329246|Device|AI-assisted Clinical Assistant PMcardio|PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
79302705|NCT02483195|Drug|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
79302706|NCT02483195|Other|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
79830295|NCT00814905|Drug|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
79830296|NCT00814905|Drug|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
79830297|NCT00814905|Drug|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
79830298|NCT00645567|Device|Unassisted Manual Transfer|No device assistance
79830299|NCT00645567|Device|Standard Transfer Board|Flat surface board
79830300|NCT00645567|Device|Glide n' Go|Flip down power lift chair
79830301|NCT00645567|Device|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
79377679|NCT04508868|Behavioral|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
79830302|NCT00645567|Device|Ryno lift|Lift for the wheelchair
79830303|NCT00611884|Drug|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
79377680|NCT04508868|Behavioral|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
79377681|NCT04524468|Diagnostic Test|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
79531607|NCT01432314|Other|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
79830304|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
79830305|NCT00611884|Drug|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
79377682|NCT03354156|Drug|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
79377683|NCT03519438|Other|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
79377684|NCT04444206|Procedure|Transvaginal ultrasound cervical length screening|Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
79830306|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
79830307|NCT00611884|Drug|metformin|Tablets, 1500-2000 mg/day
79377685|NCT04524078|Other|intensive integrated intervention care program|intensive integrated intervention care program [ICP] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
79377686|NCT03355716|Drug|bupivacaine|Bupivacaine 25 ml (0.25%)
79377687|NCT03355716|Drug|morphine|Morphine (3.0 mg)
79531608|NCT01432340|Biological|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
79830308|NCT03867825|Device|Non-invasive hemodynamic monitoring|Impedance cardiography
79531609|NCT01432353|Drug|DFRF4539A|multiple ascending doses
79531610|NCT01432418|Other|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
79531611|NCT01432431|Procedure|spiritual therapy|Undergo palliative spiritual care
79531612|NCT01432431|Other|questionnaire administration|Ancillary studies
79302707|NCT03071991|Procedure|study group|local anesthetic drug will be used
79302708|NCT03071991|Procedure|control group|no local anesthetic drug will be used
79302709|NCT02479373|Other|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
79302710|NCT02479373|Other|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
79531613|NCT01432431|Other|survey administration|Ancillary studies
79531614|NCT01432431|Other|counseling intervention|Undergo palliative spiritual care
79531615|NCT01432431|Other|psychosocial support for caregiver|Undergo palliative spiritual care
79531616|NCT01432431|Procedure|psychosocial assessment and care|Undergo palliative spiritual care
79531617|NCT01432470|Drug|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
79531618|NCT01432470|Drug|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
79531619|NCT01432483|Drug|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
79302711|NCT02479373|Other|Biodex dynamometer|To study muscle strength
79302712|NCT02479373|Other|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
79302713|NCT02479373|Other|Quality of life questionnaires|
79531620|NCT01432496|Drug|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
79531621|NCT01432496|Drug|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
79830309|NCT00420745|Biological|Rotarix™|Two-dose oral vaccination.
79830310|NCT00420745|Biological|Placebo|Two-dose oral administration
79830311|NCT00611806|Dietary Supplement|Folic Acid|Folic acid 2mg po daily
79830312|NCT00611806|Dietary Supplement|B12|B12 400 micrograms po daily
79830313|NCT00611806|Other|Placebo|1 capsule po daily
79830314|NCT00413413|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
79830315|NCT00413413|Drug|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
79830316|NCT00413413|Drug|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
79830317|NCT00886132|Drug|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
79830318|NCT01040455|Drug|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
79377688|NCT03355716|Drug|fentanyl|fentanyl (30.0 Mc)
79830319|NCT01040455|Drug|placebo|placebo once daily for eight weeks
80004680|NCT03431545|Behavioral|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
79531622|NCT01432509|Other|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and < 1,26 g/l) or fasting blood glucose ≥ 1 g/l and < 1,10 g/l with HbA1c ≥ 6,5%.~First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~End of study phone call"
79237090|NCT05501470|Drug|VSL#3|"VSL#3 (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center on a weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
79830320|NCT01040611|Behavioral|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
79377689|NCT03355716|Drug|Ketamine:|ketamine (0.5 mg/kg).
79531623|NCT01432522|Drug|Epinephrine|"Intranasal epinephrine 5 mg /spray~Intramuscular epinephrine 0.3 mg~Intranasal saline spray"
79531624|NCT01432548|Procedure|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
79830321|NCT01040767|Other|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
79531625|NCT01432587|Drug|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
79531626|NCT01432613|Procedure|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
79687547|NCT02899065|Other|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
79687548|NCT02894177|Procedure|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
79687549|NCT02893930|Drug|Sapanisertib|Given PO
80004681|NCT03431545|Behavioral|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
79237091|NCT05501470|Device|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
79237092|NCT05501470|Drug|Placebo|The placebo for the experimental drug VSL#3 (Vivomixx) is microcrystalline cellulose. It is similar in appearance to VSL#3.
79377690|NCT04524312|Procedure|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
79377691|NCT04524312|Diagnostic Test|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
79687550|NCT02840890|Procedure|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
79687551|NCT02840890|Procedure|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
79687552|NCT02796781|Biological|Lung stem cells|Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
79687553|NCT02785562|Other|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
79830322|NCT01040923|Device|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
79830323|NCT01041001|Biological|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
79830324|NCT01041001|Procedure|Microfracture treatment|
79830325|NCT01041157|Other|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
79830326|NCT01041235|Drug|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
79830327|NCT01041313|Drug|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
80004682|NCT05194657|Device|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
79830328|NCT01041313|Drug|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
80004683|NCT05194657|Device|monofocal IOL|Acrysof IQ, monofocal IOL
80004684|NCT02131376|Procedure|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
80004685|NCT02131376|Procedure|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
80004686|NCT05375370|Other|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
80004687|NCT05194501|Other|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
80004688|NCT03626727|Drug|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
79377692|NCT04524312|Device|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
79377693|NCT04524156|Other|Physiology|"Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method)."
79687554|NCT02783664|Other|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
80004689|NCT02237742|Drug|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
80004690|NCT02131454|Other|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
79377694|NCT03355638|Drug|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
79377695|NCT03355638|Drug|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
79687555|NCT02780804|Drug|Entinostat|Given PO
79687556|NCT02780804|Other|Laboratory Biomarker Analysis|Correlative studies
79687557|NCT02780804|Other|Pharmacological Study|Correlative studies
79687558|NCT02710968|Device|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
79687559|NCT02688959|Behavioral|Tai Chi|
79687560|NCT02688959|Behavioral|Exercise|
79377696|NCT03355638|Drug|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
79687561|NCT02629393|Drug|ORGN001 (formerly ALXN1101)|
79830329|NCT01041391|Procedure|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
79830330|NCT03760939|Other|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
79830331|NCT00610714|Drug|AZD0530|oral once daily dose
79830332|NCT00610714|Drug|Carboplatin|intravenous injection
79830333|NCT00610714|Drug|Paclitaxel|intravenous infusion
79830334|NCT00403585|Drug|adefovir dipivoxil 10mg|
80004691|NCT03604224|Drug|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
79377697|NCT03350646|Other|Volume of medium during embryo transfer|
79687562|NCT02604459|Device|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
79687563|NCT02604459|Device|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
79830335|NCT04038112|Other|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
80004692|NCT01373905|Procedure|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
80004693|NCT01373905|Procedure|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
79830336|NCT00886210|Procedure|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
79830337|NCT00886210|Procedure|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
79531627|NCT01432639|Other|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
79830338|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
80004694|NCT04159753|Device|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
80004695|NCT02126384|Drug|pneumovax vaccination|vaccination
79830339|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
79830340|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
79687564|NCT02604459|Procedure|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
80004696|NCT02035410|Procedure|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
79687565|NCT02604459|Procedure|General anesthesia|General anesthesia will be used in both groups
79687566|NCT02604459|Drug|propofol|propofol per protocol
80004697|NCT02404155|Drug|Clozapine|
79531628|NCT01432665|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
79531629|NCT01432665|Drug|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
79531630|NCT01432665|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
79531631|NCT01432691|Procedure|Hemi (hemialloplastik)|THA vs hemi
80004698|NCT05760235|Procedure|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
80004699|NCT02127788|Drug|Micafungin|intravenous
80004700|NCT03601650|Behavioral|Mindful eating|Attending to the sensory properties of food as it is eaten
79237093|NCT05266456|Biological|24 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
79237094|NCT05266456|Biological|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
79237095|NCT05329012|Device|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
79531632|NCT01432704|Drug|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
79687567|NCT02604459|Drug|fentanyl|fentanyl per protocol
79687568|NCT02604459|Drug|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
79687569|NCT02548351|Drug|Obeticholic Acid|
79237096|NCT05328466|Device|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
79237097|NCT05295550|Other|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
79687570|NCT02548351|Drug|Placebo|
79687571|NCT02543268|Biological|Ad26.ZEBOV-Batch #1|Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
79687572|NCT02543268|Biological|Ad26.ZEBOV-Batch #2|Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
79687573|NCT02543268|Biological|Ad26.ZEBOV-Batch #3|Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
79830341|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
79830342|NCT04037644|Procedure|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
79830343|NCT04037644|Procedure|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
79830344|NCT00403273|Drug|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
79531633|NCT01432717|Biological|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
80004701|NCT03601650|Behavioral|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
80004702|NCT05194423|Device|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
80004703|NCT03626649|Device|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~DiamondTemp Ablation Catheter~o Unidirectional and Bidirectional models~DiamondTemp Catheter-to RFG Cable~DiamondTemp GenConnect Cable~DiamondTemp FASTR Generator with Footswitch~DiamondTemp Irrigation Pump~DiamondTemp Irrigation Tubing Set"
80004704|NCT02131688|Drug|Mitoxantrone Hydrochloride Liposome|
80004705|NCT03604146|Behavioral|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
80004706|NCT01375465|Device|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
80004707|NCT03604068|Device|RecoveryRx|A pulsed shortwave therapy medical device
80004708|NCT03604068|Device|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
80004709|NCT02126462|Biological|Na-APR-1 (M74)/Alhydrogel®|
80004710|NCT02126462|Biological|Na-GST-1/Alhydrogel®|
80004711|NCT02126462|Biological|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
80004712|NCT03113071|Drug|Decitabine|Decitabine will be administered in combination with Digoxin
80004713|NCT03113071|Drug|Digoxin|Decitabine will be administered in combination with Digoxin
80004714|NCT03601572|Other|No intervention|No intervention
80004715|NCT02131844|Other|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
80004716|NCT02131844|Other|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
80004717|NCT03050307|Drug|TAK-438|TAK-438 tablets
79531634|NCT01432717|Other|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
79531635|NCT01432743|Procedure|NavX Fusion|Using NavX Fusion to guide catheter ablation
80004718|NCT03050307|Drug|Lansoprazole|Lansoprazole capsules
80004719|NCT03050307|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
80004720|NCT03050307|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
79531636|NCT01432743|Procedure|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
79531637|NCT01432769|Dietary Supplement|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
79531638|NCT01432782|Drug|Placebo|Saline 4 ml
79531639|NCT01432782|Drug|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
79531640|NCT01432795|Device|Gliding aids for medical compression stockings|"Each subject tests devices:~3 gliding aids for stockings with closed tips~3 gliding aids for stockings with open tips~2 stocking butlers using~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed compression stockings class 1 (18 - 21 mmHg)"
79531641|NCT01432821|Other|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~Sequence A during visit 2 followed by sequence B during visit 3~or sequence B during visit 2"
79687574|NCT02543268|Biological|MVA-BN-Filo|MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57.
80004721|NCT03050307|Drug|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
79302714|NCT03074955|Device|leg wrapping with tension|"Apply elastic bandages with tension to both legs before injecting propofol.~After 3 minutes, remove elastic bandages."
79687575|NCT02543268|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
79687576|NCT02535338|Drug|Erlotinib Hydrochloride|Given PO
79687577|NCT02535338|Other|Laboratory Biomarker Analysis|Correlative studies
79687578|NCT02535338|Drug|Onalespib Lactate|Given IV
79687579|NCT02535338|Other|Pharmacological Study|Correlative studies
80004722|NCT03601494|Other|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
80004723|NCT03601494|Drug|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
79830345|NCT00403273|Drug|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
79830346|NCT00885274|Drug|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
79830347|NCT00885274|Drug|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
79531642|NCT01432834|Other|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH & Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
79687580|NCT02500797|Biological|Ipilimumab|Given IV
79687581|NCT02500797|Other|Laboratory Biomarker Analysis|Correlative studies
79687582|NCT02500797|Biological|Nivolumab|Given IV
79687583|NCT02500797|Other|Quality-of-Life Assessment|Ancillary studies
80004724|NCT05760157|Other|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
79531643|NCT01432834|Other|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
79830348|NCT00885430|Drug|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
80004725|NCT02126540|Device|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
79531644|NCT01432860|Behavioral|In-person counseling|The design is a 3 [in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care] X 7 [baseline, 4, 8, 12, 16, 20, and 24 month follow-up] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
80004726|NCT03603990|Procedure|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
79531645|NCT01432860|Behavioral|Workbook|Participants will read a workbook and perform skills training exercises.
79531646|NCT01432860|Behavioral|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
79302715|NCT03074955|Procedure|Trendelenburg position|"Apply Trendelenburg position positon of 10 degree after injectin propofol~After 3 minutes, change to supine position"
79531647|NCT01432873|Drug|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
79687584|NCT02136147|Drug|methylphenidate medication|
79687585|NCT02136147|Drug|atomoxetine medication|
79687586|NCT02136147|Drug|lisdexamphetamine medication|
79687587|NCT02136147|Drug|guanfacine medication|
79687588|NCT02090101|Drug|ANAKINRA|
79687589|NCT02047461|Drug|ORGN001 (formerly ALXN1101)|IV infusion
79687590|NCT02017704|Radiation|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
79687591|NCT02017704|Drug|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
79687592|NCT02017704|Radiation|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
79687593|NCT02017704|Drug|FOLFOX6|"Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
79830349|NCT00886366|Drug|AZD6714|Oral single doses a-h suspension
79830350|NCT00886366|Drug|Placebo|Oral single doses suspension
79830351|NCT00886366|Drug|AZD6714|Oral single doses a-d suspension
79830352|NCT00886366|Drug|AZD6714|Oral single doses d and g suspension
79830353|NCT00886444|Drug|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
79830354|NCT00888550|Procedure|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
79830355|NCT00888550|Procedure|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
79830356|NCT00888706|Behavioral|Control Condition|The group participated in the usual nursing home activities and routines.
79830357|NCT00888706|Behavioral|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
79830358|NCT00888706|Behavioral|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
79830359|NCT00888706|Behavioral|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
79830360|NCT00402727|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
79830361|NCT00402727|Drug|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
79830362|NCT04037722|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
79830363|NCT04037722|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
79830364|NCT02541916|Other|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
79830365|NCT00923494|Drug|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
79830366|NCT00923494|Drug|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
79237098|NCT02269917|Drug|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
79377698|NCT03354078|Procedure|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
79377699|NCT03354078|Procedure|continous sutures|The way of closure of subcutanous tissue is by continous sutures
79377700|NCT03350568|Other|Total dietary NEAC assessed at baseline|
79237099|NCT02269917|Drug|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) as per current treatment regimen.
79237100|NCT02269917|Drug|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
79237101|NCT02522494|Behavioral|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
79377701|NCT01626664|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
79377702|NCT01626664|Drug|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
79377703|NCT01626664|Drug|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
79531648|NCT01432873|Drug|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
79531649|NCT01432912|Behavioral|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
79687594|NCT02017704|Procedure|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
79687595|NCT02014415|Procedure|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
79237102|NCT02522494|Behavioral|Video|An educational intervention delivered prior to patients' visits with primary care providers.
79237103|NCT05263570|Drug|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
79377704|NCT01626664|Drug|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
79377705|NCT04515966|Drug|Methylprednisolone Injection [Solu-Medrol]|A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
79377706|NCT04515966|Device|wrist splint|A standard wrist splint
79377707|NCT03350490|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
79377708|NCT03350490|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
79377709|NCT03355404|Other|standing patient|patient goes standing to the surgery room
79531650|NCT01432925|Procedure|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
79687596|NCT02005471|Drug|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
79830367|NCT00923494|Drug|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
79830368|NCT00886522|Procedure|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
79531651|NCT01432964|Procedure|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
79687597|NCT02005471|Drug|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
80004727|NCT03603990|Procedure|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
79531652|NCT01432977|Drug|paracetamol /droperidol|
79687598|NCT02005471|Drug|Rituximab|"Rituximab will be administered at a dose of 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
79687599|NCT01977651|Drug|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
80004728|NCT02127866|Drug|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
80004729|NCT02127866|Drug|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
80004730|NCT03601416|Drug|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
80004731|NCT03601416|Drug|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
79377710|NCT02518386|Other|No intervention|No intervention is planned
80004732|NCT04071379|Biological|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
80004733|NCT04071379|Biological|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
79687600|NCT01949311|Drug|Dupilumab|
79687601|NCT01933932|Drug|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
79377711|NCT01626820|Biological|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
79687602|NCT01933932|Drug|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
80004734|NCT03869697|Drug|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
80004735|NCT03550508|Biological|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
79377712|NCT04504656|Other|observation of postoperative leak, stenosis, mortality|detect complications in both groups
79377713|NCT04507932|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
79377714|NCT04504110|Diagnostic Test|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
79687603|NCT01933932|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
79377715|NCT03353844|Behavioral|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
79377716|NCT03355248|Other|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
79377717|NCT03350334|Drug|Duloxetine|Peri-operative Duloxetine administration
79531653|NCT01432977|Drug|paracetamol / ondansetron|
79531654|NCT01432990|Device|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
79531655|NCT01432990|Other|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
79687604|NCT01933932|Drug|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
80004736|NCT03607578|Behavioral|Other: Control Group - Minimal Intervention|Basic Campaign Folder
79830369|NCT00402649|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
79830370|NCT00888784|Procedure|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
79830371|NCT00888784|Drug|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
79830372|NCT00886678|Drug|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
79830373|NCT00886678|Drug|carboplatin|AUC=5,IV,q 21 days x 2 cycles
79830374|NCT00886678|Radiation|thoracic radiation|66 Gy over 33 fractions
79830375|NCT00886756|Drug|AZD8529|Oral
79830376|NCT00886756|Drug|Placebo|Oral
79830377|NCT00402337|Drug|linaclotide acetate|oral, once daily.
79830378|NCT00402337|Drug|Matching placebo|oral, once daily
80004737|NCT03607578|Behavioral|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
79687605|NCT01892722|Drug|Interferon beta-1a|Administration once weekly via i.m. injections.
79377718|NCT03350334|Drug|placebo|Placebo administration
79687606|NCT01892722|Drug|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
79377719|NCT04515108|Other|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
79531656|NCT01433003|Procedure|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
79687607|NCT01892722|Drug|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
79687608|NCT01892722|Drug|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
79687609|NCT01711658|Radiation|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
79830379|NCT00888862|Drug|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
79830380|NCT00886912|Other|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
79391167|NCT03177096|Behavioral|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
79391168|NCT03177096|Behavioral|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
79531657|NCT01433029|Other|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
79830381|NCT00886912|Other|normoxia|training under normoxic conditions
79830382|NCT04037332|Other|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
79830383|NCT00886990|Drug|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
79830384|NCT00886990|Drug|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
79830385|NCT00650091|Drug|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
79830386|NCT00650091|Drug|Placebo|Participants will receive placebo each day.
79830387|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
79830388|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
79687610|NCT01711658|Drug|Cisplatin|100 mg/m^2 administered intravenously on days 8 and 29
79687611|NCT01711658|Drug|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
79830389|NCT00889096|Drug|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
79830390|NCT00889096|Drug|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
79830391|NCT00818103|Drug|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
79830392|NCT00818103|Drug|β-interferon|β-interferon 50ug i.m. qod for 2 years
79830393|NCT00818103|Drug|EPO|EPO 10000U i.h. bid for 5 days
79830394|NCT00642369|Drug|quetiapine fumarate|600-750mg/day
79830395|NCT00642369|Drug|haloperidol|6-40mg/day
79237104|NCT05326828|Device|CONFIRM Rx implantable cardiac rhythm monitor (Abbott)|Implantation of CONFIRM Rx ICM
79531658|NCT01433029|Other|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
79237105|NCT05326828|Diagnostic Test|Systematic etiologic work-up for underlying causes of MINOCA|Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)
79377720|NCT04513470|Biological|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
79531659|NCT01433068|Device|NBTXR3|One intratumor implantation by injection
79531660|NCT01433094|Behavioral|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
79687612|NCT01711658|Drug|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
79687613|NCT01698008|Other|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
79687614|NCT01622868|Other|Laboratory Biomarker Analysis|Correlative studies
79687615|NCT01622868|Drug|Lapatinib Ditosylate|Given PO
79687616|NCT01622868|Radiation|Stereotactic Radiosurgery|Undergo SRS
79687617|NCT01622868|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
79830396|NCT02551575|Drug|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
79830397|NCT02551575|Drug|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
80004738|NCT03607578|Behavioral|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
79237106|NCT03484377|Device|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
79237107|NCT03484377|Device|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
79237108|NCT05261308|Other|new prosthesis|Operation to fix the new prosthesis
79237109|NCT05259514|Device|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
79377721|NCT03353766|Device|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
79237110|NCT03486093|Device|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
79531661|NCT01433094|Behavioral|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
79531662|NCT01433120|Dietary Supplement|Lactobacillus paracasei ssp paracasei F19|10^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
80004739|NCT05760079|Dietary Supplement|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
80004740|NCT03603834|Drug|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours~Leucovorin, 400 mg/m2, IV over 2 hours~Irinotecan, 150 mg/m2, IV over 90 minutes~5 FU, 400 mg/m2, IV bolus~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
79531663|NCT01433120|Dietary Supplement|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
79531664|NCT01433120|Dietary Supplement|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
79531665|NCT01433133|Biological|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
79531666|NCT01433185|Other|Text message|Text messages sent to women before and after delivery
79531667|NCT01433224|Genetic|DNA methylation analysis|
79531668|NCT01433224|Genetic|RNA analysis|
79687618|NCT01518556|Drug|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
79687619|NCT01516190|Behavioral|Exercise|Supervised exercise sessions and independent exercise
79687620|NCT01516190|Behavioral|Surgical preparation program|Book, tapes, CD
79687621|NCT01513408|Other|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
80004741|NCT03551132|Other|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
80004742|NCT02400723|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
79237111|NCT03486093|Behavioral|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
79377722|NCT01627288|Radiation|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
79377723|NCT03350178|Drug|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
80004743|NCT02400723|Behavioral|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
80004744|NCT02400723|Other|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
79391169|NCT02420886|Other|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
79531669|NCT01433224|Genetic|mutation analysis|
80004745|NCT03601338|Drug|Bemiparin|second generation low molecular weight Heparin
79531670|NCT01433224|Genetic|nucleic acid sequencing|
79531671|NCT01433224|Genetic|polymerase chain reaction|
79687622|NCT01421095|Drug|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
79687623|NCT01137643|Other|biologic sample preservation procedure|All samples collected during routine clinical care.
80004746|NCT03601338|Other|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
80004747|NCT02128022|Drug|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
80004748|NCT02128022|Drug|Glibenclamide|Oral Glibenclamide 5mg
80004749|NCT03256045|Drug|Carfilzomib|Given IV
80004750|NCT03256045|Other|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
80004751|NCT03256045|Drug|Dexamethasone|Given PO
80004752|NCT03256045|Other|Laboratory Biomarker Analysis|Correlative studies
79531672|NCT01433224|Genetic|polymorphism analysis|
79687624|NCT01137643|Other|cytology specimen collection procedure|All Samples collected during routine clinical care.
79687625|NCT00566345|Biological|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
80004753|NCT03256045|Drug|Panobinostat|Given PO
79531673|NCT01433224|Other|laboratory biomarker analysis|
79531674|NCT01433224|Other|medical chart review|
79531675|NCT01433237|Genetic|RNA analysis|
79377724|NCT04513392|Procedure|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
80004754|NCT03551054|Behavioral|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
79377725|NCT01628614|Other|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
79531676|NCT01433237|Genetic|gene expression analysis|
79531677|NCT01433237|Other|laboratory biomarker analysis|
79531678|NCT01433276|Drug|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
79531679|NCT01433276|Drug|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
79531680|NCT01433302|Procedure|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
79531681|NCT01433367|Device|CerPass® Total Disc Replacement|Single level cervical disc disease
79531682|NCT01433380|Drug|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
79531683|NCT01433380|Drug|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
79531684|NCT01433393|Drug|TAK-875|
79377726|NCT03350100|Dietary Supplement|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
79377727|NCT03122964|Diagnostic Test|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
79531685|NCT01433393|Drug|TAK-875|
79531686|NCT01433393|Drug|Placebo|
79531687|NCT01433406|Drug|TAK-875|
79531688|NCT01433406|Drug|TAK-875|
79531689|NCT01433419|Drug|TAK-875|
79687626|NCT00566345|Other|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
79687627|NCT00463814|Drug|AZD6244|oral capsule
80004755|NCT03551054|Behavioral|Health Education|
79531690|NCT01433419|Drug|TAK-875|
79531691|NCT01433432|Drug|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
79531692|NCT01433445|Drug|panobinostat|Given 3 times a week, every other week in 28-day cycles.
79531693|NCT01433445|Drug|ruxolitinib|Given twice daily in 28-day cycles.
79531694|NCT01433458|Drug|RLX030A|RLX030 is administered as a continuous 24 hour infusion
80004756|NCT03603756|Drug|SHR-1210|a novel anti-PD-1 antibody
80004757|NCT03603756|Drug|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
79531695|NCT01433484|Behavioral|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
79531696|NCT01433484|Behavioral|Maintenance of Weight Loss--Experimental|
79531697|NCT01433510|Drug|Grazax|1 tablet/day - pre and co-seasonal
79531698|NCT01433523|Drug|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
79531699|NCT01433523|Drug|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
79531700|NCT01433523|Drug|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
79531701|NCT01433562|Drug|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
79687628|NCT00317720|Drug|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
79687629|NCT00317720|Drug|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
80004758|NCT03603756|Drug|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
80004759|NCT03603756|Drug|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
80004760|NCT03603756|Drug|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
79687630|NCT00540033|Dietary Supplement|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
80004761|NCT02372409|Device|MRI-guided laser ablation|
80004762|NCT02372409|Drug|Doxorubicin|
80004763|NCT02372409|Drug|Etoposide|
80004764|NCT02372409|Device|Dynamic contrast-enhanced (DCE) MRI|
80004765|NCT02372409|Device|Dynamic susceptibility contrast (DSC) MRI|
79377728|NCT02528500|Device|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
80004766|NCT03603678|Drug|BAY2253651|100 µg (500 µg/ml * 200 µl) BAY2253651 intranasally
80004767|NCT03603678|Drug|Placebo|Matching Placebo dosing
80004768|NCT03626259|Drug|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
80004769|NCT03626259|Drug|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
80004770|NCT03551366|Behavioral|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
79377729|NCT04512612|Diagnostic Test|Chromoendoscopy|Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
80004771|NCT03551366|Behavioral|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
80004772|NCT03601260|Drug|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
79531702|NCT01433562|Drug|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
80004773|NCT03168373|Procedure|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
79531703|NCT01433575|Drug|RO4917838|10 mg single oral dose
79531704|NCT01433575|Drug|RO4917838|20 mg single oral dose
79531705|NCT01433588|Device|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
79531706|NCT01433588|Other|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
79687631|NCT00540033|Dietary Supplement|infloran|Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
79687632|NCT04661345|Other|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
79687633|NCT04661345|Other|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
79687634|NCT00540072|Drug|daptomycin|
79687635|NCT03759405|Biological|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
79237112|NCT03484221|Drug|FOLFOXIRI|IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
79237113|NCT03484221|Radiation|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy*5) after 4 cycles of FOLFOXIRI.
79237114|NCT03484221|Drug|XELOX|OXALIPLATIN 130 mg/m^2 IV over 2-h, day 1 Capecitabine 1000 mg/m^2 twice daily days 1-14 every 3 weeks for 4 cycles.
79237115|NCT03481491|Other|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
79302716|NCT03074955|Device|leg wrapping without tension|"Apply elastic bandages without tension to both legs before injecting propofol.~After 3 minutes, remove elastic bandages"
79302717|NCT03074955|Procedure|supine position|1.maintain supine position
79377730|NCT04512612|Diagnostic Test|High definition white light colonoscopy|Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
79377731|NCT04513158|Biological|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
79377732|NCT01629784|Behavioral|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
79377733|NCT03350022|Procedure|Sham Feeding|Sham feeding will be offered to participants.
79687636|NCT04661111|Device|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
79687637|NCT04660916|Drug|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
79531707|NCT01433601|Behavioral|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
79687638|NCT00540111|Dietary Supplement|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
79687639|NCT04660838|Other|ACB intervention|Stopping and/or switching ACB medication to an alternative
79830398|NCT02551575|Drug|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
80004774|NCT03717597|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
80004775|NCT03603522|Dietary Supplement|BioGaia-DSM17938|2mL per day (1x10^9 CFU) per day taken orally for 28 days
79237116|NCT03857139|Drug|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
79237117|NCT03481335|Other|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
79237118|NCT01658020|Drug|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
79237119|NCT01658020|Drug|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
79237120|NCT03481179|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
79237121|NCT03481179|Other|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM & JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
79237122|NCT05485948|Drug|Ropeginterferon alfa-2b|Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
79237123|NCT03477123|Device|Walking therapy with Exo-H2 exoskeleton|
79302718|NCT03200431|Other|New adhesive strip|This is a newly developed strip.
79302719|NCT02450149|Drug|sorafenib|
79531708|NCT01433614|Drug|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
79687640|NCT00540150|Biological|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
79531709|NCT01433614|Drug|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
79830399|NCT02541448|Device|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
79830400|NCT02552043|Other|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
80004776|NCT03603522|Other|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
80004777|NCT05193253|Procedure|Radiofrequency ablation|Treatment-naive patients with solitary HCC <= 3 cm who received ablation as the first-line treatment
80004778|NCT05193253|Procedure|Liver resection|Treatment-naive patients with solitary HCC <= 3 cm who underwent liver resection as the first-line treatment
80004779|NCT05193253|Procedure|Liver transplantation|Treatment-naive patients with solitary HCC <= 3 cm who were listed for liver transplantation as the first-line treatment
80004780|NCT05265182|Procedure|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
79687641|NCT05102253|Procedure|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
79687642|NCT05102253|Procedure|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
79830401|NCT02541994|Device|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
79830402|NCT02541994|Device|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
80004781|NCT03601104|Other|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
79830403|NCT00889408|Biological|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
79830404|NCT00887614|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
80004782|NCT03601104|Other|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
79531710|NCT01433614|Drug|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
79531711|NCT01433627|Other|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
79531712|NCT01433627|Other|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
79531713|NCT01433627|Other|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
79830405|NCT00889564|Device|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
79830406|NCT01154335|Drug|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
79830407|NCT01154335|Drug|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
80004783|NCT03601104|Other|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
80004784|NCT03601104|Other|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
80004785|NCT02131922|Procedure|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
80004786|NCT02131922|Procedure|Dental Hygienization Treatment|
80004787|NCT02131922|Drug|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
80004788|NCT03551288|Drug|SUVN-911|Tablet
80004789|NCT03607344|Procedure|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
80004790|NCT02132000|Drug|toremifene or tamoxifen|
80004791|NCT03118765|Drug|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
80004792|NCT03118765|Drug|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
80004793|NCT03118765|Drug|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
79830408|NCT00889642|Device|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
79531714|NCT01433627|Other|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
79830409|NCT00889642|Device|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
79830410|NCT02541526|Drug|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
79687643|NCT05102253|Other|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
79687644|NCT04660604|Device|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
79237124|NCT05291494|Behavioral|follow the WeChat public platform to watch the education videos|In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.
79531715|NCT01433627|Other|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
79531716|NCT01433627|Other|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
79531717|NCT01433653|Behavioral|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
79531718|NCT01433666|Drug|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
79531719|NCT01433666|Drug|Placebo|Acute intervention: single administration, capsulated form.
79531720|NCT01433666|Drug|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
79531721|NCT01433679|Behavioral|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
79687645|NCT04660253|Behavioral|LTP Plus Dads|
79687646|NCT04660292|Other|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
79687647|NCT04660292|Other|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
79687648|NCT00540189|Procedure|Initial appendectomy|
79687649|NCT00540189|Procedure|Interval appendectomy|
79687650|NCT04660409|Diagnostic Test|Blood test for serum Adropin|Blood test for serum Adropin
79687651|NCT01208233|Drug|PF-03049423|1 mg of PF-03049423 daily for 90 days
79687652|NCT01208233|Drug|PF-03049423|3 mg of PF-03049423 daily for 90 days
79687653|NCT01208233|Drug|PF-03049423|6 mg of PF-03049423 daily for 90 days
79687654|NCT01208233|Other|Placebo|Placebo of PF-03049423 daily for 90 days
79830411|NCT02541526|Drug|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
79830412|NCT01037959|Drug|Norfloxacin|400 mg/day (per os) for 6 months
79830413|NCT01037959|Drug|Placebo|1 pill/day (per os) for 6 months
79830414|NCT00887692|Behavioral|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
79830415|NCT01038037|Drug|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
79830416|NCT01038037|Drug|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
79830417|NCT01038037|Drug|panitumumab|i.v. day 1: 9 mg/kg q3w
79830418|NCT01038115|Procedure|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
79830419|NCT00645099|Drug|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
79830420|NCT00645099|Drug|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
79830421|NCT04401982|Drug|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
79830422|NCT01038271|Other|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
79830423|NCT01038271|Other|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
79237125|NCT05291494|Behavioral|regular preoperative visits and education by ward nurses.|received oral instruction from the ward nurse covering the same contents as above instead of the education video.
79302720|NCT02479217|Drug|Docetaxel|
79302721|NCT02479217|Drug|Xeloda|
79302722|NCT03200119|Behavioral|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
79302723|NCT05459909|Dietary Supplement|Synbiotic supplementation|Daily supplementation of synbiotic
79687655|NCT04660565|Drug|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
79830424|NCT01038349|Other|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
79830425|NCT00889954|Biological|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
79531722|NCT01433692|Behavioral|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
79531723|NCT01433705|Other|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
79687656|NCT04660565|Drug|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
79687657|NCT04319341|Other|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
79687658|NCT04660136|Biological|contrast enhanced ultrasound|We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
79531724|NCT01433705|Other|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
79531725|NCT01433705|Other|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
79687659|NCT01208038|Drug|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
79687660|NCT00540267|Other|No Intervention|No Intervention
79687661|NCT04659980|Device|hilotherapy|continuous cooling of hands and feet at a constant temperature
79531726|NCT01433705|Drug|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
79687662|NCT04659980|Device|frozen gloves|cooling of hands and feet using frozen gloves
79687663|NCT04659785|Drug|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
79237126|NCT03476967|Procedure|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
79687664|NCT04659785|Drug|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
79687665|NCT03609021|Procedure|Screening Mammography|Provide bilateral mammogram
79687666|NCT03609021|Procedure|Biospecimen Collection|Undergo collection of blood sample
79687667|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
79687668|NCT01207687|Biological|bevacizumab|Given IV
79687669|NCT01207687|Other|laboratory biomarker analysis|Correlative studies
79687670|NCT01207687|Procedure|quality-of-life assessment|Ancillary studies
79830426|NCT04601623|Other|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
79830427|NCT00887770|Drug|AZD5672|12 x 50mg tablet, oral, single dose
79830428|NCT00887770|Drug|Moxifloxacin|1 x 400mg capsule, oral, single dose
79830429|NCT00887770|Drug|placebo|12 x matched to AZD5672 50 mg tablet
79830430|NCT00887770|Drug|AZD5672|3 x 50mg tablet, oral. single dose
79237127|NCT03476889|Other|Infant formula|Infants are randomized to one of two infant formulas from <14 days of age to 17 weeks of age.
79830431|NCT00887770|Drug|placebo|9 x matched to AZD5672 50mg tablet
79830432|NCT00887770|Drug|placebo|1 x matched to Moxifloxacin capsule
79302724|NCT05459909|Behavioral|Dietary intervention|Increased fruits and vegetables consumption
79830433|NCT01038505|Drug|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
79830434|NCT00890032|Biological|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10^6, 5x10^6, and 2x10^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
80004794|NCT02252198|Other|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
79237128|NCT04968028|Procedure|ACAF|(1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.
79237129|NCT04968028|Procedure|Laminoplasty|(1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
79237130|NCT03476733|Other|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
79237131|NCT04713267|Device|ISABel Bed 1|During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
79237132|NCT05255770|Device|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
79237133|NCT05255770|Device|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
79237134|NCT05255770|Device|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
79531727|NCT01433718|Procedure|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
79531728|NCT01433744|Procedure|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
79531729|NCT01433757|Drug|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
79687671|NCT04659434|Drug|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
79687672|NCT01207453|Drug|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
79687673|NCT01207453|Drug|Placebo|
79687674|NCT00540345|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
79687675|NCT00540345|Drug|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
79687676|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
79687677|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
79687678|NCT04659356|Other|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
79830435|NCT01038583|Drug|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
79830436|NCT01038583|Drug|Placebo|100 mg enteric-coated placebo
79830437|NCT02551107|Device|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
79830438|NCT02541682|Other|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
79830439|NCT00818181|Drug|Biological: AL0206st|
79830440|NCT00887848|Other|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
79531730|NCT01433757|Drug|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
79687679|NCT01207414|Drug|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
79830441|NCT01038661|Drug|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
79237135|NCT04635579|Device|Blood flow restriction|Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
79531731|NCT01433770|Drug|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
79687680|NCT00540384|Drug|Placebo|Placebo
79531732|NCT01433835|Drug|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
79531733|NCT01433835|Other|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
79531734|NCT01433861|Procedure|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
79531735|NCT01433874|Procedure|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
79531736|NCT01433874|Procedure|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
79531737|NCT01433874|Procedure|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
79531738|NCT01433874|Procedure|Control group|Co2 was removed by passive exsufflation through the port site.
79687681|NCT00540384|Drug|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
79687682|NCT01207219|Behavioral|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
79687683|NCT01207219|Behavioral|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
79830442|NCT01038661|Drug|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
79830443|NCT01038661|Other|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
79237136|NCT05322538|Diagnostic Test|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
79237137|NCT05322538|Diagnostic Test|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
79237138|NCT05322538|Diagnostic Test|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
79531739|NCT01433887|Drug|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
79531740|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
79531741|NCT01433887|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
79687684|NCT04659551|Drug|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
79687685|NCT04659551|Drug|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
79687686|NCT04659551|Drug|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
79687687|NCT04659551|Drug|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
79830444|NCT02355613|Radiation|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
79830445|NCT02355613|Radiation|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
79237139|NCT05322538|Diagnostic Test|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
79237140|NCT05322538|Diagnostic Test|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
79237141|NCT05322538|Diagnostic Test|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
79237142|NCT05322538|Diagnostic Test|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
79237143|NCT05322538|Diagnostic Test|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
79531742|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
79531743|NCT01433900|Drug|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
79531744|NCT01433900|Drug|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
79531745|NCT01433952|Dietary Supplement|Thiamine|Vitamin B1
79687688|NCT04659551|Drug|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
80004795|NCT03603444|Other|No intervention are provided|
80004796|NCT02128100|Drug|Folfirinox|"Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
80004797|NCT02128100|Radiation|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
80004798|NCT03603366|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
79237144|NCT05322538|Diagnostic Test|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
79531746|NCT01433952|Dietary Supplement|Placebo|Placebo
80004799|NCT02128178|Drug|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
80004800|NCT02128178|Drug|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
80004801|NCT03606954|Combination Product|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
79237145|NCT05322538|Diagnostic Test|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
79237146|NCT05322538|Diagnostic Test|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
79237147|NCT05322538|Diagnostic Test|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
79237148|NCT05322538|Diagnostic Test|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
79531747|NCT01434004|Behavioral|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
79531748|NCT01434017|Drug|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
79687689|NCT04659668|Device|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
79237149|NCT05322538|Diagnostic Test|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
79237150|NCT05322538|Diagnostic Test|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
79302725|NCT03199807|Biological|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4-6 doses.
79830446|NCT01038817|Drug|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
80004802|NCT03600870|Drug|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
79377734|NCT03355092|Device|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
79377735|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
79377736|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
79377737|NCT02230696|Drug|Placebo nasal spray|Placebo nasal spray
79377738|NCT03353454|Drug|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
79377739|NCT03353454|Drug|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
79531749|NCT01434017|Drug|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
80004803|NCT02128256|Device|Cerament G|
80004804|NCT03600792|Genetic|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
80004805|NCT02128334|Drug|Eligard 45 mg Exposure|Subcutaneous injections
80004806|NCT01375699|Drug|Doxorubicin|As prescribed by treating provider.
80004807|NCT01375699|Drug|Sildenafil|Given PO, by mouth
79687690|NCT01206517|Drug|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
79830447|NCT01324219|Behavioral|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
79830448|NCT01324219|Behavioral|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
79830449|NCT00420511|Drug|Sitagliptin|sitagliptin 100 mg once a day
79830450|NCT00420511|Drug|Placebo|placebo once a day
79830451|NCT00420511|Drug|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
80004808|NCT02252276|Procedure|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
80004809|NCT02252276|Procedure|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
79237151|NCT05322538|Diagnostic Test|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
79237152|NCT05322538|Diagnostic Test|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
79237153|NCT05322538|Diagnostic Test|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
79302726|NCT03199807|Radiation|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F * 10F
79377740|NCT03353376|Behavioral|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
79531750|NCT01434017|Drug|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
79531751|NCT01434069|Drug|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
79830452|NCT01038895|Drug|Ramipril|tablet; 10 mg; od; 3 months
79830453|NCT01038895|Drug|Experimental|tablet; 300 mg; od; 3 months
79830454|NCT00420199|Drug|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
79830455|NCT00420199|Drug|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
79377741|NCT04507620|Device|cervical neck collar|devices used for cervical immobilization
79377742|NCT03355014|Drug|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
79377743|NCT03355014|Drug|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
79531752|NCT01434069|Drug|FOLFIRI Infusion|Standard therapy of FOLFIRI
79531753|NCT01434082|Behavioral|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
79830456|NCT01039051|Behavioral|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
79830457|NCT00649389|Drug|Olmesartan medoxomil|40mg olmesartan medoxomil
79830458|NCT00649389|Drug|Amlodipine|Amlodipine 10mg
79830459|NCT00649389|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
79377744|NCT03349944|Behavioral|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
79531754|NCT01434095|Procedure|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
79687691|NCT01206517|Drug|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
79687692|NCT01206517|Drug|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
79687693|NCT00540462|Procedure|gastric bypass|
79830460|NCT00402103|Drug|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
79531755|NCT01434108|Drug|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
79830461|NCT00402103|Drug|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
79237154|NCT03476655|Drug|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
79830462|NCT00402103|Drug|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
79237155|NCT04593537|Other|No intervention|This is an observational study, no intervention is involved
79830463|NCT00815217|Procedure|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
79237156|NCT03484065|Other|Questionnaire quality of life|
79237157|NCT04376385|Behavioral|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
79237158|NCT04459767|Drug|Vupanorsen|80 mg subcutaneous injection
79237159|NCT04459767|Drug|Placebo|Subcutaneous injection
79377745|NCT02231086|Procedure|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
79377746|NCT02231086|Drug|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
79377747|NCT02231086|Procedure|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
79531756|NCT01434134|Drug|Metoprolol|Tablet, target dose 100 mg once daily
79531757|NCT01434134|Drug|Placebo|Tablet, target dose 100 mg once daily
79531758|NCT01434134|Drug|Candesartan|Tablet, target dose 32 mg once daily
79687694|NCT00540462|Procedure|sleeve gastrectomy|
79687695|NCT04659473|Other|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
79830464|NCT00815217|Other|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
79830465|NCT00812175|Drug|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
79830466|NCT00815373|Drug|Dorzolamide+Timolol Maleate0.5%|Cosopt* b. i. d.
79830467|NCT00815373|Drug|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom* QHS
80004810|NCT03606720|Other|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
79237160|NCT03481101|Device|PET/CT|3 extra scans with FDG-PET/CT and 4 blood samples
79531759|NCT01434134|Drug|Placebo|Tablet, 32 mg once daily
79687696|NCT01206439|Drug|nebivolol|nebivolol 5 or 10 mg oral, daily
79687697|NCT01206322|Drug|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
79687698|NCT01206322|Drug|Placebo|The acute effects of intranasal sterile saline.
79687699|NCT04659200|Diagnostic Test|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
79687700|NCT01206166|Drug|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
79237161|NCT04245670|Radiation|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
80004811|NCT03606720|Other|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
80004812|NCT01373983|Drug|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
80004813|NCT03550430|Behavioral|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
80004814|NCT03550430|Behavioral|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
80004815|NCT03550430|Other|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
79237162|NCT02523573|Procedure|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
80004816|NCT03603132|Drug|Hetrombopag Olamine|7.5mg in each cycle
80004817|NCT03600636|Procedure|Diffusion tensor imaging MRI|"axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~Fluid-attenuated inversion recovery~three-dimensional axial image weighted in T1~axial echo-planar image sequence~three-dimensional pulse sequence axial flight time"
79237163|NCT04965220|Drug|HLX 208|take orally
79237164|NCT03483987|Drug|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
79377748|NCT03353298|Drug|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
79237165|NCT03483987|Drug|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
79237166|NCT03483987|Drug|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
79531760|NCT01434147|Drug|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
79531761|NCT01434160|Drug|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
79377749|NCT03353298|Drug|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
79377750|NCT03354936|Biological|Blood sample|Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research
79237167|NCT03483987|Drug|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
80004818|NCT05812638|Other|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
80004819|NCT05812638|Other|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
80004820|NCT05812625|Other|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
79377751|NCT03187210|Drug|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
79531762|NCT01434173|Drug|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
79531763|NCT01434173|Drug|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
79531764|NCT01434199|Procedure|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
80004821|NCT05812625|Other|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
80004822|NCT05812612|Drug|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
79377752|NCT03187210|Drug|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
79377753|NCT03349866|Drug|apatinib|apatinib：250mg qd po
79377754|NCT03349866|Drug|Capecitabine|1000mg/m2 bid d1-14
80004823|NCT05812599|Other|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
80004824|NCT05812586|Biological|SCB-2019/Clover|SCB-2019/Clover Vaccine
80004825|NCT05812586|Biological|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
79531765|NCT01434212|Drug|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
79531766|NCT01434225|Drug|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
79531767|NCT01434238|Other|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
80004826|NCT05812586|Biological|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
80004827|NCT05812573|Other|no intervention|No intervention, only observation
80004828|NCT05812547|Device|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
80004829|NCT05812547|Other|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
80004830|NCT05812521|Procedure|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
79531768|NCT01434251|Other|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
79377755|NCT03349866|Drug|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
79830468|NCT00641667|Drug|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
80004831|NCT05812521|Procedure|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
79531769|NCT01434264|Procedure|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
79531770|NCT01434277|Other|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
79531771|NCT01434303|Drug|Entinostat|Given PO
79531772|NCT01434303|Other|Laboratory Biomarker Analysis|Correlative studies
79531773|NCT01434303|Drug|Lapatinib Ditosylate|Given PO
80004832|NCT05812508|Device|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
79531774|NCT01434303|Biological|Trastuzumab|Given IV
79531775|NCT01434329|Genetic|DNA methylation analysis|
79531776|NCT01434329|Genetic|gene expression analysis|
79237168|NCT03483987|Drug|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
79531777|NCT01434329|Genetic|microarray analysis|
79531778|NCT01434329|Other|laboratory biomarker analysis|
79531779|NCT01434329|Other|medical chart review|
79531780|NCT01434355|Other|Laboratory Biomarker Analysis|Correlative studies
79237169|NCT03483987|Drug|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
79377756|NCT03349866|Radiation|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
79377757|NCT03354000|Behavioral|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
79830469|NCT00704184|Drug|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
79830470|NCT00704184|Drug|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
79830471|NCT00704184|Drug|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
80004833|NCT05812495|Procedure|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
80004834|NCT05812495|Procedure|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
80004835|NCT05812482|Procedure|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
80004836|NCT05812482|Procedure|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
80004837|NCT05812469|Behavioral|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
80004838|NCT05812469|Behavioral|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
80004839|NCT05812456|Other|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
80004840|NCT05812430|Drug|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
79830472|NCT00704184|Drug|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
80004841|NCT05812404|Drug|DWP14012|Potassium-competitive acid blocker
80004842|NCT05812404|Drug|DWC202201|Atorvastatin Calcium Trihydrate
80004843|NCT05812326|Drug|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
80004844|NCT03607110|Drug|Ketamine|sedation drugs
79237170|NCT02523729|Dietary Supplement|Anke Malz|non-alcoholic malt drink
80004845|NCT03607110|Drug|fentanyl|sedation drugs
79237171|NCT03476499|Device|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
79237172|NCT04459533|Device|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~If 0 response and no respiratory asynchrony: no change in flow rate~If >=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
79237173|NCT03483909|Device|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
79377758|NCT03354000|Behavioral|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
79531781|NCT01434355|Other|Questionnaire Administration|Ancillary studies
79531782|NCT01434381|Biological|Pfs25-EPA/Alhydrogel|
79830473|NCT00641043|Drug|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
79830474|NCT00641043|Drug|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
79830475|NCT04062318|Device|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
79830476|NCT02551965|Other|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
80004846|NCT03607110|Device|patient control analgesia|patient control analgesia
79377759|NCT04503798|Behavioral|Online Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
79377760|NCT01629862|Device|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
80004847|NCT05812274|Other|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
80004848|NCT05812209|Procedure|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
79237174|NCT03483909|Device|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
79237175|NCT03483909|Device|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
79531783|NCT01434394|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
79687701|NCT00540501|Drug|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
79687702|NCT04659239|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
79237176|NCT04459455|Behavioral|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
79237177|NCT04459455|Behavioral|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
79237178|NCT03476421|Procedure|Hepatic resection|Surgery of the liver; removal of a part of the liver
79531784|NCT01434407|Other|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
79531785|NCT01434420|Genetic|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
79531786|NCT01434446|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
79687703|NCT04659239|Biological|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
79687704|NCT04659083|Device|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
79687705|NCT03511248|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
79687706|NCT03511248|Dietary Supplement|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
79237179|NCT03483831|Behavioral|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
79237180|NCT03476265|Device|Electrical Stimulation of the Lower Esophageal Sphincter|Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
79237181|NCT05153577|Other|Group A: $5 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
79237182|NCT05153577|Other|Group B: $10 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
79531787|NCT01434459|Drug|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
79531788|NCT01434524|Drug|LIVACT|LIVACT contains 13.0 g of free amino acids
79531789|NCT01434550|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
79687708|NCT00540618|Drug|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
79830477|NCT02567058|Device|Ultrasound exam|"Ultrasound exam with :~2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~1 succession of 3 measures for group III"
79830478|NCT02567058|Behavioral|IPAQ questionnaire|IPAQ questionnaire
79531790|NCT01434550|Radiation|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~Necrosis/apoptosis~Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1. Aposense-PET imaging"
79830479|NCT00815451|Dietary Supplement|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
80004849|NCT05812092|Device|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
79237183|NCT03672617|Other|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
79237184|NCT03677921|Dietary Supplement|Investigational Product (Bio-Germanium)|"Ingredient: Bio-Germanium~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~Storage: Room temperature (below 25℃)~Duration of use: 8 weeks"
79830480|NCT00815451|Dietary Supplement|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
79377761|NCT01629862|Device|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
79377762|NCT03354858|Procedure|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
79830481|NCT00812409|Dietary Supplement|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
79830482|NCT00812409|Other|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
79830483|NCT02567604|Behavioral|Focus Groups|at least three focus groups lasting approximately one hour
79687709|NCT00540618|Other|Placebo|
79687710|NCT00540618|Drug|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
79687711|NCT00540618|Drug|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
79830484|NCT00815529|Device|Acupuncture, Pak-sham needle|25*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
79830485|NCT02551419|Dietary Supplement|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
79830486|NCT02551419|Dietary Supplement|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
79531791|NCT01434576|Biological|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
79830487|NCT04063644|Device|Vis Glyc Neo|1 drop in each eye, three times a day.
79830488|NCT04063644|Device|Physiological saline solution|1 drop in each eye, three times a day.
79531792|NCT01434576|Biological|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
79531793|NCT01434576|Drug|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
79830489|NCT04045275|Behavioral|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
79830490|NCT05325138|Other|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
79830491|NCT00812643|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
79830492|NCT02567916|Drug|Fresofol|
79687712|NCT04658459|Procedure|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
79830493|NCT02567916|Drug|Propofol|
79830494|NCT00815607|Drug|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
79830495|NCT00815607|Biological|INXN-3001|Intratumoral injection
79237185|NCT03677921|Dietary Supplement|Control Group - Placebo Product|"Ingredient: Corn starch~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day~Storage: Room temperature (below 25℃)~Duration of use: 8 weeks"
79377763|NCT03354780|Other|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
79377764|NCT03354780|Other|Survey on first pregnancy|rate of miscarriage was noted
79687713|NCT00557453|Drug|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
79687714|NCT00557453|Drug|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
79687715|NCT01207102|Drug|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
79687716|NCT01207102|Drug|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
80004850|NCT05812066|Procedure|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
80004851|NCT05812053|Procedure|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
80004852|NCT05812053|Radiation|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 6 and 12 months follow-up periods.
80004853|NCT05811975|Drug|KSX01-TCRT injection|individualization TCR-T cell injection
80004854|NCT05811962|Other|No intervention|No intervention, only comparison
80004855|NCT05811923|Other|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
80004856|NCT05811923|Other|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
79377765|NCT04443894|Other|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
79377766|NCT04443894|Other|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
79531794|NCT01434589|Behavioral|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
79531795|NCT01434615|Device|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
79531796|NCT01434615|Other|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
79237186|NCT05153031|Other|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
79237187|NCT05153031|Procedure|Emergency surgery|Emergency cholecystectomy
79237188|NCT05153031|Procedure|cholecystectomy|cholecystectomy
79531797|NCT01434628|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
79531798|NCT01434706|Other|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
79237189|NCT03677765|Procedure|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
79237190|NCT03623477|Behavioral|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
79302727|NCT03074877|Behavioral|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
79531799|NCT01434732|Procedure|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
79830496|NCT04045509|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
79830497|NCT04045509|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
79531800|NCT01434732|Procedure|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
80004857|NCT05811923|Other|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
80004858|NCT05811923|Other|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
80004859|NCT05811897|Behavioral|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
79531801|NCT01434836|Other|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
80004860|NCT05811897|Behavioral|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
79377767|NCT03353142|Other|Equal Breathing|"Blood pressure recorded at baseline, immediately pre- and post-trial~Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
79830498|NCT04045509|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
79830499|NCT02567526|Behavioral|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
79377768|NCT01631110|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
79377769|NCT04507698|Other|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
79377770|NCT03353064|Other|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
79377771|NCT03353064|Other|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
79237191|NCT03623477|Behavioral|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
79237192|NCT05152797|Biological|Autologous tumor-infiltrating lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
79237193|NCT03677687|Behavioral|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
79377772|NCT01631656|Drug|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
79531802|NCT01434836|Other|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
79531803|NCT01434849|Drug|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
79531804|NCT01434849|Drug|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
79531805|NCT01434862|Drug|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
79830500|NCT00402025|Biological|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
79830501|NCT00812721|Other|Preservative Free Saline|One drop will be instilled into each eye once
80004861|NCT05811884|Device|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
79531806|NCT01434862|Device|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
80004862|NCT05811832|Other|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
80004863|NCT05811819|Device|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
80004864|NCT05811806|Device|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
80004865|NCT05811793|Drug|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
80004866|NCT05811767|Other|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
79237196|NCT03476031|Diagnostic Test|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
79377773|NCT01631656|Device|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
79377774|NCT04503876|Other|Increasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
79377775|NCT04503876|Other|Decreasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
79377776|NCT04507542|Behavioral|Enriched Music-Supported Therapy|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.
79531807|NCT01434862|Drug|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
79531808|NCT01434888|Drug|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
79531809|NCT01434888|Drug|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
79531810|NCT01434888|Drug|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
79531811|NCT01434901|Drug|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
79830502|NCT00812721|Other|Optive|One drop will be instilled into each eye once
79830503|NCT00812721|Other|Refresh Moderate/Severe|One drop will be instilled into each eye once
79237197|NCT03483519|Other|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
79237198|NCT03483519|Other|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
79237199|NCT03672383|Device|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
79237200|NCT04154163|Diagnostic Test|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
79237201|NCT04154163|Diagnostic Test|Venous blood sampling|Venous blood
79237202|NCT03672305|Biological|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
79531812|NCT01434901|Drug|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
79531813|NCT01434901|Drug|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
79531814|NCT01434901|Drug|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
79830504|NCT00812721|Other|Systane|One drop will be instilled into each eye once
79687717|NCT04658732|Drug|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
79687718|NCT00540696|Drug|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
79531815|NCT01434914|Drug|octenisept®|Cutaneous solution
79830505|NCT00812721|Other|Systane Ultra|One drop will be instilled into each eye once
79830506|NCT00812799|Drug|Oralgen|19.000 BU daily
79237203|NCT02680574|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
79377777|NCT04507542|Behavioral|Graded Repetitive Arm Supplementary Program|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
79237204|NCT02680574|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
79237205|NCT03676829|Device|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
79237206|NCT02523963|Other|family work shop|"The family work shop has 5 courses, with 6 families in one course.~One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
79377778|NCT01632202|Device|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
79377779|NCT01632202|Device|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
79377780|NCT02985190|Drug|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
79377781|NCT01634620|Device|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
79830507|NCT00812799|Other|placebo control|placebo control
79830508|NCT00815763|Drug|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
79830509|NCT00815763|Drug|placebo|infusion placebo once a day and continued for 14 day
79830510|NCT00609622|Drug|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
79830511|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
79830512|NCT00609622|Drug|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
79830513|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
79830514|NCT04045119|Other|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
79830515|NCT00818415|Drug|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
79830516|NCT00818415|Drug|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
79237207|NCT03672149|Drug|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
79302728|NCT02479529|Drug|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
79377782|NCT01635244|Device|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
79377783|NCT01636102|Biological|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
79531816|NCT01434914|Drug|Placebo|Cutaneous use
79531817|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
79531818|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
80004867|NCT05811754|Other|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
80004868|NCT05811715|Other|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
79237208|NCT05152719|Behavioral|Cognitive Performance|Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
79237209|NCT03672071|Other|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
80004869|NCT05811715|Other|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
79237210|NCT04010565|Dietary Supplement|Aged black garlic extract|"Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias."
79237211|NCT04010565|Dietary Supplement|Placebo|Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
79302729|NCT02479529|Drug|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
79302730|NCT03202147|Drug|Cromolyn|Active capsules for inhalation.
79302731|NCT03202147|Other|Placebo|Non-active capsules for inhalation.
79377784|NCT01376310|Drug|GSK1120212|up to 2 mg/day
79377785|NCT01376310|Drug|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
79377786|NCT01376310|Drug|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
79531819|NCT01434940|Other|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
79531820|NCT01434953|Behavioral|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
79531821|NCT01434953|Behavioral|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
79687719|NCT04658615|Procedure|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
79687720|NCT04658420|Drug|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
79377787|NCT01376310|Drug|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
79377788|NCT01376310|Drug|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
79377789|NCT01376310|Drug|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
79377790|NCT01376310|Drug|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
79377791|NCT01376310|Drug|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
79377792|NCT01949506|Radiation|SBRT|Stereotactic Body Radiation Therapy
79377793|NCT03349788|Procedure|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
79377794|NCT03349788|Procedure|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
79687721|NCT04658420|Other|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
79687722|NCT00540735|Procedure|photodynamic therapy|
79687723|NCT00557531|Device|BL-1040|2 mL of BL-1040
79687724|NCT04658264|Dietary Supplement|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
79687725|NCT04657913|Other|cold water spray application|It will be sprayed into the mouth of patients every hour.
79687726|NCT04657913|Other|cold saline spray application|It will be sprayed into the mouth of patients every hour.
79687727|NCT04657874|Other|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
79830517|NCT04045197|Behavioral|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
79687728|NCT04657874|Other|Placebo|Oral tablet without the active principle
79687729|NCT03324438|Behavioral|Home Telehealth T1D C2oYoT1-HR|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
80004870|NCT05811689|Diagnostic Test|sm tbs group|"After collecting anthropometric data, information on environmental factors and lifestyle (smoking, alcohol intake, physical activity, sun exposure, vitamin D supplementation, fish consumption) will be acquired through a questionnaire.~The genetic and environmental aspects related to multiple sclerosis will also be studied. Disability status will be assessed through the Kurtzke Extended Disability Status Scale (EDSS). [10] All recruited patients will be administered the questionnaire (Multiple Sclerosis Quality of Life-54 (MSQOL-54) composed of 14 scales and 54 items. The scales investigate physical functions, limitations with respect to physical and emotional role, pain, emotional well-being, degree of energy, perceptions of one's health, social, cognitive and sexual functioning, distress, changes in health, satisfaction with sexual functioning and quality of life in general."
80004871|NCT05811650|Behavioral|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
79237212|NCT03671993|Procedure|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
79237213|NCT03671993|Procedure|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
79237214|NCT03475797|Device|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
79237215|NCT03475797|Other|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
79391170|NCT04342312|Procedure|Pulmonary vein isolation|Participation in this study does not influence the choice of ablation technique. Usually, cryoballoon ablation is chosen for patients with paroxysmal AF and no previous ablations. Radiofrequency ablation is often used for redo procedures or for patients with persistent AF. Hybrid ablations are most applied in persistent AF patients. However, physicians may deviate from these standard approaches for a variety of reasons, including personal experience or preference.
79830518|NCT00815841|Drug|METHYLPHENIDATE|15-20mg during one of the two sessions
79237216|NCT03483285|Device|airtraq|airtraq videolaryngoscope
79237217|NCT03483285|Device|storz|storz videolaryngoscope
79237218|NCT03475719|Drug|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
79237219|NCT03475719|Drug|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
79237220|NCT03475563|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
79237221|NCT03480945|Diagnostic Test|serotonin|Endothelium-dependent dilatation
79237222|NCT05151237|Diagnostic Test|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
79237223|NCT03483207|Drug|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
79237224|NCT03483207|Procedure|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
79391171|NCT02415504|Behavioral|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
79237225|NCT03483207|Drug|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
79830519|NCT04044963|Behavioral|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
79830520|NCT02567760|Dietary Supplement|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
79830521|NCT02567760|Other|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
79237226|NCT05132985|Drug|Icotinib|125mg 1tt(Take 1 tablet 3 times a day) orally.
79830522|NCT00813033|Other|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
80004872|NCT05811637|Other|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
80004873|NCT05811637|Other|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
80004874|NCT05811611|Behavioral|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
80004875|NCT05811611|Behavioral|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
80004876|NCT05811572|Device|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
79237227|NCT05132985|Drug|Cisplatin|75 mg/m2 (IV，Q3W)
79237228|NCT05132985|Drug|Carboplatin|AUC 5 (IV, Q3W)
79237229|NCT05132985|Drug|Pemetrexed|500 mg/m2 (IV, Q3W)
79237230|NCT03483129|Behavioral|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
79830523|NCT03897192|Drug|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
80004877|NCT05811559|Other|No intervention|No intervention
80004878|NCT05811546|Diagnostic Test|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
80004879|NCT05811507|Diagnostic Test|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
80004880|NCT05811507|Diagnostic Test|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
79237231|NCT05676320|Device|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
79237232|NCT05676320|Device|V-Steady|Bone Cement alone
79237233|NCT05091723|Drug|Nezulcitinib (TD-0903) Dose A|TD-0903 Dose A
79237234|NCT05091723|Drug|Nezulcitinib (TD-0903) Dose B|TD-0903 Dose B
79237235|NCT03163316|Other|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
79237236|NCT05079633|Biological|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
79237237|NCT05079633|Biological|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
79237238|NCT02522884|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
79687730|NCT03324438|Behavioral|Personalized Behavioral Health|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
79302732|NCT04492085|Other|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
79687731|NCT03324438|Behavioral|Personalized Adherence Feedback|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
79687732|NCT00540813|Device|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
79237239|NCT05087966|Behavioral|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
79687733|NCT04658030|Device|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
79830524|NCT00813189|Device|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
79687734|NCT04658030|Other|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
79687735|NCT00540852|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
79830525|NCT02551263|Drug|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
79830526|NCT02567214|Drug|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
79830527|NCT02567214|Drug|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
79830528|NCT04044885|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
79830529|NCT00888004|Drug|AFQ056|
79830530|NCT00888004|Drug|Placebo|
80004881|NCT05811507|Diagnostic Test|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
79531822|NCT01434966|Other|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
79531823|NCT01434966|Other|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
79531824|NCT01434966|Other|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
79687736|NCT00540891|Drug|ALFUZOSIN|
79830531|NCT00813267|Biological|mesenchymal stem cell infusion|
79830532|NCT00813267|Biological|bone marrow mononuclear cell infusion|
79830533|NCT00890110|Biological|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
79830534|NCT02566824|Behavioral|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
79687737|NCT04658225|Procedure|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
79830535|NCT02566824|Behavioral|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
79830536|NCT02566824|Other|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
79830537|NCT02566824|Drug|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
79830538|NCT00813345|Other|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
79830539|NCT00813345|Other|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
79830540|NCT00890188|Drug|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
80004882|NCT05811507|Diagnostic Test|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
80004883|NCT05811494|Device|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
80004884|NCT05811494|Device|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
80004885|NCT05811494|Device|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
80004886|NCT05811494|Device|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
79237240|NCT05518630|Behavioral|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
79237241|NCT03739593|Drug|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
79237242|NCT03739593|Drug|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
79237243|NCT03475485|Device|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
79531825|NCT01435005|Other|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
79531826|NCT01435005|Other|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
79531827|NCT01435057|Procedure|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
79687738|NCT00540930|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
79687739|NCT04657952|Procedure|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine & adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
79687740|NCT04657952|Drug|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
79687741|NCT00541008|Drug|sunitinib malate|
79237244|NCT03475485|Device|Wearable Sensor|Subjects will wear an ID-Reader
79237245|NCT03475485|Device|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
79237246|NCT05676164|Device|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 ~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
79237247|NCT05676164|Device|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
79237248|NCT03480867|Drug|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
79237249|NCT03480867|Radiation|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
79237250|NCT05254912|Drug|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
79687742|NCT04657796|Device|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
79687743|NCT03256227|Behavioral|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
80004887|NCT05811481|Procedure|TACE|Transcatheter Arterial Chemoembolization
79531828|NCT01435070|Procedure|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
79830541|NCT05388942|Procedure|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater…) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
79531829|NCT01435070|Procedure|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
79531830|NCT01435083|Drug|Desmopressin|120 µg, oral lyophilisate, sublingual use
79237251|NCT05254912|Drug|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
79237252|NCT05254912|Other|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
79237253|NCT03482895|Biological|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
79237254|NCT03482895|Biological|Feces sampling|Intestinal absorption assessment
79531831|NCT01435096|Drug|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
79687744|NCT03256227|Behavioral|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
79687745|NCT04657718|Device|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
79687746|NCT00541086|Drug|anastrozole|1 mg per day, orally
79830542|NCT05388942|Drug|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
79237255|NCT03480789|Drug|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
79237256|NCT03480789|Device|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
79237257|NCT03480711|Procedure|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
79687747|NCT00541086|Drug|exemestane|25 mg per day, orally
79687748|NCT00541086|Drug|letrozole|2.5 mg per day, orally
79687749|NCT00541086|Drug|tamoxifen citrate|20 mg per day, orally
79830543|NCT04037566|Genetic|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
79830544|NCT04037566|Drug|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
79830545|NCT04037566|Drug|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
79830546|NCT00699660|Behavioral|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
79830547|NCT00699660|Behavioral|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
80004888|NCT05811481|Drug|Regorafenib|Regorafenib alone
80004889|NCT05811455|Other|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
80004890|NCT05811455|Other|Progressive muscle relaxation|progressive muscle relaxation exercises.
79237258|NCT03480711|Procedure|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
79237259|NCT03475407|Drug|Ozurdex intravitreal injection|"Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~AC paracentesis at 6 wk~intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
79237260|NCT05286424|Procedure|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
79531832|NCT01435109|Behavioral|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
79687750|NCT04657484|Drug|Medium dose prednisolone|Same as arm description
79687751|NCT04657484|Drug|Low dose prednisolone|Same as arm description
79687752|NCT00541125|Biological|bevacizumab|
80004891|NCT05811338|Behavioral|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
79687753|NCT00541125|Biological|filgrastim|
80004892|NCT05811338|Behavioral|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
80004893|NCT05811338|Behavioral|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
79830548|NCT00888082|Drug|Goserelin acetate|3.6 mg depot injectable preparation
80004894|NCT05811325|Other|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
80004895|NCT05811325|Other|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
80004896|NCT05811273|Other|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
80004897|NCT05811273|Other|Control group|general exercises
79830549|NCT00627705|Drug|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
80004898|NCT05811221|Drug|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
79830550|NCT00627705|Other|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
79830551|NCT04062162|Behavioral|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
79237261|NCT03475329|Other|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
79531833|NCT01435109|Behavioral|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
79830552|NCT04037488|Diagnostic Test|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
79830553|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
79531834|NCT01435109|Behavioral|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
79531835|NCT01435135|Biological|ALVAC-HIV|1 mL per injection containing 10^6 CCID50/dose administered
79531836|NCT01435135|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
79687754|NCT00541125|Drug|fluorouracil|
79687755|NCT00541125|Drug|irinotecan hydrochloride|
79687756|NCT00541125|Drug|leucovorin calcium|
79687757|NCT00541164|Drug|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
79687758|NCT00541164|Dietary Supplement|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
79687759|NCT04657757|Other|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
79687760|NCT04657601|Device|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
79830554|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
79687761|NCT03231072|Device|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
79830555|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
79830556|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
79830557|NCT00890422|Biological|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
79830558|NCT00816075|Drug|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
80004899|NCT05811221|Drug|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
80004900|NCT05811208|Device|automated pupillometry|Automated pupillometry every 6 hours
79302733|NCT03213769|Drug|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
79302734|NCT03213769|Drug|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
79830559|NCT02541370|Biological|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
80004901|NCT05811208|Diagnostic Test|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
80004902|NCT05811195|Device|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
80004903|NCT05811195|Device|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
80004904|NCT05811169|Genetic|Next generation sequencing|Next generation sequencing
80004905|NCT05811104|Device|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
80004906|NCT05811078|Behavioral|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
79531837|NCT01435135|Biological|ALVAC-HIV Placebo|1 ml per injection
79687762|NCT04656977|Other|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
79687763|NCT04656977|Other|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
80004907|NCT05811052|Other|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
79237262|NCT05285956|Behavioral|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
79531838|NCT01435135|Biological|AIDSVAX B/E Placebo|1 ml per injection
79531839|NCT01435148|Procedure|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
79687764|NCT03221322|Behavioral|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
79687765|NCT04656938|Behavioral|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
79687766|NCT00541281|Drug|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
79687767|NCT00541281|Drug|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
80004908|NCT05811052|Other|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
79531840|NCT01435161|Drug|Nifedipine,|Nifedipine 30-60mg/day
79531841|NCT01435161|Drug|Telmisartan|Telmisartan 80-160mg/day
79531842|NCT01435200|Drug|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
79531843|NCT01435213|Drug|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
79531844|NCT01435213|Drug|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
79687768|NCT00541281|Drug|prednisone|2x5 mg a day
79687769|NCT04656860|Dietary Supplement|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
79687770|NCT00541320|Drug|GW813893|
80004909|NCT05811026|Device|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
80004910|NCT05811026|Device|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
79237263|NCT03482817|Drug|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
79531845|NCT01435213|Drug|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
79687771|NCT04657172|Drug|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
79687772|NCT04657172|Drug|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
79687773|NCT03199794|Biological|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
79687774|NCT04656821|Drug|Control Rx|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
79687775|NCT04656821|Procedure|Erector Spinae Block|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
79830560|NCT05045820|Procedure|acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis. Acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of treatment which contains 10 treatment sessions."
79830561|NCT05045820|Other|Sham|"Non-Tradition Acupuncture or a Placebo Comparator will be used as sham acupuncture which uses mock laser acupuncture approach. Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin. The laser will not be turned on during the treatment. Sham treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of sham treatment which contains 10 treatment sessions."
79830562|NCT00610168|Biological|Boostrix TM|Single booster dose of vaccine
79830563|NCT00921102|Drug|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
79237264|NCT03482817|Drug|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
79237265|NCT03655197|Drug|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
79830564|NCT00921102|Drug|Morphine|200 µg of a 200 µg/ml solution, intrathecally
79830565|NCT00921102|Drug|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
79830566|NCT00921102|Drug|Atropine|"100 µg of a 1 mg/ml preservative-free solution~intrathecally in group Intrathecal Atropine~intravenously in group IV Atropine"
79830567|NCT00890500|Drug|Fludarabine|30mg/m2/day IV x 6 days
79830568|NCT00890500|Drug|Melphalan|100 mg/m2/day IV x 1 day
79830569|NCT00890500|Drug|Antithymocyte Globulin|1mg/kg/day x 4 days
79830570|NCT00890500|Drug|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
79830571|NCT00890500|Drug|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
79830572|NCT00890578|Procedure|adhesive to suture|surgical closure
79830573|NCT00890734|Drug|CYT003-QbG10|subcutaneous injection
79531846|NCT01435213|Other|Cold pressor test|30-45 min cold pressor test of the foot
79531847|NCT01435213|Drug|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
79531848|NCT01435213|Drug|Placebo|A single dose of placebo (capsules) administered orally
79531849|NCT01435239|Device|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
79687776|NCT04656821|Procedure|Thoracic Paravertebral Block|Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
79830574|NCT00890734|Drug|Placebo|subcutaneous injection
79830575|NCT04061772|Drug|Bortezomib|Bortezomib injection
79830576|NCT04061772|Drug|Etoposide|Etoposide injection
79830577|NCT04061772|Drug|Cyclophosphamide|Cyclophosphamide injection
79830578|NCT04061772|Drug|Pharmorubicin|Pharmorubicin injection
79830579|NCT04061772|Drug|Prednisone|Prednisone tablet
79830580|NCT04061928|Drug|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
80004911|NCT05811000|Drug|PM012|PM012 650 mg tablet drug
80004912|NCT05811000|Drug|PM012 Placebo|PM012 tablet placebo
80004913|NCT05811000|Drug|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
80004914|NCT05811000|Drug|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
80004915|NCT05810922|Other|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
80004916|NCT05810909|Dietary Supplement|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
79687777|NCT04656509|Other|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
80004917|NCT05810350|Drug|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
80004918|NCT05810064|Other|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
80004919|NCT05807360|Device|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
80004920|NCT05801224|Drug|Nitric Oxide|20ppm for 15 minutes
80004921|NCT05801211|Procedure|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
80004922|NCT05799391|Drug|SJC|Soothing cream jel
80004923|NCT05799391|Other|Placebo|Placebo cream jel
80004924|NCT05793489|Other|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
80004925|NCT05791110|Diagnostic Test|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
80004926|NCT05780060|Behavioral|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
80004927|NCT05780060|Behavioral|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
80004928|NCT05778136|Other|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
79531850|NCT01435239|Device|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
80004929|NCT05773391|Drug|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
80004930|NCT05766982|Other|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
79377795|NCT01829386|Other|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
79531851|NCT01435252|Drug|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
80004931|NCT05766254|Device|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
80004932|NCT05766254|Device|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
80004933|NCT05754853|Drug|MRG002|Administrated intravenously
80004934|NCT05754853|Drug|Docetaxel Injection|Administrated intravenously
80004935|NCT05754853|Drug|Paclitaxel Injection|Administrated intravenously
80004936|NCT05754853|Drug|Gemcitabine Hydrochloride for Injection|Administrated intravenously
80004937|NCT05754853|Drug|Pemetrexed Disodium Injection|Administrated intravenously
80004938|NCT05750420|Other|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
80004939|NCT05747625|Biological|Panitumumab|Given IV
80004940|NCT05747625|Drug|Zirconium Zr 89 Panitumumab|Given IV
79531852|NCT01435278|Device|Glucosanol|2 tablets taken 3 times a day.
79531853|NCT01435291|Drug|Advagraf Capsule|"Other Names:~FK506E~MR4~tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
79687778|NCT00541359|Drug|bortezomib|Given IV
79687779|NCT00541359|Drug|topotecan hydrochloride|Given IV
79687780|NCT00541359|Other|immunohistochemistry staining method|Correlative studies
79377796|NCT04507386|Behavioral|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
79531854|NCT01435291|Drug|Prograf Capsule|"Other Names:~FK506E~MR4~tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
79531855|NCT01435317|Device|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
79531856|NCT01435330|Drug|BVS857|
79531857|NCT01435330|Drug|Placebo|
79531858|NCT01435343|Drug|fludarabine|30 mg/m2/day intravenously on days 1 to 4
79531859|NCT01435343|Drug|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
79531860|NCT01435343|Drug|cytarabine|2 g/m2/day intravenously on days 1 to 4
79687781|NCT00541359|Other|pharmacological study|Correlative studies
80004941|NCT05747625|Procedure|Positron Emission Tomography|Undergo PET/CT
79830581|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
79830582|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
79237266|NCT05317624|Combination Product|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
79687782|NCT04656743|Procedure|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
79377797|NCT03349554|Other|body-scan meditation|15 minutes audio-guided body-scan meditation
79687783|NCT04656743|Procedure|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
79830583|NCT00644787|Drug|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
79830584|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
79237267|NCT05317624|Combination Product|Methylprednisolone|1ml methyl prednisolone 40mg\ml mixed with normal saline and bupivacaine
79237268|NCT03482661|Other|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
79237269|NCT05283772|Behavioral|Development of eye tracker for simulation training in nursing|"Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks."
79377798|NCT03349554|Diagnostic Test|Psychological evaluation|"NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation"
79377799|NCT04506996|Behavioral|Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management|see arm/group descriptions
79377800|NCT04506996|Behavioral|Monday-Focused Written Messages for Weight Management|see arm/group descriptions
79531861|NCT01435343|Drug|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
79531862|NCT01435343|Drug|plerixafor|intravenously from days 1 to 4
80004942|NCT05747625|Procedure|Computed Tomography|Undergo PET/CT
80004943|NCT05747625|Other|Electronic Health Record Review|Ancillary studies
79531863|NCT01435395|Drug|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
79531864|NCT01435434|Device|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
79531865|NCT01435447|Drug|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
79531866|NCT01435473|Procedure|Cardiac Surgery|
79531867|NCT01435486|Drug|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
79531868|NCT01435486|Drug|Normal saline|Placebo with an equivalent volume of normal saline.
79531869|NCT01435499|Biological|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
79531870|NCT01435499|Drug|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
79531871|NCT01435538|Behavioral|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
79687784|NCT03111927|Other|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
79687785|NCT03111927|Other|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
80004944|NCT05744349|Procedure|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
80004945|NCT05742347|Device|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
79687786|NCT04656782|Other|Imaging survey|Participation as expert panelist in the imaging survey.
79687787|NCT04656782|Other|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
79830585|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
79830586|NCT00699582|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
79830587|NCT00699582|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
79237270|NCT03475095|Other|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
79830588|NCT00699582|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
79830589|NCT00821301|Drug|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
80004946|NCT05714267|Device|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
80004947|NCT05714267|Device|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
80004948|NCT05714267|Device|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
80004949|NCT05703100|Other|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
80004950|NCT05703100|Other|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
79237271|NCT04422340|Other|Group1|"Comorbidities (CIRS-G scale),~Functional status of the patient with~Clinical frailty scale (1 month before infection)~ADL score (1 month before infection)~Biological data~Blood group~TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~Resuscitation outcomes~LDH rate at the start of intensive care~PaO2 / FiO2 ratio at the start of intensive care~IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~Delay between the appearance of the first signs of infection and admission to intensive care"
79377801|NCT04506996|Behavioral|Educational Materials|After the baseline assessment and the 1st follow-up (~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
79687788|NCT00541398|Behavioral|Implementation of guideline|Outreach visits with interactive education for health staff
79237272|NCT03475017|Dietary Supplement|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
79377802|NCT04509882|Drug|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
79377803|NCT04509882|Drug|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
79830590|NCT04062084|Device|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
79830591|NCT03860727|Diagnostic Test|Welch Allyn IExaminer|Fundus Examination
79531872|NCT01435551|Other|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
79531873|NCT01435564|Behavioral|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
79531874|NCT01435564|Behavioral|pedometer only|Participants in this group will receive only a pedometer.
79531875|NCT01435590|Procedure|Curette v/s endocervical brush|
79531876|NCT01435629|Drug|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
79531877|NCT01435642|Other|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
79531878|NCT01435694|Behavioral|Lokomat (Hocoma, Switzerland)|
79830592|NCT00640341|Device|PureVision Contact Lens|contact lens for daily wear
79531879|NCT01435694|Behavioral|Conventional Therapy|
79237273|NCT03475017|Dietary Supplement|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
79237274|NCT03480555|Dietary Supplement|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
79237275|NCT03480555|Dietary Supplement|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
79237276|NCT02674568|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
79531880|NCT01435707|Other|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
79237277|NCT05490784|Other|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
79830593|NCT00640341|Device|Acuvue Oasys Contact Lens|contact lens for daily wear
79531881|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
79237278|NCT05490784|Other|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
79237279|NCT03474939|Drug|Midazolam Oral Tablet|Midazolam Oral tablet
79237280|NCT03474939|Other|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
79377804|NCT04509960|Device|direct laryngoskopy|Proseal Laryngeal mask inserted with direct laryngoskopy
79377805|NCT03352986|Biological|biological analysis|biological analysis will be performed in the 6 groups of patients
79377806|NCT03352986|Other|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
79377807|NCT03349398|Procedure|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
79237281|NCT03131271|Other|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
79377808|NCT03349398|Procedure|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
79531882|NCT01435707|Other|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
79687789|NCT04656626|Behavioral|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
79687790|NCT04656626|Behavioral|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
79830594|NCT00640341|Device|O2Optix Contact lens|contact lens for daily wear
79830595|NCT00816153|Other|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
79830596|NCT00699348|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
79830597|NCT05327634|Other|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
79830598|NCT04062786|Other|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
79237282|NCT03163160|Procedure|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
79302735|NCT05002101|Dietary Supplement|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
79531883|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
79531884|NCT01435720|Biological|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
79531885|NCT01435720|Biological|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
79531886|NCT01435720|Biological|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
79531887|NCT01435720|Biological|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
79531888|NCT01435811|Biological|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
79531889|NCT01435837|Drug|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
79531890|NCT01435837|Drug|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
79830599|NCT00643851|Drug|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
79830600|NCT00643851|Drug|Metformin XR|Tablets, Oral, Once daily, 24 weeks
79830601|NCT00816231|Behavioral|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
79830602|NCT00816231|Other|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
79237283|NCT03163160|Procedure|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
79830603|NCT00816231|Other|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
79377809|NCT01585402|Drug|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
79830604|NCT04062864|Device|Pupil size|Measures the diameter of pupil before and after painful stimuli
79377810|NCT01585402|Device|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
80004951|NCT05703100|Other|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
79377811|NCT01636414|Procedure|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
79377812|NCT01636414|Procedure|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
79377813|NCT01636414|Procedure|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
79531891|NCT01435837|Drug|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
79531892|NCT01435837|Drug|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
79531893|NCT01435850|Procedure|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
79531894|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
79531895|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
79531896|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
79687791|NCT03456921|Other|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
79687792|NCT04658069|Other|no specific interventions|no specific interventions
79830605|NCT00821457|Drug|Juvista|250ng
79830606|NCT00821457|Drug|Placebo|Powder for solution for injection
79830607|NCT00821457|Drug|Juvista|500ng
80004952|NCT05695300|Dietary Supplement|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
80004953|NCT05695300|Dietary Supplement|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
79237284|NCT03474861|Biological|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
79237285|NCT05251480|Procedure|Standard of Care|debridement, wound dressings, offloading
79237286|NCT05251480|Other|DermGEN™|Decellularized human dermal matrix created from donated human skin
79830608|NCT03667690|Drug|Rezafungin for Injection|Intravenous antifungal therapy
79830609|NCT03667690|Drug|Caspofungin|Intravenous antifungal therapy
79830610|NCT03667690|Drug|Fluconazole|Oral antifungal therapy
79830611|NCT03667690|Drug|intravenous placebo|Normal saline
79830612|NCT03667690|Drug|oral placebo|Microcrystalline cellulose
79830613|NCT00821535|Drug|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
79830614|NCT04062006|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
79830615|NCT04872582|Drug|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
79830616|NCT04061538|Dietary Supplement|zinc sulfate|zinc 20mg tablets
79377814|NCT03352830|Behavioral|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
79531897|NCT01435876|Procedure|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
79531898|NCT01435876|Procedure|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
79830617|NCT04061538|Dietary Supplement|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
79830618|NCT00888316|Procedure|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
79531899|NCT01435876|Procedure|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
79531900|NCT01435876|Procedure|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
79531901|NCT01435915|Drug|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
79531902|NCT01435941|Drug|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
79531903|NCT01435941|Drug|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
79687793|NCT04656704|Drug|hyaluronidase injected intradermally|Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
79687794|NCT03096249|Drug|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
79687795|NCT03096249|Other|Placebo|Placebo spray: single dose (3 puffs per nostril).
79687796|NCT04656548|Device|HydroPICC|PICC lines
79687797|NCT04656665|Drug|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
79687798|NCT03014622|Biological|Botulinum Toxins, Type A|Intramuscular injection
79687799|NCT03014622|Biological|Placebos|Intramuscular injection
79830619|NCT00888316|Procedure|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
79830620|NCT04351620|Drug|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
79830621|NCT00888394|Procedure|chiropody|basic procedure of chiropody in podiatry
79830622|NCT00888394|Procedure|basic orthesis|individual basic orthesis of foot
79830623|NCT00888394|Procedure|advantage orthesis|advantage orthesis of foot with special material and design
79830624|NCT00888394|Procedure|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
79830625|NCT02541760|Drug|Monteleukast|4 ml monteleukast daily for one month
79830626|NCT02541760|Drug|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
79830627|NCT00888472|Procedure|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
79830628|NCT00627393|Drug|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
79830629|NCT00627393|Biological|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).
79830630|NCT00627393|Drug|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
80004954|NCT05695300|Dietary Supplement|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
79237287|NCT03163550|Drug|ACHN-383|Oral dose
79237288|NCT03163550|Drug|ACHN-789|Oral dose
79237289|NCT03163550|Drug|Placebo|Oral dose
79237290|NCT03131583|Drug|Colchicine|Day-14~Day16 qd
79237291|NCT03131583|Drug|Febuxostat|Day1 and Day8 qd
79237292|NCT03131583|Drug|SHR4640|Day3~Day8 qd
79237293|NCT05250622|Other|Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to Japanese-translated version of evidence summaries.
79237294|NCT05250622|Other|English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to English version of evidence summaries.
79237295|NCT03131349|Diagnostic Test|serum zinc and iron|history ,examination,investigations
79237296|NCT04672928|Drug|paclitaxel|80mg/m^2,iv,Q4W
79687800|NCT04656314|Diagnostic Test|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
79687801|NCT04656119|Other|there is no intervention in our study|there is no intervention in our study
79687802|NCT04656197|Other|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
80004955|NCT05692869|Drug|Propranolol|Administered orally.
79687803|NCT04655846|Behavioral|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~Educational Session: Explain the extraction and conservation of breast milk.~Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
79687804|NCT04655846|Behavioral|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
79830631|NCT00627393|Device|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
79830632|NCT04534959|Other|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 >100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air [no supplemental oxygen] for non-mechanically ventilated patients).
79830633|NCT00816309|Device|Acapella Physiotherapy|twice daily- around 20 minutes
79830634|NCT00821691|Drug|Amantadin|Amantadin caps
79830635|NCT00821691|Drug|Placebo|Placebo caps
79830636|NCT00821847|Other|DEXA scan|DEXA scan
79830637|NCT00816387|Procedure|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
79531904|NCT01435954|Drug|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
80004956|NCT05692869|Drug|Pseudoephedrine|Administered orally.
80004957|NCT05692869|Device|ABPM and Wearable Novel Devices|ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
79237297|NCT04672928|Drug|IBI318|300mg,iv,Q4W
79237298|NCT05249842|Diagnostic Test|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
79531905|NCT01435954|Drug|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
79830638|NCT00816387|Procedure|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
80004958|NCT05692869|Other|No Intervention|No intervention during this period (Control Period)
80004959|NCT05691439|Behavioral|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
80004960|NCT05691439|Behavioral|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
79377815|NCT03352830|Other|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
79377816|NCT02518308|Behavioral|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
79237299|NCT05249842|Diagnostic Test|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
79237300|NCT05249842|Diagnostic Test|6MWT|6 minute walk test
79237301|NCT03162926|Combination Product|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
79237302|NCT03162848|Behavioral|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
79377817|NCT01636882|Biological|CVA21|
79830639|NCT05260866|Other|national population-based study|No intervention
79830640|NCT00821925|Procedure|bone densitometry|All patients do a bone densitometry after the inclusion.
79531906|NCT01435967|Other|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
79531907|NCT01435980|Procedure|Gastric Bypass|basal treatment and Gastric Bypass
79531908|NCT01435980|Drug|Exenatide|basal treatment and Exenatide
79830641|NCT00816465|Dietary Supplement|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
79531909|NCT01435993|Drug|GSK1223249|Intravenous infusion
79687805|NCT04655534|Other|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
79687806|NCT04655534|Other|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
79687807|NCT04655534|Other|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
79830642|NCT00816465|Other|Placebo|PO Placebo pill
79830643|NCT00822003|Drug|Oral GLP-1|GLP-1 tablet (2mg)
79830644|NCT00822003|Drug|Placebo|Control tablet
80004961|NCT05679284|Radiation|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
79377818|NCT04509492|Diagnostic Test|Endoscopic ultrasound ( EUS )|"- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
79830645|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
80004962|NCT05663476|Other|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
80004963|NCT05660226|Other|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
79377819|NCT03352752|Device|HTC Vive|Wearing VR helmet before operation
79377820|NCT03352752|Other|Without HTC Vive|Wearing a blindfold before operation
79377821|NCT01638052|Drug|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
79531910|NCT01435993|Other|Saline placebo|placebo intravenous infusion
79687808|NCT04655807|Drug|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
79830646|NCT00822081|Drug|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
79830647|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
79830648|NCT00822081|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
79830649|NCT00822159|Device|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
79830650|NCT00696774|Drug|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
79830651|NCT00608842|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
79830652|NCT00608842|Drug|Placebo|Matching vehicle placebo administered via intralipomal injection.
79830653|NCT00626925|Drug|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
79830654|NCT00626925|Drug|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
79830655|NCT02566746|Device|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
79830656|NCT02566746|Drug|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
80004964|NCT05660226|Other|Standard care|Standard outpatient blood pressure management
80004965|NCT05655468|Drug|Dronedarone|oral administration fed conditions
79377822|NCT03349164|Diagnostic Test|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
79377823|NCT02518152|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
79377824|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
79531911|NCT01436058|Biological|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
79531912|NCT01436097|Behavioral|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
79830657|NCT00891280|Drug|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
80004966|NCT05655468|Drug|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
79687809|NCT04655807|Drug|Placebo|Matching placebo will be administered as SC injection.
79687810|NCT04655807|Drug|Adalimumab|Adalimumab will be administered as SOC biological therapy.
80004967|NCT05650242|Drug|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
80004968|NCT05649488|Device|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
80004969|NCT05649488|Device|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
80004970|NCT05645627|Drug|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
80004971|NCT05645627|Drug|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
80004972|NCT05645627|Drug|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
80004973|NCT05644353|Drug|Mirikizumab|Administered SC.
80004974|NCT05628155|Other|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
80004975|NCT05620966|Device|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
80004976|NCT05617287|Dietary Supplement|Semaine Menopause Supplement|Synergistic Dietary Supplement
79531913|NCT01436097|Behavioral|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
79377825|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
79377826|NCT01229878|Dietary Supplement|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
79377827|NCT03352674|Drug|Insulin Glargine Ezelin|Insulin Glargine (Ezelin) once daily at individually adjusted dose
79531914|NCT01436097|Behavioral|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
79687811|NCT04655807|Drug|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
79687812|NCT04655417|Drug|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
79687813|NCT00541515|Device|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
79687814|NCT04655729|Drug|Infliximab|Blood collection
79687815|NCT02937831|Biological|RIXUBIS|
79687816|NCT00541554|Drug|Abilify (aripiprazole)|
79830658|NCT00816543|Drug|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
79830659|NCT00816543|Drug|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
79830660|NCT00816543|Drug|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
79830661|NCT00819117|Device|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
79830662|NCT00892684|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
79830663|NCT00892684|Dietary Supplement|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
79302736|NCT05002101|Drug|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
79377828|NCT03352674|Drug|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
79531915|NCT01436097|Behavioral|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
79687817|NCT04655339|Drug|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
79687818|NCT04655105|Device|root canal rotary files|post operative pain evaluation using different rotary file system
79830664|NCT00816621|Behavioral|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
80004977|NCT05615480|Other|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% ~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% ~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 ~ 100 μg or ephedrine 5 ~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
80004978|NCT05604924|Other|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
79830665|NCT00816621|Behavioral|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
79377829|NCT02249260|Behavioral|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
79377830|NCT02518074|Other|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
79377831|NCT03352596|Other|low frutose diet|
79830666|NCT00698646|Drug|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
79830667|NCT00698646|Drug|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
79830668|NCT00698646|Drug|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
80004979|NCT05600400|Radiation|Stereotactic Ablative Body Radiation|2 Fraction
79377832|NCT01639222|Drug|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
79531916|NCT01436123|Other|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
80004980|NCT05576051|Other|patterns of use of combination therapy and monotherapy|
79377833|NCT01639222|Other|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
79377834|NCT03352518|Device|WM3.4NR|The investigational medical device will collect spectral raman data from tissue.
79377835|NCT03349086|Behavioral|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
79377836|NCT04502628|Procedure|Hyperbaric oxygen therapy|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished. Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
79531917|NCT01436123|Device|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
79687819|NCT04655183|Drug|Niraparib|Niraparib will be administered orally, once daily.
79687820|NCT04655183|Drug|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
79687821|NCT04655183|Drug|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
80004981|NCT05575687|Other|Water (reference)|Ingestion of 500 ml mineral water
80004982|NCT05575687|Other|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
80004983|NCT05575687|Other|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
80004984|NCT05575687|Other|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
80004985|NCT05575687|Other|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
80004986|NCT05575687|Other|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
79830669|NCT00891358|Behavioral|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
79830670|NCT02541292|Other|No intervention, observational|
79830671|NCT02565888|Drug|Daclatasvir|
79687822|NCT04655183|Drug|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
79830672|NCT02565888|Drug|Atazanavir|
79687823|NCT04655183|Drug|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
79830673|NCT02565888|Drug|Ritonavir|
79830674|NCT02565888|Drug|Cobicistat|
79830675|NCT04061616|Behavioral|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
79687824|NCT04655183|Drug|Niraparib|Niraparib will be administered as single agent at the approved dose.
79830676|NCT00609466|Drug|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
79830677|NCT00609466|Drug|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
79830678|NCT00609466|Drug|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
79830679|NCT00822315|Drug|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
79830680|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
79830681|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
79830682|NCT00608530|Behavioral|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
79830683|NCT00608530|Behavioral|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
79830684|NCT00608530|Behavioral|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
79830685|NCT00608530|Behavioral|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
79830686|NCT00642993|Drug|SCH 497079|100 mg capsule administered orally
79830687|NCT00642993|Drug|Placebo|Placebo capsules matching SCH 497079 administered orally
79830688|NCT02541136|Behavioral|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, < 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
79531918|NCT01436136|Other|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
79531919|NCT01436136|Other|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
79830689|NCT00696696|Drug|Gemcitabine|1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
79531920|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
79531921|NCT01436188|Procedure|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
79687825|NCT00541710|Dietary Supplement|genistein|pills of 27 mg, twice per day for 12 months
79830690|NCT00696696|Drug|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
79830691|NCT00696696|Drug|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
79830692|NCT00822393|Drug|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
79830693|NCT00822393|Drug|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
79830694|NCT00892840|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
79830695|NCT00892840|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
79830696|NCT00819195|Drug|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
79830697|NCT00891514|Behavioral|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
79830698|NCT00891514|Behavioral|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
79687826|NCT00541710|Dietary Supplement|placebo|sugar pills twice per day for 12 months
79830699|NCT02567682|Drug|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
79830700|NCT00892918|Drug|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
79830701|NCT04739280|Device|CardioFlux Magnetocardiography|Magnetocardiography
79830702|NCT02551185|Drug|ACY-241|
80004987|NCT05568277|Behavioral|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
80004988|NCT05563389|Drug|Atorvastatin 20mg|active arm
79237303|NCT03482427|Behavioral|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
79377837|NCT05473338|Diagnostic Test|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
79377838|NCT05473338|Other|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
79531922|NCT01436188|Procedure|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
79531923|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
79687827|NCT04654871|Dietary Supplement|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
79531924|NCT01436188|Procedure|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
79687828|NCT04654871|Procedure|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
79687829|NCT04654871|Procedure|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
79687830|NCT04654871|Procedure|THE therapy|Interferential and Heating for 20 min
79687831|NCT00541749|Drug|rhuMAb IFNalpha|Intravenous repeating dose
79687832|NCT04654793|Device|Robot assisted inclined bed treatment and FES|FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
79830703|NCT00892996|Drug|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
79830704|NCT00892996|Drug|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
79830705|NCT02567448|Other|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
79830706|NCT02551341|Procedure|higher PEEP ventilation|
79830707|NCT00891592|Biological|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~1xE5 cells/kg~2xE6 cells/kg~3xE7 cells/kg~4xE8 cells/kg"
79830708|NCT00891592|Other|Observation Arm|Single infusion of Cord Blood Cells
79830709|NCT00822471|Behavioral|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
79830710|NCT00893230|Dietary Supplement|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
79830711|NCT00893230|Dietary Supplement|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
79830712|NCT00891670|Drug|cilostazol|100mg twice daily for at least 1 month
79830713|NCT00891670|Drug|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
79830714|NCT00891670|Drug|aspirin|aspirin 100mg
80004989|NCT05563389|Drug|Placebo|placebo arm
80004990|NCT05557214|Behavioral|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
80004991|NCT05548660|Other|Pharmacogenetic testing|Genetic testing of CYP2B6, CYP2C19, CYP2C9, CYP2C cluster CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A, HLA-B, IFNL4, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1.
79237304|NCT05317390|Diagnostic Test|DystoniaNet-based diagnosis of isolated dystonia|DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
79531925|NCT01436214|Drug|APC-100|Daily oral, dose escalation, 28-day cycle(s)
79687833|NCT04654793|Device|conventional inclined bed treatment|conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
79687834|NCT04654520|Other|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
80004992|NCT05548660|Other|Pharmacist note with genotype-guided analgesic recommendations|"CYP2C9 normal metabolizers will be recommended to receive ibuprofen and intermediate and poor metabolizers will be recommended to receive naproxen.~CYP2D6 normal metabolizers will be recommended to receive tramadol and ultrarapid, intermediate and poor metabolizers will be recommended to receive oxycodone."
79830715|NCT00699192|Drug|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
79830716|NCT00699192|Drug|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
79237305|NCT04805385|Dietary Supplement|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
79237306|NCT05676086|Behavioral|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
79237307|NCT05676086|Behavioral|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
79531926|NCT01436240|Behavioral|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
79237308|NCT03474783|Behavioral|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
79237309|NCT05513248|Procedure|anatomic lung resection|includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
79305682|NCT03236753|Procedure|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~Both BL25: transverse insertion toward iliac crest, 4cm~Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~Both BL26: oblique insertion toward iliolumbar ligament, 6cm~Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~Both BL28: oblique insertion toward sacroiliac ligament, 6cm~Both GB30: perpendicular insertion, 6cm~Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
79687835|NCT00541788|Other|Administration of Common Sage|Administration of Common Sage
79687836|NCT04654598|Other|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
79687837|NCT02731716|Behavioral|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
79687838|NCT02731716|Behavioral|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
79687839|NCT02731716|Behavioral|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
79687840|NCT04654481|Device|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
79687841|NCT04654481|Other|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
79687842|NCT04654676|Drug|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
79687843|NCT04654637|Behavioral|Nutrition and Exercise Strategies|Multiple Interactive with Nutrition and Exercise Strategies
79687844|NCT00541905|Drug|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
79830717|NCT00699192|Drug|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
79830718|NCT00699192|Drug|Placebo|1 capsule placebo to match valsartan orally once daily
79830719|NCT00891748|Genetic|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
79830720|NCT00921180|Drug|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
79830721|NCT00921180|Drug|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
79830722|NCT00891826|Dietary Supplement|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
79830723|NCT00891826|Dietary Supplement|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
79830724|NCT04060992|Drug|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
79830725|NCT04061304|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
79830726|NCT04061304|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
80004993|NCT05548660|Other|Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines|Genotype-guided recommendations for all actionable phenotypes resulted from the 16-gene PGx panel per CPIC guidelines and FDA labeling
79531927|NCT01436331|Other|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
80004994|NCT05532917|Other|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (>130 mmol/L or >1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
80004995|NCT05530434|Other|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
79237310|NCT03474705|Device|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
79237311|NCT03160820|Biological|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
79377839|NCT05473338|Other|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
79531928|NCT01436331|Behavioral|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
79531929|NCT01436383|Other|Hypoxic exposure|Hypoxic exposure
79531930|NCT01436409|Other|echography|echography during labor
79531931|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
79531932|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
79531933|NCT01436422|Biological|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
79531934|NCT01436448|Drug|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
79687845|NCT04654403|Drug|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
79687846|NCT04654559|Other|Unobtrusive data collection using wearable non-invasive sensors|Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
79687847|NCT00541983|Drug|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
79687848|NCT00541983|Drug|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
80004996|NCT05530434|Other|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
80004997|NCT05530265|Device|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
80004998|NCT05511766|Drug|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
80004999|NCT05511766|Drug|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
80005000|NCT05511766|Drug|Placebo|not containing drugs
79687849|NCT01205776|Device|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
79687850|NCT01205776|Procedure|CABG|Those patients receiving CABG
79687851|NCT04654715|Procedure|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
79830727|NCT00921336|Drug|KW-2450|Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
79237312|NCT03114722|Drug|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
79830728|NCT04036786|Behavioral|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
79830729|NCT04036786|Behavioral|standard care|standard pregnancy follow up
80005001|NCT05505422|Device|Routine ECMO|Routine ECMO during lung tansplant
80005002|NCT05505422|Device|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~Prolonged high dose pressor required to maintain adequate perfusion~A sustained drop in cerebral saturation > 25% of baseline despite initial attempts at optimization~Inability to tolerate pulmonary artery clamping~Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~Inadequate exposure to the surgical field"
79531935|NCT01435902|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
79531936|NCT01435902|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
79237313|NCT03114722|Drug|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
79237314|NCT03474627|Device|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
79237315|NCT03474627|Device|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
79305683|NCT03236753|Procedure|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
79377840|NCT04443270|Drug|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
79531937|NCT01436474|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
79687852|NCT00542022|Drug|MK0812 / Duration of Treatment: 12 Weeks|
79687853|NCT00542022|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
79687854|NCT04654442|Diagnostic Test|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
79687855|NCT00542061|Device|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
79687856|NCT01205581|Biological|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
79687857|NCT01205581|Biological|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
79830730|NCT05195112|Drug|MT921|Active ingredient
79830731|NCT05195112|Drug|Placebo|Normal Saline
80005003|NCT05501444|Other|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
79531938|NCT01436474|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
79531939|NCT01436513|Drug|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
79531940|NCT01436513|Drug|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
79531941|NCT01436513|Drug|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
79531942|NCT01436513|Drug|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
79237316|NCT03114410|Behavioral|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
79237317|NCT03482271|Other|No intervention - data collection only|No intervention - data collection only
79687858|NCT00557648|Behavioral|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
79687859|NCT00557648|Behavioral|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
79377841|NCT01598194|Device|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
79687860|NCT00542100|Device|PCMRI|
79531943|NCT01436539|Drug|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
79377842|NCT03349008|Drug|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
79531944|NCT01436539|Drug|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
79531945|NCT01436565|Drug|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
79531946|NCT01436565|Drug|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
79531947|NCT01436578|Drug|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
79687861|NCT01205269|Drug|AZD8683, 50 mcg|Dry powder for inhalation, single dose
79687862|NCT01205269|Drug|Placebo|Dry powder for inhalation, single dose
79687863|NCT01205269|Drug|AZD8683, 200 mcg|Dry powder for inhalation, single dose
80005004|NCT05495711|Biological|human umbilical cord mesenchymal stem cell complex collagen|1 * 10^7 cells (2ml)
80005005|NCT05495711|Procedure|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
79377843|NCT03349008|Drug|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
79377844|NCT03349008|Drug|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
79377845|NCT03349008|Drug|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
79377846|NCT03349008|Drug|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
79377847|NCT01598350|Device|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
79687864|NCT04654286|Procedure|Nerve transfer procedure|"Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~Donor nerve is checked for its viability with an electric stimulator during surgery~Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
79687865|NCT04654286|Procedure|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
79830732|NCT05190978|Device|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
79830733|NCT05190978|Procedure|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
79830734|NCT00893386|Procedure|LV Lead Extraction|Removal of a LV lead using any tools & techniques.
79830735|NCT04062474|Procedure|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
79830736|NCT02541214|Device|Trial Nasal Mask|
79830737|NCT00892138|Behavioral|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
80005006|NCT05495581|Drug|pudexacianinium chloride|Intravenous
80005007|NCT05479604|Device|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
80005008|NCT05479604|Device|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
80005009|NCT05468346|Drug|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi [14C]-HEC585
80005010|NCT05466734|Drug|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
80005011|NCT05466734|Drug|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
80005012|NCT05452317|Other|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
80005013|NCT05452317|Other|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
79687866|NCT02888431|Device|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
80005014|NCT05439395|Device|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
80005015|NCT05432921|Behavioral|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
80005016|NCT05421988|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
80005017|NCT05420402|Drug|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
80005018|NCT05420402|Drug|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
79237318|NCT05675852|Other|68-electrode electroencephalography with steady state visual evoked potentials|"Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes."
79237319|NCT03474549|Device|Tigertriever revascularization device|Mechanical Thrombectomy
79237320|NCT05313490|Dietary Supplement|Beetroot Juice|7 days of 140 mL per day of beetroot juice
79237321|NCT05313490|Other|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
79687867|NCT00542139|Drug|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
79687868|NCT00542139|Drug|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
79687869|NCT04653974|Behavioral|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
79687870|NCT00542217|Biological|Imprime PGG|
80005019|NCT05420402|Drug|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
79237322|NCT03163082|Other|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
79687871|NCT04654247|Behavioral|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
79830738|NCT02567370|Drug|AMG 581|Active drug
79830739|NCT02567370|Drug|Placebo|Placebo
79830740|NCT00893542|Drug|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
80005020|NCT05417087|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
80005021|NCT05417087|Drug|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
79830741|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
79830742|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
79830743|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 100 mg
80005022|NCT05416957|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
80005023|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
80005024|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
80005025|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
79830744|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 50 mg
79830745|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
80005026|NCT05408949|Behavioral|Single exercise into pain (SEP) program|"Baseline assessment & commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~Initial follow-up & progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~Second follow-up & progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~Functional rehabilitation program"
80005027|NCT05408949|Behavioral|Shoulder Symptom Modification Procedure (SSMP)|[1] Finger on the sternum,[2A] Scapula modification [3] 'Humeral head' modification [4] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
80005028|NCT05408949|Behavioral|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability[18] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units [18]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
79237323|NCT03163082|Behavioral|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
79237324|NCT03163082|Other|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
79531948|NCT01436604|Other|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~Sequences locating anatomical~T2 black blood (such as ESF)~rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
79237325|NCT03163082|Other|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
79687872|NCT04654247|Behavioral|Control|None feedback.
79687873|NCT04654091|Procedure|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
79687874|NCT04654091|Procedure|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
79687875|NCT04654169|Procedure|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
79830746|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg
79830747|NCT00401245|Drug|Placebo|Tapering placebo
79830748|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
79830749|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
79830750|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
79377848|NCT01598428|Procedure|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
79377849|NCT03352440|Device|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
79377850|NCT03352440|Device|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
79377851|NCT03352440|Device|Control Group - Kinect|Group with typical development that will perform the task on Kinect
79377852|NCT03352440|Device|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
79377853|NCT03352362|Drug|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
79377854|NCT03352362|Drug|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
79377855|NCT03352362|Drug|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
79531949|NCT01436617|Other|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
79531950|NCT01436630|Other|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
79830751|NCT04036474|Other|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
79830752|NCT04036240|Other|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
79830753|NCT00696384|Drug|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and <130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
79237326|NCT03163004|Behavioral|Implementation of standing desks|Three standing desks will be introduced to the classroom
79237327|NCT03474315|Diagnostic Test|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
79237328|NCT05246878|Drug|EDP-235|Oral administration
79830754|NCT00696384|Drug|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
79830755|NCT00696384|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
79830756|NCT04036162|Behavioral|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
79830757|NCT01041625|Drug|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
80005029|NCT05408949|Behavioral|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
79237329|NCT05246878|Drug|Placebo|Placebo to match EDP-235, oral administration
79237330|NCT03162770|Behavioral|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
79531951|NCT01436669|Device|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
79687876|NCT04654169|Procedure|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
79687877|NCT00542256|Device|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
79687878|NCT00542256|Device|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
79830758|NCT02566356|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
79830759|NCT02566356|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
79237331|NCT05245084|Drug|CKD-386(3)|QD, PO
79237332|NCT05245084|Drug|D013, D326, D337|QD, PO
79237333|NCT03480321|Drug|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
79237334|NCT03480321|Drug|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
79237335|NCT03480321|Drug|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
79237336|NCT05244616|Other|arabic version of the postoperative Quality of Recovery Score 15|The Arabic version of the Postoperative Quality of Recovery Score 15 to be completed twice by the patients: once preoperatively and once within 24 to 48 hours postoperatively.
79237337|NCT03160664|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
79531952|NCT01436695|Device|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
79830760|NCT00893620|Device|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
79237338|NCT03160664|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
79531953|NCT01436721|Device|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
79531954|NCT01436734|Other|Fasting glycemia|no intervention
79531955|NCT01436734|Other|Hypoglycemia|Insulin induced hypoglycemia
79237339|NCT03160664|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
79531956|NCT01436747|Drug|Paricalcitol|2 micrograms daily, peroral, 24 weeks
79531957|NCT01436747|Drug|Placebo|2 micrograms daily, peroral, 24 weeks
79531958|NCT01436786|Other|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
79531959|NCT01436812|Procedure|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
79531960|NCT01436812|Procedure|positive end expiratory pressure|PEEP 0 cmH2O
79531961|NCT01436825|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
79531962|NCT01436838|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
79531963|NCT01436851|Biological|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
79531964|NCT01436877|Device|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
79531965|NCT01436890|Drug|Revamilast|Tablet. Low dose, Once daily for 12 weeks
79531966|NCT01436890|Drug|Revamilast|Medium dose, Once daily for 12 weeks
79830761|NCT01039129|Procedure|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
79237340|NCT04928950|Drug|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
79531967|NCT01436890|Drug|Revamilast|High dose, Once daily for 12 weeks
79531968|NCT01436890|Drug|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
79531969|NCT01436903|Device|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
79237341|NCT03160742|Device|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
79237342|NCT03160586|Diagnostic Test|Stuttering severity instrument-3|To measure of degree of stuttering in child
79531970|NCT01436916|Drug|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
79531971|NCT01436916|Drug|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
79531972|NCT01436929|Drug|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
79531973|NCT01436929|Drug|Placebo|Placebo 1tab bid
79531974|NCT01436942|Behavioral|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
79531975|NCT01436955|Drug|Placebo|multiple oral doses
79531976|NCT01436955|Drug|RG1662|Cohorts receiving multiple oral doses
79531977|NCT01436981|Procedure|CABG|Preparation of artery mammaria interna
79531978|NCT01436994|Procedure|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
79687879|NCT04653935|Behavioral|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
79687880|NCT04653935|Behavioral|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
79687881|NCT00542295|Drug|alverine citrate and simeticone|
79687882|NCT00542295|Drug|placebo|
79830762|NCT01039129|Procedure|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
79237343|NCT03160586|Diagnostic Test|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
79237344|NCT02523651|Genetic|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
79237345|NCT02523651|Other|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
79237346|NCT03482037|Drug|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
79377856|NCT03348852|Device|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
79377857|NCT01598740|Drug|CLP|Oral administration
79377858|NCT01598740|Drug|Spironolactone|oral administration
79531979|NCT01436994|Procedure|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
79531980|NCT01436994|Drug|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
79531981|NCT01436994|Drug|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
79531982|NCT01436994|Drug|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
79687883|NCT03454841|Drug|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
79830763|NCT01039129|Procedure|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
79830764|NCT00892450|Drug|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
79830765|NCT01566565|Drug|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
80005030|NCT05408949|Behavioral|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
79237347|NCT03482037|Drug|placebo|Each vial content will be administered via the catheter used for the self-catheterization
79237348|NCT05313412|Device|Lens A (comfilcon A lens)|6 hours
79237349|NCT05313412|Device|Lens B (lehfilcon A lens)|6 hours
79237350|NCT02986269|Procedure|general anesthesia across LMA|general anesthesia across LMA
79237351|NCT02986269|Procedure|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
79237352|NCT02986269|Procedure|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
79237353|NCT03160508|Procedure|Fracture fixation with the TFNA|Fracture fixation with the TFNA
79237354|NCT03474237|Other|Hormone study and Imaging study|"Blood (basal hormone and follow up hormone study)~Imaging examination including computed tomography scan or magnetic resonance imaging"
79237355|NCT05277688|Drug|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
79237356|NCT05277688|Radiation|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
79377859|NCT03352284|Device|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
79531983|NCT01437007|Drug|TKM-080301|
79531984|NCT01437020|Drug|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
79531985|NCT01437020|Drug|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
79531986|NCT01437046|Drug|Doxazosin|Doxazosin 16mg/day
79531987|NCT01437046|Drug|Placebo|
79687884|NCT03454841|Drug|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
79687885|NCT03454802|Diagnostic Test|Passive Leg Raising|See above
79687886|NCT03454763|Drug|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
79687887|NCT03454763|Drug|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
79687888|NCT04653506|Drug|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
79687889|NCT04653506|Drug|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
79687890|NCT00542412|Drug|Riluzole|
79687891|NCT04653701|Combination Product|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
79687892|NCT04653623|Procedure|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
79687893|NCT04653623|Drug|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
79687894|NCT00542529|Biological|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
79687895|NCT04653740|Procedure|specimen sample collection|"Before and during treatment, and at progression, collection of :~Blood~Exhaled air~Saliva~Sweat~Tears~Urine"
79830766|NCT01039363|Drug|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~Gemtuzumab will be omitted in a consolidation schedule.~Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
79687896|NCT02015832|Device|Coronary stent|
79237357|NCT02923401|Other|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
79687897|NCT02015832|Radiation|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
79531988|NCT01437059|Drug|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
79687898|NCT02015832|Device|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
79687899|NCT02015832|Device|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
79830767|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
79237358|NCT02923401|Behavioral|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
79830768|NCT01039441|Procedure|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
79830769|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
79830770|NCT01039441|Other|normal saline|
79237359|NCT02923401|Behavioral|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
79237360|NCT02923401|Behavioral|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
79377860|NCT01599286|Drug|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
79687900|NCT02015832|Device|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
79687901|NCT00542568|Biological|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
79830771|NCT01034917|Drug|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
79830772|NCT01034917|Drug|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
79830773|NCT01039597|Drug|ORE1001|Oral capsules containing 300 mg of the active, study drug
79531989|NCT01437059|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79531990|NCT01437072|Other|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
79531991|NCT01437137|Device|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
79531992|NCT01437137|Device|i-gel™|Insertion of I-gel
79830774|NCT01039597|Drug|Placebo|placebo capsules
79830775|NCT01041937|Procedure|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
79531993|NCT01437150|Device|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
79531994|NCT01437150|Procedure|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
79687902|NCT04653779|Drug|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
79531995|NCT01437163|Device|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
79531996|NCT01437163|Device|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
79531997|NCT01437228|Drug|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
79830776|NCT01041937|Procedure|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
79377861|NCT01599286|Drug|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
79830777|NCT00816699|Other|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
79830778|NCT00822549|Drug|intravenous morphine titration|intravenous morphine titration
79237361|NCT02923401|Other|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
79237362|NCT05277376|Drug|Bemotrizinol (6%)|Active sunscreen ingredient (Broad spectrum UV-Filter)
79237363|NCT05259579|Procedure|Anti-reflux mucosal ablation|Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
79237364|NCT03357068|Procedure|Control|Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
79237365|NCT03357068|Procedure|Acid|Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
79237366|NCT03480165|Drug|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
79237367|NCT03480165|Drug|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
79377862|NCT04503642|Procedure|Changing the surgical team for wound closure|The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
79377863|NCT01599832|Drug|pazopanib hydrochloride|Given PO
79377864|NCT01599832|Other|laboratory biomarker analysis|Correlative studies
79531998|NCT01437228|Drug|placebo|NO İNTERVENTİON
79830779|NCT00822627|Drug|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
79531999|NCT01437254|Drug|CPERT|Single 340 MBq CPERT scan in first 10 subjects
79830780|NCT00822627|Behavioral|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
79830781|NCT00819351|Drug|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
79830782|NCT00819351|Drug|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
79830783|NCT00636675|Behavioral|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~In-House Falls Coordinator training on content and falls processes.~Case-based modules about fall prevention and tailored for various team members.~Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~Toolbox: Handbook of useful measures and worksheets."
79532000|NCT01437254|Drug|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
79532001|NCT01437280|Biological|CGTG-102|"VP=virus particle~Dose Level 1: 3x10^10 VP/injection~Dose Level 2: 1x10^11 VP/injection~Dose Level 3: 3x10^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
79532002|NCT01437293|Drug|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
79532003|NCT01437306|Drug|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
79237368|NCT03022799|Drug|KM-819|
79237369|NCT03022799|Drug|Placebo|
79237370|NCT02674334|Device|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
79237371|NCT02674334|Device|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
79377865|NCT01599832|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
79377866|NCT01599832|Other|pharmacogenomic studies|Correlative studies
79377867|NCT01600222|Drug|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
79377868|NCT05062096|Other|Blood samples|Blood samples at each protocol visit, T and NK cell analysis
79377869|NCT05062096|Other|Skin biopsy|Biopsy of the skin lesion (optional)
79532004|NCT01437358|Other|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
79532005|NCT01437371|Drug|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
79532006|NCT01437384|Drug|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
80005031|NCT05404113|Other|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
79830784|NCT00636675|Behavioral|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~In-class learning sessions introduce interaction strategies.~Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
79237372|NCT05276518|Procedure|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
79237373|NCT05676866|Procedure|Targeted axillary lymph node dissection|Targeted axillary lymph node dissection is done by marking suspicious node with metallic clip prior to neo adjuvant therapy ,then neo adjuvant therapy is given and after complete axillary response (proved by radiological and clinical examination) , targeted axillary lymph node dissection of clipped node is done along with sentinel lymph node dissection
79237374|NCT05676788|Device|Hyperspectral Imaging|Identification of the intersegmental plane
79237375|NCT05311852|Dietary Supplement|palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
79532007|NCT01437410|Procedure|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
79532008|NCT01437436|Procedure|ventilation tube|ventilation tube insertion
79532009|NCT01437462|Drug|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
79532010|NCT01437462|Drug|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
79532011|NCT01437475|Biological|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
79377870|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
79377871|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
79377872|NCT03348696|Drug|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
79377873|NCT03348696|Drug|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
79391172|NCT02415504|Behavioral|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
79391173|NCT01590797|Drug|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
79391174|NCT01590797|Drug|Placebo|Matching placebo once daily for 24 weeks
79532012|NCT01437514|Radiation|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
79532013|NCT01437553|Device|iMAP|IVUS and iMAP analysis for acute coronary syndromes
79532014|NCT01437566|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
79687903|NCT00542607|Drug|levocetirizine dihydrochloride|
79687904|NCT00542646|Procedure|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
79532015|NCT01437566|Drug|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
79532016|NCT01437566|Drug|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
80005032|NCT05404113|Other|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
80005033|NCT05402540|Other|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
79532017|NCT01437566|Drug|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
79237376|NCT05311852|Dietary Supplement|Placebo|assumption of a placebo product 2 time/day for 8 weeks
79377874|NCT04506450|Procedure|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
79532018|NCT01437566|Drug|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
79830785|NCT00699998|Drug|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
79532019|NCT01437579|Procedure|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
79532020|NCT01437579|Procedure|cystoscopy|cystoscopy under general anesthesia
79830786|NCT00699998|Drug|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
79830787|NCT00699998|Drug|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
79830788|NCT00696072|Drug|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
79830789|NCT00696072|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
79237377|NCT03026075|Device|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
79237378|NCT01373918|Drug|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
79532021|NCT01437592|Drug|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
79532022|NCT01437618|Drug|FOLFOXIRI plus bevacizumab|"BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
79532023|NCT01437631|Procedure|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
79830790|NCT00816855|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
79830791|NCT00822705|Drug|Placebo tablet|Control arm
79687905|NCT04653428|Device|Interventional treatment of tricuspid regurgitation|Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair
79687906|NCT04685031|Drug|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
79687907|NCT04685031|Drug|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
79830792|NCT00822783|Drug|Omalizumab|
79830793|NCT00822783|Drug|Placebo|
79830794|NCT00816933|Procedure|appendectomy|appendectomy according to the number of trocar
79830795|NCT00634647|Drug|Satraplatin|80 mg/m^2 days 1-5 of every 35 day cycle
79830796|NCT00634647|Drug|prednisone|5 mg twice daily every 35 days
80005034|NCT05402540|Other|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
79830797|NCT00576732|Drug|Placebo|Oral solution qd or bid for 6 weeks
80005035|NCT05398588|Other|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
80005036|NCT05398588|Other|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
79830798|NCT00576732|Drug|Risperidone high dose|Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
79830799|NCT00576732|Drug|Risperidone low dose|Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
79830800|NCT02550639|Other|BIOMARKER- elispot test|ELISPOT TEST
79830801|NCT00822861|Drug|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
79377875|NCT04506450|Procedure|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
79377876|NCT03348618|Biological|IVIG|Intravenous immunoglobulin
79532024|NCT01437644|Drug|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
79830802|NCT00822861|Drug|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
79377877|NCT03352206|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
79532025|NCT01437670|Drug|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
79377878|NCT03352206|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
79532026|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
79532027|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
79532028|NCT01437696|Other|placebo|No liquid cholecalciferol will be added to the food.
79830803|NCT00822861|Drug|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
79532029|NCT01437748|Drug|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
79830804|NCT00822861|Drug|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
79830805|NCT05180370|Other|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
79830806|NCT00817011|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
79830807|NCT00817011|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
79830808|NCT04061460|Procedure|mechanical plaque control|supra and sub gingival debridment ( plaque control)
79830809|NCT00823017|Other|Patient-preferred music|Music of patients' preference
79830810|NCT00823017|Other|Relaxation Music|Relaxation music compiled from results of first three stages of study
79830811|NCT00823017|Other|Standard Care Environment|Control, no interventions
79830812|NCT00823173|Biological|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
79830813|NCT00819429|Dietary Supplement|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
79830814|NCT00819429|Behavioral|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
80005037|NCT05396612|Other|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
80005038|NCT05391607|Drug|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
80005039|NCT05391607|Drug|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
80005040|NCT05391607|Drug|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
80005041|NCT05388097|Other|Managed Services|coordination of care and assistance with community resources (food, transportation)
80005042|NCT05386563|Procedure|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
79237379|NCT01373918|Drug|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
79532030|NCT01437748|Drug|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
79532031|NCT01437761|Device|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
79532032|NCT01437774|Device|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
79687908|NCT01972932|Dietary Supplement|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
79830815|NCT00819429|Other|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
79377879|NCT04503486|Diagnostic Test|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
79830816|NCT00697788|Drug|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
79830817|NCT02568878|Drug|Creatine monohydrate|
79830818|NCT00817167|Device|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
79830819|NCT00817167|Device|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
79377880|NCT04503486|Diagnostic Test|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
79830820|NCT00400153|Drug|Atrovent Respimat (20 mcg)|
79377881|NCT03352128|Dietary Supplement|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
79377882|NCT03352128|Dietary Supplement|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
79532033|NCT01437800|Drug|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
79532034|NCT01437813|Drug|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
79237380|NCT05310136|Behavioral|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
79237381|NCT03474003|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
79532035|NCT01437826|Drug|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
79532036|NCT01437826|Drug|placebo|placebo had an identical appearance as intervention
79687909|NCT01972932|Dietary Supplement|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
79687910|NCT04653311|Device|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
79830821|NCT00400153|Drug|COMBIVENT MDI (36/206 mcg)|
79830822|NCT00400153|Drug|Combivent Respimat (20 mcg/100 mcg)|
79830823|NCT00400153|Drug|Placebo via corresponding inhaler for blinding purposes|
79830824|NCT04062890|Drug|Vigabatrin Pill|Oral Vigabatrin Pill
79830825|NCT04062890|Drug|Placebo oral tablet|Oral Placebo Pill
79830826|NCT02566512|Other|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
79532037|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
79532038|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
79532039|NCT01437865|Drug|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
79532040|NCT01437904|Procedure|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
79532041|NCT01437904|Procedure|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
79687911|NCT00542763|Drug|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
79687912|NCT04653155|Behavioral|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
79687913|NCT00557804|Device|MUSE clinical system|non-invasive external monitoring device
79830827|NCT02566512|Other|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
79830828|NCT00823251|Device|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
80005043|NCT05386563|Procedure|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
80005044|NCT05377190|Other|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
79237382|NCT03671915|Device|Continuous Glucose Monitoring|collection of glucose data
79237383|NCT03671915|Device|External Insulin Pump|Insulin delivery
79237384|NCT03671915|Device|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
79237385|NCT03671915|Other|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
79377883|NCT03122730|Combination Product|VentaProst|Part I - an equivalent dose of VentaProst compared to conventionally-administered aerosolized epoprostenol with subsequent dose titration to achieve a clinically significant hemodynamic response Part II - Dose titration to achieve a clinically significant hemodynamic response.
79377884|NCT05286372|Drug|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
79377885|NCT05281692|Diagnostic Test|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
79237386|NCT03671837|Other|Oxygen|15 L/min O2
79237387|NCT03671837|Other|Air|15 L/min air
79377886|NCT04505904|Drug|Syntocinon|Synthetic oxytocin spray, 24 IU per spray.
79377887|NCT04505904|Drug|Placebo|Placebo spray with no active ingredient.
79237388|NCT03302195|Drug|Heparin|Based on patient body weight (UI/kg)
79237389|NCT03302195|Procedure|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
79377888|NCT04505982|Other|Data extraction from medical files|Data extraction from medical files
79377889|NCT03348462|Drug|ethosomal preparation of anthralin|once daily with short contact topical application
79377890|NCT03348462|Drug|liposomal preparation of anthralin|once daily with short contact topical application
79377891|NCT04505514|Drug|Iron Isomaltoside 1000|"single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding"
79532042|NCT01437917|Other|20% amylose bread|20% amylose bread
79532043|NCT01437917|Dietary Supplement|10% amylose bread|10% amylose bread
79687914|NCT01854684|Drug|Temoporfin|Given IV
79687915|NCT01854684|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79687916|NCT01854684|Drug|Photodynamic Therapy|Undergo intraoperative PDT
79687917|NCT01854684|Other|Laboratory Biomarker Analysis|Correlative studies
79687918|NCT01854684|Other|Pharmacological Study|Correlative studies
79687919|NCT04653077|Other|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
79830829|NCT00817245|Drug|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
80005045|NCT05377190|Other|Standard of care for the follow-up|No mobile application or digital therapeutics are used
80005046|NCT05377190|Other|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
80005047|NCT05365802|Drug|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
80005048|NCT05365802|Procedure|Computed Tomography|As part of PET/CT scan
80005049|NCT05365802|Procedure|Positron Emission Tomography|As part of PET/CT scan
79687920|NCT01827579|Biological|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
79237390|NCT03113786|Other|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
79830830|NCT02566278|Other|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
79532044|NCT01437917|Dietary Supplement|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
79687921|NCT04653233|Device|3D Systems Touch Haptic Simulator|This simulator is computer-aided and allows us to see this application on the computer screen while practicing with a haptic arm. It gives real-like feedback in hand manipulations. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option.
79687922|NCT00542802|Drug|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
79687923|NCT00542802|Drug|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
79687924|NCT04652648|Drug|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
79687925|NCT00542841|Procedure|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
79687926|NCT00542958|Drug|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m^2, and to be determined. Intravenous infusion
79687927|NCT04652492|Drug|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
80005050|NCT05365802|Procedure|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
80005051|NCT05363826|Combination Product|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
80005052|NCT05358639|Drug|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
79237391|NCT03113786|Other|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues & Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
79237392|NCT03676595|Other|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
79237393|NCT03676595|Other|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
79532045|NCT01437930|Dietary Supplement|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~linseed oil (20g/d)(PPM, Magdeburg)~echium oil (20g/d) (HARKE Nutrition)~microalgae powder(12g/d)(HARKE Nutrition)"
79687928|NCT01185210|Dietary Supplement|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
79830831|NCT05457686|Other|kinesio tape|According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other
79830832|NCT05457686|Other|Sham taping|In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.
79830833|NCT05457686|Other|Exercise|Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
79830834|NCT05132634|Other|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
79532046|NCT01437527|Behavioral|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
79532047|NCT01437527|Behavioral|therapy as usual|Body image therapy as usual
79532048|NCT01437982|Drug|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
79830835|NCT03859791|Other|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
79830836|NCT00823329|Device|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
80005053|NCT05358639|Drug|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
80005054|NCT05355090|Dietary Supplement|PP|Protein Pacing three times per day
80005055|NCT05347225|Drug|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
80005056|NCT05330871|Biological|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
79237394|NCT02667626|Other|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
79237395|NCT02667626|Other|Control|Web-based resource lists and text-based study adherence reminders
79377892|NCT04505514|Drug|Placebo|"100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding"
79532049|NCT01437982|Drug|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
79377893|NCT04505514|Drug|Iberet-Folic-500|once a day dose, to start 5 days after the intervention
79532050|NCT01438021|Other|pharmacological study|Correlative studies
79532051|NCT01438021|Drug|methotrexate|Given intraventricularly
79532052|NCT01438086|Drug|mecasermin|Intracoronary bolus
79532053|NCT01438086|Drug|mecasermin|Intracoronary bolus
79377894|NCT03352050|Dietary Supplement|mushroom|
79377895|NCT03352050|Other|ground beef|
79377896|NCT05256732|Drug|AT-527 fasted|AT-527 administered twice daily (BID) for 5 days fasted
79532054|NCT01438086|Drug|0.9% sodium chloride injection|Intracoronary bolus
79532055|NCT01438112|Biological|CG0070 Adenovirus Vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
79532056|NCT01438112|Other|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options: (same as listed above)
79687929|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
79687930|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
79687931|NCT04652336|Procedure|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
79687932|NCT04652336|Procedure|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
79830837|NCT02550483|Other|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
79377897|NCT05256732|Other|Placebo Comparator fasted|Matching placebo administered twice daily (BID) for 5 days fasted
79377898|NCT05256732|Drug|AT-527 fed|AT-527 administered twice daily (BID) for 5 days fed
79377899|NCT05256732|Other|Placebo Comparator fed|Matching placebo administered twice daily (BID) for 5 days fed
79830838|NCT02550483|Other|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
80005057|NCT05330871|Biological|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
80005058|NCT05330871|Biological|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
80005059|NCT05330871|Biological|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
79377900|NCT05256732|Drug|AT-527|AT-527 administered twice daily (BID)
79377901|NCT05256732|Drug|AT-527 single dose|AT-527 single dose fasted/fed cross-over
79532057|NCT01438125|Other|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
80005060|NCT05330871|Biological|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
80005061|NCT05330871|Biological|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
79532058|NCT01438125|Other|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
79687933|NCT00543036|Device|H-Coil deep TMS|
79687934|NCT04652297|Drug|HS-10356|Single dose of HS-10356
79687935|NCT04652297|Drug|Placebo|Single dose of Placebo
79687936|NCT04652297|Drug|HS-10356|Multiple doses of HS-10356
79687937|NCT04652297|Drug|Placebo|Multiple doses of Placebo
79377902|NCT05208918|Procedure|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
79377903|NCT05208918|Procedure|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
79532059|NCT01438138|Other|diagnostic laboratory biomarker analysis|Correlative studies
79237396|NCT03671681|Behavioral|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
79377904|NCT03348384|Radiation|[C-11]|Radiolabel
80005062|NCT05330871|Biological|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
80005063|NCT05330871|Biological|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
80005064|NCT05330871|Biological|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
80005065|NCT05330871|Biological|10 Intramuscular injection for booster groups|1 dose 0.5ml
79377905|NCT03348384|Drug|NOP-1A|Tracer
79532060|NCT01438190|Drug|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
79532061|NCT01438190|Drug|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
79532062|NCT01438203|Procedure|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
79532063|NCT01438203|Procedure|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
79532064|NCT01438242|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
79532065|NCT01438281|Drug|SYL1001|SYL1001 eye drops. topical administration
79532066|NCT01438320|Dietary Supplement|Quercetin|Bioflavonoid
79532067|NCT01438333|Dietary Supplement|lactobacillus brevis tablets|5 tablets a day for 6 weeks
79532068|NCT01438333|Dietary Supplement|PLACEBO|5 tablets a day for 6 weeks
79532069|NCT01438346|Behavioral|Substance Abuse Education|10 weeks of usual care for substance abuse.
79532070|NCT01438346|Behavioral|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
79532071|NCT05607927|Procedure|Parks surgery|Parks surgery
79532072|NCT05607927|Procedure|PE-Bacon surgery|PE-Bacon surgery
79532073|NCT05607433|Device|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
79377906|NCT02517762|Behavioral|Physical activity|
79377907|NCT03346980|Diagnostic Test|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
79377908|NCT04505748|Device|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
79377909|NCT03351972|Drug|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
79377910|NCT03351972|Other|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
79532074|NCT05607277|Procedure|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
79532075|NCT05607212|Other|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
79532076|NCT05607212|Other|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
79532077|NCT05607212|Other|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
79532078|NCT05606939|Device|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
79532079|NCT05605028|Behavioral|Mental Health lifestyle intervention|The focus is to identify 10 potential groups of causes and working on reversing them. The 10 factors are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
79532080|NCT05605028|Other|Dietitian-led|A group of people that visit the dietitian will be used as comparison against the Mental Health lifestyle intervention
80005066|NCT05330871|Biological|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
80005067|NCT05330871|Biological|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
80005068|NCT05330871|Biological|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
80005069|NCT05330871|Biological|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
79237397|NCT03671681|Drug|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
79532081|NCT05596370|Diagnostic Test|cell free DNA in blood and urine, metabolite/microbiome in urine and stool|cell free DNA in blood and urine, metabolite/microbiome in urine and stool
79687938|NCT04652024|Device|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
79687939|NCT00543075|Drug|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
79687940|NCT04651907|Other|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
79687941|NCT04651907|Other|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
79830839|NCT02550483|Other|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
79830840|NCT04646382|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
79830841|NCT04646382|Dietary Supplement|Control|Microcrystalline cellulose
79830842|NCT00817323|Procedure|Dietary amino-acid depletion|See detailed description
79830843|NCT05739188|Biological|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10^6 /kg±20%; Dose level two:6.0×10^6 /kg±20%; Dose level three:1.0×10^7 /kg±20%."
79830844|NCT02566434|Dietary Supplement|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
79830845|NCT00737750|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
79237398|NCT03479853|Procedure|Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
79830846|NCT00737750|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
79377911|NCT04503330|Procedure|buccal mucosal graft to repair iatrogenic PUJO|Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
79532082|NCT05596110|Behavioral|TENS and KT|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
79532083|NCT05596110|Behavioral|TENS and sham taping|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
79377912|NCT05585424|Other|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
79687942|NCT00543114|Drug|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
79687943|NCT00543114|Drug|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
79687944|NCT00543114|Drug|Rituximab|Given intravenously on Day 1 of each 28 day cycle
79687945|NCT03454724|Device|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
79830847|NCT00737750|Behavioral|Control|Voluntary quadriceps muscle contractions.
79830848|NCT04608318|Biological|Ibrutinib|Cycles 1 - X: 420 mg daily, d1-28 p.o.
80005070|NCT05330871|Biological|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
80005071|NCT05330871|Biological|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
80005072|NCT05330871|Biological|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
80005073|NCT05330871|Biological|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
80005074|NCT05330871|Biological|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
80005075|NCT05330871|Biological|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
80005076|NCT05330871|Biological|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
80005077|NCT05330871|Biological|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
79532084|NCT05596110|Behavioral|KT and sham TENS|KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
79687946|NCT03454724|Device|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
79687947|NCT00543153|Behavioral|Interview|Interview lasting approximately 30-45 minutes.
79687948|NCT04652258|Drug|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
79830849|NCT04608318|Biological|Venetoclax|"Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o."
79830850|NCT04608318|Biological|Obinutuzumab|Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
79237399|NCT03676517|Radiation|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
79237400|NCT05275114|Device|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
79377913|NCT05139732|Diagnostic Test|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
79237401|NCT05275114|Device|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
79237402|NCT05676632|Other|Routine Clinical Care|All participants attending the Achilles Tendon Rupture clinic will receive usual clinical care
79237403|NCT03757455|Procedure|ERAS protocol preoperative actions|"First appointment:~- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
79377914|NCT03122340|Drug|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
79532085|NCT05596110|Behavioral|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
79532086|NCT05578859|Drug|AMG 510|Single oral dose of AMG510.
79830851|NCT05733806|Other|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
79830852|NCT04063358|Drug|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
79830853|NCT00921258|Procedure|prostate biopsy|"patient of control group will have :~1 prostate biopsy 3 months after diagnostic biopsy~1 prostate biopsy each year during 2 years~1 prostate biopsy each 2 years during 8 years"
79237404|NCT03757455|Procedure|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
79237405|NCT03757455|Procedure|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
79237406|NCT03114020|Drug|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
79237407|NCT03114020|Drug|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
79377915|NCT03122340|Other|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
79377916|NCT03351894|Procedure|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
79377917|NCT03351894|Procedure|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
79532087|NCT05563688|Other|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
79687949|NCT01014546|Drug|Arsenic Trioxide|Given PO
79687950|NCT01014546|Dietary Supplement|Ascorbic Acid|Given PO
79687951|NCT01014546|Other|Laboratory Biomarker Analysis|Correlative studies
79687952|NCT01014546|Other|Pharmacological Study|Correlative studies
79830854|NCT00631917|Drug|Aliskiren|Aliskiren 300 mg once a day
79830855|NCT00631917|Drug|Ramipril|Ramipril 10 mg once a day
79830856|NCT00631917|Other|Placebo to Ramipril|Placebo capsules to match ramipril.
79830857|NCT00631917|Other|Placebo to Aliskiren|Placebo tablets to match aliskiren.
79830858|NCT00823407|Drug|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
79830859|NCT00823407|Drug|Placebo|Subjects will receive a single oral dose of placebo
79532088|NCT05563688|Other|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
79532089|NCT05563688|Behavioral|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~in normoxia (FiO2 = 21%) after a night of usual sleep (> 6 hours) ;~in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (> 6 hours);~in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
79687953|NCT04652141|Diagnostic Test|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
79830860|NCT04514523|Other|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
80005078|NCT05330871|Biological|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
80005079|NCT05330871|Biological|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
79687954|NCT04651946|Diagnostic Test|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
80005080|NCT05314153|Drug|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
80005081|NCT05313035|Biological|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
80005082|NCT05313035|Biological|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
80005083|NCT05308940|Drug|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
79237408|NCT04460079|Drug|Peg-filgrastim|PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
79687955|NCT00845442|Device|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
79687956|NCT04651829|Other|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
79687957|NCT04651829|Other|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
79687958|NCT04651517|Device|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
79687959|NCT00543231|Drug|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
79687960|NCT00557843|Drug|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
79237409|NCT03113864|Dietary Supplement|Placebo|Daily supplementation for 9 months
79237410|NCT03113864|Dietary Supplement|Lutein|Daily Supplementation for 9 months
79237411|NCT03479619|Device|Lancing device A|Glucoject Dual Plus lancing device
79377918|NCT03351816|Procedure|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
79377919|NCT03351816|Procedure|Cardioversion|External electric shock delivery under general anesthesia.
79687961|NCT00557843|Drug|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
79709843|NCT00596076|Behavioral|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
79830861|NCT00419341|Biological|Human Normal Immunoglobulin for Subcutaneous Administration|
79830862|NCT00694122|Drug|Lantus (glargine)|Described in Arm Description
80005084|NCT05308940|Drug|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
80005085|NCT05308940|Drug|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
79237412|NCT03479619|Device|Lancing device B|Droplet lancing device
79237413|NCT03479619|Device|Lancing device C|Commercially available lancing device
79237414|NCT03479619|Device|28 G lancet|Droplet 28 G
79237415|NCT03479619|Device|30 G lancet|Droplet personal lancet 30 G
79237416|NCT03479619|Device|33 G lancet|Droplet personal lancet 33 G
79237417|NCT03479619|Other|Lancing depth setting (1)|The lowest depth setting (1)
79237418|NCT03479619|Other|Lancing depth setting (5)|The highest depth setting (5)
79377920|NCT04505202|Drug|0.12% chlorhexidine gluconate|The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
79377921|NCT04505202|Drug|Placebo|The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
79391175|NCT01590797|Biological|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
80005086|NCT05308940|Drug|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
79687962|NCT04651478|Behavioral|Action Observation+Motor Imagery through BCI|Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
79532090|NCT05548946|Other|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
79532091|NCT05548946|Other|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young & Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse & Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, & Ettema, 1975, 1986, 2005) ADP-IV (Schotte & De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver & White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young & Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
79687963|NCT04651478|Behavioral|Action Observation through non-related with movement illustrations|The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
79830863|NCT00817401|Device|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
79830864|NCT03934086|Drug|rimegepant|rimegepant 75 mg
79830865|NCT02550951|Procedure|lymphangiography|
79830866|NCT05417048|Diagnostic Test|Blood Sample|Up to 5mL of blood via venipuncture
79830867|NCT03922620|Drug|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
79830868|NCT03922620|Drug|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
79830869|NCT00419263|Drug|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
79830870|NCT00419263|Drug|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
80005087|NCT05306626|Behavioral|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
79237419|NCT03669731|Other|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
79709844|NCT02272829|Behavioral|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
79709845|NCT02272829|Other|Health Education|
79709846|NCT00596115|Drug|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
79709847|NCT02272868|Biological|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
79830871|NCT00419263|Drug|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
79830872|NCT01034995|Drug|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
79237420|NCT03623399|Procedure|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
79237421|NCT03473691|Drug|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
79532092|NCT05548946|Diagnostic Test|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
80005088|NCT05302830|Behavioral|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
79687964|NCT00419328|Drug|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~starting dose: 0.2 μg/m2~following doses: 0.4, 0.8 and 1.6 μg/m2.~number of patients: 4 per dose level~Step 2:~starting dose: 3.2 μg/m2~following doses: 6.4 and 12.8 μg/m2~number of patients: 3 per dose level~Step 3:~starting dose: 19.2 μg/m2~following doses: 28.8, 43.2 and 64.8 μg/m2~number of patients: 3 per dose level~Step 4:~starting dose: 86.2 μg/m2~following doses: 114.6 and 152.4 μg/m2~number of patients: 3 per dose level"
79687965|NCT04651751|Behavioral|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
79687966|NCT00543270|Device|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
79687967|NCT00543270|Procedure|Open Surgery|Open surgical abdominal aortic aneurysm repair
79687968|NCT04651556|Drug|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
79687969|NCT04651556|Drug|paracetamol & ketorolac|parenteral analgesics
79687970|NCT02587767|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
79377922|NCT04505124|Behavioral|FutureMe App|The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
79687971|NCT02587767|Device|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
79687972|NCT04651322|Device|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~*Robot Assisted Arm training + Conventional occupational therapy"
80005089|NCT05302830|Behavioral|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
79532093|NCT05548946|Other|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
79687973|NCT04651322|Behavioral|Conventional therapy|The control group received the usual conventional therapy *Only Conventional occupational therapy
79687974|NCT03456765|Diagnostic Test|Ultrasound|US will be made to assess kidneys
79687975|NCT04651049|Drug|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
79687976|NCT04651049|Device||
79687977|NCT02497443|Biological|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
79687978|NCT04651205|Dietary Supplement|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
79687979|NCT03456648|Drug|apixaban|non-vitamin K oral anticoagulant (NOAC)
79709848|NCT02272868|Drug|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
79709849|NCT02272868|Drug|rifaximin+omeprazole+miralax|
79830873|NCT01034995|Drug|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
79830874|NCT01034995|Drug|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
79830875|NCT00921414|Drug|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
79830876|NCT00921414|Other|Watch and wait|No treatment patient follow-up every 2 months during 3 years
79830877|NCT04060914|Drug|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
79687980|NCT04651283|Other|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~Building towers and shapes with different textures weights and bright colors.~Inserting different shapes in the correct hole.~Dropping pellets.~Stringing beads.~Copying square and triangle.~Opening the bottle and close it.~Folding and Crumpling paper.~Cutting paper by scissors.~Tracing line and connecting dots.~Reaching above the level of shoulder.~Reaching across the midline.~Squeezing water out of a sponge.~Buttoning and unbuttoning button.~Playing clapping games.~Turning pages in a book.~Lacing string.~Picking up a small piece of food and bringing it into the palm.~Moving a penny from the palm to the fingers.~Removing socks.~Brush the teeth."
79709850|NCT02892864|Other|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
79830878|NCT04060914|Drug|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
79830879|NCT04060914|Drug|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
79830880|NCT03894696|Drug|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
79830881|NCT00399763|Drug|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
79830882|NCT00399763|Drug|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
80005090|NCT05293756|Behavioral|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~Six weekly web-based education sessions on hypertension management.~Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: < 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
80005091|NCT05289310|Other|Normobaric hypoxia (NH)|Low oxygen exposure to mimic ~8500 feet elevation (experimental).
80005092|NCT05289310|Other|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
79377923|NCT04505124|Behavioral|Conventional TrackingApp|The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
79377924|NCT04504890|Device|EYE-SYNC|Nystagmograph used to measure eye movement
79377925|NCT03348072|Procedure|Cardiac surgery|Cardiac surgery
79377926|NCT03346746|Dietary Supplement|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
79830883|NCT05324904|Drug|Vitamin D|"- Vitamin D~The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts > 10 mm need multiple injections at different sites)~Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
79532096|NCT05515328|Drug|[¹⁴C] BI 685509 formulation 1|[¹⁴C] BI 685509 formulation 1
79532097|NCT05515328|Drug|[¹⁴C] BI 685509 formulation 2|[¹⁴C] BI 685509 formulation 2
79532098|NCT05515328|Drug|BI 685509 formulation 3|BI 685509 formulation 3
79830884|NCT05324904|Drug|acyclovir|"-Acyclovir~Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
79830885|NCT02085265|Drug|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
79377927|NCT03346746|Dietary Supplement|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
79377928|NCT03122028|Device|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
79377929|NCT03351582|Behavioral|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
79377930|NCT05098704|Drug|clopidogrel treatment|75 mg daily during 24 months
79377931|NCT05098704|Drug|Placebo|75 mg daily during 24 months
79532099|NCT05502601|Procedure|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
79237422|NCT03676361|Drug|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
79532100|NCT05497830|Other|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
79830886|NCT02085265|Drug|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
80005093|NCT05283408|Drug|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
79377932|NCT05585268|Other|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
79687981|NCT04651283|Other|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~Building towers and shapes with different textures weights and bright colors.~Inserting different shapes in the correct hole.~Dropping pellets.~Stringing beads.~Copying square and triangle.~Opening the bottle and close it.~Folding and Crumpling paper.~Cutting paper by scissors.~Tracing line and connecting dots.~Reaching above the level of shoulder.~Reaching across the midline.~Squeezing water out of a sponge.~Buttoning and unbuttoning button.~Playing clapping games.~Turning pages in a book.~Lacing string.~Picking up a small piece of food and bringing it into the palm.~Moving a penny from the palm to the fingers.~Removing socks.~Brush the teeth."
79237423|NCT05309278|Behavioral|Physical training|Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
79237424|NCT05309278|Behavioral|Cognitive training|These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
79377933|NCT05584956|Drug|L_carnitine|l-carnitine stabilizes red blood cell membranes and thus improves the anemic state[
79532101|NCT05496855|Other|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
79532102|NCT05496855|Other|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
79830887|NCT00699842|Drug|Lenalidomide|"Dose Level Lenalidomide Schedule~15mg/day for d1-21 out of 28 days~20mg/day for d1-21 out of 28 days~25mg/day for d1-21 out of 28 days"
79237425|NCT04459845|Behavioral|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
79377934|NCT05584956|Drug|Sildenafil|selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.
79377935|NCT04502004|Device|App for health=mhealth|Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
79377936|NCT03351504|Other|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
79687982|NCT02428491|Biological|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
79830888|NCT01589107|Behavioral|video decision aid|video decision aid
79830889|NCT02567630|Behavioral|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
80005094|NCT05283408|Drug|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
80005095|NCT05283408|Drug|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
80005096|NCT05275400|Drug|Insulin Efsitora Alfa|Administered SC
79532103|NCT05485688|Other|sleep apnea|This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese [BMI>=27] & 30 non-obese [BMI<27]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
80005097|NCT05275400|Drug|Insulin Degludec|Administered SC
80005098|NCT05264103|Device|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
80005099|NCT05255172|Other|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
79532104|NCT05484830|Procedure|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT > 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
79687983|NCT00557921|Drug|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
79237426|NCT04459845|Behavioral|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
79237427|NCT03676205|Biological|PRP|Platelet-Rich Plasma
80005100|NCT05254535|Other|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
79237428|NCT03676205|Other|Traumeel|Homeophatic Treatment
79237429|NCT03676127|Other|ultrasonographic dermal thickness measurements|ultrasonographic dermal thickness measurements
79237430|NCT03481803|Drug|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
79237431|NCT02523417|Procedure|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
79237432|NCT01712763|Drug|degarelix|180 women will be treated with degarlix 80 mg, in only one administration covering three months
79237433|NCT01712763|Drug|goserelin|180 women will be treated with decapeptyl 3.6 every month for three months
79237434|NCT05237518|Device|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
79237435|NCT04458519|Other|Probiorinse|Nasal irrigations with probiotic twice-daily for a period of fourteen days
80005101|NCT05240755|Drug|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
80005102|NCT05229315|Drug|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
79237436|NCT04458519|Other|Saline solution|Nasal irrigations with saline-only twice-daily for a period of fourteen days
79237437|NCT02523183|Drug|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
79237438|NCT05218486|Drug|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
79237439|NCT03251183|Diagnostic Test|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
79377937|NCT03351426|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
79377938|NCT01376700|Biological|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
79377939|NCT04504578|Procedure|contact lens assisted corneal cross linking|40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch & Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
79687984|NCT00557921|Drug|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
80005103|NCT05229315|Procedure|Intensity modulated radiotherapy|Intensity modulated radiotherapy
80005104|NCT05222880|Device|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
79532105|NCT05484830|Procedure|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT > 480 sec. If ACT < 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT > 480 sec. during normothermic CPB, and target ACT > 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT > 40 seconds, additional protamine (25-50 mg i.v.)."
79687985|NCT03456609|Drug|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
79687986|NCT03456609|Drug|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
79830890|NCT03897608|Behavioral|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
79830891|NCT00399529|Biological|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
79830892|NCT00399529|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
79830893|NCT00399529|Drug|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
79830894|NCT00921050|Drug|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
79830895|NCT00921050|Drug|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
79237440|NCT03251183|Diagnostic Test|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
79830896|NCT01035307|Genetic|gene expression analysis|
79830897|NCT01035307|Genetic|microarray analysis|
79237441|NCT03251183|Diagnostic Test|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
79687987|NCT02346162|Behavioral|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI </=25, and when pregnant, weight gain within IOM guidelines.
79830898|NCT01035307|Genetic|proteomic profiling|
79237442|NCT03251183|Diagnostic Test|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
79377940|NCT01797965|Drug|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
79377941|NCT05017506|Other|A survey will be made.|A survey will be made.
79377942|NCT01601236|Drug|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups [8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)].
79377943|NCT01601236|Drug|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
79377944|NCT05584878|Other|Curodont repair Self- assembling peptide P11-4|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
79377945|NCT05584878|Other|Ph-chi phosphorylated - nano-chitosan|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
79377946|NCT05584878|Other|"CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate"|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
79830899|NCT01035307|Other|laboratory biomarker analysis|
79687988|NCT02346162|Other|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
79830900|NCT02565966|Other|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
79830901|NCT01035385|Drug|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
79830902|NCT00712712|Drug|Acetaminophen|Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
79830903|NCT00712712|Drug|Morphine Sulfate|Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
79830904|NCT00712712|Other|Questionnaire administration|"Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~the background morphine analgesic treatment during the last 24 hours,~the morphine analgesic treatment taken during painful attacks,~the possible undesirable effects of morphine treatment.~the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent"
79830905|NCT00712712|Procedure|Quality-of-life assessment|Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
79532106|NCT05473884|Device|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
79237443|NCT03251183|Diagnostic Test|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
79830906|NCT00712712|Procedure|Radiofrequency ablation|"Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz."
79532107|NCT05473884|Device|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
79237444|NCT05216770|Other|Brain imaging|Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers
79237445|NCT05216770|Drug|Laryngeal sensory block with topical bupivacaine|Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
79237446|NCT03675971|Drug|Cannabinol|Postoperative pain treatment
79377947|NCT01601782|Procedure|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
79377948|NCT01601782|Device|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
79532108|NCT05463757|Drug|Vismodegib|Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
79532109|NCT05463757|Drug|Sonidegib|Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
79532110|NCT05451446|Dietary Supplement|proprietary water|They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
79532111|NCT05451446|Other|Active comparator|They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
79532112|NCT05451446|Other|Placebo|They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
79687989|NCT02324283|Drug|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
79687990|NCT02324283|Drug|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
79687991|NCT00557960|Drug|Mixed salts of a single-entity amphetamine|
79687992|NCT00557960|Drug|Atomoxetine hydrochloride|
79687993|NCT00543426|Drug|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
79687994|NCT00543426|Drug|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
79687995|NCT00543465|Drug|MK0782|
79687996|NCT00557999|Other|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
79532113|NCT05435924|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants by two examiners separately.~Second application of the scales to the participants by one examiner.~Statistical analysis and scaling"
79830907|NCT00411151|Drug|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
79377949|NCT01601860|Other|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~Walking (with cervical dilation between 4 and 5 cm)~Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~Shower (with dilation> 7 cm);"
79687997|NCT00558077|Drug|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
79830908|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
79377950|NCT01601860|Other|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
79830909|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
79830910|NCT00893698|Procedure|bilateral allotransplantation|bilateral allotransplantation of upper limbs
79830911|NCT00699608|Drug|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
79830912|NCT00893776|Other|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
79377951|NCT01376388|Drug|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
79532114|NCT05426447|Other|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
79532115|NCT05426447|Other|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
79532116|NCT05418088|Biological|Anti-CD19/CD20/CD22 CAR T-Cells|Given IV
79532117|NCT05418088|Drug|Cyclophosphamide|Given IV
79532118|NCT05418088|Drug|Fludarabine Phosphate|Given IV
79532119|NCT05399966|Dietary Supplement|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
79532120|NCT05399966|Dietary Supplement|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
79532121|NCT05390034|Behavioral|ART|Session 1: Description of the group & Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
79532122|NCT05390034|Behavioral|Relaxation|Session 1: Description of the groupe & Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
79830913|NCT00895570|Drug|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
79532123|NCT05384041|Device|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
79532124|NCT05384041|Device|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
79532125|NCT05373316|Radiation|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
79830914|NCT00895570|Drug|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
79830915|NCT00895648|Drug|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
79532126|NCT05371275|Drug|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
79532127|NCT05370794|Drug|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
79532128|NCT05370794|Drug|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
79532129|NCT05343507|Drug|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
79830916|NCT00895648|Drug|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
79830917|NCT05361512|Device|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
79532130|NCT05343507|Drug|Placebo|Saline Solution
79532131|NCT05340712|Dietary Supplement|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
79687998|NCT00558077|Procedure|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
79830918|NCT05361512|Device|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
80005105|NCT05216016|Other|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
79687999|NCT00558116|Device|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
79237447|NCT03675971|Drug|Placebo oral capsule|Placebo comparator
79237448|NCT05236270|Behavioral|Text Message|Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
79830919|NCT00893854|Drug|Diclophenac|
79377952|NCT01643902|Drug|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
79377953|NCT03347994|Drug|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
79532132|NCT05340712|Dietary Supplement|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
79830920|NCT00893854|Drug|Triamcinolone|
79237449|NCT05236270|Behavioral|Motivational Interviewing|Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
79688000|NCT04650971|Biological|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
79688001|NCT04650971|Biological|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
79830921|NCT00895726|Drug|APD209|Oral tablets twice per day for 56 days
79830922|NCT00895804|Drug|MDMA|capsule, 1.6 mg/kg body weight, single dose
79830923|NCT00895804|Drug|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
79830924|NCT00895882|Drug|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
79830925|NCT00895882|Drug|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
79830926|NCT00895882|Drug|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
79830927|NCT00895882|Drug|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
80005106|NCT05213143|Drug|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
80005107|NCT05208931|Procedure|Anti-vascular endothelial growth factor therapy|0.05 ml anti-VEGF, intravitreal, monthly
79237450|NCT05236270|Behavioral|Electronic Educational Message with Tailored Questions/Prompts|Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
79237451|NCT05236036|Drug|Mycophenolate Mofetil|Given PO
79237452|NCT05236036|Other|Quality-of-Life Assessment|Ancillary studies
79237453|NCT05236036|Radiation|Radiation Therapy|Receive radiation therapy
79237454|NCT05236036|Drug|Temozolomide|Given Orally (PO)
79237455|NCT02781779|Device|Silverlon®|Silverlon wound dressings
79237456|NCT02781779|Device|AQUACEL® AG|AQUACEL® AG wound dressings
79377954|NCT01644058|Procedure|Immediate loading|
79377955|NCT04966338|Biological|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
79377956|NCT04966338|Biological|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
79377957|NCT03347916|Drug|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
79830928|NCT00895882|Drug|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
79830929|NCT03823404|Drug|COR388 capsule|BID (twice daily)
79830930|NCT03823404|Drug|Placebo capsule|BID
79830931|NCT00706706|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
79830932|NCT00894010|Drug|carbamazepine 400mg|
79830933|NCT00894010|Drug|levetiracetam 1000mg|
79532133|NCT05321914|Behavioral|Exercise training|Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
79688002|NCT00543504|Drug|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
79830934|NCT00895960|Drug|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
79830935|NCT00895960|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
79830936|NCT00895960|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
79830937|NCT00894088|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
79377958|NCT03347916|Drug|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
79830938|NCT00737828|Other|Perioperative care pathway guided by CPX results|"AT > 11ml/min/kg no myocardial ischaemia or Ve/VO2 <35 - Level 1 Ward Care~AT > 11ml/min/kg with myocardial ischaemia or Ve/VO2 >35 - Level 2/3 (ITU) Critical Care Unit~AT <11mls/min/kg - Level 2/3 Critical Care Unit~AT <8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
79532134|NCT05309941|Other|Internal Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on intuitive eating principles.
79377959|NCT03350958|Dietary Supplement|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
79377960|NCT03350958|Other|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
79830939|NCT03818178|Dietary Supplement|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
79830940|NCT03818178|Dietary Supplement|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
79830941|NCT03818178|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
79532135|NCT05309941|Other|External Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.
79830942|NCT00896194|Behavioral|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
79830943|NCT00896194|Behavioral|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
79830944|NCT00921128|Drug|Muscimol|
79830945|NCT04035460|Device|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
79830946|NCT04035460|Device|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
79532136|NCT05303298|Device|Anti-reflux oesophageal stent|Fully covered self-expanding metal stent with anti-reflux mechanism
79532137|NCT05303298|Device|Conventional oesophageal stent|Fully covered self-expanding metal stent without an anti-reflux mechanism
79830947|NCT05508776|Drug|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
79830948|NCT05508776|Drug|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
79688003|NCT00543504|Drug|Sorafenib|200 mg By Mouth Daily for 28 Days
79688004|NCT00543504|Drug|Erlotinib|50 mg By Mouth Daily for 28 Days.
79830949|NCT05508776|Drug|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
79237457|NCT05270200|Drug|Azacitidine|Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
79237458|NCT05270200|Drug|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
79237459|NCT03025217|Behavioral|Total Lifestyle Coaching (TLC)|
79237460|NCT03671135|Other|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
79688005|NCT00543504|Drug|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
79688006|NCT00543504|Drug|Lapatinib|250 mg By Mouth Daily for 21 Days.
79688007|NCT00543504|Drug|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
79688008|NCT00543504|Drug|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
79830950|NCT02565342|Procedure|Interscalene brachial plexus block|
79830951|NCT00896350|Drug|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
79237461|NCT03671057|Device|HospiAvontuur|To be included in the study children should play the game at least one time together with one parent
79237462|NCT03671057|Drug|Midazolam|current practice in Jessa
79237463|NCT03669575|Dietary Supplement|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
79377961|NCT03350802|Diagnostic Test|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
79377962|NCT01821677|Drug|Danazol Capsules|
79377963|NCT01821677|Drug|Placebo|
79377964|NCT01797731|Device|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
79532138|NCT05290883|Dietary Supplement|Novel yoghurt drink containing Polar Lipids|Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption
79532139|NCT05273281|Procedure|Transabdominal plane block|Peripheral nerve block
79532140|NCT05273281|Procedure|Quadratus lumborum block|Peripheral nerve block
79688009|NCT04651127|Drug|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
79688010|NCT04650776|Other|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
79688011|NCT00543621|Other|daily enteral nutritional product and/or behavioral changes|
79377965|NCT01797731|Device|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
79377966|NCT05651958|Other|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
79830952|NCT02565264|Other|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
79688012|NCT00543660|Procedure|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
79688013|NCT04650737|Drug|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
79237464|NCT03669575|Dietary Supplement|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
79830953|NCT00896428|Drug|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
79377967|NCT05651958|Other|Breathing Technique|15 repeatations of Breathing in morning and evening
79532141|NCT05243394|Other|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
79532142|NCT05243394|Other|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
79532143|NCT05243394|Other|Treadmill gait training|Progressive treadmill gait training
79532144|NCT05228847|Dietary Supplement|Human milk-derived HMF|Fortification with human milk-derived product
79532145|NCT05228847|Dietary Supplement|bovine milk-derived HMF|bovine milk-derived HMF
79237465|NCT05166850|Behavioral|PICHA7 mHealth program|The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
79688014|NCT04650737|Drug|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
79688015|NCT00543738|Drug|MK0767|
79830954|NCT00896428|Drug|Placebo.|1 tablet morning and evening for 12 months
79830955|NCT02962050|Procedure|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
80005108|NCT05208593|Behavioral|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
79237466|NCT05166850|Other|Standard Arm|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
79237467|NCT03675659|Drug|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
79377968|NCT04785456|Device|Active TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
79377969|NCT04785456|Device|Sham TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
79377970|NCT03062280|Drug|Hydrocortisone|Modified release hydrocortisone
79377971|NCT00709722|Drug|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
79377972|NCT03121872|Procedure|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
79688016|NCT04650503|Other|No intervention|No intervention
79688017|NCT00543816|Drug|MK0767|
79688018|NCT04650620|Device|Plenhyage® thin|0.75%
79688019|NCT04650620|Device|Plenhyage® medium|2%
79688020|NCT04650620|Device|Plenhyage® strong|2.5%
79830956|NCT02962050|Device|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
79688021|NCT04650386|Behavioral|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
79688022|NCT00665769|Other|Hypercapnia|transcutaenous CO2 50-60 mm Hg
79688023|NCT00665769|Other|Normocapnia|transcutaneous CO2 35-45 mm Hg
79688024|NCT04650308|Diagnostic Test|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
79688025|NCT00543933|Drug|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
79688026|NCT04650347|Procedure|visualized internal urethrotomy|incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
79830957|NCT02962050|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
79830958|NCT02962050|Drug|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
79830959|NCT02962050|Device|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
79830960|NCT02962050|Other|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
79830961|NCT02962050|Other|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
79830962|NCT00410605|Biological|bevacizumab|Given IV
79830963|NCT00410605|Drug|lenalidomide|Given orally
79830964|NCT00410605|Drug|dexamethasone|Given orally
79830965|NCT00742638|Drug|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
79830966|NCT00742638|Drug|Sodium valproate|Sodium valproate tablet 200 mg
79830967|NCT00418717|Drug|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
79830968|NCT01042249|Other|Pelvic Floor Muscle training|12 week training program including home exercises
79830969|NCT00572572|Drug|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
79830970|NCT00572572|Drug|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
79830971|NCT00896662|Other|immunologic technique|immunologic technique
79830972|NCT00896662|Other|laboratory biomarker analysis|laboratory biomarker analysis
79237468|NCT05234398|Biological|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
79237469|NCT03670979|Procedure|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
79237470|NCT05234320|Drug|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
79830973|NCT00896662|Other|pharmacological study|pharmacological study
79830974|NCT00896740|Genetic|microarray analysis|
79830975|NCT00896740|Procedure|biopsy|
79830976|NCT00896818|Genetic|DNA analysis|
79830977|NCT00896818|Genetic|genetic linkage analysis|
79830978|NCT00896818|Genetic|loss of heterozygosity analysis|
79830979|NCT00896818|Genetic|polymorphism analysis|
79830980|NCT00896818|Other|laboratory biomarker analysis|
79830981|NCT00896818|Other|medical chart review|
79237471|NCT05234320|Drug|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
79237472|NCT05234320|Drug|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
79237473|NCT03670901|Biological|JHL1101|JHL1101, 100mg/10mL
79237474|NCT03670901|Biological|MabThera|Rituximab, 100mg/10mL
79237475|NCT03675425|Other|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
79688027|NCT00543972|Drug|AVE9633|Intravenous Infusion
79688029|NCT02909010|Device|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
79688030|NCT02909010|Other|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
79830982|NCT00896818|Other|questionnaire administration|
79688031|NCT04649762|Behavioral|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
79688032|NCT00544011|Biological|bevacizumab|
79688033|NCT00544011|Drug|capecitabine|
79688034|NCT00544011|Drug|fluorouracil|
79688035|NCT00544011|Drug|irinotecan hydrochloride|
79688036|NCT00544011|Other|diagnostic laboratory biomarker analysis|
79688037|NCT04650113|Combination Product|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
79830983|NCT00896896|Other|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
79830984|NCT00896896|Other|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
79830985|NCT00896974|Other|Laboratory Biomarker Analysis|Correlative studies
79830986|NCT00896974|Other|Pharmacological Study|Correlative studies
79237476|NCT03675425|Other|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
79830987|NCT00896974|Drug|Retinoid 9cUAB30|Given orally
79830988|NCT00418561|Biological|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
79830989|NCT00418561|Biological|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
79830990|NCT00418561|Biological|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
79830991|NCT00897052|Genetic|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
79688038|NCT00544050|Drug|Levetiracetam|
79237477|NCT05166616|Procedure|Biopsy|Correlative studies
79237478|NCT05166616|Drug|Osimertinib|Given PO
79830992|NCT00897052|Other|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
79237479|NCT05166616|Drug|Triptolide Analog|Given PO
79237480|NCT05213728|Biological|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
79830993|NCT00897130|Drug|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
79830994|NCT00894400|Procedure|catheter ablation|catheter ablation using radiofrequency energy
79830995|NCT00398047|Drug|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
79830996|NCT04016584|Behavioral|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
80005109|NCT05208593|Behavioral|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
80005110|NCT05208593|Behavioral|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
79237481|NCT03023813|Other|Intervention|Written material provided.
79302737|NCT02483117|Other|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
79688039|NCT04649996|Procedure|Appendectomy|comparison between operative and conservative treatment
79688040|NCT02908971|Behavioral|soy based formula at infancy|The intervention is only past history of soy consumption
79688041|NCT04649723|Drug|Rifampin|single oral dose, 600 mg, fasted.
79688042|NCT04649723|Drug|SHR1459|single oral dose, 200 mg, fasted.
79688043|NCT02908893|Behavioral|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
79688044|NCT04649684|Device|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
79830997|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
79830998|NCT00631371|Drug|Temsirolimus|Temsirolimus 25 mg IV weekly
79830999|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
79831000|NCT00631371|Drug|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
79831001|NCT00897208|Other|high performance liquid chromatography|
79831002|NCT00897208|Other|laboratory biomarker analysis|
79831003|NCT00897208|Other|mass spectrometry|
79831004|NCT00897208|Other|medical chart review|
79831005|NCT00897208|Procedure|evaluation of cancer risk factors|
79831006|NCT00409747|Drug|Minocycline|
79831007|NCT04016740|Drug|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
79831008|NCT04016740|Drug|Ketamine|Intraoperative infusion
79831009|NCT04016740|Drug|Remifentanil|Intraoperative infusion
79831010|NCT04016740|Drug|Dexmedetomidine|Intraoperative infusion
79532146|NCT05226962|Dietary Supplement|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide ~0.35 g of ketone monoester per kg body mass of the participant
79532147|NCT05226962|Other|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
79532148|NCT05215210|Other|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
79688045|NCT04649684|Device|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
79688046|NCT02909088|Drug|Ecopipam 50mg|
79831011|NCT04016740|Drug|Rocuronium|Intraoperative intermittent bolus
79831012|NCT04016740|Drug|Propofol|Intraoperative infusion
79831013|NCT04016740|Drug|Sevoflurane|Intraoperative inhaled as needed
79831014|NCT04016740|Drug|Dexmedetomidine|Post-operative infusion
79831015|NCT04016740|Drug|Propofol|Post-operative infusion
79831016|NCT04016740|Device|EEG monitoring|Perioperative monitoring
79831017|NCT01035541|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
79831018|NCT02540512|Procedure|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
79237482|NCT05165836|Procedure|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
79302738|NCT03201913|Drug|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
79377973|NCT03121872|Procedure|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
79377974|NCT01645306|Drug|Revacept|single intravenous injection
79377975|NCT01645306|Drug|Placebo|single intravenous injection
79831019|NCT02540512|Device|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
79377976|NCT01820585|Drug|Placebo|Tablets
79377977|NCT01820585|Drug|ESL 400 mg|tablets
79377978|NCT01820585|Drug|ESL 800 mg|tablets
79377979|NCT01820585|Drug|ESL 1200 mg|tablets
79377980|NCT02593188|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
79532149|NCT05215210|Other|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
79532150|NCT05186064|Diagnostic Test|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
79532151|NCT05175651|Behavioral|Genetic risk assessment|A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
79532152|NCT05164159|Drug|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 ~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
79532153|NCT05164159|Drug|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
79532154|NCT05164146|Drug|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
79532155|NCT05164146|Drug|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
79688047|NCT02909088|Drug|Ecopipam 100mg|
79688048|NCT04649528|Behavioral|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
79688049|NCT04649528|Device|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
79688050|NCT04649645|Other|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
79709851|NCT02892864|Other|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
79831020|NCT02540512|Procedure|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
79831021|NCT02540512|Drug|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
79831022|NCT02540512|Drug|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
79831023|NCT01039909|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
80005111|NCT05208593|Behavioral|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
79237483|NCT05165836|Procedure|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
79532156|NCT05156333|Dietary Supplement|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
79532157|NCT05132517|Diagnostic Test|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
79688051|NCT04649645|Other|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
79688052|NCT04649645|Other|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
79688053|NCT00544128|Drug|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
79831024|NCT01039909|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
79831025|NCT00825903|Behavioral|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
79831026|NCT03742375|Diagnostic Test|HPV genotyping|Quantitative HPV genotyping on anal swab
79831027|NCT00894478|Procedure|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
79831028|NCT00894478|Procedure|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
79831029|NCT00897442|Other|Laboratory Biomarker Analysis|Correlative studies
79237484|NCT05165758|Other|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
79237485|NCT03675347|Other|angioplasty|angioplasty
79237486|NCT05232448|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
79237487|NCT01365130|Drug|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
79237488|NCT04238416|Drug|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
79237489|NCT04238416|Drug|Lactulose|Oral lactulose will be given to patients in both arms
79237490|NCT05162014|Drug|empagliflozin|empagliflozin
79688054|NCT00544128|Drug|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
79688055|NCT00544206|Other|standard enteral feeding product|16 hrs daily x 5 days
79688056|NCT00544206|Other|Diabetes specific feeding product|16 hrs daily for 5 days
79688057|NCT02908854|Other|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
79688058|NCT01240915|Drug|placebo|once every 7 days for 1- 3 doses
79688059|NCT01240915|Drug|MultiStem low dose|1-3 doses
79688060|NCT01240915|Drug|placebo|Single dose at week 8
79688061|NCT01240915|Drug|MultiStem low dose|Single dose at week 8
79688062|NCT01240915|Drug|placebo|Single dose Day 1
79688063|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
79688064|NCT01240915|Drug|placebo|Single dose at week 8
79688065|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
79688066|NCT01240915|Drug|placebo|Single dose Day 1
79831030|NCT04017676|Other|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
79831031|NCT04035772|Other|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
79831032|NCT00897520|Biological|recombinant interferon alfa|
79831033|NCT00897520|Genetic|proteomic profiling|
79377981|NCT01797263|Other|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
79688067|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
79831034|NCT00897520|Other|immunoenzyme technique|
79237491|NCT05162014|Drug|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
79237492|NCT04237558|Procedure|Vaginal hysterectomy|Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
79688068|NCT01240915|Drug|placebo|Single dose at week 8
79831035|NCT00897520|Other|laboratory biomarker analysis|
79831036|NCT00894634|Drug|Brompheniramine maleate|
79237493|NCT04237558|Procedure|Laparoscopic hysterectomy|Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
79237494|NCT05226754|Drug|Diacerein|After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
79237495|NCT05226754|Drug|placebo capsules|After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
79237496|NCT01657162|Drug|Alendronate|Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
79831037|NCT02540278|Behavioral|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
79688069|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
79688070|NCT00544245|Behavioral|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
79688071|NCT00558155|Drug|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
79688072|NCT00558155|Drug|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
79688073|NCT00558155|Drug|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
79688074|NCT00558155|Drug|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
79831038|NCT00630747|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
79831039|NCT00894712|Other|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
79831040|NCT00894712|Device|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
79831041|NCT00897754|Genetic|gene expression analysis|
79831042|NCT00897754|Genetic|protein expression analysis|
79831043|NCT00897754|Genetic|reverse transcriptase-polymerase chain reaction|
79831044|NCT00897754|Other|immunoenzyme technique|
79831045|NCT00897754|Other|immunohistochemistry staining method|
79831046|NCT00897754|Other|immunologic technique|
79831047|NCT02540902|Device|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
79831048|NCT05278078|Other|psychological support|psychological support will be given to the patients in the experimental group.
79237497|NCT04241692|Device|CarnationTM Ambulatory Monitoring Sternal ECG Patch System|A newly developed cardiac rhythm monitoring system
79688075|NCT05476432|Procedure|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
79688076|NCT05476432|Drug|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
79688077|NCT05476432|Drug|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
79688078|NCT02908815|Device|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
79532158|NCT05114447|Other|Routine medical care|"Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial."
79532159|NCT05114447|Other|Telephone interview|"Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed"
79532160|NCT05111431|Drug|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
79237498|NCT04241692|Device|Conventional 24-Hour 7 Lead Holter Monitor Recorder|Traditional recordings made using a standard 24-hour Holter monitor.
79831049|NCT05278078|Other|nutritional education|nutritional education will be given to the patients in the experimental group.
79532161|NCT05111431|Drug|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
79688079|NCT02908815|Device|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
79688080|NCT01239745|Drug|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
80005112|NCT05205772|Device|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
79237499|NCT05209906|Drug|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
79237500|NCT05209828|Device|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
79377982|NCT01797263|Other|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
79688081|NCT01239472|Drug|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
79831050|NCT05278078|Other|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
79831051|NCT05278078|Other|no intervation|No intervention will be applied to the control group
79831052|NCT00823485|Procedure|fibrinolysis in situ|intraventricular injection of actilyse
79377983|NCT01602172|Behavioral|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
79831053|NCT00823485|Procedure|drainage|drainage
79831054|NCT00897832|Other|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
80005113|NCT05191862|Drug|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
79237501|NCT05207956|Behavioral|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
79237502|NCT05207956|Other|Electronic platform|Electronic platform to collect data
79237503|NCT05157646|Behavioral|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
79237504|NCT05206552|Other|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
79237505|NCT05611346|Behavioral|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
79831055|NCT02550405|Behavioral|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
79831056|NCT00897988|Genetic|gene expression analysis|
79831057|NCT00897988|Genetic|mutation analysis|
79831058|NCT00897988|Genetic|polyacrylamide gel electrophoresis|
79831059|NCT00897988|Genetic|polymerase chain reaction|
79377984|NCT01602172|Other|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
79831060|NCT00897988|Genetic|protein expression analysis|
79831061|NCT00897988|Genetic|reverse transcriptase-polymerase chain reaction|
80005114|NCT05191862|Drug|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
80005115|NCT05189704|Drug|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
79532162|NCT05095792|Other|Observational - no intervention|This is an observational study with no intervention.
79532163|NCT05093426|Other|Stage 2 Digital sleep diary app|Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
79532164|NCT05056090|Procedure|Patients will receive MV in PP|Putting the patient in a prone position
79688082|NCT04649450|Other|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
79688083|NCT00544284|Drug|bortezomib|
79688084|NCT00544284|Drug|temozolomide|
79831062|NCT00897988|Other|flow cytometry|
79831063|NCT00897988|Other|immunoenzyme technique|
79831064|NCT00897988|Other|immunologic technique|
79831065|NCT00897988|Other|laboratory biomarker analysis|
79831066|NCT00897988|Other|pharmacological study|
80005116|NCT05189704|Drug|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
80005117|NCT05181722|Other|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
79532165|NCT05044325|Drug|GSK3884464|GSK3884464 will be administered
79532166|NCT05044325|Drug|Placebo|Placebo to match GSK3884464 will be administered.
79688085|NCT00544284|Other|pharmacological study|
79688086|NCT02888275|Drug|Dexmedetomidine|
79688087|NCT02888275|Drug|normal saline|
79688088|NCT03456531|Device|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
80005118|NCT05179421|Drug|saline (placebo) then oxytocin 1.3 micrograms|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
80005119|NCT05179421|Drug|Experimental: oxytocin 0.3 micrograms then oxytocin 7 micrograms|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
79688089|NCT03456531|Drug|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
79688090|NCT02909049|Drug|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
79688091|NCT02909049|Drug|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
79688092|NCT02909049|Drug|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
79688093|NCT02909049|Drug|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
79831067|NCT00823641|Drug|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
79377988|NCT02253108|Device|Everolimus eluting bioresorbable polymer stent|
79688094|NCT04649216|Drug|PCO371|PCO371 Capsule
79831068|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
79831069|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
79831070|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
79831071|NCT00898066|Genetic|cytogenetic analysis|marrow and peripheral blood
79831072|NCT00898066|Genetic|fluorescence in situ hybridization|marrow and peripheral blood
79831073|NCT00823875|Drug|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
79831074|NCT00823875|Drug|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
79237506|NCT04889560|Other|Experimental group|Home-based version of a computerized cognitive training (CoRe)
79377989|NCT02253108|Device|Biolimus eluting bioresorbable polymer stent|
79688095|NCT04649216|Drug|[14C]PCO371|[14C]PCO371 Oral solution
79688096|NCT04649216|Drug|[14C]PCO371|[14C]PCO371 Solution for infusion
79688097|NCT01229449|Drug|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
79688098|NCT01229449|Drug|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
79688099|NCT01229449|Drug|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
79688100|NCT01229449|Drug|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
79688101|NCT01229449|Drug|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
79688102|NCT04648865|Drug|LY3537031|Administered SC.
79688103|NCT04648865|Drug|Placebo|Administered SC.
79688104|NCT04648982|Other|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
79688105|NCT01239316|Other|Laboratory Biomarker Analysis|Correlative studies
79688106|NCT01239316|Other|Pharmacological Study|Correlative studies
79831075|NCT00823875|Drug|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
79831076|NCT00823875|Drug|control group|routine treatment
79831077|NCT00898144|Other|Papanicolaou test|
79831078|NCT00898144|Other|laboratory biomarker analysis|
79831079|NCT01042327|Device|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
79831080|NCT01042327|Device|Fresenius FX100 dialyzer|
79237507|NCT04889560|Other|Control group|Computerized cognitive training (CoRe)
79377990|NCT04500990|Radiation|MRI test|Patients will receive diagnostic MRI test on d0.
79237508|NCT02933606|Drug|BNC210|
79237509|NCT02933606|Drug|Placebo|
79237510|NCT04883788|Other|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
79237511|NCT05201482|Device|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
79377991|NCT04500990|Radiation|MRI test|Patients will receive diagnostic MRI test on d8±1.
79377992|NCT04500990|Radiation|MRI test|Patients will receive diagnostic MRI test on d30±2.
79377993|NCT01603420|Drug|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
79377994|NCT01603420|Drug|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
79377995|NCT01603420|Other|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
79377996|NCT02064036|Radiation|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
79688107|NCT01239316|Drug|Vismodegib|Given PO
79688108|NCT01239160|Device|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
79237512|NCT01373294|Drug|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
79831081|NCT04035928|Device|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
79831082|NCT00823953|Drug|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
79831083|NCT00823953|Other|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
79831084|NCT04036084|Diagnostic Test|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
79831085|NCT00397189|Drug|Circadin|Prolonged release melatonin 2 mg
79831086|NCT00397189|Drug|placebo circadin|placebo circadin tablets
79831087|NCT00824109|Device|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
79688109|NCT01239160|Device|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
79237513|NCT01373294|Drug|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
79237514|NCT05148598|Device|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
79237515|NCT05148598|Other|Standard Care|Standard care
79237516|NCT05148598|Other|Placebo|Placebo visually indistinguishable from ADRCs
79237517|NCT04367246|Other|No Intervention|No intervention is assigned.
79237518|NCT05147428|Other|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
79237519|NCT04422028|Drug|Desogestrel 0.075 MG|Test Drug
79377997|NCT02064036|Drug|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
79688110|NCT01239121|Other|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
79237520|NCT04422028|Drug|Desogestrel 0.075 MG|Reference Product
79237521|NCT04236856|Device|Robotic Endovascular Procedure|After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
79237522|NCT01656304|Biological|bevacizumab|Given IV
79237523|NCT01656304|Other|laboratory biomarker analysis|Correlative studies
79237524|NCT05143216|Other|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)
79237525|NCT05143216|Other|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
79237526|NCT05107648|Behavioral|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
79688111|NCT01239121|Other|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
79688112|NCT01239043|Biological|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
79688113|NCT01239043|Biological|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79831088|NCT00898300|Other|biologic sample preservation procedure|
79831089|NCT00898300|Procedure|biopsy|
79831090|NCT01035619|Drug|moxidectin|Single Dose Moxidectin 4 mg
79831091|NCT00819819|Dietary Supplement|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
79237527|NCT05107570|Other|Cold exposure|Cold air exposure (~ 9°C, maximum 1 hour duration)
79237528|NCT05197894|Device|Virtual Reality|The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
79688114|NCT01238848|Drug|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
79688115|NCT01238848|Drug|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
79688116|NCT02908542|Genetic|genetic analysis with massively parallel sequencing|
79688117|NCT01238575|Other|placebo|Administered for up to 8 weeks.
79237531|NCT05103124|Device|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
79377998|NCT02064036|Drug|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
79377999|NCT05645484|Drug|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
79237532|NCT05103124|Other|Placebo|The placebo product will be administered for a 30-days treatment period
80005120|NCT05137366|Diagnostic Test|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~Suprasternal window~Parasternal long axis window~Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
80005121|NCT05132816|Diagnostic Test|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
80005122|NCT05123690|Device|Neurofeedback|A device that assists in training patients in relaxing.
79532167|NCT05035199|Behavioral|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
79688118|NCT01238575|Drug|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
79237533|NCT04421872|Other|receiving general anesthesia|patients receiving surgery under general anesthesia
79688119|NCT00544323|Device|oral implant|
79532168|NCT05029713|Diagnostic Test|Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)|The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off <27 Kg in men and <16 Kg in women and a standardized muscle mass cut-off <0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
79688120|NCT02888158|Other|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
79688121|NCT02888158|Other|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
79378000|NCT05645484|Drug|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
79532169|NCT05016232|Behavioral|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
79532170|NCT05016232|Behavioral|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
79831092|NCT00819819|Dietary Supplement|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
79831093|NCT04044651|Drug|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
79831094|NCT04044651|Drug|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
79831095|NCT00606034|Drug|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
79831096|NCT00898378|Genetic|gene expression analysis|gene expression analysis
79237534|NCT05138770|Drug|VC005 Tablets|VC005 Tablets 1、5、10、25、50、100mg single dose
79378001|NCT03347682|Other|Satisfaction with Prosthesis -SATPRO|questionnaire 1
79378002|NCT03347682|Other|Nottingham Health Profile-NHP|questionnaire 2
79378003|NCT03347682|Other|Prosthesis donning and doffing questionnaire|questionnaire 3
79378004|NCT04551300|Drug|VS-505|4 dosages of experimental drug
79378005|NCT04551300|Drug|Sevelamer Carbonate|Active Comparator
79378006|NCT02232022|Device|Reveal LINQ Insertable Cardiac Monitor|
79532171|NCT05015543|Other|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
79688122|NCT06022445|Other|CARPET prognostic model|For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
79688123|NCT06022432|Other|Video of a patients testimonial|The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.
79688124|NCT06022432|Other|Writing Task|Participants write freely about their current treatment expectations / apprehensions to seek treatment
79688125|NCT06022419|Procedure|Lucerne Cast|Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.
79688126|NCT06022419|Procedure|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
79831097|NCT00898378|Genetic|polymerase chain reaction|polymerase chain reaction
79831098|NCT00898378|Genetic|polymorphism analysis|polymorphism analysis
79831099|NCT00898378|Genetic|protein expression analysis|protein expression analysis
80005123|NCT05110014|Other|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
80005124|NCT05100160|Drug|Gabapentin|Given by PO
80005125|NCT05100160|Other|Placebo|Given by PO
80005126|NCT05098093|Dietary Supplement|SBE|Hard-shell capsule
79532172|NCT04975568|Other|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
79831100|NCT00898378|Genetic|proteomic profiling|proteomic profiling
79831101|NCT00898378|Other|gas chromatography|gas chromatography
79532173|NCT04975568|Other|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
79532174|NCT04956939|Drug|Low dose levodopa|Low frequency is defined as ≤ 3 LD doses a day
79688127|NCT06022367|Diagnostic Test|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
79688128|NCT06022367|Diagnostic Test|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
79831102|NCT00898378|Other|laboratory biomarker analysis|laboratory biomarker analysis
79831103|NCT00898378|Other|liquid chromatography|liquid chromatography
80005127|NCT05098093|Dietary Supplement|DBE|Hard-shell capsule
79532175|NCT04956939|Drug|High dose levodopa|High frequency dosage is defined as ≥ 5 LD doses per day
79532176|NCT04955470|Drug|Ketamine Injectable Solution|A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
79831104|NCT00898378|Other|mass spectrometry|mass spectrometry
79237535|NCT05138770|Drug|VC005 Tablets Placebo|VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
79532177|NCT04955470|Drug|Midazolam Injectable Solution|A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
79688129|NCT06022354|Drug|SIM0278 Injection/Placebo|SIM0278 Injection/Placebo
79831105|NCT00898378|Other|questionnaire administration|questionnaire administration
79831106|NCT00819975|Dietary Supplement|Casein|
79237536|NCT05138770|Drug|VC005 Tablets food effects group|VC005 Tablets qd per period, for two periods
79237537|NCT03023423|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
79237538|NCT03023423|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
79831107|NCT00819975|Dietary Supplement|Whey Isolate|
79237539|NCT03670823|Device|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
79237540|NCT03675269|Other|HBOT|Standard practice
79237541|NCT03675269|Behavioral|Standard wound care|Standard wound care
79391176|NCT01590797|Drug|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
79391177|NCT03181074|Other|Non-Interventional|Non-Interventional
79831108|NCT00819975|Dietary Supplement|Whey Hydrolysate|
79831109|NCT00819975|Dietary Supplement|Alphalact-Albumin|
79831110|NCT00825981|Other|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
79831111|NCT04044417|Procedure|currettage|open flap debridement
79831112|NCT04044417|Drug|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
79831113|NCT04044417|Drug|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
79391178|NCT01590563|Device|IUD|Insertion of a spherical IUD, one year follow-up
79391179|NCT03180762|Drug|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
79391180|NCT03180762|Drug|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
79391181|NCT03180762|Drug|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
79831114|NCT00397033|Drug|Paliperidone ER|6mg/day paliperidone er for 6 weeks
79831115|NCT00397033|Drug|Paliperidone ER|12mg/day paliperidone er for 6 weeks
79831116|NCT00397033|Drug|Placebo|Placebo for 6 weeks
80005128|NCT05098093|Dietary Supplement|BP|Hard-shell capsule
80005129|NCT05097521|Other|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
80005130|NCT05097521|Other|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
80005131|NCT05097521|Other|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
80005132|NCT05090332|Other|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
80005133|NCT05090332|Other|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
80005134|NCT05088525|Procedure|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
79237542|NCT05136664|Drug|Patiromer Powder for Oral Suspension (Part A)|"Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
79237543|NCT05136664|Drug|Placebo (Part B)|Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
79237544|NCT05136664|Drug|Patiromer Powder for Orals Suspension (Part B)|"Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
79378007|NCT04437186|Behavioral|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
79378008|NCT04974580|Drug|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
79831117|NCT00820053|Drug|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
79532178|NCT04955470|Drug|Normal Saline 0.9% Injectable Solution|A 0.9% normal saline solution will be infused over a 40 minute period.
79688130|NCT06022341|Other|Multiomic characterization|Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.
79831118|NCT00572728|Procedure|CT|Undergo 18F-FLT PET/CT
79831119|NCT00572728|Drug|18F-FLT|Undergo 18F-FLT PET/CT
79831120|NCT00572728|Procedure|PET|Undergo 18F-FLT PET/CT
79831121|NCT00820131|Procedure|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
79378009|NCT04974580|Behavioral|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
79532179|NCT04944121|Drug|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
79532180|NCT04944121|Drug|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
79532181|NCT04925401|Behavioral|The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.|An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
79532182|NCT04922645|Drug|Ferric Citrate 1 gram Oral Tablet|Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
79532183|NCT04922645|Drug|Standard of care phosphate-lowering therapy|Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
79831122|NCT00820131|Procedure|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
79831123|NCT03857295|Other|No interventions|No intervention
79831124|NCT00699374|Drug|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
79831125|NCT00699374|Drug|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
79831126|NCT00898534|Device|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
79831127|NCT00824187|Drug|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
79831128|NCT00824187|Drug|Placebo|Inert tablet
79831129|NCT00826137|Dietary Supplement|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
79831130|NCT00826137|Dietary Supplement|Placebo|Placebo is base powder of product with no oligosaccharides.
79532184|NCT04922567|Drug|Lenalidomide|25mg po on day 1-10
79831131|NCT00606892|Drug|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
79831132|NCT00606892|Drug|Placebo|Sugar Pill
79237545|NCT03675191|Drug|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
79237546|NCT03675191|Drug|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
79237547|NCT03675113|Other|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
80005135|NCT05082857|Behavioral|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
80005136|NCT05082857|Behavioral|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
79237548|NCT03675113|Other|Control Group|Deep breathing exercises combinated with arm movements
79237549|NCT05187988|Procedure|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
79237550|NCT05187988|Procedure|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
79532185|NCT04922567|Drug|Cyclophosphamide|750mg/m² iv on day1
79237551|NCT03198689|Drug|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
79532186|NCT04922567|Drug|Doxorubicin|50mg/m² iv on day 1
79237552|NCT05135026|Diagnostic Test|Ultrasonograpgy|2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
79831133|NCT00606892|Drug|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
79831134|NCT00826215|Device|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
79831135|NCT00826215|Device|Sham laser acupuncture|Sham laser acupuncture
79237553|NCT03675035|Device|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
79378010|NCT04974580|Behavioral|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
79237554|NCT05096416|Device|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
79237555|NCT05187598|Other|Effective communication training in perinatal patient safety|Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
79378011|NCT01605292|Procedure|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
79532187|NCT04922567|Drug|Vincristine|1.4mg/m² iv on day 1
79532188|NCT04922567|Drug|Prednisone|100mg po on day1-5
79532189|NCT04899882|Other|KinHémo|Evaluation and cardiovascular training, combination of resistance and flexibility training
79532190|NCT04873232|Biological|Engensis|Injections with Engensis in study VMDN-003-2
79831136|NCT00826293|Procedure|Stabilization belt|Patients receive true stabilization.
79831137|NCT00826293|Procedure|Stabilization belt|Patients receive sham stabilization.
79831138|NCT04035538|Drug|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
79831139|NCT01042483|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
79831140|NCT00894946|Procedure|Lipiodol + IVF|IVF preceded by lipiodol
79831141|NCT00894946|Procedure|IVF|IVF alone
79831142|NCT00737906|Procedure|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
79378012|NCT01605292|Procedure|Palpation|Manual palpation for localizing radial artery for inserting needle.
79378013|NCT03121794|Procedure|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
79378014|NCT03121794|Device|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
79532191|NCT04873232|Other|Placebo|Injections with Placebo in study VMDN-003-2
79532192|NCT04851704|Behavioral|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
79532193|NCT04835077|Other|aerobic exercise|Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.
79831143|NCT00898690|Genetic|cytogenetic analysis|
79831144|NCT00898690|Genetic|gene expression analysis|
79831145|NCT00898690|Genetic|microarray analysis|
79831146|NCT00898690|Genetic|mutation analysis|
79831147|NCT00898690|Genetic|reverse transcriptase-polymerase chain reaction|
79831148|NCT00898690|Other|immunohistochemistry staining method|
79831149|NCT05312996|Other|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
79831150|NCT05312996|Other|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
79831151|NCT01035775|Procedure|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
79831152|NCT01035775|Procedure|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
79532194|NCT04835077|Other|postural stabilization exercises|Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
79831153|NCT00737984|Procedure|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
79831154|NCT04035616|Dietary Supplement|microbial cell preparation [MCP]|active microbial cell preparation
79831155|NCT04035616|Other|placebo|inactive ingredient
79831156|NCT01035853|Drug|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
80005137|NCT05073276|Other|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
80005138|NCT05073263|Other|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
80005139|NCT05052931|Drug|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m^2, D1, Q3W; oxaliplatin 85 mg/m^2, D1, Q3W; S-1 60 mg/m^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
80005140|NCT05052229|Drug|Nitric Oxide|Nitric oxide gas for inhalation
80005141|NCT05052229|Drug|Medical air|Medical grade air for inhalation (placebo)
79237556|NCT03670589|Radiation|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
79237557|NCT03670589|Procedure|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
79237558|NCT05134246|Procedure|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
79378015|NCT01797185|Drug|SPARC1104 modified dose regimen I|Subjects who exited study CLR_09_21
79831157|NCT05289362|Device|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
79831158|NCT05289362|Device|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
79378016|NCT01797185|Drug|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
79378017|NCT01797185|Drug|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
80005142|NCT05040802|Other|Not applicable / dataset analysis|Not applicable / dataset analysis
79831159|NCT01042639|Behavioral|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
80005143|NCT05020769|Drug|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
79378018|NCT04501770|Drug|Chort 1 of M802|Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
79378019|NCT04501770|Drug|Chort 2 of M802|Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
79532195|NCT04801745|Other|Healthy vegan diet|Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.
79532196|NCT04801745|Other|My Plate - Low Purine|Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.
79532197|NCT04801745|Other|Amla fruits|Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
79831160|NCT04035304|Other|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
79532198|NCT04788368|Procedure|Surgical resection|Surgical resection with either of the above mentioned techniques
80005144|NCT05020769|Drug|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
80005145|NCT05008614|Procedure|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
80005146|NCT05008614|Procedure|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
80005147|NCT05002738|Drug|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
79831161|NCT05274542|Other|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
79302739|NCT02483039|Behavioral|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
79532199|NCT04780217|Biological|T3011|T3011 will be administered through IV drip or pumping.
79831162|NCT05274542|Other|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
79831163|NCT01036243|Dietary Supplement|test formula 1|hydrolyzed formula with probiotics
79831164|NCT01036243|Dietary Supplement|test formula 2|acidified hydrolyzed formula
79831165|NCT01036243|Dietary Supplement|test formula 3|hydrolyzed formula without probiotics
79831166|NCT01036243|Dietary Supplement|reference formula|standard infant formula
79831167|NCT00895024|Behavioral|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
79378020|NCT04501770|Drug|Cohort 3 of M802|Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
79532200|NCT04765774|Other|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
79532201|NCT04765774|Other|Music|The music chosen by the patient will be played in the music group.
79831168|NCT01042717|Drug|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
79378021|NCT04501770|Drug|Cohort 4 of M802|Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
79831169|NCT00898768|Procedure|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
79391182|NCT03180762|Drug|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
79391183|NCT03180762|Drug|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
79532202|NCT04715061|Other|Resting state (Control)|Participants were asking to sit on a sofa for 50 minutes.
79532203|NCT04715061|Other|Moderate Intensity Continuous Exercise (MICE)|MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
79532204|NCT04715061|Other|High Intensity Interval Exercise (HIIE)|HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels > 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
79688131|NCT06022341|Other|In vitro drug screening|The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
79688132|NCT06022328|Biological|Assessment of the epigenetic age|Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
79831170|NCT03506932|Dietary Supplement|Untreated|Bread made with 20% yellow pea flour that was untreated.
79831171|NCT03506932|Dietary Supplement|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
79831172|NCT03506932|Dietary Supplement|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
79831173|NCT03506932|Dietary Supplement|Wheat|Bread made with 100% wheat
79831174|NCT00738140|Behavioral|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
79831175|NCT00625443|Drug|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
79831176|NCT00625443|Drug|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
79302740|NCT02482883|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized [active stimulation vs non-active (placebo) stimulation], for an initial period of 10 days.
79688133|NCT06022315|Combination Product|caloric restrction high carbohydrate low fat diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
79709852|NCT02272907|Other|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
79237559|NCT05134246|Procedure|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
79237560|NCT03674879|Other|Text Message|Patient contact attempted with text message.
79237561|NCT05185102|Other|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
79831177|NCT00625443|Drug|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
79831178|NCT00898846|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
79237562|NCT03185741|Behavioral|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
79237563|NCT03185741|Behavioral|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
79237564|NCT03669419|Diagnostic Test|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
79378022|NCT04501770|Drug|Cohort 5 of M802|Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
79378023|NCT04501770|Drug|Cohort 6 of M802|Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
79831179|NCT00920894|Dietary Supplement|plant stanol ester|the effect of plant stanol esters on plasma lipids
79831180|NCT00824343|Drug|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
79378024|NCT04501770|Drug|Cohort 7 of M802|Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
79831181|NCT00895102|Drug|ABT-333 Tablet|See Arm Description for more information.
79831182|NCT00895102|Drug|Placebo|See Arm Description for more information.
79831183|NCT00895102|Drug|ABT-333 Capsule|See arm description for more information
79831184|NCT00820287|Procedure|Biopsy of testicular tumor|testicular biopsies performed through open surgery
79831185|NCT04035148|Diagnostic Test|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
79831186|NCT00826371|Drug|ranibizumab 0.5 mg|
79378025|NCT04501770|Drug|Cohort 8 of M802|Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
79378026|NCT01691326|Biological|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
79378027|NCT01691326|Biological|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
79709853|NCT02892825|Other|Music|headphones with music
79532205|NCT04700774|Behavioral|Behavioral activation|Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko & Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
79378028|NCT04501692|Procedure|VivaSight|see above
79532206|NCT04654104|Other|check immune check points|we will evaluate the expression of immune check points
79532207|NCT04651465|Behavioral|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
79532208|NCT04636632|Drug|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
79378029|NCT04501692|Procedure|Videolaryngoscopy|see above
79378030|NCT04501068|Device|Ambu® AuraGainTM|Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
79378031|NCT01606852|Drug|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
79831187|NCT00824499|Other|Complex regional intervention|"Components of the complex intervention:~Introduction of a program coordinator~Introduction of a self-management education program~Bottom up development of a interdisciplinary care protocol~Support program for the intiation of insulin therapy in primary care~Regional audit"
79831188|NCT02540824|Drug|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
79831189|NCT02540122|Device|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
79378032|NCT01691560|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
79532209|NCT04633603|Device|FeverFriend mobile application|Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
79831190|NCT02540122|Device|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
79831191|NCT02540122|Device|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
79532210|NCT04632225|Biological|Engensis|Lyophilized biologic to be reconstituted containing Engensis
79532211|NCT04632225|Other|Placebo|Injectable liquid
79831192|NCT02540122|Device|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
79831193|NCT02540590|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
79831194|NCT02540590|Device|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
79532212|NCT04631562|Drug|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
79532213|NCT04631562|Drug|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
79532214|NCT04631562|Drug|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
79709854|NCT02892825|Other|No Music|headphones without music
79709855|NCT02273453|Drug|Songha® Night|
79709856|NCT02273453|Drug|Oxazepam|
79709857|NCT02273453|Drug|Placebo|
79709858|NCT01108510|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
79709859|NCT01108510|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
79709860|NCT01108510|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
79831195|NCT00826527|Drug|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
79831196|NCT00898924|Genetic|molecular diagnostic method|
79831197|NCT00898924|Genetic|mutation analysis|
79831198|NCT02550717|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
79831199|NCT02550717|Drug|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
79237565|NCT04421716|Drug|Ursolic Acid|Ursolic Acid 150mg
79237566|NCT04421716|Drug|Curcumin|Curcumin 600mg
79237567|NCT03176225|Procedure|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
79237568|NCT03176225|Device|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
79237569|NCT03176225|Device|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
79237570|NCT05184868|Drug|AT247|Ultra rapid acting prandial insulin aspart
79237571|NCT05184868|Drug|NovoLog|Rapid acting prandial insulin aspart
79237572|NCT05184868|Drug|Fiasp|Fast acting prandial insulin aspart
79237573|NCT03670511|Other|sit-to-stand test|to sit and stand from a chair
79237574|NCT03670511|Other|six minute walking test|to walk for six minutes
79237575|NCT02672852|Drug|Risankizumab|Risankizumab administered by subcutaneous injection
80005148|NCT04993443|Drug|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
80005149|NCT04993443|Other|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
80005150|NCT04990284|Drug|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
79237576|NCT02672852|Drug|Placebo|Placebo for risankizumab administered by subcutaneous injection
79378033|NCT01691560|Drug|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
79378034|NCT01691560|Drug|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
79378035|NCT01691560|Drug|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
80005151|NCT04990284|Drug|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
80005152|NCT04979247|Drug|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
80005153|NCT04973631|Genetic|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
79237577|NCT05370742|Procedure|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
79378036|NCT02517606|Other|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
79237578|NCT03168659|Device|HeartLight|HeartLight Endoscopic Ablation System
79532215|NCT04631562|Drug|Placebo IV|Placebo IV will be administered as an IV infusion.
79237579|NCT03168659|Procedure|Ablation|Pulmonary vein isolation ablation
79237580|NCT05129254|Device|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
79237581|NCT05129254|Procedure|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
79237582|NCT05129254|Procedure|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
79237583|NCT05183620|Device|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
79237584|NCT03674489|Other|Neurodynamic Slider Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
79378037|NCT02517606|Other|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
79378038|NCT03346278|Behavioral|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
79378039|NCT03346200|Drug|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
79378040|NCT03346200|Drug|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
79532216|NCT04629131|Biological|TNM002 Dosage 1 (10 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
79532217|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 1, given once
79532218|NCT04629131|Biological|TNM002 Dosage 2 (35 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
79688134|NCT06022315|Combination Product|caloric restrction high fat low carbohydrate diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
79688135|NCT06022289|Drug|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
79688136|NCT06022276|Drug|Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
79688137|NCT06022263|Drug|Lactic Acid|180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc
79688138|NCT06022263|Drug|Placebo|1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
79237585|NCT03674489|Other|Neurodynamic Tensioner Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
79831200|NCT00820365|Drug|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
79831201|NCT00895258|Behavioral|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
79831202|NCT00895258|Behavioral|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
79302741|NCT04997421|Device|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
79302742|NCT04997421|Device|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
79532219|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 2, given once
79532220|NCT04629131|Biological|TNM002 Dosage 3 (100 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
79532221|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 3, given once
79532222|NCT04629131|Biological|TNM002 Dosage 4 (250 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
79532223|NCT04629131|Biological|Placebo|placebo to match TNM002 Dosage 4, given once
79532224|NCT04583358|Drug|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
79532225|NCT04583358|Other|Placebo (oral)|Orally administered placebo comparator taken once daily
79831203|NCT02550249|Drug|Nivolumab|Intravenous administration of nivolumab
79831204|NCT00824811|Drug|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
79532226|NCT04576650|Device|Summit System|Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
79532227|NCT04545060|Biological|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
79831205|NCT00824811|Drug|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
79831206|NCT00824811|Drug|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
79831207|NCT00625365|Drug|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
79831208|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
79831209|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
79532228|NCT04545060|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
79831210|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
79831211|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
79831212|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
79688139|NCT06022250|Drug|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
79688140|NCT06022237|Drug|Ibandronate|Ibandronate 150 mg once monthly.
79688141|NCT06022237|Drug|Calcium|Calcium 500 mg twice daily
79688142|NCT06022237|Drug|Vitamin D3|Vitamin D3 - 1000 IU daily
79831213|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
79831214|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
80005154|NCT04969835|Drug|AVA6000|AVA6000 is a FAP-activated prodrug of doxorubicin. AVA6000 will be administered via IV infusion every 3 weeks. Dosing will occur based on the calculated patient's BSA on the day of dosing.
79688143|NCT06022198|Procedure|Bronchoalveolar Lavage|Bronchoalveolar Lavage
79688144|NCT06022133|Behavioral|Dietary sodium restriction|Selfemployed dietary sodium restriction
79831215|NCT00824967|Other|Training and valuation of the treating personnel|Training and valuation of the treating personnel
79831216|NCT00820521|Drug|active|
79831217|NCT00820521|Drug|placebo|
79532229|NCT04527913|Behavioral|Interdental Oral Hygiene Instruction (Int-OHI)|"Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist."
79378041|NCT04501458|Other|Training of youth, community health assistants and community health workers.|Training of youth, community health assistants, and community health workers in the screening, detection, contact tracing, prevention, and management of COVID-19 with concurrent maintenance of essential health services.
79831218|NCT00606580|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
79831219|NCT00606580|Drug|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
79532230|NCT04527913|Procedure|One session of professional supragingival scaling and polishing|A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
79688145|NCT06022120|Behavioral|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
79831220|NCT00606580|Drug|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
79831221|NCT00826683|Biological|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
79831222|NCT00899002|Genetic|comparative genomic hybridization|
79688146|NCT06022094|Other|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
79688147|NCT06022055|Other|Blood and tissue collection|"Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research."
80005155|NCT04965350|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
79237586|NCT03674489|Other|Sham Neurodynamic Mobilization|Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
79237587|NCT02538809|Other|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
79237588|NCT03114098|Other|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
79688148|NCT06022042|Device|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
79688149|NCT06021951|Drug|Bempedoic Acid 180 MG Oral Tablet|Bempedoic Acid 180 MG Oral Tablet [Nexletol]
79688150|NCT06021951|Drug|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet [NEXLIZET]
79688151|NCT06021912|Drug|Immunotherapy|Sublingual immunotherapy
79831223|NCT00899002|Genetic|molecular genetic technique|
79831224|NCT00899002|Genetic|mutation analysis|
79831225|NCT00899002|Genetic|polymerase chain reaction|Not noted
79831226|NCT00899002|Genetic|proteomic profiling|
79831227|NCT00899002|Other|immunohistochemistry staining method|not noted
79831228|NCT00899002|Other|laboratory biomarker analysis|not noted
79831229|NCT00899002|Other|mass spectrometry|not noted
79831230|NCT00899002|Other|medical chart review|not noted
79831231|NCT02550327|Drug|Nab-paclitaxel|125 mg/m2
79831232|NCT02550327|Drug|Gemcitabine|1000 mg/m2
79831233|NCT02550327|Drug|Cisplatin|25 mg/m2
79831234|NCT02550327|Drug|Anakinra|100 mg
79831235|NCT00881998|Procedure|Minimally Invasive Total Hip Arthroplasty|
79831236|NCT00881998|Procedure|Conventional Total Hip Arthroplasty|
80005156|NCT04955158|Drug|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
79237589|NCT05089786|Device|Exablate Neuro Type 1.0 System with Echo Focusing|MR-Guided Focused Ultrasound
79378042|NCT04501458|Other|Training clinicians in basic critical care and the management of severe COVID-19 cases|Training clinicians in basic critical care and the management of severe COVID-19 cases with concurrent maintenance of essential health services.
79391184|NCT03180762|Drug|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
79391185|NCT03180762|Drug|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
79391186|NCT03180762|Drug|Placebo|Matching placebo will be administered.
79532231|NCT04527913|Procedure|Oral Hygiene Instruction (OHI)|"OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist."
79831237|NCT00825045|Drug|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
79831238|NCT00895336|Biological|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
80005157|NCT04955158|Drug|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
79688152|NCT06021899|Other|modified constraint induced movement therapy|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
79688153|NCT06021873|Procedure|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
79688154|NCT06021847|Other|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
79237590|NCT02671760|Drug|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
79378043|NCT01819727|Drug|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
79831239|NCT00899080|Genetic|gene expression analysis|
79831240|NCT00899080|Genetic|reverse transcriptase-polymerase chain reaction|
79831241|NCT00899080|Other|immunoenzyme technique|
79831242|NCT00899080|Other|laboratory biomarker analysis|
79831243|NCT00899080|Other|platelet aggregation test|
79831244|NCT02550015|Behavioral|High intensity interval training|Uphill treadmill walking
79532232|NCT04481321|Biological|Biological/Vaccine|
79831245|NCT02550015|Behavioral|General information|Standard care
79831246|NCT00826761|Dietary Supplement|probiotic|One capsule per meal test (high dose or low dose)
79831247|NCT00826761|Dietary Supplement|placebo|1 capsuel every morning
79532233|NCT04469270|Biological|Engensis|Intramuscular injections
79532234|NCT04469270|Other|Placebo|Intramuscular injections
79532235|NCT04455152|Behavioral|self-control|avoiding eating sweets as a way of building self-control strength
79688155|NCT06021847|Other|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
79688156|NCT06021834|Other|rehabilitation|The subjects will be invited to attend the program three times per week.
79688157|NCT06021821|Other|SoundMind App|he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
79688158|NCT06021821|Other|Spotify Playlist|"Participants will listen to a calm vibes playlist by Spotify."
79688159|NCT06021782|Other|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
79237591|NCT02671760|Drug|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
79688160|NCT06021769|Other|Observational only|No intervention
79831248|NCT03855969|Procedure|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
79831249|NCT00820677|Behavioral|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
79831250|NCT00629265|Device|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
80005158|NCT04955158|Other|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
80005159|NCT04952077|Device|MRI|Magnetic Resonance Imaging (MRI)
80005160|NCT04938973|Procedure|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
80005161|NCT04938973|Procedure|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
80005162|NCT04938973|Device|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
79237592|NCT02671760|Drug|Placebo|Placebo
79302743|NCT03199729|Other|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
79237593|NCT03114176|Dietary Supplement|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
79831251|NCT00606502|Drug|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
79831252|NCT00606502|Drug|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
79831253|NCT00606502|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
79831254|NCT00606502|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
79831255|NCT02549625|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
79831256|NCT00825123|Drug|Ivabradine|Ivabradine 10 mg once
79831257|NCT00825123|Drug|Metoprolol|Metoprolol 50 mg once
79378044|NCT01649362|Other|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
79378045|NCT05584020|Procedure|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
79532236|NCT04395053|Drug|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
79831258|NCT00825123|Drug|Placebo|Lactose powder
79532237|NCT04382391|Device|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
79532238|NCT04382391|Other|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
79532239|NCT04375202|Drug|Colchicine 1 MG Oral Tablet|Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
79831259|NCT02540746|Behavioral|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
79831260|NCT02540746|Behavioral|Motivational Enhancement|Three week Motivational Enhancement group
79831261|NCT02540746|Behavioral|Family Skills Training|12-week group-based family skills training using Family Connections model
79831262|NCT00826839|Drug|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
79831263|NCT00826839|Drug|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
79831264|NCT04017988|Dietary Supplement|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
79831265|NCT04017988|Dietary Supplement|Placebo|Placebo for 8 week
79831266|NCT00899158|Other|immunologic technique|
79831267|NCT00899158|Other|laboratory biomarker analysis|
79831268|NCT00899158|Procedure|biopsy|
79831269|NCT00825201|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
79831270|NCT00825201|Other|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
79831271|NCT00825201|Other|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
79831272|NCT00825201|Other|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
79688161|NCT06021756|Drug|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
79237594|NCT05085340|Drug|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
79831273|NCT00825201|Other|laboratory biomarker analysis|Correlative studies
79831274|NCT00901030|Procedure|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
79831275|NCT00825279|Device|Bare Metal Stent|Stainless steel stent
79831276|NCT00825279|Device|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
79237595|NCT03670433|Other|Cost analysis of medication reconciliation|"The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
79831277|NCT00820833|Other|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
79237596|NCT02667236|Drug|A-101 Solution|Active Drug
79237597|NCT02667236|Other|Vehicle Solution|Placebo
79237598|NCT01126749|Drug|Gemcitabine|Gemcitabine
79831278|NCT00820833|Other|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
80005163|NCT04936958|Other|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
79237599|NCT01126749|Drug|E7389|E7389
79532240|NCT04364373|Procedure|Left colon resection|"This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed."
79532241|NCT04364373|Procedure|Sigmoid colon resection|"This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed."
79688162|NCT06021730|Behavioral|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
79688163|NCT06021730|Behavioral|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
79688164|NCT06021717|Drug|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
79688165|NCT06021717|Drug|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
79688166|NCT06021691|Behavioral|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
79831279|NCT00820911|Drug|cyclosporine (reduced exposure) / everolimus|twice daily
79831280|NCT00820911|Drug|AEB071 300 mg b.i.d. / everolimus|twice daily
79831281|NCT00820911|Drug|AEB071 200 mg b.i.d. / everolimus|twice daily
79831282|NCT00605722|Drug|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
79831283|NCT00605722|Drug|erlotinib (Tarceva)|150 mg orally (po) daily.
79831284|NCT00826995|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
79831285|NCT00820989|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
80005164|NCT04935554|Other|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
80005165|NCT04931160|Other|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
80005166|NCT04930289|Device|LungGuard|The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
80005167|NCT04928391|Drug|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
80005168|NCT04928391|Drug|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
79391187|NCT02415660|Procedure|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
79831286|NCT00882076|Drug|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
79831287|NCT00882076|Drug|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
79831288|NCT00882076|Drug|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
79831289|NCT00825435|Procedure|Coronary CT Angiogram|Coronary CT Angiogram
79831290|NCT00901108|Procedure|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
79831291|NCT00901108|Procedure|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
79831292|NCT00827151|Drug|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
80005169|NCT04928391|Other|0.9% saline|Same volume of saline placebo IV at the end of surgery
80005170|NCT04928352|Drug|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
79831293|NCT00882154|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
79831294|NCT00882154|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
79831295|NCT00825591|Dietary Supplement|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
79391188|NCT02415660|Procedure|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
79831296|NCT00825591|Dietary Supplement|Placebo Comparator|Oral administration before bed. 6 week duration.
79831297|NCT00899704|Genetic|microarray analysis|
79831298|NCT00899704|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
79831299|NCT00899704|Other|diagnostic laboratory biomarker analysis|
79688167|NCT06021665|Other|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
80005171|NCT04928352|Drug|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
79688168|NCT06021665|Other|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
79688169|NCT06021652|Device|MindCotine Virtual reality|Virtual reality platform
79831300|NCT00825669|Drug|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
79831301|NCT00825669|Procedure|Laser ablation|Laser ablation is given to the PVTT.
80005172|NCT04928352|Other|0.9% saline|Preoperative nebulized same volume of saline placebo
80005173|NCT04928300|Drug|Dexmedetomidine|low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
80005174|NCT04928300|Drug|Ketamine|low dose ketamine infusion 2.5 µ/kg/min for 5 days.
80005175|NCT04928300|Other|0.9% saline|the same dose and duration of normal saline will be given for 5 days.
80005176|NCT04924140|Drug|Aducanumab|Administered as specified in the treatment arm
80005177|NCT04920864|Device|rTMS|Repetitive transcranial magnetic stimulation
80005178|NCT04913948|Other|No intervention|No intervention
80005179|NCT04910464|Drug|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
80005180|NCT04910464|Other|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
80005181|NCT04905901|Drug|Tranexamic acid|Tranexamic acid nebulization 15 minutes before sinus surgery
79237600|NCT01126749|Drug|Cisplatin|Cisplatin
79237601|NCT02521948|Device|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
79237602|NCT03674333|Dietary Supplement|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
79237603|NCT03674333|Other|Placebo|Placebo - a sugar pill
79237604|NCT04216238|Behavioral|quasi-experimental Pre-test/Post-test design|surveys to document progress
79688170|NCT06021587|Drug|Levosimendan|Initiation of levosimendan 48 hours before surgery
79688171|NCT06021587|Drug|No Levosimendan|Without Levosimendan Infusion
79688172|NCT06021574|Drug|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
79532242|NCT04364373|Procedure|Distal sigmoid colon resection or anterior resection|"This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed."
79688173|NCT06021574|Drug|Placebo|Placebo
79688174|NCT06021535|Other|No intervention|No intervention
79378046|NCT05584020|Procedure|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
79831302|NCT00821067|Dietary Supplement|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
79688175|NCT06021522|Drug|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
79688176|NCT06021509|Device|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
79688177|NCT06021496|Behavioral|face to face health education|Face-to-face health education with home visit
79831303|NCT00821067|Dietary Supplement|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
79831304|NCT00821145|Procedure|conventional surgery|AAA patients operated using a conventional incision
79831305|NCT00821145|Procedure|laparoscopic AAA resection|laparoscopic AAA resection
79831306|NCT00821145|Procedure|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
79688178|NCT06021496|Behavioral|online health education|online health education with video call
79237605|NCT03479463|Biological|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
79378047|NCT03346590|Behavioral|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
79378048|NCT01692340|Other|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
79378049|NCT03346512|Procedure|Cardiac surgery|Cardiac surgery
79831307|NCT00900016|Genetic|protein expression analysis|
79831308|NCT00900016|Genetic|western blotting|
79831309|NCT00900016|Other|immunohistochemistry staining method|
79688179|NCT06021470|Behavioral|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
79688180|NCT06021405|Procedure|Tape stripping|a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
79831310|NCT00900016|Other|immunologic technique|
79831311|NCT00900016|Other|laboratory biomarker analysis|
79831312|NCT00900094|Genetic|fluorescence in situ hybridization|
79831313|NCT00900094|Genetic|polymerase chain reaction|
79237606|NCT05126134|Diagnostic Test|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
79237607|NCT04059107|Device|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
79237608|NCT03674099|Drug|Imatinib Mesylate|Tablets 400 mg
79237609|NCT03674099|Drug|Methylprednisolone|1 g tablets or infusion
79237610|NCT05124340|Biological|BCG vial vaccine|Intradermal injection
79709861|NCT01108510|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
79709862|NCT01108510|Drug|COBI placebo|Placebo to match COBI administered orally once daily
79831314|NCT00900094|Genetic|protein expression analysis|
79831315|NCT00900094|Other|immunohistochemistry staining method|
79831316|NCT00900094|Other|laboratory biomarker analysis|
79831317|NCT00900094|Other|mass spectrometry|
79831318|NCT00882232|Device|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
79237611|NCT05124340|Biological|BCG ampoule vaccine|Intradermal injection
79237612|NCT03479385|Behavioral|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
79237613|NCT03479385|Behavioral|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
79237614|NCT04762628|Dietary Supplement|MAF capsules 148 mg|enteric capsules based on enzymatically treated bovine colostrum
79237615|NCT04762628|Dietary Supplement|M capsules 148 mg|enteric capsules based on enzymatically treated bovine whey
79237616|NCT04762628|Other|Standard of care|Standard of care
79237617|NCT03670199|Other|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
79831319|NCT04038424|Other|Art therapy|Art therapy including coloring, painting and listening to music
79831320|NCT00900172|Biological|bevacizumab|
79831321|NCT00900172|Drug|carboplatin|
79831322|NCT00900172|Drug|paclitaxel|
79831323|NCT00900172|Genetic|gene expression analysis|
79831324|NCT00900172|Genetic|polymerase chain reaction|
79831325|NCT00900172|Genetic|polymorphism analysis|
80005182|NCT04905901|Other|Saline placebo|Normal saline placebo nebulization 15 minutes before sinus surgery
79831326|NCT00900172|Other|laboratory biomarker analysis|
79831327|NCT00605566|Drug|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
80005183|NCT04901988|Drug|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
80005184|NCT04901546|Other|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
80005185|NCT04900974|Drug|Doravirine|100mg
79378050|NCT02517450|Behavioral|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
79378051|NCT02517450|Other|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
79532243|NCT04345744|Procedure|Periodontal surgery|Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
79532244|NCT04345744|Device|Hyaluronic and 0.2% chlorhexidine mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
79709863|NCT01108510|Drug|RTV placebo|Placebo to match RTV administered orally once daily
79532245|NCT04345744|Device|Chlorhexidine 0.2% mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
79831328|NCT00605566|Drug|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
79831329|NCT00900250|Other|Cytology Specimen Collection Procedure|Correlative studies
79831330|NCT00900328|Other|laboratory biomarker analysis|Correlative Studies
79831331|NCT00882388|Drug|aspirin|aspirin 100 mg qd for 7 days
79831332|NCT00882388|Drug|celecoxib|celecoxib 200 mg bid * 7 days
79831333|NCT00882388|Drug|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
79831334|NCT00882388|Drug|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
79831335|NCT00882388|Drug|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
79831336|NCT00901420|Procedure|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
79831337|NCT00901420|Behavioral|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
79378052|NCT02517372|Drug|CRD007|
79709864|NCT04343781|Other|observation|observation of clinical symptoms related to COVID-19 disease
79709865|NCT02273258|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
79709866|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
79831338|NCT00900406|Genetic|gene expression analysis|blood collection
79831339|NCT00900406|Genetic|microarray analysis|Blood collection
79831340|NCT00900406|Genetic|polymorphism analysis|Blood collection
80005186|NCT04899687|Drug|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
80005187|NCT04899687|Drug|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
80005188|NCT04866823|Behavioral|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
79709867|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
79709868|NCT02273414|Drug|BIIL 284 BS - rising dose|
79709869|NCT02273414|Drug|Placebo|
79831341|NCT00900406|Genetic|proteomic profiling|Blood collection
79831342|NCT00900406|Other|flow cytometry|Blood collection
79831343|NCT00900406|Other|immunologic technique|Blood collection
79831344|NCT00900406|Other|laboratory biomarker analysis|Blood collection
79831345|NCT00900406|Procedure|biopsy|Blood collection
80005189|NCT04852809|Other|No intervention|This is an observational study
79237618|NCT03670199|Other|Physiotherapist intervention|Respiratory capacity Functional capacity
79688181|NCT06021327|Procedure|Erector spinae plane block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
79831346|NCT00396877|Drug|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
79237619|NCT03670199|Other|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
79378053|NCT01692496|Drug|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
79831347|NCT00396877|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
79378054|NCT05583240|Drug|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
79831348|NCT02540044|Behavioral|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
79831349|NCT02540044|Behavioral|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
80005190|NCT04843124|Device|Remote HA adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
80005191|NCT04843124|Other|Traditional hearing aid|Traditional hearing aid
80005192|NCT04838574|Other|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
80005193|NCT04829877|Behavioral|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
80005194|NCT04829877|Behavioral|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
80005195|NCT04823845|Drug|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
80005196|NCT04810962|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
80005197|NCT04810962|Drug|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
79237620|NCT03670199|Other|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
79237621|NCT03481647|Procedure|Oral care programme|Professional oral care (dental hygienist), intensified oral care measures by the patient
79237622|NCT05084404|Drug|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
79237623|NCT05084404|Drug|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
79237624|NCT03473613|Drug|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
79378055|NCT01692964|Device|InflammaDry|A noninvasive immunoassay for detecting MMP-9 levels in tears.
79378056|NCT02517216|Other|parabolic flight|
79378057|NCT02517216|Device|MRI|
79378058|NCT01649596|Device|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
79378059|NCT01649596|Other|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
79378060|NCT03346122|Drug|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
79378061|NCT03346122|Drug|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
79378062|NCT03346122|Drug|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
79378063|NCT03346122|Drug|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
79378064|NCT03346122|Drug|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
79709870|NCT02881411|Other|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
79709871|NCT02881411|Other|Fibromyalgia coping skills programme|Exercise, education programme
79378065|NCT03346122|Drug|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
79378066|NCT03346122|Drug|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
79709872|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
79831350|NCT00900484|Other|biologic sample preservation procedure|
79831351|NCT00900484|Other|immunohistochemistry staining method|
79831352|NCT00900484|Other|laboratory biomarker analysis|
79831353|NCT01040065|Procedure|distal clavicle resection|Presence of tenderness at 2 years after surgery
79831354|NCT00124891|Drug|Double-blind investigational anti-arrhythmic|
79831355|NCT00124891|Drug|GAP-486|
79378067|NCT03346122|Drug|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
79831356|NCT00882466|Drug|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
79831357|NCT00901498|Drug|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
79831358|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
79831359|NCT00901498|Drug|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
79831360|NCT00901498|Drug|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
79831361|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
79831362|NCT00628251|Drug|AZD2281|400mg Oral twice daily
79831363|NCT00628251|Drug|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
79831364|NCT00628251|Drug|AZD2281|200mg oral twice daily
79831365|NCT01036399|Drug|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
79831366|NCT01040221|Drug|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
80005198|NCT04806776|Other|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
79378068|NCT03346122|Drug|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
79378069|NCT03346122|Drug|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
79378070|NCT02516826|Drug|Rosuvastatin|
79378071|NCT02516826|Drug|Olmesartan|
79378072|NCT02516826|Drug|Combination|Rosuvastatin/Olmesartan(Combination)
79378073|NCT02516826|Drug|Placebo of Rosuvastatin|
79378074|NCT02516826|Drug|Placebo of Olmesartan|
79378075|NCT02516826|Drug|Placebo of Rosuvastatin/Olmesartan(Combination)|
79532246|NCT04329572|Drug|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
79532247|NCT04329572|Drug|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
79532248|NCT04323137|Behavioral|Risk reduction|Mailed letter, SMS, and/or patient portal message
79532249|NCT04323137|Behavioral|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
79532250|NCT04323137|Behavioral|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
79532251|NCT04322552|Drug|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
79532252|NCT04322552|Drug|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
79532253|NCT04321148|Procedure|standard of care PCI|optimal medical care PCI
79532254|NCT04321148|Procedure|Impella-protected PCI|Impella-protected PCI
79532255|NCT04316104|Behavioral|CuidaTXT|Culturally tailored text messages including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
79532256|NCT04285814|Diagnostic Test|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
79532257|NCT04240717|Behavioral|Patient Decision Aid|The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
79709873|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
79709874|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
79709875|NCT05018494|Other|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
79831367|NCT00901654|Biological|ACE527 vaccine|"First cohort: Two doses, each of 3x10^9 cfu of each strain (9x10^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10^10 cfu of each strain (9x10^10 cfu total per dose) administered on Days 0 and Day 21"
79831368|NCT00901654|Biological|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
79831369|NCT00821223|Procedure|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
79831370|NCT00821223|Procedure|manual small incision surgery|
79831371|NCT00821223|Procedure|phacoemulsification|cataract surgery
79831372|NCT00900640|Procedure|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
79831373|NCT00625131|Drug|Nicotine|Delivered through transdermal nicotine patch
79831374|NCT00625131|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
79688182|NCT06021327|Procedure|Retrolaminar block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
79831375|NCT00625131|Drug|Bupropion Sustained Release (SR)|Antidepressant
79831376|NCT00625131|Drug|Placebo patch|Pre-treatment placebo transdermal patch
79831377|NCT01036633|Device|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
79237625|NCT03473613|Drug|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
79378076|NCT01650298|Other|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
79378077|NCT01795937|Drug|Itraconazole|twice daily
79378078|NCT01795937|Drug|Atorvastatin|single dose
79831378|NCT00900718|Device|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
79831379|NCT00900718|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
80005199|NCT04806776|Other|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
80005200|NCT04806451|Drug|Crinecerfont|CRF1-receptor antagonist
80005201|NCT04806451|Drug|Placebo|Non-active dosage form
79831380|NCT02549547|Behavioral|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
79831381|NCT00923338|Device|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
80005202|NCT04806269|Device|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
80005203|NCT04805983|Drug|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
80005204|NCT04798378|Device|Neurosleeve|Myoelectric devices for restoration of independent arm function
80005205|NCT04792749|Drug|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
80005206|NCT04789070|Drug|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
80005207|NCT04789070|Drug|Placebo|Placebo
80005208|NCT04756427|Drug|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
80005209|NCT04753359|Other|Med|Mediterranean diet
80005210|NCT04753359|Other|WL|Measuring change in weight
79237626|NCT03673631|Device|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
79237627|NCT03673631|Device|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
79237628|NCT04143776|Procedure|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
79378079|NCT01795937|Drug|Faldaprevir|once daily
79378080|NCT01795937|Drug|Rosuvastatin|single dose
79378081|NCT01795937|Drug|Faldaprevir|once daily
79378082|NCT04139382|Other|Telephone Consultation|A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
79378083|NCT04139382|Other|Face-to-Face Consultation|A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
79532258|NCT04234061|Combination Product|ibrutinib and Tisagenlecleucel|Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
79532259|NCT04189848|Drug|Semaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
79688183|NCT06021314|Other|Brace|Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
79688184|NCT06021288|Other|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
79688185|NCT06021262|Other|exposure to organophosphates|organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
79688186|NCT06021249|Procedure|Traditional ventilation strategies|"Tidal volume：10ml/kg predicted body weight（PBW）；~0 cm H2O positive end expiratory pressure（PEEP）；~negative pressure extubation"
79688187|NCT06021249|Procedure|Traditional lung-protective ventilation strategies|"Tidal volume：6ml/kg PBW；~5cmH2O PEEP；~Ventilator-controlled recruitment manoeuvre；~CPAP；~negative pressure extubation"
79688188|NCT06021249|Procedure|Innovative lung-protective ventilation strategies|"Tidal volume：6ml/kg PBW；~5cmH2O PEEP；~positive pressure extubation；~postoperative breathing training"
79688189|NCT06021249|Procedure|Lung-protective ventilation|"Tidal volume：6ml/kg PBW；~5cmH2O PEEP；"
79688190|NCT06021249|Procedure|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
79688191|NCT06021249|Procedure|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
79688192|NCT06021249|Procedure|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
79688193|NCT06021236|Behavioral|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
79831382|NCT00825747|Device|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
79831383|NCT01040299|Device|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
79831384|NCT01040299|Device|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
79831385|NCT01040299|Other|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
79831386|NCT00901732|Device|Caphosol|Oral Mouth Rinse
79831387|NCT00837291|Drug|CF101|CF101 tablets 1 mg BID
79831388|NCT00837291|Drug|Placebo|Placebo tablets BID
79378084|NCT01608100|Device|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
79831389|NCT00882622|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
79831390|NCT00882622|Procedure|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
80005211|NCT04733417|Drug|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
79378085|NCT05581368|Other|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
79378086|NCT04501224|Drug|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
79378087|NCT04501224|Drug|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
79378088|NCT01817777|Drug|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
79688194|NCT06021236|Other|CIED procedure routine care|CIED procedure home care guidance
79688195|NCT06021223|Dietary Supplement|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
79688196|NCT06021223|Dietary Supplement|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
79831391|NCT02547909|Procedure|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
79831392|NCT02547909|Device|Cellvizio|
79831393|NCT02547909|Drug|fluorescein 10%|
79831394|NCT00882700|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
79831395|NCT00882700|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
80005212|NCT04733417|Drug|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
79688197|NCT06021223|Other|Placebo|140ml of placebo to be consumed daily for 2 weeks
79709876|NCT05018494|Other|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
79688198|NCT06021210|Drug|Letermovir Pill|Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021.
79688199|NCT06021171|Dietary Supplement|Partially hydrolyzed guar gum + bifidobacterium lactis|Synbiotic Supplement: Contains 5 grams of prebiotic fiber (Sunfiber®) and 8 billion active probiotics (Bifidobacterium lactis).
79688200|NCT06021171|Dietary Supplement|Partially hydrolyzed guar gum|5 g Partially hydrolyzed guar gum
79688201|NCT06021171|Dietary Supplement|Maltodextrin|5 g Maltodextrin
79688202|NCT06021132|Device|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
79688203|NCT06021119|Drug|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
79688204|NCT06021067|Biological|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4~6 weeks.
79688205|NCT06021028|Procedure|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
79688206|NCT06021015|Device|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
79688207|NCT06021015|Device|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
79831396|NCT00408499|Drug|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
79831397|NCT00408499|Drug|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
79831398|NCT00837369|Drug|Regadenoson|400ug IV bolus injection, single dosage
79831399|NCT00900874|Drug|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
79831400|NCT00900874|Drug|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
79831401|NCT00901810|Device|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
79831402|NCT00901810|Device|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
79831403|NCT00830661|Procedure|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
80005213|NCT04731441|Behavioral|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
79378089|NCT01817777|Drug|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
79688208|NCT06021002|Drug|R848|Nasal R848 administration
79688209|NCT06021002|Drug|Saline|Nasal saline administration
79688210|NCT06020989|Drug|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
79688211|NCT06020989|Drug|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
79688212|NCT06020989|Drug|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
79688213|NCT06020976|Diagnostic Test|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
79688214|NCT06020963|Procedure|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
79688215|NCT06020963|Drug|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
79688216|NCT06020924|Other|No intervention|This study is a retrospective observational study without intervention.
79688217|NCT06020911|Drug|Biodentine|17 primary second molars of 17 children will be capped with Biodentine
79831404|NCT00830661|Procedure|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
79831405|NCT02539810|Device|Renal artery Angioplasty plus stenting.|renal artery stenting
79831406|NCT02539810|Drug|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
79688218|NCT06020911|Drug|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
79688219|NCT06020885|Radiation|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
79688220|NCT06020885|Drug|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
79688221|NCT06020885|Drug|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
79688222|NCT06020872|Other|Health literacy program|Health literacy program was the health education related to healthy plate.
79831407|NCT04044183|Behavioral|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
79831408|NCT04044183|Behavioral|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
79831409|NCT00900952|Other|Clinical record review|
79831410|NCT00901888|Drug|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
79831411|NCT00901888|Drug|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
79831412|NCT04416711|Behavioral|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
79688223|NCT06020859|Device|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
79237629|NCT03859011|Other|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
79378090|NCT05576844|Behavioral|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
79378091|NCT05576844|Other|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
79688224|NCT06020859|Device|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
79688225|NCT06020859|Device|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
79688226|NCT06020833|Drug|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
79237630|NCT03859011|Other|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
79237631|NCT03670043|Drug|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
79237632|NCT03670043|Drug|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
79378092|NCT05617170|Other|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
79532260|NCT04189848|Drug|Dulaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
79532261|NCT04179695|Other|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
79532262|NCT04179695|Other|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
79532263|NCT04156334|Procedure|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
79831413|NCT04416711|Behavioral|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
79378093|NCT01693900|Procedure|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
79831414|NCT04416711|Other|Services As Usual|These participants will receive services as usual
79378094|NCT01693900|Procedure|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
79378095|NCT02516748|Behavioral|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
79378096|NCT01650844|Other|School-Based Telemedicine Enhanced Asthma Management|
79378097|NCT01650844|Other|Enhanced Usual Care|
79237633|NCT05084092|Radiation|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
79831415|NCT00908362|Drug|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
79378098|NCT01795547|Drug|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
79378099|NCT01795547|Drug|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
79831416|NCT00908362|Drug|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
79831417|NCT00908362|Drug|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
79831418|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
79831419|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
79831420|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
79237634|NCT05084092|Procedure|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
79237635|NCT02388464|Drug|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
79831421|NCT02549469|Drug|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
79831422|NCT00908440|Behavioral|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
79831423|NCT00905866|Other|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
79831424|NCT00837525|Procedure|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
79831425|NCT02539576|Drug|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
79831426|NCT00837603|Behavioral|Training|Controlled home ergometer training
79831427|NCT00905944|Other|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
79831428|NCT00923793|Device|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
79831429|NCT00923793|Device|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
79831430|NCT02548533|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
79237636|NCT02388464|Drug|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
79237637|NCT02388464|Drug|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
80005214|NCT04731441|Behavioral|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
80005215|NCT04724603|Other|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
80005216|NCT04723420|Other|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
80005217|NCT04723420|Other|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
79688227|NCT06020820|Other|Cervical Rehabilitation program (Intervention Group) Group A|"(Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs"
79831431|NCT02548533|Drug|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
79831432|NCT02548533|Drug|EMLA cream|Topical application 2 hours prior to the treatment.
79709877|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
79831433|NCT02549391|Drug|KHK7580|Oral administration
79831434|NCT02549391|Drug|KRN1493|Oral administration
79237638|NCT02388464|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
79237639|NCT03131427|Drug|Standard of care|Standard of care according to the updated national and/or international guidelines
79237640|NCT03114345|Other|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
79237641|NCT03114345|Other|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
79831435|NCT00902122|Drug|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
79831436|NCT00902122|Procedure|surgery|removal of thyroid tumor
79831437|NCT00902122|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
79237642|NCT05082376|Drug|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
80005218|NCT04722601|Drug|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
79831438|NCT00902122|Radiation|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
79831439|NCT02538172|Other|T-Track® CMV assay|
79831440|NCT00837837|Drug|Chlorpheniramine|
79831441|NCT00908674|Drug|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
80005219|NCT04722601|Drug|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
79237643|NCT04446429|Drug|Proxalutamide|200 mg q.d.
79237644|NCT04446429|Other|Standard of Care|Standard of care as determined by the PI
79237645|NCT05675384|Device|TENS Active Treatment|Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
79831442|NCT00906022|Device|Astron Pulsar Stent|Stenting with Astron Pulsar
79831443|NCT00906022|Device|PTA alone|Balloon angioplasty alone
79831444|NCT00902356|Drug|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
79831445|NCT00902356|Drug|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
80005220|NCT04722601|Drug|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
80005221|NCT04702243|Diagnostic Test|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
80005222|NCT04702243|Other|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
80005223|NCT04692844|Drug|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
79831446|NCT00621777|Drug|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
79831447|NCT00621777|Drug|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
79831448|NCT02538718|Drug|MgSO4|
79831449|NCT02538718|Drug|YTP(Ritodrine)|
79831450|NCT00827229|Device|Labor Monitor|
79831451|NCT02539420|Device|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
80005224|NCT04692844|Drug|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
80005225|NCT04657003|Drug|Tirzepatide|Administered SC
80005226|NCT04657003|Other|Placebo|Administered SC
80005227|NCT04650607|Other|Adverse event after injection of phages|rate and description of adverse event after injection of phages
80005228|NCT04648852|Other|Heart failure risk estimation|Evaluation by heart failure risk score
79237646|NCT05675384|Device|Sham Device|Using the sham (control) device combined with a moderate intensity lifestyle follow-up
79237647|NCT04432467|Biological|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
79237648|NCT04432467|Other|standard treatment|standard treatment according to clinical protocols
79237649|NCT05561660|Device|PFO device closure|Participants randomized into this group will take PFO device closure.
79378100|NCT01695304|Other|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
79831452|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
79831453|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
79831454|NCT00902512|Drug|Treatment A|Viagra® 100 mg tablet, administered with water single dose
79831455|NCT00902512|Drug|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
79831456|NCT00902512|Drug|Treatment B|Sildenafil 100 mg CT administered with water single dose
79831457|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
79831458|NCT00902512|Drug|Treatment C|Sildenafil 100 mg CT administered without water single dose
79831459|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
79831460|NCT00830973|Other|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
79831461|NCT00830973|Other|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
79831462|NCT04034914|Other|Questionnaire administration|Ancillary studies
79831463|NCT00827307|Drug|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
79237650|NCT05561660|Drug|Aspirin|Participants randomized into this group will take aspirin 200mg qd for 6 months.
79237651|NCT03042819|Drug|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
79378101|NCT03920826|Device|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
79831464|NCT00827307|Drug|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
80005229|NCT04643067|Drug|KPG-818 low dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
80005230|NCT04643067|Drug|KPG-818 mid dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
80005231|NCT04643067|Drug|KPG-818 high dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
80005232|NCT04643067|Drug|Placebo|This is the comparative arm.
80005233|NCT04625361|Drug|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
80005234|NCT04624906|Drug|Acalabrutinib|100 mg oral capsules twice daily for 1 year
80005235|NCT04624906|Drug|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
79831465|NCT04034602|Other|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
79532264|NCT04092764|Device|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
79831466|NCT04034602|Other|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
80005236|NCT04624906|Drug|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
80005237|NCT04610320|Drug|Daratumumab-SC|>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
80005238|NCT04606134|Device|Hybrid fractional laser|two treatments given one month apart
79831467|NCT00837915|Drug|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
80005239|NCT04606134|Other|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
80005240|NCT04606134|Other|Cetaphil face cream|applied twice daily
80005241|NCT04568759|Other|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
79831468|NCT00908986|Drug|Rituximab|375mg/m2 q week x 4; repeated in 6 months
80005242|NCT04556188|Procedure|Cardiac surgery|
80005243|NCT04550598|Device|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
80005244|NCT04550598|Device|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
79532265|NCT04092764|Device|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
79532266|NCT04092764|Device|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
80005245|NCT04546399|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
80005246|NCT04546399|Biological|Blinatumomab|Given IV
79532267|NCT04078906|Other|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
79532268|NCT04036968|Drug|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
79532269|NCT03980171|Drug|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
79688228|NCT06020820|Other|control group group B|"Relax shoulders and neck sufficiently~look down~turn face to the right~turn face to the left~incline head to the right~incline head to the left~turn shoulders round and round~slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening)."
79688229|NCT06020794|Behavioral|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
79688230|NCT06020794|Biological|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
79831469|NCT02539264|Other|Smoking|Influence of smoking on parameters derived from overnight PSG
79831470|NCT02539264|Other|Obesity|Influence of obesity on parameters derived from overnight PSG
79831471|NCT02539264|Other|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
80005247|NCT04546399|Drug|Cyclophosphamide|Given IV
80005248|NCT04546399|Drug|Cytarabine|Given IT
80005249|NCT04546399|Drug|Dexamethasone|Given PO or IV
80005250|NCT04546399|Drug|Etoposide|Given IV
80005251|NCT04546399|Drug|Hydrocortisone Sodium Succinate|Given IT
80005252|NCT04546399|Drug|Leucovorin Calcium|Given PO and IV
80005253|NCT04546399|Drug|Mercaptopurine|Given PO
80005254|NCT04546399|Drug|Methotrexate|Given IT, PO, and IV
80005255|NCT04546399|Biological|Nivolumab|Given IV
80005256|NCT04546399|Drug|Pegaspargase|Given IM or IV
80005257|NCT04546399|Drug|Thioguanine|Given PO
80005258|NCT04546399|Drug|Vincristine Sulfate|Given IV push or via infusion
79688231|NCT06020768|Other|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
80005259|NCT04540120|Drug|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
80005260|NCT04540120|Drug|placebo capsules|Hard opaque capsules containing 0 mg of API.
80005261|NCT04518059|Procedure|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
80005262|NCT04517383|Procedure|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
80005263|NCT04517383|Procedure|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
79831472|NCT00827463|Biological|dosage of the NFS and iron|a blood test will be made.
79831473|NCT00909142|Drug|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
79831474|NCT00906256|Drug|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
79831475|NCT00906256|Drug|Placebo|Placebo
79831476|NCT00838071|Drug|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
79831477|NCT02539186|Biological|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
79831478|NCT02539186|Device|splint|
79831479|NCT04044573|Procedure|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
79831480|NCT02538640|Other|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
79831481|NCT02538640|Other|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
79378102|NCT03920826|Device|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
79378103|NCT01794923|Drug|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
79378104|NCT01794923|Drug|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
79831482|NCT00902824|Biological|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)
79831483|NCT00902824|Biological|TBC-M4|Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
79831484|NCT00902824|Other|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
79378105|NCT01794923|Drug|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
79532270|NCT03980171|Drug|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
79688232|NCT06020742|Procedure|Autologous USC mitochondrial oocyte transplantation|Mitochondria are isolated from urine derived stem cells from fresh middle urine of the subjects, and injected into the cytoplasm of mature oocytes together with sperm
79831485|NCT02547519|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
79831486|NCT02547519|Drug|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
79831487|NCT02547285|Other|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
79378106|NCT01794923|Drug|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
79378107|NCT02517138|Other|Parabolic flight|
79378108|NCT02517138|Other|Measurements of eye movements and perception|
79378109|NCT02516514|Procedure|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
79378110|NCT02516904|Drug|CD101 IV|antifungal
79688233|NCT06020729|Other|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
79378111|NCT02516904|Drug|Placebo|normal saline
79378112|NCT03346044|Device|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
79378113|NCT03346044|Device|Medtronic Mosaic bioprostheses|
79378114|NCT04502940|Diagnostic Test|Flow Cytometric analysis|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
79378115|NCT03347604|Diagnostic Test|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
79378116|NCT01794845|Drug|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
79532271|NCT03980171|Drug|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
79532272|NCT03926013|Drug|JNJ-63898081|JNJ-63898081 will be administered.
79688234|NCT06020729|Other|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
79532273|NCT03860077|Drug|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes
79831488|NCT00909454|Dietary Supplement|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
79831489|NCT00909454|Dietary Supplement|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
79831490|NCT04312737|Device|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
79688235|NCT06020716|Drug|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
79831491|NCT04312737|Diagnostic Test|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
79831492|NCT04035070|Combination Product|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
79831493|NCT04035070|Combination Product|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
79831494|NCT04035070|Combination Product|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
79378117|NCT01794845|Drug|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
79831495|NCT00838149|Dietary Supplement|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
79831496|NCT00838149|Dietary Supplement|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
79831497|NCT02548377|Procedure|Remote ischemic preconditioning|
79831498|NCT02548377|Procedure|Sham|
79378118|NCT01794845|Radiation|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
79378119|NCT01794689|Drug|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
79378120|NCT01794689|Drug|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
79378121|NCT01794689|Behavioral|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
79378122|NCT01794689|Behavioral|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
79378123|NCT01794299|Biological|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
79532274|NCT03860077|Drug|Normal Nicotine Content Cigarettes|Normal Nicotine Content Cigarettes
79532275|NCT03848793|Drug|HS-20004|treatment
79688236|NCT06020716|Drug|Placebo|Three times daily
79688237|NCT06019091|Device|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
79688238|NCT06018740|Dietary Supplement|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
79831499|NCT02538874|Drug|BMS-986171|
79831500|NCT02538874|Other|Placebo|
79831501|NCT00408421|Drug|Duloxetine|
79831502|NCT00408421|Drug|placebo|
79831503|NCT00604786|Drug|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
79831504|NCT00604786|Drug|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
79831505|NCT00902980|Other|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
79831506|NCT04034758|Procedure|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
79831507|NCT04034758|Procedure|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
79378124|NCT01817075|Procedure|Chlorhexidine Gluconate Skin Cleanser|Given CHG cleansing
79532276|NCT03848351|Behavioral|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
79688239|NCT06018155|Other|Spine surgery|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
79831508|NCT00903136|Other|questionnaire administration|
79532277|NCT03848351|Procedure|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
79532278|NCT03847493|Other|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
79532279|NCT03763448|Procedure|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
79688240|NCT06018012|Device|MRS and ABR|Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
79831509|NCT00903136|Procedure|comparison of screening methods|
79532280|NCT03763448|Procedure|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
80005264|NCT04513665|Drug|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
79532281|NCT03729206|Diagnostic Test|intravital microscopy|intravital microscopy with sidestream dark-field imaging
79532282|NCT03687411|Procedure|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
79532283|NCT03674307|Other|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
79532284|NCT03674307|Other|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
79532285|NCT03658044|Other|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
79532286|NCT03658044|Other|Placebo|No intervention performed. Patients are offered to read the open pages on the website
79532287|NCT03654950|Other|No intervention|Interviews and questionnaires
79688241|NCT06016192|Behavioral|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
79688242|NCT06015191|Behavioral|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
79237652|NCT03042819|Drug|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
79237653|NCT02388308|Device|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
79302744|NCT03199729|Other|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
79302745|NCT03199729|Other|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
79532288|NCT03643016|Other|Surgical strategy based on a software|Surgical strategy décision based on a software
79532289|NCT03637413|Dietary Supplement|Hindmilk|Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
79831510|NCT00903136|Procedure|diagnostic endoscopic procedure|
79831511|NCT00903136|Procedure|esophagogastroduodenoscopy|
79831512|NCT00903136|Procedure|tethered capsule endoscopy|
79831513|NCT01042873|Drug|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
79378125|NCT01817075|Other|Laboratory Biomarker Analysis|Correlative studies
79378126|NCT01817075|Procedure|Mild Soap Skin Cleanser|Given control cleansing
79378127|NCT01817075|Other|Questionnaire Administration|Ancillary studies
79378128|NCT01816763|Behavioral|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
79378129|NCT01816763|Behavioral|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
79532290|NCT03576495|Other|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
79831514|NCT00906490|Device|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
79237654|NCT02388542|Behavioral|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
79532291|NCT03571347|Behavioral|Self Help Plus|5-session psychosocial intervention
79831515|NCT01042951|Biological|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
80005265|NCT04505930|Behavioral|Interventional HPV vaccination video modules|The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
80005266|NCT04505930|Behavioral|General Vaccination Education|Education session conducted using only handouts of vaccinations including HPV
79237655|NCT02832687|Drug|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. <50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
79532292|NCT03571347|Other|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
79237656|NCT02832687|Drug|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
79237657|NCT04421794|Device|NMES|Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.
79237658|NCT04421794|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
79532293|NCT03558724|Drug|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
79831516|NCT01042951|Other|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
79831517|NCT01037023|Drug|Topotecan|patients administrated Topotecan according to the prescribing information
79831518|NCT00604708|Biological|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
79831519|NCT00604708|Biological|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
79831520|NCT00909688|Drug|BLI-489|
79532294|NCT03558724|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
79831521|NCT00909688|Drug|placebo|
80005267|NCT04489524|Behavioral|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
80005268|NCT04489524|Behavioral|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
80005269|NCT04489524|Behavioral|NRT|nicotine replacement therapy
79237659|NCT02388152|Drug|Lu AF20513, low dose|
79831522|NCT00903214|Drug|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
79831523|NCT00903214|Genetic|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
79831524|NCT00903214|Procedure|axillary lymph node biopsy|
80005270|NCT04480086|Drug|Mivebresib|Tablet: Oral
80005271|NCT04480086|Drug|Navitoclax|Tablet; Oral
79237660|NCT02388152|Drug|Lu AF20513, medium dose|
79237661|NCT02388152|Drug|Lu AF20513, high dose|
79237662|NCT02388152|Drug|Lu AF20513, double high dose|
79237663|NCT02388230|Device|Ultrasound imaging|
79237664|NCT04372017|Drug|Hydroxychloroquine|Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
79237665|NCT04372017|Dietary Supplement|Vitamin D|Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
79237666|NCT04422106|Diagnostic Test|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
79831525|NCT00903214|Procedure|digital image analysis|
79831526|NCT00903214|Procedure|needle biopsy|
79831527|NCT00903214|Procedure|sentinel lymph node biopsy|
79831528|NCT00903214|Procedure|therapeutic conventional surgery|
79831529|NCT04034836|Drug|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
79831530|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
79831531|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
79378130|NCT01816763|Behavioral|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
79378131|NCT04578353|Device|The AquaPass System|The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
79831532|NCT02806336|Behavioral|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
79831533|NCT02806336|Behavioral|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
79831534|NCT00407797|Drug|Pregabalin|150 to 600 mg/day during 21 weeks
79831535|NCT00903292|Drug|erlotinib (Tarceva)|chemotherapy with erlotinib
79831536|NCT00903292|Drug|pemetrexed (Alimta)|Chemotherapy with pemetrexed
79831537|NCT02539030|Procedure|Microfracture|simple microfracture
79378132|NCT01816685|Device|CPAP|
79378133|NCT01653028|Drug|Alisertib|Given PO
79378134|NCT01653028|Other|Laboratory Biomarker Analysis|Correlative studies
79831538|NCT02539030|Device|CartiFill|add collagen when doing microfracture
79831539|NCT00906646|Dietary Supplement|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
79831540|NCT00906646|Dietary Supplement|Placebo|Placebo tablets
79831541|NCT00903604|Drug|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
79237667|NCT03479229|Device|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm^2
79237668|NCT03479229|Device|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm^2.
79378135|NCT00708552|Drug|SB-742457|investigational drug
79378136|NCT00708552|Drug|Donepezil|comparator
79378137|NCT00708552|Drug|Placebo|comparator
79378138|NCT02516436|Drug|BEMA Buprenorphine NX|Buprenorphine with naloxone
79378139|NCT02516436|Drug|Buprenorphine|Buprenorphine
79378140|NCT03347526|Drug|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
79378141|NCT03347526|Drug|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
79378142|NCT03347526|Drug|Vigabatrin|oral
79378143|NCT03742752|Other|Enteral nutrition|administration of enteral nutrition
79378144|NCT03742752|Other|Parenteral nutrition|administration of parenteral nutrition
79378145|NCT02516280|Device|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
79378146|NCT02516280|Device|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
79378147|NCT03347370|Drug|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics [SmPC]).
80005272|NCT04480086|Drug|Ruxolitinib|Tablet; Oral
80005273|NCT04476212|Other|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
79688243|NCT06015191|Behavioral|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
80005274|NCT04432688|Drug|Lurasidone HCl|This is a non-interventional, observational study
80005275|NCT04426825|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
79688244|NCT06014814|Procedure|Catheter ablation|Catheter ablation of atrial fibrillation
79688245|NCT06014294|Behavioral|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
79688246|NCT06014294|Behavioral|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
79688247|NCT06014294|Behavioral|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
79688248|NCT06014021|Behavioral|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
79688249|NCT06014021|Behavioral|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
79688250|NCT06014021|Behavioral|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
79831542|NCT00903604|Drug|Placebo|Three 10-minutes infusions of isotonic saline solution
79831543|NCT00924274|Dietary Supplement|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
79831544|NCT00924274|Dietary Supplement|sunflower oil|sunflower oil
79378148|NCT03347370|Drug|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics [SmPC]).
79378149|NCT03347370|Drug|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
79378150|NCT02516124|Procedure|Autologous HSCT|1st AHSCT
79378151|NCT02515968|Drug|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
79378152|NCT02515968|Drug|Propofol|
79378153|NCT03345966|Diagnostic Test|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
79378154|NCT03345888|Other|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
79378155|NCT03347136|Device|CPAP|
79378156|NCT03347136|Device|NIPPV|
79378157|NCT03346356|Behavioral|Teenagers as cross-age SHCP teachers for younger youth|Implementation of the SHCP using teenagers as cross-age teachers for younger youth
79688251|NCT06012656|Device|MiniMAX|Total or Partial Hip Arthroplasty
79688252|NCT06009185|Drug|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
79688253|NCT06006793|Drug|SY-5933|KRAS p.G12C inhibitor
79688254|NCT06006754|Other|Observational study|No intervention: observational study
79688255|NCT06004739|Drug|Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician [MRP]). Antibiotics choice to be selected by the MRP.
79688256|NCT06004739|Other|No Antibiotics for treatment of bacteriuria|Participants will be randomized to no antibiotics
79688257|NCT06004232|Behavioral|Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention|The PRY-D curriculum is a mindfulness-based prenatal yoga intervention which utilizes techniques to build both embodiment and mindfulness, and has previously been shown to reduce depression in a small sample of pregnant women with clinical depression.
79688258|NCT06004232|Behavioral|Treatment as Usual (TAU)|TAU involves routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
79688259|NCT06003010|Behavioral|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
79831545|NCT00903838|Drug|pardoprunox|1.5 to 12 mg/day
79831546|NCT00903838|Drug|pramipexole|0.75-4.5 mg/day
80005276|NCT04426825|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
80005277|NCT04424030|Diagnostic Test|Echocardiography|Standard echocardiography exam performed as part of clinical management.
80005278|NCT04424030|Diagnostic Test|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
80005279|NCT04424030|Diagnostic Test|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
80005280|NCT04419233|Drug|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
80005281|NCT04418479|Drug|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
79378158|NCT03122574|Other|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
79831547|NCT00924430|Drug|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
79831548|NCT00924430|Drug|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
79831549|NCT03743506|Diagnostic Test|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
79831550|NCT03743506|Diagnostic Test|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
79831551|NCT00924586|Drug|ONO-1101|Placebo for one minute IV
79378159|NCT03122574|Other|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
79532295|NCT03547037|Drug|JNJ-63723283|JNJ-63723283 will be administered intravenously.
79831552|NCT00924586|Drug|ONO-1101|0.125 mg/kg for one minute IV
79831553|NCT00568126|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
79831554|NCT00568126|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
79302746|NCT02726945|Device|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
79532296|NCT03547037|Drug|Erdafitinib|Erdafitinib will be administered orally.
79831555|NCT00903994|Drug|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
79532297|NCT03533660|Behavioral|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
79532298|NCT03533660|Behavioral|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
79532299|NCT03512496|Dietary Supplement|Acute energy drink - Placebo|Colored water
79532300|NCT03512496|Dietary Supplement|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
79532301|NCT03512496|Dietary Supplement|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
79532302|NCT03416127|Drug|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
79831556|NCT00924742|Drug|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
79532303|NCT03416127|Drug|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
79532304|NCT03416127|Drug|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
79532305|NCT03399149|Other|Systematic evaluation by an intensivist|implementation of a standardized procedure for patient care in ICU
79532306|NCT03293069|Drug|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
79532307|NCT03293069|Drug|Placebo Oral Tablet|the placebo twice daily morning and evening.
79831557|NCT02539498|Device|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
79831558|NCT00904228|Other|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
79831559|NCT00904228|Other|placement of routine cap during delivery room stabilization|
79831560|NCT00924976|Behavioral|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
80005282|NCT04418479|Drug|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
80005283|NCT04417998|Drug|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
79302747|NCT02726945|Other|Placebo|Placebo Control
79302748|NCT02449993|Device|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
79378160|NCT02507700|Procedure|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
79378161|NCT02507700|Drug|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
79378162|NCT02507700|Device|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
79378163|NCT02507700|Other|Plaster cover|Plaster cover will be used to control group for sham procedure
79378164|NCT02507700|Drug|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
79378165|NCT02507700|Other|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
79237669|NCT05233358|Procedure|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
79237670|NCT05233358|Procedure|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
79237671|NCT05233358|Drug|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
79237672|NCT05233358|Drug|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
79532308|NCT03266315|Biological|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
79532309|NCT03266315|Other|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
79831561|NCT03824860|Behavioral|Yoga|"Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~guided breathing exercises,~upper and lower extremity stretching~structured postures and movements to improve balance and strength"
79831562|NCT00407563|Drug|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
79831563|NCT00407563|Drug|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
79831564|NCT00906724|Procedure|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
79532310|NCT03232346|Drug|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
79831565|NCT01037101|Behavioral|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
79831566|NCT01037101|Behavioral|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
79237673|NCT05120752|Other|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
79237674|NCT05120440|Other|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
79237675|NCT05120440|Other|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
79237676|NCT03479151|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
79831567|NCT01037101|Drug|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
79831568|NCT01037101|Drug|Placebo|50 mg placebo administered 30 minutes before the session
79831569|NCT00904306|Dietary Supplement|Sugar Pill|placebo oral tablet taken once per day
79831570|NCT00904306|Dietary Supplement|chromium picolinate|1000 ug/day chromium picolinate for 6 months
79831571|NCT00904306|Dietary Supplement|chromium picolinate|600 ug/day chromium picolinate
79831572|NCT01788553|Other|remission prevalence of generalized anxiety disorder|
79831573|NCT00906802|Procedure|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
79831574|NCT00567892|Device|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
79831575|NCT00623103|Drug|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
79831576|NCT00623103|Drug|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm^2/day delivering 9.5 mg over a 24 hour period.
79831577|NCT01043341|Behavioral|educative folder|folder about HPV infection and vaccines
79831578|NCT01043419|Drug|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
79831579|NCT01037335|Drug|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
79831580|NCT00925210|Procedure|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
79831581|NCT04604821|Behavioral|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
79831582|NCT04604821|Behavioral|Parent Education|Parents receive information on child developmental milestones.
79831583|NCT02538952|Device|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
79532311|NCT03232346|Drug|Buprenorphine|5-week buprenorphine taper
79831584|NCT02538952|Other|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
79237677|NCT05675228|Other|data collection|Knowledge about genital herpes
79237678|NCT02387918|Drug|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
79831585|NCT04015492|Biological|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
79831586|NCT04015492|Biological|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
79831587|NCT04015570|Biological|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
79831588|NCT04015570|Other|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
79831589|NCT00904462|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
79237679|NCT02387918|Device|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
79237680|NCT04312971|Drug|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
79237681|NCT04312971|Drug|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
79237682|NCT04312971|Other|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
79532312|NCT03227731|Drug|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
79532313|NCT03209349|Procedure|Water Exchange Sigmoidoscopy|See arm description.
79532314|NCT03209349|Procedure|Air Insufflation Sigmoidoscopy|See arm description.
79532315|NCT03203512|Dietary Supplement|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
79532316|NCT03203512|Dietary Supplement|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
79532317|NCT03200015|Drug|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
79532318|NCT03149640|Drug|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
79532319|NCT03149640|Drug|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
80005284|NCT04417998|Drug|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
80005285|NCT04417998|Device|Siemens E7 Reconstruction Tool|Software to correct for motion
79532320|NCT03141736|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
80005286|NCT04414384|Other|Abdominal Binder|Abdominal Binder placement
79237683|NCT04312971|Other|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
79237684|NCT01194596|Behavioral|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
79237685|NCT01194596|Behavioral|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
79237686|NCT02737215|Device|CPAP|patients will receive CPAP therapy with Auto-CPAP
79532321|NCT03141736|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
79532322|NCT03141736|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
79237687|NCT02697123|Other|antepartum and postpartum|This is a prospective observational cohort study.
79831590|NCT00904462|Drug|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
80005287|NCT04414384|Other|Step Counter|step counter to track steps
79237688|NCT03473457|Biological|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
79831591|NCT00396565|Drug|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
79831592|NCT00396565|Drug|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
79237689|NCT05231330|Drug|silvernanoparticles|silvernanoparticles in fluoride varnish
79237690|NCT05231330|Drug|SDF|silver diamine fluoride
79532323|NCT03141736|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
79532324|NCT03098355|Biological|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
79532325|NCT03098355|Drug|Interleukin-2|Interleukin-2 of 250,000iu/m^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
79532326|NCT03090841|Biological|Bio-specimen collected|
79532327|NCT03036423|Behavioral|Online video education|
79532328|NCT03036423|Behavioral|Computerized mental exercises|
79532329|NCT02986334|Drug|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
79831593|NCT00396565|Drug|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
79831594|NCT00925366|Other|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
79831595|NCT00906880|Drug|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
79831596|NCT00925444|Device|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
79831597|NCT00925444|Device|Stapling|Stapling alon or associated with sealants
80005288|NCT04408508|Drug|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
79237691|NCT05305118|Procedure|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
79532330|NCT02986334|Drug|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
79532331|NCT02986334|Drug|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
79532332|NCT02966483|Procedure|TaTME|Transanal Total Mesorectal Excision
79532333|NCT02966483|Procedure|LpTME|Conventional Laparoscopic Total Mesorectal Excision
79532334|NCT02933073|Biological|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
80005289|NCT04399538|Drug|PF-06865571|Tablet
80005290|NCT04399538|Drug|PF-05221304|Tablet
80005291|NCT04399538|Drug|Placebo|Tablet
80005292|NCT04359433|Behavioral|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~8 anerobic movements in 20 seconds is a set~Rest for 10 seconds before another set~Finish 4 sets every time, it shall take you 4 minutes~Do 4 sets 2 to 3 times a week"
79532335|NCT02863718|Drug|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
79532336|NCT02863718|Drug|Placebo|Placebo 420mg daily
79831598|NCT00904852|Drug|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
79831599|NCT00394771|Drug|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
79831600|NCT00394771|Drug|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
79831601|NCT00394771|Drug|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
79831602|NCT00396409|Drug|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
79831603|NCT00396409|Drug|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
79831604|NCT00396409|Drug|Placebo|Placebo given during the 2006 core study
79831605|NCT01323829|Other|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
80005293|NCT04356261|Behavioral|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
79831606|NCT02924376|Drug|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
79831607|NCT00921492|Device|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
79831608|NCT00921492|Other|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
80005294|NCT04342091|Device|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
79831609|NCT02564328|Genetic|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
80005295|NCT04333342|Device|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
80005296|NCT04332731|Device|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
80005297|NCT04332731|Diagnostic Test|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
80005298|NCT04327141|Behavioral|P-IF|Protein pacing and intermittent fasting
80005299|NCT04327141|Behavioral|HH|Heart Healthy
80005300|NCT04316026|Device|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
80005301|NCT04309864|Device|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
80005302|NCT04309864|Device|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
79237692|NCT05305118|Procedure|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
79237693|NCT05675072|Drug|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
79237694|NCT05675072|Drug|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
79378166|NCT02513004|Drug|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
79302749|NCT03072225|Drug|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
79378167|NCT02513004|Drug|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
79378168|NCT04500522|Drug|INH|3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
79831610|NCT03687762|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
79831611|NCT03687762|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
79532337|NCT02836106|Other|Butter|Butter with jam and three slices of bread
79688260|NCT05994027|Behavioral|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
79532338|NCT02836106|Other|Cheese|Cheese with jam and three slices of bread
79532339|NCT02836106|Other|Whipped cream|Whipped cream with jam and three slices of bread
79532340|NCT02836106|Other|Sour cream|Sour cream with jam and three slices of bread
79532341|NCT02813850|Device|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
79532342|NCT02770066|Device|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~Antiplatelet therapy (usually standard)~Cholesterol-lowering drugs (usually standard)~Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~Smoking cessation, diet and physical activity (usually standard)"
79378169|NCT04500522|Drug|Placebo|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
79532343|NCT02679495|Behavioral|Active measures of lifestyle modification|
80005303|NCT04290611|Drug|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
79532344|NCT02668289|Other|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
79688261|NCT05993182|Drug|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension [ Base line time or starting point is first hypotension]
80005304|NCT04283188|Behavioral|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
80005305|NCT04279470|Drug|CAR T-cell and Cellular Therapies|Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
79237695|NCT05116618|Diagnostic Test|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
79237696|NCT03298269|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
79237697|NCT03298269|Behavioral|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
79378170|NCT02507310|Other|thermostat|ambient temperature as modified by thermostat
79378171|NCT03345732|Diagnostic Test|ICG and SPY system for wound complications|
79378172|NCT02513082|Procedure|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
79378173|NCT02507232|Device|NovoTTF-200A|12 cycles
79532345|NCT02668289|Other|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
79302750|NCT03072225|Drug|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
79378174|NCT02507232|Drug|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
79378175|NCT02506998|Biological|DLE|Adjuvant treatment
79378176|NCT02506998|Other|Second generation anti histamines + Nasal corticosteroids|Standard treatment
79532346|NCT02668289|Other|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
79532347|NCT02668289|Other|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
79532348|NCT02668289|Other|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
79532349|NCT02668289|Other|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
79532350|NCT02668289|Other|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
79532351|NCT02668289|Procedure|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
79688262|NCT05993182|Drug|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension [ Base line time or starting point is first hypotension]
79688263|NCT05993182|Drug|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension [ Base line time or starting point is first hypotension]
79688264|NCT05989217|Device|Occlusal Splint|Occlusion Splint
79688265|NCT05989217|Radiation|Laser Therapy|Laser Therapy
79688266|NCT05989113|Other|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
79688267|NCT05982847|Diagnostic Test|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
79532352|NCT02668289|Other|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
79532353|NCT02655315|Drug|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
79688268|NCT05981924|Other|Perioperative Music Therapy|Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
79688269|NCT05978843|Behavioral|Monetary benefit to purchase fruits and vegetables|Participants will receive varying benefit amounts to purchase fruits and vegetables.
79688270|NCT05976477|Other|educational intervention|"four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~Four recipes for tasty easy-to-prepare meals, avoiding added salt."
79831612|NCT03687762|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
79831613|NCT04060836|Drug|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
79831614|NCT04060836|Drug|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
79831615|NCT00693420|Drug|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
79831616|NCT00693420|Drug|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
79831617|NCT00742794|Other|Observation|Observation of sting frequency
79831618|NCT04034524|Drug|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
79831619|NCT04034524|Drug|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
79831620|NCT00925834|Behavioral|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
79831621|NCT04034680|Other|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
79831622|NCT04034680|Other|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
79831623|NCT00925912|Procedure|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
79831624|NCT00925912|Procedure|Perianal block|0.25% bupivacaine injected at perianal region
79831625|NCT04060602|Behavioral|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
79831626|NCT04060602|Behavioral|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
79831627|NCT00904930|Device|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
79831628|NCT00904930|Device|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
79831629|NCT03545256|Procedure|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
79831630|NCT00695136|Drug|Donepezil hydrochloride|
79302751|NCT03212677|Dietary Supplement|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
79532354|NCT02655315|Drug|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
79532355|NCT02436733|Procedure|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
79688271|NCT05975580|Drug|Topiramate|Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
79688272|NCT05975580|Drug|Phentermine|Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
79688273|NCT05975580|Drug|Placebo|Placebo is an inactive substance.
79688274|NCT05969340|Diagnostic Test|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
79688275|NCT05963347|Drug|Golidocitinib|Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
79688276|NCT05963347|Drug|CHOP Regimen|CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
79831631|NCT00695136|Behavioral|Increase REM sleep percentage|
79831632|NCT00905008|Procedure|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis <30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
79831633|NCT00905008|Device|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
79831634|NCT02565420|Other|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
79831635|NCT02565420|Other|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
79831636|NCT00905086|Other|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
79831637|NCT00905086|Procedure|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
79831638|NCT00905086|Procedure|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
79237698|NCT03179475|Drug|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
79831639|NCT00905086|Procedure|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
79831640|NCT00921570|Drug|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
79688277|NCT05945121|Other|Cardio-oncology program|Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
79831641|NCT00921570|Drug|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
79831642|NCT00926068|Drug|HO/03/03 10µg|
79831643|NCT00926068|Drug|Placebo|
79831644|NCT00905242|Drug|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
79831645|NCT02710890|Drug|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
79237699|NCT05115604|Behavioral|cognitive behavioural intervention|Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
79237700|NCT05259267|Behavioral|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
79831646|NCT00742950|Procedure|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
79532356|NCT02436733|Drug|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
79709878|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
79831647|NCT00742950|Procedure|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
79831648|NCT00742950|Procedure|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
79831649|NCT05322642|Behavioral|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
79831650|NCT05322642|Behavioral|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
80005306|NCT04261010|Procedure|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
80005307|NCT04217473|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
79237701|NCT05259267|Behavioral|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
79532357|NCT02426502|Drug|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
79532358|NCT02426502|Drug|conversion of non-immunosuppressant drugs to once daily|"Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
79532359|NCT02426502|Drug|Conversion to once daily MPA|"Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~Patients taking azathioprine will be maintained on the same dose.~Patients will be maintained on the same prednisone dose."
79688278|NCT05943964|Behavioral|Virtual exercise and rehabilitation program|"Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits."
79532360|NCT02360891|Other|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
79688279|NCT05943288|Device|OIP-1|Olympus Endoscopy Computer-Aided Detection (CADe) system
80005308|NCT04204668|Procedure|TMR|Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle
80005309|NCT04204668|Procedure|RPNI|Surgical procedure to wrap the ends of injured nerves in small muscle grafts
79532361|NCT02360683|Other|patients with Parkinson's disease|
79532362|NCT02275156|Biological|Evolocumab|Administered by subcutaneous injection
79532363|NCT02185235|Device|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
79688280|NCT05937724|Other|Family Caregiving|Family caregiving and sibling inclusive
79688281|NCT05934747|Device|DBS|Deep Brain Stimulation
79688282|NCT05928026|Behavioral|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
79688283|NCT05912049|Drug|9MW3811 Injection|Single dose intravenously infused on day 1
80005310|NCT04204668|Procedure|VDMT|Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
80005311|NCT04435340|Diagnostic Test|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
80005312|NCT04181515|Drug|Placebo oral tablet|placebo stressor
79302752|NCT03212677|Dietary Supplement|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
79532364|NCT02185235|Device|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
79532365|NCT02185235|Other|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
79532366|NCT02124902|Drug|Docetaxel|
79532367|NCT02124902|Drug|Carboplatin|
79532368|NCT02124902|Procedure|FDG-PET/MR|"Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~This is not optional for final 30 participants enrolled on the study"
79688284|NCT05912049|Drug|Placebo|Single dose of matching placebo intravenously infused on day 1
79688285|NCT05885438|Behavioral|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
79688286|NCT05880147|Device|Consent App|Family will receive their study information and consent form in an app on a tablet
79688287|NCT05880147|Other|Traditional paper-based consent|Patient/family will receive their study information and consent on a traditional paper form
79688288|NCT05857748|Drug|lifitegrast|patient newly started on medication will be followed for 6 months
80005313|NCT04181515|Drug|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
80005314|NCT04181515|Device|sham rTMS|sham rTMS (inactive coil)
80005315|NCT04181515|Device|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
80005316|NCT04180969|Drug|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
80005317|NCT04180969|Device|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
80005318|NCT04180969|Drug|Placebo oral tablet|placebo stressor
79532369|NCT02067182|Drug|Dabigatran|"Antral pulmonary vein ablation for patients with AF~left atrial fibrosis/electrical scar assessment by electroanatomical mapping~followed by 6 months OAC (3 months blanking period + 3 months observation period)~in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~Experimental arm (group A): OAC with dabigatran for 12 months~Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
79688289|NCT05847517|Drug|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
79237702|NCT02387528|Behavioral|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
79688290|NCT05847517|Drug|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
79831651|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
79237703|NCT02387528|Behavioral|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
79237704|NCT02387528|Other|3- Wait List Control Group|No intervention
79532370|NCT02003612|Other|Not applicable - observational study|No intervention exists as this is a retrospective observational study
79237705|NCT01656850|Other|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
79237706|NCT01656850|Other|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
79237707|NCT03113630|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
79831652|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
79831653|NCT00605176|Drug|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
79237708|NCT03113630|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
79237709|NCT03113630|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
79237710|NCT03113630|Device|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
79831655|NCT00926146|Behavioral|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
80005319|NCT04180969|Device|sham rTMS|sham mPFC rTMS
79237711|NCT03113630|Device|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
80005320|NCT04172649|Other|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
79532371|NCT01940341|Drug|TAF|25 mg tablet administered orally once daily
79532372|NCT01940341|Drug|TDF|300 mg tablet administered orally once daily
79532373|NCT01940341|Drug|TAF Placebo|Tablet administered orally once daily
79532374|NCT01940341|Drug|TDF Placebo|Tablet administered orally once daily
79709879|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
79532375|NCT01877837|Drug|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)]~b) Medications~i.) Alemtuzumab I. Hb S% must be < or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
79688291|NCT05828615|Other|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
79688292|NCT05828615|Other|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
79688293|NCT05826860|Behavioral|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
79688294|NCT05826860|Behavioral|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
79831656|NCT00926146|Behavioral|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
79831657|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
79831658|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
79831659|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
79831660|NCT00905320|Procedure|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
79831661|NCT00905320|Procedure|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
79831662|NCT00926224|Device|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
80005321|NCT04172649|Other|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
80005322|NCT04131725|Device|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
80005323|NCT04128969|Dietary Supplement|CS+|Oral carnitine supplementation
79237712|NCT03113630|Device|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
80005324|NCT04128969|Dietary Supplement|CS-|Placebo
79237713|NCT03177525|Behavioral|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
79237714|NCT03177525|Behavioral|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
80005325|NCT04123470|Genetic|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
80005326|NCT04123470|Biological|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
79237715|NCT03105986|Drug|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
79532376|NCT01877837|Drug|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
79532377|NCT01877837|Drug|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
79532378|NCT01877837|Procedure|Stem Cells|Infusion of Hematopoietic Stem Cells
79532379|NCT01624142|Biological|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
79532380|NCT01539746|Procedure|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
79709880|NCT05015686|Biological|Placebo|Sodium chloride and distilled water
79831663|NCT02538796|Other|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
79831664|NCT02538796|Other|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
80005327|NCT04099810|Diagnostic Test|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
80005328|NCT04097314|Drug|Zibotentan|10mg OD Zibotentan
80005329|NCT04097314|Drug|Placebo oral tablet|Placebo
79237716|NCT03105986|Drug|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
79237717|NCT02391740|Other|Questionnaire|
79237718|NCT02391662|Drug|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 & 15 in a 28 days cycle
79688295|NCT05799976|Behavioral|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
79688296|NCT05797623|Drug|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
79688297|NCT05797623|Drug|Placebo ; ciclosporin|Placebo combined with ciclosporin
80005330|NCT04080518|Drug|Dapagliflozin 10 MG [Forxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
80005331|NCT04074811|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects ~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on >50% of trials.
80005332|NCT04060108|Drug|MDMA|80mg, 120mg, Placebo
80005333|NCT04043936|Behavioral|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
80005334|NCT04043936|Behavioral|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
79237719|NCT02391662|Drug|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
79237720|NCT05076604|Drug|Cardioplegia Solution|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
79237721|NCT05076604|Drug|Microplegic Solution No. 1|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
79237722|NCT02391506|Device|Cartiva|Cartiva Synthetic Cartilage Implant
79237723|NCT05177380|Procedure|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
79688298|NCT05774288|Device|Cera™ patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
79688299|NCT05774288|Device|Another patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
79688300|NCT05753007|Drug|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
80005335|NCT04043936|Behavioral|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, & treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
80005336|NCT04036123|Other|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
79237724|NCT05177380|Other|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
79237725|NCT03116685|Biological|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
79237726|NCT03116685|Other|Placebo|Placebo
79237727|NCT05177068|Drug|fruquintinib + sintilimab + SOX|fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
79688301|NCT05753007|Drug|Placebo|Placebo solution
79532381|NCT01539746|Procedure|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
79688302|NCT05747573|Drug|GB1211|Hard tablet or capsules for oral use
79237728|NCT03058107|Dietary Supplement|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
79237729|NCT03058107|Dietary Supplement|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
80005337|NCT04023773|Device|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
80005338|NCT04017598|Dietary Supplement|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
80005339|NCT04017598|Dietary Supplement|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
80005340|NCT04017598|Dietary Supplement|Placebo of microcrystalline cellulose|placebo
80005341|NCT04014803|Drug|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~Prasugrel plus Aspirin arm~Clopidogrel plus Aspirin arm"
80005342|NCT04011371|Procedure|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
79237730|NCT02391272|Drug|rhTPO|
79237731|NCT05258955|Other|Natural honey|Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
79688303|NCT05746065|Drug|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
79237732|NCT05258955|Drug|Chlorhexidine mouthwash|Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
79532382|NCT01535807|Device|CorMatrix extra cellular matrix (ECM)|"Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
79532383|NCT01375764|Biological|Evolocumab|Administered by subcutaneous injection
79532384|NCT01375764|Drug|Ezetimibe|Administered orally once a day
79532385|NCT01375764|Other|Placebo to Evolocumab|Administered by subcutaneous injection
79688304|NCT05736770|Other|Respiratory rehabilitation and out of bed mobilization|The Respiratory rehabilitation and out of bed mobilization group will perform following exercises: pre operative out of bed mobilization, active cycle breathing techniques, forced expiratory technique and volume based incentive spirometery
79688305|NCT05736770|Other|conventional treatment|The conventional exercise program group will perform :Flow based Incentive spirometery, Chest percussion if needed
79688306|NCT05735080|Drug|INX-315|Oral administration
79688307|NCT05726617|Behavioral|Avatar Intervention|8 weekly sessions of 60 minutes.
79688308|NCT05716386|Dietary Supplement|Low salt diet|Low salt diet less than 2 gram per day
79688309|NCT05714462|Other|meals consisting of primarily animal protein sources|an omnivorous diet
79688310|NCT05714462|Other|meals consisting of plant protein sources|an herbivorous diet
79688311|NCT05714332|Other|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
79688312|NCT05714332|Other|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
79688313|NCT05708989|Procedure|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
79688314|NCT05708989|Procedure|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
79532386|NCT01286038|Drug|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
80005343|NCT04007471|Other|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
80005344|NCT03994302|Drug|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
80005345|NCT03985189|Drug|ME-401|"[Phase 1 study (DLT evaluation)] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~[Roll over study] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
80005346|NCT03978481|Combination Product|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
80005347|NCT03959410|Diagnostic Test|Cervical biopsy|in office Cervical biopsy
80005348|NCT03945903|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
80005349|NCT03943589|Drug|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
80005350|NCT03937219|Drug|Cabozantinib|Specified dose on specified days.
80005351|NCT03937219|Biological|Nivolumab|Specified dose on specified days.
79237733|NCT05174260|Device|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
79378177|NCT01608490|Device|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
80005352|NCT03937219|Biological|Ipilimumab|Specified dose on specified days.
80005353|NCT03937219|Drug|Cabozantinib-matched placebo|Specified dose on specified days.
80005354|NCT03918460|Device|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
80005355|NCT03905148|Drug|Lifirafenib|RAF Dimer Inhibitor
80005356|NCT03905148|Drug|mirdametinib|MEK Inhibitor
80005357|NCT03869268|Drug|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
80005358|NCT03869268|Drug|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
79378178|NCT04500444|Other|exercise training|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
79532387|NCT01253707|Drug|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
79532388|NCT00722046|Biological|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
80005359|NCT03868397|Diagnostic Test|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
80005360|NCT03845465|Behavioral|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
80005361|NCT03845465|Behavioral|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
80005362|NCT03843463|Drug|Escitalopram 10mg|Escitalopram tablet
80005363|NCT03843463|Drug|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
80005364|NCT03843463|Behavioral|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
79378179|NCT04498338|Other|Neural mobilization combined with conventional physical therapy program|Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.
79378180|NCT04498338|Other|Conventional physical therapy program|TENs and exercise program applied 3 times/week for successive 6 weeks.
79378181|NCT02507076|Drug|isolated limb perfusion|Undergo ILP with melphalan
79532389|NCT00722046|Biological|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
80005365|NCT03828942|Drug|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
80005366|NCT03826433|Biological|Peripheral iv|6*10^7 cells
80005367|NCT03816852|Biological|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
79237734|NCT02391194|Drug|AVB-620|
79532390|NCT00722046|Biological|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
79532391|NCT00722046|Drug|Placebo|Placebo every 60 days (10 doses total)
79532392|NCT00722046|Biological|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
79237735|NCT02391428|Procedure|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
79237736|NCT02391428|Dietary Supplement|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
79532393|NCT00722046|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
79237737|NCT03034863|Behavioral|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
79237738|NCT03034863|Behavioral|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
79237739|NCT05173324|Biological|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
79831665|NCT02538796|Other|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
79831666|NCT02538796|Other|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
79237740|NCT05173324|Diagnostic Test|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
79532394|NCT00614523|Drug|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
79831667|NCT00905398|Drug|Nilotinib|400mg, Oral, Bid, Daily for three years
79237741|NCT05173324|Biological|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
79378182|NCT02507076|Drug|melphalan|Undergo ILP with melphalan
79532395|NCT00614523|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
79532396|NCT00523341|Biological|Denosumab|Administered by subcutaneous injection once every 6 months.
79831668|NCT00905710|Procedure|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
79378183|NCT02507076|Procedure|quality-of-life assessment|Ancillary studies
79378184|NCT01609348|Drug|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
79378185|NCT01609348|Drug|Venlafaxine|225 mg daily for 12 weeks
79378186|NCT04500678|Drug|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
79378187|NCT02992366|Procedure|implant placement|implant placement
79378188|NCT02515812|Drug|I-123-MIBG|
79378189|NCT02515812|Device|CZT Camera (D-SPECT)|
79532397|NCT00364013|Drug|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
79831669|NCT00926302|Drug|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
79378190|NCT02515812|Device|Anger Camera|
79831670|NCT00926302|Drug|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
79532398|NCT00364013|Drug|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m^2 IV bolus followed by 600 mg/m^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
79831671|NCT00907036|Biological|alemtuzumab|
79532399|NCT00345839|Drug|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
79709881|NCT02881645|Behavioral|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
79831672|NCT00907036|Biological|donor lymphocytes|
79831673|NCT00907036|Drug|cyclosporine|
79831674|NCT00907036|Drug|fludarabine phosphate|
79709882|NCT04327245|Other|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
79831675|NCT00907036|Drug|melphalan|
79688315|NCT05708989|Drug|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
79831676|NCT00907036|Procedure|allogeneic hematopoietic stem cell transplantation|
79688316|NCT05708989|Drug|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
79831677|NCT02538406|Other|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
79831678|NCT00905788|Procedure|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
79831679|NCT00927238|Device|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
80005368|NCT03808467|Behavioral|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
80005369|NCT03808467|Other|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
80005370|NCT03796104|Other|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
79237744|NCT04223518|Dietary Supplement|Serum bovine immunoglobulin|Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of >90% protein which consists primarily of immunoglobulins (>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
79237745|NCT04223518|Dietary Supplement|Placebo|Hydrolyzed Collagen
79237746|NCT03478995|Drug|GX-I7|GX-I7 25mg/ml/vial
79237747|NCT02387450|Drug|Sildenafil|100 mg per day
79237748|NCT02387450|Drug|Placebo|Placebo with same presentation as the active drug
79237749|NCT04223440|Other|MRI|MRI on both shoulder
79237750|NCT04223440|Other|ultrasonographic explorations|ultrasound and elastography explorations on both shoulder
79237751|NCT04458675|Device|Vibrant capsule|The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
79688317|NCT05705440|Biological|RSVPreF3 vaccine|No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
79831680|NCT00927238|Other|Lumbar fusion surgery|Lumbar fusion surgery
79831681|NCT00926614|Drug|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
80005371|NCT03705156|Drug|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
79237752|NCT04458675|Drug|Placebo|A biodegradable capsule, which visually similar to the Vibrant active capsule
79237753|NCT04009395|Other|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
79831682|NCT00926614|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
79831683|NCT00694356|Biological|Dalotuzumab|IV infusion
79378191|NCT02512770|Procedure|endoscopic dilatation|
79831684|NCT00926692|Other|Blood draw|Subject will have blood draw.
79378192|NCT02506920|Dietary Supplement|Six different types of fat in a meal in random order|Oral fat tolerance test
79378193|NCT02512458|Drug|Cabazitaxel|
79831685|NCT00907114|Drug|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
79378194|NCT02515578|Other|Enhanced practice transformation support|
79831686|NCT00907114|Drug|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
79831687|NCT00692406|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
79378195|NCT02515578|Other|Standard practice transformation support|
79378196|NCT02507154|Drug|Cetuximab + NK cells|
79378197|NCT02515734|Drug|fluorouracil|
79378198|NCT02515734|Drug|Leucovorin|
79378199|NCT02515734|Drug|irinotecan|
79378200|NCT02515734|Drug|oxaliplatin|
79831688|NCT00927316|Biological|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
80005372|NCT03705156|Drug|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
80005373|NCT03686371|Procedure|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
80005374|NCT03667339|Procedure|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
80005375|NCT03660930|Drug|Sirolimus Albumin-bound Nanoparticles|Given IV
80005376|NCT03660930|Drug|Pazopanib hydrochloride|Given PO
79831689|NCT03889938|Diagnostic Test|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
79831690|NCT03415464|Other|Exercise|neuromuscular training
79378201|NCT02515734|Biological|bevacizumab|
79532400|NCT00345839|Drug|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
79532401|NCT00330759|Biological|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
79532402|NCT00330759|Drug|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
79532403|NCT00113763|Other|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
80005377|NCT03643796|Drug|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
80005378|NCT03643796|Drug|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
79532404|NCT00113763|Drug|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
79688318|NCT05705440|Other|Control|No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
80005379|NCT03643796|Drug|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
80005380|NCT03623854|Biological|Nivolumab|Given IV
79688319|NCT05694507|Other|Mental Well-being Chatbot|The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
80005381|NCT03623854|Biological|Relatlimab|Given via infusion
80005382|NCT03592264|Drug|OBI-3424|liquid formulation for Intravenous infusion
80005383|NCT03584334|Radiation|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
80005384|NCT03575884|Behavioral|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
79378202|NCT02515734|Biological|cetuximab|
79378203|NCT02506608|Procedure|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
79532405|NCT00102323|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
79831691|NCT03384108|Other|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
79831692|NCT03384108|Other|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
79831693|NCT02564094|Drug|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
79831694|NCT00745914|Drug|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
79831695|NCT00745914|Drug|Placebo comparator|Placebo comparator
79831696|NCT00746070|Other|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
79378204|NCT02512536|Drug|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
79831697|NCT00746148|Other|Reflexology|10 weekly sessions of 45 minutes each
79831698|NCT00746226|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10^9 CFU of a combination of L. acidophilus and B. lactis
79831699|NCT00746226|Biological|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
79831700|NCT00396331|Drug|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2*10^6 CD34+ cells/kg were collected.
79378205|NCT02506842|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
79532406|NCT00102323|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
79532407|NCT01438359|Drug|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
80005385|NCT03560167|Device|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
80005386|NCT03531892|Drug|AJM300|AJM300 film-coated tablets.
80005387|NCT03531892|Drug|Placebo|Placebo matched to AJM300 tablets.
80005388|NCT03531502|Procedure|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
80005389|NCT03531502|Other|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
80005390|NCT03531502|Procedure|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
79532408|NCT01438359|Drug|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
79532409|NCT01438359|Drug|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
79532410|NCT01438372|Drug|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
79532411|NCT01438372|Drug|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
79688320|NCT05682079|Other|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
79688321|NCT05682014|Behavioral|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
79688322|NCT05678972|Other|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
79688323|NCT05669833|Drug|Guselkumab|Guselkumab (GUS) subcutaneous injection
79688324|NCT05669833|Drug|Golimumab|Golimumab (GOL) subcutaneous injection
79688325|NCT05669833|Drug|Placebo|Guselkumab (GUS) matching placebo subcutaneous injection
79688326|NCT05661097|Procedure|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
80005391|NCT03530215|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
79532412|NCT01438385|Procedure|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
80005392|NCT03520075|Drug|ASTX029|Described above
80005393|NCT03475277|Drug|Ketamine|Acute administration
80005394|NCT03472274|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
80005395|NCT03472274|Drug|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
80005396|NCT03472274|Drug|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~Methotrexate 30mg/m2 intravenously on day 1~Vinblastine 3mg/m2 intravenously on day 2~Doxorubicin 30mg/m2 intravenously on day 2~Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~Paclitaxel 80 mg/m2 intravenously on day 1 and 8~Cisplatin 70mg/m2 intravenously on day 1"
79831701|NCT00927550|Drug|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
79831702|NCT00927550|Drug|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
79831703|NCT00926926|Drug|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
79831704|NCT00926926|Drug|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
79831705|NCT00396253|Drug|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
79831706|NCT00927628|Procedure|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
79831707|NCT00927706|Device|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
79831708|NCT00927004|Drug|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
80005397|NCT03456284|Device|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
79237754|NCT04009395|Other|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
79237755|NCT02666222|Device|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
79237756|NCT03473067|Behavioral|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
79688327|NCT05660577|Device|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
79237757|NCT03473067|Other|Capacity Building|Schools will participate in teacher training and parent training.
79237758|NCT00739401|Device|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
79688328|NCT05657496|Drug|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
79688329|NCT05657496|Biological|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
80005398|NCT03437928|Device|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
79237759|NCT02390882|Drug|Placebo|Placebo
79378206|NCT02506842|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
79378207|NCT02506842|Drug|oxaliplatin|Patients receive oxaliplatin 85 mg/m^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
79378208|NCT02506842|Drug|folinic acid|Patients receive folinic acid 200 mg/m^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
79831709|NCT00927004|Drug|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
79831710|NCT00604162|Device|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
80005399|NCT03436433|Drug|Lacosamide|LCM 100mg twice a day.
80005400|NCT03436433|Drug|Levetiracetam|LEV 1000mg twice a day.
80005401|NCT03432832|Behavioral|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
79237760|NCT02390882|Drug|HGP0412 capsule|Tamsulon high dose
79237761|NCT02390882|Drug|HIP1402 capsule|Tamsulon high dose
79237762|NCT02390570|Other|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
79237763|NCT02387138|Drug|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
79237764|NCT02387138|Drug|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
79237765|NCT02387138|Drug|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
79237766|NCT02387138|Other|G-csf|G-csf : d8 to d13 systematically
79237767|NCT05258643|Other|Blood analysis|Venipuncture and collection of serum and whole blood
80005402|NCT03432832|Behavioral|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
80005403|NCT03425318|Device|CNAP|Application of CNAP in patients with ARDS
80005404|NCT03405090|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
79532413|NCT01438398|Procedure|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
79532414|NCT01438398|Procedure|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
79532415|NCT01438437|Procedure|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
80005405|NCT03405090|Drug|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
80005406|NCT03383081|Biological|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml);
79532416|NCT01438437|Procedure|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
79532417|NCT01438450|Drug|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
79532418|NCT01438450|Other|Supportive|No specific therapy will be given
79237768|NCT02386982|Drug|HMS5552|
79532419|NCT01438463|Biological|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
79532420|NCT01438463|Biological|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
79532421|NCT01438463|Biological|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
79532422|NCT01438463|Biological|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
79532423|NCT01438463|Biological|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
79532424|NCT01438502|Drug|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
79532425|NCT01438515|Drug|Rifampin|600mg po once daily x 7 days
79532426|NCT01438515|Drug|Doxycycline|100mg po twice daily x 7 days
79688330|NCT05627063|Drug|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
79532427|NCT01438515|Other|2% mupirocin ointment|~ 1cm applied to the anterior nares twice daily for 7 days
80005407|NCT03383081|Biological|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml)
80005408|NCT03383081|Procedure|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
80005409|NCT03378414|Procedure|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml)
80005410|NCT03378414|Procedure|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml)
80005411|NCT03378414|Biological|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
79237769|NCT03418857|Drug|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
79237770|NCT03418857|Drug|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
79237771|NCT02387060|Drug|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
79237772|NCT02387060|Drug|Fentanyl|Intrathecal administration of fentanyl 25 mcg
79237773|NCT01365052|Drug|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
79237774|NCT01365052|Drug|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
79831711|NCT00604162|Procedure|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
79831712|NCT02538328|Device|Harmonic scapel|different surgical devices used in the obesity surgery
80005412|NCT03350243|Other|CCENT Intervention|"Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
80005413|NCT03324360|Drug|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
79237775|NCT05155215|Biological|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level: 100×10^6 CAR-T cells or 200×10^6 CAR-T cells
79237776|NCT05155215|Drug|Cyclophosphamide|300 mg/m^2 per day for 3 days (IV)
79378209|NCT02506842|Drug|fluorouracil|Patients receive fluorouracil 2000 mg/m^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
79688331|NCT05609929|Drug|Multiple administration of omeprazole Single administration of AB-106|Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
80005414|NCT03284307|Drug|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
80005415|NCT03284307|Drug|Ketamine|20 participants will be administered Ketamine.
80005416|NCT03284307|Drug|Propofol|20 participants will be administered Propofol.
80005417|NCT03284307|Drug|Midazolam|20 participants will be administered Midazolam.
79378210|NCT02512614|Other|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
79378211|NCT04500054|Other|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
79378212|NCT03345498|Drug|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
79378213|NCT04497558|Diagnostic Test|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
79831713|NCT02538328|Device|Ligasure|Bipolar vessel sealing system used in obesity surgery
80005418|NCT03279289|Drug|Aflibercept|4 mg/kg administered intravenous infusion on day 1
80005419|NCT03279289|Drug|Irinotecan|180 mg/m2 intravenous infusion
80005420|NCT03279289|Drug|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
79237777|NCT05155215|Drug|Fludarabine|30 mg/m^2 per day for 3 days (IV)
79237778|NCT03471585|Drug|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
79237779|NCT03471585|Drug|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
79237780|NCT02386904|Drug|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
79302753|NCT03212677|Dietary Supplement|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
79378214|NCT03121638|Biological|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
79378215|NCT03121638|Biological|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
79378216|NCT03121638|Biological|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
79378217|NCT03121638|Biological|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
79532428|NCT01438515|Other|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
79532429|NCT01438528|Device|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
79532430|NCT01438554|Drug|Pazopanib|
79532431|NCT01438554|Drug|GSK1120212|
79532432|NCT01438567|Drug|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
79831714|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
79831715|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
79831716|NCT00907192|Behavioral|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
79831717|NCT00907192|Behavioral|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
80005421|NCT03279289|Drug|5Fluorouracil|400 mg/m2 intravenous bolus
80005422|NCT03279289|Drug|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
80005423|NCT03265535|Diagnostic Test|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
80005424|NCT03207867|Drug|NIR178|NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.
79688332|NCT05607459|Other|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
79688333|NCT05607459|Behavioral|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
79831718|NCT05277610|Diagnostic Test|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
79831719|NCT04014946|Device|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
79831720|NCT00931450|Drug|exemestane|Given orally
79831721|NCT00931450|Drug|sunitinib malate|Given orally
79831722|NCT00931450|Other|placebo|Given orally
80005425|NCT03207867|Drug|PDR001|PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
80005426|NCT03186456|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.
80005427|NCT03186456|Drug|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
79237781|NCT05171608|Procedure|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
79532433|NCT01438567|Drug|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
79831723|NCT00928330|Drug|GDC-0941|Oral repeating dose
80005428|NCT03184935|Biological|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
79302754|NCT03212677|Other|Placebo|Cornstarch
79831724|NCT00928330|Drug|Trastuzumab|Intravenous repeating dose
79831725|NCT00928330|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
79831726|NCT00928798|Drug|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
79831727|NCT00928798|Drug|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
79831728|NCT00931840|Drug|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
79831729|NCT00932074|Drug|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
80005429|NCT03184935|Drug|Decitabine|Decitabine，20mg/m^2/d
80005430|NCT03180463|Drug|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells,
80005431|NCT03180463|Procedure|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
80005432|NCT03180450|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
80005433|NCT03180450|Drug|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
80005434|NCT03176498|Biological|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
80005435|NCT03176498|Drug|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
79378218|NCT03121638|Biological|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
79532434|NCT01438580|Drug|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
79532435|NCT01438580|Drug|aspirin|100mg aspirin was administrated every day
79532436|NCT01438593|Procedure|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
79532437|NCT01438606|Biological|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
79532438|NCT01438606|Biological|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
79831730|NCT04034368|Drug|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
79831731|NCT00907270|Dietary Supplement|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
80005436|NCT03126591|Drug|Olaratumab|Administered IV
80005437|NCT03126591|Drug|Pembrolizumab|Administered IV
80005438|NCT03107000|Procedure|Trabeculectomy|Incisional surgery for glaucoma
80005439|NCT03107000|Procedure|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
79688334|NCT05607459|Other|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
79688335|NCT05607459|Other|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
79831732|NCT00907348|Drug|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
80005440|NCT03094832|Drug|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
80005441|NCT03085004|Drug|Ethanol|The cyst will be lavaged for 3 to 5 minutes using >/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
80005442|NCT03085004|Drug|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
80005443|NCT03085004|Drug|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
80005444|NCT03082716|Drug|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
80005445|NCT03082716|Drug|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
80005446|NCT03069287|Behavioral|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
80005447|NCT03059862|Dietary Supplement|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
80005448|NCT03059862|Dietary Supplement|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
79831733|NCT00375505|Drug|Zoledronic acid|
79831734|NCT00375505|Drug|Placebo|Placebo
79831735|NCT00928876|Drug|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
80005449|NCT03037723|Other|CT simulation|
79378219|NCT02506686|Drug|Meropenem|Meropenem i.v.
80005450|NCT03036579|Device|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
80005451|NCT03034811|Device|Persona Partial Knee system|Fixed bearing partial knee
79378220|NCT02515500|Behavioral|Gradual Cessation|
79378221|NCT02515500|Behavioral|Gradual Cessation w/ Quitbit|
79378222|NCT04499742|Radiation|Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.|Patients will be undergoing Standard of Care procedure EAGBT for collection of duodenal fluid (aspirate and culture) and placement of a catheter into the duodenum. This catheter will be used for infusion of glucose isotope into the small bowel. Subsequently Standard of Care nuclear medicine imaging will be used to track the location of the isotope in the gut.
79378223|NCT02512380|Drug|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
79688336|NCT05607407|Drug|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
79688337|NCT05607407|Procedure|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
79688338|NCT05607407|Diagnostic Test|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
79688339|NCT05600036|Drug|ESK-001|Oral tablet
79688340|NCT05600036|Drug|Placebo|Oral tablet
79831736|NCT00928876|Drug|Placebo|placebo s/c daily for four weeks
79831737|NCT00907504|Drug|CP-751,871|CP-751,871 20mg/kg every 3 weeks
80005452|NCT03015844|Drug|131-I-meta-iodobenzylguanidine|
80005453|NCT02916862|Dietary Supplement|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
79831738|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
79831739|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
80005454|NCT02916862|Combination Product|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
80005455|NCT02916862|Dietary Supplement|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
79831740|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
79831741|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
79831742|NCT00932230|Other|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
79831743|NCT00929032|Radiation|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
79831744|NCT00932308|Dietary Supplement|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
79831745|NCT00932308|Dietary Supplement|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
80005456|NCT02916862|Combination Product|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
80005457|NCT02891447|Drug|Cisplatin|Given intraperitoneally
80005458|NCT02891447|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
80005459|NCT02891447|Drug|Mitomycin|Given intraperitoneally
80005460|NCT02867761|Drug|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
79532439|NCT01438632|Device|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
79532440|NCT01438645|Device|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
79532441|NCT01438671|Procedure|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
79831746|NCT00932386|Drug|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
79831747|NCT00932386|Drug|normal saline|0.9% normal saline infusing
80005461|NCT02867761|Drug|Placebo|27.5/15.6 mcg placebo
80005462|NCT02858050|Device|Portal-724 MEMs Cap|
80005463|NCT02740790|Biological|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
80005464|NCT02740790|Biological|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
79831748|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose under fasted conditions
79831749|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
79831750|NCT00932542|Drug|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
80005465|NCT02740777|Biological|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
80005466|NCT02719990|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
80005467|NCT02680626|Drug|Magnesium Sulfate|Given via transversus abdominis plane block
80005468|NCT02680626|Drug|Ropivacaine|Given via transversus abdominis plane block
80005469|NCT02576483|Behavioral|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
80005470|NCT02573415|Procedure|Uterus Transplant|transplant of a deceased donor uterus.
80005471|NCT02494583|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
80005472|NCT02494583|Drug|Cisplatin|Cisplatin 80 mg/m^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
80005473|NCT02494583|Drug|5-FU|5-FU 800 mg/m^2/day IV continuous from Day 1-5 of each 3-week cycle.
80005474|NCT02494583|Drug|Capecitabine|Capecitabine 1000 mg/m^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
80005475|NCT02494583|Drug|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
79378224|NCT02512380|Drug|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
79378225|NCT02512146|Procedure|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
79378226|NCT04497792|Drug|Empagliflozin 10Mg Tab|Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
79378227|NCT04497792|Drug|hypoglycemic therapy|hypoglycemic therapy.
79378228|NCT02506530|Procedure|intensive decongestive treatment|intensive decongestive treatment
79378229|NCT02506530|Device|Cellu M6|Use of Cellu M6
79378230|NCT02511990|Biological|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
79831751|NCT00932542|Drug|placebo|placebo
79831752|NCT00932542|Drug|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
79831753|NCT00907582|Procedure|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
79831754|NCT05277454|Drug|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
79831755|NCT00907660|Behavioral|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
79831756|NCT00907660|Dietary Supplement|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
80005476|NCT02466841|Procedure|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
80005477|NCT02371447|Drug|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
79532442|NCT01438671|Procedure|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
80005478|NCT02359799|Device|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
79688341|NCT05594628|Other|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
79688342|NCT05594563|Drug|DFMO|DFMO orally twice a day
79688343|NCT05594563|Drug|Placebo|Placebo orally twice a day
79688344|NCT05591755|Drug|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
79688345|NCT05591755|Drug|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
79688346|NCT05591755|Drug|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
80005479|NCT02359331|Procedure|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
79688347|NCT05591755|Drug|Experimental: Vehicle ophthalmic solution (n = 56)|Experimental: Vehicle ophthalmic solution (n = 56)
79688348|NCT05591144|Drug|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose for 5 days, followed by a taper every 2 days
80005480|NCT02359331|Drug|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
80005481|NCT02359331|Drug|Metronidazole|
79532443|NCT01438684|Drug|RPh201|400 microliter s.c. twice a week for 3 months
79532444|NCT01438684|Drug|Saline|400 microliter Saline solution s.c. twice a week for 3 months
79688349|NCT05591144|Drug|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
80005482|NCT02359331|Drug|Tetracycline|
80005483|NCT02359331|Drug|tripotassium dicitrate bismuthate|
79532445|NCT01438697|Behavioral|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
79532446|NCT01438697|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
79831757|NCT00375427|Drug|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
80005484|NCT02359331|Drug|7 days tailored therapy Proton Pump Inhibitor|
80005485|NCT02359331|Drug|Moxifloxacin|
80005486|NCT02359331|Drug|Amoxicillin|
80005487|NCT02322814|Drug|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
80005488|NCT02322814|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
79532447|NCT01438723|Drug|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
79688350|NCT05587478|Drug|EDP-323|Oral administration
79688351|NCT05587478|Drug|Placebo|Placebo to match EDP-323, oral administration
79688352|NCT05585229|Drug|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
79688353|NCT05579730|Drug|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
79688354|NCT05579730|Drug|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
79688355|NCT05579730|Drug|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
79688356|NCT05579730|Drug|Vehicle ophthalmic solution|Vehicle ophthalmic solution
79831758|NCT00929266|Biological|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
79831759|NCT04014634|Drug|Methylprednisolone|Single GON injection with methylprednisolone
79831760|NCT04014634|Other|Placebo|Single GON-injection with NaCl
79831761|NCT01043575|Drug|Rifapentine|During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants < 45 kg participants will receive 450 mg orally given 5 days per week
79831762|NCT01043575|Drug|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
79831763|NCT00932776|Device|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
79831764|NCT00932776|Device|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
79831765|NCT00393913|Device|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
80005489|NCT02322814|Drug|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
80005490|NCT02322814|Drug|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
79378231|NCT02511990|Biological|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
79688357|NCT05579262|Dietary Supplement|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
79688358|NCT05557071|Behavioral|Digital Health Behaviour Change Platform|"Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect."
79688359|NCT05548361|Combination Product|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
79831766|NCT04437238|Other|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
80005491|NCT02322814|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
80005492|NCT02234947|Procedure|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
79378232|NCT02511990|Biological|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
79378233|NCT02506218|Dietary Supplement|10 + 20 g protein consumption|whey isolate
79688360|NCT05548361|Combination Product|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
79378234|NCT02506218|Other|30 g protein breakfast|30 g mixed meal breakfast
79378235|NCT02506218|Other|10 g protein breakfast|10 g mixed meal breakfast
79378236|NCT03345264|Behavioral|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
79378237|NCT02511834|Device|VEST External Support|
79378238|NCT02511834|Procedure|Coronary Artery Bypass Surgery|
79378239|NCT02511912|Procedure|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
79378240|NCT04497714|Diagnostic Test|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
79378241|NCT03344952|Drug|Botulinum toxin type A|Repeated injections to hypertonic muscles
79378242|NCT03344952|Other|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
79378243|NCT02511756|Device|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
79378244|NCT02515266|Other|nutrition: protein intake|additional protein fortification of human milk
79532448|NCT01438723|Drug|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
79532449|NCT01438736|Drug|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
79532450|NCT01438736|Drug|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
79688361|NCT05548361|Combination Product|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
79831767|NCT04437238|Other|Control - Usual care|Participants allocated to the control condition will receive care as usual.
79831768|NCT01045837|Drug|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
79831769|NCT01045837|Behavioral|Gluten free diet|Only gluten free diet will be given in this group
79237784|NCT02523261|Procedure|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
79237785|NCT02523261|Procedure|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
79237786|NCT05072782|Drug|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
79237787|NCT05072782|Drug|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
79532451|NCT01438749|Drug|Placebo|Single dose
79237788|NCT05109754|Device|BiPAP EFL|Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD
79237789|NCT03379389|Drug|Methenamine + Methylthioninium|Methenamine + Methylthioninium
79237790|NCT03379389|Drug|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
79237791|NCT03379389|Drug|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
79688362|NCT05542667|Combination Product|Giomer varnish|After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
79688363|NCT05542667|Combination Product|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
79237792|NCT05170438|Drug|Lenvatinib Pill,Paclitaxel|Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.
79532452|NCT01438749|Drug|RO4917838|Single doses (3 dose levels)
79237793|NCT01372748|Other|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
79237794|NCT01372748|Other|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
79237795|NCT05109520|Drug|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
79237796|NCT03478605|Drug|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
79237797|NCT03478605|Drug|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
79237798|NCT03478605|Drug|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
79237799|NCT03478605|Drug|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
79688364|NCT05537428|Behavioral|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
79237800|NCT03478527|Dietary Supplement|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
79237801|NCT03478527|Other|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
79831770|NCT00932854|Procedure|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
79831771|NCT00933088|Other|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
79831772|NCT00567268|Drug|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
79831773|NCT00907894|Drug|LDT600 (Telbivudine)|LDT600 (Telbivudine)
79831774|NCT03976648|Drug|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
79532453|NCT01438749|Drug|diazepam|Single dose
79532454|NCT01438762|Behavioral|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
79831775|NCT04014556|Device|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
80005493|NCT02170168|Other|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
79688365|NCT05533671|Procedure|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
80005494|NCT02161263|Other|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
80005495|NCT01922791|Dietary Supplement|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
80005496|NCT01904188|Device|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)|The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
80005497|NCT01837862|Drug|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
80005498|NCT01837862|Drug|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients < 12kg: 0.05 mg/kg; for patient > 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
80005499|NCT01837862|Drug|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
80005500|NCT01837862|Drug|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
79237802|NCT03673475|Procedure|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
79237803|NCT02386748|Dietary Supplement|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
79237804|NCT02386748|Dietary Supplement|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
79237805|NCT02386748|Other|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
79237806|NCT05054062|Diagnostic Test|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
79237807|NCT02736825|Device|Ulthera System with standard transducer|Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
79532455|NCT01438762|Other|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
79532456|NCT01438788|Other|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
79688366|NCT05533671|Procedure|Non-operative group|Physical therapy by following a specific regimen.
79688367|NCT05532189|Procedure|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
79688368|NCT05532189|Procedure|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
79831776|NCT04014556|Drug|Aflibercept|Aflibercept
79831777|NCT00929812|Drug|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
79831778|NCT00929812|Drug|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
79831779|NCT00933322|Dietary Supplement|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
79237808|NCT02736825|Device|Ulthera System with prototype 2 simulines transducer|Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
79237809|NCT04439708|Other|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
79688369|NCT05532189|Other|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
79831780|NCT00933322|Dietary Supplement|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
79688370|NCT05532150|Procedure|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
79831781|NCT00933322|Dietary Supplement|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
80005501|NCT01837862|Drug|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
79378245|NCT02506452|Other|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
79378246|NCT02506452|Other|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
79831782|NCT00933400|Procedure|CT Coronary Angiography|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
79831783|NCT00933400|Procedure|Traditional, Standard of Care|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
79688371|NCT05532150|Procedure|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
79831784|NCT00907972|Dietary Supplement|Vitamin D3|Vitamin D3
79688372|NCT05528588|Combination Product|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
79688373|NCT05528588|Drug|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
79688374|NCT05524532|Dietary Supplement|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
79688375|NCT05524532|Dietary Supplement|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules
79688376|NCT05501717|Drug|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
79688377|NCT05501717|Drug|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
79688378|NCT05481684|Other|Normal Progesterone group|No progesterone supplementation
79831785|NCT00907972|Other|Placebo|Placebo
79831786|NCT03799744|Genetic|VCN-01|Dose level 1: 3.3x10^12 viral particles/patient and Dose level 2: 1x10^13 viral particles/patient
79831787|NCT03799744|Biological|Durvalumab|Dose: 1500 mg Q4W
79831788|NCT00933478|Device|Clay|Small dime sized piece of clay.
80005502|NCT01837862|Drug|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
79237810|NCT02390804|Device|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
79237811|NCT02390804|Device|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
80005503|NCT01675219|Procedure|white light TUR-BT|traditional transurethral bladder tumor resection
80005504|NCT01675219|Procedure|blue light TUR-BT|photodynamic transurethral bladder tumor resection
79302755|NCT04991259|Procedure|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
79378247|NCT02515422|Drug|Ketamine|Subcutaneous infiltration of ketamine
79378248|NCT02515422|Drug|Bupivacaine|Subcutaneous infiltration of bupivacaine
79378249|NCT02515422|Drug|Placebo (0.9% saline solution)|
80005505|NCT01675219|Drug|optimized MMC|six weekly optimized mitomycin-C instillations
80005506|NCT01675219|Drug|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
79378250|NCT02515344|Other|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
79378251|NCT02515344|Other|Providing general information about CRC sreening|
79378252|NCT02506296|Drug|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
79688379|NCT05481684|Other|Low Progesterone group|Progesterone level <10 ng/mL on ET day. If serum progesterone levels were <10 ng/ml at ET day, vaginal pills (Lutinus 2*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
79688380|NCT05477420|Other|Decision Aid|Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
79831789|NCT00933556|Dietary Supplement|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
79831790|NCT00933556|Dietary Supplement|sugar pill (placebo)|placebo identical to the active product will be given
79831791|NCT00929890|Behavioral|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
79831792|NCT00929890|Behavioral|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
79831793|NCT04015258|Dietary Supplement|Blueberries|fresh spanish blueberries
79831794|NCT04015258|Dietary Supplement|Blueberry powder|freeze-dried blueberry powder
79831795|NCT04015258|Dietary Supplement|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
79831796|NCT00933634|Procedure|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
79831797|NCT00933634|Drug|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
79831798|NCT00933712|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
80005507|NCT01436227|Other|Laboratory Biomarker Analysis|Correlative studies
80005508|NCT01436227|Drug|Pazopanib Hydrochloride|Given PO
79831799|NCT00933790|Drug|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
79237812|NCT05071066|Other|ADHD+|"The group-based intervention is designed to reduce participants' ADHD and related symptoms. The content of the treatment will follow an established manual which is developed by an expert group comprised of psychiatrists and clinical psychologists. Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months. The post- intervention assessments (3-month [T1], and 6-month [T2]) will be administered to all participants. During the period of intervention, all participants shall be clean from other forms of interventions to reduce any other possible confounders."
79237813|NCT05672498|Drug|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
79237814|NCT05672498|Other|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
79378253|NCT02506296|Device|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
79378254|NCT02506140|Drug|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
79831800|NCT02538250|Dietary Supplement|Nutricomp Drink Plus|Oral nutritional supplementation
79831801|NCT00930124|Procedure|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
80005509|NCT01333033|Drug|Oxaliplatin|Given IV
80005510|NCT01333033|Drug|Leucovorin Calcium|Given IV
80005511|NCT01333033|Drug|Fluorouracil|Given IV
80005512|NCT01333033|Drug|Carboplatin|Given IV
79378255|NCT02506140|Drug|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
79688381|NCT05473715|Drug|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
79831802|NCT00930124|Procedure|Distraction osteogenesis|
79831803|NCT00566254|Drug|Zonisamide|8mg/kg per day for approximately 24 weeks.
79831804|NCT00566254|Drug|Placebo|
79831805|NCT00930202|Drug|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
80005513|NCT01333033|Drug|Paclitaxel|Given IV
80005514|NCT01333033|Procedure|Positron Emission Tomography|Undergo PET/CT scan
80005515|NCT01333033|Procedure|Computed Tomography|Undergo PET/CT scan
79378256|NCT02515188|Drug|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
79378257|NCT02515188|Drug|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
80005516|NCT01333033|Radiation|Radiation Therapy|Undergo RT
80005517|NCT01327690|Behavioral|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
80005518|NCT01327690|Behavioral|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
80005519|NCT01192776|Procedure|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
80005520|NCT01169831|Other|Exercise Training|2 weeks of daily aerobic exercise training
79688382|NCT05470933|Drug|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
79831806|NCT00933868|Drug|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
79831807|NCT00933868|Drug|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
79831808|NCT00908206|Drug|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
79688383|NCT05468970|Other|NO Intervention|NO Intervention
79688384|NCT05455008|Behavioral|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
79831809|NCT00393523|Biological|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
80005521|NCT01169831|Other|Exercise Cessation|Stopping all exercise for 2 weeks
79237815|NCT03478449|Procedure|lymph node sorting for pathological examination|In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
79831810|NCT00393523|Biological|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
79378258|NCT02506062|Device|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
79378259|NCT02505672|Radiation|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
79378260|NCT01696084|Drug|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
79831811|NCT03993067|Procedure|Hemopatch|Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
79532457|NCT01438801|Drug|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS <0).
79831812|NCT03993067|Procedure|Fribrin glue and Tabotamp|Fibrin glue and Tabotampis the standard treatment
79831813|NCT00393367|Drug|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
79831814|NCT00393367|Drug|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
79831815|NCT00393367|Drug|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
80005522|NCT00904241|Other|Cytology Specimen Collection Procedure|Correlative studies
80005523|NCT00904241|Other|Laboratory Biomarker Analysis|Correlative studies
80005524|NCT00778063|Drug|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
80005525|NCT00778063|Drug|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
80005526|NCT00737399|Behavioral|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
80005527|NCT00547196|Biological|filgrastim|
79237817|NCT05258799|Drug|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
79237818|NCT02670122|Device|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
79237819|NCT02390648|Drug|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
79532458|NCT01438827|Drug|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
79532459|NCT01438827|Drug|Placebo|Suspension for Injection, Every 6 weeks for one year
79532460|NCT01438853|Biological|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
79532461|NCT01438853|Drug|Placebo|Single intravenous dose of saline control
79532462|NCT01438866|Other|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
80005528|NCT00547196|Drug|Busulfan|
80005529|NCT00547196|Drug|Cyclophosphamide|
80005530|NCT00547196|Drug|Cyclosporine|
80005531|NCT00547196|Drug|Fludarabine phosphate|
80005532|NCT00547196|Drug|Melphalan|
79688385|NCT05437172|Procedure|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
79237820|NCT02390648|Drug|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
79831816|NCT00393367|Drug|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
79831817|NCT00395863|Drug|Multihance|0.5 M at a single injection
79831818|NCT00395863|Drug|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
79831819|NCT01045915|Biological|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
79831820|NCT01043731|Procedure|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
79831821|NCT00395629|Drug|Deferasirox (ICL670)|
79831822|NCT00392665|Drug|Bevacizumab|Given intravenously on day one of each 3 week cycle
79831823|NCT00392665|Drug|erlotinib|Given orally once a day
79831824|NCT00392665|Drug|Sulindac|Given orally twice a day
79237821|NCT04233892|Drug|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
79831825|NCT01046071|Procedure|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
80005533|NCT00547196|Drug|Mycophenolate Mofetil|
79237822|NCT04233892|Drug|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
79237823|NCT04233892|Drug|Estrogen|Patients will receive regular estrogen therapy
79237824|NCT02386358|Drug|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
79237825|NCT02386358|Drug|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
79237826|NCT05053204|Other||
79831826|NCT01046071|Procedure|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
79532463|NCT01438866|Other|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
79532464|NCT01438892|Drug|tDMARDs|Traditional DMARDs for RA
79831827|NCT01043809|Behavioral|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
79831828|NCT01043809|Behavioral|expanded school-based handwashing promotion|Procter & Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
79831829|NCT01043887|Drug|ridaforolimus|single oral dose administration 10 mg ridaforolimus
80005534|NCT00547196|Procedure|allogeneic hematopoietic stem cell transplantation|
80005535|NCT00547196|Procedure|umbilical cord blood transplantation|
79237827|NCT02390726|Biological|Fecal Microbiota Transplant|
79237828|NCT02390726|Biological|Placebo|
79237829|NCT03283371|Drug|Natalizumab|As specified in the treatment arm.
79237830|NCT03283371|Other|Placebo|As specified in treatment arms.
79237831|NCT05069350|Drug|bupivacaine 0.5% and oxubuprocaine|using each drug as surface anesthesia before intravitreal injections
79237832|NCT03471351|Drug|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
79237833|NCT03471351|Biological|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
80005536|NCT00547196|Radiation|total-body irradiation|
80005537|NCT00547196|Radiation|Fractionated total body irradiation|
80005538|NCT00330941|Drug|lidocaine|
80005539|NCT02135978|Other|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
80005540|NCT03603054|Other|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
79237834|NCT02386280|Behavioral|Motivational Interviewing for Change of Parenting Styles|
79237835|NCT02386280|Behavioral|Psicoeducation|
79237836|NCT02386436|Drug|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
79532465|NCT01438892|Drug|biodmards|Biologic DMARDs
79532466|NCT01438905|Other|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
79831830|NCT01324297|Other|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
79688386|NCT05437172|Procedure|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
79831831|NCT01043965|Drug|Metformin|Metformin 850mg
79831832|NCT01044043|Procedure|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
79831833|NCT01044121|Other|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
79831834|NCT00622869|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
79831835|NCT00622869|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
79831836|NCT00622869|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
79831837|NCT00622869|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
79831838|NCT00622869|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
79831839|NCT00622869|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
79831840|NCT02548065|Other|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
79831841|NCT02548065|Other|Placebo|Bath with Thermal tap water
79831842|NCT00395083|Behavioral|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
79831843|NCT00366457|Drug|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
80005541|NCT03603054|Other|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
80005542|NCT05759923|Drug|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
80005543|NCT02136056|Behavioral|Self-management program (SMP)|A self-management course
79378261|NCT01696084|Drug|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
79378262|NCT02515032|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
79237837|NCT02386436|Drug|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume [w/v] Sodium Chloride) administered as single dose s.c.
79237838|NCT05154435|Drug|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
79237839|NCT02386592|Drug|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
79237840|NCT02386592|Behavioral|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
79237841|NCT02386592|Behavioral|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
79237842|NCT02386592|Other|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
79378263|NCT02515032|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
79688387|NCT05431686|Behavioral|SMA visits|SMA visit once every 3 months over a 12 month period
79688388|NCT05431140|Device|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
79831844|NCT00366457|Drug|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
80005544|NCT03149107|Drug|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
80005545|NCT03149107|Drug|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
80005546|NCT03149107|Behavioral|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater)
80005547|NCT03149107|Behavioral|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
79237843|NCT02390180|Other|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
79237844|NCT05138679|Procedure|Revascularization|Endovascular or surgical restoration of arterial blood flow.
79378264|NCT02514876|Device|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
79688389|NCT05415956|Behavioral|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
80005548|NCT03606564|Other|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
80005549|NCT03550976|Behavioral|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
80005550|NCT03135301|Drug|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
80005551|NCT03135301|Drug|letrozole|letrozole 5 milligram tablets
80005552|NCT03550274|Device|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
79831845|NCT00366457|Drug|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
80005553|NCT03602898|Biological|Anti-Thymocyte Globulin|Given IV
80005554|NCT03602898|Drug|Busulfan|Given IV or PO
79237845|NCT05138679|Procedure|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
79378265|NCT02511600|Other|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
79378266|NCT02511600|Other|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
79378267|NCT02511600|Behavioral|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
79378268|NCT02228824|Drug|Very low nicotine content cigarettes|0.07 mg nicotine delivery
79378269|NCT02228824|Drug|Normal nicotine content cigarettes|0.8 mg nicotine delivery
79237846|NCT05138679|Other|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
79378270|NCT02505828|Procedure|Articular punction, salivary samples, blood sample|
79378271|NCT02511366|Other|Ileal infusion of casein|Intraileal infusion of casein
79378272|NCT02511366|Other|Ileal infusion of tap water|Intraileal infusion of tap water
79378273|NCT02230540|Device|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
79378274|NCT02230540|Device|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
79378275|NCT02230540|Device|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
79378276|NCT02514954|Drug|Biochaperone® Combo|Subcutaneous injection of an individualized dose
79709883|NCT04327245|Other|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
79709884|NCT01588769|Biological|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
79709885|NCT00596310|Other|CT|Screening CT
79831846|NCT00624819|Biological|GSK1024805A|No vaccination in this trial
79831847|NCT00624819|Biological|Prevenar|No vaccination in this trial
79831848|NCT00624819|Biological|Infanrix hexa|No vaccination in this trial
79831849|NCT00624819|Biological|Havrix|No vaccination in this trial
79831850|NCT00624819|Biological|Varilrix|No vaccination in this trial
79831851|NCT01046149|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
79831852|NCT01046149|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
79237847|NCT02390258|Drug|10mg XEN-D0103|
79831853|NCT01049425|Drug|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
79831854|NCT01049425|Drug|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
79831855|NCT01049425|Drug|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
79831856|NCT01049425|Drug|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
79831857|NCT01049425|Drug|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
79831858|NCT03832387|Device|Non-invasive mechanical ventilation|
79831859|NCT03832387|Device|Continuous positive airway pressure|
80005555|NCT03602898|Drug|Cyclophosphamide|Given IV
80005556|NCT03602898|Drug|Cyclosporine|Given IV or PO
80005557|NCT03602898|Drug|Fludarabine Phosphate|Given IV
80005558|NCT03602898|Drug|Methotrexate|Given IV
79237848|NCT02390258|Drug|Placebo|
79237849|NCT02390258|Drug|30mg XEN-D0103|
79237850|NCT02390258|Drug|60mg XEN-D0103|
79688390|NCT05410132|Other|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
79688391|NCT05403450|Drug|Tolinapant|Capsule for oral administration
79688392|NCT05403450|Drug|Decitabine + Cedazuridine|Tablet for oral administration
79831860|NCT03832387|Device|Venturi mask|
79831861|NCT03832387|Device|Reservoir mask|
79831862|NCT00838227|Drug|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
79831863|NCT00827619|Device|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
80005559|NCT03602898|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
80005560|NCT03602898|Other|Quality-of-Life Assessment|Ancillary studies
80005561|NCT03602898|Other|Questionnaire Administration|Ancillary studies
79237851|NCT02390258|Drug|120mg XEN-D0103|
79237852|NCT02390258|Drug|200mg XEN-D0103|
79237853|NCT02390258|Drug|150mg XEN-D0103|
79237854|NCT03069417|Behavioral|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
79237855|NCT02390336|Other|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
79237856|NCT02390336|Other|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
79237857|NCT03059511|Drug|Nalbuphine|Opioid Pain Medicine
79378277|NCT02514954|Drug|Humalog® Mix25|Subcutaneous injection of an individualized dose
79378278|NCT04443036|Drug|Albumin-Bound Paclitaxel|"125mg/m2 IV d1、8，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity"
79831864|NCT04043559|Other|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
79688393|NCT05388708|Device|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
79831865|NCT04043559|Other|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
79378279|NCT04443036|Drug|Toripalimab|"240 mg，IV d1，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
79709886|NCT04327401|Drug|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
79709887|NCT01340027|Drug|Mirabegron|oral
79709888|NCT01340027|Drug|Solifenacin succinate|oral
79709889|NCT01340027|Drug|Placebo|oral
79709890|NCT01327053|Drug|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
79831866|NCT00366301|Drug|Insulin glargine injection|Once daily for 14 weeks
79831867|NCT00366301|Drug|metformin|Up to 4 pils per day (2g per day) maximum
79831868|NCT00366301|Drug|Placebo pill|Up to 4 pills per day
79831869|NCT00831285|Dietary Supplement|food product|food product given at one of six visits
80005562|NCT03602898|Drug|Tacrolimus|Given IV or PO
80005563|NCT03602898|Radiation|Total-Body Irradiation|Undergo TBI
80005564|NCT02983747|Other|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
79688394|NCT05388708|Other|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure <28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 < 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
80005565|NCT02983747|Drug|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
79831870|NCT00838305|Drug|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
79831871|NCT00838305|Drug|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
79831872|NCT00365989|Device|ExAblate Enhanced Sonication|
79831873|NCT00827697|Other|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
79831874|NCT00838461|Drug|HSD-016|
79831875|NCT00838461|Drug|placebo|
79831876|NCT01324375|Device|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
79831877|NCT00831363|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
80005566|NCT02128412|Device|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
79237858|NCT02390492|Drug|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous [14C]-ipatasertib on Day 1 of study
79237859|NCT02390492|Drug|Period 2 treatment|200-mg/100-mcCi oral [14C]-ipatasertib on Day 15 of study
79688395|NCT05376215|Device|Experimental hearing aid|This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
79688396|NCT05361109|Drug|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
79688397|NCT05359276|Drug|Olipudase alfa|GZ402665
79831878|NCT00831363|Procedure|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
79831879|NCT03495505|Device|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
79831880|NCT03488953|Procedure|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
79831881|NCT00622713|Drug|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm^2.
79831882|NCT01046227|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
79831883|NCT04044339|Drug|TD-5202|Study Drug to be administered orally
79831884|NCT04044339|Drug|Placebo|Placebo to be administered orally
79831885|NCT00392197|Drug|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
79831886|NCT00391807|Drug|Norethindrone acetate/ethinyl estradiol|one tablet per day
79831887|NCT00624585|Drug|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~Dose Level and Dose of dasatinib:~Starting dose (1-8 weeks)= 100 mg orally (po) daily~+1 (<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~Dose Level and Dose of dasatinib:~Starting dose = 100 mg po daily~-1 = 70 mg po daily~-2 = 50 mg po daily~OR~Dose Level and Dose of dasatinib:~Starting dose = 150 mg po daily~-1 = 120 mg po daily~-2 = 90 mg po daily~-3 = 50 mg po daily"
79831888|NCT01046305|Behavioral|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
79831889|NCT01046305|Behavioral|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
79831890|NCT01046305|Behavioral|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
80005567|NCT02128412|Device|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
80005568|NCT05759845|Drug|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
79237860|NCT03014037|Procedure|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
79237861|NCT03014037|Procedure|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
79237862|NCT04439786|Drug|placebo|the control group will be given the same volume of saline.
80005569|NCT05759845|Drug|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
80005570|NCT05759845|Drug|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
80005571|NCT03550196|Other|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
80005572|NCT03931291|Drug|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
79532467|NCT01438905|Other|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
79532468|NCT01438918|Drug|SD-6010|200 mg tablets once a day for 2 years
79532469|NCT01438918|Drug|SD-6010|50 mg tablets once a day for 2 years
79378280|NCT02514720|Other|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
79532470|NCT01438918|Drug|Placebo|Placebo tablets once a day for 2 years
79532471|NCT01438931|Drug|DA-9501|Dexmedetomidine hydrochloride variable dose
79532472|NCT01438931|Drug|placebo|
79532473|NCT01438944|Drug|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
79532474|NCT01438970|Device|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
79532475|NCT01439022|Behavioral|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
79709891|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
79831891|NCT01046383|Dietary Supplement|IMN1207|20 grams of IMN1207 per day for 40 weeks.
79831892|NCT01046383|Dietary Supplement|Casein|20 grams of Casein per day for 40 weeks
79831893|NCT04044261|Procedure|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
80005573|NCT02136212|Behavioral|Approach-positive AAT|
80005574|NCT02136212|Behavioral|Control AAT|
79378281|NCT01653418|Drug|Bortezomib|
79378282|NCT01653418|Drug|Carmustine|
79378283|NCT01653418|Drug|Etoposide|
79378284|NCT01653418|Drug|Cytarabine|
79378285|NCT01653418|Drug|Melphalan|
79378286|NCT01653418|Procedure|Stem cell infusion|
79378287|NCT02514642|Drug|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
79532476|NCT01439022|Behavioral|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
79532477|NCT01439061|Device|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
79532478|NCT01439100|Drug|Oxycodone/Naloxone Prolonged Release tablets|
79532479|NCT01439100|Drug|Placebo|Dummy tablet
79532480|NCT01439152|Drug|BAY94-9343|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
79532481|NCT01439152|Drug|BAY94-9343 (Expansion)|BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
79532482|NCT01439152|Drug|BAY94-9343 (1.8 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
79532483|NCT01439152|Drug|BAY94-9343 (2.2 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
79532484|NCT01439178|Drug|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
79532485|NCT01439191|Drug|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
79532486|NCT01439191|Drug|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
79532487|NCT01439230|Drug|Donepezil|10 mg Tablet
79532488|NCT01439230|Drug|Aricept®|10 mg Tablet
79532489|NCT01439243|Drug|Donepezil|10 mg Tablet
79532490|NCT01439243|Drug|Aricept®|10 mg Tablet
79532491|NCT01439256|Behavioral|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
80005575|NCT02136290|Behavioral|Prepackaged meals|Portion-controlled prepackaged meals
80005576|NCT02136290|Behavioral|Usual Care|Usual care dietary counseling
80005577|NCT01375855|Procedure|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
80005578|NCT00799110|Drug|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
80005579|NCT00799110|Biological|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
80005580|NCT00799110|Drug|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
79378288|NCT02514642|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
79532492|NCT01439256|Other|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
79532493|NCT01439308|Drug|Placebo|SB-705498 placebo
79532494|NCT01439308|Drug|SB-705498|12mg intranasal SB-705498
79688398|NCT05355389|Behavioral|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
79709892|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
79831894|NCT00838773|Behavioral|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
79831895|NCT00838773|Behavioral|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
80005581|NCT05199727|Device|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
80005582|NCT05199727|Drug|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
80005583|NCT03600402|Other|Experimental|6 sessions of ankle manual therapy
80005584|NCT03600402|Other|Control|6 sessions of placebo intervention
80005585|NCT02132234|Drug|Etanercept|biological treatment according to rheumatologic indication
80005586|NCT02132234|Drug|Adalimumab|biological treatment according to rheumatologic indication
80005587|NCT02132234|Drug|Certolizumab|biological treatment according to rheumatologic indication
80005588|NCT02132234|Drug|Infliximab|biological treatment according to rheumatologic indication
79378289|NCT02511210|Behavioral|regional anesthesia|preoperative anxiety
79378290|NCT02511210|Behavioral|general anesthesia|preoperative anxiety
79378291|NCT01653964|Diagnostic Test|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
79378292|NCT03344874|Device|Stethee®|Stethee® is a new wireless digital stethoscope.
79532495|NCT01439321|Biological|Eltrombopag|Switched to Eltrombopag
79532496|NCT01439321|Biological|Romiplostim|Switched to Romiplostim
79532497|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
79532498|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
79237863|NCT04439786|Drug|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
79237864|NCT03131115|Procedure|Lateral Crural Strut Graft|surgical technique as described
79237865|NCT03131115|Procedure|Bone Anchored Suspension|Surgical technique as described
79237866|NCT02686203|Device|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
79378293|NCT03344874|Device|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
79378294|NCT02505438|Behavioral|Exercise|
79378295|NCT02237950|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
79378296|NCT02237950|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
79532499|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
79532500|NCT01439386|Procedure|Catheter ablation|PVAI with or without CTI ablation
79532501|NCT01439386|Procedure|Catheter ablation|CTI ablation only
79532502|NCT01439399|Drug|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
79532503|NCT01439399|Drug|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
79688399|NCT05355389|Behavioral|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
79831896|NCT00838773|Behavioral|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
79831897|NCT00838851|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
79831898|NCT00831597|Drug|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
79831899|NCT00831597|Drug|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
79532504|NCT01439399|Drug|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
79532505|NCT01439399|Drug|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
79532506|NCT01439425|Behavioral|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
79532507|NCT01439438|Drug|Topiramate coated tablet|Test formulation
79831900|NCT00622635|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
79831901|NCT00622635|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
79532508|NCT01439438|Drug|Topamax® coated tablet|Reference formulation
79532509|NCT01439451|Procedure|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
79831902|NCT00622635|Drug|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
79831903|NCT00391027|Drug|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
79831904|NCT00391027|Drug|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
79831905|NCT00622401|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
79831906|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 30ng/kg
79831907|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 100ng/kg
79532510|NCT01439464|Device|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
79532511|NCT01439464|Device|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
79532512|NCT01439490|Other|FES-PET|Patients undergo FES-PET prior to obtaining histology
79831908|NCT00827853|Procedure|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
79831909|NCT00827853|Procedure|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
79831910|NCT04018365|Drug|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
79831911|NCT02549235|Other|Ultrasound|Routine 2D/3D ultrasound assessment
79831912|NCT00831831|Behavioral|Safety planning|See detailed description
79831913|NCT00839007|Drug|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
79831914|NCT00621621|Device|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
79831915|NCT00828087|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
79532513|NCT01439503|Behavioral|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
79532514|NCT01439516|Behavioral|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
79532515|NCT01439529|Other|Device programming: nominal|CRT device is programmed to nominal values
79532516|NCT01439529|Other|Programming optimization by QRS|CRT device is programmed by QRS optimization
79532517|NCT01439542|Radiation|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
79831916|NCT00828087|Device|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
79532518|NCT01439542|Drug|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
79532519|NCT01439607|Other|Bone marrow and blood sampling|Bone marrow and blood sampling
79532520|NCT01439646|Other|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
79688400|NCT05344300|Other|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
79831917|NCT00828165|Drug|ARRY-300, MEK inhibitor; oral|single dose, escalating
79831918|NCT00828165|Drug|Placebo|matching placebo
79688401|NCT05343975|Procedure|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
79831919|NCT00839085|Drug|GSE|grape seed extract (100 mg/6h), PO
79831920|NCT00839085|Drug|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
79532521|NCT01439698|Device|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
79831921|NCT02549313|Procedure|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
79831922|NCT00828243|Drug|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids ([1-13C1] acetate) and of surfactant protein-B ([5,5,5-2H3] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
79831923|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
79532522|NCT01439750|Drug|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
79532523|NCT01439750|Drug|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
79532524|NCT01439750|Drug|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
79532525|NCT01439789|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
79532526|NCT01439789|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
79532527|NCT01439828|Drug|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
79532528|NCT01439841|Dietary Supplement|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
79532529|NCT01439841|Dietary Supplement|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
79532530|NCT01439893|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
79532531|NCT01439893|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
79688402|NCT05341700|Behavioral|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
79831924|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
79831925|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
79831926|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
79831927|NCT00839163|Drug|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
79532532|NCT01439906|Procedure|Surgical correction of the deformity|"Three different surgical techniques are used:~lumbar fusion vs thoraco-lumbar fusion~iliac fixation vs fixation to the sacrum~posterior + interbody fusion vs posterior interbody fusion"
79688403|NCT05341700|Behavioral|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
79688404|NCT05340426|Device|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
79688405|NCT05338619|Drug|Lazertinib|Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
79831928|NCT02549001|Drug|P-3058 10%|
79831929|NCT02549001|Drug|vehicle of P-3058 10%|
79831930|NCT02549001|Drug|amorolfine 5%|
79688406|NCT05329610|Dietary Supplement|Beta-alanine|Slow-release beta-alanine.
79688407|NCT05329610|Dietary Supplement|Placebo|Taste and appearance-matched placebo (tapioca starch).
79688408|NCT05320380|Drug|Anti-CD123 ADC IMGN632|Given IV
79688409|NCT05320380|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
80005589|NCT05415241|Drug|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
80005590|NCT03602742|Device|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
80005591|NCT02136368|Behavioral|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
80005592|NCT02136368|Behavioral|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
80005593|NCT02136368|Behavioral|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
80005594|NCT05199649|Drug|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
79688410|NCT05320380|Drug|Cytarabine|Given IT and IV
79688411|NCT05320380|Drug|Fludarabine Phosphate|Given IV
79688412|NCT05320380|Drug|Hydrocortisone Sodium Succinate|Given IT
79688413|NCT05320380|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79688414|NCT05320380|Drug|Methotrexate|Given IT
79688415|NCT05320380|Drug|Prednisolone|Given IT
79378297|NCT02237950|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
79688416|NCT05320146|Other|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
79688417|NCT05316389|Procedure|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
79831931|NCT00621543|Device|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
79831932|NCT02548221|Device|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
79831933|NCT00832143|Behavioral|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
79831934|NCT00623805|Drug|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
79237867|NCT02386124|Other|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
79237868|NCT02386202|Other|No intervention|No interventions
79237869|NCT04930263|Behavioral|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
79378298|NCT04497480|Behavioral|Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System|The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
79378299|NCT02238028|Behavioral|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
79688418|NCT05309590|Drug|Dose|We are looking at the outcomes of prescribing half of the topical steroid (i.e. fluticasone [Flovent] and Swallowed viscous budesonide [Pulmicort]) in relation to the patient's remission. These patients will have already achieved remission on a full dose of the steroid.
79237870|NCT04930263|Behavioral|control group|control group received routine care and a manual on healthy living
79688419|NCT05306886|Other|ICB Medical Insoles|After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.
79688420|NCT05306886|Other|ICM Insoles|As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
79709893|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
79831935|NCT00623805|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
79831936|NCT00623805|Drug|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
79831937|NCT02548923|Drug|Dexmedetomidine|comparison to propofol
79831938|NCT04043871|Diagnostic Test|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
79831939|NCT00832221|Drug|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
79237871|NCT02665286|Drug|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
79237872|NCT02665286|Drug|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
79709894|NCT04342767|Device|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
79831940|NCT00832221|Drug|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
79831941|NCT00832221|Drug|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
79831942|NCT00828399|Dietary Supplement|Glutamine|Oral glutamine 30g/day
79237873|NCT02665286|Drug|Naproxen|Naproxen 500mg PO BID x 7 days
79237874|NCT02665286|Drug|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
79378300|NCT02511054|Drug|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
79378301|NCT02511054|Drug|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
79378302|NCT02511054|Biological|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
79831943|NCT00828399|Dietary Supplement|Whole protein|Oral whole protein 30 g/day
79831944|NCT04044027|Behavioral|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
79831945|NCT00839397|Drug|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
79831946|NCT04043715|Device|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
79709895|NCT01588808|Behavioral|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
79237875|NCT03471273|Procedure|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
79237876|NCT05440136|Drug|LY3462817 (SC)|Administered SC.
79237877|NCT05440136|Drug|Placebo (SC)|Administered SC.
79709896|NCT01107925|Drug|prasugrel|Administered orally, daily for 12 days
79709897|NCT01107925|Drug|clopidogrel|Administered orally, daily for 12 days
79709898|NCT04310293|Other|Femara,Grotwth hormone,HMG|NOVEL THERAPY
79237878|NCT05440136|Drug|LY3462817 (IV)|Administered IV.
79237879|NCT05440136|Drug|Placebo (IV)|Administered IV.
79237880|NCT02390102|Drug|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
79237881|NCT02390102|Drug|Placebo|Saline solution 0.9%
79237882|NCT02389790|Drug|MT-1303|
79237883|NCT03664219|Other|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
79237884|NCT03663673|Drug|EpiCeram|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
79237885|NCT03663673|Drug|Aveeno Daily Moisturising Sheer Hydration Lotion®|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
79237886|NCT04057963|Other|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
79532533|NCT01439932|Device|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people [Andrew 1987]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). [Linda et al 2007]"
79831947|NCT04043715|Device|Epidural spinal stimulation|Physical therapy to improve standing and walking
79831948|NCT00828477|Drug|Xibrom|Xibrom: two times a day for seven days in the first eye.
79237887|NCT04057963|Other|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
79237888|NCT04058041|Procedure|Neural Mobilization|neural exercise Will be performed in the patients
79378303|NCT04499118|Drug|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
79532534|NCT01439958|Drug|Inhalation|Twice daily inhalation for a maximum of three years.
79688421|NCT05291208|Combination Product|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
79831949|NCT00828477|Drug|Nevanac|Nevanac: three times a day for seven days in the second eye.
79532535|NCT01439984|Drug|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
79831950|NCT00828555|Other|Vaccination Program|Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis
79237889|NCT04058041|Procedure|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
79237890|NCT04058041|Procedure|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
79237891|NCT04057885|Device|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
79532536|NCT01440023|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
79532537|NCT01440023|Behavioral|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
79532538|NCT01440023|Behavioral|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
79532539|NCT01440036|Procedure|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
79831951|NCT00621309|Drug|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
79532540|NCT01440062|Drug|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
79831952|NCT00621309|Dietary Supplement|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
79831953|NCT00621309|Dietary Supplement|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
79831954|NCT00839553|Procedure|Intrapleural Minocycline application|
79831955|NCT00832611|Device|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
79831956|NCT04018521|Behavioral|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
79237892|NCT04057729|Drug|IMP4297|10mg/capsule.
79237893|NCT03664141|Drug|Cannabis oil|Treatment with cannabis oil
79237894|NCT03664141|Drug|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
79237895|NCT03664531|Other|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
79378304|NCT04499118|Drug|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
79378305|NCT01612546|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
79378306|NCT01612546|Other|Laboratory biomarker analysis|Correlative studies
79378307|NCT01612546|Other|Pharmacological studies|Correlative studies
79378308|NCT02514564|Behavioral|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
79378309|NCT02514486|Behavioral|Questionnaire|
79378310|NCT04499898|Drug|Carvedilol|Carvedilol
79532541|NCT01440062|Drug|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
79688422|NCT05291208|Behavioral|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
79688423|NCT05288218|Device|Leak-free Bronchoscope Adapter|A novel leak-free bronchoscope adapter will connect to the ventilation circuit in place of a standard adapter.
79688424|NCT05288218|Device|Standard Bronchoscope Adapter|Commercially available bronchoscope adapter (Smiths Medical)
79831957|NCT04018521|Behavioral|CSC Usual Care|standard of care provided to youth following first episode of psychosis
79831958|NCT02549079|Other|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
80005595|NCT05373576|Behavioral|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
80005596|NCT02128568|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
80005597|NCT03600246|Device|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
79237896|NCT03664531|Other|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
79237897|NCT03664531|Other|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
79237898|NCT02911519|Other|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
79532542|NCT01440075|Other|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
79688425|NCT05285865|Other|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
79688426|NCT05285865|Other|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
79688427|NCT05254951|Diagnostic Test|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
79831959|NCT00832689|Drug|Irinotecan and Gemcitabine|
79831960|NCT00567190|Drug|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
79831961|NCT00567190|Drug|Placebo|Placebo (matching pertuzumab) was administered intravenously.
79378311|NCT04499898|Procedure|Endoscopic band ligation|Endoscopic band ligation
79378312|NCT01613014|Drug|ABT-436|Target dose - 400mg BID
79831962|NCT00567190|Drug|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
79378313|NCT01613014|Drug|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
79378314|NCT02514330|Other|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
79378315|NCT02514330|Other|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
79378316|NCT02510976|Drug|prucalopride|
79378317|NCT02510976|Drug|placebo|
79378318|NCT02505516|Other|metformin|
79532543|NCT01440088|Drug|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
80005598|NCT05199181|Procedure|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
79532544|NCT01440088|Drug|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
79532545|NCT01440114|Drug|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
79831963|NCT00567190|Drug|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
79378319|NCT02510898|Behavioral|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
79688428|NCT05230888|Other|Questionnaires about symptoms|The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
79378320|NCT02514408|Procedure|Catheter Management|Insertion of venous catheter under ultrasound guidance
79688429|NCT05206058|Procedure|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
79831964|NCT00922389|Procedure|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
79378321|NCT02514408|Other|Cytology Specimen Collection Procedure|Collection of blood samples
79831965|NCT00922389|Drug|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
79532546|NCT01440114|Drug|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
79532547|NCT01440127|Drug|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
79532548|NCT01440140|Other|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
79532549|NCT01440140|Other|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
79688430|NCT05191355|Biological|blood test|Blood spot collection for sampling
79378322|NCT02514408|Other|Laboratory Biomarker Analysis|Correlative studies
79378323|NCT02505360|Other|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
79378324|NCT04499586|Combination Product|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
79378325|NCT01656460|Radiation|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy"
79378326|NCT01656460|Radiation|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
79378327|NCT01656460|Radiation|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
79688431|NCT05186168|Device|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
79688432|NCT05186168|Device|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
79688433|NCT05177393|Other|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
79688434|NCT05159739|Genetic|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
79831966|NCT00922389|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
80005599|NCT02132390|Drug|Goserelin|
80005600|NCT02132390|Drug|Toremifene|
79532550|NCT01440153|Other|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
79532551|NCT01440153|Other|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
79532552|NCT01440166|Drug|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
79532553|NCT01440166|Other|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
79688435|NCT05155098|Other|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
79688436|NCT05134649|Drug|BOTOX|Intramuscular Injection
79688437|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
79688438|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
79831967|NCT00839631|Drug|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
79831968|NCT00691938|Drug|LBH589|
79688439|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
79688440|NCT05124275|Drug|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
79831969|NCT00691938|Drug|Decitabine|
79831970|NCT00365365|Drug|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 60 mg/m^2 IV push or infusion followed by cyclophosphamide 600 mg/m^2 IV push or infusion~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
79831971|NCT00365365|Drug|Docetaxel (T) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel 100 mg/m^2 IV~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
79237899|NCT02911519|Other|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
80005601|NCT03875443|Other|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
79237900|NCT03664063|Drug|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
79237901|NCT03664063|Drug|Albendazole|"Single dose of Albendazole weight based dosing~- 400mg"
79237902|NCT03664063|Drug|Ivermectin|Ivermectin weight based dosing - max 21mg
79688441|NCT05121636|Device|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
79688442|NCT05113953|Drug|Centanafadine|Sustained-release oral tablets
79688443|NCT05113953|Drug|Placebo|Oral tablets
79237903|NCT03664063|Drug|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
79237904|NCT04057495|Other|further fasting|2 hours of fasting
79237905|NCT04057495|Other|white bread consumption|113 grams of white bread consumption
79237906|NCT04057495|Other|mango consumption|330 grams of mango consumption
79378328|NCT01656460|Radiation|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
79378329|NCT02505282|Other|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
79378330|NCT03343938|Other|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
79378331|NCT01656772|Device|Vdrive Lasso navigation|Remote robotic Lasso navigation
79378332|NCT01656772|Procedure|Manual Lasso navigation|Manually maneuver a Lasso catheter
79378333|NCT01816295|Drug|Testosterone Solution|Administered topically to axillae.
79688444|NCT05093972|Drug|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
79237907|NCT04054921|Drug|PTG-300|PTG-300 is a hepcidin Mimetic
79378334|NCT01816295|Drug|Placebo Solution|Administered topically to axillae.
79378335|NCT02514018|Biological|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
79378336|NCT02513862|Device|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
79378337|NCT01659268|Other|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
79532554|NCT01440192|Biological|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 & 8
79532555|NCT01440205|Behavioral|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
79237908|NCT02911285|Drug|N-acetylcysteine|1200mg bid (2400mg/day)
79532556|NCT01440205|Behavioral|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
79831972|NCT00365365|Drug|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 50 mg/m^2 IV push or infusion followed by cyclophosphamide 500 mg/m^2 IV push or infusion followed by docetaxel 75 mg/m^2~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
79831973|NCT00365365|Drug|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel in 75 mg/m^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
79688445|NCT05092360|Biological|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
79688446|NCT05092360|Biological|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
79688447|NCT05092360|Biological|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
79831974|NCT00365365|Drug|Bevacizumab and trastuzumab maintenance therapy|"bevacizumab 15 mg/kg was infused IV followed by~trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
79831975|NCT00365365|Drug|Bevacizumab maintenance therapy|"- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
79831976|NCT02564874|Other|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
79831977|NCT01046461|Drug|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
79831978|NCT00623727|Biological|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
79831979|NCT00623727|Biological|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
79831980|NCT00933946|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
79237909|NCT02911285|Drug|Placebo|Placebo pills bid
79237910|NCT02911285|Behavioral|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
79532557|NCT01440205|Behavioral|Control|No check box element
79831981|NCT01046539|Drug|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
79831982|NCT01046539|Drug|Placebo|0 mg
79237911|NCT02910739|Drug|MK-8931|MK-8931 40 mg
79237912|NCT03673397|Behavioral|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
79237913|NCT03663985|Other|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
79831983|NCT04015024|Drug|SKLB1028 150mg bid|150mg oral administration twice a day
79831984|NCT04015024|Drug|SKLB1028 200mg bid|200mg oral administration twice a day
79532558|NCT01440231|Drug|Placebo|Matching placebo administered by subcutaneous injection, once weekly
79532559|NCT01440231|Drug|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
79532560|NCT01440231|Drug|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
79532561|NCT01440231|Drug|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
79532562|NCT01440231|Drug|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
79532563|NCT01440270|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
79532564|NCT01440309|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
79532565|NCT01440309|Drug|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
79532566|NCT01440335|Drug|Oral R,R'-Fenoterol|
79532567|NCT01440335|Drug|Oral Racemic Fenoterol|
79532568|NCT01440348|Procedure|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
79532569|NCT01440361|Drug|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
79688448|NCT05092360|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
79688449|NCT05092360|Drug|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
79688450|NCT05092360|Drug|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
79688451|NCT05092360|Drug|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
79831985|NCT04015024|Drug|SKLB1028 300mg qd|300mg oral administration once a day
79831986|NCT01044199|Biological|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
79532570|NCT01440361|Drug|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
79237914|NCT04055935|Procedure|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
79237915|NCT04055935|Device|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
79831987|NCT01044199|Biological|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
79237916|NCT04997902|Drug|Tipifarnib|Oral administration
79688452|NCT05082077|Device|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
79831988|NCT00908284|Behavioral|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
79237917|NCT04997902|Drug|Alpelisib|Oral administration
79237918|NCT01061515|Drug|Intraperitoneal Oxaliplatin|
79237919|NCT01061515|Drug|Bevacizumab|
79378338|NCT01659268|Other|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
79532571|NCT01440400|Procedure|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
79532572|NCT01440413|Biological|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
79532573|NCT01440426|Procedure|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
79688453|NCT05072301|Behavioral|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
79688454|NCT05072301|Behavioral|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
79831989|NCT00908284|Behavioral|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
79831990|NCT00828789|Drug|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
79831991|NCT00839709|Procedure|blood sampling|peripheral blood draw
79831992|NCT00930358|Drug|MEOPA|anaesthetic gaz inhalation
79831993|NCT00930358|Drug|general anaesthesia|Anaesthetic intravenous route
79831994|NCT00832845|Behavioral|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 36 weeks.
79831995|NCT00832845|Behavioral|Treatment as usual (TAU)|Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
79237920|NCT01061515|Drug|Capecitabine|
79378339|NCT02510586|Drug|Sevoflurane|administer 1.0 MAC (1.7~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
79378340|NCT01704196|Drug|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
79378341|NCT01704196|Drug|Placebo|
79378342|NCT01610297|Drug|ICL670|Oral dose of ICL670 at 10 mg/kg daily
79831996|NCT00930436|Drug|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
79831997|NCT00372775|Drug|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
79237921|NCT01069939|Drug|Esomeprazole|20mg, capsule, 72 weeks
79237922|NCT01069939|Drug|Placebo|Placebo, capsule, 72 weeks
79237923|NCT01069705|Drug|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
79237924|NCT01069627|Drug|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
79237925|NCT01069627|Drug|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
79237926|NCT04057261|Drug|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
79237927|NCT04057261|Drug|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
79831998|NCT00832923|Behavioral|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
79532574|NCT01440426|Device|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
79831999|NCT00936676|Drug|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
79237928|NCT03673319|Procedure|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
79237929|NCT03673319|Procedure|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
79237930|NCT03622801|Drug|Iopromide (Ultravist, BAY86-4877)|Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
79237931|NCT01064245|Drug|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
79237932|NCT01064245|Other|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
79237933|NCT03669965|Drug|KRT-232|KRT-232, administered by mouth
79237934|NCT03669965|Drug|Ruxolitinib|Ruxolitinib per approved prescribing label
79532575|NCT01440439|Drug|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
79532576|NCT01440439|Drug|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
79832000|NCT00839787|Drug|Morphine Sulfate|Morphine Sulfate group: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
79237935|NCT03663049|Drug|discontinue statin|Discontinue statin as prescribed for 12 weeks
79688455|NCT05055778|Behavioral|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
79688456|NCT05054400|Drug|F18 Fluciclovine|Given by IV
79378343|NCT03343782|Combination Product|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
79832001|NCT01044355|Device|CPAP|6 weeks treatment with fixed CPAP
79832002|NCT01044355|Device|APAP|6 weeks of treatment with auto-titrating positive airway pressure
79832003|NCT01049659|Behavioral|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
79832004|NCT00936754|Dietary Supplement|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
79832005|NCT00936754|Dietary Supplement|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
79378344|NCT01660672|Drug|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
79378345|NCT02505048|Drug|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
79378346|NCT01793051|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
79378347|NCT01793051|Other|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
79532577|NCT01440478|Drug|LY2140023|Administered orally
79532578|NCT01440478|Drug|Ammonium chloride|Administered orally
79532579|NCT01440478|Drug|Sodium bicarbonate|Administered orally
79532580|NCT01440491|Other|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
79688457|NCT05054400|Other|Standard of Care|Standard of care
79237936|NCT03663439|Procedure|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
79237937|NCT04056949|Drug|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
79237938|NCT04056949|Drug|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
79237939|NCT04057417|Other|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
79237940|NCT04056793|Other|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
79237941|NCT03673241|Device|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
79378348|NCT01793051|Behavioral|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
79832006|NCT00934258|Drug|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
79832007|NCT00934258|Genetic|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
79237942|NCT03662425|Drug|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
80005602|NCT03875443|Other|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
79237943|NCT03662425|Drug|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
79237944|NCT03673163|Drug|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
79237945|NCT03673163|Drug|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
79237946|NCT03662269|Drug|indomethacin|indomethacin (75mg, bid, po, 14days)
79237947|NCT03662269|Drug|Placebo|placebo (75mg, bid, po, 14days)
79237948|NCT03662269|Drug|Omeprazole|placebo (20mg, qd, po, 14days)
79237949|NCT04056325|Drug|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
79832008|NCT00372697|Drug|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
79532581|NCT01440504|Other|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
79688458|NCT05033054|Drug|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
80005603|NCT02128646|Drug|EXPAREL|
80005604|NCT02128646|Drug|Ketorolac|
80005605|NCT02128646|Procedure|laparoscopic abdominal hernia repair|
80005606|NCT02128646|Procedure|an open surgery for abdominal hernia repair|
80005607|NCT02136446|Device|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
80005608|NCT02136446|Device|Pajunk® Nerve Block Catheter|Nerve Block Catheter
79237950|NCT04056325|Drug|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
79237951|NCT04056325|Drug|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
79237952|NCT03673085|Drug|CN128|CN128
79237953|NCT03673085|Other|placebo|The tablets without CN128
79237954|NCT03662191|Drug|Tafamidis|bioavailability study
79237955|NCT03662971|Drug|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
79237956|NCT03669341|Other|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
79237957|NCT03669341|Other|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
79237958|NCT04057183|Diagnostic Test|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
79237959|NCT03672851|Drug|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m^2) and cyclophosphamide (30 mg/m^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
79237960|NCT04057027|Procedure|Delayed umbilical cord clamping|During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
79378349|NCT02510508|Behavioral|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
79378350|NCT02510508|Behavioral|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
79378351|NCT02510508|Other|Non-intervention|Non-intervention
79378352|NCT01661764|Drug|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
79378353|NCT01661764|Drug|Oleic Acid|Placebo
79532582|NCT01440530|Behavioral|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
79688459|NCT05017818|Other|Observational retrospective data|Non-intervention
79688460|NCT05009927|Drug|Imatinib tablets|Imatinib interruption
79688461|NCT05005442|Biological|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
79709899|NCT01339559|Drug|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
80005609|NCT03785665|Device|MDI|Capsule MD1 (Motility dummy 1)
80005610|NCT02136524|Drug|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
80005611|NCT02136524|Drug|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
79532583|NCT01440530|Other|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
79532584|NCT01440582|Drug|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
79832009|NCT04014478|Device|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
79832010|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
79832011|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
79832012|NCT00934414|Drug|Technosphere Insulin Inhalation Powder|30U
79237961|NCT04057027|Procedure|Cord Milking|Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
79832013|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
79832014|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.
79832015|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.
79832016|NCT00930514|Drug|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.
79237962|NCT03021551|Device|Rainbow sensor|Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
79237963|NCT03662893|Behavioral|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
79237964|NCT03662893|Drug|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
79237965|NCT03662893|Behavioral|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
79378354|NCT02510430|Behavioral|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
79378355|NCT02510430|Behavioral|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
79532585|NCT01440582|Drug|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
79378356|NCT02510430|Behavioral|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
79378357|NCT01816061|Behavioral|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
79532586|NCT01440582|Drug|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
79532587|NCT01440582|Drug|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
79532588|NCT01440582|Behavioral|Symptom Questionnaire|Completed on day 1 of each cycle.
79832017|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.
79237966|NCT04056637|Other|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
79378358|NCT01816061|Behavioral|Control - COMPASS|Increased hours of patient-provider interactions Group.
79378359|NCT02510274|Drug|ASP3325|oral
79378360|NCT03121482|Device|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
79532589|NCT01440608|Drug|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
79532590|NCT01440608|Drug|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
79532591|NCT01440608|Dietary Supplement|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
79532592|NCT01440621|Drug|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
79378361|NCT03121482|Device|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
79378362|NCT01662778|Drug|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
79378363|NCT01662778|Drug|6 microns at 50mg|STAG generated monodisperse 6 micron particles
79378364|NCT01662778|Drug|Placebo Comparator|No drug just solvent
79378365|NCT01662778|Drug|MDI FP|
79378366|NCT03121326|Diagnostic Test|blood and urine sampling|Ten mL blood and 15mL urine are collected.
79688462|NCT05002322|Other|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
79378367|NCT03121560|Device|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
79532593|NCT01440621|Drug|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
79532594|NCT01440673|Drug|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
79688463|NCT04994301|Diagnostic Test|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
79688464|NCT04989569|Dietary Supplement|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
79832018|NCT00936988|Drug|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
79832019|NCT00934492|Drug|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
79832020|NCT00934492|Drug|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
79832021|NCT00934570|Drug|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
79832022|NCT00934570|Drug|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
79832023|NCT00934570|Behavioral|Placebo Standard exercise|Standard exercise
79532595|NCT01440686|Drug|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
79832024|NCT00934570|Behavioral|Intensive exercise|Placebo Intensive exercise
79832025|NCT03702634|Behavioral|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
79832026|NCT00930670|Drug|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
79302756|NCT04991259|Other|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
79302757|NCT03315065|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, < 1 hour
79532596|NCT01440686|Drug|Placebo|Tablets, oral administrations
79532597|NCT01440712|Drug|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
79532598|NCT01440712|Drug|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
79832027|NCT00930670|Drug|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
79532599|NCT01440725|Biological|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
79532600|NCT01440725|Procedure|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
79532601|NCT01440738|Behavioral|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
79688465|NCT04966065|Device|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
79688466|NCT04956224|Biological|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
79688467|NCT04953910|Drug|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
79532602|NCT01440751|Device|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
79378368|NCT03121560|Device|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
79378369|NCT02510196|Behavioral|reminder|
79378370|NCT01792115|Drug|Vitamin E 200 IU/d|Supplement-low dose
80005612|NCT05199103|Drug|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
80005613|NCT02132546|Drug|Chlorhexidine|
79237967|NCT04056637|Device|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
79688468|NCT04925570|Device|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
79688469|NCT04925570|Other|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
79237968|NCT03471195|Diagnostic Test|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
79237969|NCT04056559|Device|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
80005614|NCT05198947|Drug|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
79378371|NCT01792115|Drug|Vitamin E 400 IU/d|Supplement-intermediate dose
79378372|NCT01792115|Drug|Vitamin E 800 IU/d|Supplement High Dose
79532603|NCT01440751|Drug|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
79688470|NCT04915157|Device|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
79688471|NCT04915027|Other|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
79688472|NCT04915027|Other|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
79688473|NCT04902261|Drug|Tislelizumab|Tislelizumab 200 mg every three weeks
79237970|NCT01585025|Drug|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
80005615|NCT05198947|Drug|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
79237971|NCT01068769|Drug|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
79378373|NCT01792115|Behavioral|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
79378374|NCT02504814|Device|Nasal Highflow (NHF)|changes in breathing physiology in NHF
79378375|NCT01791803|Behavioral|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
79378376|NCT01791803|Drug|Nicotine|free one month supply after hospital discharge
79378377|NCT01662856|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
79378378|NCT01662856|Procedure|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
79378379|NCT01791725|Drug|ELND005|
79378380|NCT01791725|Drug|Placebo|
79378381|NCT04499976|Drug|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
79378382|NCT04499976|Drug|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
79378383|NCT04499976|Drug|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
79532604|NCT01440790|Dietary Supplement|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
79688474|NCT04902261|Drug|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
79688475|NCT04902261|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
79688476|NCT04884100|Other|Validating and improving PPG-based algorithms|Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
79237972|NCT03663127|Dietary Supplement|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
79237973|NCT03663127|Dietary Supplement|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
79688477|NCT04873596|Drug|Nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine.
79237974|NCT00328653|Drug|Cyclosporine NOVA22007 0.05%|
79832028|NCT00930670|Drug|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
79237975|NCT00328653|Drug|Cyclosporine NOVA22007 0.1%|
79688478|NCT04873596|Drug|Nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam.
79237976|NCT00328653|Drug|Vehicle|
79237977|NCT03662581|Behavioral|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~Foster peer-to-peer learning and support when it comes to coping with life challenges~Combat isolation~Increase efficiency, quality, and timeliness of care"
79832029|NCT00930670|Drug|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
79237978|NCT05258253|Other|High intensity aerobics|"London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)"
79237979|NCT05258253|Other|Pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
79237980|NCT03662113|Drug|Domperidone|5ml Domperidone prior to VCE
79378384|NCT02504658|Behavioral|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
79532605|NCT01440790|Dietary Supplement|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
79532606|NCT01440790|Dietary Supplement|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
79532607|NCT01440790|Dietary Supplement|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
79532608|NCT01440829|Drug|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
79532609|NCT01440842|Other|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
79532610|NCT01440842|Other|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
79532611|NCT01440855|Other|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
79832030|NCT00930670|Drug|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
79832031|NCT00930670|Drug|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
79832032|NCT00930670|Drug|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
79237981|NCT03662113|Dietary Supplement|water|5ml water prior to VCE
79832033|NCT00930670|Drug|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
79832034|NCT00930748|Device|MR imaging with endorectal coil|MR imaging with endorectal coil
79832035|NCT00930748|Device|MRI with endo-rectal coil|MRI with endo-rectal coil
79832036|NCT00934804|Device|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
79832037|NCT00934882|Drug|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
79832038|NCT00937144|Drug|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
79688479|NCT04868357|Behavioral|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
79832039|NCT00937144|Drug|placebo|
79832040|NCT04014400|Other|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
79832041|NCT00937222|Dietary Supplement|Peanuts and peanut butter|Peanuts and peanut butter
79832042|NCT00937300|Biological|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
79832043|NCT00931060|Dietary Supplement|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
80005616|NCT05256212|Other|exposure to environmental contaminants|to measure levels of contaminants in different matrixes
80005617|NCT05239520|Other|3D movement analysis with surface electromyography and ultrasound|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
80005618|NCT05198869|Device|Spectral scan|Consenting participants will have a SpotLight-19 scan
80005619|NCT01367834|Drug|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
79237982|NCT03478137|Behavioral|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
79237983|NCT04924023|Behavioral|kaleidoscope application|The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
79832044|NCT00937456|Procedure|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
80005620|NCT03106753|Drug|Bupivacaine|intrathecal bupivacaine 7.5 mg
79532612|NCT01440855|Other|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
79532613|NCT01440868|Procedure|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher & Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm ).
80005621|NCT03106753|Drug|Terbutaline|0.25 mg Terbutaline subcutaneously
80005622|NCT02132624|Biological|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
79532614|NCT01440894|Device|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
80005623|NCT02128880|Behavioral|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
80005624|NCT02128880|Behavioral|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
80005625|NCT02136758|Behavioral|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
80005626|NCT05385679|Procedure|Surgical Extraction of lower third molar|The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
80005627|NCT02132702|Device|Ekso|
79832045|NCT04014010|Other|Blood pressure|"Systolic Blood Pressure (SBP)~Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative SBP~Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative MAP~Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
80005628|NCT05198401|Other|covid-19|viral infection
80005629|NCT05198323|Drug|LT3001 Drug Product|Administered by intravenous infusion
80005630|NCT05198323|Drug|Placebo|Administered by intravenous infusion
80005631|NCT03550898|Diagnostic Test|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
80005632|NCT05704621|Procedure|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
79237984|NCT03662035|Drug|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
79688480|NCT04868357|Behavioral|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
80005633|NCT05704621|Drug|chemotherapy|six cycles of bevacizumab [10 mg/kg, days 1 and 15] plus carboplatin [AUC 5, day 1] plus pegylated liposomal doxorubicin [30 mg/m2, day 1] every 4 weeks, followed by maintenance bevacizumab [15 mg/kg every 3 weeks]
79688481|NCT04847635|Device|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
79688482|NCT04847635|Device|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
80005634|NCT02133014|Procedure|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
79237985|NCT03662035|Drug|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
79237986|NCT04861311|Behavioral|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
79237987|NCT03661957|Procedure|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
79237988|NCT03661957|Procedure|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
79237989|NCT03661879|Drug|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
79378385|NCT02504658|Behavioral|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
79378386|NCT01791413|Drug|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
79532615|NCT01440907|Other|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
79688483|NCT04842786|Other|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
79709900|NCT00596544|Behavioral|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
80005635|NCT02133014|Drug|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
80005636|NCT05759455|Dietary Supplement|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
79237990|NCT03661879|Drug|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
79378387|NCT01614574|Biological|velaglucerase alfa|60 U/kg every other week intravenous infusion
79378388|NCT01610063|Other|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
79709901|NCT00596544|Behavioral|questionnaires|Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
79378389|NCT04499040|Biological|Blood sample|Blood samples to assess biological parameters such as:
79532616|NCT01440933|Drug|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
79709902|NCT01588847|Procedure|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
79709903|NCT01588847|Procedure|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
79378390|NCT04499040|Other|Fecal samples|Microbiota analysis
79709904|NCT04339530|Other|Normal weight and overweight adults|Association between vitamin D levels and insulin resistance
79709905|NCT00107900|Drug|DU-176b|
79237991|NCT03478059|Behavioral|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
79237992|NCT05158881|Device|Near-infrared spectroscopy|Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
79237993|NCT05158803|Radiation|ultrasound and C.T|lung ultrasound in comparison to C.T
79237994|NCT04802577|Diagnostic Test|FACT-F questionnaire|The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.
79237995|NCT04802577|Diagnostic Test|Beck Depression Inventory|The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.
79237996|NCT04802577|Diagnostic Test|Beck Anxiety Inventory|The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.
79237997|NCT04802577|Diagnostic Test|Insomnia severity index.|The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.
79378391|NCT04499040|Behavioral|Neuropsychological|Neuropsychological assessment
79378392|NCT02510118|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
79378393|NCT02510118|Drug|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks
79832046|NCT04014010|Other|Heart rate|"Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~Relative change (%) from preoperative heart rate (positive and negative)~Maximum pulse variation (maximum heart rate minus minimum heart rate)~Longest single episode (minutes) a) below 60, and b) above 100BPM~Cumulative duration (minutes) a) below 60, and b) above 100BPM"
79832047|NCT04014010|Other|Use of hemodynamic medications (i.e. special medications for blood pressure)|"Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
79832048|NCT04014010|Other|Oxygen saturation by pulse oximetry (SpO2)|"Longest single episode (minutes) below a) 88, and b) 90%~Cumulative duration (minutes) below a) 88, and b) 90%"
79832049|NCT04014010|Other|End-tidal Carbon dioxide (EtCO2)|"Longest single episode (minutes) a) below 30, and b) above 45mmHg~Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
79832050|NCT03743272|Device|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
79832051|NCT00935116|Drug|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
79832052|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
79832053|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
79832054|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
79378394|NCT02510118|Drug|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
79378395|NCT02510118|Drug|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
79378396|NCT02509806|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
79378397|NCT02509728|Dietary Supplement|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
79237998|NCT04802577|Other|ESSPRI|The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.
79688484|NCT04841434|Drug|Voraxaze Injectable Product|High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to <40 mL/min, or in the case of decreased GFR, the decrease is >50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing >100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
79688485|NCT04838301|Drug|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
79688486|NCT04838301|Other|Placebo|Normal saline solution IV via 30-minute infusion, once per week
79688487|NCT04817189|Drug|NEPA (300mg netupitant/0.5mg palonosetron)|Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
79832055|NCT04014088|Device|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
79832056|NCT00935194|Drug|oseltamivir|75mg,bid,for 5 days
79237999|NCT04802577|Other|ESSDAI|Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.
79688488|NCT04817189|Drug|Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)|Standard of care will be administered on Day 1 of each cycle.
79238000|NCT04802577|Other|Pain Detect Questionnaire|The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
79238001|NCT05798702|Procedure|roux -en-y- gastric bypass|Roux-&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
79238002|NCT05798702|Dietary Supplement|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
79378398|NCT02509728|Dietary Supplement|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
79378399|NCT02509728|Dietary Supplement|standard nutrition|standard nutrition
79378400|NCT02509338|Device|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
79832057|NCT00935194|Other|blank|no antiviral therapy
79532617|NCT01440933|Drug|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
79688489|NCT04817189|Drug|Dexamethasone, 8 mg (oral) or equivalent IV dose|Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
79688490|NCT04811703|Drug|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
79688491|NCT04805645|Other|No intervention (Retrospective Cohort Observational)|No intervention as this study is a Retrospective Cohort Observational
79832058|NCT00935194|Drug|chinese medicinal herbs|200ml,p.o,qid,for 5 days
79832059|NCT00935194|Drug|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
79378401|NCT02501616|Drug|Metformin|
79709906|NCT00596583|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
79709907|NCT00596583|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
79709908|NCT01339052|Drug|BKM120|
79832060|NCT00937534|Drug|Fimasartan|Fimasartan 240mg/day
79832061|NCT00690378|Drug|NXL104/ceftazidime|125mg/500mg TID
79378402|NCT02501616|Drug|Dapagliflozin|
79378403|NCT02501460|Other|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
79532618|NCT01440985|Drug|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
79532619|NCT01440985|Drug|Nicotine|Nicotine gum 4 mg, Lot number GC962A
79532620|NCT01440985|Drug|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
79532621|NCT01440998|Drug|Carboplatin|Given IV
79532622|NCT01440998|Drug|Dasatinib|Given PO
79709909|NCT01339052|Procedure|Surgery|Surgery
79532623|NCT01440998|Other|Laboratory Biomarker Analysis|Correlative studies
79832062|NCT00690378|Drug|Imipenem/Cilastatin|4 x daily
79832063|NCT00937612|Radiation|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
79832064|NCT00574275|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
79832065|NCT00574275|Drug|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
80005637|NCT02129114|Device|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
80005638|NCT02129114|Device|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
80005639|NCT03653143|Behavioral|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
80005640|NCT02136992|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
80005641|NCT02136992|Drug|placebo|placebo will be taken two tablets 3 times a day during the whole study process
80005642|NCT03629119|Dietary Supplement|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
80005643|NCT02133092|Other|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
80005644|NCT03045081|Behavioral|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
79832066|NCT00574275|Drug|Gemcitabine|1000 mg/m^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
79532624|NCT01440998|Drug|Paclitaxel|Given IV
80005645|NCT03621397|Device|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
80005646|NCT02137148|Device|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
80005647|NCT02252978|Drug|ciprofloxacin|Given PO
80005648|NCT02252978|Other|placebo|Given PO
79532625|NCT01441011|Behavioral|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
80005649|NCT02252978|Other|quality-of-life assessment|Ancillary studies
80005650|NCT02252978|Other|laboratory biomarker analysis|Correlative studies
80005651|NCT05507385|Behavioral|IMAGINE-POSITIVE|The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI), to increase vividness and savouring of positive future images, in order to harness positive affect. IMAGINE-PA will follow a treatment manual and delivery will be accompanied by a therapy workbook.
80005652|NCT05507385|Behavioral|Control|Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
79378404|NCT02501460|Other|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
79378405|NCT02501460|Dietary Supplement|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
79532626|NCT01441011|Behavioral|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
79378406|NCT02501460|Other|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
79532627|NCT01441024|Drug|DAS181|20 mg per day of DAS181-FO3 for 5 days
79532628|NCT01441024|Other|Placebo|20 mg per day of Lactose for 5 days
79532629|NCT01441128|Drug|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
79532630|NCT01441128|Drug|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
79532631|NCT01441167|Biological|PfSPZ|
79532632|NCT01441193|Biological|HIV-1 Tat/delta-V2 Env combined vaccine|
79532633|NCT01441193|Biological|HIV-1 delta-V2 Env vaccine|
79532634|NCT01441193|Biological|HIV-1 Tat vaccine 7.5 microg|
79532635|NCT01441193|Biological|HIV-1 Tat vaccine 30 microg|
79832067|NCT00931216|Procedure|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
79832068|NCT00743418|Device|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
79832069|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
79832070|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|5.0 grams of PGX
79832071|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|0 grams of PGX
80005653|NCT02133170|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
79238003|NCT05798689|Combination Product|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
79238004|NCT05798689|Combination Product|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
79238005|NCT05798676|Other|overweight/obesity|the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
79238006|NCT05798598|Other|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
79238007|NCT05798546|Biological|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
79378407|NCT01790633|Other|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
79378408|NCT01790633|Other|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
79378409|NCT01788215|Drug|doxycycline|200mg/day in divided doses of 100mg twice daily
79378410|NCT01788215|Other|Sugar Pill|1 pill twice a day
79378411|NCT02503956|Device|Perforated Punctal plugs|Perforated punctal plugs
79532636|NCT01441206|Drug|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth < 32 weeks - PNA < 14 days: 10 mg/kg QD GA at birth < 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA < 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
79532637|NCT01441219|Device|Colon 2|Ingest one colon 2 capsule
79238008|NCT05798546|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
79238009|NCT05798546|Drug|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
79238010|NCT05798546|Drug|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
79378412|NCT02503956|Procedure|Crawford tube insertion|
79378413|NCT02503956|Device|Crawford lacrimal tube|
79378414|NCT01787825|Device|PillCam SB2 capsule|Capsule Endoscopy system
79378415|NCT01787825|Device|CapsoCam SV-1|Capsule endoscopy
79378416|NCT03344484|Other|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
79378417|NCT01813019|Drug|AFQ056|mGluR5 antagonist
79378418|NCT01813019|Drug|Placebo|Matched placebo
79378419|NCT02509572|Behavioral|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
79532638|NCT01441232|Drug|LX4211|400 mg of LX4211 administered as two 200 mg tablets
79532639|NCT01441232|Drug|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
79688492|NCT04755361|Behavioral|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
79688493|NCT04743479|Diagnostic Test|high-resolution MRI/CT examinations|Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
79688494|NCT04735575|Biological|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
79688495|NCT04725916|Other|Showering|Patients will be instructed to shower after surgery with drains in place
79688496|NCT04725916|Other|Restriction of Showering|Patients will be restricted from showering post operatively if they have drains in place
79532640|NCT01441258|Behavioral|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
80005654|NCT02133170|Behavioral|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
80005655|NCT02133170|Behavioral|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
80005656|NCT03107377|Drug|EVO100|5 g dose applied up to 1 hour prior to coitus
80005657|NCT03107377|Drug|Placebo|5 g dose applied up to 1 hour prior to coitus
80005658|NCT02253056|Other|Fasting / Caloric Restriction|
79532641|NCT01441258|Behavioral|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
79532642|NCT01441258|Behavioral|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
79688497|NCT04724837|Drug|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
79688498|NCT04724837|Drug|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
79688499|NCT04724837|Drug|Placebo|Participants will receive placebo as per the arms they are randomized to.
79832072|NCT00839865|Drug|herb ointment|a kind of ointment made from herb
79832073|NCT02564640|Device|videolaryngoscope|patients intubated by using the videolaryngoscope
79832074|NCT02564640|Device|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
79832075|NCT00839943|Other|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
79832076|NCT00746382|Drug|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
79832077|NCT00746382|Drug|Placebo cream|Placebo cream
80005659|NCT02253056|Other|Healthy Diet|
80005660|NCT02129270|Drug|Lidocaine HCl 2% .|comparison of different dosages of drug
79238011|NCT05798494|Behavioral|Weight loss intervention|Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
79238012|NCT05798455|Drug|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
79238013|NCT05798442|Other|smartphone health application (Opulse)|The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
79832078|NCT00833001|Device|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
79532643|NCT01441271|Procedure|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution [GoLytely®; Braintree Laboratories] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes [500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days] via a Malecot catheter [24 French] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole [500mg q8 hours] for 10 days.
79832079|NCT04060368|Procedure|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
80005661|NCT02129270|Drug|Lidocaine HCl 1%|comparison of different dosages of drug
80005662|NCT03550742|Other|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
80005663|NCT03549884|Procedure|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
80005664|NCT03549884|Procedure|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
80005665|NCT05370547|Drug|Chidamide|"Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
80005666|NCT05370547|Drug|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m^2) and cyclophosphamide (250-500 mg/m^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
79832080|NCT04060368|Procedure|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
79832081|NCT00828867|Drug|100 mg GSK investigational drug|
79832082|NCT00828867|Drug|200 mg GSK investigational drug|
79832083|NCT00828867|Drug|400 mg GSK investigational drug|
79832084|NCT00828867|Drug|800 mg GSK investigational drug|
79832085|NCT00828867|Drug|2000 mg GSK investigational drug|
79832086|NCT00828867|Drug|1500 mg GSK investigational drug|
80005667|NCT05370547|Biological|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10^6 for Relma-cel or 2 × 10^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
80005668|NCT02133326|Drug|Caldolor|Subject will be given Caldolor by IV prior to surgery.
79832087|NCT00828867|Drug|800mg fed GSK investigational drug|
79832088|NCT00828867|Drug|3000mg GSK investigational drug|
80005669|NCT02133326|Drug|Ofirmev|Subject will be given Ofirmev prior to surgery.
80005670|NCT02137304|Device|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
80005671|NCT02133482|Drug|Placebo|placebo solution
79238014|NCT05798429|Other|compassion education|6 weeks of compassion training
80005672|NCT02133482|Drug|BI 639667|oral solution BI 639667, single rising doses
79832089|NCT00828867|Drug|4000mg GSK investigational drug|
79238015|NCT05798312|Other|Customizable support material|Customizable support material will enable patients to identify their personal breast cancer information.
79378420|NCT02503878|Device|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
79378421|NCT01787591|Other|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
79238016|NCT05798312|Other|Non-customizable support material|Non-customizable support material will include general breast cancer information.
79238017|NCT05798299|Behavioral|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
79378422|NCT01787591|Other|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
79378423|NCT01787591|Other|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
79378424|NCT01787591|Other|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
79532644|NCT01441271|Procedure|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
79832090|NCT00746460|Behavioral|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
79832091|NCT00567112|Drug|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
79832092|NCT00567112|Drug|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
79832093|NCT00567112|Drug|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
79238018|NCT05798299|Behavioral|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
79532645|NCT01441284|Drug|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
79832094|NCT00567112|Drug|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
79532646|NCT01441284|Drug|placebo|placebo
79832095|NCT01742832|Drug|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
79832096|NCT01742832|Drug|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
79832097|NCT00833079|Drug|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
79832098|NCT00833079|Drug|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
79832099|NCT00833079|Drug|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
80005673|NCT05341141|Device|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
80005674|NCT05341141|Drug|ddEC-ddT|Epirubicin (E) 90~100mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m^2, i.v., d1, q2w, for 4 cycles.
80005675|NCT02137616|Drug|risperidone|Risperdal tablets
80005676|NCT02137616|Drug|olanzapine|olanzapine tablets
80005677|NCT02137616|Drug|Quetiapine|quetiapine tablets
80005678|NCT02137616|Drug|Aripiprazole|Aripiprazole tablets
80005679|NCT02129504|Device|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
80005680|NCT02133560|Behavioral|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
79832100|NCT00935506|Drug|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
79832101|NCT00935506|Drug|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
79832102|NCT00833157|Drug|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg * 3 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks.
79832103|NCT00833157|Drug|ibuprofen|Subjects are administered 600 mg * 2 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks
79832104|NCT00833157|Drug|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (*3 weekly) with both legs for 12 weeks
79832105|NCT00931294|Behavioral|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
79832106|NCT00931294|Behavioral|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
79832107|NCT00833235|Other|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
79832108|NCT00935662|Drug|AZD8329|Oral solution, single ascending doses
79832109|NCT00935662|Drug|Placebo|Oral solution, placebo
79832110|NCT00931372|Drug|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
79238019|NCT05798260|Diagnostic Test|Agilent Seahorse XF Cell Mito Stress Test|The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
79238020|NCT05798234|Device|high flow oxygen device|no intervention
79238021|NCT05798208|Diagnostic Test|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
79238022|NCT05798195|Other|conventional western medicine treatment|conventional western medicine treatment only
79378425|NCT02504034|Procedure|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
79378426|NCT02504034|Device|6-French sheath|
79378427|NCT02504034|Device|22-gauge chiba needle|
79832111|NCT00931372|Drug|Placebo|Subcutaneous injection
79832112|NCT00829257|Drug|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
79832113|NCT00829257|Drug|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
79832114|NCT00829257|Drug|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
79832115|NCT01618656|Drug|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
79832116|NCT01618656|Drug|Placebo|Sugar pill
79238023|NCT05798195|Drug|Dexamethasone oral tablet|treat with Dexamethasone for 2 weeks
79832117|NCT03978832|Drug|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
79832118|NCT03978832|Drug|Risperidone|Oral risperidone
79832119|NCT00840255|Behavioral|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
80005681|NCT02133560|Behavioral|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
80005682|NCT02133560|Behavioral|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
79238024|NCT05798195|Other|Traditional Chinese medicine decoction|treat with strengthening spleen and tonifying lung decoction for 2 weeks
79238025|NCT05798182|Diagnostic Test|Ultrasound measurement|Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
79238026|NCT05798169|Other|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
79238027|NCT05798143|Device|Accelerated Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
79238028|NCT05798065|Procedure|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
79378428|NCT02504034|Device|260-cm-long stiff shaft wire|
79378429|NCT02504034|Device|Balloon catheter|
79378430|NCT02504034|Device|Bare metal stent|
79238029|NCT05798052|Behavioral|Psychological stressors added to simulated clinical scenarios.|In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
79832120|NCT00840255|Other|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
79832121|NCT00840333|Drug|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
79832122|NCT00840489|Drug|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
79832123|NCT00840489|Drug|Colchicine|Colchicine 0.5 mg bd for 24 weeks
79832124|NCT00743496|Biological|Anti-GD2 antibody|Anti-GD2 antibody
79832125|NCT00937846|Drug|GSK1034702|Single oral 5 mg dose in liquid formulation
79832126|NCT00833391|Drug|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
79832127|NCT04044105|Other|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
79832128|NCT04044105|Other|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
79832129|NCT00829335|Procedure|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
79832130|NCT00829491|Behavioral|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
79832131|NCT02547051|Other|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
79532647|NCT01441297|Drug|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
79688500|NCT04714047|Other|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
79238030|NCT05798026|Drug|EU103|EU103 will be administered via intravenous infusion.
79532648|NCT01441310|Procedure|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
79532649|NCT01441323|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
79832132|NCT00840567|Procedure|Skin biopsy|
79238031|NCT05797961|Behavioral|HIV self-testing with online supervision|A pilot study to assess the feasibility of HIV self-testing with online supervision
79238032|NCT05797961|Other|Control|venue-based HIV testing
79238033|NCT05797948|Drug|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
79238034|NCT05797948|Drug|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
79238035|NCT05797948|Drug|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
79238036|NCT05797948|Drug|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 * 10 ^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
79378431|NCT02504034|Device|Covered stent|
79378432|NCT02503644|Drug|IVA337|Capsules of 200mg IVA337
79378433|NCT02503644|Drug|Placebo|Identical capsules without active substance
79378434|NCT01812707|Drug|Alirocumab|Two SC injections in the abdomen only
79378435|NCT01812707|Drug|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
79378436|NCT01812707|Drug|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
79378437|NCT02509182|Drug|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
79532650|NCT01441323|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
79532651|NCT01441336|Procedure|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
79532652|NCT01441362|Procedure|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
79532653|NCT01441362|Procedure|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
79532654|NCT01441388|Drug|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
79532655|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
79532656|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
79532657|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
79688501|NCT04714047|Other|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
79832133|NCT00840567|Procedure|Blood draw & sample|
79832134|NCT00829569|Dietary Supplement|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
79832135|NCT02548767|Other|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
79832136|NCT02548767|Other|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
79832137|NCT02548767|Other|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
79832138|NCT02548767|Other|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
79832139|NCT00840645|Drug|YM178|Oral
79832140|NCT00566722|Biological|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
79832141|NCT00691704|Drug|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
80005683|NCT05198011|Procedure|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
79238037|NCT05797948|Drug|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
79532658|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
79532659|NCT01441388|Drug|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
79532660|NCT01441388|Drug|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
79532661|NCT01441427|Drug|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
79532662|NCT01441427|Drug|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
79238038|NCT05797948|Drug|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
79238039|NCT05797948|Drug|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
79378438|NCT02509182|Drug|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
79378439|NCT04497090|Device|fixed-EPAP|In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
79238040|NCT05797922|Drug|DWP16001|DWP16001 0.3mg
79378440|NCT04497090|Device|auto-EPAP|In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
79378441|NCT01787279|Drug|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
79378442|NCT02728206|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79832142|NCT00691704|Drug|Sequential Maintenance Therapy|"Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):~325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
79378443|NCT04576793|Drug|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
79688502|NCT04714047|Other|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
79832143|NCT00833625|Procedure|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
79832144|NCT00833625|Other|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
79832145|NCT00829647|Drug|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
79832146|NCT02564406|Device|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
79378444|NCT04576793|Drug|18F-MK6240|MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
79238041|NCT05797883|Drug|FOLFOX/FOLFIRI|mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
79238042|NCT05797844|Other|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
79238043|NCT05797844|Other|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
79378445|NCT04576793|Drug|18F-Florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
79378446|NCT04576793|Procedure|Lumbar Puncture|Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
79378447|NCT02500992|Procedure|Transrectal sigmoidectomy|
80005684|NCT05198011|Procedure|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
80005685|NCT02133638|Drug|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
80005686|NCT02133638|Drug|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
80005687|NCT05197933|Procedure|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
80005688|NCT02545283|Drug|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m^2) intravenous (IV) infusion for 5 days of every treatment cycle.
80005689|NCT02545283|Drug|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
80005690|NCT02545283|Other|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
80005691|NCT02137694|Other|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
79378448|NCT01811225|Drug|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
79378449|NCT01811225|Drug|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
79378450|NCT02503566|Device|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
79378451|NCT01809197|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
79378452|NCT01809197|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
79238044|NCT05797818|Device|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene Blue (0.01%) + 4 minutes of light treatment"
79238045|NCT05797818|Device|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
79238046|NCT05797818|Device|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
79238047|NCT05797818|Device|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- 4 minutes of light treatment only"
79688503|NCT04714047|Other|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
79238048|NCT05797792|Drug|Intraarterial alteplase|See arm/group descriptions.
79238049|NCT05797779|Procedure|Skin biopsy|Punch biopsy of the skin
79688504|NCT04694794|Other|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
79238050|NCT05797753|Drug|SAR443820|Tablet by oral administration
79378453|NCT01809197|Device|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
79688505|NCT04605822|Device|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
80005692|NCT02260700|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
80005693|NCT02260700|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
80005694|NCT02260700|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
80005695|NCT05682391|Other|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
80005696|NCT02133716|Other|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
79238051|NCT05797753|Drug|SAR443820|Capsule by oral administration
79378454|NCT01809197|Device|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
79378455|NCT02508870|Drug|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
79378456|NCT02508870|Drug|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
79378457|NCT02508792|Device|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
79532663|NCT01441427|Drug|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
79532664|NCT01441427|Drug|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
79532665|NCT01441427|Drug|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
79532666|NCT01441453|Procedure|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
79238052|NCT05797753|Drug|Erythromycin ethyl succinate|Tablet by oral administration
79238053|NCT05797753|Drug|Itraconazole|Capsule by oral administration
79532667|NCT01441479|Device|In Vitro Diagnostic Device aid in diagnosing|
79238054|NCT05797714|Drug|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 48 weeks
79238055|NCT05797701|Drug|SAR443820|Tablet by oral administration
79238056|NCT05797701|Drug|SAR443820|Capsule by oral administration
79238057|NCT05797688|Device|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
79238058|NCT05797584|Drug|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
80005697|NCT02133716|Behavioral|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
80005698|NCT02137928|Drug|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
80005699|NCT02137928|Drug|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
79238059|NCT05797584|Other|Passive leg raising|Passive leg raising for acute volume load
79238060|NCT05797532|Other|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
79238061|NCT05797532|Other|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
79238062|NCT05797532|Other|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
79378458|NCT02508792|Device|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
79238063|NCT05797493|Drug|Atezolizumab|Upfront chemo-immunotherapy
79238064|NCT05797428|Other|logotherapy|The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
79378459|NCT01786109|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
79378460|NCT01786109|Drug|Placebo|Placebo will match study drug; taken as one dose orally with water.
80005700|NCT02138084|Drug|BMS-663068|BMS-663068
80005701|NCT02138084|Drug|Rifabutin|Rifabutin
80005702|NCT02138084|Drug|Ritonavir|Ritonavir
80005703|NCT05677087|Behavioral|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
80005704|NCT02129582|Radiation|total marrow irradiation|Undergo TMI
80005705|NCT02129582|Drug|fludarabine phosphate|Given IV
80005706|NCT02129582|Drug|busulfan|Given IV or PO
80005707|NCT02129582|Procedure|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
79378461|NCT02509104|Drug|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
79378462|NCT02509104|Drug|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
79378463|NCT02500914|Drug|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
79378464|NCT02503488|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
79532668|NCT01441505|Drug|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
79532669|NCT01441505|Drug|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
80005708|NCT02129582|Biological|anti-thymocyte globulin|Given IV
80005709|NCT02129582|Drug|tacrolimus|Given IV or PO
80005710|NCT02129582|Drug|methotrexate|Given IV
80005711|NCT02129582|Other|laboratory biomarker analysis|Correlative studies
80005712|NCT03282565|Other|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
80005713|NCT03282565|Other|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
80005714|NCT03282565|Other|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
79378465|NCT02503488|Behavioral|Treatment as Usual|See arm description
79378466|NCT02500680|Biological|MER4101|
79832147|NCT00935896|Procedure|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
79832148|NCT00935896|Procedure|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
80005715|NCT01355549|Biological|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
79688506|NCT04605822|Device|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
80005716|NCT02129738|Device|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
79238065|NCT05797415|Procedure|Sentinel Lymph Node Biopsy|"Injection of 99mTc-labeled nanocolloids~Preoperative lymphoscintigraphy~Intraoperative gamma probe search of the sentinel lymph node~Sentinel lymph node biopsy~Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy."
79238066|NCT05797363|Other|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
79532670|NCT01441518|Other|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
79688507|NCT04605822|Device|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
79832149|NCT00935896|Other|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
79832150|NCT00829725|Device|screws-internal fixation|3-4-screws-internal fixation
79832151|NCT00829725|Device|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
79832152|NCT00939328|Biological|rituximab|
79832153|NCT00939328|Drug|bendamustine hydrochloride|
79832154|NCT00746538|Device|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
79832155|NCT00829881|Drug|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
79832156|NCT00829881|Drug|Placebo Capsule|A single placebo capsule
79832157|NCT02563314|Device|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
79832158|NCT02563314|Device|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
79378467|NCT02500680|Biological|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
79378468|NCT04496778|Device|low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|"Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity"
79378469|NCT04496778|Other|aerobic exercise|3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
79378470|NCT02500446|Drug|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
79378471|NCT02500446|Other|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
79378472|NCT02500524|Drug|Cocamide diethanolamine|Topical lotion
79832159|NCT00936052|Other|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
79832160|NCT00936130|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
79832161|NCT00936130|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
79832162|NCT00936130|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
79832163|NCT00936130|Behavioral|Low Calorie Diet|Low Calorie Diet Program
79832164|NCT00829959|Behavioral|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
79238067|NCT05797350|Device|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
79238068|NCT05797220|Drug|Botulinum Toxin Type A Injection [Botox]|
79238069|NCT05797220|Drug|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
79238070|NCT05797207|Diagnostic Test|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
79238071|NCT05797207|Procedure|Colonoscopy|Colonoscopy procedure
79238072|NCT05797142|Other|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
79238073|NCT05797129|Device|CEDM|Women underwent CEDM screening
79378473|NCT02500524|Drug|Permethrin|Topical creme rinse
79378474|NCT02508714|Device|Orsiro|stents will be implanted in case of significant coronary artery disease
79378475|NCT02508714|Device|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
79688508|NCT04605822|Other|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
79688509|NCT04603001|Drug|LY3410738|Oral LY3410738
79688510|NCT04603001|Drug|Venetoclax|Oral venetoclax
79688511|NCT04603001|Drug|Azacitidine|Subcutaneous or intravenous azacitidine
79688512|NCT04602741|Behavioral|A4i Intervention|6 months of the provision of A4i on the individual's own device.
79688513|NCT04588922|Drug|GFH009|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).
79688514|NCT04588922|Drug|GFH009|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).
79378476|NCT02508558|Other|motion perception and locomotor operation performance measurements|
79378477|NCT02508558|Other|parabolic flight|
79378478|NCT02503098|Behavioral|Recovery Record adaptive smartphone application|
79378479|NCT02503098|Behavioral|Recovery Record standard smartphone application|
79378480|NCT04498962|Drug|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
79378481|NCT02508402|Drug|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
79688515|NCT04588922|Drug|GFH009, venetoclax, azacitidine|Group 3. Patients with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens
79688516|NCT04581733|Drug|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
79832165|NCT04016727|Biological|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
79832166|NCT04014244|Drug|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
79378482|NCT02508402|Drug|Placebo|two milliliters of normal saline given to placebo group .
79238074|NCT05797077|Procedure|Colorectal resection surgery.|Colorectal cancer radical resection combined with liver metastasis resection or ablation.
79832167|NCT04014244|Procedure|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
79238075|NCT05797077|Drug|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
79238076|NCT05797077|Drug|Capecitabine|Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
79378483|NCT02500134|Other|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
79832168|NCT00743808|Other|quality improvement|3-phase quality improvement intervention
79832169|NCT00834015|Other|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
79378484|NCT02500212|Drug|ENVARSUS®|
79378485|NCT02500212|Drug|ADVAGRAF®|
79378486|NCT01615120|Drug|GTx-758 125 mg|One 125 mg tablet once a day
79378487|NCT01615120|Drug|GTx-758 250 mg|two 125 mg tablets once daily
79832170|NCT02548611|Drug|Prasugrel|see arm description
79832171|NCT02548611|Drug|Clopidogrel|see arm description
79832172|NCT00743886|Biological|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
79832173|NCT00743886|Drug|saline|injection of 6 cc of saline into injured area
79532671|NCT01441518|Other|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
79238077|NCT05797064|Procedure|Natural Orifice Specimen Extraction Surgery|Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
79238078|NCT05797038|Drug|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
79238079|NCT05796986|Procedure|Endovascular procedure of treatment of wide neck saccular cerebral aneurysm|Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
79378488|NCT04496934|Behavioral|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
79378489|NCT02508168|Drug|Alogliptin|Alogliptin 12.5 mg tablets
79378490|NCT02508168|Drug|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
79378491|NCT02508168|Drug|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
79378492|NCT01616056|Biological|graft versus host disease prophylaxis/therapy|Wear bandage lenses
79532672|NCT01441531|Drug|gabapentin 600 mg po|Given one hour before surgery
79532673|NCT01441531|Drug|Placebo pill given one hour before surgery|Placebo pill given
79688517|NCT04576715|Behavioral|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~Management based on current best practices (however, may have additional education from the provider training)~Return to school letters~Primary Care Follow Up"
79832174|NCT00938002|Diagnostic Test|Acceler8 Pheno|
79832175|NCT00830193|Drug|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
79832176|NCT00830193|Drug|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
79832177|NCT00746772|Drug|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
80005717|NCT01362023|Behavioral|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
80005718|NCT02133794|Device|Tomosynthesis|
80005719|NCT05188625|Other|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
80005720|NCT02129816|Drug|Bryophyllum|
80005721|NCT05106205|Drug|DA-5213 10mg|single dose administration (one tablet once a day)
79238080|NCT05796960|Procedure|Thyroidectomy with or without lymphadenectomy or multivisceral resection|Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
79238081|NCT05796934|Behavioral|Moments that Matter (MTM) Program|"MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security & safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers)."
79238082|NCT05796908|Device|Aptis PRUJ Prosthesis|A prosthetic implant for replacement of the proximal radial ulna joint.
79532674|NCT01441544|Behavioral|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
79532675|NCT01441557|Drug|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
79688518|NCT04576715|Behavioral|Standard of Care|"Continue with CHOA current best practices for mTBI:~No TEaM Provider training (but will be offered to all providers at end of study)~Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
79688519|NCT04576364|Drug|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
79688520|NCT04576364|Drug|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
79378493|NCT01616056|Other|questionnaire administration|Ancillary studies
79832178|NCT00746772|Drug|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
79832179|NCT00938080|Biological|AG013|Mouth rinse once a day for 14 days
79378494|NCT01616056|Procedure|optical coherence tomography|Optional ancillary studies
79832180|NCT00938080|Biological|AG013|Mouth rinse three times a day for 14 days
79832181|NCT00938080|Biological|AG013|Mouth rinse six times a day for 14 days
79832182|NCT00938080|Other|Placebo|Mouth rinse once a day for 14 days
79832183|NCT00938080|Other|Placebo|Mouth rinse three times a day for 14 days
79832184|NCT00938080|Other|Placebo|Mouth rinse six times a day for 14 days
80005722|NCT05106205|Drug|DA-5213-R 10mg|single dose administration (one tablet once a day)
80005723|NCT01362101|Behavioral|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
80005724|NCT02129894|Device|abdominal Binder|placement of abdominal binder
80005725|NCT04756739|Device|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
79378495|NCT02503176|Drug|KCT-0809 ophthalmic solution|
79378496|NCT02508246|Drug|Cisplatin|Given IV
79378497|NCT02508246|Drug|Docetaxel|Given IV
79378498|NCT02508246|Other|Laboratory Biomarker Analysis|Correlative studies
79378499|NCT02508246|Other|Pharmacological Study|Correlative studies
79378500|NCT02508246|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79532676|NCT01441583|Device|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
79688521|NCT04547790|Dietary Supplement|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
79688522|NCT04547790|Dietary Supplement|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
79688523|NCT04542317|Behavioral|REACH VN|4-6 sessions delivered over the course of 2-3 months.
79688524|NCT04542317|Behavioral|Enhanced control|A single session providing education about dementia
79688525|NCT04538976|Drug|Sildenafil|Sildenafil in standard dosage
79832185|NCT00834327|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
79378501|NCT02508246|Drug|WEE1 Inhibitor AZD1775|Given PO
79832186|NCT02563938|Drug|AK001|Given parenterally.
79832187|NCT02563938|Drug|Placebo|
79832188|NCT00938158|Biological|albiglutide|single dose of subcutaneously injected albiglutide
79832189|NCT00840957|Biological|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
79832190|NCT00743964|Drug|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
79832191|NCT00743964|Drug|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
79832192|NCT00939406|Device|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
79832193|NCT00830271|Device|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
79832194|NCT00830271|Device|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
79832195|NCT02563236|Other|Parabolic flight|
79832196|NCT00830349|Drug|Risperidone|1 mg Tablet
79832197|NCT00830349|Drug|Risperidone|1 mg Tablets
79832198|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
79238083|NCT05796895|Behavioral|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
79832199|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
79832200|NCT00830427|Drug|PF-00610355|100 mcg, QD, dry powder inhaler
79238084|NCT05796895|Behavioral|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
79832201|NCT00830427|Drug|PF - 00610355|600 mcg, QD, dry powder inhaler
79832202|NCT00830427|Other|Placebo|QD, dry powder inhaler
79832203|NCT00830427|Drug|PF - 00610355|300 mcg, QD, dry powder inhaler
79238085|NCT05796830|Other|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
79238086|NCT05795985|Diagnostic Test|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
79378502|NCT01617148|Drug|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
79378503|NCT01618240|Other|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
79688526|NCT04537351|Biological|CYP-001|The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
79688527|NCT04522544|Drug|Tremelimumab|300 mg Tremelimumab C1D1
79688528|NCT04522544|Drug|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
79688529|NCT04522544|Procedure|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
79832204|NCT02563158|Procedure|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
79832205|NCT00841113|Drug|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
79832206|NCT00841113|Drug|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
79832207|NCT00741546|Procedure|Cardiac Surgery|Cardiac Surgery
79688530|NCT04522544|Procedure|DEB-TACE|Locoregional therapy will be performed as a standard-of-care procedure
79688531|NCT04521686|Drug|LY3410738|Oral LY3410738
79832208|NCT00830505|Drug|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
79832209|NCT00830505|Drug|fluticasone|2 puffs twice a day for 2 weeks
79832210|NCT00566020|Drug|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
79832211|NCT02563782|Biological|Sub-retinal transplantation of MA09-hRPE cells|transplantation
79832212|NCT02563782|Drug|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
79832213|NCT02563782|Drug|Placebo tacrolimus and mycophenolate mofetil|placebo
79832214|NCT02563782|Procedure|Sham Surgery|Sham surgery
79832215|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
79832216|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
79832217|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
79832218|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
79688532|NCT04521686|Drug|Gemcitabine|Intravenous gemcitabine
79688533|NCT04521686|Drug|Cisplatin|Intravenous cisplatin
79688534|NCT04521686|Drug|Durvalumab|Intravenous durvalumab
79688535|NCT04487678|Dietary Supplement|Ketone ester supplement|Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
79238087|NCT05795972|Dietary Supplement|inulin|patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
79688536|NCT04482036|Other|Mobile Phone Application Assessments|"The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team."
79688537|NCT04482036|Other|Standard Assessments|The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
79688538|NCT04447794|Behavioral|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
79832219|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
79832220|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
79832221|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
79832222|NCT00741624|Other|Bandage|one application for one week
79832223|NCT00830583|Procedure|blood test|There is only a blood test at the beginning.
79238088|NCT05795972|Other|standard therapy|control group (patients treated also with standard therapy)
79238089|NCT05795933|Drug|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
79238090|NCT05794269|Other|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
79238091|NCT05793476|Device|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
79238092|NCT05793476|Device|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
79378504|NCT01618240|Other|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
79378505|NCT03344406|Other|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
79378506|NCT03344406|Other|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
79378507|NCT03344406|Other|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
79378508|NCT03344406|Other|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
79378509|NCT03344406|Other|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
79532677|NCT01441583|Device|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
79532678|NCT01441622|Device|AL539 (SRETT)|recording data with AL539 (SRETT)
79532679|NCT01441648|Other|contact lens wear|tinted contact lens wear
79532680|NCT01441674|Behavioral|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
79532681|NCT01441700|Procedure|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
79688539|NCT04447794|Behavioral|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
79238093|NCT05793125|Device|Ultrasonography|"A full obstetrics ultrasound scan will be performed within 24 hours before delivery to document fetal biometry, estimated fetal weight and correlate it to fetal growth charts to exclude IUGR, amniotic fluid index and umbilical artery Doppler studies.~Fetal echocardiography will be done.Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time (At/Et) ratio will be measured in the main pulmonary artery."
79378510|NCT03344406|Other|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
79378511|NCT02249338|Drug|BIIL 284 BS|
79532682|NCT01441752|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
79532683|NCT01441752|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
79688540|NCT04444518|Behavioral|VAX-MOM Intervention|The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
79688541|NCT04444518|Behavioral|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
80005726|NCT02129972|Device|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
79688542|NCT04437043|Other|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
79688543|NCT04431635|Drug|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
80005727|NCT04715243|Device|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
79238094|NCT05792033|Other|Prospective registry|Prospective registry of patients with primary diagnosis of T1 urinary bladder cancer
79238095|NCT05791773|Procedure|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
79378512|NCT02249338|Drug|Placebo|
79378513|NCT02503020|Dietary Supplement|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
79378514|NCT02503020|Dietary Supplement|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
79378515|NCT01618942|Device|pressure algometer|
79378516|NCT02499978|Drug|Darunavir/Cobicistat|Fixed dose combination medication
79378517|NCT02499978|Drug|Dolutegravir|single tablet medication
79378518|NCT02502942|Behavioral|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
79378519|NCT02502942|Behavioral|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
79532684|NCT01441778|Drug|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
79532685|NCT01441778|Drug|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
79532686|NCT01441791|Procedure|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
79688544|NCT04431635|Drug|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
79832224|NCT00746928|Other|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
80005728|NCT04715243|Device|Helmet NIV|NIV interface
80005729|NCT04715243|Device|Face-mask NIV|NIV interface
79378520|NCT01620190|Other|Laboratory Biomarker Analysis|Correlative studies
80005730|NCT02138162|Drug|enzalutamide|oral
80005731|NCT02138318|Other|High definition (HD) endoscopy|
80005732|NCT02138318|Other|chromoendoscopy|
80005733|NCT03549572|Behavioral|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
80005734|NCT02133950|Procedure|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
80005735|NCT02133950|Procedure|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
80005736|NCT04566029|Biological|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
80005737|NCT04566029|Biological|Stool sample|The patients' stools will be collected at home
80005738|NCT04566029|Other|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
80005739|NCT02138396|Drug|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
79532687|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
79688545|NCT04431635|Drug|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
79688546|NCT04422015|Other|No intervention|No intervention
79688547|NCT04420962|Diagnostic Test|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
80005740|NCT02138396|Drug|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
79688548|NCT04373928|Procedure|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
79688549|NCT04350775|Other|RE-IADL|RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
79688550|NCT04350775|Other|General community rehabilitation|General community rehabilitation contains the activities in psychiatric rehabilitation center.
79832225|NCT00843453|Other|blood collection|blood collection
79832226|NCT00843453|Drug|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
80005741|NCT02138396|Drug|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
80005742|NCT02138474|Other|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
80005743|NCT02138474|Other|Placebo|Unmedicated sucrose pillules
80005744|NCT04560881|Biological|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
80005745|NCT04560881|Biological|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
80005746|NCT02911675|Device|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
80005747|NCT02252510|Other|HALOSPERM|
79238096|NCT05791773|Procedure|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
79378521|NCT01620190|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
79391189|NCT02415660|Behavioral|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
79532688|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
79532689|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
79532690|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
79532691|NCT01441817|Procedure|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
79688551|NCT04343820|Procedure|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
79688552|NCT04324307|Drug|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
79688553|NCT04324307|Combination Product|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
79688554|NCT04324307|Combination Product|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
79832227|NCT00921726|Drug|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
79832228|NCT00921726|Drug|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
79688555|NCT04268173|Other|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
80005748|NCT05223842|Behavioral|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
79238097|NCT05788315|Other|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
79832229|NCT00938236|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
79532692|NCT01441830|Device|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
79688556|NCT04251130|Drug|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
80005749|NCT05223842|Behavioral|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
80005750|NCT02875613|Drug|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
80005751|NCT02823457|Behavioral|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
80005752|NCT02130128|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
80005753|NCT02130206|Other|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
79688557|NCT04217395|Behavioral|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, & Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
80005754|NCT02130206|Other|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
80005755|NCT02130206|Other|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
79532693|NCT01441856|Procedure|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
79688558|NCT04216628|Other|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
79688559|NCT04192019|Drug|Micro-glucagon|Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
79832230|NCT02546739|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
79832231|NCT00744198|Procedure|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
79832232|NCT00744198|Procedure|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
80005756|NCT02130206|Other|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
80005757|NCT02815267|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
80005758|NCT02815267|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
80005759|NCT02130440|Drug|Resveratrol nasal spray|
79238098|NCT05787717|Other|Parental presence|The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
79532694|NCT01441856|Procedure|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
79532695|NCT01441869|Drug|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
79532696|NCT01441869|Drug|Diabex|Extended release oral tablets, 1000 mg, single dose
79238099|NCT05786521|Drug|Semaglutide Injectable Product|Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
79688560|NCT04192019|Drug|Mini-glucagon|Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
79688561|NCT04174170|Drug|Brexpiprazole|Up to 3 mg pill
79688562|NCT04174170|Drug|Sertraline|Up to 150 mg pill
79832233|NCT00744198|Procedure|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
79238100|NCT05786521|Behavioral|Lifestyle Counseling|Lifestyle Counseling will be provided throughout study intervention
79238101|NCT05756712|Dietary Supplement|Phase 1 Wonderlab Product|Chew two tablets of Wonderlab Product for phase 1 (day 1)
79532697|NCT01441869|Drug|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
79532698|NCT01441869|Drug|Diabex|Extended release oral tablets, 500 mg, single dose
79532699|NCT01441869|Drug|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
79532700|NCT01441908|Drug|Pravastatin|40mg or 80mg dose 28 days for 6 month period
79688563|NCT04174170|Other|Placebo|Pill
79532701|NCT01441921|Dietary Supplement|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
79688564|NCT04172779|Drug|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
79688565|NCT04165343|Radiation|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
79688566|NCT04165343|Diagnostic Test|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
79832234|NCT00834951|Radiation|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
79832235|NCT04013776|Dietary Supplement|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
79832236|NCT00741702|Other|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP >=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP>=13/80 mm Hg, increase verapamil to 240 mg/d
79532702|NCT01441921|Other|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
79688567|NCT04165343|Diagnostic Test|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
79688568|NCT04165343|Diagnostic Test|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
79688569|NCT04146298|Drug|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
79688570|NCT04146298|Drug|Fludarabine|Fludarabine will be administered prior to cell infusion.
79688571|NCT04146298|Biological|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
79832237|NCT00841347|Behavioral|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
79832238|NCT00841347|Behavioral|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
80005760|NCT02138552|Drug|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
80005761|NCT02138552|Drug|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
80005762|NCT02930837|Drug|alteplase|
80005763|NCT02138708|Other|Pharmacological test of pulmonary endothelial|
80005764|NCT03633175|Drug|Vaginal progesterone|400 mg vaginal progesterone [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
80005765|NCT02138864|Radiation|18F-FP-(+)-DTBZ|no available
80005766|NCT01362647|Procedure|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
80005767|NCT01362647|Procedure|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
79378522|NCT03121170|Other|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
79378523|NCT03121170|Other|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
79532703|NCT01441934|Drug|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
79532704|NCT01441934|Drug|Sugar pills|placebo t.i.d.
79532705|NCT01441986|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
79532706|NCT01441986|Drug|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
79532707|NCT01441986|Drug|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
80005768|NCT02539693|Drug|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
79688572|NCT04146298|Drug|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
80005769|NCT02539693|Drug|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
79688573|NCT04144738|Diagnostic Test|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
79688574|NCT04144738|Diagnostic Test|FIT test|Stool samples will be collected by the subject for the FIT test.
79832239|NCT00936286|Device|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
79378524|NCT04496856|Dietary Supplement|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
79688575|NCT04144738|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
79688576|NCT04126590|Biological|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
79688577|NCT04124614|Drug|Brexpiprazole|Up to 3 mg pill
79688578|NCT04124614|Drug|Sertraline|Up to 150 mg pill
79688579|NCT04124614|Other|Placebo|Pill
79688580|NCT04099797|Genetic|C7R-GD2.CART cells (ICV infusion)|"Dose levels in the current phase of study are ICV infusion followed by IV infusion (DL 1b, 2b, 3b, 4b)~Dose level 1b ICV: 5 x 10^6 cells/dose (followed by standard IV dose)~Dose level 2b ICV: 1 x 10^7 cells/dose (followed by standard IV dose)~Dose level 3b ICV: 2 x 10^7 cells/dose (followed by standard IV dose)~Dose level 4b ICV: 5 x 10^7 cells/dose (followed by standard IV dose)"
79688581|NCT04099797|Genetic|C7R-GD2.CART cells (IV infusion)|Standard IV dose: 30 million cells/m2 divided into two doses given at least 5 days and no greater than 10 days apart.
79688582|NCT04089488|Other|Medical Chart Review|Correlative studies
79688583|NCT04089488|Other|Survey Administration|Respond to surveys
80005770|NCT02539693|Drug|Lidocaine|3 ml lidocaine 1% is injected at each block site
80005771|NCT02539693|Procedure|Pilonidal sinus|Removal of pilonidal sinus
79238102|NCT05756712|Dietary Supplement|Phase 1 Placebo|Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).
79238103|NCT05756712|Dietary Supplement|Phase 2 Placebo|Chew two tablets of placebo for phase 1 (day 1)
79378525|NCT03120858|Behavioral|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
79238104|NCT05756712|Dietary Supplement|Phase 2 Wonderlab Product|Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).
79238105|NCT05744336|Other|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure
79378526|NCT04498884|Drug|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
79378527|NCT04498884|Drug|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
79378528|NCT04498494|Device|ECG|12-lead ECG
79378529|NCT01621672|Drug|Revlimid|10 mg/day in the morning same time each day
79688584|NCT04042935|Drug|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
79688585|NCT04038060|Behavioral|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
79688586|NCT04038060|Behavioral|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
79688587|NCT04038060|Behavioral|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
79688588|NCT04038060|Behavioral|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
79688589|NCT04009291|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
79832240|NCT00741780|Drug|Placebo|
79832241|NCT00741780|Drug|plerixafor|
79832242|NCT00741780|Drug|granulocyte colony-stimulating factor (G-CSF)|
79832243|NCT00936442|Drug|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
79832244|NCT00936442|Other|Educational materials|Reception of educational material on regular basis.
79832245|NCT00744354|Drug|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
80005772|NCT02138942|Device|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
80005773|NCT01362725|Device|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
80005774|NCT05062135|Drug|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
80005775|NCT02130518|Drug|Auriclosene Irrigation Solution, 0.2%|
79532708|NCT01441986|Drug|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
79832246|NCT00744354|Drug|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
79832247|NCT00744354|Drug|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
79832248|NCT04043325|Diagnostic Test|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
80005776|NCT02130518|Drug|Auriclosene Vehicle Solution|
80005777|NCT01355783|Drug|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
80005778|NCT05061667|Procedure|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
80005779|NCT05061667|Procedure|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
80005780|NCT02134106|Drug|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
80005781|NCT02134106|Drug|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
80005782|NCT01354301|Drug|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
80005783|NCT01354301|Drug|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
80005784|NCT01354301|Drug|Basiliximabe|days 0 and 4, according to the package insert instructions.
80005785|NCT01354301|Drug|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
79688590|NCT04009291|Combination Product|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
79378530|NCT03344328|Drug|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
79378531|NCT02499822|Drug|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
79378532|NCT02499822|Drug|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
79378533|NCT01663012|Drug|Etirinotecan pegol|
79688591|NCT03997305|Device|AltaValve|Transcatheter Mitral Valve Replacement
79688592|NCT03990506|Procedure|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; < 45D, 7.2J/cm2; 45-50D, 10J/cm2; > 50D, 15 J/cm2.
79832249|NCT00936520|Drug|SAR 1118 0.1%|Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
79832250|NCT00936520|Drug|SAR 1118 1.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
80005786|NCT01354301|Drug|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
80005787|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
80005788|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
80005789|NCT02134262|Drug|Cyclophosphamide or Bendamustine|Cyclophosphamide [1.5 g/m^2 x 1 day Intravenous (IV)] or Bendamustine [120 mg/m^2 x 2 days Intravenous (IV)] is administered as Pre-treatment medication of CD19-CAR-T.
79532709|NCT01441999|Device|Less rigid rod|Titanium rod with semi rigid end
79532710|NCT01441999|Device|Rigid Rod|Rigid Titanium rods
79532711|NCT01442012|Other|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
79532712|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
79532713|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
79832251|NCT00936520|Drug|SAR 1118 5.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
79832252|NCT02564562|Drug|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + [14C] PF-06463922
79832253|NCT05311566|Combination Product|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
79832254|NCT00564070|Behavioral|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
79832255|NCT00564070|Behavioral|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
80005790|NCT02134262|Genetic|Dose Level -1|CD19-CAR-T [1 x 10^5 cells/kg x 1 day and 2 x 10^5 cells/kg x 1 day Intravenous (IV)] are administered.
80005791|NCT02134262|Genetic|Dose Level 1|CD19-CAR-T [1/3 x 10^6 cells/kg x 1 day and 2/3 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
80005792|NCT02134262|Genetic|Dose Level 2|CD19-CAR-T [1 x 10^6 cells/kg x 1 day and 2 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
80005793|NCT02134262|Genetic|Dose Level 3|CD19-CAR-T [1/3 x 10^7 cells/kg x 1 day and 2/3 x 10^7 cells/kg x 1 day Intravenous (IV)] are administered.
80005794|NCT01355861|Behavioral|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
79378534|NCT02499744|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
79532714|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
79532715|NCT01442051|Procedure|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB < 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB <7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
79688593|NCT03990506|Procedure|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; < 45D, 7.2J/cm2; 45-50D, 10J/cm2; > 50D, 15 J/cm2.
79688594|NCT03954431|Diagnostic Test|Dedicated breast CT(BCT)|The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
79688595|NCT03953131|Procedure|Computed Tomography|Undergo PET/CT
79688596|NCT03953131|Radiation|Gallium Ga 68-DOTATATE|Given IV
79688597|NCT03953131|Procedure|Positron Emission Tomography|Undergo PET/CT
80005795|NCT01343277|Drug|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
80005796|NCT01343277|Drug|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
80005797|NCT02130596|Behavioral|Acceptance-Based Behavioral Intervention|
79378535|NCT02499744|Device|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
79378536|NCT02499588|Device|Esteem Plus with ConvaTec Moldable Technology|
79378537|NCT02499588|Device|Natura with ConvaTec Moldable Technology|
79688598|NCT03947424|Device|LP Er:YAG|LP Er:YAG applied to oral mucosa
80005798|NCT02130596|Other|Nutritional Counselling|
80005799|NCT02130674|Drug|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
80005800|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
80005801|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
80005802|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
80005803|NCT03135899|Drug|BI 443651|Three doses, each 12 hours apart
80005804|NCT03135899|Drug|Placebo|Three doses, each 12 hours apart
80005805|NCT02253212|Device|SonoCloud|SonoCloud : dose escalation
80005806|NCT02253212|Drug|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
80005807|NCT01355939|Procedure|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
80005808|NCT01356017|Drug|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
80005809|NCT01356017|Drug|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
79378538|NCT02499588|Device|Natura Accordion with ConvaTec Moldable Technology|
79238106|NCT05744336|Other|Group 2 Control Group|Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
79378539|NCT02499588|Device|Esteem synergy Plus with ConvaTec Moldable Technology|
79532716|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
79832256|NCT00835029|Drug|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
79832257|NCT00835029|Drug|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
79832258|NCT02562768|Drug|LY3154207|Administered orally
79832259|NCT02562768|Drug|Placebo|Administered orally
79832260|NCT00843609|Device|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
79832261|NCT00744510|Other|Reflexology|10 weekly sessions of 45 minutes each
79832262|NCT00835107|Drug|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
79832263|NCT00835107|Drug|placebo|placebo comparator, oral capsules, BID, for one month
79532717|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
79532718|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
79532719|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
79532720|NCT01442116|Procedure|stress echocardiography|safety and efficacy of stress echocardiography
79688599|NCT03947424|Device|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
79688600|NCT03947424|Device|sham|Er:YAG laser applied to oral mucosa with no energy
79688601|NCT03938571|Procedure|Duodenal Switch|
79832264|NCT02562846|Other|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
79688602|NCT03936517|Drug|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
79688603|NCT03936517|Drug|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
79688604|NCT03889795|Drug|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
79688605|NCT03889795|Drug|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
79238107|NCT05741723|Device|OCS Heart|Transplanted with OCS preserved heart.
79238108|NCT05740865|Procedure|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
79378540|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
79378541|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
79378542|NCT02502552|Other|blood specimen|blood specimen
79378543|NCT02499510|Device|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
79688606|NCT03889795|Drug|Digoxin|Digoxin oral pill will be taken once daily.
79688607|NCT03839108|Other|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
79832265|NCT00843765|Other|acupuncture, massage and basic TCM treatment|"During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
79378544|NCT04496622|Other|WBV technique|"Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
79832266|NCT00843765|Other|rehabilitation and WM basic treatment|"there two steps:~during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
79832267|NCT00843921|Drug|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
79688608|NCT03839108|Drug|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
79688609|NCT03819075|Device|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
79302883|NCT05713019|Diagnostic Test|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
79378545|NCT04496622|Other|Whole body vibration technique|"Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
79532721|NCT01442142|Behavioral|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
79532722|NCT01442142|Behavioral|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
79832268|NCT00690612|Drug|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
79832269|NCT02546505|Other|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
79832270|NCT02546505|Other|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
79832271|NCT00841503|Other|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
79832272|NCT00742014|Drug|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
79832273|NCT00742092|Drug|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
79832274|NCT00742092|Drug|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
79832275|NCT00841581|Drug|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
79832276|NCT00742248|Drug|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
79378546|NCT02499432|Behavioral|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
79378547|NCT02502474|Other|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
79532723|NCT01442142|Behavioral|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
79832277|NCT00742248|Drug|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
79832278|NCT00742248|Drug|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
79832279|NCT04249167|Drug|Atezolizumab|Given IV
79832280|NCT04249167|Procedure|Cryosurgery|Undergo cryoablation of the primary tumor
79832281|NCT04249167|Drug|Nab-paclitaxel|Given IV
79832282|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
79832283|NCT00621153|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
79832284|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
79832285|NCT02546427|Radiation|Helical TomoTherapy (HT)|
79832286|NCT02546427|Radiation|CyberKnife SBRT|
79832287|NCT02546427|Radiation|Permanent Prostate Implant (PPI)|
79832288|NCT02546427|Radiation|HDR brachytherapy|
79378548|NCT02499276|Device|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
79378549|NCT04496700|Procedure|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
79378550|NCT04495140|Drug|[14C]PF-06882961, 50 mg|A single oral dose of [14C]PF-06882961, will be administered as a liquid formulation.
79378551|NCT04495140|Drug|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961 will be administered via intravenous infusion.
79378552|NCT03343548|Drug|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
79378553|NCT03343548|Drug|normal saline|2cc of normal saline will be administered epidurally
79532724|NCT01442168|Drug|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
79832289|NCT00747084|Procedure|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
79688610|NCT03819075|Other|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
79832290|NCT00835419|Drug|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
79832291|NCT00747162|Device|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
79832292|NCT00747162|Device|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
79832293|NCT00574119|Drug|spironolactone|spironolactone 50 mg daily for 6 months
79832294|NCT00841737|Other|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
79832295|NCT00841737|Other|Control Group|In the control group the depression is treated as usual with the conventional treatment.
79832296|NCT00705614|Biological|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
79532725|NCT01442168|Drug|atovaquone/proquanil|malanil according to label
79688611|NCT03808025|Behavioral|opioid education|see arm/group descriptions
79832297|NCT00844155|Drug|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
79532726|NCT01442207|Procedure|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
79688612|NCT03802084|Drug|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
79832298|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
79832299|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
79832300|NCT00620763|Other|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
79832301|NCT00620763|Other|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
79832302|NCT00844233|Device|Irinotecan Bead|Irinotecan eluting bead
79832303|NCT00841893|Dietary Supplement|Mustard (dijon)|The specific spice added to a brunch meal
79688613|NCT03790280|Diagnostic Test|HFO analysis|We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
79688614|NCT03777462|Drug|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
79832304|NCT00841893|Dietary Supplement|Placebo|Placebo added to a brunch meal
79688615|NCT03777462|Drug|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
79688616|NCT03777462|Drug|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
79832307|NCT00844311|Drug|rFSH|150 iu/day of rFSH
79832308|NCT00844311|Drug|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
79832309|NCT00844311|Drug|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
79832310|NCT00844311|Drug|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
79832311|NCT02547597|Drug|Carvedilol|
79832312|NCT02547597|Drug|Atenolol|
79832313|NCT00844389|Device|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
79832314|NCT00844389|Device|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
79832315|NCT02567474|Behavioral|5 A model|self management program based on 5A model
79832316|NCT00835887|Dietary Supplement|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
79832317|NCT00738218|Other|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
79832318|NCT00842049|Device|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
79832319|NCT00842049|Other|No lumbar drain|No lumbar drain
79832320|NCT05220878|Biological|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
79832321|NCT05220878|Biological|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
79378554|NCT02507934|Device|Lubricin|Lubricin 150 µg/ml eye drops
79378555|NCT02507934|Device|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
79378556|NCT02234128|Device|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
79378557|NCT02504112|Other|there is no intervention|
79832322|NCT00844467|Biological|serotypes and resistance|screening patients with invasive pneumococci
79532727|NCT01442207|Procedure|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
79238109|NCT05738837|Behavioral|A-EAAA Sexual Assault Resistance Education Program immediately|Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.
79688617|NCT03745326|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
79832323|NCT00842127|Drug|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
79832324|NCT04062500|Other|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
79238110|NCT05738837|Behavioral|Usual care + A-EAAA at 6 months|Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
79238111|NCT05714683|Drug|Semaglutide|All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
79832325|NCT00835965|Drug|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
79238112|NCT05703854|Drug|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
79832326|NCT00835965|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
79832327|NCT00835965|Drug|Placebo Dexamethasone|
79532728|NCT01442233|Procedure|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
79532729|NCT01442233|Procedure|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
79832328|NCT02567786|Procedure|Surgery with CPB|
79832329|NCT02567786|Other|Fresh Frozen Plasma|
79832330|NCT02567786|Other|Plasmalyte|
79832331|NCT00844623|Genetic|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
79238113|NCT05703854|Drug|Fludarabine phosphate|Given by IV (vein)
79238114|NCT05703854|Drug|Cyclophosphamide|Given by IV (vein)
79378558|NCT01622296|Drug|Sodium bicarbonate|8.4% neutralizing solution
79532730|NCT01442259|Drug|AFQ056|
79532731|NCT01442272|Drug|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
79532732|NCT01442272|Drug|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
79532733|NCT01442272|Drug|Habitual medication|Habitual medication
79832332|NCT05667740|Biological|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
79832333|NCT05667740|Biological|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
79688618|NCT03745326|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day IVPB daily over 30 minutes for 5 days.
79688619|NCT03745326|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
79832334|NCT05667740|Biological|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
79832335|NCT05667740|Drug|Placebo|Saline
79832336|NCT00842205|Drug|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
79832337|NCT00842205|Drug|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
79832338|NCT00738296|Drug|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
79688620|NCT03745326|Biological|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
79688621|NCT03730181|Drug|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
79832339|NCT00738296|Drug|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
79832340|NCT00738296|Drug|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
79832341|NCT00836043|Drug|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
79832342|NCT02567396|Other|Laboratory Biomarker Analysis|Correlative studies
79832343|NCT02567396|Other|Pharmacological Study|Correlative studies
79832344|NCT02567396|Drug|Talazoparib|Given PO
79832345|NCT02547831|Other|Observational approach|Patients will be placed under wait and see approach without any specific treatment
79832346|NCT00738452|Other|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
80005810|NCT02134340|Drug|[I-124]-CPD-1028 Injection|A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
79532734|NCT01442285|Behavioral|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
79532735|NCT01442298|Procedure|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
79532736|NCT01442298|Procedure|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
79688622|NCT03730181|Drug|Isoniazid|Isoniazid. 25mg/kg
79688623|NCT03701568|Drug|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
79688624|NCT03679559|Other|Best Practice|Continue usual physical activity
79688625|NCT03679559|Behavioral|Exercise Intervention (home walking program and resistance training)|Complete home-based walking program and resistance training
79688626|NCT03679559|Behavioral|Exercise Intervention (home-based Zumba program and resistance training)|Complete home-based Zumba program and resistance training
79688627|NCT03679559|Behavioral|Exercise Intervention (HIIT program and resistance training)|Complete HIIT program and resistance training
79832347|NCT00738452|Other|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
79832348|NCT00738452|Procedure|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
79832349|NCT00738452|Procedure|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
79832350|NCT00738452|Radiation|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
79688628|NCT03679559|Other|Informational Intervention|Watch video
79832351|NCT00738452|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
79832352|NCT00836121|Procedure|right thoracotomy|complete surgical resection
79688629|NCT03679559|Other|Laboratory Biomarker Analysis|Correlative studies
79688630|NCT03679559|Device|Monitoring Device|Wear Fitbit
79832353|NCT05667428|Drug|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
79832354|NCT05667428|Drug|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
79832355|NCT00844779|Procedure|Bariatric surgery|Gastric bypass.
79832356|NCT00844779|Procedure|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
79832357|NCT05664542|Other|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
80005811|NCT02134340|Biological|CPD-1061|[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
80005812|NCT04723615|Other|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
79238115|NCT05702918|Device|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
79238116|NCT05702918|Other|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
79238117|NCT05699070|Drug|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
79238118|NCT05699070|Drug|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
79238119|NCT05699070|Drug|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
79688631|NCT03679559|Other|Quality-of-Life Assessment|Ancillary studies
79688632|NCT03679559|Other|Questionnaire Administration|Ancillary studies
79688633|NCT03674671|Drug|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
79832358|NCT05664542|Drug|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
80005813|NCT04723615|Other|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
79832359|NCT00562978|Biological|filgrastim|
79832360|NCT00562978|Drug|cyclophosphamide|
79832361|NCT00562978|Drug|etoposide|
79238120|NCT05697653|Behavioral|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
79832362|NCT00562978|Procedure|AHSCT|
79832363|NCT00562978|Radiation|yttrium Y 90 ibritumomab tiuxetan|
79832364|NCT00921206|Biological|VAX102|1 ug i.m. compared to 2 ug s.c.
79532737|NCT01442311|Other|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
79532738|NCT01442311|Other|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
79532739|NCT01442324|Procedure|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
79832365|NCT00842439|Behavioral|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
79688634|NCT03674671|Procedure|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
79688635|NCT03668119|Biological|Nivolumab|Specified dose on specified days
79688636|NCT03668119|Biological|Ipilimumab|Specified dose on specified days
79832366|NCT00842439|Dietary Supplement|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
79832367|NCT00940264|Procedure|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
79832368|NCT04013230|Behavioral|Usual care|Visit doctor and nurse at the clinic.
80005814|NCT04723615|Other|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
80005815|NCT04723615|Other|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
79238121|NCT05692999|Drug|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
79238122|NCT05692999|Drug|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m^2 Q3W
79238123|NCT05692999|Drug|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
79532740|NCT01442415|Behavioral|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
79532741|NCT01442428|Drug|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
79532742|NCT01442428|Drug|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
79532743|NCT01442428|Drug|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
79688637|NCT03659799|Drug|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
79688638|NCT03659799|Drug|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
79688639|NCT03659799|Other|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
79688640|NCT03659799|Other|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
79832369|NCT04013230|Behavioral|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
79832370|NCT00842595|Drug|rituximab|6 courses every 28 days
79832371|NCT00842595|Drug|vinorelbine|6 courses every 28 days
79832372|NCT00842595|Drug|ifosfamide|6 courses every 28 days
79832373|NCT00842595|Drug|Mitoxantrone|6 courses every 28 days
79832374|NCT00842595|Drug|Prednisone|6 courses every 28 days
79832375|NCT04013698|Other|PEEP level 5 cmH2O|PEEP level set for 45 minutes
79832376|NCT04013698|Other|PEEP level 15 cmH2O|PEEP level set for 45 minutes
79832377|NCT00845091|Behavioral|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
79832378|NCT00845091|Behavioral|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
79832379|NCT00938626|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
79832380|NCT00938626|Procedure|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
79832381|NCT00938626|Procedure|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
79238124|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
79832382|NCT05193344|Device|A digital care solution for patients with Heart Failure|A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
79832383|NCT05193344|Other|Standard of Care for patients with Heart Failure|The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
79832384|NCT00842673|Drug|ST101|30 mg; administered once/day
79832385|NCT00842673|Drug|ST101|90 mg; administered once/day
79832386|NCT00842673|Drug|ST101|180 mg; administered once/day
79832387|NCT00842673|Drug|Placebo|placebo to match ST101 tablets
79832388|NCT04013308|Procedure|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
79832389|NCT00836199|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
80005816|NCT01356095|Other|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
79238125|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
79238126|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg*2 in the fed state.
79238127|NCT05692934|Drug|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg*2 in the fast state.
79532744|NCT01442428|Drug|Placebo|Atorvastatin placebo
79238128|NCT05661591|Drug|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
79532745|NCT01442454|Other|chronic pancreatitis|No intervention, subjects followed through surgery
79532746|NCT01442480|Dietary Supplement|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
79532747|NCT01442480|Dietary Supplement|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
79532748|NCT01442506|Other|biopsies|taking biopsies
79532749|NCT01442506|Other|biopsy|biopsy
79688641|NCT03653364|Drug|Baloxavir Marboxil|"Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age.~Participants will be recruited in parallel to the following three cohorts:~Cohort I: ≥ 3 months to < 12 months old (minimum 8 participants): 2 mg/kg~Cohort II: ≥ 4 weeks to < 3 months old (minimum 4 patients): 1 mg/kg~Cohort III: birth to < 4 weeks old (minimum 4 patients): 1 mg/kg"
79688642|NCT03624244|Drug|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
79688643|NCT03620019|Drug|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
79688644|NCT03620019|Drug|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
79832390|NCT00836199|Biological|Placebo vaccine|Placebo vaccine given 6 times over 6 months
79832391|NCT05280262|Diagnostic Test|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
79832392|NCT04062188|Other|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
79238129|NCT05661591|Drug|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
79238130|NCT05661201|Drug|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
79238131|NCT05661201|Drug|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
79238132|NCT05660369|Drug|CARv3-TEAM-E T cells|Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
79238133|NCT05660018|Device|active rTMS first, then sham rTMS|Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
79238134|NCT05660018|Device|sham rTMS first, then active rTMS|Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
79832393|NCT04013386|Drug|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
79832394|NCT04013386|Drug|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
79832395|NCT04013386|Drug|Dexamethasone|Dexamethasone 8 mg IVI
79832396|NCT02567084|Device|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
79832397|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
79832398|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
79832399|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
79832400|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
80005817|NCT01356095|Other|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
80005818|NCT02134418|Behavioral|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
80005819|NCT04712305|Other|No intervention required|No intervention required
79832401|NCT00845169|Procedure|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
79832402|NCT00842907|Drug|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
79832403|NCT00842907|Drug|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
79238135|NCT05647174|Procedure|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
79832404|NCT05181488|Radiation|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
79832405|NCT05180396|Other|Questionnaires|Application of a study based questionnaire described in the protocol
79832406|NCT04013074|Procedure|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
79238136|NCT05647174|Procedure|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
79238137|NCT05634148|Drug|Dexmedetomidine|Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
79238138|NCT05625126|Other|Rumination Intervention for individuals with PTSD|The intervention utilises evidence-based cognitive behavioural therapy (CBT) techniques.
79238139|NCT05624385|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
79238140|NCT05622253|Combination Product|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
79238141|NCT05622123|Drug|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
79832407|NCT04013074|Other|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
79832408|NCT00620373|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
79832409|NCT00620373|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
79832410|NCT00620373|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
79832411|NCT02567318|Device|MRI-scan|Magnetic resonance imaging scan of the brain
79832412|NCT03360292|Other|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
79832413|NCT00940654|Other|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
79832414|NCT00845247|Other|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
79832415|NCT05081882|Drug|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
79832416|NCT05081882|Drug|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
79832417|NCT00845325|Behavioral|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
79832418|NCT00845325|Behavioral|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
79832419|NCT00940732|Other|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
79832420|NCT00940732|Other|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
80005820|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
79302884|NCT05713019|Diagnostic Test|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
79302885|NCT05713019|Diagnostic Test|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
79688645|NCT03620019|Drug|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
79302886|NCT04990089|Device|VIVO|VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
79302887|NCT03198403|Drug|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
79688646|NCT03591770|Biological|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
79832421|NCT00940732|Other|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
79832422|NCT02567006|Behavioral|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
79832423|NCT02567006|Other|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
79832424|NCT00843063|Drug|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
79832425|NCT04013464|Drug|Escitalopram|Escitalopram 10-20mg/d
79832426|NCT04043247|Device|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
79832427|NCT04043247|Device|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
79832428|NCT04012918|Drug|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
79832429|NCT04012918|Drug|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
79832430|NCT04062578|Behavioral|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
80005821|NCT02139098|Drug|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
79532750|NCT01442519|Biological|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
79832431|NCT05131490|Behavioral|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~Module 3: Current developments on gynecological cancers will be included.~Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
79832432|NCT00939718|Dietary Supplement|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
80005822|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
80005823|NCT02139098|Drug|Placebo|Placebo
80005824|NCT02130752|Device|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
80005825|NCT02130752|Device|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
80005826|NCT01362257|Drug|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
80005827|NCT01362257|Drug|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
80005828|NCT02487979|Drug|Glembatumumab Vedotin|Given IV
80005829|NCT02487979|Other|Laboratory Biomarker Analysis|Correlative studies
80005830|NCT02487979|Other|Pharmacological Study|Correlative studies
80005831|NCT02134496|Procedure|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
80005832|NCT01356173|Drug|GDC-0349|Oral escalating dose
80005833|NCT02130830|Drug|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
80005834|NCT02130830|Drug|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
79302888|NCT03314441|Behavioral|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
80005835|NCT02279771|Procedure|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
79302889|NCT03198793|Drug|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily [QD]) over 8 weeks.
79832433|NCT00843141|Behavioral|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
79832434|NCT00843141|Behavioral|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
79832435|NCT04062968|Other|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
79832436|NCT00938938|Other|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
79832437|NCT00843219|Procedure|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
79832438|NCT02568098|Drug|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
79832439|NCT02568098|Drug|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
79832440|NCT02568098|Drug|DHA-PQP|Regimen 6: DHA-PQP
79832441|NCT02732626|Procedure|radiofrequency ablation|
79832442|NCT00836667|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
79532751|NCT01442519|Drug|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
79238142|NCT05616806|Behavioral|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
79378559|NCT01622296|Drug|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
79532752|NCT01442532|Drug|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
79532753|NCT01442532|Drug|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
79832443|NCT00836667|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
79832444|NCT03898232|Radiation|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
79832445|NCT00940030|Other|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
79238143|NCT05614245|Biological|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
79302890|NCT04990245|Diagnostic Test|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
79532754|NCT01442532|Drug|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
79832446|NCT00940030|Other|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
79832447|NCT00845559|Drug|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
79832448|NCT00939016|Other|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
79832449|NCT02567240|Other|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
79378560|NCT01705288|Procedure|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
79532755|NCT01442532|Drug|Placebo|Form=tablet, route=oral use, for 14 days
79832450|NCT00940810|Procedure|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
79378561|NCT01705288|Drug|intravenous narcotics|given for pain management after surgery per physician orders
79378562|NCT01705288|Drug|standard anesthesia|inhalant or intravenous during surgery
79378563|NCT01705288|Drug|regional anesthesia|given by spinal or epidural infusion
79378564|NCT01705288|Drug|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
79238144|NCT05599321|Diagnostic Test|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
79532756|NCT01442532|Drug|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
79832451|NCT00940810|Procedure|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
79238145|NCT05594082|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
79378565|NCT02507778|Device|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
79832452|NCT00843297|Device|Coolgard|invasive Cooling via femoral ICY-catheter
79832453|NCT00843297|Device|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
79832454|NCT00843297|Other|Conventional treatment|Intensive care-treatment without cooling
79238146|NCT05593185|Biological|Galinpepimut-S|
79238147|NCT05577026|Behavioral|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
79378566|NCT01707238|Device|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
79378567|NCT01707238|Device|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
79378568|NCT02507622|Other|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
79532757|NCT01442545|Drug|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
79832455|NCT05107778|Drug|ASC42 10mg|ASC42 10mg orally once daily;
79832456|NCT05107778|Drug|ASC42 15mg|ASC42 15mg orally once daily.
79832457|NCT05107778|Drug|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
79832458|NCT05107778|Drug|Entecavir|Entecavir 0.5 mg orally once daily.
79832459|NCT05107778|Drug|Placebo|Placebo orally once daily.
79832460|NCT00372619|Drug|clofarabine|Given IV for 5 days
79832461|NCT00372619|Drug|cytarabine|Given IV
79238148|NCT05577026|Behavioral|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
79832462|NCT00372619|Drug|methotrexate|Given intrathecally or IT age based dosage
79832463|NCT00372619|Other|laboratory biomarker analysis|
79238149|NCT05574374|Drug|DWP14012|Potassium-competitive acid blocker
79238150|NCT05574374|Drug|DWC202202|Clopidogrel Bisulfate
79238151|NCT05574374|Drug|DWC202203|Proton pump inhibitor
79238152|NCT05550779|Behavioral|Mental Exercise|Participant perform a 10-minute mental exercise
79238153|NCT05539157|Drug|JCXH-211|JCXH-211 administered once every 28 days
79238154|NCT05535816|Diagnostic Test|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
79238155|NCT05528965|Procedure|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
79378569|NCT02507622|Other|Parabolic flight|
79378570|NCT02507466|Behavioral|exercise|Variable conditions of stepping practice
79532758|NCT01442558|Drug|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
79532759|NCT01442571|Device|Hyaluronic Acid Injection|
79532760|NCT01442571|Drug|Saline Injection|
79532761|NCT01442584|Procedure|ovarian transplantation|ovarian transplantation
79532762|NCT01442597|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
79832464|NCT02546115|Device|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
79832465|NCT02546115|Other|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
80005836|NCT02279771|Procedure|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
79378571|NCT03343002|Drug|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
79378572|NCT03343002|Drug|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
80005837|NCT02279771|Device|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
79832466|NCT04477616|Drug|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
79832467|NCT04477616|Drug|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
79832468|NCT00851175|Drug|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
79832469|NCT00851175|Drug|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
80005838|NCT02139332|Behavioral|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
80005839|NCT02139332|Behavioral|Resource & Referral Group|The Resource & Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
80005840|NCT01360151|Drug|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
80005841|NCT02134652|Other|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
80005842|NCT03633097|Other|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
80005843|NCT03633097|Drug|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
79378573|NCT03120936|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
79832470|NCT04043013|Device|Mini-Taurus® (Rocky Mountain©) Brackets|
79378574|NCT03120936|Behavioral|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
79378575|NCT03121092|Drug|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
79532763|NCT01442597|Behavioral|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
79832471|NCT04043013|Device|Smart Clip® SL3 High Torque (3M Unitek©)|
79378576|NCT02234752|Drug|Galantamine ER|
79378577|NCT02234752|Drug|Memantine XR|
79378578|NCT04496388|Behavioral|exercise|different type of exercise
79532764|NCT01442597|Behavioral|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
79532765|NCT01442610|Drug|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
79832472|NCT04043013|Device|Tip-Edge Plus® (TP Orthodontics©)|
79832473|NCT04043013|Device|Victory® (3M Unitek©)|
79832474|NCT00845637|Drug|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
79832475|NCT00845637|Drug|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
79378579|NCT04496388|Behavioral|No exercise intervention|No exercise intervention
79532766|NCT01442610|Drug|Placebo|Placebo 1tablet once daily for 8 weeks
79532767|NCT01442623|Other|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
79532768|NCT01442636|Device|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
79532769|NCT01442662|Drug|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
79832476|NCT03992833|Other|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume < 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume > 300 mm3 (positive)."
79832477|NCT02566226|Drug|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
79832478|NCT02566226|Drug|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
79832479|NCT00837057|Procedure|crrt|early CRRT (35 ml/kg/h)& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
80005844|NCT02139410|Procedure|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
80005845|NCT02139488|Other|Fiducial markers|
80005846|NCT02139488|Other|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
80005847|NCT03765320|Procedure|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
80005848|NCT03765320|Procedure|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
80005849|NCT01363037|Drug|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
80005850|NCT01363037|Drug|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
79832480|NCT01046617|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
79832481|NCT00837135|Other|Screening|"A. SCREENING~Consent~Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~Physical Exam, History, Blood Tests~Skin Test (for allergy to saccaromyces cerevisiae) yeast.~Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~Consent~Chemotherapy~GI-4000 Vaccine #1 + Prevnar + Activated T Cells~GI-4000 Vaccine #2~Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
80005851|NCT01363037|Other|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
79238156|NCT05528965|Procedure|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
79238157|NCT05524116|Behavioral|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
79238158|NCT05524116|Behavioral|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
79238159|NCT05520463|Procedure|Sacral lateral branch radiofrequency ablation under ultrasound guidance|Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.
79832482|NCT00837135|Biological|GI-4000 Vaccine|"Chemotherapy and Radiation~GI-4000 Vaccine #3~GI-4000 Vaccine #4"
79832483|NCT00837135|Biological|GI-4000 Vaccine + Activated T Cells|"Apheresis #2~Chemoradiation~Activated T Cells + GI-4000 Vaccine #3~GI-4000 Vaccine #4"
80005852|NCT01363037|Drug|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
80005853|NCT02130908|Other|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
80005854|NCT02130908|Other|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
80005855|NCT02130908|Other|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
80005856|NCT01363115|Dietary Supplement|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
80005857|NCT01363115|Dietary Supplement|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
79238160|NCT05520463|Procedure|Sacral lateral branch radiofrequency ablation under fluoroscopy guidance|Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
79238161|NCT05506787|Drug|Esketamine|Esketamine
79238162|NCT05506787|Drug|Placebo|Placebo
79238163|NCT05503511|Drug|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
79238164|NCT05503355|Drug|BST-236|"In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
80005858|NCT01363115|Behavioral|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
80005859|NCT02134730|Behavioral|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
80005860|NCT01356329|Drug|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
80005861|NCT05579522|Procedure|Fat graft injection|Fat graft injection in the interdental papilla.
79832484|NCT00837135|Biological|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
79832485|NCT00562588|Drug|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
79832486|NCT00562588|Drug|ASA 100 mg qd|
79832487|NCT00851331|Genetic|genome analyzes (genetic defects and pathophysiological mechanisms )|
79832488|NCT00845715|Other|Early motion|Early referral to physical therapy for range of motion (2 days post)
80005862|NCT05579522|Procedure|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
80005863|NCT04579939|Diagnostic Test|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
79238165|NCT05503355|Drug|venetoclax|"In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
79302891|NCT03198949|Drug|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
79688647|NCT03569813|Behavioral|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
79688648|NCT03569813|Other|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
79832489|NCT00845715|Other|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
79832490|NCT02546349|Drug|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
79832491|NCT00845793|Behavioral|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
79832492|NCT00851487|Drug|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
79832493|NCT00851487|Drug|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
79832494|NCT00622167|Device|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
79832495|NCT00622167|Device|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
79832496|NCT02547675|Drug|Rociletinib|Rociletinib will be administered to patients orally
79832497|NCT04042857|Device|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
79832498|NCT04235907|Other|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
79688649|NCT03559647|Drug|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
79688650|NCT03557502|Other|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
79688651|NCT03557502|Other|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
79832499|NCT04235907|Other|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
79832500|NCT00562354|Biological|13vPnC|13vPnC for both stratum
79832501|NCT00372385|Drug|Ribavirin|tablet
79832502|NCT00372385|Drug|Pegylated Interferon Alfa 2a|Solution for injection
79832503|NCT00372385|Drug|Placebo|tablet
79832504|NCT00372385|Drug|Telaprevir|tablet
79832505|NCT03830281|Drug|Ultra-Rapid Lispro|Administered SC
79832506|NCT03830281|Drug|Insulin Lispro|Administered SC
79832507|NCT00563368|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
79832508|NCT00563368|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
79832509|NCT00563368|Drug|topiramate|topiramate 46 mg, po once daily
79832510|NCT00563368|Drug|topiramate|topiramate 92 mg, po once daily
79832511|NCT00563368|Drug|phentermine|phentermine 7.5 mg, po once daily
79832512|NCT00563368|Drug|phentermine|phentermine 15 mg, po once daily
80005864|NCT02139566|Behavioral|Video consent (high-tech)|Consent provided by an animated video with captions
80005865|NCT02139566|Behavioral|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
79832513|NCT00563368|Drug|VI-0521|placebo, po once daily
79832514|NCT02535013|Device|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
79832515|NCT00390013|Drug|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
79832516|NCT00390013|Drug|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
79832517|NCT00561652|Behavioral|Education & Exercise|Education & Exercise
79832518|NCT00561652|Procedure|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education & Exercise)
79832519|NCT00697346|Drug|Alisertib|Alisertib (MLN8237) PIC or ECT
80005866|NCT02139566|Behavioral|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
80005867|NCT02139566|Behavioral|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
79238166|NCT05486052|Other|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
79302892|NCT04990011|Procedure|BioXclude amnion chorion membrane|The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
79302893|NCT02447809|Drug|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)* 12 month.
79688652|NCT03489057|Behavioral|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
79378580|NCT02502084|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
79688653|NCT03489057|Behavioral|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
79688654|NCT03360643|Diagnostic Test|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
79302894|NCT02447809|Drug|acetylsalicylic acid (ASA)|
79532770|NCT01442701|Other|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
79688655|NCT03360643|Diagnostic Test|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
79378581|NCT01664806|Device|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
79378582|NCT02498886|Dietary Supplement|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
79378583|NCT02498886|Dietary Supplement|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
79378584|NCT02499042|Drug|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
79832520|NCT00562120|Drug|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
79832521|NCT00562120|Drug|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
79832522|NCT00562120|Drug|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
79832523|NCT00562120|Drug|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
79832524|NCT00941044|Device|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
79832525|NCT00939172|Drug|TTP607|3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
79532771|NCT01442727|Drug|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
79532772|NCT01442727|Drug|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
79532773|NCT01442740|Procedure|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
79688656|NCT03321734|Drug|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
79378585|NCT01665040|Device|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
79688657|NCT03321734|Drug|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
79832526|NCT01563016|Dietary Supplement|glucose drink|participants will receive a drink rich in glucose
79832527|NCT00561730|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
79832528|NCT00697112|Drug|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
79302895|NCT04989933|Procedure|Ultrasound-guided erector spinae plane block|Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
79302896|NCT04989855|Drug|Fruquintinib plus Tislelizumab|2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
79302897|NCT04987125|Behavioral|Dyspnea Neuroscience education|"Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour."
79378586|NCT04494984|Drug|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
79832529|NCT00621855|Drug|placebo|matched placebo
79832530|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
79832531|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
79832532|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
79832533|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
79832534|NCT04012762|Device|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
79832535|NCT04258280|Behavioral|Education and counseling|Education includes a workbook, counseling includes peer support.
79832536|NCT04258280|Behavioral|Education|Education includes a workbook.
79832537|NCT00940966|Dietary Supplement|standard ADA diet|standard ADA diet
79832538|NCT00940966|Dietary Supplement|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
79832539|NCT00940966|Dietary Supplement|low glycemic diet|restricted ketogenic diet
79832540|NCT00851565|Procedure|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
79378587|NCT04494984|Drug|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
79378588|NCT01665508|Drug|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
79378589|NCT02507544|Drug|TRX-818 capsules|
79832541|NCT00851565|Procedure|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
79378590|NCT03344094|Drug|ocrelizumab|FDA-approved MS drugs
79832542|NCT00561574|Drug|Esmirtazapine|One tablet daily
79832543|NCT03898076|Device|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
79378591|NCT03343392|Drug|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
79532774|NCT01442753|Behavioral|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
79532775|NCT01442766|Drug|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
79832544|NCT03898076|Other|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
79532776|NCT01442766|Drug|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
79832545|NCT03898076|Other|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
79832546|NCT00619827|Drug|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
79832547|NCT00619827|Drug|Placebo tablet|Placebo tablet once daily during four months
79832548|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832549|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832550|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832551|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832552|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832553|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832554|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
79832555|NCT00848055|Drug|AbGn168 subcutaneous injection|single dose subcutaneous injection
79238167|NCT05486052|Other|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
79238168|NCT05486052|Other|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
79832556|NCT00687804|Drug|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
79378592|NCT03343392|Drug|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
79532777|NCT01442805|Behavioral|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
79832557|NCT00687804|Procedure|Laser|Laser photocoagulation treatment
79238169|NCT05484206|Drug|VIR-2218|VIR-2218 given by subcutaneous injection.
79238170|NCT05484206|Drug|VIR-3434|VIR-3434 given by subcutaneous injection.
79302898|NCT04987125|Behavioral|Usual care|General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
79378593|NCT03344016|Other|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
79378594|NCT03342924|Other|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
79378595|NCT02498496|Drug|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
79378596|NCT02498496|Drug|Placebo|Administration of 100 mL of Normal Saline
79378597|NCT02502708|Drug|Indoximod|Indoximod will be administered orally twice daily.
79378598|NCT02502708|Drug|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
79532778|NCT01442805|Behavioral|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
79532779|NCT01442818|Drug|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
79532780|NCT01442818|Drug|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
79532781|NCT01442831|Drug|Human ADME|Oral single dose
79532782|NCT01442857|Radiation|MRI|High resolution MRI of the brachial plexus
79832558|NCT00687804|Procedure|Sham laser|Sham to laser procedure.
79832559|NCT00687804|Drug|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
79832560|NCT00848133|Procedure|mini-midvastus surgical approach for total knee arthroplasty|
79532783|NCT01442870|Drug|Metformin|Metformin
79532784|NCT01442883|Device|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
79532785|NCT01442909|Drug|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
79532786|NCT01442922|Other|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
79832561|NCT00848133|Procedure|mini-subvastus surgical approach for total knee arthroplasty|
79832562|NCT02568020|Drug|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
79832563|NCT00848445|Device|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
79832564|NCT00848445|Device|Atrial pacing preference turned on or off|programing changes in the device
79832565|NCT02545881|Other|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
79832566|NCT02563704|Drug|Artesunate|
79832567|NCT02563704|Drug|Quinine|
79378599|NCT02502708|Radiation|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
79832568|NCT00848523|Drug|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
79832569|NCT00742404|Drug|bortezomib|
79832570|NCT00742404|Drug|dexamethasone|
79832571|NCT00742404|Drug|pegylated liposomal doxorubicin hydrochloride|
79832572|NCT00742404|Genetic|protein analysis|
79832573|NCT00742404|Other|immunologic technique|
79832574|NCT05279950|Device|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
79832575|NCT05279950|Device|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
79832576|NCT00848601|Drug|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
79832577|NCT00742482|Drug|HL 10|Freeze dried HL 10
79832578|NCT00939250|Behavioral|Diabetes and depression intervention|Disease self management for diabetes and depression
79832579|NCT00939250|Behavioral|Diabetes intervention|Disease self management for diabetes
79832580|NCT00744666|Drug|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
79832581|NCT04013620|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
79832582|NCT02562222|Procedure|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79832583|NCT02562222|Procedure|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79238171|NCT05473143|Other|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
79378600|NCT02502708|Drug|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
79378601|NCT02502708|Drug|Etoposide|Etoposide will be administered orally daily.
79378602|NCT02498574|Device|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
79378603|NCT02498574|Behavioral|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
79532787|NCT01442922|Other|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
80005868|NCT02139566|Behavioral|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
80005869|NCT05188079|Dietary Supplement|Beetroot juice|high nitrate supplement
79532788|NCT01442935|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
79532789|NCT01442935|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
80005870|NCT05188079|Dietary Supplement|Placebo drink|placebo
80005871|NCT04579549|Device|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
80005872|NCT05188001|Other|Not an Interventional Study|Not an interventional Study
79378604|NCT02728596|Other|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
79378605|NCT02728596|Other|Quality-of-Life Assessment|Ancillary studies
79378606|NCT02728596|Other|Questionnaire Administration|Ancillary studies
79532790|NCT01442935|Drug|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
79532791|NCT01442935|Drug|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
79532792|NCT01442935|Drug|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
79832584|NCT02562222|Procedure|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79832585|NCT02562222|Procedure|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79832586|NCT02562222|Procedure|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79532793|NCT01442935|Drug|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
79532794|NCT01442935|Drug|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
79532795|NCT01442961|Procedure|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
79532796|NCT01442961|Procedure|vaginal : vaginal hysterectomy|Vaginal hysterectomy
79688658|NCT03316196|Behavioral|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
79688659|NCT03316196|Behavioral|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
80005873|NCT03549806|Diagnostic Test|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
80005874|NCT01356485|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
80005875|NCT01356485|Drug|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
79238172|NCT05473143|Other|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
79238173|NCT05458193|Drug|Daridorexant|Film-coated tablet for oral use
79238174|NCT05458193|Drug|Placebo|Film-coated tablet for oral use
79532797|NCT01442974|Drug|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
79532798|NCT01442987|Drug|Irbesartan/Atorvastatin A|once daily, P.O. 8week
79532799|NCT01442987|Drug|Irbesartan|once daily, P.O. 8week
79532800|NCT01442987|Drug|Atorvastatin A|once daily, P.O. 8week
79688660|NCT03306316|Dietary Supplement|Prebiotic|Prebiotic experimental group
79688661|NCT03306316|Dietary Supplement|Dextrose Control|Dextrose Control
79688662|NCT03261830|Drug|Cefazolin|Primary intervention
79532801|NCT01442987|Drug|Placebo|once daily, P.O. 8week
79532802|NCT01442987|Drug|Irbesartan/Atorvastatin B|once daily, P.O. 8week
79532803|NCT01442987|Drug|Atorvastatin B|once daily, P.O. 8week
79532804|NCT01443013|Other|Renal Transplant|urinary sample at month 3, 6 and 12
79532805|NCT01443039|Drug|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
79238175|NCT05445024|Procedure|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
79238176|NCT05445024|Procedure|sufentanil group|sufentanil (1/1000* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
79832587|NCT02562222|Procedure|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79832588|NCT02562222|Procedure|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
79832589|NCT04012684|Device|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
79832590|NCT04012684|Device|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
79832591|NCT05051228|Device|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
79832592|NCT00944788|Other|qi-gong|Physical activity similar to tai-chi
79832593|NCT00749112|Drug|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
79832594|NCT00848679|Drug|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
79302899|NCT04492163|Device|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
79378607|NCT01707472|Biological|Simtuzumab|700 mg intravenously for a total of 12 infusions.
79378608|NCT01666210|Drug|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
79378609|NCT01666210|Drug|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
79378610|NCT01666912|Drug|Contraceptive implant|
79532806|NCT01443052|Other|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
79532807|NCT01443065|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
79532808|NCT01443065|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
79688663|NCT03261830|Drug|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
79688664|NCT03261830|Drug|Saline|Placebo Intervention
79688665|NCT03237182|Drug|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
79832595|NCT00848679|Drug|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
79302900|NCT03209245|Biological|Purethal Mites|perennial allergren specific immunotherapy during 24 months
79532809|NCT01443065|Drug|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
79532810|NCT01443065|Drug|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
79532811|NCT01443065|Drug|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
79532812|NCT01443091|Other|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
79532813|NCT01443091|Other|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
79832596|NCT02567864|Other|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
79832597|NCT02567864|Other|control|participants maintain their daily activities.
79832598|NCT04012606|Drug|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
79302901|NCT03209245|Other|placebo injection|perrenial injection wich were administered in same protocol as Purethal
79302902|NCT03209245|Diagnostic Test|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
79302903|NCT03209245|Diagnostic Test|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
79302904|NCT04915287|Drug|Avatrombopag maleate|"Mean baseline platelet count 40 to less than 50 × 10^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~Mean baseline platelet count less than 40 × 10^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure"
79302905|NCT04915287|Biological|Platelet transfusion|Mean baseline platelet count less than 50 × 10^9/L pre-procedure: platelet transfusion if needed
79378611|NCT03341988|Drug|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
79688666|NCT03237182|Drug|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
79688667|NCT03224819|Drug|Emerfetamab|Administered by intravenous (IV) infusion.
79832599|NCT00744744|Other|informational intervention|Patient educational information
79532814|NCT01443104|Device|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
79832600|NCT00744744|Other|questionnaire administration|Survey
79532815|NCT01443104|Device|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
79302906|NCT04915287|Drug|Medicine|Mean baseline platelet count less than 50 × 10^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
79378612|NCT02501850|Drug|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
79378613|NCT02501850|Drug|metformin|Treatment with metformin and/or sulphonilurea
79688668|NCT03215043|Dietary Supplement|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
79832601|NCT00744744|Procedure|management of therapy complications|Survey
79832602|NCT00744744|Procedure|psychosocial assessment and care|Survey
79832603|NCT00744744|Procedure|quality-of-life assessment|Survey
79832604|NCT02545959|Drug|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
79832605|NCT02545959|Drug|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
79832606|NCT02545959|Drug|Rituximab IV|Blood infusion of rituximab (375mg/m2)
79832607|NCT04012528|Other|ERAS program|ERAS program
80005876|NCT01363193|Drug|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = [9270 x weight (kg)] / [6680+216 x BMI] Female = [9270 x weight (kg)] / [8780+244 x BMI]"
79302907|NCT05709353|Behavioral|Prolonged exposure therapy|"COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist."
79378614|NCT01709032|Drug|Deferasirox and deferiprone|
79378615|NCT02498340|Dietary Supplement|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
79378616|NCT01667536|Drug|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
79378617|NCT02496078|Drug|Daclatasvir|Daclatasvir tablet 60mg
79378618|NCT02496078|Drug|Asunaprevir|Asunaprevir soft capsule 100 mg
79378619|NCT01667848|Device|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
79378620|NCT01667848|Device|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
79378621|NCT02501694|Other|Auscultation|Electronic stethoscope
79832608|NCT04062110|Device|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
79832609|NCT00747630|Other|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
79832610|NCT02545647|Device|BRYGB|65 patients undergo a banded RYGB
79832611|NCT00744900|Drug|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
79832612|NCT00727090|Drug|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
80005877|NCT03764930|Other|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
80005878|NCT02134808|Drug|Creatine|Creatine is a nutritional supplement.
80005879|NCT02134808|Drug|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
79532816|NCT01443117|Biological|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
79532817|NCT01443117|Biological|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
79532818|NCT01443117|Biological|Placebo Vaccine|Administered as a 0.5 mL IM dose
80005880|NCT01319279|Drug|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
79832613|NCT00852033|Behavioral|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
79832614|NCT00852033|Behavioral|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
79302908|NCT05709353|Drug|MDMA|Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
79302909|NCT05709353|Drug|Niacin|Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
79302910|NCT03195673|Drug|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
79532819|NCT01443143|Other|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
79532820|NCT01443143|Dietary Supplement|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
79532821|NCT01443169|Drug|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532822|NCT01443169|Drug|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79378622|NCT02495922|Drug|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
79832615|NCT00852033|Behavioral|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
79832616|NCT00852033|Other|Assessment only|No intervention, assessment only.
79832617|NCT00944944|Behavioral|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
79532823|NCT01443169|Drug|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79378623|NCT02495922|Drug|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
79688669|NCT03215043|Other|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
79688670|NCT03064568|Drug|Misoprostol 100Mcg Tab|
79688671|NCT03064568|Drug|Placebo|
79688672|NCT03048786|Behavioral|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
79378624|NCT02495922|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
79391190|NCT02415660|Behavioral|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
79391191|NCT02415660|Procedure|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
79832618|NCT00944944|Behavioral|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
79832619|NCT00848835|Device|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
79832620|NCT00950014|Other|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
79832621|NCT00855621|Procedure|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
79532824|NCT01443169|Drug|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
79391192|NCT02415660|Device|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
79391193|NCT02415738|Procedure|Prone positioning|
79832622|NCT00689052|Drug|pramipexole ER|
79391194|NCT02420730|Drug|AGN-232411|AGN-232411 topical ophthalmic solution
79302911|NCT03195673|Procedure|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
79532825|NCT01443169|Drug|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
79688673|NCT03048786|Behavioral|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
79688674|NCT02885142|Procedure|Local excision for early rectal cancer|
79688675|NCT02879201|Procedure|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
79532826|NCT01443169|Drug|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79688676|NCT02836522|Behavioral|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
79688677|NCT02785042|Device|Heidelberg Spectralis OCT|OCT imaging
79688678|NCT02785029|Device|OCT|
79688679|NCT02783950|Other|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
79688680|NCT02773004|Other|EPClin genomic test|
79688681|NCT02691078|Other|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
79688682|NCT02549573|Drug|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
79688683|NCT02549573|Behavioral|Physical Therapy|All subjects will participate in a standardized PT intervention
79688684|NCT02542657|Drug|Clarithromycin|Given PO
79688685|NCT02542657|Drug|Dexamethasone|Given PO
79688686|NCT02542657|Drug|Ixazomib Citrate|Given PO
79688687|NCT02542657|Drug|Pomalidomide|Given PO
79688688|NCT02503423|Drug|ASTX660|described above
79832623|NCT00689052|Drug|placebo|
79832624|NCT04012450|Procedure|Epidural anesthesia|Performing an epidural anesthesia
79832625|NCT04012450|Procedure|spina-epidural anesthesia|Performing a spina-epidural anesthesia
79832626|NCT00945022|Device|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
79532827|NCT01443169|Drug|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
79532828|NCT01443169|Drug|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532829|NCT01443169|Drug|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532830|NCT01443169|Drug|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
79532831|NCT01443169|Drug|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79688689|NCT02485418|Drug|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
79302912|NCT02481791|Drug|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
79391195|NCT02420730|Drug|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
79391196|NCT02415192|Drug|Levacalm|
79391197|NCT02415192|Drug|Valsartan/amlodipine|
79832627|NCT02565212|Drug|Montelukast,mometazon froat|
79832628|NCT00848913|Other|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
79832629|NCT00848913|Other|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
79832630|NCT00747708|Drug|Granulocyte-colony stimulating factor|5 days subcutaneous injection
79832631|NCT00747708|Procedure|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
79832632|NCT00747708|Procedure|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
79832633|NCT05602064|Drug|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
79832634|NCT05602064|Drug|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
79832635|NCT05602064|Other|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
79832636|NCT02565134|Drug|PAC-14028 cream 0.1%|Topical application
79832637|NCT02565134|Drug|PAC-14028 cream 0.3%|Topical application
79832638|NCT02565134|Drug|PAC-14028 cream 1.0%|Topical application
79832639|NCT02565134|Drug|PAC-14028 cream vehicle|Topical application
79832640|NCT00747942|Behavioral|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
79832641|NCT00560950|Biological|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
80005881|NCT02139722|Behavioral|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
80005882|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
80005883|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
79832642|NCT02562144|Drug|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
80005884|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
79832643|NCT02562144|Drug|Placebo|Cutaneous placebo before intravenous cannulation.
79832644|NCT02562300|Drug|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
80005885|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
80005886|NCT02134886|Drug|Erlotinib Hydrochloride|Given PO
80005887|NCT02134886|Other|Laboratory Biomarker Analysis|Correlative studies
80005888|NCT02134886|Other|Pharmacological Study|Correlative studies
79532832|NCT01443169|Drug|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532833|NCT01443169|Drug|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
79532834|NCT01443169|Drug|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532835|NCT01443169|Drug|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
79532836|NCT01443169|Drug|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
80005889|NCT02134886|Other|Quality-of-Life Assessment|Ancillary studies
80005890|NCT01360463|Behavioral|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
79532837|NCT01443169|Drug|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532838|NCT01443169|Drug|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79532839|NCT01443169|Drug|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
79832645|NCT02562300|Drug|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
79832646|NCT00945178|Drug|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
80005891|NCT01360463|Behavioral|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
80005892|NCT02139956|Device|ultrasonography|open
80005893|NCT01360541|Procedure|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
80005894|NCT01360541|Other|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
80005895|NCT02253368|Other|sleep|
79832647|NCT00945178|Drug|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
79238177|NCT05440955|Device|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
79832648|NCT00945178|Drug|Naproxen|Tablet, single oral dose, 500mg
79832649|NCT00945178|Drug|Placebo for Naproxen|Tablet, single oral dose
79238178|NCT05440669|Behavioral|white noise|white noise will reduce pain and stress in nasal cpap application
79378625|NCT02495922|Drug|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
79238179|NCT05440318|Device|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes [ePRO] capability) will be provided to each participant enrolled in the study.
79378626|NCT01669096|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
79688690|NCT02378181|Behavioral|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
79378627|NCT01709422|Drug|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
79532840|NCT01443169|Drug|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
79532841|NCT01443182|Behavioral|STAIR|Skills Training in Affective and Interpersonal Regulation
79532842|NCT01443182|Behavioral|MPE|Modified prolonged exposure (MPE)
79688691|NCT02378181|Behavioral|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
79688692|NCT02371460|Dietary Supplement|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
79532843|NCT01443182|Behavioral|EMDR|Eye movement desensitization and reprocessing
79832650|NCT00749346|Device|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
79832651|NCT05301478|Device|standard of care insole|standard of care diabetic insole
79832652|NCT05301478|Device|3D Printed Insole - pressure based|3D Printed Insole - pressure based
79832653|NCT05301478|Device|3D Printed Insole - FEA|3D Printed Insole - FEA
79832654|NCT00945412|Device|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
79832655|NCT00945412|Device|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
79832656|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
79832657|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
79832658|NCT00945568|Drug|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
79832659|NCT02562690|Other|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
79832660|NCT00950092|Device|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
79832661|NCT00576758|Drug|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
79832662|NCT00576758|Drug|rituximab|375 mg/m^2 rituximab IV infusion once a week for 4 weeks.
79832663|NCT00923676|Drug|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
79832664|NCT00923676|Drug|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
79832665|NCT00923676|Drug|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
79832666|NCT00950326|Procedure|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
79238180|NCT05439252|Behavioral|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
79238181|NCT05437146|Behavioral|puppet|pain and fear during blood collection
79238182|NCT05429814|Other|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
79238183|NCT05420337|Procedure|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
79378628|NCT01709422|Drug|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
79378629|NCT01709422|Drug|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
79378630|NCT01669642|Drug|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
79378631|NCT01669720|Drug|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
79378632|NCT01670110|Drug|Pasireotide LAR|Injectible, 60mg per month
79378633|NCT01670110|Drug|Placebo|To be injected once per month
79378634|NCT01672996|Drug|Ioforminol 160 mgI/mL|Given as s single administration to the subject
79532844|NCT01443195|Drug|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~Before starting iron supplementation (maximum one week before).~At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
79532845|NCT01443208|Drug|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
79832667|NCT00950326|Procedure|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
79832668|NCT00950326|Procedure|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
79832669|NCT00745446|Procedure|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
79832670|NCT00921284|Drug|NaCl 9/00|Same volume as in the dexmedetomidine group
79832671|NCT00921284|Drug|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
79378635|NCT01672996|Drug|Ioforminol 200 mgI/mL|Given as a single administration to the subject
79378636|NCT01672996|Drug|Iopamidol 300 mgI/mL|Given as a single administration to the subject
79378637|NCT01674478|Dietary Supplement|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
79532846|NCT01443208|Drug|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
79532847|NCT01443208|Drug|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
79532848|NCT01443221|Drug|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
79832672|NCT00748020|Procedure|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
79832673|NCT00748020|Procedure|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
79832674|NCT00749502|Drug|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
79832675|NCT00560794|Biological|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
79832676|NCT03879330|Device|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
79378638|NCT01674478|Dietary Supplement|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
79832677|NCT00749736|Dietary Supplement|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
79832678|NCT00749736|Dietary Supplement|doxercalciferol|1 mcg of doxercalciferol per day
79532849|NCT01443221|Drug|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
79532850|NCT01443234|Other|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
79832679|NCT00749736|Dietary Supplement|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
79832680|NCT00950404|Drug|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
79832681|NCT00950404|Drug|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
79832682|NCT00950404|Drug|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
79832683|NCT00950404|Drug|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
79832684|NCT00749814|Dietary Supplement|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
79532851|NCT01443234|Other|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
79532852|NCT01443247|Drug|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
79532853|NCT01443260|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
79532854|NCT01443273|Other|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
79688693|NCT02371460|Combination Product|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
79688694|NCT02346838|Dietary Supplement|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
79688695|NCT02346838|Dietary Supplement|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
79832685|NCT00749814|Other|Placebo tablets|Placebo
79832686|NCT00950482|Procedure|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
79832687|NCT00950482|Other|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
79832688|NCT00950482|Other|WC|Waiting Group
79832689|NCT00748176|Procedure|spinal anesthesia|spinal anesthesia with bupivacaine
79832690|NCT00941122|Device|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
79832691|NCT02565758|Drug|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
79832692|NCT04159922|Other|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
79832693|NCT00941200|Biological|Blood collection|
79378639|NCT02245360|Drug|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
79532855|NCT01443312|Genetic|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
79688696|NCT02301663|Other|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
79688697|NCT02301663|Other|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
79688698|NCT02301663|Other|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
79688699|NCT02229968|Drug|Amicar (ε-aminocaproic acid)|
79688700|NCT02229968|Drug|normal saline|
79688701|NCT02222844|Other|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
79688702|NCT02201108|Drug|Teriflunomide|Pharmaceutical form:film-coated tablet, Route of administration: oral
79832694|NCT00945880|Drug|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
79832695|NCT04061174|Other|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
79378640|NCT02245360|Drug|placebo|placebo tablet given once daily over 60 days
79688703|NCT02201108|Drug|Placebo|Pharmaceutical form:tablet, Route of administration: oral
79832696|NCT04061174|Other|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
80005896|NCT03548870|Other|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
79832697|NCT00950638|Drug|ARC1905|intravitreal injection
79832698|NCT02565290|Dietary Supplement|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
80005897|NCT03548870|Other|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
80005898|NCT01356563|Behavioral|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
80005899|NCT01356641|Drug|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
80005900|NCT01356641|Procedure|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
80005901|NCT03103087|Drug|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
79532856|NCT01443325|Drug|lidocaine patch|1 patch for 12 hours within each 24 hours period
80005902|NCT03103087|Drug|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
80005903|NCT03103087|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
79832699|NCT02565290|Dietary Supplement|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
79832700|NCT00941278|Drug|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
80005904|NCT03103087|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
80005905|NCT05579288|Drug|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
80005906|NCT05579288|Drug|Oxygen (O2)|Oxygen (O2) as placebo for control group
80005907|NCT02081105|Other|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
79378641|NCT02245516|Drug|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
79378642|NCT02245516|Drug|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
79532857|NCT01443338|Drug|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
79832701|NCT00619359|Drug|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
80016727|NCT04450498|Biological|Yuxi Walvax MPV ACYW® vaccine|Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects > 2 years of age and have shown to be safe and immunogenic.
79832702|NCT00619359|Drug|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
79532858|NCT01443338|Drug|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
79238184|NCT05420337|Procedure|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
79238185|NCT05418751|Other|Manual therapy|Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.
79238186|NCT05418751|Other|Placebo treatment|Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
79238187|NCT05390905|Drug|HSK21542 Injection|1μg/kg/dose
79238188|NCT05390905|Drug|Tramadol hydrochloride|50mg/dose
79238189|NCT05390905|Drug|placebo|placebo
79532859|NCT01443377|Biological|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
79832703|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
79832704|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
79832705|NCT00619359|Drug|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
80005908|NCT05579210|Behavioral|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
79532860|NCT01443416|Biological|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
80005909|NCT05579210|Behavioral|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
80005910|NCT01363505|Device|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
80005911|NCT02134964|Drug|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
80005912|NCT02134964|Drug|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
80005913|NCT01363583|Drug|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
79378643|NCT05710822|Device|pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter
79532861|NCT01443416|Biological|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
79532862|NCT01443429|Drug|beraprost sodium(BPS)|
79688704|NCT02180243|Behavioral|Mindfulness meditation/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
79832706|NCT00950716|Behavioral|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
79832707|NCT00950716|Behavioral|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
80005914|NCT01363583|Drug|normal saline|0.5-1.5 ml/hour during 4 days
80005915|NCT02135120|Drug|Combined spinal epidural anesthesia technique with intrathecal morphine|
80005916|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
80005917|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
80005918|NCT02135198|Drug|2 mg AZD7325|A single 2 mg oral dose of AZD7325
79688705|NCT02180243|Other|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
80005919|NCT02135198|Drug|10 mg AZD7325|A single 10 mg oral dose of AZD7325
80005920|NCT02135198|Drug|Placebo|A single oral dose
79378644|NCT01677286|Drug|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
79378645|NCT02246062|Behavioral|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
79378646|NCT02246062|Behavioral|smartphone|the child received smartphone application immediately before entering the operating room
79378647|NCT05147038|Device|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
79532863|NCT01443455|Behavioral|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
80005921|NCT03131999|Drug|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
80005922|NCT03131999|Drug|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
80005923|NCT01319357|Drug|Saxagliptin|orally 5 mg/d for 6 weeks
80005924|NCT01319357|Drug|Placebo|orally for 6 weeks
79688706|NCT02153229|Radiation|Photodynamic Therapy|
79688707|NCT02153229|Procedure|Radical Pleurectomy|
79688708|NCT02153229|Radiation|Chemotherapy|
79832708|NCT00848991|Drug|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
79832709|NCT00848991|Drug|Propofol|evaulation of propofol for emergence from anesthesia
79688709|NCT02153229|Drug|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
79832710|NCT00941434|Dietary Supplement|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
80005925|NCT02135354|Drug|Azithromycin|"From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
80005926|NCT02135354|Drug|Placebo|"From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
79378648|NCT01678846|Behavioral|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
79378649|NCT02502630|Device|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
79378650|NCT04498260|Drug|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
79378651|NCT04498260|Drug|Oral steroid - predonisolone|(predonisolone)
79532864|NCT01443455|Behavioral|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
79688710|NCT01975597|Procedure|Bone marrow aspirates and biopsy|
79688711|NCT01864460|Behavioral|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
79688712|NCT01842204|Device|Magnetic field therapy device|Therapy device for 1 week.
79688713|NCT01842204|Device|Non magnetic field therapy device.|Non-active device for 1 week.
79688714|NCT01816100|Other|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
79688715|NCT01816100|Behavioral|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
79688716|NCT01789879|Drug|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
79832711|NCT02545725|Other|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
79832712|NCT00950794|Drug|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
79832713|NCT00950794|Drug|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
79832714|NCT00852189|Drug|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
79832715|NCT00852189|Drug|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
79832716|NCT00852189|Drug|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
80005927|NCT01319435|Procedure|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
80005928|NCT05416099|Procedure|laser|grid vs micropulse laser
80005929|NCT02140034|Procedure|Extensive Peritoneal Lavage|
80005930|NCT02055053|Drug|0.5% Bupivicaine|Local anesthetic
80016728|NCT04450498|Biological|Sanofi Pasteur Menactra® vaccine|The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
80016729|NCT00654992|Drug|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
79532865|NCT01443455|Behavioral|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------"
79688717|NCT01789879|Drug|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
79688718|NCT01789879|Drug|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
79832717|NCT00951028|Behavioral|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
79832718|NCT00951028|Behavioral|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
79832719|NCT00951028|Behavioral|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
79832720|NCT00849069|Biological|GSK2231395A|3 doses intramuscular injections
79832721|NCT00849069|Biological|TwinrixTM|3 doses intramuscular injections
79532866|NCT01443481|Drug|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
79832722|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
79832723|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
79832724|NCT04042545|Drug|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
79832725|NCT04042545|Drug|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
79832726|NCT00951106|Drug|Pyrimethamine/sulfdoxine (Fansidar)|
79532867|NCT01443507|Other|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
79688719|NCT01772563|Drug|volasertib|Solution for infusion
79688720|NCT01772563|Drug|itraconazole|capsules
79688721|NCT01771900|Behavioral|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
79832727|NCT00852267|Other|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
79832728|NCT00852267|Other|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
79832729|NCT00852267|Other|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
79832730|NCT00372229|Drug|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
80016730|NCT00654992|Drug|Normal Saline|300 IU/kg of normal saline intravenously before surgery
79832731|NCT00372229|Drug|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
79832732|NCT00372229|Drug|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
79832733|NCT05301010|Drug|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
79532868|NCT01443520|Drug|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
79532869|NCT01443520|Drug|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
79832734|NCT05301010|Drug|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
79832735|NCT05301010|Drug|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
79832736|NCT00855699|Drug|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
79832737|NCT00855777|Drug|etoricoxib|etoricoxib 120 mg/day for 3 days
79832738|NCT00855777|Drug|ibuprofen|ibuprofen 1,800 mg/day for 3 days
80016731|NCT05208203|Other|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
80016732|NCT02282462|Other|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
80016733|NCT02282462|Other|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
80016734|NCT02282462|Other|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
79688722|NCT01771900|Behavioral|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
79688723|NCT01765439|Dietary Supplement|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
79688724|NCT01622725|Procedure|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
79688725|NCT01622725|Procedure|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
79832739|NCT04012294|Drug|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
79832740|NCT00849459|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
79832741|NCT00852345|Drug|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
79832742|NCT00698828|Drug|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
80016735|NCT02282462|Other|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
79378652|NCT05341336|Procedure|total surgical excision|"patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics."
79378653|NCT01679314|Device|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
79378654|NCT01680172|Drug|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
79378655|NCT01680172|Drug|Placebo|Single dose of liquid placebo solution taken by mouth
79378656|NCT01680328|Other|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
79688726|NCT01622127|Device|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
79688727|NCT01543789|Procedure|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
79832743|NCT00698828|Drug|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
79832744|NCT00698828|Drug|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
79832745|NCT00619515|Other|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
80016736|NCT02282462|Other|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
80016737|NCT02282462|Other|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
79378657|NCT01680328|Drug|sodium chloride 0.9% solution|Solution for injection.
79378658|NCT02235064|Drug|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
79378659|NCT02235064|Drug|Placebo|Capsule containing cellulose powder of same color as experimental arm
79378660|NCT05710588|Other|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
79688728|NCT01543789|Procedure|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
79688729|NCT01445171|Device|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
79688730|NCT01316523|Drug|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
79688731|NCT01316523|Drug|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
79688732|NCT01307657|Other|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
79832746|NCT00619515|Procedure|implanted fiducial-based imaging|Undergo fiducial placement imaging
79832747|NCT00619515|Radiation|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
79688733|NCT01258933|Drug|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
79832748|NCT00951184|Behavioral|telephone-based intervention|
79832749|NCT00951184|Other|screening questionnaire administration|
79832750|NCT00951184|Other|study of socioeconomic and demographic variables|
79832751|NCT00951184|Procedure|assessment of therapy complications|
79832752|NCT00951184|Procedure|psychosocial assessment and care|
79832753|NCT03469843|Other|Non intervention|patients without intervention
79832754|NCT00941746|Biological|PG110|Single, slow intravenous infusion
80005931|NCT01360697|Other|JADE|"The nurse will complete the CA using standardized protocol including blood & urine tests, eye & feet examination.~Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications & healthy lifestyles, perform self blood glucose monitoring as appropriate.~At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight & blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~After the FU visit, the patients will see the nurse or HCA again to clarify any issues & concerns, reinforce compliance & record any changes in medications.~After each FU visit, the HCA will generate summary reports to be given to patients & doctors to promote sharing of information."
80005932|NCT01360697|Other|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
80005933|NCT02135510|Drug|metoclopramide|
80005934|NCT02135510|Drug|dexamethason|
79378661|NCT05710588|Other|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
79378662|NCT01680640|Dietary Supplement|Synbiotic|The synbiotic to be used is fructo-oligosacharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
79378663|NCT01680640|Dietary Supplement|Maltodextrin|
80005935|NCT02135510|Drug|palonosetron|
80005936|NCT02140112|Biological|Trichuris suis ova|
79688734|NCT01200927|Other|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
79688735|NCT01109771|Device|permanent mesh fixation|Permanent mesh fixation will be used.
79688736|NCT01109771|Device|absorbable mesh fixation|Absorbable mesh fixation will be used.
79688737|NCT01042561|Dietary Supplement|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
79688738|NCT01042561|Dietary Supplement|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
79688739|NCT00959244|Other|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
79688740|NCT00959244|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
79688741|NCT00959244|Other|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
79688742|NCT00959244|Other|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
79688743|NCT00848328|Biological|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
79688744|NCT00848328|Drug|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
79688745|NCT00573339|Other|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
79688746|NCT00573027|Procedure|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
79688747|NCT00569543|Other|high performance liquid chromatography|urine analysis
79688748|NCT00569543|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
79688749|NCT00569543|Other|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
79688750|NCT00569543|Other|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
79832755|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832756|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832757|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832758|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832759|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832760|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832761|NCT00941746|Biological|PG110|Single, slow intravenous infusion
79832762|NCT00941746|Biological|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
80005937|NCT02140112|Other|Placebo|
79238190|NCT05379348|Other|Cognitive Assessment|Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
79532870|NCT01443520|Drug|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
80005938|NCT02263885|Device|ExAblate Transcranial System|Transcranial MRgFUS
80005939|NCT02192671|Procedure|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
80005940|NCT02192671|Procedure|Radiofrequency Ablation|
79378664|NCT02249806|Other|PH target therapy according to physician|Patients receiving PH target therapy
80005941|NCT03548714|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
80005942|NCT03548714|Other|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
79378665|NCT05118490|Drug|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
79378666|NCT05118490|Drug|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
79378667|NCT05710510|Behavioral|Local Care + Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity."
79688751|NCT01237951|Drug|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
79688752|NCT01237951|Drug|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
79688753|NCT01237951|Drug|Gemcitabine|1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
80005943|NCT02160691|Device|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
80005944|NCT02135588|Drug|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
79532871|NCT01443533|Behavioral|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
79532872|NCT01443559|Genetic|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
79688754|NCT01237951|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
79688755|NCT01237951|Drug|Melphalan|60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
79688756|NCT01237951|Procedure|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
79688757|NCT01237951|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
80005945|NCT03633019|Drug|rhTPO|high dose rhTPO ih
80005946|NCT05755243|Device|glucose sensor|skin biopsy (punch)
80005947|NCT05578508|Drug|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
79238191|NCT05367505|Device|iFuse-3D implant|The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
80005948|NCT01491763|Drug|Imatinib|600 mg p.o. from day 1 until consolidation
80005949|NCT03597750|Device|Repose®|"Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors"
79238192|NCT05367115|Other|longitudinal observational study|longitudinal observational study
79378668|NCT05710510|Behavioral|Team Care Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience."
79532873|NCT01443559|Genetic|homogenic cornea|homogenic corneas were sterilised by radiation
79378669|NCT05710432|Other|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
79532874|NCT01443572|Drug|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
79532875|NCT01443572|Drug|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
79688758|NCT02908581|Drug|Placebo|Administered orally once daily
79688759|NCT02908581|Drug|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
79688760|NCT00544362|Biological|cetuximab|
79688761|NCT00544362|Drug|cisplatin|
79688762|NCT00544362|Drug|fluorouracil|
79688763|NCT00544362|Procedure|conventional surgery|
80005950|NCT03549260|Biological|LIB003|LIB003 or placebo
80005951|NCT01563302|Drug|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
80005952|NCT04254341|Other|patients with OSA|Sleep study
80005953|NCT02237586|Biological|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
79238193|NCT05366621|Drug|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
79238194|NCT05362227|Drug|Low volume macrogol|Clensia 2 lt
79688764|NCT02908776|Dietary Supplement|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
79238195|NCT05362227|Drug|High volume macrogol|Selg 4 lt
79832763|NCT00852423|Drug|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
79832764|NCT00852423|Drug|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
79238196|NCT05359146|Drug|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
80005954|NCT02252822|Behavioral|Overcoming Bulimia Online Programme|
79238197|NCT05359146|Drug|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= [Tyr]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
79238198|NCT05344599|Diagnostic Test|Autonomic Function Testing|Autonomic function test (orthostatic blood pressure and heart rate response to tilt, heart rate response to deep breathing, the Valsalva ratio, and beat-to-beat blood pressure measurements during phases II and IV of the Valsalva maneuver, tilt, and deep breathing). These combined tests provide a measurement of adrenergic, cardiovagal responses.
79238199|NCT05344599|Diagnostic Test|Genetic Testing|Genetic testing: for Acute hepatic porphyria panel - with intent to use Saliva kit
79238200|NCT05344599|Diagnostic Test|Urine Testing|Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine
79238201|NCT05344599|Diagnostic Test|Blood laboratory Testing|"To determine the following laboratory analyses:~CBC, CMP, Iron studies (Ferritin and iron studies)"
79238202|NCT05340166|Procedure|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
79238203|NCT05340166|Procedure|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
79238204|NCT05335252|Drug|Dronabinol|5mg 2x daily for 7 days
79238205|NCT05335252|Drug|Placebo|1 caplet 2x daily for 7 days
79238206|NCT05331846|Behavioral|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
79238207|NCT05325775|Drug|ACER-801 50 mg BID|50 mg BID (twice daily)
79238208|NCT05325775|Drug|ACER-801 100 mg BID|100 mg BID (twice daily)
79378670|NCT05710432|Other|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique [IO], external oblique [EO], transversus abdominis [TrA] and rectus abdominis [RA] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
79378671|NCT02246608|Device|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
79688765|NCT02908776|Other|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
79238209|NCT05325775|Drug|ACER-801 200 mg BID|200 mg BID (twice daily)
79238210|NCT05325775|Drug|Placebo|Placebo
79688766|NCT04648943|Procedure|Ex-Press mini shunt insertion|
79688767|NCT04648943|Procedure|Trabeculectomy|
79688768|NCT02908503|Other|Placebo Film|placebo vaginal films
79688769|NCT04648670|Behavioral|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
79688770|NCT01239394|Drug|ofatumumab|Weekly infusion for 8 weeks
80005955|NCT01363817|Drug|BMS-906024|
79378672|NCT02246608|Device|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
79378673|NCT02237092|Procedure|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
79832765|NCT00852423|Drug|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
79832766|NCT00852423|Drug|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
79832767|NCT00941824|Drug|mycophénolate acid|"Day 0 to Day 7, 720 mg twice daily~Day 8 to Day 30, 540 mg twice daily~Day 30 to Day 90, 360 mg twice daily"
79832768|NCT00849537|Drug|Triamcinolone|Injection of intravitreal Triamcinolone
79832769|NCT03167606|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
79238211|NCT05324033|Radiation|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
79238212|NCT05324033|Procedure|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
79832770|NCT00951262|Behavioral|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
79832771|NCT01049815|Drug|sevelamer hydrochloride|800-3200 mg with each meal
79832772|NCT01049815|Drug|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
79832773|NCT00849615|Drug|Docetaxel|50mg/m2 qd15
79832774|NCT00849615|Drug|5-Fluorouracil|2600mg/m2 qd15
79832775|NCT00849615|Drug|Oxaliplatin|85mg/m2 qd15
79832776|NCT00849615|Drug|folinic acid|200mg/m2 qd15
79238213|NCT05319028|Drug|Mivavotinib|oral tablet
79238214|NCT05310045|Behavioral|Personalised primary prevention intervention|"Personalised primary prevention intervention~Consultation 1~Assess caregiver's situation regarding their cancer risk factors~Explain the causal links between risk factors and cancer~Inform about national recommendations to prevent and limit cancer risk~Clarify informal caregiver situation with respect to national screening programs~Define a personalised primary prevention program~Implementation: personalised primary prevention program~Carried out by the informal caregiver~Supervised by the coordinating nurse~Consultation 2~Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~Identify barriers and facilitators to their implementation whether actions or no actions have been done.~Adapt the personalised primary prevention program to informal caregiver needs."
79238215|NCT05308381|Behavioral|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
79238216|NCT05308381|Behavioral|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
79238217|NCT05308381|Behavioral|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
79532876|NCT01443585|Device|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
79532877|NCT01443624|Drug|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
79532878|NCT01443650|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
79532879|NCT01443663|Biological|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
79532880|NCT01443676|Drug|Bevacizumab|Bevacizumab will be added to radiotherapy
79688771|NCT00553293|Drug|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
79832777|NCT00946036|Drug|Sertraline Hydrochloride|
80005956|NCT01363817|Drug|Dexamethasone|
79238218|NCT05287997|Diagnostic Test|Neurolytixs Index|Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.
79688772|NCT00553293|Drug|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
79688773|NCT04648514|Procedure|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
79688774|NCT04648514|Behavioral|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
79832778|NCT00688740|Drug|Docetaxel|intravenous
79832779|NCT00688740|Drug|5-fluorouracil|intravenous
79832780|NCT00688740|Drug|Doxorubicin|intravenous
79832781|NCT00688740|Drug|Cyclophosphamide|intravenous
79832782|NCT01049893|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
80005957|NCT03597048|Behavioral|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
79532881|NCT01443676|Radiation|Radiation therapy|Radiation therapy
80005958|NCT03597048|Behavioral|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
80005959|NCT03597048|Behavioral|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
80005960|NCT02140268|Drug|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
80005961|NCT02140268|Drug|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
80005962|NCT02140268|Drug|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
80005963|NCT05187689|Behavioral|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
80005964|NCT05187689|Behavioral|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
79532882|NCT01443689|Biological|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
79532883|NCT01443689|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
79532884|NCT01443689|Drug|Conventional therapy|Participants will be given conventional therapy only.
80005965|NCT03548636|Behavioral|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of >50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
80005966|NCT01360775|Behavioral|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
80005967|NCT03600168|Device|PuraStat®|Synthetic haemostatic material
79238219|NCT05284084|Other|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
79532885|NCT01443702|Drug|Lapis Judaicus|2 g capsule per day.
79378674|NCT01681030|Biological|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
79378675|NCT01681030|Biological|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
79238220|NCT05284084|Other|Data collection for comparison|Data collection for comparison
79378676|NCT01681030|Other|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
79378677|NCT01681810|Drug|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
79532886|NCT01443702|Drug|Placebo|2 g capsule per day.
79238221|NCT05275673|Drug|sapanisertib|capsules for oral administration
79238222|NCT05271760|Procedure|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
79378678|NCT01683526|Procedure|Direct laryngoscopy|
79378679|NCT01683526|Device|Video laryngoscopy (Glidescope)|
79532887|NCT01443715|Behavioral|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
79378680|NCT02249416|Drug|Tipranavir (TPV) low|
79378681|NCT02249416|Drug|Ritonavir (RTV) low|Norvir®
79378682|NCT02249416|Drug|Tipranavir (TPV) high|Retrovir®
79378683|NCT02249416|Drug|Ritonavir (RTV) high|
79378684|NCT02249416|Drug|Zidovudine|
79378685|NCT01685242|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
79378686|NCT01685242|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
79532888|NCT01443715|Behavioral|Treatment as Usual|Standard treatment in the community
79532889|NCT01443741|Other|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
79832783|NCT04088942|Other|High-intensity smoking cessation intervention|"Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~A hotline is established which the high-intensity group can call.~Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
79832784|NCT04088942|Drug|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
79832785|NCT02545803|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
79832786|NCT02534857|Procedure|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
79832787|NCT00951340|Other|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
79832788|NCT00951340|Behavioral|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
79832789|NCT00951340|Behavioral|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
79832790|NCT00748332|Dietary Supplement|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
79832791|NCT00748332|Dietary Supplement|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
79832792|NCT02545569|Device|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
79832793|NCT05323058|Drug|tulsi extract|4% topical oral spray
79832794|NCT05323058|Drug|Benzydamine Hydrochloride|0.15% topical oral spray
79832795|NCT02561910|Device|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
79832796|NCT00552760|Drug|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
79832797|NCT00552760|Drug|Placebo|one tablet at bedtime for up to 6 months
79832798|NCT01046773|Drug|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
79832799|NCT01046773|Drug|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
80005968|NCT02252900|Other|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
80005969|NCT01363895|Procedure|Percutaneous closure of LAA|Percutaneous closure of LAA
80005970|NCT01363895|Procedure|Catheter ablation of AF|Catheter ablation of AF
80005971|NCT02237664|Procedure|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
79378687|NCT01685320|Procedure|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
79832800|NCT00745602|Procedure|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
79832801|NCT00850005|Biological|Intravenous immunoglobulin|2 g/kg divided over five days
79832802|NCT00850005|Biological|Normal Saline|Same volume as experimental arm
79832803|NCT00941980|Biological|Osteocel Plus|biologic
79832804|NCT04060706|Radiation|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
79832805|NCT04012372|Other|ROSA Water|Ad libitum hydration with ROSA oligomineral water
79832806|NCT04012372|Other|Control water|Ad libitum hydration with other waters
79832807|NCT00852501|Other|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
80005972|NCT02237664|Procedure|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
79378688|NCT04937296|Behavioral|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
79378689|NCT04937296|Other|Usual care|Usual care.
79378690|NCT00708162|Drug|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
79832808|NCT02562534|Device|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
79832809|NCT00852579|Drug|Azithromycin|Daily dose 250mg
79832810|NCT00852579|Drug|Placebo|Placebo
79832811|NCT00942058|Other|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
80005973|NCT05750095|Behavioral|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
80005974|NCT05750095|Behavioral|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
80005975|NCT05578352|Other|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
80005976|NCT05578352|Other|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
80005977|NCT05578352|Other|Change insulin|Change premix insulin to long-acting insulin
80005978|NCT04090229|Drug|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
80005979|NCT04090229|Drug|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
80005980|NCT03602508|Drug|mirabegron|oral
80005981|NCT03602508|Drug|solifenacin|oral
80005982|NCT03602508|Drug|darifenacin|oral
80005983|NCT03602508|Drug|imidafenacin|oral
80005984|NCT03602508|Drug|tolterodine|oral
79532890|NCT01443754|Procedure|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
79688775|NCT00544401|Other|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
80005985|NCT03602508|Drug|oxybutynin|oral
80005986|NCT03602508|Drug|trospium|oral
80005987|NCT03602508|Drug|fesoterodine|oral
80005988|NCT03602508|Drug|propiverine|oral
80005989|NCT05546671|Diagnostic Test|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI >28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI >29: hand grip strength ≤21 kg"
80005990|NCT03549728|Drug|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
80005991|NCT03549728|Procedure|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
80005992|NCT01356797|Drug|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
80005993|NCT01356797|Drug|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
80005994|NCT05200585|Behavioral|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
80005995|NCT05200585|Behavioral|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
80005996|NCT03600012|Other|Cycling Functional Electrical Stimulation|
80005997|NCT03600012|Other|Physiotherapy|
80005998|NCT05747443|Other|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
80005999|NCT05747443|Other|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
79378691|NCT00708162|Drug|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
79532891|NCT01443754|Procedure|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
79688776|NCT02908737|Device|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
79688777|NCT04648397|Other|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
79688778|NCT04648397|Other|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
79378692|NCT00708162|Drug|EVG placebo|Placebo to match elvitegravir administered orally once daily
79832812|NCT02562456|Procedure|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
79832813|NCT02562456|Procedure|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
79832814|NCT00942136|Drug|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
79832815|NCT00942136|Drug|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
80006000|NCT02140346|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
80006001|NCT02140346|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
79378693|NCT00708162|Drug|RAL placebo|RAL placebo administered orally twice daily.
79688779|NCT00544518|Drug|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
79688780|NCT00544518|Drug|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
79688781|NCT04648592|Dietary Supplement|Low salt diet plus sodium chloride supplements|Patients will receive a low salt diet plus salt supplements.
79378694|NCT00708162|Drug|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
79378695|NCT04930042|Drug|Stelara|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
80006002|NCT02238132|Drug|ATROVENT® inhalets|
80006003|NCT05200507|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
80006004|NCT03595722|Device|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
80006005|NCT05200429|Drug|Trikafta|Highly Effective CFTR Modulator Therapy
80006006|NCT02000219|Biological|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
80006007|NCT02135666|Procedure|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
80006008|NCT03595488|Drug|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
79378696|NCT04930042|Drug|AVT04|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
79378697|NCT04898920|Drug|Normal saline|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
79378698|NCT04898920|Drug|Dexamethasone|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
79378699|NCT02249884|Drug|Urea Dose A|Urea cream for topical use.
79378700|NCT02249884|Drug|Urea Dose B|Urea cream for topical use.
79532892|NCT01443780|Dietary Supplement|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
79532893|NCT01443806|Drug|Oseltamivir|75 mg, one time
79532894|NCT01443832|Dietary Supplement|Fe57 and Fe58-FeSO4 stable isotopes|[57Fe] and [58Fe]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
79532895|NCT01443871|Other|Aromatherapy|Subject will assigned inhale aromatherapy
79532896|NCT01443871|Other|Pure water|Subject will assigned inhale Pure water
79378701|NCT02249884|Drug|Urea Dose C|Urea cream for topical use.
79378702|NCT02249884|Drug|Chamomile Dose A|Chamomile gel for topical use.
79688782|NCT04648592|Dietary Supplement|Low salt diet plus placebo|Patients will receive a low salt diet plus placebo.
79688783|NCT02908698|Drug|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
79688784|NCT02908698|Drug|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
79688785|NCT00544596|Drug|R-(-)-gossypol acetic acid|Given orally
79688786|NCT00544596|Drug|cisplatin|Given IV
79378703|NCT02249884|Drug|Chamomile Dose B|Chamomile gel for topical use.
79378704|NCT02249884|Drug|Chamomile Dose C|Chamomile gel for topical use.
79688787|NCT00544596|Drug|etoposide|Given IV
79688788|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
79688789|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
79238223|NCT05271760|Procedure|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
79832816|NCT00942136|Drug|Placebo|Placebo Suspension as a single dose.
79832817|NCT00942136|Drug|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
79832818|NCT00748488|Other|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
79832819|NCT00748488|Other|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
80006009|NCT01356875|Drug|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
79238224|NCT05271760|Procedure|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
79378705|NCT03342846|Device|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
79378706|NCT01686646|Drug|paracetamol + caffeine|paracetamol with caffeine
79378707|NCT01686646|Drug|paracetamol|paracetamol
79378708|NCT02498262|Other|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
79378709|NCT02501772|Device|acupressure by ankle band|
79378710|NCT02495688|Procedure|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
79378711|NCT02495688|Procedure|General anesthesia|Standard procedure.
79532897|NCT01443884|Dietary Supplement|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
79532898|NCT01443884|Dietary Supplement|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
79532899|NCT01443897|Dietary Supplement|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
79688790|NCT00544635|Device|no intervention|no intervention
79832820|NCT05300932|Drug|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
79832821|NCT05300932|Drug|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
79832822|NCT02545491|Behavioral|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
79832823|NCT02545491|Behavioral|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
79832824|NCT00942214|Drug|Natalizumab|300mg, IV, every 4 weeks
79832825|NCT00850161|Drug|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
79832826|NCT00850161|Drug|Nasulin™|100 IU(2 puffs in each nostril)
80006010|NCT01356875|Drug|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
80006011|NCT03594708|Dietary Supplement|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
79532900|NCT01443897|Dietary Supplement|placebo capsule|0 IU vitamin D2
80006012|NCT03594708|Dietary Supplement|Placebo supplement|rice starch, light olive oil, vegetable oil
79378712|NCT01687036|Device|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
79378713|NCT02325856|Device|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
79532901|NCT01443897|Other|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
79688791|NCT00544635|Device|light|scars will be treated with light
79688792|NCT00558233|Behavioral|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
79688793|NCT00558233|Behavioral|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
79532902|NCT01443897|Other|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
79832827|NCT00951574|Drug|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
79532903|NCT01443897|Other|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
79532904|NCT01443936|Biological|Ad4-H5-VTN vaccination-tonsillar route|
79532905|NCT01443936|Biological|Ad4-H5-vaccination-oral route|
79688794|NCT02908425|Other|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
79832828|NCT00951574|Drug|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
79832829|NCT00686790|Biological|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
79832830|NCT00850239|Drug|dutogliptin|400 mg
79688795|NCT02908191|Drug|ABI-H0731|
79832831|NCT00850239|Drug|placebo|
79832832|NCT00946426|Other|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
79832833|NCT00942292|Dietary Supplement|Lipidem- fish oil emulsion BBraun UK|
80006013|NCT05578196|Drug|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
80006014|NCT05578196|Drug|physiological saline solution|physiological saline solution 20ml
79238225|NCT05269875|Other|ACP|The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
79378714|NCT02325856|Behavioral|Clinical judgement|
79532906|NCT01443962|Other|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
79532907|NCT01443962|Other|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
79532908|NCT01443975|Procedure|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
79532909|NCT01443988|Device|iStent|Implantation of two iStent devices
79378715|NCT02495766|Drug|XCEL-MC-ALPHA|Single infusion
79532910|NCT01443988|Drug|Travoprost|Travoprost drops
79532911|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
79688796|NCT02908191|Drug|Placebo for ABI-H0731|
80006015|NCT05200273|Drug|AK114|AK114 administered by subcutaneous injection
80006016|NCT01363973|Device|VITALSTIM transcutaneous electrical stimulation|
79238226|NCT05263401|Dietary Supplement|3-hydroxybutyrate|Orally administered pre-meal drinks.
79378716|NCT02495766|Drug|Placebo|Single infusion
79378717|NCT01687114|Other|cranberry juice|27% cranberry juice
79378718|NCT03342768|Other|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
79688797|NCT02908191|Drug|Entecavir|Used to treat adults with chronic hepatitis B virus
79688798|NCT02908191|Drug|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
79688799|NCT02908191|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
79688800|NCT02908191|Drug|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
79378719|NCT05709730|Diagnostic Test|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
79532912|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
79532913|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
79532914|NCT01444014|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
79532915|NCT01444053|Device|No Intervention|No Intervention
79532916|NCT01444066|Procedure|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
79688801|NCT04648007|Diagnostic Test|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
79688802|NCT00544752|Other|16|indoor temperature of 16 degrees celcius
79688803|NCT00544752|Other|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
79688804|NCT00544752|Other|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
79832834|NCT00942292|Procedure|Digital Contrast MRI scan|
79832835|NCT02563392|Procedure|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
79832836|NCT02563392|Procedure|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
79832837|NCT00856089|Drug|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
79832838|NCT00942370|Device|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~EMG and MMG Signals of rectus abdominis of the abdomen,~Respiratory flow,~An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
80006017|NCT02135822|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
79688805|NCT00544791|Drug|melatonin|5 mg, oral, daily dose for 6 months
79688806|NCT00544791|Drug|placebo like melatonin tablets|
79688807|NCT04647812|Behavioral|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
79378720|NCT04495920|Drug|CGB-S-100|Alcohol and choline geranate
79378721|NCT01687972|Combination Product|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
79832839|NCT04041999|Behavioral|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
79832840|NCT00686712|Drug|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings <120 mg/dL)
79832841|NCT00686712|Drug|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings <120 mg/dL)
79832842|NCT00686712|Drug|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses <120 mg/dL)
79832843|NCT00852735|Dietary Supplement|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
79832844|NCT02545257|Other|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
79832845|NCT00852813|Dietary Supplement|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
79832846|NCT00748644|Drug|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
79832847|NCT00748644|Drug|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
79832848|NCT04042779|Other|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
79832849|NCT04042779|Other|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
79832850|NCT04042779|Other|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
79832851|NCT04042779|Other|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
79832852|NCT00748722|Device|CT Angiography|Injection of contrast material (iodine)
79238227|NCT05251571|Other|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
79238228|NCT05251571|Other|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
79832853|NCT00745836|Drug|statin|
79832854|NCT00853203|Behavioral|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
79832855|NCT00853203|Behavioral|Questionnaires|Written survey taking about 1 hour.
79378722|NCT01687972|Combination Product|Absorbable sutures|placement of absorbable sutures at cesarean section
79832856|NCT00853203|Other|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
79832857|NCT00853203|Behavioral|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
79378723|NCT03342612|Procedure|Brain Magnetic Resonance Imaging (MRI)|
79378724|NCT01688596|Drug|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
79832858|NCT00853203|Behavioral|Written Materials|Written educational materials plus community resource information.
79832859|NCT00748800|Behavioral|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
79238229|NCT05248295|Behavioral|Unison speech (vs. solo)|Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
79238230|NCT05238532|Genetic|CT303|"Once a time, intravenous injection~CT303 Starting Dose : 1.0*10^6 cells/kg~CT303 Increasing Quantity Dose : 2.0*10^6 cells/kg"
79378725|NCT02495532|Other|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
79688808|NCT04647812|Behavioral|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
79688809|NCT04647773|Drug|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
79688810|NCT04647773|Drug|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
79832860|NCT00748800|Behavioral|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
80006018|NCT02135822|Drug|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
80006019|NCT05534893|Dietary Supplement|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
80006020|NCT05534893|Dietary Supplement|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
80006021|NCT02238210|Drug|Atrovent®|
80006022|NCT05739955|Other|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
80006023|NCT05739955|Other|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
80006024|NCT05739955|Other|Routine Disinfection|Routine disinfection at the study hospital
80006025|NCT02978456|Device|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus ~10% of distal reference vessel diameter).
80006026|NCT02978456|Device|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
80006027|NCT03598686|Diagnostic Test|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
79532917|NCT01444118|Biological|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
79832861|NCT00856167|Drug|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
79832862|NCT00856167|Behavioral|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
79832863|NCT00686634|Drug|Sitagliptin|Sitagliptin 100 mg by mouth once daily
79832864|NCT00856401|Drug|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
79832865|NCT00560404|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
79832866|NCT00560404|Drug|Epoetin alfa|As prescribed
79832867|NCT00751920|Procedure|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
80006028|NCT05736913|Biological|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
80006029|NCT05736913|Biological|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
80006030|NCT03598452|Drug|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
80006031|NCT03549182|Drug|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
80006032|NCT03549182|Drug|placebo treatment|oral administration of placebo (102.3g)
80016738|NCT05207969|Procedure|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
79532918|NCT01444131|Drug|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
79532919|NCT01444131|Drug|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
79532920|NCT01444144|Other|Fracture union|Retrospective records review post-operatively until fracture resolved.
79688811|NCT04647773|Drug|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
79688812|NCT04647773|Drug|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
79688813|NCT04647773|Drug|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
79832868|NCT00850551|Other|Early Intervention|Twice a week home spirometry and symptom assessment
79832869|NCT00850629|Behavioral|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
79832870|NCT00850629|Behavioral|placebo|no intervention, only follow up
79688814|NCT04647773|Drug|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
79688815|NCT01237678|Drug|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
79688816|NCT01237678|Drug|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
79688817|NCT04647461|Drug|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
79688818|NCT04647461|Drug|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
79688819|NCT04684992|Device|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
79832871|NCT00951730|Other|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
79832872|NCT02546037|Device|FX100 dialyzer|comparison of dialyzers
79832873|NCT02546037|Device|SOLACEA 21H|comparison of dialyzers
79832874|NCT00942526|Drug|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
79832875|NCT00942526|Other|Water|perioperative gargling with water
79832876|NCT00853281|Other|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
80006033|NCT05736055|Diagnostic Test|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
79238231|NCT05223556|Device|Full Self-Diagnostic device in a remote diagnostic imaging site|Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
79238232|NCT05223556|Device|Human imager operated diagnostic device in the hospital|Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
79238233|NCT05215548|Procedure|therapeutic thoracic surgery|The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.
79238234|NCT05215548|Drug|Afatinib|The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
79832877|NCT00853281|Other|Standard vector control measures|Insectice-treated net
79238235|NCT05209555|Diagnostic Test|MoCA|MoCA test to identify Mild Cognitive Impairment
79238236|NCT05209555|Device|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
79832878|NCT04042389|Behavioral|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
79832879|NCT04042389|Behavioral|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
79532921|NCT01444157|Other|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
79378726|NCT02495532|Other|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
79832880|NCT04042389|Behavioral|Control|No messages sent.
79832881|NCT03967444|Device|Hyaluronic acid|Injectable gel for lip augmentation
79832882|NCT03967444|Device|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
79832883|NCT00850785|Biological|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
80006034|NCT03598296|Other|Large size tube|Patients in Group A are inserted the large size tube (28F).
79832884|NCT05300854|Procedure|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
80006035|NCT03598296|Other|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
80016739|NCT03055195|Drug|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
79378727|NCT02498184|Other|acupuncture|
79378728|NCT04869592|Biological|low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
79532922|NCT01444170|Dietary Supplement|dicreatinol sulfate|nutritional supplement
79832885|NCT05300854|Procedure|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
79832886|NCT00946504|Drug|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
79832887|NCT00946504|Drug|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
79832888|NCT00619983|Drug|donepezil|Group 1: Will receive donepezil 5mg once a day
79832889|NCT00619983|Drug|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
79832890|NCT00619983|Drug|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
79832891|NCT00619983|Drug|placebo|Group 4: Will receive placebo pills
79832892|NCT00619983|Drug|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
79832893|NCT00946582|Behavioral|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
79832894|NCT00942682|Drug|Sorafenib|Taken orally twice daily
79832895|NCT00942682|Drug|RAD001|Taken orally once daily in the morning
79832896|NCT00853515|Other|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
79832897|NCT00576420|Biological|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
79832898|NCT00576420|Biological|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
79832899|NCT00576420|Procedure|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
79832900|NCT00951964|Drug|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
79832901|NCT00951964|Drug|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
79832902|NCT00942760|Device|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
79832903|NCT00853983|Drug|[14C] AZD0530|Solution, Oral, once
80006036|NCT05501834|Other|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
80006037|NCT03549026|Drug|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
79238237|NCT05209555|Diagnostic Test|DeltaScan|EEG to detect acute encephalopathy
79238238|NCT05209555|Diagnostic Test|Salivette|To collect saliva for cortisol analysis
79378729|NCT04869592|Biological|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
79378730|NCT04869592|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
79688820|NCT01229371|Biological|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
79688821|NCT01229371|Biological|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
79688822|NCT02908230|Behavioral|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
79688823|NCT02908230|Behavioral|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
79688824|NCT02908230|Behavioral|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
79688825|NCT02908152|Dietary Supplement|curcumin|"1500 mg~1 capsule / day for 12 weeks"
79688826|NCT02908152|Dietary Supplement|placebo|"1500 mg~1 capsule / day for 12 weeks"
80016740|NCT03055195|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
79238239|NCT05209555|Diagnostic Test|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
79238240|NCT05202145|Drug|ALXN2050|Oral tablet.
79378731|NCT05709652|Diagnostic Test|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
79238241|NCT05202145|Drug|Cyclosporine|Oral capsule.
79378732|NCT05709652|Diagnostic Test|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
79378733|NCT02498028|Procedure|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
79238242|NCT05202145|Drug|Tacrolimus|Oral capsule.
79238243|NCT05202145|Drug|MMF|Oral tablet.
79378734|NCT02498028|Procedure|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
79532923|NCT01444170|Drug|placebo sugar pill|
79532924|NCT01444183|Behavioral|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
79532925|NCT01444183|Behavioral|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
79532926|NCT01444196|Drug|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
79688827|NCT01237327|Drug|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
79832904|NCT02545179|Other|web-based daily care training|12 week interactive web based caring training education
79832905|NCT00749034|Biological|VPM1002|live vaccine
79832906|NCT00749034|Biological|BCG|commercially available live vaccine BCG
79832907|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
79832908|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
79832909|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
79832910|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
79832911|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
79832912|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
79832913|NCT04059510|Procedure|rectovaginal swab|Self taken rectal and vaginal swab
79238244|NCT05172102|Other|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
79832914|NCT04059510|Procedure|pregnancy test|Urine pregnancy test
79688828|NCT01237327|Drug|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
79238245|NCT05168722|Other|No interventions|No interventions
79238246|NCT05156073|Other|Educational Materials|"Patient care partner cohort:~a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~Primary care physician cohort:~education on deprescribing through a 15-45-minute presentation~one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations."
79238247|NCT05147922|Behavioral|Booster Training with the Neonatal Resuscitation Quality Improvement Cart|The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
79532927|NCT01444235|Drug|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
79688829|NCT02907021|Drug|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
80006038|NCT03549026|Drug|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
80006039|NCT03101371|Drug|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
80006040|NCT03101371|Procedure|Standard of care catheter insertion|Catheter inserted right out of package.
79378735|NCT04495842|Other|Essential Oil Blend|5 drops of on a tester strip
79378736|NCT04495842|Other|Control Blend|5 drops on a tester strip
79378737|NCT03336996|Biological|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
79378738|NCT03336996|Procedure|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
79532928|NCT01444235|Drug|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
79532929|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg once daily
79532930|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg bid
79532931|NCT01444261|Dietary Supplement|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
79532932|NCT01444261|Other|control|No dietary supplements
79532933|NCT01444274|Device|Obalon Gastric Balloon(s)|One or two balloons administered per patient
79688830|NCT01237054|Drug|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
79688831|NCT01237054|Other|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
79832915|NCT04059510|Procedure|Menstrual cup|Menstrual cup vaginal fluid collection
79832916|NCT04059510|Procedure|Blood test|Venous blood sample
79832917|NCT04059510|Other|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
79832918|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79832919|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79832920|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79832921|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79832922|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79832923|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79832924|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
79532934|NCT01444313|Device|narafilcon A contact lens|Soft contact lenses with UV protection
79832925|NCT00755742|Other|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
79832926|NCT00857025|Biological|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
79832927|NCT00857025|Other|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
79532935|NCT01444313|Device|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
79832928|NCT00857025|Other|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
79238248|NCT05147831|Other|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
79532936|NCT01444326|Other|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
79532937|NCT01444339|Biological|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
79832929|NCT00857025|Other|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
79238249|NCT05146284|Drug|PXL770|Tablet
79238250|NCT05144815|Other|Exercise protocol + IPC|"Exercise protocol: endurance training protocol consisting of walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion."
79378739|NCT02495298|Procedure|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
79832930|NCT00750048|Drug|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
79532938|NCT01444339|Biological|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
79532939|NCT01444339|Biological|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
79688832|NCT01237054|Drug|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
79688833|NCT02906982|Other|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
79688834|NCT02906982|Other|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
80006041|NCT03588078|Drug|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
80006042|NCT03588078|Drug|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
80006043|NCT02238366|Drug|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
79688835|NCT04319536|Other|no intervention|self-sampling
79378740|NCT02495298|Procedure|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
79378741|NCT01690000|Drug|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
79378742|NCT02495220|Drug|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
79378743|NCT02495220|Drug|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
79532940|NCT01444339|Biological|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
79532941|NCT01444339|Biological|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
79532942|NCT01444339|Biological|Placebo|0.5 mL, intramuscular
79532943|NCT01444352|Biological|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
79532944|NCT01444352|Biological|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
79532945|NCT01444352|Biological|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
79532946|NCT01444352|Biological|Placebo|0.5 mL, Intramuscular
79532947|NCT01444404|Drug|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
79532948|NCT01444443|Device|Closed-loop control|Blood glucose controlled by algorithm
79532949|NCT01444443|Other|Open-loop control|Blood glucose controlled by patient
79532950|NCT01444482|Biological|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
79832931|NCT00942838|Drug|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
79832932|NCT00942838|Radiation|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
79238251|NCT05144815|Other|Exercise protocol + Sham IPC|Patients in this group (n=20) will undergo the same training as the previous group and with the same frequency and duration (i.e. 3 times a week, for 6 weeks), but the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.
79832933|NCT04041765|Drug|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
79832934|NCT00752076|Other|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
79832935|NCT02546271|Behavioral|GPS|
79832936|NCT04057014|Drug|Amoxicillin|Antibiotic given at different dosages and durations.
79832937|NCT04057014|Procedure|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
79832938|NCT00946738|Other|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
79832939|NCT00946738|Other|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
79832940|NCT00857103|Behavioral|CHOICE|Use of Choice support system as preparation for patient consultations
79832941|NCT00364351|Drug|Vandetanib|once daily oral tablet
79238252|NCT05142904|Device|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
79238253|NCT05142904|Drug|Radioactive iodine|I-131 according to standardized doses-calculation.
79532951|NCT01444482|Biological|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
79832942|NCT00364351|Drug|Erlotinib|oral dose
79832943|NCT00854139|Drug|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
79832944|NCT00854139|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
79832945|NCT00854139|Radiation|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
79532952|NCT01444508|Drug|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
79688836|NCT04647695|Drug|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
80006044|NCT05494190|Drug|Docetaxel|60 mg/m2 i.v. day 1
80006045|NCT05494190|Drug|Cisplatin|60 mg/m2 i.v. day 1-3
80006046|NCT05494190|Drug|Capecitabine|750 mg/m2 po bid day 1-14
80016741|NCT02282540|Procedure|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
79238254|NCT05142904|Drug|Radioactive iodine|I-131 according to local standard.
79238255|NCT05136248|Procedure|intraarticular injection|Ultrasound-guided intraarticular injection
79238256|NCT05136248|Procedure|peng block|Ultrasound-guided PENG block
79238257|NCT05134038|Diagnostic Test|anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications
79532953|NCT01444508|Drug|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
79532954|NCT01444521|Drug|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
79688837|NCT04647695|Drug|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
79688838|NCT02908113|Behavioral|collection data|
79688839|NCT02908113|Behavioral|IRM|
79688840|NCT04647305|Other|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
79688841|NCT04647305|Other|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
79688842|NCT04647344|Drug|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
79832946|NCT00854139|Procedure|Bone marrow transplant from a related donor|• Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated
79832947|NCT00755820|Behavioral|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
79832948|NCT00755820|Behavioral|Exposure Therapy + Placebo|Exposure therapy with placebo medication
79832949|NCT00755820|Behavioral|Supportive Psychotherapy|Supportive psychotherapy
79532955|NCT01444534|Device|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
79688843|NCT04647344|Drug|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
79832950|NCT00952042|Other|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
79832951|NCT00952042|Other|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
79832952|NCT00854217|Procedure|acute normovolemic hemodilution|
79832953|NCT00943228|Drug|mycophenolate mofetil|High dose 4gms daily
79832954|NCT00850941|Behavioral|Questionnaire|Information collection.
79832955|NCT00952198|Drug|ARRY-403, glucokinase activator; oral|multiple dose, escalating
79238258|NCT05115864|Device|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
79688844|NCT02906748|Procedure|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
79832956|NCT00952198|Drug|Placebo; oral|matching placebo
79832957|NCT00750126|Drug|Fludarabine, Busulfan, Thymoglobulin|"study :~acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~the effectiveness of the protocol on tumor response~overall survival"
79832958|NCT00851019|Behavioral|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
79832959|NCT00851019|Behavioral|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
79832960|NCT00946816|Behavioral|Nutritional Intervention|Nutritional Intervention
79532956|NCT01444534|Device|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
79532957|NCT01444547|Drug|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
79832961|NCT00755976|Drug|epirubicin hydrochloride|
79688845|NCT02906748|Procedure|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
79832962|NCT00755976|Drug|sulindac|
79832963|NCT00755976|Other|immunologic technique|
79832964|NCT04012060|Procedure|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
79688846|NCT04647149|Behavioral|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
79688847|NCT02906865|Other|Proximal hamstring tendons repair|Proximal hamstring tendons repair
79688848|NCT04647266|Procedure|endoscopic submucosal dissection|endoscopic submucosal dissection
79832965|NCT04012060|Procedure|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
79832966|NCT00752310|Drug|Darunavir|
79832967|NCT00943462|Radiation|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
79832968|NCT00943462|Drug|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
79832969|NCT02560974|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
79832970|NCT02560974|Drug|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m^2 on Day 1 of each 3-week cycle for 8 cycles.
79832971|NCT00946894|Procedure|Total thyroidectomy|Total thyroidectomy
79832972|NCT00946894|Procedure|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
79832973|NCT00946894|Procedure|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
79832974|NCT00854451|Drug|omeprazole plus amoxicillin|
79832975|NCT00854451|Drug|omeprazole plus amoxicillin|
79832976|NCT00854451|Drug|omeprazole plus amoxicillin|
79832977|NCT00854451|Drug|omeprazole plus amoxicillin|
79832978|NCT00946972|Drug|JNJ-38431055; Placebo|
79532958|NCT01444573|Device|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
79532959|NCT01444586|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
79832979|NCT00854529|Drug|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
79832980|NCT00947050|Other|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
79832981|NCT00861237|Drug|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
79832982|NCT00861237|Drug|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
79832983|NCT02544867|Behavioral|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
79832984|NCT00952432|Drug|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
79832985|NCT00952432|Procedure|Acupuncture|Acupuncture
79238259|NCT05114564|Device|Lens A (comfilcon A lens)|1 month
79238260|NCT05114564|Device|Lens B (lehfilcon A lens)|1 month
79378744|NCT01690546|Drug|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
79378745|NCT01690546|Drug|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
79832986|NCT00861315|Drug|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
79832987|NCT00861315|Drug|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
79832988|NCT00861315|Drug|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
79832989|NCT00861315|Drug|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
79832990|NCT00388297|Drug|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
79832991|NCT00388297|Drug|Placebo for Levothyroxine|
79832992|NCT00943540|Drug|raltegravir QD|Raltegravir 800mg QD
79378746|NCT01690546|Drug|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
79532960|NCT01444612|Drug|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
79532961|NCT01444612|Drug|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
79532962|NCT01444612|Drug|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
79532963|NCT01444612|Drug|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
79532964|NCT01444625|Other|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
79532965|NCT01444625|Other|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
79532966|NCT01444638|Device|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
79832993|NCT00943540|Drug|atazanavir|atazanavir
79832994|NCT00943540|Drug|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
79832995|NCT00861393|Behavioral|CBT|12 Session CBT group
79832996|NCT00861393|Behavioral|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
79832997|NCT00943696|Dietary Supplement|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
79832998|NCT00854685|Drug|ART621|3.0mg/kg s.c. - weekly
79832999|NCT00854685|Drug|ART621|3.0mg/kg s.c. - fortnightly
79833000|NCT00854685|Drug|ART621|1.5mg/kg s.c. - weekly
79833001|NCT00854685|Drug|ART621|1.5mg/kg s.c. - fortnightly
79833002|NCT00854685|Drug|Placebo|Placebo s.c. - weekly
79833003|NCT00854685|Drug|Placebo|Placebo s.c. - fortnightly
79238261|NCT05105113|Procedure|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
79238262|NCT05081414|Behavioral|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
80006047|NCT05494190|Radiation|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65~70 Gy in total, 1.7~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50~60 Gy in total, 1.7~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
79378747|NCT02495376|Behavioral|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
80006048|NCT05494190|Procedure|Surgery|Neck dissection and primary tumor resection
80006049|NCT03582540|Procedure|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
80006050|NCT05360095|Behavioral|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
79532967|NCT01444664|Procedure|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
79238263|NCT05062369|Device|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
79302913|NCT02481791|Drug|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
79378748|NCT05709418|Behavioral|Intensiv support for first graders in Norway|Intervention targeting early numeracy skills that are known to be important for mathematical development, focusing on counting skills, counting strategies, number knowledge, word problem solving and basic understanding of addition and subtraction
79378749|NCT02498106|Dietary Supplement|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins [B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene] and minerals [Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid [EPA] and docosahexaenic acid [DHA])
79378750|NCT03120390|Other|Best Practice|Undergo usual care
80006051|NCT05360095|Behavioral|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
79378751|NCT03120390|Behavioral|Exercise Intervention|Undergo AE
80016742|NCT02921919|Drug|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
79302914|NCT02481791|Drug|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
79378752|NCT03120390|Behavioral|Exercise Intervention|Undergo RE
79378753|NCT03120390|Other|Laboratory Biomarker Analysis|Correlative studies
79378754|NCT03120390|Device|Monitoring Device|Receive Polar heart rate monitor
79378755|NCT03120390|Other|Quality-of-Life Assessment|Ancillary studies
79378756|NCT03120390|Other|Questionnaire Administration|Ancillary studies
79378757|NCT03276286|Device|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
79378758|NCT03336918|Drug|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
79378759|NCT02494830|Drug|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
79378760|NCT03215836|Procedure|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
79532968|NCT01444677|Drug|MB12066|MB12066 300mg
79532969|NCT01444677|Drug|MB12066|MB12066 400mg
79532970|NCT01444677|Drug|MB12066|MB12066 100mg
79532971|NCT01444677|Drug|MB12066|MB12066 200mg
79532972|NCT01444677|Drug|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
79532973|NCT01444690|Drug|Dimiracetam|Capsules for oral administration twice daily
79532974|NCT01444690|Drug|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
79688849|NCT02907957|Device|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
79688850|NCT02907957|Procedure|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
79688851|NCT04646954|Diagnostic Test|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
79688852|NCT04646954|Diagnostic Test|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
80006052|NCT05360095|Behavioral|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
80006053|NCT03548480|Dietary Supplement|Placebo|Intervention with a daily dose of placebo
80006054|NCT03548480|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic
80006055|NCT03587766|Drug|Fexinidazole|Drug: fexinidazole (FEXI)
80006056|NCT03587766|Drug|Placebo Oral Tablet|Drug: fexinidazole
80006057|NCT03734185|Other|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
80006058|NCT03548402|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
80006059|NCT05485610|Dietary Supplement|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
80006060|NCT05485610|Other|Placebo|NMN-free placebo capsules for 3 months
80006061|NCT02850276|Drug|Pyridostigmine|
80006062|NCT05418517|Procedure|Tracheostomy|temporary tracheostomy insertion
80006063|NCT05418517|Procedure|Overnight intubation|Patient who had overnight intubation
79302915|NCT02447731|Device|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
79378761|NCT03341832|Drug|NVP-1203|oral dose for 7 days
79833004|NCT01864720|Behavioral|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
79378762|NCT03341832|Drug|NVP-1203-R|oral dose for 7 days
79378763|NCT03341832|Drug|NVP-1203 placebo|oral dose for 7 days
79378764|NCT03341832|Drug|NVP-1203-R placebo|oral dose for 7 days
80006064|NCT03592134|Other|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
80006065|NCT05577962|Drug|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
80006066|NCT05577884|Diagnostic Test|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
80006067|NCT03862170|Drug|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
80006068|NCT03862170|Drug|Cefazolin|
80006069|NCT02140580|Device|Minimally invasive surfactant therapy|Active Comparator
80006070|NCT02140580|Other|Continuation on CPAP|Sham Comparator
79378765|NCT05484180|Other|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
79532975|NCT01444703|Other|licorice solution|licorice (0.5 g)
80006071|NCT04955431|Behavioral|Sleep Restriction|Participants will be allowed ~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
80006072|NCT04955431|Behavioral|Normal Sleep|Participants will be allowed ~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
80006073|NCT05577806|Drug|Dydrogesterone|progestin primed ovarian stimulation
79532976|NCT01444703|Other|sugar solution|sugar (5 g).
79532977|NCT01444729|Drug|Xiapex|Xiapex administration will follow SMPC
79532978|NCT01444729|Procedure|surgery|Non-pharmacological treatment
79532979|NCT01444768|Other|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
80006074|NCT03591432|Device|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
79302916|NCT03314285|Other|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
79302917|NCT04484467|Dietary Supplement|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
79532980|NCT01444807|Drug|sorafenib|sorafenib 400 mg bid
79833005|NCT01864720|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
80006075|NCT03591432|Device|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
79833006|NCT00857571|Drug|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
80006076|NCT03547388|Device|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
80006077|NCT03591276|Drug|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
79238264|NCT05062369|Behavioral|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
79238265|NCT05057377|Diagnostic Test|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
79378766|NCT02239744|Behavioral|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
79378767|NCT04351048|Procedure|Stepwise Excavation|"stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
79833007|NCT00857571|Drug|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
79833008|NCT00857571|Drug|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
79833009|NCT00857571|Drug|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
79833010|NCT00857571|Drug|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
79378768|NCT04351048|Procedure|One Step Excavation|*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
79378769|NCT03336840|Drug|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
79378770|NCT03336840|Drug|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
79378771|NCT03336840|Drug|1. Metformin tablets; 2. ProMetS probiotics powder|"0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
79378772|NCT03336762|Diagnostic Test|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
79378773|NCT03336762|Diagnostic Test|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
79378774|NCT03336684|Behavioral|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
79378775|NCT03049072|Radiation|Protons and Carbon Ions|
79833011|NCT00857571|Drug|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
79833012|NCT00857571|Drug|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
79833013|NCT00857571|Drug|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
79833014|NCT00857571|Drug|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
79833015|NCT00857571|Drug|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
80006078|NCT03582384|Drug|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
80006079|NCT03783468|Other|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
79238266|NCT05057377|Diagnostic Test|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
79833016|NCT00943774|Other|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
79833017|NCT00861627|Biological|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
79238267|NCT05048758|Other|No intervention|No intervention
79833018|NCT00861627|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
79238268|NCT05042648|Drug|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
79688853|NCT04647188|Other|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
79833019|NCT00861627|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
79238269|NCT05038865|Other|Malocclusion and Orthodontic Treatment|"Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment."
79688854|NCT04646876|Drug|Magnesium Sulfate|Prospective , comparative , double blind study
79238270|NCT05036395|Other|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
79238271|NCT05036395|Other|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
79238272|NCT05036317|Drug|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
79378776|NCT02497872|Procedure|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
79378777|NCT02497638|Drug|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
79378778|NCT02497638|Drug|Atorvastatin|Atorvastatin 20 mg once daily until progression.
79688855|NCT04646876|Drug|Placebo|Prospective , comparative , double blind study
79688856|NCT04646915|Other|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
79833020|NCT00943930|Drug|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
79833021|NCT00854763|Drug|olmesartan|olmesartan
79833022|NCT00952666|Device|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
79833023|NCT00854841|Drug|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
79238273|NCT05036317|Other|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
79238274|NCT05034874|Drug|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
79378779|NCT02497638|Drug|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
79378780|NCT02497638|Drug|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
79378781|NCT02495064|Drug|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
79688857|NCT02906904|Other|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
79688858|NCT02906904|Other|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
79238275|NCT05034874|Other|Placebo|Saline
79532981|NCT01444820|Radiation|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
79688859|NCT02908035|Drug|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
79238276|NCT05026476|Dietary Supplement|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
79238277|NCT04990388|Biological|UX053|mRNA-based biologic
79833024|NCT00944008|Drug|DepoCyte|
79833025|NCT00854919|Drug|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
79833026|NCT00854919|Behavioral|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
79238278|NCT04990388|Other|Placebo|consists of the same components as the formulation buffer for UX053
79238279|NCT04990388|Drug|Antipyretic|participants will receive oral premedication prior to infusion
79238280|NCT04990388|Drug|H2 Blocker|participants will receive oral premedication prior to infusion
79238281|NCT04990388|Drug|H1 Blocker|participants will receive oral premedication prior to infusion
79378782|NCT02494908|Behavioral|Playing a computer game simulating a car race|Playing a computer game simulating a car race
79378783|NCT02494752|Procedure|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
79378784|NCT02494752|Procedure|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
79378785|NCT02494674|Behavioral|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
79378786|NCT02493192|Drug|pethidine and haloperidol injection|
79688860|NCT02908035|Drug|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
79688861|NCT04646759|Drug|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
79688862|NCT04646759|Drug|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
79833027|NCT00861783|Drug|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
79833028|NCT00861783|Drug|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
79688863|NCT02906826|Device|Video game|Video game operated by performing therapy correctly
79688864|NCT04646798|Other|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
79238282|NCT04964206|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
79238283|NCT04964206|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
79238284|NCT04958200|Behavioral|mhealth-pc for alcohol and pain|Smartphone-based intervention that includes in-person initial session and 8 video lessons, daily activities, and weekly check-ins.
79238285|NCT04958200|Behavioral|Treatment As Usual|psychoeducation on pain and alcohol use and treatment resource information
79238286|NCT04909541|Other|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
79302918|NCT04484467|Other|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
79302919|NCT03209167|Behavioral|Questionnaire|Two study-specific questionnaires
79378787|NCT02493192|Other|birth ball|
79532982|NCT01444820|Radiation|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."
79532983|NCT01444833|Drug|Candesartan|32 mg per day duration 6 months
79532984|NCT01444846|Drug|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
79302920|NCT02478203|Device|Airtraq|videolaryngoscope for difficult airway
79532985|NCT01444846|Drug|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
79532986|NCT01444846|Drug|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
79532987|NCT01444846|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
79688865|NCT04646798|Other|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
79688866|NCT02907801|Behavioral|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
79833029|NCT00947128|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
79833030|NCT00947128|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
79833031|NCT00947206|Behavioral|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
79833032|NCT00947206|Behavioral|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
80006080|NCT03854526|Other|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
79833033|NCT00857805|Procedure|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
79378788|NCT02749084|Biological|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
79378789|NCT03341754|Biological|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
79833034|NCT00857805|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
79833035|NCT00947362|Other|Electro-thermo-coagulation|
79833036|NCT00947362|Drug|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
79833037|NCT00947362|Drug|saline|physiological saline
79833038|NCT00861861|Drug|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
79833039|NCT00861861|Drug|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
80006081|NCT04928287|Biological|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
79833040|NCT01529866|Device|New Abutment Connection implant|New abutment connection implant
79378790|NCT03341754|Biological|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
79378791|NCT03341754|Other|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
79833041|NCT01529866|Device|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
79833042|NCT00857883|Drug|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
80006082|NCT04928287|Other|Placebo|Placebo will be administered intravenously to study participants who qualify.
80006083|NCT03590964|Procedure|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
80006084|NCT03590964|Procedure|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
80006085|NCT03548948|Other|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
80006086|NCT03548948|Other|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
79302921|NCT02478203|Device|Glidescope|videolaryngoscope for difficult airway
79302922|NCT02478203|Device|direct laryngoscopy|gold standart for intubation
79302923|NCT03198247|Other|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
79302924|NCT03198247|Other|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
79833043|NCT00952900|Behavioral|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
79833044|NCT00952900|Behavioral|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
79833045|NCT02545413|Drug|Probiotic VSL#3|
79302925|NCT03198169|Device|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
79302926|NCT03198169|Device|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
79302927|NCT03195361|Device|SRS - Self Retaining Support system|
79833046|NCT02545413|Drug|Placebo|
79833047|NCT00944086|Other|Recruitment Manoeuvre|Recruitment Manoeuvre
79833048|NCT00855075|Device|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
79833049|NCT00944164|Behavioral|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
79833050|NCT00944164|Behavioral|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
79238287|NCT04908241|Other|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
80006087|NCT03548948|Other|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
79238288|NCT04908241|Other|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
79238289|NCT04906135|Other|Experimental manipulation of stimulation parameters|This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
79238290|NCT04896866|Behavioral|Antimicrobial stewardship prospective audit and feedback|Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
79238291|NCT04882592|Device|SCiP|Noninvasive spinal cord neuromodulator
79238292|NCT04837131|Drug|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
79238293|NCT04821570|Biological|COVID-19 Vaccine|Per recommended dosing schedule
79238294|NCT04807400|Drug|Inclisiran|Inclisiran 300 mg 3 monthly (Day 1 and Day 90)
79238295|NCT04807400|Behavioral|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period.
79238296|NCT04788433|Diagnostic Test|glycomic analysis|Analysis of glycans on plasma samples
79532988|NCT01444859|Dietary Supplement|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
79688867|NCT04646525|Diagnostic Test|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
80006088|NCT04926337|Device|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
80006089|NCT04926337|Device|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
80006090|NCT02238444|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
79378792|NCT05705752|Other|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
79378793|NCT05705752|Other|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
79378794|NCT03341598|Procedure|CAF|Periodontal surgical technique to treat gingival recessions.
79378795|NCT03341598|Procedure|R|Restorative procedure to treat tooth structure loss.
79378796|NCT03341598|Procedure|MC|Xenogenous graft placed in the surgical site.
79378797|NCT02497716|Drug|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
79378798|NCT02238808|Drug|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
79532989|NCT01444859|Dietary Supplement|Placebo|Daily placebo for 10 weeks
79532990|NCT01444872|Drug|TRV120027|IV infusion
79532991|NCT01444872|Drug|Normal Saline|IV infusion
79532992|NCT01444885|Drug|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
79532993|NCT01444976|Drug|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
79532994|NCT01444976|Behavioral|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
79532995|NCT01444976|Drug|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
80006091|NCT02238444|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
80006092|NCT02238444|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
80006093|NCT02238444|Drug|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
79833051|NCT00686166|Biological|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m^2, IV, Day 1; Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78"
79833052|NCT00686166|Drug|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)"
79833053|NCT00686166|Drug|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78"
79833054|NCT00686166|Procedure|therapeutic surgical procedure|Surgical resection
79833055|NCT00686166|Radiation|radiation therapy|IMRT (intensity-modulated radiation therapy)
79833056|NCT04280536|Drug|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
79532996|NCT01444989|Other|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
79532997|NCT01444989|Other|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
79532998|NCT01445002|Biological|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
79688868|NCT02906514|Drug|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
79688869|NCT02906514|Drug|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
79688870|NCT02906475|Other|standardized skin care regimen|"Application of a standardized daily skin care regimen:~milk lotion once daily and~application of addendum for bathing as needed"
79688871|NCT02907723|Device|Sleep Recording|the device records movements during patients' sleep
79688872|NCT02907567|Drug|CT1812|Active study drug
79688873|NCT02907567|Drug|Placebo|non-active study drug
79688874|NCT04646018|Other|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
79688875|NCT04646018|Other|Sham Manipulation|Lumbar non-thrust manipulation without force applied
79688876|NCT02906436|Device|Xvivo Chamber|
79688877|NCT04646135|Drug|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
79833057|NCT04280536|Drug|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
79833058|NCT00944242|Drug|Sertraline|
79833059|NCT00944242|Drug|Sertraline Hydrochloride|
79833060|NCT00363649|Biological|GM-K562 cell vaccine|Given by injection
79238297|NCT04788433|Other|Phone interview|patients are followed up by phone up to 1 year
79302928|NCT02726399|Drug|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
79302929|NCT02726399|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
79532999|NCT01445002|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
79533000|NCT01445002|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
79533001|NCT01445002|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
79533002|NCT01445015|Behavioral|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
79533003|NCT01445015|Other|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
79688878|NCT02906553|Drug|Glyceryl Trinitrate|
79688879|NCT02906553|Drug|Placebo|
79688880|NCT06237777|Genetic|SKG0106 intravitreal injection dose level 1, 2 or 3|SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
79688881|NCT06237764|Other|No intervention|No intervention.
79688882|NCT06237751|Drug|Sildenafil 25 MG|Sildenafil 25mg orally half an hour before surgery
79833061|NCT00363649|Biological|Interferon alfa|Given by injection
79833062|NCT00363649|Biological|Sargramostim|Given by injection
79833063|NCT00855153|Other|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
79833064|NCT00855153|Drug|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
79833065|NCT00947440|Drug|ABT-072|See arm description for more information
79833066|NCT02545023|Other|Quality-of-Life Assessment|Complete an in-person one-on-one interview
79833067|NCT02545023|Other|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
79833068|NCT00952978|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
79833069|NCT00952978|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
79833070|NCT01046851|Drug|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
79833071|NCT01046851|Drug|Placebo|Placebo in a manner similar to the active comparator
79833072|NCT00861939|Drug|Bupropion HCI 300 mg Extended-Release Tablets EON|
79833073|NCT00861939|Drug|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
79833074|NCT01046929|Dietary Supplement|limonene|oral dosing at 2 gram QD
79833075|NCT00953134|Dietary Supplement|Ferrous fumarate (iron)|60 mg of ferrous fumarate
79833076|NCT00953134|Dietary Supplement|folic acid|400 mcg folic acid
79238300|NCT04755101|Procedure|EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
79833077|NCT02544945|Other|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
79238301|NCT04755101|Procedure|EPS, electro-anatomical mapping, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
79533004|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
79238302|NCT04751916|Dietary Supplement|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
79238303|NCT04751916|Dietary Supplement|Beneprotein®|Whey protein supplement
79238304|NCT04748146|Other|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
79238305|NCT04745715|Procedure|craniectomy|craniectomy outcomes and survival
79378799|NCT02497794|Other|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
79533005|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
79533006|NCT01445054|Drug|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
79833078|NCT02544945|Other|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
79533007|NCT01445106|Drug|Nelfinavir|
79833079|NCT00944398|Dietary Supplement|Zinc fortified food|Daily consumption
79833080|NCT00944398|Dietary Supplement|Zinc supplement|Liquid supplement containing zinc sulfate
79833081|NCT00944398|Other|Placebo supplement|Liquid placebo supplement
79833082|NCT00944398|Dietary Supplement|Non-fortified food|Non-fortified complementary food.
79533008|NCT01445106|Drug|Nelfinavir Mesylate|
79533009|NCT01445119|Drug|Enzastaurin (LY317615)|
79533010|NCT01445119|Drug|Carboplatin|
79533011|NCT01445132|Drug|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
79533012|NCT01445197|Biological|Biostate|200 IU/kg administered daily
79533013|NCT01445210|Procedure|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
79533014|NCT01445210|Procedure|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
79533015|NCT01445223|Drug|Lopinavir ritonavir|400mg BD 100mg BD
79533016|NCT01445223|Drug|Atazanavir ritonavir|300mg QD 100mg QD
79533017|NCT01445223|Drug|Efavirenz|600mg QD
79533018|NCT01445236|Other|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
79533019|NCT01445249|Procedure|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
79533020|NCT01445249|Procedure|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
79533021|NCT01445262|Drug|Levocetirizine|
79533022|NCT01445275|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
79833083|NCT00862017|Dietary Supplement|MSg supplementation|
79833084|NCT00862017|Dietary Supplement|NaCl supplementation|
80006094|NCT03638479|Other|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
79533023|NCT01445275|Other|Medical Chart Review|Ancillary study
79833085|NCT00944476|Procedure|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
79833086|NCT00953368|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
79833087|NCT00855387|Other|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
79833088|NCT00947596|Drug|atropine sulfate|dry powder for inhalation
79238306|NCT04729075|Other|ARDS and COVID19 treatments|Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
79833089|NCT00947596|Drug|atropine sulfate|intramuscular injection
79833090|NCT00865059|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
79833091|NCT00865059|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
79833092|NCT00956410|Biological|CAD106|
79833093|NCT00865137|Drug|Tacrolimus, modified release|Oral
79833094|NCT00947674|Device|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
79833095|NCT00862095|Drug|Placebo|Every month for 3 months
80006095|NCT02783768|Device|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
79688883|NCT06237738|Behavioral|Stress Ball Use|The intervention in this study involves the use of stress balls provided to participants in the intervention group. These are specially designed medium-firm silicone balls intended for squeezing with the hand opposite the one receiving cannulation during hemodialysis sessions. The primary objective of this intervention is to offer a simple, non-pharmacological method to potentially alleviate the pain associated with the cannulation process. Participants are instructed to use the stress ball for a period of three minutes before the start of cannulation. This activity is hypothesized to focus the participant's attention and possibly reduce the perception of pain, contributing to a more comfortable and less distressing cannulation experience.
79238307|NCT04724460|Drug|Long DOAC|Administration of Rivaroxaban for 18 months
79238308|NCT04724460|Drug|Short DOAC|Administration of Rivaroxaban for 6 months
79238309|NCT04723069|Drug|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
79238310|NCT04723069|Drug|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
79533024|NCT01445275|Other|Study of Socioeconomic and Demographic Variables|Ancillary studies
79833096|NCT00862095|Drug|Propranolol|target does 80 mg per day for 3 months
79378800|NCT01483612|Behavioral|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
79378801|NCT02497560|Dietary Supplement|proprietary formula|
79378802|NCT03336294|Radiation|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
79378803|NCT02497326|Drug|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
79533025|NCT01445340|Drug|Romidepsin (FR901228)|
79533026|NCT01445379|Drug|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
79533027|NCT01445392|Biological|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 &amp; 5 of a 21 day cycle for 2 cycles
79533028|NCT01445392|Drug|Pemetrexed|500 mg/m^2 on day 1 of each 21 day cycle until disease progression
79533029|NCT01445392|Drug|Cisplatin|75 mg/m^2 on day 1 of each 21 day cycle until disease progression
79533030|NCT01445392|Biological|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
79833097|NCT00862095|Drug|Amitriptyline|Target does of 50 mg per day for 3 months
79833098|NCT00862095|Drug|Topiramate|Target dose 100 mg a day for 3 months
79833099|NCT04054128|Drug|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
79833100|NCT04054128|Drug|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
79833101|NCT00956566|Behavioral|dietary intervention|dietary counseling, group teaching
79833102|NCT00865215|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
79833103|NCT00865215|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
79833104|NCT00684060|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
79833105|NCT00684060|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
79833106|NCT00865371|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
79833107|NCT00865371|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
79833108|NCT00865449|Drug|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
79833109|NCT00865449|Drug|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
79833110|NCT00865527|Other|Fecal occult blood test|FOBT
79833111|NCT00865527|Procedure|Virtual colonoscopy|computed tomographic colonography
79833112|NCT00865527|Procedure|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
79833113|NCT00756210|Other|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
79833114|NCT00858195|Drug|Indomethacin 75mg Extended-Release Capsules, Sandoz|
79833115|NCT00858195|Drug|Indocin 75mg SR Capsules|
79833116|NCT00858351|Behavioral|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
79833117|NCT00858351|Behavioral|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
79833118|NCT03131648|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
79833119|NCT03131648|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
79833120|NCT00618813|Other|radiation therapy|Undergo radiation therapy
79238311|NCT04706416|Dietary Supplement|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
79238312|NCT04706416|Other|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
79238313|NCT04701749|Device|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
79378804|NCT02497326|Drug|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
79378805|NCT02497326|Drug|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
79378806|NCT02497170|Behavioral|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
80006096|NCT02783768|Other|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
79533031|NCT01445405|Drug|Bortezomib (Velcade, PS-341)|
79533032|NCT01445405|Drug|Cetuximab|
79688884|NCT06237725|Other|Nutrition of Continuous|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
79688885|NCT06237725|Other|Nutrition of Bolus|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
79688886|NCT06237699|Other|Digital ICU diary|A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
79238314|NCT04701749|Other|No Percutaneous left atrial closure|No Percutaneous left atrial closure
79378807|NCT03341442|Procedure|No hip precautions|No hip precautions practiced after THA surgery
79533033|NCT01445405|Drug|Cisplatin|
79533034|NCT01445405|Procedure|Radiation Therapy|
79533035|NCT01445418|Drug|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
79533036|NCT01445431|Other|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
79533037|NCT01445431|Other|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
79688887|NCT06237686|Device|CP363|All subjects will test both Test product A and B, with a minimum of 7 days apart. In total, each subject will be enrolled in the investigation for 8 days +3 days.
79688888|NCT06237673|Diagnostic Test|CT|CT-directed clinical management strategy
79688889|NCT06237673|Diagnostic Test|invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
79833121|NCT00618813|Other|therapeutic conventional surgery|Undergo surgery
79833122|NCT00618813|Drug|etoposide|Given IV
79833123|NCT00618813|Drug|ifosfamide|Given IV
79833124|NCT00618813|Drug|doxorubicin hydrochloride|Given IV
79833125|NCT00618813|Drug|cyclophosphamide|Given IV
79833126|NCT00618813|Drug|vincristine sulfate|Given IV
79833127|NCT00618813|Drug|topotecan hydrochloride|Given IV
79833128|NCT00618813|Biological|filgrastim|Given SC
79833129|NCT00685698|Drug|TG-873870 (Nemonoxacin)|750 mg
79833130|NCT00858429|Drug|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
79833131|NCT00858429|Radiation|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
79833132|NCT00756366|Other|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
79833133|NCT00756366|Other|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
79833134|NCT00756366|Other|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
79833135|NCT02566928|Drug|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
79833136|NCT02566928|Other|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
79533038|NCT01445444|Behavioral|Habit Reversal Training|"8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~components:~Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~Session 2. implement habit reversal, including awareness training, competing response training, and social support.~Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
79833137|NCT02566928|Behavioral|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
79833138|NCT00756522|Other|There is no intervention. Study is observational.|There is no intervention. Study is observational.
79833139|NCT00865605|Drug|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
79833140|NCT00865605|Drug|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
79833141|NCT00756756|Drug|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
79833142|NCT00756756|Drug|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
79833143|NCT02565056|Other|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
79833144|NCT00865683|Dietary Supplement|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
79833145|NCT00865683|Dietary Supplement|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
79833146|NCT00953446|Procedure|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
79833147|NCT02560818|Other|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
79833148|NCT02560818|Other|use of a previous blood collection for patients|
79833149|NCT03058250|Other|Transesophageal echocardiography|
79833150|NCT00956644|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
79302930|NCT02726399|Drug|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
79533039|NCT01445522|Drug|ABT-888|
79533040|NCT01445522|Drug|Cyclophosphamide|
79688890|NCT06237660|Procedure|Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy|These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study
79688891|NCT06237660|Diagnostic Test|Skin prick test|To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months
79833151|NCT00956644|Drug|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
79833152|NCT00756834|Device|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
79833153|NCT03895268|Device|ALiA Analyser|NPS specimens shall be tested with the investigational device
79302931|NCT02726399|Drug|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
79533041|NCT01445561|Drug|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
79833154|NCT03895268|Device|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
79833155|NCT00858663|Radiation|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
80006097|NCT02783768|Drug|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
80006098|NCT02783768|Drug|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
80006099|NCT02238522|Drug|ZEN003365|
79688892|NCT06237660|Diagnostic Test|Finger prick blood test|Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
79688893|NCT06237660|Diagnostic Test|Forced oscillation technique (FOT)|Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
79688894|NCT06237660|Procedure|Sputum induction|Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
79833156|NCT00858663|Drug|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
79833157|NCT03894488|Diagnostic Test|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
79833158|NCT02544789|Drug|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
79688895|NCT06237660|Diagnostic Test|Oropharyngeal swab|Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
79833159|NCT00956722|Drug|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
79688896|NCT06237647|Dietary Supplement|Hyaluronic acid, HA|improve tissue repair
79833160|NCT00858741|Radiation|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
79833161|NCT00858741|Radiation|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
79833162|NCT04985864|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
79833163|NCT04985864|Device|Treadmill gait training|Lokomat robot training was applied to stroke patients.
79238315|NCT04692922|Diagnostic Test|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
79238316|NCT04692922|Diagnostic Test|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
79238317|NCT04684563|Biological|huCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
79238318|NCT04683926|Drug|Desmetramadol|Analgesic
79238319|NCT04681170|Drug|Lomitapide|2mg,5mg, 10mg and 20mg capsules
79238320|NCT04670133|Dietary Supplement|Inulin|Supplementation with a prebiotic, specifically inulin.
79238321|NCT04670133|Dietary Supplement|Maltodextrin|Supplementation with maltodextrin (placebo)
79833164|NCT00953602|Other|Genetically modified potato|Genetically modified potato
79833165|NCT00956800|Other|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
79833166|NCT00956800|Other|Normal care|Control group will receive 5 routine office visits in one year
79378808|NCT02245672|Drug|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
79238322|NCT04667793|Drug|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
79302932|NCT03198091|Drug|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
79378809|NCT02245672|Drug|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
79378810|NCT02245672|Drug|Placebo|Placebo administered via the CRC749 and Diskus devices
79378811|NCT03336138|Other|AMA (Assistance for ambulatory patients)|telephone follow-up modality
79378812|NCT03341286|Drug|TK3|Tryptophan and thiamine as on oral supplement
79833167|NCT02565836|Drug|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
79833168|NCT02565836|Drug|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
79833169|NCT00865761|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
79833170|NCT00865761|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under fasting conditions
79833171|NCT00953758|Drug|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
80006100|NCT03131687|Drug|tirzepatide|Administered SC
80006101|NCT03131687|Drug|Dulaglutide|Administered SC
80006102|NCT03131687|Drug|Placebo|Administered SC
79238323|NCT04653818|Drug|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
79238324|NCT04640857|Device|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
79238325|NCT04629807|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
79238326|NCT04629794|Procedure|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
79238327|NCT04629794|Procedure|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
79238328|NCT04626076|Other|Comparative Observational Cohort Study|This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
79238329|NCT04605302|Device|MCC/MCC-T|Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
79238330|NCT04605302|Device|Standard gastroscopy|Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
79238331|NCT04598841|Dietary Supplement|supplement nutritional supporting|Special medical formula for the purpose of formula food
79533042|NCT01445587|Drug|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
79533043|NCT01445587|Drug|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
79688897|NCT06237634|Other|splint and exercise and advices|A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
79688898|NCT06237634|Other|Triamsinolon Asetonid ozone|40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
79688899|NCT06237634|Other|ozone|In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
79688900|NCT06237621|Device|SnapshotNIR imaging|SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
79688901|NCT06237608|Behavioral|Dialectical behavioural therapy (DBT)-informed skills group|16 week 1.5hr DBT-informed skills group facilitated by the lead researcher and two charity facilitators
79688902|NCT06237595|Device|Vagus nerve stimulation|Electrical stimulation of the vagus nerve.
79688903|NCT06237595|Drug|Medical treatment|Medical treatment for fibromyalgia patients
79688904|NCT06237595|Combination Product|Combined vagus nerve stimulation and medical treatment|Combination of the two interventions
79688905|NCT06237582|Procedure|epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of ovarian carcinomatosis by this way
80006103|NCT03579888|Biological|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
80006104|NCT03579888|Drug|Cyclophosphamide|Given IV
80006105|NCT03579888|Drug|Fludarabine|Given IV
80006106|NCT05344027|Drug|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
80006107|NCT05435144|Dietary Supplement|Elderberry|European black elderberry extract
80006108|NCT05435144|Other|Placebo|Inactive placebo
80006109|NCT05343247|Diagnostic Test|Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
80006110|NCT05343247|Diagnostic Test|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
79833172|NCT00947908|Biological|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
79833173|NCT00865839|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
80006111|NCT05343247|Diagnostic Test|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
80006112|NCT03586986|Diagnostic Test|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
80006113|NCT05430698|Drug|PD-1antibody plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~Three weeks is a course of treatment,a total of 6-8 courses."
80006114|NCT03585972|Behavioral|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
79533044|NCT01445587|Drug|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
79688906|NCT06237569|Drug|Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia|"A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth."
79688907|NCT06237543|Other|hypotension|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
79833174|NCT00865839|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
79688908|NCT06237530|Behavioral|Visceral body scan (VBS)|The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord & Garfinkel, 2022)
79688909|NCT06237530|Behavioral|Somatosensory body scan (SBS)|The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).
80006115|NCT05577416|Procedure|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
80006116|NCT05577416|Drug|Part A: AB-218|Part A: AB-218 orally 250 mg BID for 28 days.
80006117|NCT05577416|Procedure|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of AB-218.
80006118|NCT05577416|Drug|Part B: AB-218|Part B: AB-218 orally 250 mg BID for 28 days for up to 12 cycles.
80006119|NCT03585894|Other|Sumatriptan|Receive intravenous infusion of sumatriptan
80006120|NCT03585894|Other|Ketorolac|Receive intravenous infusion of ketorolac
80006121|NCT04912921|Dietary Supplement|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
80006122|NCT04912921|Dietary Supplement|Placebo|4 tablets taken daily (2 in am and 2 in pm)
79688910|NCT06237530|Behavioral|External control meditation (ECM)|The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment.
79688911|NCT06237517|Behavioral|Assessment of Vasomotion of People With Idiopathic Chilblains|Investigation of vasomotion of people with and without idiopathic chilblains
79688912|NCT06237504|Device|SaCoVLM™|Patients will receive general anesthesia with their airways maintained with the SaCoVLM, which is a newer supraglottic airway device with a video port to directly visualize the upper airway.
79688913|NCT06237504|Device|Ambu®Auragain™|Patients will receive general anesthesia with their airways maintained with the Ambu Auragain, which is a conventional 2nd generation supraglottic airway device.
79833175|NCT00549328|Drug|Pazopanib (GW786034)|Pazopanib monotherapy
79833176|NCT00865917|Drug|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
79833177|NCT00865917|Drug|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
79833178|NCT00865917|Drug|Placebo|matching appearance
79833179|NCT00696410|Drug|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels ~10-12.
80006123|NCT04912921|Dietary Supplement|Curcumin|500 mg HydroCurc® twice a day
80006124|NCT04912921|Dietary Supplement|Control (microcrystalline cellulose)|2 tablets taken daily
80006125|NCT03590808|Biological|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
80006126|NCT05420324|Drug|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
80006127|NCT05420324|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
80006128|NCT05420324|Drug|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
79833180|NCT00865995|Procedure|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
80006129|NCT02238288|Drug|Aminocaproic acid|Crushed tablet in the dental socket
80006130|NCT02238288|Other|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
79378813|NCT03336060|Diagnostic Test|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
79533045|NCT01445587|Drug|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
79533046|NCT01445600|Drug|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
80006131|NCT02238288|Drug|lidocaine and epinephrine|2%
80006132|NCT02238288|Drug|Paracetamol|750 mg
79238332|NCT04581304|Device|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
79238333|NCT04581304|Device|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
79533047|NCT01445639|Drug|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
79688914|NCT06237491|Drug|177Lu-LNC1003 Injection group 1|The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
79688915|NCT06237491|Drug|177Lu-LNC1003 Injection group 2|The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
79688916|NCT06237491|Drug|177Lu-LNC1003 Injection group 3|The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
79688917|NCT06237478|Drug|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.
79688918|NCT06237478|Drug|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
79533048|NCT01445639|Drug|Normal saline|as placebo
79533049|NCT01445691|Drug|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
79533050|NCT01445704|Dietary Supplement|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
79688919|NCT06237465|Drug|Normal saline|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
79688920|NCT06237465|Drug|Botulinum toxin type A|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
79688921|NCT06237439|Behavioral|Move with HaRT|Move with HaRT is a group-based, manualized mind-body intervention.
80006133|NCT04901455|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
80006134|NCT01364129|Procedure|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
80006135|NCT01561040|Dietary Supplement|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
80006136|NCT03590496|Dietary Supplement|Calcium-Propionate 500mg|Calcium-Propionate capsules
80006137|NCT03590496|Other|Placebo|Placebo capsules without any active ingredient
79238334|NCT04580693|Other|PET Scan|PET scan using a tracer that is under a physician sponsored IND.
79238335|NCT04578652|Drug|Metformin 850 mg oral tablet bid|MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
79238336|NCT04578652|Dietary Supplement|Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.|The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
79238337|NCT04570631|Drug|Eftozanermin alfa|Intravenous (IV) infusion
79378814|NCT03341208|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
79238338|NCT04570631|Drug|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
79533051|NCT01445704|Dietary Supplement|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
79533052|NCT01445743|Biological|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
79533053|NCT01445756|Drug|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
79533054|NCT01445756|Drug|Placebo|Placebo; no topical lidocaine administered
79688922|NCT06237413|Drug|ZG2001 Tosilate Tablets|ZG2001 will be administered orally once or twice daily in a continuous regimen
79833181|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
79533055|NCT01445782|Drug|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
79533056|NCT01445782|Drug|Placebo|Multiple dose, oral inhalation (nebuliser solution)
79833182|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
79238339|NCT04570631|Drug|Dexamethasone|Oral Tablet
79378815|NCT04461418|Drug|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
79533057|NCT01445808|Behavioral|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
79688923|NCT06237400|Drug|ZG19018|ZG19018 Given by PO (mouth)
79833183|NCT00947986|Other|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
80006138|NCT03914651|Drug|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
79378816|NCT02497092|Other|Technique of injection|
79378817|NCT05667610|Other|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
79688924|NCT06237374|Behavioral|Digital Vaccine Education Training & Patient-facing Chatbot Tool|The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.
80006139|NCT03914651|Drug|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
80006140|NCT03101293|Drug|TAK-831|TAK-831 film-coated tablet.
79238340|NCT04533542|Other|Measurement|Undergo sensory measurements
79238341|NCT04533542|Other|Questionnaire Administration|Ancillary studies
79238342|NCT04508998|Diagnostic Test|Blood tests including genotyping|Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway
79238343|NCT04508998|Diagnostic Test|Exercise Tolerance Test|Treadmill exercise test using the Bruce protocol
79238344|NCT04507061|Drug|runcaciguat|Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
79533058|NCT01445808|Behavioral|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
79533059|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
79533060|NCT01445860|Drug|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
79688925|NCT06237374|Behavioral|Standard Training|All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
79688926|NCT06237361|Other|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
79688927|NCT06237361|Other|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
79833184|NCT00862329|Dietary Supplement|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
79833185|NCT00862329|Dietary Supplement|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
80006141|NCT01356953|Other|Aerobic exercise|Intensity of aerobic exercise
80006142|NCT05577260|Drug|magnesuim sulphate|magnesuim sulphate
79238345|NCT04507061|Other|Placebo|Sham-titrated dose of matching placebo will be administered orally once a day.
79833186|NCT00862329|Dietary Supplement|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
79833187|NCT00862329|Dietary Supplement|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
80006143|NCT05577260|Drug|Dexmedetomidine|Dexmedetomidine
80006144|NCT05577260|Drug|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
79238346|NCT04477629|Drug|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
79238347|NCT04477629|Drug|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
80006145|NCT01361087|Other|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
80006146|NCT03590340|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
80006147|NCT03590340|Other|Normal saline|Normal saline is 0.9% sodium chloride
80006148|NCT03590340|Biological|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
80006149|NCT03760562|Drug|Glucocorticoids|Oral Glucocorticoids.
80006150|NCT01357031|Drug|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
80006151|NCT01357031|Drug|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
80006152|NCT01357031|Drug|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
79238348|NCT04477629|Drug|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
79238349|NCT04477629|Drug|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
79238350|NCT04476589|Diagnostic Test|Functional MRI|measurement of functional brain networks
79378818|NCT02497014|Device|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
79688928|NCT06237348|Device|Simeox|Daily airway clearance therapy at home during 2 months
79688929|NCT06237348|Combination Product|Control|Daily airway clearance therapy at home during 2 months
79688930|NCT06237309|Drug|REGN5381|Single dose intravenous (IV) infusion
80006153|NCT05577104|Procedure|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
80006154|NCT05577104|Procedure|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
79238351|NCT04430517|Drug|Nicotinamide riboside|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
79238352|NCT04414943|Drug|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
79238353|NCT04414943|Drug|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
79688931|NCT06237309|Drug|Placebo|Single dose IV infusion
79688932|NCT06237296|Biological|RSV/hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
79238354|NCT04405258|Procedure|Pulmonary vein isolation|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
79238355|NCT04405258|Procedure|Left posterior wall isolation|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
79238356|NCT04396613|Procedure|Closure technique|Randomized assignment to one of three known, effective closure techniques
79688933|NCT06237296|Biological|RSV/hMPV mRNA LNP 2|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
79688934|NCT06237296|Biological|RSV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
79688935|NCT06237296|Biological|hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
79688936|NCT06237257|Biological|SHR-1316|SHR-1316（Adebrelimab Injection）
79688937|NCT06237257|Drug|Cisplatin Injection/Carboplatin Injection|Cisplatin Injection/Carboplatin Injection
79688938|NCT06237257|Radiation|External Beam Radiotherapy (EBRT)/Brachytherapy|External Beam Radiotherapy (EBRT)/Brachytherapy
79688939|NCT06237218|Behavioral|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
79688940|NCT06237205|Drug|Niraparib|a highly selective PARP1 and PARP2 inhibitor
79688941|NCT06237192|Drug|blinatumomab for B-ALL, venetoclax for T-ALL|MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
79533061|NCT01445925|Procedure|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
79833188|NCT00956956|Drug|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
79378819|NCT02497014|Device|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
79533062|NCT01445925|Procedure|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
79833189|NCT00956956|Drug|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
79833190|NCT00866073|Drug|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
79833191|NCT00957112|Procedure|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
79833192|NCT00957112|Procedure|standard follow-up care|Patients receive standard care
79833193|NCT02544711|Device|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
79833194|NCT02544711|Procedure|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
79833195|NCT00752466|Drug|Topiramate; flunarizine|
79688942|NCT06237153|Drug|Triamcinolone Acetonide extended release suspension|Active steroid
79688943|NCT06237140|Other|PNF+ biofeedback exercise group|Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.
79833196|NCT04982588|Device|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~EnVeo™ PRO Delivery Catheter System (DCS)~EnVeo™ PRO Loading System (LS)"
79833197|NCT00957190|Drug|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
79688944|NCT06237127|Dietary Supplement|Goji berry|Participants will be instructed to consume 28 grams of goji berries 5 days a week for 6 months
79688945|NCT06237127|Dietary Supplement|Fiber|Participants will be instructed to consume the fiber supplements 5 days a week for 6 months
79833198|NCT00866229|Drug|Rosuvastatin|10 mg per day for 12 weeks
80006155|NCT01357109|Drug|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
80006156|NCT01357109|Drug|Placebo|Matched placebo bid
79238357|NCT04364295|Device|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
79238358|NCT04354025|Biological|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
79238359|NCT04354025|Drug|Fludarabine|-Fludarabine (dose: 30 mg/m^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
79238360|NCT04354025|Drug|Ara-C|-Ara-C (dose: 2000mg/m^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
79688946|NCT06237101|Drug|High dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
79688947|NCT06237101|Drug|Medium dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
79688948|NCT06237088|Other|online mindfulness program|The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
79688949|NCT06237088|Other|eight-week mindfulness programs|The intervention consists of 2.5-hour classes per week over a period of eight weeks.
79688950|NCT06237075|Device|transcranial direct current stimulation|2-milliamp stimulation for 5~15 min
79688951|NCT06237062|Other|erenumab|This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
79688952|NCT06237023|Other|epidemyolojical|The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.
79378820|NCT05654428|Other|Mckenzie Extension Exercises|The exercises used to create space between under lying structures of lumber spine which help centralization of pain and can be performed in prone lying such as prone press ups, prone on elbow, and head lift in prone.
79533063|NCT01445925|Drug|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
79533064|NCT01445938|Drug|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
79533065|NCT01445938|Drug|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
79533066|NCT01445964|Drug|Atenolol|Atenolol oral administration
79533067|NCT01445964|Drug|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
79533068|NCT01445964|Drug|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
79533069|NCT01445990|Device|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
79533070|NCT01446029|Device|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
79533071|NCT01446055|Device|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
79833199|NCT00866229|Drug|Simvastatin|20 mg per day
79833200|NCT04051398|Other|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
79833201|NCT00953914|Drug|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
79833202|NCT00953914|Drug|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
79833203|NCT00858975|Procedure|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
80006157|NCT04808492|Device|CureWave High Intensity Laser|"The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~Power (44 Watts)~Mode (continues wave)~Time on (60000 ms)~Time off (1 ms)~Repeats (9)~Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
79833204|NCT03891290|Other|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
80006158|NCT04808492|Other|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
79378821|NCT05654428|Other|William Flexion Exercises|Exercises for strengthening of gluteal and abdominal muscles which help to reduce pressure on the nerve root by promoting flexion at lumber spine such as knee to chest, double knee to chest, bridging(Gluets bridge), and straight leg raise (SLR).
79378822|NCT05641792|Device|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
79378823|NCT03335982|Procedure|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
79378824|NCT03335904|Other|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
79533072|NCT01446055|Device|Ficoll conventional cell processing method|Comparison of different cell processing methods
79533073|NCT01446068|Dietary Supplement|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
79533074|NCT01446081|Behavioral|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
79533075|NCT01446094|Drug|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
79533076|NCT01446107|Other|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
79533077|NCT01446107|Other|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
79833205|NCT00756912|Drug|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
79833206|NCT00948220|Drug|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
79833207|NCT00756990|Drug|Depot Naltrexone|228mg of injectable naltrexone
80006159|NCT03896399|Procedure|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
80006160|NCT02850978|Drug|Spiolto|
79833208|NCT05301244|Other|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
79533078|NCT01446107|Other|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
79833209|NCT05301244|Other|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
79378825|NCT03335904|Other|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
79833210|NCT05301244|Other|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
79833211|NCT05301244|Other|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
79833212|NCT05301244|Other|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
79833213|NCT02561286|Behavioral|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
80006161|NCT02253446|Drug|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
80006162|NCT02253446|Drug|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
80006163|NCT03589170|Diagnostic Test|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
80016743|NCT02737553|Procedure|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
79378826|NCT03335904|Other|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
79378827|NCT03335904|Other|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
79378828|NCT03335904|Drug|Losartan|Losartan, 50mg, BID
79533079|NCT01446107|Other|placebo control|application of water onto tooth surface every year
79378829|NCT03335904|Drug|Placebo|Placebo, 50mg, BID
79533080|NCT01446120|Drug|NPH-Insulin Injection|
79378830|NCT05233020|Device|robotic|fifteen patients undergo robotic operation
79378831|NCT05233020|Device|hybrid|fifteen patients undergo hybrid operation
79378832|NCT03335826|Procedure|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia.
79378833|NCT03335826|Procedure|General anesthesia|General anesthesia and postoperative intravenous analgesia.
79378834|NCT03335748|Other|Cognitive training Cogmed program|Cognitive training Cogmed program
79378835|NCT01711294|Device|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
79378836|NCT01711294|Device|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
79378837|NCT01711294|Device|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
79378838|NCT03340818|Other|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
79378839|NCT03340818|Other|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
79533081|NCT01446120|Drug|Insulin loaded Orally Dissolved Films (insulin-ODF|
79533082|NCT01446146|Behavioral|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
79533083|NCT01446146|Behavioral|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
79533084|NCT01446185|Device|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
79533085|NCT01446211|Drug|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
79833214|NCT02561286|Behavioral|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
79833215|NCT00757068|Behavioral|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
79833216|NCT00757068|Behavioral|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
80006164|NCT05417893|Device|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
79238361|NCT04354025|Drug|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
79238362|NCT04354025|Drug|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
79238363|NCT04354025|Procedure|Leukapheresis|-Donor only
79238364|NCT04347720|Drug|Indomethacin|Intravenous formulation
79238365|NCT04347720|Drug|Ibuprofen|Intravenous and oral formulations
79378840|NCT05622760|Other|Audiovisual information|The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
79533086|NCT01446211|Drug|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
79833217|NCT00957346|Drug|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
79833218|NCT00957346|Drug|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
79833219|NCT04061096|Diagnostic Test|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
79833220|NCT04061096|Diagnostic Test|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
79833221|NCT04061096|Diagnostic Test|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
80006165|NCT03135431|Procedure|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
80006166|NCT03135431|Procedure|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
80006167|NCT03546452|Diagnostic Test|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
79238366|NCT04347720|Drug|Acetaminophen|Intravenous and oral formulations
79238367|NCT04343755|Biological|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
79238368|NCT04325802|Drug|Naltrexone|50mg Naltrexone daily
79238369|NCT04325802|Other|Placebo|Placebo (Mannitol) daily
79238370|NCT04314583|Behavioral|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
79238371|NCT04314583|Behavioral|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
79238372|NCT04300777|Device|SeaSpine Non-Cervical Pedicle Screw Systems|Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
79238373|NCT04285346|Drug|Ganaxolone|titration followed by maintenance and extension period
79238374|NCT04266873|Device|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
79238375|NCT04253899|Procedure|Appendectomy|Interval Appendectomy
79238376|NCT04253899|Other|Observation|observation and follow up
79238377|NCT04241562|Other|Injection of Nerve Growth Factor|Injection of Nerve Growth Factor to the right masseter
79378841|NCT05622760|Other|Written information|The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
79378842|NCT03340740|Drug|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
79378843|NCT03340740|Drug|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
79833222|NCT00750984|Procedure|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
79833223|NCT00750984|Procedure|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
79833224|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
79833225|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
79833226|NCT00954070|Device|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
79238378|NCT04234555|Diagnostic Test|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
79238379|NCT04234555|Diagnostic Test|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
79238380|NCT04234555|Diagnostic Test|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
79533087|NCT01446224|Drug|Pazopanib|Patients treated with pazopanib
79533088|NCT01446224|Drug|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
79533089|NCT01446263|Procedure|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
79533090|NCT01446276|Dietary Supplement|Resveratrol|500 mg 3 times daily for six month
79533091|NCT01446276|Other|Placebo|1 placebo tablet 3 times daily for six month
79688953|NCT06236997|Drug|Adebrelimab|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
79833227|NCT00752544|Drug|TMC435350|
79833228|NCT00957502|Device|ENTact™ Septal Stapler|1 year aged septal staples
79833229|NCT00957502|Device|ENTact™ Septal Stapler|18 Month Aged Staples
79238381|NCT04234555|Diagnostic Test|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
79238382|NCT04234555|Diagnostic Test|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
79238383|NCT04234542|Other|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
79238384|NCT04234542|Other|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
79238385|NCT04226144|Device|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
79533092|NCT01446302|Dietary Supplement|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
79533093|NCT01446315|Behavioral|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
79533094|NCT01446315|Behavioral|Asthma APGAR tools|Usual care
79533095|NCT01446328|Drug|Amisulpride|Tablets, dose range 50-1200 mg/ day
79533096|NCT01446328|Drug|Aripiprazole|Tablets, dose range 5-30 mg/ day
79533097|NCT01446328|Drug|Olanzapine|Tablets, dose range 2.5-20 mg/ day
79833230|NCT00751062|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
79833231|NCT00751062|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
79833232|NCT04031456|Biological|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
79833233|NCT04031456|Biological|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
79833234|NCT00948376|Genetic|IFT80 screening|Natural History
79833235|NCT00752700|Other|Conventional resistance training|Conventional resistance training program (CRT)
79833236|NCT00752700|Other|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
80006168|NCT03585348|Other|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
80016744|NCT02737553|Procedure|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
79833237|NCT00957736|Genetic|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
80006169|NCT03579810|Other|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
80006170|NCT03579810|Other|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
80016745|NCT00393068|Drug|Erlotinib|Erlotinib
80016746|NCT00393068|Drug|Bevacizumab|Bevacizumab
79238386|NCT04226144|Device|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
79238387|NCT04213144|Device|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
79238388|NCT04213144|Device|Sham MED|Sham MED is intended to be used for soft tissue healing
79238389|NCT04213053|Procedure|strabismus surgery|Lees screen before and after concomitant strabismus surgery
79238390|NCT04209192|Drug|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
79238391|NCT04209192|Drug|Amikacin|Is the prophylactic drug which will be used in the control group.
79378844|NCT01711372|Device|Groundskeeper game for controls|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
79378845|NCT01711372|Device|Groundskeeper game for ADHD|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
79533098|NCT01446341|Procedure|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
79688954|NCT06236997|Radiation|Radiation Therapy|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
79688955|NCT06236997|Drug|etoposide, carboplatin(EC)|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
79378846|NCT03340662|Drug|CC-122|CC-122
79378847|NCT03340662|Drug|Itraconazole|CYP3A Inhibitor
79378848|NCT03340662|Drug|Fluvoxamine|CYP1A2 Inhibitor
79688956|NCT06236984|Other|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
79688957|NCT06236971|Behavioral|MRI scanning first at supine position and then turn into lateral position|Magnetic resonance imaging was used to scan the upper airway of sedated subjects, first at supine position and then turn into lateral position.
79533099|NCT01446341|Procedure|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
79533100|NCT01446406|Device|MONARCA|Monitoring affective symptoms entered by the patient every day.
79533101|NCT01446406|Device|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
79533102|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
79533103|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
80016747|NCT00393068|Drug|Paclitaxel|Paclitaxel
80016748|NCT00393068|Drug|Carboplatin|Carboplatin
80016749|NCT00393068|Drug|5-FU|5-FU
79238392|NCT04199468|Drug|Active Delta-9-THC|Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
79238393|NCT04199468|Drug|Placebo Delta-9-THC|A placebo dose given intravenously (IV)
79238394|NCT04199468|Drug|Active Ketamine|Active Ketamine (0.2 mg/kg) given intravenously (IV)
79238395|NCT04199468|Drug|Placebo Ketamine|A placebo dose given intravenously (IV)
79238396|NCT04178148|Other|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
79238397|NCT04163822|Other|no intervention|no intervention, only observation
79238398|NCT04148287|Drug|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
79238399|NCT04138914|Device|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
79378849|NCT03340662|Drug|Rifampin|CYP3A Inducer
79378850|NCT03342300|Drug|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
80016750|NCT00393068|Procedure|Radiation therapy|Radiation therapy
80016751|NCT00393068|Procedure|Surgery|Surgery
79833238|NCT00957736|Other|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
79833239|NCT00751374|Drug|gentamicin|topical gentamicin cream on daily basis
79833240|NCT00751374|Drug|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
79833241|NCT02566694|Procedure|Implant|orthopaedic implant
80006171|NCT03556085|Device|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
79378851|NCT03342300|Drug|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
79378852|NCT01711918|Drug|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
79378853|NCT03120468|Drug|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
79378854|NCT03120468|Drug|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
79378855|NCT02493270|Behavioral|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
79378856|NCT02493270|Procedure|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
79378857|NCT01712230|Drug|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
79378858|NCT01712230|Behavioral|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
79378859|NCT01712230|Drug|Placebo|Placebo
79533104|NCT01446458|Drug|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
79533105|NCT01446458|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
79833242|NCT00954148|Procedure|PET/CT|5 visits with PET/CT as only testing
79833243|NCT00954148|Procedure|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
79833244|NCT03951194|Biological|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
79238400|NCT04126681|Drug|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
79238401|NCT04126681|Drug|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
79833245|NCT03951194|Other|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
79833246|NCT00957814|Behavioral|Nutritional education|Systematic nutritional orientation program
79833247|NCT00757224|Behavioral|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
79833248|NCT00954304|Drug|HM30181AK 1mg|HM30181AK 1mg tablet
79833249|NCT00954304|Drug|HM30181AK 5mg|HM30181AK 5mg tablet
79833250|NCT00954304|Drug|HM30181AK 15mg|HM30181AK 15mg tablet
79833251|NCT00954304|Drug|HM30181AK 60mg|HM30181AK 60mg tablet
79833252|NCT00954304|Drug|Loperamide 2mg|Loperamide 2mg capsule
79833253|NCT00752778|Other|pet-scan FDG-F18|
79833254|NCT00363415|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
79833255|NCT00363415|Drug|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
79833256|NCT00363415|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
80006172|NCT03767634|Other|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
80006173|NCT01563224|Drug|Baclofen 10mg|Baclofen 10mg single dose po
80006174|NCT01563224|Drug|Baclofen 60mg|Baclofen 60mg single dose po
79238402|NCT04126681|Drug|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
80006175|NCT01563224|Drug|placebo|placebo
80006176|NCT01361243|Behavioral|NOURISH+|6 week face-to-face parent intervention.
79833257|NCT00757302|Device|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
79833258|NCT00757380|Procedure|Trypan Blue|Membranepeeling with TB
79833259|NCT00757380|Procedure|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
79833260|NCT00957970|Device|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
79833261|NCT00957970|Device|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
79833262|NCT00752934|Drug|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
80006177|NCT01361243|Behavioral|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
79378860|NCT03335514|Diagnostic Test|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
79833263|NCT00752934|Drug|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
79833264|NCT00948532|Biological|biologic, Osteocel Plus|Osteocel® Plus
79833265|NCT00696020|Drug|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
79833266|NCT00696020|Drug|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
79833267|NCT00696020|Device|Respimat® Inhaler|
79833268|NCT00751608|Drug|APL180|
80006178|NCT03632629|Other|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
80006179|NCT05576870|Other|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
79238403|NCT04126681|Drug|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
79238404|NCT04118855|Drug|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
79378861|NCT01712776|Device|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
79833269|NCT00751608|Drug|APL180|
79833270|NCT00751608|Drug|Placebo|
79833271|NCT00958048|Device|non-invasive ventilation|CPAP, BiPAP
80006180|NCT05576870|Dietary Supplement|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
80006181|NCT01369979|Procedure|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
79238405|NCT04118855|Drug|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
79378862|NCT01712776|Device|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
79833272|NCT00751686|Procedure|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
79833273|NCT00751686|Other|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
79833274|NCT01047085|Procedure|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
79833275|NCT00576576|Drug|Atorvastatin|Atorvastatin 80 mg a day
79833276|NCT01049971|Device|wound protector|after minilaparotomy, the wound protector is applied
79833277|NCT01049971|Device|no wound protector|use of woven drape instead of wound protector
79833278|NCT04056156|Behavioral|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
80006182|NCT03577860|Drug|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
80006183|NCT03577860|Drug|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
80006184|NCT03547661|Other|P-Dragees rosa Lichtenstein|Placebo dragées
80016752|NCT03659643|Diagnostic Test|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
79238406|NCT04092790|Device|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
80016753|NCT03658863|Procedure|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
80016754|NCT03658863|Procedure|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
79833279|NCT04056156|Behavioral|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
79833280|NCT00751764|Drug|Moxidectin|
79833281|NCT00757458|Drug|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
79833282|NCT00757458|Other|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
79833283|NCT00757458|Other|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
79833284|NCT00757458|Other|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
79833285|NCT02919098|Behavioral|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
79833286|NCT02919098|Behavioral|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
79833287|NCT00923247|Drug|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
80006185|NCT03577782|Biological|Entyvio (Vedolizumab)|"Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
79238407|NCT04074226|Procedure|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
79238408|NCT04074226|Procedure|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
79238409|NCT04021394|Diagnostic Test|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
79238410|NCT04021394|Diagnostic Test|Parsortix CTC platform|EMT-independent platform
79378863|NCT02496390|Biological|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
79833288|NCT00923247|Drug|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
79833289|NCT00757536|Procedure|Encircling Band|ppVE and encircling band
79833290|NCT00757536|Procedure|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
79833291|NCT03890354|Procedure|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
79833292|NCT00757614|Genetic|DNA analysis|
79833293|NCT00757614|Genetic|polymorphism analysis|
79833294|NCT00757614|Other|laboratory biomarker analysis|
79833295|NCT00757614|Other|questionnaire administration|
79833296|NCT00757692|Drug|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
79833297|NCT00757692|Drug|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
79833298|NCT04041141|Diagnostic Test|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
79833299|NCT04041141|Device|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
79833300|NCT00866385|Drug|AZD8566|Single 6 mg oral solution dose
79833301|NCT00866385|Drug|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
79833302|NCT00757770|Biological|Rotarix|Two oral doses.
79833303|NCT00757770|Biological|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
79833304|NCT04847648|Procedure|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
79833305|NCT04847648|Procedure|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
79833306|NCT02544555|Procedure|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
79833307|NCT02544555|Procedure|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
79833308|NCT00753168|Drug|OT-730 ophthalmic solution|one eye drop twice daily
79833309|NCT00753168|Drug|timolol maleate ophthalmic solution|one eye drop twice daily
79833310|NCT00753168|Drug|OT-730 placebo|one eye drop twice daily
79833311|NCT02565602|Other|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
79833312|NCT02565602|Other|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
79833313|NCT02565602|Dietary Supplement|Vitamin D|One tablet daily (400IU per tablet)
79833314|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
79833315|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
79833316|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
79833317|NCT04051164|Other|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
79833318|NCT04051164|Other|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
79833319|NCT03823118|Drug|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
80006186|NCT03548090|Other|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
80006187|NCT03548090|Other|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
80006188|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
79378864|NCT02496390|Biological|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
79833320|NCT00866541|Device|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
79833321|NCT00695864|Drug|Ondansetron and Placebo crossover|
79833322|NCT00684996|Drug|etaracizumab|Given IV
79238411|NCT04012151|Other|Physical measurement|Parturients of gestational week >= 32 weeks will have their arms and fingers measured to generate the conicity index.
79238412|NCT04012151|Other|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
79378865|NCT03342222|Device|Interference Screws|tibial fixation for ACL reconstruction
79378866|NCT03340584|Other|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
79833323|NCT00684996|Biological|bevacizumab|Given IV
79833324|NCT04841408|Other|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
79833325|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
79833326|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
79833327|NCT00751842|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
79833328|NCT05325008|Drug|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
79833329|NCT05325008|Other|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
80006189|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
79378867|NCT03340584|Other|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
79688958|NCT06236958|Device|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
79688959|NCT06236958|Other|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 ~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 ~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 ~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500~3000 ml/d; the infusion time is 8~12 h/d. After exhaustion, start to eat through the mouth.
79688960|NCT06236932|Dietary Supplement|Mediterranean diet|Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
79688961|NCT06236932|Dietary Supplement|Melatonin supplementation|Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
79688962|NCT06236919|Behavioral|VR cognitive training|The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
79688963|NCT06236919|Behavioral|VR nature exposure relaxation|The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
79688964|NCT06236906|Device|Device supported behavioural treatment|The method involves behavioral change supported by a digital support system, including daily home weighings, a clear weight curve in a mobile app, and communication with the treatment team through the same app.
79688965|NCT06236880|Drug|GM-2505|IV
79688966|NCT06236867|Other|KaleidoscopeGroup|The group consists of 34 people. Pain level was measured during 3 dialysis sessions.In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
79688967|NCT06236867|Other|Ice Application Group|The group consists of 34 people. Pain level was measured during 3 dialysis sessions. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point)
79688968|NCT06236867|Other|Control Group|The group consists of 34 people. Pain level will be measured during 3 dialysis sessions. In the control group, the vital signs of the patients before AVF cannulation will be recorded.
79833330|NCT00684762|Drug|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
79833331|NCT00684762|Drug|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
79833332|NCT00753246|Drug|nimotuzumab|monoclonal antibody
79833333|NCT00695786|Drug|Lenalidomide|Given PO
79833334|NCT00695786|Biological|Rituximab|Given IV
79833335|NCT02561676|Other|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
80016755|NCT03658863|Procedure|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
80016756|NCT03658863|Device|Ultrasound endoscope|Endoscope with built-in ultrasound function
79238413|NCT04011150|Device|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
79238414|NCT04011150|Drug|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
79238415|NCT04011150|Drug|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
79238416|NCT03984695|Behavioral|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
79238417|NCT03972709|Drug|Galegenimab|Intravitreal (ITV) injections of galegenimab
79378868|NCT03335436|Drug|Gabapentin|Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
79378869|NCT03335436|Drug|Placebo|Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
79688969|NCT06236854|Other|Delirium assessment (observational, not interventional)|As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.
79833336|NCT02561676|Other|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
79833337|NCT02560740|Dietary Supplement|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
79833338|NCT02560740|Dietary Supplement|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
79238418|NCT03972709|Drug|Sham Control|Sham control
79238419|NCT03935321|Drug|NG-101|6 intrathecal bolus injections, each of 45mg
79833339|NCT03893942|Other|Questionnaires administration|Psychological and quality of life questionnaires
79833340|NCT03893942|Other|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
79833341|NCT03893942|Other|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
79833342|NCT03893942|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
79378870|NCT02494284|Drug|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
79833343|NCT03893942|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
79833344|NCT03893942|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
79833345|NCT03893942|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
79833346|NCT03893942|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
79833347|NCT04049838|Procedure|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
79833348|NCT00753324|Drug|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
79833349|NCT00757926|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
79833350|NCT00757926|Other|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
79833351|NCT02561520|Biological|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
79833352|NCT02561520|Biological|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
79833353|NCT00387127|Drug|Lapatinib oral tablets|Lapatinib is administered orally once daily.
79833354|NCT00387127|Drug|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
79688970|NCT06236828|Device|Mechanical Thrombectomy|The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
79688971|NCT06236802|Device|ProVee device|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
79238420|NCT03935321|Drug|Placebos|6 intrathecal bolus injections, each of 45mg
79688972|NCT06236789|Drug|Ifosfamide/mesna|Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression
79688973|NCT06236763|Device|TOFscan foot|TOFscan will be applied on the foot and recovery from neuromuscular blockade will be observed over time. These will be compared with the control (TOFscan at the hand) on the same patient (gold standard monitor).
79688974|NCT06236750|Device|EPIFIX|EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
79238423|NCT03927378|Drug|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
79238424|NCT03927378|Drug|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
79238425|NCT03923686|Procedure|EUS-guided drainage using LAMS with DPS|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
79833355|NCT00387127|Drug|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
79833356|NCT00683592|Drug|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
79833357|NCT00683592|Drug|placebo|placebo
79833358|NCT00695396|Drug|Placebo|Matching volume 2 mLfor 48 weeks
79238426|NCT03923686|Procedure|EUS-guided drainage using LAMS alone|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
79238427|NCT03875391|Drug|Oxytocin|Drug: Oxytocin nasal spray
79238428|NCT03875391|Drug|Placebo|Drug: Placebo nasal spray
79238429|NCT03869905|Drug|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
79238430|NCT03869905|Drug|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
79238431|NCT03857620|Other|Best Practice|Receive usual care
79238432|NCT03857620|Other|Informational Intervention|Receive OPTI-Surg program materials
79238433|NCT03857620|Other|Questionnaire Administration|Ancillary studies
79238434|NCT03857620|Other|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
79238435|NCT03836066|Drug|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
79238436|NCT03835741|Device|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
79238437|NCT03835741|Other|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
79833359|NCT00695396|Drug|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
79833360|NCT00695396|Drug|Placebo|Matching volume 1 mL for 48 weeks
79833361|NCT00695396|Drug|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
79833362|NCT00753402|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
79833363|NCT00753402|Biological|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes/Epinephrine 30mcg/kg/min
79238438|NCT03831256|Diagnostic Test|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
79238439|NCT03831256|Diagnostic Test|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
79238440|NCT03831256|Diagnostic Test|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
79238441|NCT03831256|Diagnostic Test|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
79238442|NCT03826173|Behavioral|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
79238443|NCT03826173|Behavioral|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
79688975|NCT06236737|Other|Sensorimotor Exercise|The sensorimotor group was given oculomotor, gaze stability and postural stability exercises. Each session lasted 40 minutes in total.
79833364|NCT05434884|Procedure|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
79833365|NCT05434884|Procedure|endocrown restorations|endocrown restorations
79833366|NCT00758004|Drug|Atorvastatin|A single dose of 80 mg atrovastatin tablet
79833367|NCT00758004|Drug|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
79833368|NCT02656706|Drug|Ipilumumab|
79833369|NCT02656706|Drug|Nivolumab|
79833370|NCT00753480|Drug|D4064A|
79833371|NCT00758082|Device|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
79833372|NCT00758082|Device|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
79833373|NCT04049916|Drug|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
79833374|NCT04049916|Drug|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
79833375|NCT04049916|Drug|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
79833376|NCT00753558|Drug|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
80016757|NCT02280278|Procedure|Radical surgery|
80016758|NCT02280278|Drug|Adjuvant chemotherapy|
79833377|NCT02561208|Other|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
79833378|NCT02559960|Drug|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
79833379|NCT00921596|Procedure|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
79833380|NCT03625544|Procedure|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
79833381|NCT03625544|Device|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
80006190|NCT03548090|Other|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
79238444|NCT03803995|Procedure|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
79238445|NCT03803995|Procedure|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
79238446|NCT03778242|Drug|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
79238447|NCT03778242|Drug|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
79238448|NCT03772613|Drug|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
79238449|NCT03766022|Device|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
79533106|NCT01446484|Biological|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
79533107|NCT01446484|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
79533108|NCT01446484|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
79533109|NCT01446484|Drug|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
79533110|NCT01446484|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
79833382|NCT03625544|Procedure|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
79833383|NCT00575328|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
79833384|NCT00575328|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
80016759|NCT02280278|Biological|Cytokine-induced killer cell immunotherapy|
80016760|NCT02280434|Drug|CBP-307|
80016761|NCT02280434|Drug|Placebo|
80016762|NCT02285348|Procedure|Lumbar puncture|Lumbar puncture is done according to general practice
80016763|NCT00391196|Drug|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
80016764|NCT00391196|Drug|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
80016765|NCT00391196|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
79238450|NCT03760029|Other|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
79378871|NCT02494284|Drug|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
79378872|NCT01713400|Drug|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
79378873|NCT01713400|Drug|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
79378874|NCT01713400|Drug|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
79833385|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
80006191|NCT03548090|Other|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
80006192|NCT03548090|Other|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
80006193|NCT03548090|Other|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
80006194|NCT01364441|Drug|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
80006195|NCT01364441|Drug|Placebo|Placebo dosed in the same manner as ONO-2952
79238451|NCT03739437|Behavioral|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
79238452|NCT03739437|Behavioral|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
79238453|NCT03701555|Other|PvP001 placebo|placebo
79238454|NCT03701555|Drug|PvP001 100 mg|PvP001 100 mg
79238455|NCT03701555|Drug|PvP001 300 mg|PvP001 300 mg
79238456|NCT03701555|Drug|PvP001 900 mg|PvP001 900 mg
79238457|NCT03701555|Drug|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
79533111|NCT01446484|Drug|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
79533112|NCT01446484|Drug|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
79533113|NCT01446484|Procedure|Kidney transplantation|Living related kidney transplantation
80006196|NCT02238756|Biological|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
80006197|NCT02238756|Biological|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
79238458|NCT03701555|Drug|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
79238459|NCT03701555|Drug|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
79238460|NCT03701555|Other|PvP002 placebo|Placebo
79238461|NCT03701555|Drug|PvP001 600 mg|PvP001 600 mg
79238462|NCT03701555|Drug|PvP003 placebo|Placebo tablet orally.
79238463|NCT03701555|Drug|PvP003|PvP003 tablet orally.
79238464|NCT03701555|Drug|PvP003 150 mg|PvP003 150 mg
79238465|NCT03685422|Other|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Hospital Anxiety and Depression Scale (HADS), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
79238466|NCT03673748|Drug|Mesenchymal stem cells (MSC)|Endovenous injection of MSV in saline solution
79238467|NCT03673748|Drug|Placebo|Endovenous injection of saline solution without cells
79238468|NCT03659617|Device|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
79238469|NCT03657667|Procedure|Ureteroscopy|Endoscopic removal of kidney stones
79533114|NCT01446497|Drug|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
79533115|NCT01446497|Drug|Timolol|Twice per day, 1 drop at each time
79533116|NCT01446510|Other|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
79533117|NCT01446523|Drug|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
79533118|NCT01446523|Drug|Lactulose|Syrup 30 ml BD for 12 weeks
79833386|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
79833387|NCT00753792|Drug|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
79833388|NCT05434494|Drug|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
80006198|NCT02238756|Biological|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
80006199|NCT03432065|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
80006200|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
80006201|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
79833389|NCT05434494|Drug|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
79833390|NCT05433792|Device|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
79833391|NCT05433792|Device|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
79833392|NCT00753870|Biological|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
79533119|NCT01446536|Other|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
79533120|NCT01446549|Other|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
79688976|NCT06236737|Other|Yoga Exercise|A flow was created for the yoga group. Each session lasting 40 minutes was included ocular motor, balance, meditation and stretching. Practices illustrated in table one were repeated for the eight weeks. Beginning of each session was focused on breathing exercises and the yoga flow is designed. Weeks 1-2. were prepared by focusing mostly on sagittal plane asanas. While 3-5. tweeks were focused on frontal plane asanas, 6-8. weeks were focused on transvers plan. Each session commenced with a 5-minute practice of a three dimensional breathing technique. This was followed by a 25-minute yoga asana flow, concluding with a 10-minute meditation in shavasana, also known as Corpse Pose. NDY was taught by an academician physiotherapist who has completed graduation in yoga therapy.
79833393|NCT00575094|Drug|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
79238470|NCT03640858|Device|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
79533121|NCT01446549|Procedure|Deep Brain Stimulation|Deep Brain Stimulation implantation
79833394|NCT00553696|Drug|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
79833395|NCT00553696|Drug|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
79238471|NCT03604705|Drug|APX001|APX001
79238472|NCT03571165|Behavioral|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
79533122|NCT01446562|Biological|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
79533123|NCT01446588|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
79533124|NCT01446601|Device|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
79533125|NCT01446614|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
79533126|NCT01446627|Other|There is no intervention for this study|None, no intervention made.
79533127|NCT01446640|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10^6 MSCs per kg; intrathecal administration of up to 1x10^6 MSCs per kg.
79688977|NCT06236711|Device|tDCS|tDCS is a form of noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes. The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A (Soterix Medical, Inc., New York, NY, USA) device will be used in the study. The tDCS device is comprised of a small battery-operated control box that delivers the current through electrodes placed on the scalp, held in place by elastic bands or head straps and worn over the forehead like a headband.
79688978|NCT06236698|Diagnostic Test|24-hour urinary aldosterone|Collect 24-hour urine from each participant and complete the detection of urinary aldosterone content.
79688979|NCT06236672|Drug|GLP-1 receptor agonist|GLP-1 RA initiated between January 2019 and December 2022
79688980|NCT06236672|Drug|basal insulin|basal insulin initiated between January 2019 and December 2022
79833396|NCT00553696|Drug|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
79833397|NCT05430126|Drug|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
79833398|NCT05427864|Diagnostic Test|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
79833399|NCT00553540|Device|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
79833400|NCT02559804|Other|survival and late effects|survival and late effects
79833401|NCT03877380|Other|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
79833402|NCT00958204|Procedure|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
79833403|NCT00958204|Procedure|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
79833404|NCT00958204|Drug|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
79833405|NCT00958204|Drug|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
79833406|NCT00954460|Drug|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
79833407|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
79833408|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
79533128|NCT01446653|Behavioral|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
79688981|NCT06236646|Other|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
79688982|NCT06236646|Other|Control (CON)|The CON group did not have any intervention but usual care.
79833409|NCT00617409|Drug|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
79833410|NCT00617409|Biological|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
79833411|NCT00617409|Drug|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
79833412|NCT00695318|Drug|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
79833413|NCT00695318|Drug|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
79833414|NCT00754104|Drug|ABT-869|0.25 mg/kg. daily.
79833415|NCT00754104|Drug|Tarceva|150mg, daily.
79238473|NCT03569059|Device|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
79833416|NCT00386425|Drug|Drotrecogin alfa (activated)|intravenous
79833417|NCT05300230|Device|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~Visit 1: it will be carried out the first contact and learning the measurement procedure.~Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
79833418|NCT00758238|Other|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
79833419|NCT05352412|Behavioral|Shared Decision Making Aid|Patients will be randomized to the shared decision making aid intervention.
79833420|NCT05352412|Behavioral|Baseline Counseling As usual|Patients will be randomized to the baseline counseling as usual.
79833421|NCT00859365|Procedure|Real Acupuncture|Real acupuncture treatment in real acupuncture points
79833422|NCT00859365|Procedure|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
79238474|NCT03569059|Behavioral|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
79378875|NCT01713400|Drug|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
79378876|NCT03342066|Diagnostic Test|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
79378877|NCT04226872|Behavioral|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
79533129|NCT01446653|Behavioral|Video|Video arm will provide information via documentary video
79533130|NCT01446653|Behavioral|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
79533131|NCT01446679|Drug|atrovastatin|oral
79533132|NCT01446718|Biological|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
79688983|NCT06236620|Dietary Supplement|Processing of wheat|Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
79688984|NCT06236607|Device|Device specific training|Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.
79688985|NCT06236607|Other|Study clinician/educator visit|Participants will receive insulin dose and other diabetes management guidance.
79688986|NCT06236581|Behavioral|GEM Intervention|Lifestyle coaching
79833423|NCT00859365|Procedure|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
79833424|NCT00948844|Device|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
79533133|NCT01446731|Biological|mRNA transfected dendritic cell|"Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
79833425|NCT02544477|Device|High-flow Nasal Cannula Oxygen (HFNCO)|
79833426|NCT02544477|Device|Conventional oxygen treatment|
79833427|NCT00949000|Device|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
79833428|NCT03993145|Behavioral|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
79833429|NCT00859599|Device|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
79833430|NCT00859599|Device|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
79833431|NCT00694304|Drug|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
79833432|NCT05352334|Diagnostic Test|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
79833433|NCT00371839|Procedure|Audiological Evaluation|Tests of hearing, cognition, and speech perception
79378878|NCT02496312|Behavioral|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
79833434|NCT00866853|Drug|TMC435|
79533134|NCT01446731|Drug|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
79833435|NCT05386836|Device|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
79833436|NCT00949156|Procedure|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
80006202|NCT03412799|Drug|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
80006203|NCT03412799|Drug|nab-paclitaxel|Administered as intravenous (IV) infusion
79378879|NCT03335358|Behavioral|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
79688987|NCT06236555|Diagnostic Test|8-iso Prostaglandin F2α and Adenosine Deaminase|We took gingival crevicular fluid samples from patients who applied to our clinic and evaluated the -iso Prostaglandin F2α and Adenosine Deaminase levels in the samples.
79688988|NCT06236542|Device|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
79688989|NCT06236542|Device|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
79688990|NCT06236542|Device|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
79688991|NCT06236529|Behavioral|Health Behavior Change Counseling|A telephone-based intervention employing principles and practices of motivational interviewing.
79833437|NCT02544399|Other|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
79833438|NCT01044511|Behavioral|Home visits|home visits by specialist nurse 2 times and 1 phonecall
79833439|NCT01044511|Behavioral|standard|hotline
79833440|NCT04011904|Other|Cross-over study|Traditional Inuit Diet vs Westernized Diet
79378880|NCT02248246|Device|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~Inferior mesenteric artery (IMA)~Inferior mesenteric vein (IMV) (if identified)"
79833441|NCT04040517|Diagnostic Test|Evoked potential audiometer|The ASSR [ steady state response] test stimuli are modulated pure tones with insert earphone..
79833442|NCT00682890|Drug|placebo|placebo birth control pill daily
79833443|NCT00682890|Drug|metformin|2000 mg per day for 3 months daily birth control pill
79833444|NCT02565368|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
79833445|NCT02565368|Drug|CKD-395 0.5/1000mg|single oral administration
80006204|NCT03412799|Drug|Gemcitabine Injection|Administered as intravenous (IV) infusion
80006205|NCT03375359|Diagnostic Test|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
79688992|NCT06236529|Behavioral|Self-management program|An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
79833446|NCT00949390|Behavioral|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
79833447|NCT04040595|Procedure|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
79833448|NCT03992365|Drug|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
79833449|NCT03992365|Drug|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
79833450|NCT04011514|Behavioral|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
79238475|NCT03569059|Device|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
79238476|NCT03552731|Behavioral|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
79833451|NCT00921804|Drug|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
79688993|NCT06236503|Behavioral|Real Stimulation|"Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months."
79833452|NCT00921804|Drug|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
79833453|NCT00921804|Drug|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
79833454|NCT00921804|Drug|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
79833455|NCT02534779|Other|Placebo Vaginal Insert|Placebo insert
79833456|NCT00867399|Drug|ABT-126|See arm for details
79238477|NCT03541733|Other|mid-gut tubing|mid-gut tubing at different time
79302933|NCT03209323|Device|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
79378881|NCT03335280|Drug|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
79378882|NCT04494828|Drug|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
79378883|NCT04494828|Drug|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
79378884|NCT01713868|Behavioral|Safe Sleep Nursery Education|Nursery-based program for safe sleep
79378885|NCT01713868|Behavioral|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
79688994|NCT06236503|Behavioral|Placebo Stimulation|Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
79833457|NCT00758316|Other|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
79833458|NCT00758316|Procedure|Thoracoscopy|Talc poudrage
79833459|NCT00859755|Drug|ARRY-403, glucokinase activator; oral|single dose, escalating
79833460|NCT00859755|Drug|Placebo; oral|matching placebo
79833461|NCT00754182|Device|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
79833462|NCT00754182|Device|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
80006206|NCT03579732|Drug|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. < 150 mg daily
80006207|NCT03579732|Other|No drug|Non-consumers
80006208|NCT01365533|Drug|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
80006209|NCT01365533|Drug|Placebo|Placebo, one tablet once daily, orally
80006210|NCT03583788|Behavioral|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
79833463|NCT00859911|Dietary Supplement|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
79833464|NCT00954694|Device|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
79833465|NCT00385723|Dietary Supplement|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
79833466|NCT00385723|Dietary Supplement|Placebo|matching placebo capsule daily for 4 months
79833467|NCT00698516|Drug|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
79378886|NCT01713868|Behavioral|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
79833468|NCT00859989|Behavioral|behavioral dietary intervention|
79833469|NCT00859989|Behavioral|exercise intervention|
79833470|NCT00859989|Behavioral|telephone-based intervention|
79833471|NCT00859989|Other|counseling intervention|
79833472|NCT00859989|Other|educational intervention|
79833473|NCT00859989|Other|immunoenzyme technique|
79833474|NCT00859989|Other|laboratory biomarker analysis|
79833475|NCT00859989|Other|questionnaire administration|
79378887|NCT01713868|Behavioral|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
79688995|NCT06236464|Other|Multiparameter analysis of each sample|Retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.
79688996|NCT06236438|Drug|Livmoniplimab|Intravenously (IV) Infusion
79688997|NCT06236438|Drug|Budigalimab|IV Infusion
79833476|NCT00859989|Other|study of socioeconomic and demographic variables|
79833477|NCT00859989|Procedure|evaluation of cancer risk factors|
80006211|NCT03583788|Other|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
80016766|NCT04879459|Other|Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder|The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
79238478|NCT03406468|Radiation|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
79238479|NCT03403998|Other|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
79238480|NCT03403998|Other|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
79238481|NCT03395145|Device|Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
79238482|NCT03377179|Drug|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
79378888|NCT04494906|Other|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
79378889|NCT04494906|Other|Square stepping exercise|Square stepping exercise
79378890|NCT01714024|Device|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
79688998|NCT06236438|Drug|Pembrolizumab|IV Infusion
79688999|NCT06236438|Drug|Pemetrexed|IV Infusion
79689000|NCT06236438|Drug|Cisplatin|IV Infusion
79833478|NCT00859989|Procedure|support group therapy|
79833479|NCT00679302|Drug|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
79833480|NCT00679302|Drug|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
79833481|NCT04011124|Drug|Fluzoparib|single dose on Day 1 and Day 12
79833482|NCT04011124|Drug|Rifampicin|QD on Day 5-14 for 10 days
79833483|NCT00862797|Other|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
79833484|NCT01047397|Drug|1278863A|25mg, 50mg, 100mg
79833485|NCT01047397|Drug|Placebo|matching placebo
80006212|NCT03548012|Behavioral|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
79238483|NCT03377179|Drug|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
80006213|NCT05272345|Procedure|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
80006214|NCT05191589|Other|Haptic|Trainees are randomized in this group to use the haptic device.
79238484|NCT03261102|Biological|Adalimumab|
79238485|NCT03104257|Drug|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
79238486|NCT03083548|Diagnostic Test|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
79238487|NCT03083548|Diagnostic Test|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
79378891|NCT01714024|Device|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
79378892|NCT01714336|Drug|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
79378893|NCT01714336|Drug|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
79689001|NCT06236438|Drug|Carboplatin|IV Injection
79689002|NCT06236438|Drug|Carboplatin|IV Infusion
80006215|NCT05477095|Biological|UB-313|A synthetic peptide-based immunotherapy
79689003|NCT06236412|Behavioral|Health education|Health education about the contents listed under each arm will be provided for the participants.
80006216|NCT05477095|Biological|Placebo|Normal saline
79238488|NCT03083548|Diagnostic Test|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
79378894|NCT01714492|Device|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
79378895|NCT01714804|Device|Accell Evo3 Prospective Use|
79378896|NCT01716208|Drug|Ofatumumab + Fresh Frozen Plasma|
80006217|NCT03547934|Device|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
80006218|NCT02259816|Drug|Telmisartan|
80006219|NCT02259816|Drug|Amlodipine|
80006220|NCT04639505|Diagnostic Test|ELISA|ELISA kit detecting the serum AMH level
80006221|NCT04639505|Diagnostic Test|Chemiluminescence|CLIA method detecting the serum AMH level
80006222|NCT03547310|Behavioral|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
79238489|NCT03052283|Diagnostic Test|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
79238490|NCT03045965|Procedure|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
79238491|NCT02960776|Behavioral|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
79238492|NCT02902952|Behavioral|Physical Exercise|An eight week physical exercise intervention
79378897|NCT00706992|Biological|ALVAC-MART-1 vaccine|Given subcutaneously
79378898|NCT00706992|Biological|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
79378899|NCT00706992|Biological|Aldesleukin|Given subcutaneously
79378900|NCT00706992|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
79378901|NCT00706992|Biological|incomplete Freund's adjuvant|Given subcutaneously
79689004|NCT06236386|Other|VR Experience|VR headset and video experience.
79689005|NCT06236373|Other|Focus Groups or Interviews|Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
79689006|NCT06236360|Behavioral|Mediterranean Diet Intervention|The primary goal is to evaluate whether tele-intervention can elevate the level of flavonoids, anthocyanins, proteins, omega-3 fatty acids, short fatty acids, fruits and vegetables, and fibers (all previously associated with a better response to immunotherapy) and limit foods with added sugars.
79689007|NCT06236347|Behavioral|Smoking cessation e-visit|Electronic visits (e-visits) for smoking cessation
79689008|NCT06236347|Behavioral|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
80006223|NCT03577548|Other|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
80006224|NCT01567735|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
79833486|NCT02564822|Procedure|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
79833487|NCT00862875|Drug|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
80006225|NCT04631471|Drug|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
80006226|NCT04631471|Procedure|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
80006227|NCT04631471|Drug|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
80006228|NCT03577470|Drug|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
80006229|NCT05269771|Drug|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
80006230|NCT03577392|Drug|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
80006231|NCT03577392|Drug|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
80006232|NCT05575778|Diagnostic Test|computed tomographic perfusion|The recruited patients would complete both pre- and post-operative computed tomographic perfusion
80006233|NCT03577314|Other|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
80006234|NCT04534517|Device|JJV Investigational Multifocal Contact Lens|TEST Lens
79378902|NCT02249728|Drug|IV PBT2 microtracer and oral PBT2 single dose|
79378903|NCT02249728|Drug|oral 14C-PBT2|
79378904|NCT03335202|Diagnostic Test|analysis of microbiome|microbial profiling by next generation sequencing
79378905|NCT03340194|Radiation|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
79533135|NCT01446757|Procedure|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
79533136|NCT01446757|Procedure|control group|No intervention
79533137|NCT01446770|Device|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
79689009|NCT06236334|Behavioral|ELFI lifestyle intervention|A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
79689010|NCT06236321|Other|Fast Field Cycling MRI scan|Three scans to be done over the period of cancer treatment
79689011|NCT06236321|Other|Provision of saliva and faecal samples|Three times over the period of cancer treatment
79833488|NCT02566616|Device|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
79833489|NCT00867477|Procedure|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
80006235|NCT04534517|Device|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
80006236|NCT03577236|Device|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
79378906|NCT03340194|Procedure|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
79378907|NCT03335124|Drug|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
79378908|NCT03335124|Drug|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
79378909|NCT03335124|Drug|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
79378910|NCT03335124|Drug|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
79533138|NCT01446783|Drug|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
79833490|NCT00867477|Behavioral|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
79833491|NCT00867477|Procedure|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
79833492|NCT00867555|Dietary Supplement|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
79833493|NCT00955006|Biological|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
79833494|NCT00955006|Biological|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
79238493|NCT02902952|Behavioral|Control Intervention|An eight week sedentary control intervention
79378911|NCT04072744|Device|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
79689012|NCT06236308|Biological|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
79378912|NCT04072744|Device|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
79378913|NCT03340116|Procedure|Burn surgery|Burn surgery including wound debridement, skin grafting
79378914|NCT03340116|Diagnostic Test|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
79238494|NCT02856412|Other|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
79238495|NCT02856412|Other|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
79238496|NCT02848131|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
79378915|NCT03340038|Other|Non-ICU Specialty ward|
79378916|NCT03339960|Other|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
79378917|NCT02248558|Behavioral|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
79378918|NCT02248558|Behavioral|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
79378919|NCT03339882|Drug|Remifemin|Remifemin 0.2g po bid*12 weeks at the beginning of the LHRH-a treatment
79689013|NCT06236308|Biological|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
79689014|NCT06236308|Biological|Placebo Comparator: Control Saline|2 mL Sterile, preservative free 0.9% NaCl
79689015|NCT06236295|Drug|SHR6508|SHR6508 will be administered to all the eligible subjects
79689016|NCT06236282|Device|ArtiSential®|Articulated laparoscopic device made by Livsmed Co, South Korea.
79378920|NCT03339804|Other|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
79378921|NCT02248636|Drug|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
79378922|NCT02248636|Drug|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
79533139|NCT01446783|Drug|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
79533140|NCT01446822|Device|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
79689017|NCT06236269|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
79833497|NCT02544165|Dietary Supplement|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
80006237|NCT03579654|Biological|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
79833498|NCT02544165|Other|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
79833499|NCT02544165|Other|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
79833500|NCT00955084|Drug|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
79238497|NCT02848131|Drug|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
80006238|NCT04508075|Biological|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
79238498|NCT02792075|Other|5-year Follow-up|
79238499|NCT02712385|Other|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
79238500|NCT02712385|Device|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
79238501|NCT02712385|Procedure|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
79533141|NCT01446822|Device|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
79238502|NCT02712385|Behavioral|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
79238503|NCT02650778|Procedure|Breast ultrasound|automated whole breast ultrasound
79238504|NCT02619760|Drug|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
79238505|NCT02619760|Drug|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
79533142|NCT01446835|Device|nelfilcon A contact lens with print|Investigational spherical contact lens
79689018|NCT06236256|Device|MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system|The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
79238506|NCT02613988|Device|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
79689019|NCT06236256|Other|MDI/CSII|Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
79833501|NCT05343156|Drug|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
79833502|NCT00955162|Drug|Buprenorphine (Subutex)|Sublingual tablet
80006239|NCT04508075|Biological|Placebo|Placebo manufactured by PT. Bio Farma
80006240|NCT05259397|Drug|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
79238507|NCT02613988|Device|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
79238508|NCT02613988|Device|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
79238509|NCT02613988|Device|Dynamic susceptibility contrast MRI|dual echo EPI sequence
79238510|NCT02600936|Device|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
79378923|NCT02494362|Other|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
79378924|NCT03339648|Behavioral|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
79378925|NCT02248714|Dietary Supplement|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
79533143|NCT01446835|Device|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
79533144|NCT01446848|Dietary Supplement|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
79238511|NCT02590601|Drug|Bromocriptine|
79238512|NCT02590601|Other|Guideline-driven medical therapy (GDMT)|
79238513|NCT02554773|Drug|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
79302934|NCT03209323|Device|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
79378926|NCT02494128|Other|Education|Education in group leadership
79378927|NCT03331224|Device|OTSC|OTSC placement
79533145|NCT01446887|Other|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
79238514|NCT02406274|Other|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated & or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) & record their findings. They will then interpret the CESM & record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding & will either be called negative & followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
79238515|NCT02393885|Device|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
79238516|NCT02240498|Drug|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
79378928|NCT03331224|Device|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
79533146|NCT01446900|Drug|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
79533147|NCT01446900|Drug|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
79833503|NCT00955162|Drug|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
79833504|NCT00742664|Behavioral|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
79533148|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
79833505|NCT00742664|Behavioral|Wait-list control|The subject will not receive active treatment during this interval.
79833506|NCT00862953|Dietary Supplement|Normal protein energy-restricted|Normal protein diet energy restricted
79533149|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
79533150|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
79533151|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
79833507|NCT00862953|Dietary Supplement|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
79533152|NCT01446926|Biological|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
79533153|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
79689020|NCT06236243|Dietary Supplement|Korean Red Ginseng Extract Powder 120 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
79833508|NCT00949546|Drug|etanercept|etanercept 50 mg sc twice weekly
79833509|NCT00742742|Behavioral|healthy life style education|healthy life style education
79833510|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
79238517|NCT02240498|Drug|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
79378929|NCT03331146|Drug|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
79378930|NCT03331146|Drug|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
79378931|NCT02491866|Other|to develop and validate a Computerized Adaptative Testing|"Elaboration of a pool of items, based on literature review and interview with patients.~Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~Metrological validation of the CAT.~Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
79533154|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
79533155|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
79689021|NCT06236243|Dietary Supplement|Korean Red Ginseng Extract Powder 500 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
79689022|NCT06236243|Dietary Supplement|Placebo|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
79833511|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
79833512|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
79833513|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
79533156|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
79533157|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
79533158|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
79533159|NCT01446952|Drug|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
79533160|NCT01446978|Biological|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
79533161|NCT01446978|Biological|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
79533162|NCT01446991|Drug|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
79833514|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
79833515|NCT00949624|Drug|Docetaxel|Intravenous 100 mg/m2 every three weeks
79833516|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
79833517|NCT00949624|Drug|AG-013736|Oral tablet 5 mg BID continuous
79833518|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
79833519|NCT02560272|Biological|Minhai-HIB|0.5ml, intramuscular
79833520|NCT02560272|Biological|Act-HIB®|0.5ml, intramuscular
79833521|NCT04019379|Other|Low Calcium/High Phosphorus Diet|Controlled research diet of low calcium/high phosphorus
79238518|NCT02240498|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
79238519|NCT02240498|Device|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
79238520|NCT02240498|Device|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
79238521|NCT02240498|Device|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
79378932|NCT03331068|Behavioral|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
79378933|NCT02491554|Device|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
79238522|NCT02240498|Device|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
79378934|NCT02491554|Device|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
79378935|NCT02491320|Other|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
79378936|NCT02491320|Drug|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
79378937|NCT02491242|Other|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
79378938|NCT03330990|Drug|Entrectinib|600 mg oral capsule (fasted and fed)
79533163|NCT01446991|Drug|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
79533164|NCT01447043|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
79533165|NCT01447056|Biological|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10^7 cells/m2; Dose Level 2: 1×10^8 cells/m2; Dose Level 3: 2×10^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
79689023|NCT06236230|Drug|levodopa/carbidopa/entacapone|"On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study."
79689024|NCT06236217|Other|Carotid Ultrasound|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
79689025|NCT06236217|Other|Electrical cardiometry|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
79689026|NCT06236204|Procedure|Arthroscopic Scapholunate Ligament Reconstruction|reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
79689027|NCT06236191|Device|transcranial pulsed current stimulation|A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
79689028|NCT06236191|Drug|Melatonin|Melatonin
79689029|NCT06236178|Drug|Corticosteroid|1 ml of 40 mg methylprednisolone acetate
79689030|NCT06236178|Drug|Autologous Blood|1 ml of autologous venous blood
79689031|NCT06236178|Drug|Local Anesthetic|1 ml of 2% prilocaine HCl
79689032|NCT06236152|Drug|Ferrous sulfate|Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.
79833522|NCT04019379|Other|High Calcium/Low Phosphorus Diet|Controlled research diet of high calcium/low phosphorus
79833523|NCT00690482|Drug|AZD1981|Oral tablet, twice daily
79833524|NCT00690482|Drug|Placebo|Placebo Oral tablet, twice daily
79833525|NCT00385255|Biological|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
79833526|NCT00385255|Biological|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
79833527|NCT04009005|Behavioral|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
79833528|NCT05299996|Procedure|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
80006241|NCT05259397|Drug|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
79833529|NCT02560506|Device|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
80006242|NCT03579576|Drug|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
79833530|NCT04005339|Drug|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
80006243|NCT01364519|Drug|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
80006244|NCT01364519|Drug|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
80006245|NCT03579420|Behavioral|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
79833531|NCT04005339|Drug|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
79833532|NCT04005339|Drug|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
80006246|NCT03579420|Behavioral|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
80006247|NCT01370057|Device|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
80006248|NCT02239146|Drug|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
79238523|NCT02240498|Device|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
79833533|NCT00949780|Drug|Chloral Hydrate|
80006249|NCT02239146|Drug|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
80006250|NCT03225365|Biological|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
79833534|NCT02560350|Other|no intervention|no intervention
79833535|NCT02544243|Drug|Vinorelbine|
79833536|NCT02544243|Drug|Gemcitabine|
80006251|NCT02831257|Drug|AZD2014|
80006252|NCT03577158|Device|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
80006253|NCT03577158|Device|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
80006254|NCT03577158|Device|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
79833537|NCT02544243|Drug|Cisplatin|
79833538|NCT04061408|Radiation|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
79833539|NCT04011670|Other|200 mg caffeine tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
79833540|NCT04011670|Other|Non-active tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
79833541|NCT01581073|Drug|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
80006255|NCT03092609|Behavioral|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
79378939|NCT03330990|Drug|Midazolam Hydrochloride|2 mg oral syrup (fasted)
79689033|NCT06236152|Drug|Deltacortril|Deltacortil 10mg was given orally once daily for 4 to 6 weeks
79689034|NCT06236139|Biological|Anti-STEAP1 CAR T-cells|Given IV
79238524|NCT02240498|Device|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
79302935|NCT03209323|Device|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
79689035|NCT06236139|Procedure|Biopsy|Undergo tumor biopsy
79689036|NCT06236139|Procedure|Biospecimen Collection|Undergo blood sample collection
79689037|NCT06236139|Procedure|Bone Scan|Undergo NM bone scan
79689038|NCT06236139|Procedure|Computed Tomography|Undergo CT scan
79689039|NCT06236139|Drug|Cyclophosphamide|Given IV
79689040|NCT06236139|Procedure|Echocardiography|Undergo ECHO
79689041|NCT06236139|Drug|Enzalutamide|Given PO
79689042|NCT06236139|Drug|Fludarabine|Given IV
80006256|NCT03092609|Behavioral|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
80006257|NCT02253914|Drug|BILR 355 BS, solution|
79238525|NCT02240498|Device|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
79833542|NCT00742820|Drug|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
79833543|NCT00742820|Drug|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
79833544|NCT00742820|Dietary Supplement|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
79833545|NCT00860145|Procedure|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
79833546|NCT00860145|Procedure|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
79833547|NCT00754728|Device|JACTAX DES|Drug Eluting Stent
79238526|NCT02178098|Drug|ETC-1002|ETC-1002 capsules taken once daily
79833548|NCT05301166|Behavioral|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
80006258|NCT02253914|Drug|BILR 355 BS, tablet|
79238527|NCT02178098|Drug|Placebo|Placebo capsules taken once daily
79238528|NCT02087852|Other|salvia for germline DNA|
79378940|NCT03335046|Behavioral|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
80006259|NCT02253914|Drug|Ritonavir|
79378941|NCT03335046|Behavioral|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
79378942|NCT03330912|Device|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
79689043|NCT06236139|Procedure|Leukapheresis|Undergo leukapheresis
79689044|NCT06236139|Procedure|Magnetic Resonance Imaging|Undergo MRI
79689045|NCT06236139|Procedure|Multigated Acquisition Scan|Undergo MUGA
79689046|NCT06236139|Procedure|Positron Emission Tomography|Undergo PET scan
79689047|NCT06236126|Procedure|1% Lidocaine Injection|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal) or subcutaneously (Group Subcutaneous).
79533166|NCT01447069|Drug|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains <100 bpm
79238529|NCT02087852|Behavioral|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
79378943|NCT03330912|Device|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
79533167|NCT01447095|Drug|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
79533168|NCT01447095|Drug|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
79533169|NCT01447095|Drug|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
79238530|NCT02087852|Behavioral|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
79238531|NCT02087852|Other|Blood draw|
79689048|NCT06236100|Behavioral|Strengthening Families Program + Family Advocate|This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.
79833549|NCT05301166|Other|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
80006260|NCT02253914|Drug|Placebo|
80006261|NCT01364675|Drug|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
79238532|NCT02087852|Behavioral|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
79238533|NCT01885689|Drug|clofarabine|Given IV
79238534|NCT01885689|Drug|melphalan|Given IV
79238535|NCT01885689|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
79833550|NCT00742898|Other|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
80006262|NCT01364675|Drug|Placebo tablet|Identical Placebo Tablet
79378944|NCT03330912|Device|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
79689049|NCT06236100|Behavioral|Strengthening Families Program|This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.
80006263|NCT03577080|Other|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
79238536|NCT01885689|Drug|tacrolimus|Given IV or PO
79238537|NCT01885689|Drug|sirolimus|Given PO
79238538|NCT01885689|Other|Pharmacological Study|Correlative studies
79238539|NCT01798004|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
79238540|NCT01798004|Drug|Busulfan|Given IV
79378945|NCT03330912|Device|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
79689050|NCT06236074|Other|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
80006264|NCT02253758|Drug|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
80006265|NCT05191511|Radiation|Far- infrared|safety of far- infrared
79238541|NCT01798004|Drug|Cisplatin|Given IV
79238542|NCT01798004|Drug|Cyclophosphamide|Given IV
79238543|NCT01798004|Drug|Doxorubicin Hydrochloride|Given IV
79238544|NCT01798004|Drug|Etoposide|Given IV
79378946|NCT03330912|Device|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
79378947|NCT03339414|Other|collect blood|collect blood at different time point
79378948|NCT03339336|Drug|BIIB074|Administered as specified in the treatment arm.
79238545|NCT01798004|Radiation|External Beam Radiation Therapy|Undergo EBRT
79238546|NCT01798004|Biological|Filgrastim|Given SC or IV
79238547|NCT01798004|Other|Laboratory Biomarker Analysis|Optional correlative studies
79238548|NCT01798004|Drug|Melphalan|Given IV
79238549|NCT01798004|Drug|Mesna|Given IV
79238550|NCT01798004|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
79238551|NCT01798004|Other|Pharmacological Study|Correlative studies
79238552|NCT01798004|Drug|Topotecan Hydrochloride|Given IV
79238553|NCT01798004|Drug|Vincristine Sulfate|Given IV
79302936|NCT03209323|Device|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
79302937|NCT02477969|Drug|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
79302938|NCT02477969|Drug|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
79378949|NCT03339336|Drug|Placebo|Administered as specified in the treatment arm.
79378950|NCT01785875|Drug|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
79378951|NCT02496546|Drug|LEO 32731 cream|Applied for 3 weeks
79378952|NCT02496546|Drug|LEO 32731 cream vehicle|Applied for 3 weeks
79689051|NCT06236074|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
80006266|NCT03100825|Drug|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
80006267|NCT03547232|Drug|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
80006268|NCT03547232|Drug|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
80006269|NCT02250534|Other|Very low nicotine content cigarettes|
79833551|NCT04040283|Procedure|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
80006270|NCT01370135|Drug|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
80006271|NCT05252221|Other|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
80006272|NCT03634787|Diagnostic Test|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
80006273|NCT05266586|Drug|Obicetrapib|tablets
80006274|NCT05266586|Drug|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
80006275|NCT05266586|Other|Obicetrapib placebo|tablets; no active ingredient
79378953|NCT03330756|Procedure|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
79533170|NCT01447108|Device|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
79378954|NCT03330756|Procedure|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
79378955|NCT03334890|Diagnostic Test|plasma mSEPT9 level|the plasma level of methylated SEPT9
79378956|NCT03330678|Dietary Supplement|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
79533171|NCT01447160|Drug|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
79533172|NCT01447173|Drug|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
79533173|NCT01447186|Behavioral|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
79533174|NCT01447186|Behavioral|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
80006276|NCT05266586|Other|Ezetimibe placebo|capsules; no active ingredient
80006277|NCT01370291|Other|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
80006278|NCT01370291|Other|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
79533175|NCT01447186|Behavioral|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
79533176|NCT01447199|Behavioral|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
79533177|NCT01447212|Drug|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
79533178|NCT01447212|Drug|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
79689052|NCT06236061|Drug|LCZ|LCZ 200 mg
79689053|NCT06236061|Drug|LCZ/AML|LCZ/AML 200 mg/2.5 mg, 200 mg/5 mg and 200 mg/10 mg
79689054|NCT06236048|Procedure|MRI scan|7 Tesla MRI scan
79689055|NCT06236048|Procedure|PET-MR scan|18F-fluorodeoxyglucose PET-MR scan
79689056|NCT06236022|Drug|Sirolimus|at a dose of 2 mg once daily
79689057|NCT06236009|Drug|TAK-004|TAK-004 subcutaneous injections.
79689058|NCT06236009|Drug|Placebo|Matching- placebo subcutaneous injections.
79689059|NCT06235983|Drug|LY3537982|Administered orally.
79689060|NCT06235957|Other|Cast 3 weeks|patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
79689061|NCT06235957|Other|Brace 1 week|patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
80006279|NCT01370291|Other|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
80006280|NCT05575544|Procedure|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
80006281|NCT01364831|Behavioral|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
80006282|NCT01364909|Other|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
80006283|NCT01364909|Other|Usual practice|These patients will not receive exercise early in their intensive care admission
80006284|NCT05179772|Drug|Olanzapine|Olanzapine (2.5 mg to 20 mg)
79833552|NCT05435430|Other|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
79833553|NCT01324843|Drug|EMLA Cream|
79833554|NCT01324843|Drug|Aveeno Daily Moist|
79833555|NCT01324843|Device|Derma Vax|
79833556|NCT01324843|Procedure|Intradermal Electroporation|
79378957|NCT03330600|Behavioral|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
79533179|NCT01447212|Drug|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
79833557|NCT01324843|Procedure|Visual Analogue Scale|
79833558|NCT01324843|Procedure|Present Pain Intensity|
79833559|NCT01324843|Procedure|McGill Pain Questionnaire|
79833560|NCT01324843|Procedure|Skin Assessment|
79833561|NCT02566460|Other|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
79689062|NCT06235944|Procedure|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
79833562|NCT00863031|Behavioral|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
80006285|NCT05191199|Diagnostic Test|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
79833563|NCT00863031|Behavioral|Video-viewing|Three sessions of viewing health educational videos.
79833564|NCT00949936|Device|CAdisc™-L (Total Disc Replacement)|
79833565|NCT00742976|Drug|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
79833566|NCT00742976|Drug|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
79833567|NCT04040985|Procedure|Total Knee Arthroplasty using Legion Total Knee System|Primary Total Knee Arthroscopy using Legion Total Knee System
79833568|NCT00955240|Biological|cetuximab|
79833569|NCT00955240|Drug|cisplatin|
79833570|NCT00955240|Drug|fluorouracil|
79833571|NCT00955240|Other|laboratory biomarker analysis|
79833572|NCT00955240|Radiation|radiation therapy|
79833573|NCT02566382|Procedure|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
79833574|NCT03844893|Procedure|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
79689063|NCT06235944|Procedure|Sacral erector spinae block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
79689064|NCT06235931|Drug|Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib|"Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day)."
79833575|NCT05261100|Other|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
79833576|NCT05261100|Other|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
79833577|NCT00867867|Drug|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
79833578|NCT00867867|Drug|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
79833579|NCT00867867|Drug|Placebo|9.3 mg once per day, 6 days per week, for 9 months
79833580|NCT00955318|Drug|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
79833581|NCT01044667|Behavioral|GI and Quality of Life Assessment|
79533180|NCT01447212|Drug|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
79833582|NCT01766492|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
79833583|NCT00860223|Drug|Digoxin|
79833584|NCT00860223|Drug|Neratinib|HKI-272
79238554|NCT01770418|Radiation|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
79833585|NCT05223504|Device|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
79833586|NCT01044823|Other|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
79833587|NCT02564276|Procedure|Sentinel lymph node biopsy|
79833588|NCT00860301|Other|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
79833589|NCT01047631|Behavioral|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Exercise classes & activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
79833590|NCT01047631|Behavioral|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
79833591|NCT04018287|Other|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
79833592|NCT00698204|Drug|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
80006286|NCT05417503|Other|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
79833593|NCT00698204|Drug|placebo|Subject was asked to take placebo each day that radiation therapy was given.
79833594|NCT02560194|Procedure|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
79833595|NCT02560194|Other|Fecal occult blood test|Test for hemoglobin in faeces
79833596|NCT00549718|Drug|Lurasidone HCl|Once daily
79833597|NCT00863187|Biological|rituximab|b cell depletion
79238555|NCT01766297|Radiation|Proton Radiotherapy|
79833598|NCT00754884|Drug|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
79833599|NCT00754884|Drug|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
79833600|NCT00743210|Drug|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
79833601|NCT00743210|Drug|Placebo|Placebo, 3 grams once per day for 3 weeks.
79833602|NCT00371761|Biological|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
79238556|NCT01758445|Radiation|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol & physician.
79533181|NCT01447238|Device|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
79833603|NCT00371761|Drug|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
79833604|NCT05435274|Drug|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
79833605|NCT03888794|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
79833606|NCT05351398|Drug|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
79833607|NCT05351398|Drug|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
79833608|NCT00860613|Other|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
79833609|NCT00754962|Drug|protriptyline|10 mg tablet
79533182|NCT01447251|Behavioral|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS <4.5, moderate risk as PreDx DRS ≥4.5 and <8.0, and high risk as PreDx DRS ≥8.0.
79833610|NCT02564666|Other|telephone counseling|regular telephone counseling for compliance and advese event
79833611|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
79833612|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
79533183|NCT01447264|Procedure|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
79533184|NCT01447264|Procedure|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
79833613|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
79833614|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
79833615|NCT00868023|Drug|Placebo|Placebo
79238557|NCT01693380|Biological|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
79238558|NCT01693380|Biological|Control vaccine|"Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
79378958|NCT03330600|Behavioral|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
79533185|NCT01447277|Procedure|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
79833616|NCT05300386|Drug|Escitalopram|We use Escitalopram 5~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
79833617|NCT01050127|Drug|ABT-436|See Arm Description for details.
79833618|NCT01050127|Drug|Placebo|See Arm Description for details.
79833619|NCT00955396|Drug|GSK1014802|Tablets
79833620|NCT00955396|Drug|Placebo|Tablets
79833621|NCT00863499|Drug|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
79238559|NCT01630434|Device|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
79378959|NCT04576559|Other|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
79533186|NCT01447277|Procedure|Femoral Block only|Performing a preoperative sciatic nerve block only
79533187|NCT01447303|Other|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
79833622|NCT00863499|Drug|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
79833623|NCT04061642|Device|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
79833624|NCT03992053|Other|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
79833625|NCT00755118|Drug|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
79238560|NCT01630434|Device|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
79689065|NCT06235918|Drug|Tislelizumab|Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
79833626|NCT00755118|Drug|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
79833627|NCT00755118|Drug|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
79238561|NCT01542879|Procedure|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
79238562|NCT01542879|Procedure|18-F-FDG PET scan|
79833628|NCT00755118|Drug|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
79833629|NCT00755118|Drug|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
79833630|NCT00755118|Drug|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
79238563|NCT01542879|Drug|Ferumoxytol|
79238564|NCT01542879|Procedure|18-F-FDG PET/MR scan|
79238565|NCT01492972|Radiation|Radiation|"Consists of:~Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
79238566|NCT01492972|Drug|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
79238567|NCT01376752|Procedure|Maximal cytoreductive surgery|Maximal cytoreductive surgery
79378960|NCT04576559|Other|Regular dental visual aids|Regular dental visual aids
79533188|NCT01447316|Other|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
79533189|NCT01447342|Device|Cryo-Touch II|Percutaneous treatment with the device
79238568|NCT01376752|Drug|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
79238569|NCT01256398|Biological|Alemtuzumab|Given IV
79238570|NCT01256398|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
79238571|NCT01256398|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
79238572|NCT01256398|Drug|Cyclophosphamide|Given IV
79238573|NCT01256398|Drug|Cytarabine|Given IV
79238574|NCT01256398|Drug|Dasatinib|Given PO
79238575|NCT01256398|Drug|Daunorubicin Hydrochloride|Given IV
79238576|NCT01256398|Drug|Dexamethasone|Given PO or IV
79689066|NCT06235918|Drug|Nab-paclitaxel|260mg/m^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
79689067|NCT06235918|Drug|Carboplatin|AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
79689068|NCT06235866|Other|Pulmonary rehabilitation|According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.
79689069|NCT06235853|Diagnostic Test|Blood serum: sUPAR, PAI-1, IL-8.|The concentration of described biomarkers were measured in serum.
79238577|NCT01256398|Drug|Etoposide Phosphate|Given IV
79238578|NCT01256398|Biological|Filgrastim|Given SC
79238579|NCT01256398|Drug|Fludarabine Phosphate|Given IV
79378961|NCT03330522|Other|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
79533190|NCT01447355|Drug|cholecalciferol|Given PO
79533191|NCT01447368|Drug|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
79533192|NCT01447368|Procedure|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
79533193|NCT01447394|Biological|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
79689070|NCT06235853|Diagnostic Test|Urine: IL-8, APOE, VEGF.|The concentration of described biomarkers were measured in urine.
79689071|NCT06235840|Behavioral|working memory adaptive training|The computerized n-back training lasted 4 weeks and consisted of 12 training sessions, 3 per week, about 45 minutes for each
79689072|NCT06235840|Behavioral|multi-domain non-adaptive control training|The cognitive training in active control groups included cognitive tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. The training schedule in active control groups was the same as in the experimental groups.
79533194|NCT01447394|Biological|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
79533195|NCT01447394|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
79833631|NCT00755352|Drug|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
79833632|NCT00755352|Drug|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
79833633|NCT00549640|Drug|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
79533196|NCT01447459|Behavioral|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
79833634|NCT00549640|Drug|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
79833635|NCT00868335|Device|Activ C disc prosthesis|cervical disc prosthesis
79833636|NCT00868335|Procedure|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
79238580|NCT01256398|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
79533197|NCT01447472|Drug|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
79833637|NCT00860691|Procedure|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
79833638|NCT00860691|Procedure|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
79238581|NCT01256398|Other|Laboratory Biomarker Analysis|Correlative studies
79238582|NCT01256398|Drug|Leucovorin Calcium|Given IV or PO
79238583|NCT01256398|Drug|Melphalan|Given IV
79378962|NCT03330522|Other|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. …. If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
79533198|NCT01447485|Drug|Valsartan (VAL489)|
79689073|NCT06235827|Dietary Supplement|Green tean group|Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.
79833639|NCT00860691|Other|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
80006287|NCT05417503|Other|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
79378963|NCT03339024|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
79378964|NCT03339024|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
79238584|NCT01256398|Drug|Mercaptopurine|Given PO
79238585|NCT01256398|Drug|Methotrexate|Given IT, IV, or PO
79238586|NCT01256398|Biological|Pegfilgrastim|Given SC
79238587|NCT01256398|Other|Pharmacological Study|Correlative studies
79238588|NCT01256398|Drug|Tacrolimus|Given IV or PO
79238589|NCT01256398|Drug|Vincristine Sulfate|Given IV
79238590|NCT01230866|Radiation|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
79238591|NCT01230866|Radiation|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
79302939|NCT02477969|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
79378965|NCT06038526|Procedure|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
79378966|NCT06038526|Procedure|Bronchoscopy|Undergo bronchoscopy
79689074|NCT06235827|Dietary Supplement|Control group|Patients in Group B will not be consuming green tea during 6 months of study period.
79689075|NCT06235775|Drug|GV1001 Placebo|0.9% normal saline
79689076|NCT06235775|Drug|GV1001 1.12mg|Lyophilized peptide from hTERT
79833640|NCT04444804|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
79833641|NCT04444804|Drug|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
79833642|NCT05226741|Device|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
79833643|NCT04010890|Behavioral|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
79833644|NCT00921882|Procedure|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
79833645|NCT00863577|Drug|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
79833646|NCT05351320|Drug|WX-0593 Tablets|WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
80006288|NCT05575232|Behavioral|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
80006289|NCT01370681|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001|
80006290|NCT01370681|Drug|Period I : CJ30001, Period II : HKB0701 and SLM0807|
79689077|NCT06235762|Behavioral|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
80006291|NCT02848326|Drug|Atogepant|Atogepant capsule.
79689078|NCT06235749|Drug|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
79689079|NCT06235749|Drug|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
80006292|NCT02848326|Drug|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
79302940|NCT02477969|Drug|Metformin|0.5mg,oral,tid.
79302941|NCT03195205|Diagnostic Test|OraQuick HCV Rapid Antibody Test|HCV Screening
79302942|NCT02481401|Behavioral|Intensive Individual Intervention Program|
79302943|NCT02481401|Behavioral|Peer-To-Peer Program Intervention|
79378967|NCT06038526|Biological|Canakinumab|Given SC
79378968|NCT06038526|Procedure|Carbon Monoxide Measurement|Undergo CO testing
79302944|NCT03209011|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
79302945|NCT02481323|Drug|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
79378969|NCT06038526|Other|Survey Administration|Ancillary studies
79378970|NCT06038461|Drug|Surufatinib Combined With Temozolomide and S-1|"Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D"
79689080|NCT06235697|Radiation|Radiation|"46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate~+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months"
79689081|NCT06235697|Radiation|Radiation SBRT only|25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT)
79833647|NCT05351320|Drug|chemotherapy|Platinum-based chemotherapy
79833648|NCT05351320|Radiation|Thoracic Radiation Therapy（TRT）|Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
79833649|NCT00868413|Drug|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
79833650|NCT00868413|Drug|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
79833651|NCT00868413|Drug|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
79833652|NCT05351008|Other|Cognitive physical therapy|Cognitive therapy techniques, TENS, ultrasound, massage
79833653|NCT05351008|Other|Physical therapy|TENS, ultrasound, massage, exercise
79833654|NCT00860769|Behavioral|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
79833655|NCT00860769|Behavioral|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
79833656|NCT04010500|Device|no mouthguard|Control (not using mouthguard)
79833657|NCT04010500|Device|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
79833658|NCT04010500|Device|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
80006293|NCT05190965|Device|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
80006294|NCT02477657|Procedure|Paracentesis|Paracentesis
79302946|NCT02481323|Drug|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
79302947|NCT03197779|Drug|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
79302948|NCT03197779|Drug|Aspirin|Oral administration
79302949|NCT03197779|Other|Placebo|Oral administration
79378971|NCT06038422|Drug|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
79833659|NCT04040829|Behavioral|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
79833660|NCT04040829|Behavioral|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
79833661|NCT04040829|Other|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
79833662|NCT03897348|Drug|Placebo|Oral medication
79833663|NCT03897348|Drug|Lacosamide 100 mg|Oral medication
79833664|NCT03897348|Drug|Lacosamide 200 mg|Oral medication
79833665|NCT04010734|Procedure|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
79833666|NCT00868491|Drug|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
80006295|NCT02477657|Device|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
79238592|NCT01151423|Biological|Caplacizumab|"Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~Subjects received caplacizumab up to 30 days after the last PE session."
79378972|NCT06038409|Drug|Ketamine|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
79378973|NCT06038383|Device|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
79378974|NCT06038383|Device|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
79378975|NCT06038383|Device|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
79378976|NCT06038383|Device|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
79378977|NCT06038370|Behavioral|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
79378978|NCT06038357|Behavioral|CBITS|The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
79533199|NCT01447498|Other|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~screening and risk assessment~control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: < 60: 0; 60-69: 1; 70-79: 2; >=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
79533200|NCT01447524|Behavioral|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
79533201|NCT01447537|Other|Exercise + relaxation|Exercise + relaxation
79833667|NCT00868491|Radiation|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
80006296|NCT02477657|Device|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
80006297|NCT04450043|Behavioral|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
80006298|NCT04450043|Behavioral|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
79833668|NCT00868491|Drug|cetuximab, cisplatin|"cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
79378979|NCT06038357|Other|TAU+|In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
79378980|NCT06038344|Behavioral|Gluten-free food guide teaching|Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
79833669|NCT00955630|Drug|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
79833670|NCT00955630|Drug|ranibizumab|prn injections of ranibizumab throughout the study
79833671|NCT00868569|Procedure|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
79833672|NCT00868569|Procedure|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
79833673|NCT00863733|Drug|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
79238593|NCT01151423|Biological|Placebo|"Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~Subjects received placebo up to 30 days after the last PE session."
79238594|NCT01040026|Other|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at <1x10e5/kg
79238595|NCT01020383|Drug|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
79238596|NCT01020383|Drug|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
79238597|NCT00889876|Drug|Metformin group|2000 mg/day for one year
79238598|NCT00889876|Behavioral|Exercise|3 times/week with a personal coach for one year. Endurance training.
79238599|NCT00625417|Procedure|breast biopsy|
79238600|NCT00625417|Procedure|histopathologic examination|
79238601|NCT00625417|Procedure|light-scattering spectroscopy|
79238602|NCT00625417|Procedure|therapeutic conventional surgery|
79302950|NCT03197623|Drug|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
79302951|NCT03197623|Drug|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
79378981|NCT06038279|Drug|INI-2004|INI-2004 (a toll-like receptor [TLR]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
79378982|NCT06038279|Drug|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
79378983|NCT06038266|Procedure|cardiac surgeries|predict perioperative risk factors for readmission after cardiac surgeries
79533202|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
79533203|NCT01447550|Drug|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
79533204|NCT01447563|Drug|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
79533205|NCT01447563|Drug|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
79833674|NCT00549562|Drug|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
79833675|NCT00860925|Drug|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
79833676|NCT00860925|Drug|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
79833677|NCT00860925|Drug|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
79833678|NCT00860925|Drug|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
80006299|NCT04450043|Behavioral|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
79833679|NCT00681564|Procedure|One-Stage Full-Mouth Disinfection|"Scaling and root planing, four quadrants in one session~Tongue brushing with a 1% chlorhexidine gel (1 minute)~Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~Subgingival chlorhexidine (1%) irrigation in all pockets~Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~Basic oral hygiene instructions~Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
79833680|NCT00681564|Procedure|Periodontal care|"Basic oral hygiene instructions~Supragingival plaque removal"
79833681|NCT05350852|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
79833682|NCT00955786|Drug|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
80006300|NCT01567514|Procedure|Glass ionomer cement lining|Resin-modified glass ionomer lining
80006301|NCT01364987|Drug|ASP015K|oral
79238603|NCT00587067|Drug|FLOXURIDINE|"[0.16* mg/kg/day X 30 ml] / pump flow rate~* If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
79238604|NCT00579514|Genetic|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
79238605|NCT00565617|Device|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
79689082|NCT06235684|Other|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion|During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
80006302|NCT01364987|Drug|Mycophenolate Mofetil|oral
80006303|NCT01365923|Drug|remifentanil|remifentanil effect site-TCI 2-4ng/ml
79533206|NCT01447589|Drug|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
79533207|NCT01447589|Radiation|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
79689083|NCT06235671|Procedure|Chiropractic care|6 weeks of chiropractic care
79533208|NCT01447602|Behavioral|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
79533209|NCT01447615|Behavioral|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
79689084|NCT06235658|Behavioral|Gentle Yoga|Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
79833683|NCT04237012|Drug|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
79833684|NCT04237012|Other|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
80006304|NCT01365923|Drug|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
80006305|NCT03579342|Behavioral|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
80006306|NCT03579342|Behavioral|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
80006307|NCT03128723|Device|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
80006308|NCT05575154|Device|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
80006309|NCT03579264|Behavioral|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
79238606|NCT00453154|Drug|Carboplatin|Given IV
79238607|NCT00453154|Drug|Cisplatin|Given IV
79238608|NCT00453154|Drug|Etoposide|Given IV
79238609|NCT00453154|Other|Laboratory Biomarker Analysis|Correlative studies
79238610|NCT00453154|Other|Placebo Administration|Given PO
79238611|NCT00453154|Drug|Sunitinib Malate|Given PO
79238612|NCT00309257|Drug|ACE I, ATA II and Statins|
79302952|NCT03195595|Device|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
79533210|NCT01447615|Behavioral|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
79533211|NCT01447615|Other|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
79833685|NCT00863889|Drug|Depomedrol injection|1 cc of Depomedrol 80
79833686|NCT00863889|Drug|Lidocaine, Marcaine|4 cc of each local anesthetic
79533212|NCT01447641|Other|Polysomnography|Overnight physiological recording of sleep
79378984|NCT06038214|Other|core exercises|"1.5 minutes walking 2. Stretching exercise~hallowing in supine and side lying position~Bracing in supine and side lying position~Bracing on the prone and forearms~Bracing in the crawling position~Bracing in laptop, half-lap and standing position~Heel slide exercise~Bridge building exercise~Unilateral limb flexion exercise in crawling position~Reciprocal heel slide exercise in supine position~Bilateral lower extremity lifting exercise~Unilateral lower extremity flexion in bridging position~Side bridging exercise with knees extended~Unilateral lower extremity extension in crawling position~Contralateral lower and upper extremity lift in the crawling position~Straight and oblique trunk flexion~Straight and oblique trunk flexion with hip and knee flexed to 90°~bracing on the ball~squat~bracing while walking"
79533213|NCT01447641|Other|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
79689085|NCT06235645|Diagnostic Test|Lung ultrasound (LUS)|"If included, an LUS will be performed by an experienced operator, blinded to the results of the chest CT and PFT.~A linear probe (4 to 12 MHz) will be used. The patient will be installed́ in a semi-seated position with the homolateral arm above the head for the anterior and axillary evaluation then, depending on his comfort, in a seated position or in right then left lateral decubitus, arms alongside the body, for the posterior evaluation. It will be practiced by experienced operators (pneumologist) and according to a validated protocol allowing the exploration of 14 intercostal spaces. LUT will be timed, recorded and anonymized.~The operator will note the 3 ultrasound signs (total number of B lines, pleural line thickening and percentage of pleural line irregularity), their location and severity.~The radiologist, on his part, will evaluate the patient's chest CT (gold standard), blinded to the results of the LUS, to make or not the diagnosis of RA-ILD."
79833687|NCT05299450|Dietary Supplement|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
79533214|NCT01447654|Drug|Losartan|100 mg for 12 months.
79533215|NCT01447654|Drug|Placebo|100 mg for 12 months.
79533216|NCT01447693|Procedure|application of ointment (olive-omega 3 ointment)|
79533217|NCT01447732|Drug|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
79833688|NCT05299450|Behavioral|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
79833689|NCT05299450|Other|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
79833690|NCT00861003|Device|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
79238613|NCT00309257|Drug|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
79238614|NCT00258960|Drug|Liposomal Doxorubicin|
79238615|NCT00258960|Drug|Cyclophosphamide|
79238616|NCT00258960|Drug|Trastuzumab|
79238617|NCT00149305|Other|Genetic analyses|
79238618|NCT00149305|Other|Genetic analyses|
79238619|NCT00121992|Drug|Docetaxel|
79238620|NCT00121992|Drug|5-fluorouracil|
79238621|NCT00121992|Drug|Doxorubicin|
79238622|NCT00121992|Drug|Cyclophosphamide|
79238623|NCT00070564|Biological|pegfilgrastim|Given IV
79238624|NCT00070564|Drug|AC regimen|Given IV
79238625|NCT00070564|Drug|cyclophosphamide|Given IV
79238626|NCT00070564|Drug|doxorubicin hydrochloride|Given IV
79238627|NCT00070564|Drug|paclitaxel|Given IV
79238628|NCT04610775|Other|Order of cuff sizes during blood pressure measurements|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
79238629|NCT05158725|Device|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
79833691|NCT01563250|Device|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
79833692|NCT00677352|Drug|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
79833693|NCT00677352|Drug|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
79833694|NCT00861081|Behavioral|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
79833695|NCT00861081|Behavioral|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
79833696|NCT04010110|Diagnostic Test|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
79833697|NCT00864045|Drug|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
79833698|NCT00864045|Drug|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
79533218|NCT01447758|Drug|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
79533219|NCT01447758|Drug|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
79689086|NCT06235632|Behavioral|Policy and Training Intervention|The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers
79689087|NCT06235632|Behavioral|Usual and Customary Policy and Training (UC-PT) (Control) Condition|The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission
79689088|NCT06235580|Other|Biological Samples|"For patients, different types of banked frozen or fresh biological samples will be used in this research:~Blood~Skin biopsy or other tissues (liver, muscle, brain, lung...)~Urine~Saliva~Cerebrospinal fluid~Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used."
79689089|NCT06235567|Drug|Dextenza 0.4Mg Ophthalmic Insert|This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
79689090|NCT06235554|Procedure|Renal Stimulation|Renal Denervation procedure as per hospital routine practice
79689091|NCT06235541|Drug|GENA-104A16|GENA-104A16 is administered as a 1 hour (h) [-5 minutes and +60 minutes , i.e., 55-120 minutes as window time] as intravenous (IV) infusion on q2w.
79689092|NCT06235515|Other|rehabilitation program|conventional treatment (hotpack and TENS and exercise)
79689093|NCT06235515|Other|virtual reality|virtual reality treatment
79238630|NCT05158725|Device|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
79238631|NCT05158725|Device|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
79689094|NCT06235502|Other|Home-based cycle-exercise for COPD patients|Patients will cycle in their own home using a pedal exerciser connected to the 4M-video app
79833699|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
79833700|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
79833701|NCT00755508|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
79833702|NCT00755508|Drug|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
79833703|NCT00755508|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
79833704|NCT02544087|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
79833705|NCT02544087|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
79833706|NCT02544087|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
79833707|NCT03680352|Drug|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
79833708|NCT00955942|Dietary Supplement|flaxseed|Given orally
79833709|NCT00955942|Other|placebo|Given orally
79833710|NCT00864201|Drug|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
79833711|NCT00864279|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
79833712|NCT00864279|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
79238632|NCT00702351|Drug|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
79833713|NCT02559648|Drug|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
79833714|NCT02559648|Drug|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
79833715|NCT05299372|Other|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
79833716|NCT00870285|Radiation|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
79689095|NCT06235502|Other|Standard of Care|Exercise at Fitness Center, home based exercise according to a programme
79378985|NCT06038214|Other|home exercises|"Right and left rotation of the head~lateral flexion of the head~Flexion and extension of the head~Stretching the neck extensors~pectoral stretch~Stretching the hip extensors~Hamstrig stretching~Stretching the lumbar extensors~Abdominal strengthening~bridging~Hip abduction strengthening~hip extension strengthening~Upper extremity resistant flexion~Upper extremity resistant abduction~Upper extremity relaxation exercise~Capsule stretching~Stretching the hip flexors~Stretching the lower extremity adductors~relaxation exercise"
79378986|NCT06038201|Procedure|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
79689096|NCT06235489|Other|Palfique Bulk Flow|removal of caries in primary molars and placement of restorative materials
79689097|NCT06235476|Dietary Supplement|whey protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
79689098|NCT06235476|Dietary Supplement|mixed plant-based protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
79238633|NCT05158647|Other|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
79238634|NCT05158647|Drug|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
79238635|NCT03477981|Other|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
79302953|NCT03195595|Device|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
79833717|NCT00755586|Procedure|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 * 10e8 cells in the m. biceps brachii.
79833718|NCT00755586|Procedure|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 * 10e8 cells in the m. biceps brachii.
79833719|NCT00755586|Procedure|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
79833720|NCT00864357|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
79833721|NCT00864357|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
79833722|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
79533220|NCT01447771|Behavioral|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
79533221|NCT01447784|Biological|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
79689099|NCT06235476|Other|e-health application|Daily use of an e-health application with dietary intake counselling to increase protein intake. The overall goal of these advices is to increase protein intake from <1.0g/kg/bw/d to >1.2g/kg/bw/d which is approximately 30 grams of additional protein per day (similar to the other arms of the intervention).
79833723|NCT02559492|Drug|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
79833724|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
79833725|NCT02559492|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
79833726|NCT00864435|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
79833727|NCT00864435|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
79833728|NCT00755664|Dietary Supplement|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
80006310|NCT05261906|Behavioral|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
80006311|NCT03579108|Other|Retrospective Chart Review|Chart review
80006312|NCT01370759|Other|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
80006313|NCT05154110|Other|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
79689100|NCT06235476|Dietary Supplement|isocaloric carbohydrate control|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
79833729|NCT00956098|Drug|oltipraz|60mg bid 90mg qd
79833730|NCT00956098|Drug|placebo|
79689101|NCT06235463|Other|Osteopathic Pedal Pump|Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
79833731|NCT00864591|Procedure|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
79833732|NCT00864591|Procedure|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
79689102|NCT06235463|Other|Light Touch Treatment|Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
79689103|NCT06235450|Device|iLIDS100|Subject applies iLIDS accessory to the iTEAR100 device. Applies to Eyelid margin similar to commercial products
79689104|NCT06235437|Biological|ASD141|Subjects will receive one of 4 dose levels of ASD141.
79833733|NCT05350384|Drug|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
79833734|NCT00870441|Drug|ASP2151|Oral
79833735|NCT00870441|Drug|Valacyclovir|Oral
79833736|NCT00870441|Drug|Placebo|Oral
79833737|NCT04786704|Diagnostic Test|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
79833738|NCT04786704|Diagnostic Test|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
79833739|NCT04079452|Drug|Doravirine|Doravirine 100 mg tablet
79833740|NCT04079452|Drug|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
79833741|NCT00864669|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
79689105|NCT06235372|Device|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph .
79833742|NCT00864669|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
79833743|NCT00760890|Dietary Supplement|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
79833744|NCT00760890|Dietary Supplement|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
79533222|NCT01447784|Biological|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
79833745|NCT00864747|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
79833746|NCT00864747|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
79533223|NCT01447797|Drug|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
79533224|NCT01447810|Other|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
79533225|NCT01447862|Drug|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
79833747|NCT05279716|Drug|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
79833748|NCT04619628|Biological|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
79833749|NCT04619628|Other|Placebo|normal saline
79833750|NCT02543853|Other|direct trocar entry|direct trocar entry to provide pneumoperitoneum
79833751|NCT02543853|Other|veres needle entry|veres needle entry to provide pneumoperitoneum
79533226|NCT01447862|Drug|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
79533227|NCT01447875|Other|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
79689106|NCT06235320|Other|routine clinical treatment of pain with paracetamol or ibuprofen|No intervention beside clinical routine management
79689107|NCT06235242|Biological|GT201 injection in combination with teraplizumab injection|GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
79689108|NCT06235229|Biological|GC012F|GC012F is a BCMA/CD19 dual CAR product
79689109|NCT06234878|Device|REEV SENSE|Gait analysis with an Inertial Measurement Unit (IMU) sensor
79689110|NCT06234878|Device|Motion capture system|Gait analysis with reflective markers and pressure sensors
79833752|NCT02543931|Drug|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
79833753|NCT02543931|Drug|placebo|Placebo capsules containing inert ingredients
79833754|NCT04604652|Drug|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
79533228|NCT01447875|Drug|propofol or mexmedetomidine|
79533229|NCT01447940|Device|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
79833755|NCT05350228|Diagnostic Test|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
79833756|NCT00870519|Drug|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
79833757|NCT00870519|Drug|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
79833758|NCT02559102|Drug|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
79833759|NCT02559102|Drug|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
79833760|NCT02559102|Procedure|Caudal anaesthesia|single shot caudal anaesthesia
79833761|NCT02559102|Procedure|Inguinal hernia surgery|Infant inguinal hernia repair.
79833762|NCT05348668|Drug|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
79833763|NCT05309044|Behavioral|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
79833764|NCT05309044|Other|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
79378987|NCT06038201|Procedure|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
79833765|NCT05309044|Other|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
79833766|NCT00864825|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
79833767|NCT00870597|Procedure|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
79378988|NCT06038149|Diagnostic Test|Transthoracic echocardiogram|A painless ultrasound scan of the heart.
79238636|NCT03477825|Dietary Supplement|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~Supplement appearing similar to Herbal formulations~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 4 placebo tablets per day"
79378989|NCT06038110|Diagnostic Test|axillary ultrasound|usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery
80006314|NCT05154110|Other|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
79378990|NCT06038097|Procedure|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
79238637|NCT03477825|Dietary Supplement|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~Each tablet contains 500 mg of R. cordifolia per tablet."
79238638|NCT03477825|Dietary Supplement|Triphala|"Group C: Triphala group (n= 10)~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
79238639|NCT04234659|Device|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
79689111|NCT06234202|Device|Bioactive Sleeve|Pitchers will wear a bioactive sleeve immediately post-game through overnight.
79238640|NCT02523105|Device|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
79238641|NCT03637959|Device|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
79238642|NCT02738151|Drug|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
79378991|NCT06038084|Drug|Bronpass Tab.|Twice a day
79378992|NCT06038084|Drug|Placebo of Erdos capsule|Three times a day (It is for the masking.)
79378993|NCT06038084|Drug|Erdos capsule|Three times a day
79378994|NCT06038084|Drug|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
79378995|NCT06038058|Drug|BRY812 for injection|BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
79689112|NCT06234202|Device|Control Sleeve|Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.
79689113|NCT06234124|Device|Variable Friction Shoe Training|The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
79833768|NCT00870597|Procedure|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
79833769|NCT00956176|Drug|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
79833770|NCT00864981|Drug|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
79833771|NCT00864981|Drug|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
80006315|NCT01370915|Drug|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
79238643|NCT02738151|Drug|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
79238644|NCT02738151|Drug|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
79238645|NCT03472911|Other|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
79238646|NCT04457661|Dietary Supplement|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
79378996|NCT06038019|Diagnostic Test|Oral food challenge|Patients will undergo oral food challenge with increasing amounts of food allergen
79533230|NCT01447953|Other|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
79533231|NCT01447953|Other|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
79689114|NCT06234124|Device|Ankle Foot Orthosis (AFO) Training|The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
79689115|NCT06233916|Drug|[14C] D-1553|[14C] D-1553 (approximately 400 mg/80 μCi)
79833772|NCT00371683|Drug|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
79833773|NCT00371683|Drug|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
79833774|NCT05286580|Behavioral|Morbidity and mortality conference toolkit|"Standardized slide deck~Code of conduct~Conference planning checklist~Case documentation form"
79833775|NCT00876057|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy
79833776|NCT00876057|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
79833777|NCT05276128|Dietary Supplement|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
79238647|NCT05222139|Biological|COVID-19 vaccination|Monitoring COVID-19 vaccination
79238648|NCT02120222|Drug|selinexor|Given PO
79378997|NCT06038006|Diagnostic Test|Sleep Respiratory Monitoring System|Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
79378998|NCT06037954|Other|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
79378999|NCT06037954|Other|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
79533232|NCT01447966|Behavioral|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
79533233|NCT01447979|Device|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
79533234|NCT01448005|Device|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
79833778|NCT05226273|Other|no intervention|no intervention
79833779|NCT00956332|Biological|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
80006316|NCT01370915|Drug|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
80006317|NCT03577002|Other|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
79533235|NCT01448018|Drug|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
79533236|NCT01448018|Procedure|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
79689116|NCT06233903|Drug|18F-mFBG|18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
79689117|NCT06233669|Other|Analysis of Burnout|No intervention used.
80006318|NCT05574998|Drug|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
79833780|NCT00956332|Biological|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
79833781|NCT00870753|Behavioral|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
79833782|NCT03825718|Biological|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
79833783|NCT00876135|Drug|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
79833784|NCT05214742|Other|Diagnostic Test|Molecular diagnosis carried out in the context of care
79833785|NCT00870831|Other|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
79833786|NCT03588286|Procedure|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting > 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
80006319|NCT03576846|Other|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
80006320|NCT03576846|Other|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
79238649|NCT02120222|Other|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
80006321|NCT03547778|Drug|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
79238650|NCT00969111|Radiation|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
79238651|NCT00969111|Radiation|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
79379000|NCT06037954|Other|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~Provide education about depression and treatment options~Identify treatment preferences and a personal goal achievable with mental health care~Assess barriers to treatment initiation~Recommend a referral using standardized referral options~Address barriers to accessing care"
79533237|NCT01448031|Drug|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
79533238|NCT01448031|Drug|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
79238652|NCT00969111|Radiation|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
79238653|NCT00969111|Radiation|Proton to 66.6 CGE|Post-Op Non High Risk
79238654|NCT05212389|Drug|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
79379001|NCT06037941|Diagnostic Test|E-Nose testing|At baseline (before any treatment is administered) and at three points after treatment (1, 3, and 6 months). A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
79379002|NCT06037941|Diagnostic Test|Research blood|Research blood tests will be obtained at baseline, 1, 3, and 6 months post-treatment to determine whether serum biomarkers of MPM.
79833787|NCT03588286|Other|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
79238655|NCT05212389|Drug|Placebo|Placebo
79238656|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
79238657|NCT03472755|Other|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
79238658|NCT03471039|Drug|PACAP27|Infusion of PACAP27 over 20 minutes.
79238659|NCT03471039|Drug|Saline|Infusion of Saline over 20 minutes.
79238660|NCT03472677|Other|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
79238661|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
79833788|NCT03588286|Procedure|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) <30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
79833789|NCT00876291|Dietary Supplement|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
79833790|NCT00876291|Dietary Supplement|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
79833791|NCT03563482|Diagnostic Test|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
79833792|NCT00870909|Procedure|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
80006322|NCT03547778|Drug|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
80006323|NCT02238912|Drug|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
80006324|NCT03547700|Drug|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
80006325|NCT03547700|Drug|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
79238662|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
79533239|NCT01448070|Drug|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
79833793|NCT00870909|Procedure|sham tDCS|sham condition as delivered by the stimulator
79833794|NCT04039815|Drug|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
79533240|NCT01448083|Other|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
79533241|NCT01448096|Drug|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
79533242|NCT01448096|Procedure|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
80006326|NCT02239458|Drug|Saxagliptin|
80006327|NCT03546218|Device|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
80006328|NCT03546218|Device|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
80006329|NCT03574740|Other|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
80006330|NCT04606550|Device|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
80006331|NCT03574662|Other|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
79833795|NCT04039815|Drug|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
80006332|NCT03574662|Other|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
80006333|NCT03578952|Device|TAVR with Evolut R valve|TAVR with Evolut R valve
79238663|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
79238664|NCT03472677|Drug|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
79379003|NCT06037902|Device|CPAP|patients undergo simulation twice, with and without CPAP
79379004|NCT06037850|Device|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
79379005|NCT06037850|Device|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
79379006|NCT06037837|Procedure|Robotic Surgery|Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
79833796|NCT00870987|Biological|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
79833797|NCT00870987|Biological|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
80006334|NCT03128411|Drug|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
80006335|NCT03578874|Drug|Sorafenib|PO
80006336|NCT03578874|Drug|Capecitabine|PO
80006337|NCT03578874|Drug|Oxaliplatin|IV
80006338|NCT02847858|Behavioral|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
80006339|NCT05168306|Device|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
80006340|NCT01366001|Drug|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
80006341|NCT01366001|Drug|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
80006342|NCT01366001|Drug|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
80006343|NCT03574584|Drug|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
80006344|NCT03574584|Drug|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
79533243|NCT01448109|Drug|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
79379007|NCT06037824|Other|cryotherapy|"cryotherapy was added to rehabilitation*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
79533244|NCT01448109|Drug|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
80006345|NCT03574584|Drug|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
80006346|NCT03546998|Diagnostic Test|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
80006347|NCT01365065|Drug|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
80006348|NCT03576456|Drug|Alprazolam 0.5 mg|receive alprazolam prior to angio
80006349|NCT03576456|Drug|Placebo Oral Tablet|receive placebo prior to angio
80006350|NCT04537988|Other|Behavioral: eCHANGE|eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
79533245|NCT01448122|Other|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
79533246|NCT01448135|Other|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
79533247|NCT01448135|Other|Osmolite 1.2|High protein enteral formula
79238665|NCT04943601|Other|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
80006351|NCT04380701|Biological|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
80006352|NCT04380701|Biological|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
80006353|NCT04380701|Biological|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
80006354|NCT04380701|Biological|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
80006355|NCT05572190|Drug|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
80006356|NCT01365143|Procedure|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
80006357|NCT01365143|Procedure|Open Radical Prostatectomy|Open radical prostatectomy
79238666|NCT04943601|Other|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
79238667|NCT04917705|Other|Collection of biological samples|Skin, muscle fiber and blood sampling
79238668|NCT02673567|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
79379008|NCT06037785|Behavioral|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
79533248|NCT01448148|Other|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
80006358|NCT02035722|Behavioral|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
80006359|NCT02035722|Behavioral|Video|AMD-related information is presented as in the form of a video
79238669|NCT02673567|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
79238670|NCT02673567|Drug|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
80006360|NCT01365221|Drug|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
80006361|NCT01365221|Drug|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
79238671|NCT02673567|Drug|Placebo|Matching Placebo
79833798|NCT03951766|Behavioral|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
79833799|NCT00876603|Procedure|ACDF|Anterior cervical decompression and fusion
79833800|NCT00876603|Procedure|Cervical laminoplasty|Cervical laminoplasty
79833801|NCT00371137|Drug|Xyrem®|two doses
79833802|NCT00371137|Drug|Placebo|Oral Solution
79833803|NCT01050283|Procedure|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
79238672|NCT00702195|Drug|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
79379009|NCT06037772|Other|subcutaneous injection administration game|The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.
79533249|NCT01448148|Other|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
79533250|NCT01448174|Drug|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
79533251|NCT01448200|Drug|PPI-668|capsules
79689118|NCT06233578|Device|RADPAD|The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
79833804|NCT00961870|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
79833805|NCT05175417|Other|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
79833806|NCT01047787|Other|Polysomnography|examination for sleep disorders
80006362|NCT03576222|Device|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
80006363|NCT03576222|Device|MEPORE dressing|MEPORE dressing
80006364|NCT01366079|Procedure|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
80006365|NCT01366079|Procedure|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
79238673|NCT00702195|Drug|Placebo|single dose of placebo (administered under protocol 38805)
79238674|NCT00702195|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
79238675|NCT01550237|Radiation|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
79238676|NCT01550237|Radiation|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
79379010|NCT06037772|Other|control group|only
79379011|NCT06037733|Radiation|CTV omitted or delineated|Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
79533252|NCT01448200|Drug|Placebo|capsules
79533253|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
79689119|NCT06233357|Drug|treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)|IgG seronegative SARSCoV2-Spike antibody (< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP > 75 mg/l or IL-6 > 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
79833807|NCT00871299|Behavioral|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
80006366|NCT03124199|Drug|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
79238677|NCT02915159|Biological|Abatacept|
79238678|NCT02915159|Other|Placebo|
79238679|NCT04058951|Other|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
79238680|NCT04058951|Other|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
79379012|NCT06037720|Device|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
79238681|NCT03669263|Drug|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
79533254|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
79833808|NCT00871299|Behavioral|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
79833809|NCT02534545|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
79533255|NCT01448252|Biological|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
79833810|NCT02534545|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
79238682|NCT03658915|Device|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
79238683|NCT01208987|Other|Medication History was printed|
79533256|NCT01448252|Biological|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
79533257|NCT01448265|Procedure|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
79689120|NCT06232850|Other|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
79533258|NCT01448278|Procedure|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
79689121|NCT06232759|Drug|Transarterial chemoembolization combined with Donafenib and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Donafenib and Tislelizumab
79833811|NCT00962026|Drug|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
79833812|NCT03753789|Device|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
79689122|NCT06232681|Behavioral|Progressive relaxation exercise|The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
79833813|NCT00876681|Procedure|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
79833814|NCT05299840|Diagnostic Test|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
79833815|NCT05299840|Diagnostic Test|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
79833816|NCT03991897|Dietary Supplement|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
79833817|NCT03991897|Dietary Supplement|Isocaloric diet|Patients will follow an isocaloric diet
79833818|NCT00616239|Drug|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
79689123|NCT06232629|Device|TUS Active|Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
79689124|NCT06232629|Device|TUS Sham|"Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa"
79833819|NCT00616239|Drug|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
79833820|NCT03234166|Other|Non interventional study|Only data will be taken of patient's file.
79833821|NCT01045213|Other|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
79533259|NCT01448278|Procedure|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
79833822|NCT00876759|Radiation|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
79833823|NCT00876759|Radiation|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
79833824|NCT01045291|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
79833825|NCT05167539|Procedure|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
79238684|NCT03477747|Device|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
79689125|NCT06232538|Diagnostic Test|The level of CNV|The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
79833826|NCT01047943|Drug|Topical application of STA-21 ointment for treatment of psoriasis|
79833827|NCT00547534|Drug|bortezomib|1.3 mg/m^2 on days 1, 4, 8, 11
79833828|NCT00547534|Drug|bendamustine|90 mg/m^2 days 1 and 4
79379013|NCT06037655|Drug|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
79833829|NCT00547534|Drug|rituximab|375 mg/m^2 day 1
79833830|NCT00871455|Drug|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
79833831|NCT00962182|Drug|STAN1|3-4 capsules/day at meals
79379014|NCT06037642|Behavioral|ABC 0-2 years|Four 1 hour meetings and homework
79379015|NCT06037642|Other|waiting list|Will be put on hold for four weeks
79379016|NCT06037577|Drug|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
79379017|NCT06037577|Drug|Placebo|Placebo Comparator
79379018|NCT06037551|Diagnostic Test|blood glucose measuremen subject|measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood
79379019|NCT06037551|Diagnostic Test|blood glucose measuremen reference|measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
79379020|NCT06037538|Diagnostic Test|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
79533260|NCT01448291|Drug|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
79533261|NCT01448304|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
79533262|NCT01448317|Drug|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79533263|NCT01448317|Drug|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
79533264|NCT01448317|Drug|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79689126|NCT06232148|Device|Type of surgery|
79689127|NCT06231771|Drug|Allogeneic mesenchymal stem cells (MSCs)|Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
79833832|NCT00962182|Drug|Placebo enzyme|3-4 capsules/day at meals
79833833|NCT00962182|Drug|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
79833834|NCT00871533|Drug|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
79833835|NCT00871533|Drug|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
79833836|NCT00871533|Drug|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
79833837|NCT00871533|Drug|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
79833838|NCT05157022|Device|ESWT|Extracorporeal Shock-wave Therapy
79833839|NCT00962260|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
79833840|NCT00877149|Drug|telbivudine/LDT600|
79238685|NCT04058483|Other|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
79238686|NCT02924051|Behavioral|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
79833841|NCT00877227|Drug|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
79238687|NCT02924051|Behavioral|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
79533265|NCT01448317|Drug|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
79238688|NCT04058249|Device|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
79379021|NCT06037538|Diagnostic Test|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
79533266|NCT01448330|Drug|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
79533267|NCT01448343|Device|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
79533268|NCT01448369|Device|Blephasteam|10 minute treatment twice daily
79689128|NCT06231771|Drug|Normal Saline|Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
79689129|NCT06231394|Other|multimodal pelvic floor rehabilitation|A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
79689130|NCT06231342|Device|Direct Laryngoscope (DL)|DL allows visualization of the larynx. It is used during general anesthesia, for surgical procedures of the larynx, and during resuscitation.
79833842|NCT05149846|Procedure|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
79833843|NCT00871767|Drug|AZD5672|40 mg tablet (Test formulation)
79238689|NCT03668795|Procedure|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
79379022|NCT06037512|Diagnostic Test|subject|blood glucose measurement by subject
79379023|NCT06037512|Diagnostic Test|reference|blood glucose measurement with reference
79833844|NCT00871767|Drug|AZD5672|40 mg tablet (Reference formulation)
79238690|NCT02923427|Device|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
79833845|NCT00871767|Drug|AZD5672|100 mg tablet (Test formulation)
79833846|NCT00871767|Drug|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
79238691|NCT02923427|Device|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
79379024|NCT06037499|Diagnostic Test|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
79379025|NCT06037486|Diagnostic Test|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
79379026|NCT06037473|Drug|Polyethylene glycol recombinant human growth hormone injection|0.1-0.3mg/kg.w
79833847|NCT05279248|Biological|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
79533269|NCT01448369|Device|EyeGiene|10 minute treatment, twice daily
79533270|NCT01448369|Device|Hot compresses|10 minute treatment, twice daily
79533271|NCT01448382|Device|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
79533272|NCT01448395|Drug|[14C]NXL104|500mg/100mL intravenous solution
79533273|NCT01448434|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
79533274|NCT01448434|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
79833848|NCT05279248|Biological|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
80006367|NCT03546920|Behavioral|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
80006368|NCT03574428|Drug|GNbAC1|Monoclonal Antibody infused i.v.
79238692|NCT02669264|Drug|ADCT-402|Intravenous infusion
79238693|NCT02521870|Drug|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
80006369|NCT03574428|Other|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
80006370|NCT01366157|Genetic|microarray analysis|
80006371|NCT01366157|Genetic|protein expression analysis|
79238694|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
79238695|NCT02521870|Drug|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
79238696|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
79238697|NCT02521870|Biological|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
79533275|NCT01448473|Other|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
79533276|NCT01448473|Other|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
79238698|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
79379031|NCT06037395|Biological|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
79379032|NCT06037395|Biological|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
79379033|NCT06037356|Device|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
79533277|NCT01448499|Drug|Clozapine|escalating dose of clozapine up to 900 mg/day
79833849|NCT05279248|Biological|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
80006372|NCT01366157|Other|immunohistochemistry staining method|
80006373|NCT01366157|Other|laboratory biomarker analysis|
79238699|NCT02923349|Drug|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
79238700|NCT02386046|Other|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
79238701|NCT02385656|Drug|Modafinil|200mg of modafinil daily for 4 weeks
79379034|NCT06037356|Procedure|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
79379035|NCT06037330|Drug|Nalbuphine|Nalbuphine was injected intravenously. The target CPOT score was <2, and the target RASS score was -2 ~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was <2, and the maximum daily dose was 160mg.
79533278|NCT01448499|Drug|Amisulpride|escalating dose of amisulpride up to 800 mg/day
79533279|NCT01448499|Drug|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
79689131|NCT06231342|Device|Video laryngoscope (VL)|VL facilitates intubation while allowing clinicians to share and record real-time high-resolution images and video.
79833850|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
79833851|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79238702|NCT02389868|Drug|Lovastatin|
79238703|NCT03668717|Device|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
79238704|NCT02521792|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
79238705|NCT03623087|Drug|Cisplatin|SIMPLE
79238706|NCT03623087|Drug|Gemcitabine|SIMPLE
79238707|NCT03623087|Drug|Etoposide (VP-16)|SIMPLE
79238708|NCT03623087|Device|Ifosfamide|SIMPLE
79238709|NCT03623087|Drug|Dexamethasone|SIMPLE
79238710|NCT03623087|Drug|L-asparaginase|SIMPLE
79238711|NCT02390024|Device|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
79238712|NCT05066932|Other|Additionnal blood samples|Additionnal blood samples
79833852|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79833853|NCT00877305|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
79833854|NCT00877305|Other|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
80006374|NCT03574350|Behavioral|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
80006375|NCT03574350|Behavioral|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
80006376|NCT01365377|Other|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
80006377|NCT03578640|Drug|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
80006378|NCT02035644|Drug|Jinlida granules|
80006379|NCT02035644|Drug|placebo granules|
79238713|NCT03668171|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
79238714|NCT03669185|Drug|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
79379036|NCT06037330|Drug|Sufentanil|Sufentanil was injected intravenously, and the target CPOT score was <2, and the target RASS score was -2 ~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was <2 points
79533280|NCT01448512|Behavioral|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
79833855|NCT04039659|Device|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
79533281|NCT01448512|Other|Usual Care|4 time matched sessions focused on health education
79833856|NCT02715388|Device|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
79833857|NCT05119894|Drug|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
79833858|NCT05119894|Drug|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
79833859|NCT05119894|Drug|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
79833860|NCT05119894|Drug|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
80006380|NCT03578562|Other|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
79379037|NCT06037304|Other|no intervention|no intervention
79379038|NCT06037291|Dietary Supplement|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
79533282|NCT01448538|Drug|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
79689132|NCT06231342|Procedure|Endotracheal Tube (ETT) 180|A novel maneuver has been described to decrease the insult from stylet named Endotracheal Tube (ETT) 180; a clockwise rotation of the stylet-loaded Endotracheal Tube (ETT) 180 degrees on its axis right after the tip of Endotracheal Tube (ETT) passes the patient's vocal cords (glottis) before fully inserting the Endotracheal Tube (ETT) and then, pulling the stylet out. This maneuverer allows the stylet to match the posterior angulation of the trachea.
79833861|NCT00877539|Drug|PF-03526299|Inhaled, two doses 4 hours apart
80006381|NCT04465916|Drug|EYP001a|Oral tablets
80006382|NCT04465916|Drug|Placebo|Oral tablets
79238715|NCT03669185|Drug|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
79238716|NCT03668093|Other|ICCM|comprehensive system for caries management
79238717|NCT03668093|Other|CAMBRA|Caries risk assessment model
79238718|NCT03623165|Device|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
79238719|NCT04058327|Diagnostic Test|blood ammonia test, neurophysiological/psychological tests, blood markers.|Let the patients do neuropsychological/psychological tests and use blood test for ammonia and blood markers.
79379039|NCT06037291|Dietary Supplement|Placebo|The study foresees the intake of 1 capsule per day during 56 days
79379040|NCT06037278|Device|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
79833862|NCT00877539|Drug|Placebo|Inhaled, two doses 4 hours apart
79833863|NCT00877539|Drug|Fluticasone propionate|Inhaled
80006383|NCT04465916|Drug|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
80006384|NCT03575988|Other|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
79833864|NCT04039737|Drug|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
79833865|NCT00872157|Drug|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
79833866|NCT00872235|Drug|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
79833867|NCT00877617|Behavioral|QOL Questionnaire|Mailed survey.
79238720|NCT04058327|Drug|HE drug treatments in clinical real world|record the HE drug treatments in clinical real world if doctors use them
79238721|NCT05021120|Drug|AK127|Subjects will receive AK127 by intravenous administration
79833868|NCT00877695|Behavioral|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
79833869|NCT00872391|Radiation|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
79833870|NCT00872469|Drug|Tranexamic acid|1-2 grams by intravenous injection
79833871|NCT00872469|Drug|Placebo [Saline]|Matched to active comparator
79238722|NCT05021120|Drug|AK104|After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
79238723|NCT05065528|Dietary Supplement|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
79238724|NCT05065528|Drug|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
79238725|NCT03113396|Drug|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
79238726|NCT03113396|Drug|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
79238727|NCT03020615|Drug|Hydroxyurea|Given orally once daily.
79238728|NCT03020069|Device|CGMS Device|
79238729|NCT03020069|Other|No Device|
79379041|NCT06037265|Device|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
79833872|NCT00872547|Device|DePuy ASR™ Hip System|Resurfacing system
79833873|NCT00872547|Device|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
79833874|NCT05225883|Genetic|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
79833875|NCT00878007|Drug|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
79833876|NCT00878007|Behavioral|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness & vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
79833877|NCT00878007|Other|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
79833878|NCT00872625|Drug|cyclophosphamide|
79238730|NCT05064046|Behavioral|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
79238731|NCT04058405|Behavioral|Observational|Cross-sectional observations
79238732|NCT05063500|Drug|bicyclol, 25mg/ tablet|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
79238733|NCT05063500|Drug|polyene phosphatidylcholine capsules, 228mg/ particle.|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
79238734|NCT04058171|Diagnostic Test|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
79833879|NCT00872625|Drug|docetaxel|
79833880|NCT00872625|Drug|epirubicin hydrochloride|
79833881|NCT00872625|Drug|fluorouracil|
79833882|NCT00872625|Procedure|neoadjuvant therapy|
79833883|NCT00872625|Procedure|therapeutic conventional surgery|
79833884|NCT00872625|Radiation|hypofractionated radiation therapy|
79833885|NCT00872625|Radiation|image-guided radiation therapy|
79833886|NCT00872625|Radiation|radiation therapy|
79379042|NCT06037239|Drug|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
79833887|NCT00872625|Radiation|stereotactic radiosurgery|
79833888|NCT00878085|Device|Robot Therapy Device|3x a week for 4 weeks
79833889|NCT00878085|Behavioral|Occupational Therapy|3x a week for 4 weeks
79833890|NCT00878241|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
79833891|NCT00878319|Procedure|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
79833892|NCT00878319|Other|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
79833893|NCT00872781|Drug|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
79833894|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
79379043|NCT06037226|Behavioral|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
79833895|NCT00384085|Drug|Insulin Glargine|Subcutaneous injection once-a-day
79833896|NCT00384085|Drug|Premixed Insulin|Subcutaneous injection twice-a-day.
79833897|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
79833898|NCT00878397|Device|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
79833899|NCT00872859|Procedure|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
79833900|NCT00361231|Drug|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
79833901|NCT00361231|Drug|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
79833902|NCT00361231|Drug|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
79833903|NCT01050361|Procedure|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
79833904|NCT01048021|Procedure|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
79833905|NCT01050439|Procedure|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
79833906|NCT01050439|Other|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
79833907|NCT00676650|Drug|Prednisone|5 mg BID, oral
79833908|NCT00676650|Drug|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
79833909|NCT00676650|Drug|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
79833910|NCT00676650|Drug|Prednisone|5 mg BID, oral
79833911|NCT01045369|Drug|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
79833912|NCT00573183|Behavioral|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
79833913|NCT00573183|Behavioral|Treatment as Usual|
79833914|NCT00615459|Drug|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
79833915|NCT00615459|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
79302954|NCT05679323|Other|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
79302955|NCT02449603|Drug|Exenatide|
79302956|NCT02449603|Drug|Biphasic insulin Aspart 30|
79302957|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
79379044|NCT06037200|Device|Urin-based test by the DOASENSE Dipstick Device|Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
79302958|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
79302959|NCT02481479|Drug|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
79302960|NCT03208777|Genetic|taking blood samples|taking blood samples and measure telomeric abnormalities
79833916|NCT00615459|Drug|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
79689133|NCT06230874|Behavioral|HOME Protocol|The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
79689134|NCT06230874|Behavioral|Control Journaling Protocol|The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
79689135|NCT06230679|Device|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
79238735|NCT04995796|Other|Surveys for Research Purposes|"VISIT #1:~Pre-Testing:~Pre Knowledge Test~Pre SURE (decisional conflict) test~Independent DSI/DA Interaction~Post-Testing:~Post Knowledge Test~Post SURE (decisional conflict) Test~Acceptability Index~Modified Single Item Literacy Screen~Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
79833917|NCT04048902|Device|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
79833918|NCT04048902|Device|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
79379045|NCT06037161|Procedure|Mandibular Incisor root coverage procedure|Mucogingival procedure to cover mandibular incisor tooth with receded gums
79833919|NCT03839511|Procedure|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
79833920|NCT03876366|Other|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
79833921|NCT03876366|Other|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
79833922|NCT00383149|Drug|Ixabepilone|Intravenous Infusion (IV), 32 mg/m^2 every 21 days.
79833923|NCT00383149|Drug|Cetuximab|Initial dose of 400 mg/m^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m^2 IV over 1 hour.
79833924|NCT03364296|Other|Blood Samples|Blood sample retrieved for biological assessment and biobanking
79379047|NCT06037096|Other|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
79833925|NCT00878631|Drug|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
79833926|NCT00878631|Drug|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
80006385|NCT01366235|Drug|chloroquine phosphate 1000 mg|1000 mg, 1day
79379048|NCT06037083|Device|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
79833927|NCT00921960|Other|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
79833928|NCT00878787|Device|Transcranial magnetic stimulation|
79833929|NCT00382993|Drug|Placebo|Matching placebo tablet
79833930|NCT00382993|Drug|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
79833931|NCT04585464|Drug|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
79833932|NCT04585464|Drug|Placebo|Placebo is administered orally as a single dose or once daily
80006386|NCT03578484|Diagnostic Test|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
80006387|NCT04871165|Diagnostic Test|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
79833933|NCT00873405|Procedure|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
79833934|NCT00873405|Procedure|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
79238736|NCT04058093|Behavioral|Functional Training Program|"Functional training program (FTP) include:~Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students."
79238737|NCT03669107|Drug|Gum|no gum
79689136|NCT06230679|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
79238738|NCT05063110|Drug|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
79238739|NCT03668483|Other|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
79238740|NCT05062954|Dietary Supplement|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
79238741|NCT05062954|Dietary Supplement|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
79833935|NCT04049682|Behavioral|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
79833936|NCT00760968|Drug|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
79238742|NCT03021005|Behavioral|HIV Self-testing|
79238743|NCT02389478|Procedure|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
79238744|NCT02389478|Procedure|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
79238745|NCT05048524|Drug|S-1, leucovorin, oxaliplatin and gemcitabine|"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day [depending on patient's body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~BSA < 1.25 m2: 80 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day~BSA ≥ 1.5 m2: 120 mg/day"
79833937|NCT00760968|Drug|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
79833938|NCT00369967|Drug|NuvaRing|Initiation of NuvaRing for contraception
79833939|NCT00878865|Drug|Alprazolam|1 mg tablet one oral dose
79833940|NCT00878865|Drug|Alprazolam|1 mg tablet
79833941|NCT00873483|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
79238746|NCT02389400|Drug|methotrexate|Single Group Assignment
79238747|NCT02914457|Procedure|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
79238748|NCT05048446|Other|observational|Non intervention
79238749|NCT05047744|Device|Touch Dual Mobility CMC I Prosthesis|Surgery
79238750|NCT04221412|Drug|JNJ-53718678|JNJ-53718678 will be administered as directed by treating physician.
79238751|NCT02389322|Biological|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
79238752|NCT02389322|Biological|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
79238753|NCT02389322|Biological|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
79689137|NCT06230016|Other|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
79689138|NCT06230016|Other|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
79833942|NCT01050517|Drug|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
79833943|NCT01050517|Drug|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
79833944|NCT02534467|Drug|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
80006388|NCT04871165|Diagnostic Test|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
79833945|NCT01050595|Drug|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
79833946|NCT01050595|Drug|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
79238754|NCT02389322|Biological|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
79238755|NCT04993768|Drug|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
80006389|NCT04871165|Diagnostic Test|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
80006390|NCT05090852|Device|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
79689139|NCT06228742|Other|Unilateral leg immobilization|Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
79689140|NCT06228742|Other|Contralateral active leg|One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
79689141|NCT06228573|Procedure|Yoga|Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
79689142|NCT06228482|Drug|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of [68Ga]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up [68Ga]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
79689143|NCT06228456|Drug|Ticagrelor 60mg|Patients in the ticagrelor arm will receive a 180 mg loading dose of ticagrelor followed by ticagrelor 60 mg bid maintenance dose for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
79689144|NCT06228456|Drug|Clopidogrel|Patients in the clopidogrel arm will continue to receive clopidogrel 75 mg/daily for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
79689145|NCT06227585|Device|REVEAL 475 System|The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.
79689146|NCT06227585|Drug|Bevonescein|All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
79689147|NCT06227130|Behavioral|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
79689148|NCT06226909|Procedure|different types of ultrasound technique|Shear-wave elastography-guided or B-mode ultrasound-guided
79833947|NCT00616629|Drug|AZD1305|Intravenous infusion
80006391|NCT03578406|Drug|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
80006392|NCT03575676|Drug|SOM3355 100mg BID|Oral
80006393|NCT03575676|Drug|SOM3355 200mg BID|Oral
80006394|NCT03575676|Drug|Placebo BID|Oral
80006395|NCT04249739|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
79379049|NCT06037083|Device|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
80006396|NCT03574272|Other|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
80006397|NCT01366313|Drug|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
80006398|NCT01366313|Drug|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
79238756|NCT04993768|Drug|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
79238757|NCT04993768|Drug|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
79238758|NCT04993768|Drug|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
79379050|NCT06037083|Device|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~Between 24 and 48 hours post extubation (total 3 hours)~Between 72 and 96 hours post extubation (total 3 hours)"
79379051|NCT06037057|Other|no intervention name|no intervention description
79833948|NCT03991975|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
79833949|NCT03991975|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79833950|NCT04039269|Other|Preoperative video information|
79833951|NCT02534311|Drug|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
79833952|NCT00873561|Drug|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
79833953|NCT04039425|Procedure|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
79833954|NCT02534389|Dietary Supplement|omega-3 fish oil|2,4g of EPA + DHA
80006399|NCT01366313|Drug|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
80006400|NCT05190809|Procedure|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
80006401|NCT01371149|Other|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
79238759|NCT02665052|Device|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
79238760|NCT02665052|Device|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
79238761|NCT02665052|Behavioral|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
79379052|NCT06037044|Other|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
79379053|NCT06037044|Other|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
79689149|NCT06226428|Other|Bed cyclo-ergonometry|The MotoMed Letto 2 device will be used, with a progressive pattern, starting at 5 minutes and lasting up to 30 minutes. It will be performed once a day, during weekdays (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light).
79833955|NCT00878943|Drug|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
79833956|NCT00873639|Drug|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
79833957|NCT00873639|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
80006402|NCT02253524|Drug|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
80006403|NCT02253524|Drug|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
80006404|NCT01371227|Drug|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
80006405|NCT02253602|Drug|Ferumoxytol|maximum rate of administration 1 ml/sec
79379054|NCT06037018|Biological|CC312|Doses from 0.3 to 45 µg/dose by intravenous infusion
80006406|NCT05190497|Device|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
79689150|NCT06226428|Other|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.
79689151|NCT06226428|Other|Progressive upper and lower limb strength training|Performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.
79689152|NCT06224569|Other|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
79689153|NCT06224569|Other|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
79689154|NCT06224569|Other|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
79689155|NCT06224569|Other|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
79689156|NCT06224569|Other|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
79689157|NCT06224569|Other|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
79689158|NCT06223113|Device|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
79689159|NCT06222528|Behavioral|Brief video intervention (Black Girl)|A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
79689160|NCT06222528|Behavioral|Brief video intervention (Black Boy)|A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
79833958|NCT00879021|Drug|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
79238762|NCT03019289|Drug|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
79833959|NCT00879021|Drug|matching placebo|150 mg by mouth ,twice a day for 49 weeks
79238763|NCT02389166|Device|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
79238764|NCT02389166|Device|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
79689161|NCT06222528|Behavioral|Brief video intervention (Latinx Girl)|A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
79833960|NCT00879099|Drug|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
79833961|NCT00879099|Drug|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
79833962|NCT00879099|Drug|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
79833963|NCT00879099|Drug|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
79833964|NCT00369655|Biological|ziv-aflibercept|
79833965|NCT00615069|Device|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
79833966|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
79833967|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
80006407|NCT03575520|Drug|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
80006408|NCT03575520|Drug|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
80006409|NCT01366391|Drug|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
79238765|NCT03669029|Drug|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
79379056|NCT06036979|Procedure|Paravertebral plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
79689162|NCT06222528|Behavioral|Brief video intervention (Latinx Boy)|A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
79689163|NCT06222528|Behavioral|Brief video intervention (White Girl)|A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
79689164|NCT06222528|Behavioral|Brief video intervention (White Boy)|A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
79833968|NCT00879177|Drug|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
79833969|NCT00879177|Behavioral|behavioral therapy|confirmed negative smoking status at different time points
79833970|NCT01050829|Drug|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
79833971|NCT01050829|Drug|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
79833972|NCT00873717|Other|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
79238766|NCT03669029|Drug|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
79238767|NCT05059444|Diagnostic Test|Guardant Reveal|Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
79238768|NCT02385578|Other|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
79238769|NCT03668015|Other|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
79238770|NCT03668015|Other|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
79238771|NCT03668405|Drug|Lu AF20513|Injection
79379057|NCT06036979|Procedure|Erector spinae plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
79833973|NCT00873717|Other|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
79533283|NCT01448551|Behavioral|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
79533284|NCT01448564|Other|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
79533285|NCT01448564|Other|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
79533286|NCT01448603|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
80006410|NCT04589195|Behavioral|Mindfulness Training|The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
80006411|NCT03546764|Device|Percutaneous catheter|tube inserted to drain hemothorax
79533287|NCT01448603|Biological|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
80006412|NCT04408586|Drug|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
79533288|NCT01448629|Device|Standard Care|"Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names."
80006413|NCT04408586|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
79238772|NCT02385734|Other|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
79533289|NCT01448629|Device|River|River is a new developed product with Coloplast as manufacturer
79238773|NCT02385734|Procedure|Coronally Advanced Flap|Periodontal plastic surgery technique
79238774|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
79238775|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
79533290|NCT01448642|Drug|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
79533291|NCT01448642|Drug|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
79533292|NCT01448681|Other|No Interventions|
79533293|NCT01448694|Other|No treatment|No treatment, only collecting observational data.
79689165|NCT06222528|Behavioral|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
79689166|NCT06222528|Behavioral|Control Condition|A video that will provide information about depression and how to seek help but does not include a personal story.
79689167|NCT06222489|Drug|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
79689168|NCT06221943|Behavioral|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
79833974|NCT00873717|Other|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
79833975|NCT00676338|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
79533294|NCT01448720|Drug|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
79689169|NCT06221943|Behavioral|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
79833976|NCT00676338|Drug|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
79238776|NCT02385500|Drug|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
79238777|NCT02385500|Drug|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
79238778|NCT02385422|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
79533295|NCT01448733|Drug|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
79833977|NCT00676338|Drug|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
79833978|NCT00676338|Drug|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
80006414|NCT04408586|Other|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
79238779|NCT02385422|Drug|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
79833979|NCT02534623|Procedure|Spinal anesthesia|
79833980|NCT02534623|Procedure|General anesthesia|
79689170|NCT06221943|Behavioral|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
79689171|NCT06218225|Dietary Supplement|Verum|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout
79833981|NCT02534623|Drug|bupivacaine|
79833982|NCT02534623|Drug|fentanyl|
80006415|NCT00075816|Biological|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
80006416|NCT00075816|Biological|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
80006417|NCT04479917|Drug|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
80006418|NCT04479917|Drug|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
80006419|NCT05159726|Other|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
80006420|NCT03578328|Procedure|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
80006421|NCT05542862|Biological|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
79533296|NCT01448746|Drug|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
79689172|NCT06218225|Dietary Supplement|Placebo|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
79833983|NCT02534623|Drug|propofol|
79833984|NCT02534623|Drug|sevoflurane|
79833985|NCT00873795|Drug|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
79833986|NCT00879489|Biological|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
79833987|NCT00382291|Drug|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
79238780|NCT02520388|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
79833988|NCT00382291|Drug|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
79833989|NCT00382291|Drug|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
79833990|NCT00873951|Other|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
79833991|NCT00873951|Dietary Supplement|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
79833992|NCT00873951|Dietary Supplement|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
79833993|NCT00873951|Dietary Supplement|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
79833994|NCT00874107|Biological|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
79833995|NCT00874107|Biological|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
79833996|NCT00874107|Drug|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
79833997|NCT00874107|Drug|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
80006422|NCT03575442|Behavioral|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
79238781|NCT02520388|Drug|Placebo|
79238782|NCT03667937|Combination Product|CUTIMED|Hydrophobic Dressing
79238783|NCT03667937|Other|AQUACEL silver|Silver Dressing
79238784|NCT03666767|Other|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
79238785|NCT02385344|Device|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
79533297|NCT01448759|Other|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
79238786|NCT03667235|Other|Treatment of human pericardium with glutaraldehyde in OZAKI procedure|10 versus 20 minutes treatment of human pericardium with 0.6% glutaraldehyde in OZAKI procedure
79238787|NCT03667235|Other|Treatment of human aortic valve tissue with glutaraldehyde|10 versus 20 minutes treatment of human aortic valve tissue with 0.6%glutaraldehyde
79238788|NCT03666689|Procedure|surgical technique|surgical reconstruction
79238789|NCT05043922|Drug|CYH33|a Selective PI3Kα Inhibitor
79238790|NCT02668640|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
79238791|NCT05043766|Drug|PF614|PF614 is an oxycodone prodrug
79238792|NCT05043766|Drug|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
79238793|NCT05043766|Drug|OxyContin|Bioequivalence single-dose comparison to OxyContin
79533298|NCT01448772|Drug|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
79533299|NCT01448772|Drug|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
79533300|NCT01448785|Device|abiliti system implant|Subjects will receive implanted abiliti System.
79833998|NCT00761358|Drug|Z-338|Oral
79833999|NCT00761358|Drug|Placebo|Oral
79834000|NCT05213637|Biological|Expanded Activated Lymphocytes (EAL)|12~20 doses of EAL (1×10^9~2×10^10 cells per dose) will be infused into patients.
79834001|NCT05213637|Procedure|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
79834002|NCT03992989|Device|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
79834003|NCT03992989|Device|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
79834004|NCT00879723|Dietary Supplement|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
79834005|NCT00874341|Other|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
79834006|NCT00874419|Drug|erlotinib|erlotinib 150 mg oral, once a day
79834007|NCT00874419|Drug|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
79238794|NCT05043298|Drug|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
79238795|NCT04991818|Other|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
79238796|NCT02389010|Biological|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
79238797|NCT02389010|Other|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
79238798|NCT05042830|Procedure|Blood sampling|Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
79834008|NCT00547378|Device|InterStim|
79834009|NCT00547378|Drug|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
79834010|NCT00381043|Drug|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
79834011|NCT02534701|Device|ERIC® and SOFIA™|a self-expanding clot retrieval system
79533301|NCT01448785|Device|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
80006423|NCT03578250|Other|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
79238799|NCT05042830|Procedure|Nasal biopsies|Nasal biopsies will be taken from the lower fringe of the inferior turbinate, approximately 1-2cm from the anterior curved edge for RNA sequencing and confocal microscopy staining
80006424|NCT03575286|Diagnostic Test|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
80006425|NCT03578016|Other|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
79689173|NCT06214624|Behavioral|Two types of exercise interventions|"HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at ~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
80006426|NCT03578016|Other|Treatment as Usual|TAU consists of clinical assessment and treatment.
80006427|NCT02239614|Biological|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
79238800|NCT05042830|Biological|Nasal specimen collection|Nasal specimen collection will be conducted. Nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)) will be obtained.
79689174|NCT06214156|Biological|T3011|T3011 will be given intratumorally， Q2W；
79834012|NCT00962338|Behavioral|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
79834013|NCT01050985|Drug|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
79238801|NCT05042830|Procedure|Mucosal RNA sampling|A 10 cm nasal curette will be used (Rhino-Probe, Arlington Scientific, USA). The curette is brought to lie against the mid-inferior portion of the inferior turbinate under direct visualisation. The curette is rubbed against the mucosal surface, going outwards. To ensure successful sample acquisition, this motion will be repeated 2-3 times
79238802|NCT05042830|Procedure|Intranasal challenge|The extract of birch pollen (Allergopharma, Vienna, Austria) will be freshly diluted in a 0.9 percent sterile sodium chloride solution and administered by means of a metered pump. The allergen will be administered supplying 15 μl per puff to both nostrils. Azelastine nasal spray or desloratadine 5mg will be given if the patient suffers from nasal or eye symptoms after the challenge. Equivalent amount of saline without allergens will be given to the control group.
79238803|NCT05042830|Procedure|Skin prick test|"In order to evaluate the patient's sensitization profile at the screening visit, a regular skin prick test will be conducted with commercial birch pollen extract and a panel of allergens used in routine diagnosis in the allergy clinic of the ear, nose, and throat (ENT) department.~Titrated skin prick test: Titrated skin prick test (SPT) to birch pollen extract is conducted by using increasing dilutions up to 1:100 000. As a result, it is possible to determine the lowest concentration that leads in a skin reaction."
79238804|NCT05042830|Procedure|Peak Nasal Inspiratory Flow (PNIF)|The functionality and convenience of the PNIF presents a rare opportunity to rapidly obtain objective measurements of nasal peak inspiratory flow. It was also validated during other nasal allergen challenge as a study tool
79379058|NCT06036966|Drug|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
79533302|NCT01448798|Procedure|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
79533303|NCT01448798|Procedure|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
79533304|NCT01448811|Device|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI>40, titrate up propofol dosage, AAI<25, titrated down propofol dosage.
79689175|NCT06213831|Drug|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
79689176|NCT06211764|Drug|TAR-200|Participants will receive TAR-200 intravesically.
79689177|NCT06211764|Drug|Mitomycin C|Participants will receive MMC intravesically.
79689178|NCT06211764|Drug|Gemcitabine|Participants will receive gemcitabine intravesically.
79834014|NCT04010656|Procedure|PVR-based self-catheterization|Home self-catheterization based on standard of care
79834015|NCT00962416|Device|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
79834016|NCT00962416|Device|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
80006428|NCT02239614|Biological|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
79834017|NCT00614991|Drug|Raltegravir|400mg BID
79834018|NCT00614991|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
79834019|NCT00614991|Drug|Ritonavir|100 mg BID or QD
79834020|NCT00962494|Behavioral|Cancer: Thriving and Surviving Online Workshop|
79834021|NCT04010032|Device|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
79834022|NCT04010032|Device|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
79238805|NCT05042830|Biological|Pregnancy test|In female patients, a regular urine pregnancy test will rule out pregnancy. The test will be conducted at the screening visit before the first skin prick test and then once a month afterwards.
79834023|NCT00360529|Drug|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
79834024|NCT04858971|Other|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
80006429|NCT05031572|Other|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
79238806|NCT02388854|Genetic|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
79379059|NCT06036953|Device|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
79834025|NCT02247388|Behavioral|Computerized Alcohol Screening|iPad based automated alcohol screening
79533305|NCT01448811|Procedure|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
79379060|NCT06036940|Other|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
79689179|NCT06211673|Other|Semi-structured interviews|"3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively."
79834026|NCT02247388|Behavioral|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
79834027|NCT00874575|Dietary Supplement|Placebo|
79834028|NCT00874575|Dietary Supplement|Vitamin D|
79834029|NCT00874575|Dietary Supplement|Beta-hydroxy-Beta-methylbutyrate|
79834030|NCT00874575|Drug|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
79834031|NCT02009800|Biological|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
79834032|NCT05205213|Other|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
79834033|NCT05205057|Other|Saliva|Unstimulated whole saliva is collected
79834034|NCT00874653|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
80006430|NCT02253680|Procedure|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
79379061|NCT06036901|Diagnostic Test|Coronary CT|Coronary CT evaluation
79379062|NCT06036888|Other|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
80006431|NCT03572400|Drug|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
79238807|NCT03462368|Procedure|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
79238808|NCT03462368|Procedure|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
79238809|NCT03462368|Procedure|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
79238810|NCT02664272|Procedure|Total Hip Arthroplasty|
79379063|NCT06036875|Other|Non-Interventional Study|Non-interventional study
79533306|NCT01448837|Drug|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
79533307|NCT01448837|Drug|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
79533308|NCT01448863|Other|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
79533309|NCT01448889|Drug|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
79834035|NCT00369577|Drug|Inhaled Placebo|Inhaled Placebo, single dose
79834036|NCT00369577|Drug|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
80006432|NCT03572400|Drug|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
80006433|NCT02253836|Drug|Tipranavir|TPV
80006434|NCT02253836|Drug|Ritonavir|RTV
80006435|NCT02253836|Drug|Atazanavir|TAZ
80006436|NCT03575130|Drug|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
80006437|NCT03575130|Drug|Optive eye drops|Artificial tears (placebo)
80006438|NCT03575130|Procedure|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
80006439|NCT02241018|Drug|CD25 monoclonal antibody|
79533310|NCT01448889|Drug|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
79834037|NCT00369577|Drug|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
79834038|NCT02559336|Other|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
80006440|NCT02241018|Drug|calcineurin inhibitors|
80006441|NCT02241018|Biological|MSCs|
80006442|NCT04039022|Drug|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
80006443|NCT03570684|Device|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
79238811|NCT02663882|Behavioral|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
79238812|NCT02663882|Behavioral|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
79238813|NCT02388620|Drug|LEE011|400 mg
79834039|NCT00879957|Drug|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
79238814|NCT02388698|Procedure|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
79238815|NCT02388698|Radiation|PET-CT|PET-CT will be completed 3 month post chemoradiation.
79238816|NCT02388698|Biological|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
79379064|NCT06036862|Procedure|Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction|Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
79533311|NCT01448902|Drug|OC000459|OC000459 200mg bid for 8 days
79533312|NCT01448902|Drug|Placebo|Placebo bid for 8 days
79533313|NCT01448928|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
79238817|NCT02383238|Drug|Dapagliflozin|10 mg, oral for 6 weeks
79238818|NCT02383238|Drug|Placebo|oral for 6 weeks
79238819|NCT03011333|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
79238820|NCT03011333|Drug|Bupivacaine HCl without epinephrine|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
79238821|NCT03011333|Drug|Saline Placebo|Saline placebo via nerve block.
79302961|NCT03195829|Behavioral|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
79533314|NCT01448941|Procedure|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
79533315|NCT01448941|Procedure|Primary arthrodesis|Primary arthrodesis
79533316|NCT01448941|Procedure|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
79533317|NCT01448980|Procedure|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
79834040|NCT00879957|Drug|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
79834041|NCT00874809|Device|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
79834042|NCT02534155|Device|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
79834043|NCT02534155|Procedure|Mitral valve Surgery|Repair or replace mitral valve
79834044|NCT00880035|Device|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
79834045|NCT00761436|Biological|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
79834046|NCT00880113|Procedure|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
80006444|NCT02244450|Biological|SCID screening|
80006445|NCT04000178|Device|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
80006446|NCT04000178|Device|silicone stent|silicone stent
80006447|NCT03573726|Other|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
80006448|NCT03573570|Other|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
80006449|NCT00109772|Drug|lenalidomide|Two 5 mg capsules taken one time per day
79238822|NCT02383004|Other|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
79379065|NCT06036849|Procedure|Spinal manipulation|The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history & physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.
79379066|NCT06036849|Procedure|Spinal mobilization|The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
79379067|NCT06036797|Drug|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
79379068|NCT06036797|Drug|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
79379069|NCT06036797|Drug|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
79533318|NCT01448980|Procedure|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
79533319|NCT01448993|Drug|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
79533320|NCT01448993|Drug|Placebo|
79533321|NCT01449019|Drug|exendin(9-39)amide|intravenous infusion of exendin(9-39)
79834047|NCT00880347|Device|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
79834048|NCT00874965|Device|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
79834049|NCT00874965|Device|Sham stimulation|30 min; 5 times / week
79834050|NCT00875199|Behavioral|contingency management|Prize-based contingency management for weight loss
79834051|NCT00875199|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
79834052|NCT00875355|Drug|temozolomide|Given orally
79834053|NCT00875355|Radiation|radiation therapy|Patients undergo radiotherapy
79834054|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
79834055|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
79834056|NCT04772859|Behavioral|Online Lifestyle Intervention|"The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week."
79834057|NCT04772859|Other|Control Group|They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
80006450|NCT00109772|Drug|Placebo|Two placebo capsules taken one time per day
80006451|NCT03573492|Other|Education|Type of teaching being assigned to student arms
79533322|NCT01449019|Drug|saline|intravenous infusion of saline
79533323|NCT01449019|Other|duodenal meal|duodenal perfusion of a meal
79533324|NCT01449019|Other|duodenal saline|duodenal perfusion of saline
79533325|NCT01449032|Biological|MSC|No of cells after culture expansion
79533326|NCT01449032|Biological|Saline|3 cc saline
79533327|NCT01449045|Drug|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
80006452|NCT03572010|Dietary Supplement|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
80006453|NCT03572010|Dietary Supplement|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
79533328|NCT01449045|Drug|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
80006454|NCT03572010|Dietary Supplement|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L);
80006455|NCT03572010|Dietary Supplement|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
80006456|NCT03571932|Behavioral|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
80006457|NCT02245152|Dietary Supplement|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
79379070|NCT06036771|Device|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
79238823|NCT02383316|Other|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
79238824|NCT03011099|Device|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
79302962|NCT03195829|Behavioral|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
79533329|NCT01449058|Drug|BYL719|taken orally
79689180|NCT06211673|Other|Heteroquestionnaires|7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.
79834058|NCT00880659|Behavioral|Soap|Promotion of handwashing with soap
79834059|NCT04038879|Diagnostic Test|MRI|MRI of the heart
79834060|NCT00880815|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
79834061|NCT00880815|Biological|Anti-Thymocyte Globulin|Given IV
79533330|NCT01449058|Drug|MEK162|taken orally
79834062|NCT00880815|Drug|Bendamustine|Given IV
79379072|NCT06036745|Drug|Pembrolizumab + SOX|Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
79379073|NCT06036706|Radiation|Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
79834063|NCT00880815|Biological|Filgrastim|Given IV
79834064|NCT00880815|Drug|Fludarabine|Given IV
79834065|NCT00880815|Drug|Methotrexate|Given IV
79834066|NCT00880815|Biological|Rituximab|Given IV
79834067|NCT00880815|Drug|Tacrolimus|Given IV and PO
79834068|NCT00369343|Drug|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
79834069|NCT00369343|Drug|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
79834070|NCT00880971|Radiation|Postoperative 3D-CRT or IMRT|Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.
79834071|NCT03992599|Procedure|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
79533331|NCT01449084|Procedure|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
79689181|NCT06209827|Behavioral|Intervention for reducing benzodiazepines long-term use.|"Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor."
79834072|NCT00881049|Drug|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
79834073|NCT00881127|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
79834074|NCT00881127|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
79238825|NCT03011099|Other|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
79238826|NCT02382926|Other|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
79302963|NCT03195049|Diagnostic Test|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
79379074|NCT06036706|Radiation|Hypo-fractionated stereotactic brain irradiation|Patients receiving hypo-fractionated stereotactic brain irradiation
79379075|NCT06036706|Radiation|Normo-fractionated proton therapy brain irradiation|Patients receiving normo-fractionated proton therapy brain irradiation
79379076|NCT06036706|Other|Cognitive assessment by a trained neuropsychologis|Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
79379078|NCT06036654|Device|infrared thermotherapy instrument|Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
79379079|NCT06036615|Other|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 4-month de-training period, continuing their normal physical activity.
79379080|NCT06036589|Drug|CA and BAM8-22|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
79689182|NCT06208319|Other|data collection|data collection from the patient's medical record. The data will be that of routine care, with no procedures added by the research.
79689183|NCT06208150|Drug|Talquetamab|Talquetamab will be administered as a SC injection.
79689184|NCT06208150|Drug|Pomalidomide|Pomalidomide will be administered orally.
79689185|NCT06208150|Drug|Teclistamab|Teclistamab will be administered as a SC injection.
79689186|NCT06208150|Drug|Elotuzumab|Elotuzumab will be administered intravenously.
79834075|NCT00369265|Drug|Lansoprazole|Lansoprazole 30mg twice daily
79834076|NCT00369265|Dietary Supplement|Sugar pill|placebo twice daily
79834077|NCT00875745|Drug|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
79834078|NCT00368875|Drug|vorinostat|Given orally
79834079|NCT00368875|Drug|paclitaxel|Given IV
79834080|NCT00368875|Biological|bevacizumab|Given IV
79834081|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
79834082|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
79834083|NCT00614055|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
79834084|NCT00614055|Drug|metformin|Tablets, 1500-2000 mg/day
80006458|NCT02245152|Behavioral|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
79238827|NCT03667157|Drug|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
79834085|NCT01051141|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
80006459|NCT02245152|Behavioral|National policy well-baby visits|
80006460|NCT03571854|Device|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
79238828|NCT03667157|Drug|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
79238829|NCT02382770|Procedure|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
79533332|NCT01449084|Other|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
79238830|NCT03667859|Diagnostic Test|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
79238831|NCT04570397|Drug|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
79238832|NCT02385188|Drug|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
79379081|NCT06036589|Drug|Vehicle and BAM8-22 application|Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
79379082|NCT06036589|Drug|CA|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm
79533333|NCT01449097|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
79238833|NCT02385188|Drug|paracetamol|
79238834|NCT02385188|Drug|lidocaine in Vaseline ointment|
79238835|NCT04580927|Behavioral|Breastfeeding self-efficacy (BSE)|Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
79238836|NCT02385032|Drug|Ursodiol|
79238837|NCT02385032|Drug|URSO Forte|
79238838|NCT02384798|Other|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
79238839|NCT02384798|Other|interval training|interval training
79379083|NCT06036589|Drug|vehicle|Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
79533334|NCT01449097|Procedure|The femoral nerve block|US-guided femoral nerve block with ropivacaine
79533335|NCT01449097|Procedure|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
79689187|NCT06208150|Drug|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
79689188|NCT06208150|Drug|Bortezomib|Bortezomib will be administered as a SC injection.
79689189|NCT06207864|Procedure|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
79689190|NCT06207864|Procedure|Return of Results|Receive results
80006461|NCT03571854|Device|Group VCV|Volume controlled ventilation
80006462|NCT01560104|Drug|Veliparib|
79238840|NCT02384954|Biological|Rituximab|Intravenous infusion; Patients will receive a 4-week induction cycle consisting of Rituximab given on Day 1, 8, 15, 22. Eligible patients will receive a consolidation treatment consisting of Rituximab given on Day 78, 134, 190, 246.
79238841|NCT02384954|Biological|ALT-803|Intravenous infusion for cohort 1, 2 and 3; subcutaneous injection for cohort 4, 5, 6 and 7; Patients will receive a 4-week induction cycle consisting of ALT-803 given on Day 2, 8, 15, 22 for patients in cohort 1, 2, 3, 4 and Day 1, 8, 15 and 22 for patients in cohort 5, 6, 7. Eligible patients will receive a consolidation treatment consisting of ALT-803 given on Day 78, 134, 190, 246.
79238842|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
79379084|NCT06036576|Drug|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
79379085|NCT06036550|Diagnostic Test|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
79379086|NCT06036537|Diagnostic Test|diagnosis of Interstitial lung disease|Serum marker detection，High resolution computed tomography scan
79689191|NCT06207864|Other|Survey Administration|Surveys and Interviews
79689192|NCT06207305|Drug|Dexamethasone|Given by PO
79689193|NCT06207305|Drug|Diphenhydramine|Given by PO
79689194|NCT06207305|Drug|Famotidine|Given by PO
79689195|NCT06207305|Drug|Paclitaxel|Given by PO
79689196|NCT06207149|Behavioral|ASISTIR|This will be a 24 hour advocacy program focused on adult disability services.
80006463|NCT01560104|Drug|Carboplatin|
80006464|NCT01560104|Drug|paclitaxel|
80006465|NCT01560104|Drug|placebo|
80006466|NCT03573258|Dietary Supplement|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
79834086|NCT01051141|Behavioral|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
79834087|NCT01051141|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
79834088|NCT04040127|Biological|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
79834089|NCT04040127|Other|Saline solution|saline solution used to rinse the canal.
79834090|NCT00613821|Drug|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
79834091|NCT00613821|Drug|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
79834092|NCT04038723|Behavioral|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
79834093|NCT00882765|Dietary Supplement|genistein|Given orally
79834094|NCT04543695|Combination Product|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
79533336|NCT01449110|Dietary Supplement|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~capsule/day of placebo (350 mg maltodextrin) for 6 months~capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
79834095|NCT04543695|Drug|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
79834096|NCT04543695|Drug|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
79533337|NCT01449110|Dietary Supplement|Placebo in secondary prevention|"12 months follow-up:~capsule/day (350 mg maltodextrin) for 6 months~capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
79533338|NCT01449110|Dietary Supplement|Grape extract in primary prevention (PP)|"12 months follow-up:~capsule/day (350 mg grape extract) for 6 months~capsules/day (350 mg + 350 mg grape extract) for 6 months"
79689197|NCT06199089|Drug|CM313 Injection|"Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
79834097|NCT04543695|Procedure|TME|Total mesorectal excision
79834098|NCT00548548|Drug|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
80006467|NCT00101972|Biological|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
80006468|NCT02245854|Device|Exacto™|Cold snare polypectomy
79379087|NCT06036498|Device|Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography|We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.
79379088|NCT06036485|Device|Kerecis Omega 3|Decellularized intact fish skin developed for the management of chronic wounds
79379089|NCT06036485|Procedure|Surgical debridement|Superficial sharp surgical debridement technique
79391198|NCT02415426|Behavioral|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek & Steffen Moritz, http://clinical-neuropsychology.de/metacognitive_training_for_depression.html).
79834099|NCT00548548|Drug|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
79834100|NCT00548548|Drug|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
79834101|NCT00548548|Drug|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
80006469|NCT00100256|Drug|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
80006470|NCT03571698|Device|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
79834102|NCT00548548|Drug|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
79834103|NCT00613509|Biological|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
79834104|NCT00613509|Biological|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
79834105|NCT00881439|Drug|Aliskiren|Oral, 300 mg, once daily, 6 months
79379090|NCT06034431|Other|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
79533339|NCT01449110|Dietary Supplement|Grape extract in SP|"12 months follow-up:~capsule/day (350 mg grape extract) for 6 months~capsules/day (350 mg + 350 mg grape extract) for 6 months"
79238843|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
79379091|NCT06034197|Drug|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
79379092|NCT06034171|Device|dental implant|Dental implant surgery in the lower jawbone.
79379093|NCT06034145|Other|No intervention|No intervention
79379094|NCT06034132|Other|Stock healing abutments|2ND stage surgery will be performed and stock healing abutment were placed
79533340|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
79533341|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
79834106|NCT00881439|Drug|Placebo|Matching Placebo once daily, 6 months
79834107|NCT00881517|Drug|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
79834108|NCT00881517|Drug|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
79834109|NCT00881595|Drug|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
79834110|NCT00881595|Radiation|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
79834111|NCT00881595|Procedure|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
79834112|NCT00883155|Drug|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
79834113|NCT00883155|Drug|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
79834114|NCT01505062|Drug|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
79834115|NCT00881673|Drug|AL38583 Ophthalmic Solution|Topical ophthalmic
79834116|NCT00881673|Drug|Maxidex|Topical ophthalmic
79834117|NCT00881673|Drug|Vehicle|AL38583 Vehicle
79238844|NCT02384642|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
79834118|NCT00881829|Device|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
79834119|NCT01293448|Device|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
79834120|NCT00961714|Device|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
79834121|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
80006471|NCT02245932|Dietary Supplement|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
79238845|NCT02384642|Behavioral|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
79238846|NCT02384720|Other|Age: 20-40years|
79238847|NCT02384720|Other|Age: 41-64years|
79238848|NCT02384720|Other|Age: ≥65years|
80006472|NCT02245932|Dietary Supplement|Placebo|4 weeks of placebo supplementation (two doses per day)
80006473|NCT03573102|Drug|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
80006474|NCT03573102|Drug|ACE inhibitor|ACE inhibitor once daily
80006475|NCT02246088|Procedure|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
80006476|NCT02246088|Procedure|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
80006477|NCT02254070|Drug|BIBT 986 BS|
80006478|NCT04944368|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
80006479|NCT04944368|Biological|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
80006480|NCT03545672|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
80006481|NCT02783066|Device|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
80006482|NCT03754868|Diagnostic Test|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
80006483|NCT03546530|Drug|Interferon|Interferon
79238849|NCT03013985|Drug|Glargine U300|Glargine U300 is a new generation long-acting insulin.
79238850|NCT03013985|Drug|Glargine U100|Glargine U100 is a long-acting insulin.
79238851|NCT03013985|Drug|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
79238852|NCT02377388|Drug|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
79238853|NCT02377388|Drug|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
79379095|NCT06034132|Other|Compoiste healing abutments|2ND stage surgery will be performed and composite healing abutment were placed
79834122|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
80006484|NCT03546530|Drug|Interferon+resveratrol|Interferon+resveratrol
80006485|NCT03568526|Other|Educational Intervention|Attend a therapy session
80006486|NCT03568526|Behavioral|Exercise Intervention|Complete exercise
79238854|NCT03016403|Behavioral|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
79238855|NCT03016403|Behavioral|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
79238856|NCT02382536|Device|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
79238857|NCT02382536|Device|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
79379096|NCT06034119|Behavioral|Split belt treadmill|Participants will walk on a dual belt treadmill with each belt moving at a different speed which is known as a split belt treadmill to provide implicit modifications of the walking pattern
79834123|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
80006487|NCT03568526|Other|Quality-of-Life Assessment|Ancillary studies
80006488|NCT03568526|Other|Questionnaire Administration|Ancillary studies
80006489|NCT03568526|Other|Survey Administration|Ancillary studies
80006490|NCT03545828|Diagnostic Test|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
79302964|NCT03195439|Device|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
79379097|NCT06034119|Behavioral|Biofeedback|The Gait Real-time Analysis Interactive Lab (GRAIL) system has an immersive virtual reality screen that provides real-time information to participants of their walking pattern and provides visual instructions on how to walk more symmetrically
79379098|NCT06034106|Behavioral|Pomegranate (Punica granatum) peel compress|Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.
79533342|NCT01449123|Drug|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
79533343|NCT01449136|Other|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
79533344|NCT01449188|Drug|ondansetron|FDA approved drug used to treat nausea and vomiting
79533345|NCT01449188|Drug|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
79533346|NCT01449188|Other|saline|USP saline IV solution used as placebo for ondansetron IV.
79533347|NCT01449201|Drug|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
80006491|NCT04178252|Other|mask|investigators will add eye mask to standard treatment
79238858|NCT02382380|Drug|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
79238859|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
79238860|NCT02382302|Device|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
79834124|NCT04487925|Drug|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
79238861|NCT02382224|Behavioral|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
79238862|NCT02382224|Behavioral|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
79379099|NCT06034106|Behavioral|Hot compress|Hot compress was applied 3 days a week for 3 weeks.
79689198|NCT06199089|Drug|Placebo Injection|"Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration."
79834125|NCT04487925|Drug|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
79834126|NCT00547300|Drug|Metoprolol ER|Metoprolol ER once daily, oral administration
79379100|NCT06034093|Device|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
79379101|NCT06034080|Other|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
79379102|NCT06034080|Other|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
79834127|NCT00547300|Drug|Nebivolol|Nebivolol once daily, oral administration
79834128|NCT04386759|Other|Cohort|None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
79834129|NCT00958516|Drug|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
79834130|NCT00881985|Device|continuous positive airway pressure|Use CPAP whenever sleep
79834131|NCT00962572|Behavioral|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
80006492|NCT04178252|Other|headset|investigators will add headset to standard treatment
79834132|NCT00612807|Behavioral|Weekly marital therapy|Weekly marital therapy for 6 months.
80006493|NCT04178252|Other|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
80006494|NCT04872140|Dietary Supplement|Low phytate pea powder|Exercise performance with low phytate pea powder
80006495|NCT04872140|Dietary Supplement|Regular pea powder|Exercise performance with regular pea powder
80006496|NCT04872140|Dietary Supplement|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
80006497|NCT01371305|Drug|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
79238863|NCT02382458|Behavioral|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
79302965|NCT02481089|Other|validation group|
79379103|NCT06034080|Other|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
79533348|NCT01449214|Procedure|Ultrasound|Ultrasound-guided technique
79533349|NCT01449214|Procedure|Landmarking|Landmark-guided technique
79533350|NCT01449253|Drug|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
79533351|NCT01449253|Drug|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
80006498|NCT01371305|Drug|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
80006499|NCT03397550|Other|salt restriction education|Salt intake target：<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
80006500|NCT03545204|Other|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
80006501|NCT03545204|Other|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
80006502|NCT01366547|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
79379104|NCT06034080|Other|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
79689199|NCT06196723|Procedure|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
80006503|NCT01366547|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
80006504|NCT01366547|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
80006505|NCT01319669|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
80006506|NCT04032041|Device|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
80006507|NCT05190341|Drug|Ibuprofen 800 mg oral|1 hour before HSG
80006508|NCT05190341|Drug|Ketorolac 30mg oral|1 hour before HSG
80006509|NCT04347239|Drug|Placebos|Placebos
79238864|NCT02382458|Behavioral|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
79379105|NCT06034080|Other|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
79689200|NCT06189833|Drug|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
80006510|NCT04347239|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
80006511|NCT00109928|Drug|cisplatin|
80006512|NCT00109928|Drug|etoposide|
80006513|NCT00109928|Drug|gemcitabine|
80006514|NCT00109928|Drug|methylprednisolone|
80006515|NCT02104310|Drug|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
80006516|NCT00109850|Biological|cetuximab|400mg/m^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m^2 maintenance dose, IV over 60 min, Days 8 & 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
80006517|NCT00109850|Drug|cisplatin|30mg/m^2, bolus intravenous (IV), on Days 1 & 8 of each cycle.
80006518|NCT00109850|Drug|irinotecan hydrochloride|65mg/m^2, intravenous (IV) over 30 min, on Days 1 & 8 of each cycle.
80006519|NCT00109850|Radiation|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
80006520|NCT02143232|Device|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
80006521|NCT03318770|Drug|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
79238865|NCT02377154|Device|Slit lamp|Examination of cornea
79238866|NCT02377154|Device|Autorefractor|Measurement of refraction
79238867|NCT02377154|Device|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
79238868|NCT02377154|Device|Pentacam HR|Measurement of white-to-white distance; Keratometry
79238869|NCT02377154|Device|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
79391199|NCT03178734|Device|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
79391200|NCT02415348|Device|Fibroscan|
79689201|NCT06189833|Drug|Bortezomib|Bortezomib will be administered via a subcutaneous injection (SC)
79238870|NCT02377154|Device|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
79238871|NCT02377232|Behavioral|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
79238872|NCT02377232|Behavioral|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
79238873|NCT02382146|Drug|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
79238874|NCT02382146|Drug|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
79689202|NCT06189833|Drug|Lenalidomide|Lenalidomide will be administered orally
79689203|NCT06189833|Drug|Dexamethasone|Dexamethasone will be administered orally
79689204|NCT06185790|Other|LCHF diet|Low-carb high-fat (LCHF) diet
80006522|NCT05499273|Procedure|scalpel-bougie tracheostomy|"The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~An 8 FR Frova catheter is inserted through the orifice into trachea.~A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently."
80006523|NCT05499273|Procedure|rapid sequence tracheotomy|"Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently."
80006524|NCT01065519|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
80006525|NCT01065519|Device|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
80006526|NCT01342926|Drug|GSK933776|GSK933776
80006527|NCT01342926|Drug|Placebo|Placebo
80006528|NCT03626181|Device|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
80006529|NCT02524002|Dietary Supplement|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
80006530|NCT02524002|Dietary Supplement|Usual clear diet|Usual clear liquids
79238875|NCT02382068|Drug|Dexamethasone|Given via intratympanic injection
80006531|NCT01810016|Biological|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
79238876|NCT02382068|Other|Placebo|Given via intratympanic injection
80006532|NCT01810016|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
79533352|NCT01449292|Device|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
80006533|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
80006534|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
79238877|NCT02382068|Drug|Cisplatin|"Standard of care treatment with the following treatment course criteria:~Dose: > 50 mg/m2~Frequency: q3 -q4 weeks~Cycles: 7 maximum"
79238878|NCT02376842|Behavioral|Severe sepsis early warning best practice alert|
79238879|NCT02376842|Behavioral|Standard care|
79379106|NCT06034054|Other|nursing counceling|"Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~Answering the information and questions that the patient needs in addition, and receiving contact information in October.~Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
79238880|NCT04731272|Drug|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
79238881|NCT02520310|Device|AVJ-514|Patients receiving AVJ-514 device
79379107|NCT06034041|Drug|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
79379108|NCT06034041|Drug|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
79379109|NCT06034015|Drug|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
79238882|NCT02381912|Other|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
79689205|NCT06174259|Other|intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
79689206|NCT06173635|Device|Maxi Move 5|4 comparative devices will be used to evaluate the MM5 device
79689207|NCT06172621|Procedure|Spinal Cord Associative Plasticity (SCAP)|Paired non-invasive brain and spinal cord stimulation.
79689208|NCT06172621|Procedure|Upper extremity task-oriented exercise|Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
79379110|NCT06034015|Drug|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
79379111|NCT06033989|Drug|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
79379112|NCT06033989|Drug|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
79689209|NCT06172075|Behavioral|Brief video intervention (Black Woman)|A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
79689210|NCT06172075|Behavioral|Brief video intervention (Latinx Woman)|A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
79689211|NCT06172075|Behavioral|Brief video intervention (White Woman)|A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
79689212|NCT06172075|Behavioral|Vignette Control|A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
80006535|NCT02843178|Behavioral|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
79379113|NCT06033989|Procedure|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
79379114|NCT06033976|Procedure|Endoscopic submucosal dissection (ESD)|Endoscopic injection of fluid into the gastrointestinal submucosal space followed by endoscopic knife dissection around and under the lesion so as to remove the lesion specimen in one piece with lesion free resection margins.
79834133|NCT00612807|Drug|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
79834134|NCT00962806|Behavioral|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
80006536|NCT03571620|Drug|Q301 Cream|1.0% or 1.4% Q301 Cream
79689213|NCT06167603|Diagnostic Test|FDG-PET|Among other neuroimaging techniques, FDG-PET represents a unique tool to study the early metabolic alterations associated with neurodegeneration, both at the group and individual subject level.
79834135|NCT00962806|Behavioral|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
79834136|NCT05299684|Other|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
79834137|NCT04038801|Procedure|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
80006537|NCT03571620|Drug|Vehicle|Vehicle Control
80006538|NCT03571542|Other|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
80006539|NCT03571464|Device|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
80006540|NCT03123185|Drug|Placebo|Tablet and solution formulation
80006541|NCT03123185|Drug|BI 705564 (Test)|Fed state
80006542|NCT03123185|Drug|BI 705564 (Reference)|Fasting state
80006543|NCT03123068|Drug|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
80006544|NCT03123068|Other|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
79302966|NCT03195283|Other|Meal service|The type of meal service in the hospital (usual care)
79302967|NCT05667155|Biological|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
79302968|NCT02449759|Behavioral|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
79302970|NCT03198013|Drug|Prednisolone|Specified dose on specified days
79302971|NCT03198013|Drug|BMS-791826|Specified dose on specified days
79302972|NCT03198013|Drug|Placebo|Specified dose on specified days
79834138|NCT04038801|Procedure|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
79834139|NCT04038801|Procedure|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
79689214|NCT06167603|Diagnostic Test|Blood test and clinical examination.|baseline, 12-months and 24 months.
79238883|NCT02381600|Drug|Vitamin D|"Experimental :~Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
79238884|NCT03113084|Biological|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
79834140|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
79379115|NCT06033937|Device|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
79379116|NCT06033924|Behavioral|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
79834141|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
79834142|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
79834143|NCT00962962|Behavioral|Exercise and Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
80006545|NCT01372631|Device|miniature spectral imaging system|Use of miniature spectral imaging system
79533353|NCT01449292|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
79533354|NCT01449318|Device|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
79533355|NCT01449344|Drug|Rituximab|Rituximab 375mg/m² IV , day 1
79533356|NCT01449344|Drug|High dose Ara-C|Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
79302973|NCT05651399|Drug|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
79379117|NCT06033924|Behavioral|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
79379118|NCT06033846|Drug|Minocycline|treatment with minocycline combined with first/second-line drugs for autoimmune encephalitis
79379119|NCT06033794|Device|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
79533357|NCT01449344|Drug|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
79533358|NCT01449344|Drug|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
79689215|NCT06164743|Drug|VVN461 Ophthalmic Solution 1.0%|Topical ocular drug
79689216|NCT06164743|Drug|VVN461 Ophthalmic Solution 0.5%|Topical ocular drug
79689217|NCT06164743|Drug|Vehicle|Topical ocular drug
79689218|NCT06161571|Drug|Efruxifermin|Administered by subcutaneous (SC) injection
79689219|NCT06161571|Drug|Placebo|Administered by SC injection
79689220|NCT06160752|Drug|Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
79689221|NCT06160752|Drug|Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
79689222|NCT06159933|Procedure|Supine positioning|According to our local protocol, until December 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
79834144|NCT00882063|Drug|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
79238885|NCT03113084|Biological|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
79238886|NCT02384408|Procedure|Endometrial Biopsy|Histological assessment
79238887|NCT02384408|Device|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
79238888|NCT02384408|Procedure|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
79379120|NCT06033755|Other|Norwegian psychomotor physiotherapy|"The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months."
79834145|NCT00958672|Other|Endoscopic capsule|Endoscopic capsule
79533359|NCT01449357|Drug|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
79689223|NCT06159933|Procedure|Early pronation|According to our local protocol, starting from January 2022, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
79834146|NCT00958750|Drug|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
79834147|NCT00882141|Behavioral|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
79834148|NCT00882141|Behavioral|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
80006546|NCT01372631|Device|Bench-top optical spectrometer|Use of bench-top optical spectrometer
80006547|NCT01372631|Device|High resolution microendoscope|Use of high resolution microendoscope
79238889|NCT04852640|Procedure|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
79302974|NCT05651399|Drug|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
79379121|NCT06033742|Drug|HS-10374 tablets|Single or multiple dosing of HS-10374 orally in a fasting state
79379122|NCT06033742|Drug|HS-10374-matched placebo tablets|Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
79379123|NCT06033729|Drug|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
79379124|NCT06033729|Drug|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
79379125|NCT06033729|Drug|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
79533360|NCT01449383|Dietary Supplement|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
79533361|NCT01449383|Dietary Supplement|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
79533362|NCT01449396|Other|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
79533363|NCT01449396|Procedure|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
79533364|NCT01449396|Procedure|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
79533365|NCT01449422|Device|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
79533366|NCT01449422|Device|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
79533367|NCT01449435|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
79834149|NCT04902274|Other|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
79834150|NCT04902274|Other|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
79834151|NCT04902274|Other|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
79834152|NCT00958906|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
79834153|NCT00882219|Device|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
79834154|NCT00959062|Drug|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
79834155|NCT00959062|Drug|placebo|Preparation visually identical to clonidine.
79834156|NCT04296981|Other|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
79834157|NCT04009564|Dietary Supplement|Date coffee|45 g of date seeds coffee in 280 ml of water
79834158|NCT04009564|Dietary Supplement|Normal coffee|6 g of normal coffee in 280ml of water
79834159|NCT04009564|Dietary Supplement|Placebo|water, food colouring and coffee flavouring
79834160|NCT04038411|Drug|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
79834161|NCT04009642|Other|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
79834162|NCT00882297|Procedure|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
79834163|NCT00883467|Procedure|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
79834164|NCT00883467|Procedure|no preconditioning|no preconditioning
79834165|NCT00963118|Dietary Supplement|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
79834166|NCT00882375|Drug|Nicotine|Nicotine administered using novel NRT user instructions
79238890|NCT04852640|Procedure|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
79238891|NCT02377076|Dietary Supplement|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
79834167|NCT00882375|Drug|Placebo|Placebo administered using novel NRT user instructions
79834168|NCT00963196|Dietary Supplement|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
79834169|NCT00963196|Drug|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
79834170|NCT00882453|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
79834171|NCT04860778|Dietary Supplement|BDNF Essentials|Participants will take two capsules, twice daily with water for 84 days.
79834172|NCT00883545|Other|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
79238892|NCT02377076|Dietary Supplement|Control|Control (Whey protein, vitamin D, sugar and salt)
79238893|NCT02381756|Device|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
79238894|NCT02376764|Procedure|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
79379126|NCT06033729|Drug|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
79379127|NCT06033716|Other|Measurement correlation variable|resilience and anxiety and depression
79379128|NCT06033690|Behavioral|multidisciplinary guide|use of the food guide for education, clarification of doubts
79379129|NCT06033651|Radiation|x-ray|A sample of blood will be taken and sent to a lab in Surrey to check for metal ions.
79379130|NCT06033612|Drug|RV299|Oral Suspension
79379131|NCT06033612|Drug|Placebo|matching placebo
79379132|NCT06033612|Drug|Midazolam|pre-filled oral syringe
79533368|NCT01449448|Drug|Ketorolac|Subacromial injection
79533369|NCT01449448|Drug|Triamcinolone|Subacromial Injection
79533370|NCT01447992|Device|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
79533371|NCT01449474|Device|Patient matched instruments|The patients undergo TKA with using patient matched instruments
79533372|NCT01449474|Device|Jig based instruments|The patients undergo TKA with using jig based instruments
79834173|NCT00883545|Other|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
79834174|NCT04812340|Other|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
79533373|NCT01449487|Drug|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
79834175|NCT04812340|Other|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
79834176|NCT00882531|Drug|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
79834177|NCT00882531|Drug|placebo|
79834178|NCT00923403|Dietary Supplement|plant sterol enriched soymilk|plant sterol enriched soymilk
79834179|NCT00923403|Dietary Supplement|control dairy milk|control dairy milk
79834180|NCT00963274|Drug|Bortezomib|Starting dose: 1.3 mg/sq m
79238895|NCT02381834|Procedure|Bladder stimulation technique|
79834181|NCT00963274|Drug|Romidepsin|Starting dose: 8 mg/sq m
79834182|NCT00882609|Device|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
79834183|NCT00883623|Drug|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
79834184|NCT00959218|Drug|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
79834185|NCT00959218|Drug|Placebo|oral solution
79834186|NCT04009954|Other|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
79834187|NCT00678210|Drug|CP-690,550|tablets, 2 mg BID for 12 weeks
79238896|NCT02381210|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
79238897|NCT02384252|Other|functional tissu atrial analysis|
79238898|NCT02384564|Device|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
79834188|NCT00678210|Drug|CP-690,550|tablets, 5 mg BID for 12 weeks
79834189|NCT00678210|Drug|CP-690,550|tablets, 15 mg BID for 12 weeks
79834190|NCT00678210|Drug|Placebo|tablets, BID for 12 weeks
79834191|NCT00959296|Device|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
79834192|NCT00611715|Drug|erlotinib hydrochloride|OSI-774 150 mg/day
79834193|NCT00611715|Drug|letrozole|Letrozole 2.5 mg/day
79834194|NCT00611715|Genetic|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
79834195|NCT00611715|Other|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
79834196|NCT00611715|Other|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
79834197|NCT04722718|Drug|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
79238899|NCT02384564|Device|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
79533374|NCT01449487|Drug|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
79533375|NCT01449500|Dietary Supplement|L. reuteri|Chewable tablet, one tablet/day for 28 days
79238900|NCT05041972|Drug|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
79238901|NCT02384486|Behavioral|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
79533376|NCT01449500|Dietary Supplement|Placebo|Chewable tablet, one tablet per day for 28 days
79533377|NCT01448954|Drug|ADC3680B oral|Once daily for 28 days
79533378|NCT01448954|Drug|Placebo oral|Once daily for 28 days
79834198|NCT04649710|Biological|BMS-986036|Specified dose on specified days
79834199|NCT04649710|Other|Placebo|Specified dose on specified days
79834200|NCT00885573|Device|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
79834201|NCT00761670|Drug|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
79689224|NCT06159933|Procedure|Late pronation|According to our local protocol, until December 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
79689225|NCT06158152|Dietary Supplement|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
79689226|NCT06158152|Dietary Supplement|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
79834202|NCT00963664|Drug|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
79379133|NCT06033599|Other|MORE and MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
79834203|NCT00963664|Drug|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
79834204|NCT00677820|Biological|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
79834205|NCT00677820|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
79834206|NCT00611559|Biological|Infanrix™ penta|Subjects received a booster dose
79834207|NCT00611559|Biological|Infanrix™ hexa|Subjects received a booster dose
79834208|NCT00963742|Device|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
79834209|NCT00963898|Device|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
79238902|NCT02384486|Other|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
79834210|NCT00761904|Behavioral|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
79834211|NCT00963976|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
79834212|NCT00964054|Other|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
79238903|NCT05041348|Diagnostic Test|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
79238904|NCT02384174|Dietary Supplement|Resistant starch|
79238905|NCT02384174|Dietary Supplement|Dietary fibre (arabinogalactan, gum guar, pectin)|
79834213|NCT00964054|Other|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
79238906|NCT04439474|Drug|Vitamin D3|For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
79238907|NCT04439474|Drug|Routine treatment|In this group, patients receive their usual medications and treatments
79238908|NCT02662556|Drug|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
79689227|NCT06158152|Dietary Supplement|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
79689228|NCT06158113|Drug|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
79689229|NCT06157255|Drug|AZD4604 Inhalation Powder, 1 mg|3 mg dose, inhaled, fasted
79689230|NCT06157255|Drug|[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)|30 μg, intravenous, fasted
79689231|NCT06157255|Drug|[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)|4 mg, oral, fasted
79238909|NCT05055076|Device|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
79379134|NCT06033599|Other|MORE and No MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
79379135|NCT06033599|Other|Support Group and MI and NRT|Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
79379136|NCT06033599|Other|Support Group and No MI and NRT|Eight group support group sessions and and nicotine replacement therapy.
79533379|NCT01449552|Drug|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
79533380|NCT01449552|Procedure|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
79689232|NCT06153693|Drug|Placebo|Placebo once daily (QD) for 12 weeks
79689233|NCT06153693|Drug|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
79689234|NCT06153693|Drug|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
79689235|NCT06151652|Drug|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
79834214|NCT02559258|Drug|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
79834215|NCT02559258|Drug|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
79834216|NCT02559258|Drug|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
79834217|NCT02559258|Drug|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
79834218|NCT02559258|Drug|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
79834219|NCT00964132|Drug|NRX194204|Once Daily, Oral
79834220|NCT02558868|Drug|Irinotecan|
79834221|NCT02558868|Drug|Oxaliplatin|
79834222|NCT00611247|Drug|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
79834223|NCT04038177|Behavioral|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
79834224|NCT04038177|Behavioral|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
79834225|NCT00885651|Drug|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
79834226|NCT00885651|Drug|Placebo|
79238910|NCT05039242|Other|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
79238911|NCT05039242|Other|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
79238912|NCT05039242|Other|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
79689236|NCT06151652|Drug|Placebo|placebo
79689237|NCT06150560|Drug|Losartan|50mg administered orally once daily for 52 weeks.
79834227|NCT00885729|Procedure|stem cells|Stem cells or chondrocytes under a commercial available membrane
79834228|NCT00885729|Procedure|Chondrocytes|Implantation of chondrocytes
79834229|NCT00885729|Other|Rehabilitation program|Strength exercises, neuromuscular exercises
79834230|NCT00883935|Drug|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
79834231|NCT00883935|Drug|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
79834232|NCT00883935|Drug|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
80006548|NCT02254148|Drug|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
79689238|NCT06150560|Drug|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
79834233|NCT00883935|Drug|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
79689239|NCT06150560|Drug|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
79834234|NCT00675948|Drug|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
79834235|NCT00675948|Drug|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
79834236|NCT02659878|Procedure|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
79834237|NCT02529696|Device|Accelerometer|Measures patient movement
79834238|NCT00885885|Drug|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
80006549|NCT02254148|Drug|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
80006550|NCT02254148|Drug|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
80006551|NCT02254148|Drug|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
80006552|NCT02254148|Drug|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
79689240|NCT06150157|Drug|JNJ-88549968|JNJ-88549968 will be administered.
79834239|NCT00885885|Drug|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
79834240|NCT04077762|Procedure|Radial Access|Radial Access
79834241|NCT04077762|Procedure|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
79834242|NCT04077762|Procedure|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
79238913|NCT05054686|Other|Stretching and Aerobic Exercise at Clinic|In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.
79238914|NCT05054686|Other|Strenghthening and Aerobic Exercise|In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.
79834243|NCT00610935|Drug|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
79834244|NCT00610935|Drug|Placebo|Single intramuscular injection
79834245|NCT00761982|Procedure|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
79834246|NCT04049448|Drug|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
79834247|NCT02303028|Drug|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
79834248|NCT02287818|Drug|Placebo|Placebo twice daily from Day 1 to Week 12
79834249|NCT02287818|Drug|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
79834250|NCT02287818|Drug|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL
79834251|NCT02542449|Dietary Supplement|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
79238915|NCT05054686|Other|Strengthening, Stretching and Aerobic Exercises at clinic|In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
79379137|NCT06033573|Diagnostic Test|contrast-enhanced spectral mammography|After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing
79834252|NCT02542449|Dietary Supplement|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
79834253|NCT00762060|Device|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
79689241|NCT06149689|Combination Product|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin [70 mg per square meter of body surface area], irinotecan [130 mg per square meter], leucovorin [200 mg per square meter], and fluorouracil [2000 mg per square meter] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
79834254|NCT00762060|Drug|Patient controlled analgesia|IV opioids delivered via PCA
79834255|NCT00884169|Drug|M518101|Proper quantity twice a day
79834256|NCT00884169|Drug|placebo|Proper quantity twice a day
79834257|NCT00886041|Procedure|laparoscopy|subjected to laparoscopy
79689242|NCT06148181|Drug|ABBV-141|Infusion; intravenous (IV)
79379138|NCT06033560|Device|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
79834258|NCT00886041|Other|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
79379139|NCT06033521|Drug|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
79689243|NCT06148181|Drug|Placebo for ABBV-141|Infusion; IV
80006553|NCT02254148|Drug|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
80006554|NCT02254148|Drug|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
79238916|NCT04439864|Device|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
79238917|NCT04988620|Other|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
79379140|NCT06033482|Procedure|The reasonable range of No.12a lymph node dissection|The lymph node overlying the proper hepatic artery is defined as No.12aa. The lymph node overlying the left side of the portal vein is defined as No.12av. Observation of lymph node metastasis rates in two groups.
79379141|NCT06033469|Drug|Infliximab|Pediatric patients with IBD suitable for treatment with infliximab
79379142|NCT06033469|Drug|Adalimumab|Pediatric patients with IBD suitable for treatment with adalimumab
79238918|NCT02376608|Dietary Supplement|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
79238919|NCT02376608|Dietary Supplement|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
79689244|NCT06148181|Drug|ABBV-141|Injection; subcutaneous (SC)
79689245|NCT06148181|Drug|Placebo for ABBV-141|Injection; SC
79689246|NCT06145607|Drug|ABBV-CLS-7262|ABBV-CLS-7262
79689247|NCT06143878|Drug|JNJ-77242113|JNJ-77242113 will be administered orally.
79834259|NCT05278923|Device|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
79834260|NCT00610857|Drug|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
79834261|NCT00672984|Drug|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
79834262|NCT00672984|Drug|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
79834263|NCT00672984|Drug|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
79834264|NCT02543697|Radiation|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
79238920|NCT02376608|Dietary Supplement|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
79238921|NCT02376608|Dietary Supplement|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
79391201|NCT03180606|Other|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
79391202|NCT03178812|Procedure|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
79689248|NCT06143878|Drug|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
79689249|NCT06143878|Drug|Deucravacitinib|Deucravacitinib will be administered orally.
79689250|NCT06143878|Drug|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
79689251|NCT06139406|Drug|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
79689252|NCT06139406|Drug|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
79689253|NCT06139406|Drug|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
79689254|NCT06135545|Combination Product|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
79689255|NCT06135545|Combination Product|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
79834265|NCT00762138|Device|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
79834266|NCT02543775|Procedure|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
79689256|NCT06135259|Drug|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
79689257|NCT06135259|Drug|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
79834267|NCT00758472|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
79834268|NCT00886275|Drug|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
79834269|NCT00886275|Drug|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
79834270|NCT00886275|Drug|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
79834271|NCT02543619|Other|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
79689258|NCT06134154|Other|Endoscopic insufflation gas|Carbon dioxide gas versus air for endoscopic insufflation
79834272|NCT00886353|Biological|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
79834273|NCT00886353|Other|Placebo|Physiological saline administrated i.v.
79834274|NCT02543463|Device|Trident X3 Insert with Navigation system|
79834275|NCT02543463|Device|Trident X3 Insert with conventional instrumentation|
79834276|NCT04017897|Drug|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
79834277|NCT02543541|Behavioral|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
79834278|NCT02543541|Behavioral|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
79834279|NCT02542137|Radiation|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
80006555|NCT01366625|Device|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
80006556|NCT02842866|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
79238922|NCT02381366|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
79238923|NCT04987918|Diagnostic Test|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
79238924|NCT04732520|Device|Pulsed electric field treatment using the Aliya System|pulsed electric field treatment of a single NSCLC tumor
79379143|NCT06033456|Procedure|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning"
79391203|NCT03178812|Diagnostic Test|Laboratory Blood test|Laboratory Blood Test
79391204|NCT02415270|Other|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
79689259|NCT06130787|Biological|Blood and bone marrow sample|"Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36"
79834280|NCT02542137|Drug|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
80006557|NCT02842866|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
80006558|NCT03078296|Other|survey respondents|all survey participants will be asked to complete a questionnaire
80006559|NCT01316913|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
79238925|NCT04845776|Dietary Supplement|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
79238926|NCT05036590|Other|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
79238927|NCT05036590|Other|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
79238928|NCT02376452|Drug|Raltitrexed|2mg/m2 iv gtt, d1
80006560|NCT01316913|Drug|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
79834281|NCT00886431|Other|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
79834282|NCT00886509|Biological|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
79834283|NCT00886509|Other|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
79834284|NCT00886665|Drug|placebo|placebo, 4 g, powder, oral, 3 times a day
79834285|NCT00886665|Drug|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
79834286|NCT02543385|Drug|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
80006561|NCT01316913|Drug|GSK573719|125 mcg once-daily
80006562|NCT01316913|Drug|tiotropium bromide|18 mcg once-daily
79238929|NCT02376452|Drug|Irinotecan|180 mg/m2 iv gtt, d1
79689260|NCT06130553|Drug|AZD3470|AZD3470 is a novel, potent and selective, second-generation, methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
79689261|NCT06130254|Drug|Adagrasib|Given by PO BID
79834287|NCT00886977|Drug|YAM80|Oral administration, 2 to 6 mg, once a day.
79834288|NCT00884481|Other|Natalizumab|Participants treated with Tysabri
79834289|NCT02543307|Procedure|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
79238930|NCT02376452|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
79238931|NCT02376452|Drug|Leucovorin|400mg/m2 iv gtt,d1
79238932|NCT02383784|Dietary Supplement|Low GI index diet|Low glycemic index diet
79238933|NCT02383784|Dietary Supplement|High GI diet|High glycemic index diet
80006563|NCT02875067|Biological|Pembrolizumab|
80006564|NCT02875067|Drug|Lenalidomide|
80006565|NCT03544580|Procedure|immediate implant with dentine chips|Using dentin chips
80006566|NCT03544580|Procedure|conventional immediate implant|using xenograft
79238934|NCT02383394|Other|follow up antenatal care|ultrasound follow up of pregnancy
79238935|NCT02383550|Other|Observational Cognitive assessments|Observational
79238936|NCT02372084|Drug|osilodrostat|
79238937|NCT02516098|Drug|hyoscine butylbromide|
79689262|NCT06130254|Drug|Olaparib|Given by PO BID
79834290|NCT02543151|Procedure|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
79834291|NCT02543229|Drug|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
80006567|NCT02254538|Drug|BILR 355 BS|
80006568|NCT02254538|Drug|PEG 400|
80006569|NCT03572946|Procedure|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
79238938|NCT02372318|Drug|Nalmefene|18mg of Nalmefen will be administered orally
79238939|NCT02372318|Drug|Placebo|Placebo tablet
79238940|NCT03105752|Other|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
79238941|NCT03105674|Drug|Multi-drug local anesthetics (Combination)|"Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
79238942|NCT03105674|Drug|Standard local anesthetics (Combination)|Marcaine and Lidocaine
79238943|NCT02380898|Drug|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
79238944|NCT02380898|Drug|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
79689263|NCT06127849|Dietary Supplement|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One Placebo capsule to be taken 30 minutes after sachet in the morning."
79689264|NCT06127849|Dietary Supplement|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~- One Placebo capsule to be taken 30 minutes after whey protein in the morning"
80006570|NCT03572946|Procedure|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
80006571|NCT01366703|Device|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
80006572|NCT02143544|Device|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
80006573|NCT03570294|Drug|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
80006574|NCT02143622|Biological|LJM716|antibody
80006575|NCT02143622|Biological|cetuximab|antibody
79238945|NCT02380976|Drug|combination drug: DW330SR, DW1030|
79238946|NCT02380976|Drug|DW340|
80006576|NCT03142659|Other|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
80006577|NCT02781506|Drug|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
79238947|NCT02381132|Drug|Norco 7.5mg/325|
79238948|NCT02381132|Drug|MNK155|
79533381|NCT01449552|Other|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
79238949|NCT05034484|Drug|ALPN-303|Multiple dose levels will be evaluated.
79238950|NCT05034484|Drug|Placebo|Placebo will be administered
79379144|NCT06033456|Procedure|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
79379145|NCT06033456|Procedure|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
79834292|NCT02543229|Drug|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
79834293|NCT02543073|Biological|MSCs|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment.
79379146|NCT06033443|Other|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
79379147|NCT06033365|Behavioral|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
79379148|NCT06033339|Other|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
79533382|NCT01449552|Other|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
79533383|NCT01449565|Drug|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
79533384|NCT01449565|Drug|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
79834294|NCT02543073|Drug|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
79834295|NCT02543073|Drug|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
79834296|NCT02542995|Other|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
79834297|NCT00887055|Device|CRT device|
79834298|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
80006578|NCT02781506|Radiation|SAbR|SAbR (1-3 lesions)
80006579|NCT03780179|Biological|MMRvaxpro|MMRvaxpro vaccine
80006580|NCT03780179|Biological|Placebo|Placebo
80006581|NCT03570216|Other|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
79238951|NCT04985032|Radiation|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
79238952|NCT02376296|Drug|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
79238953|NCT02376296|Other|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
79238954|NCT05034172|Other|Clinical follow-up|"Clinical Follow-up:~demographic data and history,~Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only);~Family history - Neurological examination:~Diagnosis Clinical examination;~Rating scales specific to the pathology under investigation;~Cerebral MRI (optional)~Biological samples (optional)"
79238955|NCT02380820|Device|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
79238956|NCT02380820|Device|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
79834299|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
79834300|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
79834301|NCT00884559|Other|instruction|Debriefing
79834302|NCT00546364|Drug|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
79834303|NCT00546364|Drug|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
79834304|NCT00546364|Drug|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
79834305|NCT00887211|Device|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
79834306|NCT00887211|Device|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
79533385|NCT01449578|Drug|Dexpramipexole|Oral Tablet at varying doses
79533386|NCT01449578|Drug|Dexpramipexole Placebo|Oral tablet at varying doses
79689265|NCT06127849|Dietary Supplement|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of EB-PA to be taken 30 minutes after whey protein in the morning"
79834307|NCT00887367|Drug|GSK598809|Two 175 mg doses of GSK598809 will be given.
79302975|NCT02477891|Drug|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
79379149|NCT06033313|Behavioral|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
79834308|NCT00887367|Other|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
79689266|NCT06126991|Drug|Cetirizine|Oral administration of cetirizine at 10mg once daily will be used.
79834309|NCT00887445|Drug|SLV341|5 - 1000mg once daily
80006582|NCT03570216|Other|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
79302976|NCT02447263|Procedure|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
79379150|NCT06033313|Behavioral|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
79379151|NCT06033300|Biological|blood sample|blood sample
79391205|NCT02415270|Other|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
79533387|NCT01449604|Radiation|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
79533388|NCT01449604|Radiation|stereotactic radiosurgery|Radio surgery 12 Gy
79689267|NCT06126991|Drug|Midazolam and Fentanyl|Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
79689268|NCT06126952|Drug|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
79689269|NCT06126952|Drug|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
79689270|NCT06126952|Drug|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
79689271|NCT06122389|Drug|SHR2554; Chidamide analog tablets|SHR2554 + Chidamide analog tablets
79834310|NCT00887445|Drug|placebo|
80006583|NCT03570216|Other|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
79302977|NCT03208543|Device|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
79302978|NCT02477813|Drug|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
79302979|NCT03119311|Diagnostic Test|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
79302980|NCT03119311|Diagnostic Test|APCT|alternative prism cover test
79533389|NCT01449617|Drug|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
79533390|NCT01449643|Device|Threshold|
79533391|NCT01449643|Device|Sham Threshold|
79533392|NCT01449656|Device|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
79689272|NCT06122389|Drug|SHR2554 analog tablets; Chidamide|SHR2554 analog tablets + Chidamide
79238957|NCT02371928|Other|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
79834311|NCT00964210|Drug|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
79238958|NCT02371928|Other|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
79238959|NCT02380664|Device|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
79834312|NCT00964288|Drug|GSK1014802 low dose|oral tablet
79834313|NCT00964288|Drug|Lidocaine|positive control
79238960|NCT02380664|Behavioral|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
79379152|NCT06033287|Drug|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
79533393|NCT01449656|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
79533394|NCT01449695|Behavioral|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
79533395|NCT01449695|Behavioral|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
79689273|NCT06117670|Combination Product|posterior colporrhaphy using gamma-irradiated amniotic membrane as a graft|Posterior colporrhaphy with application of the gamma-irradiated amniotic membrane graft will be done
79689274|NCT06116786|Drug|JNJ-86974680|JNJ-86974680 will be administered.
79689275|NCT06116786|Drug|Cetrelimab|Cetrelimab will be administered.
79834314|NCT00964288|Drug|GSK1014802 high dose|oral tablet
79689276|NCT06116786|Radiation|Radiation Therapy|Radiation therapy will be administered.
79834315|NCT00964288|Drug|Placebo|To match GSK drug and positive control
79834316|NCT00964522|Other|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
79834317|NCT05955001|Drug|Tadalafil 5mg|Patients after Endoscopic Enucleation of Prostate will receive single daily dose of Tadalafil for 3 months
80006584|NCT03132753|Behavioral|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
79238961|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
79238962|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
79689277|NCT06114550|Other|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
79379153|NCT06033274|Device|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
79533396|NCT01449695|Behavioral|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
79533397|NCT01449760|Other|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
79689278|NCT06114550|Other|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
79834318|NCT05954975|Combination Product|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
79238963|NCT02376374|Other|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
79533398|NCT01449760|Other|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
79238964|NCT05032534|Device|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
79689279|NCT06112171|Procedure|Intravascular lithotripsy|Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
79689280|NCT06112171|Procedure|Standard lesion preparation|Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
79834319|NCT05954923|Other|Amino acid bolus infusion|Equimolar bolus infusions of amino acids or saline (placebo)
79834320|NCT05954897|Drug|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
79834321|NCT05954884|Other|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~Community- and team-based model of hypertension care delivery~Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~Community-based, multi-month prescription refills from CC~Training of clinic and research staff on BP measurement following standard techniques~Site monitoring and mentorship to ensure screening and patient enrollment/registration~Use of text messages to promote follow-up visits and medication adherence"
79834322|NCT05954858|Procedure|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
79834323|NCT05954806|Drug|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
79834324|NCT05954780|Drug|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
79238965|NCT05032534|Device|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
79238966|NCT02371694|Other|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
79238967|NCT02371772|Other|Training|Patients were trained to monitor INR and dose warfarin
79238968|NCT02380586|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
79834325|NCT05954767|Drug|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
79238969|NCT02375828|Drug|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
79238970|NCT02380508|Drug|BCG SSI|Intradermal injection
79379154|NCT06033248|Diagnostic Test|urine sample|urine sample will be collected
79379155|NCT06033235|Diagnostic Test|CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit
79379156|NCT06033183|Biological|Blood sample|Blood sample collection : 2 X 5 ml
79379157|NCT06033170|Device|CELOX™ PPH|Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.
79379158|NCT06033144|Diagnostic Test|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~Lingual clinical examination~Nasofibroscopy~Ultrasonography"
79379159|NCT06033118|Drug|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
79533399|NCT01449773|Dietary Supplement|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
79533400|NCT01449773|Dietary Supplement|Placebo|5 capsules/day containing corn and soybean oil
79533401|NCT01449786|Drug|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
79533402|NCT01449786|Drug|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
79689281|NCT06108427|Other|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
79834326|NCT05954754|Other|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
79834327|NCT05954689|Other|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
79834328|NCT05954650|Behavioral|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
79834329|NCT05954611|Biological|GR2002 injection|one single dose of GR2002 injection
79834330|NCT05954611|Biological|Placebo|one single dose of placebo
79834331|NCT05954598|Dietary Supplement|probiotic|This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
79834332|NCT05954572|Diagnostic Test|standardized skin surface biopsy (SSSB)|This technique is applied in four facial localizations, including the forehead, cheeks, and nose. The surface biopsy procedure is performed as follows: one cm² area was marked on a glass slide using a fine ruler. The designated skin area for sampling is gently swabbed with a dry gauze pad to create mild irritation. Subsequently, one drop of cyanoacrylate adhesive is applied to the marked area on the glass slide. The glass slide is carefully pressed onto the skin, allowing the adhesive to adhere. After approximately one minute, the glass slide is gently lifted. The sampled area on the glass slide is examined under x10 and x40 magnification. Immersion oil is applied to enhance visualization and determine the number of Demodex parasites within the marked area. An increased demodicosis is defined as the presence of five or more Demodex parasites per square centimeter of skin.
79689282|NCT06105736|Behavioral|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
79834333|NCT05954520|Device|Tympan|Participants will wear a prototype hearing aid (called the Tympan)
79834334|NCT05954429|Drug|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
79834335|NCT05954429|Drug|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
79834336|NCT05954390|Dietary Supplement|Undenatured beta-glucan solution|The active comparator is a solution containing undenatured beta-glucans
79834337|NCT05954390|Other|Placebo|The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
79834338|NCT05954260|Diagnostic Test|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
79834339|NCT05954234|Other|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
79834340|NCT05954234|Other|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
79834341|NCT05954234|Other|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
79834342|NCT05954221|Procedure|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
79238971|NCT02380508|Other|No vaccination|
79238972|NCT02380508|Drug|BCG Sii|intradermal injection
79238973|NCT02380430|Other|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
79238974|NCT02371538|Dietary Supplement|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
79238975|NCT02376218|Drug|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
79238976|NCT02376062|Other|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~Weekly case conferences~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
79238977|NCT02371226|Drug|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
79834343|NCT05954221|Procedure|Conventional processing|The tissue is fixed with 10% formalin.
79834344|NCT05954208|Other|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
79238978|NCT02371304|Radiation|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
79834345|NCT05954208|Other|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
79834346|NCT05954195|Other|high intensity interval training|high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
79834347|NCT05954156|Other|injectable composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
79834348|NCT05954130|Other|Education|Sexual Health in Pregnancy
79834349|NCT05954117|Procedure|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
79834350|NCT05954091|Drug|OH2 Injection|OH2 injection will be given intratumorally, and Q2W.
79834351|NCT05954078|Drug|mFOLFIRINOX adjuvant chemotherapy|mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
79834352|NCT05954078|Drug|mFOLFOX6/XELOX adjuvant chemotherapy|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
79834353|NCT05954052|Drug|Glutathione|Giving supplement orally
79238979|NCT02371304|Procedure|Additional TME surgery|
79689283|NCT06105606|Device|AveCure Flexible Microwave Ablation Probe|Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
79689284|NCT06105359|Behavioral|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
79834354|NCT05954039|Dietary Supplement|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
79834355|NCT05954039|Dietary Supplement|Placebo|The study foresees the intake of 2 capsules per day during 84 days
79834356|NCT05954013|Behavioral|PD_Pal intervention|The PD_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD_Pal intervention, i.e. the PD_Pal nurse. In the PD_Pal intervention, the patient, family caregiver and PD_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD_Pal nurse.
80006585|NCT03572868|Other|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter < 5th centile during the second or the third trimester of pregnancy.
80006586|NCT05190185|Biological|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106~1×108 CAR-T/kg. And the subjects will be administered once.
79689285|NCT06105359|Other|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
79238980|NCT02371304|Drug|capecitabine|
79238981|NCT02380352|Drug|Amoxicillin|
79238982|NCT02380352|Drug|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
79689286|NCT06104566|Drug|lisaftoclax +BTK inhibitor|lisaftolax + BTK inhibitor
79689287|NCT06104566|Drug|BTK inhibitor|BTK inhibitor
79238983|NCT02375750|Device|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
79238984|NCT02375750|Other|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
79238985|NCT02375594|Other|Exercise in park equipment|
79379160|NCT06033105|Device|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
79689288|NCT06104540|Other|Experimental I liquid vaseline groups|Patients in the liquid vaseline group will apply liquid vaseline twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
79834357|NCT05953987|Other|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
79834358|NCT05953987|Other|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
79834359|NCT05953987|Other|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
79834360|NCT05953948|Other|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
79834361|NCT05953922|Other|core stability exersises|core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
80006587|NCT03571230|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
79379161|NCT06033092|Drug|Tamoxifen 10 Mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
79379162|NCT06033092|Other|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
79689289|NCT06104540|Other|Experimental II extra virgin olive oil groups|Patients in the extra virgin olive oil group will apply extra virgin olive oil twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
79689290|NCT06104540|Other|Control Croup|No intervention will be made other than the recommendations of the institution's physicians and nurses.
79834362|NCT05953909|Drug|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
79834363|NCT05953909|Drug|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
79689291|NCT06099652|Drug|611 300 mg Q2W|611 subcutaneous (SC) injection
79689292|NCT06099652|Drug|611 450 mg Q2W|611 subcutaneous (SC) injection
79834364|NCT05953909|Drug|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m^2, D1,8 Q3W+Cisplatin 75mg/m^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m^2 D1 Q3W (or paclitaxel 175mg/ m^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
79834365|NCT05953896|Combination Product|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
79834366|NCT05953896|Combination Product|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
79834367|NCT05953883|Procedure|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
80006588|NCT03571230|Drug|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
80006589|NCT03571230|Drug|one proton pump inhibitor(PPI)|All the patients need this drug.
80006590|NCT03571230|Drug|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
79379163|NCT06033092|Behavioral|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
79379164|NCT06033053|Device|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
79379165|NCT06033040|Other|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
79689293|NCT06099652|Drug|Matching placebo|placebo subcutaneous (SC) injection
80006591|NCT03571230|Drug|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
79238986|NCT02380118|Drug|Olanzapine|Intramuscular injection
79238987|NCT02380118|Drug|Haloperidol|Intramuscular injection
79238988|NCT02380118|Drug|Midazolam|Intramuscular injection
79238989|NCT03113708|Drug|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
79238990|NCT03113474|Other|Food palatability|Food palatability is modulated
79238991|NCT02371148|Drug|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22* Rituximab: 375 mg/sqm i.v. day 1** Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles *In case of toxicity is omitted~**In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
79238992|NCT02375360|Other|Oral immunotherapy|
79238993|NCT02379962|Other|no intervention|
79238994|NCT02375516|Behavioral|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
79238995|NCT02380040|Device|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
79238996|NCT03113318|Procedure|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
79238997|NCT03113318|Procedure|Only pulmonary metastasectomy|
79533403|NCT01449786|Other|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
79238998|NCT02370992|Radiation|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
79238999|NCT02370680|Drug|Aspirin|steady-state run-in prior to Durlaza treatment
79379166|NCT06032988|Dietary Supplement|LactoLevure|Participants will receive LactoLevure^R probiotic dietary supplement or matching placebo once a day.
79379167|NCT06032962|Procedure|salpingectomy|surgical removal of the fallopian tubes
79379168|NCT06032936|Drug|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
80006592|NCT03644615|Other|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
80006593|NCT03644615|Other|Usual care|No intervention on the patients
79379169|NCT06032936|Drug|osimertinib|Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
79533404|NCT01449799|Drug|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
79533405|NCT01449799|Drug|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
79239000|NCT02370680|Drug|Durlaza™|comparison of different numbers of capsules
79239001|NCT02370758|Drug|Valganciclovir or Ganciclovir|
79239002|NCT03113240|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
79239003|NCT03113240|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
79239004|NCT02370836|Other|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
79239005|NCT02375282|Procedure|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
79239006|NCT03105596|Drug|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
79239007|NCT04669964|Procedure|Intravenous Hydration|Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
79302981|NCT02481011|Drug|antithrombotic drugs|
79302982|NCT02480855|Other|Questionnaire and feedback|
79239008|NCT02379182|Behavioral|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
79239009|NCT02379182|Device|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
80006594|NCT01468454|Drug|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
79834368|NCT05953792|Procedure|Select the vertebra above sagittal stable vertebra as the distal fusion level|The surgeries were performed by the same surgical team. Multi-level Ponte osteotomies were performed across the apex of the kyphosis after complete exposure of the spine, with resection of supra- and inter-spinous ligaments, ligamentum flavum, and the whole facet joints. After placement of the pedicle screws at the expected fusion levels, pre-contoured rods were attached to the screws followed by segmental compression. During rod placement, two to three rounds of compression in the area with Ponte osteotomies were employed to enhance kyphosis correction. Satellite rods were routinely added to long rods and implanted with duet screws. The final tightening was performed, and the posterior fusion was completed with a mixture of local and allogeneic bone. Due attention was given to preserving the posterior ligamentous structures at the upper and lower junctional areas.
79239010|NCT02379182|Device|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
80006595|NCT01366781|Other|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
80006596|NCT02143700|Other|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
79239011|NCT02370524|Drug|[18F]T807|All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
79239012|NCT02370446|Other|personalized medication log|
79239013|NCT02370446|Other|standard of care|
79689294|NCT06096818|Behavioral|Experimental Group: Kegel exercises and abdominal exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled."
80006597|NCT04151225|Drug|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
80006598|NCT04151225|Drug|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
80006599|NCT03067077|Procedure|SMILE|SMILE surgery
80006600|NCT03067077|Procedure|LASIK|LASIK surgery
80006601|NCT02143856|Drug|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
80006602|NCT03545438|Biological|LIB003|LIB003 or placebo
80006603|NCT01372709|Device|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
79239014|NCT02370446|Behavioral|questionnaires|
79379171|NCT06032897|Other|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
79379172|NCT06032884|Procedure|continuous renal replacement therapy (CRRT)|renal replacement therapy (RRT).
79379173|NCT06032884|Procedure|Intermittent hemodialysis (IHD)|renal replacement therapy (RRT).
80006604|NCT02939612|Behavioral|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
80006605|NCT02254226|Drug|Salmeterol Diskus low|
79379174|NCT06032871|Procedure|high frequency chest wall oscillation|Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
79379175|NCT06032858|Drug|Apremilast 30mg|Apremilast 30mg twice daily
79379176|NCT06032845|Drug|Tislelizumab|a PD-1 immune check inhibitor
79379177|NCT06032845|Drug|Lenvatinib|Lenvatinib capsules
79379178|NCT06032845|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
80006606|NCT02254226|Drug|Salmeterol Diskus high|
80006607|NCT02254226|Drug|Salmeterol MDI low|
80006608|NCT02254226|Drug|Salmeterol MDI high|
80006609|NCT02143934|Drug|Primaquine|
80006610|NCT02143934|Drug|Placebo|Sugar pills, appearance identical to Primaquine tablets
80006611|NCT02143934|Drug|Chloroquine|
80006612|NCT02143934|Drug|Artemether Lumefantrine|
79834369|NCT05953779|Behavioral|Clinician-administered Need-focused Single Session Intervention|All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
79834370|NCT05953727|Other|Low level laser therapy with proprioceptive stimulation|10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
79834371|NCT05953727|Other|Low level laser therapy without proprioceptive stimulation|10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
79379179|NCT06032832|Other|soy protein concentrate-meat analog|Baked Meat analogs-soy protein concentrate containing 57Fe as ferrous sulfate
79379180|NCT06032832|Other|soy protein concentrate-meat analog_dephytinization|Baked dephytinized_Meat analogs-soy protein concentrate containing 58Fe as ferrous sulfate
79379181|NCT06032832|Other|Farinata|Pancake made from chickpea flour contains 57Fe as ferrous sulfate
79379182|NCT06032832|Other|Farinata_dephytinization|Pancake made from dephytinized chickpea flour contains 58Fe as ferrous sulfate.
80006613|NCT01366859|Dietary Supplement|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
79239015|NCT02370446|Behavioral|Cognitive Interview|
79239016|NCT03105440|Other|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
79239017|NCT03105440|Other|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
79533406|NCT01449799|Drug|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
79533407|NCT01449799|Drug|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
79834372|NCT05953714|Other|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
80006614|NCT01366859|Dietary Supplement|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
79379183|NCT06032806|Other|moderate intensity|"Arm circles~Leg swings~Lunges"
79379184|NCT06032806|Other|High intensity|"Arm circles~Leg swings~Lunges~Butt kicks"
79379185|NCT06032793|Other|Breathing exercises|Pursed lip breathing, Diaphragmatic breathing and powered breathing
79239018|NCT03105440|Other|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
79239019|NCT03105440|Other|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
79302983|NCT02450617|Behavioral|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
79379186|NCT06032728|Drug|Sunitinib|The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
79379187|NCT06032702|Procedure|tooth alignment|Alignment will be assessed by Little's Irregularity Index
79834373|NCT05953675|Drug|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
79239020|NCT03105440|Other|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
79689295|NCT06096818|Behavioral|Control Group: Kegel exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled."
79834374|NCT05953675|Drug|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
79834375|NCT05953649|Device|Extracorporeal Diaphragm Pacing|In the EDP group, a pacer using the extracorporeal diaphragm pacemaker provided by Guangzhou Xueliang Biotechnology Developing Co., Ltd., the pacing electrode is pasted on the body surface closest to the phrenic nerve at the outer edge of the lower end of the sternocleidomastoid muscle under ultrasound guidance, and the auxiliary electrode is placed between the second intercostal of the midline of the clavicle. The intensity of treatment parameters was set from low to high, and the intensity of treatment was increased when the patient could tolerate it, pacing 12-18 times/min at a frequency of 40 hertz (Hz)/30min/time, and performed every 12 hours for a week.
79834376|NCT05953649|Device|Tilt Table Verticalization|VitalGo bed (VitalGo Systems Ltd., Fort Lauderdale） is used for verticalization. Verticalization was set to minimum 30°, depending on cardiopulmonary parameters (respiratory rate, heart rate, blood pressure, oxygen saturation), vertical position was gradually increased (in 5° steps) to a maximum of 90°, as long as the above-named cardiopulmonary parameters of the patient remained stable and remain this position for 30 minutes simultaneously with extracorporeal diaphragm pacing for a week.
79834377|NCT05953649|Other|Conventional Physiotherapy|Patients receive early mobilization, which refers to a series of clinical intervention protocols (such as passive movement or active exercises, etc.) that confers physical benefits at an early period in collaboration with a multidisciplinary team (intensive care physicians, rehabilitation physicians, physical therapists, occupational therapists, respiratory therapists, and nurses). The study intervention take place during working time between 8 a.m. and 17 p.m. Patients of all three study groups receive this rehabilitation program until they transfer out of ICU.
79834378|NCT05953636|Dietary Supplement|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
79834379|NCT05953623|Biological|Albumin|This is a 3 + 3 dose-escalation study with 5 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation.
79834380|NCT05953571|Procedure|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
79834381|NCT05953558|Device|Patients implanted with Micra AV|The first 1000 patients implanted by the device in France
79834382|NCT05953519|Behavioral|Unified Protocol|The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
79834383|NCT05953506|Drug|HS-10506|HS-10506 will be administered orally once on Day 1.
79834384|NCT05953506|Drug|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
79834385|NCT05953467|Other|No intervention, observational.|None, observational study
79239021|NCT03105440|Other|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
79239022|NCT02379026|Dietary Supplement|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
79239023|NCT02379026|Behavioral|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
79239024|NCT02379026|Dietary Supplement|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
79239025|NCT02515942|Drug|CLG561|
79239026|NCT02515942|Drug|LFG316|
79239027|NCT02515942|Drug|Sham injection|Empty syringe (without a needle) placed against the eye
79379188|NCT06032689|Combination Product|Xtra-fill|the material was placed in bulk.
79379189|NCT06032689|Combination Product|x-base|The x-base liner was placed and then veneered with Xtra-fill.
79379190|NCT06032689|Combination Product|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
79379191|NCT06032689|Combination Product|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
79379192|NCT06032663|Diagnostic Test|PET-MRI|Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
79391206|NCT02415270|Other|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
79834386|NCT05953454|Other|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
79834387|NCT05953441|Other|AI-powered doctor|AI-powered virtual doctor
79834388|NCT05953441|Other|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
79834389|NCT05953389|Drug|Pitolisant|histamine H3 receptor antagonist/inverse agonist
80006615|NCT03096847|Drug|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
80006616|NCT03096847|Drug|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
79379193|NCT06032624|Procedure|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
79391207|NCT02415114|Dietary Supplement|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
79689296|NCT06096519|Behavioral|Information, motivation, behavioral skills treatment arm|Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old gay, bisexual, and queer (GBQ) adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old GBQ adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of adolescent sexual minority men and transgender and gender diverse adolescents.
79689297|NCT06096519|Behavioral|Information only control arm|This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
79689298|NCT06096116|Drug|Human plasma derived antithrombin|A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
79689299|NCT06096116|Drug|Placebo|Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
79689300|NCT06095102|Drug|JNJ-77242113|JNJ-77242113 will be administered orally.
79689301|NCT06095102|Drug|Placebo|Placebo will be administered orally.
79689302|NCT06092879|Other|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
79689303|NCT06088914|Device|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
79834390|NCT05953389|Drug|Placebo|Matching placebo of pitolisant tablets
79834391|NCT05953376|Drug|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
79834392|NCT05953350|Drug|600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
79834393|NCT05953350|Drug|RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.|After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
79834394|NCT05953324|Other|Kiwifruit|2 kiwifruit for 6 weeks
79834395|NCT05953311|Other|Blood analysis|Blood analysis for neurological biomarkers measurements
80006617|NCT03096847|Drug|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
80006618|NCT01365182|Behavioral|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
80006619|NCT01365182|Behavioral|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
79302984|NCT02450617|Behavioral|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
79302985|NCT02450617|Behavioral|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
79302986|NCT02480933|Procedure|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
79834396|NCT05953311|Other|Cognitive tests|Questionnaires assessing cognitive function
79834397|NCT05953298|Device|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
79302987|NCT02480933|Other|Biopsy|Biopsy of BI-RADS 3 and superior lesions
79239028|NCT02374892|Behavioral|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
79689304|NCT06088914|Device|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
80006620|NCT05190107|Diagnostic Test|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
79834398|NCT05953272|Other|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
80006621|NCT02144090|Device|Fractional flow reserve measurement|Fractional flow reserve measurement
80006622|NCT03019575|Drug|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight >60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
80006623|NCT03019575|Drug|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
80006624|NCT03634709|Behavioral|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
80006625|NCT02144168|Dietary Supplement|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
79239029|NCT02991859|Drug|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
79239030|NCT02991859|Drug|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
79239031|NCT02991859|Drug|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
79379194|NCT06032611|Diagnostic Test|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~cognitive tests~medical questionnaire~lifestyle/fragility questionnaire~digital clock test~fine motor skills tests They will also wear a connected watch for 7 days."
79379195|NCT06032572|Procedure|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
79379196|NCT06032572|Procedure|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
79379197|NCT06032559|Behavioral|MORE|MORE plus TAU
79379198|NCT06032559|Behavioral|SMP|SMP plus TAU
79533408|NCT01449825|Drug|Pazopanib use|Treatment with pazopanib
79379199|NCT06032559|Other|TAU|TAU only
79391208|NCT03178422|Drug|CQSS2|Nicotine Replacement Therapy
79391209|NCT03178422|Drug|NicoDerm CQ Patch|Nicotine Replacement Therapy
79391210|NCT02420496|Drug|Enteral fish oil|
79533409|NCT01449825|Drug|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
79533410|NCT01449838|Drug|Colistimethate sodium|active
79533411|NCT01449838|Drug|Saline|placebo
79533412|NCT01449877|Drug|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
79689305|NCT06086912|Drug|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
79689306|NCT06086912|Drug|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
79689307|NCT06086912|Drug|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
79689308|NCT06080685|Behavioral|Character Strengths Intervention|Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
79834399|NCT05953272|Other|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
79834400|NCT05953259|Device|Combination of STERN FIX and wires|Closure of the median sternotomy using a combination of at least one STERN FIX device and wires for a total of 5 fixation points.
79834401|NCT05953259|Device|Wires|Closure of the median sternotomy using the standard of care with steel wires.
79834402|NCT05953220|Other|Exclusive tobacco smoking|No intervention, participants own tobacco products
80006626|NCT02144168|Dietary Supplement|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
79239032|NCT02991859|Drug|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
79379200|NCT06032520|Behavioral|FAST|FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
79379201|NCT06032507|Procedure|Bone lavage previous to cementation|Bone lavage previous to cementation in total knee arthroplasty
79379202|NCT06032481|Procedure|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
79533413|NCT01449890|Behavioral|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
79689309|NCT06075953|Drug|Tamoxifen|For premenopausal women: 20 mg or 5 mg tamoxifen orally for postmenopausal women: For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (5 mg) or standard dose (20 mg) of tamoxifen
79689310|NCT06075953|Drug|Exemestane|for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
79689311|NCT06075953|Drug|Letrozole|for postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily,
79689312|NCT06075953|Drug|Anastrazole|for postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily;
79689313|NCT06075953|Drug|Testosterone + Anastrazole|Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
79689314|NCT06075953|Drug|Elacestrant|Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
79689315|NCT06075953|Drug|Z-endoxifen|Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
79834403|NCT05953220|Other|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
79834404|NCT05953220|Other|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
79834405|NCT05953220|Other|No use of e-cigarettes or tobacco smoking|No intervention
79834406|NCT05953181|Procedure|Active surveillance|Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
79834407|NCT05949034|Device|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
79834408|NCT05947578|Drug|CLZ-2002|Low dose group (6×10^6 cells), Mid dose group (12×10^6 cells), High dose group (24×10^6 cells)
79239033|NCT04721366|Other|Standard of Care|Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
79689316|NCT06072807|Diagnostic Test|Brain Imaging with 18F-FES|Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
80006627|NCT03128099|Behavioral|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
80006628|NCT03545516|Drug|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
80006629|NCT03545516|Drug|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
79239034|NCT02370290|Other|Medical Chart Review|Clinical and imaging information collected
79239035|NCT02370290|Other|Informational Intervention|Clinical and imaging data collected
79239036|NCT02370134|Device|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
79239037|NCT02370134|Device|sham glove|
79239038|NCT02374970|Other|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
79379203|NCT06032468|Device|ARC Intellicare|wearable devices to guide rehabilitation exercise
79379204|NCT06032468|Other|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
79391211|NCT02420496|Drug|Ursodeoxycholic Acid|
79391212|NCT02420496|Drug|Placebo|
79533414|NCT01449916|Other|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
79834409|NCT05945472|Other|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
80006630|NCT03545516|Drug|Placebo|Injection of a placebo into the surgical wound
79239039|NCT02374970|Other|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
79533415|NCT01449942|Biological|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
79834410|NCT05945472|Other|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
79834411|NCT05942833|Procedure|Sigmoid resection|Timing of sigmoid resection
79379205|NCT06032442|Dietary Supplement|ARTNEO|"Dietary Supplement: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
79533416|NCT01449942|Other|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
79533417|NCT01449968|Other|home visit|home visit of UMG
79533418|NCT01449968|Other|telephone management|telephone management of the situation reported by the patient's GP
79533419|NCT01449981|Behavioral|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
79834412|NCT05937113|Biological|RABIVAX-S|"1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~Intramuscular 1ml on days D0, D7 and D21+7~Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28"
79834413|NCT05937074|Other|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
79834414|NCT05936944|Other|Exposure to totally artificial lighting|The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
79834415|NCT05928312|Drug|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~[1] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~[2] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
79834416|NCT05926687|Behavioral|Social Communication|Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week
79834417|NCT05926687|Behavioral|Disruptive Behavior|Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week
80006631|NCT04756453|Device|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
80006632|NCT04545333|Diagnostic Test|clonoSEQ Assay|minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
79239040|NCT02370212|Dietary Supplement|Creatine|
79239041|NCT02370212|Dietary Supplement|Placebo|
79239042|NCT02370212|Other|High intensity interval training|
79379206|NCT06032442|Drug|Artra|"Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months."
79391213|NCT02414880|Drug|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
79239043|NCT02374736|Drug|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
79239044|NCT02375048|Radiation|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
79689317|NCT06067178|Behavioral|Health Dialogue Intervention|"Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
79834418|NCT05926687|Behavioral|Social Communication + Reduce Frequency|Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour once/week
79239045|NCT02375048|Radiation|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
79239046|NCT02369978|Drug|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
79533420|NCT01449981|Behavioral|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
79834419|NCT05926687|Behavioral|Social Communication + Add Tools|Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week
79834420|NCT05926687|Behavioral|Disruptive Behavior + Reduce Frequency|Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour every other week
79834421|NCT05926687|Behavioral|Disruptive Behavior + Add Tools|Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week
79239047|NCT02369978|Drug|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
79239048|NCT02369978|Drug|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
79239049|NCT04055545|Other|HIIT|"5 min. warm up~10 × 60 seconds burst~60 seconds recovery after each burst~Burst phase: HRR >90%~Recovery phase: HRR btw. 30-39%~5 min. cool down"
79533421|NCT01449994|Device|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
79379207|NCT06032429|Other|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
79379208|NCT06032403|Behavioral|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
79379209|NCT06032390|Other|AI assisted mammography screening interpretation|Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in consensus. Examinations with an AI score of 9.8 and above will be selected to consensus by default. Risk scores and AI image markings are provided to the readers only in consensus. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
79379210|NCT06032390|Other|Standard mammography screening interpretation|Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in consensus, and the readers will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
79379211|NCT06032325|Diagnostic Test|Neutrophil Gelatinase and Kidney Injury Molecule-1|To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
79533422|NCT01450072|Device|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
79533423|NCT01450072|Other|Control arm|Venography and sham angioplasty
79239050|NCT04055545|Other|MICT|"5 min. warm up~20 min. continuous cycling: HRR btw. 40% - 59%~5 min. cool down"
79239051|NCT02379260|Other|Interview with a sociologist|
79239052|NCT02379104|Device|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
79239053|NCT03661489|Drug|Remimazolam|For induction and maintenance of general anesthesia
79239054|NCT03661489|Drug|Propofol|For induction and maintenance of general anesthesia
79239055|NCT02378948|Dietary Supplement|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
79239056|NCT04056169|Drug|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
79239057|NCT04056169|Drug|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
79239058|NCT04947670|Procedure|Renal arteriography followed by renal denervation|Renal arteriography followed by renal denervation
79239059|NCT04947670|Procedure|Sham Renal arteriography|Renal arteriography only
79239060|NCT04439630|Dietary Supplement|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
79689318|NCT06067178|Other|Opportunistic Screening|"Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
79834422|NCT05924009|Procedure|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
79689319|NCT06064825|Other|2 year follow-up of neurodevelopment using a parental questionnaire|A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
79689320|NCT06061952|Behavioral|Customized Adherence Enhancement for Schizophrenia (CAE-S)|6-session series spaced out over approximately 6-10 weeks
79689321|NCT06061952|Other|Enhanced Treatment as Usual (eTAU)|eTAU participants will view a pre-taped series of 6 videos
79689322|NCT06060665|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for up to 52 weeks
79834423|NCT05922774|Device|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
79834424|NCT05919602|Other|Visualization of an image catalogue|Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
79834425|NCT05919147|Drug|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
79834426|NCT05919147|Drug|Placebo|Placebo will have the same appearance as the active drug.
79834427|NCT05919030|Radiation|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
79834428|NCT05919030|Drug|Tislelizumab|200 mg IV Q3W
79689323|NCT06060665|Drug|Placebo|One capsule daily for up to 52 weeks
79834429|NCT05919030|Drug|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
79834430|NCT05919030|Drug|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
79239061|NCT04439630|Dietary Supplement|Test product without the active components|Test product without the active components
79239062|NCT03660709|Behavioral|Intervention|"Standard-of-care HIV testing and counseling~Watch a video clip while waiting for the HIV testing result on a tablet.~Receive a pamphlet and post-test counselling promoting HIV retesting.~Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~Receive brief e-health reminder for retesting at Month 3 and 5."
79239063|NCT03660709|Behavioral|Control|Standard-of-care HIV testing and counseling
79239064|NCT02374658|Behavioral|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
79239065|NCT02369822|Dietary Supplement|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
79239066|NCT03016325|Drug|HNO Donor|Infusion
79239067|NCT03016325|Drug|Placebo|Infusion
79379212|NCT06032312|Other|description|no intervention, just description of the groups
79379213|NCT06031597|Radiation|radiotherapy|"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."
79379214|NCT06031597|Drug|Platinum-Based Drug|Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.
79834431|NCT05917509|Drug|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
79834432|NCT05917509|Drug|Cabotegravir (CAB) LA|CAB LA will be administered as an intramuscular injection once every 2 months in combination with RPV LA.
79834433|NCT05917509|Drug|Rilpivirine (RPV) LA|RPV LA will be administered as an intramuscular injection once every 2 months in combination with CAB LA.
79834434|NCT05902520|Biological|DP CD8 TIL|intravenous infusion of T cell suspension
79834435|NCT05902520|Biological|DP CD8 TIL KD|intravenous infusion of T cell suspension
79834436|NCT05902520|Biological|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
80006633|NCT01372787|Procedure|Assessment of Therapy Complications|Ancillary studies
79239068|NCT04983004|Behavioral|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
79379215|NCT06031597|Drug|Immunotherapy|Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
80006634|NCT01372787|Other|Medical Chart Review|Ancillary studies
79239069|NCT04983004|Behavioral|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
79239070|NCT02988115|Drug|bempedoic acid|bempedoic acid 180 mg tablet
79379216|NCT06031597|Drug|Immunotherapeutic Agent|All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
79834437|NCT05895201|Drug|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
79533424|NCT01450163|Drug|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
79689324|NCT06058832|Device|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
79689325|NCT06058832|Other|Kegel Exercises|"The training program consists of active exercises. Each patient will be taught how to contract the pelvic-floor muscles. He will be asked to mimic holding in the flow of urine and to contract the target muscles as hard as possible. The exercises will be done in a supine position with the knees flexed because it is easier to feel the pelvic-floor muscles in this position.~The patient will be asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will be done with the patient sitting or standing.~Patient will be asked to repeat the contractions daily. Each patient will be performed 40 short and 50 long-lasting contractions in a prone, sitting, or standing position. Patients will be asked to do 30 contractions in the morning, 30 contractions in the afternoon, and 30 contractions in the evening."
79834438|NCT05895201|Drug|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
79834439|NCT05895201|Drug|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
79834440|NCT05891106|Device|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
79834441|NCT05887895|Drug|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
79834442|NCT05880368|Other|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
79834443|NCT05876494|Diagnostic Test|serum lactate|assessment of serum lactate and mean platelets volume
79834444|NCT05873387|Device|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
79834445|NCT05870956|Drug|Nintedanib|Nintedanib
79834446|NCT05870527|Device|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
79834447|NCT05870384|Behavioral|Group Interpersonal Psychotherapy|Ten sessions of IPT-G, which focuses on the common problem area of patient relatives, will be applied.
79834448|NCT05848908|Other|Telehealth Visit|telemedicine visit and follow-up surveys
79834449|NCT05847348|Drug|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
79379217|NCT06031571|Procedure|dynamic cupping|Dynamic cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction then performing circular and transverse movements
79379218|NCT06031571|Procedure|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
79533425|NCT01450163|Drug|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
79533426|NCT01450267|Drug|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
80006635|NCT01372787|Other|Quality-of-Life Assessment|Ancillary studies
80006636|NCT01372787|Other|Questionnaire Administration|Ancillary studies
80006637|NCT02886494|Drug|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
80006638|NCT02886494|Drug|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
80006639|NCT04660903|Procedure|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
79239071|NCT02988115|Other|placebo|Matching placebo tablet
79379219|NCT06031571|Procedure|traditional exercise (neck stretching and strengthening exercses)|Stretching exercises are therapeutic exercises that aim to improve ranges of motion and tissue elasticity. Strengthening exercises are therapeutic exercises that aim to improve muscle power and maintain the gained ranges of motion
79834450|NCT05847348|Other|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
80006640|NCT04519749|Biological|4D-310|4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
80006641|NCT00204477|Dietary Supplement|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
79533427|NCT01450267|Drug|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
80006642|NCT00204477|Dietary Supplement|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
79834451|NCT05843383|Drug|Ciprofol|Ciprofol group will be started and maintained total intravenous anesthesia with ciprofol and remifentanil
79533428|NCT01450436|Other|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
79834452|NCT05843383|Drug|Propofol|Propofol group will be started and maintained total intravenous anesthesia with propofol and remifentanil
79533429|NCT01450449|Radiation|Radiotherapy|25 Gy in 5 daily fractions over 1 week
79533430|NCT01450449|Radiation|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
79379220|NCT06031467|Device|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
79533431|NCT01450995|Drug|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
79834453|NCT05842668|Behavioral|ESWL Group|Increasing comfort and reducing pain during ESWL
79533432|NCT01450995|Drug|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
79834454|NCT05836753|Drug|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
79834455|NCT05836753|Drug|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
80006643|NCT02835326|Behavioral|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
79239072|NCT02374502|Behavioral|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
79239073|NCT02378792|Device|Vagus Nerve Stimulation|Vagus Nerve Stimulator
79239074|NCT04982770|Other|Survey|Reading of ethical guidelines.
79379221|NCT06031467|Device|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
79533433|NCT01451320|Drug|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
79533434|NCT01451320|Drug|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
79689326|NCT06053593|Device|Testing of self collected urine|Each PWD will test their self-collected urine.
79689327|NCT06053593|Device|Labeling Evaluation|Each PWD will complete a labeling evaluation.
79834456|NCT05831280|Behavioral|Laughter Yoga|"Warm-up exercises (5 minutes),~Deep breathing exercises (5 minutes),~Childlike playfulness (5 minutes),~Laughter exercises (15 minutes)."
79689328|NCT06053593|Device|Urine Control testing|Each PWD will test four urine control solutions.
79689329|NCT06050811|Dietary Supplement|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
79689330|NCT06050811|Dietary Supplement|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
79689331|NCT06049017|Drug|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
80006644|NCT02835326|Behavioral|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
80006645|NCT04514367|Drug|ANX005|Intravenous Infusion
80006646|NCT03545048|Other|Internet based exercises|Exercises for knee OA (online- digital health)
80006647|NCT02846532|Drug|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to <8 kilogram (kg) will receive 2.2 milligram (mg); 8 to <10 kg will receive 3.2 mg; 10 to<12 kg will receive 3.4 mg; 12 to <20 will receive 4.0 mg and 20 to <30 will receive 5.0 mg.
79689332|NCT06049017|Drug|Placebo|Placebo tablet will be administered orally.
79689333|NCT06047782|Other|Cardiac MRI (with contrast agent)|Cardiac MRI with contrast agent
79239075|NCT02378870|Drug|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
79239076|NCT02378870|Drug|Placebo|
79834457|NCT05830123|Drug|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
79533435|NCT01451320|Drug|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
80006648|NCT02846532|Drug|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
79533436|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
80006649|NCT02809521|Other|Activity Liking|
80006650|NCT02744001|Other|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
79689334|NCT06045234|Other|Urine sampling|"Among the 300 people recruited:~300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
79689335|NCT06043089|Dietary Supplement|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
80006651|NCT03634631|Other|Focused Ultrasound|Test ultrasound in 7T MRI scanner
79689336|NCT06042114|Behavioral|Surah Inshirah|Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
79689337|NCT06041100|Device|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
79689338|NCT06040710|Device|POSEIDON size estimation software with the EndoMind polyp detection system|Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.
79689339|NCT06040541|Drug|RMC-9805|Oral Tablets
79689340|NCT06040255|Drug|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
80006652|NCT01371461|Drug|Paroxetine|
79689341|NCT06038591|Behavioral|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
79689342|NCT06030427|Behavioral|Behavioral Dietary Intervention|Participate in weight management program
79834458|NCT05827211|Procedure|Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive systemic antibiotics
79834459|NCT05827211|Procedure|Non-Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive placebo
79834460|NCT05822063|Drug|Lidocaine topical|lidocaine spray
80006653|NCT02731521|Device|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
79533437|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
79533438|NCT01451489|Drug|FK506|FK506:0.05-0.1mg/kg/d
79533439|NCT01451489|Drug|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
79533440|NCT01451697|Behavioral|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
79533441|NCT01451697|Behavioral|Control (Placebo)|The control condition will involve relaxation training.
79533442|NCT01451853|Drug|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
79533443|NCT01451853|Drug|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
79689343|NCT06030427|Other|Educational Intervention|Receive patient education handouts
79834461|NCT05822063|Other|cold packs|ice packs
79834462|NCT05822063|Device|flash lights|flash lights by camera
80006654|NCT02731521|Device|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
80006655|NCT02728557|Behavioral|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
80006656|NCT02728557|Behavioral|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
80006657|NCT03571152|Other|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
80006658|NCT05337527|Dietary Supplement|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
80006659|NCT05324423|Drug|Colchicine|Colchicine0.5 mg Oral Tablet Day-7~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
79533444|NCT01451853|Drug|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
79533445|NCT01451853|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
79834463|NCT05820503|Procedure|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
79834464|NCT05820503|Procedure|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
79689344|NCT06030427|Other|Health Promotion and Education|View behavioral educational PowerPoint presentation
79239077|NCT03127111|Genetic|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
79689345|NCT06030427|Other|Internet-Based Intervention|Complete virtual behavioral weight management with an integrated mindfulness component program
79834465|NCT05817097|Drug|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
79834466|NCT05815420|Device|Non invasive ventilation|Treatment by non invasive ventilation
79834467|NCT05814354|Drug|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
79834468|NCT05814354|Drug|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
79239078|NCT03127111|Genetic|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
79239079|NCT03127111|Genetic|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
79239080|NCT03127111|Genetic|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
80006660|NCT03570138|Device|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
80006661|NCT03570138|Device|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
79239081|NCT03127111|Genetic|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
79689346|NCT06030427|Other|Interview|Ancillary studies
79834469|NCT05812222|Behavioral|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
80006662|NCT02659605|Procedure|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
79239082|NCT02369666|Dietary Supplement|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
79239083|NCT02369666|Dietary Supplement|Placebo|Contains MCT oil.
79239084|NCT02374268|Behavioral|Exercise program alone|
79239085|NCT02374268|Dietary Supplement|Combined exercise program and nutrition supplement|
79239086|NCT02374268|Other|Waitlist control group|
79689347|NCT06030427|Other|Medical Device Usage and Evaluation|Wear Fitbit
79689348|NCT06030427|Behavioral|Mindfulness Relaxation|Complete mindfulness components
80006663|NCT02659605|Procedure|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
80006664|NCT03570060|Biological|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
79689349|NCT06030427|Other|Physical Performance Testing|Ancillary studies
79689350|NCT06030427|Other|Questionnaire Administration|Ancillary studies
79689351|NCT06029023|Combination Product|MTA Cement, propolis nano particle, curcumin nanoparticles|MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.
79689352|NCT06028074|Drug|GIM122|GIM-122 administered IV once every 3 weeks
79689353|NCT06020014|Drug|AZD4604|AZD4604
79689354|NCT06020014|Other|Placebo|Placebo
80006665|NCT03570060|Procedure|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
80006666|NCT03570060|Procedure|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
79239087|NCT03658681|Other|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
79239088|NCT03658681|Other|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
79239089|NCT02369588|Other|Food portion size|
79689355|NCT06015516|Drug|Minoxidil Tablets|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
79239090|NCT02921425|Behavioral|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
79239091|NCT05028712|Behavioral|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
79533446|NCT01452243|Drug|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
79533447|NCT01452256|Drug|Desflurane|4-6 Vol %
79689356|NCT06015516|Drug|Minoxidil topical solution 20 mg/ml|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
79834470|NCT05796674|Device|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
79834471|NCT05796674|Device|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
79834472|NCT05796674|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
79239092|NCT05028712|Behavioral|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
79379222|NCT06031311|Diagnostic Test|Echocardiography and HRCT|Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.
79379223|NCT06030362|Dietary Supplement|Probiotic|Dietary Supplement taken once daily for 3 months (90 days).
79533448|NCT01452256|Drug|Propofol|TIVA to achieve BIS value of 40-60
79533449|NCT01452373|Drug|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
79533450|NCT01452373|Drug|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
79533451|NCT01452607|Drug|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
79834473|NCT05794659|Biological|AST-201|i.d. (3-week interval, 3 cycles in total)
79533452|NCT01452607|Drug|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
79533453|NCT01452672|Radiation|Radiotherapy|RT 40 Gy in 15 fractions
79533454|NCT01452672|Radiation|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
79689357|NCT06014255|Drug|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
79689358|NCT06014255|Other|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
79834474|NCT05794659|Drug|Paclitaxel|3-week interval, 6 cycles in total
79834475|NCT05794659|Drug|Carboplatin|3-week interval, 6 cycles in total
80006667|NCT05232539|Device|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
79379224|NCT06030362|Dietary Supplement|Placebo|Dietary Supplement taken once daily for 3 months (90days).
79379225|NCT06030024|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
79379226|NCT06029556|Other|Mobility out of Bed|Active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conduct on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low-intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned
79379227|NCT06029556|Other|Ergometry in Bed|Ankle pumps (5*2), knee extension (5*2), breathing exercises with elbow flexion and extension(5*2), spirometry and progressive early ambulation (from bed to wheelchair and wheelchair to standing and from standing to few steps), and conventional chest physical activity (5 minutes on precursor)
79533455|NCT01452958|Biological|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
79533456|NCT01452958|Biological|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
79533457|NCT01453062|Drug|Arzerra|Treatment with Arzerra
79533458|NCT01453283|Drug|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
79533459|NCT01453608|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
79533460|NCT01453608|Drug|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
79533461|NCT01454128|Behavioral|exercise|36 session supervised exercise intervention
79533462|NCT01454232|Other|stools sampling|stools sampling at baseline, 1, 3 and 12 months
79533463|NCT01454232|Other|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
80006668|NCT02242188|Drug|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
79533464|NCT01454375|Behavioral|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
79533465|NCT01454700|Device|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
79533466|NCT01454700|Other|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
80006669|NCT02242188|Dietary Supplement|Placebo|Maltodextrin (packed in identical sachets as active products)
80006670|NCT04704843|Drug|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
80006671|NCT04704843|Drug|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
80006672|NCT03572712|Other|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
80006673|NCT05189873|Drug|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
79533467|NCT01454752|Drug|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
79533468|NCT01454752|Other|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
79533469|NCT01454869|Drug|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
79533470|NCT01454869|Drug|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
79533471|NCT01455116|Procedure|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
79239093|NCT03008915|Drug|Aspirin|81mg aspirin taken once per day in the morning
79239094|NCT03008915|Drug|Placebo|placebo taken once per day in the morning
79239095|NCT03008915|Other|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
79533472|NCT01455259|Biological|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
79533473|NCT01455272|Procedure|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
79533474|NCT05964387|Device|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
79834476|NCT05794659|Drug|Placebo|i.d. (3-week interval, 3 cycles in total)
79239096|NCT02374190|Other|Standard Hospital Care|We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
79239097|NCT03658603|Procedure|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
79239098|NCT03658603|Procedure|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
79533475|NCT05964387|Device|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
79533476|NCT05964374|Device|Goal-directed therapy|Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
79533477|NCT05964348|Procedure|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
79533478|NCT05964309|Other|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
79533479|NCT05964309|Other|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
79689359|NCT06011031|Device|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
79834477|NCT05794659|Drug|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
79834478|NCT05793645|Device|personalized care plan|Algorithm that defines personalized care plan
79834479|NCT05785650|Diagnostic Test|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
79834480|NCT05784857|Other|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
80006674|NCT05189873|Drug|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
79239099|NCT04439162|Procedure|retrograde cardioplegia protection|antegrade-retrograde cardioplegia
80006675|NCT02524080|Procedure|Triage to optimal healthcare level|Triage to optimal healthcare level
80006676|NCT01367015|Other|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
80006677|NCT01367015|Other|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
79689360|NCT06011031|Device|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
80006678|NCT01371617|Drug|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
80006679|NCT04051671|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
80006680|NCT02243982|Other|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
80006681|NCT02552277|Biological|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
80006682|NCT02552277|Drug|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
79533480|NCT05964270|Device|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
80006683|NCT05185817|Biological|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
80006684|NCT03571074|Other|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
80006685|NCT00842348|Drug|lanreotide (Autogel formulation)|Autogel 120 mg
80006686|NCT03095599|Biological|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
80006687|NCT03095599|Other|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
79533481|NCT05964257|Drug|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
79689361|NCT06010680|Drug|[14C]SHR2554|Patients will receive single dose of orally [14C]SHR2554 on Day 1.
79689362|NCT06003426|Drug|BMS-986278|Specified dose on specified days
79689363|NCT06003426|Drug|BMS-986278 Placebo|Specified dose on specified days
80006688|NCT03569826|Other|Observational; no intervention|Observational; no intervention
80006689|NCT02144246|Other|Non-hormonal period|
79239100|NCT03667625|Other|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
79239101|NCT03667625|Other|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
79239102|NCT03658525|Device|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
79239103|NCT03622489|Drug|Acetaminophen|mentioned above
79239104|NCT03622489|Drug|Ibuprofen 400 mg|mentioned above
79689364|NCT06001918|Drug|Nectero EAST System|Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
79239105|NCT03622489|Drug|Dipyrone|mentioned above
79239106|NCT03622489|Drug|Tramadol|mentioned above
79239107|NCT03622489|Drug|Morphine|mentioned above
80006690|NCT02144246|Drug|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
79533482|NCT05964257|Drug|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
79834481|NCT05775133|Device|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
80006691|NCT03569670|Device|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
79239108|NCT03622489|Drug|Tramal|mentioned above
79689365|NCT05991596|Behavioral|Psychodramatic psychotherapy|"The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~1 individual motivational interview;~1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo."
79533483|NCT05964244|Device|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
79689366|NCT05991596|Behavioral|Self-help activities|"The self-help activities will include:~1 individual motivational interview;~1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo."
79689367|NCT05984667|Behavioral|C-SMART|The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
79689368|NCT05978492|Drug|TXN10128|Participants receive TXN10128 capsules orally once daily.
79689369|NCT05973890|Behavioral|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
79689370|NCT05973890|Behavioral|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
79834482|NCT05771584|Drug|AST-301|100 μg
79533484|NCT05964244|Device|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
79533485|NCT05964166|Device|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
79533486|NCT05964140|Drug|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
79533487|NCT05964127|Device|Air flow device|An air/powder device for surface decontamination
79834483|NCT05771584|Drug|rhuGM-CSF|100 μg
79239109|NCT03667001|Drug|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
79533488|NCT05964127|Other|Hand instruments|Periodontal hand instruments
79834484|NCT05761041|Drug|Sodium Fluoride Varnish (5%)|Applied at baseline
79834485|NCT05761041|Behavioral|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
79834486|NCT05761041|Drug|SDF|Applied bianually
80006692|NCT03569670|Device|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
80006693|NCT03544502|Device|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
79391214|NCT02414880|Drug|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
79391215|NCT02414880|Drug|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
79379228|NCT06028880|Behavioral|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature & Relation with suffering (S1), Emotional regulation & Multiple selves (S2), Creative hopelessness & Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion & Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; & Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame & Anger (S10), Coming out & Compassionate behaviour (assertiveness) (S11), Positive emotions & Preparing for the future (S2).
79379229|NCT06028607|Dietary Supplement|QD-27|Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
79834487|NCT05760339|Behavioral|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
79834488|NCT05760339|Dietary Supplement|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
79834489|NCT05756946|Procedure|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
79834490|NCT05756946|Procedure|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
79834491|NCT05750966|Drug|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
79834492|NCT05750966|Drug|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
79379230|NCT06028126|Procedure|Intermittent Superficial Parasternal Intercostal Plane Block - Experimental|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
79379231|NCT06028126|Procedure|Intermittent Superficial Parasternal Intercostal Plane Block - Sham|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
80006694|NCT03544502|Device|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
79239110|NCT03667001|Drug|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
79379232|NCT06027931|Procedure|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
79533489|NCT05964127|Procedure|Access flap surgery|To improve the surgical access for implant decontamination
79533490|NCT05964114|Drug|Vancomycin|Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
79239111|NCT04439084|Other|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
79302988|NCT03197857|Behavioral|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
79533491|NCT05964101|Drug|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
79533492|NCT05964062|Device|active rTMS treatment|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
79533493|NCT05964062|Device|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
79239112|NCT04055779|Other|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
79689371|NCT05971381|Device|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
79239113|NCT04055779|Other|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
79239114|NCT02379650|Drug|Hydroxychloroquine (HCQ)|
79533494|NCT05964049|Device|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
79239115|NCT02379650|Drug|Placebo|
79239116|NCT02374034|Other|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
79239117|NCT03666923|Drug|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
79239118|NCT03666923|Drug|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
79239119|NCT03666923|Drug|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
79239120|NCT02369432|Drug|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
79239121|NCT03658369|Dietary Supplement|Lanconone®|2 capsules
79239122|NCT03658369|Dietary Supplement|Methyl crystalline cellulose|2 Capsules
79239123|NCT03667469|Procedure|Laparoscopic one anastomosis gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
79379233|NCT06027645|Behavioral|Crawling stimulation with a mini-skateboard (i.e. the crawliskate)|Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
79239124|NCT03667469|Dietary Supplement|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
79533495|NCT05964049|Device|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
79533496|NCT05963971|Behavioral|PEDALL|twenty-six hour nutrition education intervention delivered virtually over a six month period
79689372|NCT05970263|Drug|Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.|2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.
79689373|NCT05970263|Other|External Comparator|Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
79533497|NCT05963971|Other|Standard of care|Nutrition education per institutional standard of care
79533498|NCT05963958|Combination Product|Active HD-tDCS|Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
79533499|NCT05963958|Combination Product|Sham HD-tDCS|Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
79689374|NCT05967832|Other|7T MRI|Patients and healthy volunteers will have a 7T MRI
79689375|NCT05963984|Drug|Samuraciclib|Samuraciclib tablet by mouth once a day
79689376|NCT05963984|Drug|Fulvestrant|Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
79689377|NCT05963074|Drug|Ibrutinib|Ibrutinib capsules will be administered orally.
79689378|NCT05963074|Drug|Venetoclax|Venetoclax tablets will be administered orally.
79689379|NCT05957536|Biological|D3L-001|Intravenous administration
79689380|NCT05953688|Drug|ESK-001|Oral tablet
80006695|NCT03544502|Device|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
79239125|NCT03622645|Device|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
79239126|NCT03666299|Drug|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
79239127|NCT03666299|Drug|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
80006696|NCT03544502|Procedure|Ambient operating room noise|patients were exposed to the ambient operating room noise.
79239128|NCT03661099|Diagnostic Test|colonoscopy|endoscopists' performance outcome
79239129|NCT04420780|Dietary Supplement|Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
79239130|NCT04420780|Dietary Supplement|Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
79379234|NCT06027359|Other|Therapeutic play hospital fear and nursing interventions|"Children assigned to the study group will be divided into 5 groups, with a maximum of 8 children. The researcher will perform a therapeutic play activity with each group consisting of maximum 8 children one day of the week in the room and time determined by the school. Each activity will last an average of 30 minutes. Therapeutic play activities will be completed in 4 weeks.~Therapeutic play activities will not be performed with the children in the control group.~One week after the completion of the therapeutic play intervention, the researcher will re-fill the Child Nursing Interventions and Fear of Materials Scale-uncommon materials sub-dimension face-to-face with the children in the study and control groups."
79533500|NCT05963945|Device|Carebot AI CXR|The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
79533501|NCT05963919|Other|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
79379235|NCT06026267|Biological|20% High Dose Albumin|A]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy
79379236|NCT06026267|Other|Standard Medical Treatment|Standard Medical Treatment
79689381|NCT05953090|Device|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
79689382|NCT05949801|Drug|Neucardin|10 days IV infusion of 0.6 ug/kg/day
79533502|NCT05963919|Other|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
79533503|NCT05963919|Other|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
79689383|NCT05949801|Drug|Placebo|10 days IV infusion of 0 ug/kg/day
79689384|NCT05947890|Biological|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
79689385|NCT05947890|Biological|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
79239131|NCT03660397|Procedure|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
79239132|NCT03660397|Drug|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
79239133|NCT03591380|Drug|Belimumab|Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
79239134|NCT03704740|Biological|NBP607-QIV|Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
79239135|NCT03704740|Biological|Agrippal|Influenza virus surface antigens of three strains (trivalent)
79379237|NCT06026267|Biological|20% Reduced Dose Albumin|B]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy
79239136|NCT04057469|Drug|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
79239137|NCT04057469|Drug|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
79239138|NCT03660319|Other|Environmental Music Therapy|Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
79239139|NCT03666221|Drug|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
79239140|NCT02378324|Other|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
79239141|NCT03623009|Behavioral|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
80006697|NCT03572556|Biological|Blood samples|"5 mL dry tube to separate serum~Two 6 mL EDTA tubes for plasma separation~Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
79239142|NCT03623009|Behavioral|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
79533504|NCT05963919|Other|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
79533505|NCT05963893|Behavioral|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
79689386|NCT05946239|Other|Manage My Pain App|This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
79239143|NCT03658291|Drug|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
79533506|NCT05963880|Device|Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)|All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
79533507|NCT05963789|Other|Cervical proprioceptive training|Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.
79834493|NCT05737901|Other|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
80006698|NCT03572556|Other|Epistaxis charts|Three monthly epistaxis charts to be completed
79379238|NCT06025760|Other|patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness|All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
79533508|NCT05963789|Other|Traditional exercises|Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
79533509|NCT05963776|Device|spirometry|pulmonary function tests using spirometry
79239144|NCT03658291|Drug|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
79239145|NCT03658291|Drug|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
79239146|NCT02378168|Other|no intervention; retrospective study|
79239147|NCT04054973|Drug|L-arginine|6000mg of L-arginine daily for 14 days
79239148|NCT04054973|Drug|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
79533510|NCT05963750|Other|virtual reality|virtual reality
79689388|NCT05939843|Behavioral|Pain Coping Information|A three minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery)
79689389|NCT05939843|Behavioral|Mindfulness Practice (alone)|A 3-minute audio-guided mindfulness practice.
79689390|NCT05939843|Behavioral|Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to the practice of mindfulness followed by a 2-minute audio-guided mindfulness practice
79239149|NCT02373956|Device|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
79239150|NCT02373956|Procedure|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
79239151|NCT02369198|Drug|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
79239152|NCT03658213|Drug|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
79239153|NCT03658213|Drug|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
79834494|NCT05737901|Other|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
79533511|NCT05963724|Device|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
79689391|NCT05939843|Behavioral|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to pain, followed by a 1-minute audio-recorded introduction the practice of mindfulness, followed by a 1-minute audio-guided mindfulness practice
79689392|NCT05936502|Other|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
80006699|NCT03095521|Drug|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
80006700|NCT03095521|Drug|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
80006701|NCT01372865|Drug|Mometasone furoate|
80006702|NCT01372865|Drug|Mometasone furoate|
80006703|NCT05368116|Other|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
80006704|NCT05368116|Other|Standard of care|Standard of care
79239154|NCT02373878|Behavioral|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
79239155|NCT02373878|Behavioral|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
79239156|NCT02369276|Other|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
79239157|NCT02920957|Device|comfilcon A|contact lens
79379239|NCT06024980|Procedure|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
79391216|NCT02423694|Device|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5~1.0 mA"
79391217|NCT02423694|Drug|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
79391218|NCT02423538|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
79533512|NCT05963724|Procedure|Stanford Colonoscopy|This involves white-light colonoscopy
79533513|NCT05963711|Other|chlorhexidine gluconate 4%|"In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes.~In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow."
79689393|NCT05932654|Drug|BSI-045B|Patients in monotherapy cohorts will be treated with BSI-045B.
79689394|NCT05932654|Drug|Dupilumab|Patients in add-on cohorts will be treated with BSI-045B and dupilumab.
79689395|NCT05921045|Other|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
79689396|NCT05921045|Other|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
79689397|NCT05910554|Drug|Metformin|Patients randomized to metformin will be assigned the active arm.
79689398|NCT05910554|Drug|Cellulose|Patients randomized to cellulose will be assigned the placebo arm.
80006705|NCT05708898|Device|Pharyngeal exerciser|
80006706|NCT05708898|Device|sham pharyngeal exerciser|
80006707|NCT02144324|Device|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
79239158|NCT02920957|Device|senofilcon C|contact lens
79302989|NCT03197857|Behavioral|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
79239159|NCT02369120|Other|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
79834495|NCT05730374|Behavioral|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
79834496|NCT05730374|Behavioral|Music therapy|"The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
79834497|NCT05725096|Diagnostic Test|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
79834498|NCT05725096|Other|No Intervention|Chinese guidelines for lipid management (2023)
79834499|NCT05722587|Other|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
79834500|NCT05721274|Behavioral|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
79834501|NCT05711953|Other|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
79834502|NCT05709964|Other|Self-reported|Self-reported height, weight, and neck circumference
79239160|NCT02369120|Other|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
79239161|NCT03006887|Drug|lenvatinib|lenvatinib capsules
79239162|NCT03006887|Drug|pembrolizumab|pembrolizumab intravenous infusion
79239163|NCT02377934|Radiation|Cardiac Magnetic Resonance Imaging (MRI)|
79239164|NCT02377856|Drug|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
79239165|NCT03658135|Drug|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
79239166|NCT03658135|Other|Placebo|Inactive ingredient
79239167|NCT02373800|Device|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
79239168|NCT03665987|Behavioral|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
79239169|NCT02377778|Drug|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
79239170|NCT02377778|Drug|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
79239171|NCT02514772|Biological|GP2013 - A Proposed biosimilar rituximab|
79379240|NCT06024980|Procedure|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~Total cordectomy (type IV).~Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~Extended cordectomy, which includes the arytenoid (type Vb).~Extended cordectomy, which encompasses the subglottis (type Vc).~Extended cordectomy, which consists of the ventricle (type Vd)."
79533514|NCT05963685|Other|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
79379241|NCT06024876|Biological|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
79391219|NCT02423538|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
79533515|NCT05963646|Diagnostic Test|Natural history study|Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.
79533516|NCT05963620|Other|percutaneous coronary intervention vs bypass graft surgery|retrieve long term follow up data on clinical outcome of study population, no intervention
79239172|NCT02514772|Biological|Originator rituximab - Rituxan ® or MabThera ®|
79834503|NCT05709964|Other|Measured|Height, weight, and neck circumference measured by the investigator.
79834504|NCT05709769|Other|There are no interventions.|There are no interventions.
79834505|NCT05703542|Drug|BXCL701|Tablet, taken Orally
79533517|NCT05963607|Other|Weighted blanket|A blanket sewn with extra weight in it.
79834506|NCT05701293|Procedure|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
79834507|NCT05688397|Dietary Supplement|Experimental 1|L. gasseri oral capsule once a day (1 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
79834508|NCT05688397|Dietary Supplement|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
79834509|NCT05688397|Dietary Supplement|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
79834510|NCT05683327|Dietary Supplement|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
79834511|NCT05683327|Dietary Supplement|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
79834512|NCT05683327|Dietary Supplement|Placebo|Take 2 capsules per day at any time.
80006708|NCT01372943|Biological|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
79533518|NCT05963594|Dietary Supplement|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
79689399|NCT05909683|Diagnostic Test|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
79379242|NCT06023537|Behavioral|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
79379243|NCT06023173|Diagnostic Test|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
79379244|NCT06022809|Behavioral|Dada Kwa Dada (individual-level)|Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
79379245|NCT06022809|Behavioral|DADA (group-level)|DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
79533519|NCT05963594|Dietary Supplement|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
79533520|NCT05963490|Drug|Regorafenib|Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
79533521|NCT05963490|Drug|Toripalimab|240 mg intravenously every 3 weeks
79689400|NCT05909683|Other|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
79689401|NCT05909371|Other|exercise|Application of two different exercises to liver transplant individuals.
79834513|NCT05679921|Drug|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
79834514|NCT05673317|Other|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
79834515|NCT05673304|Radiation|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
80006709|NCT02254382|Device|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
80006710|NCT03569592|Behavioral|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
80006711|NCT01371773|Procedure|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
80006712|NCT00475280|Procedure|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
79834516|NCT05672797|Other|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
79834517|NCT05672797|Behavioral|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
79834518|NCT05667129|Drug|XEN-101|Capsule formulation
79834519|NCT05667129|Drug|Placebo|capsule formulation
79379246|NCT06016205|Procedure|intrathecal morphine injection|Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
80006713|NCT00475280|Procedure|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
79239173|NCT03658057|Drug|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
79239174|NCT02378012|Other|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
79239175|NCT02378012|Other|Computer-Assisted Intervention|Receive iPad and instruction manuals.
79239176|NCT02378012|Other|Questionnaire Administration|Ancillary studies
79239177|NCT03664817|Behavioral|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
79379247|NCT06016205|Procedure|ultrasound guided PECS2 block|ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
79533522|NCT05963490|Radiation|High/low-dose radiotherapy|4-8 fractions of 8-12Gy via SABR and up to 1-10Gy at 0.5-2Gy/fraction via LDRT.
79533523|NCT05963490|Drug|Regorafenib|Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
79533524|NCT05963477|Procedure|laparatomy|all abdominal procedures which are approached by different incisions
79689402|NCT05907629|Other|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
79689403|NCT05906628|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79689404|NCT05906628|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
79689405|NCT05902962|Drug|VP-001|Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
79689406|NCT05900388|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
79689407|NCT05900388|Drug|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
79239178|NCT03664817|Behavioral|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
79239179|NCT03657979|Drug|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
79239180|NCT03657979|Drug|Placebo|TAP-block with placebo
79239181|NCT02373488|Other|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
79391220|NCT02420418|Dietary Supplement|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
79533525|NCT05963464|Device|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
79689408|NCT05900115|Behavioral|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
79689409|NCT05900115|Behavioral|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
79689410|NCT05898568|Device|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
79689411|NCT05898568|Behavioral|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
79689412|NCT05897190|Biological|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
79689413|NCT05897190|Biological|CoronaVac®|Dose B
79834520|NCT05661500|Other|Creative Darama Group|Postmortem care training given by creative drama method
79239182|NCT02373488|Other|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
79834521|NCT05661500|Other|Classical Education Group|Postmortem care training given by classical education method
79834522|NCT05658380|Drug|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
79834523|NCT05658380|Drug|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
79834524|NCT05653531|Other|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
79834525|NCT05647902|Diagnostic Test|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
79834526|NCT05646251|Device|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
79834527|NCT05642052|Dietary Supplement|low carb diet|low carb meals will be 50% less carbs than the regular meals
79834528|NCT05642052|Dietary Supplement|Regular diet|Regular diet
79834529|NCT05631171|Behavioral|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
79834530|NCT05629221|Other|TreC Diabete App|Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).
79834531|NCT05625295|Other|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
79834532|NCT05603819|Device|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
79239183|NCT02373488|Other|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
79689419|NCT05891223|Other|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
79834533|NCT05601115|Procedure|Robot assisted therapy|In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
79834534|NCT05601115|Procedure|Conventional Therapy Group|An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
80006714|NCT03569358|Device|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
79239184|NCT03660007|Procedure|Fresh or frozen embryo transfer IVF|
79239185|NCT03659851|Drug|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
79834535|NCT05598047|Behavioral|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
79834536|NCT05595122|Device|EUS-CDS|EUS-CDS with FCSEMS through LAMS
79834537|NCT05577065|Dietary Supplement|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
79834538|NCT05577065|Dietary Supplement|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
79239186|NCT05026060|Diagnostic Test|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
79239187|NCT03659383|Combination Product|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
79834539|NCT05571969|Drug|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
79239188|NCT04978792|Behavioral|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
79239189|NCT04978792|Behavioral|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
79239190|NCT02368730|Drug|desmopressin|
79834540|NCT05566015|Other|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
79533526|NCT05963412|Other|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
79834541|NCT05551104|Drug|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
79533527|NCT05963386|Drug|177Lu-DOTA-EB-FAPI radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 100 mCi (3.7 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
79689420|NCT05891223|Other|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
79834542|NCT05551104|Drug|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
79834543|NCT05534191|Other|Experimental, comparator and control|"To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group from the Danish football strength and conditioning concept Fodboldperformance and a control group."
79834544|NCT05533970|Procedure|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
79239191|NCT03622931|Drug|Standard chemotherapy|Chemotherapy
79533528|NCT05963373|Diagnostic Test|Urine analysis|Diagnostic test
79533529|NCT05963334|Drug|Carboplatin/paclitaxel|Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
79689421|NCT05891223|Other|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application."
79689422|NCT05891223|Other|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
79834545|NCT05527418|Drug|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
80006715|NCT03569358|Device|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
79239192|NCT03622931|Drug|Romiplostim|
79239193|NCT03622931|Drug|Placebos|
79239194|NCT03659305|Biological|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
79239195|NCT03659305|Biological|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
79239196|NCT02368808|Behavioral|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
79302990|NCT03197857|Behavioral|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
79834546|NCT05527418|Drug|Placebo|Placebo during 16 weeks.
79834547|NCT05520333|Behavioral|BIPAS Alcohol|Weekly text messages for three months.
79834548|NCT05515614|Dietary Supplement|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
79379248|NCT06015204|Procedure|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
79834549|NCT05515614|Dietary Supplement|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
79533530|NCT05963321|Device|TDCS|Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region. The equipment will apply a current of 2 mA for 20 minutes.
79834550|NCT05512481|Drug|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
79834551|NCT05493293|Drug|NBI-921352|Tablets for oral administration
79533531|NCT05963308|Behavioral|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
79533532|NCT05963295|Diagnostic Test|toxoplasma igG|Dignosis of toxoplasma
79533533|NCT05963256|Device|Twitch Electrode Array|Monitor train-of-four (TOF) count and percentage
79689423|NCT05891223|Other|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. Courtesy meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
79689424|NCT05891223|Other|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
79689425|NCT05891223|Other|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
79834552|NCT05492110|Device|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
79834553|NCT05492110|Other|Sham-procedure|Implantation procedure with no device implanted
79834554|NCT05492110|Diagnostic Test|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
79834555|NCT05482412|Device|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X [Cranial Nerve Ten Vagus]
79834556|NCT05481424|Other|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
79533534|NCT05963217|Biological|TBI-2001|"Phase-I portion:~cohort 1: 3×10^5 cells/kg, cohort 2: 1×10^6 cells/kg, cohort 3: 3×10^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
79533535|NCT05963217|Drug|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
79689426|NCT05891223|Other|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
79689427|NCT05890300|Device|Use of an occupational passive back-exoskeleton|The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
79689428|NCT05888922|Drug|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
79834557|NCT05481424|Other|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
79834558|NCT05473273|Drug|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
79834559|NCT05473273|Drug|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
79834560|NCT05472831|Behavioral|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
79689429|NCT05888922|Drug|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
79834561|NCT05472831|Behavioral|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
79379249|NCT06015204|Procedure|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
79379250|NCT06014983|Dietary Supplement|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
79379251|NCT06014983|Dietary Supplement|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
79391221|NCT02420418|Other|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
79391222|NCT03180372|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
79391223|NCT02423616|Other|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
79391224|NCT02414802|Device|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
79533536|NCT05963217|Drug|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
79533537|NCT05963204|Combination Product|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
79533538|NCT05963204|Combination Product|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
79834562|NCT05467163|Device|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
79834563|NCT05467163|Device|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
79834564|NCT05467163|Procedure|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
79834565|NCT05464680|Other|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
79834566|NCT05463068|Drug|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
79239197|NCT04978246|Behavioral|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
79239198|NCT03107455|Device|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
79379252|NCT06013826|Other|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
79379253|NCT06009263|Other|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
79533539|NCT05963191|Device|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
79533540|NCT05963178|Behavioral|Pre-operative counselling|"A preoperative speech therapy counseling will be carried out the day before the Total Thyroidectomy with the aim of informing patients about the possible conditions of the immediate post-operative period. Therefore, indications of vocal hygiene and hydration standards will be simultaneously administered, to be implemented from the first post-operative day.~Patients will undergo phoniatric follow-up in the immediate post-operative period, at 7 days, 1 month and 3 months post-operatively.~Patients who, at follow-up checks, should present the symptoms of functional post-thyroidectomy syndrome will undergo a cycle of post-operative speech therapy of 8 sessions."
79379254|NCT06009263|Other|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
79379255|NCT06009263|Other|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
79379256|NCT06008379|Drug|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
79379257|NCT06008379|Drug|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
79379258|NCT06008366|Drug|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
79379259|NCT06008366|Drug|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
79834567|NCT05453513|Other|MRI study - everyone scanned.|This is an observational study without an intervention.
79239199|NCT02369042|Device|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
79689430|NCT05888922|Drug|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
79834568|NCT05453175|Other|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
79834569|NCT05441033|Other|Group-FHB|This is the group where pregnant women and their spouses listen to the fetal heartbeat.
79834570|NCT05441033|Other|Group-GIT|This is the group in which the guided imagery technique is applied to pregnant women and their spouses.
79834571|NCT05440604|Other|Fortified milk|Commercially available milk-based fortified beverage that has an updated profile of key micronutrients along with appropriate levels of protein and other macro- and micro- nutrients, in accordance with global and local nutritional recommendations
79533541|NCT05963165|Behavioral|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
79834572|NCT05438004|Other|Ambulatory nice birth|discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
79239200|NCT05024890|Other|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~Water storage tanks and water filtration systems~Durable plastic drinking water and handwashing stations~New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~Training of focal teachers to organise student 'hygiene club'~Annual soap drive and soap restocking~Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~Toilets have water tap, bucket and waste bin~Emergency menstrual hygiene products available at school~Training of focal teachers to organise student 'gender club'~Education on puberty and menstruation for all pupils above 10 and parent resource guide"
79239201|NCT02368964|Drug|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
79379260|NCT06005961|Behavioral|Module-Based Psychological (MBP) Intervention|Participants will receive one core module related to emotional management and maximum two tailor-made modules according to the participant's needs. Each weekly session lasts for 1 hours. The core module will last for 6 weeks and the tailor-made modules will last for 3 - 4 weeks.
79834573|NCT05433246|Behavioral|Massage therapy group|Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
79533542|NCT05963126|Other|No intervention.|No intervention.
79533543|NCT05963100|Biological|TCR-like CAR-T|intravenous drip of TCR-like CAR-T with indicated doses
80006716|NCT03033875|Behavioral|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
79239202|NCT02368964|Drug|high dose hCG 500 mcg|Treatment for triggering
79239203|NCT05024812|Drug|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m^2, ivgtt 2h, D1,Q3W.
79379261|NCT06001567|Drug|Avatrombopag|Avatrombopag (platelet count [PLT] <40×10^9/L, 60mg P.O. QD; PLT of 40-75×10^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10^9/L, the treatment will be discontinued.
79391225|NCT02414802|Procedure|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
79391226|NCT02414802|Drug|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
79391227|NCT02414802|Drug|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
79533544|NCT05963087|Drug|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
79533545|NCT05963035|Drug|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
79689431|NCT05888922|Drug|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
79689432|NCT05887635|Device|RF Vapor Ablation|RF Vapor ablation of the duodenum
79689433|NCT05886920|Drug|D3S-002|Oral
80006717|NCT03033875|Behavioral|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
80006718|NCT02144402|Other|infant formula with DHASCO|
80006719|NCT02144402|Other|infant formula with DHASCO-B|
80006720|NCT03569046|Drug|local anaesthetic injection|ear block by 0.25% bupivacaine
80006721|NCT03569046|Drug|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
79379262|NCT06000579|Other|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
79379263|NCT06000462|Drug|Dapagliflozin 10mg Tab|Mentioned in detailed description.
80006722|NCT03569046|Drug|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
80006723|NCT03569046|Drug|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
80006724|NCT02935595|Drug|Ketamine|Ketamine Hydrochloride Injection
80006725|NCT02140658|Behavioral|multiple health education interventions|
79379264|NCT06000085|Procedure|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
79391228|NCT01701401|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
79533546|NCT05962983|Behavioral|Small Steps for Big Changes Program|Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for ~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
80006726|NCT02140658|Behavioral|conventional health education|
80006727|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
80006728|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
80006729|NCT02817347|Drug|piperacillin 2% + tazobactam 0.25%|
79689434|NCT05882877|Drug|Rocatinlimab|Subcutaneous (SC) injection
80006730|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5%|
80006731|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0%|
80006732|NCT02503111|Device|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
80006733|NCT02503111|Other|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
80006734|NCT01367327|Behavioral|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
80006735|NCT01367327|Behavioral|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
79689435|NCT05882877|Other|Placebo|SC injection
80006736|NCT05708820|Behavioral|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
80006737|NCT05708820|Behavioral|Standard education programme|Face-to-face educacion programme in a group session
80006738|NCT05417191|Behavioral|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
79239204|NCT02786251|Other|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
79239205|NCT02786251|Other|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (~26-28°C).
79239206|NCT02373722|Procedure|Mohs Surgery|Undergo Mohs surgery
79239207|NCT02373722|Other|Internet-Based Intervention|Watch website application based educational video
79239208|NCT02373722|Behavioral|Telephone-Based Intervention|Receive text messages
79239209|NCT02373722|Other|Educational Intervention|Watch website application based educational video
79834574|NCT05425290|Behavioral|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
80006739|NCT05417191|Behavioral|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
79834575|NCT05425238|Other|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
79834576|NCT05425238|Other|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
79834577|NCT05420090|Behavioral|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
79834578|NCT05420090|Behavioral|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
80006740|NCT02742311|Procedure|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
80006741|NCT03570762|Procedure|hybrid percutaneous intervention|
80006742|NCT02464553|Other|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
79379265|NCT06000085|Procedure|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
79689436|NCT05877599|Biological|Autologous, engineered T Cells targeting TP53 R175H|"Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~Single infusion TCR T cells~Post-infusion recombinant interleukin-2 (rIL-2)"
79689437|NCT05872425|Drug|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
80006743|NCT05708508|Drug|ROVALCYTE|"Immuno-guided strategy arm"
79689438|NCT05872425|Drug|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
80006744|NCT01373021|Drug|Fentanyl|Fentanyl 2500mcg+NS50ml
79239210|NCT02373722|Behavioral|Exercise Intervention|Use Fitbit
79689439|NCT05871515|Device|3D ultrasound|A 3D ultrasound is performed preoperatively to measure various aneurysm characteristics
79689440|NCT05869955|Drug|CC-97540|Specified dose on specified days
79689441|NCT05869955|Drug|Fludarabine|Specified dose on specified days
79379266|NCT06000007|Device|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
79379267|NCT06000007|Other|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
79689442|NCT05869955|Drug|Cyclophosphamide|Specified dose on specified days
79239211|NCT02373722|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
79239212|NCT02373722|Other|Questionnaire Administration|Ancillary studies
79239213|NCT02373722|Other|Survey Administration|Ancillary studies
79239214|NCT05024578|Device|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
79239215|NCT05024578|Device|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
79834579|NCT05420090|Behavioral|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
79834580|NCT05411692|Other|Functional electrical stimulations and motor priming exercise|"One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion. The third pair of electrodes is placed on the subject's skin, above the extensor digitorum muscle, to generate finger extension. Motor priming exercises will be done (functional task practice, FTP) for 20 minutes. Participants will be asked to spend at least 20 minutesDuration of training will be 4 weeks, 5 days per week, one session per day, and one hour per session."
79834581|NCT05411692|Other|Functional electrical stimulations|"Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve. One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion for 20 minutes"
79834582|NCT05411692|Other|Conventional physical therapy|a structured exercise protocol targeting strength (2 days/week) and endurance (3days/week) training
80006745|NCT01373021|Drug|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
79689443|NCT05865535|Biological|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
79689444|NCT05863143|Behavioral|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
79689445|NCT05860894|Device|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
79689446|NCT05859698|Drug|Valbenazine|Valbenazine capsules for oral administration
80006746|NCT03568812|Drug|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
80006747|NCT03568812|Other|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
79379268|NCT05997641|Drug|DF-003|Oral administration by capsules (1 mg, 5 mg, or 25 mg).
79533547|NCT05962944|Device|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
79533548|NCT05962931|Biological|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
79533549|NCT05962931|Procedure|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
80006748|NCT01367405|Procedure|Surgical decompression|Surgical decompression within 24 hour postinjury
80006749|NCT01367405|Procedure|Conservative treatment|Usual conservative treatment without surgery
79379269|NCT05997641|Drug|Placebo|Visually matching 0 mg DF-003 capsules.
79379270|NCT05994859|Procedure|SIRT|The patients will receive 1-2 sessions of SIRT. If the patients have invasive tumors, extensive liver involvement or vascular invasion, systematic treatment will be added.
79689447|NCT05858164|Drug|BAY2862789|Oral administration, solution or tablets
79689448|NCT05857670|Behavioral|Genetic predisposition to breast cancer|Guilt feelings about procreating
79689449|NCT05854537|Procedure|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
79689450|NCT05854537|Procedure|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
79239216|NCT03659149|Drug|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
79239217|NCT03659149|Drug|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
79239218|NCT03659149|Drug|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
79239219|NCT04202770|Other|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
79239220|NCT03000179|Drug|Avelumab|Avelumab through a vein once every 2 weeks
79239221|NCT03622567|Behavioral|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
79379271|NCT05994183|Drug|Dexamethasone Oral|Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
79379272|NCT05992740|Device|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
79834583|NCT05409430|Device|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
79379273|NCT05992584|Drug|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
79379274|NCT05991739|Behavioral|Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)|FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
79379275|NCT05989490|Other|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
79834584|NCT05402137|Behavioral|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
79834585|NCT05396391|Drug|IAP0971|IAP0971 should be subcutaneous injected，q2w
79834586|NCT05396352|Device|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
80006750|NCT03568734|Other|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
80006751|NCT02144480|Behavioral|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
80006752|NCT02144480|Behavioral|traditional training|usual care: conventional rehabilitation
80006753|NCT03568578|Drug|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
80006754|NCT03568578|Drug|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
80006755|NCT04700371|Device|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
80006756|NCT04700371|Device|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
80006757|NCT01367483|Drug|IV methylnaltrexone (MNTX)|
79379276|NCT05986825|Other|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
79379277|NCT05981443|Device|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
79533550|NCT05962918|Other|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
80006758|NCT02140736|Drug|Epoetin biosimilar|
79834587|NCT05389813|Drug|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
80006759|NCT05417035|Drug|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
80006760|NCT01968785|Radiation|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
80006761|NCT01968785|Radiation|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
79379278|NCT05981443|Other|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
79379279|NCT05981274|Diagnostic Test|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
79379280|NCT05979948|Drug|Zanubrutinib|Zanubrutinib, 160 mg oral capsules twice daily for 12 months
79379281|NCT05979948|Drug|Bendamustine|Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.
79834588|NCT05389813|Drug|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
79834589|NCT05389813|Drug|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
79834590|NCT05387512|Drug|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
79834591|NCT05371106|Other|exposure to mycotoxins|self-report eating questionnaire
79834592|NCT05365997|Other|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
79379282|NCT05979948|Drug|Rituximab|Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
79689455|NCT05849142|Device|MRIdian Linac|Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
79689456|NCT05848258|Drug|LY3871801|Administered orally
79689457|NCT05848258|Drug|Placebo|Administered orally
79689460|NCT05833646|Device|Group 1|In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
79379283|NCT05977998|Drug|Paclitaxel|Given by IP (Intraperitoneal injection)
79834593|NCT05363943|Procedure|double plating|open reduction and internal fixation by using lateral and medial plates.
79834594|NCT05363943|Procedure|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
79834595|NCT05363293|Drug|AL 001|a crystal engineered lithium-salicylate-proline lithium delivery product
79834596|NCT05363293|Drug|Placebo|matching placebo formulation
80006762|NCT01373099|Procedure|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
80006763|NCT01373099|Procedure|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
79379284|NCT05977998|Drug|Dexamethasone|Given by IV (vein)
79379285|NCT05977998|Drug|Diphenhydramine|Given by IV (vein)
79379286|NCT05977998|Drug|Famotidine|Given by IV (vein)
79391229|NCT01701401|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79533551|NCT05962879|Behavioral|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
79533552|NCT05962853|Other|Experimental group (Transcutaneous Electrical Nerve Stimulation)|The application will be applied at 8 hour intervals in the first 24 hours after the surgery.
79533553|NCT05962840|Drug|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
79533554|NCT05962840|Other|Placebo of Telitacicept|Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
79834597|NCT05358236|Other|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~Primarily, external reproductive organs were shown to mothers through pictures.~Urethra, Vagina, Anus, Perineum areas were mentioned.~The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~Information was given on how to change their menstrual pads.~Information was provided on what to look for when using underwear~What to watch out while taking a bath:~What to pay attention to in your stitch area"
79834598|NCT05345743|Procedure|Surgery|All types of surgery requiring general anesthesia
79834599|NCT05341167|Device|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
79834600|NCT05341167|Drug|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
79834601|NCT05339555|Other|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
79834602|NCT05325047|Procedure|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
79239222|NCT03659071|Other|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
79379287|NCT05975671|Behavioral|Multifaceted de-implementation strategy to reduce vancomycin overuse|"Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."
79239223|NCT02373644|Other|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
79239224|NCT02373644|Other|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
79379288|NCT05967741|Other|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
79379289|NCT05967741|Other|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
79533555|NCT05962814|Device|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
79533556|NCT05962775|Procedure|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
79239225|NCT03664973|Procedure|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
79379290|NCT05966285|Other|suture repair|Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.
79689461|NCT05833646|Device|Group 2|In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
79239226|NCT03658993|Drug|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
79689462|NCT05833646|Device|Group 3|In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
79689463|NCT05831111|Biological|mRNA-1195.1|Sterile liquid for injection
79689464|NCT05831111|Biological|mRNA-1195.2|Sterile liquid for injection
79689465|NCT05831111|Biological|mRNA-1189|Sterile liquid for injection
79689466|NCT05831111|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79689467|NCT05827003|Other|Exercise|Supervised exercise program with a physiotherapist for 6 weeks, two days a week
79834603|NCT05319054|Device|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
79834604|NCT05319054|Device|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
79834605|NCT05319054|Other|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
79834606|NCT05318027|Device|ChatBot|The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
79834607|NCT05311007|Other|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
79834608|NCT05301751|Drug|AG-73305|AG-73305 Ophthalmic Solution
79834609|NCT05293132|Drug|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
79834610|NCT05293132|Drug|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
79834611|NCT05293132|Drug|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
79834612|NCT05281627|Other|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
79834613|NCT05265949|Behavioral|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
79834614|NCT05259774|Device|Relizema cram|Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
79533557|NCT05962749|Other|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
79239227|NCT02373566|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
79239228|NCT03664661|Drug|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
79379291|NCT05966285|Other|mesh repair|Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
79379292|NCT05966259|Other|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
79533558|NCT05962723|Procedure|EUS|EUS examination and cystic fluid will be aspirated for analysis, including cystic fluid Glucose, CEA, amylase. Morey's biopsy will be done in the cases feasible for biopsy.
79533559|NCT05962710|Device|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
79533560|NCT05962697|Other|SA controller|Novel controller to be tested
79533561|NCT05962697|Other|TA controller|original controller to be tested
79533562|NCT05962697|Other|SA controller early testing|Novel controller to be tested early testing
79533563|NCT05962684|Other|ERAS|Implementation of ERAS protocol in elective craniotomy patients
79689468|NCT05827003|Other|Exercise&Topical Agent|Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.
79689469|NCT05827003|Other|Topical Agent|Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
79689470|NCT05824442|Biological|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
79689471|NCT05823441|Drug|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
79689472|NCT05823441|Drug|Placebo|Volunteers inhale 24 units of placebo spray
79689473|NCT05823441|Behavioral|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
79834615|NCT05237908|Device|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
79834616|NCT05234892|Device|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
79239229|NCT03657901|Behavioral|Music listening|Guided music listening for 30 minutes before sleep onset
79689474|NCT05823441|Behavioral|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
79834617|NCT05231980|Dietary Supplement|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
79834618|NCT05231980|Drug|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
79689475|NCT05822076|Procedure|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
79834619|NCT05231980|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
79834620|NCT05223166|Drug|Pitolisant|Wakix tablet
79834621|NCT05223166|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
79834622|NCT05205980|Behavioral|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
79834623|NCT05202938|Diagnostic Test|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
79834624|NCT05202938|Diagnostic Test|FDG PET scan|FDG venous injection and positron emission tomography scan.
79834625|NCT05202938|Diagnostic Test|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
79834626|NCT05202938|Diagnostic Test|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
79834627|NCT05202938|Diagnostic Test|Blood sampling|Collecting 20ml of venous blood.
79533564|NCT05962671|Drug|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
79239230|NCT03657901|Behavioral|Slow breathing|Guided slow breathing for 30 minutes before sleep onset
79239231|NCT02373410|Procedure|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
79239232|NCT02373410|Procedure|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
79834628|NCT05186233|Behavioral|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
79834629|NCT05182632|Behavioral|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
79689476|NCT05822076|Procedure|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
79689477|NCT05814523|Drug|Ganaxolone|Ganaxolone will be administered as IV solution.
79834630|NCT05182476|Drug|Placebo|Oral tablets
79834631|NCT05182476|Drug|Luvadaxistat|Oral tablets
79834632|NCT05180227|Device|DS8R|transcutaneous stimulation of the spinal cord.
79834633|NCT05180227|Diagnostic Test|Orthostatic tilt|perform an orthostatic tilt without and with stimulation.
79239233|NCT02373410|Procedure|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
79533565|NCT05962671|Drug|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
79533566|NCT05962658|Other|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
79533567|NCT05962645|Drug|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
79533568|NCT05962632|Drug|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
79533569|NCT05962632|Drug|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
79689478|NCT05814523|Drug|Placebo|Placebo will be administered as IV solution.
79689479|NCT05814523|Drug|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
79834634|NCT05173051|Other|Solid Medication intake vs. crushed medication intake|The swallowing ability for solid and crushed medications in stroke patients is evaluated.
79834635|NCT05171062|Drug|bexmarilimab (FP-1305)|standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
79834636|NCT05171062|Drug|Pembrolizumab|Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
79834637|NCT05164471|Genetic|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
79834638|NCT05148962|Biological|GRT-R910 10 mcg Dose (after AZ)|10 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
79834639|NCT05148962|Biological|GRT-R910 30 mcg Dose (after AZ)|30 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
79834640|NCT05148962|Biological|GRT-R910 10 mcg Dose (After Adenovirus based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
79834641|NCT05148962|Biological|GRT-R910 10 mcg Dose (after mRNA based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
79834642|NCT05140941|Drug|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
79834643|NCT05130840|Diagnostic Test|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
79834644|NCT05130840|Diagnostic Test|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
79834645|NCT05119842|Device|APrevent® VOIS-Implant|To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
79834646|NCT05108441|Other|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
79834647|NCT05101902|Other|Pre-Screening|No intervention given
79834648|NCT05094882|Procedure|pulmonary lobectomy|resection of lung lobe
79689480|NCT05810194|Device|StrataXRT|StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
79689481|NCT05810194|Drug|Calendula|Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
79239234|NCT02373410|Procedure|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
79239235|NCT02373410|Drug|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
79834649|NCT05072574|Other|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
79379293|NCT05966259|Other|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
79379294|NCT05965219|Drug|Emraclidine|Emraclidine tablets.
79689482|NCT05810194|Drug|Aquaphor|Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.
79689483|NCT05807971|Drug|ATH-063|12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
79689484|NCT05807971|Drug|Placebo|Identical capsule to the drug without the active ingredient.
79689485|NCT05800964|Drug|AMG 305|Short-term intravenous (IV) infusion
79834650|NCT05070988|Other|Semi-structured interview|Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
79834651|NCT05068440|Drug|Zanubrutinib|administered orally as capsules
79834652|NCT05059938|Behavioral|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
79834653|NCT05050305|Drug|Marizomib|Intravenous Infusion
79834654|NCT05050305|Drug|Pomalidomide|Taken orally
79239236|NCT02373410|Drug|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
79239237|NCT02373410|Drug|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
79239238|NCT02373410|Drug|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
79379295|NCT05965219|Drug|Itraconazole|Itraconazole oral solution.
79379296|NCT05965219|Drug|Carbamazepine|Carbamazepine tablets.
79379297|NCT05965219|Drug|Metformin|Metformin tablets.
79379298|NCT05963451|Other|No intervention|No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
79379299|NCT05957809|Other|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~Strength training on unstable surfaces - 25 minutes~Aerobic exercise - 25 minutes~Cool-down program - 10 minutes"
79834655|NCT05050305|Drug|Dexamethasone|Taken orally
79834656|NCT05048667|Device|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
79834657|NCT05048667|Drug|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
79834658|NCT05048667|Other|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
79834659|NCT05048667|Other|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
79834660|NCT05044104|Device|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
79379300|NCT05957484|Device|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
79379301|NCT05954546|Drug|Enco+bini|Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment
79834661|NCT05036616|Device|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
79834662|NCT05034276|Other|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
79689486|NCT05798780|Behavioral|ENHANCE Intervention - Exercise and Nutrition|During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
79834663|NCT05029154|Behavioral|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
79834664|NCT05029154|Behavioral|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
79834665|NCT05026554|Genetic|Tape stripping|Optional genetic analysis for chronic hand eczema
79834666|NCT05020327|Drug|Graded Oral Amoxicillin Challenge|Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
79834667|NCT05020327|Other|De-labelling in electronic medical record|Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
79834668|NCT05020327|Other|Referral to Allergy Immunology/Retention of Allergy Label|Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
79834669|NCT04994704|Drug|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
79834670|NCT04994704|Drug|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
79239239|NCT04975672|Other|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
79239240|NCT02920177|Drug|platelet-rich plasma injection|platelet-rich plasma injection
79239241|NCT02920177|Drug|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
79239242|NCT03006341|Drug|Dabigatran etexilate|observed upto 12 months
79379302|NCT05953012|Drug|PMC-403|PMC-403 will be administered Intravitreal.
79379303|NCT05947474|Drug|ORB-011|Drug: ORB-011 is dosed via IV infusion
79379304|NCT05946798|Drug|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10^-10M - 10^-1 M) for 5 minutes each
79379305|NCT05946798|Drug|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10^-8M - 10^-4 M) for 10 minutes each
79239243|NCT03006341|Drug|Warfarin|Observed upto 12 months
79239244|NCT05022784|Drug|Nintedanib|Nintedanib
79239245|NCT02368574|Procedure|Class II hysterectomy|Class II hysterectomy
79239246|NCT02368418|Procedure|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
79239247|NCT02368418|Procedure|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
79379306|NCT05946785|Drug|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10^-10M - 10^-1 M) for 5 minutes each
79379307|NCT05946785|Drug|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10^-8M - 10^-4 M) for 10 minutes each
79379308|NCT05945719|Behavioral|Behavioral therapy|Behavioral and supportive therapy
79379309|NCT05945394|Other|No intervention|This is an obvertional study, and there is no intervention.
79379310|NCT05944978|Drug|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
79379311|NCT05941819|Device|ARC-IM Thoracic System implantation|Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
79379312|NCT05940961|Drug|Inotuzumab Ozogamicin|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
79379313|NCT05939518|Other|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains <0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches >0.3 ml/kg/h.
79533570|NCT05962632|Device|Mobile application|examine the impact of Mobile application on caries prevention
79834671|NCT04990817|Other|Average American Diet With SoFAS Replaced With Avocado|Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet
79834672|NCT04990817|Other|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
79834673|NCT04988451|Behavioral|ASL Services|ASL specialist meets with participants and provides ASL instruction
79834674|NCT04981951|Drug|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
79834675|NCT04977063|Device|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
79834676|NCT04977063|Device|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
80006764|NCT05354388|Procedure|Resection surgery of gastrointestinal stromal tumor|oral administration of Ripretinib 150 mg QD. Resection of gastrointestinal stromal tumors was performed in patients who achieved PR or SD
79239248|NCT02744365|Other|Observational|"All women of the biobank have provided:~blood samples (plasma, serum and Buffy-coat)~urine samples~demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~mean arterial blood pressure~ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
79379314|NCT05939518|Other|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
79379315|NCT05934500|Drug|Cannabidiol Oil|Subjects will self administer CBD sublingually
79379316|NCT05934019|Device|EMPATIA 1|The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
79533571|NCT05962632|Combination Product|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
79834677|NCT04947527|Drug|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
79834678|NCT04947527|Drug|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
79834679|NCT04939935|Drug|Metformin XR|Extended release metformin.
79834680|NCT04939935|Other|Control|Placebo is inactive tablets that is identical to the intervention Metformin tablets.
79834681|NCT04909827|Procedure|3D-printed endocrown|pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
79834682|NCT04909827|Procedure|Zirconia crown|pulpotomy and restoration with prefabricated zirconia crown
79834683|NCT04908722|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
79834684|NCT04907214|Drug|Empagliflozin 25 MG|Oral empagliflozin daily
79834685|NCT04907032|Drug|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
79834686|NCT04907032|Device|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
79834687|NCT04904809|Device|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
79834688|NCT04897633|Device|transcranial electric stimulation|Simon's task assessment when under tDCS
79834689|NCT04883918|Biological|ASC930|4 intravenous doses of ASC930
79834690|NCT04882930|Procedure|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
79834691|NCT04882917|Drug|M4076|M4076 will be administered orally, in Part 1A and Part 1B.
79834692|NCT04866563|Drug|AX-8|orally disintegrating tablets, BID
80006765|NCT03095287|Biological|Alphanate|Bolus IV injection.
80006766|NCT01335581|Device|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
80006767|NCT01335581|Drug|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
79834693|NCT04866563|Drug|Placebo|orally disintegrating tablets, BID
79834694|NCT04864418|Drug|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
79834695|NCT04861051|Drug|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
79834696|NCT04846127|Device|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
79834697|NCT04842409|Radiation|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
79834698|NCT04839575|Drug|Latiglutenase|Administered orally (daily)
79834699|NCT04839575|Drug|Placebo|Administered orally (daily)
79834700|NCT04834375|Drug|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
79834701|NCT04812964|Dietary Supplement|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
79834702|NCT04812964|Dietary Supplement|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
80006768|NCT05354310|Combination Product|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
79239249|NCT03455465|Other|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
80006769|NCT05204563|Drug|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
80006770|NCT05204563|Drug|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
80006771|NCT02144558|Other|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
80006772|NCT03566940|Biological|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
80006773|NCT03566940|Biological|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
80006774|NCT02144636|Dietary Supplement|herbalife protein shake|
79239250|NCT02368496|Device|HR-pQCT|
79239251|NCT03935594|Biological|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
79239252|NCT03935594|Drug|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
79379317|NCT05930925|Drug|[phenyl-14C]ARV-471|Participants will receive a single dose of [phenyl-14C]ARV-471 by mouth
79379318|NCT05930925|Drug|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of [oxoisoindolin-14C]ARV-471 by mouth
79379319|NCT05926947|Dietary Supplement|Verum A|Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract
79379320|NCT05926947|Dietary Supplement|Verum B|Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate
79379321|NCT05926947|Dietary Supplement|Placebo|Micro crystalline cellulose
79834703|NCT04788745|Drug|Trimetazidine Dihydrochloride|Oral tablet, twice-daily
79834704|NCT04770519|Genetic|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
79834705|NCT04752579|Other|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts & Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
79834706|NCT04741672|Behavioral|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
79834707|NCT04741672|Behavioral|Discharge routine procedure.|Discharge routine procedure.
79834708|NCT04739709|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
79834709|NCT04739709|Drug|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
79834710|NCT04717479|Other|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
79834711|NCT04712903|Drug|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
79834712|NCT04712903|Drug|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
79834713|NCT04712903|Drug|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
79834714|NCT04712903|Drug|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
79834715|NCT04710927|Device|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
80006775|NCT03566862|Diagnostic Test|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
80006776|NCT03545360|Device|BTL-703 (Treatment group)|Treatment with BTL-703 device
80006777|NCT03566784|Procedure|Inguinal hernia repair|Standard procedure for inguinal hernia repair
80006778|NCT01209923|Device|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
79239253|NCT03665753|Drug|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
79379322|NCT05926167|Diagnostic Test|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
79379323|NCT05923788|Diagnostic Test|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
79379324|NCT05920863|Procedure|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
79689487|NCT05798780|Behavioral|ENHANCE Intervention - Nutrition Only|During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
79834716|NCT04710927|Device|Papain-Based Gel|Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
79239254|NCT03566108|Procedure|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
79379325|NCT05920863|Drug|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight <60kg, 8mg/day; weight ≥60kg, 12mg/day.
79689488|NCT05797168|Drug|AZD5335|IV Antibody-drug conjugate
79239255|NCT03566108|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
79239256|NCT02512042|Drug|Test-Brinzolamide 1% Ophthalmic suspension|
79239257|NCT02512042|Drug|Reference-Brinzolamide 1% Ophthalmic suspension|
79834717|NCT04710927|Device|High Viscosity Glass Ionomer Cement (HVGIC)|The molar will be restored with HVGIC
79689489|NCT05797168|Drug|AZD5305|Oral PARP inhibitor
79689490|NCT05784753|Behavioral|HEART Camp|Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
79239258|NCT02377544|Dietary Supplement|Probiotic|
79379326|NCT05920096|Other|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~inform participants on the association between smoking and diabetic complications;~motivate and encourage smokers to quit;~support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
79834718|NCT04694976|Biological|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
79834719|NCT04694313|Device|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
79834720|NCT04692701|Device|Pulvinar deep brain stimulation|Stimulation of the medial pulvinar
79834721|NCT04691596|Behavioral|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
79834722|NCT04691596|Behavioral|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
79379327|NCT05920096|Behavioral|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
79834723|NCT04691596|Behavioral|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
79834724|NCT04691596|Behavioral|App use instructions|Received a basic training with the StepUp app
79834725|NCT04691011|Other|Muscular MRI|MRI (1.5T)
79834726|NCT04691011|Other|Electrophysiological exam|MUNIX
79834727|NCT04691011|Other|Brain MRI|MRI (7T)
79834728|NCT04691011|Other|Spinal cord MRI|7T and 3T MRI
79834729|NCT04690998|Other|Blood Samples|Genetic, proteomic, neurofilament analysis
79834730|NCT04690998|Other|MRI|Spinal and muscular MRI
79834731|NCT04689997|Behavioral|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
79834732|NCT04689035|Drug|AVLX-144|Test drug
79834733|NCT04689035|Drug|Placebo|Placebo
79834734|NCT04684862|Device|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
79239259|NCT02377544|Other|Placebo|
79689491|NCT05784753|Behavioral|HEART Camp Connect|Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
79834735|NCT04683627|Drug|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
79834736|NCT04683627|Drug|Placebo patch|A placebo patch without diclofenac sodium was used for the placebo arm.
79834737|NCT04657666|Drug|Nabiximols|oromucosal spray
79834738|NCT04657666|Drug|Placebo|oromucosal spray
79834739|NCT04652687|Biological|VIA Disc NP|VIA Disc NP - Allograft tissue injection
79834740|NCT04646967|Drug|Bupivacain|See active comparator description
79834741|NCT04646967|Drug|Sevoflurane|See active comparator description
79834742|NCT04646967|Drug|Acetaminophen|See active comparator description
79834743|NCT04646967|Drug|Ibuprofen|See active comparator description
79834744|NCT04646967|Drug|Ketorolac|See experimental arm description
79834745|NCT04633512|Device|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
80006779|NCT02140814|Dietary Supplement|Niacinamide|
80006780|NCT03015090|Drug|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
80006781|NCT02140892|Procedure|respiratory physical therapy manual technique- Autogenic Drainage|
80006782|NCT02140892|Device|respiratory physical therapy technique- IPV|
79689492|NCT05784441|Drug|JNJ-90009530|JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
79689493|NCT05776979|Drug|Isatuximab|Given by vein over about 75 minutes
79689494|NCT05776979|Drug|lenalidomide|Given by PO
79834746|NCT04614324|Device|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
79834747|NCT04606355|Diagnostic Test|Visual Acuity|autostereoscopic, monocular dynamic force choice test
79834748|NCT04606355|Diagnostic Test|stereopsis|autostereoscopic dynamic forced-choice depth perception test
80006783|NCT00139139|Biological|Hepatitis A vaccine|
79834749|NCT04606355|Diagnostic Test|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
79834750|NCT04589286|Behavioral|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
80006784|NCT02141048|Behavioral|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
79379328|NCT05919368|Dietary Supplement|Yam pill|It consists of sweet potato, white art and ginseng
79379329|NCT05917587|Drug|Metformin Hydrochloride|12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
79379330|NCT05917587|Other|placebo|12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
79379331|NCT05914116|Drug|DB-1311|Administered I.V.
79689495|NCT05774184|Biological|barzolvolimab|subcutaneous administration
79689496|NCT05774184|Drug|Matching Placebo|subcutaneous administration
79834751|NCT04589286|Other|Electronic Handouts|Generic wellness-related electronic handouts
79834752|NCT04563754|Diagnostic Test|mHRME (Mobile High resolution microendoscope)|"SOC (standard of care) HRA with Lugol's iodine will be performed. Unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)).~The mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
79689497|NCT05770401|Behavioral|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
79834753|NCT04563754|Drug|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
79834754|NCT04563754|Diagnostic Test|High resolution anoscopy|SOC (standard of care) HRA with Lugol's iodine will be performed.
79834755|NCT04557111|Device|remote monitoring|CIED monitoiring with remote monitoring device
79834756|NCT04539249|Drug|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
79239260|NCT03665519|Dietary Supplement|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
80006785|NCT01367639|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
80006786|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
80006787|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
80006788|NCT02620748|Drug|Tranexamic Acid|
79689498|NCT05770401|Behavioral|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
79689499|NCT05767671|Other|Non-Bronchoscopic Mini Bronchoalveolar Lavage|"A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml."
80006789|NCT02620748|Other|Saline Solution|
79379332|NCT05908799|Drug|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
79239261|NCT03665519|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid treatment will be given for 3 months.
79239262|NCT02919475|Drug|JTE-051|Active drug tablets containing JTE-051
79239263|NCT02919475|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
79379333|NCT05908799|Drug|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
79689500|NCT05763797|Behavioral|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
79834757|NCT04539249|Drug|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
79834758|NCT04513002|Dietary Supplement|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
79834759|NCT04495829|Device|Phorcides Analytical Engine|Surgery planning using the Phorcides analytical engine.
79239264|NCT02373332|Other|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
79834760|NCT04492891|Drug|Cyclosporine|2.5 mg/kg PO BID 7 days
79834761|NCT04492891|Other|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
79834762|NCT04449198|Drug|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
79239265|NCT03664505|Device|Compression garment (manual)|Garment based on manual measurement
79239266|NCT03664505|Device|Compression garment (scan)|Garment based on scan measurement
79239267|NCT03543605|Behavioral|PROA Experimental|PROA Control plus clinical advice
79239268|NCT03543605|Other|PROA Control|PROA Control
79239269|NCT02368262|Other|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
79379334|NCT05907824|Other|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
79379335|NCT05906303|Drug|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
79379336|NCT05906303|Drug|Normal Saline|Provide normal saline to serve as a placebo
79379337|NCT05905718|Other|assessment|Assessments of thoracic kyphosis angle, balance performance, and gait performance.
79391230|NCT04482504|Diagnostic Test|3 tests: Posturography, Questionnaire, vitamin D|Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
79391231|NCT02414568|Drug|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
79391232|NCT02414568|Drug|Prednisone|Prednisone 40 mg/m² PO
79689501|NCT05763797|Behavioral|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
79689502|NCT05763251|Other|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
79834763|NCT04449198|Other|Placebo|placebo for 12 weeks
79834764|NCT04446559|Procedure|Sitting in chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
79834765|NCT04432337|Procedure|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
79834766|NCT04417595|Drug|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
79834767|NCT04417595|Drug|Olive Oil|Olive Oil Supplement
79391233|NCT02414568|Drug|Vinblastine|Vinblastine 6 mg/m² IV
79834768|NCT04385082|Drug|Active Cannabis|Smoked cannabis with THC
79239270|NCT02368262|Procedure|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
79689503|NCT05756556|Combination Product|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks [Q2W], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily [QD] for the first 21 days of each 28-day cycle)
79689504|NCT05746117|Device|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
79239271|NCT01066897|Drug|Pramipexole|Patients will received increasing dose of pramipexole
79689505|NCT05746117|Device|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
79689507|NCT05736536|Behavioral|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
79689508|NCT05734625|Drug|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
79834769|NCT04385082|Drug|Placebo Cannabis|Placebo smoked cannabis (no THC)
79834770|NCT04353960|Diagnostic Test|electrocardiograph|electrocardiograph monitor during strabismus surgery
79834771|NCT04342481|Other|Educational Screening tool|Educational Screening tool
79834772|NCT04312945|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
79834773|NCT04312945|Other|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
79834774|NCT04299659|Diagnostic Test|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
80006790|NCT01373255|Procedure|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
80006791|NCT03566706|Behavioral|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
79239272|NCT02373254|Drug|Ibuprofen|Ibuprofen 400 mg and 800 mg
80006792|NCT03566706|Behavioral|Discussion Tool: Marijuana Use|Parent Discussion Tools
80006793|NCT03566706|Behavioral|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
79239273|NCT02373254|Drug|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
79239274|NCT04376372|Diagnostic Test|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
79391234|NCT02414568|Drug|Doxorubicin|Doxorubicin 40 mg/m² IV
79391235|NCT02420340|Behavioral|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
79689509|NCT05734625|Drug|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
79834775|NCT04271189|Drug|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
79834776|NCT04271189|Drug|Standard of care|Usual medical care to treat diabetes.
79834777|NCT04243551|Drug|Latiglutenase|Administered orally (daily)
79834778|NCT04243551|Other|Placebo|Administered orally (daily)
79834779|NCT04221945|Biological|Pembrolizumab|IV infusion
79834780|NCT04221945|Drug|Placebo for pembrolizumab|IV infusion
79834781|NCT04221945|Drug|Cisplatin|IV infusion
79834782|NCT04221945|Radiation|External Beam Radiotherapy (EBRT)|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
79834783|NCT04221945|Radiation|Brachytherapy|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
79834784|NCT04206501|Device|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
80006794|NCT03566628|Other|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
79239275|NCT03657355|Drug|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
79239276|NCT03657355|Drug|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
80006795|NCT03566628|Other|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
79239277|NCT03657355|Drug|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
79239278|NCT03657355|Drug|Placebo|Matching-placebo will be used.
79834785|NCT04199325|Dietary Supplement|Probiotics|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
80006796|NCT02141126|Other|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
79834786|NCT04199325|Drug|uric-acid-lowering drug|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
79834787|NCT04189133|Drug|Lutropin alfa|daily increasing dosages of lutropin alfa
80006797|NCT02141126|Other|Usual care|Standard inpatient 'usual care' physiotherapy
80006798|NCT03566472|Diagnostic Test|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
80006799|NCT02144792|Drug|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
80006800|NCT03564990|Other|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
80006801|NCT03564990|Other|conventional approach|conventional follow-up
80006802|NCT02144870|Behavioral|Habit Reversal Training|awareness training, competing response training
79689510|NCT05729620|Device|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
80006803|NCT02144870|Behavioral|Resources activation|
79689511|NCT05726396|Drug|RMT|A single loading dose of RMT capsules containing ~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
79239279|NCT03818516|Other|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
79834788|NCT04189133|Drug|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
79834789|NCT04158804|Diagnostic Test|procalcitonin|accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
79834790|NCT04157725|Drug|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
80006804|NCT03566394|Drug|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
80006805|NCT03544424|Other|No intervention|No intervention
80006806|NCT00033293|Other|Clinical Observation|Undergo observation
80006807|NCT00033293|Drug|Cyclophosphamide|Given IV
79379338|NCT05903053|Behavioral|Early Self-Regulation Intervention|"Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total)."
79391236|NCT04410497|Other|Porcine xenograft (wound dressings)|commercial porcine xenograft, derived from acellular dermis from porcine.
79689512|NCT05726396|Drug|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
80006808|NCT00033293|Other|Laboratory Biomarker Analysis|Correlative studies
80006809|NCT00033293|Procedure|Magnetic Resonance Imaging|Correlative studies
80006810|NCT00033293|Drug|Prednisone|Given orally
80006811|NCT00033293|Biological|Therapeutic Immune Globulin|Given IV
80006812|NCT03566316|Drug|Telmisartan/Amlodipine|
80006813|NCT03566316|Drug|Rosuvastatin|
80006814|NCT03566316|Drug|Telmisartan|
80006815|NCT02144948|Drug|e.-coli-nissle|1 ml qd for 24 weeks
79239280|NCT02985541|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
79379339|NCT05900427|Drug|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
79379340|NCT05900427|Drug|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
79379341|NCT05897840|Device|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
79379342|NCT05897307|Drug|Ropivacaine|dexmedetomidine
79379343|NCT05897086|Drug|Polyethylene Glycol 3350|Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
80006816|NCT03566004|Diagnostic Test|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
79379344|NCT05896683|Drug|Lazertinib|Lazertinib will be administered orally.
79379345|NCT05894772|Behavioral|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
79379346|NCT05887102|Behavioral|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
79379347|NCT05884619|Device|Dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
79379348|NCT05875025|Other|Placebo formulated with HFA-152a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
79379349|NCT05875025|Other|Placebo formulated with HFA-134a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
79379350|NCT05869760|Other|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
79379351|NCT05869760|Other|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
79379352|NCT05868863|Other|datas of medical record.|"Analysis datas of medical record:~Feasibility of the technique~Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~Analgesic intake before and after the procedure~Functional criteria: early rising, walking"
79379353|NCT05856539|Procedure|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
80006817|NCT03565926|Other|Manual Therapy|"Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
80006818|NCT03565926|Other|Hypopressive exercises|Protocol 5 Hypopressive exercises
79379356|NCT05841615|Other|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W~12W for 40 seconds
79379357|NCT05841615|Other|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
79689513|NCT05721989|Drug|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
79689514|NCT05721989|Drug|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
80006819|NCT02145104|Drug|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
79379358|NCT05839808|Other|Reliability and validity study|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
79379359|NCT05839795|Other|Assessment study|Evaluation of musculoskeletal-related pain, posture, spine function, lumbar and neck regions, musculoskeletal disorder, fatigue, and quality of life
79689515|NCT05721989|Drug|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
79689516|NCT05721001|Device|Surgical Repair|In Frozen Elephant Trunk procedure, the proximal aortic arch is replaced with a dacron graft, and a thoracic stent graft, sutured to the distal end of the dacron prosthesis, is deployed antegradely into the descending aorta. This mostly one-stage alternative approach eliminates the interval mortality rate related to the conventional elephant trunk procedure. Moreover, it constitutes a solution in fragile patients who cannot safely complete a second major operation after surviving the first.
79689517|NCT05715697|Procedure|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
79689518|NCT05715697|Procedure|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
80006820|NCT03565848|Procedure|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
80006821|NCT02145338|Drug|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
79379360|NCT05829629|Biological|FluBHPVE6E7|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
79834791|NCT04157725|Drug|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
79834792|NCT04145518|Drug|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
79834793|NCT04140903|Drug|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
79834794|NCT04140903|Drug|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
79834795|NCT04130126|Behavioral|Taking cold showers|Showering behaviour
79834796|NCT04118998|Behavioral|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
79834797|NCT04118998|Behavioral|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
79834798|NCT04101721|Drug|aflibercept|Administered IVT
79834799|NCT04101721|Procedure|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
79834800|NCT04057872|Procedure|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
79834801|NCT03995368|Other|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
80006822|NCT02145338|Other|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
79379361|NCT05829629|Drug|Placebo|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
79379362|NCT05829525|Other|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
79379363|NCT05825742|Device|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
79689519|NCT05715242|Behavioral|Core Behavioral Weight Loss Intervention|All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
79689520|NCT05715242|Behavioral|Easier Step Goal|Participants will receive an easier daily step goal.
79689521|NCT05715242|Behavioral|Harder Step Goal|Participants will receive a more challenging daily step goal.
79689522|NCT05715242|Behavioral|Easier Calorie Goal|Participants will receive an easier daily calorie goal.
79689523|NCT05715242|Behavioral|Harder Calorie Goal|Participants will receive a more challenging daily calorie goal.
79689524|NCT05715242|Behavioral|Easier Eating Window Goal|Participants will receive an easier daily eating window goal.
79689525|NCT05715242|Behavioral|Harder Eating Window Goal|Participants will receive a more challenging daily eating window goal, akin to time-restricted eating.
79689526|NCT05715242|Behavioral|Easier Red Zone Food Goal|Participants will receive an easier daily Red Zone Food goal.
79689527|NCT05715242|Behavioral|Harder Red Zone Food Goal|Participants will receive a more challenging daily Red Zone Food goal.
79689528|NCT05706935|Diagnostic Test|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
79834802|NCT03977129|Device|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
79834803|NCT03977129|Other|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
79379364|NCT05825742|Other|Standard oral health instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
79391237|NCT04410497|Other|Silver foam (wound dressings)|commercial silver containing foam dressing
79391238|NCT02420106|Procedure|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
79391239|NCT03116880|Procedure|Endovascular aortic repair|Endovascular aortic repair
79689529|NCT05703282|Drug|AD-104-A|PO, Single-Dose, AD-104-A
79689530|NCT05693129|Drug|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
79239281|NCT01946672|Procedure|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
79834804|NCT03968640|Dietary Supplement|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
79834805|NCT03968640|Dietary Supplement|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
79834806|NCT03962504|Behavioral|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
79834807|NCT03948074|Drug|Cannabis|Medicinal Cannabis Oil
79834808|NCT03939104|Drug|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
80006823|NCT03565770|Other|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
79379365|NCT05824208|Behavioral|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
80006824|NCT03565770|Other|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
79533572|NCT05962619|Procedure|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
79689531|NCT05689372|Drug|Semaglutide|Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
79689532|NCT05688215|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79689533|NCT05688215|Procedure|Computed Tomography|Undergo a CT scan
79689534|NCT05688215|Procedure|Core Biopsy|Undergo core biopsy
79689535|NCT05688215|Drug|Fluorouracil|Given IV
79689536|NCT05688215|Drug|Irinotecan|Given IV
79689537|NCT05688215|Drug|Leucovorin|Given IV
79689538|NCT05688215|Drug|Leucovorin Calcium|Given IV
79689539|NCT05688215|Drug|Oxaliplatin|Given IV
79689540|NCT05688215|Drug|Quemliclustat|Given intravenously (IV)
79689541|NCT05688215|Drug|Zimberelimab|Given IV
79689542|NCT05683691|Device|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
79689543|NCT05683509|Procedure|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
79689544|NCT05683509|Procedure|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane only
79689545|NCT05682170|Drug|ZN-d5 ZN-c3|Oral agent
79689546|NCT05682170|Drug|ZN-c3|Oral agent
79689547|NCT05675878|Behavioral|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
79239282|NCT02368028|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
79239283|NCT04385095|Drug|SNG001|SNG001 via inhalation
79239284|NCT04385095|Drug|Placebo|Placebo via inhalation
79689548|NCT05675332|Behavioral|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
79689549|NCT05675332|Behavioral|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
79834809|NCT03939104|Drug|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
79834810|NCT03939104|Drug|Artesunate-mefloquine+piperaquine|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~24 mg/kg/day in patients <25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
79834811|NCT03939104|Drug|Artesunate-mefloquine+placebo|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
79834812|NCT03932318|Biological|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
79834813|NCT03932318|Drug|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
79834814|NCT03932318|Drug|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
79834815|NCT03926949|Other|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
79834816|NCT03926949|Other|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
79834817|NCT03923725|Drug|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
79689550|NCT05672511|Behavioral|Simulation Teaching Method|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
79834818|NCT03923725|Drug|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
80006825|NCT03565692|Biological|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~Separation of the pellet and supernatant, stored at -20 ° C until testing~Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~Pseudomonas aeruginosa load measured by qPCR"
80006826|NCT03565692|Biological|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
80006827|NCT02254616|Behavioral|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
80006828|NCT02254616|Behavioral|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
80006829|NCT02254616|Behavioral|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
80006830|NCT02254616|Behavioral|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
80006831|NCT02254694|Other|high heeled shoes|see detailed study description
79834819|NCT03923725|Drug|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~24 mg/kg/day in patients <25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
79834820|NCT03923725|Drug|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
79834821|NCT03918603|Other|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
80006832|NCT03565614|Behavioral|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
80006833|NCT03565614|Behavioral|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
80006834|NCT03565536|Drug|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
80006835|NCT03565536|Procedure|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
80006836|NCT03565536|Radiation|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
80006837|NCT05128253|Other|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
80006838|NCT05193383|Behavioral|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
79239285|NCT02368106|Radiation|Radiation Therapy|targeted radiation treatment
79379366|NCT05823623|Drug|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
79689551|NCT05670509|Drug|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
79689552|NCT05670509|Drug|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
79689553|NCT05670509|Drug|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
80006839|NCT05193383|Behavioral|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
79239286|NCT03113006|Procedure|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
79239287|NCT02367950|Behavioral|Exercise|10 exercise sessions with a personal trainer
79239288|NCT02365532|Drug|GS-6615|GS-6615 tablets administered orally
79239289|NCT02365532|Drug|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
79239290|NCT02365532|Drug|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
79239291|NCT02365532|Drug|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
79239292|NCT03113162|Biological|Autologous Hematopoietic Stem Cell|
79239293|NCT03113162|Drug|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
79379367|NCT05823623|Drug|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
79379368|NCT05823623|Drug|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
79379369|NCT05822856|Other|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
79834822|NCT03912155|Other|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
79834823|NCT03896347|Other|ViBone®|Viable bone allograft
79834824|NCT03896347|Other|Demineralized Bone Matrix|Demineralized Bone Matrix
79834825|NCT03896347|Other|Bone Morphogenetic Protein|Bone Morphogenetic Protein
79834826|NCT03864926|Drug|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
80006840|NCT05193383|Behavioral|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
79239294|NCT02461225|Device|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
79302991|NCT03197857|Behavioral|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
79379370|NCT05821699|Behavioral|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~Opioid Risk Education~Therapeutic Intervention~Clinical Pain Coordination"
79379371|NCT05821699|Behavioral|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
79834827|NCT03864926|Drug|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
79834828|NCT03855735|Behavioral|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
79834829|NCT03853434|Procedure|Embolization|Angiographic embolization
79834830|NCT03836261|Drug|Acalabrutinib|Acalabrutinib,
79834831|NCT03836261|Drug|Venetoclax|Venetoclax
79834832|NCT03836261|Drug|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
79834833|NCT03836261|Drug|Obinutuzumab|Obinutuzumab
79834834|NCT03809533|Drug|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
79834835|NCT03808922|Drug|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
79834836|NCT03808922|Drug|Placebo|Placebo nebulized qd x 7 OR 10 days
79834837|NCT03808922|Drug|DAS181 COVID-19|DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
79834838|NCT03808922|Drug|DAS181 OL|DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days < 40kg
79391240|NCT01701245|Device|GammaCore|vagal stimulation
79391241|NCT03117114|Device|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
79533573|NCT05962619|Procedure|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
79533574|NCT05962593|Other|Telephone call|The patients will be randomized for a postoperative telephone call
79533575|NCT05962580|Procedure|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
79533576|NCT05962580|Procedure|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
79834839|NCT03796793|Procedure|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
79834840|NCT03796793|Other|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
80006841|NCT05193383|Behavioral|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
80006842|NCT03565458|Drug|Gemigliptin|zemiglo 50mg,LG Chem
79834841|NCT03763864|Other|Skin Biopsy|Skin Biopsy
79689554|NCT05670509|Drug|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
79834842|NCT03760016|Behavioral|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
79239295|NCT02461225|Device|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
79834843|NCT03760016|Behavioral|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
79834844|NCT03756870|Procedure|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
79239296|NCT02368340|Other|Pulmonary function test|Pulmonary function testing performed
79689555|NCT05670509|Drug|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
79834845|NCT03718234|Drug|Subcutaneous hydrocortisone|Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
79834846|NCT03718234|Drug|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
79834847|NCT03717519|Diagnostic Test|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
79834848|NCT03708276|Other|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
79834849|NCT03689439|Diagnostic Test|bone scintigraphy|bone scintigraphy
79239297|NCT02368340|Other|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
79834850|NCT03667248|Device|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
79239298|NCT02368340|Other|Sample collection|Blood and urine sample collections
79834851|NCT03643107|Drug|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
79834852|NCT03643107|Combination Product|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
79834853|NCT03641703|Biological|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
79834854|NCT03623243|Drug|Siponimod|Siponimod 2mg tablets taken once daily
80006843|NCT03565458|Drug|Dapagliflozin|forxiga, dapagliflozin 10mg
80006844|NCT03565458|Drug|Empagliflozin|jardiance 25mg, empagliflozin
80006845|NCT01367717|Dietary Supplement|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
79239299|NCT02910037|Device|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
80006846|NCT01367717|Dietary Supplement|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
80006847|NCT03565302|Drug|Formoterol|Subjects are treated with daily inhalation of formoterol
79391242|NCT03117114|Other|Standard polypectomy|Absence of an EVD, standard polypectomy
79689556|NCT05670509|Drug|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
79689557|NCT05662033|Drug|AZD6793|AZD6793 will be administered orally
79689558|NCT05662033|Drug|Placebo|Placebo will be administered orally
79689559|NCT05658432|Other|Exercise via telehealth|Same as arm/group description
80006848|NCT03565302|Drug|Terbutaline|Subjects are treated with daily inhalation of terbutaline
79533577|NCT05962567|Other|Non surgical periodontal therapy|scaling and subgingival debridement
79689560|NCT05658432|Other|Exercise unsupervised|Same as arm/group description
79239300|NCT02372864|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
79834855|NCT03619707|Drug|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
79533578|NCT05962554|Behavioral|iJobs|iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
79239301|NCT04059848|Combination Product|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
79239302|NCT04059848|Combination Product|NMES(Enraf Nonius, Endomed-182, Netherlands)|
79689561|NCT05651555|Behavioral|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution
79379372|NCT05816915|Behavioral|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
79379373|NCT05814497|Other|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
79689562|NCT05649670|Other|Mobile Stroke Unit deployment|Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
79834856|NCT03611673|Other|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
79834857|NCT03603717|Behavioral|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
79379374|NCT05814497|Other|Graphesthesia|Trace numbers on skin.
79379375|NCT05814497|Other|Divided attention|Divide attention between two noxious stimuli.
79834858|NCT03603717|Behavioral|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
79834859|NCT03597568|Dietary Supplement|Resveratrol|Oral supplementation for 6 weeks
79834860|NCT03597568|Other|Placebo|Oral supplementation for 6 weeks
79379376|NCT05805306|Behavioral|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, & sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
79391243|NCT02420028|Device|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
79533579|NCT05962541|Drug|PDD-TURBT with hexaminolevulinate (Hexvix®)|In order to undergo PDD-TURBT, all eligible patients in the experimental arm will be administered the photosensitizer hexaminolevulinate (85 mg in 50 ml of phosphate buffered saline, Hexvix®) on an inpatient setting through a urethral catheterization of the participant's bladder. During the PDD-TURBT surgery, the bladder will be illuminated with blue light (wavelength 380-450 nm). The operating rooms of the participant institutions will therefore need to have the specialized equipment consisting in the blue-light source (POWER LED SAPHIRA [TM]).
79533580|NCT05962541|Device|Power Led Saphira (TM) from KARL STORZ|This is a light source based on LED technology. It can be used for both White Light (WL) and fluorescence applications in blue light (i.e., Photodynamic diagnosis PDD) for visualizing tumor lesions during trans-urethral resection of bladder tumors (PPD- TURBT).
79533581|NCT05962528|Device|Soft lens|Patients were randomly fitted with five different designs of soft lenses
79834861|NCT03593408|Drug|Dexmedetomidine|Administered for sedation management per hospital protocol
80006849|NCT03565302|Other|Placebo|Subjects are treated with placebo
80006850|NCT03568032|Diagnostic Test|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
79533582|NCT05962515|Procedure|ultrasound guided dry needling|Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
79239303|NCT02356705|Drug|Midazolam|midazolam 0.2 mg/kg given intranasally
79239304|NCT02356705|Drug|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
79239305|NCT02356705|Drug|saline placebo|intranasal saline given as placebo
79834862|NCT03593408|Drug|Fentanyl|Administered for sedation management per hospital protocol
79834863|NCT03593408|Drug|Midazolam|Administered for sedation management per hospital protocol
79834864|NCT03593408|Drug|Morphine|Administered for sedation management per hospital protocol
79834865|NCT03591445|Device|Flexible Bronchoscopy|Flexible Bronchoscopy
79834866|NCT03572582|Drug|Nivolumab|Nivolumab therapy combined with standard TACE treatment
79834867|NCT03572582|Drug|TACE|TACE is performed by using drug eluting beads
79834868|NCT03562832|Drug|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
79379377|NCT05805306|Behavioral|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, & sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
79689566|NCT05645003|Device|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
79834869|NCT03492164|Drug|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
79834870|NCT03432871|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
79834871|NCT03399942|Procedure|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
80006851|NCT03568032|Diagnostic Test|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
80006852|NCT03568032|Diagnostic Test|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
80006853|NCT03568032|Diagnostic Test|Montreal Cognitive Assessment|Cognitive assessment
79239306|NCT02373176|Drug|[14C]PRC 4016 (Icosabutate)|Single oral dose
79239307|NCT02511184|Drug|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
79239308|NCT02511184|Drug|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
79689567|NCT05645003|Device|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
79689568|NCT05642468|Drug|Ritivixibat|10mg tablet A3907 administered orally
79834872|NCT03399318|Drug|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
79834873|NCT03399318|Drug|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
79834874|NCT03399318|Drug|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
79834875|NCT03399318|Drug|placebo for ibuprofen|placebo for ibuprofen
79834876|NCT03389139|Device|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
79834877|NCT03389139|Device|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
79834878|NCT03382938|Drug|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
79834879|NCT03382938|Drug|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
79834880|NCT03382938|Drug|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
79834881|NCT03382938|Other|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
79834882|NCT03380468|Drug|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
79834883|NCT03356366|Other|MRI 3T|Magnetic Resonance Imaging 3 Tesla
79239309|NCT02367638|Biological|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
79533583|NCT05962437|Device|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
79533584|NCT05962437|Device|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
79533585|NCT05962437|Behavioral|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
79834884|NCT03356366|Other|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
80006854|NCT03568032|Other|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
80006855|NCT03567798|Dietary Supplement|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
79533586|NCT05962411|Other|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
79689578|NCT05634278|Behavioral|Preoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
79689579|NCT05634278|Behavioral|Postoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
79689580|NCT05634278|Behavioral|Mind wandering|"A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander."
79834885|NCT03356366|Other|MRI 7T|Magnetic Resonance Imaging 7 Tesla
79834886|NCT03322774|Behavioral|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
80006856|NCT03567798|Other|Placebo|Placebo
79239310|NCT02367638|Biological|VARIVAX|VARIVAX is administered by subcutaneous injection
79239311|NCT02367560|Procedure|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
79239312|NCT02367560|Procedure|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
79239313|NCT02367560|Drug|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
79239314|NCT02367560|Device|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
79239315|NCT02372942|Drug|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
79239316|NCT02372942|Drug|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
79239317|NCT04975048|Dietary Supplement|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
79689581|NCT05631236|Device|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
79379378|NCT05799183|Drug|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
79379379|NCT05799183|Drug|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
79379380|NCT05797025|Other|To assess pressure pain threshold and pinch grip strengths.|To assess pressure pain threshold and pinch grip strengths.
79379381|NCT05797012|Other|To assess headache severity, head posture, cervical muscle endurance and neck disorders.|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
79379382|NCT05795309|Device|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
79391244|NCT02420028|Device|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
79239318|NCT04975048|Dietary Supplement|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
79239319|NCT02365220|Behavioral|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
79239320|NCT02365220|Behavioral|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
79834887|NCT03322774|Behavioral|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
79834888|NCT03322774|Behavioral|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
79834889|NCT03304483|Other|246-km running|Spartathlon 2017
79834890|NCT03284892|Behavioral|SOC program|A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
79689582|NCT05631236|Device|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
79834891|NCT03279952|Drug|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
79834892|NCT03271242|Other|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
79834893|NCT03271242|Other|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
79834894|NCT03258853|Device|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
79834895|NCT03258853|Other|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
79834896|NCT03236155|Drug|opioid pain pills|patient will receive their pain pill prescription
79834897|NCT03216551|Diagnostic Test|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
79834898|NCT03192202|Drug|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
79834899|NCT03177122|Drug|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
79834900|NCT03169166|Drug|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
79834901|NCT03140735|Other|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
79391245|NCT04348877|Other|Antibody-Rich Plasma from COVID-19 recovered patients|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
79834902|NCT03140735|Other|Control group without heart disease|Control group without heart disease
79834903|NCT03068780|Drug|Oleogel-S10|10% birch bark extract in 90% sunflower oil
80006857|NCT01372007|Drug|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
79239321|NCT02365220|Behavioral|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
79239322|NCT02365220|Behavioral|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
79239323|NCT02365142|Biological|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
79239324|NCT02365142|Biological|Platelet Rich plasma (PRGF)|3 injections of PRGF
79239325|NCT02364986|Drug|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
79239326|NCT02364986|Drug|Avonex|Avonex 30µg (day 1 and 8) i.m.
79533587|NCT05962359|Behavioral|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
79689589|NCT05625204|Behavioral|Center based attention control|Center based attention control
79239327|NCT02373020|Other|colonoscopic biopsies|
79239328|NCT02372786|Drug|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
79239329|NCT02372786|Drug|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
79379383|NCT05794633|Other|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
79379384|NCT05794633|Other|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
79391246|NCT03176628|Dietary Supplement|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
79391247|NCT03176628|Dietary Supplement|Placebo|Placebo capsule(s)
79533588|NCT05962333|Biological|Intra-arterial delivery of autologous MABs|three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval
79533589|NCT05962320|Other|Education and counselling|Education and counselling of patients and their parents
79689590|NCT05625204|Behavioral|Center based HIIT|Center based HIIT
79689591|NCT05625204|Behavioral|Home based HIIT|Home based HIIT
79689592|NCT05624918|Drug|Nab paclitaxel|125 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
79689593|NCT05624918|Drug|Gemcitabine|1000 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
79689594|NCT05624918|Device|NovoTTF-200T(P)|Worn > 18 hr /day starting C1D1 until completion of cycle 3
79834904|NCT03068780|Drug|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
79834905|NCT03006848|Drug|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
79834906|NCT03006848|Other|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
79834907|NCT02981069|Drug|Dapagliflozin|10mg
79834908|NCT02981069|Drug|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
79834909|NCT02981069|Drug|Placebo|Placebo for Dapagliflozin
79834910|NCT02980991|Drug|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
79834911|NCT02980991|Drug|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
79834912|NCT02958462|Other|follow up|
79834913|NCT02923128|Drug|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
79834914|NCT02923128|Drug|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
79834915|NCT02923128|Drug|Saline|Saline is used to dilute other drugs
79834916|NCT02839642|Drug|Rivastigmine|
79834917|NCT02839642|Drug|Placebo|
80006858|NCT01372007|Drug|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
79379385|NCT05794308|Behavioral|Non-Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot does not, or only minimally, provide relational behavioral cues. Participants will view their progress of daily step counts.
79379386|NCT05794308|Behavioral|Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot provides relational behavioral cues. Participants will view their progress of daily step counts.
79379387|NCT05794295|Other|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored during one night in the UC Davis Epilepsy Monitoring Unit (EMU).
79689595|NCT05623306|Device|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
79689596|NCT05623306|Device|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
79533590|NCT05962320|Other|Avoiding the use of nasogastric catheters, drains and urinary catheters|Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
79689599|NCT05617066|Behavioral|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
79689600|NCT05617014|Radiation|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
79689601|NCT05617014|Radiation|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
79689602|NCT05617014|Radiation|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
79689603|NCT05617014|Radiation|MK-6240|Tau PET imaging with MK-6240 injection
79689604|NCT05617014|Radiation|NAV4694|Amyloid PET imaging with NAV4694 injection
79689605|NCT05617014|Radiation|PI-2620|Tau PET imaging with PI-2620 injection
79689606|NCT05616013|Biological|Bimagrumab|Human monoclonal antibody to the activin receptor type II
79834918|NCT02810444|Biological|IgG Next Generation (BT595)|
79834919|NCT02672748|Other|Garden|Two years of financial and technical home gardening support for new gardeners
79834920|NCT02612311|Biological|Obinutuzumab|Obinutuzumab: IV infusion
79391248|NCT02414490|Drug|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
79533591|NCT05962320|Other|Stimulation of intestinal motility in the postoperative period|Stimulation of intestinal motility in the postoperative period
79533592|NCT05962320|Other|Initiation of oral intake in the early postoperative period|Initiation of oral intake in the early postoperative period
79533593|NCT05962320|Other|Early removal of the patient by reducing postoperative IV fluid infusion|Early removal of the patient by reducing postoperative IV fluid infusion
79533594|NCT05962320|Other|Initiation of early mobilization of the patient in the postoperative period|Initiation of early mobilization of the patient in the postoperative period
79689607|NCT05616013|Drug|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist
79689608|NCT05616013|Other|Bimagrumab Placebo|Placebo
79689613|NCT05610150|Device|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
79689614|NCT05610150|Device|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
79834921|NCT02612311|Biological|Ublituximab|Ublituximab: IV infusion
79834922|NCT02612311|Drug|TGR-1202|TGR-1202: Oral daily dose
79834923|NCT02612311|Drug|Chlorambucil|Chlorambucil: Oral dose
79834924|NCT02607319|Drug|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
79834925|NCT02596191|Other|Clinical evaluation|
79834926|NCT02596191|Other|electrophysiological record|
79834927|NCT02596191|Other|Muscle MRI|
79834928|NCT02596191|Other|blood samples analysis|
79834929|NCT02582021|Procedure|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
79834930|NCT02582021|Procedure|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
79533595|NCT05962320|Other|Reducing opioid use and ensuring pain management|Reducing opioid use and ensuring pain management
79689615|NCT05596058|Other|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
79689616|NCT05596058|Other|active exercise|Physical activity and motor task only
79689617|NCT05596058|Other|cognitive task only|cognitive exercise in executive functions
79689618|NCT05595642|Drug|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
79689619|NCT05595642|Drug|Placebo|Participants will receive SC placebo Q2W
79689620|NCT05590962|Other|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥3 for Stage IV cancer patients and ≥5 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
79689621|NCT05585632|Biological|mRNA-1010|Sterile liquid for injection
79689622|NCT05585632|Biological|mRNA-1345|Sterile liquid for injection
79689623|NCT05585632|Biological|mRNA-1273.214|Sterile liquid for injection
79689624|NCT05585632|Biological|mRNA-1045|Formulation for injection
79689625|NCT05585632|Biological|mRNA-1230|Formulation for injection
79689626|NCT05581199|Drug|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
79689627|NCT05581199|Drug|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
79834931|NCT02582021|Procedure|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
79834932|NCT02582021|Procedure|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
80006859|NCT03037164|Device|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
79239330|NCT02372786|Device|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
79239331|NCT02372786|Device|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
79533596|NCT05962320|Other|Implement nausea and vomiting prophylaxis|Implement nausea and vomiting prophylaxis
79533597|NCT05962320|Other|Management of thirsty|Management of thirsty
79533598|NCT05962320|Other|Management of fear and stress|Use of recommended non-pharmacological interventions in the management of fear and stress
79533599|NCT05962307|Drug|Bulevirtide|dose of 2 mg/day subcutaneously
79689628|NCT05581199|Drug|Placebo|Matching placebo SC
79689629|NCT05574491|Behavioral|Super Skills for Life: traditional version|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~The intervention will be administered by trained clinical psychologists in SSL. Sessions will be held once a week for eight weeks, with each session lasting approximately forty five minutes.~The program includes emotional education, social skills training, cognitive restructuring, relaxation techniques, self-observation, problem solving and behavioural activation. These contents are learned through playful exercises, activities, readings, and role-playing.~Both modalities of intervention will be in-person.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. & Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández."
79239332|NCT02364908|Other|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
79239333|NCT02372552|Device|CROMA|Microwave coagulation of small blood vessels
79239334|NCT02372708|Drug|dinitrophenyl(DNP)|
79239335|NCT02372708|Radiation|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
79391249|NCT01590017|Drug|cisplatin|
79391250|NCT01590017|Radiation|external beam radiation therapy|
79391251|NCT02419716|Device|Cologuard|Prescription of Cologuard for at-home stool collection
79391252|NCT02419794|Procedure|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
79391253|NCT01700621|Biological|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
79391254|NCT01700621|Biological|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
79689630|NCT05574491|Behavioral|Super Skills for Life: computerized version|Structured and manualized intervention with a manual for the therapist and multimedia material for the children.
79239336|NCT02364674|Radiation|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
79239337|NCT02367404|Drug|Duloxetine|Duloxetine 60mg OD for 3 months
79239338|NCT02367404|Behavioral|Pelvic Floor Muscle Training|PMFT weekly for 3 months
79239339|NCT02367248|Drug|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
79834933|NCT02582021|Procedure|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
79834934|NCT02582021|Procedure|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
79834935|NCT02582021|Procedure|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
79834936|NCT02581085|Drug|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
79834937|NCT02581085|Other|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
79834938|NCT02575963|Drug|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
79834939|NCT02575963|Biological|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
79834940|NCT02575963|Drug|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
79834941|NCT02575963|Drug|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
79834942|NCT02541305|Other|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
79834943|NCT02541305|Other|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
79834944|NCT02507284|Drug|SRX246|
79239340|NCT02367248|Drug|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
79834945|NCT02507284|Drug|Placebo|
79239341|NCT02367248|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
79239342|NCT02984995|Drug|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
79239343|NCT02367326|Other|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
79533600|NCT05962281|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
79689631|NCT05574062|Device|Study Phase: MiniMed 780G Auto Mode with G4S sensor|Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
79689632|NCT05574062|Device|Study Phase: MiniMed 780G Manual Mode with G4S sensor|Subjects will start using the MiniMed™ 780G system in Manual Mode.
79689633|NCT05574062|Device|Continuation phase: MiniMed 780G BLE 2.0 with DS5 sensor|Subjects will start using the MiniMed 780G BLE 2.0 with DS5 sensor
79689634|NCT05574062|Device|Continuation Phase MiniMed 780G Auto Mode with G4S sensor|Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
79689635|NCT05571423|Behavioral|Medical Play|Study subject will be engage in the medical play.
79689636|NCT05571423|Behavioral|Routine Play|Study subject will be engage in the routine play (coloring exercise).
79239344|NCT03656965|Drug|Acyclovir 800 MG|Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
79239345|NCT03656965|Combination Product|Radiotherapy and chemotherapy|Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
79239346|NCT02364830|Drug|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
79239347|NCT02364830|Other|Placebo|One Placebo Capsule/Day for 4 Weeks
79239348|NCT02364830|Drug|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
79834946|NCT02501096|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
79834947|NCT02501096|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
79834948|NCT02455622|Drug|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
79834949|NCT02432248|Drug|Dehydroepiandrosterone|75mg/day, PO for 90 days
79834950|NCT02432248|Other|placebo(medical starch)|75mg/day, PO for 90 days
79533601|NCT05962268|Other|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
79533602|NCT05962268|Other|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
79533603|NCT05962255|Drug|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
79533604|NCT05962255|Drug|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
79533605|NCT05962255|Drug|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
79533606|NCT05962216|Drug|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
79689637|NCT05570721|Behavioral|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
79689638|NCT05569317|Other|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
79689639|NCT05567588|Combination Product|Drug: Pembrolizumab|200mg(body weight >75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
79689640|NCT05564429|Drug|18F-SF12051|Injected IV followed by PET scanning
79689641|NCT05551858|Drug|Proglumide|(CAS: 6620-60-6.)
79689642|NCT05551858|Drug|Placebo|Avicel fiber filled capsule taken by mouth three times daily
79834951|NCT02418143|Device|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
79834952|NCT02370797|Radiation|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
79834953|NCT02364089|Procedure|Laparoscopic surgical removal of the adrenal tumor|
79834954|NCT02364089|Drug|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~step 4: Add-on of Indapamide LP 1.5 mg~step 5: Add-on of Spironolactone 25 mg~step 6: Add-on of Bisoprolol 10 mg~step 7: Add-on of Prazosine LP 5mg/day."
79239349|NCT03622333|Genetic|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
79533607|NCT05962203|Diagnostic Test|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring & management systems, e.g. community-based and home-based exercise programs, polypharmacy
79533608|NCT05962190|Behavioral|Diet|High fat (~60% of total energy intake) diet enriched with either SFA or UFA
79533609|NCT05962138|Behavioral|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
79689643|NCT05533866|Combination Product|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
79689644|NCT05530889|Device|TEST Lens|ACUVUE® Theravision® with Ketotifen
79689645|NCT05530889|Device|CONTROL Lens|1-DAY ACUVUE® MOIST.
79834955|NCT02347995|Other|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
80006860|NCT03037164|Device|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
80006861|NCT01373411|Drug|ticagrelor|ticagrelor 90 mg BID for 90 days
79834956|NCT02347995|Other|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
79834957|NCT02186418|Genetic|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
79834958|NCT02122562|Drug|Ketamine|Treatment
79834959|NCT02122562|Other|Alcohol Infusion|Biomarker
80006862|NCT01373411|Drug|Placebo|Placebo 1 pill BID for 90 days
80006863|NCT03567564|Diagnostic Test|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
79239350|NCT02364518|Procedure|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
79239351|NCT03270956|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
79239352|NCT02384239|Drug|Palbociclib|Given orally (PO)
79239353|NCT02384239|Drug|Tamoxifen|Given orally (PO)
79239354|NCT02384239|Drug|Fulvestrant|Given by intramuscular (IM) injection.
79239355|NCT02372474|Biological|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
79239356|NCT02364752|Procedure|Blood Draw|
79239357|NCT02364752|Procedure|Loop Diuretic Withdrawal/Salt Load|
79239358|NCT03657199|Diagnostic Test|Cardiac computed tomography|Routine computed tomography of the heart before discharge
79379388|NCT05794295|Other|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored during one night in the UC Davis Epilepsy Monitoring Unit (EMU).
79834960|NCT02121873|Device|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
79533610|NCT05962112|Other|Metabolic investigations after night-shifts|Metabolic investigations after night-shifts
79834961|NCT02121873|Device|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
79533611|NCT05962099|Behavioral|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
79533612|NCT05962073|Device|HFNC|High-flow oxygen therapy before intubation for preoxygenation
79834962|NCT02121873|Device|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
79834963|NCT02115724|Dietary Supplement|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
79834964|NCT02115724|Other|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
79834965|NCT02115724|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
79239359|NCT02372240|Drug|VLX1570 and dexamethasone|
79239360|NCT02364596|Biological|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
79239361|NCT02364596|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
79391255|NCT02419872|Drug|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
79391256|NCT03178500|Drug|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
79391257|NCT02414412|Dietary Supplement|Ulmus macrocarpa water extract|
79391258|NCT02414100|Other|Laboratory Biomarker Analysis|Correlative studies
79533613|NCT05962060|Other|Proprioceptive neuromuscular facilition|PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.
79834966|NCT02115724|Drug|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
79834967|NCT02036372|Drug|Liraglutide|
79834968|NCT02036372|Drug|Insulin bolus|
79834969|NCT02036372|Drug|GIK infusion|continuous infusion
80006864|NCT03567408|Procedure|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
80006865|NCT03567408|Drug|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
80006866|NCT05354154|Procedure|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
79533614|NCT05962060|Other|Electrical muscle stimulator|Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
79533615|NCT05962047|Other|Games of WonderTree Augmented Reality|Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
79689646|NCT05529303|Behavioral|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
79239362|NCT02364440|Device|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
79834970|NCT01965249|Device|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
79689647|NCT05522673|Drug|11(R)-rolipram|Injected IV followed by PET scanning
79689648|NCT05516628|Procedure|Surgical Resection|Resection of Primary Hepatocellular Cancer Tumour.
79834971|NCT01965249|Device|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
79689649|NCT05516628|Drug|Adjuvant Atezolizumab-Bevacizumab Therapy|Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following resection of hepatocellular cancer tumour.
79834972|NCT01807936|Procedure|Lymphadenectomy|
79834973|NCT01633541|Drug|AT-101|Patients will receive AT-101 40 mg orally two times a day.
79834974|NCT01633541|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
79834975|NCT01633541|Drug|Cisplatin|Cisplatin 100 mg/m2
79834976|NCT01633541|Drug|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
79834977|NCT01466036|Drug|Cabozantinib|60 mg QD orally in cycles of 28 days
79834978|NCT01399372|Biological|Rituximab|One 28-day cycle = 500 mg/m^2 intravenously on day 1 and day 5.
79239363|NCT02364206|Drug|LY2228820|
79239364|NCT02364206|Drug|Temozolomide|
79391259|NCT02414100|Other|Cytology Specimen Collection Procedure|Correlative studies
79533616|NCT05962047|Other|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
79533617|NCT05962021|Drug|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
79689650|NCT05511519|Drug|ATI-450|Oral, small molecule MK2 inhibitor
79689651|NCT05511519|Drug|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
79689652|NCT05506670|Other|Diagnostic test and phone call|Viral diagnostic test will be performed at inclusion. In case of RSV positive results, follow up phone calls will be scheduled at day 14 and day 30 to collect data.
79689653|NCT05506670|Diagnostic Test|Diagnostic test|Viral diagnostic test will be performed at inclusion. In case of RSV negative result, no more intervention will be required.
79689654|NCT05502549|Drug|CB03-154|CB03-154 tablet once daily.
79834979|NCT01399372|Drug|Cytarabine|One 28-day cycle = 3 g/m^2 intravenously on day 1 and day 2.
79834980|NCT01399372|Drug|Methotrexate|One 28-day cycle = 3.5 g/m^2 intravenously (standard hydration/leucovorin support) on day 2.
79834981|NCT01399372|Drug|Procarbazine|One 28-day cycle = 100 mg/m^2 orally on days 2-8.
79834982|NCT01399372|Drug|Vincristine|One 28-day cycle = 1.4 mg/m^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
79834983|NCT01399372|Radiation|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
79834984|NCT01267604|Drug|Recombinant FSH (rFSH)|225IU
79834985|NCT01267604|Dietary Supplement|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
79834986|NCT01244399|Dietary Supplement|Inositol|
79834987|NCT01087125|Drug|No Interventions|No Interventions
80006867|NCT05354076|Drug|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
79239365|NCT02364206|Radiation|radiotherapy|
79239366|NCT02366858|Procedure|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
79239367|NCT02366858|Procedure|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
79239368|NCT02372162|Other|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
79391260|NCT03179982|Behavioral|Safe South Africa|"Core components of the Safe South Africa intervention include the following:~Theory driven, best-evidence intervention approaches to adolescent HIV prevention~Linkages between HIV and IPV~Victim Empathy~Healthy Norms Regarding Masculinity~Bystander Intervention Skills"
79391261|NCT03116958|Device|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
79834988|NCT01063517|Drug|olaparib|100mg BID oral tablet continuous
79834989|NCT01063517|Drug|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
79834990|NCT01063517|Drug|Placebo|100mg BID oral tablet to match olaparib tablet
79834991|NCT01047111|Procedure|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
79689655|NCT05502549|Drug|Placebo|Placebo tablet once daily.
79239369|NCT02372162|Other|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
79239370|NCT02366546|Drug|TBI-1301|TBI-1301(5*10^8 or 5*10^9) is administered.
79689656|NCT05488782|Behavioral|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
79689657|NCT05488782|Other|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
79689658|NCT05483803|Behavioral|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
79689659|NCT05483166|Behavioral|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~Becoming aware of the child's core strengths and difficulties~Helping the child to be optimally responsive to the guidance of the parent(s), and~Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
79689660|NCT05482711|Other|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
79834992|NCT00920621|Dietary Supplement|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
79834993|NCT00920621|Dietary Supplement|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
79834994|NCT00903591|Other|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
79239371|NCT02366546|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
79239372|NCT02366546|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
79239373|NCT02984683|Drug|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
79239374|NCT02524327|Other|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
79239375|NCT02524327|Other|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
79239376|NCT02364362|Drug|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m^2
79239377|NCT02364362|Drug|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m^2
79239378|NCT02364362|Drug|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m^2
79239379|NCT02364128|Behavioral|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
79239380|NCT04574180|Other|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
79239381|NCT02909101|Device|Active Cognitive Training (ACT)|Cognitive training games
79533618|NCT05961995|Behavioral|Heartfulness meditation|Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart.
79533619|NCT05961982|Procedure|Chemical Ablation|Undergo EUS-guided chemoablation
79834995|NCT00832702|Procedure|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
79834996|NCT00820430|Other|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
79834997|NCT00311324|Behavioral|Special Intervention|
79834998|NCT00311324|Behavioral|Delayed Intervention|
79533620|NCT05961982|Procedure|Computed Tomography|Undergo CT
79533621|NCT05961982|Other|Electronic Health Record Review|Ancillary studies
79533622|NCT05961982|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Undergo EUS-FNA
79533623|NCT05961982|Procedure|Endoscopic Ultrasound-Guided Radiofrequency Ablation|Undergo EUS-RFA
79533624|NCT05961982|Procedure|Magnetic Resonance Cholangiopancreatography|Undergo MRI/MRCP
79533625|NCT05961982|Procedure|Magnetic Resonance Imaging|Undergo MRI/MRCP
79533626|NCT05961969|Procedure|Robotic surgery|"Patients with rectal cancer.~Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
79834999|NCT00964600|Procedure|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
79835000|NCT00964756|Genetic|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
79835001|NCT00964756|Drug|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
79835002|NCT00964834|Drug|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
79835003|NCT00964834|Drug|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
79689661|NCT05480085|Behavioral|School-based extracurricular intervention focusing on screen media use and time spent with friends|"The intervention includes the following components:~Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan."
79689662|NCT05479032|Drug|Amantadine|2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
79835004|NCT00964834|Drug|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
79835005|NCT00612105|Drug|Retigabine|150mg/day up to 900mg/day
79835006|NCT00612105|Drug|Placebo|daily
79835007|NCT04017741|Drug|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
80006868|NCT05192993|Other|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
80006869|NCT05192993|Other|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
79239382|NCT02909101|Device|Control Training (CON)|Cognitive training games
80006870|NCT05192993|Other|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
79689663|NCT05477576|Drug|RYZ101|RP3D as determined in Phase 1b
80006871|NCT05065697|Other|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
80006872|NCT01367951|Procedure|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
79239383|NCT03656575|Biological|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
79239384|NCT03656887|Device|Continuous interstitial glucose sensor|Installing and removing the sensor
79689664|NCT05477576|Drug|Everolimus 10 mg|Everolimus 10 mg daily by mouth
79689665|NCT05477576|Drug|Sunitinib 37.5 MG|Sunitinib 37.5 mg daily by mouth
79835008|NCT04017741|Drug|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
79239385|NCT03656887|Other|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
79239386|NCT03004469|Drug|P-3074|
79239387|NCT03004469|Drug|Finasteride|
79239388|NCT03004469|Drug|P-3074 Vehicle|
79239389|NCT03004469|Drug|Finasteride Placebo|
79689666|NCT05477576|Drug|Octreotide LAR 60 MG Injection|High-dose octreotide LAR 60 mg Q4W by i.m. injection
79835009|NCT00546052|Drug|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
79239390|NCT02358902|Device|tDCS|tDCS - DC stimulator, Neurocom, Germany
79239391|NCT02358902|Procedure|active intervention of aerobic exercise|different types of aerobic exercise
79239392|NCT02358902|Device|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
79239393|NCT02358902|Procedure|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
79239394|NCT02366702|Device|Lower Limb Powered Knee-Ankle Prosthesis|
79689667|NCT05477576|Drug|Lanreotide 120Mg Sa Susp Inj Syringe|High dose frequency lanreotide 120 mg Q2W by deep s.c. injection
80006873|NCT05708664|Procedure|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
79835010|NCT00887601|Drug|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
80006874|NCT05192759|Device|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
80006875|NCT05192681|Drug|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
79239395|NCT02366780|Procedure|Pump|Breast milk expression using manually or using an electric pump
79239396|NCT02910713|Device|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
79239397|NCT04478786|Other|Focus group discussion|There is no intervention. This is a qualitative piece of work only.
79533627|NCT05961943|Behavioral|RESPONSE-2-PAD|The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.
79239398|NCT02358824|Drug|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
79239399|NCT02358824|Drug|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
79239400|NCT02358824|Drug|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
79239401|NCT02998541|Drug|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
79533628|NCT05961930|Behavioral|Questionnaire|Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
79533629|NCT05961917|Other|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
79533630|NCT05961917|Other|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
79533631|NCT05961904|Other|Breastmilk|Study group with receive orally 2 ml breast milk before the heel prick.
79689668|NCT05468892|Drug|Trifluridine Tipiracil|"Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest"
79689669|NCT05468892|Drug|Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]|Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
79835011|NCT00887601|Drug|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
79835012|NCT00887601|Drug|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
79835013|NCT00887601|Drug|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
79835014|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
79689672|NCT05453006|Device|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview intervention clinics.
79689673|NCT05444244|Other|Relational Research Recruitment and Engagement Intervention|"Specified recruiter/point of contact~Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~Resource matching (financial, transportation constraints)"
79689674|NCT05443256|Device|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
79689675|NCT05432596|Drug|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
79689676|NCT05432596|Drug|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
79689677|NCT05432596|Drug|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
79835015|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
79835016|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
79835017|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
79835018|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
79835019|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
79835020|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
80006876|NCT01368029|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
79835021|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
79835022|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
79835023|NCT00964912|Drug|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
79835024|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
79835025|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
79835026|NCT00887757|Drug|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
79835027|NCT00887757|Drug|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
79835028|NCT00965068|Other|Cholesterol|
79835029|NCT02542527|Procedure|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
79835030|NCT00965224|Biological|dendritic cell vaccination (active specific immunotherapy)|
79835031|NCT00887835|Device|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
80006877|NCT01368029|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
80006878|NCT03634553|Other|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
80006879|NCT03634553|Other|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
79835032|NCT04392921|Drug|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
79835033|NCT04392921|Drug|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
80006880|NCT01368107|Drug|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
79689678|NCT05432596|Drug|Vehicle|Vehicle topical solution
79835034|NCT00959530|Procedure|lingualized occlusion|occlusal surface arranged by lingualized occlusion
79835035|NCT00959530|Procedure|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
79835036|NCT00959608|Behavioral|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
79835037|NCT00959608|Behavioral|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
79835038|NCT00673920|Drug|Methotrexate|Oral or parenteral repeating dose
79835039|NCT00673920|Drug|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
80006881|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
80006882|NCT01368107|Drug|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
79835040|NCT00673920|Drug|Placebo|Intravenous repeating dose
79835041|NCT00959686|Drug|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
79835042|NCT00379795|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
80006883|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
79689679|NCT05426733|Drug|Odevixibat|Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
79689680|NCT05421663|Biological|JNJ-90014496|JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
79689681|NCT05397951|Device|Multi-modality Noninvasive Biosensor|The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.
79689682|NCT05397951|Device|Oximeter|The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.
79835043|NCT04588948|Drug|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
79835044|NCT00758628|Drug|Bromefenac|Bromfenac BID 3 months
79835045|NCT00758628|Drug|Blink|Blink BID for 3 months
79835046|NCT00959998|Other|Self-administered Acupressure|
79835047|NCT01048411|Drug|Naja-comp.|homeopathic remedy
79835048|NCT01048411|Drug|Placebo|s.c. injection of NaCl-solution three times a week
79835049|NCT00765024|Drug|Ivermectin|single dose of 200 mcg/kg
79379389|NCT05790486|Behavioral|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
79689683|NCT05397951|Device|Portable Blood Pressure Monitor|The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.
79835050|NCT00765024|Drug|ivermectin|two single dose of 200mcg/kg in 2 weeks
79835051|NCT00765024|Drug|Albendazole|Albendazole 7 days
79835052|NCT01743391|Procedure|Office-hysteroscopy with biopsy|
79835053|NCT05279638|Diagnostic Test|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
79689684|NCT05397951|Device|Vicorder Pulse Wave Velocity Monitor|The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
79835054|NCT02557932|Drug|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
79689685|NCT05394428|Other|No intervention|No intervention
79835055|NCT02557932|Drug|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
79835056|NCT00965614|Other|MCG|Cardiac Arrhythmia,Heart Disease
79835057|NCT00762684|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
79835058|NCT00762684|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
79689686|NCT05386238|Behavioral|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
79689687|NCT05386238|Behavioral|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
79689688|NCT05385484|Behavioral|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
79689689|NCT05384626|Drug|NVL-655|Oral Tablet of NVL-655
79835059|NCT00960232|Drug|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
79835060|NCT00960232|Drug|placebo|placebo
79835061|NCT00765180|Device|TRE vs. NBI|TRE NBI
79835062|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
79835063|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
79835064|NCT00610155|Drug|Placebo|BID
79835065|NCT00610155|Drug|Pregabalin|Dose 75 mg titrated to 150 mg, bid
79835066|NCT00610155|Drug|Tramadol SR|Dose 50mg titrated to 200 mg, bid
79835067|NCT00960466|Behavioral|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
80006884|NCT02039674|Biological|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
80006885|NCT02039674|Drug|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
79689690|NCT05382208|Drug|Doxycycline|Doxycycline 100 mg orally twice a day.
79689691|NCT05382208|Drug|Placebo|Matching placebo orally twice a day.
79835068|NCT00960466|Behavioral|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
79835069|NCT00758940|Device|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
79835070|NCT00759018|Biological|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
79835071|NCT00965770|Device|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
80006886|NCT02039674|Drug|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
80006887|NCT02039674|Biological|Bevacizumab|IV on Day 1 of each 3-week cycle
79547151|NCT01551680|Radiation|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
79835072|NCT02541825|Device|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
79835073|NCT02541825|Device|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
79835074|NCT00884871|Procedure|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
79835075|NCT00765414|Biological|Myozyme|30 mg/kg qow f and 40 mg/kg qow
79835076|NCT00960544|Drug|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
79835077|NCT00888147|Dietary Supplement|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
79689692|NCT05374395|Behavioral|Peer Recovery Support-Delivered Dropout Prevention enhancement|Peer recovery supports will meet with emerging adults for four weekly sessions plus monthly check-ins during the next two months. Peer recovery supports will engage the emerging adults in motivational and skills-based strategies aimed at increasing adherence to services and attendance to treatment sessions.
79689693|NCT05369715|Other|Exercise|Aerobic exercise
79835078|NCT04049136|Diagnostic Test|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
79835079|NCT04037631|Diagnostic Test|Diagnostic device|Diagnostic test
79835080|NCT00762840|Device|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
79835081|NCT00762840|Procedure|Conventional endodontic procedure|Standard root canal treatment
79835082|NCT00888225|Procedure|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
79835083|NCT00888225|Procedure|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
79835084|NCT00765492|Drug|AZD8529|oral
79835085|NCT00765492|Drug|Placebo|oral
79835086|NCT00960700|Device|Visual Acuity|Assessment of visual acuity
79835087|NCT00960700|Device|Contrast sensitivity|Assessment of contrast sensitivity
79835088|NCT00960700|Device|Reading Speed|Assessment of reading speed
79835089|NCT00960700|Procedure|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
79835090|NCT02541747|Behavioral|massage|massage
80006888|NCT02039674|Drug|Pemetrexed|IV on Day 1 of each 3-week cycle
80006889|NCT02039674|Biological|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
79689694|NCT05367440|Drug|AZD5305|Patients will receive an oral dose of AZD5305 once daily
80006890|NCT02039674|Drug|Erlotinib|Orally tablet once daily
79689695|NCT05367440|Drug|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
79689696|NCT05367440|Drug|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
79689697|NCT05367440|Drug|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
79835091|NCT04488952|Device|nerve block combined with general anesthesia|Patients in this group receive nerve block combined with general anesthesia.
79835092|NCT04488952|Device|spinal anesthesia|Patients in this group receive spinal anesthesia.
79835093|NCT00888303|Drug|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
79835094|NCT00888303|Drug|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
79835095|NCT00888303|Procedure|Thyroidectomy, total or partial|Surgical standard intervention
79835096|NCT00967642|Drug|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
79835097|NCT02541591|Other|Neuroprotective goal directed hemodynamic optimization|
79835098|NCT02541591|Other|MAP > 65mmHg|MAP > 65mmHg
79835099|NCT00961012|Procedure|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
79835100|NCT00674700|Drug|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
79835101|NCT00674700|Drug|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
79835102|NCT00674700|Drug|Placebo tablet|One sublingual tablet daily for one year
79835103|NCT00888537|Other|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
80006891|NCT02039674|Drug|Gefitinib|Oral tablet once daily
80006892|NCT03126227|Biological|AR101|AR101 powder provided in capsules
80006893|NCT03126227|Biological|Placebo|Placebo powder provided in capsules
80006894|NCT01373567|Drug|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
80006895|NCT01373645|Device|Yinyi stent|subjects with Yinyi stent implantation
80006896|NCT03099187|Drug|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
80006897|NCT03099187|Drug|Placebo|Matching placebo capsules three times in a day.
80006898|NCT04192474|Device|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
79547152|NCT01551706|Dietary Supplement|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
79835104|NCT00888537|Other|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
79689698|NCT05365477|Behavioral|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to <2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to <100 mg/day
79689699|NCT05365477|Drug|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
79689700|NCT05365477|Behavioral|Selective Therapy: Diet|"Diet:~Volume <2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium >250mg male, >200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to<2000mg/d, avoid vitamin D + calcium supplements~Oxalate >40mg Reduce dietary oxalate intake to <100 mg/d; increase fiber intake to 25-35 g/d~Citrate <450mg male, <550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid >800mg male, >750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium >150mmol Reduce sodium intake to <2000mg/d~Sulfate > 80mEq or urine urea nitrogen >14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
79689701|NCT05365477|Drug|Selective Therapy: Drug|"Drug(s):~For calcium >250mg male, >200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate <450mg male, <550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid >800mg male, >750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
79835105|NCT02542371|Other|Arterial Imaging|
79835106|NCT00762918|Dietary Supplement|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
79835107|NCT00546910|Drug|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
79835108|NCT00546910|Drug|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
79835109|NCT00763074|Behavioral|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30~35kcal/day"
79835110|NCT00763074|Behavioral|Diet restriction|"Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
79835111|NCT00763074|Behavioral|Exercise|"Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
79835112|NCT00763074|Behavioral|Diet and exercise|"Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group"
79835113|NCT02541513|Drug|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
79835114|NCT00888693|Drug|ABT-288|See Arm Description for details.
79835115|NCT00888693|Drug|Placebo|See Arm Description for details.
80006899|NCT03634475|Drug|PP-001|Drug - no placebo
79835116|NCT02558712|Other|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
79835117|NCT05278767|Other|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
79835118|NCT00961168|Other|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
79835119|NCT00961168|Other|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
79835120|NCT00885183|Procedure|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
79835121|NCT00763152|Other|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
79835122|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
80006900|NCT04162756|Biological|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
80006901|NCT04162756|Drug|Fludarabine|Administered per package insert
80006902|NCT04162756|Drug|Cyclophosphamide|Administered per package insert
80006903|NCT04544267|Biological|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
80006904|NCT04544267|Biological|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
80006905|NCT05036746|Other|No intervention|No intervention
79547153|NCT01551706|Other|Placebo|Placebo
79547154|NCT01551719|Behavioral|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
79547155|NCT01551732|Behavioral|ACT|10 session manualized cognitive behavioral anger control therapy
79547156|NCT01551732|Behavioral|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
79835123|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
79835124|NCT00759720|Drug|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
79239402|NCT02998541|Drug|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
79689702|NCT05361668|Drug|Randomized: 40 mg Paltusotine|Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
79689703|NCT05361668|Drug|Randomized: 80 mg Paltusotine|Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
79835125|NCT04037319|Diagnostic Test|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
79835126|NCT00888069|Drug|CTAP101 Capsules|Single dose oral administration
79835127|NCT00888069|Drug|CTAP101 Injection|single IV injection
79835128|NCT00763230|Device|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
79689704|NCT05361395|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
79689705|NCT05361395|Drug|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion.
79689706|NCT05361395|Drug|Etoposide|Etoposide will be administered as an intravenous (IV) infusion.
79689707|NCT05361395|Drug|Atezolizumab|Atezolizumab will be administered as an intravenous (IV) infusion.
79239403|NCT02998541|Other|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
79239404|NCT02359136|Procedure|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
79239405|NCT02359136|Procedure|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
79239406|NCT02359136|Procedure|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
79835129|NCT00379639|Drug|Romidepsin|7, 10 or 12 mg/m^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
79835130|NCT00379639|Drug|Gemcitabine|800 or 1000 mg/m^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
79835131|NCT03948334|Drug|ZPL389 30mg|30mg of ZPL389; once daily
79239407|NCT02363582|Other|formula|An infant formula contains prebiotics and lactoferrin
79239408|NCT02366078|Behavioral|SMART|Paced breathing meditation with cognitive training
79239409|NCT02366156|Dietary Supplement|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
79379390|NCT05790486|Behavioral|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
79689708|NCT05361395|Drug|Durvalumab|Durvalumab will be administered as an intravenous (IV) infusion.
79689709|NCT05354102|Drug|BMC128|A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
79689710|NCT05354102|Drug|Nivolumab|A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
79835132|NCT03948334|Drug|ZPL389 50mg|50mg of ZPL389; once daily
79835133|NCT03948334|Drug|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
79835134|NCT00609765|Drug|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
79835135|NCT00609765|Drug|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m^2 iv bolus daily days 1-5
79835136|NCT00609765|Drug|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m^2 iv bolus day 1
79835137|NCT00609765|Drug|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
79835138|NCT00609765|Drug|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
79835139|NCT00609765|Drug|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
80006906|NCT04535453|Biological|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
79239410|NCT02366156|Dietary Supplement|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
79239411|NCT02366156|Dietary Supplement|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
79689711|NCT05351489|Drug|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
79835140|NCT00763308|Behavioral|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
79835141|NCT01051219|Drug|Losartan|50 milligrams to be taken orally, daily
79835142|NCT00885417|Drug|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
79835143|NCT00766272|Device|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
79239412|NCT02366390|Behavioral|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
79835144|NCT00961246|Behavioral|general health information|participants received general health information
79835145|NCT00961246|Behavioral|individually-tailored intervention|participants received individually-tailored intervention
79835146|NCT01048489|Behavioral|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
79835147|NCT00961324|Drug|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
79835148|NCT00961324|Drug|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
79835149|NCT00766350|Drug|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
79239413|NCT02358980|Device|KIDNEY therapy|
79239414|NCT02998151|Drug|Acamprosate|two 666mg pills
79835150|NCT00766350|Drug|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
79835151|NCT00889161|Drug|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
79835152|NCT03992755|Drug|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
79835153|NCT01563328|Drug|DTG|50 mg q24h
79835154|NCT01563328|Drug|BCV|800 mg q8h
79835155|NCT01563328|Drug|TVR|750 mg q8h
79835156|NCT00889239|Other|lithia-disilicate-based crown|all-ceramic crown
79835157|NCT00760032|Drug|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
79835158|NCT00760032|Drug|Placebo|Placebo capsules, one capsule per day during four weeks.
79835159|NCT00961480|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
79835160|NCT00961480|Drug|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
80006907|NCT04535453|Other|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
80006908|NCT04926220|Device|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
79239415|NCT02998151|Drug|Lovastatin|two 20mg pills
79239416|NCT02998151|Drug|Minocycline|two 135mg pills
79239417|NCT02998151|Drug|Placebo|placebo pill
79239418|NCT02998151|Drug|Baclofen|one 30mg pill
79239419|NCT02358590|Behavioral|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
79239420|NCT02358590|Behavioral|Standard care|The treating physician will advice participants to take vitamin D
79239421|NCT03664349|Device|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
79547157|NCT01551771|Drug|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
79547158|NCT01551771|Drug|GW824575 matched-placebo|Placebo
79547159|NCT01551797|Drug|Paracetamol 500 mg|Standard Paracetamol formulation
79547160|NCT01551797|Drug|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
79547161|NCT01551797|Drug|Paracetamol 750 mg|Paracetamol Sustained Release formulation
79547162|NCT01551836|Drug|Paracetamol formulation 1|formulation 1
79547163|NCT01551836|Drug|Paracetamol formulation 2|Formulation 2
79547164|NCT01551862|Procedure|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
79547165|NCT01551901|Device|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
79547166|NCT01551914|Device|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
79547167|NCT01551914|Device|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
79533632|NCT05961891|Procedure|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~The finger is immobilized for two weeks in a below elbow dorsal slab.~Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
79379391|NCT05790486|Other|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
79689712|NCT05348694|Dietary Supplement|Pendulum WBF-038|"All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
79835161|NCT00961480|Drug|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
79835162|NCT00961480|Drug|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
79835163|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
79835164|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
79835165|NCT00961480|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
79835166|NCT00961480|Drug|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
79835167|NCT00760110|Device|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
79835168|NCT00608829|Device|GORE TAG® Thoracic Endoprosthesis|Implant
80006909|NCT04926220|Device|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
79689713|NCT05348694|Dietary Supplement|Pendulum Placebo|Pendulum placebo capsules containing magnesium stearate
79835169|NCT04462393|Other|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
79835170|NCT04049370|Other|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
79835171|NCT00961558|Procedure|Varicocelectomy|Varicocelectomy
79835172|NCT00889317|Device|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
79835173|NCT00763464|Procedure|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
79835174|NCT00763464|Procedure|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
79835175|NCT00973492|Other|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
79835176|NCT00760188|Device|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
79835177|NCT00973570|Behavioral|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
80006910|NCT04926220|Device|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
79391262|NCT03116958|Device|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
79835178|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
79689714|NCT05342974|Drug|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
79689715|NCT05342974|Drug|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
80006911|NCT04463069|Other|Adapted physical activity|This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
80006912|NCT04397029|Device|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
80006913|NCT04893460|Behavioral|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
80006914|NCT04835272|Procedure|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
79835179|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
80006915|NCT04811248|Other|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
80006916|NCT01373333|Drug|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
80006917|NCT01368341|Drug|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
80006918|NCT01368341|Drug|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
80006919|NCT01368341|Drug|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
80006920|NCT01368419|Drug|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
79239422|NCT02994290|Drug|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
79835180|NCT00766662|Drug|Sulfadoxine pyrimethamine|
79835181|NCT00965926|Drug|YM178|oral
79835182|NCT00889395|Behavioral|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
79835183|NCT02557776|Genetic|Germline genetic testing of BRCA1 and BRCA2|
79835184|NCT00966004|Drug|YM178|oral
79835185|NCT00966004|Drug|Placebo|oral
79835186|NCT00966004|Drug|tolterodine|oral
79835187|NCT00892671|Other|Simulation|simulation of airway management and vascular access
79835188|NCT04048590|Other|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
79239423|NCT02994290|Behavioral|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
79835189|NCT00966082|Procedure|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
79835190|NCT00966082|Procedure|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
79835191|NCT00766740|Device|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
79835192|NCT00766740|Device|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
79835193|NCT00892749|Drug|ASP1585|oral
79835194|NCT00763542|Behavioral|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
80006921|NCT01368419|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
80006922|NCT03139864|Procedure|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
80006923|NCT05171933|Behavioral|Survey|This study is based on a survey made on COVID-19
79533633|NCT05961878|Dietary Supplement|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
79533634|NCT05961852|Device|Angioplasty|Angioplasty with cutting and drug-coated balloon
79533635|NCT05961813|Behavioral|Intensive intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
79533636|NCT05961813|Behavioral|Brief intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
79533637|NCT05961800|Behavioral|Cutaneous Probe|A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
79835195|NCT00763542|Behavioral|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
79835196|NCT00889629|Drug|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
79533638|NCT05961800|Behavioral|Quantitative Sensory Testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
79533639|NCT05961800|Behavioral|Computer Tasks|Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
79379392|NCT05790486|Other|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
79533640|NCT05961787|Device|SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)|"Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~Lesions ≤35 mm in length (visual), diameter 3-4 mm.~A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)"
79533641|NCT05961774|Device|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
79533642|NCT05961774|Device|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
79533643|NCT05961761|Drug|Propranolol|propranolol 40 mg x2 daily
79533644|NCT05961761|Drug|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
79689716|NCT05338320|Procedure|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
79835197|NCT00889629|Drug|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
79835198|NCT00889629|Drug|25-OH Vitamin D3|All groups received cholecalciferol
79533645|NCT05961735|Other|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
79533646|NCT05961735|Other|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
79533647|NCT05961722|Other|preoperative IV 0.9% saline 200 ml|Group 1 will be infused with IV 0.9% saline 400 mL/h for half an hour (200 mL) starting two hours before anesthesia.
79835199|NCT00966160|Drug|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
79835200|NCT00966160|Drug|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
79835201|NCT00766818|Drug|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
79835202|NCT04009252|Behavioral|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
79835203|NCT04036383|Other|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
79689717|NCT05338320|Drug|Intrathecal morphine|General anesthesia and intrathecal morphine
80006924|NCT01373723|Other|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
80006925|NCT04516564|Drug|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
79391263|NCT03178188|Device|Pulsed-dye Laser|595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval
79391264|NCT03178188|Device|Sham|Cryogen spray with the setting of dynamic cooling device 30/20
79689718|NCT05338320|Other|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
79689719|NCT05335954|Drug|noradrenaline|noradrenaline
79689720|NCT05335629|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
79689721|NCT05333289|Biological|mRNA-1030|Sterile liquid for injection
79689722|NCT05333289|Biological|mRNA-1020|Sterile liquid for injection
79689723|NCT05333289|Biological|mRNA-1010|Sterile liquid for injection
79689724|NCT05333289|Biological|Active Comparator|Sterile liquid for injection
79835204|NCT04036383|Other|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
79835205|NCT04036383|Other|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
79835206|NCT02558556|Device|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
79835207|NCT02558556|Other|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
79835208|NCT00966316|Drug|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
79239424|NCT04058015|Other|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
79239425|NCT04058015|Other|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
79239426|NCT04058015|Other|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose < 200 mg/dL in the patients with Diabetes mellitus.
79533648|NCT05961722|Other|preoperative dextrose 5% 200 ml|Group 2 will be infused with dextrose 5% 400 mL/h for half an hour (200 mL) starting two hours before anesthesia .
79533649|NCT05961722|Other|preoperative and intraoperative dextrose 5% 200 ml|Group 3 will be infused with dextrose 5% 400 mL/h for half an hour (200 mL) starting two hours before anesthesia and with dextrose 5% 400 mL/h for half an hour (200 mL) during surgery .
79689725|NCT05329623|Drug|JDQ443|All the participants will receive a single oral dose of JDQ443.
79689726|NCT05323396|Drug|Antiparasitic medication|"Participants in the parasite-positive group (based on positive result of either stool microscopy, stool PCR, or Strongyloides IgG) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with stool microscopy, stool PCR, and Strongyloides IgG all negative will not be administered treatment, thus will serve as controls."
79689727|NCT05322993|Device|GI Genius|The use of artificial intelligence during colonoscopy to improve polyp detection.
79689728|NCT05322993|Device|Standard white light colonoscope|Standard colonoscopy.
79835209|NCT00889785|Behavioral|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
79835210|NCT00889785|Behavioral|Usual Care|Will receive usual care and monthly phone calls as an active control.
80006926|NCT04516564|Drug|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
79379393|NCT05782868|Other|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
79239427|NCT04058015|Other|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose < 200 mg/dL in patients who were absent of Diabetes mellitus.
79239428|NCT04057781|Procedure|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
79379394|NCT05782868|Other|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
79379395|NCT05782868|Other|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
79379396|NCT05781347|Procedure|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under general anesthesia which uses radiofrequency (RF) energy delivered to the lower esophageal sphincter and cardia.
79533650|NCT05961709|Drug|Cemiplimab|Given by IV (vein)
79533651|NCT05961683|Device|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
79533652|NCT05961670|Device|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
79533653|NCT05961657|Diagnostic Test|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
79689729|NCT05317234|Genetic|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
79533654|NCT05961553|Behavioral|Physical Activity Counseling session|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
79533655|NCT05961553|Other|Pulmonary Reabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
79835211|NCT04049292|Other|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
79835212|NCT04049292|Other|Usual care|Usual care is determined by the treating health care professional
79239429|NCT04057781|Procedure|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
79835213|NCT00892827|Drug|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
79835214|NCT00766896|Drug|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
79239430|NCT03388775|Other|deep venous thrombosis|Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
79239431|NCT03664271|Behavioral|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
79239432|NCT03664271|Behavioral|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
79239433|NCT03663491|Procedure|Nasal Gastroscopy|Use of transnasal endoscopes for routine gastroscopy in adults.
79239434|NCT03663491|Procedure|Oral Gastroscopy, unsedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
79379397|NCT05781347|Device|Stretta|Stretta is a FDA approved device for the management of GERD.
79689730|NCT05312398|Drug|Cetuximab|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
79835215|NCT00889941|Procedure|LASIK|laser-assisted in situ keratomileusis
79239435|NCT03663491|Procedure|Oral Gastroscopy, sedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
79239436|NCT03663491|Procedure|Oral Gastroscopy with transnasal endoscope, sedated|Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
79239437|NCT04057625|Device|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
79689731|NCT05312398|Drug|FOLFIRI|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
79689732|NCT05312398|Drug|FOLFOX regimen|"II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
79835216|NCT00766974|Device|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
79379398|NCT05778812|Behavioral|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
79533656|NCT05961501|Drug|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
79835217|NCT00766974|Device|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
79533657|NCT05961501|Other|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
79533658|NCT05961488|Other|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
79239438|NCT01066819|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
80006927|NCT05166317|Other|This is an observational study|This is an observational study
79689733|NCT05312398|Drug|Irinotecan|"III LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
79835218|NCT00890019|Biological|AdCh63 ME-TRAP|"A:Intradermal injection 1x10^8 vp at day 0~A:Intradermal injection 1x10^9 vp at day 0~A:Intradermal injection 1x10^10 vp at day 0~A:Intradermal injection 5x10^10 vp at day 0~5:Intramuscular injection 1x10^10 vp at day 0~6A:Intramuscular injection 5x10^10 vp at day 0~7A: Intramuscular injection 2x10^11 vp at day 0"
79239439|NCT01066819|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
79689734|NCT05306353|Drug|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
79239440|NCT04056299|Biological|AR201 powder|AR201 powder (Hen Egg allergen formulation) provided in capsules
79239441|NCT04056299|Biological|Placebo powder|Placebo powder provided in capsules
79239442|NCT04057937|Drug|Apremilast|Apremilast
79239443|NCT04057937|Drug|Placebo|Placebo
79239444|NCT04057547|Drug|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
79379399|NCT05778812|Behavioral|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
79379400|NCT05775913|Device|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
79379401|NCT05773118|Device|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
79379402|NCT05773118|Device|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
79379403|NCT05773118|Device|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
79533659|NCT05961475|Dietary Supplement|Fruit snack 1|Fruit snacks with original level of sugar
79533660|NCT05961475|Dietary Supplement|Fruit Snack 2|Fruit snacks with original level of sugar and mulberry leaf extract
79533661|NCT05961475|Dietary Supplement|Fruit Snack 3|Fruit snacks with reduced level of sugar
79689735|NCT05306353|Drug|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
80006928|NCT04455100|Drug|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
80006929|NCT04332523|Drug|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
80006930|NCT04439578|Drug|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
80006931|NCT04082585|Behavioral|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
80006932|NCT03110848|Drug|Atorvastatin|Atorvastatin 20 mg daily
80006933|NCT03110848|Drug|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
80006934|NCT03992417|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
80006935|NCT03139474|Drug|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
79239445|NCT01069523|Drug|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
79239446|NCT01069523|Drug|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
79239447|NCT01069289|Drug|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
79239448|NCT01069289|Drug|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
79379404|NCT05771909|Other|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
79379405|NCT05771909|Other|Control|"The Control Group does not receive the NeurodigitX application."
79533662|NCT05961475|Dietary Supplement|Fruit Snack 4|Fruit snacks with zero added sugar
79533663|NCT05961475|Dietary Supplement|White Bread|White bread with matched carbohydrate as control
79533664|NCT05961449|Behavioral|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
79835219|NCT00890019|Biological|AdCh63 ME-TRAP; MVA ME-TRAP|"B: AdCh63 ME-TRAP intradermally at dose of 1x10^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)"
79835220|NCT00973726|Other|Glucose test|Subjects ingest an oral glucose tolerance test.
79533665|NCT05961449|Behavioral|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase >25% from baseline.
79689736|NCT05306353|Drug|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
79689737|NCT05292651|Procedure|PCI|percutaneous coronary intervention
79835221|NCT00763620|Device|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
79239449|NCT04057313|Dietary Supplement|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
79379406|NCT05771896|Drug|Darolutamide|"Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (>56 days between cycles). Any participant requiring dose interruption >28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly."
79835222|NCT00973804|Drug|EPOCH-F/R|
79835223|NCT00973804|Drug|FLAG|
79835224|NCT00973804|Drug|Transplant Preparative Regimen (Flu/Cy/Mes)|
79835225|NCT00973804|Drug|GVHD Prophylaxis (tacrolimus and sirolimus)|
79835226|NCT00973804|Procedure|Double Cord Blood Transplantation|
79379407|NCT05771896|Drug|Radium-223|"Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption >28 consecutive days (>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice."
79533666|NCT05961436|Procedure|PENG block|Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
79533667|NCT05961436|Procedure|FN block|Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
79533668|NCT05961423|Procedure|Robotic surgery|The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
79533669|NCT05961358|Procedure|snapshots or videos of monitor|The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.
79689738|NCT05291156|Drug|Cetuximab|"Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week."
79689739|NCT05291156|Drug|Avelumab|Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
79835227|NCT04018131|Drug|Cimetidine|Antihistamine 2 antagonist
79835228|NCT04018131|Drug|Placebos|Placebo drug
79835229|NCT00767052|Drug|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
79835230|NCT00767052|Drug|Placebo|Placebo tablet matching to the active in multiple dose part.
79835231|NCT00767052|Drug|AZD1236|75mg single dose will be administered in relative bioavailability part.
79835232|NCT00767052|Drug|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
79239450|NCT03663413|Device|non-invasive monitor|cutaneous EEG monitor
79239451|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
79835233|NCT00973882|Drug|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
79835234|NCT00973882|Drug|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
79835235|NCT02558322|Other|Primary medical care|All study participants receive primary care as usual in the respective region
79533670|NCT05961358|Procedure|Pressure transducer|Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
79239452|NCT03303989|Drug|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
79239453|NCT03303989|Drug|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
79533671|NCT05961345|Other|experimental group|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
79547168|NCT01551940|Drug|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
79689740|NCT05289648|Drug|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
79835236|NCT03666819|Device|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
79835237|NCT03666819|Other|Questionnaire Administration|Ancillary studies
79835238|NCT05278455|Behavioral|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
79689741|NCT05274776|Device|EOS calculator|For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
79239454|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
79379408|NCT05769465|Drug|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
79379409|NCT05767567|Behavioral|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
79379410|NCT05764863|Radiation|fMRI|The participant will then complete a series of working memory tasks under three distinct conditions as described above (visual spatial, visual non-spatial, auditory). The instructions and tasks will be administered via an MRI compatible monitor and headset system (NordicNeuroLab). During the tasks, the participant's brain activity will be recorded. Finally, at the end of the experiment, a high-resolution anatomical image of the brain will be acquired in order to facilitate the subsequent data processing steps and to define the position of the interparietal sulcus for each subject. The visit will be completed by a visual imaging questionnaire.
79379411|NCT05764642|Drug|Definity|Ultrasound contrast agent administered intravenously
79547169|NCT01551940|Drug|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
79547170|NCT01551953|Behavioral|Tai chi|12 week tai chi class
79835239|NCT02558088|Drug|Salmeterol|
79835240|NCT05279482|Other|observation for outcome of methylprednisolone dose|no intervention as it is retrospective study for outcome
80006936|NCT03139474|Drug|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach > 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
80006937|NCT05166148|Other|Session (a)|Eccentric cycling
79379412|NCT05764642|Diagnostic Test|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
79379413|NCT05763914|Behavioral|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
79379414|NCT05763914|Behavioral|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
79547171|NCT01551953|Behavioral|Mind-body breathing|12 week breathing class
79835241|NCT00890175|Drug|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
79835242|NCT00890175|Drug|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
79835243|NCT00966472|Drug|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
79835244|NCT00767208|Other|oral glucose load|oral ingestion of 13C labeled glucose
79835245|NCT00892983|Behavioral|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
79533672|NCT05961319|Device|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
79835246|NCT00892983|Behavioral|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
79835247|NCT00760422|Device|NIR|Thermometer
79239455|NCT02510794|Drug|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
79533673|NCT05961280|Procedure|Mastectomy with sentinel lymph node biopsy|
79547172|NCT01551953|Behavioral|Education|12 week education class
79239456|NCT04056923|Procedure|3D-printing guided|3D printed navigational template guided
79239457|NCT04056923|Procedure|CT-guided|CT-guided
79379415|NCT05763914|Behavioral|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
79835248|NCT00890253|Drug|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
79835249|NCT00890253|Drug|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
79835250|NCT00890253|Drug|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
79835251|NCT00890253|Drug|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
79835252|NCT00760500|Other|Nasopharyngeal Swab|Nasopharyngeal Swab
80006938|NCT05166148|Other|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
80006939|NCT05166148|Other|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
80006940|NCT01368575|Procedure|CABG|CABG
79379416|NCT05763914|Behavioral|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
79689742|NCT05266937|Combination Product|Atezolizumab,Paclitaxel, Carboplatin|"Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor)."
79379417|NCT05763914|Behavioral|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
79379418|NCT05763914|Behavioral|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
79689743|NCT05259839|Drug|ABBV-383|Intravenous (IV) Infusion
79689744|NCT05259839|Drug|Dexamethasone|Oral; Tablet or IV Infusion
79689745|NCT05259839|Drug|Lenalidomide|Oral; Capsule
79239458|NCT04056923|Drug|Indocyanine Green|The results are shown by comparison of different colors.
79239459|NCT04056923|Drug|Methylene blue|The results are shown by comparison of different colors.
79391265|NCT02423460|Other|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
79689746|NCT05259839|Drug|Pomalidomide|Oral; Capsule
79689747|NCT05259839|Drug|Nirogacestat|Oral; Tablet
79689748|NCT05259839|Drug|Daratumumab|Subcutaneous Injection (SC)
79689749|NCT05252364|Drug|HP518 - Dose Escalation|"Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment."
79689750|NCT05252364|Drug|HP518 - Dose expansion|"Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1."
79835253|NCT00545818|Device|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
79689751|NCT05237999|Behavioral|KopOpOuders-PTSD|See arm description
79835254|NCT00545818|Device|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
80006941|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
79239460|NCT04056923|Procedure|Preoperative|Preoperative localization.
79239461|NCT04056923|Procedure|Intraoperative|Intraoperative localization.
79239462|NCT03664115|Drug|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
79239463|NCT03664115|Drug|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
79239464|NCT03370757|Other|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
80006942|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
79835255|NCT00674154|Drug|Cholecalciferol|2800 IE daily in 52 weeks
79835256|NCT00974038|Behavioral|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
79835257|NCT00967954|Drug|antiandrogen therapy|
79689752|NCT05225740|Behavioral|Standard Exposure|The standard intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a post-exposure exercise. The post-exposure exercise will involve completing a set of questions regarding the exercises and the group experience.
79689753|NCT05225740|Behavioral|Stress Management Training|Stress management training (SMT) is designed to help people better cope with feelings of anxiety that accompany high levels of anxiety sensitivity. SMT will involve group instruction in healthy ways to experience and cope with stress whenever difficult situations arise. Participants will teach participants ways to maintain a healthy lifestyle, targeting things like nutrition, exercise, and sleep hygiene. This intervention will also involve progressive muscle relaxation training.
79689754|NCT05225740|Behavioral|Enhanced Exposure|The enhanced intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a processing exercise. The post-processing exercise will involve completing a set of questions that will highlight harm expectancy violations.
79835258|NCT00967954|Drug|releasing hormone agonist therapy|
79835259|NCT00967954|Genetic|DNA analysis|
80006943|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
80006944|NCT01368575|Procedure|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
80006945|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
80006946|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
79835260|NCT00967954|Genetic|RNA analysis|
80006947|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
80006948|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
80006949|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
79239465|NCT03370757|Other|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
80006950|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
79239466|NCT03622853|Drug|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
79391266|NCT02423382|Procedure|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
79391267|NCT02423304|Genetic|blood samples collected from all patients|blood samples collected from brachial pluxes
79391268|NCT02414334|Radiation|Stereotactic Ablative Radiotherapy (SABR)|
79835261|NCT00967954|Genetic|comparative genomic hybridization|
79835262|NCT00967954|Genetic|gene expression analysis|
79835263|NCT00967954|Other|laboratory biomarker analysis|
79835264|NCT00967954|Procedure|diffusion-weighted magnetic resonance imaging|
79835265|NCT00967954|Procedure|magnetic resonance spectroscopic imaging|
79835266|NCT04048980|Behavioral|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
79835267|NCT00974116|Behavioral|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
79835268|NCT00974116|Behavioral|Control Group|No intervention
79835269|NCT00767286|Drug|flutamide|
79835270|NCT00767286|Drug|goserelin acetate|
80006951|NCT01372163|Drug|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
80006952|NCT04170478|Device|Echolaser X4 system|Transperineal laser ablation
80006953|NCT03943966|Diagnostic Test|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
80006954|NCT01373801|Device|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
79239467|NCT02363426|Device|INVOcell Culture Device|INVOcell is a vaginal culture device
79239468|NCT02363426|Device|IVF Incubation|IVF Incubator
79239469|NCT02363504|Other|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
79239470|NCT04052243|Diagnostic Test|Invasive exercise testing|Invasive hemodynamic exercise testing
79239471|NCT02363348|Dietary Supplement|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
79239472|NCT02363348|Other|Placebo|calcined magnesia
79239473|NCT02358434|Radiation|Observational use of fluoroscopy|
79391269|NCT01589237|Drug|LCQ908|
80006955|NCT01373801|Device|Control|Standard packing gauze roll bandage.
79835271|NCT00767286|Radiation|low-LET cobalt-60 gamma ray therapy|
79835272|NCT00767286|Radiation|low-LET photon therapy|
79835273|NCT00966628|Drug|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
79835274|NCT00966628|Drug|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
79835275|NCT00968110|Drug|omalizumab|Dosing table established for omalizumab
79835276|NCT00608517|Biological|anti-thymocyte globulin|Given IV
79239474|NCT04056845|Device|Valgus knee brace (Medex K39-OA Corrector)|Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
79391270|NCT01700387|Drug|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
79689755|NCT05219175|Drug|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (~80 mg MDMA) to 140 mg MDMA HCL (~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (~100 mg MDMA) to 180 mg MDMA HCL (~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (~280 mg MDMA) to 500 mg MDMA HCL (~435 mg MDMA)"
79835277|NCT00608517|Drug|cyclophosphamide|Given IV
79835278|NCT00608517|Drug|fludarabine phosphate|Given IV
79835279|NCT00608517|Drug|methylprednisolone|Given IV
79835280|NCT00608517|Radiation|total-body irradiation|Given daily for 1-4 days
79835281|NCT00966706|Drug|capecitabine|Given systemically
79689756|NCT05212779|Diagnostic Test|Signatera testing|26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
79835282|NCT00966706|Drug|cisplatin|Given systemically
79689757|NCT05212779|Diagnostic Test|Altera Testing|6ml blood and tissue sample.
79835283|NCT00966706|Drug|docetaxel|Given systemically
79835284|NCT00966706|Drug|epirubicin hydrochloride|Given systemically
79835285|NCT00966706|Drug|gemcitabine hydrochloride|Given systemically
79835286|NCT00763776|Device|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
79239475|NCT04056845|Other|Physiotherapy and oral analgesic (diclofenac and panadol)|Physiotherapy and oral analgesic (diclofenac and panadol)
79239476|NCT02363192|Behavioral|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
79302992|NCT02480777|Biological|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
79689758|NCT05211882|Other|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
79689759|NCT05211882|Other|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
79689760|NCT05203341|Drug|Placebo|Matching placebo tablets
79689761|NCT05203341|Drug|NBI-1065845|NBI-1065845 tablets
79835287|NCT00763776|Device|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
79835288|NCT00966784|Other|Dietary Fibers|
79835289|NCT00893061|Drug|anastrozole|Given orally
79835290|NCT00893061|Drug|exemestane|Given orally
79835291|NCT00893061|Drug|letrozole|Given orally
79835292|NCT00893061|Drug|tamoxifen citrate|Given orally
79835293|NCT00763932|Biological|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
79835294|NCT00966862|Other|Other: Dietary Fibers|
79835295|NCT00890331|Behavioral|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
79835296|NCT00890331|Behavioral|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
79835297|NCT00974194|Procedure|Single Trocar CCK|CCK using Triport
79835298|NCT00974194|Procedure|Standard CCK|CCK using three or four ports
79835299|NCT00974272|Drug|Exenatide|Single subcutaneous injection (10 μg)
79835300|NCT00974272|Other|Normal Saline|Single subcutaneous injection
79835301|NCT02558478|Genetic|blood sampling|
79835302|NCT00974428|Dietary Supplement|Wobenzym® N|4 tablets TID, 6 weeks
79835303|NCT00974428|Dietary Supplement|Placebo|4 tablets TID
79835304|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
79835305|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
79835306|NCT00974506|Other|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
79379419|NCT05756465|Device|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
79835307|NCT00974506|Other|Routine care therapy|Routine care therapy by general practitioner
80006956|NCT01372241|Behavioral|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
80006957|NCT03442504|Diagnostic Test|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
79239477|NCT03663959|Procedure|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
80006958|NCT03140566|Diagnostic Test|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index >50% in addition to relief of symptoms and signs of congestion before discharge.
79379420|NCT05755217|Dietary Supplement|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
79379421|NCT05755217|Dietary Supplement|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
79379422|NCT05750030|Combination Product|FMT combined with Atezolizumab plus Bevacizumab|Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
79379423|NCT05742958|Drug|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
79533674|NCT05961267|Behavioral|Questionnaire|A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
79835308|NCT00764010|Dietary Supplement|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
79689762|NCT05202678|Device|AGN1 LOEP|Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
79689763|NCT05176626|Behavioral|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
79533675|NCT05961254|Device|assesment of difficult endotracheal intubation by airway ultrasound|preoperative assesment of airway by ultrasound to predict difficult endotracheal intubation in patients undergoing general anesthsia
79533676|NCT05961228|Other|exercise|"Three different posture with and without correction according to the Schroth method"
79835309|NCT00764010|Dietary Supplement|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
79835310|NCT00764010|Dietary Supplement|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
79835311|NCT00968188|Behavioral|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
79835312|NCT00968188|Behavioral|Information only|Medically fact based HIV information delivered online.
79533677|NCT05961202|Drug|Hydroxychloroquine|Hydroxychloroquine 200mg bid
79533678|NCT05961202|Drug|Prednisolone|Prednisolone 15mg qd
79835313|NCT00974584|Drug|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n
79835314|NCT00974584|Drug|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
80006959|NCT03140566|Diagnostic Test|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
80006960|NCT01319747|Procedure|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
79835315|NCT00974584|Drug|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n
79835316|NCT00974584|Drug|cisplatin|Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n
79533679|NCT05961137|Other|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
79835317|NCT00974584|Drug|paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n
79533680|NCT05961137|Other|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
79379424|NCT05742958|Drug|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
79379425|NCT05742841|Drug|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
79379426|NCT05742672|Other|ABDOMINAL MASSAGE APPLICATION|"Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~Routine treatment and care practices in the clinic will continue."
79689764|NCT05176626|Drug|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
79835318|NCT00974584|Drug|pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.
79835319|NCT00608205|Drug|cisplatin|Given IV
79835320|NCT00608205|Drug|fluorouracil|Given IV
79835321|NCT00608205|Radiation|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
79835322|NCT00974662|Drug|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 & 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
79835323|NCT00974740|Drug|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
79835324|NCT00974740|Drug|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
79533681|NCT05961111|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
79835325|NCT00967096|Drug|Rifaximin|Rifaximin for Bone marrow transplant patients
79835326|NCT04037163|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
79689765|NCT05174065|Drug|Apremilast|Oral tablets
79689766|NCT05174065|Drug|Placebo|Oral tablets
79835327|NCT05227300|Drug|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
79835328|NCT05227300|Drug|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
79835329|NCT00890487|Other|hyaluronic acid pill|pill, 220 mg, once a day, three months
79835330|NCT02541357|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
79835331|NCT02541357|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
79835332|NCT00890565|Drug|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
79835333|NCT00890643|Drug|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
79835334|NCT00890643|Drug|placebo|placebo
79835335|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
79835336|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
79835337|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
79835338|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
79835339|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
79835340|NCT00670800|Drug|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
79835341|NCT00764166|Drug|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~To D1 of every cycle in the dose of 70 mg/m²,~Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
79835342|NCT00764166|Drug|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
79835343|NCT00770406|Drug|botulinum toxin type A|100 or 200 units intravesically
79379427|NCT05736653|Device|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
79835344|NCT02557542|Other|One Stop Vein Clinic|Same day diagnosis and treatment
79835345|NCT02557542|Device|Radiofrequency ablation|Venous ablation
79835346|NCT02557542|Device|Endovenous laser ablation|Venous ablation
79835347|NCT02557542|Drug|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
79835348|NCT00767754|Drug|Paxil CR|12 week treatment of Paxil(20-40mg)
79835349|NCT00607893|Device|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
79835350|NCT00607893|Device|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
79835351|NCT00571038|Behavioral|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
79835352|NCT00571038|Behavioral|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
79835353|NCT00764244|Procedure|Vitrectomy|Vitrectomy
79689767|NCT05170737|Drug|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 & 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 & 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
79835354|NCT00764244|Drug|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
79835355|NCT00764244|Procedure|Laser photocoagulation|Laser photocoagulation
79835356|NCT00770640|Drug|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
79835357|NCT00770640|Drug|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
79835358|NCT00764400|Behavioral|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
79835359|NCT00770718|Drug|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
80006961|NCT01319747|Procedure|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
80006962|NCT02038972|Genetic|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
80006963|NCT03895684|Drug|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
79835360|NCT00770718|Drug|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
79689768|NCT05170737|Drug|Placebo|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 & 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 & 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort."
79835361|NCT00770718|Biological|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
79835362|NCT00770796|Drug|Atorvastatin|80 mg die
79835363|NCT00770796|Drug|Placebo|
79835364|NCT00767988|Dietary Supplement|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
79835365|NCT00767988|Other|Placebo|Capsule once daily at approximately the same time each day for 6 months.
79835366|NCT00545740|Drug|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
79835367|NCT00545740|Drug|SPD476 (2.4 g)|2.4g SPD476 QD orally
79835368|NCT00545740|Drug|SPD476 (4.8 g)|4.8g SPD476 QD orally
79379428|NCT05736653|Device|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed ~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
79533682|NCT05961072|Device|Vibrotactile sensory feedback device|"The company Saphenus Medical Technology GmbH will provide all of the devices for this study. The non-invasive vibrotactile sensory feedback device consists of 4 vibration -motors, which are placed in a cuff or pant on the patient's residual limb (RL). Furthermore, the system consists of a foot sole with integrated sensors and transmitters. The patient will put the sole of their foot into the shoe of the amputated side.~There are 4 sensors matching the vibration motors - 3 under the forefoot and 1 on the heel - in the foot sole. Depending on whether the patient loads their forefoot or their heel while walking, the assigned vibration motor vibrates on the skin of their RL. The patient will learn which vibration motor is assigned to their forefoot and which to their heel. This gives the patient sensory feedback without having to check with their eyes which part of the prosthetic foot is currently touching the ground."
79835369|NCT00545740|Drug|Placebo|QD orally
79835370|NCT05208190|Drug|Clozapine|treatment will occur naturalistically, as per standard clinical guidelines
79835371|NCT05208190|Drug|treatment as usual|naturalistic treatment with any other antipsychotic medication except clozapine
79835372|NCT00609609|Procedure|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
79835373|NCT00609609|Drug|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
79835374|NCT00968422|Drug|ABT-384|3 escalating doses will be administered daily for 21 days
79835375|NCT00968422|Drug|Matching placebo to ABT-384|Doses will be administered daily for 21 days
79835376|NCT00673452|Drug|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
79835377|NCT00673452|Drug|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
79835378|NCT00890799|Device|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
79835379|NCT00890799|Procedure|surgery|Patient in this group received open surgical repair of pmVSD.
79835380|NCT00967174|Drug|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
79835381|NCT00967174|Drug|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
79835382|NCT00967174|Drug|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
79835383|NCT00890877|Drug|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
79835384|NCT00967252|Drug|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
79835385|NCT00967252|Drug|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
79835386|NCT00967252|Drug|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
79835387|NCT00967252|Drug|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
79835388|NCT00967252|Other|Control|No statin being taken
79835389|NCT00890955|Drug|Amrubicin|"Dose Level -1: 20mg/m2~Dose Level 1: 25mg/m2~Dose Level 2: 30mg/m2~Dose Level 3: 35mg/m2~Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
79835390|NCT00890955|Drug|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
79533683|NCT05961007|Biological|Intravitreal injection of IBI302(dose 1)|IBI302(dose 1) intravitreal injection given as protocol
79533684|NCT05961007|Biological|Intravitreal injection of IBI302(dose 2)|IBI302(dose 2) intravitreal injection given as protocol
79689769|NCT05167747|Dietary Supplement|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
79689770|NCT05167747|Other|Placebo|Oral administration: 2 tablets/day at evening meal
79689771|NCT05164133|Drug|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
80006964|NCT01368887|Drug|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
79533685|NCT05961007|Biological|Intravitreal injection of IBI302(dose 3)|IBI302(dose 3) intravitreal injection given as protocol
79239478|NCT03663959|Procedure|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
79379429|NCT05736653|Device|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS ~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
79533686|NCT05961007|Drug|Intravitreal injection of Aflibercept|Aflibercept intravitreal injection given as protocol
79533687|NCT05960981|Behavioral|Online-delivered Group-based Parent Mediated Intervention for Young Children with ASD|The program consists of eight weekly 2-hour group sessions, with each group consisting of 8 to 10 families. During the sessions, supervisors present the strategies to the parents and explain how to integrate them into their interactions with their children. Sample videos are shown to illustrate the strategies, and group discussions allow parents to discuss their application. In the second half of each session, the parents' recorded videos are watched, and supervisors provide feedback on whether the strategies were accurately implemented. At the end of each session, supervisors address any questions the parents may have.
79379430|NCT05736068|Procedure|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
79379431|NCT05736068|Procedure|Surgical treatment|Closed reduction with or without fixation
79689778|NCT05153083|Procedure|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
79689779|NCT05147649|Diagnostic Test|functional magnetic resonance imaging|functional magnetic resonance imaging
79689780|NCT05141682|Drug|Oral Azacitidine|Given PO
80006965|NCT01368887|Other|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
80006966|NCT01368887|Drug|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
79689781|NCT05135000|Drug|LTP001|LTP001 will be administered orally once daily in the morning
79689782|NCT05135000|Drug|Placebo|Placebo to LTP001 will be administered once daily in the morning
79689783|NCT05110157|Drug|Placebo|Oral capsules
79689784|NCT05110157|Drug|Valbenazine|Oral capsules
79689785|NCT05105256|Drug|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
79689786|NCT05105256|Drug|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
79533688|NCT05960916|Procedure|Densah® burs|Osseodensification is a non-excavating implant site preparation technique, it creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects.
79533689|NCT05960916|Procedure|Conventional Burs|Conventional burs is the gold standard that used to prepare the osteotomy site by drilling of the bone and creating a bed for implant placement, it is used according to the manufacturer instructions.
79533690|NCT05960838|Device|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
79835391|NCT00974896|Drug|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
79533691|NCT05960838|Device|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
79533692|NCT05960825|Combination Product|injectable platelet rich fibrin versus microosteoperforation|injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
79835392|NCT04008550|Procedure|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
79835393|NCT00893295|Other|informational intervention|
79835394|NCT00893295|Other|medical chart review|
79835395|NCT00893295|Other|screening questionnaire administration|
80006967|NCT01368887|Drug|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
80006968|NCT03859258|Device|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
80006969|NCT05049083|Drug|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
80006970|NCT05049083|Drug|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
80006971|NCT01369043|Dietary Supplement|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
79239479|NCT02510014|Drug|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
79533693|NCT05960799|Device|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
79533694|NCT05960799|Device|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
79835396|NCT00893295|Other|study of socioeconomic and demographic variables|
79835397|NCT00893295|Procedure|barium enema injection|
79835398|NCT00893295|Procedure|colon imaging study|
79835399|NCT00893295|Procedure|screening colonoscopy|
79835400|NCT00893295|Procedure|sigmoidoscopy|
79835401|NCT00975052|Drug|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
79835402|NCT00975052|Drug|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
79835403|NCT00975052|Drug|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
79835404|NCT00975052|Drug|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
80006972|NCT04477096|Drug|HS-10234|HS-10234
79835405|NCT00891033|Drug|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
79835406|NCT00891033|Drug|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
79835407|NCT00770952|Drug|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
80006973|NCT04477096|Drug|Emtricitabine|Emtricitabine
80006974|NCT01369121|Drug|XERECEPT|BID dosing, subcutaneous for 1 year
80006975|NCT03868150|Drug|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
79379432|NCT05735561|Diagnostic Test|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
79379433|NCT05735535|Drug|Antiviral Agents|two-drug one-pill once day
79391271|NCT01700387|Drug|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
79239480|NCT02510014|Drug|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
79533695|NCT05960786|Device|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
79533696|NCT05960786|Device|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
79533697|NCT05960721|Drug|Rivaroxaban 15mg|QD
79835408|NCT00770952|Drug|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
79239481|NCT03663881|Drug|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
79835409|NCT00891111|Behavioral|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
79239482|NCT02358512|Other|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
79835410|NCT00891111|Behavioral|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
79835411|NCT00764556|Drug|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
79835412|NCT00968578|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
79835413|NCT00968578|Drug|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
79835414|NCT00893373|Drug|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
79835415|NCT00893373|Drug|placebo|Standard AML chemotherapy plus placebo
79835416|NCT00891267|Drug|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
79835417|NCT00891267|Drug|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
79533698|NCT05960721|Drug|Aspirin 100mg|QD
79533699|NCT05960721|Drug|Clopidogrel 75mg|QD
79835418|NCT00891267|Drug|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
79835419|NCT04036617|Drug|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
79835420|NCT04036617|Drug|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
79835421|NCT00891345|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
79835422|NCT02541279|Procedure|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
79835423|NCT00545584|Drug|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
79835424|NCT00545584|Behavioral|Comparator: Diet|Diet
79835425|NCT00545584|Behavioral|Comparator: Physical Activity|Physical Activity
79835426|NCT00378703|Biological|Bevacizumab|Given IV
79239483|NCT03257579|Other|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
79239484|NCT03257579|Behavioral|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
79239485|NCT02358746|Other|combined endo/epicardial approach|
79239486|NCT02358746|Other|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
79239487|NCT03663803|Behavioral|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
79239488|NCT02789774|Procedure|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
79239489|NCT02789774|Procedure|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
79835427|NCT00378703|Other|Laboratory Biomarker Analysis|Correlative studies
79835428|NCT00378703|Other|Pharmacological Study|Correlative studies
79835429|NCT00378703|Drug|Sorafenib Tosylate|Given PO
79835430|NCT00378703|Drug|Temsirolimus|Given IV
79835431|NCT00893451|Drug|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
79835432|NCT00893451|Drug|Placebo|Placebo orally twice daily
79835433|NCT00893529|Dietary Supplement|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
79835434|NCT00893529|Dietary Supplement|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
79835435|NCT00967408|Drug|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
79835436|NCT00967408|Drug|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
79533700|NCT05960721|Drug|Rivaroxaban 10mg|QD
79533701|NCT05960721|Drug|Rivaroxaban 2.5mg|B.I.D
79533702|NCT05960669|Procedure|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
79835437|NCT00967408|Other|Rehabilitative treatment|Rehabilitative treatment
79835438|NCT00891423|Drug|Meropenem short infusion|
79835439|NCT00891423|Drug|Meropenem extended infusion|
79835440|NCT04035382|Procedure|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
79835441|NCT00891501|Procedure|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
79239490|NCT03662945|Other|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
79391272|NCT01700387|Drug|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
79835442|NCT00891501|Procedure|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
79835443|NCT00967564|Other|epidemiologic study|QoL assessment
79835444|NCT02541045|Drug|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
79835445|NCT02541045|Other|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
79835446|NCT05131282|Diagnostic Test|Blood test of PE risk|A blood test is applied to women at the 1st or early 2nd trimester to evaluate risk of developing PE
79835447|NCT00968656|Radiation|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
79835448|NCT00968656|Other|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
79835449|NCT00968656|Other|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
79835450|NCT00968656|Other|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
79835451|NCT00968656|Drug|F-18-ISO|Patients receive F-18-ISO-1 i.v.
79391273|NCT01699685|Drug|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
79835452|NCT04036149|Device|Intraocular lens|Implantation as part of cataract surgery
79835453|NCT00975442|Other|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
79835454|NCT00975442|Device|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
79835455|NCT00975442|Device|Forearm band|All patients were instructed to use a forearm band during all daily activities.
79835456|NCT00891579|Drug|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
79835457|NCT00891579|Drug|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
79835458|NCT00968734|Dietary Supplement|colecalciferol|50.000UI single oral dose
79239491|NCT02509312|Drug|Ketorolac|Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
79391274|NCT01699685|Drug|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
79391275|NCT01699685|Drug|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
79391276|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 1-12
79835459|NCT03620643|Drug|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
79835460|NCT03620643|Drug|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
79835461|NCT04008316|Drug|Colchicine|colchicine 1mg/day
79835462|NCT00893607|Drug|NRL001|10mg NRL001 was administered as a slow release suppository
79835463|NCT00969046|Drug|EPO906 (patupilone)|
79835464|NCT05011708|Device|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
79835465|NCT05011708|Device|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
79835466|NCT00893685|Device|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
79835467|NCT05008354|Drug|Pyridoxine|Pyridoxine tablet 40mg once daily
79835468|NCT05008354|Drug|Placebo|Placebo tablet once daily
79835469|NCT00975754|Drug|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
79391277|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 13-24
79391278|NCT01587989|Drug|placebo|methotrexate placebo orally weekly, Weeks 13-24
79391279|NCT01587989|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
79835470|NCT00975754|Drug|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
79835471|NCT00975754|Drug|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
79835472|NCT00975754|Drug|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
79835473|NCT01045681|Drug|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
80006976|NCT03868150|Device|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
79239492|NCT02509312|Drug|Placebo|Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
79533703|NCT05960643|Other|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
79533704|NCT05960643|Other|Control|No intervention will be made against people in this group.
79533705|NCT05960617|Drug|Empagliflozin|"Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count > 1.0 × 10^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count < 1.0 × 10^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count < 1.0 × 10^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above."
79239493|NCT03662477|Biological|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
79533706|NCT05960591|Device|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
79835474|NCT00868647|Procedure|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
79533707|NCT05960136|Procedure|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
79533708|NCT05960136|Procedure|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
79689787|NCT05102279|Dietary Supplement|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
79835475|NCT00868725|Other|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
79835476|NCT00975910|Drug|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
79835477|NCT00975910|Drug|saline|Saline arm: infused at the same rate as lidocaine
79239494|NCT02362880|Radiation|Florbetaben|single dose of Florbetaben followed by PET scan
79689788|NCT05098483|Procedure|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
79835478|NCT01048567|Other|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
79835479|NCT01048567|Other|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
79835480|NCT00969202|Radiation|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
79835481|NCT01051375|Behavioral|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
79835482|NCT03617913|Drug|Avelumab|Given IV
79835483|NCT03617913|Drug|Cisplatin|Given IV
79835484|NCT03617913|Drug|Fluorouracil|Given IV
79835485|NCT03617913|Drug|Mitomycin|Given IV
79835486|NCT03617913|Other|Quality-of-Life Assessment|Ancillary studies
79835487|NCT03617913|Radiation|Radiation Therapy|Undergo RT
79835488|NCT05073328|Other|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
79835489|NCT00975988|Drug|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
79239495|NCT04057079|Combination Product|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
79239496|NCT04057079|Combination Product|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
79239497|NCT03662399|Device|Insoles|Orthotic Insoles
79533709|NCT05959928|Device|Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely|The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)
79533710|NCT05959902|Other|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
79533711|NCT05959902|Other|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
79689789|NCT05098483|Procedure|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
79689790|NCT05098483|Procedure|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
79689791|NCT05096260|Behavioral|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
79689792|NCT05086315|Drug|SAR443579|Powder for solution for infusion; by IV infusion
79689793|NCT05084599|Drug|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
79689794|NCT05084599|Drug|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
79689795|NCT05062083|Drug|11C-MCI|Injected IV followed by PET scanning
79689796|NCT05062083|Drug|11C-PS13|Injected IV followed by PET Scanning
79689798|NCT05052398|Drug|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
79689799|NCT05052398|Drug|Placebo PSP NEURO SERUM|Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
79689800|NCT05042258|Drug|Dupilumab|12 week dupilumab administration
79689801|NCT05041803|Drug|CTP-543|Twice daily dosing
79689802|NCT05035030|Drug|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
79689803|NCT05033886|Drug|fezolinetant|oral
79689804|NCT05033886|Drug|placebo|oral
79689805|NCT05021757|Device|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
79689806|NCT05011058|Drug|Nanatinostat in combination with valganciclovir|"Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Other name: VRx-3996~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles"
79689807|NCT05002998|Drug|Teprotumumab|"Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration"
79239498|NCT03662399|Other|Standard shoe|Standard shoe
79239499|NCT02362958|Drug|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
79239500|NCT04973800|Drug|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
79239501|NCT04973800|Drug|Placebo|Sucrose placebo ON PO for 28-30 days
79302993|NCT03197311|Other|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
79302994|NCT02480543|Drug|Misoprostol (cytotec)|
80006977|NCT03606239|Radiation|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
80006978|NCT03551795|Biological|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) in one course of treatment.
80006979|NCT03141892|Device|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
80006980|NCT05084794|Procedure|Internal fixation|Fixation of posterior malleolus with either plate or screws.
80006981|NCT03521687|Drug|Apremilast|30 mg BID
80006982|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
80006983|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
80006984|NCT03141658|Drug|Placebo|Multiple doses of placebo once daily for 6 days
79239502|NCT03662867|Behavioral|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
79239503|NCT03662867|Other|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
79533712|NCT05959837|Other|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
79533713|NCT05959811|Other|yoga|60 minutes yoga practice ,twice a week for 8 weeks
79533714|NCT05959642|Device|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
79689808|NCT05002998|Drug|Placebo|Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
80006985|NCT03141658|Other|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
80006986|NCT03139396|Procedure|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
80006987|NCT03498911|Procedure|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
80006988|NCT03142048|Other|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
79689809|NCT05000658|Drug|Dexamethasone phosphate|HSC injection of 4mL
79689810|NCT04999462|Other|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
79689811|NCT04999462|Other|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
79689812|NCT04999462|Other|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
80006989|NCT05411419|Procedure|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
80006990|NCT03498131|Drug|3 mg Melatonin|3 mg melatonin once each day
80006991|NCT03498131|Drug|5 mg Melatonin|5 mg Melatonin once each day
80006992|NCT03141580|Diagnostic Test|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
80006993|NCT05013827|Behavioral|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
80006994|NCT03287752|Device|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
80006995|NCT03287752|Device|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
80006996|NCT04566289|Device|PiCSO|Percutaneous coronary intervention
80006997|NCT01319825|Drug|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
80006998|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
80006999|NCT01369277|Drug|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
79533715|NCT05959642|Device|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
79689813|NCT04990232|Drug|Anakinra or rhIFNγ|In hyper-inflammation anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. In immunoparalysis IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days.
79689814|NCT04990232|Drug|Placebo|20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
80007000|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
79239504|NCT03662243|Behavioral|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
79302995|NCT03197233|Other|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
79302996|NCT02447185|Drug|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
79379434|NCT05732285|Behavioral|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
79379435|NCT05732285|Behavioral|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
79379436|NCT05732285|Behavioral|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
79379437|NCT05732285|Behavioral|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
79379438|NCT05730855|Diagnostic Test|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
79689815|NCT04989023|Other|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
79689816|NCT04986553|Device|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
79689817|NCT04977271|Drug|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
79689818|NCT04972786|Device|Repetitive Transcranial Magnetic Stimulation|TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
79835490|NCT00976066|Drug|Part A Assessing GSK1521498|"Each participant will receive up to three [11C]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
80007001|NCT02983006|Biological|DS-8273a|"Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
80007002|NCT02983006|Biological|Nivolumab|5 mg/kg IV Q 3 weeks
79379439|NCT05727774|Other|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
79835491|NCT00976066|Drug|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three [11C]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
80007003|NCT05409859|Other|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
79835492|NCT00976066|Drug|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three [11C]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
79835493|NCT00976144|Drug|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
79689819|NCT04971707|Other|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
80007004|NCT04983953|Device|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
79689820|NCT04971707|Other|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
79689821|NCT04971161|Biological|allo-APZ2-CVU|Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.
80007005|NCT03811756|Dietary Supplement|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
80007006|NCT03811756|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
80007007|NCT03125915|Behavioral|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
79379440|NCT05727774|Other|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
79379441|NCT05721729|Drug|Mizagliflozin|Encapsulated
79379442|NCT05721729|Drug|Placebo|Encapsulated
79689822|NCT04971161|Drug|Placebo|One topical application with a syringe
79689823|NCT04969978|Behavioral|Enhanced Academic Detailing|"Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~Follow-up booster sessions~Monthly performance audit and feedback"
79689824|NCT04969978|Other|Informational Intervention|Receive overview of Quitline services and use of Quitline eReferral via online materials
79689825|NCT04969744|Device|ICE|Intermittent Cooling Exposure using cooling garment for 1-2 hours
80007008|NCT03125915|Behavioral|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
80007009|NCT03125915|Behavioral|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
80007010|NCT03141268|Diagnostic Test|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
80007011|NCT03139006|Device|Dual-layer spectral detector CT|A dual energy CT approach
79379443|NCT05720715|Drug|cyclosporine A 0.05% eye drops|"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."
79379444|NCT05720169|Diagnostic Test|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
79379445|NCT05720169|Diagnostic Test|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
79379446|NCT05720169|Diagnostic Test|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
79379447|NCT05720169|Diagnostic Test|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
79379448|NCT05718895|Drug|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
79391280|NCT01697969|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
79391281|NCT01586819|Drug|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
79533716|NCT05959538|Behavioral|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
79835494|NCT04008472|Other|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
79835495|NCT00969592|Drug|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
79835496|NCT00969592|Drug|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
80007012|NCT03122171|Other|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
80007013|NCT03138850|Device|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
79533717|NCT05959538|Behavioral|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
79835497|NCT00368641|Drug|Extraneal|Periotneal Dialysis
79239505|NCT03662555|Device|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
79835498|NCT00976222|Drug|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
79835499|NCT00979888|Other|educational intervention|
79835500|NCT00979888|Other|informational intervention|
79835501|NCT00979888|Other|psychosocial support for caregiver|
79835502|NCT00979888|Other|questionnaire administration|
79835503|NCT00979888|Procedure|dyspnea management|
80007014|NCT03138850|Device|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
79239506|NCT03662165|Behavioral|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
79239507|NCT03662165|Behavioral|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
79835504|NCT00979888|Procedure|management of therapy complications|
79835505|NCT00976300|Drug|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
80007015|NCT03138850|Device|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
80007016|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
79835506|NCT00976300|Drug|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
79835507|NCT00976378|Drug|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
79533718|NCT05959395|Device|VectRx Thermal Therapy|Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
79835508|NCT00976378|Drug|NOX-A12|single IV dose, at efficacious dose level
79835509|NCT00976534|Drug|AZD1386|90 mg, capsules, oral, during 3 weeks
79835510|NCT00976534|Drug|Placebo|capsules, oral, during 3 weeks
79835511|NCT00979966|Drug|Temsirolimus|25 mg intravenously, once weekly infusion
79835512|NCT00979966|Drug|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
79835513|NCT00969826|Drug|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
79835514|NCT04007926|Behavioral|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
79835515|NCT04007926|Behavioral|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
79835516|NCT00969904|Drug|N-acetylcysteine|600 mg TID for 12 weeks
79835517|NCT00969904|Drug|placebo|placebo tablet TID for 12 weeks
79835518|NCT00976612|Drug|Nilotinib|Nilotinib 400mg bid daily
79835519|NCT00976690|Drug|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
79835520|NCT00976768|Drug|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
79835521|NCT00608985|Drug|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
79239508|NCT03662165|Behavioral|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
79835522|NCT00608985|Drug|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
79835523|NCT00608985|Drug|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
79835524|NCT00608985|Drug|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
79835525|NCT00969982|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
79835526|NCT00969982|Drug|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
79835527|NCT00976846|Device|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
79835528|NCT00976924|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
79835529|NCT00970060|Behavioral|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
79835530|NCT00970138|Drug|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
79835531|NCT00892125|Drug|paliperidone ER; Carbamazepine|
79835532|NCT00977002|Other|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
80007017|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
79835533|NCT00977002|Other|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
79835534|NCT00869037|Drug|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
80007018|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
80007019|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
79835535|NCT00869037|Drug|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
79835536|NCT00980356|Drug|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
79835537|NCT00869115|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
79835538|NCT00869115|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
80007020|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
80007021|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
80007022|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
80007023|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
80007024|NCT03663088|Other|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
79239509|NCT02509156|Biological|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
79239510|NCT02509156|Biological|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
79547173|NCT01551966|Device|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
79239511|NCT03662087|Combination Product|HMA+DLI|HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
80007025|NCT03663088|Other|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
80007026|NCT03138928|Device|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
80007027|NCT03634696|Other|mPCL|Smart phone application to support palliative care among late-stage cancer patients
80007028|NCT03634696|Other|Usual Care|Usual care through OCRI palliative care clinic
80007029|NCT03634163|Behavioral|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
80007030|NCT03634163|Behavioral|Quality of Life Assessment|Completion of baseline measures
80007031|NCT05084170|Procedure|Bilateral anterior cingulotomy|Stereotactic bilateral anterior cingulotomy is a brain operation with demonstrated efficacy in the treatment of intractable pain from a variety of causes, including a few cases of spinal cord injury related neuropathic pain.
80007032|NCT03316781|Drug|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
80007033|NCT03316781|Drug|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
80007034|NCT03138772|Other|This is an observational study, no intervention used.|No intervention is being used in this study.
80007035|NCT01427725|Drug|Lipacreon|This study was an observational study and no intervention was specified
80007036|NCT01319903|Biological|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
80007037|NCT05084014|Other|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
80007038|NCT05084014|Other|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
80007039|NCT03138694|Other|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
79239512|NCT03662087|Biological|DLI|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
79239513|NCT03661619|Procedure|Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
79533719|NCT05957900|Behavioral|Multisensory stimulation module|"Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~Vestibular Stimulation; neonates placed in a hammock for 3 min.~Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~Olfactory Stimulation for 3 min. using mother's milk.~Auditory Stimulation listening to mother's heart beats for 3 min."
79239514|NCT03661619|Procedure|Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
80007040|NCT02839200|Drug|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
79533720|NCT05957679|Diagnostic Test|Magnetic Resonance Elastography|Undergo MRE and routine MRI
79689831|NCT04962776|Drug|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
80007041|NCT02839200|Drug|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
80007042|NCT02839200|Drug|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
80007043|NCT02839200|Drug|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
79239515|NCT03661931|Diagnostic Test|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
80007044|NCT02839200|Drug|Placebo 1|Placebo capsules matching ACT-541468 capsules
79239516|NCT01654666|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
79239517|NCT01654666|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
79689832|NCT04962776|Drug|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
79689833|NCT04962776|Other|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
79689834|NCT04961632|Drug|Tamoxifen|Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of >30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
79239518|NCT01654666|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
79689835|NCT04961632|Drug|Tamoxifen|Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
79689836|NCT04950686|Behavioral|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
79689837|NCT04950686|Behavioral|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
79689838|NCT04939597|Procedure|Biospecimen Collection|Undergo blood sample collection
79689839|NCT04939597|Procedure|Cognitive Assessment|Complete cognitive testing
79689840|NCT04939597|Procedure|Magnetic Resonance Imaging|Undergo MRI
79689841|NCT04939597|Drug|Memantine Hydrochloride|Given PO
79689842|NCT04939597|Drug|Placebo Administration|Given PO
79689843|NCT04939597|Other|Questionnaire Administration|Ancillary studies
79835539|NCT00869115|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
80007045|NCT02839200|Drug|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
80007046|NCT04846907|Other|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
79239519|NCT04973332|Device|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
79239520|NCT04971928|Drug|GSK3228836|GSK3228836 will be administered
79239521|NCT02519842|Drug|Fosaprepitant|
79239522|NCT02519842|Drug|Placebo for fosaprepitant|
79239523|NCT02519842|Drug|Ondansetron|
79689844|NCT04926142|Device|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
79835540|NCT00869115|Drug|Istaroxime|Placebo continuous i.v. infusion for 24 hours
80007047|NCT05083936|Drug|[18F]FET|Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
80007048|NCT01375907|Drug|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
80007049|NCT05083858|Other|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
79835541|NCT00368251|Other|Placebo|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg, 25 mg and 50 mg~Route of Administration: Oral use"
79835542|NCT00368251|Drug|BRV 2.5 mg|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
79835543|NCT00368251|Drug|BRV 25 mg|"Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
79835544|NCT00368251|Drug|BRV 50 mg|"Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
79379449|NCT05711537|Device|Auricular Acupressure with Vaccaria 600t ear seeds|Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
79379450|NCT05709496|Radiation|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
79835545|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
79835546|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
79379451|NCT05698173|Biological|blood sample|48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
79533721|NCT05957679|Procedure|Assessment and Recording|Undergo grading and recording of tumor stiffness and adhesion during surgery
79533722|NCT05955859|Procedure|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
79533723|NCT05955430|Other|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
79379452|NCT05698173|Biological|blood sample|blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
79835547|NCT00893841|Drug|placebo|placebo
80007050|NCT05083858|Other|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
80007051|NCT05083858|Other|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
80007052|NCT01369667|Dietary Supplement|Vitamin D3|
80007053|NCT01369667|Other|Placebo|
79689845|NCT04926142|Procedure|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
79689846|NCT04909138|Device|DRG stimulation 20 Hz 30/90|Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
79689847|NCT04909138|Device|DRG stimulation 5 Hz 30/90|Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
79689848|NCT04908579|Drug|bupivacaine(intraperitoneally) and ketamine (intraperitoneally)|"40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~10 ml normal saline 0.9% will be given intravenous."
79835548|NCT00893841|Drug|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
79835549|NCT02541123|Other|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
79835550|NCT00980512|Behavioral|Parent Training|16 weeks of parent training led by trained group facilitator
79835551|NCT02534077|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
79835552|NCT02534077|Drug|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
79835553|NCT02534077|Drug|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
79835554|NCT00977158|Procedure|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
79239524|NCT02519842|Drug|Dexamethasone|
79239525|NCT02519842|Drug|5-HT3 antagonist|
79239526|NCT02509078|Drug|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
79239527|NCT02993783|Drug|Vedolizumab|Vedolizumab IV infusion
79239528|NCT03661853|Behavioral|Control|60 minute psycho-education on alcohol and drugs.
79239529|NCT03661853|Behavioral|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
79379453|NCT05681741|Procedure|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
80007054|NCT05083702|Procedure|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
80007055|NCT05083702|Procedure|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
79533724|NCT05955430|Other|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
79533725|NCT05955430|Other|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
79533726|NCT05955430|Other|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
79835555|NCT00977236|Device|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
80007056|NCT03564912|Drug|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
80007057|NCT05083624|Behavioral|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
80007058|NCT01369901|Behavioral|A functional exercise program|
80007059|NCT01369901|Behavioral|A stretching exercise program|
79239530|NCT03661853|Behavioral|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
79239531|NCT03661853|Behavioral|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
79239532|NCT03661775|Drug|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
79379454|NCT05681065|Device|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
79239533|NCT04055597|Other|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
79239534|NCT04055597|Other|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
79239535|NCT04055363|Other|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
79239536|NCT03205475|Behavioral|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
79239537|NCT03205475|Behavioral|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
79379455|NCT05680792|Drug|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
79379456|NCT05680792|Drug|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
79239538|NCT03205475|Behavioral|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
79689849|NCT04908579|Drug|bupivacaine(intraperitoneally) and ketamine (intravenously)|"40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites."
79689850|NCT04908579|Drug|bupivacaine(intraperitoneally)|"40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~10 ml normal saline 0.9% will be given intravenous."
79689851|NCT04907461|Procedure|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
79689852|NCT04901741|Drug|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
79689853|NCT04901741|Drug|Pembrolizumab|200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
79689854|NCT04896229|Other|Talk STEM Familia Treatment Condition|This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.
79689855|NCT04895436|Drug|Venetoclax|Oral tablet
79689856|NCT04895436|Drug|Obinutuzumab|Intravenous (IV) infusion
79689857|NCT04881240|Biological|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
79689858|NCT04881240|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
79689859|NCT04881240|Drug|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
79689860|NCT04881240|Drug|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
79689861|NCT04881240|Device|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
79689862|NCT04881240|Procedure|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
79239539|NCT03205475|Behavioral|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
79239540|NCT03205475|Behavioral|Video Feedback Only Phase 2|Receive video feedback and calls only
79835556|NCT00977236|Device|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
79835557|NCT00378079|Other|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
79239541|NCT03660761|Drug|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
79239542|NCT03660761|Drug|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
79239543|NCT02993471|Drug|Drug Cocktail|Administered orally
79239544|NCT02993471|Drug|Ixekizumab|Administered SC
79239545|NCT02988713|Device|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
79239546|NCT01068743|Drug|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
79239547|NCT01068743|Drug|metformin|Tablets, Oral, 850 mg, once daily, single dose
79239548|NCT01068743|Drug|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
79835558|NCT00378079|Drug|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
79379457|NCT05677880|Other|Study Procedures|"Participants will experience~Neurocognitive Tests and Self-Report Measures~Clinical Interviews~Neurological Exam~MRI screening at baseline, 18 months, 36 months~Fasted Blood draw"
79379458|NCT05676814|Drug|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
79689867|NCT04844866|Genetic|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
79689868|NCT04844866|Drug|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
80007060|NCT01567969|Behavioral|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
79533727|NCT05955430|Other|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
79533728|NCT05953818|Diagnostic Test|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
79533729|NCT05951140|Other|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
80007061|NCT01567969|Behavioral|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
80007062|NCT03551626|Drug|Dabrafenib|Supplied as dabrafenib 50 mg, 75 mg Capsules for oral use
80007063|NCT03551626|Drug|Trametinib|supplied as trametinib 0.5mg, 2.0mg tablets for oral use
79533730|NCT05947747|Drug|EXO-CD24|Twice a day for 5 days, dose 10^10
79533731|NCT05947747|Other|Placebo|Twice a day for 5 days
80007064|NCT03565146|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
79239549|NCT02992691|Drug|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
79379459|NCT05676814|Drug|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
79689869|NCT04840394|Drug|BDB018|BDB018 is an immunotherapy agent.
79835559|NCT00378079|Drug|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
79835560|NCT00970450|Drug|Paracetamol|Paracetamol 1 g i.v. once
79835561|NCT00970450|Drug|Tropisetron|Tropisetron 5 mg i.v. once
79835562|NCT00970450|Drug|Placebo|Saline
80007065|NCT05353686|Drug|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
79835563|NCT00970528|Drug|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
80007066|NCT05353686|Drug|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
80007067|NCT05760053|Drug|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
80007068|NCT03509116|Other|Observations|Consultation observations
80007069|NCT03509116|Other|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
79239550|NCT02992691|Drug|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
79239551|NCT02992691|Drug|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
79379460|NCT05676242|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
79379461|NCT05669404|Behavioral|Salt Restriction Group (SRG)|Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
79533732|NCT05944159|Behavioral|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
79689870|NCT04840394|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
79835564|NCT00970528|Drug|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
79835565|NCT00977392|Behavioral|compliance monitoring|
79835566|NCT00977392|Other|cervical Papanicolaou test|
79835567|NCT00977392|Other|educational intervention|
79835568|NCT00977392|Other|screening questionnaire administration|
79239552|NCT02992691|Drug|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
79239553|NCT02992691|Drug|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
79835569|NCT00977392|Other|survey administration|
79835570|NCT00977392|Procedure|colposcopy|
79835571|NCT03936244|Device|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
79835572|NCT04009486|Device|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
79835573|NCT05279404|Other|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
79835574|NCT05191576|Other|Children's sleep habits questionnaire (CSHQ)|"Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~SDQ).is used to screen emotional and behavioral problems in children.~SDQ is used to screen emotional and behavioral problems in children."
79835575|NCT00970762|Drug|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
79835576|NCT00970762|Drug|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
79533733|NCT05944159|Other|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
79533734|NCT05942599|Biological|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
79835577|NCT00970762|Drug|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
79835578|NCT00970762|Drug|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
79835579|NCT00970762|Drug|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
79533735|NCT05939687|Procedure|mesh|We'll use mesh repair for prevention of stoma-site hernias in the study group.
79689871|NCT04833348|Other|Motor function measurement using inertial sensors|"Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:~Free motor skills in the supine position~Motricity in the supine position stimulated by a play frame~Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry~Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control"
79689872|NCT04832802|Behavioral|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
79689873|NCT04832802|Behavioral|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
79689874|NCT04832178|Dietary Supplement|SUMOR|"SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:~S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg~Betaine hydrochloride 250 mg~Vitamin C 80 mg~Vitamin B1 1.1 mg~Vitamin B2 1.4 mg~Vitamin B6 1.4 mg~Vitamin B12 2,5 µg~Folic Acid 200 µg~Selenium 37 µg"
79689875|NCT04832178|Other|Placebo|Placebo tablet will be identical in appearance to the experimental product (SUMOR).
79239554|NCT03622541|Drug|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
79239555|NCT03658733|Drug|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
79239556|NCT03658733|Drug|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
79835580|NCT00970762|Drug|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
79835581|NCT00970762|Drug|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
79239557|NCT02921087|Device|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
79239558|NCT02921087|Device|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
79239559|NCT03660605|Other|Rhythmic Auditory Stimulation|Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
79533736|NCT05939687|Procedure|non-mesh|We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
79835582|NCT00980824|Behavioral|Cognitive behavioural therapy|Six sessions brief CBT.
79835583|NCT00980824|Other|Standard treatment|Referral to NHS services appropriate to patient's needs
79835584|NCT00977626|Drug|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
79835585|NCT00977626|Drug|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
79835586|NCT00977626|Drug|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
79533737|NCT05932680|Other|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
79835587|NCT00970840|Dietary Supplement|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
79533738|NCT05931666|Other|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
79533739|NCT05931666|Other|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
79533740|NCT05930145|Device|Double stentriever|Double stentriever technique
79533741|NCT05930145|Device|Single stentriever|Single stentriever technique
79533742|NCT05928611|Procedure|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
79835588|NCT00978172|Drug|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
79689876|NCT04823741|Genetic|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
79689877|NCT04818918|Device|Absolute coronary flow measurement|Absolute coronary flow will be measured.
79835589|NCT00970918|Procedure|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
79239560|NCT04056143|Diagnostic Test|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
79239561|NCT03658655|Biological|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
79689878|NCT04818918|Device|Microvascular resistance measurement|Microvascular resistance will be measured.
79835590|NCT00970918|Biological|Blood sample testing for hs-CRP|one time, blood sample taking
79835591|NCT03923530|Drug|Eplerenone|Eplerenone 50 mg daily
79239562|NCT03661463|Drug|Aspirin|Drug
79239563|NCT03660527|Other|Not refered|No intervention was refered.
79533743|NCT05928611|Procedure|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
79533744|NCT05928611|Procedure|Inferior alveolar nerve block|Using articaine for injection
79835592|NCT00608907|Drug|bortezomib|1.3 mg/m^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
79835593|NCT00608907|Drug|bortezomib, rifampicin|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
79835594|NCT00608907|Drug|bortezomib, dexamethasone|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
79835595|NCT00970996|Drug|Temozolomide|250 mg/m^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
79533745|NCT05917912|Drug|Amitriptyline Hydrochloride|hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
79533746|NCT05917912|Drug|Placebo|hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
79835596|NCT00970996|Drug|Abraxane|100 mg/m^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m^2 given on day 5 of each 21-day cycle.
79533747|NCT05913518|Device|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
79689879|NCT04818918|Other|Cardiac MRI|Cardiac MRI will be performed to evaluate myocardial viability.
79239564|NCT03622463|Drug|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
79239565|NCT03622463|Other|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
79239566|NCT03658499|Behavioral|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
79239567|NCT03658499|Behavioral|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
79533748|NCT05913518|Device|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
79239568|NCT03661229|Device|CVInsight Monitoring|All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
79239569|NCT03658421|Drug|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
79239570|NCT03658421|Procedure|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
79533749|NCT05912452|Other|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
79533750|NCT05912452|Other|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
79835597|NCT00970996|Drug|Cisplatin|20 mg/m^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
79835598|NCT00970996|Biological|Interleukin-2|9 MIU/m^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
79835599|NCT00970996|Biological|Interferon alpha 2b|5 MIU/m^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
79835600|NCT00869193|Dietary Supplement|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
79835601|NCT00869193|Dietary Supplement|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
79835602|NCT04009018|Other|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
79239571|NCT03658421|Device|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
79835603|NCT00869271|Procedure|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
79835604|NCT00869271|Procedure|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
79835605|NCT00971074|Drug|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
79835606|NCT00971074|Other|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
79835607|NCT00971152|Drug|menotropins for injection|comparison of different dosages
79239572|NCT03658421|Procedure|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
79689880|NCT04814368|Biological|canakinumab|intra-articular injection (into the knee)
79835608|NCT00971152|Drug|urofollitropin for injection|comparison of different dosages
79835609|NCT00893919|Drug|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
79835610|NCT00981136|Procedure|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
79835611|NCT00981136|Procedure|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
79835612|NCT05278689|Other|No intervention|No intervention
79835613|NCT00377611|Biological|Fluarix™|
79239573|NCT02991521|Procedure|Fast exam|Positional change before Fast exam
79689881|NCT04814368|Biological|LNA043|intra-articular injection (into the knee)
79689882|NCT04814368|Other|Placebo to canakinumab|intra-articular injection (into the knee)
79689883|NCT04810572|Dietary Supplement|Composition with Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
79689884|NCT04810572|Dietary Supplement|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
79689885|NCT04800471|Device|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
79689886|NCT04800471|Other|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
79835614|NCT00978328|Drug|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
79835615|NCT00869427|Drug|vitamin C|vitamin C 1g bid for 1 year
79835616|NCT00971230|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
79835617|NCT00971230|Drug|Placebo|Placebo
79239574|NCT03660293|Drug|Atorvastatin|cardio-protective agents
79239575|NCT03660293|Drug|Captopril|cardio-protective agents
79239576|NCT03660293|Drug|L-carnitine|cardio-protective agents
79239577|NCT03660137|Device|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
79239578|NCT02907619|Biological|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
79239579|NCT02986373|Biological|risankizumab|Risankizumab administered by subcutaneous injection.
79239580|NCT03659903|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy
79239581|NCT02986139|Drug|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
79239582|NCT02986139|Drug|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
79835618|NCT00892359|Drug|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
79835619|NCT00892515|Behavioral|exercise intervention|
79835620|NCT00892515|Other|counseling intervention|
79835621|NCT00892515|Other|gas chromatography|
79835622|NCT00892515|Other|immunoenzyme technique|
79835623|NCT00892515|Other|immunologic technique|
79835624|NCT00892515|Other|laboratory biomarker analysis|
79835625|NCT00892515|Other|mass spectrometry|
79835626|NCT00892515|Other|physiologic testing|
80007070|NCT03121157|Behavioral|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
79239583|NCT02989805|Behavioral|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
79239584|NCT03622255|Procedure|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
79391282|NCT01586819|Procedure|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution [a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel [35% Trichloroacetic acid] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
79835627|NCT00892515|Other|questionnaire administration|
79835628|NCT00892515|Other|survey administration|
79835629|NCT00892515|Procedure|dual x-ray absorptometry|
79835630|NCT00892515|Procedure|magnetic resonance imaging|
79835631|NCT00892515|Procedure|study of high risk factors|
79835632|NCT00978484|Behavioral|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
79835633|NCT00978484|Behavioral|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
79835634|NCT01051531|Drug|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
79835635|NCT00971308|Drug|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
79835636|NCT00971308|Drug|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
79689887|NCT04796818|Procedure|Diffusion Weighted Imaging|Undergo IVIM DWI
79689888|NCT04791371|Behavioral|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
79689889|NCT04789837|Drug|Cilostazol 50 MG|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
79689890|NCT04789837|Drug|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
79689891|NCT04784130|Behavioral|Physical Activity|Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
79689892|NCT04784130|Behavioral|Medication Adherence|Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
79689893|NCT04784130|Behavioral|Dietary Modification|Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
79835637|NCT00971308|Drug|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
79835638|NCT00971308|Drug|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
79835639|NCT00971308|Drug|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
80007071|NCT03505060|Biological|DNA CON-S env|Administered by intramuscular injection in the deltoid.
79835640|NCT00869583|Behavioral|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents [METS]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
79533751|NCT05912452|Other|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
79689894|NCT04783038|Other|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
79835641|NCT02533843|Procedure|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
80007072|NCT03505060|Biological|IHV01|Administered by intramuscular injection in the deltoid.
79533752|NCT05905601|Behavioral|NORTH|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
79533753|NCT05905601|Behavioral|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
80007073|NCT03505060|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
80007074|NCT03500614|Behavioral|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
80007075|NCT03500614|Behavioral|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
80007076|NCT03495700|Procedure|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
80007077|NCT03495700|Procedure|DBBM|The use of bovine xenograft will be analysed
79239585|NCT03622255|Procedure|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
79239586|NCT02236351|Device|Pinch Patch/ flat Patch|
79239587|NCT03659825|Dietary Supplement|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
79689895|NCT04783038|Other|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
79689896|NCT04779125|Procedure|Gluteus plasty enhanced with Progrip self gripping mesh|Intervention group will be compared to historical patients in a case-control setting. Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
79239588|NCT03659825|Dietary Supplement|Taste Matched Placebo|Placebo that tastes similar to active intervention
79239589|NCT03659825|Other|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
79239590|NCT03659747|Dietary Supplement|Probiotic|- 6 g sachet containing probiotic powder (1.8 x 10^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
79239591|NCT03659747|Dietary Supplement|Lactrase|- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
79379462|NCT05669404|Behavioral|DASH Diet combined with salt restriction Group (DDG)|Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
79391283|NCT01697579|Drug|Fosaprepitant|Administered intravenously (IV) as a single dose
79391284|NCT01697579|Drug|Fosaprepitant Placebo|Administered IV as a single dose
79391285|NCT01697579|Drug|Ondansetron|Administered IV according to local labeling and/or local standard of care
79689897|NCT04772196|Drug|Vitamin D3|50,000 IU Vitamin D3 weekly for 8 weeks
79689898|NCT04761848|Drug|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
79835642|NCT00971386|Behavioral|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
79835643|NCT00971464|Behavioral|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
79835644|NCT00971464|Device|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
79835645|NCT03992911|Drug|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
79835646|NCT03992911|Drug|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
79835647|NCT03992911|Drug|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
79835648|NCT03992911|Drug|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
79835649|NCT00895479|Procedure|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
79835650|NCT01324765|Behavioral|TARGET|12-session group therapy twice weekly 6 weeks
79835651|NCT01324765|Behavioral|SGT|12 sessions supportive group therapy twice weekly 6 weeks
79835652|NCT02541201|Dietary Supplement|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
79239592|NCT03659747|Other|Placebo|- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
79239593|NCT03658265|Other|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
79239594|NCT03658265|Other|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
79689899|NCT04761848|Drug|Placebo|Placebo tablet twice daily
79835653|NCT02541201|Dietary Supplement|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
79835654|NCT00545272|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
79835655|NCT00545272|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
79835656|NCT00545272|Drug|placebo to indacaterol|Placebo TWISTHALER® device
79835657|NCT00545272|Drug|placebo to formoterol|Placebo AEROLIZER® device
79835658|NCT00545272|Drug|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
79835659|NCT00869739|Behavioral|telephone-based intervention|
79239595|NCT03658265|Other|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
79239596|NCT03658265|Other|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
79689900|NCT04757571|Drug|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
79835660|NCT00869739|Other|educational intervention|
79835661|NCT00869739|Other|partner-assisted coping skills training|
79835662|NCT00869739|Other|questionnaire administration|
79239597|NCT03658187|Dietary Supplement|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
79239598|NCT03658187|Dietary Supplement|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
79239599|NCT03659591|Behavioral|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
79689901|NCT04757571|Drug|Placebo|Placebo tablet plus standard therapy
79689902|NCT04749914|Drug|Lasmiditan|Administered orally.
79689903|NCT04749914|Drug|Dabigatran Etexilate|Administered orally.
79689904|NCT04749914|Drug|Rosuvastatin|Administered orally.
79689905|NCT04746547|Drug|Dolutegravir 50 MG|Twice daily dolutegravir with rifampicin containing TB treatment
79689906|NCT04746547|Drug|Dolutegravir 10 MG|Twice daily dolutegravir with rifampicin containing TB treatment
79689907|NCT04740164|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with LMA Gastro
79835663|NCT00869739|Procedure|psychosocial assessment and care|
79835664|NCT00869739|Procedure|quality-of-life assessment|
79835665|NCT00377455|Drug|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
79835666|NCT00377455|Drug|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
79835667|NCT00895557|Drug|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
79835668|NCT01051609|Other|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
79835669|NCT01051609|Other|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
80007078|NCT04811170|Other|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
80007079|NCT03118739|Drug|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
79239600|NCT03659591|Behavioral|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
79835670|NCT01051609|Behavioral|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
79835671|NCT01051609|Other|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
79835672|NCT01051609|Procedure|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
80007080|NCT03118739|Drug|Placebo|Capsule administered orally, once daily for 24 weeks
79835673|NCT00869895|Drug|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
79835674|NCT00978640|Other|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
79835675|NCT00978640|Other|exercise|exercise 1 h 50% VO2max
79835676|NCT02533687|Procedure|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
79835677|NCT02533687|Procedure|Bipolar TURP-2|Bipolar TURP
79835678|NCT02533687|Procedure|Monopolar TURP|Monopolar TURP
79835679|NCT00869973|Drug|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
79835680|NCT00869973|Drug|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
79835681|NCT01048645|Drug|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
80007081|NCT03181126|Drug|Navitoclax|tablet
79689908|NCT04740164|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with standard nasal cannula
79835682|NCT01048645|Other|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
80007082|NCT03181126|Drug|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
80007083|NCT03181126|Drug|Venetoclax|tablet
80007084|NCT03157492|Behavioral|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
80007085|NCT03157492|Behavioral|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
79835683|NCT04008784|Drug|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
79835684|NCT04008784|Drug|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
79835685|NCT03544905|Drug|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
79835686|NCT04008394|Genetic|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
79835687|NCT00895635|Behavioral|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
79835688|NCT00895635|Behavioral|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
79835689|NCT00895635|Behavioral|Usual Care|Usual care for PAD
80007086|NCT03146338|Other|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
80007087|NCT02995889|Device|FLT-PET|
79391286|NCT01697579|Drug|5-hydroxytryptamine 3 antagonist|Administered IV according to local labeling and/or local standard of care
79391287|NCT01586195|Drug|Vemurafenib|Vemurafenib 960 mg BID
79391288|NCT01585961|Device|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
79391289|NCT01697501|Other|Interleukin 28B testing|Blood sampling for IL28B genotyping
79391290|NCT01697345|Drug|Testosterone|
79689909|NCT04722575|Drug|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
79689910|NCT04722575|Drug|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
79689911|NCT04722575|Drug|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
79689912|NCT04708808|Behavioral|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
79835690|NCT01051687|Drug|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
79835691|NCT00978718|Dietary Supplement|high-selenium baker's yeast|Given orally
79835692|NCT00978718|Dietary Supplement|selenium|Given orally
79835693|NCT00978718|Other|placebo|Given orally
79835694|NCT00894153|Drug|chemotherapy plus p53|chemotherapy plus p53
79835695|NCT00894153|Drug|chemotherapy|chemotherapy
79835696|NCT00894153|Radiation|radiotherapy|radiotherapy
79835697|NCT01048801|Device|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
80007088|NCT03141502|Device|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
79835698|NCT01048801|Other|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
79835699|NCT00971542|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
79835700|NCT00895713|Drug|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
79835701|NCT01051765|Drug|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
79689913|NCT04708470|Drug|Bintrafusp Alfa|"Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
79835702|NCT00978796|Drug|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
79835703|NCT00978796|Drug|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
79835704|NCT00894231|Drug|levocetirizine (Xyzal)|5mg po QD
79835705|NCT00894231|Drug|placebo|sugar tablet
79835706|NCT00870207|Behavioral|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
79835707|NCT05030974|Biological|mRNA-1273|SARS-CoV-2 vaccination
79689914|NCT04708470|Drug|NHS-IL12|NHS-IL12 will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of NHS-IL12 will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of NHS-IL12 used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.
79239601|NCT03656497|Other|Observational|No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia
79835708|NCT05030974|Biological|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
79835709|NCT00377299|Drug|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
80007089|NCT03141502|Procedure|Skin grafting|the standard technique of skin grafting after wound preparation.
79239602|NCT03656419|Procedure|photodynamic therapy|aPDT with methylene blue and red led irradiation.
79835710|NCT00377299|Drug|Placebo|Placebo matching active medication in all other physical aspects
79835711|NCT00981604|Procedure|SILS|Single Incision Laparoscopic Cholecystectomy
79835712|NCT00981604|Procedure|Standard Laparoscopic Cholecystectomy|4 port technique
79835713|NCT03472365|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
79835714|NCT03472365|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
79835715|NCT03472365|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
79835716|NCT03472365|Drug|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
79835717|NCT03200977|Other|Non-Interventional|Non-Interventional
79835718|NCT00971776|Device|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
79835719|NCT00978952|Device|Large Diameter Advanta™ V12 Covered Stent|Stent placement
79835720|NCT00896259|Other|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
79835721|NCT00971854|Procedure|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
79835722|NCT00894621|Drug|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
79835723|NCT00894621|Drug|Placebo|
79835724|NCT00901095|Behavioral|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
79533754|NCT05905120|Drug|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
79835725|NCT00979108|Other|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
79835726|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
79239603|NCT03656419|Procedure|Tongue scraper|Tongue scraper 10 times from de back to the top.
79239604|NCT04295395|Device|NONIN SenSmart model X-100 near- infrared spectrometer|for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
79533755|NCT05904262|Other|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
79835727|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
79533757|NCT05895357|Other|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
79533758|NCT05892523|Procedure|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
79835728|NCT00376675|Drug|methylphenidate hydrochloride|Given orally
79835729|NCT00376675|Other|placebo|Given orally
79835730|NCT02539875|Behavioral|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
79835731|NCT00979186|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
79835732|NCT04017663|Other|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
79835733|NCT00979264|Behavioral|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
79835734|NCT02539719|Drug|SC-003|
79835735|NCT02539719|Drug|SC-003 in combination with ABBV-181|
79835736|NCT04007614|Other|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
79835737|NCT05178628|Drug|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
79835738|NCT05178628|Drug|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
79835739|NCT00896571|Drug|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
79835740|NCT00896727|Genetic|gene expression analysis|
79835741|NCT00896727|Genetic|protein expression analysis|
79835742|NCT00896727|Other|fluorescent antibody technique|
79835743|NCT00896727|Other|laboratory biomarker analysis|
79239605|NCT02906917|Drug|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
79239606|NCT02906917|Drug|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
79239607|NCT02906917|Drug|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
79391291|NCT01769092|Dietary Supplement|Fish Oil|The daily dose is divided; capsules are taken with meals for a period of 6 months.
79391292|NCT01769092|Other|Safflower Oil|Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
79391293|NCT03528226|Behavioral|Exercise Training Procedure|Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)
79391294|NCT03528226|Behavioral|Normal life procedure|No supervised exercise training during the 4 month period.
79379463|NCT05669404|Behavioral|Mediterranean Diet combined with salt restriction Group (MDG)|Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
79533759|NCT05891301|Other|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
79533760|NCT05887726|Drug|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
79689915|NCT04708470|Drug|Entinostat|The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
79533761|NCT05887726|Drug|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
79689916|NCT04693520|Drug|ALZ-801|ALZ-801 265 mg twice daily (BID)
79689917|NCT04687306|Diagnostic Test|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
79689918|NCT04680403|Other|Exercise|supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
79835744|NCT00981838|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients > 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
79835745|NCT03931330|Device|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
79835746|NCT00901329|Device|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
79835747|NCT00901329|Device|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
79835748|NCT01048957|Behavioral|Real Time Feedback Training|
79835749|NCT01051999|Dietary Supplement|Glutamine|Oral glutamine powder
79835750|NCT01051999|Dietary Supplement|L-alanine|L-alanine oral powder
79835751|NCT00894777|Other|Clinical record review|
79835752|NCT00981994|Behavioral|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
79239608|NCT03656341|Behavioral|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
79239609|NCT03656263|Diagnostic Test|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
79835753|NCT01049113|Drug|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
79835754|NCT04017585|Dietary Supplement|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
79239610|NCT03655795|Biological|Bronchial basal cells|Autologous transplantation of bronchial basal cells
79533762|NCT05887726|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
79835755|NCT04017585|Dietary Supplement|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
79835756|NCT02533765|Drug|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
80007090|NCT04477252|Device|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
80007091|NCT04477252|Other|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
80007092|NCT03094195|Drug|EMA401|EMA401
79533763|NCT05887726|Drug|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
79533764|NCT05887726|Drug|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
79533765|NCT05887726|Drug|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
79533766|NCT05886985|Drug|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
80007093|NCT03094195|Drug|Placebo|Placebo
80007094|NCT03140410|Other|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
79689919|NCT04674306|Biological|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1c: 50 mcg~D1d: 50 mcg (D1d will only be utilized if D1c is deemed too toxic)"
80007095|NCT05759975|Device|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
80007096|NCT05759975|Device|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
79547174|NCT01551992|Procedure|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
79547175|NCT01552005|Drug|Saxagliptin|No Intervention
80007097|NCT04799548|Drug|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
80007098|NCT04799548|Drug|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
80007099|NCT05083234|Other|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
79239611|NCT02982187|Device|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
79239612|NCT02982187|Device|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
79239613|NCT02982187|Device|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
80007100|NCT05083234|Other|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
79239614|NCT02982187|Device|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
79239615|NCT02982187|Other|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
79379464|NCT05669222|Diagnostic Test|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
80007101|NCT05083234|Other|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
79239616|NCT02982187|Other|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
79239617|NCT02982187|Other|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
79239618|NCT02982187|Other|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
79239619|NCT03655483|Drug|GLS-010|Full-human anti-pd-1 monoclonal antibodies
79239620|NCT02981953|Device|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
79239621|NCT03656653|Behavioral|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
79239622|NCT03655873|Drug|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
79239623|NCT03655873|Drug|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
79239624|NCT03655327|Other|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
79379465|NCT05669222|Diagnostic Test|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
79379466|NCT05664867|Other|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
79379467|NCT05664867|Other|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
79391295|NCT00362830|Drug|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
80007102|NCT01375985|Drug|AVI-7100|Single intravenous administration
80007103|NCT01375985|Drug|Placebo|Single intravenous administration
80007104|NCT05391295|Other|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
80007105|NCT01376063|Drug|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
80007106|NCT02893150|Behavioral|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
79689920|NCT04674306|Biological|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL2: 100 mcg~DL3: 10 mcg~D1b: 10 mcg~D1c: 50 mcg~D1d: 30 mcg (D1d will only be utilized if D1c is deemed too toxic)"
80007107|NCT02893150|Behavioral|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
80007108|NCT02893150|Behavioral|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems[47]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
80007109|NCT05759897|Drug|HRS-7535|HRS-7535
80007110|NCT05759897|Drug|Placebo|Placebo
80007111|NCT03981497|Procedure|Microwave ablation (MWA)|Thermal ablation
80007112|NCT04754074|Behavioral|Education|Weekly education related to behavior change
80007113|NCT04754074|Behavioral|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
80007114|NCT04754074|Behavioral|Weekly behavior modification challenges|Weekly challenges to address behavior change
80007115|NCT05039047|Other|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
80007116|NCT04741594|Device|Densah|Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement. Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA). This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies , , , , , . Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge. Human clinical studies , , , , have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods. No standardization method or long-term evaluation of peri-implant health was reported.
80007117|NCT02654080|Biological|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
79239625|NCT03655249|Other|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
79239626|NCT03655249|Drug|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
79239627|NCT03655171|Diagnostic Test|Video-based quantitative methods|The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
79239628|NCT03655093|Other|Validation of AMSQ questionnaire|"Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management."
79239629|NCT02021071|Radiation|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
79239630|NCT02021071|Radiation|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
79239631|NCT03654937|Biological|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH & Co. KG, Munich, Germany, batch: AFLBA 152AB."
79689921|NCT04652843|Procedure|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
79689922|NCT04652843|Procedure|Coloscopy|Coloscopy for colonic biospsies collection
79689923|NCT04638413|Behavioral|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
79835757|NCT00979342|Device|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
79835758|NCT04035993|Other|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
80007118|NCT02654080|Biological|rVSV HIV envC vaccine|1 × 10^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
79547176|NCT01552018|Drug|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
79547177|NCT01552018|Drug|Placebo|Placebo, 1 tablet per day for 3 months.
80007119|NCT02654080|Biological|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
80007120|NCT03140332|Other|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
79547178|NCT01552044|Drug|Spironolactone|25mg tablet once a day for 1 month
79239632|NCT01066585|Drug|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
79239633|NCT01066585|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
79547179|NCT01552044|Drug|Placebo|one tablet once a day for 1 month
79547180|NCT01552070|Behavioral|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
79689924|NCT04638413|Behavioral|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
79689925|NCT04634071|Drug|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
79689926|NCT04634071|Drug|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
79239634|NCT03654781|Drug|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
79239635|NCT03654781|Procedure|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
79239636|NCT03654703|Drug|Cyclophosphamide|cyclophophamide
79239637|NCT02980783|Device|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
79239638|NCT02980705|Drug|SUNPG1622 I dose|Injection
79239639|NCT02980705|Drug|Placebo dose|Injection
79239640|NCT03654625|Behavioral|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
79239641|NCT03654625|Behavioral|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
79239642|NCT03654625|Behavioral|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
79239643|NCT02989649|Drug|Alogliptin|Alogliptin tablets
79239644|NCT02989649|Drug|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
79239645|NCT02989649|Drug|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
79239646|NCT03659435|Drug|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
79391296|NCT03465592|Drug|Nivolumab|Administered IV
79391297|NCT02975050|Other|Location|
79391298|NCT02441062|Drug|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
79391299|NCT02442700|Drug|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
79391300|NCT02442700|Drug|placebo|Treatment B = administration placebo for 12 weeks
79391301|NCT02442856|Device|Thigh Cuff|
79391302|NCT02443792|Procedure|Unicirc with tissue adhesive|As above
79391303|NCT02443792|Procedure|Open Surgical|As above
79391304|NCT02445196|Behavioral|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
79391305|NCT02445196|Device|Smartphone|All participants must have a smartphone, either apple or android.
79835759|NCT00367237|Drug|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
79835760|NCT00367237|Drug|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
79835761|NCT04006912|Procedure|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
79835762|NCT02540889|Behavioral|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
79239647|NCT03659435|Drug|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
79239648|NCT02905435|Device|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
79835763|NCT00894855|Behavioral|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
79239649|NCT02978833|Biological|PRP|
79239650|NCT02978833|Biological|Whole Blood|
79379468|NCT05660863|Drug|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
79379469|NCT05660863|Drug|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
79379470|NCT05655598|Drug|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
79379471|NCT05655598|Drug|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
79547181|NCT01552070|Other|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
79547182|NCT01552083|Other|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
79835764|NCT00894855|Behavioral|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
79835765|NCT00894855|Other|dermatologist skin exam|Full body skin exam.
79835766|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835767|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835768|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835769|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79239651|NCT02978833|Device|Ultrasound|
79239652|NCT01067339|Drug|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
79239653|NCT01067339|Drug|placebo|placebo, by mouth, once daily for six months
79239654|NCT02198911|Other|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
79239655|NCT02198911|Other|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
79239656|NCT02198911|Other|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
79239657|NCT03654391|Dietary Supplement|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
79239658|NCT03654391|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
79239659|NCT04484675|Drug|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
79379472|NCT05655598|Drug|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
79379473|NCT05655598|Drug|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
79391306|NCT00619528|Biological|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
79835770|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835771|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835772|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835773|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79689927|NCT04634071|Drug|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
79689928|NCT04634071|Behavioral|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
79835774|NCT00984646|Drug|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
79835775|NCT03991585|Behavioral|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
79835776|NCT00901407|Drug|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
79835777|NCT00901407|Drug|placebo|placebo: 1-2 tablets bid; 10 weeks
79835778|NCT00901407|Drug|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
79239660|NCT04484675|Drug|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
79379474|NCT05655234|Behavioral|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
79533767|NCT05868005|Other|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
79239661|NCT03658109|Drug|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
79239662|NCT03658109|Procedure|QL block|Patients will undergo a posterior QL block pre-operatively
79239663|NCT03658109|Drug|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
79533768|NCT05867550|Drug|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
79533769|NCT05867550|Drug|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
79533770|NCT05867550|Drug|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
79689929|NCT04634071|Behavioral|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
79689930|NCT04634071|Other|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
79835779|NCT01052155|Other|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
79835780|NCT00896883|Device|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
79239664|NCT03658109|Procedure|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
79239665|NCT03654313|Biological|MEDI6570|MEDI6570
79239666|NCT03654313|Biological|Placebo|Placebo
79835781|NCT00984724|Behavioral|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
79835782|NCT00984724|Behavioral|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
79835783|NCT00984724|Behavioral|Quitline|Letter referring participants to a Quitline providing quit smoking services.
79835784|NCT00984724|Behavioral|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
80007121|NCT05082532|Other|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
79239667|NCT03654313|Biological|Part B Placebo|Placebo
79239668|NCT03660995|Behavioral|Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.|"Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child."
79239669|NCT03654235|Other|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
79835785|NCT04035915|Procedure|Limited driving pressure|Keep driving pressure <15 cmH2O
79239670|NCT03654235|Other|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
79379475|NCT05655234|Behavioral|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
79533771|NCT05867550|Drug|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
79689931|NCT04634071|Drug|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
79379476|NCT05652296|Device|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
79379477|NCT05651867|Device|EPIONE device|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
79689932|NCT04632433|Drug|Cemiplimab|350 mg every 3 weeks
79689933|NCT04622293|Drug|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
79835786|NCT04035915|Procedure|Conventional mechanical ventilation strategies|Keep tidalvolume </= 8
79533772|NCT05866809|Drug|HK-660S|Administered orally
79689934|NCT04622293|Drug|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
79835787|NCT00972400|Genetic|protein analysis|
80007122|NCT05079724|Procedure|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
80007123|NCT02835690|Biological|Pembrolizumab|IV infusion
80007124|NCT04629820|Device|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
80007125|NCT02486224|Dietary Supplement|Kona Deep|Subjects will receive Kona Deep post exercise
80007126|NCT02486224|Dietary Supplement|Spring Water|Subjects will receive Spring Water post exercise
79239671|NCT03654235|Other|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
79533773|NCT05866809|Drug|Placebo|Administered orally
79533774|NCT05863806|Other|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
79533775|NCT05863806|Other|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
79689935|NCT04613999|Drug|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
79689936|NCT04608773|Other|Remineralizing Extreme Dry Mouth Spray with Xylitol|oral hydrating spray
79533776|NCT05861583|Other|fat tissue|fat tissue sample collected while cosmetical liposuction
79239672|NCT03658031|Drug|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
79239673|NCT03660917|Drug|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
79239674|NCT03660917|Drug|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
79533777|NCT05861583|Other|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
79533778|NCT05861583|Other|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
79689937|NCT04608773|Device|Alcohol-Free Moisturizing Dry Mouth Spray|oral hydrating spray
79835788|NCT00972400|Other|laboratory biomarker analysis|
79835789|NCT00972400|Other|mass spectrometry|
79835790|NCT00972400|Other|questionnaire administration|
79835791|NCT00972400|Procedure|assessment of therapy complications|
79835792|NCT00972400|Procedure|cognitive assessment|
79835793|NCT00972400|Procedure|quality-of-life assessment|
79835794|NCT00896961|Drug|EF5|
79835795|NCT00896961|Other|diagnostic laboratory biomarker analysis|
79835796|NCT00896961|Other|pharmacological study|
79835797|NCT00984802|Drug|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
79835798|NCT00984802|Drug|Placebo control|Vehicle solution for IV administration single dose.
80007127|NCT02486224|Dietary Supplement|Sports Drink|Subjects will receive Sports Drink post exercise
79689938|NCT04601532|Device|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
79689939|NCT04601532|Drug|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
79689940|NCT04599660|Other|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
79835799|NCT00901563|Drug|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
79835800|NCT00901563|Other|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
79835801|NCT00901641|Device|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
79835802|NCT00972556|Drug|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
79835803|NCT00972556|Drug|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
79835804|NCT00897039|Other|flow cytometry|
79835805|NCT00897039|Other|immunohistochemistry staining method|
79835806|NCT00984880|Drug|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
79835807|NCT02540499|Radiation|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
79835808|NCT00972634|Other|computer-assisted intervention|symptom assessment
79835809|NCT00972634|Other|questionnaire administration|Symptom assessment
79533779|NCT05861583|Other|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
79835810|NCT00972634|Procedure|assessment of therapy complications|Symptom assessment
79533780|NCT05859308|Other|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
79835811|NCT00972634|Procedure|quality-of-life assessment|Symptom assessment
79835812|NCT00901719|Drug|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
79835813|NCT00901719|Drug|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
79835814|NCT00901719|Drug|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
79835815|NCT00901719|Drug|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
79239675|NCT02573259|Drug|PF-06801591|IV every 21 days (Part 1)
79239676|NCT02573259|Drug|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
79239677|NCT02785991|Procedure|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
79239678|NCT02977507|Other|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
79239679|NCT02977507|Drug|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
79239680|NCT02977507|Other|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
79239681|NCT02977507|Other|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
79239682|NCT02977507|Other|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
79239683|NCT03657953|Other|surgical approach|
79239684|NCT03622177|Procedure|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
79533781|NCT05859308|Other|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
79533782|NCT05856591|Behavioral|Food Resources & Kitchen Skills (FoRKS)|Food Resources & Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
79533783|NCT05856591|Behavioral|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
79533784|NCT05854251|Drug|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
79533785|NCT05854251|Drug|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
79547183|NCT01552122|Drug|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
79379478|NCT05646472|Diagnostic Test|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
79379479|NCT05644132|Device|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
79379480|NCT05643027|Behavioral|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
79835816|NCT00972712|Drug|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
80007128|NCT03564834|Procedure|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
80007129|NCT03564834|Procedure|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
79835817|NCT00984958|Device|Bulkamid|injection of Bulkamid in the urethra
79835818|NCT00984958|Device|Bulkamid expectation|expectance
79835819|NCT00897273|Genetic|comparative genomic hybridization|
79835820|NCT00897273|Genetic|gene expression analysis|
80007130|NCT02033980|Device|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
80007131|NCT05352906|Diagnostic Test|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
80007132|NCT03564210|Behavioral|Screen time permitted|Cohort will not be directed to abstain from screen time
80007133|NCT03564210|Behavioral|Screen Time Abstain|Cohort will be directed to abstain from screen time
80007134|NCT04496986|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
80007135|NCT04496986|Diagnostic Test|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
80007136|NCT04496986|Other|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
80007137|NCT04496986|Other|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
80007138|NCT04496986|Other|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
79835821|NCT00897273|Other|study of socioeconomic and demographic variables|
79835822|NCT00897273|Procedure|evaluation of cancer risk factors|
80007139|NCT04496986|Diagnostic Test|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
80007140|NCT02837952|Drug|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
79835823|NCT00897273|Procedure|study of high risk factors|
79835824|NCT04007302|Other|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
80007141|NCT02837952|Drug|Placebo|Placebo
80007142|NCT02832167|Biological|Nivolumab|Specified dose on specified days
79239685|NCT03622177|Biological|blood drawn|Additional blood drawn by venepuncture
79239686|NCT04471415|Drug|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
79239687|NCT04471415|Biological|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
79239688|NCT02976103|Device|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
79239689|NCT02976103|Other|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
79533786|NCT05849753|Device|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
79533787|NCT05848947|Drug|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
79533788|NCT05847426|Other|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
79835825|NCT04007302|Other|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
79835826|NCT04007302|Other|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
79835827|NCT00901797|Procedure|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
79835828|NCT00901797|Procedure|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
79835829|NCT02539641|Radiation|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
79835830|NCT02539641|Other|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
79835831|NCT00544882|Drug|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
79835832|NCT00544882|Drug|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
79835833|NCT00544882|Drug|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
79835834|NCT04035603|Drug|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
79835835|NCT04035603|Drug|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
79835836|NCT04035603|Behavioral|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
79835837|NCT04035603|Drug|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
79835838|NCT00606801|Drug|Galantamine|Galantamine 8 mg/day
79835839|NCT00606801|Drug|placebo|sugar pill
79835840|NCT00972790|Procedure|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
79835841|NCT04007458|Behavioral|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
79379481|NCT05639270|Device|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
79379482|NCT05629780|Drug|Resuscitation fluid|Cristalloid fluids given as a resuscitational intervention
79379483|NCT05621044|Behavioral|FitBrothers smartphone active app|The FitBrothers smartphone active app is designed to assist African American men with adopting and maintaining PA. The app will be developed with significant input from African American men and contain self-monitoring, goal setting, reward, and educational components. The app will include additional elements including PA adoption strategies, competitions, incentives, health information, and greater compatibility with activity monitoring devices. The intervention is based on the Social Cognitive and Self-Determination theories and is culturally tailored.
79533789|NCT05847426|Other|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
80007143|NCT04941040|Drug|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~Lidocaine loading dose 1.5 mg/kg i.v. infusion.~Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~Dexmedetomidine 0.25-0.5 μg/kg/h~Lidocaine 0.375-0.75 mg/kg/h~Ketamine 0.0625- 0.125 mg/kg/h"
80007144|NCT04941040|Drug|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
80007145|NCT03632395|Diagnostic Test|computed tomography|computed tomography
79533790|NCT05846932|Behavioral|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
79533791|NCT05846932|Behavioral|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
80007146|NCT04937374|Other|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
80007147|NCT04937374|Other|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
80007148|NCT05708430|Drug|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
79533792|NCT05842733|Drug|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
79533793|NCT05842733|Drug|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
79533794|NCT05842733|Drug|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
79533795|NCT05842239|Device|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
79533796|NCT05841420|Drug|Gemcitabine|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
79533797|NCT05841420|Drug|Nab paclitaxel|Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
79689942|NCT04590521|Biological|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
80007149|NCT04936516|Device|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
80007150|NCT00913705|Drug|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
80007151|NCT00913705|Drug|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
80007152|NCT00913705|Procedure|Surgery|Surgery
80007153|NCT04934410|Drug|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
79533798|NCT05838053|Procedure|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
79835842|NCT04007458|Behavioral|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
80007154|NCT04934410|Drug|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
80007155|NCT04934410|Drug|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
80007156|NCT02787239|Drug|HLX01|
80007157|NCT02787239|Drug|Rituximab|
80007158|NCT02787239|Drug|CHOP|
80007159|NCT03140956|Drug|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
80007160|NCT02681237|Drug|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
80007161|NCT02681237|Drug|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
80007162|NCT03141112|Procedure|renal replacement therapy|
80007163|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
80007164|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r ATLL
80007165|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r PTCL
80007166|NCT02674529|Drug|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
79835843|NCT00897351|Genetic|mutation analysis|
79239690|NCT03659279|Behavioral|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
79379484|NCT05621044|Behavioral|Nike Training Club|The app is designed to increase fitness in users through a variety of mechanisms. Users are able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior.
79379485|NCT05617742|Diagnostic Test|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
79689945|NCT04586270|Drug|TAS0612|oral tablets
80007167|NCT02674529|Drug|Placebo|Placebo
80007168|NCT02674529|Behavioral|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
80007169|NCT05082064|Diagnostic Test|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
79689946|NCT04584801|Device|Structured Light Plethysmography|"Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment"
79835844|NCT00897351|Genetic|polymorphism analysis|
80007170|NCT05000437|Other|HIIT|3x/week high intensity interval training for 12 weeks
80007171|NCT05250427|Other|No treatment given|No treatment given
80007172|NCT05081908|Procedure|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
79835845|NCT00897351|Genetic|protein expression analysis|
79835846|NCT00897351|Other|immunohistochemistry staining method|
79835847|NCT00897351|Other|laboratory biomarker analysis|
80007173|NCT01374035|Other|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
80007174|NCT02626949|Behavioral|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
80007175|NCT02626949|Behavioral|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
80007176|NCT03140878|Dietary Supplement|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
79239691|NCT03654001|Biological|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
79239692|NCT03654001|Other|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
79239693|NCT03659201|Drug|Neosil complete|Oral, during 24 weeks.
79239694|NCT03659201|Drug|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
79239695|NCT03659201|Drug|Neosil|Oral, during only 12 weeks.
79302997|NCT02447185|Drug|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
79689947|NCT04574505|Dietary Supplement|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
79689948|NCT04574505|Dietary Supplement|Placebo|Placebo
79689949|NCT04572815|Drug|Placebo Administration|Given IV and SC
80007177|NCT03140878|Dietary Supplement|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
79835848|NCT04008862|Behavioral|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
80007178|NCT01374113|Drug|50mg safinamide|50 mg safinamide on Day 1
80007179|NCT02666599|Radiation|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
79239696|NCT03653923|Behavioral|Exposure Therapy|"Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase."
79239697|NCT03653845|Procedure|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
79835849|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
79689950|NCT04572815|Other|Quality-of-Life Assessment|Ancillary studies
80007180|NCT04459936|Other|URICORI|Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
80007181|NCT04459936|Other|CONTROL|Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
79239698|NCT03653845|Drug|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
79239699|NCT04630977|Dietary Supplement|Multi-ingredient Pre-workout supplement|Every important issue has been detailed before.
79379486|NCT05605288|Procedure|Coronary angiography +/- percutaneous coronary intervention|Coronary angiography +/- percutaneous coronary intervention
79379487|NCT05604040|Behavioral|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
79533799|NCT05838053|Procedure|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
79533800|NCT05837156|Drug|Heptaflurane combined Cyclophenol|Heptaflurane combined Cyclophenol
79533801|NCT05837156|Drug|Heptaflurane|Heptaflurane only
79689951|NCT04572815|Other|Questionnaire Administration|Ancillary studies
79689952|NCT04572815|Biological|Ustekinumab|Given IV and SC
79689953|NCT04569331|Procedure|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
79835850|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|
80007182|NCT02616887|Radiation|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
80007183|NCT03632317|Drug|Panobinostat|30 mg/m^2
80007184|NCT03632317|Drug|Everolimus|3.0 mg/m^2
80007185|NCT04394494|Other|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
79239700|NCT04630977|Other|Progressive Resistance Training|The information about it has been detailed in advance.
79239701|NCT04630977|Behavioral|Nutritional Patterns Guideline|This intervention has also been described in advance.
79239702|NCT03470961|Drug|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
79379488|NCT05601869|Device|UNYQ Prosthetic Ankle-Feet System|The UNYQ system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
79379489|NCT05598580|Drug|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
79379490|NCT05598580|Drug|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
79379491|NCT05597280|Drug|BE-PEP Bedaquiline|bedaquiline
79533802|NCT05837156|Drug|Cyclophenol|Cyclophenol only
79533803|NCT05835427|Other|Cervical Extensor Stretch|Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
79835851|NCT00972868|Device|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
79835852|NCT00897429|Procedure|laboratory biomarker analysis|Correlative studies
79239703|NCT03470961|Drug|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
79379492|NCT05597280|Drug|SDR-PEP Rifampicin|SDR-PEP: rifampicin
79533804|NCT05835427|Other|Cervical Extensor Stretch|Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
79533805|NCT05834608|Behavioral|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
79835853|NCT00982306|Behavioral|Brief intervention|20 minute one to one counseling session
79835854|NCT00985036|Procedure|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
79835855|NCT00972946|Biological|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
79835856|NCT00972946|Drug|Administration of Endorem|single dose, intravenous
79835857|NCT00973180|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
79835858|NCT00606177|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
79835859|NCT00606177|Drug|placebo|oral, 0mg(4tablets)/day
79835860|NCT00985270|Drug|Rifampicin|
79239704|NCT03470883|Other|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (> 12 months)
79547184|NCT01552122|Drug|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
79835861|NCT00985270|Drug|Placebo|
79239705|NCT05017857|Device|RepetiveTranscrainal Magnetic Stimulation (rTMS)|RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.
79835862|NCT00359281|Drug|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
79835863|NCT00359281|Drug|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
79835864|NCT00359281|Drug|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
79835865|NCT00359281|Drug|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
79835866|NCT00359281|Drug|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
79835867|NCT00359281|Drug|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
79239706|NCT05017857|Behavioral|Problem-Solving Training (PST)|Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
79239707|NCT03130881|Drug|PLB1003|PLB1003 is a capsule and is administered orally.
79239708|NCT01066039|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
79379493|NCT05597280|Drug|BE-PEP Rifampicin|BE-PEP rifampicin
79379494|NCT05596175|Behavioral|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
79379495|NCT05593965|Device|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
79379496|NCT05593965|Device|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
79547185|NCT01552122|Other|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
79689954|NCT04569331|Procedure|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
79689955|NCT04565145|Drug|Kava Dietary Supplement|Participants will be given three 75mg kava capsules per day for one week
79835868|NCT00982384|Other|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
80007186|NCT04394494|Other|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
80007187|NCT02591784|Drug|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
79835869|NCT00982384|Other|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
80007188|NCT02591784|Radiation|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
79239709|NCT02919995|Drug|RPL554|RPL554 suspension administered using a nebuliser
79533806|NCT05832723|Device|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
79239710|NCT02919995|Drug|Placebo|Placebo solution administered using a nebuliser
79533807|NCT05832060|Device|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
79533808|NCT05832060|Device|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
79533809|NCT05832060|Device|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
79835870|NCT00982462|Dietary Supplement|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
79835871|NCT00982462|Dietary Supplement|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
79239711|NCT04972695|Diagnostic Test|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
79835872|NCT03992287|Dietary Supplement|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
79835873|NCT03992287|Dietary Supplement|Placebo|Placebo for 12 weeks
79239712|NCT04355793|Drug|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
79239713|NCT03653767|Device|Adjustable Furniture|The intervention will include adjustable school furniture.
79239714|NCT03653689|Dietary Supplement|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
79379497|NCT05593965|Device|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
79379498|NCT05593757|Drug|Quinidine|Oral quinidine
79835874|NCT02540343|Other|questionnaires|fill out all questionnaires twice
79835875|NCT00973258|Dietary Supplement|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
79835876|NCT00973258|Other|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
79835877|NCT00973258|Other|Cognitive Training|"The proposed cognitive training intervention program comprises:~Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
79835878|NCT00973258|Other|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
79835879|NCT00973258|Other|Placebo|Participants will receive their usual diet and placeboes.
79302998|NCT05714813|Behavioral|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
79379499|NCT05593757|Drug|Verapamil|Oral verapamil
79379500|NCT05586451|Behavioral|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
79835880|NCT00902031|Drug|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
79835881|NCT00902031|Drug|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
79835882|NCT03991039|Radiation|Gamma knife|Microvascular decompression
79835883|NCT00897663|Genetic|gene expression analysis|
79835884|NCT00897663|Genetic|microarray analysis|
79689956|NCT04565145|Drug|Placebo|Participants will be given three placebo capsules per day for one week
79835885|NCT00897663|Genetic|protein expression analysis|
79835886|NCT00897663|Other|diagnostic laboratory biomarker analysis|
79835887|NCT00897663|Other|immunohistochemistry staining method|
79835888|NCT00985348|Drug|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
79835889|NCT00973336|Drug|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
79835890|NCT00902109|Device|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
79835891|NCT00902109|Device|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
79835892|NCT00902109|Device|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
79835893|NCT03991273|Other|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
79835894|NCT03991273|Other|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
79835895|NCT00973414|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
79835896|NCT00973414|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
79239715|NCT03653689|Dietary Supplement|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
79239716|NCT03653689|Dietary Supplement|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
79835897|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
79239717|NCT04396379|Device|Implant an epicardial device to reshape the mitral valve annulus|The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
79533811|NCT05823077|Other|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
79533812|NCT05823077|Other|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
79533813|NCT05818852|Drug|VX-548|Tablets for oral administration.
79533814|NCT05818852|Drug|Moxifloxacin|Capsules for oral administration.
79533815|NCT05818852|Drug|Moxifloxacin Placebo|Capsules for oral administration.
79533816|NCT05818852|Drug|VX-548 Placebo|Tablets for oral administration.
79835898|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
79689957|NCT04564963|Other|Cryotherapy|Application of cryotherapy (e.g. ice in resealable zipper storage bags, gel packs, ice packs) over largest closed incision in the post-operative period every 4 hours, at minimum, for up to 72 hours (while participant is awake and admitted to hospital). The cryotherapy should not be placed in direct contact with skin.
79689958|NCT04560894|Drug|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
79689959|NCT04560894|Drug|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
79689960|NCT04560894|Drug|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
79689961|NCT04550962|Drug|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
79835899|NCT01052233|Procedure|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
79835900|NCT01052233|Procedure|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
79835901|NCT00902343|Procedure|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
79835902|NCT00902343|Procedure|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
79835903|NCT01052311|Drug|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
79835904|NCT01052311|Drug|Placebo|Placebo tablets once daily
79835905|NCT01052311|Drug|Tredaptive|Tredaptive 1 g [Laropiprant 20 mg(LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
79835906|NCT00988078|Drug|Placebo|Capsule (without biologic action) administered three times a day for six months
80007189|NCT05203003|Other|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
79835907|NCT00988078|Drug|Metformin|Metformin 500mg three times a day for six months
80007190|NCT03116399|Behavioral|PRISM 2.0 Condition|Access to the PRISM 2.0 program
79835908|NCT00895089|Drug|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
80007191|NCT03116399|Behavioral|Tablet Condition|Access to the tablet
80007192|NCT02653963|Drug|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
80007193|NCT02623933|Radiation|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
80007194|NCT05092997|Diagnostic Test|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL >200 c/ml will receive additional adherence counseling, following the STREAM protocol, [26] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
80007195|NCT05092997|Other|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
80007196|NCT03939364|Drug|SBS-101|Isotretinoin Oral-Adhesive Film
80007197|NCT03939364|Drug|Placebo|Placebo
80007198|NCT05418829|Drug|AT-007|AT-007 20 mg/kg once daily
80007199|NCT04288960|Device|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
80007200|NCT03097861|Drug|Lubiprostone|24 mcg administered orally BID
80007201|NCT03097861|Drug|Placebo|24 mcg administered orally BID
80007202|NCT04215562|Combination Product|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
80007203|NCT03137914|Biological|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
80007204|NCT03137914|Procedure|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
79835909|NCT00895089|Drug|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
79533819|NCT05813392|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
79533820|NCT05813041|Device|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
80007205|NCT03137758|Drug|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
80007206|NCT05087927|Behavioral|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
79533821|NCT05812261|Other|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
79533822|NCT05803733|Other|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
80007207|NCT05087927|Behavioral|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
80007208|NCT05087927|Behavioral|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
80007209|NCT05087927|Behavioral|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
80007210|NCT01376141|Drug|Sumatriptan|
80007211|NCT04180852|Other|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
80007212|NCT03861689|Diagnostic Test|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
80007213|NCT03137680|Behavioral|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
79835910|NCT00982540|Drug|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
79835911|NCT00897741|Genetic|microarray analysis|
79835912|NCT00897741|Other|laboratory biomarker analysis|
79835913|NCT04674358|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
79835914|NCT04674358|Drug|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
79835915|NCT00897819|Genetic|DNA methylation analysis|
79835916|NCT00897819|Genetic|loss of heterozygosity analysis|
79835917|NCT00897819|Genetic|microsatellite instability analysis|
79835918|NCT00897819|Other|laboratory biomarker analysis|
79689962|NCT04549311|Drug|Antibiotic 1 arm (amoxicillin + clavulanic acid)|Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
79689963|NCT04549311|Drug|Antibiotic 2 arm (ciprofloxacin + metronidazole)|Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
79835919|NCT00366535|Drug|Placebo|4 tabs b.i.d.
79835920|NCT00366535|Drug|Neurotropin|4 tabs b.i.d.
80007214|NCT03215914|Device|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
79239718|NCT04457427|Device|NeuRx Diaphragm Pacing System (DPS)|4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
79239719|NCT04457583|Device|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
79302999|NCT05714813|Behavioral|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
79303000|NCT05714735|Radiation|Cerebral Venography|Cerebral Venography Observation by DSA examinations
79379501|NCT05586451|Behavioral|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
79533823|NCT05803733|Other|Routine strength training|range of motion exercises and strength training
79533824|NCT05801341|Device|Lollipop|An oral lollipop swab will be obtained by placing a flocked swab into the mouth and sucking on the swab for 20 seconds as one would suck on a lollipop
79533825|NCT05801315|Device|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
79533826|NCT05801315|Device|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
79533827|NCT05800444|Drug|BAY3283142|Oral administration as tablet.
79533828|NCT05800444|Other|Placebo|Oral administration as tablet.
79533829|NCT05798403|Device|electroacupuncture|"All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used."
79533830|NCT05798403|Drug|Solifenacin Succinate Tablets|"During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out."
79835921|NCT00982618|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
79835922|NCT00982618|Procedure|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
79835923|NCT00982618|Drug|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
79835924|NCT00895167|Dietary Supplement|curcumin|one oral dose of 12 caplets = 12 g curcumin
79835925|NCT00988234|Procedure|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
79835926|NCT00988234|Procedure|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
79835927|NCT00988234|Procedure|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
79835928|NCT00988234|Procedure|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
79835929|NCT00902421|Drug|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
79835930|NCT00902421|Drug|Antimuscarinics|Antimuscarinics for 3 months
79835931|NCT00985660|Drug|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
79835932|NCT00985660|Drug|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
79239720|NCT03109821|Other|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
79533831|NCT05783596|Drug|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
79533832|NCT05783596|Drug|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
79533833|NCT05783141|Dietary Supplement|New prebiotic follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
79533834|NCT05783141|Dietary Supplement|Standard follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
79533835|NCT05780853|Diagnostic Test|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
79533836|NCT05780853|Diagnostic Test|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
79533837|NCT05780853|Other|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
79533838|NCT05776667|Radiation|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
79533839|NCT05772429|Drug|Epidiolex|Administered as an oral solution
79689964|NCT04548661|Procedure|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
79835933|NCT00350545|Drug|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
79835934|NCT00350545|Drug|Prednisone|1 mg/kg; po per day with taper
79239721|NCT05156697|Dietary Supplement|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
79835935|NCT00350545|Drug|Cyclosporine A|trough 200-300 or lower; po
79239722|NCT05156697|Other|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
79239723|NCT04217967|Drug|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
79379502|NCT05586451|Behavioral|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
79533840|NCT05772221|Other|Screening|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
79533841|NCT05761873|Other|Provision of audit and feedback via email and paper|Provision of A&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
79533842|NCT05761873|Other|Provision of audit and feedback via paper only|Provision of A&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
79533843|NCT05759182|Device|pediatric/adolescent exoskeleton walking system|A pediatric/adolescent exoskeleton will be differentially applied according to each patient's gait level, 30 minutes a day, 3 times a week, 24 times in total for 8 weeks. When applying the intervention, the use of an appropriate stabilizing device (crutches, cane, harness, etc.) will be used according to the gait level of the study subject.
79533844|NCT05748821|Device|Delfi Personal Tourniquet Systems|Measure within & between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
79835936|NCT00350545|Drug|tacrolimus|trough 5-10 or lower; po
79835937|NCT04006054|Drug|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
79835938|NCT04006054|Drug|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
79835939|NCT00897975|Dietary Supplement|red yeast rice|600 mg 3 capsules bid
79835940|NCT00897975|Drug|phytosterol|phytosterol 450 mg 2 tabs bid with food
79835941|NCT00897975|Behavioral|therapeutic lifestyle program|TLC - 12 weeks
79835942|NCT00897975|Drug|placebo|placebo
79835943|NCT00985816|Dietary Supplement|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
79835944|NCT00985816|Dietary Supplement|Placebo|Placebo
79835945|NCT01052389|Drug|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
79835946|NCT01052389|Drug|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
79239724|NCT04217967|Drug|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
79239725|NCT02919761|Drug|Acthar Gel|80 Units Acthar Gel per 1 mL for subcutaneous injection
79689965|NCT04548661|Procedure|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
79689966|NCT04547868|Other|Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
79835947|NCT01052389|Drug|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
79239726|NCT02919761|Drug|Placebo|Matching placebo 1 mL for subcutaneous injection
79835948|NCT02539485|Other|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
79835949|NCT01052467|Drug|Xamiol® Gel|Once daily application for about 4 weeks
79835950|NCT05277987|Drug|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10^6 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
79835951|NCT05277987|Drug|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10^6.5 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group.
79835952|NCT05277987|Drug|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10^7 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group.
79239727|NCT04211181|Other|The multifaceted interventions|"An evidence-based clinical guideline and pathway in hospital.~A series Written care protocols for the implementation of performance measures.~A computer-based clinical decision support system(CDSSs) and a computerized reminder, which was referred to as a key element to enhance VTE assessment and prophylaxis. A well-designed computer program will be integrated into the Electronic Medical Record(EMR) of intervention group and By processing, analyzing, summarizing and representing crucial information, physicians can be altered.~A full-time quality coordinator~A trained physician or nurse in each intervention cluster will be acted as a quality coordinator. The responsibility of the quality coordinator includes:"
79239728|NCT04211181|Other|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
79239729|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
79239730|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
79239731|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
79239732|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
79239733|NCT04458285|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
79533845|NCT05726461|Device|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
79533846|NCT05726461|Device|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
79533847|NCT05725291|Drug|AMT-116|Administered intravenously
79533848|NCT05717530|Procedure|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
79835953|NCT00895323|Other|enzyme-linked immunosorbent assay|
79835954|NCT00895323|Other|pharmacological study|
79239734|NCT04458285|Drug|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
79239735|NCT05156541|Drug|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
79303001|NCT05714657|Radiation|adjuvant radiotherapy|Shortened Course Adjuvant Radiotherapy Following TORS
79835955|NCT00895323|Procedure|whole-body scintigraphy|
79835956|NCT00895323|Radiation|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
79835957|NCT00898053|Other|laboratory biomarker analysis|Correlative studies
79835958|NCT00349921|Drug|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
79835959|NCT00349921|Drug|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
79835960|NCT00349921|Drug|placebo|inactive substance
79835961|NCT00349921|Drug|placebo|inactive substance
79835962|NCT00902655|Drug|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
79303002|NCT03118219|Other|Positive adjustment coping intervention|see arm description
79303003|NCT03118219|Other|Brainteaser|see arm description
79533849|NCT05717530|Procedure|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
79239736|NCT03469869|Other|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
79239737|NCT01067105|Drug|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
79239738|NCT03470727|Device|Citrate dialysate|Change form acetate to citrate dialysate
79239739|NCT03657719|Biological|GC3114|High-dose Quadrivalent influenza vaccine
79689967|NCT04547868|Other|Decaffeinated Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of decaffeinated coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
79835963|NCT01052623|Drug|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
79239740|NCT03657719|Biological|GCFLU Quadrivalent|Quadrivalent influenza vaccine
79239741|NCT03924765|Device|Powered hip exoskeleton|The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
79533850|NCT05712096|Drug|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
79835964|NCT00902733|Other|medical chart review|
80007215|NCT03691402|Behavioral|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
79239742|NCT02910089|Behavioral|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
79239743|NCT02985515|Behavioral|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
79239744|NCT03470649|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
79239745|NCT03657563|Other|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
80007216|NCT03691402|Behavioral|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
79533851|NCT05698745|Procedure|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
79533852|NCT05687825|Procedure|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
79835965|NCT00902733|Other|questionnaire administration|
79835966|NCT00902733|Procedure|fatigue assessment and management|
79835967|NCT00902733|Procedure|psychosocial assessment and care|
79533853|NCT05686031|Other|No interventions were done between groups|No interventions were done between groups
79547186|NCT01552122|Dietary Supplement|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
79835968|NCT00902733|Procedure|quality-of-life assessment|
79835969|NCT01058785|Biological|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
79835970|NCT00898209|Genetic|protein expression analysis|Blood and exhaled breath condensate will be collected.
79835971|NCT00898209|Genetic|proteomic profiling|Blood and exhaled breath condensate will be collected.
79835972|NCT00898209|Other|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
79835973|NCT00898209|Other|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
79835974|NCT00898209|Other|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
79835975|NCT00898209|Other|questionnaire administration|Questionnaire will be completed.
80007217|NCT03636100|Device|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
80007218|NCT01816139|Drug|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
80007219|NCT01816139|Drug|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
79689968|NCT04547868|Other|Warm water|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of warm water will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
79835976|NCT01325077|Other|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
79533854|NCT05684042|Other|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
79239746|NCT03657329|Diagnostic Test|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
79379503|NCT05586087|Other|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
79379504|NCT05569941|Drug|ABI-4334 Tablet|ABI-4334 Tablet
79379505|NCT05569941|Drug|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
79835977|NCT00902811|Drug|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
79835978|NCT00902811|Drug|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
79835979|NCT00902811|Drug|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
79835980|NCT00902811|Drug|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group <6yrs of age, a subdivision according to weight is made
79835981|NCT00902811|Drug|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
80007220|NCT03443674|Drug|SCB-313|Lyophilized powder in a single-use vial
80007221|NCT01100879|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
79379506|NCT05567393|Drug|TAK-951 Placebo|TAK-951 placebo-matching SC injection
80007222|NCT05070689|Procedure|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
80007223|NCT00904553|Radiation|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
79379507|NCT05567393|Drug|TAK-951|TAK-951 SC injection
79533855|NCT05676853|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
79547187|NCT01552122|Dietary Supplement|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
79547188|NCT01552122|Other|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
79379508|NCT05563181|Behavioral|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
79379509|NCT05563181|Behavioral|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
79379510|NCT05563181|Behavioral|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
79379511|NCT05562713|Behavioral|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
79379512|NCT05562713|Behavioral|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
79239747|NCT02696759|Other|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
79379513|NCT05562310|Drug|Total parenteral nutrition (TPN). This is total nutrition provided by central vein.|phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
79835982|NCT04035681|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
79689969|NCT04528836|Drug|BBP-398 (Formerly known as IACS-15509)|oral capsules
79835983|NCT04035681|Other|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
79379514|NCT05561790|Behavioral|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
79835984|NCT02539173|Other|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
79835985|NCT00898287|Drug|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
79835986|NCT00898287|Drug|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
79835987|NCT02539251|Behavioral|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
79835988|NCT04034823|Biological|KN035|KN035 5 mg/kg s.c. Q3W
79835989|NCT04034823|Biological|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
79835990|NCT04034823|Drug|Docetaxel|100 mg/m2 Q3W IV
79835991|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
79239748|NCT03706911|Drug|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
79379515|NCT05560113|Other|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
79689970|NCT04523766|Behavioral|Mindfulness of Breath|The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.
79689971|NCT04523766|Behavioral|Mindful Interoceptive Mapping|The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
79689972|NCT04517838|Procedure|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
79689973|NCT04507360|Behavioral|Study 1, Generic Response|Participants will be provided with the generic/current response to screening.
79689974|NCT04507360|Behavioral|Study 1, Tailored Response|Participants will be provided with a response to screening that is tailored to the match between screening score (above or below depression criteria) and expressed need for mental health support (yes or no).
79689975|NCT04507360|Behavioral|Study 1, Top Resources|Participants will be provided with links to the top list of 4 MHA resources.
79689976|NCT04507360|Behavioral|Study 1, Tailored Resources by Desired Resources|Participants will be provided with links to MHA resources aligned with their expressed interest (e.g., additional screening, self help tools).
79689977|NCT04507360|Behavioral|Study 1, Embedded single-question DIY|A single DIY question will be embedded within the content page.
79689978|NCT04507360|Behavioral|Study 1, Embedded full DIY within content page|The full DIY tool will be embedded within the content page.
79689979|NCT04507360|Behavioral|Study 1, Single question plus full DIY|A single question plus the full DIY tool will be embedded within the content page.
79689980|NCT04507360|Behavioral|Study 1, Content-as-usual|The content page will not include any embedded DIY tool.
79835992|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
79835993|NCT00895401|Dietary Supplement|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
79689981|NCT04507360|Behavioral|Study 2, Control|Participants in the DIY control group will receive psychoeducation materials in W0. They will view content as usual (no DIY).
79835994|NCT00895401|Other|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
79835995|NCT00606021|Drug|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
79835996|NCT00606021|Drug|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
79835997|NCT00337675|Drug|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
79835998|NCT00337675|Drug|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
79835999|NCT00337675|Drug|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
79836000|NCT00898521|Drug|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
79836001|NCT03985579|Other|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
79836002|NCT00902967|Drug|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
79239749|NCT03469635|Other|Nutritional deficiencies in pregnant women after bariatric surgery|compare maternal nutritional parameters and neonatal outcomes after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) and to assess the impact of nutritional alterations on fetal growth.
79239750|NCT02910011|Drug|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
79239751|NCT03472131|Procedure|Unilateral Posterolateral Approach and Debridement|
79379516|NCT05560113|Other|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
79379517|NCT05556434|Diagnostic Test|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
79533856|NCT05675306|Behavioral|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal & Gildersleeve-Neumann, 2011; Maas & Farinella, 2012; Maas et al., 2019; Strand & Debertine, 2000; Strand & Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
79689982|NCT04507360|Behavioral|Study 2, DIY tool without AI|Participants in the DIY tool without AI group will be instructed to use the DIY tool 3 times a week.
79239752|NCT03472131|Other|Titanium cage insertion supplemented by screw fixation|
79239753|NCT03657485|Dietary Supplement|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
79239754|NCT03472053|Drug|BIO-11006 plus standard of care|BIO-11006 is administered 125mg BID plus standard of care.
79239755|NCT03472053|Drug|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
79239756|NCT03657017|Diagnostic Test|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
79239757|NCT02908841|Device|Surgicel Snow|
79379518|NCT05548283|Drug|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
79379519|NCT05548283|Drug|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
79533857|NCT05672316|Biological|Balstilimab|Given IV
79533858|NCT05672316|Procedure|Biospecimen Collection|Undergo collection of blood
79689983|NCT04507360|Behavioral|Study 2, DIY tool with AI|Participants in the DIY tool with AI group will be instructed to use the DIY tool with AI 3 times a week.
79689984|NCT04507360|Behavioral|Study 1, Tailored Resources by Demographics|Participants will be provided with links to MHA resources tailored to sexuality (Lesbian, Gay, Bisexual, Transgender, or Queer) status and age range.
79689985|NCT04500665|Drug|Colchicine|Colchicine
79689986|NCT04500665|Drug|Placebo|Placebo
79836003|NCT00902967|Drug|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
79836004|NCT01324921|Other|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
79836005|NCT01324921|Other|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
79836006|NCT01324921|Other|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
79836007|NCT00898599|Dietary Supplement|Prebiotic|Inulin type fructooligosaccharides
80007224|NCT05392660|Other|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling & squatting positions )
79533859|NCT05672316|Biological|Botensilimab|Given IV
79239758|NCT02908841|Other|Standard of Care|
79379520|NCT05547672|Device|UroMems artificial urinary sphincter|Implantation of the device
79533860|NCT05672316|Procedure|Computed Tomography|Undergo CT
79533861|NCT05672316|Drug|Regorafenib|Given PO
79689987|NCT04498715|Procedure|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
79689988|NCT04498715|Drug|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
79533862|NCT05671172|Drug|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
79689989|NCT04498715|Device|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
79689990|NCT04494347|Procedure|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
79689991|NCT04488250|Other|Robot Therapy|Robot Therapy
79689992|NCT04482179|Device|Active TMS|Active TMS will be delivered at 100% motor threshold
79239759|NCT04706559|Drug|Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii|Interventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients).
79239760|NCT04706559|Drug|Conventional treatment|topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
79239761|NCT04457037|Biological|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells
79239762|NCT04456803|Drug|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
79239763|NCT04456803|Drug|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
79239764|NCT02909153|Drug|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
79239765|NCT03470571|Diagnostic Test|CMR|Outcome analysis of CMR features in suspected myocarditis patients
79239766|NCT02522949|Device|ColdZyme® mouth spray|
79379521|NCT05540210|Device|measurement of PSP|one or two blood samples
79239767|NCT02522949|Device|Placebo|
79379522|NCT05539196|Device|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
79379523|NCT05532618|Procedure|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
79379524|NCT05532618|Drug|Levobupivacaine|Levobupivacaine
79379525|NCT05532618|Drug|Placebo|10 ml of sodium chloride 0.9%
79379526|NCT05530304|Device|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
79379527|NCT05527704|Drug|salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
79379528|NCT05527704|Drug|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
79533863|NCT05671172|Drug|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
79533864|NCT05664646|Device|DS8R|transcutaneous stimulation of the spinal cord.
79533865|NCT05664646|Other|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
79533866|NCT05664646|Other|Cool Environment|Study 2 will be completed in a cool environment setting.
79533867|NCT05659719|Other|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
79533868|NCT05652413|Behavioral|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
79533869|NCT05651438|Other|Assessment|Assessment of pain, fatigue, sleep quality, and e-sports-specific features
79689993|NCT04482179|Behavioral|CILT|60-90 minutes of CILT will be administered during each treatment session
79689994|NCT04482179|Device|Sham TMS|Sham TMS will be administered
80007225|NCT01374191|Drug|onabotulinum toxin type-A|1 injection of Btx-A
79836008|NCT00898599|Dietary Supplement|Placebo|Maltodextrin as placebo
79836009|NCT01055665|Other|cognitive behavior therapy|6 cognitive behavior therapy groups
79379529|NCT05526222|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
79689995|NCT04482140|Device|Genta-Foil resorb®|Use of Genta-Foil resorb® to prevent adhesions in patients undergoing hand surgery
79836010|NCT00903045|Drug|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
79836011|NCT00903045|Drug|Placebo|Identical placebo twice a day
80007226|NCT01374191|Other|placebo|1 injection of saline solution
79239768|NCT02908529|Drug|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
79239769|NCT02908529|Drug|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
79239770|NCT04456725|Behavioral|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
79239771|NCT04456725|Behavioral|Control|Usual care
79689996|NCT04477356|Procedure|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
79836012|NCT02539095|Device|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
79836013|NCT02539095|Device|Normal saline|"Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
79239772|NCT04989543|Diagnostic Test|vaginal swabs|"Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab"
79836014|NCT00337285|Drug|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
79836015|NCT03991117|Behavioral|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
79836016|NCT04035525|Dietary Supplement|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
80007227|NCT01374191|Drug|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
80007228|NCT04021810|Device|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
79239773|NCT02443181|Device|Activa PC+S|Implementation of closed loop DBS for essential tremor
79239774|NCT03656861|Other|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
79239775|NCT03130803|Behavioral|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
79239776|NCT02984267|Device|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
79239777|NCT02984267|Other|Palpation|Using palpation only to evaluate the spine prior to epidural placement
79239778|NCT03130725|Procedure|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
79239779|NCT03130725|Procedure|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
79303004|NCT05714579|Procedure|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
79379530|NCT05523856|Procedure|Active Surveillance|It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
79533870|NCT05650645|Drug|incobotulinum toxin A|The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
79533871|NCT05650645|Drug|Placebo-Saline|Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
80007229|NCT04021810|Device|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
80007230|NCT03140098|Device|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
79239780|NCT04579575|Device|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
79836017|NCT04035525|Dietary Supplement|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
79379531|NCT05523856|Procedure|Robot-Assisted Radical Prostatectomy|It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
79379532|NCT05523856|Radiation|Intensity-Modulated Radiotherapy|Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
79533872|NCT05650359|Device|OrthoPulse|"The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners."
79689997|NCT04477356|Procedure|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
79836018|NCT04035525|Dietary Supplement|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
79836019|NCT04035057|Other|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
79836020|NCT04035057|Other|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
79836021|NCT04034979|Behavioral|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
79836022|NCT00905853|Procedure|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
79836023|NCT00905853|Drug|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
80007231|NCT03140020|Procedure|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
80007232|NCT03140020|Procedure|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
80007233|NCT03764735|Drug|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
79239781|NCT03469557|Drug|Tislelizumab|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
79379533|NCT05523856|Radiation|Real-time brachytherapy|Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
80007234|NCT03764735|Drug|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
79689998|NCT04475393|Device|Carmat Total Artificial Heart|Heart Replacement Therapy
79689999|NCT04474106|Device|Shock waves|The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.
79836024|NCT00905931|Drug|Lycopene|30 mg oral, daily, for 21 days
79690000|NCT04474106|Device|dummy head|The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves
79690001|NCT04458584|Procedure|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
79690002|NCT04458584|Procedure|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
79836025|NCT00905931|Drug|placebo|starch
79836026|NCT02540187|Other|blood specimen|
79836027|NCT04035291|Other|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
79836028|NCT00898833|Other|laboratory biomarker analysis|
79836029|NCT04035135|Drug|ANX005|investigational drug
79690003|NCT04458584|Procedure|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
79836030|NCT04035135|Drug|Intravenous immunoglobulin|investigational drug
79836031|NCT00898911|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
79836032|NCT04034745|Drug|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
79836033|NCT00903279|Drug|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
79836034|NCT00903279|Drug|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
79836035|NCT00903435|Other|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
79836036|NCT02539017|Drug|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
79836037|NCT02539017|Biological|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
79836038|NCT04034667|Other|No intervention|No intervention
79836039|NCT00605865|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
79379534|NCT05520476|Device|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
79836040|NCT00899145|Other|Laboratory Biomarker Analysis|Correlative studies
79836041|NCT00922467|Drug|NaCl 9/00|Same volume as in the esmolol group
80007235|NCT03764735|Drug|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
79379535|NCT05518669|Device|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
79379536|NCT05517837|Drug|BMS-986421|Specified dose on specified days
79379537|NCT05517837|Other|Placebo|Specified dose on specified days
79690004|NCT04433741|Drug|Oxytocin|Oxytocin administered intravenously
79836042|NCT00922467|Drug|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
79836043|NCT00903747|Drug|prucalopride|2-10 mg prucalopride
79836044|NCT00903747|Drug|moxifloxacin|400 mg moxifloxacin (Group 2a)
79836045|NCT00903747|Drug|placebo|placebo (Group 2b)
79836046|NCT02538627|Drug|MM-151|MM-151
79836047|NCT02538627|Drug|MM-121|MM-121
79836048|NCT02538627|Drug|MM-141|MM-141
79836049|NCT02538627|Drug|trametinib|trametininb
79836050|NCT00899457|Genetic|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
79836051|NCT00899457|Other|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
79379538|NCT05517707|Device|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
79379539|NCT05516797|Device|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
79533873|NCT05650359|Other|No intervention|No intervention
79533874|NCT05647317|Other|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
79533875|NCT05645978|Device|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
79533876|NCT05645965|Device|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
79533877|NCT05645939|Other|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
79533878|NCT05645926|Procedure|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
79690005|NCT04433741|Drug|Placebo|Placebo administered intravenously
79836052|NCT00899457|Other|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
79836053|NCT00899457|Procedure|bronchoscopy|Collection of breath condensate.
79836054|NCT00906321|Behavioral|Web-Based Decision Support|
79533879|NCT05645926|Procedure|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
79690006|NCT04410341|Drug|Vildagliptin 50 MG|Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk.
79690007|NCT04410341|Drug|Escitalopram 20 mg|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
79836055|NCT00903825|Procedure|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
79836056|NCT00903825|Procedure|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
79836057|NCT00899535|Genetic|DNA analysis|
79836058|NCT00899535|Genetic|RNA analysis|
79836059|NCT00899535|Genetic|microarray analysis|
79836060|NCT00899535|Genetic|mutation analysis|
79239782|NCT03469557|Drug|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
79533880|NCT05645913|Drug|Oral anticoagulant|Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
79690008|NCT04409080|Drug|REGN7257|Administered by intravenous (IV) infusion, in Part A and B.
80007236|NCT03957694|Drug|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
80007237|NCT05759507|Procedure|abdominal surgery|
79239783|NCT03469557|Drug|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
79239784|NCT03469557|Drug|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
79239785|NCT03469557|Drug|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
79239786|NCT04466553|Device|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
79239787|NCT03109587|Dietary Supplement|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
79239788|NCT03109587|Dietary Supplement|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
79239789|NCT02675751|Device|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
79239790|NCT03109665|Diagnostic Test|SD-OCT Angiography|SD-OCT Angiography
79533881|NCT05636540|Drug|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
79836061|NCT00899535|Genetic|polymorphism analysis|
79836062|NCT00903981|Drug|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
79836063|NCT00903981|Drug|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
80007238|NCT05041673|Drug|Metformin|Antidiabetic drugs
80007239|NCT03907540|Drug|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
80007240|NCT03907540|Drug|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
79239791|NCT03109665|Diagnostic Test|SD-OCT|SD-OCT
79533882|NCT05630326|Other|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
79533883|NCT05630326|Other|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
79533884|NCT05630326|Other|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
79533885|NCT05630326|Other|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
79533886|NCT05620901|Drug|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
79533887|NCT05620901|Drug|Pred Forte|To treat perioperative ocular inflammation and pain;
79547189|NCT01552148|Other|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
79547190|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
79547191|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
80007241|NCT03907540|Drug|[14C]-KD025 200 mg capsule|test investigational medicinal product
80007242|NCT05759429|Other|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
79836064|NCT00903981|Drug|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
79836065|NCT00899613|Other|laboratory biomarker analysis|
79836066|NCT00899613|Procedure|study of high risk factors|
79836067|NCT00899691|Genetic|protein expression analysis|
79836068|NCT00899769|Genetic|protein expression analysis|
79239792|NCT02643381|Drug|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
79239793|NCT02643381|Drug|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
79836069|NCT00899769|Genetic|proteomic profiling|
80007243|NCT05759429|Other|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
80007244|NCT04005209|Drug|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
79239794|NCT02643381|Procedure|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
79239795|NCT02643381|Device|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
79239796|NCT04363281|Other|preoperative questionnaire|"Three questions to predict acute pain:~Verbal numeric score Anxiety 0-10~Anticipated postoperative pain level~Anticipated analgesic requirements~Speilberger STATE-TRATE inventory index~Pain Catastrophizing Scale"
79379540|NCT05514964|Behavioral|Feasibility study|"Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures."
79379541|NCT05503134|Biological|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
79379542|NCT05497349|Other|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
79239797|NCT04363281|Other|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
79239798|NCT04363281|Other|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
79303005|NCT02449447|Behavioral|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
79379543|NCT05497349|Other|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
79690009|NCT04377386|Dietary Supplement|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
79690010|NCT04377386|Dietary Supplement|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
79690011|NCT04375306|Procedure|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
79690012|NCT04375306|Procedure|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
79836070|NCT00899769|Other|immunoenzyme technique|
79836071|NCT00899769|Other|laboratory biomarker analysis|
79836072|NCT00899769|Other|liquid chromatography|
79836073|NCT00899769|Other|mass spectrometry|
79836074|NCT00904059|Drug|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
79836075|NCT00904059|Drug|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
79836076|NCT00904059|Drug|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
79836077|NCT00904059|Drug|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
79836078|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
79836079|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
79836080|NCT00904137|Procedure|Cast|
79836081|NCT00904137|Procedure|Splint|
79836082|NCT00904137|Procedure|Tape|
79836083|NCT00906477|Procedure|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
79836084|NCT03987607|Device|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
80007245|NCT04005209|Other|Pain management|Pain management
80007246|NCT05088304|Other|no intervention|
79533888|NCT05610995|Device|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
79533889|NCT05603104|Drug|Clozapine|See arm description
79836085|NCT00900003|Genetic|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
79836086|NCT00900003|Other|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
80007247|NCT05088226|Drug|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
80007248|NCT01376219|Other|asthma control test|results of asthma control testing collected
80007249|NCT03751553|Drug|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
79239799|NCT04363281|Other|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
79379544|NCT05496972|Behavioral|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
79379545|NCT05495854|Diagnostic Test|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
79379546|NCT05494424|Behavioral|Goal Management Training (GMT)|Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
79379547|NCT05491447|Drug|BMX-010|Ointment
79533890|NCT05603104|Drug|Esketamine Nasal Product|See arm description
80007250|NCT03904108|Drug|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
79239800|NCT04363281|Other|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
79379548|NCT05491447|Drug|Placebo|Ointment
79533891|NCT05603104|Drug|Escitalopram|See arm description
79533892|NCT05603104|Drug|Sertraline|See arm description
79533893|NCT05603104|Drug|Duloxetine|See arm description
79533894|NCT05603104|Drug|Venlafaxine|See arm description
80007251|NCT03636581|Behavioral|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
79239801|NCT03469479|Drug|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
79239802|NCT03469479|Procedure|Hepatic resection|R0 resection
79239803|NCT02974855|Biological|PF-06741086|PF-06741086 subcutaneous (SC) injection
79239804|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
79379549|NCT05491031|Other|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
79379550|NCT05490238|Procedure|Complex PCI with Ultimaster Tansei (Terumo Corp., Japan) drug-eluting stent|Large-bore radial access for complex PCI with Ultimaster Tansei (Terumo Corp., Japan) drug-eluting stent
79533895|NCT05603104|Drug|Lithium|See arm description
79533896|NCT05603104|Drug|Lamotrigine|See arm description
79533897|NCT05603104|Drug|Valproate acid|See arm description
79690013|NCT04368117|Behavioral|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
79690014|NCT04358393|Drug|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
79690015|NCT04358393|Drug|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
79690016|NCT04356859|Drug|Albumin Human|Addition of albumin during acute resuscitation following burn injury
79690017|NCT04351204|Radiation|radiotherapy|multiple new techniques and software for MR-guided adaptive radiation therapy.
79690018|NCT04334421|Device|Composite mesh|Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
79533898|NCT05603104|Drug|Quetiapine|See arm description
79836087|NCT00906555|Procedure|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
79836088|NCT00337207|Biological|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
79836089|NCT01052857|Procedure|acupuncture|acupuncture application
79836090|NCT01055743|Procedure|Radical resection|Radical resection of hepatocellular carcinoma
79836091|NCT01055743|Drug|Fluorouracil Implants|Implanted during the surgical treatment
79836092|NCT00604695|Drug|Tenecteplase|Intracoronary injection of IV tenecteplase.
79836093|NCT00604695|Drug|Sterile Saline|Intracoronary injection of IV sterile saline
79836094|NCT01055821|Drug|pegylated interferon and ribavirin|48 weeks
79239805|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
79239806|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
79239807|NCT04473651|Drug|Lu AG06479|capsules, orally (Part A and B)
79379551|NCT05490043|Drug|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
79379552|NCT05482815|Device|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
79690019|NCT04332887|Behavioral|Multidimensional Exercise Program|Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
79690020|NCT04332068|Drug|Oral ivermectin|Ivermectin (NT007) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.
79379553|NCT05480683|Diagnostic Test|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
79690021|NCT04332068|Drug|Permethrin Cream|permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.
79690022|NCT04332068|Other|Placebo tablet|placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
79690023|NCT04332068|Other|Placebo cream|A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
79836095|NCT01055821|Biological|TG4040 + SOC|6 injections
79836096|NCT01055821|Biological|TG4040 + SOC|13 injections
79836097|NCT00900081|Other|immunohistochemistry staining method|
79239808|NCT04473651|Drug|Placebos|Placebo - capsules, orally (Part A only)
79239809|NCT04328961|Drug|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
79239810|NCT04328961|Drug|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
79303006|NCT02449447|Other|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
79303007|NCT03196921|Drug|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
79379554|NCT05465954|Procedure|Biospecimen Collection|Correlative studies
79379555|NCT05465954|Biological|Efineptakin alfa|Given IM
79379556|NCT05465954|Biological|Pembrolizumab|Given IV
79533899|NCT05603104|Drug|Second-line Antidepressants|See arm description
79533900|NCT05603104|Drug|Second-line Antipsychotics|See arm description
79533901|NCT05603104|Drug|Ketamine Hydrochloride|See arm description
79533902|NCT05603104|Drug|Esketamine hydrochloride|See arm description
79533903|NCT05602493|Drug|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
79836098|NCT00900081|Other|laboratory biomarker analysis|
79836099|NCT00900081|Other|medical chart review|
79836100|NCT03990727|Diagnostic Test|Retina Analysis-mosaic|Fundus retina pattern study
79836101|NCT03990727|Diagnostic Test|Autofluorescence|Fundus reflectance-functionality
79303008|NCT02477735|Device|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
79533904|NCT05602493|Drug|sterile saline|sterile saline
79533905|NCT05602467|Device|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
79836102|NCT03990727|Diagnostic Test|OCT- 1 micra|Fine tomography fundus retina
79836103|NCT03990727|Procedure|Genotype analysis|Molecular target retina dystrophy analysis
79836104|NCT02540031|Drug|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
79836105|NCT02540031|Drug|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
79836106|NCT00904293|Other|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
79836107|NCT00904293|Other|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
79836108|NCT00900549|Device|CRT on|12 months
79836109|NCT00900549|Device|CRT off|12-month
79836110|NCT00904449|Drug|Oxymorphone ER|10mg, 20mg, and 40mg PO
79533906|NCT05602467|Other|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
79533907|NCT05601973|Drug|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is <80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
79690024|NCT04326153|Drug|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
79836111|NCT00904527|Behavioral|relaxation (Schultz)|Patients have relaxation consultations during 2 months
79836112|NCT00348595|Drug|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
79836113|NCT02538939|Drug|Sodium thiosulfate|
79836114|NCT00904605|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
79836115|NCT00904605|Drug|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
79836116|NCT00904761|Other|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
79836117|NCT00337129|Drug|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
79836118|NCT00905073|Drug|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
79836119|NCT02538705|Drug|Neovasculgen|
79836120|NCT00905229|Drug|Phytonadione|2.5 mg po
79836121|NCT00905229|Drug|Phytonadione|0.5 mg IV
79836122|NCT01052935|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
79836123|NCT00605085|Biological|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
79836124|NCT00605085|Biological|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
79836125|NCT00905463|Procedure|Lung transplantation|Lung transplantation
79239811|NCT04228575|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend ~15 mins. per week/per client.
79239812|NCT03653533|Device|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
79533908|NCT05601973|Drug|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
79836126|NCT00905541|Drug|simvastatin|40 mg/day
79836127|NCT00905541|Drug|simvastatin|80 mg simvastatin acute-on-chronic
79836128|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
79836129|NCT00348283|Biological|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
79836130|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
79836131|NCT00905697|Procedure|Living donor lung transplantation|Living donor lung transplantation
79836132|NCT01055899|Biological|REGN88|Single SC Dose
79836133|NCT01055899|Biological|REGN88|Single SC Dose
79836134|NCT01055899|Biological|REGN88|Single SC Dose
79836135|NCT00336895|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
79836136|NCT01059019|Dietary Supplement|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
79239813|NCT03653533|Device|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
79533909|NCT05601973|Drug|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
79690025|NCT04321200|Diagnostic Test|PANDA Gym|Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.
80007252|NCT04976309|Drug|Lu AG09222|Single dose
80007253|NCT04976309|Drug|Placebo|Single dose
80007254|NCT05392348|Dietary Supplement|stachyose|Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1->6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
79239814|NCT03653533|Device|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
79239815|NCT04172025|Diagnostic Test|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
79239816|NCT03653377|Other|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
79239817|NCT00455403|Drug|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
79239818|NCT00455403|Drug|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
79239819|NCT04061031|Behavioral|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
79239820|NCT04061031|Behavioral|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
79239821|NCT04397367|Drug|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
79303009|NCT02480465|Drug|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
79303010|NCT02480465|Drug|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
79391307|NCT02447926|Procedure|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
79533910|NCT05589831|Device|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
79533911|NCT05587010|Device|AFO|ankle foot orthosis
79533912|NCT05587010|Device|lycra sock|custom fitted lycra sock
79533913|NCT05587010|Device|OrthPed splint|novel compression splint
79533914|NCT05586789|Drug|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
79533915|NCT05586789|Drug|Placebo|Two tablets 3 times per day for 28 days
79547192|NCT01552187|Drug|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (<70kg) 48 to 72 hours before surgery till 1 months after surgery
79547193|NCT01552187|Drug|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
79690026|NCT04321200|Other|Mobile App|"The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app."
79533916|NCT05574127|Behavioral|Behavioral Activation|"Sessions for both arms (BP & SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
79547194|NCT01552200|Procedure|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
79690027|NCT04311788|Device|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
79690028|NCT04311788|Device|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
79690029|NCT04283916|Drug|Botulinum Toxins|Botulinum toxin injection to abdominal wall
79690030|NCT04282733|Behavioral|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
80007255|NCT05392348|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
80007256|NCT03137524|Device|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
79239822|NCT04397367|Drug|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
79379557|NCT05464199|Other|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
79547195|NCT01552200|Procedure|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
79690031|NCT04274023|Drug|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
79690032|NCT04264208|Drug|68-Ga RM2.|PET radiopharmaceutical
79690033|NCT04264208|Drug|68-Ga PSMA11|PET radiopharmaceutical
79690034|NCT04264208|Device|PET/MRI|PET/MR scanner by GE healthcare
79690035|NCT04253184|Drug|Micra AV Transcatheter Pacing System|The Micra AV Transcatheter Pacing System (TPS) is a miniaturized single chamber pacemaker that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart to provide bipolar sensing and pacing. The Micra AV system provides a form of VDD pacing that is based on mechanical atrial sensing utilizing a 3-axis accelerometer.
79690036|NCT04228120|Behavioral|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
79690037|NCT04219878|Behavioral|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
80007257|NCT02833350|Drug|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
79836137|NCT00336583|Drug|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
80007258|NCT02833350|Drug|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
80007259|NCT02833350|Drug|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
79303011|NCT03208465|Drug|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
79303012|NCT03208465|Drug|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
79836138|NCT00336505|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
79239823|NCT04397367|Drug|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
79239824|NCT04397367|Drug|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
79379558|NCT05462756|Drug|Insulin Efsitora Alfa|Administered SC
79379559|NCT05462756|Drug|Insulin Lispro (U100)|Administered SC
79533917|NCT05574127|Behavioral|Supportive Psychotherapy|"Sessions for both arms (BP & SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
79690038|NCT04219878|Other|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
79836139|NCT00336505|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
79836140|NCT00357877|Drug|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
80007260|NCT02833350|Drug|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
80007261|NCT02833350|Drug|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
79239825|NCT05160909|Procedure|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
79239826|NCT05160909|Procedure|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
80007262|NCT03137602|Device|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
80007263|NCT03137212|Combination Product|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
79239827|NCT05160831|Biological|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
79239828|NCT03471897|Diagnostic Test|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
79303013|NCT03196999|Behavioral|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
79690039|NCT04214652|Drug|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
79303014|NCT03196999|Behavioral|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
79379560|NCT05462756|Drug|Insulin Glargine (U100)|Administered SC
79379561|NCT05455775|Device|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
79379562|NCT05454358|Drug|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
79379563|NCT05453721|Procedure|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
79379564|NCT05453721|Procedure|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
79379565|NCT05450887|Drug|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
79379566|NCT05450887|Drug|UDCA|UDCA：13~15 mg/kg/day
79379567|NCT05450887|Drug|Placebo|Placebo：Once a day (QD) by mouth (PO).
79690040|NCT04214652|Drug|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
79690041|NCT04214639|Drug|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
79836141|NCT00357877|Other|Placebo|
79836142|NCT03990337|Device|Ultrasound|Ultrasonography of cricoid cartilage.
79836143|NCT03987529|Other|sevoflurane|volatile anesthetic
79836144|NCT03987529|Other|propofol|intravenous anesthetic
79836145|NCT03990259|Other|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
79690042|NCT04214639|Drug|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
79533918|NCT05568550|Biological|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
79690043|NCT04213794|Drug|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
79690044|NCT04213794|Procedure|Cytoreductive Surgery|Undergo cytoreduction
79690045|NCT04213794|Drug|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
79239829|NCT04394169|Behavioral|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~Visit 1 Intervention Group, four weeks after hospital discharge.~Visit 2 Intervention Group, eight weeks after hospital discharge.~Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~Interview and physical examination.~Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
79239830|NCT03470337|Drug|Phlogenzym|Bromelain / Trypsin / Rutoside
79239831|NCT03470337|Other|Placebo|
79379568|NCT05448222|Diagnostic Test|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
79379569|NCT05444634|Behavioral|Distraction Card|"Suitable for children over 3 years old. 1 set of 32 pieces of thick cardboard cards It has been prepared by child development experts in line with pedagogical principles.~Size: 13cm x 8cm, Each card illustrates the skills and actions the children do."
79379570|NCT05444634|Behavioral|Stress Ball|Brain Shaped Stress Ball, White rope in the form of mesh around the inner silicone Size: Approx 2.4 inches (6 cm), Color: Colorful, When squeezed, the silicone structure comes out in the mesh spaces and turns into a bunch of grapes.
79379571|NCT05443230|Diagnostic Test|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
79391308|NCT00568672|Drug|Olanzapine|Olanzapine 5 mg / day for 6 months
79533919|NCT05568550|Drug|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
79690046|NCT04213794|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
79690047|NCT04213794|Drug|Sodium Thiosulfate|Given IV
79690048|NCT04213794|Procedure|Computed Tomography|Undergo CT scan
79690049|NCT04213794|Procedure|Magnetic Resonance Imaging|Undergo MRI
79533920|NCT05568550|Drug|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
79690050|NCT04213794|Procedure|Positron Emission Tomography|Undergo PET/CT
79690051|NCT04213794|Procedure|Biospecimen Collection|Undergo blood sample collection
79533921|NCT05568550|Radiation|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
79547196|NCT01552226|Device|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
79690052|NCT04207255|Drug|Opaganib|500mg of Opaganib orally twice a day continuously.
79239832|NCT04162275|Drug|Finamine tablets|taken Finamine tablets orally
79239833|NCT04162275|Drug|Placebo tablets|taken Placebo tablets orally
79239834|NCT03470259|Drug|IV adminstration of EMI-137|Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
79690053|NCT04207255|Drug|Abiraterone|IV as directed by SOC
79690054|NCT04207255|Drug|Enzalutamide|IV as directed by SOC
79690055|NCT04207255|Drug|Opaganib|250mg of Opaganib orally twice a day continuously.
79690056|NCT04201548|Other|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
79690057|NCT04201548|Other|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
79836146|NCT00335959|Drug|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
79836147|NCT00335959|Drug|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
79239835|NCT03470259|Device|Multispectral Fluorescence Reflectance Imaging|A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
79239836|NCT03470259|Device|Spectroscopy|A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
79379572|NCT05443217|Diagnostic Test|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
80007264|NCT03137212|Combination Product|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
79836148|NCT00335959|Procedure|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
79533923|NCT05558956|Drug|illuccix 68Ga-PSMA-11 Total Body PET-CT|Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) 68Ga-PSMA-11
79836149|NCT00335959|Radiation|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
79836150|NCT01056133|Other|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
80007265|NCT03137134|Drug|Crizotinib|Crizotinib in a coated microsphere formulation
79379573|NCT05431101|Procedure|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
79379574|NCT05426902|Behavioral|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 & 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 & 2 SLE.
79379575|NCT05426746|Drug|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
79533924|NCT05542849|Drug|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
79836151|NCT01059097|Procedure|Pancreaticoduodenectomy|
79836152|NCT01053091|Behavioral|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
79836153|NCT03987061|Device|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
79836154|NCT01053169|Biological|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
79836155|NCT01053169|Biological|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
79836156|NCT01053169|Other|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
79836157|NCT01059253|Other|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
79836158|NCT01059331|Drug|Pregabalin|150 mg x 2 daily for 2 days
79836159|NCT01059331|Drug|Sugar pill|1 tablet x 2 daily, for 2 days
79239837|NCT02979613|Drug|TAF|25 mg tablet administered orally once daily
79379576|NCT05426746|Other|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
79391309|NCT04744246|Other|load carriage|35 pound load carried on the back
79533925|NCT05542056|Other|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
79836160|NCT03985345|Device|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
79836161|NCT01059409|Procedure|Meniscal Allograft|Meniscal Allograft
79836162|NCT01059487|Other|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
79836163|NCT01059721|Procedure|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
79533926|NCT05531552|Drug|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
79547197|NCT01552226|Device|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
79836164|NCT03985111|Device|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
80007266|NCT03137134|Drug|Esomeprazole|Proton pump inhibitor, esomeprazole
80007267|NCT03137368|Drug|Exemestane Tablets|drug therapy
80007268|NCT03137368|Other|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
80007269|NCT03137368|Genetic|CYP2D6*10 gene test|CYP2D6*10 gene test
80007270|NCT03137368|Drug|Tamoxifen|drug therapy
79239838|NCT02979613|Drug|TDF|300 mg tablet administered orally once daily
79239839|NCT02979613|Drug|TAF Placebo|Tablet administered orally once daily
79239840|NCT02979613|Drug|TDF Placebo|Tablet administered orally once daily
79239841|NCT03811665|Procedure|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
79379577|NCT05404022|Other|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~Information on side-effects that may affect eating and their mitigation~Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~Feedback on assessment of food intake and how to improve~a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~a recipe book Making the most of every bite~tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
79836165|NCT03742063|Drug|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
79239842|NCT03811665|Radiation|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
79239843|NCT03469401|Other|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
79239844|NCT04458129|Drug|Treatment with polyethylene glycol (Macrogol 4000)|3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
79239845|NCT03576261|Other|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
79239846|NCT03576261|Diagnostic Test|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
79239847|NCT03469323|Drug|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
79379578|NCT05393765|Behavioral|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
79379579|NCT05373121|Behavioral|Online Peer Support|Signposting to online peer support groups and forums
79379580|NCT05371509|Device|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
79379581|NCT05371509|Other|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
79836166|NCT03741985|Behavioral|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
79836167|NCT03741985|Behavioral|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
79836168|NCT01059955|Drug|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
79836169|NCT01059955|Drug|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
79836170|NCT01060033|Device|MR Spectroscopy|
80007271|NCT05391958|Behavioral|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC > 2.
79379582|NCT05370430|Biological|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
79379583|NCT05364190|Drug|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
79836171|NCT01060033|Device|Fat-Saturation and Diffusion-Weighted Imaging|
79239848|NCT03469323|Drug|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
79836172|NCT01060033|Device|Dynamic Contrast Enhancement MRI (MR-DCE)|
79836173|NCT01060033|Device|Diffusion Tensor Imaging (DTI)|
79836174|NCT01060189|Drug|Ulinastatin|
79836175|NCT01060189|Drug|Tranexamic Acid|
79836176|NCT01060189|Drug|Saline Solution|
79836177|NCT03984877|Diagnostic Test|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
79836178|NCT01060267|Drug|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
80007272|NCT05391958|Behavioral|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC > 2.
80007273|NCT05391958|Genetic|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ ~ Ⅲ.
79239849|NCT05160285|Drug|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
79239850|NCT03652831|Other|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints~Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
79239851|NCT03652831|Other|Soft Tissue Mobilization without Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints~Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
79836179|NCT01060267|Drug|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
79239852|NCT03622099|Drug|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
79690058|NCT04201548|Other|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
79239853|NCT03470181|Dietary Supplement|Ensure|Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
79379584|NCT05364190|Drug|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
79391310|NCT02448862|Device|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
79690059|NCT04196530|Drug|BDB001|BDB001 is an immunotherapy agent.
79690060|NCT04196530|Drug|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
79690061|NCT04194346|Procedure|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
79836180|NCT01060423|Drug|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
79836181|NCT01060423|Drug|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
79690062|NCT04186676|Other|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
79690063|NCT04186676|Diagnostic Test|CCTA Phenotypes|"Complete normal coronary arteries~Diffuse non-obstructive coronary artery disease~Non-obstructive high-risk plaques~Myocardial bridges"
79690064|NCT04180488|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79690065|NCT04180488|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79690066|NCT04180488|Drug|non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: oral administration
79690067|NCT04173208|Other|Fecal microbial transplant|Fecal microbial transplant
79690068|NCT04173208|Other|Placebo|Placebo
79690069|NCT04166019|Behavioral|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
79690070|NCT04166019|Behavioral|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
79836182|NCT01060423|Device|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
79836183|NCT03984721|Diagnostic Test|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
80007274|NCT05391958|Genetic|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ ~ Ⅲ.
79239854|NCT03622021|Drug|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
79239855|NCT03653299|Device|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
79239856|NCT03469245|Other|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
79239857|NCT03130491|Procedure|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
79239858|NCT03130491|Device|EMBLOK filter|Embolic Filter Protection System During TAVR
79239859|NCT03471819|Diagnostic Test|Serum serotonin level|blood sample will be obtained to evaluate serum level of serotonin
79239860|NCT03653221|Other|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
79239861|NCT03653221|Other|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
79239862|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
79239863|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
79239864|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
79533927|NCT05525299|Behavioral|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, _____ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
79690071|NCT04166019|Behavioral|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
79690072|NCT04120766|Drug|Nicorandil|20 mg po qd
79690073|NCT04120766|Drug|Placebo|Matching tablet
79690074|NCT04114539|Drug|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
80007275|NCT05391802|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
79239865|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
79239866|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
79239867|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
79239868|NCT03618693|Procedure|Spinal anesthesia|Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
79239869|NCT03618693|Device|TAP Block|TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
79379585|NCT05363930|Device|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
79391311|NCT01697267|Biological|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
79533928|NCT05525143|Procedure|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
79690075|NCT04097379|Drug|LRX712|LRX712 intra-articular injections
79690076|NCT04097379|Drug|Placebo|Placebo intra-articular injections
79690077|NCT04091386|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
79239870|NCT03618693|Other|Standard|Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
79239871|NCT01064167|Drug|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
79239872|NCT04205305|Drug|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure <180 mmHg.
80007276|NCT03138616|Drug|vitamin D|take 1600 units of vitamin D daily for nine months
80007277|NCT03137290|Drug|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
79239873|NCT04205305|Drug|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure <140 mmHg.
79239874|NCT03470103|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
79239875|NCT02974543|Device|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
79533929|NCT05523934|Drug|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
79533930|NCT05515263|Dietary Supplement|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
79239876|NCT02974543|Device|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
79379586|NCT05363930|Device|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
79836184|NCT01060501|Drug|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
79690078|NCT04081701|Diagnostic Test|Ga68-DOTATATE-PET/MRI|"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."
79690079|NCT04076423|Drug|Dual Therapy|DTG + 3TC
79690080|NCT04076423|Drug|Triple therapy|BIC / FTC / TAF
79690081|NCT04027777|Device|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
79836185|NCT00670488|Drug|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
79239877|NCT03471741|Radiation|IMRT with concomitant boost|
79239878|NCT03471741|Radiation|3D-RT with sequential boost|
79239879|NCT01064947|Drug|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
79239880|NCT02523027|Dietary Supplement|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
79239881|NCT02523027|Dietary Supplement|Oral nutritional supplement|(List No- P968/Z0)
79379587|NCT05362032|Device|Biopsy|Undergo transrectal MRI-targeted biopsy
79379588|NCT05362032|Procedure|Endorectal Magnetic Resonance Imaging|Endorectal MRI
79379589|NCT05352893|Drug|Imsidolimab high dose|intravenous
79379590|NCT05352893|Drug|Imsidolimab low dose|intravenous
79379591|NCT05352893|Other|Placebo|intravenous
79533931|NCT05515263|Dietary Supplement|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
79533932|NCT05515250|Device|Use of neurostimulation device|In humans, abdominal pain is modulated by the vagus nerve. Stimulation of the vagus nerve has been suggested to reduce visceral sensitivity and abdominal pain. IB-stim is the Percutaneous Electrical Nerve Field Stimulation (PENS) device. It is a non-invasive, outpatient therapy. PENFS has been shown to be efficacious in pediatric patients with abdominal pain.
79533933|NCT05510154|Behavioral|Brief advice|A single, brief advice session on switching to electronic cigarettes.
79533934|NCT05510154|Behavioral|Single Training|A single, in-depth training session on switching to electronic cigarettes.
79836186|NCT00671658|Drug|Rituximab|375 mg/m2 by vein
79836187|NCT00671658|Drug|Cyclophosphamide (CTX)|300 mg/m2 by vein
79690082|NCT04027647|Drug|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
79690083|NCT03984396|Other|Educational Materials - Patient & Clinician|deprescribing information for patient & clinician
79690084|NCT03983824|Drug|Cytarabine|Given IV
79836188|NCT00671658|Drug|Doxorubicin|50 mg/m2 by vein
79836189|NCT00671658|Drug|Vincristine|2 mg by vein
79836190|NCT00671658|Drug|Dexamethasone|40 mg by vein or by mouth (P.O.)
79836191|NCT00671658|Drug|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
79239882|NCT02523027|Other|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
79239883|NCT05391009|Diagnostic Test|PNF|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
79239884|NCT05391009|Diagnostic Test|TRT|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
79239885|NCT05159271|Device|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
79239886|NCT05159271|Device|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
79239887|NCT03469947|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
79836192|NCT00671658|Drug|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
79836193|NCT00671658|Drug|G-CSF|10 ug/kg subcutaneous injection
79836194|NCT00671658|Drug|Mesna|600 mg/m2 a day by vein
79836195|NCT00671658|Drug|Pegylated asparaginase|2000 International units/m2 by vein
79836196|NCT00671658|Drug|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
79836197|NCT00671658|Drug|Solumedrol|40 mg by vein for Courses 2,4,6,8
79836198|NCT00768378|Device|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
79836199|NCT00764712|Drug|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
79836200|NCT00768456|Drug|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
79836201|NCT00768456|Drug|Isotonic NaCl|Local Infiltration with NaCl
79239888|NCT05157087|Drug|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
79239889|NCT02974153|Biological|ALD403 (Eptinezumab)|
79239890|NCT02974153|Biological|Placebo|
79533935|NCT05510154|Behavioral|Training to Competency|Multiple, in-depth training sessions on switching to electronic cigarettes.
79533936|NCT05508100|Biological|IO-108|IO-108, intravenously, on Day 1 of each 21-day cycle.
79533937|NCT05508100|Biological|IO-108 + pembrolizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
79533938|NCT05508100|Biological|IO-108 + tislelizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
79533939|NCT05505448|Drug|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
79533940|NCT05505448|Drug|Matching Placebo|Single ascending IV or SC administration per the protocol
79690085|NCT03983824|Drug|Etoposide Phosphate|Given IV
79690086|NCT03983824|Drug|Mitoxantrone Hydrochloride|Given IV
79690087|NCT03983824|Drug|Peposertib|Given PO
79690090|NCT03959176|Drug|Brimonidine|2 drops administered once in the left eye in both study arms
79836202|NCT00542386|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
79836203|NCT00542386|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
79836204|NCT00768612|Drug|SCA-136 50mg/day|
79836205|NCT00768612|Drug|SCA-136 150 mg/day|
79836206|NCT00768612|Drug|SCA-136 300mg/day|
79836207|NCT00768612|Drug|Risperidone 4mg/day|
79836208|NCT00604383|Drug|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
79836209|NCT00604383|Drug|placebo|1 tablet, orally, daily, up to 42 months
79239891|NCT05134623|Diagnostic Test|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
79836210|NCT00771108|Behavioral|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
79836211|NCT04048200|Drug|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
79836212|NCT04048200|Drug|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
80007278|NCT03137290|Drug|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
80007279|NCT03782818|Drug|Olaparib|Olaparib up to 300 mg BID for 24 weeks
80007280|NCT05391724|Drug|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
80007281|NCT03137446|Other|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
80007282|NCT03641248|Drug|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
80007283|NCT03641248|Drug|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
80007284|NCT03138460|Other|standard medications crossed over to cannabis|
80007285|NCT05391490|Genetic|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
80007286|NCT03355534|Drug|Intravenous dexmedetomidine|drug is intravenously infused to patients
79239892|NCT05124639|Behavioral|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
79303015|NCT03196999|Behavioral|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
79379592|NCT05349617|Biological|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
79379593|NCT05349617|Biological|Placebo|Placebo is comprised of formulation buffer
79379594|NCT05341921|Behavioral|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
79379595|NCT05341921|Behavioral|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
80007287|NCT03355534|Drug|nasal dexmedetomidine|drug is nasally given to patients
80007288|NCT03355534|Drug|intravenous saline|saline is given to patients intravenously
79379596|NCT05341921|Behavioral|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
79690091|NCT03959176|Drug|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
79690092|NCT03959176|Drug|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
79690093|NCT03911726|Radiation|Single PET/MR-measurement|A single PET/MR-measurement using [18F]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
80007289|NCT03355534|Drug|nasal saline|normal saline is given to patients nasally
80007290|NCT05341284|Other|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
80007291|NCT05385640|Other|NO intervention|NO intervention
80007292|NCT05385562|Drug|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
79690094|NCT03904693|Drug|FDC macitentan/tadalafil|Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
79690095|NCT03904693|Drug|Macitentan 10 mg|Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
79690096|NCT03904693|Drug|Tadalafil 40 mg|Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.
79836213|NCT00985894|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
79836214|NCT00985894|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
79836215|NCT04034589|Drug|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
79836216|NCT04048434|Device|Cytosorb|extracorporeal cytokine adsorption
79836217|NCT00988312|Biological|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
79836218|NCT00906867|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
79836219|NCT00906867|Procedure|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
79836220|NCT00768690|Drug|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
79836221|NCT00768690|Drug|ketoconazole|Tablet, see arms for intervention description
79379597|NCT05339594|Device|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
79239893|NCT04053829|Device|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
79836222|NCT00768690|Drug|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
79239894|NCT04053829|Other|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
79239895|NCT04054063|Drug|HSK3486+ etomidate|
79836223|NCT02538549|Behavioral|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
79836224|NCT00982774|Biological|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
79836225|NCT00775008|Behavioral|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
79836226|NCT00985972|Behavioral|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
79836227|NCT02539953|Device|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
79239896|NCT03652519|Behavioral|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
79239897|NCT05107245|Diagnostic Test|1test1|Loss of bacterial diversity diagnosis
79690097|NCT03904693|Drug|Placebo FDC|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
79690098|NCT03904693|Drug|Placebo macitentan|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
79690099|NCT03904693|Drug|Placebo tadalafil|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
79836228|NCT00768768|Other|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
79836229|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
79836230|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
80007293|NCT05385562|Drug|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
79239898|NCT03652441|Drug|Brentuximab Vedotin|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
79379598|NCT05339594|Device|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
79379599|NCT05337150|Behavioral|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
79690100|NCT03904290|Other|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
79836231|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
79836232|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
79379600|NCT05337150|Behavioral|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
79239899|NCT02508532|Drug|Avapritinib|avapritinib tablets
79836233|NCT00988390|Behavioral|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
79836234|NCT00775086|Drug|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
79836235|NCT00908427|Procedure|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
79836236|NCT00908427|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
79836237|NCT00988468|Procedure|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
79533941|NCT05501327|Drug|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
79836238|NCT00988468|Behavioral|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
79836239|NCT00988468|Behavioral|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
79836240|NCT02557854|Drug|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
79836241|NCT02557854|Device|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
79836242|NCT00908505|Procedure|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
79239900|NCT04455165|Procedure|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
79239901|NCT04455321|Procedure|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
79239902|NCT02918071|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
79239903|NCT05162703|Diagnostic Test|AsthmaTuner|Exercise challenge test using AsthmaTuner mobile phone app and spirometer.
79239904|NCT05162625|Drug|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|Topical moxifloxacin 0,5% 01 drop every 3 hours
79239905|NCT05162625|Drug|Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]|Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
79239906|NCT05314959|Other|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
79239907|NCT05314959|Other|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
79533942|NCT05498233|Drug|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
79239908|NCT02506816|Drug|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
79533943|NCT05485285|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
79533944|NCT05484297|Behavioral|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
79533945|NCT05484297|Behavioral|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
79533946|NCT05476588|Other|Screening|Screening and validation of assessment tool translated into Spanish
79836243|NCT00988546|Other|Computer based template for exam documentation|exam documentation performed using computer based template
79836244|NCT00988546|Other|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
79836245|NCT02557386|Drug|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
79836246|NCT02557386|Drug|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
79836247|NCT02557386|Drug|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
79836248|NCT02557386|Drug|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
79836249|NCT02557386|Drug|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
79836250|NCT02557386|Drug|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
79836251|NCT00986050|Drug|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
79836252|NCT00986050|Device|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
79836253|NCT00986050|Device|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
79533947|NCT05476510|Drug|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
79239909|NCT02506036|Other|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
79379601|NCT05337150|Behavioral|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
79379602|NCT05336903|Behavioral|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~taking a comprehensive history~screening for pathologies contributing to the participant's chronic pain~a physical assessment~screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~identifying psychosocial risk factors associated with pain and disability~evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
79379603|NCT05330897|Procedure|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
79379604|NCT05330897|Device|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
79533948|NCT05476393|Other|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
79836254|NCT00986128|Drug|topiramate|100 mg tablet twice daily for 3 weeks
80007294|NCT01343043|Drug|NY-ESO-1(c259)T Cells|Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
79239910|NCT05017168|Drug|CT-P63|CT-P63 will be administered
79239911|NCT05017168|Drug|Placebo|Placebo-matching CT-P63
79533949|NCT05473026|Behavioral|Gratitude Intervention|Gratitude journaling and goal setting for exercise readiness over eight weeks.
79239912|NCT05009901|Drug|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600 mg daily for 8 weeks
79533950|NCT05472142|Other|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
79533951|NCT05472142|Other|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
79836255|NCT00986128|Drug|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
79836256|NCT00771342|Drug|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
80007295|NCT01343043|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy.
80007296|NCT01343043|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy.
79239913|NCT05009901|Drug|Placebo|Placebo one tablet daily for 8 weeks
79239914|NCT05015374|Dietary Supplement|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
79239915|NCT05015374|Dietary Supplement|Placebo|Placebo
79239916|NCT04988529|Behavioral|Smartphone-based serious game intervention|Smartphone-based serious game intervention consists in the use of a serious game designed specifically to improve depressive symptoms. The psychological content consists of CBT intervention with the following psychotherapeutic components: Motivation for change, Psychoeducation, Cognitive Flexibility, Behavioural Activation, and positive psychotherapeutic strategies. To encourage physical activity, the serious game incorporates a mixed reality through physical activities such as taking a walk in real life affects aspects inside the game.
79239917|NCT04970680|Procedure|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
79239918|NCT03109509|Behavioral|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
79239919|NCT03109509|Behavioral|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
79239920|NCT04421326|Other|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
80007297|NCT03139708|Drug|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
79239921|NCT05162235|Device|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
80007298|NCT03139708|Drug|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
80007299|NCT03139708|Drug|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
80007300|NCT03548987|Drug|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
80007301|NCT03548987|Drug|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
80007302|NCT01358760|Drug|Placebo|Placebo vaginal suppository
79379605|NCT05322928|Behavioral|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
79379606|NCT05320237|Other|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
79379607|NCT05319236|Device|Gabi System|See arm description
79379608|NCT05315479|Drug|N1539|Once daily
79379609|NCT05315206|Dietary Supplement|Citicoline|"The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine."
79533952|NCT05472077|Diagnostic Test|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
79379610|NCT05315206|Dietary Supplement|Placebo|The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
79533953|NCT05471336|Procedure|Enteral Feeding|Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
79690101|NCT03900468|Device|Activa™ PC and Percept™ PC Neurostimulation Systems|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
79690102|NCT03898479|Drug|CTP-543|Twice daily dosing
79379611|NCT05311254|Drug|Fosfomycin Calcium|Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count >0,5x109/L.
79690103|NCT03891953|Drug|DKY709|Novel immunomodulatory agent
79690104|NCT03891953|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
80007303|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
79690105|NCT03891238|Drug|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
80007304|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
80007305|NCT03139942|Device|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
80007306|NCT05692557|Device|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
80007307|NCT05692557|Procedure|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
80007308|NCT03137056|Device|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
79379612|NCT05303376|Biological|IBIO123|5 or 10 mg
79379613|NCT05303376|Other|Placebo|matching placebo
79379614|NCT05302583|Other|Aromatherapy Inhaler|Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
79379615|NCT05300633|Behavioral|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
79379616|NCT05299580|Drug|dabrafenib|Dabrafenib 150 mg bid
79533954|NCT05467735|Other|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
79690106|NCT03888989|Biological|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
79836257|NCT00771342|Drug|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
80007309|NCT03137056|Device|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
80007310|NCT03137056|Device|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
80007311|NCT04432701|Behavioral|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
80007312|NCT05330364|Drug|Chidamide|Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
80007313|NCT05330364|Drug|Cladribine|Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
80007314|NCT05087602|Drug|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
80007315|NCT05087368|Biological|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
79239922|NCT01063855|Drug|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
79379617|NCT05299580|Drug|Trametinib|Trametinib 2mg qd
79379618|NCT05294757|Other|Physical exercise|1. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
79533955|NCT05467345|Device|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
79239923|NCT01063855|Drug|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
79239924|NCT01063855|Drug|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
79690107|NCT03882034|Drug|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
79690108|NCT03879161|Device|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
79690109|NCT03878823|Drug|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
79690110|NCT03836040|Drug|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
79836258|NCT00775164|Drug|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
79836259|NCT00775164|Drug|Metformin|Metformin XR; 1000 mg once daily
79239925|NCT05162001|Drug|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
79239926|NCT03469167|Device|CEGP003|Application of CEGP003 to peptic ulcer bleeding
79239927|NCT03469167|Device|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
79836260|NCT00988624|Drug|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
79836261|NCT00988624|Drug|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
80007316|NCT05087368|Biological|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
79836262|NCT00988624|Drug|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
79239928|NCT01063153|Drug|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
79239929|NCT05161299|Procedure|Surgery (across all specialities)|Surgery performed by a surgeon in an operating theatre during the patient inclusion period
79239930|NCT01062841|Behavioral|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
79379619|NCT05289557|Drug|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
79379620|NCT05289557|Drug|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
79836263|NCT00988624|Drug|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
79533956|NCT05467215|Drug|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
79836264|NCT00988624|Drug|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
79239931|NCT05161221|Drug|OxyCODONE 5 mg Oral Tablet|Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
79836265|NCT00771420|Drug|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
79239932|NCT05161221|Drug|Naproxen 500 Mg|Participant will receive Naproxen 500 Mg post surgery for pain control
79239933|NCT05161221|Drug|Tylenol Pill|Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
80007317|NCT05087368|Biological|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
79239934|NCT05161221|Drug|Liposomal bupivacaine|Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
79379621|NCT05283187|Behavioral|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
79239935|NCT05161221|Procedure|Femoral Nerve Catheter|Participants will receive pre-operative femoral nerve catheter
79836266|NCT00771420|Drug|CAM-3001|Dosed at 0.1mg/kg.
79836267|NCT00771420|Drug|CAM-3001|Dosed at 0.3mg/kg
80007318|NCT01341990|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
80007319|NCT01341990|Device|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
79379622|NCT05278676|Drug|Dotinurad|Dotinurad oral tablet.
79239936|NCT02505334|Drug|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
79547198|NCT01552239|Radiation|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
79547199|NCT01552252|Dietary Supplement|apple juice|unaltered(0% POs-Ca) commercially available apple juice
79836268|NCT00771420|Drug|CAM-3001|Dosed at 1.0 mg/kg.
79836269|NCT00771420|Drug|CAM-3001|Dosed at 3.0 mg/kg.
79836270|NCT00771420|Drug|CAM-3001|Dosed at 10 mg/kg.
79836271|NCT00771420|Other|Placebo|Active: Placebo 5:1 for arms 2-6
80007320|NCT01341990|Device|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
80007321|NCT05087134|Drug|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
79239937|NCT03469089|Drug|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
79239938|NCT03469089|Drug|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
79239939|NCT03469089|Drug|Modafinil|Modafinil tablet 100 mg placed in a capsule
79239940|NCT03469089|Drug|Placebo for ketamine|0.9 % NaCl infusion solution
79379623|NCT05277831|Other|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
79836272|NCT00983008|Behavioral|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
79836273|NCT04767256|Drug|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
79836274|NCT04767256|Drug|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
80007322|NCT05086900|Other|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
79533957|NCT05457881|Dietary Supplement|Scandi-Shake|Scandi-Shake [any of 4 flavors - vanilla, strawberry, banana cream, and caramel] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
80007323|NCT03048747|Drug|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
80007324|NCT05086822|Drug|Irinotecan liposome|Irinotecan liposome
80007325|NCT05354128|Drug|Thrombolytic|Standard intravenous thrombolysis.
80007326|NCT05354128|Procedure|percutaneous coronary stenting|Percutaneous coronary stenting
79379624|NCT05277831|Other|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
79239941|NCT03469089|Drug|Placebo for modafinil|Placebo capsule for modafinil capsule
79379625|NCT05276947|Other|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
79379626|NCT05272956|Procedure|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
79379627|NCT05249868|Other|Exposure SARS-CoV-2 Infection|"The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for <5 days is positive on a PRAg test."
79379628|NCT05244486|Device|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
79379629|NCT05244486|Device|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
79379630|NCT05237440|Biological|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
79533958|NCT05449795|Device|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
79533959|NCT05445518|Behavioral|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
80007327|NCT03670277|Device|etafilcon A|Test Soft Contact Lens
80007328|NCT03670277|Device|Habitual Orthokeratology Lenses|CONTROL
80007329|NCT05230186|Procedure|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
80007330|NCT04954469|Biological|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
79239942|NCT05161143|Drug|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
80007331|NCT04051827|Drug|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
80007332|NCT04051827|Drug|TAK-788|TAK-788 Oral Capsules.
79239943|NCT01062061|Biological|VARIVAX™|Attenuated live varicella vaccine
79239944|NCT03652207|Other|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
79239945|NCT03652207|Other|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
79239946|NCT04969510|Drug|10 mg PRAX-114|Once daily oral treatment
79239947|NCT04969510|Drug|20 mg PRAX-114|Once daily oral treatment
79239948|NCT04969510|Drug|40 mg PRAX-114|Once daily oral treatment
80007333|NCT05346874|Drug|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
79533960|NCT05445518|Behavioral|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
79533961|NCT05434000|Drug|Hydroxyurea|Children at risk of developing stroke (TCD values>200cm/s) will be given 20mg/kg of Hydroxyurea
79690111|NCT03836040|Drug|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
79379631|NCT05231187|Diagnostic Test|T2Resistance Panel|"The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~blaKPC~blaCTX-M~blaNDM / blaVIM / blaIMP~blaOXA-48 Group~vanA / vanB~mecA / mecC~AmpC (blaCMY / blaDHA)"
79379632|NCT05230576|Diagnostic Test|Deep learning training cohort|train the deep learning model
79836275|NCT04767256|Other|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
79533962|NCT05433571|Device|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
79379633|NCT05230576|Diagnostic Test|Deep learning validation cohort|evaluate the model
79690112|NCT03836040|Drug|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
79836276|NCT04767256|Other|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
79836277|NCT00771498|Drug|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
79379634|NCT05227599|Other|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
79533963|NCT05433480|Drug|BPI-16350|BPI-16350 400 mg, orally once daily
79533964|NCT05433480|Drug|placebo|Placebo 400 mg, orally once daily
79533965|NCT05433480|Drug|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
79533966|NCT05432674|Combination Product|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
79533967|NCT05428735|Procedure|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
79533968|NCT05428215|Drug|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
79547200|NCT01552252|Dietary Supplement|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
79690113|NCT03836040|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
79690114|NCT03805477|Drug|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
79690115|NCT03803774|Drug|Birinapant|Given IV
79690116|NCT03803774|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRRT
79690117|NCT03799939|Device|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
79836278|NCT00986206|Diagnostic Test|Biomarker LPA and HE4|Non Interventional Trial
79836279|NCT00986284|Drug|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
79836280|NCT00768846|Device|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
80007334|NCT05346874|Drug|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
80007335|NCT05346874|Procedure|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
80007336|NCT03730636|Procedure|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
79547201|NCT01552252|Dietary Supplement|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
79690118|NCT03798626|Drug|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
79690119|NCT03798626|Drug|Bevacizumab|25 mg/mL concentration; administered IV
79690120|NCT03798626|Drug|Modified FOLFOX6|Oxaliplatin [5 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]
79690121|NCT03798626|Drug|FOLFIRI|Irinotecan [20 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]
79690122|NCT03798626|Drug|Ramucirumab|10 mg/mL concentration; administered IV
79690123|NCT03798626|Drug|Paclitaxel|6 mg/mL concentration; administered IV
79690124|NCT03798626|Drug|Cabozantinib|60 mg tablet; administered orally
80007337|NCT03136588|Device|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
80007338|NCT02123823|Drug|Everolimus|10mg dose
80007339|NCT02123823|Drug|Everolimus|at recommended dose as per Phase I data
80007340|NCT02123823|Drug|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
80007341|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
80007342|NCT02123823|Drug|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
79239949|NCT04969510|Drug|60 mg PRAX-114|Once daily oral treatment
79379635|NCT05226260|Behavioral|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
79379636|NCT05222438|Drug|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
79379637|NCT05219487|Drug|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) [as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
79836281|NCT00768846|Device|Xience V Stent|Everolimus-eluting Xience V Stent
79836282|NCT00988702|Behavioral|Dan Tian Breathing|Dan Tian Breathing for one month
79379638|NCT05209997|Other|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
79379639|NCT05205616|Device|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
79533969|NCT05419960|Diagnostic Test|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~Video Head Impulse Test (vHIT)~Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
79533970|NCT05419960|Diagnostic Test|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
79836283|NCT00988702|Behavioral|Progressive muscle training|Progressive muscle training for one month
80007343|NCT02123823|Drug|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
79836284|NCT00988780|Drug|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
80007344|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
80007345|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
80007346|NCT03380273|Behavioral|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~Antibiotic prophylaxis~Perioperative antibiotics~Oxygen administration~Patient temperature~Surgeon protective wear~Patient operative skin preparation~Suction drains~Blood glucose level~Red cell transfusion~Dressing changes"
80007347|NCT05086666|Drug|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
80007348|NCT05086042|Diagnostic Test|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
79239950|NCT04969510|Drug|Placebo|Once daily oral treatment
79239951|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
79379640|NCT05205616|Device|Reciprocating saw|See above description
79239952|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
79239953|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
79239954|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
79239955|NCT05014516|Drug|129Xenon gas|Observational
79239956|NCT01061671|Drug|simvastatin|40 mgms of simvastatin daily
79239957|NCT01061671|Drug|Placebo|Matched placebo pill daily
79239958|NCT04969120|Drug|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
79379641|NCT05199870|Device|Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head.
79379642|NCT05199012|Dietary Supplement|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
79690125|NCT03795493|Behavioral|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
79690126|NCT03784313|Procedure|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
79836285|NCT00988780|Drug|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
79533971|NCT05419960|Diagnostic Test|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
79533972|NCT05417646|Other|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
79690127|NCT03784313|Procedure|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
79690128|NCT03768505|Drug|Zandelisib (ME-401)|Zandelisib (ME-401) 60 mg
79690129|NCT03761563|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
79690130|NCT03741127|Drug|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
79690131|NCT03662308|Device|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
79836286|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
79239959|NCT04969120|Drug|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
79239960|NCT03652363|Drug|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
79239961|NCT00709995|Drug|Enzastaurin|Administered orally
79239962|NCT00709995|Drug|Sunitinib|Administered orally
79239963|NCT00709995|Drug|Placebo|Administered orally
79239964|NCT03652129|Procedure|Disinfection|Disinfection maneuver using LASER and nano irrigant
79533973|NCT05417646|Drug|Placebo|Placebo comparator to empagliflozin
79239965|NCT02503540|Drug|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
79239966|NCT03621865|Dietary Supplement|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
79239967|NCT03621865|Dietary Supplement|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
79239968|NCT03621865|Dietary Supplement|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
79239969|NCT03621865|Dietary Supplement|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
79239970|NCT03621865|Dietary Supplement|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
79239971|NCT04222101|Diagnostic Test|Oral glucose tolerance test|measure insulin, glucose and FGF21 levels in response to oral glucose challenge
79239972|NCT04054297|Behavioral|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
79239973|NCT04054297|Behavioral|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
79239974|NCT04054219|Device|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
79533974|NCT05417646|Drug|Empagliflozin|Single-dose, 25 mg, two hours before clamp
79533975|NCT05415943|Device|Diagnostic microprobe (inPROBE) medical device|Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
79547202|NCT01552252|Dietary Supplement|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
79547203|NCT01552252|Dietary Supplement|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
79690132|NCT03662308|Device|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
79690133|NCT03651700|Device|Active TMS|Active TMS will be at 90% motor threshold
79690134|NCT03651700|Device|Sham TMS|Sham TMS will be administered
79836287|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
79239975|NCT03652597|Device|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
79239976|NCT02502526|Device|Centurion® Vision System, 45° Balanced Tip|
79239977|NCT02502526|Device|Centurion® Vision System, 45° MFK Tip|
79239978|NCT02502526|Device|lnfiniti® Vision System, 45° MFK Tip|
79533976|NCT05414903|Behavioral|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head > 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
79836288|NCT00986518|Biological|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
80007349|NCT03138304|Behavioral|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
79690135|NCT03651700|Behavioral|CILT|60-90 minutes of CILT will be administered during each treatment session
79239979|NCT02502526|Device|INTREPID® Ultra infusion sleeve|
80007350|NCT03138304|Behavioral|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
79239980|NCT02502526|Device|Ultra infusion sleeve|
79239981|NCT05390697|Other|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
79379643|NCT05197998|Behavioral|Color Brave Program|The intervention will consist of a 6-week multi-module program that will be delivered via a mobile application. This program is designed for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
79239982|NCT02972515|Behavioral|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
79239983|NCT02972515|Device|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
79239984|NCT05012332|Procedure|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
79690136|NCT03612258|Diagnostic Test|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
79379644|NCT05197972|Other|cardiac coherence program coupled with hypnosis|"At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape)."
79379645|NCT05197075|Drug|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
79379646|NCT05195398|Device|Anodal transcranial Direct Current Stimulation (A-tDCS)|Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
79379647|NCT05195398|Device|Sham Intervention|Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
79379648|NCT05187013|Behavioral|mHealth for Hypertension in Homeless Persons|SMS text messages sent to participants' mobile phones
79836289|NCT00769158|Drug|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
80007351|NCT03287687|Drug|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
79690137|NCT03611868|Drug|APG-115+Pembrolizumab|dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
79836290|NCT00769158|Other|Placebo|Placebo Comparator
80007352|NCT03287687|Drug|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
80007353|NCT01991067|Biological|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
80007354|NCT03138148|Other|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
79379649|NCT05182567|Drug|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
79239985|NCT04455087|Other|sensitization|sensitization of doctor to decrease the prescription of abuse exams
79239986|NCT04967482|Procedure|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.
79379650|NCT05182567|Drug|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
79379651|NCT05182567|Drug|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
79379652|NCT05182567|Drug|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
79379653|NCT05178498|Procedure|Follow-Up|Undergo follow up
80007355|NCT03285269|Diagnostic Test|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
80007356|NCT03285269|Device|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
80007357|NCT03285269|Procedure|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
80007358|NCT05085652|Procedure|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
79239987|NCT04967482|Procedure|Conventional transarterial chemoembolization (cTACE)|The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
79836291|NCT00983086|Drug|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
79239988|NCT04053985|Combination Product|TAI combine lenvatinib|TAI combine lenvatinib
79239989|NCT04053985|Drug|Lenvatinib|lenvatinib only
79379654|NCT05178498|Procedure|Physical Examination|Complete physical measurements
79379655|NCT05178498|Other|Questionnaire Administration|Complete questionnaires
80007359|NCT01940835|Procedure|Upper endoscopy with small bowel biopsies and brushings.|
79533977|NCT05414903|Behavioral|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
79533978|NCT05414903|Behavioral|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker [SR Research, EyeLink, Ontario, Canada])."
79533979|NCT05412173|Drug|Molnupiravir|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
79547204|NCT01552291|Dietary Supplement|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
79547205|NCT01552291|Drug|Placebo|30g oral maltodextrin / day for 5 days before surgery
79836292|NCT00775320|Procedure|FLT-PET scan|Imaging test
80007360|NCT01940835|Other|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
80007361|NCT01940835|Other|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
80007362|NCT03089398|Procedure|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
79379656|NCT05169788|Device|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
80007363|NCT03089398|Device|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
79239990|NCT04455243|Drug|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
79379657|NCT05169697|Drug|A:YH002+YH001|YH002 on CnD1,YH001 on CnD8,Q3W
79379658|NCT05169697|Drug|B:YH002+YH001|YH002 and YH001 on same day,Q3W
79239991|NCT04455243|Drug|Placebo|Matching placebo administered in the same schedule and volume as NAC
79379659|NCT05169697|Drug|YH002+YH001|A traditional 3+3 dose escalation algorithm
79379660|NCT05168735|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
79836293|NCT00983164|Dietary Supplement|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
79836294|NCT00769236|Other|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
79836295|NCT00769236|Other|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
80007364|NCT03089398|Device|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
79239992|NCT04854993|Drug|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
79690138|NCT03610360|Drug|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
79690139|NCT03595592|Drug|Trastuzumab|Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
79690140|NCT03595592|Drug|Pertuzumab|Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
79690141|NCT03595592|Drug|Carboplatin|Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
79690142|NCT03595592|Drug|Paclitaxel|Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
79690143|NCT03595592|Drug|Doxorubicin|Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
79690144|NCT03595592|Drug|Cyclophosphamide|Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
79690145|NCT03595592|Drug|Atezolizumab|Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
79239993|NCT04854993|Drug|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
79239994|NCT02972359|Drug|Neridronic acid|Neridronic acid administered as intravenous infusion.
79239995|NCT04455009|Dietary Supplement|Fitness Drink Formula|Single drink provided following baseline assessments
79239996|NCT04454775|Diagnostic Test|coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.|
79379661|NCT05168735|Behavioral|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
79379662|NCT05168735|Behavioral|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
79379663|NCT05164822|Other|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
79379664|NCT05163782|Device|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
79690146|NCT03595592|Procedure|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
79690147|NCT03593226|Drug|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
79690148|NCT03575819|Drug|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
79690149|NCT03563716|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
79690150|NCT03563716|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79690151|NCT03563716|Drug|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79690152|NCT03540563|Other|Blood draw|Blood will be drawn to assess ctDNA
79690153|NCT03538626|Biological|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
79836296|NCT00769236|Other|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
79836297|NCT00988936|Drug|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with [F-18]RGD-K5
80007365|NCT01872273|Other|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
80007366|NCT02886845|Genetic|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
80007367|NCT01787643|Other|Height-Adjustable Desk Intallation in Office|
80007368|NCT01374503|Biological|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
79239997|NCT04911777|Drug|Pentarlandir™ UPPTA|Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
79239998|NCT04911777|Drug|Placebo|The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
79239999|NCT05390619|Procedure|50% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
79690154|NCT03538626|Biological|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
79533980|NCT05407337|Behavioral|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
79836298|NCT00333775|Drug|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
79379665|NCT05163782|Device|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
79836299|NCT00333775|Drug|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
79533981|NCT05403268|Device|DeltaScan|Twice daily DeltaScan observations
79533982|NCT05396859|Drug|Decitabine and Cedazuridine|Given PO
79836300|NCT00333775|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
79836301|NCT00771732|Device|light therapy|6 minute light therapy
79836302|NCT00771732|Device|light therapy|combination of wavelengths
79379666|NCT05163782|Device|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
79836303|NCT03860428|Drug|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
79379667|NCT05163782|Device|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
79836304|NCT03860428|Drug|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
79836305|NCT03860428|Other|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
79836306|NCT02557074|Drug|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
79379668|NCT05163288|Drug|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
79379669|NCT05163288|Other|Placebo|Matching Placebo Sachet
79533983|NCT05396859|Drug|Entrectinib|Given PO
79533984|NCT05396859|Other|Laboratory Biomarker Analysis|Correlative studies
79533985|NCT05393830|Behavioral|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
79533986|NCT05390892|Drug|SGLT2 inhibitor|Empagliflozin, dapagliflozin, or canagliflozin
79533987|NCT05390892|Drug|GLP-1 receptor agonist|Dulaglutide, liraglutide, semaglutide
79533988|NCT05390892|Drug|Combination drug|SGLT2 inhibitor and GLP-1 receptor agonist
79533989|NCT05388045|Other|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
79690155|NCT03535857|Device|PTNS|Use of PTNS on the ankle for 30 minutes
79690156|NCT03532100|Device|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
79836307|NCT02557074|Drug|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
79836308|NCT00771888|Drug|lanreotide|lanreotide
79836309|NCT00989170|Behavioral|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
79836310|NCT00989170|Behavioral|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
79836311|NCT00771966|Procedure|Standard therapy|Standard therapy
79836312|NCT00771966|Procedure|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
79836313|NCT00605475|Drug|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
79836314|NCT00605475|Drug|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
80007369|NCT01374503|Biological|Placebo|single or multiple i.v. administration
80007370|NCT05085418|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
80007371|NCT05759195|Diagnostic Test|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
80007372|NCT03466996|Behavioral|Intervention group|More frequent follow up with face to face interaction.
79379670|NCT05156853|Dietary Supplement|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
79533990|NCT05384067|Behavioral|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
79533991|NCT05382845|Diagnostic Test|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
79836315|NCT00605475|Drug|Metformin|Participants continued on their stable daily dose of metformin throughout the study
79690157|NCT03532100|Device|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
79690158|NCT03532100|Device|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
79690159|NCT03532100|Device|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
79690160|NCT03532100|Device|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
79690161|NCT03521154|Drug|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
79690162|NCT03521154|Drug|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
79690163|NCT03505398|Procedure|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
79690164|NCT03505398|Procedure|visual acuity|using ETDRS scales
79690165|NCT03505398|Procedure|automated visual field|recording visual attention based on central or peripheral visual information
79690166|NCT03505398|Procedure|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
79690167|NCT03496168|Drug|mavacamten|mavacamten capsules
79690168|NCT03487380|Procedure|Fecal sample collection|Fecal sample collection
79690169|NCT03486301|Drug|BDB001|BDB001 is an immunotherapy agent.
79690170|NCT03486301|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
79836316|NCT00986596|Dietary Supplement|vitamin D3|4000 IU once daily by mouth for 4 months
79533992|NCT05380089|Other|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
79690171|NCT03477201|Procedure|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
80007373|NCT03466996|Behavioral|Standard of care group|Transition goal setting during annual follow up.
80007374|NCT01709331|Drug|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
79533993|NCT05376709|Dietary Supplement|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
79690172|NCT03477201|Procedure|Standard laparoscopic inguinal hernia repair|Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
79690173|NCT03467373|Drug|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
79690174|NCT03467373|Drug|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
79690175|NCT03467373|Drug|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
79690176|NCT03467373|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
79690177|NCT03467373|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 administered IV on Day 1 of each 21-day cycle
79836317|NCT00986596|Dietary Supplement|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
79836318|NCT00772044|Device|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
79836319|NCT00772044|Device|Sham Device|Sham device will be applied
79836320|NCT00333619|Behavioral|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
80007375|NCT01709331|Drug|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
79533994|NCT05376397|Behavioral|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
79533995|NCT05366218|Biological|Tafasitamab|Antibody vaccination
79533996|NCT05351476|Behavioral|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
79533997|NCT05351476|Behavioral|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
79533998|NCT05348421|Procedure|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
79533999|NCT05348421|Procedure|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
79534000|NCT05345301|Diagnostic Test|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
79534001|NCT05336630|Device|Forceps|The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
79534002|NCT05334758|Device|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
79690178|NCT03467373|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle
79690179|NCT03467373|Drug|Vincristine|Vincristine 1.4 mg/m^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
79690180|NCT03467373|Drug|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
79836321|NCT00333619|Behavioral|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
79534003|NCT05334758|Device|Standard of Care COVID-19 Test|Standard of care
79690181|NCT03467373|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
79379671|NCT05156853|Dietary Supplement|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
79690182|NCT03462719|Drug|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
79836322|NCT00986752|Device|Stenting (Smart Stent)|Nitinol stent
79690183|NCT03462719|Drug|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
79534004|NCT05334758|Diagnostic Test|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
79534005|NCT05333276|Drug|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
79534006|NCT05316324|Procedure|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
79534007|NCT05316324|Procedure|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
79534008|NCT05314374|Dietary Supplement|Ileocolonic-release conjugated bile acid|1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days
79534009|NCT05314374|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient. 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days.
79690184|NCT03462719|Drug|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
79690185|NCT03462719|Drug|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
79836323|NCT00986752|Device|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
79836324|NCT00986752|Procedure|Atherectomy (SilverHawk device)|Atherectomy
79836325|NCT00772122|Drug|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
79836326|NCT00772122|Drug|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
80007376|NCT04883099|Device|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
80007377|NCT03136510|Drug|Apixaban 5 mg|"Bood collection for biological analyses at:~inclusion visit~follow-up visit at 1 month~end of research at 3 month"
79379672|NCT05154006|Behavioral|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply [5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)]
79836327|NCT04006678|Procedure|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
79836328|NCT00769470|Biological|trastuzumab|Given IV
80007378|NCT05693259|Device|Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer|Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
79379673|NCT05154006|Behavioral|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) [4.1 Instruction on how to perform a behavior (Michie et al., 2013)]"
79379674|NCT05154006|Behavioral|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). [6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)]
79379675|NCT05154006|Behavioral|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. [3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).]
79379676|NCT05148338|Other|Comprehensive risk factor treatment|"Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~Smoking cessation at specialized outpatient clinic~Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~Motivation and education through a digital health platform"
79836329|NCT00769470|Drug|carboplatin|Given IV
79836330|NCT00769470|Drug|docetaxel|Given IV
79836331|NCT00769470|Drug|lapatinib ditosylate|Given orally
79836332|NCT04854382|Behavioral|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
79836333|NCT00605319|Drug|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
79534010|NCT05307250|Behavioral|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE|"In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate."
79534011|NCT05307250|Behavioral|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).|In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
79690186|NCT03462719|Drug|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
79690187|NCT03459157|Drug|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
79836334|NCT04006834|Other|No intervention involved|No intervention involved
79836335|NCT00922038|Behavioral|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
79836336|NCT00983320|Drug|quetiapine|flexible dosage (50 to 300 mg)
79836337|NCT00983320|Drug|placebo|placebo
79836338|NCT00908661|Device|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
79836339|NCT00989248|Other|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
79836340|NCT00983398|Drug|Carboplatin|Given IA
79836341|NCT00983398|Drug|Mannitol|Given IA
79836342|NCT00983398|Drug|Melphalan|Given IA
79836343|NCT00983398|Other|Quality-of-Life Assessment|Ancillary studies
79836344|NCT00983398|Other|Questionnaire Administration|Ancillary studies
79534012|NCT05307250|Other|Bolstered Standard of Care (BSOC)|All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
79534013|NCT05304221|Other|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
79836345|NCT00983398|Drug|Sodium Thiosulfate|Given IV
79534014|NCT05301348|Device|Photoacoustic Flow Cytometry|Detection of circulating blood clots
79534015|NCT05300698|Device|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
79534016|NCT05295121|Drug|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
79534017|NCT05294250|Drug|XC8|XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
79690188|NCT03450343|Drug|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
79690189|NCT03450343|Drug|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
79690190|NCT03445936|Device|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
79690191|NCT03445936|Device|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
79836346|NCT00333229|Drug|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
79836347|NCT00333229|Drug|Placebo|Matching Placebo
79836348|NCT00769548|Drug|flutamide|Drug used for TAS.
79836349|NCT00769548|Drug|goserelin acetate|Drug used for TAS.
79379677|NCT05148338|Other|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
79690192|NCT03430076|Procedure|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
79690193|NCT03430076|Device|Propaten®|Propaten®
79240000|NCT05390619|Procedure|70% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
79690194|NCT03430076|Device|Crude PTFE|Crude PTFE
79690195|NCT03424941|Device|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
79690196|NCT03424941|Device|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
79690197|NCT03412760|Diagnostic Test|Exome sequencing|Expansive genetic test performed for affected fetus or neonate.
79690198|NCT03405779|Procedure|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
79690199|NCT03395210|Drug|Rilzabrutinib|BTK inhibitor
79690200|NCT03388593|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
79836350|NCT00769548|Radiation|low-LET photon therapy|radiation therapy
79836351|NCT05277675|Drug|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
79836352|NCT05277675|Procedure|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
79836353|NCT00769626|Other|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
79836354|NCT00769626|Other|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
79240001|NCT04857411|Behavioral|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
79379678|NCT05147532|Procedure|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
79379679|NCT05135819|Behavioral|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
79379680|NCT05120960|Drug|tepotinib|Given by PO
79379681|NCT05120960|Drug|tepotinib plus osimertinib|Given by PO
79379682|NCT05116163|Behavioral|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
79534018|NCT05293769|Other|questionnaire|questionnaire will be filled in by all participants
79690201|NCT03388593|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
79690202|NCT03361748|Biological|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
79690203|NCT03312699|Biological|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
79690204|NCT03312699|Biological|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
79836355|NCT03984409|Dietary Supplement|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
79379683|NCT05116163|Other|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
79379684|NCT05111405|Procedure|CMC Arthroplasty|Surgical intervention to treat CMC arthritis
79690205|NCT03312699|Biological|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
80007379|NCT03451474|Procedure|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
80007380|NCT05693181|Biological|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
79379685|NCT05104645|Other|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
80007381|NCT05693181|Other|Control vehicle (sterile saline)|Sterile saline infusion in control patients
79379686|NCT05104645|Other|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
79379687|NCT05104645|Other|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
79379688|NCT05101681|Diagnostic Test|Teledentistry|Teledentistry using mobile photographs
79379689|NCT05086705|Device|EMBr Wave|Use EMBr Wave
79534019|NCT05292911|Drug|ALT-801|Injected subcutaneously (SC)
80007382|NCT03136354|Procedure|Endoscopic Submucosal Dissection|
80007383|NCT03136354|Procedure|Laparoscopic assisted Gastrectomy|
80007384|NCT05692245|Drug|Ondansetron|Administered Medication
80007385|NCT05692245|Drug|Dexamethasone|Administered Medication
80007386|NCT03136276|Other|IPS Empress CAD|standard etchable glass ceramics
80007387|NCT03136276|Other|polished Celtra Duo|new glass ceramic material
80007388|NCT05693103|Device|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
79379690|NCT05086705|Other|Questionnaire Administration|Ancillary studies
79379691|NCT05084924|Device|Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
79379692|NCT05070104|Drug|CPI-613|250-1000mg/m2 -14 day cycle
79379693|NCT05070104|Drug|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
79534020|NCT05292911|Other|Placebo|Injected subcutaneously (SC)
79534021|NCT05291533|Other|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
79690206|NCT03312699|Biological|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
79690207|NCT03312699|Biological|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
79690208|NCT03312699|Biological|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm [temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)] drink on alternate days, e.g., days 1, 3, 5 and 7.
79690209|NCT03300310|Other|nursing visit|nursing visit at patient home
79690210|NCT03300310|Other|no nursing visit|the patient take his treatment without nursing visit
79379694|NCT05070104|Drug|Bevacizumab|5mg/kg IV
80007389|NCT05085106|Drug|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
80007390|NCT05085106|Drug|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
79690211|NCT03284242|Procedure|Apheresis|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
79240002|NCT03770559|Procedure|Minimal Invasive RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery
79240003|NCT03770559|Procedure|Open RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
80007391|NCT03079336|Behavioral|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
79240004|NCT01790035|Drug|LGG|
80007392|NCT03079336|Behavioral|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
80007393|NCT03079336|Behavioral|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
80007394|NCT05084872|Drug|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
79534022|NCT05289323|Drug|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
79690212|NCT03280862|Device|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
79240005|NCT01790035|Drug|Placebo|
79240006|NCT03651817|Device|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
79240007|NCT05390541|Behavioral|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, we will use memory practice. Participants will be asked to self-code if they are correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
80007395|NCT00159796|Drug|Asenapine|Asenapine, 3 weeks
80007396|NCT00159796|Drug|Olanzapine|Olanzapine, 3 weeks
80007397|NCT00159796|Drug|Placebo|placebo, 3 weeks
79240008|NCT01381159|Behavioral|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
79240009|NCT01381159|Behavioral|Control|Standard medical care
79534023|NCT05289323|Drug|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
79534024|NCT05288556|Device|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
79690213|NCT03276221|Behavioral|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
79836356|NCT00900939|Behavioral|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
79836357|NCT00900939|Behavioral|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
79836358|NCT00775554|Other|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
79240010|NCT03651739|Device|Knee Connect|An electronic goniometer with smart phone application
79379695|NCT05069259|Other|Stool sample collection|collection for measuring calprotectin levels
79379696|NCT05066854|Procedure|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
79690214|NCT03266770|Device|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
79690215|NCT03246932|Behavioral|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
79690216|NCT03246932|Behavioral|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
79534025|NCT05283512|Other|Preventive treatment with IV-hydration|IV hydration with isotonic 0.9% NaCl
79690217|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
79690218|NCT03243422|Other|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
79690219|NCT03243422|Other|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
79690220|NCT03238196|Drug|Erdafitinib|4mg - 8mg
79690221|NCT03238196|Drug|Palbociclib|125 mg
79690222|NCT03238196|Drug|Fulvestrant|500 mg
80007398|NCT03626571|Other|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
79240011|NCT04723251|Behavioral|taking photographs|"Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks.~Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph."
79240012|NCT03604185|Behavioral|Choir Singing|A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
79240013|NCT03604185|Behavioral|Music Appreciation|A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
79240014|NCT00843817|Drug|Pulmozyme|Pulmozyme® 2.5mg by inhalation
79379697|NCT05066854|Procedure|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
79240015|NCT04655547|Other|Dietary guidance|Dietary guidance with focus on texture and energy intake, preformed by certified dietitians.
79240016|NCT03651661|Drug|human insulin|human insulin administered as nasal spray
79379698|NCT05063513|Biological|Autologous Hematopoietic Stem Cell Transplantation|Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
79379699|NCT05063513|Drug|Rituximab|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
79379700|NCT05062629|Genetic|Whole Genome Sequencing|Whole Genome Sequencing
79534026|NCT05283512|Other|Preventive treatment with oral hydration|Oral hydration with regular bottled water
79240017|NCT03651661|Drug|placebo|placebo administered as nasal spray
79240018|NCT03651661|Diagnostic Test|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
79534027|NCT05281380|Dietary Supplement|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
79534028|NCT05275738|Dietary Supplement|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
79534029|NCT05275738|Other|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
79534030|NCT05273619|Drug|XC8, film-coated tablets, 10 mg|80 mg/day: 4 tablets (40 mg) twice a day
79534031|NCT05273619|Drug|Placebo|4 tablets twice a day
79690223|NCT03225989|Drug|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
79690224|NCT03207373|Diagnostic Test|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
79690225|NCT03201965|Drug|Cyclophosphamide|Participants will receive 300 mg/m^2 of cyclophosphamide as an oral or IV dose.
79690226|NCT03201965|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 of bortezomib as an subcutaneous (SC) injection.
79690227|NCT03201965|Drug|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
79690228|NCT03201965|Drug|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
79690229|NCT03183609|Other|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
79690230|NCT03183609|Other|Rice Flour in Protein Shake|15 Grams Rice Flour BID
79690231|NCT03173560|Drug|lenvatinib|lenvatinib capsules.
79240019|NCT01682317|Behavioral|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, < 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
80007399|NCT03368014|Behavioral|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
80007400|NCT03361462|Behavioral|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
80007401|NCT03327844|Drug|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
79240020|NCT03574389|Biological|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
79240021|NCT03574389|Biological|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
79240022|NCT04455945|Procedure|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
79240023|NCT04455945|Procedure|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
79240024|NCT01060111|Drug|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
79240025|NCT01060111|Drug|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
79240026|NCT01060111|Drug|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
79379701|NCT05048810|Radiation|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
79379702|NCT05045677|Other|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
79534032|NCT05272943|Other|Oxgen saturation measurement with validated pulse oximetry|Oxgen saturation will be measured with validated pulse oximetry
79534033|NCT05272943|Other|Oxgen saturation measurement with smart electronics|Oxgen saturation will be measured with smart electronics
79690232|NCT03173560|Drug|everolimus|everolimus tablets.
79690233|NCT03155425|Drug|SHR-1210|A humanized monoclonal immunoglobulin
79690234|NCT03150329|Other|Laboratory Biomarker Analysis|Correlative studies
79379703|NCT05045677|Other|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
79379704|NCT05043675|Drug|[18F]APN-1607|Subjects will receive one injection of [18F]APN-1607 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
79534034|NCT05269849|Drug|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
79240027|NCT04586907|Drug|LY3537021|Administered SC.
79240028|NCT04586907|Drug|Placebo|Administered SC.
79534035|NCT05264389|Device|Poly-Tape|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
79534036|NCT05264168|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
79534037|NCT05264168|Drug|Apixaban|Any apixaban dispensing claim is used as the exposure group
79547206|NCT01552304|Other|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
79690235|NCT03150329|Biological|Pembrolizumab|Given IV
79690236|NCT03150329|Drug|Vorinostat|Given PO
79690237|NCT03133208|Procedure|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
79690238|NCT03063606|Behavioral|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
79836359|NCT00775554|Other|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
79534038|NCT05262504|Device|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
79534039|NCT05258903|Procedure|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
79379705|NCT05037656|Behavioral|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
79690239|NCT03063606|Drug|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
79690240|NCT03057431|Drug|Placebo oral capsule|Once daily for 3 years
79690241|NCT03057431|Drug|12.5 mg hydrochlorothiazide|Once daily for 3 years
79379706|NCT05016219|Device|Circadian-Effective Light|Narrowband blue light
79379707|NCT05016219|Device|Rhythmic Light|40 hertz (Hz) flicker
79690242|NCT03057431|Drug|25.0 mg hydrochlorothiazide|Once daily for 3 years
79690243|NCT03057431|Drug|50.0 mg hydrochlorothiazide|Once daily for 3 years
79690244|NCT03053986|Dietary Supplement|Apple polyphenols|1 tablet per day at evening before sleeping
79240029|NCT03651583|Behavioral|Kiko exercises-combines breathing and movement|
79240030|NCT02969863|Device|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
79379708|NCT05016219|Device|Placebo Light|Narrowband red light
79836360|NCT04005820|Other|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
79240031|NCT02969863|Device|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
79379709|NCT05016219|Device|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
79379710|NCT05012176|Behavioral|Behavioral Intervention|Participate in EFT
79379711|NCT05012176|Behavioral|Behavioral Intervention|Participate in ERT
79379712|NCT05012176|Other|Quality-of-Life Assessment|Ancillary studies
79379713|NCT05012176|Other|Questionnaire Administration|Ancillary studies
79547207|NCT01552304|Other|Control group|
79690245|NCT03053986|Other|Placebo|1 tablet per day at evening before sleeping
79690246|NCT03052127|Drug|Light-activated AU-011|Study treatment
79690247|NCT03052127|Device|Laser Activation|Study treatment
79690248|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL.
79690249|NCT03020199|Radiation|nb-UVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application will be performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face is recommended
79690250|NCT03020199|Drug|Calcipotriol|Its a topical treatment for Psoriasis. the concentration it is used is 50mcg/g
79690251|NCT03020199|Drug|Betamethasone|this is topical cream which is used in 0.5mg/g concentration
79379714|NCT05001516|Drug|LM-302|All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
79690252|NCT03008291|Procedure|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
79690253|NCT03008291|Procedure|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
79690254|NCT03008291|Procedure|Dual Chamber Pacemaker Implantation|
79690255|NCT03001414|Biological|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
79690256|NCT03001414|Biological|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
79690257|NCT03001414|Biological|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
79836361|NCT04005820|Other|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
79836362|NCT02538159|Device|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
79690258|NCT02991469|Drug|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79240032|NCT02969863|Other|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
79534040|NCT05258903|Procedure|Radial artery cannulation|Radial artery will be cannulated under USG guidance
79534041|NCT05257967|Diagnostic Test|Lumbar puncture and Phlebotomy|Sampling of cerebral spinal fluid and plasma.
79534042|NCT05257174|Dietary Supplement|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
79534043|NCT05257174|Dietary Supplement|Placebo|intake Placebo twice daily for three months
79534044|NCT05256797|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
79534045|NCT05256797|Drug|Apixaban|Any apixaban dispensing claim is used as the exposure group
79534046|NCT05227404|Diagnostic Test|LumiraDX|Point-of-care test for SARS-CoV-2
80007402|NCT03327844|Drug|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
79690259|NCT02978521|Other|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
79690260|NCT02967692|Biological|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
79690261|NCT02967692|Other|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
79690262|NCT02967692|Drug|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
79690263|NCT02967692|Drug|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
79690264|NCT02953457|Biological|Durvalumab|Given IV
79240033|NCT02969863|Other|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
79240034|NCT03651427|Drug|Estradiol|Induced hypogonadism and re-institution of CSHT
79240035|NCT05285293|Biological|Platelet Rich Fibrin (PRF)|Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
79240036|NCT05285293|Biological|Platelet Rich Fibrin (PRF) and Retinol|Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
79534047|NCT05227404|Diagnostic Test|RightSign|Point-of-care test for SARS-CoV-2
79534048|NCT05227404|Diagnostic Test|Case Control|Genscript assay performed on the plasma sample
79534049|NCT05226468|Drug|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
79534050|NCT05226195|Other|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
79534051|NCT05220787|Biological|Cold stored platelets in 100% plasma stored for 10-14 days|Subjects will receive cold stored platelets from the start of surgery until 24 hours after the end of surgery
79534052|NCT05220787|Biological|Room temperature stored platelets in 100% plasma stored for up to 7 days|Subjects will receive room temperature stored platelets from the start of surgery until 24 hours after the end of surgery
79534053|NCT05219994|Other|Hyperoxia Exposure|2 hours of hyperoxia exposure during OGTT
79534054|NCT05219994|Other|Normoxia Exposure|2 hours of normoxia exposure during OGTT
79690265|NCT02953457|Other|Laboratory Biomarker Analysis|Correlative studies
79690266|NCT02953457|Drug|Olaparib|Given PO
79690267|NCT02953457|Biological|Tremelimumab|Given IV
79690268|NCT02939573|Drug|Colchicine|Randomized to colchicine 0.6 mg x 2/day
79690269|NCT02939573|Drug|Dapsone|Randomized to dapsone 150 mg/day
79690270|NCT02939573|Drug|Azathioprine|Randomized to azathioprine 2 mg/kg/day
79690271|NCT02925416|Drug|Oritavancin|Administered intravenously
79690272|NCT02925416|Drug|Placebo (D5W)|Administered intravenously
79690273|NCT02882074|Drug|Human albumin|human albumin 5% during surgery
79690274|NCT02882074|Drug|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
79690275|NCT02844465|Device|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
79534055|NCT05218720|Diagnostic Test|EuroSCORE II|"Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk <1, low risk 1-2.99, moderate risk 3-4.99, high risk >5.~CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
80007403|NCT03288766|Procedure|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
79240037|NCT02969707|Device|MagPro TMS system (MagVenture, Denmark)|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
79379715|NCT05000827|Device|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
79534056|NCT05218083|Behavioral|REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)|"REmotely Monitored, Mobile health-supported, High Intensity Interval Training consists of remotely monitored tailored, structured, progressive multidomain physical rehabilitation & personalized instruction & coaching.~Patients complete 3 structured exercise sessions/week consisting of HIIT, strength, balance, and mobility exercises. Following warmup, patients increase workload at a heart rate corresponding to 95% VO2peak for 1-minute before returning to warm-up speed for 1-minute at a heart rate corresponding to 60% VO2peak.~Strength includes functional strengthening exercises for lower extremities & general resistance exercises for major muscle groups.~Balance incorporates static & dynamic exercises, including progressively narrowing base of support with eyes open or closed, reaching forward & backward starting within base of support & progressing to outside base of support.~Mobility rehabilitation includes dynamic start/stop while walking and changing direction while walking."
79547208|NCT01552317|Other|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
79690276|NCT02806843|Device|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
79690277|NCT02720068|Biological|Favezelimab|IV infusion
79690278|NCT02720068|Biological|Pembrolizumab|IV infusion
79690279|NCT02720068|Drug|Oxaliplatin|IV infusion
79690280|NCT02720068|Drug|Irinotecan|IV infusion
79690281|NCT02720068|Drug|Leucovorin (Calcium Folinate)|IV infusion
79690282|NCT02720068|Drug|Fluorouracil [5-FU]|IV infusion
79836363|NCT02538159|Device|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
79836364|NCT00983554|Drug|Anastrazole|Arimidex 1mg daily
79836365|NCT00983554|Drug|Testosterone|Testim 10g daily
80007404|NCT03230032|Device|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
79379716|NCT05000827|Other|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI >5%
79379717|NCT04990726|Behavioral|Assessment|Undergo medical assessments
79379718|NCT04990726|Procedure|Biospecimen Collection|Undergo collection of blood samples
79379719|NCT04990726|Other|Quality-of-Life Assessment|Ancillary studies
79379720|NCT04990726|Other|Questionnaire Administration|Complete questionnaires
79690283|NCT02720068|Biological|Favezelimab/Pembrolizumab|IV infusion
79690284|NCT02720068|Drug|Lenvatinib|Oral
79690285|NCT02705196|Genetic|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
79836366|NCT00983554|Drug|Dutasteride|Avodart 2.5mg daily
79836367|NCT00983554|Drug|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
80007405|NCT05691855|Drug|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
79836368|NCT00908739|Genetic|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
79379721|NCT04989790|Other|PICU Up!|PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
79379722|NCT04973085|Device|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
79379723|NCT04973085|Device|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
79379724|NCT04973007|Drug|Gadoxetate disodium|Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.
79836369|NCT00908739|Other|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
79534057|NCT05213650|Other|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
79836370|NCT00908739|Other|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
79836371|NCT00908817|Drug|triamcinolone acetonide|paste applied over tracheal tube for lubrication
79240038|NCT02969707|Behavioral|Hypnosis|Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
79240039|NCT03651193|Diagnostic Test|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
79534058|NCT05213650|Other|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
79836372|NCT00908817|Drug|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
79547209|NCT01552330|Drug|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
79690286|NCT02705196|Drug|gemcitabine|chemotherapy
79836373|NCT04005898|Device|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
80007406|NCT03123640|Other|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
79240040|NCT03650257|Biological|gp96|25 mcg IH
79690287|NCT02705196|Drug|nab-paclitaxel|chemotherapy
79690288|NCT02705196|Biological|atezolizumab|anti-PD-L1 antibody
79690289|NCT02700230|Procedure|Computed Tomography|Undergo CT scan
79690290|NCT02700230|Other|Laboratory Biomarker Analysis|Correlative studies
79690291|NCT02700230|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
79690292|NCT02700230|Other|Quality-of-Life Assessment|Ancillary studies
79836374|NCT00332839|Drug|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
79836375|NCT00332839|Drug|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
79836376|NCT00332839|Drug|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
79836377|NCT00332839|Drug|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
79836378|NCT00332839|Drug|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
80007407|NCT03068416|Biological|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
79240041|NCT03650257|Drug|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
79240042|NCT03650257|Radiation|radiotherapy|Stupp regimen of radiotherapy
79240043|NCT03649399|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
79690293|NCT02700230|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT imaging
79690294|NCT02700230|Procedure|Magnetic Resonance Imaging|Undergo MRI
79836379|NCT00983632|Procedure|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
79836380|NCT00983632|Device|selective vagus nerve stimulation|electrical vagus stimulation
79836381|NCT00927147|Radiation|BNCT|Boronophenylalanine infusion followed by neutron irradiation
79836382|NCT00927147|Drug|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
79836383|NCT05712616|Drug|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
79240044|NCT03651115|Diagnostic Test|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
79836384|NCT05712616|Drug|Lacto-N-Hexaose|Placebo look alike drug
79836385|NCT00927225|Drug|ropivacaine 0.2%, 50 mL|
79240045|NCT03650179|Other|Observational study : No intervention|Observational study : No intervention. Only exporting data
79379725|NCT04973007|Drug|Gadobenate dimeglumine|The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
79534059|NCT05213650|Other|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
79836386|NCT00927225|Drug|normal saline|
79836387|NCT00357097|Drug|Ropinirole|
79836388|NCT00983710|Behavioral|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
79240046|NCT03649243|Drug|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
79240047|NCT03649165|Drug|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
79240048|NCT03649165|Drug|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
79379726|NCT04963673|Other|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
79534060|NCT05213650|Other|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
79534061|NCT05205746|Biological|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
79534062|NCT05205746|Biological|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S[recombinant]) Intramuscular
79690295|NCT02700230|Procedure|Ultrasound Imaging|Undergo ultrasound imaging
79690296|NCT02700230|Procedure|Biospecimen Collection|Undergo blood sample collection
79690297|NCT02700230|Procedure|Biopsy|Undergo tissue biopsy
79690298|NCT02700230|Other|Questionnaire Administration|Ancillary studies
79690299|NCT02660125|Procedure|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
79690300|NCT02658097|Drug|Pembrolizumab|200mg Pembrolizumab by IV infusion
79690301|NCT02658097|Radiation|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
79836389|NCT00983710|Behavioral|Usual care|Booklet on coping with localized prostate cancer
79836390|NCT00927303|Device|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
79836391|NCT00927303|Device|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
79836392|NCT00983788|Drug|Bezafibrate|3 x 200 mg/ day
79836393|NCT00983788|Other|Placebo|Placebo
79836394|NCT00983866|Behavioral|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
79836395|NCT00983944|Biological|bleomycin sulfate|Given IV
79836396|NCT00983944|Biological|rituximab|Given IV
79379727|NCT04962009|Combination Product|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
79240049|NCT03649165|Drug|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
79379728|NCT04954599|Drug|CP-506|CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
79379729|NCT04954599|Drug|Carboplatin|Antineoplastic agent, ATC Code: LO1X A02
79379730|NCT04954599|Drug|Immune checkpoint inhibitor|Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
79240050|NCT03649165|Drug|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
79240051|NCT03649165|Drug|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
79240052|NCT03649087|Other|Vitrification|Vitrification of ovarian tissue
79379731|NCT04948697|Drug|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
79379732|NCT04948697|Drug|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
79379733|NCT04948697|Drug|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
79379734|NCT04943523|Dietary Supplement|Krill Oil|Krill oil supplements 4g/day
79534063|NCT05196750|Other|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
79534064|NCT05195905|Device|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
79534065|NCT05190575|Drug|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
79534066|NCT05179512|Drug|Tiotropium|Tiotropium dispensing claim is used as the reference group.
79534067|NCT05179512|Drug|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
79690302|NCT02646475|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
79534068|NCT05166902|Device|Lens A (comfilcon A lens)|1 month
79690303|NCT02646475|Drug|Saline|Normal saline will be used as a placebo comparator.
79690304|NCT02620280|Drug|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
79836397|NCT00983944|Drug|EPOCH regimen|Given IV or orally
79836398|NCT00983944|Drug|cyclophosphamide|Given IV or orally
79240053|NCT03651037|Behavioral|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
79240054|NCT03649009|Other|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
79379735|NCT04943523|Dietary Supplement|Vegetable Oil|vegetable oil supplements 4g/day
79379736|NCT04932265|Dietary Supplement|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
79379737|NCT04932265|Combination Product|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
79379738|NCT04926545|Drug|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
79534069|NCT05166902|Device|Lens B (lehfilcon A lens)|1 month
79534070|NCT05164926|Other|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
79690305|NCT02620280|Drug|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
79690306|NCT02620280|Drug|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
79690307|NCT02620280|Procedure|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
79836399|NCT00983944|Drug|doxorubicin hydrochloride|Given IV or orally
79836400|NCT00983944|Drug|etoposide|Given IV or orally
79379739|NCT04926545|Other|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
79534071|NCT05164081|Combination Product|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
79690308|NCT02620280|Drug|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
79690309|NCT02603276|Dietary Supplement|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
79690310|NCT02603276|Dietary Supplement|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
79690311|NCT02603276|Dietary Supplement|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
79690312|NCT02564978|Drug|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
79690313|NCT02561962|Drug|AMG 224|Administered as an IV infusion.
79690314|NCT02536118|Device|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
79690315|NCT02534168|Device|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
79379740|NCT04926545|Drug|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
79379741|NCT04916548|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
79690316|NCT02519348|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
79836401|NCT00983944|Drug|prednisone|Given IV or orally
80007408|NCT03109912|Behavioral|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
79379742|NCT04887831|Drug|Trilaciclib|Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
80007409|NCT03109912|Behavioral|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
79836402|NCT00983944|Drug|vincristine sulfate|Given IV or orally
79379743|NCT04887831|Drug|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
79836403|NCT00927459|Drug|PRO-040201|Single dose IV infusion
79836404|NCT00927459|Drug|Placebo|placebo
79836405|NCT00356863|Behavioral|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
79534072|NCT05164081|Combination Product|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
79534073|NCT05162183|Drug|Glimepiride|Glimepiride dispensing claim is used as the reference group.
79534074|NCT05162183|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
79534075|NCT05143749|Other|video tutorial|get video tutorial
79836406|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
79534076|NCT05142566|Device|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
79240055|NCT03649009|Drug|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
79240056|NCT03649009|Drug|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
79240057|NCT03649009|Other|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
79240058|NCT03650023|Dietary Supplement|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
79240059|NCT03650023|Dietary Supplement|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
79240060|NCT04054999|Drug|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
79379744|NCT04887831|Drug|Cisplatin|Cisplatin administered IV on Day 1 of each 21-day cycle
80007410|NCT03109912|Behavioral|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
79240061|NCT04054999|Drug|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
79379745|NCT04887831|Drug|Carboplatin|Carboplatin administered IV on Day 1 of each 21-day cycle
79379746|NCT04887831|Drug|Avelumab|Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
79379747|NCT04886011|Combination Product|placebo gel|just methyl cellulose gel was applied to the ulcer
79379748|NCT04886011|Combination Product|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
79690317|NCT02519348|Biological|Durvalumab|Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
79690318|NCT02519348|Biological|Bevacizumab|Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
79690319|NCT02496156|Behavioral|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
79690320|NCT02496156|Behavioral|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
79836407|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
79379749|NCT04883749|Biological|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
80007411|NCT03109912|Behavioral|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
79534077|NCT05134636|Other|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
79690321|NCT02492464|Dietary Supplement|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
79690322|NCT02492464|Dietary Supplement|Placebo|
79240062|NCT03649945|Drug|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
79240063|NCT03649945|Drug|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
79240064|NCT03649945|Drug|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
79240065|NCT03650959|Other|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
79379750|NCT04881656|Other|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
79379751|NCT04874870|Drug|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]|1 injection of 0.58mg will be injected into applicable cord.
79379752|NCT04874870|Combination Product|Xiaflex + Hand-Based Custom Orthosis|1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
79379753|NCT04872543|Drug|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
79379754|NCT04860297|Biological|mRNA-1273|Sterile liquid for injection
79379755|NCT04857372|Drug|IAG933|Capsule
80007412|NCT05691621|Drug|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
80007413|NCT05058820|Other|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
80007414|NCT05058820|Other|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
79379756|NCT04851509|Procedure|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
80007415|NCT05691543|Procedure|sacrospinous fixation Using Posterior Vaginal wall flap|"Identification of the sacro spinous ligament.~Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
80007416|NCT05042206|Biological|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
79534078|NCT05120167|Diagnostic Test|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
79836408|NCT00987064|Device|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
79240066|NCT03648775|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
79240067|NCT03650881|Drug|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
79240068|NCT03650881|Drug|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
79534079|NCT05120167|Diagnostic Test|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
79690323|NCT02488733|Procedure|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
79690324|NCT02488733|Drug|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)[50] and determined on an individual basis [52].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
79836409|NCT00987064|Device|Placebo TLA|TLA treatment with disabled filtration function
79836410|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
80007417|NCT05008510|Drug|Sabizabulin|Sabizabulin (Veru-111)
80007418|NCT05008510|Drug|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
80007419|NCT05008510|Drug|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
80007420|NCT05001256|Other|questionnaire study|Participants will be surveyed through face-to-face interviews.
79240069|NCT03648307|Diagnostic Test|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
79240070|NCT02904265|Drug|Diazepam|
79836411|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
79240071|NCT02904265|Drug|Acetazolamide|
79240072|NCT03648229|Procedure|Selective laser trabeculoplasty (SLT)|Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
79240073|NCT03648229|Drug|Latanoprost ophthalmic solution|Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
79240074|NCT03648229|Drug|Timolol ophthalmic solution|Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
79836412|NCT00909129|Drug|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
80007421|NCT03019510|Behavioral|No exercise|No exercise will be done on the day of the study night to be tested
80007422|NCT03019510|Behavioral|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
80007423|NCT03019510|Behavioral|Evening exercise|Evening exercise will be done on the day of the study night to be tested
79379757|NCT04851509|Procedure|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
79379758|NCT04848480|Drug|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
79534080|NCT05120167|Diagnostic Test|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
79534081|NCT05107466|Diagnostic Test|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
79379759|NCT04848480|Drug|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
79379760|NCT04848480|Drug|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
79379761|NCT04848389|Procedure|Skin Adhesive procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
79547210|NCT01552330|Drug|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
79690325|NCT02486718|Drug|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
79690326|NCT02486718|Drug|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of up to four 21-day cycles.
79836413|NCT00909129|Drug|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
79836414|NCT01053325|Drug|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
79836415|NCT01053325|Drug|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
79836416|NCT04733404|Device|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
79836417|NCT05277363|Other|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
79836418|NCT03990181|Dietary Supplement|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
79836419|NCT03990181|Dietary Supplement|meal matrix & CS|Test meal consumed with the control supplement
79836420|NCT03990181|Dietary Supplement|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
79836421|NCT03990181|Dietary Supplement|no-matrix & CS|Test drink consumed with the control supplement
79836422|NCT05712148|Biological|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
79836423|NCT00909207|Behavioral|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
79836424|NCT01053403|Drug|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
80007424|NCT04402996|Other|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
79379762|NCT04848389|Procedure|Standard suture procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
79534082|NCT05106361|Behavioral|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
79534083|NCT05106361|Behavioral|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
79836425|NCT00987142|Drug|CX501|Cultured chimeric skin
79690327|NCT02486718|Drug|Vinorelbine|Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
79690328|NCT02486718|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.
79836426|NCT00987142|Device|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
79836427|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intracoronary)
79836428|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intravenous)
79836429|NCT03990103|Drug|S1|80-120 mg/day, PO, D1-14, every 21 days
80007425|NCT04402996|Other|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
80007426|NCT05194995|Drug|JAB-21822|JAB-21822 administered orally as a tablet.
79379763|NCT04843436|Device|Symani Surgical System|Robotically Assisted Microsurgery
79534084|NCT05099198|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the reference
79534085|NCT05099198|Drug|Glimepiride|Glimepiride dispensing claim is used as the reference
79534086|NCT05089071|Device|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
79690329|NCT02486718|Drug|Gemcitabine|Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
79836430|NCT03990103|Drug|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
79836431|NCT03990103|Drug|Bevacizumab|200 mg, IP, D1, every 21 days
79836432|NCT03990103|Drug|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
79836433|NCT00927693|Other|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
79836434|NCT00987220|Drug|Placebo|Oral
79836435|NCT00987220|Drug|donepezil (Aricept)|5mg oral
79379764|NCT04841018|Drug|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
79379765|NCT04841018|Drug|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
79534087|NCT05088798|Drug|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-[18F]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
79547211|NCT01552421|Procedure|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
79547212|NCT01552447|Other|EpiFix|Dehydrated placental tissue
79690330|NCT02486718|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
79836436|NCT01581151|Drug|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
79836437|NCT01581151|Drug|Monthly Ranibizumab|30 days between treatments
80007427|NCT05194995|Drug|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
80007428|NCT02972944|Procedure|Laparoscopic cholecystectomy|
80007429|NCT02972944|Procedure|Non-operative treatment|
79690331|NCT02477696|Drug|Acalabrutinib|Participants will receive oral acalabrutinib as stated in arm description.
79690332|NCT02477696|Drug|Ibrutinib|Participants will receive oral ibrutinib as stated in arm description.
79690333|NCT02361944|Drug|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
79690334|NCT02361944|Drug|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
79690335|NCT02246621|Drug|Abemaciclib|Administered orally
79836438|NCT00909285|Device|TMS stimulation|TMS stimulation and cognitive training
79836439|NCT00909285|Device|Sham comparator|Sham comparator
79836440|NCT00909285|Behavioral|Cognitive training|TMS stimulation and cognitive training
80007430|NCT03136978|Diagnostic Test|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
79240075|NCT03461211|Biological|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
79240076|NCT03648697|Biological|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
79240077|NCT03648619|Diagnostic Test|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
79534088|NCT05086172|Behavioral|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
79534089|NCT05086081|Drug|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
79547213|NCT01552447|Other|Compression Therapy|Compression bandaging
79836441|NCT01053481|Dietary Supplement|vitamin D|Vitamin D supplement
79836442|NCT01053481|Behavioral|exercise program (rebounding on a trampoline)|40 days at 30 min/d
79836443|NCT05712070|Behavioral|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
79836444|NCT05712070|Behavioral|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
79836445|NCT00927771|Drug|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
79836446|NCT00927771|Drug|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
79690336|NCT02246621|Drug|Anastrozole|Administered orally
79690337|NCT02246621|Drug|Letrozole|Administered orally
79690338|NCT02246621|Drug|Placebo|Administered orally
79690339|NCT02242773|Device|Multi-Parametric MRI|Multi-Parametric MRI
79690340|NCT02242773|Device|MRI-Guided Biopsy|MRI-Guided Biopsy
79690341|NCT02133885|Drug|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
79690342|NCT02133885|Other|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
79836447|NCT01053559|Drug|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
79836448|NCT00987298|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
79836449|NCT00909441|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
79836450|NCT00984100|Procedure|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
79836451|NCT01053637|Drug|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
79836452|NCT01053637|Drug|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
79836453|NCT00928005|Behavioral|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
80007431|NCT05187039|Other|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
79836454|NCT00928005|Behavioral|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
79836455|NCT00928161|Drug|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
79836456|NCT00909519|Drug|naproxcinod|naproxcinod 750 mg bid
79836457|NCT00909519|Drug|Naproxen|Naproxen 500 mg bid
79240078|NCT04535037|Biological|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
79240079|NCT04535037|Biological|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
79240080|NCT04535037|Biological|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
79240081|NCT02967679|Drug|MD1003|
79836458|NCT00909519|Drug|placebo|placebo
80007432|NCT04401280|Drug|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
80007433|NCT04401280|Drug|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
80007434|NCT04401280|Drug|CPP-ACP|applied in accordance with the manufacturer's specifications
79379766|NCT04837859|Drug|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
79534090|NCT05086081|Drug|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
79534091|NCT05083949|Drug|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
79534092|NCT05083949|Drug|Empagliflozin|empagliflozin 10mg (R1)
79534093|NCT05083949|Drug|Glifage®|Glifage® 850mg (R2)
79836459|NCT00909519|Drug|furosemide|furosemide
79836460|NCT00928239|Procedure|laparoscopic sacropexy with mid vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
80007435|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
80007436|NCT02963272|Other|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
79240082|NCT04447053|Drug|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
79240083|NCT03650647|Procedure|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
79240084|NCT03104205|Behavioral|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
79534094|NCT05083455|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
79534095|NCT05083455|Drug|Enoxaparin|Any enoxaparin dispensing claim is used as the reference group
80007437|NCT03137836|Behavioral|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
79379767|NCT04837066|Diagnostic Test|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
79379768|NCT04833855|Biological|Tezepelumab Dose 1|Subcutaneous injection.
79379769|NCT04833855|Biological|Tezepelumab Dose 2|Subcutaneous injection.
79379770|NCT04833855|Biological|Omalizumab|Subcutaneous injection.
79534096|NCT05083429|Drug|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
79534097|NCT05083429|Drug|Tiotropium|Tiotropium dispensing claim is used as the reference
79547214|NCT01552473|Behavioral|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
79534098|NCT05078879|Drug|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count [ANC] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
80007438|NCT05181891|Behavioral|Contingency Management|Incentives for submitting negative-alcohol urine samples
79690343|NCT02076009|Drug|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
79534099|NCT05078307|Procedure|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
79534100|NCT05075980|Drug|Cisplatin|Given IV
79534101|NCT05075980|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
79534102|NCT05075980|Other|Quality-of-Life Assessment|Ancillary studies
79690344|NCT02076009|Drug|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
79690345|NCT02076009|Drug|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants > 75 years old or with a body mass index < 18.5).
79690346|NCT02021578|Behavioral|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
79690347|NCT02021578|Behavioral|Written information|Reading materials about depression
79690348|NCT01988883|Drug|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
79240085|NCT03647605|Behavioral|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
79379771|NCT04833855|Biological|Placebo|Subcutaneous injection.
79240086|NCT02966509|Behavioral|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
79240087|NCT04361799|Device|CamAPS|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
79240088|NCT04361799|Drug|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
79240089|NCT03647995|Dietary Supplement|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
79240090|NCT03647995|Other|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
79240091|NCT05390073|Diagnostic Test|growth hormone level and insulin like growth factor 1|laboratory test
79240092|NCT03752541|Biological|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
79240093|NCT02966353|Drug|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
79240094|NCT04260789|Device|Seraph 100,The Microbind Affinity Blood Filter|Treatment with Seraph 100 in one arm
79240095|NCT03647839|Drug|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
79379772|NCT04827355|Device|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
79379773|NCT04827355|Device|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
79379774|NCT04824547|Other|exercise|All exercises programs will applied two sessions per week, totally eight week..
79534103|NCT05075980|Other|Questionnaire Administration|Ancillary studies
79690349|NCT01988883|Drug|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
79690350|NCT01988883|Drug|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
79690351|NCT01955499|Drug|Ibrutinib|Given PO
79690352|NCT01955499|Drug|Lenalidomide|Given PO
79690353|NCT01955499|Other|Pharmacological Study|Correlative studies
79690354|NCT01946204|Drug|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
80007439|NCT05181891|Behavioral|Non-contingent control|Incentives for submitting urine samples
80007440|NCT05180487|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
80007441|NCT04896970|Other|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc…) with approximately 200 participants.
79547215|NCT01552473|Behavioral|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
79547216|NCT01552486|Other|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
79547217|NCT01552486|Other|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
79690355|NCT01946204|Drug|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
79690356|NCT01829568|Drug|Ibrutinib|Given PO
79690357|NCT01829568|Other|Laboratory Biomarker Analysis|Correlative studies
79240096|NCT03647839|Drug|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
79690358|NCT01829568|Drug|Lenalidomide|Given PO
79240097|NCT03647839|Drug|BBI608|BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
79690359|NCT01829568|Other|Pharmacological Study|Correlative studies
79690360|NCT01829568|Biological|Rituximab|Given IV
79240098|NCT05389917|Procedure|Pancreaticoduodenectomy|"In Pre Operative phase~64 Slice MD CT scan will be taken in all patients undergoing PD in pre op period 3D reconstruction of Peripancreatic vascular system using MDCT images Measure longitudinal distance between Root of Left renal vein, origin of IPDA Measure distance between origin of SMA , MCA and the IPDA~In Intraoperative period~Distance will be measured using standard disposable ruler from Root of Left renal vein to IPDA after Transection of Pancreas followed by specimen removal and to measure the distance between MCA, SMA and IPDA using standard disposable ruler ."
79690361|NCT01822314|Drug|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
79690362|NCT01822314|Drug|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
79690363|NCT01818674|Behavioral|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
79690364|NCT01818674|Behavioral|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
79690365|NCT01776840|Drug|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
79690366|NCT01776840|Drug|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
79690367|NCT01776840|Drug|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
79690368|NCT01776840|Drug|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
79690369|NCT01762839|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
80007442|NCT03136666|Drug|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
80007443|NCT03255083|Drug|DS-1205c|DS-1205c 200 mg capsule
80007444|NCT03255083|Drug|Osimertinib|Osimertinib 80 mg tablet
79240099|NCT03647683|Other|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
79379775|NCT04805489|Other|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
79379776|NCT04799886|Other|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
79379777|NCT04795401|Device|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
79547218|NCT01552499|Other|Standard of care|
79547219|NCT01552499|Other|Applications of EpiFix|
79547220|NCT01552512|Dietary Supplement|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
79534104|NCT05067816|Behavioral|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
79534105|NCT05064202|Device|Impella 5.5|temporary Mechanical Circulatory Support (tMCS)
79534106|NCT05064202|Drug|Inotropes|Enoximone, Dobutamine, Dopamine, Milrinone
79690370|NCT01762839|Drug|Placebo|Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
79836461|NCT00928239|Procedure|laparoscopic sacropexy with caudal vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
79836462|NCT00928317|Drug|ART621|3.0mg/kg s.c.
79836463|NCT00928317|Drug|ART621|1.5mg/kg s.c.
79836464|NCT00928317|Drug|ART621|0.75mg/kg s.c.
79379778|NCT04790201|Behavioral|Friendship Bench Delivered by Professional Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.
79379779|NCT04790201|Behavioral|Friendship Bench Delivered by Lay Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.
79240100|NCT03647683|Other|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
79240101|NCT03647683|Other|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
79379780|NCT04790201|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.
79379781|NCT04788823|Drug|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
80007445|NCT02514148|Behavioral|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
80007446|NCT02514148|Other|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
79240102|NCT03647683|Other|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
79379782|NCT04786106|Drug|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)|Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
79379783|NCT04786106|Procedure|Penile Plication Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.
79534107|NCT05063201|Drug|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
79690371|NCT01762839|Drug|Moxifloxacin|Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
79836465|NCT00928317|Drug|Placebo|Placebo s.c.
79836466|NCT00355615|Drug|Rosuvastatin|oral
79836467|NCT00355615|Drug|Placebo|oral
80007447|NCT02514148|Other|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
79240103|NCT04454541|Procedure|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
79690372|NCT01693822|Drug|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
79836468|NCT00907179|Drug|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
79240104|NCT04454619|Drug|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
79240105|NCT04454853|Other|Lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
79240106|NCT04454853|Other|Suspected lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
79240107|NCT04454853|Other|Positive methylated DNA|Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
79240108|NCT03647449|Dietary Supplement|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
79240109|NCT03647449|Behavioral|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
79240110|NCT03647449|Dietary Supplement|Plant-based meal|Participants will be eating ~900 kcal/day in pre-prepared plant-based meals.
79240111|NCT04454307|Drug|Tramadol|tramadol 100 mg twice daily for 10 days
79240112|NCT04454307|Other|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
79379784|NCT04786106|Procedure|Incision and Grafting (I&G) Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.
79534108|NCT05063201|Drug|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
79534109|NCT05062304|Drug|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
79534110|NCT05062304|Drug|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
79534111|NCT05058638|Drug|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
79534112|NCT05057091|Other|Lomber roll techniques group (n=23)|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
79836469|NCT00907179|Drug|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
79836470|NCT00347269|Behavioral|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
79240113|NCT03647371|Procedure|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
79379785|NCT04786106|Device|RestoreX Penile Traction Device|RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
79379786|NCT04782479|Procedure|hand position|For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
79379787|NCT04765943|Device|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
79379788|NCT04762277|Drug|Spesolimab|Spesolimab
79379789|NCT04762277|Drug|Placebo|Placebo
79240114|NCT03647371|Procedure|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
79379790|NCT04751552|Procedure|Erector Spinae Plane Block (for postoperative pain relief)|A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
79379791|NCT04751409|Procedure|Chest Radiography|Undergo CXR
79379792|NCT04751409|Procedure|Computed Tomography|Undergo CT-chest
79379793|NCT04751409|Procedure|Follow-Up|Undergo intense follow-up
79534113|NCT05057091|Other|Posterior- anterior central vertebral manipulation techniques (n=23)|After initial assessments were made, both groups had high velocity and low amplitude (HVLA) or V. Level manipulation will be applied in the form of 2 different direct manipulation techniques
79534114|NCT05047068|Device|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
79534115|NCT05045534|Drug|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
79534116|NCT05030324|Drug|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
79534117|NCT05030324|Drug|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
79534118|NCT05030324|Drug|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
79534119|NCT05029466|Drug|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
79534120|NCT05018481|Drug|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
79534121|NCT05018481|Drug|Placebo|A placebo will be given in capsule form to study participants
79534122|NCT05017649|Biological|Blood sample|Blood sampling.
79379794|NCT04751409|Procedure|Follow-Up|Undergo limited follow-up
79534123|NCT05007795|Diagnostic Test|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
79534124|NCT05006885|Drug|ALT-801|Injected subcutaneously (SC)
79534125|NCT05006885|Other|Placebo|Injected subcutaneously (SC)
79690373|NCT01615029|Drug|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
79379795|NCT04751409|Procedure|Imaging Technique|Undergo imaging
79379796|NCT04751409|Other|Questionnaire Administration|Ancillary studies
79534126|NCT05001750|Drug|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
79534127|NCT04994665|Procedure|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
79534128|NCT04994665|Procedure|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
79534129|NCT04984473|Device|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
79534130|NCT04982575|Drug|Semaglutide 2.4 mg|Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
79240115|NCT02522793|Other|No intervention; this is an observational study|
79534131|NCT04982575|Drug|Cagrilintide 2.4 mg|Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
79534132|NCT04982575|Drug|Placebo (semaglutide)|"Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
79534133|NCT04982575|Drug|Placebo (cagrilintide)|"Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
79534134|NCT04979884|Drug|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
79534135|NCT04971304|Drug|Receipt of granulocyte-colony stimulating factor|Receipt of originator or biosimilar
79379797|NCT04751396|Other|Best Practice|Receive standard educational information
79379798|NCT04751396|Other|Educational Intervention|Navigate educational tool
79379799|NCT04751396|Other|Interview|Participate in interview
79379800|NCT04751396|Other|Questionnaire Administration|Complete questionnaire
79379801|NCT04751396|Other|Survey Administration|Complete surveys
79379802|NCT04747496|Drug|Edoxaban|This is a non-interventional, observational study.
79379803|NCT04747145|Device|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
79379804|NCT04747145|Drug|Concurrent Chemotherapy (Temozolomide)|75mg/m^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
79690374|NCT01615029|Drug|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
79836471|NCT00347269|Drug|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
79240116|NCT03647293|Procedure|Ultrasound Guided Central Catheter Insertion|
79240117|NCT03647293|Procedure|Peripherally Inserted Central Catheter|
79534136|NCT04962061|Other|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
79534137|NCT04962061|Other|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
79547221|NCT01552512|Other|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
79690375|NCT01615029|Drug|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
79690376|NCT01615029|Drug|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously [injection of a substance into a vein]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index [BMI] less than [<] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
79690377|NCT01575834|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
79690378|NCT01575834|Drug|Placebo|Administered by subcutaneous injection once a month (QM)
79240118|NCT05388123|Drug|Low dose vemurafenib plus rituximab|Vemurafenib 960 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
79240119|NCT03647059|Diagnostic Test|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
79240120|NCT04455711|Drug|Lidocaine Iv|Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
79240121|NCT04455711|Drug|Remifentanil|Continuous infusion of remifentanil 1.5 ng/ml until extubation
79240122|NCT04052503|Behavioral|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
79690379|NCT01575834|Drug|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
79836472|NCT00347269|Behavioral|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
79836473|NCT00928473|Behavioral|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
79240123|NCT04052347|Behavioral|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
79240124|NCT04052347|Behavioral|routine shared decision-making|control group
79240125|NCT03717987|Drug|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
79240126|NCT03717987|Dietary Supplement|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
79379805|NCT04747145|Drug|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
79379806|NCT04736654|Other|Survey study|Headache Disability Questionnaire (HDQ) will be applied.
79690380|NCT01509742|Drug|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
79836474|NCT01053793|Other|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
79836475|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
79836476|NCT01056211|Procedure|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
79836477|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
79836478|NCT00924105|Drug|CYT013-IL1bQb|s.c. injection
79690381|NCT01509742|Drug|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
79690382|NCT01385176|Device|Implant of investigational device system|Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
79240127|NCT03646903|Behavioral|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
79836479|NCT00924105|Drug|Placebo|s.c. injection
79836480|NCT00544648|Drug|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
79836481|NCT00544648|Drug|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
79836482|NCT00544648|Radiation|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
79836483|NCT00924183|Other|Treatment-as-usual|
79836484|NCT00346333|Drug|Lutein|12mg/d
79836485|NCT00346333|Dietary Supplement|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
80007448|NCT02514148|Other|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
79240128|NCT03646903|Behavioral|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
79391312|NCT01697267|Drug|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
79240129|NCT04101903|Diagnostic Test|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
79240130|NCT04062669|Biological|Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) low dose formulation, administered intramuscularlyat Days 1 and 61.
79391313|NCT02449174|Biological|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
79534138|NCT04962061|Other|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
79391314|NCT02449174|Biological|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
79391315|NCT02449798|Device|"AccuCath 2.25 BC Intravascular Catheter"|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
79391316|NCT00362908|Behavioral|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
79391317|NCT00362908|Behavioral|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
79534139|NCT04951115|Drug|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
79534140|NCT04951115|Drug|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
79534141|NCT04951115|Drug|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
79690383|NCT01385176|Procedure|Titration during the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.
79391318|NCT00362986|Drug|sunscreen|
79391319|NCT00362986|Other|placebo|
79534142|NCT04951115|Drug|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
79690384|NCT01385176|Procedure|Titration after the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
79690385|NCT01385176|Diagnostic Test|Blood Draw|Blood draw before implant and 6 months after implant at the end of the randomization phase.
79836486|NCT00924261|Other|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
79836487|NCT00924261|Other|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
79836488|NCT00928551|Drug|vabicaserin|
79836489|NCT01053871|Drug|propofol|conscious sedation using propofol
79836490|NCT01053871|Drug|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
79836491|NCT00984178|Other|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
79836492|NCT00984178|Other|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
80007449|NCT05234853|Drug|PUR001|Monoclonal antibody
80007450|NCT03240419|Dietary Supplement|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
79534143|NCT04951115|Radiation|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
79534144|NCT04949503|Drug|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
79240131|NCT04062669|Biological|Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 1 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly at Day 1.
79690386|NCT01186328|Drug|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
79690387|NCT01186328|Drug|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~- 1.99 years: 16 mg~- 2.99 years: 20 mg~- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
79690388|NCT01186328|Drug|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
79836493|NCT04034277|Other|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
79836494|NCT04034277|Other|Conventional Treatment|"speech rehabilitation protocol comprehend:~Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
79240132|NCT04062669|Biological|Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lower dose (Lrd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lower dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
79240133|NCT04062669|Biological|Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lowest dose (Ltd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lowest dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
79240134|NCT04062669|Drug|Saline Placebo|Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.
79240135|NCT04062669|Biological|RabAvert|Subjects in the RabAvert Group will receive 2 doses of RabAvert vaccine, administered intramuscularly, at Days 1 and 61.
79836495|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
79240136|NCT04456335|Genetic|Collection of supragingival plaque from caries free children|Supragingival plaque samples were collected from posterior molar teeth
79240137|NCT04456257|Device|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
79240138|NCT05387967|Drug|Sacubitril/valsartan|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
79240139|NCT00389649|Device|heart rate setting|
79240140|NCT05389137|Biological|Inavtivated Quadrivalent Influenza Virus Split Vaccine|Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
79240141|NCT03856359|Drug|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
79534145|NCT04944043|Drug|TQ05105 Tablet|TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
79534146|NCT04940507|Procedure|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
79534147|NCT04940507|Procedure|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
79534148|NCT04940182|Drug|XC221|Participants will receive XC221 100 mg 2 times a day during 14 full days
79534149|NCT04940182|Drug|Placebo|Participants will receive Placebo 2 times a day during 14 full days
79534150|NCT04938466|Drug|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
79547222|NCT01552538|Device|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
79547223|NCT01552551|Behavioral|Assessment and education|PA Healthy Steps program
79547224|NCT01552551|Behavioral|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
79547225|NCT01552551|Behavioral|Healthy Steps in Motion|Group exercise program
80007451|NCT03240419|Dietary Supplement|Placebo|capsule manufactured to mimic probiotic capsules.
80007452|NCT01665118|Device|Trusculpt (Radio Frequency) Device|
79547226|NCT01552564|Procedure|Index of microvascular resistance|
79690389|NCT01186328|Drug|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
79690390|NCT01186328|Drug|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
79240142|NCT03663855|Drug|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
79534151|NCT04937283|Procedure|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
79240143|NCT02965573|Biological|ARGX-113|
79534152|NCT04937283|Procedure|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
79534154|NCT06257342|Procedure|6 minutes walk|A 6 minutes walk test
79690391|NCT01186328|Drug|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
79690392|NCT01186328|Drug|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
79690393|NCT01186328|Drug|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
79379807|NCT04729205|Drug|Promitil|The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
79379808|NCT04726306|Diagnostic Test|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
79690394|NCT01130519|Drug|Bevacizumab|Commercially available. Administered by intravenous infusion.
79690395|NCT01130519|Drug|Erlotinib|Commercially available. Administered orally.
79690396|NCT01054196|Drug|lenalidomide|daily dose dependent on dose-escalation schedule
79690397|NCT01054196|Drug|melphalan|100 mg/m2 given Days -2 and -1
79690398|NCT01041508|Drug|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
79690399|NCT01041508|Radiation|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
79690400|NCT01041508|Other|Stem Cell Transplantation|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
79690401|NCT01041508|Drug|Cyclosporine|"Cyclosporine is given IV based on body weight at:~Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml."
80007453|NCT03735537|Drug|Teriparatide Pen Injector|
79240144|NCT02965573|Drug|Placebo|
79240145|NCT04052659|Drug|Sintilimab|200 mg IV, every 3 weeks, d1
79240146|NCT04052659|Drug|Chidamide|30 mg PO, 2 times every week, d1 and d4
79240147|NCT04052659|Drug|Azacidine|100 mg SC, every 3 weeks, d1 to d7
79240148|NCT02898727|Other|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
79240149|NCT02964325|Device|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
79534155|NCT06257329|Other|register|Multicentre prospective observational register
79534156|NCT06257303|Other|Frontal Plane Projection Angle|During the frontal plane projection angle (FPPA) measurement, a straight line will be drawn from the anterior superior spina iliaca along the femur to the midpoint of the patella, and the midpoint of the ankle will be determined as the reference point by a straight line drawn from the midpoint of the patella. Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times. The FPPA degree is measured from the medial aspect of the knee and calculated by subtracting 360. FPPA of 195° and above will be considered pathological.
79534157|NCT06257290|Biological|blood sample|at Day 1 - date of patient inclusion at time of VTE diagnosis
79240150|NCT02964325|Device|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
79240151|NCT03645889|Other|PLTG|A combination of 13 herbal granules
79240152|NCT03645889|Other|Placebo|90% starch filler and 10% PLTG
79240153|NCT02964247|Drug|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
79379809|NCT04723446|Drug|Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
79379810|NCT04723446|Drug|Colgate Peroxyl® -1.5% Hydrogen peroxide|Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
79379811|NCT04723446|Other|Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|The Oral-B® Gum & Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
79379812|NCT04723446|Other|No rinsing|No rinsing
79534158|NCT06257290|Biological|blood sample|at 6 months (in the patient follow-up)
79534159|NCT06257277|Drug|GBCAs|GBCAs are given per routine clinical practice.
79534160|NCT06257264|Drug|BG-68501|Planned doses administered orally.
79240154|NCT02964247|Drug|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
79534161|NCT06257264|Drug|Fulvestrant|Standard dose administered via intramuscular injection.
79534162|NCT06257225|Procedure|Guided Bone regeneration|After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks
79240155|NCT03645733|Procedure|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
79240156|NCT05284279|Other|Exploring health professionals' perceptions of patients with ECC using semi-structured interviews|"Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences."
79240157|NCT03645655|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
79240158|NCT04051801|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
79240159|NCT04051801|Drug|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
79240160|NCT03846115|Behavioral|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
79240161|NCT03846115|Behavioral|Control app|This app offers the Seeking Safety content but without the enhanced features
79379813|NCT04721860|Behavioral|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
79379814|NCT04721860|Behavioral|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
79379815|NCT04717570|Device|Foldax TRIA Mitral Valve|Mitral Valve Replacement
79379816|NCT04712877|Diagnostic Test|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
79690402|NCT01041508|Drug|Mycophenolate Mofetil|MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
79690403|NCT00984490|Drug|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
79690404|NCT00984490|Other|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
79690405|NCT00977977|Drug|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
79690406|NCT00977977|Drug|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
79240162|NCT05283967|Diagnostic Test|urine colorimetric assay|Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
79240163|NCT03654729|Drug|Calmangafodipir (2 µmol/kg)|Solution in 20 mL single dose glass vials
79240164|NCT03654729|Drug|Calmangafodipir (5 µmol/kg)|Solution in 20 mL single dose glass vials
79240165|NCT03654729|Drug|Placebo|Solution in 20 mL single dose glass vials
79240166|NCT03646747|Diagnostic Test|MRI scan|Additional imaging using MRI scan
79240167|NCT04052269|Drug|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
79240168|NCT03827317|Radiation|[18F]GE-226|[18F]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
79534163|NCT06257186|Other|Art Therapy|Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
79534164|NCT06257160|Procedure|Surgical infiltration|"During surgery, local anesthetics are injected as follow: in the deep plane and in the subcutaneous territory.~Infiltration of the deep plane corresponds to pericotyloid injection, with particular attention to the posterior subcapsular area, the obturator foramen and the psoas muscle. Infiltration of the muscular planes is added, with infiltration of the gluteal and pelvitrochanteric muscles."
79240169|NCT03130647|Device|Focused ultrasound|Focused ultrasound
79379817|NCT04710862|Behavioral|Breathing training without a device|Breathing training without a mouth device
79690407|NCT00859794|Other|fMRI|Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
79690408|NCT00859794|Other|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
79240170|NCT03646591|Drug|Chemotherapy|Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
79240171|NCT03645265|Behavioral|Auditory|Use of auditory cues to improve speech production
79379818|NCT04710862|Behavioral|Breathing training with a device|Breathing training with a mouth device
79690409|NCT00859794|Other|Additional electrode implantation|Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
79240172|NCT03645265|Behavioral|Gestures|Use of gestures to improve speech production
79240173|NCT01377987|Drug|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
79240174|NCT01377987|Drug|Placebo|4 mg/kg, once daily before bed, for 7 days
79534165|NCT06257160|Procedure|PENG Block ultrasound-guided|"We perform the femoral block under ultrasound after anesthesia (general or rachianesthesia). The PENG block is a peripheral diffusion nerve block that specifically targets the articular divisions of the femoral, obturator and accessory obturator nerves.~The femoral nerve innervates the four parts of the joint capsule, with inconsistency in the anterior inferomedial part of the capsule.~The obturator nerve innervates the inferior part of the anterior face of the capsule.~The accessory obturator nerve innervates the medial half of the hip joint capsule in over 50% of cases."
79547227|NCT01552564|Other|Cardiac magnetic resonance|
79240175|NCT03645187|Drug|FOLFERI|FOLFERI regimen
79240176|NCT03645187|Drug|Folferi and celecoxib|Folferi regimen and celecoxib
79240177|NCT03646513|Device|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
79240178|NCT03645109|Dietary Supplement|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
79240179|NCT03645109|Other|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
79379819|NCT04695171|Device|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
79240180|NCT05380167|Dietary Supplement|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
79240181|NCT05380167|Dietary Supplement|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
79240182|NCT03573375|Behavioral|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
79690410|NCT00859794|Other|Electrical brain stimulation|Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
79836496|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
79240183|NCT05165745|Behavioral|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
79240184|NCT05165667|Other|rehabilitation team|The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
79240185|NCT03351387|Combination Product|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
79379820|NCT04695171|Procedure|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
79534166|NCT06257147|Behavioral|multifaceted antibiotic stewardship intervention|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
79547228|NCT01552564|Other|Blood markers|
79690417|NCT00648635|Behavioral|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
79240186|NCT05165589|Device|ActiveInsights accelerometer device|Accelerometer device
79240187|NCT04455555|Drug|LY03003( the name of rotigotine)|LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
79379821|NCT04689828|Drug|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
79379822|NCT04689828|Drug|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
79379823|NCT04689828|Drug|ARDT|administered orally on a continuous basis, as per package insert and guidelines
79690418|NCT00455858|Drug|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
79690419|NCT00408005|Drug|Asparaginase|Given IM or IV
79690420|NCT00408005|Drug|Cyclophosphamide|Given IV
79690421|NCT00408005|Drug|Cytarabine|Given IT, IV, or SC
79690422|NCT00408005|Drug|Daunorubicin Hydrochloride|Given IV
79690423|NCT00408005|Drug|Dexamethasone|Given IV or PO
79690424|NCT00408005|Drug|Doxorubicin Hydrochloride|Given IV
79690425|NCT00408005|Other|Laboratory Biomarker Analysis|Correlative studies
79836497|NCT00928629|Procedure|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
79836498|NCT04005508|Diagnostic Test|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
79836499|NCT00987376|Device|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
79240188|NCT04455555|Other|Placebo|Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
79240189|NCT02898259|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
79240190|NCT02898259|Drug|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~Starting lenalidomide Dose (20mg)~Calculated Creatinine Clearance: >=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~Calculated Creatinine Clearance: >= 30 and < 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
79240191|NCT02898259|Drug|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
79379824|NCT04689828|Other|Best supportive care|Best supportive/best standard of care as defined by the local investigator
79690426|NCT00408005|Drug|Leucovorin Calcium|Given PO
79690427|NCT00408005|Drug|Mercaptopurine|Given PO
79690428|NCT00408005|Drug|Methotrexate|Given IT or PO
79690429|NCT00408005|Drug|Nelarabine|Given IV
79690430|NCT00408005|Drug|Pegaspargase|Given IM or IV
79690431|NCT00408005|Drug|Prednisone|Given IV or PO
79690432|NCT00408005|Radiation|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
79534167|NCT06257134|Other|No systematic monitoring of symptoms|No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.
79836500|NCT00924339|Dietary Supplement|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
79690433|NCT00408005|Drug|Thioguanine|Given PO
79690434|NCT00408005|Drug|Vincristine Sulfate|Given IV
79836501|NCT00924339|Dietary Supplement|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
79836502|NCT00987454|Drug|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
79836503|NCT00987454|Drug|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
80007454|NCT03735537|Drug|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
79836504|NCT03986983|Device|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
79836505|NCT03986983|Other|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
79240192|NCT03646435|Device|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
79240193|NCT03645343|Device|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
79240194|NCT03645343|Device|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
79240195|NCT05283733|Procedure|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
79240196|NCT03644875|Device|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
79240197|NCT03704545|Other|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
79836506|NCT00924417|Behavioral|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
80007455|NCT04552587|Behavioral|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
79240198|NCT03704545|Other|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
79379825|NCT04683172|Device|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
79534168|NCT06257134|Other|Systematic monitoring of symptoms|"once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase."
79690435|NCT00075946|Biological|rituximab|Given IV
79690436|NCT00001595|Procedure|MRI|
79690437|NCT00001595|Procedure|Tissue specimen collection|
79690438|NCT04646291|Device|Insemination with the Mosie Baby Kit|The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
79690439|NCT02907684|Dietary Supplement|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
79690440|NCT02907684|Dietary Supplement|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
80007456|NCT04809922|Device|cardiac wearable devices|"five cardiac wearable devices~Apple Watch, Apple Inc., Model Number: A1977 / A1978~Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~Fitbit Sense, Fitbit, Inc, Model Number: FB512~Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
80007457|NCT04531059|Drug|Esomeprazole|Proton pump inhibitor
80007458|NCT04531059|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
79534169|NCT06257121|Device|OSMS position management|Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
79534170|NCT06257108|Other|Class II Cavity Restorations|The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.
79836507|NCT00924417|Behavioral|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
80007459|NCT04531059|Drug|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
80007460|NCT04531059|Drug|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
79534171|NCT06257095|Behavioral|Stepped-care social and mental health engagement|Each student will be matched to an older adult and the students will make one call o the older adult which lasts upto 1 hour each week for 8 weeks. Ending each call, the student will assess symptoms of depression anxiety through questionnaires. If the participant responds yes on two consecutive calls to any of these questions, they will be asked if they would like to receive a call from the University of Texas Health Science Center Trauma and Resilience Center to discuss free counseling services.
79836508|NCT04015245|Drug|Stronger Neo-Minophagen C|intravenous injection after TACE
79240199|NCT03704545|Other|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
79836509|NCT03983785|Other|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
80007461|NCT03136744|Behavioral|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
80007462|NCT05171127|Procedure|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
79391320|NCT00363376|Drug|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
79240200|NCT03646279|Device|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
79836510|NCT03983785|Other|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
79836511|NCT00924495|Device|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
80007463|NCT05090176|Other|povidone-soaked suture|suture soak with povidone solution for 3 mins
79240201|NCT03644797|Genetic|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
79240202|NCT03644407|Other|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
79836512|NCT04005664|Drug|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
79240203|NCT03646201|Behavioral|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
79240204|NCT02963935|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
79240205|NCT02963935|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
79836513|NCT00928785|Biological|REPEVAX|1 dose of 0.5 mL at Day 0
79836514|NCT00928785|Biological|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
79836515|NCT00330967|Drug|20% Intralipid|lipid infusion
79836516|NCT00928863|Other|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
79836517|NCT03983629|Other|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
79836518|NCT00987610|Device|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
79836519|NCT00924573|Drug|Metformin|oral administration
80007464|NCT05090176|Other|ordinary suture|suture no need to soak with povidone solution
79836520|NCT00924573|Drug|placebo|oral administration
80007465|NCT05090020|Procedure|Treatment|Surgery and PAIR
80007466|NCT05158335|Drug|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
80007467|NCT05158335|Drug|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
80007468|NCT05158335|Drug|Placebo|Single SC dose or repeated SC doses of placebo.
79240206|NCT02963935|Behavioral|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
79391321|NCT00363376|Drug|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
79391322|NCT00363376|Drug|Zonisamide|zonisamide ranging from 100mg to 600mg daily
79836521|NCT00924573|Drug|Glimepiride (HOE490)|oral administration
80007469|NCT04716166|Other|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
80007470|NCT04716166|Other|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
79690441|NCT04646096|Device|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
79690442|NCT04681989|Behavioral|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~Instructions on how to use the physical therapy-based education materials by a research staff member~a range of motion wand~a small ball~MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
79690443|NCT04646447|Dietary Supplement|L-serine|"L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient."
79690444|NCT04682184|Drug|Propranolol|Administered orally.
79690445|NCT04682184|Drug|Pseudoephedrine|Administered orally.
79690446|NCT04682184|Device|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
79690447|NCT02907450|Device|TwiCare®.|
79690448|NCT04645901|Drug|Drug: SYHA1805 tablets|Oral tablets of SYHA1805 with several doses
79690449|NCT04645901|Drug|Placebo|Oral tablets of placebo with matching several doses
79690450|NCT04645940|Drug|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
80007471|NCT04701502|Dietary Supplement|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
79690451|NCT04645940|Drug|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
79240207|NCT03644329|Other|Control group|The volunteers will not performed the interventions.
79240208|NCT03644329|Other|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
79240209|NCT03644329|Other|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
79240210|NCT03644329|Other|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
79240211|NCT03644719|Behavioral|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
79534172|NCT06257095|Behavioral|APS Usual care|Participants will receive a phone call for data collection. Then they will be offered to receive an abbreviated version of the stepped-care social and mental health engagement intervention, lasting only 6-weeks with the option to continue calls if agreeable between the student and older adult.
79534173|NCT06257082|Other|Online Survey|Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
79690452|NCT02906280|Device|EBUS-TBNA needle|tissue sampling
79690453|NCT02906085|Drug|Endothelin-1|
79690454|NCT02906085|Drug|Placebo|Isotonic saline
79690455|NCT00558506|Drug|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
79836522|NCT01054027|Drug|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
79836523|NCT00928941|Behavioral|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
80007472|NCT04701502|Dietary Supplement|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
80007473|NCT04701502|Drug|Standard Care|Standard care for COVID-19
79240212|NCT03644641|Procedure|Desflurane Group|General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).
79391323|NCT00363376|Drug|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
79391324|NCT02451202|Procedure|Deep Neuromuscular Blockade|"During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
79391325|NCT02451202|Procedure|Moderate Neuromuscular Blockade|- During maintenance phase, if recovery at the presence of <10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
79391326|NCT02451202|Drug|Sugammadex|
79379826|NCT04683172|Device|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
79534174|NCT06257056|Device|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
79534175|NCT06257030|Device|Transarterial Radioembolization|(TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
79534176|NCT06257017|Drug|gemcitabine|1,000 mg/m2 intravenous gemcitabine on day 1 and day 8
79690456|NCT02907411|Other|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
79836524|NCT00928941|Behavioral|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
79836525|NCT01054105|Drug|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
79836526|NCT00987688|Other|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
79836527|NCT05277597|Diagnostic Test|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
79836528|NCT05277597|Diagnostic Test|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
79836529|NCT00907413|Procedure|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
79836530|NCT00907413|Procedure|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
80007474|NCT01316055|Drug|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
79240213|NCT03644641|Procedure|Propofol Group|General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).
79379827|NCT04677374|Other|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
79534177|NCT06257017|Drug|Cisplatin|70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
79534178|NCT06257004|Genetic|Saliva collection (screening of all participants)|All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
79534179|NCT06257004|Genetic|Bloodsampling|Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
79240214|NCT05283421|Diagnostic Test|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
79240215|NCT05283421|Diagnostic Test|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
79240216|NCT03643627|Drug|SYNT001|single IV infusion
79240217|NCT03643627|Drug|Placebo|single IV infusion
79391327|NCT02451202|Drug|Rocuronium|
79534180|NCT06256965|Diagnostic Test|Detection of peri-operative atrial fibrillation|atrial tissue and plasma from patients with atrial fibrillation detection were analyzed for determine lipid and protein oxidation, and detect markers of myocardial injury.
79547229|NCT01552616|Procedure|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
79547230|NCT01552629|Drug|QGE031|
79690457|NCT00558545|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
79690458|NCT02907645|Behavioral|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
79836531|NCT00330343|Drug|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
79836532|NCT00987766|Drug|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
79836533|NCT00987766|Drug|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
79836534|NCT00987766|Drug|oxaliplatin|Given through a vein in the arm 1 time every other week.
79836535|NCT00987766|Other|laboratory biomarker analysis|Blood and tissue collection.
79836536|NCT00984412|Procedure|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
79240218|NCT03641521|Behavioral|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
79534181|NCT06256952|Behavioral|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
79836537|NCT00330187|Drug|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
79836538|NCT00330187|Behavioral|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
79379828|NCT04677374|Behavioral|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
79379829|NCT04677374|Behavioral|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
79534182|NCT06256952|Behavioral|social exclusion (Cyberball task)|Social exclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social exclusion, subjects will be systematically excluded by one co-player, and during social inclusion, ball tosses will be balanced between all three players.
79534183|NCT06256952|Diagnostic Test|Saliva samples|Assessing acute stress effects in AUD and HC subjects
79836539|NCT00330187|Other|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
79836540|NCT00987844|Drug|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
79836541|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
79836542|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
79836543|NCT04006132|Device|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
79836544|NCT03986905|Drug|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
79836545|NCT03986905|Other|Placebo|placebo nasal gel + placebo patch
79240219|NCT03641443|Device|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
79240220|NCT03641365|Device|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
79379830|NCT04677374|Behavioral|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
79379831|NCT04671797|Behavioral|Early dinner|Dinner at DLMO-3, sleep at DLMO+2
79379832|NCT04671797|Behavioral|Late Dinner|Dinner at DLMO+1, sleep at DLMO+2
79379833|NCT04671797|Behavioral|Late Dinner + Late Sleep|Dinner at DLMO+1, sleep at DLMO+6
79379834|NCT04665648|Drug|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
79547231|NCT01552629|Drug|Placebo|
79547232|NCT01552629|Drug|Cyclosporine A|
79547233|NCT01552642|Behavioral|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
79547234|NCT01552655|Radiation|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
79547235|NCT01552668|Drug|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
79547236|NCT01552668|Drug|Placebo|Receive Placebo twice daily
79836546|NCT00987922|Device|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
79836547|NCT03595774|Dietary Supplement|Beet root juice|Beet root juice
79836548|NCT03914950|Diagnostic Test|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
79836549|NCT00329797|Dietary Supplement|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
79836550|NCT00329797|Dietary Supplement|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
79534184|NCT06256952|Diagnostic Test|basic psychological assessment|"Sociodemographics~ASSIST~Quantity Frequency: Alcohol, tobacco/e-cigarette, Cannabis & other illegal drugs~SCID: AUD criteria and tabak use disorder life time and last year & acute depressive symptoms & symptoms for Mania and psychotic disorder~Edinburgh Handedness Inventory (EHI)~Fagerström Test for Nicotine depend (FTND)~Barratt Impulsiveness Scale - Kurzversion (BIS-15)~Allgemeine Depressionsskala (ADS)~State-Trait-Anxiety Inventory (STAI-T)~Alcohol Use Disorders Identification Test (AUDIT)~Cannabis Use Disorder Identification Test (CUDIT)~CAS -A (Alkohol)~Fragebogen zur Sozialen Unterstützung (F-SozU K-14)~Oslo-3-Items-Social-Support Scale~Social Skills Rating System (SSRS)~Trier Inventory for chronic stress (TICS)~Rejection Sensitivity Questionnaires (RSQ-9)~Need to belong scale (NTBS)~Fragebogen zu Gedanken und Gefühlen (FGG-14)~Internationale Trauma Questionnaire (ITQ)~Zahlen-Symbol-Test (DST)~Wortschatztest (verbal intelligence)"
79534185|NCT06256952|Diagnostic Test|pre and post cyberball task|Positive and Negative Affect Schedule(PANAS)
79534186|NCT06256952|Diagnostic Test|VAS|subjective arousal, subjective stress, valence, perceived ostracisms/loneliness
79690459|NCT02907645|Behavioral|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
79690460|NCT00558623|Dietary Supplement|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
79836551|NCT00329797|Radiation|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
79836552|NCT00329797|Drug|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
79836553|NCT00329797|Dietary Supplement|Vitamin D|400 IU (10μg), orally each day for 3 years.
79240221|NCT03641365|Device|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
79240222|NCT02963701|Drug|Ibuprofen|Fixed dose combination
79379835|NCT04665648|Drug|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
79379836|NCT04644952|Other|Electronic Health Record Review|Review of medical records
79534187|NCT06256952|Diagnostic Test|after cyberball task|"Need Threat Scale~Manipulation check (VAS scale)"
79534188|NCT06256952|Behavioral|social inclusion (Cyberball task)|Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.
79534189|NCT06256939|Other|Therapy BRIDGE Program|A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
79534190|NCT06256926|Drug|Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)|Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
79690461|NCT02905968|Device|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
79690462|NCT00558662|Device|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
79690463|NCT00558662|Device|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
79240223|NCT02963701|Drug|Pseudoephedrine-HCl|Fixed dose combination
79240224|NCT01345591|Procedure|Fat Grafting|
79240225|NCT03644251|Other|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
79240226|NCT03621319|Device|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
79240227|NCT03621319|Device|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
79379837|NCT04637594|Drug|Pembrolizumab|Given IV
79379838|NCT04637594|Drug|Nivolumab|Given IV
79379839|NCT04637594|Drug|Atezolizumab|Given IV
79379840|NCT04637594|Drug|Durvalumab|Given IV
79379841|NCT04637594|Drug|Avelumab|Given IV
79836554|NCT00541450|Drug|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
79836555|NCT00541450|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
79379842|NCT04635111|Drug|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
79379843|NCT04633057|Drug|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
79379844|NCT04633057|Drug|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
79690464|NCT02906046|Device|Weight in Lower Limbs|
79690465|NCT00558740|Other|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
79690466|NCT02907528|Biological|Bone|Furcation defect regenerated with bone graft material
79690467|NCT02907528|Biological|EMD|Furcation defect regenerated with EMD
79690468|NCT04645472|Device|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
79379845|NCT04627493|Behavioral|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
79534191|NCT06256926|Drug|Placebo product|Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
79690469|NCT02905890|Drug|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
79534192|NCT06256900|Other|Flow-controlled ventilation|FCV mode during robot-assisted laparoscopic surgery
79534193|NCT06256900|Other|Pressure-controlled ventilation|PCVmode during robot-assisted laparoscopic surgery
79534194|NCT06256874|Behavioral|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
79534195|NCT06256861|Behavioral|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
79690470|NCT02905890|Device|Condoms|Latex male condoms
79690471|NCT02906163|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
79690472|NCT02906163|Drug|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
79690473|NCT04645745|Dietary Supplement|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
79690474|NCT02907060|Device|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
79690475|NCT02907060|Drug|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
79690476|NCT02905851|Other|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
79690477|NCT02905851|Other|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
79240228|NCT02961751|Drug|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
79240229|NCT03643549|Drug|Bortezomib and Temozolomide Phase IB|In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
79240230|NCT03643549|Drug|Bortezomib and Temozolomide Phase II|The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
79240231|NCT02963311|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
79240232|NCT02963311|Drug|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
79240233|NCT03643471|Device|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
79379846|NCT04625751|Other|CO2-enriched air|To assess cardiovascular reactivity
79379847|NCT04625751|Other|Meal response test|Meal response test to assess changes in splanchnic blood flow.
79379848|NCT04623099|Drug|Escitalopram|Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
79379849|NCT04619680|Drug|Nintedanib|150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
79690478|NCT04645043|Other|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
79690479|NCT02905695|Drug|Chirocaine|
79690480|NCT02905695|Other|Placebo|
79690481|NCT04645238|Other|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
79379850|NCT04619680|Drug|Placebo|placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
79690482|NCT04645238|Other|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
79534196|NCT06256861|Behavioral|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
79690483|NCT02907333|Behavioral|Advice to use condoms|
79690484|NCT00558779|Procedure|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
79690485|NCT00558779|Procedure|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
79690486|NCT04645082|Diagnostic Test|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
79690487|NCT02905773|Other|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
79690488|NCT02905773|Other|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
79690489|NCT04644848|Diagnostic Test|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~Round shape.~Cortical thickness > 3 mm~Eccentric cortical thickness.~Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
79379851|NCT04614571|Dietary Supplement|Gluten Powder|Administered orally daily for 14 days
79690490|NCT04644848|Procedure|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
79690491|NCT04644848|Diagnostic Test|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
79836556|NCT00541450|Drug|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
79240234|NCT02263209|Device|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
79240235|NCT02263209|Device|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
79240236|NCT03641053|Other|Honey|Substance is given topically after the wound has been sutured
79240237|NCT03641053|Other|Povidone-iodine|Substance is given topically after the wound has been sutured
79379852|NCT04613778|Procedure|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
79379853|NCT04595630|Other|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
79379854|NCT04590547|Drug|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
79836557|NCT00541450|Drug|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
79836558|NCT00541450|Drug|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
79836559|NCT00541450|Drug|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
79836560|NCT03989635|Drug|QAW039|QAW039 450mg
79836561|NCT03986827|Behavioral|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
79379855|NCT04590547|Drug|Placebo|Placebo looks like GLS-1027
79379856|NCT04587752|Behavioral|CBT for Weight Bullying|Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
79547237|NCT01552707|Biological|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
79547238|NCT01552707|Procedure|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
79547239|NCT01552733|Device|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
79240238|NCT03641053|Other|Paraffin gauze|Substance is given topically after the wound has been sutured
79240239|NCT04455477|Drug|Nesiritide|The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.
79240240|NCT05261113|Procedure|CE-IOUS|Use of contrast-enhanced intraoperative ultrasound during liver surgery
79690492|NCT04644848|Procedure|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
79690493|NCT02907294|Drug|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
79690494|NCT02907294|Drug|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
79690495|NCT02907294|Drug|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
79547240|NCT01552733|Other|Standard of care|Rehabilitation Therapy
79379857|NCT04579367|Drug|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
79547241|NCT01552759|Procedure|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
79690496|NCT04644887|Other|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA < 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) >2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
79836562|NCT03986827|Behavioral|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
79836563|NCT01054261|Drug|avanafil|200 mg avanafil tablet QD
79836564|NCT01056679|Drug|Doxorubicine|50mg/m2 day 1 + 15
79240241|NCT05348343|Biological|Autologous platelet-rich plasma|PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
79379858|NCT04572256|Drug|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
79240242|NCT03643393|Procedure|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
79379859|NCT04572256|Drug|Placebo|An oral placebo will be taken daily for 6 months post surgery.
79379860|NCT04571580|Drug|Normal Saline|intracoronary infusion with normal saline
79379861|NCT04571580|Drug|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
79379862|NCT04571580|Drug|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
79379863|NCT04567108|Behavioral|Maintain usual SSBs|Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
79379864|NCT04567108|Behavioral|Substitute to non-SSBs|Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)
79379865|NCT04567108|Behavioral|Study app|Engage with a motivational mobile app to track beverage intake and complete study data collection
79379866|NCT04567108|Behavioral|Beverage delivery|Select from approved beverages for a monthly at-home delivery (months 0-6)
79391328|NCT02451514|Biological|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
79391329|NCT02452060|Drug|Ketamine|0.4mg/kg infusion
79547242|NCT01552759|Behavioral|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
79547243|NCT01552759|Behavioral|Test meal|Subjects are presented with an ad libitum buffet meal.
79690497|NCT04644887|Other|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (~2%), normal fat cheese (~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
79690498|NCT00553371|Other|biomarker analysis|
79690499|NCT00553371|Procedure|computed tomography|
79690500|NCT04644926|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
79690501|NCT04682262|Procedure|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
79836565|NCT01056679|Drug|DTIC|375mg/m2 day 1 + 15
79836566|NCT01056679|Drug|Lenalidomide|day 1 - 21
79391330|NCT02452060|Other|Placebo Comparator|0.4mg/kg infusion
79391331|NCT01696955|Biological|Cetuximab|Given IV
79391332|NCT01696955|Other|Laboratory Biomarker Analysis|Correlative studies
79391333|NCT01696955|Drug|Tivantinib|Given PO
79391334|NCT02452528|Drug|ARC-520|
79391335|NCT02452528|Drug|Placebo|
79391336|NCT02452528|Drug|Entecavir|0.5 or 1.0 mg/day orally
79547244|NCT01552785|Device|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
79690502|NCT00558818|Drug|Clevudine|clevudine 30 mg qd
79690503|NCT02907138|Other|Medical Yoga|
79690504|NCT02907138|Other|Treatment as Usual (physical therapy)|
79690505|NCT04644341|Combination Product|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
79690506|NCT04681911|Drug|Inetetamab|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
79836567|NCT01056679|Drug|Vinblastine|6mg/m2 day 1 + 15
79836568|NCT03989791|Dietary Supplement|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
80007475|NCT04685668|Behavioral|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
80007476|NCT05349357|Other|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
80007477|NCT05349357|Other|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
79240243|NCT04805619|Device|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
79391337|NCT02452528|Drug|Tenofovir|300 mg/day orally
80007478|NCT05349357|Other|Stretching exercises|Stretching exercises
80007479|NCT05349357|Device|TENS|TENS
79534197|NCT06256848|Behavioral|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
80007480|NCT04674124|Behavioral|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
80007481|NCT01340976|Drug|LY2787106|Administered IV.
80007482|NCT01340976|Dietary Supplement|Iron Supplementation|Administered orally.
80007483|NCT05089240|Device|Ophthalmic lens with extra power|
79303016|NCT05714423|Procedure|Mini-PCNL|Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
79391338|NCT02452528|Drug|diphenhydramine|50 mg orally as pretreatment antihistamine
80007484|NCT05089006|Procedure|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
80007485|NCT05088915|Behavioral|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
79391339|NCT04743700|Procedure|Piezocision|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
79547245|NCT01552798|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
79547246|NCT01552798|Drug|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
79690507|NCT04681911|Drug|Pyrotinib|Pyrotinib: 400mg, oral, every day.
79690508|NCT04681911|Drug|Capecitabine|Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
79690509|NCT04681911|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
79690510|NCT04681911|Drug|Vinorelbine|Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
79690511|NCT04681911|Drug|Carboplatin|Carboplatin, AUC = 6, 3-week cycle
79690512|NCT04681911|Drug|Albumin paclitaxel|Albumin paclitaxel, 100 mg/m2, weekly
79690513|NCT04681911|Drug|Eribulin|Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
79690514|NCT04644302|Diagnostic Test|microcirculation recording|non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
79690515|NCT02907255|Device|Oximetry monitor|Wireless respiratory monitoring system
79690516|NCT04644458|Other|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
79690517|NCT02905656|Behavioral|Brief Advice|Psychoeducation
79690518|NCT02905656|Behavioral|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
79690519|NCT02905656|Behavioral|Rate Reduction|Reducing the number of cigarettes consumed.
79690520|NCT02905656|Drug|Pharmacological|Nicotine Replacement Therapy in the form of gum.
79690521|NCT02905656|Behavioral|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
79303017|NCT05714423|Procedure|RIRS|RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
79690522|NCT00558857|Device|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
79690523|NCT02905539|Drug|Iron Isomaltoside 1000|
79836569|NCT03989791|Dietary Supplement|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
79836570|NCT00355147|Behavioral|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
79836571|NCT00355147|Behavioral|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
79836572|NCT00355147|Other|Attention Control Group|Received Phone Calls from Staff to Control for Attention
79836573|NCT05711368|Behavioral|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
79836574|NCT03983551|Drug|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
79836575|NCT03983551|Drug|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
79836576|NCT05709574|Drug|Tadalafil 20 MG|Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
79836577|NCT04767100|Device|Social telepresence robot|Use of a social telepresence robot at home, during three months with the aim of reducing the feeling of loneliness and social isolation among the elderly.
79690524|NCT02905539|Drug|Ferric Carboxymaltose|
79690525|NCT02905734|Drug|Nicotine patch|Single administration of an active treatment (nicotine patch)
79690526|NCT02905734|Other|placebo patch|Single administration of a placebo treatment
79547247|NCT01552798|Drug|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
79547248|NCT01552096|Drug|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
79547249|NCT01552824|Procedure|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
79690527|NCT04644380|Device|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
79690528|NCT04644107|Drug|Marizomib|Marizomib will be administered via IV
79690529|NCT02899572|Procedure|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
79690530|NCT04644146|Genetic|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
79690531|NCT04644185|Drug|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
79690532|NCT04644185|Other|Placebo|all SCTA01 excipients without active component+best supportive care
79690533|NCT02899494|Other|Antenatal classes|
79690534|NCT02899494|Other|Physical and psychic preparation|
79690535|NCT02899260|Device|Peanut Exercise Ball|A Peanut shaped exercise ball.
79690536|NCT04643756|Other|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
79690537|NCT04643756|Other|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
79690538|NCT02905461|Behavioral|Contraceptive text messages|
79690539|NCT02905461|Other|Text messages not about contraception|
79690540|NCT04643873|Other|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
79690541|NCT04643873|Behavioral|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
79690542|NCT02899533|Drug|[18F] FES|[18F] FES PET/CT scan, imaging tracer
79690543|NCT02905383|Other|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
79690544|NCT04643717|Other|Electronic pupillometer analysis|Electronic pupillometer analysis
79690545|NCT02907840|Device|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
79690546|NCT04643522|Other|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
79690547|NCT02905305|Device|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
79534198|NCT06256848|Behavioral|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
79534199|NCT06256835|Behavioral|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
79534200|NCT06256835|Behavioral|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
80007486|NCT05088915|Behavioral|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
80007487|NCT05088850|Other|no intervention|no intervention
79534201|NCT06256796|Other|fresh frozen plasma|repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
79534202|NCT06256783|Drug|Baozhu Keli|Once enrolled, participants will be administrated Baozhu Keli
79534203|NCT06256757|Procedure|fenestration|Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
79534204|NCT06256744|Other|exercise|Resistance exercise
79534205|NCT06256731|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
80007488|NCT05665959|Other|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
79534206|NCT06256718|Other|Educational Intervention|Evidence-based strategy (PC TEACH)
79690548|NCT02905305|Device|Contour Advance electrode|Standard Contour Advance electrode
79690549|NCT04643444|Diagnostic Test|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
79690550|NCT04643444|Other|Online Questionnaire|Questions on working place, risk profiles and PPE
79690551|NCT02899182|Drug|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
79690552|NCT02899182|Other|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
79690553|NCT00558935|Dietary Supplement|Red Wine|20g alcohol daily/red wine for 4 weeks
79690554|NCT02905227|Drug|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
79690555|NCT04643600|Drug|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
79690556|NCT02899455|Drug|HGP0904|
79240244|NCT03640975|Other|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
79379867|NCT04557748|Other|Observational|"Treatment:~Up to five interactions: In-person visits at Baseline, 3 months, and 12 months after initial visit, and phone/online interaction at 6 months and 9 months after initial visit.~Each in-person follow up visit is expected to last up to 2 hours and each phone/online interaction is expected to last up to 1½ hours.~Answering questions about your general health and urinary symptoms - may be done remotely Physical exam Completing Self- Reported Measures questionnaires - may be done remotely Completing voiding/intake and food diaries, either online or on paper Weekly text message survey regarding symptom and treatment changes~Biosample collection:~At baseline: Up to 4 tablespoons of whole blood, dried blood spots, and urine At baseline: Whole blood will be collected with other biospecimens At 3 months: Up to 4 tablespoons of blood, dried blood spots and urine At 12 months: Dried blood spots"
79690557|NCT02899455|Drug|HGP0608|
79690558|NCT02899455|Drug|HGP0816|
79690559|NCT02899455|Drug|HGP0904 Placebo|
79379868|NCT04557748|Other|Observational Controls|One in-person visit that is expected to last up to 2 hours Answering questions about your general health and urinary history Physical exam Completing Self- Reported Measures questionnaires Completing voiding/intake and food diaries, either online or on paper Biosample collection of up to 4 tablespoons of whole blood, dried blood spots, and urine
79379869|NCT04557748|Other|Central Sensitization|"One in-person visit expected to take up to 30 minutes, that include:~Segmental Mechanical Hyperalgesia - a hand-held device with a small flat rubber surface will be placed above the pubic bone and forearm, and will apply pressure. Participant will be asked about the intensity and unpleasantness that they experience.~Pinprick Temporal Summation - participant will receive tactile stimulation by a pointed skin probe (pinprick stimulator) being placed above the pubic bone and forearm. Participant will be asked to rate the sensation they are feeling.~Current treatment information including prior surgery or procedures, medication use, other current treatment/therapy used at the time of the visit.~Self-reported measures questionnaires"
79534207|NCT06256653|Dietary Supplement|Freeze-dried blueberries|"Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~Additional product will be supplied in case of delay of study visit or loss of Study Product.~Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~Participants will be provided with a urine collection kit and instructions for collecting and storing."
79547250|NCT01552824|Procedure|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
79547251|NCT01552837|Drug|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
79379870|NCT04557748|Other|Physical Activity and Sleep Tracker|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period starting at baseline prior to treatment and again at 3 months. During each 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
79379871|NCT04557748|Other|Physical Activity and Sleep Tracker Controls|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period at baseline prior to treatment. During the 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
79547252|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
79690560|NCT02899455|Drug|HGP0816 Placebo|
79690561|NCT04643561|Other|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
79690562|NCT02898909|Device|nuclear lens fragmentation in 8 pieces|
80007489|NCT04592692|Drug|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
79690563|NCT02898909|Device|nuclear lens fragmentation in 16 pieces|
79690564|NCT04643483|Drug|Certolizumab pegol|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods."
80007490|NCT04558294|Drug|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
80007491|NCT04558294|Drug|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
80007492|NCT04558294|Drug|Ketanserin|A dose of 40 mg Ketanserin will be administered.
79690565|NCT04643483|Drug|Adalimumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods."
80007493|NCT05088538|Other|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
79690566|NCT04643483|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods."
79690567|NCT02905071|Other|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
79836578|NCT05706142|Other|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
79690568|NCT02905071|Other|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
79690569|NCT02905071|Other|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
79690570|NCT00559052|Drug|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
79690571|NCT02899104|Drug|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
79690572|NCT00559130|Device|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
79379872|NCT04557748|Other|Organ-Based|"One in-person visit involving:~Urethral vibratory sensation threshold Urethral Pressure Profilometry Cystometry Uroflowmetry Lidocaine Pre-Treatment Cystometry"
79379873|NCT04557748|Other|Qualitative Assessment of Patients with Urinary Urgency|"Participation will include two interviews with a research assistant over the phone and are expected to take up to 60 minutes for each interview. The first interview will be done within four weeks from enrollment, before the start of treatment. The interview will include questions about participant's urinary urgency, including symptoms experienced, the onset of symptoms and other factors that affect urgency.~Approximately three months after the start treatment the participant will be interviewed again. This interview will cover changes in symptoms and experience with treatment, such as side effects and satisfaction with treatment."
79836579|NCT04697212|Behavioral|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
79836580|NCT04697212|Behavioral|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
79836581|NCT00540124|Drug|Tadalafil|5 mg once a day
79836582|NCT00540124|Drug|Placebo|once a day
79836583|NCT00540124|Drug|Tamsulosin|0.2 mg once a day
79379874|NCT04556513|Other|Paraclinical examination|Respiratory functional tests
79379875|NCT04556513|Other|Clinical Examination|Clinical Examination
79379876|NCT04556513|Other|Semi-directive interview|By phone
79379877|NCT04556513|Other|quality of life questionnaires|SF36, VSRQ, IESR, HADS
79379878|NCT04553198|Behavioral|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
79379879|NCT04550741|Other|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
79690573|NCT04643132|Drug|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
79690574|NCT04643132|Drug|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
79690575|NCT04643132|Drug|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
79690576|NCT02904993|Other|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
79836584|NCT00540046|Device|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
79836585|NCT04613830|Drug|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
79240245|NCT03160365|Procedure|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
79240246|NCT05165277|Drug|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
79240247|NCT03468777|Drug|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
79240248|NCT03468777|Drug|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
79379880|NCT04542070|Drug|Cabotegravir Tablets|CAB tablets will be available as film coated tablets for oral administration.
79379881|NCT04542070|Drug|Cabotegravir Injectable Suspension (CAB LA)|CAB LA will be available as sterile suspension for injection in GSK1265744 for administration as IM injection.
79690577|NCT02904993|Other|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
79690578|NCT04643171|Device|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
79690579|NCT04643171|Device|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
79690580|NCT02899143|Drug|Antibiotic|Targeted antimicrobial therapy
79690581|NCT04643288|Procedure|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
79690582|NCT04643288|Procedure|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
79534208|NCT06256653|Dietary Supplement|Placebo|"Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~Participants will be provided with a urine collection kit and instructions for collecting and storing."
79690583|NCT02899026|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
79690584|NCT02899026|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
79690585|NCT02899026|Drug|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
79836586|NCT04613830|Drug|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
79836587|NCT05676892|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed, and the skin was sutured"
79836588|NCT00689936|Drug|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
80007494|NCT01680016|Biological|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
80007495|NCT01680016|Biological|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
80007496|NCT04530994|Drug|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
80007497|NCT03378466|Drug|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
79379882|NCT04542070|Drug|Rilpivirine Tablets|RPV will be administered as tablets for oral administration.
79690586|NCT04643054|Dietary Supplement|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
79379883|NCT04542070|Drug|Rilpivirine Injectable Suspension (RPV LA)|RPV LA will be available as a sterile suspension of RPV to be administered as an IM injection.
79379884|NCT04542070|Drug|BIKTARVY Tablets (BIK)|BIK will be a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
79379885|NCT04538950|Diagnostic Test|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
79690587|NCT02904837|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
79690588|NCT02904837|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
80007498|NCT03378466|Other|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
80007499|NCT05080270|Biological|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
79379886|NCT04538950|Drug|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
79690589|NCT04643210|Behavioral|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
79836589|NCT00689936|Drug|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
79836590|NCT00689936|Drug|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
79836591|NCT04528576|Device|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
79836592|NCT05279170|Other|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
79836593|NCT01563718|Drug|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
79836594|NCT05485714|Other|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
79836595|NCT05473234|Drug|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
79836596|NCT05473234|Drug|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
79836597|NCT04500418|Drug|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
79836598|NCT04500418|Drug|Placebo|Optically identical pills without CVC.
79836599|NCT05473156|Drug|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D[s]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W [± 1days]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W [± 3 days]) for all the following doses."
79379887|NCT04530305|Drug|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
79836600|NCT05473156|Drug|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
80007500|NCT05077540|Drug|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
80007501|NCT05077540|Drug|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
79379888|NCT04522388|Dietary Supplement|Ensure Enlive|Ensure Enlive shake twice a day
79379889|NCT04513951|Drug|5Fluorouracil|phase II
79379890|NCT04513951|Drug|L-leucovorin|phase II
79379891|NCT04513951|Drug|Irinotecan|phase II
79379892|NCT04513951|Drug|Oxaliplatin|phase II
79379893|NCT04513951|Drug|Cetuximab|phase II
79379894|NCT04513951|Drug|Avelumab|phase II
79534209|NCT06256640|Device|Mandibular advancement Device|Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
79534210|NCT06256627|Drug|recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine|"Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."
79534211|NCT06256614|Other|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive three doses of WMT for T1DM.
79534212|NCT06256588|Drug|Dostarlimab|Dostarlimab will be administered as an intravenous (IV) infusion
79534213|NCT06256588|Drug|Placebo|Placebo will be administered as an IV infusion
79690590|NCT04643210|Other|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
79690591|NCT02904798|Drug|Polypodium Leucotomos|- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
79690592|NCT00559169|Drug|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
79690593|NCT02898948|Biological|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
79690594|NCT02898831|Other|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
79690595|NCT02904876|Radiation|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
79690596|NCT04642664|Drug|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
79836601|NCT04005196|Diagnostic Test|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
79836602|NCT00671034|Drug|Calaspargase Pegol-mknl|Given IV
79836603|NCT00671034|Drug|Cyclophosphamide|Given IV
79240249|NCT03468777|Drug|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
79240250|NCT00431457|Device|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
79240251|NCT00431457|Procedure|amygddohyppocampertomy|Resective surgery
79240252|NCT03640377|Drug|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
79240253|NCT05283655|Behavioral|Gut-directed hypnotherapy|hypnotherapy
79240254|NCT03643315|Behavioral|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
79534214|NCT06256510|Drug|Midazolam|Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
79534215|NCT06256510|Drug|Vepdegestrant|Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
79690597|NCT04642742|Dietary Supplement|Chewable plant sterol|Chewable plant sterol (gummy)
79690598|NCT02904759|Drug|Desmopressin|
79534216|NCT06256497|Device|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation & rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
79690599|NCT02904759|Drug|Placebo|
79690600|NCT02898792|Drug|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
79690601|NCT02904642|Behavioral|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
79690602|NCT02904642|Behavioral|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
79690603|NCT04642313|Other|Magnesium and/ or Potassium|Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
79690604|NCT02904447|Other|x-ray and pedobar foot pressure mapping|
79690605|NCT04642157|Other|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~A systematic initial contact with an ELIOS web-clinician~Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
79690606|NCT04642157|Other|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~The General Practitioner (GP)~The closest medico-psychologic center (CMP)~The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
79690607|NCT02904525|Device|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
79690608|NCT04642118|Procedure|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
79690609|NCT04641884|Other|Not concerned|Not concerned
79690610|NCT04641923|Other|Adhesion barrier|Adhesion barrier application at the time of first surgery
79690611|NCT02904564|Drug|MMP with 5-FU|MMP with 5-FU using tattoo device
79690612|NCT02904564|Drug|MMP with Saline infusion|MMP with saline infusion using tattoo device
79836604|NCT00671034|Drug|Cytarabine|Given IV, IT, PO, or SC
79836605|NCT00671034|Drug|Daunorubicin Hydrochloride|Given IV
79836606|NCT00671034|Drug|Dexamethasone|Given PO or IV
79534217|NCT06256484|Drug|ATA3219|ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
79240255|NCT03643315|Behavioral|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
79534218|NCT06256471|Other|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months for detection of impact of parasitic infection on these diseases courses
79534219|NCT06256458|Device|NanoBone® Bone Graft|The surgical technique used by the surgeon and the choice of the specific NanoBone product is or was determined solely by the surgeon and is independent of this observational study.
79836607|NCT00671034|Drug|Doxorubicin Hydrochloride|Given IV
79836608|NCT00671034|Other|Laboratory Biomarker Analysis|Correlative studies
79836609|NCT00671034|Drug|Mercaptopurine|Given PO
79240256|NCT03643237|Behavioral|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
79240257|NCT03643237|Other|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
79240258|NCT05044923|Device|Targeted Epidural Spinal Stimulation|Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
79379895|NCT04510558|Device|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"Antibioprophylaxis using cefuroxime and metronidazole~Standard disinfection and sterile draping~Circular incision around the stoma using the scalpel blade~Dissection around the stoma until entering the abdominal cavity~Closure of the stoma using a linear stapler~A midline laparotomy may be performed or not~Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~No subcutaneous stitches~Partial purse string skin closure using Monocryl 3-0~Standard wound dressing"
79379896|NCT04510558|Procedure|Stoma closure without mesh|"Antibioprophylaxis using cefuroxime and metronidazole~Standard disinfection and sterile draping~Circular incision around the stoma using the scalpel blade~Dissection around the stoma until entering the abdominal cavity~Closure of the stoma using a linear stapler~A midline laparotomy may be performed or not~Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~No subcutaneous stitches~Partial purse string skin closure using Monocryl 3-0~Standard wound dressing"
79534220|NCT06256432|Drug|Ambrisentan|Endothelin receptor antagonist
79534221|NCT06256432|Drug|Terlipressin|Terlipressin
79534222|NCT06256419|Drug|GLP-1 receptor agonist|Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
79534223|NCT06256419|Drug|responders group and nonresponders group|"For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated."
79690613|NCT04642040|Other|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
79547253|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
79547254|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
79836610|NCT00671034|Drug|Methotrexate|Given IV, IT, or PO
79836611|NCT00671034|Drug|Pegaspargase|Given IV
79836612|NCT00671034|Other|Pharmacological Study|Correlative studies
79836613|NCT00671034|Drug|Prednisone|Given IV or PO
79836614|NCT00671034|Radiation|Radiation Therapy|Some patients undergo RT
79240259|NCT05246449|Other|individualised treatment plan (VitalCare) and associated remote medical monitoring|VitalCare is a treatment plan to help in the personalisation of patient care.
79240260|NCT05165043|Procedure|position change|The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
79240261|NCT03643081|Device|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
79690614|NCT02904486|Behavioral|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
79690615|NCT04642001|Other|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
79836615|NCT00671034|Drug|Thioguanine|Given PO
79836616|NCT00671034|Drug|Vincristine Sulfate|Given IV
79690616|NCT04642001|Other|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
79690617|NCT04642001|Radiation|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
79240262|NCT03130569|Behavioral|Web-based Module Group|
79534224|NCT06256406|Other|in the field of rehabilitation and neonatal care: the combination of Kangaroo care method and music therapy|Kangaroo care is a practice involving skin-to-skin contact between the infant and a caregiver,. Music therapy is a therapeutic approach that utilizes the expressive and emotional qualities of music to address physical, emotional, cognitive needs of individuals.
79690618|NCT04642001|Combination Product|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
79690619|NCT02904681|Other|No intervention. Observational and descriptive study|
79534225|NCT06256341|Other|Cell cultivation, Antigen testing|"day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research."
79690620|NCT02904408|Behavioral|psychotherapy|Group psychotherapy
79534226|NCT06256328|Drug|ONO-4578|Specified dose, once daily
79690621|NCT04641845|Other|Cork inlay wedge|
79690622|NCT04641689|Device|Desk Only|Provision of height-adjustable desk
79690623|NCT04641689|Behavioral|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
79690624|NCT02898753|Drug|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
79690625|NCT02898753|Drug|RhGAA|Active comparator
79690626|NCT04641572|Other|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
79534227|NCT06256328|Drug|Oxaliplatin|Specified dose on specified days
79836617|NCT04483648|Other|Exercise|Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
79836618|NCT04432792|Other|Questionnaire|Study survey participants will be administered 3 online surveys.
79836619|NCT00743522|Device|ICD/ CRT-D|Cardiac device
79240263|NCT03642925|Dietary Supplement|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
79240264|NCT03640897|Device|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
79240265|NCT03640897|Other|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
79240266|NCT03640897|Other|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
79534228|NCT06256328|Drug|Capecitabine|Specified dose on specified days
79534229|NCT06256328|Drug|S-1|Specified dose on specified days
79534230|NCT06256328|Drug|Nivolumab|Specified dose on specified days
79690627|NCT02898324|Other|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
79690628|NCT04641533|Procedure|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
79690629|NCT04641533|Procedure|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
79690630|NCT02898675|Device|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
79240267|NCT03642847|Biological|Prevnar 13|13 valent Pneumococcal Conjugate
79534231|NCT06256328|Drug|Placebo|Specified dose, once daily
79547255|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
79690631|NCT02898675|Device|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
79690632|NCT02898558|Behavioral|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
79690633|NCT02898558|Device|magnifying lenses|
79690634|NCT04641494|Dietary Supplement|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
79690635|NCT04641494|Dietary Supplement|High oleic acid safflower oil capsules|
79240268|NCT03642847|Biological|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
79240269|NCT03642847|Biological|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
79534232|NCT06256315|Procedure|Hyper-ERAS Program|Patients who met the inclusion criteria were treated with Hype-ERAS protocol, including preoperative education, intraoperative quality control, postoperative preventive analgesia, early ambulation, early recovery of diet, early removal of the drainage tube, urinary catheter, and gastric tube, and discharge within 48 hours or more than 48 hours safter surgery, and closely and standardized follow-up outside the hospital.
79690636|NCT02898636|Other|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
79690637|NCT02898363|Other|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
79690638|NCT04641377|Other|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
79690639|NCT04641377|Other|Health Education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
79690640|NCT02898441|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
79690641|NCT04641455|Drug|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
79690642|NCT04641455|Drug|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
79690643|NCT04641455|Drug|Water|Administration of water before upper endoscopy
79836620|NCT05623462|Device|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
79836621|NCT05623462|Other|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
79836622|NCT00743600|Other|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
79836623|NCT00743600|Other|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
79836624|NCT04425070|Combination Product|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~Etoposide l00 mg/m2, iv infusion, on Days 1-3;~ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
79836625|NCT04425070|Combination Product|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
79836626|NCT04425070|Combination Product|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
79836627|NCT00743678|Drug|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
79836628|NCT00743756|Dietary Supplement|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
79836629|NCT00743756|Dietary Supplement|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
79391340|NCT04743700|Procedure|Micro-osteoperforations|Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
79391341|NCT02702388|Drug|Lenvatinib|Lenvatinib capsule.
79534233|NCT06256302|Procedure|Transverses Abdominis Plane Block|Transverses abdominis plane block will be provided randomly using prospective double-blinding.
79534234|NCT06256302|Procedure|Local wound infiltration|Local wound infiltration will be provided randomly using prospective double-blinding.
79534235|NCT06256289|Drug|Canagliflozin 100mg Tab|Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
79534236|NCT06256289|Drug|Metformin Hydrochloride|Metformin 1000mg twice daily
79690644|NCT02898480|Procedure|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
79690645|NCT04641182|Other|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
79690646|NCT02898402|Procedure|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
79690647|NCT00559286|Drug|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
79379897|NCT04509596|Drug|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
79836630|NCT00743756|Behavioral|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
79836631|NCT05604508|Other|Many posters with prices|No poster number or price restrictions
79836632|NCT05604508|Other|Many posters, no prices|No poster number restrictions, but price restrictions
79836633|NCT05604508|Other|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
79836634|NCT00772278|Procedure|carotid artery stenting|carotid artery angiography, angioplasty and stenting
79836635|NCT00772278|Procedure|carotid endarterectomy|open surgery including endarterectomy
79379898|NCT04499235|Drug|Mometasone furoate|Topical mometasone furoate
79379899|NCT04499235|Drug|AKST4290|Oral AKST4290
79379900|NCT04499235|Drug|Placebo|Oral placebo
79379901|NCT04487548|Other|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~A brief (<5 minutes) advice~Preoperative smoking cessation video prepared by QuitNow~Patients will be provided brochures on smoking cessation~A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
79379902|NCT04476446|Drug|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
79836636|NCT02679508|Drug|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
79836637|NCT02679508|Drug|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
80007502|NCT03619473|Behavioral|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~proper helmet wearing~how to differentiate non-standard and standard helmets~how to keep motorcycle safe using ABCD concept~importance of wearing bright clothes~police summon for not wearing helmets~live demo on poor performance of non-standard helmet~giving away standard motorcycle child safety helmets~oath taking by parents and children~distribution and placement of VEM on parents' motorcycles"
79240270|NCT03621163|Procedure|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
79379903|NCT04465344|Device|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
79379904|NCT04465344|Device|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
79303018|NCT03197155|Drug|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
79379905|NCT04465071|Drug|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
79379906|NCT04445688|Drug|AD036|Oral administration before bed
79379907|NCT04445688|Drug|Atomoxetine|Oral administration before bed
79379908|NCT04445688|Drug|Placebo|Oral administration before bed
79690648|NCT02898519|Other|cohort|Blood sampling
79379909|NCT04442737|Drug|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
79379910|NCT04442737|Drug|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
79379911|NCT04442737|Drug|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
79379912|NCT04439643|Device|vascuCAP|time to event and phenotype classification model
79391342|NCT02702388|Drug|Lenvatinib matching placebo|Lenvatinib matching placebo capsule.
79836638|NCT00775632|Drug|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
79836639|NCT00775632|Drug|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
79836640|NCT04047654|Drug|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
79836641|NCT04404478|Behavioral|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
79836642|NCT04404478|Behavioral|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
79534237|NCT06256276|Dietary Supplement|Whey protein powder and L-carnitine|Dietary supplement intervention for 16 weeks
79690649|NCT00559403|Behavioral|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
79690650|NCT00559403|Behavioral|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
79690651|NCT02898285|Behavioral|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
79690652|NCT02898285|Behavioral|Individual sport condition|Participants will choose from a list of individual sports.
79690653|NCT02898285|Behavioral|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
79534238|NCT06256276|Dietary Supplement|Maltodextrin placebo powder and Psyllium Husk capsules|Maltodextrin placebo powder and Psyllium Husk capsules
79690654|NCT04640870|Drug|Afatinib|Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
79690655|NCT04640558|Device|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
79690656|NCT02898168|Device|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
79690657|NCT02898168|Other|Control|Conventional rehabilitation therapy and gait training without WA.
79690658|NCT04640207|Device|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
79690659|NCT02897934|Drug|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
79240271|NCT03621163|Procedure|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
79240272|NCT04871763|Other|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
79690660|NCT04640129|Drug|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
79379913|NCT04437914|Diagnostic Test|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
79240273|NCT04871763|Other|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
79534239|NCT06256263|Procedure|total laryngectomy|pharyngeal repair after total laryngectomy
79690661|NCT04640129|Drug|Tenofovir Disoproxil Fumarate|TDF monotherapy
80007503|NCT05412225|Diagnostic Test|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
79240274|NCT04871763|Other|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
79379914|NCT04437862|Device|Q Revascularization System|Q Revascularization System for mechanical thrombectomy
79379915|NCT04436250|Drug|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
79547256|NCT01552850|Drug|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
79379916|NCT04436250|Drug|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
79547257|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
79547258|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
79547259|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
79836643|NCT00772356|Device|Accu-Chek Spirit Insulin Pump|
79836644|NCT00772356|Device|Comparator insulin pump|
80007504|NCT05412225|Radiation|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
79690662|NCT02898012|Drug|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
79836645|NCT04360096|Drug|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
80007505|NCT05412225|Procedure|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
79836646|NCT04360096|Drug|Placebo|Normal Saline Inhalation
79836647|NCT04360096|Device|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
79836648|NCT04005040|Procedure|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
80007506|NCT05407545|Device|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
80007507|NCT05407545|Device|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
80007508|NCT01340898|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
80007509|NCT01340898|Biological|SynflorixTM|Intramuscular injection
79240275|NCT04760535|Device|Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)|Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
79240276|NCT04760535|Device|Tooth-borne Hyrax-type maxillary expander|The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
79240277|NCT03632187|Drug|Abatacept|Subcutaneous abatacept every weeks during 3 months
79379917|NCT04436250|Drug|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
79379918|NCT04433910|Drug|Convalesscent Plasma|Transfusion
79534240|NCT06256250|Procedure|pulpectomy treatment will be done using the adaptive xp endo shaper.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the canal patency will be checked with a # 10 K file, and gliding path until #15 K- file. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation . the endomotor will be activated at aspeed of 800 rpm and 1 Ncm torque. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
79547260|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
80007510|NCT01340898|Biological|Infanrix-IPV/HiberixTM|Intramuscular injection
79240278|NCT03632187|Drug|Placebos|Subcutaneous placebo every week during 3 months
79240279|NCT05110209|Other|Aflibercept|intravitreal injection
79379919|NCT04423484|Other|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
79379920|NCT04414046|Biological|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
79379921|NCT04382755|Drug|Zilucoplan®|14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
79379922|NCT04382755|Drug|Placebo|standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
79379923|NCT04365556|Behavioral|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
79547261|NCT01552863|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
79547262|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
79547263|NCT01552941|Device|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
79547264|NCT01552967|Drug|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
79836649|NCT04048044|Device|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
79836650|NCT00775710|Device|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
79836651|NCT04047888|Other|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
79836652|NCT04047888|Other|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
79836653|NCT04004650|Procedure|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
79836654|NCT03730792|Behavioral|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
79547265|NCT01552980|Drug|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
80007511|NCT02426749|Device|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
79690663|NCT02898012|Drug|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage > grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
79690664|NCT04640324|Drug|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
79690665|NCT02897895|Biological|levels of CNI in whole blood|
79690666|NCT02897895|Biological|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
79690667|NCT04640285|Other|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
79690668|NCT04640285|Other|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
80007512|NCT02426749|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
79690669|NCT04640285|Other|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
79690670|NCT04640285|Other|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
79690671|NCT02898129|Other|Questionnaire|
79547266|NCT01552993|Drug|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
79690672|NCT02898129|Device|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
79836655|NCT04394182|Radiation|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
79836656|NCT04394182|Device|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
79836657|NCT04394182|Drug|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
79836658|NCT04394182|Drug|Hydroxychloroquine|200 mg/12h
79836659|NCT04394182|Drug|Azithromycin|500 mg/24h, 3 days
79836660|NCT04394182|Drug|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
79836661|NCT04394182|Drug|Low molecular weight heparin|prophylactic doses
79836662|NCT04394182|Drug|Corticosteroid injection|250mg x 3 boluses
79836663|NCT04394182|Drug|Tocilizumab|600mg single dose
79836664|NCT05376124|Other|original therapy|Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
79547267|NCT01552993|Drug|sucrose|pacifier and sucrose
79690673|NCT00559442|Other|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
79690674|NCT00559481|Drug|dexamethasone|
79547268|NCT01553006|Drug|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
79547269|NCT01553019|Radiation|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
79547270|NCT01553019|Drug|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
79547271|NCT01553097|Other|Neurocognitive impairment observation|None - observational
79547272|NCT01553123|Drug|Ulipristal Acetate|once daily, oral
79547273|NCT01553123|Drug|Iron|once daily, dried ferrous sulfate
79547274|NCT01553162|Genetic|DNA analysis|
79547275|NCT01553162|Genetic|RNA analysis|
79690675|NCT00559481|Drug|ketoconazole|
79690676|NCT00559481|Drug|therapeutic hydrocortisone|
79690677|NCT00559481|Procedure|pharmacological study|
79690678|NCT02897739|Procedure|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
79690679|NCT02897739|Biological|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
79690680|NCT02897739|Radiation|PET CT|PET study for metabolic pathway study
79690681|NCT02897739|Behavioral|Psychological assessment|Assessment by a psychologist
79690682|NCT00559520|Dietary Supplement|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
79690683|NCT00559520|Dietary Supplement|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
79690684|NCT01236352|Drug|BMS-911543|
79690685|NCT02897856|Drug|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
79240280|NCT05110209|Other|Ranibizumab|intravitreal injection
79690686|NCT02897856|Drug|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
79690687|NCT00559559|Device|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
79547276|NCT01553162|Genetic|gene expression analysis|
79690688|NCT00559559|Procedure|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
80007513|NCT03563820|Behavioral|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
79547277|NCT01553162|Other|laboratory biomarker analysis|
79690689|NCT00559598|Genetic|proteomic profiling|
80007514|NCT05328492|Device|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
79240281|NCT05110209|Other|Bevacizumab|intravitreal injection
79240282|NCT04454151|Drug|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
79240283|NCT05697315|Procedure|Control|No block was performed
79690690|NCT00559598|Other|medical chart review|
79836665|NCT05376124|Other|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
79240284|NCT05697315|Procedure|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
79836666|NCT04244890|Device|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
80007515|NCT05328492|Device|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
79379924|NCT04356469|Biological|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
79379925|NCT04355832|Drug|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
79379926|NCT04355832|Drug|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
79690691|NCT02897661|Procedure|WMT|Washed microbiota transplantation (WMT) through mid-gut
79690692|NCT02897661|Dietary Supplement|EEN|Exclusive enteral nutrition (EEN) through feeding tube
79690693|NCT03454685|Other|without intervention type|Without intervention,this study is just an observational study.
79690694|NCT02897505|Behavioral|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
79690695|NCT04639934|Genetic|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
79690696|NCT02897544|Behavioral|Individualized Manualized Health Education Intervention|
79690697|NCT04640090|Behavioral|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
79690698|NCT02897622|Other|Case management|Case management by Eira unit
79690699|NCT04639739|Biological|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
79836667|NCT04223206|Dietary Supplement|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
79240285|NCT00965757|Drug|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
79240286|NCT00965757|Drug|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
79240287|NCT03468699|Combination Product|Autologous BMMC transplantation|Stem cell transplantation
79379928|NCT04322539|Drug|Fruquintinib|Oral VEGFR inhibitor
79379929|NCT04322539|Drug|Placebo|Placebo capsule
79379930|NCT04307862|Drug|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
79391343|NCT04744168|Other|Acupuncture|Puncture of 5 points 4GI, 6RP, 34VB, 36E, 3F
79391344|NCT04744168|Other|Placebo Acupuncture|Puncture of point HM
79547278|NCT01553175|Genetic|DNA analysis|
79547279|NCT01553175|Genetic|gene expression analysis|
79547280|NCT01553175|Genetic|mutation analysis|
79547281|NCT01553175|Genetic|protein expression analysis|
79547282|NCT01553175|Other|immunohistochemistry staining method|
79547283|NCT01553175|Other|laboratory biomarker analysis|
79690700|NCT04639700|Behavioral|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information & Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional & Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
79690701|NCT01236118|Drug|LY2439821|Administered subcutaneously
79690702|NCT02897583|Procedure|YAG vitreolysis|
79690703|NCT04206631|Drug|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
79836668|NCT03472768|Diagnostic Test|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
79836670|NCT04144348|Biological|mRNA-1653|Sterile liquid for injection
79836671|NCT04144348|Biological|Placebo|Sterile liquid for injection
79303019|NCT02447107|Other|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
79303020|NCT02447107|Other|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
79379931|NCT04307862|Drug|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
79534241|NCT06256250|Procedure|pulpectomy treatment will be done using FANTA AF baby files.|"the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. The canal patency will be checked with a #10 K-file, and a glide path until #15 K-file will be created .the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.Open file: #17, taper 08.~BTF1: #20, taper 04, Yellow~BTF2: #25, taper 04, Red~BTF3: #30, taper 04, Blue The file will be activated at speed 350 rpm and torque 2 N until reaching the full working length. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown."
79690704|NCT04206631|Procedure|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
79690705|NCT04639817|Drug|Levofloxacin|Levofloxacin administration
79690706|NCT04639817|Drug|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
79836672|NCT00539734|Drug|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
79836673|NCT03907072|Drug|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
79836674|NCT03907072|Drug|Placebo|Buffered saline solution
79836675|NCT04004338|Drug|Kyprolis|Patients receiving kyprolis (carfilzomib)
79836676|NCT04209322|Procedure|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
79836677|NCT04209322|Procedure|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
79303021|NCT03118687|Other|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
79379932|NCT04307862|Drug|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
79690707|NCT02897154|Diagnostic Test|In-vitro|
79690708|NCT05496634|Behavioral|Sedantary|An informative presentation
79690709|NCT05496634|Behavioral|Exercise therapy|Pilates exercise therapy
79690710|NCT02897193|Device|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
79836678|NCT04004572|Drug|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
79836679|NCT04050436|Drug|Cemiplimab|Cemiplimab administered intravenously
79836680|NCT04050436|Biological|RP1|RP1 administered intratumorally
79836681|NCT04045912|Other|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
79836682|NCT04045912|Other|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
79836683|NCT01093976|Drug|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
80007516|NCT03097315|Drug|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
79303022|NCT02446873|Other|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
79303023|NCT02477033|Dietary Supplement|Butyricicoccus pullicaecorum 25-3T|
79391345|NCT02456896|Drug|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
79690711|NCT02897193|Device|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
79690712|NCT02897193|Device|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
79690713|NCT02897193|Device|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
79690714|NCT04639856|Procedure|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
79690715|NCT01236001|Drug|Lacosamide|
79690716|NCT04639349|Behavioral|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
79690717|NCT04639349|Other|control group|the control group will not be trained
80007517|NCT05530707|Other|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
80007518|NCT05376475|Device|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
80007519|NCT05376475|Device|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
79240288|NCT03130413|Device|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
79303024|NCT02477033|Other|Maltodextrin|
79303025|NCT03118453|Behavioral|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
79303026|NCT03118453|Behavioral|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
79534242|NCT06256250|Procedure|pulpectomy treatment will be done using hand k files.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files starting with #15 stainless steel hand K file. they are manual files, they are standard for root canal treatment (control group). the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
79534243|NCT06256237|Drug|JS004|Specified dose on specified days.
79534244|NCT06256237|Drug|Toripalimab|Specified dose on specified days.
79534245|NCT06256237|Procedure|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
79534246|NCT06256237|Drug|Etoposide|Specified dose on specified days.
79534247|NCT06256237|Drug|Platinum|Specified dose on specified days.
79534248|NCT06256224|Drug|Toripalimab|Toripalimab combined with CCRT
79534249|NCT06256224|Radiation|CCRT|CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)
79547284|NCT01553227|Device|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
79690718|NCT02897466|Other|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
79690719|NCT04639544|Dietary Supplement|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
79690720|NCT04639544|Dietary Supplement|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
79690721|NCT02897232|Other|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
79690722|NCT01229254|Drug|Amiodarone|Patients on Amiodarone
79690723|NCT01229254|Drug|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
79690724|NCT01229254|Drug|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
80007520|NCT05376475|Device|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
80007521|NCT05376475|Device|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
80007522|NCT05372731|Other|Recruitment Maneuver|RM after BAL
80007523|NCT03518671|Behavioral|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
80007524|NCT03518671|Behavioral|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
79690725|NCT01229254|Drug|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
79690726|NCT04639232|Dietary Supplement|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
79690727|NCT04639232|Dietary Supplement|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
79690728|NCT04639232|Dietary Supplement|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
80007525|NCT03039699|Drug|Ergoferon|
79690729|NCT02897388|Other|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling & promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
79690730|NCT01235728|Drug|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
79836684|NCT04597346|Device|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
79240289|NCT03130413|Device|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
79240290|NCT05697237|Drug|Carrelizumab|Carrelizumab 200mg/3 weeks
79240291|NCT05697237|Drug|Solfantinib|Solfantinib 300mg/d
79379936|NCT04298450|Behavioral|Active SMS Intervention|Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
79379937|NCT04298450|Behavioral|Sham SMS|Single welcome message letting participant know they will be contacted to book an appointment.
79836685|NCT00329719|Procedure|Conventional Surgery|Undergo surgery
79836686|NCT00329719|Other|Laboratory Biomarker Analysis|Correlative studies
79379938|NCT04278144|Drug|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
79379939|NCT04278144|Drug|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
79836687|NCT00329719|Drug|Sorafenib Tosylate|Given PO
79836688|NCT00329719|Drug|Temsirolimus|Given IV
79379940|NCT04270422|Other|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
79379941|NCT04270422|Other|Usual physiotherapy|Usual evidence based physiotherapy
79379942|NCT04257929|Drug|Pitolisant oral tablets|Pitolisant 4.45 mg or 17.8 mg tablets
79379943|NCT04257929|Drug|Placebo oral tablet|Matching placebo tablets
79534250|NCT06256211|Drug|Paracetamol|"All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~Rectal dose~Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~Intravenous dose~Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study."
79534251|NCT06256198|Other|measurement of serum lactate and procalcitonin and PCO2 gap|measurement of serum lactate, procalcitonin and PCO2 gap
79534252|NCT06256185|Procedure|esophagectomy|Resection of esophageal tumor and lymph node dissection
79534253|NCT06256172|Device|Medlink|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
79690731|NCT01235728|Drug|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
79836689|NCT04008628|Drug|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
79836690|NCT04004806|Device|Hill Rom tracking device|Location tracking devices from Hill Rom company.
79836691|NCT00743834|Drug|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
80007526|NCT03039699|Drug|Placebo|
80007527|NCT02003443|Behavioral|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
80007528|NCT02833974|Drug|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
79690732|NCT01235728|Drug|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
79690733|NCT00559676|Drug|capecitabine|
79690734|NCT00559676|Drug|fluorouracil|
79690735|NCT00559676|Drug|irinotecan hydrochloride|
79379944|NCT04257695|Behavioral|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
79379945|NCT04255810|Procedure|Surgical collection of biospecimens|Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
79379946|NCT04249882|Drug|Placebo|Matched to active medication
79690736|NCT00559676|Drug|leucovorin calcium|
79690737|NCT00559676|Drug|oxaliplatin|
79690738|NCT00559676|Other|laboratory biomarker analysis|
79690739|NCT00559676|Other|pharmacological study|
79690740|NCT04639271|Drug|Pyrotinib Plus And|Pyrotinib::400mg/d,qd,po
79690741|NCT04639271|Drug|Trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
79836692|NCT00743834|Behavioral|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
80007529|NCT02833974|Drug|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
79303027|NCT02477579|Device|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
79303028|NCT02446639|Other|Blood collection|
79303029|NCT02476721|Other|detection of pulmonary embolism|
79303030|NCT04484779|Device|IIM System|IIM System
79303031|NCT04484779|Drug|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
79379947|NCT04249882|Drug|Naltrexone|50 mg once a day
79379948|NCT04249882|Drug|Varenicline|1 mg twice a day
79379949|NCT04249401|Drug|Rivaroxaban (Xarelto)|NOAC, reduced dose
79379950|NCT04249401|Drug|Apixaban|NOAC, reduced dose
79379951|NCT04249401|Drug|Dabigatran|NOAC, reduced dose
79379952|NCT04249401|Drug|Warfarin|VKA
79379953|NCT04245748|Drug|Escitalopram|Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.
79379954|NCT04245748|Drug|Duloxetine|Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
79379955|NCT04245436|Drug|Duloxetine|Encapsulated duloxetine 30 mg, 60 mg; once-daily
79379956|NCT04245436|Drug|Escitalopram|Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
79391346|NCT01696877|Drug|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
79391347|NCT01696877|Drug|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
79690742|NCT04639271|Drug|Abraxane|Abraxane 125mg/M2, qw iv
79690743|NCT02896764|Device|Cone-beam CT|
79690744|NCT02896959|Procedure|Arthroscopic rotator cuff repair|
79690745|NCT04639076|Behavioral|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
79690746|NCT04639076|Behavioral|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
79690747|NCT02896725|Device|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
79690748|NCT02896725|Device|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
79836693|NCT00743912|Drug|rifaximin|550 mg TID
79836694|NCT02563886|Other|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
79303032|NCT02476643|Other|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
79534254|NCT06256159|Other|12 MSWS questionnaire|The subject has to perform different gait assessments and fill out the 12-item multiple sclerosis walking scale questionnaire in one visit. Maximum 8 weekes after the first visit the subject has to fill out the same questionnaire again.
79534255|NCT06256133|Procedure|Enhanced Recovery After Surgery protocol|Preoperative oral carbohydrate loading, Ultrasound-assisted thoracic epidural catheter placement, Intraoperative individualized goal-directed fluid therapy, Active warming techniques, The inspired fractional concentration of oxygen was maintained, Multimodal postoperative nausea and vomiting (PONV) prevention strategies, Anesthesia was maintained using a target-controlled infusion (TCI) of propofol and remifentanil, Scheduled administration of an intravenous (IV) or oral nonsteroidal anti-inflammatory drug (NSAID) (50 mg of dexketoprofen)
79379957|NCT04241848|Device|Keeogo|A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.
79391348|NCT01696877|Drug|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
79391349|NCT02416102|Drug|Losartan 50 mg|50 mg Losartan taken orally once daily for 4 consecutive weeks.
79690749|NCT04639154|Procedure|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
79690750|NCT04681053|Drug|Ivermectin Powder|- Administration through inhalation (6mg) BID for 3 days
79836695|NCT02563886|Other|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
79836696|NCT05306080|Drug|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~Injection #1/Day 1:~o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
80007530|NCT03632005|Device|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
80007531|NCT03632005|Other|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
79836697|NCT04060472|Drug|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
80007532|NCT05303493|Biological|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
80007533|NCT03093415|Drug|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
79534257|NCT06256107|Device|Virtual Reality Headset|Virtual Reality Headset
79534258|NCT06256094|Dietary Supplement|a2 Platinum Premium Infant Formula Stage 1|Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)
79534259|NCT06256094|Dietary Supplement|Frisolac Infant Formula Stage 1 (Dutch Edition)|Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
79534260|NCT06256081|Device|Hear Glue ear application|Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
79534261|NCT06256055|Biological|UCMYM802 Injection|1×10^8~2×10^9 cells will be infused intravenously for 4 times.
79534262|NCT06256042|Procedure|Occlusal splint|a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
79690751|NCT04639193|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
79690752|NCT04639193|Drug|Eszopiclone|Eszopiclone tablet (encapsulated)
79303033|NCT02477501|Drug|Norepinephrine|continuous infusion
79303034|NCT02477501|Drug|Ephedrine|continuous infusion
79303035|NCT02446795|Drug|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
79303036|NCT02446795|Drug|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
79534263|NCT06256042|Procedure|Arthrocentesis|The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
80007534|NCT04145817|Genetic|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
79534264|NCT06256029|Procedure|Recruitment maneuver|The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
79690753|NCT04639193|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
79690754|NCT04639193|Drug|Venlafaxine|Venlafaxine capsule
79690755|NCT01235689|Biological|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
79690756|NCT01235689|Drug|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
79836698|NCT02563730|Procedure|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
79690757|NCT01235689|Drug|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
79690758|NCT04680819|Dietary Supplement|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
79690759|NCT04638764|Other|Aerobic interval training combined with high intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
79836699|NCT00329641|Drug|carboplatin|Given IV
79836700|NCT00329641|Drug|paclitaxel|Given IV
79836701|NCT00329641|Drug|sorafenib tosylate|Given orally
79836702|NCT02566070|Other|Continuous Gastric Feeding|
79836703|NCT02566070|Other|Bolus Gastric Feeding|
79836704|NCT02533219|Drug|18 F-DOPA|Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of [18F]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
79836705|NCT03366220|Drug|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
79836706|NCT03366220|Drug|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
80007535|NCT04145817|Genetic|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
80007536|NCT04145817|Behavioral|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
80007537|NCT05470257|Other|Cast|Application of fiberglass long arm cast.
80007538|NCT01358526|Drug|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
80007539|NCT01358526|Drug|Placebo|Placebo tablets to match OXN taken orally every 12 hours
79836707|NCT00743990|Other|Ointment containing camphor, eucalyptus oil, and menthol|One time use
79836708|NCT00743990|Other|Petroleum jelly|One time use
79534265|NCT06255990|Other|Standard of care|Standard of care
79836709|NCT00329407|Drug|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
79690760|NCT04638764|Other|Aerobic interval training combined with low intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
79690761|NCT04638764|Other|Aerobic interval training|Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
79690762|NCT04680858|Other|DECT|Use of a digital enhanced telecommunication headset for team communication
79690763|NCT04680429|Drug|RP7214|Participants will receive single and multiple ascending doses of RP7214
79690764|NCT04680429|Drug|Placebo|Participants will receive single and multiple ascending doses of matching placebo
79836710|NCT04595006|Other|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
79836711|NCT04595006|Other|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
79836712|NCT04595006|Other|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
79836713|NCT04004728|Procedure|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
79836714|NCT01056757|Drug|Ribavirin|1000 mg bid, po, q28days
79836715|NCT00744068|Behavioral|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
79240292|NCT05164497|Other|Deliberate practice training|"The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response."
79379958|NCT04241848|Other|Ambulation training|Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
79379959|NCT04241419|Behavioral|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
79391350|NCT02416102|Drug|Losartan 100 mg|50 mg Losartan taken orally twice daily for 4 consecutive weeks.
79391351|NCT02414256|Other|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
79534266|NCT06255977|Drug|CN-105|Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
79534267|NCT06255964|Drug|IAP0971|Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
79534268|NCT06255964|Combination Product|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
79690765|NCT02896842|Drug|Posology dose modification|
79690766|NCT02896842|Other|active comparator|
79690767|NCT04638530|Other|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
79690768|NCT00559715|Drug|bevacizumab|1.25 mg intravitreally monthly/on demand
79690769|NCT00559715|Drug|ranibizumab|0.5 mg intravitreally monthly/on demand
79690770|NCT02896998|Procedure|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
79690771|NCT02896998|Procedure|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
79690772|NCT00559832|Other|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
79690773|NCT02896803|Drug|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
79690774|NCT02897037|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
79690775|NCT02897037|Drug|heparin|heparin monotherapy
79690776|NCT00559871|Drug|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
79690777|NCT00559910|Drug|PH-797804|PH-797804 at four dose levels
79534269|NCT06255964|Combination Product|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
79690778|NCT00559910|Drug|Placebo|Placebo
79690779|NCT02896530|Other|No intervention. Description study|
79690780|NCT04680624|Procedure|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
79690781|NCT04638608|Other|EMBRACE (relatives)|Online support program for both relatives
79690782|NCT04638608|Other|EMBRACE (Health care providers)|Online support program for health care providers
79690783|NCT00553683|Drug|cyclophosphamide|
79690784|NCT00553683|Drug|poly ICLC|
79690785|NCT00553683|Procedure|hepatic artery embolization|
79690786|NCT00553683|Radiation|3-dimensional conformal radiation therapy|
79690787|NCT04638179|Other|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
79690788|NCT01229176|Biological|Vi-CRM197 vaccine|
79690789|NCT01229176|Biological|Vi Polysaccharide (PS) vaccine|
79690790|NCT01229176|Biological|Pneumococcal conjugate vaccine|
79690791|NCT02896686|Radiation|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
79690792|NCT02896686|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
79690793|NCT02896686|Procedure|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
80007540|NCT03564054|Procedure|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
79379960|NCT04233970|Behavioral|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
79534270|NCT06255938|Diagnostic Test|smears|PCR smears for HPV testing will be performed
79534271|NCT06255925|Behavioral|KF-STRIDE® Into Work!|Treatment group will receive 10 web based sessions of a strength-based training tool(once or twice a week). Sessions are approximately 60 minutes long.
79534272|NCT06255899|Behavioral|Education Program on Injury Prevention|The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
79690794|NCT04638101|Behavioral|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
79690795|NCT01228747|Drug|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
79690796|NCT01228747|Drug|Placebo|Matching oral placebo tablets twice daily for 28 weeks
79690797|NCT02896413|Drug|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
79690798|NCT02896413|Drug|Control group|0.9% saline infusion
79690799|NCT01228591|Device|Acuvue Advance Plus|Silicone hydrogel contact lens.
79690800|NCT01228591|Device|Acuvue Advance|Silicone hydrogel contact lens
79690801|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
79690802|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
79690803|NCT00553722|Drug|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
79690804|NCT00553722|Drug|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
79690805|NCT01235338|Drug|LDX + Venlafaxine XR|"Day 1-5 LDX 30mg~Day 6-10 LDX 50mg~Day 11-15 LDX 70mg~Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~Day 31-34 Venlafaxine XR 150mg daily~Day 35-38 Venlafaxine XR 75mg daily."
79836716|NCT01056835|Drug|prostaglandin I2 analogue|
79690806|NCT01235338|Drug|Venlafaxine XR + LDX|"Day 1-5 Venlafaxine XR 75mg~Day 6-10 Venlafaxine XR 150mg~Day 11-15 Venlafaxine XR 225mg~Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~Day 21-25 Venlafaxine XR and LDX 50mg daily~Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~Day 31-34 Venlafaxine XR 150mg~Day 35-38 Venlafaxine XR 75mg."
80007541|NCT03564054|Procedure|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
80007542|NCT02156232|Procedure|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
79836717|NCT03989323|Other|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
79836718|NCT03986515|Drug|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
79836719|NCT03989479|Behavioral|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
79836720|NCT03989479|Behavioral|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
79836721|NCT01056991|Other|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
79240293|NCT05164497|Other|Theoretical teaching|The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
79240294|NCT05272683|Drug|GLPG3667|On day 1 and day 8, participants will receive a single dose
79240295|NCT05272683|Drug|Itraconazole|On days 5 to 11, participants will receive itraconazole once daily
79379961|NCT04233970|Behavioral|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
79379962|NCT04221997|Drug|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
79547285|NCT01553266|Behavioral|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
79547286|NCT01553305|Other|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
79547287|NCT01553305|Other|Exercise programme|Supervised exercise programme
79547288|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
79836722|NCT01056991|Other|warming blanket|
79836723|NCT00328783|Device|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
79836724|NCT00328783|Radiation|Radiation Therapy|
79836725|NCT00567489|Drug|Physioneal|Physioneal 40 or Physioneal 35
79836726|NCT00567489|Drug|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
79836727|NCT00567489|Drug|Extraneal|7.5% Icodextrin
79836728|NCT00567489|Drug|Nutrineal|Amino Acids 1.1%
80007543|NCT02156232|Procedure|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
79836729|NCT00669942|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
79836730|NCT00669942|Drug|Placebo|Placebo to AIN457
79836731|NCT00929019|Biological|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
79303037|NCT02446795|Drug|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
79303038|NCT02477267|Drug|SL spray|
79303039|NCT02477267|Drug|SL film|
79303040|NCT03196765|Drug|Sobetirome (NV1205)|Once a day oral dose of the study drug
79303041|NCT03196843|Drug|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
79303042|NCT03196843|Radiation|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
79379963|NCT04208919|Biological|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
79379964|NCT04194554|Drug|Niraparib|given PO per dose escalation schedule
79690807|NCT04638296|Other|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
79690808|NCT02896491|Radiation|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
79690809|NCT04638023|Device|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
79240296|NCT05649423|Other|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
79303043|NCT03196609|Biological|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
79379965|NCT04194554|Drug|Leuprolide|22.5 mg q3 month
79379966|NCT04194554|Drug|Abiraterone Acetate|1000 mg daily
79379967|NCT04194554|Radiation|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
79379968|NCT04193605|Behavioral|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
79379969|NCT04191889|Combination Product|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
79379970|NCT04181255|Drug|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
79379971|NCT04181255|Drug|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
79379972|NCT04170894|Other|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
79379973|NCT04170894|Other|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
79534273|NCT06255899|Behavioral|Individualized Feedback + Education Program on Injury Prevention|In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
79690810|NCT01234675|Drug|Milnacipran|50 mg twice daily
79379974|NCT04169737|Drug|Acalabrutinib|Given PO
79379975|NCT04169737|Biological|Obinutuzumab|Given IV
79379976|NCT04169737|Drug|Venetoclax|Given PO
79534274|NCT06255886|Drug|Protein pump inhibitor. Continuing nutrition containing cows' milk protein.|1 mg/kg /day
79690811|NCT01234675|Drug|Placebo|50 mg twice daily
79836732|NCT00907491|Device|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
79836733|NCT00929097|Other|Implementation aids|"Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~Clinicians receive the guidelines and a risk communication tool, as well as education"
79836734|NCT00929097|Other|Control|Dissemination of guidelines
79836735|NCT00769938|Device|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
79836736|NCT00907569|Radiation|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
79836737|NCT02538393|Drug|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state in Treatment A
79690812|NCT02895984|Behavioral|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
79690813|NCT04638452|Behavioral|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
79690814|NCT04638452|Behavioral|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
79534275|NCT06255886|Behavioral|Mother or infant diet|Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed
79690815|NCT02896101|Drug|Pimecrolimus Cream, 1%|
79690816|NCT02896101|Drug|Elidel® (pimecrolimus) Cream|
79690817|NCT02896101|Drug|Placebo of Pimecrolimus Cream, 1%|
79690818|NCT04637789|Behavioral|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
79690819|NCT04637789|Behavioral|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
79690820|NCT04638218|Device|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
79534276|NCT06255886|Drug|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
79534277|NCT06255847|Drug|Pomalidomide, cyclophosphamide combined with dexametha|The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
79690821|NCT02896062|Behavioral|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
79690822|NCT04638257|Biological|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =<18 weeks of gestation in singleton pregnancy
79690823|NCT04638257|Other|Placebo|Daily oral placebo starting at =<18 weeks of gestation in singleton pregnancy
79690824|NCT02896179|Device|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
79690825|NCT02896179|Device|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
79690826|NCT04637906|Dietary Supplement|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
79836738|NCT02538393|Drug|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
79836739|NCT00770016|Drug|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
79836740|NCT00924963|Device|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
79836741|NCT00924963|Device|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
79690827|NCT02896023|Drug|human menopausal gonadotropin|Induction of ovulation followed by ICSI
79836742|NCT00924963|Drug|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
79836743|NCT00770094|Device|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
79836744|NCT00770094|Device|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
79836745|NCT00770094|Device|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
79836746|NCT00925041|Device|Vedera KXS|one treatment with the Vedera KXS
79836747|NCT00775788|Procedure|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
79836748|NCT00929175|Device|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
79836749|NCT00929175|Device|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
79690828|NCT04637750|Behavioral|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
79690829|NCT02896140|Other|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
79690830|NCT04637633|Drug|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
79690831|NCT02896218|Other|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
79690832|NCT04637867|Other|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~Salivary sample~Nasopharyngeal sample"
79690833|NCT01228318|Drug|Zoledronic acid|"A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
79690834|NCT02895867|Other|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
79690835|NCT02895867|Other|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
79836750|NCT00929409|Drug|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
79836751|NCT00929409|Drug|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
79836752|NCT00772512|Drug|PF-04802540|5 mg capsule, single dose
79240297|NCT05649423|Other|Postural drainage|"Each position should be held for a minimum of five minutes.~In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
79379977|NCT04165291|Behavioral|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
79379978|NCT04165291|Behavioral|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
79534278|NCT06255834|Drug|IPG11406|"IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 ~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets"
79534279|NCT06255821|Behavioral|Exposure|One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
79379979|NCT04153760|Drug|Aspirin 81 mg|Aspirin 81 mg p.o. daily
79379980|NCT04153760|Drug|Placebo|Placebo p.o. daily
79534280|NCT06255795|Drug|chidamide, anti-PD1 antibody, and pegaspargase|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
79534281|NCT06255795|Drug|DDGP|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
79690836|NCT02895867|Other|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
79690837|NCT04637828|Drug|GNS561|study drug
79690838|NCT04206475|Other|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
79690839|NCT04206475|Other|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
79836753|NCT00772512|Drug|PF-04802540|15 mg capsule, single dose
79836754|NCT00772512|Drug|Placebo|Placebo capsule, single dose
79836755|NCT00925197|Other|INR self-testing program|
79690840|NCT05512624|Behavioral|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
79690841|NCT02895828|Other|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
79690842|NCT02895828|Other|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
79690843|NCT02895672|Drug|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
79690844|NCT04637711|Procedure|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision|Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
79240298|NCT05164185|Procedure|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
79836756|NCT00775866|Procedure|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
79836757|NCT00669864|Drug|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
79836758|NCT00669864|Drug|metformin|Tablets, 1000 - 2000 mg daily
79836759|NCT00770172|Biological|filgrastim|Given subcutaneously
79379981|NCT04128709|Device|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
79391352|NCT03178110|Behavioral|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
79391353|NCT03177876|Procedure|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
79836760|NCT02557620|Drug|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
79836761|NCT02557620|Drug|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
79534282|NCT06255782|Genetic|ECUR-506|ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
79534283|NCT06255769|Device|Magnetocardiography|Magnetocardiography
79534284|NCT06255769|Device|Single photon emission computed tomography (SPECT)|Single photon emission computed tomography (SPECT)
79534285|NCT06255743|Diagnostic Test|Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies|determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients
79836762|NCT00776022|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
79836763|NCT00772824|Dietary Supplement|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
79836764|NCT00772824|Dietary Supplement|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
79836765|NCT03875040|Behavioral|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
79836766|NCT04047732|Biological|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
79836767|NCT00772902|Drug|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
79836768|NCT00772902|Drug|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
79836769|NCT02557152|Device|GentleWave System Treatment|
79836770|NCT00779220|Drug|placebo|Intravenous repeating dose
79240299|NCT03789357|Diagnostic Test|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
79240300|NCT05164029|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
79240301|NCT04455399|Device|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
79391354|NCT03177876|Procedure|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
79690845|NCT02895516|Device|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
79690846|NCT04637516|Device|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
79690847|NCT01227967|Drug|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
79690848|NCT01227967|Drug|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
79690849|NCT02895555|Procedure|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested aulograft.
79690850|NCT02895555|Procedure|Allograft|Approx 50 g of allograft bone in the fused site
79690851|NCT00560027|Other|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
79690852|NCT00560144|Drug|RG1507|3mg/kg iv weekly
79836771|NCT00779220|Drug|methotrexate|Oral repeating dose
79836772|NCT00779220|Drug|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
79836773|NCT00779220|Drug|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
79240302|NCT04455399|Device|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
79240303|NCT05219721|Drug|CAR-T (CAR-GPRC5D)|CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain. The amplification and persistence of CAR T are enhanced by 4-1BB costimulation signal.
79240304|NCT03934671|Device|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
79534286|NCT06255730|Procedure|Stellate Ganglion Block|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
79690853|NCT00560144|Drug|RG1507|9mg/kg iv weekly
79690854|NCT00560144|Drug|RG1507|Pharmacokinetic-derived dose, <=16mg/kg iv weekly
79690855|NCT02895477|Device|hearing aid|
79690856|NCT04317391|Behavioral|Pain management program|Mindfulness based stress reduction
79836774|NCT00779220|Drug|ocrelizumab 500mg|Intravenous repeating dose (500mg)
79836775|NCT00776256|Dietary Supplement|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
79836776|NCT00779376|Drug|Zidovudine 300mg tablets|
79240305|NCT03934671|Device|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
79240306|NCT03891381|Device|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
79836777|NCT00779454|Drug|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
79836778|NCT00779454|Drug|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
79836779|NCT00772980|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
79836780|NCT00772980|Drug|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
79391355|NCT02458768|Drug|IVF-M HP Inj.|
79391356|NCT02458768|Drug|Menopur® Inj.|
79391357|NCT02423226|Procedure|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
79391358|NCT02423226|Drug|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
79547289|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
79690857|NCT00553761|Device|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
79690858|NCT04637477|Behavioral|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
79690859|NCT04637204|Drug|Cabozantinib|oral therapy
79690860|NCT04637204|Drug|Axitinib|oral therapy
79690861|NCT02895633|Other|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
79690862|NCT02895633|Other|CT scan|With injection of Iomeron 400
79690863|NCT02895633|Other|MRI|With injection of gadolinium (Multihance)
79836781|NCT00773058|Drug|hydrocortisone|hydrocortisone 100mg q8h
79836782|NCT00773058|Drug|placebo|normal saline 100ml q8h
79836783|NCT00776334|Drug|Fosinopril 40mg Tablets|
79836784|NCT00779610|Procedure|Vibration with flexion|Vibration with forearm flexion (active contraction)
79690864|NCT04637126|Other|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
79836785|NCT00779610|Procedure|Vibration without flexion|Vibration without forearm flexion (passive)
79836786|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
79836787|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
79240307|NCT03791853|Diagnostic Test|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
79240308|NCT03338361|Behavioral|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
79240309|NCT03338361|Behavioral|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
79240310|NCT03338361|Behavioral|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
79379982|NCT04125862|Diagnostic Test|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
79690865|NCT01227928|Drug|Pazopanib|Pazopanib 800 mg daily for 24 months
79690866|NCT01227928|Drug|Placebo comparator|Placebo 800 mg daily for 24 months
79240311|NCT03338361|Behavioral|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
79240312|NCT03587883|Other|Cocoa flavanols I|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
79379983|NCT04125862|Diagnostic Test|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
79534287|NCT06255730|Drug|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
79534288|NCT06255717|Behavioral|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
79690867|NCT02895438|Dietary Supplement|gluten|
79690868|NCT04637360|Drug|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
79690869|NCT04637360|Drug|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
79690870|NCT04317703|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
79836788|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
79836789|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
79836790|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
79836791|NCT00667992|Drug|Budesonide HFA|standard daily inhaled dose
79836792|NCT00667992|Drug|Budesonide CFC|standard daily inhaled dose
79836793|NCT02556294|Behavioral|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
79836794|NCT02556294|Behavioral|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
79240313|NCT03587883|Other|Control I|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
79379984|NCT04125862|Diagnostic Test|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
79534289|NCT06255717|Behavioral|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
79836795|NCT00779688|Device|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
79836796|NCT00776490|Drug|Glimepiride 1mg Tablets|
79836797|NCT00779844|Procedure|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
79836798|NCT00779844|Procedure|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
79836799|NCT00773214|Behavioral|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
79836800|NCT00776568|Procedure|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
79836801|NCT00776568|Drug|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
79836802|NCT00779922|Drug|lenalidomide|
79836803|NCT00776646|Drug|hydrochlorothiazide 50 mg tablet|
79836804|NCT00780078|Procedure|extubation|extubation failure in patients intubated orotracheally
79836805|NCT00773448|Device|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
79836806|NCT00773448|Other|Limited Malignancy Screening|"1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if > 18 and < 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year."
79240314|NCT03587883|Other|Cocoa flavanols II|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
79379985|NCT04125862|Diagnostic Test|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
79379986|NCT04125017|Device|ICSI with laser pulse|Using laser pulse before ICSI
79379987|NCT04125017|Device|ICSI with micro needle technique|Using micro needle technique before ICSI
79379988|NCT04097717|Behavioral|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
79836807|NCT00776724|Drug|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
79240315|NCT03587883|Other|Control II|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
79240316|NCT03160443|Behavioral|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~Blood sampling~Calorimetry~Osteodensitometry~Psychiatric assessment~Endocrinologic assessment~Dietetic assessment~Neuropsychological assessment~Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
79240317|NCT05216679|Device|Night splints|A night splint is a brace the patient wears on their foot to keep it in a dorsiflexed position while they sleep. It is the first line treatment for plantar fasciitis.
79240318|NCT05216679|Device|Triceps Surae Stretching and Flexibility Assessment Device (TESS)|The TESS device is a slant board with a bar added for balance that the participant will stand on in 5 minute intervals throughout the day to stretch their calves, and potentially treat their plantar fasciitis symptoms.
79690871|NCT04317703|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
79690872|NCT02895399|Other|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
79379989|NCT04097717|Other|Usual Care|Usual medical care will vary among participants.
79240319|NCT05159895|Drug|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of [14C] as a single administration
79690873|NCT05656846|Device|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
79690874|NCT05656846|Device|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
79690875|NCT04317352|Procedure|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
79690876|NCT00624598|Behavioral|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
79836808|NCT00776724|Drug|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
79836809|NCT00773526|Drug|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
79836810|NCT00776802|Drug|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
79534290|NCT06255704|Drug|Zanubrutinib and RCHOP/RDHAP|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。"
79836811|NCT00776802|Drug|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
79240320|NCT03130179|Drug|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
79240321|NCT03130179|Drug|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
79534291|NCT06255678|Diagnostic Test|Angiography-based vessel fractional flow reserve (vFFR) calculation|vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
79690877|NCT02895126|Behavioral|"Appui Parental program"|
79690878|NCT02895126|Behavioral|Regular parental support|
79379999|NCT04085094|Dietary Supplement|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
79380000|NCT04085094|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
79380001|NCT04085094|Diagnostic Test|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
79690879|NCT04636892|Other|MindMics earbud|Novel noninvasive wearable infrasound sensor
79690880|NCT05656690|Other|Exposure to disability|Disability status assessed by functional measures
79690881|NCT05656612|Other|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
79690882|NCT05656612|Other|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
79690883|NCT05656612|Other|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
79690884|NCT04636580|Behavioral|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
79836812|NCT00780312|Other|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
79534294|NCT06255652|Drug|Cephradin|Velosef
79836813|NCT00776880|Other|ASA scale|ASA scale evaluation before operation
79240322|NCT05400135|Behavioral|Qungasvik (Tools for Life)|The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
79836814|NCT00776880|Other|PPS scale|PPS scale evaluation before operation
79836815|NCT00780390|Other|Autonomic Function Assessment|
79836816|NCT00780468|Behavioral|Existing diet plan|
79240323|NCT05399901|Other|Electromyographic biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback
79240324|NCT05399901|Other|M-mode US biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
79380002|NCT04085094|Other|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
79836817|NCT00780468|Behavioral|New diet plan|
79380003|NCT04082312|Other|No intervention|No intervention
79380004|NCT04081805|Procedure|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
79534295|NCT06255613|Device|Belun Ring|The Belun Ring sensor should be placed on the palmar side of the proximal phalanx of the index finger and the sensor should be placed along the radial artery such that the accuracy of the device will be minimally affected by skin color. The Ring has 7 adjustable arms for different finger sizes. Each device is reusable after thorough cleaning with an alcohol swab.
79534296|NCT06255613|Device|Belun Cor|"The Belun Cor body sensor accessory is composed of an accelerometer, a temperature sensor, and a lithium battery. It will be placed immediately below the xiphoid process in the upper abdomen with a medical adhesive to detect the body temperature, body posture, respiratory rate, and respiratory efforts."
79534297|NCT06255587|Other|Screening|cross sectional
79534298|NCT06255561|Device|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
79836818|NCT00773682|Other|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
79836819|NCT00773760|Other|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
79836820|NCT00773916|Drug|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
79240325|NCT03467451|Procedure|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
79690885|NCT05656456|Other|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
79690886|NCT05656339|Dietary Supplement|CHO+WP|Oral supplement containing carbohydrates plus whey protein
79836821|NCT00773994|Other|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
79836822|NCT00774072|Drug|Tobramycin (Gernebcin®)|1 ml / day in each nostril
79836823|NCT00774150|Behavioral|Cognitive Behavioral Therapy|16 sessions of CBT
79836824|NCT00774150|Behavioral|Client Centered Therapy|16 sessions of CCT
79836825|NCT02556996|Biological|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
79836826|NCT02556996|Other|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)
79690887|NCT05656339|Dietary Supplement|CHO|Oral supplement containing carbohydrates
79690888|NCT05656339|Dietary Supplement|Fast|Fast condition of 12 hours
79690889|NCT05656300|Diagnostic Test|MRI scan using USPIO particles|Diagnostic imaging
79836827|NCT00774228|Device|I-ZIP Ocular Bandage|
79836828|NCT00774228|Device|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
79836829|NCT00780624|Device|NIPPV|Ventilator is Bird VIP.
79836830|NCT00780624|Device|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
79380005|NCT04081805|Procedure|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
79690890|NCT04636541|Behavioral|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
79690891|NCT04636541|Behavioral|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
79836831|NCT00780624|Device|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
79836832|NCT04047498|Device|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
79836833|NCT00780702|Drug|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
79836834|NCT00780702|Drug|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
79836835|NCT00780780|Drug|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
79836836|NCT00780780|Drug|triamcinolone intravitreal injection|triamcinolone intravitreal injection
79380006|NCT04081805|Drug|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
79836837|NCT00780858|Drug|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
79836838|NCT00780936|Procedure|femoral nerve block|
79836839|NCT00776958|Other|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
79836840|NCT00774384|Biological|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
79836841|NCT00777114|Drug|bortezomib, tositumomab|"0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
79534299|NCT06255548|Other|Immersive virtual reality group|The children in the IVR group were offered two video games from the Oculus Quest gallery. These games were Ocean Rift and Epic Roller Coaster-T-Rex Kingdom. Ocean Rift is the world's first VR water safari park. It has 12 different marine animals such as dolphins, sharks, and turtles and a habitat. Here one can visit a vibrant underwater world that extends all the way to the Arctic and Atlantis. Epic Roller Coaster-T-Rex Kingdom takes one on a roller coaster ride through the Age of Dinosaurs. There are more than 10 species of dinosaurs such as terrestrial, flying, herbivorous and carnivorous.
79380007|NCT04075656|Behavioral|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
79534300|NCT06255548|Other|Music group|In musical interventions, it is recommended to play music chosen by individuals. Disposable ear pads were used for each child and the headphones were cleaned after each intervention.
79836842|NCT00669396|Drug|Copper T380 IUD|Copper T380 IUD
79836843|NCT00669396|Drug|levonorgestrel|1.5 mg
79836844|NCT00774462|Drug|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
79836845|NCT00777192|Behavioral|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
79836846|NCT00669318|Biological|alemtuzumab|
79836847|NCT00669318|Biological|rituximab|
79836848|NCT00669318|Drug|pentostatin|
79836849|NCT00669318|Drug|sargramostim|
79240326|NCT03467295|Procedure|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
79836850|NCT00781092|Other|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
79690892|NCT02895009|Device|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
79836851|NCT00781092|Other|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
79836852|NCT00781170|Procedure|allogeneic hematopoietic SCT|
80007544|NCT03563898|Other|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
80007545|NCT01310010|Drug|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
79380008|NCT04075656|Behavioral|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
79534301|NCT06255535|Device|active iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
79534302|NCT06255535|Device|sham iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
79690893|NCT02895009|Device|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
79690894|NCT04638959|Other|collect gastric tissue and stool samples|collect gastric tissue and stool samples
79690895|NCT00624637|Other|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
79690896|NCT05656144|Device|Cadonilimab|AK104, 6mg/kg, Q2W
79836853|NCT00774540|Drug|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
79836854|NCT00774540|Drug|Placebo|Saline
79836855|NCT00777270|Procedure|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
79836856|NCT00777270|Procedure|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
79836857|NCT00774618|Device|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
79836858|NCT00669240|Drug|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
79836859|NCT00669162|Drug|Docetaxel|20mg/m2 IV weekly for 7 weeks
79836860|NCT00669162|Radiation|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
79836861|NCT00669162|Drug|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
79240327|NCT03467295|Procedure|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
79240328|NCT05399745|Other|Neurocognitive monitoring|Neurocognitive tests and MRI of the brain
79690897|NCT05656066|Behavioral|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
79836862|NCT00774696|Drug|clarithromycin 500mg tablets|
79836863|NCT00774774|Device|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
80007546|NCT02830776|Drug|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
80007547|NCT03039621|Drug|Ergoferon|For oral use.
80007548|NCT03039621|Drug|Placebo|For oral use.
80007549|NCT01235130|Drug|OMEGA-3|600mg, 2 caps, twice a day
79690898|NCT05656066|Behavioral|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
79690899|NCT04680663|Diagnostic Test|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
79836864|NCT00774774|Device|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~during the night,~when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
79690900|NCT04680663|Diagnostic Test|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
79240331|NCT05439837|Procedure|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
79836865|NCT02556060|Drug|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
79836866|NCT02556060|Drug|Placebo|Same dosing schedule as study drug
79836867|NCT00354770|Drug|Placebo|daily
79836868|NCT00354770|Drug|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
79240332|NCT05439837|Procedure|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
79240333|NCT05399589|Combination Product|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
79240334|NCT05399589|Combination Product|use healing cap in control group|use healing cap in control group
79380009|NCT04070534|Other|PALS|patient activated learning system
79836869|NCT00741494|Device|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
79836870|NCT00744146|Biological|Protexia|Single 50 mg IM dose
79836871|NCT00744146|Biological|Protexia|Single 100 mg dose
79240335|NCT03467139|Other|Abdominal breathing exercise|Deep Breathing Exercise
79380010|NCT04068922|Behavioral|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
79380011|NCT04066517|Procedure|SBRT|Multimodal-imaging guided SBRT for VT ablation.
79380012|NCT04051866|Procedure|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
79836872|NCT00744146|Biological|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
79380013|NCT04051866|Other|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
79380014|NCT04045379|Procedure|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
79534303|NCT06255522|Procedure|Fully guided implant placement|Through guided surgery, previously planned and designed based on CBCT study and CAD/CAM scanning, implant placement of Conelog Progressive line implants (Biohorizons Camlog, Iberia) will be performed in maxilla or mandibula in a one stage surgery. Postoperative CBCT in ECO mode (35μSv) will be taken after the implant placement to assess the final position and comparing with the initial digital planning.
79534304|NCT06255496|Diagnostic Test|Quantra Hemostasis Analyzer with the QStat Cartridge|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79534305|NCT06255483|Other|Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction|"A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node ."
79534306|NCT06255470|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
79690901|NCT00560222|Dietary Supplement|bovine lactoferrin|1gm of lactoferrin will be given each day
79690902|NCT00560222|Dietary Supplement|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
79836873|NCT00744146|Biological|Protexia|Single 500 mg dose, IM
79836874|NCT00744146|Biological|Protexia|Single 750 mg dose, IM
79836875|NCT00744224|Drug|Placebo|Single dose of placebo with saline infusion
79836876|NCT00744224|Drug|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
79836877|NCT00744224|Drug|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
79690903|NCT04317508|Drug|Topicale GelPatch (Benzocaine 18%)|Intervention group
79690904|NCT04317508|Drug|Benzocaine oral gel 20%|control group
79690905|NCT05655988|Diagnostic Test|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
79690906|NCT04636658|Other|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
79690907|NCT04636658|Other|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
79690908|NCT05655910|Dietary Supplement|Ensure Surgery Immunonutrition shake|Nutrition shake to support immune health and recovery from surgery.
79240336|NCT04726761|Diagnostic Test|Ambulatory Blood Pressure Monitoring, frequent/non-frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.
79240337|NCT04726761|Diagnostic Test|Ambulatory Blood Pressure Monitoring, non-frequent/frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
79836878|NCT00744302|Drug|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
79836879|NCT00666588|Drug|idarubicin|Given IV
79240338|NCT05439525|Other|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
79380015|NCT04045379|Procedure|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
79534307|NCT06255457|Procedure|Mitral valve surgery|Mitral valve repair or replacement of mitral regurgitation
79836880|NCT00666588|Drug|cytarabine|Given IV or IT
79240339|NCT05439525|Other|conventional therapy|"Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~Strengthen the rotator cuff and scapular stabilizers.~Improve upper-quarter postural awareness"
79240340|NCT05398965|Drug|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
79534308|NCT06255431|Drug|Ezerra cream|"The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen."
79534309|NCT06255405|Behavioral|Self-compassion|The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
79690909|NCT04636463|Procedure|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
79690910|NCT04636736|Diagnostic Test|HIV drug resistance testing|HIV drug resistance testing in people newly diagnosed in HIV in Poland
79690911|NCT04680702|Diagnostic Test|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
79690912|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
79836881|NCT00666588|Drug|bortezomib|Given IV
79240341|NCT05398965|Drug|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
79240342|NCT03467061|Dietary Supplement|Nitrate-rich beetroot juice|concentrated beetroot juice
79690913|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
79380016|NCT04045379|Drug|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
79690914|NCT00560300|Drug|1 alpha D2|Vitamin D sterol
79380017|NCT04045067|Procedure|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
79690915|NCT00560300|Drug|1,25 dihydroxy vitamin D3|Active vitamin D sterol
79836882|NCT00666588|Drug|etoposide|Given IV
79836883|NCT00666588|Other|laboratory biomarker analysis|Correlative studies
79836884|NCT00689390|Biological|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
79836885|NCT00689390|Biological|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
79534310|NCT06255392|Drug|Fluzoparib|Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
79534311|NCT06255392|Drug|Apatinib Mesylate|Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
79836886|NCT00689390|Biological|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
79240343|NCT03467061|Dietary Supplement|Nitrate-depleted beetroot juice|concentrated beetroot juice
79240344|NCT03467061|Other|Mouthwash|2 x 10 mL antibacterial mouthwash per day for 14 days
79534312|NCT06255392|Drug|Capecitabine tablets|Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
79836887|NCT00689390|Drug|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
79380018|NCT04045067|Procedure|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
79380019|NCT04039789|Behavioral|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
79380020|NCT04039789|Procedure|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
79380021|NCT04031521|Diagnostic Test|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
79534313|NCT06255392|Drug|Vinorelbine Tartrate Oral|For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
79534314|NCT06255392|Drug|Eribulin mesylate injection|Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
79534315|NCT06255392|Drug|Gemcitabine Hydrochloride|Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
79534316|NCT06255392|Drug|Paclitaxel-albumin|Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
80007550|NCT01235130|Drug|Placebo soybean oil|600mg, 2caps twice a day
79534317|NCT06255379|Drug|Fuquinitinib+Tegafur Gimeracil Oteracil|Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 < BSA （body surface area）< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） >1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
79534318|NCT06255366|Drug|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
79534319|NCT06255366|Drug|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
79534320|NCT06255366|Drug|0.9% Sodium Chloride Injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
79690916|NCT00560300|Drug|Sevelamer HCl|Phosphate binder
79690917|NCT00560300|Drug|Calcium Carbonate|Phosphate binder
79690918|NCT02895243|Other|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
79690919|NCT02904369|Drug|Emtricitabine|
79690920|NCT02904369|Drug|Tenofovir alafenamide|
79690921|NCT02904369|Drug|Tenofovir disoproxil|
79240345|NCT05398887|Radiation|Low radiation dose CT|Underwent low dose chest CT with 30% lower radiation dose
79240346|NCT05398887|Radiation|Underwent ultra dose chest CT|Underwent ultra dose chest CT with 90% lower radiation dose
79240347|NCT05398887|Other|Artificial Intelligence based model|Deep-learning based contrast boosting algorithms
79240348|NCT03466983|Drug|Iron Isomaltoside|administered IV
79240349|NCT03466983|Drug|Ferric Carboxymaltose|administered IV
79690922|NCT02904330|Drug|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
79690923|NCT00560378|Drug|Tacrolimus ointment 0.1%|Topical
79690924|NCT00560456|Other|Chronic sleep restriction and driving simulator|"One night of normal sleep~Driving simulator~Night 1: night of total sleep deprivation~Night 2: night of sleep recovery~Night 1 to 5: nights of sleep restriction~Driving simulator after night 1 to 5~Night 6: night of sleep recovery~Driving simulator"
79690925|NCT00560534|Procedure|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
79690926|NCT04636424|Other|assesment of gait|speed and weight distribution during gait
79836888|NCT00689390|Other|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
79380022|NCT04018651|Behavioral|PrEP Master Adherence Intervention|"The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~Importance of daily adherence;~Three week delay for full effectiveness describing PrEP like taking the birth control pill;~Condom use for other sexually transmitted infection (STI) prevention;~Pregnancy prevention plans;~Plans for follow up calls~Referral to other treatment services if necessary"
79240350|NCT03466905|Other|Ambulant assessment|
79240351|NCT05439213|Drug|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
79240352|NCT05439213|Drug|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
79836889|NCT00781248|Device|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
79240353|NCT03466827|Drug|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
79240354|NCT05398575|Behavioral|Music|Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
79240355|NCT03466749|Device|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
79240356|NCT05398419|Other|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
79380023|NCT04015167|Device|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
79240357|NCT05398419|Other|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
79534321|NCT06255353|Device|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
79534322|NCT06255353|Behavioral|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
79534323|NCT06255353|Device|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
79534324|NCT06255340|Drug|BI 3031185|BI 3031185
79690927|NCT04636346|Behavioral|Acceptance and Commitment Therapy|Seven group sessions
79690928|NCT04636346|Other|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
79836890|NCT00567879|Drug|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
79240358|NCT03466671|Drug|TTA-121|A nove intranasal spray of oxytocin and placebo
79534325|NCT06255340|Drug|Placebo matching BI 3031185|Placebo
79690929|NCT02895321|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
79690930|NCT02895321|Other|Colgate, Protection Caries|a fluorine-based toothpaste gels
79690931|NCT02895321|Other|Placebo gel|a glycerin and water gel
79690932|NCT04636385|Other|Observational study no intervention|No intervention
79690933|NCT02894970|Device|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
79690934|NCT02904174|Behavioral|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question & answer session were included in the group education.
79240359|NCT05438901|Biological|leech therapy|effects of medicinal leeches
79240360|NCT03466593|Other|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
79690935|NCT02894931|Dietary Supplement|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
79690936|NCT02894931|Dietary Supplement|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
79690937|NCT02894931|Dietary Supplement|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
79836891|NCT00567879|Drug|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
79836892|NCT00781404|Drug|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
79836893|NCT00777504|Drug|usage oral angiogenesis inhibitor|see under 'study arms'
79836894|NCT00777504|Drug|stop oral angiogenesis inhibitor|see under 'study arms'
79240361|NCT03466593|Other|Routine care|Preoperative information
79836895|NCT00781482|Drug|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
79836896|NCT00925275|Drug|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
79836897|NCT00907725|Other|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
79380024|NCT04015154|Device|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
79380025|NCT04006613|Other|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
79380026|NCT04006613|Other|Usual Care|Exercises aimed at improving mobility and balance
79240362|NCT03466593|Other|Extra early mobilization|Mobilization the day of surgery
79380027|NCT04002115|Drug|Clofarabine|"Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total."
79380028|NCT04002115|Drug|Fludarabine|Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
79380029|NCT04002115|Drug|Busulfan|Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
79380030|NCT04002115|Procedure|Total Body Irradiation (TBI)|TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
79380031|NCT04002115|Drug|Cyclophosphamide|Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
79380032|NCT04002115|Drug|Granulocyte Colony-Stimulating Factor|G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
79534326|NCT06255327|Other|I COUGH care program|I COUGH care program included a flow-incentive spirometer 10 times every 2 hours (10 efforts each set), from awake until discharge, coughing and deep breathing 3-5 times every 2 hour, and oral care at 8:00 am and 8:00 pm. including brushing teeth and rinsing with mouthwash; understanding by education of patient and family; getting out of bed to chair at least once on the day of the operation, walking at least once on the day of the operation, and out of bed to chair and walking in corridor at least three times per day, and raising the head of the bed more than 30 degrees.
79534327|NCT06255314|Procedure|ventral hernia repair|"Laparoscopic transabdominal retromuscular repair is a minimally invasive approach to the open Rives Stoppa retromuscular sublay repair for ventral hernia.~In ventral hernia repair, it relies on initiation of dissection in one retrorectus space and then crossover to the contralateral retrorectus space The sublay mesh technique is an open surgical procedure for ventral and incisional hernias"
79836898|NCT00907725|Other|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
80007551|NCT05708118|Diagnostic Test|Echocardiographic assessment.|Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
79240363|NCT03466593|Other|Standard mobilization|Mobilization the day after surgery
79240364|NCT05438823|Other|Educational Programe|IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
79380033|NCT04002115|Drug|Tacrolimus|Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
79380034|NCT04002115|Drug|Cellcept|Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
79690938|NCT02894931|Dietary Supplement|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
79690939|NCT02894931|Other|Control- water|Chilled water flavored with lemon juice as control
79690940|NCT04635956|Drug|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
79690941|NCT02904018|Other|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
79690942|NCT02903979|Other|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
79690943|NCT02903979|Other|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
79690944|NCT04635488|Procedure|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
79690945|NCT02895204|Dietary Supplement|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
79690946|NCT02895204|Dietary Supplement|Placebo|6g of maltodextrin
79836899|NCT00603915|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) day 1 and day 8
80007552|NCT05708118|Diagnostic Test|Computed-tomography assessment|All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
79380035|NCT03999021|Drug|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
79380036|NCT03996499|Diagnostic Test|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
79380037|NCT03990233|Drug|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
79534328|NCT06255288|Other|SNAK intervention|The intervention consists of structured dialogue, patient information, and a protein supplement. The structured dialogue part of the intervention consists of an A3 poster with illustrations and keywords which will be hanging in the outpatient clinics. The poster will be utilized by nurses, patients, and their relatives to facilitate a dialogue regarding nutrition and wound healing. The patient information part of the intervention consists of a leaflet with easy-to-read information, which patients and their relatives can bring home after their visit to the outpatient clinic. The leaflet will consist of general information as well as food categories and recipes they can use to enhance their daily protein intake. For the protein supplement part of the intervention, the patients will have access to protein supplement beverages while they are in the outpatient clinic waiting room. Furthermore, they will receive prescriptions for protein drinks, that they can pick up at their local pharmacy.
79690947|NCT04635371|Device|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
79690948|NCT02894892|Drug|(A)Bismuth|
79690949|NCT02894892|Drug|(B)Bismuth|
79690950|NCT02894892|Drug|(C)Bismuth|
79240365|NCT03466515|Procedure|stem cells injection|two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
79240366|NCT04520841|Device|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
79240367|NCT04520841|Device|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
79240368|NCT04501731|Other|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
79690951|NCT02894892|Drug|(D)Esomeprazole and Bismuth|
79690952|NCT02894892|Drug|(E)Esomeprazole and Bismuth|
79690953|NCT02894892|Drug|(F)Esomeprazole and Bismuth|
79690954|NCT02894892|Other|(G)Control|
79690955|NCT04635566|Drug|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
79690956|NCT04635566|Drug|Placebo|Placebo one time/day at the evening.
79690957|NCT02894853|Genetic|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
79690958|NCT04635293|Procedure|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
79690959|NCT04635293|Procedure|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
79690960|NCT02894736|Device|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
79690961|NCT04635215|Device|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
79690962|NCT02903862|Behavioral|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support & assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
79690963|NCT02903862|Device|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
79240369|NCT04501731|Other|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
79380038|NCT03990233|Drug|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
79534329|NCT06255275|Other|neurocognitifs tests + pedestrian crossign whith virtual reality|Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
79534330|NCT06255262|Drug|Surufatinib|"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."
79534331|NCT06255262|Drug|Durvalumab|1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
79534332|NCT06255236|Device|Bispectral index (BIS)|"All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~Sedative medication can be given as appropriate.~Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
79534333|NCT06255223|Radiation|High-dose Radiotherapy (HDRT)|SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
79534334|NCT06255223|Radiation|Low-dose Radiotherapy (LDRT)|Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
79836900|NCT00603915|Drug|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
79836901|NCT00603915|Drug|erlotinib|150mg daily (post GC therapy)
79690964|NCT04635410|Other|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
79690965|NCT01227889|Drug|GSK2118436|150 mg twice daily
79690966|NCT01227889|Drug|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
79836902|NCT00929487|Device|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
79836903|NCT00929487|Other|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
79836904|NCT00929487|Device|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
79836905|NCT00603837|Device|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
79690967|NCT02894814|Behavioral|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
79836906|NCT00603837|Device|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
80007553|NCT05708196|Other|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
79240370|NCT04501731|Other|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
79240371|NCT04501731|Other|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
79380039|NCT03976544|Drug|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
79380040|NCT03976544|Drug|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
79380041|NCT03971656|Dietary Supplement|Nutritional Supplement|Oral nutritional supplementation
79380042|NCT03971656|Behavioral|Preoperative Dietitian Consult|Nutritional assessment
79690968|NCT02894814|Behavioral|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
79836907|NCT04015089|Dietary Supplement|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
79836908|NCT04015089|Dietary Supplement|Standard formula (SF)|Infant formula with intact protein
80007554|NCT05708196|Other|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
79240372|NCT03466437|Device|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
79380043|NCT03971656|Behavioral|Education|Informational materials about nutrition
79690969|NCT04635332|Behavioral|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
79690970|NCT04635332|Behavioral|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
79690971|NCT02894541|Drug|CKD-519 100mg|
79690972|NCT02894541|Drug|CKD-519 200mg|
79690973|NCT02894541|Drug|CKD-519 100mg|
79690974|NCT02894541|Drug|CKD-519 200mg|
79690975|NCT02888392|Other|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
79690976|NCT02888392|Dietary Supplement|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
79690977|NCT04635020|Procedure|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
79690978|NCT04635020|Procedure|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
79240373|NCT03466437|Device|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
79690979|NCT04635020|Procedure|Cataract surgery|Conventional cataract surgery
79836909|NCT00925509|Procedure|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
79836910|NCT00925665|Device|Glidescope|Patients are to be intubated using the Glidescope technique
79240374|NCT03466437|Device|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
79240375|NCT05438745|Other|Copenhagen Burnout Inventry|Questionnaire
79240376|NCT03466359|Behavioral|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
79240377|NCT03466359|Behavioral|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
79690980|NCT05655871|Other|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
79690981|NCT05655871|Other|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
79690982|NCT04681716|Other|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
79534335|NCT06255223|Drug|Anti-PD-1 monoclonal antibody|At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
79534336|NCT06255210|Drug|Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)|When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is < 25%, patients were treated with the CEP regimen for induction chemotherapy.
79534337|NCT06255184|Behavioral|Sernity intervention|Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
79690983|NCT04681716|Other|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
79690984|NCT04681521|Other|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
79836911|NCT00925665|Device|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
79836912|NCT00925743|Drug|cabazitaxel (XRP6258)|"administered by IV infusion~in addition to cisplatin treatment"
79240378|NCT05438433|Device|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
79240379|NCT03466281|Behavioral|Structured patient group education|Patient education in a group setting
79690985|NCT04634942|Device|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
79690986|NCT04634942|Device|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
79690987|NCT01227577|Drug|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
79534338|NCT06255171|Behavioral|Reading journalistic posts and articles on social media on nature|Reading journalistic posts and articles, published on social media, regarding nature.
79690988|NCT04681599|Device|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
79690989|NCT04681599|Device|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
79534339|NCT06255171|Behavioral|Reading journalistic posts and articles on social media on deaths by suicide|Reading journalistic posts and articles, published on social media, regarding deaths by suicide.
79690990|NCT04635137|Procedure|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
79836913|NCT00925821|Procedure|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
79836914|NCT00925821|Drug|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
79836915|NCT00925977|Drug|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
79240380|NCT03466281|Behavioral|Education via Internet|Patient education via the internet
79380044|NCT03968172|Behavioral|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~Diagnosis and disease progression~Support in disease processing~Techniques for coping with stress and depressive symptoms as well as developing positive emotions~Optimisation of dietary behaviour~Optimisation of physical activity behaviour~Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
79240381|NCT03465969|Drug|tacrolimus|oral
79240382|NCT05397873|Device|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
79240383|NCT05397795|Drug|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
79534340|NCT06255171|Behavioral|Reading journalistic posts and articles on social media on traffic-related deaths|Reading journalistic posts and articles, published on social media, regarding traffic-related deaths
79534341|NCT06255158|Behavioral|INSIGHT Program|"INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills."
79534342|NCT06255158|Other|Treatment As Usual (TAU)|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
79690991|NCT05655793|Diagnostic Test|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
79690992|NCT05655793|Diagnostic Test|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
79836916|NCT00925977|Drug|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
79836917|NCT00926055|Drug|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
79836918|NCT00926055|Drug|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
79836919|NCT04015635|Other|None involved|NO intervention
79836920|NCT00926133|Other|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
79836921|NCT00907959|Drug|BZL101|Oral BZL101 20 grams/day (10 grams BID).
79836922|NCT00667602|Biological|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
79836923|NCT00667602|Biological|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
79836924|NCT00667602|Biological|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
79836925|NCT00667602|Biological|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
79240384|NCT05397795|Drug|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
79690993|NCT00624676|Drug|Lipo Hydroxy Acid|Twice a day
79240385|NCT03130101|Other|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
79240386|NCT01067521|Drug|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
79690994|NCT00624676|Drug|5% benzoyl peroxide gel|Once a day
79690995|NCT04634903|Behavioral|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
79690996|NCT04634903|Behavioral|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
79690997|NCT04634903|Behavioral|Growth Mindset SSI|Online, 30-minute self-administered program for youth
79690998|NCT05655754|Drug|Methohexital|anesthesia during ECT
79690999|NCT05655754|Drug|Ketofol|anesthesia during ECT
79691000|NCT02894385|Drug|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
79691001|NCT05655715|Radiation|Stereotactic body radiotherapy|8 Gray x 3
79691002|NCT05655715|Drug|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
79691003|NCT05655715|Drug|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
79691004|NCT05655715|Procedure|Biopsies|From soft tissue metastases.
79691005|NCT05655676|Drug|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
79691006|NCT04634864|Device|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
79691007|NCT04634864|Device|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
79691008|NCT02894463|Other|questionnaire|
79240387|NCT01067521|Drug|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
79380045|NCT03968172|Behavioral|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~Disease progression~Invisible symptoms of multiple sclerosis~Symptomatic therapy~Immunotherapy decision support~Coping strategies~Autonomy~Fatigue~Quality of life~Physical activity~Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
79380046|NCT03964415|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
79380047|NCT03964415|Biological|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
79380048|NCT03964415|Biological|Placebo|Participants will receive matching placebo.
79380049|NCT03960866|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
79380050|NCT03960866|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
79380051|NCT03959826|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
79380052|NCT03959826|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
79691009|NCT04317235|Drug|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
79691010|NCT00560690|Drug|Metformin|500 mg oral three times a day for 6 months
79691011|NCT00560690|Drug|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
79691012|NCT00560690|Drug|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
79691013|NCT01227421|Drug|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
79691014|NCT01227421|Drug|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
79691015|NCT01227421|Drug|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
79691016|NCT05655559|Other|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
79691017|NCT05655559|Device|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
79691018|NCT00560729|Dietary Supplement|Renutryl 500|
79691019|NCT00560729|Dietary Supplement|Generique|
79691020|NCT00560729|Dietary Supplement|Generique + Renutryl 500|
79691021|NCT02903901|Drug|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
79691022|NCT02903901|Drug|Placebo|10 mg liquid placebo at 7 pm for 1 week
79691023|NCT00560768|Device|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~A right ventricular defibrillation lead~In case of use of a dual chamber ICD a right atrial pacing lead~A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
79691024|NCT02904213|Biological|ComBe Five (Liquid)|
79691025|NCT01227265|Drug|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
79691026|NCT01227265|Drug|Placebo|Preladenant-matching placebo oral tablet taken twice daily
79691027|NCT00560807|Procedure|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
79836926|NCT00667602|Biological|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
79691028|NCT04319302|Procedure|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
79691030|NCT04634981|Procedure|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
79534343|NCT06255145|Device|Bioelectrical Impedance Analysis|"Bioelectrical Impedance Analysis Beurer BF 1000 Super Precision device was used to measure the body composition of the participants. Operating on the principle of BIA, the device allows the body composition to be evaluated by giving an imperceptible electric current to the body.~Fatigue Severity Scale (FSS) Fatigue Severity Scale (FSS) was used to measure participants' fatigue levels. Rivermead Mobility Index Rivermead Mobility Index (RMI) was used to assess the mobility levels of the participants.~Functional Independence Measure Functional Independence Measure (FIM) was used to evaluate the functional status of the participants."
79691031|NCT05655286|Drug|38% SDF treatment|Children with active caries will receive 38% silver diamine fluoride treatment
79691032|NCT05655286|Behavioral|not to rinse for at least 30 minutes after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
79691033|NCT05655286|Behavioral|rinse mouth immediately after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
79836927|NCT04034199|Drug|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
79836928|NCT04034199|Drug|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
79240388|NCT05434455|Device|RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
79240389|NCT05397483|Behavioral|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
79380053|NCT03953833|Biological|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
79380054|NCT03949465|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
79534344|NCT06255132|Device|Automated pupillometer NPi-200|"Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS > 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon)."
79534345|NCT06255119|Device|3D Therapy Thrive|A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
79240390|NCT05397483|Behavioral|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
79380055|NCT03944512|Drug|Pravastatin|20 mg Pravastatin taken daily
79534346|NCT06254339|Procedure|OAGB|using OAGB procedure as metabolic bariatric surgery
79534347|NCT06254339|Procedure|DJB-SG|using DJB-SG procedure as metabolic bariatric surgery
79534348|NCT06254131|Drug|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
79534349|NCT06254131|Drug|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
79836929|NCT02538237|Drug|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
79836930|NCT02538237|Drug|Ibuprofen 2% mouthwash|
79534350|NCT06253910|Other|Patients selection|Patient selection were selected according to selected criteria.
79380056|NCT03944512|Other|Placebo|Identical appearing placebo pill
79534351|NCT06253910|Other|Recall visits|Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.
79534352|NCT06253884|Device|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
79691034|NCT02904252|Other|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F>2).
79691035|NCT04318990|Procedure|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
79691036|NCT04318990|Procedure|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
79534353|NCT06253546|Drug|TV-44749|"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"
79380057|NCT03930797|Behavioral|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
79534354|NCT06253546|Drug|Oral Olanzapine|"Pharmaceutical form:~tablet~Route of administration:~oral"
79691037|NCT04319107|Other|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
79691038|NCT00553449|Drug|rabeprazole|
79534355|NCT06253442|Procedure|Patients will receive Supra scapular nerve block and Axillary nerve block.|"Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood.~For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique."
79534356|NCT06253442|Procedure|Patients will receive Interscalene block.|Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
79534357|NCT06253403|Behavioral|psychotherapy|psychotherapy related to sexual intervention
79380058|NCT03930797|Behavioral|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
79534358|NCT06252948|Other|Gut microbiome studies in patients with POEMS syndrome and other plasma cell disorders.|None-Collection of samples for future analysis
79836931|NCT00691028|Drug|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
79836932|NCT00691028|Drug|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
79836933|NCT00691028|Drug|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
80007555|NCT03563664|Procedure|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
80007556|NCT03563664|Drug|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
79380059|NCT03928418|Behavioral|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
79380060|NCT03928418|Behavioral|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
79691039|NCT04319263|Drug|induction regimen of intravesical BCG|intravesical instillation of 6 weekly doses of BCG
79691040|NCT05655169|Procedure|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied."
79691041|NCT05655169|Procedure|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
79691042|NCT05655169|Other|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
79534359|NCT06252610|Drug|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of [68Ga]CBP8;~6-10 mCi of [68Ga]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~The catheter will be flushed with 0.9% saline solution;~The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
79691043|NCT04634630|Genetic|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
79691044|NCT02903589|Other|observational|
79691045|NCT05658406|Drug|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
79836934|NCT05277441|Diagnostic Test|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
79380061|NCT03928418|Behavioral|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
79691046|NCT05658406|Drug|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
79691047|NCT05658406|Drug|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
79691048|NCT05658406|Drug|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
79691049|NCT05658367|Procedure|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
79691050|NCT05658367|Procedure|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
79691051|NCT05658367|Procedure|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
79691052|NCT04319146|Procedure|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
79691053|NCT04206592|Device|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
79836935|NCT05280327|Other|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
79836936|NCT00929721|Procedure|Blood draw|culture for Streptococcus pneumoniae Frequency-1
79240391|NCT02735577|Drug|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
79380062|NCT03926572|Other|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
79380063|NCT03908567|Drug|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
79534360|NCT06252610|Drug|Contrast Media, Magnetic Resonance|"The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~The catheter will be flushed before and after injection with 0.9% saline solution;~About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~The contrast will then be injected."
79836937|NCT00929721|Procedure|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
79836938|NCT00929721|Procedure|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
79836939|NCT00929721|Procedure|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
79836940|NCT00929721|Procedure|sputum|culture for Streptococcus pneumoniae Frequency-1
79691054|NCT02894697|Device|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
79691055|NCT02894697|Device|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
79240392|NCT03642535|Drug|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
79240393|NCT04453605|Other|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
79691056|NCT04634474|Behavioral|Suction|Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
79691057|NCT05658250|Device|CRE8 polymer-free Amphilimus-eluting stent|Percutaneous coronary intervention using a Cre8 stent for long lesions
79691058|NCT05469997|Behavioral|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (~70-75% of your daily caloric intake) and lean proteins (~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
79691059|NCT05469997|Dietary Supplement|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level [ATP]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
79836941|NCT04533230|Behavioral|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
79836942|NCT04533230|Behavioral|Information on treatment guidelines|Written information on treatment guidelines.
79836943|NCT00908193|Device|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
80007557|NCT03563664|Procedure|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
80007558|NCT03041181|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
80007559|NCT03041181|Drug|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
80007560|NCT03041181|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
80007561|NCT03041181|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
79240394|NCT02522559|Other|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
79240395|NCT05171257|Drug|IV antibiotic treatment from prior|patients receiving same IV antibiotic treatment from prior
80007562|NCT02828436|Device|Precision Spectra System|Spinal Cord Stimulation
80007563|NCT02828436|Behavioral|Exercise Intervention|Standard Exercise
80007564|NCT05278221|Device|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
79240396|NCT05171257|Drug|differing IV antibiotic treatment|patients receiving differing IV antibiotics from prior
79240397|NCT03640741|Procedure|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
79380064|NCT03908567|Drug|Oral Tablet|Oral dosing with tablets 3 times a day
79380065|NCT03908567|Other|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
79380066|NCT03898661|Drug|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
79380067|NCT03884855|Other|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
79380068|NCT03884855|Other|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
79691060|NCT04633967|Drug|Alemtuzumab Injection|"This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed"
79691061|NCT00560846|Dietary Supplement|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
79691062|NCT00560846|Dietary Supplement|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
79691063|NCT04634006|Device|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
79691064|NCT04633850|Drug|Dexamethasone|Intravenous dexamethasone 8 mg. Given once at the end of surgery.
79691065|NCT04633850|Drug|Bupivacain|"Bupivacaine dose according to weight. <60 kg: Total dose 100mg 60-90kg: Total dose 150mg >90kg: Total dose 200mg~Given once at the end of surgery."
79534361|NCT06252610|Diagnostic Test|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
80007565|NCT05369247|Other|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., > 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
79380069|NCT03861273|Biological|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
79380070|NCT04208516|Procedure|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
79380071|NCT04208516|Procedure|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
79380072|NCT04208516|Procedure|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
79380073|NCT04208516|Procedure|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
79380074|NCT04208516|Drug|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
79534362|NCT06252337|Other|bioceramic sealer group|epoxy resin based + carrier based technique group. The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
79534363|NCT06251804|Other|Water exercise program|The exercise program includes a short foot exercise and will be given in water.
79691066|NCT04633538|Device|Smartphone app|Use of smartphone app to measure 6 minute walk test (6MWT)
79691067|NCT02903784|Device|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
79691068|NCT02903784|Procedure|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
79691069|NCT02903784|Other|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
79691070|NCT04633382|Combination Product|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
79691071|NCT02903628|Behavioral|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
80007566|NCT05369247|Other|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
79240398|NCT05397327|Other|3D virtual planning software|3D virtual planning software developed by Sectra AB (Linköping, Sweden)
79240399|NCT03640819|Procedure|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
79240400|NCT05397249|Behavioral|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
79240401|NCT01068613|Drug|QAX028|QAX028 60 mcg via inhalation device
79240402|NCT01068613|Drug|QAX028|QAX028 20 mcg via inhalation device
79240403|NCT01068613|Drug|Tiotropium|Tiotropium via inhalation device
79240404|NCT01068613|Drug|Placebo|Placebo to QAX028 via inhalation device
79691072|NCT02903706|Other|Measure of Plasmodium prevalence (PCR)|
79691073|NCT04633733|Drug|HL237 tablet|HL237 400mg will be administered orally twice a day.
79691074|NCT04633733|Drug|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
79836944|NCT00908193|Procedure|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
79836945|NCT03885050|Other|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
79836946|NCT00781638|Device|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
79836947|NCT00781716|Device|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
79836948|NCT05461586|Device|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
79836949|NCT05461586|Device|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
80007567|NCT04059159|Device|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
80007568|NCT05342103|Procedure|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
79380075|NCT04208516|Drug|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
79380076|NCT04208516|Drug|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
79380077|NCT04208516|Drug|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
79380078|NCT04208516|Drug|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
79380079|NCT03860207|Biological|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
79380080|NCT03860207|Other|Blood draw|In cycle 1, blood is drawn for PK studies.
79380081|NCT03851068|Device|Foldax Tria Aortic Valve|Aortic Valve Replacement
79380082|NCT03844061|Drug|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
79534364|NCT06251804|Other|Land-based-program|The exercise program includes a short foot exercise and will be given on land.
79534365|NCT06251791|Other|conventional physiotherapy+ IMT|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
79534366|NCT06251791|Other|conventional physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
79534367|NCT06251271|Device|Point-of-Care Ultrasound|Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.
79534368|NCT06251128|Behavioral|Stroke Self management Program|"Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants"
79534369|NCT06251089|Drug|CPC mouthwash|0.07% CPC mouthwash
79534370|NCT06251089|Drug|Placebo|placebo of the CPC mouthwash
79691075|NCT02903745|Other|observational|
79691076|NCT04633265|Device|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
79691077|NCT05427942|Drug|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
79691078|NCT04632875|Behavioral|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
79691079|NCT04632875|Behavioral|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
79691080|NCT05427903|Procedure|Cryotherapy|Ice packs application for 5 minutes after IANB injection
79691081|NCT05427903|Procedure|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
79691082|NCT04633109|Procedure|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
79691083|NCT04633109|Diagnostic Test|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
80007569|NCT05323071|Other|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, >37 weeks : 1 mL"
80007570|NCT05263713|Other|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
80007571|NCT02828124|Biological|BMS-986183|specified dose on specified days
79836950|NCT00690794|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
79836951|NCT00690794|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
80007572|NCT02828124|Biological|Nivolumab|specified dose on specified days
80007573|NCT03619629|Other|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
79380083|NCT03844061|Drug|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
79534371|NCT06250699|Procedure|Tubeless laparoscopic adrenalectomy|No drainage tube placed after laparoscopic adrenalectomy
79836952|NCT00741650|Behavioral|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
79836953|NCT00741650|Behavioral|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
79836954|NCT00666276|Drug|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
79836955|NCT00567255|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
79836956|NCT00567255|Drug|Placebo|
79836957|NCT00567255|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
79836958|NCT00744458|Other|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
80007574|NCT03619629|Other|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
80007575|NCT03619629|Other|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
80007576|NCT03619629|Other|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
80007577|NCT02259894|Drug|BIRT 2584 XX|
80007578|NCT02259894|Drug|Placebo|
80007579|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
80007580|NCT02829996|Drug|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
80007581|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
80007582|NCT02829996|Drug|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
80007583|NCT02829996|Drug|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
79380084|NCT03844061|Other|Placebo Subcutaneous Injection|Normal Saline
79534372|NCT06250699|Procedure|Drainage tube|Placing drainage tubes after laparoscopic adrenalectomy
79534373|NCT06250491|Device|Deep active rTMS with Hesed coil|This brain neurostimulation method targets the motor cortex bilaterally
79836959|NCT00744458|Other|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
79836960|NCT00744458|Other|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
79836961|NCT00781794|Drug|NSA-789 at 2 different doses|
80007584|NCT02827500|Drug|ivabradine|Active Comparator: ivabradine
80007585|NCT02827500|Other|Usual Care|Placebo Comparator: usual care
80007586|NCT05385549|Drug|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
79380085|NCT03844061|Other|Placebo Infusion|Normal Saline
79534374|NCT06250491|Device|Sham rTMS with Hesed coil|This brain sham neurostimulation method targets the motor cortex bilaterally
79534375|NCT06249854|Drug|Bojungikki-tang(BJIKT)|"Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~Protective effect of intestine and hematopoietic organs against radiation damage~Improving localized radiotherapy-induced immune deterioration~Improving cancer-related fatigue and QOL~Reducing radiation or chemotherapy induced side effects"
80007587|NCT05238285|Behavioral|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
79534376|NCT06249854|Drug|Pembrolizumab|It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
79380086|NCT03844061|Drug|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
79691084|NCT04633109|Diagnostic Test|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
79534377|NCT06249763|Dietary Supplement|High gluten diet|Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
79534378|NCT06249763|Dietary Supplement|Gluten free diet|Trial period B: gluten free diet added daily granola bars with <1 g gluten/day (placebo).
79534379|NCT06248645|Drug|Oxygen|High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
79836962|NCT00746174|Drug|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
79836963|NCT00746174|Drug|Placebo|Placebo 1 tablet PO daily for 16 weeks
79836964|NCT00784446|Drug|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
80007588|NCT03563586|Other|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
79534380|NCT06248593|Drug|Continuous infusion of Norepinephrine|The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
79691085|NCT04633109|Diagnostic Test|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
79691086|NCT04633109|Diagnostic Test|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
79836965|NCT00744536|Drug|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
79836966|NCT05028972|Other|Personal Amplifier|The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
79836967|NCT05028972|Other|No Personal Amplifier|The control group will not receive personal amplifiers while they receive care in the ED
79836968|NCT00744614|Procedure|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
79836969|NCT00929799|Drug|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
80007589|NCT03563586|Other|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
79380087|NCT03827967|Biological|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
79380088|NCT03809715|Device|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
79380089|NCT03807479|Drug|Ponatinib|2 film-coated tablets à 15mg for oral administration on a daily basis
79691087|NCT04633109|Diagnostic Test|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
79240405|NCT05222425|Drug|Xagrotin|A herbal compound
79240406|NCT05222425|Drug|Green tea|Normal green tea
79240407|NCT05396937|Radiation|Multifocal Stereotactic Radiotherapy|Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.
79240408|NCT05396937|Drug|Atezolizumab Injection [Tecentriq]|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
79836970|NCT00777738|Drug|BORTEZOMIB|"Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~For responding patients : up to 6 cycles~For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
79691088|NCT04633109|Other|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
79691089|NCT04633109|Other|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
79534381|NCT06248593|Drug|Continuous infusion of Phenylephrine|The rate of phenylephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
79836971|NCT00744770|Drug|TMC278|
79836972|NCT00926523|Other|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
79836973|NCT00926523|Other|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
79534382|NCT06247969|Device|endotracheal tube|Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
79534383|NCT06247345|Drug|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
79534384|NCT06247345|Drug|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
79534385|NCT06247345|Drug|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
79380092|NCT03782558|Procedure|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
79534386|NCT06247345|Drug|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
79691090|NCT04633070|Behavioral|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
79836974|NCT00926523|Other|Spirometry|To assess subjects lung function
79836975|NCT00926523|Other|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
79836976|NCT00781872|Biological|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
79836977|NCT00741728|Other|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
79836978|NCT00784680|Drug|Anastrozole|1mg, orally, once daily
79836979|NCT00784680|Drug|Tamoxifen|20mg, orally, once daily
79836980|NCT00908271|Drug|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
79836981|NCT02556840|Other|insulin therapy|
79836982|NCT00741806|Biological|GHB04L1|single dose intranasal administration of GHB04L1
79380093|NCT03782545|Device|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
79836983|NCT00741806|Other|Placebo|SPGN buffer
79836984|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
79836985|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
79836986|NCT00929877|Drug|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
79836987|NCT00741884|Drug|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
79836988|NCT00741884|Drug|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
79836989|NCT00741884|Drug|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
79691091|NCT05427747|Drug|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~Decrease of peritoneal fluid PMN count to < 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
79691092|NCT04633031|Device|Boston|
79534387|NCT06245564|Drug|Ketamine 0.5%|Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
79691093|NCT04633031|Device|Cheneau|
79691094|NCT04632914|Other|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
79691095|NCT04632914|Other|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
79691096|NCT05427591|Procedure|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
79691097|NCT05427591|Procedure|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
79691098|NCT05427591|Procedure|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
79691099|NCT05427591|Procedure|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
79691100|NCT04632602|Other|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
80007590|NCT03929679|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
79836990|NCT00741884|Drug|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
80007591|NCT02826798|Drug|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
80007592|NCT02826798|Drug|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
79380094|NCT03782415|Drug|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
79380095|NCT03782415|Drug|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
79380096|NCT03780842|Device|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
79380097|NCT03763032|Behavioral|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
79691101|NCT02903316|Procedure|Fluids|
79836991|NCT00741884|Drug|Placebo|Placebo BID for 7 weeks
79380098|NCT03757130|Drug|AMG 598|AMG 598 administered by subcutaneous injection
79380099|NCT03757130|Drug|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
79534388|NCT06245564|Drug|Amitriptyline|Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
79534389|NCT06245564|Drug|ketamine + amitriptyline|A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
79534390|NCT06245564|Other|Vehicle|A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
79534391|NCT06245564|Other|Histamine|After the cream removal, itch will be induced using histamine in the first session
79534392|NCT06245564|Other|Cowhage|After the cream removal, itch will be induced using cowhage in the second session
79691102|NCT02903199|Dietary Supplement|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
79691103|NCT02903199|Dietary Supplement|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
79836992|NCT00777816|Drug|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
80007593|NCT02826798|Drug|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
80007594|NCT02826798|Drug|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
80007595|NCT02826798|Drug|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
80007596|NCT02829138|Genetic|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
79691104|NCT02903199|Dietary Supplement|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
79691105|NCT02903433|Other|High-intake avocados|Families will receive 14 avocados on a weekly basis.
79691106|NCT02903433|Other|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
79691107|NCT02903433|Behavioral|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
80007597|NCT02829138|Behavioral|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
79380100|NCT03757130|Drug|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
79380101|NCT03743142|Procedure|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
79380102|NCT03719807|Other|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
79534393|NCT06245369|Behavioral|learning modules (within app)|"Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~A brief educational video discussing the week's topic~A brief video sharing ideas for applying the educational content into daily life~PDF of meal swap examples~A weekly goal or challenge~Recipes"
79691108|NCT02903433|Behavioral|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
79691109|NCT00445406|Drug|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
79691110|NCT00445406|Drug|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
79691111|NCT00445445|Other|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
79380103|NCT03719807|Other|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
79380104|NCT03712202|Drug|Bleomycin|Given IV
79380105|NCT03712202|Drug|Brentuximab Vedotin|Given IV
79691112|NCT00445445|Other|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
79691113|NCT00445445|Procedure|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
79691114|NCT00445445|Procedure|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
79691115|NCT00445445|Procedure|study of high risk factors|"Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
79691116|NCT00445523|Biological|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
80007598|NCT03832842|Diagnostic Test|Blood sample|Blood sample
79380106|NCT03712202|Drug|Dacarbazine|Given IV
79380107|NCT03712202|Drug|Doxorubicin|Given IV
79380108|NCT03712202|Biological|Nivolumab|Given IV
79380109|NCT03712202|Other|Quality-of-Life Assessment|Ancillary studies
79380110|NCT03712202|Drug|Vinblastine|Given IV
79380111|NCT03692065|Drug|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
79240409|NCT05396937|Drug|Bevacizumab|Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
79240410|NCT01345123|Behavioral|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
79240411|NCT01345123|Behavioral|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
79240412|NCT03642223|Other|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
79534394|NCT06245369|Behavioral|SWITCH app (self-regulation features) - Experimental|"Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full."
79691117|NCT00445523|Drug|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
79836993|NCT00777816|Drug|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
79836994|NCT00931437|Dietary Supplement|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
79240413|NCT03640663|Other|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
79240414|NCT03642145|Drug|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
79240415|NCT05396625|Behavioral|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
79240416|NCT05396625|Behavioral|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention 'SAFE Children,' which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children (e.g., separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community). Each session lasts about one to one and a half hours and will be delivered by facilitator and co-facilitator at the SOS Child and Family Center.
79240417|NCT05396625|Behavioral|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
79380112|NCT03682068|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
79380113|NCT03682068|Drug|Tremelimumab|Tremelimumab IV (intravenous infusion)
79380114|NCT03682068|Drug|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
79380115|NCT03682068|Drug|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
79380116|NCT03667573|Device|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
79380117|NCT03667573|Device|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
79380118|NCT03667573|Other|textured shoe insoles|textured shoe insoles
79380119|NCT03661528|Drug|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
79836995|NCT00741962|Dietary Supplement|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
79836996|NCT00741962|Dietary Supplement|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
79836997|NCT00782028|Other|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
80007599|NCT03563430|Other|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
80007600|NCT03563430|Other|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
80007601|NCT03563430|Other|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
80007602|NCT05218590|Device|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
80007603|NCT02825550|Device|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
79380120|NCT03661528|Drug|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
79380121|NCT03660046|Drug|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
79380122|NCT03660046|Drug|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
79836998|NCT00782028|Other|Standard Care|
79836999|NCT04014621|Device|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
79837000|NCT00742040|Drug|Captopril|A rapid 3-day up-titration protocol
79837001|NCT00742040|Drug|Captopril|A slower 9-day up-titration protocol
80007604|NCT03563352|Other|Interview|Attend an interview
80007605|NCT03563352|Other|Survey Administration|Ancillary studies
80007606|NCT05197062|Drug|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
80007607|NCT03563196|Radiation|Chest Radiograph|Chest radiogram will be obtained on day 1
80007608|NCT03563196|Diagnostic Test|Lung Ultrasound|Lung ultrasound will be done on day 1
80007609|NCT05004870|Device|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
79837002|NCT00777894|Radiation|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
79837003|NCT00777894|Radiation|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
80007610|NCT05122260|Drug|Q-Griffithsin|intranasal spray administered as a single dose
79534395|NCT06245369|Behavioral|SWITCH app (self-regulation features) - Comparator|"Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals."
79534396|NCT06245057|Other|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
79240418|NCT05396625|Other|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
79534397|NCT06244784|Behavioral|effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital|"Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups."
80007611|NCT05122260|Other|Placebo|intranasal spray administered as a single dose
79240419|NCT03640585|Other|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
80007612|NCT05000736|Drug|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
79380123|NCT03660046|Drug|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
79380124|NCT03656601|Diagnostic Test|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
79380125|NCT03650673|Diagnostic Test|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
80007613|NCT05000736|Drug|fulvestrant|fulvestrant monotherapy
79240420|NCT01064791|Drug|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
79240421|NCT01064791|Drug|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
79240422|NCT01064791|Drug|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
79240423|NCT01064791|Drug|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
79240424|NCT03465501|Radiation|Brachytherapy|Brachytherapy
79240425|NCT05191147|Dietary Supplement|Dietary supplement|We will study dietary supplement consumption among pregnant women
79380126|NCT03643198|Drug|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
79240426|NCT03641989|Other|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD&C Blue No. 1.
79380127|NCT03643198|Other|CONTROL|NO treatment
79380128|NCT03641469|Device|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
79837004|NCT00777894|Radiation|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
79534398|NCT06242366|Behavioral|Intervention group|"Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management."
79837005|NCT00926757|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
79837006|NCT00926757|Drug|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
79837007|NCT00746408|Other|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
79837008|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
79837009|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|"IV infusion of IGIV, 10% to determine pharmacokinetics~Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
79240427|NCT03641989|Other|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD&C Blue No. 1.
79240428|NCT03465423|Procedure|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
79240429|NCT05161351|Drug|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
79240430|NCT05161351|Drug|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
79240431|NCT02588001|Drug|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
79240432|NCT03465345|Drug|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
79240433|NCT03465345|Drug|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
79240434|NCT03465267|Device|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
79380129|NCT03621956|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
79380130|NCT03621956|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
79837010|NCT00929955|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
79837011|NCT00929955|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
79837012|NCT00929955|Drug|Placebo|Placebo added to TAU
79837013|NCT00742118|Procedure|Colic biopsies|colic biopsies and analysis
79837014|NCT00784914|Drug|temsirolimus|Receive temsirolimus IV
79380131|NCT03598842|Dietary Supplement|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
79380132|NCT03598842|Dietary Supplement|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
79380133|NCT03598842|Drug|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
79837015|NCT00784914|Other|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
80007614|NCT02744040|Drug|ART initiation at time of HIV diagnosis|Immediate ART initiation
80007615|NCT02744040|Drug|ART at 24 weeks|ART initiation 24 weeks after enrollment
80007616|NCT03833856|Procedure|colonoscopy perforation|The development of perforation after colonoscopy
79534399|NCT06240702|Other|Telerehabilitation Group|Unlike the control group, the experimental group will be given a phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Within the scope of the Phase II telerehabilitation program, breathing exercises and calisthenic exercises will be performed at increasing intensity according to the patient's tolerance, 3 days a week for 3 weeks. In addition, walking training will be continued over increasing distances. In addition, it will be aimed to increase sleep quality by giving a sleep hygiene education brochure to the patients in the experimental group. During the sessions, the vital signs and clinical status of the patients will be monitored according to the severity level determined by the finger pulse oximeter device, digital blood pressure monitor, perceived difficulty level (Borg Scale) and maximum heart rate. In addition, patients will be kept in a diary to monitor their compliance with the treatment program.
79534400|NCT06239025|Other|ultrasound-guided Transversus Thoracis Muscle Plane Block|block with ropivacaine 0.5 %, 30 mL
79534401|NCT06236815|Drug|Delta-9-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
79534402|NCT06236815|Drug|Delta-8-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
79534403|NCT06236815|Drug|Placebo|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
79837016|NCT00784914|Other|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
80007617|NCT02743962|Device|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
80007618|NCT02743962|Other|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
80007619|NCT05314920|Behavioral|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
79534404|NCT06235905|Drug|NV-5138|NV-5138 is a novel , orally bioavailable, activator of mTORC1
80007620|NCT05314920|Behavioral|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
80007621|NCT03834792|Other|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
79240435|NCT03465267|Device|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
80007622|NCT03563274|Device|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
79240436|NCT04230135|Device|Hap-pas-Hapi|Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
79380134|NCT03587116|Drug|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
79380135|NCT03587116|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
79380136|NCT03581136|Device|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
79837017|NCT04060238|Diagnostic Test|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
80007623|NCT03828162|Drug|Anticoagulants|
80007624|NCT03563040|Drug|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
80007625|NCT03563040|Device|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
79380137|NCT03574103|Behavioral|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
80007626|NCT03828552|Other|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
79240437|NCT02735421|Drug|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
79240438|NCT02735421|Drug|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
79240439|NCT04469205|Other|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
79240440|NCT02983799|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily
79240441|NCT03622307|Device|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
79240442|NCT04320017|Diagnostic Test|Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care|"12 derivations electrocardiogram done at baseline and repeated every 3 days~transthoracic echocardiography at baseline~clinical features at baseline: WHO performans status comorbidities and treatments~biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide"
79380138|NCT03574103|Behavioral|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
79534405|NCT06235723|Device|Virtual Reality|Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
79534406|NCT06234891|Drug|Nsaid|Medical treatment
79534407|NCT06234891|Other|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
79534408|NCT06232980|Procedure|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
79534409|NCT06230393|Device|STREAMLINE® SURGICAL SYSTEM|STREAMLINE® SURGICAL SYSTEM
79534410|NCT06229184|Diagnostic Test|Fecal Calprotectin Test|Fecal samples are taken fom obese and healthy adolescents for study
79380139|NCT03574103|Behavioral|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
79380140|NCT03570372|Behavioral|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
79534411|NCT06228768|Other|Acupressure|9 acupoints will be stimulated for 3 minutes per point
79534412|NCT06228768|Other|Acupressure|9 areas will be stimulated for 3 minutes per point
79534413|NCT06228521|Other|Liquid nitrogen sprayed|Liquid nitrogen sprayed on each wart using a standardised technique. Freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals.
79534414|NCT06228521|Other|980nm diode laser applied|980nm diode laser applied to each wart for 5 seconds at 2W power and 1mm spot size. 4 sessions at weekly intervals.
79534415|NCT06227858|Dietary Supplement|Safr'Inside supplement (Activ'Inside, SAS)|Dietary supplementation will be taken in addition to habitual diet of the patients
79534416|NCT06227858|Other|Plcebo|Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)
79534417|NCT06226168|Other|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
79534418|NCT06226168|Other|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
79534419|NCT06225557|Other|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
79534420|NCT06225557|Other|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
79534421|NCT06225427|Procedure|Biopsy|Undergo tissue biopsy
79534422|NCT06225427|Procedure|Biospecimen Collection|Undergo blood sample collection
79534423|NCT06225427|Procedure|Computed Tomography|Undergo CT scan
79534424|NCT06225427|Procedure|Echocardiography|Undergo echocardiography
79534425|NCT06225427|Drug|Gilteritinib|Given PO
79534426|NCT06225427|Procedure|Magnetic Resonance Imaging|Undergo MRI
79534427|NCT06225427|Other|Questionnaire Administration|Ancillary studies
79534428|NCT06225024|Device|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
79534429|NCT06225024|Drug|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
80007627|NCT04777734|Biological|efgartigimod|an intravenous infusion of efgartigimod
79691118|NCT05427357|Other|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
79305684|NCT02453477|Genetic|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
79380141|NCT03570372|Behavioral|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö & Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
79691119|NCT02903082|Biological|Residue of blood further to NFS|
79691120|NCT02903082|Biological|Residue of blood further to preoperative workup|
79691121|NCT02903082|Biological|Bone marrow collected during a myelogram carried out for hematological pathology workup|
79691122|NCT02903082|Biological|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
79305685|NCT03236597|Other|Treadmill desk|A standing height desk with a treadmill attached.
79534430|NCT06224647|Behavioral|Mobile Transdiagnostic Emotion Regulation Intervention|"The intervention aims to provide a tailored and engaging way for users to manage and comprehend their emotional well-being.~It consist of 5 components:~Daily tracking of emotions~A suite of exercises placed in six categories facilitating adaptive emotion regulation skills (i.e., upregulation of positive effect, self-compassion, cognitive defusion and cognitive restructuring, mindfulness, breathing techniques),~A self-assessment module where users can complete surveys evaluating their states (e.g., wellbeing) and traits (e.g., perfectionistic tendencies),~A personal toolkit area (i.e., each exercise is represented by an object commonly found in a student's room. Users can collect objects of favoured exercises in the virtual ROOM, enabling them quick access to exercises they liked / found helpful),~A recommendation system linking users to the content based on their specific needs or preferences"
79534431|NCT06223958|Drug|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
79534432|NCT06223958|Drug|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
79534433|NCT06222346|Behavioral|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~A discussion forum~A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~A resources page giving access to evidence-based psychoeducation material on the mind-body link~A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
79691123|NCT00445562|Other|biologic sample preservation procedure|
79691124|NCT00445562|Other|informational intervention|
79691125|NCT02903004|Drug|Trabectedin|
79691126|NCT02903004|Drug|Pegylated Liposomal Doxorubicin|
79691127|NCT02903004|Drug|Topotecan|
79691128|NCT02903004|Drug|Gemcitabine|
79691129|NCT02903004|Drug|Weekly Paclitaxel|
79380142|NCT03562273|Radiation|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
79380143|NCT03555565|Drug|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
79380144|NCT03519386|Combination Product|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
79691130|NCT02903004|Drug|Carboplatin|
79691131|NCT00445718|Procedure|computed tomography|
79691132|NCT00445718|Procedure|3-Tesla magnetic resonance imaging|
79380145|NCT03519386|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
79691133|NCT00445718|Procedure|Abdominal Sonogram|Sonogram of the abdomen area
79691134|NCT00445757|Procedure|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
79691135|NCT00445757|Radiation|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
79691136|NCT04699175|Drug|HR021618|Treatment group A:HR021618; high dose
79691137|NCT04699175|Drug|HR021618|Treatment group B:HR021618; low dose
79691138|NCT04699175|Drug|Placebo|Treatment group C: HR021618 blank preparation.
79691139|NCT03277781|Other|Screening|Screening for AAA
79691140|NCT02902887|Device|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
79691141|NCT00445796|Drug|Artesunate|
79691142|NCT00445796|Drug|Amodiaquine|
79691143|NCT01225822|Drug|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
79691144|NCT01225822|Drug|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
79691145|NCT01225822|Drug|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
79691146|NCT01225822|Drug|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
80007628|NCT03094416|Drug|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
79303044|NCT02477345|Drug|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
79303045|NCT02446561|Drug|MRXXX|
79303046|NCT02446561|Drug|MR1XXX|
79380146|NCT03508648|Drug|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
79534434|NCT06222346|Behavioral|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
79691147|NCT01225822|Drug|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
80007629|NCT03094416|Drug|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
80007630|NCT03094416|Drug|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
80007631|NCT03106038|Drug|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
80007632|NCT03041025|Drug|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
80007633|NCT03041025|Drug|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
80007634|NCT04765566|Device|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
79380147|NCT03508648|Drug|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
79380148|NCT03487185|Device|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
79380149|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
79380150|NCT03474159|Device|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
79380151|NCT03474159|Device|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
79380152|NCT03474159|Device|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
79380153|NCT03463798|Device|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
79534438|NCT06221696|Dietary Supplement|Active Fiber Supplement Group|Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
79534439|NCT06221696|Other|Placebo Group|Three daily packets of placebo powder, taken 30 minutes before each main meal.
79534440|NCT06221475|Drug|BAY2927088 coated tablet 10 mg|4 coated tablets (10 mg) per single dose 30 min after a light meal
79691148|NCT00445835|Other|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
79691149|NCT00445835|Other|Conservative arm|Conservative medical approach
80007635|NCT01338870|Drug|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
80007636|NCT01338870|Drug|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
80007637|NCT01338870|Drug|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
80007638|NCT01338870|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
80007639|NCT01338870|Drug|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
80007640|NCT01338870|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
80007641|NCT02824224|Drug|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
80007642|NCT02824224|Drug|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
79534441|NCT06221475|Drug|[14C]-BAY2927088 solution for infusion|IV infusion 15 min ending at 2 hours oral post-dose
79691150|NCT00445874|Drug|Ketotifen with a Contact Lens (no generic name)|
79691151|NCT02902731|Drug|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
79691152|NCT02902731|Drug|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
79534442|NCT06221475|Drug|[14C]-BAY2927088 oral solution|After a light meal
80007643|NCT03824964|Biological|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
80007644|NCT01338792|Drug|oxaliplatin|Given IV
79691153|NCT00445913|Biological|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
80007645|NCT01338792|Drug|pemetrexed disodium|Given IV
80007646|NCT01338792|Other|questionnaire administration|Ancillary studies
80007647|NCT01338792|Other|laboratory biomarker analysis|Correlative studies
80007648|NCT01338792|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
80007649|NCT01338792|Genetic|polymorphism analysis|Correlative studies
79240443|NCT03465033|Other|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
79240444|NCT03954249|Procedure|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
79240445|NCT03954249|Procedure|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
79534443|NCT06220188|Drug|[177Lu]Lu-PSMA I&T|2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of [177Lu]Lu-PSMAI&T radioligand therapy at 6-week intervals
79534444|NCT06217822|Drug|225Ac-PSMA-Trillium (BAY3563254)|Intravenous slow injection on Day 1 of a 6 week treatment cycle.
79534445|NCT06217822|Drug|Tris-POC (BAY2688901)|0.5 mg/mL (7.5 mg/vial), i.v slow injection, Tris-POC will be administered approximately 15 minutes prior to the second dose of the 111In-PSMA-Trillium imaging agent.
79534446|NCT06217822|Drug|111In-PSMA-Trillium (BAY3632687)|111In dose of 185 MBq (5 mCi) ± 10% and PSMA-Trillium-DOTA peptide dose of approximately 0.05 to 0.08 mg (approximately 0.04 mg if dosed the day after manufacture), slow intravenous injection bolus followed by 10 mL flush of normal saline
80007650|NCT04752072|Behavioral|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
79534447|NCT06216431|Other|Physical Evaluations of individuals|Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
80007651|NCT04752072|Behavioral|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
80007652|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
79240446|NCT05386641|Other|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
79240447|NCT05386641|Other|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
79240448|NCT05386641|Other|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
79303047|NCT02446561|Drug|MR2XXX|
79303048|NCT02446561|Drug|MR3XXX|
79534448|NCT06212986|Device|Promotion of mental training through mobile application Perform-UP Tennis|"Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises."
79534449|NCT06211296|Device|Shortcut|Splitting bioprosthetic aortic valve leaflets
79534450|NCT06208618|Other|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~What is Diabetes?~Treatment in Diabetes~Insulin Therapy~Nutritional Therapy~Physical Activity/Exercise~Acute Complications of Diabetes~Hypoglycemia~Hyperglycemia~Diabetic Ketoacidosis~Diabetes Management in Illness~Motivational interviews will consist of the following stages:~First Meeting - Pre-awareness (Pre-contemplation)~Second Meeting - Awareness (Contemplation)~Third Meeting - Preparation~Fourth Meeting - Taking Action (Action)~Fifth Meeting - Maintenance~Sixth Meeting - Termination or Review"
79691154|NCT00445913|Biological|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
79691155|NCT02902926|Behavioral|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
79691156|NCT02902926|Behavioral|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
79240449|NCT05386641|Other|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
79240450|NCT05386641|Other|measurement of skin temperature|measurements will be taken by the thermographic camera
79240451|NCT05386641|Other|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
79240452|NCT05386641|Other|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
79240453|NCT05386641|Other|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
79240454|NCT03464877|Other|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
79534451|NCT06207630|Device|Dressing Device|Use of a dress at the end of surgery in the operating room, making sure not to stick it on the openings of the chest drains.
79534452|NCT06206421|Drug|Fezolinetant|oral
79534453|NCT06206421|Drug|Placebo|oral
80007653|NCT01314105|Drug|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
80007654|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
79534454|NCT06206408|Drug|Fezolinetant|oral
79534455|NCT06206408|Drug|Placebo|oral
79691157|NCT00445952|Other|clinical observation|
79691158|NCT00445952|Procedure|management of therapy complications|
79691159|NCT01225549|Drug|AZD5423|Suspension for nebulisation once daily 7 days
79691160|NCT01225549|Drug|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
79240455|NCT05385705|Drug|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
79240456|NCT05385705|Drug|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
79240457|NCT05385705|Drug|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
79240458|NCT05385705|Biological|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
79240459|NCT05385705|Drug|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
79240460|NCT05329701|Other|Individualized treatment duration strategy|As listed under arm description.
79240461|NCT04390503|Biological|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2.
79240462|NCT04390503|Biological|Control (albumin 5%)|Albumin (Human) 5% is a sterile aqueous solution for intravenous use containing the albumin component human plasma.
79691161|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
79240463|NCT05381337|Procedure|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
79240464|NCT05381337|Procedure|coronal scalp incision|Coronal scalp incisions were used as control group.
79240465|NCT03654261|Behavioral|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
79240466|NCT02186847|Radiation|Radiation Therapy|Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).
79240467|NCT02186847|Drug|Carboplatin|2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.
79303049|NCT02477189|Procedure|Silicone Block|
79691162|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
79691163|NCT05469685|Drug|Vonoprazan|Potassium-competitive acid blocker
79534456|NCT06203535|Other|Aerobic training|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
79534457|NCT06202443|Other|Early PT|Physical therapy delivered within the first three months after surgery.
79534458|NCT06202443|Other|Delayed PT|Physical therapy delivered greater than 3 months after surgery.
79837018|NCT00784992|Procedure|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
79240468|NCT02186847|Drug|Metformin|Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),
79240469|NCT02186847|Drug|Paclitaxel|50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
79380154|NCT03463798|Device|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
79380155|NCT03456128|Other|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
79380156|NCT03456089|Diagnostic Test|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
79380157|NCT03454204|Other|Pharmacokinetic|Analysis of blood samples
79380158|NCT03452332|Biological|Durvalumab|Given IV
79380159|NCT03452332|Other|Laboratory Biomarker Analysis|Correlative studies
79534459|NCT06198686|Drug|Nalmefene|Opioid antagonist
79534464|NCT06187259|Device|caries removal by carbide bur|caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
79534465|NCT06187259|Device|caries removal by polymer bur II|carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
79837019|NCT00745004|Drug|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
80007655|NCT03562884|Drug|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
79240470|NCT01066871|Drug|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
79240471|NCT01066871|Drug|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
79240472|NCT01066871|Drug|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
79240473|NCT01066871|Other|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
79380160|NCT03452332|Radiation|Stereotactic Radiosurgery|Undergo SABR
79380161|NCT03452332|Biological|Tremelimumab|Given IV
79534468|NCT06185933|Drug|Lidocaine Spray|Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
79240474|NCT03464799|Other|immunohistochemical staining|immunohistochemical staining
79534469|NCT06185933|Drug|Lidocaine Viscous+Lidocane spray|Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
79534470|NCT06179043|Behavioral|Nutrient warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~Labels that read high in sugars and high in calories~A label that reads high in sugars"
79691164|NCT05469685|Drug|Amoxicillin|Antibiotic for H. pylori eradication
79691165|NCT02956772|Drug|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
79691166|NCT02956772|Drug|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
79691167|NCT04680234|Procedure|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
79837020|NCT00745004|Drug|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
79837021|NCT00745160|Other|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
79837022|NCT04060550|Biological|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
80007656|NCT03562884|Drug|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
79240475|NCT05288205|Drug|JAB-21822|KRAS G12C inhibitor
79691168|NCT04680234|Device|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
79240476|NCT05288205|Drug|JAB-3312|SHP2 inhibitor
79240477|NCT05274789|Drug|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
79240478|NCT05274789|Other|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
79691169|NCT01225159|Drug|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
79691170|NCT01225159|Drug|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
79240479|NCT03622229|Diagnostic Test|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
79240480|NCT02353247|Drug|Norethindrone acetate|
79303050|NCT02476955|Drug|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
79303051|NCT02476955|Drug|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
79380162|NCT03431090|Device|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
79380163|NCT03424148|Device|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive laser treatments
79380164|NCT03405792|Drug|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
79380165|NCT03405792|Device|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
79380166|NCT03405792|Drug|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
79380167|NCT03391973|Drug|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
79691171|NCT00446069|Drug|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
79837023|NCT00921674|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
79837024|NCT00667446|Drug|Leuprolide Acetate 3 Month Depot|
79837025|NCT00742430|Procedure|PCI|percutaneous coronary intervention in stable coronary artery disease
79837026|NCT03873168|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
79534471|NCT06179043|Behavioral|Text-only health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay"
79691172|NCT02902692|Other|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
79691173|NCT05464459|Procedure|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
79691174|NCT01224925|Procedure|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
79691175|NCT01224925|Procedure|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
79691176|NCT02902653|Drug|Oral misoprostol|hourly titrated misoprostol
80007657|NCT05339724|Other|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
80007658|NCT05297799|Device|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
80007659|NCT05265156|Other|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
79240481|NCT03389217|Device|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
79240482|NCT03389217|Device|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
79380168|NCT03385655|Drug|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
79534472|NCT06179043|Behavioral|Graphic health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay"
79534473|NCT06179043|Behavioral|Control labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~A neutral bar code label~A neutral quick response (QR) code label (not scannable)"
79691177|NCT02902653|Drug|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
79691178|NCT02902653|Drug|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
79691179|NCT00446303|Drug|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
79240483|NCT03656471|Device|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
79380169|NCT03385655|Drug|Savolitinib|600mg once daily, orally.
79380170|NCT03385655|Drug|Darolutamide|600mg twice daily, orally.
79380171|NCT03385655|Drug|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
79380172|NCT03385655|Drug|Ipatasertib|400mg daily 3 weeks on, 1 week off
79380173|NCT03385655|Drug|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
79380174|NCT03385655|Drug|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
79691180|NCT04680351|Procedure|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
79691181|NCT01223404|Drug|Placebo|Participants are administered a placebo patch and a placebo capsule
79691182|NCT01223404|Drug|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
79837027|NCT00688844|Drug|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
79837028|NCT02555670|Other|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
79534474|NCT06177977|Device|SS-HH-OCT|The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
79534475|NCT06175793|Behavioral|ASPIRE Intervention|In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
79534476|NCT06171022|Other|Cherry seed pillow|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
79534477|NCT06171022|Other|Control|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
79534478|NCT06167239|Other|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
79534479|NCT06164678|Behavioral|OMSC|The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
79534480|NCT06162949|Drug|Vonoprazan|an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
79691183|NCT01223404|Drug|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
79691184|NCT00446342|Drug|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
79837029|NCT00777972|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
79837030|NCT00745238|Other|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
79240484|NCT05357703|Device|Standard treatment + Active B-Cure laser|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/minute.
79837031|NCT00782262|Dietary Supplement|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
79837032|NCT00778050|Drug|Amoxicillin 600mg|
79837033|NCT00746486|Drug|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
79837034|NCT00746486|Drug|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
79837035|NCT00785148|Drug|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
79837036|NCT00745550|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
79240485|NCT03368937|Device|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
79240486|NCT05354661|Device|Hypotension Prediction Index|treatment of hypotension before the appearance following HPI algorithm
79240487|NCT03464721|Device|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
79240488|NCT04343651|Drug|Placebo|Placebo
79380175|NCT03369665|Drug|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
79380176|NCT03361436|Drug|Eribulin Mesylate|Given IV
79380177|NCT03361436|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79380178|NCT03361436|Other|Laboratory Biomarker Analysis|Correlative studies
79380179|NCT03361436|Other|Quality-of-Life Assessment|Ancillary studies
79380180|NCT03361436|Other|Questionnaire Administration|Ancillary studies
79691185|NCT05657821|Dietary Supplement|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
79691186|NCT00446381|Drug|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
79837037|NCT00778128|Drug|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
79837038|NCT00778128|Drug|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
79837039|NCT00778284|Drug|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
79837040|NCT02563418|Device|Eye-tracking|
79837041|NCT00749060|Other|conventional treatment|with our without brace
79534481|NCT06162949|Drug|Amoxicillin|An antibiotic of penicillins antibiotic group
79837042|NCT00749060|Procedure|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
79240489|NCT04343651|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
79240490|NCT03464643|Other|embryo culture|Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
79240491|NCT03464565|Device|Penumbra System|Penumbra System
79380181|NCT03361436|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79380182|NCT03353870|Other|qualitative interview|individual qualitative interview
79380183|NCT03333590|Biological|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
79380184|NCT03323112|Biological|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
79380185|NCT03311503|Biological|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
79380186|NCT03304249|Behavioral|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
79380187|NCT03304249|Other|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
79380188|NCT03279887|Diagnostic Test|Lung Ultrasound|
79240492|NCT05333367|Other|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
79240493|NCT03464487|Dietary Supplement|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
79240494|NCT03464331|Behavioral|Zero-time exercises|The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
79240495|NCT03464331|Behavioral|relaxation exercises and deep-breathing exercises|The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
79240496|NCT05324241|Dietary Supplement|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
79240497|NCT05309889|Other|no intervention|no intervention
79303052|NCT02476955|Drug|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
79380189|NCT03278847|Dietary Supplement|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
79380190|NCT03278847|Dietary Supplement|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
79534482|NCT06162949|Drug|Clarithromycin|An antibiotic of macrolide group
79534483|NCT06162949|Drug|Esomeprazole|An acid suppressor therapy that blocks the proton pump.
79534484|NCT06159647|Behavioral|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
79534485|NCT06159647|Behavioral|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
79534486|NCT06159647|Behavioral|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
79534487|NCT06159647|Behavioral|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
79534488|NCT06159647|Behavioral|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
79534489|NCT06159647|Behavioral|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
79534490|NCT06159647|Behavioral|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
79691187|NCT00446381|Drug|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
79691188|NCT04680273|Drug|[14C]-GDC-9545|Participants will receive a single oral dose of [14C]-GDC-9545 capsule, 30 milligrams (mg) (not more than [NMT] 4.6 megabecquerel [MBq]; 124 microcurie [μCi]) with approximately 240 millilitres (mL) water in the fasted state.
79691189|NCT04680273|Drug|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
79837043|NCT00749060|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
80007660|NCT03562962|Behavioral|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle & Linnerooth, 2000; Kohlenberg & Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg & Tsai, 1991).
79380191|NCT03278847|Dietary Supplement|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
79837044|NCT00749138|Drug|tamoxifen|giving drug tamoxifen
79837045|NCT05001906|Behavioral|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
79240498|NCT03464253|Device|Performance of the transcranial Doppler (TCD)|Within 24 hour before the operation, TCD is performed using Siemens Acuson X300 machine with ultrasound frequency is 1 - 5 MHz probe to measure Mean Velocity and Pulsatility Index in the right middle cerebral artery.postoperatively, TCD study is performed twice at 24h and 48h after spinal anesthesia. For 5 days postoperatively, the Patients are assessed clinically for the occurrence of headache. Patients who developed PDPH will be identified and their pre and post puncture measurements will be compared with the corresponding measurements of PDPH free patients.
79380192|NCT03278847|Dietary Supplement|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
79380193|NCT03259620|Drug|CLS006|Furosemide Topical Gel
79380194|NCT03259620|Drug|CLS006 Vehicle|Vehicle Topical Gel
79534491|NCT06159647|Behavioral|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
79534492|NCT06159647|Behavioral|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
79534493|NCT06159647|Behavioral|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
79837046|NCT02563340|Other|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
80007661|NCT03040713|Drug|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie [mCi]) injection, single dose
79240499|NCT04327089|Drug|Setanaxib|Nox 1/4 inhibitor
79240500|NCT05302869|Other|None intervention|None intervention
79240501|NCT05301699|Other|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
79240502|NCT03463863|Procedure|rectus sheath midurethral sling|
79240503|NCT03129789|Other|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
79380195|NCT03253341|Behavioral|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
79380196|NCT03253341|Behavioral|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
79534494|NCT06159647|Behavioral|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
79534495|NCT06159647|Behavioral|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
79534496|NCT06159647|Behavioral|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
79534497|NCT06159647|Behavioral|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
79534498|NCT06159647|Behavioral|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
79534499|NCT06159647|Behavioral|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
79691190|NCT04680273|Drug|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
79691191|NCT04680273|Drug|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
79691192|NCT00446420|Drug|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
79534500|NCT06159647|Behavioral|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
79534501|NCT06158438|Device|BTL-754-4 Treatment|Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
79534502|NCT06157892|Drug|disitamab vedotin|Given into the vein (IV; intravenous)
79534503|NCT06157892|Drug|tucatinib|300mg given twice daily by mouth (orally)
79691193|NCT00446498|Device|CPAP and Non Invasive Ventilation|
79691194|NCT04679922|Procedure|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants *. Group II (Experimental Group): FLA **+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
79691195|NCT00446537|Procedure|Methylphenidate|
79691196|NCT05426889|Procedure|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
79380197|NCT03226522|Drug|AXS-05|AXS-05
79380198|NCT03226522|Drug|Bupropion|Bupropion
79534504|NCT06157411|Behavioral|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
79691197|NCT05426889|Drug|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
79691198|NCT00446576|Drug|Epoetin Alfa|
79691199|NCT02902419|Other|Wound dressing removal.|
79691200|NCT00446615|Behavioral|computer decision support tool|
79691201|NCT00446615|Behavioral|audit and feedback|
79691202|NCT00446615|Behavioral|group learning session|
79691203|NCT02902341|Dietary Supplement|Nutrition Therapy|Nutrition based on measured caloric needs.
79691204|NCT02902341|Dietary Supplement|Control|Standard protocol nutrition based on calculated caloric needs.
79691205|NCT03277664|Behavioral|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
79691206|NCT02902302|Drug|Ibuprofen 400 mg/10 mL oral suspension|
79691207|NCT02902302|Drug|MOMENT 400 mg coated tablet|
79837047|NCT02563340|Other|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
79837048|NCT00782652|Drug|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
79380199|NCT03226522|Drug|Placebo|Placebo
79380200|NCT03225677|Procedure|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
79380201|NCT03225508|Diagnostic Test|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
79691208|NCT03277625|Procedure|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
79691209|NCT02902458|Other|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
79691210|NCT02957318|Dietary Supplement|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
79691211|NCT02957318|Dietary Supplement|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
79691212|NCT02957318|Dietary Supplement|Placebo|Low-fiber control
79837049|NCT00782652|Drug|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
79691213|NCT01223365|Drug|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
79691214|NCT02956811|Drug|Dapagliflozin|SGLT2 inhibitor
79691215|NCT02956811|Drug|Placebo|Matching Placebo
79691216|NCT04319419|Dietary Supplement|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
79837050|NCT00746642|Device|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
79691217|NCT04319419|Other|Nutrition education|Group received nutrition education program during 6 months
79837051|NCT02562092|Behavioral|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
80007662|NCT03040713|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
79691218|NCT05657782|Biological|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
79240504|NCT05150223|Other|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
79240505|NCT05150223|Other|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
79691219|NCT05426694|Other|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
79691220|NCT05426694|Other|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
79691221|NCT00446693|Device|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
80007663|NCT04726176|Biological|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
80007664|NCT01966471|Drug|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
79380202|NCT03225508|Diagnostic Test|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
79380203|NCT03225508|Diagnostic Test|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
79380204|NCT03224949|Other|Blood draw|Patients will have a one time blood draw
79380205|NCT03212976|Procedure|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
79380206|NCT03201757|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
79380207|NCT03189706|Drug|Irinotecan|50mg/m^2/day IV will be administered from day 1-5
79837052|NCT02562092|Behavioral|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
79837053|NCT00745706|Device|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
79837054|NCT00785382|Drug|Placebo|Lactulose Placebo
79837055|NCT00785382|Drug|Pregabalin 150 mg|150 mg Q12H x 2 doses
79837056|NCT00745784|Behavioral|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
79837057|NCT00745862|Behavioral|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
79837058|NCT00667368|Drug|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
79534505|NCT06157411|Behavioral|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
79837059|NCT00785460|Drug|Benfotiamine|
79837060|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
79534506|NCT06151158|Behavioral|Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+)|Stanley Brown Safety Planning completed in the emergency department with 3 follow-up contacts after discharge
79837061|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
79240506|NCT05253105|Drug|TAB006|Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
79240507|NCT05253105|Drug|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
79240508|NCT03463707|Drug|BP101|Investigational product BP101, nasal spray
79380208|NCT03189706|Drug|temozolomide|(given concurrently with Irinotecan) 150mg/m^2/day orally
79380209|NCT03189706|Biological|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
79380210|NCT03189706|Drug|GM-CSF|250mcg/m2/day SC will be administered on days 6-10
79380211|NCT03181893|Drug|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
79380212|NCT03181893|Drug|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
79380213|NCT03181893|Drug|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
79380214|NCT03180840|Biological|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
79380215|NCT03157804|Procedure|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
79380216|NCT03157804|Biological|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
79380217|NCT03157804|Other|Laboratory Biomarker Analysis|Correlative studies
79534507|NCT06151158|Behavioral|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)|Five session crisis focused version of IPT for adolescents.
79691222|NCT04319029|Behavioral|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
79691223|NCT05657704|Drug|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
79240509|NCT03463707|Drug|Placebo|Placebo to Investigational product BP101, nasal spray
79240510|NCT05226897|Drug|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
79240511|NCT05226897|Drug|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
79380218|NCT03157804|Biological|Filgrastim|Given subcutaneously (SC)
79380219|NCT03157804|Drug|Plerixafor|Given SC
79380220|NCT03157804|Procedure|Bone Marrow Aspiration|
79380221|NCT03139227|Procedure|Bio specimen Collection|Patients undergo collection of blood and urine
79240512|NCT05226897|Drug|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
79240513|NCT05226897|Drug|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
79380222|NCT03139227|Dietary Supplement|Dietary Intervention|Consume celery-banana bread
79380223|NCT03139227|Other|Laboratory Biomarker Analysis|Correlative studies
79380224|NCT03135327|Dietary Supplement|Ocufolin|Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
79380225|NCT03128879|Drug|Ibrutinib|Given PO
79380226|NCT03128879|Drug|Venetoclax|Given PO
79380227|NCT03128879|Drug|Acalabrutinib|Given BID
79380228|NCT03124160|Drug|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini
79380229|NCT03124160|Drug|ParaGard® CuT380A|ParaGard® CuT380A
79380230|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - deintensified|60 Gy at 2 Gy/fx
79380231|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - standard|70 Gy at 2 Gy/fx
79380232|NCT03077243|Drug|Cisplatin (or alternative) - deintensified|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses.
79534508|NCT06146855|Procedure|Tunneling procedure with Amnion Membrane|Root Coverage by tunneling procedure with the addition of Amnion Membrane as a soft tissue substitute
79837062|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
79837063|NCT05264844|Other|Masking tape|IV catheters will be fixed with masking tape
79837064|NCT00785616|Other|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
79691224|NCT04319185|Other|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
79691225|NCT00446732|Device|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
79691226|NCT00446771|Drug|Mannitol|
79691227|NCT01222078|Biological|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
79837065|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
79837066|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
79534509|NCT06146855|Procedure|Tunneling procedure with De-epithelialized Free Gingival Graft|Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
80007665|NCT01966471|Drug|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
80007666|NCT01966471|Drug|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
80007667|NCT01966471|Drug|Paclitaxel|IV infusion of paclitaxel 80 mg/m^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
80007668|NCT01966471|Drug|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
80007669|NCT01966471|Drug|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
80007670|NCT01966471|Drug|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter [mg/m^2] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m^2 in the first cycle and escalate to 100 mg/m^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
80007671|NCT01966471|Drug|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
80007672|NCT01966471|Drug|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
79240514|NCT05224635|Procedure|Vascular Injury|The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
79240515|NCT04453761|Drug|Neurobion|Intravenous Thiamine 2 mg/kg in Neurobion injection
79240516|NCT04453761|Drug|Placebo|Intravenous NaCl0.9%
79303053|NCT04484389|Other|Telerehabilitation|Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.
79691228|NCT03277586|Drug|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
79691229|NCT03277586|Drug|Placebo|Identically formulated and packaged inactive substance
79691230|NCT02902536|Other|No interventions|
79691231|NCT04317157|Dietary Supplement|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
79837067|NCT00567567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
79837068|NCT00567567|Drug|Carboplatin|Given IV
79837069|NCT00567567|Drug|Cisplatin|Given IV
79303054|NCT04484389|Other|Exercise brochure|General exercise protocol will be prepared and given to the control group as a brochure
79534510|NCT06143839|Drug|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
79534511|NCT06143514|Other|No intervention|No intervention
79534512|NCT06136819|Combination Product|RT-310|Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
79534513|NCT06136741|Drug|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
79534514|NCT06136741|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
79691232|NCT04317157|Other|Placebo|Placebo pill.
79691233|NCT04318873|Other|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
79691234|NCT04317079|Dietary Supplement|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
79691235|NCT04317079|Other|Diet|Consultation by a dietitian was offered to all participants
79691236|NCT03277430|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
79691237|NCT03277430|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
79691238|NCT03277430|Drug|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
79691239|NCT02902575|Procedure|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
79691240|NCT05657431|Other|essential oils (Ylang ylang oil)|inhaler aromatherapy
79691241|NCT05657431|Other|placebo (saline solutions)|placebo saline solutions
80007673|NCT01568437|Procedure|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
79240517|NCT03463629|Other|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
79240518|NCT03463629|Other|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
79240519|NCT03463551|Drug|ABL-101|ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
79240520|NCT03463551|Other|0.9% NaCl|Placebo
79534515|NCT06135220|Diagnostic Test|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
79534516|NCT06133283|Behavioral|High intensity endurance exercise|High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
79534517|NCT06133283|Behavioral|Stretching exercise|Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
79534518|NCT06133283|Behavioral|Virtual reality (VR)-based gaming|VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
79534519|NCT06131437|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously.
79691242|NCT05657431|Other|essential oils (lemon oil)|inhaler aromatherapy
79691243|NCT04699214|Drug|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
79240521|NCT03463395|Device|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
79240522|NCT03463317|Device|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
79240523|NCT03463317|Drug|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
79240524|NCT03463317|Drug|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
79380233|NCT03077243|Drug|Cisplatin (or alternative) - standard|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 7 total doses.
79380234|NCT03077243|Procedure|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
79380235|NCT03066596|Behavioral|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
79691244|NCT04699214|Drug|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
79691245|NCT02902380|Drug|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
79691246|NCT02902380|Drug|control group|0.9% saline infusion
79837070|NCT00567567|Drug|Cyclophosphamide|Given IV
79837071|NCT00567567|Drug|Doxorubicin Hydrochloride|Given IV
79837072|NCT00567567|Drug|Etoposide|Given IV
79837073|NCT00567567|Radiation|External Beam Radiation Therapy|Undergo EBRT
79837074|NCT00567567|Biological|Filgrastim|Given IV or SC
79837075|NCT00567567|Drug|Isotretinoin|Given orally
79837076|NCT00567567|Other|Laboratory Biomarker Analysis|Correlative studies
79837077|NCT00567567|Drug|Melphalan|Given IV
79837078|NCT00567567|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
79837079|NCT00567567|Other|Pharmacological Study|Correlative studies
80007674|NCT01568437|Other|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
79240525|NCT03463317|Drug|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
79240526|NCT03463317|Drug|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
79240527|NCT03463317|Drug|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
79534520|NCT06131437|Drug|Semaglutide|Semaglutide will be administered subcutaneously.
79534521|NCT06131437|Drug|Tirzepatide|Tirzepatide will be administered subcutaneously.
79240528|NCT03463317|Drug|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
79240529|NCT03463317|Drug|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
79380236|NCT03064035|Drug|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
79240530|NCT03463317|Drug|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
79534522|NCT06127199|Device|Ovaprene|Non-hormonal intravaginal ring
80007675|NCT04188847|Drug|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
79240531|NCT03462147|Device|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
79534523|NCT06123195|Other|Constipation treatment|Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
79534524|NCT06122662|Drug|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
79837080|NCT00567567|Drug|Thiotepa|Given IV
79837081|NCT00567567|Drug|Topotecan Hydrochloride|Given IV
79240532|NCT02906579|Drug|Matching Placebo|
79240533|NCT02906579|Drug|IW-1973|
79240534|NCT03461913|Procedure|Cesarean section|Lower segment elective Cesarean section
79240535|NCT04975347|Drug|kisspeptin 112-121|Six IV doses of kisspeptin 112-121
79240536|NCT04975347|Drug|GnRH|Two IV doses of GnRH
79240537|NCT04975347|Drug|Naloxone|One bolus and one infusion of naloxone
79240538|NCT03463083|Drug|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
79303055|NCT02634801|Drug|Fumaric Acid Esters|Administered orally
79303056|NCT02634801|Drug|Methotrexate|Administered orally
79303057|NCT02634801|Drug|Ixekizumab|Administered SC
79303058|NCT03196453|Dietary Supplement|Probiotic|probiotic and/or placebo intervention in toddlers
79380237|NCT03054181|Biological|HyQvia|
79380238|NCT03028311|Procedure|Angiography|Undergo angiography
79303059|NCT05587595|Other|questionnaires & data collection|questionnaires
79380239|NCT03028311|Procedure|Computed Tomography|Undergo SPECT-CT
79380240|NCT03028311|Procedure|Planar Imaging|Undergo planar imaging
79534525|NCT06122662|Other|Placebo|Matching Placebo Comparator
79534526|NCT06120504|Drug|SGN-35T|Given into the vein (IV; intravenously)
79534527|NCT06117891|Drug|Atezolizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
79534528|NCT06117891|Drug|Bevacizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
79534529|NCT06117891|Drug|Durvalumab|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
79534530|NCT06117891|Drug|Tremelimumab,|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
79534531|NCT06117553|Procedure|thorough flushing|The thorough flushing strategy refers to the thorough flushing of all liquid and foam accumulation areas during the inspection. Make all liquid accumulation parts in the intestinal cavity free of aspiratable liquid retention
79534532|NCT06115486|Other|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
79534533|NCT06115486|Other|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
79534534|NCT06114186|Device|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
79534535|NCT06114186|Other|standard of care|self reported HbA1C or GMI
79837082|NCT00567567|Drug|Vincristine Sulfate Liposome|Given IV
79534536|NCT06113016|Procedure|Biospecimen Collection|Undergo collection of blood samples
79380241|NCT03028311|Radiation|Radioembolization|Undergo radioembolization
79691247|NCT03277235|Behavioral|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
79691248|NCT05426577|Diagnostic Test|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
79691249|NCT01221727|Drug|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
79691250|NCT01221727|Drug|Midazolam|All subjects will receive two oral dose administrations of midazolam.
79691251|NCT03277157|Dietary Supplement|B. lactis B94|A probiotic dose of 15 billion per capsule.
79691252|NCT03277157|Dietary Supplement|Placebo|Placebo capsule
79837083|NCT00666198|Drug|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
79691253|NCT02902614|Procedure|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
79691254|NCT02902614|Procedure|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
79837084|NCT00778596|Drug|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
79837085|NCT00778596|Drug|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
79837086|NCT00785694|Drug|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
79837087|NCT00778674|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
80007676|NCT05255107|Combination Product|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution [0.23%], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
79380242|NCT03028311|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT-CT
79240539|NCT03463083|Drug|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
79380243|NCT03028311|Radiation|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
79380244|NCT03028311|Other|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
79380245|NCT03018730|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
79380246|NCT02971891|Drug|CLS006 (Furosemide) Topical Gel|
79534537|NCT06113016|Other|Educational Intervention|Receive handout on physical activity
79534538|NCT06113016|Other|Exercise Intervention|Receive individually tailored exercise intervention
79534539|NCT06113016|Drug|Fisetin|Given PO
79534540|NCT06113016|Other|Physical Performance Testing|Ancillary studies
79380247|NCT02971891|Drug|Vehicle Topical Gel|
79380248|NCT02953717|Radiation|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
79380249|NCT02953717|Radiation|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
79380250|NCT02918474|Other|Decision Aid|Use decision making tool
79380251|NCT02918474|Other|Questionnaire Administration|Ancillary studies
79534541|NCT06113016|Drug|Placebo Administration|Given PO
79534542|NCT06113016|Other|Quality-of-Life Assessment|Ancillary studies
79534543|NCT06113016|Other|Questionnaire Administration|Ancillary studies
79534544|NCT06112990|Dietary Supplement|creatine monohydrate|Creatine is part of the phosphagen system and plays a critical role in energy metabolism. Creatine monohydrate supplementation increases availability of creatine and phosphocreatine in the skeletal muscle. Increased phosphocreatine enables greater buffering of adenosine triphosphate, an organic compound providing energy to cells, enhancing training volume (e.g., an individual can work-out harder and longer).This augmentation in exercise capacity amplifies training adaptations. Additionally, creatine monohydrate supplementation reduces levels of inflammatory markers, which are associated with severe muscle loss.
79534545|NCT06112990|Other|Placebo|Placebo supplementation consists of a flavorless, colorless, dextrose powder and will be supplied in concealed, unlabeled packaging.
80007677|NCT05255107|Other|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
80007678|NCT04788589|Other|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
80007679|NCT04774081|Device|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
80007680|NCT05224843|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
80007681|NCT05200741|Biological|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
80007682|NCT05200741|Biological|Matching placebo|Solution for Intranasal Spray
80007683|NCT03227471|Drug|IVA|IVA tablet for oral administration
79691255|NCT05657392|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
80007684|NCT03227471|Drug|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
79691256|NCT05657392|Other|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
79691257|NCT03277118|Device|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
79534546|NCT06112990|Behavioral|Home-based, telehealth|Home-based, individualized, whole-body RT program, supervised via the telehealth platform within the electronic medical record system. The RT program consists of 12 resistance exercises, focusing on all major muscle groups including upper and lower body, core, and whole-body. Exercises within each participant's individualized RT program progress with a periodization model as recommended by the American College of Sports Medicine. In addition, the cancer exercise trainer will inquire about space availability in the home for completing resistance prior to developing the personalized prescription. This logistical information is key to ensure feasibility of completing the exercises prescribed. Participants will be provided with beginner and advanced sets of elastic resistance bands to enable progression throughout the 52-week study.
79534547|NCT06106464|Other|Aerobic exercise+6.5 h of prolonged sitting|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then sit in the chair for 6.5 hours. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
79691258|NCT01221181|Drug|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
79691259|NCT05657314|Dietary Supplement|Active Comparator|Consists of 15 grams of pea protein
79691260|NCT03277079|Drug|statin + ezetimibe|Combination of two drugs
79691261|NCT03277079|Drug|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
79691262|NCT05657236|Other|medical treatment|traditional medical treatment and regular follow-up
79691263|NCT05657236|Other|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
79691264|NCT02902224|Dietary Supplement|Tap water|300ml tap water via nasogastric tube
79691265|NCT02902224|Dietary Supplement|Glucose|300ml tap water with 75g glucose via nasogastric tube
79691266|NCT02902224|Dietary Supplement|Fructose|300ml tap water with 25g fructose via nasogastric tube
80007685|NCT03227471|Drug|VX-445|VX-445 tablet for oral administration.
80007686|NCT03227471|Drug|Matched Placebo|Matched placebo.
80007687|NCT03227471|Drug|TEZ|Tablet for oral administration.
80007688|NCT03227471|Drug|VX-561|Tablet for oral administration.
80007689|NCT03227471|Drug|VX-445|VX-445 IV injection
80007690|NCT01354314|Drug|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
80007691|NCT01354314|Drug|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
80007692|NCT01354314|Drug|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
79691267|NCT01220557|Behavioral|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
80007693|NCT01354314|Drug|Placebo|One capsule in the morning, three capsules in the evening
79691268|NCT01220557|Behavioral|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
79534548|NCT06106464|Other|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 2-minute walks at 35-40% of their heart rate reserve every 30 minutes for 6.5 hours after moderate-intensity aerobic exercise. They will make a twelve interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
79691269|NCT04317001|Drug|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
79691270|NCT04317001|Drug|Placebo|placebo
79691271|NCT03277040|Other|CSA membership|Bi-weekly fresh food delivery
79691272|NCT02887339|Other|Training Website|Additional training website can be found at gtextraing.org
79691273|NCT02887339|Other|Control|Standard training given by OPOs and GTEx staff
80007694|NCT04567836|Other|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
80007695|NCT04561908|Device|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
80007696|NCT04561908|Device|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
79691274|NCT05426499|Drug|Patients requiring cefotaxime treatment|Dosage according to SmPC
79240540|NCT03463083|Drug|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
79380252|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
79380253|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
79380254|NCT02872025|Drug|Pembrolizumab|Injected intralesionally
79380255|NCT02872025|Biological|Intralesional mRNA 2752|Injected intralesionally
79380256|NCT02824029|Drug|Ibrutinib|Given PO
79691275|NCT05426499|Drug|Patients requiring meropenem treatment|Dosage according to SmPC
79691276|NCT05426499|Drug|Patients requiring fluconazole treatment|Dosage according to SmPC
79691277|NCT05426499|Drug|Patients requiring isavuconazole treatment|Dosage according to SmPC
79691278|NCT05426499|Drug|Patients requiring anidulafungin treatment|Dosage according to SmPC
79691279|NCT05658094|Device|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
79691280|NCT01220401|Behavioral|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
79380257|NCT02824029|Other|Laboratory Biomarker Analysis|Correlative studies
79691281|NCT00446810|Drug|Benfotiamine|
79691282|NCT00446810|Drug|Placebo|
79380258|NCT02824029|Other|Pharmacological Study|Correlative studies
79380259|NCT02822573|Drug|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
79691283|NCT05657197|Behavioral|Exercise intervention|A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
79691284|NCT05657197|Other|Usual care|Usual care, including general advice concerning chronic fatigue.
79691285|NCT00446888|Behavioral|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
79691286|NCT00446888|Dietary Supplement|Forticare|400 ml of commercially-available nutritional supplement.
79691287|NCT00446888|Dietary Supplement|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
80007697|NCT04509336|Drug|Orphenadrine|100 mg twice daily
80007698|NCT04509336|Drug|Baclofen|initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
80007699|NCT03194321|Drug|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
80007700|NCT04684602|Biological|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
80007701|NCT04367142|Diagnostic Test|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
79380260|NCT02822573|Drug|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
79534549|NCT06106464|Other|Aerobic exercise+4 minutes of walking breaks every 1-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 4-minute walks at 35-40% of their heart rate reserve every 1 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
79534550|NCT06106464|Other|Aerobic exercise+8 minutes of walking breaks every 2-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 8-minute walks at 35-40% of their heart rate reserve every 2 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
79691288|NCT02887300|Behavioral|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
79691289|NCT05657158|Other|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
79691290|NCT01220167|Drug|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
79691291|NCT01220167|Drug|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
80007702|NCT04367142|Diagnostic Test|Biosensor|Portable and Connected Biosensor viral
79380261|NCT02795676|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
79380262|NCT02795676|Biological|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
79380263|NCT02784535|Drug|Atomoxetine|norepinephrine transporter inhibitor
79380264|NCT02784535|Drug|Placebo|placebo
79240541|NCT04971837|Dietary Supplement|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
79380265|NCT02750072|Procedure|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
79691292|NCT01220167|Drug|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
80007703|NCT02259972|Drug|BI 113823 solution|
79380266|NCT02750072|Procedure|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
79380267|NCT02723409|Procedure|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
80007704|NCT02259972|Drug|BI 113823 tablet|
80007705|NCT02259972|Drug|Placebo|
79380268|NCT02723409|Procedure|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
79380269|NCT02723409|Procedure|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
80007706|NCT02259972|Other|High fat, high calorie breakfast|only for dose group 5
80007707|NCT01374581|Drug|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to < 15 kg 1 tablet per dose 15 to < 25 kg 2 tablets per dose 25 to < 35 kg 3 tablets per dose"
80007708|NCT01374581|Drug|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to < 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to < 18 kg)1 tablet(25mg/67,5mg)for 3 days"
80007709|NCT01374581|Drug|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to < 11 kg: ½ tablets 12 to < 19 kg: 1 tablets per dose 20 to < 27 kg: 1½ tablets per dose 28 to < 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
79240542|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil (1:1 ratio of CBD to Medium Chain Triglycerides oil)
79240543|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base
79240544|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base
79240545|NCT04971837|Dietary Supplement|Cannabidiol (CBD) Isolate in water formulation|formulation
79240546|NCT04971837|Dietary Supplement|CBD matching Placebo|Matching Placebo
79240547|NCT03465189|Device|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
79240548|NCT01328535|Drug|temozolomide|Given PO
79380270|NCT02723409|Procedure|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
79380271|NCT02723409|Procedure|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
79380272|NCT02708836|Procedure|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
79534551|NCT06105866|Diagnostic Test|Tricuspid Annular Plane Systolic Excursion|Transthoracic echocardiography will be performed on patients during hospitalization and preoperatively to investigate the relationship between preoperative fasting and right ventricular functions. This will be examined by looking at TAPSE
80007710|NCT02585921|Behavioral|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
79691293|NCT00447044|Behavioral|Resistance Exercise|Subjects will lift weights with their legs.
79691294|NCT00447044|Dietary Supplement|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
79691295|NCT00447044|Dietary Supplement|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
80007711|NCT02585921|Behavioral|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
80007712|NCT04501536|Behavioral|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
80007713|NCT03562650|Behavioral|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
80007714|NCT03562650|Behavioral|Present Centered|Participants are asked to try to increase their focus on the present.
80007715|NCT01354938|Drug|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
80007716|NCT02516969|Radiation|Stereotactic Body Radiotherapy|Radiation
80007717|NCT04364256|Device|RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)|Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
80007718|NCT03092791|Biological|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
80007719|NCT03092791|Biological|Reference IPV|Reference IPV intramuscular injection
80007720|NCT03092791|Biological|sIPV Placebo|sIPV placebo-matching intramuscular injection
80007721|NCT03065556|Drug|188-0551 Solution|Topical solution containing active drug
80007722|NCT03065556|Drug|Vehicle Solution|Topical solution containing no active drug
79240549|NCT01328535|Other|flow cytometry|Correlative studies
79380273|NCT02708836|Device|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
79380274|NCT02708836|Device|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
79380275|NCT02708836|Procedure|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
79380276|NCT02708836|Procedure|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
80007723|NCT01374737|Drug|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
80007724|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
80007725|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
80007726|NCT02350595|Other|Lean fish|
79240550|NCT01328535|Other|staining method|Correlative studies
79240551|NCT01328535|Procedure|biopsy|Optional correlative studies
79240552|NCT01328535|Other|laboratory biomarker analysis|Correlative studies
79240553|NCT03129633|Other|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
79240554|NCT03461679|Procedure|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
79240555|NCT03461679|Procedure|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
79691296|NCT02902185|Drug|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
79691297|NCT02902185|Drug|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
80007727|NCT02350595|Other|Fatty fish|
80007728|NCT02203409|Procedure|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
79240556|NCT03461601|Procedure|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
79240557|NCT03461601|Procedure|IUI|Intrauterine insemination (IUI)
79240558|NCT03461601|Procedure|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
79547290|NCT01553357|Drug|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
79547291|NCT01553370|Other|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
79534554|NCT06101693|Diagnostic Test|Plasma biomarker levels|"This study will investigate the diagnostic utility and performance of:~Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP <125 ng/L~The prevalence of HF in people with suspected HF and low NT-proBNP <125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
79691298|NCT00447161|Drug|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water
79380277|NCT02708836|Procedure|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
79691299|NCT00447161|Drug|Placebo|Matched placebo
79380278|NCT02708836|Procedure|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
79691300|NCT00447200|Procedure|Esophagus Doppler monitoring|
79240559|NCT03463005|Other|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
79380279|NCT02708836|Procedure|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
79380280|NCT02699151|Drug|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
79380281|NCT02699151|Procedure|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
79380282|NCT02699151|Other|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
79380283|NCT02690545|Biological|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10^8 cells/m^2 and 2x10^8 cells/m^2. Phase II patients will receive the dose level decided upon in Phase I.
79380284|NCT02643069|Other|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
79380285|NCT02632448|Drug|LY2880070|Capsules
79691301|NCT00447200|Procedure|Fluid optimization|
79691302|NCT00447239|Procedure|glucontrol (insulin therapy)|
79691303|NCT02901873|Device|Electrical Impedance Spectroscopy|
79691304|NCT00447317|Behavioral|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
79691305|NCT00447317|Behavioral|Attention control|Standard peritoneal dialysis dietary education
79380286|NCT02632448|Drug|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
79380287|NCT02617511|Dietary Supplement|Omega-3 Supplementation|
79691306|NCT05425914|Drug|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
80007729|NCT05172505|Device|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
79380288|NCT02617511|Dietary Supplement|Placebo|
79380289|NCT02587234|Device|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
79380290|NCT02561091|Other|Placebo|
79380291|NCT02561091|Drug|AM-111 0.4 mg/ml|
79380292|NCT02561091|Drug|AM-111 0.8 mg/ml|
79547292|NCT01553370|Other|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
79691307|NCT05425914|Drug|Artificial tear|Conventional dry eye treatment
79691308|NCT00447356|Drug|recombinant interferon alfa|
79691309|NCT02902068|Device|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
79691310|NCT00447434|Drug|Natto extract (Nattokinase)|
79691311|NCT00447473|Drug|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
79691312|NCT00447473|Drug|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
79240560|NCT03463005|Procedure|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
79240561|NCT04949061|Behavioral|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.
79691313|NCT00447473|Drug|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
80007730|NCT01374893|Behavioral|Exercise|The intervention group will perform the multi-session per day training program
80007731|NCT01374893|Behavioral|Control|Usual care
79837088|NCT00778752|Drug|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
79837089|NCT00926835|Drug|paroxetine|6 weeks, 20-50mg/day
79837090|NCT00926835|Drug|Escitalopram|10-20mg/day for 6 weeks
79837091|NCT00926835|Drug|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
79837092|NCT00926835|Drug|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
80007732|NCT04638127|Behavioral|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
80007733|NCT04638127|Behavioral|Attention Control|usual care and welcome videos
79380293|NCT02489604|Drug|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
79534555|NCT06098911|Device|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
79837093|NCT00926835|Drug|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
79837094|NCT00926835|Drug|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
79837095|NCT00926835|Drug|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
79837096|NCT00926835|Drug|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
79837097|NCT00926835|Drug|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
80007734|NCT05197283|Other|Glucose as reference food|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
80007735|NCT05197283|Other|White bread|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from white bread, along with 300ml water, tested two times, in different visits, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79691314|NCT05425602|Drug|MAX-40279-01: 50mg/70mg|[Stage 1]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. [Stage 2]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
79691315|NCT00447512|Drug|ghrelin|acylated ghrelin
79691316|NCT00553488|Drug|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
79837098|NCT00930033|Procedure|Nephrectomy|Current surgery
80007736|NCT05197283|Other|Regular spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from regular spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79380294|NCT02489604|Drug|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
79380295|NCT02473276|Drug|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
79380296|NCT02473276|Drug|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
79380297|NCT02451423|Drug|Atezolizumab|1200 mg Given IV
79380298|NCT02444442|Device|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
79380299|NCT02444442|Other|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
79380300|NCT02411773|Drug|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate > 30).
79837099|NCT00930033|Other|Sunitinib alone|Sunitinib alone without nephrectomy
79837100|NCT00931593|Device|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~Subject selection~Obtaining of written informed consent~Visit V1 (day 0):~Fasting subject~Randomization to determine the examination order~Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
79691317|NCT00553488|Drug|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
80007737|NCT05197283|Other|Whole wheat spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from whole wheat spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79691318|NCT00447551|Drug|Poly-L-Lactic Acid|Deep dermal injection
79691319|NCT00447629|Drug|PPM-204|
80007738|NCT05197283|Other|High fibre - low carbohydrates spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from high fibre - low carbohydrate spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
80007739|NCT03631615|Drug|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
80007740|NCT05197205|Procedure|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
80007741|NCT03631537|Other|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
79691320|NCT00553527|Procedure|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
80007742|NCT05197127|Device|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
80007743|NCT04275817|Other|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
79691321|NCT00447668|Behavioral|Yoga|Yoga for back pain
80007744|NCT01376375|Procedure|Acupuncture|
79691322|NCT00447668|Behavioral|Exercise|exercises for back pain
80007745|NCT04632667|Behavioral|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
80007746|NCT04632667|Behavioral|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
80007747|NCT01376453|Drug|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
80007748|NCT01376453|Drug|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m^2 daily through a catheter in a large vein continuously until the last day of radiation.
80007749|NCT01376453|Radiation|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
79240562|NCT04949061|Other|Enhanced Treatment as Usual (ETA-U)|Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
79691323|NCT00447668|Behavioral|Self-care book recommendations|Self-care book for back pain
79691324|NCT05425407|Dietary Supplement|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
79240563|NCT02905331|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
79240564|NCT02905331|Drug|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
79303060|NCT02449135|Procedure|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
79303061|NCT02476253|Drug|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
79691325|NCT05425407|Dietary Supplement|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
79691326|NCT00447707|Behavioral|Positive Choice|
79691327|NCT03455322|Drug|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6h.
79380301|NCT02411773|Drug|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
79837101|NCT00664560|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
79837102|NCT00664560|Drug|celebrex|200 mg celecoxib qd
79534564|NCT06094296|Drug|BMS-986315|Specified dose on specified days
79534565|NCT06094296|Drug|Nivolumab|Specified dose on specified days
80007750|NCT05196893|Behavioral|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
80007751|NCT04569253|Device|TempSure|Non-invasive radiofrequency treatments
80007752|NCT05420779|Drug|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
80007753|NCT05420779|Drug|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
80007754|NCT05420779|Drug|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 ~ 30 mg/m2 each time, intravenous drip (15 ~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 ~ 5 min)
79380302|NCT02411773|Behavioral|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
79380303|NCT02411773|Behavioral|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
79534566|NCT06094296|Drug|Pemetrexed|Specified dose on specified days
79534567|NCT06094296|Drug|Cisplatin|Specified dose on specified days
79691328|NCT00447746|Procedure|D1 or D2 lymphadenectomy for gastric cancer patients|
79691329|NCT05425368|Drug|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
80007755|NCT02547311|Behavioral|Team Clinic|
79380304|NCT02378428|Drug|MIBG|
79380305|NCT02328599|Procedure|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
79534568|NCT06094296|Drug|Carboplatin|Specified dose on specified days
79534569|NCT06094296|Drug|Paclitaxel|Specified dose on specified days
79534570|NCT06094283|Drug|YCT-529|Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
79534571|NCT06094283|Drug|YCT-529 Placebo|YCT-529 Placebo
80007756|NCT01376531|Procedure|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
79534572|NCT06093672|Drug|Givinostat Hydrochloride|Oral. Starting dose of 50 mg BID with individualized dose titration ranging from 50 mg OD to 100 mg BID based on safety and efficacy
79534573|NCT06093672|Drug|Hydroxy Urea|Oral. Starting dose of 500 mg BID with individualized dose titration ranging from 500 mg OD to 1500 mg BID based on safety and efficacy
79534574|NCT06093100|Device|wearable technology|Three wearable devices
79534575|NCT06079918|Dietary Supplement|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
79534576|NCT06079918|Dietary Supplement|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
79534577|NCT06079918|Dietary Supplement|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
79534578|NCT06079320|Drug|Sisunatovir|Participants will receive tablets from Day 1 to Day 5
79534579|NCT06079320|Drug|Placebo|Participants will receive matching placebo tablets from Day 1 to Day 5
79534580|NCT06079047|Procedure|group Dexamethasone|Adductor canal block with dexamethasone
79534581|NCT06079047|Procedure|group Controle|Adductor canal block with saline solution
79547293|NCT01553383|Device|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
79547294|NCT01553422|Other|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
79547295|NCT01553422|Other|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
79547296|NCT01553435|Drug|Dextromethorphan|The study medicines shall be administered via tube.
79547297|NCT01553435|Drug|Placebo|The study medicines shall be administered via tube.
79547298|NCT01553448|Genetic|gene expression analysis|
79691330|NCT05425368|Drug|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
79691331|NCT02901522|Other|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
79534582|NCT06073353|Behavioral|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
79534583|NCT06069817|Device|High flow nasal cannula|home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
79534584|NCT06069817|Device|nebulized normal saline|home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
79534585|NCT06068868|Drug|ABBV-787|Intravenous (IV) Infusion
79837103|NCT00664560|Drug|Placebo|sugar pill bid
79837104|NCT00664560|Drug|Rescue Antacid|Antacid Tablets
79837105|NCT00566709|Procedure|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
79837106|NCT00785850|Drug|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
79837107|NCT00931671|Other|Exercise training|aerobic exercise training
79837108|NCT00931749|Device|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
79837109|NCT00931749|Device|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
79380306|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
79380307|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
79380308|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|single dose of 1 × 10(7) cells intrathecally
79534586|NCT06066788|Other|CHAMPS|Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
79837110|NCT00783042|Drug|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
79837111|NCT00783042|Drug|Placebo|Tablet, oral, once daily for 1 month (double blind)
79837112|NCT02556528|Behavioral|Health Coaching|
79837113|NCT00688688|Drug|Mirabegron|Tablets
79837114|NCT00688688|Drug|Tolterodine|Extended release capsules
80007757|NCT01568125|Drug|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
80007758|NCT05598931|Device|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
79240565|NCT02522169|Drug|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A< 6month, group B < 6 month). Observation period is one year."
79240566|NCT04307537|Procedure|Post-urethroplasty urethrography|Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
79240567|NCT03656393|Drug|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
79240568|NCT03656393|Drug|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
79380309|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
79380310|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|2 doses of 1 × 10(8) cells intrathecally each 1 month apart
79380311|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
79837115|NCT00688688|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
79837116|NCT00688688|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
79837117|NCT00926991|Other|No intervention|No intervention; observation only
79837118|NCT00930189|Drug|intravitreal injection of ranibizumab|
79837119|NCT00930189|Drug|intravitreal injection of triamcinolone|
79837120|NCT00930189|Procedure|photodynamic therapy|
79837121|NCT00936819|Biological|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
79837122|NCT00936819|Biological|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
79534587|NCT06066671|Other|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
79534588|NCT06065449|Drug|Radiation Therapy|"Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV)."
79837123|NCT00936819|Biological|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
79837124|NCT00937053|Other|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
79837125|NCT00937053|Other|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
79837126|NCT00937053|Other|Platelet transfusion|Patients whose platelets fall below 10 x 10*9 will be transfused with platelets
79837127|NCT04013997|Device|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
79837128|NCT00931827|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
79534589|NCT06064916|Diagnostic Test|Visual Acuity|Monocular and binocular measurement of distance, intermediate, and near visual acuity
79240569|NCT03656393|Drug|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
79240570|NCT03656237|Other|Usual Training|Training in a classroom setting of health care providers
79240571|NCT03656237|Other|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
79534590|NCT06064916|Diagnostic Test|Defocus Curve|Measurement of a defocus curve
79240572|NCT03656003|Device|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
79240573|NCT03656003|Device|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
79240574|NCT02979197|Drug|OE 10 mg amlodipine besylate tablet|
79534591|NCT06064916|Other|Intraocular Lens Satisfaction (IOLSAT) Questionnaire|Self-reported post-operative patient satisfaction with vision after surgery
79240575|NCT02979197|Drug|OE 200 mg celecoxib capsule|
79240576|NCT02979197|Drug|Matched placebo for OE amlodipine besylate tablet|
79534592|NCT06064916|Other|Quality of Vision After Surgery (QUVID) Questionnaire|Self-reported post-operative patient vision quality after surgery
79534593|NCT06064916|Other|Visual Disturbance Questionnaire|Questionnaire of self-reported visual disturbances of patients
79534594|NCT06064916|Diagnostic Test|Topography and Tomography|Topography and tomography measurements with Atlas, iTrace, and/or Pentacam
79534595|NCT06064279|Drug|Poly ICLC|Tol like receptor 3 agonist
79534596|NCT06064279|Drug|IVIG|pooled IVIG
79240577|NCT02979197|Drug|Matched placebo for OE celecoxib capsule|
79240578|NCT02982239|Behavioral|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
79534597|NCT06063486|Procedure|Biospecimen Collection|Undergo collection of blood samples
79534598|NCT06063486|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79534599|NCT06063486|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79534600|NCT06063486|Dietary Supplement|Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement|Given PO
79534601|NCT06063486|Dietary Supplement|Piperine Extract (Standardized)|Given PO
79534602|NCT06063486|Drug|Placebo Administration|Given PO
79534603|NCT06063486|Other|Questionnaire Administration|Ancillary studies
79547299|NCT01553448|Genetic|protein expression analysis|
79547300|NCT01553448|Other|enzyme-linked immunosorbent assay|
79547301|NCT01553448|Other|immunohistochemistry staining method|
79547302|NCT01553448|Other|laboratory biomarker analysis|
79547303|NCT01553448|Other|medical chart review|
79837129|NCT00931827|Drug|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
79837130|NCT00664326|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
79837131|NCT04015323|Device|Interferential current|An electrotherapy current with different carrier frequencies
79837132|NCT00778908|Radiation|Late-course accelerated hyperfractionated IMRT|"IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
79837133|NCT00778908|Drug|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
79534604|NCT06063434|Behavioral|Night Shift|"The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously."
79534605|NCT06063434|Behavioral|Usual education|Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).
79837134|NCT00778908|Radiation|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
79837135|NCT00931905|Drug|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
79240579|NCT02982239|Device|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
79240580|NCT02982239|Device|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
79240581|NCT02982239|Device|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
79240582|NCT02982239|Other|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
79380312|NCT02315027|Biological|Autologous Mesenchymal Stem Cells|Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
79240583|NCT02982239|Behavioral|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
79240584|NCT03655925|Diagnostic Test|plasmatic HLA-G|plasmatic HLA-G by blood sample
79380313|NCT02297256|Procedure|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
79534606|NCT06062303|Other|Usual care (UC)|- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, heart rate (HR) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
79837136|NCT00931905|Other|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
79837137|NCT02561468|Drug|Nefopam|
79837138|NCT02561468|Drug|Saline|
79837139|NCT02555748|Drug|Pazopanib|
79837140|NCT02555748|Drug|Sunitinib|
79837141|NCT04014933|Diagnostic Test|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
80007759|NCT02505425|Behavioral|Behavioral Support|"ENABLE CHF-PC includes:~In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
79380314|NCT02297256|Procedure|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
79380315|NCT02278666|Procedure|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
79380316|NCT02278666|Device|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
79380317|NCT02278666|Device|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
79380318|NCT02189720|Drug|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients > 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age < 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg."
79380319|NCT02184195|Drug|Olaparib|Tablet -100mg
79837142|NCT00751946|Behavioral|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis & Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
79240585|NCT03655535|Drug|BTI320|Non-systemic galactomannan complex polysaccharide
79240586|NCT03655535|Other|Placebo|Placebo
79534607|NCT06061328|Behavioral|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
79837143|NCT00751946|Behavioral|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, & Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
79837144|NCT02555592|Procedure|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2~4 weeks after adjuvant chemotherapy.
80007760|NCT02505425|Behavioral|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
79240587|NCT03654365|Other|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
79240588|NCT03654365|Other|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
79240589|NCT03654287|Other|Treatment|The CELS way to intervene severe sepsis and refractory shock
79380320|NCT02184195|Drug|Olaparib|Tablet-150mg
79380321|NCT02184195|Drug|Placebo|Match Olaparib 100mg placebo
79240590|NCT03655847|Drug|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
79240591|NCT03655457|Device|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
79240592|NCT03655457|Device|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
79240593|NCT03653975|Other|no intervention|no intervention
79240594|NCT03655379|Device|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
79240595|NCT01066793|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
79240596|NCT01066793|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
79240597|NCT03985293|Drug|Placebo|4 matching placebo tablets taken twice a day (BID)
79240598|NCT03985293|Drug|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
79380322|NCT02184195|Drug|Placebo|Match Olaparib 150mg placebo
79380323|NCT02181413|Drug|Ixazomib Citrate|Ixazomib citrate capsules
79380324|NCT02181413|Drug|Placebo|Ixazomib citrate placebo-matching capsules
79380325|NCT02151981|Drug|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
79534608|NCT06061328|Behavioral|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
79534609|NCT06059638|Device|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated|Antihypertensive therapy utilizing atrioventricular interval modulation.
79534610|NCT06059638|Device|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated|AVIM therapy is deactivated
79547304|NCT01553487|Other|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
79691332|NCT02901522|Other|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
79240599|NCT03655145|Other|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
79691333|NCT02901522|Other|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
79240600|NCT03655145|Other|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
79380326|NCT02151981|Drug|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
79380327|NCT02138617|Drug|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
79380328|NCT02138617|Drug|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
79380329|NCT02138617|Drug|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
79534611|NCT06057831|Radiation|Total Neo-adjuvant Therapy|"TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~Chemotherapy regimen for Concurrent CRT: Capecitabine~Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist"
79534612|NCT06057831|Other|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
79534613|NCT06057519|Drug|Optimised dose rifampicin|Optimized dose of rifampicin
79534614|NCT06057519|Drug|Standard dose rifampicin|Standard dose rifampicin
79691334|NCT02901522|Other|Teleconsultation|The general practioner received phone call to asthma care.
79691335|NCT00447824|Procedure|Introduction of better conditions during blood sampling|
79691336|NCT04681326|Device|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
80007761|NCT05196425|Genetic|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
79240601|NCT03654911|Diagnostic Test|EEG|EEG
79240602|NCT03654911|Genetic|ApoE|ApoE
79240603|NCT03654755|Drug|ASN002|Daily dose of ASN002 for up to 110 weeks
79240604|NCT03654677|Biological|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
79240605|NCT03654677|Biological|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
79380330|NCT02138617|Drug|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
79380331|NCT02118584|Drug|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
79380332|NCT02040207|Drug|AM-101|AM-101 gel for intratympanic injection
79380333|NCT02040194|Drug|AM-101|AM-101 gel for intratympanic injection
79380334|NCT02040194|Drug|Placebo|Placebo gel for intratympanic injection
79380335|NCT02021019|Procedure|Renal Denervation|Renal Denervation
79534615|NCT06056505|Procedure|partial kidney nephrectomy|surgery for partial nephrectomy
79534616|NCT06056505|Device|DaVinci Robot|device to perform the surgery for partial nephrectomy (not the intervention of interest)
79534617|NCT06056505|Device|Innersight 3D software|investigational product to generate the 3D model
79691337|NCT00447863|Drug|Levonorgestrel/Ethinyl Estradiol|
79691338|NCT02901600|Other|Detection of the expression of DMTB1 by immunohistochemistry|
79691339|NCT00447941|Drug|SCA-136|
79691340|NCT05425329|Dietary Supplement|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
79691341|NCT05425329|Dietary Supplement|Placebo treatment|Capsule containing maltodextrin.
79691342|NCT00448097|Drug|cetuximab|No verifiable data available, PI relocated
79691343|NCT00448097|Drug|docetaxel|No verifiable data available, PI relocated
79691344|NCT03455283|Drug|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
79691345|NCT03455283|Other|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
79691346|NCT00448214|Drug|YM150|Oral
79691347|NCT00448214|Drug|warfarin|Oral
79691348|NCT02901639|Other|counseling|
79691349|NCT00448253|Biological|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
79691350|NCT00448292|Drug|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
79691351|NCT00448292|Drug|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
79691352|NCT00553566|Procedure|medical chart review|
79691353|NCT00553566|Procedure|questionnaire administration|
79691354|NCT00553566|Procedure|study of socioeconomic and demographic variables|
79837145|NCT04059614|Procedure|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
79837146|NCT00930345|Drug|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
79534618|NCT06051591|Behavioral|Food FARMacia Program|Twice monthly delivery of groceries with about 12 meals per household member for up to 4 household members for 6 months.
79837147|NCT00786006|Drug|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
79837148|NCT00786006|Drug|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
79240606|NCT03468621|Procedure|Wound closure|Method of wound closure
79240607|NCT03653897|Device|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
79240608|NCT03653897|Device|Wearable Sensor|Subjects will wear an ID-Reader
79240609|NCT03462849|Other|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
79240610|NCT02980601|Device|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
79240611|NCT02980601|Procedure|STSG|0.012mm STSG
79380336|NCT01996605|Drug|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
79380337|NCT01996605|Drug|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
79380338|NCT01996605|Drug|Placebo|placebo will be administered spinally
79534619|NCT06051591|Behavioral|Self-directed meal preparation support|Nutrition education and anticipatory guidance to support healthy meal preparation
79691355|NCT02901561|Drug|misoprostol 200|
79691356|NCT02901561|Drug|misoprostol 400|
79240612|NCT03462771|Drug|Fish oil|4g of fish oil daily for 14 weeks
79240613|NCT03462771|Drug|sunflower oil|4g of sunflower oil daily for 14 weeks
79240614|NCT04453371|Drug|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
79380339|NCT01981720|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
79380340|NCT01974440|Drug|Bendamustine|90 milligram per meter square (mg/m^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
79240615|NCT04453371|Drug|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
79240616|NCT03461133|Other|Intervention|The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
79380341|NCT01974440|Drug|Rituximab|375 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
79380342|NCT01974440|Drug|Cyclophosphamide|750 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
79380343|NCT01974440|Drug|Doxorubicin|50 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
79380344|NCT01974440|Drug|Vincristine|1.4 mg/m^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
79380345|NCT01974440|Drug|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
79534620|NCT06048822|Behavioral|Pickleball|Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
79691357|NCT00448409|Biological|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
79691358|NCT00448409|Drug|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
79691359|NCT02901678|Device|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
79691360|NCT02901756|Dietary Supplement|Antemig|Participants were instructed to take one tablet every morning for three months.
79240617|NCT03654521|Diagnostic Test|Fetal interventricular septum thickness|Two-dimensional ultrasound fetal cardiac imaging test
79240618|NCT03462693|Other|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
79380346|NCT01974440|Drug|PCI-32765 (Ibrutinib)|560 mg (4*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
79837149|NCT02562326|Drug|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
79837150|NCT02562326|Drug|Humalog®|Injection immediately before the start of the individualised standard meal
79240619|NCT03462615|Diagnostic Test|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
79380347|NCT01974440|Drug|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
79380348|NCT01921166|Drug|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
79691361|NCT00448526|Behavioral|low protein diet|
79837151|NCT00930501|Biological|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
79380349|NCT01921166|Drug|Leuprolide flare|Leuprolide flare ovulation induction
79837152|NCT00783120|Other|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
80007762|NCT03089047|Biological|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
80007763|NCT03089047|Biological|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
79380350|NCT01906970|Device|ClampArt|
79380351|NCT01855477|Procedure|Histological biopsy procedure|
79380352|NCT01836744|Device|Survival rate dental implant (OsseoSpeed™)|
79534621|NCT06048237|Diagnostic Test|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
79837153|NCT00783120|Other|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
80007764|NCT01371006|Drug|low dose|efavirenz single dosing once daily
80007765|NCT01371006|Drug|normal dose|efavirenz once daily
80007766|NCT01371006|Drug|low dose|Efavirenz single dosing once daily
80007767|NCT05195957|Procedure|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
79240620|NCT03462537|Device|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
79240621|NCT03462537|Device|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
79380353|NCT01805076|Procedure|Breast surgery|
79534622|NCT06046014|Other|BI Focused writing|BI Focused writing program
79691362|NCT05424939|Procedure|Colectomy|Colon resection
79837154|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
80007768|NCT05195957|Procedure|Open transversus abdominis release operation|Original open TAR using midline incision.
79380354|NCT01805076|Procedure|Magnetic resonance imaging|
79380355|NCT01805076|Procedure|Mammography|
79691363|NCT05424939|Procedure|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
79837155|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
79837156|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
79837157|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
79380356|NCT01802281|Procedure|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
79380357|NCT01802281|Procedure|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
79380358|NCT01796795|Drug|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
79691364|NCT05424939|Procedure|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
79691365|NCT05424705|Diagnostic Test|OCT, NIRS|
79691366|NCT03276884|Other|Experimental Infant Formula|amino acid-based infant formula powder
79691367|NCT03276884|Other|Control Infant Formula|amino acid-based infant formula powder
79691368|NCT02901366|Drug|14C-FYU-981|14C-FYU-981, (Oral single dosing)
79534623|NCT06046014|Other|Control|Attention Control Writing
79691369|NCT03276806|Behavioral|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
79837158|NCT00783276|Drug|SYN115|100 mg single dose
79837159|NCT00783276|Drug|PLACEBO|PLACEBO
80007769|NCT05009173|Procedure|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
80007770|NCT05009173|Procedure|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
80007771|NCT04864925|Drug|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
79240622|NCT03462537|Device|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
79240623|NCT03461055|Other|Lavender|Lavender aromatherapy
79240624|NCT03461055|Other|Water|Water
79380359|NCT01796795|Drug|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
79380360|NCT01796795|Drug|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
79380364|NCT01755650|Radiation|18F FPM|
79380365|NCT01696461|Drug|Plerixafor|
79380366|NCT01688492|Drug|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson & Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
79534624|NCT06045325|Diagnostic Test|Orbscan II|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
79534625|NCT06045325|Diagnostic Test|IOL Master 700|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
79534626|NCT06045325|Diagnostic Test|IOL Master 500|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
79534627|NCT06045325|Diagnostic Test|Atlas 9000|Diagnostic assessment to measure white-to-white.
79534628|NCT06045325|Diagnostic Test|Lenstar 900|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
79691370|NCT03276806|Behavioral|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
79691371|NCT03276806|Other|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
79691372|NCT03276806|Other|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
79837160|NCT00932061|Other|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
79837161|NCT00932061|Other|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
79837162|NCT02562170|Device|TiLoop Bra|
80007772|NCT04864925|Drug|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
80007773|NCT04111068|Device|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
80007774|NCT04111068|Device|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
79534629|NCT06045325|Diagnostic Test|Pentacam|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
79837163|NCT02562170|Device|Protexa|
79837164|NCT03538197|Other|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
79837165|NCT00686972|Drug|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
79837166|NCT00937287|Other|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
79240625|NCT03462381|Dietary Supplement|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
79240626|NCT04928157|Device|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
79240627|NCT03462303|Combination Product|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
79837167|NCT00665652|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
80007775|NCT03820050|Device|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
80007776|NCT04180098|Behavioral|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
80007777|NCT04180098|Other|No intervention|Participants in the control group are placed on a waiting list.
79837168|NCT00937365|Behavioral|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
80007778|NCT02288897|Drug|PV-10 (10% rose bengal disodium)|
79380367|NCT01678898|Drug|PRX-102|
80007779|NCT02288897|Drug|Dacarbazine, temozolomide or talimogene laherparepvec|
80007780|NCT01371552|Device|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
80007781|NCT01371552|Device|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
80007782|NCT01371552|Device|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
80007783|NCT02207075|Drug|[C11]PK-1195 PET scan|PET scan with tracer [C11]PK-1195
80007784|NCT05707572|Drug|methylprednisolone|a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
79380368|NCT01606098|Procedure|Surgery of the primary tumour|Surgical resection of the colon tumour
79380369|NCT01606098|Drug|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
79240628|NCT03462303|Combination Product|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
79240629|NCT03462303|Combination Product|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
79380370|NCT01568307|Drug|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
79380371|NCT01508221|Drug|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
79534630|NCT06045325|Diagnostic Test|iTrace|Diagnostic assessment to measure white-to-white and corneal thickness.
79240630|NCT03462303|Combination Product|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
79534631|NCT06045325|Diagnostic Test|Argos|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
79534632|NCT06045325|Diagnostic Test|Manual caliper measurement|Manual diagnostic assessment to measure white-to-white.
79380372|NCT01508221|Dietary Supplement|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
79380373|NCT01485861|Drug|Abiraterone|Orally once daily
79380374|NCT01485861|Drug|Apitolisib|Orally once daily
79380375|NCT01485861|Drug|Ipatasertib|Orally once daily
79380376|NCT01485861|Drug|Placebo|Orally once daily
79380377|NCT01485861|Drug|Prednisone|Orally bid
79380378|NCT01485861|Drug|Prednisolone|Orally bid
79534633|NCT06042153|Drug|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
79547305|NCT01553500|Dietary Supplement|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
79837169|NCT00937365|Procedure|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
80007785|NCT05707572|Procedure|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
80007786|NCT04854629|Other|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
80007787|NCT04068636|Procedure|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
80007788|NCT03633071|Other|Web-knee brace|Web -Knee Brace
80007789|NCT02035800|Drug|Adalimumab|Patient will received medication as standard of care
80007790|NCT04807361|Behavioral|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
80007791|NCT05195021|Device|EDDY|EDDY (VDW) sonic irrigation activation system
79380379|NCT01452503|Device|Path Women's Condom|comparison between 3 types of female condoms
79691373|NCT03276767|Other|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
80007792|NCT05195021|Device|Diode Laser device|980-nm diode laser device
80007793|NCT05195021|Device|Conventional irrigation|Conventional root canal irrigation with 31-guage side port needle
79380380|NCT01452503|Device|FC2 female condom|comparison between 3 types of female condoms
79380381|NCT01452503|Device|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
79380382|NCT01374984|Biological|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
79380383|NCT01241734|Drug|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
79380384|NCT01220674|Other|cognitive testing|computer-based cognitive assessment
79380385|NCT01101438|Drug|metformin hydrochloride|Given orally
79534634|NCT06042153|Drug|Placebo|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
79534635|NCT06041139|Diagnostic Test|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
79534636|NCT06041139|Diagnostic Test|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
79534637|NCT06041139|Diagnostic Test|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
79534638|NCT06041139|Other|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
79534639|NCT06027671|Behavioral|Group SPARCS Intervention|Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on their location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).
79547306|NCT01553500|Behavioral|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
79691374|NCT05424666|Procedure|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
79691375|NCT03276689|Drug|Duloxetine|The patients will take duloxetine for 8 weeks.
79691376|NCT03276689|Drug|Pregabaline|The patients will take pregabaline for 8 weeks.
79691377|NCT03276689|Other|Placebo|The patients will take placebo for 8 weeks.
79691378|NCT03276650|Other|data collection|biological, administrative, clinical, outcome date
79837170|NCT00937365|Procedure|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
80007794|NCT05707650|Procedure|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
80007795|NCT03993912|Drug|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~once every week for 8 weeks~then once every other week for 16 weeks~thereafter once every 4 weeks, until progression"
79240631|NCT02980523|Drug|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
79240632|NCT02980523|Drug|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
79240633|NCT02980523|Drug|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
79240634|NCT02980523|Drug|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
79240635|NCT03468465|Drug|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
79380386|NCT01101438|Other|placebo|Given orally
79837171|NCT00783588|Biological|ISF35|Subjects participating in this study will receive up to two doses of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
79837172|NCT02561390|Procedure|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
79303062|NCT03196531|Drug|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
79380387|NCT01094769|Drug|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
79380388|NCT01094769|Drug|Placebo|lactose capsule taken once daily
79837173|NCT02561390|Other|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
79837174|NCT00937443|Other|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
80007796|NCT03993912|Drug|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
79380389|NCT01088633|Other|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
79380390|NCT01046825|Drug|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
80007797|NCT03993912|Drug|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
79240636|NCT03468465|Device|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
79380391|NCT01046825|Drug|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
79380392|NCT01046825|Drug|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
79534640|NCT06027671|Behavioral|ART-SPARCS Intervention|"ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs."
79534641|NCT06023589|Biological|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
79534642|NCT06023589|Other|Placebo|Participants will be receiving subcutaneous injection of matching placebo
79534643|NCT06017765|Behavioral|Meditation Training|"The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~Education about stress response~Elicitation of the Relaxation Response through Mindfulness Training~Creating adaptive perspectives~Coping strategiest."
79534644|NCT06017765|Behavioral|Waitlist|The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
79837175|NCT00937443|Biological|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
80007798|NCT05194943|Procedure|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
80007799|NCT05598697|Behavioral|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
80007800|NCT05598697|Behavioral|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
80007801|NCT05598697|Other|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
80007802|NCT01568749|Drug|Paracetamol|Paracetamol
80007803|NCT01568749|Drug|Paracetamol formulation 1|Paracetamol
80007804|NCT01568749|Drug|Paracetamol Formulation 2|Paracetamol
80007805|NCT01568749|Drug|Paracetamol formulation 3|Paracetamol
79240637|NCT04939233|Device|Exoskeleton glove|A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
79303063|NCT03196531|Drug|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
79303064|NCT04996407|Device|survival thermal blanket|patients were given a thermal blanket
79691379|NCT04699370|Other|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
79691380|NCT04699370|Behavioral|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
80007806|NCT01568749|Drug|Paracetamol formulation 4|paracetamol
80007807|NCT03920358|Device|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
80007808|NCT03633851|Device|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
80007809|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
80007810|NCT04443829|Biological|CD19CAR T-cells|Infusion with: CD19CAR T-cells
80007811|NCT02819310|Drug|BLI400 Laxative|oral laxative
80007812|NCT03633773|Biological|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
80007813|NCT01375361|Drug|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
80007814|NCT01375361|Drug|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
79240638|NCT03460743|Biological|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
79240639|NCT03460743|Biological|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
79240640|NCT02980133|Drug|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
79380393|NCT01007773|Drug|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
79380394|NCT01007773|Drug|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
79380395|NCT01007773|Drug|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
80007815|NCT03087643|Other|Passive mobilization - PM|
80007816|NCT05194865|Device|cardiac MRI|assessment of the viability using CMR
80007817|NCT05194865|Procedure|Percutaneous coronary intervention|direct revascularization using PCI
80007818|NCT02821962|Behavioral|Sedentary prompts from a VTAP device|
80007819|NCT05598541|Procedure|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
80007820|NCT01376765|Drug|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
79240641|NCT02980133|Drug|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
79240642|NCT02980133|Drug|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
79240643|NCT03460665|Procedure|Arteriography|knee arteriography
80007821|NCT01376765|Other|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
79534650|NCT06007235|Device|CACIPLIQ20|CACIPLIQ20 contains RGTA heparan sulphate mimetics
79534651|NCT06007235|Drug|Placebo|Saline solution in identical spray bottles
79691381|NCT04699370|Other|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
80007822|NCT01376765|Biological|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
80007823|NCT04404205|Diagnostic Test|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
80007824|NCT04788563|Other|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
79240644|NCT03654443|Diagnostic Test|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
79240645|NCT04867161|Diagnostic Test|Inflammatory markers sampling|"Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~microbiology: microscopic examination, standard cultivation test~biochemistry: albumin, total protein~Pathology: cytology~PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load"
79240646|NCT03653819|Other|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
79380396|NCT01007773|Drug|Propofol|Propofol will be titrated to an ICP < 20 mm Hg until achievement of sustained ICP control.
79380397|NCT01004640|Genetic|DNA analysis|
80007825|NCT04788563|Drug|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
79240647|NCT03653819|Other|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
79240648|NCT03653663|Drug|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
79240649|NCT03653663|Drug|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
79240650|NCT02521857|Drug|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
79240651|NCT03468387|Procedure|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
79240652|NCT03468387|Procedure|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
79380398|NCT01004640|Genetic|Southern blotting|
79380399|NCT01004640|Genetic|cytogenetic analysis|Correlative studies
79534652|NCT06006871|Behavioral|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).
79534653|NCT06006871|Drug|Usual treatment for ADHD|All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
79534654|NCT06003231|Drug|disitamab vedotin|Given into the vein (IV, intravenous) every 2 weeks
79534655|NCT06002204|Other|Observational Study|No Treatment or Intervention Provided
79380400|NCT01004640|Genetic|polymerase chain reaction|
79380401|NCT00966979|Device|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
80007826|NCT04788563|Other|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
80007827|NCT04788563|Drug|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
79380402|NCT00936663|Drug|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
79380403|NCT00936663|Drug|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
79534656|NCT06001268|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
79691382|NCT02901210|Procedure|Modified delorme procedure|
79691383|NCT04699448|Other|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
79691384|NCT01220128|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
80007828|NCT04788563|Other|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
79534657|NCT06001268|Behavioral|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
80007829|NCT04788563|Drug|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
79240653|NCT03460509|Drug|Sugammadex|Dose-response
80007830|NCT05196347|Drug|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip <20%.
80007831|NCT03092479|Behavioral|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
80007832|NCT01358201|Drug|vINCRISTINE|
79240654|NCT03879915|Procedure|Dental Implant placement|Surgical placement of dental implant not associated with prior or concurrent bone augmentation
79534658|NCT06001268|Behavioral|Survey|Participants will take a survey at baseline and weeks 4,8,& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
79691385|NCT01220128|Drug|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
80007833|NCT01358201|Drug|Dexamethasone|
80007834|NCT01358201|Drug|Methotrexate|
80007835|NCT01358201|Drug|Cytosine arabinoside|
80007836|NCT00732797|Behavioral|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
80007837|NCT00732797|Behavioral|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
80007838|NCT03086551|Device|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
80007839|NCT03086551|Device|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
80007840|NCT03086551|Behavioral|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
80007841|NCT01375439|Other|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
79240655|NCT03460431|Device|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm session, every month for 4 months
79240656|NCT03460431|Device|Nd YAG laser1064 nm|Nd YAG laser1064 nm laser session, every month for 4 months
79240657|NCT04452903|Behavioral|communication skills|3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
80007842|NCT05193773|Other|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
79240658|NCT02979431|Biological|ALX-0171 3.0 mg/kg|
79240659|NCT02979431|Biological|ALX-0171 6.0 mg/kg|
79240660|NCT02979431|Biological|ALX-0171 9.0 mg/kg|
79240661|NCT02979431|Other|Placebo|
79240662|NCT03460275|Drug|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
79240663|NCT03460197|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
79240664|NCT03460119|Device|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
79240665|NCT03468231|Drug|Sorafenib|Oral Sorafenib, 400mg, Bid
79240666|NCT03468231|Drug|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
79240667|NCT03468231|Drug|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
79303065|NCT04996407|Device|draping fabric|Patients were given a draping fabric
79303066|NCT02476799|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
80007843|NCT05193617|Drug|GP+Peramprizumab+Anlotinib|GP combine with peramprizumab and anlotinib neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy
79691386|NCT01220128|Drug|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
79837176|NCT00752024|Device|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
79837177|NCT00752024|Drug|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
79837178|NCT04046952|Device|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
79240668|NCT03652883|Other|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
79837179|NCT04046952|Device|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
79837180|NCT00937599|Dietary Supplement|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
79837181|NCT00937677|Drug|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
79837182|NCT00786162|Other|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
79837183|NCT00786162|Other|BP cuff at workplace|Provided BP cuff for communal use at the worksite
79837184|NCT00778986|Device|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
79240669|NCT03652883|Other|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
79534659|NCT05999253|Procedure|Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~to be administered only approximately 20-30 minutes before the onset of anaesthesia."
79534660|NCT05999253|Procedure|Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~to be administered only approximately 20-30 minutes before the onset of anaesthesia"
79534661|NCT05997771|Other|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
79837185|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
79240670|NCT03468153|Biological|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
79534664|NCT05989828|Biological|Aldesleukin|Given IV
79691387|NCT01220128|Drug|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79691388|NCT01220128|Drug|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
79691389|NCT01220128|Drug|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79240671|NCT03653195|Other|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
79837186|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
79837187|NCT04498923|Drug|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
79240672|NCT03460041|Drug|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
79240673|NCT03460041|Drug|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
79240674|NCT03460041|Drug|Bupivacaine|Caudal bupivacaine for pain management
79837188|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
79837189|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
79837190|NCT04046874|Drug|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
79534665|NCT05989828|Biological|Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|Given IV
79837191|NCT04046874|Other|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
79534666|NCT05989828|Procedure|Biopsy|Undergo biopsy of breast tumor
79837192|NCT00932217|Drug|filgrastim|subcutaneous filgrastim administration
79240675|NCT03459885|Device|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
79837193|NCT00932217|Drug|lenograstim|subcutaneous lenograstim administration
79534667|NCT05989828|Procedure|Biospecimen Collection|Undergo blood sample collection
79534668|NCT05989828|Procedure|Computed Tomography|Undergo CT scan
79534669|NCT05989828|Drug|Cyclophosphamide|Given IV
79534670|NCT05989828|Procedure|Echocardiography|Undergo ECHO
79534671|NCT05989828|Drug|Fludarabine|Given IV
79534672|NCT05989828|Procedure|Leukapheresis|Undergo leukapheresis
79837194|NCT00786318|Drug|ziprasidone|ziprasidone 20mg IM
79837195|NCT00786318|Drug|Standard therapy|Haldol 5mg/ Ativan 2mg IM
79837196|NCT00783666|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
79837197|NCT00566631|Drug|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
79837198|NCT00932295|Other|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
79837199|NCT00932295|Other|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
79837200|NCT00932295|Other|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
79837201|NCT00932295|Other|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
79240676|NCT03622151|Other|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
79240677|NCT02522013|Drug|Aminophylline|
79240678|NCT02522013|Drug|isotonic saline|
79240679|NCT03459573|Behavioral|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
79240680|NCT03459573|Behavioral|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
79534673|NCT05989828|Procedure|Magnetic Resonance Imaging|Undergo breast MRI
79534674|NCT05989828|Procedure|Mammogram|Undergo mammogram
79534675|NCT05989828|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
79534676|NCT05989828|Procedure|Ultrasound Imaging|Undergo ultrasound of breast
79534677|NCT05989672|Biological|HSVTI Formulation 1|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F1 Group.
79534678|NCT05989672|Biological|HSVTI Formulation 2|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F2 Group.
79534679|NCT05989672|Biological|Placebo|This intervention will be administered intramuscular as 2 doses to Placebo group.
79534680|NCT05989048|Drug|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
79534681|NCT05989048|Drug|Placebo|Single dose of matching placebo taken within Treatment Phase.
79534682|NCT05988658|Device|ESTOP - AKI 2.0|Medical software as a Noninvasive medical device, which at the time of the project will not implement directly into subject/clinical care.
79837202|NCT04014699|Procedure|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
79837203|NCT04014699|Procedure|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
79837204|NCT00937911|Drug|YM150|oral
79837205|NCT00937989|Other|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
79837206|NCT00937989|Other|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
79837207|NCT00937989|Other|medical chart review|Baseline, 3, 6 and 9 months after starting the study
79837208|NCT00937989|Other|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
79691390|NCT01220128|Drug|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79691391|NCT01220128|Drug|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79691392|NCT01220128|Drug|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79691393|NCT01220128|Drug|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79691394|NCT01220128|Drug|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
79534683|NCT05987449|Drug|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
79837209|NCT00937989|Other|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
79837210|NCT00937989|Procedure|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
79240681|NCT03459573|Behavioral|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
79240682|NCT02978417|Drug|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
79240683|NCT02978417|Drug|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
79380404|NCT00931606|Biological|Sotatercept|up to 4 subcutaneous doses of sotatercept given once every 28 days
79534684|NCT05982093|Drug|Elacestrant|Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
79534685|NCT05982093|Drug|Triptorelin|Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
79534686|NCT05980533|Diagnostic Test|Ultrasound|Ultrasound at hospital discharge and at follow up at 7-10 days
79534687|NCT05977907|Drug|Pembrolizumab|Pembrolizumab is an investigational drug in this study
79534688|NCT05977907|Drug|IO102-103|IO102-103 is an investigational drug in this study.
79380405|NCT00931606|Drug|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
79380406|NCT00912587|Drug|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
79380407|NCT00776035|Procedure|PET (positron Emission Tomography)|this is a diagnostic scan that requires the injection of radioactive tracers into an IV placed in the arm.
79380408|NCT00776035|Procedure|Echocardiogram|an ultrasound of the heart
79380409|NCT00776035|Procedure|VO2 peak test|walking on a treadmill during which you will breath in and out through a tube
79380410|NCT00776035|Procedure|Body composition Study|a scan of your entire body measuring Body Mass Index, fat percentage etc...
79380411|NCT00776035|Radiation|15O water|radioactive tracer used to study blood flow during the PET scan
79380412|NCT00776035|Radiation|11C Acetate|radioactive tracer that helps study heart metabolism
79380413|NCT00776035|Radiation|11C Palmitate|radioactive tracer used to study fatty acid usage in the heart
79380414|NCT00776035|Radiation|11C Glucose|radioactive tracer usde to study glucose usage in the heart
79380415|NCT00681343|Drug|Thymoglobulin|Induction
79380416|NCT00681343|Drug|Campath-1H|Induction
79380417|NCT00681343|Drug|Daclizumab|Induction
79534689|NCT05970731|Drug|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
79691395|NCT04699409|Other|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
79691396|NCT04699409|Other|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
79837211|NCT00938067|Behavioral|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
80007844|NCT05193617|Drug|GP+Peramprizumab|GP combine with peramprizumab neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy
79240684|NCT03459183|Device|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
79240685|NCT03459183|Device|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
79240686|NCT03459183|Device|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
79240687|NCT03459183|Device|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
79534690|NCT05970731|Other|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
79691397|NCT05424588|Diagnostic Test|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
79691398|NCT04698941|Drug|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m^2 on Day 1 of each 21-day cycle.
79240688|NCT03458637|Behavioral|LITE Program and Usual Care|Family based lifestyle Intervention
79240689|NCT03458637|Behavioral|Usual Care|Usual care consisting of 3 visits to weight management clinic
79380418|NCT00665457|Biological|filgrastim|
79380419|NCT00665457|Drug|capecitabine|
79837212|NCT00938223|Biological|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
79691399|NCT04698941|Drug|Simvastatin|20mg daily oral tablet taken.
79534691|NCT05970731|Device|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
79691400|NCT04206202|Device|3D-Printed Patient-Specific Intramedullary Guide|The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.
79691401|NCT02901288|Drug|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
79691402|NCT02901288|Drug|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
79691403|NCT02901288|Drug|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
79837213|NCT04014777|Biological|NGM621|NGM621 Dose 1
79837214|NCT04014777|Biological|NGM621|NGM621 Dose 2
79837215|NCT04014777|Biological|NGM621|NGM621 Dose 3
79240690|NCT03458559|Drug|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
79240691|NCT03458559|Drug|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
79240692|NCT02522091|Device|functional brain MRI|
79240693|NCT02522091|Other|Neuropsychology tests|
79240694|NCT03458169|Device|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
79303067|NCT02476799|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
79380420|NCT00665457|Drug|celecoxib|
79380421|NCT00665457|Drug|cyclophosphamide|
79380422|NCT00665457|Drug|docetaxel|
79380423|NCT00665457|Drug|doxorubicin hydrochloride|
79380424|NCT00665457|Genetic|gene expression analysis|
79380425|NCT00665457|Genetic|polymorphism analysis|
79380426|NCT00665457|Genetic|protein expression analysis|
79380427|NCT00665457|Genetic|reverse transcriptase-polymerase chain reaction|
79380428|NCT00665457|Other|imaging biomarker analysis|
79380429|NCT00665457|Other|immunohistochemistry staining method|
79380430|NCT00665457|Other|laboratory biomarker analysis|
79380431|NCT00665457|Other|pharmacogenomic studies|
79380432|NCT00665457|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79534692|NCT05968573|Other|Video Format|A video created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
79534693|NCT05968573|Other|Health Educator|The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
79837216|NCT04014777|Biological|NGM621|NGM621 Dose 4
80007845|NCT03265249|Device|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
79534694|NCT05968339|Other|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
79534695|NCT05966636|Procedure|Fractional CO2 Laser Ablative Resurfacing|Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
79534696|NCT05964868|Drug|Liposomal Bupivacaine|Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
79240695|NCT03458169|Device|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
79534697|NCT05964868|Drug|0.25% bupivacaine with 1:200,000 epinephrine|Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
79240696|NCT03458169|Device|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
79240697|NCT03457623|Other|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
79380433|NCT00665457|Procedure|needle biopsy|
79380434|NCT00665457|Procedure|neoadjuvant therapy|
79691404|NCT02901288|Drug|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
79240698|NCT03457545|Behavioral|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
79691405|NCT02901288|Drug|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
79691406|NCT00448643|Radiation|Vaginal Brachytherapy|High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
79837217|NCT00930891|Drug|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
79837218|NCT00930891|Drug|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
79837219|NCT00930891|Drug|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
79240699|NCT03457545|Other|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
79240700|NCT03457467|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
79240701|NCT03457467|Radiation|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
79240702|NCT03467841|Device|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
79240703|NCT03130335|Procedure|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
79240704|NCT03130335|Biological|BMA|Bone marrow will be aspirated from the iliac crest.
79380435|NCT00665457|Procedure|radiomammography|
79380436|NCT00665457|Procedure|ultrasound imaging|
79380437|NCT00613041|Procedure|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
79380438|NCT00597870|Device|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
79380439|NCT00574730|Drug|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
79380440|NCT00574730|Drug|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
79380441|NCT00518167|Behavioral|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~weight reduction~dietary fibre 15 g /1000 kcal or more~energy proportion of dietary fat less than 30%~energy proportion of saturated fat less than 10%~moderate physical activity >30 minutes per day or 4 hours per week"
79691407|NCT00448643|Drug|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
79380442|NCT00503269|Procedure|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
79380443|NCT00503269|Procedure|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
79837220|NCT00938301|Drug|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
79691408|NCT00448643|Radiation|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
80007846|NCT04778111|Other|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
80007847|NCT04772261|Diagnostic Test|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
79837221|NCT00938301|Drug|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
80007848|NCT05193461|Procedure|Pulsed mood radiofrequency on dorsal root ganglion|3) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
80007849|NCT04726475|Behavioral|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
80007850|NCT04726475|Dietary Supplement|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
80007851|NCT04726475|Dietary Supplement|Placebo Oil|3ml oral dose of MCT coconut oil.
80007852|NCT05183945|Device|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
80007853|NCT05183945|Device|Coil|A coil which is used for preoperative localization of lung nodules.
79380444|NCT00496756|Drug|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
79380445|NCT00483561|Drug|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
79380446|NCT00483366|Drug|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~500 mg/m2 bid~600 mg/m2 bid~600 mg/m2 bid~725 mg/m2 bid~725 mg/m2 bid~850 mg/m2 bid~850 mg/m2 bid"
79380447|NCT00483366|Drug|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~550 mg/m2~550 mg/m2~675 mg/m2~675 mg/m2~825 mg/m2~825 mg/m2~1000 mg/m2"
79380448|NCT00483366|Drug|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d"
79380449|NCT00483366|Genetic|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
79691409|NCT03276455|Genetic|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
79691410|NCT00448799|Radiation|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of [123I] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
79691411|NCT02901327|Procedure|Lumbar Stabilisation Exercise|"McGill protocol starting with:~'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~'curl-up' exercise 10 repetitions with 7 seconds hold each~'side-bridge' exercise 10 repetitions with 7 seconds hold each~'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
79691412|NCT02901327|Procedure|treadmill walk exercise|"Bruce protocol~This include:~'5 minutes warm up' at zero degree inclination.~'20 minutes active exercise with increasing speed and inclination'~'5 minutes cool down'"
79837222|NCT00938379|Drug|20% deet insect repellent|skin-applied repellent lotion
80007854|NCT02951767|Drug|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
80007855|NCT05182541|Other|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
79240705|NCT03456297|Other|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
79240706|NCT05191875|Drug|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g * 6, Produced by The French encyclopedia pharmaceutical Factory"
79303068|NCT02476799|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
79837223|NCT00938379|Drug|placebo control|Identical base formulation of lotion but without any deet active
80007856|NCT05182541|Other|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
80007857|NCT05182541|Other|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
79837224|NCT00938535|Behavioral|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
80007858|NCT05182541|Other|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
80007859|NCT05181839|Drug|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
80007860|NCT05760833|Procedure|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
79691413|NCT05424393|Drug|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
80007861|NCT05170763|Drug|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
80007862|NCT05170763|Drug|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
80007863|NCT05170763|Drug|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
80007864|NCT05170763|Drug|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
80007865|NCT05170763|Drug|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
80007866|NCT05170763|Drug|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
80007867|NCT05170763|Drug|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
80007868|NCT05734391|Diagnostic Test|Routine Infection control|routine part of hospital IPC activities
80007869|NCT03093181|Other|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
79240707|NCT05191875|Drug|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g * 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg * 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
79240708|NCT03454971|Other|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~Consultation with a hospital pharmacist~Consultation with a nurse care coordinator~Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~potential medical interactions,~possible adverse effects of therapy,~information on the prescribed drug,~informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
79240709|NCT04475679|Device|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth surface
79240710|NCT04475679|Device|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth
79240711|NCT03467607|Procedure|tidal volume ventilation|low tidal volume ventilation
79240712|NCT04370145|Drug|Sulperazon|moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
79691414|NCT05424393|Drug|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
79837225|NCT00661830|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
79837226|NCT00661830|Drug|Placebo|Placebo
80007870|NCT03093181|Other|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
80007871|NCT03093181|Other|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
79837227|NCT00661830|Drug|Sorafenib|Sorafenib 400 mg bid orally continuously
80007872|NCT03093181|Other|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
80007873|NCT05200091|Other|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~Forward tilt of base of support;~Backward tilt of base of support;~Translation forward;~Translation backward;~Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
80007874|NCT04666181|Behavioral|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
80007875|NCT02922439|Behavioral|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
80007876|NCT02922439|Behavioral|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
80007877|NCT05199623|Drug|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
80007878|NCT05199623|Behavioral|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
80007879|NCT05413031|Device|relative motion splint|splint with ability to move the fingers
80007880|NCT05413031|Device|static splint|splint with immobility of wrist, and fingers
80007881|NCT03091777|Drug|GDC-229|GDC-229 is a vaginal gel.
80007882|NCT03091777|Drug|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
80007883|NCT03091777|Drug|Placebo|Inactive arm of the study
80007884|NCT04648085|Device|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
79240713|NCT04370145|Drug|Teicoplanin|severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
79240714|NCT04370145|Drug|Meropenem Injection|cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
79240715|NCT03453723|Procedure|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
79240716|NCT03453723|Drug|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
79380450|NCT00483366|Genetic|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
79534698|NCT05964868|Other|Placebo - Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
79691415|NCT05424354|Device|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
79837228|NCT00932529|Drug|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
80007885|NCT03632837|Device|Hemoadsorption|see arm description
80007886|NCT04624997|Other|biological sample|biological sample
80007887|NCT05601947|Other|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
80007888|NCT05601947|Other|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
79240717|NCT03634683|Biological|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
79240718|NCT03452787|Other|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
79534699|NCT05963139|Drug|Bupivacaine|US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.
79534700|NCT05963139|Drug|Morphine Sulfate|In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
79534701|NCT05950399|Procedure|Echocardiography|Undergo resting echocardiography
79534702|NCT05950399|Other|Electronic Health Record Review|Ancillary studies
79534703|NCT05950399|Other|Questionnaire Administration|Ancillary studies
80007889|NCT05392361|Drug|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
80007890|NCT05392361|Drug|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
80007891|NCT05760755|Behavioral|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
80007892|NCT05335655|Drug|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
80007893|NCT05335655|Drug|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
80007894|NCT04589351|Drug|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
79240719|NCT04774965|Device|Slumber Curve sleep aid|Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
79380451|NCT00483366|Genetic|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
79380452|NCT00290368|Procedure|Skin Prick Test|
79380453|NCT00290368|Procedure|Nasal allergen challenge|
80007895|NCT04589351|Drug|Placebo|Matching placebo
80007896|NCT05202743|Other|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
79380454|NCT00290368|Procedure|Nasal filter paper placement|
79534704|NCT05950399|Procedure|Stress Echocardiography|Undergo stress echocardiography
79534705|NCT05948189|Other|exercise program|The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
79691416|NCT05424354|Other|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
80007897|NCT04580615|Device|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
80007898|NCT02818998|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
80007899|NCT05042219|Diagnostic Test|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
79240720|NCT03452709|Behavioral|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
79240721|NCT03452709|Device|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
79691417|NCT00448838|Biological|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
79691418|NCT00448838|Drug|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
79691419|NCT00448838|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
79837229|NCT00932529|Drug|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
80007900|NCT05579015|Device|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to ~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
79240722|NCT03577119|Dietary Supplement|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
79380455|NCT00290368|Procedure|Nasal lavage|
79380456|NCT00290368|Procedure|Nasal scrape|
79837230|NCT00932529|Drug|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
79837231|NCT00932529|Drug|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
79837232|NCT00783744|Drug|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
79837233|NCT00783744|Drug|Glimepiride|Glimepiride 3 or 4 mg
79837234|NCT00783744|Drug|Metformin|At least 850 mg od
80007901|NCT05579015|Other|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
79380457|NCT00290368|Procedure|Nasal symptoms score|
79380458|NCT00278083|Drug|Study drug administration|
79837235|NCT00783744|Drug|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
79837236|NCT00932607|Drug|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
79837237|NCT00783822|Other|RGCT|rapid genetic counseling and testing
79837238|NCT00932685|Drug|Midazolam|Midazolam 0.5mg/kg
80007902|NCT05575583|Device|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
80007903|NCT05575583|Device|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
80007904|NCT02821416|Biological|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
80007905|NCT02821416|Other|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
80007906|NCT03108521|Drug|Sitagliptin|100mg.QD for 3 months
79691420|NCT03455244|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
79691421|NCT03276338|Behavioral|HOLA|To increase condom use and HIV testing
79691422|NCT01219933|Drug|methylprednisolone|starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
79691423|NCT01219933|Drug|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
79691424|NCT00448877|Device|fNIR light emitting and sensing device|
80007907|NCT03992274|Other|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
79240723|NCT03577119|Dietary Supplement|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
79691425|NCT05368441|Drug|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
79837239|NCT00932685|Device|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
79837240|NCT05000346|Drug|Drug, inhalation|Solution administered by inhalation
80007908|NCT04500509|Drug|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
79240724|NCT03452553|Device|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
79240725|NCT03452475|Drug|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
79240726|NCT03452475|Drug|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
79240727|NCT03452475|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
79380459|NCT00278083|Procedure|Tuberculin intradermal skin test|
79380460|NCT00278083|Procedure|Lung function test for FEV1|
79380461|NCT00278083|Procedure|Asthma symptom scores diary|
79380462|NCT00278083|Procedure|Quality of life diary|
79837241|NCT00931125|Drug|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
79837242|NCT00931125|Procedure|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
79837243|NCT00789984|Device|noncontact specular microscopy|
79837244|NCT00932763|Drug|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
79837245|NCT00932763|Drug|Norvasc|10 mg dose (Pfizer, USA)
79240728|NCT03451461|Other|No intervention|Observational study. Clinical data recorded
79240729|NCT03451305|Other|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
79380463|NCT00278083|Procedure|Breath nitric oxide|
79380464|NCT00278083|Procedure|Breath condensate|
79380465|NCT00278083|Procedure|Sputum induction|
79380466|NCT00278083|Procedure|Blood sampling|
79380467|NCT00278083|Procedure|Urinalysis|
79380468|NCT00159341|Procedure|Nasal lavage|Nasal lavage was carried out at specified timepoints
79380469|NCT00159341|Procedure|Nasal filter paper|Nasal filter paper was placed at specified timepoints
80007909|NCT04500509|Drug|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
80007910|NCT03854838|Drug|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
80007911|NCT03854838|Radiation|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
79240730|NCT03451227|Drug|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
79380470|NCT00159341|Procedure|Blood sampling|Blood sampling was performed as a routine safety check
79380471|NCT00135642|Biological|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
79380472|NCT00135642|Procedure|Venepuncture: 20 ml blood sample taken on 2 separate visits|
79837246|NCT00786396|Behavioral|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
79380473|NCT03338946|Device|CIED interrogation|CareLink Express interrogation
79380474|NCT03338868|Other|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
79380475|NCT03338868|Other|Physical activity level|assessed by the International Physical Activity Questionnaire-7
79380476|NCT03338868|Other|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
79380477|NCT03338868|Other|Quality of life|assessed by the Nottingham Health Profile
79380478|NCT03338868|Other|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
79380479|NCT03338868|Diagnostic Test|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
79380480|NCT04494204|Combination Product|Immunofree tablets and Reginmune capsule|2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
79691426|NCT05368441|Drug|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
79691427|NCT00448955|Drug|ARD-0403|ARD-0403
79691428|NCT05657080|Device|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
79691429|NCT02901015|Behavioral|Assessment battery A|"Social cognition tests version A are administered to the patients"
80007912|NCT05001191|Other|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
80007913|NCT05760599|Drug|Candonilimab|10mg/kg, iv.drip, every 3 week
80007914|NCT05760599|Drug|Bevacizumab|15mg/kg, iv.drip, every 3 week
80007915|NCT04454255|Behavioral|FunSpeech|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
80007916|NCT04454255|Behavioral|Control|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
79240731|NCT03451227|Drug|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
79380481|NCT03330444|Procedure|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
79691430|NCT02901015|Behavioral|Assessment battery B|"Social cognition tests version B are administered to the patients"
79240732|NCT03449277|Drug|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
79240733|NCT03508323|Drug|Teneligliptin|20mg/qd
79240734|NCT03508323|Drug|Placebo|1T/qd
79240735|NCT02529813|Drug|Cyclophosphamide|Given IV
79240736|NCT02529813|Drug|Fludarabine Phosphate|Given IV
79240737|NCT02529813|Other|Laboratory Biomarker Analysis|Correlative studies
79380482|NCT03330366|Dietary Supplement|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
79380483|NCT03330366|Dietary Supplement|Placebo|take two capsules per day
79380484|NCT03334578|Drug|Gastrografin|Gastrografin group
79380485|NCT02493972|Procedure|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
79380486|NCT02493972|Procedure|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
79380487|NCT03330210|Procedure|3D printing|Manufacturing and use of a model printed in 3D
79380488|NCT03338478|Diagnostic Test|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
79380489|NCT02492412|Drug|HE 10|
79380490|NCT02492412|Drug|Restasis|
79380491|NCT03330054|Device|fundoscope|Fundoscope for eye examination
79380492|NCT03329898|Procedure|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
79691431|NCT04316845|Diagnostic Test|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
79691432|NCT05423886|Other|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
79691433|NCT00449228|Procedure|-preoperative education and total hip replacement|-preoperative education and total hip replacement
79240738|NCT02529813|Biological|Tisagenlecleucel|Given IV
79240739|NCT03129711|Other|glazed Celtra Duo|zirconia reinforced lithium silicate
79240740|NCT03129711|Other|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
79240741|NCT03440463|Behavioral|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
79534706|NCT05946629|Device|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
79534707|NCT05946629|Device|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain < 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
79837247|NCT04014543|Other|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
79837248|NCT00783900|Other|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
79837249|NCT00932841|Other|Placebo|One packet PO daily x 8 weeks.
79837250|NCT00932841|Drug|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
79534708|NCT05946278|Other|Sample collection for gene expression|This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
79691434|NCT01218802|Drug|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
79691435|NCT01218802|Drug|Placebo|participants will take a sugar pill daily for 96 weeks
79691436|NCT00449267|Device|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
79691437|NCT02887222|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
79691438|NCT01218646|Biological|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
79691439|NCT01218646|Biological|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
79691440|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
79691441|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
79837251|NCT00932841|Drug|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
79837252|NCT00783978|Other|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
79837253|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
79837254|NCT00938613|Drug|Placebo|nasal spray, one spray per nostril at time 0
79837255|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
79837256|NCT00786552|Drug|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
79240742|NCT03440463|Behavioral|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
79240743|NCT03440463|Behavioral|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
79240744|NCT05322057|Drug|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
79240745|NCT03433599|Other|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
79837257|NCT00938691|Procedure|Intradermal Suture|
79837258|NCT00938691|Procedure|Intradermal Suture|
79691442|NCT02901171|Behavioral|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
79691443|NCT02901171|Behavioral|ACT group treatment|
80007917|NCT04442945|Drug|ANAVEX3-71|Active oral dose of ANAVEX3-71
80007918|NCT04442945|Drug|Placebo|Oral placebo
79240746|NCT03433599|Other|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
79380493|NCT03329898|Device|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
79380494|NCT03329898|Drug|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
79380495|NCT03329898|Drug|dydrogesterone Tablets|oral dydrogesterone Tablets
79380496|NCT03334110|Procedure|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
79380497|NCT03334110|Procedure|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
79380498|NCT03329742|Other|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
79380499|NCT03329742|Other|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
79380500|NCT03329664|Biological|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
79380501|NCT03329664|Other|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
79380502|NCT03338322|Device|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
79380503|NCT03338322|Device|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
79380504|NCT02493816|Drug|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
79380505|NCT02492568|Drug|pembrolizumab|
79380506|NCT02492568|Radiation|Stereotactic Body Radiation Therapy|
79380507|NCT03329586|Other|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
79380508|NCT03334032|Other|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
79380509|NCT01722292|Drug|LY2940680|Administered orally
79380510|NCT01722292|Drug|Carboplatin|Administered IV
79380511|NCT01722292|Drug|Etoposide|Administered IV
79534709|NCT05945615|Drug|Oxymetazoline 0.1% (Pf) Oph Soln Ud|"Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis."
79534710|NCT05945615|Other|Preservative free lubricating drops|Over the counter ophthalmic lubricating drop.
79534711|NCT05937906|Drug|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
79691444|NCT02901171|Behavioral|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
79691445|NCT00449345|Procedure|Blood test for Quantiferon-GOLD assay|
80007919|NCT04441073|Drug|Lignocaine|preoperative nebulization of lignocaine
80007920|NCT04441073|Drug|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
79380512|NCT01722292|Drug|Placebo|Administered orally
80007921|NCT03633539|Procedure|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
79240747|NCT03433599|Other|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
79303069|NCT02476799|Drug|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
79380513|NCT03329430|Other|Foot orthoses|Customized foot orthoses
79380514|NCT02494050|Behavioral|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
79534712|NCT05937906|Drug|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
79691446|NCT02900937|Device|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
79691447|NCT00449384|Behavioral|Diagnostic Screening|
79691448|NCT00449423|Drug|acipimox|
79837259|NCT04046640|Device|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a NEC InfRec R450 infrared thermal imaging camera~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
79837260|NCT00938769|Other|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
80007922|NCT03633539|Procedure|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
79380515|NCT02494050|Behavioral|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
79380516|NCT02494050|Behavioral|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
79534713|NCT05937906|Drug|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
79534714|NCT05937906|Drug|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
79534715|NCT05937906|Drug|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
79534716|NCT05937854|Drug|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
79534717|NCT05937854|Drug|Placebo|one or two encapsulated tablets of placebo po QD
79534718|NCT05926960|Drug|encorafenib|encorafenib
79534719|NCT05926960|Drug|binimetinib|binimetinib
79837261|NCT00938769|Other|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
80007923|NCT02036034|Device|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
80007924|NCT02036034|Device|warming blanket|warming blanket placed on torso of patient under the drape.
79303070|NCT02449369|Drug|Preop acetaminophen IV|
79303071|NCT02449369|Drug|Preop orphenadrine IV|
79303072|NCT02449369|Drug|Postop oral oxycodone & acetaminophen|
79303073|NCT02449369|Drug|Postop hydromorphone IV|
79303074|NCT02449369|Drug|Postop oral orphenadrine|
79534720|NCT05926960|Drug|pembrolizumab|pembrolizumab
79534721|NCT05926960|Drug|ipilimumab|ipilimumab
79534722|NCT05926960|Drug|nivolumab|nivolumab
79534723|NCT05925582|Other|vestibular based exercise program|this group's participants will involve in vestibular based exercise program
79534724|NCT05925582|Other|calisthenic based exercise program|this group's participants will involve in calisthenic based exercise program
79534725|NCT05920824|Diagnostic Test|Echocardiogram|Ultrasound scan of the heart
79534726|NCT05917249|Device|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
79534727|NCT05917119|Other|BLT|Bright light therapy delivered via glasses
79691449|NCT05423847|Diagnostic Test|POCUS|POCUS of lungs, pericardium and abdomen
79691450|NCT00449462|Procedure|consumption of CLA enriched food|
79691451|NCT00449501|Drug|Budesonide/formoterol pMDI|
79691452|NCT00449501|Drug|Budesonide HFA pMDI|
79303075|NCT02449369|Drug|Postop oral oxycodone|
79303076|NCT02449369|Drug|Postop acetaminophen IV|
79303077|NCT02449369|Drug|Postop orphenadrine IV|
79305686|NCT02453165|Procedure|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
79691453|NCT03276299|Other|six minute walking test|six minute walking test
79691454|NCT03276299|Other|six minute walking test|six minute walking test with encouragement
80007925|NCT04343989|Drug|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
80007926|NCT04343989|Drug|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
80007927|NCT04343989|Other|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
80007928|NCT05598073|Behavioral|Vinyasa yoga session|One hour of vinyasa yoga will be completed.
80007929|NCT04089787|Other|Intervention|Shortened antibiotic treatment of 5 days
80007930|NCT04089787|Other|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
79380517|NCT02249494|Other|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
80007931|NCT02817828|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
79691455|NCT04680078|Procedure|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
79837262|NCT04047186|Drug|Nivolumab Injection|Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
80007932|NCT03632681|Drug|Intranasal Insulin|Intranasal insulin
79837263|NCT00931203|Drug|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
80007933|NCT03632681|Drug|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
80007934|NCT05483387|Device|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
79837264|NCT00784056|Drug|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
80007935|NCT05597995|Drug|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
79240748|NCT03433599|Other|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
79380518|NCT02249494|Other|nutritional counseling|Performing routine nutritional counseling in their clinical practice
79380519|NCT02249494|Device|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
79380520|NCT02493894|Drug|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
79380521|NCT02493894|Drug|placebo|placebo each 8 hours for 24 hours
79837265|NCT00540592|Biological|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
79837266|NCT00540592|Biological|Fluarix|Single dose, Intramuscular injection
79240749|NCT05321823|Device|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
79240750|NCT05321823|Other|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
79240751|NCT05321823|Diagnostic Test|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
79240752|NCT05321823|Diagnostic Test|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
79691456|NCT04680078|Procedure|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
79691457|NCT03276260|Device|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
79691458|NCT02900820|Other|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
79240753|NCT03449121|Behavioral|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
79240754|NCT03449043|Other|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
79534728|NCT05917119|Other|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
79534729|NCT05914909|Biological|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
79534730|NCT05914909|Other|Placebo|Placebo
79534731|NCT05913544|Other|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
79691459|NCT02900820|Other|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
79691460|NCT03276182|Device|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
79691461|NCT01188772|Drug|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
79691462|NCT01188772|Drug|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
79691463|NCT01188772|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
79691464|NCT01188772|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
79837267|NCT03970395|Other|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
79837268|NCT03970395|Other|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
79837269|NCT03970395|Other|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
79837270|NCT00790140|Dietary Supplement|Prosure|This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
79240755|NCT03448965|Diagnostic Test|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
79240756|NCT05321589|Other|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
79240757|NCT05321511|Drug|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
79240758|NCT05321511|Drug|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
79240759|NCT05321511|Drug|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
79240760|NCT02733627|Drug|BI 1467335|
79240761|NCT02733627|Drug|Placebo|
79240762|NCT02417103|Drug|GLP-1 (Liraglutide)|GLP-1 Analogon
79240763|NCT02417103|Drug|Placebo|Placebo
79380522|NCT02493894|Drug|Cefazolin|cefazolin 1gram, every 6hours for 2 days
79380523|NCT03338166|Other|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
79380524|NCT02493738|Drug|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
79691465|NCT00449579|Device|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
79691466|NCT04679883|Drug|5% GLH8NDE|5% GLH8NDE as eye drops
79380525|NCT02493738|Drug|Sporanox 100mg|Sporanox 100mg single dose under fed condition
79691467|NCT04679883|Drug|Placebo|Placebo as eye drops
79837271|NCT00790140|Dietary Supplement|Ensure Plus|This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
80007936|NCT04880057|Other|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition[3]. It took the participants 25 minutes to complete AeT."
80007937|NCT04880057|Other|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
80007938|NCT02817906|Drug|ITI-007|
80007939|NCT02817906|Drug|Placebo|
80007940|NCT05597605|Device|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
80007941|NCT04338971|Device|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
79240764|NCT02097225|Drug|Dabrafenib|Given PO
79240765|NCT02097225|Other|Laboratory Biomarker Analysis|Correlative studies
79240766|NCT02097225|Drug|Onalespib|Given IV
79380526|NCT03333798|Behavioral|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~The Cognitive-Behavioral model~Tackling traumatic events~Cognitive reprocessing~Relaxation techniques~Prevention of revictimization~Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
79240767|NCT02097225|Other|Pharmacological Study|Correlative studies
79240768|NCT02097225|Drug|Trametinib|Given PO
79380527|NCT03333798|Behavioral|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
79380528|NCT02493582|Biological|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
79380529|NCT02493582|Drug|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
79380530|NCT05560360|Drug|SHR1459 tablet|100 mg/tablet; administered orally
79534732|NCT05912257|Behavioral|Structured perioperative nutrition and exercise|Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.
79534733|NCT05912257|Behavioral|Nutrition and Exercise Counseling|nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
79380531|NCT05560360|Drug|Efavirenz tablet|600 mg/tablet; administered orally
79534734|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 1|Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
79534735|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 2|Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
79837272|NCT00565773|Drug|Belatacept|Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
79534736|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 3|Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
79240769|NCT02958865|Drug|PF-06651600 or Placebo|Delivered orally for 8 weeks.
79240770|NCT02958865|Drug|PF-06700841 or Placebo|Delivered orally for 8 weeks.
79240771|NCT02958865|Drug|PF-06700841|Delivered orally for 24 weeks.
79240772|NCT02958865|Drug|PF-06651600|Delivered orally for 24 weeks.
79240773|NCT01990209|Drug|Orteronel|
79240774|NCT05321277|Dietary Supplement|Walnuts|Participants will consume 56 g of walnuts daily for 3 weeks. Participants will also follow a diet devoid of ellagitannin-rich, high fiber, and fermented foods.
79380532|NCT03329118|Drug|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
79534737|NCT05907213|Drug|Ketamine (Ketalar) Dose Level 4|Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
79534738|NCT05906368|Diagnostic Test|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
79691468|NCT01188655|Drug|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
79534739|NCT05906368|Diagnostic Test|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
79240775|NCT05321277|Dietary Supplement|No-nut diet|Participants will exclude all nuts and nut-derived products; high-fiber, fermented and ellagitannin-rich foods will also be excluded.
79691469|NCT02900703|Biological|stool samples|
79240776|NCT03141099|Other|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
79380533|NCT03333720|Dietary Supplement|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
79380534|NCT01723384|Drug|Intermittent Oral Naltrexone|
79534740|NCT05904743|Biological|Afrezza|Pharmaceutical form: powder Route of administration: inhalation
79534741|NCT05904743|Biological|insulin degludec|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79534742|NCT05904743|Biological|Rapid-acting Insulin Analog|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
79534743|NCT05904743|Biological|Basal Insulin|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
79534744|NCT05904522|Diagnostic Test|biopsy|biopsy for histopathological examination
79534745|NCT05904392|Other|Music|Music played prior to injection
79691470|NCT00449618|Drug|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
79691471|NCT00449618|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
79691472|NCT00449618|Procedure|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
79691473|NCT00449618|Drug|Placebo|Use of placebo on awakening versus bedtime
79691474|NCT01188538|Drug|Epiduo gel|Once daily application on the face in the evening for 12 weeks
79691475|NCT01188538|Drug|BPO|Once daily application on the face in the evening for 12 weeks
79691476|NCT04316767|Behavioral|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
79691477|NCT00449657|Drug|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
79691478|NCT00449657|Procedure|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
79691479|NCT00449657|Drug|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 & 9
79240777|NCT03141099|Other|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
79240778|NCT03141099|Other|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
79534746|NCT05902780|Drug|Caudal Bupivacaine injection|- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
79534747|NCT05902780|Drug|Caudal Dexmedetomidine Injection|- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
79534748|NCT05895786|Drug|PF-06823859|anti-interferon beta therapy
79534749|NCT05895786|Drug|Placebo|Placebo for PF-06823859
79534750|NCT05890872|Device|Aliya Pulsed Electric Fields (PEF)|Percutaneous or Endobronchial PEF
80007942|NCT03796650|Other|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
79691480|NCT00449657|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 & 9
79691481|NCT04318444|Drug|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
79691482|NCT04318444|Drug|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
79691483|NCT02900898|Other|Dynamic exercise and Mediterranean diet|DE, MD
79691484|NCT02900898|Other|Dynamic exercise|DE
79691485|NCT02900898|Other|Mediterranean diet|MD
79240779|NCT03141099|Other|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
79240780|NCT03448887|Device|Theranova|Extended HD with theranova
79691486|NCT02900898|Other|Control|Control
79837273|NCT00565773|Drug|Sirolimus|Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
79837274|NCT00565773|Drug|Alemtuzumab|All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
79837275|NCT00932919|Behavioral|Thought field therapy|5 sessions with Thought field therapy
79837276|NCT00932919|Behavioral|Cognitive therapy|12 sessions of Cognitive therapy
80007943|NCT03796650|Drug|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
79837277|NCT00932919|Behavioral|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
79837278|NCT00932997|Behavioral|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
80007944|NCT05597527|Drug|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
80007945|NCT04234295|Procedure|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
79240781|NCT03448887|Device|Online hemodiafiltration|Online hemodiafiltration
79240782|NCT02958553|Device|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
79240783|NCT02958553|Device|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
79240784|NCT02501902|Drug|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
79380535|NCT01723384|Drug|Placebo|
79380536|NCT03329040|Other|No Intervention.|No intervention.
79534752|NCT05888831|Drug|BMS-986449|Specified dose on specified days
79534753|NCT05888831|Drug|Nivolumab|Specified dose on specified days
79534754|NCT05887284|Radiation|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
79534755|NCT05887284|Radiation|mock radiation treatment|6 times 0.0 Gy
79691487|NCT03276143|Drug|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
79837279|NCT00932997|Other|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
79837280|NCT00932997|Other|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
79837281|NCT00932997|Other|questionnaire administration|Baseline and 9 months after enrollment and intervention
79837282|NCT00932997|Procedure|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
79837283|NCT00932997|Procedure|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
79837284|NCT00570492|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
80007946|NCT02912143|Other|documentation only|
80007947|NCT05198999|Other|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
80007948|NCT05198999|Other|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
80007949|NCT02036112|Procedure|conventional ELAPE|device
80007950|NCT02036112|Procedure|Individual ELAPE|device
80007951|NCT05707416|Device|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
80007952|NCT05707416|Other|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
79380537|NCT02492490|Other|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
79380538|NCT02492490|Drug|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
79534756|NCT05887284|Radiation|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
80007953|NCT02036268|Behavioral|Standard|Standard ostomy education
79240785|NCT02501902|Drug|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
79534757|NCT05883410|Other|Exercise|It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program
79691488|NCT03276143|Drug|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
79691489|NCT03276143|Drug|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
79691490|NCT05423574|Procedure|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
79691491|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
80007954|NCT02036268|Behavioral|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
79240786|NCT03641833|Diagnostic Test|blood sample for brain biomarkers|Transcranial Doppler will be performed to evaluate a.cerebri media blood flow speed during surgery.
80007955|NCT02036268|Behavioral|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
80007956|NCT04749251|Procedure|Individualized blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
80007957|NCT04749251|Procedure|Standard blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
80007958|NCT04215185|Device|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
80007959|NCT04187495|Drug|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
79240787|NCT03641599|Diagnostic Test|echocardiography|echocardiographic assessment of the RV and LV systolic function
79240788|NCT03076047|Device|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
79240789|NCT03640429|Device|non-invasive blood pressure monitor|non-invasive oscillometric blood pressure monitor will be applied at the arm, forearm, and at the wrist.
79380539|NCT03328962|Behavioral|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
79534758|NCT05883410|Other|PNF Technique|While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.
79534759|NCT05883410|Other|Mulligan Mobilization|In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
79534760|NCT05877963|Biological|Ublituximab|Administered as an IV infusion.
79534761|NCT05877196|Behavioral|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
79837285|NCT00570492|Drug|Placebo nasal spray|Placebo nasal spray
80007960|NCT03633383|Device|Transcatheter aortic valve|Self-expandable aortic valve prothesis
79240790|NCT03640429|Device|invasive blood pressure monitor|invasive blood pressure monitor will be connected to a cannula inserted at the radial artery.
79240791|NCT05320575|Drug|Zanubrutinib|The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
80007961|NCT05198141|Drug|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
80007962|NCT05198141|Procedure|laparoscopic salpingectomy|laparoscopic salpingectomy
80007963|NCT02813694|Drug|lefamulin|antibacterial agent
80007964|NCT02813694|Drug|Moxifloxacin|antibacterial agent
80007965|NCT03632161|Drug|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
80007966|NCT03632161|Drug|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
80007967|NCT03631459|Drug|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
79240792|NCT03740217|Drug|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
79240793|NCT05320341|Procedure|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
79380540|NCT03333642|Procedure|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
79380541|NCT03333564|Dietary Supplement|VD3|50,000 IU VD3 / week for 8 weeks
79380542|NCT03333564|Dietary Supplement|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
79380543|NCT03333564|Dietary Supplement|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
79380544|NCT03333564|Other|Control|No intervention was given
79380545|NCT05464446|Device|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
79380546|NCT02493504|Drug|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
79534762|NCT05877196|Behavioral|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
79534763|NCT05877196|Behavioral|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
80007968|NCT03103919|Device|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
80007969|NCT03103919|Device|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
79534764|NCT05877196|Behavioral|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
79534765|NCT05869773|Drug|JZP258|0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
79691492|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
80007970|NCT03103919|Drug|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
80007971|NCT01568203|Drug|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
79240794|NCT05320341|Procedure|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
79240795|NCT03448731|Drug|Doxycycline 50Mg Tablet|Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
79534766|NCT05864872|Procedure|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
79691493|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
79837286|NCT00931281|Drug|ABT-450|capsules, QD or BID, 14 days, ascending doses
79837287|NCT00931281|Drug|ritonavir|capsules, QD or BID, 14 days, ascending doses
79837288|NCT00931281|Drug|Placebo for ABT-450|capsule, QD or BID, 14 days
79837289|NCT00931281|Drug|Placebo for ritonavir|capsule, QD or BID, 14 days
79837290|NCT00933075|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
79837291|NCT04014855|Drug|Iron Supplement|in iron deficiency anemia
80007972|NCT01568203|Drug|Placebo|Matching placebo control for AMG 579 at each dose level
80007973|NCT02036892|Behavioral|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
80007974|NCT02036892|Behavioral|Lifestyle counseling|Lifestyle counseling
80007975|NCT04173325|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
80007976|NCT04173325|Drug|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
80007977|NCT05597449|Behavioral|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
79240796|NCT01955109|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
79534767|NCT05862545|Drug|BGF (budesonide/glycopyrrolate/formoterol fumarate)|BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.
79691494|NCT00449774|Drug|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
79691495|NCT00449774|Drug|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
79837292|NCT00933153|Dietary Supplement|Ensure Plus|Ensure plus supplement with meals
79691496|NCT02900742|Drug|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
79691497|NCT02900742|Drug|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
79837293|NCT00933153|Dietary Supplement|Meals on Wheels|Two Meals on Wheels twice daily
79837294|NCT00571922|Drug|Acamprosate|2 gr/day (333 mg, TID)
80007978|NCT02810964|Drug|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
80007979|NCT02810964|Drug|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
80007980|NCT05596123|Behavioral|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
80007981|NCT05596123|Behavioral|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
80007982|NCT04392947|Device|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
80007983|NCT04392947|Device|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
80007984|NCT05591131|Other|genetic testing|Undergo genetic testing
80007985|NCT05591131|Other|Survey Administration|Complete survey
80007986|NCT02036346|Dietary Supplement|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
80007987|NCT02036346|Other|Advise on calculated oral fluid requirements|
79240797|NCT04452669|Drug|VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)|VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
79240798|NCT03467997|Behavioral|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
79240799|NCT03467997|Other|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
79380547|NCT03333330|Drug|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
79380548|NCT00706914|Drug|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
79380549|NCT00706914|Drug|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
79380550|NCT00706914|Drug|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
79837295|NCT00571922|Drug|placebo|matching placebo
80007988|NCT02036346|Other|No nutritional advice will be given|
80007989|NCT02810652|Other|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
79534768|NCT05857644|Drug|PF-07923568|One time dose of 4 capsules taken orally.
79837296|NCT00786630|Behavioral|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
79837297|NCT00786630|Behavioral|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
79837298|NCT00933231|Drug|tacrolimus|Standard dose, Oral
79837299|NCT00933231|Drug|tacrolimus|Low dose, Oral
79837300|NCT00933231|Biological|Simulect|IV
80007990|NCT02810652|Other|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
80007991|NCT05197985|Behavioral|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
80007992|NCT02742883|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
80007993|NCT05760131|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
80007994|NCT04167943|Drug|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
80007995|NCT04073147|Drug|Venetoclax|Venetoclax per os
80007996|NCT04073147|Drug|Obinutuzumab|ObintuzumabIV
80007997|NCT02707159|Drug|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
79380551|NCT00706914|Drug|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
79380552|NCT03337776|Other|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
79534769|NCT05853289|Other|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
79691498|NCT02900742|Drug|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
79691499|NCT02900742|Drug|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
79691500|NCT02900742|Drug|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
79691501|NCT02900742|Drug|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
79691502|NCT02900742|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
79691503|NCT00449813|Drug|Pantoprazole|40 mg Pantoprazole
79691504|NCT01188226|Device|Denture teeth|Denture teeth made of nano hybrid composite material
79691505|NCT02900547|Other|Patients with systolic heart failure|
79691506|NCT05423067|Procedure|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
79837301|NCT00933231|Drug|Cellcept|Oral
79837302|NCT00933231|Drug|Corticosteroids|IV and Oral
79837303|NCT00933231|Drug|Ramipril|Oral
79837304|NCT00933231|Drug|Irbesartan|Oral
79837305|NCT00746876|Device|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
79240800|NCT04452279|Device|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
79240801|NCT05304897|Procedure|Conventional treatment|Conventional treatments for Tracheobronchial fistula, including the application of metallic endoclips
79534770|NCT05848791|Other|Exercise exposure|Participants are exposed to three different air quality environments in central London, chosen to maximise differences in nontailpipe air pollution. Participants will cycle at 60% of estimated maximum vo2 on static bikes for six 15 minute bouts with 15 minutes rest between bouts.
79691507|NCT01218100|Drug|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
79691508|NCT01218100|Drug|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
79691509|NCT01218100|Drug|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
79691510|NCT01218100|Drug|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
79691511|NCT02900508|Other|Exergaming training|
79691512|NCT02900508|Other|Physical therapy intervention|
79837306|NCT00746876|Device|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
79837307|NCT00790374|Drug|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
79837308|NCT00790374|Drug|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
79837309|NCT00790374|Drug|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
79837310|NCT04054466|Behavioral|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
79837311|NCT04054466|Behavioral|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
79837312|NCT03489525|Biological|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
79837313|NCT03489525|Biological|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
79837314|NCT00784212|Drug|BGG492|
79837315|NCT00784212|Drug|BGG492|
79837316|NCT00784212|Drug|Placebo|
79837317|NCT00752180|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
80007998|NCT05197907|Procedure|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
80007999|NCT05197907|Procedure|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
80008000|NCT04113187|Drug|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
79534771|NCT05848011|Biological|lorigerlimab|Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
79534772|NCT05848011|Drug|docetaxel|Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
79691513|NCT02900196|Other|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
79837318|NCT00752180|Biological|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
79837319|NCT00784290|Drug|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
79240802|NCT05304897|Procedure|PRP treatment|PRP treatment following the conventional treatment for Tracheobronchial fistula
79240803|NCT03811041|Other|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
80008001|NCT04113187|Drug|Placebo|per os, twice a day (morning and evening) during three months
79240804|NCT03811041|Other|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
80008002|NCT03103763|Drug|Warfarin|Patients on warfarin for atrial fibrillation
80008003|NCT04092127|Other|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
80008004|NCT05197517|Drug|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
79240805|NCT03811041|Other|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
79240806|NCT03719001|Drug|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
79534773|NCT05848011|Drug|Prednisone|A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
79534774|NCT05842174|Drug|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
79534775|NCT05842174|Drug|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
79240807|NCT03719001|Drug|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
79240808|NCT03719001|Drug|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
79240809|NCT03719001|Other|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
79240810|NCT03719001|Other|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
79240811|NCT03719001|Drug|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
79240812|NCT02500732|Drug|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
79691514|NCT02900196|Other|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
79691515|NCT02900313|Other|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
79240813|NCT02500732|Drug|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
79240814|NCT03448497|Other|Non-interventional|Non-interventional
79240815|NCT02518048|Drug|LEO 90100 Aerosol foam|
79240816|NCT02518048|Drug|Betesil® 2.25 mg|
79691516|NCT00449852|Behavioral|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
79837320|NCT00752336|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
79240817|NCT03129399|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
79534776|NCT05842174|Drug|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
79837321|NCT00752414|Drug|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
79837322|NCT00752414|Drug|Placebo|same frequency as MP-376
79837323|NCT00790530|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
79837324|NCT00790530|Other|Usual Care|Usual Care
79240818|NCT03129399|Device|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
79305687|NCT02453165|Procedure|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
79305688|NCT02453243|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
79305689|NCT02453243|Behavioral|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
79691517|NCT04681209|Behavioral|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
79691518|NCT04681209|Behavioral|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
79240819|NCT03792711|Dietary Supplement|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
79240820|NCT03448809|Behavioral|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
79240821|NCT03448809|Behavioral|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
79837325|NCT03396562|Other|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years.
80008005|NCT05499559|Behavioral|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
79240822|NCT05009914|Procedure|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
79240823|NCT03788577|Dietary Supplement|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
79380553|NCT03337776|Other|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
79380554|NCT03328728|Device|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
79380555|NCT03328728|Device|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
79380556|NCT03333174|Diagnostic Test|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
79380557|NCT03328572|Other|E-max Endocrown|Endocrown preparation
79534777|NCT05840471|Drug|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
79691519|NCT05423028|Procedure|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
79691520|NCT02900235|Drug|MT-3995|
79691521|NCT00449969|Device|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
79691522|NCT00449969|Device|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
79691523|NCT05422989|Diagnostic Test|X-ray, CT|Just a diagnostic procedure to confirm the diagnosis
80008006|NCT04011475|Drug|Tiotropium + Olodaterol|Spiolto®
79380558|NCT03328572|Other|Cerasmart Endocrown|Endocrown preparation
79380559|NCT03328494|Drug|BOS172722|Oral capsules
79837326|NCT02554266|Device|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
80008007|NCT04011475|Drug|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
80008008|NCT04011475|Drug|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
79534778|NCT05840471|Other|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
79534779|NCT05840107|Biological|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
79534780|NCT05838625|Device|Digital Therapeutic|A prescription digital therapeutic in the form of a smartphone app.
79534781|NCT05831124|Other|Low dose multivalent pneumococcal conjugate vaccine formulation A|Biological
79837327|NCT00786942|Procedure|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
79837328|NCT00786942|Procedure|higi tibial osteotomy|the gap of the tibia is unfilled
79534782|NCT05831124|Other|Low dose multivalent pneumococcal conjugate vaccine formulation B|Biological
79240824|NCT03788577|Dietary Supplement|Placebo|Placebo
79240825|NCT03129243|Diagnostic Test|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
79380560|NCT03328494|Drug|Paclitaxel|IV infusion
79837329|NCT02193958|Drug|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
80008009|NCT05063903|Other|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
80008010|NCT04212221|Drug|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
79380561|NCT02491398|Drug|Bendamustine + Rituximab|
79534783|NCT05831124|Biological|Low dose of multivalent pneumococcal conjugate vaccine control|low dose multivalent pneumococcal conjugate vaccine
79534784|NCT05831124|Biological|Standard dose multivalent pneumococcal conjugate vaccine control|multivalent pneumococcal conjugate vaccine
79240826|NCT03448575|Other|Control - Provider Medication Alert Only|Simple text medication alert referencing Choosing Wisely guidelines.
79534785|NCT05827978|Biological|mRNA-1010|Sterile liquid for injection
79534786|NCT05827978|Biological|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
79534787|NCT05818085|Drug|ABP-671|Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
79534788|NCT05818085|Drug|Allopurinol|Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
79837330|NCT00686894|Procedure|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
79240827|NCT03448575|Other|Intervention - Alert + CAP Review AND Enhanced BH Access|Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
79240828|NCT03448263|Procedure|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
79837331|NCT00686894|Drug|Infliximab|"5 mg/kg~IV~Frequency : weeks 0,2,6"
79837332|NCT00328627|Drug|Alogliptin|Alogliptin tablets.
79837333|NCT00328627|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
79380562|NCT03337464|Other|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
79380563|NCT03333096|Device|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
79380564|NCT03333096|Diagnostic Test|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
79534789|NCT05818085|Other|Placebo|ABP-671 matching placebo
79534790|NCT05813912|Drug|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
79534791|NCT05813912|Drug|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
79837334|NCT00328627|Drug|Pioglitazone|Pioglitazone tablets.
79837335|NCT00328627|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
79380565|NCT02492256|Device|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
79534792|NCT05813288|Drug|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
80008011|NCT04212221|Drug|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
80008012|NCT03663335|Biological|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
80008013|NCT03663335|Drug|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
79380566|NCT02492256|Device|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
79534793|NCT05813288|Drug|Placebo|Oral administration of placebo tablet
79534794|NCT05809934|Drug|AZD2693|AZD2693 solution SC once per month
80008014|NCT03632915|Drug|Levetiracetam|Standard of care
79534795|NCT05809934|Other|Placebo|Sodium chloride 0.9% solution SC once per month
79534796|NCT05800743|Device|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
79534797|NCT05800743|Device|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
79534798|NCT05800743|Procedure|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
80008015|NCT03632915|Drug|Lacosamide|Standard of care
80008016|NCT03632915|Drug|Phenytoin|Standard of care
79380567|NCT02492256|Device|ILR implantation|Implantation the ECG loop recorder according to standard procedure
80008017|NCT03632915|Drug|Phenobarbital|Standard of care
79380568|NCT03337386|Diagnostic Test|inferior vena cava collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
79380569|NCT03337386|Diagnostic Test|subclavian vein collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
79380570|NCT03337386|Diagnostic Test|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
79534799|NCT05790668|Behavioral|Traditional Schedule Thinning|During traditional schedule thinning during functional communication training with discriminative stimuli (e.g., multiple schedules, chained schedules), practitioners correlate a unique stimulus with reinforcement (e.g., a green card) and another for extinction (e.g., a red card). When the reinforcement and extinction stimuli are presented, the child's communication responses are honored or not honored, respectively. Behavior analysts begin with a brief period of extinction (e.g., 2 s) and gradually increase that duration as the child displays low levels of destructive behavior and high levels of discriminated communication responses (i.e., communication requests during reinforcement components only) until the child reaches a terminal schedule informed by caregiver/child preference (e.g., 2.5-min reinforcement, 10-min extinction). Typically, the starting extinction period is brief and arbitrarily selected and there are no competing stimuli programmed.
79534800|NCT05790668|Behavioral|PIA-Informed Schedule Thinning|This intervention involves the same general components as Traditional Schedule Thinning. However, rather than starting with an arbitrary duration of the extinction component (e.g., 2 s), the behavior analyst empirically derives the starting point based on a progressive-interval assessment (PIA). The PIA involves rapidly increasing the duration of the extinction component within a single session to determine the leanest schedule of reinforcement that does not produce untoward effects. Behavior analysts will progress through the following extinction durations within a single session: 3 s, 11 s , 21 s, 34 s, 50 s, 70 s, 95 s, 126 s, 164 s, 213 s, and 270 s. For example, if the participant displays destructive behavior at 164 s consistently, but not at 126 s, the experimenters will start schedule thinning with a 126-s extinction component. There will be no competing stimuli programmed in this intervention.
80008018|NCT03632915|Drug|Ketamine|Standard of care
80008019|NCT03632915|Drug|Valproic Acid|Standard of care
80008020|NCT04836845|Device|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
80008021|NCT04836845|Device|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
80008022|NCT04836845|Device|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
80008023|NCT03538535|Behavioral|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
79691524|NCT00450008|Drug|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
79534801|NCT05790668|Behavioral|PIA-Informed Schedule Thinning with Competing Stimuli|This intervention is identical to PIA-Informed Schedule Thinning except that behavior analysts will program competing activities (e.g., alternative activities like toys or therapist attention) during extinction components. The competing stimuli will be derived from a competing stimulus assessment in which destructive behavior is analyzed across various conditions in which only the activity is manipulated during the extinction period (e.g., a session with action figures during extinction, a session with tablet during extinction). The items that produce the highest levels of child engagement and lowest levels of destructive behavior are known as highly competing items.
79691525|NCT00450008|Drug|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
79691526|NCT00450008|Drug|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
79691527|NCT02900469|Biological|denosumab|denosumab: 120 mg subcutaneous injection
79691528|NCT02900469|Procedure|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
79691529|NCT00450047|Device|Speed-feedback therapy system with a bicycle ergometer|
80008024|NCT04769375|Other|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
80008025|NCT04769375|Other|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
80008026|NCT04769375|Other|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
79240829|NCT03448263|Procedure|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
79691530|NCT00450047|Device|Ergometer at conventional settings|
79691531|NCT00450086|Drug|Budesonide|9 mg per day
79691532|NCT00450086|Drug|Mesalazine|3 g per day
79691533|NCT00450086|Drug|Placebo|0 g per day
79691534|NCT05422950|Other|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
79240830|NCT03448263|Procedure|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
79691535|NCT05422911|Drug|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
79691536|NCT05422911|Drug|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
79691537|NCT05422911|Drug|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
79380571|NCT03328416|Device|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
79380572|NCT03333018|Drug|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
79691538|NCT00450125|Other|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
79691539|NCT00450125|Other|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
79691540|NCT00450164|Procedure|esofagic varices ligation|
79691541|NCT00450164|Drug|Nadolol|
79691542|NCT00450164|Drug|Isosorbide mononitrate|
79691543|NCT00450164|Drug|Prazosin|
79691544|NCT02900430|Other|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
79691545|NCT02900430|Drug|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
80008027|NCT03524729|Device|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
79240831|NCT02499952|Drug|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
79240832|NCT02499406|Behavioral|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
79380573|NCT03333018|Drug|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
79691546|NCT05422833|Other|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
79691547|NCT02900040|Other|kidney transplantation|
79691548|NCT00450203|Biological|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
79691549|NCT00450203|Drug|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
80008028|NCT03524729|Device|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
80008029|NCT03524729|Device|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
79691550|NCT00450203|Drug|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
80008030|NCT04717505|Other|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
80008031|NCT04717505|Other|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
80008032|NCT04717505|Other|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
80008033|NCT04717505|Other|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
80008034|NCT05649605|Drug|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
79691551|NCT00450203|Drug|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
79691552|NCT00450203|Procedure|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
79691553|NCT00450203|Procedure|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
80008035|NCT05649605|Other|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
79691554|NCT00450203|Procedure|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
79691555|NCT00450203|Drug|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
80008036|NCT05321927|Device|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.
79240833|NCT05113485|Behavioral|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
79240834|NCT05113485|Behavioral|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
80008037|NCT05321927|Other|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
80008038|NCT05321927|Device|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
80008039|NCT04712123|Other|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
80008040|NCT05312021|Drug|IMR-687|150 mg and 200 mg tablets
80008041|NCT05312021|Other|IMR-687 Placebo|Matching placebo to IMR-687
80008042|NCT05640479|Drug|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
80008043|NCT05640479|Drug|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
80008044|NCT05309525|Drug|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
80008045|NCT05309525|Drug|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
79380574|NCT03333018|Drug|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
79380575|NCT03328260|Device|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
79380576|NCT03332940|Drug|Tc 99M Sulfur Colloid|Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
79380577|NCT03332940|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
79380578|NCT03332862|Procedure|catheter ablation|catheter ablation for atrial fibrillation treatment
79380579|NCT03327948|Device|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
79380580|NCT03337230|Behavioral|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
80008046|NCT03101267|Drug|ASP4070|Intradermal vaccination at 2-week intervals
80008047|NCT03101267|Drug|Placebo|Intradermal vaccination at 2-week intervals
80008048|NCT04922801|Diagnostic Test|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
80008049|NCT04922801|Diagnostic Test|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
79240835|NCT03333135|Procedure|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
79240836|NCT03333135|Procedure|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
79380581|NCT03337230|Behavioral|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
79380582|NCT03337230|Behavioral|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
79380583|NCT02493348|Device|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
79534802|NCT05790005|Other|therapeutic play|2 days after the operation, 1 hour before the dressing, a warm-up game will be played with the child in the playroom of the pediatric surgery service, aiming to put the organs prepared by the researcher in their correct places on the picture for the first 10 minutes. Then, the teddy bear, which is given the appearance of an operation area by sewing a zipper on his stomach, will be given to the child and he will be asked to make the first dressing of the teddy bear. therapeutic game, in which the dramatization method is used, will last 20 minutes. During the 30-minute play practice, the child's questions will be answered.
79534803|NCT05785624|Drug|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
79691556|NCT05422677|Drug|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
80008050|NCT04922801|Diagnostic Test|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
80008051|NCT04922801|Device|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
80008052|NCT04922801|Diagnostic Test|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
80008053|NCT04911101|Device|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
80008054|NCT04911101|Device|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
80008055|NCT05296187|Device|TEAS|Transcutaneous electrical acupuncture stimulation
80008056|NCT04905563|Drug|Acetaminophen-Hydrocodone|Narcotic
80008057|NCT04905563|Drug|Acetaminophen and Ibuprofen|Non-narcotic
80008058|NCT04886219|Other|Eye examination|"Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~ocular biometry~corneal topography~monocular photographs in photopic and scotopic condition"
80008059|NCT02810418|Drug|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
80008060|NCT02810418|Drug|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
80008061|NCT02810418|Device|Mesothelin Expression|Research blood test for Arm B1 eligibility
79380584|NCT03337074|Other|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
79380585|NCT03337074|Other|Questionnaire|Participants are asked to complete a questionnaire.
79380586|NCT03337074|Other|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
79380587|NCT01723696|Dietary Supplement|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
79534804|NCT05785624|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
79534805|NCT05777993|Drug|Mitapivat|Tablets
79691557|NCT00450281|Genetic|chromogenic in situ hybridization|
79691558|NCT00450281|Genetic|gene expression analysis|
80008062|NCT02810418|Drug|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
80008063|NCT05417945|Device|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
79534806|NCT05775848|Drug|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets to provide 3 g BBP-418 per sachet. The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
79534807|NCT05775848|Other|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
79837336|NCT02562248|Other|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
79837337|NCT02562248|Other|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
79837338|NCT03977727|Drug|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
80008064|NCT02959541|Drug|Leucovorin|
80008065|NCT02736305|Drug|Regorafenib|Once a day for 21 days in a 28 days cycle
80008066|NCT05417633|Procedure|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
80008067|NCT04849871|Radiation|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
80008068|NCT02810340|Biological|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
80008069|NCT02810340|Biological|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
79303078|NCT02476331|Behavioral|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
79303079|NCT04989777|Device|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
79303080|NCT03192943|Drug|BMS-986205|Specified dose on specified days
79380588|NCT01723696|Dietary Supplement|Placebo tablet+prenatal vitamin|
79380589|NCT04494282|Procedure|Endoscopic retrograde pancreatography|Endoscopic cannulation of main pancreatic duct
79380590|NCT03332706|Other|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
79380591|NCT01726036|Device|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
79380592|NCT01726036|Device|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
79380593|NCT03327558|Drug|Apriso 0.375G ER CAP|ER capsule
79534808|NCT05775471|Procedure|Biopsy|Undergo tissue biopsy
79691559|NCT00450281|Genetic|mutation analysis|
79691560|NCT00450281|Genetic|polymerase chain reaction|
79691561|NCT00450281|Genetic|polymorphism analysis|
79691562|NCT00450281|Other|fluorescent antibody technique|
79380594|NCT03327558|Drug|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
79380595|NCT02492646|Procedure|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
79380596|NCT02492646|Procedure|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
79534809|NCT05775471|Procedure|Biospecimen Collection|Undergo blood and urine collection
79534810|NCT05775471|Drug|Enfortumab Vedotin|Given IV
79691563|NCT00450281|Other|immunohistochemistry staining method|
79691564|NCT00450281|Other|laboratory biomarker analysis|
79691565|NCT00450281|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
79691566|NCT00450281|Other|study of socioeconomic and demographic variables|
79691567|NCT00450281|Procedure|study of high risk factors|
79691568|NCT02900274|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
79691569|NCT05421390|Other|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
79691570|NCT05421390|Other|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
79837339|NCT03977727|Drug|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
79837340|NCT03977727|Device|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
79837341|NCT02563184|Biological|Fluzone|
79837342|NCT00663858|Drug|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
79534811|NCT05775471|Procedure|MR Urography|Undergo MRU
80008070|NCT02810340|Biological|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
79534812|NCT05775471|Procedure|Nephroureterectomy|Undergo nephroureterectomy
79534813|NCT05775471|Biological|Pembrolizumab|Given IV
79691571|NCT04699097|Drug|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
79691572|NCT02900001|Procedure|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
79534814|NCT05775159|Drug|Volrustomig|CTLA-4/Anti-PD-1 Bispecific Antibody
79534815|NCT05775159|Drug|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
79534816|NCT05775159|Drug|Lenvatinib|Daily use per oral (8 mg capsules/day for participants < 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
79534817|NCT05775159|Drug|Rilvegostomig|anti- PD-1 and TIGIT bispecific antibody
79691573|NCT02900001|Procedure|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
79837343|NCT00663858|Drug|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
79534818|NCT05775159|Drug|Gemcitabine|1000 mg/m2, IV infusion
79534819|NCT05775159|Drug|Cisplatin|25 mg/m2, IV infusion
80008071|NCT05695014|Other|Teach Back Metod|teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
79240837|NCT03443817|Behavioral|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
79240838|NCT02498392|Drug|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
79534820|NCT05768854|Drug|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
79837344|NCT00663858|Other|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
79837345|NCT00749372|Other|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
79534821|NCT05768854|Biological|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
79837346|NCT05223400|Drug|Clindamycin Injection|it is a clindamycin use evaluation study
79534822|NCT05768347|Biological|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
79534823|NCT05765851|Drug|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
79534824|NCT05765851|Drug|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
79534825|NCT05765318|Procedure|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
79534826|NCT05764369|Behavioral|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
79534827|NCT05764369|Behavioral|TAU|The TAU condition is the standard of care offered to parents in RT settings.
79534828|NCT05763719|Behavioral|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
79534829|NCT05763719|Behavioral|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
79534830|NCT05763719|Behavioral|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
79534831|NCT05763329|Drug|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
79534832|NCT05763329|Drug|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
79534833|NCT05763329|Drug|Placebo Day 1|Patients will receive placebo on the first day of sleep test
79534834|NCT05763329|Drug|Placebo Day 2|Patients will receive placebo on the second day of sleep test
79691574|NCT02899923|Other|Data collection|
79691575|NCT00450320|Drug|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
79837347|NCT00790608|Drug|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
79837348|NCT02562014|Other|Glucose|75g glucose
79534835|NCT05763121|Drug|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
79534836|NCT05763121|Drug|Placebo|oral administration of placebo tablet
79837349|NCT02562014|Other|Inulin|75g glucose plus 24g inulin
79837350|NCT02562014|Other|Resistant Starch|75g glucose plus 28.2g resistant starch
80008072|NCT02036658|Behavioral|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
80008073|NCT02036658|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
80008074|NCT05705700|Drug|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
80008075|NCT05705700|Drug|Abiraterone|1000 mg PO daily
79240839|NCT02498392|Other|Placebo|Matching Placebo will be administered orally.
79240840|NCT03205605|Drug|oxybutynin|patch
79380597|NCT01726504|Device|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
79534837|NCT05761301|Drug|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
79534838|NCT05761301|Drug|Placebo|Placebo will be administered by subcutaneous (SC) injection.
79534839|NCT05757219|Drug|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
79534840|NCT05757219|Biological|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
79691576|NCT05421234|Other|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
79691577|NCT00450359|Procedure|breast imaging study|
79691578|NCT00450359|Procedure|comparison of screening methods|
79691579|NCT00450359|Procedure|radiomammography|
79691580|NCT00450398|Drug|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
79691581|NCT00450398|Drug|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
79691582|NCT05421195|Drug|corticosteroids therapy|Oral corticosteroids
79691583|NCT05421195|Other|Olfactory training|repeat and deliberate sniffing of a set of odorants
79691584|NCT00450476|Device|Hi-Lo Evac Endotracheal Tube|
80008076|NCT05227547|Other|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
80016767|NCT04861831|Other|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
80016768|NCT03558126|Device|silicone tube|
79240841|NCT03205605|Drug|oxybutynin|gel
79240842|NCT03443661|Drug|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
79240843|NCT05008588|Biological|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
79240844|NCT05008588|Biological|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10^6 UC-MSCs
79240845|NCT05008588|Procedure|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
79240846|NCT03443583|Other|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
79691585|NCT00450515|Drug|capecitabine|
79691586|NCT00450515|Drug|vinflunine|
79691587|NCT05420259|Behavioral|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
79691588|NCT05420259|Behavioral|Standard Care|Standard Care
79691589|NCT02899845|Other|postural task|
79691590|NCT02899845|Other|walk task|
79380598|NCT01726504|Device|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
79380599|NCT03332472|Other|Telemedicine group|
79380600|NCT03332472|Other|Conventional group|
79380601|NCT02242630|Drug|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
79691591|NCT03276104|Procedure|IOL repositioning|Intraocular lens repositioning by scleral suturing
79837351|NCT00787098|Other|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
79837352|NCT00749450|Drug|capecitabine|Given orally
79380602|NCT02242630|Drug|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
79837353|NCT00749450|Drug|fluorouracil|Given IV
79691592|NCT03276104|Procedure|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
79837354|NCT00749450|Drug|oxaliplatin|Given IV
79837355|NCT00795444|Drug|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
79837356|NCT00790686|Procedure|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
79691593|NCT03275987|Behavioral|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
79691594|NCT03275987|Behavioral|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
79691595|NCT03275987|Behavioral|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
79691596|NCT02956850|Other|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
79691597|NCT02956850|Drug|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
79691598|NCT04699019|Other|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
79691599|NCT04699019|Other|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
79691600|NCT04698863|Device|Oxygen reserve index|eveluating oxygen reserve in blood
79691601|NCT02899806|Other|Written Information|A written information on peridural anesthesia is delivered
79691602|NCT02899806|Other|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
79837357|NCT02561936|Drug|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
79837358|NCT02561936|Drug|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10*2.5 mg tablets.
79837359|NCT02561936|Drug|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10*2.5 mg tablets.
79837360|NCT02561936|Drug|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
79837361|NCT02561936|Dietary Supplement|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter [mL]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) [189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins]).
79837362|NCT00790764|Biological|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
79837363|NCT00790764|Other|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
79837364|NCT00752492|Other|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
79837365|NCT02554968|Other|Questionnaires|
79837366|NCT00752648|Drug|TMC435350|
79303081|NCT03192943|Biological|Nivolumab|Specified dose on specified day
79303082|NCT02724839|Behavioral|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
79303083|NCT02724839|Device|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
79303084|NCT04986813|Drug|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
79303085|NCT04986813|Other|Normal Saline|100 ml
80008077|NCT04796909|Behavioral|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
80008078|NCT04796909|Behavioral|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
79534841|NCT05756582|Diagnostic Test|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection [LTBI] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed [higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
79691603|NCT00450593|Genetic|gene expression analysis|
79240847|NCT03048045|Procedure|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD >/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
79691604|NCT00450593|Genetic|microarray analysis|
79691605|NCT00450593|Genetic|molecular genetic technique|
79691606|NCT00450593|Genetic|mutation analysis|
79691607|NCT00450593|Other|laboratory biomarker analysis|
79691608|NCT00450593|Procedure|mutation carrier screening|
79691609|NCT00450593|Procedure|study of high risk factors|
79240848|NCT03443505|Diagnostic Test|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
79380603|NCT02242630|Drug|Triamcinolone, 20 mg|Compared with methylprednisolone
79691610|NCT05419713|Other|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
79691611|NCT00450671|Procedure|Collagen Plug Placement|
79691612|NCT00450671|Procedure|Seton placement|
79240849|NCT05006950|Device|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
79380604|NCT02242630|Drug|Triamcinolone, 40 mg|Compared with methylprednisolone
79380605|NCT03327480|Other|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
79534842|NCT05754229|Device|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
79534843|NCT05753436|Dietary Supplement|Puritans Pride Turmeric curcumin® 500 mg|Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
79534844|NCT05748600|Drug|Dexpramipexole Dihydrochloride|administration of dexpramipexole tablet
79534845|NCT05748600|Drug|Placebo|administration of placebo tablet
79837367|NCT00790920|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
79837368|NCT00790920|Drug|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
79837369|NCT02563262|Other|body angles measurements during weightlessness|
79837370|NCT04053218|Combination Product|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
79837371|NCT04053218|Dietary Supplement|Placebo|Olive oil placebo
79837372|NCT00659880|Other|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
79837373|NCT00752882|Drug|ceftazidime|
79534846|NCT05747144|Diagnostic Test|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
79534847|NCT05747144|Diagnostic Test|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
80008079|NCT05416619|Device|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
79534848|NCT05747144|Diagnostic Test|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
79691613|NCT05419167|Behavioral|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
79691614|NCT00450710|Procedure|ileal interposition with a sleeve gastrectomy|
79240850|NCT05006638|Drug|Lipid Emulsion, Intravenous|Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
79691615|NCT04698824|Procedure|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
79691616|NCT00450827|Biological|bevacizumab|
79240851|NCT05006638|Drug|Atropine|a drug used as an antidote for some types of pesticides
79240852|NCT05006638|Drug|Toxogonin|a drug used as an antidote for some types of pesticides
79380606|NCT02980744|Behavioral|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
79534849|NCT05747144|Diagnostic Test|Microperimetry|1) fixation pattern 2) retinal sensitivity map
79691617|NCT00450827|Biological|filgrastim|
79240853|NCT05006638|Drug|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
79240854|NCT04451889|Device|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
79240855|NCT03443349|Device|Vibwife One|"Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control."
79240856|NCT02498236|Drug|Intranasal Oxytocin|
79691618|NCT00450827|Procedure|autologous hematopoietic stem cell transplantation|
79691619|NCT00450827|Radiation|iodine I 131 monoclonal antibody 3F8|
80008080|NCT02817516|Drug|TAK-828|TAK-828 solution.
79240857|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
79380607|NCT03109158|Drug|NC-6004|NC-6004 provided by NanoCarrier
79534850|NCT05747144|Diagnostic Test|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
79534851|NCT05740137|Device|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
79534852|NCT05735639|Drug|Dalteparin Sodium|Low molecular weight heparin
79534853|NCT05735639|Drug|Tinzaparin Sodium|Low molecular weight heparin
79534854|NCT05735639|Drug|Enoxaparin Sodium|Low molecular weight heparin
79534855|NCT05735639|Drug|Rivaroxaban|Direct oral anticoagulant
79691620|NCT00450905|Device|PRIMA Device|
79691621|NCT00450944|Biological|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
79691622|NCT05417607|Behavioral|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
79691623|NCT00451061|Drug|Alfuzosin|
79691624|NCT00451061|Drug|Tamsulosin|
80008081|NCT02817516|Drug|Placebo|TAK-828 placebo-matching solution.
79380608|NCT03109158|Drug|Cetuximab|Commercially Available
79240858|NCT01443819|Other|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
79837374|NCT01060735|Dietary Supplement|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
79380609|NCT03109158|Drug|5-FU|Commercially Available
79837375|NCT00747032|Drug|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
79837376|NCT00747032|Drug|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
79837377|NCT01057303|Genetic|RNA analysis|
79240859|NCT01443819|Other|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
79240860|NCT04961086|Other|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
79380610|NCT03324906|Device|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
79380611|NCT03324828|Drug|Hydroxyzine|Hydroxyzine solution
79534856|NCT05735639|Drug|Apixaban|Direct oral anticoagulant
79240861|NCT01283997|Other|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
79380612|NCT03324828|Other|Clowns intervention|Clowns intervention
79534857|NCT05735639|Drug|Dabigatran Etexilate|Direct oral anticoagulant
79691625|NCT03455127|Other|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
79691626|NCT02931578|Other|Glucose100|
79691627|NCT02931578|Other|Glucose50|
79691628|NCT02931578|Other|Glucose42|
79691629|NCT02931578|Other|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
79691630|NCT02931344|Dietary Supplement|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
79691631|NCT02931383|Drug|Liraglutide 3 mg (Saxenda)|
79391359|NCT02418676|Drug|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
79691632|NCT02931383|Drug|Liraglutide 3 mg placebo|
79837378|NCT01057303|Genetic|gene expression analysis|
79534858|NCT05731544|Drug|BMF-219|Investigational Product
79534859|NCT05729373|Drug|SEP-363856|once daily tablet
79534860|NCT05729373|Drug|Placebo|once daily tablet
79534861|NCT05723055|Drug|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
79534862|NCT05723055|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
79534863|NCT05722483|Other|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
79534864|NCT05722418|Biological|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
79691633|NCT02931422|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
79691634|NCT02931461|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
79691635|NCT04593641|Biological|CT-P59|administered
79837379|NCT01057303|Genetic|reverse transcriptase-polymerase chain reaction|
79837380|NCT01057303|Other|laboratory biomarker analysis|
79837381|NCT00683774|Drug|diazoxide|100mg orally three times per day for 10 days
79837382|NCT03741907|Procedure|FAUCS|extraperitoneal cesarean with a paramedian left section
79837383|NCT03741907|Procedure|MLC|Gold standard
79837384|NCT00787410|Drug|ZD1839|250mg tablet, once daily, orally administered
79534865|NCT05720780|Other|MS group|"All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training"
79691636|NCT04341441|Drug|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
79691637|NCT04341441|Drug|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
79691638|NCT04341441|Other|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
79691639|NCT04341441|Diagnostic Test|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
79837385|NCT02555124|Drug|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
79837386|NCT02555124|Drug|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
79240862|NCT01283997|Drug|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
79837387|NCT02555124|Drug|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
79240863|NCT02496676|Dietary Supplement|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
79240864|NCT02496676|Other|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
79240865|NCT02496676|Drug|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
79391360|NCT02418676|Drug|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
79240866|NCT02517268|Procedure|Pancreaticoduodenectomy|
79240867|NCT04957342|Biological|amnion-chorion membrane|allograft to be placed on palate
79240868|NCT04957342|Procedure|Sutures|Sutures (e.g. interrupted, crisscross compression) to be placed on palate
79837388|NCT02555124|Drug|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
79837389|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
79837390|NCT03989557|Device|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
79837391|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
79837392|NCT00787488|Device|Hyperthermia|Every 3 weeks
79837393|NCT01054495|Drug|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
79837394|NCT01054495|Device|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
79837395|NCT01054495|Device|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
79837396|NCT00790998|Drug|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
80008082|NCT05416463|Procedure|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
79240869|NCT05001490|Other|Smartphone application based reminder|Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
79240870|NCT01160211|Drug|lapatinib|1000 mg by mouth once a day
80008083|NCT02498951|Procedure|Cognitive Assessment|Ancillary studies
79691640|NCT04341441|Diagnostic Test|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
79240871|NCT01160211|Drug|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
79240872|NCT01160211|Drug|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
79240873|NCT01160211|Drug|lapatinib|1500 mg by mouth once daily
79380613|NCT03324594|Device|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
79691641|NCT04341441|Diagnostic Test|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
79837397|NCT00790998|Drug|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
79837398|NCT01057459|Other|laboratory biomarker analysis|Correlative studies
79837399|NCT02555046|Procedure|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
79837400|NCT00787878|Drug|somatropin|SGA previously treated with Norditropin®
79837401|NCT00787878|Drug|No treatment given|Untreated SGA
79837402|NCT00787878|Drug|No treatment given|AGA (Average gestational age)
79837403|NCT00787956|Behavioral|Internet Chronic Disease Self-Management Program (ICDSMP)|
79837404|NCT00354679|Biological|bevacizumab|
79837405|NCT00354679|Drug|cisplatin|
79240874|NCT03443271|Procedure|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
79240875|NCT03443271|Procedure|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
79240876|NCT01064687|Drug|LY2189265|
79837406|NCT00354679|Drug|irinotecan hydrochloride|
79837407|NCT00354679|Genetic|proteomic profiling|
79837408|NCT00354679|Other|diagnostic laboratory biomarker analysis|
79837409|NCT00354679|Other|mass spectrometry|
79837410|NCT00354679|Procedure|adjuvant therapy|
79837411|NCT00354679|Procedure|neoadjuvant therapy|
79837412|NCT00354679|Procedure|therapeutic conventional surgery|
79837413|NCT00354679|Radiation|radiation therapy|
79837414|NCT00683696|Device|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
79837415|NCT00345631|Other|Manual Compression|Manual compression
79837416|NCT00345631|Device|Vascular Closure Device|Investigational vascular closure device
79837417|NCT00540514|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
79837418|NCT00540514|Drug|Paclitaxel|Administered by intravenous infusion.
80008084|NCT02498951|Biological|Obinutuzumab|Given IV
80008085|NCT02498951|Other|Quality-of-Life Assessment|Ancillary studies
79240877|NCT01064687|Drug|Exenatide|
79240878|NCT01064687|Drug|Placebo|
79240879|NCT01064687|Drug|Metformin|
79240880|NCT01064687|Drug|Pioglitazone|
79240881|NCT05029167|Other|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
79240882|NCT05029167|Other|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
79837419|NCT00540514|Drug|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate [GFR] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
79837420|NCT00663702|Drug|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
79837421|NCT03986281|Other|Omron Wearable Device|Omron wearable device compared to arterial line readings
79837422|NCT03986281|Other|Standard Arterial Line|Omron wearable device compared to arterial line readings
79837423|NCT02022592|Drug|Lormetazepam|
79837424|NCT02022592|Drug|Midazolam|
79837425|NCT00683618|Drug|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
79837426|NCT00683618|Drug|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
79837427|NCT01057537|Drug|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
80008086|NCT05687214|Other|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~Pompage Cv4;~Occipital-sternal technique;~Relaxining manipulation of the diaphragmatic domes;~Pelvic and abdominal diaphragm synchronization;~Dynamogenic technique;~Mesenteric traction;~Release of colic angles;~Manipulation and mobilization of the sacrum."
79240883|NCT05029167|Other|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
79240884|NCT05029167|Other|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
79380614|NCT03327246|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
79380615|NCT03327168|Drug|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
79380616|NCT03327168|Other|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
79380617|NCT01726738|Drug|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
79691642|NCT04341441|Other|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 &7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
79837428|NCT01057537|Drug|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
79837429|NCT00795678|Drug|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
79837430|NCT00795678|Drug|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
80008087|NCT02260050|Drug|WAL 801 CL dry syrup new formulation|
79240885|NCT04983693|Behavioral|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
79240886|NCT03447873|Drug|Continue with triple therapy|To continue with triple therapy
79240887|NCT03447873|Drug|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
79240888|NCT03447873|Drug|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
79240889|NCT03447795|Procedure|Alveolar ridge preservation|grafting procedure using autogenous tooth.
79240890|NCT02493946|Biological|Botulinum toxin type A|
79240891|NCT02493946|Drug|Placebo|
79240892|NCT03447717|Device|ActiGait|implanted device for peroneal nerve stimulation
79240893|NCT02495337|Other|Tissue Collection|
79240894|NCT02310633|Behavioral|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
79240895|NCT02310633|Behavioral|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
79240896|NCT02310633|Behavioral|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
79380618|NCT02492178|Drug|Intrarectal artesunate|
79380619|NCT02492178|Drug|Intravenous artesunate|
79380620|NCT02492178|Drug|Intravenous quinine|
79380621|NCT03327090|Other|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
79380622|NCT03699280|Other|Virtual Reality|Oculus Go VR device
79380623|NCT03324516|Procedure|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
79691643|NCT04525937|Other|Patient Questionnaire|Patient Questionnaire
79691644|NCT04525937|Other|Provider Questionnaire|Provider Questionnaire
79691645|NCT01187953|Drug|Prograf (tacrolimus)|Administered per current product labeling
80008088|NCT02260050|Drug|WAL 801 CL dry syrup conventional formulation|
79240897|NCT04451967|Procedure|thrombolysis|transfer after thrombolysis for STEMI patients within 6h since onset
79240898|NCT02267421|Behavioral|Home based Aerobic exercise training|
79240899|NCT01064531|Device|MIS Femoral Neck Stem implant|
79380624|NCT03324516|Procedure|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
79380625|NCT05542576|Drug|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
79691646|NCT01187953|Drug|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
79837431|NCT00795678|Drug|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
79837432|NCT00795678|Drug|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
79837433|NCT00795678|Drug|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
79240900|NCT04451811|Drug|OPL-002|Spray dried dispersion and tablet formulation
79240901|NCT03653039|Device|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
79240902|NCT03653039|Device|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
79240903|NCT03621995|Other|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
79380626|NCT03332082|Procedure|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
79380627|NCT03327012|Drug|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
79240904|NCT02220855|Drug|BKM120|
79240905|NCT04054583|Other|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
79380628|NCT03327012|Drug|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
79380629|NCT03683992|Device|Triathlon total knee system|Implantable
79691647|NCT05381259|Behavioral|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
79691648|NCT02900157|Biological|MEDI9090|MEDI9090 will be administered by IV infusion
79691649|NCT02900157|Biological|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
79691650|NCT02931305|Drug|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
79691651|NCT02931305|Drug|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
79691652|NCT04262817|Drug|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
79691653|NCT04262817|Other|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
79240906|NCT03443037|Drug|amantadine sulphate|
79240907|NCT03442959|Other|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
79240908|NCT04915599|Device|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
79240909|NCT03442881|Procedure|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
79240910|NCT03442803|Device|Target-Controlled Infusion|Propofol Target-Controlled Infusion
79380630|NCT03326934|Dietary Supplement|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
79380631|NCT03326934|Dietary Supplement|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
79380632|NCT03326778|Procedure|AVR and CABG|Combined AVR with CABG
79380633|NCT03332004|Drug|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
79380634|NCT03620500|Behavioral|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
79380635|NCT03324204|Other|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
80008089|NCT05415995|Device|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
79240911|NCT03442647|Diagnostic Test|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
79691654|NCT04679259|Diagnostic Test|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
79691655|NCT04679259|Diagnostic Test|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
79837434|NCT00795678|Drug|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
79837435|NCT00795678|Drug|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
79837436|NCT00795678|Drug|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
79837437|NCT00753038|Biological|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
79837438|NCT00753038|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
79837439|NCT00753038|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
79837440|NCT00753116|Device|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
79837441|NCT00795756|Drug|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
79240912|NCT03442491|Procedure|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
79240913|NCT03447561|Behavioral|Anticipatory + consummatory food reward|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
79534866|NCT05720780|Other|C group|All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
79240914|NCT03447561|Behavioral|Consummatory food reward|Exposure to consummatory food reward (drinking sips of chocolate milkshake).
79837442|NCT00795756|Drug|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
79837443|NCT04058522|Other|Rotator cuff rehabilitation classes|
79240915|NCT03447483|Other|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~every 6 weeks for treatment regimen administered every 2 or 3 weeks~at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
79240916|NCT02918279|Drug|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
79240917|NCT02918279|Drug|Placebo|Administered once daily subcutaneously (s.c., under the skin)
79534867|NCT05717283|Diagnostic Test|Nasal swab|We will take nasal swabs from anterior and middle nostril, once a week for each newborn included.
79691656|NCT04679259|Diagnostic Test|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
79691657|NCT02931149|Drug|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
79837444|NCT04058522|Other|Individual Physiotherapy|
79837445|NCT04058522|Drug|Triamcinolone Injection|Subacromial Injection 40mg/1ml
79837446|NCT04004026|Other|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
79837447|NCT00795834|Dietary Supplement|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
80008090|NCT02047656|Drug|LFF269|LFF269 capsules twice daily (b.i.d)
80008091|NCT02047656|Drug|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
80008092|NCT04761965|Diagnostic Test|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
80008093|NCT02047890|Drug|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
80008094|NCT02047890|Drug|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
80008095|NCT02047968|Behavioral|wake therapy|
80008096|NCT02048124|Device|25g standard needle|
79534868|NCT05711576|Other|Non surgical peri-implant mucositis therapy with one-stage full-mouth scaling|Patients were treated with full mouth non surgical peri-implant mucositis therapy performed with only full mouth scaling and root planing
79534869|NCT05711576|Other|Non surgical peri-implant mucositis therapy with one-stage full-mouth scaling and chlorexidine|Patients were treated with full mouth non surgical peri-implant mucositis therapy performed with only full mouth scaling and root planing and chlorexidine
80008097|NCT02048124|Device|25d ProCor needle|
79534870|NCT05705258|Drug|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
79534871|NCT05697809|Drug|OXU-001|Suprachoroidal sustained release dexamethasone acetate
79837448|NCT00795834|Dietary Supplement|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
79837449|NCT00791232|Drug|extended-release (ER) OROS paliperidone|
79380636|NCT03324204|Other|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
79837450|NCT00749840|Behavioral|Questionnaire|Questionnaire taking 60-90 minutes.
80008098|NCT03729102|Biological|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
79240918|NCT03447327|Procedure|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
79240919|NCT04268745|Behavioral|Balance training|Progressive balance training within virtual environments
79240920|NCT04268745|Behavioral|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
79380637|NCT03331926|Drug|Xiapex|Follow-up of effect of treatment
79240921|NCT03447171|Device|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
79240922|NCT00356655|Behavioral|Psychoeducation|
79240923|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
79240924|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
79240925|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
79240926|NCT02956837|Drug|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
79303086|NCT04996329|Other|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
79380638|NCT02490618|Other|Probiotic tablet- Biogaia|
79380639|NCT02490618|Other|Placebo tablet|
79380640|NCT05464290|Procedure|NANOfat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
79380641|NCT03331848|Drug|Placebo oral capsule|BID
79380642|NCT03331848|Drug|PXT002331 - 20mg|Oral
79380643|NCT01728844|Device|beta-tricalcium phosphate alone|
79837451|NCT01563952|Device|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
79837452|NCT01563952|Device|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
79837453|NCT01563952|Device|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
80008099|NCT02036736|Drug|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~Sufentanil (0.15 mg / kg intravenously (IV))~Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
79380644|NCT01728844|Device|GFeBGS 0.1%|
79380645|NCT01728844|Device|GFeBGS 0.3%|
79380646|NCT01728844|Device|GFeBGS 0.4%|
79534872|NCT05697809|Device|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
79534873|NCT05697809|Drug|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
79534874|NCT05696561|Device|Canaloplasty Device|Canaloplasty
79534875|NCT05695950|Drug|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
79534876|NCT05695950|Drug|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
79534877|NCT05693935|Drug|TV-44749 - Dose level 1|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
79534878|NCT05693935|Drug|TV-44749 - Dose level 2|In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
79534879|NCT05693935|Drug|TV-44749 - Dose level 3|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
79534880|NCT05693935|Drug|Placebo|In Period 1, 2 monthly injections (Period 1 only)
79534881|NCT05680077|Diagnostic Test|KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
79534882|NCT05678075|Behavioral|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
79534883|NCT05666206|Procedure|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
79534884|NCT05663580|Drug|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
80008100|NCT02036736|Drug|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~Sufentanil (0.15 mg / kg IV)~Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
80008101|NCT05415839|Device|Laser|Laser
80008102|NCT05693688|Drug|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
79240927|NCT02521935|Device|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination & diagnosis & initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
79691658|NCT04679766|Procedure|Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence|Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
79691659|NCT01217944|Drug|Ranibizumab|0.5 mg ranibizumab intravitreal injection
79691660|NCT01217944|Drug|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
80008103|NCT03813966|Diagnostic Test|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
80008104|NCT03814044|Device|PEEK Suture Anchors|Subjects who have undergone hip joint repair using PEEK Suture Anchors: Bioraptor Knotless Suture Anchor and SpeedLock Hip
80008105|NCT03671850|Biological|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
79240928|NCT02521935|Device|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, & tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
79240929|NCT03447093|Drug|Methimazole Pill|Patients who developed GD received methimazole treatment
79240930|NCT03447093|Drug|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
79380647|NCT04494126|Drug|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
79380648|NCT04494126|Drug|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
79534885|NCT05662293|Other|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
80008106|NCT03671850|Other|Placebo|Peripheral blood mononuclear cell, PBMC
79240931|NCT04054037|Other|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
79240932|NCT03442257|Behavioral|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
79534886|NCT05662293|Other|Data collection: Quality of Life (QoL) Questionnaire (prospective part)|"Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life."
79691661|NCT01217944|Drug|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
79691662|NCT01217944|Drug|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
79691663|NCT04238013|Other|Whole Body Vibration (WBV)|The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
79837454|NCT01563952|Device|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
79837455|NCT00795912|Drug|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
79534887|NCT05662293|Other|Data collection (retrospective study)|Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
79837456|NCT02562794|Behavioral|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
79837457|NCT05360134|Drug|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
79534888|NCT05662293|Other|Data collection (prospective study database)|Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
79837458|NCT05360134|Other|Placebo|Placebo will be given in a similar manner
79534889|NCT05661916|Drug|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
79691664|NCT04238013|Other|Electrical Stimulation|The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
79240933|NCT01063595|Biological|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
79691665|NCT04689737|Drug|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
79837459|NCT00788034|Drug|Lu AA21004|5 or 10 mg/day
79837460|NCT00788034|Drug|Placebo|Once daily
79837461|NCT04058444|Combination Product|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
79837462|NCT05208814|Drug|TPN171H single dose|10 mg TPN171H taken once
80008107|NCT02036814|Behavioral|Program Health Education|
79240934|NCT01063595|Biological|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
79303087|NCT04986735|Drug|Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
79303088|NCT04995783|Diagnostic Test|Coral FRS test|A novel clinical test to predict autoimmune medication response
79534890|NCT05661916|Drug|Placebo|Placebo will be administered by SC injection.
79534891|NCT05653349|Biological|Ianalumab|Intravenous infusion, prepared from concentrate solution
79534892|NCT05653349|Drug|Placebo|Intravenous infusion, prepared from matching placebo
79534893|NCT05653349|Drug|Corticosteroids|Oral or parental (if clinically justified)
79534894|NCT05645406|Drug|Estrogel 0.06 % Topical Gel|estradiol topical products
79534895|NCT05645406|Drug|Compounded estradiol gel|estradiol topical products
79534896|NCT05645393|Drug|topical estrogen product|estrogen topical gel or cream
79534897|NCT05645328|Other|Iowa Cancer Affiliate Network (ICAN)|Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
79837463|NCT04004884|Drug|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
79837464|NCT00688064|Drug|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
79837465|NCT00688064|Drug|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
79837466|NCT00788112|Drug|vorinostat|
79837467|NCT00788112|Genetic|protein expression analysis|
79837468|NCT00788112|Other|immunohistochemistry staining method|
79837469|NCT00788112|Other|laboratory biomarker analysis|
79837470|NCT00788112|Procedure|neoadjuvant therapy|
79837471|NCT00788112|Procedure|therapeutic conventional surgery|
79837472|NCT04058600|Behavioral|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
79837473|NCT00788190|Procedure|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
79837474|NCT00788190|Other|Conservative Management|Conservative management of Distal Radius Fractures
79837475|NCT00749918|Dietary Supplement|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
79837476|NCT00791310|Drug|Flucis|FDG injected i.v
80008108|NCT02048280|Procedure|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
80008109|NCT02048280|Other|NAVA level|Increase NAVA level every 3 minutes
80008110|NCT03562260|Procedure|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
80008111|NCT02047422|Drug|Furosemide|furosemide (doubling previous furosemide dose)
80008112|NCT02047422|Drug|metolazone|metolazone (add 2.5mg qod)
80008113|NCT02047422|Drug|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
80008114|NCT02047422|Drug|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
80008115|NCT02048358|Drug|2B3-201|
79534898|NCT05639556|Diagnostic Test|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
79534899|NCT05639556|Diagnostic Test|Anthropometric Measurements|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
79534900|NCT05639556|Diagnostic Test|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
79534901|NCT05639556|Diagnostic Test|Six-minute walk Test|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
79534902|NCT05639556|Diagnostic Test|Sit-to-Stand Test|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
79534903|NCT05639556|Diagnostic Test|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
79534904|NCT05639556|Diagnostic Test|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
79534905|NCT05639556|Diagnostic Test|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
79534906|NCT05639556|Other|Gastrointestinal (GI) and nutrition questionnaires:|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
79534907|NCT05639556|Other|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
79534908|NCT05639556|Other|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
80008116|NCT02048358|Drug|Placebo|
80008117|NCT02048358|Drug|Methylprednisolone hemisuccinate|
80008118|NCT03562338|Other|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
79303089|NCT03069729|Other|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
79303090|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
79534909|NCT05639556|Other|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
79534910|NCT05639556|Other|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
79534911|NCT05639556|Other|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
79534912|NCT05639556|Other|12-month Questionnaire|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
80008119|NCT03562338|Other|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
80008120|NCT02051478|Other|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
80008121|NCT02051478|Other|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
80008122|NCT02048514|Device|The Nellix® EndoVascular Aneurysm Sealing System|
80008123|NCT02928029|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
80008124|NCT02928029|Drug|Placebo|Matching placebo
80008125|NCT02928029|Drug|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
80008126|NCT02928029|Drug|Dexamethasone|Dexamethasone is administered orally at 40 mg
80008127|NCT03562182|Other|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
80008128|NCT02048592|Dietary Supplement|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support |(Nutridrink) for another 8 weeks."
79534913|NCT05639556|Other|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
79534914|NCT05639556|Device|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
79240935|NCT03640351|Drug|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
79240936|NCT03640351|Drug|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
79691666|NCT04689815|Drug|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
79303091|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children < 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
79534915|NCT05639556|Diagnostic Test|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
79534916|NCT05639556|Diagnostic Test|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
79534917|NCT05639556|Diagnostic Test|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
79691667|NCT05341557|Drug|BPI-371153|Subjects will receive BPI-371153 until disease progression
79691668|NCT01187446|Radiation|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
80008129|NCT02048592|Dietary Supplement|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
80008130|NCT02050074|Drug|Colesevelam|
80008131|NCT02050074|Drug|Metformin|
79691669|NCT01187446|Drug|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
79691670|NCT02931110|Drug|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
80008132|NCT02050074|Other|Placebo|
79691671|NCT04224285|Other|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
79691672|NCT02930993|Biological|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
79691673|NCT02931227|Procedure|temperature obtained by the non-invasive method of zero-heat flux|
80008133|NCT02050152|Behavioral|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
79240937|NCT03640351|Drug|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
79691674|NCT02931227|Procedure|esophageal temperature|
79691675|NCT02931227|Procedure|intracerebral temperature|
79691676|NCT02931227|Procedure|arterial temperature|
79691677|NCT04191798|Behavioral|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
79691678|NCT04191798|Behavioral|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
80008134|NCT02050152|Drug|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
80008135|NCT02050230|Biological|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
80008136|NCT02806986|Biological|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
80008137|NCT02050386|Other|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
80008138|NCT02050386|Other|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
80008139|NCT03562104|Other|videofluoroscopy|Swallowing description in Minimally consciousness Patient
80008140|NCT03562104|Other|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
79240938|NCT03640273|Drug|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
79534918|NCT05639556|Diagnostic Test|Psychosocial questionnaire: Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
79534919|NCT05639556|Other|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
79534920|NCT05639556|Diagnostic Test|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
79534921|NCT05639556|Other|Psychosocial questionnaire: Additional Health Questionnaire|Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
79534922|NCT05635500|Procedure|Different Approach to endotracheal intubation.|Different insertion way.
79534923|NCT05633654|Drug|Sacituzumab govitecan-hziy (SG)|Administered intravenously
79534924|NCT05633654|Drug|Pembrolizumab|Administered intravenously
79534925|NCT05633654|Drug|Capecitabine|Tablets administered orally
79691679|NCT02931071|Drug|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
79691680|NCT02931071|Drug|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
79534926|NCT05629676|Behavioral|BMT-VR|BMT-VR is a novel psychosocial intervention that addresses the supportive care needs of patients undergoing BMT. BMT-VR includes six sections focused on: 1) psychoeducation to help patients increase their awareness to stress and challenges that may accompany the BMT journey; 2) supportive psychotherapy strategies to help patients adjust to the intense BMT hospitalization; 3) psychosocial skill building to promote mindfulness, acceptance and gratitude while living with uncertainty; 4) psychoeducation to manage expectations and enhance preparedness for extended hospitalization; 5) psychosocial skill-building to promote effective coping; and 6) an overview of psychosocial skills grounded in cognitive behavior therapy, mindfulness, and positive psychology
79534927|NCT05629585|Drug|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
79534928|NCT05629585|Drug|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
79534929|NCT05629585|Drug|Capecitabine|Active Comparator. Tablet. Oral route of administration
79240939|NCT03640273|Drug|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
80008141|NCT02037360|Behavioral|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
79240940|NCT03449823|Diagnostic Test|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
80008142|NCT02037360|Behavioral|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
79240941|NCT03442023|Drug|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
79240942|NCT03442023|Drug|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
79534930|NCT05629585|Drug|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
79691681|NCT02931032|Procedure|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
79691682|NCT01187407|Drug|LY2216684|
79691683|NCT01187407|Drug|Placebo|
79691684|NCT01187407|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
79691685|NCT00554034|Drug|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
80016769|NCT02285426|Device|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality [visual scale adapted from Herth 2009 and Zaric 2013] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
79240943|NCT03441945|Other|magnetic steering|magnetic steering
79240944|NCT01063283|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 intravenously over 10 minutes
79240945|NCT01063283|Drug|Carboplatin|Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
79691686|NCT02930681|Dietary Supplement|Glucosanol 500mg|
79240946|NCT01063283|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
79240947|NCT01063283|Drug|Bevacizumab 15 mg/kg|Bevacizumab at 15 mg/kg intravenously over 90 minutes
79691687|NCT02930681|Dietary Supplement|Placebo|
79691688|NCT05310058|Dietary Supplement|C6 ketone di-ester|C6 ketone di-ester
79691689|NCT05308576|Biological|SCTV01E|D0; intramuscular injection
79691690|NCT05308576|Biological|Placebo|D0; intramuscular injection
79691691|NCT02930876|Behavioral|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
79534931|NCT05626101|Drug|BCG|Intravsical induction and maintenance BCG injections.
79534932|NCT05626101|Drug|Gemcitabine|Intravsical induction and maintenance gemcitabin injections.
79534933|NCT05624788|Other|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
79534934|NCT05624723|Drug|INCB054707|INCB054707 75 mg will be administered orally
79534935|NCT05617677|Drug|Deucravacitinib|Specified dose on specified days
79691692|NCT05329311|Procedure|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
79534936|NCT05617677|Other|Placebo|Specified dose on specified days
79534937|NCT05614102|Drug|BAY2965501|Daily oral application
79240948|NCT03441867|Behavioral|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
79240949|NCT03441867|Other|Standard Medical Care|Observational - standard medical care
79240950|NCT02521779|Other|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
79240951|NCT02521779|Other|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
79240952|NCT02521779|Other|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
79240953|NCT02521779|Other|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
80008143|NCT02037750|Behavioral|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
79534938|NCT05614102|Drug|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
79691693|NCT05329311|Procedure|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
79837484|NCT03050476|Drug|bRESCAP|intravenous application before, during, and for 24, 48, or 96 hours after heart surgery
79837485|NCT03050476|Drug|placebo|intravenous application before, during, and for 24, 48, or 96 hours after heart surgery
80008144|NCT02050542|Procedure|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
79240954|NCT03438279|Other|Non-Interventional|Non-Interventional
79534939|NCT05612256|Diagnostic Test|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of < 10 % of the maximum impedance changes are called 'Silent Spaces'.
79534940|NCT05612256|Diagnostic Test|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
79534941|NCT05612256|Diagnostic Test|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
79534942|NCT05610345|Procedure|Placental Blood Drainage|Immediately after vaginal delivery following delayed cord clamping and cutting of the cord, the cord will be unclamped and blood will be drained from the placenta until cessation of flow.
79534943|NCT05610345|Procedure|Placenta Blood Not Drained|Placenta Blood Not Drained
79691694|NCT01186978|Radiation|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
79691695|NCT04506905|Drug|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
79691696|NCT04506905|Drug|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
79691697|NCT05326230|Device|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
79691698|NCT05326230|Device|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
79240955|NCT01062971|Drug|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
79240956|NCT03446937|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
79240957|NCT03446937|Drug|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
79240958|NCT03446937|Drug|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
79691699|NCT01186939|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m^2/day.
79837486|NCT00791544|Drug|AVE1642|intravenous infusion
79837487|NCT00791544|Drug|sorafenib|oral intake
79837488|NCT00791544|Drug|erlotinib|oral intake
79837489|NCT00753350|Device|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
80008145|NCT02050542|Procedure|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
80016770|NCT02250144|Device|Foot orthoses|
80008146|NCT02048748|Device|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
80008147|NCT02048748|Device|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
80008148|NCT02048982|Behavioral|Guideline|Physicians will receive information on the Choosing Wisely Guideline
79534944|NCT05608408|Device|Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system|Stimulation of site with the Medtronic Percept PC system using low frequency stimulation at 0.5 Hz.
79534945|NCT05608408|Device|Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system|Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system using standard of care high frequency stimulation parameters.
79534946|NCT05604131|Drug|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
79534947|NCT05604131|Drug|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
79534948|NCT05592002|Device|Genio System|The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
79837490|NCT00753428|Other|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
79837491|NCT00990028|Drug|Rosuvastatin|20 mg oral, for 10 days
79837492|NCT00990028|Drug|Placebo|20 mg vehicle
79837493|NCT04052906|Other|Training|Planned Inhaler Medication Trainning
79837494|NCT05361226|Other|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
80008149|NCT02048982|Behavioral|Cost|Physicians will receive cost information.
79240959|NCT03652493|Drug|Carboplatin|Tumoral evaluation every 3 cycles
79534949|NCT05583188|Device|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
79691700|NCT04318483|Other|survey|parents' telephone interview to collect medical history
79691701|NCT00554112|Behavioral|Exercise|Exercise
79691702|NCT05463172|Other|abdominal strengthening exercises|abdominal strengthening exercises
79691703|NCT05463172|Other|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
79691704|NCT05461105|Drug|rencofilstat, 75 mg|1 softgel capsule
79837495|NCT00663234|Drug|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
79837496|NCT00683384|Drug|Etanercept (Enbrel)|
79691705|NCT05461105|Drug|rencofilstat, 150mg|2 softgel capsules
79837497|NCT00753662|Device|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
79837498|NCT00753662|Device|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
79837499|NCT00753662|Device|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
80008150|NCT02048982|Behavioral|Victim|Physicians will receive information on an identifiable victim.
80008151|NCT02051556|Behavioral|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
79691706|NCT05461105|Drug|rencofilstat, 225 mg|3 softgel capsules
79691707|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
79691708|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
79691709|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
79691710|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
79691711|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
79691712|NCT04447040|Drug|Placebo|Placebo tablets administered as a single two-tablet dose.
80008152|NCT02051556|Behavioral|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
80008153|NCT02051556|Behavioral|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
80016771|NCT02282618|Device|Cardiac Sympathetic Blockade|
79691713|NCT02930642|Behavioral|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
79240960|NCT02521701|Drug|NFL101|"Level 1: 100 µg~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
79240961|NCT03652415|Device|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
79303092|NCT03069651|Other|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
79534950|NCT05583188|Drug|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
79837500|NCT04003714|Device|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
79837501|NCT04003714|Device|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
79837502|NCT02561312|Other|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
79837503|NCT02561312|Other|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
79837504|NCT05361148|Other|no interventions will be used|This is a cohort study with no interventions.
79837505|NCT00788346|Behavioral|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
79837506|NCT00788346|Behavioral|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
79691714|NCT02930642|Other|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
79837507|NCT00753740|Drug|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
79837508|NCT00753740|Drug|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
79837509|NCT00753740|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
79837510|NCT00796380|Drug|Xingnaojing|injection
79534951|NCT05583188|Drug|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
79837511|NCT00326911|Biological|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
79837512|NCT00326911|Biological|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
79534952|NCT05583188|Other|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
79691715|NCT03455205|Drug|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
79691716|NCT03455205|Drug|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
79837513|NCT00326911|Drug|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
79837514|NCT00326911|Biological|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
79547307|NCT01553513|Other|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
79691717|NCT02930954|Drug|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
80008154|NCT02049060|Drug|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
79691718|NCT02930954|Drug|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
79837515|NCT00990262|Radiation|Cardiac Computed Tomography|"Localization of the heart position in a projectional topographic scan of the chest.~Determination of contrast agent transit time: 10 ml contrast agent.~CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
79837516|NCT00791622|Drug|Paliperidone ER|
80008155|NCT02049216|Other|Flexible tape|Flexible, elasticised, adhesive athletic tape
80008156|NCT02049216|Other|Fixomull|
79303093|NCT03109223|Other|sole source nutrition|Infant formula
79240962|NCT03446859|Other|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
80008157|NCT02049216|Other|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
79534953|NCT05581030|Drug|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
79534954|NCT05581030|Drug|Calaspargase Pegol|Calaspargase pegol 2000 IU/m^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
80008158|NCT03095651|Biological|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
79534955|NCT05581030|Drug|Rituximab|Rituximab 375mg/m^2 will be administered once per cycle for patients with CD20+ ALL.
80008159|NCT03095651|Biological|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
80008160|NCT03095651|Biological|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
79534956|NCT05579847|Other|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
79534957|NCT05579847|Behavioral|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
80008161|NCT03095651|Biological|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
80008162|NCT03095651|Biological|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
80008163|NCT03095651|Biological|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
80008164|NCT03095651|Drug|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
79380649|NCT05517694|Other|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
79240963|NCT04054349|Other|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
79691719|NCT02930954|Drug|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
79837517|NCT00747110|Drug|budesonide|3x 3mg budesonide capsules once daily
79837518|NCT00747110|Drug|mesalazine|3x 1000mg mesalazine onc daily
79837519|NCT00796458|Drug|docetaxel|Given IV
80008165|NCT03095651|Biological|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
80008166|NCT02808312|Drug|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
80008167|NCT03561948|Procedure|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
80008168|NCT03561948|Procedure|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
80008169|NCT04717193|Drug|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
80008170|NCT04717193|Procedure|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
80008171|NCT02050698|Procedure|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
80016772|NCT04790227|Device|MRI|MRI
79837520|NCT00796458|Drug|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
79380650|NCT05517694|Other|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
79534958|NCT05579847|Behavioral|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
79534959|NCT05579847|Behavioral|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
79534960|NCT05579847|Behavioral|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
79534961|NCT05573464|Drug|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
79534962|NCT05573464|Drug|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
79534963|NCT05572073|Other|Natural History Study|Natural History Study
79534964|NCT05571839|Drug|SGN-BB228|Given into the vein (IV; intravenous)
79534965|NCT05569681|Drug|Bemiparin 3500|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
79534966|NCT05569681|Drug|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
79534967|NCT05568719|Diagnostic Test|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
79534968|NCT05564104|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection.
80008172|NCT02050698|Procedure|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
80008173|NCT02050776|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
79534969|NCT05560451|Behavioral|Peer health coach intervention|Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
79534970|NCT05558904|Drug|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
79534971|NCT05558904|Procedure|Computed Tomography|Undergo PET/CT
79837521|NCT00753818|Other|DHA and ARA|various levels of DHA and ARA
79837522|NCT00753818|Other|Control|
80008174|NCT02051634|Drug|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
79837523|NCT05359744|Diagnostic Test|Performance testing|Performance testing on a bicycle ergometer.
79240964|NCT03446703|Behavioral|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
79240965|NCT03446703|Behavioral|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
79837524|NCT00747188|Behavioral|PBL|
80008175|NCT02051634|Drug|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
79691720|NCT05290467|Behavioral|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
79691721|NCT02930759|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-096)
79691722|NCT03457649|Biological|ARGX-113|
79837525|NCT04046016|Drug|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
80008176|NCT05212025|Drug|Adavosertib|Taken Orally
79837526|NCT01057615|Dietary Supplement|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
79837527|NCT01057615|Dietary Supplement|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
79837528|NCT01057615|Dietary Supplement|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
79837529|NCT01057615|Dietary Supplement|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
79837530|NCT04046718|Device|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
79240966|NCT03652727|Device|ECG-EM Guidance|"ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) [CE marked device, C. R. Bard, Inc.].~At the end of procedure, a chest x-ray is performed to assess the PICC position"
79240967|NCT03652727|Device|FX Guidance|"FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position"
79240968|NCT01348165|Drug|BI 137882|Powder for oral solution
79240969|NCT01348165|Drug|Placebo|Powder for oral solution
79380651|NCT03324048|Other|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
79534972|NCT05558904|Other|Laboratory Biomarker Analysis|Correlative studies
79534973|NCT05558904|Procedure|Positron Emission Tomography|Undergo PET/CT
79534974|NCT05558475|Behavioral|Virtual Coaching|The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
79534975|NCT05557591|Drug|BNT116|BNT116 is administered by IV injection.
79534976|NCT05557591|Drug|Cemiplimab|Cemiplimab is administered Q3W by IV infusion
79691723|NCT03457649|Biological|Placebo|
79837531|NCT02561858|Other|acid load test|
79837532|NCT05124418|Diagnostic Test|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
79837533|NCT00788424|Drug|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
79837534|NCT00747422|Device|Ulthera™ System|ultrasound treatment
79837535|NCT04003870|Device|CASO|Customized arch support orthoses (CASO)
79837536|NCT04003870|Device|HL|Orthotic Heel Lift (HL)
79837537|NCT00796536|Behavioral|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
79837538|NCT00796536|Behavioral|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
79837539|NCT04057274|Other|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
80008177|NCT05212025|Drug|Gemcitabine|Intravenous Infusion
80008178|NCT02051868|Drug|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
80008179|NCT02051868|Drug|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
80008180|NCT02051868|Drug|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
79691724|NCT04141917|Combination Product|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged <12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
79691725|NCT02930525|Other|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
79691726|NCT02930525|Other|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
79691727|NCT04117659|Other|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
79837540|NCT02686060|Device|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
79837541|NCT00791856|Drug|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
79837542|NCT00791856|Drug|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
79240970|NCT02493868|Drug|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
79240971|NCT02493868|Drug|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
79391361|NCT02418676|Drug|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
79837543|NCT02561780|Behavioral|Curriculum|A mental health educational resource delivered in the classroom by trained educators
79534977|NCT05554679|Drug|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
79534978|NCT05553639|Biological|HB-302/HB-301 Alternating 2-Vector Therapy|Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
79837544|NCT02561780|Behavioral|eLearning Follow-up|An online mental health education module that students access individually
79837545|NCT00796692|Drug|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
79837546|NCT00796692|Drug|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
79837547|NCT00540436|Drug|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
80008181|NCT02051868|Drug|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
80008182|NCT04696757|Drug|Capecitabine|Capecitabine without surgery
79391362|NCT02423148|Drug|Indocyanine green (ICG)|
79534979|NCT05550038|Diagnostic Test|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
79534980|NCT05548296|Drug|ACR-368|ACR-368 is an experimental drug
79534981|NCT05548296|Drug|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
79691728|NCT02930798|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-116)"
79691729|NCT02930408|Procedure|electrocardiogram|
79691730|NCT02930408|Procedure|Echocardiography|
79691731|NCT04116606|Drug|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
80008183|NCT02049294|Biological|Omalizumab (Xolair)|
80008184|NCT02049294|Drug|Placebo|
80016773|NCT02910219|Drug|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
79691732|NCT04116606|Drug|Placebo|Matching placebo containing the same excipients
79691733|NCT02930915|Device|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
79534982|NCT05548296|Diagnostic Test|OncoSignature|Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue
79534983|NCT05537571|Drug|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
79534984|NCT05537571|Drug|Placebo|Sodium chloride, solution for injection
79691734|NCT02930447|Device|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
79691735|NCT04679571|Biological|Albumin|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
79837548|NCT00754286|Other|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
79380652|NCT05503966|Behavioral|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
79240972|NCT02493868|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
79391363|NCT02423148|Device|FluoSCOPE|
79534986|NCT05528718|Drug|Nitrous oxide gas for inhalation|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
79534987|NCT05528718|Drug|Midazolam injection|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
79534988|NCT05528328|Device|CACIPLIQ20®|CACIPLIQ20®
79240973|NCT02493868|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
79534989|NCT05528328|Drug|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
79240974|NCT02493868|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
79534990|NCT05526989|Drug|Dostarlimab|300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
79534991|NCT05526989|Drug|Niraparib|200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
79534992|NCT05523908|Radiation|High-dose hypofraction Arm|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f
79534993|NCT05523908|Radiation|Low-dose hypofraction Arm (Standard BED)|Patients in this arm would receive low-dose fractionated radiotherapy with 48Gy/12f
79534994|NCT05516485|Other|Assessment|Undergo grading and recording of tumor consistency/stiffness
79534995|NCT05516485|Device|Magnetic Resonance Elastography|Undergo MRE
79534997|NCT05513859|Procedure|Craniotomy|Undergo craniotomy
79534998|NCT05513859|Device|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
79534999|NCT05513547|Other|LE protocol 1: exposure to artificial light|Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
79535000|NCT05513547|Other|LE protocol 2: natural daylight|Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
79380653|NCT02492022|Dietary Supplement|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
79691736|NCT04679571|Drug|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
79691737|NCT02930369|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
79691738|NCT02930486|Device|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
79691739|NCT02930486|Device|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
79837549|NCT00754286|Other|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
79837550|NCT00796770|Biological|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~an opportunistic infection~a CDC class C-defining event (defined in appendix 2)~a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
79837551|NCT00788580|Drug|pazopanib hydrochloride|
79837552|NCT00788580|Drug|temsirolimus|
79691740|NCT02930330|Behavioral|INT|"5 min warm-up (40% Pmax*)~30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
79837553|NCT00788580|Procedure|immunoenzyme technique|
79837554|NCT00788580|Procedure|laboratory biomarker analysis|
79837555|NCT00788580|Procedure|pharmacological study|
80016774|NCT02250222|Drug|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex [β-cyclodextrin] sulfobutylether sodium, NF)
79240975|NCT02493868|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
79380654|NCT02492022|Dietary Supplement|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
79240976|NCT03619057|Other|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
79691741|NCT02930330|Behavioral|CONT|"5 min warm-up (40% Pmax*)~30 min moderate intensity continuous training (60% Pmax)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
79691742|NCT02929940|Other|No intervention|No Intervention, observational
79691743|NCT02930057|Drug|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
79691744|NCT02930057|Procedure|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
79691745|NCT02930057|Drug|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
79691746|NCT05238363|Drug|HLX07|HLX07 1500mg ivgtt Q3W
79691747|NCT02930135|Procedure|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
79837556|NCT00788658|Behavioral|Diet modifications|Diet consultation
79837557|NCT00788658|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
80016775|NCT02250222|Drug|Placebo (Captisol ®)|betadex [β-cyclodextrin] sulfobutylether sodium, NF
79240977|NCT04884867|Behavioral|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
79305690|NCT03236363|Behavioral|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
79380655|NCT02492022|Other|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
79380656|NCT03323970|Other|semi-structured interviews|individual semi-structured interviews
79380657|NCT01730872|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
79380658|NCT01730872|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
79380659|NCT02491086|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT
79380660|NCT02491086|Behavioral|Smoking cessation counseling|Smoking cessation counseling
80008185|NCT05155943|Device|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
80008186|NCT02051946|Device|Retroject Device|
79837558|NCT03878498|Other|therapeutic management|therapeutic management of anal fistula in Crohn Disease
79691748|NCT04080492|Other|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
80008187|NCT02051946|Drug|ethacrynic acid injection|
80008188|NCT02051946|Drug|balanced salt solution|
80008189|NCT02049528|Drug|CC-122|CC-122
80008190|NCT02049528|Drug|CC-122|CC-122
80008191|NCT02049528|Drug|CC-122|CC-122
80008192|NCT02049606|Drug|LAYLA tablet|1 Tablet twice a day
80008193|NCT02049606|Drug|CENATONE tablet|2 Tablets once a day
79380661|NCT02491710|Device|Training on low-cost box trainer|
80008194|NCT02049684|Procedure|Patch|
79380662|NCT02491710|Device|Training on standard box trainer|
79380663|NCT03469492|Drug|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
79380664|NCT03469492|Behavioral|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
80008195|NCT02037516|Device|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
80008196|NCT02037516|Drug|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
80008197|NCT02037516|Device|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
79380665|NCT03469492|Dietary Supplement|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
79380666|NCT02490696|Device|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
79691749|NCT04049721|Procedure|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
79837559|NCT00792012|Radiation|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
79837560|NCT00792012|Drug|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
79837561|NCT00990418|Drug|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
80008198|NCT01568099|Biological|AFFITOPE® PD01A|s.c. injection
80008199|NCT01568099|Other|Control|Untreated control
80008200|NCT02050932|Dietary Supplement|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
79380667|NCT02490696|Device|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
80008201|NCT03561792|Other|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
80008202|NCT02052024|Drug|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
80008203|NCT02052024|Drug|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
80008204|NCT02037672|Drug|metformin|
80008205|NCT02037672|Drug|metformin and roflumilast|
80008206|NCT02049762|Drug|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
80008207|NCT02049840|Device|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
80008208|NCT02037594|Behavioral|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
80008209|NCT02037594|Behavioral|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
80008210|NCT02037594|Behavioral|PrEP Information (Active Control)|Standard of Care Information about PrEP
80016776|NCT00530114|Drug|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
79380668|NCT03331770|Drug|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
79380669|NCT03323814|Device|Slow-wave optimization|employing sensory stimulation to enhance slow waves
79380670|NCT02491164|Other|BAC TWO|BAC TWO administration
79380671|NCT02491164|Device|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
79691750|NCT04049721|Other|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
80008211|NCT02037594|Behavioral|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
79380672|NCT03326700|Procedure|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
79691751|NCT02930252|Device|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
80008212|NCT02052102|Radiation|Radiation therapy|
79691752|NCT02930252|Device|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
80008213|NCT03561558|Drug|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
80008214|NCT03561558|Drug|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
79240978|NCT04451655|Drug|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
79240979|NCT03438201|Dietary Supplement|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
79240980|NCT03438201|Dietary Supplement|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
79240981|NCT03446625|Drug|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
79240982|NCT03446625|Drug|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
79240983|NCT04957186|Other|Collection of postoperative information|The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
79535001|NCT05513547|Other|LE protocol 3: natural daylight with reduced short-wavelength proportions|Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
79535002|NCT05513027|Device|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC FDG-PET/CT scan. Will take approximately 3-5 minutes longer.
79691753|NCT04017000|Diagnostic Test|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
79691754|NCT04017000|Other|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
79837562|NCT02562950|Drug|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
80008215|NCT02037906|Radiation|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
80008216|NCT02037906|Radiation|Constant Energy SWL|Constant dose at 20 kv
80008217|NCT02037906|Radiation|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
80008218|NCT03099161|Drug|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
80008219|NCT03099161|Biological|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
80008220|NCT04309565|Behavioral|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
79380673|NCT03331692|Other|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
79391364|NCT02413866|Behavioral|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
79535003|NCT05513027|Device|FDG-PET/CT|-Standard of care
80008221|NCT04309565|Behavioral|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
80016777|NCT00530114|Drug|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
79240984|NCT04957186|Other|Analysis of postoperative information collected from patients|All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
79240985|NCT03441399|Other|Financial incentives|Providing money for taking antidepressant medication
79240986|NCT02516410|Drug|VX-661 plus ivacaftor combination|
79240987|NCT02516410|Drug|Ivacaftor|
79240988|NCT02516410|Drug|Placebo (matched to VX-661 plus ivacaftor combination)|
79837563|NCT02562950|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
79691755|NCT04007406|Drug|DP13|DP13 systemic administration
80008222|NCT04855487|Behavioral|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
80008223|NCT04304339|Other|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
80008224|NCT03095027|Device|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
79240989|NCT02516410|Drug|Placebo (matched to ivacaftor)|
79240990|NCT03438123|Device|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
79240991|NCT02493712|Drug|High dose|6 capsules of IBD98-M, twice a day
79240992|NCT02493712|Drug|Low dose|4 capsules of IBD98-M
79240993|NCT02493712|Drug|Placebo|Placebo
79240994|NCT04851483|Drug|BAY2328065|Solid Form, Oral administration.
79240995|NCT04851483|Drug|Placebo|Matching placebo of BAY2328065.
79240996|NCT04850859|Other|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
79240997|NCT04850859|Other|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
79240998|NCT03437967|Device|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
79380674|NCT05317156|Other|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
79380675|NCT03331614|Device|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
79380676|NCT03326622|Other|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
80008225|NCT03095027|Device|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
79380677|NCT03326622|Other|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
79391365|NCT02413866|Behavioral|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
79691756|NCT02929901|Dietary Supplement|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
80008226|NCT04639115|Drug|Ozanimod|Ozanimod
80008227|NCT04260659|Drug|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
79691757|NCT02929901|Dietary Supplement|caffeine|caffeine plus placebo
79691758|NCT02929901|Dietary Supplement|chlorogenic acid|chlorogenic acid plus placebo
79691759|NCT02929901|Dietary Supplement|placebo|placebo plus placebo
79691760|NCT05237661|Dietary Supplement|Moon Balance|Moon Balance is a blend of 6 food ingredients
79691761|NCT02929784|Device|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
80008228|NCT04260659|Drug|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
80008229|NCT04260659|Drug|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
79240999|NCT03441087|Device|Transvaginal ultrasound|
79241000|NCT03441087|Device|Hysteroscopy|
79241001|NCT03446547|Drug|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
79241002|NCT02516332|Drug|Lexapro|
79241003|NCT02516332|Drug|Placebo|
79241004|NCT02516332|Behavioral|Supervised Aerobic Exercise|
79241005|NCT03437811|Device|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
79241006|NCT03446469|Other|Fascial Manipulation|Myofascial release of densified centers of coordination
79241007|NCT04954846|Dietary Supplement|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
79691762|NCT02929784|Device|Sham|no meaningful stimulation will be given.
79837564|NCT02562950|Drug|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
79535004|NCT05513027|Drug|18F- fluorodeoxyglucose|-Standard of care given with FDG-PET/CT
79380678|NCT02491008|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
79535005|NCT05512962|Drug|Triamcinolone Acetonide|Single suprachoroidal Administration of Triamcinolone acetonide
79380679|NCT02491008|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
79380680|NCT05316844|Other|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
79535006|NCT05512962|Device|Semi-automated Suprachoroidal Microcatheter|Ophthalmic Adminstration Device
79535007|NCT05510687|Device|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
79535008|NCT05507307|Behavioral|mindfulness-based pregnancy education program.|Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
79535009|NCT05506059|Diagnostic Test|Ultrasound|Participants will have ultrasounds of the heart by two different emergency medicine doctors.
79241008|NCT04954846|Dietary Supplement|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
79535010|NCT05504291|Procedure|Biospecimen Collection|Undergo correlative studies
79535011|NCT05504291|Drug|Carboplatin|Given IV
79535012|NCT05504291|Drug|Etoposide|Given IV
79535013|NCT05504291|Procedure|Examination Under Anesthesia|Undergo imaging of the eye during EUA
79535014|NCT05504291|Drug|Melphalan|Given I-VITRE
79535015|NCT05504291|Procedure|Ultrasound Biomicroscopy|Undergo UBM during EUA
79535016|NCT05504291|Drug|Vincristine|Given IV
79535017|NCT05501704|Drug|Tamoxifen|Taken orally
79535018|NCT05501704|Drug|Anastrozole|Taken orally
79535019|NCT05501704|Drug|Degarelix|Subcutaneous (under the skin) injection
79535020|NCT05501704|Drug|Abemaciclib|Taken orally
79535021|NCT05501054|Drug|Ipilimumab|Given by IV (vein)
79535022|NCT05501054|Drug|Nivolumab|Given by IV (vein)
79837565|NCT02599948|Other|no intervention|
79837566|NCT00788814|Behavioral|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
79837567|NCT00796848|Device|Navigator Continuous Glucose Monitor|
79241009|NCT03129477|Procedure|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
79241010|NCT02483572|Behavioral|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
79241011|NCT03441009|Other|Physio-/occupational therapy|Physio-/occupational therapy, ADL
79535023|NCT05501054|Drug|Ciforadenant|Given by PO
79241012|NCT03440931|Diagnostic Test|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
79535024|NCT05496738|Drug|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
79535025|NCT05496738|Drug|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
79535026|NCT05496738|Other|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
79535027|NCT05496738|Other|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
79535028|NCT05492838|Procedure|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
79535029|NCT05490446|Drug|AG-946|AG-946 Tablet
79535030|NCT05490446|Drug|Placebo|Matching-placebo Tablet
79535031|NCT05489640|Other|No Intervention|No Intervention will be administered in this study.
79535032|NCT05485766|Drug|Pembrolizumab|200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
79535033|NCT05485766|Drug|Paclitaxel|80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
79837568|NCT00754754|Procedure|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
79535034|NCT05485766|Drug|Carboplatin|Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
79535035|NCT05485766|Drug|Olaparib|300 mg BID (twice daily) orally
79535036|NCT05485766|Procedure|Definitive Surgery|Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
79535037|NCT05484999|Other|Meals|12 weeks of medically tailored meals
79535038|NCT05484999|Other|Meals + Social Support|12 weeks of medically tailored meals and12 weeks of social media based support
79535039|NCT05484999|Other|Control|Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
79535040|NCT05477953|Drug|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
79535041|NCT05474066|Device|ERP Testing|"Attention & Concentration:~Continuous Visual Memory Test (CVMT):~Flanker Task:~Hayling Test:"
79837569|NCT00792090|Other|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
79241013|NCT03437655|Procedure|Carie removal|Carie removal with a low speed handpiece
79241014|NCT03437655|Procedure|Relative isolation|Relative isolation with cotton and gauze.
79241015|NCT03437655|Procedure|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
79535042|NCT05467449|Device|DxFLEX 10C|A device combining flow cytometry and reagents for immunophenotyping analysis
79691763|NCT02929706|Genetic|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
79691764|NCT02929628|Device|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
79691765|NCT00553878|Drug|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
79691766|NCT04407689|Drug|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
79691767|NCT04407689|Drug|Placebo|Intramuscular (IM) placebo (normal saline) at the same frequency
79691768|NCT05225064|Behavioral|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
79691769|NCT05225064|Device|Mask|Individuals are given cloth masks
79691770|NCT05225064|Behavioral|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
79691771|NCT05225064|Behavioral|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
79691772|NCT05225064|Behavioral|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
79691773|NCT05222919|Dietary Supplement|Bare performance supplement|dietary supplement
79691774|NCT05222919|Dietary Supplement|Placebo|Placebo
79691775|NCT02929862|Drug|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
79691776|NCT04381052|Drug|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
79691777|NCT04381052|Other|Placebo|Intravenously administered over 30 minutes.
79691778|NCT03956940|Device|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
79691779|NCT00624325|Drug|interferon alfa-2b|12 MU daily continuously subcutaneous
79691780|NCT00624325|Drug|interferon alfa-2b|9 MU daily continuously subcutaneous
79691781|NCT00624325|Drug|interferon alfa-2b|6 MU daily continuously subcutaneous
79241016|NCT03437655|Procedure|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
79241017|NCT03437655|Procedure|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
79241018|NCT03437655|Procedure|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
79241019|NCT04813497|Diagnostic Test|Serology to determine SARS-CoV-2 infection|Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
79535043|NCT05447741|Diagnostic Test|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
79535044|NCT05447520|Drug|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
79241020|NCT03446391|Procedure|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
79241021|NCT03446391|Procedure|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
79535045|NCT05447520|Drug|Placebo|Oral tablet once daily
79535046|NCT05447520|Drug|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
79535047|NCT05442710|Biological|ARTICE|Extracorporal treatment with purified granulocyte concentrate
79535048|NCT05440656|Drug|Cohort|Participants with Severe Eosinophilic Asthma
79241022|NCT03446391|Device|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
79535049|NCT05440422|Drug|anifrolumab|This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
79535050|NCT05440422|Other|Placebo|non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
79535051|NCT05438992|Drug|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
79691782|NCT02929745|Procedure|Skin biopsy|Four 4-5 mm punch biopsies of the skin
79691783|NCT02929745|Procedure|Blood draw|Blood will be drawn to test for HLA-cw6 status
79691784|NCT05204823|Other|Experimental product|Chocolate milk shakes
79691785|NCT05204823|Other|Control product|Glucose
79691786|NCT04322279|Diagnostic Test|Serology|SARS-CoV-2 serology
79691787|NCT04322279|Genetic|Sequencing|Whole exome sequencing
79691788|NCT03934398|Diagnostic Test|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
79691789|NCT03934398|Diagnostic Test|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
79691790|NCT03934398|Diagnostic Test|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
80008230|NCT04260659|Drug|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
80008231|NCT04260659|Drug|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
80008232|NCT04260659|Drug|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension > 140/90 mmHg or tachycardia > 120min occurs. If necessary rescue dosis may be repeated.
79837570|NCT00792090|Other|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
79380681|NCT03331536|Procedure|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
79691791|NCT03934398|Diagnostic Test|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
79837571|NCT00792168|Drug|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
79380682|NCT03331536|Procedure|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
79535052|NCT05424484|Device|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
79535053|NCT05419258|Device|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
79535054|NCT05412030|Biological|Prevnar 13|PCV13 administered intramuscularly 4 times within 12 months
79535055|NCT05412030|Biological|AFX3772|AFX3772 administered intramuscularly 4 times within 12 months
79535056|NCT05405387|Drug|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
79837572|NCT00792168|Other|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
80008233|NCT05068661|Drug|Ropivacaine 0.1% Injectable Solution|DPE
80008234|NCT05068661|Drug|Bupivacaine 0.25% Injectable Solution|CSE
80008235|NCT04340609|Biological|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
79535057|NCT05405387|Drug|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
79535058|NCT05405309|Drug|RP-3500 in combination with Olaparib|"During dose escalation, four DLs of combination therapy of RP-3500 and olaparib may be explored. Subjects will be enrolled in cohorts of three starting with DL 1. Enrollment will be placed on hold to allow for all members of a cohort to complete the Dose Limiting Toxicity (DLT) period. Once all subjects in a cohort have completed the defined DLT evaluation period, the assignment of the dose level for the following cohort will be made per the decision algorithm.~Once RP2D is assigned continuous enrollment will begin among the 2 expansion cohorts."
79691792|NCT02929550|Other|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C<1.8 mmol/l
79691793|NCT02929511|Procedure|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
79691794|NCT02929511|Procedure|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
79691795|NCT02929511|Procedure|Active comparator Protaper multi-file system|
79837573|NCT02554188|Biological|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
79837574|NCT02554188|Other|Diet|A 5-day low calorie fasting-mimicking diet
80008236|NCT04148495|Drug|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
80008237|NCT04148495|Drug|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
80008238|NCT04227197|Other|Down Syndrome Clinic to You (DSC2U)|DSC2U is a web-based tool for families to get up-to-date, personalized health and wellness information, based on national guidelines and expert consensus, for a person with Down syndrome.
80008239|NCT03632447|Device|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
80008240|NCT03632447|Device|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
80008241|NCT05051189|Drug|Fentanyl Citrate|Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
80008242|NCT04540289|Drug|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2016 ESC guidelines for the management of acute and chronic heart failure"
80008243|NCT04540289|Device|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
80008244|NCT05027165|Other|Non-interventional|No intervention
80008245|NCT04172597|Drug|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
80008246|NCT04172597|Drug|Loperamide|Loperamide as prescribed by the physician.
80008247|NCT04097873|Other|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
80008248|NCT04097873|Other|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
80008249|NCT04087655|Behavioral|Exercise|Eight weeks of interval exercise training
80008250|NCT04015427|Device|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
80008251|NCT00446225|Drug|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
80008252|NCT00446225|Drug|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
79535059|NCT05402592|Dietary Supplement|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
79535060|NCT05402592|Other|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
79535061|NCT05391945|Diagnostic Test|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
79535062|NCT05389995|Drug|Potassium citrate|7 days potassium citrate followed by 24 hour urine collection
79535063|NCT05389995|Drug|Crystal light|7 days crystal light followed by 24 hour urine collection
79535064|NCT05389995|Drug|Potassium citrate + crystal light|7 days potassium citrate + crystal light followed by 24 hour urine collection
79535065|NCT05382637|Drug|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
79535066|NCT05374915|Combination Product|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
79691796|NCT03934281|Device|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
79691797|NCT03934281|Device|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
80008253|NCT00446225|Drug|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
79535067|NCT05369351|Drug|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
79535068|NCT05369351|Other|Standard treatment|Standard treatment
79241023|NCT03437499|Procedure|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
79535069|NCT05365347|Behavioral|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
79691798|NCT04689893|Drug|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
79691799|NCT04689893|Drug|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
79691800|NCT03922854|Other|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
79691801|NCT05184426|Diagnostic Test|Echocardiogram|Ultrasound study to assess cardiac anatomy and function
79691802|NCT05184426|Diagnostic Test|Cardiac magnetic resonance|MR to assess cardiac anatomy, function and tissue damage
79691803|NCT05184426|Diagnostic Test|Coronary angiography|Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
80008254|NCT00446225|Drug|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
80008255|NCT00446225|Drug|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
79241024|NCT03437499|Procedure|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
79241025|NCT03446313|Behavioral|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
79241026|NCT03437343|Procedure|Hip arthroplasty|
79691804|NCT05184426|Diagnostic Test|Endomyocardial biopsy|Optic microscopy, immunofluorescence, transmission electron microscopy
79241027|NCT01062425|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
79691805|NCT04689425|Drug|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
79241028|NCT01062425|Drug|Cediranib Maleate|Given PO
79691806|NCT04689425|Drug|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
79691807|NCT05184192|Drug|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
79691808|NCT05184192|Drug|Placebo|lactose monohydrate NF
80008256|NCT03080935|Drug|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
80008257|NCT04031105|Device|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
80008258|NCT03976115|Drug|DDO-3055|Oral
80008259|NCT03976115|Drug|Placebos|Oral
80008260|NCT03973255|Behavioral|Rehabilitation|Posturography, Whole body vibration
79380683|NCT03331536|Procedure|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
79535070|NCT05362955|Drug|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
79535071|NCT05359861|Drug|SRF388|SRF388 will be administered by intravenous injection (IV)
79535072|NCT05359861|Drug|Atezolizumab|Azezolizumab will be administered by IV
79535073|NCT05359861|Drug|Bevacizumab|Bevacizumab will be administered by IV
79535074|NCT05359861|Drug|Placebo|Placebo will be administered by IV
79535075|NCT05356338|Behavioral|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
79691809|NCT04689581|Other|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
79691810|NCT04689581|Other|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
79241029|NCT01062425|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
79241030|NCT01062425|Other|Laboratory Biomarker Analysis|Correlative studies
79241031|NCT01062425|Other|Placebo Administration|Given PO
79241032|NCT01062425|Drug|Temozolomide|Given PO
79305691|NCT03236363|Behavioral|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
80008261|NCT04479449|Drug|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
79691811|NCT03887676|Drug|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
79837575|NCT00687440|Drug|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
80008262|NCT04479449|Drug|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
80008263|NCT05303207|Dietary Supplement|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
80008264|NCT04434131|Drug|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
80008265|NCT01383811|Other|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
80008266|NCT01383811|Other|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
80008267|NCT05418959|Diagnostic Test|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
80008268|NCT03787901|Other|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
80008269|NCT03674567|Drug|FLX475|tablet
80008270|NCT03674567|Drug|Pembrolizumab|IV infusion
80008271|NCT03503435|Behavioral|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
79241033|NCT03446235|Behavioral|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
80008272|NCT05291273|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST). The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
79241034|NCT03446235|Behavioral|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
79241035|NCT03440541|Combination Product|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
79241036|NCT03437187|Procedure|Cholecystectomy|Laparoscopic technique
80016778|NCT04769401|Other|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
79691812|NCT03887676|Other|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
79691813|NCT04689620|Device|laser|treating the venous ulcer with laser
79837576|NCT00687440|Drug|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
79241037|NCT05127525|Drug|IRX-101|IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
79241038|NCT05127525|Drug|Control|Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
79305692|NCT03236285|Behavioral|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
79305693|NCT03236285|Behavioral|Continous exercise training in the fed state|Continous exercise training in the fed state
79535076|NCT05352815|Drug|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
79535077|NCT05352815|Drug|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
79837577|NCT00687440|Drug|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
79535078|NCT05344092|Behavioral|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
79837578|NCT02554734|Drug|levodopa, carbidopa, ODM-104|
79837579|NCT02554734|Drug|levodopa, carbidopa, entacapone|
79837580|NCT00990496|Drug|Fludarabine|30 mg/m2
79837581|NCT00990496|Drug|Cyclophosphamide|600 mg/m2
79535079|NCT05340309|Biological|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
79535080|NCT05340309|Other|Survey Administration|Ancillary studies
79535081|NCT05338671|Drug|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
79535082|NCT05328973|Other|ELEQUIL|patch placed on skin
80008273|NCT05291273|Diagnostic Test|Prone Bridge Test|"The prone bridge test also known as the plank or hover measures the muscular endurance of the abdominal muscles. Subjects will start in the down push up position with their feet together and their hands shoulder width apart. When the test starts the subject will push up to the prone bridge position so they are resting on their hands and toes making sure they maintain a straight line from the shoulders through the hips to the knees. The outcome measure will be the time where the subject stay in this position."
80008274|NCT05291273|Diagnostic Test|Measurement of the muscle strength of the shoulder complex|Maximum isometric force of the external and internal rotators and abductors/adductors measured by a dynamometer.
79837582|NCT00990496|Biological|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
79837583|NCT00754910|Drug|porfimer sodium|Given IV
80008275|NCT05418881|Device|Mobile Tracking Device (one spot)|Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
80008276|NCT05418881|Device|Mobile Tracking Device + Activity Sensor (longitudinal)|Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
80008277|NCT03845335|Device|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
80008278|NCT02868541|Other|Naso pharyngeal swab|Naso pharyngeal swab
80008279|NCT01568983|Dietary Supplement|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
80008280|NCT01568983|Dietary Supplement|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
80008281|NCT01568983|Dietary Supplement|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
80008282|NCT01383733|Drug|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
80008283|NCT01383655|Drug|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
80008284|NCT01383655|Drug|Placebo|NaCl
80008285|NCT01623193|Other|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
80008286|NCT01623193|Procedure|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
79535083|NCT05327868|Other|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
79837584|NCT00754910|Procedure|bronchoscopy|Patients undergo bronchoscopy
80008287|NCT01615159|Behavioral|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
79535084|NCT05327868|Other|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
79837585|NCT00755066|Drug|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
79837586|NCT00755066|Drug|Placebo|Placebo intranasal spray
79837587|NCT00990574|Device|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
79837588|NCT00990574|Device|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
79837589|NCT00659490|Drug|AZD1940|800ug oral administration
79837590|NCT00659490|Drug|Naproxen|500mg oral administration
79837591|NCT00659490|Drug|Placebo|Placebo given pre-surgery
80008288|NCT02136355|Radiation|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
80008289|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
80008290|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
80008291|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
80008292|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
80016779|NCT04769401|Other|Low Progesterone group|Progesterone level <10 ng/mL on ET day. If serum progesterone levels were <10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
80016780|NCT02094222|Drug|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
80016781|NCT02280512|Device|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
79305694|NCT03236285|Behavioral|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
79305695|NCT03236285|Behavioral|Continous exercise training in the fasting state|Continous exercise training in the fasting state
79305696|NCT03235895|Other|Educational material|Educational material given as a part of CME activity as through enhanced internet method
79305697|NCT03236051|Procedure|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
79837592|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
79691814|NCT02929472|Behavioral|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
80008293|NCT01013935|Other|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
80008294|NCT01013935|Other|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
80008295|NCT03965143|Device|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
80008296|NCT01383577|Procedure|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
80008297|NCT01383577|Procedure|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
79241039|NCT01060553|Other|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
79380684|NCT03331536|Procedure|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
79535085|NCT05315752|Procedure|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~for patients with a BMI >40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss >7%) or~for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
79535086|NCT05314088|Behavioral|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
79691815|NCT02929472|Behavioral|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
79691816|NCT02929433|Other|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
79691817|NCT04291469|Drug|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
79691818|NCT04291469|Dietary Supplement|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
79691819|NCT04291469|Dietary Supplement|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
79837593|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
79837594|NCT00539500|Drug|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
79837595|NCT00539500|Drug|Etoposide|300 mg/m^2 by vein over 24 hours for 4 days
79837596|NCT00539500|Drug|Melphalan|70 mg/m^2 Intravenous Bolus for 3 Days
80008298|NCT02921789|Drug|Bleselumab|Intravenous infusion
80008299|NCT02921789|Drug|Basiliximab|Bolus injection
80008300|NCT02921789|Drug|Mycophenolate Mofetil (MMF)|Oral Intravenous
80008301|NCT02921789|Drug|Tacrolimus Capsules|Oral Capsule
80008302|NCT02921789|Drug|Methylprednisone|Oral or Intravenous
79241040|NCT05090241|Diagnostic Test|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
79241041|NCT03621917|Device|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
79241042|NCT05077995|Device|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
79241043|NCT03437109|Diagnostic Test|Laboratory tests|Testosterone HSBG Hb1Ac LH
80008303|NCT02921789|Drug|Prednisone|Oral Tablet
80008304|NCT05420155|Procedure|Surgical resection|Surgical treatment of hepatic hydatidic cyst
80008305|NCT05419843|Other|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
80008306|NCT01568333|Drug|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
80008307|NCT03437005|Drug|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
80008308|NCT03437005|Drug|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
79241044|NCT03436953|Drug|CX-8998|T-type calcium channel blocker
79380685|NCT03331458|Behavioral|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
79535087|NCT05314088|Behavioral|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
79535088|NCT05311384|Behavioral|Keys Constraint-induced Movement Therapy protocol|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
79535089|NCT05300048|Drug|Serabelisib|serabelisib administered orally
79535090|NCT05300048|Other|Insulin Suppressing Diet|3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
79535091|NCT05300048|Drug|Nab paclitaxel|nab-paclitaxel administered intravenously weekly
79535092|NCT05298930|Other|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
80008309|NCT03943823|Drug|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
80008310|NCT03943823|Drug|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
80008311|NCT03097289|Device|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
80008312|NCT02419742|Drug|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams*milliliter/minute [mg*mL/min]) multiplied by (Glomerular Filtration Rate [GFR] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
80008313|NCT02419742|Drug|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
79241045|NCT03436953|Drug|Placebo|Placebo comparator
79380686|NCT04826692|Drug|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
79380687|NCT04826692|Drug|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
79241046|NCT02491684|Drug|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
79241047|NCT02491684|Drug|Placebo|Placebo solution for once daily inhalation for 14 days
79305698|NCT03236051|Procedure|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
79305699|NCT03236207|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
79305700|NCT03236207|Other|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
79380688|NCT03326544|Other|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
79380689|NCT03326544|Other|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
79380690|NCT02490930|Drug|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
79380691|NCT04825990|Drug|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
80008314|NCT02419742|Drug|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
80008315|NCT02419742|Drug|Doxorubicin|Participants will receive Doxorubicin 60 mg/m^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
80008316|NCT02419742|Drug|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
80008317|NCT02419742|Drug|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
80008318|NCT02409290|Drug|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
80008319|NCT02409290|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
80008320|NCT02409290|Drug|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
80008321|NCT02409290|Drug|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
80008322|NCT02409290|Drug|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
80008323|NCT02409290|Drug|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
80008324|NCT02409290|Drug|Prothionamide|Prothionamide has a bacteriostatic action.
80008325|NCT02409290|Drug|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
80008326|NCT02409290|Drug|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
80008327|NCT02409290|Drug|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
80008328|NCT02351414|Device|Total Knee Arthroplasty (EVOLUTION®)|
79535093|NCT05296798|Drug|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase [rHuPH20]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
79535094|NCT05296798|Drug|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
79535095|NCT05296798|Drug|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
79691820|NCT03882294|Other|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
79691821|NCT03882294|Other|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
79691822|NCT02929121|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
79691823|NCT02929121|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
79691824|NCT02929277|Other|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
79691825|NCT03871998|Other|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
79691826|NCT02929394|Drug|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
79691827|NCT05159037|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
79691828|NCT05159037|Behavioral|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
80008329|NCT02145494|Radiation|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
80008330|NCT02147756|Device|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
80008331|NCT02147756|Device|Repair|
80008332|NCT05435755|Biological|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
80008333|NCT05435755|Biological|placebo (saline)|2 times placebo (normal saline) injections as control group
80008334|NCT02147912|Other|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
79691829|NCT02929316|Drug|Vedolizumab|IV infusion week 0, 2 and 6
80008335|NCT02898077|Drug|Ramucirumab|Administered IV
80008336|NCT02898077|Drug|Paclitaxel|Administered IV
80008337|NCT02898077|Drug|Placebo|Administered IV
80008338|NCT03544346|Other|Exploratory brain and general health assessment|Exploratory brain and general health assessment
80008339|NCT03544892|Other|Low carbohydrate diet|60-80 g total carbohydrate per day
80008340|NCT03544892|Other|Standard of care diet|> 150 g total carbohydrate per day
80008341|NCT03692975|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
80008342|NCT03692975|Other|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
80008343|NCT03692975|Other|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
80008344|NCT03692975|Device|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
80008345|NCT02145650|Other|No Intervention|There is no intervention administered in this study.
80008346|NCT02145728|Behavioral|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
80008347|NCT02145728|Behavioral|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
80008348|NCT03544034|Behavioral|HomeTeam Toolkit|"A multi-component intervention (8S's)~Safety at home through partnership.~Safety risk assessment at the admission~Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~Safety tools. Cognitive tools to support patient/family after discharge~Safety education. Enhanced Patient/ family medication safety education~Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~Safety through learning routines across the care continuum~Safety assessment after discharge"
80008349|NCT03543956|Behavioral|Questionnaire|Questionnaire
80008350|NCT02145884|Drug|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
80008351|NCT02145962|Device|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
79241048|NCT04755465|Device|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
79241049|NCT04755465|Other|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
79241050|NCT03128697|Behavioral|Satiating diet|
79241051|NCT03128697|Behavioral|Control diet|
79241052|NCT01061723|Drug|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
79241053|NCT01061723|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
79241054|NCT03445767|Other|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
79241055|NCT03445611|Drug|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
79691830|NCT03841539|Behavioral|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
79691831|NCT03841539|Dietary Supplement|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
79691832|NCT03841539|Behavioral|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
80008352|NCT02145962|Device|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
80008353|NCT02148068|Procedure|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
79691833|NCT02929238|Other|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
79837597|NCT00539500|Procedure|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10^8 TNC cells/kg CD133+ selected) on Day 0.
80008354|NCT02148146|Drug|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
80008355|NCT03544814|Drug|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
79241056|NCT03445611|Drug|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
79241057|NCT03440307|Behavioral|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
79241058|NCT03440307|Behavioral|Email Only|Participants received health and fitness education.
79535096|NCT05296798|Drug|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
79535097|NCT05296798|Drug|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
80008356|NCT03544814|Drug|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
80008357|NCT03097133|Drug|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
79535098|NCT05296798|Drug|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
79535099|NCT05294471|Device|Non-contrast MRI with novel MRI software|The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
79691834|NCT02929238|Other|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
79380692|NCT04816474|Behavioral|Online education and Phone Counseling Service|Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
79391366|NCT02419690|Behavioral|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
79691835|NCT05152836|Device|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
79837598|NCT00539500|Device|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
79837599|NCT00662532|Drug|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
79837600|NCT00686036|Drug|vandetanib|300 mg orally, once daily for up to 18 months
79837601|NCT00686036|Drug|Placebo|
79837602|NCT00788970|Behavioral|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
80008358|NCT03097133|Drug|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
80008359|NCT03097133|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
79691836|NCT05152836|Device|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
79691837|NCT05152836|Device|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
79241059|NCT03440151|Procedure|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
79241060|NCT03440151|Procedure|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
79380693|NCT03323424|Radiation|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
79691838|NCT05152836|Device|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
80008360|NCT02148380|Drug|pemetrexed plus carboplatin|
80008361|NCT02148380|Drug|gefitinib|
80008362|NCT02146118|Drug|Erlotinib|Erlotinib 150 mg/day q 4 weeks
80008363|NCT02146118|Dietary Supplement|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
80008364|NCT02146196|Device|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
79241061|NCT04054739|Device|Robot-assisted gait training|intervention with robot-assisted gait training
79241062|NCT04054739|Device|Treadmill gait training|intervention with treadmill gait training
79241063|NCT03440073|Other|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
79380694|NCT03323424|Other|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
79380695|NCT03323268|Device|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
79380696|NCT04809298|Device|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
79380697|NCT04809298|Device|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
79535100|NCT05291507|Device|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
79535101|NCT05290064|Other|Ultra-processed food, high energy density|Ultra-processed diet that is high in non-beverage energy density and low in hyperpalatable foods
79535102|NCT05290064|Other|Ultra-processed food, both low|Ultra-processed diet that is low in both non-beverage energy density and hyperpalatable foods
79535103|NCT05290064|Other|Ultra-processed food, both high|Ultra-processed diet that is high in both non-beverage energy density and hyperpalatable foods
79691839|NCT02929199|Other|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
79691840|NCT02929199|Other|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
79691841|NCT03791112|Drug|BPI-16350|BPI-16350 capsules administered orally
79691842|NCT02929355|Other|carotid assesment by duplex ultrasonography|
79691843|NCT02929043|Other|air puffs|
79691844|NCT02928926|Other|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
79691845|NCT05099211|Procedure|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
80008365|NCT02146196|Device|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
80008366|NCT05418569|Device|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
80008367|NCT05418569|Other|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
79691846|NCT05099211|Other|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
79691847|NCT05099211|Biological|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
79837603|NCT00792324|Drug|Etravirine|Four 100mg tablets daily for 12-24 weeks
80008368|NCT02142140|Behavioral|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
80008369|NCT02142140|Behavioral|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
80008370|NCT02142140|Behavioral|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
80008371|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
79241064|NCT03440073|Other|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
79241065|NCT04360629|Drug|Tranexamic Acid|Tranexamic Acid will be given through central vein
79241066|NCT04360629|Drug|normal saline|normal saline will be given through central vein
79535104|NCT05290064|Other|Unprocessed food diet|Unprocessed diet that is low in both non-beverage energy density and hyperpalatable foods
79535105|NCT05288348|Drug|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
79535106|NCT05288348|Drug|standard care pain treatment|standard care pain treatment given in Emergency Department
79535107|NCT05286658|Behavioral|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
79535108|NCT05286658|Behavioral|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
79535109|NCT05286658|Behavioral|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
79691848|NCT05099211|Other|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
79691849|NCT05099211|Other|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~st visit:~Nutritional assessment~Body composition~Psychometric tests of quality of life + IPAQ Test~VO2pic~nd visit:~Neuromuscular tests~Functional tests"
79837604|NCT00792324|Drug|Efavirenz|One 600mg tablet daily
79837605|NCT00747734|Drug|MNRP1685A|Escalating intravenous dose
79837606|NCT00990808|Drug|anacetrapib|[Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks.
79837607|NCT00990808|Drug|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
79837608|NCT00990808|Drug|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
79241067|NCT04741035|Other|Modified sternal precautions|"Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position"
79241068|NCT04741035|Other|Conventional sternal precautions|Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
79837609|NCT00990808|Drug|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
80008372|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
80008373|NCT02148458|Other|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
80008374|NCT02148458|Other|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
80008375|NCT02148536|Procedure|Transjugular intrahepatic portosystemic shunt|
79241069|NCT03445455|Device|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
79380698|NCT03331302|Drug|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
79241070|NCT03445377|Device|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
79380699|NCT03331302|Drug|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
79380700|NCT01738672|Drug|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
79380701|NCT02488512|Drug|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) [45-46], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
79691850|NCT05099211|Other|Evaluation 2 post-surgery|"st visit:~Body composition~Nutritional assessment~Psychometric tests of quality of life~nd visit:~neuromuscular tests~Functional tests~Familiarization with training equipment if patient participates in re-training"
79691851|NCT05099211|Other|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
79691852|NCT05099211|Other|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
80008376|NCT02142218|Drug|Nivolumab|
79241071|NCT03445377|Device|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
79241072|NCT03436719|Drug|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
79241073|NCT03436719|Drug|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
79241074|NCT03436719|Drug|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
79241075|NCT04182659|Device|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
79241076|NCT04182659|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
79241077|NCT04452123|Procedure|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
79380702|NCT03323190|Behavioral|Inpatient COPD education|
79391367|NCT02419638|Drug|Rebif (IFN β-1a subcutaneous three times per week)|
79691853|NCT02928809|Device|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
79837610|NCT00750230|Dietary Supplement|NEM|see Treatment Arm
79837611|NCT00797082|Device|MRI|MRI = Myocardial Perfusion Stress
79837612|NCT00797082|Device|MPS|MPS = Myocardial Perfusion Scintigraphy
79837613|NCT00755144|Device|LCS Knee|Cementless total knee arthroplasty with LCS Knee
80008377|NCT03543800|Device|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
80008378|NCT03543800|Device|PRP kit|PRP kit legally marketed in Canada for PRP
79391368|NCT02419638|Drug|Tecifdera (dimethyl fumarate)|
79535110|NCT05280743|Drug|Oxycodone|exposure to opioids after Cesarean Section
79535111|NCT05260268|Behavioral|TEST Intervention|The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
79535112|NCT05259865|Diagnostic Test|Genetic test for drug response prediction|"There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study."
79535113|NCT05247788|Behavioral|Blood alcohol concentration (BAC) discrimination training|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be trained to accurately estimate their BAC using the Body Scan Exercise with BAC feedback.
80008379|NCT02142296|Drug|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
80008380|NCT02148614|Drug|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
79837614|NCT00755144|Device|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
79691854|NCT02928809|Other|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
79691855|NCT03731598|Procedure|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
79837615|NCT00797160|Drug|propofol|2mg/Kg IV in bolus before tracheal intubation
79837616|NCT00682448|Drug|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
79837617|NCT00682448|Drug|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
79837618|NCT00797238|Other||No intervention in this study
79837619|NCT04003792|Drug|oxaliplatin|intra-arterial oxaliplatin administration
80008381|NCT02148614|Drug|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
79241078|NCT04452123|Procedure|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
79241079|NCT03439995|Other|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
79241080|NCT03439995|Other|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
79535114|NCT05247788|Behavioral|Performance feedback training|This training element targets the driver's self-efficacy by increasing their awareness of the behavioral impairing effects of alcohol that are experienced at BACs at and even below the legal limit (50-80 mg/dl).
79535115|NCT05247788|Behavioral|Blood alcohol concentration (BAC) discrimination training for controls|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be given a general Body Scan Exercise with no feedback.
79837620|NCT04003792|Drug|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
79380703|NCT04790578|Device|ZoeInsights Application|ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
79241081|NCT04452201|Behavioral|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
79241082|NCT01061333|Drug|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
79241083|NCT01061333|Drug|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
79380704|NCT04790578|Behavioral|EXCEL Exercise Class|The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
79391369|NCT02413944|Procedure|ACTH stimulation test|ACTH stimulation test
79535116|NCT05243342|Drug|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
79535117|NCT05243342|Drug|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
79691856|NCT02928731|Other|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
79691857|NCT02928731|Other|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
79691858|NCT02928965|Drug|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
79837621|NCT04003792|Drug|Bevacizumab|systemic bevacuzimab therapy
79837622|NCT00747890|Procedure|Modified tonsillectomy|"Tonsillectomy~Uvulectomy~Soft palatal resection~Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
79837623|NCT00747890|Other|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
79837624|NCT00789048|Other|radiograph|One radiograph with the patient lying on his contralateral side
79837625|NCT00990886|Drug|Placebo|Once daily for 12 weeks
79837626|NCT00990886|Drug|Oxybutynin chloride|15 mg once daily for 12 weeks
79837627|NCT00755300|Procedure|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
79837628|NCT00789126|Drug|VX-509|
79837629|NCT00755378|Drug|AZD8529|Oral
79837630|NCT00755378|Drug|Placebo|Oral
80008382|NCT03889639|Drug|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
80008383|NCT03889639|Drug|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
79241084|NCT01061333|Drug|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
79535118|NCT05242770|Other|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
79535119|NCT05242770|Other|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
79837631|NCT00789204|Other|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
79837632|NCT00789204|Other|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
79241085|NCT01061333|Drug|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
79241086|NCT03445299|Behavioral|Music|Listening to music for 30 minutes at bedtime
79241087|NCT02489968|Drug|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
79380705|NCT03326232|Device|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
79380706|NCT05316454|Behavioral|self-efficacy support|self-efficacy support
79380707|NCT01808651|Drug|Fluoxetine|Administered orally
79380708|NCT03326154|Other|No intervention, observational|Observation
79380709|NCT02488590|Drug|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
79380710|NCT02488590|Drug|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
79535120|NCT05242770|Other|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
79691859|NCT02928965|Drug|Placebo|Matching placebo with appearance of over - encapsulated minocycline
79691860|NCT04679220|Procedure|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
79691861|NCT02928692|Drug|Minocycline|
79535121|NCT05242770|Other|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
79691862|NCT02928692|Drug|Placebo|
79691863|NCT04679142|Drug|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
79837633|NCT01899976|Device|X-Suit NIR Covered Biliary Stent|
79837634|NCT00797394|Dietary Supplement|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
79837635|NCT00797394|Dietary Supplement|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
80008384|NCT03889639|Drug|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
80008385|NCT02148692|Procedure|Higher PEEP|
79241088|NCT02489968|Drug|empagliflozin 10 mg|empagliflozin low dose once daily
79241089|NCT02489968|Drug|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
79241090|NCT02489968|Drug|empagliflozin 25 mg|empagliflozin high dose once daily
79241091|NCT02489968|Drug|Placebo|
79241092|NCT03439761|Drug|PT-112 Injection|PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
79241093|NCT04941586|Other|Education in pain, Manual Therapy and Exercises|twice a week, lasting 60 minutes, for one month
79241094|NCT04941586|Other|Manual Therapy and Exercises|twice a week, lasting 40 minutes, for one month
79691864|NCT02928653|Dietary Supplement|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
79691865|NCT02928419|Drug|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
79691866|NCT02928419|Other|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
80008386|NCT02148692|Procedure|Lower PEEP|
79380711|NCT02488590|Drug|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
79691867|NCT02928419|Drug|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
80008387|NCT02142452|Behavioral|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
79837636|NCT00792480|Behavioral|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
79837637|NCT00681824|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
80008388|NCT02142452|Other|Usual Prenatal Care|
80008389|NCT05418985|Behavioral|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
80008390|NCT02142530|Drug|Carfilzomib|
80008391|NCT02142530|Drug|Belinostat|
80008392|NCT05418439|Dietary Supplement|Drink Poppi Soda|Drink Poppi Vinager Soda
80008393|NCT01383343|Biological|Bevacizumab|Given IV
80008394|NCT01383343|Drug|Fluorouracil|Given IV
80008395|NCT01383343|Drug|Irinotecan Hydrochloride|Given IV
80008396|NCT01383343|Drug|Leucovorin Calcium|Given IV
80008397|NCT01383343|Drug|Sorafenib Tosylate|Given PO
80008398|NCT02254850|Procedure|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
79380712|NCT02488590|Drug|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
79380713|NCT02488590|Drug|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
79535122|NCT05242770|Other|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
79535123|NCT05231785|Drug|ALN-APP|ALN-APP will be administered intrathecally (IT)
79535124|NCT05231785|Drug|Placebo|Placebo will be administered IT
79691868|NCT00554151|Device|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
79691869|NCT02928614|Drug|Liraglutide 3 mg (Saxenda)|
79691870|NCT02928614|Drug|Liraglutide 3 mg placebo|
80008399|NCT02254850|Drug|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
80008400|NCT02254850|Drug|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
80008401|NCT02254850|Drug|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
80008402|NCT02254850|Drug|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
80008403|NCT02142686|Device|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
80008404|NCT02142686|Device|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
79535125|NCT05226351|Drug|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
79535126|NCT05226351|Drug|Placebo|single administration of placebo oral (oily solution)
79535127|NCT05221320|Drug|Ulixertinib|small molecule ERK 1/2 inhibitor
79535128|NCT05221320|Drug|Hydroxychloroquine|Autophagy inhibitor
79691871|NCT02928458|Drug|Omnipaque|
79691872|NCT02928458|Drug|MD-Gastroview|
79691873|NCT03685500|Drug|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
80008405|NCT02142686|Device|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
80008406|NCT05416645|Procedure|patients with GERD after LSG|patients with GERD after LSG
80008407|NCT02148770|Device|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
80008408|NCT03631147|Drug|Rifaximin|400mg bid for 8 weeks
80008409|NCT02148848|Drug|Risedronate|Take risedronate 35 mg orally every week
80008410|NCT03265145|Drug|Stiolto Respimat|Duration - 12 months
80008411|NCT03265145|Drug|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
80008412|NCT03265145|Drug|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
79535129|NCT05204797|Procedure|Robot-assisted UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.
80008413|NCT03265145|Drug|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
80008414|NCT03786679|Device|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
79535130|NCT05204797|Procedure|Standard technique UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
79535131|NCT05203172|Drug|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
79535132|NCT05203172|Drug|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
79691874|NCT03685500|Drug|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
79691875|NCT02928575|Drug|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
79691876|NCT02928575|Drug|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
79691877|NCT02928575|Radiation|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
79691878|NCT05052918|Behavioral|Exercise|1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
79837638|NCT00681824|Procedure|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
79837639|NCT00797472|Drug|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
80008415|NCT02146664|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
80008416|NCT02146664|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
80008417|NCT05402059|Drug|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
80008418|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
80008419|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
80008420|NCT02146742|Drug|ASP1707|oral
80008421|NCT02146742|Drug|Placebo|oral
80008422|NCT05344495|Drug|hyalase group|bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
79535133|NCT05203172|Drug|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
80008423|NCT05344495|Drug|midazolam group|2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
80008424|NCT05079386|Device|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
80008425|NCT01593241|Drug|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
80008426|NCT01593241|Radiation|Involved node RT|Involved node RT
79691879|NCT02928302|Other|TVU CL screening|Transvaginal ultrasound cervical length screening
79691880|NCT02928263|Other|Non-Interventional|Other
79691881|NCT02928146|Procedure|Hernia Repair|
80008427|NCT01590355|Radiation|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
80008428|NCT01590355|Procedure|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
80008429|NCT05960565|Drug|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
80008430|NCT05960539|Procedure|surgical training|surgical residency focussed on visceral robotic procedures
79837640|NCT00797472|Drug|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
79837641|NCT00991042|Other|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
79837642|NCT00789282|Other|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
80008431|NCT05960526|Drug|extract Binahong|Extract Binahong 2.5% as nasal irrigation solution
80008432|NCT05960526|Drug|Isotonic saline nasal irrigation|NaCl 0.9% as nasal irrigation solution
80008433|NCT05960487|Other|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
80008434|NCT05960474|Other|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
80008435|NCT05960435|Other|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
80008436|NCT05960435|Other|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
79241095|NCT04451421|Behavioral|Change of standing Angle|Change the patient's standing Angle by using an electric bed
79241096|NCT03436329|Procedure|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
79380714|NCT01738750|Other|Cost Information Included|
79535134|NCT05203172|Drug|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
79241097|NCT03436329|Procedure|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
79535135|NCT05203172|Drug|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
79535136|NCT05198076|Device|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
79535137|NCT05183854|Biological|Pneumococcal 20-valent Conjugate Vaccine|Given IM
79535138|NCT05183854|Biological|Pneumococcal Polyvalent Vaccine|Given IM
79535139|NCT05183854|Other|Questionnaire Administration|Ancillary studies
79837643|NCT00789282|Other|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
79837644|NCT00789282|Other|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
79837645|NCT00681668|Drug|Quetiapine|150-800 mg, oral, twice a day (bid)
79241098|NCT04451577|Other|No intervention|No intervention, analysis of biological samples
79241099|NCT04451343|Other|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
79380715|NCT02488668|Device|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
79380716|NCT05316376|Drug|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
79380717|NCT05316376|Drug|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
79391370|NCT02460172|Device|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
79837646|NCT00792558|Drug|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
79837647|NCT00539188|Drug|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
79837648|NCT00539188|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
80008437|NCT05960409|Procedure|chest tube - emergency thoracotomy|chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients
80008438|NCT05960396|Behavioral|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
80008439|NCT05960383|Diagnostic Test|BioFire Pneumonia Panel Plus|Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
80008440|NCT05960370|Other|Observational non intervention study|An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
79837649|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|400 IU daily (low dose)
80008441|NCT05960357|Other|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
79535140|NCT05179395|Other|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
79535141|NCT05177705|Behavioral|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
80008442|NCT05960344|Procedure|Spirometry|Supervised v unsupervised spirometry
80008443|NCT05960331|Behavioral|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
80008444|NCT05960331|Behavioral|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
80008445|NCT05960279|Device|MD100|"The MD100 (Medfield Diagnostics, Gothenburg, Sweden) consists of 8 antennas and measurement electronics integrated into a single device; rechargeable ion batteries power the instrument. The radiation transmitted from the device equals approximately 1% of the radiation emitted from a mobile phone. The device is non-invasive and small enough that it can be moved around with ease.~The system transmits microwaves with an output of 0.2 milliWatts (mW) for less than 90 seconds. The power absorbed by the body is 100mW/kg which is a factor of 200 less than what is established by the existing safety standard for microwaves. A mobile phone output, by comparison, can be up to 250mW.~The patient's head is placed in the instrument during measurement while the patient is supine. The procedure takes, on average, 5 minutes to perform."
80008446|NCT05960266|Biological|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
80008447|NCT05960227|Drug|Iron dextran|Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
80008448|NCT05960227|Drug|Placebo|250ml of saline 0,9% for 4 hours insusion.
80008449|NCT05960201|Drug|[18F]fluoroestradiol (FES)|F-18 FES 111~222 MBq(megabecquerel) injection
80008450|NCT05960188|Behavioral|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
79535142|NCT05176704|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
79535143|NCT05175105|Drug|Mitapivat|Tablets or granules
79837650|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|2000 IU daily (high dose)
79837651|NCT04980456|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
79837652|NCT04980456|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
80008451|NCT05960162|Diagnostic Test|90K|Blood test
79837653|NCT04980456|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
79837654|NCT05359432|Drug|Empagliflozin|Receiving allocated drug dosage as per clinical needs
79837655|NCT05359432|Drug|Vildagliptin|Receiving allocated drug dosage as per clinical needs
79837656|NCT00755456|Drug|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
80008452|NCT05960149|Drug|using Indocyanine Green|Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
80008453|NCT05960149|Procedure|Nerve-sparing robot-assisted laparoscopic radical prostatectomy|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
80008454|NCT05960123|Procedure|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
80008455|NCT05960110|Drug|Fluoride varnish|Fluoride varnish 26200 ppm
80008456|NCT05960110|Drug|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
80008457|NCT05960084|Other|screening|screening for colistin resistant E. coli
80008458|NCT05960071|Procedure|protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
80008459|NCT05960071|Procedure|protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
80008460|NCT05960045|Dietary Supplement|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
79535144|NCT05175105|Drug|Mitapivat-matching placebo|Tablets or granules
79535145|NCT05174884|Drug|22.2 mg Etonogestrel (ENG)|Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants
79535146|NCT05174884|Drug|44.4 mg Etonogestrel (ENG)|Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
79535147|NCT05174884|Drug|22.2-66.6 mg Etonogestrel (ENG)|Subdermal insertion of 1-3 Casea S pellets (22.2 - 66.6 mg ENG) in healthy female participants
79535148|NCT05172687|Behavioral|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
79535149|NCT05172687|Behavioral|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
80008461|NCT05960045|Dietary Supplement|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
80008462|NCT05960006|Other|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
80008463|NCT05959967|Behavioral|Vestibular Rehabilitation Exercises|The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
79241100|NCT03444987|Genetic|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~Reduced glutathione, an antioxidant marker by a colorimetric method"
79535150|NCT05169515|Drug|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days for Cycle 1 and 28 days for Cycles 2-12)
79691882|NCT02928068|Behavioral|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
80008464|NCT05959967|Behavioral|General Fitness Training|The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
80008465|NCT05959954|Diagnostic Test|Quantitative Sensory Testing (QST)|Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
80008466|NCT05959889|Other|Placebo|Patients will receive placebo tablets for 4 cycles of AC.
80008467|NCT05959889|Drug|Montelukast|Patients will receive motelukast 10 mg for 4 cycles of AC.
80008468|NCT05959863|Diagnostic Test|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
80008469|NCT05959824|Device|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
79380718|NCT03326076|Diagnostic Test|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
79380719|NCT03326076|Other|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
79535151|NCT05169515|Drug|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
79535152|NCT05169515|Drug|CC-220|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
79535153|NCT05169515|Drug|CC-99282|Arm 1: Participants will receive oral CC-99282 from Day 1-14 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-99282 from Day 1-10 of Cycle 3-12 (cycle length = 21 days)
79535154|NCT05169515|Drug|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
79691883|NCT02927951|Drug|Pregabalin|150mg bid
80008470|NCT05959824|Other|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
80008471|NCT05959798|Procedure|High power short duration ablation|Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
79380720|NCT03326076|Diagnostic Test|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
79391371|NCT02460172|Device|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
79535155|NCT05169515|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
79535156|NCT05162755|Drug|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
79691884|NCT02927951|Drug|Placebo|150mg bid
79241101|NCT03436251|Device|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
79241102|NCT03436251|Device|LEEP or cold knife|For patients with HPV+ / CIN-2
80008472|NCT05959785|Procedure|Basic and light cervical mobilization exercises|This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
80008473|NCT05959785|Procedure|Abdominal or diaphragmatic breathing exercises|The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
80008474|NCT05959772|Radiation|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
79380721|NCT03326076|Diagnostic Test|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
79380722|NCT01743976|Drug|Donepezil|donepezil 5 mg once daily for 6 weeks
80008475|NCT05959759|Drug|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months), 30 patients for this arm.
80008476|NCT05959759|Drug|Placebo|placebo with the same appearance (color, taste, size, shape), 30 patients for this arm.
80008477|NCT05959681|Device|Compression garment with Vari-pad microdots ink-printed on inside.|Initially, participants wear a garment with Vari-pads on one side (left or right) only and swap to a garment with Vari-pads on both sides if / when the participants notice a difference between the sides. Wearing garment 8 hours per 24 hours.
80008478|NCT05959616|Biological|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
80008479|NCT05959616|Drug|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
80008480|NCT05959603|Drug|Vancomycin|Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
80008481|NCT05959590|Drug|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
79691885|NCT02927678|Other|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
79691886|NCT03457532|Drug|Glumetinib for tablet|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
80008482|NCT05959577|Procedure|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
79380723|NCT01743976|Drug|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
80008483|NCT05959577|Procedure|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
79380724|NCT05316064|Biological|probiotic|oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
79535157|NCT05162755|Drug|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
79535158|NCT05162755|Drug|S095029 and Sym021 and anti-HER2 therapy|Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
79535159|NCT05162755|Drug|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
79535160|NCT05160597|Procedure|Biopsy of Prostate|Undergo image-guided prostate biopsy
80008484|NCT05959551|Device|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
80008485|NCT05959460|Other|Deuterium dose-to-mother method for assessing breastfeeding|Exclusive breastfedding practice was compared between maternal recall and the deuterium dose-to-mother method.
80008486|NCT05959408|Procedure|Collection of throat swab|Introduction of a cotton swab for self-collection
80008487|NCT05959408|Procedure|Collection of anal swab|Introduction of a cotton swab for self-collection
80008488|NCT05959408|Procedure|Collection of first void urine|first void urine collected on urine pot
80008489|NCT05959382|Device|Dental Loupe|Magnification aid
80008490|NCT05959382|Device|Dental Operation Microscope|Magnification aid
79535161|NCT05160597|Other|Gallium Ga 68 Gozetotide|Given IV
79535162|NCT05160597|Procedure|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
79380725|NCT05316064|Other|placebo|oral administration of primarily carrier without the probiotic for 12 weeks
79380726|NCT05315986|Dietary Supplement|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
79380727|NCT05315986|Behavioral|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
79380728|NCT05315986|Dietary Supplement|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
79837657|NCT00755456|Drug|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
79837658|NCT00991120|Device|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
79535163|NCT05158140|Biological|V110|Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
79691887|NCT02927600|Other|Low GI Breakfast|Intake of low GI breakfast
79837659|NCT00755534|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
80008491|NCT05959369|Diagnostic Test|y balance test, core endurance and strength test, foot posture ındex|First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
80008492|NCT05959304|Other|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
79241103|NCT03436251|Device|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
79241104|NCT03129165|Other|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
79241105|NCT03436173|Drug|Fluoxetine|Fluoxetine 10 mg/2.5 ml mixed with water
79241106|NCT03436173|Other|Peppermint syrup|Liquid peppermint syrup measured to the equivalent volume and mixed with water
79241107|NCT03436095|Other|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
79241108|NCT03444831|Drug|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
79241109|NCT03444831|Drug|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
79241110|NCT03439215|Drug|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
79535164|NCT05158140|Biological|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
79535165|NCT05158140|Biological|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
79535166|NCT05158140|Biological|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
79535167|NCT05158140|Biological|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
79535168|NCT05155345|Drug|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
79691888|NCT02927600|Other|High GI Breakfast|Intake of high GI breakfast
79691889|NCT02927600|Other|Low GI Dinner|Intake of Low GI dinner
79241111|NCT03439059|Behavioral|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (>1.5 METS) 3x/day for 6 weeks
79241112|NCT03128463|Drug|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
79535169|NCT05155345|Drug|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
79535170|NCT05155202|Drug|Antihypertensive Agents|Administration of intravenous Nicardipine or Urapidil
79691890|NCT02927600|Other|High GI Dinner|Intake of high GI dinner
79691891|NCT02927561|Other|Diabetic Retinopathy screening|Diabetic Retinopathy screening
79691892|NCT02927405|Drug|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
79691893|NCT02927405|Procedure|TAP Block|a procedure done anesthetize the anterior abdominal wall
79691894|NCT02927444|Biological|NBP606|A single intramuscular injection into the thigh
79691895|NCT02927444|Biological|Prevnar13|A single intramuscular injection into the thigh
79691896|NCT04967820|Other|resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak
79691897|NCT02927483|Dietary Supplement|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
79691898|NCT02927483|Dietary Supplement|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
79837660|NCT00755534|Drug|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
79837661|NCT00755534|Drug|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
79837662|NCT00755534|Drug|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
79837663|NCT00326599|Drug|carboplatin|Given IV
79837664|NCT00326599|Drug|cediranib maleate|Given orally
79837665|NCT00326599|Drug|gemcitabine hydrochloride|Given IV
79837666|NCT00797550|Biological|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
79837667|NCT00797550|Procedure|Autologous bone graft|
80008493|NCT05959278|Other|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
79837668|NCT05004688|Biological|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
79837669|NCT00797628|Behavioral|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
79837670|NCT00797628|Behavioral|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
80008494|NCT05959265|Behavioral|exercise|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
80008495|NCT05959239|Drug|TB006|TB006 will be provided as single-use injectable glass vials.
80008496|NCT05959226|Behavioral|Exercise Intervention|"Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
80008497|NCT05959226|Dietary Supplement|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
80008498|NCT05959187|Diagnostic Test|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
80008499|NCT05959174|Device|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
79380729|NCT05464212|Procedure|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
79391372|NCT03176550|Device|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
79691899|NCT02927210|Drug|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
79691900|NCT02927210|Drug|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
79691901|NCT04679649|Other|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
79691902|NCT02927522|Drug|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
79691903|NCT02927522|Drug|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
79837671|NCT00750386|Drug|Paclitaxel|175 mg/m2, I.V, every 2 weeks
79837672|NCT00750386|Drug|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
80008500|NCT05959174|Device|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
80008501|NCT05959161|Procedure|DBS|We observed the prognostic changes of patients after DBS surgery
80008502|NCT05959148|Other|Monochromatic infrared energy|The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
80008503|NCT05959148|Other|Traditional physical therapy|The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
79837673|NCT04972266|Device|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
79691904|NCT04679688|Other|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
79691905|NCT04679493|Drug|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
79837674|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79837675|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79837676|NCT00797706|Drug|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
79837677|NCT00685802|Drug|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
79837678|NCT00685802|Drug|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
80008504|NCT05959122|Diagnostic Test|CBC serum iron serum ferritin|"Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin"
80008505|NCT05958992|Other|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
80008506|NCT05958979|Other|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
80008507|NCT05958979|Other|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
80008508|NCT05958966|Other|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
80008509|NCT05958953|Procedure|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
80008510|NCT05958940|Procedure|Bright Light Therapy|In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR < 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
79241113|NCT04953364|Behavioral|SMART|SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
79535171|NCT05144984|Drug|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
79535172|NCT05144984|Drug|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
79837679|NCT00991198|Drug|Topical oxygen|0.5% concentration of Topical oxygen
80008511|NCT05958940|Device|Blue Light Blocking Glasses|Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
79535173|NCT05144984|Drug|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
79837680|NCT00991198|Drug|Topical oxygen|0.25% concentration topical oxygen
80008512|NCT05958914|Diagnostic Test|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
80008513|NCT05958914|Diagnostic Test|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
80008514|NCT05958914|Diagnostic Test|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
79535174|NCT05144984|Drug|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
79535175|NCT05144256|Drug|Mitapivat|Tablets or granules
80008515|NCT05958914|Diagnostic Test|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
80008516|NCT05958914|Diagnostic Test|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
80008517|NCT05958914|Diagnostic Test|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
79241114|NCT04953364|Behavioral|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
79241115|NCT03438903|Device|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
79691906|NCT04679493|Drug|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
79241116|NCT01061177|Drug|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
79241117|NCT02481934|Procedure|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
79691907|NCT04679493|Drug|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
79691908|NCT04679493|Drug|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
79691909|NCT04679493|Drug|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
79535176|NCT05144256|Drug|Mitapivat-matching placebo|Tablets or granules
79837681|NCT00991198|Drug|placebo|no O2
79837682|NCT01054651|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
79535179|NCT05132582|Drug|Tucatinib|300mg given by mouth (orally) twice daily
79535180|NCT05132582|Drug|Trastuzumab|6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
79535181|NCT05132582|Drug|Pertuzumab|420mg given by IV every 21 days
79535182|NCT05132582|Drug|Combination product: Trastuzumab + Pertuzumab|600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
79535183|NCT05132582|Drug|Placebo|Given orally twice daily
79837683|NCT01054651|Drug|Praziquantel|
79837684|NCT00792714|Drug|Mannitol|400mg twice daily for 7 days
79837685|NCT04961554|Other|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
79837686|NCT04059692|Other|Cervical manipulation intervention|Cervical manipulative technique
79535184|NCT05131945|Other|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
79837687|NCT04059692|Other|Placebo intervention|Sham intervention
80008518|NCT05958914|Diagnostic Test|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
80008519|NCT05958914|Diagnostic Test|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
80008520|NCT05958901|Other|pulmonary hypertension|The final outcome observed was a diagnosis of pulmonary hypertension.
80008521|NCT05958849|Drug|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
80008522|NCT05958836|Device|pacemaker|Micra TPS or traditional PM group
80008523|NCT05958823|Procedure|Serratus anterior plane block|Serratus anterior plane block
80008524|NCT05958823|Procedure|PECS I-II|PECS I-II
80008525|NCT05958810|Drug|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)"
80008526|NCT05958810|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
79241118|NCT02481934|Drug|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
79241119|NCT02481934|Drug|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
79241120|NCT03436017|Other|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
79535185|NCT05131945|Other|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
79241121|NCT03438825|Procedure|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
79241122|NCT03444519|Drug|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
79241123|NCT04309383|Diagnostic Test|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
79391373|NCT02422836|Other|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
79391374|NCT02419924|Device|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
79837688|NCT00789594|Behavioral|laboratory monitoring alerts|laboratory monitoring alerts
79837689|NCT00789594|Behavioral|Result management module|Result management module
79535188|NCT05128825|Drug|ZN-c3|ZN-c3 is an investigational drug.
80008527|NCT05958797|Drug|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
79391375|NCT02419482|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
79535189|NCT05125562|Drug|ExoFlo|Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
80008528|NCT05958797|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
79241124|NCT03129009|Drug|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
79241125|NCT03129009|Drug|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
79241126|NCT03129087|Behavioral|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
79241127|NCT03438669|Other|no intervention|no intervention
79241128|NCT03438591|Device|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
79241129|NCT02973425|Behavioral|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience & Suite of mHealth motivational tools and mini-games.
79241130|NCT02973425|Behavioral|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
79241131|NCT03435861|Drug|VX-745|active drug capsules
79241132|NCT03435861|Drug|placebo|placebo capsules
79241133|NCT02489500|Drug|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
79241134|NCT02489500|Drug|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
79837690|NCT00354601|Drug|capecitabine|oral capecitabine twice daily on days 1-21
79837691|NCT00354601|Drug|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
80008529|NCT05958784|Dietary Supplement|L-Phenylalanine|100 mg/kg
80008530|NCT05958771|Drug|ROTAVAC 5D|monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU
80008531|NCT05958771|Drug|Placebo|Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
80008532|NCT05958758|Drug|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
79241135|NCT02489500|Drug|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
80008533|NCT05958745|Behavioral|Aerobic Exercise|Aerobic exercise training Program
80008534|NCT05958745|Behavioral|Aerobic + resistance exercise|Aerobic + resistance exercise training Program
80008535|NCT05958732|Other|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
80008536|NCT05958732|Other|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
80008537|NCT05958719|Drug|Chidamide|chidamide 30mg biw, p.o, 28 days for a cycle.
80008538|NCT05958719|Drug|Azacitidine|75mg/m2, continuous i.h. on day 1-7，28 days for a cycle.
80008539|NCT05958290|Other|Discontinuation of antibiotics|Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
80008540|NCT05958251|Other|Cicaben|Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
80008541|NCT05958043|Device|3D- printed Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
80008542|NCT05958043|Device|CAD/CAM-milled Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
80008543|NCT05956938|Device|Stroboscopic Glasses|"A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus).~The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz)"
80008544|NCT05956938|Device|Action Video Game|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
79241136|NCT02489500|Procedure|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
79241137|NCT02489500|Procedure|Stem cell infusion|infusion of previously collected autologous stem cells
79241138|NCT03438513|Behavioral|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
79241139|NCT03438513|Behavioral|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
79241140|NCT03438513|Behavioral|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
79241141|NCT03438513|Behavioral|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
79241142|NCT03652649|Other|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
79241143|NCT03438435|Drug|QRH-882260 Heptapeptide|Imaging agent
79241144|NCT04053959|Drug|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
79241145|NCT04053959|Drug|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
79535190|NCT05123326|Diagnostic Test|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
79303094|NCT03069885|Device|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
79535191|NCT05123326|Diagnostic Test|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
79535192|NCT05123326|Diagnostic Test|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
79535193|NCT05121051|Procedure|Biospecimen Collection|Undergo collection of blood, buccal cell, and nasal epithelial cell samples
79535194|NCT05121051|Dietary Supplement|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
79535195|NCT05121051|Drug|Placebo Administration|Given PO
80008545|NCT05956314|Drug|IMP Application KM-001|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
80008546|NCT05956314|Diagnostic Test|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, and at ET visit):~The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~Symptom-directed physical examinations will be performed at all other trial visits.~Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
80008547|NCT05956314|Diagnostic Test|Vital Signs|"Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, and at ET visit. Vital signs will be measured in supine position after at least 5 minutes of rest.~Will be examined pre-dose at Visit 2 (Day 1, enrolment)."
80008548|NCT05956314|Diagnostic Test|Serum chemistry|"Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments at the screening visit, on Days 1 (baseline), 7, and 84 (EoT), at the follow-up visit on Day 112 or ET visit. Serum chemistries will include assessment of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.~Will be examined pre-dose at Visit 2 (Day 1, enrolment)."
79241146|NCT03433443|Behavioral|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
79241147|NCT03433443|Behavioral|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
79241148|NCT03652571|Drug|Nortriptyline|"Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg"
79241149|NCT03652571|Drug|Placebo|Placebo
79837692|NCT05360914|Other|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
79837693|NCT05360914|Other|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
79837694|NCT00792792|Device|Modulated Imaging|Modulated Imaging Spectroscopy
79241150|NCT03433365|Other|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
79837695|NCT01563640|Other|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
79241151|NCT03652103|Procedure|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
79241152|NCT03652103|Drug|Bupivacaine 0.25% Injectable Solution|Perineural Injection
79241153|NCT03433209|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
79241154|NCT03433209|Device|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
79391376|NCT02419482|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
79391377|NCT02461966|Other|Aflatoxin|Evaluation of Aflatoxin level
79391378|NCT03179358|Device|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
79535196|NCT05121051|Other|Questionnaire Administration|Ancillary studies
79535197|NCT05117502|Device|intermittent Theta Burst Stimulation|intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
79535198|NCT05117502|Device|Placebo intermittent Theta Burst Stimulation|The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
79837696|NCT01563640|Other|washing|normal washing of school uniforms, without permethrin insecticide impregnation
79535199|NCT05112601|Procedure|Biospecimen Collection|Undergo collection of blood samples
79535200|NCT05112601|Procedure|Computed Tomography|Undergo CT
79837697|NCT00792870|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
79837698|NCT00750620|Drug|YM178|oral
79837699|NCT03827473|Drug|Abiraterone Acetate|Given PO
79837700|NCT03827473|Drug|Antiandrogen Therapy|Given per standard of care
79837701|NCT03827473|Drug|Docetaxel|Given IV
80008549|NCT05956314|Diagnostic Test|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) at the screening visit, on Days 1 (baseline), 7, and 84 (EoT), at the follow-up visit on Day 112 or at ET visit. The CBC assessment will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute [abs.]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
80008550|NCT05956314|Diagnostic Test|Serology|Approx. 5 mL whole blood will be collected for serology assessments at the screening visit. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
80008551|NCT05956314|Diagnostic Test|Urinalysis|General urinalysis will be performed, by dipstick, at the screening visit, on Days 1 (baseline), 7, and 84 (EoT), at the follow-up visit on Day 112 and at ET visit. At least 7 to 10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
80008552|NCT05956314|Diagnostic Test|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84 and 112, and at ET visit After the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTC interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
80008553|NCT05956314|Diagnostic Test|Pharmacokinetics Assessments|"Blood samples for PK will be collected at screening (Day -1 to -7) at any time during the visit, on Days 7 and 84 (EoT) at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28 and 42 visit: 1 sample after the first dose, before the second dose, as late as possible in the visit, on Day 112 and ET visit: at any time during the visit.~• Altogether approx. 24 mL of blood will be withdrawn for PK at the screening and on Days 7, 28, 42, 84, and 112 or at ET visit."
79535201|NCT05112601|Biological|Ipilimumab|Given IV
79241155|NCT03444441|Procedure|Foot or ankle surgery|Surgery for foot or ankle
79241156|NCT03652337|Device|BlephEx|Electronic lid margin debridement
79241157|NCT03652337|Device|Manual debridement|Manual lid margin debridement
79241158|NCT03652025|Procedure|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
79241159|NCT03444363|Device|Laser group|Laser application in addition to SRP
79241160|NCT03444363|Device|Control group|Placebo laser application in addition to SRP
79241161|NCT01725425|Other|Control|The control is designed to determine average mood.
79241162|NCT01725425|Other|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
79241163|NCT01725425|Other|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
79535202|NCT05112601|Procedure|Magnetic Resonance Imaging|Undergo MRI
79837702|NCT03827473|Drug|Prednisone|Given PO
79535203|NCT05112601|Biological|Nivolumab|Given IV
79837703|NCT03827473|Other|Quality-of-Life Assessment|Ancillary studies
79837704|NCT03827473|Other|Questionnaire Administration|Ancillary studies
79837705|NCT00800592|Drug|sildenafil|10 mg sildenafil bolus
79837706|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
79837707|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
79241164|NCT01725425|Other|Mixed Portions|The purpose is to determine if a change in mood will occur.
79241165|NCT03444285|Other|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
79241166|NCT03444285|Other|Hot Pack|20 minutes of hot-pack on both hamstring
79241167|NCT03651947|Drug|QL1206|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
79241168|NCT03651947|Drug|Xgeva®|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
79241169|NCT02732847|Other|A delayed prescription dated 2 days after clinical office visit|
79241170|NCT02732847|Drug|Usual Dated|
79241171|NCT04003701|Behavioral|Usual care|Control group: minimal distraction
79241172|NCT04003701|Behavioral|Robot-assisted puncture procedure|Experimental group: distraction with robot
79303095|NCT03069885|Other|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
79391379|NCT02413710|Other|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
79391380|NCT02413710|Behavioral|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
79391381|NCT02419950|Device|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
79391382|NCT03179592|Drug|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
79837708|NCT00755690|Behavioral|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
79837709|NCT00991354|Biological|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
79837710|NCT00991354|Biological|IL-12 DNA plasmids|Adjuvant for HIV vaccines
79837711|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
79837712|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
79535204|NCT05106647|Behavioral|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
79691910|NCT02927132|Behavioral|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
79837713|NCT00755768|Behavioral|additional review by dietician|
79837714|NCT05360836|Other|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
79837715|NCT05360836|Other|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
79837716|NCT00797784|Drug|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
79837717|NCT03983395|Biological|ISB 1302 250 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
80008554|NCT05956314|Diagnostic Test|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, and at ET visit).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
79241173|NCT05006703|Behavioral|Breathe4T|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma and how it affects the lungs, as well as how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan their practice, log how their practice went and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include FAQs and a progress chart.
79241174|NCT03651869|Drug|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
80016782|NCT03662061|Other|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
80016783|NCT02250378|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
79241175|NCT03651869|Drug|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
79241176|NCT03651869|Drug|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
79241177|NCT03651869|Drug|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
79837718|NCT03983395|Biological|ISB 1302 325 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
79241178|NCT04966221|Diagnostic Test|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
79241179|NCT03651791|Combination Product|USPIO labeled MSC injection|USPIO labeled MSC injection
79241180|NCT04053647|Other|Non-interventional study|Non-interventional study
79535205|NCT05103839|Behavioral|Gentle Yoga|Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
79535206|NCT05103332|Drug|Olmesartan|Olmesartan administered orally
79535207|NCT05103332|Drug|Amlodipine|Amlodipine administered orally
79535208|NCT05103332|Drug|Indapamide|Indapamide administered orally
79535209|NCT05103332|Drug|Placebo|Placebo administered by subcutaneous (SC) injection
79837719|NCT03983395|Biological|ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
79837720|NCT03983395|Biological|ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
79535210|NCT05103332|Drug|Zilebesiran|Zilebesiran administered by SC injection
79535211|NCT05098392|Behavioral|Sibling-mediated intervention|Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
79691911|NCT02927132|Behavioral|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
79241181|NCT04958655|Behavioral|Tetris Task|a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
79691912|NCT02927054|Other|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
79691913|NCT04938648|Behavioral|Pharmacist-led deprescribing intervention|1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
79691914|NCT02926976|Drug|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
79691915|NCT02926976|Drug|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
79691916|NCT02926976|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
79837721|NCT03983395|Biological|ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
79837722|NCT03983395|Biological|ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
79837723|NCT03983395|Biological|ISB 1302 escalating doses,1200 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
79241182|NCT04958655|Behavioral|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
79241183|NCT03651323|Device|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
79391383|NCT02413632|Other|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
79391384|NCT02413632|Other|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
79535212|NCT05094466|Behavioral|Behavioral Intervention|Receive peer support sessions
79535213|NCT05094466|Other|Counseling|Receive health coaching sessions
79535214|NCT05094466|Procedure|Discussion|Attend focus groups
79535215|NCT05094466|Other|Educational Intervention|Receive handbook
79837724|NCT03983395|Biological|ISB 1302 at the MTD and/or RP2D dose|ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
79837725|NCT00747968|Drug|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol*kg-1*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
79837726|NCT00793026|Drug|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
79837727|NCT00755924|Dietary Supplement|Vinegar|Apple cider vinegar 2 TBlsp/day
79241184|NCT03435549|Behavioral|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
79535216|NCT05094466|Other|Informational Intervention|Receive navigation sessions
79535217|NCT05094466|Other|Interview|Participate in interview
79535218|NCT05092347|Drug|REGN5459|Administered by intravenous (IV) infusion
79535219|NCT05092347|Drug|REGN5458|Administered by intravenous (IV) infusion
79535220|NCT05091567|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
79391385|NCT02421094|Drug|GR-MD-02|GM-MD-02 active
79391386|NCT02421094|Drug|Placebo|Placebo
79391387|NCT03179514|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
79391388|NCT03179514|Drug|Lipid Regulating Drugs|Mainly including statins
79391389|NCT03179514|Drug|Coronary Vasodilator|Mainly including nitrates
79391390|NCT03179514|Drug|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
79391391|NCT02462122|Drug|IDP-118 Lotion|Lotion
79391392|NCT02462122|Drug|IDP-118 Vehicle Lotion|Lotion
79535221|NCT05091567|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
79535222|NCT05091567|Drug|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
79535223|NCT05091567|Drug|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
79241185|NCT03435549|Behavioral|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
79241186|NCT03651713|Behavioral|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
79241187|NCT03651713|Dietary Supplement|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
79241188|NCT03433131|Drug|Pitolisant|Tablets
79241189|NCT03651557|Drug|Neu2000KWL High-dose group|1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
79380730|NCT05464212|Procedure|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
79691917|NCT02926976|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
79535224|NCT05087095|Behavioral|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy~Within one week after its completion,~3 months after the CALM intervention is complete~After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
79535225|NCT05084391|Device|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
79691918|NCT02926976|Device|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
79691919|NCT02926976|Device|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
79691920|NCT04917393|Device|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
79691921|NCT04917393|Other|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
79691922|NCT03455166|Diagnostic Test|Serum Markers|Serum Markers
79241190|NCT03651557|Drug|Neu2000KWL Low-dose group|1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
79241191|NCT03651557|Drug|Placebo|1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
79241192|NCT05056467|Procedure|Induction of Labor|Induction of Labor at 39 weeks of gestation
79241193|NCT03435471|Other|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
79535226|NCT05084391|Other|Standard of Treatment|Standard of care
79535227|NCT05083338|Procedure|Biospecimen Collection|Undergo blood sample collection
79535228|NCT05083338|Procedure|Pain Assessment|Undergo pain assessment
79535229|NCT05083338|Other|Questionnaire Administration|Complete questionnaires
79535230|NCT05081245|Drug|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
79535231|NCT05081245|Drug|ML-004 Placebo|Participants will receive matching placebo once daily.
79535232|NCT05070871|Dietary Supplement|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
79535233|NCT05070871|Other|Placebo|Pure maltodextrin.
79535234|NCT05070871|Dietary Supplement|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
79535235|NCT05069415|Device|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
79691923|NCT02927015|Other|Purple Majesty potato chips|Purple Majesty potato chips
79691924|NCT02927015|Other|Mountain Rose potato chips|Mountain Rose potato chips
79691925|NCT02927015|Other|White potato chips|White potato chips
79691926|NCT02927015|Other|Crackers|Crackers
79837728|NCT00755924|Other|Placebo|Water placebo colored with balsamic vinegar
79837729|NCT00797940|Drug|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
79837730|NCT00800748|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
79837731|NCT00800748|Drug|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
80008555|NCT05956314|Diagnostic Test|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment period (Days 1, 7, 28, 42, 63, 84, and ET visit).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
80008556|NCT05956314|Diagnostic Test|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit (Days 1, 7, 28, 42, 63, 84) and at ET visit.~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
80008557|NCT05956314|Diagnostic Test|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, and at ET visit.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
80008558|NCT05956314|Diagnostic Test|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, and at ET visit.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
80008559|NCT05956314|Diagnostic Test|Lesion photography|"High-quality photographic documentation of the treated lesions will be performed on Days 1, 7, 42, 63, 84, 112 and at ET visit before treatment if applicable.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
80008560|NCT05956015|Other|stable isotopes|The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
80008561|NCT05955976|Other|BIOPSY|biopsy
79691927|NCT02926820|Behavioral|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
80016784|NCT02250378|Procedure|therapeutic conventional surgery|Undergo wedge resection
80016785|NCT02250378|Other|laboratory biomarker analysis|Correlative studies
79241194|NCT03435471|Other|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
79241195|NCT03435393|Procedure|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
79380732|NCT05315830|Biological|HER2 Tumor Vaccine|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
79691928|NCT04910412|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
79691929|NCT02926781|Device|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
79241196|NCT02489344|Drug|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
79691930|NCT00553956|Behavioral|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
79691931|NCT02926742|Device|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
79691932|NCT04887246|Biological|COVID-19 vaccines|COVID-19 vaccines available at Colombia
79837732|NCT00345397|Device|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
79380733|NCT05315830|Biological|HER2 Tumor Vaccine+ Standard of Care chemotherapy|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
79380734|NCT05464056|Behavioral|Be Unstoppable in Life Together (BUILT)|Participants will complete weekly sleep, food, and exercise home challenges focused on creating sustainable healthy eating, sleep, and exercise routines. Parents will participate in weekly support calls by UIC and Chicago Park District staff to provide support and accountability. Children will have the opportunity to win small prizes based on completing weekly challenges. The intervention will be co-facilitated by UIC students and Chicago Park District staff and will largely take place on-line. For additional details visit: https://built.ahs.uic.edu.
79391393|NCT00707304|Drug|Talactoferrin|Oral, 1.5 grams twice per day
79391394|NCT00707304|Drug|Placebo|Oral, twice per day
79837733|NCT00793260|Behavioral|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
79691933|NCT02926703|Other|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
79691934|NCT04878549|Diagnostic Test|5-gene transcription signature|This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
80008562|NCT05955885|Drug|Flurbiprofen Oral Lozenge|This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
80008563|NCT05955885|Drug|Difflam|This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
79241197|NCT03433053|Behavioral|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
79241198|NCT03433053|Behavioral|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
79380735|NCT03322956|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
79380736|NCT04442568|Other|ERAS|early mobilisation, early oral intake, early discharge
79380737|NCT04716322|Behavioral|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
79691935|NCT02926664|Other|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
79837734|NCT00793260|Behavioral|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
79380738|NCT03109236|Drug|GCSF|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
79391395|NCT02423122|Drug|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
79837735|NCT00756080|Drug|citrulline|0.06 G/kg three times/day during 7 days
79837736|NCT00756080|Drug|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
79837737|NCT00798252|Drug|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
79837738|NCT00798252|Drug|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
79837739|NCT00798252|Drug|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
80008564|NCT05955885|Drug|Flurbiprofen 8.75 MG|This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
79535236|NCT05069415|Device|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
79535237|NCT05065944|Behavioral|Telemedicine|Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.
79535238|NCT05065944|Behavioral|In Person Visit|Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
79535239|NCT05057702|Other|Specialized Tumor Board Treatment Plan|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
80008565|NCT05952752|Other|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
80008566|NCT05952752|Other|Dexamethsone IV|4 mg IV dexamethasone
79535240|NCT05057494|Drug|Acalabrutinib|Dose formulation: Capsule or Tablet
79535241|NCT05057494|Drug|Venetoclax|Dose formulation: Tablet
79535242|NCT05057494|Drug|Obinutuzumab|Dose formulation: Injection
79241199|NCT04451031|Behavioral|LiFT Program|
79691936|NCT02926625|Behavioral|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~Children who are getting worse should come back immediately or at any time for a re-assessment~All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~HEW should fill out a loose child assessment form~If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
79691937|NCT02926625|Behavioral|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
79691938|NCT02926508|Dietary Supplement|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
79691939|NCT02926508|Other|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
79691940|NCT02926469|Device|Virtual Reality|Using Virtual Reality during labor
79691941|NCT04680195|Drug|Thalidomide|"The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months."
79691942|NCT02926313|Other|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
79380739|NCT03109236|Procedure|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10^6 and up to 50-100 x 10^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
79380740|NCT05463822|Drug|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
79241200|NCT03432975|Drug|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
79380741|NCT04639960|Drug|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
79380742|NCT04639960|Drug|Placebo|Twelve weeks of placebo treatment.
79691943|NCT04864431|Dietary Supplement|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
79691944|NCT04864431|Other|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
79691945|NCT02926118|Dietary Supplement|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
79691946|NCT02926118|Dietary Supplement|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
79691947|NCT00553995|Drug|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
79691948|NCT00553995|Drug|Placebo|
79241201|NCT03432975|Drug|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
79241202|NCT04906629|Biological|INO-4201|One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
79380743|NCT03320616|Drug|EYP001a|Oral EYP001a capsules - 100 mg strength
79380744|NCT04597996|Other|web based education for students|"Web-based education will include modules on the following subjects;~Mental health literacy knowledge level~Improving help-seeking behavior~Avoiding self-stigmatization in seeking psychological help"
79380745|NCT03109314|Drug|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
79691949|NCT02926430|Biological|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
79691950|NCT02926430|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
79691951|NCT02926430|Drug|Placebo|Participants will receive placebo as formulation buffer.
79691952|NCT04798287|Drug|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
79691953|NCT04798287|Drug|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
79691954|NCT02926157|Behavioral|Life Style and Sleep Intervention|
79691955|NCT04798209|Drug|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
79691956|NCT04798209|Drug|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
79691957|NCT04798209|Drug|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
79691958|NCT04798209|Drug|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
79691959|NCT04798209|Drug|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
80016786|NCT02250378|Other|quality-of-life assessment|Ancillary studies
79241203|NCT04906629|Biological|Placebo|One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
79691960|NCT04798209|Drug|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
79691961|NCT04798209|Drug|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
79691962|NCT04798209|Drug|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
79691963|NCT04784013|Procedure|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
79691964|NCT04784013|Procedure|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
79691965|NCT02926040|Procedure|Irreversible electroporation|
79691966|NCT04783350|Device|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
79691967|NCT02925767|Device|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
80008567|NCT05950789|Other|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
80008568|NCT05950568|Procedure|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
79241204|NCT03444207|Behavioral|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
79241205|NCT03444207|Behavioral|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
79241206|NCT03444129|Behavioral|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
79241207|NCT03444129|Behavioral|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
79380746|NCT03109314|Behavioral|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
79380747|NCT03109314|Behavioral|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
79380748|NCT04566016|Procedure|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
79380749|NCT03320538|Other|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
79380750|NCT03320538|Other|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
79691968|NCT02925767|Device|308-nm excimer laser|XTRAC, PhotoMedex, US
79380751|NCT03320538|Drug|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
79547308|NCT01553513|Procedure|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
79691969|NCT04764708|Behavioral|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
79691970|NCT04764708|Behavioral|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
79691971|NCT02925962|Other|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
79837740|NCT00798252|Drug|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
79241208|NCT03444051|Procedure|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
79241209|NCT03444051|Procedure|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
79241210|NCT02488330|Drug|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
79691972|NCT02925962|Other|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
79241211|NCT02488330|Drug|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
79380752|NCT03322878|Drug|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
79241212|NCT02488330|Drug|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
79380753|NCT03322800|Drug|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
79241213|NCT04451499|Other|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
79303096|NCT02475941|Other|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
79380754|NCT03322800|Other|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
79380755|NCT03325998|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
79380756|NCT03325920|Device|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
79380757|NCT03320460|Drug|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
79380758|NCT03320460|Device|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
79691973|NCT02925845|Device|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
79837741|NCT00798252|Drug|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
79380759|NCT03320460|Other|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
79837742|NCT00798252|Drug|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
79380760|NCT03320460|Other|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
79380761|NCT03325764|Other|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
79837743|NCT00748046|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
79837744|NCT00326209|Drug|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
79380762|NCT02488434|Device|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
79241214|NCT03435159|Diagnostic Test|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
80008569|NCT05950568|Procedure|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
79241215|NCT03435159|Procedure|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
79380763|NCT01746784|Drug|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
79380764|NCT01746784|Drug|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
79380765|NCT04493970|Other|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
79380766|NCT04513678|Behavioral|ImmunOncoTool Condition|Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
79380767|NCT00706134|Drug|Placebo|Placebo tablet taken once daily in the morning with a light meal.
79380768|NCT00706134|Drug|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
79380769|NCT00706134|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
79380770|NCT00706134|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
79535243|NCT05056922|Behavioral|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
79535244|NCT05056922|Behavioral|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment & Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
79535245|NCT05056220|Drug|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
79535246|NCT05056220|Drug|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
79535247|NCT05049837|Other|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
79535248|NCT05049837|Other|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
79535249|NCT05049837|Other|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
79535250|NCT05049837|Other|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
79535251|NCT05049837|Other|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
79535252|NCT05049837|Other|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
79535253|NCT05047536|Drug|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
79535254|NCT05037968|Device|MagnetOs Flex Matrix|Procedure: Instrumented Posterolateral Lumbar Fusion
80008570|NCT05950568|Procedure|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
80008571|NCT05933681|Device|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
79691974|NCT04679454|Radiation|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
80008572|NCT05922566|Combination Product|fMRI + Mukbang videos|Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
80008573|NCT05920733|Behavioral|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
79691975|NCT04679454|Radiation|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
79691976|NCT02925728|Other|Finger-Food|Finger-Food at lunch and having diner
79691977|NCT02925728|Other|Without Finger-Food|Without finger-food
79535255|NCT05027958|Drug|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
79535256|NCT05014984|Behavioral|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1).36 In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
79691978|NCT02925884|Device|Gunnar OTC Glasses Condition|Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
79691979|NCT04744974|Behavioral|Diet intervention|Participants will be given dietician counseling on their assigned diet
79691980|NCT04242251|Other|SPARKLE Model of care|Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
79241216|NCT03435159|Device|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
79691981|NCT04725786|Other|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
79837745|NCT00537940|Drug|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
79837746|NCT00537940|Drug|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
79837747|NCT00661362|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
79837748|NCT00661362|Drug|Placebo|oral tablet, once daily for 24 weeks
79837749|NCT00661362|Drug|Metformin|oral tablet, once daily for 24 weeks
80008574|NCT05919810|Other|Probiotic|Oral probiotic
80008575|NCT05919810|Dietary Supplement|Oral herbal powder supplement|oral herbal powder
79837750|NCT00991432|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
79837751|NCT00748202|Drug|C1-Esterase Inhibitor|1000 I.E.
79837752|NCT00325897|Drug|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
79837753|NCT00325897|Drug|Placebo|Placebo taken on a daily basis
79837754|NCT00800826|Drug|dexmedetomidine|
79241217|NCT02521545|Drug|BIIB061|Capsule
79241218|NCT02521623|Device|SurgiMend® Acellular Dermal Matrix|See arm description.
79241219|NCT02521623|Device|Strattice™ Acellular Dermal Matrix|See arm description.
79241220|NCT02521467|Biological|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
79241221|NCT02521467|Other|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
79691982|NCT04723524|Combination Product|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
79837755|NCT00756392|Procedure|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
79837756|NCT03989089|Drug|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
79837757|NCT00756626|Behavioral|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
79837758|NCT00793338|Drug|Sildenafil|Sildenafil 20mg three times a day for 3 months.
79837759|NCT00756704|Behavioral|Smoking cessation guideline implementation|"a tutorial on brief cessation counseling for ED nurses and physicians~use of an ED algorithm that includes recommended tobacco counseling items~fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~group feedback to ED staff"
79535257|NCT05014984|Behavioral|telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone. Update as of 11-2023, the New York Harbor VA paused their offering of telephone-delivered MOVE!. Participants in both arms are offered the in-person or video-delivered MOVE! program. For participants who do not want or are unable to attend group-based MOVE!, they are offered TeleMOVE!.
79535258|NCT05014984|Behavioral|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study.Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
79535259|NCT05014984|Behavioral|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies.12 To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
79535260|NCT05012579|Device|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
79535261|NCT05005221|Behavioral|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
79535262|NCT04999202|Drug|BAY2416964|Oral, twice or three times daily
79535263|NCT04999202|Drug|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
79535264|NCT04999202|Drug|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
79691983|NCT04723524|Other|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
79691984|NCT02925806|Other|Non-interventional study - retrospective database review|
79691985|NCT04706754|Other|Questionnaires|Prospectively enrolled participants will be provided with survey packets comprised of different questionnaires at the initial/baseline visit and every 3 months and/or whenever there is an update in their treatment protocol
79241222|NCT03434925|Genetic|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
79241223|NCT03432663|Drug|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
79241224|NCT03432663|Drug|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
79241225|NCT03443895|Drug|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
79241226|NCT03443895|Drug|Placebo oral capsule|Matching placebo capsule
79691986|NCT04689308|Drug|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
79691987|NCT04672122|Device|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
79837760|NCT00798408|Dietary Supplement|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
79691988|NCT04689191|Biological|Experimental Group A and C meningococcal polysaccharide vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
79837761|NCT00798408|Dietary Supplement|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
79837762|NCT00344773|Drug|Gefitinib|250mg tablet oral tablet once daily
79837763|NCT02561546|Drug|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
79837764|NCT02561546|Drug|Trans-catheter embolization|Trans-catheter embolization alone
80008576|NCT05916222|Behavioral|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
80008577|NCT05914857|Drug|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
79535265|NCT04993170|Diagnostic Test|Bleeding assessment tool|The standardized application of the questionnaire serves to identify patients at risk of bleeding at an early stage and to adapt and optimize perioperative coagulation management accordingly by initiating targeted diagnostics and therapy
79535266|NCT04981223|Device|ExactVu|clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
80008578|NCT05914857|Behavioral|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
80008579|NCT05909696|Drug|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
79535267|NCT04956757|Other|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
79691989|NCT04689191|Biological|Control Group A and C meningococcal polysaccharide vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
79691990|NCT04671498|Procedure|Biospecimen Collection|Undergo collection of blood sample
79691991|NCT04671498|Procedure|Droplet-BC Test|Undergo Droplet-BC Test
79837765|NCT00991588|Procedure|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
79837766|NCT02554344|Drug|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
79837767|NCT00750854|Dietary Supplement|NEM Formulation X|see Treatment Arms
79837768|NCT00750854|Dietary Supplement|NEM Formulation Y|see Treatment Arms
79691992|NCT04671498|Other|Electronic Health Record Review|Medical records are reviewed
80008580|NCT05909527|Biological|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
80008581|NCT05907811|Procedure|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
80008582|NCT05903300|Other|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
79241227|NCT03434847|Other|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
79241228|NCT03432585|Behavioral|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
79241229|NCT03432507|Other|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
79241230|NCT03428841|Procedure|Audiometry|
80008583|NCT05901350|Drug|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
80008584|NCT05894967|Behavioral|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately ~80% contrast threshold) across all training sessions.
79380771|NCT04471714|Drug|Baclofen|Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
79380772|NCT03322644|Behavioral|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
79691993|NCT04689113|Behavioral|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
79535268|NCT04954027|Behavioral|Questionnaires|"5 visits are planned during the study :~the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~4 telephone interviews for follow-up by investigator"
79380773|NCT05405790|Procedure|thoracic endovascular aortic repair|In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
80008585|NCT05894967|Behavioral|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
80008586|NCT05894967|Behavioral|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
80008587|NCT05894967|Behavioral|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
80008588|NCT05894967|Behavioral|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
80008589|NCT05894967|Behavioral|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
80016787|NCT02282696|Other|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
79380774|NCT05315284|Procedure|the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle|Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
79380775|NCT02488278|Device|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
79380776|NCT02488356|Dietary Supplement|Litramine|
79380777|NCT03325686|Dietary Supplement|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
79535269|NCT04952688|Other|OCT- Angiographie|Ophthalmological examinations
79535270|NCT04948450|Behavioral|Physical activity intervention|"Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily."
79691994|NCT02925572|Other|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
79691995|NCT04664673|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
79691996|NCT04664673|Behavioral|Regular care|customary or usual treatment given to any adult stroke survivor
79691997|NCT02925377|Behavioral|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
79691998|NCT02925377|Behavioral|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
79691999|NCT04654299|Procedure|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
79380778|NCT03325686|Other|Placebo|placebo
79380779|NCT05315128|Drug|Methotrexate|A randomized comparative effectiveness clinical trial
79380780|NCT03322488|Procedure|Fistulodesis|"Fistulodesis comprises the following treatment steps:~Curettage and/or brushing of the fistula tract~Mini-excision of the inner (endoanal) fistula opening~Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
79380781|NCT05315050|Other|Educational session and Information Pamphlet|"Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week."
79380782|NCT05315050|Other|Information Pamphlet|Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
79380783|NCT02488200|Other|No intervention|No intervention
79837769|NCT01054963|Behavioral|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
79241231|NCT03428763|Device|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~Joint score by the patient~Patient global disease activity measured on a 0-100 mm visual analogue scale.~CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
79241232|NCT03428763|Other|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
79241233|NCT04450875|Dietary Supplement|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
79241234|NCT04450641|Other|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
79380784|NCT05314504|Device|YVOIRE Y-Solution 360|Cross-linked sodium hyaluronate gel for injection with lidocaine
79380785|NCT03322410|Biological|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~ High : D/P creatinine>0,8; D/D0 glucose<0,25~High average : 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38~Low average : 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48~Low  : D/P creatinine<0,5 ; D/D0 glucose>0,49."
79380786|NCT05300308|Other|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
79380787|NCT03325530|Behavioral|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
79535271|NCT04948450|Behavioral|Cognitive stimulation intervention|"The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week."
79535272|NCT04948450|Behavioral|Social intervention|Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.
79535273|NCT04948450|Other|Management of metabolic and vascular risk factors|"Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 7.5 %."
79535274|NCT04941430|Diagnostic Test|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
79535275|NCT04932512|Drug|ION224|ION224 will be administered by SC injection.
79535276|NCT04932512|Other|Placebo|ION224-matching placebo solution will be administered by SC injection.
79837770|NCT02554422|Device|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
79837771|NCT01055041|Drug|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
79241235|NCT03432273|Drug|Nicotine lozenge|Nicotine mint lozenge, 2 mg
79535277|NCT04929483|Drug|BIO89-100|Subcutaneous injection
79535279|NCT04922229|Procedure|RCT|This is the standard of care for this diagnosis
79535280|NCT04922229|Procedure|Pulpotomy|For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
79535281|NCT04909294|Radiation|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
79837772|NCT01055041|Drug|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
79837773|NCT01055041|Drug|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
79837774|NCT02561624|Behavioral|Behaviour change communication via text message|
80008590|NCT05894967|Behavioral|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
80008591|NCT05894967|Behavioral|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
80008592|NCT05894967|Behavioral|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
80008593|NCT05894967|Behavioral|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
80008594|NCT05894967|Behavioral|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
80008595|NCT05894967|Behavioral|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
80008596|NCT05894967|Behavioral|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
79241236|NCT03432273|Drug|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
79535282|NCT04903717|Behavioral|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
79692000|NCT02925299|Device|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
79692001|NCT02925299|Device|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
79837775|NCT01060813|Dietary Supplement|Leucine supplements|leucine supplements
79837776|NCT00793416|Device|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
79241237|NCT02481310|Drug|Cyclophosphamide|Given IV
79241238|NCT02481310|Drug|Cytarabine|Given IT or intraventricularly
79241239|NCT02481310|Drug|Doxorubicin Hydrochloride|Given IV
79241240|NCT02481310|Drug|Etoposide|Given IV
79241241|NCT02481310|Drug|Ixazomib Citrate|Given PO
79241242|NCT02481310|Other|Laboratory Biomarker Analysis|Correlative studies
79241243|NCT02481310|Drug|Methotrexate|Given IT or intraventricularly
79241244|NCT02481310|Drug|Prednisone|Given PO
79241245|NCT02481310|Biological|Rituximab|Given IV
79241246|NCT02481310|Drug|Therapeutic Hydrocortisone|Given IT or intraventricularly
79241247|NCT02481310|Drug|Vincristine Sulfate|Given IV
79241248|NCT04450485|Procedure|Total knee arthroplasty|Total knee arthroplasty
79241249|NCT03432195|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
79241250|NCT04450251|Other|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
79692002|NCT02925533|Drug|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
79692003|NCT02925533|Drug|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
79837777|NCT00748280|Procedure|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
80008597|NCT05894018|Drug|Fluzoparib|150mg, orally, bid
80008598|NCT05894018|Procedure|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
79241251|NCT03432117|Other|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
79241252|NCT03432117|Other|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
79241253|NCT03432039|Behavioral|Psychoeducation|This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
79303097|NCT02475941|Other|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
79303098|NCT02475863|Device|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
79391396|NCT02464540|Procedure|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
79535283|NCT04896814|Procedure|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
79535284|NCT04896814|Procedure|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
79535285|NCT04895579|Drug|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
79535286|NCT04895579|Drug|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
79535287|NCT04891770|Drug|Tenofovir Alafenamide|Administered as film-coated oral tablets
79535288|NCT04891770|Drug|VIR-2218|Administered as a sub-cutaneous (SC) injection
79535289|NCT04891770|Drug|Nivolumab|Administered intravenously
79535290|NCT04891770|Drug|Selgantolimod|Administered as film-coated oral tablets
79535291|NCT04881903|Behavioral|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
79692004|NCT02925260|Other|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
79692005|NCT02917889|Drug|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
79692006|NCT02917889|Drug|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
79837778|NCT00748280|Procedure|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
79837779|NCT00798642|Behavioral|Hypnotherapy|8 weeks of gut-directed hypnotherapy
80008599|NCT05893407|Diagnostic Test|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
80008600|NCT05892497|Other|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
80008601|NCT05888675|Drug|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
79241254|NCT03432039|Behavioral|Behavioral|This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
79241255|NCT03431961|Drug|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
79391397|NCT02464540|Procedure|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
79535292|NCT04881903|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
79535293|NCT04880824|Behavioral|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
79692007|NCT02917889|Other|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
79692008|NCT02917889|Other|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
79692009|NCT04573842|Other|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
79692010|NCT04564092|Drug|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
79837780|NCT00798642|Behavioral|Standard care|8 weeks of standard of care
79837781|NCT00798642|Behavioral|Mind Body Therapy|8 weeks of mind-body therapy
79837782|NCT00325819|Drug|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
79837783|NCT00325819|Other|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
79241256|NCT03431961|Drug|Placebo|twice daily for 14 days
79241257|NCT02480764|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
79241258|NCT02480764|Drug|Valsartan|Valsartan 80 mg capsules
79241259|NCT02480764|Drug|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
79692011|NCT02917967|Drug|Botulinum toxin injection|"BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
79692012|NCT04536909|Other|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
79837784|NCT00801216|Drug|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
79837785|NCT00756782|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
79837786|NCT00756782|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
79837787|NCT00748358|Drug|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
79837788|NCT00751088|Procedure|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
79241260|NCT02480764|Drug|Valsartan Placebo|Valsartan placebo-matching capsules
79535294|NCT04874480|Drug|Decitabine|Given IV
79241261|NCT03434691|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
79241262|NCT03434691|Drug|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
79241263|NCT03434613|Drug|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
79241264|NCT03434613|Drug|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
79241265|NCT03434535|Device|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
79241266|NCT04953052|Drug|Imatinib Mesylate|An isotonic sterile solution of imatinib.
79241267|NCT04953052|Drug|Placebo|An isotonic sterile solution
79535295|NCT04874480|Drug|Tegavivint|Given IV
79535296|NCT04873713|Device|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension over low back
79535297|NCT04873713|Device|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
80008602|NCT05882084|Dietary Supplement|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
80008603|NCT05882084|Dietary Supplement|Placebo|Placebo
79241268|NCT03428685|Drug|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
79241269|NCT03428685|Drug|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
79303099|NCT02475863|Other|Standard Practice|Warfarin dose adjustments according to standard unit protocol
79303100|NCT03071055|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection
79535298|NCT04871269|Drug|Dronabinol|Dronabinol
79535299|NCT04871269|Drug|Placebo|Placebo
79535300|NCT04863885|Drug|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
79535301|NCT04863885|Drug|Nivolumab|Participants will receive Nivoumab 1mg/kg
79535302|NCT04863885|Drug|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
79535303|NCT04862156|Device|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
79535304|NCT04858490|Drug|Diazepam|Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
79535305|NCT04856462|Behavioral|Education Support|Structured education is provided every other week (biweekly) to family caregivers over the course of 12 weeks, along with facilitated video-teleconferencing group meetings.
79837789|NCT00751088|Procedure|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
80008604|NCT05870462|Drug|Semaglutide Pen Injector|"0.25 mg/week (non-therapeutic dose) during Weeks 1-4~0.50 mg/week during Weeks 5-8~1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
79241270|NCT05665647|Drug|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
79535306|NCT04856462|Behavioral|Phone Call|Participants will participate in an unstructored support group phone call
79241271|NCT05665647|Drug|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
80008605|NCT05861102|Drug|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
80008606|NCT05861102|Drug|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
79241272|NCT05665647|Drug|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
79241273|NCT04941196|Drug|Anplag (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
79535307|NCT04854694|Device|FaceView Mask™|transparent surgical N95 respirator designed to improve communication
79535308|NCT04854694|Device|conventional surgical N95 respirator|standard N95 respirator
79241274|NCT04941196|Drug|Brilinta (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
79241275|NCT02487472|Other|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
79535309|NCT04843800|Procedure|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
79535310|NCT04837846|Other|Differing Tube Voltage Administration|Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
79535311|NCT04827186|Procedure|Spleen Transplantation/Removal|Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
79535312|NCT04812743|Behavioral|Colorectal Health Research Champions|"20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs."
79692013|NCT04536909|Procedure|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
79692014|NCT04688840|Procedure|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
80008607|NCT05830500|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
80008608|NCT05830292|Device|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
79241276|NCT03431805|Drug|Tranexamic Acid Injectable Solution|After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
79241277|NCT03431805|Drug|Sodium Chloride 0.9%|After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
79241278|NCT02451670|Behavioral|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
79303101|NCT04433559|Drug|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
79303102|NCT04433559|Drug|Placebo oral tablets|Use of placebo in control group
79535313|NCT04808323|Drug|Capecitabine|825 mg/m^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
79535314|NCT04808323|Device|Initial Dose of Radiation before Dose Escalation|50 Gy over 25 frac.
79535315|NCT04808323|Device|Cohort A: Dose Escalation Radiation|Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
79692015|NCT04688879|Procedure|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
80008609|NCT05829421|Other|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
79837790|NCT00751088|Procedure|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
79837791|NCT00751088|Procedure|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
79837792|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
79241279|NCT03928119|Behavioral|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
79241280|NCT03428607|Drug|AZD6738|AZD6738 160mg QD
79241281|NCT03428607|Drug|Olaparib|Olaparib 300mg BID
79241282|NCT02521233|Drug|Candesartan + Chlorthalidone (8mg+12,5mg)|
79241283|NCT02521233|Drug|Candesartan + Chlorthalidone (8 mg + 25 mg)|
79391398|NCT02423200|Drug|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
79535316|NCT04808323|Device|Cohort B: Dose Escalation Radiation|Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
79535317|NCT04808323|Device|Cohort C: Dose Escalation Radiation|Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
79535318|NCT04808323|Drug|FOLFOX|After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
79535319|NCT04806035|Biological|TG-1801|It is a bispecific, first-in-class, CD47 and CD19 antibody
79535320|NCT04806035|Biological|Ublituximab|recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
79535321|NCT04804033|Drug|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
79535322|NCT04804033|Drug|Placebo|Matching placebo softgel capsule.
79692016|NCT04688957|Procedure|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
79692017|NCT04688957|Procedure|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
79837793|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
79837794|NCT00748436|Drug|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
80008610|NCT05822440|Drug|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
79241284|NCT02521233|Drug|losartan+hydrochlorothiazide|
79241285|NCT04942522|Biological|probiotics PS128|6×10^10 CFU/capsule
79241286|NCT04942522|Drug|placebo (Microcrystalline cellulose )|450 mg/capsule
79303103|NCT03071211|Device|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
79303104|NCT03071211|Device|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
79391399|NCT02422758|Device|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative & Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
79391400|NCT02422758|Other|Passive Prewarming|
79391401|NCT02423980|Drug|Glucagon|
79535323|NCT04802759|Drug|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
79692018|NCT04517721|Other|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
79692019|NCT02917733|Drug|LY3039478|Administered orally
79535324|NCT04802759|Drug|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
79692020|NCT02917655|Behavioral|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
79692021|NCT02917655|Behavioral|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
79692022|NCT02917655|Behavioral|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
79692023|NCT02917655|Behavioral|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
79692024|NCT02917655|Behavioral|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
79837795|NCT00751244|Behavioral|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
80008611|NCT05822440|Drug|Itraconazole|Interacting drug which will be given for 7 days in period 2
79241287|NCT00434837|Procedure|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
80008612|NCT05822141|Dietary Supplement|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
79380788|NCT03320148|Behavioral|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
79535325|NCT04802759|Drug|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
79241288|NCT03434145|Other|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
79241289|NCT02486692|Other|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
79535326|NCT04802759|Drug|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
79241290|NCT03428529|Drug|Capecitabine Oral Product|Neoadjuvant Capecitabine concomitant to external beam radiotherapy
79241291|NCT03428529|Drug|5Fluorouracil|Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
79241292|NCT03433989|Diagnostic Test|telephone interview|questionnaire PDEQ et IES-R
79535327|NCT04802759|Drug|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
79535328|NCT04802759|Drug|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
79692025|NCT02917655|Behavioral|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
79692026|NCT02917655|Behavioral|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
79692027|NCT02917655|Behavioral|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
79692028|NCT02917655|Behavioral|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
79692029|NCT02917655|Behavioral|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
80008613|NCT05822141|Dietary Supplement|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
80008614|NCT05819203|Device|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
80008615|NCT05819203|Device|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
79241293|NCT00427193|Behavioral|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
79692030|NCT02917655|Behavioral|Sessions with the physical educators team|Participate in a extra session group with the physical educators
79535329|NCT04802759|Drug|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
79837796|NCT00751244|Behavioral|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
79837797|NCT00751244|Other|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
79837798|NCT00751322|Other|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
79837799|NCT00751322|Other|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
79241294|NCT00427193|Behavioral|Control|Participants continue their current diet for 24 months
79241295|NCT03428451|Drug|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
79380789|NCT03320148|Other|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
79535330|NCT04802759|Drug|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
79837800|NCT00756860|Drug|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
79837801|NCT00756860|Drug|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
79241296|NCT03428451|Drug|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
79241297|NCT03428451|Drug|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
79241298|NCT03128541|Diagnostic Test|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
79241299|NCT04450017|Diagnostic Test|The demographic, clinical, laboratory, and instrumental data|Measurement of the demographic, clinical data, laboratory data, and instrumental data
79380790|NCT03325374|Other|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
79380791|NCT03325296|Drug|LEO 124249|Ointment containing LEO 124249
79380792|NCT03325296|Other|Ointment vehicle|Ointment without active ingredients
79380793|NCT01808573|Drug|neratinib|
79380794|NCT01808573|Drug|capecitabine|
79380795|NCT01808573|Drug|lapatinib|
79380796|NCT01746940|Drug|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
79535331|NCT04802759|Drug|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
79692031|NCT02917655|Behavioral|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
79692032|NCT02917655|Behavioral|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
79692033|NCT02917538|Procedure|RFA|Both groups will receive radiofrequency ablation treatment
79692034|NCT04485273|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
79837802|NCT00757016|Drug|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
79837803|NCT00757016|Drug|Saline solution|Saline solution
79837804|NCT00687362|Biological|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
79837805|NCT00757250|Drug|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
79380797|NCT01746940|Drug|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
79241300|NCT03431649|Drug|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
79241301|NCT03431649|Drug|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
79241302|NCT03431571|Procedure|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
79241303|NCT03431415|Procedure|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
79241304|NCT03431415|Radiation|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
79535332|NCT04802759|Drug|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
79241305|NCT03428295|Device|Dose Safety AP system|Device will be used to automatically dose insulin
79241306|NCT04450095|Drug|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
79303105|NCT02475785|Device|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
79380798|NCT01746940|Drug|Placebo Topical Solution|Placebo Topical Solution
79692035|NCT04485273|Drug|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
79692036|NCT04485273|Procedure|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
79692037|NCT04485273|Drug|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
79692038|NCT04485273|Drug|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
79692039|NCT02205528|Drug|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
79692040|NCT02205528|Drug|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
79837806|NCT00751478|Drug|ALO-01|ALO-01 capsules
79837807|NCT00751478|Drug|MSIR|immediate release morphine sulfate
79837808|NCT00751478|Drug|Placebo|Placebo
79837809|NCT00751556|Drug|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
79241307|NCT03101475|Drug|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
79241308|NCT03101475|Drug|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
79241309|NCT03101475|Radiation|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
79241310|NCT03101475|Other|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
79241311|NCT03431181|Behavioral|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
79692041|NCT02205528|Drug|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
79692042|NCT02205528|Drug|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
79692043|NCT03532022|Drug|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
79241312|NCT03431181|Behavioral|Usual care|Patients in the control arm will receive usual care (as per local practices).
79241313|NCT01060007|Radiation|External beam radiation|
79241314|NCT01060007|Drug|Oxaliplatin|
79241315|NCT01060007|Drug|Leucovorin|
79241316|NCT01060007|Drug|5-FU|
79241317|NCT01060007|Drug|Capecitabine|
79241318|NCT03431103|Behavioral|Exercise|12 week home exercise program
79241319|NCT03431025|Device|Wearable sensors and biofeedback|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
79241320|NCT04187937|Device|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
79241321|NCT02971163|Behavioral|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
79241322|NCT04175925|Drug|BMS-986322|Specified Dose on Specified Days
79241323|NCT04175925|Other|BMS-986322 Placebo|Specified Dose on Specified Days
79241324|NCT04175925|Drug|famotidine|Specified Dose on Specified Days
79303106|NCT02475785|Device|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
79303107|NCT04989153|Diagnostic Test|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
79303108|NCT04911959|Drug|Lenvatinib|Lenvatinib is taken orally.
79303109|NCT04911959|Procedure|TACE|TACE treatment once.
79692044|NCT03532022|Drug|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
79692045|NCT02205099|Drug|SKL15508|
79692046|NCT02205099|Drug|Placebo|
79692047|NCT02200380|Drug|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
79692048|NCT02200380|Drug|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
79692049|NCT02196792|Device|E-Poly liner|E-Poly liner with a titanium cup
79692050|NCT02196792|Device|ArComXL liner|ArComXL liner with a titanium cup
79692051|NCT02196792|Device|32 mm femoral head|Stem with a 32 mm CoCr femoral head
79692052|NCT02196792|Device|36 mm femoral head|Stem with a 36 mm CoCr femoral head
79692053|NCT02917499|Device|TMS|Transcranial magnetic stimulation
79692054|NCT02191878|Drug|TKM-080301|TKM-080301 intravenous infusion
79692055|NCT03411083|Procedure|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery including same day surgery
79692056|NCT02187003|Drug|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
79692057|NCT02187003|Other|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
79837810|NCT00751556|Drug|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
79837811|NCT00748592|Drug|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
79837812|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
79837813|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
79837814|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
79837815|NCT00748670|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
79837816|NCT00757640|Procedure|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
79837817|NCT00325195|Other|placebo|placebo by intravenous infusion every 2 weeks
79535333|NCT04792775|Behavioral|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
79837818|NCT00325195|Biological|pegloticase|8 mg pegloticase by intravenous infusion
80008616|NCT05819190|Device|Healsea Rescue*|Subjects will be administered with Healsea Rescue* by spraying 2 puffs in each nostril 2 times per day during 7 days.
80008617|NCT05819190|Device|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue* by spraying 2 puffs in each nostril 2 times per day during 7 days.
80008618|NCT05817526|Drug|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
79241325|NCT04140435|Device|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
79241326|NCT02971007|Drug|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
79241327|NCT02971007|Drug|Fluconazole|
79241328|NCT03881553|Device|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
79241329|NCT03881553|Device|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
79241330|NCT03651167|Other|Survey|Participants will complete a survey online
79535334|NCT04770753|Drug|Placebo Matching Mitapivat|Tablets
79241331|NCT04069611|Other|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
79241332|NCT04069611|Other|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
79241333|NCT04069611|Procedure|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
79241334|NCT02970929|Drug|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
79380799|NCT03322254|Other|respiratory pathogen panel|lab testing for respiratory pathogens
79380800|NCT03322176|Other|Genetic testing|LYNCH genetic testing
79380801|NCT01747330|Drug|Pancreatin|Doses of Pancreatin <2500 lipase u/kg/feed or <4000 lipase U/g fat/intake or <10000 lipase U/kg/day given orally are used
79535335|NCT04770753|Drug|Mitapivat|Tablets
79535336|NCT04763915|Other|Correlative Studies (Survey)|Administer surveys
79535337|NCT04763915|Other|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
79692058|NCT03330509|Other|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
79692059|NCT00554814|Drug|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
79692060|NCT00554814|Drug|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
79692061|NCT00554814|Drug|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
79692062|NCT02161419|Drug|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
79837819|NCT02562560|Behavioral|Neuropsychological tests|
79837820|NCT02562560|Device|Cerebral imaging (MRI, PET-FDG)|
79837821|NCT03976401|Drug|EFX|Administered by subcutaneous injection
79837822|NCT03976401|Drug|Placebo|Administered by subcutaneous injection
79837823|NCT00757718|Device|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
79837824|NCT00757718|Device|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
79837825|NCT00748748|Biological|Culturelle|10^10 Lactobacillus rhamnosus GG per capsule
79837826|NCT02532907|Procedure|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
79692063|NCT02161419|Drug|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
79692064|NCT02917616|Other|Alkaline drinking-water|
79692065|NCT02917616|Other|Neutral drinking-water|
79692066|NCT02160678|Drug|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
79692067|NCT02160678|Drug|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
79837827|NCT00751712|Device|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
79837828|NCT00938847|Device|PCI|Stent implantation after acute myocardial infarction
79692068|NCT02160678|Drug|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
80008619|NCT05817526|Procedure|Autograft harvesting from chin|Autograft
79692069|NCT02917304|Biological|GC3110A vaccine|0.5mL, Intramuscular
80008620|NCT05814341|Drug|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
79241335|NCT03817593|Other|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
79241336|NCT00148733|Drug|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
79380802|NCT03319992|Device|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
79380803|NCT04493580|Behavioral|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
79692070|NCT02917226|Other|Clinical decision support and monitoring system|
79692071|NCT02153502|Drug|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
79692072|NCT02153502|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
79692073|NCT02917343|Behavioral|mirror therapy and repetitive task training|
79692074|NCT02917148|Other|Peripheral Venipuncture or Blood draw from Central Line|
79692075|NCT02151474|Drug|INCB047986|
79692076|NCT02151474|Drug|Placebo|
79692077|NCT02917070|Other|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
79692078|NCT02144181|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79692079|NCT02917109|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
79837829|NCT02562638|Other|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
80008621|NCT05805839|Drug|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
80008622|NCT05805839|Drug|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
80008623|NCT05805839|Diagnostic Test|PET/CT scan|Imaging of entire brain
79241337|NCT03430713|Procedure|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
79241338|NCT03430635|Procedure|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
79692080|NCT02916992|Radiation|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
79692081|NCT02916992|Genetic|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
79692082|NCT02916914|Other|Q2 feeding|Infants are going to be fed every 2 hours
79692083|NCT02130687|Drug|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
80008624|NCT05805839|Diagnostic Test|MRI|Magnetic Resonance Imaging of the Brain
80008625|NCT05795114|Behavioral|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
80008626|NCT05790772|Behavioral|Vigorous Exercise|50 minutes of running on a treadmill
80008627|NCT05790252|Drug|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
80008628|NCT05790252|Other|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
80008629|NCT05784480|Diagnostic Test|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
80008630|NCT05782985|Diagnostic Test|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
79535338|NCT04763915|Behavioral|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
79535339|NCT04763915|Behavioral|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
80008631|NCT05781555|Device|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
79535340|NCT04763915|Behavioral|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
80008632|NCT05780593|Other|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
79535341|NCT04763915|Other|Access to Education Materials|Receive access to VUS educational materials
79535342|NCT04759131|Drug|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV
80008633|NCT05780593|Other|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
80008634|NCT05779397|Device|Masimo RAD-GT|Non-contact infrared thermometry device
80008635|NCT05779280|Other|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
80008636|NCT05779280|Other|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
80008637|NCT05771805|Other|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
79380804|NCT04493580|Behavioral|In-Person DBT|In-person DBT
79380805|NCT04769128|Other|Traditional physical therapy programe|thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
80008638|NCT05771805|Other|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
79380806|NCT05253274|Device|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
79380807|NCT04442958|Other|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
79535344|NCT04742400|Drug|tolebrutinib 60mg|60 mg orally
79535345|NCT04742400|Drug|tolebrutinib 120mg|120 mg orally
79535346|NCT04740918|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
79535347|NCT04740918|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
79535348|NCT04740918|Other|Placebo|Placebo matched to atezolizumab
79535349|NCT04737031|Other|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
79535350|NCT04737031|Other|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
79837830|NCT04013607|Dietary Supplement|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
79692084|NCT02130687|Drug|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
79837831|NCT04875156|Other|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
79241339|NCT04053413|Other|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
79241340|NCT03428139|Procedure|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
79241341|NCT03428139|Drug|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
79380808|NCT02990962|Drug|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
79380809|NCT02990962|Drug|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
79380810|NCT04443114|Other|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
79535351|NCT04728412|Device|High Flow Oxygen Therapy (HFOT)|HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
79692085|NCT02130687|Drug|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
79692086|NCT02130687|Other|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
79535352|NCT04724369|Drug|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
79535353|NCT04707001|Other|Catheterization based on ultrasound|Bladder volume ultrasound
79837832|NCT00685334|Drug|Olanzapine|Participants will take olanzapine daily for 12 weeks.
79837833|NCT00685334|Drug|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
79837834|NCT00325039|Procedure|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
79535354|NCT04707001|Other|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
79535355|NCT04701333|Drug|Cabergoline 1 MG|Dopamine agonist
79535356|NCT04701333|Drug|Placebo|Placebo
79535357|NCT04700969|Other|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
79535358|NCT04686305|Drug|T-DXd|T-DXd: administered as an IV infusion
79692087|NCT02916836|Other|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
79837835|NCT00325039|Procedure|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
79837836|NCT00801294|Drug|BIBF 1120 and BIBW 2992|
79241342|NCT03651089|Drug|SP16|subcutaneous injection of experimental anti-inflammatory drug
79241343|NCT03651089|Drug|Placebos|subcutaneous injection of sterile saline
79241344|NCT04449939|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
79241345|NCT03651635|Diagnostic Test|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM & CT-proET-1
79241346|NCT03428061|Other|Integrated care for cardiovascular risk management|Disease management program for the prevention of cardiovascular diseases
79241347|NCT03127917|Dietary Supplement|L-citrulline|L-citrulline capsules given at 6 g/day
79241348|NCT03127917|Other|Placebo|Maltodextrin capsules given as placebo
79241349|NCT03427983|Procedure|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
79241350|NCT03427983|Procedure|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
79535359|NCT04686305|Biological|Durvalumab|Durvalumab: administered as an IV infusion
79535360|NCT04686305|Drug|Cisplatin|Cisplatin: administered as an IV infusion
79535361|NCT04686305|Drug|Carboplatin|Carboplatin: administered as an IV infusion
79692088|NCT02916836|Other|No Use of therapeutic drug conciliation sheet (TDC)|
79692089|NCT02916758|Other|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
79692090|NCT01228656|Drug|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
79837837|NCT04013919|Drug|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
79837838|NCT04013919|Drug|Single insulin injections|Basal insulin injections only
79837839|NCT00938925|Procedure|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
79837840|NCT00938925|Procedure|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
79837841|NCT04864548|Biological|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
79837842|NCT03743181|Other|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
79837843|NCT04045938|Other|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
79837844|NCT00344461|Drug|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
80008639|NCT05766280|Behavioral|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
80008640|NCT05757999|Drug|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
80008641|NCT05757999|Drug|Saline|The patients will be pretreated with either an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min. before induction of anesthesia.
80008642|NCT05755958|Device|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
80008643|NCT05755958|Device|SHAM HIFU procedure|SHAM HIFU procedure
79241351|NCT03427905|Procedure|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
79241352|NCT03427905|Procedure|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
79241353|NCT03650543|Drug|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
79241354|NCT03650543|Drug|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
79241355|NCT03427671|Device|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
79241356|NCT03650777|Other|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
79241357|NCT03427593|Genetic|FACS analyses|FACS analyses
79241358|NCT03427593|Genetic|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
79241359|NCT03427593|Genetic|Whole Exome Sequencing|Whole Exome Sequencing
79241360|NCT03785769|Procedure|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
79241361|NCT03785769|Procedure|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
79241362|NCT02970305|Drug|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
79241363|NCT02970305|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth
79241364|NCT03754881|Behavioral|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
79241365|NCT03743571|Device|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
79241366|NCT03743571|Behavioral|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
79241367|NCT03430557|Procedure|PRP|platelet rich plasma
79692091|NCT01228656|Drug|Mometasone furoate|Dermatologic ointment applied once a day
79692092|NCT02916641|Drug|Fuzhenghuayu|
79692093|NCT02916641|Drug|UDCA|
79692094|NCT02916680|Procedure|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
79692095|NCT02125266|Drug|V404|Sustained Release
79692096|NCT02916524|Behavioral|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
79535362|NCT04686305|Drug|Pemetrexed|Pemetrexed: administered as an IV infusion (drug not used)
79535363|NCT04686305|Drug|MEDI5752|MEDI5752: administered as an IV infusion
79535364|NCT04679896|Device|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
79692097|NCT02116998|Biological|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~GB104: ABC transporter, substrate-binding protein~GB144: Maltose/maltodextrin binding protein, ABC transporter~GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
79692098|NCT02116998|Biological|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
79692099|NCT02116998|Biological|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
79837845|NCT00939081|Behavioral|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
79380811|NCT04443114|Other|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
79535365|NCT04679844|Device|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
79535366|NCT04679844|Device|Demineralized Bone Matrix mixed with Autograft Bone|Demineralized Bone Matrix mixed with Autologous bone graft used in instrumented posterolateral fusion, 7cc-10cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
79692100|NCT02916329|Other|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
79692101|NCT02110368|Drug|Testosterone Topical Gel, 1.62% Metered Pump|
79692102|NCT02110368|Drug|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
79692103|NCT02916485|Device|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
79692104|NCT01709214|Drug|Cebranopadol (GRT6005) Low-Dose Range|Capsules
79837846|NCT00939081|Behavioral|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
79380812|NCT02246530|Procedure|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
79535367|NCT04673617|Drug|AB-101|NK cell therapy
79535368|NCT04673617|Drug|Rituximab|Anti-CD20 antibody therapy
79535369|NCT04673617|Drug|Interleukin-2|Immune cytokine
79535370|NCT04673617|Drug|Cyclophosphamide|Lymphodepleting chemotherapy
79692105|NCT01709214|Drug|Cebranopadol (GRT6005) High-Dose Range|Capsules
79692106|NCT01709214|Drug|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
79692107|NCT01709214|Drug|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
79692108|NCT02916602|Drug|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
79692109|NCT02916602|Drug|HCP0605|amlodipine, Losartan FDC
79692110|NCT02110212|Procedure|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
79692111|NCT02110212|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
79692112|NCT02916797|Other|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
79241368|NCT03430557|Procedure|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
79380813|NCT02246530|Drug|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
79535371|NCT04673617|Drug|Fludarabine|Lymphodepleting chemotherapy
79535372|NCT04673617|Drug|Bendamustine|Chemoimmunotherapy
79535373|NCT04673383|Drug|SPL026|Intravenous solution
79535374|NCT04673383|Drug|Placebo|SPL026-matched placebo
79535375|NCT04665206|Drug|VT3989|25 or 100 mg capsules for oral administration.
79837847|NCT00685178|Drug|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
79837848|NCT00685178|Behavioral|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
79241369|NCT03698409|Drug|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
79241370|NCT03650465|Behavioral|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
79241371|NCT04449783|Other|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
79241372|NCT04449783|Other|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
79692113|NCT02916290|Drug|Fuzhenghuayu|
79837849|NCT00685178|Drug|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
79837850|NCT00537394|Drug|Enfuvirtide|90mg subcutaneously twice daily
79837851|NCT00537394|Drug|Raltegravir|400 mg twice daily
79837852|NCT00537394|Drug|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
79837853|NCT00537394|Drug|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
79241373|NCT03429933|Drug|BMS-986278|Specified dose on specified days
79241374|NCT03429933|Other|Placebo|Specified dose on specified days
79692114|NCT02916290|Drug|UDCA|
79692115|NCT01708551|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79241375|NCT03650621|Device|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
79241376|NCT03650621|Device|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
79241377|NCT05285657|Diagnostic Test|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~PfHRP2(-)/pLDH(-): negative results~PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
79241378|NCT03649763|Drug|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
79241379|NCT03649763|Drug|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
79241380|NCT03649763|Drug|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
79241381|NCT03650309|Device|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
79241382|NCT03648593|Behavioral|work recovery intervention|Recover! app: one hour weekly for two months
79241383|NCT03648593|Behavioral|waiting list control|no treatment during 6 months,then Recover! app
79241384|NCT03649607|Other|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
79241385|NCT04449627|Other|Feeling Good Digital App|Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
79241386|NCT03649529|Biological|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
79692116|NCT02916251|Drug|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
79692117|NCT02916251|Drug|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
79692118|NCT01707264|Drug|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
79692119|NCT02916095|Drug|Kanitinib|Oral administration of Kanitinib tablets.
79692120|NCT02106546|Drug|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
79837854|NCT00537394|Drug|Etravirine|Two 100-mg tablets twice daily
79241387|NCT03427515|Dietary Supplement|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10^9 CFU/day
79241388|NCT03427515|Dietary Supplement|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10^9 CFU/day
79241389|NCT03427515|Dietary Supplement|Placebo|30 days of supplementation
79241390|NCT03427437|Drug|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
79241391|NCT03427437|Drug|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
79241392|NCT03427437|Device|Ultrasound|caudal block was performed by ultrasound method
79692121|NCT02106546|Drug|Veliparib|Capsules taken orally twice a day, 12 hours apart.
79692122|NCT02106546|Drug|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
79837855|NCT00537394|Drug|Maraviroc|Dosage dependent on regimen in which maraviroc is included
79535376|NCT04662190|Device|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
79837856|NCT00793494|Other|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
79837857|NCT00793494|Other|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
79692123|NCT02106546|Drug|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
79241393|NCT03649373|Procedure|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
79241394|NCT03648515|Diagnostic Test|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
79692124|NCT02916173|Drug|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
79692125|NCT02916173|Drug|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
79692126|NCT02916134|Procedure|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
79837858|NCT03187977|Behavioral|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
79837859|NCT03986359|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
80008644|NCT05751122|Other|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
79837860|NCT02554110|Device|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
79837861|NCT02554110|Device|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
79241395|NCT03648515|Diagnostic Test|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
79241396|NCT03648515|Diagnostic Test|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
79241397|NCT03427359|Drug|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
79241398|NCT05053659|Drug|Loncastuximab tesirine|Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.
79837862|NCT00933309|Drug|Exemestane|25 mg tablets orally once a day
79837863|NCT00933309|Drug|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
79837864|NCT00352885|Drug|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
79241399|NCT05053659|Drug|Venetoclax|"Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS)."
79535377|NCT04662190|Procedure|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
79535378|NCT04631900|Behavioral|Christianity approach as framework for spiritual intervention|Intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group. Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose.
79535379|NCT04630353|Drug|HB-201 IV|HB-201 given IV, one (1) time, on day 1.
79535380|NCT04630353|Drug|HB-201 IV|HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
79535381|NCT04626635|Drug|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
79692127|NCT02916134|Drug|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
79692128|NCT02916212|Other|Optimized alarm profiles|
79837865|NCT00352885|Drug|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
79837866|NCT00352885|Drug|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
80008645|NCT05751122|Other|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
79380814|NCT03319758|Procedure|buccal bone augmentation|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
79380815|NCT03322098|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
79380816|NCT03322098|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
79380817|NCT04400578|Device|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
79535382|NCT04626635|Drug|cemiplimab|administered concomitantly Q3W by IV infusion or SC injection
79535383|NCT04626635|Drug|Platinum-based doublet chemotherapy|administered IV Q3W
79535384|NCT04624230|Drug|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
79837867|NCT00933387|Drug|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
79837868|NCT00660660|Drug|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
79837869|NCT00660660|Drug|Placebo|once daily
79837870|NCT02560766|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
79837871|NCT02560766|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
79380818|NCT03319680|Other|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
79380819|NCT03322020|Radiation|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
79380820|NCT03322020|Radiation|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
79692129|NCT04688606|Diagnostic Test|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
79692130|NCT02104245|Drug|Ciprofloxacin dispersion for inhalation|
79692131|NCT02104245|Drug|Placebo|
79692132|NCT04688489|Dietary Supplement|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
80008646|NCT05748782|Other|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
80008647|NCT05748782|Device|Endotracheal tube|BASKA Mask
80008648|NCT05739747|Other|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~Patient registration.~Complete medical history.~Gendolcat scale (including the Spanish version of the SF-12 scale).~Spanish version of the catastrophizing scale."
80008649|NCT05739747|Other|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
80008650|NCT05739747|Other|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
80008651|NCT05739747|Other|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
80008652|NCT05739747|Other|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
79380821|NCT01808339|Drug|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
79380822|NCT01808339|Drug|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
79380823|NCT01749904|Drug|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
79380824|NCT01749904|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
79380825|NCT01749904|Drug|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
79692133|NCT01699737|Drug|JTT-851|
79837872|NCT02560766|Drug|Placebo|Placebo once daily
80008653|NCT05734300|Procedure|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
80008654|NCT05734300|Procedure|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
79380826|NCT02484846|Behavioral|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
79380827|NCT04585139|Device|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
79241400|NCT03649295|Other|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
79241401|NCT03649295|Other|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
79535385|NCT04601064|Behavioral|Collaborative Care Model|Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
79380828|NCT02488044|Drug|AEB1102|modified human arginase I
79241402|NCT03423615|Behavioral|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
79380829|NCT04311268|Device|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
79380830|NCT02484768|Drug|Iron isomaltoside 1000|Intravenous treatment
79380831|NCT02484768|Drug|Sodium Chloride 0.9%|Intravenous treatment
79380832|NCT05190874|Device|Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
79380833|NCT02488122|Other|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
79692134|NCT01699737|Drug|Glimepiride|Encapsulated Glimepiride tablets
79692135|NCT01699737|Drug|Placebo for Active|
79380834|NCT02488122|Other|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
80008655|NCT05731921|Behavioral|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
80008656|NCT05729646|Drug|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
79241403|NCT03650231|Other|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
79241404|NCT03648203|Behavioral|Technology Enabled Asthma Management System|See description of arm
79241405|NCT03128073|Device|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
79380835|NCT02240134|Behavioral|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
79380836|NCT02240134|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
79380837|NCT02240134|Device|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
79692136|NCT01699737|Drug|Placebo for comparator|
80008657|NCT05729646|Drug|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
80008658|NCT05729646|Drug|S1|S-1 orally intake as perioperative chemotherapy
79692137|NCT04688723|Drug|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
79837873|NCT00933465|Drug|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
79241406|NCT03650153|Procedure|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
79241407|NCT03650153|Procedure|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
79241408|NCT03423537|Drug|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
79241409|NCT03423537|Drug|Placebo|100IU per day containing N/S 0.9% will be injected
79241410|NCT03650075|Drug|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
79241411|NCT03649139|Drug|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
79380838|NCT03319602|Device|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
79535386|NCT04593875|Device|Active LIFUP Treatment|Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
80008659|NCT05726240|Drug|Ghrelin|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
80008660|NCT05726201|Diagnostic Test|ultrasound|Point-Of-Care Ultrasound (POCUS) As an Early Screening Tool for Diagnosing Skull Fractures In Children With Mild Closed Head Injuries
80008661|NCT05698485|Other|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
79241412|NCT03649139|Drug|Placebo drops|sublingual placebo drops
79380839|NCT02484612|Behavioral|acute exercise|
79535387|NCT04593875|Device|Sham LIFUP Treatment|The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
79692138|NCT04688723|Drug|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
80008662|NCT05698485|Other|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
80008663|NCT05698485|Other|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
80008664|NCT05688527|Other|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
79241413|NCT03423381|Other|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
79241414|NCT03423381|Other|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
79241415|NCT03423381|Other|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
79241416|NCT03423381|Other|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
79241417|NCT03423381|Other|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
79692139|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
79692140|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
79692141|NCT01699464|Drug|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
79837874|NCT00933465|Drug|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
79837875|NCT00757874|Drug|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
79837876|NCT00757874|Drug|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
79241418|NCT03423381|Other|Control product|A cereal based product with low concentrations of df
79241419|NCT03648125|Device|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
79241420|NCT03648125|Device|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
79380840|NCT03316326|Drug|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
79380841|NCT03316326|Drug|Oxaliplatin|85 mg/m2, D1
79380842|NCT03316326|Drug|Irinotecan|150 mg/m2, D8
79380843|NCT01751230|Behavioral|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
79837877|NCT00933621|Procedure|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
79380844|NCT03321942|Drug|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
80008665|NCT05688527|Other|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
80008666|NCT05688527|Other|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
80008667|NCT05688527|Other|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
80008668|NCT05688527|Other|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
79380845|NCT03321942|Drug|Control group|Conventional treatment were used to treat patients with chronic renal failure.
80008669|NCT05687890|Drug|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
79241421|NCT03429855|Other|trunk training|Bobath based trunk training
80008670|NCT05687890|Drug|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
80008671|NCT05687890|Drug|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
80008672|NCT05687890|Drug|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
79380846|NCT05164432|Diagnostic Test|MRI scan|Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
79692142|NCT04688645|Drug|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
79241422|NCT03429855|Other|physiotherapy|conventional physiotherapy
80008673|NCT05674344|Device|Masimo Temperature device|Non-invasive temperature device
80008674|NCT05661409|Drug|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
79241423|NCT03648047|Device|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
79380847|NCT02487732|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
79241424|NCT03648047|Other|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
79241425|NCT03648047|Other|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
79535393|NCT04586244|Drug|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
79535394|NCT04586244|Drug|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
80008675|NCT05661409|Drug|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
79241426|NCT03429777|Device|HearMe Smartphone Application|The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
79241427|NCT03649997|Drug|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
79241428|NCT03649997|Drug|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
79241429|NCT03649997|Drug|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
79380848|NCT02487732|Drug|Prasugrel|Prasugrel 10mg once daily for 5 weeks
79380849|NCT03833362|Drug|Narlaprevir|yellow film-coated 100 mg. tablets
79380850|NCT03833362|Drug|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
79380851|NCT03833362|Drug|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
79380852|NCT03833362|Drug|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
79380853|NCT03833362|Drug|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
79837878|NCT04050254|Device|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
79241430|NCT03429699|Behavioral|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
79837879|NCT04050254|Device|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
79837880|NCT04050254|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
79837881|NCT00933699|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
79837882|NCT00344305|Biological|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.
79837883|NCT00933777|Drug|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
79380854|NCT03833362|Drug|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight <75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight <65 kg) - 1400 (patient weight >105 kg) mg/day with Peginterferon alfa-2b"
79380855|NCT03321864|Procedure|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
79380856|NCT05463588|Other|Exercising with virtual reality glasses|"GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training"
79380857|NCT03316248|Other|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
79837884|NCT00757952|Other|Fourier transform ion cyclotron resonance mass spectrometry|
79380858|NCT03316248|Other|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
79535395|NCT04586244|Drug|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
79837885|NCT00757952|Other|chromatography|
79837886|NCT00757952|Other|diagnostic laboratory biomarker analysis|
79837887|NCT00757952|Other|questionnaire administration|
79837888|NCT01564030|Other|Empty|overnight fast
79380859|NCT02487888|Other|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
79535396|NCT04586244|Drug|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
79692143|NCT04688645|Drug|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
79692144|NCT00555282|Device|central venous catheter|coated central venous catheter
79837889|NCT01564030|Other|Fluid|250mL apple juice
79837890|NCT01564030|Other|Solid|breakfast
79837891|NCT00801450|Drug|Triamcinolone acetonide|4 mg
79380860|NCT02487888|Other|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
79837892|NCT00801450|Drug|Triamcinolone acetonide|40 mg
79380861|NCT03316092|Diagnostic Test|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
79380862|NCT02490774|Drug|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
79380863|NCT02490774|Drug|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
79692145|NCT00555282|Device|central venous catheter|standard central venous catheter
79692146|NCT04688372|Other|Surge Index|See study description above
79692147|NCT02104050|Drug|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
79692148|NCT02104050|Drug|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
79837893|NCT05434988|Procedure|appendectomy|Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
79837894|NCT00989326|Other|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
79380864|NCT02490774|Drug|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
79692149|NCT02915861|Other|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
79692150|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
79692151|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
79692152|NCT02915861|Other|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
79380865|NCT02490852|Other|Investigational infant formula|fed ad libitum
79380866|NCT02490852|Other|Active Comparator: Commercially available Infant formula|fed ad libitum
79692153|NCT03200132|Diagnostic Test|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
79692154|NCT01694277|Drug|Masitinib|12 mg/kg/day
79380867|NCT02490852|Other|Active Comparator: Human milk|fed ad libitum
79692155|NCT01694277|Drug|Sunitinib|50 mg/day
79837895|NCT00933855|Behavioral|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
80008676|NCT05652803|Behavioral|bibliotherapy-based psychoeducation program|In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.
79380868|NCT03316014|Other|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
79380869|NCT02487654|Procedure|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
79380870|NCT02487654|Procedure|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
80008677|NCT05652803|Behavioral|psychoeducation program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
80008678|NCT05645887|Drug|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations <35g/l.
80008679|NCT05645887|Other|Saline solution|Saline solution from day 0 to day 7.
79380871|NCT03315936|Drug|BI 894416|Oral solution
79380872|NCT03315936|Drug|Placebo|Oral solution
79380873|NCT03315936|Drug|BI 894416 (treatment X and Z)|Tablet
79535397|NCT04579692|Device|ExAblate Transcranial treatment|Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
79535398|NCT04570839|Drug|COM701 in combination with BMS-986207 and nivolumab.|Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
79535399|NCT04562480|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79535400|NCT04562480|Other|Quality-of-Life Assessment|Ancillary studies
79535401|NCT04562480|Other|Questionnaire Administration|Ancillary studies
79535402|NCT04562480|Procedure|Resection|Undergo surgical resection
79692156|NCT02100150|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
79692157|NCT02100150|Drug|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
79692158|NCT03103490|Drug|18F-FSPG|Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
79380874|NCT03315936|Drug|BI 894416 (treatment Y)|Oral solution
79692159|NCT01669980|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~Subjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
79692160|NCT01669980|Drug|IV Ceftriaxone and Vancomycin|"IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
79692161|NCT02915666|Drug|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
79692162|NCT02915666|Drug|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
79692163|NCT02915666|Drug|Trametinib|trametinib 2 mg PO daily for 8-week cycles
79380875|NCT02484144|Other|modern information|information by video for coronarography
79380876|NCT02484144|Other|usual information|usual information for coronarography
79692164|NCT02915822|Procedure|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
79692165|NCT02915822|Procedure|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
79692166|NCT02098473|Drug|RPC4046|
79692167|NCT02098473|Drug|Placebo|
79692168|NCT02915627|Device|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
79692169|NCT02915588|Other|early isometric loading after rotator cuff surgery|
79692170|NCT02915588|Other|passive motion after rotator cuff surgery|
79692171|NCT02915510|Dietary Supplement|Glycomacropeptide-based protein substitute|
79692172|NCT02098278|Drug|CAT-2003|
79692173|NCT02098278|Drug|Placebo|
79692174|NCT02915471|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
79692175|NCT04677894|Device|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
80008680|NCT05634291|Other|Standard of care|Standard of care as prescribed by healthcare provider.
80008681|NCT05634291|Device|Nottingham AR smartphone app with active intervention|AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
79380877|NCT02490540|Drug|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
79380878|NCT02490540|Drug|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
79380879|NCT02490540|Drug|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
79380880|NCT02490462|Other|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
79692176|NCT02915276|Procedure|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
79692177|NCT02915276|Procedure|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
79692178|NCT02915315|Dietary Supplement|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
79692179|NCT02092935|Drug|SMT19969|
79692180|NCT02092935|Drug|Vancomycin|
79692181|NCT02915237|Dietary Supplement|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
80008682|NCT05627531|Behavioral|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
80008683|NCT05626738|Device|ENDORAIL|In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
80008684|NCT05621239|Biological|BNT162b2|BNT162b2 half dose and full dose
79692182|NCT02915237|Dietary Supplement|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
79692183|NCT01666977|Drug|AMG 386|15mg/kg
79837896|NCT02554578|Other|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
79837897|NCT03988777|Device|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
79837898|NCT00660816|Drug|erlotinib hydrochloride|Given orally once daily on days 2-19.
80008685|NCT05614908|Other|11 weeks of immobilization|"Patients wear a scotch cast for the first 4 weeks. After that they are provided with a ROM-WALKER to be worn for the next 7 weeks, during which the ROM-walker is slowly moved from 30 degrees of plantarflexion up to 0 degrees. During the first 10 weeks, patients are not allowed any weight-bearing on the injured leg.~From week 11 they are allowed 30 kg of weight-bearing in the ROM WALKER, and from week 12 full weight-bearing with a 1 cm heel lift in their shoes."
80008686|NCT05586217|Other|INCENTIVE SPIROMETRY|"Sit up and hold the device.~Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~Breathe out (exhale) normally.~Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~If you breathe in too fast, the ball will shoot to the top.~If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
79837899|NCT00660816|Drug|pemetrexed disodium|Given IV over 10 minutes on day 1
79837900|NCT00660816|Drug|docetaxel|IV over 60 minutes on day 1.
79837901|NCT00991666|Procedure|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
79241431|NCT03429699|Behavioral|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
79380881|NCT02490462|Other|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
79380882|NCT03319290|Genetic|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
79380883|NCT02484300|Dietary Supplement|Melatonin|
79837902|NCT00801528|Drug|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
79380884|NCT02484300|Other|Placebo|
79380885|NCT02484066|Device|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
79692184|NCT01666977|Drug|AMG 386|30 mg/kg
79692185|NCT01666977|Drug|AMG 386 Placebo|AMG 386 Placebo
79692186|NCT01666977|Drug|Pemetrexed|Pemetrexed 500 mg/m2
79692187|NCT01666977|Drug|Carboplatin|Carboplatin AUC 6
79692188|NCT02915354|Drug|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
79303110|NCT03070665|Drug|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
79303111|NCT04988919|Dietary Supplement|4D|multi-ingredient supplement mixed with 24 ounces of water
79303112|NCT04988919|Dietary Supplement|placebo|taste-matched placebo mixed with 24 ounces of water
79692189|NCT01661634|Drug|Ularitide|
79692190|NCT01661634|Drug|Placebo|
79837903|NCT01060891|Drug|colimycin|
79837904|NCT04003402|Drug|ASP8062|oral
79837905|NCT04003402|Drug|Alcohol|oral
79837906|NCT04003402|Drug|ASP8062 Placebo|oral
79837907|NCT04003402|Drug|Alcohol Placebo|oral
79837908|NCT04045860|Procedure|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
79837909|NCT04045860|Other|Observation|Standard of care is currently observation
79837910|NCT00576056|Drug|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
80008687|NCT05586217|Other|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
80008688|NCT05563636|Device|standard pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
79535403|NCT04559074|Drug|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
79535404|NCT04558619|Behavioral|Kōmmour Prenatal|Centering Pregnancy, a group prenatal care model, is a promising intervention that challenges the standard model of one-on-one counseling of prenatal care. The model, is currently implemented at the UAMS, but as of yet to be adapted for Pacific Islanders. Centering Pregnancy replaces the individual prenatal care visit with a group model for obstetrically low-risk women. This model provides substantially more health promotion content than the traditional one-on-one prenatal care model. The intervention occurs from week 14 of pregnancy through birth, following the same same schedule as individual care. Group visits are 90-120 minutes each and follow a unique structured curriculum that incorporates standards of care. In the group setting, credentialed prenatal providers conduct a one-on-one assessment with each patient (30 min) and then facilitate group discussions on the topics of pregnancy, using adult learning principles (60-90 min).
80008689|NCT05563636|Device|high-voltage long-term pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
79535405|NCT04557982|Procedure|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
79535406|NCT04550494|Procedure|Biopsy|Undergo biopsy
79692191|NCT02915081|Other|Blue light|"Illumination: High illumination lighting will be instituted with a Day*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
79837911|NCT00576056|Drug|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
79837912|NCT00798798|Device|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
79241432|NCT03423225|Drug|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~Duration of treatment The investigational product will be administered for 24 weeks."
79535407|NCT04550494|Procedure|Biospecimen Collection|Undergo blood sample collection
79535408|NCT04550494|Procedure|Computed Tomography|Undergo CT scan
79535409|NCT04550494|Procedure|Magnetic Resonance Imaging|Undergo MRI
79535410|NCT04550494|Drug|Talazoparib|Given PO
79535411|NCT04546009|Drug|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
79535412|NCT04546009|Drug|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
79535413|NCT04546009|Drug|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
79535414|NCT04546009|Drug|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
79837913|NCT05360602|Dietary Supplement|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
79837914|NCT05360602|Drug|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
79837915|NCT00793728|Procedure|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
79692192|NCT02914847|Behavioral|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
79692193|NCT01661166|Drug|Fesoterodine|4 mg
79692194|NCT01661166|Drug|Placebo oral tablet|Placebo
79692195|NCT02915003|Behavioral|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
79692196|NCT01659138|Drug|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
79692197|NCT01659138|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79692198|NCT02915042|Drug|Dexmedetomidine|Analgesic Efficacy
79692199|NCT02915042|Drug|Placebo|Saline placebo
79692200|NCT01658826|Drug|AIC316|100 mg oral administration
79241433|NCT02521077|Drug|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
79241434|NCT02521077|Other|Normal Saline|Saline 0.9%
79241435|NCT03422991|Other|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
79380886|NCT02484066|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
79380887|NCT02484066|Device|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
79535415|NCT04546009|Drug|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
79692201|NCT01658826|Drug|Valacyclovir|500 mg oral administration
79241436|NCT02732691|Device|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
79241437|NCT03427203|Device|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
79380888|NCT03319056|Other|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
79380889|NCT02727660|Drug|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
79535416|NCT04546009|Drug|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
79535417|NCT04541017|Procedure|Biospecimen Collection|Undergo blood sample collection
79837916|NCT00991744|Drug|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
79241438|NCT03427203|Device|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
79241439|NCT03427203|Device|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
79241440|NCT03427203|Device|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
79303113|NCT05382533|Dietary Supplement|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
79380890|NCT02727660|Drug|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
79535418|NCT04541017|Procedure|Computed Tomography|Undergo PET/CT or diagnostic CT
79535419|NCT04541017|Biological|Magrolimab|Given IV
79535420|NCT04541017|Biological|Mogamulizumab|Given IV
79535421|NCT04541017|Procedure|Positron Emission Tomography|Undergo PET/CT
79535422|NCT04541017|Procedure|Punch Biopsy|Undergo skin punch biopsy
79535423|NCT04540211|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
79535424|NCT04540211|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
79535425|NCT04540211|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
79535426|NCT04540211|Drug|Cisplatin|Cisplatin 60-80 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
79303114|NCT02475473|Other|Exercise Training|Chronic High-Intensity Resistance Training
79303115|NCT03070743|Procedure|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
79380891|NCT02727660|Drug|FF MDI (PT005) 9.6 μg|Blinded Treatment
79380892|NCT03321474|Procedure|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
79380893|NCT02490384|Procedure|Physical exam indicated cerclage|Cervical cerclage
79535427|NCT04540211|Drug|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
79535428|NCT04540211|Drug|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
79535429|NCT04536792|Drug|AG-946|AG-946, oral encapsulated coated-granules or tablets.
79535430|NCT04536792|Drug|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
79535431|NCT04533737|Biological|Brodalumab|Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection
79692202|NCT02914769|Drug|Ayahuasca|patients will receive a single dose of ayahuasca.
79692203|NCT02914769|Drug|placebo|patients will receive a single dose of a passive placebo.
79692204|NCT04677582|Behavioral|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
79692205|NCT02914925|Device|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
79692206|NCT02092077|Drug|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
79837917|NCT00991744|Drug|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
79837918|NCT00575510|Behavioral|Intervention|Multiple component intervention based in the unified theory of behavior
79837919|NCT00575510|Behavioral|Active control|Partial intervention (full intervention minus cultural-specific component)
79837920|NCT00798876|Dietary Supplement|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
79837921|NCT00798876|Dietary Supplement|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
79535432|NCT04533737|Other|Placebo|The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
79535433|NCT04533737|Biological|Guselkumab|Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
79837922|NCT00798876|Dietary Supplement|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
79837923|NCT00798876|Dietary Supplement|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
79837924|NCT00798876|Other|Medical Examination|Subjects will have a routine medical exam.
79241441|NCT03422913|Procedure|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0~5cm H2O, if CVP is still >5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) > 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 ~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
80008690|NCT05561881|Other|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
79535434|NCT04530552|Drug|Apalutamide|Given PO
79535435|NCT04530552|Procedure|Biospecimen Collection|Undergo collection of blood samples
79241442|NCT03422835|Procedure|R-TME|Conventional Robotic Total Mesentery Excision
79241443|NCT03422835|Procedure|R-TaTME|Robotic Transanal Total Mesentery Excision
79241444|NCT03429621|Drug|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
79241445|NCT03426969|Drug|Cyclophosphamide|Given IV
79241446|NCT03426969|Biological|Filgrastim|Given SC
79241447|NCT03426969|Drug|Fludarabine Phosphate|Given IV
79241448|NCT03426969|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
79535436|NCT04530552|Other|Quality-of-Life Assessment|Ancillary studies
79535437|NCT04529265|Drug|Methylene Blue|Intraoperative infusion of 2mg/kg MB after induction of anesthesia and 1mg/kg MB at the end of surgery
79535438|NCT04529265|Drug|Placebo|Equal volume of normal saline after induction of anesthesia and at the end of surgery
79535439|NCT04526795|Drug|Cytarabine|Given IV
79535440|NCT04526795|Drug|Fludarabine|Given IV
79535441|NCT04526795|Drug|Pegcrisantaspase|Given IV
79535442|NCT04514484|Procedure|Biospecimen Collection|Undergo blood sample collection
79535443|NCT04514484|Drug|Cabozantinib S-malate|Given PO
79535444|NCT04514484|Procedure|Computed Tomography|Undergo CT
79535445|NCT04514484|Procedure|Magnetic Resonance Imaging|Undergo MRI
79535446|NCT04514484|Biological|Nivolumab|Given IV
79837925|NCT00798876|Other|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
79535447|NCT04513522|Biological|Nivolumab|Specified dose on specified days
79535448|NCT04513522|Biological|Ipilimumab|Specified dose on specified days
79692207|NCT02092077|Drug|somatropin|Dose may be adjusted as required
79692208|NCT01651143|Drug|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
79692209|NCT01651143|Drug|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
79837926|NCT00798876|Other|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
79837927|NCT00798876|Procedure|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
79837928|NCT00989404|Drug|Zanamivir|Rotahaler placebo 10mg BID 5 days
79837929|NCT00989404|Drug|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
79837930|NCT00989404|Drug|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
79837931|NCT00758030|Drug|Paliperidone ER OROS|
80008691|NCT05561881|Other|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
79692210|NCT02914886|Drug|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
79837932|NCT02636439|Behavioral|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
79837933|NCT02636439|Behavioral|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
79837934|NCT00343915|Biological|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, & 6)
80008692|NCT05558735|Other|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
80008693|NCT05558735|Other|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
79241449|NCT03426969|Drug|Melphalan|Given IV
79241450|NCT03426969|Drug|Mycophenolate Mofetil|Given PO
79241451|NCT03426969|Drug|Tacrolimus|IV or PO
79241452|NCT03426969|Radiation|Total-Body Irradiation|Undergo TBI
79380894|NCT02490072|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
79535449|NCT04509765|Radiation|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
79837935|NCT00343915|Biological|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)
80008694|NCT05557136|Device|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
80008695|NCT05557136|Device|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
79241453|NCT03422757|Device|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
79241454|NCT03422757|Device|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
79535450|NCT04493372|Diagnostic Test|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
79535451|NCT04493372|Diagnostic Test|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
79535452|NCT04493372|Diagnostic Test|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
79241455|NCT03426813|Other|Historical control group for early mobilization|
79303116|NCT02475551|Drug|IdeS|Intravenous infusion
79535453|NCT04493242|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
79535454|NCT04493242|Other|Intravenous normal saline|Placebo
79535455|NCT04486118|Drug|Lisinopril Pills|Tablets will be taken by oral administration daily, based on titration
79535456|NCT04486118|Drug|Benazepril Pill|Tablets will be taken by oral administration daily, based on titration
79535457|NCT04479995|Behavioral|Horizon Program|Telehealth videoconferencing sessions and questionnaires.
79535458|NCT04479995|Behavioral|Usual Care|Standard medical visits with additional paper or electronic booklet.
79535459|NCT04476654|Behavioral|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
79692211|NCT02914886|Drug|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
79380895|NCT02490072|Drug|normal saline(Saline 0.9%)|
79380896|NCT02490228|Procedure|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
79692212|NCT01650051|Drug|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
79692213|NCT01650051|Drug|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
79535460|NCT04476277|Drug|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
79535461|NCT04461821|Diagnostic Test|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
79535462|NCT04461821|Diagnostic Test|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
79535463|NCT04461821|Diagnostic Test|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
79535464|NCT04461821|Diagnostic Test|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
79241456|NCT03429465|Other|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, & Anguera, 2016; Journal of Medical Internet Research).
79535465|NCT04461821|Diagnostic Test|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
79380897|NCT02483910|Behavioral|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
79692214|NCT01643226|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
79692215|NCT01643226|Drug|placebo solution|0.0% riboflavin ophthalmic solution
79692216|NCT01643226|Device|KXL System|30 mW/cm2
79692217|NCT02089425|Drug|K-103-IP|
80008696|NCT05553509|Other|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
79692218|NCT02089425|Drug|Placebo|Placebo comparator
79692219|NCT02914652|Drug|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
79692220|NCT02914652|Drug|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
79692221|NCT02081703|Drug|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
79692222|NCT02081703|Drug|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
79692223|NCT02081703|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
79692224|NCT02081703|Drug|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
79241457|NCT03422601|Diagnostic Test|Immunoscore test|To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
79380898|NCT02483910|Behavioral|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
79692225|NCT02914691|Drug|Dapagliflozine 10 mg once daily tablet treatment|
79837936|NCT00343915|Biological|placebo|In the primary study: 1 deep intramuscular injection (month 1)
80008697|NCT05551273|Drug|Selgantolimod|1.5 mg tablet
80008698|NCT05551273|Drug|Placebo|Matching placebo tablet
79380899|NCT03318822|Device|Q-Collar|An externally-worn medical device that applies mild jugular compression
79380900|NCT02490150|Drug|Corifollitropin alfa|
79692226|NCT02914691|Drug|Placebo identical once daily tablet treatment|
79692227|NCT02081118|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
79692228|NCT02081118|Drug|Placebo|Placebo for HM11260C
79692229|NCT02078310|Drug|ITI-007|ITI-007 for Part 1
79535466|NCT04461158|Behavioral|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
79535467|NCT04439357|Drug|Trametinib Dimethyl Sulfoxide|Given PO
79692230|NCT02078310|Drug|Placebo|ITI-007 for Part 1
79692231|NCT02078310|Drug|ITI-007|ITI-007 for Part 2
79692232|NCT02078310|Drug|Placebo|Placebo for Part 2
79692233|NCT02914574|Other|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
79692234|NCT02077881|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
79692235|NCT02077881|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
79241458|NCT02022033|Drug|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
79241459|NCT03422445|Drug|Apatinib|Apatinib：500mg/d，qd，po，d1-28
79241460|NCT03422445|Drug|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
79380901|NCT02487576|Other|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
79380902|NCT02487576|Other|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
79380903|NCT02483598|Drug|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
79241461|NCT03429387|Diagnostic Test|FDG-PET/CT|FDG-PET performed with low dose CT
79241462|NCT03429387|Diagnostic Test|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
79380904|NCT02483598|Drug|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
79380905|NCT02483832|Behavioral|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
79380906|NCT03321318|Drug|AK-R215|Investigational product is prescribed to all ofrandomized subjects
79380907|NCT03321318|Drug|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
79837937|NCT00751868|Drug|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
79837938|NCT00991822|Drug|Dorzolamide 2%|
79837939|NCT00991822|Drug|Timolol 0.5%|
79837940|NCT00798954|Device|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
79241463|NCT03429309|Drug|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
79241464|NCT03429231|Dietary Supplement|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
79241465|NCT03426735|Other|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
79241466|NCT03426735|Other|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
79380908|NCT03321318|Drug|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
79380909|NCT01784861|Drug|X-82|
79380910|NCT01784861|Drug|Everolimus|
79380911|NCT03318744|Drug|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
79380912|NCT03318744|Drug|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
79535468|NCT04431726|Drug|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
79535469|NCT04424303|Drug|Tofacitinib|Observational study
79692236|NCT02077881|Drug|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
79692237|NCT02914418|Device|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for ~200sec and can promote changes in neural activity.
79692238|NCT04677699|Diagnostic Test|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
79692239|NCT02074410|Drug|OMS643762|
79692240|NCT02074410|Drug|Placebo|
79692241|NCT02914340|Device|Spiration Valve System|
79535470|NCT04419480|Device|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
79692242|NCT02914262|Drug|AKB-4924|Comparison of different dosages of AKB-4924
80008699|NCT05543551|Other|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
79241467|NCT01852851|Behavioral|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
79241468|NCT03429075|Drug|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
79241469|NCT03429075|Drug|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
79241470|NCT03422367|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
79241471|NCT03428919|Procedure|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
79380913|NCT02489994|Device|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
79535471|NCT04418271|Behavioral|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
79535472|NCT04408638|Drug|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
79380914|NCT02487342|Other|milk|small serving (217 mL) of british semi-skimmed milk
79380915|NCT02487342|Other|orange fruit-juice|small serving (217 mL) of orange juice
79535473|NCT04408638|Drug|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
79535474|NCT04408638|Drug|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
79535475|NCT04408638|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
79535476|NCT04408638|Drug|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
79380916|NCT02489916|Drug|CM4307|CM4307 300mg bid, each 4 week cycle
79692243|NCT02914262|Other|Placebo|Placebo comparator
79692244|NCT02915900|Other|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
79692245|NCT02915900|Other|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
79692246|NCT01632228|Drug|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
79692247|NCT01632228|Drug|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
79380917|NCT01751308|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
79692248|NCT01632228|Drug|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
79692249|NCT02914223|Drug|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
79692250|NCT01628094|Drug|RO5024048|
79692251|NCT01628094|Drug|RO5190591|
79692252|NCT01628094|Drug|RO5466731|
79692253|NCT01628094|Drug|ribavirin [Copegus]|
79692254|NCT01628094|Drug|ritonavir|
79837941|NCT00798954|Device|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
79380918|NCT02483364|Other|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
79535477|NCT04408638|Drug|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
79535478|NCT04401995|Drug|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
79535479|NCT04401995|Biological|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
79241472|NCT03428919|Procedure|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
79241473|NCT03422289|Dietary Supplement|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
79837942|NCT02560064|Procedure|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
79837943|NCT00989482|Behavioral|Computer kiosk Education|computerized patient education; guidelines for physicians
79837944|NCT04348981|Device|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
79241474|NCT03422289|Dietary Supplement|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
79535480|NCT04401995|Other|[18F]F-AraG PET/CT|[18F]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional [18F] and existing small molecule PET agents being investigated for immuno-monitoring. [18F]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
79241475|NCT03422211|Other|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
79241476|NCT02521389|Drug|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
79241477|NCT03422133|Other|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
79380919|NCT02487186|Drug|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
79535481|NCT04358419|Diagnostic Test|Aspergillus specific proteins in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
79837945|NCT00934011|Other|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
79241478|NCT03505671|Procedure|Acupuncture Therapy|Undergo acupuncture therapy
79837946|NCT00934011|Other|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
79380920|NCT02487186|Procedure|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
79380921|NCT03315624|Device|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
79380922|NCT01751386|Drug|Baclofen|
79380923|NCT01751386|Other|Placebo|
79380924|NCT02486874|Device|PoreSkin|a human acellular dermal matrix
79837947|NCT02554032|Procedure|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
79380925|NCT02489760|Biological|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
79380926|NCT02489760|Biological|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
79837948|NCT02554032|Procedure|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
79380927|NCT01752400|Drug|AUY922|
79380928|NCT03321240|Procedure|visual and quantitative SEEG signal analysis|signal SEEG analysis
79692255|NCT02914106|Other|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
79692256|NCT01627314|Biological|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
79692257|NCT01627314|Biological|Untreated CB|Cord Blood
79692258|NCT03026504|Drug|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
79837949|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
79837950|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
80008700|NCT05543551|Other|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~Place one hand on your upper chest and the other on your belly, just below your rib cage.~Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
80008701|NCT05541653|Other|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
80008702|NCT05541653|Other|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
80008703|NCT05523206|Other|No intervention|No intervention
79380929|NCT03321240|Procedure|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
79535482|NCT04358419|Diagnostic Test|Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
79241479|NCT03505671|Other|Best Practice|Receive usual care
79241480|NCT03505671|Other|Quality-of-Life Assessment|Ancillary studies
79241481|NCT03505671|Other|Questionnaire Administration|Ancillary studies
79241482|NCT04449159|Dietary Supplement|Vinh Wellness Collagen|Vinh Wellness Collagen is hydrolyzed collagen
79241483|NCT04449159|Dietary Supplement|Placebo|Placebo
79380930|NCT01752712|Drug|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
79380931|NCT01752712|Drug|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
79535483|NCT04356794|Other|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
79535484|NCT04356794|Other|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
79837951|NCT01055119|Dietary Supplement|Omega-3 fatty acids|duration: 4 month
79837952|NCT00934167|Biological|heparin sodium - Hipolabor|5.000 UI/0,25mL
79837953|NCT00934167|Biological|Heparin sodium - APP|5.000 USP/mL
79837954|NCT00801606|Drug|Zinc|Zinc 20 mg/day
79837955|NCT00801606|Drug|Micronutrient without zinc|Multimineral 2 RDA
79837956|NCT00801606|Drug|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
79837957|NCT00801606|Drug|Placebo|Placebo
79837958|NCT05408806|Other|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
79241484|NCT03422055|Drug|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
79241485|NCT04449315|Other|Young Living Lavender Essential Oil|For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
79241486|NCT04449237|Other|music therapy|music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
79241487|NCT04449471|Drug|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
79837959|NCT00934245|Biological|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
79380932|NCT03318510|Device|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
79380933|NCT02489370|Device|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
80008704|NCT05509218|Behavioral|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
80008705|NCT05508698|Behavioral|Precommitment Nudge|Ask participants to commit to a decision about getting a flu shot
80008706|NCT05508698|Behavioral|Salience|Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
80008707|NCT05507931|Dietary Supplement|1 Serving of broccoli sprouts|Participants will take 1 serving of broccoli sprouts daily for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
80008708|NCT05507931|Dietary Supplement|3 Servings of broccoli sprouts|Participants will take 3 servings of broccoli a day for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
80008709|NCT05502081|Drug|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
80008710|NCT05502081|Drug|Remdesivir|antiviral drug
80008711|NCT05502081|Drug|Favipiravir|antiviral drug
80008712|NCT05494385|Drug|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
80008713|NCT05494385|Drug|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
80008714|NCT05494073|Procedure|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
80008715|NCT05494073|Procedure|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
80008716|NCT05486286|Device|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
80008717|NCT05483712|Device|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
79241488|NCT03426189|Procedure|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
79241489|NCT03426189|Procedure|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
79241490|NCT03127371|Drug|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
80008718|NCT05482997|Dietary Supplement|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
80008719|NCT05482997|Dietary Supplement|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
79837960|NCT00934245|Biological|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
79380934|NCT05127928|Dietary Supplement|Dietary Supplement: Vitamin C and vitamin E|Antioxidant supplementation
79535485|NCT04354246|Drug|Dose escalation: COM902 monotherapy.|COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
79535486|NCT04354246|Combination Product|Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)|Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
79535487|NCT04354246|Drug|Cohort expansion: COM902 (RDFE) monotherapy.|COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
79535488|NCT04354246|Drug|Cohort expansion: COM902 in combination with COM701 (both at the RDFE).|COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
79535489|NCT04354246|Combination Product|Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.|Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
79535490|NCT04340882|Drug|Docetaxel|Given IV
79535491|NCT04340882|Biological|Pembrolizumab|Given IV
79535492|NCT04340882|Biological|Ramucirumab|Given IV
79837961|NCT05394532|Other|Education|Common Education
79837962|NCT02560688|Drug|DS-1040b|20 mg single 12-hour intravenous infusion
79837963|NCT02560688|Drug|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
79837964|NCT00939549|Drug|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
79837965|NCT00799032|Device|PCI|coronary stent implantation
79837966|NCT00758186|Procedure|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
79241491|NCT03127371|Drug|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
79241492|NCT02796027|Other|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~HCT using CTR with Rapid Testing~ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
79241493|NCT04448925|Other|inertial-load exercise (ILE)|Length of time between exercise bouts
79241494|NCT04448691|Diagnostic Test|CCTA|requested follow up CCTA
79380935|NCT05127928|Dietary Supplement|Placebo|Placebo administration
79380936|NCT03315546|Radiation|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
79380937|NCT01754350|Dietary Supplement|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to < 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
79380938|NCT01754350|Dietary Supplement|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
79380939|NCT02483130|Dietary Supplement|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
79380940|NCT02483130|Other|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
79380941|NCT03318354|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
79380942|NCT03318354|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
79380943|NCT02727192|Device|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
79837967|NCT00758186|Procedure|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
79535493|NCT04338204|Drug|tofacitinib|Observational study
79535494|NCT04337931|Drug|sotigalimab|Sotigalimab is a CD40 agonistic monoclonal antibody
79535495|NCT04309188|Device|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
79535496|NCT04309188|Other|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
79837968|NCT00989560|Procedure|endoscopy|patients receive best treatment and care with an additional endoscopy
79837969|NCT00934323|Drug|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
79837970|NCT00934323|Drug|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
79692259|NCT02073123|Drug|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
79692260|NCT02073123|Drug|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
79692261|NCT02073123|Drug|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
79535497|NCT04300062|Procedure|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
79380944|NCT02252068|Behavioral|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
79380945|NCT02252068|Behavioral|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
79535498|NCT04298437|Behavioral|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
79692262|NCT02073123|Drug|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
79692263|NCT02914145|Drug|Dihydroartemisinin-piperaquine|Mass drug administration
80008720|NCT05471414|Behavioral|Whole-food, Plant-Based Diet|Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
79692264|NCT02913989|Other|Smoking habits characterization|
79241495|NCT03421821|Drug|Ropivacaine|Subfascial injection OR extrafascial injection
79241496|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
79241497|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
79241498|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
79535499|NCT04295421|Procedure|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
79535500|NCT04295421|Procedure|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
79692265|NCT00554892|Procedure|bowel preparation|oral laxatives, retrograde enemas
79692266|NCT00554892|Procedure|no preparation bowel|no preparation bowel
79692267|NCT01626573|Drug|Itacitinib|
79692268|NCT01626573|Drug|Itacitinib Placebo|
79692269|NCT02913950|Other|validation of pediatric stool scale|validation of pediatric stool scale
79692270|NCT01621152|Other|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
79692271|NCT01621152|Other|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
79692272|NCT02914028|Procedure|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
79692273|NCT02914028|Drug|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
79692274|NCT02913911|Other|feedback|Sit to stand training with external feedback
79241499|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
79241500|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
79692275|NCT02065284|Other|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
79692276|NCT02913833|Other|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
79692277|NCT02913755|Behavioral|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
79241501|NCT03421743|Drug|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
79380946|NCT05093140|Drug|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
79535501|NCT04295408|Procedure|Pericapsular nerve group block with saline solution|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the saline solution was injected in 5-mL increments while observing for adequate fluid spread in this plane.a total volune of 40 ml saline solution was injected.
79692278|NCT02064426|Drug|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
79692279|NCT02064426|Biological|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
79692280|NCT00899301|Other|biologic sample preservation procedure|Tissue, urine and blood collection.
79692281|NCT02913677|Dietary Supplement|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
79535502|NCT04295408|Procedure|Pericapsular nerve group block with ropivacaine|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, local anesthetic was injected in 5-mL increments while observing for adequate fluid spread in this plane. a 2 mg.kg-1Ropivacaine in 40 ml of saline was injected
79535503|NCT04292782|Procedure|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
79692282|NCT02913716|Drug|defactinib|Single oral dose of 400 mg [14C]-defactinib
79535504|NCT04292782|Procedure|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
79692283|NCT02063997|Drug|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
79692284|NCT02063997|Drug|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
79692285|NCT02063997|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
79692286|NCT02063997|Drug|Placebo|Placebo tablets once daily for 12 weeks
79692287|NCT02063997|Drug|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
79241502|NCT03421665|Device|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
79241503|NCT03416907|Behavioral|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
79692288|NCT02913443|Drug|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
79692289|NCT00585507|Drug|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
79241504|NCT03416907|Behavioral|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
79692290|NCT02913287|Dietary Supplement|Aquamin/Aquamin MG|Marine-based nutraceutical
79692291|NCT02913287|Other|Maltodextrin Placebo|Maltodextrin Placebo
79241505|NCT03416907|Behavioral|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
79241506|NCT03416907|Behavioral|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
79241507|NCT03416907|Behavioral|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
79241508|NCT03421587|Behavioral|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
79241509|NCT02747433|Device|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
79241510|NCT02747433|Device|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
79692292|NCT02063685|Drug|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
79692293|NCT02063685|Drug|Observation|not maintenance therapy and followed-up with MRD monitoring.
79692294|NCT02063685|Drug|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
79692295|NCT02063685|Drug|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
79380947|NCT05076214|Behavioral|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
79692296|NCT02063685|Drug|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
79535505|NCT04289987|Biological|CVI-HBV-002|Investigational Product
79692297|NCT02913248|Procedure|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
79692298|NCT02063295|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
79692299|NCT02063295|Drug|ZGN-440 for injectable suspension|
79535506|NCT04289987|Biological|Normal Saline(placebo)|Investigational Product
79535507|NCT04285333|Procedure|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
79535508|NCT04285333|Procedure|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
79535509|NCT04250155|Drug|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
79535510|NCT04250155|Drug|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
79535511|NCT04250155|Drug|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
79535512|NCT04246086|Drug|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
79535513|NCT04246086|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
79535514|NCT04246086|Drug|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
79535515|NCT04246086|Drug|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
79535516|NCT04231968|Drug|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
79535517|NCT04231968|Drug|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
79535518|NCT04227067|Device|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
79535519|NCT04227067|Device|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
79535520|NCT04222673|Behavioral|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
79535521|NCT04213547|Behavioral|Loss frame sleep extension intervention|Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
79535522|NCT04212117|Other|The Patient Activated Learning System (PALS)|Randomization into PALS arm.
79535523|NCT04212117|Other|WebMD|Randomization into WebMD arm.
79535524|NCT04201405|Drug|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
79535525|NCT04199182|Behavioral|Exercise Training|A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.
79535526|NCT04199182|Other|Healthy Aging Attention Control (HA-ATC)|"Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months."
79692300|NCT02913170|Dietary Supplement|Nattokinase|
79692301|NCT02913170|Dietary Supplement|Placebo|
79692302|NCT02057172|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
79380948|NCT05076214|Behavioral|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
79692303|NCT02057172|Drug|liraglutide|Liraglutide is a GLP-1 agonist.
79692304|NCT02057172|Drug|Placebo|Placebo
79241511|NCT03421509|Other|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
79380949|NCT05021848|Other|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
79380950|NCT00705666|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
79380951|NCT00705666|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
79380952|NCT04955236|Drug|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
79380953|NCT04955236|Drug|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
79380954|NCT02489292|Biological|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
79380955|NCT04943770|Procedure|Spinal cord stimulator implant|"Patients will undergo spinal cord implant procedures as per standard of care and be implanted with the WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system.~Implant Procedures will be followed by a healing period (4-6 weeks) during which patients will be offered therapy (up to one 1Khz). Patients will then be randomised to receive therapy at four different rates (A, B, C, D) in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit."
79380956|NCT04943770|Diagnostic Test|Healing period|Acute opioid pain medications may be continued. No additional scheduled assessments will be completed during this period.
79380957|NCT04943770|Device|WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|Patients will then be randomised to receive therapy (up to 1KHz) at four different rates in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit.
79380958|NCT05463510|Diagnostic Test|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
79380959|NCT04086862|Procedure|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm^2 and 100% duty cycle sequentially to each masseter muscle.
79380960|NCT02489136|Other|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
79380961|NCT04044274|Device|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
79380962|NCT04044274|Device|Suction Cup|Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
79535527|NCT04198272|Behavioral|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.
79692305|NCT02913404|Procedure|ACL Reconstruction|standard surgical procedure
79692306|NCT02913404|Procedure|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
79692307|NCT02053116|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
79692308|NCT02053116|Drug|Placebo|Tablet, 0 mg, twice daily, 2 weeks
79692309|NCT02912975|Other|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
79241512|NCT01103349|Drug|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
79241513|NCT01103349|Drug|Placebo|Patients receive placebo capsules and/or encapsulated tablets
79241514|NCT01103349|Drug|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
79241515|NCT03416751|Biological|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
79241516|NCT03416751|Other|Placebo|Placebo enemas
79241517|NCT03416673|Procedure|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
79241518|NCT03416673|Procedure|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
79241519|NCT02022423|Behavioral|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
79241520|NCT02022423|Behavioral|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
79241521|NCT03416595|Dietary Supplement|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
79241522|NCT03416595|Dietary Supplement|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
79241523|NCT03421275|Drug|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
79241524|NCT03421275|Drug|Fentanyl Citrate|intravenous fentanyl given intranasally
79241525|NCT03421275|Drug|Saline Nasal|intravenous saline given intranasally as placebo
79241526|NCT03416517|Drug|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
79241527|NCT03416517|Drug|Irinotecan|Irinotecan 20 or 15mg/m^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
79380963|NCT04021030|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention consists of 8, one-hour individual therapy sessions delivered over the course of 2 to 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.
79380964|NCT03315234|Genetic|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
79380965|NCT03957304|Drug|Dexmedetomidine|Intranasal dexmedetomidine
79535528|NCT04187170|Other|Strength physical training|progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
79837971|NCT00793962|Radiation|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
79535529|NCT04180215|Drug|HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
79837972|NCT00793962|Radiation|conventional fractionation radiotherapy|50Gy/25/f/5w
79241528|NCT03416439|Other|lifestyle intervention|lifestyle intervention program carried out by trained professionals
79241529|NCT03426111|Device|Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)|This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
79241530|NCT03426111|Behavioral|Lifestyle modification|Hypocaloric diet and moderate physical exercise
79241531|NCT03421119|Drug|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
79241532|NCT03421119|Drug|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
79241533|NCT03421119|Drug|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
79241534|NCT03426033|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
79241535|NCT03426033|Drug|Warfarin|25mg tablet administered orally
79241536|NCT03416205|Device|Erbao electric knife|Erbao electric knife is used to cut the Duodenal sphincter
79241537|NCT03416205|Device|Three-cavity incision knife|Three-cavity incision knife is used to cut the Duodenal sphincter
79241538|NCT03416205|Device|Columnar expansion balloon|Columnar expansion balloon is used to expand the the Duodenal sphincter
79241539|NCT03420885|Behavioral|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
79391402|NCT02422914|Behavioral|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
79535530|NCT04180215|Drug|HB-202 intravenous administration alternating with HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
79535531|NCT04180215|Drug|HB-201 intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
79535532|NCT04180215|Drug|HB-202 / HB-201 alternating intravenous administration + pembrolizumab.|Dose Expansion
79535533|NCT04180215|Drug|HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
79241540|NCT03420885|Behavioral|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
79692310|NCT02912975|Other|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
79692311|NCT02894307|Drug|Rivaroxaban|In patients with mechanical valves and unstable INR
79692312|NCT02913014|Other|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
79692313|NCT02052648|Drug|Indoximod|
79837973|NCT00575666|Drug|Insulin or Placebo|intranasal, 40IU, 4 times daily
80008721|NCT05471414|Behavioral|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
80008722|NCT05469555|Procedure|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
80008723|NCT05468398|Device|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
80008724|NCT05459519|Drug|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
80008725|NCT05459519|Drug|Placebo|Placebo, 4 capsules each time, twice daily
80008726|NCT05459519|Drug|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
80008727|NCT05455294|Drug|Navitoclax|See Arm Description
80008728|NCT05455294|Drug|Venetoclax|See Arm Description
79241541|NCT04567173|Drug|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
79241542|NCT04522089|Biological|AdimrSC-2f|AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
79241543|NCT03425955|Device|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
79241544|NCT03425955|Device|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
79241545|NCT03420729|Procedure|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
79535534|NCT04180215|Drug|HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)|Dose escalation; 10 patients
79535535|NCT04169841|Drug|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
79692314|NCT02052648|Drug|Temozolomide|
79692315|NCT02052648|Drug|Bevacizumab|
79692316|NCT02052648|Radiation|Stereotactic Radiation|
79692317|NCT02913053|Behavioral|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
79692318|NCT02913053|Behavioral|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
79692319|NCT02894112|Dietary Supplement|non-fat milk|1 serving of non-fat fluid milk
79692320|NCT02894112|Dietary Supplement|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
79692321|NCT02894112|Dietary Supplement|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
79692322|NCT01186744|Drug|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
79692323|NCT01186744|Drug|CP-690,550|10 mg oral BID
79692324|NCT01186744|Drug|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
79692325|NCT01186744|Drug|CP-690,550|5 mg oral BID
80008729|NCT05455294|Drug|Decitabine|See Arm Description
79692326|NCT02912936|Dietary Supplement|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
79535536|NCT04165096|Biological|Pembrolizumab|IV infusion
79692327|NCT02912936|Dietary Supplement|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
79692328|NCT02044341|Drug|AR01|drops administered an needed for pain
79692329|NCT02044341|Drug|Glycerin ear drops|placebo drops administered for ear pain
79241546|NCT03420729|Device|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
79535537|NCT04165096|Biological|Boserolimab|IV infusion
79535538|NCT04165096|Biological|MK-4830|IV infusion
79241547|NCT03415971|Procedure|EMG befor denture treatment|
79241548|NCT03415971|Procedure|EMG in a month after termination of treatment|
79241549|NCT03415971|Procedure|EMG in a 3 months after termination of treatment|
79241550|NCT02959177|Drug|Galcanezumab|Administered SC
79241551|NCT02959177|Drug|Placebo|Administered SC
79241552|NCT03420495|Behavioral|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
79241553|NCT03415815|Procedure|Surgeries|Radical resection of esophageal cancer
79241554|NCT02432547|Drug|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
79535539|NCT04165096|Drug|diphenhydramine|PO
79535540|NCT04165096|Drug|acetaminophen|PO
79535541|NCT04165096|Biological|MK-0482|IV infusion
79692330|NCT02912819|Other|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
79692331|NCT00555399|Drug|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
79692332|NCT00555399|Drug|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m^2/day PO x 21 days; Level -I = 100 mg/m^2/day PO x 21 days; Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days."
79692333|NCT00555399|Procedure|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
79692334|NCT00555399|Drug|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
80008730|NCT05442346|Biological|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
80008731|NCT05437796|Device|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
80008732|NCT05437796|Device|No Hypnotic virtual reality|Group without Hypnotic virtual reality
80008733|NCT05399095|Behavioral|Supine positioning: 5 days|Supine positioning for 5 days after DMEK
80008734|NCT05399095|Behavioral|Supine positioning: 1 days|Supine positioning for 1 days after DMEK
79535542|NCT04165083|Biological|Pembrolizumab|IV infusion
79535543|NCT04165083|Biological|MK-4830|IV infusion
79535544|NCT04165083|Biological|MK-0482|IV infusion
79692335|NCT03454932|Other|Blood sampling|
79692336|NCT02912663|Drug|Verapamil and Magnesium Sulfate|Single dose strategy will be used
79535545|NCT04165070|Biological|Pembrolizumab|IV infusion
79535546|NCT04165070|Drug|Carboplatin|IV infusion
79535547|NCT04165070|Drug|Paclitaxel|IV infusion
79535548|NCT04165070|Drug|Pemetrexed|IV infusion
79535549|NCT04165070|Biological|Vibostolimab|IV infusion
79535550|NCT04165070|Biological|Boserolimab|IV infusion
79535551|NCT04165070|Biological|MK-4830|IV infusion
79535552|NCT04165070|Biological|MK-0482|IV Infusion
79535553|NCT04162873|Drug|Celecoxib|Given PO or via feeding tube
79535554|NCT04162873|Other|Placebo|Given PO or via feeding tube
79535555|NCT04162873|Other|Quality-of-Life Assessment|Ancillary studies
79241555|NCT02432547|Procedure|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
79241556|NCT03640195|Other|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
79241557|NCT03415737|Other|Questionnaire|Profile Fitness Mapping Neck Questionnaire
79241558|NCT03420417|Device|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
79692337|NCT02912663|Other|Placebo|Single matching dosing strategy will be used
79692338|NCT02026401|Biological|NGM282|
80008735|NCT05393882|Radiation|Computed tomography coronary angiogram|"Preparation~Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~Scanning coverage: From the thoracic inlet to diaphragm"
80008736|NCT05392868|Device|SDF|38% silver diamine fluoride solution
79241559|NCT03618433|Other|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
79380966|NCT02483286|Behavioral|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
79380967|NCT02483286|Behavioral|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
79380968|NCT02483286|Behavioral|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
79380969|NCT03318276|Drug|SID142|SID142 is administrated to patients with PAD for 12 weeks
79535556|NCT04162873|Other|Questionnaire Administration|Ancillary studies
79692339|NCT02026401|Biological|Placebo|
80008737|NCT05392868|Device|KNO3|5% potassium nitrate solution
79380970|NCT03318276|Drug|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
79380971|NCT02483208|Drug|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
79380972|NCT02483208|Drug|Advate|Advate infusion to analyze pharmacokinetics.
79535557|NCT04158258|Drug|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
79535558|NCT04158258|Drug|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
79535559|NCT04158258|Drug|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
79535560|NCT04158258|Drug|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
79692340|NCT02912741|Drug|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
79692341|NCT02912741|Drug|resin infiltration|low viscous light cure resin applied in layers and cured
79692342|NCT05355298|Drug|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
79692343|NCT05355298|Drug|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
79692344|NCT04318522|Device|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
79692345|NCT02894151|Drug|Depot medroxyprogesterone acetate|
79692346|NCT02894151|Device|LNG-IUS|
79535561|NCT04158258|Drug|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
79692347|NCT02912858|Device|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
79692348|NCT02894229|Behavioral|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
79692349|NCT02894229|Behavioral|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
79692350|NCT02021370|Drug|BAY85-3934|25mg Tablet
79241560|NCT03618433|Other|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
79241561|NCT03415659|Drug|HWH340 tablet|"single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group."
79241562|NCT02031757|Other|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
79241563|NCT02031757|Other|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
79241564|NCT02345733|Other|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
79535562|NCT04158258|Drug|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
79535563|NCT04153149|Drug|Vutrisiran|Vutrisiran 25 mg will be administered by SC injection q3M.
79535564|NCT04153149|Drug|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection q3M.
79535565|NCT04145297|Drug|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
79535566|NCT04145297|Drug|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
79535567|NCT04143217|Drug|SPN-812|SPN-812 200 to 600 mg/day
79535568|NCT04141462|Genetic|blood sample|blood test
79241565|NCT02345733|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
79241566|NCT03618901|Other|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
79241567|NCT03618901|Other|PD SAFEx|Progressive proprioception training.
79241568|NCT03420261|Biological|0.9% saline|Fluid administration
79241569|NCT03420261|Biological|HES 130/0.4|Fluid administration
79380973|NCT03321162|Diagnostic Test|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
79380974|NCT03321084|Other|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
79380975|NCT03321084|Other|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
79380976|NCT03320928|Other|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
79380977|NCT02488902|Drug|Placebo|Placebo
79380978|NCT02488902|Drug|Tafenoquine 25mg|Tafenoquine 25mg
79380979|NCT02488902|Drug|Tafenoquine 50mg|Tafenoquine 50mg
79380980|NCT02488902|Drug|Tafenoquine 100 mg|Tafenoquine 100 mg
79380981|NCT02488902|Drug|Tafenoquine 200 mg|Tafenoquine 200 mg
79692351|NCT02021370|Drug|Placebo|Matching placebo tablet
79380982|NCT02488902|Drug|Mefloquine 250 mg|Mefloquine 250 mg
79380983|NCT05404776|Other|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
79692352|NCT02912702|Drug|Pegaspargase|2000U/m2 day5
79692353|NCT02912702|Drug|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
79692354|NCT02912702|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
79692355|NCT02912702|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
79692356|NCT02912702|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
79692357|NCT02912702|Drug|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
79692358|NCT02894073|Device|skin transilluminator|VeinViewer
79692359|NCT02912585|Biological|Oropharyngeal administration of own mother's colostrum|
79692360|NCT02912585|Other|Oropharyngeal administration of sterile water (placebo)|
79535569|NCT04133675|Device|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
79535570|NCT04133675|Device|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
79380984|NCT05404776|Other|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
79692361|NCT02912585|Biological|Oropharyngeal administration of donor human milk|
79692362|NCT02016534|Drug|AMG 337|AMG 337 300mg orally daily.
80008738|NCT05390788|Other|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
80008739|NCT05381779|Other|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
80008740|NCT05381779|Other|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
79380985|NCT02253160|Device|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
79692363|NCT02912429|Device|Patellofemoral Arthroplasty|
79692364|NCT02010333|Drug|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
79241570|NCT03618745|Device|CT brain|noninvasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body.
79241571|NCT02331147|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment
79241572|NCT02331147|Other|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
79692365|NCT02912390|Procedure|Cerclage|Macdonald cerclage placed in standard fashion
79692366|NCT02912390|Other|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
79692367|NCT02894346|Other|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
79692368|NCT02912273|Other|Baseline Participant Assessment|"Section 1 contains demographic questions~Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~Section 3 has the participant list all medication~Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
79241573|NCT03415503|Drug|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
79241574|NCT03127683|Other|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
79241575|NCT03127683|Other|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
79241576|NCT03127683|Other|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
79241577|NCT03127683|Other|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
79241578|NCT03127683|Device|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
79241579|NCT03415347|Procedure|Abscess de-roofing and curettage|Abscess de-roofing and curettage
79241580|NCT03415347|Procedure|Abscess wide local excision|Abscess wide local excision
79241581|NCT03415269|Drug|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
80008741|NCT05381779|Other|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
79241582|NCT03618589|Drug|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
80008742|NCT05367882|Diagnostic Test|ELISA|collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
80008743|NCT05357560|Biological|Matrix-M with RH5.2 VLP and/or R21|3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
79241583|NCT03618589|Drug|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
79241584|NCT03425877|Device|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
80008744|NCT05356585|Genetic|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
80008745|NCT05345769|Biological|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
79241585|NCT03425877|Behavioral|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, & Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley & Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
79241586|NCT03425877|Behavioral|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
79241587|NCT03425877|Behavioral|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
79380986|NCT02253160|Device|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
79380987|NCT02253160|Drug|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
79380988|NCT05459766|Behavioral|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
79535571|NCT04122768|Behavioral|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
79380989|NCT05459766|Behavioral|Usual care|Participants will be educated about the postoperative rehabilitation program
79380990|NCT02254252|Drug|Nicorandil|nicorandil (10mg tablets, two times a day)
79380991|NCT02254252|Drug|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
79380992|NCT03315156|Diagnostic Test|Electrogustometery|Taste assessment using EGM
79380993|NCT02483052|Device|RejuvenAir|RejuvenAir
80008746|NCT05345392|Behavioral|Mindfulness-Based Intervention (MBI)|The mindfulness-based intervention is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
79380994|NCT03318198|Other|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
79380995|NCT03318198|Other|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
79380996|NCT02255032|Drug|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
79692369|NCT02912273|Other|Baseline Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
79692370|NCT02912273|Other|Follow-up Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
79692371|NCT02912273|Other|Follow-up Healthcare Provider Assessment|"Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
79692372|NCT02912273|Other|End-of-study Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
80008747|NCT05345392|Behavioral|Health and Wellness Intervention (HWI)|The control intervention is inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
80008748|NCT05345158|Procedure|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
80008749|NCT05339997|Other|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
79380997|NCT02255032|Drug|0.8 mg CLS-TA|8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
79380998|NCT03315078|Biological|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
79380999|NCT03315078|Drug|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
80008750|NCT05304689|Diagnostic Test|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
80008751|NCT05298891|Other|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~energy equal to daily energy expenditure (estimated by indirect calorimetry * physical activity factor)~fats 28-35%~carbohydrates 50-60%~proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
79381000|NCT03315078|Drug|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
79381001|NCT03320772|Drug|TMVP1-ICG|Detection of SLN
79381002|NCT03320772|Drug|ICG|Detection of SLN
79535572|NCT04122768|Behavioral|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
79692373|NCT02912273|Other|End-of-study Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
79692374|NCT02008344|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
79381003|NCT02255110|Drug|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
79381004|NCT02255110|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
79535573|NCT04113707|Behavioral|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
79692375|NCT02008344|Drug|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
79692376|NCT02912546|Procedure|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
79241588|NCT03425877|Behavioral|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
79241589|NCT03127449|Drug|Alflutinib|patients take Alflutinib orally once per day at different dose
79381005|NCT03320694|Drug|Metformin|metformin 500mg twice daily & increased until 2500mg till normoglycemia was achieved and was continued till delivery
79241590|NCT03420105|Other|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
79381006|NCT03320694|Drug|Insulin|The insulin group was given 3 S/C injections of regular insulin & one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
79381007|NCT03318042|Other|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
79535574|NCT04111133|Drug|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
79535575|NCT04111133|Drug|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
79535576|NCT04103424|Behavioral|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
79241591|NCT03420105|Drug|Hormonotherapy|Adjuvant hormone therapy
80008752|NCT05271643|Behavioral|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
80008753|NCT05269888|Other|Blood Test 1|"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
79241592|NCT03425721|Other|No Intervention|No Intervention is administered in this study.
79381008|NCT03318042|Other|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
79535577|NCT04099004|Other|Neural Imaging|During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
79535578|NCT04097821|Drug|Ruxolitinib|5 mg tablets for oral use
79381009|NCT02482740|Drug|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
79381010|NCT02482740|Drug|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
79381011|NCT03317886|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
79381012|NCT03315000|Drug|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
79381013|NCT03315000|Drug|Fluticasone Furoate|Same as fluticasone arm description
79535579|NCT04097821|Drug|Siremadlin|10 mg, 20 mg, or 40 mg capsules for oral use
79535580|NCT04097821|Drug|Crizanlizumab|100 mg/mL concentrate for infusion for intravenous use
79535581|NCT04097821|Drug|Sabatolimab|100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
79692377|NCT02912156|Drug|Vaway FC Tablets 200mg (Voriconazole)|
79692378|NCT02912156|Drug|VFEND FC Tablets 200mg (Voriconazole)|
79692379|NCT03455049|Other|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
79692380|NCT02912234|Drug|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
79692381|NCT02912234|Drug|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
79381014|NCT03315000|Drug|Placebos|Same as placebo arm description
79381015|NCT04892602|Diagnostic Test|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
79381016|NCT02482818|Drug|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
79381017|NCT02482818|Drug|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
79692382|NCT04676139|Drug|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
79692383|NCT04676139|Drug|Placebo|placebo for 12 months
79692384|NCT01999764|Drug|QLT091001|QLT091001 administered orally at multiple time points.
79692385|NCT01999764|Other|Placebo|Placebo is administered orally at multiple time points.
79535582|NCT04097821|Drug|Rineterkib|100 mg capsule for oral use
80008754|NCT05269888|Other|Blood Test 2|"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
80008755|NCT05263557|Dietary Supplement|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
79692386|NCT02912039|Device|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
80008756|NCT05263557|Dietary Supplement|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
80008757|NCT05219110|Other|Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing < 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
79692387|NCT02912039|Device|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
80008758|NCT05219110|Other|Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution|Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
80008759|NCT05212948|Drug|S-268019-b|Solution for IM injection
80008760|NCT05212948|Drug|Placebo|Saline solution for IM injection
80008761|NCT05212155|Behavioral|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
79535583|NCT04097821|Drug|NIS793|700 mg/7 mL concentrate for intravenous use
79535584|NCT04068103|Drug|Capecitabine|Given PO
80008762|NCT05201300|Drug|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
80008763|NCT05201300|Drug|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
80008764|NCT05201300|Drug|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
79381018|NCT02989870|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
79381019|NCT02989870|Drug|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
79381020|NCT02989870|Drug|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
79535585|NCT04068103|Drug|Fluorouracil|Given IV
79535586|NCT04068103|Drug|Leucovorin|Given IV
79535587|NCT04068103|Drug|Leucovorin Calcium|Given IV
79535588|NCT04068103|Drug|Oxaliplatin|Give IV
79535589|NCT04068103|Other|Patient Observation|Undergo active surveillance
79535590|NCT04064437|Diagnostic Test|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
79692388|NCT02911961|Drug|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
79692389|NCT01998828|Drug|Momelotinib|Momelotinib tablet administered orally once daily
79692390|NCT02912000|Behavioral|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
79692391|NCT04675944|Drug|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
79692392|NCT04675944|Drug|treprostinil|1 mg (1 extended-release tablet), oral route
79692393|NCT02911766|Drug|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
79692394|NCT02911766|Drug|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
79692395|NCT02911766|Drug|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
79692396|NCT01993641|Drug|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
80008765|NCT05176106|Behavioral|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
80016788|NCT03056157|Behavioral|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
79692397|NCT01993641|Drug|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
79692398|NCT01993641|Drug|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
79692399|NCT00555516|Other|EW02|"Name: EW02~Dosage form: capsule.~Dose(s): 350mg per capsule, 2 capsule tid.~Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
79692400|NCT01991184|Drug|GDC-0853|Multiple escalating doses
79692401|NCT02911727|Procedure|Fast-track discharge|As described above
79692402|NCT02911883|Device|Optical Coherence Tomography Angiography|
80008766|NCT05163275|Diagnostic Test|Video recording and EMG|"The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total"
80008767|NCT05155280|Other|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
80008768|NCT05155280|Behavioral|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
80008769|NCT05152771|Other|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
79241593|NCT02521155|Behavioral|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
79241594|NCT03415191|Drug|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
79381021|NCT02488746|Device|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
79381022|NCT02480088|Drug|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
79381023|NCT02480088|Drug|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
79381024|NCT01807624|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
79535591|NCT04064437|Diagnostic Test|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
79535592|NCT04064437|Diagnostic Test|Biochemical tests|The investigators perform blood and urine tests in every participant.
79535593|NCT04064437|Diagnostic Test|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
79535594|NCT04064437|Diagnostic Test|AGE Reader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
79535595|NCT04036045|Other|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
79535596|NCT04036045|Other|Echocardiogram|Patients will have an echocardiogram at four time points during the study
79535597|NCT04036045|Other|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
79535598|NCT04029857|Dietary Supplement|Nutritional Supplement Drink|Given standard of care nutritional supplementation
79692403|NCT04675905|Other|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged >= 65 years
79692404|NCT02911649|Other|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
79692405|NCT02911649|Other|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
79535599|NCT04029857|Dietary Supplement|Nutritional Supplementation|Given Impact Advanced Recovery PO or via feeding tube
79535600|NCT04005638|Biological|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
79535601|NCT04005638|Biological|urine sample|12 ml
79535602|NCT03995121|Radiation|[11C]APP311|It has been shown that [11C]APP311 (aka [11C]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
79535603|NCT03976063|Drug|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
79535604|NCT03976063|Drug|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
80008770|NCT05139589|Other|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
80008771|NCT05139433|Behavioral|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
80008772|NCT05139433|Behavioral|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
79535605|NCT03965130|Biological|Glucagon|PINTA study with or without glucagon
79535606|NCT03964259|Drug|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
79535607|NCT03960021|Radiation|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
79692406|NCT02911649|Other|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
79692407|NCT02911649|Other|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
79692408|NCT01989429|Drug|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
79692409|NCT02911532|Procedure|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
79692410|NCT01989234|Drug|YKP10811|
79692411|NCT01989234|Drug|Placebo|
79692412|NCT02911493|Behavioral|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
79692413|NCT02911493|Behavioral|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
79692414|NCT04675671|Other|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
80008773|NCT05119439|Drug|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
79535608|NCT03956095|Dietary Supplement|Ensure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
79535609|NCT03956095|Other|Daily Food Intake form|On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
79692415|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
79692416|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
79241595|NCT03415191|Drug|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
79241596|NCT03420027|Other|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
79241597|NCT03414957|Diagnostic Test|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
79241598|NCT03419949|Drug|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
80008774|NCT05065346|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79535610|NCT03941288|Drug|Cannabidiol|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
80008775|NCT05041569|Other|MRI sequences|perform additional sequences added by research
80008776|NCT05040503|Biological|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~patient: H0: 0-6h post-admission~healthy volunteer: at inclusion"
80008777|NCT05040503|Biological|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
79535611|NCT03941288|Other|placebo|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
80008778|NCT05040503|Other|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
79535612|NCT03938870|Other|L-Leucine 13C6|
79535613|NCT03902951|Drug|Abiraterone Acetate|Given PO
79535614|NCT03902951|Drug|Apalutamide|Given PO
79535615|NCT03902951|Drug|Leuprolide Acetate|Given SC
79535616|NCT03902951|Other|Quality-of-Life Assessment|Ancillary studies
79535617|NCT03902951|Other|Questionnaire Administration|Ancillary studies
79535618|NCT03902951|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79535619|NCT03899844|Other|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
79692417|NCT01984788|Drug|BCX4161|
79241599|NCT03419949|Drug|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
79535620|NCT03896321|Drug|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
79535621|NCT03896321|Drug|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
79535622|NCT03891446|Drug|Bimatoprost SR|Intraocular implant
79535623|NCT03891446|Other|Standard of Care|Standard of care treatment based on investigator's judgement.
79535624|NCT03873428|Other|FES PET|FES injection
79535625|NCT03869437|Drug|Cefiderocol|2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
79535626|NCT03869437|Other|Best Available Therapy|Standard of care was determined by the investigator
79535627|NCT03853798|Drug|AG-348|Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
79535628|NCT03850782|Drug|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
79535629|NCT03845283|Behavioral|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
79535630|NCT03845283|Behavioral|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
79535631|NCT03845283|Behavioral|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
79692418|NCT01984788|Drug|Placebo|
80008779|NCT05036512|Drug|GBT021601|Administered orally with water as a single dose in the morning.
79241600|NCT03414879|Drug|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
79241601|NCT03414879|Drug|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
79692419|NCT02911337|Dietary Supplement|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
79692420|NCT01983306|Drug|SP-333 1 mg|Tablet
79241602|NCT03419793|Device|segmental vibration device|segmental vibration device
79241603|NCT03419793|Other|physical therapy exercises|
79692421|NCT01983306|Drug|SP-333 3 mg|Tablet
79692422|NCT01983306|Drug|SP-333 6 mg|Tablet
79692423|NCT01983306|Drug|Placebo|Tablet
80008780|NCT05020392|Drug|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10^6/kg on day 0 and day 1 respectively.
80008781|NCT05020392|Drug|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10^6/kg on day 0 and day 1 respectively.
79692424|NCT02911220|Genetic|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
79692425|NCT02911454|Other|Infant formula|
79535632|NCT03845283|Behavioral|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
79535633|NCT03845283|Behavioral|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
79241604|NCT03414801|Other|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
79241605|NCT03425487|Behavioral|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
79535634|NCT03845075|Drug|Tesofensine/Metoprolol|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
79241606|NCT03425487|Behavioral|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
79391403|NCT02422914|Behavioral|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
79535635|NCT03845075|Drug|Placebo|During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
79535636|NCT03834701|Device|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
79535637|NCT03830918|Biological|Atezolizumab|Given IV
79535638|NCT03830918|Drug|Niraparib|Given PO
79535639|NCT03830918|Other|Quality-of-Life Assessment|Ancillary studies
79535640|NCT03830918|Other|Questionnaire Administration|Ancillary studies
79535641|NCT03830918|Drug|Temozolomide|Given PO
79535642|NCT03821935|Drug|Livmoniplimab|Liquid for intravenous infusion.
79692426|NCT01982175|Biological|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------"
79692427|NCT01975818|Drug|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
79692428|NCT01975818|Biological|Epoetin alfa/beta|
79692429|NCT02911259|Device|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
79535643|NCT03821935|Drug|Budigalimab|Lyophilized powder for solution for intravenous infusion.
79535644|NCT03810196|Device|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
79692430|NCT02911259|Device|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
79692431|NCT04676919|Device|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
79692432|NCT04676919|Device|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
79692433|NCT04676919|Device|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
79692434|NCT02911415|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
79692435|NCT02911181|Other|BIVA measurement|
79692436|NCT02910947|Procedure|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
79692437|NCT01973049|Drug|Daclatasvir|
79692438|NCT01973049|Drug|Asunaprevir|
79692439|NCT01973049|Drug|BMS-791325|
79692440|NCT01973049|Drug|Ribavirin|
79692441|NCT01973049|Drug|Placebo matching Ribavirin|
79692442|NCT01185964|Biological|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
79535645|NCT03809299|Other|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
79535646|NCT03809299|Other|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
79535647|NCT03804996|Drug|TG-1801|Intravenous infusion over 1 hour every 4 weeks
79535648|NCT03804996|Biological|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"
79535649|NCT03790267|Other|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
79535650|NCT03764033|Behavioral|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
80008782|NCT05006430|Biological|Fecal Microbiota Transplantation|It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.
80008783|NCT05006430|Other|Placebo|Placebo will be identical to the investigational product but will not contain fecal material.
79692443|NCT01185964|Drug|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
79692444|NCT02910869|Genetic|Pathway Genomics FIT test|
79692445|NCT01972854|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
79692446|NCT01972854|Drug|placebo solution|0.0% riboflavin ophthalmic solution
80008784|NCT05004883|Behavioral|Regulation of Cues Enhanced|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
80008785|NCT05004883|Behavioral|Behavioral Weight Loss|The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
79535651|NCT03764033|Behavioral|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
79692447|NCT01972854|Device|KXL System|30mW/cm2
79692448|NCT01217476|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
79692449|NCT04677075|Procedure|mastectomy|mastectomy either simple or modified radical
79535653|NCT03755206|Other|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
79535654|NCT03709758|Drug|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
79535655|NCT03709758|Drug|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
79535656|NCT03709758|Drug|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
79535657|NCT03704532|Procedure|Operative treatment|Open surgical repair of tendon rupture
79535658|NCT03704532|Procedure|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
79692450|NCT04318756|Behavioral|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
80008786|NCT05004883|Behavioral|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
80008787|NCT04992468|Drug|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
80008788|NCT04992468|Drug|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
79241607|NCT03425487|Other|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
79241608|NCT03419715|Drug|Bimatoprost Topical Solution|One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
79535659|NCT03696498|Procedure|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
79692451|NCT02888002|Behavioral|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
79692452|NCT04675437|Other|Aerobic exercise|12-weeks aerobic exercise program
79692453|NCT02605538|Biological|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
79692454|NCT04677192|Combination Product|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
79692455|NCT02550470|Device|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
80008789|NCT04990674|Behavioral|REMOTION|REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).
80008790|NCT04990674|Behavioral|TAU|Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
80008791|NCT04984343|Radiation|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have >72 hours between beginning of each fraction."
79535660|NCT03696498|Procedure|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
79535661|NCT03689946|Drug|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
79692456|NCT02550470|Device|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
79535662|NCT03689946|Diagnostic Test|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
79692457|NCT02550470|Drug|Sevoflurane|
79692458|NCT04688216|Other|risk factors of infection with multidrug-resistant organisms|"General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
80008792|NCT04981548|Other|no intervention|no intervention
80008793|NCT04975100|Drug|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
80008794|NCT04975100|Drug|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
80008795|NCT04970342|Drug|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
79535663|NCT03689946|Diagnostic Test|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
79535665|NCT03677882|Behavioral|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
79535666|NCT03671590|Drug|TG-1701|Oral daily dose
79381025|NCT02482506|Behavioral|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
79692459|NCT04675359|Procedure|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
80008796|NCT04970342|Drug|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
80008797|NCT04970342|Drug|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / <0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
80008798|NCT04970342|Drug|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
79241609|NCT03419715|Drug|Control|One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
79381026|NCT02482506|Behavioral|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
79381027|NCT03317808|Diagnostic Test|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
79381028|NCT02480244|Behavioral|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
79381029|NCT02480244|Other|Control|Control arm receives no health-related behavioral intervention
79381030|NCT01808326|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
79381031|NCT05714358|Behavioral|Education|"The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~After the training, the biochemical parameters of the patients were followed for 6 months.~In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
79692460|NCT04675203|Procedure|Tooth extraction|Tooth extraction
79692461|NCT02910518|Drug|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79692462|NCT02910518|Drug|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79692463|NCT02910518|Drug|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
79692464|NCT02910518|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79692465|NCT02910518|Drug|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
79692466|NCT02910518|Drug|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
79837974|NCT05378230|Dietary Supplement|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
80008799|NCT04959981|Drug|ERAS-007|Administered orally
79241610|NCT03618355|Drug|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
79692467|NCT02910518|Drug|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
80008800|NCT04959981|Drug|ERAS-601|Administered orally
80008801|NCT04959981|Drug|Osimertinib|Administered orally
80008802|NCT04959981|Drug|Sotorasib|Administered orally
80008803|NCT04951193|Behavioral|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
79692468|NCT01217437|Biological|Bevacizumab|Given IV
79692469|NCT01217437|Drug|Irinotecan Hydrochloride|Given IV
79692470|NCT01217437|Drug|Temozolomide|Given PO
79692471|NCT02910479|Device|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
79837975|NCT00934479|Drug|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
79837976|NCT00658632|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
79535667|NCT03671590|Drug|Umbralisib|Oral Daily Dose
79837977|NCT00658632|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
79381032|NCT03317730|Drug|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
79381033|NCT02486484|Drug|ziv-aflibercept|zaltrap injection
79381034|NCT01808560|Device|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
79381035|NCT01808560|Device|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
79381036|NCT03317652|Other|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
79381037|NCT03317652|Other|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
79381038|NCT03317652|Drug|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
79381039|NCT02479854|Drug|Asmakast|1 chewable tablet contains 5 mg montelukast
79381040|NCT02479854|Drug|Singulair|1 chewable tablet contains 5 mg montelukast
79381041|NCT02486172|Behavioral|Peer support program|Peer support program as an additional service to the routine clinical service
79381042|NCT01809106|Drug|Morphine|60 mg /24 ore
79381043|NCT01809106|Drug|Fentanyl|25 microg/h
79381044|NCT01809106|Drug|Buprenorphine|35 microg/h
79535668|NCT03671590|Biological|Ublituximab|IV infusion
79535669|NCT03667716|Drug|COM701|COM701 monotherapy.
79535670|NCT03667716|Drug|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
79381045|NCT01809106|Drug|Oxycodone|40 mg /24 ore
79381046|NCT02479932|Other|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
79535671|NCT03662659|Biological|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
79535672|NCT03662659|Biological|Nivolumab|Specified dose on specified days
79535673|NCT03662659|Drug|XELOX|Oxaliplatin + capecitabine
79535674|NCT03662659|Drug|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
79535675|NCT03662659|Drug|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
79535676|NCT03652740|Drug|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
79535677|NCT03652259|Genetic|SRP-9003|SRP-9003 will be administered through a single systemic injection.
79535678|NCT03649308|Device|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
79535679|NCT03649308|Procedure|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
79535680|NCT03646058|Drug|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
79535681|NCT03646058|Drug|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
79535682|NCT03641560|Drug|Enzalutamide|Enzalutamide will be administered orally
79692472|NCT02910479|Device|Rectal thermometer|
79692473|NCT02910479|Device|Esophageal thermometer|
79692474|NCT02910479|Device|Vital sense capsule thermometer|
79692475|NCT00624364|Drug|biphasic insulin aspart|
79692476|NCT00624364|Drug|metformin|
79692477|NCT02910596|Drug|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
79692478|NCT02910596|Device|early bladder training|early bladder training start on 3rd - 5thpostoperative day
79692479|NCT02910596|Other|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
79692480|NCT02910596|Other|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
79692481|NCT04316377|Drug|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
79692482|NCT04677036|Other|No intervention is given|No intervention given
80016789|NCT03056157|Behavioral|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on problems occurring in the present (with no focus on trauma or re-visiting past experiences).
79241611|NCT04706403|Behavioral|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
79381047|NCT02479932|Other|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
79692483|NCT02886988|Drug|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
79692484|NCT02886988|Drug|normal saline|0.1mlof normal saline will be injected with a 30G needle.
79692485|NCT02887144|Device|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
79692486|NCT02887144|Device|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
79692487|NCT06227455|Procedure|Maxillary alveolar ridge augmentation|The surgical procedure involves careful flap reflection, autogenous graft harvesting, and placement and fixation of the barriers over mixture of Autogenous graft and xenograft particles.
79535683|NCT03641560|Drug|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
79535684|NCT03628287|Other|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
79535685|NCT03628287|Other|Original Care Coordination Program|Original Care Coordination
79692488|NCT06227442|Diagnostic Test|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
79692489|NCT06227416|Other|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
79692490|NCT06227403|Behavioral|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP-M seeks to foster these improvements in youth of color as a strategy to combat structural racism encountered at school- and neighborhood-levels and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
79692491|NCT06227403|Behavioral|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
79692492|NCT06227390|Procedure|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
80008804|NCT04951193|Behavioral|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
80008805|NCT04933162|Dietary Supplement|High Protein and Low Fiber Diet|Protein intake will be increased to be >40% calories from protein, and the fiber intake will remain <15gm/day.
80008806|NCT04933162|Dietary Supplement|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to <10% total calories from protein.
79535688|NCT03625791|Biological|blood sample|1 tube with 4 ml of blood per patient
79692493|NCT06227364|Diagnostic Test|MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
79692494|NCT06227364|Diagnostic Test|metabolic patients|patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
80008807|NCT04906941|Device|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~* Sense 2 * 2: 9min33s"
80008808|NCT04901377|Combination Product|Estradiol valerate/ Dienogest|Combined hormonal contraceptive (combined oral contraceptives, COCs)
79241612|NCT03454165|Combination Product|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
79241613|NCT03454165|Combination Product|Ibrutinib|A novel BTK inhibitor.
79241614|NCT03425409|Device|Integra Pulse Portable- Continuous flow|4 liters per minute oxygen flow
79381048|NCT03852394|Other|Respiratory mechanics assessment|The study protocol consisted of two consecutive phases; in the first step measurements of static respiratory mechanics and end expiratory lung volume (EELV) were performed after 30 minutes of MV in volume control mode. In the second step transdiaphragmatic pressure (Pdi) was calculated by means of a sniff maneuver (Maximal Pdi) after 30 minutes of spontaneous breathing trial. Linear regression analysis and Pearson's correlation coefficient was used to asses the association between Maximal Pdi values and static and dynamic mechanical features and the association between Maximal Pdi and Pdi/Maximal Pdi.
79381049|NCT02482662|Procedure|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
79535689|NCT03623373|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
79535690|NCT03623373|Drug|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
79535691|NCT03623373|Drug|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
79535692|NCT03623373|Drug|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
79837978|NCT05408650|Other|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
80008809|NCT04881357|Other|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
80008810|NCT04881357|Other|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
79381050|NCT03828136|Device|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
79535693|NCT03623373|Procedure|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
79535694|NCT03623373|Procedure|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
79535695|NCT03623373|Procedure|Oral rinse|-Baseline
79535696|NCT03623373|Procedure|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
79535697|NCT03601923|Drug|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
79381051|NCT03828136|Device|Allograft Ring or Block|Standard of Care
79535698|NCT03586258|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
79535699|NCT03586258|Other|Brain Imaging|Anatomical, diffusion, and/or functional MRI
79535700|NCT03586258|Other|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
79535701|NCT03581318|Device|MRI|MRI for up to two hours, some without- and some with- administration of intravenous gadolinium based contrast agents (GBCAs), as well as some without and some with pharmacologic or physical stress.
79535702|NCT03556488|Diagnostic Test|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
79535703|NCT03542682|Device|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
79535704|NCT03542682|Device|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
79535705|NCT03537690|Other|Laboratory Biomarker Analysis|Correlative studies
79535706|NCT03537690|Drug|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
79535707|NCT03537690|Other|Pharmacokinetic Study|Correlative studies
79692495|NCT06227351|Procedure|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
79837979|NCT00677534|Drug|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
80008811|NCT04871737|Biological|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
80008812|NCT04865367|Other|Exposure to culture media|Exposure to culture media
80008813|NCT04795245|Drug|afatinib|afatinib
79381052|NCT03314610|Other|Gait speed|No intervention, only propose water and wait for need to void
79381053|NCT03804580|Drug|osimertinib|Non-randomized trial, all patients receive therapy
79381054|NCT02482584|Device|CPAP|CPAP intervention
79381055|NCT02482584|Other|Control|Control
80016790|NCT02280590|Drug|Rosuvastatin(Cresnon®)|10mg
80016791|NCT02280590|Drug|Rosuvastatin(Crestor®)|10mg
79381056|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
79381057|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
79381058|NCT01765972|Device|etafilcon A with Lacreon|contact lens with Lacreon
79381059|NCT01765972|Device|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
79381060|NCT01765972|Device|etafilcon A with print|contact lens with print
80016792|NCT02090244|Drug|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
79381061|NCT01765972|Device|Spectacles (habitual)|Spectacles
79381062|NCT02486250|Other|Validation Study|
79535708|NCT03522259|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
79692496|NCT06227351|Procedure|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
79837980|NCT00940173|Device|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
79837981|NCT00940173|Device|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
79837982|NCT00940173|Device|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
79535709|NCT03514173|Device|Remote Patient Monitoring|Use of remote patient monitoring
79535710|NCT03485547|Drug|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
79692497|NCT06227325|Drug|RC48 combined with Sintilimab and XELOX|RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
79692498|NCT06227312|Device|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
79692499|NCT06227312|Other|exercises|calf raises and modified drop jumps
79837983|NCT00940173|Device|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
79837984|NCT02559284|Other|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~Gentle blowing of the nose~Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
80016793|NCT02282774|Drug|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
79241615|NCT03425409|Device|Integra Pulse Portable- Pneumatic pulsed flow|Oxygen flow determined by test device
79241616|NCT03618277|Procedure|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
79241617|NCT03414645|Biological|CAM-101 10%|fibrinogen-depleted human platelet lysate
79241618|NCT03414645|Biological|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
79241619|NCT03414645|Biological|CAM-101 30%|fibrinogen-depleted human platelet lysate
79241620|NCT03618511|Behavioral|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
79381063|NCT01810666|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
79381064|NCT02482272|Drug|Lamivudine|Lamivudine 100mg/day orally
79241621|NCT03618511|Behavioral|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
79241622|NCT03618511|Behavioral|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
79241623|NCT03618511|Behavioral|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
79381065|NCT02482272|Drug|Adefovir|Adefovir 10mg/day orally
79381066|NCT02482272|Drug|Entecavir|Entecavir 1mg/day orally
79381067|NCT01766440|Drug|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
79381068|NCT03317340|Other|Background Sounds|Background music or sound of running water
79381069|NCT05714124|Procedure|Embolization|Endovascular treatment for patients with primary and secondary liver tumors
79535711|NCT03480386|Behavioral|Home Based Pulmonary Rehabilitation|Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
79535712|NCT03476343|Device|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
79535713|NCT03475134|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
79535714|NCT03475134|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
79535715|NCT03475134|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
79535716|NCT03475134|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
79535717|NCT03475134|Drug|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
79241624|NCT03618511|Behavioral|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
79241625|NCT03618511|Behavioral|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
79692500|NCT06227273|Dietary Supplement|Hydrogen water|Daily consumption of hydrogen water for 16 weeks.
79692501|NCT06227260|Other|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
79692502|NCT06227221|Drug|Sorafenib|Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.
79692503|NCT06227221|Drug|Placebo|Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
79692504|NCT06227208|Device|Continuous vital sign monitoring|Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
79837985|NCT00801762|Device|Fibered confocal microscope|
79837986|NCT00989716|Drug|Transdermal glyceryl trinitrate patch|5mg per day
79837987|NCT00989716|Drug|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
79837988|NCT00660348|Drug|morphine sulfate|This is morphine given in the traditional methods.
80008814|NCT04788394|Other|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection [40].~Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
80016794|NCT02282774|Drug|Sham subtenon block|
79241626|NCT02236585|Procedure|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
79381070|NCT02482116|Other|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
79381071|NCT01811212|Drug|Cabozantinib S-malate|Given PO
79535718|NCT03471338|Behavioral|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
79535719|NCT03471338|Behavioral|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
79837989|NCT00660348|Device|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
79837990|NCT05408416|Procedure|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
79837991|NCT00940251|Drug|Mersina|capsule, 3g/day, 3 months
79837992|NCT04013373|Device|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
79381072|NCT01811212|Other|Laboratory Biomarker Analysis|Correlative studies
79381073|NCT03314532|Procedure|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
79837993|NCT03734198|Drug|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
79692505|NCT06227182|Diagnostic Test|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
79535720|NCT03467191|Drug|Alcohol|target BAC .08%
79535721|NCT03467191|Other|Placebo|placebo beverage
79535722|NCT03447860|Behavioral|PAACC|Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
79692506|NCT06227182|Diagnostic Test|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
79692507|NCT06227156|Drug|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle or every 3 weeks is a treatment cycle
79535723|NCT03447860|Behavioral|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
79535724|NCT03441165|Procedure|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
79535725|NCT03412591|Drug|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
79535726|NCT03400332|Drug|BMS-986253|Specified dose on specified days
79535727|NCT03400332|Biological|Nivolumab|Specified dose on specified days
79535728|NCT03400332|Biological|Ipilimumab|Specified dose on specified days
79535729|NCT03400332|Other|Placebo|Specified dose on specified days
79692508|NCT06227117|Drug|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
79837994|NCT03734198|Drug|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
79837995|NCT00660192|Drug|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
79535730|NCT03389477|Drug|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
79241627|NCT02236585|Procedure|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
79381074|NCT02482194|Biological|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
79381075|NCT01767064|Other|Posted commitment letter|
79241628|NCT04649307|Behavioral|MI-CBT|Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
79381076|NCT03317184|Procedure|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
79381077|NCT03317184|Procedure|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
79381078|NCT04350814|Behavioral|Self-Compassion Step by Step|This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)
79381079|NCT04350814|Behavioral|Self-Reflection Active Control|Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
79535731|NCT03389477|Drug|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
79535732|NCT03389477|Drug|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
79535733|NCT03389477|Radiation|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
79535734|NCT03389477|Procedure|Tumor biopsy|"Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
79535735|NCT03389477|Procedure|Peripheral blood draw|Baseline and post-treatment
79692509|NCT06227117|Drug|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
79692510|NCT06227117|Drug|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
79692511|NCT06227117|Drug|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
79692512|NCT06227117|Drug|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
79692513|NCT06227117|Drug|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
79241629|NCT04448457|Drug|Sufentanil Sublingual Tablet|15 mcg with lockout interval of 20 min
79241630|NCT04448457|Drug|Oxycodone oral tablet and oxycodone extended-release oral tablet|Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
79241631|NCT03425175|Other|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
79535736|NCT03375216|Behavioral|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
79535737|NCT03375216|Behavioral|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
79535738|NCT03372291|Other|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
79837996|NCT00660192|Other|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
79837997|NCT01564108|Drug|Ranibizumab|Series of intravitreal injections of Ranibizumab
79837998|NCT00801918|Drug|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
80008815|NCT04788394|Other|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection [40].~Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
79381080|NCT01811680|Device|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
79692514|NCT06227117|Drug|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
79381081|NCT02479776|Biological|stem cell injection|Injection of autologous bone marrow derived stem cells
79381082|NCT02479620|Drug|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
79381083|NCT02482038|Device|geko|neuromuscular electrostimulator
79535739|NCT03372291|Other|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
79535740|NCT03353584|Other|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
79535741|NCT03328663|Other|CARE|Promote effective coping and reduce caregiving burden.
79535742|NCT03328663|Other|Standard Transplant Care|Standard cared administered by the hospital.
79535743|NCT03328455|Behavioral|Inhibitory control training|Cognitive training is inhibitory task-related.
79381084|NCT03552562|Device|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
79837999|NCT00801918|Drug|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
79381085|NCT02481960|Procedure|CM-BC2 Irinotecan drug-eluting bead|
79381086|NCT01767688|Drug|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
79381087|NCT03317028|Drug|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
79381088|NCT04492176|Device|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
79535744|NCT03328455|Behavioral|Knowledge-based training|Training is not inhibitory task-related.
79381089|NCT05713968|Other|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
79535745|NCT03317964|Other|Saliva sample|Extract sample of saliva only once
79535746|NCT03316053|Other|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
79535747|NCT03310957|Drug|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
79535748|NCT03310957|Drug|Pembrolizumab|IV infusion every 3 weeks
79535749|NCT03296371|Procedure|Biospecimen Collection|Undergo saliva or buccal mucosa collection
79535750|NCT03296371|Other|Laboratory Biomarker Analysis|Correlative studies
79535751|NCT03296371|Other|Questionnaire Administration|Ancillary studies
79692515|NCT06227104|Device|Convection-based Hemodiafiltration|Convection-based Hemodiafiltration with pre substitution fluid
79535752|NCT03289039|Drug|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
79535753|NCT03289039|Drug|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
79692516|NCT06227091|Dietary Supplement|Beetroot juice|acute dose of beetroot juice
79692517|NCT06227091|Dietary Supplement|Placebo|depleted nitrate beetroot juice
79838000|NCT00799188|Drug|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
79838001|NCT00799344|Device|Catania Stent|coronary stent implantation
80008816|NCT04749901|Other|Psycho-emotional and semiological measures|Surveys, interviews and measures
80008817|NCT04742101|Drug|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks preceded by ramp-up doses. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
80008818|NCT04715984|Other|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated
80008819|NCT04715984|Procedure|Neural stimulation|Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
79381090|NCT05713968|Other|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
80008820|NCT04707937|Other|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
79381091|NCT03314376|Device|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
80008821|NCT04707937|Other|Regular standard of care education|Access only to regular standard of care education
79241632|NCT02236663|Behavioral|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
79535754|NCT03275402|Biological|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
80008822|NCT04706728|Other|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
79305701|NCT03235973|Drug|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~Dose 1: 10 mg/m²/d~Dose 2: 15 mg/m²/d~Dose 3: 20 mg/m²/d~Dose 4: 25 mg/m²/d~IV busulfan will be given on day-6 using fixed dose as following:~If age ≤ 60 years: starting dose of 130 mg/m²~If age > 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
79535755|NCT03269474|Procedure|Experimental Group|Subjects with EB diagnosis
79535760|NCT03239899|Drug|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
79535761|NCT03195166|Diagnostic Test|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
79535762|NCT03172715|Procedure|Locking plate|Osteosynthesis
79535763|NCT03172715|Procedure|TKR|Total knee arthroplasty
79535764|NCT03171025|Drug|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
79535765|NCT03138512|Biological|nivolumab|Specified dose on specified days
79535766|NCT03138512|Biological|ipilimumab|Specified dose on specified days
79535767|NCT03138512|Drug|nivolumab placebo|Specified dose on specified days
79535768|NCT03138512|Drug|ipilimumab placebo|Specified dose on specified days
79535769|NCT03137888|Radiation|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
79535770|NCT03137888|Procedure|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
79535771|NCT03137888|Drug|Temozolomide|Given PO
79535772|NCT03117751|Drug|Prednisone|Given orally (PO).
79535773|NCT03117751|Drug|Vincristine|Given intravenously (IV).
79535774|NCT03117751|Drug|Daunorubicin|Given IV.
79535775|NCT03117751|Drug|Pegaspargase|Given IV or intramuscularly (IM) .
79535776|NCT03117751|Drug|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
79535777|NCT03117751|Drug|Cyclophosphamide|Given IV.
79535778|NCT03117751|Drug|Cytarabine|Given IV or by subcutaneous injection (SQ).
79535779|NCT03117751|Drug|Mercaptopurine|Given PO.
79535780|NCT03117751|Drug|Dasatinib|Given PO.
79535781|NCT03117751|Drug|Methotrexate|Given IV.
79535782|NCT03117751|Drug|Blinatumomab|Given IV.
79535783|NCT03117751|Drug|Ruxolitinib|Given PO.
79535784|NCT03117751|Drug|Bortezomib|Given IV or subcutaneously (SQ).
79535785|NCT03117751|Drug|Dexamethasone|Given PO.
79535786|NCT03117751|Drug|Doxorubicin|Given IV.
79535787|NCT03117751|Drug|Etoposide|Given IV.
79535788|NCT03117751|Drug|Clofarabine|Given IV.
79535789|NCT03117751|Drug|Vorinostat|Given PO.
79535790|NCT03117751|Drug|Idarubicin|Given IV.
79535791|NCT03117751|Drug|Nelarabine|Given IV.
79692518|NCT06227078|Device|Kinesiotaping|"Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results."
79535792|NCT03117751|Drug|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
79535793|NCT03117751|Drug|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
79692519|NCT06227065|Drug|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
79692520|NCT06227065|Drug|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
79692521|NCT06227065|Drug|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
79692522|NCT06227065|Drug|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
79692523|NCT06227052|Device|Num Vapocoolant Spray|This is the study arm. Partipants in this arm will receive Num vapocoolant spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Num Vapocoolant spray is currently FDA approved to be used on skin prior to injections. We are using it in the same fashion but in the vagina on the cervix to help with the pain of the paracervical block injection.
79692524|NCT06227052|Other|Placebo|This is the placebo. This group will receive Natures tear normal saline spray.
79692525|NCT06227039|Other|Vibroacoustic stimulation on|Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.
79692526|NCT06227039|Other|Augmented Reality on|Visual stimulus is provided through augmented reality glasses in the form of a game.
79692527|NCT06227039|Other|Vibroacoustic stimulation off|Vibroacoustic device is worn but turned off.
79241633|NCT02236663|Behavioral|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
79535794|NCT03117751|Drug|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
79535795|NCT03114306|Procedure|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
79692528|NCT06227039|Other|Augmented reality off|Augmented reality glasses are worn but turned off.
79692529|NCT06227013|Behavioral|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
79692530|NCT06226987|Diagnostic Test|68Ga-DOTATATE PET/MRI|PET/MRI scanning
79692531|NCT06226948|Device|CGM|Patients will wear CGM monitors for 10 days.
79692532|NCT06226948|Diagnostic Test|Visualization|Enriched visualization of SCORE2 CVD risk.
79692533|NCT06226922|Other|No intervention|No intervention
79535796|NCT03114306|Procedure|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
79535797|NCT03101319|Drug|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
79535798|NCT03101319|Drug|B Complex Oral Tablet|As mentioned in the description of the study arm
79692534|NCT06226883|Drug|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
79692535|NCT06226883|Drug|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
79692536|NCT06226870|Other|biodentin|Pulp capping material
79692537|NCT06226844|Device|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
79692538|NCT06226831|Other|Structured interview|In-person structured interviews will be performed by the investigators.
79692539|NCT06226805|Drug|BB-031|Solution for injection
79692540|NCT06226805|Drug|Placebo|0.9% sodium chloride for injection
79305702|NCT03235661|Device|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
79535799|NCT03085524|Diagnostic Test|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
79535800|NCT03085524|Diagnostic Test|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
79692541|NCT06226779|Behavioral|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
79692542|NCT06226779|Behavioral|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
79692543|NCT06226779|Behavioral|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
79381092|NCT01768000|Behavioral|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
79381093|NCT04492878|Drug|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
79381094|NCT02725866|Drug|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
79381095|NCT02725866|Drug|Dasabuvir|Tablet
79692544|NCT06226766|Drug|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
79241634|NCT05384743|Drug|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
79381096|NCT02725866|Drug|Ribavirin|Tablet
79535801|NCT03076788|Other|electrocardiogram and echocardiography|"We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.~Standard 12 lead ECG~Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow."
79692545|NCT06226740|Other|Single Visit Non Surgical Root Canal Treatment Protocol|The current study aimed to compare the effects of different obturation techniques on postoperative pain level and radiographic healing in non-surgical endodontic treatment applied in a single visit in teeth with single root canal and apical periodontitis.
79692546|NCT06226727|Drug|BR1019|One tablet administered alone
79692547|NCT06226727|Drug|BR1019-1|One tablet administered alone
79692548|NCT06226727|Drug|BR1019-2|One tablet administered alone
79692549|NCT06226714|Biological|MCV4|1 dose of MCV4 on Day 0
79692550|NCT06226714|Biological|MPSV4|1 dose of MSPV4 on Day 0
80008823|NCT04706728|Other|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
79241635|NCT03414333|Procedure|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
79535802|NCT03057106|Drug|Durvalumab|MEDI4736
79692551|NCT06226701|Device|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
79692552|NCT06226675|Procedure|PENG Block|To apply local anesthetic under psoas tendon
79241636|NCT03414333|Drug|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
79381097|NCT05713812|Procedure|Kinesiotaping|Kinesiotape will be applied
79535803|NCT03057106|Drug|Tremelimumab|Tremelimumab
79535804|NCT03057106|Drug|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
79535805|NCT03012529|Drug|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
79535806|NCT03012529|Drug|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
79535807|NCT02995330|Procedure|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
79535808|NCT02995330|Drug|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
79535809|NCT02995330|Drug|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
79535810|NCT02991547|Other|Observational|
79535811|NCT02988128|Device|Treatment for intracranial aneurysms|Embolization of aneurysms
79535812|NCT02988128|Device|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
79381098|NCT05713812|Procedure|Control Treatment|IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
79381099|NCT05454072|Procedure|Sinonasal Microbiota Transfer|Pre-screened donor mucus, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
79692553|NCT06226675|Procedure|LFCN block|to apply local anesthetic around lateral femoral cutaneous nerve
79692554|NCT06226649|Behavioral|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~Access to CKD Health Education Information;~Supportive Information for Significant Others;~Physiological Values Logging for Self-Monitoring;~Reminders for Clinical Appointments and Daily Self-Management Tasks;~Kidney Health Diary for Lifestyle Modification Progress Tracking;~Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
79692555|NCT06226636|Other|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
79692556|NCT06226610|Drug|Dupilumab|injection every two weeks while on study
79692557|NCT06226610|Other|Placebo|injection every two weeks while on study
79692558|NCT06226597|Device|Fitbit device|Daily use of a fitbit wearable activity tracker device.
79692559|NCT06226584|Dietary Supplement|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
79692560|NCT06226571|Drug|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
79692561|NCT06226571|Drug|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
79381100|NCT05454072|Procedure|Sham Sinonasal Microbiota Transfer|Saline, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
79692562|NCT06226571|Drug|HiDAC|Consolidation: Participants will receive HiDAC IV.
79692563|NCT06226545|Drug|LASN01|Low dose of LASN01 will be administered intravenously.
79692564|NCT06226545|Drug|LASN01|High dose of LASN01 will be administered intravenously.
79381101|NCT04492644|Other|No intervention|No intervention
79535813|NCT02984566|Device|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
79692565|NCT06226545|Drug|Placebo|Placebo will be administered intravenously.
80008824|NCT04706728|Other|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
80008825|NCT04705025|Behavioral|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
79692566|NCT06226532|Drug|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
80008826|NCT04705025|Other|Interview|Complete interview
80008827|NCT04705025|Other|Quality-of-Life Assessment|Ancillary studies
79241637|NCT03618043|Drug|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
79535814|NCT02975869|Other|Standard Leukemia Care|
79535815|NCT02975869|Other|Palliative Care|
79535816|NCT02935361|Drug|Atezolizumab|Given IV
80008828|NCT04705025|Other|Questionnaire Administration|Ancillary studies
79241638|NCT02031835|Procedure|BWSTT (3 days a week for maximum of 20 minutes session)|
79241639|NCT03618121|Device|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
79305703|NCT03235661|Device|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
79381102|NCT03316794|Drug|SC-005|intravenous
79381103|NCT02481726|Radiation|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
79381104|NCT02481882|Device|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
79381105|NCT02481882|Drug|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
79535817|NCT02935361|Drug|Guadecitabine|Given SC
79535818|NCT02871726|Device|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.
79535819|NCT02871726|Other|TRUS biopsy|Uronav for prostate biopsy.
79535820|NCT02864953|Drug|BIIB093|Administered as specified in the treatment arm.
79535821|NCT02864953|Drug|Placebo|Administered as specified in the treatment arm.
79535822|NCT02829918|Drug|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
79692567|NCT06226532|Drug|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
80008829|NCT04693013|Device|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
80008830|NCT04688749|Diagnostic Test|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
80008831|NCT04679402|Other|Carbon monoxide 200 ppm in air|Low dose carbon monoxide
80008832|NCT04665557|Behavioral|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
79535823|NCT02791204|Device|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
79381106|NCT02481804|Other|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
80008833|NCT04654507|Drug|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
80008834|NCT04654507|Drug|Placebo|Placebo
79535824|NCT02791204|Device|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
79535825|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
79692568|NCT06226519|Diagnostic Test|11C-MET-PET/RMN|60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.
79381107|NCT02481804|Other|Standard treatment|Standard treatment will be continued
80008835|NCT04654039|Other|Other: Non intervention|Non intervention
79381108|NCT03314298|Drug|testosterone anastrozole|subcutaneous testosterone and anastrozole
79381109|NCT02479542|Other|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
79381110|NCT02479542|Device|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
79692569|NCT06226506|Drug|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
80008836|NCT04646655|Drug|Enoxaparin|subcutaneous injections
80008837|NCT04629443|Drug|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
80008838|NCT04627922|Drug|N-Acetyl cysteine|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
80016795|NCT02090322|Procedure|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
79381111|NCT02479308|Drug|Moxifloxacin|Single administration
79535826|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
79692570|NCT06226506|Drug|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
79692571|NCT06226454|Drug|VX-993|Suspension for oral administration.
79692572|NCT06226454|Drug|Placebo|Suspension for oral administration.
79692573|NCT06226441|Procedure|Continuous Renal Replacement Therapy|CRRT
79381112|NCT02479308|Drug|ALKS 5461|Daily administration for a total of 12 dosing days
79381113|NCT02479308|Drug|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
79381114|NCT02485782|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
79535827|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
79535828|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
79692574|NCT06226402|Drug|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
79535829|NCT02730923|Drug|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
79692575|NCT06226402|Drug|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
79692576|NCT06226389|Procedure|4 different bulk-fill composite|Posterior cavities either class 1/2
79535830|NCT02730923|Drug|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
79535831|NCT02689466|Drug|[18F]FP-TZTP|radioligand
79535832|NCT02686606|Dietary Supplement|Vital 1.5|Oral nutritional supplement
79692577|NCT06226376|Device|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
79692578|NCT06226363|Drug|LNF1901 Monoclonal Antibody Injection|LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
80008839|NCT04627922|Other|Placebo comparator|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.
80008840|NCT04627922|Behavioral|Cognitive behavioral therapy (CBT)|Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
79692579|NCT06226350|Drug|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
79535833|NCT02686606|Dietary Supplement|Ensure Plus|Oral nutritional supplement
79838002|NCT00571688|Drug|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score > 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
80008841|NCT04609332|Diagnostic Test|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
80008842|NCT04608110|Drug|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
80008843|NCT04581226|Diagnostic Test|Lung ultrasound|All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
80008844|NCT04577716|Diagnostic Test|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
79241640|NCT03618121|Device|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax & Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
79692580|NCT06226337|Other|listen music|During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
80008845|NCT04577716|Diagnostic Test|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
80008846|NCT04577716|Diagnostic Test|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
80008847|NCT04577716|Other|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
80016796|NCT02282852|Device|Wireless Capsule Endoscopy|
80016797|NCT02282852|Device|Magnetically steerable capsule endoscopy|
79241641|NCT03618121|Behavioral|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
79305704|NCT02453087|Drug|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
79535834|NCT02630589|Device|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
79241642|NCT03618121|Behavioral|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
79692581|NCT06226324|Other|neuropsychological test|The subjects were evaluated for memory, cognition, mood and sleep
79692582|NCT06226311|Other|Data collection|Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years
79692583|NCT06226311|Other|Diagnostic Test: Urinary|Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
79692584|NCT06226298|Device|Xiaxi postural hammock|Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
79381115|NCT02485782|Device|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
79692585|NCT06226298|Behavioral|Yoga mat|Lie in the Yoga mat for 10 minutes for 5 days.
79692586|NCT06226285|Device|TechQoL4Carers Platform|"The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care."
79692587|NCT06226272|Device|Spinal Fusion|Cervical Spinal Fusion
79838003|NCT00571688|Drug|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
79838004|NCT00989794|Device|GelrinC|Applied once during surgery
79381116|NCT02485782|Device|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
79692588|NCT06226272|Device|Spinal Fusion|Thoracic / Lumbar Spinal Fusion
79692589|NCT06226272|Device|Spinal Deformities Correction|Spinal Deformities Correction
79381117|NCT02479386|Other|No intervention|No intervention was administered in this study.
79692590|NCT06226233|Other|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
79838005|NCT00794274|Drug|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
79838006|NCT00989872|Drug|EDP-322|
79838007|NCT02560610|Drug|OC000459|
79838008|NCT02560610|Drug|Placebo|
79838009|NCT00799500|Other|Screening|Weekly vaginal pH
79838010|NCT05590546|Other|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
79838011|NCT02560532|Drug|Clazosentan|Concentrated solution for intravenous injection
79838012|NCT00799656|Drug|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
79381118|NCT02481492|Device|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
79381119|NCT02481492|Device|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
79838013|NCT00799656|Drug|placebo|oral administration once daily for 28 days
79838014|NCT05408182|Procedure|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
79241643|NCT03617107|Other|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
79241644|NCT03617029|Device|Microcoil|Needle localization with microcoil
79241645|NCT03617029|Drug|Lipiodol|Needle localization with contrast injection
79241646|NCT03616873|Other|Early Mobilization|The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
79241647|NCT03616795|Drug|LY3154207|Administered orally
79381120|NCT05461560|Dietary Supplement|Sucrose solution|50 g of sucrose dissolved in 500 ml of tap water
79381121|NCT05461560|Dietary Supplement|Seaweed extract in sucrose solution|1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
79692591|NCT06226220|Procedure|Sacral neuromodulation|Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as >50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
79692592|NCT06226181|Procedure|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
79692593|NCT06226181|Procedure|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
80016798|NCT02095782|Drug|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
79381122|NCT03314220|Behavioral|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
79381123|NCT02481570|Other|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
79241648|NCT03616795|Drug|[14C]-LY3154207|Administered orally
79241649|NCT03616639|Drug|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
79241650|NCT03616639|Drug|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
79241651|NCT03616561|Drug|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
79381124|NCT02479464|Genetic|Genotyping results|Genotyping results provided in Phase II
79381125|NCT05713578|Drug|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
79381126|NCT05713578|Drug|apantamide+ADT treatment|apantamide+ADT treatment
79381127|NCT02485548|Drug|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
79381128|NCT02485548|Drug|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
79381129|NCT02485548|Drug|Cisplatin|All patients will receive concurrent cisplatin.
79381130|NCT02485548|Radiation|IMRT|All patients will receive IMRT
79692594|NCT06226142|Procedure|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
79692595|NCT06226129|Drug|Gadopiclenol|Gadopiclenol for contrast enhanced MRI
79692596|NCT06226116|Procedure|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
79305705|NCT02453087|Drug|Rituximab|Participants will receive rituximab at a dose of 375 mg/m^2 of body surface area as intravenous infusion.
79692597|NCT06226116|Procedure|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
79838015|NCT04050020|Biological|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
79838016|NCT04050020|Biological|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
79305706|NCT02453087|Drug|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
79305707|NCT03235583|Device|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
79381131|NCT02478840|Drug|Lamazym|recombinant human alpha-mannosidase
79381132|NCT02479152|Device|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
79381133|NCT02478918|Other|Phone call|Automated phone call reminder
79381134|NCT02478996|Other|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
79692598|NCT06226116|Procedure|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
79692599|NCT06226103|Other|Aerobic Exercise and Computerized Cognitive Training|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function."
79692600|NCT06226103|Other|Conventional Exercises and Brain health lectures|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks
79241652|NCT03617965|Diagnostic Test|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
79241653|NCT03617887|Other|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
79838017|NCT05408104|Drug|tolvaptan|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
79241654|NCT03617887|Other|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
79241655|NCT03617809|Procedure|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
79305708|NCT03235193|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
79381135|NCT02479074|Drug|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
79381136|NCT02479074|Drug|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
79381137|NCT02479074|Drug|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
79535835|NCT02542852|Drug|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
79692601|NCT06226090|Drug|TG103 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
79838018|NCT00802152|Other|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
79838019|NCT00343291|Biological|Cetuximab|Administered intravenously
79535836|NCT02517294|Device|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
79838020|NCT00343291|Biological|Bevacizumab|Administered intravenously
80016799|NCT03659487|Procedure|Nissen|Laparoscopic total (Nissen) fundoplication
79381138|NCT02478762|Procedure|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
79381139|NCT02478762|Procedure|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
79381140|NCT02478684|Other|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
79381141|NCT02478684|Other|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
79535837|NCT02517294|Device|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
79535838|NCT02512965|Radiation|20 Gy in 5 fractions|
79535839|NCT02512965|Radiation|Conventional SBRT: 24 Gy in 2 fractions|
79692602|NCT06226090|Drug|Placebo 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
79838021|NCT00343291|Drug|Paclitaxel|Administered intravenously
80016800|NCT03659487|Procedure|Toupét|Laparoscopic posterior 270 degrees partial fundoplication
79692603|NCT06226090|Drug|TG103 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
79692604|NCT06226090|Drug|Placebo 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
79692605|NCT06226090|Drug|TG103 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
79692606|NCT06226090|Drug|Placebo 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
79838022|NCT00343291|Drug|Carboplatin|Administered intravenously
79381142|NCT05715060|Procedure|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire & Polydioxanone (PDS)
79838023|NCT00799734|Drug|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
79838024|NCT05407870|Drug|Etomidate Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
79838025|NCT05407870|Drug|Propofol Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
79838026|NCT03988231|Drug|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
79381143|NCT02481180|Drug|T0001|injection (SC) T0001 15mg weekly for 12 weeks
79241656|NCT03615313|Biological|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
79241657|NCT03617653|Diagnostic Test|Group A|Refer to detailed study Description
79241658|NCT03617575|Dietary Supplement|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf [total of 1.5 mg iron]) in a maize porridge (extrinsically labeled)
79381144|NCT02481180|Drug|T0001|injection (SC) T0001 30mg weekly for 12 weeks
79241659|NCT03617575|Dietary Supplement|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
79381145|NCT02481180|Drug|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
79381146|NCT02481180|Drug|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
79381147|NCT02481180|Drug|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
79381148|NCT02480946|Drug|MBS2320|As described in the arm descriptions
79692607|NCT06226077|Behavioral|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
79692608|NCT06226077|Behavioral|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
79838027|NCT03988231|Drug|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
79838028|NCT03988465|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79241660|NCT03617575|Dietary Supplement|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
79381149|NCT02480946|Drug|Placebo|As described in the arm descriptions
79381150|NCT02480946|Drug|Methotrexate|Background therapy as described in the arm descriptions
79381151|NCT02480868|Device|ARTEBONE|4,3 g Bone Void Filler
79692609|NCT06226064|Drug|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
79692610|NCT06226064|Drug|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
79692611|NCT06226038|Other|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
79692612|NCT06226038|Other|Stainless steel|For control
79381152|NCT02478528|Device|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
79381153|NCT02478528|Device|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
79381154|NCT02478528|Other|control condition|No exposure of the subject to any light sources (control condition)
79381155|NCT03316716|Procedure|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
79692613|NCT06226012|Device|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
79692614|NCT06226012|Device|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
79692615|NCT06225999|Drug|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
80008848|NCT04576416|Other|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( >10 years of experience) through a web-based review system developed by our group."
80008849|NCT04572269|Other|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
80008850|NCT04569487|Procedure|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
79381156|NCT02478606|Other|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
80008851|NCT04562883|Other|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
80008852|NCT04540588|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
80008853|NCT04534127|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
80008854|NCT04532242|Behavioral|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
79241661|NCT03617575|Dietary Supplement|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
79241662|NCT03617575|Dietary Supplement|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
79241663|NCT03617575|Dietary Supplement|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
79241664|NCT02983617|Drug|Tirabrutinib|Administered orally once daily
79241665|NCT02983617|Drug|Entospletinib|Administered orally once daily
79241666|NCT02983617|Drug|Obinutuzumab|Administered intravenously
79381157|NCT01769170|Drug|Brincidofovir|
79381158|NCT01769170|Other|Placebo|
79381159|NCT05714904|Drug|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
79381160|NCT04350970|Other|High flow nasal therapy|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.
79535840|NCT02509520|Dietary Supplement|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver ~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
79692616|NCT06225999|Drug|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
79692617|NCT06225999|Drug|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
79692618|NCT06225999|Drug|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
79241667|NCT03401203|Procedure|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
79241668|NCT03401203|Procedure|Balloon angioplasty|Percutaneous coronary intervention
79305709|NCT03235193|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
79381161|NCT04350970|Other|Non-invasive ventilation|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.
79381162|NCT04350970|Other|Control|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
79692619|NCT06225986|Behavioral|LMH-4-DCP|Reminiscence-based intervention for family caregiver-PwD dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
79692620|NCT06225986|Behavioral|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
79692621|NCT06225973|Drug|TL-925|TL-925 is an eye drop.
79692622|NCT06225973|Other|Placebo|The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
79692623|NCT06225934|Behavioral|Exercise and home program to increase lateral flexion and rotation angles|Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
79692624|NCT06225908|Procedure|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
79692625|NCT06225895|Drug|normal saline|patients will receive a sham block with 20 ml of normal saline on each side followed by general anesthesia.
79692626|NCT06225895|Procedure|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
79692627|NCT06225895|Procedure|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
79692628|NCT06225895|Drug|Bupivacaine|20 ml of bupivacaine 0.25%
79692629|NCT06225882|Drug|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
79692630|NCT06225869|Behavioral|Assessments in ON and OFF levodopa state|Neurological assessment, neuropsychological assessment, and fMRI in ON and OFF levodopa state
79692631|NCT06225843|Biological|Sotevtamab|Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
80008855|NCT04521413|Drug|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
80008856|NCT04521413|Drug|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
80008857|NCT04516057|Drug|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
80008858|NCT04516057|Other|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
79241669|NCT03616405|Drug|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
79241670|NCT03419559|Biological|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
79535841|NCT02508324|Biological|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
79692632|NCT06225843|Combination Product|FOLFOX|FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
79692633|NCT06225830|Device|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
79692634|NCT06225804|Drug|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
79692635|NCT06225791|Behavioral|MMS (90x2) + BCC or expanded BCC|Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
79692636|NCT06225791|Behavioral|MMS (180x1) + BCC or expanded BCC|Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
79692637|NCT06225778|Other|Exercise|6-week online exercise group
79692638|NCT06225765|Procedure|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
80008859|NCT04507464|Behavioral|Ecological Momentary Intervention|Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
79241671|NCT03419559|Drug|Durvalumab|PD-L1 antagonist monoclonal antibody
79692639|NCT06225765|Procedure|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
80008860|NCT04484571|Device|Neuroexsos elbow module|The treatment group will be further divided into two levels (sub-groups), based on pathological severity: Level 1 corresponds to an FM score equal or below 28, and Level 2 with FM greater than 28. The two sub-groups will receive different combinations of robotically assisted passive mobilization (PM) and active mobilization (AM) treatment modalities, according to their differing clinical needs
80008861|NCT04483245|Biological|Blood sampling|Blood sampling
79305710|NCT02128763|Drug|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
79305711|NCT02128763|Drug|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
79381163|NCT02480634|Drug|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
79381164|NCT02480634|Radiation|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
79381165|NCT01815502|Diagnostic Test|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
80008862|NCT04474613|Diagnostic Test|Liquid biopsy|Liquid biopsy done on a blood draw, taking approximately 7 days
79305712|NCT02124772|Drug|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
79305713|NCT02124772|Drug|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
79381166|NCT01769248|Device|Fine needle aspiration|Fine needle aspiration
79381167|NCT01769248|Device|Fine needle biopsy|FNB
79381168|NCT03399292|Drug|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
79381169|NCT02726022|Drug|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
79305714|NCT02159482|Drug|Interferon Alfa-2a|
79305715|NCT05269030|Drug|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
79305716|NCT05269030|Drug|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
79692640|NCT06225726|Procedure|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
79692641|NCT06225687|Other|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
79692642|NCT06225674|Device|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
79305717|NCT02622321|Drug|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
79305718|NCT02622321|Drug|rFVIIa|Participants will continue to receive rFVIIa.
79305719|NCT02622321|Drug|aPCC|Participants will continue to receive aPCC.
79305720|NCT02187172|Drug|Ustekinumab|
79305721|NCT02187172|Drug|Placebo|
79305722|NCT03056937|Other|Bariatric surgery|evaluations pre and post bariatric surgery.
79305723|NCT03056937|Other|Control|without intervention, it will be performed only evaluations
79381170|NCT02726022|Drug|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
79381171|NCT05714748|Biological|EBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
79381172|NCT02258152|Drug|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
79305724|NCT03057015|Drug|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
79381173|NCT02258152|Drug|Placebo|Placebo QD
79692643|NCT06225661|Behavioral|SAFE Intervention|Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
80008863|NCT04441892|Device|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
80008864|NCT04436497|Drug|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
80008865|NCT04436497|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
80008866|NCT04434755|Other|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
80008867|NCT04424641|Biological|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
80008868|NCT04421846|Other|Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
80008869|NCT04414345|Drug|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
80008870|NCT04414345|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
80008871|NCT04403633|Other|mobile health educational tool|Interactive educational tool delivered on iPad
79692644|NCT06225661|Behavioral|NAV (Telephone Navigation)|Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
79692645|NCT06225635|Drug|Ezerosu(monolayer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
79692646|NCT06225635|Drug|Ezerosu(double layer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
80008872|NCT04393103|Drug|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~Group A (Control Group) : Follow Up of 30 patients.~Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
80008873|NCT04393103|Drug|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
80008874|NCT04368195|Procedure|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
80008875|NCT04335370|Other|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~Prior to start of infusion~End of infusion~One hour after end of infusion~Three hours after end of infusion~Eight hours after start of infusion"
80008876|NCT04334629|Drug|Ibuprofen|Lipid ibuprofen 200 mg
79305725|NCT03057015|Drug|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
79305726|NCT03057015|Drug|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
79305727|NCT03057015|Drug|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
79381174|NCT02725788|Device|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
79692647|NCT06225622|Drug|Irinotecan Liposome|"In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible."
79692648|NCT06225622|Drug|Oxaliplatin|85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
79692649|NCT06225622|Drug|5-FU|2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
79692650|NCT06225622|Drug|LV|400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.
79692651|NCT06225622|Drug|Bevacizumab|5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
79692652|NCT06225622|Drug|Cetuximab|500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
79692653|NCT06225609|Procedure|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
79692654|NCT06225609|Procedure|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
79692655|NCT06225570|Drug|Isotretinoin|This arm aims to study the effectiveness, side effects and patient satisfaction of taking isotretinoin on a weekly basis as opposed to current standard daily dosing.
79692656|NCT06225570|Drug|Tetracycline|This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
79692657|NCT06225544|Drug|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
79692658|NCT06225518|Behavioral|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
80008877|NCT04296890|Drug|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
80008878|NCT04276090|Device|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
80008879|NCT04276090|Drug|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
79692659|NCT06225505|Diagnostic Test|ctDNA monitoring|For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
79692660|NCT06225505|Diagnostic Test|68Ga-FAPI-46-PET-CT|). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
79692661|NCT06225466|Drug|Rocuronium|After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
79692662|NCT06225466|Drug|Sugammadex|When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
80008880|NCT04276090|Drug|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
80008881|NCT04276090|Drug|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
80008882|NCT04273139|Drug|IBRUTINIB|Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
80008883|NCT04273139|Drug|Venetoclax|Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
79535842|NCT02508324|Biological|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
80008884|NCT04248023|Behavioral|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
80008885|NCT04244370|Device|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
80008886|NCT04207437|Device|Vibration therapy|vibration therapy using hand held vibration device
80008887|NCT04207359|Dietary Supplement|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
79381175|NCT02725788|Device|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
80008888|NCT04195503|Procedure|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
79241672|NCT03616327|Device|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
79381176|NCT02485626|Procedure|2D tissue doppler echocardiography|
79381177|NCT01817374|Diagnostic Test|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
79535843|NCT02480803|Drug|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
79535844|NCT02480803|Device|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
80008889|NCT04193475|Other|Analysis|No intervention planned. Novel analysis of echocardiographic data.
79535845|NCT02458014|Biological|Blinatumomab|Given IV
79535846|NCT02458014|Other|Laboratory Biomarker Analysis|Correlative studies
80008890|NCT04159168|Behavioral|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
79535847|NCT02456857|Biological|Bevacizumab|Given IV
79535848|NCT02456857|Drug|Everolimus|Given PO
79535849|NCT02456857|Other|Laboratory Biomarker Analysis|Correlative studies
80008891|NCT04159168|Behavioral|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
79241673|NCT03419247|Procedure|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
79535850|NCT02456857|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79535851|NCT02446444|Drug|Enzalutamide|
79535852|NCT02446444|Drug|Conventional NSAA|
79535853|NCT02446444|Drug|LHRHA|
79692663|NCT06225466|Other|Anesthesia without neuromuscular blockade|Anesthesia without rocuronium or sugammadex
79692664|NCT06225440|Dietary Supplement|Levagen+® Palmitoylethanolamide (PEA)|Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
79241674|NCT03419247|Procedure|Blood draw|Blood will be taken by a needle from a vein.
80008892|NCT04134689|Device|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
80008893|NCT04134689|Other|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
79241675|NCT03419247|Procedure|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
79535854|NCT02446444|Radiation|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
79535855|NCT02435849|Biological|CTL019|Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10^8 tisagenlecleucel (for patients >50 kg).
79241676|NCT03615157|Other|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
79535856|NCT02367040|Drug|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
79535857|NCT02367040|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
79535858|NCT02367040|Drug|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
79535859|NCT02197234|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
80008894|NCT04105842|Device|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
79535860|NCT02197234|Drug|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
79692665|NCT06225440|Dietary Supplement|Placebo|Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
79692666|NCT06225414|Other|Usual Care|The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.
79692667|NCT06225414|Behavioral|Brief Patient Education|Brief one-page education material on lung cancer screening benefits and risk
80008895|NCT04092803|Other|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
80008896|NCT04088734|Drug|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10^13 vg/kg
79241677|NCT03414177|Other|Asthma Subspecialty Follow-up Visits|Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
79241678|NCT02873689|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule
79241679|NCT02873689|Drug|Placebo|Dexlansoprazole placebo-matching capsules
79241680|NCT03414099|Drug|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
79241681|NCT03414099|Drug|Placebo|Placebo drink matched for taste and appereance
79241682|NCT02901431|Drug|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
79241683|NCT02901431|Drug|RO5285119|Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
79241684|NCT02873377|Drug|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
79535861|NCT02197234|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
79535862|NCT02197234|Procedure|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
79535863|NCT02197234|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
79535864|NCT02177292|Radiation|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
79535865|NCT02168140|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
79692668|NCT06225414|Behavioral|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
79692669|NCT06225414|Behavioral|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
79692670|NCT06225414|Behavioral|Patient Reminders|within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.
79692671|NCT06225414|Behavioral|Provider Reminders|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
79692672|NCT06225401|Other|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
79692673|NCT06225401|Other|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
80008897|NCT04081688|Drug|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
80008898|NCT04081688|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
79241685|NCT02873377|Drug|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
79241686|NCT02873377|Other|Smoking Quitline Referral|Fax referral to the State smoking Quitline
79241687|NCT02873377|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
79381178|NCT04492332|Diagnostic Test|standard lumbar puncture|Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
79381179|NCT02485470|Other|MPACT|Maintaining Physical Activity during Cancer Treatment
79381180|NCT02478294|Procedure|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
79381181|NCT02478294|Drug|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
79381182|NCT02485392|Device|Da Vinci Single Site Robot-Assisted Cholecystectomy|
79381183|NCT02485392|Device|Single Incision Laparoscopic Cholecystectomy|
79381184|NCT01770652|Drug|Deferiprone|Oral iron chelator
79381185|NCT02485314|Other|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
79535866|NCT02168140|Drug|bendamustine hydrochloride|Given IV
79535867|NCT02157051|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
79535868|NCT02157051|Other|Laboratory Biomarker Analysis|Correlative studies
80008899|NCT04081688|Drug|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
80008900|NCT04068155|Device|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
79241688|NCT03649919|Other||Patients receive routine diagnostic and treatment medications.
79241689|NCT02966795|Drug|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
79241690|NCT04052789|Other|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
79241691|NCT03648749|Behavioral|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
79381186|NCT01820416|Radiation|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
79381187|NCT01820416|Other|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
79381188|NCT03316482|Drug|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
79381189|NCT03143218|Biological|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
79535869|NCT02152631|Drug|Abemaciclib|Administered orally
79535870|NCT02152631|Drug|Erlotinib|Administered orally
79535871|NCT02128802|Procedure|Gastric Bypass|
79535872|NCT02128802|Other|Weight Loss Program|
79535873|NCT02114229|Drug|alisertib|Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
79535874|NCT02114229|Drug|methotrexate|Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
79692674|NCT06224855|Drug|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
80008901|NCT04064814|Drug|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
80008902|NCT04064814|Drug|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
80008903|NCT04060966|Behavioral|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
80008904|NCT04060966|Behavioral|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (~30°C) for 3 minutes.
79535875|NCT02114229|Drug|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
79692675|NCT06224725|Other|dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)|Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
79692676|NCT06224595|Drug|CS32582 capsule|Participants receive CS32582 orally single or multiple doses
79692677|NCT06224595|Drug|Placebo capsule|Participants receive placebo matching CS32582 orally single or multiple doses
79692678|NCT06224517|Other|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
79692679|NCT06224322|Other|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
79838029|NCT03742219|Behavioral|Lifestyle Modification|"Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
79838030|NCT00658788|Drug|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
79241692|NCT04053257|Other|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
79241693|NCT04053179|Device|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
79381190|NCT03143218|Biological|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
79381191|NCT03143218|Drug|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
79838031|NCT00658788|Drug|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
79381192|NCT03143218|Drug|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
79535876|NCT02114229|Drug|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
79535877|NCT02114229|Drug|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
79838032|NCT05407402|Behavioral|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
79838033|NCT05407402|Behavioral|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
79535878|NCT02114229|Drug|etoposide|"Etoposide will be given 100 mg/m^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
79535879|NCT02114229|Drug|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
79838034|NCT01060969|Drug|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
79838035|NCT01060969|Drug|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
80008905|NCT04060966|Device|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
80008906|NCT04041609|Drug|LYR-210|A single administration of LYR-210 depot
79241694|NCT03647813|Radiation|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
79381193|NCT02480556|Procedure|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction & cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
80008907|NCT04041609|Other|Sham comparator|Sham comparator
79381194|NCT02480556|Procedure|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu & uterus is massaged awaiting spontaneous placental separation"
79535880|NCT02114229|Drug|vincristine|Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
80008908|NCT04008563|Procedure|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
80008909|NCT04001478|Diagnostic Test|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
80008910|NCT03995082|Other|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
79535881|NCT02114229|Procedure|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
79692680|NCT06224166|Diagnostic Test|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
79535882|NCT02114229|Radiation|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
79535883|NCT02111681|Device|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
79535884|NCT02106572|Drug|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
80008911|NCT03989011|Diagnostic Test|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
80008912|NCT03989011|Diagnostic Test|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~Peripheral pressure parameters~Central and abdominal aneurysm pressure parameters (derived using a transfer function)~Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
80008913|NCT03967626|Device|external cooling with the xxxxx device|external cooling with the xxxxx device
80008914|NCT03940963|Device|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
80008915|NCT03940963|Procedure|Standard Neurectomy|Surgical excision of symptomatic neuroma
79381195|NCT01771666|Device|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
79241695|NCT03647813|Radiation|Placebo|The same laser protocol was followed but with the device switched off.
79381196|NCT01771666|Drug|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
79381197|NCT01771666|Drug|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
79381198|NCT01771666|Drug|99technetium-sulfur colloid radiolabel|
79381199|NCT05713188|Device|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
79535885|NCT02106572|Drug|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
79692681|NCT06224023|Diagnostic Test|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
79241696|NCT03647735|Other|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
79241697|NCT03647579|Drug|midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine|midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
79381200|NCT02485236|Device|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
79241698|NCT03647579|Drug|Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine|Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
79535886|NCT02075840|Drug|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
79535887|NCT02075840|Drug|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
79535888|NCT02073994|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
79535889|NCT02048813|Drug|Cyclophosphamide|Given IV
79535890|NCT02048813|Drug|Fludarabine Phosphate|Given IV
79535891|NCT02048813|Drug|Ibrutinib|Given PO
79535892|NCT02048813|Other|Laboratory Biomarker Analysis|Correlative studies
79535893|NCT02048813|Other|Pharmacogenomic Study|Correlative studies
79535894|NCT02048813|Other|Quality-of-Life Assessment|Ancillary studies
79535895|NCT02048813|Biological|Rituximab|Given IV
79692682|NCT06223854|Dietary Supplement|Iodized salt|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
79692683|NCT06223854|Dietary Supplement|Experimental: Iodized salt with lower-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
79241699|NCT02873221|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
79241700|NCT02873221|Drug|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
79692684|NCT06223854|Dietary Supplement|Experimental: Iodized salt with higher-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
79692685|NCT06221813|Biological|PHV02|Nipah virus vaccine
79692686|NCT06221813|Biological|Lactated Ringer's|Placebo
79692687|NCT06220916|Behavioral|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
79692690|NCT06219252|Device|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
79692691|NCT06219252|Other|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
79692692|NCT06219226|Procedure|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
79692693|NCT06219226|Procedure|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
79241701|NCT02873221|Drug|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
79241702|NCT04046861|Dietary Supplement|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
79381201|NCT02485236|Device|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
79381202|NCT01821352|Device|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
79381203|NCT01821352|Device|Placebo Laser|Emits light that has no therapeutic effect
79692694|NCT06219031|Other|no intervention|no intervention
79692695|NCT06218836|Other|Pre-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
79241703|NCT04046861|Other|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
79241704|NCT02236741|Drug|Mirapexin® (Sifrol®)|
79241705|NCT03616249|Other|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
79305728|NCT03057015|Drug|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
79381204|NCT02485002|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
79381205|NCT02485002|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
79381206|NCT01772758|Drug|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
79305729|NCT04929717|Other|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
79305730|NCT04929717|Other|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
79381207|NCT01772758|Drug|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
79381208|NCT01772758|Dietary Supplement|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
79381209|NCT05712954|Other|music group|music
79535896|NCT02030860|Drug|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
79692696|NCT06218836|Other|Non-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
79241706|NCT03616249|Other|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
79535897|NCT02030860|Drug|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
79241707|NCT02966015|Device|Coloplast test catheter|This is a newly developed catheter
79381210|NCT05712954|Other|video group|video
79381211|NCT01775410|Device|Wolverine System to perform atherectomy|
79535898|NCT02030860|Drug|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
79381212|NCT02485080|Drug|Simeprevir|
79535899|NCT02029001|Drug|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
79535900|NCT02029001|Drug|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
79535901|NCT02029001|Drug|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
79535902|NCT02029001|Drug|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
79381213|NCT02485080|Drug|Sofosbuvir|
79381214|NCT02480322|Procedure|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
79381215|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
79381216|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
79535903|NCT02029001|Drug|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.
79535904|NCT02029001|Drug|Olaparib (300 mg BID)|"ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement"
79535905|NCT02029001|Combination Product|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
79535906|NCT02013583|Other|No intervention|This is an observational registry. No interventions are required or provided.
79692697|NCT06218238|Device|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
79535907|NCT01853488|Radiation|DXA|Osteodensitometry
79535908|NCT01853488|Radiation|pQCT|Osteodensitometry
79692698|NCT06218238|Device|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
79692699|NCT06214143|Biological|T3011 high dose|T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
79692700|NCT06214143|Biological|T3011 middle dose|T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
79381217|NCT05029830|Combination Product|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
79692701|NCT06214143|Biological|T3011 low dose|T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
79535909|NCT01785719|Behavioral|Commercial Weight Loss Program|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
79692702|NCT06213766|Diagnostic Test|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
79692703|NCT06213766|Other|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~Demographic data such as age, gender, weight, height, education level;~Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~Quality of sleep over the previous month and the previous night;~Cognitive reserve questionnaire from Rami et al., 2011;~Concomitant treatment and comorbidities."
79535910|NCT01615731|Drug|Mifepristone|200mg Mifepristone orally
79838036|NCT05407246|Drug|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
79838037|NCT01061047|Drug|Ertapeneme|
79381218|NCT01824082|Drug|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
79241708|NCT03616093|Other|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
79241709|NCT03616093|Other|Placebo Beverage|Placebo supplement containing negligible nitrate
79241710|NCT03616015|Biological|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
79381219|NCT02725710|Drug|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
79381220|NCT02725710|Drug|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
79381221|NCT02256358|Drug|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
79381222|NCT02256358|Drug|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
79535911|NCT01615731|Other|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
79535912|NCT01615731|Drug|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
79535913|NCT01615731|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op
79535914|NCT01589302|Drug|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
79838038|NCT00799890|Drug|Sunphenon EGCG|200-800mg (1-4 capsules)
79241711|NCT03616015|Biological|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
79381223|NCT05521542|Device|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable coronary artery disease
79535915|NCT01589302|Other|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
79838039|NCT00799890|Drug|Placebo|1-4 capsules
79241712|NCT03616015|Behavioral|Anxiety test|Test of Spielberger
79241713|NCT03616015|Behavioral|Stress test|Test of Cohen
79241714|NCT03648671|Drug|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
79241715|NCT03648671|Drug|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
79241716|NCT03648671|Drug|rasagilina mesilato (12 weeks)|rasagilina mesilato
79241717|NCT03648671|Drug|rasagilina mesilato (12 weeks)|rasagilina mesilato
79241718|NCT03617341|Procedure|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
79241719|NCT02968433|Drug|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
79241720|NCT03647423|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
79241721|NCT03647423|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79838040|NCT01057771|Behavioral|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
79838041|NCT01057771|Behavioral|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
79241722|NCT03647423|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79838042|NCT00799968|Drug|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
79838043|NCT00799968|Drug|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
79241723|NCT03647423|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
79241724|NCT03647423|Biological|GI-6301|Brachyury yeast
79241725|NCT03647423|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
79381224|NCT04999098|Drug|Echinaforce Forte tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients"
79241726|NCT03647423|Drug|Avelumab|injection
79241727|NCT03647423|Drug|Cetuximab|Injection
79241728|NCT03647423|Drug|Cyclophosphamide|Capsules
79381225|NCT04999098|Drug|Echinaforce Chewable tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients"
79381226|NCT04999098|Drug|Echinaforce tincture|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)"
79381227|NCT01824160|Device|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
79535916|NCT01589302|Other|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
79535917|NCT01517945|Behavioral|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over < 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
79535918|NCT01479842|Drug|BTK inhibitor PCI-32765|Given PO
79241729|NCT03647423|Radiation|SBRT|Stereotactic body radiation therapy
79241730|NCT03615781|Procedure|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
79838044|NCT01061125|Other|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
79838045|NCT01055275|Device|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
79838046|NCT00800046|Device|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
79241731|NCT03615781|Procedure|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
79241732|NCT03615781|Drug|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
79241733|NCT03615781|Drug|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
79241734|NCT03646097|Procedure|Angio-PCI|PCI only with angiography and without OCT findings
79241735|NCT03646097|Procedure|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
79241736|NCT03646097|Procedure|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
79241737|NCT02872285|Drug|Drug: LYC-30937-EC|
79241738|NCT02872285|Drug|Placebo|
79241739|NCT03647345|Device|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
79241740|NCT03647345|Device|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
79241741|NCT03647345|Device|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
79241742|NCT04052711|Drug|FMX-101|
79692704|NCT06213766|Device|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
79692705|NCT06213766|Biological|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~Sample 1: plasmatic Quanterix p-tau217 assay;~Sample 2: apolipoprotein E genotyping;~Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
79838047|NCT04002544|Drug|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
79838048|NCT04002544|Other|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
79838049|NCT04829214|Drug|OTO-313|Single intratympanic injection
79838050|NCT04829214|Drug|Placebo|Single intratympanic injection
79838051|NCT00802308|Drug|Morphine sulphate|Extended release tablet combined with alcohol or water
79838052|NCT00562965|Drug|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
79838053|NCT00562965|Drug|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
79838054|NCT00562965|Drug|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
79241743|NCT03619265|Dietary Supplement|Prickly pear juice|3 ounces daily for 8 weeks.
79241744|NCT03619265|Dietary Supplement|Pear-flavored juice|3 ounces daily for 8 weeks.
79241745|NCT03646955|Radiation|No partial breast irradiation|Omission of radiation therapy
79241746|NCT02871739|Behavioral|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
79381228|NCT02478216|Procedure|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
79381229|NCT04977726|Behavioral|STRIVE curriculum|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
79381230|NCT01775800|Other|Treatment modification|
79535919|NCT01479842|Biological|rituximab|Given IV
79535920|NCT01479842|Drug|bendamustine hydrochloride|Given IV
79535921|NCT01479842|Other|pharmacogenomic studies|Correlative studies
79535922|NCT01479842|Other|pharmacological study|Correlative studies
79535923|NCT01479842|Other|laboratory biomarker analysis|Correlative studies
79241747|NCT02871739|Behavioral|DA viewing|Participants will receive 3 decisions aids to review.
79241748|NCT02871739|Behavioral|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
79241749|NCT02032069|Other|no intervention|
79241750|NCT03621683|Procedure|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
79241751|NCT03621683|Dietary Supplement|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
79241752|NCT05284331|Other|addition of two follow-up visits post infection|"Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection"
79241753|NCT03614845|Procedure|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
79241754|NCT03614845|Procedure|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
79381231|NCT02478060|Biological|Birch-SPIRE|
79381232|NCT02478060|Biological|Placebo|
79381233|NCT02724462|Behavioral|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
79381234|NCT02724462|Behavioral|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
79535924|NCT01477502|Other|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
79535925|NCT01477502|Other|standard treatment without homeopathy|participants receive standard UTI prophylaxis
79535926|NCT01349400|Other|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
79535927|NCT01349400|Procedure|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
79838055|NCT00562965|Drug|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
79241755|NCT03614845|Diagnostic Test|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
79241756|NCT03621605|Biological|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
79692706|NCT06212349|Other|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
79241757|NCT03621605|Drug|Placebos|Placebo administered by slow IV infusion or SC injection.
79241758|NCT03614065|Drug|endostar|endostatin
79241759|NCT03614065|Drug|Placebos|saline solution
79381235|NCT01825408|Drug|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
79692707|NCT06212349|Other|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
79692708|NCT06208787|Behavioral|Neurofeedback training|Neurofeedback training involving auditory feedback upon measurement of non-harmonic alpha-theta ratios during focused attention meditation
79692709|NCT06208787|Behavioral|Sham Training|Sham neurofeedback involving auditory feedback at random timepoints during focused attention meditation such that no learning can take place
79692710|NCT06208592|Device|Sevoflurane with AnaConDa|Sevoflurane administered with AnaConDa device
79838056|NCT00562965|Drug|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
79381236|NCT01825408|Drug|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
79381237|NCT01825408|Drug|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
79535928|NCT01345136|Drug|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
79535929|NCT01299792|Other|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
79838057|NCT00562965|Drug|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
79838058|NCT00562965|Drug|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
79838059|NCT00562965|Drug|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
79838060|NCT00562965|Drug|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
79241760|NCT03614065|Radiation|radiotherapy|radiotherapy
79381238|NCT03108612|Diagnostic Test|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
79838061|NCT05358496|Diagnostic Test|Data collection|Clinical data collection
79838062|NCT05407090|Dietary Supplement|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
79838063|NCT05407090|Dietary Supplement|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
79838064|NCT00802620|Procedure|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
79838065|NCT05406934|Biological|Infliximab|obseravation with investigation
79838066|NCT00800124|Procedure|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
79692711|NCT06207877|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously.
79692712|NCT06207877|Drug|Semaglutide|Semaglutide will be administered subcutaneously.
79692713|NCT06207877|Drug|Placebo|Placebo will be administered subcutaneously.
79838067|NCT00940329|Drug|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
79838068|NCT00940329|Drug|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
79241761|NCT03621527|Other|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
79241762|NCT03621527|Other|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
79241763|NCT02032147|Drug|NGF group|This group will be treated with NGF 18u per day im for 60 days
79241764|NCT03647189|Device|Hybrid Fractional Laser|Hybrid Fractional Laser
79241765|NCT03645317|Diagnostic Test|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
79692718|NCT06206460|Other|Online Assessment|"Online Assessment which consists of:~Sociodemographic data (life changes, medical and gynaecological history)~German PMS symptom diary retrospectively for last menstrual cycle~Quality of Life Inventory (SF-12)~Expectancy of relief"
79838069|NCT00794898|Biological|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
79838070|NCT00934557|Drug|ATG Fresenius|
79838071|NCT00934557|Drug|ATG Fresenius|
79838072|NCT00934557|Drug|ATG Fresenius|
79838073|NCT00934557|Drug|ATG Fresenius|
79241766|NCT03615625|Behavioral|Power Training Session|"3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds."
79241767|NCT03646799|Drug|CKD-387|test drug
79241768|NCT03646799|Drug|D484|reference drug
79241769|NCT03646721|Drug|DA-1241|"[Part1] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~[Part2] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
79241770|NCT03646721|Drug|Placebo|[Part1] Administration once daily for 28 days. [Part2] Administration once daily for 56 days.
79241771|NCT03646721|Drug|Sitagliptin|[Part2] Administration of Sitagliptin 100mg once daily for 56 days.
79241772|NCT04052399|Device|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
79381239|NCT01776268|Other|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
79381240|NCT02477904|Other|Ketogenic Diet|Dietary
79381241|NCT04945824|Drug|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
79381242|NCT04945824|Device|Dilator|Intracanalicular Dilator Device
79838074|NCT00934557|Drug|ATG Fresenius|
79838075|NCT00934557|Drug|ATG Fresenius|
79838076|NCT00934557|Drug|ATG Fresenius|
79838077|NCT00934557|Drug|ATG Fresenius|
79381243|NCT01777126|Other|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
79838078|NCT05357092|Device|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
79838079|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
79381244|NCT01777126|Other|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
79381245|NCT04937634|Drug|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m^2/day. Infuse Melphalan over 30 minutes.
79381246|NCT01826812|Other|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
79838080|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
79838081|NCT00800280|Drug|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
79838082|NCT04014153|Procedure|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
79381247|NCT01826812|Other|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
79381248|NCT02725476|Biological|XmAb5871|
79381249|NCT04931628|Drug|Salvianolic Acid|salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
79535948|NCT00695981|Procedure|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
80008916|NCT03938987|Biological|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
80008917|NCT03924414|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
79535949|NCT00695981|Procedure|Conservative treatment|Physiotherapy according to a standardized protocol
80008918|NCT03924414|Other|Placebo|Normal Saline 100 ml (placebo) IV infusion
80008919|NCT03914703|Procedure|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
79241773|NCT04052399|Device|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
79241774|NCT04052399|Device|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
79241775|NCT03613831|Device|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
79241776|NCT03646643|Procedure|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
79381250|NCT04931628|Drug|0.9% NaCl|0.9% NaCl
79381251|NCT02262130|Drug|Omalizumab|
79381252|NCT02578342|Device|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
79535950|NCT00637013|Procedure|Acromioplasty|Arthroscopic or open acromioplasty
79535951|NCT00637013|Procedure|Physiotherapy|Physiotherapy according to a standardized protocol
79692719|NCT06206005|Other|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
79692720|NCT06205628|Drug|ADX-850|siRNA duplex oligonucleotide
79692721|NCT06205628|Drug|Placebo|Saline
79535952|NCT00521846|Device|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
79692722|NCT06205628|Drug|Angiotensin Receptor Blockers|Angiotensin receptor blocker
79535953|NCT00186927|Biological|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10^5 to 5 x 10^7 EID(50) units.
79535954|NCT00004847|Drug|([18F]-DOPA)|is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, [18F]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using [18F]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
79692723|NCT06205407|Drug|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
79692724|NCT06205407|Drug|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
79838083|NCT04996576|Procedure|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
80008920|NCT03910933|Other|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
79381253|NCT02476188|Procedure|Sample of Blood|
79381254|NCT04887870|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
79381255|NCT04887870|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
79381256|NCT04887870|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
80008921|NCT03904927|Other|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
79241777|NCT03646643|Procedure|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
79241778|NCT03613753|Drug|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
79241779|NCT03613753|Drug|irinotecan|irinotecan chemotherapy alone
79381257|NCT04887870|Drug|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
79535955|NCT00004847|Drug|([18F]-6F-DA)|is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. [18F]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, [18F]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of [18F]-6F-DA, the much faster disappearance of [18F]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
79535956|NCT04932980|Drug|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
79692725|NCT06205368|Behavioral|Combine mobile app|"HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing~Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator.~Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors~Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication~Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits."
79692726|NCT06205368|Behavioral|Motivational interview|The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)
79838084|NCT04996576|Procedure|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
79838085|NCT00800358|Drug|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
79241780|NCT04051853|Drug|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
79381258|NCT04887870|Drug|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
79381259|NCT02476344|Other|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~sack carrying exercise.~crawling exercise.~combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
79535957|NCT04932980|Drug|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
79535958|NCT04932980|Procedure|early treat and extend (T&E)|extension of treatment intervals (T&E) from the beginning of treatment
79535959|NCT04927390|Drug|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
79535960|NCT04912336|Diagnostic Test|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
79838086|NCT00800358|Drug|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
79838087|NCT00934713|Drug|montelukast|montelukast 4mg once per day for 8 weeks period
79838088|NCT00802698|Device|Transcorneal electric stimulation|central artery occlusion
79838089|NCT00802698|Device|Transcorneal stimulation|new waveform
79838090|NCT00802698|Device|transcorneal electric stimulation|Novel waveform central artery occlusion
79838091|NCT00935025|Drug|AZD1305|single and multiple oral doses, extended-release capsule
79241781|NCT04051853|Other|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
79241782|NCT04051853|Other|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
79241783|NCT03646409|Other|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
79241784|NCT03646331|Drug|Imeglimin Reference product|Reference product
79241785|NCT03646331|Drug|Imeglimin|Test product (new formulation tablet)
79241786|NCT03869177|Other|Implementation support program|"The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures"
79241787|NCT03645629|Diagnostic Test|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
79535961|NCT04912336|Diagnostic Test|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
79535962|NCT04912336|Other|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
79241788|NCT03843593|Behavioral|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
79535963|NCT04910711|Drug|Dolutegravir|Dolutegravir-based antiretroviral therapy
79535964|NCT04910711|Drug|Levonorgestrel implant|Women initiating the levonorgestrel implant
79535965|NCT04910711|Drug|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
79241789|NCT03843593|Behavioral|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 [definitely not], 2 [probably not], 3 [maybe], 4 [probably], 5 [definitely]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
79535966|NCT04909333|Drug|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
79535967|NCT04909333|Drug|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
79535968|NCT04907487|Device|MRI|"MRI of routine care includes at least the following sequences:~3D T1 TFE (2 minutes)~T2 TSE (2 minutes)~3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~SWI QSM 1.0iso 8 echoes (10 minutes)~SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)"
79535969|NCT04903249|Behavioral|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to >90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
79391404|NCT02422914|Behavioral|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
79535970|NCT04902014|Behavioral|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
79535971|NCT04902014|Behavioral|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
79391405|NCT02424526|Other|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
79692727|NCT06205368|Behavioral|HIV/STI testing|Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.
79692728|NCT06203847|Drug|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
79692729|NCT06203847|Drug|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
79692730|NCT06202040|Procedure|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
79838092|NCT00935025|Drug|Placebo|single and multiple oral doses, capsule
79838093|NCT00802776|Procedure|Femtosecond laser assisted keratoplasty|
79838094|NCT00802776|Procedure|PKP|
79838095|NCT00939861|Procedure|laparoscopy|colorectal resection
79838096|NCT00939861|Procedure|laparotomy|colorectal resection
79391406|NCT02424526|Device|Treadmill|
79241790|NCT03843593|Behavioral|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
79241791|NCT03843593|Behavioral|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
79692731|NCT06202040|Procedure|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
79692732|NCT06199466|Drug|Gemcitabine|Given by IV
79381260|NCT05665452|Procedure|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
79381261|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
79535972|NCT04902014|Behavioral|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
79381262|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
79535973|NCT04902014|Behavioral|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
79535974|NCT04900168|Device|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
79535975|NCT04897958|Drug|Degarelix|Degarelix dispensing claim is used as the reference group.
79535976|NCT04897958|Drug|Leuprolide|Leuprolide dispensing claim is used as the exposure group.
79535977|NCT04895384|Device|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
79692733|NCT06199466|Drug|Nab-paclitaxel|Given by IV
79692734|NCT06199466|Drug|YL-13027|Given by PO
79692735|NCT06199297|Drug|Atezolizumab combined with Bevacizumab|Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
79692736|NCT06199297|Drug|Sintilimab combined with Bevacizumab|Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
79838097|NCT00802932|Device|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
79838098|NCT00802932|Device|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
79838099|NCT01057849|Drug|risperidone|3-6 mg per day
79838100|NCT01057849|Drug|olanzapine|5-20 mg per day
79838101|NCT01057849|Drug|Aripiprazole|10-30 mg per day
79241792|NCT03843593|Behavioral|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 [Strongly Agree], 2 [Agree], 3 [Neither Agree Nor Disagree], 4 [Disagree], 5 [Strongly Disagree].
79241793|NCT03843593|Behavioral|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
79241794|NCT03645551|Diagnostic Test|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
79241795|NCT03646253|Other|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
79241796|NCT03645473|Device|Monarch Airway Clearance System|HFCWO Airway Clearance Device
79241797|NCT03838991|Other|Blood sample|A study specific blood sample will be collected.
79692737|NCT06199297|Procedure|Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy|The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
79692738|NCT06194461|Biological|AZD5851|Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
80008922|NCT03904927|Drug|Systemic therapy|"First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
80008923|NCT03886181|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
80008924|NCT03868787|Device|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
80008925|NCT03868787|Device|Sham TENS|Non-active TENS unit
80008926|NCT03856320|Behavioral|Educational Video|An educational video describing obesity treatment options available in the VA.
80008927|NCT03846388|Diagnostic Test|follicular stimulating hormone|in the serum of our patients
79241798|NCT03838991|Other|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
79241799|NCT03816995|Device|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
79241800|NCT03816995|Device|Alexis O Wound Protector|wound retraction
79241801|NCT03614767|Diagnostic Test|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
79241802|NCT03643835|Device|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
79381263|NCT01828216|Device|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
79381264|NCT01828216|Device|conventional polysomnography|conventional type I sleep study according to international guidelines
79381265|NCT01780324|Drug|Lidocaine|Intervention - intraurethral lidocaine
79381266|NCT02989792|Genetic|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
79535978|NCT04894877|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
79535979|NCT04894877|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
79381267|NCT02989792|Other|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
79535980|NCT04894877|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
79535981|NCT04894877|Behavioral|Lifestyle|diet, physical activity, smoking cessation
79535982|NCT04894877|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
79535983|NCT04892758|Drug|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
80008928|NCT03846388|Diagnostic Test|Anti-mullerian hormone|in the serum of our patients
79535984|NCT04892758|Drug|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
79535985|NCT04892732|Drug|Budesonide|Budesonide dispensing claim is used as the reference group.
80008929|NCT03846388|Radiation|Basal antral follicle count|by ultrasound
80008930|NCT03804671|Drug|BI 730357|Oral dose
80008931|NCT03804671|Drug|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
80008932|NCT03804255|Other|Survey Administration|Complete surveys
80008933|NCT03675815|Drug|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
80008934|NCT03675815|Drug|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
79241803|NCT03643835|Other|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
79241804|NCT03645161|Diagnostic Test|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
79241805|NCT03645083|Behavioral|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
79241806|NCT03645083|Behavioral|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
79535986|NCT04892732|Drug|Budesonide-Formoterol|Budesonide-Formoterol dispensing claim is used as the exposure group.
79535987|NCT04882176|Drug|LM-061|The subjects in each dose level will be administered single oral dose of LM-061 tablet on C0D1, and washout for 5 days. After that, the subjects will be administered multiple oral doses once daily (QD) in continuous 28 days (4 weeks) per treatment cycle, until meet the treatment termination criteria, including disease progression or unaccepted toxicity, etc. After obtaining MTD/RP2D, the Safety Review Committee (SRC) may combine the data of safety, PK, and preliminary efficacy to explore other dosing schedules (such as 3 weeks on and 1 week off).
79838102|NCT00940407|Device|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
79838103|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (low dose)|
79838104|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (high dose)|
79838105|NCT00794976|Drug|Dexamethasone Passive Patch|
79838106|NCT00794976|Drug|Placebo Patch|
80008935|NCT03675815|Drug|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
79838107|NCT00939939|Drug|sitagliptin|sitagliptin 100 mg/d for 10 weeks
79838108|NCT00939939|Drug|glimepiride|glimepiride 1 mg/d for 10 weeks
79838109|NCT00537082|Drug|FTY720|Administered orally once daily for 6 months
80008936|NCT03675815|Drug|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
80008937|NCT03675815|Drug|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
80008938|NCT03675815|Drug|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
79241807|NCT03645005|Behavioral|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
79241808|NCT03645005|Behavioral|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
79381268|NCT02476266|Other|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
79381269|NCT01780870|Dietary Supplement|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
79535988|NCT04879420|Drug|Teriparatide|Teriparatide dispensing claim is used as the reference group.
79381270|NCT02472600|Drug|Colistin|
79381271|NCT02472600|Drug|Neomycin|
79535989|NCT04879420|Drug|Risedronate|Risedronate dispensing claim is used as the exposure group.
79535990|NCT04875520|Other|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
79535991|NCT04875520|Other|No screening testing strategy|a group of schools will not receive screening testing.
79535992|NCT04870840|Radiation|Proton Beam Radiation Therapy|Undergo radiation therapy
80008939|NCT03675815|Drug|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
80008940|NCT03669133|Drug|Vitamin E|Vitamin E 800 IU/daily
79535993|NCT04870840|Other|Quality-of-Life Assessment|Ancillary studies
79535994|NCT04870840|Other|Questionnaire Administration|Ancillary studies
79838110|NCT00537082|Drug|Placebo|Administered orally once daily for 6 months
79838111|NCT03828487|Device|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
79838112|NCT03828487|Device|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
79838113|NCT00795054|Other|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
79838114|NCT04012983|Diagnostic Test|gingival crevicular fluid level|gingival crevicular fluid collection
79838115|NCT00805662|Drug|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
79838116|NCT03988153|Combination Product|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
79838117|NCT04014309|Other|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
79838118|NCT04014309|Other|Usual care|Usual care
80008941|NCT03669133|Drug|Placebo|Matching placebo daily
80008942|NCT03647969|Drug|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
80008943|NCT03647969|Drug|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
80008944|NCT03647969|Drug|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
80008945|NCT03647969|Drug|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
79692739|NCT06192563|Drug|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
79535995|NCT04858035|Behavioral|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
79692740|NCT06192017|Diagnostic Test|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
79692741|NCT06174480|Other|Cryostimulation|Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
80008946|NCT03644186|Drug|Paclitaxel|Chemotherapy plus HER2 Blockade
80008947|NCT03644186|Drug|Trastuzumab|Chemotherapy plus HER2 Blockade
79692742|NCT06169371|Drug|Abemaciclib|Week 1 50mg orally BID
80008948|NCT03644186|Drug|Pertuzumab|Chemotherapy plus HER2 Blockade
80008949|NCT03644186|Drug|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
80008950|NCT03644186|Drug|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
80008951|NCT03644186|Drug|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
80008952|NCT03644186|Drug|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
80008953|NCT03622814|Behavioral|Partners at Meals|The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.
79241809|NCT03644459|Biological|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
79692743|NCT06169371|Drug|Abemaciclib|Week 2 100mg orally BID
79692744|NCT06169371|Drug|Abemaciclib|Week 3 150mg orally QAM, 100mg orally QHS
79692745|NCT06169371|Drug|Abemaciclib|Week 4 150mg orally BID
79692746|NCT06169072|Drug|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
79692747|NCT06169072|Device|Technetium99|Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
79692748|NCT06166732|Behavioral|Music-based Mindfulness|The participants will receive a single 20-minute music-based mindfulness session in person. The participants will listen to instrumental music during the session.
80008954|NCT03622814|Behavioral|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
79381272|NCT02472600|Drug|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
79381273|NCT02472600|Drug|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
79692749|NCT06166732|Behavioral|Control Group|The participants will receive a single 20-minute information session in person. The information session will introduce the definition, history, basic concepts, and benefits of mindfulness practice.
79838119|NCT04978012|Drug|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
79838120|NCT00803088|Device|The Alair System|Treatment of airways with the Alair System
79838121|NCT01061203|Drug|Grazax|Treatment with 75.000 SQ-T once daily
79838122|NCT01061203|Drug|Placebo|Tablet with no active grass component.
80008955|NCT03616470|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
80008956|NCT03616470|Drug|Placebo|Saline, 0.9% Sodium Chloride
80008957|NCT03593759|Drug|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
80008958|NCT03593759|Drug|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
80008959|NCT03557905|Device|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
80008960|NCT03557905|Device|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
79535996|NCT04858035|Behavioral|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
79535997|NCT04856150|Drug|Q-1802|Q-1802 will be administered intravenously.
79381274|NCT01781806|Drug|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to <50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl <30 mL/min, Truvada will be discontinued.
79535998|NCT04849910|Biological|VOR33|Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein
79535999|NCT04849910|Drug|Mylotarg|Infusion of Mylotarg
79241810|NCT03643757|Procedure|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
79241811|NCT03643757|Drug|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
79241812|NCT03718793|Diagnostic Test|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
79536000|NCT04848519|Drug|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
79536001|NCT04848519|Drug|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
79692750|NCT06155344|Other|Food Frequency Questionnaire|We will obtain a global index of vegetalization of the diet (the Plant based Diet Index: PDI) from data obtained using semi-quantitative questionnaires on food frequency (Food Frequency Questionnaire (FFQ)) validated on the national ELFE cohort (French Longitudinal Study from Childhood (https://www.elfe-france.fr)) and completed by women in the 1st trimester of pregnancy (T1) and at delivery.
79692751|NCT06155344|Other|Collection of 4 mL maternal blood|One tube collection of 4 mL maternal blood in the first trimester and at delivery.
79692752|NCT06154824|Other|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
79381275|NCT05315076|Other|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
79241813|NCT02896361|Device|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
79381276|NCT05315076|Other|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
79381277|NCT04769284|Other|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~International Physical Activity Questionnaire (IPAQ)~Abbreviated Goldberg Anxiety Scale EADG~Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
79381278|NCT04844892|Device|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
79381279|NCT02477592|Procedure|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
79381280|NCT02477592|Procedure|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
79381281|NCT02477514|Drug|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
79381282|NCT02477514|Drug|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
79381283|NCT02477514|Drug|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
79692753|NCT06154824|Other|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
79692754|NCT06148974|Dietary Supplement|Polar lipid 1|15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
79692755|NCT06148974|Dietary Supplement|Polar lipid 2|15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
79692756|NCT06148974|Dietary Supplement|Non-polar lipids|15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
79381284|NCT01784848|Procedure|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
80008961|NCT03548155|Drug|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
79692757|NCT06148974|Other|No lipids|A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
79692758|NCT06141369|Biological|individualized mRNA neoantigen vaccine (mRNA-0523-L001)|Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
79536002|NCT04848519|Drug|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
79536003|NCT04848519|Drug|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
79241814|NCT03643679|Other|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
79241815|NCT03621371|Behavioral|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
79838123|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
79838124|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
79838125|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
79536004|NCT04841798|Other|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using [11C]SL25.1188 PET
79692759|NCT06136598|Drug|MK-5684|Tablets to be taken orally.
79838126|NCT00935181|Behavioral|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
79838127|NCT00324961|Drug|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
79838128|NCT04002232|Device|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
79838129|NCT04013451|Behavioral|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
79838130|NCT05357014|Diagnostic Test|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
79838131|NCT04846140|Device|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
79241816|NCT03621371|Behavioral|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
79381285|NCT01784848|Other|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
79536005|NCT04839614|Other|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
79536006|NCT04829188|Behavioral|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
79692760|NCT06136598|Drug|Dexamethasone|Tablets to be taken orally
79838132|NCT00935337|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
79838133|NCT00935337|Behavioral|Sleep Hygiene|treatment as usual
80008962|NCT03548155|Drug|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
80008963|NCT03548155|Drug|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
79241817|NCT03703895|Drug|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
79241818|NCT03703895|Drug|Topical Placebo|Placebo Comparator, Topical Placebo.
79381286|NCT01753648|Device|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
79381287|NCT01753648|Other|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
79381288|NCT01753648|Other|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
79692761|NCT06136598|Drug|Fludrocortisone|Tablets to be taken orally.
79692762|NCT06136598|Drug|Hydrocortisone|Tablet to be taken orally as a rescue medication.
79838134|NCT00809250|Biological|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
79838135|NCT00935415|Drug|Montelukast|Montelukast 5 mg
79838136|NCT00935415|Drug|Placebo|capsules of matching placebo
79241819|NCT03643601|Other|Non-Interventional|Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
79692763|NCT06132360|Drug|RN0191|This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
79692764|NCT06132256|Drug|Axatilimab|Administered as intravenous (IV) infusion
79692765|NCT06132256|Other|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
80008964|NCT03516708|Drug|Epacadostat|Patients will receive epacadostat at the designated dose level starting the day of radiation therapy, throughout the chemotherapy, and until the day of surgery. If the patient dose not proceed with the surgery, epacadostat will be discontinued after the last biopsy is performed, and after the investigator confirms non-operative management plans.
80008965|NCT03516708|Radiation|Short-course radiation|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
80008966|NCT03516708|Drug|CAPOX chemotherapy|CAPOX is typically capecitabine at 1000 mg/m2 PO BID (Days 1-14 of each 3-week cycle) and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts. Patient will receive a total of 6 cycles of CAPOX chemotherapy.
80008967|NCT03512899|Procedure|Right internal jugular access.|Implantation using percutaneous puncture.
79241820|NCT03644771|Drug|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
79241821|NCT03643523|Diagnostic Test|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
79241822|NCT02962739|Drug|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
79241823|NCT03644693|Dietary Supplement|Nutritional Formulation Containing Exogenous Ketones|A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
79241824|NCT03644693|Dietary Supplement|Placebo Formulation|A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
79381289|NCT02472288|Device|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
79381290|NCT02472288|Device|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
79381291|NCT02476110|Dietary Supplement|Oral nutritive supplements|
79381292|NCT02472054|Drug|Alemtuzumab|
79381293|NCT02472054|Drug|Methyl Prednisolone (MP)|
79536007|NCT04829188|Behavioral|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
79536008|NCT04829188|Behavioral|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
79536009|NCT04829188|Behavioral|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
79692766|NCT06131203|Device|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
79692767|NCT06109662|Diagnostic Test|Cystatin C eGFR|Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
79692768|NCT06109662|Other|Bioimpedance Analysis (Body composition analysis)|Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
79692769|NCT06104371|Device|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
79692770|NCT06101264|Device|Virtual Reality Intervention|Participants will be given a virtual reality (VR) intervention following corrective scoliosis surgery for adolescent idiopathic scoliosis. The VR intervention will utilize a commercial device manufactured by Oculus. The intervention will utilize a software that simulates a low-physical load environment for the user. Starting on postoperative day 1, the participant will receive a 20-minute VR intervention 30 minutes prior to each physical therapy session. There will be two physical therapy sessions daily. Outcome measures will be assessed before and after every VR intervention and after the physical therapy session. The VR interventions will continue for each postoperative day until the participant is discharged from the hospital.
80008968|NCT03512899|Procedure|Left internal jugular access.|Implantation using percutaneous puncture.
80008969|NCT03512899|Procedure|Right axillary vein access.|Implantation using percutaneous puncture.
80008970|NCT03512899|Procedure|Left axillary vein access.|Implantation using percutaneous puncture.
79536010|NCT04829188|Behavioral|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
79536011|NCT04809506|Biological|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
79536012|NCT04796285|Device|Lab Clasp|Finger-based interstitial fluid assessment device
79536013|NCT04793529|Drug|Cholecalciferol|Cholecalciferol injection
79241825|NCT03643445|Behavioral|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
79536014|NCT06040684|Diagnostic Test|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
79536015|NCT06040671|Other|Vectra M3 imaging|Study subjects from both arms will undergo Vectra M3 imaging to evaluate the result of the surgery.
79381294|NCT02472054|Drug|Cyclosporin A (CSA)|
79381295|NCT01782898|Drug|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
79536016|NCT06040658|Diagnostic Test|Frailty assessment|Rockwood Clinical Frailty Scale
79692771|NCT06090370|Device|N95 Respirator|The participants in this group will be provided with N95 respirator masks to protect from dust and debris while working in the brick kiln and trained on proper usage.
79381296|NCT01782898|Drug|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
79381297|NCT02472132|Device|POC US|Use of point of care ultrasound in insertion of CVC
79381298|NCT02475876|Drug|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose =12 mg/kg;~Cohort 3; No. Subjects = 5; Age >1-2 years; Dose =12 mg/kg.~Cohort 4; No. Subjects = 4; Age >2-6 years; Dose =12 mg/kg.~Cohort 5; No. Subjects = 4; Age >6-12 years; Dose =10 mg/kg.~Cohort 6; No. Subjects = 4; Age >12-16 years; Dose =10 mg/kg."
79692772|NCT06090370|Device|Protective Eyewear|The participants in this group will be provided with eye wear to protect the eyes from dust and debris while working in the brick kiln and trained on proper usage
79692773|NCT06090370|Other|Baseline Survey|A quantitative, cross-sectional survey will be distributed to enrolled participants to understand baseline worker perceptions on silicosis and personal protective equipment (PPE).
79381299|NCT02475876|Drug|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose = 6 mg/kg.~Cohort 3; No. Subjects = 5; Age >1-2 years; Dose = 6 mg/kg.~Cohort 4; No. Subjects = 4; Age >2-6 years; Dose = 6 mg/kg.~Cohort 5; No. Subjects = 4; Age >6-12 years; Dose = 6 mg/kg.~Cohort 6; No. Subjects = 4; Age >12-16 years; Dose = 4 mg/kg."
79692774|NCT06090370|Other|Design of Workshop|A co-creation human centered design workshop to elicit feedback on PPE training prototypes and types of PPE.
79536017|NCT06040658|Diagnostic Test|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
79536018|NCT06040658|Diagnostic Test|Frailty assessment|Clinician's subjective 'end-of-bed' test
79536019|NCT06040658|Diagnostic Test|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
79536020|NCT06040658|Diagnostic Test|Frailty assessment|11-item modified Frailty Index (mFI-11)
79536021|NCT06040606|Procedure|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
79536022|NCT06040554|Other|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
79536023|NCT06040515|Drug|Probiotic Formula|Capsule with 25 billion live strains of Escherichia coli Nissle 1917
79536024|NCT06040489|Drug|Miltefosine 50mg|Oral Miltefosine 50mg bid
79536025|NCT06040489|Drug|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
79692775|NCT06090370|Other|Training Workshop Pilot|Qualitative workshops will be held to elicit feedback on the piloted PPE training program.
79692776|NCT06087302|Behavioral|child-Parent Relationship Therapy (CPRT)|The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
79692777|NCT06066944|Other|Self-Thai Foot Massage|It is a specific technique and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Self-Thai foot massage is often based on traditional Thai massage techniques but adapted for self-application.
79838137|NCT00935571|Drug|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
79838138|NCT00324649|Drug|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
79838139|NCT00324649|Drug|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
79536026|NCT06040489|Drug|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
79536027|NCT06040476|Biological|hUCB|hUCB
79536028|NCT06040437|Behavioral|Be-Prox|Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
79536029|NCT06040411|Other|Acupressure|Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
79536030|NCT06040398|Behavioral|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
79536031|NCT06040385|Device|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
79536032|NCT06040372|Drug|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
79536033|NCT06040372|Drug|Placebo|Placebo is provided as a matching placebo
79536034|NCT06040359|Other|The Thriving Mamas programme|Enhanced antenatal course plus usual perinatal care
79536035|NCT06040359|Other|Usual care|Usual perinatal care
79536036|NCT06040333|Other|Exercise|Dynamic Neuromuscular Stabilisation Exercise
79536037|NCT06040333|Other|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
79536038|NCT06040216|Other|optical coherence tomography|We observed the postoperative improvement in EIFL severity with optical coherence tomography
79536039|NCT06040177|Drug|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
79536040|NCT06040177|Radiation|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy*5F) for portal vein thrombus within 21 days after entry
79536041|NCT06040177|Drug|Renvatinib|Renvatinib: 8mg (weight <60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
79692778|NCT06066047|Other|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~5 minutes bilateral touch on external malleolus~5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
79692779|NCT06066047|Other|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~5 minutes bilateral touch on external malleolus~5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
79692780|NCT06063720|Device|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
80008971|NCT03501173|Other|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
79241826|NCT03643445|Behavioral|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
79381300|NCT02472210|Drug|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
79381301|NCT01831960|Drug|cortexolone 17α-propionate|
79381302|NCT04825236|Other|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
79381303|NCT04802148|Procedure|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
79536042|NCT06040164|Other|Observational study|No intervention will be performed
80008972|NCT03494556|Other|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
80008973|NCT03457701|Drug|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
80008974|NCT03457701|Drug|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
79536043|NCT06040151|Device|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
79381304|NCT04802148|Procedure|collagen plug|after tooth extraction, the socket was filled with collagen plug
79381305|NCT02475798|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
79692781|NCT06062368|Behavioral|Rate of Entry|The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
79692782|NCT06059651|Procedure|Metabolic & Bariatric Surgery|Roux-en-Y metabolic and bariatric surgery
79692783|NCT06048744|Procedure|external oblique intercostal block|U S guided external oblique intercostal block after induction.
79692784|NCT06048744|Procedure|Erector Spine block|US guided erector spine block after induction
79692785|NCT06048718|Drug|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
79692786|NCT06044311|Drug|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
79692787|NCT06044311|Drug|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
79692788|NCT06044311|Radiation|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
79692789|NCT06039826|Drug|LY3437943|Administered SC.
80008975|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
80008976|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
79381306|NCT01783054|Procedure|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
80008977|NCT03403231|Behavioral|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
80008978|NCT03347292|Drug|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
79381307|NCT01783054|Genetic|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
79381308|NCT01783054|Drug|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
79381309|NCT02475642|Other|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
79536044|NCT06040138|Diagnostic Test|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
79536045|NCT06040112|Device|Tendoregen (Atelocollagen)|Tendoregen (Atelocollagen) injection
79536046|NCT06040047|Other|Proprioceptive neuromuscular facilitation|Contract relax technique for each neck motion for three repetitions.
79536047|NCT06040047|Other|Passive mobilization|To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
79536048|NCT06040021|Other|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
79692790|NCT06039826|Drug|Ethinyl Estradiol|Administered orally
79692791|NCT06039826|Drug|Drospirenone|Administered orally
79692792|NCT06036836|Biological|favezelimab/pembrolizumab|IV infusion
79692793|NCT06036836|Biological|pembrolizumab|IV infusion
79692794|NCT06036836|Drug|lenvatinib|Oral administration of capsule
79692795|NCT06008197|Drug|Finerenone|Oral finerenone
79692796|NCT06008197|Drug|Placebo|Matching oral placebo
79692797|NCT06007521|Other|interview with neurologist|interview with neurologist
80008979|NCT03347292|Drug|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
80008980|NCT03269526|Drug|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
79692798|NCT06004037|Drug|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
79838140|NCT03743259|Drug|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
80008981|NCT03182426|Drug|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
80008982|NCT03182426|Drug|Alemtuzumab|T-cell depletion
80008983|NCT03182426|Drug|Anakinra|Anti-inflammatory
80008984|NCT03182426|Drug|Etanercept|Anti-inflammatory
79692805|NCT05991817|Procedure|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
79692806|NCT05987592|Behavioral|Brain Education and WELLness with Migraine Group A|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
79692807|NCT05987592|Behavioral|Brain Education and WELLness with Migraine Group B|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
79692808|NCT05987033|Drug|NVDX3|NVDX3 is implanted during a single surgical intervention.
79692809|NCT05985655|Drug|GTAEXS617|GTAEXS617 tablets daily
79692810|NCT05963763|Behavioral|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~Career pathway navigation~Employee benefit maximization~Financial literacy and wealth building~Services funds for resources that mitigate specific barriers or needs."
79692811|NCT05959473|Device|Idylla EGFR_IUO/3.20 Mutation Test|Clinical Performance Study Protocol for Idylla EGFR_IUO/3.20 Mutation Test The EGFR_IUO/3.20 is automated on the Idylla™ Platform, which executes the entire process from sample to result including sample liquefaction, cell lysis, real-time PCR amplification/detection, and data analysis and reporting.
79838141|NCT03743259|Drug|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
79838142|NCT03743259|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
80008985|NCT03182426|Drug|Liraglutide|Beta-cell regeneration
80008986|NCT03102593|Drug|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
79381310|NCT02475642|Other|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
79536049|NCT06040008|Genetic|blood collection|"3 blood collections over a period of 6 weeks~V0 - Inclusion~V1 - 3 weeks ± 14 days~V2 - 3 weeks ± 14 days~1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~Clinical information obtained at each visit"
79692812|NCT05955170|Drug|Tucatinib in Combination of Oral VP16 and trastuzumab|Combination of tucatinib-Oral VP16-trastuzumab
79692813|NCT05948293|Device|Machine learning model called IDoser|Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
79692814|NCT05948293|Procedure|Standard clinical practice|Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
79692815|NCT05947071|Biological|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
80008987|NCT03102593|Other|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
80008988|NCT03078946|Drug|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
80008989|NCT03078946|Drug|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
80008990|NCT02915601|Drug|Sodium bicarbonate|
79536050|NCT06039969|Other||This is an obvertional study and there is no intervention
79838143|NCT04045782|Drug|single arm|switch from originator (Humira) to biosimilar (Imraldi)
79381311|NCT05405088|Other|Questionnaires|Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
79838144|NCT02553720|Other|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
79838145|NCT02553720|Other|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
79838146|NCT00935727|Other|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
79838147|NCT00803478|Procedure|LASIK|
79838148|NCT03983239|Drug|Fedratinib|Fedratinib
79838149|NCT03983239|Drug|Rifampin|Rifampin
79838150|NCT03983239|Drug|Efavirenz|Efavirenz
79838151|NCT00935805|Drug|Metformin|850 mg TID
79838152|NCT00935805|Drug|Glybenclamide|10 mg BID
79838153|NCT00935805|Drug|NPH insulin|Variable SC dose
79838154|NCT00935805|Drug|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
80008991|NCT02915601|Drug|Placebo|
79381312|NCT04784520|Drug|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
79381313|NCT02725008|Drug|Dexamethasone|
79381314|NCT02725008|Drug|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
79381315|NCT02475486|Device|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
80008992|NCT02878473|Procedure|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
80008993|NCT02760238|Other|Observational|
80008994|NCT02743741|Drug|Lutetium-177 Octreotate|Radiopharmaceutical
80008995|NCT02694978|Drug|Ferumoxytol|
80008996|NCT02694978|Drug|FCM|
79692816|NCT05947071|Biological|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
79305250|NCT04943055|Procedure|Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
79692817|NCT05946733|Procedure|Group A|After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
79692818|NCT05946733|Procedure|Group B|After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
79692819|NCT05946733|Other|Group C|the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
79692820|NCT05931796|Other|NON-ERAS pathway|All patients received best of care practice, with standardization of preoperative and postoperative care
80008997|NCT02663518|Drug|PF-0791800 (TTI-621)|Monotherapy
79381316|NCT02471976|Other|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
79381317|NCT01832506|Drug|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
79381318|NCT02477748|Drug|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
79381319|NCT02477748|Drug|Placebo|Tablet PO, taken once daily for 10 weeks.
79381320|NCT02477436|Drug|Avanafil|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~Investigational products were administered prior to the sexual intercourse for total 8 weeks."
79381321|NCT02477436|Drug|Placebo|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~Placebos were administered prior to the sexual intercourse for total 8 weeks."
79381322|NCT01783522|Drug|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
79692821|NCT05931796|Other|ERAS pathway|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
79692822|NCT05923333|Dietary Supplement|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
79692823|NCT05923333|Dietary Supplement|Placebo|Maltodextrin
79692824|NCT05921955|Device|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
79692825|NCT05919472|Dietary Supplement|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
79692826|NCT05919472|Biological|COVID-19 vaccine|Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
79692827|NCT05919472|Biological|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
80008998|NCT02663518|Drug|PF-07901800 (TTI-621) plus Rituximab|Combination therapy
80008999|NCT02663518|Drug|PF-07901800 (TTI-621) plus Nivolumab|Combination therapy
79381323|NCT01783522|Other|quality-of-life assessment|Ancillary studies
79381324|NCT01783522|Other|placebo|Given PO
79381325|NCT04734366|Procedure|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
79381326|NCT04734366|Procedure|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
79692828|NCT05919472|Dietary Supplement|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
79692829|NCT05919472|Biological|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
79692830|NCT05918094|Drug|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
79838155|NCT00935805|Drug|Propranolol|40 mg BID
79838156|NCT00935805|Drug|Captopril|50 mg TID
80009000|NCT02563002|Drug|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
80009001|NCT02563002|Drug|FOLFIRI|Regimen consists of irinotecan 180 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-FU 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
79692831|NCT05918094|Drug|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
79692833|NCT05905068|Drug|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
79838157|NCT00935805|Drug|Amlodipine|10 mg QD
79305731|NCT04955613|Device|MyMove/VR system|"The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers."
79838158|NCT03986125|Behavioral|Emotional Awareness & Expression Therapy|emotion-focused
79838159|NCT03986125|Behavioral|Mindfulness Meditation Training|meditation training and practice
80009002|NCT02563002|Biological|pembrolizumab|MK-3475 SCH 900475 KEYTRUDA®
80009003|NCT02563002|Biological|bevacizumab|
80009004|NCT02563002|Biological|cetuximab|
80009005|NCT02454933|Drug|AZD9291|Once daily tablet 80 mg
79305732|NCT04955613|Device|Mirror therapy|Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
79381327|NCT02471820|Drug|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
79381328|NCT02471820|Drug|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
79381329|NCT02471820|Drug|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
79381330|NCT01833130|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
79838160|NCT00935961|Drug|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
80009006|NCT02454933|Drug|MEDI4736|10mg/kg q2w (IV) infusion
79536051|NCT06039956|Procedure|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
79536052|NCT06039943|Device|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
80009007|NCT02430480|Drug|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
80009008|NCT02430480|Drug|Enzalutamide|160mg orally, daily for 24 weeks
80009009|NCT02430480|Device|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
79536053|NCT06039917|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
80009010|NCT02263274|Device|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
80009011|NCT02207439|Drug|Nelfinavir (Viracept®) 1250 mg|Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
80009012|NCT02207439|Other|Chemoradiation|Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
79536054|NCT06039917|Other|Manually remind the patients|Medical staff remind patients to review manually.
79536055|NCT06039904|Device|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
79838161|NCT00656370|Drug|recombinant human hyaluronidase|150 Units in 1mL
79838162|NCT01055431|Other|Control bread|Control bread
79838163|NCT01055431|Other|Teff Bread|Teff bread
79838164|NCT00936039|Behavioral|unloading|2 weeks of unloading of a single leg
79838165|NCT00803556|Drug|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
80009013|NCT01689766|Drug|Technetium Tc 99m EC20|
80009014|NCT01205048|Device|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
80009015|NCT01205048|Device|Juvederm® Ultra|24mg/mL
80009016|NCT01052779|Drug|Ferumoxytol|IV Ferumoxytol
80009017|NCT01052779|Drug|Iron Sucrose|IV Iron Sucrose
80009018|NCT00785525|Drug|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
80009019|NCT00743262|Device|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
79536056|NCT06039904|Device|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
79305251|NCT04943055|Procedure|YAG lacrimal duct laser combined with lacrimal duct catheter|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
79536057|NCT06039891|Drug|Nimotuzumab、Tislelizumab|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
79381331|NCT01833130|Drug|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
79381332|NCT02475408|Device|Amplatzer vascular plug|
79536058|NCT06039865|Behavioral|Immediate Intervention|Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.
79536059|NCT06039865|Behavioral|Waitlist control|Participants only receive usual care from the sleep center.
79381333|NCT02471664|Device|Mitral Loop Cerclage Annuloplasty|
79536060|NCT06039839|Procedure|Closure of the donor area after CTG harvesting without the use of collagen matrix|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~Suturing of the wound in the donor site."
79692834|NCT05900245|Other|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
79692835|NCT05898607|Other|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
79692836|NCT05898607|Other|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
79692837|NCT05892744|Drug|Sertraline|50-200mg/day
79692838|NCT05873439|Radiation|Genomically Guided Radiation Therapy (RT)|Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
79692839|NCT05864118|Diagnostic Test|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
79692840|NCT05864118|Diagnostic Test|COVID-19 antibody test|COVID-19 antibody test
79692841|NCT05860036|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10^6 anti-BCMA CAR+T cells/kg.
79692842|NCT05860036|Drug|VRd|Bortezomib, Lenalidomide and Dexamethasone
80009020|NCT00591370|Drug|Temozolomide (TMZ)|One group treatment study
80009021|NCT03064763|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
80009022|NCT02782676|Device|Investigational Healon5 OVD|ophthalmic viscosurgical device
79381334|NCT01783912|Behavioral|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
79381335|NCT01783912|Behavioral|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
79381336|NCT01783912|Drug|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
79381337|NCT01783912|Behavioral|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
79381338|NCT02475330|Dietary Supplement|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
79381339|NCT02475174|Other|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
79381340|NCT02475174|Other|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
80009023|NCT02782676|Device|Healon5 OVD|ophthalmic viscosurgical device
80009024|NCT03033095|Drug|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
79305252|NCT04943133|Device|Blood pressure measurement and collection of the oscillometric curve for later SFATI analysis|Brachial systolic arterial blood pressure will be systematically taken with acquisition of the oscillometric curve for analysis and measurement with the SFATI system and simultaneous electronic recording of the Korotkoff sound (auscultatory method) and a search for SFATI arterial stiffness markers for all patients. Brachial systolic arterial blood pressure will be measured with the help of a cuff equipped with a Biopac SS30L electronic stethoscope and a MA-300 phonocardiographic microphone, placed side-by-side immediately downstream from the brachial occlusion cuff. The various signals (pneumatic cuff, oscillometric signal and Korotkoff sounds) will be digitalized by an MP35 system.
79692843|NCT05850013|Device|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
79692844|NCT05847582|Behavioral|Standard inpatient psychiatric care|All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.
79692845|NCT05847582|Behavioral|Inpatient Skills Training|Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.
79692846|NCT05847582|Behavioral|mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)|mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
79692847|NCT05838495|Other|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
79692848|NCT05836090|Behavioral|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
79692849|NCT05836090|Behavioral|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
79692850|NCT05828823|Device|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
79692851|NCT05828823|Other|Hemodialysis thrice weekly|Conventional hemodialysis regimen
79692852|NCT05815160|Drug|Debio 0123|Administered as capsules.
79692853|NCT05815160|Drug|Etoposide|Administered as IV infusion.
79838166|NCT00803556|Drug|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
79838167|NCT00803556|Drug|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
79692854|NCT05815160|Drug|Carboplatin|Administered as IV infusion.
79838168|NCT00936195|Drug|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
79838169|NCT00936195|Drug|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
79838170|NCT02552550|Procedure|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
79838171|NCT00680186|Drug|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
79838172|NCT00680186|Drug|Dabigatran etexilate|150mg bid
79838173|NCT00936429|Biological|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
79381341|NCT01783990|Drug|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
79381342|NCT05582382|Other|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA & ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~Hospital admission on the first encounter to ED~Admission to ICU for the duration of the COVID-19 hospitalization~In hospital and out of hospital mortality~Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
79381343|NCT01733056|Biological|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
79381344|NCT04672824|Biological|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
79381345|NCT04672824|Other|Saline|0.5ml saline placebo
79838174|NCT00936429|Biological|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
79838175|NCT00656292|Drug|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
79838176|NCT00656292|Drug|Placebo|1 pill po/NG every day x 6 days
79838177|NCT00936507|Other|Energy Density/Portion Size|
79838178|NCT00352417|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
79838179|NCT00352417|Drug|Placebo|oral dosing, 1 time daily for 12 weeks
79381346|NCT01833988|Device|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
79536061|NCT06039839|Procedure|Closure of the donor area after CTG harvesting with collagen matrix|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~Adaptation of sterile collagen matrix to the donor site~Suturing of the wound in the donor site"
79536062|NCT06039800|Other|No intervention|No intervention
79692855|NCT05806294|Behavioral|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
79692856|NCT05805384|Device|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
79692857|NCT05798650|Behavioral|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
79838180|NCT00944541|Drug|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
79241827|NCT03644537|Procedure|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
79241828|NCT03641495|Other|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
79241829|NCT03641495|Other|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
79241830|NCT03643055|Diagnostic Test|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
79241831|NCT03641417|Drug|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
79241832|NCT03641417|Other|Placebo|Same as GLWL-01, but no active ingredient
79241833|NCT01344629|Drug|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
79241834|NCT01344629|Drug|Telmisartan|Telmisartan 80 mg tablet
79381347|NCT01833988|Other|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
79381348|NCT02471742|Procedure|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
79381349|NCT02471742|Procedure|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
79381350|NCT02477046|Biological|tOPV|administered per protocol
79536063|NCT06039748|Other|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
79536064|NCT06039722|Device|Pulse ablation catheter|Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential
79536065|NCT06039670|Procedure|biliary biopsy|biliary biopsy through a percutaneous approach during a percutaneous biliary drainage
79536066|NCT06039657|Other|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
79838181|NCT00809640|Behavioral|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
80009025|NCT02471339|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
79241835|NCT01344629|Drug|Amlodipin|Amlodipin 5mg tablet
79241836|NCT01092117|Device|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
79381351|NCT02477046|Biological|bOPV|administered per protocol
79381352|NCT02477046|Biological|IPV|administered per protocol
79391407|NCT03176316|Drug|Naloxone|"Blinding/labeling/preparation of agents: No blinding is required in this study. The study drug will be prepared, unit dose labelled, and patient labelled according to institutional protocols.~Storage: Secured at room temperature in the central pharmacy then dispensed as a patient specific supply and stored at room temperature the automated dispensing cabinet. No more than a 24 hour supply will be dispensed at any given time.~Administration: 1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours"
79391408|NCT02419170|Procedure|Standard of care surgery|
79391409|NCT02419170|Procedure|Apheresis|
79536067|NCT06039657|Other|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
79692858|NCT05794555|Behavioral|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
79692859|NCT05794555|Drug|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
79692860|NCT05794555|Behavioral|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
79692861|NCT05794555|Behavioral|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
79692862|NCT05794022|Other|MRI|1 MRI at 1 month with gadolinium injection
79692863|NCT05794022|Biological|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
79692864|NCT05794022|Behavioral|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
79692865|NCT05792020|Device|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
79838182|NCT01055509|Behavioral|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
79838183|NCT00944619|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
79838184|NCT00944619|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
79838185|NCT00805896|Drug|Songyou|4g/pack
79381353|NCT02475096|Behavioral|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
79381354|NCT02475018|Dietary Supplement|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
79381355|NCT02475018|Dietary Supplement|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
79381356|NCT05363436|Drug|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
79536068|NCT06039631|Procedure|Surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended.
79692866|NCT05791032|Device|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
79838186|NCT00805896|Drug|placebo|4g/pack
79838187|NCT00323869|Drug|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
79838188|NCT00323869|Drug|Gemcitabine|Nucleoside analog
79838189|NCT00323869|Drug|Carboplatin|Alkylating agent
79381359|NCT04575870|Other|waiting period|amount of time between clinical procedure and modified functional endoscopic exam of swallowing
79391410|NCT02419170|Drug|Cyclophosphamide|
79391411|NCT02419170|Biological|Personalized mature dendritic cell vaccine|
79391412|NCT00363454|Drug|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m^2; Level 2: 25 mg/m^2; 35 mg/m^2; 45 mg/m^2.
79391413|NCT02419326|Behavioral|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
79838190|NCT05434832|Behavioral|Virtual Reality|Distraction method
79838191|NCT05434832|Behavioral|Local cold-vibration|Distraction method
79838192|NCT01057927|Drug|OC000459|OC000459 capsules 2x100mg BID for 28 days
79838193|NCT01057927|Drug|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
79838194|NCT02559986|Other|telephone interview|telephone interview about their care received during the first year of life and associated events
79838195|NCT01058083|Drug|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
79536069|NCT06039631|Radiation|Radiation|"In the surgical group, depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended.~In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin at a dosage of 30 mg/m²."
79692867|NCT05787106|Other|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
79692868|NCT05773989|Drug|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
79692869|NCT05773989|Drug|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
79838196|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
80009026|NCT02142842|Biological|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
80009027|NCT03632057|Device|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
79241837|NCT03642977|Diagnostic Test|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
79241838|NCT03414021|Diagnostic Test|SPECT-CT Scan|Injection of a Tracer and SPECT-CT Scan
79381360|NCT02474940|Behavioral|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
79241839|NCT03641261|Other|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
79241840|NCT03413943|Other|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
79241841|NCT03621293|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
79391414|NCT02974426|Radiation|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
79391415|NCT02974426|Radiation|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
79536070|NCT06039631|Drug|Toripalimab|In the both groups, starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
79536071|NCT06039592|Drug|Captopril Tablets|0.3mg/kg, tid
79692870|NCT05763004|Drug|IOS-1002|monotherapy
79692871|NCT05763004|Drug|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
79692872|NCT05760794|Procedure|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
79838197|NCT01058083|Drug|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
79838198|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
79838199|NCT01058083|Drug|Placebo|Placebo, Oral, 0 mg, daily, 28 days
79838200|NCT05434676|Device|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
80009028|NCT03632057|Device|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
80009029|NCT05075720|Dietary Supplement|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
79536072|NCT06039592|Drug|Metoprolol Oral Tablet|0.2mg/kg, bid
79692873|NCT05760794|Procedure|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
79536073|NCT06039592|Drug|Spironolactone Tablets|2-4mg/kg, bid
79381361|NCT02474940|Behavioral|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
79692874|NCT05756725|Other|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
79838201|NCT00323557|Drug|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
79838202|NCT00323557|Biological|Pneumococcal Vaccine|Subcutaneously on Day 0
79241842|NCT04835727|Other|Semi-vegetarian diet and increase fiber consumption|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
79241843|NCT03642743|Other|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
79838203|NCT02559050|Other|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
79241844|NCT03419169|Device|Light load BFR resistance training|A novel training light load resistance training modality.
79241845|NCT03419169|Procedure|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
79241846|NCT03419091|Device|single-use flexible digital ureteroscope|Device being tested.
79241847|NCT03419091|Device|Reusable Ureteroscope|Comparative device.
79536074|NCT06039592|Drug|Torsemide Tablets|0.2-0.5mg/mg, bid
79838204|NCT00558363|Drug|Avodart|0.5 mg administered orally once daily
79838205|NCT00558363|Other|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
79838206|NCT00323479|Drug|Anastrozole|1mg/Day oral
79838207|NCT00352105|Drug|cisplatin|20mg/m2/d IV continuous infusion x4 days
79838208|NCT00352105|Drug|fluorouracil|1000mg.m2/d IV continuous x 4 days
79838209|NCT00352105|Drug|Iressa|250mg/PO qd x 2 years
79241848|NCT03413865|Other|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
79241849|NCT03419013|Other|New adhesive strip|This strip is made of a newly developed adhesive
79536075|NCT06039592|Drug|Potassium citrate powder|0.06g/kg, tid
79536076|NCT06039553|Procedure|pulmonary artery banding|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
79536077|NCT06039540|Drug|Captopril Tablets|0.3mg/kg, tid
79536078|NCT06039540|Drug|Metoprolol Oral Tablet|0.2mg/kg, bid
79536079|NCT06039540|Drug|Spironolactone Tablets|2-4mg/kg, bid
79241850|NCT05229419|Other|complete blood count|complete blood count will be done for corrosive cases
79241851|NCT03641105|Diagnostic Test|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
79241852|NCT03413709|Other|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
79241853|NCT03413631|Behavioral|Prenatal mentalization intervention|
79241854|NCT03413631|Other|Prenatal obstetric treatment as usual|
79241855|NCT04448769|Biological|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~sign the consent form after receiving complete information~complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
79536080|NCT06039540|Drug|Torsemide Tablets|0.2-0.5mg/mg, bid
79536081|NCT06039540|Drug|Potassium citrate powder|0.06g/kg, tid
79838210|NCT00352105|Radiation|hyperfractionated radiation therapy|120cGy bid
79838211|NCT00944775|Behavioral|Exercise training|10-month exercise training program during hemodialysis sessions
79838212|NCT03988075|Other|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
79692875|NCT05751941|Drug|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
79692876|NCT05751941|Drug|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
80009030|NCT05075720|Dietary Supplement|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
79241856|NCT03642353|Drug|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
79381362|NCT02474940|Behavioral|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
79241857|NCT03642353|Drug|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
79241858|NCT03413553|Device|immediate implant|Patient will receive immediate implant alone.
79241859|NCT03413553|Biological|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
79241860|NCT03413553|Biological|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
79381363|NCT01784614|Drug|LY2624803 - Solution|Administered orally as reconstituted solution
79381364|NCT01784614|Drug|LY2624803 - Capsule|Administered orally as a capsule
79381365|NCT01784614|Drug|Placebo - Solution|Administered orally as solution
79381366|NCT01784614|Drug|Placebo - Capsule|Administered orally as a capsule
79536082|NCT06039488|Behavioral|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to ~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
79536083|NCT06039462|Behavioral|Application of a virtual reality headset|Use of a headset to experience a different reality
79692877|NCT05751941|Drug|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
79692878|NCT05751941|Drug|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
79692879|NCT05746897|Drug|NM1F Injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
80009031|NCT05075720|Dietary Supplement|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
79241861|NCT03642275|Behavioral|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
79241862|NCT03413475|Behavioral|quality of life|
79241863|NCT03424863|Other|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
79241864|NCT05284175|Drug|Orelabrutinib|Orelabrutinib, orally, 50 mg QD
79241865|NCT03642197|Behavioral|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
79241866|NCT03424785|Other|drug, stent, surgical treatment|drug, stent, surgical treatment
79241867|NCT03642041|Behavioral|smoking|smoking behavior
79241868|NCT03424707|Drug|DW340(pelubiprofen/eperisone)|DW340
79241869|NCT03424707|Drug|Pelubi(pelubiprofen)|pelubiprofen
79241870|NCT03424707|Drug|Placebo Oral Tablet|Placebo Oral Tablet
79381367|NCT05314686|Other|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
79838213|NCT03988075|Other|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
79838214|NCT00944853|Dietary Supplement|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
79241871|NCT05174351|Other|beta blocker discontinuation|beta blocker discontinuation
79241872|NCT03418935|Drug|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
79838215|NCT00944853|Dietary Supplement|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
80009032|NCT02931851|Other|ICU Families Website|Professionally developed website for relatives of ICU patients
79241873|NCT03418935|Drug|Ringer's Solution|Intravenous infusion, 400 or 800 ml
79241874|NCT03641963|Device|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
79241875|NCT03641885|Behavioral|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
79241876|NCT03641885|Behavioral|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
79381368|NCT05314686|Other|Telerehabilitation|"An eight-week program including:~Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~Daily walking with automated coaching.~Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
79381369|NCT01733212|Drug|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
79381370|NCT01733212|Drug|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
79241877|NCT03641885|Behavioral|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
79381371|NCT02474706|Drug|Cefoxitin|
79381372|NCT02474706|Drug|imipenem|
79536084|NCT06039423|Procedure|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
79536085|NCT06039423|Drug|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
79391416|NCT02974426|Drug|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
79536086|NCT06039332|Procedure|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
79536087|NCT06039319|Other|Physical activity|30 minute bout of moderate intensity physical activity performed on a treadmill
79692880|NCT05746897|Drug|Pembrolizumab injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
79692881|NCT05741528|Drug|SEP-363856|SEP-363856 tablet
79692882|NCT05741060|Drug|S-equol|Experimental drug
79692883|NCT05741060|Drug|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
79838216|NCT00944853|Dietary Supplement|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
79838217|NCT03987997|Device|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
79838218|NCT03985891|Drug|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
79838219|NCT03985891|Drug|Chemotherapy|Folfox
79838220|NCT00350779|Drug|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
79838221|NCT00350779|Drug|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
80009033|NCT02931851|Other|Placebo|Standard Information provided online
80009034|NCT02146820|Device|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
80009035|NCT02142920|Drug|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
79381373|NCT01784770|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
79381374|NCT02471274|Drug|sotagliflozin|single 400 mg dose
79536088|NCT06039306|Dietary Supplement|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
79536089|NCT06039280|Drug|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
79536090|NCT06039280|Drug|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
79536091|NCT06039280|Other|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
79241878|NCT00530049|Other|questionnaire administration|
79692884|NCT05729477|Device|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
79692885|NCT05729477|Device|Phaco Subject Cohort|Phaco Subject Cohort
79692886|NCT05726305|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
79692887|NCT05726305|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
79838222|NCT00350779|Drug|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
79838223|NCT00350779|Drug|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
79838224|NCT00350779|Drug|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
79241879|NCT00530049|Procedure|assessment of therapy complications|
79241880|NCT00530049|Procedure|psychosocial assessment and care|
79241881|NCT00530049|Procedure|quality-of-life assessment|
79381375|NCT01784926|Procedure|Intraocular lens repositioning by scleral suturing|
79381376|NCT01784926|Procedure|Intraocular lens exchange with retropupillary iris-claw lens|
79536092|NCT06039267|Other|Gut Microbiome Testing|Stool microbiome testing using shotgun metagenomic sequencing
79241882|NCT03413319|Drug|ABBV-8E12|Solution for infusion
79241883|NCT03644303|Radiation|SBRT + ADT|Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
79536093|NCT06039254|Drug|HRS-1780|Single dose in each arm
79536094|NCT06039215|Other|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
79536095|NCT06039202|Drug|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
79536096|NCT06039202|Drug|TAS-102|TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.
79536097|NCT06039202|Biological|Bevacizumab|Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
79536098|NCT06039176|Device|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
79692888|NCT05721144|Drug|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
79241884|NCT03418623|Drug|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
79241885|NCT03418623|Other|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
79241886|NCT05188937|Procedure|validity and reliability study|Validity and reliability assessment of the Dual-task Questionnaire
79241887|NCT03424629|Biological|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
79381377|NCT02471196|Drug|ORM-12741|ORM-12741 low dose twice a day
79381378|NCT02471196|Drug|ORM-12741|ORM-12741 high dose twice a day
79692889|NCT05709132|Behavioral|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
79692890|NCT05708859|Drug|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
79692891|NCT05708859|Drug|Placebo|Volume matched Subcutaneous Solution
79692894|NCT05699525|Behavioral|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
79692895|NCT05699525|Behavioral|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
79692896|NCT05698199|Drug|ITI-1001|ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
79536099|NCT06039163|Drug|HH-120|Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
79692897|NCT05693558|Biological|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
79838225|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
79838226|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
79838227|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
79838228|NCT00656136|Drug|placebo|Patients receive placebo once daily
79838229|NCT00656136|Drug|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
79838230|NCT00676520|Device|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
79838231|NCT00652938|Biological|HPV Vaccine (GSK580299) Cervarix TM|IM administration
79241888|NCT03424629|Biological|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
79241889|NCT03424629|Drug|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
79241890|NCT03641807|Other|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
79381379|NCT02471196|Drug|Placebo|Placebo twice a day
79381380|NCT02471508|Device|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
79241891|NCT03641807|Other|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
79241892|NCT04618029|Other|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~Fix the back of the rugs and mats with adhesive/heavy duty tape~Buy non-slip mats~Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~Buy a torch light~To replace worn light bulbs~Buy a light switch~Bathroom~Provide recommendations to:~Buy a non-slip mat~Install a grab rail~Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
79536100|NCT06039163|Drug|placebo|Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
79536101|NCT06039150|Procedure|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
79536102|NCT06039150|Procedure|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
79692898|NCT05688423|Behavioral|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~Medications for SUD as integral to management of infectious complications~Integration of ID and SUD care~Longitudinal care with familiar providers~Multidisciplinary care and care coordination~Tailored antibiotic options and care settings~Harm reduction"
79692899|NCT05688423|Behavioral|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
79241893|NCT04618029|Other|Education|"Techniques Description Energy Conservation~Take your time~Go to the toilet more often, so you don't have to rush~Use a nearby toilet: commode, different bathroom~Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~Adjust equipment before changing position~Avoid transfers when tired~Ask for help if you feel sick or especially tired~Allow time for eyes to adjust to change in lighting~Task Simplification~Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~Proper positioning while doing tasks~Safe mobility around the home"
79692900|NCT05687903|Drug|TAK-861|TAK-861 tablets
79692901|NCT05687903|Drug|Placebo|TAK-861 placebo matching tablets
79241894|NCT05283707|Behavioral|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
79692902|NCT05687032|Drug|inotuzumab ozogamicin|Given IV
79838232|NCT00652938|Biological|Engerix B|IM administration
79838233|NCT05434520|Procedure|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
79838234|NCT02559908|Device|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
79838235|NCT00805974|Biological|Biological examinations (blood and urinary).|
79381381|NCT01835626|Drug|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
79241895|NCT02358122|Other|Wholegrain rye|A variety of cereal foods providing >100g/day wholegrain from rye
79838236|NCT00322621|Drug|Duloxetine|
79838237|NCT02558972|Drug|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
79838238|NCT02558972|Drug|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
79838239|NCT02558972|Drug|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
79241896|NCT02358122|Other|Wholegrain wheat|A variety of cereal foods providing >100g/day wholegrain from wheat
79241897|NCT02358122|Other|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
79381382|NCT01835626|Radiation|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
79536103|NCT06039124|Other|bevacizumab treatment|Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
79241898|NCT03424551|Device|vibrator|Local or whole body vibration was applied at six different frequencies
79536104|NCT06039111|Procedure|ICG alone|SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy
79536105|NCT06038994|Other|No intervention|This is an obvertional study, and there is no intervention.
79536106|NCT06038942|Behavioral|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
79692903|NCT05673460|Drug|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
79381383|NCT04491786|Drug|Gabapentin|Gabapentin plus nefopam
79381384|NCT04749784|Dietary Supplement|High Dose Arterin Cholesterol|240mg active ingredient daily
79381385|NCT04749784|Dietary Supplement|Low Dose Arterin Cholesterol|120mg active ingredient daily
79381386|NCT04749784|Dietary Supplement|Placebo|Placebo tablet
79692904|NCT05670405|Other|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R&R."
79692905|NCT05664243|Biological|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
79692906|NCT05664243|Biological|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
79692907|NCT05661734|Drug|VX-548|Tablets for oral administration.
79536107|NCT06038942|Behavioral|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
79536108|NCT06038890|Procedure|Holmium laser enucleation of the prostate using the veil-sparing technique|Holmium laser enucleation of the prostate using the veil-sparing technique
79838240|NCT02558972|Drug|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
79241899|NCT03641729|Other|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
79536109|NCT06038877|Other|Interviews|Individual semi-structured interviews
79241900|NCT02366000|Other|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
79241901|NCT03641573|Drug|[14C] ASN002|[14C] ASN002
79536110|NCT06038877|Other|Qualitative analysis|Thematic analysis of the content of responses
79692908|NCT05656196|Other|Chinese herbal tea VGH-DESJS-1|Chinese herbal tea VGH-DESJS-1.
79838241|NCT00809718|Drug|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
79838242|NCT05427266|Other|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
79241902|NCT03424473|Drug|Tucatinib|
79241903|NCT04448379|Drug|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
79241904|NCT03621215|Dietary Supplement|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
79241905|NCT03621215|Other|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
79241906|NCT03640871|Device|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)
79536111|NCT06038864|Diagnostic Test|2 clinical evaluations with 1 month in between|Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
79536112|NCT06038838|Device|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
79536113|NCT06038786|Behavioral|Resilience Training|A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
79692909|NCT05653999|Device|Hearing Aids|Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
79838243|NCT00575042|Drug|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
79838244|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
79838245|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
79838246|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
79838247|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
79536114|NCT06038773|Diagnostic Test|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
79536115|NCT06038747|Other|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
79241907|NCT04448223|Drug|CKD-351|Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
79536116|NCT06038747|Other|Individual Psychotherapy|Individual psychotherapy sessions
79838248|NCT00676208|Behavioral|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
80009036|NCT03544112|Behavioral|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
79241908|NCT04448223|Drug|Latanoprost+Dorzolmamide|Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
79536118|NCT06038552|Drug|imatinib (IM)|Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.
79536119|NCT06038552|Procedure|hepatic resection (HR)|HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.
79536120|NCT06038552|Procedure|radiofrequency ablation (RFA)|RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
79838249|NCT02533297|Other|Providing clinical skills conditions|
79838250|NCT00656058|Drug|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
79838251|NCT03871764|Diagnostic Test|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
79838252|NCT00537316|Biological|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
79241909|NCT03644225|Device|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
79241910|NCT03644225|Device|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
79241911|NCT03644147|Drug|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
79381387|NCT01786252|Drug|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
79381388|NCT01786252|Drug|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
79381389|NCT02470026|Drug|yohimbine|single low dose treatment
79241912|NCT01543256|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
79381390|NCT02470026|Drug|placebo|single control treatment
79381391|NCT04749316|Procedure|AcuTENS|Stimulation of acupuncture points with TENS machine
79381392|NCT03238794|Procedure|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
79381393|NCT03238794|Other|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
79391417|NCT02413242|Other|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
79692912|NCT05646121|Device|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
79692913|NCT05640102|Drug|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
79692914|NCT05634057|Drug|Anisodamine hydrobromide combined with heparin|The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
79692915|NCT05630885|Drug|CVC 150 mg|Administered as one 150-mg tablet by mouth once a day with food.
79692916|NCT05630885|Drug|CVC 300 mg|Administered as two 150-mg tablets by mouth once a day with food.
79838253|NCT00537316|Drug|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
79838254|NCT00537316|Drug|Placebo to Azathioprine|Placebo to AZA tablet orally every day
79838255|NCT00537316|Drug|Placebo infusion|Placebo to IFX intravenous (IV) infusion
79838256|NCT00803868|Drug|varenicline|up to 1mg po bid for 9 weeks
79838257|NCT00803868|Drug|placebo|placebo matching study drug up to 1mg po bid
80009037|NCT03544112|Drug|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
79241913|NCT01543256|Device|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
79241914|NCT02743923|Drug|carboplatin|AUC 6
79241915|NCT02743923|Drug|paclitaxel|200mg/m2
79241916|NCT02743923|Drug|Bevacizumab|15 mg/kg
79241917|NCT02743923|Drug|Pemetrexed|500 mg/m2
79241918|NCT02743923|Drug|cisplatin|75 mg/m2
79838258|NCT03827395|Biological|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
79838259|NCT03827395|Other|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 [4.5 - 7.0]).
79838260|NCT04504708|Drug|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
79241919|NCT01065779|Drug|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
79241920|NCT01065779|Drug|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
79241921|NCT03424395|Other|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
79241922|NCT02357966|Biological|514G3|True Human Monoclonal Antibody
79536121|NCT06038552|Procedure|transarterial chemoembolization (TACE)|TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
79536122|NCT06038253|Device|Fibroscan|Fibroscan is device to detect degree of liver fibrosis in NAFLD patients Dexa scan device detect degree of osteoporosis in NAFLD patients
79536123|NCT06038071|Other|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
79692917|NCT05630885|Other|Placebo for CVC 150 mg|Administered as one 150-mg matching placebo tablets by mouth once a day with food.
79692918|NCT05630885|Other|Placebo for CVC 300 mg|Administered as two 150-mg matching placebo tablets by mouth once a day with food.
79692919|NCT05630703|Behavioral|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
79692920|NCT05630703|Other|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
79692921|NCT05626114|Biological|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
79241923|NCT02357966|Drug|Placebo|Buffered saline solution
79241924|NCT02357966|Drug|Standard IV antibiotic therapy|standard antibiotic therapy will be determined by the attending physician and will be guided by the results of cultures with sensitivities.
79692922|NCT05625698|Drug|MagTrace only|see information in arm descriptions
79692923|NCT05625698|Combination Product|MagTrace and Magseed|see information in arm descriptions
79838261|NCT00655980|Drug|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
79838262|NCT00655980|Drug|Nitrous oxide and placebo|
79838263|NCT00655980|Other|standard of care|
79838264|NCT00679172|Biological|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
79838265|NCT00679172|Biological|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
79838266|NCT00679172|Biological|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
79536124|NCT06038071|Other|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
79692924|NCT05624112|Drug|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
79692925|NCT05612425|Behavioral|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
79692926|NCT05612425|Behavioral|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
79692927|NCT05612100|Other|Electronic Health Record Review|Ancillary studies
79692928|NCT05612100|Other|Questionnaire Administration|Complete alopecia questionnaires
79692929|NCT05612100|Other|Survey Administration|Complete alopecia surveys
79838267|NCT00679172|Biological|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
79838268|NCT00679172|Other|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
80009038|NCT02142998|Other|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
79241925|NCT03570359|Drug|Interferon Beta-1A|Interferon Beta-1A via inhalation
79241926|NCT03570359|Other|Placebo|Placebo via inhalation
79241927|NCT03424317|Behavioral|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
79241928|NCT03424317|Behavioral|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
79381394|NCT03208296|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
79381395|NCT02989480|Radiation|PET CT|PET CT scans
79381396|NCT02989480|Other|Cardiac MRI|Cardiac MRI
79536125|NCT06038071|Other|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
79692930|NCT05601414|Device|BIO-Z|a novel cuffless continuous BP wrist monitor
79692931|NCT05601414|Device|Finapres Nova|a cuffless continuous BP monitor
79692932|NCT05581602|Device|Wearing bracelets (3-Axis Logging Accelerometer)|Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
79241929|NCT01345838|Procedure|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
79536126|NCT06037811|Drug|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
79692933|NCT05571579|Biological|blood and/or csf collection|"blood and/or collection~Only once :~1 tube of blood of 4 mL on dry tube with or without gel,~2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
79838269|NCT01063621|Drug|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
79241930|NCT02358200|Drug|BMN-673|
79241931|NCT02358200|Drug|Carboplatin|
79241932|NCT02358200|Drug|Paclitaxel|
79241933|NCT03418311|Device|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
79241934|NCT03112616|Other|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
79241935|NCT03413085|Device|soft contact lens|"Group A~Group B"
79241936|NCT02963441|Device|LumineticsCore (formerly IDX-DR)|Retrospective confirmatory analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
79381397|NCT01786876|Drug|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
79381398|NCT05230290|Biological|KD6001 Injection|Solution for intravenous injection
79381399|NCT01786954|Device|Icare rebound tonometry|
79381400|NCT01786954|Device|Tonopen applanation|
79381401|NCT01786954|Device|Goldmann applanation|
79536127|NCT06037811|Drug|Prednisone|Prednisone as per standard of care.
79536128|NCT06037616|Other|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
79838270|NCT02533141|Device|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
79838271|NCT02533141|Device|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
79838272|NCT02533141|Drug|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
79692934|NCT05569551|Device|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
79692935|NCT05568888|Drug|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
79692936|NCT05568888|Drug|Placebo|Administered by intravenous (IV) infusion
79692937|NCT05563272|Drug|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
79838273|NCT02533141|Other|Placebo|Placebo, once daily for 4 weeks
79838274|NCT00809796|Drug|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
79838275|NCT05589454|Drug|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
79838276|NCT05589454|Drug|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
79838277|NCT01063699|Procedure|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
79838278|NCT00803946|Drug|Ibuprofen Tablets, 800 mg|
79838279|NCT00676130|Drug|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
79838280|NCT00676130|Drug|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
79838281|NCT04874818|Diagnostic Test|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
79381402|NCT01837654|Behavioral|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
79838282|NCT02553408|Device|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
79692938|NCT05563246|Drug|LY3473329|Administered orally
79692939|NCT05563246|Drug|Placebo|Administered orally
79692940|NCT05561166|Other|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
79692941|NCT05559697|Device|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
79692942|NCT05559697|Device|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
79692943|NCT05556447|Behavioral|Internet delivered pain coping skills training|Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
79692944|NCT05550376|Other|Registry|Non-interventional registry
79838283|NCT03742882|Drug|CC-90001|CC-90001
79838284|NCT00804024|Device|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
79838285|NCT00809874|Dietary Supplement|Casein|
79381403|NCT01837654|Behavioral|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
79381404|NCT02474862|Behavioral|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
79536129|NCT06037616|Other|video skill|Video showing skill to perform a skin suture
79536130|NCT06037616|Other|video errors|Video showing errors of skin suture
79536131|NCT06037447|Procedure|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
79536132|NCT06037434|Drug|Captopril Tablets|0.3mg/kg, tid
79536133|NCT06037434|Drug|Metoprolol Oral Tablet|0.2mg/kg, bid
79536134|NCT06037434|Drug|Spironolactone Tablets|2-4mg/kg, bid
79536135|NCT06037434|Drug|Torsemide Tablets|0.2-0.5mg/mg, bid
79692945|NCT05540717|Biological|PQ Grass|Suspension for Injection
79692946|NCT05540717|Biological|Placebo|Solution for injection
79692947|NCT05536752|Drug|QA102/Placebo|Capsules
79692948|NCT05536752|Drug|QA102|Capsules
79838286|NCT00809874|Dietary Supplement|Whey Isolate|
79838287|NCT00809874|Dietary Supplement|Whey Hydrolysate|
79838288|NCT00809874|Dietary Supplement|Alphalact-Albumin|
79838289|NCT00809952|Procedure|recombinant FSH|
79838290|NCT00676052|Drug|GSK233705 12.5mcg|Once daily via dry powder inhaler
79838291|NCT00676052|Drug|GSK233705 25mcg|once daily via dry powder inhaler
79692949|NCT05536752|Drug|Placebo|Capsules
79838292|NCT00676052|Drug|GSK233705 50mcg|Once daily via dry powder inhaler
79838293|NCT00676052|Drug|GSK233705 100mcg|Once daily via dry powder inhaler
79692950|NCT05514054|Drug|Imlunestrant|Administered orally.
79838294|NCT00676052|Drug|GSK233705 200mcg|Once daily via dry powder inhaler
79241937|NCT03112772|Other|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
79241938|NCT03112772|Other|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
79381405|NCT02474862|Behavioral|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
79838295|NCT00676052|Drug|Placebo|Once daily via dry powder imhaler
79838296|NCT05436158|Other|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
79838297|NCT05436002|Device|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
79692951|NCT05514054|Drug|Tamoxifen|Administered per local approved label.
79241939|NCT03413007|Diagnostic Test|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
79241940|NCT01065935|Drug|ALN-RSV01|Administered by nebulization once daily for 5 days
79692952|NCT05514054|Drug|Anastrozole|Administered per local approved label.
79692953|NCT05514054|Drug|Letrozole|Administered per local approved label.
79692954|NCT05514054|Drug|Exemestane|Administered per local approved label.
79692955|NCT05507580|Drug|Upadacitinib|Oral tablet
79381406|NCT02261428|Device|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
79381407|NCT02261428|Device|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
79381408|NCT01838980|Device|Motus GI Clean-Up Device|
79381409|NCT01839058|Other|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
79381410|NCT01839604|Drug|AZD9150|Intravenous infusion over 3 hours.
79536136|NCT06037434|Drug|Potassium citrate powder|0.06g/kg, tid
79536137|NCT06036433|Device|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
79536138|NCT06036433|Device|Infrared & Red LED photobiomodulation device|Infrared & red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
79536139|NCT06035523|Device|Endoform™ Antibacterial|Application of Endoform™ Antibacterial
79536140|NCT06035523|Device|Endoform™ Natural|Application of Endoform™ Natural
79536141|NCT06035523|Device|Symphony™|Application of Symphony™
79692956|NCT05502315|Drug|Cabozantinib|40 mg taken orally
79692957|NCT05502315|Drug|Nivolumab|480 mg by infusion
79241941|NCT01065935|Drug|Normal Saline|Administered by nebulization once daily for 5 days
79241942|NCT02357888|Drug|V0018|Oromucosal - Single dose
79241943|NCT02357888|Drug|Placebo|Oromucosal - Single dose
79381411|NCT02261818|Behavioral|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
79391418|NCT02413476|Procedure|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
79692958|NCT05493241|Behavioral|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
79838298|NCT02560376|Drug|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
79838299|NCT05435690|Device|Computer-assisted arthroplasty|Computer-assisted arthroplasty
79838300|NCT00535288|Drug|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
79838301|NCT00535288|Drug|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
79838302|NCT00921830|Drug|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
79536142|NCT06035237|Other|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
79692959|NCT05493241|Behavioral|Attention control|An attention control (AC) group will be used to control for the social interaction and educational aspects of ACTIVaTE. The AC arm will consist of 6 weekly one-hour VVC-delivered sessions including friendly social conversation plus education on remaining active within the physical, cognitive, and social domains during older adulthood. During each session, the interventionist will review a relevant handout or other educational materials with the participant. AC interventionists will not be trained in the ACTIVaTE intervention, and the investigators will assess whether any key features of ACTIVaTE (activity monitoring/planning, values exploration, problem-solving) are incidentally incorporated into this arm during fidelity assessment.
79838303|NCT05435534|Other|ActiveFLS intervention|"A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~Osteoporosis treatments according to national guideline~A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
79838304|NCT05435534|Other|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
79838305|NCT02560220|Biological|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
79838306|NCT05356078|Drug|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
79838307|NCT05435456|Other|Exercise|Strengthening and Relaxation Exercises
79536143|NCT06031740|Procedure|Sclerotherapy with 1.5% polidocanol|"2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.~- Group 2: Foam sclerotherapy."
79381412|NCT01840072|Other|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
79381413|NCT01789138|Behavioral|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
79381414|NCT01841632|Drug|MultiStem|
79381415|NCT01807949|Drug|Placebo|Matching placebo tablet
79381416|NCT01807949|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
79692960|NCT05489926|Drug|Pamiparib|Pamiparib, 60mg PO BID
79692961|NCT05485961|Drug|CSL300|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
79692962|NCT05485961|Drug|Placebo|0.9% w/v NaCl
79692963|NCT05485961|Drug|Placebo|Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
79381417|NCT01807949|Drug|Ivacaftor|Film-coated tablet
79536144|NCT06031740|Procedure|Foam sclerotherapy.|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
79536145|NCT06029725|Device|radiofrequency microneedling combined with 1927 nm thulium laser|"session: radiofrequency microneedling + 1927 nm thulium laser~session: 1927 nm thulium laser monotherapy~session: 1927 nm thulium laser monotherapy"
79692964|NCT05479643|Device|Surface Electromyography|Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
79838308|NCT04836832|Drug|Acalabrutinib|Given PO
79838309|NCT04836832|Drug|Duvelisib|Given PO
79838310|NCT02917928|Dietary Supplement|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
79838311|NCT02917928|Drug|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
79838312|NCT03904420|Other|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
79838313|NCT03904420|Other|Traditional Model|Standard clinical practice and education
79692965|NCT05478681|Device|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
79838314|NCT05358184|Device|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
80009039|NCT02142998|Other|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
80009040|NCT01383785|Other|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
79536146|NCT06029725|Device|radiofrequency microneedling monotherapy|1 session: radiofrequency microneedling monotherapy
79692966|NCT05472909|Other|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
80009041|NCT01383785|Other|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
80009042|NCT01383785|Other|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
80009043|NCT02146898|Other|Position|
80009044|NCT02146976|Drug|propofol|introvenious infusion of propofol
80009045|NCT02146976|Drug|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
79536147|NCT06029218|Radiation|Proteus ONE one daily beam|A single daily beam is used, doubling the dose delivered for this treatment incidence.
79692967|NCT05472909|Other|Personal Choice of Music|Participants listen to their preferred music during surgery.
79692968|NCT05446870|Biological|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
79381418|NCT02989558|Drug|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
79381419|NCT02989558|Drug|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
79381420|NCT01806779|Drug|Chantix|
79381421|NCT01806779|Drug|Zyban|
79838315|NCT02783300|Drug|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
80009046|NCT02365883|Device|Photoacoustic Imaging System|manufactured by Endra
80009047|NCT02147054|Drug|Rocuronium|
80009048|NCT02147054|Drug|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
80009049|NCT02149082|Device|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
80009050|NCT02149160|Drug|FRM-0334|
80009051|NCT02149160|Drug|Placebo|
80009052|NCT02149238|Dietary Supplement|flavanol|
79381422|NCT01806779|Drug|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
79381423|NCT01789840|Device|Embosphere Microspheres|
79536148|NCT06029218|Radiation|Proteus ONE two daily beam|two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
79536149|NCT06013943|Drug|Envafolimab+Gemox|"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."
79692969|NCT05446870|Drug|Paclitaxel|175 mg/m^2 by IV infusion on Day 1 of each 21-day cycle
79692970|NCT05446870|Drug|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
79692971|NCT05446870|Biological|Avastin|According to local practice and at the choice of the investigator.
79692972|NCT05446870|Biological|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
79381424|NCT01789840|Procedure|TURP|
79381425|NCT01878526|Drug|Alginic acid|Algycon 1 tab chew tid after meal
79692973|NCT05446870|Drug|Docetaxel|75 mg/m^2 by IV infusion on Day 1 of each 21-day cycle
79692974|NCT05442515|Biological|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
79692975|NCT05442515|Drug|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
79838316|NCT02783300|Drug|Pembrolizumab|Pembrolizumab will be administered.
79381426|NCT01878526|Drug|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
79381427|NCT01878526|Drug|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
79381428|NCT01878526|Drug|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
79381429|NCT01878604|Genetic|Gene analysis|Gene analysis
79381430|NCT01878604|Other|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
79692976|NCT05442515|Drug|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
79692977|NCT05433662|Behavioral|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
79692978|NCT05424978|Other|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
79692979|NCT05424380|Drug|GSK3745417|GSK3745417 will be administered
79692980|NCT05424081|Behavioral|EMBER|Self-help tool to increase weight management engagement
80009053|NCT02149238|Dietary Supplement|methylxanthine|
79692981|NCT05424081|Behavioral|Control|List of weight management programs
79692982|NCT05422794|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
79692983|NCT05422794|Procedure|Biopsy|Undergo biopsy
79838317|NCT02781272|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
79838318|NCT02781272|Procedure|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
79838319|NCT02781272|Procedure|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
79838320|NCT04293484|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
79838321|NCT04293484|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
79838322|NCT05355922|Other|Electrical electrostimulation of the quadriceps muscle|Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
79838323|NCT05355922|Other|Electrical electrostimulation of the quadriceps muscle (placebo)|Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
80009054|NCT02149238|Dietary Supplement|flavanol + methylxanthine|
80009055|NCT02149316|Procedure|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
80009056|NCT02149316|Procedure|control|a deflated cuff placed on the right upper arm
79838324|NCT00675506|Drug|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
79838325|NCT00675506|Drug|Placebo|2-mg sub-cutaneous injections once daily for 12 months
79838326|NCT02558660|Behavioral|Education|Educational intervention about an existing SNAP healthy food incentive program
79241944|NCT03418233|Drug|CardioCell|"Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
79241945|NCT03418233|Drug|Placebos|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
79241946|NCT03127605|Drug|Inotuzumab Ozogamicin|
79381431|NCT01878604|Other|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
79381432|NCT01792024|Device|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
79381433|NCT01792024|Procedure|magnetic resonance imaging|Undergo MR-guided LITT
79381434|NCT02266576|Behavioral|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
79381435|NCT02266576|Behavioral|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
79838327|NCT02558660|Behavioral|voucher|$10 voucher to spend on produce at farmers markets
80009057|NCT02149394|Other|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
79692984|NCT05422794|Procedure|Biospecimen Collection|Undergo collection of blood samples
79838328|NCT04001920|Other|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
79838329|NCT05435378|Drug|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
79536150|NCT06011239|Behavioral|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
79536151|NCT06010927|Drug|ketamine/midazolam|premedication
79536152|NCT06010927|Drug|Ketofol|Pre-extubation
79536153|NCT06008444|Other|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
79692985|NCT05422794|Procedure|Computed Tomography|Undergo CT
79692986|NCT05422794|Procedure|Magnetic Resonance Imaging|Undergo MRI
79536154|NCT06008444|Other|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
79536155|NCT06006897|Other|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
79536156|NCT06006897|Other|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
79838330|NCT05435378|Drug|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
80009058|NCT02149394|Other|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
79241947|NCT03112538|Device|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
79692987|NCT05422794|Drug|Nab-paclitaxel|Given IV
79692988|NCT05422794|Biological|Pembrolizumab|Given IV
79692989|NCT05420844|Other|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
79692990|NCT05405426|Other|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
79692991|NCT05393037|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
79692992|NCT05393037|Biological|Placebo|Saline in each 0.5 mL sterile solution
79692993|NCT05393037|Biological|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
79692994|NCT05393037|Biological|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
79692995|NCT05384262|Drug|AZD0780|Subjects will receive AZD0780 orally as a single ascending dose.
79692996|NCT05384262|Drug|AZD0780|Subjects will receive AZD0780 orally as a multiple ascending dose.
79692997|NCT05384262|Drug|AZD0780|Subjects will receive AZD0780 orally as a single and multiple ascending dose.
79536158|NCT05987046|Behavioral|Contrast training|Three sets of three repetitions of parallel squats at 90% of 1RM
79536159|NCT05982717|Other|No intervention|As this is an observational study, no intervention will be administered.
79838331|NCT05435378|Drug|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
80009059|NCT02143076|Behavioral|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
79536160|NCT05982405|Other|Training group: Inspiratory muscle training|The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.
79536161|NCT05982405|Other|Control group: Thoracic expansion exercise|"Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
79536162|NCT05958147|Biological|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
80009060|NCT02143076|Behavioral|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
80009061|NCT02143076|Behavioral|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
79381436|NCT02266810|Device|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
79381437|NCT02266810|Procedure|Sinus Surgery alone|Sinus surgery only, without implant placement
79381438|NCT02266810|Device|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
79381439|NCT01879540|Biological|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
79536167|NCT05916196|Drug|18F-Fluoroestradiol|18F-FES PET/CT
79536168|NCT05912946|Drug|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
79536169|NCT05912946|Drug|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
79536170|NCT05912946|Drug|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
79536171|NCT05879523|Drug|HRS-1893|subcutaneous, single dose, multiple doses
80009062|NCT02147210|Other|biological analysis|
79381440|NCT01842646|Drug|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
79381441|NCT04350736|Drug|TD-0903|Study drug to be administered by inhalation
79381442|NCT04350736|Drug|Placebo|Placebo to be administered by inhalation
79381443|NCT01607957|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
79381444|NCT01607957|Drug|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
79381445|NCT01845220|Drug|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
79381446|NCT01845220|Drug|Placebo|80% acetone
79536172|NCT05879523|Drug|Placebo|subcutaneous, single dose, multiple doses
79838332|NCT05435378|Procedure|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
79692998|NCT05384262|Drug|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
79692999|NCT05384262|Drug|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
79693000|NCT05384262|Drug|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
79693001|NCT05384262|Drug|Rosuvastatin|Subjects will receive rosuvastatin orally.
79838333|NCT04002622|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79838334|NCT04003324|Behavioral|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
79838335|NCT02560454|Behavioral|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
80009063|NCT00107978|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
80009064|NCT00107978|Drug|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
79381447|NCT01795534|Dietary Supplement|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
79381448|NCT01795534|Dietary Supplement|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
79381449|NCT01806623|Drug|Fluconazole|Single oral dose of 150mg Fluconazole
79381450|NCT01806545|Biological|SRM003|One time implant (2 SRM003 pieces) on surgery day.
79381451|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
79381452|NCT01846702|Drug|Placebo|Given as a SC injection.
79536173|NCT05831475|Behavioral|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
79536174|NCT05831475|Behavioral|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
79381453|NCT01846702|Drug|LY3084077|Given as a SC injection.
79381454|NCT01847014|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
79536175|NCT05828979|Device|UroMems artificial urinary sphincter|Implantation of the device
79693002|NCT05370079|Biological|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
79693003|NCT05367245|Drug|Cal-Mag Butyrate|Supplements
79381455|NCT01847638|Drug|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
79381456|NCT01847638|Drug|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
79381457|NCT05328778|Drug|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
79381458|NCT01796236|Device|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
79381459|NCT01796236|Device|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
79536176|NCT05812040|Diagnostic Test|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
79693004|NCT05367245|Drug|Placebo|Only Cal-Mag but no Butyric acid
79693005|NCT05367076|Behavioral|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~Warm-up activities~Aerobic activities and fitness training in a game-like fashion~Organized sports/games~Cool down activity~Snack/reward time"
79536177|NCT05810649|Drug|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
79536178|NCT05806931|Drug|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
79536179|NCT05804487|Device|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
79693009|NCT05359783|Drug|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
80009065|NCT03543644|Other|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
79241948|NCT03112538|Drug|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
80009066|NCT03543644|Other|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
80009067|NCT03543644|Other|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
80009068|NCT02781818|Drug|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
79241949|NCT03644069|Biological|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
79241950|NCT03644069|Biological|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
79241951|NCT03418155|Drug|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
79381460|NCT02470962|Other|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
79381461|NCT02474628|Dietary Supplement|sodium bicarbonate|
79381462|NCT02474628|Dietary Supplement|calcium carbonate|
79693010|NCT05348863|Behavioral|SPARK|The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
79693011|NCT05342636|Biological|Pembrolizumab|200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
79241952|NCT03418155|Drug|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
79241953|NCT03112694|Other|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
79241954|NCT05283551|Drug|Famciclovir|Famciclovir (500mg BD)
79241955|NCT02357732|Drug|Nivolumab|
79241956|NCT02357732|Drug|Trametinib|
79241957|NCT02357732|Drug|Dabrafenib|
79241958|NCT03412851|Other|A Direct Aspiration First Pass Technique|Distal aspiration technique
79241959|NCT03412851|Other|Stentriever Thrombectomy|Thrombectomy with stent retriever
79241960|NCT02353052|Other|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
79241961|NCT03412695|Device|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
79241962|NCT02357498|Procedure|transsphenoidal surgery|
79381463|NCT03108768|Device|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
79381464|NCT03108768|Device|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
79381465|NCT03099564|Drug|Pembrolizumab|pembrolizumab 200mg IV every three weeks
79381466|NCT03099564|Device|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
79381467|NCT02469948|Drug|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
79381468|NCT02469792|Procedure|Liposuction|
79381469|NCT02469792|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
79693012|NCT05342636|Biological|Coformulation favezelimab/pembrolizumab|800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
79536180|NCT05799430|Behavioral|Multidisciplinary medication review|"FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~FP and PCN communicate to PCP final agreement with patient and/or carer~FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures"
79536181|NCT05799430|Behavioral|Control group|Usual care by FP an PCN
79536182|NCT05799326|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
79536183|NCT05799326|Drug|Levofloxacin simulant|Levofloxacin simulant is placebo.
79536184|NCT05796544|Behavioral|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
79536185|NCT05796544|Behavioral|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
79536186|NCT05782010|Device|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
79693013|NCT05342636|Biological|MK-4830|800 mg administered via IV infusion Q3W
79693014|NCT05342636|Drug|Lenvatinib|20 mg administered via oral capsules each day
79693015|NCT05342636|Drug|Irinotecan|180 mg/m^2 administered via IV infusion on day 1 of every 14-day cycle.
80009069|NCT02781818|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
80009070|NCT02781818|Drug|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
80009071|NCT02149550|Other|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
79381470|NCT02469792|Procedure|Arthroscopic surgery|
79381471|NCT02469792|Other|Intraarticular administration of autologous ADRC|
79693016|NCT05342636|Drug|Paclitaxel|80-100 mg/m^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
79693017|NCT05338697|Diagnostic Test|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
80009072|NCT02149550|Other|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
80009073|NCT02149550|Other|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
80009074|NCT02149550|Other|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
79241963|NCT02362568|Procedure|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
79241964|NCT04479254|Dietary Supplement|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
79241965|NCT03423927|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
79381472|NCT02869932|Radiation|Lung CT scan|Lung CT scan without injection
79381473|NCT04362228|Behavioral|Whole-body exercise|10-week one-on-one, virtual, whole-body exercise class, 3x/week, focused on increasing respiratory rate through moderate-intensity aerobic exercises.
79391419|NCT02413476|Procedure|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
80009075|NCT02149550|Other|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
80009076|NCT02149550|Other|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
80009077|NCT02149628|Drug|propofol|
80009078|NCT02149628|Drug|Desflurane|
80009079|NCT02147366|Behavioral|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
80009080|NCT02147366|Behavioral|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
80009081|NCT02927873|Biological|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
80009082|NCT02927873|Biological|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
79381474|NCT05328544|Procedure|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
79381475|NCT05328544|Procedure|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
80009083|NCT02927873|Biological|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
79381476|NCT05328310|Drug|Nebivolol|Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
80009084|NCT02927873|Drug|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
80009085|NCT01383629|Behavioral|Counselling|Preoperative counselling
79381477|NCT01848184|Device|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
80009086|NCT02460419|Drug|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
80009087|NCT02460419|Other|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
80009088|NCT01220999|Drug|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111^In (5-7 mCi).
80009089|NCT03513731|Device|Adipose-derived stem cell injection|ADRC injection into the facet joint
79381478|NCT01797328|Procedure|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
79381479|NCT01797328|Procedure|warm arm|To the best of ability avoid feeling cold during 6 weeks
79381480|NCT01849822|Device|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
79536187|NCT05776901|Device|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
79536188|NCT05775731|Diagnostic Test|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
79536189|NCT05775068|Radiation|Radiotherapy|Radiotherapy
79536190|NCT05732753|Other|Mindfulness + Education in Neurophysiology of pain|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
79693018|NCT05333471|Drug|MTP 101-LF|Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
80009090|NCT03513731|Drug|Corticosteroid injection|Corticosteroid injection into the facet joint
80009091|NCT01568411|Drug|TD-1211|Period 1
80009092|NCT01568411|Drug|TD-1211+ itraconazole|Period 2
79241966|NCT03127293|Diagnostic Test|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
79241967|NCT03412461|Other|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
79241968|NCT03412461|Other|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
80009093|NCT00142415|Drug|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
80009094|NCT00142415|Drug|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m^2 in the initial cohort.
80009095|NCT01383551|Behavioral|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
79241969|NCT03153722|Procedure|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
79536191|NCT05731024|Device|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
79381481|NCT05328232|Other|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
79381482|NCT01797484|Drug|Ranolazine|Improvement of myocardial microcirculation
79381483|NCT01798186|Drug|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
79536192|NCT05731024|Device|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
79536193|NCT05722821|Other|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
79536194|NCT05721560|Device|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
79693019|NCT05331729|Radiation|FMISO-PET Protocol|"injection of 18F-FMISO~Monitoring for 2 h~PET scan (30 min) 2h post injection~Monitoring for 2h~PET (30min) 4h post injection~Discharge of the subject with appropriate recommendations after a PET/CT"
79693020|NCT05309733|Genetic|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
80009096|NCT03631745|Behavioral|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
79381484|NCT01851772|Device|Treatment with Electronic Brachytherapy|
79381485|NCT01852084|Device|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
79536195|NCT05720468|Other|Exercise|Combined endurance and resistance exercise training
79381486|NCT01852084|Device|enVista control lens|Spherical Control lens
79381487|NCT01798264|Drug|ITCA 650 (exenatide in DUROS)|
79536196|NCT05720468|Other|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
79536197|NCT05711602|Other|Pilates|raining based on a basic level Pilates exercise program will be as follows: A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
79536198|NCT05710783|Biological|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
79536199|NCT05710783|Biological|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
79693021|NCT05306834|Procedure|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
79693022|NCT05306834|Genetic|Blood sample|Analyses of molecular biomarkers including
79693023|NCT05306834|Procedure|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
79381488|NCT01798966|Device|SENSIMED Triggerfish|
79381489|NCT05326984|Drug|Metformin|Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
79693024|NCT05306834|Procedure|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
79693025|NCT05306834|Other|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
79536200|NCT05696847|Drug|Tirzepatide|Administered SC
79536201|NCT05696847|Drug|Placebo|Administered SC
79536202|NCT05695469|Device|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
79693026|NCT05306834|Other|Geriatric Depression Scale (GDS)|15 items
79693027|NCT05306834|Other|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
79693028|NCT05306834|Diagnostic Test|Unipodal standing test|Unipodal standing test
79693029|NCT05306834|Other|Walking speed measurement|over 5 meters
79838336|NCT02560454|Behavioral|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
79693030|NCT05302908|Behavioral|NuestraSaludSegura|It blends peer navigation and mHealth
79838337|NCT03895840|Drug|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
80009097|NCT05420363|Other|different walking surfaces|different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
80009098|NCT05420363|Other|traditional gait training over hard surface only|The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
80009099|NCT03631901|Drug|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
80009100|NCT03631901|Drug|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
80009101|NCT03631589|Biological|MSCs|mesenchymal stem cells therapy
80009102|NCT01383395|Drug|simvastatin/cilostazol|
80009103|NCT05084651|Drug|Ganaplacide|Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
80009104|NCT05084651|Combination Product|Lumefantrine|Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
80009105|NCT05084651|Drug|Itraconazole|200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
80009106|NCT05419271|Procedure|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
80009107|NCT01825187|Device|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
79693031|NCT05293106|Biological|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
79241970|NCT03418077|Dietary Supplement|Energy Drink|Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
79305253|NCT04943133|Device|Blood pressure measurement with the usual equipment used in the department|Brachial systolic blood pressure will be taken via the conventional oscillometric method, only for hospitalized women. Blood pressure will be measured on the same arm with the help of a conventional Dinamap-type automat (GE), with at least 2 minutes between the end of the first measurement and the start of the second inflation.
79381490|NCT01799278|Drug|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
79381491|NCT01800838|Drug|silicon phthalocyanine 4|Given topically
79536203|NCT05695469|Other|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
79693032|NCT05292846|Drug|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
79381492|NCT01800838|Drug|photodynamic therapy|Undergo PDT
79693033|NCT05282342|Diagnostic Test|Diagnostic tests|No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
79693034|NCT05282121|Drug|Avenciguat (BI 685509)|Avenciguat (BI 685509)
79381493|NCT01800838|Other|pharmacological study|Correlative studies
79381494|NCT01800838|Other|laboratory biomarker analysis|Correlative studies
79381495|NCT01854034|Drug|AUY922|AUY922 administered intravenously once a week at 70mg/m2
79381496|NCT01802554|Behavioral|Pleasant Events Program (PEP)|Behavioral Activation Therapy
79693035|NCT05282121|Drug|Empagliflozin|Empagliflozin
79693036|NCT05270837|Drug|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
79693037|NCT05270837|Other|Diet Only|Diet Control
79838338|NCT00310375|Drug|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
80009108|NCT01825187|Device|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
80009109|NCT01825187|Other|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
80009110|NCT02781584|Drug|SEL|Administered orally once daily
80009111|NCT02781584|Drug|FIR|Administered orally once daily
80009112|NCT02781584|Drug|CILO|Administered orally once daily
80009113|NCT02781584|Drug|FENO|Administered orally once daily
80009114|NCT02781584|Drug|VAS|Administered orally two times daily
80009115|NCT02149706|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
79381497|NCT01802554|Behavioral|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
79838339|NCT01061281|Device|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
79693038|NCT05269355|Drug|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
79838340|NCT01061281|Device|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
79838341|NCT02532985|Other|Negative Control|No added fiber beverage
79838342|NCT02532985|Other|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
79838343|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
79838344|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
79305254|NCT04943133|Device|systematic measurement of pulse wave velocity (aortic and brachial)|"Carotid to femoral and carotid to radial pulse wave velocity (Complior) will be systematically determined for hospitalized women and offered to all women seen for consultation.~Pulse wave velocity will be measured with the help of a Complior tonometric system (Alam Medical, Vincennes, France), with which the aorta and the arterial axes of the upper limb used to measure blood pressure can also be measured."
79305255|NCT03058263|Drug|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
79381498|NCT01781975|Drug|Imatinib Mesylate|
79381499|NCT01781975|Drug|Placebo (For imatinib mesylate)|
79381500|NCT01855360|Drug|Tauroursodeoxycholic Acid and Doxycycline|
79381501|NCT01802710|Behavioral|Psychological support|
79693039|NCT05269355|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
79693040|NCT05269355|Other|Placebo|Placebo will be administered as per the schedule specified in the arm description.
79693041|NCT05268315|Behavioral|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
79693042|NCT05237648|Other|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
79381502|NCT01802710|Other|No intervention|
79381503|NCT04351126|Drug|Fludrocortisone 0.1 Milligrams (mg)|0.2-0.6 mg/day of fludrocortisone is prescribed
79381504|NCT04351126|Drug|Bromocriptine|2.5 mg prescribed Vaginally twice daily
79381505|NCT01804673|Drug|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
79381506|NCT01856218|Drug|UX003|
79693043|NCT05237648|Other|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
79838345|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
79838346|NCT00309907|Biological|etanercept|Given IV and subcutaneously
79838347|NCT00309907|Drug|methylprednisolone|Given IV and orally
79838348|NCT01063777|Other|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
79838349|NCT01063777|Other|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
79838350|NCT00655824|Drug|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
79838351|NCT03985969|Drug|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
79838352|NCT03985969|Drug|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
80009116|NCT02149706|Biological|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
80009117|NCT03544658|Procedure|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
80009118|NCT03544658|Procedure|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
79381507|NCT01774097|Biological|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
79381508|NCT01774097|Biological|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
79381509|NCT01856530|Drug|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
79381510|NCT01856530|Drug|Placebo|Matched placebo nasal spray
79381511|NCT05302336|Drug|Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide|"All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide)."
79838353|NCT01061437|Drug|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
79305256|NCT04942821|Procedure|Platelet rich fibrin and coronally advanced flap|CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
79381512|NCT01804036|Drug|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
79536204|NCT05679492|Biological|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
79838354|NCT01061437|Drug|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
79838355|NCT01061437|Drug|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
79838356|NCT00575588|Drug|Metformin|open-label metformin
79838357|NCT00575588|Drug|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
79693044|NCT05232708|Drug|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
79693045|NCT05232708|Drug|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
79693046|NCT05232708|Drug|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
79693047|NCT05232708|Drug|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
79381513|NCT01804036|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
79381514|NCT01856764|Drug|0.5% Roflumilast Cream|Roflumilast 0.5% cream
79381515|NCT01856764|Drug|Vehicle Cream|Roflumilast formulation vehicle
79838358|NCT00575588|Drug|Saxagliptin|Saxagliptin 5 mg tablets
79838359|NCT01058317|Drug|Propranolol|Propranolol 2mg/kg divided twice daily
79838360|NCT02553096|Device|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
79381516|NCT01857232|Drug|Ondansetron|5HT3-antagonist
79381517|NCT01857232|Drug|Placebo|Comparator
79693048|NCT05230758|Drug|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
79381518|NCT01857232|Drug|Dexamethasone|Corticosteroid
79381519|NCT01857232|Drug|Fosaprepitant|NK1 antagonist
79693049|NCT05230758|Drug|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
79693050|NCT05229107|Device|Cereset Research|Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
79693051|NCT05226494|Drug|fb-PMT|Daily dosing based on patient weight
79838361|NCT00810030|Drug|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
79838362|NCT00810030|Drug|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is >25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height [m] x height [m].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
79536205|NCT05679492|Other|Normal saline|Normal saline
79693052|NCT05224531|Drug|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
79693053|NCT05222828|Drug|Carbocaine Injectable Product|One injection per patient
79838363|NCT00804102|Device|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
79838364|NCT00804102|Device|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
79241971|NCT03418077|Dietary Supplement|Placebo-control|Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
79381520|NCT01857232|Drug|APD403 IV|Amisulpride IV 20 mg
79381521|NCT01857232|Drug|APD403 oral|Amisulpride oral 10, 20 or 40 mg
79381522|NCT01804114|Procedure|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
79381523|NCT01804114|Procedure|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
79381524|NCT05275036|Device|early detection test|Blood collection and early detection testing
79381525|NCT01766128|Drug|Zonisamide|The first arm will be treated by zonisamide
79381526|NCT01766128|Drug|Placebo|The second arm will receive placebo
79381527|NCT02859558|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
79536206|NCT05664087|Drug|Periowave®|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Piperway Laser periodontal therapy instrument) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
79536207|NCT05637177|Behavioral|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
79536208|NCT05637177|Behavioral|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
79536209|NCT05637177|Behavioral|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
79536210|NCT05637177|Behavioral|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
79536211|NCT05637177|Behavioral|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
79536212|NCT05607784|Behavioral|Formative Research- Content Translation|"This formative research includes brainstorming translation of content and reviewing wireframe prototypes generated from this process. It also includes attending to cultural, developmental, and gender considerations.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
79693054|NCT05217108|Device|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
79693055|NCT05212246|Drug|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
79838365|NCT00804180|Behavioral|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
79838366|NCT00675428|Drug|BG00002 (natalizumab)|
79838367|NCT04049396|Other|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
79838368|NCT00760916|Drug|UT-15C 1 mg|UT-15C 1 mg
79838369|NCT00760916|Drug|UT-15C 0.25 mg|UT-15C 0.25 mg
79838370|NCT00760916|Drug|UT-15C 5 mg|UT-15C 5 mg
79838371|NCT00760916|Drug|Placebo|Placebo
79536213|NCT05607784|Behavioral|Formative Research- Content Feedback and Acceptability|"This formative research includes providing feedback on the proposed content and ensure contextual acceptability in schools.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
79693056|NCT05212246|Drug|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
79693057|NCT05212090|Diagnostic Test|EOS X-Ray|Repeated AP Pelvis x-ray and Lateral Lumbar EOS x-ray
79693058|NCT05206500|Drug|Antibiotic|FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC >0 and <10,000
79693059|NCT05206500|Device|Next Gen|Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
79693060|NCT05192954|Device|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
79693061|NCT05191680|Drug|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
79693062|NCT05191680|Drug|Placebo|Placebo to match apalutamide
79693063|NCT05170399|Biological|Fluzone|Annual Influenza Vaccine
79693064|NCT05170399|Biological|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
79693065|NCT05170399|Biological|Flucelvax|Annual Influenza Vaccine
79693066|NCT05170399|Biological|Afluria|Annual Influenza Vaccine
79693067|NCT05170399|Biological|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
79693068|NCT05170399|Biological|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
80009119|NCT03544658|Procedure|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
79693069|NCT05170399|Biological|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
80009120|NCT03544658|Procedure|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
79693070|NCT05170399|Biological|FluLaval|Annual Influenza Vaccine
79693071|NCT05170399|Biological|Fluarix|Annual Influenza Vaccine
79693072|NCT05170399|Biological|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
80009121|NCT02147678|Drug|Etomidate|
79241972|NCT03112304|Behavioral|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
79381528|NCT02830542|Drug|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
79381529|NCT02830542|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
79381530|NCT02267356|Drug|VT-1161|
79381531|NCT02267356|Drug|Placebo|
79381532|NCT05229250|Other|Cycling test|RAMP and MULTI-STAGE test
79381533|NCT05229250|Other|Occlusion tests|Occlusion test before and after exercise
79381534|NCT05229250|Device|NIRS during cycling|NIRS devices measuring oxygenation during exercise
79693073|NCT05170399|Drug|PREVNAR 20|Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
79838372|NCT05166200|Other|Experimental Formula|Diabetes-specific study formula
79838373|NCT05166200|Other|Test Meal|Instant oatmeal
79838374|NCT00761228|Drug|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
80009122|NCT02147678|Drug|Propofol|
80009123|NCT02147678|Drug|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2~0.4 μg/kg/min.
80009124|NCT02147678|Drug|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
80009125|NCT02151344|Biological|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
79381535|NCT05229250|Device|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
79381536|NCT05229250|Device|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
79381537|NCT01860586|Drug|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
79693074|NCT05170399|Drug|AREXVY, ABRYSVO|Respiratory Syncytial Virus Vaccine
79838375|NCT00761228|Drug|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
79838376|NCT00921908|Other|2 mBq radioactive technetium diluted in 20 mL saline|
79838377|NCT02558738|Device|ear spray|
80009126|NCT02151344|Biological|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
79241973|NCT03112304|Other|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
79241974|NCT05171361|Procedure|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
79381538|NCT05166382|Behavioral|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
79381539|NCT05166382|Behavioral|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
79381540|NCT02273206|Behavioral|Prevention Care Management for Depression and Cancer Screening|
79381541|NCT02273206|Behavioral|Prevention Care Management for Cancer Screening|
79381542|NCT00705432|Biological|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
79381543|NCT00705432|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
79381544|NCT00705432|Drug|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
79381545|NCT00705432|Drug|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
79381546|NCT04491708|Other|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
79381547|NCT00704964|Biological|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
79381548|NCT00704964|Drug|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
79381549|NCT02474238|Device|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
79693075|NCT05161507|Procedure|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
79693076|NCT05161507|Procedure|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
79693077|NCT05161507|Procedure|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
79693078|NCT05149534|Behavioral|Written Exposure Therapy|Narrative written disclosure of trauma administered in an evidence-based protocol.
79693079|NCT05149534|Device|repetitive transcranial magnetic stimulation|Noninvasive magnetic neuromodulation device
79693080|NCT05096403|Drug|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
79693081|NCT05091788|Device|Venus Aime|Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
79693082|NCT05079256|Device|595 nm Pulsed dye laser (Candela V-beam perfecta)|595 nm pulsed dye laser therapy. 2 treatments Fluence ~ 6 - 9 J/cm^2 Pulse duration ~ 0.45 - 3.0 ms 33% overlap.
79241975|NCT03160196|Other|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
79241976|NCT03160196|Other|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
79381550|NCT02474238|Device|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
79381551|NCT02474394|Device|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
79381552|NCT02474394|Device|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
79381553|NCT01861054|Drug|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
79381554|NCT00704808|Procedure|Primary surgical treatment|Primary surgery for tumor resection.
79381555|NCT00704808|Radiation|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
79381556|NCT00704808|Drug|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
79381557|NCT04241718|Device|Aquadex FlexFlow System and BVA-100|Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
79693083|NCT05070793|Behavioral|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
79838378|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
79241977|NCT03412383|Drug|Pyrotinib|Pyrotinib 400mg/day
79381558|NCT05323032|Device|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
79241978|NCT03112148|Drug|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
79381559|NCT01861756|Other|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
79381560|NCT05301582|Diagnostic Test|Tidal volume challenge test|The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
79381561|NCT02474316|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
79381562|NCT02474316|Drug|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
79693084|NCT05069974|Drug|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
79693085|NCT05069974|Drug|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
79693086|NCT05068414|Diagnostic Test|Blood panel|"Thrombin generation test~Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~International Normalized Ratio (if anti-vitamin K therapy is prescribed)~Platelet aggregation test"
79693087|NCT05065411|Drug|Enobosarm & Abemaciclib Combo|Subjects will receive a combo of Enobosarm & Abemaciclib
79693088|NCT05065411|Drug|non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant|Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
79693089|NCT05055570|Other|No intervention|No intervention
79381563|NCT01862536|Drug|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
79381564|NCT01862536|Drug|placebo|Daily use in double blind study.
79381565|NCT03108378|Procedure|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
79381566|NCT01862614|Drug|Articaine Hydrochloride + Epinephrine|
79381567|NCT01862614|Drug|Buffered Articaine Hydrochloride + Epinephrine|
79693090|NCT05053997|Behavioral|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
79693091|NCT05026177|Drug|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
79693092|NCT05026177|Drug|Placebo|Matching placebo given b.i.d. for 76 weeks
79693093|NCT05018299|Biological|FB704A placebo|Placebo
79693094|NCT05018299|Biological|FB704A|Anti-IL-6 antibody
79838379|NCT00758732|Drug|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
79838380|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
79241979|NCT03423849|Drug|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
79241980|NCT03423849|Drug|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
79241981|NCT03423849|Drug|Cisplatin|25mg/m2,day 1,every 3 weeks
79241982|NCT03423849|Drug|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
79241983|NCT02362490|Drug|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
79381568|NCT00558688|Procedure|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
79381569|NCT02470650|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
79381570|NCT02470650|Drug|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
79381571|NCT02470650|Drug|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
79381572|NCT02470650|Drug|Ritonavir|Ritonavir 100 mg recovered tablet once a day
79381573|NCT02470650|Drug|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
79381574|NCT02470650|Drug|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
79381575|NCT01866592|Drug|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
79693095|NCT05017545|Biological|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
79381576|NCT01375608|Drug|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
79381577|NCT02474004|Procedure|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis & knee scores 6 mo after the procedures
79381578|NCT02473848|Drug|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
79381579|NCT01868776|Drug|buffered lidocaine|
79838381|NCT00758732|Drug|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
79838382|NCT00761384|Drug|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
79838383|NCT00758888|Procedure|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
79381580|NCT01868776|Drug|nonbuffered lidocaine|
79381581|NCT02469558|Dietary Supplement|Winclove 851 and 110|prebiotic and probiotic mixture
79241984|NCT03417843|Device|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
79381582|NCT02469558|Dietary Supplement|Placebo|white powder without pro/probiotic
79381583|NCT05748340|Procedure|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
79381584|NCT00704418|Drug|Bromfenac|sterile ophthalmic solution
79693096|NCT05017545|Biological|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
79693097|NCT05017545|Procedure|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
79838384|NCT00758888|Procedure|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
79838385|NCT00758888|Other|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
79241985|NCT03159962|Device|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
79838386|NCT02559674|Biological|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
79838387|NCT02559674|Biological|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
79838388|NCT02559674|Biological|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
79838389|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
79838390|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
79838391|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
79838392|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
79241986|NCT03159962|Device|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
79241987|NCT03423771|Drug|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
79241988|NCT04324814|Drug|SHR-1701|Anti-PD-L1/TGFβ fusion protein
79381585|NCT00704418|Drug|Placebo|sterile ophthalmic solution
79381586|NCT01869634|Drug|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
79381587|NCT02047578|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
79381588|NCT05232552|Drug|Anlotinib hydrochloride|anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
79381589|NCT05232552|Drug|induction chemotherapy|docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
79693098|NCT05005416|Behavioral|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
79693099|NCT05005416|Behavioral|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
79693100|NCT05000645|Behavioral|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
79838393|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
79241989|NCT03417765|Drug|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
79693101|NCT05000645|Behavioral|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
79838394|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
79838395|NCT04913636|Device|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
80009127|NCT02151422|Behavioral|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
79241990|NCT03126903|Device|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
79381590|NCT05232552|Radiation|concurrent chemoradiation|definitive IMRT (GTV>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
79241991|NCT02362256|Drug|Naltrexone|
79381591|NCT02470572|Other|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
79241992|NCT02362256|Drug|Clonidine|
79241993|NCT02362256|Drug|Lorazepam|
79381592|NCT02470572|Other|Conventional light microscope|Conventional light microscope
79693102|NCT04993625|Procedure|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
79838396|NCT04913636|Other|Sham Control|Subjects will perform their regular denture cleaning routine.
79241994|NCT03417609|Device|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
79241995|NCT03417609|Procedure|Blood sampling|Blood sampling
79241996|NCT03417609|Diagnostic Test|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
79241997|NCT03417609|Diagnostic Test|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
79241998|NCT03417609|Diagnostic Test|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
79241999|NCT03417609|Device|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
79381593|NCT02266108|Behavioral|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
79381594|NCT01201590|Dietary Supplement|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
79381595|NCT01201590|Dietary Supplement|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
79391420|NCT02426476|Behavioral|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
79391421|NCT02426476|Behavioral|sham HRVB training|passive relaxation
79838397|NCT00761696|Drug|IPI-926|Oral daily dosing
79838398|NCT00759122|Drug|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
79838399|NCT00759122|Drug|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
79242000|NCT03417609|Diagnostic Test|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
79693103|NCT04992728|Other|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
79838400|NCT00759200|Drug|alb-interferon alfa 2b|900 mcg every 4 weeks
79838401|NCT00759200|Drug|alb-interferon alfa 2b|1200 mcg every 4 weeks
79242001|NCT00592592|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
79838402|NCT00759200|Drug|alb-interferon alfa 2b|1500 mcg every 4 weeks
79838403|NCT00759200|Drug|alb-interferon alfa 2b|1800 mcg every 4 weeks
79242002|NCT03126981|Other|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
79381596|NCT00916656|Biological|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
79838404|NCT00759200|Drug|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
79838405|NCT00557505|Drug|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
79838406|NCT02558816|Drug|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
79838407|NCT00759278|Procedure|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
79381597|NCT00916656|Biological|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
79381598|NCT01871506|Behavioral|Standard Care (SC)|"Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
79391422|NCT02413554|Drug|Rivastigmine patch|acetylcholine esterase inhibitor
79391423|NCT02422602|Drug|Xarelto|Taking conventional charge
79391424|NCT02422602|Other|Experimental: Personalized information intervention|
79838408|NCT01299753|Drug|placebo|identically packed placebo
79693104|NCT04989816|Drug|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
79838409|NCT01299753|Drug|propranolol|20-40 mg q6-8h
79838410|NCT02559440|Drug|mometasone furoate|50μg, 1 puff in each nostril every evening
80009128|NCT02151500|Behavioral|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
79242003|NCT03126981|Other|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
79242004|NCT02362100|Other|Non operative|non operative treatment
79242005|NCT02362100|Procedure|locking plate surgical fixation|
79391425|NCT02465632|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
79391426|NCT02465632|Drug|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
79391427|NCT02465632|Drug|Placebo|
79391428|NCT02466412|Other|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
79693105|NCT04989699|Drug|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
79693106|NCT04989699|Drug|Aflibercept/Sham|Aflibercept administered every 8 weeks
79693107|NCT04987086|Diagnostic Test|PSMA PET|PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
79838411|NCT02559440|Drug|Placebo|1 puff in each nostril every evening
79838412|NCT02559440|Drug|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
79838413|NCT02559440|Drug|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
79838414|NCT02559440|Drug|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
79838415|NCT02559440|Drug|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
79838416|NCT01190943|Other|Laboratory Biomarker Analysis|Correlative studies
79838417|NCT00944931|Device|DC Brain Polarization|
79536214|NCT05606432|Other|Instructor-led, one-on-one exercise group|Participants will participate in 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. The program focuses on improving heart and lung fitness using movement with music. The program will be fit to individuals' abilities. The exercise is prescribed at a moderate intensity level, which is monitored through a wearable heart rate monitor and custom designed online platform (Telerehab). A tablet will be given by the study. Data collected include exercise minutes and heart rate. Live sessions that participants attended with the instructor will be video-recorded and later uploaded to the telehealth platform. Upon completion of the 24-week program, participants will be able to access exercise routines online for an additional 12 weeks. In addition, participants will receive access to live exercise classes offered by the National Center on Health, Physical Activity and Disability.
79693108|NCT04980300|Behavioral|Expanded Intervention|Participants in the Expanded Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
79693109|NCT04980300|Behavioral|Brief Intervention|Participants in the Brief Intervention arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
79693110|NCT04965493|Drug|Pirtobrutinib|Oral
79838418|NCT04861220|Behavioral|Physical exercise|"The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes."
79838419|NCT00202761|Behavioral|PIH|Intensified training
79242006|NCT03412305|Drug|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
79242007|NCT03412305|Other|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
79693111|NCT04965493|Drug|Venetoclax|Oral
79242008|NCT02352740|Dietary Supplement|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
79381599|NCT01871506|Behavioral|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
79381600|NCT05351892|Drug|Elinzanetant (BAY3427080)|Soft gel capsule, oral
79693112|NCT04965493|Drug|Rituximab|Intravenous (IV)
79693113|NCT04951778|Drug|CC-91633|Administered orally according to the assigned treatment schedule
79693114|NCT04948749|Device|Drug Eluting Stent implantation|The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
79242009|NCT02352740|Dietary Supplement|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
79242010|NCT02109081|Drug|Dexamethasone|
79242011|NCT02109081|Drug|Placebo|
79242012|NCT02352584|Biological|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
79242013|NCT02352584|Biological|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
79242014|NCT02352584|Biological|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
79242015|NCT03423693|Other|No any intervention|No any intervention is applied to any groups in this study
79242016|NCT02352662|Other|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
79242017|NCT03417453|Device|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
79242018|NCT03417453|Device|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
79242019|NCT05171283|Other|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
79242020|NCT02352428|Other|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
79242021|NCT02352272|Other|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
79536215|NCT05606432|Other|Self-guided control with virtual fitness membership|Participants will receive a tablet and 36-week virtual fitness membership that is offered via Lakeshore Foundation. The membership will give participants full access to live and recorded adapted classes, such as Seated Yoga, ABC's of Balance, and Total Body Conditioning. Participants will be given further details during the orientation (after the physical tests of the baseline assessment).
79693115|NCT04948749|Drug|Aggressive medical treatment|Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
79693116|NCT04948749|Behavioral|Risk factor management|Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
79536216|NCT05587348|Behavioral|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
79693117|NCT04948749|Drug|Standard medical treatment|Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
79693118|NCT04927663|Procedure|Computed Tomography|Undergo CT imaging
79693119|NCT04927663|Procedure|Magnetic Resonance Imaging|Undergo MRI
79693120|NCT04927663|Procedure|Positron Emission Tomography|Undergo PET imaging
79693121|NCT04927663|Drug|11C-YJH08|Given IV
80009129|NCT03543488|Diagnostic Test|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
79242022|NCT04448067|Behavioral|Dietary Lentil Intake|Dietary intake of moderate or high dose of lentils at midday meals
79242023|NCT04448067|Behavioral|No Dietary Lentil CONTROL|Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
79242024|NCT03417375|Procedure|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
79381601|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
79381602|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
79536217|NCT05587348|Behavioral|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
79536218|NCT05568381|Device|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
79693125|NCT04908423|Drug|Xeomin®|To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
79693126|NCT04894591|Drug|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
79693127|NCT04892017|Drug|DCC-3116|Oral Tablet Formulation
79693128|NCT04892017|Drug|Trametinib|Oral Tablet Formulation
79693129|NCT04892017|Drug|Binimetinib|Oral Tablet Formulation
79693130|NCT04892017|Drug|Sotorasib|Oral Tablet Formulation
79693131|NCT04869943|Drug|Enobosarm|Oral Enobosarm 9mg per day
80009130|NCT02149784|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
79242025|NCT02362178|Procedure|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time>40 mm and/or platelets (PLTs 10 units/Kg) for MA<30 mm
79242026|NCT02362178|Procedure|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR>1.8 and/or PLTS (10 units/Kg) If PLTs count < 50000/μl
79242027|NCT04894305|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
79242028|NCT03112850|Device|Hearing aid|LOF hearing aid
79242029|NCT03112850|Behavioral|Auditory Training|
79381603|NCT00555646|Drug|Control|No treatment control.
79381604|NCT01873846|Device|Silicone Hydrogel Contact Lens|
79381605|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
79381606|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
79381607|NCT01874392|Drug|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
79693132|NCT04869943|Drug|Exemestane|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
79693133|NCT04849728|Drug|IVA337|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
79693134|NCT04849728|Drug|Placebo|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
79693135|NCT04840823|Drug|Enoxacin|Oral 200mg tablet
79693136|NCT04840823|Drug|Placebo|Oral tablet
79838420|NCT04012281|Device|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
79838421|NCT00674570|Drug|Hydrocortisone|25 mg/oral one hour prior to extinction task
79838422|NCT00674570|Drug|D-Cycloserine|50 mg/oral one hour prior to extinction task
79838423|NCT00674570|Drug|Placebo|One hour prior to extinction task
79536219|NCT05568381|Other|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
79536220|NCT05549362|Other|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
79242030|NCT05170971|Other|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
79381608|NCT01874392|Device|Artificial Pancreas (AP) device (APS©)|"Device includes:~OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~Dexcom® G4® CGM System (CGM) from Dexcom® Corp~Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
79536221|NCT05548985|Drug|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
79536222|NCT05548985|Drug|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
79536223|NCT05546827|Procedure|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
79381609|NCT04064346|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
79693137|NCT04838743|Drug|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
79381610|NCT04064346|Drug|Placebo|Matching placebo
79693138|NCT04832932|Biological|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
79838424|NCT00940563|Drug|Imatinib|
79536224|NCT05540106|Behavioral|Nature Coloring Packet|Coloring packet containing nature scenes
79838425|NCT00759512|Other|Therapeutic Touch|
79838426|NCT00940641|Drug|AZD7325|IV Dose
79838427|NCT00940641|Drug|AZD7325|oral dose
79838428|NCT00761852|Drug|Ruboxistaurin|32 mg daily for 2 weeks
80009131|NCT02155634|Drug|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
79242031|NCT02356952|Behavioral|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
79242032|NCT02356952|Behavioral|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
79381611|NCT05747872|Behavioral|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
79536225|NCT05540106|Behavioral|Geometric Shape Coloring Packet|Coloring packet containing geometric shapes
79536226|NCT05540106|Behavioral|Activity Book|Pages containing word searches, connect the dots, etc.
79536227|NCT05540106|Behavioral|Blank Paper and Pencil|Blank sheets of paper and a pencil.
79536228|NCT05535270|Diagnostic Test|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
79536229|NCT05528315|Drug|ABX-002|ABX-002
79536230|NCT05528315|Drug|Placebo|Placebo
79693139|NCT04832282|Device|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
79693140|NCT04832282|Other|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
79693141|NCT04830111|Device|heart rate variability biofeedback Application (Eureka iDestressor)|heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
79838429|NCT00761852|Drug|Placebo|1 tab po QD for 2 weeks
79838430|NCT00940719|Dietary Supplement|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
79838431|NCT00940797|Drug|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
79838432|NCT00940797|Drug|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
79838433|NCT00759590|Procedure|CT scan and Pressure volume curve|CT scan
79838434|NCT04012905|Drug|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
80009132|NCT02151578|Other|home/community case management|
79242033|NCT02356952|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
79242034|NCT04854447|Device|Single-Vision Spectacles|Spectacle correction for myopia treatment
79242035|NCT04447599|Other|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
79693142|NCT04827979|Biological|daratumumab|"Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~cPRA >98% (with >5 years of waiting time) awaiting living donor transplant"
79838435|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
79242036|NCT02352194|Other|Rehabilitation|Physiotherapy and physical activity
79838436|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
79838437|NCT02559518|Device|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
79838438|NCT02559518|Device|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
80009133|NCT02151656|Drug|F17464|
80009134|NCT02151656|Drug|Placebo|
80009135|NCT03543020|Radiation|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
80009136|NCT02155790|Device|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
79242037|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 1 or Placebo-dose 1
80009137|NCT02151734|Drug|KALOMIN™ Tab.|
80009138|NCT02151734|Drug|Umckamin syrup|
80009139|NCT02151812|Device|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
80009140|NCT02151812|Device|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
80009141|NCT02155868|Other|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood < 35 mmHg; mean arterial pressure < 60 mmHg; central venous pressure > 10 mmHg; cardiac index < 2.0 l/min/m2; mixed venous oxygen saturation < 60%; hemoglobin < 65 g/L during cardiopulmonary bypass or hemoglobin < 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
80009142|NCT02155868|Other|Standard treatment|Standard treatment
80009143|NCT02151890|Biological|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
80009144|NCT02151968|Procedure|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
79242038|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 2 or Placebo-dose 2
79242039|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 3 or Placebo-dose 3
79242040|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 4 or Placebo-dose 4
79242041|NCT04802811|Drug|SHR2150；Placebo|Single dose；SHR2150-dose 5 or Placebo-dose 5
79381613|NCT00576654|Drug|Irinotecan Hydrochloride|Given IV
80009145|NCT02151968|Procedure|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
80009146|NCT02776670|Other|Propylene glycol, 0.6% eye drops|
80009147|NCT02776670|Other|Lubricant eye drops|
79242042|NCT02352350|Other|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
79242043|NCT02352350|Other|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
79242044|NCT04795557|Dietary Supplement|ADAPT-232 oral solution|"One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients"
79242045|NCT04795557|Other|Placebo oral solution|Excipients
79381614|NCT00576654|Other|Laboratory Biomarker Analysis|Correlative studies
79381615|NCT00576654|Other|Pharmacological Study|Correlative studies
79381616|NCT00576654|Drug|Veliparib|Given PO
79381617|NCT05747716|Drug|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
79391429|NCT02466412|Other|mCC|Single use of subject's own menthol conventional cigarette (mCC)
79693143|NCT04827979|Biological|belatacept|Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
79242046|NCT02357030|Drug|Methyl-P plus GWI Nutrient Formula|"Week 1:~One tablet of Methyl-P (5mg) twice daily~Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~Two tablets of Methyl-P (10mg) twice daily~Four tablets of GWI Nutrient Formula twice daily"
79693144|NCT04827979|Procedure|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
79838439|NCT02559518|Device|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
80009148|NCT02149862|Other|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
79838440|NCT02559518|Device|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
79838441|NCT02559518|Device|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
79838442|NCT04012515|Device|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
80009149|NCT02149940|Other|heart-failure related pharmaceutical intervention|
80009150|NCT03744260|Diagnostic Test|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
79242047|NCT03397875|Procedure|Zinc oxide based sealer|After root canal treatment obturation will be done using zinc oxide eugenol based sealer.
79242048|NCT03397875|Procedure|Epoxy resin based sealer|After root canal treatment obturation will be done using epoxy resin based sealer.
80009151|NCT02150018|Other|non invasive ventilation|
80009152|NCT02150096|Other|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
79242049|NCT03397875|Procedure|Bioactive silicone based sealer|
79242050|NCT02362022|Drug|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
79242051|NCT02361866|Biological|GC1107|0.5 ml, Intramuscular, single dose(day0)
80009153|NCT02150096|Other|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
80009154|NCT02150096|Other|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
80009155|NCT04906226|Behavioral|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
80009156|NCT02150174|Behavioral|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
80009157|NCT02156024|Drug|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
80009158|NCT02150252|Drug|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
79242052|NCT02361866|Biological|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
79381618|NCT03314142|Other|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79381619|NCT03314142|Other|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79381620|NCT03314142|Other|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79693145|NCT04821375|Drug|bazedoxifene plus conjugated estrogens|6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
79693146|NCT04821141|Drug|Bazedoxifene and Conjugated Estrogens|BZA (20 mg) plus CE (0.45 mg) taken together once daily
79693147|NCT04820790|Other|Mobile applications|Monitoring of patients with home oxygen through a mobile application
79693148|NCT04815291|Device|Receives SCOUT at biopsy|SCOUT Reflector
79693149|NCT04810091|Drug|Placebo Administration|Given PO
79381621|NCT03314142|Other|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79242053|NCT03412149|Procedure|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~Mini Gastric Bypass Arm~Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
79381622|NCT03314142|Other|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79536231|NCT05525091|Other|Feeding Evaluation|Feeding Evaluation with Device
79536232|NCT05499962|Behavioral|Social Networking Strategies|Assess whether PrEP-using Black SMM can serve as an Interventionist to get their social and sexual network members to uptake and adhere to PrEP
79693150|NCT04810091|Other|Questionnaire Administration|Ancillary studies
79838443|NCT00759746|Behavioral|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
79242054|NCT03412149|Procedure|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~Mini Gastric Bypass Arm~Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
79242055|NCT03153644|Behavioral|Interview|1 hour semi-structured
79381623|NCT05747482|Other|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
79536233|NCT05496959|Drug|Lutetium Lu-177 PNT2002|Given IV
79381624|NCT00704340|Device|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
79838444|NCT00759746|Behavioral|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
79242056|NCT03153644|Behavioral|Observation|Field Observation
79381625|NCT00704340|Other|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
79381626|NCT03314064|Drug|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
79381627|NCT00552058|Biological|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
79242057|NCT03412071|Drug|Oral Tinidazole|Please see description under arms
79381628|NCT00552058|Other|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
79242058|NCT03412071|Drug|Topical metronidazole|Please see description under arms
79242059|NCT03412071|Drug|Topical Clindamycin|Please see description under arms
79242060|NCT03412071|Drug|Topical Hydrogen Peroxide|Please see description under arms
79536234|NCT05496959|Other|Quality-of-Life Assessment|Ancillary studies
79536235|NCT05496959|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79536236|NCT05484622|Drug|Vorasidenib|Administered orally as tablets.
79536237|NCT05484622|Drug|Pembrolizumab|Administered as IV infusion.
79536238|NCT05473741|Drug|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
79536239|NCT05435300|Other|PET Scan|Participants will undergo two PET scans throughout the study.
79536240|NCT05435053|Drug|Nivolumab|"Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
79536241|NCT05435053|Device|Irreversible electroporation (IRE)|"Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use."
79693151|NCT04810091|Drug|Telotristat Ethyl|Given PO
79693152|NCT04801368|Drug|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
79693153|NCT04794894|Behavioral|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
79693154|NCT04792099|Procedure|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
79242061|NCT02356874|Behavioral|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
79242062|NCT02352038|Device|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
79242063|NCT02352038|Other|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
79381629|NCT02473692|Other|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~Introduction to the series~Getting to know migraine~Making the most of your medical care~Partnering with your doctor~Best use of migraine medication~Keeping tabs on your migraine~Take home message (summary)"
79381630|NCT02473302|Other|ham|160g per day during 4 days
79693155|NCT04792099|Procedure|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
79693156|NCT04782336|Other|Sample Collection|"Sample Collection - Adult Population:~Two (2) Nasal AND/OR~Two (2) Throat Swabs AND/OR~One (1) Saliva Sample~Sample Collection - Paediatric Population:~Two (2) Nasal OR~Two (2) Throat Swabs AND/OR~One (1) Saliva Sample"
79693157|NCT04777435|Diagnostic Test|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
79838445|NCT00759746|Behavioral|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
79838446|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
80009159|NCT02152202|Other|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
79381631|NCT02473302|Other|ham + pomegranate extract|160g per day during 4 days
79536242|NCT05433116|Drug|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
79536243|NCT05433116|Drug|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
79838447|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
79838448|NCT00940953|Drug|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
80009160|NCT02152202|Other|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
80009161|NCT02152280|Drug|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
80009162|NCT02152280|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
79536244|NCT05418998|Behavioral|Executive function (EF) training|EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
79838449|NCT00759824|Drug|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
79838450|NCT04012593|Behavioral|Diary|
80009163|NCT02255084|Behavioral|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
79242064|NCT03397797|Drug|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
79242065|NCT03411993|Diagnostic Test|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
79381632|NCT02473302|Other|ham + tocopherol|160g per day during 4 days
79381633|NCT02473302|Other|rare sirloin steak|110g per day during 4 days
79381634|NCT02473302|Other|marinated rare sirloin steak|110g per day during 4 days
79381635|NCT02473302|Other|marinated cooked sirloin steak|110g per day during 4 days
79381636|NCT02473458|Drug|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~Starch-filled capsules (as placebo)~450 mg whole licorice extract capsules~900 mg whole licorice extract capsules"
79536245|NCT05401214|Drug|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
79381637|NCT02473458|Drug|Placebo|
79536246|NCT05401214|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
79242066|NCT03153332|Other|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
79838451|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
79838452|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
79838453|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
79838454|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
80009164|NCT02255084|Behavioral|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
80009165|NCT02150330|Drug|Dehydroepiandrosterone (DHEAS)|
79381638|NCT02473380|Device|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
80009166|NCT02255162|Drug|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
80009167|NCT02255162|Genetic|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
80009168|NCT02255162|Drug|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
79242067|NCT05170191|Behavioral|Sleep Deprivation|The participants will stay awake for 24 hours.
80009169|NCT02152436|Other|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
80009170|NCT02152514|Drug|Intrathecal Morphine/Sufentanil|
80009171|NCT02152514|Device|PCA|
79242068|NCT02361710|Procedure|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
79381639|NCT05747326|Drug|oral vinorelbine and capecitabine|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
79381640|NCT03108300|Drug|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
80009172|NCT02261090|Drug|Formulation B: Pramipexole Slow release (SR) tablet|
79242069|NCT02361632|Dietary Supplement|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
79242070|NCT02357108|Other|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
79242071|NCT02357108|Behavioral|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
79381641|NCT03108300|Drug|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
79536247|NCT05379010|Procedure|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
79536248|NCT05377151|Other|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
79242072|NCT03397641|Drug|HBI-3000|Small molecule, multi-ion channel blocker
79536249|NCT05373212|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
79242073|NCT03397641|Other|Placebo|Normal Saline
79242074|NCT04479098|Other|Resistance exercise training|The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
79838455|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
79838456|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
80009173|NCT02261090|Drug|Formulation C: Pramipexole Slow release tablet|
80009174|NCT02261090|Drug|Formulation D: Pramipexole Slow release tablet|
80009175|NCT02261090|Drug|Formulation E: Pramipexole Slow release tablet|
80009176|NCT02261090|Drug|Formulation F: Pramipexole Slow release tablet|
79242075|NCT04479098|Other|Exercise detraining|The exercise detraining will last 12 weeks without exercise.
79242076|NCT05169879|Procedure|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
79242077|NCT05169879|Procedure|Non coronal flaring|No coronal flaring will be performed
79242078|NCT02356796|Other|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
79242079|NCT02356796|Other|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
79381642|NCT02473224|Biological|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10^2 GEC or 1.2 x10^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, or 1.2 x 10^6 GEC, or 1.2 GEC x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
79381643|NCT02473224|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
79242080|NCT05170581|Drug|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
79838457|NCT00760058|Device|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
79381644|NCT03313908|Procedure|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
79381645|NCT02274688|Behavioral|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
79381646|NCT02470338|Procedure|MBP plus arthroscopy (Group A)|
79381647|NCT02470338|Procedure|MBP alone (Group B)|
79381648|NCT03313830|Dietary Supplement|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
79381649|NCT03313830|Dietary Supplement|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
79381650|NCT03313752|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
79242081|NCT02039024|Drug|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
79381651|NCT03313752|Other|Placebo|placebo
79242082|NCT02356718|Behavioral|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
79242083|NCT02356718|Behavioral|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
79242084|NCT03397563|Device|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
79242085|NCT03397563|Device|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
79242086|NCT02351882|Drug|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
79242087|NCT02351882|Drug|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
79242088|NCT04710693|Diagnostic Test|CAD polyp-detection system|Software will be used during the procedure to aid the detection of polyps during the procedure.
79381652|NCT02473068|Device|CPAP|
79381653|NCT03313674|Device|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
79381654|NCT05747092|Procedure|gingival graft|"investigators:~Donor site:~tissue graft harvesting from the palate behind the palatal rugae .~placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
79381655|NCT02470104|Dietary Supplement|Breastmilk|"A registered dietician will supervise milk provision.~If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
79381656|NCT03313596|Drug|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
79838458|NCT00760058|Device|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
79536250|NCT05373212|Drug|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
79381657|NCT03313596|Procedure|LT|Orthotopic LT and subsequent immunosuppression therapy
79536251|NCT05373199|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
79536252|NCT05373199|Drug|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
79536253|NCT05373199|Drug|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
79242089|NCT02356640|Procedure|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
79242090|NCT02356640|Procedure|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson &Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
79838459|NCT00760058|Device|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
79242091|NCT02356640|Device|Olympus UM 2000|
79242092|NCT02356640|Device|B-D Quincke Type Point|
79381658|NCT05746936|Procedure|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
79242093|NCT02356640|Drug|Levobupivacaine|
79381659|NCT05746858|Other|no intervention (observational study)|No intervention (observational study)
79381660|NCT03313518|Device|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
79381661|NCT03313518|Device|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
79381662|NCT04491630|Behavioral|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
79536254|NCT05366907|Other|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
79536255|NCT05359692|Biological|INCAGN01876|INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
79242094|NCT05169801|Drug|BP102, paclitaxel, carboplatin|BP102, paclitaxel, carboplatin
79242095|NCT05169801|Drug|Avastin®, paclitaxel, carboplatin|Avastin®, paclitaxel, carboplatin
79536256|NCT05359692|Biological|retifanlimab|retifanlimab will be administered via IV Q4W
79536257|NCT05353361|Drug|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
79536258|NCT05353361|Drug|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
79536259|NCT05353361|Drug|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
79242096|NCT03397485|Dietary Supplement|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
79381663|NCT04491630|Behavioral|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
79536260|NCT05353361|Drug|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
79536261|NCT05352919|Drug|Litifilimab|Administered as specified in the treatment arm.
79838460|NCT00762242|Procedure|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
80009177|NCT02261090|Drug|Formulation G: Pramipexole Slow release tablet|
80009178|NCT02261090|Drug|Formulation H: Pramipexole Slow release tablet|
79381664|NCT04491630|Behavioral|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
80009179|NCT02261090|Drug|Pramipexole immediate release (IR) tablets|
80009180|NCT03542396|Behavioral|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
80009181|NCT02152592|Drug|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
80009182|NCT02152592|Drug|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
80009183|NCT02152748|Genetic|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
79536262|NCT05352919|Drug|Litifilimab-matching placebo|Administered as specified in the treatment arm.
80009184|NCT03543332|Diagnostic Test|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
80009185|NCT01307423|Drug|Apremilast 20mg|Apremilast 20mg twice daily, orally
79242097|NCT03397485|Dietary Supplement|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
79242098|NCT02356406|Radiation|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
79381665|NCT02989012|Drug|GanMaoKangNing Granules|3 times a day, 2 bags each time.
79381666|NCT02989012|Drug|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
79381667|NCT02989012|Drug|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
79381668|NCT02989012|Drug|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
79381669|NCT03313440|Other|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
79381670|NCT03313440|Other|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
79381671|NCT02276638|Device|Specular Microscope Nidek CEM-530|Nidek CEM-530
79381672|NCT02276638|Device|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
79381673|NCT03313362|Device|SPEAC System|Seizure Monitoring and Alerting System
79536263|NCT05344560|Device|soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore|TEST Lens
79536264|NCT05344560|Device|ACUVUE OASYS 1-Day for Astigmatism|CONTROL Lens
79536265|NCT05313607|Other|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
79536266|NCT05313607|Other|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
79536267|NCT05313607|Other|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
80009186|NCT01307423|Drug|Apremilast 30mg|Apremilast 30mg twice daily, orally
80009187|NCT01307423|Drug|Placebo|Placebo
80009188|NCT04849052|Behavioral|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
80009189|NCT04849052|Behavioral|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
80009190|NCT03542318|Other|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
80009191|NCT02156336|Drug|Ranolazine|Oral administration, BID; for a maximum of 51 days.
80009192|NCT02156336|Drug|Placebo|Oral administration, BID; for a maximum of 51 days.
80009193|NCT03542240|Dietary Supplement|Curcumin|500 milligram daily supplement
79381674|NCT03313362|Device|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
79381675|NCT03108534|Drug|CHF1535 NEXThaler|Rescue treatment
79381676|NCT03108534|Drug|CHF1535 pMDI|Rescue treatment
79381677|NCT03108534|Drug|Placebo|Rescue treatment
79536268|NCT05313607|Other|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
79536269|NCT05296681|Drug|NBT-NM108|Patients receive irinotecan-based chemotherapy per standard of care.
79536270|NCT05287763|Procedure|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
79242099|NCT05169645|Other|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~Physical activity using daily step count~Additional physical activity entries~Heart rate~Sleep quality~Calories burned~Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~Urticaria symptomatology using the urticaria control test~Symptoms of depression using 2 items from the PHQ 9~Symptoms of anxiety using two items from the GAD~Short form self-compassion scale"
79242100|NCT03153176|Behavioral|Training|Training program 30 hours accumulated before, during and after intervention
79242101|NCT03153176|Behavioral|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
79536271|NCT05284214|Biological|Sargramostim|Sargramostim for injection
79381678|NCT05746780|Procedure|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
79381679|NCT02472834|Dietary Supplement|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing ~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
79536272|NCT05284214|Biological|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
79242102|NCT03153176|Behavioral|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
79838461|NCT02558426|Procedure|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
80009194|NCT02778074|Behavioral|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
79536273|NCT05273476|Procedure|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft|Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
79242103|NCT03411681|Other|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
79242104|NCT03152396|Other|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
79838462|NCT00561951|Drug|fesoterodine fumarate|8mg tablets OD for 12 weeks
79242105|NCT04447443|Dietary Supplement|Prebiotic Fiber Supplement + loperamide hydrochloride capsule|"2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
79242106|NCT04447443|Dietary Supplement|Maltodextrin + loperamide hydrochloride capsule|"2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
79838463|NCT00561951|Drug|Placebo|Corresponding placebo tablets OD for 12 weeks
79381680|NCT03832894|Drug|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
79381681|NCT02472990|Other|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
79381682|NCT02989324|Drug|MisoprostoL|Vaginal MisoprostoL
79381683|NCT02989324|Device|Foley Catheter|Misoprostol Plus Foley Catheter
79381684|NCT02472678|Other|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
79838464|NCT00561951|Drug|fesoterodine fumarate|4mg tablets OD for 12 weeks
79838465|NCT02558348|Drug|AL3818|Administered orally
79838466|NCT00762398|Device|Masimo hemoglobin-meter|Placing a probe on the finger
79838467|NCT00762398|Biological|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
79838468|NCT00760136|Procedure|Computed Tomography|CT imaging of bilateral knee
79381685|NCT02472678|Other|Standard care|The control group will receive standard care.
79381686|NCT00550732|Drug|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
79381687|NCT03311100|Other|immunohistochemistry assay|biomarkers expression
79381688|NCT03311022|Drug|Nefopam Hydrochloride 30mg Tablets|
79381689|NCT03311022|Drug|Acupan® 30mg Tablets|
79381690|NCT03310866|Device|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
80009195|NCT02778074|Behavioral|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
80009196|NCT00911183|Biological|filgrastim|Given subcutaneously
80009197|NCT00911183|Biological|pegfilgrastim|Given subcutaneously
80009198|NCT00911183|Biological|rituximab|Given IV
79536274|NCT05263063|Other|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
79838469|NCT04552886|Biological|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
80009199|NCT00911183|Drug|cyclophosphamide|Given IV
80009200|NCT00911183|Drug|liposome-encapsulated doxorubicin citrate|Given IV
80009201|NCT00911183|Drug|prednisone|Given orally
80009202|NCT00911183|Drug|vincristine sulfate|Given IV
80009203|NCT05414435|Behavioral|Reading of informed consent form|Patients that adequately read informed consent forms
80009204|NCT05056805|Other|Aerobic Exercise|Receive aerobic exercise encouragement
79242107|NCT03411603|Other|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
79242108|NCT02361242|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
79381691|NCT03310866|Device|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
79381692|NCT02469480|Drug|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
79381693|NCT02469480|Drug|Ferro sanol|200 mg ferro sanol per day over 12 weeks
79381694|NCT03313284|Procedure|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
79381695|NCT03313284|Procedure|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
79838470|NCT00762632|Drug|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
79838471|NCT00762632|Drug|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
79838472|NCT00322387|Drug|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
79838473|NCT00561015|Drug|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
79838474|NCT00561015|Drug|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
79838475|NCT00561015|Drug|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
79838476|NCT00945087|Other|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
79838477|NCT00560937|Drug|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
79381696|NCT03313284|Procedure|Control|No intervention
79381697|NCT02469402|Dietary Supplement|Standard infant formula|
79381698|NCT02469402|Dietary Supplement|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
79838478|NCT00560937|Drug|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
79838479|NCT00945165|Behavioral|Exercise intervention|various exercise characteristics
79838480|NCT00945165|Behavioral|No exercise|No exercise control period
79242109|NCT02520687|Dietary Supplement|Beetroot juice|200mls daily for seven days
79242110|NCT02520687|Dietary Supplement|Nitrate-depleted beetroot juice|200mls daily for seven days
79242111|NCT02356328|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
79242112|NCT03397407|Other|No intervention|
79242113|NCT04695873|Device|Corn Foam Cushion|An anatomically shaped foam pad with a central hole. The upper layer is made from a honeycomb of interconnecting cells, the external facing surface is smooth, the underside is coated with adhesive.
79242114|NCT02361086|Drug|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
79838481|NCT04012437|Device|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
79838482|NCT04012437|Behavioral|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
80009205|NCT05056805|Other|Dietary Intervention|Consume high protein snack/meal/shake
80009206|NCT05056805|Other|Nutritional Intervention|Receive nutritional consultation and guidelines
80009207|NCT05056805|Other|Quality-of-Life Assessment|Ancillary studies
80009208|NCT05056805|Other|Questionnaire Administration|Ancillary studies
80009209|NCT05056805|Other|Resistance Training|Complete strengthening exercise
80009210|NCT03631121|Drug|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
80009211|NCT01568489|Drug|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
80009212|NCT03392519|Other|Chronic stroke|MRI data acquisition and behavioral test
79838483|NCT00945399|Procedure|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
79838484|NCT00945399|Procedure|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
79838485|NCT00941187|Other|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
80009213|NCT05023226|Procedure|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
79242115|NCT03411525|Behavioral|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
79242116|NCT03411525|Other|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
79242117|NCT01345253|Drug|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
79242118|NCT01345253|Drug|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
79242119|NCT02038712|Dietary Supplement|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
79381699|NCT02274844|Behavioral|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
79381700|NCT05736094|Device|SURF|Dual-frequency ultrasound
79536275|NCT05223673|Biological|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
79838486|NCT04012359|Diagnostic Test|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
79838487|NCT04012359|Diagnostic Test|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
79242120|NCT02038712|Dietary Supplement|Fasted condition|Subjects will consume 600mL plain water.
79242121|NCT02038712|Procedure|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
79381701|NCT03656016|Device|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
79536276|NCT05223673|Drug|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
79838488|NCT04012359|Diagnostic Test|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
79838489|NCT04012359|Other|Clinical examination|Standard clinical examination performed by investigating physician
79536277|NCT05223673|Drug|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
79536278|NCT05221944|Other|Patients had a history of antithrombotic therapy|Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.
79242122|NCT02038712|Behavioral|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
79381702|NCT03304938|Drug|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
79381703|NCT03304938|Drug|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
79381704|NCT03310554|Procedure|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
79381705|NCT03310554|Procedure|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
79838490|NCT04012047|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
79838491|NCT04012047|Drug|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
79838492|NCT00941265|Drug|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
79838493|NCT00941265|Drug|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
80009214|NCT05023226|Procedure|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight [PBW]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
79536279|NCT05221944|Other|Patients had no history of antithrombotic therapy|Patients had no history of antithrombotic therapy
79536280|NCT05215197|Drug|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
80009215|NCT01568567|Dietary Supplement|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
79242123|NCT02038712|Procedure|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
79242124|NCT03411447|Other|Parenteral nutrition|
79242125|NCT03411447|Other|Enteral nutrition|
79242126|NCT03411135|Other|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
79242127|NCT03640715|Other|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
79242128|NCT02351726|Device|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
79242129|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
79242130|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
79242131|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
79838494|NCT00941343|Drug|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
79242132|NCT01065077|Drug|Placebo|Infusion of placebo during 48h
79242133|NCT03397329|Drug|AG-348 Sequence A|"Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~Washout Period 7 days~Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
79242134|NCT03397329|Drug|AG-348 Sequence B|"Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~Washout Period 7 days~Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
79242135|NCT03150134|Drug|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
79536281|NCT05209191|Behavioral|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
79536282|NCT05203198|Behavioral|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
79242136|NCT03150134|Drug|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
79242137|NCT02351648|Other|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
79536283|NCT05194267|Device|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
79536284|NCT05188196|Procedure|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
79536285|NCT05168163|Biological|Atezolizumab|Given IV
79838495|NCT00561795|Drug|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
79838496|NCT00561795|Drug|carboplatin|IV over one hour every 3 weeks of 6 cycles
80009216|NCT03542162|Biological|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
79242138|NCT02351648|Other|Control|Patients receive usual standard of care from the internal medicine team
79242139|NCT03411057|Behavioral|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
79242140|NCT03411057|Other|Control|Standard of care including an educational video.
79242141|NCT02356094|Procedure|Pentacam|Corneal topography using Scheimpflug Pentacam examination
79242142|NCT03411369|Dietary Supplement|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
79242143|NCT03411369|Other|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
79536286|NCT05168163|Drug|Cabozantinib|Given PO
79536287|NCT05168163|Drug|Lenvatinib|Given PO
79536288|NCT05122182|Drug|Candesartan Cilexetil|Angiotensin Receptor Blocker (ARB)
79536289|NCT05122182|Drug|Repagermanium|C-C chemokine receptor type 2 (CCR2) antagonist
80009217|NCT05420597|Drug|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
80009218|NCT02775344|Device|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
79838497|NCT00561795|Drug|paclitaxel|IV 175 mg/m^2 given over 3 hours on day one of a 21 day cycle for six cycles
80009219|NCT05420441|Device|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
80009220|NCT05420441|Device|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
79242144|NCT03160352|Other|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
79242145|NCT04653207|Other|Glucose Solution 1|50g glucose dissolve in 300ml of water
79242146|NCT04653207|Other|Glucose Solution 2|50g glucose dissolve in 300ml of water
79242147|NCT04653207|Other|Glucose Solution 3|50g glucose dissolve in 300ml of water
79381706|NCT03310554|Procedure|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
79381707|NCT03310476|Other|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
79381708|NCT03310398|Behavioral|NeuroImaging|standard anatomical and functional imaging
79536290|NCT05122182|Drug|Candesartan Placebo|Angiotensin Receptor Blocker (ARB) placebo
79838498|NCT00652626|Drug|azacitidine|
79838499|NCT00941421|Device|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
79838500|NCT00560703|Drug|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
80009221|NCT05420441|Procedure|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
80009222|NCT05598593|Drug|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
79242148|NCT04653207|Other|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
79242149|NCT04653207|Other|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
79242150|NCT04653207|Other|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
79242151|NCT04653207|Other|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
79242152|NCT04653207|Other|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
79536291|NCT05122182|Drug|Repagermanium Placebo|C-C chemokine receptor type 2 (CCR2) antagonist placebo
79536292|NCT05113784|Drug|Meplazumab for Injection|humanized antibody target CD147
79242153|NCT04653207|Other|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
79242154|NCT03411291|Device|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
79242155|NCT02355782|Biological|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
79242156|NCT02351804|Drug|Ropivacaine + dexamethasone|Adductor canal block, single bolus
79242157|NCT02351804|Drug|Ropivacaine + placebo|Adductor canal block, single bolus
79381709|NCT03310398|Behavioral|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
79381710|NCT00550420|Drug|Rosiglitazone XR|experimental drug
79381711|NCT03312972|Radiation|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
79381712|NCT03312894|Drug|TAK-653|TAK-653 tablets
79381713|NCT03312894|Drug|Placebo|Placebo-matching tablets
79536293|NCT05113784|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
79536294|NCT05113186|Drug|Lenvatinib Pill|"The design of study is summarized as follows:~Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
79536295|NCT05086627|Drug|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
79536296|NCT05086627|Radiation|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
79838501|NCT00560703|Drug|placebo|sugar capsule
79838502|NCT00308737|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
79838503|NCT00308737|Drug|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
79838504|NCT04711902|Drug|Secukinumab (AIN457)|Biological
79838505|NCT04711902|Other|Secukinumab Placebo|Matching placebo
79838506|NCT00941499|Drug|HAI Oxaliplatin|140 mg/m^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
79838507|NCT00941499|Drug|5-FU|900-1750 mg/m^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
79838508|NCT00941499|Drug|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
80009223|NCT01569269|Behavioral|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
80009224|NCT01569269|Behavioral|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
80009225|NCT01569269|Behavioral|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
79242158|NCT03411213|Device|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
79242159|NCT03149900|Drug|Secukinumab|See Arm Description
79242160|NCT03410979|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
79381714|NCT00559936|Drug|Topical Avastin 1%|Avastin (bevacizumab) 1%
79381715|NCT03304860|Other|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
79381716|NCT03304782|Other|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
79242161|NCT03410979|Drug|Placebo single dose|Placebo, oral suspension.
79536297|NCT05086627|Drug|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
79242162|NCT03410979|Drug|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
79242163|NCT03410979|Drug|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
79242164|NCT02356016|Behavioral|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
79242165|NCT02356016|Behavioral|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
79536298|NCT05074420|Drug|Baricitinib|Given Orally
79536299|NCT05069597|Drug|CREON|Capsule; Oral
79536300|NCT05058391|Biological|Elaprase|Participants will receive a single dose of Elaprase 0.5 mg/kg intravenous infusion every week on Day 1.
79536301|NCT05052983|Drug|Nemolizumab|Participants will receive either 1 [30 milligram (mg)] or 2 (2×30 mg) subcutaneous injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
79536302|NCT05052983|Drug|Placebo|Participants will receive either 1 (30 mg) or 2 (2x30 mg) subcutaneous injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
79536303|NCT05048173|Procedure|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
79536304|NCT05048173|Procedure|Lymphadenectomy|Conventional lymphadenectomy
79536305|NCT05036252|Diagnostic Test|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
79536306|NCT05036252|Diagnostic Test|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
79536307|NCT05036252|Diagnostic Test|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
79838509|NCT00941499|Drug|Cetuximab|Loading dose of 250-500mg/m^2 and Maintenance dose of 125-250 mg/m^2 by vein on Day 1 of 21 day cycle.
79838510|NCT00941499|Drug|Leucovorin|200 mg/m^2 by vein on Days 1 and 2 of each 21 day cycle.
79242166|NCT02356016|Other|control (dietary counseling)|Monthly dietary counseling only
79242167|NCT02355860|Behavioral|assessment|assessment
79381717|NCT04768738|Device|Auricular Vagus Nerve Stimulation Level Of Above Threshold|Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
80009226|NCT01569269|Other|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
80009227|NCT02777918|Behavioral|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
80009228|NCT05337449|Other|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
79381718|NCT04768738|Device|Auricular Vagus Nerve Stimulation Level Of Subthreshold|biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
80009229|NCT05337449|Other|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
80009230|NCT02156414|Procedure|Radical Prostatectomy|Radical Prostatectomy
79381719|NCT04768738|Device|Auricular Vagus Nerve Stimulation Sham Method|Participants were shown that the device was working, but no current was given.
80009231|NCT02156414|Procedure|Extended Lymphadenectomy|Extended Lymphadenectomy
79242168|NCT03640403|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
79242169|NCT03640403|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
79838511|NCT00941499|Drug|5-FU|300-400 mg/m^2 bolus + 600-1000 mg/m^2 infusion over 22 hours on Days 1-2 of each cycle.
79242170|NCT03126357|Other|Product A|Usual Brand Cigarette
79242171|NCT03126357|Other|Product B|FT21039 an electronic tobacco vapor product
79242172|NCT03126357|Other|Product C|FT21092 an electronic tobacco vapor product
79242173|NCT03126357|Other|Product D|FT21018 an electronic tobacco vapor product
79242174|NCT03126357|Other|Product E|4mg nicotine gum
79242175|NCT02477800|Drug|Aducanumab (BIIB037)|Low dose
79242176|NCT02477800|Drug|Aducanumab (BIIB037)|High dose
79242177|NCT02477800|Drug|Placebo|Placebo
79242178|NCT02361398|Other|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
79242179|NCT02355938|Drug|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
79536308|NCT05034913|Other|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
79242180|NCT02355938|Drug|Placebo|1 dose of placebo every 6 hours x 2 doses
79242181|NCT02355938|Drug|Vancomycin|Vancomycin 125 mg every 6 hours
79242182|NCT03397173|Drug|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
79242183|NCT03397173|Drug|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
79381720|NCT04768738|Diagnostic Test|5 Minutes Bicycle Exercise|Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
79381721|NCT03312816|Other|cookies enriched with POP|Cookies
79381722|NCT03310320|Drug|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
79381723|NCT03310320|Drug|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
79381724|NCT05721118|Diagnostic Test|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
79536309|NCT05034822|Drug|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
79838512|NCT00941499|Drug|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
79838513|NCT04752384|Drug|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
80009232|NCT02150720|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
80009233|NCT02150720|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
80009234|NCT02150720|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
80009235|NCT04835714|Drug|BI 1701963|BI 1701963
80009236|NCT04835714|Drug|BI 3011441|BI 3011441
80009237|NCT05234957|Procedure|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
80009238|NCT02150798|Other|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
80009239|NCT02150798|Other|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
80009240|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
79693158|NCT04763746|Device|Lifelight Data Collect Sub-protocol 1|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets."
79838514|NCT04752384|Drug|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
80009241|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
79838515|NCT04752384|Device|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
79838516|NCT00941577|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
80009242|NCT02153138|Device|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
79242184|NCT02957747|Behavioral|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
79381725|NCT03304548|Other|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
79381726|NCT05353192|Drug|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
79381727|NCT03310242|Behavioral|Sunlight Exposure|"Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~Completing a Sun Diary after sunlight exposure"
79381728|NCT03310242|Dietary Supplement|Vitamin D Supplementation|- Supplementation of vitamin D3 500 IU/day for 8 weeks
79838517|NCT00941577|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
79838518|NCT00945789|Drug|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
79381729|NCT03310242|Other|Placebo|- Intake of placebo for 8 weeks
79838519|NCT00945789|Procedure|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
79838520|NCT00945789|Biological|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
79838521|NCT04737096|Drug|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
79838522|NCT04737096|Drug|Placebo|placebo
79242185|NCT02360852|Drug|A4250|A4250 once daily
79242186|NCT03126279|Procedure|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
79381730|NCT00557128|Drug|COREG CR and lisinopril (FDC)|
79381731|NCT05341492|Biological|EGFR/B7H3 CAR-T|2 × 10^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
79838523|NCT04737096|Device|tDCS|tDCS
79838524|NCT00941811|Drug|Imiquimod|Local Imiquimod three times weekly for 16 weeks
79838525|NCT04725006|Device|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
79242187|NCT02361008|Device|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
79381732|NCT03312660|Dietary Supplement|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
79381733|NCT03312660|Dietary Supplement|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
79381734|NCT03312582|Drug|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
79693159|NCT04763746|Device|Lifelight Data Collect Sub-protocol 2|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.~This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets."
79838526|NCT02553018|Drug|Methotrexate|
79838527|NCT00950079|Drug|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
79838528|NCT00950079|Drug|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
79838529|NCT00941967|Drug|gemcitabine hydrochloride|Given IV
79838530|NCT00941967|Drug|oxaliplatin|Given IV
79838531|NCT00941967|Drug|sorafenib tosylate|Given orally.
79838532|NCT00655746|Drug|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
79838533|NCT00338455|Drug|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
79838534|NCT00338455|Drug|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
79838535|NCT00950157|Other|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
80009243|NCT02153138|Device|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
79242188|NCT02361008|Procedure|Surgery repair with CBP|Traditional surgery repair under the CBP.
79242189|NCT03397095|Combination Product|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
79242190|NCT03397095|Device|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
79242191|NCT03640247|Drug|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
79536310|NCT05024058|Drug|Ligelizumab|Ligelizumab treated groups and arms
79242192|NCT03640247|Drug|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
79242193|NCT03396939|Device|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
79242194|NCT03640169|Other|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
79242195|NCT03394131|Drug|Hylase|hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline
79536311|NCT05024058|Other|Placebo|Placebo treated groups and arms
79536312|NCT05013008|Drug|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
79536313|NCT05013008|Drug|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
79536314|NCT05011188|Biological|FOR46|Given intravenously (IV)
79838536|NCT00806208|Drug|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
79838537|NCT00806208|Drug|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
79838538|NCT00806208|Drug|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
79242196|NCT03394131|Drug|Insulin|hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline
79242197|NCT03394131|Other|saline|hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
79242198|NCT02360618|Drug|Metformin|See Group Description
79242199|NCT02360618|Drug|Simvastatin|See Group Description
79381735|NCT03312582|Procedure|Placebo|
79536315|NCT05011188|Biological|Enzalutamide|Given orally (PO)
79838539|NCT00806208|Drug|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
79838540|NCT00806208|Other|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
79838541|NCT00942045|Biological|Biologic - Osteocel Plus|Osteocel Plus
80009244|NCT02153138|Device|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
80009245|NCT03542864|Dietary Supplement|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
80009246|NCT03542864|Other|Control|Progress registration of body composition values
79381736|NCT03304470|Drug|ATx201 2% Cream|Anhydrous Cream
79381737|NCT03304470|Drug|ATx201 Cream Vehicle|Anhydrous Cream
79381738|NCT04350580|Drug|Human immunoglobulin|Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
79381739|NCT04350580|Drug|Placebo|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
80009247|NCT03542864|Other|Data analysis|Statistical analysis of all data
79536316|NCT05011188|Drug|Pegfilgrastim|6mg given subcutaneously (subQ)
79693160|NCT04763746|Device|Lifelight Data Collect Sub-protocol 3|"The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.~This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets."
79838542|NCT05301309|Behavioral|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
79838543|NCT00651924|Behavioral|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
79838544|NCT00804258|Drug|intraperitoneal chemotherapy|
79536317|NCT05002387|Device|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
79838545|NCT00804258|Other|educational intervention|
79838546|NCT00804258|Other|medical chart review|
79838547|NCT00804258|Other|questionnaire administration|
79838548|NCT00804258|Procedure|assessment of therapy complications|
79838549|NCT00804258|Procedure|end-of-life treatment/management|
79838550|NCT00804258|Procedure|psychosocial assessment and care|
79838551|NCT00804258|Procedure|quality-of-life assessment|
79381740|NCT03312504|Other|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
79242200|NCT03640091|Procedure|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
79838552|NCT00950313|Other|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
79838553|NCT00950313|Other|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
79838554|NCT00678392|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
79838555|NCT00678392|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
79838556|NCT00950391|Drug|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
79838557|NCT00804336|Drug|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
79242201|NCT02360462|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
79242202|NCT02360462|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
79242203|NCT01344161|Dietary Supplement|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
79391430|NCT02422680|Procedure|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
79536318|NCT05001269|Drug|nedosiran|Monthly subcutaneous dosing throughout study period
79536319|NCT04992299|Behavioral|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
79536320|NCT04992299|Behavioral|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
79536321|NCT04992299|Behavioral|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
79536322|NCT04945486|Other|Peer-mentor intervention|Peer-mentor support for up to 6 months
79536323|NCT04936022|Other|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
79838558|NCT00804336|Drug|RAD001|Given orally once a day
79838559|NCT00942201|Drug|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
79242204|NCT01344161|Dietary Supplement|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
79838560|NCT00942201|Drug|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
79838561|NCT00804414|Drug|SBG|Solution for topical use
79838562|NCT00804414|Drug|Placebo Comparator|Solutin for topical use
79838563|NCT00942435|Drug|YM150|oral
79838564|NCT00942435|Procedure|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
79838565|NCT05301075|Drug|Rhomboid Intercostal and Sub-Serratus block|Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
79838566|NCT00950547|Device|CARDIOPAT|Cell Saver System at bedside for ICU stay
79838567|NCT00950547|Device|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
79838568|NCT00946179|Biological|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
79838569|NCT00946257|Drug|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
79536324|NCT04936022|Behavioral|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
79536325|NCT04935671|Dietary Supplement|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
79242205|NCT02360540|Other|Gestalt estimation|
79242206|NCT03410745|Behavioral|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
79536326|NCT04917861|Biological|mRNA-1893|Solution for injection
79536327|NCT04917861|Biological|Placebo|0.9% sodium chloride solution for injection
79536328|NCT04905849|Behavioral|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
79536329|NCT04905849|Behavioral|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
79536330|NCT04895956|Procedure|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
79242207|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
79536331|NCT04895956|Procedure|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
79242208|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
79536332|NCT04895956|Device|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
79536333|NCT04888767|Other|Interval Training Hight Intensity Program|"Rehabilitation stay in hospitalization with 18 days of training sessions~Training on an ergometer~Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
79536334|NCT04883827|Other|Blood collection|20-40 mL of blood to extract cell free DNA
79381741|NCT03312504|Other|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
79536335|NCT04883827|Other|Urine collection|up to 15 mL of urine to extract cell free DNA
79391431|NCT02466646|Drug|Klorhex® Gel, rinse and spray|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
79693161|NCT04763746|Device|Lifelight Data Collect Sub-protocol 4|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.~Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets."
79838570|NCT00950625|Drug|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
79838571|NCT00950625|Drug|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
79242209|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
79242210|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
79242211|NCT04754373|Dietary Supplement|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
79242212|NCT04754373|Other|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
79242213|NCT02360384|Drug|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
79242214|NCT02360384|Dietary Supplement|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
79242215|NCT03396861|Drug|Aflibercept|Subconjunctival aflibercept
79391432|NCT02466646|Procedure|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
80009248|NCT01383239|Other|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
80009249|NCT01383239|Other|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
80009250|NCT02156570|Drug|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
79838572|NCT00942513|Other|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
79838573|NCT00942513|Other|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
80009251|NCT05208749|Device|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
80009252|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
80009253|NCT05188547|Device|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
80009254|NCT02153294|Procedure|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
79693162|NCT04757922|Procedure|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
79838574|NCT00942513|Other|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
80009255|NCT02153294|Procedure|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
80009256|NCT05598437|Device|Dry eye device|Dry eye analysis
80009257|NCT02153372|Other|BMC2012|
79242216|NCT03410589|Other|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
79242217|NCT04924972|Procedure|Blepharoplasty|90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
79242218|NCT03149744|Device|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
79242219|NCT02520843|Drug|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
79242220|NCT02749721|Drug|vortioxetine|Open-label vortioxetine
79242221|NCT02351336|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~- CL measurement using 2D ultrasound ( in cm)"
79242222|NCT03396627|Diagnostic Test|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
79242223|NCT02351102|Drug|Valacyclovir|
79242224|NCT02351102|Drug|Placebo|
79693163|NCT04747834|Device|MICOR-304|The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.
80009258|NCT02767856|Device|IO-therapy Glasses|
80009259|NCT03087851|Drug|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
80009260|NCT02156726|Drug|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
80009261|NCT02153450|Drug|metformin hydrochloride|Given PO
80009262|NCT02153450|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
80009263|NCT05598281|Drug|AMG 510|Oral tablet
80009264|NCT05598281|Drug|Digoxin|Oral tablet
80009265|NCT03979417|Other|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
80009266|NCT03956407|Device|Repetitive peripheral nerve stimulation|Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
80009267|NCT03956407|Device|Sham Repetitive peripheral nerve stimulation|Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
80009268|NCT03092375|Drug|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
80009269|NCT03092375|Drug|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
80016801|NCT02280668|Other|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
80009270|NCT04983485|Other|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
80009271|NCT01995513|Drug|Enzalutamide|160 mg by mouth once daily
80009272|NCT01995513|Drug|Abiraterone|1000 mg by mouth once daily
80009273|NCT01995513|Drug|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
79381742|NCT02469324|Behavioral|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
80009274|NCT01995513|Drug|Prednisone|5 mg by mouth twice daily
79242225|NCT03393897|Other|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
79242226|NCT03393897|Other|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
79242227|NCT02350868|Drug|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
79381743|NCT02469324|Behavioral|Compassionate Mind Training|see above
79381744|NCT03310086|Device|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
79381745|NCT03310086|Procedure|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
79536336|NCT04869085|Behavioral|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
79693164|NCT04742439|Device|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
79693165|NCT04742439|Device|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
79693166|NCT04742439|Device|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
79242228|NCT02351024|Drug|OXP005|
79242229|NCT02351024|Drug|Naprosyn®|
79305733|NCT04929639|Other|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
79381746|NCT03310008|Biological|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
80009275|NCT04953377|Behavioral|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
80009276|NCT05038761|Device|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
80009277|NCT05038761|Procedure|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
80009278|NCT05598125|Device|electronic cigarette (e-cigarette)|
80009279|NCT05598125|Device|conventional tobacco cigarette|
80009280|NCT03180359|Biological|Recommended vaccine scheme according to French Vaccine Schedule 2015|"BCG~Measles mumps rubella (MMR)~Varicella (chicken pox)~Rotavirus~Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~Yellow Fever~Diphteria tetanus poliomyelitis whopping cough (DTwP)~Haemophilus influenzae type b~Hepatitis B~Meningococcus conjugate~Pneumococcus~Human papillomavirus~Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
80009281|NCT00948129|Other|Laboratory Biomarker Analysis|Correlative studies
80009282|NCT00948129|Behavioral|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
80009283|NCT00948129|Behavioral|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
80009284|NCT00948129|Other|Tobacco Cessation Counseling|Undergo smoking cessation counseling
80009285|NCT01382771|Drug|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
79305734|NCT04431531|Other|10 Sessions of yogatherapy associate with EMDR|The first group will have Yogatherapy plus EMDR treatment
79838575|NCT00942513|Other|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
79838576|NCT00942513|Other|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
80009286|NCT01382771|Drug|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
80009287|NCT04819451|Other|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
79838577|NCT00942513|Other|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
79838578|NCT00942513|Other|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
80009288|NCT02927171|Other|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
80009289|NCT04933253|Procedure|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
79536337|NCT04826900|Procedure|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
80009290|NCT04878419|Other|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
79242230|NCT04631367|Behavioral|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
79242231|NCT04631367|Device|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
79242232|NCT02355704|Drug|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
79693167|NCT04742439|Device|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
79693168|NCT04734106|Drug|Desert Harvest Aloe Vera Capsules|600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
79693169|NCT04734106|Other|Placebo Capsules|550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
80009291|NCT01382693|Behavioral|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
80009292|NCT01382693|Behavioral|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
80009293|NCT01304511|Drug|Orgalutran|
79242233|NCT02355704|Drug|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
79242234|NCT03396549|Device|new sham tDCS|1 ch TCT transcranial stimulator
79242235|NCT03396549|Device|real tDCS|1 ch TCT transcranial stimulator
79242236|NCT02355548|Other|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
79242237|NCT03396393|Drug|Dihydroartemisinin tablet|DHA tablet
79242238|NCT03396393|Drug|Placebo tablet|Placebo tablet
79242239|NCT02355470|Behavioral|GIFTSS|Universal education and brief counseling regarding sexual violence
79305735|NCT04431531|Other|The second group will have EMDR without yogatherapy|the second one will have EMDR treatment
79693170|NCT04729413|Behavioral|Couples Counseling|Psychoeducational counseling on relationships and maternal and child health in the context of HIV.
79693171|NCT04729413|Other|Enhanced Standard of Care|Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
79838579|NCT04049318|Other|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
79838580|NCT04049630|Drug|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
79693172|NCT04727944|Other|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
79838581|NCT04049630|Drug|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
79838582|NCT04049630|Drug|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
79838583|NCT04049630|Drug|Placebo|5 tablets of placebo will be administrated to the participants.
79838584|NCT00942591|Drug|Interferon beta 1b|
79381747|NCT03304392|Behavioral|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
79242240|NCT02355470|Behavioral|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
79242241|NCT03393819|Drug|DuraPrep|DuraPrep surgical solution
79242242|NCT03393819|Drug|ChloraPrep|ChloraPrep surgical solution
79242243|NCT03393663|Other|CKD-related outcomes|the study is observational
79381748|NCT03304392|Behavioral|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
79536338|NCT04826900|Other|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
79838585|NCT00942591|Drug|Atorvastatin|
79838586|NCT02559362|Behavioral|Survey|
79838587|NCT00950781|Procedure|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
79838588|NCT00946335|Drug|veliparib|Given PO
79838589|NCT00946335|Drug|temozolomide|Given PO
79838590|NCT00946335|Other|pharmacological study|Correlative studies
79838591|NCT00946335|Other|laboratory biomarker analysis|Correlative studies
79242244|NCT03619187|Drug|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
79242245|NCT02360306|Procedure|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
79242246|NCT03393585|Other|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
79242247|NCT02360150|Radiation|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
79242248|NCT02355392|Other|Telemedical home blood pressure measurements|
79242249|NCT03393507|Drug|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
79242250|NCT03393507|Drug|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
79242251|NCT01348139|Drug|AZD3199|Inhaled via single inhaler device (SID)
79381749|NCT00558064|Drug|telmisartan+amlodipine|
79381750|NCT00558064|Drug|amlodipine|
79381751|NCT03309930|Behavioral|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
79838592|NCT00760370|Drug|Zoledronic Acid|4 mg intravenous (iv), one treatment
79838593|NCT00762944|Device|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
79693173|NCT04727944|Other|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
79838594|NCT00763022|Drug|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
79838595|NCT00763022|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
80009294|NCT03087617|Device|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
79242252|NCT01348139|Drug|AZD3199|Inhaled via Turbuhaler inhaler
79242253|NCT01348139|Other|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
79381752|NCT03312426|Drug|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
79381753|NCT03309774|Diagnostic Test|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~Questionnaire KIDSCREEN 52~Visual Analogue Scale (EVA)~Neuropathic Pain 4 (DN4)~Pain of the child Gustave Roussy (DEGR)"
79381754|NCT03309774|Diagnostic Test|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
79536339|NCT04826900|Other|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
80009295|NCT03087617|Behavioral|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
80009296|NCT03087617|Other|Usual Care|Usual Care for Lung Cancer Screening patients.
79381755|NCT03309774|Diagnostic Test|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
79381756|NCT03309774|Other|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
79536340|NCT04826900|Other|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
79536341|NCT04819906|Drug|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
80009297|NCT00103610|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
79381757|NCT03304158|Behavioral|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
79381758|NCT03312192|Device|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
79381759|NCT03312192|Device|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
79391433|NCT02466646|Procedure|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
79693174|NCT04712851|Biological|Pembrolizumab|Given IV
79693175|NCT04702425|Drug|VOB560|Powder for concentrate for solution for infusion
79693176|NCT04702425|Drug|MIK665|Concentrate for solution for infusion
79693177|NCT04700124|Biological|Pembrolizumab|200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
79242254|NCT02359760|Procedure|Piezocision|Flapless corticotomies
79838596|NCT00763022|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
79838597|NCT00760448|Drug|insulin detemir|
79838598|NCT00760448|Drug|insulin NPH|
80016802|NCT02280668|Other|the eccentric muscle damage exercise|
80016803|NCT02094378|Drug|Esketamine|84 mg esketamine administered intranasally
79242255|NCT03393429|Other|DAVID assisted training|DAVID device assisted training under supervision
79242256|NCT03393429|Other|training recommendation|"training recommendation to stay active"
79242257|NCT02355236|Drug|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
79242258|NCT02355236|Drug|Celecoxib 200mg|Capsule, o.d.
79242259|NCT02355236|Drug|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
79242260|NCT02355236|Drug|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
79305736|NCT04929561|Behavioral|Video-conferencing group|No intervention
79536342|NCT04819906|Drug|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
79838599|NCT04392284|Behavioral|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting ~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
80009298|NCT00103610|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
80009299|NCT01568801|Behavioral|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
80009300|NCT02151188|Dietary Supplement|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
80009301|NCT02151188|Device|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
80009302|NCT05597579|Diagnostic Test|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
80009303|NCT02156960|Drug|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
80009304|NCT02156960|Drug|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
79242261|NCT03393351|Other|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~shared decision-making trainings for health care professionals,~individual coaching for physicians,~patient activation strategy,~provision of patient information material and decision aids,~revision of the clinics quality management documents, and~critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
79242262|NCT03393351|Other|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
79242263|NCT03619031|Other|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
79242264|NCT03619031|Other|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
79242265|NCT03619031|Other|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
79242266|NCT05196867|Behavioral|Intervention Group|Participants in the intervention group will receive (1) weekly telephone or videoconference coaching; (2) health education print materials and tip sheets;(3) navigation to programs and resources to help participants meet behavioral goals (e.g., fitness events, classes and webinars, etc); (4) text messages related to behavioral skills; (5) a Fitbit activity tracker and Aria scale; (6) resistance tubes and instructional video for strengthening exercise (if resistance exercise module is chosen); and (7) tools to manage portion sizes.
79381760|NCT03304002|Other|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
79381761|NCT03312036|Device|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
79381762|NCT02468622|Other|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
79381763|NCT03309618|Drug|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
79536343|NCT04819906|Drug|Placebo|Five placebo tablets orally once
79536344|NCT04819906|Drug|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
79536345|NCT04809766|Biological|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
79536346|NCT04809766|Drug|Cyclophosphamide|Given IV
79536347|NCT04809766|Drug|Fludarabine|Given IV
79536348|NCT04809766|Drug|Bendamustine|Given IV
79536349|NCT04785287|Biological|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
79536350|NCT04785287|Biological|Nivolumab|Given IV
79536351|NCT04785287|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79536352|NCT04780269|Device|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
80009305|NCT02156960|Drug|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
80009306|NCT03630965|Other|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
80009307|NCT02153606|Drug|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
80009308|NCT02153606|Other|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
80009309|NCT03631511|Procedure|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
79536353|NCT04780269|Drug|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
79693178|NCT04700124|Biological|Enfortumab vedotin (EV)|1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
79536354|NCT04769323|Device|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
79838600|NCT04392284|Behavioral|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting ~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
79242267|NCT05196867|Behavioral|Control Group|Patients in the control arm will initially receive written education material about the risk factors for liver cancer and management options. They will be offered the intervention after they complete the 6-month assessment.
79536355|NCT04769323|Other|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
79536356|NCT04742907|Drug|TU-100|Treatment with investigational product
79536357|NCT04742907|Drug|Placebo|Treatment with placebo product
79693179|NCT04700124|Procedure|RC + PLND|Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
79838601|NCT00760604|Procedure|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
79536358|NCT04735926|Drug|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
79693180|NCT04700124|Drug|Gemcitabine|1000 mg/m^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
79693181|NCT04700124|Drug|Cisplatin|70 mg/m^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
79693182|NCT04698876|Procedure|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
79693183|NCT04698876|Procedure|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
79693184|NCT04698876|Procedure|Blood pressure|Blood pressure measurement for 24 h
79693185|NCT04682197|Device|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
79242268|NCT02359682|Other|No intervention|No Intervention
79242269|NCT05169255|Drug|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
79242270|NCT02359604|Drug|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
79536359|NCT04735926|Drug|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
79536360|NCT04735926|Drug|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
79838602|NCT00763178|Drug|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
79242271|NCT02359604|Procedure|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
79242272|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
79242273|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
79381764|NCT03309618|Drug|placebo|
79381765|NCT03303924|Drug|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
79391434|NCT02703636|Drug|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
79536361|NCT04735926|Other|Placebo|Soft gelatin capsule. Oral administration once per week.
79536362|NCT04735926|Other|Placebo|Soft gelatin capsule. Oral administration once per week.
80009310|NCT02157038|Device|Pedometer|
80009311|NCT02157038|Device|MRI|
79693186|NCT04681677|Radiation|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
79693187|NCT04681677|Drug|Bevacizumab|Bevacizumab
80009312|NCT02153762|Drug|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
80009313|NCT02153762|Drug|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
80009314|NCT04687631|Drug|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
79242274|NCT03410511|Other|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
79242275|NCT03410511|Other|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
79242276|NCT03410511|Other|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
79381766|NCT03309540|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
79381767|NCT03309462|Device|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
79381768|NCT03311880|Behavioral|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
79381769|NCT03303768|Diagnostic Test|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
79381770|NCT03311568|Device|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
79536363|NCT04721158|Device|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
79536364|NCT04693338|Other|Quality-of-Life Assessment|Ancillary studies
79536365|NCT04693338|Other|Questionnaire Administration|Ancillary studies
79536366|NCT04693338|Other|Supportive Care|Receive ICP tasks
79536367|NCT04625270|Drug|avutometinib (VS-6766)|avutometinib (VS-6766) monotherapy
79536368|NCT04625270|Drug|avutometinib (VS-6766) and defactinib|avutometinib (VS-6766) and defactinib combination
79536369|NCT04620811|Drug|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
79536370|NCT04619043|Device|Ankle Orthotic|
79536371|NCT04595825|Biological|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
79536372|NCT04595825|Other|Placebo|Placebo - intravenous infusion
79536373|NCT04595097|Device|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
79536374|NCT04594772|Drug|Folfirinox|Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).
79536375|NCT04594772|Drug|Gemcitabine|At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
79536376|NCT04594772|Radiation|radiation therapy|Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.
79693188|NCT04680065|Biological|AAV2-GDNF gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
80009315|NCT04687631|Drug|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
80009316|NCT02159300|Behavioral|experience brain activity recording|Intervention: experience brain activity recording
80009317|NCT05597501|Behavioral|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis&logotherapy
80016804|NCT02094378|Drug|Placebo|Placebo administered intranasally
79381771|NCT03311490|Device|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
79693189|NCT04680065|Procedure|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dural penetration
79536377|NCT04594772|Procedure|Pancreatectomy|Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
80009318|NCT04833023|Drug|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
80009319|NCT04833023|Drug|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
79381772|NCT00557830|Drug|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
79381773|NCT00557830|Drug|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
79536378|NCT04561206|Drug|Brentuximab Vedotin|Given IV
80009320|NCT02159378|Other|Fructosamines|
80009321|NCT02159456|Other|Continuous enteral feeding via infusion pump|
79536379|NCT04561206|Biological|Nivolumab|Given IV
79536380|NCT04536363|Drug|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
79693190|NCT04674813|Drug|CC-95266|Specified dose on specified days
79693191|NCT04674813|Drug|Fludarabine|Specified dose on specified days
79693192|NCT04674813|Drug|Cyclophosphamide|Specified dose on specified days
79693193|NCT04674813|Drug|Bendamustine|Specified dose on specified days
79693194|NCT04662515|Procedure|Type of surgery|surgical or non-surgical extraction one or more teeth
79381774|NCT05207202|Device|electrical impedance tomography|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
80009322|NCT02159456|Other|Intermittent enteral feeding via gravity-based infusion|
80009323|NCT03091439|Drug|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
79391435|NCT02419014|Device|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
79391436|NCT02419014|Device|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
79693195|NCT04662515|Drug|Dabigatran|
79693196|NCT04662515|Drug|Rivaroxaban|
79693197|NCT04662515|Drug|Apixaban|
79693198|NCT04662515|Drug|Edoxaban|
79693199|NCT04662515|Drug|Warfarin|
79693200|NCT04643457|Drug|UCB9741|- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
79693201|NCT04643457|Drug|Intravenous Placebo|- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
79693202|NCT04643457|Drug|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
80009324|NCT03091439|Drug|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
80009325|NCT02153840|Drug|PSORI-CM01（YXBCM01） granule|
80009326|NCT02153840|Drug|placebo|
80009327|NCT03631823|Other|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
79693203|NCT04626518|Biological|Pembrolizumab|Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
79693204|NCT04626518|Biological|MK-4830|Administered via IV infusion at a dose of 800 mg Q3W
79693205|NCT04626518|Drug|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
80009328|NCT02157272|Drug|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
79242277|NCT03126669|Device|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
79381775|NCT02468466|Behavioral|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
79381776|NCT02468466|Behavioral|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
79381777|NCT03304236|Device|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
79381778|NCT05080686|Device|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
79381779|NCT03303690|Procedure|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
79381780|NCT03309228|Other|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
79381781|NCT00557440|Drug|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
79381782|NCT00557440|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
79381783|NCT00557440|Drug|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
79381784|NCT00557440|Drug|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
79381785|NCT03303534|Dietary Supplement|ScandiShake|weight gain supplement low in protein
79381786|NCT03308994|Other|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
79381787|NCT03308994|Other|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
79381788|NCT03311178|Drug|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
79381789|NCT02469012|Drug|Combination #1|Sofosbuvir + Ribavirin
79693206|NCT04626518|Drug|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
79242278|NCT03126669|Device|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
79381790|NCT02469012|Drug|Combination #2|Sofosbuvir + Daclatasvir
79381791|NCT02469012|Drug|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
79381792|NCT02469012|Drug|Combination #4|Sofosbuvir + Ledipasvir
79381793|NCT02469012|Drug|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
79693207|NCT04626518|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
79693208|NCT04626518|Biological|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
79693209|NCT04624243|Drug|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
79693210|NCT04624243|Drug|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
79693211|NCT04624243|Drug|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
79242279|NCT02355314|Other|Doppler-based renal|Doppler-based renal : day 0 and day 3
79242280|NCT02355314|Biological|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
79242281|NCT02868229|Drug|COR-001|
79242282|NCT02868229|Other|Placebo|
79242283|NCT02355080|Behavioral|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
79242284|NCT02355080|Behavioral|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
79305737|NCT04934241|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
79305738|NCT04929093|Biological|Novel dose adjustment of Alutard SQ|novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
79381794|NCT02468856|Drug|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
79693212|NCT04624243|Drug|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
79693213|NCT04623554|Behavioral|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
79838603|NCT00760682|Procedure|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
80009329|NCT05597423|Other|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
80009330|NCT05597423|Other|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
79242285|NCT05169021|Drug|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
79242286|NCT05169021|Drug|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
79242287|NCT05169021|Drug|Amlodipine+intensive antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
79242288|NCT05169021|Drug|Amlodipine+standard antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~Add candesartan 4mg;~Add indapamide 2.5mg;~Increase dose of candesartan to 8mg;~Increase dose of amlodipine to 7.5mg-10mg."
79381795|NCT02468856|Drug|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
79381796|NCT03303456|Other|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
79381797|NCT05202106|Behavioral|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
79391437|NCT02422056|Drug|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
79391438|NCT02422056|Drug|Saline|Infusion of saline in the same rate used for the intervention group
79693214|NCT04621890|Behavioral|LOAN2DOSE and COIN2DOSE|This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
79693215|NCT04598399|Behavioral|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
79693216|NCT04598399|Behavioral|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
79693217|NCT04576117|Procedure|Biospecimen Collection|Undergo blood sample collection
79693218|NCT04576117|Procedure|Magnetic Resonance Imaging|Undergo MRI
79693219|NCT04576117|Other|Quality-of-Life Assessment|Ancillary studies
79693220|NCT04576117|Other|Questionnaire Administration|Ancillary studies
79693221|NCT04576117|Drug|Selumetinib Sulfate|Given PO
79693222|NCT04576117|Drug|Vinblastine Sulfate|Given IV
79242289|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI|
79242290|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI|
79242291|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
79242292|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
79242293|NCT02359292|Drug|Placebo pMDI|
79242294|NCT05168787|Drug|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
79242295|NCT05168553|Other|Revascualrization|Regain pulp vascularity for mature permenant teeth
79242296|NCT05168553|Other|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
80009331|NCT04729712|Procedure|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
79693223|NCT04570579|Device|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
79838604|NCT04351178|Behavioral|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
79838605|NCT04351178|Behavioral|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
79838606|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
79838607|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
79838608|NCT00308581|Other|Placebo|placebo administered 4-weekly in Active 1
80009332|NCT04729712|Procedure|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
80009333|NCT01382537|Device|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
80009334|NCT01382537|Device|InterX 5000|Placebo treatment
79242297|NCT02359214|Dietary Supplement|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
79381798|NCT05202106|Other|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
79693224|NCT04531904|Device|EMBOVAC Aspiration Catheter|The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature.
79693225|NCT04527926|Behavioral|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
79693226|NCT04527926|Behavioral|Usual Care|Standard of Care
79838609|NCT00678080|Drug|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
79838610|NCT00678080|Drug|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
79838611|NCT00658320|Drug|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
80009335|NCT02154074|Drug|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
80009336|NCT02154074|Drug|Isoflurane|inhale Isoflurane 1.5MAC
80009337|NCT02154074|Drug|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
80009338|NCT02154074|Drug|normal saline|the same volume of saline + Isoflurane during operation
80009339|NCT02154152|Drug|Homoeopathic Medicine causticum 200c|
80009340|NCT03086447|Device|Investigational Contact Lens|Senofilcon C Toric
80009341|NCT03086447|Device|Marketed Contact Lens|Air Optix for Astigmatism
79242298|NCT02359214|Other|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
79242299|NCT04480437|Device|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
79242300|NCT02359370|Drug|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
79242301|NCT02359370|Drug|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
79242302|NCT02956967|Other|Overall satisfaction questionnaires of home use of Nivestim|
79242303|NCT02359448|Drug|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
79305739|NCT04929093|Biological|conventional dose adjustment of Alutard SQ|conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
79381799|NCT03308760|Other|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
79838612|NCT00658320|Drug|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
79381800|NCT03308760|Other|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
79242304|NCT02359526|Drug|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
79242305|NCT03410433|Device|Silk 4.0|Silk suture 4.0
79381801|NCT03308760|Other|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
79381802|NCT03303378|Drug|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
79381803|NCT03303378|Drug|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
79536381|NCT04536363|Drug|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
79381804|NCT04491474|Drug|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
79381805|NCT04491474|Drug|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
79381806|NCT00556894|Drug|CF101|orally q12h
79536382|NCT04520971|Device|780G|780G closed-loop insulin delivery system (Medtronic)
79381807|NCT00556894|Drug|Placebo|orally q12h
79536383|NCT04520971|Device|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
79536384|NCT04515524|Other|Non-Interventional|No study treatment will be administered in this study
79536385|NCT04504526|Drug|68Ga-Pentixafor|Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
79381808|NCT03308682|Drug|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
79536386|NCT04500912|Device|Supraflex Cruz 60 Micron|percutaneous coronary intervention
79838613|NCT00658320|Drug|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
79838614|NCT00658320|Drug|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
79838615|NCT00658320|Drug|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
79381809|NCT03303222|Diagnostic Test|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
79381810|NCT05182372|Behavioral|Enhanced dCBT-I|Telehealth Coaching
79391439|NCT02466958|Drug|levomilnacipran|antidepressant
79838616|NCT02558192|Dietary Supplement|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
79838617|NCT02558192|Dietary Supplement|PLACEBO|1 vials q12 for 15 days
79838618|NCT04137614|Procedure|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
79391440|NCT02466958|Drug|Placebo|an inactive drug
79536387|NCT04500912|Device|Ultimaster Tansei 80 Micron|percutaneous coronary intervention
79838619|NCT04137614|Procedure|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
79242306|NCT03410433|Device|PG 910 4.0|PG 910 4.0
79242307|NCT03410433|Device|PP 4.0|PP 4.0
79242308|NCT03410433|Device|Silk 5.0|Silk 5.0
79242309|NCT03410433|Device|PG910 5.0|PG910 5.0
79242310|NCT03410433|Device|PP 5.0|PP 5.0
79242311|NCT03410433|Device|APG 5.0|APG 5.0
79242312|NCT03410433|Device|ePTFE 5.0|ePTFE 5.0
79242313|NCT03618953|Biological|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
79242314|NCT03618953|Biological|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
79242315|NCT03618953|Biological|Atezolizumab|monoclonal antibody; checkpoint inhibitor
79391441|NCT02418936|Device|gene diagnostic kit|
79838620|NCT02553252|Other|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
79838621|NCT02558270|Drug|Dapagliflozin|
79838622|NCT02558270|Drug|Placebo|
79381811|NCT03308604|Drug|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg."
79381812|NCT03308604|Radiation|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
80009342|NCT02159534|Other|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
79381813|NCT03308604|Radiation|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
79536388|NCT04498650|Drug|PQ912|PQ912 50 mg tablets and 150 mg tablets
79536389|NCT04498650|Drug|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
79536390|NCT04494334|Procedure|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
79381814|NCT03308604|Drug|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
79536391|NCT04488419|Drug|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
79536392|NCT04488419|Drug|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
79242316|NCT03147872|Other|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
79391442|NCT02422134|Other|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
79391443|NCT02467504|Drug|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
79693227|NCT04510506|Device|Artificial Pancreas (AP)|The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.
79391444|NCT02467504|Drug|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
79536393|NCT04481919|Drug|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
79536394|NCT04446585|Device|Automated External Defibrillator (AED)|Deployment of AEDs
79536395|NCT04446585|Other|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
79693228|NCT04502862|Drug|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
79838623|NCT00804492|Behavioral|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
79838624|NCT00763568|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
79242317|NCT03396159|Diagnostic Test|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
79242318|NCT02354768|Drug|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
79242319|NCT02354768|Drug|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
80009343|NCT02159612|Other|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
79242320|NCT00000125|Drug|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
79242321|NCT03613441|Behavioral|Mindful Awareness Practices (MAPs)|Please refer to arm description
79536396|NCT04446585|Other|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
79536397|NCT04427306|Drug|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
79536398|NCT04421222|Drug|EPI-7386 (QD)|Once daily oral dose of EPI-7386
79242322|NCT02354612|Drug|TRC105|
79242323|NCT02354612|Drug|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
79536399|NCT04421222|Drug|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
79536400|NCT04421222|Drug|Abiraterone acetate|Once daily dose of abiraterone acetate
79242324|NCT02354612|Drug|Axitinib|companion therapy selection depends on companion therapy used in the parent study
79536401|NCT04421222|Drug|Apalutamide|Once daily dose of apalutamide
79536402|NCT04421079|Dietary Supplement|Trans-resveratrol|150mg, 300mg, 450mg
79536403|NCT04421079|Dietary Supplement|Concord grape juice|8 oz, 16 oz, 24 oz
79536404|NCT04421079|Dietary Supplement|Grape seed polyphenol extract|450mg, 900mg, 1200mg
79536405|NCT04421079|Drug|Placebo|Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
79693229|NCT04502862|Drug|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
79693230|NCT04470921|Procedure|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
79693231|NCT04467502|Other|cognitive-behavioral therapy for gambling disorder|6 sessions of cognitive-behavioral therapy for gambling disorder
80009344|NCT02933801|Drug|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
80009345|NCT02933801|Other|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
80009346|NCT04794725|Procedure|Blood sampling|blood samples from venepuncture (10mL)
80009347|NCT04787393|Device|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
80009348|NCT04787393|Device|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
79838625|NCT00763568|Biological|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
79838626|NCT04049006|Other|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
79838627|NCT00806754|Drug|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
80009349|NCT04666025|Procedure|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
80009350|NCT04666025|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
80009351|NCT04666025|Other|Electronic Health Record Review|Medical charts are reviewed
79381815|NCT05168956|Other|Collect data of medical record|"Collect data of medical record:~Genealogy characteristics~Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category"
79381816|NCT00553306|Biological|therapeutic autologous lymphocytes|Given IV
79381817|NCT00553306|Biological|aldesleukin|Given subcutaneously
79381818|NCT00553306|Drug|cyclophosphamide|Given IV
79381819|NCT00553306|Procedure|biopsy|Optional correlative studies
79381820|NCT00553306|Other|immunohistochemistry staining method|Optional correlative studies
79536406|NCT04416152|Procedure|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
79536407|NCT04414683|Procedure|staging surgery|laparoscopic or laparotomic staging surgery
79536408|NCT04412928|Procedure|mid-urethral sling procedure|mid-urethral sling procedure
79536409|NCT04396145|Diagnostic Test|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
80009352|NCT04666025|Other|Questionnaire Administration|Complete questionnaire
80009353|NCT05460455|Drug|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
79381821|NCT00553306|Other|flow cytometry|Correlative studies
79381822|NCT00553306|Genetic|polymerase chain reaction|Correlative studies
79381823|NCT05110612|Behavioral|Episodic Future Thinking|Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
79391445|NCT02467504|Drug|MTX|Methotrexate (oral administration)
79391446|NCT02467504|Drug|Folic Acid|Folic Acid (oral administration)
79391447|NCT02467504|Drug|Loxoprofen|Loxoprofen (oral administration)
79536410|NCT04395261|Diagnostic Test|Wideband Tympanometry|
79536411|NCT04390724|Other|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
79536412|NCT04328714|Drug|Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells|"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."
79693232|NCT04467502|Other|imaginal exposure therapy focus on gambling cues|6 sessions of imaginal exposure therapy focus on gambling cues
79693233|NCT04467502|Other|virtual reality exposure therapy focus on gambling cues|6 sessions of virtual reality exposure therapy focus on gambling cues
79838628|NCT00806754|Drug|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
79838629|NCT00760760|Drug|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
79838630|NCT00760760|Drug|control|equivalent amount of fat as butter
79838631|NCT00764816|Other|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
80009354|NCT03104413|Drug|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
79381824|NCT05110612|Behavioral|Control Episodic Thinking|Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
79838632|NCT00764816|Other|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
79381825|NCT02722044|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
79381826|NCT02722044|Device|Autoinjector|Subcutaneous administration
79381827|NCT05728008|Drug|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
79381828|NCT05728008|Drug|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
79381829|NCT03302988|Other|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
79381830|NCT03302988|Other|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
79838633|NCT00810654|Dietary Supplement|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
80009355|NCT03104413|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
80009356|NCT03104413|Drug|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
79381831|NCT04490382|Device|32 channel external stimulator|Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
79381832|NCT02988700|Drug|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
79381833|NCT02988700|Drug|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
79381834|NCT03308370|Biological|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
79381835|NCT03308292|Other|Exercise|Aerobic exercise program
79381836|NCT03302832|Other|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
79381837|NCT03302832|Other|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
80009357|NCT05451875|Device|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
79381838|NCT03308214|Drug|Imipenem|Imipenem 1.0 q 8h
79381839|NCT03308136|Procedure|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
79381840|NCT03308136|Procedure|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.
79381841|NCT03308136|Drug|1% Lidocaine|1% Lidocaine
79536413|NCT04298892|Other|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
79838634|NCT00810654|Dietary Supplement|Placebo|Placebo
79838635|NCT00764894|Device|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
79838636|NCT00804726|Device|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
79242325|NCT02354612|Drug|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
79242326|NCT02354612|Drug|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
79242327|NCT05168397|Other|RV4857A|RV4857A formula CD2110 is a sunscreen product
79242328|NCT02236897|Other|PET Scanning|
79242329|NCT02348450|Drug|Irinotecan|40mg
79242330|NCT02348450|Drug|Etoposide|5ml：0.1g
79242331|NCT02348450|Drug|Cisplatin|6ml：30mg
80009358|NCT04536155|Other|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
79242332|NCT03393273|Drug|Elotuzumab|"Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
79536414|NCT04296110|Behavioral|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
79693234|NCT04463368|Procedure|Isolated hepatic perfusion|The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.
79693235|NCT04463368|Drug|Ipilimumab|4 courses of ipilimumab 3mg/kg every third week
79838637|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
79242333|NCT03613597|Drug|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
79381842|NCT02466906|Drug|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC>20.0X109/L.
79536415|NCT04296110|Other|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
79242334|NCT03613597|Drug|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
79242335|NCT03393195|Behavioral|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
79242336|NCT03393195|Behavioral|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
79242337|NCT02348372|Drug|GSK1278863A Placebo|Matching size, shape and color
79381843|NCT02466906|Drug|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
79242338|NCT02348372|Drug|GSK1278863A|A round, biconvex, white film coated tablet
79381844|NCT02467140|Device|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
79242339|NCT02031731|Drug|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
79242340|NCT02031731|Drug|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
79242341|NCT02031731|Drug|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
79242342|NCT03614533|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
79242343|NCT03614533|Biological|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
79242344|NCT03396003|Device|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
79242345|NCT03396003|Device|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
79693236|NCT04463368|Drug|Nivolumab|4 courses of nivolumab 1mg/kg every third week
79693237|NCT04460053|Procedure|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
79693238|NCT04454528|Radiation|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
79838638|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
79838639|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
80009359|NCT04536155|Other|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
80009360|NCT04536155|Other|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. & Morrison, T. (2010)."
79693239|NCT04454528|Drug|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
79693240|NCT04454528|Procedure|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
79693241|NCT04421963|Drug|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
79838640|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
79838641|NCT00322153|Drug|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
79838642|NCT00322153|Drug|Placebo|Matching placebo oral administration once daily.
79838643|NCT00806910|Drug|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
80009361|NCT04536155|Other|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
80009362|NCT01382147|Drug|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
80009363|NCT03630887|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
80009364|NCT01382069|Drug|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
79242346|NCT03147404|Drug|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
79242347|NCT03614455|Drug|Milademetan|Milademetan 100 mg capsule for oral administration
79242348|NCT03614455|Drug|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
79242349|NCT03614455|Drug|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
79242350|NCT03393117|Drug|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
79242351|NCT03393117|Drug|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
79381845|NCT02467140|Device|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
79381846|NCT02467062|Device|MRI|MRI measurement to evualuate for 4D blood flow pattern
79693242|NCT04420884|Drug|Dazostinag|Dazostinag intravenous Infusion.
79693243|NCT04420884|Drug|Pembrolizumab|Pembrolizumab intravenous Infusion.
79693244|NCT04420884|Drug|Platinum|Carboplatin or Cisplatin intravenous infusion
79693245|NCT04420884|Drug|5-fluorouracil|5-fluorouracil intravenous infusion
79693246|NCT04385485|Procedure|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
79381847|NCT02466984|Drug|metoclopramide intravenous|Administration route
79381848|NCT00556426|Device|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
79536416|NCT04294771|Drug|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
79693247|NCT04385485|Procedure|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
79381849|NCT05727852|Diagnostic Test|Breath test using the Compact PTR-TOF-MS|Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
79536417|NCT04294264|Drug|Oxaliplatin|Given IV
79536418|NCT04294264|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79536419|NCT04263766|Other|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
79536420|NCT04250415|Procedure|Surgery|
79536421|NCT04237649|Drug|KAZ954|KAZ954 will be administered in every arm.
79693248|NCT04369131|Device|Functional electrical stimulation|Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
79693249|NCT04349501|Other|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
79838644|NCT00806910|Other|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
79838645|NCT00807066|Drug|Gefitinib|Gefitinib 250 mg/day
79838646|NCT00807066|Drug|Platinum|Platinum based chemotherapy with cycles every 21 days
79838647|NCT01058551|Device|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
80009365|NCT01382069|Drug|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
80009366|NCT01381991|Device|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
80009367|NCT01381835|Drug|TMC435|150 mg capsule once daily for 7 days
80009368|NCT04429685|Drug|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
80009369|NCT04429685|Drug|Saline (placebo)|Saline (placebo)
79381850|NCT05727852|Diagnostic Test|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
79381851|NCT05727852|Diagnostic Test|Assessment of arterial stiffness using the VaSera VS-1500N|Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
79693250|NCT04337021|Behavioral|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
79838648|NCT00804960|Drug|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
79838649|NCT00804960|Drug|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
79838650|NCT00805116|Dietary Supplement|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
79381852|NCT03302754|Drug|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
79693251|NCT04330664|Drug|MRTX849|KRAS G12C Inhibitor
79381853|NCT00555568|Behavioral|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
79381854|NCT00555568|Behavioral|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
79838651|NCT00805116|Dietary Supplement|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
79693252|NCT04330664|Drug|TNO155|SHP2 Inhibitor
79838652|NCT03985735|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
79838653|NCT00807222|Drug|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
80009370|NCT04411277|Device|Application of the FreeStyle Libre Flash Glucose CGM.|Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.
79242352|NCT03393117|Drug|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
79381855|NCT03302676|Dietary Supplement|Chewing gum|
80009371|NCT04411277|Diagnostic Test|InBody 270 multifrequency bioimpedance|analysis of body composition to calculate appendicular skeletal muscle.
80009372|NCT01379417|Dietary Supplement|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
79242353|NCT03393117|Drug|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
79242354|NCT02032225|Other|Skin biopsy|
79242355|NCT03147326|Diagnostic Test|FDG-PET-CT|scanning method
79242356|NCT03147326|Diagnostic Test|NaF-PET-CT|scanning method
79242357|NCT03147326|Diagnostic Test|Whole-body MRI|scanning method
79242358|NCT02032303|Procedure|Assessment of coronary flow reserve|
79242359|NCT02032303|Procedure|Percutaneous Coronary Intervention|
79242360|NCT02032303|Drug|Ticagrelor loading|
79242361|NCT02032303|Drug|Prasugrel loading|
79381856|NCT02988778|Drug|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
79536422|NCT04237649|Drug|PDR001|KAZ954 + PDR001
79536423|NCT04237649|Drug|NIR178|KAZ954 + NIR178
79536424|NCT04237649|Drug|NZV930|KAZ954 + NZV930
79536425|NCT04225988|Drug|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
79536426|NCT04225988|Drug|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
79536427|NCT04211155|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
79536428|NCT04211155|Other|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
79381857|NCT02988778|Drug|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
79536429|NCT04203199|Device|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
79536430|NCT04203199|Device|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
79536431|NCT04199351|Drug|AMG 171|2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.
79536432|NCT04199351|Drug|Placebo|AMG 171 placebo
79536433|NCT04191733|Device|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
80009373|NCT01384279|Drug|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
79242362|NCT04297293|Drug|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
79242363|NCT03147560|Biological|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
80009374|NCT01568879|Other|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
80009375|NCT01568879|Other|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
80009376|NCT01383265|Procedure|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
80009377|NCT01383265|Procedure|Water method|Control method will use plain water with water method for screening colonoscopy
80009378|NCT01381601|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
79381858|NCT04490460|Dietary Supplement|WBF-0031|Medical food formulation WBF-0031
79381859|NCT03302598|Diagnostic Test|serum C-reactive protein|
80009379|NCT05216965|Drug|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
80009380|NCT02823353|Drug|Fenofibrate|Fenofibrate 200mg/day
79242364|NCT03147560|Biological|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
79242365|NCT03147560|Biological|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
79381860|NCT04883112|Device|Magnetic Tape®|Magnetic tape® is applied without creating any tension over low back
79381861|NCT04883112|Device|Kinesiology Tape|Kinesiology tape is applied without creating any tension over low back
79381862|NCT03307902|Biological|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
79381863|NCT03307902|Biological|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
79381864|NCT03307902|Biological|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
79381865|NCT04490772|Diagnostic Test|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
79536434|NCT04170634|Other|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
79536435|NCT04170335|Procedure|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
79536436|NCT04163640|Other|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
79536437|NCT04149249|Other|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
79381866|NCT03302442|Other|Non interventional study|Not applicable - Non interventional Study
79536438|NCT04149249|Other|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
79536439|NCT04129138|Other|Survey Administration|Complete survey
79693253|NCT04315181|Drug|Opioid Agonist|Active opioid agonist or placebo, administered orally
79693254|NCT04315181|Drug|Sedatives|Active sedative or placebo, administered orally
79693255|NCT04303169|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
80009381|NCT02823353|Drug|UDCA|UDCA 13-15mg/kg/day
79536440|NCT04068038|Other|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
79536441|NCT04049097|Drug|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
79536442|NCT04033679|Other|Active TDCS|Participants will receive active TDCS stimulation.
79536443|NCT04033679|Other|Sham TDCS|Participants will receive sham TDCS stimulation.
79838654|NCT00657618|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
79536444|NCT04023253|Drug|Mirabegron|Mirabegron 25 mg
79536445|NCT04023253|Drug|Solifenacin|Solifenacin 5 mg
79242366|NCT03614377|Diagnostic Test|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
79242367|NCT02350790|Procedure|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
80009382|NCT04509193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)
80009383|NCT04509193|Drug|Warfarin|Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
79536446|NCT04017793|Behavioral|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
79536447|NCT04017793|Behavioral|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
79693256|NCT04303169|Biological|Vibostolimab|Administered via IV infusion at a specified dose on specified days
79693257|NCT04303169|Biological|Gebasaxturev|Administered via IT injection at a specified dose on specified days
79693258|NCT04303169|Biological|MK-4830|Administered via IV infusion at a specified dose on specified days
79693259|NCT04303169|Biological|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
79242368|NCT02350790|Procedure|Robotic excision|Robotic excision of endometriosis
79381867|NCT05120310|Behavioral|The Calm App|Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge). Participants will be asked to download the Calm app to their mobile phone. The Calm Coaching for sleep program is administered by Calm for six weeks. Participants are asked to complete weekly modules and interact with a coach to help them improve their sleep. Participants also complete a sleep diary throughout the program.
80009384|NCT01379339|Drug|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
79242369|NCT03392961|Drug|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
79242370|NCT03392961|Other|Placebo comparator|Placebo tablet for oral use
79381868|NCT05117346|Drug|CARDIX-101A, CARDIX-101B, CARDIX-101C|Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
79381869|NCT05116410|Drug|HS-20094|Administrated SC
79381870|NCT05116410|Drug|Placebo|Administrated SC
79381871|NCT05727618|Drug|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
79381872|NCT05727618|Drug|normal saline|Intravenous infusion of normal saline at the same dose and speed
79381873|NCT03302364|Drug|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
79381874|NCT00702702|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
79381875|NCT00702702|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
79381876|NCT00702702|Drug|Placebo|Placebo, 2 capsules daily for 3 months
79536448|NCT04007029|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
79536449|NCT04007029|Drug|Cyclophosphamide|Given IV
79536450|NCT04007029|Drug|Fludarabine Phosphate|Given IV
79693260|NCT04303169|Drug|ATRA|Administered via oral capsules at a specified dose on specified days
79693261|NCT04291573|Device|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes ~4cm away
79693262|NCT04291573|Device|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes ~4cm away
79536451|NCT04007029|Biological|Tocilizumab|Given IV
79693263|NCT04282018|Drug|BGB-10188|Administered as specified in the treatment arm
79693264|NCT04282018|Drug|Zanubrutinib|Administered as specified in the treatment arm
79242371|NCT02350946|Drug|Oxytocin|
79242372|NCT02350946|Drug|Placebo|
79693265|NCT04282018|Drug|Tislelizumab|Administered as specified in the treatment arm
79693266|NCT04268641|Other|Arm 1|"Materials used for the course :~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair + Seat back + Positioning cushion + Belt"
79693267|NCT04268641|Other|Arm 2|"Materials used for the course :~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair + Seat back + Positioning cushion"
79693268|NCT04268641|Other|Arm 3|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair"
80009385|NCT01379339|Drug|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
79693269|NCT04268641|Other|Arm 4|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion + Belt"
79693270|NCT04268641|Other|Arm 5|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion"
79242373|NCT00000371|Drug|D-cycloserine|50 mg/daily by mouth
79242374|NCT00000371|Drug|Placebo|50 mg/day of placebo by mouth
79838655|NCT02553564|Other|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~Determination of the participants's estimated dry weight (EDW).~The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~Write new dialysis orders.~Dialysis Access- review access and determine any changes required in treatment"
79381877|NCT03307668|Device|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
79381878|NCT03307668|Device|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
79838656|NCT00657540|Drug|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
79838657|NCT00657540|Drug|Saline|50 mL of saline infused over 10 minutes
79242375|NCT04222647|Drug|WO533|Intravaginal application
79242376|NCT02350712|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
79242377|NCT02350712|Drug|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
79838658|NCT00672620|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
79838659|NCT00672620|Drug|Duloxetine|Duloxetine capsules
79838660|NCT00672620|Drug|Placebo|Placebo-matching capsules
79838661|NCT00805272|Other|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
79242378|NCT02350712|Drug|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
79381879|NCT02467920|Drug|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
79381880|NCT02467920|Drug|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
79242379|NCT02350712|Drug|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
79381881|NCT04927312|Drug|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
79381882|NCT04927312|Drug|Metronidazole|Metronidazole 0.5 g solution for injection.
79536452|NCT04003051|Other|Internet-Based Intervention|Use Project Prepare website
79536453|NCT04003051|Other|Quality-of-Life Assessment|Ancillary studies
79536454|NCT04003051|Other|Questionnaire Administration|Ancillary studies
79536455|NCT04002310|Drug|BI 754132|One single injection
79536456|NCT03982511|Behavioral|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
79536457|NCT03959631|Behavioral|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
79536458|NCT03931265|Diagnostic Test|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
79536459|NCT03905525|Drug|CFZ533|Biological
79536460|NCT03905525|Other|Placebo|liquid placebo for injections
79536461|NCT03887650|Drug|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
79536462|NCT03887650|Drug|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
79536463|NCT03877341|Procedure|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
79536464|NCT03877341|Procedure|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
79536465|NCT03854500|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
79536466|NCT03854500|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
79536467|NCT03810924|Behavioral|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
79838662|NCT00764972|Drug|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
80009386|NCT01379339|Drug|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
79536468|NCT03810924|Behavioral|Ergometer|Riding ergometer
79242380|NCT03614299|Other|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
79242381|NCT03614299|Diagnostic Test|Interferometry|Evaluation of the mebomian function using the LipiView methodology
79242382|NCT03618875|Other|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
79242383|NCT03618875|Other|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
79242384|NCT02867995|Device|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
79242385|NCT03618797|Drug|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
79693271|NCT04268641|Other|Arm 6|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair"
79693272|NCT04242329|Procedure|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
79693273|NCT04242329|Drug|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
79693274|NCT04239625|Drug|ALK-001|Oral administration of a pill for up to 24 months
79838663|NCT00765050|Biological|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
79242386|NCT03618797|Drug|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
79381883|NCT02467218|Other|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
79381884|NCT03307590|Drug|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
79381885|NCT03307590|Drug|Bupivacaine|Caudal block by bupivavaine alone
79381886|NCT03302208|Drug|Pregabalin|Pregabalin capsule 150 mg oral
79381887|NCT03302208|Drug|Placebo|Placebo
79242387|NCT02350556|Other|Dynamic Avoidance Task|
79242388|NCT02350556|Procedure|physical therapy|
79242389|NCT02350556|Device|3D motion on optoelectronic device|
79242390|NCT03149432|Procedure|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
79242391|NCT03149432|Drug|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
79242392|NCT03149432|Procedure|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
79242393|NCT03149432|Other|Local care|local care for directed healing of the stump.
79381888|NCT03307512|Drug|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
79381889|NCT03307512|Drug|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
79381890|NCT02466828|Drug|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
79381891|NCT02467998|Device|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
79381892|NCT03307434|Other|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
79381893|NCT03307434|Other|regular training|The regular training will be performed by control group according to the standard practice.
79381894|NCT02721966|Biological|Secukinumab|Anti IL-17a monoclonal antibody
79536469|NCT03810924|Behavioral|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
79536470|NCT03810924|Behavioral|Reading Newspaper|Participants read newspaper
79381895|NCT02721966|Drug|Secukinumab and Placebo|Placebo matching AIN457
79381896|NCT00553462|Drug|carboplatin|
79381897|NCT00553462|Drug|erlotinib hydrochloride|
79381898|NCT00553462|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
79381899|NCT00553462|Radiation|radiation therapy|
79381900|NCT03307278|Biological|House dust mite|As a stimulant to induce inflammasome activation
79381901|NCT02989090|Other|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
79536471|NCT03783949|Drug|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
79536472|NCT03783949|Drug|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
79536473|NCT03783949|Drug|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
80009387|NCT01379339|Drug|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
80009388|NCT01379339|Drug|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
80009389|NCT01383187|Procedure|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
80009390|NCT01383187|Procedure|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
79242394|NCT03618329|Other|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
80009391|NCT02782247|Device|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal < 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis >11.5kPa. It cannot be used in patients with ascites."
80009392|NCT02782247|Device|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
80009393|NCT02697383|Drug|Ixazomib (MLN9708)|
80009394|NCT02697383|Drug|Dexamethasone|
80009395|NCT01383031|Procedure|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
79242395|NCT03147014|Biological|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
79242396|NCT05384483|Drug|Cariprazine|Cariprazine 1.5 to 3 mg per day
79242397|NCT05384483|Drug|Placebo|Matching placebo
79242398|NCT02354300|Device|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
79242399|NCT03618563|Other|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
79242400|NCT02354066|Device|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
79381902|NCT02989090|Other|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
79381903|NCT05727228|Other|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
79381904|NCT05727150|Procedure|Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap|Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
79381905|NCT02988388|Procedure|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
79381906|NCT03307122|Other|Routine Infant Formula 1|Routine infant formula with probiotic
79381907|NCT03307122|Other|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
79381908|NCT03306966|Device|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
79536474|NCT03783949|Drug|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
79242401|NCT02354066|Device|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
79242402|NCT02354066|Device|Retail Shoe|Brake response time measurement before surgery (control run)
79242403|NCT03086629|Other|Patient Concerns Inventory|
79242404|NCT03086629|Other|No Patient Concerns Inventory|
80009396|NCT01383031|Procedure|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
80009397|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
80009398|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
79305740|NCT04929093|Biological|Routine continuous cluster of Alutard SQ|Patient receiving continuous cluster SCIT for DM during the same period
79838664|NCT00673790|Drug|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
79838665|NCT00673790|Drug|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
80009399|NCT05422547|Diagnostic Test|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
80009400|NCT03631303|Device|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
80009401|NCT05422469|Device|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
80009402|NCT04173949|Drug|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
80009403|NCT04150133|Other|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
80009404|NCT01382017|Drug|Lacosamide|Lacosamide 200 or 400 mg
80009405|NCT01382017|Drug|Placebo|Placebo
80009406|NCT01382017|Drug|Carbamazepine|Carbamazepine 600 mg
80009407|NCT01381523|Drug|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
80009408|NCT01381523|Drug|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
79242405|NCT03077191|Other|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
79242406|NCT05061563|Drug|Elinzanetant (BAY3427080)|Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
79242407|NCT05061563|Drug|Esomeprazole|Esomeprazole given orally once daily for 5 days in Period 2.
79242408|NCT03147170|Diagnostic Test|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
79381909|NCT03301974|Procedure|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
79381910|NCT03301974|Procedure|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
79381911|NCT03301974|Procedure|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
79536475|NCT03783949|Drug|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 & d8)
79536476|NCT03764891|Procedure|Uphold|Uphold system in treating women with cystocele
79536477|NCT03764891|Procedure|Perigee|Perigee system in treating women with cystocele
79536478|NCT03755297|Other|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
79536479|NCT03722719|Other|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
79536480|NCT03722719|Other|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
79693280|NCT04234360|Drug|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
79693281|NCT04234360|Drug|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
79693282|NCT04211961|Drug|Scopolamine|The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study
79693283|NCT04211961|Other|Placebo|The placebo group will receive a 100ml infusion of saline at 4 visits during the study
79693284|NCT04206787|Drug|Afatinib|drug
79693285|NCT04206436|Drug|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
79838666|NCT00673790|Drug|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
80009409|NCT01382953|Device|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
79242409|NCT03147092|Drug|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
79693286|NCT04201782|Drug|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
79693287|NCT04195477|Behavioral|vDPP|virtual Diabetes Prevention Program
79693288|NCT04190563|Behavioral|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
79693289|NCT04190563|Behavioral|Pain Education|Experimenter-administered education.
79693290|NCT04165486|Drug|ION464|ION464 will be administered by IT injection.
79693291|NCT04165486|Drug|Placebo|ION464-matching placebo will be administered by IT injection.
79693292|NCT04154683|Device|Cellvizio®|use of the Cellvizio® optical biopsy
79693293|NCT04137380|Drug|Mirikizumab - IV|Administered IV
79693294|NCT04137380|Drug|Mirikizumab - SC|Administered SC
79242410|NCT03147092|Drug|Atenolol|Treatment of hypertensive subjects
79381912|NCT03306888|Other|Physical Activity Coaching|Physical activity coaching over 4 months
79693295|NCT04137380|Drug|Placebo - IV|Administered IV
79693296|NCT04137380|Drug|Placebo - SC|Administered SC
79381913|NCT03306810|Other|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
79693297|NCT04122690|Behavioral|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
79693298|NCT04122690|Behavioral|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
79693299|NCT04076683|Device|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
79693300|NCT04075825|Biological|Darvadstrocel|Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
79693301|NCT04075292|Drug|Acalabrutinib|acalabrutinib 100 mg twice daily orally
79693302|NCT04075292|Drug|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
79381914|NCT02468388|Other|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
79381915|NCT02468388|Other|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
79536481|NCT03722719|Other|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
79693303|NCT04075292|Drug|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
79693304|NCT04068194|Drug|Avelumab|Given IV
79693305|NCT04068194|Procedure|Biopsy|Undergo biopsy of tumor
79693306|NCT04068194|Procedure|Biospecimen Collection|Correlative studies
79693307|NCT04068194|Procedure|Computed Tomography|Undergo CT scan
79693308|NCT04068194|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
79693309|NCT04068194|Drug|Peposertib|Given PO
79693310|NCT04047862|Drug|Ociperlimab|Administered as an intravenous (IV) injection
79242411|NCT03147092|Drug|Losartan potassium 50mg|Treatment of hypertensive subjects
79242412|NCT03147092|Drug|Clonidine|Treatment of hypertensive subjects
79242413|NCT03613285|Device|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
79242414|NCT03613285|Device|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
79242415|NCT03613285|Device|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
79242416|NCT03149588|Drug|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
79381916|NCT02468388|Other|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
79536482|NCT03699254|Drug|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
79693311|NCT04047862|Drug|Tislelizumab|Administered as an IV injection
79693312|NCT04047862|Drug|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
79693313|NCT04047862|Drug|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
79693314|NCT04047862|Drug|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
79693315|NCT04047862|Drug|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
79242417|NCT03149588|Drug|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
79381917|NCT03306732|Drug|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"After anesthesia induction~After separation from CPB~On the evening of the day of surgery (22:00)~On POD 1 twice a day at 8:00 and 22:00~On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
79838667|NCT00763646|Drug|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
79838668|NCT00763880|Drug|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
79838669|NCT00763880|Drug|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
79838670|NCT00765440|Dietary Supplement|therapeutic nutritional supplementation|Given orally
79838671|NCT00765440|Other|placebo|Given orally
79838672|NCT00657150|Drug|Enoxaparin|40 mg once daily
79838673|NCT00657150|Drug|Dabigatran etexilate|220 mg once daily
79305257|NCT04942821|Procedure|Connective tissue graft and coronally advanced flap|Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
79381918|NCT03306732|Drug|Normal saline (100ml)|"After anesthesia induction~After separation from CPB~On the evening of the day of surgery (22:00)~On POD 1 twice a day at 8:00 and 22:00~On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
79381919|NCT03306654|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
79693316|NCT04047862|Drug|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
79693317|NCT04047862|Drug|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
79693318|NCT04047862|Drug|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
79305258|NCT04415853|Drug|Lerotinib|Specification: 50 mg/capsule and 150 mg/capsule
79381920|NCT03306498|Drug|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
79381921|NCT02468310|Other|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
79381922|NCT02809014|Other|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
79381923|NCT02809014|Other|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
79381924|NCT02809014|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
79381925|NCT02809014|Other|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
79693319|NCT04047862|Drug|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
79693320|NCT04047862|Drug|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
79693321|NCT04036331|Behavioral|Brenner FIT Standard|After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
79838674|NCT00770354|Drug|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
79838675|NCT00770354|Drug|Letrozole|Daily 2.5 mg oral letrozole tablet
79838676|NCT02553486|Other|quality of life evaluation|
79838677|NCT00670748|Biological|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
79838678|NCT00670748|Drug|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
79838679|NCT00670748|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
79838680|NCT00670748|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
80009410|NCT04233047|Drug|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
80009411|NCT01381445|Drug|GW870086 0.2%|White to slightly coloured opaque cream
79693322|NCT04036331|Behavioral|By Design Essentials|A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
79242418|NCT03613207|Other|Dermal pharmacokinetic measurement|"Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~Each test site receives 2 dOFM probes~Dosing:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site~ISF sampling: 24 hours post-dose~Blood sampling: 7 samples post-dose"
79536483|NCT03699254|Drug|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
79693323|NCT04036331|Behavioral|Dyad Plus|"This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each."
79838681|NCT00670748|Biological|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
79838682|NCT00646776|Drug|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
79838683|NCT00646776|Drug|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
79381926|NCT02466594|Device|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
79381927|NCT05726760|Behavioral|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
79242419|NCT03613207|Drug|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
79242420|NCT03613207|Drug|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
79536484|NCT03693690|Procedure|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
79838684|NCT00765596|Other|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
79242421|NCT03613207|Device|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
79242422|NCT03613207|Procedure|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
79242423|NCT02350322|Other|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
79242424|NCT02350322|Other|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
79242425|NCT02350322|Dietary Supplement|Supplement|Omega-3 capsules three times a week for 12 weeks
79536485|NCT03680755|Behavioral|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
79536486|NCT03634930|Behavioral|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
79536487|NCT03559621|Behavioral|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
79536488|NCT03550131|Behavioral|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
79536489|NCT03550131|Behavioral|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
79536490|NCT03522246|Drug|Rucaparib|Oral rucaparib will be administered twice daily
79536491|NCT03522246|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
79536492|NCT03522246|Drug|Placebo Oral Tablet|Placebo tablets will be administered twice daily
79536493|NCT03522246|Drug|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
79536494|NCT03513328|Drug|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
79536495|NCT03513328|Drug|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
79536496|NCT03502967|Drug|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
79536497|NCT03502967|Drug|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
80009412|NCT01381445|Drug|GW870086 2%|White to slightly coloured opaque cream
79536498|NCT03498716|Drug|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
79536499|NCT03498716|Drug|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m^2 every week for 12 weeks.
80009413|NCT01381445|Drug|Clobetasol Propionate|White cream
80009414|NCT01381445|Drug|Placebo|White to slightly coloured opaque cream
79381928|NCT05726760|Device|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
79381929|NCT05726760|Device|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
80009415|NCT05421845|Behavioral|mobile-based combining with hospital-based lifestyle interventions|The same as that stated in arm descriptions.
79242426|NCT02032381|Other|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
79242427|NCT03392883|Behavioral|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
79242428|NCT02350634|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
79242429|NCT03613051|Behavioral|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
79242430|NCT03159182|Device|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
79242431|NCT03159182|Device|Pressure garment|Custom made fabric pressure garment
79305259|NCT04415853|Drug|Irinotecan/Tegafur|Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule
79381930|NCT05726760|Device|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
79381931|NCT03301818|Device|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
79381932|NCT02468544|Other|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
79536500|NCT03498716|Drug|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m^2) every 2 weeks for a total of 4 doses"
79536501|NCT03498716|Drug|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m^2 every 2 weeks for 4 doses
79536502|NCT03447119|Behavioral|Living Well with a Disability|Implementation of an adapted health promotion program.
79536503|NCT03441295|Procedure|Dynamic Intraligamentary Stabilization|DIS, Ligamys
79536504|NCT03441295|Procedure|Internal Brace Ligament Augmentation|IBLA
79536505|NCT03441295|Procedure|ACL Reconstruction|Conventional
79536506|NCT03430310|Other|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
79838685|NCT04048928|Behavioral|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
79838686|NCT02558114|Drug|Ribavirin|
80009416|NCT01568957|Behavioral|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
80009417|NCT01379261|Procedure|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
80009418|NCT05421767|Procedure|nerve stimulation guided renal denervation procedure|RNS-in
80009419|NCT03083639|Drug|Esomeprazole Capsule|Esomeprazole Capsule
80009420|NCT03083639|Drug|Esomeprazole Tablet|Esomeprazole Tablet
80009421|NCT02927431|Drug|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
80016805|NCT03659409|Behavioral|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
79536507|NCT03430310|Other|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
79536508|NCT03424161|Device|Secret RF|Subjects will receive treatment with the Secret RF device
79536509|NCT03413189|Other|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
79536510|NCT03413189|Other|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
79536511|NCT03413189|Other|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
79693324|NCT04032587|Behavioral|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
79242432|NCT03612739|Biological|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
79242433|NCT02350400|Device|DEBIRI|DEBIRI TACE
79242434|NCT03612895|Behavioral|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
79242435|NCT03612895|Behavioral|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
79381933|NCT04491162|Other|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
79381934|NCT04491162|Other|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
79381935|NCT02467764|Other|Retrospective study|
79381936|NCT04491318|Other|Observational|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
79381937|NCT05726526|Device|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
79381938|NCT00553150|Drug|everolimus|
79381939|NCT00553150|Drug|temozolomide|
79693325|NCT04032587|Behavioral|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
79693326|NCT04024540|Dietary Supplement|isocaloric dietary restriction|Very low caloric diet
79693327|NCT04024540|Procedure|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
79693328|NCT04021537|Device|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
79693329|NCT04013152|Other|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
80009422|NCT02927431|Drug|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
79381940|NCT00553150|Radiation|radiation|
79381941|NCT03301662|Diagnostic Test|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
79536512|NCT03409159|Device|LAAC|Left atrial appendage closure
79693330|NCT04011644|Behavioral|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
79838687|NCT00770666|Drug|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
79536513|NCT03404180|Procedure|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
79536514|NCT03404180|Drug|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
79242436|NCT03612895|Behavioral|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
79693331|NCT04011644|Behavioral|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
79693332|NCT04011644|Behavioral|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
79693333|NCT04000061|Other|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
79693334|NCT04000061|Other|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
79242437|NCT03149510|Behavioral|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
79536515|NCT03404180|Procedure|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
79536516|NCT03404180|Procedure|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
79536517|NCT03403465|Other|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
79693342|NCT03944941|Drug|Avelumab|Given IV
79693343|NCT03944941|Drug|Cetuximab|Given IV
79693344|NCT03936777|Drug|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
79536518|NCT03390686|Drug|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
79536519|NCT03390686|Drug|HD204|15 mg/kg IV every 3 weeks on Day 1
79536520|NCT03390686|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
79536521|NCT03390686|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
79242438|NCT03612817|Drug|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
79242439|NCT03392805|Behavioral|physical activity|beginning of regular physical activity under the supervision of a coach
79242440|NCT02347904|Drug|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
79242441|NCT03990285|Drug|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
79242442|NCT03612427|Dietary Supplement|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
79242443|NCT02353910|Procedure|Ultrasound|
79242444|NCT03392727|Device|Study Box|Baby box (bassinet) with infant items
79536522|NCT03373552|Diagnostic Test|Platelet function assay|Platelet function assay
79536523|NCT03373201|Drug|Tasimelteon|Oral capsule
79536524|NCT03373201|Drug|Placebo|Oral capsule
79536525|NCT03357926|Diagnostic Test|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
79536526|NCT03345342|Drug|PP6M|Participants will receive intramuscular injection of PP6M.
79242445|NCT03392727|Device|Community Box|Baby box (bassinet)
79381942|NCT03301584|Other|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
79693345|NCT03929666|Drug|ZW25 (Zanidatamab)|"Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~Part 2: RD identified in Part 1"
79693346|NCT03929666|Drug|Capecitabine|Administered orally twice daily (PO bid)
79693347|NCT03929666|Drug|Cisplatin|Administered IV
79693348|NCT03929666|Drug|Fluorouracil|Administered IV
79381943|NCT03301584|Other|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
79693349|NCT03929666|Drug|Leucovorin|Administered IV
80009423|NCT02927431|Drug|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
80009424|NCT02927431|Drug|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
79242446|NCT03392727|Behavioral|Education Session|Face to face education and baby box orientation session
79242447|NCT03392727|Behavioral|Online Education|Online baby box education
79381944|NCT03306186|Device|HemoSpec|Blood sampling for analysis
79381945|NCT03301428|Other|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
79693350|NCT03929666|Drug|Oxaliplatin|Administered IV
79242448|NCT03612349|Behavioral|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
79381946|NCT03301428|Other|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
79381947|NCT03026218|Other|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
79381948|NCT03026218|Other|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
79536527|NCT03345342|Drug|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
79536528|NCT03345342|Drug|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
79536529|NCT03345342|Drug|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
79536530|NCT03345342|Other|Placebo|Participants will receive matching placebo.
79536531|NCT03290547|Device|Cutera enLighten laser|Subjects will receive laser treatments.
79536532|NCT03270969|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
79536533|NCT03264131|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
79693351|NCT03929666|Drug|Bevacizumab|Administered IV
79693352|NCT03929666|Drug|Gemcitabine|Administered IV
79693353|NCT03919929|Drug|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
79693354|NCT03919929|Other|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
79693355|NCT03904862|Drug|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
79693356|NCT03900221|Other|No intervention|No intervention
79693357|NCT03894566|Other|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
79693358|NCT03893916|Procedure|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
79838688|NCT00770666|Drug|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
79242449|NCT03146858|Drug|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
79242450|NCT03612661|Behavioral|Group Intervention|Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
79381949|NCT03306108|Device|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
79381950|NCT03306030|Drug|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
79381951|NCT03306030|Drug|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
79381952|NCT03193996|Device|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
79381953|NCT02495610|Other|Gait analysis and MRI:|"Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
79381954|NCT05726448|Behavioral|Telehealth solution|Mobile-friendly nutrition education platform
79536534|NCT03264131|Drug|CHEP|"Cyclophosphamide- 750 mg/m^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
79536535|NCT03233347|Drug|Brentuximab Vedotin|Given IV
79536536|NCT03233347|Drug|Dacarbazine|Given IV
79536537|NCT03233347|Drug|Doxorubicin|Given IV
79536538|NCT03233347|Other|Laboratory Biomarker Analysis|Correlative studies
79536539|NCT03233347|Biological|Nivolumab|Given IV
79693359|NCT03879395|Procedure|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
79693360|NCT03872284|Other|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
79693361|NCT03861897|Other|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
79693362|NCT03861897|Other|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
79693363|NCT03843008|Dietary Supplement|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
79242451|NCT03612661|Behavioral|Guided Self-Help|Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
79242452|NCT03146702|Other|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
79242453|NCT03408405|Drug|Acthar Gel 80 UNT/ML Injectable Solution|Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
79536540|NCT03233347|Drug|Vinblastine|Given IV
79536541|NCT03192176|Drug|Fezolinetant|Oral Capsule
79536542|NCT03192176|Drug|Placebo|Oral Capsule
79536543|NCT03151564|Diagnostic Test|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
79693364|NCT03838536|Dietary Supplement|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
79693365|NCT03838536|Dietary Supplement|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
80009425|NCT03083483|Device|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
79693366|NCT03833622|Other|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
79693367|NCT03832998|Drug|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
79693368|NCT03832998|Drug|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
79536544|NCT03151564|Diagnostic Test|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
79536545|NCT03151564|Diagnostic Test|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
79242454|NCT02350088|Drug|probiotics|probiotics
79693369|NCT03832998|Drug|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
79693370|NCT03832998|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
79693371|NCT03829475|Drug|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
79242455|NCT02350088|Drug|placebo|placebo
80009426|NCT05421221|Device|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
79381955|NCT04754152|Other|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
79381956|NCT04754152|Drug|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
79693372|NCT03829475|Drug|Placebo|placebo is an infusion of normal saline.
79693373|NCT03829475|Drug|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
79693374|NCT03824444|Device|PODS|Percutaneous Osseointegrated device for transhumeral patients
79693375|NCT03819985|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
79242456|NCT03408093|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
79242457|NCT03612115|Device|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
79242458|NCT04679623|Combination Product|Midazolam|Midazolam Injection, 10mg
79693376|NCT03819985|Other|Quality-of-Life Assessment|Ancillary studies
79693377|NCT03819985|Other|Questionnaire Administration|Ancillary studies
79693378|NCT03811886|Drug|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
79693379|NCT03807401|Behavioral|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
79693380|NCT03807401|Behavioral|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
79242459|NCT04679623|Drug|Seizalam|Seizalam, 10 mg
79242460|NCT02353988|Drug|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade >= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
79242461|NCT02353988|Other|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
79242462|NCT03395769|Biological|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
79381957|NCT03141346|Behavioral|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
79536546|NCT03114462|Radiation|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
79536547|NCT03114462|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
79536548|NCT03076606|Diagnostic Test|ophthalmologist examination|ophthalmologist examination after geriatric consultation
79536549|NCT03061123|Other|Questionnaire|
79838689|NCT00764036|Drug|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
79838690|NCT00764114|Drug|antibiotic|6 or 12 weeks
79381958|NCT03141346|Behavioral|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
80009427|NCT05027893|Drug|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
79536550|NCT03024333|Other||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
79536551|NCT03016013|Biological|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.Study investigator evaluate the patients of curative effect.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
79536552|NCT03016013|Biological|RC18 160 mg plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
79536553|NCT02990130|Other|Observational|
79838691|NCT00811200|Drug|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
79838692|NCT00811200|Drug|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
79536556|NCT02988271|Other|Interview|Participate in interview
79838693|NCT00811200|Other|sham|at baseline one sham-injection
80009428|NCT05027893|Drug|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
79242463|NCT03149354|Other|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
79381959|NCT03141346|Other|Home water delivery|Home delivery of bottled water administered over 24 months
79381960|NCT04630834|Drug|Ibuprofen|Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
79693381|NCT03807401|Behavioral|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
79838694|NCT00764192|Procedure|blood sample|blood sample before and after a single HD
79242464|NCT03405675|Other|SLAS 1|NA. Observational study, no interventions administered.
79242465|NCT03405675|Other|SLAS 2|NA. Observational study, no interventions administered.
79242466|NCT03611803|Device|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
79242467|NCT03611803|Other|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
79381961|NCT04630834|Drug|Acetaminophen|patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
79381962|NCT04630834|Drug|Placebo|patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
79381963|NCT03301350|Drug|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
79381964|NCT03301350|Drug|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
79381965|NCT03301350|Drug|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
79838695|NCT00764192|Procedure|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
79838696|NCT00811356|Drug|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
79838697|NCT00765908|Device|Angioplasty balloon|90 second balloon inflation x 2
79838698|NCT00765908|Device|Angioplasty balloon|30 seconds or less balloon inflations x 2
79838699|NCT00765986|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
79838700|NCT00765986|Other|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
80009429|NCT05027893|Other|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
79381966|NCT03301350|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
79536557|NCT02988271|Procedure|Meditation Therapy|Complete meditation therapy
79381967|NCT03301350|Drug|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
79536558|NCT02988271|Procedure|Quality-of-Life Assessment|Complete questionnaires
79536559|NCT02988271|Procedure|Supportive Care|Receive supportive care
79536560|NCT02940496|Drug|Elbasvir/Grazoprevir|Given PO
79536561|NCT02940496|Other|Laboratory Biomarker Analysis|Correlative studies
79536562|NCT02940496|Biological|Pembrolizumab|Given IV
79536563|NCT02940496|Drug|Ribavirin|Given PO
79693382|NCT03777267|Device|Active CR|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
79693383|NCT03744468|Drug|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
79693384|NCT03744468|Drug|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
79693385|NCT03744468|Drug|LBL-007|Human anti LAG-3 IgG4-kappa antibody
79693386|NCT03725007|Drug|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
79838701|NCT00766064|Drug|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily*, Week 6: fixed dose,~*Criteria to increase the dose from 3 mg to 6 mg daily are 1] absence of any side effects, 2] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
79838702|NCT00770744|Drug|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
79838703|NCT00770744|Drug|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
79381968|NCT03301350|Drug|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
79381969|NCT04737304|Drug|BEN2293 (0.25% or 1.0% w/w) or matching placebo|BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
79242468|NCT03146780|Procedure|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
79242469|NCT03146780|Procedure|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
79242470|NCT03146780|Procedure|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
79242471|NCT03146780|Procedure|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
79242472|NCT05383807|Behavioral|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
79381970|NCT02466750|Biological|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
79536564|NCT02910492|Device|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
79536565|NCT02897908|Procedure|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
79536566|NCT02848885|Other|Active TDCS|Participants will receive active tDCS stimulation.
79536567|NCT02848885|Other|Sham TDCS|Participants will receive sham tDCS stimulation
79536568|NCT02828761|Device|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
79536569|NCT02828761|Procedure|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
79536570|NCT02823171|Drug|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
79536571|NCT02823171|Drug|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
79536572|NCT02808455|Drug|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
79536573|NCT02808455|Drug|(Treatment B)|A single 80-mg oral solution dose of pacritinib
79536574|NCT02807207|Drug|A: pacritinib|Treatment A
79536575|NCT02807207|Other|B: Placebo|Treatment B
79536576|NCT02807207|Drug|C: moxifloxacin|Treatment C
79536577|NCT02807116|Drug|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
79536578|NCT02807116|Drug|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
79536579|NCT02807116|Drug|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
79536580|NCT02704377|Other|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
79536581|NCT02704377|Procedure|Dual X-ray Absorptiometry|Undergo iDXA
79242473|NCT03392571|Drug|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
79381971|NCT03301194|Other|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
79381972|NCT04735432|Biological|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
79381973|NCT04735432|Biological|efgartigimod IV|Intravenous infusion of efgartigimod
79381974|NCT04717492|Other|Observational|Observational
79536582|NCT02704377|Other|Laboratory Biomarker Analysis|Correlative studies
79536583|NCT02704377|Other|Quality-of-Life Assessment|Ancillary studies
79381975|NCT02722278|Drug|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
79693387|NCT03685890|Drug|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
79693388|NCT03685890|Procedure|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
79693389|NCT03670680|Device|Use of the Lina LibrataTM|Use of the Lina LibrataTM
79693390|NCT03632473|Diagnostic Test|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
79693391|NCT03613532|Drug|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
79242474|NCT03112460|Device|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
79305260|NCT04415151|Drug|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
79381976|NCT02722278|Drug|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
79381977|NCT03024034|Drug|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
79381978|NCT03305952|Behavioral|CBCT|
79381979|NCT03305952|Other|TAU|
79381980|NCT03305796|Radiation|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
79381981|NCT03305718|Other|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
79381982|NCT03305718|Other|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
79381983|NCT03305718|Other|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
79381984|NCT03305718|Other|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
79381985|NCT03305718|Other|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
79381986|NCT03305718|Other|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
79536584|NCT02704377|Other|Questionnaire Administration|Ancillary studies
79536585|NCT02680743|Other|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
79536586|NCT02677961|Other|Observation|
79536587|NCT02603835|Device|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
79536588|NCT02531594|Behavioral|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
79693392|NCT03613532|Drug|Fludarabine|Given once daily for 4 days
79693393|NCT03613532|Drug|Busulfan|Given twice daily for 4 days
79693394|NCT03613532|Drug|Venetoclax|Part 2 and Part 3: 14 doses for 8-12 cycles depending on dose level assigned
79381987|NCT03305718|Other|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
79381988|NCT03305718|Other|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
79242475|NCT03612505|Behavioral|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~Introduction (10 minutes)~Lesson on *Early Childhood Development* topic (20 minutes)~Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~Observe caretakers one-on-one in play role with the child (25 minutes)~Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
79381989|NCT03305718|Other|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
79381990|NCT03305718|Other|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
79536589|NCT02531594|Behavioral|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
79536590|NCT02495311|Procedure|myomectomy or adenomyomectomy|
79838704|NCT00770822|Device|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
80009430|NCT04113083|Other|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
80009431|NCT01381783|Procedure|Phacoemulsification|Phacoemulsification under topical anesthesia
80009432|NCT01381367|Biological|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
80009433|NCT01381367|Drug|Normal Saline|normal saline, 0.5ml given subcutaneously
79242476|NCT03392493|Behavioral|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
79242477|NCT03392493|Behavioral|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
79242478|NCT04656067|Drug|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
79381991|NCT03305718|Other|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
79381992|NCT03305718|Other|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
79536591|NCT02465541|Procedure|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
79693395|NCT03613532|Drug|Azacitidine|Part 2: 5 doses for 8-12 cycles depending on dose level assigned
79693396|NCT03613532|Drug|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
79838705|NCT00770822|Device|Brachytherapy|Standard of care
80009434|NCT04989361|Procedure|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
79242479|NCT04226222|Diagnostic Test|TEP-TDM FDG|Semi-quantitative PET-TDM FDG Data and Texture Analysis
79242480|NCT03612037|Dietary Supplement|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
79242481|NCT03612037|Dietary Supplement|Cellulose|600mg/day oral dose of placebo cellulose
79242482|NCT03395691|Procedure|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
79305261|NCT04415151|Drug|Placebo|Matching placebo tablets will be administered.
79381993|NCT03300960|Drug|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
79381994|NCT03300960|Drug|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
79381995|NCT04583254|Radiation|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
79381996|NCT04583254|Radiation|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
79381997|NCT04583254|Drug|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
79381998|NCT03305640|Procedure|acetabular fracture surgery|acetabular fracture surgery
79381999|NCT02964442|Other|Capsinoids|12 mg of Gel capsules
79382000|NCT02964442|Other|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
79536592|NCT02465541|Other|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
79536593|NCT02465541|Other|educational intervention|Undergo enhanced usual care
79536594|NCT02465541|Other|quality-of-life assessment|Ancillary studies
79536595|NCT02465541|Other|questionnaire administration|Ancillary studies
79838706|NCT00764348|Other|no treatment|
79838707|NCT00655668|Drug|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
79838708|NCT00770900|Drug|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children >15 years took 10mg tablet of montelukast"
80009435|NCT04989361|Procedure|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
80009436|NCT01381289|Drug|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
80009437|NCT01382875|Other|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
80009438|NCT05420987|Dietary Supplement|Jing Si herbal tea liquid packet|Jing Si herbal tea includes eight Taiwan native-grown herbs: such as mugwort leaves, fish needle grass, Ophiopogon japonicus, platycodon, perilla leaves, chrysanthemum, and licorice
79693397|NCT03605927|Drug|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
80009439|NCT04899193|Drug|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
79242483|NCT03395691|Procedure|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
79242484|NCT02348138|Other|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
79382001|NCT04768582|Diagnostic Test|P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay|The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
80009440|NCT04899193|Drug|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
79242485|NCT04713241|Procedure|Electro-acupuncture|"20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions~A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level."
79382002|NCT03300882|Other|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
79838709|NCT00770900|Drug|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
79838710|NCT00766220|Drug|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
79838711|NCT00766220|Drug|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
79242486|NCT04713241|Other|Standard of Care Bowel rest|Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated
79242487|NCT03611959|Other|Non Applicable|
79242488|NCT02350166|Procedure|laparoscopic surgery|laparoscopic-assisted small-incision surgery
79536596|NCT02370875|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
79838712|NCT00766220|Drug|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
79838713|NCT00807300|Radiation|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
79305262|NCT04942743|Diagnostic Test|MRI|MRI OF TMJ
79305263|NCT04949997|Other|diagnose|HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
79305264|NCT04950231|Other|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
79382003|NCT02485444|Drug|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
79382004|NCT03300726|Diagnostic Test|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
79382005|NCT03300726|Radiation|Functional MRI|Functional MRI during resting state and semantic memory task activation
79382006|NCT04490538|Diagnostic Test|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
79536597|NCT02370875|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
79536598|NCT02365467|Device|Valiant Mona LSA Thoracic Stent Graft System|
79536599|NCT02350205|Biological|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
79536600|NCT02284074|Other|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
79536601|NCT02284074|Other|Experimental: Nasal LPS spray 1µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
79382007|NCT04490304|Other|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
79536602|NCT02284074|Other|Experimental: Nasal LPS spray 10 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
79693398|NCT03605927|Drug|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
79693399|NCT03605927|Drug|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
79693400|NCT03595293|Device|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
79693401|NCT03595293|Device|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
79693402|NCT03531450|Behavioral|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
79838714|NCT00807300|Procedure|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
79382008|NCT03305484|Other|No intervention|No intervention, observation only
79382009|NCT02468076|Device|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
79382010|NCT04428346|Behavioral|Incentive payment|Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
79382011|NCT04490694|Drug|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients <60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79305265|NCT04960761|Other|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
79382012|NCT04490694|Procedure|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
79382013|NCT04601584|Biological|Cohort 1, GNR-084|0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
79382014|NCT04601584|Biological|Cohort 2, GNR-084|0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
79382015|NCT04601584|Biological|Cohort 3, GNR-084|1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
80009441|NCT04899193|Drug|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
79305266|NCT03059277|Drug|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
79536603|NCT02284074|Other|Experimental: Nasal LPS spray 30 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
79382016|NCT04601584|Biological|Cohort 4, GNR-084|4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
79382017|NCT04601584|Biological|Cohort 5, GNR-084|10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
79382018|NCT04601584|Biological|Cohort 6, GNR-084|20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
79382019|NCT02988310|Other|No intervention|
79536604|NCT02284074|Other|Experimental: Nasal LPS spray 100 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
79536605|NCT02265770|Drug|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
79693403|NCT03504241|Biological|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
79693404|NCT03504241|Drug|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
79693405|NCT03504241|Drug|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
79693406|NCT03504241|Drug|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
79242489|NCT05168241|Other|song/melodica group|"The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks."
79242490|NCT05168241|Other|control group|"In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions."
80009442|NCT04899193|Drug|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
80009443|NCT01381705|Biological|rituximab|
80009444|NCT01381705|Genetic|DNA analysis|
80009445|NCT01381705|Genetic|gene expression analysis|
79536606|NCT02265770|Drug|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
80009446|NCT01381705|Genetic|polymorphism analysis|
79242491|NCT02350244|Behavioral|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
79382020|NCT02988076|Device|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
79382021|NCT02359474|Drug|Trabectedin|
79693407|NCT03504241|Drug|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
79693408|NCT03504241|Drug|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
79693409|NCT03504241|Drug|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
79536607|NCT02265770|Drug|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
79693410|NCT03501706|Behavioral|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
79693411|NCT03501706|Behavioral|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
79693412|NCT03501706|Behavioral|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
79693413|NCT03501706|Behavioral|Verbal Memory--Visual|word recognition AT memory component
79693414|NCT03471247|Device|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
79693415|NCT03471247|Other|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
80009447|NCT01381705|Other|laboratory biomarker analysis|
80009448|NCT01381705|Other|medical chart review|
80016806|NCT03659409|Behavioral|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
80016807|NCT02285660|Procedure|4D PET-CT Scan|
80016808|NCT02285660|Other|No intervention|
79838715|NCT00813540|Behavioral|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
80009449|NCT03613675|Device|Video games|"The 4 videos games consists of:~Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
80009450|NCT03085927|Behavioral|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
80009451|NCT03085927|Behavioral|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
80009452|NCT05418803|Drug|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
79242492|NCT03886155|Procedure|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
79242493|NCT04653181|Drug|Ferric carboxymaltose|Iron-arm treated with Ferric carboxymaltose, non-iron arm without
79382022|NCT02359474|Genetic|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
79382023|NCT02467686|Behavioral|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
79536608|NCT02265770|Radiation|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
79693416|NCT03467243|Behavioral|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
79693417|NCT03467243|Behavioral|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
79693418|NCT03467243|Behavioral|Treatment as usual|TAU is when Veterans continue to receive their usual care.
79693419|NCT03454035|Drug|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
79693420|NCT03454035|Drug|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
79693421|NCT03376126|Other|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
79693422|NCT03353805|Behavioral|questionnaire|questionnaire
79693423|NCT03326596|Drug|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
79838716|NCT00813540|Other|Usual Care|Usual Care
79242494|NCT04203446|Other|Assessment of correctness of inhaling technique|Assessment of correctness of inhaling technique in patients with asthma or COPD
79242495|NCT04447209|Other|Dietary counselling on Food Groups according to IYC Feeding practices, WHO|Monitoring of Dietary diversity and growth
79242496|NCT04199624|Drug|Omeprazole 20mg|Omeprazole twice daily x 5 days
79242497|NCT04199624|Dietary Supplement|Vitamin C|Ascorbic acid x 1 on day 5
79242498|NCT04643353|Device|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
79242499|NCT04643353|Other|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
79305267|NCT04942509|Behavioral|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
79838717|NCT00770978|Drug|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
79305268|NCT04949763|Other|rehabilitation|Patients underwent ususal rehabilitation treatment
80009453|NCT05418803|Drug|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
80009454|NCT04401709|Drug|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 ~ 21 days for 4 weeks
80009455|NCT04401709|Drug|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 ~ 14 days for 3 weeks
80009456|NCT02472665|Drug|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
80009457|NCT04392583|Device|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
80009458|NCT04497987|Drug|Bamlanivimab|Administered IV.
79382024|NCT02467686|Behavioral|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
79536609|NCT02265770|Drug|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
79382025|NCT02467686|Behavioral|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
79382026|NCT02467686|Drug|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
79382027|NCT02467686|Drug|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
79382028|NCT02467686|Drug|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
79693424|NCT03323905|Device|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
80009459|NCT04497987|Drug|Placebo|Administered IV.
79382029|NCT02987608|Device|Power Up|Smartphone phone app
80009460|NCT04497987|Drug|Etesevimab|Administered IV.
79382030|NCT05707962|Drug|Magnesium sulfate|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
79382031|NCT02218840|Other|Smoking topography|Evaluation of cigar smoking topography
79693425|NCT03320304|Device|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
79693426|NCT03318939|Drug|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~Cohorts 1-3: 16 mg QD~Cohort 4: 8 mg BID~Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~Cohorts 6 and 7: 8 mg BID"
79693427|NCT03310905|Procedure|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
79838718|NCT00770978|Drug|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
79838719|NCT02557724|Procedure|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
79838720|NCT02557724|Procedure|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
80009461|NCT01381627|Drug|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
80009462|NCT01381627|Drug|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
80009463|NCT04726813|Behavioral|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
80009464|NCT04726813|Behavioral|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
80016809|NCT02095860|Drug|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
80016810|NCT02285738|Drug|Aspirin|81mg/day for 4 weeks
79305269|NCT04942587|Behavioral|LISTENING TO THE RECORDINGS SAYING BY PARENTS|The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
79305270|NCT04942431|Behavioral|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
79305271|NCT04942119|Other|Multifactorial intervention|"Correction of magnesium and/or potassium deficit and the underlying disease.~Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
79305272|NCT04949451|Dietary Supplement|Whey protein supplement|Participants consume whey protein at the beginning of the eating period.
79305273|NCT04949451|Dietary Supplement|Ketogenic aid|Participants consume ketogenic aid upon waking.
79305274|NCT04949451|Other|Control group - time restricted feeding only|Time restricted feeding.
79382032|NCT03305328|Device|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
79693428|NCT03310905|Procedure|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
79693429|NCT03295682|Device|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
79536610|NCT02265770|Drug|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
79838721|NCT00766298|Behavioral|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
79536611|NCT02265770|Radiation|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
79536612|NCT02140242|Drug|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
79693430|NCT03283085|Drug|25 mg Ontamalimab|Ontamalimab sterile aqueous buffered solution will be administered in dose of 25 mg subcutaneously.
79693431|NCT03283085|Drug|75 mg Ontamalimab|Ontamalimab sterile aqueous buffered solution will be administered in dose of 75 mg subcutaneously.
79693432|NCT03266276|Other|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
79693433|NCT03224767|Drug|Vemurafenib|Given PO
79838722|NCT00766298|Behavioral|Weight Loss|The reduction of kcal/day through implementation of low fat diet
79838723|NCT00766298|Behavioral|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
79242500|NCT03395535|Procedure|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
79305275|NCT04942197|Other|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
79305276|NCT04949217|Procedure|Inlay Bristow|A modified Bristow procedure
79382033|NCT04350346|Drug|Motilitone|"Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~Pharmacological action:~It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
79536613|NCT02140242|Procedure|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
79693434|NCT03224767|Drug|Cobimetinib|Given PO
79693435|NCT03224767|Other|Laboratory Biomarker Analysis|Correlative studies
79305277|NCT04949217|Procedure|Bristow|Traditional Bristow procedure
79536614|NCT02050906|Behavioral|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
79693436|NCT03224767|Other|Quality-of-Life Assessment|Ancillary studies
79693437|NCT03202602|Other|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
79693438|NCT03202602|Other|Standard care|Office visits and monitoring of CPAP treatment at each visit.
79693439|NCT03198416|Device|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
79838724|NCT00569166|Behavioral|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
79838725|NCT00569166|Behavioral|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
79838726|NCT00569166|Behavioral|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
79838727|NCT00764426|Drug|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
79838728|NCT00764426|Drug|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
79242501|NCT03395535|Drug|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
79242502|NCT03611491|Device|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
79242503|NCT02748863|Drug|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
79838729|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
79242504|NCT02748863|Drug|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
79242505|NCT02748863|Drug|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
79242506|NCT02244554|Device|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
79536615|NCT02050906|Behavioral|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
79242507|NCT03611413|Procedure|ERAS care|ERAS PROTOCOL
79242508|NCT03392337|Device|Narrowband UVB phototherapy|Ultraviolet B phototherapy
79242509|NCT03611179|Drug|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
79693440|NCT03181399|Drug|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
79242510|NCT03126123|Procedure|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
79242511|NCT02353676|Drug|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
79693441|NCT03181061|Other|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
79242512|NCT02353676|Other|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
79242513|NCT03395457|Drug|Care as usual|Application of usual pharmacological care for chronic migraine
79242514|NCT03395457|Other|Manual Therapy|5 sessions of manual therapy over 12 weeks
79242515|NCT02032615|Dietary Supplement|Education plus Gudness Nutritional Bar|
79242516|NCT02032615|Other|Education|
79242517|NCT02347748|Behavioral|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
79242518|NCT02347748|Behavioral|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
79536616|NCT02050906|Other|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
79536617|NCT02050906|Behavioral|telephone based counseling|Undergo behavioral activity and nutritional counseling
79693442|NCT03173950|Drug|Nivolumab|Participants will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
79242519|NCT02347748|Behavioral|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
79242520|NCT02520375|Other|Prebiotic|
79242521|NCT02520375|Other|Control|
79242522|NCT03617627|Behavioral|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
79242523|NCT03611647|Dietary Supplement|Probiotic|Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.
79242524|NCT03611647|Dietary Supplement|Placebo|Placebo, taken by mouth once daily for 4-6 weeks.
79693443|NCT03142893|Drug|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
79693444|NCT03142893|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
79242525|NCT03395379|Procedure|RFA|Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
79242526|NCT02347514|Behavioral|Diabetes group visit|
79536618|NCT02050906|Procedure|quality-of-life assessment|Ancillary studies
79536619|NCT02050906|Other|questionnaire administration|Ancillary studies
79693445|NCT03142893|Drug|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
79693446|NCT03142893|Drug|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
79693447|NCT03142893|Drug|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
79693448|NCT03142893|Drug|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
79838730|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
80016811|NCT02285738|Drug|Simvastatin|Daily dose of Simvastatin for 4 weeks
79838731|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
79838732|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
79242527|NCT03392259|Behavioral|Smartphone app|Installment and use of smartphone app
79242528|NCT02032849|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
79242529|NCT02032849|Device|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
79242530|NCT02347592|Device|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
79242531|NCT02347592|Device|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
79242532|NCT03395301|Device|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
79242533|NCT03617315|Drug|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
79242534|NCT02349932|Other|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
79838733|NCT00807378|Other|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
79242535|NCT05168007|Drug|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
79242536|NCT05168007|Drug|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
79382034|NCT04350346|Drug|Gasmotin|"Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
79242537|NCT05168007|Drug|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
79242538|NCT04203173|Behavioral|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
79242539|NCT04203173|Behavioral|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
79305278|NCT04960449|Procedure|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
79305279|NCT04410393|Procedure|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
79382035|NCT00703092|Drug|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
79693449|NCT03142893|Drug|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
79693450|NCT03142893|Drug|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
79693451|NCT03142893|Drug|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
79382036|NCT03305172|Behavioral|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
79536620|NCT02043158|Behavioral|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
79693452|NCT03142893|Drug|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
79536621|NCT02043158|Behavioral|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
79536622|NCT01990196|Drug|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
79693453|NCT03142893|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
79693454|NCT03142893|Drug|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
79838734|NCT04048772|Behavioral|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
79838735|NCT04048772|Other|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
79838736|NCT00764582|Drug|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
80016812|NCT02285738|Other|Observation|participants will be observed for thrombotic evens for 4 weeks
80016813|NCT03556410|Behavioral|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
79382037|NCT05697822|Other|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
79382038|NCT01968538|Radiation|Radiation Therapy|
79693455|NCT03094312|Procedure|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
79693456|NCT03073304|Drug|Crystalloid based prime solution|Crystalloid based prime solution
79838737|NCT00764582|Drug|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
79693457|NCT03073304|Drug|Erythrocyte based prime solution|Erythrocyte based prime solution
79693458|NCT02999022|Drug|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
79838738|NCT00766454|Genetic|DNA analysis|
79242540|NCT02032927|Drug|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
79242541|NCT02032927|Drug|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
79242542|NCT02353598|Drug|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
79382039|NCT03300414|Other|One time blood draw|Same as part 1
79382040|NCT04058470|Drug|Toripalimab, Rituximab|Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.
79536623|NCT01990196|Drug|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
79536624|NCT01990196|Drug|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
79536625|NCT01990196|Drug|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
79693459|NCT02999022|Drug|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
79693460|NCT02996955|Behavioral|social support|behaviour change intervention
79693461|NCT02996955|Behavioral|treatment of illness perceptions|educational interview
79693462|NCT02996955|Device|Activ8|wearing a move monitor
79693463|NCT02996955|Other|activity advice|walking or cycling 5 days a week during at least half an hour
79693464|NCT02927301|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
79693465|NCT02907398|Device|Inspire therapy|
79693466|NCT02907398|Other|No intervention|
79693467|NCT02892123|Drug|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
79693468|NCT02892123|Drug|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
79838739|NCT00766454|Genetic|mutation analysis|
79838740|NCT00766454|Genetic|polymorphism analysis|
79838741|NCT00766454|Other|laboratory biomarker analysis|
79838742|NCT00766454|Other|medical chart review|
79838743|NCT00766454|Other|questionnaire administration|
79838744|NCT00766454|Procedure|evaluation of cancer risk factors|
79838745|NCT00813618|Drug|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
79838746|NCT00813618|Drug|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
79838747|NCT00813618|Drug|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
79838748|NCT00771212|Other|Observational pain control study|Observational pain control study
79838749|NCT02557802|Biological|Fluenz Tetra|Intranasal spray, 0.2 ml dose
79838750|NCT02557802|Biological|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
79838751|NCT04048226|Drug|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
79693469|NCT02892123|Drug|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
79536626|NCT01780727|Procedure|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
79693470|NCT02892123|Drug|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
79693471|NCT02892123|Drug|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
79693472|NCT02892123|Drug|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
79693473|NCT02754323|Device|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
79242543|NCT02353598|Drug|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
79693474|NCT02737878|Behavioral|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
79838752|NCT04048226|Drug|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
79838753|NCT00811746|Drug|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
79838754|NCT00811746|Drug|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
79242544|NCT02353598|Drug|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
79242545|NCT02353598|Drug|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
79242546|NCT03392181|Drug|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
79242547|NCT02353520|Other|motricity index strength assessment|
79242548|NCT03617159|Device|Magnetic Resonance Imaging|Diagnostic Modality
79382041|NCT04058470|Drug|R-CHOP Protocol|After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
79382042|NCT05696808|Dietary Supplement|IHPD|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
79838755|NCT00811746|Other|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
79242549|NCT03862989|Procedure|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
79382043|NCT05696808|Dietary Supplement|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
79536627|NCT01612351|Drug|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
79242550|NCT03158324|Drug|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
79242551|NCT04871945|Diagnostic Test|Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
79536628|NCT01612351|Drug|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
79838756|NCT00766766|Behavioral|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
79838757|NCT00766766|Behavioral|Telephone Coaching Sessions|Telephone Coaching Sessions
79838758|NCT00766766|Behavioral|Physician Feedback Letter|Physician Feedback Letter
79838759|NCT04048070|Drug|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
79242552|NCT03611257|Diagnostic Test|dRAST|Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
79536629|NCT01612351|Drug|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
79838760|NCT04048070|Drug|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
79838761|NCT04048070|Behavioral|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
79242553|NCT03611257|Diagnostic Test|Current standard method|Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
79242554|NCT03392103|Drug|Raltitrexed|concurrent chemotherapy
79242555|NCT03392103|Radiation|postoperative radiotherapy|concurrent postoperative radiation therapy
79242556|NCT03617081|Drug|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
79242557|NCT03617081|Drug|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
79838762|NCT04048070|Behavioral|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
79838763|NCT04048070|Behavioral|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
79242558|NCT02350010|Device|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
79382044|NCT04465708|Behavioral|Homework, Organization, and Planning Skills|HOPS is a 16-session, skills training program, provided individually to students in grades 6 through 8 who have OTMP skills deficits that contribute to academic difficulties. HOPS includes two parent consultations and one teacher consultation to promote generalization and maintenance of effects.
79382045|NCT02467530|Other|AGE|
79382046|NCT02467296|Other|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
79242559|NCT03616925|Biological|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
79536630|NCT01612351|Drug|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
79693475|NCT02737878|Behavioral|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
79693476|NCT02737878|Behavioral|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
79693477|NCT02737878|Behavioral|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
79693478|NCT02735109|Other|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
79693479|NCT02735109|Procedure|biopsy normal area|biopsy done to compare with abnormal area
79838764|NCT04048070|Behavioral|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
79838765|NCT00655356|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
79838766|NCT00655356|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
79242560|NCT03616925|Procedure|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
79242561|NCT02349776|Other|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
79536631|NCT01612351|Drug|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
79536632|NCT01612351|Radiation|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
79536633|NCT01612351|Radiation|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
79536634|NCT01612351|Procedure|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
79536635|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
80009465|NCT04487691|Biological|Nebulized Platelet Lysate|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
79693480|NCT02720874|Behavioral|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
80009466|NCT04487691|Other|Nebulized Sterile Saline|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
79242562|NCT03392025|Other|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
79242563|NCT03392025|Other|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
79242564|NCT03392025|Dietary Supplement|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
79382047|NCT03300102|Other|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
79536636|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
79536637|NCT01376505|Biological|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
79536638|NCT01376505|Biological|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
79693481|NCT02720874|Behavioral|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
79693482|NCT02720874|Behavioral|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
79838767|NCT00571064|Drug|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
80009467|NCT01382641|Device|Hoya AF-1 IOL|The patients will be assessed for three months
79536639|NCT01336920|Drug|carfilzomib|Given IV
80009468|NCT01382641|Device|Revital vision|The patients will be assessed for three months.
80009469|NCT04694833|Behavioral|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
79536640|NCT01256593|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
80009470|NCT04694833|Behavioral|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
79242565|NCT03610945|Drug|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
79242566|NCT03610945|Drug|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
79242567|NCT03610945|Drug|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
79242568|NCT03610945|Drug|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
79242569|NCT03616847|Other|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
79242570|NCT03616847|Other|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
79382048|NCT02720484|Other|Laboratory Biomarker Analysis|Correlative studies
79382049|NCT02720484|Drug|Nivolumab|Given IV
79382050|NCT05438550|Drug|14-day high-dose Tegoprazan Dual Therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
79242571|NCT02349854|Procedure|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm & 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
79242572|NCT02032693|Dietary Supplement|Everycell™|
79242573|NCT02032693|Other|Placebo|
79242574|NCT03391947|Procedure|semilunar coronally positioned flap|The description of this intervention has been already given before
79242575|NCT03391947|Procedure|coronally advanced flap|The description of this intervention has been already given before
79693483|NCT02720874|Behavioral|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
79242576|NCT02349698|Biological|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
79536641|NCT01215201|Procedure|Scaling and Root Planing|Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
79693484|NCT02720874|Behavioral|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
79242577|NCT03616769|Drug|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
79242578|NCT03610867|Drug|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
79242579|NCT03610867|Drug|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
79242580|NCT03610867|Drug|Placebo (SAD)|Each subject will receive the sample once by oral administration.
79242581|NCT03610867|Drug|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
79242582|NCT05167851|Drug|Lazertinib , a combination group of SBRT|"* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
79242583|NCT05167851|Drug|Lazertinib single administration group|"* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
79382051|NCT03299868|Device|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
79382052|NCT02466672|Other|none - observational only|
79536642|NCT01215201|Procedure|Diode Laser + Scaling and Root Planing|First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
79242584|NCT02236715|Drug|Atrovent®|
79382053|NCT05403684|Other|High-volume breastmilk|Preterm infants will be given high-volume breastmilk
79382054|NCT02466282|Device|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
79693485|NCT02669394|Behavioral|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
79693486|NCT02669394|Behavioral|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
79536643|NCT01179009|Drug|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.).
79693487|NCT02659930|Drug|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
79693488|NCT02659930|Drug|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
79242585|NCT02349620|Biological|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
79536644|NCT01179009|Drug|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
79536645|NCT01179009|Drug|placebo|IV saline (i.e. placebo ketamine)
79242586|NCT02032771|Device|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
79242587|NCT03823365|Biological|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~(starting dose) 3.0 x 109~6.0 x 109~9.0 x 109~12.0 x 109"
79242588|NCT03616691|Drug|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
79536646|NCT01000038|Other|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
79382055|NCT02466282|Device|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
79382056|NCT03299790|Other|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
79693489|NCT02653976|Drug|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
79693490|NCT02611037|Drug|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
79838768|NCT00811824|Behavioral|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
79382057|NCT03299790|Other|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
80009471|NCT00974571|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
80009472|NCT00974571|Drug|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
80009473|NCT00974571|Drug|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
79242589|NCT03616691|Drug|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
79242590|NCT03158168|Drug|Candida Antigen|Candida Albicans Antigen injection
79242591|NCT03158168|Drug|Zinc Sulfate|Zinc Sulfate injection
79242592|NCT03157154|Other|Non interventional study|A query form to all concerned patients by each investigating centre will be send
79242593|NCT04282317|Other|MRI scan|MRI scan
79242594|NCT02865499|Drug|acarbose|acarbose treatment with meals
79382058|NCT03299712|Device|ArteFill|soft tissue filler
79382059|NCT05388396|Other|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
79536647|NCT01000038|Other|Walking|Half hour daily, five days a week for 8 weeks
79536648|NCT00918775|Other|Follow-Up Care|Undergo follow-up
79536649|NCT00918775|Other|Laboratory Biomarker Analysis|Correlative studies
79536650|NCT00798551|Behavioral|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
79536651|NCT00562640|Biological|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
79536652|NCT00562640|Biological|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
79536653|NCT00562640|Drug|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
79536654|NCT00562640|Other|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
80009474|NCT02766608|Drug|BFF MDI 320/9.6 μg|Blinded Treatment
80009475|NCT02766608|Drug|BFF MDI 160/9.6 μg|Blinded Treatment
80009476|NCT02766608|Drug|FF MDI 9.6 μg|Blinded Treatment
80009477|NCT02766608|Drug|BD MDI 320 μg|Blinded Treatment
80009478|NCT02766608|Drug|Symbicort® TBH 400/12 μg BID|Open Label
79242595|NCT04478552|Procedure|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
79242596|NCT04478552|Procedure|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
79242597|NCT04619953|Other|Dynamic Postural Stability Training|The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
79242598|NCT04619953|Other|Cognitive-Motor Training|The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
79693491|NCT02611037|Drug|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m^2).
80016814|NCT03556410|Behavioral|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
79242599|NCT04619953|Other|Conventional Therapy|The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
79242600|NCT02870933|Biological|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
79693492|NCT02611037|Drug|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
80016815|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
79242601|NCT03156062|Drug|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
79242602|NCT04269603|Device|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
79242603|NCT02031887|Dietary Supplement|formula with synbiotics|
79242604|NCT02031887|Dietary Supplement|formula without synbiotics|
79382060|NCT03299634|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
79382061|NCT05382858|Device|Deep brain stimulation|active DBS with optimal stimulating parameters
79382062|NCT03299556|Other|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
79536655|NCT04791917|Behavioral|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
79536656|NCT04791917|Behavioral|Concentric Biceps Flexion|Muscle shortening biceps exercise
79536657|NCT04791384|Drug|Abemaciclib|taken orally
80016816|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
79242605|NCT05167617|Drug|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
79242606|NCT05239377|Other|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
79242607|NCT03146624|Other|attachment retained obturator|obturator which retained by attachment
79242608|NCT03146624|Other|clasp retained obturator|obturator which retained by clasp
79242609|NCT03616613|Diagnostic Test|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
79382063|NCT05352204|Procedure|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization after liver resection
79382064|NCT05327556|Drug|Epinephrine 0.5 mcg/kg|Syringe with 5 mcg/mL epinephrine
79382065|NCT05327556|Drug|Epinephrine 1 mcg/kg|Syringe with 10 mcg/mL epinephrine
79382066|NCT02466438|Drug|Piperacillin-tazobactam|"Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~Acute Kidney injury : Dosing as prescribed by treating physician"
79382067|NCT05587062|Biological|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
79382068|NCT05587062|Biological|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
79536658|NCT04791384|Drug|Elacestrant|taken orally
79536659|NCT04787302|Drug|CVL-231|Cohort 1: 30mg dose of CVL-231
79536660|NCT04787302|Drug|CVL-231|Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded
79693493|NCT02611037|Other|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
79242610|NCT02033161|Behavioral|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
79242611|NCT02349464|Other|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
79242612|NCT05239065|Behavioral|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
79536661|NCT04787302|Drug|CVL-231|Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
79536662|NCT04787289|Drug|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
79536663|NCT04785417|Other|touch screen tablet|traditional occupational therapy in addition to games on tablet
79536664|NCT04784221|Radiation|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
79536665|NCT04781361|Drug|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
79693494|NCT02607202|Drug|nab-paclitaxel|
79693495|NCT02607202|Drug|Carboplatin|
79693496|NCT02607202|Drug|Gemcitabine|
79693497|NCT02573441|Behavioral|Jump Math|Jump Math is a workbook based program aimed at improving math skills
79536666|NCT04781361|Drug|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride < 130 mmol/L"
79693498|NCT02573441|Behavioral|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
79693499|NCT02573441|Behavioral|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
79536667|NCT04773587|Drug|ARQ-151 Active|ARQ-151 Cream 0.15% - Active
79536668|NCT04773587|Drug|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
79693500|NCT02560662|Behavioral|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
79693501|NCT02429479|Behavioral|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
80016817|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
79305280|NCT04960527|Dietary Supplement|Tart cherry juice|250 mL tart cherry juice (30 mL tart cherry concentrate [CherryActive, UK] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
79382072|NCT05322876|Behavioral|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
79382073|NCT03299400|Device|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
79382074|NCT02464566|Behavioral|Intensive lifestyle intervention|
79382075|NCT02464566|Other|Health Education|
79693502|NCT02429479|Behavioral|Standard advance care planning|This is a online simple living will form.
79693503|NCT02402660|Drug|ALK-001|Daily, oral administration for 24 months
79305281|NCT04960527|Other|Water|250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
79305282|NCT04948593|Procedure|Native kidney biopsy|
79382076|NCT05516004|Device|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
79382077|NCT05257512|Drug|SY-3505|The third-generation ALK TKI
79382078|NCT04489680|Other|Educational|Teaching session
79382079|NCT02463006|Drug|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
79536669|NCT04767555|Procedure|ILM (inner limiting membrane) peeling|The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
79536670|NCT04751760|Biological|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
79693504|NCT02402660|Drug|Placebo|Daily, oral administration for 24 months
79305283|NCT00700817|Drug|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
79305284|NCT00700817|Drug|sitagliptin|Tablets, 100 mg daily
79693505|NCT02347228|Drug|OB318 capsule|Oral qd, at least 30 minutes before breakfast
79838769|NCT04045626|Procedure|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
80016818|NCT02090400|Drug|Bazedoxifene|20 mg Oral daily for 12 months
79305285|NCT00700817|Drug|metformin|Tablets, minimum 1500 mg daily
79382080|NCT02463006|Drug|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
79382081|NCT02463084|Other|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
79382082|NCT02463084|Other|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
79382083|NCT04756908|Device|Cataract Surgery|The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
79382084|NCT02466204|Drug|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
80016819|NCT02090400|Drug|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
80016820|NCT04471610|Other|Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day|Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
79693506|NCT02309840|Behavioral|choice architecture|"Place vegetables at the beginning of the lunch line.~Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~Promote fruits and vegetables with prominently displayed signage and images.~Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
79242613|NCT05239065|Behavioral|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
79693507|NCT02309840|Other|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
79382085|NCT02466204|Drug|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
79693508|NCT02162420|Drug|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
79693509|NCT02162420|Drug|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
79382086|NCT02462694|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
79382087|NCT02462694|Behavioral|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
79382088|NCT02715804|Other|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
79382089|NCT02715804|Drug|Placebo|Matching placebo for PEGPH20
79693510|NCT02162420|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
79693511|NCT02162420|Radiation|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
79693512|NCT02162420|Biological|Stem Cell Transplant|Stem cell transplant on day 0.
79693513|NCT02162420|Drug|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
79693514|NCT02040376|Drug|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
79838770|NCT04045392|Behavioral|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
80016821|NCT02090478|Other|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
79242614|NCT03616457|Device|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
79242615|NCT02349308|Device|CentrosFLO Long Term Hemodialysis Catheter|
79242616|NCT03404739|Drug|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
79242617|NCT03404739|Drug|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
79382090|NCT02715804|Drug|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
79382091|NCT02715804|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
79693515|NCT02040376|Drug|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
79693516|NCT01944761|Behavioral|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) [10 mins], ii) aerobic training/fitness games [30 mins], iii) organized sports [30 mins], iv) cool down (i.e. stretching, low intensity games) [10 mins] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
79693517|NCT01850888|Drug|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
79693518|NCT01850888|Drug|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
79693519|NCT01850888|Drug|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000).
79536671|NCT04749641|Biological|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
79242618|NCT03155516|Other|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
79838771|NCT00811980|Drug|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
79242619|NCT03155516|Other|Current practice procedure|Current practice clinical procedure for pain management
79382092|NCT04749264|Behavioral|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
79838772|NCT00766844|Device|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
79382093|NCT02466360|Behavioral|Back Belief questionnaire|
79382094|NCT02466360|Behavioral|QUEBEC scale|
79382095|NCT02466360|Behavioral|Fear Avoidance beliefs questionnaire|
79693520|NCT01850888|Procedure|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum > 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum >2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
79382096|NCT02466360|Behavioral|Visual analog scale|
79838773|NCT03895372|Drug|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
79242620|NCT02031965|Biological|oncolytic HSV-1716|Given IT
79242621|NCT02031965|Drug|dexamethasone|Given IV
79382097|NCT02466360|Behavioral|individual interviews|
79242622|NCT02031965|Procedure|therapeutic conventional surgery|Undergo surgical resection
79382098|NCT02466360|Behavioral|Focus groups|
79382099|NCT04745130|Drug|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
79242623|NCT02031965|Other|laboratory biomarker analysis|Correlative studies
79382100|NCT04745130|Drug|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
79382101|NCT02462616|Other|not intervention|This is a cross-sectional study, no intervention was performed.
79382102|NCT04490226|Dietary Supplement|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
79382103|NCT04490226|Dietary Supplement|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
79693521|NCT01785316|Procedure|IHP|
79693522|NCT01652092|Drug|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
79693523|NCT01652092|Drug|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
79693524|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
79838774|NCT03895372|Drug|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
79838775|NCT02551926|Behavioral|mobile text messages|
79838776|NCT02551926|Behavioral|virtual community|
79838777|NCT02551926|Behavioral|brochures|
79838778|NCT02551926|Other|Usual care|
79838779|NCT02551926|Device|mobile phone|
79838780|NCT00775034|Drug|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
79838781|NCT00775034|Procedure|Drainage|Mesh repair for open incisional hernia repair with drainage
79838782|NCT00813696|Drug|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
79838783|NCT00813696|Drug|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
79838784|NCT02557880|Behavioral|Sleep Application Diary|Tool used to document sleep hygiene.
79838785|NCT02557880|Behavioral|Treatment As Usual|Sleep hygiene counseling
79838786|NCT00771290|Procedure|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
79838787|NCT00813774|Biological|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
79838788|NCT00813774|Biological|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
79693525|NCT01652092|Biological|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10^7 nucleated cells/kg."
79838789|NCT00813774|Biological|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
79242624|NCT03395067|Behavioral|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
79693526|NCT01652092|Drug|Fludarabine phosphate 40 mg|40 mg/m^2 IV on days -5 through -2 (for children < 6 months and/or < 10 kg weight dose at 1.33 mg/kg)
79693527|NCT01652092|Drug|Melphalan|140 mg/m^2 IV on day -3
79693528|NCT01652092|Drug|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
79242625|NCT02347280|Procedure|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
79693529|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
79838790|NCT02557490|Drug|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
79242626|NCT02347280|Procedure|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
79382104|NCT04490226|Dietary Supplement|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
79382105|NCT04490226|Dietary Supplement|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
80009479|NCT01382485|Other|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
79242627|NCT03404271|Dietary Supplement|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
79838791|NCT00775112|Device|pillow|use of pillow for lumbar punctures
80016822|NCT02090478|Other|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
79242628|NCT03404271|Other|Resistance Training|Performing supervised resistance training three times per week.
79242629|NCT03404271|Dietary Supplement|Protein Supplementation|Consuming a protein supplement daily.
79242630|NCT03404271|Behavioral|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
79242631|NCT03615209|Device|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
79242632|NCT03615209|Device|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
79242633|NCT03149120|Biological|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
79242634|NCT03149120|Drug|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
79242635|NCT04849325|Device|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
79382106|NCT02464800|Procedure|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
79382107|NCT02462304|Procedure|End-Point-Management grid laser|
79382108|NCT02462304|Drug|ranibizumab|
79693530|NCT01652092|Drug|Fludarabine phosphate 30 mg|fludarabine 30 mg/m^2 IV on days -8 through -4
79693531|NCT01652092|Drug|MESNA|administered as per the standard institutional protocol.
79693532|NCT01566695|Drug|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
79693533|NCT01566695|Drug|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
79693534|NCT01566695|Other|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell [pRBC] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
79693535|NCT01506141|Drug|Idursulfase-IT|Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
79693536|NCT01506141|Drug|Elaprase|Participants will receive weekly IV infusions of commercially available Elaprase.
79693537|NCT01468883|Procedure|M|Modified radical mastectomy
79693538|NCT01468883|Radiation|X|Excisional biopsy plus radiation
79693539|NCT01451502|Biological|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
79242636|NCT04849325|Device|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
79693540|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
79242637|NCT03403023|Device|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
79693541|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
79693542|NCT01081951|Drug|olaparib|Tablets Oral BID
79838792|NCT00813852|Behavioral|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
79242638|NCT03403023|Drug|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
79242639|NCT03155594|Device|Freestyle Libre|Continuous glucose monitoring patch
79693543|NCT01081951|Drug|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
79838793|NCT02551848|Drug|Botulinum toxin type A|
79242640|NCT02864407|Drug|Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
79382109|NCT02462304|Drug|Bevacizumab|
79382110|NCT04489602|Other|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
79382111|NCT05140200|Biological|GSK3511294|GSK3511294 will be administered.
79382112|NCT05133102|Other|Sample collection|Collection of saliva sample
79382113|NCT03369210|Drug|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
79693544|NCT01081951|Drug|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
79693545|NCT01081951|Drug|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
79693546|NCT01081951|Drug|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
79693547|NCT00777582|Drug|AZD2281|Oral single dose formulation
79838794|NCT00807534|Drug|ipratropium bromide|ipratropium bromide nebulization
79838795|NCT00807534|Drug|placebo|placebo nebulization
79838796|NCT00807534|Behavioral|constant rate step test|nebulization of 500ug
79838797|NCT00807534|Behavioral|constant rate shuttle walk test|nebulization of 500ug
80016823|NCT03134846|Drug|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
79242641|NCT03391791|Genetic|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
79242642|NCT03149198|Other|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
79305286|NCT00700817|Drug|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
79382114|NCT02466048|Procedure|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
79693548|NCT00736385|Drug|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
79693549|NCT00736385|Drug|Placebo|placebo 2000 mg daily for 12 months
79693550|NCT00392327|Drug|Carboplatin|Given IV
79693551|NCT00392327|Drug|Cisplatin|Given IV
79693552|NCT00392327|Drug|Cyclophosphamide|Given IV
79693553|NCT00392327|Biological|Filgrastim|Given IV or SC
79693554|NCT00392327|Drug|Isotretinoin|Given PO
79693555|NCT00392327|Other|Laboratory Biomarker Analysis|Correlative studies
79693556|NCT00392327|Other|Quality-of-Life Assessment|Ancillary studies
79693557|NCT00392327|Radiation|Radiation Therapy|Undergo radiation therapy
79693558|NCT00392327|Drug|Vincristine Sulfate|Given IV
79838798|NCT00812058|Drug|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
79838799|NCT00812058|Drug|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
79838800|NCT05589142|Behavioral|Time Restricted Eating|Eating calories only during a specific feeding window.
79838801|NCT05589064|Behavioral|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
80009480|NCT01382485|Other|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
80009481|NCT03630731|Drug|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
80009482|NCT01382407|Drug|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
80009483|NCT02235857|Device|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
79242643|NCT03149198|Other|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
79838802|NCT05589064|Dietary Supplement|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
79242644|NCT03616301|Drug|Clavamox|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
79693559|NCT00357565|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
80009484|NCT01382329|Biological|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
80009485|NCT03325231|Other|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
80009486|NCT03317119|Other|Laboratory Biomarker Analysis|Correlative studies
80009487|NCT03317119|Drug|Trametinib|Given PO
80009488|NCT03317119|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
80009489|NCT05347589|Other|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
80009490|NCT05347589|Other|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
80016824|NCT02094456|Procedure|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
79242645|NCT03616301|Drug|Augmentin®|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
79382115|NCT02466048|Device|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
79693560|NCT00357565|Drug|busulfan|Administered 1.1 mg/kg if <12 kg intravenous (IV) every 6 hours (0.8 mg/kg if >12 kg IV every 6 hours on Days -8 through -5.
79693561|NCT00357565|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of >200 ng/mL. For children < 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
79838803|NCT05589064|Behavioral|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
79838804|NCT00807690|Drug|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
79242646|NCT03149276|Other|Interpreter services|
79382116|NCT02465970|Device|STARSTIM|"Multifocal transcranial direct current stimulation.~CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~The stimulation is applied during a 60 min session"
79382117|NCT02465970|Device|sham TDCS|
79242647|NCT03391713|Behavioral|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
79242648|NCT03394989|Drug|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
79242649|NCT03394989|Other|Placebo|Placebo
79242650|NCT03394989|Drug|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
79382118|NCT04662372|Other|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
79693562|NCT00357565|Drug|fludarabine phosphate|Administered 25 mg/m^2 intravenous (IV) over 60 minutes on Days -4 through -2.
79693563|NCT00357565|Drug|melphalan|Administered 60 mg/m^2 intravenous (IV) over 30 minutes on Days -4 through -2.
80009491|NCT05347355|Other|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
79382119|NCT02465892|Behavioral|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
80009492|NCT05347355|Other|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
80009493|NCT02157350|Procedure|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
79382120|NCT02465814|Drug|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
79382121|NCT02465814|Drug|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
79382122|NCT02465814|Drug|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
79382123|NCT02465814|Drug|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
79242651|NCT02033239|Drug|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
79242652|NCT02033239|Drug|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
79242653|NCT02353364|Other|PGS|Embryos screened by the validated NGS technology CNV-Seq
79305287|NCT04960293|Procedure|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
79382124|NCT02465814|Drug|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
79382125|NCT02465814|Drug|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
79382126|NCT02465814|Drug|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
79382127|NCT04645212|Biological|ADVM-022|Long term follow-up of subjects that received ADVM-022
79693564|NCT00357565|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients <45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
79693565|NCT00357565|Procedure|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
79693566|NCT00352534|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
79693567|NCT00352534|Biological|Dactinomycin|Given IV
79693568|NCT00352534|Drug|Doxorubicin Hydrochloride|Given IV
79382128|NCT05093244|Device|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
79382129|NCT05093244|Device|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
79382130|NCT04617132|Behavioral|MBCT/MBSR|This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
79382131|NCT04489446|Drug|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
79382132|NCT04489446|Drug|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
79693569|NCT00352534|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79693570|NCT00352534|Drug|Vincristine Sulfate|Given IV
79693572|NCT00001721|Drug|Cholesterol Suspension|
79693573|NCT00001721|Drug|CRH|
79693574|NCT00001721|Drug|Cholesterol|
80009494|NCT03252535|Biological|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
80009495|NCT03252535|Biological|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
79242654|NCT05167149|Procedure|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
79305288|NCT04960293|Procedure|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
79693575|NCT02910440|Drug|DCL-101 vs Golytely|
79382133|NCT03198234|Biological|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
79382134|NCT02717832|Drug|hyperinsulinemic-euglycemic clamp|
79382135|NCT02717754|Drug|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
79382136|NCT02717754|Drug|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
79382137|NCT04550676|Behavioral|HIIT (intervention)|Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
79382138|NCT04550676|Behavioral|CME (active control)|Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
79382139|NCT03136848|Drug|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
79382140|NCT02465658|Other|Medical records were reviewed.|retrospective study
79382141|NCT05040750|Other|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
79693576|NCT04676997|Biological|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
79693577|NCT04676997|Drug|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
79693578|NCT04676997|Drug|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
79693579|NCT04676997|Drug|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
79838805|NCT00813930|Behavioral|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
80009496|NCT03252535|Other|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
79382142|NCT04705350|Drug|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
79693580|NCT01217047|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
79693581|NCT01217047|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
80009497|NCT04356495|Dietary Supplement|Vitamins|2 tablets daily from the first day (day 0) to day 9
80009498|NCT04356495|Drug|Telmisartan|1 tablet daily from the first day (day 0) to day 9
80009499|NCT04356495|Drug|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
80009500|NCT04356495|Drug|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
80009501|NCT03542084|Other|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
80009502|NCT03230695|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
80009503|NCT03230695|Device|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
79382143|NCT04705350|Drug|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
80009504|NCT03230695|Device|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
79242655|NCT05167149|Procedure|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
79242656|NCT03615131|Diagnostic Test|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
79382144|NCT04467606|Behavioral|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
79242657|NCT02486302|Drug|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
79242658|NCT02353286|Device|Endoscopic insertion of biodegradable biliary stent|Endoscopic insertion of biodegradable biliary stent
79242659|NCT03394911|Biological|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
79382145|NCT02717130|Drug|Aripiprazole|
80009505|NCT05654961|Other|Use of telemedicine|Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
79693582|NCT01217047|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
80009506|NCT02154230|Dietary Supplement|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
80009507|NCT02154230|Dietary Supplement|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
80009508|NCT01384045|Other|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
79242660|NCT02033629|Drug|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
79242661|NCT02033629|Drug|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
79382146|NCT04947384|Diagnostic Test|To discern micro-RNA specific for right and left heart induced PH|While undergoing other procedures, the investigators will be collecting a total of three blood samples. The first sample will be obtained on arterial cannulation before the initiation of the intervention, the second sample will be collected upon the end of the procedure prior to leaving the procedure room, and the third sample will be collected on the day of discharge from the hospital.
79382147|NCT02256696|Drug|PA-824|200 mg QD
79693583|NCT01217047|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
79693584|NCT00624403|Device|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
79693585|NCT00624403|Device|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
80009509|NCT04724941|Other|No intervention|No intervention
79382148|NCT02256696|Drug|Rifampin|600 mg QD
79382149|NCT02256696|Drug|Rifabutin|300 mg QD
79382150|NCT02256696|Drug|Pyrazinamide|25mg/kg QD
79838806|NCT05355844|Drug|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
80009510|NCT04200963|Drug|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
80009511|NCT04200963|Drug|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
80009512|NCT02157428|Drug|Flumazenil|
80009513|NCT02157428|Drug|saline|
80009514|NCT01383967|Drug|LY2979165|Administered orally
80009515|NCT01383967|Drug|placebo|Administered orally
80009516|NCT02254928|Drug|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
80009517|NCT01383889|Other|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
80009518|NCT00960141|Drug|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
80009519|NCT00960141|Drug|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
79382151|NCT02256696|Drug|Ethambutol|15mg/kg QD
79382152|NCT02256696|Drug|Isoniazid|300 mg QD
80009520|NCT00960141|Drug|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
80009521|NCT02771522|Device|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black & white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
79382153|NCT02464488|Other|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
80009522|NCT00759655|Biological|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
79242662|NCT02033629|Drug|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
79305289|NCT04941495|Other|conventional physiotherapy|"TENS for 15 minutes on Constant Mode according to patient comfort.~Infrared for 15 minutes.~Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius & Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~Home Plan: self stretches and isometrics.~Postural Education: posture correction in daily life activities in sitting, walking, lying."
79382154|NCT02331498|Drug|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
79382155|NCT02192502|Drug|human albumin 5%|
79382156|NCT02192502|Drug|HES 130/0.4 (Voluven)|
79382157|NCT01781429|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
79382158|NCT01773473|Drug|Insulin Lispro Mix25|Administered SC
79382159|NCT01773473|Drug|Insulin Lispro Mix50|Administered SC
79382160|NCT01772693|Device|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
79382161|NCT01772693|Device|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
79382162|NCT01779869|Drug|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
79382163|NCT01772537|Drug|Propofol|Intravenous anesthetic
79382164|NCT01772537|Drug|isoflurane|
79693586|NCT02910128|Behavioral|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
80009523|NCT00518869|Drug|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
80009524|NCT02255006|Device|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
79382165|NCT04572581|Other|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
79382166|NCT01772147|Drug|Umeclidinium bromide 62.5mcg|Inhalation powder
80009525|NCT02255006|Device|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
80016825|NCT02094456|Procedure|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
80016826|NCT04471688|Diagnostic Test|infectious disease screening|Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
79382167|NCT01772147|Drug|Umeclidinium bromide 125mcg|Inhalation powder
79382168|NCT01772147|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
79382169|NCT01771913|Genetic|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
79536675|NCT04737616|Device|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
79536676|NCT04737616|Device|OCT|Optical coherence tomography endoscope
79536677|NCT04725201|Drug|Intravenous unfractionated heparin|See experimental arm description for intervention description.
79536678|NCT04725201|Drug|Sham|See sham comparator arm description for intervention description.
79536679|NCT04724239|Drug|Sintilimab|200mg IV on Day 1 Q3W
79536680|NCT04724239|Drug|Chidamide|30mg PO BIW each 3-week cycle
79693587|NCT01968720|Drug|CAT-2003|
79382170|NCT01771913|Genetic|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
79242663|NCT03148886|Other|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
79382171|NCT01606787|Drug|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
79536681|NCT04724239|Drug|IBI305|7.5mg/kg IV on Day 1 Q3W
79536682|NCT04715750|Drug|[18F]-PI2620|[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
79536683|NCT04705870|Device|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~3D T1 TFE (2 minutes)~T2 TSE (2 minutes)~3D FLAIR (3 minutes)~SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~SWI non EPI QSM 6 echo (10 minutes)~SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
79693588|NCT01968720|Drug|Placebo|
79693589|NCT02910206|Drug|Etomidate|etomidate is given intravenously
80009526|NCT02255006|Drug|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
79382172|NCT01606787|Other|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
79382173|NCT01778855|Other|IV t-PA and normothermia|
79382174|NCT01778855|Device|IV-tPA and hypothermia|
79382175|NCT04570319|Dietary Supplement|Probiotic Bths-08|A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks
79382176|NCT04570319|Dietary Supplement|Placebo|A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
79382177|NCT01777997|Drug|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
79536684|NCT04705727|Drug|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
80009527|NCT02255006|Drug|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
80009528|NCT02771366|Drug|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
80009529|NCT02771366|Other|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
80009530|NCT03396471|Drug|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
80009531|NCT03396471|Radiation|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
79536685|NCT04705727|Drug|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
79536686|NCT04677777|Biological|PP-007|PP-007 is pegylated carboxyhemoglobin
79693590|NCT02910206|Drug|propofol|propofol is given intravenously
79693591|NCT02910206|Drug|Sufentanil|sufentanil is given intravenously
79693592|NCT02910206|Drug|Cisatracurium|Cisatracurium is given intravenously
79693593|NCT04675086|Drug|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
79693594|NCT04675086|Drug|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
79536687|NCT04677777|Other|Standard of care|Patients randomized to this treatment will not receive the experimental treatment, but will receive the standard of care at the institution.
79536688|NCT04674683|Drug|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight < 40 kg, nivolumab will be dosed at specific doses on specific days.
79693595|NCT02909972|Drug|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
79838807|NCT00814008|Drug|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
79693596|NCT02909972|Drug|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
79693597|NCT01961778|Device|Radio-Frequency Ablation|
79838808|NCT00814008|Drug|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
79242664|NCT05166759|Device|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
79242665|NCT03610243|Behavioral|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
79382178|NCT01770509|Device|NMBM|Daily application of NMBM in addition to compression therapy
79382179|NCT01770509|Other|Compression garments|Compression garments
79382180|NCT01770353|Drug|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
79382181|NCT01770353|Drug|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
79382182|NCT01777763|Drug|Posaconazole 200 mg|
79382183|NCT01777763|Drug|Posaconazole 300 mg|
79693598|NCT01961778|Device|Cryotherapy|
79693599|NCT04687943|Combination Product|PELOID therapy, kinesio tape, exercise|126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
79693600|NCT04674657|Drug|blood drug concentration|blood drug concentration
79693601|NCT04688060|Diagnostic Test|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
79693602|NCT04674735|Drug|APSLXR|Oral coated tablets once a day for 60 days.
79693603|NCT00555594|Drug|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
79838809|NCT00814086|Drug|Paclitaxel|Given IV or intraperitoneally
79838810|NCT00814086|Drug|Cisplatin|Given intraperitoneally
79838811|NCT04114786|Device|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
79838812|NCT04114786|Device|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
79838813|NCT00669110|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"tablet~subjects randomly assigned to 10-200 mg/day by age group~6 month treatment period(~182 days)"
80009532|NCT00103142|Biological|falimarev|Given subcutaneously and intradermally
80009533|NCT00103142|Biological|inalimarev|Given subcutaneously and intradermally
79382184|NCT01769339|Drug|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
79382185|NCT01769105|Device|Lipiflow|Patients receive a single Lipiflow-treatment
79382186|NCT01769105|Behavioral|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
79382187|NCT01777139|Drug|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
80009534|NCT00103142|Biological|sargramostim|Given subcutaneously
80009535|NCT00103142|Biological|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
79242666|NCT02033473|Drug|Apelin|An apelin clamp in which an apelin infusion will be administered
79242667|NCT02033473|Drug|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
79838814|NCT04604860|Behavioral|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
79242668|NCT03615989|Behavioral|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
79242669|NCT03615989|Dietary Supplement|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
79242670|NCT03615989|Dietary Supplement|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
79242671|NCT03391557|Diagnostic Test|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
79242672|NCT03148808|Combination Product|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
79242673|NCT02034097|Drug|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
79382188|NCT01768637|Drug|Aspirin|Aspirin 81 mg by mouth daily
79536689|NCT04674683|Drug|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
79536690|NCT04672161|Other|Vaccine Education|A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
79536691|NCT04666740|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
79536692|NCT04666740|Drug|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
79536693|NCT04662944|Drug|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
79536694|NCT04662944|Drug|ranibizumab|There is no treatment allocation. Patients administered Ranibizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
79536695|NCT04662944|Drug|aflibercept|There is no treatment allocation. Patients administered Aflibercept by prescription that have started before inclusion of the patient into the study will be enrolled.
79382189|NCT01768637|Drug|Clopidogrel|Clopidogrel 75 mg by mouth once daily
79382190|NCT01768559|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
79382191|NCT01768559|Drug|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
79536696|NCT04657822|Drug|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
79536697|NCT04648410|Other|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
79536698|NCT04646499|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
79536699|NCT04635826|Drug|Adderall 10Mg Tablet|Participants will be administered Adderall
79536700|NCT04635826|Drug|Placebo|Participants will be administered placebo
79536701|NCT04629781|Drug|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
79536702|NCT04624945|Diagnostic Test|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
79536703|NCT04614922|Behavioral|Acceptance and Commitment Therapy|ACT-based rehabilitation is an interdisciplinary group rehabilitation which includes 7 sessions of group-based ACT therapy. Each session lasts 2½ hours and is offered twice a week. The ACT sessions will be based on a detailed intervention manual, developed specifically for group treatment. Each group will include a maximum of eight patients. The patients are asked to do homework between each ACT-group session.
79838815|NCT00654732|Drug|Bleomycin|Given IV
79838816|NCT00654732|Drug|Dacarbazine|Given IV
79242674|NCT02034097|Drug|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
79838817|NCT00654732|Drug|Doxorubicin Hydrochloride|Given IV
79838818|NCT00654732|Biological|Rituximab|Given IV
79536704|NCT04613349|Other|MRI|"All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:~New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;~Gold standard: Intraoperative examination."
79536705|NCT04608474|Drug|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
79693604|NCT02910050|Drug|Bicalutamide|50mg once a day orally
79693605|NCT02910050|Drug|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
79693606|NCT04674930|Other|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
79242675|NCT03614897|Behavioral|Education|Education on guidelines for care of individuals at risk of falling
79382192|NCT01768559|Drug|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
79382193|NCT01768559|Drug|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
79536706|NCT04608474|Drug|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
79693607|NCT02909933|Drug|liraglutide|
79693608|NCT02909933|Drug|metformin and liraglutide|
79693609|NCT01960686|Biological|Low dose RSV F Antigen|
79693610|NCT01960686|Biological|High dose RSV F Antigen|
79693611|NCT01960686|Biological|Dose 1 of Aluminum Adjuvant|
79693612|NCT01960686|Biological|Dose 2 of Aluminum Adjuvant|
79693613|NCT01960686|Biological|Dose 3 of Aluminum Adjuvant|
79693614|NCT01960686|Biological|Dose 4 of Aluminum Adjuvant|
79693615|NCT01960686|Biological|Placebo|
79693616|NCT02910245|Drug|Mercaptopurine (Purinethol)|
79693617|NCT02910245|Drug|Placebo|
79693618|NCT02910245|Drug|Mesalamine|
79838819|NCT00654732|Drug|Vinblastine|Given IV
79838820|NCT00771368|Drug|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
80009536|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
80009537|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
79242676|NCT05238051|Other|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
79693619|NCT02910245|Drug|Prednisone|
79693620|NCT04674891|Other|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
79693621|NCT04674891|Other|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~Hot pack: 10 min~TENS: 10 min~Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
79693622|NCT01185340|Drug|LY2216684|
79693623|NCT01185340|Drug|Placebo|
79693624|NCT01185340|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
79693625|NCT02910284|Biological|Observational|
79693626|NCT01959282|Drug|Placebo|Participants will receive placebo once daily
79693627|NCT01959282|Drug|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
79693628|NCT01959282|Drug|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
79242677|NCT03148730|Device|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
79242678|NCT03610477|Dietary Supplement|Medium chain triglycerides|Gel capsules, each containing 1 gram
79242679|NCT03610477|Dietary Supplement|Long chain triglycerides|Gel capsules, each containing 1 gram
79693629|NCT01959282|Drug|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
79693630|NCT01959282|Drug|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
79693631|NCT01216189|Radiation|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
79693632|NCT02909738|Other|Volunteer to pedal a bicycle|
79838821|NCT00767156|Other|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
79838822|NCT00767156|Other|Base cream|The subjects use the base cream on the face, twice per day
80009538|NCT00943683|Drug|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
80009539|NCT00943683|Drug|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
80009540|NCT02154308|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
79242680|NCT03615833|Drug|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
79242681|NCT03391401|Procedure|Bariatric surgery|Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
79242682|NCT02347436|Procedure|24-hr ambulatory blood pressure measurement|
79242683|NCT03615755|Other|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
79382194|NCT01768559|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
79693633|NCT04674696|Other|Approach|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
79693634|NCT02909699|Other|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
79693635|NCT01958853|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
79693636|NCT01185301|Biological|adalimumab|Pre-filled syringe every other week
80009541|NCT03738644|Other|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
80009542|NCT03542006|Drug|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
80009543|NCT02157740|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
80009544|NCT02154464|Drug|Paracetamol|
80009545|NCT02154464|Drug|Placebo|
79242684|NCT02747875|Drug|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
79382195|NCT00983619|Drug|MEDI-551|MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
80009546|NCT00911547|Drug|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
80009547|NCT00911547|Drug|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
80009548|NCT00911547|Drug|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
80009549|NCT00911547|Drug|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
80009550|NCT02159690|Drug|Enzalutamide|160mg
79382196|NCT00983619|Drug|Rituximab|Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
80009551|NCT02159690|Drug|Abiraterone acetate|1000mg
79536707|NCT04600414|Other|Collaborative Care for Mental Health Disorders|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
79693637|NCT01185301|Drug|methotrexate|weekly oral capsule dosing
79693638|NCT02909855|Other|No intervention|Participants in this study will not receive any interventions as part of the study.
79693639|NCT01957722|Procedure|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
79693640|NCT01957722|Biological|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
79693641|NCT02909660|Other|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
79838823|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
80009552|NCT02159690|Drug|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
80009553|NCT02159690|Drug|Dutasteride|0.5mg
79838824|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
80009554|NCT02159690|Drug|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
80009555|NCT02154542|Device|Neurovent Monitor XIII|
79693642|NCT02909894|Other|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
79693643|NCT02909894|Other|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
79693644|NCT01955616|Drug|RM-131|
79693645|NCT01955616|Drug|Placebo|
79693646|NCT02909621|Dietary Supplement|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
79693647|NCT02909621|Other|PLACEBO|
79693648|NCT04675008|Drug|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
79838825|NCT05358028|Other|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
80009556|NCT03696771|Drug|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
80009557|NCT02157818|Drug|midazolam|
79305481|NCT03057327|Behavioral|Improve awareness of checking moles|"Intervention:~Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
79382197|NCT01767857|Drug|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
79693649|NCT02909543|Other|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
79693650|NCT01954173|Radiation|3D conformal radiation therapy|Undergo conformal radiation therapy
80009558|NCT02157818|Drug|Dexmedetomidine|
80009559|NCT02154620|Procedure|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
80009560|NCT02154620|Device|Synthes TCP volar plate|
79305482|NCT03057327|Other|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
79305483|NCT03244397|Other|Physical therapy + educational strategy|See arm/group descriptions
79382198|NCT01767857|Drug|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
79693651|NCT01216072|Drug|Fingolimod|0.5 mg/day oral capsule
79693652|NCT01216072|Drug|Standard MS DMTs|
79693653|NCT02909582|Procedure|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
79693654|NCT01940991|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
79693655|NCT01940991|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
79693656|NCT02909465|Drug|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
79693657|NCT02909465|Drug|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
80009561|NCT03542786|Dietary Supplement|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Lactobacillus plantarum CECT7484~Lactobacillus plantarum CECT7485~Pediococcus acidilactici CECT7483"
80009562|NCT03542786|Dietary Supplement|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Partially Hydrolyzed Guar Gum (PHGG)~Inulin HPD~Oat Beta-Glucans~Pectin~Inulin Low Protein Diet (LPD)~Polydextrose~Maltrodextrins"
79305484|NCT03244397|Behavioral|Educational strategy|See arm/group descriptions
79305485|NCT03244241|Drug|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
79305486|NCT04932837|Biological|Blood and Saliva collection|Serological, viral RNA and antigenic test
80009563|NCT03542786|Dietary Supplement|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
80009564|NCT02154698|Other|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
80009565|NCT02154698|Other|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
80009566|NCT00899379|Drug|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
79242685|NCT02747875|Drug|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
79536708|NCT04600414|Other|Collaborative Care for Opioid Use Disorder|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
79536709|NCT04593043|Drug|Warfarin|Warfarin dispensing claim is used as the reference
79382199|NCT04394091|Device|ultrasensitive PET CT|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
79382200|NCT04553835|Behavioral|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
79536710|NCT04593043|Drug|Dabigatran|Dabigatran dispensing claim is used as the exposure
79536711|NCT04593030|Drug|Warfarin|Warfarin dispensing claim is used as the reference
79536712|NCT04593030|Drug|Apixaban|Apixaban dispensing claim is used as the exposure
79536713|NCT04566302|Device|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
79536714|NCT04565509|Behavioral|General Communication Message|A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
79536715|NCT04565509|Behavioral|Focused/Targeted Message|A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
79382201|NCT04553835|Behavioral|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
79391448|NCT02422212|Other|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
79536716|NCT04565509|Behavioral|Best Message Alone|The best message will be either the general or focused/targeted message described above.
79693658|NCT02909465|Drug|placebo|distilled water
79693659|NCT02909465|Drug|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
79693660|NCT04312555|Drug|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
79693661|NCT04674579|Device|MRI|magnetic resonance imaging
79693662|NCT01184989|Drug|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
79693663|NCT02909192|Device|Light Therapy Device|
79693664|NCT04674423|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
79693665|NCT02909387|Behavioral|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
79693666|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
79693667|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
79693668|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
79693669|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
79693670|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
79693671|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
79536717|NCT04565509|Behavioral|Best Message + Augmented Message or Implementation Strategy|The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
79536718|NCT04563741|Behavioral|MOVE!+UP|behavioral weight management intervention developed for Veterans with PTSD
79382202|NCT04553835|Behavioral|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
79693672|NCT02909426|Device|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
80009567|NCT00899379|Drug|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
79536719|NCT04563741|Behavioral|MOVE!|standard VA weight management intervention
79536720|NCT04556240|Device|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
79382203|NCT04553835|Behavioral|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
80009568|NCT04984538|Other|Pharmacogenomic Testing|Cheek swab as a part of routine care
79693673|NCT02909426|Device|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
79382204|NCT05608785|Drug|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
79382205|NCT05608785|Drug|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
79382206|NCT05608785|Drug|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
79536721|NCT04554394|Device|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
79536722|NCT04536870|Diagnostic Test|Echocardiography|Ultrasound of heart
79693674|NCT00555867|Drug|Anastrozole|oral
79693675|NCT02909309|Device|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
79693676|NCT01932099|Device|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
79693677|NCT03457376|Diagnostic Test|Hand Grip Force|Hand Grip Force
79693678|NCT03457376|Diagnostic Test|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
79693679|NCT03457376|Diagnostic Test|Maximal Expiratory Pressure|Maximal Expiratory Pressure
79693680|NCT00555945|Procedure|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
79693681|NCT00555945|Procedure|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
79693682|NCT02909270|Device|Mediclore|to apply mediclore fully around thyroid gland
80009569|NCT02255318|Device|Taurolock|
80009570|NCT02255318|Drug|Placebo|
80009571|NCT04326439|Drug|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
80009572|NCT04326439|Drug|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
80009573|NCT04326439|Drug|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
79242686|NCT03394833|Other|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
79242687|NCT02347358|Device|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
79242688|NCT02347358|Drug|IV r-tPA|intravenous recombinant human tissue plasminogen activator
79242689|NCT03391323|Device|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
79242690|NCT03391323|Device|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
80009574|NCT04326439|Drug|Etoposide|150 mg/m²/dose IV Days 1-5
80009575|NCT04326439|Drug|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
80009576|NCT04326439|Procedure|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
80009577|NCT04326439|Drug|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
80016827|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
80016828|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
79693683|NCT00555984|Drug|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
79693684|NCT00555984|Drug|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
79693685|NCT01917825|Drug|MDT-15|
79693686|NCT01912560|Drug|CAT-2003|
79693687|NCT01912560|Drug|Placebo|
79693688|NCT01912560|Drug|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
79693689|NCT01910025|Drug|ADI-PEG 20|
79693690|NCT03457337|Drug|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
79693691|NCT03457337|Drug|Gefitinib|Gefitinib: 250mg, 1 day, orally
79693692|NCT04674540|Other|No Intervention|No Intervention
79838826|NCT05358028|Other|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
79242691|NCT03155282|Procedure|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
79242692|NCT03610321|Drug|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
79242693|NCT03610321|Drug|Statin|Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
79242694|NCT03394755|Biological|Thrombosomes|Freeze-dried platelets
79242695|NCT02236793|Drug|BioChaperone PDGF-BB|
79242696|NCT02236793|Other|Standard of Care|
79242697|NCT02347046|Drug|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
79382207|NCT05608785|Drug|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
79242698|NCT02451124|Device|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
79382208|NCT05608785|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79382209|NCT05608785|Drug|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
79536723|NCT04536870|Diagnostic Test|ECG screening|Single lead ECG screening twice daily for two weeks
79536724|NCT04536870|Diagnostic Test|ECG Screening|12-lead ECG screening
79536725|NCT04535128|Other|No intervention|No intervention
79536726|NCT04532229|Drug|Nimotuzumab+CRT(concurrent IMRT and TMZ)|"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
79536727|NCT04519879|Other|Clinical Observation|Undergo clinical observation
79693693|NCT04674501|Procedure|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
79693694|NCT03455010|Other|Increased load|Participants walk with 120% body weight achieved with a weight vest
79242699|NCT02451124|Other|Questionnaire Administration|Ancillary studies
79242700|NCT02451124|Other|Laboratory Biomarker Analysis|Correlative studies
79242701|NCT02451124|Procedure|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
79382210|NCT04394013|Behavioral|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
79536728|NCT04519879|Other|Patient Observation|Undergo active surveillance
79693695|NCT03455010|Other|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
79693696|NCT05311280|Other|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
79536729|NCT04519879|Other|Questionnaire Administration|Ancillary studies
79536730|NCT04519879|Drug|White Button Mushroom Extract|Given PO
79693697|NCT05311280|Other|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
79693698|NCT01908738|Drug|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
80009578|NCT02255240|Behavioral|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
80009579|NCT03541928|Drug|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
80009580|NCT03541928|Drug|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
79242702|NCT03391245|Diagnostic Test|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
79382211|NCT04394013|Behavioral|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
79693699|NCT01908738|Drug|10%lidocaine spray|
79693700|NCT04673955|Drug|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
80009581|NCT03541928|Drug|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
80009582|NCT03541928|Drug|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
79242703|NCT03146234|Genetic|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
79242704|NCT02236871|Behavioral|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
79242705|NCT02236871|Behavioral|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
79242706|NCT03401619|Combination Product|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
79382212|NCT04552509|Radiation|Stereotactic Body Radiotherapy|Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
79382213|NCT05608551|Behavioral|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
79536731|NCT04519177|Behavioral|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
79536732|NCT04518410|Biological|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
79536733|NCT04518410|Biological|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
79536734|NCT04518410|Biological|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
79536735|NCT04518410|Biological|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
79536736|NCT04518410|Drug|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
79382214|NCT05608551|Behavioral|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
79693701|NCT04673955|Drug|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
79693702|NCT04673838|Other|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
79838827|NCT00771524|Drug|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
79838828|NCT00649428|Biological|Autologous Human Fibroblast (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
79242707|NCT02349230|Other|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
79693703|NCT04673838|Other|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
79693704|NCT05298293|Device|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
79693705|NCT01904409|Drug|Placebo|
79693706|NCT01904409|Drug|Rifaximin SSD 40 mg IR tablet|
79693707|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet|
79693708|NCT01904409|Drug|Rifaximin SSD 40 mg SER tablet|
79693709|NCT01904409|Drug|Rifaximin SSD 80 mg SER tablet|
79838829|NCT00649428|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three injection visits administered 5 ± 1 weeks apart on each side of the face."
79838830|NCT05588050|Device|smart phone application and AutoCAD software|to assess the validity and reliability of smart phone application and AutoCAD software in assessing knee joint position sense in patients with patellofemoral pain syndrome
79838831|NCT00767234|Procedure|Observation|Standard of Care
79242708|NCT03400527|Other|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
79242709|NCT02353208|Other|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
79242710|NCT02353208|Other|Placebo|Participants will not be asked to chew bacon bits
79242711|NCT03399903|Drug|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
79693710|NCT01904409|Drug|Rifaximin SSD 80mgIR/80mgSER tablet|
79242712|NCT03148652|Other|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
79242713|NCT03399825|Device|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
79242714|NCT03391167|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
79536737|NCT04518410|Drug|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
79536738|NCT04518410|Biological|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
79536739|NCT04518410|Biological|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
79536740|NCT04518410|Biological|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
79536741|NCT04518410|Drug|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
79693711|NCT02277158|Drug|Chemoradiotherapy|S-1 CCRT
79693712|NCT01902381|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
79693713|NCT04673916|Drug|Healing evaluation|Treatments were topically applied for 5 days
79838832|NCT00767390|Device|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
79838833|NCT02552082|Device|Scorpio NRG posterior stabilized (PS)|
79838834|NCT04000438|Drug|DF01|The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
79838835|NCT04000438|Drug|PL1|The subject receives sc injections once daily of placebo solution for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
79838836|NCT00771680|Drug|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
79242715|NCT03391167|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
80009583|NCT03541928|Radiation|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
80009584|NCT03541928|Procedure|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
80009585|NCT00145795|Drug|Kaletra + Current Dual NRTI Backbone|
80009586|NCT00145795|Drug|Current Regimen|
80009587|NCT01379365|Device|Cryo-Touch III|Percutaneous treatment with the device
80009588|NCT02771210|Biological|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
80009589|NCT02771210|Drug|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
80009590|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
80009591|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
80009592|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
79536742|NCT04518410|Drug|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
79536743|NCT04518410|Drug|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
80009593|NCT01382095|Biological|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
80009594|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
80009595|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
80009596|NCT00898677|Drug|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
80009597|NCT00898677|Drug|Comparator: Placebo|placebo to rizatriptan
80009598|NCT01381393|Drug|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
80009599|NCT02154776|Drug|LEE011|3 weeks on and 1 week off
80009600|NCT02154776|Drug|Buparlisib|daily
80009601|NCT02154776|Drug|Letrozole|2.5 mg daily;
80009602|NCT04967157|Dietary Supplement|Placebo supplement|Cellulose
80009603|NCT04967157|Dietary Supplement|Citicoline supplement|Cognizin®
79242716|NCT02346968|Other|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
79536744|NCT04518410|Drug|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
79536745|NCT04518410|Drug|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
79536746|NCT04518410|Drug|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
79536747|NCT04518410|Drug|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
79838837|NCT00771680|Drug|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
80009604|NCT03388749|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
80009605|NCT02770820|Biological|Aldesleukin|Given SC
80009606|NCT02770820|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
80009607|NCT02770820|Other|Laboratory Biomarker Analysis|Correlative studies
80009608|NCT01377571|Biological|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
80009609|NCT04051359|Other|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (~130 grams of carbohydrates)
80009610|NCT02154854|Drug|Tacrolimus targeted half-dose|
80009611|NCT02154854|Drug|Tacrolimus targeted plain dose|
80009612|NCT01377493|Dietary Supplement|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
80009613|NCT02160080|Drug|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
80009614|NCT05422495|Behavioral|training with Cycléo device (COTTOS ®),|8 weeks of training
80009615|NCT05422495|Other|non intervention|non intervention
80009616|NCT03541538|Device|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
80016829|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
80009617|NCT03541538|Device|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
79536748|NCT04518410|Drug|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
80009618|NCT05422183|Drug|Envafolimab|400mg，sc，d1，Q3W
79838838|NCT00771680|Drug|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
79838839|NCT02552784|Behavioral|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
80009619|NCT05422183|Drug|Lenvatinib|8 mg(BW<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
79242717|NCT03391089|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
79242718|NCT03146468|Drug|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
79536749|NCT04518410|Drug|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
79536750|NCT04518410|Drug|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
79536751|NCT04518410|Drug|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
80009620|NCT05422183|Drug|VP-16|50 mg/d, po,d1-14，Q3W
80009621|NCT00702585|Drug|Org 36286|Org 36286 single-dose subcutaneous injection
80009622|NCT00702585|Drug|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
80009623|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
79242719|NCT03391011|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
79242720|NCT02353130|Drug|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
79536752|NCT04518410|Biological|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
80009624|NCT02160158|Drug|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
79536753|NCT04517864|Drug|PF-06651600|50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
79536754|NCT04517864|Drug|Placebo|tablet, dosed as 4 tablets QD or 1 tablet QD
79242721|NCT02033551|Drug|Veliparib|
79242722|NCT02033551|Drug|Carboplatin|
79536755|NCT04507204|Drug|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
79536756|NCT04507204|Drug|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
79536757|NCT04500457|Behavioral|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
79693714|NCT01887366|Drug|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
79838840|NCT04003558|Other|No interventions|As this is a patient registry, there are no interventions.
79838841|NCT00767468|Drug|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
79838842|NCT05074914|Procedure|oesophagectomy|removal of oesophagus
80009625|NCT02160158|Drug|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
80009626|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
79242723|NCT02033551|Drug|Paclitaxel|
79242724|NCT02033551|Drug|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
79242725|NCT02450578|Drug|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
79242726|NCT02450578|Drug|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
79242727|NCT02450578|Biological|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
79242728|NCT02450578|Drug|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
79242729|NCT02346890|Drug|AZD1722|
79242730|NCT02346890|Drug|Renvela|
79693715|NCT01887366|Drug|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
79693716|NCT01887366|Drug|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
80009627|NCT02160158|Drug|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
80009628|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
80009629|NCT02160158|Drug|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
80009630|NCT02160158|Drug|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
80009631|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
80009632|NCT02160158|Drug|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
80009633|NCT05421871|Behavioral|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
80009634|NCT05421871|Behavioral|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
80009635|NCT01381315|Procedure|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur <3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
80009636|NCT01381315|Procedure|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is <0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
80009637|NCT02160236|Drug|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
80009638|NCT02160236|Drug|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
80009639|NCT02160236|Drug|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
80009640|NCT03273855|Other|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
80009641|NCT03273855|Other|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
80009642|NCT05421559|Procedure|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
80009643|NCT02154932|Drug|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
80009644|NCT02154932|Drug|single dose misoprostol|1 dose, 1 hours, prior surgery
79242731|NCT03980145|Device|G-EO System (Reha Technology AG: Olten, Switzerland)|Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
79242732|NCT03980145|Other|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
79693717|NCT04674072|Other|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
80009645|NCT05421403|Procedure|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade >2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
80016830|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
79242733|NCT03146390|Drug|Essential oils|all subjects will perform all interventions of all arms
79242734|NCT03146390|Drug|Alcohol free essential oils|all subjects will perform all interventions of all arms
79242735|NCT03146390|Other|Water|all subjects will perform all interventions of all arms
79242736|NCT03610009|Device|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
79242737|NCT03610009|Device|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
79242738|NCT02039180|Drug|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
79242739|NCT02039180|Drug|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
79693718|NCT04674072|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
79693719|NCT04674150|Device|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
79693720|NCT04674150|Device|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
79693721|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
79693722|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
80009646|NCT05421403|Behavioral|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of ~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
80009647|NCT02158286|Other|Measuring emptying rate from the gastric tube|
80009648|NCT02961465|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
79242740|NCT02039180|Drug|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
79382215|NCT04556097|Behavioral|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
79382216|NCT03828760|Behavioral|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
79382217|NCT01775501|Drug|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79382218|NCT01775501|Drug|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79382219|NCT01775501|Drug|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
80009649|NCT03659773|Biological|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
80009650|NCT03541772|Dietary Supplement|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
80009651|NCT03541772|Dietary Supplement|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
80009652|NCT01381237|Behavioral|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
79242741|NCT04924582|Other|Capacity Coaching|Capacity Coaching focuses on developing the capacity within patients to adapt, endure, and function optimally in their lives along with illness and treatment.
79242742|NCT02346734|Device|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
79242743|NCT02346812|Other|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
79242744|NCT02346812|Other|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
79838843|NCT00812136|Behavioral|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
80009653|NCT03542630|Diagnostic Test|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
79242745|NCT02449018|Drug|QBW251|QBW251 capsule(s) taken orally twice per day
79382220|NCT01775501|Drug|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79838844|NCT00669032|Device|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
79838845|NCT00669032|Other|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
80009654|NCT03542630|Other|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
80009655|NCT03542630|Other|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
80009656|NCT01377415|Drug|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
80009657|NCT02678403|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
79693723|NCT01885260|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
79693724|NCT01876719|Drug|AR08|
79693725|NCT01876719|Drug|Placebo|
79693726|NCT05285540|Drug|DT-216|DT-216 will be administered by intravenous (IV) injection
79242746|NCT02449018|Drug|Placebo|Matching placebo capsule(s) taken orally twice per day
79242747|NCT03146312|Dietary Supplement|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
79242748|NCT03146312|Dietary Supplement|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
79382221|NCT03786640|Radiation|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
79536758|NCT04498052|Other|EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening|"The intervention will consist of the following core items:~An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~Improvements may also be introduced based on user feedback. All major enhancements will be introduced with the support and approval of the appropriate governance group.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption."
79536759|NCT04494048|Other|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
79693727|NCT05285540|Drug|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
79693728|NCT04673799|Drug|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
79693729|NCT04673799|Drug|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
79693730|NCT04673487|Diagnostic Test|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
79693731|NCT01873677|Drug|M518101|
79693732|NCT01873677|Drug|Vehicle|
79693733|NCT05236400|Device|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
79693734|NCT05236400|Procedure|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
79693735|NCT04673526|Procedure|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
79242749|NCT02859415|Drug|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
79693736|NCT04673526|Procedure|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
79693737|NCT01215955|Drug|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
79693738|NCT01215955|Drug|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
79693739|NCT01873404|Drug|BG00010|As specified in the treatment arm
79693740|NCT01873404|Drug|Placebo|As specified in the treatment arm
79242750|NCT03390855|Other|Broccoli sprouts|
79242751|NCT02346656|Device|Implantation with the commercially available Axium neurostimulator|
79242752|NCT03943329|Procedure|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
79242753|NCT03943329|Procedure|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
79382222|NCT04124835|Other|Swiss Ball|"Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation."
79382223|NCT04124835|Other|Control Grup|Habitual Care of the Service.
79382224|NCT03721042|Device|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
79693741|NCT05212220|Behavioral|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
79838846|NCT04001998|Drug|BLD-2660|Randomized to active product
79838847|NCT04045236|Other|Registry|Data collection
79536760|NCT04487574|Drug|XC221|Participants will receive XC221 100 mg 2 times a day during 14 days
80009658|NCT02678403|Device|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
80009659|NCT02155088|Drug|BYL719|Dose escalation beginning at 250 mg/day
80009660|NCT02155088|Drug|Gemcitabine|Dose escalation beginning at 800 mg/m^2
79242754|NCT02346500|Device|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
79536761|NCT04487574|Drug|Placebo|Participants will receive Placebo 2 times a day during 14 days
79536762|NCT04486391|Drug|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
79536763|NCT04486391|Drug|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
79536764|NCT04482855|Device|Low-level laser|Low-level laser therapy
79536765|NCT04481893|Behavioral|Use of a virtual reality headset|"The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)"
79536766|NCT04481139|Drug|SHR0302|SHR0302, oral, once daily
79693742|NCT05212220|Behavioral|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
79693743|NCT04677270|Behavioral|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
79693744|NCT02887105|Other|Standard neuropsychological assessment|
79693745|NCT02887105|Other|Brain MRI|
79693746|NCT01871415|Drug|aleglitazar|150 mcg orally daily
79693747|NCT01871415|Drug|metformin|pre-existing background regimen and dose
79693748|NCT01871415|Drug|placebo|matching aleglitazar placebo orally daily
80009661|NCT02155088|Drug|(nab)-paclitaxel|125 mg/m^2 dose
79242755|NCT02871791|Drug|Palbociclib|
79382225|NCT04553445|Behavioral|Chronotype|Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
79382226|NCT04553445|Behavioral|Green exercise|Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
79536767|NCT04481139|Drug|SHR0302 placebo|SHR0302 placebo, oral, once daily
80009662|NCT03625635|Other|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
80009663|NCT02160392|Procedure|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
79242756|NCT02871791|Drug|Everolimus|
79242757|NCT02871791|Drug|Exemestane|
79242758|NCT02346578|Drug|Enzalutamide|
79242759|NCT02346578|Drug|Flutamide|
79242760|NCT03399747|Drug|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
79242761|NCT04446897|Biological|mesenchymal stem cells|autologous mesenchymal stem cells
79536768|NCT04472026|Behavioral|Counseling using the electronic conversation aid|This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
79536769|NCT04463667|Other|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
79536770|NCT04462497|Other|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
79536771|NCT04458532|Other|Aerobic Training|300 min/wk for 16 weeks
79536772|NCT04458532|Other|Aerobic Training|150 min/wk for 32 weeks
79536773|NCT04458532|Other|Aerobic Training|300 min/wk for 32 weeks
79536774|NCT04458532|Other|Aerobic Training|150 min/wk for 16 weeks
79693749|NCT05189717|Drug|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
79838848|NCT04045314|Other|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
79536775|NCT04448938|Other|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
79536776|NCT04448938|Other|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
79382227|NCT04129827|Other|Clinical, self-reported psychological and biomechanical assessments|"medical check up~active and passive Range Of Motion (ROM)~anterior drawer test~knee's alignment~modified cincinnati rating system questionnaire (mCRSQ)~tegner lysholm knee scoring scale (TLKS)~Tegner Activity Level Score (TALS)~self-reported psychological questionnaires~Tampa Scale of Kinesiophobia (TSK)~ACL Return to Sport after Injury (ACL-RSI) score~biomechanical tests~Stability test: to balance on one/two legs on a free to move disc for 30s~Jump test: i) a maximize jump with both legs; ii) a maximize jump with only one leg; three consecutive jumps; iv) jump coordination path where the patient had to perform a forward-backward-forward jump and a sideway jump on one leg~Coordination test: a square hurdle was used for the quick test, where the patient had to step in and out with both feet for a total of 15-rep as quickly as possible~fatigue test: to rise and sit from a chair for 30-rep as quickly and safely as possible"
79536777|NCT04444622|Biological|AlloStim|Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
79536778|NCT04442971|Behavioral|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
79693750|NCT05182463|Drug|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
79693751|NCT05182463|Drug|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
79693752|NCT04673643|Device|Transcutaneous Auricular Vagus Nerve Stimulation|to use taVNS to treat Reflux Esophagitis
79693753|NCT05125484|Other|experimental Bowen Technique|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
79693754|NCT05125484|Other|Experimental Myofacial release technique|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
80009664|NCT02160470|Behavioral|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
80009665|NCT02160470|Behavioral|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
79693755|NCT04673097|Other|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
79693756|NCT04673097|Other|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
79693757|NCT05108129|Procedure|M-TAPA block|"After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
80009666|NCT02160470|Behavioral|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
79382228|NCT04347525|Other|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
79382229|NCT01880320|Drug|CD0271 0.3% / CD1579 2.5%|
79536779|NCT04442971|Behavioral|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
79536780|NCT04442971|Behavioral|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
79693758|NCT05108129|Procedure|OSTAP block|"The patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
79693759|NCT01854294|Drug|GM604|GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
80009667|NCT02160470|Behavioral|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
80009668|NCT02160548|Drug|Standard care|Standard management for OP poisoning
80009669|NCT02160548|Drug|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
79242762|NCT04446897|Other|standard treatment|standard treatment according to clinical protocols
79242763|NCT02346266|Other|SMART Education|
79242764|NCT03112382|Drug|zinc supplement plus vitamin A and E|
79242765|NCT03112382|Drug|vitamin A and E|
79242766|NCT03399669|Drug|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
79242767|NCT03148574|Drug|Misoprostol|intrauterine tablets
79242768|NCT03148574|Drug|Oxytocin|intravenous
79242769|NCT03390777|Procedure|surgery|surgery without the use of prgf
79242770|NCT03390777|Device|PRGF after surgery|surgery and application of PRGF
79242771|NCT03148340|Diagnostic Test|VIPS Monitoring|Bioimpedance asymmetry
79242772|NCT03390699|Diagnostic Test|Microbial profile|microbiological testing
79242773|NCT02343536|Drug|Oral Azacitidine|
79242774|NCT02343536|Drug|Rituximab|
79382230|NCT01880320|Drug|CD0271 0.1% / CD1579 2.5%|
79382231|NCT01880320|Drug|Topical Gel Vehicle|
79382232|NCT04346667|Drug|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
79382233|NCT04346667|Drug|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
79242775|NCT02343536|Drug|cyclophosphamide|
79382234|NCT04346667|Drug|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
79382235|NCT04346667|Drug|Placebo|Standard of Care plus placebo
80009670|NCT02160548|Drug|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
79382236|NCT04129983|Combination Product|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
80009671|NCT02158598|Drug|Vitamin D chewable tablet supplementation|
79382237|NCT05608239|Device|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
79382238|NCT03426358|Device|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
80009672|NCT02158598|Drug|Vitamin D pill supplementation|
80009673|NCT03082729|Drug|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
80009674|NCT02513043|Drug|medical abortion|medical abortion
80009675|NCT02160704|Drug|Enclomiphene citrate|25 mg daily for 16 weeks
80009676|NCT02160704|Other|Placebo|placebo daily for 16 weeks
79242776|NCT02343536|Drug|Vincristine|
79242777|NCT02343536|Drug|Prednisone|
79242778|NCT04446975|Other|BPA|At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
79242779|NCT03148184|Diagnostic Test|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
79242780|NCT02343614|Drug|Celecoxib|
79242781|NCT04446819|Device|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
79242782|NCT02871635|Drug|BI 695501|
79242783|NCT02871635|Drug|HUMIRA|
79242784|NCT03147950|Procedure|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
79242785|NCT03147950|Procedure|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
79242786|NCT03390543|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
79242787|NCT03390543|Device|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
79242788|NCT04093700|Device|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
79242789|NCT03390465|Drug|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
79536781|NCT04442061|Device|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
79242790|NCT05255198|Procedure|Anterior versus lateral approach to hip joint|
79382239|NCT05608161|Diagnostic Test|speech in noise test|The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
79838849|NCT00775424|Biological|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
79838850|NCT00775424|Biological|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
79242791|NCT03394677|Drug|RVT-501 0.5% ointment|Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
79242792|NCT03394677|Drug|Vehicle ointment|Placebo comparator - ointment twice daily (BID) for 4 weeks.
79838851|NCT00775424|Biological|PLACEBO|PLACEBO
79242793|NCT02348996|Other|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
79242794|NCT02348996|Other|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
79242795|NCT02342990|Other|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
79242796|NCT02342990|Other|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
79242797|NCT03390387|Drug|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
79536782|NCT04442061|Device|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
79693760|NCT01854294|Drug|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
79536783|NCT04442061|Device|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
79536784|NCT04442061|Device|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
79838852|NCT00775424|Biological|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
79838853|NCT04652622|Device|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
79838854|NCT00814242|Procedure|surgical resection|radical resection performed in patinets with HCC.
79838855|NCT00814242|Procedure|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
79838856|NCT00775502|Drug|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
79838857|NCT05582668|Procedure|Bariatric surgery|Bariatric surgery
79838858|NCT00775580|Drug|Atenolol 100mg Tablets|
79242798|NCT03390387|Drug|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
79305784|NCT04402437|Procedure|QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
79838859|NCT00767546|Drug|Botulinum toxin|60- 100 units Local injection to the rash area
79838860|NCT00654498|Drug|Pramipexole|
79838861|NCT00654498|Drug|Placebo|
79838862|NCT00771992|Procedure|Bronchoscopy|Bronchoscopy with segmental allergen challenge
79838863|NCT00670046|Drug|valproic acid|given orally
79838864|NCT00670046|Other|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
79693761|NCT02277197|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
79838865|NCT00814398|Procedure|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
80009677|NCT03541382|Device|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
79242799|NCT03390387|Drug|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
79242800|NCT03390387|Drug|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
79838866|NCT00814398|Procedure|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
79242801|NCT03390387|Drug|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
79838867|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
79838868|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
79242802|NCT03390387|Drug|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
79242803|NCT03390387|Drug|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
79242804|NCT03390387|Drug|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
79382240|NCT02983929|Procedure|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
79382241|NCT03024489|Drug|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
79838869|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
79382242|NCT03024489|Drug|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
79382243|NCT03024489|Drug|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
79382244|NCT03024489|Drug|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
79382245|NCT03024489|Drug|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
79838870|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
79838871|NCT00560391|Drug|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
80009678|NCT03542552|Drug|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
79536785|NCT04442061|Genetic|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
79536786|NCT04442061|Other|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
80009679|NCT03542552|Drug|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
79242805|NCT03390387|Drug|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
79693762|NCT02277197|Drug|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
79242806|NCT03390387|Drug|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
79242807|NCT03146000|Drug|lidocaine-prilocaine cream|topical cream
79242808|NCT03146000|Drug|meloxicam rectal suppository|suppository
79242809|NCT02343146|Behavioral|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
79242810|NCT03155438|Diagnostic Test|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
79242811|NCT03155438|Diagnostic Test|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
79242812|NCT03125889|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
79242813|NCT02346188|Dietary Supplement|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
79242814|NCT02346188|Dietary Supplement|Zinc oxide|Tablet formulated from 30 mg zinc oxide
79242815|NCT02346188|Dietary Supplement|Placebo|
79242816|NCT05166525|Other|Medically tailored meals|Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
79242817|NCT02477332|Biological|QGE031|
79242818|NCT02477332|Biological|Omalizumab|
79242819|NCT02477332|Other|Placebo|
79242820|NCT02346110|Drug|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
79382246|NCT03024489|Radiation|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
79382247|NCT04129749|Procedure|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
79242821|NCT02346110|Drug|Dexamethasone|4 mg
79382248|NCT02268994|Drug|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
79382249|NCT02268994|Drug|Placebo|Matching placebo
79382250|NCT04129593|Behavioral|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
79382251|NCT04129593|Behavioral|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
79242822|NCT02346110|Other|Sodium chloride|1 mL of sodium chloride solution as placebo
79242823|NCT03394599|Device|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
79242824|NCT03394599|Device|TheraTrainer Only|TheraTrainer will be used.
79242825|NCT03390309|Other|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
79242826|NCT03390309|Other|Normal Formula|Normal Formula
79242827|NCT02348528|Drug|Lenalidomide|
79242828|NCT02348528|Drug|Dexamethasone|
79382252|NCT04768894|Procedure|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
79382253|NCT01775189|Drug|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
79382254|NCT01775189|Drug|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
79693763|NCT00555087|Drug|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
79693764|NCT04672902|Procedure|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
80009680|NCT02158676|Dietary Supplement|Prebiotic|Fructooligosaccharides
79242829|NCT03394521|Other|Routine clinical practice|This is an observational study
79382255|NCT01775189|Drug|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
79382256|NCT01775189|Drug|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
79838872|NCT00767780|Device|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
79693765|NCT04673253|Other|Passive leg Raise|The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.
79242830|NCT03390231|Combination Product|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
79242831|NCT02345798|Procedure|Standard Follow-Up Care|Undergo usual care
79242832|NCT02345798|Other|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
79242833|NCT02345798|Other|Educational Intervention|Undergo video-assisted intervention
79242834|NCT02345798|Other|Quality-of-Life Assessment|Undergo quality of life assessment
79242835|NCT02345798|Other|Questionnaire Administration|Undergo questionnaire administration
79242836|NCT03390153|Other|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
79305785|NCT04920591|Other|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
79305786|NCT02621931|Drug|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
79382257|NCT03832582|Drug|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
79382258|NCT04768816|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
79382259|NCT04768816|Biological|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
79693766|NCT04673253|Other|control|The controlled group was positioned in the normal supine position.
79693767|NCT05096897|Other|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
79693768|NCT04673214|Drug|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
79693769|NCT04673214|Drug|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
79693770|NCT04672473|Biological|DC-CTL|DAC combined with Ag-CTL
79693771|NCT05040113|Drug|CBP-307|CBP-307 capsules oral administration
79693772|NCT01845987|Drug|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
79693773|NCT01845987|Drug|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
79693774|NCT00556023|Drug|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
79382260|NCT02988154|Other|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
79382261|NCT02988154|Other|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
79382262|NCT04129203|Device|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
79382263|NCT04128813|Device|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
79693775|NCT05011214|Drug|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
79693776|NCT05011214|Drug|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
79693777|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
79838873|NCT00775736|Drug|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
79838874|NCT00775736|Drug|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
79838875|NCT00775736|Drug|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
79693778|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
79693779|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
79693780|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
79693781|NCT04672668|Diagnostic Test|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
79693782|NCT04676841|Device|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
79693783|NCT04676841|Device|Conventional ventilation + standard instrumental tables|Control
79693784|NCT04676841|Device|Laminar airflow ventilation + standard instrumental tables|Control
79693785|NCT04949438|Drug|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
79693786|NCT04676763|Drug|Substance P|Participants will receive Substance P
79305787|NCT02621931|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
79305788|NCT04926441|Diagnostic Test|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
79382264|NCT01881412|Drug|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
79536787|NCT04417127|Other|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
79536788|NCT04417127|Other|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
79536789|NCT04414397|Device|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC injectable gel
79536790|NCT04414397|Other|No-treatment control|Participants received no treatment for 3 months and then received an optional delayed treatment with JUVÉDERM VOLUMA® XC and an optional touch-up treatment 30 days later.
79536791|NCT04404036|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
79305789|NCT02621073|Drug|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
79305790|NCT02621073|Device|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
79536792|NCT04385108|Biological|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
79536793|NCT04385108|Biological|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
79536794|NCT04373005|Diagnostic Test|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
79693787|NCT04676763|Drug|Normal Saline|Participants will receive normal saline as Negative control
79693788|NCT04676763|Drug|Histamine|Participants will receive histamine as Positive control
79693789|NCT04944563|Procedure|Segmentectomy|Patients receive segmentectomy
79693790|NCT04944563|Procedure|Lobectomy|Patients receive lobectomy
79693791|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|32 mg
79693792|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|48 mg
79693793|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|64 mg
79693794|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|80mg
79693795|NCT04932083|Drug|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
79693796|NCT04932083|Drug|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
79693797|NCT04932083|Drug|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
79838876|NCT00942669|Device|SleepStrip OTC(TM)|self contained SAS screening device
79536795|NCT04337944|Procedure|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
79536796|NCT04331002|Drug|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
79536797|NCT04331002|Other|Placebo|5 mL normal saline
79536798|NCT04327973|Biological|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
79693798|NCT04932083|Drug|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
79693799|NCT04672629|Device|echocardiography|follow up echocardiography
79693800|NCT00555126|Device|Forced Air Warming|Warming after Randomization
79693801|NCT00555126|Device|Warming with endovascular catheter + forced air warming|Warming after Randomization
79693802|NCT04920071|Device|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
79382265|NCT01881412|Other|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
80009681|NCT02158676|Dietary Supplement|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
79382266|NCT03378609|Other|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
79382267|NCT03832816|Drug|Placebo|Placebo vapor (distilled water)
79382268|NCT03832816|Drug|Vaporized THC alone|Acute exposure to vaporized THC
79382269|NCT03832816|Drug|Vaporized CBD alone|Acute exposure to vaporized CBD
79382270|NCT03832816|Drug|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
79693803|NCT04672785|Behavioral|SF36 questionary|patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
79693804|NCT01825980|Drug|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
79382271|NCT04129047|Drug|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
79536799|NCT04327973|Drug|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
79536800|NCT04320394|Diagnostic Test|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
79693805|NCT01825980|Drug|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
80009682|NCT02158676|Other|Placebo|Maltodextrin
79536801|NCT04291820|Procedure|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
79693806|NCT01825980|Drug|Placebo|Placebo
80009683|NCT02155166|Drug|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
80009684|NCT02155166|Drug|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
79382272|NCT04129047|Drug|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
79382273|NCT02987764|Other|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
79536802|NCT04291820|Procedure|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
79536803|NCT04279054|Drug|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
80009685|NCT02158754|Diagnostic Test|Corus CAD (ASGES)|
80009686|NCT00398931|Drug|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
80009687|NCT00398931|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
80009688|NCT02160938|Other|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
80009689|NCT02155400|Device|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
79693807|NCT04672200|Other|Group exercise|Weekly group exercises delivered online and face to face
79382274|NCT04231084|Drug|Vasodilator testing (Inhaled Nitric Oxide)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
79693808|NCT04676685|Drug|E2730|E2730 capsules.
79536804|NCT04279054|Drug|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
79382275|NCT04231084|Drug|Vasodilator testing (Inhaled Epoprostenol)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
79382276|NCT04551105|Diagnostic Test|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
80009690|NCT02155400|Device|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
80009691|NCT01593111|Other|Environmental Intervention|Home-based environmental intervention
80009692|NCT03541694|Biological|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
79382277|NCT04551105|Diagnostic Test|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
79382278|NCT04551105|Diagnostic Test|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
79382279|NCT04551105|Diagnostic Test|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
79382280|NCT04128345|Device|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
79536805|NCT04273867|Other|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
79536806|NCT04263051|Drug|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
79536807|NCT04263051|Drug|standard chemotherapy|Second line chemotherapy at the choice of the investigator
79693809|NCT04676685|Drug|E2730-matched placebo|E2730-matched placebo capsules.
79693810|NCT04672317|Drug|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
79693811|NCT04791878|Drug|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
79693812|NCT04672278|Dietary Supplement|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
79693813|NCT04676568|Procedure|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
79693814|NCT04676295|Behavioral|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
79693815|NCT01655225|Drug|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
79693816|NCT01655225|Drug|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
80009693|NCT02158832|Device|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current >sensation threshold & maintained at a level that is comfortable/painless & does not elicit skeletal muscle contractions (~5mA, <10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', ~15⁰ perpendicular to the skin, ~15⁰ lateral to the midline. Depth: ~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' ~15⁰ perpendicular to the skin, ~15⁰ medial. Depth: ~1.5 cm (secure anchorage)."
80009694|NCT02155478|Device|ISERT 250 (HOYA, Japan): a standard IOL|
80009695|NCT02155478|Device|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
80009696|NCT04956003|Behavioral|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
79305791|NCT04431297|Other|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
79305792|NCT04926519|Other|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
79305793|NCT03056235|Device|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
79305794|NCT03056235|Device|Saline|Saline control
79536808|NCT04243148|Combination Product|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
79536809|NCT04243148|Combination Product|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435*, Bifidobacterium infantis DSM 24737® / NCIMB 30436*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440**~* Re-classified as B. lactis ** Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
79536810|NCT04243148|Combination Product|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
79536811|NCT04243148|Combination Product|No specific intervention.|Follow up as a clinical practice
79536812|NCT04237935|Drug|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
79536813|NCT04237935|Drug|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
79536814|NCT04237922|Drug|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
79536815|NCT04237922|Drug|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
79536816|NCT04233021|Drug|Osimertinib|Osimertinib 80 mg/d
79693817|NCT01655225|Drug|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
79693818|NCT01655225|Drug|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
80009697|NCT00920361|Drug|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
79382281|NCT01883440|Drug|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
79382282|NCT01883440|Drug|Saline+glucose|Placebo arm
79382283|NCT01770743|Biological|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
79382284|NCT01770743|Biological|BioThrax|
79382285|NCT04124211|Biological|Fecal Microbiota Transplantation (FMT)|FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
79382286|NCT04128657|Diagnostic Test|MA_LARS|Validation of the MA_LARS and MA_Wexner
79536817|NCT04228289|Drug|Oxytocin|40 IU intranasal spray
79536818|NCT04228289|Other|Placebo|matching intranasal spray
79536819|NCT04227821|Other|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
79693819|NCT01655225|Drug|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
79838877|NCT01058629|Device|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
79382287|NCT04124289|Other|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
79536820|NCT04215536|Drug|Empagliflozin|Empagliflozin dispensing claim is exposure
79382288|NCT03305146|Genetic|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( <50ng) DNA."
79536821|NCT04215536|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
79693820|NCT01655225|Drug|Abemaciclib|Administered orally
79693821|NCT01655225|Drug|Letrozole|Administered orally
79693822|NCT00555165|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
79693823|NCT03457298|Device|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
79693824|NCT03457298|Device|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
79838878|NCT00537238|Drug|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
79838879|NCT00537238|Drug|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
79242837|NCT03390153|Other|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
79242838|NCT02342756|Device|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
79242839|NCT02346032|Drug|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
79536822|NCT04215523|Drug|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
79242840|NCT03394443|Behavioral|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~As a first step, it will be a vertical analysis of the thematization of each interview~Then, in a second step, a transversal analysis between the contents of the different interviews."
79242841|NCT02345954|Procedure|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
79536823|NCT04215523|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
79536824|NCT04215081|Device|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
79536825|NCT04210726|Drug|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
79693827|NCT04671888|Other|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
79693828|NCT04722653|Drug|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
79693829|NCT04722653|Drug|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
79693830|NCT01818921|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
79693831|NCT01818921|Drug|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
79693832|NCT01818921|Drug|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
79838880|NCT00772226|Device|music pillow|according to randomisation patients will receive with/without music.
79838881|NCT00772226|Device|pillow without music|According to randomisation patients will receive a pillow with/without music
80009698|NCT02161094|Behavioral|Give incentives to physicians based on their patient's HbA1c improvement|
79242842|NCT02345954|Procedure|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
79242843|NCT02348294|Other|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
79242844|NCT02342834|Dietary Supplement|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
79536826|NCT04210726|Other|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
79536827|NCT04202731|Behavioral|PBS Study|Sleep extension intervention
79536828|NCT04169347|Drug|Oxaliplatin|2 week cycles
79536829|NCT04165408|Device|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
79536830|NCT04135937|Drug|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
79693833|NCT04700345|Device|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
79693834|NCT04700345|Procedure|Burr-hole|Burr-hole drainage of subdural hematoma
79693835|NCT04700345|Other|Medical Management|best medical management
79693836|NCT01815450|Drug|BLI1100|BLI1100 topical cream
80009699|NCT02161094|Behavioral|Give incentives to patients based on their own HbA1c improvement|
80009700|NCT00651807|Drug|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
79536831|NCT04135937|Drug|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
79536832|NCT04135937|Behavioral|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
79536833|NCT04135937|Drug|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
79536834|NCT04135937|Behavioral|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
80009701|NCT00651807|Drug|Placebo|Every day one tablet up to 8 weeks
80009702|NCT01381081|Biological|platelet-rich plasma|a single intra-articular injection
79536835|NCT04135703|Behavioral|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
79536836|NCT04135703|Behavioral|Risk Prevention Services Only|opioid and related prevention services for 6 months
79693837|NCT01815450|Drug|BLI1100 - modified formulation|BLI1100 topical cream
79693838|NCT01815450|Drug|Placebo|Placebo topical cream
79693839|NCT01810575|Drug|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
79693840|NCT01810575|Drug|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
79838882|NCT00946413|Behavioral|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
79838883|NCT00946413|Behavioral|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
79242845|NCT02342912|Behavioral|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
79382289|NCT04127799|Other|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
79382290|NCT04127799|Other|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
79382291|NCT04127877|Device|NICAS|Electric regional bio impedance device
79693841|NCT01810575|Drug|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
79382292|NCT04768660|Other|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
79382293|NCT04128033|Other|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
79382294|NCT04128033|Other|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
79242846|NCT02345876|Other|no intervention|
79242847|NCT02342600|Drug|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
79242848|NCT02342600|Drug|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
79382295|NCT01883986|Behavioral|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
79536837|NCT04134754|Other|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
79693842|NCT04671524|Other|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
79693843|NCT04671849|Drug|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
79693844|NCT04664777|Device|Masimo Model RDS7A|Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
79693845|NCT01785771|Drug|ITCA 650 (exenatide in DUROS)|
79693846|NCT04664582|Procedure|Sentinel Lymph Node Biopsy|see intervention group description
79693847|NCT04671537|Drug|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
79242849|NCT03147638|Drug|Warfarin, NOAC|duration of treatment
79242850|NCT03147716|Other|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
79242851|NCT03147716|Other|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
79305795|NCT04912167|Drug|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
79693848|NCT00556101|Procedure|Whole body magnetic resonance angiography|
79838884|NCT03982771|Drug|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
79838885|NCT03982771|Drug|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
79242852|NCT03147716|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
79242853|NCT03147716|Other|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
79242854|NCT02477020|Drug|TAK-063 20 mg|TAK-063 tablet.
79242855|NCT02477020|Drug|Placebo|TAK-063 matching-placebo tablet.
79242856|NCT03147794|Device|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
79382296|NCT01884064|Device|rTMS|rTMS
79382297|NCT01884064|Device|Sham rTMS|Sham rTMS
79382298|NCT04123899|Drug|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
79382299|NCT04123899|Drug|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
79382300|NCT04124055|Diagnostic Test|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
79382301|NCT01884844|Drug|Vitamin D3, Cholecalciferol|
79382302|NCT01884844|Drug|Placebo|
79382303|NCT04123431|Device|Total Hip Replacement|Primary elective total hip replacement
79382304|NCT04123587|Drug|discontinuation of Sulfonylureas|"Discontinuation of sulfonylurea, alternative drug administration.~If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
79382305|NCT01890226|Behavioral|Mobile Personal Health Record App.|
79536838|NCT04126070|Drug|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
79536839|NCT04126070|Drug|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
79382306|NCT04127721|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
79382307|NCT04127721|Drug|Busulfan|Given IV
79382308|NCT04127721|Drug|Fludarabine|Given IV
79382309|NCT04127721|Drug|Itacitinib|Given PO
79382310|NCT04127721|Drug|Methotrexate|Given IV
79382311|NCT04127721|Drug|Tacrolimus|Given IV and PO
79382312|NCT04123743|Drug|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
79693849|NCT04620356|Device|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
79693850|NCT01784874|Biological|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
79382313|NCT04123743|Other|Facial Wash|Wardah brand facial wash
79536840|NCT04126070|Drug|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
79536841|NCT04120987|Drug|Lifitegrast 5% Ophthalmic Solution|BID OU
79693851|NCT01784874|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
79693852|NCT01784133|Drug|omiganan|
79693853|NCT01784133|Drug|placebo|
79693854|NCT04607252|Drug|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
79693855|NCT04607252|Drug|Megestrol Acetate|megestrol acetate 160mg per day, oral
79693856|NCT01782729|Drug|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
79838886|NCT03982771|Drug|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
79838887|NCT00775814|Drug|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
79838888|NCT00775814|Drug|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
80009703|NCT01381081|Drug|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
79536842|NCT04118530|Other|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
79838889|NCT03966885|Behavioral|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
79838890|NCT03966885|Behavioral|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
79838891|NCT04048148|Device|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
79838892|NCT00772460|Device|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
79536843|NCT04106102|Device|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
79838893|NCT03965403|Device|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
79382314|NCT04123743|Other|Sunscreen Cream|Parasol sunscreen cream SPF 33
79838894|NCT00775892|Device|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
79838895|NCT00775970|Behavioral|walking activity|
79382315|NCT04123743|Other|Placebo|Placebo topical cream
79536844|NCT04106102|Device|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
79693857|NCT04671264|Device|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
79693858|NCT04671303|Drug|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
79693859|NCT01780428|Drug|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
79693860|NCT01780428|Drug|Placebo|
79693861|NCT04578392|Procedure|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
79693862|NCT04578392|Procedure|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
79838896|NCT00942747|Drug|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
80009704|NCT05583513|Diagnostic Test|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
79242857|NCT02342522|Device|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
79242858|NCT02342522|Device|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
79242859|NCT02342366|Drug|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
79242860|NCT02342366|Drug|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
79305796|NCT04912167|Drug|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
79382316|NCT04123119|Biological|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 & 10 weeks.
79382317|NCT04393077|Behavioral|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
79536845|NCT04101110|Other|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
79536846|NCT04060147|Drug|Cilofexor|Tablets administered orally once daily
79536847|NCT04038567|Behavioral|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 8 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
79693863|NCT04671420|Drug|HLX01|Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
79693864|NCT04671420|Drug|Mabthera®|Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
79838897|NCT03863470|Behavioral|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
79838898|NCT00946491|Drug|Haloperidol 10 mg Tablets (Cord Laboratories)|
79838899|NCT00946491|Drug|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
79382318|NCT02996799|Other|Umbilical cord milking|Milking of the umbilical cord at delivery
79693865|NCT04573556|Drug|Lemborexant|Lemborexant oral tablets.
79838900|NCT00776126|Device|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
79382319|NCT02996721|Biological|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
79242861|NCT02337296|Behavioral|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
79382320|NCT02705404|Genetic|Multifocal Tissue Banking|
79693866|NCT04671108|Device|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
79242862|NCT02862535|Drug|Andecaliximab|Administered via intravenous (IV) infusion (approximately 30 minutes)
79242863|NCT02862535|Drug|S-1|Administered orally
79242864|NCT02862535|Drug|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
79838901|NCT03336190|Behavioral|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
79838902|NCT00776204|Device|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
79838903|NCT00776204|Device|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
80009705|NCT05583513|Diagnostic Test|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
79242865|NCT02862535|Drug|Oxaliplatin|Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
79838904|NCT00776204|Device|Taxus Libertè|Taxus Libertè stent placed in coronary artery
79838905|NCT04011969|Diagnostic Test|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
79242866|NCT02862535|Drug|Nivolumab|Administered via IV infusion (approximately 60 minutes) every 2 weeks
79242867|NCT02345564|Device|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
79382321|NCT02666326|Procedure|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is <9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is <14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
79382322|NCT04122963|Procedure|High power CLOSE-guided PVI ablation|CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)
79382323|NCT04122963|Procedure|Standard CLOSE-guided PVI ablation|Standard AF ablation according to the CLOSE-protocol
80009706|NCT02161250|Dietary Supplement|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
79382324|NCT04122885|Combination Product|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
79382325|NCT04122885|Procedure|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
79382326|NCT04122651|Procedure|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
79536848|NCT04031014|Device|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
79536849|NCT04031014|Device|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
79242868|NCT02342210|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
79838906|NCT04011969|Diagnostic Test|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
79838907|NCT04011969|Diagnostic Test|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
79838908|NCT05355610|Drug|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
79305797|NCT04912167|Drug|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
79382327|NCT04122651|Procedure|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
79693867|NCT04573166|Procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
79382328|NCT03022851|Device|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
79536851|NCT04019093|Drug|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
79536852|NCT04019093|Other|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
79693868|NCT01779453|Drug|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
79693869|NCT01779453|Drug|Placebo|Placebo once daily for 8 weeks
79838909|NCT05355610|Drug|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
79838910|NCT00552669|Drug|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
79838911|NCT00552669|Device|Drug Eluting stent|Any Drug eluting stent
79838912|NCT02557568|Other|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
79838913|NCT00768170|Drug|MK0633|MK0633 (50 mg) Oral, single dose
79305798|NCT04925661|Drug|HEC53856|Either dose of HEC53856 will be administered after fasting .
79305799|NCT04925661|Drug|Roxadustat|Roxadustat will be administered after fasting .
79382329|NCT04122417|Other|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
79382330|NCT04122573|Diagnostic Test|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
79382331|NCT04122573|Diagnostic Test|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
79382332|NCT04122573|Diagnostic Test|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
79536853|NCT04019041|Drug|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
79536854|NCT04019041|Drug|placebo|placebo 2 mL pre-filled syringe
79536855|NCT04018092|Device|Active NIR-PBM|See Experimental arm for description.
79536856|NCT04018092|Device|Sham NIR-PBM|See Sham Comparator arm for description.
79536857|NCT04013399|Device|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
79838914|NCT00943059|Drug|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
79838915|NCT00943059|Drug|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
80016831|NCT02095938|Drug|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
79242869|NCT02033707|Drug|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
79242870|NCT02448706|Device|Hearing Aid Fitting A|
79242871|NCT02448706|Device|Hearing Aid Fitting B|
79242872|NCT02337140|Device|Pacemaker SORIN Group KORA DR|
79242873|NCT02337140|Procedure|transcatheter aortic valve implantation (TAVI)|
79536858|NCT04011891|Procedure|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
79536859|NCT04011891|Procedure|Open Partial Nephrectomy|Standard open partial nephrectomy
79838916|NCT00943137|Drug|5-Fluorouracil|"Chemotherapy will be one of the following:~de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
79838917|NCT05547568|Procedure|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
79838918|NCT00772616|Drug|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
79838919|NCT00772616|Drug|Sufentanil|dosage according to usual criteria
79536860|NCT03988439|Drug|IDP-118 Lotion|Topical
79838920|NCT00768326|Drug|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
79242874|NCT02039336|Drug|Dacomitinib|
79242875|NCT02039336|Drug|PD-0325901|
79242876|NCT02039336|Drug|Docetaxel|
79242877|NCT02342054|Radiation|MRI-TRUS fusion guided Single Frac HDR|
79242878|NCT02341898|Other|Educational programme for all nurses|
79536861|NCT03975946|Procedure|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
79536862|NCT03975946|Biological|Blood Sample|Biological analysis
79838921|NCT00768326|Drug|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
79242879|NCT02341898|Other|Training and structured support for nominated key nurses|
79242880|NCT02341898|Other|Facultative train-the-trainer module for key nurses|
79838922|NCT00768326|Drug|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
79242881|NCT02341898|Other|Printed study material|
79242882|NCT02341898|Other|Supportive material (poster, mugs etc.)|
79242883|NCT05255042|Other|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
79242884|NCT02345096|Dietary Supplement|Saccharomyces cerevisiae|
79242885|NCT02345096|Dietary Supplement|Placebo|
79242886|NCT02345174|Drug|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
79838923|NCT00768326|Drug|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
79838924|NCT00768326|Drug|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
79838925|NCT00768326|Drug|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
80016832|NCT04471376|Drug|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
79242887|NCT02345174|Drug|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
79242888|NCT04935476|Drug|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
79242889|NCT04935476|Drug|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
79305800|NCT04925661|Drug|Placebo|Either dose of placebo will be administered after fasting .
79305801|NCT04919889|Other|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
79536863|NCT03975946|Procedure|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
79536864|NCT03974958|Genetic|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
79536865|NCT03956745|Behavioral|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep ~12h opposite their usual sleep time.
79536866|NCT03956745|Behavioral|constant routine|Study participants will spend ~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
79693870|NCT01779453|Drug|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
79693871|NCT04687982|Biological|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
79693872|NCT04671147|Procedure|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
79693873|NCT04571723|Behavioral|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
79536867|NCT03954002|Diagnostic Test|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
79242890|NCT04891016|Drug|delayed toripalimab|chemotherapy plus toripalimab and toripalimab was delayed on day 3. If the pCR was not achieved after surgery, then the patients received five cycles of FLOT plus toripalimab every two weeks, then toripalimab maintenance until one year. If pCR was achieved, then then the patients received two cycles of original regimen and then toripalimab maintenance until one year.
79242891|NCT04891016|Drug|control|chemotherapy and toripalimab were given on same day. If the pCR was not achieved after surgery, then the patients received four cycles of FLOT plus toripalimab every two weeks, then toripalimab maintenance until one year. If pCR was achieved, then then the patients received two cycles of original regimen and then toripalimab maintenance until one year.
79536868|NCT03938532|Device|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
79693874|NCT04571723|Behavioral|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
79242892|NCT02868281|Drug|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
79242893|NCT02868281|Drug|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
79242894|NCT02476006|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
79693875|NCT01776606|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
79693876|NCT01776606|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
79242895|NCT02476006|Drug|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
79242896|NCT02476006|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
79693877|NCT04670952|Other|Low Pressure Laparoscopic Cholecystectomy|Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
79693878|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
79693879|NCT01774578|Drug|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
79242897|NCT02476006|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
79242898|NCT02476006|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
79242899|NCT02476006|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
79242900|NCT02344940|Drug|Toremifene|patients will take toremifene 60 mg qd.
79242901|NCT02344940|Drug|Tamoxifen|patients will take tamoxifen 10 mg bid.
79242902|NCT02341976|Other|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
79242903|NCT03615677|Drug|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
79242904|NCT03615677|Drug|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
79242905|NCT03615443|Diagnostic Test|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
79242906|NCT02344862|Drug|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
79242907|NCT02344862|Drug|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
79242908|NCT02344862|Drug|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
79242909|NCT02344862|Drug|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
79305802|NCT04925115|Other|Brisk walking|"Warm up and cool down (10 minutes before physical activity)~Brisk walking ( 30 minutes each session for 5 days in a week)"
79536869|NCT03938532|Device|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
79536870|NCT03936465|Drug|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
79536871|NCT03936465|Drug|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
79536872|NCT03936062|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
79693880|NCT01774578|Biological|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
79693881|NCT01774578|Drug|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
79693882|NCT01774578|Drug|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
79693883|NCT01756482|Drug|GS-5806|GS-5806, powder for oral solution
79693884|NCT01756482|Drug|Placebo|
79838926|NCT00951717|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
79693885|NCT04543994|Drug|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
79838927|NCT00768404|Drug|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
79838928|NCT00776282|Drug|loratadine 10 mg orally disintegrating|
79242910|NCT03614429|Drug|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
79693886|NCT04543994|Drug|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
79242911|NCT03111836|Behavioral|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
79242912|NCT03111836|Behavioral|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
79242913|NCT03111836|Behavioral|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
79242914|NCT03614117|Dietary Supplement|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
79242915|NCT03614117|Dietary Supplement|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
79242916|NCT03614117|Dietary Supplement|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
79242917|NCT02341742|Device|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
79242918|NCT03614351|Dietary Supplement|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
79693887|NCT04543994|Other|Placebo|Normal saline
79693888|NCT04519697|Drug|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
79536873|NCT03936062|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
79693889|NCT04519697|Other|Placebo|Normal Saline
79693890|NCT04670601|Drug|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
79838929|NCT00943293|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
79838930|NCT00943293|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
79838931|NCT00943293|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
79536874|NCT03936049|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group
79536875|NCT03936049|Drug|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
79536876|NCT03936036|Drug|Linagliptin|Linagliptin dispensing claim is used as the exposure
79536877|NCT03936036|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
79838932|NCT00776360|Drug|oxytocin|80mIE/min as continuous infusion for 70 minutes
79838933|NCT00776360|Drug|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
79838934|NCT00946725|Drug|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
79536878|NCT03936010|Drug|Canagliflozin|Canagliflozin dispensing claim is exposure
79536879|NCT03936010|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
79838935|NCT00946725|Drug|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
79838936|NCT03041740|Drug|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
79838937|NCT00772694|Drug|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
79536880|NCT03930849|Behavioral|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
79536881|NCT03930849|Behavioral|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
79536882|NCT03930381|Other|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
79242919|NCT03614351|Other|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
79242920|NCT02475850|Other|Evidence-based tailored fall prevention|
79242921|NCT02475850|Other|Usual care|
79382333|NCT04122573|Diagnostic Test|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
79382334|NCT04122573|Diagnostic Test|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
79693891|NCT04670601|Drug|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
79536883|NCT03921541|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
79536884|NCT03921541|Drug|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
79382335|NCT04122807|Procedure|Cardiac catheter ablation|Cryoablation
79382336|NCT03875716|Radiation|Radiation therapy|Radiation therapy
79382337|NCT04126941|Other|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
79382338|NCT04122027|Other|Cerebral oximeter|Near infra-red spectroscopy, NIRS
79536885|NCT03919448|Biological|Bevacizumab|Single-dose infusion
79536886|NCT03904615|Dietary Supplement|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
79536887|NCT03904615|Dietary Supplement|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
79693892|NCT04670913|Drug|Camrelizumab|A human anti-PD-1 monoclonal antibody
79693893|NCT04670913|Drug|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
79693894|NCT04671069|Drug|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
79693895|NCT04671069|Drug|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
79242922|NCT03614273|Drug|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
79536888|NCT03904615|Dietary Supplement|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
79536889|NCT03900637|Drug|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
79536890|NCT03900637|Drug|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
79242923|NCT03614273|Drug|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
79242924|NCT02341430|Device|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
79242925|NCT02032121|Procedure|Blood specimen|
79242926|NCT02032121|Procedure|Echocardiography|
79242927|NCT02336984|Biological|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
79242928|NCT02336984|Drug|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
79242929|NCT02336984|Drug|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
79382339|NCT04122105|Drug|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
79382340|NCT02385214|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
79382341|NCT02385214|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
79382342|NCT03202641|Procedure|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
79536891|NCT03900637|Genetic|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
79536892|NCT03893045|Drug|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
80009707|NCT02161250|Dietary Supplement|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
79382343|NCT03202641|Procedure|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
79382344|NCT04121793|Device|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
79382345|NCT04127019|Drug|Paclitaxel|Paclitaxel chemotherapy (injection)
79536893|NCT03893045|Drug|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
79536894|NCT03878407|Other|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
79536895|NCT03877354|Other|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
79382346|NCT04127019|Drug|Docetaxel|Docetaxel chemotherapy (injection)
79536896|NCT03877354|Other|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
79382347|NCT04127019|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
79536897|NCT03867344|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
80009708|NCT03344887|Other|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
79382348|NCT04127019|Drug|Epirubicin|Epirubicin chemotherapy (injection)
79382349|NCT04127019|Drug|5-fluorouracil|5-fluorouracil chemotherapy (injection)
79382350|NCT02244034|Procedure|hypothermia|
79382351|NCT04127175|Device|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
79536898|NCT03867344|Other|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
79536899|NCT03865836|Biological|ATB200|
79536900|NCT03865836|Drug|AT2221|
79536901|NCT03832985|Genetic|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
79536902|NCT03832985|Genetic|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
79838938|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
79838939|NCT00951873|Drug|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
79838940|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
79536903|NCT03832985|Genetic|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
79536904|NCT03821272|Biological|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
79536905|NCT03821272|Biological|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
79536906|NCT03818737|Biological|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
79536907|NCT03818737|Biological|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
79838941|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
79242930|NCT03613805|Device|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
79242931|NCT03613805|Device|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
79242932|NCT03145610|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
79536908|NCT03818737|Biological|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
79693896|NCT04374539|Biological|Plasma exchange|"Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick <50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~Tocilizumab 400 mg (weight <75Kgs) or 600 mg (weight ≥ 75 Kg)~Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~Clexane 40-60 mg/d"
79242933|NCT03145610|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
79693897|NCT04374539|Drug|Standar medical treatmen|"Kaletra: lopinavir/ritonavir: 2c/12h 7 days~Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~Tocilizumab 400 mg (weight <75Kgs) or 600 mg (weight ≥ 75 Kg)~Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~Clexane 40-60 mg/d"
79693898|NCT01753167|Drug|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
79242934|NCT03145922|Other|Observational Study|Observational study utilizing bronchoscopy, and imaging
79242935|NCT02341586|Other|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
79242936|NCT02341586|Dietary Supplement|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
79382352|NCT02076646|Drug|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
79536909|NCT03818737|Drug|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
79536910|NCT03801785|Other|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
79536911|NCT03795922|Drug|MT10109L|MT10109L will be injected into the GL.
79693899|NCT01753167|Drug|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
79693900|NCT01753167|Drug|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
79693901|NCT01741194|Drug|AC-1204|AC-1204 taken once daily, by mouth
79693902|NCT01741194|Drug|Placebo|Placebo taken once daily, by mouth
79693903|NCT04363346|Drug|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
79693904|NCT04670718|Device|Optical Coherence Tomography Probe|Use of OCT probe for examination of gastrointestinal tract
79242937|NCT02341586|Other|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
79242938|NCT02336906|Drug|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
79242939|NCT02336906|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
79242940|NCT02336906|Behavioral|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
79382353|NCT02076646|Drug|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
79382354|NCT02076646|Drug|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
79382355|NCT04127097|Other|cartoon group|The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
79382356|NCT04121481|Dietary Supplement|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
79382357|NCT04121481|Dietary Supplement|Broad Spectrum Safety|Benefits in Sports Nutrition
79536912|NCT03795922|Drug|Placebo|Placebo will be injected into the GL.
79536913|NCT03794089|Behavioral|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
79536914|NCT03794089|Behavioral|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
79693905|NCT04332458|Behavioral|A focus group interview|this is a qualitative study using focus group interviewing.
79693906|NCT01823016|Drug|Placebo|Placebo tablet, taken once daily
79693907|NCT01823016|Drug|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
79693908|NCT04670211|Device|maxillary distractor|the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
80009709|NCT03344887|Other|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
80009710|NCT02161328|Other|EIT belt|
80009711|NCT03541148|Dietary Supplement|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
79242941|NCT03614039|Dietary Supplement|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
79693909|NCT04322123|Drug|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
79693910|NCT04322123|Drug|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
79693911|NCT04670328|Diagnostic Test|not required|Diagnostic tests( hematological parameters) were assessed.
79242942|NCT03614039|Dietary Supplement|Placebo|
79242943|NCT02341508|Biological|0.5 mg/kg Lpathomab|
79242944|NCT02341508|Biological|1.0 mg/kg Lpathomab|
79242945|NCT02341508|Biological|3.0 mg/kg Lpathomab|
79382358|NCT04121715|Device|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
79382359|NCT04121715|Drug|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
79382360|NCT01894906|Drug|Soluble Ferric Pyrophosphate|
79382361|NCT01894906|Other|Placebo|
79382362|NCT04121247|Other|nonpharmacological approaches to parents of children with sickle cell disease training program|use of non-pharmacological approaches in children with sickle cell disease, parent education
79382363|NCT04121091|Drug|Pramipexole Pill|Add-on pramipexole
79693912|NCT04670367|Behavioral|Walk 30mins|aerobic exercise
79693913|NCT04670367|Behavioral|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
79693914|NCT04670367|Other|usual care|routine care
79693915|NCT04670367|Behavioral|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
79709910|NCT04327323|Device|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
80009712|NCT01377337|Drug|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
80009713|NCT05655039|Other|Rehabilitation|Stroke Rehabilitation Program
80009714|NCT02158910|Drug|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
80009715|NCT01381003|Genetic|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
80009716|NCT05058339|Other|Survey Administration|Complete survey
80009717|NCT02158988|Procedure|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
79242946|NCT02341508|Biological|10 mg/kg Lpathomab|
79382364|NCT04127253|Device|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
79382365|NCT04127253|Device|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
79382366|NCT04127253|Behavioral|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
79242947|NCT02341508|Biological|20 mg/kg Lpathomab|
79242948|NCT02341508|Other|Saline solution for intravenous infusion|
79242949|NCT03613961|Drug|Anesthetics|The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
80009718|NCT05225493|Behavioral|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
79693916|NCT04313348|Behavioral|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
79693917|NCT04670289|Drug|TenoMiR (Low Dose)|Mimic of miR29a
79693918|NCT04670289|Drug|TenoMiR (Medium Dose)|Mimic of miR29a
79693919|NCT04670289|Drug|TenoMiR (High Dose)|Mimic of miR29a
79536915|NCT03789149|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
80009719|NCT05225493|Diagnostic Test|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
80009720|NCT02159144|Other|cold stress|
80009721|NCT02764190|Behavioral|I-ACT with Check Yourself|
79536916|NCT03777982|Drug|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
79536917|NCT03777982|Drug|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
79536918|NCT03777982|Drug|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
80009722|NCT02161796|Drug|FG-4592|Oral
79536919|NCT03777982|Drug|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
79536920|NCT03769025|Behavioral|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
79536921|NCT03769025|Other|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
79693920|NCT04670289|Drug|Placebo|0.9% saline
79693921|NCT01741155|Drug|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
79693922|NCT01741155|Drug|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
80009723|NCT02161796|Drug|Placebo|Oral
79242950|NCT03613571|Drug|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
79242951|NCT02341352|Drug|fluoride varnish|Sodium fluoride 50mg/ml
79242952|NCT02341352|Biological|Immunoglobulin Yolk|anti-Streptococcus mutans IgY
79242953|NCT02341352|Dietary Supplement|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
79242954|NCT03613883|Procedure|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
79242955|NCT02344550|Drug|Everolimus(afinitor)|Everolimus 10mg p.o. daily
79242956|NCT02344550|Drug|Letrozole|Letrozole 2.5 mg p.o. daily
79242957|NCT02344550|Drug|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
79242958|NCT02419612|Drug|Saxagliptin|
79693923|NCT04244630|Combination Product|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
79693924|NCT04670406|Behavioral|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
79693925|NCT04239053|Drug|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
80009724|NCT03541070|Device|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
80009725|NCT03077659|Drug|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
80009726|NCT05225181|Behavioral|perform physical exercise|one 60-min session of physical training
80009727|NCT05225181|Behavioral|cognitive training|one 60-min session of cognitive training
80009728|NCT05225181|Behavioral|control group|perform body stretching(15min) and health education courses(90min)
80009729|NCT05052723|Drug|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
79693926|NCT04670250|Diagnostic Test|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
79693927|NCT00556179|Drug|Lactoserum (Dermacyd Femina®)|Once a day during three months
79536922|NCT03762473|Drug|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
80009730|NCT05052723|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
79693928|NCT04687592|Procedure|reduction and fixation|"Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
79242959|NCT02419612|Drug|Dapagliflozin|
79242960|NCT02419612|Drug|Glimepiride|
79382367|NCT03029338|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
79382368|NCT03283605|Radiation|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
79382369|NCT03283605|Drug|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
79382370|NCT03283605|Drug|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
79382371|NCT03814564|Device|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
79382372|NCT01895062|Device|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
79382373|NCT04121013|Other|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
79382374|NCT04126707|Drug|[14C] HQP1351|Orally, single dose of 30mg
79536923|NCT03762473|Drug|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
79536924|NCT03760237|Other|observation only|No intervention, observational study only
79536925|NCT03745989|Drug|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
79536926|NCT03745989|Drug|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
79693929|NCT01718145|Drug|Daclatasvir|
79536927|NCT03737695|Procedure|Biospecimen Collection|Undergo biospecimen collection
79693930|NCT01718145|Drug|Asunaprevir|
79838942|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
79838943|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
79838944|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
80016833|NCT02094690|Device|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
80016834|NCT02094690|Device|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
79536928|NCT03737695|Other|Medical Chart Review|Undergo clinical information collection
79536929|NCT03729739|Diagnostic Test|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
79536930|NCT03729739|Diagnostic Test|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
79536931|NCT03724552|Device|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
79693931|NCT01718145|Drug|Ribavirin|
79693932|NCT01718145|Biological|pegIFNα-2b|
79693933|NCT01718145|Drug|Telaprevir|
79242961|NCT02419612|Other|Placebo|
79242962|NCT03612947|Drug|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
79242963|NCT03612947|Drug|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
79242964|NCT02341196|Procedure|CEA|Patients in both groups received an intra-operative angiography
79242965|NCT03613415|Other|Expansion|non invasive technique to increase thickness of thin ridge
79242966|NCT02344784|Device|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
79242967|NCT02344784|Drug|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
79242968|NCT03613337|Other|clinical restenosis|The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
79693934|NCT04687748|Device|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
79693935|NCT04687748|Other|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
79693936|NCT00556257|Drug|Cyclosporine|Standard of care
80009731|NCT05578131|Procedure|high flow nasal oxygen|In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was > 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.
79242969|NCT04913350|Other|Russian current|One of the preferred common neuromuscular electrical stimulation techniques for muscle strengthening is the Russian current (RC) It stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy.
79242970|NCT04913350|Device|elbow support|tennis elbow brace is recommended to decrease pain and improve function by restricting the movement of the forearm or relieving loads on the origin of the muscles of the extensor
79242971|NCT02447848|Drug|sufentanil sublingual 30 mcg tablet|
79536932|NCT03724552|Device|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
79242972|NCT02336516|Drug|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
79242973|NCT02336516|Drug|Placebo (glucose solution 10%)|
79242974|NCT02344706|Device|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
79242975|NCT02039258|Drug|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
79242976|NCT03145454|Device|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
79242977|NCT03145454|Device|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
79242978|NCT03145454|Device|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
79242979|NCT03145454|Device|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
79382375|NCT01896544|Dietary Supplement|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
79536933|NCT03721783|Procedure|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
79242980|NCT03145454|Device|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
79242981|NCT03145376|Diagnostic Test|geriatric assessment|"Clinical evaluation and geriatric assessment with:~CIRS: CIRS (Cumulative Illness Rating Scale)~ADL (Activities of Daily Living);~IADL (InstrumentalActivities of Daily Living);~Mini Nutritional Assessment;~Evaluation of quality of life (Short Form 36, SF-36).~Making a traditional 12-lead ECG.~A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~transthoracic echocardiogram."
79242982|NCT02344394|Device|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
79242983|NCT02344394|Device|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
79382376|NCT01896544|Dietary Supplement|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
79242984|NCT02344394|Device|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
79305803|NCT04925037|Behavioral|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
79305804|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
79382377|NCT04120623|Drug|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
79382378|NCT04120623|Drug|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
79382379|NCT01767467|Biological|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
79536934|NCT03674983|Behavioral|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
79693937|NCT00556257|Drug|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
79536935|NCT03665688|Device|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L&D unit for standard protocol of labor induction.
79693938|NCT04687787|Other|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
79693939|NCT04687787|Other|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
79693940|NCT01712451|Drug|salmeterol xinafoate, fluticasone propionate|LIPO-102
79693941|NCT01712451|Drug|Placebo|Placebo
79693942|NCT01712451|Drug|salmeterol xinafoate|Salmeterol
79693943|NCT00541268|Device|ICD|Intracardioverter defibrillators from 2 different manufacturers
79693944|NCT00541268|Other|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
79693945|NCT01712217|Drug|AT13387|HSP90 inhibitor
79693946|NCT01712217|Drug|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
79709911|NCT04338360|Biological|COVID-19 convalescent plasma|COVID-19 convalescent plasma
79709912|NCT00107315|Biological|bevacizumab|
79242985|NCT02342132|Device|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
79242986|NCT02342132|Device|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
79242987|NCT02342132|Device|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
79242988|NCT02344160|Other|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
79305805|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
79305806|NCT02158936|Drug|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
79382380|NCT01767467|Drug|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
79382381|NCT02988232|Drug|Sogyeonghwalhyeol-tang|herbal extract
79382382|NCT02988232|Drug|Placebo|extract powder with same appearance, odor and color as SGHH
79382383|NCT04758897|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
79382384|NCT01931878|Drug|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
79536936|NCT03665688|Device|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
79709913|NCT00107315|Drug|capecitabine|
79709914|NCT01335971|Drug|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
79709915|NCT01335971|Dietary Supplement|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
80016835|NCT02285894|Other|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
80016836|NCT02285972|Drug|saline|before the anesthesia induction, 2mL saline iv injection
79709916|NCT01335971|Other|Placebo|Microcrystalline cellulose once daily by mouth
80009732|NCT05578131|Procedure|face mask|In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
79536937|NCT03659045|Other|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
80009733|NCT05417737|Other|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
80009734|NCT05576571|Diagnostic Test|Met-score|methylation analysis
80009735|NCT05224947|Other|Infant Formula|Two infant formulas differing in composition
79242989|NCT03115463|Other|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
79536938|NCT03648021|Drug|Paracetamol|">50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
79536939|NCT03648021|Drug|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
79536940|NCT03646656|Behavioral|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
79536941|NCT03640845|Other|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~the transmission, the collection and the organization of the data,~the analysis of the data and their confrontation with the referential and recommendations~the writing of a Personalized Pharmaceutical Plan"
79536942|NCT03613792|Drug|Remifentanil|Opioid analgesic
79536943|NCT03613792|Drug|Fentanyl|Opioid analgesic
80009736|NCT02807883|Drug|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
80009737|NCT02807883|Procedure|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
80009738|NCT04051281|Behavioral|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
79242990|NCT02344082|Other|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
79242991|NCT02336126|Behavioral|Biopsychological intervention|
79242992|NCT05254652|Drug|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
79242993|NCT05254652|Drug|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
79536944|NCT03613792|Drug|Midazolam|Benzodiazepine
79536945|NCT03613792|Drug|Ketamine|Analgesic
79536946|NCT03594734|Behavioral|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
79536947|NCT03594734|Other|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
79536948|NCT03575598|Drug|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
79536949|NCT03575598|Biological|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
80009739|NCT03082261|Device|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
80009740|NCT04051047|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
80009741|NCT04051047|Procedure|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
80009742|NCT00102440|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
80009743|NCT00102440|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
80009744|NCT00102440|Drug|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
79242994|NCT02343926|Drug|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
79242995|NCT02343926|Drug|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
79693947|NCT04046237|Other|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
79693948|NCT00555243|Procedure|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
79693949|NCT00555243|Procedure|Traditional Surgical Education|Traditional surgical teaching (no simulator)
79693950|NCT04014764|Other|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
79693951|NCT04669821|Drug|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
79693952|NCT04669821|Drug|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
79693953|NCT04670055|Drug|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
79693954|NCT00532025|Drug|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
79693955|NCT04669119|Dietary Supplement|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
79693956|NCT04669119|Dietary Supplement|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
79693957|NCT04669119|Dietary Supplement|Placebo|Placebo
80009745|NCT02742363|Other|Collecting data|Collecting data from patient records
80009746|NCT05224791|Procedure|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
80009747|NCT05224791|Procedure|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
79242996|NCT02343926|Drug|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
79242997|NCT02343848|Device|smart bracelet.|Physical activity will be evaluated using smart bracelet.
79536950|NCT03572166|Diagnostic Test|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
79693958|NCT04669080|Behavioral|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
80009748|NCT01380847|Genetic|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
79242998|NCT03112226|Other|GnRHant + E2|GnRH antagonist with estradiol add-back
79709917|NCT00596661|Device|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
79709918|NCT04337892|Device|Standard of Care4|The current standard of care for surgical planning for the participating investigator surgeon is to use Zeiss Veracity Surgical, so this same method will be used for the surgery actually performed on participating patients.
80009749|NCT05224167|Drug|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
80009750|NCT05224167|Drug|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
80009751|NCT01377259|Other|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
80016837|NCT02285972|Drug|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
80016838|NCT02285972|Drug|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
80016839|NCT02096016|Procedure|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
79242999|NCT03112226|Other|GnRHant + Placebo|GnRH antagonist with placebo add-back
79243000|NCT02343770|Other|blood sample for identifying biomarkers|
79243001|NCT03612869|Drug|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
79536951|NCT03572166|Diagnostic Test|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
79536952|NCT03570450|Drug|Adipose derived Stem Cell|4 doses
79536953|NCT03570450|Other|placebo|placebo
79536954|NCT03563417|Procedure|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
79536955|NCT03563417|Other|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
80009752|NCT05223933|Behavioral|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
80009753|NCT05223777|Device|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
80009754|NCT05223777|Device|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
79693959|NCT03954080|Device|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
80009755|NCT05409547|Drug|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
80009756|NCT04994535|Drug|OnabotulinumtoxinA|Injection
80009757|NCT04994535|Drug|Placebo|Injection
80009758|NCT03909607|Drug|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
79243002|NCT02343692|Procedure|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
79243003|NCT03618251|Diagnostic Test|specific MRI sequences|MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
79243004|NCT02332616|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
79243005|NCT02332616|Drug|Isotonic Sodium Chloride|Placebo
79243006|NCT02332148|Drug|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
79243007|NCT02332148|Drug|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
79243008|NCT03618173|Drug|Dexamethasone|IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
79243009|NCT03618173|Drug|Placebos|IV saline serum at the dose of 0,2mL/kg maximum 8mL
79243010|NCT02336048|Drug|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
79243011|NCT02336048|Drug|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
79382385|NCT01931878|Drug|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
79382386|NCT01932112|Drug|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
79536956|NCT03555435|Other|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
79536957|NCT03555435|Behavioral|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
79536958|NCT03555435|Behavioral|Wait|Participants in this group will wait 6 weeks.
80009759|NCT03909607|Drug|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
79243012|NCT02336048|Drug|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
79243013|NCT02336048|Other|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
79243014|NCT02336048|Drug|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
79243015|NCT03612401|Drug|Mirabegron|Beta-3 adenoreceptor agonist
79243016|NCT02335970|Other|Training group|"After 1 week~Chest expansions~Static thoracic extension in prone~Lateral flexion of the spine in standing~Bilateral shoulder flexion~Shoulder external rotation of shoulders~Rotation of the thoracic spine in sitting~Static back extensor strength in prone~After 1 month~Thoracic extension, rotation and flexion abduction~Hand in neck and in back~Bilateral active flexion abduction~Strength training of leg muscles~Static back extensor strength~After 2 months~Strength training of legs and back muscles~Push-ups against a wall~Thoracic extension in sitting and standing~Thoracic rotation in lying~Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
79382387|NCT02987452|Other|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
79709919|NCT00107276|Drug|capecitabine|
79536959|NCT03551392|Device|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
79536960|NCT03551392|Device|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
79536961|NCT03551392|Device|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
79536962|NCT03551392|Device|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
79243017|NCT03612323|Drug|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
79693960|NCT04669353|Drug|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
79693961|NCT00532064|Procedure|Biospecimen Collection|Undergo collection of blood
79536963|NCT03540732|Other|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
79693962|NCT00532064|Other|Questionnaire Administration|Ancillary studies
79536964|NCT03540732|Procedure|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
79693963|NCT04669977|Dietary Supplement|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
79693964|NCT04668807|Device|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
79693965|NCT04668807|Device|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
79693966|NCT03849248|Other|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
79243018|NCT03612323|Drug|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
79693967|NCT04669392|Drug|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
79243019|NCT02332304|Procedure|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
79382388|NCT02987452|Other|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
79382389|NCT02987452|Other|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
79382390|NCT04120389|Device|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
79382391|NCT04120389|Procedure|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
79382392|NCT04120077|Dietary Supplement|EyePromise DVS, EyePromise DVS plus EyePromise EZTears|Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
79693968|NCT00532142|Drug|Intravitreal Triamcinolone|
79693969|NCT00532142|Procedure|Radial Optic Neurotomy|
79693970|NCT00532142|Other|Placebo - Sham Intravitreal Injection|
79693971|NCT04668963|Device|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
79709920|NCT00107276|Drug|cyclophosphamide|
80009760|NCT03909607|Drug|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
79243020|NCT02994719|Drug|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
79243021|NCT02994719|Device|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
79243022|NCT02340650|Device|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
79305807|NCT02158936|Drug|Azacitidine|Subcutaneous Injection (IV if local standard)
79305808|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets
79536965|NCT03521518|Diagnostic Test|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
79536966|NCT03521115|Behavioral|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
79693972|NCT04865627|Device|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
79536967|NCT03520413|Other|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
79382393|NCT01897402|Biological|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
79536968|NCT03520413|Other|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
79536969|NCT03447509|Device|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
79382394|NCT01897402|Biological|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
79536970|NCT03447509|Other|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
79536971|NCT03447509|Device|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
79536972|NCT03447509|Other|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
79536973|NCT03440567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
79243023|NCT03612167|Behavioral|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
79243024|NCT03612167|Behavioral|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
79243025|NCT02340416|Device|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
79243026|NCT04686227|Diagnostic Test|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
79243027|NCT04346108|Biological|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
79536974|NCT03440567|Drug|Avelumab|Given IV
79536975|NCT03440567|Drug|Carboplatin|Given IV
79382395|NCT04126239|Other|Online survey - questionnaire|Online survey - questionnaire
79382396|NCT04122339|Drug|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
79382397|NCT02280226|Device|magnetic resonance imaging (MRI)|
79536976|NCT03440567|Drug|Etoposide Phosphate|Given IV
79536977|NCT03440567|Drug|Ibrutinib|Given PO
79536978|NCT03440567|Drug|Ifosfamide|Given IV
79693973|NCT04669626|Other|Use of Ocetnilin|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~Removal of old dressing~Applying a soaked gaze with Octenilin® on the wound (5 minutes)~Mechanical debridement if necessary~Wound cleansing with Octenilin®~Application of new dressing (according to the wound healing phases, medical prescription)"
79838945|NCT00943371|Drug|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
79243028|NCT04346108|Biological|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
79243029|NCT03612635|Device|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
79243030|NCT03612011|Other|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
79243031|NCT02340494|Behavioral|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
79305809|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets will be supplied
79305810|NCT03054441|Other|Actigraph|Actigraphs worn on wrists
79382398|NCT01897792|Dietary Supplement|Vitamin C|
79382399|NCT01897792|Dietary Supplement|Vitamin E|
79536979|NCT03440567|Other|Laboratory Biomarker Analysis|Correlative studies
79536980|NCT03440567|Biological|Rituximab|Given IV
79536981|NCT03440567|Biological|Utomilumab|Given IV
79536982|NCT03423667|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
79536983|NCT03423667|Drug|Lactose powder|Placebo comparator.
79536984|NCT03419897|Drug|Tislelizumab|Administered intravenously
79536985|NCT03418129|Device|Mindfulness|Neuromodulatory intervention for pain management
79536986|NCT03418129|Device|Neurofeedback|Neuromodulatory intervention for pain management
79536987|NCT03418129|Device|Relaxation|Neuromodulatory intervention for pain management
79536988|NCT03411239|Device|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
79536989|NCT03378531|Drug|AEB1102|modified human arginase I
79536990|NCT03377049|Drug|Acetazolamide|1 g acetazolamide through a peripheral IV line
79536991|NCT03355976|Drug|Nivolumab|240mg flat dose every 2 weeks
79536992|NCT03355976|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
79243032|NCT05253950|Other|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
79693974|NCT04669626|Other|Use of NaCl 0.9%|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~Removal of old dressing~Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~Mechanical debridement if necessary~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
79693975|NCT04669470|Procedure|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
79693976|NCT04669431|Other|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
79693977|NCT04669431|Other|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
79693978|NCT00533312|Drug|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
79693979|NCT00533312|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
79693980|NCT00533312|Drug|Comparator : niacin / Duraton of Treatment: 4 Weeks|
79693981|NCT04668612|Device|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
79536993|NCT03345563|Behavioral|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
79243033|NCT03611855|Device|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
79243034|NCT03611855|Other|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
79382400|NCT01897792|Dietary Supplement|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
79536994|NCT03345563|Behavioral|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
79536995|NCT03345563|Behavioral|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
79536996|NCT03344796|Behavioral|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
79536997|NCT03335488|Drug|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
79693982|NCT04668612|Device|Standard bolus|Standard boluses for all meals
79693983|NCT04669314|Procedure|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
79693984|NCT00533390|Drug|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
79693985|NCT00556296|Drug|NRP104|NRP104 30mg capsule once daily in a.m.
79693986|NCT00556296|Drug|NRP104|NRP104 50mg capsule once daily in a.m.
79693987|NCT00556296|Drug|NRp104|NRP104 70mg capsule once daily in a.m.
79693988|NCT00556296|Drug|Placebo|Placebo
79536998|NCT03335488|Drug|NaPBA|"NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
79243035|NCT02335736|Drug|Gonadotropins releasing hormone antagonist|
79243036|NCT04632173|Other|non interventional study|There is no intervention
79693989|NCT04709003|Diagnostic Test|Serologic test|A blood test to check antibodies type and amount
79693990|NCT04709003|Diagnostic Test|Respiratory swabs|PCR test to Covid-19
79693991|NCT00556335|Procedure|manual aspiration|air aspiration
79693992|NCT00556335|Procedure|conventional drainage|drainage, pneumocath
79693993|NCT04668456|Drug|Dexmedetomidine|the drug administered either subtenon ot iv
79693994|NCT04668456|Drug|lidocaine 2%|subtenon injection
79243037|NCT02335814|Drug|FLX925|
79243038|NCT03613259|Drug|Fluorothymidine F-18|Given IV
79243039|NCT03613259|Other|Laboratory Biomarker Analysis|Correlative studies
79243040|NCT03613259|Procedure|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
79243041|NCT02332070|Procedure|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
79243042|NCT03611699|Drug|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
79382401|NCT01897792|Drug|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
79382402|NCT02982915|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
79382403|NCT02982915|Biological|Fluzone High Dose Vaccine|Intramuscular injection
79382404|NCT01933984|Drug|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
79382405|NCT04126083|Drug|Lofexidine Oral Tablet|lofexidine 0.54 mg 4 times daily
79693995|NCT04668456|Drug|bupivacine 0.5%|subtenon injection
79838946|NCT00943371|Drug|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
79693996|NCT04668456|Drug|Normal saline|either subtenon or iv
79693997|NCT04668417|Behavioral|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
79693998|NCT04668417|Behavioral|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
79693999|NCT04686968|Procedure|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
79694000|NCT04686968|Procedure|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
79694001|NCT00556413|Biological|cetuximab|
79694002|NCT00556413|Drug|fluorouracil|
79838947|NCT00552513|Procedure|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (and within 24 hours of randomisation).
79243043|NCT03611699|Drug|Placebo|Placebo inhaler
79243044|NCT02032355|Procedure|spinal anesthesia|
79243045|NCT03095456|Drug|Revefenacin|Revefenacin administered via nebulization.
79694003|NCT00556413|Drug|irinotecan hydrochloride|
79243046|NCT03095456|Combination Product|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
79243047|NCT03095456|Drug|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
79243048|NCT03095456|Drug|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
79243049|NCT03612557|Drug|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
79243050|NCT05253638|Diagnostic Test|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
79243051|NCT03611543|Device|New investigational curved paddle|X-ray imaging of breast tissue
79243052|NCT03067844|Drug|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
79243053|NCT02340572|Drug|PRS-080#022-DP|hepcidin antagonist
79243054|NCT02340572|Drug|PRS-080-Placebo#001|Placebo treatment
79243055|NCT03105284|Procedure|Liposuction|Fat harvest by liposuction (Colemans method)
79243056|NCT02340260|Behavioral|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
79536999|NCT03324802|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79537000|NCT03324802|Other|Quality-of-Life Assessment|Ancillary studies
79537001|NCT03324802|Radiation|Radiation Therapy|hypofractionated radiation therapy
79537002|NCT03323437|Drug|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
79537003|NCT03306355|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
79537004|NCT03306355|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
79694004|NCT00556413|Drug|leucovorin calcium|
79694005|NCT00556413|Drug|oxaliplatin|
79694006|NCT04687085|Other|10 minute mindful meditation recording|10 minute mindful meditation recording
79694007|NCT04668573|Other|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
79243057|NCT02340260|Behavioral|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
79537005|NCT03300141|Other|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
79537006|NCT03300141|Other|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
79537007|NCT03300141|Other|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
79838948|NCT00552513|Procedure|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
79838949|NCT00946803|Behavioral|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
79838950|NCT00943449|Drug|4SC-201|oral administration
79838951|NCT00943449|Drug|Sorafenib|oral administration
79838952|NCT00952029|Biological|bevacizumab|
79537008|NCT03298633|Other|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
79243058|NCT02331758|Behavioral|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
79694008|NCT04686695|Device|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
79694009|NCT04668690|Drug|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
79694010|NCT04668690|Drug|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
79243059|NCT02340182|Drug|Vancomycin|250mg 3dd2
79243060|NCT02340182|Drug|Ciprofloxacin|500mg 2dd1
79243061|NCT02340182|Drug|Metronidazole|500mg 3dd1
79243062|NCT02331836|Device|Arc Endocuff (AEC 110, 120, 130, 140)|
79243063|NCT02331836|Device|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
79243064|NCT02331836|Device|Standard colonoscope|
79243065|NCT05226182|Other|visualisation of a digital care path|The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
79243066|NCT02339948|Radiation|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
79243067|NCT02339792|Other|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
79537009|NCT03298633|Other|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
79537010|NCT03273972|Other|Written Informed Consent|To be completed prior to conducting any study related procedures
79537011|NCT03273972|Other|Inclusion/Exclusion check|Eligibility check
79537012|NCT03273972|Other|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
79537013|NCT03273972|Other|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
79537014|NCT03273972|Other|Pregnancy Test|If applicable for women of child bearing potential
79694011|NCT04668534|Device|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
79694012|NCT04668534|Device|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
79694013|NCT04668534|Device|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
79838953|NCT00952029|Drug|FOLFIRI regimen|
79243068|NCT02339714|Other|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
79243069|NCT02339714|Drug|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
79305811|NCT04924647|Drug|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
79382406|NCT02282722|Other|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
79537015|NCT03273972|Other|12 Lead ECG|participant resting supine
79838954|NCT00952029|Drug|fluorouracil|
79838955|NCT00952029|Drug|irinotecan hydrochloride|
79838956|NCT00952029|Drug|leucovorin calcium|
79838957|NCT00560313|Biological|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
79382407|NCT02282722|Other|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
79382408|NCT04393545|Device|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
79382409|NCT04393545|Other|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
79694014|NCT04658979|Other|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
79694015|NCT04593992|Device|HTEMS|high-tone external muscle stimulation
79694016|NCT04593992|Device|Placebo|Placebo stimulation
79243070|NCT02335190|Procedure|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
79243071|NCT02335190|Procedure|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
79243072|NCT02335190|Drug|Lidocaine|
79243073|NCT02339870|Other|Psychosocial Support for Caregiver|Complete expressive disclosure writing
79382410|NCT04393545|Other|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
79382411|NCT04393155|Other|COVID-19+ observational|This is observational -- there is no intervention
79382412|NCT01935622|Drug|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
79838958|NCT00560313|Biological|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
79838959|NCT00667862|Drug|Panobinostat|
79537016|NCT03273972|Other|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
79537017|NCT03273972|Other|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
79537018|NCT03273972|Other|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
79537019|NCT03273972|Other|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
79838960|NCT00952107|Device|FLARE imaging system|Testing of operation of imaging system
79838961|NCT00952185|Other|cytology specimen collection procedure|
79243074|NCT02339870|Other|Psychosocial Support for Caregiver|Complete benefit finding writing
79382413|NCT01935622|Drug|placebo|Placebo 1 tablet every 12 hours for 14 days
79243075|NCT02339870|Other|Questionnaire Administration|Ancillary studies
79243076|NCT02339870|Other|Sham Intervention|Complete writing on an emotionally neutral topic
79243077|NCT02335112|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
79243078|NCT02335112|Device|NanoKnife|
79243079|NCT02335034|Behavioral|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
79382414|NCT03010917|Drug|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
79382415|NCT03010917|Drug|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
79382416|NCT03008187|Drug|SEL24/MEN1703|SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
79382417|NCT01936324|Drug|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
79382418|NCT01936324|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
79382419|NCT04274673|Device|measuring cotinine level|Measuring of the cotinine levels
79382420|NCT02979561|Drug|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
79537020|NCT03273972|Other|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
79537021|NCT03273972|Other|Concomitant medication check|Review of medication taken by the participant
79537022|NCT03273972|Other|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
79537023|NCT03273972|Other|Physical examination|Check overall health
79537024|NCT03273972|Other|Medical history|Review of volunteers medial history
79537025|NCT03273972|Other|AE/SAE review & reporting|Monitor safety from the point of consent
79537026|NCT03273972|Drug|Dosing|To be performed at the end of the visit following completion all other study visits
79537027|NCT03268200|Other|segmental reexamination|segmental reexamination during colonoscopy
79838962|NCT00952185|Other|fluorescent antibody technique|
79838963|NCT00952185|Procedure|assessment of therapy complications|
79838964|NCT00776516|Drug|mirabegron|oral
79838965|NCT00776516|Drug|rifampin|oral
79838966|NCT00946959|Procedure|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
79838967|NCT00768638|Drug|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
79838968|NCT00768638|Drug|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
80016840|NCT03134300|Diagnostic Test|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
79243080|NCT02335034|Behavioral|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
79243081|NCT02334878|Biological|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
79537028|NCT03261700|Behavioral|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
79537029|NCT03261700|Other|Information and referral condition|Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
79694017|NCT04668729|Other|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
79537030|NCT03244072|Drug|Moxifloxacin|Intracameral injection
79537031|NCT03244072|Drug|Placebo|intracameral injection
79694018|NCT00533585|Drug|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
79694019|NCT00533585|Drug|Paclitaxel|200 mg/m^2 By Vein Over 3 Hours on Day 1.
79838969|NCT00952263|Biological|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
79243082|NCT02334878|Procedure|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra & through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted & the remaining tape cut off at the level of the skin.
79243083|NCT02331524|Behavioral|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
79382421|NCT02979561|Drug|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
79382422|NCT01766921|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
79382423|NCT01937026|Drug|Baricitinib|Administered orally
79382424|NCT01937026|Drug|Probenecid|Administered orally
79382425|NCT04759053|Procedure|FNB|Fine needle aspiration from the nodules
79694020|NCT00533585|Drug|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
79382426|NCT04759053|Procedure|Core biopsy|Core biopsy from thyroid nodules
79382427|NCT04393467|Device|tSMS|tSMS delivered on bilateral motor cortex
79694021|NCT00533585|Drug|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
79838970|NCT02557958|Drug|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
79838971|NCT02557958|Drug|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
79838972|NCT00776672|Drug|Fosinopril 40mg Tablets|
79838973|NCT00535132|Drug|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
79838974|NCT00535132|Drug|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
79382428|NCT04393467|Device|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
79382429|NCT01774799|Behavioral|Advance care planning intervention|
79382430|NCT01774799|Other|Control group|
79694022|NCT04585100|Drug|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
79838975|NCT00570908|Drug|sunitinib|Sutent
79838976|NCT00570908|Drug|capecitabine|concurrently
79838977|NCT00570908|Radiation|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
79694023|NCT04585100|Drug|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
79694024|NCT04585100|Drug|Placebo|Placebo BID for 28 days
80009761|NCT02498925|Behavioral|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
80009762|NCT02762084|Drug|Patidegib|
80009763|NCT02762084|Drug|Vehicle gel|
80009764|NCT03902509|Drug|Pirfenidone|pirfenidone capsule made in China
80009765|NCT03902509|Drug|basic treatment|glucocorticoid and expectant treatment etc.
80009766|NCT05223543|Diagnostic Test|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
80009767|NCT02159222|Procedure|Additional physical therapy|
79243084|NCT02331524|Other|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
79382431|NCT03825783|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
79537032|NCT03238417|Other|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
79537033|NCT03226197|Dietary Supplement|Ketone ester drink|Ketone ester drink
80009768|NCT01380613|Behavioral|Workshop|10 session intervention
79243085|NCT02339636|Other|PDUS examination|
79243086|NCT02581592|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
79243087|NCT02578082|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
79537034|NCT03219047|Other|Best Practice|Receive standard of care
79537035|NCT03219047|Drug|Ibrutinib|Given at standard dose and schedule
79537036|NCT03219047|Other|Patient Derived Xenograft|Xenograft developed
79382432|NCT03824223|Diagnostic Test|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
79382433|NCT03828903|Device|Cryoprobe|"The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~The frozen tissue is going to be extracted by gently pulling of the probe.~Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~The biopsy sample will be released from the probe by thawing in the saline.~The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
79537037|NCT03219047|Other|Personalized Medicine|Receive treatment based on the results of the PDX models
79537038|NCT03215277|Drug|Bimekizumab|One bimekizumab dose will be administered.
80009769|NCT01380613|Behavioral|Workshop control|1 session intervention on standard HIV/STD information
79537039|NCT03215277|Drug|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
79537040|NCT03215277|Other|Placebo|Placebo will be provided to maintain the blinding.
79537041|NCT03200340|Drug|EC-18|Oral administration of EC-18 twice daily
79537042|NCT03200340|Drug|Placebo|Placebo to match EC-18 capsule administration
79537043|NCT03185013|Biological|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
79694025|NCT04585100|Drug|FM101 150 mg|FM101 (150 mg) BID for 28 days
79694026|NCT04585100|Drug|FM101 300 mg|FM101 (300 mg) BID for 28 days
79694027|NCT04659252|Other|n/a - samples collected along routine care samples only|This is a non-interventional study.
79694028|NCT04668378|Other|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
79694029|NCT04668378|Other|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
80009770|NCT02166632|Procedure|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
80009771|NCT02166632|Procedure|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
80009772|NCT03625401|Drug|AD-35 60mg group|AD-35 60mg QD
80009773|NCT03625401|Drug|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
80009774|NCT02161952|Drug|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
80009775|NCT02161952|Drug|Matched equivalent placebo|
80009776|NCT05223465|Other|Survey|Google form distributed for students and faculties
79694030|NCT04668222|Drug|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
79694031|NCT04668222|Drug|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
79694032|NCT04668222|Drug|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
79694033|NCT04668222|Drug|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
79382434|NCT01937260|Drug|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
79694034|NCT04668222|Drug|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
79694035|NCT04659057|Drug|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
79694036|NCT04659057|Drug|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
79694037|NCT04659057|Drug|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
79694038|NCT04659057|Other|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
79694039|NCT04668261|Other|Advanced imaging investigation|MRI imaging
79694040|NCT04658745|Device|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
79694041|NCT04658745|Behavioral|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
79694042|NCT04658745|Device|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
79694043|NCT04658745|Behavioral|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
79694044|NCT00533741|Drug|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
79694045|NCT00533741|Drug|Placebo|Saline for injection.
79694046|NCT00533741|Biological|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
80009777|NCT03590145|Diagnostic Test|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
80009778|NCT05202249|Procedure|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
79382435|NCT04125381|Other|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
79537044|NCT03185013|Biological|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
79537045|NCT03185013|Device|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
79537046|NCT03182907|Biological|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
79537047|NCT03182907|Drug|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
79537048|NCT03182907|Drug|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
79694047|NCT04658511|Device|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
79694048|NCT04668027|Diagnostic Test|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
80009779|NCT04984161|Other|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
80009780|NCT04979403|Other|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
79243088|NCT02339324|Drug|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
79243089|NCT02334956|Other|Brain MRI|
79694049|NCT04668027|Diagnostic Test|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
79243090|NCT03105206|Procedure|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
79694050|NCT04668027|Diagnostic Test|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
80009781|NCT03705039|Other|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
79243091|NCT02334566|Behavioral|NET TX|Intervention procedures are a behavioral intervention (NET & KIDNET) with 8-12 sessions administered on a weekly basis.
80009782|NCT03705039|Other|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
79243092|NCT02339480|Other|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
79243093|NCT02418754|Drug|REGN2176-3|
79243094|NCT02418754|Drug|Intravitreal Aflibercept Injection (IAI)|
79243095|NCT02334488|Drug|Everolimus|Active Comparator
79243096|NCT02334488|Drug|Tacrolimus|Active Comparator
79243097|NCT02334488|Drug|Mycophenolate sodium|Experimental Arm
79243098|NCT03105050|Other|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
79243099|NCT02334644|Dietary Supplement|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
79243100|NCT02334644|Dietary Supplement|Placebo|2 sachets/day x 12 weeks
79537049|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
79537050|NCT03170960|Drug|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
79537051|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
79537052|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
79243101|NCT02447458|Drug|MLN3126|MLN3126 tablets
79243102|NCT02447458|Drug|MLN3126 Placebo|MLN3126 placebo-matching tablets
79243103|NCT02862457|Drug|Epacadostat 25 mg|Oral administration
79243104|NCT02862457|Drug|Epacadostat 100 mg|Oral administration
79243105|NCT02862457|Biological|pembrolizumab 200 mg|Intravenous (IV) infusion
79243106|NCT02862457|Drug|Cisplatin 75 mg/m^2|IV infusion
79243107|NCT02862457|Drug|Carboplatin Area Under the Curve (AUC) 5|IV infusion
79243108|NCT02862457|Drug|Pemetrexed 500 mg/m^2|IV infusion
79243109|NCT02862457|Drug|Paclitaxel 200 mg/m^2|IV infusion
79243110|NCT02862457|Drug|Carboplatin AUC 6|IV infusion
79243111|NCT04103138|Device|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
79243112|NCT04103138|Device|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
79243113|NCT02334332|Other|Educational Intervention|Receive educational brochure
79243114|NCT02334332|Procedure|Standard Follow-Up Care|Receive standard post-operative care
79243115|NCT02334332|Procedure|Quality-of-Life Assessment|Ancillary studies
79243116|NCT02334254|Drug|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
79243117|NCT02334254|Drug|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
79243118|NCT02447302|Drug|Etrasimod|
79243119|NCT02447302|Drug|Placebo|
79243120|NCT02334410|Device|Whole body vibration (WBV)|Side-alternating WBV
79243121|NCT02482519|Other|High calorie diet|High calorie diet for 10 days
79243122|NCT02482519|Other|Fasting|10 day fast
79243123|NCT02039570|Other|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
79243124|NCT02331602|Drug|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
79243125|NCT02331602|Drug|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
79537053|NCT03159676|Radiation|Proton beam|Proton beam
79537054|NCT03143673|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
79537055|NCT03091725|Procedure|Roux-en-Y gastric bypass surgery|A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
79537056|NCT03091725|Behavioral|Very low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
79537057|NCT03036813|Drug|voxelotor|
79537058|NCT03036813|Other|Placebo|
79243126|NCT02454517|Behavioral|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
79243127|NCT02454517|Behavioral|Exercise Intervention|Undergo DPP lifestyle intervention
79243128|NCT02454517|Other|Informational Intervention|Receive oral and written guidelines and meet with dietician
79243129|NCT02454517|Other|Laboratory Biomarker Analysis|Correlative studies
79694051|NCT00533819|Other|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
79694052|NCT04658589|Procedure|Laparoscopic versus open distal gastrectomy|Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
79838978|NCT00773084|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
79243130|NCT02454517|Other|Quality-of-Life Assessment|Ancillary studies
79838979|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
79243131|NCT02454517|Other|Questionnaire Administration|Ancillary studies
79382436|NCT04125615|Behavioral|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
79243132|NCT02338934|Drug|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
79243133|NCT03610087|Behavioral|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
79305812|NCT04919577|Diagnostic Test|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
79537059|NCT03027141|Behavioral|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
79537060|NCT03007953|Behavioral|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
79537061|NCT02984163|Behavioral|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
79537062|NCT02981940|Drug|Abemaciclib|Abemaciclib capsule
79537063|NCT02981940|Procedure|Surgery|Surgery
79537064|NCT02930668|Dietary Supplement|Glucosanol 350mg|
79537065|NCT02930668|Dietary Supplement|Glucosanol 500mg|
79537066|NCT02930668|Dietary Supplement|Placebo|
79537067|NCT02922192|Drug|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
79537068|NCT02921191|Drug|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
79694053|NCT04545671|Other|trifocal lens|not applicable as patients are already implanted with the trifocal lens
79694054|NCT04658394|Other|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
79694055|NCT04667988|Diagnostic Test|JAK expression|JAK2 assessment in blood by PCR
79694056|NCT04536116|Device|Virtual Reality headset|MRI simulation with a Virtual Reality headset
79838980|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to <10.5 g/dL had occurred.
79537069|NCT02920021|Drug|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
79243134|NCT03610087|Behavioral|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
79537070|NCT02920021|Drug|Placebo|Administered by intravenous infusion
79838981|NCT00781391|Drug|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
79382437|NCT01902004|Drug|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
79382438|NCT01902004|Drug|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
79382439|NCT01902004|Drug|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
79382440|NCT04125303|Behavioral|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
79537071|NCT02919618|Radiation|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
79537072|NCT02911701|Drug|Acetaminophen|
79537073|NCT02911701|Drug|Ibuprofen|
79537074|NCT02905370|Behavioral|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
79537075|NCT02905370|Behavioral|Enhanced Usual Care (EUC)|"Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
79537076|NCT02896257|Other|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
79537077|NCT02881203|Device|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
79537078|NCT02881203|Device|RPM|Varian Real-time Position Management (RPM) system
79537079|NCT02874742|Drug|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
79694057|NCT04668183|Procedure|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
79694058|NCT04668183|Procedure|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
79537080|NCT02874742|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
79537081|NCT02874742|Drug|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
79537082|NCT02874742|Drug|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
79694059|NCT04521998|Device|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
79694060|NCT04521998|Device|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
79694061|NCT04658706|Other|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
80009783|NCT03704961|Behavioral|music and audiobook listening|
79243135|NCT02330900|Other|Study group|Exposure to cell phone interference of the ICD
79838982|NCT00781391|Drug|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
80009784|NCT05322447|Drug|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
79537083|NCT02840019|Device|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
79537084|NCT02840019|Procedure|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
79243136|NCT03861039|Drug|Tirzepatide|Administered SC
79243137|NCT03861039|Drug|Oral antihyperglycemic medication (OAM)|Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
79243138|NCT04365673|Other|Pharmacist transition of care consultation|Pharmacist-delivered comprehensive medication review
79243139|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
79243140|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
79243141|NCT02334176|Drug|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
79243142|NCT02236975|Device|BuMA Supreme Biodegradable drug coating coronary stent system|
79243143|NCT02236975|Device|Resolute Integrity durable polymer stent system|
79243144|NCT02338856|Drug|MB12066 200mg|100mg bid (multiple dose, day 8)
79243145|NCT02338856|Drug|Placebo|100mg bid (multiple dose, day 8)
79537085|NCT02818842|Other|Primary Health Insurance Fund data|"Data collected are:~First and last name of mother~Age~Mother's date of birth~Theorical date of beginning of pregnancy~Childbirth date"
79382441|NCT03829995|Other|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
79382442|NCT01938040|Drug|ibuprofen|single preoperative dose prior to surgery
79537086|NCT02818842|Other|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~First and last name of the mother~Mother's birth date~Mother Obstetric history~Course of pregnancy~Drug exposure (name, decision period)~Medical termination of pregnancy (date, cause ...)~Malformations (description, test results, gender of the child,~Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
79537087|NCT02818842|Other|Mother and child protection data collection|"Date collected are :~Name and surname of Mother~Date of birth of the mother~Obstetric history of the mother (the first certificate to 8 days)~Course of pregnancy (1st certificate to 8 days)~Birth data (1 certificate to 8 days)~Child gender,~Age of the child at the time of the review,~Weight, height and head circumference of the child~American Pediatric Gross Assessment Record (1 certificate to 8 days)~Neonatal diseases (1 certificate to 8 days)~Birth defects (1 certificate to 8 days)~Death (age at death)~History (certificates at 9 and 24 months)~Current diseases (certificates at 9 and 24 months)~Psychomotor development (certificates at 9 and 24 months).~Date of drugs issue~Amount of drug issued~Type of feeding (1 certificate to 8 days)"
79537088|NCT02818842|Other|Medicalisation Program of Information Systems data|"Data collected are :~First and last name of the mother~Mother's birth date~History of abortions (date and cause)"
79537089|NCT02805023|Biological|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
79537090|NCT02805023|Biological|Control medium|Intramuscular injections - single treatment session
79537091|NCT02793999|Device|Near-Infrared Spectroscopy (NIRS)|
79537092|NCT02791880|Procedure|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
79537093|NCT02749292|Drug|Rituximab|re-dosing dependent on interventional arm parameter.
79694062|NCT04658706|Other|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
79243146|NCT03609931|Procedure|Mitral Valve Model|Creation of a mitral valve patient specific model to see if it mimics the patients valve
79243147|NCT02338778|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
79243148|NCT02338778|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
79243149|NCT03609307|Drug|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
79243150|NCT03609307|Drug|Intravitreal bevacizumab|these patients receive only Bevacizumab
79243151|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
79243152|NCT03399435|Combination Product|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
79243153|NCT03399435|Combination Product|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
79382443|NCT01938040|Other|sugar water/placebo|single preoperative dose prior to surgery
79382444|NCT04125849|Procedure|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
79382445|NCT04125849|Procedure|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
79694063|NCT04520555|Device|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
79694064|NCT04520555|Device|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
79694065|NCT00533858|Drug|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
79838983|NCT00781391|Drug|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
79838984|NCT00781391|Drug|placebo warfarin|placebo warfarin
79838985|NCT00781391|Drug|placebo edoxaban|placebo edoxaban
79243154|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
79243155|NCT03399435|Drug|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
79382446|NCT01765751|Procedure|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
79243156|NCT03399435|Drug|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
79243157|NCT03399435|Drug|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
79382447|NCT03829839|Drug|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
79382448|NCT03829839|Drug|Lorazepam 1 mg|Oral administration of 1mg lorazepam
79537094|NCT02734017|Other|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
79537095|NCT02715609|Drug|Disulfiram|
79537096|NCT02715609|Drug|Copper Gluconate|
79537097|NCT02715609|Procedure|Surgery|
79537098|NCT02715609|Radiation|Radiation|
79537099|NCT02715609|Drug|Temozolomide|
79537100|NCT02707744|Other|no intervention|
79537101|NCT02689076|Other|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
79694066|NCT04658355|Other|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
79694067|NCT04658355|Other|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
79694068|NCT04498442|Behavioral|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
79694069|NCT04498442|Behavioral|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
79694070|NCT04667598|Drug|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
79694071|NCT04667676|Device|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
79694072|NCT00533936|Biological|trastuzumab|
79243158|NCT03399435|Combination Product|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
79243159|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
79243160|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
79382449|NCT03829839|Drug|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
79382450|NCT03829839|Drug|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
79382451|NCT01938664|Drug|Candesartan with CBT|8 mg, po (by mouth)
79537102|NCT02689076|Other|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
79537103|NCT02619136|Procedure|Transfusion|Red Blood Cell Transfusion
79537104|NCT02576990|Biological|Pembrolizumab|IV infusion
79694073|NCT00533936|Drug|cyclophosphamide|
79694074|NCT00533936|Drug|doxorubicin hydrochloride|
79694075|NCT00533936|Drug|fluorouracil|
79838986|NCT00776750|Biological|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
79838987|NCT00534976|Drug|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
79838988|NCT00534976|Drug|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
79243161|NCT02338700|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
79537105|NCT02550561|Device|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
79838989|NCT00768794|Dietary Supplement|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
79838990|NCT00768794|Dietary Supplement|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
79537106|NCT02524171|Behavioral|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
79838991|NCT00773162|Drug|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
79537107|NCT02513225|Behavioral|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
79243162|NCT02338700|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
79382452|NCT01938664|Other|Placebo with CBT|
79382453|NCT03829917|Drug|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
79382454|NCT03829917|Drug|miltefosine|28 days of miltefosine
79382455|NCT03829917|Drug|paromomycin|28 days of paromomycin creaam
79382456|NCT03829449|Drug|rVA576 (Coversin)|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
79382457|NCT01736657|Device|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
79382458|NCT04124679|Other|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
79382459|NCT02284126|Drug|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
79382460|NCT01736579|Drug|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
79382461|NCT02974335|Behavioral|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
79537108|NCT02513225|Other|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
79537109|NCT02511106|Drug|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
79537110|NCT02511106|Drug|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
79694076|NCT00533936|Drug|paclitaxel|
79694077|NCT00533936|Procedure|adjuvant therapy|
79694078|NCT00533936|Procedure|conventional surgery|
79694079|NCT00533936|Procedure|neoadjuvant therapy|
79838992|NCT00773162|Drug|Sugar Pill|Sugar pill to match seroquel
79838993|NCT00768950|Procedure|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
79838994|NCT00768950|Procedure|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
79838995|NCT00769028|Drug|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
79838996|NCT00769028|Drug|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
79243163|NCT01936688|Drug|MK-3222 200 mg|MK-3222 200 mg administered SC.
79243164|NCT01936688|Drug|MK-3222 100 mg|MK-3222 100 mg administered SC.
79243165|NCT01936688|Drug|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
79243166|NCT01936688|Drug|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
79382462|NCT01939288|Device|Neuromuscular stimulation, followed by intermittent pneumatic compression|
79382463|NCT01939288|Device|Intermittent pneumatic compression, followed by neuromuscular stimulation|
79382464|NCT01940146|Drug|SPARC Placebo|Placebo
79382465|NCT01940146|Drug|SPARC1310 I|SPARC1310 I
79382466|NCT01940146|Drug|SPARC1310 II|SPARC1310 II
79382467|NCT01940146|Drug|SPARC1310 III|SPARC1310 III
79694080|NCT04686539|Drug|CBD|CBD oil not containing THC, to be administered sub-lingual.
79694081|NCT04686539|Drug|Placebo|Placebo Oil
79694082|NCT00557544|Drug|metoclopramide|metoclopramide 0,15 mg/kg
79694083|NCT00557544|Drug|placebo|placebo per os
79694084|NCT00557544|Drug|ketoprofen|ketoprofen 1 mg/Kg
79694085|NCT04667871|Procedure|cataract surgery|Eyes for cataract surgery
79694086|NCT04667832|Diagnostic Test|selective coronary artery angiography|Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
79694087|NCT04667910|Drug|601 1.25mg|Solution for injection (intravitreal use)
79694088|NCT04667910|Drug|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
79694089|NCT04404608|Diagnostic Test|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
80009785|NCT05322447|Drug|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
80009786|NCT03704727|Dietary Supplement|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus
80009787|NCT03704649|Behavioral|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
79243167|NCT01936688|Drug|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
79243168|NCT03399357|Biological|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
79243169|NCT02338544|Drug|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
79537111|NCT02511106|Drug|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
79694090|NCT04668105|Other|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
79243170|NCT04446663|Drug|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
79243171|NCT04446663|Drug|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
79243172|NCT04446663|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
79243173|NCT04446663|Radiation|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
79243174|NCT01861496|Drug|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
79382468|NCT01765673|Device|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
79382469|NCT04124913|Drug|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
79382470|NCT04124913|Drug|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
79838997|NCT00321763|Biological|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
79838998|NCT00321763|Biological|Fluarix TM|Single dose, Intramuscular injection
79243175|NCT03399279|Procedure|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
79243176|NCT03399279|Other|Perforated collagen membrane|Membrane perforations using dental needle
79243177|NCT03399279|Other|Occlusive membrane|Biotech collagen membrane
79243178|NCT03399279|Other|Nanohydroxyapetite|Nanbone Particles
79243179|NCT02333942|Device|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
79243180|NCT02334020|Other|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
79243181|NCT02520219|Drug|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
79243182|NCT02520219|Biological|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
79243183|NCT02333786|Other|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
79382471|NCT03828279|Diagnostic Test|functional and antigenic C1 inhibitor|Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
79382472|NCT02987920|Drug|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
79382473|NCT02987920|Drug|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
79382474|NCT02987920|Drug|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
79382475|NCT02987920|Drug|Oxycodone|Multimodal analgesic regimen to Group A and Group B
79382476|NCT02987920|Drug|Celecoxib|Multimodal analgesic regimen to Group A and Group B
79382477|NCT02987920|Drug|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
79382478|NCT02987920|Drug|Ketorolac|Multimodal analgesic regimen to Group A and Group B
79382479|NCT02987920|Drug|Gabapentin|Multimodal analgesic regimen to Group A and Group B
79382480|NCT02987920|Drug|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
79838999|NCT02822716|Procedure|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
79839000|NCT02822716|Device|Ultrasound|
79839001|NCT00776828|Drug|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
79839002|NCT04002466|Other|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
79243184|NCT02333786|Other|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
79382481|NCT03902301|Dietary Supplement|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
79243185|NCT02334098|Dietary Supplement|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
79243186|NCT02334098|Dietary Supplement|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
79243187|NCT03394287|Drug|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
79243188|NCT03394287|Drug|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
79839003|NCT00776906|Device|Advance® 18PTX® Balloon Catheter|
79839004|NCT00776906|Device|Advance® 18LP Balloon Catheter|
79839005|NCT00773240|Drug|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
79839006|NCT00773240|Drug|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
79243189|NCT02338622|Drug|olaparib|olaparib BD
79243190|NCT02338622|Drug|AZD5363|AZD5363 BD
79243191|NCT02338466|Drug|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
79243192|NCT02338466|Drug|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
79243193|NCT05099510|Biological|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
79243194|NCT05099510|Biological|Placebo|Placebo control for NatrunixTM subcutaneous injection.
79243195|NCT03394209|Drug|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
79243196|NCT03394209|Drug|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
79243197|NCT02333864|Device|POGO® BGMS|SMBG
79243198|NCT03399201|Procedure|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
79382482|NCT03902301|Dietary Supplement|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
79382483|NCT01764659|Other|Contrast-enhanced 4D computed tomography|All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
79382484|NCT03828123|Biological|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
79382485|NCT02974257|Drug|Thiamine|Thiamine 500mg IV twice daily for 2 days
79382486|NCT02974257|Other|placebo|100mL normal saline IV every 12 hours for 2 days
79382487|NCT01736189|Drug|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
79382488|NCT01903564|Device|magnetocardiography|recording of magnetic heart activity
79382489|NCT01903564|Device|postnatal ECG|postnatal ECG
79382490|NCT01903564|Device|fetal echocardiography|fetal echocardiography
79382491|NCT02970981|Biological|Nivolumab|
79382492|NCT02970981|Biological|Ipilimumab|
79382493|NCT02987842|Device|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
79382494|NCT04169711|Drug|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
79382495|NCT03829137|Device|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
79382496|NCT03829137|Device|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
79382497|NCT03829293|Device|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
79694091|NCT04668105|Other|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
79694092|NCT04333043|Diagnostic Test|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
80009788|NCT05278377|Behavioral|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
79382498|NCT03828435|Device|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
79243199|NCT03399201|Procedure|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
79243200|NCT03399201|Diagnostic Test|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
79382499|NCT02983773|Drug|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
79243201|NCT02331056|Other|fluid loading|"Fluid loading at defined period~500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
79382500|NCT02983773|Drug|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
79537112|NCT02500589|Behavioral|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
79694093|NCT04667286|Procedure|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
79694094|NCT04657965|Drug|LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
79243202|NCT02331056|Procedure|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
79243203|NCT02331056|Procedure|thoracotomy|the patient group for scheduled open pulmonary lobectomy
79243204|NCT02520453|Drug|Durvalumab|
79243205|NCT02520453|Drug|Placebo|
79382501|NCT02983773|Drug|Placebo|1 smoked placebo marijuana cigarette
79382502|NCT03828591|Procedure|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
79694095|NCT00534014|Dietary Supplement|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
79694096|NCT04658004|Drug|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
79694097|NCT00534053|Other|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
79694098|NCT04658043|Other|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
79694099|NCT04657848|Procedure|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
79382503|NCT03828591|Procedure|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
79382504|NCT01941472|Other|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
79694100|NCT04657614|Other|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
79694101|NCT04657614|Other|Anterior Alignment|Alignment that is anterior displaced pylon.
79694102|NCT04657614|Other|Posterior Alignment|Alignment that is posteriorly displaced pylon.
79694103|NCT00534170|Dietary Supplement|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
80009789|NCT04907799|Behavioral|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
80009790|NCT04907799|Other|Standard advice control|Initial nutrition consultation without subsequent counseling
79243206|NCT02331212|Other|Cytology Specimen Collection Procedure|Correlative studies
79243207|NCT02331212|Other|Laboratory Biomarker Analysis|Correlative studies
79243208|NCT03399123|Other|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
79694104|NCT04244513|Device|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
79694105|NCT04657536|Device|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
79382505|NCT04274205|Other|Intervention group|Brief supportive psychotherapy
79694106|NCT04657536|Drug|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
79694107|NCT04236206|Behavioral|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~Patients will be encouraged to send messages/call the researcher for any queries encountered."
79243209|NCT02330744|Behavioral|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
79243210|NCT02330744|Behavioral|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
79709921|NCT04326777|Procedure|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
79709922|NCT01335698|Drug|Atazanavir Sulphate|
80009791|NCT04050735|Other|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
79709923|NCT01335698|Drug|Ritonavir|
80009792|NCT04050735|Other|Placebo|Placebo beverage
80009793|NCT04784559|Drug|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
79243211|NCT05043428|Behavioral|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
79243212|NCT03389919|Biological|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
79243213|NCT02338388|Procedure|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
79243214|NCT02731755|Other|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
79382506|NCT03828669|Behavioral|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
79243215|NCT02731755|Other|Control|60g cream of rice
79243216|NCT03389841|Other|Education|Education of the caregiver about early symptoms and signs of heart failure
79243217|NCT03389763|Drug|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
79243218|NCT01704404|Drug|TD-4208|
79243219|NCT01704404|Drug|Placebo|
79382507|NCT01941628|Drug|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
79537113|NCT02500589|Other|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
79537114|NCT02494882|Drug|Ruxolitinib|
79537115|NCT02494882|Drug|Dasatinib|
79537116|NCT02494882|Drug|Dexamethasone|
79537117|NCT02481830|Drug|Nivolumab|
79243220|NCT02866175|Drug|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
79537118|NCT02481830|Drug|Topotecan|
79537119|NCT02481830|Drug|Amrubicin|
79709924|NCT00596700|Device|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
79839007|NCT01063933|Drug|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
79839008|NCT02556866|Drug|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
79537120|NCT02478138|Procedure|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
80009794|NCT04784559|Drug|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
79537121|NCT02478138|Drug|Indocyanine Green (ICG)|
79839009|NCT02556866|Drug|Prednisone|
79243221|NCT02866175|Drug|Clopidogrel|Clopidogrel 75 mg once-daily
79537122|NCT02478138|Device|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
79839010|NCT02556866|Drug|Placebo|
79839011|NCT01064011|Procedure|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
79243222|NCT02866175|Drug|Prasugrel|prasugrel 5mg or 10 mg once-daily
79243223|NCT02866175|Drug|Ticagrelor|ticagrelor 90 mg twice-daily
79243224|NCT02866175|Drug|Vitamin K antagonist|VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
79243225|NCT03399045|Procedure|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
79243226|NCT03399045|Procedure|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
79537123|NCT02477111|Device|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
79537124|NCT02467738|Radiation|Brachytherapy|Undergo brachytherapy with Cesium-131
79537125|NCT02467738|Drug|Cesium-131|Undergo brachytherapy with Cesium-131
79537126|NCT02467738|Procedure|Conventional surgery|Undergo surgical resection
79537127|NCT02426814|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
79537128|NCT02426814|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
79839012|NCT01064011|Procedure|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
79839013|NCT00769106|Biological|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
79839014|NCT01064089|Drug|HSP990|
79839015|NCT00773318|Procedure|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
79839016|NCT03946306|Drug|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
79839017|NCT03946306|Device|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
80009795|NCT04784559|Drug|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
79243227|NCT02330822|Drug|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
79537129|NCT02425943|Device|injectable poly-L-lactic acid Sculptra Aesthetic|
79537130|NCT02416674|Procedure|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
79537131|NCT02416674|Drug|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
79537132|NCT02383173|Other|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
79537133|NCT02383173|Other|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
79537134|NCT02380690|Behavioral|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
79694108|NCT04657653|Procedure|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
79694109|NCT04686617|Diagnostic Test|Mechanical Vibration|Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
79694110|NCT04657419|Other|survey|"Self-questionnaires will be completed by the participants :~General health and mental health~Fatigue~Burn-Out~Sleepiness~Sleep hygiene~Symptoms of COVID"
80009796|NCT04784559|Drug|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
79243228|NCT02333396|Other|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
79243229|NCT02333396|Other|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
79382508|NCT01941628|Drug|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
79537135|NCT02368132|Behavioral|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
79694111|NCT00556569|Other|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
79694112|NCT04184804|Behavioral|Behavioral Intervention|"The intervention package will be consisted of:~Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~Signs in school areas about organic fruits and vegetables~Workshops and interactive games for children~Seminars for parents"
79694113|NCT00556608|Device|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
80009797|NCT03704571|Drug|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
79537136|NCT02368132|Behavioral|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
80009798|NCT03704493|Diagnostic Test|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
79382509|NCT02987218|Drug|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
79694114|NCT00556608|Device|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
79694115|NCT00534287|Drug|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
79694116|NCT00534287|Drug|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
79243230|NCT02338310|Drug|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
79382510|NCT02987218|Drug|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
79382511|NCT03822429|Drug|Controlled ovarian stimulation|Hormonal therapy to induce ovulation by multiple ovarian follicles
79382512|NCT01735175|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
79243231|NCT03389607|Diagnostic Test|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
79382513|NCT01735175|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
79694117|NCT00556647|Procedure|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
79694118|NCT00556647|Procedure|conventional diagnosis|out-patient diagnosis
79243232|NCT02817789|Drug|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
79694119|NCT00534326|Procedure|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
79243233|NCT02817789|Drug|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
79243234|NCT02333474|Biological|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
79243235|NCT02333474|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
79243236|NCT05383625|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|intralesional 0.1 ml every two weeks
79243237|NCT05383625|Drug|Bivalent Human Papilloma Virus Vaccine|Intralesional 0.1 ml every two weeks
79694120|NCT00534326|Procedure|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
79694121|NCT04686656|Other|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
79694122|NCT04686656|Other|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
79694123|NCT04168502|Drug|Glasdegib|After randomization patients in both arms will be randomized to maintenance with glasdegib vs clinical observation
79694124|NCT04168502|Drug|Gemtuzumab Ozogamicin|Both arms, before randomization, will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
79694125|NCT04666896|Other|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
79694126|NCT04666896|Other|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
79694127|NCT04666935|Other|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
79694128|NCT04666935|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
79694129|NCT00534443|Procedure|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
79243238|NCT05383625|Drug|Saline|intralesional into the largest warts every two weeks
79243239|NCT02330432|Biological|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
79382514|NCT03822273|Procedure|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
79537137|NCT02362997|Drug|Pembrolizumab|Anti-PD-1 monoclonal antibody
79537138|NCT02341118|Genetic|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
79537139|NCT02311673|Drug|Setmelanotide|subcutaneous injection
79537140|NCT02311673|Drug|Placebo|Subcutaneous injection
79537141|NCT02300870|Drug|Optison|Echocardiogram with IV contrast
79537142|NCT02285725|Procedure|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
79537143|NCT02285725|Procedure|Injections of BMAC + PRP + HA|All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
79537144|NCT02269150|Biological|fecal microbiota transplantation (FMT)|
79537145|NCT02269150|Other|No fecal microbiota transplantation (FMT), routine management|
79694130|NCT04667091|Other|Physiotherapy|"Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)"
79694131|NCT00534482|Behavioral|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
79694132|NCT00534482|Behavioral|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
79694133|NCT00534482|Behavioral|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
79243240|NCT02330432|Other|Best standard care|Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
79537146|NCT02233738|Behavioral|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
79243241|NCT03398967|Biological|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~Other: Laboratory Biomarker Analysis"
79537147|NCT02233738|Behavioral|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
79243242|NCT02337998|Other|load carriage|
79243243|NCT02330354|Behavioral|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
79537148|NCT02220426|Drug|Xenon|Inhalation of hyperpolarized xenon gas
79537149|NCT02123121|Drug|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
79382515|NCT03822273|Procedure|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz]; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
79537150|NCT02123121|Drug|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
79537151|NCT02123121|Other|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
79839018|NCT05356624|Other|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
80009799|NCT04050657|Other|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
80009800|NCT03704337|Dietary Supplement|Commercially Available Food Bar|Active
80009801|NCT03704337|Dietary Supplement|Placebo|Placebo
80009802|NCT04910763|Behavioral|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
80009803|NCT03704259|Other|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
79243244|NCT03125577|Biological|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
79243245|NCT03125577|Biological|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
79243246|NCT03125577|Biological|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
79243247|NCT03125577|Biological|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
79243248|NCT03125577|Biological|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
79243249|NCT03125577|Biological|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
79243250|NCT02330666|Behavioral|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
79243251|NCT02039648|Other|Rumex acetosa L. extract|
79243252|NCT02039648|Other|Placebo|
79382516|NCT03822273|Procedure|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
80009804|NCT03704181|Drug|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
79537152|NCT02123121|Other|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
79839019|NCT05356624|Other|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
79839020|NCT00308113|Drug|Prednisone|Prednisone 0/75 mg/kg/day.
80009805|NCT03704181|Drug|Placebo Oral Tablet|placebo twice day for one year
80009806|NCT03625011|Drug|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
80009807|NCT04891965|Biological|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10^9 CFU/capsule. Subjects will receive 1 capsule daily.
80009808|NCT04891965|Drug|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
80009809|NCT03701841|Drug|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
80009810|NCT03701685|Procedure|nerve flap|sensory reconstruction via a nerve graft included in the flap
80009811|NCT04775355|Procedure|Biospecimen Collection|Undergo collection of stool and urine
80009812|NCT04775355|Other|Electronic Health Record Review|Medical records are reviewed
79243253|NCT03389451|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
79243254|NCT02337842|Biological|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units.
79243255|NCT02337842|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
79537153|NCT02009579|Drug|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
79537154|NCT02009579|Drug|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
79537155|NCT01959698|Drug|Carboplatin|Given IV
79839021|NCT00308113|Dietary Supplement|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
79839022|NCT03903640|Device|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
80009813|NCT04775355|Other|Quality-of-Life Assessment|Complete quality of life questionnaires
80009814|NCT04775355|Other|Questionnaire Administration|Complete questionnaires
80009815|NCT02763644|Drug|LFG316 active drug|LFG316
79243256|NCT03610919|Drug|Nasal Sprays|Intranasal administration of 24 international units per dose.
79243257|NCT03385395|Drug|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
79243258|NCT03385395|Drug|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
79243259|NCT02333318|Drug|VVZ-149 injection|Colorless, transparent liquid in water for injection
79839023|NCT03903640|Biological|Nivolumab|-Standard of care
80009816|NCT02763644|Other|Standard of care treatment|SoC (site specific)
80009817|NCT02162030|Behavioral|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
80009818|NCT03703713|Drug|Sodium chloride|Treatment with Sodium chloride
80009819|NCT04722627|Drug|AT-752|Parallel Assignment
79243260|NCT02333318|Other|Placebo|water for injection
79243261|NCT03611387|Device|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
79243262|NCT03389373|Device|GC Strep Mutans Saliva Sampling|Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
80009820|NCT04722627|Drug|Placebo|Parallel Assignment
80009821|NCT04728555|Procedure|Game about radiotherapy|A digital pedagogical game about radiotherapy
80009822|NCT03625167|Other|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
80009823|NCT04893759|Drug|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
79243263|NCT03385317|Behavioral|Mindfulness|
79243264|NCT03610841|Diagnostic Test|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
79243265|NCT03610841|Diagnostic Test|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
79537156|NCT01959698|Drug|Carfilzomib|Given IV
79537157|NCT01959698|Drug|Etoposide|Given IV
79537158|NCT01959698|Drug|Ifosfamide|Given IV
79537159|NCT01959698|Other|Laboratory Biomarker Analysis|Correlative studies
79839024|NCT03903640|Biological|Ipilimumab|-Standard of care
79839025|NCT03982849|Drug|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
79839026|NCT03982849|Drug|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
79839027|NCT05154344|Drug|Capmatinib|Available through expanded access
79243266|NCT02330120|Drug|propofol|
79243267|NCT02330120|Drug|dexmedetomidine|
79243268|NCT03389295|Radiation|Reduced Target Delineation and Radiation Doses|"The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices."
79694134|NCT00534482|Behavioral|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
79839028|NCT05357872|Device|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
79839029|NCT05357872|Device|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
79243269|NCT02032589|Behavioral|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
79537160|NCT01959698|Other|Pharmacological Study|Correlative studies
79243270|NCT01592643|Device|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
80009824|NCT04576689|Drug|IBE-814 70ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
79537161|NCT01959698|Biological|Rituximab|Given IV
79694135|NCT04667052|Drug|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
79694136|NCT04667052|Drug|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
79694137|NCT04136522|Procedure|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
79839030|NCT03983005|Procedure|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
79839031|NCT01061593|Dietary Supplement|Immunoxel|1 lozenge once per day
79839032|NCT01061593|Other|Placebo|1 lozenge once per day
79839033|NCT00769262|Other|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
80009825|NCT04576689|Drug|IBE-814 140ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
80009826|NCT04575909|Behavioral|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
79243271|NCT03718988|Behavioral|Meat products|Traditional meat products (beef burger patties, pork sausage, etc.)
79243272|NCT03718988|Behavioral|Plant Alternative products|Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
79537162|NCT01790373|Behavioral|Suubi+Adherence|"Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~Financial education and workshops on asset-building, future planning, and protection from risks~Mentorship from a young adult/near-peer~Family-based microenterprise development training~Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
79694138|NCT04136522|Procedure|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
79839034|NCT00769262|Other|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
79839035|NCT03979261|Diagnostic Test|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
79839036|NCT00777218|Drug|propranolol|standard pediatric doses, based on body weight
79839037|NCT00777218|Drug|zonisamide|standard pediatric dosages, based on body weight
79839038|NCT00777218|Drug|topiramate|standard pediatric dosages, based on body weight
79839039|NCT04047758|Drug|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment [3 weeks on (days 1-21) and 1 week off (days 22-28)], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
80009827|NCT04575909|Behavioral|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.
80009828|NCT04573491|Genetic|Pharmacogenetic test|genotyping for genes that affect drug metabolism
79537163|NCT01790373|Behavioral|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
79694139|NCT04667130|Behavioral|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
79694140|NCT01215916|Drug|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid [350 micrograms (µg) to 1000 µg orally, daily], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone [4 milligrams (mg) orally, twice daily or equivalent]."
79694141|NCT01215916|Drug|Pemetrexed|"375 to 500 milligrams per square meter (mg/m^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
79839040|NCT04047758|Drug|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
80009829|NCT04573491|Other|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
79839041|NCT00922064|Procedure|ECT|ECT series consisting of 6 to 14 ECTs
79243273|NCT02647749|Device|Cardioinsight® mapping system|
79243274|NCT02647749|Other|Conventional method without non-invasive mapping|
79243275|NCT04003766|Diagnostic Test|biopsy|Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
79382517|NCT01942720|Device|Capsule endoscopy and Ileocolonoscopy tests|
79382518|NCT03827577|Procedure|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
79382519|NCT03827577|Radiation|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
79382520|NCT03827577|Drug|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
79537164|NCT01772420|Drug|Eltrombopag Olamine|Given PO
79839042|NCT05355064|Drug|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
79839043|NCT00307801|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
79839044|NCT00307801|Drug|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
79839045|NCT00671060|Drug|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
79839046|NCT00671060|Drug|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
79839047|NCT00769418|Drug|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
80009830|NCT03701607|Other|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
80009831|NCT04718727|Drug|Placebo|oral Placebo tablets one-hour preoperatively
80009832|NCT04718727|Drug|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
80009833|NCT04718727|Drug|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
80009834|NCT03703557|Diagnostic Test|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
80009835|NCT03703557|Diagnostic Test|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
79243276|NCT02337608|Drug|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
79243277|NCT02337608|Drug|Placebo|placebo daily dosing in the morning daily for 12 weeks
79243278|NCT03983564|Other|Cutoff Validation|We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
79243279|NCT01500681|Procedure|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
79243280|NCT03398889|Diagnostic Test|Plasma levels of metabolites|plasma levels of metabolites
79537165|NCT01772420|Other|Laboratory Biomarker Analysis|Correlative studies
79537166|NCT01772420|Drug|Lenalidomide|Given PO
79243281|NCT03398889|Behavioral|Dietary questionnaire|Harvard food frequency questionnaire
79243282|NCT03398889|Diagnostic Test|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
79243283|NCT01295697|Drug|EZN-2208|Experimental
79537167|NCT01728363|Drug|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
79537168|NCT01614197|Drug|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
79537169|NCT01614197|Drug|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
79537170|NCT01614197|Drug|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
79537171|NCT01614197|Drug|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~Age 1 - 1.99 give 8 mg of methotrexate~Age 2 - 2.99 give10 mg of methotrexate~Age 3 - 8.99 give 12 mg of methotrexate~Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
79839048|NCT00769418|Drug|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
79839049|NCT05257252|Behavioral|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
79382521|NCT01762943|Drug|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
79839050|NCT00773552|Drug|solifenacin succinate|5mg PO Qday x 90 days
79839051|NCT00773552|Drug|placebo|1 tab PO Qday x 90 days
79243284|NCT03398811|Drug|Depot medroxy-progesterone acetate|Injection every 3 months
79243285|NCT03398811|Drug|Etonogestrel|68 mg implant
79243286|NCT03398811|Drug|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
79243287|NCT03398733|Device|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
79382522|NCT01762943|Drug|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
79537172|NCT01614197|Drug|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
79537173|NCT01614197|Drug|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~Age 1 - 1.99 give 30 mg of Cytarabine~Age 2 - 2.99 give 50mg of Cytarabine~Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~16 mg for patients age 1-1.99~20 mg for patients age 2-2.99~24 mg for patients 3-8.99 years of age~30 mg for patients >9 years of age"
79839052|NCT04002700|Drug|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
79839053|NCT04002700|Drug|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
80009836|NCT03703479|Other|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
80009837|NCT03701529|Drug|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
80009838|NCT03701529|Drug|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
79243288|NCT01300143|Other|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
79243289|NCT01300143|Other|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
79243290|NCT01336205|Drug|NKTR-118|25 mg oral tablet once daily
79243291|NCT01336205|Drug|Usual care|As prescribed by the investigator
79243292|NCT02333240|Other|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
79243293|NCT02033135|Procedure|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
79243294|NCT02033135|Other|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
79243295|NCT02033135|Device|Zilver PTX|
79243296|NCT02337374|Device|Midurethral sling mesh|
79382523|NCT01762943|Drug|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
79382524|NCT01943110|Device|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
79839054|NCT04002700|Drug|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
79537174|NCT01584063|Behavioral|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
79537175|NCT01520701|Device|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
79537176|NCT01520701|Drug|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
79537177|NCT01422148|Drug|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
79537178|NCT01422148|Drug|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
79537179|NCT01341964|Drug|Clopidogrel|600mg (2 pills)
80009839|NCT04050891|Device|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
79243297|NCT02865395|Drug|Belladonna and Opium Suppository|
79243298|NCT02865395|Procedure|Rectal Exam|
79243299|NCT02327390|Procedure|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
79382525|NCT01943110|Device|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
79382526|NCT03331354|Behavioral|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
79382527|NCT03331354|Other|Basic vocational services|self-help manual
79694142|NCT00534521|Device|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
79839055|NCT00769496|Drug|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
80009840|NCT04553133|Drug|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
79382528|NCT01943344|Device|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
79382529|NCT04392063|Drug|Melatonin 3 mg|The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
79382530|NCT01903798|Drug|Mycophenolate mofetil|Immunosuppressive agent
79382531|NCT01903798|Drug|Prednisolone|Corticosteroid
79537180|NCT01341964|Drug|Aspirin|325mg (1 pill)
80009841|NCT04553133|Drug|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
79243300|NCT02327390|Biological|X-ACT|Administered as an IV infusion
79243301|NCT02329496|Device|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
79243302|NCT03611231|Drug|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
79243303|NCT02333084|Dietary Supplement|PRN Joint Health Formula|
79382532|NCT01903798|Drug|Rilonacept|
79382533|NCT03821961|Procedure|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
79243304|NCT02333084|Dietary Supplement|placebo|
79243305|NCT02333084|Dietary Supplement|PRN Flex Omega Benefits® combination|
79243306|NCT03610685|Drug|Prednisolone|Given daily for 2 weeks
79243307|NCT03610685|Drug|Placebo oral capsule|Given daily for 2 weeks
79382534|NCT01909180|Device|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
79382535|NCT04273815|Drug|TQ-A3334|TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
79382536|NCT04273815|Drug|Anlotinib|Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
79537181|NCT01341964|Drug|Aspirin|81mg (1 pill)
79537182|NCT01293214|Procedure|Limb transplantation|
79537183|NCT01267812|Drug|bortezomib|Given SC or IV
79839056|NCT05354908|Other|scientific and academic productivity|Number and quartile of scientific products generated by the group
79839057|NCT04098653|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
79839058|NCT04098653|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
79243308|NCT02333006|Other|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
79243309|NCT02327234|Drug|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
79243310|NCT02327234|Drug|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
79243311|NCT01123707|Drug|Aripiprazole|Aripiprazole oral capsules
79243312|NCT01123707|Drug|Escitalopram|Escitalopram oral capsules
79243313|NCT02332772|Other|Data Collection|Data collected from endoscopy procedures.
79243314|NCT02755103|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
79243315|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
79537184|NCT01267812|Biological|rituximab|Given IV
79382537|NCT01945138|Device|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
80009842|NCT04553133|Drug|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
79382538|NCT03810339|Drug|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
79382539|NCT01734785|Drug|Linagliptin|tablet
79537185|NCT01267812|Other|laboratory biomarker analysis|Correlative studies
79243316|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
79243317|NCT01258803|Drug|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
79243318|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
79243319|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
79243320|NCT01258803|Drug|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
79243321|NCT01258803|Drug|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
79243322|NCT01258803|Drug|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
79243323|NCT02327156|Drug|dexmedetomidine|adding dexmedetomidine to the local anesthetic
79243324|NCT02033291|Procedure|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
79243325|NCT02329340|Behavioral|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
79243326|NCT02329340|Behavioral|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
79243327|NCT03610529|Device|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
79382540|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
79382541|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
79382542|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
79382543|NCT01734785|Drug|Empaglifozin placebo + Linagliptin placebo|Matching Empaglifozin + Linagliptin low dose
79382544|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
79382545|NCT03821805|Other|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
79382546|NCT03008031|Procedure|CESM with a reduced dose of contrast agent|
79382547|NCT03821415|Drug|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
79382548|NCT03821181|Device|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
79382549|NCT03821181|Device|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
79382550|NCT03821025|Device|Biliary stent|Palliation of malignant biliary obstruction
79382551|NCT01734395|Drug|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
79382552|NCT03820869|Other|Family Training|Family Training
79382553|NCT03820869|Other|Occupational Therapy|Occupational Therapy
79537186|NCT01267812|Other|immunohistochemistry staining method|Correlative studies
79537187|NCT01267812|Genetic|RNA analysis|Correlative studies
79537188|NCT01267812|Genetic|gene expression analysis|Correlative studies
79537189|NCT01267812|Genetic|DNA analysis|Correlative studies
79537190|NCT01267812|Other|pharmacological study|Correlative studies
79537191|NCT01267812|Other|pharmacogenomic studies|Correlative studies
79537192|NCT01267812|Other|Questionnaire Administration|
79537193|NCT01247974|Device|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
79839059|NCT04098653|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79839060|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
80009843|NCT04553133|Drug|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
80009844|NCT04553133|Drug|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
80009845|NCT04553133|Drug|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
79243328|NCT03610529|Device|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
79243329|NCT02039804|Drug|Corticosteroids|Intra-bursal injection
79243330|NCT02039804|Device|Hyaluronic acid|Intra-bursal injection
79537194|NCT01236521|Drug|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
79243331|NCT02865083|Device|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
79243332|NCT03112070|Other|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
79243333|NCT03385161|Procedure|Botulinum toxin A|
79694143|NCT00534521|Device|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
79694144|NCT04666818|Device|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
79382554|NCT03820713|Procedure|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
79382555|NCT03820713|Procedure|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
79382556|NCT01945294|Drug|Boceprevir|800 mg three times daily orally
79382557|NCT01945294|Biological|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
79382558|NCT01945294|Drug|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
79382559|NCT01947946|Biological|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
79537195|NCT01236521|Behavioral|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
80009846|NCT04553133|Drug|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
79243334|NCT03385161|Procedure|Ethanol|
79243335|NCT02327000|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
79243336|NCT02327000|Drug|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
79243337|NCT02032979|Behavioral|Psychiatric test|
79243338|NCT01036113|Drug|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
79243339|NCT03111524|Other|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
79243340|NCT03111524|Other|No intervention|No intervention is administered in this group as these are control groups
79243341|NCT02033057|Procedure|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
79243342|NCT02329184|Drug|MYK-461|
79243343|NCT02558699|Procedure|physician's personal experience|physician's personal experience
79243344|NCT02558699|Procedure|Virtual rotor mapping|Virtual rotor mapping
79243345|NCT02033603|Drug|Ropivacaine|30mls of 0.5% ropivacaine
79243346|NCT02326922|Device|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
79243347|NCT00862251|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
79243348|NCT00862251|Drug|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
79243349|NCT00862251|Drug|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
79694145|NCT00534560|Drug|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
79694146|NCT00534560|Drug|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
79694147|NCT00534560|Drug|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
79694148|NCT01184872|Drug|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
79839061|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
80009847|NCT03703245|Other|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
80009848|NCT03703245|Other|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
79537196|NCT01226797|Drug|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
80009849|NCT03701451|Drug|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
79537197|NCT01226797|Drug|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
79243350|NCT00862251|Drug|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
79537198|NCT01142908|Behavioral|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
79537199|NCT01051895|Other|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
79537200|NCT01051895|Other|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
79537201|NCT01042379|Drug|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
79243351|NCT02329106|Device|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
79537202|NCT01042379|Drug|AMG 386 with or without Trastuzumab|Arm is closed.
79694149|NCT01184872|Drug|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
79694150|NCT04666779|Other|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
79694151|NCT02887924|Device|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
79694152|NCT01215721|Drug|Vesicare|5 mg daily
79243352|NCT03144986|Device|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
79243353|NCT02329028|Device|Prehospital mini-EEG|Observational
79694153|NCT02886910|Other|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
80009850|NCT04703985|Dietary Supplement|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
80009851|NCT03703089|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
80009852|NCT03703089|Drug|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
79243354|NCT02332538|Procedure|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
79243355|NCT02332538|Procedure|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
79243356|NCT02332538|Procedure|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
79243357|NCT00885963|Drug|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
79243358|NCT02332694|Device|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
79243359|NCT00725127|Drug|aspirin|100 mg/day upon awakening for five years
79243360|NCT00725127|Drug|aspirin|100 mg/day at bedtime for five years
79537203|NCT01042379|Drug|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
79537204|NCT01042379|Drug|MK-2206 with or without Trastuzumab|Arm is closed.
79537205|NCT01042379|Drug|AMG 386 and Trastuzumab|Arm is closed.
79537206|NCT01042379|Drug|T-DM1 and Pertuzumab|Arm is closed.
79537207|NCT01042379|Drug|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
79537208|NCT01042379|Drug|Ganetespib|Arm is closed.
79537209|NCT01042379|Drug|ABT-888|Arm is closed.
79537210|NCT01042379|Drug|Neratinib|Arm is closed.
79537211|NCT01042379|Drug|PLX3397|Arm is closed.
79537212|NCT01042379|Drug|Pembrolizumab - 4 cycle|Arm is closed.
79839062|NCT04002154|Device|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
79839063|NCT00777374|Drug|Patch|epicutaneous application of allergen patch
79243361|NCT02326766|Dietary Supplement|KRG|5g Korea red ginseng (KRG)
79243362|NCT02326766|Dietary Supplement|Placebo|5g placebo
79537213|NCT01042379|Drug|Talazoparib plus Irinotecan|Arm is closed.
79537214|NCT01042379|Drug|Patritumab and Trastuzumab|Arm is closed.
79537215|NCT01042379|Drug|Pembrolizumab - 8 cycle|Arm is closed.
79243363|NCT02329262|Behavioral|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
79537216|NCT01042379|Drug|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
79537217|NCT01042379|Drug|Durvalumab plus Olaparib|Arm is closed.
79537218|NCT01042379|Drug|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for >T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
79537219|NCT01042379|Drug|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
79537220|NCT01042379|Drug|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
79243364|NCT02329262|Behavioral|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
79537221|NCT01042379|Drug|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
79243365|NCT00590109|Other|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
79243366|NCT00590109|Other|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
79243367|NCT02328950|Drug|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
79243368|NCT04949685|Procedure|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
79243369|NCT03398577|Drug|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
79243370|NCT03398577|Drug|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
79243371|NCT03389061|Drug|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
79537222|NCT01042379|Drug|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
79537223|NCT01042379|Drug|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
79694154|NCT02886910|Other|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
79694155|NCT02887027|Behavioral|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
79839064|NCT00777374|Drug|Placebo patch|epicutanoeus application of a placebo patch
79839065|NCT05297123|Drug|All-trans retinoic acid|All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
79839066|NCT05297123|Drug|Arsenic Trioxide|ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
79839067|NCT05297123|Drug|Realgar-Indigo naturalis formula|60 mg/kg/d for 8 weeks
79839068|NCT00654420|Drug|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
79839069|NCT00654420|Drug|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
79839070|NCT00773630|Drug|Cilostazol|100 mg Cilostazol
79839071|NCT03683836|Diagnostic Test|No intervention|No intervention
80009853|NCT03703011|Device|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
80009854|NCT03701373|Drug|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
80009855|NCT03701373|Other|Observation|Observation without anti-tumor treatment
80009856|NCT03702933|Dietary Supplement|D-serine|dosage
80009857|NCT02807844|Drug|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
80009858|NCT02807844|Drug|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
80009859|NCT03702855|Drug|Tetrabenazine Tablets 25 mg|
79694156|NCT04113239|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
80009860|NCT04542681|Drug|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
80009861|NCT04542681|Drug|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
80009862|NCT04542681|Drug|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
79243372|NCT03389061|Drug|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
79243373|NCT02038868|Drug|ASP4901|oral
79243374|NCT02038868|Drug|Tamsulosin|oral
79382560|NCT01947946|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
79839072|NCT05356312|Biological|Vaccination|Personalized neoantigen vaccination
79694157|NCT04113239|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
80009863|NCT02052180|Drug|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
80009864|NCT02052180|Drug|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
80009865|NCT03561402|Drug|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
79382565|NCT03820635|Diagnostic Test|Osteopontin (OPN)|the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
79382566|NCT03820401|Device|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
79694158|NCT04666506|Other|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
80009866|NCT02053428|Procedure|percutaneous image-guided gastrostomy|
80016841|NCT02096094|Procedure|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
79243375|NCT02038868|Drug|Placebo|oral
79243376|NCT03398499|Device|VIOFOR (Med & Life)|Device: VIOFOR (Med & Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
79243377|NCT03385083|Behavioral|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
79243378|NCT03385083|Behavioral|Step count monitoring without consultation|Subject counseled on step counts at initial visit
79243379|NCT03385083|Device|Fitbit tracker|Fitbit tracker given to participant
79243380|NCT02326688|Other|Kinematic analysis of trunk compensation|
79305813|NCT04919421|Drug|Dental injection and topical gel application|Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
79382567|NCT03820401|Other|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
79382568|NCT03820401|Other|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
79382569|NCT03820401|Other|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
79382570|NCT03820245|Dietary Supplement|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
79382571|NCT03820245|Dietary Supplement|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
79694159|NCT04072211|Biological|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
80016842|NCT02096094|Procedure|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
79243381|NCT03388983|Other|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
79243382|NCT03388905|Device|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
79694160|NCT00534677|Drug|Terlipressin|2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
79243383|NCT02328794|Behavioral|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
79839073|NCT05353114|Other|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
79839074|NCT04016922|Other|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\U ratio.~* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
79839075|NCT03646474|Drug|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
79839076|NCT03646474|Drug|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
79839077|NCT00808002|Drug|Raltegravir|Raltegravir 400 mg every 12 hours
79839078|NCT00808002|Drug|Maraviroc|Maraviroc 300 mg every 12 hours
79839079|NCT00808002|Drug|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
79839080|NCT00307489|Drug|tenofovir DF|300 mg tablet, once daily (QD)
79243384|NCT02328794|Behavioral|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
79839081|NCT00307489|Drug|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
79382572|NCT03820245|Dietary Supplement|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
79382573|NCT03820245|Dietary Supplement|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
79382574|NCT01597505|Drug|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
79382575|NCT01597505|Drug|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
79839082|NCT04001764|Procedure|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
79839083|NCT04001764|Procedure|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
79839084|NCT04001764|Procedure|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
79839085|NCT00812292|Drug|TMC278|
79839086|NCT04003168|Drug|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
79839087|NCT00812370|Drug|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
79382576|NCT01597505|Drug|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
79382577|NCT03821571|Diagnostic Test|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
79382578|NCT03821103|Behavioral|Training|The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
79382579|NCT03821103|Behavioral|Behavioral economic enhanced arm|Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
79243385|NCT02328794|Behavioral|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
79243386|NCT02328794|Behavioral|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
79694161|NCT00534677|Drug|Octreotide|Octreotide 50mcg/hr infusion & a placebo of Terlipressin
79694162|NCT00556764|Drug|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
79694163|NCT00556764|Drug|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
79694164|NCT00556803|Procedure|radiofrequency ablation|radiofrequency ablation
79694165|NCT00556803|Procedure|TACE after RFA|TACE after RFA within one month
79694166|NCT00556959|Drug|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
79382580|NCT05735860|Behavioral|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
79839088|NCT05284786|Device|nerve ultrasonography|Ultrasonography of different nerves was performed using a high frequency 18 MHz probe (esaote Ultrasound systems). Each nerve was scanned in axial plane, and the cross-sectional area (CSA) was measured at standardized anatomical points, in brief: median nerve in upper arm, elbow, forearm; ulnar nerve in upper arm and forearm; tibial nerve in popliteal and ankle; peroneal nerve in popliteal fossa, sural nerve in the calf and the vagus nerve.
79839089|NCT00645840|Drug|Anakinra|Patients will receive daily anakinra therapy for 28 days
79839090|NCT00773708|Drug|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
79839091|NCT00307333|Device|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
80016843|NCT02096094|Procedure|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
79382581|NCT05735860|Behavioral|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
79382582|NCT03826485|Drug|PRIC|Pranlukast hydrate 50mg
79537224|NCT01042379|Drug|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
79537225|NCT01042379|Drug|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
79537226|NCT01042379|Drug|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
79243387|NCT02328794|Behavioral|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
79243388|NCT03564080|Other|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
79537227|NCT01042379|Drug|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
79839092|NCT00762359|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
79839093|NCT00762359|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
79839094|NCT04003090|Drug|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
79839095|NCT00777530|Drug|Bosutinib (SKI-606)|
79839096|NCT00814476|Other|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
80016844|NCT02921763|Drug|Dydrogesterone|
80016845|NCT02094768|Dietary Supplement|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
79243389|NCT03388827|Device|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
79382583|NCT03826485|Drug|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
79382584|NCT03029572|Drug|Diet supplementation|Micronutriment supplementation therapy
79382585|NCT03029572|Procedure|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
79243390|NCT03388827|Drug|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
79243391|NCT02328716|Procedure|Cytoreduction|Cytoreduction
79243392|NCT02328716|Drug|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
79243393|NCT03398187|Device|cardiac catheterization|diagnostic and interventional cardiac catheterization
79243394|NCT03144284|Other|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
79243395|NCT00445107|Drug|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
79839097|NCT00814476|Other|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
79839098|NCT04002856|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
79839099|NCT01061749|Biological|Cixutumumab|Given IV
79839100|NCT01061749|Other|Laboratory Biomarker Analysis|Correlative studies
79839101|NCT01061749|Other|Pharmacological Study|Correlative studies
80009867|NCT02166710|Device|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
80009868|NCT02166710|Device|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
79243396|NCT05077592|Drug|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
79243397|NCT03398109|Device|Customized toric IOL for post-DALK atigmatism|
79243398|NCT03144362|Procedure|Bilateral Sliding Techniques|Bilateral Sliding Techniques
79243399|NCT03144362|Procedure|Unilateral Sliding Techniques|Unilateral Sliding Techniques
79243400|NCT00038727|Behavioral|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
79382586|NCT03126747|Drug|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
79382587|NCT03117777|Behavioral|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
79382588|NCT01911910|Behavioral|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
79537228|NCT01042379|Drug|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
79537229|NCT01042379|Drug|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
79839102|NCT01061749|Drug|Selumetinib|Given PO
79839103|NCT02551614|Procedure|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
79537230|NCT01042379|Drug|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
79537231|NCT01042379|Drug|VV1 + Cemiplimab|VV1, 3x10^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
79537232|NCT01042379|Drug|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
79537233|NCT01042379|Drug|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
79537234|NCT01042379|Drug|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
79694167|NCT00556959|Drug|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
79694168|NCT00556959|Drug|placebo|placebo tablets for 8 weeks
79694169|NCT04008641|Other|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
79694170|NCT00557037|Drug|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
79839104|NCT02551614|Procedure|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
80009869|NCT02053506|Dietary Supplement|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
79243401|NCT00038727|Drug|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
79839105|NCT02551614|Procedure|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
79243402|NCT00038727|Behavioral|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
79243403|NCT00038727|Behavioral|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
79694171|NCT01184326|Drug|pazopanib|
79694172|NCT01184326|Drug|everolimus|
79839106|NCT05350306|Device|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
79839107|NCT05350306|Other|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
79839108|NCT03978949|Drug|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
79243404|NCT05077358|Procedure|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
79243405|NCT05077358|Procedure|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
79243406|NCT02864381|Drug|Andecaliximab|800 mg administered via IV infusion
79839109|NCT03978949|Drug|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
79243407|NCT02864381|Drug|Nivolumab|3 mg/kg administered via IV infusion
80009870|NCT02053506|Dietary Supplement|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
79243408|NCT05077202|Device|ultra sound|chest ultrasound
79243409|NCT05230472|Drug|Simvastatin|simvastatin 60 mg tab
79243410|NCT05174325|Drug|Sintilimab + chemotherapy|Biological : Sintilimab 100mg: 10ml Method of administration: 200mg IV D1 Q3W. Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W. Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.
79243411|NCT03111368|Procedure|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
79382589|NCT03820791|Device|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
79382590|NCT03823989|Drug|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
79382591|NCT03823989|Radiation|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
79382592|NCT03826719|Biological|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
79694173|NCT04666350|Other|to assess the consistency and reproducibility of two consecutive direct skin feeding assays (DSFA) at 24-hour interval.|"The results from this experimental medicine study will inform whether the preferred Before-After trial design in which each human volunteer serves as their own internal control can be utilized for a follow-on Phase 2b trial."
79382593|NCT03826719|Biological|Agrippal|Influenza virus surface antigens of three strains(trivalent)
79382594|NCT03823677|Procedure|Hypoxia|hypoxia
79382595|NCT01951066|Drug|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
79537235|NCT01042379|Drug|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
79537236|NCT01042379|Drug|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
79537237|NCT01042379|Drug|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
79537238|NCT01042379|Drug|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
79694174|NCT01215253|Drug|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
79694175|NCT03898115|Behavioral|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
79694176|NCT04666233|Procedure|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
80016846|NCT02094768|Dietary Supplement|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
79243412|NCT03398031|Drug|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
79243413|NCT03398031|Drug|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
79243414|NCT03111680|Other|environmental intervention|a multi component environmental intervention
79243415|NCT02039960|Drug|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
79243416|NCT05383313|Drug|Psilocybin|Effect of psilocybin on treatment-resistant depression
79243417|NCT05383313|Drug|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
79243418|NCT05383313|Drug|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
79243419|NCT02033681|Procedure|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
79243420|NCT02033681|Procedure|Saline Solution|Saline solution is injected into the tissue as a placebo control.
79243421|NCT02328248|Procedure|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
79243422|NCT03610217|Other|Interstitial lung disease induction algorithm|Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
79243423|NCT03610217|Other|Pulmonary arterial hypertension algorithm|Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
79243424|NCT03610217|Other|Raynaud's phenomenon algorithm|"Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option."
79537239|NCT01033188|Procedure|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
79537240|NCT01033188|Procedure|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith & Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
79243425|NCT03610217|Other|Digital ulcer algorithm|"Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option."
80009871|NCT02053506|Dietary Supplement|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
80009872|NCT02763254|Biological|baltaleucel-T|Autologous EBV-specific T cells
80009873|NCT02053662|Procedure|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
79537241|NCT00544115|Drug|busulfan|
79537242|NCT00544115|Drug|cyclophosphamide|
79382596|NCT01951066|Drug|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
79537243|NCT00544115|Drug|cyclosporine|
79243426|NCT03610217|Other|Inflammatory arthritis algorithm|Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
79537244|NCT00544115|Drug|etoposide|
79537245|NCT00544115|Drug|fludarabine phosphate|
79243427|NCT03610217|Other|Gastroesophageal reflux algorithm|Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
79382597|NCT05735626|Combination Product|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
79382598|NCT05735626|Combination Product|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
79382599|NCT05735626|Combination Product|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
79382600|NCT03826329|Other|observational study|this is an observational study, there is no intervention in this study
79382601|NCT03826017|Dietary Supplement|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
79382602|NCT03826017|Dietary Supplement|Placebo|Placebo for 12 weeks.
79382603|NCT01913314|Drug|[^14C]-LY2835219|Administered as oral solution
79537246|NCT00544115|Drug|melphalan|
79537247|NCT00544115|Drug|methotrexate|
79537248|NCT00544115|Drug|mycophenolate mofetil|
79537249|NCT00544115|Drug|sirolimus|
79537250|NCT00544115|Drug|tacrolimus|
79694177|NCT04666233|Procedure|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
79694178|NCT01184053|Drug|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
80009874|NCT04694781|Drug|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
79537251|NCT00544115|Procedure|allogeneic hematopoietic stem cell transplantation|
79537252|NCT00544115|Procedure|peripheral blood stem cell transplantation|
79537253|NCT00544115|Radiation|total-body irradiation|
79537254|NCT00150488|Device|Uracyst|2% weekly for 6 weeks, monthly for 4 months
79537255|NCT01455285|Device|transcutaneous electrical nerve stimulation|
79537256|NCT01455350|Procedure|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
79537257|NCT01455350|Drug|lidocaine|10 weeks of daily topical 5% lidocaine application
79694179|NCT04206241|Diagnostic Test|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
79694180|NCT03895814|Behavioral|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
79694181|NCT04666194|Procedure|Cold forceps|
79694182|NCT04666194|Procedure|Cold snare|
79694183|NCT04666194|Procedure|Hot snare|
79694184|NCT03870698|Procedure|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
80009875|NCT04694781|Drug|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
79243428|NCT03610217|Other|Bacterial overgrowth algorithm|Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
79243429|NCT03610217|Other|Constipation algorithm|Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
79243430|NCT03610217|Other|Skin involvement algorithm|"Patients with skin involvement and modified Rodnan skin score <32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score >32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option."
79537258|NCT01455636|Other|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
79243431|NCT03610217|Other|Pain algorithm|Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score <32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
79537259|NCT01455636|Dietary Supplement|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
79537260|NCT01455636|Other|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
79537261|NCT01455636|Dietary Supplement|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
79537262|NCT01456026|Dietary Supplement|Glycated beta-lactoglobulins.|oral, 20 g, single administration
79839110|NCT05356234|Behavioral|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
79839111|NCT00769964|Drug|VA111913 TS / placebo|
79537263|NCT01456026|Dietary Supplement|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
79839112|NCT03327922|Device|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
80009876|NCT02166866|Other|Quality of Life Questionairre and Education|
80009877|NCT03624855|Other|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
80009878|NCT02805972|Drug|Naloxone|4 mg / 0.1 ml
80009879|NCT02805972|Drug|Placebo|0.1 ml
79243432|NCT02328482|Drug|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
79243433|NCT02328092|Device|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
79243434|NCT02328170|Other|EUROIMMUN Allergy|Immunoblot assay
79243435|NCT02328170|Other|ImmunoCap|Fluoroallergosorbent test
79243436|NCT02860169|Behavioral|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
79243437|NCT05069402|Dietary Supplement|Immunonutrition|diet with immunonutrients
79243438|NCT05069402|Dietary Supplement|High-protein|Oral nutrition with high-protein content
79243439|NCT05069402|Dietary Supplement|Standard ONS|Oral nutrition with standard ingredients
79243440|NCT03609983|Other|Daily weighing with daily feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
79305814|NCT04919421|Device|Dental injection and virtual reality device|Dental injection will be made while the participants are wearing virtual reality device.
79305815|NCT04924959|Other|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
79243441|NCT03609983|Other|Weekly weighing with weekly feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
79694185|NCT04666077|Behavioral|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
79694186|NCT04666077|Behavioral|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
79694187|NCT04666077|Other|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
79243442|NCT05069090|Behavioral|Lockdown and other social distancing measures|During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
79694188|NCT04666116|Dietary Supplement|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
79537264|NCT01456078|Drug|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
79243443|NCT03144050|Device|SFDI Imaging|Imaging with SFDI device
79243444|NCT02328638|Behavioral|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
79243445|NCT02328638|Behavioral|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
79537265|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
79243446|NCT03145220|Drug|EA-230|Active intervention
79243447|NCT03145220|Other|Placebo (NaCl)|Placebo intervention
79537266|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
79839113|NCT01066117|Other|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
79839114|NCT00770042|Drug|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
79243448|NCT03144128|Dietary Supplement|Vitamin D|5,000IU vitamin D given daily for 12 weeks
79243449|NCT03144128|Dietary Supplement|Placebo|Placebo capsules given daily for 12 weeks
79243450|NCT02326532|Other|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
79243451|NCT02326532|Other|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
79537267|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
79537268|NCT01456520|Drug|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
79537269|NCT01456520|Drug|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
79839115|NCT00770042|Drug|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
79839116|NCT00770042|Drug|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
79243452|NCT02326610|Drug|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
79243453|NCT00409773|Drug|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
79243454|NCT00409773|Drug|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
79839117|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 8
79839118|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 6
79839119|NCT00770042|Drug|Avanafil|Avanafil 200mg Days 1 and 6
80009880|NCT03702699|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
79694189|NCT03813875|Drug|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
80009881|NCT03032523|Diagnostic Test|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
79243455|NCT00409773|Drug|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
79382604|NCT04768192|Procedure|Physical Rehabilitation without lokomat|"Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~strengthening exercises had to involve all the lower limb joints (no segmental intervention)~during each session, at least 4 out of the 7 categories above had to be delivered~the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings."
80009882|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
79537270|NCT01456559|Other|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
80009883|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
80009884|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
79243456|NCT02326376|Drug|anakinra (Kineret)|
79243457|NCT02034422|Dietary Supplement|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
79537271|NCT01456572|Dietary Supplement|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
79537272|NCT01456572|Dietary Supplement|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
79537273|NCT01456585|Other|Gemcitabine|
79537274|NCT01456585|Drug|CP-870,893|
79537275|NCT01456650|Drug|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
79839121|NCT03982615|Device|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
79839122|NCT03982615|Device|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
79839123|NCT00777686|Procedure|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
79839124|NCT00654186|Drug|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
79243458|NCT02034422|Other|Exercise rehabilitation|8 weeks of exercise rehabilitation
79243459|NCT02861807|Device|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
79243460|NCT02325986|Drug|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
79537276|NCT01456806|Other|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
79537277|NCT01457040|Drug|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
80009885|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
79243461|NCT02325986|Drug|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
79694190|NCT03813875|Other|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
79839125|NCT03275818|Drug|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
79243462|NCT02325986|Radiation|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
79243463|NCT02327780|Other|FODMAP diet|
80009886|NCT03701217|Drug|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
79382605|NCT04768192|Procedure|Physical Rehabilitation with Lokomat|"The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games."
79382606|NCT03826251|Procedure|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
79839126|NCT03979105|Drug|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
80009887|NCT02052258|Drug|Oxytocin|
80009888|NCT03701139|Procedure|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
79382607|NCT01951768|Drug|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
80009889|NCT03701139|Procedure|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
80009890|NCT02053740|Drug|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
80009891|NCT02053740|Drug|Routine western medicine|
79243464|NCT00398151|Drug|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
79243465|NCT03610139|Dietary Supplement|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
79243466|NCT02327624|Drug|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
79537278|NCT01457040|Drug|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10~-6d; AraC: 1g/m2/d, -10d~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
79537279|NCT01457209|Other|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
79537280|NCT01457248|Device|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
79537281|NCT01457248|Device|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
79839127|NCT00773942|Behavioral|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
79243467|NCT02327624|Drug|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
79243468|NCT02327624|Drug|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
80009892|NCT03702543|Behavioral|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
79243469|NCT03388671|Procedure|TAB Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
79243470|NCT03388671|Procedure|Psoas Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
79537282|NCT01457508|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
79537283|NCT01457508|Biological|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
79839128|NCT00773942|Behavioral|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
79839129|NCT01061905|Behavioral|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
79537284|NCT01457508|Biological|Hib (Hiberix™)|Three doses administered intramuscularly
79537285|NCT01457586|Biological|Blood transfusion|Blood transfusion in perioperative period.
79839130|NCT01061905|Behavioral|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
80009893|NCT02053818|Drug|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
79694191|NCT03813875|Drug|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
79382608|NCT01951768|Drug|Systemic Antibiotic|"Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
79382609|NCT04758585|Procedure|Arthroscopy|Shoulder Arthroscopy
79694192|NCT03813875|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
79839131|NCT01061905|Behavioral|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
80009894|NCT02053818|Drug|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
80009895|NCT03702387|Procedure|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
80009896|NCT03031899|Procedure|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
79382610|NCT02987140|Behavioral|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
80009897|NCT03031899|Diagnostic Test|Rose Bengal|the lesions stained positive were subjected to biopsy
80009898|NCT03031899|Diagnostic Test|toluidine blue|the lesions stained positive were subjected to biopsy
80009899|NCT03700983|Dietary Supplement|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
80009900|NCT03700905|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
79243471|NCT03388671|Drug|Bupivacaine|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
79243472|NCT03609671|Behavioral|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
79243473|NCT03609671|Other|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
79243474|NCT02327936|Drug|Fesoterodine|Administer medication to patients with overactive bladder
79243475|NCT02327936|Drug|Oxybutynin XL|Administer medication to patients with overactive bladder
79243476|NCT03384849|Diagnostic Test|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
79382611|NCT04273659|Dietary Supplement|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
79537286|NCT01457586|Biological|No blood transfusion|No transfusion in the perioperative period.
79537287|NCT01457794|Other|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
79537288|NCT01458093|Other|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
79537289|NCT01458145|Behavioral|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
79694193|NCT03813875|Drug|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
79537290|NCT01458184|Behavioral|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
80009901|NCT03700905|Radiation|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
80009902|NCT03700905|Drug|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
79839132|NCT00814554|Behavioral|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
79839133|NCT00814554|Behavioral|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
79839134|NCT00814554|Other|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
79537291|NCT01458314|Other|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
80009903|NCT03700905|Drug|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
79382612|NCT05735470|Device|antibacterial bone traction needles|Whether to use bone traction needles containing antibacterial coatings
79839135|NCT00761969|Other|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
79839136|NCT00774020|Drug|Zoledronic acid|5mg, i.v. single dose
79839137|NCT04100447|Drug|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
79839138|NCT03274804|Biological|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
79839139|NCT03274804|Drug|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
79839140|NCT05493449|Combination Product|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
79839141|NCT05493449|Combination Product|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
80009904|NCT03700905|Drug|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
80009905|NCT03702153|Procedure|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
80009906|NCT03700827|Other|Resistance Training|High-intensity Resistance Training Group
80009907|NCT03700827|Other|Aerobic Training|Aerobic Interval Training Group
80009908|NCT03700749|Drug|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
79243477|NCT02327858|Other|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
79243478|NCT03609905|Biological|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10~7 diluted on 100 mL of normal saline
79243479|NCT03609905|Other|Conventional drugs|5-amino-salicylic acid or glucocorticoid
79243480|NCT02326142|Drug|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
79382613|NCT03825861|Drug|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
79382614|NCT01760447|Drug|Sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
79537292|NCT01458314|Other|Rehabilitation without NIV|Training in patients without NIV adoption
79537293|NCT01458353|Procedure|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
79537294|NCT01458353|Procedure|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
79839142|NCT00774098|Drug|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
79839143|NCT00774098|Drug|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
79839144|NCT00774098|Dietary Supplement|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
79839145|NCT00774098|Drug|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
79839146|NCT00761891|Other|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
79537295|NCT01458431|Drug|Levobupivacaine|continuous levobupivacaine subfascial infusion
79243481|NCT02326142|Drug|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
79839147|NCT00777842|Device|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
79382615|NCT01760447|Drug|Placebo to metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
79537296|NCT01458431|Drug|NaCl|continuous NaCl subfascial infusion
79537297|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
79537298|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
79537299|NCT01458782|Procedure|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
79537300|NCT01458808|Other|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
79839148|NCT04002076|Behavioral|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
79839149|NCT04002076|Behavioral|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
79839150|NCT00774332|Drug|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
79839151|NCT00321685|Biological|Bevacizumab|Given IV
79382616|NCT01760447|Drug|Metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
79537301|NCT01458808|Other|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
79537302|NCT01459328|Radiation|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~Injected Leucovorin 20 mg/m2/day for 5 days"
79537303|NCT01459328|Radiation|Radiotherapy|"Conventional long course chemo-radiation:~Radiation 50Gy in 25 daily fractions over 5 weeks~Bolus 5 Fluorouracil 350mg/m2/d for 5 days~Injected Leucovorin 20mg in both the first and last (5th) week of radiation~Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
79537304|NCT01459393|Drug|5-ALA Photodynamic Therapy|
79537305|NCT01459393|Drug|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
79537306|NCT01459445|Drug|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
79839152|NCT00321685|Drug|Capecitabine|Given PO
79839153|NCT00321685|Drug|Fluorouracil|Given IV
80009909|NCT03700749|Drug|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
79243482|NCT04486001|Biological|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
79382617|NCT01760447|Drug|Placebo to sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
79382618|NCT01760447|Drug|Sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
79382619|NCT01760447|Drug|Placebo to metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
79694194|NCT03813875|Drug|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
79694195|NCT01183858|Drug|Erlotinib [Tarceva]|Single daily oral dose
79694196|NCT04665882|Procedure|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
79243483|NCT03142490|Other|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
79243484|NCT03142490|Other|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
79305816|NCT04924725|Procedure|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
80009910|NCT03700749|Drug|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
80009911|NCT03700749|Drug|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
79243485|NCT03609515|Other|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
79694197|NCT04686344|Drug|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
79694198|NCT04686344|Drug|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
79839154|NCT00321685|Drug|Leucovorin Calcium|Given IV
79839155|NCT00321685|Drug|Oxaliplatin|Given IV
79839156|NCT00321685|Radiation|Radiation Therapy|Undergo radiotherapy
80009912|NCT03086369|Drug|Olaratumab|Administered IV
80009913|NCT03086369|Drug|Nab-paclitaxel|Administered IV
79694199|NCT05450536|Other|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
79694200|NCT05349136|Other|Synchronous telerehabilitation group|This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
79839157|NCT00321685|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79694201|NCT05349136|Other|Asynchronous telerehabilitation group|This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
79839158|NCT00778076|Device|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
79839159|NCT00778076|Device|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
79694202|NCT04316416|Procedure|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge & 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
79839160|NCT05196412|Device|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
79839161|NCT00779090|Procedure|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
79839162|NCT04002778|Diagnostic Test|Fine needle aspiration|
79839163|NCT04002778|Diagnostic Test|Rapid on-site evaluation|
79839164|NCT02557022|Other|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
79839165|NCT01564342|Procedure|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
79839166|NCT00779480|Drug|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
80009914|NCT03086369|Drug|Gemcitabine|Administered IV
80009915|NCT03086369|Drug|Placebo|Administered IV
80009916|NCT03700593|Device|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
80009917|NCT00101582|Drug|Placebo|
80009918|NCT00101582|Drug|palifermin|
80009919|NCT00101582|Drug|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m^2 on Days 1, 22, and 43.
80009920|NCT00101582|Radiation|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
79243486|NCT03384771|Behavioral|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
79243487|NCT03144908|Other|Standard Operating Procedures|Observational on Standard Operating Procedures
79839167|NCT03902392|Dietary Supplement|NaturOx Group (A)|Comparison between dietary supplement and placebo
80009921|NCT05326373|Drug|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
80009922|NCT03370107|Device|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
79839168|NCT03902392|Other|Placebo Group (B)|Comparison between dietary supplement and placebo
79839169|NCT00306787|Drug|Famciclovir|Famciclovir 500 mg tablet
79839170|NCT00306787|Drug|Valacyclovir|Valacyclovir 500 mg capsule
79839171|NCT00306787|Drug|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
79839172|NCT00306787|Drug|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
79839173|NCT00778232|Drug|Gabapentin tablets 800 mg|
79839174|NCT01564264|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
80016847|NCT03658473|Drug|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
79537307|NCT01459458|Behavioral|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
79839175|NCT00774488|Other|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
79839176|NCT01066195|Drug|iressa|iressa 250mg per day every day
79839177|NCT01066195|Drug|alimta|alimta 500mg/m2 every 3 weeks
79243488|NCT03388515|Biological|SSS11|IV infusion for 60 min.
79537308|NCT01459523|Procedure|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
79537309|NCT01459523|Procedure|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
79694203|NCT04316416|Procedure|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge & 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
79694204|NCT04316416|Drug|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
79839178|NCT03147742|Drug|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
79243489|NCT03388515|Other|placebo|IV infusion for 60 min.
79243490|NCT03609827|Drug|Melphalan|
79243491|NCT05076968|Procedure|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
79243492|NCT03125733|Procedure|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
79305817|NCT04911933|Behavioral|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
79382620|NCT01760447|Drug|Insulin|"Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine."
79382621|NCT01760447|Drug|Placebo to sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
79537310|NCT01459523|Procedure|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
79839179|NCT00774644|Drug|Clarithromycin 500mg|
79839180|NCT03979027|Dietary Supplement|Breakfast: ready-to-eat-cereal and milk|
79839181|NCT00778388|Biological|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
79839182|NCT00778388|Drug|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
79839183|NCT05123092|Other|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
79839184|NCT05123092|Other|Intrathecal Morphine injection|Injecting intrathecal morphine
79839185|NCT05356156|Procedure|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
79839186|NCT05356156|Procedure|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
79694205|NCT05449522|Other|Vitamin D|High dose of vitamin D is given in divided dose orally or enterally via a feeding tube
79537311|NCT01459523|Procedure|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
79694206|NCT05449522|Other|Placebo|Placebo
79382622|NCT01760447|Drug|Metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
79694207|NCT04665804|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
79694208|NCT04665804|Dietary Supplement|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
79694209|NCT04665804|Other|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
79839187|NCT04001530|Drug|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
79839188|NCT04001530|Drug|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
79537312|NCT01459744|Behavioral|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
79694210|NCT04665804|Other|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
79694211|NCT04665804|Procedure|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
79839189|NCT05344846|Other|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
79839190|NCT05282056|Diagnostic Test|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
79243493|NCT03609749|Behavioral|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
79382623|NCT01952470|Drug|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
79839191|NCT05278936|Other|The cataract surgery and the anterior vitrectomy|Surgical
79839192|NCT00991900|Device|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
79839193|NCT00769067|Drug|Erlotinib|Continuous oral dosing at 150 mg daily.
79839194|NCT00769067|Drug|PF-00299804|Continuous oral dosing at 45mg daily
79243494|NCT02858401|Drug|Vesatolimod|Tablet(s) administered orally once every 2 weeks
79243495|NCT02858401|Drug|Placebo|Tablet(s) administered orally once every 2 weeks
79243496|NCT02858401|Drug|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
79694212|NCT04665804|Procedure|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
79694213|NCT05434468|Other|Sustained neutral apophyseal glides|gong mobilization
79694214|NCT04316455|Other|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
79694215|NCT05431192|Behavioral|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
79839195|NCT00321373|Biological|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
79839196|NCT00321373|Biological|FluarixTM|Single dose, Intramuscular injection
79839197|NCT02826928|Biological|blood sample withdrawn|
79839198|NCT04001608|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
79839199|NCT04001608|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
79839200|NCT00667394|Biological|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
79839201|NCT00667394|Drug|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
79839202|NCT00667394|Procedure|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
79839203|NCT04103021|Device|Port-A-Cath|Totally implanted central venous access device
79839204|NCT05357326|Drug|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
79839205|NCT05357326|Device|Orthokeratology|wear orthokeratology at night while sleeping
80009923|NCT01379105|Other|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
79839206|NCT05357326|Drug|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
80009924|NCT01379105|Other|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
80009925|NCT02166944|Drug|tamoxifen 40 mg daily for one year|both arms with riluzole daily
79243497|NCT05024396|Diagnostic Test|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
79694216|NCT05431192|Other|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
79839207|NCT00778466|Drug|metformin hydrochloride 1000 mg tablets|
80009926|NCT03238677|Behavioral|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
79243498|NCT02236949|Behavioral|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
79243499|NCT03126825|Device|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
79382624|NCT01952470|Drug|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
79839208|NCT00761735|Biological|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
79839209|NCT00761735|Drug|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
79243500|NCT03126825|Device|CP910/CP920|The approved CP910 or CP920 Sound Processor.
79243501|NCT03144596|Drug|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
79839210|NCT00569946|Drug|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
79839211|NCT00778544|Drug|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
79839212|NCT04001374|Drug|Ticagrelor|90mg tablet bid for 12 months
79243502|NCT03144596|Drug|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
79243503|NCT02033915|Other|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
79243504|NCT00127647|Drug|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
79243505|NCT00127647|Drug|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
79243506|NCT03388437|Device|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
79382625|NCT03820011|Other|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
79382626|NCT01915108|Drug|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
79382627|NCT03825471|Procedure|electrotherapy|Cranial electrotherapy stimulation
79382628|NCT03825471|Drug|Opioid Anesthetics|consumption of opioids during general anesthesia
79382629|NCT03825471|Procedure|colon cancer surgery|laparoscopic colon cancer surgery
79537313|NCT01459744|Other|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
79694217|NCT00534755|Other|Breast Cancer database|prospective breast cancer database
79694218|NCT00534872|Drug|SB-649868|10 mg
79243507|NCT03388437|Device|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
79694219|NCT04665414|Diagnostic Test|MRI|preoperative MRI
79694220|NCT04665414|Diagnostic Test|transvaginal ultrasound|preoperative transvaginal ultrasound
79839213|NCT04001374|Drug|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
79839214|NCT02602067|Combination Product|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
79839215|NCT02556320|Drug|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
79382630|NCT05735392|Other|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
79382631|NCT03825705|Drug|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79382632|NCT03825705|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
79537314|NCT01459757|Other|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
79694221|NCT04665414|Diagnostic Test|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
79694222|NCT00534911|Behavioral|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
79839216|NCT02556320|Biological|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
79243508|NCT03111602|Other|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
79243509|NCT03388359|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
79694223|NCT00534911|Behavioral|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
79243510|NCT03388359|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
79305818|NCT04912011|Drug|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
79839217|NCT05330494|Other|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
79839218|NCT03869658|Behavioral|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
79839219|NCT05265910|Drug|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
79839220|NCT05265910|Drug|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
79839221|NCT05265910|Drug|Tears Naturale|Tears Naturale® II (eyedrop)
79382633|NCT03096639|Device|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
79382634|NCT01917136|Drug|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
79382635|NCT01917136|Drug|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
79382636|NCT01917136|Other|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
79537315|NCT01459874|Behavioral|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
79537316|NCT01459965|Procedure|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
79537317|NCT01459965|Procedure|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
79537318|NCT01460004|Device|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
79537319|NCT01460017|Procedure|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
79537320|NCT01460017|Procedure|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
79537321|NCT01460030|Drug|Cinacalcet HCl|Oral administration
79382637|NCT03825549|Behavioral|Individual audit feedback|Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
79839222|NCT05265910|Drug|Placebo|Placebo tablet (tablet)
79839223|NCT02601521|Behavioral|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
79839224|NCT02601521|Behavioral|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
79839225|NCT00814866|Drug|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
79839226|NCT00991978|Other|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
79839227|NCT00645528|Other|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
79243511|NCT03388359|Other|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
79243512|NCT03388359|Other|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
79382638|NCT03825549|Behavioral|Peer comparison feedback|"Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber."
79382639|NCT01450215|Drug|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
79537322|NCT01460043|Drug|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
79537323|NCT01460043|Drug|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
79694224|NCT04665609|Drug|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
79694225|NCT04665609|Drug|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
79694226|NCT03737981|Drug|Ibrutinib|Given PO
79839228|NCT04001140|Behavioral|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
79839229|NCT00812448|Dietary Supplement|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
79839230|NCT05326672|Drug|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
79243513|NCT03388359|Biological|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
79243514|NCT03388359|Device|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
79243515|NCT03388359|Biological|Eosinophils|Eosinophils are isolated from peripheral blood
79305819|NCT04912011|Drug|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
79537324|NCT01460069|Drug|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
79537325|NCT01460069|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
79537326|NCT01460095|Other|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
79694227|NCT03737981|Biological|Obinutuzumab|Given IV
79694228|NCT03737981|Other|Observation|Undergo observation
79694229|NCT03737981|Drug|Venetoclax|Given PO
79694230|NCT04665492|Diagnostic Test|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
79537327|NCT01460108|Device|AeriSeal System|20 mL
79839231|NCT05326672|Drug|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
79839232|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
79839233|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
79839234|NCT00295633|Drug|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
79243516|NCT03388359|Biological|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
79243517|NCT03388359|Biological|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
79839235|NCT00295633|Drug|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
79382640|NCT01450293|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|1x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
79243518|NCT03111446|Procedure|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
79243519|NCT03111446|Procedure|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
79839236|NCT00295633|Drug|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
79382641|NCT01450293|Biological|AdCH63 ME-TRAP, MVA ME-TRAP|5x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
79537328|NCT01460121|Device|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
79537329|NCT01460121|Device|Placebo|
79537330|NCT01460134|Drug|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
79839237|NCT00295633|Drug|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
79305820|NCT04918719|Drug|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
79382642|NCT01953874|Device|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
79839238|NCT00812526|Procedure|Suction cup application|
79382643|NCT01953874|Drug|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
79382644|NCT01450371|Device|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
79382645|NCT01450371|Device|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
79537331|NCT01460134|Drug|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
79694231|NCT04665492|Diagnostic Test|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
79694232|NCT04665492|Diagnostic Test|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
79694233|NCT04665492|Diagnostic Test|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
79694234|NCT04665492|Diagnostic Test|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
79694235|NCT04665492|Diagnostic Test|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
79694236|NCT04665492|Diagnostic Test|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
79694237|NCT04665492|Diagnostic Test|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
79839239|NCT00812526|Procedure|Squatting|
79839240|NCT02368444|Behavioral|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
79839241|NCT05068596|Other|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
79537332|NCT01460134|Drug|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
79537333|NCT01460147|Other|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
79694238|NCT04665492|Diagnostic Test|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
79382646|NCT04391829|Diagnostic Test|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
79537334|NCT01460173|Other|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
79694239|NCT04665219|Behavioral|HBM-based text messages|"The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant."
79839242|NCT05068596|Other|CONTROL|Designed physical therapy program
79839243|NCT00570674|Drug|Abraxane|
79839244|NCT00570674|Drug|Erbitux|
79243520|NCT04540523|Behavioral|Exergaming intervention group|In addition to usual daily activity, the parent and child from each family will receive 3 game consoles (Wii, Kinect, and LeapTV) and various exergames (e.g., Nickelodeon Fit, Dance and Sports, Just Dance) with all necessary peripherals to play the games. Specifically, they will receive one game console and related exergames every 2 months to experience the variety of exergames and maintain interest in the games over time. Each parent will receive a booklet (established in our pilots studies) provides a standardized gameplay curriculum to play during each session, and attend training workshops at baseline and 3rd month in the PI's lab. The parent will be instructed to have the child perform exergaming at home for 30 minutes/session, 5 times per week, for 6 months. The games will be age appropriate for children 4-5-years-old. The games have been easy for children to learn and use in our pilot studies.
79243521|NCT04540523|Behavioral|Traditional physical activity comparison|Home-based behavioral (e.g., nutrition/PA) interventions for young children usually only target parent for multiple reasons. In this study, group workshop sessions will offered to parents at baseline, 3rd month and 6th month, including information concerning how to promote PA and reduce sedentary behaviors. Identical curricular contents (e.g., dance/sports) for home PA will be offered to parents at baseline and 3rd month in the PI's lab. Parents will also learn about PA and sedentary behavior and their impact on health and cognition. Meanwhile, the intervention staff will encourage parents to increase their lifestyle activity such as taking stairs instead of the elevator and housecleaning. Parents will also learn to shape their child and their PA and sedentary behaviors to attain the following goals: 2 hour or less screen time and at least 180 min. PA per day for children; and at least 150 min. moderate PA for parents per week.
79243522|NCT02327546|Drug|AKB-6548|
79243523|NCT02327546|Drug|Ferrous Sulfate|
79382647|NCT01954264|Procedure|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
79382648|NCT01954264|Other|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
79382649|NCT03825159|Device|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
79382650|NCT03825159|Device|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
79382651|NCT01917214|Other|Sutent: Observational Study|Sutent oral therapy
79537335|NCT01460186|Other|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
79537336|NCT01460199|Drug|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
79537337|NCT01460199|Drug|placebo|tablets
79537338|NCT01460212|Drug|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
79537339|NCT01460212|Behavioral|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
79694240|NCT04665219|Behavioral|Standard text message|Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
79694241|NCT04665102|Other|Image classification using deep learning algorithm|Image classification using deep learning algorithm
79694242|NCT04665141|Biological|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
79694243|NCT04665141|Biological|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
79839245|NCT00570674|Drug|Carboplatin|
79839246|NCT00570674|Radiation|Intensity Modulated Radiation Therapy|
80016848|NCT03658473|Drug|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
79243524|NCT03388281|Other|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
79243525|NCT03144830|Device|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
80009927|NCT03238677|Behavioral|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
79243526|NCT02034071|Drug|DCCR|
79243527|NCT02034071|Drug|Placebo|
79537340|NCT01460251|Drug|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
80009928|NCT03238677|Behavioral|Distributed Practice|2 sessions per week for 10 weeks
79243528|NCT04925336|Other|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
79243529|NCT03609359|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
79243530|NCT03609359|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
79243531|NCT03380793|Drug|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
79243532|NCT03384615|Behavioral|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee & James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
79243533|NCT04894448|Biological|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
79382652|NCT03825237|Diagnostic Test|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
79382653|NCT01450605|Drug|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
79382654|NCT01955434|Drug|Cyclophosphamide|Given PO
79382655|NCT01955434|Other|Laboratory Biomarker Analysis|Correlative studies
79537341|NCT01460277|Procedure|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
79694244|NCT04665141|Biological|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
79694245|NCT04665141|Biological|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
80009929|NCT03238677|Behavioral|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
80009930|NCT03540836|Drug|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
79243534|NCT03388203|Diagnostic Test|25(OH)D measurement, PTH measurement|25(OH)D analyses by LC-MS/MS were performed as part of our routine clinical work with a commercial kit from Recipe (Munich, Germany) ; PTH was measured in lithium-heparin plasma using the PTH STAT assay from Roche Diagnostics (Mannheim, Germany) on a Cobas 8000 auto-analyzer.
79243535|NCT05075642|Other|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
79694246|NCT04665141|Biological|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
79694247|NCT04665063|Biological|Auto CAR-T|Biological: Auto CAR-T
79694248|NCT04665063|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
79694249|NCT04665063|Procedure|Leukapheresis|Leukapheresis
79694250|NCT00534950|Radiation|5 vs 6 weekly fraction of RT|Chemotherapy
79694251|NCT04664868|Procedure|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
79694252|NCT04664712|Dietary Supplement|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) [17, 18], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
79243536|NCT02121275|Device|Ultrasound of the lungs|Ultrasound examination of the lungs
79382656|NCT01955434|Other|Pharmacological Study|Correlative studies
80009931|NCT03540836|Drug|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
79243537|NCT02121275|Device|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
79243538|NCT03380715|Device|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
79243539|NCT03380715|Device|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
79243540|NCT04833764|Drug|Rosuvastatin|Oral administration of 20 mg rosuvastatin for at least 3 months
79694253|NCT04664712|Device|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
79243541|NCT03388125|Drug|Injection Sclerotherapy|5% ethanolamine oleate group
79243542|NCT03388125|Drug|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
79243543|NCT03609281|Radiation|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
79243544|NCT04822376|Drug|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
79243545|NCT04822376|Biological|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
79243546|NCT03388047|Device|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
79243547|NCT04314011|Biological|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
79382657|NCT01955434|Other|Quality-of-Life Assessment|Ancillary studies
79537342|NCT01460277|Procedure|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
79537343|NCT01460316|Biological|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
79694254|NCT04664439|Diagnostic Test|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
79694255|NCT04664595|Drug|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
80009932|NCT03540836|Drug|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
80009933|NCT05274737|Device|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
79382658|NCT01955434|Drug|Smac Mimetic LCL161|Given PO
79382659|NCT04758429|Device|Machine-learning Algorithm|System technology/Software
79382660|NCT01450839|Drug|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
79382661|NCT01450839|Drug|Placebo|Matching Placebo tablets and tape
79382662|NCT01917682|Procedure|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
79382663|NCT01732913|Drug|Placebo|Tablets administered orally twice daily
79537344|NCT01460329|Device|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
79537345|NCT01460355|Drug|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
79537346|NCT01460355|Drug|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
79537347|NCT01460420|Drug|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
79839247|NCT00808314|Drug|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
79839248|NCT00808314|Drug|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
79839249|NCT00812682|Drug|Symbicort|
79839250|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
79382664|NCT01732913|Drug|Rituximab|375 mg/m^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
79382665|NCT01732913|Drug|Idelalisib|150 mg tablets administered orally twice daily
79243548|NCT04314011|Biological|Placebo|Placebo
79839251|NCT00768989|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
79839252|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
79243549|NCT05173545|Drug|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
79243550|NCT04263467|Other|Exercise intervention|The exercise intervention will consist a intermediate to high aerobic exercise training program.
79243551|NCT04263467|Other|Standard oncological treatments|Standard oncological treatments
79243552|NCT05173467|Procedure|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
79839253|NCT00768989|Drug|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
79839254|NCT00768989|Drug|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
79243553|NCT05173467|Procedure|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
79243554|NCT03769701|Procedure|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
79243555|NCT05383183|Drug|Choline Alfoscerate 400mg|Oral administration
79243556|NCT05383183|Drug|Placebo|Oral administration
79243557|NCT05173311|Behavioral|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
79382666|NCT03824925|Drug|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
79382667|NCT03824925|Drug|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
79382668|NCT03825081|Drug|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
79537348|NCT01460420|Drug|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
79537349|NCT01460433|Procedure|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
79537350|NCT01460459|Behavioral|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
79537351|NCT01460472|Biological|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
79839255|NCT04991038|Device|DAISe Device|Thrombectomy using the DAISE device
79243558|NCT02857283|Other|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
79243559|NCT02857283|Other|Filtered Air|Participants will be exposed to filtered clean air
79243560|NCT02857283|Device|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
79243561|NCT02327702|Drug|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
79243562|NCT03609775|Drug|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
79243563|NCT03609775|Other|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
79243564|NCT03609775|Other|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
79839256|NCT04991038|Device|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
79839257|NCT00779714|Drug|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
79839258|NCT00779714|Drug|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
79839259|NCT00779714|Drug|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
79243565|NCT03609775|Other|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
79243566|NCT03690765|Drug|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
79537352|NCT01460472|Other|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
79839260|NCT00812760|Drug|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
79839261|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
79243567|NCT03690765|Drug|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
79243568|NCT05073146|Other|interview|Starting from the user as an extended starting point, through on-site visits and interviews with relevant personnel, such as personal management, professional service teams, cases, family members, other long-term care service providers (home service assistants), etc., collect relevant information and summarize successful strategies and related elements of long-term professional services (including conditions, demand analysis, service usage, professional team interaction, payment and payment systems, characteristics of case, etc.) of model cases.
79243569|NCT02033941|Drug|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
79243570|NCT02033941|Drug|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
79382669|NCT01918072|Other|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
79839262|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
80009934|NCT05274737|Device|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
79243571|NCT05383235|Other|ROUTINE CARE|1. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
79382670|NCT04273971|Other|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
79382671|NCT01451073|Biological|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
79382672|NCT05735002|Diagnostic Test|13C-butyrate breath test|breath test
79382673|NCT04758663|Behavioral|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
79382674|NCT04758663|Behavioral|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
79382675|NCT01920802|Drug|olanzapine|5mg BID up to 4 weeks
79382676|NCT01920802|Drug|iloperidone|6 mg BID up to 4 weeks
79382677|NCT01920802|Drug|Placebo|BID up to 4 weeks
79382678|NCT01451151|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
79537353|NCT01460498|Drug|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
79537354|NCT01460498|Drug|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
79537355|NCT01460498|Drug|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
79537356|NCT01460537|Drug|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
79382679|NCT01732835|Device|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
79537357|NCT01460537|Drug|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
79537358|NCT01460537|Drug|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
79537359|NCT01460537|Drug|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
79537360|NCT01460537|Drug|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
79839263|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
79839264|NCT00814944|Drug|Sirolimus|Subconjunctival injection of placebo in each eye.
79839265|NCT05308498|Diagnostic Test|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
79839266|NCT05308498|Diagnostic Test|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
79839267|NCT00779792|Drug|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
79839268|NCT00779792|Drug|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
79839269|NCT00779792|Drug|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
80009935|NCT02255630|Other|Cycling Exercise|
79694256|NCT04665024|Procedure|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
79537361|NCT01460550|Procedure|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
79694257|NCT04665024|Procedure|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
79694258|NCT01215175|Biological|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
79694259|NCT01215175|Biological|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
79694260|NCT01215175|Biological|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
79243572|NCT05383235|Device|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2. RUN-IN PERIOD :~Eligibility criteria will be assessed during the multidisciplinary meeting;~Study presentation, delivery of the information note and consent form; 3. STUDY:~Collection of consent form;~Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~Neuropsychological evaluation (TOM-15);~Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~Debriefing."
79537362|NCT01460550|Procedure|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
79537363|NCT01460563|Drug|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
79243573|NCT03143972|Drug|Dexmedetomidine|Single drug administration
79243574|NCT03143972|Drug|Remifentanil|Single drug administration
79382680|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
79537364|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
79243575|NCT02237027|Biological|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
79382681|NCT05734924|Device|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
79537365|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
79537366|NCT01460602|Drug|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~(VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
79537367|NCT01460615|Drug|Hydrocortisone|
79537368|NCT01460667|Drug|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
79537369|NCT01460667|Drug|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
79382682|NCT03824613|Diagnostic Test|Urinary miRNA|MiRNA detection in urine
79382683|NCT01451229|Drug|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
79537370|NCT01460693|Drug|Imatinib|Oral Imatinib 100mg daily
79537371|NCT01460693|Drug|Dasatinib|Oral Dasatinib 100mg daily
79537372|NCT01460706|Drug|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
79537373|NCT01460758|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
79694261|NCT04664283|Device|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
79694262|NCT03580148|Drug|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
79694263|NCT03580148|Biological|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
79694264|NCT04664517|Procedure|Flexible intramedullary nail (FIN)|Both bone FIN
79694265|NCT04664517|Procedure|Reduction auder general anesthesia and long arm cast|Reduction and cast
79694266|NCT01215097|Drug|Linagliptin|once a day
79694267|NCT01215097|Drug|placebo|once a day
79694268|NCT04664322|Device|non invasive ventilation and high flow nasal canulae oxygen therapy|patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
79839270|NCT00779792|Drug|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
79243576|NCT02237027|Biological|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
79243577|NCT03608995|Diagnostic Test|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
79537374|NCT01460758|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
79839271|NCT00779792|Drug|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
79382684|NCT01957384|Device|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
79382685|NCT01957384|Device|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
79537375|NCT01460758|Device|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
79537376|NCT01460771|Device|TDCS (Transcranial Direct-current Stimulation)|active TDCS
79537377|NCT01460771|Device|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
79839272|NCT00992134|Drug|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
79839273|NCT02551536|Drug|Montelukast|
79839274|NCT02551536|Drug|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
79839275|NCT02551536|Drug|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
79839276|NCT02556164|Procedure|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
79839277|NCT02556164|Other|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
79839278|NCT00815022|Drug|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
79839279|NCT00774722|Drug|Metronidazole|10% ointment, three times daily for 14 days
79839280|NCT00808392|Biological|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
79537378|NCT01460797|Other|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
79839281|NCT00808392|Biological|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
79839282|NCT04045548|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
79305821|NCT04918719|Drug|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
79305822|NCT04911699|Behavioral|breast adenocarcinoma receiving chemotherapy|for chemotherapy
79305823|NCT04911699|Behavioral|Control-for|hormonal drug treatment
79382686|NCT01957384|Device|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~Dansac: Nova 1 & Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~B. Braun: Flexima Active & Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
79382687|NCT01451619|Drug|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
79382688|NCT01451619|Drug|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
79537379|NCT01460823|Procedure|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
79537380|NCT01460836|Drug|Tobramycin solution for inhalation|
79537381|NCT01460836|Drug|Aztreonam lysine for inhalation|
79537382|NCT01460888|Drug|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
79839283|NCT04045548|Drug|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
79839284|NCT02262988|Procedure|Total knee replacement|Total knee replacement (TKA)
79839285|NCT02556944|Device|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
79839286|NCT00808548|Other|counseling, emotional support|
79839287|NCT00808548|Other|emotional support|emotional support during the interview
79839288|NCT00808548|Other|emotional support|emotional supporting during the interview
80009936|NCT02163122|Procedure|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
80016849|NCT03658473|Drug|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
79243578|NCT03608995|Diagnostic Test|Quikcheck fFN ™|- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
79243579|NCT03380637|Other|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
79694269|NCT04318795|Procedure|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
79243580|NCT03387969|Procedure|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
79694270|NCT04318795|Procedure|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
79694271|NCT03527576|Drug|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
79694272|NCT03527576|Drug|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
79839289|NCT04920136|Procedure|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
79839290|NCT04920136|Procedure|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
79839291|NCT00780104|Drug|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
79839292|NCT00780104|Drug|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
79839293|NCT00815100|Drug|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
79382689|NCT03054519|Drug|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
79382690|NCT03054519|Drug|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
79382691|NCT01921894|Dietary Supplement|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
79537383|NCT01460888|Radiation|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
79537384|NCT01460953|Behavioral|health literacy training video|participants will watch a training video
79382692|NCT03047577|Behavioral|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
79537385|NCT01460966|Procedure|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
79537386|NCT01460966|Procedure|Thrombus aspiration catheter|Thrombus aspiration catheter only
79537387|NCT01460979|Drug|Temsirolimus|25mg weekly intravenous until progression
79243581|NCT02034227|Drug|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
79305824|NCT04924335|Procedure|Erector spinae plane block|Preoperative ultrasound-guided bilateral erector spinae plane block with 20 ml 0.025% bupivacaine.
79382693|NCT01452009|Drug|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
79382694|NCT01452009|Drug|TRAVATAN®|TRAVATAN® administered one drop once daily
79382695|NCT03824379|Dietary Supplement|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
79382696|NCT03824379|Drug|Antidiabetic|insulin or oral hypoglycemics
79537388|NCT01460992|Procedure|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
79694273|NCT04664010|Drug|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
79537389|NCT01461018|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
79537390|NCT01461031|Drug|nefopam|nefopam infusion for postoperative 24 hours
79694274|NCT04664010|Drug|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
79537391|NCT01461031|Drug|normal saline (control)|normal saline infusion for postoperative 24 hours
79537392|NCT01461083|Drug|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of [18F]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not >10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
79694275|NCT04664010|Drug|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
79694276|NCT00534989|Procedure|FDG PET|FDG PET
79839294|NCT00815100|Drug|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
79839295|NCT00992212|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
79839296|NCT04047680|Drug|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
79839297|NCT04047680|Drug|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
79839298|NCT04047680|Drug|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
79243582|NCT03608917|Drug|Total Glucosides of Paeony(TGP)|Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
79694277|NCT04664127|Drug|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment [Valacyclovir + Kagocel ° ] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). * Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
79694278|NCT04664127|Drug|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment [Valacyclovir] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)*.~* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
79839299|NCT04047680|Drug|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
79839300|NCT04047680|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
79243583|NCT03608917|Device|Narrow band-ultraviolet b（NB-UVB）|phototherapy on treating vitiligo
79243584|NCT03608917|Drug|Total Glucosides of Paeony(TGP) analogue|Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
79243585|NCT02237105|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
79243586|NCT03380481|Other|observational only-no intervention|Observational only and no predesigned interventions in this study.
79243587|NCT04186819|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
79243588|NCT04704752|Diagnostic Test|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
79243589|NCT03384459|Device|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
79537393|NCT01461109|Drug|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
79537394|NCT01461148|Biological|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
79537395|NCT01461174|Drug|Modafinil|200 mg tablet, single dose
79839301|NCT04047680|Drug|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
80009937|NCT02163122|Other|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
79537396|NCT01461174|Drug|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
79537397|NCT01461174|Drug|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
79537398|NCT01461187|Other|exercise during pregnancy|supervised aerobic physical exercises twice a week.
79537399|NCT01461200|Other|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
79537400|NCT01461213|Drug|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
79694279|NCT04664049|Dietary Supplement|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
79694280|NCT00535028|Drug|AER 001|AER 001 25 mgs s.c. once daily for 28 days
79839302|NCT00815178|Behavioral|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
79839303|NCT00815178|Behavioral|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
79243590|NCT03143582|Other|Running|A 13-week running program where youth run for 30 minutes twice weekly.
79839304|NCT00774878|Drug|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
79839305|NCT00774878|Drug|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
79243591|NCT03609125|Other|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
79382697|NCT01957930|Drug|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
79839306|NCT04917172|Diagnostic Test|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell [WBC] count and C-Reactive Protein [CRP]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
80009938|NCT02163122|Biological|Cat allergen (FelD1)|
79382698|NCT01957930|Drug|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
80009939|NCT04507269|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
79382699|NCT01759511|Drug|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
79537401|NCT01461239|Procedure|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
79537402|NCT01461239|Procedure|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
80009940|NCT04507269|Drug|Placebo|Saline given by subcutaneous injection
80009941|NCT02162264|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
79537403|NCT01461239|Procedure|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
80009942|NCT03700515|Drug|Erythropoietin|Subjects receive weekly infusions of EPO
80009943|NCT03700515|Drug|Placebo|Subjects receive weekly infusions of saline
80009944|NCT05113277|Behavioral|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
79243592|NCT03387891|Device|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
79243593|NCT04185259|Other|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
79382700|NCT03824457|Drug|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
79382701|NCT03824457|Drug|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
79537404|NCT01461252|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
79694281|NCT00535028|Drug|placebo|sterile saline
79537405|NCT01461252|Procedure|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
79694282|NCT04664088|Procedure|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
79694283|NCT04664088|Drug|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
79694284|NCT00535067|Behavioral|Questionnaire|Questionnaires taking 60 minutes total to complete.
79694285|NCT00557115|Other|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
79694286|NCT00535106|Device|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
79694287|NCT00535106|Device|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
79694288|NCT00535106|Other|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
79694289|NCT04663854|Drug|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
79694290|NCT04664244|Combination Product|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
79839307|NCT00815256|Procedure|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
79839308|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
79839309|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
79382702|NCT01958320|Other|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
79382703|NCT01958320|Other|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
79537406|NCT01461265|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
79694291|NCT04663815|Behavioral|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
79382704|NCT01958320|Drug|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
79694292|NCT04663815|Other|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
79382705|NCT04414007|Behavioral|Internet+ home-based cardiac rehabilitation|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
79382706|NCT04414007|Behavioral|Conventional rehabilitation|We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
79694293|NCT04663581|Other|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
79694294|NCT04663581|Other|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
79537407|NCT01461330|Other|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
79243594|NCT04185259|Other|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, ~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
79243595|NCT02034383|Other|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
79694295|NCT04663698|Other|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
79694296|NCT04663698|Other|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
79694297|NCT04663698|Other|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
79694298|NCT04663698|Other|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
79694299|NCT04663698|Other|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
79694300|NCT04663659|Other|no intervention|no intervention
79839310|NCT00815334|Procedure|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
79382707|NCT01452087|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
79382708|NCT01452321|Procedure|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
80009945|NCT05113277|Behavioral|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
79243596|NCT02034383|Other|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
79382709|NCT01732757|Drug|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
79382710|NCT01732757|Drug|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
79382711|NCT01732757|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
79382712|NCT03824301|Device|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
79537408|NCT01461330|Other|ADA diet|Adoption of ADA diet.
79382713|NCT03824301|Device|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
79382714|NCT01452399|Procedure|Shave margins|Partial mastectomy with shave margins.
79694301|NCT04663971|Procedure|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
79694302|NCT04663971|Procedure|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
79694303|NCT04663386|Drug|Budesonide-Formoterol|Dry powder inhaler
79243597|NCT02034383|Other|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
79243598|NCT02034383|Other|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
79243599|NCT02034383|Other|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
79382715|NCT01452399|Procedure|No Shave Margins|Partial mastectomy without shave margins.
79382716|NCT03824067|Diagnostic Test|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
79382717|NCT03824067|Diagnostic Test|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
79537409|NCT01461343|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
79537410|NCT01461356|Procedure|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
79694304|NCT04663542|Procedure|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
79694305|NCT04663269|Drug|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
79694306|NCT04663269|Drug|Control Test|Peritubal block - standard local analgesic administration
79694307|NCT03465020|Other|Observation|Safety and efficacy outcomes of patients on different treatments
79839311|NCT00778778|Drug|cefprozil 500mg tablets|
79839312|NCT00815412|Behavioral|Counseling in use of health care|
79839313|NCT00815412|Behavioral|Counseling in diet, exercise|
79839314|NCT00815412|Other|Control|
79537411|NCT01461356|Procedure|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
79382718|NCT01758731|Drug|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
79537412|NCT01461382|Other|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
79694308|NCT04686500|Device|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
79694309|NCT03303339|Drug|Onvansertib|Onvansertib orally
79694310|NCT03303339|Drug|Cytarabine|subcutaneously
79694311|NCT03303339|Drug|Decitabine|intravenously
80009946|NCT03702075|Other|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
79694312|NCT04686461|Drug|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
79694313|NCT03422471|Other|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
79694314|NCT03299946|Drug|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
79694315|NCT03299946|Drug|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
79694316|NCT03399929|Other|Post Acute Rehabiltation|
79839315|NCT00305773|Drug|vorinostat|Given orally once daily
79243600|NCT03387345|Other|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
79243601|NCT03387345|Other|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
79537413|NCT01461382|Other|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
79694317|NCT00535340|Drug|SR58611A|
79694318|NCT00535379|Drug|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
79694319|NCT00535418|Drug|Letrozole|
79243602|NCT03387345|Other|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
79694320|NCT03288948|Other|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
79243603|NCT03387345|Other|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
79694321|NCT03307382|Device|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
79243604|NCT03387345|Other|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
79243605|NCT03387345|Other|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
79694322|NCT04679064|Drug|Niraparib|PARP-inihibitor
79694323|NCT04679064|Drug|Dostarlimab|PD-1 inihibitor
79839316|NCT00305773|Drug|vorinostat|Given orally three times daily
79839317|NCT00778856|Procedure|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
79839318|NCT02552004|Device|pCLE|Histological examination by pCLE technique preceding the frozen section
79243606|NCT02034487|Other|retrospective data collection|
79243607|NCT03608969|Other|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
79382719|NCT01758731|Drug|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
79382720|NCT01758731|Radiation|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
79382721|NCT01452477|Drug|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
79382722|NCT01452477|Drug|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
79382723|NCT04168775|Device|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
80009947|NCT03700359|Drug|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
79537414|NCT01461408|Behavioral|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
79694324|NCT04679064|Drug|Pegylated liposomal doxorubicin|Chemotherapy drug
79243608|NCT03609463|Behavioral|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
79694325|NCT04679064|Drug|Paclitaxel|Chemotherapy drug
79694326|NCT04679064|Drug|Gemcitabine|Chemotherapy drug
79694327|NCT04679064|Drug|Topotecan|Chemotherapy drug
79839319|NCT02552004|Drug|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
79243609|NCT03609463|Behavioral|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
79243610|NCT03609463|Other|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
79243611|NCT05172453|Other|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
79243612|NCT03143738|Procedure|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
79243613|NCT03143738|Procedure|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
79243614|NCT03143738|Procedure|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
79243615|NCT03608891|Device|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
79243616|NCT03608891|Device|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
79243617|NCT03384303|Other|Standardized meal test|Preoperatively and postoperatively standardized meal test
79382724|NCT01452555|Behavioral|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
79382725|NCT01452633|Drug|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
79382726|NCT01452633|Drug|Saline will be injected at the study port site prior to incision|Injection will precede incision
79694328|NCT04679064|Drug|Bevacizumab|Chemotherapy drug
79382727|NCT01452633|Drug|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
79694329|NCT01183780|Biological|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
79694330|NCT01183780|Biological|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
79694331|NCT01183780|Drug|Irinotecan|180 milligrams/square meter (mg/m^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
79694332|NCT01183780|Drug|Folinic Acid|400 mg/m^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
79839320|NCT00780182|Drug|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
79839321|NCT00812994|Drug|Escitalopram|SSRI antidepressant
79839322|NCT00812994|Drug|Placebo|
79839323|NCT00780260|Behavioral|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
79243618|NCT04393753|Drug|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
80009948|NCT03700359|Drug|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
79243619|NCT04647903|Drug|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
79243620|NCT04647903|Drug|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
79839324|NCT00784394|Drug|diindolylmethane|Given PO
80009949|NCT03700359|Drug|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
80009950|NCT02047955|Procedure|Shoulder Arthroplasty|
79243621|NCT04647903|Drug|Placebo|placebo for oral and intranasal administration
79243622|NCT05080634|Other|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
79243623|NCT04593225|Behavioral|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
79382728|NCT01452633|Drug|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
79382729|NCT01606319|Drug|Acetaminophen|15 mg/kg every 6 hours as needed
79537415|NCT01461421|Behavioral|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
79537416|NCT01461421|Behavioral|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
79537417|NCT01461421|Behavioral|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
79694333|NCT01183780|Drug|5-Fluorouracil|400 mg/m^2 bolus immediately followed by 2400 mg/m^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
79839325|NCT00784394|Other|placebo|Given PO
79839326|NCT00784394|Other|pharmacological study|Correlative studies
79839327|NCT00784394|Other|laboratory biomarker analysis|Correlative studies
80009951|NCT02167178|Other|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
80009952|NCT02167178|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
79243624|NCT04593225|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
79243625|NCT03608813|Other|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
79243626|NCT03142256|Behavioral|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
79243627|NCT03142256|Drug|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
79243628|NCT04308655|Other|Interview|Semi-structured interviews
79243629|NCT04308655|Other|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
79305825|NCT03056391|Drug|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
79382730|NCT01606319|Drug|Ibuprofen|9.4 mg/kg every 6 hours as needed
79382731|NCT01452711|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
79382732|NCT01452711|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
79382733|NCT01452711|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
79382734|NCT01452711|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
79694334|NCT04662957|Dietary Supplement|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
79694335|NCT04662957|Dietary Supplement|Maltodextrin|Maltodextrin as placebo
79694336|NCT00535457|Other|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
79694337|NCT04679103|Biological|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
79694338|NCT04663191|Procedure|anatomical resection|Anatomical resection with systematic lymph-node dissection
79694339|NCT00535535|Dietary Supplement|Fructose|Fructose, 0.5 g/kg
79694340|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
79694341|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
79694342|NCT00535574|Drug|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
79839328|NCT00784394|Other|quality-of-life assessment|Ancillary studies
80009953|NCT02167178|Other|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
80009954|NCT02167178|Other|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
80009955|NCT01379027|Behavioral|Pure self-help Internet CBT for depression|Internet, CBT, Depression
80009956|NCT01379027|Behavioral|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
80009957|NCT01379027|Behavioral|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
80016850|NCT03658473|Drug|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
80016851|NCT02096250|Other|NaFeEDTA|
80016852|NCT02096250|Other|Ferrous fumarate|
80016853|NCT02096250|Other|NaFeEDTA + ferrous fumarate|
80016854|NCT02286050|Other|CF Nursing Program|
80009958|NCT03625089|Drug|Atorvastatin|"Group 1 patients will be prescribed statin when FRS > 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
79243630|NCT03387189|Other|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
79243631|NCT03142178|Drug|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
79243632|NCT03142178|Drug|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
79243633|NCT03142178|Drug|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
79243634|NCT03142178|Drug|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
79382735|NCT02630121|Drug|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
79537418|NCT01461421|Behavioral|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
79537419|NCT01461434|Device|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
79537420|NCT01461447|Biological|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
79537421|NCT01461460|Drug|TR-701 FA 1200 mg|6 tablet of T-701 FA
79382736|NCT02630121|Drug|Placebo|Proportion of the subjects with 50% reduction in AHI.
79382737|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
79382738|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
79382739|NCT02956785|Drug|10 mg Dinoprostone; CTS, UK|
79382740|NCT02956785|Drug|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
79382741|NCT02956785|Drug|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
79537422|NCT01461460|Drug|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
79537423|NCT01461460|Drug|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
79537424|NCT01461460|Drug|Placebo|6 placebo tablets
79537425|NCT01461486|Device|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
79694343|NCT00535574|Drug|bexarotene|75 mg/day 6 weeks
79694344|NCT04678830|Drug|Placebos|Placebos
79243635|NCT03142178|Drug|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
79243636|NCT03142178|Drug|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
79243637|NCT01343459|Radiation|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~IOERT is performed on mobile or fixed linacs~Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~Single reference dose per fraction: 2,7 Gy (ICRU)~Number of fractions: 15, Number of fractions per week: 5~Total WBRT dose: 40,5 Gy"
79243638|NCT04289155|Drug|GX-I7|patients will receive the assigned dose of GX-I7 intramuscular injection every 4~12 weeks
79243639|NCT03380403|Radiation|PDT|clinical treatment of infected diabetic foot
79243640|NCT03380403|Other|Ciprofloxacin|antibiotics and or surgical debridment
79243641|NCT03609229|Procedure|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
79382742|NCT01452867|Device|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
79382743|NCT01452867|Device|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
79382744|NCT01452867|Device|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
79382745|NCT04273503|Behavioral|Mentoring/educational session|12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
79537426|NCT01461486|Device|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
79537427|NCT01461512|Drug|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
79537428|NCT01461512|Drug|Placebo administration|NaCl isotonic
79537429|NCT01461525|Procedure|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
79537430|NCT01461525|Procedure|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
79537431|NCT01461564|Procedure|Colonoscopy|Screening colonoscopy
79694345|NCT04678830|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
79694346|NCT01183468|Biological|Aralast NP 45 mg dose|- 45 mg/kg/week
79694347|NCT01183468|Biological|Aralast NP 90 mg dose|- 90 mg/kg/week
79694348|NCT01183468|Biological|Aralast NP 180 mg dose|- 180 mg/kg/week
79694349|NCT03245021|Drug|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
79839329|NCT00778934|Other|Intimate Health Gel|Intimate Health Gel
79839330|NCT04047524|Other|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
79694350|NCT04678791|Drug|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
79694351|NCT04678791|Drug|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
79537432|NCT01461577|Drug|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
79694352|NCT04678791|Radiation|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
79839331|NCT02556398|Behavioral|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
79382746|NCT02947581|Drug|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
79537433|NCT01461590|Other|Whole blood|30mls/kg transfused over fours hours
79537434|NCT01461590|Other|Whole blood|20mls/kg transfused over four hours
79839332|NCT00305695|Other|Laboratory Biomarker Analysis|Correlative studies
79382747|NCT02947581|Drug|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
79382748|NCT01453257|Drug|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
79537435|NCT01461603|Dietary Supplement|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
79694353|NCT04678791|Radiation|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 ~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
79694354|NCT01183390|Drug|Anastrozole|1 mg Tablets
79694355|NCT01183390|Drug|Anastrozole|1 mg Tablets
79694356|NCT02887807|Drug|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
79694357|NCT02887807|Drug|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
79694358|NCT04663035|Drug|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
79839333|NCT00305695|Drug|Zoledronic Acid|Given IV
79839334|NCT00784472|Drug|oxycodone|intravenous according to patients weight, pn.
80009959|NCT01378949|Drug|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
80009960|NCT01378949|Drug|Morphine|Morphine 1 mg/cc
79382749|NCT01453491|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
79537436|NCT01461603|Dietary Supplement|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
79537437|NCT01461616|Drug|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
79537438|NCT01461616|Drug|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
79537439|NCT01461616|Drug|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
79537440|NCT01461642|Other|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
79537441|NCT01461681|Procedure|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
79839335|NCT00784472|Drug|morphine|intravenous administration according to patients weight, pn.
79839336|NCT00779012|Biological|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
79839337|NCT00784706|Other|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
79839338|NCT00784706|Other|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
80009961|NCT03701997|Device|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
80009962|NCT03540446|Device|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
79694359|NCT04663035|Procedure|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
79694360|NCT04662762|Other|Nursing intervention programme|educational information
79839339|NCT00784706|Other|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
79839340|NCT00647556|Drug|adapalene gel, 0.3%|applied topically once daily in the evening
79382750|NCT03823599|Behavioral|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
79537442|NCT01461694|Device|Intense Pulsed Light (IPL)|Half Face Treated with IPL
79537443|NCT01461694|Device|Alexandrite Laser|Half face treated with Alexandrite Laser
79694361|NCT03191942|Device|Modified ortho-k lenses|KETT MC lens
79537444|NCT01461720|Other|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
79694362|NCT03191942|Device|Ortho-k lenses|KATT BeFree lens
79694363|NCT04662606|Behavioral|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
79694364|NCT03058952|Behavioral|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
79694365|NCT03058952|Behavioral|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
79694366|NCT04662528|Drug|Placebo|4 x 1g capsules/day
79382751|NCT03823599|Behavioral|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
79839341|NCT00647556|Drug|tretinoin 0.05% emollient cream|applied topically once daily in the evening
79839342|NCT03978559|Drug|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
79839343|NCT03978559|Drug|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
79382752|NCT01453647|Other|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
79537445|NCT01461720|Biological|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
79537446|NCT01461746|Drug|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
79537447|NCT01461746|Drug|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
79537448|NCT01461746|Radiation|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
79537449|NCT01461759|Drug|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
79537450|NCT01461759|Drug|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
79537451|NCT01461772|Radiation|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
79537452|NCT01461772|Drug|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
79537453|NCT01461772|Drug|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
79537454|NCT01461785|Biological|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
79694367|NCT04662528|Drug|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
79694368|NCT02830997|Device|Stereotactic guidance system|
79694369|NCT03098706|Procedure|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
79694370|NCT03098706|Procedure|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
79839344|NCT03978559|Drug|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
79839345|NCT03981133|Behavioral|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
79839346|NCT03981133|Behavioral|no pacifier|not to offer a pacifier at 15 days of life
79839347|NCT00813072|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
79537455|NCT01461785|Procedure|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
79537456|NCT01461798|Dietary Supplement|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
79537457|NCT01461798|Dietary Supplement|Placebo Yogurt|Yogurt without the active principle
79537458|NCT01461798|Dietary Supplement|yogurt|yogurt without plant stanols
79537459|NCT01461850|Drug|Neoadjuvant chemotherapy + Interval Debulking Surgery|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
79243642|NCT03609229|Procedure|Abdominal Sacrocolpopexy|"By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~The right-handed operator double gloves, and places the left hand in the vagina.~With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
79694371|NCT02802488|Procedure|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
79382753|NCT01453803|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
79694372|NCT04662333|Procedure|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
79694373|NCT04662333|Procedure|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
79694374|NCT05300672|Drug|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
79839348|NCT00813072|Drug|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79382754|NCT04273893|Radiation|SBRT with additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
79382755|NCT04273893|Radiation|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
79382756|NCT04273893|Diagnostic Test|Blood Draws|CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
79382757|NCT01453881|Device|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
79382758|NCT01453881|Device|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
79382759|NCT05608473|Other|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
79694375|NCT03098589|Drug|Revlimid|Revlimid
79694376|NCT05298137|Procedure|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
79694377|NCT04662177|Drug|Dexmedetomidine|The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
79839349|NCT00813072|Drug|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
79839350|NCT03980821|Drug|AZD4635|AZD4635 taken orally
79243643|NCT03143426|Procedure|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
79243644|NCT02034539|Device|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
79243645|NCT03380325|Drug|Iloprost infusion|Iloprost is a stable prostacyclin analogue
79243646|NCT02237053|Drug|Glucagon|
79243647|NCT02237053|Drug|Octreotide|
79243648|NCT02237053|Behavioral|Placebo|
79243649|NCT02237053|Drug|Insulin|
80009963|NCT01381133|Behavioral|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
79694378|NCT05292560|Other|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
79694379|NCT00537953|Drug|Miltefosine , meglumine antimoniate|
79839351|NCT00813228|Drug|Sitagliptin (Januvia)|
80009964|NCT01381133|Behavioral|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
80009965|NCT01381133|Behavioral|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
79243650|NCT03142100|Device|cochlear implants and hearing aids|speech perception tests and bimodal fitting
79243651|NCT05172219|Behavioral|Physician Sent Outreach with Embedded Asynchronous Care in Portal Message|PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
79243652|NCT05172219|Behavioral|Physician Sent Outreach without Embedded Asynchronous Care in Portal Message|Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
79243653|NCT05172219|Behavioral|System Sent Outreach with Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
79382760|NCT04391751|Procedure|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
79382761|NCT04391751|Procedure|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
79382762|NCT02983851|Procedure|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
79694380|NCT02971098|Procedure|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
79694381|NCT05259449|Behavioral|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
79694382|NCT05259449|Other|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
79839352|NCT00320593|Device|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
79839353|NCT00320593|Device|Single Vision Lenses (SVLs)|Single vision lenses
79839354|NCT00813306|Drug|AZD2066|13 mg oral solution, 1 single dose
79839355|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
79243654|NCT05172219|Behavioral|System Sent Outreach without Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
79694383|NCT05259449|Other|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
79243655|NCT03140930|Dietary Supplement|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
79243656|NCT03140930|Dietary Supplement|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
79243657|NCT03140930|Dietary Supplement|Placebo duodenal|Duodenal infusion of placebo (tap water)
79243658|NCT03140930|Dietary Supplement|Placebo ileal|Ileal infusion of placebo (tap water)
79243659|NCT04127825|Procedure|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
79243660|NCT03609151|Procedure|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
79243661|NCT03609151|Radiation|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
79243662|NCT03384147|Dietary Supplement|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
80009966|NCT01381055|Drug|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
80009967|NCT01381055|Drug|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
79694384|NCT04661943|Drug|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
79694385|NCT05252000|Device|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
79839356|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
79839357|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
79839358|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
79839359|NCT00813384|Drug|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
79839360|NCT01061983|Device|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
79243663|NCT03384147|Other|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
79243664|NCT04964570|Behavioral|Video _ behavioral change module|"A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support."
79839361|NCT00808626|Drug|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
79839362|NCT04017078|Other|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
80009968|NCT01380977|Behavioral|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
79243665|NCT02237131|Drug|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
79243666|NCT02237131|Drug|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
79243667|NCT03384069|Behavioral|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
79839363|NCT00808704|Drug|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
79839364|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
80009969|NCT02163278|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
80009970|NCT02163278|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
79839365|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
79839366|NCT00320515|Drug|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
79382763|NCT02983851|Procedure|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
79694386|NCT05252000|Device|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
79839367|NCT00320515|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
79839368|NCT02551458|Other|Systematic surgery|
79839369|NCT02551458|Other|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
79243668|NCT03384069|Behavioral|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
79243669|NCT02734667|Device|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
79382764|NCT02884401|Device|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
79382765|NCT04391361|Drug|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
79382766|NCT04391361|Drug|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
79382767|NCT05603325|Other|Person Centered Practice|"Staff will be asked to:~Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~Attend a final focus group to evaluate the workshop programme."
79382768|NCT05603325|Other|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
79382769|NCT01454037|Procedure|Prostate cryotherapy|cryoablate the prostate
79694387|NCT05252000|Device|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
79694388|NCT04662138|Drug|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
79839370|NCT01066273|Device|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
79839371|NCT00808782|Device|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
79839372|NCT00808782|Device|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
79839373|NCT02550834|Other|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
80009971|NCT02167334|Device|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
79243670|NCT04997174|Drug|Celecoxib|Patients in ERAS group received celecoxib
79382770|NCT01454037|Procedure|Radical prostatectomy|Remove prostate
79382771|NCT01454037|Procedure|Radiation|Radiate prostate
79382772|NCT04272957|Drug|HMPL-306|HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
79382773|NCT04273191|Drug|Brexanolone|Brexanolone will be initiated and administered per the USPI and the associated REMS.
79694389|NCT00557154|Device|ultrasound|ultrasound used to identify target vein
79694390|NCT00557154|Device|standard technique for venipuncture|routine equipment
79694391|NCT05237414|Device|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
79694392|NCT05237414|Device|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
79694393|NCT05237414|Behavioral|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
79694394|NCT05237414|Behavioral|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
79382774|NCT04391985|Drug|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
80009972|NCT02167334|Procedure|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
79839374|NCT00662012|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
79839375|NCT00808860|Dietary Supplement|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
80009973|NCT03122613|Dietary Supplement|Curcumin|3g of Curcumin per day
80009974|NCT03122613|Drug|Placebo|3g of Curcumin Placebo per day
79243671|NCT02237209|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
79243672|NCT02237209|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
79243673|NCT03383991|Procedure|Reverse Total Shoulder Arthroplasty|
79243674|NCT03383991|Procedure|Hemiarthroplasty|
79694395|NCT05226299|Biological|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
79694396|NCT05226299|Biological|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
79694397|NCT00557232|Drug|bevacizumab|1.25mg/month
79694398|NCT02797119|Drug|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
79243675|NCT03608605|Device|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
79243676|NCT03387111|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
79243677|NCT03387111|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79243678|NCT03387111|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
79243679|NCT03387111|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79382775|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
79382776|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
79694399|NCT02797119|Drug|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
79694400|NCT02797119|Drug|Saline Solution (TA0)|
79839376|NCT00808860|Dietary Supplement|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
80009975|NCT03700281|Behavioral|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
80009976|NCT03700281|Behavioral|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
80009977|NCT03630575|Procedure|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
80009978|NCT03540368|Drug|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
80009979|NCT03540368|Other|Placebo|Administering placebo or sodium chloride 0,9% intravenously
80009980|NCT02162342|Other|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
79243680|NCT03387111|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
79243681|NCT03387111|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79243682|NCT03387111|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
79243683|NCT03387111|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
79243684|NCT03387111|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
79243685|NCT03387111|Drug|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
79382777|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
79694401|NCT05173259|Behavioral|F|The participant will be asked to chew the two-coloured chewing gum naturally.
80009981|NCT03086135|Device|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
80016855|NCT03659331|Dietary Supplement|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
79243686|NCT03387111|Drug|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
79243687|NCT03387111|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79243688|NCT03387111|Drug|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
79243689|NCT03387111|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
79694402|NCT05173259|Behavioral|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
79243690|NCT03387111|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79243691|NCT03387111|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79243692|NCT03387111|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79243693|NCT03387111|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
79243694|NCT03387111|Drug|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
79243695|NCT03387111|Procedure|SBRT|Stereotactic Body Radiation Therapy
79243696|NCT03387111|Biological|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
79382778|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
79382779|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
79382780|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
79537460|NCT01461850|Procedure|Primary Debulking Surgery + Adjuvant Chemotherapy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
79537461|NCT01461876|Drug|antiretroviral therapy|Standard of care antiretroviral therapy
79537462|NCT01461889|Other|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
79537463|NCT01461889|Other|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
79694403|NCT05173259|Behavioral|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
79694404|NCT05173259|Behavioral|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
79694405|NCT05173259|Behavioral|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
79694406|NCT05173259|Behavioral|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
80016856|NCT02094846|Behavioral|Voice messages|Voice messages reinforced with self-efficacy
79243697|NCT04477070|Procedure|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
79243698|NCT04477070|Procedure|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
79243699|NCT03608293|Diagnostic Test|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
79243700|NCT03608501|Drug|Ixazomib|Ixazomib capsules.
79243701|NCT03608501|Drug|Thalidomide|Thalidomide capsules.
79243702|NCT03608501|Drug|Dexamethasone|Dexamethasone tablets.
79243703|NCT04609436|Device|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
79243704|NCT03608345|Other|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
79243705|NCT03608761|Drug|Rebamipide|rebamipide 2%
79243706|NCT03608761|Biological|autologous serum|AS for 3 months
79243707|NCT03608761|Other|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
79243708|NCT03383913|Behavioral|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
79243709|NCT03608267|Device|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
79382781|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
79382782|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
79382783|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
79382784|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
79382785|NCT01454115|Drug|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
79382786|NCT01454115|Drug|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
79382787|NCT01455597|Drug|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
79382788|NCT01454271|Procedure|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
79694407|NCT00557388|Dietary Supplement|Protein/Amino Acids|Casein Whey Leucine
79694408|NCT00557388|Other|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
80016857|NCT02096328|Drug|POL7080|Intravenous infusion
79537464|NCT01461941|Drug|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
79537465|NCT01461941|Drug|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
79537466|NCT01461967|Drug|Placebo|Single ascending doses
79694409|NCT05161208|Drug|OC-01 (varenicline 0.6mg/ml) Nasal Spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
79839377|NCT04045002|Other|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
79839378|NCT00815568|Drug|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
79839379|NCT00815646|Drug|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
80009982|NCT02162498|Behavioral|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
79243710|NCT04150081|Procedure|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
79694410|NCT05161208|Drug|Placebo (vehicle) nasal spray|Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
79694411|NCT00537992|Procedure|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
80009983|NCT03700125|Procedure|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
80009984|NCT02163590|Other|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
80009985|NCT02163590|Other|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
80009986|NCT02163590|Other|Placebo|Intervention that mimics the experimental procedures
80009987|NCT02167568|Genetic|Genetic|
80009988|NCT02255396|Other|ESTRADIOL|
80009989|NCT02163668|Other|Yoga Group|8 months of Yoga training
79243711|NCT03383835|Dietary Supplement|Omega-3 Supplementation|"DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months"
79243712|NCT04568174|Drug|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
79243713|NCT04568174|Drug|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
79243714|NCT02033447|Other|Magnetic Nanoparticle Injection|
79243715|NCT02715115|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
79243716|NCT02715115|Drug|Placebo|Strawberry flavored solution and Water for Injection
79537467|NCT01461967|Drug|RO5508887|Single ascending doses
79537468|NCT01461967|Drug|RO5508887|Single doses
79537469|NCT01462006|Drug|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
79694412|NCT00538070|Dietary Supplement|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
79694413|NCT04662021|Other|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
79694414|NCT00538109|Drug|Glivec®/Gleevec®|Chemotherapy
80009990|NCT02167646|Procedure|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
80009991|NCT02163980|Drug|Caudal ropivacaine + normal saline|
80009992|NCT02163980|Drug|Caudal ropivacaine + dexmedetomidine|
79243717|NCT04554836|Drug|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
79243718|NCT04554836|Other|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
79243719|NCT03386955|Drug|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
79243720|NCT04536272|Drug|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
79243721|NCT04536272|Drug|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
79243722|NCT03608527|Behavioral|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
79839380|NCT01066351|Drug|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
80009993|NCT02164058|Device|TandemHeart System|
79243723|NCT03608527|Behavioral|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
79382789|NCT01453101|Drug|Fludarabine monophosphate, melphalan, Bortezomib|"Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
79537470|NCT01462006|Other|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
79537471|NCT01462019|Device|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
79537472|NCT01462032|Behavioral|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
79537473|NCT01462032|Behavioral|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
79537474|NCT01462058|Dietary Supplement|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
79694415|NCT04661904|Device|Continuous theta burst stimulation (cTBS)|Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
79839381|NCT01066351|Drug|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
79839382|NCT00817752|Dietary Supplement|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
79839383|NCT03980353|Other|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
79839384|NCT00808938|Device|MST|Magnetic Seizure Therapy
80009994|NCT02164058|Procedure|Percutaneous coronary intervention|
79243724|NCT03380169|Other|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
80009995|NCT02164136|Procedure|L-PANP-TME|
80009996|NCT02164136|Procedure|O-PANP-TME|
80009997|NCT01380821|Radiation|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
80009998|NCT02162654|Procedure|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
80009999|NCT02162654|Procedure|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
79243725|NCT03380169|Other|Prophylactic conventional wound dressing|Conventional gauze dressing
79243726|NCT02034721|Dietary Supplement|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
79243727|NCT02034721|Dietary Supplement|Placebo|Placebo
79243728|NCT04521842|Procedure|Total hip replacement|Total hip replacement in treatment of end-stage osteoarthritis
79382790|NCT01454349|Drug|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
79382791|NCT01454349|Drug|Placebo|Single intraprostatic injection of matching placebo
79382792|NCT02935257|Biological|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
79382793|NCT01454661|Dietary Supplement|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
79382794|NCT01454661|Dietary Supplement|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
79382795|NCT01454661|Dietary Supplement|Placebo|Microcrystalline cellulose is used as placebo.
79382796|NCT02085447|Behavioral|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
79382797|NCT04847193|Other|Dietary Intervention 1: Placebo|Participants receive a study drink supplemented with a placebo for 5 days
79537475|NCT01462058|Drug|Placebo|Placebo, daily, 12 weeks
79537476|NCT01462123|Other|endoscopic assessment of colonic polyps|
79537477|NCT01462136|Drug|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
79537478|NCT01462149|Drug|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
79537479|NCT01462149|Drug|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
79537480|NCT01462175|Drug|RO5503781|
79537481|NCT01462188|Procedure|Immediate stenting|Primary coronary stenting
79537482|NCT01462188|Procedure|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
79839385|NCT02532361|Device|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
79839386|NCT02532361|Procedure|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
79839387|NCT00809016|Radiation|3-dimensional conformal radiation therapy|
79694416|NCT04661904|Device|Sham stimulation|The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
79839388|NCT00809016|Radiation|fludeoxyglucose F 18|
80010000|NCT04733222|Other|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
79243729|NCT03383601|Other|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
79537483|NCT01462201|Device|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
79243730|NCT03383601|Other|Smoking combustible cigarettes|Current smoking of combustible cigarettes
79243731|NCT02746679|Other|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
79243732|NCT03380013|Procedure|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
79537484|NCT01462214|Drug|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
79537485|NCT01462240|Device|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
79839389|NCT00809016|Radiation|intensity-modulated radiation therapy|
79839390|NCT03980431|Diagnostic Test|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
79243733|NCT03608215|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
79243734|NCT03608215|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
79243735|NCT04138927|Drug|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
79243736|NCT04504604|Diagnostic Test|FoundationOne CDx and FoundationOne Liquid CDx|Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
79243737|NCT03610373|Behavioral|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
79537486|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
79537487|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
79537488|NCT01462331|Other|Sucrose|12g/dose, three times a day
79694417|NCT04661865|Other|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
79694418|NCT00538148|Drug|Telithromycin|
79839391|NCT00817830|Drug|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
79243738|NCT03610295|Procedure|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
79839392|NCT00815724|Behavioral|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
80010001|NCT04733222|Other|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
79243739|NCT03610295|Procedure|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
80010002|NCT01378793|Behavioral|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
80010003|NCT01378793|Behavioral|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
79243740|NCT03142022|Other|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
79243741|NCT02034643|Procedure|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
79243742|NCT02033525|Drug|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
79243743|NCT02033525|Other|Rehabilitation|Standard rehabilitation program
79382798|NCT04847193|Other|Dietary Intervention 2: Xanthohumol and Iso-alpha acids|Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
79537489|NCT01462396|Device|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
79537490|NCT01462409|Device|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
79537491|NCT01462409|Device|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
79537492|NCT01462409|Device|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
79537493|NCT01462422|Drug|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
79537494|NCT01462422|Drug|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
79243744|NCT04638842|Behavioral|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
79537495|NCT01462448|Procedure|Blood Draw|Single blood draw of 30 ml
79537496|NCT01462474|Drug|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
79839393|NCT02552862|Drug|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
79243745|NCT02731131|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
79243746|NCT02731131|Drug|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
79243747|NCT02746705|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
79243748|NCT02746705|Device|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
79243749|NCT02746705|Behavioral|Cognitive Training Program|
79537497|NCT01462474|Drug|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
79537498|NCT01462474|Radiation|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
79537499|NCT01462487|Drug|Treatment with zanamivir|Subjects treated with zanamivir
79537500|NCT01462500|Drug|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
79537501|NCT01462513|Biological|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
79537502|NCT01462513|Biological|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
79537503|NCT01462552|Drug|Lapatanib|Prescription of lapatinib (Tykerb)
79537504|NCT01462591|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
79243750|NCT04585724|Drug|Abemaciclib|Given PO
79537505|NCT01462604|Other|non-drug intervention educational programme|educational programme
79537506|NCT01462617|Drug|GSK2269557|Study Drug
79694419|NCT04661553|Device|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
79243751|NCT04585724|Drug|Palbociclib|Given PO
79243752|NCT04585724|Other|Quality-of-Life Assessment|Ancillary studies
79243753|NCT04585724|Drug|Ribociclib|Given PO
79694420|NCT04661553|Device|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
79243754|NCT03608111|Other|single task balance training|single task balance training
79243755|NCT03608111|Other|dual task balance training|dual task balance training
79243756|NCT03386877|Procedure|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
79537507|NCT01462617|Drug|GSK2269557 matching placebo|Study Drug
79537508|NCT01462643|Drug|LAS41004|once daily, topical ointment, 100 microgram per day
79537509|NCT01462656|Drug|Non-EZG containing AED polytherapy|AED polytherapy without EZG
79537510|NCT01462656|Drug|EZG containing AED polytherapy|AED polytherapy including EZG
79537511|NCT01462656|Drug|Non-EZG AED monotherapy|AED monotherapy without EZG
79537512|NCT01462656|Drug|EZG AED monotherapy|Any off-label use of EZG as monotherapy
79537513|NCT01462669|Drug|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
79537514|NCT01462669|Drug|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
79537515|NCT01462669|Drug|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
79537516|NCT01462669|Drug|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
79537517|NCT01462708|Drug|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not >10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.
79537518|NCT01462721|Device|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
79694421|NCT05134025|Other|Pump settings|Alteration in the pump setting prior to exercise commencement
79694422|NCT04661670|Device|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
79694423|NCT02470884|Device|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
79694424|NCT05114174|Other|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
79694425|NCT04661826|Drug|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
79839394|NCT02552862|Drug|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
79694426|NCT05110391|Drug|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
79243757|NCT02237261|Drug|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
79243758|NCT03386643|Drug|Bifidobacterium animalis subsp. lactis HN019|The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
79243759|NCT03386643|Drug|Clobetasol propionate 0.05%|The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
79243760|NCT02746627|Behavioral|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
79243761|NCT02746627|Behavioral|Education|Educational materials on diabetes management
79537519|NCT01462734|Procedure|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
79537520|NCT01462747|Device|KULIST|Twice daily dosing for 8 weeks
79537521|NCT01462786|Drug|ATX-101|2 mg/cm2 ATX-101
79382799|NCT03473847|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
79694427|NCT04661631|Diagnostic Test|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
79537522|NCT01462799|Behavioral|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
79382800|NCT03473847|Device|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
79839395|NCT00661778|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
79243762|NCT04456166|Dietary Supplement|noNPO|"Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography."
79243763|NCT02237287|Other|wound dressing with VAC and sNAG without antiaggregation|
79694428|NCT00538187|Drug|obatoclax mesylate|Given IV
79694429|NCT00538187|Drug|bortezomib|Given IV
79537523|NCT01462799|Behavioral|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
79243764|NCT02237287|Procedure|wound dressing with VAC|
79694430|NCT00538187|Other|laboratory biomarker analysis|correlative study
79694431|NCT00538187|Other|pharmacological study|correlative study
79243765|NCT02237287|Drug|wound dressing with VAC and sNAG under Antiaggregation|
79694432|NCT04661709|Drug|Wen Xin granule|one dose daily, two times per day.
79694433|NCT04661709|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
79694434|NCT04661709|Drug|Atorvastatin Calcium|20 mg tablet, one tablet each night.
79694435|NCT04661709|Drug|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
79694436|NCT04661709|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
79694437|NCT04661709|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
79694438|NCT04661709|Drug|WXG placebo|one dose daily, two times per day.
79694439|NCT04661709|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
79839396|NCT00661778|Drug|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
79839397|NCT00661778|Drug|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
79694440|NCT04661709|Drug|glyceryl trinitrate|be taken when angina pectoris attacks.
79694441|NCT00538226|Device|External Electric Muscle Stimulation|
79243766|NCT05171985|Procedure|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
79243767|NCT02237365|Drug|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
79694442|NCT02466867|Drug|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
79694443|NCT02466867|Drug|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
79694444|NCT02462850|Drug|CL-108|
79694445|NCT00538265|Drug|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
79839398|NCT04045080|Device|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
79839399|NCT04045080|Other|Training|training
79839400|NCT04045080|Other|OT Training|training
79839401|NCT00789932|Behavioral|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
79839402|NCT00789932|Behavioral|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
79243768|NCT02237365|Drug|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
79243769|NCT02237365|Drug|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
79243770|NCT04396652|Procedure|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
79243771|NCT04396652|Procedure|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
79243772|NCT04396652|Procedure|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
79243773|NCT03383367|Behavioral|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
79243774|NCT04499846|Other|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
79243775|NCT03379935|Procedure|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
79243776|NCT02856113|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets.
79537524|NCT01462825|Dietary Supplement|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
79694446|NCT00538265|Drug|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
79382801|NCT03473847|Device|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
79382802|NCT03473847|Device|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
79382803|NCT04273035|Drug|Midazolam oral solution|Oral Buccolam
79537525|NCT01462825|Dietary Supplement|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
79537526|NCT01462838|Biological|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
79537527|NCT01462851|Drug|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
79694447|NCT00538265|Drug|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
79537528|NCT01462851|Drug|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
79839403|NCT04047212|Diagnostic Test|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
79839404|NCT04047212|Diagnostic Test|periodontal examination|Periodontal clinical examination to all by periodontal charting
79839405|NCT00319735|Procedure|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
80010004|NCT02162888|Drug|Test Product (Bendamustine)|
80010005|NCT04494867|Device|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
80010006|NCT04494867|Other|Standard of Care|Standard temperature management and treatment
80010007|NCT01569035|Drug|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
79243777|NCT02856113|Drug|Placebo|Alogliptin placebo-matching tablets.
79839406|NCT00319735|Procedure|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
79839407|NCT00319735|Procedure|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
79839408|NCT02556242|Other|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
79839409|NCT02556242|Other|Generalised Indoor residual spraying|IRS is carried out as normally practiced
79839410|NCT01062139|Drug|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
79839411|NCT01062139|Drug|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
79243778|NCT04471766|Other|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents > 10 years old
79243779|NCT04471766|Behavioral|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
79243780|NCT03386565|Drug|sodium chloride solution|intraoperative IV infusion
79243781|NCT03386565|Drug|Lidocaine|intraoperative IV infusion
79243782|NCT04351802|Diagnostic Test|Lung ultrasound|Focused lung ultrasound examination
79243783|NCT04273724|Other|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
79382804|NCT04273035|Device|IPAD|Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
79382805|NCT02836899|Drug|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
79537529|NCT01462851|Drug|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
79537530|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
79537531|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
79382806|NCT02836899|Other|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
79839412|NCT00780650|Drug|Atomoxetine|80 mg oral dose, once per day for 6 weeks
79243784|NCT04055636|Diagnostic Test|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
79243785|NCT04055636|Diagnostic Test|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
79243786|NCT04055636|Diagnostic Test|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
79243787|NCT05171829|Other|Track U|Track U diary
79243788|NCT02237339|Drug|Allopurinol|Uric acid lowering medication.
79243789|NCT02237339|Drug|Placebo|
79243790|NCT03386331|Behavioral|diet and exercise|Diet and lifestyle intervention
79243791|NCT02034929|Device|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
79382807|NCT01454817|Behavioral|Quality of life|Improving Quality of Life
79382808|NCT01454895|Behavioral|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
79537532|NCT01462864|Behavioral|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
79537533|NCT01462903|Biological|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
79694448|NCT02462811|Drug|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
79694449|NCT02462811|Drug|Placebo|
79694450|NCT02462811|Drug|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
79694451|NCT00538382|Drug|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
79694452|NCT00538421|Drug|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
79694453|NCT00538421|Drug|Sevoflurane|0,7-1,5 MAC
79694454|NCT04661475|Drug|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
79243792|NCT02034929|Device|Standard colonoscopy|Standard colonoscopy
79243793|NCT04048538|Other|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
79243794|NCT04048538|Other|usual standard of care|individuals will receive treatment as per the usual standard of care
79243795|NCT05171751|Drug|Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
79243796|NCT02035007|Device|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
79243797|NCT03143192|Combination Product|Micropulse Laser|Aflibercept injection with Micropulse laser.
79243798|NCT03143192|Device|Sham Laser|Aflibercept injection with Sham Laser
79537534|NCT01462916|Dietary Supplement|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control [I/C] and control to intervention [C/I] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
79537535|NCT01462968|Device|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
79537536|NCT01462994|Other|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
79537537|NCT01463020|Behavioral|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
79537538|NCT01463020|Other|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
79537539|NCT01463046|Drug|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
79243799|NCT03386175|Device|therapy with negative pression and instillation|therapy with negative pression and instillation
79382809|NCT01454895|Behavioral|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
79537540|NCT01463046|Drug|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
79537541|NCT01463046|Drug|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
79537542|NCT01463085|Other|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
79537543|NCT01463124|Behavioral|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
79537544|NCT01463124|Behavioral|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
79537545|NCT01463137|Behavioral|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
79694455|NCT04661475|Drug|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
79694456|NCT04661436|Diagnostic Test|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
79694457|NCT00554268|Drug|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
79243800|NCT04000685|Other|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
79243801|NCT04000685|Other|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
79537546|NCT01463150|Drug|Clopidogrel|Clopidogrel 150mg per day for 15 days
79537547|NCT01463150|Drug|Prasugrel|Prasugrel 5mg per day for 15 days
79537548|NCT01463163|Drug|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
79694458|NCT00538499|Drug|Fentanyl citrate|
79694459|NCT00538499|Drug|Bupivacaine hydrocloride|
79694460|NCT00538499|Procedure|videothoracoscopy|
79694461|NCT00554307|Device|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
79694462|NCT00538538|Drug|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
79694463|NCT00538538|Drug|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
79694464|NCT00554346|Drug|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
79694465|NCT04661046|Drug|Traditional Chinese Medicine|Chinese medicine prescription
79694466|NCT00538655|Drug|modafinil|400mg vs. 200mg (PO) daily
79243802|NCT04000685|Other|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
79243803|NCT03143348|Procedure|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
79243804|NCT03143348|Procedure|Multiple blood draws|Blood draw at 6 peri-operative time points.
79243805|NCT03143348|Procedure|Multiple blood draws|Blood draw at 7 peri-operative time points
79537549|NCT01463163|Drug|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
79537550|NCT01463176|Behavioral|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
79537551|NCT01463189|Behavioral|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
79382810|NCT01454895|Behavioral|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
79537552|NCT01463215|Drug|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
79537553|NCT01463228|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
79537554|NCT01463228|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
79382811|NCT02902029|Drug|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
79694467|NCT04661319|Procedure|video editing training|"The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~Select a random experimental group.~For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
79694468|NCT00538694|Drug|daptomycin|
79694469|NCT02436096|Drug|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
79382812|NCT02902029|Drug|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
79382813|NCT02902029|Drug|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
79382814|NCT02933697|Drug|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
79382815|NCT02933697|Drug|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
79382816|NCT04848285|Other|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
79382817|NCT04848285|Other|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
79382818|NCT01455129|Drug|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
79382819|NCT01455129|Drug|placebo|placebo, once daily, inhaled by HandiHaler
79694470|NCT02436096|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
79694471|NCT00538772|Other|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
79694472|NCT02435121|Drug|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
79694473|NCT00538811|Drug|interferon alpha-2b, ribavirin, interferon-gamma,|
79694474|NCT00538811|Drug|interferon alpha-2b, ribavirin, amantadine|
79694475|NCT04660773|Device|NB UVB phototherapy|ultraviolet phototherapy sessions
79694476|NCT04660773|Drug|Pregabalin|oral medication
79694477|NCT00538889|Drug|Lecozotan SR|
79382820|NCT02790411|Device|Imaging devices|technological adjustment tests
79382821|NCT02790411|Device|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
79382822|NCT01455207|Behavioral|Neuropsychological testing|assessment of memory, executive functions and ataxia
79382823|NCT01455207|Biological|blood draw|hepatic markers, red blood markers and vitamin markers
79382824|NCT01455207|Genetic|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
79694478|NCT00538889|Drug|Citalopram|
79694479|NCT02413827|Drug|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
79839413|NCT00780650|Drug|Placebo|80 mg dose once per day for 6 weeks
79537555|NCT01463241|Behavioral|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills [Belief Repair, Action, Solving Problems, Incentives, and Calming]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
79537556|NCT01463280|Drug|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
79537557|NCT01463319|Other|air insufflation|air insufflation during insertion phase colonoscopy
79694480|NCT02413827|Drug|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
79694481|NCT00538928|Other|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
79694482|NCT04660656|Diagnostic Test|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
79694483|NCT00538967|Drug|doxycycline|2 weeks once daily
79694484|NCT04660851|Behavioral|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
79382825|NCT01455207|Other|Brain imaging examination|MRI, DTI and PET examinations
79694485|NCT02410356|Drug|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
79694486|NCT02410356|Drug|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
79694487|NCT00539084|Device|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
79694488|NCT04660734|Procedure|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
79694489|NCT00539123|Behavioral|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
79382826|NCT01455363|Procedure|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
79382827|NCT01455363|Other|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
79537558|NCT01463319|Other|warm water irrigation|warm water irrigation during insertion phase colonoscopy
79694490|NCT00539123|Behavioral|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
79694491|NCT02385201|Device|Senza|Spinal Cord Stimulation
79839414|NCT00653328|Drug|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
79839415|NCT00653328|Drug|doxil|50 mg/m2 intravenously every 28 days
80010008|NCT02762708|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
80010009|NCT02762708|Behavioral|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
79839416|NCT01664182|Biological|Bevacizumab|Given IV
79839417|NCT01664182|Drug|Pazopanib Hydrochloride|Given PO
79382828|NCT01455363|Other|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
79382829|NCT02865447|Device|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
79839418|NCT01664182|Drug|Sorafenib Tosylate|Given PO
79839419|NCT01664182|Drug|Sunitinib Malate|Given PO
79839420|NCT01664182|Biological|Trebananib|Given IV
79839421|NCT00780728|Drug|Sildenafil|
79839422|NCT00809172|Drug|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
79382830|NCT04846959|Drug|Risankizumab|Subcutaneous Injection
79382831|NCT04846959|Drug|Comparator|Subcutaneous or Intravenous Injection
79382832|NCT01455441|Other|Training and liraglutide|
79382833|NCT01455441|Other|Training and placebo|
79694492|NCT00539318|Procedure|Blood drawing|Once when enroll in study
79839423|NCT00809172|Drug|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
79839424|NCT02552940|Drug|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
80016858|NCT02283008|Behavioral|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
79243806|NCT03985007|Drug|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
79243807|NCT05161923|Procedure|Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.[1] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
79243808|NCT03971084|Other|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
79243809|NCT03971084|Other|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
79243810|NCT03379779|Diagnostic Test|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
79243811|NCT02855411|Drug|PF-04958242|Administered as specified in the treatment arm
79243812|NCT02855411|Drug|placebo|placebo, twice daily (BID) for 12 weeks, capsule
79243813|NCT03891368|Other|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
79243814|NCT03891368|Other|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
79243815|NCT04172324|Device|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
79382834|NCT01455675|Drug|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
79382835|NCT01455675|Drug|Placebo|Placebo, 70 ml gargling solution, once daily
79694493|NCT02382510|Drug|TRN-157|
79694494|NCT02382510|Other|Placebo|
79694495|NCT02382510|Drug|Tiotropium|
79694496|NCT00539357|Device|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
79382836|NCT02858583|Procedure|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
79694497|NCT00539396|Drug|Technosphere Insulin|
79694498|NCT04660695|Device|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
79694499|NCT03456986|Behavioral|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
79694500|NCT03456986|Behavioral|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
79694501|NCT02376465|Drug|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
79694502|NCT02376465|Drug|PEG based bowel preparation|Oral bowel preparation for colonoscopy
79694503|NCT00539435|Procedure|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
79694504|NCT04660578|Procedure|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
79694505|NCT00539474|Procedure|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
79694506|NCT04660266|Diagnostic Test|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
79694507|NCT00539630|Drug|Docetaxel|
79839425|NCT00780806|Biological|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
79839426|NCT00780806|Procedure|Blood draw|Blood draw
79694508|NCT04660461|Drug|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
79694509|NCT04660461|Drug|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
79694510|NCT04685330|Procedure|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
79694511|NCT04685330|Device|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
79694512|NCT00539669|Drug|Docetaxel|
79839427|NCT02551380|Drug|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
79839428|NCT02551380|Other|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
79839429|NCT00784862|Drug|Anastrozole|1mg, orally, once daily
79839430|NCT00784862|Drug|Tamoxifen|20mg, orally, once daily
79839431|NCT02556476|Procedure|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
79839432|NCT02556476|Procedure|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
79839433|NCT02556476|Procedure|renal replacement therapy|the procedures used to treat acute kidney injury
80010010|NCT02762708|Drug|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
79243816|NCT04172324|Other|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
79243817|NCT03379623|Other|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
79243818|NCT03607721|Device|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
79839434|NCT02556476|Procedure|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
79839435|NCT00642642|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
79243819|NCT03308721|Drug|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."
79243820|NCT03308721|Drug|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
79839436|NCT00642642|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
79243821|NCT04122482|Behavioral|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
79243822|NCT05152407|Other|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
79243823|NCT02745145|Drug|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
79243824|NCT02745145|Drug|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
79243825|NCT02745145|Drug|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
79243826|NCT03646448|Behavioral|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
79243827|NCT03383055|Biological|CMV-MVA Triplex Vaccine|"CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~TDap administered on Day 56"
79382837|NCT02858583|Procedure|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
79382838|NCT01455753|Other|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
79382839|NCT01455753|Other|Base Proximity|We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
79537559|NCT01463332|Drug|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
79537560|NCT01463332|Drug|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
79382840|NCT03823053|Other|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
79537561|NCT01463332|Drug|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
79537562|NCT01463345|Other|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
79537563|NCT01463345|Other|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
79537564|NCT01463436|Dietary Supplement|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
79537565|NCT01463436|Dietary Supplement|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
79537566|NCT01463449|Procedure|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
79694513|NCT00554424|Drug|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
79694514|NCT00554424|Drug|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
79839437|NCT00780884|Device|acupuncture|16 sessions of acupuncture treatment, twice a week.
79839438|NCT00818064|Drug|anti-IL-20|Single s.c. injection (per dose cohort)
79839439|NCT00818064|Drug|placebo|Single s.c. injection (per dose cohort)
79839440|NCT00784940|Drug|Anastrozole|1mg, orally, once daily
79839441|NCT00784940|Drug|Tamoxifen|20mg, orally, once daily
79839442|NCT00790166|Device|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
79382841|NCT03823053|Other|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
79382842|NCT01455831|Drug|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
79382843|NCT01455831|Drug|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
79537567|NCT01463475|Procedure|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
79694515|NCT00539708|Procedure|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
79694516|NCT04660305|Drug|AT278|Concentrated rapid acting insulin aspart
79694517|NCT04660305|Drug|NovoRapid|Rapid acting insulin aspart
79537568|NCT01463488|Drug|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
79694518|NCT00554502|Drug|supportive therapy with: ACE-inhibitor / ARB / Statin|"Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~Other antihypertensive medications depending on the clinical decision and following current guidelines.~Statin therapy~Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
79694519|NCT00554502|Drug|supportive and immunosuppressive therapy|"supportive therapy as outlined above~depending on GFR:~methylprednisolone and prednisolone~cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~Concomitant medication with the immunosuppressive treatment following current clinical practice"
79694520|NCT00539786|Drug|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
79537569|NCT01463488|Drug|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
79537570|NCT01463501|Other|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
79694521|NCT00539825|Drug|GSK704838|
79839443|NCT00790166|Device|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
79839444|NCT00790166|Device|CPAP + No added humidity|ambient humidity
79839445|NCT02552706|Dietary Supplement|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
79839446|NCT02552706|Dietary Supplement|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
79839447|NCT00790244|Drug|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
79839448|NCT00790244|Drug|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
79839449|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
79839450|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
79537571|NCT01463501|Other|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
79537572|NCT01463514|Procedure|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
79537573|NCT01463514|Procedure|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
79243828|NCT04083014|Drug|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
79537574|NCT01463540|Device|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
79694522|NCT04660071|Other|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
79694523|NCT04660071|Other|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
79694524|NCT00554541|Other|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
79694525|NCT00540020|Other|Rehabilitation|
79694526|NCT00554580|Procedure|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
79243829|NCT03386097|Other|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
79382844|NCT04840641|Drug|Flucloxacillin|Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
79694527|NCT00554580|Procedure|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
79694528|NCT02359227|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
79839451|NCT00818142|Behavioral|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
79243830|NCT03563066|Drug|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 & 56.
79382845|NCT01455909|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
79694529|NCT00540098|Drug|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
79382846|NCT01455909|Drug|sitagliptin|sitagliptin oral 100 mg/day
79382847|NCT04844619|Drug|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
79382848|NCT04844619|Drug|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
79243831|NCT03563066|Drug|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 & 56.
79243832|NCT05152095|Other|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 ~ 3 hours, for 5 days.
79243833|NCT05152095|Other|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
79243834|NCT03606265|Device|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
79243835|NCT03606265|Device|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
79243836|NCT03143114|Procedure|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
79382849|NCT01757171|Drug|Cabazitaxel|20mg IV over 1 hour every 3 weeks
79537575|NCT01463540|Device|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
79537576|NCT01463553|Procedure|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
79537577|NCT01463566|Device|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
79537578|NCT01463579|Other|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
79537579|NCT01463579|Other|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
79537580|NCT01463592|Biological|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
79537581|NCT01463592|Drug|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
79243837|NCT03386019|Other|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
79382850|NCT04847349|Dietary Supplement|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
79537582|NCT01463592|Biological|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
79537583|NCT01463605|Drug|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
79537584|NCT01463644|Drug|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
79537585|NCT01463644|Drug|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
79537586|NCT01463709|Device|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
79537587|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
79537588|NCT01463735|Dietary Supplement|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
79382851|NCT04847349|Dietary Supplement|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
79382852|NCT04847349|Dietary Supplement|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
79537589|NCT01463748|Other|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
79537590|NCT01463748|Other|Placebo|starch
79537591|NCT01463761|Device|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
79537592|NCT01463774|Drug|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
79694530|NCT00540098|Drug|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
79694531|NCT00540098|Drug|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
79694532|NCT00540098|Drug|Placebo + relaxation|placebo pill once daily + regular relaxation training
79694533|NCT00540137|Drug|nevirapine|400mg once daily
79694534|NCT00540137|Drug|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
79694535|NCT04660110|Drug|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
79305826|NCT04404153|Device|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
80010011|NCT02762708|Drug|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
80010012|NCT03699969|Radiation|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
80010013|NCT03841565|Biological|Daratumumab|Given IV
80010014|NCT03841565|Drug|Dexamethasone|Given PO
80010015|NCT03841565|Drug|Pomalidomide|Given PO
80010016|NCT02162966|Drug|High Dose Colistin|High Dose Colistin
79382853|NCT01456065|Biological|Procure|The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
79243838|NCT03386019|Other|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
79243839|NCT03386019|Other|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
79243840|NCT03111134|Procedure|modified component separation technique|a new abdomen closure technique based on component separation technique
79382854|NCT01456065|Biological|Procure|The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
79382855|NCT04842123|Diagnostic Test|Electrocardiogram|Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
79382856|NCT02555787|Drug|Tacrolimus|oral
79382857|NCT04847583|Drug|Telacebec|Telacebec 100 mg tablet
79382858|NCT04847583|Drug|COVID-19 Standard of care|The Standard of Care treatment and administration thereof will be determined by the Investigator
80010017|NCT02162966|Drug|Standard Dose Colistin|Standard Dose Colistin
79382859|NCT01730729|Drug|cabergoline|Given orally
79382860|NCT03822819|Dietary Supplement|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
79382861|NCT03822819|Dietary Supplement|placebo capsules|Daily uptake of placebo capsule for three weeks
79382862|NCT01756157|Biological|CINRYZE with rHuPH20|
79382863|NCT02931513|Other|Blood samples|
79382864|NCT02931513|Device|Fibroscan|
79382865|NCT02931513|Other|Questionnaires|
79382866|NCT02931513|Biological|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
79382867|NCT01756079|Drug|boceprevir|
79382868|NCT01756079|Biological|PegIFN-2b|
79382869|NCT01756079|Drug|RBV|
79382870|NCT05587101|Diagnostic Test|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
80010018|NCT02839317|Biological|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
79537593|NCT01463774|Drug|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
80010019|NCT04697420|Procedure|Thoracic paravertebral block|Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
80010020|NCT04697420|Procedure|Transversus abdominis plane block|Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
80010021|NCT04919525|Device|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
80010022|NCT03540290|Procedure|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
80016859|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
79382871|NCT05587101|Diagnostic Test|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
79382872|NCT05587101|Diagnostic Test|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
79243841|NCT05151939|Diagnostic Test|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
79537594|NCT01463774|Drug|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
79537595|NCT01463787|Procedure|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
79839452|NCT00815958|Procedure|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
79839453|NCT00815958|Procedure|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
79839454|NCT00785018|Drug|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
79839455|NCT00785018|Drug|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
79382873|NCT04272645|Drug|Abemaciclib 200 MG|200 MG orally BID Days 1-21
79382874|NCT04272645|Drug|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
79839456|NCT00821340|Genetic|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
79537596|NCT01463787|Procedure|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
79537597|NCT01463800|Behavioral|Structured exercise training|12 weeks low level ambulatory structured exercise training
79537598|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
79694536|NCT00540176|Drug|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
79694537|NCT02341560|Drug|QPI-1007 Injection - 1.5 mg|
79839457|NCT00790322|Drug|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
79839458|NCT00790322|Other|Placebo|Solution for oral use
80010023|NCT01595321|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
79382875|NCT04272645|Drug|Abemaciclib 150 MG|150 MG orally BID Days 1-21
79382876|NCT03822585|Diagnostic Test|CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study|"high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%."
79382877|NCT04390815|Drug|Insulin|Adding insulin to conventional wound treatment
79382878|NCT01456611|Drug|Diclofenac|Diclofenac Sodium Gel 1%
79382879|NCT01456611|Drug|Placebo|Placebo Topical Gel
79537599|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
79537600|NCT01463813|Dietary Supplement|Placebo|Inactive placebo
79694538|NCT02341560|Drug|QPI-1007 Injection - 3.0 mg|
79694539|NCT02341560|Other|Sham Injection Procedure|Sham Procedure
79694540|NCT00540215|Other|Glucagonlike peptide|450 nmol native form, synthetic
79694541|NCT00540254|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
79694542|NCT00540254|Other|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
79694543|NCT00540332|Drug|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
79694544|NCT00540332|Drug|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
79694545|NCT02336685|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
79694546|NCT02336685|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
79694547|NCT02336685|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
79382880|NCT01456689|Drug|LGH447|
79839459|NCT00534352|Drug|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
79839460|NCT00642174|Drug|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
79839461|NCT00642174|Drug|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
79839462|NCT04001296|Behavioral|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
79839463|NCT00992290|Biological|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
79839464|NCT00992290|Biological|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
80010024|NCT01595321|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
80010025|NCT01595321|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).
79839465|NCT02550444|Drug|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
79382881|NCT01456689|Drug|midazolam|
79382882|NCT05827185|Biological|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
79537601|NCT01463852|Drug|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
79537602|NCT01463865|Drug|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
79537603|NCT01463865|Drug|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
79537604|NCT01462760|Device|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
79839466|NCT02550444|Drug|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
79839467|NCT02550444|Drug|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
80010026|NCT01595321|Drug|FOLFIRINOX|FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).
80010027|NCT03699891|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
79243842|NCT05151939|Diagnostic Test|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
79537605|NCT01462760|Device|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
79537606|NCT01463904|Procedure|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
79537607|NCT01463917|Drug|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
79537608|NCT01463917|Drug|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
79694548|NCT02336685|Drug|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
79694549|NCT00540410|Drug|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
79839468|NCT00665366|Drug|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
79839469|NCT00665366|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
79839470|NCT00665366|Drug|Lithium|Participant's ongoing dose
79839471|NCT00665366|Drug|Valproate|Participant's ongoing dose
79839472|NCT00992368|Procedure|reduction mammaplasty|patients submitted to reduction mammaplasty
80010028|NCT02167724|Other|Bucco-dental examination|
80010029|NCT02167724|Other|Blood sample|
80010030|NCT02167724|Other|Clinical and social questionnaire|
79537609|NCT01463930|Behavioral|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
79537610|NCT01463930|Behavioral|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
79537611|NCT01463943|Other|Probiotic|
79537612|NCT01463943|Other|Probiotic|
79537613|NCT01463943|Other|Probiotic|
79537614|NCT01463956|Drug|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
79537615|NCT01463956|Biological|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
79537616|NCT01463956|Drug|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: <65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; >105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
79537617|NCT01464008|Drug|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
79537618|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
79694550|NCT00540410|Drug|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
80010031|NCT03699813|Other|Comparison of two approaches to bleeding management|
80010032|NCT02164214|Drug|etanercept Treatment|
79694551|NCT00540488|Other|Adult enteral formula|
79382883|NCT05827185|Biological|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
79537619|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
79537620|NCT01464073|Behavioral|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
79537621|NCT01464073|Behavioral|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
79537622|NCT01464073|Behavioral|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
79694552|NCT04659837|Behavioral|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
79694553|NCT00540527|Drug|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
79694554|NCT00540527|Drug|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
80010033|NCT03698565|Other|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
80010034|NCT03768947|Other|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of ~12-15 visits (45 min each) of immersion in to a hot tub.
80010035|NCT03699735|Device|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
80010036|NCT02164292|Procedure|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
80010037|NCT03722849|Drug|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
79537623|NCT01464073|Dietary Supplement|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
79537624|NCT01464086|Other|whole body MRI|whole body MRI at inclusion, one and two years
79537625|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
79537626|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
79537627|NCT01464112|Drug|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
79537628|NCT01464125|Drug|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
79537629|NCT01464125|Drug|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
79537630|NCT01464138|Drug|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
79537631|NCT01464203|Other|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
79537632|NCT01464203|Other|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
79537633|NCT01464242|Drug|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
79839473|NCT01141738|Behavioral|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
80010038|NCT03722849|Drug|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
80010039|NCT03722849|Other|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
80010040|NCT03699657|Device|DSM|Monopolar RFA using dual switching mode (DSM)
79382884|NCT05827185|Biological|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
79382885|NCT05827185|Biological|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
79382886|NCT05827172|Procedure|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
79382887|NCT05827172|Other|medical therapy|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
79537634|NCT01464242|Drug|Placebo|Placebo 400mg orally 3 times a day for 20 days
79537635|NCT01464242|Drug|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
79537636|NCT01464281|Drug|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
79537637|NCT01464294|Device|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
79537638|NCT01464294|Device|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
79537639|NCT01464320|Drug|ABT-614|Active
79537640|NCT01464320|Drug|Placebo Comparator|Placebo
79537641|NCT01464372|Device|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
79537642|NCT01464372|Device|Sham Nerve Stimulation Device|Use of the sham device
79537643|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
79537644|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237 mL
79537645|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
79537646|NCT01464398|Behavioral|Stress reduction|8 weekly sessions
79537647|NCT01464398|Behavioral|Stress reduction with Health education|8 weekly sessions
79537648|NCT01464450|Drug|Rivaroxaban|Single 20 mg-dose
79537649|NCT01464463|Behavioral|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
79537650|NCT01464463|Behavioral|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
79537651|NCT01464463|Behavioral|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
79537652|NCT01464476|Drug|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
79537653|NCT01464476|Drug|Placebo|Dose-matched placebo. Once daily, oral administration
79839474|NCT01141738|Behavioral|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
79537654|NCT01464489|Drug|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
79537655|NCT01464489|Drug|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
79537656|NCT01466608|Drug|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
79537657|NCT01463657|Device|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
79694555|NCT04659720|Device|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
79694556|NCT04659720|Behavioral|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
79839475|NCT00775684|Drug|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
79694557|NCT00540605|Drug|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
79694558|NCT04659915|Drug|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
79694559|NCT04659915|Drug|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
79694560|NCT00557427|Drug|hypericum|250mg tablets twice daily for 8 weeks
79839476|NCT00775684|Drug|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
79694561|NCT00557427|Drug|fluoxetine|20mg - 40mg daily for 8 weeks
79243843|NCT03935906|Other|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
79694562|NCT00540800|Drug|docetaxel|given in combination with epirubicin or capecitabine
79694563|NCT00540800|Drug|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
79243844|NCT03935906|Other|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
79243845|NCT05151861|Other|Complete removal of pharmacological treatment|Removal of treatment
79243846|NCT05151861|Drug|Control|Maintenance of pharmacological treatment
79243847|NCT03605875|Behavioral|Web-App|Cambian IT Health solutions from Surrey BC developed the infrastructure
79243848|NCT03605875|Behavioral|Paper|Contains similar questions to the Web-App tool
79243849|NCT03379467|Other|SMS Reminder|A text message sent as a reminder for immunization on the registered phone number
79243850|NCT03379467|Other|Interactive Reminder|A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
79243851|NCT05144607|Other|Muscle Pressure curve (Pmus)|The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
79243852|NCT03111056|Behavioral|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
79243853|NCT03115749|Other|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
79243854|NCT03115749|Other|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
79243855|NCT03140384|Biological|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
79243856|NCT05135403|Device|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
79243857|NCT05117307|Drug|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
79243858|NCT03739268|Drug|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
79243859|NCT03739268|Drug|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
79537658|NCT01463657|Device|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
79537659|NCT01466634|Procedure|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
79537660|NCT01466647|Drug|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
79537661|NCT01466712|Drug|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
79537662|NCT01466712|Drug|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
80010041|NCT03699657|Device|SSM|Monopolar RFA using single switching mode (SSM)
79537663|NCT01466738|Biological|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
80010042|NCT03699657|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
79243860|NCT05109507|Behavioral|Visitor Mindset|Single-session, self-guided intervention
79537664|NCT01466738|Biological|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
79537665|NCT01466777|Procedure|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
79537666|NCT01466777|Procedure|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
79537667|NCT01466803|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
79537668|NCT01466803|Drug|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
79243861|NCT05109507|Behavioral|Relaxing with Nature|Single-session, self-guided intervention
79243862|NCT02787590|Drug|Simvastatin|
79243863|NCT02787590|Drug|Matched Placebo (for Simvastatin)|
79537669|NCT01466816|Dietary Supplement|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
79537670|NCT01466829|Drug|Parathyroid hormone|100 microgram daily. S.c
79537671|NCT01466829|Drug|Placebo|Placebo; saline injection.
79537672|NCT01466842|Procedure|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
79537673|NCT01466855|Drug|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
79694564|NCT00540800|Drug|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
79694565|NCT00540878|Drug|SB-751689 oral tablets (400 mg)|
79694566|NCT00540917|Procedure|cooling spray during laser treatment|skin temperature measurement
79694567|NCT04659876|Diagnostic Test|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
79694568|NCT00540956|Drug|cytarabine|
79694569|NCT00540956|Other|laboratory biomarker analysis|
79694570|NCT04678596|Device|EonAligner|EonAligner system is one stage system.
79694571|NCT04678596|Device|Clearfix|Clearfix system is three-stage system.
79694572|NCT00541073|Dietary Supplement|vitamin B12|
79694573|NCT00541073|Drug|cisplatin|
79694574|NCT00541073|Drug|pemetrexed disodium|
79694575|NCT00541073|Genetic|gene expression analysis|
79243864|NCT04041674|Biological|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
79694576|NCT00541073|Other|laboratory biomarker analysis|
79694577|NCT00541073|Other|pharmacological study|
79694578|NCT04678323|Drug|Lifestyle Management|Participants in this group will receive lifestyle management.
79694579|NCT00541112|Biological|cetuximab|
79694580|NCT00541112|Drug|capecitabine|
79243865|NCT04041674|Biological|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
79243866|NCT04041674|Biological|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
79243867|NCT04041674|Biological|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
79243868|NCT04041674|Biological|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
79537674|NCT01466868|Drug|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
79537675|NCT01466894|Biological|IMM 124-E|Tablets orally twice a day for 24 weeks
79694581|NCT00541112|Drug|fluorouracil|
79694582|NCT00541112|Drug|leucovorin calcium|
80010043|NCT02170844|Drug|BIBR 1048 MS|
80010044|NCT02170844|Drug|Placebo of BIBR 1048 MS|
79243869|NCT03379311|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
79537676|NCT01466894|Biological|Placebo|Tablets orally twice daily for 24 weeks
79382888|NCT05827094|Other|Mobile app|The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.
79243870|NCT03699410|Radiation|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
79694583|NCT00541112|Drug|oxaliplatin|
79243871|NCT03699410|Drug|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
79382889|NCT05827094|Other|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
79382890|NCT05827029|Procedure|Preopertive drink|"Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking."
79382891|NCT05826977|Behavioral|CASI-Plus|See arm description
79382892|NCT05826925|Other|Decision aid|A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
79382893|NCT05826821|Drug|Pirfenidone|Intervention drug
79382894|NCT05826795|Procedure|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
79382895|NCT05826769|Dietary Supplement|Energy- Protein Enriched Nutritional Formula|EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
79382896|NCT05826730|Other|Eccentric Exercises|Eccentric Exercises for neck muscles.
79382897|NCT05826717|Other|Apple|20g fructose in [x] g of apple
79694584|NCT00541112|Procedure|adjuvant therapy|
79694585|NCT00541112|Procedure|conventional surgery|
79694586|NCT00541112|Procedure|neoadjuvant therapy|
79382898|NCT05826717|Other|Mashed apple|20g fructose in [x] g of mashed apple
79382899|NCT05826717|Other|Apple juice|20g fructose in [x] ml apple juice
79382900|NCT05826717|Other|Fructose powder in water|20g fructose in [x] ml water
79382901|NCT05826704|Dietary Supplement|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
79537677|NCT01466907|Other|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
79537678|NCT01466907|Other|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
79694587|NCT00541112|Radiation|radiation therapy|
79694588|NCT04678011|Procedure|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
79694589|NCT00541151|Device|MiniArc|sling system
79694590|NCT04659447|Drug|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
79694591|NCT05086523|Device|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
79694592|NCT05086523|Device|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
79694593|NCT04659525|Drug|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
79694594|NCT04659525|Drug|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
79243872|NCT03699410|Procedure|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
79537679|NCT01466933|Behavioral|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
79537680|NCT01466933|Behavioral|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
79694595|NCT04659525|Drug|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
79694596|NCT03456908|Combination Product|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
79694597|NCT02333643|Drug|CLS003|
79694598|NCT02333643|Drug|Furosemide|
79694599|NCT02333643|Drug|Digoxin|
79694600|NCT02333643|Drug|Vehicle topical|
79694601|NCT03456869|Device|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
79243873|NCT04446195|Behavioral|Individualized Intervention|In this study, patients with the risk factors of insufficient intestinal preparation were treated with individualized intervention (mainly from the following aspects: chronic constipation, intestinal preparation not strictly in accordance with the requirements, body mass index > 25 kg / m2, age > 70 years old, with other diseases such as diabetes, Parkinson's disease, history of stroke or spinal cord injury, etc., application of tricyclic antidepressants or anesthetics).
79243874|NCT04445727|Combination Product|Vitamin C|Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.
79243875|NCT04445727|Combination Product|spinal manipulation|Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.
79243876|NCT04445727|Combination Product|Transcutaneous electrical nerve stimulation (TENS)|Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.
79243877|NCT03379155|Other|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem & Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
79382902|NCT05826691|Procedure|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
79537681|NCT01466946|Behavioral|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin & Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
79537682|NCT01466959|Other|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
79537683|NCT01466959|Other|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
79537684|NCT01466998|Other|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
79694602|NCT04659330|Behavioral|Online education (BdandMe) for injection technique|patients were referred to the relevant modules on BD and Me™ (for online education)
79694603|NCT04659330|Device|4mm needles|Providing a supply of needles for single use of 4mm insulin injection needle.
79694604|NCT00541424|Procedure|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
79694605|NCT02330445|Drug|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
79694606|NCT00541463|Drug|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
79694607|NCT00541463|Drug|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
79694608|NCT04659486|Behavioral|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
79694609|NCT02324985|Drug|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
79694610|NCT02324985|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
79694611|NCT00541541|Procedure|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
79694612|NCT02314299|Drug|MTP-131|
79694613|NCT04659681|Diagnostic Test|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
79694614|NCT04659681|Diagnostic Test|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
80010045|NCT03624465|Device|Levita Magnetic Surgical System|Device for use as a surgical tool.
80010046|NCT02170922|Drug|BIBR 1048 MS tablet|
80010047|NCT02170922|Drug|BIBR 1048 MS solution|
80010048|NCT03698253|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
79243878|NCT03382743|Drug|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
79243879|NCT02976129|Drug|V565|Daily dosing of V565 three times a day orally for 6 weeks
79243880|NCT02976129|Drug|Placebo|Daily dosing of placebo three times a day orally for 6 weeks
79243881|NCT02854631|Drug|Selonsertib|18 mg tablet administered orally once daily
79694615|NCT04659642|Drug|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
79694616|NCT04659642|Drug|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
79694617|NCT04659642|Combination Product|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
79243882|NCT02854631|Drug|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
79243883|NCT02854631|Drug|Placebo|Selonsertib placebo tablet administered orally once daily
79243884|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 14 days
79243885|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
79243886|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 28 days
79243887|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
79537685|NCT01466998|Other|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
79537686|NCT01467011|Drug|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
79537687|NCT01467024|Other|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
79537688|NCT01467050|Other|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
79537689|NCT01467050|Other|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
79694618|NCT00541736|Drug|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
79537690|NCT01467089|Other|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
79537691|NCT01467115|Radiation|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
79537692|NCT01467115|Drug|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
79537693|NCT01467115|Biological|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
79243888|NCT02034773|Drug|Placebo|Placebo will be administered once daily for up to 28 days
79243889|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
79243890|NCT02034773|Drug|CC-220|CC-220 1mg (once every 7 days for 28 days)
79243891|NCT02034773|Drug|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
79243892|NCT02035163|Procedure|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
79243893|NCT03607643|Drug|Cannabidiol|"Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
79243894|NCT03607643|Drug|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
79243895|NCT03607643|Drug|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
79243896|NCT03607643|Drug|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
79243897|NCT03607643|Drug|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
79243898|NCT03607643|Drug|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
79694619|NCT02306811|Drug|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
79694620|NCT00541814|Drug|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
79694621|NCT04659564|Device|User of Dayspring device|The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
79694622|NCT00541853|Drug|Candesartan|Candesartan upto 8mg
79694623|NCT00541853|Drug|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
79382903|NCT05826678|Device|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
80010049|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
79243899|NCT03607643|Drug|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
79382904|NCT05826678|Behavioral|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice[46]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
79382905|NCT05826652|Other|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
79243900|NCT03607643|Drug|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
79382906|NCT05826652|Other|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
79382907|NCT05826626|Device|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation procedure with the administration of serious games for cognitive training using a tablet
79382908|NCT05826626|Behavioral|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
79537694|NCT01467115|Drug|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
79537695|NCT01467115|Drug|Erythropoetin|Subcutaneous or intravenous
79537696|NCT01467115|Drug|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
79537697|NCT01467115|Drug|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
80010050|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
80010051|NCT03698253|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
80010052|NCT02167958|Drug|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)~Fludarabine dosage should be reduced per standard of care."
79382909|NCT05826548|Behavioral|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
79382910|NCT05826548|Behavioral|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
79382911|NCT05826522|Other|observationnal|cohort of blood collection and severals exams
79382912|NCT05826483|Drug|Almonertinib|Almonertinib Mesilate Tablets
79382913|NCT05826444|Diagnostic Test|Echocardiography|Echocardiography with afterload change
79694624|NCT00541853|Drug|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
79243901|NCT03607643|Drug|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
79243902|NCT03496922|Behavioral|Experimental Tobacco Marketplace|See arm group description.
79382914|NCT05826444|Diagnostic Test|Magnetic resonance imaging|Stress-MRI
79243903|NCT03608033|Biological|OMS721|Biological: OMS721
79243904|NCT03608033|Other|Vehicle (D5W or saline)|5% Dextrose in water or normal saline solution
80016860|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
79243905|NCT03952364|Other|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
79382915|NCT05826444|Diagnostic Test|Magnetocardiography|Magnetocardiography
80016861|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
79537698|NCT01467115|Drug|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
80010053|NCT02167958|Drug|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide [50mg/kg] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
80010054|NCT02167958|Drug|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
80010055|NCT02167958|Radiation|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
79243906|NCT02855359|Drug|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
79243907|NCT02855359|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
79243908|NCT02855359|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
79382916|NCT05826444|Diagnostic Test|Histology|Histological analysis
79382917|NCT05826444|Diagnostic Test|Genetics|miRNA sequencing
79382918|NCT05826444|Diagnostic Test|calcium signaling|cardiomyocyte calcium signaling
79694625|NCT02301234|Drug|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
79243909|NCT02855359|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
79243910|NCT02855359|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
79243911|NCT02855359|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
79382919|NCT05826444|Diagnostic Test|IMR|Index of microvascular resistance measurement
79382920|NCT05826444|Diagnostic Test|Angio-IMR|Angiography derived post-processing index if microvascular resistance
79694626|NCT02301234|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
79694627|NCT02301234|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
79694628|NCT02301234|Drug|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
79694629|NCT02301234|Drug|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
79694630|NCT00541892|Other|Medium with no human serum albumine added|See above
79694631|NCT00541892|Other|Conventional medium|See above
79694632|NCT00542048|Drug|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
79243912|NCT01107821|Device|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
79243913|NCT05084456|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
79243914|NCT02032004|Biological|Allogeneic Mesenchymal Precursor Cells (MPCs)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
79243915|NCT02032004|Other|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
79243916|NCT02949297|Device|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
79243917|NCT03607903|Biological|Adalimumab ID|Adalimumab intradermal using MicronJet600 microneedle from NanoPass
79243918|NCT03607903|Biological|Adalimumab SC|Adalimumab subcutaneous using regular needle
79243919|NCT03607903|Other|Saline ID|Saline intradermal using MicronJet600 microneedle from NanoPass
79243920|NCT03607903|Other|Saline SC|Saline subcutaneous using regular needle
79382921|NCT05826431|Device|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
79382922|NCT05826405|Other|No intervention|No intervention, it's an observational study
79382923|NCT05826340|Behavioral|Tailored progressive loading and return to sport|Participants will undergo a 5-stage progressive return to sport tool.
79382924|NCT05826340|Behavioral|Pain guided activity|Participants will be provided on information on how to guide activity based on pain response.
79382925|NCT05826262|Procedure|diagnostic laparoscopy|diagnosis and management of patients with penetrating anterior abdominal wall injuries
79382926|NCT05826249|Drug|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
79382927|NCT05826236|Device|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
79382928|NCT05826210|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
79537699|NCT01467128|Other|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
79694633|NCT02300142|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
79694634|NCT02300142|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
79694635|NCT02300142|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79694636|NCT02300142|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79537700|NCT01467128|Other|No Intervention|Normal hospital pharmaceutical care
79839477|NCT00775684|Drug|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
79839478|NCT04001218|Drug|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
79243921|NCT03141866|Other|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
79382929|NCT05826158|Diagnostic Test|18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)|18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
79694637|NCT02300142|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79694638|NCT00539903|Behavioral|Physical activity (PA) and immigrants|
79839479|NCT04001218|Drug|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
79243922|NCT03141866|Other|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
79382930|NCT05826145|Behavioral|Vocal Expression|There will be a total of 8 sessions. At baseline (week 0), only questionnaires will be completed. There will be 7 treatment sessions beginning at week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration where the vocal expression sessions will be provided.
79382931|NCT05826145|Behavioral|Cognitive Behavioral|There will be 8 treatment sessions where part of the baseline session of session 1 (week 0) will include some instruction, session 2 will occur in week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration. Sessions will include various cognitive-behavioral techniques including completing a grief monitoring diary, imaginal revisiting, cognitive restructuring, describing positive memories of the deceased, and identifying future goals.
79382932|NCT05826106|Procedure|R anastomosis|Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
79382933|NCT05826093|Procedure|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
79382934|NCT05825976|Dietary Supplement|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
79382935|NCT05825976|Other|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
79537701|NCT01467141|Drug|insulin aspart|Injected s.c. (under the skin) three times a day
79537702|NCT01467141|Drug|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
79537703|NCT01467141|Drug|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
79537704|NCT01467180|Device|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
79694639|NCT01214668|Drug|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
79694640|NCT01214668|Drug|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
79694641|NCT00542126|Drug|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
79839480|NCT02556008|Drug|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
79839481|NCT00992524|Drug|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
79839482|NCT00992524|Drug|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
79839483|NCT00785096|Other|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
79839484|NCT00998842|Device|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
79839485|NCT00998842|Device|GE 5000 ECG Monitor System|Wired ECG system
79243923|NCT03125499|Other|Previous treated with TPX-100|No intervention, only observational
79243924|NCT04112797|Biological|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
80010056|NCT02167958|Other|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
79839486|NCT00781040|Other|Severe sepsis vs. non-severe sepsis|To compare these two groups
79839487|NCT00995254|Behavioral|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
79243925|NCT04438850|Drug|Ivermectin|Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
79694642|NCT02886832|Dietary Supplement|Prostate Health formulation|
79839488|NCT00785174|Device|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
80010057|NCT02167958|Drug|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
80016862|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
80016863|NCT02922153|Device|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
80016864|NCT02922153|Drug|Standard of Care|Institutional SOC for pain management will be followed.
79243926|NCT04438850|Other|Placebo|Patients should take placebo orally on an empty stomach with water
79243927|NCT03385863|Drug|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
79243928|NCT03385863|Other|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
79243929|NCT02035111|Drug|Tianshu capsule|
79243930|NCT02035111|Drug|Sugar pill|
79243931|NCT03378999|Dietary Supplement|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
79243932|NCT03378999|Dietary Supplement|Control|Capsules containing microcrystalline cellulose
79694643|NCT02293941|Drug|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
79537705|NCT01467180|Device|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
79839489|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
79839490|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
79243933|NCT03605797|Other|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
79243934|NCT03865394|Biological|Application of allogeneic ADSC stem cells in fibrin gel|Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.
79243935|NCT03865394|Procedure|Standard care in diabetic foot ulcer|Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
79243936|NCT03605641|Other|JUUL|JUUL Virginia Tobacco
79243937|NCT03605641|Other|VUSE Solo|VUSE SOLO Original
79243938|NCT03605641|Other|Conventional Cigarette|Subject preferred conventional cigarette
79243939|NCT03093038|Device|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem & Delta-TT cup with a polyethylene insert
79243940|NCT03093038|Device|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem & Delta Delta-TT cup with a Ceramic insert
79537706|NCT01467193|Dietary Supplement|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
79537707|NCT01467193|Other|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
79694644|NCT02293941|Drug|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
79694645|NCT02293941|Drug|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
79694646|NCT02293941|Drug|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
79694647|NCT00542165|Drug|Alfuzosin|
79694648|NCT02289846|Drug|IW-9179|
79694649|NCT02289846|Drug|Matching Placebo|
79537708|NCT01467206|Behavioral|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
79243941|NCT03093038|Device|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
79694650|NCT00542204|Behavioral|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
79694651|NCT04648800|Drug|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~lyophilised BCG vaccine~one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
79839491|NCT00992680|Device|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
79839492|NCT00642018|Drug|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
79243942|NCT03605563|Procedure|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
80010058|NCT02167958|Drug|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
80010059|NCT02167958|Drug|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
80010060|NCT03698175|Behavioral|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
80010061|NCT03698175|Behavioral|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
79243943|NCT03605563|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
79243944|NCT03382431|Drug|PC786|Repeat doses
79537709|NCT01467206|Behavioral|Standard care|Standard care as it is given to all stoke patients after stroke
79243945|NCT03382431|Drug|Placebo/vehicle|Repeat doses
79382936|NCT05825872|Procedure|internal superior laryngeal nerve block|"A linear 4- to 12-MHz ultrasound probe will be placed in the oblique parasagittal plane to obtain an image of the hyoid bone and the thyroid cartilage. The probe will be kept parasagitally, and the following structures will be identified anteriorly to posteriorly: omohyoid muscle, sternohyoid muscle, thyrohyoid muscle, thyrohyoid membrane, superior laryngeal artery, and pre-epiglottis space.~After identifying the local anatomic structure, a needle will be inserted out-plane from anterior to posterior. The muscles above the thyrohyoid membrane will be penetrated and hydrodissected; local anesthetic will be injected into the superior laryngeal nerve space. The superior laryngeal nerve space will be located between the hyoid bone (cephalad) and the thyroid cartilage (caudal) and delimited between the thyrohyoid muscle, anteriorly, and the thyrohyoid membrane and the pre-epiglottis space, posteriorly"
79382937|NCT05825872|Drug|Lidocaine 2% Injectable Solution|0.5 ml will be injected
79382938|NCT05825872|Drug|Bupivacaine 0.5% Injectable Solution|1.5 ml will be injected
79537710|NCT01467219|Procedure|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
79537711|NCT01467219|Procedure|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
79694652|NCT04648800|Drug|0.9% saline|0.9% saline
79694653|NCT00542243|Drug|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
79537712|NCT01467219|Procedure|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
79537713|NCT01467219|Radiation|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
79537714|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
79694654|NCT00542243|Drug|Placebo|Placebo will be given once a day for 6 months.
79694655|NCT02286804|Device|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
79537715|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
79694656|NCT02286765|Device|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
79839493|NCT00642018|Drug|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
79839494|NCT00642018|Drug|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
79839495|NCT00532948|Drug|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
79839496|NCT00998920|Drug|S-equol|oral, BID, 14 days
79839497|NCT00998920|Drug|Placebo|oral, BID, 14 days
80010062|NCT01384331|Drug|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
79243946|NCT03141944|Other|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
79537716|NCT01467258|Drug|Amantadine|Single dose
79537717|NCT01467284|Behavioral|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
79694657|NCT00542360|Behavioral|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
79537718|NCT01467284|Behavioral|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
79694658|NCT02283957|Drug|CNTX-4975|
79839498|NCT00998998|Behavioral|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
80010063|NCT03699423|Drug|0.01% atropine eye drops|0.01% atropine sulphate
79537719|NCT01467297|Drug|ceftidoren|ceftidoren 200 mg bid for 5 days
79839499|NCT00998998|Behavioral|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
79839500|NCT00998998|Dietary Supplement|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
79839501|NCT00992758|Biological|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
79839502|NCT00641706|Drug|vorinostat|Given orally
79839503|NCT00641706|Procedure|therapeutic conventional surgery|Patient undergoes surgery
79839504|NCT00641706|Drug|bortezomib|Given IV
80010064|NCT03699423|Drug|0.02% atropine eye drops|0.02% atropine sulphate
80010065|NCT03699423|Drug|0.03% atropine eye drops|0.03% atropine sulphate
80010066|NCT02164448|Drug|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
79537720|NCT01467297|Drug|levofloxacin|levofloxacin 500 mg once daily for 7 days
79839505|NCT00995332|Drug|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
79839506|NCT00992914|Procedure|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
80010067|NCT02164448|Drug|the control group|saline infusion from induction of anesthesia to end of surgery
79537721|NCT01467310|Drug|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
79537722|NCT01467323|Drug|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
79537723|NCT01467323|Drug|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
79839507|NCT00992914|Procedure|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
79839508|NCT00999232|Drug|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
79839509|NCT00999232|Drug|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
79839510|NCT00993070|Drug|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
79839511|NCT00993070|Drug|placebo|vehicle gel, applied 4 times per day for 8 weeks
80010068|NCT03612713|Drug|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
79243947|NCT03605485|Device|Nasal Pillows CPAP mask|Investigative Nasal pillows Mask to be used for OSA therapy
79305827|NCT04404153|Device|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
79305828|NCT04924413|Drug|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
79694659|NCT02283957|Other|Placebo|
79839512|NCT00993304|Drug|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
79839513|NCT00993304|Drug|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
79839514|NCT05189002|Drug|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
79839515|NCT05189002|Drug|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
79243948|NCT03125421|Procedure|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
79243949|NCT03125421|Procedure|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
79243950|NCT03605407|Other|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
79243951|NCT03141632|Drug|Dulaglutide|Evaluation visit with assessment of fluid intake
79382939|NCT05825820|Behavioral|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
79694660|NCT04648995|Device|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
79694661|NCT04648995|Device|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
79839516|NCT05189002|Drug|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
79839517|NCT00644358|Drug|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
79839518|NCT01564498|Other|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
79839519|NCT00993538|Procedure|Blood sampling|
79839520|NCT00993538|Procedure|Bone marrow aspiration|
79839521|NCT00821418|Device|PulseHaler treatment|treatment is for two weeks, 3 times per day
79694662|NCT00542399|Drug|Levemir (insulin detemir)|Levemir once a day
79694663|NCT00542399|Drug|Levemir twice a day|Levemir twice a day
80010069|NCT03612713|Drug|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
79694664|NCT04648722|Procedure|Hemithyroidectomy|We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
79694665|NCT00542516|Drug|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
79694666|NCT00542516|Drug|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
79839522|NCT00821418|Device|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
79839523|NCT00993694|Drug|chemotherapy|
80010070|NCT02164526|Other|Routine therapy|Routine therapy
79839524|NCT00993694|Drug|dapsone|
79839525|NCT00993694|Other|medical chart review|
79839526|NCT00993694|Procedure|assessment of therapy complications|
79839527|NCT04000828|Device|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
79839528|NCT00640926|Drug|Radezolid|300 mg/day, orally for 7-10 days
79839529|NCT00640926|Drug|Radezolid|450 mg/day orally for 7-10 days
79839530|NCT00640926|Drug|Radezolid|900 mg/day orally for 7-10 days
79839531|NCT03892564|Drug|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79839532|NCT03892564|Drug|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79839533|NCT03892564|Drug|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79694667|NCT03456830|Drug|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
79694668|NCT03456830|Drug|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
79694669|NCT02265393|Drug|OTO-104|
79694670|NCT02265393|Drug|Placebo|
79694671|NCT00542555|Drug|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
79839534|NCT03892564|Drug|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79839535|NCT03892564|Drug|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
80010071|NCT03697941|Procedure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
80010072|NCT03697941|Procedure|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
80010073|NCT01380509|Drug|Metronidazole|Capsules, single-dose, fasting
80010074|NCT01380509|Drug|Flagyl|Capsules, single-dose, fasting
79243952|NCT03141632|Other|Placebo|Evaluation visit with assessment of fluid intake
79243953|NCT04282239|Procedure|PECS2 block|Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
79382940|NCT05825690|Other|Retrospective evaluation of specific brain MRI features|"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~Brain MRI changes in the acute stage, i.e. < 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~Brain MRI changes after acute phase resolution (> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
79382941|NCT05825677|Device|tDCS actif|Active brain stimulation
79382942|NCT05825677|Device|tDCS Sham|Sham brain stimulation
79382943|NCT05825664|Procedure|Endoscopic resection|Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
79694672|NCT00542555|Drug|Naproxcinod 375 mg|
79243954|NCT04282239|Drug|Ropivacaine 0.5% Injectable Solution|15 mL on each side of anterior chest for a total of 30mL
79243955|NCT04282239|Drug|Lidocaine Epinephrine|10 mL on each side of anterior chest for a total of 20mL
79243956|NCT04282239|Drug|Dexmedetomidine 0.004 MG/ML|10 mL
79305829|NCT02158546|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79305830|NCT02158546|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79694673|NCT00542555|Drug|Naproxen|
79694674|NCT00542555|Drug|Naproxcinod 750 mg|
79694675|NCT04648488|Other|Experimental early mobilisation|early activ assisted exercises treatment
79694676|NCT04648488|Other|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
79694677|NCT04685018|Device|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
79694678|NCT02260674|Drug|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
79694679|NCT02260674|Drug|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
79694680|NCT02260674|Drug|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
79694681|NCT00542711|Drug|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
79694682|NCT04679025|Other|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose > 10.0 mmol/L) within 72 hours of a surgical procedure
79694683|NCT04678128|Behavioral|Dance4Healing Telehealth Live Zoom Sessions|"Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class."
79694684|NCT04678128|Behavioral|Dance Buddy|"Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods."
79694685|NCT00542906|Other|localization|localization of the several types of somatosensory stimuli
80010075|NCT03699267|Other|US-guided Bilateral TAP block|
80010076|NCT01378715|Drug|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
80010077|NCT04818515|Drug|Atogepant|Oral; Tablet
80010078|NCT04818515|Drug|Ubrogepant|Oral; Tablet
80010079|NCT02760602|Drug|Solanezumab|Administered IV
80010080|NCT02760602|Drug|Placebo|Administered IV
80010081|NCT04129073|Other|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
80010082|NCT04687241|Drug|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
80010083|NCT04687241|Drug|Placebo Almonertinib|Placebo Almonertinib
79382944|NCT05825638|Other|Continuous training session|Continuous training consists of a 5 minute warm up, 5 minute cool down and 20 minutes of moderate intensity work. The workload is set at 60% of the patient's maximum power
79382945|NCT05825638|Other|Interval training session|Interval training consists of a 5-minute warm-up, a 5-minute cool-down and 20 minutes of alternating 60 seconds of high-intensity work (100% of the maximum power recorded in the incremental test that was carried out when the patient was admitted to the pulmonary rehabilitation department) and 60 seconds of unloaded pedalling or rest.
79382946|NCT05825599|Device|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
79382947|NCT05825586|Device|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
79382948|NCT05825547|Procedure|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
79382949|NCT05825508|Device|ankle robot|home ankle robot and video game
79382950|NCT05825456|Procedure|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
79382951|NCT05825456|Procedure|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
80010084|NCT00976131|Drug|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
80010085|NCT00976131|Other|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
80010086|NCT00976131|Drug|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
79382952|NCT05825456|Procedure|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
79382953|NCT05825378|Drug|Dexamethasone 8mg+0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
79382954|NCT05825378|Drug|0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
79382955|NCT05825339|Diagnostic Test|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
79537724|NCT01467336|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
79537725|NCT01467362|Drug|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
79694686|NCT04678674|Procedure|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
79382956|NCT05825313|Behavioral|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
80010087|NCT00976131|Drug|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
80010088|NCT01384253|Other|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
79243957|NCT03605329|Other|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH <15 / hour."
79243958|NCT02639078|Drug|TD-0714|One time dosing in capsule formulation
79382957|NCT05825287|Other|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
79537726|NCT01467362|Drug|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
79537727|NCT01467362|Drug|desonide 0.1% cream|cream, once a day (in the evening) during flares
79243959|NCT02639078|Drug|Placebo Comparator|One time dosing in capsule formulation
79537728|NCT01467362|Other|Foaming gel|for the washing and cleaning
79537729|NCT01467375|Drug|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
79537730|NCT01467388|Procedure|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
80010089|NCT01384253|Biological|trastuzumab|4 mg/kg.
80010090|NCT03697863|Procedure|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
80010091|NCT03631277|Device|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
80010092|NCT03631277|Drug|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
80010093|NCT02171000|Drug|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
79694687|NCT00542945|Device|ICD|Implantation of an ICD
79694688|NCT00542945|Other|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
80010094|NCT01378637|Device|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
79839536|NCT00821496|Drug|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
79839537|NCT00999622|Other|laboratory biomarker analysis|
80010095|NCT03697785|Device|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
80010096|NCT02261168|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
79694689|NCT04677933|Drug|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
79694690|NCT04677933|Drug|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
79382958|NCT05825287|Other|Management training|Management training
79694691|NCT04677933|Drug|C: Placebo|10 patients will receive Placebo BIW
79694692|NCT00542984|Drug|teriparatide 20 micrograms/day subcutaneous|
79694693|NCT00542984|Drug|salmon calcitonin 100 IU/day subcutaneous|
79694694|NCT02257983|Drug|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
80010097|NCT03699189|Behavioral|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
79243960|NCT02671071|Behavioral|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
79243961|NCT03605251|Drug|TAS5315 low dose|Oral administration for 12 or 36 weeks
79243962|NCT03605251|Drug|TAS5315 high dose|Oral administration for 12 or 36 weeks
79243963|NCT03605251|Drug|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
79243964|NCT03141710|Dietary Supplement|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
79243965|NCT03605173|Diagnostic Test|free vitamin d test|using the patient's blood serum ELISA test for free vitamin d can be performed
79382959|NCT05825274|Device|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
79382960|NCT05825248|Other|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
79382961|NCT05825248|Other|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
79537731|NCT01467401|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
79537732|NCT01467401|Drug|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
79537733|NCT01467414|Drug|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
79537734|NCT01467440|Device|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
79537735|NCT01467453|Device|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
79537736|NCT01467518|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
79537737|NCT01467518|Drug|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
79537738|NCT01467531|Drug|Dolutegravir|50mg q 24h
79537739|NCT01467531|Drug|Rlipivirine|25mg q24h
79537740|NCT01467531|Drug|GSK1265744|30mg q24h
79537741|NCT01467544|Other|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
79694695|NCT02257983|Drug|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
79694696|NCT00543023|Drug|teriparatide 20 micrograms/day subcutaneous|
79694697|NCT00543023|Drug|salmon calcitonin 100 IU/day subcutaneous|
79694698|NCT04648917|Drug|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
79839538|NCT00999622|Other|questionnaire administration|
79839539|NCT00818220|Procedure|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
79839540|NCT00818220|Other|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
79839541|NCT03891862|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
79694699|NCT00543179|Drug|Somatuline (Lanreotide Autogel®)|
79694700|NCT04648527|Procedure|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
79839542|NCT03891862|Drug|Placebo oral capsule|non-active dosage form
79839543|NCT00640614|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
79243966|NCT03605173|Diagnostic Test|total vitamin d|routinely measured from serum
80010098|NCT02164604|Drug|intravitreal injection of 0.03ml ranibizumab|
80010099|NCT04380831|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
80010100|NCT04380831|Drug|Cyclophosphamide|Undergo HSCT
79839544|NCT02550912|Drug|Vitamin D3|vitamin D drops for paediatrics
79382962|NCT05825196|Diagnostic Test|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
79382963|NCT05825157|Device|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
79382964|NCT05825144|Device|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
80010101|NCT04380831|Radiation|Intensity-Modulated Radiation Therapy|Undergo TBI using IMRT
79243967|NCT03141320|Other|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
79382965|NCT05825144|Other|Conventional rehabilitation|Regular post-stroke rehabilitation
79839545|NCT02550912|Other|Placebo|glucose syrup with same taste and color to vitamin D3 drops
79839546|NCT00999700|Drug|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
79243968|NCT03378843|Other|Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine
79382966|NCT05825118|Diagnostic Test|Neutrophil/Lymphocyte ratio and lactate/ albumin ratio will be measured in all patients.|Blood will be drawn from peripheral vein, arterial or a central catheter for evaluation of whole blood count, serum lactate and serum albumin.
79382967|NCT05825053|Behavioral|Gait adaptability training|Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
79382968|NCT05825053|Behavioral|Home-based exercise training|Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
79694701|NCT00543218|Drug|teriparatide 20 micrograms/day subcutaneous|
79694702|NCT00543218|Drug|calcitonin 100 IU/day subcutaneous|
79694703|NCT00543257|Other|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
79694704|NCT00543257|Other|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
79694705|NCT02252835|Drug|Arhalofenate|800 mg once daily orally for four weeks
79694706|NCT02252835|Drug|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
79694707|NCT02252835|Drug|Arhalofenate|600 mg once daily orally for four weeks
79839547|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
80010102|NCT04380831|Procedure|Total-Body Irradiation|Undergo TBI using IMRT
79243969|NCT03140618|Other|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
80010103|NCT02168114|Other|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
79243970|NCT03605095|Drug|nitroglycerin|Vasodilatator solution is dropped on the gingiva.
79243971|NCT03378765|Behavioral|Diet and physical activity monitoring|Lifestyle monitoring
79243972|NCT03604939|Diagnostic Test|Evaluation of social, cultural and behavioral factors|Evaluation of the social, cultural and behavioral factors that impact the uptake of the NCD prevention and control services among women, using the RARE methodology
80010104|NCT02168114|Procedure|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
80010105|NCT04676048|Biological|ASC618|ASC618 will be given as a single IV infusion
80010106|NCT03697473|Other|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
79537742|NCT01467596|Device|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
79537743|NCT01467622|Procedure|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
79694708|NCT02252835|Drug|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
80010107|NCT03697473|Other|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
79243973|NCT03604939|Diagnostic Test|Evaluation of the feasibility and acceptability of delivery of early detections services|Evaluation of the feasibility and acceptability of delivery of the NCD early detections services by the trained community health workers at home settings
79243974|NCT03382353|Dietary Supplement|Nutritional supplementation|Daily consumption of Tramiprosate (100 mg) for 1 year
79243975|NCT03382353|Behavioral|Educational training|16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
79694709|NCT02252835|Drug|Colchicine|0.6 mg daily
79694710|NCT03456752|Drug|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
79694711|NCT03456752|Drug|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
79694712|NCT02227290|Drug|Naftin Cream|
79694713|NCT02227290|Drug|Placebo Cream|
80010108|NCT04571645|Drug|Dociparastat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
79382969|NCT05824949|Procedure|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
79382970|NCT05824949|Procedure|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
79382971|NCT05824897|Other|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
79537744|NCT01467635|Device|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
79537745|NCT01467648|Drug|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
79243976|NCT03382353|Behavioral|Counselling on a brain-healthy diet|4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
79537746|NCT01467648|Drug|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
79243977|NCT03382353|Behavioral|Physical exercise training|80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
79243978|NCT03382353|Behavioral|Computerized cognitive training|16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
79243979|NCT03140540|Other|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta <20 ,200ml colloid bolus to be administered.
79537747|NCT01467687|Drug|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
79537748|NCT01467726|Drug|Velusetrag|Capsules
79537749|NCT01467726|Drug|Velusetrag|Capsules
79694714|NCT03456713|Biological|LY3074828|Administered SC
79694715|NCT04648137|Diagnostic Test|study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)|single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
79694716|NCT04648137|Diagnostic Test|Control intervention: Placebo|Identical placebo (only mannitol) capsules
79694717|NCT03456674|Device|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
79694718|NCT04648332|Drug|Bupivacaine Hydrochloride|compartment psoas block
79694719|NCT03456596|Other|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
79694720|NCT04647981|Other|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
80010109|NCT04571645|Other|Placebo|0.9% Normal Saline
80010110|NCT04050267|Drug|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
80010111|NCT04050267|Other|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
79537750|NCT01467726|Drug|Placebo|Capsules
79537751|NCT01467739|Device|Ambu ® aScope®|
79382972|NCT05824793|Combination Product|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
79382973|NCT05823844|Drug|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
79694721|NCT03456557|Radiation|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
79694722|NCT04648566|Procedure|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
79694723|NCT04648566|Procedure|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
79839548|NCT00999700|Drug|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
79839549|NCT00999700|Drug|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
79839550|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
79839551|NCT00818298|Drug|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
80010112|NCT03086057|Behavioral|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
79243980|NCT03140540|Other|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV >10, 200 ml of colloid bolus to be given
79243981|NCT03604861|Other|Not applicable - no defined intervention|Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.
79243982|NCT03382275|Drug|Iron Supplement|any oral or intravenous prescription iron supplement
79243983|NCT05080478|Drug|Clopidogrel, Ticagrelor|P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
79243984|NCT03382197|Device|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
79243985|NCT03382197|Device|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
79382974|NCT05823844|Drug|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
79382975|NCT05823831|Diagnostic Test|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
79382976|NCT05823831|Diagnostic Test|Brief Infant Sleep Questionnaire (BISQ) questionnaire|A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
79537752|NCT01467739|Device|a conventional reusable fiberscope|
79537753|NCT01467752|Procedure|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
79537754|NCT01467765|Other|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
79537755|NCT01467778|Device|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
79537756|NCT01467778|Device|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
79537757|NCT01467791|Other|Observation|Observe patients
79839552|NCT00821574|Drug|Fluvastatin|Fluvastatin: daily 80 mg, oral
79839553|NCT00821574|Drug|Valsartan|Valsartan: daily 160 mg, oral
79839554|NCT00821574|Drug|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
79839555|NCT00995800|Drug|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
79839556|NCT00818376|Other|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
79839557|NCT00993850|Behavioral|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
79839558|NCT00993850|Other|Bipolar education|Psychoeducation
79537758|NCT01467804|Drug|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
79537759|NCT01467804|Drug|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
79537760|NCT01467817|Behavioral|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
79537761|NCT01467817|Behavioral|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
79537762|NCT01467830|Procedure|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
79537763|NCT01467843|Behavioral|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
79537764|NCT01467843|Behavioral|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
79694724|NCT05078411|Behavioral|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
79839559|NCT00816192|Procedure|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
79839560|NCT00999778|Behavioral|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
79839561|NCT00999778|Behavioral|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
80010113|NCT03086057|Behavioral|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
79243986|NCT03382197|Device|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
79243987|NCT03608449|Other|questionnaires|questionnaire about mental health status during psychotherapy
79243988|NCT03140774|Biological|Previously exposed to Ebola vaccine|Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
79243989|NCT03382119|Device|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
79382977|NCT05823831|Diagnostic Test|Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire|A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
79382978|NCT05823831|Diagnostic Test|Brief Symptom Inventory (BSI) questionnaire|A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
79382979|NCT05823662|Procedure|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
79382980|NCT05823662|Drug|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
79382981|NCT05823363|Drug|Exparel with Bubivacaine|10ml Exparel mixed with10ml bupivicaine in vaginal cuff
79382982|NCT05823363|Drug|Bupivacaine only|20ml of Bubivacaine in the vaginal cugg
79382983|NCT05821816|Device|tDCS|Use of Transcranial direct current stimulation for 20 minutes per day, 5 days a week, at 2mA
79382984|NCT05821816|Other|Conventional rehabilitative treatment|Physiotherapy treatment consisting in two treatments per day of 40 minutes each
79537765|NCT01467856|Procedure|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP > 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
79537766|NCT01467908|Device|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
79537767|NCT01467921|Drug|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
79537768|NCT01467986|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
79694725|NCT05078411|Behavioral|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
79694726|NCT04648176|Device|Moses technology|Using Holmium laser with Moses technology or conventional one
79243990|NCT03382119|Device|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
79243991|NCT02853929|Biological|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
79243992|NCT05082974|Drug|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
79243993|NCT05082974|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray [control]
79537769|NCT01467986|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
79694727|NCT00543335|Drug|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
79243994|NCT03604471|Drug|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
79243995|NCT02667639|Biological|RPH-104|Anti-IL-1 Mab
79382985|NCT05821608|Other|Message variation 1|Message before call letting member know they will be called (variation 1)
79382986|NCT05821608|Other|Message variation 2|Message before call letting member know they will be called (variation 2)
79382987|NCT05821543|Drug|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
79382988|NCT05821543|Drug|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
79537770|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
79537771|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
79537772|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
79243996|NCT02667639|Other|Sodium chloride Sterile Injection 0.9% w/v|Sterile saline solution
79243997|NCT02237443|Drug|Rocuronium|Administration of a NMBD
79694728|NCT00543335|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
79694729|NCT02223039|Biological|AbGn-168H|AbGn-168H monoclonal antibody
79694730|NCT02223039|Biological|Placebo|Placebo of AbGn-168H
79839562|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
79243998|NCT02237443|Drug|Vecuronium Bromide|Administration of a NMBD
79243999|NCT02237443|Drug|Succinylcholine|Administration of a NMBD
79244000|NCT03141398|Diagnostic Test|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
79244001|NCT03141398|Diagnostic Test|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
79244002|NCT03141398|Diagnostic Test|T2* MRI of the Pancreas|MRI [Magnetic resonance imaging] of the pancreas which is safe and takes around 30 minutes.
79382989|NCT05821101|Device|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
79537773|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
79537774|NCT01468025|Drug|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
79537775|NCT01468025|Other|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
79694731|NCT00543413|Drug|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
79694732|NCT00543413|Drug|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
79694733|NCT00543413|Drug|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
79244003|NCT03733418|Drug|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
79244004|NCT03733418|Drug|Placebo|Placebo was administered by the VIOLET parent study. A single, liquid enteral dose of placebo was administered.
79244005|NCT02237521|Other|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
79244006|NCT02237521|Other|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
79244007|NCT03607331|Device|Auricular vagus nerve stimulation|Auricular vagus nerve stimulation is a typical representative of TCM modernization.
79244008|NCT03607331|Drug|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
79244009|NCT05082896|Procedure|Type of anesthesia choice|Use of conscious sedation vs. general anesthesia
79244010|NCT03607955|Drug|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
79382990|NCT05820971|Other|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (6a)~Sample size (7a)~Sequence generation (8a)~Allocation concealment (9)~Blinding (11a)~Outcomes and estimation (17a/b)~Harms (19)~Registration (23)~Protocol (24)~Funding (25)"
79382991|NCT05820724|Diagnostic Test|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
79382992|NCT05820724|Other|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
79382993|NCT05820724|Drug|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
79382994|NCT05811949|Drug|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
79382995|NCT05806684|Other|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
79382996|NCT05805670|Other|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
79382997|NCT05800639|Procedure|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
79244011|NCT03607955|Drug|Paclitaxel|Commercially available
79244012|NCT03607955|Drug|Carboplatin|Commercially available
79244013|NCT03607955|Procedure|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
79244014|NCT03607955|Procedure|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
79244015|NCT03607955|Procedure|Interval Debulking|"Standard of Care~Research tissue samples will be collected"
79382998|NCT05800639|Procedure|General anesthesia|General anesthesia will be performed as standard practice of our institution.
79537776|NCT01468025|Drug|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
79537777|NCT01468038|Drug|Trazodone|active trazodone and sentra pm-like placebo
79694734|NCT00554658|Drug|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
79694735|NCT00543452|Other|Oxygen|4 liters of oxygen a minute
79694736|NCT00543452|Other|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
79694737|NCT00543491|Drug|MK0767|
79694738|NCT00543530|Drug|MK0831|
79839563|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
79839564|NCT00761657|Drug|Roxadustat|Capsule
79839565|NCT00761657|Drug|Placebo|Capsule
79694739|NCT00554736|Biological|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
79694740|NCT00543608|Drug|iclaprim|
79839566|NCT00816270|Procedure|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
79694741|NCT00543608|Drug|vancomycin|
79694742|NCT00554775|Drug|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
79694743|NCT00554775|Drug|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
79694744|NCT00543647|Drug|Fenofibrate 160 mg tablet|
79694745|NCT00543647|Drug|Placebo|
79839567|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
79537778|NCT01468038|Other|Sentra PM|Active Sentra PM and trazodone-like placebo
79694746|NCT04647747|Other|Self measurement with pulse oximeter|Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
79839568|NCT00999856|Device|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
79839569|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
79839570|NCT00999856|Device|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
80010114|NCT03697317|Behavioral|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
80010115|NCT03697317|Behavioral|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
79244016|NCT03607955|Procedure|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
79382999|NCT05797454|Procedure|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
79383000|NCT05797454|Procedure|Wire-guided localization|Positioning guide wire in the center of the lesion
79244017|NCT03607955|Procedure|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
79244018|NCT02067975|Drug|Tryptophan|
79244019|NCT02067975|Drug|Placebo|
79383001|NCT05788757|Device|Optetrak Total Knee System|Total Knee Arthroplasty using Exactech's Optetrak branded components.
79383002|NCT05788120|Other|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
79537779|NCT01468038|Drug|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
79694747|NCT04647669|Drug|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
79694748|NCT04647669|Drug|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
80010116|NCT02759120|Drug|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight < 50 kilograms or 100mg twice daily if weight > 50 kilograms for up to 36 months
79694749|NCT04647669|Drug|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
79694750|NCT04647669|Other|Standard of Care|Treatment according to local hospital protocol
80010117|NCT02759120|Other|No Intervention: Standard of Care|Standard of care
80010118|NCT01569113|Drug|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
79305831|NCT04923711|Behavioral|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
79305832|NCT04923711|Behavioral|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
79383003|NCT05783635|Behavioral|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
79537780|NCT01468038|Drug|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
79537781|NCT01468051|Biological|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
79839571|NCT00999856|Device|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
79244020|NCT03143036|Drug|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
79537782|NCT01468051|Biological|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
79537783|NCT01468064|Genetic|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
79244021|NCT03607253|Other|repetitive heel rise activity|Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
79839572|NCT00319501|Drug|Placebo|Intramuscular autoinjector; administered at onset of an episode
79244022|NCT04903587|Device|Ultrasonography and MRI|Abdominal Ultrasonography and axial MRI
79383004|NCT05783635|Behavioral|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
79383005|NCT05783635|Behavioral|Usual surgical care (post-operative)|This group will receive standard post-operative care.
79537784|NCT01468064|Genetic|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
79537785|NCT01468064|Genetic|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
79537786|NCT01468103|Procedure|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
79537787|NCT01468103|Procedure|Laser Iridotomy|alternative choice to surgical iridectomy
79537788|NCT01468129|Other|Cell Saver|
79537789|NCT01468155|Drug|dabigatran|30 days pre ablation and 90 days post ablation
79537790|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
79537791|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
79694751|NCT00543686|Drug|Montelukast|Intake of Montelukast
79839573|NCT00319501|Drug|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
79839574|NCT00994006|Dietary Supplement|Magnesium oxide|520 mg of elemental magnesium q.d.
79839575|NCT00994006|Dietary Supplement|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
79839576|NCT00818610|Drug|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
79244023|NCT03694418|Behavioral|We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth|N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epi Team to enhance the coordination and implementation of SRH services at Fort Peck.
79537792|NCT01468168|Drug|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
79537793|NCT01468194|Other|Breathing procedure 1|inhalation during one step, exhalation during the next step
79537794|NCT01468194|Other|Breathing procedure 2|inhalation and exhalation during one step
79537795|NCT01468220|Other|Endurance training|Endurance training three times per week over six weeks
79537796|NCT01468259|Drug|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
79537797|NCT01468272|Drug|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
79537798|NCT01468272|Drug|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
79694752|NCT00543686|Drug|Fluticasone|Intake of Fluticasone
79694753|NCT04647864|Device|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
79694754|NCT00543842|Drug|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
79694755|NCT00543842|Drug|Capecitabine|Starting Dose 650 mg/m^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
79694756|NCT00543842|Drug|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
79839577|NCT00818610|Drug|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
80010119|NCT01569113|Drug|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
80010120|NCT04435821|Drug|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg [18F]FTC-146. A whole-body PET/MRI scan will be performed after injection.
79694757|NCT00543842|Radiation|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
79537799|NCT01468285|Drug|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
79244024|NCT04852185|Biological|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
79244025|NCT04852185|Biological|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
79537800|NCT01468285|Other|placebo|placebo tablets b.i.d., six weeks treatment
79244026|NCT03607097|Procedure|Secondary prevention program for drug related problems|The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
79537801|NCT01468298|Other|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
79244027|NCT03606863|Drug|Perioperative peripheral parenteral nutrition|
79694758|NCT00543842|Procedure|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
79694759|NCT04638816|Device|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
79694760|NCT04638816|Device|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
79244028|NCT03381885|Behavioral|Gentle Nudge|Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.
79244029|NCT03381885|Behavioral|Usual Standard Procedure|Clinicians ordering imaging studies required mandatory phone to radiology
79244030|NCT05082506|Behavioral|Acupressure|Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
79244031|NCT03607877|Behavioral|Pedometer walking training and positive education|"Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions."
79244032|NCT03607877|Behavioral|Pedometer walking with training|Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
79244033|NCT03607877|Behavioral|pedometer walking|Intervention: pedometer walking at least 30 minutes per day and at least three times per week
79383006|NCT05783635|Behavioral|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
79383007|NCT05783635|Behavioral|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
79383008|NCT05769075|Drug|TY-2136b|"Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)"
79694761|NCT00543881|Device|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
79694762|NCT00543881|Device|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
79694763|NCT04638855|Device|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
79694764|NCT04638855|Device|Placebo|No device after hysteroscopy surgery
79694765|NCT00543920|Drug|MK0777|
79694766|NCT04638738|Device|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
79244034|NCT03381807|Biological|hAESCs|5*10^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
79244035|NCT05078684|Procedure|Left ganglion stellate block|Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.
79244036|NCT05078684|Procedure|Sham left ganglion stellate block|Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
79244037|NCT03606707|Drug|Steroids|intra-articular steroid injection for atlantoaxial joint
79244038|NCT05080010|Drug|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
79244039|NCT04255329|Other|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
79694767|NCT00543959|Drug|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
79694768|NCT00543959|Drug|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
79694769|NCT00543959|Drug|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
79244040|NCT04255329|Other|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
79694770|NCT04638972|Device|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
79694771|NCT00543998|Device|Optical Measurement transillumination|Optical Measurement of sinus
79383009|NCT05769075|Drug|TY-2136b|"Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage"
79839578|NCT01000012|Device|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
79244041|NCT03606629|Device|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
79244042|NCT04253691|Device|Virtual Reality Mediated Relaxation|Participants will use a brief Virtual Reality relaxation protocol to improve their insomnia. Their workbook will contain a handout that outlines the details. Participants will be encouraged to refer to it at home if they forget any part of the procedure.
79244043|NCT03606551|Device|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
79244044|NCT02030756|Device|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
79244045|NCT02030756|Device|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
79244046|NCT03385551|Drug|Estradiol|Estradiol or Promestriene depending on the arm
79244047|NCT04217655|Diagnostic Test|Low-dose computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
79694772|NCT04638777|Device|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
79244048|NCT04217655|Diagnostic Test|Standard-dose computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
79244049|NCT05079542|Procedure|Timepoint of Implant placement of Bonelevel tapered implants|Implant surgery on different time points
79244050|NCT05079542|Combination Product|Material for tooth restoration - Lithiumdisilicate glass ceramic or zirconia|Tooth restoration with a certain material
79244051|NCT03606473|Drug|d-amphetamine|is used to stimulate dopamine release in the brain
79244052|NCT03606473|Radiation|[C-11]NPA|PET radiotracer
79244053|NCT03385473|Genetic|Pharmacogenomic index|All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
79244054|NCT03385473|Diagnostic Test|Therapeutic drug monitoring|The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
79694773|NCT04638777|Device|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
79694774|NCT04638777|Device|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
79244055|NCT03316274|Drug|Intra-lesional injection of nivolumab|10mg in 1 mL injection into a KS lesion in the skin, every 2 weeks
79244056|NCT03606395|Drug|NV-5138|single ascending dose
79383010|NCT05758428|Drug|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
79383011|NCT05758428|Drug|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
79383012|NCT05753618|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
79694775|NCT00544037|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
79694776|NCT04647357|Drug|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
79694777|NCT00544154|Drug|CDP870|
79537802|NCT01468298|Other|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
79694778|NCT04638582|Drug|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
79244057|NCT03606395|Drug|Placebos|Placebo liquid solution to mimic NV-5138
79244058|NCT04046757|Other|Mechanical thrombectomy|Neuroradiological endovascular treatment
79694779|NCT04638582|Drug|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
79694780|NCT04638582|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
79694781|NCT04638582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
79694782|NCT00544193|Drug|gemcitabine hydrochloride|
79839579|NCT01000012|Device|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
79244059|NCT03252626|Drug|Alprostadil|"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline."
79244060|NCT03252626|Drug|Normal saline|2ml normal saline injection added into 10ml 0.9% saline.
79383013|NCT05753618|Drug|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
79537803|NCT01468324|Drug|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
79537804|NCT01468363|Device|Dry weight adjustment|Dry weight adjustment according to BCM results
79244061|NCT03605615|Other|vocalization|The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
79244062|NCT05072054|Drug|Atorvastatin Oral Tablet|Atorvastatin 40 mg
79244063|NCT05072054|Drug|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
79694783|NCT00544193|Genetic|polymerase chain reaction|
79244064|NCT02035241|Dietary Supplement|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79244065|NCT02035241|Dietary Supplement|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79383014|NCT05752461|Drug|SHR-2004 injection|low dose subcutaneous injection once
79383015|NCT05752461|Drug|SHR-2004 injection|medium dose subcutaneous injection once
79694784|NCT00544193|Other|immunohistochemistry staining method|
79694785|NCT00544193|Procedure|conventional surgery|
79694786|NCT00544193|Radiation|intraoperative radiation therapy|
79694787|NCT00544193|Radiation|radiation therapy|
79694788|NCT00544232|Drug|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
79694789|NCT00544232|Drug|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
79839580|NCT02551302|Device|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
79244066|NCT02035241|Dietary Supplement|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79244067|NCT02035241|Dietary Supplement|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79244068|NCT02035241|Dietary Supplement|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79383016|NCT05752461|Drug|SHR-2004 injection|high dose subcutaneous injection once
79383017|NCT05752461|Drug|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
79383018|NCT05750277|Other|Evening Time-Restricted Eating|Eating between 8am-6pm.
79537805|NCT01468376|Dietary Supplement|GLU-01|14 day dosing
79537806|NCT01468376|Dietary Supplement|GLU-02|14 day dosing
79537807|NCT01468376|Dietary Supplement|GLU-03|14 day dosing
79537808|NCT01468376|Dietary Supplement|GLU-04|14 day dosing
79694790|NCT04647318|Behavioral|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
79694791|NCT00544271|Biological|INFANRIX|
79244069|NCT02035241|Dietary Supplement|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
79383019|NCT05733546|Drug|Psilocybin|COMP360 Psilocybin administered under supportive conditions
79383020|NCT05724550|Drug|Sugammadex|"Sugammadex(100mg/mL), 2mg/kg~After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
79244070|NCT05062616|Procedure|Toenail surgery|modified Winograd procedure
79244071|NCT03142880|Combination Product|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
79244072|NCT04019301|Other|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
79537809|NCT01468376|Dietary Supplement|GLU-05|14 day dosing
79537810|NCT01468376|Dietary Supplement|GLU-06|14 day dosing
79537811|NCT01468389|Drug|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
79537812|NCT01468389|Drug|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
79839581|NCT02551302|Device|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
79839582|NCT00995878|Procedure|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
79244073|NCT04019301|Other|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
79244074|NCT03605537|Drug|Drug-eluting Stent Mometasone|The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
79244075|NCT03605459|Device|Comfort Plug™|
79383021|NCT05724550|Drug|Neostigmine|"Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
79383022|NCT05708274|Drug|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
79383023|NCT05708274|Drug|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
79694792|NCT00544271|Biological|BOOSTRIX|
79694793|NCT00544271|Biological|HAVRIX|
79244076|NCT05013086|Drug|1.11 GBq of 177Lu-AB-3PRGD2|accepted intravenous injection of 177Lu-AB-3PRGD2
79537813|NCT01468402|Procedure|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
79537814|NCT01468415|Drug|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
79537815|NCT01468441|Drug|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
79537816|NCT01468441|Drug|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
79694794|NCT01191268|Drug|Insulin Glargine|
79537817|NCT01468467|Drug|AC220|Oral Liquid
79537818|NCT01468480|Drug|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
79694795|NCT01191268|Drug|LY2189265|
79694796|NCT01191268|Drug|Insulin Lispro|
79694797|NCT04647552|Drug|Drug Steroid|hydrocortisone injection
79537819|NCT01468480|Drug|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
79244077|NCT03381495|Drug|Ropivacaine Hydrochloride, Sufentanil|In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
79694798|NCT04647279|Diagnostic Test|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
79694799|NCT00544310|Biological|Anti adhesion agent|Adhesions prevention
79839583|NCT00995878|Procedure|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
79839584|NCT00761579|Drug|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
79839585|NCT00994084|Behavioral|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
79244078|NCT03602417|Device|Flare type stent|Flare type has a wide diameter at proximal portion to prevent stent migration.
79244079|NCT03602417|Device|Conventional D-type stent|This stent is an original full covered stent to treat malignant colorectal obstruction.
79244080|NCT03381417|Drug|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
79244081|NCT03381417|Drug|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
79244082|NCT03059498|Procedure|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
79244083|NCT03059498|Procedure|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
79244084|NCT03059498|Drug|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
79244085|NCT03548727|Diagnostic Test|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
79383024|NCT05708274|Drug|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
79244086|NCT03142646|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
79244087|NCT03602183|Device|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
79537820|NCT01468480|Drug|MultiCal|application of Multical in forth group as a pulp dressing agent
79537821|NCT01468480|Drug|Dycal|application of Dycal in first group as a pulp dressing agent
79694800|NCT00544349|Biological|cetuximab|
79383025|NCT05708274|Drug|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
79537822|NCT01468519|Drug|Insulin|Insulin via continuous subcutaneous insulin infusion
79694801|NCT00544349|Drug|fluorouracil|
79694802|NCT00544349|Drug|leucovorin calcium|
79694803|NCT00544349|Drug|oxaliplatin|
79694804|NCT01191190|Drug|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
79839586|NCT00994084|Behavioral|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
79839587|NCT04100525|Behavioral|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
79839588|NCT01000168|Other|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
79839589|NCT01000246|Biological|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
79244088|NCT03602183|Device|Miller laryngoscope|intubation will be performed using Miller laryngoscope
79244089|NCT03602183|Device|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
79244090|NCT03602183|Device|GlideScope|intubation will be performed using GlideScope video - laryngoscope
79244091|NCT03378453|Device|PET-scan18F-AV-45|The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr
79537823|NCT01468519|Drug|Insulin|insulin via multiple daily injections
79537824|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
79537825|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
79537826|NCT01468571|Drug|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
79694805|NCT00544388|Drug|levocetirizine dihydrochloride|
79694806|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
79694807|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
79694808|NCT00544505|Drug|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
79694809|NCT00544583|Procedure|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
79694810|NCT00544583|Procedure|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
79839590|NCT00627042|Biological|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
80010121|NCT03699033|Radiation|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
80010122|NCT03699033|Drug|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
80010123|NCT03699033|Drug|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
79383026|NCT05699954|Diagnostic Test|Presence of Blink impression features for cancer in colorectal polyps|"20 LNPCPs will be collected from the UZ Ghent database (all LNPCPs, ICF present).~A survey will be made where participant endoscopist will be informed about the study. They will here be asked for electronic consent.~The survey asks for demographics of the participant endosopists (experience, country where they work).~The last part of the survey is where the 20 images of the LNPCPs are shown. After evere image 4 questions are asked. Is this a colorectal polyp? (Yes/No)~Is your Blink (first) Impression that this polyp contains cancer? (Yes/No)~If yes, why do you think that? (Free comment box)~What treatment would you recommend for this polyp? (piecemeal endoscopic mucosal resection/endoscopic submucosal disection/surgery)~Study will be closed after 2 weeks.~Data analysis"
79537827|NCT01468571|Drug|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
79244092|NCT03378453|Device|PET-scan18F-AV-45|PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
79244093|NCT04992884|Device|Gastric Alimetry|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
79537828|NCT01468610|Drug|desvenlafaxine|50-100 mg daily for 8 weeks
79244094|NCT03605225|Device|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
79383027|NCT05659329|Device|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
79537829|NCT01468623|Other|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
79537830|NCT01468623|Other|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
79537831|NCT01468636|Drug|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
79537832|NCT01468636|Drug|Placebo|200mg BID x 8 weeks
79694811|NCT00544622|Procedure|structured therapeutic chain of stroke treatment|
79694812|NCT00544700|Biological|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
79694813|NCT00544700|Other|no maintenance|No treatment until progression
79694814|NCT00559884|Drug|GSK189075 (Modified and immediate release formulations)|
79694815|NCT05824676|Device|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
79694816|NCT05824676|Device|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
79694817|NCT05824663|Drug|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
80010124|NCT03697239|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
80010125|NCT03697239|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
80010126|NCT03697239|Drug|Cisplatin|25mg/m2 in 500*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
80010127|NCT03697239|Drug|Gemcitabine|1000mg/m2 in 500*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
80010128|NCT03629015|Biological|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
80010129|NCT02164682|Procedure|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
80010130|NCT02164682|Procedure|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
80010131|NCT01378559|Other|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
80010132|NCT02164760|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
79537833|NCT01468649|Device|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
79839591|NCT00319111|Drug|bosentan|"Oral bosentan~Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight < 40 kg)"
79839592|NCT00994396|Dietary Supplement|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
80010133|NCT01380431|Drug|Lisinopril|Tablets, 40 mg, single oral dose
80010134|NCT01380431|Drug|lisinopril|Tablets, 40 mg, single, oral dose
80010135|NCT01380431|Drug|Lisinopril|50% of subjects received the Par formulated product.
80010136|NCT03697161|Drug|OV101 (gaboxadol)|OV101 (gaboxadol)
79244095|NCT03142724|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single [18F]MNI-968 injections and PET scans.
79244096|NCT03541083|Drug|Blinatumomab|prephase and consolidation (I and II)
79244097|NCT03605147|Dietary Supplement|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
79244098|NCT03605147|Dietary Supplement|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
79383028|NCT05653232|Other|Prophylaxis (P2W)|For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
79537834|NCT01468688|Drug|STI571|
79537835|NCT01468688|Drug|BKM120|BKM120 combination therapy
79537836|NCT01468714|Drug|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
79537837|NCT01468727|Dietary Supplement|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
79537838|NCT01468727|Dietary Supplement|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
79537839|NCT01468740|Drug|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79839593|NCT00994396|Dietary Supplement|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
80010137|NCT02168192|Behavioral|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
80010138|NCT02168192|Behavioral|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
79839594|NCT00818688|Procedure|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
79839595|NCT03978013|Other|Pomegranate juice|Pomegranate juice
79839596|NCT03978013|Other|Apple juice|Apple juice
80010139|NCT02171156|Drug|nintedanib|soft gelatin capsule
80010140|NCT01380353|Drug|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].
80010141|NCT02168348|Other|biological examination at consultations at 3 and 6 months|
80010142|NCT01384175|Procedure|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
80010143|NCT01384175|Procedure|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
80010144|NCT01384175|Procedure|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
80010145|NCT02171312|Device|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
79694818|NCT05824624|Other|ANIMAL-ASSISTED INTERVENTION|It will be ensured that the child is introduced to the goldfish when he is lying in the observation room, that the child will name the fish, and that he will communicate and feed the fish during his stay. Thus, it is aimed to turn the attention of the child to the goldfish while in the emergency room, to distract the child with the fish while all nursing interventions are presented, and to reduce the fear.
79694819|NCT05824624|Other|Routine Care|Routine nursing care will be provided.
79839597|NCT00821808|Device|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
80010146|NCT02171312|Behavioral|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
80010147|NCT02168426|Procedure|Guardix|Applying 6g of guardix during abdominal surgery
80010148|NCT02168426|Procedure|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
79244099|NCT05079152|Biological|COVAX+PPV23;COVAX+IIV4|1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
79244100|NCT05079152|Biological|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
79244101|NCT05079152|Biological|PPV23 for the 1st dose and IIV4 for the 2nd dose|1st dose: PPV23 only; 2nd dose: IIV4 only
79244102|NCT03378375|Other|nutritional assessement|
79244103|NCT03605069|Drug|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
79244104|NCT03605069|Drug|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
79383029|NCT05653232|Other|Transmit and Treat (T&T)|For participants enrolled in T&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
79383030|NCT05653102|Device|Truliant Total Knee System|Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
79537840|NCT01468740|Drug|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79537841|NCT01468740|Drug|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
79537842|NCT01468740|Drug|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
79537843|NCT01468740|Drug|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79694820|NCT05824585|Drug|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
79694821|NCT05824520|Other|ITS plus OMT|Invasive treatment strategy plus optimal medical therapy
79694822|NCT05824520|Other|OMT|Optimal medical therapy alone
79694823|NCT05824481|Drug|Cadonilimab|Injectable solution
79694824|NCT05824481|Drug|Lenvatinib|Capsule
80010149|NCT01380275|Drug|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
80010150|NCT01380275|Drug|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
80010151|NCT02171390|Drug|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
80010152|NCT02171390|Drug|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
79244105|NCT02730819|Drug|Illuminate Cream|Topical compound applied daily
79244106|NCT03602027|Drug|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
79244107|NCT03602027|Drug|Gefitinib|Gefitinib 250mg orally daily for three weeks
79244108|NCT03141476|Drug|Cefuroxime 1,5g|Patients with BMI of <30kg/m*m: 1,5 g Cefuroxime
79244109|NCT03141476|Drug|Cefuroxime 3g|Patients with BMI of 30-50kg/m*m: 3g Cefuroxime
79244110|NCT03141476|Drug|Cefuroxime 4,5g|Patients with BMI of >50kg/m*m: 4,5 g Cefuroxime
79694825|NCT05824468|Drug|Zimberelimab|Injectable solution
79694826|NCT05824468|Drug|Lenvatinib|Capsule
79694827|NCT05824455|Combination Product|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
79694828|NCT05824429|Other|Urotherapy|Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
79694829|NCT05824429|Other|Diaphragmatic Breathing Exercises|In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
79694830|NCT05824429|Other|PFM Exercises|PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
79839598|NCT00821808|Device|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
79244111|NCT03437889|Other|Cold Stimulus (Ice)|The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
79383031|NCT05646498|Procedure|Closed sinus lift procedure|The closed sinus lift is the elevation of the sinus membrane through the osteotomy
79383032|NCT05646498|Device|Crestal sinus lift|The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
79383033|NCT05612750|Behavioral|Education|Participants will receive one of two educational programs.
79537844|NCT01468740|Drug|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79537845|NCT01468740|Drug|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79383034|NCT05600543|Device|Lumbar belt|"All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)"
79383035|NCT05580419|Behavioral|4PCP Course|4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
79383036|NCT05565833|Behavioral|SHUTi OASIS|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program
79537846|NCT01468740|Drug|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79537847|NCT01468740|Drug|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
79244112|NCT03601871|Drug|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
79244113|NCT03601871|Drug|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
79244114|NCT03601871|Drug|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
79383037|NCT05565833|Other|Patient Education|An educational website containing information on insomnia
79383038|NCT05525403|Other|Knee Extension Exercise|Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.
79383039|NCT05525403|Other|Quiet Rest|Participants will sit quietly for two minutes, three times.
79391798|NCT02556112|Behavioral|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
79694831|NCT05824429|Other|Connective Tissue Manipulation|"CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region."
79244115|NCT03124485|Procedure|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
79244116|NCT03124485|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
79694832|NCT05824390|Drug|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
79694833|NCT05824312|Drug|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
79694834|NCT05824286|Other|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
79694835|NCT05824247|Device|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
79694836|NCT05824221|Device|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
79694837|NCT05824156|Biological|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
79839599|NCT04000984|Behavioral|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
79839600|NCT04000984|Behavioral|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
79383040|NCT05500833|Other|Multidimentional observation scale (MDP)|Upon arriving to the hospital (for an hospitalization or a consultation), a trained and declared investigator will inform the patients and their parents of the study, orally and using a written information note. Participation to the study will also be proposed to under aged children in an adequate language and a specific information note will be handed to them. If they wish, they will have a 20 min reflexion time before deciding on participating to the study.One the patient is included, the study will unfold as follows. First, Evaluation of acute dyspnea: general data and dyspnea scores will be collected upon inclusion, and dyspnea score will be collected once again 30 min later, and subsequently one a day until the end of hospitalization (test-retest). Data from clinical examination and treatment modifications will also be collected daily. Second, Evaluation of chronic dyspnea: general data and dyspnea scores will be collected upon inclusion and 1 to 1.5h later
79537848|NCT01468753|Procedure|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
79244117|NCT02859038|Procedure|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
79244118|NCT02859038|Procedure|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
79537849|NCT01468766|Other|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
79537850|NCT01468766|Other|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
79694838|NCT05824156|Other|Placebo|Placebo
79694839|NCT05824117|Other|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
79839601|NCT00816426|Drug|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
80010153|NCT03697005|Other|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
79694840|NCT05824091|Drug|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
79244119|NCT03381027|Procedure|Baby Massage|Structured massage of the baby
80010154|NCT03697005|Other|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
80010155|NCT01378481|Drug|Vorinostat|Given PO
79383041|NCT05496036|Drug|Pembrolizumab|400mg IV
79383042|NCT05493176|Other|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
79694841|NCT05824091|Other|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
79244120|NCT03380949|Procedure|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
79244121|NCT03380949|Procedure|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
79244122|NCT03604757|Drug|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
79244123|NCT03604757|Drug|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
79244124|NCT04799379|Drug|microporous polysaccharide hemospheres (MPH) agent in rectal surgery|Use of microporous polysaccharide hemospheres (MPH) agent in patients after rectal surgery to avoid pelvic collections and the use of any drain
79694842|NCT05823935|Procedure|Bakay purse string|After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.
79694843|NCT05823935|Procedure|Cuff closure via vaginal route group|After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
79244125|NCT03604679|Drug|SyB C-0501|Specified dose on specified days
79244126|NCT02681120|Procedure|Biopsy|
79244127|NCT02681120|Procedure|Blood draw|
79244128|NCT02681120|Procedure|Mammogram|
79244129|NCT02681120|Procedure|MRI|
79244130|NCT03604601|Procedure|salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate
79244131|NCT03124329|Procedure|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
79391799|NCT02556112|Behavioral|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
79537851|NCT01468779|Dietary Supplement|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
79537852|NCT01468779|Dietary Supplement|Sugar pill|
79537853|NCT01468948|Drug|Octanoic Acid|
79537854|NCT01468961|Behavioral|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
79537855|NCT01468805|Procedure|Cockroach mitigation/extermination|
79537856|NCT01469026|Radiation|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
79537857|NCT01469078|Drug|Monofer®|Single Bolus Injections
79537858|NCT01469091|Behavioral|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
79694844|NCT05823909|Device|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
79694845|NCT05823909|Device|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
79694846|NCT05823883|Drug|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
79694847|NCT05823870|Drug|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
79839602|NCT00816426|Drug|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
79391800|NCT02556112|Behavioral|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
79537859|NCT01469104|Other|3 day fast|Subjects will fast for 72 hours
79537860|NCT01469104|Other|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
79694848|NCT05823792|Diagnostic Test|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
79839603|NCT00816426|Drug|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
79537861|NCT01469117|Other|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
79537862|NCT01469130|Drug|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
79537863|NCT01469143|Drug|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
79839604|NCT00816426|Drug|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
79839605|NCT00816426|Drug|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
79839606|NCT00996190|Drug|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
79244132|NCT03124329|Procedure|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
79244133|NCT03124329|Biological|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
79305833|NCT04923945|Drug|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib [Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight <50 kg] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
79839607|NCT03860064|Other|Non intervention|Non
79694849|NCT05823779|Other|Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
79694850|NCT05823766|Behavioral|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
79694851|NCT05823766|Procedure|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
79694852|NCT05823766|Behavioral|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
79839608|NCT00996268|Drug|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
79839609|NCT00996268|Drug|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
79839610|NCT00816504|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
79244134|NCT03124329|Device|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
79839611|NCT01000402|Drug|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
79244135|NCT05078372|Drug|ropivacaine and midazolam intraarticular administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.
79383043|NCT05488496|Behavioral|Nature-based social intervention (NBSI)|"The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct."
79694853|NCT05823766|Procedure|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
79694854|NCT05823766|Procedure|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
79694855|NCT05823766|Behavioral|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
79383044|NCT05488496|Behavioral|Usual care + menu with nature-based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
79383045|NCT05393999|Biological|BMS-986414|Broadly neutralising antibodies BMS-986414
79383046|NCT05393999|Biological|BMS-986413|Broadly neutralising antibodies BMS-986413
79383047|NCT05364918|Drug|Jeksung combined with anti-radiation spray|Treat radiation stomatitis with Jeksung combined with anti-radiation spray
79537864|NCT01469143|Drug|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
79537865|NCT01469169|Drug|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
79537866|NCT01469260|Other|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
79694856|NCT05823740|Other|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
79839612|NCT00640224|Drug|rosiglitazone|4 mg daily for 6 months
79839613|NCT00640224|Drug|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
79839614|NCT01000558|Other|biologic sample preservation procedure|
79383048|NCT05363215|Drug|S-217622|Tablet for oral administration
79537867|NCT01469273|Drug|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
79839615|NCT02550990|Behavioral|Cognitive training|
79839616|NCT02550990|Behavioral|Aerobic exercise training|
79537868|NCT06078462|Other|job related activities|Different types of effort offered by female physiotherapist and female dentist during clinical practicing with patients in internship year
79694857|NCT05823740|Other|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
79694858|NCT05823740|Other|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
79244136|NCT05078372|Drug|ropivacaine and midazolam epidural administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
79694859|NCT05823740|Other|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
79694860|NCT05823740|Other|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
79383049|NCT05359380|Other|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
79383050|NCT05336747|Behavioral|Voice lessons|12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
79383051|NCT05320068|Drug|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
79839617|NCT02550990|Behavioral|Sequential combination of aerobic exercise and cognitive training|
79839618|NCT03742804|Biological|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
79839619|NCT00822042|Other|Samples and procedures|"Scanner, histomorphometry : at the inclusion and M3 visits~whole blood samples, cytoponction : at the inclusion and M3 visits"
79537869|NCT06078449|Device|Therapeutic Ultrasonic|Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of >20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves & to reduce friction.
79537870|NCT06078449|Drug|Hyaluronan intra-articular injection|The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
79537871|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
79537872|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
79383052|NCT05320068|Drug|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
79537873|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
79383053|NCT05296551|Other|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
79839620|NCT01000714|Drug|Psirelax|
80010156|NCT01378481|Radiation|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
80010157|NCT01378481|Other|Laboratory Biomarker Analysis|Correlative studies
80010158|NCT01378481|Other|Pharmacological Study|Correlative studies
79391801|NCT02406924|Procedure|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
79694861|NCT05823740|Other|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
79694862|NCT05823740|Other|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
79694863|NCT05823740|Other|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
79694864|NCT05823714|Drug|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day*7days."
79694865|NCT05823701|Drug|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
79694866|NCT05823701|Drug|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
79694867|NCT05823701|Biological|obinutuzumab|1000mg d4 intravenous infusion per cycle
79694868|NCT05823701|Drug|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
80010159|NCT01378481|Procedure|Therapeutic Conventional Surgery|Undergo neurosurgery
80010160|NCT02168582|Behavioral|physiotherapy as usual in primary care|
80010161|NCT02171468|Drug|Dabigatran high dose|
80010162|NCT02171468|Drug|Dabigatran low dose|
79244137|NCT03601793|Behavioral|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
79244138|NCT03601793|Behavioral|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
79244139|NCT03380871|Biological|NEO-PV-01|Personal Cancer Vaccine
79244140|NCT03380871|Biological|Pembrolizumab|monoclonal antibody against PDL1
79244141|NCT03380871|Other|Adjuvant|immune adjuvant
79244142|NCT03380871|Drug|Carboplatin|chemotherapy
79694869|NCT05823649|Dietary Supplement|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
79694870|NCT05823610|Diagnostic Test|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
79839621|NCT00822198|Device|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
79839622|NCT01000792|Drug|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
79694871|NCT05823597|Behavioral|Sugar Intensive Treatment|see arm description
79694872|NCT05823597|Behavioral|General Health Control|see arm description
79839623|NCT01000792|Drug|Levocetirizine|Levocetirizine
79244143|NCT03380871|Drug|Pemetrexed|chemotherapy
79244144|NCT02237495|Drug|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
79244145|NCT02237495|Drug|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
79244146|NCT02486666|Drug|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES AND CHILDREN WITH THROMBOSIS (FiXET)
79244147|NCT02237807|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
79244148|NCT02237807|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
79383054|NCT05296551|Other|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
79383055|NCT05291377|Other||
79537874|NCT06078423|Biological|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
79537875|NCT06078410|Procedure|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
79694873|NCT05823519|Device|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
79839624|NCT02550756|Drug|CTNX-4975|
79244149|NCT03366753|Procedure|acute normovolemic hemodilution|acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
79244150|NCT03366753|Procedure|In-vitro hemodilution|Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
79244151|NCT03604367|Device|GAITRite assessment|The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
79839625|NCT01000870|Drug|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
79244152|NCT03125265|Other|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
79839626|NCT01000948|Drug|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
79244153|NCT03125187|Biological|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
79391802|NCT02406924|Radiation|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
79391803|NCT02406924|Other|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
79839627|NCT01001026|Biological|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
79839628|NCT01001026|Biological|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
79839629|NCT01001182|Other|non interventional|non interventional
79839630|NCT01001260|Drug|No ASA|Alternative antiplatelet therapy instead of aspirin
79839631|NCT01001260|Drug|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
79839632|NCT01001260|Drug|325 mg ASA|high dose of aspirin prior to PTCA
79839633|NCT00996424|Drug|Acetylcysteine|Inhalation with N-Acetylcysteine
79839634|NCT00996424|Drug|normal saline|Inhalation with normal saline solution
79537876|NCT06078371|Other|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
79537877|NCT06078254|Device|ULTRASOUND|Ultrasound and CT chest for all patients
79537878|NCT06078202|Drug|ABBV-903|Tablet; oral
79537879|NCT06078163|Other|supplementation|daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
79694874|NCT05823493|Behavioral|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
79694875|NCT05823493|Device|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
79694876|NCT05823428|Procedure|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
79694877|NCT05823428|Procedure|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
79839635|NCT00994474|Procedure|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
79244154|NCT03125187|Biological|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
79839636|NCT00994474|Procedure|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
79694878|NCT05823415|Procedure|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
79694879|NCT05823415|Procedure|CAF with CTG|Gold standard surgical technique
79694880|NCT05823389|Procedure|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
79839637|NCT05220280|Drug|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
79839638|NCT05220280|Drug|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
79839639|NCT00318643|Drug|Mitomycin C|intravesical administration
79839640|NCT00318643|Drug|Chemophase|intravesical administration
79839641|NCT00996814|Behavioral|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
79839642|NCT01001650|Biological|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
79244155|NCT03299439|Other|acupuncture|a stimulation of the body or auricular points
79244156|NCT03375177|Other|Natural history of disease|registry plan
79244157|NCT02038946|Drug|Nivolumab|
79537880|NCT06078163|Other|rehabilitation|rehabilitation protocol lasting 20 sessions.
79537881|NCT06078137|Other|Usual PROMs and new PROMs strategy|Patients randomized to intervention receive both usual PROMs and new PROMs strategy
79694881|NCT05823389|Procedure|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
79694882|NCT05823350|Other|Abdominal massage|Abdominal massage after colonoscopy
79694883|NCT05823324|Behavioral|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
79694884|NCT05823285|Drug|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
79694885|NCT05823272|Other|ONS|oral nutritional supplement
79694886|NCT05823246|Drug|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
79839643|NCT01001728|Radiation|Imaging investigations (with radiation)|
79839644|NCT00318565|Device|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
79244158|NCT03377985|Procedure|brachial plexus block|
79244159|NCT03377907|Drug|ketamine in hematoma block|ketamine used in local hematoma block only
79244160|NCT03377907|Drug|ketamine in local intravenous anesthesia|ketamine will be used with lidocaine in local intravenous anesthesia
79839645|NCT00994552|Other|Pressure support ventilation|Pressure support ventilation
79244161|NCT03377907|Drug|Lidocaine Hydrochloride|2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
79694887|NCT05823194|Procedure|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
79694888|NCT05823181|Device|laparoscopy|laparoscopic exploration of common bile duct
79694889|NCT05823168|Drug|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
79244162|NCT05082350|Dietary Supplement|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
79694890|NCT05823155|Procedure|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
79694891|NCT05823103|Diagnostic Test|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
79694892|NCT05823103|Diagnostic Test|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
79839646|NCT00994552|Other|Pressure control ventilation|Pressure control ventilation
79839647|NCT01001884|Other|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
79383056|NCT05286359|Diagnostic Test|NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device|"NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
79383057|NCT05284565|Device|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
79839648|NCT03983083|Behavioral|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
79383059|NCT05397132|Genetic|Blood draw|Patients will provide a blood draw for research and repository
79537882|NCT06078124|Behavioral|Sibling Support for Adolescent Girls in Emergencies|"The Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention is a gender-transformative, 12-week program utilizing a whole family approach wherein an adolescent girl, her male sibling, and a male and female caregiver participate in sessions that are age- and gender-specific and combined with family-wide discussions of session learnings. The sessions are interactive, engaging, and promote self-reflection and discussion on topics such as power, gender, interpersonal communication, and healthy relationships. Given the whole-family approach, SSAGE addresses intersections between spousal relationships, caregiver-child relationships, and relationships between siblings, as they pertain to supporting the mental health and psychosocial well-being of adolescent girls."
79537883|NCT06078111|Behavioral|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
79537884|NCT06078111|Behavioral|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
79537885|NCT06078098|Other|Clinical Information|We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
79537886|NCT06078085|Other|Postoperative rehabilitation program|The rehabilitation program is created by a physical therapist
79537887|NCT06078059|Biological|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
79537888|NCT06078059|Other|Knee aspiration|Knee aspiration
79537889|NCT06078046|Behavioral|Mind-body interventions|Parallel randomized controlled trial
79537890|NCT06078020|Other|Interview|Semi-structured interview to assess understanding and acceptability at 3+/-2 and 14+/-7 days after consent
79694893|NCT05823051|Other|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
79839649|NCT01325389|Dietary Supplement|Myo-Mel|
79839650|NCT01325389|Dietary Supplement|Placebo|
79839651|NCT00994708|Drug|esomeprazole|
79244163|NCT03143829|Other|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
79244164|NCT03141554|Drug|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
79839652|NCT01064557|Drug|all-trans retinoic acid (ATRA)|
79537891|NCT06078007|Behavioral|MyMoodCoach|The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
79383060|NCT05225168|Procedure|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
79839653|NCT01001962|Drug|empagliflozin|ACTIVE TREATMENT FOR DIABETES
79839654|NCT01001962|Drug|Metformin|ACTIVE TREATMENT FOR DIABETES
80010163|NCT03502031|Drug|Renin-Angiotensin (RAAS) alone|maximal RAAS blockade alone for 24months.
79244165|NCT03141554|Drug|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
79383061|NCT05225168|Procedure|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
79383062|NCT01456377|Drug|predinose oral|1 mg for kg for 3 wekees
79383063|NCT01456377|Drug|placebo group|use a oral placebo
80010164|NCT03502031|Drug|Renin-Angiotensin (RAAS) blockers in combination with Spironolactone|maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
80010165|NCT02168738|Drug|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
79244166|NCT03141554|Drug|Normal saline gargle|Normal saline gargle
79305834|NCT03056469|Other|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
79305835|NCT04918563|Drug|Nitroglycerin|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
79383064|NCT05214950|Device|ORI monitoring|Oxygen reserve index monitoring during the surgery
79383065|NCT05204160|Biological|Pembrolizumab|Given IV
79537892|NCT06077890|Other|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
79383066|NCT05169151|Other|Smartphone Application|Utilize smartphone application
79383067|NCT05161637|Drug|TLC590|TLC590 490mg or 588mg
79383068|NCT05161637|Drug|Bupivacain|Bupivacaine 75mg
79383069|NCT05161637|Drug|Ropivacaine|Ropivacaine 150mg
79537893|NCT06077890|Other|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
79694894|NCT05822999|Device|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
79694895|NCT05822999|Device|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
79694896|NCT05822973|Device|3.0 monocryl suture|incision will be closed with absorbable suture
79694897|NCT05822973|Device|3.0 nylon suture|incision will be closed with non-absorbable suture
79694898|NCT05822947|Other|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
79839655|NCT01002040|Biological|Arepanrix|Group A receives one dose of Arepanrix
79839656|NCT01002040|Biological|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
79839657|NCT03978169|Diagnostic Test|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
80010166|NCT02168738|Drug|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
80010167|NCT02168738|Drug|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
80010168|NCT02171546|Drug|Dabigatran etexilate capsules|
79383070|NCT05161637|Drug|Normal saline|Normal saline 20mL or 24mL
79383071|NCT05148559|Behavioral|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
79383072|NCT05148559|Behavioral|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
79383073|NCT05147116|Other|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
80010169|NCT02171546|Drug|Quinidine sulfate tablets|
80010170|NCT02171546|Drug|Fexofenadine tablets|
80016865|NCT02283086|Behavioral|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
80016866|NCT03555630|Diagnostic Test|Thromboelastogram|Blood sample processing for thromboelastogram
80016867|NCT02286440|Other|AssureRx GeneSight genotyping results|
79694899|NCT05822947|Other|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
79694900|NCT05822908|Drug|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
79694901|NCT05822882|Procedure|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
79244167|NCT05082194|Procedure|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
79383074|NCT05138666|Biological|respiratory sample|tracheal aspirate or sputum if the patient is not intubated
79694902|NCT05822804|Device|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
79694903|NCT05822804|Device|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
79839658|NCT00304915|Behavioral|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
79383075|NCT05138666|Biological|blood sample|Blood sampling drawn from an existing arterial line twice a week
79383076|NCT05103722|Other|Combined Aerobic and Resistance Exercise Training|Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
79383077|NCT05102773|Procedure|Biospecimen Collection|Undergo collection of blood and stool
79383078|NCT05102773|Procedure|Computed Tomography|Undergo CT
79537894|NCT06077851|Device|Continuously monitoring|Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.
79537895|NCT06077825|Other|postoperative rehabilitation|30 patients took postoperative rehabilitation after total hip arthroplasty surgery, 3 times a week, for 6 weeks. They took conventional rehabilitation (hip range of motion exercises, progressive strengthening exercises for hip and knee muscles, balance and proprioceptive exercises and gait training).
79537899|NCT06077747|Procedure|Coil Embolization of the Lumbar Vein|Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
79839659|NCT05206786|Other|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
80016868|NCT02286440|Other|Treatment as usual|
79244168|NCT03375099|Behavioral|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
79244169|NCT03375099|Behavioral|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
79383079|NCT05102773|Other|Laboratory Biomarker Analysis|Correlative studies
79694904|NCT05822778|Device|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
79694905|NCT05822778|Device|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
79694906|NCT05822739|Drug|BBM-P002|Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
79694907|NCT05822726|Diagnostic Test|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
79383080|NCT05102773|Other|Questionnaire Administration|Complete questionnaire
79694908|NCT05822713|Drug|Amisulpride|5mg/2ml
80016869|NCT02094924|Drug|GSK587323|Single dose of FDC tablet formulation to be taken orally.
80016870|NCT02094924|Drug|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
79383081|NCT04981782|Other|No study specific intervention, regular care.|Chiropractic care (regular care)
79537900|NCT06077734|Other|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
79694909|NCT05822713|Drug|Amisulpride Placebo|2ml
79694910|NCT05822700|Procedure|Kirschner wire|Transfixing femoral head Kirschner wire
80010171|NCT04385693|Procedure|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
79383082|NCT04967885|Behavioral|Ecological Momentary Implementation Intentions Intervention (EMI-II)|To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.
80010172|NCT04385693|Procedure|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
79244170|NCT03141164|Other|computerized training|Computerized training
79244171|NCT03375021|Drug|CX717 200 mg|CX717 200 mg capsules BID
79244172|NCT03375021|Drug|CX717 800 mg|CX717 4 X 200 mg capsules BID
79244173|NCT03375021|Drug|Placebo|Placebo 200 mg or 800 mg capsules BID
79244174|NCT03141008|Other|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
79244175|NCT03377829|Procedure|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
79244176|NCT03377829|Procedure|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
79244177|NCT04806074|Behavioral|Experimental Group|Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
79383083|NCT04967599|Behavioral|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
79694911|NCT05822687|Behavioral|Education|This is a constant component; all participants will get a psychoeducation digital module.
79694912|NCT05822687|Behavioral|Reappraisal Coping|This digital module will teach reappraisal coping skills.
79694913|NCT05822687|Behavioral|Distraction Coping|This digital module will teach distraction coping skills.
79694914|NCT05822687|Behavioral|Relaxation Coping|This digital module will teach relaxation coping skills.
79694915|NCT05822674|Drug|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
79694916|NCT05822674|Drug|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
79694917|NCT05822661|Dietary Supplement|Black Seed Oil|Dietary supplement
79694918|NCT05822661|Dietary Supplement|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
79694919|NCT05822622|Other|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
79694920|NCT05820425|Other|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
80010173|NCT02171624|Drug|dabigatran etexilate|
80010174|NCT02171624|Drug|quinidine|
80010175|NCT03705351|Device|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
80010176|NCT03705351|Drug|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
80010177|NCT03705351|Radiation|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
80010178|NCT02691767|Drug|pazopanib|
80010179|NCT03696849|Other|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
80010180|NCT04360083|Other|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
80010181|NCT04360083|Other|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
79537901|NCT06077708|Dietary Supplement|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 [1000 IU] and 11.25 µg K2 in each drop were given per day to participants in the test group.
79537902|NCT06077708|Other|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
79537903|NCT06077682|Drug|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
79537904|NCT06077682|Drug|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
79244178|NCT04806074|Behavioral|Comparison Group|Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
79383084|NCT04967599|Behavioral|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
79537905|NCT06077604|Other|Assessment of exposure to air pollution|For each patient, exposure to air pollution will be assessed over a period immediately prior to any flare-up and over four periods at a distance from the flare-up.
79537906|NCT06077539|Drug|Dexmedetomidine|a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.
79839660|NCT05206786|Other|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
79839661|NCT03980197|Other|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
79537907|NCT06077539|Drug|Ketamine|NMDA (N-methyl-D-aspartate) receptor antagonist
79694921|NCT05820360|Behavioral|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
79839662|NCT03980197|Other|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
79244179|NCT03369873|Other|Guidance Manual|The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
79244180|NCT04754360|Other|Evaluation of functional impairment|Symptom burden and functional impairment will be evaluated with EHRA Score, 6-min walk test and 30-second sit-to-stand test
79383085|NCT04962477|Other|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
79383086|NCT04947410|Device|CPAP or nasal dilators|CPAP = active comparator nasal dilators = placebo comparator
79383087|NCT04932148|Other|Incremental HD|Starting haemodialysis at twice weekly frequency
79244181|NCT04754360|Other|Evaluation of pulmonary function|Pulmonary function will be evaluated using basic spirometry and respiratory pressure meter.
79244182|NCT04754360|Other|Evaluation of quality of life|Quality of life will be evaluated using Short Form-36 Questionnaire.
79244183|NCT04754360|Other|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire Short Form
79244184|NCT03369795|Drug|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
79305836|NCT04918563|Drug|Acetylcholine|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
79383088|NCT04932148|Other|Conventional HD|Starting haemodialysis at thrice weekly frequency
79383089|NCT04903353|Drug|Comparison of Risperidone and Aripiprazole|Comparing two FDA approved medications for treatment of irritability in autism
79383093|NCT04902508|Behavioral|Implicit-only|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment.
79694922|NCT05819294|Procedure|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
79694923|NCT05819008|Diagnostic Test|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, & Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, & Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, & De Haes, 1995)."
79694924|NCT05817474|Drug|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
79694925|NCT05812560|Other|postural changes|application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
79694926|NCT05812170|Behavioral|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
79694927|NCT05811013|Device|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
79694928|NCT05811013|Device|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
79694929|NCT05808179|Device|Light|Broad-spectrum white light flashes are ~4000 lux, 2 msec long, occur every 20 s
79694930|NCT05808179|Behavioral|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
79694931|NCT05808179|Device|Sham Light|Broad-spectrum white light flashes are ~4000 lux, 2 msec long, occur once
79694932|NCT05805150|Device|Control Contact Lens (stenfilcon A)|One week wear
80010182|NCT04398849|Biological|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
80010183|NCT03696693|Device|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
79383094|NCT04902508|Behavioral|Explicit-added|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment. Interventionists will also present the rule/pattern guiding the target form.
79383095|NCT04889417|Behavioral|Comprehensive training program|The COPE-iOS program is a pragmatic comprehensive training program that combines computerized cognitive training and progressive supervised video conference physical exercise sessions performed 2-4 weeks prior to surgery and for 3 months after discharge.
79383096|NCT04889417|Behavioral|Active control|The active attention control will include control computer games and supervised video conference stretching exercises performed 2-4 weeks prior to surgery and for 3 months after discharge.
79391804|NCT02406924|Other|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
79537908|NCT06077539|Drug|Magnesium|NMDA (N-methyl-D-aspartate) receptor antagonist
79537909|NCT06077539|Other|normal saline 0.9% NaCL|saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
79537910|NCT06077474|Other|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
79537911|NCT06077448|Device|MRI|imaging modality
79537912|NCT06077435|Device|AI|AI system
80010184|NCT03698721|Procedure|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
80010185|NCT04263207|Other|No intervention|No intervention
80010186|NCT03692793|Other|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
79537913|NCT06077409|Other|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
79694933|NCT05805150|Device|Test Contact Lens (senofilcon A)|One week wear
79694934|NCT05805137|Device|WoundWatch wound management system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch wound management system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
79694935|NCT05797480|Other|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
79694936|NCT05797480|Other|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
79694937|NCT05780567|Drug|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
79694938|NCT05780567|Drug|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
79694939|NCT05751629|Drug|Dostarlimab|Dostarlimab was administered.
80010187|NCT03692637|Biological|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
80010188|NCT03692559|Other|full aseptic dressing|Replacement of the central venous catheters in the dressing process
80010189|NCT03705195|Drug|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 & 5.
79383097|NCT04850807|Behavioral|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
79694940|NCT05751629|Drug|Bevacizumab|Bevacizumab was administered.
79244185|NCT03369795|Other|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
79244186|NCT04733924|Other|Aqueous extract of roots plus leaves of Withania somnifera 125 mg|One capsule before breakfast for 84 days
79244187|NCT04733924|Other|Aqueous extract of roots plus leaves of Withania somnifera 250 mg|One capsule before breakfast for 84 days
79244188|NCT04733924|Other|Microcrystalline Cellulose|One capsule before breakfast for 84 days
79244189|NCT03374865|Other|Facetalk|Area of interest: communication during Facetalk consultations
79244190|NCT03374865|Other|Face-to-face consultation|Area of interest: communication during face-to-face consultations
79694941|NCT05751629|Drug|Niraparib|Niraparib was administered.
79694942|NCT05744271|Device|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
79244191|NCT03377751|Procedure|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~Proportion of low voltage area to area of left atrium body <10% : PVI only~Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
79383098|NCT04848883|Behavioral|Advanced AMS program|"- Telephone acces to infectious disease experts to discuss patients' therpies during working days.~- Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group."
79391805|NCT02404896|Drug|Metreleptin|Metreleptin open-label treatment
79391806|NCT04743622|Drug|Monoprost|preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
79694943|NCT05736640|Drug|Denosumab|
79694944|NCT05736640|Drug|Placebo|
79694945|NCT05734014|Behavioral|Healthy Relationship|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
79694946|NCT05728294|Procedure|Femoral nerve block with ropivacaine 0.5%, 20 ml|Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
80010190|NCT03705117|Biological|V565|Capsules for oral administration
80010191|NCT00101192|Biological|cetuximab|
80010192|NCT00101192|Drug|cisplatin|
80010193|NCT03688269|Drug|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
80010194|NCT03688269|Drug|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
80010195|NCT03688269|Drug|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
80010196|NCT03688191|Drug|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
79244192|NCT03377751|Procedure|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~Proportion of low voltage area to area of left atrium body <10% : PVI only~Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
79694947|NCT05728294|Procedure|Sciatic nerve block with ropivacaine 0.5%, 20 ml|Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
79694948|NCT05725577|Other|care via the telemedicine system|Care via the telemedicine system
79244193|NCT03377751|Procedure|PVI only group|PVI will be performed in this arm.
79537914|NCT06077409|Behavioral|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
79537915|NCT06077383|Dietary Supplement|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
79537916|NCT06077370|Device|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
79537917|NCT06077370|Device|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
79537918|NCT06077357|Other|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
79839663|NCT00997048|Procedure|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
79839664|NCT00997048|Procedure|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
80010197|NCT02255708|Other|Proprioceptive Neuromuscular Facilitation - PNF|
79244194|NCT03374787|Device|Fusion Sound Processor|Sound Processor
79244195|NCT03140306|Diagnostic Test|Patients who have had split dose CT|Computed tomography
79244196|NCT03369561|Diagnostic Test|Serum urea and creatinine and the calculated e GFR|The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
79305837|NCT04918641|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
79305838|NCT02123446|Drug|Cephalexin|Administered orally.
79537919|NCT06077357|Other|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
79537920|NCT06077357|Other|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
79694949|NCT05725577|Other|Routine care|Routine care
79694950|NCT05704829|Drug|Trastuzumab deruxtecan|T-DXd i.v.
79694951|NCT05704829|Drug|Standard-of-Care|Chemotherapy+T+P
79694952|NCT05676840|Procedure|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
79694953|NCT05657366|Procedure|Peritoneal lavage|Continuous abdominal flushing with normal saline
79694954|NCT05638347|Drug|HRS-7085 tablets|Single oral administration
79694955|NCT05638347|Drug|Placebo tablet|Single oral administration
79839665|NCT02532829|Other|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
79839666|NCT01002196|Behavioral|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
79839667|NCT01002196|Behavioral|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
79839668|NCT01066429|Drug|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
80010198|NCT03540602|Dietary Supplement|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
80010199|NCT03540602|Other|Placebo Oral Capsule [CEBOCAP]|Rice flour
80010200|NCT02164838|Drug|Axitinib|
80010201|NCT03688113|Behavioral|Tinnitus application|Use of tinnitus application
80010202|NCT02171702|Drug|BIBW 2992|
80010203|NCT03031431|Device|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
80010204|NCT03540056|Diagnostic Test|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
79537921|NCT06077357|Other|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
79244197|NCT05078216|Other|Physical exercise intervention|"12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity."
79244198|NCT03374709|Drug|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
79244199|NCT05387330|Diagnostic Test|ELISA kit|Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
79244200|NCT02519751|Dietary Supplement|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
79244201|NCT02519751|Dietary Supplement|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
79244202|NCT05393492|Behavioral|Dialectical Behavior Therapy and Radically Open dialectical behavior therapy|"Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions."
79537922|NCT06077357|Other|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
79694956|NCT05636748|Diagnostic Test|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
79694957|NCT05636748|Diagnostic Test|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
79694958|NCT05636748|Diagnostic Test|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
79694959|NCT05636748|Diagnostic Test|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
79694960|NCT05633017|Combination Product|CereVu Objective Dyspnea Score|Small forehead wearable and mobile app
79694961|NCT05628142|Radiation|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
79694962|NCT05591586|Behavioral|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be <15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
79694963|NCT05591586|Behavioral|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
79694964|NCT05564221|Drug|YH35324|Subcutaneous injection of YH35324
79839669|NCT01002274|Drug|MCS-2|2 soft-gel capsules Qd for 40 weeks
79839670|NCT03978247|Diagnostic Test|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
80010205|NCT03696615|Other|Tabata Kettlebell Swing Workout|See description of experimental arm.
80010206|NCT03696615|Other|Control|see description of control arm
80010207|NCT02171780|Drug|BI 1744 CL|
80010208|NCT02171780|Drug|Placebo|
80010209|NCT03540524|Drug|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
80010210|NCT03540524|Drug|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
80010211|NCT03540524|Drug|GLPG2222|GLPG2222 tablet for oral use, daily.
80010212|NCT03540524|Drug|GLPG2737|GLPG2737 capsules for oral use, daily.
80010213|NCT03539978|Other|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
79839671|NCT05200390|Device|Continuous glucose monitor|FreeStyle Libre 2 system
79839672|NCT00994786|Drug|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
79839673|NCT00994786|Drug|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
79839674|NCT01002430|Biological|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
79383099|NCT04848883|Behavioral|Standard AMS program|"- Educational materials.~- Updated local antibiotic guidelines.~- Promotion of delayed antibiotic prescription.~- Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~- Daily report to GP of multiresistant bacteria isolates in urinary samples.~- Quarterly reports to prescribers of AMS outcomes at the centre-level."
79383100|NCT04844021|Behavioral|Nudge|"EHR-based nudge"
79383101|NCT04844021|Behavioral|Nudge+|"EHR-based nudge plus facilitation"
79383102|NCT04831047|Drug|Oxymetazoline hydrochloride 0.1% ophthalmic solution|One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
79383103|NCT04831047|Drug|Placebo|One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
79383104|NCT04792268|Other|Access to eCDSS on wards|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR)."
79694965|NCT05564221|Drug|Placebo|Subcutaneous injection of None of active ingredient
79694966|NCT05564221|Drug|Omalizumab|Subcutaneous injection of Omalizumab
79694967|NCT05557357|Procedure|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
79839675|NCT01002508|Biological|Influenza vaccine|One dose of influenza vaccine
79839676|NCT01002586|Other|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
79839677|NCT01002586|Other|Walking exercise program|walking exercise program
79839678|NCT01002664|Drug|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
79839679|NCT01002664|Drug|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
79839680|NCT00997282|Drug|OPC-262 2.5 mg|orally administered once daily for 24 weeks
79839681|NCT00997282|Drug|OPC-262 5 mg|orally administered once daily for 24 weeks
79839682|NCT00997282|Drug|Placebo|orally administered once daily for 24 weeks
79839683|NCT00997360|Drug|PKI-179|
80010214|NCT02255864|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
79839684|NCT00994942|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
79244203|NCT03377673|Diagnostic Test|CMR|CMR is performed using a 1,5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany)
79244204|NCT05393414|Drug|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
79244205|NCT05393414|Drug|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
79244206|NCT03374397|Drug|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
79244207|NCT05393336|Other|V-sitting posture stabilization|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
79244208|NCT05393336|Other|Modified clamshell exercises|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
79244209|NCT03377595|Drug|Exparel|TAP (Transversus Abdominis Plane) block
79383105|NCT04775680|Biological|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
79383106|NCT04775680|Biological|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
79383107|NCT04743154|Other|In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
79391807|NCT04743622|Drug|Xalatan|preserved latanoprost 1 drop once a day for 12 weeks to target eyes
79694968|NCT05557357|Procedure|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
79694969|NCT05557357|Other|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
79694970|NCT05556564|Drug|observational study|No intervention, observational study
79839685|NCT00995098|Dietary Supplement|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
80010215|NCT02168894|Procedure|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
79244210|NCT03377595|Drug|Exparel|Wound infiltration
79383108|NCT04743154|Other|After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
79383109|NCT04736576|Device|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
79383110|NCT04733950|Other|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
79244211|NCT03377439|Other|Platelet function tests|Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
79244212|NCT05387252|Dietary Supplement|Mulberry juice|Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
79383111|NCT04733950|Other|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
79537923|NCT06077357|Other|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
79537924|NCT06077318|Other|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
79537925|NCT06077318|Other|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
79244213|NCT03369483|Other|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
79244214|NCT04108052|Radiation|Low CT scanner without injection dose|CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
79537926|NCT06077292|Behavioral|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
79537927|NCT06077292|Behavioral|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
79537928|NCT06077279|Behavioral|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
79537929|NCT06077162|Other|Diabetes Nutrition Education Classes|Diabetes nutrition education offered by registered dietitian in group-based classes.
79694971|NCT05550896|Diagnostic Test|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
79694972|NCT05540886|Behavioral|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
80010216|NCT02168894|Procedure|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
79839686|NCT00995098|Dietary Supplement|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
79383112|NCT04725565|Behavioral|Genetics ADvISER Decision Aid Plus Standard Genetic Counselling|The decision aid will educate patients about the types of incidental finding they can learn from genomic sequencing and will give them opportunity select what types of results they would like to receive.
79383113|NCT04725565|Behavioral|Standard Genetic Counseling|Standard Genetic counseling to learn about and select incidental results from genomic sequencing.
79537930|NCT06077162|Other|Healthy Food Security Resource|Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
80010217|NCT02168894|Behavioral|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
79839687|NCT01003912|Biological|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
79839688|NCT01002898|Drug|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
80010218|NCT02171936|Other|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
80010219|NCT05142488|Biological|Covid -19 (recombinante) vaccine|Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
80010220|NCT02172014|Drug|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
80010221|NCT02172014|Drug|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
80010222|NCT02168972|Device|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
80010223|NCT02165150|Other|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
79383114|NCT04719936|Procedure|inferior capsulotomy|inferior capsulotomy will be conducted during posterior approach.
79383115|NCT04719936|Procedure|superior capsulotomy|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
79391808|NCT02400918|Other|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
79694973|NCT05517460|Other|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
79694974|NCT05517460|Other|health education|health education for self-care and medication adherence
79839689|NCT01003054|Drug|Busulfan|130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
79839690|NCT01003054|Drug|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
79839691|NCT01003054|Drug|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.
80010224|NCT02165228|Behavioral|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
80010225|NCT02165228|Behavioral|Nutrition Enhancement|Nutrition education class and behavioral intervention
80010226|NCT02172092|Drug|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
80010227|NCT02261246|Procedure|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
80010228|NCT02165306|Behavioral|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
79244215|NCT04108052|Radiation|Ultra-low dose CT scanner without injection|CT acquisition will be performed at 80 kVp for patient with a body mass index<30, and 100 kVp with a body mass index>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
79537931|NCT06077136|Other|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~frequency: 12 Hz~Amplitude: 2 (fixed)~duration of each exercise: 2-3 minutes~starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
79537932|NCT06077110|Other|P-OMICs-flow services|The Service Intervention is the P-OMICs-flow clinic being delivered at The Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
79537933|NCT06077097|Genetic|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
79537934|NCT06077084|Other|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
79694975|NCT05511792|Procedure|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
79694976|NCT05511792|Procedure|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
79694977|NCT05501561|Biological|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79694978|NCT05501561|Biological|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79694979|NCT05501561|Biological|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79839692|NCT01003054|Procedure|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
79244216|NCT03369327|Drug|sofosbuvir and daclatasvir|"Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~Daclatasvir 30 mg and sofosbuvir 400 mg~Daclatasvir 60 mg and sofosbuvir 400 mg~Daclatasvir 90 mg and sofosbuvir 400 mg"
79244217|NCT02034500|Biological|S. sonnei 1790GAHB|
80010229|NCT02165306|Behavioral|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
80016871|NCT02286206|Drug|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
79244218|NCT02034500|Biological|Placebo|
79244219|NCT05393102|Other|No interventions|No interventions
79244220|NCT03369171|Device|Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)|"MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2)."
79244221|NCT03139994|Other|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
79537935|NCT06077058|Other|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
79537936|NCT06077058|Behavioral|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
79694980|NCT05501561|Biological|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
79694981|NCT05490888|Drug|PHIN-214 Subcutaneous injection|Single or multiple subcutaneous injection(s) with PHIN-214 terlipressin derivative, single ascending dose or multiple ascending dose
79694982|NCT05489081|Behavioral|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
79694983|NCT05468996|Drug|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
79694984|NCT05431179|Drug|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
79694985|NCT05431179|Drug|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
79694986|NCT05431179|Drug|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
79694987|NCT05410301|Device|Static Magnetic and Electric (sBE) device|Home-based Static Magnetic and Electric (sBE) device that is slept in
79694988|NCT05410301|Drug|Lomustine|Chemotherapy drug
79694989|NCT05410301|Drug|Bevacizumab|Chemotherapy and targeted therapy drug
79694990|NCT05409989|Device|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
79694991|NCT05400434|Behavioral|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
80010230|NCT02169206|Radiation|Bilateral shoulder anteroposterior radiography|"Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~In the same position, the patient only elevates the arm up to 90 degrees of abduction."
80010231|NCT03539120|Other|Follow up for survival|No intervention, this is an observational study of survival outcomes.
80010232|NCT02169362|Device|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
80010233|NCT02172170|Drug|BI 10773 single rising dose|
80010234|NCT02172170|Drug|Placebo|
80010235|NCT02255942|Other|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
80010236|NCT02255942|Other|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
79839693|NCT01003132|Other|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
79839694|NCT01004068|Other|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
79839695|NCT01004068|Drug|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
80010237|NCT02255942|Other|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
80010238|NCT02255942|Other|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
80010239|NCT03029247|Drug|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
80010240|NCT03029247|Drug|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
80010241|NCT03696459|Drug|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
80010242|NCT03696459|Drug|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
79537937|NCT06077058|Other|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
79537938|NCT06077058|Other|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
79537939|NCT06077019|Drug|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
79537940|NCT06077019|Drug|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
79537941|NCT06077019|Drug|Placebo|Participants inhale placebo daily
79537942|NCT06077006|Other|questionnaires Only|questionnaires Only
79537943|NCT06076993|Behavioral|BodyKind programme|"BodyKind is a four-session, teacher-led, school-based programme for adolescents aged 15-17 years. This programme was developed by a team of international experts in body image and incorporates empirically supported principles of cognitive dissonance (which involves publicly criticising body ideals) and self-compassion (which involves reappraising self-critical evaluations). BodyKind also contains a social activism component that aims to tackle appearance biases, discrimination and racism and promote greater inclusivity and compassion for others.~Programme Outline Lesson 1. Appearance Bias Lesson 2. Self-compassion & social media Lesson 3. Compassion for others Lesson 4. Becoming agents of change Learning Objectives~To cultivate skills in awareness, mindfulness, non-judgement, reflection, conscientiousness, compassion~To decrease levels of body dissatisfaction and self-criticism~To improve levels of self-compassion, positive body image, psychological wellbeing"
79537944|NCT06076967|Behavioral|Mindfulness Awareness Practices for ADHD (adapted)|The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.
79537945|NCT06076967|Behavioral|Services-As-Usual|Services-As-Usual includes the standard academic support services provided by university disability/accessibility offices.
79694992|NCT05400434|Behavioral|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
79839696|NCT01004068|Behavioral|Structured exercise program plus hypocaloric diet|SET plus diet
79839697|NCT03687970|Other|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
79839698|NCT03687970|Other|Hospital Anxiety and Depression Scale|"14 item scale with even of the items relating to anxiety and seven relating to depression~Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
79839699|NCT03687970|Other|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia [pain provoked by light touch]). Each of the parameters includes recall of the past 24 hours
79839700|NCT03687970|Procedure|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
79839701|NCT03687970|Procedure|Quantitative sensory testing|"Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
80010243|NCT03696459|Drug|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
79839702|NCT03687970|Procedure|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
80010244|NCT03696459|Drug|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
80010245|NCT03696459|Drug|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
80010246|NCT03696459|Drug|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
80010247|NCT03696459|Drug|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
79537946|NCT06076954|Behavioral|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
79694993|NCT05390450|Device|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
79537947|NCT06076941|Other|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
79694994|NCT05390450|Device|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
79694995|NCT05387694|Other|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
79694996|NCT05377411|Device|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
79694997|NCT05377411|Behavioral|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
79839703|NCT03687970|Other|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
79839704|NCT01004224|Drug|BGJ398|
79839705|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
79839706|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
79839707|NCT00530920|Drug|tipranavir|
80010248|NCT03696381|Other|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
79839708|NCT00530920|Drug|ritonavir|
79839709|NCT01004302|Procedure|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
79839710|NCT01003444|Procedure|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
79839711|NCT01004380|Drug|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
79244222|NCT02519517|Procedure|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
79244223|NCT03377283|Biological|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
79244224|NCT03377283|Other|organ perfusion with saline|
79537948|NCT06076928|Device|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
79537949|NCT06076928|Device|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
79244225|NCT03140228|Device|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
79244226|NCT03140228|Device|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
79694998|NCT05375877|Device|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
79694999|NCT05366439|Drug|AT-752|Parallel Assignment
79695000|NCT05366439|Drug|Placebo Comparator|Parallel Assignment
79695001|NCT05365230|Other|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
79695002|NCT05365230|Other|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
79695003|NCT05348226|Diagnostic Test|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
79383116|NCT04715087|Other|Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)|A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.
79391809|NCT02404974|Behavioral|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
79391810|NCT03168984|Drug|UCB0942|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use"
79537950|NCT06076928|Other|Standard Treatment of Care|Standard Conventional Occupational Therapy
79695004|NCT05339893|Device|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
79695005|NCT05330793|Dietary Supplement|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
79695006|NCT05330793|Dietary Supplement|Placebo|placebo without Oral probiotic or toothpaste
79244227|NCT03139760|Behavioral|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
79244228|NCT02890797|Radiation|radiology|The investigators propose to performed a chest ultrasound in infants (<24 months) admitted for bronchiolitis with an available chest X-ray
79244229|NCT03955640|Drug|Olaparib|Given PO
79537951|NCT06076915|Behavioral|Exergame training|"During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation."
79695007|NCT05306977|Device|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by ~50 min rest intervals.
79839712|NCT01003522|Other|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
79244230|NCT03955640|Procedure|Hyperthermia Treatment|Undergo hyperthermia treatment
79244231|NCT03955640|Other|Questionnaire Administration|Ancillary studies
79244232|NCT03955640|Other|Quality-of-Life Assessment|Ancillary studies
80010249|NCT03696381|Other|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
79244233|NCT03369093|Drug|Amoxicillin|Twice daily doses of injectable amoxicillin
79695008|NCT05297578|Biological|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
79695009|NCT05297578|Biological|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
79839713|NCT01003522|Other|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
79839714|NCT01003522|Procedure|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
79839715|NCT01003522|Procedure|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
79839716|NCT01003522|Other|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
79244234|NCT03369015|Drug|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
79839717|NCT01003522|Other|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
80010250|NCT03624153|Behavioral|Robotic-assisted intervention|Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
79839718|NCT01003522|Other|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
79839719|NCT01004458|Behavioral|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
79839720|NCT01004458|Other|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
80010251|NCT03624153|Behavioral|Conventional rehabilitation intervention|Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
79244235|NCT03369015|Drug|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
79383117|NCT04715087|Other|Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)|"A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application"
79383118|NCT04704973|Behavioral|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
79383119|NCT04700514|Drug|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
79537952|NCT06076902|Device|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
79537953|NCT06076902|Device|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
79695010|NCT05267496|Device|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
80010252|NCT03624075|Other|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
79695011|NCT05267496|Procedure|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~Directed ventilation~Physical conditioning Post-surgical rehabilitation~Diaphragmatic mobilization~Thoracic expansion through incentive flow spirometry"
79244236|NCT03369015|Drug|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
79695012|NCT05265715|Other|Low AGE diet|"The recommended daily AGE intake will be either:~7,500 kilounits [ku], which is a 50% reduction from the average 15,000 ku consumed by most adults or~a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
79244237|NCT05178680|Other|relaxation session combining music and soft light|The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
79244238|NCT02038322|Device|The Stork - Conception Aid|
79244239|NCT03140072|Drug|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
79695013|NCT05265715|Procedure|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
79695014|NCT05260944|Device|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
79244240|NCT03140072|Drug|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
79244241|NCT03374241|Biological|HM15211 or Placebo|Long-acting tri-agonist
79537954|NCT06076889|Behavioral|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the portal for 2 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference.
79537955|NCT06076850|Device|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~EFD 0.096 mJ/mm2~2 sessions / week; 5000 shocks / session~6 weeks treatment~total: 12 sessions~Li-ESWT to start after removal of indwelling catheter"
79695015|NCT05260944|Device|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
79695016|NCT05260944|Other|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
79839721|NCT01003600|Behavioral|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
79839722|NCT01004536|Device|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
79839723|NCT01004536|Other|no treatment|left untreated during the study period
79244242|NCT03890744|Drug|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
79537956|NCT06076850|Device|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~EFD 0 mJ/mm2~2 sessions / week; 5000 shocks / session~6 weeks treatment~total: 12 sessions~Li-ESWT to start after removal of indwelling catheter"
79537957|NCT06076837|Drug|Botensilimab|an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
79537958|NCT06076837|Drug|Balstilimab|a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
79839724|NCT01003678|Drug|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
79839725|NCT01003756|Other|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
79839726|NCT04000204|Device|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
80010253|NCT03692247|Other|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
79244243|NCT03374163|Drug|intralipid 20%|milky soulation for energey supplement.
79244244|NCT03137732|Device|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
79244245|NCT03374007|Biological|Geptanolimab Injection 1mg/kg|single-dose:1mg/kg
79244246|NCT03374007|Biological|Geptanolimab Injection 3mg/kg|single-dose: 3mg/kg
79244247|NCT03374007|Biological|Geptanolimab Injection 10mg/kg|single-dose:10mg/kg
79244248|NCT03374007|Biological|Geptanolimab Injection 1mg/kg, q2w*6|multiple dosing: 1mg/kg, q2w*6
79244249|NCT03374007|Biological|Geptanolimab Injection 3mg/kg, q2w*6|multiple dosing: 3mg/kg, q2w*6
79244250|NCT03374007|Biological|Geptanolimab Injection 10mg/kg, , q2w*6|multiple dosing: 10mg/kg, , q2w*6
79244251|NCT03374007|Biological|Geptanolimab Injection 280mg, q3w|multiple dosing: 280mg, q3w
79244252|NCT03374007|Biological|Geptanolimab Injection 3mg/kg, q2w|multiple dosing: 3mg/kg, q2w
79244253|NCT04525521|Other|Hand sanitizer and hand washing|All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
79839727|NCT04000204|Device|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
79839728|NCT01003834|Behavioral|Computerized brief intervention|Intervention based on Motivational Interviewing technique
79244254|NCT05392166|Diagnostic Test|blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound|blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
79244255|NCT02853331|Biological|Pembrolizumab|Intravenous infusion
79244256|NCT02853331|Drug|Axitinib|Oral tablet
79244257|NCT02853331|Drug|Sunitinib|Oral capsule
79244258|NCT04525209|Other|No intervention|No intervention
79244259|NCT03139292|Device|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
79244260|NCT03139292|Device|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
79244261|NCT02519673|Device|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
79244262|NCT03137654|Other|Affective Training|Intervention includes up to 12 training sessions (~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
79244263|NCT03137654|Other|Neutral Training|Intervention includes up to 12 training sessions (~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
79244264|NCT03136640|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
79383120|NCT04669145|Drug|Ropivacaine|Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
79383121|NCT04667364|Device|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
79244265|NCT03604237|Diagnostic Test|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
79383122|NCT04652050|Drug|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
79383123|NCT04651634|Drug|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
79391811|NCT03168984|Other|Placebo|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use"
79537959|NCT06076837|Drug|Chloroquine Phosphate|an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
79537960|NCT06076837|Drug|Celecoxib|a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
79537961|NCT06076824|Drug|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
79537962|NCT06076824|Other|Placebo|Saline solution
79537963|NCT06076772|Drug|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
79537964|NCT06076759|Drug|Intrathecal morphine or dexmedetomidine|Intrathecal injection
79537965|NCT06076720|Device|New head-mounted visual aids|New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
79537966|NCT06076642|Biological|TAK-881|Participants will receive SC infusion of TAK-881.
79537967|NCT06076629|Other|Low temperature (16#) group|The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.
79537968|NCT06076629|Other|Moderate temperature (22#) group|The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
79537969|NCT06076616|Behavioral|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
79537970|NCT06076603|Drug|nebulized polymyxin B|The experimental group received intravenous combined nebulization of polymyxin B
79537971|NCT06076590|Drug|maintenance fluid|Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
79537972|NCT06076577|Behavioral|Prehabilitation Exercise Group|A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
79839729|NCT01003834|Behavioral|Computerized health screening|Behavioral intervention
79839730|NCT01003834|Behavioral|Computerized assessment|Behavioral intervention
79839731|NCT01003834|Behavioral|Therapist-delivered motivational intervention|Behavioral intervention
79244266|NCT02675439|Drug|ADU-S100|
79244267|NCT02675439|Biological|ipilimumab|
79244268|NCT02035423|Dietary Supplement|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
79244269|NCT02035423|Dietary Supplement|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
79695017|NCT05260112|Other|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
79839732|NCT01004692|Device|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
79839733|NCT04000126|Device|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
79383124|NCT04650074|Drug|LIDOCAINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
79383125|NCT04650074|Drug|LIDOCAINE 20 mg + KETAMINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
79839734|NCT04000126|Device|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
79839735|NCT04000126|Drug|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
79839736|NCT04000126|Drug|Placebo|100ml 0,9% NaCl iv 10min before intubation
79839737|NCT04000126|Device|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
79839738|NCT04000126|Device|HR|HR in beats/min will be measured by the electrocardiogram monitor
79839739|NCT04000126|Device|BP|BP will be measured automatically by an occluding upper arm cuff
79839740|NCT01004926|Device|Echelon foot|One Echelon foot for each subject, for a period of a month.
79839741|NCT01008826|Dietary Supplement|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
79244270|NCT02035423|Dietary Supplement|Non-Fortified Milk|Daily consumption of non-fortified milk
79244271|NCT03124641|Device|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
79383126|NCT04650074|Drug|LIDOCAINE 20 mg + KETAMINE 40 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute"
79383127|NCT04631445|Other|Ketogenic Diet|Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to < 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
79383128|NCT04620304|Biological|UB-421 SC(dB4C7C22-6 mAb)|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
79244272|NCT03124641|Procedure|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
79839742|NCT01005004|Biological|HuCNS-SC cells|intracerebral transplantation
79839743|NCT01005082|Behavioral|Low salt diet|
79839744|NCT01005082|Behavioral|Water therapy alone|
79244273|NCT05104970|Drug|SunnyD insta ampoule|Cholecalciferol 200000 IU insta ampoule
79244274|NCT05104970|Dietary Supplement|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU softgel capsule
79244275|NCT05104970|Drug|Placebo SunnyD insta ampoule|Olive oil
79244276|NCT05104970|Dietary Supplement|Placebo SunnyD STAT softgel capsule|Olive oil
79244277|NCT03604081|Other|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
79383129|NCT04620278|Genetic|DNA or RNA Sequencing|Samples will be used for whole exome (DNA) or RNA sequencing
79383130|NCT04606173|Other|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
79383131|NCT04601571|Device|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
79383132|NCT04589598|Device|Femoral Neck System|femoral neck system using bolt and antirotation screw with one/two hole plate
79839745|NCT01008982|Drug|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
80010254|NCT03692169|Procedure|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
79695018|NCT05256836|Other|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
79695019|NCT05217004|Other|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
79695020|NCT05217004|Other|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
79695021|NCT05206487|Dietary Supplement|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
79695022|NCT05203497|Drug|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
79695023|NCT05181709|Drug|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
79695024|NCT05181709|Biological|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108^8 EID50."
79695025|NCT05181709|Biological|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10^8 EID50."
79695026|NCT05181709|Biological|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
79839746|NCT03999736|Device|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
79839747|NCT01005160|Drug|Metformin|CKD-501 0.5mg, metformin 1000mg
79383133|NCT04589598|Device|Multiple Cannulated Screw|multiple cannulated screw using 3 or 4 cannulated screw
79383134|NCT04578886|Drug|Guanfacine|Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
79383135|NCT04578886|Drug|Placebo|Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
79383136|NCT04571060|Drug|Zavegepant|One dose of zavegepant
79383137|NCT04571060|Drug|Placebo|One dose of matching placebo
79383138|NCT04550585|Other|Education: Session 1 - Basics of type 1 management|"In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
79383139|NCT04550585|Other|Session 2 - Carbohydrate counting|"In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
79383140|NCT04550585|Other|Education: Session 3 - Insulin self- adjustment|"In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
79383141|NCT04550585|Other|Education: Session 4 - Sick day rules and physical activity dose adjustments|"In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
79383142|NCT04550585|Other|Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)|"In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?"
79383143|NCT04550585|Other|Education: Session 6 - Trouble shooting the pump (for pump users)|"In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?"
79383144|NCT04548713|Device|4% EDTA|Sterile Catheter Lock Solution
79383145|NCT04548713|Device|Saline|Saline Lock Solution
79383146|NCT04545515|Drug|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
79383147|NCT04545515|Drug|IVA|Tablet for oral administration.
79383148|NCT04512066|Drug|RO6889450|Participants will receive oral RO6889450 QD.
79383149|NCT04512066|Drug|Placebo|Participants will receive oral placebo QD.
79383150|NCT04512066|Drug|Risperidone|Participants will receive oral risperidone QD.
79383151|NCT04506892|Behavioral|Meditation|meditation
79695027|NCT05181709|Biological|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
79695028|NCT05166980|Dietary Supplement|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
79695029|NCT05166980|Dietary Supplement|Iodized salt|Salt fortified with iodine
79695030|NCT05166460|Device|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
79695031|NCT05110495|Drug|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
79383152|NCT04448847|Dietary Supplement|Bif195|Active trial product with minimum 100 billion CFU daily dose
80010255|NCT03624309|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
79383153|NCT04448847|Other|Placebo|Placebo similar to trial product but without Bif195
79839748|NCT01005160|Drug|CKD-501|CKD-501 0.5mg, metformin 1000mg
79839749|NCT03878758|Device|BD Nano™ PRO|Insulin Pen needle
79839750|NCT03878758|Device|33G Artsana Insupen Extr3me|Insulin Pen Needle
80010256|NCT03624309|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
80010257|NCT03624387|Other|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
80010258|NCT04050111|Biological|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
79244278|NCT03604081|Other|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
79244279|NCT03368703|Device|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
79383154|NCT04426318|Behavioral|Healthy Minds Program Foundations Training|The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
79383155|NCT04421092|Procedure|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
79383156|NCT04421092|Procedure|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
80010259|NCT03687879|Other|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
80010260|NCT03696147|Device|Magnetic resonance imaging|Diffusion weighted sequence of MRI
80010261|NCT03687801|Behavioral|Online hearing support|The intervention group will follow an online hearing support for five weeks
80010262|NCT03687801|Behavioral|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
79383157|NCT04421092|Procedure|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
79383158|NCT04412083|Behavioral|PPA Tele-Savvy Pilot Intervention|We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
79383159|NCT04406727|Biological|UB-421|UB-421 in combination with their ARV
79383160|NCT04406727|Other|Antiretroviral (ARV)|Antiretroviral (ARV)
79383161|NCT04401891|Behavioral|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
79383162|NCT04397614|Other|mHealth Assessments|Daily symptom tracker
79537973|NCT06074367|Drug|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins & vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
79537974|NCT06074367|Drug|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
79537975|NCT06074367|Drug|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
79537976|NCT06074354|Behavioral|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
79839751|NCT03878758|Device|34G Artsana Insupen Extr3me|Insulin Pen Needle
79839752|NCT03878758|Device|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
79383163|NCT04385732|Device|2D or 3D Melanoma Surveillance Photography|Total body imaging using 2D or 3D Melanoma Surveillance Photography plus digital dermoscopy.
79383164|NCT04364945|Drug|dexmedetomidine|administration of dexmedetomidine 1 mcg/kg/hr
79839753|NCT03878602|Procedure|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
79839754|NCT03878602|Procedure|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
79839755|NCT01005238|Drug|Lamivudine|
79839756|NCT01005238|Drug|Telbivudine|
79839757|NCT01009216|Drug|ABT-384|Doses will be administered daily for 5 days.
79695032|NCT05108883|Device|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
79695033|NCT05094011|Biological|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10^7 per hemisphere (total 6×10^7 cells) or 1×10^8 per hemisphere (total 2×10^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
80010263|NCT03687645|Diagnostic Test|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
80010264|NCT03692091|Procedure|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
79244280|NCT03368703|Device|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
79695034|NCT05086276|Drug|FX-322|Active Comparator
79244281|NCT03604003|Drug|potassium losartan|treated with bedtime or awakening doses of potassium losartan
79695035|NCT05086276|Drug|Placebo|Placebo
79244282|NCT03139526|Other|observational study so no intervention|observational study, so no intervention
79244284|NCT05391854|Dietary Supplement|Pep2dia|700 mg Pep2Dia® 15 min prior to breakfast and 700 mg Pep2Dia® 15 min prior to dinner
79244285|NCT05391854|Dietary Supplement|Placebo|700 mg placebo 15 min prior to breakfast and 700 mg placebo 15 min prior to dinner
79244286|NCT03607669|Other|Mangafodipir trisodium|Manganese-based MRI contrast agent
79244287|NCT02518581|Procedure|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
79695036|NCT05065294|Drug|Psilocybin therapy|- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
79383165|NCT04364945|Drug|remifentanil|administration of remifentanil 0.1-0.2 mcg/kg/min
79383166|NCT04364945|Drug|Sevoflurane|Anesthesia is maintained using sevoflurane.
79383167|NCT04356963|Behavioral|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
79383168|NCT04356963|Behavioral|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
79383169|NCT04356963|Behavioral|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
79383170|NCT04319731|Biological|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
79391812|NCT02701296|Drug|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
79695037|NCT05058287|Drug|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
79244288|NCT05391776|Drug|TST002 Injection|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
79244289|NCT05391776|Drug|placebo|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
79244290|NCT03607591|Other|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
79244291|NCT03364010|Behavioral|Evaluation of proprioception|Velocity perception and Position perception
79244292|NCT03364010|Behavioral|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
79244293|NCT03364010|Behavioral|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
79244294|NCT03607513|Drug|JNJ-64264681|For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
79244295|NCT03607513|Drug|Placebo|Matching placebo to JNJ-64264681 will be administered as oral solution.
79695038|NCT05058287|Drug|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
79695039|NCT05016375|Other|Interview|Interview with individuals with T2DM
79695040|NCT04990609|Device|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic Ultrasound (EUS)-guided Radiofrequency Ablation (RFA) consists of the application of alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor which induces the release of large amounts of cellular debris which represent a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
79695041|NCT04990609|Drug|Neoadjuvant chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician [possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)].
79695042|NCT04968899|Drug|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
80010265|NCT03695991|Procedure|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
80010266|NCT03692013|Drug|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
79695043|NCT04968899|Drug|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
79695044|NCT04965818|Drug|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
79695045|NCT04963205|Device|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
79244296|NCT03607435|Device|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
79244297|NCT03122288|Behavioral|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
79383171|NCT04263948|Device|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
79695046|NCT04963205|Other|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
79695047|NCT04957693|Behavioral|vegan diet and lifestyle changes|vegan diet and lifestyle changes
79695048|NCT04941105|Drug|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
79695049|NCT04941105|Drug|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
79695050|NCT04925687|Biological|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
79695051|NCT04922632|Behavioral|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
79839758|NCT01005394|Device|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
80010267|NCT03687489|Device|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
79244298|NCT03122288|Other|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
79244299|NCT03368469|Device|transcranial direct current stimulation|The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
79383172|NCT04235608|Drug|Inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
79383173|NCT04235608|Drug|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs.
79383174|NCT04233554|Behavioral|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
79391813|NCT02701296|Drug|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
79391814|NCT02558374|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
79537977|NCT06074354|Behavioral|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
79537978|NCT06074341|Behavioral|Mindfulness-based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
79695052|NCT04922632|Behavioral|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
79695053|NCT04922632|Behavioral|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
79695054|NCT04922632|Behavioral|Treatment As Usual (TAU)|TAU is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
79695055|NCT04922138|Drug|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
79695056|NCT04906590|Drug|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
79695057|NCT04873102|Drug|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
79695058|NCT04871516|Other|Quality-of-Life Assessment|Ancillary studies
79695059|NCT04871516|Other|Questionnaire Administration|Ancillary studies
79695060|NCT04871516|Radiation|Radiation Boost|Undergo radiation therapy boost
79695061|NCT04871516|Procedure|Therapeutic Surgical Procedure|Undergo standard surgery
79839759|NCT05224414|Behavioral|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
79695062|NCT04871516|Radiation|Whole Breast Irradiation|Undergo standard WBI
79839760|NCT05224414|Behavioral|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
79244300|NCT03603769|Dietary Supplement|Food supplement capsules containing Salmon-Polar Lipids|Postprandial decreased Platelet activation/aggregation in subjects, after the food supplement capsule consumption
79391815|NCT02558374|Drug|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
80010268|NCT04313283|Behavioral|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
79391816|NCT02558374|Other|Placebo|1 drop QD, AM, OU
79391817|NCT01582451|Drug|LY2605541|
79537979|NCT06074341|Behavioral|Online Mutual Support Groups|Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
79537980|NCT06074328|Device|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
79695063|NCT04871516|Other|Breast MRI|A baseline breast MRI
79695064|NCT04870710|Device|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
79695065|NCT04860375|Procedure|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
79695066|NCT04860375|Other|Standard care|Standard care in Sweden
80010269|NCT03695835|Drug|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
80010270|NCT03695835|Device|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
79244301|NCT03603769|Dietary Supplement|Placebo food supplement capsule|Postprandial unaffected platelet activation/aggregation in subjects, after the food supplement capsule consumption
79305839|NCT04918953|Drug|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
79391818|NCT01582451|Drug|Insulin glargine|
79537981|NCT06074276|Other|Food: whole almonds|60 grams or (~2 oz) will be consumed 5 times per week.
79695067|NCT04860141|Drug|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
79695068|NCT04860141|Drug|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
79839761|NCT01005472|Drug|sunitinib malate|
79839762|NCT01005472|Drug|temozolomide|
79839763|NCT03742726|Device|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
79244302|NCT03052010|Other|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
79695069|NCT04858802|Device|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
79695070|NCT04858802|Procedure|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
80010271|NCT03691701|Other|strict blood pressure control|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
79244303|NCT03052010|Drug|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
79244304|NCT03052010|Drug|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
79244305|NCT03368391|Drug|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
79244306|NCT03368391|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
79244307|NCT03368391|Drug|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
79244308|NCT03368391|Drug|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
79244309|NCT03368391|Drug|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
79244310|NCT02035501|Drug|L-Tyrosine|
79244311|NCT02035501|Drug|Placebo|
79244312|NCT03603691|Diagnostic Test|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
79383175|NCT04231097|Other|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
79383176|NCT04180020|Other|ID/LAB|ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
79383177|NCT04180020|Other|TAU|TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
79383178|NCT04161027|Drug|Pregabalin 75mg|Pregabalin 75 mg capsule
79383179|NCT04161027|Drug|Placebos|Placebo capsule
79383180|NCT04144842|Biological|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
79244313|NCT03603691|Diagnostic Test|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
79244314|NCT03603691|Diagnostic Test|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
79244315|NCT03603691|Diagnostic Test|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
79244316|NCT03603691|Diagnostic Test|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
79244317|NCT03603691|Diagnostic Test|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
79383181|NCT04043104|Drug|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10^11 vg/gland
79383182|NCT04043104|Drug|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10^10 vg/gland
79537982|NCT06074276|Other|Food: non-nut snack|Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth
79537983|NCT06074250|Dietary Supplement|Fish oil|1500mg EPA +1000mg DHA daily
79537984|NCT06074250|Dietary Supplement|Probiotics|Combination strain of lactobacillus and bifidobacteria
79537985|NCT06074250|Behavioral|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
79537986|NCT06074250|Behavioral|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
79537987|NCT06074224|Other|Sleep assessment score|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
79695071|NCT04857697|Procedure|Biopsy|Undergo biopsy
79695072|NCT04857697|Procedure|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
79695073|NCT04857697|Drug|Probiotic|Given PO
79695074|NCT04857697|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
79695075|NCT04834128|Drug|TCB008|administration of gamma delta T cells by IV bolus injection
79695076|NCT04823156|Dietary Supplement|Calcium|Daily calcium food supplement.
79695077|NCT04816825|Device|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
79839764|NCT01005550|Drug|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
79839765|NCT01005550|Drug|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
79839766|NCT01005550|Drug|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
79839767|NCT01005550|Drug|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
79839768|NCT03999580|Drug|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion < 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion < 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
79839769|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po
79839770|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
79839771|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
79244318|NCT02509442|Procedure|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
79244319|NCT03373305|Drug|Brentuximab Vedotin|Given IV
79244320|NCT03373305|Drug|Lenalidomide|Given PO
79244321|NCT03373305|Other|Laboratory Biomarker Analysis|Correlative studies
79537988|NCT06074224|Other|No Score|The patients in the control group will include those for whom their clinician was not given their sleep questionnaire result before the visit.
79839772|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
79839773|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
79839774|NCT05734222|Procedure|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
79839775|NCT01005628|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
79839776|NCT00530842|Drug|Tiotropium plus Salmeterol|
79839777|NCT00530842|Drug|Fluticasone/Salmeterol|
79839778|NCT01005784|Drug|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
79244322|NCT03603613|Behavioral|YRI|The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
79383183|NCT04043104|Drug|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10^11 vg/gland
79383184|NCT04043104|Drug|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10^11 vg/gland
79383185|NCT04043104|Drug|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10^12 vg/gland
79383186|NCT04043104|Drug|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10^11 vg/gland
79383187|NCT04043104|Drug|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10^12 vg/gland
79383188|NCT04043104|Drug|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10^12 vg/gland
79839779|NCT01005784|Drug|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
79537990|NCT06074172|Drug|Cannabidiol in Oral Dose Form|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
79839780|NCT05734144|Procedure|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
79839781|NCT05734144|Procedure|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
79839782|NCT01005862|Biological|PF-04360365|10 mg/kg, single dose administered intravenously
79839783|NCT01005862|Drug|Placebo|Placebo
79839784|NCT01005940|Device|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
79839785|NCT05733988|Procedure|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
79839786|NCT01006096|Drug|erlotinib|100mg tablet, once daily for 16 weeks
80010272|NCT03695757|Biological|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
79244323|NCT03603613|Behavioral|EPP|The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
79244324|NCT05391464|Procedure|Peripheral Nerve Block|Utilized preoperatively with sedation during surgery, or postoperatively for additional anesthesia after GA.
79244325|NCT03607279|Procedure|NGAL|
79383189|NCT04031170|Behavioral|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
79383190|NCT04031170|Other|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
79383191|NCT04019964|Drug|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
79383192|NCT04007432|Other|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
79383193|NCT03996291|Drug|Tolebrutinib|Pharmaceutical form: Film coated tablet Route of administration: Oral
79383194|NCT03977584|Drug|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
79383195|NCT03977584|Drug|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
79383196|NCT03977584|Other|[^18F]GTP1|IV [^18F]GTP1 will be administered up to three times. The first primary [^18F]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second [^18F]GTP1 tau PET scan from Week 248 to Week 260. The third and optional [^18F]GTP1 tau PET scan will supplement the two primary scans.
79383197|NCT03949881|Biological|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
79695078|NCT04816825|Other|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
79695079|NCT04813653|Drug|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
79695080|NCT04803747|Drug|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
80010273|NCT03695757|Biological|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
80010274|NCT03687255|Drug|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
79244326|NCT03139214|Behavioral|Parenting Intervention|
79244327|NCT03602443|Behavioral|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
79244328|NCT03602443|Behavioral|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
79383198|NCT03941483|Drug|ASP1128|Intravenous Infusion
79383199|NCT03941483|Drug|Placebo|Intravenous Infusion
79383200|NCT03927521|Procedure|Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance|Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
79383201|NCT03914716|Diagnostic Test|Study group|Subjects will have physical, imaging examinations and provide samples for biological markers
79383202|NCT03889756|Drug|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
79383203|NCT03889756|Drug|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
79695081|NCT04803747|Drug|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
80010275|NCT03687255|Drug|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
79695082|NCT04790474|Drug|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~ixazomib 3 mg on Days 1, 4, 8 and 11~pomalidomide 4 mg on Days 1 through 14~dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~ixazomib 4 mg on Days 1, 8 and 15~pomalidomide 4 mg on Days 1 through 21~dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
79695083|NCT04789161|Procedure|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
79383204|NCT03887559|Behavioral|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
79383205|NCT03887559|Other|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
79695084|NCT04789161|Procedure|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
79695085|NCT04787055|Device|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
79695086|NCT04777617|Other|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
79695087|NCT04767529|Drug|EFX|Administered by subcutaneous injection
79695088|NCT04767529|Drug|Placebo|Administered by subcutaneous injection
79695089|NCT04743570|Drug|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
79695090|NCT04743570|Drug|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
79839787|NCT01006096|Other|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
79839788|NCT01006174|Other|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
79839789|NCT01006174|Other|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
79839790|NCT01006174|Other|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
79244329|NCT03376815|Diagnostic Test|landscape sample method|200 cases of different tumor tissues will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .
79383206|NCT03882580|Drug|Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
79383207|NCT03856177|Behavioral|Emotion Induction|Described in arm
79383208|NCT03845114|Other|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
79839791|NCT05733442|Other|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
79383209|NCT03845114|Other|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
79383210|NCT03845114|Other|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
79383211|NCT03845114|Other|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
79839792|NCT05733442|Other|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
79839793|NCT01006408|Procedure|Low Level Laser|Low Level Laser twice a week for 8 weeks
79839794|NCT01006408|Procedure|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
79244330|NCT03139136|Drug|MBS2320|As described in the arm descriptions
79244331|NCT03139136|Drug|Placebo|As described in the arm descriptions
79244332|NCT03376737|Drug|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
79244333|NCT03607201|Other|No intervention|Routine care
79244334|NCT03139058|Other|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
79244335|NCT03373227|Drug|Envarsus|Patients will take once daily Envarsus
79383212|NCT03778502|Drug|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
79383213|NCT03775200|Drug|Psilocybin|Dose-finding
79383214|NCT03774121|Device|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve & anterior femoral cutaneous nerve) guided by ultrasound visualization.
79383215|NCT03774121|Other|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
79383216|NCT03774121|Device|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
79537991|NCT06074172|Drug|Placebo in Oral Dose Form|Placebo press pills provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
79537992|NCT06074159|Behavioral|In-clinic report-back|Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
79537993|NCT06074107|Drug|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
79537994|NCT06074094|Drug|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
79695091|NCT04736030|Behavioral|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
79695092|NCT04718025|Drug|Ticagrelor 90mg|Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
79839795|NCT01006486|Other|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
79839796|NCT01006486|Other|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
79244336|NCT03607123|Other|programing of pacemaker|Different programing parameters will be set in different group/stage
79244337|NCT03607123|Procedure|AF ablation|AF ablation can only be performed in Step 3
79383217|NCT03761498|Other|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
79244338|NCT03607123|Drug|Anti arryhthmic drugs|Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
79244339|NCT02484716|Drug|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
79695093|NCT04718025|Drug|Ticagrelor 60mg|Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
79839797|NCT01006564|Other|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
79839798|NCT01006564|Other|Other|Insertion of gold seeds into prostate for image registration.
79839799|NCT01006720|Drug|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
79839800|NCT01006720|Drug|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
79383218|NCT03737864|Behavioral|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
79383219|NCT03737864|Behavioral|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
79383220|NCT03689855|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
79537995|NCT06074081|Other|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
79839801|NCT01006720|Drug|Saline|Saline 0.9% (Saline)
79839802|NCT04000048|Genetic|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
79244340|NCT02484716|Drug|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
79244341|NCT03367611|Diagnostic Test|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
79537996|NCT06074081|Other|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
79244342|NCT03602365|Device|Gentle Jogger (GJ)|Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
79244343|NCT03607045|Device|headless screw|headless screw group
79305840|NCT04918953|Drug|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
79305841|NCT04918485|Other|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
79537997|NCT06074042|Other|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
80010276|NCT03695523|Behavioral|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
79537998|NCT06073990|Behavioral|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
79537999|NCT06073964|Behavioral|Trauma Resilience & Understanding Self-help Therapy|A self-help psychosocial therapeutic intervention requiring one to undergo a basic training in its community-based utilization.
79839803|NCT05733052|Other|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
80010277|NCT03687177|Other|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
79839804|NCT01006876|Drug|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
79839805|NCT01006876|Drug|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
79839806|NCT01006876|Drug|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
80010278|NCT03687177|Other|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
80010279|NCT03691545|Behavioral|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
80010280|NCT03691467|Device|immediate dental implant|immediate dental implant placement in freshly extracted socket.
80010281|NCT03691467|Drug|Hyaluronic Acid|topical application of hyaluronic acid
79839807|NCT05043220|Device|PPG and PROM|description will follow
80010282|NCT03968211|Biological|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
80010283|NCT03695289|Behavioral|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
80010284|NCT03695289|Behavioral|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
79383221|NCT03689855|Drug|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
79383222|NCT03689855|Procedure|Peripheral blood draw|-Baseline and Cycle 2 Day 1
79383223|NCT03689855|Procedure|Biopsy|"If archival biopsy tissue not available, participant will undergo biopsy at baseline~When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
79383224|NCT03636568|Other|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients < 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients >100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~Serum Na level must be < 145 mEq/l~Patient should be taking fluids by mouth~Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
79383225|NCT03635996|Drug|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
79383226|NCT03635996|Device|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
79383227|NCT03613181|Drug|ANG1005|Investigational drug
79538000|NCT06073925|Drug|VIT D|50000 IU per week of VIT D
80010285|NCT02165540|Other|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
80010286|NCT02165618|Other|Medication review, based on but not limited to the RASP list|"Systematic approach:~Medication reconciliation~Applying the RASP list~Expert review (not based on the RASP list)~Multidisciplinary discussion"
79538001|NCT06073912|Procedure|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
79538002|NCT06073912|Procedure|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
79538003|NCT06073912|Procedure|Bone graft harvesting|Bone graft harvesting from the chin area
79538004|NCT06073912|Procedure|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
79538005|NCT06073912|Procedure|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
79244344|NCT03373149|Drug|Growth hormone/HPuFSH/GnRH antagonist|"Growth hormone (Somatropin, Sedico, Egypt) [4 IU/day] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) [300 IU/day] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
79244345|NCT03373149|Drug|HPuFSH/GnRH antagonist|"Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) [300 IU/day] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
79538006|NCT06073912|Device|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
79244346|NCT03138902|Dietary Supplement|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
79244347|NCT03603379|Drug|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
79244348|NCT05386784|Drug|Raloxifene plus cholecalciferol|Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily
79383228|NCT03613181|Drug|Physician's Best Choice|Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
79383229|NCT03598439|Biological|Standard IIV4|Standard inactivated influenza vaccine
79383230|NCT03598439|Biological|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
79538007|NCT06073912|Device|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
79538008|NCT06073873|Drug|Ozanimod|According to local product label
79695094|NCT04718025|Drug|Aspirin|Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
79695095|NCT04711148|Other|placebo|placebo
79695096|NCT04711148|Drug|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
79839808|NCT01006954|Drug|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
79839809|NCT01006954|Drug|Flare up|Flare up protocol in poor responders for IVF/ICSI
79839810|NCT05732818|Device|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
79839811|NCT01007188|Other|1.5PD almonds|average American diet plus 1.5 oz per day almonds
79244349|NCT05386784|Drug|Cholecalciferol|D3 oral base drop, 4 drops once daily (800 IU)
79244350|NCT03602287|Drug|Lignocaine 2% Injection 20Ml Vial (Product)|2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
79244351|NCT03602287|Drug|Normal saline|5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
79244352|NCT03372915|Behavioral|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
79244353|NCT03372915|Behavioral|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
79383231|NCT03598439|Biological|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
79383232|NCT03595878|Radiation|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
79383233|NCT03595878|Radiation|Standard WBRT|Standard Whole Brain Radiation Therapy
79839812|NCT01007188|Other|3.0PD almonds|average American diet plus 3.0 oz per day almonds
79244354|NCT03373929|Device|PFO Closure Rate|Suture Mediated PFO Closure and Septal Repair
79244355|NCT03373929|Device|Published PFO Device Closure|Suture Mediated PFO Closure and Septal Repair
79244356|NCT03606811|Procedure|fluroscopic guided block|SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
79305842|NCT04922931|Procedure|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
79538009|NCT06073860|Drug|Luspatercept|According to the approved label
79538010|NCT06073847|Drug|Fedratinib|According to the approved label
79538011|NCT06073808|Device|AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft|Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
79538012|NCT06073808|Device|Control Device|Control device will be applied to non-experimental breast. Each patient will serve as their own control.
79695097|NCT04666948|Device|vancomycin model-informed precision dosing|A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg*h/L
79695098|NCT04666948|Drug|Vancomycin|Vancomycin treatment
79244357|NCT03606811|Procedure|double modality (ultrasound and fluroscopic) guided block|SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A & dead lateral)
79244358|NCT03137498|Drug|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
79244359|NCT03137498|Drug|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
79538013|NCT06073795|Procedure|sympathetic block|LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
80010287|NCT02165696|Other|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
80010288|NCT02165696|Other|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
79244360|NCT03606733|Procedure|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
79538014|NCT06073769|Drug|Oral azacitidine|Maintenance therapy according to the approved label
80010289|NCT03539588|Device|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
79244361|NCT05377814|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
79383234|NCT03558945|Biological|Personalized neoantigen vaccine|Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
79383235|NCT03552120|Behavioral|MORE|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
79538015|NCT06073756|Radiation|Echocardiogram|Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
79538016|NCT06073730|Procedure|Experimental: Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time >2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
79538017|NCT06073730|Procedure|Active Comparator: Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
79538018|NCT06073691|Behavioral|Exercise intervention|Practice systematic and regular aerobic physical exercise (walking and running).
79538019|NCT06073691|Other|Placebo|Placebo
79538020|NCT06073678|Other|Photobiomodulation|Irradiation with red laser on palate wound each 48h for 4 sessions.
79538021|NCT06073678|Other|Protection with surgical dressing|Protection of the palatal wound with surgical dressing for 7 days
79538022|NCT06073639|Procedure|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
79538023|NCT06073613|Diagnostic Test|oral health status|"CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,…) were recorded from medical records:~Pemphigus~Mixed connective tissue disease~Atopic dermatitis~Psoriasis~Erythroderma~oral health status: oral clinical parameters were evaluated:~Full mouth bleeding on probing scores~Pocket probing depth~Clinical attachment level~debris index~calculus index~the number of oral lesions"
79695099|NCT04660526|Other|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
79695100|NCT04660526|Other|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
79244362|NCT03602209|Procedure|Removal of infected implant|
79695101|NCT04660526|Other|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
79839813|NCT01007188|Other|Base (without almonds)|average American diet without almonds
80010290|NCT03539588|Device|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
79244363|NCT03602209|Drug|Antibiotic durations|
79244364|NCT05372822|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
79244365|NCT05372822|Procedure|Sham spinal cord stimulation|No spinal cord stimulation is provided
79244366|NCT05372822|Device|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead"
79839814|NCT05035576|Drug|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
79244367|NCT03367377|Drug|LY3209590|Administered SC
79383236|NCT03552120|Behavioral|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
79695102|NCT04660526|Other|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
79695103|NCT04630080|Device|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
79695104|NCT04609176|Drug|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
79695105|NCT04609176|Drug|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
79695106|NCT04562090|Drug|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
79839815|NCT03882424|Biological|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
79839816|NCT03882424|Biological|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
79839817|NCT03882424|Biological|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
79839818|NCT05732662|Radiation|SBRT|24-50Gy/8-12.5Gy/3-4f
79839819|NCT05732662|Drug|Cadonilimab|10 mg/kg,q3w
79839820|NCT03879772|Drug|Mometasone furoate nasal spray|intranasal administration
80010291|NCT03695211|Procedure|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
79383237|NCT03490045|Other|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
79383238|NCT03490045|Other|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
79383239|NCT03484078|Device|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
79383240|NCT03484078|Device|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
79383241|NCT03468478|Drug|Sirolimus|sirolimus combined to reduced dose of tacrolimus
79538024|NCT06073587|Diagnostic Test|Scintigraphy scan|Scans will be performed as specified in the arm description.
79538025|NCT06073574|Diagnostic Test|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
79538026|NCT06073548|Other|Questionnaires and interviews|Patients wiill be asked to fulfill questionnaires at inclusion and 6 months after. An interview will be offered to a sub-sample of patients (approximately 20 patients).
79383242|NCT03468478|Drug|Everolimus|everolimus combined to reduced dose of tacrolimus
79383243|NCT03468478|Drug|Mycophenolic acid|Control arm: mycophenolate combined to regular tacrolimus
79383244|NCT03451708|Device|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
79383245|NCT03409367|Other|Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream|Lipid-rich emollient serving as skin barrier
79538027|NCT06073483|Device|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
79538028|NCT06073392|Other|Educational video|Educational video in animation mode
79538029|NCT06073327|Dietary Supplement|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
79695107|NCT04560920|Other|Availability of contextual PGD at the visit|Contextual PGD will be availability in a display at the visit.
79695108|NCT04560647|Other|No intervention - Psoriasis Subject|Not currently treated plaque psoriasis patients
79695109|NCT04560647|Other|No intervention - Control Subject|Control subjects without plaque psoriasis and no family history of psoriasis
79695110|NCT04557189|Drug|TAK-951|TAK-951 SC injection
79695111|NCT04557189|Drug|Ondansetron|Ondansetron IV injection
79695112|NCT04557189|Drug|Ondansetron Placebo|Ondansetron placebo-matching IV injection
79695113|NCT04557189|Drug|TAK-951 Placebo|TAK-951 placebo-matching SC injection
79695114|NCT04556461|Drug|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
79839821|NCT03879772|Drug|Beclomethasone dipropionate nasal spray|intranasal administration
79839822|NCT03879772|Drug|Placebo nasal spray|intranasal administration
79839823|NCT03879772|Drug|Chlorpheniramine maleate syrup|oral administration
79839824|NCT01007266|Behavioral|Assignment of a Lay Patient Partner|
79839825|NCT05027620|Other|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
79839826|NCT01007344|Dietary Supplement|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
79839827|NCT01007344|Dietary Supplement|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
79538030|NCT06073327|Dietary Supplement|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
79538031|NCT06073288|Other|Surgical specimens of CD and no-IBD patients|Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
79695115|NCT05306197|Behavioral|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
79695116|NCT05306197|Behavioral|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
79695117|NCT05306197|Behavioral|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
79695118|NCT04530838|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
79839828|NCT01007422|Behavioral|telephone-based intervention|
79244368|NCT03367377|Drug|Insulin Glargine|Administered SC
79244369|NCT03138980|Behavioral|BodiMojo Buddy for IBS|"Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature."
79244370|NCT02519127|Other|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
79538032|NCT06073236|Behavioral|The healthy day-project|The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
79695119|NCT04530838|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
79695120|NCT04474054|Device|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
79839829|NCT01007422|Other|communication intervention|
79839830|NCT01007422|Other|intervention by caregiver|
79244371|NCT02519127|Other|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
79244372|NCT03602131|Drug|Chidamide|30 mg oral twice weekly for 2 weeks
79244373|NCT03602131|Drug|Cladribine|6 mg/m2 intravenously once daily for 5 days
79244374|NCT03602131|Drug|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
79244375|NCT03602131|Drug|Busulfan|3.2 mg/kg intravenously once daily for 4 days
79244376|NCT03602131|Procedure|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
79383246|NCT03381729|Biological|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
79383247|NCT03381105|Diagnostic Test|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
79383248|NCT03318692|Procedure|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
79383249|NCT03318692|Procedure|CT|CT of operated area is performed within 7 days of surgery
79383250|NCT03240237|Device|Optimizer SMART|Cardiac Contractility Modulation
79695121|NCT04442919|Drug|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
79695122|NCT04442919|Drug|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
80010292|NCT03695211|Procedure|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
79244377|NCT03137420|Diagnostic Test|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
79244378|NCT03376503|Drug|Pegfilgrastim|PK,PD and safety assessment
79244379|NCT03603067|Procedure|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
79305843|NCT02123134|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79383251|NCT03234114|Drug|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
79383252|NCT03234114|Drug|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
79383253|NCT03234114|Drug|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
79538033|NCT06073197|Procedure|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
79695123|NCT04442919|Drug|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
79695124|NCT04424901|Drug|Placebo|Daily dose while hospitalized up to 9 days
79695125|NCT04424901|Drug|Dipyridamole Tablets|Daily dose while hospitalized up to 9 days
79839831|NCT01007422|Other|medical chart review|
79839832|NCT01007422|Other|survey administration|
79839833|NCT01007422|Procedure|end-of-life treatment/management|
79839834|NCT01007422|Procedure|pain therapy|
79839835|NCT01007422|Procedure|psychosocial assessment and care|
80010293|NCT03687099|Other|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
80010294|NCT02165774|Device|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
79244380|NCT03138746|Procedure|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
79244381|NCT03138746|Procedure|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
79695126|NCT04415060|Drug|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
79538034|NCT06073197|Procedure|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
79244382|NCT05851599|Other|SKF7® Labisia pumila standardized extract|Botanical extract of Labisia pumila (Kacip Fatimah)
79244383|NCT05851521|Device|Temporary prostatic stent (Exime®)|Placement of temporary prostatic stent (Exime®) following the procedure described in the product information
79383254|NCT03229031|Drug|ES135|ES135 will be administered via intrathecal
79383255|NCT03176836|Diagnostic Test|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
79383256|NCT03176836|Diagnostic Test|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
79383257|NCT03176836|Diagnostic Test|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
79383258|NCT03168464|Drug|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
79695127|NCT04415060|Drug|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
79839836|NCT01007500|Drug|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
79538035|NCT06073171|Biological|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
79538036|NCT06073171|Biological|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
79695128|NCT04410445|Biological|Bempegaldesleukin|Specified dose on specified days
79695129|NCT04410445|Biological|Nivolumab|Specified dose on specified days
79695130|NCT04381091|Drug|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
79244384|NCT05851521|Device|Indwelling catheter|Placement of indwelling catheter
79244385|NCT05851495|Procedure|physiotherapist-led groups, home-based follow up groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
79244386|NCT05851482|Diagnostic Test|High resolution manometry|Standard chicago classification 4.0 HRM protocol
79244387|NCT05851456|Drug|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
79244388|NCT05851417|Device|Fast Field-Cycling (FFC) imaging|FFC scan
79538037|NCT06073171|Genetic|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
79538038|NCT06073145|Device|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
79538039|NCT06073080|Other|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
79538040|NCT06073028|Other|20-minute gait training|All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
79538041|NCT06073015|Drug|Esketamine|Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
79538042|NCT06072989|Biological|B4T2-001 autologous CAR-T|Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
79538043|NCT06072976|Dietary Supplement|Standard of Care|Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.
79695131|NCT04342494|Behavioral|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
79839837|NCT01007500|Drug|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
79839838|NCT05725252|Drug|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
79695132|NCT04342494|Device|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
79839839|NCT05725252|Drug|NVP-2203-R|administration of active comparator
79848963|NCT05755815|Procedure|retrolaminar block|A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
79848964|NCT05755815|Procedure|Peritoneal block|before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
79848965|NCT05755802|Procedure|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
79848966|NCT05755802|Procedure|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
79848967|NCT05754073|Drug|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
79244389|NCT05851404|Procedure|Thyroidectomy|Total thyroidectomy or lobectomy
79538044|NCT06072976|Dietary Supplement|Exclusive Human Milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
79538045|NCT06072963|Drug|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
79538046|NCT06072963|Drug|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
79538047|NCT06072963|Other|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
79538048|NCT06072963|Other|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
79538049|NCT06072950|Other|Usual care|Patients received usual care
79848968|NCT05754073|Drug|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
79848969|NCT05754073|Drug|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
80010295|NCT02165774|Device|Turning ON the neuromodulator|
79244390|NCT05851391|Drug|Burst Suppression EEG Target Intravenous Anesthesia|The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
79244391|NCT05851391|Drug|Seizure Suppression EEG Target Intravenous Anesthesia|is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
79538050|NCT06072937|Device|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
79538051|NCT06072924|Behavioral|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
79383259|NCT03168464|Drug|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
79383260|NCT03168464|Radiation|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
79383261|NCT03164447|Biological|UB-421|Monoclonal antibody by IV infusion
79383262|NCT03164447|Drug|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
79383263|NCT03136094|Behavioral|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
79383264|NCT03136094|Behavioral|SBIRT+Usual Care|Patients receive usual SBIRT care
79383265|NCT03054792|Drug|18F-FAZA (F18-Fluoroazomycin Arabinoside)|Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.
79383266|NCT03054792|Diagnostic Test|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
79538052|NCT06072924|Behavioral|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-5kPa) 30x/day
79695133|NCT04342494|Device|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
79695134|NCT04342494|Device|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
79695135|NCT04342494|Device|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
79695136|NCT04340921|Biological|COVID-19 exposure|Observation only
79839840|NCT00642954|Drug|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
79839841|NCT00642954|Drug|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
79383267|NCT03054792|Diagnostic Test|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
79383268|NCT03054792|Diagnostic Test|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
79383269|NCT03047694|Other|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
79383270|NCT03047694|Other|usual care|speech therapy
79383271|NCT02875262|Drug|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
79383272|NCT02875262|Other|placebo|placebo (NaCl 0.9%) in equal dose to treatment
79538053|NCT06072898|Drug|Psilocybin|Psilocybin ([3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate), 25mg PO.
79538054|NCT06072898|Drug|Niacin|Niacin (Vitamin B3; nicotinic acid), 100mg PO.
79538055|NCT06072872|Device|Use of portable CPAP|Patients use portable CPAP during exercise
79538056|NCT06072859|Other|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
79538057|NCT06072859|Other|Virtual Reality using Surface Pro and headphones|Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual. This is paired with headphones to experience ambient forest sounds.
79538058|NCT06072846|Behavioral|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
79538059|NCT06072820|Device|Salivary Sampling|"Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit."
79839842|NCT00642954|Drug|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
79839843|NCT01007890|Other|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
79244392|NCT05851352|Diagnostic Test|serum anti-endometrial antibodies|- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
79538060|NCT06072729|Other|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
79695137|NCT04314817|Drug|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
79538061|NCT06072716|Drug|Chitosan|chitosan loaded with miconazole nanoparticles gel
79695138|NCT04312269|Other|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
79695139|NCT04307030|Diagnostic Test|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
79538062|NCT06072677|Behavioral|Healthy Minds Program|The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
79538063|NCT06072625|Dietary Supplement|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
79695140|NCT04294563|Dietary Supplement|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
79695141|NCT04294563|Other|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
79839844|NCT00816660|Biological|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
79839845|NCT00816660|Biological|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
79839846|NCT00819000|Drug|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
79839847|NCT00640146|Drug|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
79839848|NCT00640146|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
79538064|NCT06072573|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538065|NCT06072573|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79538066|NCT06072560|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538067|NCT06072560|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79839849|NCT00819078|Drug|Bupropion|300 mg/d
79244393|NCT05851339|Other|SF- 36 Questionnaire|applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
79244394|NCT05851274|Procedure|transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm
79305844|NCT02123134|Drug|Placebo|Phosphate buffered saline placebo for injection
79305845|NCT03054207|Drug|Clopidogrel 300Mg Tablet|
79538068|NCT06072547|Other|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
79538069|NCT06072547|Other|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
79538070|NCT06072547|Other|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
79538071|NCT06072508|Biological|Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.
79538072|NCT06072495|Other|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
79839850|NCT00819078|Drug|Placebo|no dosage
79839851|NCT01008046|Drug|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
79839852|NCT01008046|Drug|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
79839853|NCT00819312|Drug|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
79695142|NCT04284969|Behavioral|PROADAPT program|"A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~Pre-operative physical training including strength, endurance and breathing exercises.~A nutrition activity.~An activity to educate patients (on nutrition, exercise).~The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
80010296|NCT02165852|Procedure|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
79244395|NCT05851274|Procedure|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
79383273|NCT02823444|Other|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
79538073|NCT06072443|Behavioral|Digital Health Companion (mobile App)|Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
79839854|NCT01008124|Other|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
79839855|NCT01008124|Other|Placebo maneuver|3 cycles placebo maneuver initial session.
79839856|NCT05006560|Other|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
79848970|NCT05747950|Other|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
79848971|NCT05747950|Other|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
79848972|NCT05747950|Other|Conventional Therapy|Conventional exercises
80010297|NCT02165852|Procedure|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
79538074|NCT06072417|Other|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
79538075|NCT06072417|Other|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
79538076|NCT06072404|Biological|OxigenOzone_Insufflation|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
79244396|NCT05851261|Drug|PA3670|Placebo as control
79305846|NCT03054207|Drug|Prasugrel 60Mg|
79305847|NCT03055689|Behavioral|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
79305848|NCT03055689|Behavioral|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
79538077|NCT06072365|Other|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
79538078|NCT06072352|Other|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
79538079|NCT06072352|Other|Normal saline|Perineal cleansing using normal saline
79538080|NCT06072248|Drug|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
79538081|NCT06072248|Procedure|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
79538082|NCT06072248|Device|ventilator|ventilator
79538083|NCT06072235|Behavioral|Verbal communication|Verbal communication; by talking and listening
79538084|NCT06072222|Drug|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
79538085|NCT06072222|Procedure|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
79538086|NCT06072222|Device|ventilator|ventilator
79538089|NCT06072118|Drug|Adrenomedullin|Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
79538090|NCT06072105|Other|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
79695143|NCT04242953|Drug|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
80010298|NCT03695133|Behavioral|Group-based interventions|"Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
79695144|NCT04242953|Drug|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
79839857|NCT05006560|Other|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
79839858|NCT05006560|Other|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
79839859|NCT05005624|Other|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
79303502|NCT02467985|Procedure|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
79383274|NCT02818920|Drug|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 & 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
79383275|NCT02811510|Drug|Placebo|Placebo pill (no active cannabinoids)
79383276|NCT02811510|Drug|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
79383277|NCT02786264|Drug|Dexmedetomidine with propofol|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
79538091|NCT06072105|Other|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
79538092|NCT06072092|Device|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
79538093|NCT06072066|Dietary Supplement|Skin Barrier Oral Supplement|Supplment powder
79538094|NCT06072027|Diagnostic Test|cytology|Conventional cytology will be performed in parallel with VISIOCYT cytology in order to compare the two results.
79695145|NCT04226898|Biological|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
79695146|NCT04226898|Biological|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
79695147|NCT04225312|Drug|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
79695148|NCT04225312|Drug|Standard interval dosing|Standard interval dosing in control group and historic group
79695149|NCT04209205|Drug|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
79695150|NCT04209205|Drug|Placebo|Matching placebo to AIN457 i.v. infusion
79695151|NCT04209205|Drug|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
79695152|NCT04193787|Other|EPIC-P|EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
79695153|NCT04193046|Other|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
79839860|NCT00317473|Biological|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
79244397|NCT05851248|Procedure|Buccal muco-gingival tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation. The incisions will be made in the same way as in the recipient area, including both papillae. The vertical incision will measure the distance from the cementoenamel junction (CEJ) to the bony dehiscence in the GR tooth, plus at least 2 mm. The tissue between the incisions will be elevated fjull or partial thickness close to the bone in the keratinized portion and superficially in the mucosal portion. A soft tissue substitute will be adapted and sutured to protect the donor site."
79244398|NCT05851248|Procedure|Palatal connective tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation A connective tissue graft will be taken from the palatal area, at the level of the premolars, which will include the two papillae. The size of the graft will be the same as that of the recipient area. A soft tissue substitute will be adapted and sutured to protect the donor site, especially if there is exposed bone."
79244399|NCT05851235|Other|Prehabilitation course|During prehabilitation course, patients will follow a nutritional programme, a cardiovascular and motor programme and a psychological programme.
79839861|NCT00317473|Biological|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
79244400|NCT05851144|Behavioral|Bienestar/Neema Coordinated School Health Program (BN CSHP)|Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
79244401|NCT05851131|Other|Approach to Diagnosis and Treatment of Osteoporosis Questionnaire|"The survey will use multiple-choice questions to assess primary care physicians' knowledge on the diagnosis and treatment of osteoporosis. The questions will cover various aspects, including medication options, their mechanisms of action, side effects, and recommended vitamin D supplementation dosages. The physicians will also be asked about their sources of knowledge and how they keep themselves updated on the topic, as well as their self-evaluation of their knowledge. Background information, such as their professional and demographic characteristics, will also be collected. The survey questionnaire used in other studies will be adapted for this survey based on the Updated approach for the management of osteoporosis in Turkey: a consensus report."
79244402|NCT05851105|Biological|α-globin restored autologous hematopoietic stem cells|α-globin restored autologous hematopoietic stem cells modified with LentiHBA T>C
79538095|NCT06072014|Other|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
79538096|NCT06072001|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79839862|NCT00530218|Drug|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
79244403|NCT05851092|Drug|HRS-2189 Tablets|HRS-2189 Tablets
79383278|NCT02786264|Drug|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
79383279|NCT02778971|Drug|[18F]Flutemetamol|amyloid PET imaging with [18F]Flutemetamol and subsequent modification of diagnosis and management
79383280|NCT02756533|Other|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours."
79538097|NCT06072001|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79538098|NCT06071988|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538099|NCT06071988|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
80010299|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
80010300|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
80010301|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
80010302|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
80010303|NCT03695055|Drug|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
80010304|NCT03694977|Drug|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
80010305|NCT02172248|Drug|BI 10773|
80010306|NCT02172248|Drug|Metformin|
80010307|NCT03691233|Drug|Clinical audit on diagnosis and management of neonatal shock|intervenous
80010308|NCT03691155|Other|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
79839863|NCT00761267|Drug|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
80010309|NCT02172326|Drug|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
80010310|NCT02169596|Drug|Ticagrelor|Blood tests taken for flow cytometry
80010311|NCT02169596|Other|EndoPAT - endothelial assessment|
79244404|NCT05851079|Diagnostic Test|TCT test|These tests were performed on cervical exfoliated cells.
79244405|NCT05851079|Diagnostic Test|Vaginoscopy|To obtain the results of the patient's pathology report.
79244406|NCT05851079|Diagnostic Test|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
79244407|NCT05851079|Diagnostic Test|Cobas HPV test|To obtain HPV typing results.
79695154|NCT04158908|Behavioral|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~Principles of introducing prognosis in the setting of worsened scan results~Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~Addressing informational needs and psychological reactions~Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
79695155|NCT04157595|Other|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
79695156|NCT04129086|Drug|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
79383281|NCT02756533|Other|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
79839864|NCT00761267|Drug|Fluconazole|Subjects may be switched to oral fluconazole [6-12 mg/kg/day (not to exceed 800mg/day] provided they meet specified criteria. Maximum total treatment duration is 49 days.
79839865|NCT03982303|Drug|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
79839866|NCT04099979|Other|No Intervention|There is no intervention for this study
80010312|NCT02166008|Drug|Repamipide|
80010313|NCT02166008|Drug|Placebo|
80010314|NCT02166086|Procedure|Endoscopy|Endoscopy involving advanced imaging techniques
80010315|NCT02169752|Drug|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
80010316|NCT02172404|Device|Placebo capsule administered via the HandiHaler®|
79244408|NCT05851053|Diagnostic Test|Echocardiography|"During echocardiography, the following parameters will be assessed:~Dimensions~Left ventricle function~Right ventricle function~Valves: Aorta valve and pulmonic valve~Other findings such as: frequency, rhythm, quality"
80010317|NCT02172404|Device|Ipratropium metered dose inhaler (MDI)|
80010318|NCT03538964|Procedure|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
79244409|NCT05851040|Other|Observation study|Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug
80010319|NCT03538964|Procedure|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
80010320|NCT02166164|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
80010321|NCT02166164|Other|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
80010322|NCT02166164|Other|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
80010323|NCT02169908|Device|Thermotest|
79244410|NCT05851027|Drug|QL0911|Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
79244411|NCT05851014|Drug|GB491 combined with Letrozole|Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
79303503|NCT03306329|Drug|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
79383282|NCT02726061|Behavioral|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
80010324|NCT02169908|Device|von Frey hairs|
80010325|NCT02166320|Device|Partially covered SEMS|
80010326|NCT02166320|Device|Fully covered SEMS|
80010327|NCT02166398|Drug|UI15AML055MT|tab, PO
79695157|NCT04129086|Drug|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
79244412|NCT05851014|Drug|Placebo combined with Letrozole|Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
79244413|NCT05851001|Other|Progressive Muscle Relaxation exercise|This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
79244414|NCT05851001|Other|Muscle relaxation exercise|The participant was asked to listen to relaxation music for 30 minutes in a private room.
79244415|NCT05850975|Other|intervention with this name in MindEase app|MindEase is an app which provides interventions against anxiety. The interventions are based on mindfulness, acceptance and commitment therapy, and cognitive behavioural therapy.
79839867|NCT00303667|Biological|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
79383283|NCT02444546|Other|Laboratory Biomarker Analysis|Correlative studies
79383284|NCT02444546|Biological|Sargramostim|Given SC
79383285|NCT02444546|Biological|Wild-type Reovirus|Given IV
79695158|NCT04117685|Other|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
79695159|NCT04103632|Diagnostic Test|EVH test|"Spirometry~Skin prick test~Peripheral blood test~FeNO measurement"
79383286|NCT02436941|Radiation|Proton or Photon|
80010328|NCT02166398|Drug|Amosartan 5/50|tab, PO
80010329|NCT00109538|Drug|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
80010330|NCT00109538|Other|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
79244416|NCT05850975|Other|reading about anxiety|Participants are given an educational text to read about anxiety.
79244417|NCT05850962|Other|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
79383287|NCT01993498|Procedure|blood sampling|blood samples collection
79383288|NCT01965912|Drug|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
79383289|NCT01948505|Drug|Intravenous acetaminophen|
79383290|NCT01948505|Drug|Placebo for IV acetaminophen|
79383291|NCT01934296|Device|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
79383292|NCT01916005|Device|18F-FDG PET/CT|
79383293|NCT01454401|Device|LeucoPatch treatment|weekly
79383294|NCT01344018|Procedure|therapeutic conventional surgery|
79538100|NCT06071975|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538101|NCT06071975|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79538102|NCT06071962|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538103|NCT06071962|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79538104|NCT06071949|Drug|Adezunap|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538105|NCT06071949|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79538106|NCT06071936|Drug|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
79538107|NCT06071936|Drug|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
79538108|NCT06071897|Drug|monoclonal antibodies GD2|"Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy"
79538109|NCT06071871|Drug|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant)."
79538110|NCT06071871|Drug|Polatuzumab vedotin|Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
79695160|NCT04062448|Drug|Ibrutinib|Ibrutinib 420 mg will be administered orally.
79695161|NCT04062448|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered intravenously.
79839868|NCT00303667|Biological|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10^7 cells/kg.
79839869|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
79839870|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 40 mg/m^2 on Days -18 through -14
79839871|NCT00303667|Procedure|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
79839872|NCT00303667|Radiation|total body irradiation|Administered on Day -13, 200 cGy two times.
79839873|NCT00303667|Biological|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
79839874|NCT00303667|Drug|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
79839875|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
79538111|NCT06071871|Drug|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
79839876|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 35 mg/m^2 on Days -18 through -14
79538112|NCT06071832|Other|Instructions for family Zoom session|Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
79839877|NCT01066741|Drug|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
79839878|NCT01066741|Drug|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
79839879|NCT00761189|Drug|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
79244418|NCT05850949|Dietary Supplement|Konjac Grain|Without supplementation, followed by Supplementation with Dietary Fibre the Konjac-Grain week 1, repeated until week 6, blood collected with a fine needle 10ml citrate-Tube Glucose was measured with disposable 'test-strip', which is then inserted into an electronic blood glucose meter (device: Accu-Check Instant S Glucose from Roche) . Normal value:70 to 99 mg/dL (3.9 to 5.5 mmol/L). Further HbA1c (glycated Hemoglobin A1c) concentration was checked with disposable 'test-strip', which is then inserted into an electronic HbA1c meter (device: Accu-Check Instant S HbA1c from Roche). Unit value fir HbA1c = mg/dl
79383295|NCT01344018|Radiation|3-dimensional conformal radiation therapy|
79383296|NCT01160926|Drug|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
79839880|NCT01064869|Behavioral|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
79383297|NCT01160926|Drug|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
79383298|NCT01126957|Drug|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
79383299|NCT01126957|Drug|Placebo|Placebo given as an bolus to control group.
79383300|NCT01126957|Drug|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
79538113|NCT06071819|Diagnostic Test|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
79538114|NCT06071806|Other|Topical Application of 5-Fluorouracil|The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
79839881|NCT01062295|Device|Siesta-System|
79839882|NCT01062295|Device|Standard headrest|
79839883|NCT00529516|Biological|Fluarix|Single dose, Intramuscular injection
79839884|NCT00529516|Biological|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
79839885|NCT01008358|Biological|CP 675,206|
79839886|NCT01008436|Drug|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
79303504|NCT03306329|Drug|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
79303505|NCT03306329|Drug|Placebo|Placebo tablets administered once daily
79383301|NCT01126957|Drug|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
79383302|NCT00811122|Radiation|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
79383303|NCT00811122|Radiation|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
79839887|NCT01008436|Drug|Control|Traditional surgical Hemostasis
79839888|NCT00316693|Biological|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
79839889|NCT00316693|Biological|Aimmugen™|Intramuscular injection, 3 doses
79383304|NCT00651885|Drug|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
79383305|NCT00651885|Drug|Placebo|Placebo
79383306|NCT00247377|Procedure|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
79383307|NCT00247377|Procedure|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
79383308|NCT01456767|Dietary Supplement|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
79839890|NCT01008514|Procedure|adjuvant therapy|
79839891|NCT01008514|Radiation|accelerated partial breast irradiation|
79839892|NCT01008514|Radiation|intracavitary balloon brachytherapy|
80010331|NCT02172482|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
80010332|NCT02169986|Behavioral|electronic reminders|
80010333|NCT02172560|Drug|Tiotropium|
79695162|NCT04040764|Procedure|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
79839893|NCT05099692|Behavioral|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
80010334|NCT00106808|Drug|Muraglitazar|
80010335|NCT00106808|Drug|Pioglitazone|
79383309|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
79383310|NCT01890369|Dietary Supplement|3g Leucine|Dissolved in 250ml water.
80010336|NCT02166554|Other|Saline|On the day of initial surgery
80010337|NCT02166554|Device|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
79538115|NCT06071689|Device|screw retained prosthesis|all-on-4 screw-retained prosthesis.
79839894|NCT01008592|Drug|levocetirizine or placebo|oral administration, single tablet, 5 mg.
79839895|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
79538116|NCT06071533|Drug|Dandshen|Dandshen injection 20ml /day
79538117|NCT06071364|Diagnostic Test|Ultrasonography imaging and Hand-held dynamometer (HHD)|"Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength"
80010338|NCT02170142|Device|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
79839896|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
79839897|NCT00316303|Drug|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
79839898|NCT00316303|Behavioral|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
79839899|NCT01062529|Drug|Somatostatin|4 h of 150 microgram infusion
79839900|NCT00760877|Drug|Nilotinib|Supplied in 200 mg capsules
79839901|NCT00760877|Drug|Imatinib|Supplied in 100 mg and 400 mg capsules
79839902|NCT03977545|Diagnostic Test|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
79839903|NCT00302731|Drug|Estradiol , estriol , progesterone|
79839904|NCT00302731|Drug|estradiol, progesterone|
80010339|NCT02172638|Procedure|Fast-Track Protocol|
79839905|NCT00302731|Drug|estriol, progesterone|
79839906|NCT00302731|Drug|equine estrogens m-progesteroneacetate|
80010340|NCT02172638|Procedure|Usual management|
79839907|NCT00780143|Drug|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
80010341|NCT03538886|Procedure|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
80010342|NCT03538886|Procedure|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
80010343|NCT03539510|Behavioral|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
80010344|NCT03538730|Behavioral|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
80010345|NCT02172716|Procedure|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
79303506|NCT03304457|Drug|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
79303507|NCT03304457|Drug|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
79383311|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
79383312|NCT01890447|Other|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
79383313|NCT01456923|Other|Treatment with chemotherapy|
79383314|NCT01456923|Other|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
79383315|NCT01456923|Procedure|surgery|
79383316|NCT01890603|Other|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
79538118|NCT06071312|Biological|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
79695163|NCT04013295|Other|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
79839908|NCT01581229|Procedure|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
80010346|NCT03694899|Behavioral|phone contact|patients will be called prior to their outpatient appointment
80010347|NCT03687021|Drug|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
80010348|NCT02170454|Procedure|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
80010349|NCT02174744|Other|numeric pain rating scale|
79383317|NCT01890603|Other|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
79839909|NCT01581229|Procedure|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
79695164|NCT04006665|Diagnostic Test|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
79695165|NCT04006665|Diagnostic Test|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
79839910|NCT01007968|Drug|LBH589|
79839911|NCT03999034|Diagnostic Test|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
79839912|NCT01065025|Drug|4SC-205|Repeated ascending oral doses of 4SC-205.
80010350|NCT03694743|Device|2Shape rotary system|root canal preparation
80010351|NCT02172794|Drug|Tiotropium|
80010352|NCT02172794|Drug|Placebo to tiotropium|
80010353|NCT02172794|Drug|Salmeterol|
80010354|NCT02172794|Drug|Placebo to salmeterol|
79383318|NCT04845321|Drug|VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
79839913|NCT00779909|Drug|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
79839914|NCT00779909|Other|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
80010355|NCT04173819|Biological|3BNC117-LS-J|300mg
80010356|NCT04173819|Biological|10-1074-LS-J|300mg
80010357|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
79303508|NCT03306095|Other|Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
80010358|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
79303509|NCT03306095|Other|Delayed refeeding group|Food Intake by patient after 4 hours i.e > 4 hours after the EVL procedure
79303510|NCT03304301|Behavioral|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
79303511|NCT04490759|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79383319|NCT04845321|Drug|Placebo for VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
79383320|NCT01457001|Drug|25-OH-D vitamin|
79383321|NCT02846883|Biological|MSCs|Intravenous infusion of 1 million allogeneic MSCs/kg.
79538119|NCT06071312|Biological|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
80010359|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
80010360|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
80010361|NCT04173819|Biological|Placebo|0.9% Saline
79383322|NCT02846883|Biological|MSCs|Intravenous infusion of 3 million allogeneic MSCs/kg
80010362|NCT04173819|Biological|Placebo|Buffer Solution
79538120|NCT06071273|Other|Group A: online real-time home based exercise using the online platform|"Patients that will be randomly assigned to this group will be exercising at home by providing data of their vital signs during exercise and at rest. To succeed this, they will be provided with the appropriate equipment (e.g., a smart watch able to assess the electrical signs of the heart (i.e., ECG) and heart rate, an automated blood pressure monitor, and an electrical body scale) which will be directly linked to the online platform.~The online real-time supervised home-based exercise program is identical to Group B, the only difference is that it is performed at home. Each session has a duration of 60 minutes consisting of 40 mins of aerobic exercise and 20mins of resistance training. The overall intensity is kept to moderate based on ratings of perceived exertion (i.e., 13-14 in Borg's scale 6-20). The program will last for 6 months with exercise sessions taking place thrice per week."
79244419|NCT05850936|Drug|Assigned Interventions: IOP-lowering eye drops|"IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment.~If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added.~If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added.~The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study."
79244420|NCT05850871|Drug|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
79538121|NCT06071273|Other|Group B: supervised community based exercise intervention|Identical exercise program to Group A, the only difference is that Group performs the supervised exercise in community based health clubs/gyms.
79383323|NCT02846883|Drug|Placebo|Intravenous infusion of Plasmalyte A (placebo)
79538122|NCT06071208|Drug|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
79538123|NCT06070415|Device|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
79538124|NCT06070415|Other|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
79538125|NCT06070415|Other|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
79538126|NCT06070207|Procedure|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
79538127|NCT06070207|Procedure|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
79538128|NCT06070181|Device|Enamel matrix derivate|'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
79538129|NCT06070181|Procedure|Non-surgical periodontal treatment|No additional/adjunctive treatment with Emdogain
79244421|NCT05850871|Other|Conventional treatment|Conventional treatment
79244422|NCT05850858|Diagnostic Test|ascetic fluid study|ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
79244423|NCT05850845|Device|Microscopic hyperspectral imaging system|CTX for idiopathic membranous nephropathy
79244424|NCT05850832|Drug|Esmolol|loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
79244425|NCT05850832|Drug|Magnesium sulfate|loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
79383324|NCT01457235|Other|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
79383325|NCT01457391|Behavioral|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
79538130|NCT06070142|Procedure|TEP Group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
79244426|NCT05850780|Device|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) Wavelength 660 nm will be used, and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied to the surface of the pulp stumps for 60 seconds. The pulp chamber will then be filled with reinforced zinc oxide-eugenol (IRM, Dentsply, Mount Waverley, Australia) to ensure proper sealing.~Then, each tooth in both groups will finally be restored with a stainless-steel crown (SSC)40 (3M/ESPE, St. Paul, Minn., USA) in the same visit, which will be cemented onto the tooth using glass ionomer cement.~Finally, reapplication of laser with the same parameters will be done around inserted crowns to promote tissue healing and decrease post operative pain."
79383326|NCT01457391|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
79383327|NCT01457391|Behavioral|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
79383328|NCT02816775|Device|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
79383329|NCT02816775|Device|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
79383330|NCT01457469|Other|questionnaire administration|Ancillary studies
79244427|NCT05850780|Drug|MTA|Three parts of MTA powder will be mixed with one part of distilled water to obtain paste. This mixture will then be placed on the radicular pulp stumps and condensed lightly with a moistened cotton pellet. then the access cavities will be sealed with glass ionomer cement
79538131|NCT06070142|Procedure|eTEP Group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
79538132|NCT06069687|Biological|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
79839917|NCT01065103|Procedure|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
79839918|NCT04273685|Behavioral|Cognitive remediation training, social recovery therapy|10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.
79244428|NCT05850754|Dietary Supplement|Vantage Hemp CBD|Participants will consume 1 Vantage Hemp capsule, daily for 4 weeks.
79383331|NCT01457469|Procedure|quality-of-life assessment|Ancillary studies
79383332|NCT01457469|Other|counseling intervention|Undergo counseling session
79244429|NCT05850754|Dietary Supplement|Vantage Hemp Placebo Capsule|Vantage Hemp Placebo Capsule Intervention
79839919|NCT04273685|Other|treatment as usual|10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
79839920|NCT00302107|Drug|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
79839921|NCT00302107|Drug|Placebo|Look-a-like placebo tablets under double-blind conditions
79839922|NCT02602301|Drug|Oxytocin|different oxytocin diluents and effect on fetal bilirubin&sodium levels.
79383333|NCT01457469|Other|internet-based intervention|Receive enhanced quitline intervention
79383334|NCT01457469|Behavioral|telephone-based intervention|Receive enhanced quitline intervention
79383335|NCT01457469|Other|educational intervention|Receive usual care plus
79383336|NCT01457469|Drug|nicotine replacement therapy|Receive nicotine replacement patches
79383337|NCT01457469|Other|educational intervention|Receive enhanced quitline intervention
79839923|NCT04097483|Behavioral|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
79383338|NCT01457547|Biological|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
79383339|NCT01457547|Biological|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
79383340|NCT01457859|Drug|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
79244430|NCT05850702|Drug|Lidocaine|inhale 5ml of 2% lidocaine by nebulization
79383341|NCT01457859|Other|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
79383342|NCT01890993|Drug|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
79538133|NCT06069557|Other|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
79244431|NCT05850702|Drug|Saline|inhale 5ml of saline by nebulization
79538134|NCT06068478|Drug|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
79538135|NCT06068478|Drug|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
79538136|NCT06068387|Procedure|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
79538137|NCT06067932|Radiation|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
79695166|NCT04000555|Drug|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
79695167|NCT04000555|Other|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
79695168|NCT03994822|Device|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
79695169|NCT03994822|Device|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
79695170|NCT03994393|Drug|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
79244432|NCT05850650|Other|Application of a collagen sponge after surgical extraction of impacted 3rd molar|Application of a collagen sponge after surgical extraction of impacted 3rd molar
79695171|NCT03994393|Drug|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
79244433|NCT05850650|Other|No collagen sponge application after surgical extraction of impacted 3rd molar|No collagen sponge application after surgical extraction of impacted 3rd molar
79383343|NCT02979483|Procedure|Integrative supportive care|"At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened"
79383344|NCT01457937|Drug|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
79383345|NCT05023629|Other|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
79383346|NCT05026671|Procedure|Endotracheal Tube Alone|Intubating the trachea with an endotracheal tube alone ( without stylet).
79383347|NCT05026671|Procedure|Endotracheal Tube+ Stylet|Intubating the trachea with an endotracheal tube + stylet.
79383348|NCT05026671|Procedure|Endotracheal Tube + Video-laryngoscope|Intubating the trachea with an endotracheal tube + Video- laryngoscope
79383349|NCT05026671|Procedure|Endotracheal tube + stylet with Video-laryngoscope|Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
79383350|NCT05028699|Other|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
79383351|NCT04346355|Drug|Tocilizumab|In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
79383352|NCT04272255|Drug|scopolamine HBr|Nasal Gel
79383353|NCT04272255|Drug|Transdermal Scopolamine|Patch
79383354|NCT04271787|Other|questionnaire|Questionnaire
79538138|NCT06067932|Diagnostic Test|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
79538139|NCT06067698|Drug|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
79538140|NCT06067698|Drug|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
79538141|NCT06067295|Other|Non-Interventional Study|Non-interventional study
79538142|NCT06067282|Other|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
79695172|NCT03991624|Diagnostic Test|cognitive assessment|"MMSE : Mini-Mental State Examination~5 words of Dubois~Direct Assessment of Functional Status~Trail Making Test~BREF : Fast Front End Efficiency Battery~short battery of praxies~Quality of Life in Alzheimer's Disease"
79839924|NCT04925206|Biological|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
79839925|NCT04908358|Other|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
79244434|NCT05850637|Radiation|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
79244435|NCT05850624|Other|ice massage|active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
79244436|NCT05850624|Other|virtual reality animation|cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
79303512|NCT03306017|Other|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
79383355|NCT01458015|Drug|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
79383356|NCT02843763|Other|Blood sample|Blood sample (28 ml)
79383357|NCT01891071|Procedure|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
79383358|NCT01891227|Drug|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
79383359|NCT01891227|Drug|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
79383360|NCT04273113|Other|Difficulties in Emotional Regulation Scale, Five Facet Mindfulness Questionnaire, Becks Depression and Becks Anxiety|Patients asked to complete these 4 questionnaires pre, during and post biofeedback training
79538143|NCT06067191|Drug|RV299|Oral Suspension
79538144|NCT06067191|Drug|Placebo|matching placebo
79538145|NCT06067100|Drug|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
79839926|NCT04908358|Other|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
79839927|NCT00760487|Device|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
79839928|NCT00316225|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2) IV every 21 days for 6 cycles
79839929|NCT04097405|Drug|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
79839930|NCT04097405|Drug|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
79839931|NCT00586703|Device|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
79244437|NCT05850559|Diagnostic Test|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer by Enzyme-linked immunosorbent assay (ELISA
79839932|NCT04988152|Biological|sotrovimab|sotrovimab IV infusion, single dose
79839933|NCT04988152|Other|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
79538146|NCT06067100|Drug|Placebo|Participants are administered placebo
79538147|NCT06067100|Drug|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
79538148|NCT06066853|Drug|MDMA|MDMA-assisted psychotherapy
79538149|NCT06066827|Drug|Minoxidil Topical|20 subjects received minoxidil only for the treatment of AGA
79695173|NCT03991624|Other|Inhibition evaluation|"Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
79695174|NCT03991624|Other|Assessment of mental flexibility|"a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
79695175|NCT03991624|Other|Evaluation of the update|"an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
79695176|NCT03991624|Other|working memory|"the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
79695177|NCT03991624|Other|episodic memory|- A recognition task with a Remember/Know paradigm
79695178|NCT03970733|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
79695179|NCT03970733|Biological|Placebo|PBS (Phosphate Buffered Saline)
79839934|NCT04988152|Biological|sotrovimab|Sotrovimab IM injection, single dose
79839935|NCT04988152|Other|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
79839936|NCT04854148|Other|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
79839937|NCT00586625|Drug|Bepreve|One drop, both eyes, twice a day
79839938|NCT00586625|Drug|Placebo|One drop, both eyes, twice a day
79839939|NCT03999502|Device|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
79383361|NCT04273113|Behavioral|HRV Biofeedback (Healing Rhythms)|Sensors placed on fingers to capture heart rate and skin temperature
79383362|NCT04391439|Drug|Intravenous Methylprednisolone|
79383363|NCT01458483|Device|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
79383364|NCT02884245|Drug|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
79538150|NCT06066827|Other|Secretome from adipose-derived stem cells|20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
79538151|NCT06066827|Combination Product|Combination of minoxidil and secretome from adipose-derived stem cells|20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
79839940|NCT00636168|Drug|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
79839941|NCT00636168|Drug|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
79839942|NCT04098263|Biological|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
79839943|NCT04102631|Diagnostic Test|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
79839944|NCT04102631|Diagnostic Test|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
79839945|NCT00759941|Drug|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
79839946|NCT00759941|Drug|Placebo eye drops|One drop three times a day in both eyes for 3 months
79839947|NCT00759941|Drug|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
79839948|NCT00915863|Procedure|Billroth-II-type reconstruction|surgical procedure
79839949|NCT00915863|Procedure|Isolated Roux-en-Y type reconstruction|surgical procedure
80010363|NCT03539354|Device|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
80010364|NCT03539354|Procedure|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
80010365|NCT03539354|Drug|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
80010366|NCT03686943|Other|Family pharmacy|Observation of the family pharmacy in elderly group
79244438|NCT05850507|Biological|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
79244439|NCT05850507|Biological|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
79244440|NCT05850468|Drug|fentanyl infusion after general anesthesia and erector spinea block|intraoperative opioid infusion in active comparative group
79244441|NCT05850468|Drug|lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block|intraoperative non opioid infusion in experimental group
79303513|NCT03304145|Other|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
79383365|NCT01891461|Drug|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
79383366|NCT01458717|Drug|Neoadjuvant chemoradiation|"Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~4 weeks rest, re-evaluation for resectability~operation~start maintenance chemotherapy within 4~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
79695180|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
79695181|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
79695182|NCT03943017|Other|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
79839950|NCT00528424|Biological|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
79839951|NCT00315445|Drug|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
79839952|NCT00315445|Drug|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
79839953|NCT00315445|Drug|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
79839954|NCT00315445|Drug|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
80010367|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
80010368|NCT02174900|Drug|Artemether-Lumefantrine (AL) combination|
79695183|NCT03921411|Biological|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
79695184|NCT03906851|Behavioral|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
79695185|NCT03855475|Behavioral|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
79839955|NCT03687736|Biological|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
79839956|NCT04861324|Behavioral|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
79839957|NCT04857580|Device|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
79839958|NCT00779675|Biological|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
79839959|NCT03980119|Other|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
79839960|NCT04097093|Other|No intervention|No intervention
79839961|NCT04097171|Other|Diet|Participants will consume each diet for 14 days in a crossover design.
80010369|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
79244442|NCT05850377|Drug|5-Aminolevulinic Acid (5-ALA) Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
79244443|NCT05850377|Procedure|Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)|During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
79695186|NCT03855475|Behavioral|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
79695187|NCT03798639|Biological|Ipilimumab|Given IV
79244444|NCT05850338|Device|cold pad pillow|cold pad pillow application when women have vasomotor symptoms for 8 weeks
79695188|NCT03798639|Biological|Nivolumab|Given IV
79244445|NCT05850338|Behavioral|autogenic training|Autogenic relaxation for three times a day for eight weeks
79244446|NCT05850325|Other|Group 1 Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
79244447|NCT05850325|Other|Group 2 Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
79303514|NCT03304067|Behavioral|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
79538152|NCT06065774|Procedure|The Laterally Closed Tunnel Technique with SCTG|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments [devmed] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
79695189|NCT03798639|Radiation|Radiation Therapy|Receive radiation therapy
79839962|NCT00759863|Behavioral|Lifezig|Personalized Reminiscence Video
79839963|NCT03998722|Device|Vagivital|Vagivital once Daily for 12 weeks
79839964|NCT04102943|Drug|tacrolimus tablet|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
79839965|NCT04102943|Drug|tacrolimus capsules|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
79839966|NCT00759785|Drug|dalotuzumab (MK0646)|Single intravenous infusion
79839967|NCT00300781|Drug|neratinib|
79839968|NCT00315055|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
79839969|NCT00315055|Biological|DTaP-IPV//PRP~T combined|0.5 mL, IM
79839970|NCT00315055|Biological|Hepatitis B vaccine|0.5 mL, IM
79839971|NCT00528970|Drug|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
80010370|NCT02170610|Drug|BIBR 1048 MS|
80010371|NCT02170610|Drug|Pantoprazole|
79244448|NCT06042686|Device|RF Health MAC Device|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
79244449|NCT06042673|Dietary Supplement|Pomegranate seed oil|10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
79244450|NCT06042673|Dietary Supplement|Mixed vegetable oil|50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
79244451|NCT06042660|Other|the prevalence of comorbid conditions|analysis of history of comorbidities at the time of CML diagnosis
79695190|NCT03774901|Drug|Avelumab|intravenous 10 mg/kg every 2 weeks
80010372|NCT03686865|Device|dental implants|extraction sockets regenerated with xenograft
80010373|NCT02173106|Drug|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
79244452|NCT06042595|Behavioral|Psychotherapy|Patients treated at the inpatient psychotherapy unit of the University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers, and physiotherapists.
79244453|NCT06042582|Procedure|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
79244454|NCT06042556|Other|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
79244455|NCT06042504|Other|Survey|"Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS)."
79244457|NCT06042426|Drug|Dexamethasone|Two 8 mg doses. One dose applied prior to incision and the other at POD1
79244458|NCT06042426|Drug|Morphine|Morphine 0.1 mg per kg intravenous every 6 hours
79383367|NCT01458717|Procedure|Upfront surgery|"Operation at time of diagnosis~Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~start maintenance chemotherapy within 4~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
79383368|NCT01891617|Other|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
79538153|NCT06065774|Drug|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments [devmed] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
79695191|NCT03762018|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
79695192|NCT03762018|Drug|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
79695193|NCT03762018|Drug|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
79695194|NCT03762018|Drug|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
79695195|NCT03750825|Device|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
79839972|NCT00528970|Drug|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
79839973|NCT00759395|Drug|AZD2327|Tablet, Oral, Daily
79244459|NCT06042426|Drug|Oxycodone and acetaminophen|2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
79244460|NCT06042387|Genetic|Blood or saliva sample collection|Blood or saliva sample & clinical data collection
79305849|NCT04911387|Device|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
79383369|NCT01458795|Procedure|Endovenous laser ablation|
79383370|NCT04272567|Drug|Norepinephrine|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
79383371|NCT04272567|Drug|Normal saline|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
79383372|NCT01458873|Drug|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
79383373|NCT01458873|Drug|diluted sodium bicarbonate 2.1%|50ml
79383374|NCT01458873|Drug|normal saline|50ml
79244461|NCT06042374|Other|Progressive Core Stabilization Training|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.
79244462|NCT06042374|Other|Standard Core Strengthening Exercises|The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
79244463|NCT06042361|Behavioral|Smokefree Implementation Framework and Toolkit|"Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities."
79695196|NCT03747146|Device|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
79695197|NCT03747146|Device|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
79244464|NCT06042348|Diagnostic Test|Trans abdominal ultrasound|Ultra sound of the uterus and uterine blood vessels
80010374|NCT03932721|Drug|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
79244465|NCT06042309|Other|Rubber accelerators and control chamber/solution for NON-SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
79383375|NCT01891773|Behavioral|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
80010375|NCT00106340|Drug|vildagliptin|
79839974|NCT00759395|Drug|Placebo|Tablet, Oral, Daily
80010376|NCT00106340|Drug|glimepiride|
79383376|NCT01459029|Drug|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
79383377|NCT01891851|Drug|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
79383378|NCT01891851|Drug|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
80010377|NCT00106340|Drug|Metformin|
80010378|NCT00106340|Drug|Vildagliptin matching placebo|
80010379|NCT00106340|Drug|Glimepiride matching placebo|
80010380|NCT02255786|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
80010381|NCT03538496|Drug|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
79244466|NCT06042309|Other|SLS|Exposure to SLS on a randomized arm
79305850|NCT02185534|Drug|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
79383379|NCT02831283|Drug|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
79383380|NCT02831283|Drug|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
79383381|NCT02831283|Procedure|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
79383382|NCT01459185|Drug|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
79383383|NCT02826681|Drug|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
79383384|NCT02826681|Drug|Placebo (Normal Saline)|Normal Saline Solution
79383385|NCT01891929|Behavioral|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
79383386|NCT01891929|Behavioral|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
79383387|NCT01459263|Device|ClariVein|Using the ClariVein device, the GSV will be occluded.
79538154|NCT06065774|Procedure|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
79839975|NCT00293293|Other|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
79839976|NCT00293293|Other|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
79244467|NCT06042309|Other|Rubber accelerators and control chamber/solution for SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
79244468|NCT06042309|Other|Patch test on back|Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
79839977|NCT00293293|Other|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
79839978|NCT00293293|Drug|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
79839979|NCT05774613|Dietary Supplement|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
79244469|NCT06042296|Other|Expression of CD44, E-cadherin and PCNA|The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
79244470|NCT06042244|Other|Multimodal Exercise Group|Listed in arm/ group descriptions
79383388|NCT04390035|Device|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
79538155|NCT06065774|Drug|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
79695198|NCT03728582|Device|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
79695199|NCT03728582|Device|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
79695200|NCT03614234|Drug|pegunigalsidase alfa|Recombinant human alpha galactosidase A
79839980|NCT05774574|Dietary Supplement|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
79839981|NCT05774574|Dietary Supplement|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
79839982|NCT05774561|Diagnostic Test|Arm A - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
79839983|NCT05774561|Diagnostic Test|Arm B - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
80010382|NCT03694665|Other|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
79244471|NCT06042244|Other|Waitlist|listed in arm/group description
79383389|NCT05022693|Drug|BIO89-100|Subcutaneous Injections
79383390|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
79244472|NCT06042218|Behavioral|Xiaxi intervention program|The Xiaxi sessions will follow the same structure in both intervention groups. First of all, 8-minute warm-up where the participants will work on: postural awareness; active static stretching of the pectoral, hamstring and psoas muscles; and mobility. The main part will include the following blocks of content during the 12 weeks of intervention (46 minutes will be spent on this part in each session): breathing; mobility; active and dynamic static stretching of the tonic muscles with effects on the spine dynamic; strength of the phasic muscles with effects on the spine dynamic, alternating upper limb, lower limb and core; postural awareness; and passive static stretching of the tonic muscles with effects on the spine dynamic. The cool down will be similar in each session (6 minutes) and will focus on: postural awareness and passive static stretching of the pectoral, hamstring and psoas muscles.
79244473|NCT06042192|Drug|TK-254RX|Two TK-254RX per day to predetermined application site
79538156|NCT06064955|Behavioral|Peer Support|Former caregivers will be paired with a current caregiver based on a similar personal attribute (e.g., relationship to care recipient). Each pair will complete at least five virtual face-to-face (video) interactions and at least 10 other interactions either via phone call, email, or text messaging over the 6-month time period.
79839984|NCT05774535|Other|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~informed consent;~personal data and medical records;~registration of medical therapy and post-procedural pharmacological protocol~surgical check;~supra-aortic trunks EchocolorDoppler;~pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~surgical checks;~registration of drug therapy;~recording of all adverse events that occurred during hospitalization~supra-aortic trunks EchocolorDoppler and cIMT measurement;~blood sampling."
79839985|NCT05774522|Other|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
79305851|NCT03056079|Drug|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
79383391|NCT05029089|Device|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
79383392|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
79538157|NCT06064864|Drug|Infliximab-Dyyb|Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
79538158|NCT06064422|Behavioral|BeatIt-MV|BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
79538159|NCT06062095|Procedure|AI-powered computer-aided diagnosis (CADx)|Real time AI will be used to diagnosis polyps found during colonoscopy.
79538160|NCT06060704|Drug|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
79695201|NCT03613077|Procedure|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
79695202|NCT03593395|Other|Peer Mentoring [PM]|Virtual Peer Mentoring
79695203|NCT03593395|Other|Structured Education Based Transition Program STE|Education-based program
79695204|NCT03579680|Behavioral|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
79695205|NCT03579680|Behavioral|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
79695206|NCT04501328|Behavioral|CIC+VA-CRAFT|CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
79383393|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
79538161|NCT06060704|Drug|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
79695207|NCT04501328|Behavioral|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
79695208|NCT03566017|Drug|pegunigalsidase alfa|Recombinant human alpha galactosidase A
79695209|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
79695210|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
79695211|NCT03548467|Biological|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
80010383|NCT03538418|Other|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
79695212|NCT03548467|Drug|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
79244474|NCT06042140|Device|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
79695213|NCT03525990|Other|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
79244475|NCT06042075|Other|Questionnaire on congenital birthmarks|Questions will be put to health professionals on representation using a semi-quantitative questionnaire.
79244476|NCT06042023|Device|Lifesignals Wearable Sensor|"The participants will wear the patch for 3-5 days and be provided with the mobile device, which records data transmitted wirelessly directly from the biosensor patch. During the monitoring period, participants can continue their normal activities.~Remote monitoring will be undertaken using the CE-marked LifeSignals wearable biosensor. The biosensor communicates with a commercially available mobile device, which relays data to a secure Cloud server (GDPR compliant data transfer).~Participants will subsequently undergo their planned surgery in the usual way. Data captured from the remote monitoring will not be used or made accessible to inform decisions about clinical care.~There will be no clinical intervention from the researchers if abnormalities in vital signs are picked up by the monitoring patch, as all data will be analysed retrospectively after the participant's operation. Any clinical concerns about the device that arise will be reported to the relevant clinical team."
79244477|NCT06042010|Drug|Oral zinc supplement|patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
79244478|NCT06042010|Drug|triamcinolone acetonide Oral paste|patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
79244479|NCT06041984|Drug|Glycopyrrolate|Intravenous injection of glycopyrrolate 0.2mg
79244480|NCT06041984|Other|Placebo|Intravenous injection of saline 1ml
79244481|NCT06041906|Procedure|Shunt Closure|Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
79244482|NCT06041893|Drug|ATG-LDPTCy|antithymocyte globulin with low dose post-transplant cyclophosphamide
79244483|NCT06041867|Biological|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
79244484|NCT06041867|Dietary Supplement|Agaricus bisporus capsules|Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily
79383394|NCT05029089|Procedure|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
80010384|NCT03686787|Drug|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
79383395|NCT01459419|Drug|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
79383396|NCT01459419|Drug|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
79383397|NCT01892241|Drug|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
79695214|NCT03490669|Biological|MSC-1|humanized monoclonal antibody for intravenous administration
79695215|NCT03456882|Drug|RNS60|normal saline plus oxigen in nanobubble
79695216|NCT03433807|Drug|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
79839986|NCT05774522|Other|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
79839987|NCT05774522|Other|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
79839988|NCT05774457|Behavioral|Voice training|Traditional vs. virtual reality
79839989|NCT05774418|Biological|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
79244485|NCT06041867|Dietary Supplement|Control capsules|Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
79305852|NCT04923009|Procedure|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
79383398|NCT01892241|Drug|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
79383399|NCT04391127|Drug|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
79839990|NCT05774379|Device|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
79839991|NCT05774379|Behavioral|fatigue education|fatigue education for children
79839992|NCT05774275|Drug|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
79839993|NCT05774275|Drug|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
80010385|NCT02174978|Biological|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
79695217|NCT03416179|Drug|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
79383400|NCT04391127|Drug|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
79383401|NCT04391127|Drug|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
79695218|NCT03416179|Drug|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
79695219|NCT03416179|Drug|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
79695220|NCT03416179|Drug|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
79695221|NCT03416179|Drug|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
79695222|NCT03416179|Drug|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
79695223|NCT03416179|Drug|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults <60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
79695224|NCT03416179|Procedure|HSCT|If required, and done per standard of care post Induction(s).
79695225|NCT03408964|Other|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
79839994|NCT05774275|Drug|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
79839995|NCT05774275|Radiation|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
79383402|NCT04390893|Device|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
79839996|NCT05774262|Procedure|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
79839997|NCT05774262|Procedure|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate > 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
79839998|NCT05774171|Other|no intervention|no intervention
79839999|NCT05774158|Other|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
80010386|NCT02174978|Other|P falciparum Controlled Human Malaria Infection (CHMI)|
79383403|NCT04390893|Diagnostic Test|air leakage test|Anesthesiologist would use air leakage test to position the LMA
79244486|NCT06041763|Procedure|Meniscal Repair Procedure|All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.
79538162|NCT06060704|Drug|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
79538163|NCT06060275|Diagnostic Test|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
79538164|NCT06058884|Drug|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
79538165|NCT06058520|Drug|Fecal Microbiota - lyophilized|Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
79695226|NCT03406767|Other|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
79695227|NCT03406767|Other|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
79695228|NCT03372902|Device|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
79695229|NCT03372902|Device|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
79695230|NCT03372902|Other|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
79695231|NCT03372902|Procedure|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
80010387|NCT03694587|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
80010388|NCT03694587|Drug|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
79383404|NCT01892475|Behavioral|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~Accurately predicting step target attainment the following months (SGD10)~Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
79383405|NCT01892475|Behavioral|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
79383406|NCT01892553|Device|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~Cathodal tDCS: Intensity of 1.25 mA during 15 min~Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
79383407|NCT01459809|Drug|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
79538166|NCT06058520|Drug|Placebo drug|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
79538167|NCT06058403|Dietary Supplement|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
79538168|NCT06058403|Dietary Supplement|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
79538169|NCT06058403|Dietary Supplement|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
79538170|NCT06058403|Dietary Supplement|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
79695232|NCT03372902|Behavioral|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
79695233|NCT03361215|Other|Biosampling for molecular analysis|Observational study with no therapeutic intervention. Biosampling for molecular analysis
79695234|NCT03349528|Biological|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
79695235|NCT03349528|Biological|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
79695236|NCT03338764|Drug|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
79695237|NCT03338764|Drug|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
79695238|NCT03313544|Drug|Nivolumab|NIVOLUMAB
80010389|NCT03539276|Behavioral|Knowledge exchange|OptimaMed
80010390|NCT03694509|Other|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
80010391|NCT03694509|Other|Water|Water 250ml.
80010392|NCT02175056|Biological|HL2351|Dose-escalation For 5 level dose groups A ~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
79695239|NCT03313544|Device|MRI|Cardiac MRI 6 MONTHS
79695240|NCT03313544|Biological|BLOOD SAMPLES|biological (BNP and troponin)
79538171|NCT06057246|Other|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
79538172|NCT06056739|Device|Alio platform|Remote monitoring platform
80010393|NCT02175056|Biological|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
79538173|NCT06054295|Other|Biospecimen collection|Collection of both blood and saliva samples from participants at the time of study enrollment
79538174|NCT06054295|Other|Questionnaire Administration|The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
80010394|NCT02173184|Biological|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
79538175|NCT06052410|Other|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
80010395|NCT02173184|Biological|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
80010396|NCT03694431|Other|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
80010397|NCT03694431|Other|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
80010398|NCT02170766|Drug|BIBR 1048 low1|
80010399|NCT02170766|Drug|BIBR 1048 low2|
79383408|NCT01459809|Drug|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
79383409|NCT01459887|Drug|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
79383410|NCT01459887|Drug|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
80010400|NCT02170766|Drug|BIBR 1048 medium|
80010401|NCT02170766|Drug|BIBR 1048 high|
80010402|NCT02170766|Drug|Pantoprazole|
80010403|NCT04156659|Biological|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
80010404|NCT03538340|Procedure|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
80010405|NCT03538340|Procedure|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
80010406|NCT03694119|Drug|Phenelzine|Phenelzine
80010407|NCT03694119|Drug|Tyramine|Tyramine
80010408|NCT03694119|Drug|Phenelzine placebo|Phenelzine placebo
80010409|NCT03694119|Drug|ozanimod placebo|ozanimod placebo
79383411|NCT01892631|Other|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
79383412|NCT01892631|Other|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
79383413|NCT01890057|Drug|Sugammadex|The dose of sugammadex
79383414|NCT01890135|Drug|Zibotentan (ZD4054)|10 mg
79383415|NCT01890135|Drug|placebo|randomized double blind
79383416|NCT02876211|Drug|Paricalcitol|Paricalcitol 2 capsules/three times per week
79383417|NCT02876211|Drug|Epoetin beta|epoetin 1-3 times per week
79383418|NCT02876211|Drug|Placebo|Placebo 2 capsules/three times per week
79538176|NCT06052410|Other|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
79538177|NCT06050915|Drug|DISC-3405|DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
79538178|NCT06050915|Drug|DISC-3405|DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
79538179|NCT06050915|Drug|Placebo|Placebo is administered as a single dose IV infusion or subcutaneous injection
79538180|NCT06050915|Drug|Placebo|Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
80010410|NCT03694119|Drug|ozanimod|ozanimod
80010411|NCT02178254|Drug|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
80010412|NCT02178254|Drug|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
80010413|NCT02173262|Drug|G-CSF|
80010414|NCT02173262|Drug|Ciprofloxacin|
80010415|NCT02175134|Other|Blood and Ascites ELISPOT|
79695241|NCT03313544|Device|trans-thoracic echocardiography|1, 3 and 6 months
79538181|NCT06050109|Drug|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
79695242|NCT03309579|Other|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
79695243|NCT03309579|Other|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
79695244|NCT03251859|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
79244487|NCT06041763|Device|BEAR Implant|The BEAR Implant (22 mm in diameter and 45mm in length) is cylindrical in shape and comprised of collagen and extracellular matrix derived from bovine connective tissue, which has been cleaned, disinfected and processed by a proprietary manufacturing method. The implant has been terminally sterilized by electron-beam inadiation and is intended to be used with up to 10 ml of autologous blood drawn during the surgical implantation procedure. The BEAR Implant is resorbed within 8 weeks and replaced with a fibrovascular repair tissue.
79383419|NCT05587023|Procedure|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
79538182|NCT06050109|Diagnostic Test|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
79383420|NCT01890213|Biological|AVX701|
79538183|NCT06049134|Biological|PCV20|Given by Injection into the muscle
79538184|NCT06049056|Other|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
79695245|NCT03251859|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg daily
79695246|NCT03156660|Behavioral|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~Daily self-monitoring of steps and number of Small Changes~Daily weight self-monitoring on the BodyTraceTM e-scale~Fit Bit Alta activity trackers to self-monitor steps"
79538185|NCT06048588|Drug|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg for 2 weeks. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg for 4 weeks.
79538186|NCT06048588|Drug|Placebo for YN001|The injection solution to mimic the YN001
79695247|NCT03156660|Behavioral|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~Tailored calorie and fat goals based on their baseline weight.~Daily dietary intake and physical activity self-monitoring using a website or app.~Daily weight self-monitoring on the BodyTraceTM e-scale~Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~Fit Bit Alta activity trackers to self-monitor steps"
79695248|NCT03156660|Behavioral|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~EatingWell Diet book.~Daily weight self-monitoring on the BodyTraceTM e-scale"
79695249|NCT03118349|Drug|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
79695250|NCT03118349|Drug|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
80010416|NCT03537638|Behavioral|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
79244488|NCT06041750|Procedure|Elective surgical procedure under general anesthesia|The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
79244489|NCT06041724|Drug|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|"Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years."
79244490|NCT06041698|Other|Planned Notification|Receive text notification
79383421|NCT02682147|Drug|Hypoxia administration study group|scan completed after 5 minutes of breathing in hypoxic air
79695251|NCT03053115|Drug|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
79383422|NCT02682147|Drug|Hyperoxia administration study group|scan completed after up to 15 minutes of breathing in hyperoxic air
79383423|NCT02682147|Drug|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
79383424|NCT02681601|Dietary Supplement|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
79538187|NCT06048588|Drug|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily for 4 weeks.
79538188|NCT06040450|Other|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
79538189|NCT06035458|Diagnostic Test|Diagnostic radiology|Clinical procedures include bone mineral measurement (bone densitometry, dxa) performed according to clinical practice; venipunctures for laboratory assessments (haematology and blood chemistry; bone turnover biomarkers P1NP and CTX).
79538190|NCT06032598|Dietary Supplement|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
79383425|NCT02681601|Other|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
79383426|NCT02681601|Dietary Supplement|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
79695252|NCT03053115|Drug|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
79695253|NCT03053115|Drug|Placebos|Controls will take placebo two hours after dinner
80010417|NCT04150653|Device|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
79695254|NCT03049969|Device|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
79840000|NCT05774106|Behavioral|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
80010418|NCT03690687|Procedure|Primary anastomosis|
80010419|NCT03690687|Procedure|Delayed anastomosis|
79244491|NCT06041698|Other|Survey Administration|Complete surveys
79244492|NCT06041698|Behavioral|Behavioral Intervention|Participate in TXT-Chatbot
79244493|NCT06041698|Other|Electronic Health Record Review|Ancillary studies
79244494|NCT06041698|Other|Interview|Ancillary studies
79695255|NCT03003026|Other|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
80010420|NCT03690687|Procedure|Enterostomy|
80010421|NCT02173418|Drug|Phrenic nerve block with Ropivacaine|
79244495|NCT06041698|Other|Survey Administration|Complete surveys
80010422|NCT02173418|Drug|Phrenic nerve block with saline|
80010423|NCT03686709|Diagnostic Test|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
80010424|NCT02173496|Other|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
80010425|NCT02173574|Drug|DEB025|
80010426|NCT02173574|Drug|EDP239|
80010427|NCT03932331|Drug|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
80010428|NCT02178488|Drug|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
79244496|NCT06041698|Other|Planned Notification|Receive email notification
79244497|NCT06041698|Behavioral|Behavioral Intervention|Participate in MyChart/Patient Portal
79244498|NCT06041698|Other|Electronic Health Record Review|Ancillary studies
79244499|NCT06041698|Other|Interview|Ancillary studies
79244500|NCT06041633|Diagnostic Test|Clinical|Questionnaire
79244501|NCT06041594|Device|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
79244502|NCT06041542|Diagnostic Test|10-second hand grip and release test|To grip and release hand in ten seconds
79244503|NCT06041529|Drug|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
79244504|NCT06041529|Drug|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
79305853|NCT02121808|Procedure|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
79383427|NCT01892787|Drug|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
79383428|NCT01892787|Drug|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
79538191|NCT06032598|Dietary Supplement|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
79538192|NCT06032598|Dietary Supplement|Placebo|The study foresees the intake of 1 capsule per day during 84 days
79538193|NCT06032169|Other|Patients of a surgical intensive care unit having an arterial catheter|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of AP in the two studied positions (semi-recumbent or horizontal).
80010429|NCT02178488|Other|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
79695256|NCT03003026|Other|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
79695257|NCT02932332|Other|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
79840001|NCT05774028|Drug|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
79840002|NCT05773937|Drug|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
79244505|NCT06041490|Drug|multi-kinase inhibitors in combination with bevacizumab|The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
79244506|NCT06041477|Drug|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
79244507|NCT06041477|Drug|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
79244508|NCT06041477|Drug|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
79244509|NCT06041477|Drug|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
79305854|NCT02121808|Procedure|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
79383429|NCT01893723|Procedure|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
79383430|NCT01893723|Procedure|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
79695258|NCT02932332|Other|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
79383431|NCT01453959|Drug|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
79383432|NCT01453959|Other|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
79383433|NCT02669901|Behavioral|Naloxone Auto-Injector|Naloxone auto-injector is the only product FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
79383434|NCT01755767|Drug|Tivantinib|Tivantinib tablets
79383435|NCT01755767|Drug|Placebo|Matching placebo tablets
79383436|NCT05023707|Biological|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
79383437|NCT01893099|Drug|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
79383438|NCT01893099|Device|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
79538197|NCT06028295|Dietary Supplement|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
79538198|NCT06028295|Dietary Supplement|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
79538199|NCT06028295|Dietary Supplement|Placebo|The study foresees the intake of 2 capsules per day during 84 days
79538200|NCT06025994|Other|MULTI-DOMAIN LIFESTILE INTERVENTION|All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
79695259|NCT02932332|Other|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
79840003|NCT05773924|Device|triLift system|To evaluate the efficacy of the triLift™ treatment
79840004|NCT05773911|Device|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
79840005|NCT05773911|Device|Reciprocal Chitosan brush|Reciprocal Chitosan brush
79840006|NCT05773898|Other|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
79695260|NCT02932332|Other|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
79840007|NCT05773885|Device|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
79840008|NCT05773885|Other|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
79244510|NCT06041477|Drug|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
79244511|NCT06041464|Other|cell culture|isolation of cell culture
79383439|NCT05586633|Procedure|deep paravertebral periforaminal ozone injeciton|"Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
79383440|NCT05586633|Procedure|transforaminal steroid injeciton|"Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
79383441|NCT02327403|Drug|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
79538201|NCT06021938|Device|Immersive virtual reality (IVR) & Music therapy|The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
79383442|NCT02372877|Device|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
79383443|NCT01893177|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
79383444|NCT01922050|Drug|LEO 43204 Formulation 1|
79383445|NCT01922050|Drug|LEO 43204 Formulation 2|
79538202|NCT06020781|Drug|bupivacaine and dexmedetomidine.|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
79538203|NCT06020781|Drug|bupivacaine only|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
79538204|NCT06020781|Drug|bupivacaine|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
79244512|NCT06041451|Drug|Intravenous Immunoglobulins, Human|patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
79383446|NCT01922050|Drug|LEO 43204 Formulation 1 Dose X|
79383447|NCT01922050|Drug|LEO 43204 Formulation 1 Dose Y|
79538205|NCT06017791|Other|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade above the maxillary canines in the alveolar mucosa~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
79695261|NCT02918409|Drug|Colistin|
79695262|NCT02918409|Drug|Tobramycin|
79244513|NCT06041451|Drug|Methylprednisolone 500 MG Injection|patients were treated with methylprednisolone
79695263|NCT02901574|Device|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
79305855|NCT04923087|Device|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
80010430|NCT03686631|Behavioral|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
79840009|NCT05773859|Biological|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
79383448|NCT01922050|Drug|LEO 43204 Formulation 2 Dose XX|
79840010|NCT05773833|Behavioral|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
79383449|NCT01922050|Drug|LEO 43204 Formulation 2 Dose YY|
79538206|NCT06017583|Drug|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
79383450|NCT01922050|Drug|Placebo Formulation 1|
79383451|NCT01922050|Drug|Placebo Formulation 2|
79383452|NCT02655393|Dietary Supplement|Mitopure|
79383453|NCT02360943|Other|4 blood samples|PK and / or PD measurements during hospitalization
79383454|NCT01922986|Device|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
79840011|NCT05773807|Other|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
79840012|NCT05773807|Other|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
80010431|NCT02173652|Drug|BI 1356, high dose|
80010432|NCT02173652|Drug|BI 1356, low dose|
80010433|NCT03694041|Drug|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
79383455|NCT01922986|Device|sham rTMS|20 minutes of sham rTMS stimulation
79538207|NCT06017583|Drug|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
79538208|NCT06017583|Drug|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
79538209|NCT06017583|Radiation|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
79538210|NCT06017583|Radiation|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
79244516|NCT06041399|Drug|hypoglycemic Agents(metformin)|patients treated with hypoglycemic Agents(metformin)
79538211|NCT06008353|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
79538212|NCT06007365|Device|Z5m Dental Implants|This is an observational study, collecting data on the use of Z5m Dental Implants.
80010434|NCT03694041|Drug|SAD: Placebo|Drug: Placebo Placebo for 1day
80010435|NCT03694041|Drug|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
80010436|NCT03694041|Drug|MAD: Placebo|Matching study drug will be repeatedly administered.
79244517|NCT06041399|Drug|lipid-lowering drug(Statin)|patients treated with lipid-lowering drug(Statin)
79244518|NCT06041386|Drug|Mepolizumab|Mepolizumab will be prescribed based on physician decision.
79244519|NCT06041386|Other|Spirometry|Lung function via spirometry will be collected.
79244520|NCT06041360|Diagnostic Test|Pure tone audiometry PTA ,Speech audiometry ,Otoacoustic emission,Auditory evoked potentials including (ABR).|Neurological tests for diagnosis of peripheral neuropathy
79305856|NCT03055845|Drug|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
79383456|NCT01922986|Behavioral|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
79383457|NCT05740150|Device|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
79383458|NCT05740150|Device|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
79383459|NCT02359383|Other|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
79383460|NCT05734612|Drug|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
79383461|NCT05734612|Drug|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
79383462|NCT02349867|Drug|Gemcitabine|Given IV
79383463|NCT02349867|Drug|Sorafenib|Given PO
79383464|NCT02349867|Drug|Vorinostat|Given PO
79383465|NCT02349867|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
79383466|NCT02349867|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
80010437|NCT03694041|Other|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
79695264|NCT02901574|Device|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
79538213|NCT06002906|Drug|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
79695265|NCT02901574|Behavioral|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
79840013|NCT05773807|Procedure|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
79244521|NCT06041347|Diagnostic Test|Transvaginal ultrasound|Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI.
79244522|NCT06041321|Device|Reparel Sleeve|For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
79840014|NCT05773807|Drug|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
79840015|NCT05773794|Dietary Supplement|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
79244523|NCT06041321|Device|Placebo Sleeve|Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
79383467|NCT02349867|Other|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
79383468|NCT02349867|Other|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
79383469|NCT01924390|Device|Mineralized freeze-dried bone allograft alone|
79695266|NCT02868450|Biological|Blood Sample|
79840016|NCT05773794|Dietary Supplement|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
80010438|NCT03694041|Other|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
80010439|NCT02173730|Drug|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
79383470|NCT01924390|Device|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
79383471|NCT01730339|Drug|PF-06473871|Single dose administered by injection four different times
79383472|NCT01730339|Drug|PF-06473871|Single dose administered by injection three different times
79383473|NCT01925404|Behavioral|Free physical activity classes|100 hours of free activity classes will be provided
79383474|NCT01925404|Behavioral|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
79695267|NCT02868411|Other|Rectal Swab|
79695268|NCT02868346|Other|Anal swab|
79840017|NCT05773781|Other|PuraBond|Application of PuraBond to surgical field
79383475|NCT05734534|Other|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
79695269|NCT02866565|Drug|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
79840018|NCT05773729|Genetic|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
79840019|NCT05773716|Behavioral|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2~6-second and a 2~6-second relaxation following each one.
80010440|NCT02173730|Drug|Pantoprazole|Pantoprazole tablet 40 mg
80010441|NCT03686553|Other|laboratory-based data collection|laboratory-based surveillance of SSI
80010442|NCT03686475|Other|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
80010443|NCT03686475|Other|MTA pulpotomy|MTA pulpotomy
79538214|NCT06002906|Device|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
79538215|NCT06002399|Device|cataract surgery|cataract surgery
79538216|NCT05999955|Drug|Neomycin|The active-control in the phase II study was a commercial form of nasal spray containing Neomycin. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis.
79695270|NCT02866201|Other|Rectal swab|
79695271|NCT02861768|Biological|Pharyngeal swab|
79695272|NCT02859792|Drug|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
79695273|NCT02859792|Drug|Placebo|placebo capsules 25 or 50 mg
79695274|NCT02859792|Biological|Blood Samples|v1;v2;v3;v4
79695275|NCT02858687|Other|Nasopharyngeal swab|
79695276|NCT02858661|Other|Nasopharyngeal swab|
79695277|NCT02858609|Other|Nasopharyngeal Swab|
79840020|NCT05773716|Other|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
79695278|NCT02851771|Other|Nasopharyngeal Swab|
79695279|NCT02846753|Procedure|trans catheter heart valve replacement|trans catheter heart valve replacement
79695280|NCT02842333|Other|Additional biological samples|Blood samples
79695281|NCT02828085|Biological|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
79695282|NCT02827175|Other|blood sample|
79695283|NCT02822807|Biological|Blood sampling|
79695284|NCT02820623|Behavioral|Self-report|
79695285|NCT02820623|Behavioral|Chart-Stimulated Recall|
79695286|NCT02820623|Behavioral|Behavioral Rehearsal|
79695287|NCT02819232|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
79695288|NCT02819206|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
79840021|NCT05773716|Other|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
79244524|NCT06041295|Behavioral|on-the-job training of lung expansion therapy|on-the-job training of lung expansion therapy
79244525|NCT06041243|Other|Game-Based Exercises|Exercises aimed to improve postural balance with four different games
79244526|NCT06041230|Device|Ozone Generator|Ultrasound guided ozone therapy
79538217|NCT05999955|Combination Product|Bacillus subtilis DSM32444|DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device.
79538218|NCT05998317|Drug|At-night Dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
79695289|NCT02819128|Other|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
79695290|NCT02819128|Other|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
79695291|NCT02816307|Other|blood samples|
79695292|NCT02774005|Drug|Idebenone|
79538219|NCT05998317|Drug|At-induction Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
79695293|NCT02747849|Device|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
79695294|NCT02700828|Drug|Hydrocortisone|4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
79695295|NCT02700828|Drug|Placebo|4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
79695296|NCT02695771|Drug|Mitomycin C|Cancer chemotherapeutic agent
79695297|NCT02695771|Drug|Gemcitabine|Cancer chemotherapeutic agent
79695298|NCT02658032|Behavioral|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
79695299|NCT02658032|Behavioral|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
79695300|NCT02658032|Other|standard care|
79695301|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
79695302|NCT02462460|Device|MRI|
79695303|NCT02462460|Behavioral|Optional Screening Questionnaire|
80010444|NCT02175446|Drug|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
79244527|NCT06041230|Device|Extracorporeal shock wave therapy device|Extracorporeal shock wave therapy device
79244528|NCT06041191|Diagnostic Test|Assessment|The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
79244529|NCT06041178|Drug|2.5% flurbiprofen|Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
79244530|NCT06041178|Drug|98% aloe vera|the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
79695304|NCT02339701|Radiation|IMRT|
79538220|NCT05996458|Other|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
79840022|NCT05773690|Other|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
80010445|NCT03686319|Other|Reflexology|Reflexology: foot massage
79383476|NCT05734534|Other|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
79383477|NCT02629419|Drug|Amphotericin B|Lipid crystal nano-particle formulation of amphotericin B
79383478|NCT05740072|Other|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
79383479|NCT05740072|Other|No drying before wrapping|Immediately after birth, the infant will be put in a plastic bag without wrapping
80010446|NCT03686241|Procedure|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
79244531|NCT06041178|Other|Placebo|saline
79383480|NCT02334735|Biological|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10^6 cells)"
79695305|NCT02339701|Radiation|SBRT|
80010447|NCT03686241|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
80010448|NCT02178644|Drug|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
79244532|NCT06041165|Drug|JS401|Single dose of JS401 by subcutaneous (sc) injections
79244533|NCT06041165|Drug|Placebo|Calculated volume to match active treatment
79244534|NCT06041061|Biological|Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
79244535|NCT06041061|Biological|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
79244536|NCT06041035|Drug|QLS31905|Administered as an intravenous infusion.
79383481|NCT02334735|Biological|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
79383482|NCT02334735|Biological|Poly-ICLC|1.4 mg
79244537|NCT06041035|Drug|Nab paclitaxel|125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
79244538|NCT06041035|Drug|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
79244539|NCT06041035|Drug|Oxaliplatin|85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
79244540|NCT06041035|Drug|Capecitabine|1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
79383483|NCT02329600|Drug|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
79383484|NCT02329600|Drug|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
79383485|NCT02620761|Drug|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
79383486|NCT02620761|Drug|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
79383487|NCT01754753|Other|Telephone Friendship groups|
79538221|NCT05996458|Other|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
79695306|NCT02209142|Other|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
79695307|NCT02209142|Other|psychometric data collection|
79695308|NCT02200276|Biological|Influenza|
79695309|NCT02190305|Device|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
79695310|NCT02167711|Drug|SIRT Yttrium-90|
80010449|NCT03686163|Drug|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
79538222|NCT05996458|Other|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
79695311|NCT01975428|Device|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
79695312|NCT01975428|Behavioral|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
80010450|NCT03686163|Drug|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
80010451|NCT02256098|Device|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
80010452|NCT02256098|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
80010453|NCT03690609|Dietary Supplement|CytoQuel|3 capsules daily.
79244541|NCT06041035|Drug|Cisplatin|25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
79244542|NCT06041022|Other|Exposure factors|Including demographical data, laboratory features and liver histological indicators.
79383488|NCT04758273|Biological|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
79383489|NCT04758273|Biological|high dosage inactivated SARS-CoV-2 vaccine|high dosage
79383490|NCT04758273|Biological|Placebo|placebo
79383491|NCT02613273|Behavioral|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
80010454|NCT03690609|Dietary Supplement|CytoQuel|2 capsules twice daily.
80010455|NCT02173808|Biological|levonorgestrel butanoate|
79383492|NCT02613273|Behavioral|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
79383493|NCT01729871|Drug|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
79383494|NCT01729871|Drug|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
79383495|NCT02611323|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
80010456|NCT03690531|Device|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
79383496|NCT02611323|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
79538223|NCT05996380|Drug|SHR-3167|SHR-3167, Single administration
79538224|NCT05996380|Drug|SHR-3167 Placebo|SHR-3167 Placebo Single administration
79538225|NCT05996354|Device|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
79695313|NCT01941641|Drug|neoadjuvant FOLFOXIRI|
79695314|NCT01941641|Drug|Capecitabine|
79695315|NCT01792934|Drug|XELOX regimen according to standard procedures|
79695316|NCT01792934|Drug|FOLFOX regimen according to standard procedures|
79695317|NCT01792934|Procedure|Surgery|
80010457|NCT03690531|Device|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
80010458|NCT02256020|Other|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
80010459|NCT02256020|Other|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
80010460|NCT03690297|Device|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
80010461|NCT04132401|Diagnostic Test|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
79244543|NCT06040996|Behavioral|Improving Parenting Skills adult ADHD (IPSA)|Parent training program for parents with ADHD. The program combines structured group-based skills training with individualized support, including occupational therapist support to help parents improve their own prerequisites for bringing about change and facilitate use of the introduced parenting skills.
79244544|NCT06040996|Other|Continued Routine Services|Continued Routine Services while waiting for IPSA (offered approximately 6 months later)
79244545|NCT06040983|Device|FR-101 Chest Dressing|"Subject will receive FR-101 chest dressing and be instructed to use the product on the target skin area accepted radiation therapy once every 2 days, taking care of avoiding applications from 1 to 4 h before treatment to prevent Build-up effect. If the application time is longer than the recommendation, discomfort may happen depending on subject's condition."
79244546|NCT06040970|Drug|Sacituzumab|"Dose 0: Sacituzumab govitecan 10 mg/kg~Dose 1: Sacituzumab govitecan 7.5 mg/kg"
79244547|NCT06040970|Drug|Cisplatin|Cisplatin 70 mg/m2 IV
80010462|NCT02173886|Drug|Bupropion SR and XL|
80010463|NCT03690219|Other|no intervention|no intervention
80010464|NCT02173964|Drug|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
79538226|NCT05984433|Device|Auricular acupuncture|Electro auricular acupuncture
79383497|NCT02611323|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
79695318|NCT01792934|Other|radiofrequency ablation (RFA)|
79695319|NCT01792934|Other|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
79695320|NCT01792934|Radiation|stereotactic body radiation therapy (SBRT)|
79695321|NCT01792934|Drug|Bevacizumab|may be added to both regimens according to standard procedures
79695322|NCT01792934|Procedure|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
79383498|NCT02611323|Drug|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
79383499|NCT02608359|Drug|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
79383500|NCT01729559|Drug|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
79383501|NCT01729559|Drug|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
79383502|NCT01893333|Procedure|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy~sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
79383503|NCT01926496|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
79383504|NCT01926496|Drug|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
79538227|NCT05984004|Drug|0.9% NaCl isotonic saline solution|The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
79538228|NCT05984004|Combination Product|Bacillus subtilis DSM32444, inactivated|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
79695323|NCT01751438|Other|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
79695324|NCT01751438|Other|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
79695325|NCT01751438|Behavioral|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
79695326|NCT01751438|Other|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
79695327|NCT01669915|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
79695328|NCT01669915|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79695329|NCT01669915|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
80010465|NCT02173964|Drug|water|same amount of water for pinverin administration
80010466|NCT03690141|Drug|tomivosertib (eFT508)|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
80010467|NCT02175602|Drug|Escitalopram|10 milligrams administered each morning
79383505|NCT04559555|Drug|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
79383506|NCT05739916|Drug|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
79383507|NCT05739916|Drug|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
79383508|NCT01728779|Drug|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
79695330|NCT01669915|Dietary Supplement|Fish oil placebo|Fish oil placebo
79383509|NCT01728779|Radiation|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
79383510|NCT01927120|Drug|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
79383511|NCT01927120|Drug|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
79383512|NCT01927120|Drug|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
79383513|NCT05586867|Procedure|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
79383514|NCT01728623|Drug|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
79695331|NCT01653223|Drug|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
80010468|NCT02175602|Drug|Sertraline|50 milligrams administered each morning
79695332|NCT01549587|Drug|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
79383515|NCT05586399|Behavioral|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
79840023|NCT05773690|Other|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
79840024|NCT05773625|Device|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
79840025|NCT05773612|Other|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
79383516|NCT02579655|Behavioral|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
79538229|NCT05982860|Behavioral|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries & sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
79695333|NCT01549587|Device|toothbrush|brush thoroughly twice daily
79383517|NCT02579655|Behavioral|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
79383518|NCT02573337|Device|Emervel Classic Lidocaine|Treatment of wrinkles and folds
79695334|NCT01549587|Device|dental floss|floss the whole mouth once daily
79695335|NCT01549587|Drug|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
79695336|NCT01549587|Device|toothbrush|twice daily brush thoroughly for 2 minutes
79840026|NCT05773560|Device|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
79840027|NCT05773547|Device|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
79840028|NCT05773534|Diagnostic Test|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
79840029|NCT05773508|Device|Video regulation and emergency kit|Video regulation and emergency kit
79840030|NCT05773469|Other|Exercise|Ski traverse of Greenland polar Icecap
80010469|NCT02175602|Drug|DCV 3DAA FDC|Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
80010470|NCT02175602|Drug|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
79695337|NCT01549587|Drug|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
79695338|NCT01549587|Device|dental floss|floss the whole mouth once daily
79695339|NCT01047540|Drug|AIC316|Oral administration
79695340|NCT01047540|Drug|AIC316|Oral administration
79695341|NCT01047540|Drug|AIC316|Oral administration
79244550|NCT06040944|Drug|antipsychotic drugs inducing hyperprolactinemia|not exposed
79244551|NCT06040931|Procedure|Bronchoscopy|Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
79383519|NCT02573337|Device|Emervel Deep Lidocaine|Treatment of wrinkles and folds
79383520|NCT02781363|Other|Thoracic ultrasound|
79383521|NCT02781363|Other|CXR|
79695342|NCT01047540|Drug|AIC316|Oral administration
79695343|NCT01047540|Drug|Placebo|Oral administration
79695344|NCT00521222|Drug|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
79695345|NCT00521222|Drug|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
79695346|NCT00521222|Drug|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
79695347|NCT00521222|Drug|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
79695348|NCT00544856|Behavioral|complex cognitive training|
79244552|NCT06040892|Diagnostic Test|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
79840031|NCT05773469|Other|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
79840032|NCT05773443|Device|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
79538230|NCT05982548|Other|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
79383522|NCT04757727|Other|Decriptive study of EDB|data on EDB will be register
79538231|NCT05982548|Other|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
79538232|NCT05982262|Other|Naturopathic-pharmacological consultation|The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
79695349|NCT00560001|Behavioral|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
79840033|NCT05773430|Behavioral|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
79538233|NCT05978713|Drug|Tirzepatide|Administered SC
79538234|NCT05975385|Device|Acupuncture|Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
79538235|NCT05974852|Other|Ocrelizumab|Non-interventional
79538236|NCT05974839|Other|Ocrelizumab|Non-interventional
79840034|NCT05773235|Diagnostic Test|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
79538237|NCT05974254|Device|Acupuncture|Electroacupuncture
79840035|NCT05773183|Drug|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
79383523|NCT01728077|Drug|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
79840036|NCT05773183|Drug|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
79840037|NCT05773144|Behavioral|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
79383524|NCT04757181|Other|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
79383525|NCT02307279|Device|Gelesis100|
79244553|NCT06040892|Diagnostic Test|FRASIMAT Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
79244554|NCT06040892|Diagnostic Test|Kid SSQ questionnaire of life : The Speech, Spatial and Other Qualities of Hearing Scale|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
79305857|NCT03055845|Drug|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
79305858|NCT04922775|Procedure|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
79538238|NCT05973383|Behavioral|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
79538239|NCT05973383|Behavioral|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
79538240|NCT05973383|Behavioral|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
79383526|NCT02307279|Device|placebo|
79383527|NCT01606007|Drug|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
79244555|NCT06040892|Other|spatial hearing rehabilitation program|The tool makes it possible to propose rehabilitation programs adapted to the performance and expectations of each child. This program will manipulate both the ambient sound with varying background noise to simulate daily life environments (i.e. making auditory detection more or less complex), and also manipulate virtual immersive environment (i.e. giving more or less relevant visual cues related to real sound location).
79244556|NCT06040879|Procedure|PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK|During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
79383528|NCT01606007|Drug|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
79695350|NCT04647045|Dietary Supplement|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
79695351|NCT00544934|Drug|GLY-230|125, 250 0r 375 mg bid for 14 days
79538241|NCT05970484|Behavioral|DrinksRation|DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.
79695352|NCT00544934|Other|Placebo|No drug administered
79695354|NCT00545012|Drug|Levetiracetam|
79695355|NCT04647123|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
79840038|NCT05773144|Behavioral|Progressive stretching|Static stretching of eight major muscle groups
80010471|NCT03686085|Drug|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
79695356|NCT00545090|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
79695357|NCT00545207|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
79695358|NCT00545207|Drug|Placebo|po monthly for 2 years
79695359|NCT04647006|Procedure|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
79695360|NCT04638504|Other|ultrasonography|vascular and adipose tissue measurement by ultrasonography
79305859|NCT04922775|Procedure|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
79305860|NCT02157376|Drug|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
79383529|NCT01606007|Drug|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
79383530|NCT01606007|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
79695361|NCT04684784|Device|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
79695362|NCT04684784|Device|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
79695363|NCT00545246|Drug|aflibercept (AVE0005)|intravenous infusion
79695364|NCT00545246|Drug|docetaxel|intravenous infusion
79695365|NCT04638114|Procedure|Mini-open DAA|Direct anterior approach hip
79840039|NCT05773131|Device|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
80010472|NCT03686085|Drug|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
79305861|NCT02157376|Drug|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
79383531|NCT01606007|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
79383532|NCT02301819|Device|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
79695366|NCT04638114|Procedure|Hip arthroscopy|arthroscopic treatment of hip pathology
79695367|NCT00545285|Procedure|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
79695368|NCT04637997|Device|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
79695369|NCT04637997|Device|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
79695370|NCT03456440|Diagnostic Test|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
79695371|NCT03456401|Drug|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
79695372|NCT04638192|Device|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
80010473|NCT03693963|Device|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
79244557|NCT06040866|Other|Exercise training|Exercise training will be applied in the non-menstrual period during 2 menstrual cycles as stretching and relaxation exercises. Stretching exercises will include general stretching and specific stretching exercises and will take approximately 20 minutes in total. After the stretching exercises, relaxation exercise will be performed with diaphragmatic breathing for 10 minutes. The exercises will be performed with music accompanied by a physiotherapist once a week, and it will be recommended to do the exercises as a home program for 2 sessions a week.
79244558|NCT06040866|Other|Pain neuroscience education|Participants in the first research arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
79538242|NCT05970484|Behavioral|BeAlcoholSmart|BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
79695373|NCT03456362|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
79695374|NCT04646538|Other|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
79695375|NCT03456323|Behavioral|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
79840040|NCT05773027|Behavioral|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
80010474|NCT02754440|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
79538243|NCT05965895|Procedure|Ultrasound-guided continuous serratus anterior plane block|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
79695376|NCT03456323|Other|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
79695377|NCT04638270|Biological|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
79695378|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
79695379|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
79695380|NCT00545519|Drug|thymoglobulin|
80010475|NCT03690063|Other|Follow up|Follow up of treatment, behavior, co-morbidity
80010476|NCT03689829|Drug|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
80010477|NCT03689829|Drug|Placebo|Corresponding placebo s.c. injections.
79244559|NCT06040866|Other|Biomedical pain education|Participants in the second research arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
79244560|NCT06040853|Drug|Tranexamic acid intravenous administration|Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
79244561|NCT06040853|Drug|Saline|Participant was given intravenous 100 ml saline
79383533|NCT02301819|Other|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
79383534|NCT01928290|Drug|Irinotecan|
79695381|NCT04637685|Device|Centurion Phacoemulsification System|Infusion Pressure
79695382|NCT00545558|Drug|Efavirenz|600 mg tablet taken orally daily
79695383|NCT00545558|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
80010478|NCT02174042|Drug|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
79244562|NCT06040827|Device|Total Knee Arthroplasty|The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
79383535|NCT01928290|Drug|Trastuzumab|
79383536|NCT01928290|Drug|Oxaliplatin|
79383537|NCT01928290|Drug|Leucovorin|
79383538|NCT01928290|Drug|Fluorouracil|
79383539|NCT04272177|Other|Shared decision making with the used of patient decision aids|PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
79383540|NCT01893489|Other|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
79840041|NCT05773027|Behavioral|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
79840042|NCT05772975|Biological|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
79538244|NCT05965895|Drug|intravenous dexmedetomidine infusion|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
79244563|NCT06040814|Behavioral|Rehabilitation Training|12 week Rehabilitation Training course
80010479|NCT03693885|Other|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
79695384|NCT04638426|Drug|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
79244564|NCT06040788|Procedure|immediate implant placement with customized healing abutment|immediate implant placement with customized healing abutment
79244565|NCT06040294|Other|DDS program|dementia virtual reality and disability simulation of activity design for seniors
79244566|NCT06040294|Other|dementia course with no DDS|Regular dementia course and group discussions of activity design for seniors with no DDS
79538245|NCT05964400|Behavioral|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
79538246|NCT05963425|Other|Physical activity|This physical activity program will be based only on the work of basic physical traininig, in which specifically and mainly the strength and resistance will be worked, but also flexibility
79538247|NCT05963425|Other|usual clinical practice|usual clinical practice
80010480|NCT02174120|Drug|propofol|
79695385|NCT04638426|Drug|Placebo of HL237 tablet|Placebo of HL237, twice a day
79695386|NCT00545597|Drug|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
79695387|NCT04646577|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
79695388|NCT04646577|Device|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
80010481|NCT02174120|Drug|etomidate|
80010482|NCT03922893|Other|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
80010483|NCT03922893|Genetic|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
80010484|NCT03922893|Genetic|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
80010485|NCT03922893|Other|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
80010486|NCT02175914|Drug|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
80010487|NCT03693729|Device|HD-tDCS|Participants will complete a metamemory and memory task
80010488|NCT02753816|Drug|Tranexamic Acid|
80010489|NCT02753816|Drug|Placebo Comparator|
79244567|NCT06039618|Other|Referral to Centre of Higher Organizational Level|Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
79244568|NCT06039228|Behavioral|Acceptance and commitment therapy|Four sessions of group acceptance and commitment therapy, with each session lasting for 1.5 hours.
79244569|NCT06038396|Drug|RC118|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
79244570|NCT06038396|Drug|Toripalimab|Toripalimab is a recombinant humanized anti-PD1 monoclonal antibody
79305862|NCT04918251|Procedure|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
79383541|NCT01894113|Procedure|transbronchial lung biopsy|
79383542|NCT02772939|Device|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
80010490|NCT03689751|Other|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
80010491|NCT03689751|Other|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
80010492|NCT03689673|Other|Data collection|
80010493|NCT02178878|Genetic|Progress, Pain|Progress, Pain
80010494|NCT03689517|Other|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
79383543|NCT02282319|Drug|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
79383544|NCT02282319|Other|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
79383545|NCT02282319|Drug|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
79383546|NCT02281695|Other|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
79383547|NCT02278965|Drug|Metformin|Metformin 850mg, oral, twice a day for 12 months
79538249|NCT05958225|Behavioral|SEE Change Business and Personal Agency Training|"A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals."
79538250|NCT05957822|Drug|TXA|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
79840043|NCT05772975|Biological|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
79695389|NCT00545636|Other|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
79695390|NCT04646421|Behavioral|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
79695391|NCT04684667|Drug|Propranolol Therapy for Infantile Hemangioma|If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
79840044|NCT05772936|Behavioral|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
79840045|NCT05772923|Radiation|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
79840046|NCT05772923|Procedure|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
79244571|NCT06037759|Diagnostic Test|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
79244572|NCT06037759|Diagnostic Test|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
79305863|NCT04918251|Procedure|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
79383548|NCT02278965|Drug|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
79383549|NCT02514837|Device|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
79383550|NCT02276313|Device|Passeo-18 Lux|Endovascular Therapy
79383551|NCT01928446|Drug|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
79383552|NCT01928446|Drug|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
79383553|NCT02983149|Device|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
79383554|NCT02983149|Device|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
79383555|NCT02983149|Device|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
79538251|NCT05957822|Diagnostic Test|TEG6|performing thromboelastography (TEG6)
79538252|NCT05956171|Other|Intra-articular corticosteroid injection|5 ml blind intra-articular corticosteroid injection
79538253|NCT05956171|Other|Ultrasound Guided Hydrodilatation with corticosteroid injection|15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
79695392|NCT04637919|Biological|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
79840047|NCT05772884|Other|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
79840048|NCT05771571|Other|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
79840049|NCT05771571|Other|Control|Refined olive oil
79840050|NCT05771519|Behavioral|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
79840051|NCT05771467|Other|Optical Coherence Tomography Angiography (OCTA) • Biometry • Auto refractometry • Non contact tonometry|Ophthalmologic Examination Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
79840052|NCT05769894|Other|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
79840053|NCT05769296|Device|Headpulse measurements|Placement of headset on subject
80010495|NCT03689517|Device|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
80010496|NCT03685851|Procedure|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
79840054|NCT05768893|Device|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
79840055|NCT05768893|Device|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
79840056|NCT05767866|Drug|YK-029A|Daily dose of YK-029A
79840057|NCT05766995|Device|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
79840058|NCT05766995|Device|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
79840059|NCT05766995|Device|Waxed Dental Floss|Nylon string used to clean between the teeth manually
80010497|NCT02179034|Drug|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
80010498|NCT02179034|Other|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
79244573|NCT06037759|Diagnostic Test|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
79383556|NCT02983383|Procedure|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
79383557|NCT02983383|Procedure|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
79383558|NCT02987296|Dietary Supplement|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
79538254|NCT05954182|Behavioral|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
79538255|NCT05945602|Other|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
79695393|NCT04637919|Biological|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
79695394|NCT04637919|Biological|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
79695395|NCT04637919|Biological|Placebo|Placebo, three doses, 28 days interval
80010499|NCT02179034|Other|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
80010500|NCT03623997|Other|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
79695396|NCT00545675|Drug|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
80010501|NCT02174588|Drug|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
80010502|NCT02174588|Drug|propofol|propofol are used for sedation drug
80010503|NCT03693573|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
80010504|NCT03693573|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
80010505|NCT02176304|Drug|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
80010506|NCT02176304|Drug|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
79305864|NCT03055455|Diagnostic Test|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
79695397|NCT00545675|Drug|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
80010507|NCT02176460|Drug|Colchicine|0.5mg twice daily for 16 weeks
80010508|NCT02176460|Drug|Placebo|1 tablet twice daily
79695398|NCT00545831|Device|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
79695399|NCT00545831|Device|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
79538256|NCT05943626|Behavioral|Circadian Intervention|The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
79840060|NCT05761119|Other|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
79695400|NCT04637958|Device|THA|Total hip arthroplasty
79695401|NCT00545870|Drug|bevacizumab|intravitreal application
79840061|NCT05761106|Other|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
79840062|NCT05761106|Other|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
79840063|NCT05746130|Behavioral|Plastic-free nutrition program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
79840064|NCT05746130|Behavioral|Interactive education|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
79840065|NCT05746130|Behavioral|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
80010509|NCT03623919|Other|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
80010510|NCT02179112|Procedure|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
80010511|NCT03693495|Diagnostic Test|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
79244574|NCT06037746|Other|Graston|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 10 minutes in the longitudinal, vertical and oblique directions.
79383559|NCT02987296|Dietary Supplement|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
79538258|NCT05939674|Drug|Flumazenil|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.
79244575|NCT06037746|Other|Percussive massage|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 5 minutes in all directions without being bound to a single direction.
79383560|NCT02748369|Drug|Somatostatin|Somatostatin infusion to create a low insulin state.
79383561|NCT02748369|Drug|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
79383562|NCT01928524|Drug|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79383563|NCT01928524|Drug|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79695402|NCT00545870|Drug|Ranibizumab|intravitreal application
79695403|NCT04637451|Procedure|Root coverage treatment|Gingival unit graft Connective tissue graft
79695404|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
79695405|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
79695406|NCT04637568|Diagnostic Test|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
79695407|NCT04637412|Other|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
79840066|NCT05743335|Biological|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
79840067|NCT05743335|Biological|Active Comparator|Participants will be randomized in Phase 2 to either JCXH-221 or a FDA approved Active Comparator,
79840068|NCT05743335|Other|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
79840069|NCT05739513|Diagnostic Test|miRNA analysis in plasma|blood sample
79538259|NCT05939674|Drug|normal saline|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
80010512|NCT03693495|Diagnostic Test|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
80010513|NCT03693495|Diagnostic Test|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
79244578|NCT06036186|Device|BaroPacing treatment|BaroPacing for the first 3 weeks (day 8 to day 28) and then crossover to standard treatment for another 3 weeks (day 29 to day 49).
79244579|NCT06036186|Device|Standard treatment|Individual Standard treatment as prescribed by the Physician to each subject for the first 3 weeks (day 8 to day 28) and then crossover to BaroPacing for another 3 weeks (day 29 to day 49).
79244580|NCT06034600|Other|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
79538260|NCT05939427|Other|NGAGE tool|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
79538261|NCT05937308|Device|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
79244581|NCT06034600|Other|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
79695408|NCT05050292|Other|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
79305865|NCT04922541|Drug|PD-1 inhibitor|dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
79383564|NCT01928524|Drug|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79383565|NCT01928524|Drug|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79383566|NCT01928524|Drug|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79383567|NCT01928524|Drug|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79383568|NCT01928524|Drug|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
79695409|NCT05050292|Other|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
80010514|NCT02176538|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days
80010515|NCT02176538|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
80010516|NCT03623841|Other|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
80010517|NCT03623841|Other|Treadmill training|Participants in control group will do treadmill training only
80010518|NCT02256254|Drug|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
80010519|NCT02256254|Drug|Placebo|2 placebo capsules every evening for 14 days
80010520|NCT02256332|Dietary Supplement|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
80010521|NCT02256332|Dietary Supplement|High dose plant based ingredient|Reference food with high dose of plant based ingredient
80010522|NCT02256332|Dietary Supplement|Reference food format|Reference food without plant-based ingredient
79305866|NCT02157298|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
79383569|NCT05739760|Behavioral|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
79383570|NCT05739760|Behavioral|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
79383571|NCT01894191|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
79383572|NCT01894191|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
79383573|NCT01894191|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
80010523|NCT03689361|Combination Product|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion).
79538262|NCT05936047|Biological|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
79695410|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
79244582|NCT06032052|Drug|Single drug chemotherapy plus immunotherapy|The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
79840070|NCT05737147|Device|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
79840071|NCT05736796|Other|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
79840072|NCT05736796|Other|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
79840073|NCT05736471|Diagnostic Test|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
79840074|NCT05732298|Device|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
79840075|NCT05732051|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
79840076|NCT05732051|Dietary Supplement|Placebo|Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
79840077|NCT05731479|Other|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
79244583|NCT06028776|Behavioral|MS Ballroom Fitness|A personalized dance-based concept focusing on balance, walking capacity, and well-being.
79244584|NCT06026423|Other|Clinical examination and pictures|A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
79538263|NCT05935306|Drug|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
79538264|NCT05935306|Other|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
79244585|NCT06026423|Other|Questionnaire|The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
79244586|NCT06019806|Other|POSTURAL CORRECTION four exercises|"The program will involve four exercises, including two strengthening exercises and two stretching exercises.~Chin tuck (deep cervical flexor)~Strengthening shoulder retractors~Sternocleidomastoid muscle stretch~Pectoralis stretch Participants will be instructed to perform three sets of 12 repetitions for the strengthening exercises, with a 30-second rest period allotted between each set. For the stretching exercises, participants will be instructed to hold each stretch for 30 seconds, with a 30-second rest period allotted between each exercise The experimental group will also receive postural Correction education"
79244587|NCT06019806|Other|postural Correction education with a manuscript|The control group would receive postural Correction education and they would be provided with a manuscript. They would be then guided to follow these guidelines as a home plan for four weeks. At the end of the Fourth week, they would be assessed.
79538265|NCT05935306|Device|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
79538266|NCT05935306|Other|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
79695411|NCT04645914|Behavioral|Use of nicotine product (smoking/vaping)|The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
79840078|NCT05731479|Other|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
79840079|NCT05717088|Other|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight < 1500g, 1500-2500g, and > 2500g respectively."
79840080|NCT05715099|Drug|Saffron|Dietary Supplement: saffron supplement for IBD
79840081|NCT05715099|Drug|Placebo|Dietary Supplement: placebo for IBD
79305867|NCT02157298|Drug|Placebo tablet|Placebo tablet. Oral dose
79305868|NCT04904055|Other|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
79695412|NCT04684433|Other|Data extraction from medical files|Data extraction from medical files
79840082|NCT05713357|Procedure|Catheter ablation|Endocardial catheter ablation
79840083|NCT05708716|Behavioral|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
79840084|NCT05708716|Behavioral|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
79840085|NCT05707195|Other|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
79840086|NCT05687396|Device|virtual reality|virtual reality designed as cycling in the forest
79383574|NCT01928680|Drug|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
79383575|NCT02488785|Behavioral|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
79383576|NCT02488785|Device|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
79538267|NCT05934838|Drug|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
79538268|NCT05930678|Procedure|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
79538269|NCT05930678|Procedure|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
79538270|NCT05926219|Behavioral|Fatiguing Exercise|Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
79695413|NCT04646070|Procedure|Reduction mammaplasty|Breast reduction surgery
79695414|NCT00545987|Device|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
79695415|NCT00545987|Device|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
79695416|NCT00546026|Other|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
79695417|NCT00546065|Drug|esomeprazole treatment|concomitant esomeprazole treatment
79695418|NCT00558324|Procedure|LASIK|Mechanical microkeratome Hansatome 160 microns
79695419|NCT00558324|Procedure|LASIK|Mechanical microkeratome K 3000 130 microns
79695420|NCT00558324|Procedure|LASIK|Femtoseconds laser 100 microns
79695421|NCT00546143|Drug|Omalizumab|
79840087|NCT05687396|Other|conventional pulmonary rehabilitation|pulmonary rehabilitation
80010524|NCT03689361|Diagnostic Test|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion)
80010525|NCT03689361|Other|telephone consultation|telephone consultation
80010526|NCT02176616|Procedure|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
79244588|NCT06019780|Other|blood flow restriction trainin|"Following exercise will be performed~Side lying external rotation~Prone horizontal abduction~Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient [Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated."
79244589|NCT06019780|Other|exercise|"Following exercises will be performed without application of pneumatic cuff~Side lying external rotation~Prone horizontal abduction~Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)"
79383577|NCT02488785|Device|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
79383578|NCT01929460|Drug|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
79383579|NCT01929460|Other|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
79383580|NCT03029416|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
79695422|NCT00546143|Drug|Omalizumab|
79695423|NCT00546143|Drug|Omalizumab|
80010527|NCT02176616|Procedure|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
79383581|NCT01753193|Biological|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
80010528|NCT03689283|Other|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
79538271|NCT05921487|Behavioral|Time Restricted Eating|Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 12-hour TRE window for the first two weeks of the study, and then transition to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
80010529|NCT03689283|Other|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
79695424|NCT04645992|Device|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
79244590|NCT06017323|Drug|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
79695425|NCT04645992|Device|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
79695426|NCT00546221|Behavioral|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
79244591|NCT06017323|Drug|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
79244592|NCT06017323|Drug|Proglumide Dose level 1|Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
79383582|NCT02477163|Other|Ayurveda treatment|"Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
79383583|NCT02470377|Device|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
79695427|NCT00546221|Behavioral|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
79695428|NCT04646772|Procedure|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
79695429|NCT05037383|Other|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
79695430|NCT00560079|Drug|Allopurinol|Allopurinol 600mg/day bid for 28 days
79695431|NCT00560079|Drug|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
80010530|NCT02182076|Drug|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
80010531|NCT03693417|Device|Heated circuit on|Heated circuit will be turned on.
79244593|NCT06017323|Drug|Proglumide Dose level 2|Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
79383584|NCT02283814|Drug|BIA 2-093|
79383585|NCT02283814|Drug|Topamax|
79383586|NCT02737293|Other|Control Diet|4-week intake of Control Diet 5 day rotating menu
79383587|NCT02737293|Other|Med Diet|4-week intake of Med Diet 5 day rotating menu
79695432|NCT00560079|Drug|Placebo|Placebo
79695433|NCT04646265|Other|periodontal treatment|non-surgical root debridement
79695434|NCT00560118|Drug|fotemustine|
79244594|NCT06014788|Device|NPWTi|The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.
79244595|NCT06014788|Device|Conventional NPWT|Conventional NPWT
79244596|NCT06013592|Other|0 kcal liquid|Flavoured water
79695435|NCT00560118|Genetic|gene expression analysis|
79695436|NCT00560118|Genetic|polymerase chain reaction|
80010532|NCT03693417|Device|Heated circuit off|Heated circuit will be turned off.
80010533|NCT02179268|Drug|sertraline|50mg, 50-150mg/d,qd for one year
80010534|NCT02179268|Drug|citalopram|20mg, 20-40mg/d,qd,for one year
80010535|NCT02179268|Drug|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
80010536|NCT02179268|Drug|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
80010537|NCT02179268|Behavioral|control|50min, every week for three months, every month, for nine months
80010538|NCT02182154|Drug|BIBF 1120 ES|
80010539|NCT03693339|Drug|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
79840088|NCT05685771|Device|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
80010540|NCT02176694|Behavioral|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
80010541|NCT03689127|Device|Heated breathing circuit on|Heated breathing circuit will be turned on.
80010542|NCT03689127|Device|Heated breathing circuit off|Heated breathing circuit will be turned off.
79244597|NCT06013592|Dietary Supplement|600 kcal liquid meal|Fortisip Compact Vanilla
79244598|NCT06013592|Dietary Supplement|1200 kcal liquid meal|Fortisip Compact Vanilla
79244599|NCT06013592|Dietary Supplement|1800 kcal liquid meal|Fortisip Compact Vanilla
79244600|NCT06003985|Other|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
79244601|NCT06000501|Drug|Serdexmethylphenidate/dexmethylphenidate|Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
79244602|NCT05998031|Device|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
79244603|NCT05998031|Device|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
79244604|NCT05996874|Drug|Semaglutide|Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
79383588|NCT02737293|Other|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
79244605|NCT05994833|Behavioral|VPT|The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
79383589|NCT02231697|Other|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
79383590|NCT02466009|Drug|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
79383591|NCT05739604|Diagnostic Test|Blood sample analysis|The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
79383592|NCT05729152|Other|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
79383593|NCT02462421|Drug|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
79383594|NCT02727387|Drug|TEMIRI|Window therapy frontline for VHR patients
79383595|NCT02727387|Drug|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
79383596|NCT02727387|Drug|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
79383597|NCT02727387|Drug|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
79383598|NCT02727387|Drug|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
79383599|NCT02727387|Drug|BUMEL|Consolidation phase
79383600|NCT02727387|Drug|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
79538272|NCT05910736|Behavioral|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
79538273|NCT05910216|Other|Dance & Music (Online)|This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization
79695437|NCT00560157|Dietary Supplement|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
80010543|NCT02176772|Other|Stable iron isotopes, non-drug intervention|
80010544|NCT03538184|Procedure|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
80010545|NCT03538184|Procedure|Drill|Preparation of implant beds entirely with conventional implant drills
80010546|NCT02182232|Drug|BIBF 1120|
80010547|NCT02182232|Drug|Paclitaxel|
80010548|NCT02182232|Drug|Carboplatin|
80010549|NCT04356560|Diagnostic Test|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
80010550|NCT02179502|Drug|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
80010551|NCT02179502|Drug|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
80010552|NCT02179502|Drug|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
79244606|NCT05992701|Device|Directional deep brain stimualtion|Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
79244607|NCT05987371|Drug|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
79244608|NCT05987371|Drug|TQC3721 matching placebo for inhalation|Placebo without active substance.
79244609|NCT05987371|Drug|Salbutamol sulfate inhalation aerosol|Salbutamol is short-acting β2 receptor agonists.
79244610|NCT05981898|Device|OPTIVF dosage|Dosage predicted by Opt-IVf
79244611|NCT05981898|Device|traditional Dosage|Dosage used traditionally by doctors
79695438|NCT00546299|Drug|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
79244612|NCT05981833|Device|Repair with DAA (dermal allograft augmentation)|Patients undergo rotator cuff repair with dermal allograft augmentation.
79383601|NCT01727297|Device|REVEAL Implantable Cardiac Monitor|
79383602|NCT05583357|Biological|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
79538274|NCT05910216|Other|Multimodal Therapeutic Exercise & Music (Online)|This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
79538275|NCT05900466|Drug|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
79383603|NCT05583357|Biological|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
79538276|NCT05900466|Drug|Placebo|Matching tablets once daily in the morning for 8 weeks
79695439|NCT00558402|Behavioral|Meditation|meditation class 1/week for 8 weeks
79695440|NCT00558402|Behavioral|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
80010553|NCT02179502|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
80010554|NCT02182310|Drug|BI 201335 low dose|
80010555|NCT02182310|Drug|BI 201335 placebo|
79244613|NCT05972187|Other|Temperature and Humidity|Temperature and Humidity of room changed
79244614|NCT05968495|Device|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
79383604|NCT05583357|Biological|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
79383605|NCT05583357|Biological|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
79383606|NCT05726968|Drug|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
79383607|NCT04757025|Device|Electrical Impedance Tomography|In 27 patients ventilation will be guided with an Electrical Impedance Tomography system
79383608|NCT04757025|Device|Peripheral arterial Saturation|The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
79538277|NCT05895929|Drug|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
79695441|NCT00558402|Behavioral|Respite only|Respite care 90 mins per week for 8 weeks
79383609|NCT05583045|Other|Olive Leaf Tea|Olive leaf tea (individual tea bags provided to participants with instructions of preparation)
79383610|NCT05583045|Behavioral|Lifestyle behavior change program (LBC)|"Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)"
79695442|NCT00546494|Drug|Effexor® (Venlafaxine)|
79695443|NCT04637607|Other|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
79695444|NCT00546533|Drug|Etanercept|
79695445|NCT00558441|Device|IVMRI|Intra Vascular Magnetic Resonance Imaging
79695446|NCT00558480|Drug|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
79695447|NCT00558480|Drug|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
79695448|NCT04637100|Other|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
79695449|NCT04637100|Other|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
79695450|NCT00546611|Drug|PEP005|
79695451|NCT04637490|Device|patellar component|patellar resurfacing
79695452|NCT04645875|Other|Sit regimen|See Sit regimen arm description
80010556|NCT02182310|Drug|Moxifloxacin|
80010557|NCT02182310|Drug|BI 201335 high dose|
79840089|NCT05681637|Other|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
79840090|NCT05667922|Drug|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
79840091|NCT05667909|Drug|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
79244615|NCT05955911|Behavioral|Exercise|20 minutes of Moderate intensity (40%-59% heartrate reserve) walking on a treadmill.
79244616|NCT05955911|Behavioral|Coloring|20 minutes of coloring in adult coloring book
79538278|NCT05891626|Behavioral|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~missed opportunities and doubts/hesitancy about immunization as a whole;~specific questions with regard to specific vaccines;~health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
79538279|NCT05891483|Drug|SHR-1905 Injection|SHR-1905 Injection
79538280|NCT05891483|Drug|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
79538281|NCT05890833|Diagnostic Test|The risk of falls|Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
79538282|NCT05888519|Other|FID123300 ocular lubricant|Investigational ocular lubricant
79538283|NCT05888519|Other|FID123301 ocular lubricant|Investigational ocular lubricant
79695453|NCT04645875|Other|SitLess regimen|See SitLess regimen arm description
79840092|NCT05667896|Drug|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
79840093|NCT05667883|Drug|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
79840094|NCT05667805|Drug|Platelet Concentrate|Liberal use (standard treatment)
79244617|NCT05948787|Behavioral|Psychosocial intervention|A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
79840095|NCT05667805|Drug|Prothrombin Complex Concentrate|Liberal use (standard treatment)
79840096|NCT05667805|Other|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
79538284|NCT05888519|Other|FID122505 ocular lubricant|Comparator ocular lubricant
80010558|NCT02176850|Drug|Micardis®|
79244618|NCT05944887|Drug|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
79383611|NCT05583045|Other|Placebo tea|Placebo tea containing 2,6g cellulose and a caramel coloring
79383612|NCT01753115|Biological|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
79383613|NCT01753115|Drug|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
79538285|NCT05880004|Behavioral|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
79695454|NCT00546650|Drug|Sumatriptan succinate|NP101 iontophoretic transdermal system
79244619|NCT05944887|Drug|Saline administration as placebo|administration of a bolus of saline solution as a placebo
79244620|NCT05944887|Drug|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol
79244621|NCT05944887|Procedure|gastroscopy|esogastroduodenoscopy
79695455|NCT00546650|Drug|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
79695456|NCT04637373|Diagnostic Test|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
79695457|NCT00546767|Behavioral|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
79244622|NCT05943275|Device|Magnetic sensor|During the right heart catheterization procedure, measurement of hemodynamic pressures by the non-invasive experimental method (Magnetic sensor) and the invasive control method
79244623|NCT05937620|Diagnostic Test|99mTC nanocolloid albumin injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
79383614|NCT02445651|Dietary Supplement|Intravenous and Oral n-acetyl cysteine|
79695458|NCT00546767|Behavioral|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
79695459|NCT00546767|Behavioral|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
79695460|NCT00546767|Behavioral|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
79840097|NCT05660460|Diagnostic Test|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
79840098|NCT05657288|Other|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
79244624|NCT05937620|Diagnostic Test|ICG injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
79244625|NCT05914077|Drug|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
79383615|NCT05739370|Other|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
79840099|NCT05651542|Behavioral|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
79840100|NCT05651542|Other|Control|The control group will receive standard care.
79840101|NCT05644496|Drug|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
79840102|NCT05616780|Other|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
79244626|NCT05914077|Procedure|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
79244627|NCT05914077|Procedure|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
79538286|NCT05879159|Behavioral|Questionnaires|Survey
79244628|NCT05912504|Other|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
79244629|NCT05904834|Other|Flexibility training|Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
79538287|NCT05877612|Device|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
79538288|NCT05876533|Device|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
79695461|NCT04645758|Combination Product|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
79695462|NCT00546806|Other|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
79695463|NCT04637178|Behavioral|Resistance training|Resistance training sessions twice a week for ten weeks
79695464|NCT04637178|Behavioral|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
79244630|NCT05896761|Drug|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
79244631|NCT05896761|Drug|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
79695465|NCT00546845|Device|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
79695466|NCT00546845|Device|Use of self-expanding Expert stent|Nitinol stent
79695467|NCT00546923|Drug|Venlafaxine XR|
79695468|NCT00560196|Other|Observation|
79695469|NCT04645563|Other|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
79383616|NCT02986828|Drug|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
79383617|NCT02986828|Drug|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
79383618|NCT02986828|Device|Ultrasound|
79383619|NCT05724940|Other|clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients|"All patients will be subjected to the following:~Thorough medical history of the patients~Full clinical examination including:~General examination and vital signs.~Complete rheumatological examination.~SLE disease activity index SLEDAI (ref).~SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).~Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).~Renal investigations:~Kidney functions~Urine analysis~24 hours protein in urine and/or A/C ratio~Renal biopsy if indicated.~ANA (Antinuclear Antibodies)test.~ANA profile for the most common 19 autoantibodies by immunoblot."
79538289|NCT05875961|Biological|Low dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
79538290|NCT05875961|Biological|Intermediate dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
79840103|NCT05607498|Drug|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
79840104|NCT05603416|Dietary Supplement|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
79840105|NCT05603416|Dietary Supplement|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
79840106|NCT05594654|Other|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
79840107|NCT05573243|Other|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
79383620|NCT02204709|Other|2N Trout|Diploid/2N trout source
79383621|NCT02204709|Other|3N Trout|Triploid/3N trout source
79383622|NCT02204709|Other|Tilapia|Tilapia/control fish source
79383623|NCT01893957|Procedure|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
79383624|NCT01893957|Procedure|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
79383625|NCT01893957|Device|Neurodyn High Volt Model (IBRAMED)|
79538291|NCT05875961|Biological|High dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
79538292|NCT05875961|Biological|High dose A/H2N3c non-adjuvanted|Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
79695470|NCT04637217|Diagnostic Test|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
79695471|NCT04637061|Combination Product|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
79695472|NCT04637061|Diagnostic Test|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
79695473|NCT04637061|Diagnostic Test|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
79695474|NCT00558675|Biological|AlloStim|single intravenous infusion of 1 x 10^9 AlloStim cells
79695475|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7
79695476|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14
79695477|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21
79695478|NCT04637139|Drug|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi [14C]VBR.
79840108|NCT05554978|Drug|Landiolol|patient receives landiolol in addition to standard-of-care
79244632|NCT05892770|Drug|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
79840109|NCT05554978|Drug|Sodium Chloride (NaCl) 0.9%|Placebo
79840110|NCT05538273|Other|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
79840111|NCT05538273|Other|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
79244633|NCT05892770|Drug|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
79244634|NCT05860803|Device|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
79383626|NCT02284516|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
79383627|NCT02284516|Drug|Placebo|Placebo to match active treatment, BID for 84 days
79383628|NCT05581485|Procedure|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow(HFNO).
79840112|NCT05516212|Dietary Supplement|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
79383629|NCT05738980|Biological|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
79383630|NCT02721537|Dietary Supplement|Nicotinamide Riboside|Three capsules, twice per day for 84 days
79383631|NCT02721537|Other|Matching placebo|Three matching capsules, twice per day for 84 days
79383632|NCT04748614|Other|Cost|ICU cost
79383633|NCT02185209|Drug|Placebo|Place capsule to mimic antibiotics
79383634|NCT02185209|Drug|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
79383635|NCT02185209|Drug|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
79383636|NCT02185209|Drug|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
79695479|NCT00547001|Drug|Estradiol|1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
79695480|NCT05034107|Other|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
79840113|NCT05516212|Dietary Supplement|CAFMIPS_1 supplementation|"CAFMIPS_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
79840114|NCT05516212|Dietary Supplement|CAFMIPS_2 supplementation|"CAFMIPS_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
79840115|NCT05516212|Dietary Supplement|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
79840116|NCT05509959|Behavioral|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
79840117|NCT05509959|Behavioral|Control|Single group session and access to website
79383637|NCT02718105|Genetic|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
79383638|NCT01894035|Drug|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
79383639|NCT05457400|Drug|ENSO 16|30 g ENSO 16 dissolved in Water
79383640|NCT05457400|Drug|Glucose Powder|30 g Glucose Powder dissolved in Water
79383641|NCT01727141|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
79383642|NCT01727141|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
79383643|NCT01727141|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
79383644|NCT01727141|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
79383645|NCT05738668|Other|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
79383646|NCT02716311|Drug|Afatinib|
79383647|NCT02716311|Drug|Cetuximab|
79695481|NCT04645485|Biological|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
79695482|NCT05030792|Other|Attention-restorative therapy (ART)-based virtual reality (VR)|The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
79695483|NCT04636866|Other|NO intervention|NO intervention
79840118|NCT05508243|Other|Hyaluronic Nasal Spray|Health care product - nasal application
79840119|NCT05505019|Other|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
80010559|NCT02177006|Behavioral|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
79244635|NCT05860803|Behavioral|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
79383648|NCT05439694|Drug|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
79244636|NCT05854329|Behavioral|Virtual Reality Exposure|Virtual Reality device using the immersive dental game.
79244637|NCT05848063|Other|Global hip muscles strengthening exercises|Strengthening exercises will be given to all hip muscles
79244638|NCT05848063|Other|Hip abductors strengthening exercises|Strengthening exercises will be given to hip abductor muscles
79244639|NCT05842642|Other|Cervical|6 weeks of treatment
79244640|NCT05842642|Other|Oculomotor|6 weeks of treatment
79244641|NCT05842057|Biological|BioDFence G3 Placental Tissue Membrane|The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.
79383649|NCT05738590|Procedure|muscle biopsy|true cut needle biopsy
79383650|NCT03029182|Other|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
79383651|NCT03029182|Behavioral|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
79383652|NCT05738512|Procedure|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
79383653|NCT05738512|Procedure|Submucous Resection|Submucous Resection
79383654|NCT05430178|Other|Oral sugar tolerance test|Measurement of glucose and insulin for calculation of insulin sensitivity
79383655|NCT05430178|Other|De novo lipogenesis test|Oral consumption of deuterated water to measure incorporation of label into lipids
79383656|NCT05430178|Other|Gluconeogenesis test|Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
79383657|NCT04350034|Other|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
79383658|NCT04350034|Other|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
79538293|NCT05875961|Biological|Lowest dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
79695484|NCT05016674|Device|LipoLife system|Abdominal Laser-Assisted Liposuction
79383659|NCT02290444|Drug|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
79695485|NCT04645641|Device|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
79695486|NCT04636476|Procedure|Modified Nesbit's procedure and dorsal dartos flap|Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
79695487|NCT04645407|Drug|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
79695488|NCT00547040|Other|no intervention|no intervention
79695489|NCT04645056|Other|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
79695490|NCT04684316|Other|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
79695491|NCT04636788|Procedure|Venous sampling|venous sampling of 12ml
79840120|NCT05505019|Other|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
80010560|NCT02177084|Device|PTNS|
79538294|NCT05875961|Biological|Low dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
79538295|NCT05868408|Other|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
79538296|NCT05868408|Other|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
79538297|NCT05868408|Other|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
79695492|NCT00547235|Biological|therapeutic allogeneic lymphocytes|
79695493|NCT00547235|Procedure|allogeneic bone marrow transplantation|
79695494|NCT00547235|Radiation|total-body irradiation|
79695495|NCT04636749|Device|Erbium laser|Vaginal laser therapy
79840121|NCT05494346|Device|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
79840122|NCT05481931|Drug|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
79840123|NCT05476289|Other|No intervention|No intervention
79840124|NCT05466630|Diagnostic Test|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
79383660|NCT01726517|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
79383661|NCT01726517|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79383662|NCT05738356|Combination Product|Adhesive bonding systems|Three different adhesive bonding systems were used; one system per group
79840125|NCT05466630|Diagnostic Test|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
79840126|NCT05466630|Diagnostic Test|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
79383663|NCT01752023|Drug|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
79538298|NCT05860881|Drug|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
79538299|NCT05860881|Other|Placebo|Cream containing only the base, or vehicle.
79840127|NCT05466630|Diagnostic Test|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
79840128|NCT05462132|Drug|SYNB1353|SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
80010561|NCT02179580|Drug|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
80010562|NCT02179580|Drug|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
80010563|NCT02182388|Drug|Placebo|
80010564|NCT02182388|Drug|BI 207127 NA powder for solution|
79538300|NCT05858502|Biological|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
79538301|NCT05858502|Other|Saliva sample collection|Saliva sample collection between inclusion and 3 months
79538302|NCT05858502|Other|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
79538303|NCT05858502|Other|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
79538304|NCT05847244|Drug|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
79538305|NCT05830929|Procedure|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
79695496|NCT04636749|Device|Sham laser|Sham laser therapy
80010565|NCT02182388|Drug|BI 207127 NA tablet|
80010566|NCT03537326|Drug|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
79383664|NCT01752023|Drug|Cisplatin + Gemcitabine|Active Comparator
79383665|NCT02986906|Drug|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
79383666|NCT02986906|Drug|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
79383667|NCT02986906|Device|Ultrasound|The ultrasound was used for injection guidance
79383668|NCT01726049|Drug|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
79695497|NCT00547274|Drug|MK0767|
79695498|NCT00547352|Drug|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
79695499|NCT00547352|Drug|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
79695500|NCT04645095|Device|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
79695501|NCT04645095|Device|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
79695502|NCT00547391|Procedure|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
79695503|NCT00547391|Other|no intervention|No intervention (controls). Follow up started from the day of randomization.
79695504|NCT04636827|Biological|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
79695505|NCT04636827|Biological|sIPV|sIPV at the age of 18 month old
79695506|NCT04636827|Biological|DTaP|DTaP at the age of 18 month old
79244642|NCT05842057|Procedure|Robot-Assisted Radical Prostatectomy|Robot-assisted surgical removal of the prostate, administered standard of care.
79695507|NCT04636827|Biological|HepA|HepA at the age of 18 month old
79695508|NCT00547469|Drug|DDP733|
79695509|NCT04636515|Drug|F520|200mg，Q3W
79695510|NCT04636593|Drug|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
79695511|NCT02277275|Dietary Supplement|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
79695512|NCT02277275|Dietary Supplement|Placebo|Placebo will be provided to the other two arms for six months
79695513|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
79840129|NCT05458622|Biological|Blood sample|"- Total volume of blood (on each sampling occasion): 54,5mL.~Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
79695514|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
79840130|NCT05458622|Biological|Urine sample|- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
79840131|NCT05458622|Biological|Saliva sample|- Saliva: will be collect in special container for saliva microbiome and methylation;
79244643|NCT05838664|Drug|No OAC|AF Patient who were not exposed to oral anticoagulation
79840132|NCT05458622|Biological|Stood sample|- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
80010567|NCT02182466|Device|Colon capsule endoscopy|
80010568|NCT02182544|Drug|WAL801CL dry syrup|
80010569|NCT02182544|Drug|Ketotifen fumarate dry syrup|
79244644|NCT05838664|Drug|VKA|AF patients who received VKA
79244645|NCT05838664|Drug|apixaban|AF patients who received apixaban
79244646|NCT05838664|Drug|rivaroxaban|AF patients who received rivaroxaban
79538306|NCT05829005|Device|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
79244647|NCT05838664|Drug|dabigatran|AF patients who received dabigatran
79244648|NCT05836402|Dietary Supplement|Low carbohydrate diet intervention|"Patients will receive a study kit. The kit will contain the following:~Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)"
79695515|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
79695516|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
79695517|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
79695518|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
79695519|NCT00560274|Drug|Pegasys|As prescribed
79695520|NCT00560274|Drug|Ribavirin|As prescribed
79695521|NCT00560274|Drug|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
80010570|NCT02182544|Drug|Ketotifen fumarate dry syrup placebo|
80010571|NCT02182544|Drug|WAL 801 CL dry syrup placebo|
80010572|NCT03537248|Device|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
79383669|NCT01726049|Drug|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
79383670|NCT02162667|Drug|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
79383671|NCT01605617|Drug|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
79383672|NCT01605617|Drug|Placebo|PTNS + placebo for 12 weeks
79538307|NCT05824182|Device|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
79695522|NCT00547547|Dietary Supplement|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
80010573|NCT03537248|Device|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
79840133|NCT05458622|Procedure|Tissue sample|"- Tissue samples for organ-specific manifestations:~Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
79244649|NCT05834218|Other|split body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
79840134|NCT05450224|Behavioral|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
79840135|NCT05446051|Device|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
80010574|NCT02177240|Device|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
80010575|NCT02177240|Device|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
80010576|NCT02179658|Drug|OPT-80|oral
80010577|NCT02179658|Drug|vancomycin|oral
79244650|NCT05834218|Other|full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
79383673|NCT01605617|Procedure|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
79244651|NCT05834205|Other|Plyometric Training|"Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5&6"
79244652|NCT05834205|Other|Drills|Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
79244653|NCT05832008|Behavioral|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
79383674|NCT05651854|Other|pranayama breathing|Bhramari and sheetali pranayama breathing
79383675|NCT05403190|Device|da Vinci SP system|using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
79383676|NCT05402020|Drug|Tiotropium (Tio)|Tiotropium (Tio)
79383677|NCT05402020|Drug|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
79695523|NCT00547547|Drug|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
79695524|NCT00547547|Drug|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
79695525|NCT00547625|Drug|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
79695526|NCT00547625|Drug|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
79695527|NCT04645368|Drug|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
80010578|NCT02177318|Drug|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
80010579|NCT03693261|Procedure|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
80010580|NCT03693261|Procedure|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
80010581|NCT03685695|Other|Laboratory Biomarker Analysis|Correlative studies
80010582|NCT03685695|Device|Monitoring Device|Wear Fitbit Charge 2
79383678|NCT05402020|Drug|Olodaterol (Olo)|Olodaterol (Olo)
79383679|NCT05402020|Drug|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
79244654|NCT05832008|Behavioral|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
79695528|NCT00547664|Drug|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
79840136|NCT05446051|Device|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
79840137|NCT05441267|Drug|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
79840138|NCT05441267|Drug|Placebo oral tablet|Placebo oral semaglutide
79840139|NCT05438888|Drug|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
79244655|NCT05824416|Device|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
79244656|NCT05824416|Behavioral|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
79244657|NCT05810766|Other|mobilization with movement|MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
79244658|NCT05810766|Other|conventional physical therapy|Hot pack for 15 minutes
79244659|NCT05805904|Drug|BMS-986278|Specified dose on specified days.
79383680|NCT05402020|Device|Combined Inhaler|Combined Inhaler
79383681|NCT02284828|Drug|BIA 2-093|
80010583|NCT03685695|Other|Physical Activity|Complete aimed walking steps
79383682|NCT01751867|Drug|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
79383683|NCT01751867|Drug|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
79383684|NCT05637658|Other|Exercise|aerobic exercise
80010584|NCT03685695|Other|Quality-of-Life Assessment|Ancillary studies
79695529|NCT00547664|Other|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
79695530|NCT04644939|Other|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
79695531|NCT04644939|Other|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
79695532|NCT04644939|Other|Colonoscopy|Patients will undergo colonoscopy
79695533|NCT00547742|Procedure|PET/CT Scan|
79695534|NCT00547742|Procedure|phlebotomy|
79695535|NCT00560430|Drug|telmisartan|80 mg per day, orally, weeks 1-14
79695536|NCT00560430|Drug|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
80010585|NCT03685695|Other|Questionnaire Administration|Ancillary studies
80010586|NCT02177396|Drug|Telmisartan|
80010587|NCT02177396|Drug|Valsartan|
80010588|NCT02177396|Drug|Placebo|
79695537|NCT00560430|Drug|placebo|placebo; orally weeks 1-14
79244660|NCT05805904|Drug|Placebo|Specified dose on specified days
79244661|NCT05798923|Drug|LAM-001|LAM-001 administered via dry powder inhalation
79244662|NCT05794347|Other|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
79244663|NCT05772286|Biological|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
79244664|NCT05767177|Other|Glucemia following Mixed Meal Test|On day 12 of each diet, a venous catheter is placed in one arm for blood sampling and the research person must answer questions about any gastrointestinal complaints in connection with the current diet. At approximately 09:00, the research subject may eat a brunch for approximately 15 minutes (sandwich, juice, fried egg and sausage; 550-600kcal). Venous blood samples are taken before and 15, 30, 45, 60, 90 and 120 minutes after the meal.
79383685|NCT02418195|Drug|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
79383686|NCT05633914|Drug|Tucidinostat|20mg, po., biw, q3w
79383687|NCT05633914|Drug|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
79383688|NCT04756947|Procedure|surgical treatment according to standard indication criteria|internal fixation according to standard indication criteria
79383689|NCT04756947|Procedure|conservative treatment according to standard indication criteria|conservative therapy according to standard indication criteria
79695538|NCT00547781|Procedure|PGD|
79695539|NCT04644588|Diagnostic Test|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
79695540|NCT00547820|Other|placebo|
79695541|NCT00547820|Device|Urinary sensor|
79695542|NCT00560469|Other|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
79840140|NCT05438888|Drug|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
79840141|NCT05430074|Device|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
79840142|NCT05430074|Device|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
80010589|NCT02030054|Drug|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
79244665|NCT05767177|Other|Enteroscopy - mucosal ketogenic activity as well as glucose transport|On day 14 of each diet period, an enteroscopy is performed. This step is performed to obtain samples (biopsy) of the mucosa of the small intestine (duodenum and jejunum) and is performed at the Gastro-endoscopic departments SU-Sahlgrenska, or SU-Eastern hospital. Endoscopy is experienced by some individuals as unpleasant, which is why local anesthesia and sometimes sedation (midazolam + pethidine or rapifen) can be offered according to standard routine in the endoscopy department.
79244666|NCT05735379|Drug|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
79244667|NCT05731115|Biological|Experimental 23-valent Pneumococcal|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
79244668|NCT05709613|Device|Use of a chest compressions' feedback device|The participants will have access to a chest compressions' feedback device
79244669|NCT05708638|Other|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
79244670|NCT05708638|Other|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
79244671|NCT05695781|Drug|BRM421 Ophthalmic Solution|A topical drop of BRM421 ophthalmic solution.
79383690|NCT05383612|Procedure|Warm compresses|Commercial eye patch, 10 min before lid massage.Warm compresses and lid massage every 2 weeks，5 times in total（0，2, 4, 6, 8W）.
79695543|NCT00560547|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
79695544|NCT04644510|Device|Lung ultrasonography|Standardized eight-point Lung ultrasonography
79840143|NCT05424406|Behavioral|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
80010590|NCT02030054|Drug|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
80010591|NCT02182622|Drug|Docetaxel|
79244672|NCT05695781|Drug|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
79244673|NCT05680740|Drug|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
79244674|NCT05646771|Behavioral|Partner support|Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
79244675|NCT05639712|Drug|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
79383691|NCT05383612|Drug|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
79538308|NCT05820698|Other|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
80010592|NCT02182622|Drug|Prednisone|
80010593|NCT02182622|Drug|LDE225|
80010594|NCT02182700|Drug|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
79695545|NCT04636047|Other|The method of gene mutation detection|All samples were detected by NGS CGP panel.
79383692|NCT05382364|Drug|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
79383693|NCT02712801|Drug|Zidovudine|Dose will be adjusted according to the child's weight.
79383694|NCT02712801|Drug|Nevirapine|Dose will be adjusted according to the child's weight.
79383695|NCT02712801|Drug|Lamivudine|Dose will be adjusted according to the child's weight.
79383696|NCT02712801|Drug|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
79383697|NCT05381896|Other|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
79695546|NCT00547937|Device|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
79383698|NCT05381896|Other|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
79383699|NCT02712723|Drug|Letrozole|Nonsteroidal aromatase inhibitor
79695547|NCT04644900|Other|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
79695548|NCT04644900|Other|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
79695549|NCT00547976|Drug|[C-11]PBR28|
79695550|NCT00548015|Behavioral|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
79695551|NCT04636125|Drug|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
79695552|NCT04636242|Procedure|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
79695553|NCT04636242|Drug|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
79840144|NCT05424406|Behavioral|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
79840145|NCT05424406|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
79840146|NCT05424406|Behavioral|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
79840147|NCT05423327|Procedure|No Intervention|Single blood draw
80010595|NCT02182778|Drug|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
80010596|NCT02182778|Drug|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
79695554|NCT00548054|Biological|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
79695555|NCT00548054|Biological|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
79244676|NCT05639712|Drug|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
79244677|NCT05639712|Drug|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
79244678|NCT05639712|Drug|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
79695556|NCT04644432|Drug|Medication (A specification is listed under each arm)|Study drugs and dosages are listed in the description of arms.
79244679|NCT05639712|Drug|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
79244680|NCT05639712|Drug|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
79244681|NCT05639712|Drug|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
79244682|NCT05639712|Drug|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
79244683|NCT05639712|Drug|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
79244684|NCT05639712|Drug|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
79695557|NCT04644432|Other|Patient reported outcomes measurement|"PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish."
79695558|NCT00548288|Drug|pamidronate|
79840148|NCT05411731|Other|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
79840149|NCT05411731|Other|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
79840150|NCT05407480|Other|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
79840151|NCT05392504|Other|Core stability exercise|The core stability training consist of three phases
79840152|NCT05392504|Other|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
80010597|NCT03688971|Drug|Omiganan|Omiganan Topical Gel
80010598|NCT03688971|Drug|Ketoconazole|Ketoconazole Cream
80010599|NCT03688971|Drug|Placebo|Vehicle
80010600|NCT03536624|Behavioral|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
80010601|NCT03693027|Dietary Supplement|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
79383700|NCT02712723|Drug|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
79383701|NCT02712723|Drug|Placebo|Placebo for ribociclib
79383702|NCT02152683|Device|Renova|Low- Intensity Shockwave
79383703|NCT02149719|Other|Desensitisation using boiled peanut|
79383704|NCT02149719|Other|Desensitisation using boiled peanut (deferred start)|
79383705|NCT05736250|Diagnostic Test|biopsie|gingival biopsie
79840153|NCT05377541|Procedure|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
79840154|NCT05377112|Drug|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
79840155|NCT05377112|Other|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
79840156|NCT05354362|Combination Product|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
79840157|NCT05351736|Drug|Lurasidone|Treatment with lurasidone
79840158|NCT05343065|Device|BlueStar 10|An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
80010602|NCT03693027|Dietary Supplement|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
79244685|NCT05633784|Other|Teleassistance|Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
79244686|NCT05633784|Other|Teleconsultation|Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
79244687|NCT05633784|Other|Telerehabilitation|Support from a physiotherapist (if needed)
79244688|NCT05633784|Other|Telemonitoring|Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
79244689|NCT05633784|Other|mHealth|The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
79244690|NCT05633784|Other|telepsycology|Psychological support (if necessary)
79244691|NCT05633784|Other|Quality of life|Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
79244692|NCT05633784|Other|Biochemistry evaluation|Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
79244693|NCT05633784|Other|Clinical evaluation|6-minute-walking test, IMC, NYHA class, Ejection fraction
79244694|NCT05633784|Other|State of health of the patient|Severity Index and Comordbidity index
79383706|NCT01751165|Biological|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
79383707|NCT02145351|Device|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
79383708|NCT02145351|Device|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
79244695|NCT05619172|Drug|Nanrilkefusp alfa|Subcutaneous (SC) injection
79244696|NCT05619172|Drug|Cetuximab|Intravenous (IV) infusion via peripheral or central venous line
79244697|NCT05611242|Drug|IV-Antiplatelet Drugs|Within the stenting arm, there will be 2 different subgroups based on the antiplatelet treatment protocol per the site standard of care (oral antiplatelet or IV antiplatelet medication (e.g.,Cangrelor or others). Each arm will be assessed at the first interim analysis to consider dropping an arm if predetermined safety boundaries are exceeded.
79244698|NCT05611242|Procedure|MT+CAS with IV-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added intravenous antiplatelet therapy.
79244699|NCT05611242|Procedure|MT+CAS with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy.
79244700|NCT05611242|Procedure|MT+CAT with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy
79244701|NCT05611242|Drug|PO-Antiplatelet Drugs|Within the stenting arm, there will be 2 different subgroups based on the antiplatelet treatment protocol per the site standard of care (oral antiplatelet or IV antiplatelet medication (e.g.,Cangrelor or others). Each arm will be assessed at the first interim analysis to consider dropping an arm if predetermined safety boundaries are exceeded.
79244702|NCT05611242|Device|RX ACCULINK Carotid Stent System|Abbott Carotid Stenting System used within the MT+CAS ARM
79383709|NCT01751087|Other|Mifepristone|oral mifepristone 200 mg on Day 1.
79383710|NCT01751087|Drug|misoprostol|buccal misoprostol 400 mcg on Day 2
79383711|NCT01751087|Device|Osmotic dilators|osmotic dilators on Day 1
79383712|NCT01751087|Other|placebo|placebo for mifepristone, on day 1
79383713|NCT01751087|Other|placebo|placebo for misoprostol, on day 2
79840159|NCT05337098|Other|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
80010603|NCT02179814|Drug|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
80010604|NCT02179814|Drug|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
79695559|NCT04644354|Drug|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
79383714|NCT04566419|Device|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
79840160|NCT05335928|Drug|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
79840161|NCT05335928|Drug|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
79840162|NCT05310097|Behavioral|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
79840163|NCT05310097|Behavioral|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
79840164|NCT05286957|Drug|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
79840165|NCT05286957|Drug|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
79840166|NCT05286957|Drug|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
79840167|NCT05282108|Drug|Carcemia|Generic Imatinib
79840168|NCT05282108|Drug|Glivec|Imatinib
79840169|NCT05275751|Drug|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
79840170|NCT05275751|Drug|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
79840171|NCT05275751|Drug|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
79840172|NCT05275751|Drug|Placebo|No pharmacological intervention
79244703|NCT05611242|Procedure|Balloon Angioplasty|A medical procedure that is used to treat the narrowing and blocking of the the blood vessels.
79244704|NCT05611242|Device|EMBOGUARD Balloon Guide Catheter|The primary purpose of a balloon guide catheter is to temporarily block blood flow in the target vessel or artery during procedures like clot retrieval or the placement of embolic coils in the brain.
79840173|NCT05275751|Drug|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
79695560|NCT00548366|Other|Sodium restriction|4 gram sodium diet
79840174|NCT05268133|Dietary Supplement|Aronia|As described in experimental arm
79840175|NCT05268133|Dietary Supplement|Control|As described in placebo comparator arm
79383715|NCT04566419|Other|Oxygen|oxygen delivered by Venturi mask
79383716|NCT02706093|Other|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at ~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
79383717|NCT02706093|Other|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
79383718|NCT02706093|Other|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax [25min; ~150kcals; 4d/wk]
79383719|NCT02706093|Other|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax [15min; ~90kcals; 4d/wk]
79383720|NCT02393157|Drug|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
79383721|NCT02393157|Drug|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
79383722|NCT02393157|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
79383723|NCT02393157|Drug|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
79695561|NCT00548366|Other|Sodium restriction|2 gram sodium diet
79695562|NCT04644081|Behavioral|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
79840176|NCT05262725|Behavioral|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
79840177|NCT05255276|Drug|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
79840178|NCT05255276|Drug|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
80010605|NCT02179814|Drug|Placebo|Placebo at the second, third and fourth medication intake time point
80010606|NCT03688893|Device|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
79383724|NCT02393157|Drug|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
79695563|NCT04644081|Behavioral|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
79840179|NCT05255276|Drug|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
79840180|NCT05255276|Drug|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
80010607|NCT03688815|Diagnostic Test|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
79695564|NCT04644081|Drug|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
79695565|NCT00548444|Biological|MVA85A|Vaccine. Dose: 1 x 10^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
79244705|NCT05606601|Behavioral|Minder|"There are four main components of the Minder app: The Chatbot, Services, Community, and Peer Coaching components. The Services component asks participants to complete a series of questions on various mental health, substance use, and general life issues. It then recommends community and on-campus resources based on their current needs. The Community component of the app matches individuals with groups (e.g., student clubs) and events at the university or in the broader community that they may be interested in. The Chatbot component of the app contains pre-formatted conversational scripts that users engage with via a chatbot and videos designed to teach evidence-based skills (e.g., cognitive strategies to manage anxiety) that can be applied to everyday life. To support use of the app, all users in the intervention group will be offered access to trained peer coaches to help users navigate the different app components and provide non-clinical peer support."
79695566|NCT00548444|Other|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
79695567|NCT04636359|Behavioral|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
79244706|NCT05582694|Biological|UB-421|UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
79695568|NCT00548483|Drug|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
79383725|NCT01750697|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
79383726|NCT02127723|Device|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
79383727|NCT01750229|Device|Sham|Frequency Setting - Sham
79383728|NCT01750229|Device|1200 Hz|Frequency Setting - 1200 Hz
79695569|NCT04635813|Procedure|Thyroidectomy|Thyroidectomy
79695570|NCT04635852|Drug|Fentanyl|
79695571|NCT04635852|Drug|Immediate release morphine|
79840181|NCT05252858|Device|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
79840182|NCT05252858|Other|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
79840183|NCT05243199|Drug|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
79383729|NCT01750229|Device|3030 Hz|Frequency Setting - 3030 Hz
79383730|NCT01750229|Device|5882 Hz|Frequency Setting - 5882 Hz
79695572|NCT00548561|Drug|Dexrazoxane|
79695573|NCT00548600|Procedure|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
79695574|NCT00548600|Radiation|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
79695575|NCT04635618|Behavioral|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
79695576|NCT04635618|Behavioral|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
79695577|NCT04635618|Behavioral|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
79695578|NCT04684355|Other|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
79383731|NCT05586711|Drug|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
79695579|NCT00548639|Other|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
79695580|NCT00548639|Other|Control Pamphlet|ADA Diabetes Sheet
79695581|NCT04635696|Drug|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
79695582|NCT04635696|Other|Tissue culture grade water|Pressurized water mist
79695583|NCT04644120|Drug|ABBV-47D11|Intravenous (IV) infusion.
79695584|NCT04644120|Drug|Placebo for ABBV-47D11|Intravenous (IV) infusion.
79695585|NCT04644120|Drug|ABBV-2B04|Intervenous (IV) Infusion
79695586|NCT04644120|Drug|Placebo for ABBV-2B04|Intervenous (IV) Infusion
79695587|NCT00558909|Drug|BI 44847|
79695588|NCT00558909|Drug|placebo for BI 44847|
79695589|NCT04942145|Device|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
79695590|NCT04643964|Behavioral|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
79695591|NCT04643964|Behavioral|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
79695592|NCT04643964|Behavioral|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
79695593|NCT04643964|Behavioral|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
79695594|NCT00548678|Drug|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
79695595|NCT00548678|Drug|ketorolac|intravenous ketorolac
79695596|NCT00548678|Drug|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
79695597|NCT00548678|Drug|aspirin|oral aspirin
79695598|NCT00548834|Drug|CDP870|
79695599|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
79695600|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
79695601|NCT00548951|Other|Control|Receive no sessions in a Snoezelen Room.
79695602|NCT04635501|Device|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
79695603|NCT04684199|Dietary Supplement|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
79840184|NCT05243199|Drug|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
79840185|NCT05229211|Device|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
79840186|NCT05227716|Drug|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
79840187|NCT05218343|Behavioral|"EHR-based nudge interventions"|Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
79244707|NCT05575570|Device|EVAR|EVAR stent graft and embolization material CE marked.
79244708|NCT05569772|Drug|Semaglutide Pen Injector|maintenance dose of 1mg SC once weekly
79244709|NCT05569772|Drug|Semaglutide placebo|maintenance dose of 1mg SC once weekly
79383732|NCT05586711|Drug|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
79695604|NCT04684199|Dietary Supplement|Placebo|
79695605|NCT04635267|Other|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
79695606|NCT00548990|Behavioral|cardiovascular exercise training|
79695607|NCT00548990|Behavioral|flexibility/balance control|
79695608|NCT00560586|Drug|Budesonide|1 puff each nostril (32 micrograms) at bedtime
79695609|NCT00560586|Drug|placebo|1 puff each nostril at bedtime
79695610|NCT00549029|Genetic|DNA|withdraw 5~10mL blood from vein only once during the whole design
79695611|NCT00549068|Drug|Risedronate Sodium (Actonel)|
79840188|NCT05217433|Other|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
79244710|NCT05567783|Biological|VIR-2482 (dose 1)|VIR-2482 given by intramuscular injection
79244711|NCT05567783|Biological|VIR-2482 (dose 2)|VIR-2482 given by intramuscular injection
79244712|NCT05567783|Biological|Placebo|Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection
79244713|NCT05567094|Drug|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
79244714|NCT05567094|Drug|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
79244715|NCT05560243|Behavioral|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
79244716|NCT05555888|Drug|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
79383733|NCT03029260|Other|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
79383734|NCT03029260|Other|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
79383735|NCT01724489|Drug|Growth hormone|
79383736|NCT01724489|Drug|Placebo|
79383737|NCT01996293|Drug|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
79383738|NCT02986750|Device|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
79695612|NCT04644198|Biological|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 & 2.
79840189|NCT05217433|Other|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
79244717|NCT05555888|Drug|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
79244718|NCT05555888|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
79840190|NCT05195996|Drug|Propranolol|intravenous propranolol for case patients
79840191|NCT05195996|Drug|Saline|intravenous saline for placebo
79244719|NCT05555888|Radiation|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
79244720|NCT05554211|Drug|Tranexamic acid|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
79383739|NCT02986750|Device|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
79383740|NCT02986750|Device|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
79383741|NCT05304364|Combination Product|Combination Product: Naltrexone|Naltrexone Implant
79383742|NCT01992393|Behavioral|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
79538309|NCT05820698|Other|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
79695613|NCT04643730|Other|Acupressure methods|Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
79695614|NCT04643730|Other|Foot Reflexology Methods|Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
79695615|NCT04643730|Other|Control Grup|No pre-application was made to the babies in the control group as a routine procedure.
79695616|NCT00549107|Drug|Levosimendan|
79695617|NCT00549107|Drug|Milrinone|
79695618|NCT04635306|Diagnostic Test|Approved GEBT test meal|FDA-approve GEBT test meal
79695619|NCT00549146|Drug|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
79840192|NCT05195359|Behavioral|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
79840193|NCT05192876|Radiation|Radiotherapy|Outcomes and adverse events using radiation therapy
79840194|NCT05190939|Diagnostic Test|water as bladder distending media|water will be used for bladder dissension during cystoscopy
79840195|NCT05190939|Diagnostic Test|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
79840196|NCT05190939|Diagnostic Test|No intervention|Saline only, no dye
79840197|NCT05187858|Drug|LNP3794|LNP3794 capsules administered orally once daily
80010608|NCT02179970|Drug|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
80010609|NCT03538028|Biological|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
80010610|NCT03537950|Drug|PLC|Single oral dose of PLC.
80010611|NCT03537950|Drug|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
80010612|NCT03537950|Drug|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
79244721|NCT05554211|Drug|Normal saline|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
79244722|NCT05550584|Device|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).|In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
79244723|NCT05550584|Device|LMA|Mechanical ventilation performed by a laringeal mask
79244724|NCT05545111|Drug|NBI-1117568|Active treatment with orally administered NBI-1117568
79244725|NCT05545111|Drug|Placebo|Placebo matching NBI-1117568
79244726|NCT05529602|Other|conventional physical therapy|"core stability exercises~A total of 3 sessions per week were given for 15-20 minutes"
79244727|NCT05529602|Other|relaxation exercise|"the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes"
79244728|NCT05526950|Device|Device: CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
79383743|NCT01724177|Drug|Lenalidomide|25 mg of Lenalidomide administered orally once daily
79695620|NCT00549146|Drug|fluticasone propionate DISKUS 500mcg|
79840198|NCT05172752|Other|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
79840199|NCT05172752|Other|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
79840200|NCT05120089|Other|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
79840201|NCT05113966|Drug|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
79840202|NCT05113966|Drug|Sacituzumab Govitecan-hziy|10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
79840203|NCT05110326|Other|ERGON Technique|"Hot pack for 15 minutes.~Patient position: Prone with knee flexion approximately 45◦.~Position of therapist: Standing at the affected side of patient.~Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~Strengthening exercises for quadriceps and hamstring will then be performed.~Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~Wall sits: For 10 seconds, 5 sets."
79840204|NCT05110326|Other|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~The procedure will be repeated 3 times in every session.~Strengthening Exercises:~Same as ERGON Group"
79840205|NCT05109884|Diagnostic Test|PSMA PET Scan|[68Ga]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
79840206|NCT05109884|Diagnostic Test|FDHT PET Scan|[18F]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
79840207|NCT05101564|Drug|Alpelisib|Alpelisib 300 mg
79840208|NCT05101564|Drug|Tamoxifen|Tamoxifen 20 mg
79383744|NCT02117817|Drug|BKM120|
79383745|NCT02117817|Drug|Nabpaclitaxel|Given IV
79840209|NCT05101564|Drug|Zotatifin|Zotatifin 0.10mg/kg (by weight)
79383746|NCT05257798|Drug|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
79383747|NCT05257798|Other|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
79383748|NCT05693740|Procedure|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
79840210|NCT05101564|Drug|Fulvestrant|Fulvestrant 500 mg
79840211|NCT05061316|Dietary Supplement|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
80010613|NCT03685617|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
79383749|NCT05529784|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab 300mg in pre-filled injector Q2W
79695621|NCT04643496|Procedure|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
79695622|NCT00549185|Drug|SAR3419|Intravenous infusion
79695623|NCT04643847|Drug|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
79695624|NCT00549263|Drug|SB797620|
79695625|NCT00549341|Drug|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
79695626|NCT00549341|Other|Physiologic saline|Single injection.
79244729|NCT05522751|Device|DBS|Bilateral DBS electrodes will be implanted into the limbic pallidum of participants with severe alcohol use disorder and advanced but compensated liver disease.
79695627|NCT00549380|Device|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
79695628|NCT00549419|Drug|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
79695629|NCT00549419|Drug|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
79695630|NCT00549419|Drug|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
79695631|NCT04635540|Behavioral|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
79695632|NCT00549458|Behavioral|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
79695633|NCT00549458|Procedure|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
79695634|NCT04635150|Behavioral|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
79695635|NCT03456050|Behavioral|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
79244730|NCT05522296|Drug|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
79244731|NCT05511467|Behavioral|Visuomotor learning task|Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.
79538310|NCT05820698|Other|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
79244732|NCT05498402|Device|i-gel ® device|Ventilations will be delivered through an i-gel ® device
79244733|NCT05498402|Device|bag-valve-mask ventilation|Ventilations will be delivered using a bag-valve-mask
79244734|NCT05481333|Drug|REGN7999|Ascending IV or SC dose administered per protocol
79244735|NCT05481333|Drug|Placebo|Ascending IV or SC dose administered per protocol
79244736|NCT05475327|Other|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
79244737|NCT05475327|Other|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
79244738|NCT05474599|Other|conventional physical therapy|TENS
79244739|NCT05474599|Other|Dry cupping therapy|Experimental group was given Dry cupping therapy along with TENS.
79538311|NCT05818475|Other|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
79538312|NCT05818475|Other|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
79538313|NCT05817318|Device|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
79538314|NCT05816148|Other|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
79244740|NCT05463952|Drug|ARV-471|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
79695636|NCT03456050|Behavioral|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
79695637|NCT04643691|Drug|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
79695638|NCT03456011|Other|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
79695639|NCT03455972|Biological|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
79695640|NCT03455972|Drug|Immunomodulatory drugs|Maintenance therapy
79383753|NCT04415866|Behavioral|Paced Auditory Serial Addition task (PASAT)|Single and double digits are presented at intervals between 2 and 3 seconds and the participant must add each new digit to the one immediately prior to it. The participants will be asked to indicate by electronic button press whether the sum of the addition is 13 or not. The duration of the PASAT will be two 12-min tasks.
79538315|NCT05801913|Biological|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
79538316|NCT05801913|Procedure|Biospecimen Collection|Undergo blood sample collection
79538317|NCT05801913|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79538318|NCT05801913|Procedure|Computed Tomography|Undergo CT
79538319|NCT05801913|Procedure|Leukapheresis|Undergo leukapheresis per SOC
79538320|NCT05801913|Procedure|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
79538321|NCT05801913|Procedure|Magnetic Resonance Imaging|Undergo MRI
79695641|NCT03455933|Other|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
79695642|NCT03455933|Other|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
79840212|NCT05058963|Behavioral|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
79840213|NCT05036993|Behavioral|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
79840214|NCT05022290|Procedure|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
79840215|NCT05010525|Drug|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
79538322|NCT05801913|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
79538323|NCT05801913|Procedure|Positron Emission Tomography|Undergo PET
79538324|NCT05801913|Procedure|X-Ray Imaging|Undergo x-ray
79695643|NCT03455933|Other|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
79695644|NCT04634994|Drug|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo [F-18]SDM-8 PET Scanning to measure synaptic density.
79695645|NCT00549497|Drug|GW870086X|
79695646|NCT00549536|Dietary Supplement|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
79244743|NCT05442554|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion.
79383754|NCT04349488|Device|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
79538325|NCT05798481|Drug|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
79538326|NCT05791435|Device|PneuRIP|Measuring respiratory indices through Respiratory Inductance Plethysmography
79538327|NCT05791435|Other|biofeedback to assist with breathing|Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
79695647|NCT04643613|Dietary Supplement|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
79244744|NCT05439876|Drug|Melatonin|Melatonin 2 mg daily for 4 weeks
79244745|NCT05439876|Drug|Placebo|Placebo daily for 4 weeks
79244746|NCT05421910|Device|robotic training combined with electrical stimulation|Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
79695648|NCT00549575|Drug|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
79695649|NCT00549575|Drug|Placebo|After double blind randomization, patients received a placebo.
79383755|NCT02076867|Behavioral|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
79840216|NCT05005741|Drug|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
79244747|NCT05419518|Biological|EXTERNAL BEAM RADIATION|A minimum of three daily radiation therapy treatments are required in any given week. Any missed radiation treatments will be made up at the end of the treatment schedule, such that the total number of delivered 5 Gy fractions remains ten.
79244748|NCT05412394|Drug|Prednisolone|Liquid, 5mg/kg per week, for one year
79244749|NCT05408559|Drug|Sulforaphane|Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
79244750|NCT05408091|Drug|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
79695650|NCT00549614|Drug|acipimox|capsule, 250 mg, 4 times daily for 28 days
79695651|NCT00549614|Drug|placebo|capsule, 250 mg, 4 times daily for 28 days
79695652|NCT00558987|Behavioral|Discipline Video|"The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
79695653|NCT00558987|Behavioral|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
79695654|NCT00549653|Drug|GW856553|
79695655|NCT00560664|Procedure|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
79840217|NCT05005741|Drug|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
79840218|NCT05002829|Other|Restricted Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
79244756|NCT05385159|Drug|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
79244757|NCT05385159|Drug|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
79244758|NCT05380440|Behavioral|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
79244759|NCT05380440|Behavioral|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
79538328|NCT05791279|Other|Heart age|information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.
79538329|NCT05789303|Drug|Belantamab mafodotin|Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
79840219|NCT05002829|Other|Liberal Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
79244760|NCT05374278|Drug|[18F]RP-115 PET/MRI or PET/CT and MRI|An I.V. bolus injection of up to 10 millicurie (mCi) [18F]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
79538330|NCT05789303|Drug|Carfilzomib|"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"
79695656|NCT00560664|Procedure|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
79695657|NCT00549692|Drug|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
79840220|NCT04974216|Drug|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
79840221|NCT04974216|Drug|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
79244761|NCT05368064|Other|observational|collection of phenotype data
79244762|NCT05356481|Device|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
79840222|NCT04974216|Drug|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
79840223|NCT04972552|Dietary Supplement|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
79840224|NCT04972552|Other|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
79840225|NCT04972552|Other|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
79840226|NCT04972552|Other|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
79840227|NCT04955925|Diagnostic Test|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
79244763|NCT05347849|Drug|BPL-003|A single dose of BPL-003 will be administered intranasally
79244764|NCT05347849|Other|Placebo|A single dose of placebo will be administered intranasally
79244765|NCT05346406|Device|Long Peripheral Catheter|Bard Powerglide 8 cm midline catheter
79383756|NCT02076867|Behavioral|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
79383757|NCT04406740|Device|TwitchView EMG Unit|The TwitchView device is a new generation electromyographic monitor that uses a disposable electrode array that combines stimulating and recording electrodes.
79538331|NCT05789303|Drug|Pomalidomide|3 mg Day 1-21 of 28-day Cycle
79538332|NCT05789303|Drug|Dexamethasone|"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"
79538333|NCT05788484|Drug|CDX-585|CDX-585 is administered by infusion every 2 weeks
79538334|NCT05788328|Drug|Dabigatran etexilate (DE)|Dabigatran etexilate (DE) as oral capsule
79538335|NCT05788328|Drug|Rosuvastatin|Rosuvastatin as oral tablet
79538336|NCT05788328|Drug|PF-07081532|PF-07081532 as oral tablets
79538337|NCT05787249|Behavioral|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
79538338|NCT05787249|Behavioral|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
79695658|NCT00560742|Procedure|Control|Coronary artery bypass grafting without bone marrow cells injection
79695659|NCT00560742|Procedure|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
79695660|NCT00560742|Procedure|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
79695661|NCT00560781|Drug|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
79695662|NCT00559026|Biological|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
79538339|NCT05784311|Drug|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
79695663|NCT00559026|Other|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
79695664|NCT00549809|Procedure|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
79538340|NCT05784311|Drug|Metronidazole|500mg IV metronidazole thrice daily during five days.
79695665|NCT00549887|Drug|Analog or Human Insulin|prescribed in accordance with usual clinical practice
79244766|NCT05346406|Device|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
79244767|NCT05319639|Drug|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
79695666|NCT00549926|Drug|Fluvastatin|
79244768|NCT05319639|Drug|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
79244769|NCT05319639|Drug|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
79244770|NCT05319639|Drug|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
79244771|NCT05319639|Drug|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
79695667|NCT00549926|Drug|Pravastatin|
79695668|NCT00549926|Drug|Pitavastatin|
79695669|NCT00549926|Drug|Atorvastatin|
79695670|NCT04634448|Procedure|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
79840228|NCT04947865|Other|Peripheral nerve stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
79244772|NCT05319639|Drug|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
79244773|NCT05308511|Device|PC-I and COLON2|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
79244774|NCT05308511|Device|COLON2 and PC-I|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
79244775|NCT05305950|Other|Patient population|Questionnaire, standard of care
79244776|NCT05260684|Drug|Encorafenib|450 mg QD
79383758|NCT04406740|Device|Novel QTOF Device|The QTOF consists of an electrical stimulator that is just like the stimulator in the traditional TOF devices that are commonly used (both accelerometric and EMG-based), combined with a novel sensor that sticks to the belly of the muscle being measured (most commonly the adductor pollicis, the thumb muscle in the palm of the hand).
79383759|NCT01894659|Other|24% oral sucrose|
79244777|NCT05260684|Drug|Binimetinib|45 mg BID
79383760|NCT01894659|Other|30% oral glucose|
79538341|NCT05782673|Device|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
79538342|NCT05779852|Other|self-hypnosis and dressing|self-hypnosis during dressing
79695671|NCT04634448|Diagnostic Test|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
79695672|NCT00549965|Drug|Risedronate Sodium|
79695673|NCT04634487|Other|No intervention|No intervention
79695674|NCT00550004|Drug|RP101|190 mg oral tablet
79695675|NCT00550004|Drug|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
79695676|NCT04634721|Drug|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
79695677|NCT04643262|Procedure|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
79244778|NCT05260684|Drug|Vemurafenib|960 mg BID for 28 days/cycle
79244779|NCT05260684|Drug|Cobimetinib|60 mg QD for 21 days/cycle
79244780|NCT05260684|Drug|Dabrafenib|150 mg BID
79244781|NCT05260684|Drug|Trametinib|2 mg QD
79244782|NCT05233852|Other|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
79244783|NCT05228925|Other|Maternal vitamin D status|Maternal vitamin D status (serum 25-hydroxyvitamin D) was collected during the GraviD study, while the woman was pregnant with the child now being followed-up in the GraviD-child study
79383761|NCT04404712|Drug|[11C]MK-3168|One PET scan involving administration of PET ligand [11C]MK-3168
79383762|NCT04349800|Drug|KVD900|Active
79383763|NCT04349800|Drug|Placebo to KVD900|Placebo
79383764|NCT01962753|Drug|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
79383765|NCT01530009|Drug|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
79538343|NCT05779852|Other|dressing|dressing without self-hypnosis
79538344|NCT05779228|Behavioral|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
79538345|NCT05778851|Device|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
79695678|NCT04634565|Drug|PF-06651600|oral PF-06651600 tablet 200 mg once daily
79695679|NCT00550121|Drug|vitamin C|
79695680|NCT00550121|Drug|placebo|
79383766|NCT01530009|Other|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
79695681|NCT04643028|Other|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
79695682|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
79840229|NCT04947865|Device|Commercial knee brace|Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
79840230|NCT04934332|Procedure|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
79840231|NCT04934332|Procedure|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
79840232|NCT04934332|Procedure|Clinical examination|Weekly clinical examination from week-2 to week-5.
79840233|NCT04924699|Drug|MRG002|Administrated intravenously
79840234|NCT04924699|Drug|Trastuzumab Emtansine for Injection|Administrated intravenously
79538346|NCT05777824|Combination Product|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
79840235|NCT04909229|Device|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
79538347|NCT05777824|Radiation|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
79840236|NCT04909229|Device|Fitbit|Patients will receive a Fitbit and receive standard of care
79840237|NCT04909229|Behavioral|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
79840238|NCT04907539|Drug|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
79840239|NCT04907539|Biological|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
79383767|NCT04919590|Behavioral|This is Quitting|Text message-based intervention for quit vaping support.
79383768|NCT04919590|Other|Assessment only control|Assessment only
79538348|NCT05767086|Drug|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
79538349|NCT05767086|Drug|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
79538350|NCT05767086|Drug|Dydrogesterone|clinical pregnancy rates
79538351|NCT05766748|Drug|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
79538352|NCT05765890|Other|No treatment given|No treatment given
79538353|NCT05762250|Other|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
79695683|NCT04643028|Other|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
79840240|NCT04907539|Biological|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
79840241|NCT04907097|Dietary Supplement|Monomeric and oligomeric flavanols|Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
79840242|NCT04907097|Other|Placebo|Placebo capsuled will be used as a comparator.
79840243|NCT04894682|Biological|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
79840244|NCT04885205|Behavioral|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
79840245|NCT04884087|Behavioral|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
79840246|NCT04884087|Behavioral|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
79840247|NCT04884087|Behavioral|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
79840248|NCT04884087|Behavioral|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
79840249|NCT04864639|Other|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
79383769|NCT04919590|Other|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
79383770|NCT01895595|Behavioral|Guided Imagery|
79383771|NCT01895595|Behavioral|Digital Storytelling|
79383772|NCT01894737|Other|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
79383773|NCT01894737|Other|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
79840250|NCT04830397|Drug|QLS-101|Ophthalmic solution 1x daily
79695684|NCT00550160|Drug|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
79695685|NCT00550199|Drug|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
80010614|NCT03685617|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
80010615|NCT02182856|Drug|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
79244784|NCT05224206|Device|Theta burst stimulation|Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
79244785|NCT05224206|Device|Theta burst stimulation|Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
79383774|NCT04915144|Drug|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
79383775|NCT04871464|Drug|Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules|Oral
79383776|NCT04871464|Other|Placebo|Oral
79383777|NCT01724021|Drug|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
79538354|NCT05759286|Behavioral|Aromatherapy|Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
79538355|NCT05759286|Behavioral|Music|Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
79695686|NCT04643301|Drug|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
80010616|NCT02182856|Drug|Ipratropium 500 µg|
79244786|NCT05211440|Dietary Supplement|Placebo + Meal|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a placebo capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
79244787|NCT05211440|Dietary Supplement|BC-006 + Meal|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a BC-006 capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
79383778|NCT01724021|Drug|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
79383779|NCT01724021|Drug|Bendamustine|Standard chemotherapy
79383780|NCT01724021|Drug|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
79383781|NCT01724021|Drug|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
79383782|NCT01724021|Drug|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
79383783|NCT01724021|Drug|Rituximab|1400 mg SC, Day 1 Cycles 5-8
79538356|NCT05759286|Behavioral|Control|using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
79538357|NCT05756985|Procedure|Specimen Collection|Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
79538358|NCT05750745|Drug|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity & Gum toothpaste is containing 0.454% w/w SnF2.
79383784|NCT05197504|Drug|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
79383785|NCT02293096|Drug|metoprolol succinate|
79383786|NCT02293096|Genetic|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
79383787|NCT02293096|Procedure|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
79538359|NCT05750745|Drug|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
79538360|NCT05750745|Drug|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
79695687|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
79840251|NCT04830397|Drug|Timolol Maleate|Ophthalmic solution 1x daily
79840252|NCT04821960|Behavioral|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
79840253|NCT04821960|Behavioral|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
79840254|NCT04804891|Biological|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
79840255|NCT04802590|Drug|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
79695688|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
79840256|NCT04802590|Drug|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
79840257|NCT04802590|Drug|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
79695689|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
79695690|NCT00550355|Drug|Placebo|3 doses of Placebo administered over 12 weeks
79840258|NCT04802590|Drug|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
79244788|NCT05196646|Device|Respiratory Acoustic Sensors|Wireless sensor that contains a dual microphone and an inertial measurement unit (IMU) will capture the breathing sound and respiratory effect. Two wireless sensors will be used, with one placed on the suprasternal notch and the other placed on the right upper chest of the infant, in order to determine the sensor placement yielding the best respiratory signal. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller (ISP1807, Insight SIP) and stored on the same device for future analysis.
79244789|NCT05196646|Device|Nasal thermistor|The nasal temperature probe that detects changes in temperature between inhaled and exhaled gases allows for the surrogate measure of airflow. It will be placed in one naris and secured with tape at the upper lip or cheek. The nasal temperature signal will be acquired using the Power Lab analog-digital acquisition system and stored for later analysis.
79695691|NCT04634292|Behavioral|EEG|EEG + walking task + auditory task
79695692|NCT00550433|Device|Bazedoxifene/Conjugated Estrogens|
79840259|NCT04797260|Genetic|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
79383788|NCT04866082|Other|questionnaire|Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
79383789|NCT01723397|Drug|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
79383790|NCT01723397|Other|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
79383791|NCT01723397|Biological|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
79695693|NCT00559143|Other|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
79695694|NCT00550472|Dietary Supplement|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
79695695|NCT04634370|Biological|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
79695696|NCT00550511|Radiation|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
79695697|NCT04642989|Other|Sham Treatment|All movements of facial effleurage except applying pressure
79695698|NCT04642989|Other|Facial Effleurage|Facial massage to remove any lymphatic blockages
79695699|NCT04642989|Drug|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
79840260|NCT04780477|Dietary Supplement|Experimental: High Fiber Diet (HFD)|Experimental: High Fiber Diet (HFD) pre-portioned entrées for two meals/d in mos. 1-3, and one meal/d in mos. 4-6. Participants continue on their respective diets in mos. 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250g of legumes per day (~1 ½ cups cooked) in months 1-3 provided in two pre-portioned single serving entrées (i.e. ~125g each). A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.
79840261|NCT04780477|Dietary Supplement|Healthy American Diet|Healthy American Diet pre-portioned meal replacement entrées with legumes replaced by lean chicken/meat. A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.
79840262|NCT04776993|Drug|Methimazole|Methimazole for 72 weeks
79840263|NCT04776993|Procedure|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
79840264|NCT04771663|Other|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
79840265|NCT04766138|Device|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
79840266|NCT04753658|Drug|lorlatinib|Oral
79840267|NCT04752891|Other|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
79840268|NCT04752891|Other|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
80010617|NCT02182856|Drug|Salbutamol sulphate 3 mg|
80010618|NCT02182856|Drug|Salbutamol sulphate 6 mg|
79840269|NCT04741932|Other|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
79840270|NCT04679961|Device|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
79840271|NCT04671875|Drug|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
79244790|NCT05196646|Device|Respiratory Inductive Plethysmography|Two respiratory bands will be placed circumferentially around the infant's chest (at the level of nipple line) and around the abdomen (just above the level of the umbilicus) in order to measure chest and abdominal wall movements, respectively. These movements will be recorded using Respiratory Inductive Plethysmography (Respitrace QDC®, Viasys® Healthcare, USA). The Respitrace® signals will be acquired using the Power Lab data acquisition system and stored for later analysis.
79383792|NCT01723163|Behavioral|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
79538361|NCT05749887|Procedure|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~No parametrial involvement, extrafascial hysterectomy;~There is parametrial involvement, extensive hysterectomy(Q-MC);~Only bladder invasion, anterior pelvic exenteration;~Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~Invasion of bladder and rectum, total exenteration.~The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
79538362|NCT05746546|Drug|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
79383793|NCT01723163|Behavioral|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
79383794|NCT02293798|Device|silk surgical scaffold|surgical implant
79383795|NCT01722071|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
79383796|NCT01722071|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
79383797|NCT05171842|Behavioral|Observe the prognosis after stent implantation|Observe the prognosis of patients after undergoing specific operations. Specific surgery: Use femoral artery or brachial artery to implant naked stent (stent with diameter ≤7mm, stents with >7mm are not restricted) to restore the blood flow of the true lumen superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulant therapy should be performed for at least 1 day after surgery. Anticoagulant drugs are not restricted. After discharge from the hospital, the double antibody should be taken for 3 months, and the monoclonal antibody should be maintained for at least 1 year.
79538363|NCT05746273|Drug|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
79695700|NCT04634058|Drug|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
79538364|NCT05746273|Drug|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
79695701|NCT00550628|Genetic|DNA methylation analysis|
79695702|NCT00550628|Genetic|fluorescence in situ hybridization|
79695703|NCT00550628|Genetic|gene expression analysis|
79695704|NCT00550628|Genetic|polymerase chain reaction|
79695705|NCT00550628|Genetic|protein expression analysis|
79840272|NCT04669249|Behavioral|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
79840273|NCT04667702|Behavioral|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
79244791|NCT05196646|Device|Pneumotachometer|The pneumotachometer is a pressure-differential based flow sensor that is used to measure respiratory flow. It will be connected to a standard face mask that is gently applied to cover the infant's mouth and nose. The face mask will be similar to the masks used as part of standard of care in the NICU for infants who require continuous positive pressure, with or without ventilation. The flow measurements will be recorded using the Power Lab data acquisition system and stored for later analysis.
79538365|NCT05744700|Dietary Supplement|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
79244792|NCT05165394|Drug|Placebo|Tablets for oral administration
79695706|NCT00550628|Genetic|reverse transcriptase-polymerase chain reaction|
79695707|NCT00550628|Other|diagnostic laboratory biomarker analysis|
80010619|NCT03685383|Device|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
79695708|NCT00550628|Other|immunoenzyme technique|
79695709|NCT00550628|Other|immunohistochemistry staining method|
79695710|NCT00550628|Procedure|biopsy|
80010620|NCT03685383|Device|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
79538366|NCT05744700|Dietary Supplement|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
79695711|NCT00550628|Procedure|therapeutic conventional surgery|
79695712|NCT00550628|Radiation|fludeoxyglucose F 18|
79695713|NCT00560820|Drug|Deferasirox|30 mg/kg/day
79695714|NCT00550784|Biological|filgrastim|
79695715|NCT00550784|Drug|cisplatin|
79695716|NCT00550784|Drug|cyclophosphamide|
79695717|NCT00550784|Drug|melphalan|
79695718|NCT00550784|Drug|paclitaxel|
79695719|NCT00550784|Drug|topotecan hydrochloride|
79695720|NCT00550784|Genetic|TdT-mediated dUTP nick end labeling assay|
79695721|NCT00550784|Genetic|gene expression analysis|
79695722|NCT00550784|Other|immunohistochemistry staining method|
79695723|NCT00550784|Other|pharmacological study|
79695724|NCT00550784|Procedure|peripheral blood stem cell transplantation|
79695725|NCT04633941|Other|Standard Care|Standard Care
79695726|NCT00550823|Device|Cardiac CT 0BRILLIANT 64|Cardiac CT
79695727|NCT04633785|Other|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
80010621|NCT02182934|Drug|Ginsana|
80010622|NCT02182934|Drug|Placebo|
79244793|NCT05165394|Drug|NBI-1065846|Tablets for oral administration
79244794|NCT05163886|Drug|LAM-002A|LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
79244795|NCT05163886|Other|Placebo|Microcrystalline cellulose in Swedish orange, size 0 capsules.
79244796|NCT05144334|Drug|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
79244797|NCT05142722|Drug|Placebo|placebo tablet made to resemble active
79244798|NCT05142722|Drug|Obicetrapib|10mg obicetrapib tablet
79538367|NCT05742295|Drug|Vitamin K|Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
79538368|NCT05741216|Other|OTF Ocular Lubricant|Ocular lubricant in 1 of 3 test formulations
79538369|NCT05741216|Other|Ocular Lubricant|Commercially available ocular lubricant
79538370|NCT05740956|Drug|HS-10502|HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
79538371|NCT05738486|Drug|Donanemab|Administered IV
79538372|NCT05738486|Drug|Placebo|Administered IV
79695728|NCT00550901|Drug|cisplatin|
79695729|NCT00550901|Drug|dexrazoxane hydrochloride|
79695730|NCT00550901|Other|high performance liquid chromatography|
79695731|NCT00550901|Other|laboratory biomarker analysis|
79695732|NCT00550901|Other|mass spectrometry|
79695733|NCT00550901|Other|pharmacological study|
79695734|NCT04633746|Diagnostic Test|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
79695735|NCT04633629|Other|Lung ultrasound|We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
79695736|NCT04643223|Other|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
79695737|NCT04643223|Other|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
79695738|NCT00551018|Drug|Vicriviroc|one 30 mg tablet QD
79695739|NCT00551018|Drug|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
80010623|NCT03692949|Drug|LY3451838|One dose administered (IV)
80010624|NCT03692949|Drug|Placebo|Administered IV
80010625|NCT03692949|Drug|Placebo|Administered SC
80010626|NCT03692949|Drug|LY3451838|One dose administered SC
79695740|NCT00551057|Behavioral|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
79695741|NCT00551096|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
79695742|NCT00551096|Drug|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
79695743|NCT00551096|Drug|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
79840274|NCT04660162|Device|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
79840275|NCT04660162|Other|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
79840276|NCT04570553|Procedure|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
80010627|NCT02183012|Drug|Ibuprofen extrudate|
79840277|NCT04546516|Device|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
79244799|NCT05133531|Drug|Ravulizumab|Administered Intravenous (IV) per the protocol
79840278|NCT04546152|Device|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
79244800|NCT05133531|Drug|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
79695744|NCT04642872|Other|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
79695745|NCT04642872|Other|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
79695746|NCT04642872|Other|Conventional therapy|Following the usual therapy in the baby.
79840279|NCT04545944|Drug|Vonoprazan|20 mg tablets administered orally
79840280|NCT04545944|Drug|Midazolam|2 mg syrup administered orally
79840281|NCT04529928|Device|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
79840282|NCT04522804|Drug|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
80010628|NCT02183012|Drug|Ibuprofen lysinate|
79244801|NCT05133531|Drug|Cemdisiran|Administered SC per the protocol
79244802|NCT05133531|Drug|Eculizumab|Administered IV per the protocol
79538373|NCT05736939|Other|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both <4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
79695747|NCT04642872|Other|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
79244803|NCT05129904|Other|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
79244804|NCT05120388|Dietary Supplement|Extra Virgin Olive Oil Addition|Daily dietary addition of olive oil (three tablespoons)
79244805|NCT05115331|Radiation|Experimental Radiation Dose|16 Gy in 2 fractions
79383803|NCT04155580|Drug|ASTX660|Capsule for oral administration
79383804|NCT04155580|Drug|ASTX727|Tablet for oral administration
79383805|NCT01721759|Drug|Nivolumab|
80010629|NCT02183012|Drug|Ibuprofen|
80010630|NCT03688737|Other|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
80010631|NCT03688737|Other|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
79695748|NCT00551252|Drug|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
79538374|NCT05733364|Dietary Supplement|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
79538375|NCT05733364|Other|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
79538376|NCT05731765|Diagnostic Test|Machine Learning Model|Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
79695749|NCT04642716|Other|Saliva collection of patients and salivary free amino acids analysis|
79695750|NCT00551330|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily
79538377|NCT05728372|Drug|Copper Cu 64-DOTA-pembrolizumab|Given IV
79695751|NCT00551330|Drug|Placebo|One tablet of placebo once daily
79695752|NCT04642794|Other|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
79695753|NCT04892966|Diagnostic Test|TXI Light Imaging|Standard Colonoscopy using TXI imaging
79695754|NCT04892966|Diagnostic Test|WLI Imaging|Standard Colonoscopy using White Light Imaging
79695755|NCT04642521|Device|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
79840283|NCT04520763|Other|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
79383806|NCT01721369|Diagnostic Test|Transient Loss of Consciousness (T-LOC)|
79538378|NCT05728372|Procedure|Positron Emission Tomography|Undergo PET scan
79538379|NCT05728372|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79538380|NCT05727007|Diagnostic Test|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
79538381|NCT05727007|Diagnostic Test|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
79538382|NCT05717907|Device|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
79695756|NCT00551486|Procedure|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
79695757|NCT04642248|Other|Personalized Run Practice|A combination of drills, flexibility, and strength activities combined with a gait retraining program
79383807|NCT02298322|Device|CoolSculpting System|
79695758|NCT03455894|Device|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
79695759|NCT04642482|Dietary Supplement|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
79695760|NCT04642482|Drug|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
79695761|NCT03455777|Drug|AKCEA-ANGPTL3-LRX|Single open-label cohort
79695762|NCT03455738|Other|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a >10% decrease in mean arterial pressure (MAP).
79840284|NCT04520763|Other|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
79840285|NCT04503395|Device|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
79244806|NCT05115331|Radiation|Conventional Radiation Dose|8 Gy in a single fraction
79383808|NCT04776850|Drug|Bortezomib|Given IV
79383809|NCT04776850|Drug|Busulfan|Given IV
79383810|NCT04776850|Drug|Cyclophosphamide|Given IV
79383811|NCT04776850|Drug|Dexamethasone|Given IV
79383812|NCT04776850|Drug|Fludarabine Phosphate|Given IV
79383813|NCT04776850|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
79383814|NCT04776850|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
79383815|NCT04776850|Drug|Mycophenolate Mofetil|Given IV or PO
79383816|NCT04776850|Procedure|Plasmapheresis|Undergo plasmapheresis
79383817|NCT04776850|Biological|Rituximab|Given IV
79383818|NCT04776850|Drug|Tacrolimus|Given IV or PO
79383819|NCT04132648|Drug|Curcumin|Oral supplement one time at 2,000 mg
79383820|NCT04132648|Other|Placebo|Oral supplement one time at 2,000 mg
79383821|NCT02331940|Drug|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
79383822|NCT02331940|Device|Handihaler|Inhalation via the HandiHaler once daily
79538383|NCT05717179|Diagnostic Test|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
79538384|NCT05714020|Other|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
79695763|NCT04642209|Device|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS <4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
79695764|NCT01167374|Radiation|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
79695765|NCT01125761|Drug|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
79538385|NCT05714020|Other|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
79538386|NCT05702684|Other|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
79695766|NCT01125761|Drug|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
79695767|NCT04642326|Device|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
79695768|NCT04642092|Behavioral|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
79695769|NCT04642092|Behavioral|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
79695770|NCT04641780|Drug|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
79695771|NCT04641624|Other|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
79695772|NCT05431127|Device|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
79695773|NCT04641546|Procedure|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
79695774|NCT04641546|Procedure|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
79695775|NCT05427656|Radiation|[18F] TRACK|We propose to use the radiotracer [18F] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq [18F] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes ([18F] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for [18F] TRACK after a transmission scan.
79695776|NCT05427656|Device|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
79695777|NCT04641585|Diagnostic Test|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
79695778|NCT00559221|Drug|FLAG+IDA|Fludarabine, cytarabine, G-CSF
79840286|NCT04503395|Device|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
79538387|NCT05700045|Drug|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
79538388|NCT05699941|Device|Ectoin® Inhalation Solution|Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.
79538389|NCT05696834|Procedure|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
79538390|NCT05695261|Biological|Microbial Transplantation Therapy|Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
79695779|NCT05408312|Biological|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
79695780|NCT05408312|Biological|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
79840287|NCT04455724|Device|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
80010632|NCT02180048|Dietary Supplement|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
80010633|NCT02180048|Dietary Supplement|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
79538391|NCT05695261|Drug|Antibiotic|Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
79695781|NCT05408312|Biological|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
79695782|NCT05408312|Biological|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
79538392|NCT05695261|Other|Placebo (in place of MTT)|Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
79538393|NCT05695261|Other|Placebo (in place of antibiotics)|Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
79695783|NCT04641468|Procedure|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
79695784|NCT04683497|Other|Contrast-enhanced Intraoperative Ultrasound|Intraoperative ultrasound with the administration of a contrast agent I.V.
79695785|NCT00559260|Device|Passive monitoring with pulse-oximetry, NIBP and ECG|
79695786|NCT04641117|Other|Exercise|Walking and Power Training
79695787|NCT04641390|Other|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
79538394|NCT05695183|Device|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
79538395|NCT05684692|Drug|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
79695788|NCT04641390|Other|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
79695789|NCT00559299|Drug|GSK163090|
80010634|NCT02180048|Dietary Supplement|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
80010635|NCT03688659|Drug|Vancomycin and gentamycin|intravenous
79538396|NCT05684692|Drug|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
79538397|NCT05684692|Drug|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
79538398|NCT05684692|Drug|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
79538399|NCT05671146|Device|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
79695790|NCT05358080|Drug|Entelon Tab. 50mg|twice daily for 24months
79695791|NCT05358080|Drug|Placebo|twice daily for 24months
79695792|NCT00559338|Drug|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
79695793|NCT00559338|Drug|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
79840288|NCT04455724|Device|Standard sterile dressing|A standard, sterile island dressing
79840289|NCT04425434|Other|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
79840290|NCT04425421|Other|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
79840291|NCT04409925|Drug|rhDNase I|Inhaled nebulisations
80010636|NCT02180126|Other|Follow-up|Follow-up of of patients with borderline positive ANCA test results
80010637|NCT03683043|Drug|Long GnRH agonist protocol|"8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
79695794|NCT05352737|Diagnostic Test|methylmalonic acid testing|
79538400|NCT05671146|Other|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
79538401|NCT05671146|Other|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
79695795|NCT04641429|Behavioral|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
79695796|NCT04641429|Behavioral|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
79538402|NCT05669027|Device|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
79695797|NCT00559416|Drug|Cell Transfer|
79840292|NCT04394325|Behavioral|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
79840293|NCT04393285|Drug|Abemaciclib|Abemaciclib 150mg orally twice a day
79840294|NCT04393285|Drug|Letrozole|Letrozole 2.5mg orally once a day
79840295|NCT04391283|Drug|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
79244807|NCT05111899|Behavioral|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
79244808|NCT05102721|Drug|Avelumab and Pepinemab|IV Infusions every two weeks.
79244809|NCT05097573|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
79538403|NCT05669027|Device|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
79383823|NCT02331940|Device|Respimat|Inhalation via the Respimat once daily
79383824|NCT04095208|Drug|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [240 mg].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [80 mg]."
79383825|NCT04095208|Drug|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [240 mg]."
79383826|NCT02291302|Other|integrated pest management|integrated pest management and environmental strategy
79383827|NCT02291302|Other|air purifier|air purifiers
79538404|NCT05658146|Drug|Mavacamten Capsule 1|Specified dose on specified days
79538405|NCT05658146|Drug|Mavacamten Capsule 2|Specified dose on specified days
79538406|NCT05658146|Drug|Mavacamten Capsule 3|Specified dose on specified days
79538407|NCT05656248|Drug|CPX-351|Given Intraveneously (IV)
79538408|NCT05656248|Drug|MHA|Given Intrathecal (IT)
79695798|NCT04640883|Behavioral|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of ~50% in load compared to habitual training.
79695799|NCT04640883|Behavioral|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (>four hours per session), distance-matched to sprint group.
79840296|NCT04374799|Drug|Heparin|two doses of heparin
79244810|NCT05086471|Device|NaviCam SB|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
79244811|NCT05086471|Device|PillCam SB3|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
79840297|NCT04374799|Drug|Placebos|placebo
79840298|NCT04373382|Behavioral|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
79244812|NCT05048784|Drug|Sotorasib|Oral tablet
79383828|NCT02291302|Other|No intervention (control)|no integrated pest management and sham air purifier
79383829|NCT02292082|Drug|Bupivacaine|
79383830|NCT02292082|Drug|Morphine|
79383831|NCT02292082|Drug|Methylprednisolone|
79383832|NCT02292082|Drug|Cefazolin|
79383833|NCT02292082|Drug|Normal saline|
79383834|NCT02292082|Drug|Midazolam|
79383835|NCT02292082|Drug|Propofol|
79840299|NCT04373382|Behavioral|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
79538409|NCT05656248|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
79538410|NCT05654948|Other|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
79840300|NCT04367857|Other|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
79695800|NCT04640883|Behavioral|Recovery for 10 days (low training load)|Habitual low-intensity cycling (>0.5-2 hours per session)
79695801|NCT00553124|Drug|selenium|
79695802|NCT00553124|Drug|vitamin E|
79695803|NCT00553124|Procedure|biopsy|
79538411|NCT05646602|Drug|Collagenase Clostridium Histolyticum|Intralesional injection
79695804|NCT00553124|Procedure|chemoprevention|
79695805|NCT00553124|Procedure|cryopreservation|
79840301|NCT04367857|Behavioral|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
79840302|NCT04343586|Device|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
79840303|NCT04333238|Other|New progress note template|Residents assigned to document with new progress note template
79840304|NCT04333238|Other|Standard progress note template|Residents assigned to document with standard progress note template
79840305|NCT04298723|Device|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (WatchmanTM or Watchman FLXTM) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
79840306|NCT04288947|Other|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
79840307|NCT04288570|Procedure|suture anchor socket creation with punch|suture anchor socket creation with punch
79840308|NCT04288570|Procedure|suture anchor socket creation with drill|suture anchor socket creation with drill
79538412|NCT05646602|Device|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
79538413|NCT05646199|Drug|Metformin|Participants will receive metformin
79538414|NCT05646199|Drug|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
79538415|NCT05643690|Diagnostic Test|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
79695806|NCT00553124|Procedure|cytology specimen collection procedure|
79695807|NCT00553124|Procedure|diagnostic procedure|
79244813|NCT05038228|Drug|Apixaban|Anticoagulant
79244814|NCT05038228|Drug|Rivaroxaban|Anticoagulant
79244815|NCT05038228|Drug|Dabigatran|Anticoagulant
79383836|NCT02292082|Drug|Dexamethasone|
79383837|NCT02292082|Device|8 MHz. Chiba needle, 22 G / 4 inches|
79695808|NCT00553124|Procedure|gene expression analysis|
79695809|NCT00553124|Procedure|immunohistochemistry staining method|
79244816|NCT05038228|Drug|Vitamin K antagonist (VKA)|Anticoagulant
79244817|NCT05002569|Biological|Nivolumab|Specified dose on specified days
79244818|NCT05002569|Biological|Nivolumab + Relatlimab Fixed Dose Combination|Specified dose on specified days
79244819|NCT04985799|Device|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
79244820|NCT04985799|Device|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
79383838|NCT05072704|Drug|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
79383839|NCT05072704|Drug|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
79383840|NCT03951454|Behavioral|Conexiones|5 Conexiones telephone sessions
79383841|NCT03951454|Behavioral|Taking Time|1 Taking Time telephone session
79383842|NCT04349956|Drug|UBX0101 or placebo|This is an observational study. No intervention is administered.
79695810|NCT00553124|Procedure|laboratory biomarker analysis|
79695811|NCT00553124|Procedure|medical chart review|
79695812|NCT00553124|Procedure|mutation analysis|
79695813|NCT00553124|Procedure|polymerase chain reaction|
79695814|NCT00553124|Procedure|quality-of-life assessment|
79695815|NCT00553124|Procedure|questionnaire administration|
79695816|NCT00553124|Procedure|study of socioeconomic and demographic variables|
79695817|NCT04640649|Other|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
79695818|NCT05340335|Drug|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
79695819|NCT04640805|Dietary Supplement|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
79848973|NCT05724082|Other|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
79244821|NCT04979962|Device|EW10-EC02 (Endoscopy Support Program)|EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
79244822|NCT04970810|Behavioral|My Diabetes Goal|Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
79244823|NCT04970810|Behavioral|My Diabetes Goal + CommunityRx|"Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations."
79244824|NCT04950504|Drug|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of ~5 μg of PPE per mg of PLGA.
79244825|NCT04950504|Drug|Placebo|CNP-201 Placebo
79383843|NCT04648774|Procedure|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
79383844|NCT04648774|Procedure|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
79383845|NCT02980588|Device|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
79383846|NCT03208504|Device|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
79383847|NCT04349878|Diagnostic Test|gingival crevicular fluid evaluation|anaysis of interleukins in gingival crevicular fluid
79383848|NCT02299258|Device|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
79383849|NCT02299258|Device|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
79383850|NCT04607122|Drug|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
79383851|NCT04607122|Drug|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
79383853|NCT03057964|Device|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
79538416|NCT05641649|Drug|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
79538417|NCT05640115|Procedure|Ureteral Stent|A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
79538418|NCT05640115|Procedure|Percutaneous Nephrostomy Tube Placement|A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
79538419|NCT05639972|Drug|Conditioning, E7 TCR-T cells, and aldesleukin|Participants will receive induction E7 TCR-T cell therapy.
79538420|NCT05638776|Drug|REGEND001 Autologous Therapy Product|Transplantation of Autologous Therapy Product by
79538421|NCT05638776|Drug|Placebo|Transplantation of Placebo
79538422|NCT05632523|Other|Blood sample|Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
79695820|NCT04640805|Other|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
79695821|NCT04640844|Biological|blood sample|measuring the expression and function of lymphocyte A2A receptors.
79695822|NCT04640610|Other|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
79695823|NCT05327075|Other|questionnaire|it is in the form of questionnaire and scoring tool
79695824|NCT04640454|Procedure|nipple sparing mastectomy|The investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (DTI), transversus rectus abdominis myocutaneous (TRAM) flap, latissimus dorsi myocutaneous (LD) flap, or LD with implant.
79538423|NCT05632523|Other|urinary sample|Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
79840309|NCT04266275|Drug|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
79848974|NCT05720611|Behavioral|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
79244826|NCT04949854|Device|B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter|control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
79244827|NCT04949854|Device|B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter|Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
79244828|NCT04940221|Behavioral|Shared Decision Making|Telephone delivered non-persuasive shared decision-making for lung cancer screening.
79244829|NCT04933448|Other|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
79383854|NCT03057964|Device|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
79383855|NCT01721057|Drug|Placebo|Administered orally
79383856|NCT01721057|Drug|Baricitinib|Administered orally
79695825|NCT04640181|Drug|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
79695826|NCT04640181|Drug|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
79695827|NCT04640103|Other|No interventions|No interventions
79244830|NCT04919824|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
79244831|NCT04919824|Procedure|Endoscopic Mucosal Resection|Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
79383857|NCT01721057|Drug|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
79383858|NCT04570384|Drug|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
79383859|NCT04570384|Drug|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
79695828|NCT00559455|Drug|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
79695829|NCT00559455|Drug|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
79695830|NCT00559455|Drug|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
79695831|NCT00559494|Drug|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
79244832|NCT04900675|Other|Bright light intervention|Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.
79244833|NCT04900675|Other|Reddish placebo light|Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
79383860|NCT02928172|Device|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
79695832|NCT00559494|Drug|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
79383861|NCT02928172|Device|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
79538424|NCT05632211|Biological|AVT05|Pre filled syringes filled with AVT05
79538425|NCT05632211|Biological|Simponi|Pre filled syringes filled with Simponi
79538426|NCT05629091|Device|FibDex|Nanofibrillar cellulose wound dressing
79538427|NCT05629091|Device|Epicite hydro|Wound dressing
79538428|NCT05629091|Device|Epiprotect|Wound dressing
79695833|NCT00559494|Procedure|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
79695834|NCT00559494|Procedure|SCPP control|maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
79695835|NCT03455621|Procedure|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
79695836|NCT00559533|Drug|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
79244834|NCT04897542|Drug|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
80010638|NCT03683043|Procedure|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
80010639|NCT02180204|Drug|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
79244835|NCT04894123|Drug|Trifluridine/Tipiracil|"Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
79244836|NCT04894123|Drug|Oxaliplatin|Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
79244837|NCT04892953|Drug|Carboplatin|Given IV
79538429|NCT05625906|Other|Multi-media experiential training programme|"Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~Writing a reflective journal after the role play with standardised patients"
79538430|NCT05625438|Device|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
79538431|NCT05623449|Other|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
79840310|NCT04266275|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
79244838|NCT04892953|Biological|Durvalumab|Given IV
79244839|NCT04892953|Drug|Gemcitabine|Given IV
79848975|NCT05715047|Behavioral|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
79244840|NCT04892953|Procedure|Local Consolidation Therapy|Undergo LCT
79848976|NCT05715047|Behavioral|Usual Care|Standard transplant care.
79244841|NCT04892953|Drug|Nab-paclitaxel|Given IV
79244842|NCT04892953|Drug|Paclitaxel|Given IV
79538432|NCT05623449|Other|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
79538433|NCT05623449|Procedure|pain scale|Measurement of pain intensity
79383864|NCT02299570|Biological|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
79383865|NCT02299570|Other|Placebo|A suspension of saline and cryoprotectant
79383866|NCT02301364|Drug|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
79383867|NCT04507828|Radiation|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
79538434|NCT05623449|Procedure|hypnosis consultation|5 hypnosis consultation
79383868|NCT02637778|Dietary Supplement|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
79244843|NCT04892953|Drug|Pemetrexed|Given IV
79244844|NCT04892953|Other|Quality-of-Life Assessment|Complete questionnaire
79244845|NCT04892953|Other|Questionnaire Administration|Complete questionnaire
79244846|NCT04885322|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
79244847|NCT04884282|Drug|Tedopi|TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)
79244848|NCT04884282|Drug|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
79244849|NCT04884282|Drug|Docetaxel|Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
79244850|NCT04876781|Drug|Tofacitinib XR|Tofacitinib XR 11mg
79848977|NCT05709470|Other|No-intervention|Observational cross-sectional study design with no intervention
79840311|NCT04245449|Behavioral|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required ~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
79840312|NCT04210700|Procedure|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
79538435|NCT05623449|Procedure|Maintenance|Qualitative assessment
79244851|NCT04865276|Behavioral|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
79383869|NCT02637778|Dietary Supplement|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
79538436|NCT05623449|Other|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
79538437|NCT05609825|Drug|LY3875383|Administered SC.
79383870|NCT03664726|Behavioral|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
79538438|NCT05609825|Drug|Placebo|Administered SC.
79538439|NCT05606757|Drug|BOTOX Dose A|Injection; intramuscular
79538440|NCT05606757|Drug|Placebo for BOTOX|Placebo
79538441|NCT05606757|Drug|BOTOX Dose B|Injection; intramuscular
79538442|NCT05606757|Drug|BOTOX Dose C|Injection; intramuscular
79538443|NCT05605470|Biological|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
79538444|NCT05605470|Biological|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
79695837|NCT05286632|Device|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
79695838|NCT00559572|Behavioral|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
79695839|NCT00559572|Other|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
79695840|NCT00559611|Procedure|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
80010640|NCT02180204|Drug|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
80010641|NCT03685227|Other|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
79383871|NCT03664726|Behavioral|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
79695841|NCT00559611|Procedure|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
79695842|NCT05208086|Diagnostic Test|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
79383872|NCT03664726|Behavioral|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
79383873|NCT03664726|Behavioral|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
79538445|NCT05605470|Biological|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
79538446|NCT05589038|Other|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
79538447|NCT05589038|Other|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
79538448|NCT05586308|Behavioral|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
79695843|NCT03454698|Other|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
79695844|NCT05186675|Procedure|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
79695845|NCT04639908|Other|Interview|interview with patient
79695846|NCT04639791|Other|No intervention|Observation only, no intervention
79695847|NCT04639557|Behavioral|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
79695848|NCT05165693|Other|Experimental Formula|Diabetes-specific study formula
79695849|NCT05165693|Other|Test Meal|Instant oatmeal
79695850|NCT04639362|Drug|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
79695851|NCT04639362|Drug|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
80010642|NCT02183090|Drug|Meloxicam ampoule|
80010643|NCT02183090|Drug|Meloxicam tablet|
80010644|NCT03685071|Other|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~correlation between the outcome and CBC will be done."
80010645|NCT02752802|Device|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
80010646|NCT04077099|Drug|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
80010647|NCT02180282|Device|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
79305487|NCT04937205|Behavioral|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
79383874|NCT03648112|Dietary Supplement|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
79383875|NCT03648112|Dietary Supplement|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
79538449|NCT05586308|Behavioral|Financial incentive|"Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
80010648|NCT02177474|Behavioral|Telephone based peer support|
79383876|NCT03648112|Dietary Supplement|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
79383877|NCT03648112|Dietary Supplement|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
79383878|NCT03648112|Dietary Supplement|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
80010649|NCT02180360|Other|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
80010650|NCT02177552|Drug|Carboplatin|
80010651|NCT02177552|Drug|Docetaxel|
80010652|NCT02177552|Drug|Capecitabine|
80010653|NCT02177552|Drug|Epirubicin|
80010654|NCT02177552|Drug|Oxaliplatin|
80010655|NCT03682653|Drug|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
80010656|NCT03682653|Drug|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
79538450|NCT05586308|Behavioral|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
79840313|NCT04210700|Procedure|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
79244852|NCT04863729|Behavioral|Asdzaan Be'eena Program|"The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).~Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers' home or another private place of their choosing, such as our local Johns Hopkins offices."
79383879|NCT02563522|Genetic|Engensis (VM202)|gene therapy
79383880|NCT02563522|Drug|Placebo|Standard of care plus placebo
79383881|NCT03578146|Combination Product|PRT064445/Rivaroxaban|
79840314|NCT04194359|Drug|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
79840315|NCT04066907|Other|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
79244853|NCT04856904|Drug|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
79383882|NCT03578146|Combination Product|Placebo/Rivaroxaban|
79383883|NCT03578146|Drug|Placebo|
79383884|NCT02464332|Drug|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
79383885|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
79383886|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
79695852|NCT04683536|Procedure|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
80010657|NCT04548128|Device|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
80010658|NCT03684993|Drug|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
80010659|NCT03684993|Drug|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
79244854|NCT04856904|Drug|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
79383887|NCT01895673|Other|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
79538451|NCT05585411|Procedure|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~RBBB configuration observed during unipolar tip pacing~One of the following should be met:~Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 [LV activation time]) of >10ms during increasing output~Short and constant stim-LVAT and the shortest stim-LVAT <75ms in non-LBBB and <85ms in LBBB~Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~LBB potential (LBB-V interval of 15 to 35ms)~Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
79244855|NCT04849845|Combination Product|Afrezza Dose 1|The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
79244856|NCT04849845|Combination Product|Afrezza Dose 2|The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
79538452|NCT05585411|Procedure|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
79538453|NCT05580289|Other|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
79538454|NCT05575531|Other|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
79840316|NCT04053491|Procedure|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
80010660|NCT03684993|Drug|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
79383888|NCT02716896|Radiation|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
79383889|NCT02716896|Procedure|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
79695853|NCT04639401|Other|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
79383890|NCT02986360|Behavioral|Vidscrip educational video|Vidscrip educational video provide to women
79383891|NCT02465346|Device|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
79383892|NCT02465346|Device|Control stroke management|Conventional stroke management
79695854|NCT04683419|Device|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
79840317|NCT04041232|Drug|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
79383893|NCT03510988|Diagnostic Test|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
79538455|NCT05570422|Drug|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
80010661|NCT03684915|Device|Rotary files|using rotary files in cleaning root canals of infected primary molars
80010662|NCT02177630|Other|Endomyocardial Biopsy|
79538456|NCT05570422|Radiation|External Beam Radiation Therapy|"Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~Intensity-modulated radiotherapy (IMRT) must be used.~IMRT should be given once daily Monday-Friday, 5 fractions per week."
79538457|NCT05570422|Drug|cisplatin|"Weekly concomitant cisplatin (40 mg/m2) during EBRT~Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
79305488|NCT03244085|Drug|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
79538458|NCT05570422|Radiation|brachytherapy|"BT treatment planning will be based on 3D-image-guided BT by MRI.~Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
79538459|NCT05569148|Combination Product|Faricimab PFS Configuration|Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
79538460|NCT05565092|Drug|ALXN1820|ALXN1820 will be administered subcutaneously.
79538461|NCT05560802|Other|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
79538462|NCT05558124|Drug|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
79538463|NCT05558124|Drug|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
79695855|NCT04639284|Drug|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
79695856|NCT05103800|Behavioral|invasive interventions|listening the white noise during the invasive interventions
79695857|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
79695858|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
79244857|NCT04827615|Behavioral|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability & affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care & medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community & service provider~Community level: Screening of hypertension & diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization & active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
79695859|NCT05089214|Device|Intra oral cameras|Diagnostic comparison of two intra oral cameras
79244858|NCT04805788|Radiation|Proton Stereotactic Body Radiation Therapy|Undergo SBPT
79244859|NCT04805788|Other|Quality-of-Life Assessment|Ancillary studies
79538464|NCT05557513|Device|STANDARD Q COVID-19 Ag Test|"Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)"
79538465|NCT05549765|Procedure|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
79244860|NCT04803877|Drug|Regorafenib 40 MG|For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
79538466|NCT05549765|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
79538467|NCT05548647|Behavioral|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh < 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
79538468|NCT05548647|Drug|Placebo|An inactive saline solution administered via subcutaneous injection
79538469|NCT05548647|Drug|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
79538470|NCT05548114|Procedure|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
79538471|NCT05548114|Procedure|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic (preferred) or open technique, as clinically appropriate.
79538472|NCT05547698|Procedure|Off-pump lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.
79695860|NCT04639440|Other|Adipose tissue|Adipose tissue sampling
79695861|NCT04629027|Drug|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
79695862|NCT00561249|Procedure|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
79695863|NCT05076656|Dietary Supplement|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
79695864|NCT05076656|Biological|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
79695865|NCT05076656|Drug|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
79695866|NCT00561288|Drug|acetaminophen|2 x 1000 mg doses per day
79695867|NCT00561288|Other|cornstarch|2 x 1000 mg cornstarch per day
79695868|NCT00561327|Drug|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
79695869|NCT05060939|Diagnostic Test|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
79695870|NCT00561366|Drug|Placebo|Placebo t.i.d.
79695871|NCT00561366|Drug|Arimoclomol|capsule, 400 mg t.i.d.
79244861|NCT04803877|Drug|Regorafenib 20MG|For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
79538473|NCT05547698|Procedure|Venoarterial ECMO lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
79538474|NCT05540418|Other|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
79538475|NCT05536492|Procedure|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
79695872|NCT00561405|Behavioral|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
79383894|NCT02462226|Behavioral|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
79695873|NCT00561405|Behavioral|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
79695874|NCT00561444|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
79840318|NCT04038541|Dietary Supplement|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
79840319|NCT04038541|Dietary Supplement|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
79383895|NCT02462226|Behavioral|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
79383896|NCT02465502|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
79538476|NCT05536492|Procedure|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
80010663|NCT04059315|Other|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
80010664|NCT04062279|Diagnostic Test|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
79538477|NCT05535049|Procedure|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
79695875|NCT05043974|Other|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
79695876|NCT05041088|Dietary Supplement|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
80010665|NCT03623685|Diagnostic Test|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
80010666|NCT02756078|Device|TEST Contact Lens|
80010667|NCT02756078|Device|CONTROL Contact Lens|
80010668|NCT02030132|Behavioral|Feedback compared to 75th percentile|
80010669|NCT02030132|Behavioral|Forgiveness|
79244862|NCT04803877|Drug|Nivolumab|"For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle."
79840320|NCT04037501|Other|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
79840321|NCT04030000|Drug|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
79244863|NCT04796246|Other|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
79244864|NCT04796246|Other|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
79244865|NCT04793750|Diagnostic Test|Cepheid GeneXpert HIV-1 Qual POC HIV VL test|POC Nucleic acid-based test for HIV RNA.
79244866|NCT04793750|Diagnostic Test|DPP HIV-Syphilis test system|POC Tests for antibodies to HIV 1/2 and Treponema pallidum.
79383897|NCT01516593|Drug|Induction Phase|"dd -2 to 1: Methylprednisolone~dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~dd 2, Rituximab~dd 7, Methotrexate~dd 14, Rituximab~dd 15, Etoposide~dd 21, Methotrexate~dd 29, Rituximab and Doxorubicin~dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~pts in CR: consolidation phase followed by bulky site irradiation~pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
79538478|NCT05534412|Other|Academic Detailing|"Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails."
79695877|NCT00561522|Drug|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
79695878|NCT00561522|Other|No other preventive treatment|No other preventive treatment
79695879|NCT05009264|Procedure|OMT|OMT will be performed on identified areas of trapezius trigger points
79840322|NCT04030000|Radiation|Pelvic radiation therapy|EBRT and vaginal brachytherapy
79840324|NCT03983161|Drug|Fedratinib|Fedratinib
79244867|NCT04793750|Diagnostic Test|OraQuick|POC oral fluid swab test for HIV 1/2 antibodies.
79244868|NCT04774744|Other|Educational Intervention|Receive digital health coaching program
79244869|NCT04774744|Other|Questionnaire Administration|Ancillary studies
79244870|NCT04774744|Other|Supportive Care|Receive standard of care support services
79244871|NCT04761549|Procedure|Adolescent Idiopathic Scoliosis|Adolescent Idiopathic Scoliosis
79383898|NCT01516593|Drug|Consolidation Phase (on day +50)|"dd 1-2: cytarabine twice a day~dd 3 and 11: rituximab~dd 11-13: leukapheresis for PBPC collection."
79695880|NCT03454659|Procedure|Craniotomy|Extracting the part of the sculpt
79695881|NCT03454620|Drug|irinotecan|GC1118 combination with irinotecan
79695882|NCT03454620|Drug|FOLFIRI|GC1118 combination with FOLFIRI
79695883|NCT04628559|Drug|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
79840325|NCT03965676|Other|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia < 360μmol/L (baseline DECT is in the domain of usual care).
79840326|NCT03957590|Drug|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
79840327|NCT03957590|Drug|Placebo|Placebo to match tislelizumab
79840328|NCT03957590|Drug|Paclitaxel|Administered as 135 mg/m² IV injection
79840329|NCT03957590|Drug|Cisplatin|Administered as 25 mg/m² IV injection
79840330|NCT03957590|Radiation|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
79840331|NCT03921866|Drug|Palbociclib|Palbociclib
79538479|NCT05534412|Other|Electronic Clinical Decision Support|Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
79840332|NCT03888027|Behavioral|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
79840333|NCT03887221|Drug|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
79840334|NCT03887221|Drug|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
79840335|NCT03863808|Behavioral|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
79840336|NCT03863808|Other|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
79840337|NCT03859648|Device|BONEBRIDGE|Bone Conduction Implant
79244872|NCT04758871|Drug|Dydrogesterone 10 MG Oral Tablet|10 mg three times daily
79840338|NCT03852875|Other|Education|Same
79840339|NCT03852875|Other|Control|Same
79244873|NCT04758871|Drug|Micronized progesterone|2x 200 mg vaginal tablets two times daily
79383899|NCT01516593|Drug|Intensification phase|"One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
79383900|NCT01516593|Drug|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
79383901|NCT01516593|Radiation|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
79383902|NCT02042391|Drug|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
79538480|NCT05534412|Other|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
79538481|NCT05534412|Other|Electronic Referral|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
79695884|NCT04628559|Drug|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
79695885|NCT04628559|Drug|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
79695886|NCT04683341|Drug|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA < 20 IU/mL) will be enrolled.
79840340|NCT03786666|Procedure|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
79840341|NCT03760588|Drug|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
79840342|NCT03729778|Biological|Prevnar-13|One time administration of prevnar-13 vaccine
79244874|NCT04753736|Procedure|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Intrauterine administration of hCG-activated peripheral blood mononuclear cells
79383903|NCT02042391|Drug|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
79695887|NCT04683302|Device|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
79695888|NCT04683302|Device|2D US catheterization|2D short axis internal jugular vein catheterization
79695889|NCT04683263|Other|Placebo|topical cream with same composition as Intervention but without active ingredients
79244875|NCT04740957|Other|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
79538482|NCT05511805|Other|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
79383904|NCT02042391|Drug|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
79383905|NCT02042391|Drug|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
79383906|NCT02465424|Other|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
79383907|NCT02465580|Drug|hrIL-2 active|active group: placebo group =1:1
79383908|NCT02465580|Drug|hrIL-2 placebo|active group: placebo group =1:1
79538483|NCT05511805|Other|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
79538484|NCT05511805|Other|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
79538485|NCT05511805|Device|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
79538486|NCT05511805|Device|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
79695890|NCT04683263|Other|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
79695891|NCT04628676|Drug|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
80010670|NCT02030132|Behavioral|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
79383909|NCT02461836|Drug|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
79383910|NCT02461836|Radiation|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
79695892|NCT04628676|Drug|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
79695893|NCT00561561|Behavioral|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
79695894|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
79840343|NCT03718260|Diagnostic Test|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with [18F]-DCFPyL PET/CT Scan (PSMA PET).
80010671|NCT02030132|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
80010672|NCT02183246|Drug|Porfiromycin|
79383911|NCT01986946|Other|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
79383912|NCT01986946|Drug|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
80010673|NCT02183246|Drug|Placebo|
79840344|NCT03649048|Drug|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
79840345|NCT03649048|Drug|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
79840346|NCT03649048|Radiation|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
79840347|NCT03642626|Drug|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
79383913|NCT02034747|Drug|Advagraf|oral
79840348|NCT03642626|Drug|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
79840349|NCT03642626|Drug|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
79840350|NCT03642626|Drug|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
79840351|NCT03642626|Drug|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
80010674|NCT02183246|Radiation|Radiotherapy|
79383914|NCT02034747|Drug|Corticosteroid|oral
79383915|NCT01987414|Behavioral|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
79383916|NCT01987414|Device|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
79383917|NCT01987414|Other|No treatment|Participants will maintain their daily routines during the no treatment period.
79383918|NCT02464254|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
79383919|NCT02464254|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
79383920|NCT01909713|Drug|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
79383921|NCT02427724|Drug|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
79538487|NCT05511805|Device|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
79695895|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
79695896|NCT01214629|Drug|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
79695897|NCT04628325|Drug|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
79840352|NCT03642626|Drug|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
79840353|NCT03642626|Drug|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
79840354|NCT03642626|Drug|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
79840355|NCT03642626|Drug|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
79840356|NCT03642626|Drug|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
79840357|NCT03642626|Drug|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
79840358|NCT03642626|Drug|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
80010675|NCT02183324|Drug|Low dose of BI 1356 BS|
80010676|NCT02183324|Drug|Medium dose of BI 1356 BS|
80010677|NCT02183324|Drug|High dose of BI 1356 BS|
80010678|NCT02183324|Drug|Placebo|
79383922|NCT02427724|Drug|lidocaine 7%/tetracaine 7% topical anesthetic|
79383923|NCT02427724|Drug|placebo vehicle|
79383924|NCT02427724|Device|Q-switched 532nm Laser|
79383925|NCT03437200|Drug|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
79383926|NCT03437200|Drug|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
79383927|NCT03437200|Other|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
79383928|NCT05566587|Other|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
80010679|NCT02183402|Drug|Digoxin|
80010680|NCT02183402|Drug|BI 1356|
80010681|NCT02183480|Drug|Linagliptin, low dose|
80010682|NCT02183480|Drug|Linagliptin, medium dose|
80010683|NCT02183480|Drug|Linagliptin, high dose|
79840359|NCT03621982|Drug|ADCT-301|intravenous infusion
79840360|NCT03621982|Biological|Pembrolizumab|intravenous infusion
79244876|NCT04737603|Drug|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores >=8. Participants who weigh > 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh <= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
79244877|NCT04713787|Drug|Albendazole|Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
79244878|NCT04713787|Drug|Oxfendazole|The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
79244879|NCT04700280|Drug|GLPG3970|GLPG3970 film-coated tablet.
79244880|NCT04700280|Drug|Placebo|Placebo film-coated tablet.
79244881|NCT04679675|Other|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
79695900|NCT04318600|Drug|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
79383929|NCT05566587|Other|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
79695901|NCT04657497|Drug|FOY-305|Specified Dosage and Duration of Treatment
79383930|NCT01903473|Drug|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
79383931|NCT01903473|Other|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
79695902|NCT04657497|Drug|Placebo|Specified Dosage and Duration of Treatment
79840361|NCT03612648|Radiation|Three Fraction Accelerated Partial Breast Irradiation|"TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
79840362|NCT03612648|Procedure|Partial mastectomy|-Standard of Care
79840363|NCT03608163|Drug|Naloxone|Naloxone Nasal Spray
79840364|NCT03608163|Drug|Diazoxide|Diazoxide (oral)
79840365|NCT03608163|Drug|Placebo (for Naloxone)|Sterile water nasal spray
79244882|NCT04679675|Behavioral|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
79244883|NCT04679675|Behavioral|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
79695903|NCT01214434|Device|Promiseb Topical Cream|topical non steroidal cream, twice daily
79695904|NCT01214434|Other|Bland emollient|Eucerin cream twice daily
79695905|NCT04318639|Combination Product|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
79695906|NCT04628403|Other|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
79695907|NCT04628403|Device|lasertherapy|lasertherapy
79695908|NCT04628403|Device|shock waves|shock waves
79695909|NCT01214395|Drug|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
79840366|NCT03608163|Drug|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
79840367|NCT03604445|Drug|BI 905677|Solution for infusion
79840368|NCT03573700|Drug|Cyclophosphamide|Given IV
79840369|NCT03573700|Drug|Fludarabine|Given IV
79840370|NCT03573700|Drug|Mesna|Given IV
80010684|NCT05141864|Biological|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
80010685|NCT05141864|Drug|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
79695910|NCT04656834|Procedure|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
79695911|NCT04656834|Procedure|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
79695912|NCT01214239|Drug|Placebo|once a day
79695913|NCT01214239|Drug|Linagliptin|once a day
79695914|NCT04628520|Procedure|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
79695915|NCT04628520|Procedure|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
79695916|NCT04628520|Procedure|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
79695917|NCT01214200|Device|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
79840371|NCT03573700|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
79840372|NCT03573700|Biological|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
79244884|NCT04679675|Behavioral|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
79695918|NCT04967534|Behavioral|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
79244885|NCT04660435|Diagnostic Test|Thymidine kinase activity|DiviTum® assay determines the enzymatic activity of TK in serum samples
79695919|NCT04967534|Behavioral|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
79695920|NCT01214044|Drug|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
79840373|NCT03567837|Other|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
79840374|NCT03539848|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
79244886|NCT04648150|Device|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
79695921|NCT04628286|Other|Sham Laser|Sham Laser in plantar fascia
79244887|NCT04626128|Drug|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
79244888|NCT04626128|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
79695922|NCT04628286|Other|Myofascial Induction|Myofascial Induction in plantar fascia
79695923|NCT01213966|Drug|OZ439|po, single dose
79840375|NCT03530371|Drug|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
79244889|NCT04611997|Drug|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
79244890|NCT04595838|Device|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
79244891|NCT04595838|Other|Best Supportive Care only|Standard Oral care for Chemotherapy
79695924|NCT04628598|Behavioral|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
79695925|NCT01213264|Other|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
79840376|NCT03521830|Drug|Nivolumab|480mg IV every 4 weeks
79840377|NCT03521830|Drug|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
79840378|NCT03521830|Drug|Relatlimab|480 mg IV q4wks
79840379|NCT03496610|Drug|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
79695926|NCT01213264|Drug|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
79244892|NCT04582435|Drug|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
79840380|NCT03496610|Procedure|QL Block|Patient will receive ultrasound guided QL Block
79840381|NCT03489122|Behavioral|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
79840382|NCT03489122|Behavioral|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
79840383|NCT03456934|Other|Modified infant formula|Test formula with lower protein content than standard formula
79840384|NCT03456934|Other|Standard infant formula|Standard infant formula
79840385|NCT03449485|Drug|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
79840386|NCT03448783|Drug|Apixaban|Patients are tested for their normal prescription apixaban medication
79840387|NCT03433417|Device|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
79840388|NCT03418649|Drug|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
79840389|NCT03418649|Drug|Placebo Oral Tablet|PO once daily for 10 days
79840390|NCT03346343|Device|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
79840391|NCT03327441|Other|Almonds|Almonds will be provided as 15% energy
79840392|NCT03327441|Other|Omelette|Omelettes will be provided as 15% energy
79244893|NCT04581850|Behavioral|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
79244894|NCT04581850|Behavioral|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
79244895|NCT04581850|Other|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~PTSD severity~chronotype~Sleep quality~Daytime sleepiness~Mood state~Depression~Mental disorders and their consequences"
79244896|NCT04536298|Dietary Supplement|vitamin D|Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
79244897|NCT04536298|Dietary Supplement|Placebo|Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
79244898|NCT04523571|Biological|BNT162b1|Intramuscular injection
79244899|NCT04523571|Other|Placebo|Intramuscular injection
79244900|NCT04492995|Diagnostic Test|injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
79383932|NCT01900977|Other|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
79840393|NCT03326141|Behavioral|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
79840394|NCT03326141|Device|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
79840395|NCT03326141|Behavioral|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
79695927|NCT01213264|Drug|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
79695928|NCT04628247|Device|Spring gravity bar|"contain two wooden board length (160 cm) and width (15 cm)~contain pair of spring at every end of board~two wooden board connect in the middle"
79840396|NCT03326141|Behavioral|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
79840397|NCT03326141|Other|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
79244901|NCT04492995|Diagnostic Test|injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
79244902|NCT04478630|Other|Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract|Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
79383933|NCT01900977|Other|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
79383934|NCT01900977|Other|Standard of Care|
79383935|NCT02715726|Drug|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
79383936|NCT02715726|Drug|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
79383937|NCT02715726|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
79383938|NCT02715726|Drug|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
79383939|NCT02715726|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
79538488|NCT05511805|Device|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
79695929|NCT04628637|Other|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
79695930|NCT04628208|Diagnostic Test|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
79840398|NCT03315832|Drug|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
79383940|NCT02715726|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
79840399|NCT03315832|Drug|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
79840400|NCT03292601|Device|Cinch Smart Strap|"The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient."
79383941|NCT02715726|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
79383942|NCT01893567|Drug|Clobex Spray|
79538489|NCT05510843|Drug|THB001|100 mg capsules for oral administration
79538490|NCT05509660|Behavioral|PUMA+|Transdiagnostic CBT
79538491|NCT05509660|Behavioral|PUMA|Transdiagnostic CBT
79840401|NCT03292601|Other|Cinch Mobile App|The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
79840402|NCT03124355|Drug|placebo sugar pill|placebo single oral dose
79840403|NCT03124355|Drug|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
79840404|NCT03124355|Drug|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
79840405|NCT03124355|Device|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
79244903|NCT04448002|Behavioral|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication.
79383943|NCT04249596|Drug|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
79383944|NCT01476501|Drug|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
79840406|NCT03124355|Device|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
79383945|NCT04248816|Behavioral|Usual care|Subjects will receive outreach through their providers as is standard of care.
79538492|NCT05508022|Behavioral|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
79383946|NCT04248816|Behavioral|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
79383947|NCT04248816|Behavioral|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
79695931|NCT04656912|Procedure|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
79840407|NCT03122652|Drug|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
79840408|NCT03122652|Drug|Placebo Oral Tablet|1 tablet once a day
79840409|NCT03028779|Procedure|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
79840410|NCT03011268|Other|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
80010686|NCT05141864|Other|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
79538493|NCT05493722|Other|PS and OS stimulation order 1|PS, OS, OS
79538494|NCT05493722|Other|PS and OS stimulation order 2|OS, PS, OS
79538495|NCT05493722|Other|PS and OS stimulation order 3|OS, OS, PS
79695932|NCT04657107|Drug|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
79695933|NCT04657107|Other|normal saline|Saline group: pregnant women received saline, intravenous drip
79695934|NCT04657107|Drug|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
79695935|NCT04657029|Behavioral|Treadmill|30 minutes of moderate-high intensity treadmill training.
79538496|NCT05493007|Procedure|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
79840411|NCT03011268|Other|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
79840412|NCT02956031|Other|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
79840413|NCT02956031|Other|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
79840414|NCT02956031|Procedure|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
79840415|NCT02945774|Radiation|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
80010687|NCT02177864|Dietary Supplement|Fiber|
80010688|NCT02177864|Other|Placebo (low fiber bar)|
80010689|NCT02180516|Drug|Meloxicam|
80010690|NCT02180516|Drug|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
79695936|NCT04657185|Other|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
80010691|NCT03537872|Behavioral|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
79244904|NCT04448002|Behavioral|mHealth Attention Control Condition|Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management.
79538497|NCT05493007|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
79538498|NCT05491681|Biological|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
79538499|NCT05487378|Dietary Supplement|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
79538500|NCT05487196|Drug|Clonidine|Clonidine belongs to the drug classification of antihypertensives
79538501|NCT05487196|Drug|Dexmedetomidine|Dexmedetomidine belongs to the drug classification of sedatives
79538502|NCT05487196|Drug|Fentanyl|Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
79840416|NCT02944578|Drug|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
80010692|NCT03537872|Behavioral|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
79244905|NCT04421820|Drug|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)|625 mg/m2 IV over 30 minutes, q2weeks
79244906|NCT04421820|Drug|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)|320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
79244907|NCT04411654|Genetic|LY3884961|Participants will receive a single dose of LY3884961 administered intracisternally.
79244908|NCT04411654|Drug|Methylprednisolone|Single IV pulse administered as concomitant medication.
79244909|NCT04411654|Drug|Sirolimus|Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
79244910|NCT04411654|Drug|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
79538503|NCT05487196|Drug|Ropivacaine|Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
79538504|NCT05482828|Drug|JGT (Jaeumgeonbi-Tang) tablet|JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
80010693|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
80010694|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
80010695|NCT02183636|Drug|Linagliptin tablet|5 mg
79244911|NCT04410237|Device|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
79244912|NCT04410237|Other|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
79244913|NCT04367090|Drug|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
79244914|NCT04367090|Drug|Pyrotinib|Pyrotinib 400/320 mg orally daily
79383948|NCT03426124|Device|EkoSonic Endovascular System with thrombolytic|The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
79383949|NCT04240080|Device|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
79383950|NCT02464020|Drug|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
79383951|NCT04756089|Device|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
79383952|NCT04756089|Other|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
79383953|NCT02465112|Drug|In111-Pentetréotide|
79383954|NCT02465112|Other|simple monitoring without active therapy|
80010696|NCT02183636|Drug|pioglitazone tablet (Actos®)|45 mg
80010697|NCT05141786|Drug|MRG002|Administrated intravenously
79538505|NCT05482828|Drug|Placebo tablet|Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
80010698|NCT02180750|Other|Memory Work Therapy|
79538506|NCT05480579|Biological|placebo|Dose4 placebo of single IV injection
79840417|NCT02944578|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
80010699|NCT02180750|Other|Standard care|Pediatric clinic, ART
80010700|NCT02183714|Drug|Songha Night ®|
80010701|NCT02183714|Drug|Placebo|
80010702|NCT02256410|Device|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
80010703|NCT02256410|Other|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
80010704|NCT02183948|Drug|Oxytocin|
80010705|NCT02183948|Drug|Placebo|
80010706|NCT02184026|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
80010707|NCT03537716|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
80010708|NCT05141630|Procedure|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
80010709|NCT05141084|Other|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
80010710|NCT02178020|Device|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
80010711|NCT02178020|Device|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
79538507|NCT05480579|Biological|IBI311|Dose2 IBI311 of single IV injection
79538508|NCT05480579|Biological|IBI311|Dose4 IBI311 of single IV injection
80010712|NCT04530032|Other|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
79244915|NCT04361617|Behavioral|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
79244916|NCT04346381|Drug|Camrelizumab|Intravenous (IV) camrelizumab on Day 1 of each cycle
79244917|NCT04346381|Drug|Famitinib|famitinib po qd
79538509|NCT05480579|Biological|placebo|Dose3 placebo of single IV injection
79244918|NCT04337450|Drug|Dolutegravir (DTG) and lamivudine (3TC)|Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
79383955|NCT01888887|Other|Cetaphil Daily Facial Cleanser|
79383956|NCT03397888|Drug|Betrixaban|80 mg capsule
79383957|NCT01886859|Drug|Ibrutinib|Given PO
79383958|NCT01886859|Drug|Lenalidomide|Given PO
79383959|NCT00877344|Procedure|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
79538510|NCT05480579|Biological|placebo|Dose1 placebo of single IV injection
79538511|NCT05480579|Biological|IBI311|Dose1 IBI311 of single IV injection
79538512|NCT05480579|Biological|IBI311|Dose 3 IBI311 of single IV injection
79538513|NCT05480579|Biological|placebo|Dose2 placebo of single IV injection
79538514|NCT05479968|Device|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
79538515|NCT05471700|Drug|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
79538516|NCT05471700|Drug|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
79538517|NCT05469178|Drug|Bemcentinib|Bemcentinib capsules will be administered orally.
79538518|NCT05469178|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as part of CIT every 3 weeks.
80010713|NCT04530032|Other|Standard diet|standard (normal) diet use
80010714|NCT02184104|Dietary Supplement|Caffeine|
80010715|NCT02184182|Procedure|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
79538519|NCT05469178|Drug|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
79695938|NCT04656483|Other|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
79695939|NCT04656483|Other|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
79695940|NCT00561717|Drug|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
79695941|NCT00561717|Drug|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
79695942|NCT00561717|Drug|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
79695943|NCT00561717|Drug|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
79695944|NCT04901351|Procedure|Smear|In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
79695945|NCT00561756|Biological|plasmid DNA vaccine therapy|
79695946|NCT00561756|Other|flow cytometry|
79244919|NCT04337450|Drug|SOC|2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
79538520|NCT05469178|Drug|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks.
79538521|NCT05461378|Drug|Evusheld|Participants who have received or plan to receive Evusheld.
79695947|NCT00561756|Other|immunoenzyme technique|
79695948|NCT04860401|Device|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
79695949|NCT04628130|Other|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
79695950|NCT04827485|Other|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
79695951|NCT04827485|Other|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
79840418|NCT02943291|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
79840419|NCT02943291|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
79244920|NCT04321993|Drug|Baricitinib (janus kinase inhibitor)|Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
79244921|NCT04321993|Drug|Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|"Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner."
79538522|NCT05460988|Procedure|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
79538523|NCT05460988|Procedure|Non surgical re-instrumentation|The sites showing remaining pockets (PD>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
79538524|NCT05452642|Behavioral|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
79538525|NCT05452642|Behavioral|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
79840420|NCT02893943|Dietary Supplement|Probiotics|
79840421|NCT02893943|Dietary Supplement|Placebo|
79840422|NCT02889523|Drug|Tazemetostat|Tablets 200 mg, to be administrated per os
79840423|NCT02889523|Drug|Rituximab|375 mg/m²/dose, D1
79840424|NCT02889523|Drug|Cyclophosphamide|750 mg/m²/dose, D1
79840425|NCT02889523|Drug|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
79538526|NCT05447286|Drug|NYX-783|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
79244922|NCT04321993|Drug|Remdesivir (antiviral)|Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
79538527|NCT05447286|Drug|Placebo|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
79695952|NCT04656756|Behavioral|Personalized Care|A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
79695953|NCT04683107|Other|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
79695954|NCT04683107|Other|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
79840426|NCT02889523|Drug|Doxorubicin|50 mg/m²/dose, D1
79840427|NCT02889523|Drug|Prednisolone|40 mg/m2 in the morning D1 to D5
79840428|NCT02782741|Drug|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
79840429|NCT02782741|Drug|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
79244923|NCT04321993|Drug|Tocilizumab (interleukin 6 inhibitor)|Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
79383960|NCT00877344|Procedure|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
80010716|NCT02184260|Drug|Metamizole|
79244924|NCT04307628|Other|Walnut|Study participants will eat 2 ounces of walnuts each day.
79244925|NCT04307628|Other|Nut-Free|Study participants will not eat nuts.
79538528|NCT05447286|Drug|Oxycodone|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
79695955|NCT04683146|Drug|Hand antisepsis with Propanolol- 1 60%.|"Pre-washing for one minute with neutral soap to remove the transient flora.~Hand antisepsis using Propanolol-1 60% in both hands.~Bacterial sample collection from right hand.~Sterile surgical glove in both hands.~Bacterial sample collection from left hand three hours later"
79695956|NCT04683146|Drug|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"Pre-washing for one minute with neutral soap to remove the transient flora.~Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~Bacterial sample collection from right hand.~Sterile surgical glove in both hands.~Bacterial sample collection from left hand three hours later."
79695957|NCT04656717|Other|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
79695958|NCT00557583|Drug|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
79244926|NCT04296305|Drug|Hydromorphone|Given IV after
79244927|NCT04296305|Drug|Placebo Administration|Given IV after
79244928|NCT04296305|Other|Questionnaire Administration|Ancillary studies
79840430|NCT02771626|Drug|CB-839|Glutaminase inhibitor
79840431|NCT02771626|Drug|Nivolumab|PD-1 inhibitor
79840432|NCT02616302|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
79840433|NCT02515370|Other|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
80010717|NCT02184260|Drug|Placebo|
79244929|NCT04233567|Drug|Infigratinib|Given PO
79244930|NCT04213729|Behavioral|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
79383961|NCT01885377|Other|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
79383962|NCT01885377|Other|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
79695959|NCT04627935|Behavioral|The COPD Assessment Test|Used to assess symptoms in COPD patients.
79840434|NCT02469753|Drug|NSAIDs|continuous daily
79840435|NCT02469753|Drug|NSAIDs|on demand
79840436|NCT02469753|Drug|anti-TNF|
79840437|NCT02374242|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.
79695960|NCT04627935|Diagnostic Test|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
79538529|NCT05446766|Behavioral|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
79695961|NCT04627935|Behavioral|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
79695962|NCT04627935|Behavioral|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
79695963|NCT04627935|Behavioral|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
79695964|NCT04800302|Procedure|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum & psoas major muscles with ultrasound guidance.
79695965|NCT04800302|Procedure|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
79538530|NCT05442112|Behavioral|Wellness Patient Message|The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
79695966|NCT04800302|Procedure|Intra-venous Morphine|Intra-venous Morphine [0.1 mg/kg] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
79695967|NCT04795037|Drug|CU06-1004, Single dose|"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"
79538531|NCT05439226|Other|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
79695968|NCT04795037|Drug|CU06-1004, Multiple doses|"Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"
79840438|NCT02374242|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
80010718|NCT02178176|Behavioral|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
79383963|NCT01989130|Device|Roche AMPLICOR CT/NG|
79695969|NCT04795037|Drug|Placebo|Placebo matched to CU06-1004, oral capsule
79695970|NCT04723706|Diagnostic Test|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
79695971|NCT04711304|Biological|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
79695972|NCT04711304|Device|Hyaluronic acid|Intraarticular injection
79695973|NCT04711304|Other|Saline|Intraarticular injection
79840439|NCT02366598|Other|Hemp shake|Hemp protein shake
79840440|NCT02366598|Other|Soybean shake|Soybean protein shake
79840441|NCT02366598|Other|Control|Non-protein shake
80010719|NCT02178176|Behavioral|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
80010720|NCT05140928|Other|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
79383964|NCT01989130|Device|Cepheid Xpert CT/NG Test|
79383965|NCT01894971|Device|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
79383966|NCT03298932|Procedure|Aortic valve surgery|Aortic valve surgery
79383967|NCT01989910|Drug|Raltegravir|Raltegravir 400mg oral twice daily
79383968|NCT01989910|Drug|Efavirenz|Efavirenz 600mg oral at bedtime
79383969|NCT02464722|Drug|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
79695974|NCT04710719|Drug|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
79695975|NCT04710719|Drug|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
79840442|NCT02314988|Drug|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
79840443|NCT02314988|Drug|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
79840444|NCT02256904|Procedure|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
79840445|NCT02256904|Procedure|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
79840446|NCT02190500|Other|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
79840447|NCT02174055|Behavioral|Patient Interviews|participate in a brief interview
80010721|NCT05140928|Other|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
80010722|NCT02180984|Device|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
79244931|NCT04213729|Other|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
79244932|NCT04213729|Behavioral|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
79244933|NCT04212494|Procedure|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
79695976|NCT04649372|Procedure|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
79695977|NCT04683185|Drug|E6742|E6742 tablets.
79695978|NCT04683185|Drug|Placebo|E6742-matched placebo tablets.
79695979|NCT04656405|Other|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
79695980|NCT04656405|Other|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
79840448|NCT02174055|Behavioral|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
79244934|NCT04212494|Procedure|PCI Alone|Percutaneous Coronary Intervention without manual aspiration thrombectomy
79244935|NCT04183595|Drug|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
79840449|NCT02174055|Behavioral|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
79840450|NCT02091583|Dietary Supplement|Butter, sunflower and safflower oil|
79840451|NCT02091583|Dietary Supplement|High Oleic Canola Oil and DHA (HOCO-DHA)|
79840452|NCT02091583|Dietary Supplement|Barley beta-glucan|
79840453|NCT02091583|Dietary Supplement|HOCO-DHA and Barley beta-glucan|
79840454|NCT02032953|Dietary Supplement|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
79840455|NCT02032953|Drug|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg*min. Ten minuts after starting the insulin, and when the the blood glucose is<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
79840456|NCT02029833|Other|Regular Canola Oil|
79840457|NCT02029833|Other|High Oleic Canola Oil|
79840458|NCT02029833|Other|Western Type Diet - Common Dietary Oils|
79244936|NCT04183595|Other|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
79840459|NCT01850355|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
79840460|NCT01582776|Drug|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
79244937|NCT04170140|Other|No intervention|Questionnaire
79244938|NCT04122001|Device|Active HD-tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
79244939|NCT04122001|Device|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
79383970|NCT02464722|Drug|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
79538532|NCT05433220|Other|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
79538533|NCT05431595|Drug|Haloperidol|Given by Vein (IV)
79538534|NCT05431595|Drug|Chlorpromazine|Given by Vein (IV)
79840461|NCT01464164|Drug|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
79538535|NCT05431595|Drug|Valproate|Given by Vein (IV)
79840462|NCT01464164|Drug|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
79840463|NCT00602459|Drug|Cyclophosphamide|Given IV
79840464|NCT00602459|Drug|Fludarabine Phosphate|Given IV or PO
79840465|NCT00602459|Other|Laboratory Biomarker Analysis|Correlative studies
79383971|NCT02464722|Drug|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
79383972|NCT02464722|Drug|Propofol|Anesthesia was induced with propofol 2 mg kg-1
79840466|NCT00602459|Drug|Lenalidomide|Given PO
79840467|NCT00602459|Biological|Rituximab|Given IV
79383973|NCT02464722|Drug|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
79538536|NCT05431595|Drug|Placebo|Given by Vein (IV)
79538537|NCT05427006|Device|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
79538538|NCT05427006|Device|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
79840468|NCT00591175|Behavioral|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
79538539|NCT05415514|Other|Instrumented assessment of muscle function|During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
79538540|NCT05412914|Drug|Remimazolam infusion|Remimazolam infusion for anesthesia induction
79695981|NCT04656405|Other|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
79695982|NCT04656288|Drug|BI 764198 - Formula A|BI 764198
79695983|NCT04656288|Drug|BI 764198 - Formula B|BI 764198
79695984|NCT04656288|Drug|BI 764198 - Formula C|BI 764198
79695985|NCT04656288|Drug|BI 764198 - Formula D|BI 764198
79695986|NCT04592276|Dietary Supplement|PS128|Participants took two capsules with PS128 after dinner for 30 days.
79695987|NCT04592276|Dietary Supplement|placebo|Participants took two capsules without PS128 after dinner for 30 days.
79538541|NCT05412914|Drug|Propofol infusion|Propofol infusion for anesthesia induction
79538542|NCT05408195|Device|CHATBOT use|Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.
79538543|NCT05407389|Drug|KT-301 (formerly US-APR2020)|KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
79538544|NCT05407038|Other|Exercise Counseling|Receive call from health coach
79538545|NCT05407038|Other|Exercise Intervention|Undergo routine exercise
79538546|NCT05407038|Other|Internet-Based Intervention|Receive Android tablet
79695988|NCT04627779|Drug|preemptive analgesia with flurbiprofen axetil|give flurbiprofen axetil 15 min before surgery
79695989|NCT04656327|Other|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
79695990|NCT04627584|Combination Product|MW33 injection|a recombinant fully human antibody to coronavirus
79695991|NCT04627584|Combination Product|MW33 injection placebo|Placebo
79538547|NCT05407038|Other|Interview|Complete a qualitative interview
79538548|NCT05407038|Other|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
79695992|NCT04537598|Procedure|Morphine patient controlled analgesia|30 patients will receive PCA only for postoperative analgesia
79840469|NCT00591175|Behavioral|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
79538549|NCT05407038|Other|Questionnaire Administration|Ancillary studies
79538550|NCT05406856|Radiation|External beam radiation therapy: IMRT/VMAT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
79538551|NCT05406856|Radiation|External beam radiation therapy: IMPT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
79538552|NCT05406856|Drug|Cisplatin|The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
79695993|NCT04537598|Procedure|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia
79695994|NCT04627467|Drug|Chloroquine|250mg tablet (150mg base chloroquine)
79695995|NCT04656015|Device|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~Regional or global myocardial signal intensity increase in T2-weighted images~Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
79695996|NCT04656093|Behavioral|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
79695997|NCT04656093|Behavioral|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
79695998|NCT04656093|Behavioral|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
79695999|NCT04656093|Behavioral|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
79696000|NCT04531631|Drug|Dorzagliatin|tablet
79696001|NCT04531631|Drug|placebo|placebo
79696002|NCT04529447|Other|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
79696003|NCT04627623|Diagnostic Test|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
79696004|NCT04627740|Drug|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
79696005|NCT04656366|Diagnostic Test|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
79696006|NCT04525469|Behavioral|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
79840470|NCT00591175|Behavioral|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
79840471|NCT00199069|Drug|Asparaginase|
79840472|NCT00199069|Drug|Vincristine|
79840473|NCT00199069|Drug|Daunorubicin, Adriamycin|
79840474|NCT00199069|Drug|Cyclophosphamide|
79840475|NCT00199069|Drug|Ifosfamide|
79840476|NCT00199069|Drug|Cytarabine|
79840477|NCT00199069|Drug|Mitoxantrone|
79840478|NCT00199069|Drug|Methotrexate|
79840479|NCT00199069|Drug|6-Mercaptopurine|
79840480|NCT00199069|Drug|6-Thioguanine|
79840481|NCT00199069|Drug|VM26|
79840482|NCT00199069|Drug|Dexamethasone / Prednisolone|
79840483|NCT00199069|Procedure|CNS Irradiation|
79840484|NCT00199069|Procedure|Mediastinal Irradiation|
79840485|NCT00199069|Procedure|Stem Cell Transplantation|
79538553|NCT05406856|Radiation|Brachytherapy|Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
79538554|NCT05356572|Device|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
79538555|NCT05356572|Device|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
79538556|NCT05356572|Device|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
79538557|NCT05354726|Other|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
79538558|NCT05352971|Other|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
79538559|NCT05351294|Other|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
79538560|NCT05351294|Combination Product|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
79538561|NCT05350163|Biological|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
79538562|NCT05330195|Other|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
79538563|NCT05330195|Other|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
79840486|NCT00199043|Drug|Allopurinol|
79840487|NCT00199043|Drug|Rasburicase|
79840488|NCT02601989|Drug|Tadalafil|
79840489|NCT02601989|Drug|Placebo|Per oral intake of placebo for six weeks
79840490|NCT01067053|Drug|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
79840491|NCT04097015|Device|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
79840492|NCT01067131|Biological|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
79840493|NCT01067131|Biological|PEV7C9|capsule intravaginal application contains excipient only
79244940|NCT04122001|Other|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
79538564|NCT05325307|Other|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
79538565|NCT05325307|Other|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
79696007|NCT04509167|Biological|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
79696008|NCT04627155|Drug|LY03003|Rotigotine,extended-release microspheres
79696009|NCT04508972|Device|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
79696010|NCT04656249|Drug|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
79696011|NCT04656054|Procedure|liposuction|liposuction procedure and observation of the hematological changes on the patients
79696012|NCT04627350|Other|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
79696013|NCT04472156|Procedure|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
79696014|NCT04655859|Diagnostic Test|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
79696015|NCT04682951|Procedure|Decompressive Craniectomy|
79696016|NCT04655898|Drug|[14C]CC-90001|Oral
79696017|NCT04682756|Diagnostic Test|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
79383974|NCT04197258|Other|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
79383975|NCT02314156|Drug|Telapristone Acetate|Given transdermally
79696018|NCT04682795|Device|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
79383976|NCT02314156|Other|Placebo|Given PO
79383977|NCT02314156|Drug|Telapristone Acetate|Given PO
79696019|NCT04682795|Device|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
79696020|NCT04627116|Drug|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
79840494|NCT01067131|Biological|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
79840495|NCT01067131|Biological|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
79840496|NCT02601287|Biological|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
79383978|NCT02314156|Other|Placebo|Given transdermally
79538566|NCT05307692|Drug|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
79538567|NCT05307692|Drug|Placebo|Matching placebo will be administered orally as a tablet.
79696021|NCT04655742|Device|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
79696022|NCT04395482|Other|Lung CT scan analysis in COVID-19 patients|This research project will evaluate the morphological characteristics of the lung by CT scan analysis in COVID-19 patients which will be identified as specific patterns using artificial intelligence technology and their impact on outcome.
79840497|NCT01067365|Drug|Androxal|12.5 mg once daily
79840498|NCT01067365|Drug|Androxal|25 mg once daily
79840499|NCT00568776|Drug|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
79840500|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
79840501|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
79840502|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
79840503|NCT04021511|Other|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
79840504|NCT01067443|Drug|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
79383979|NCT02314156|Other|Laboratory Biomarker Analysis|Correlative studies
79383980|NCT02314156|Other|Questionnaire Administration|Ancillary studies
79383981|NCT02463786|Other|No intervention|No intervention
79696023|NCT04627233|Drug|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
79696024|NCT04627233|Drug|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
79696025|NCT04655664|Diagnostic Test|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
79244941|NCT04021914|Device|EnChroma glasses|Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
79383982|NCT03297138|Procedure|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
79383983|NCT01991548|Device|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
79383984|NCT03298854|Device|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
79383985|NCT02461680|Procedure|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
79383986|NCT02461680|Procedure|suture|
79383987|NCT02461914|Drug|PEX168|200µg,injected subcutaneously,once a week.
79383988|NCT02461914|Drug|Warfarin|5mg,oral,two times.
79383989|NCT01991860|Drug|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
79383990|NCT01991860|Drug|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
79383991|NCT01986790|Behavioral|Plain Language|
79383992|NCT01986790|Behavioral|Plain Language + Visuals|
79383993|NCT01986790|Behavioral|Plain Language + Narratives|
79383994|NCT02463552|Drug|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
79383995|NCT01992016|Drug|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
79538568|NCT05307198|Drug|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
79538569|NCT05307198|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
79840505|NCT01067443|Drug|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
79383996|NCT01871571|Biological|bevacizumab|Given IV
79383997|NCT01871571|Drug|oxaliplatin|Given IV
79383998|NCT01871571|Drug|leucovorin calcium|Given IV
79383999|NCT01871571|Drug|fluorouracil|Given IV
79840506|NCT01067443|Drug|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
79384000|NCT01871571|Other|laboratory biomarker analysis|Correlative studies
79384001|NCT01992172|Drug|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
79384002|NCT01992172|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
79384003|NCT03296982|Other|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
79384004|NCT03296982|Drug|edoxaban|
79384005|NCT03296982|Drug|Enoxaparin|
79384006|NCT03296982|Drug|Saline sham|
79384007|NCT03296904|Device|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
79538570|NCT05307198|Drug|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
79244942|NCT04014322|Other|E-cigarette|"All participants will be provided with 8 weeks of e-cigarettes at no cost based on self-report of regular cigarette use.~All participants will receive a total of 8-10 remote counseling sessions (via phone or video conference) and during which they will discuss ways to switch from smoking cigarettes to exclusively using e-cigarettes, barriers and strategies to overcome them. (All participants will receive sessions at baseline, 2 days, 7 days, 2 weeks, 3 weeks, and 4 weeks, 6 weeks , and 8 weeks after the baseline assessment. Two additional sessions at 5 weeks and 7 weeks (after the baseline assessment) will be provided to those who are still smoking combustible cigarettes at 4-week assessment.)"
79696026|NCT04655664|Diagnostic Test|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
79538571|NCT05307198|Drug|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
79538572|NCT05304104|Behavioral|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
79696027|NCT04365179|Drug|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
79696028|NCT04655508|Drug|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
79696029|NCT04655508|Drug|Placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
79696030|NCT04355546|Other|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
79696031|NCT04627272|Device|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
79696032|NCT04655781|Procedure|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
79244943|NCT03988309|Diagnostic Test|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
79538574|NCT05293938|Drug|Obeticholic Acid 5 MG|once daily, oral administration
79538575|NCT05293938|Drug|Obeticholic Acid 10 MG|once daily, oral administration
79696033|NCT04626999|Procedure|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
79696034|NCT04626999|Procedure|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
79696035|NCT02906774|Biological|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
79696036|NCT02907008|Other|Polysomnography|
79244944|NCT03978988|Device|Carotid Stenting|emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion.
79840507|NCT01065259|Drug|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
79696037|NCT04655040|Drug|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
79696038|NCT04655040|Other|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
79696039|NCT02906735|Procedure|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
79840508|NCT01065259|Drug|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
79840509|NCT00822666|Drug|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
79840510|NCT00816816|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
79840511|NCT00816894|Drug|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
79244945|NCT03978988|Drug|Procedural Aspirin|After carotid stenting, an intravenous bolus of 250mg of Aspirin will be given at the end of the procedure in case of absence of complication.
79244946|NCT03978988|Drug|Dual dual antiplatelet therapy after 24-hours imaging follow-up|A dual antiplatelet therapy is administered after 24-hours imaging follow-up excluding intracranial hemorrhagic complications (the type and the dose of the dual antiplatelet therapy are left to the discretion of the local practice)
79696040|NCT04626765|Drug|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
79244947|NCT03978988|Procedure|Intracranial thrombectomy|Intracranial thrombectomy is the endovascular procedure. In the experimental group, thrombectomy will be completed with a extracranial carotid stenting.
79391819|NCT02404662|Other|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
79696041|NCT04626765|Drug|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
79696042|NCT04626765|Drug|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
79696043|NCT04626765|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
79840512|NCT00816894|Drug|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
79840513|NCT00922350|Other|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
79696044|NCT04626765|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
79696045|NCT02906969|Other|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
79696046|NCT02906969|Other|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
79696047|NCT02906891|Device|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
79696048|NCT04655274|Diagnostic Test|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
79696049|NCT04626648|Behavioral|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
79244948|NCT03950427|Behavioral|Videogame-based physical activity|videogame-based physical activity
79538576|NCT05293938|Drug|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
79538577|NCT05290493|Drug|NB-001|NB-001 is a non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs).
79538578|NCT05290493|Other|Placebo|Matching, inactive placebo
79696050|NCT02906618|Drug|LY3039478|Administered orally
79696051|NCT02906618|Drug|3C 15N 2H-LY3039478 IV|Administered IV
79696052|NCT04626726|Drug|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
79840514|NCT00922350|Other|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
79840515|NCT00922350|Other|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
80010723|NCT02181062|Behavioral|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
80010724|NCT03684837|Dietary Supplement|Vitamine D supplementation|a vitamine D dose for week
80010725|NCT03684837|Other|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
80010726|NCT03902691|Drug|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
79244949|NCT03950427|Behavioral|sedentary videogame|sedentary videogame
79244950|NCT03950427|Drug|Bupropion|Bupropion
79391820|NCT02404662|Other|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
79244951|NCT03950427|Behavioral|Counseling|Counseling for smoking cessation
79538579|NCT05287100|Drug|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
79538580|NCT05287100|Other|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is < 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to < 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
79538581|NCT05285670|Behavioral|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
79696053|NCT04626726|Drug|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
79696054|NCT04626726|Drug|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
79696055|NCT04626726|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
79696056|NCT04626726|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
79696057|NCT04655235|Genetic|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
79696058|NCT04654962|Procedure|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
79244952|NCT03911505|Biological|Cipaglucosidase Alfa|Enzyme Replacement Therapy via intravenous infusion
79391821|NCT02560324|Drug|Ramelteon|
79391822|NCT02560324|Drug|Placebo|
79391823|NCT02406846|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
79391824|NCT02406846|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
79244953|NCT03911505|Drug|Miglustat|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
79244954|NCT03909178|Procedure|Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)|Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.
79391825|NCT03173118|Procedure|Endoscopic ultrasound elastography|Endoscopic ultrasound elastography performed on both groups of patients as per routine
79538582|NCT05279014|Other|Meal timing|A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
79696059|NCT04654884|Other|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
79696060|NCT02906501|Procedure|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
79840516|NCT00922350|Other|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
79840517|NCT00635154|Biological|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
79840518|NCT00635154|Drug|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
79840519|NCT00778895|Biological|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
79840520|NCT00778895|Biological|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
79244955|NCT03909178|Procedure|Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)|PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
79244956|NCT03851588|Other|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
79244957|NCT03851588|Drug|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
79538583|NCT05275426|Drug|LY2880070|Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20
79384008|NCT02463630|Procedure|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
79538584|NCT05275426|Drug|Gemcitabine|Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
79538585|NCT05271903|Behavioral|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
79538586|NCT05262907|Device|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
80010727|NCT03902691|Drug|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
80010728|NCT03808155|Drug|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
80010729|NCT03808155|Drug|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
80010730|NCT03677583|Other|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
79244958|NCT03850600|Other|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
79244959|NCT03850444|Biological|pembrolizumab|
79244960|NCT03850444|Drug|carboplatin|
79244961|NCT03850444|Drug|paclitaxel|
79244962|NCT03850444|Drug|pemetrexed|
79244963|NCT03850379|Drug|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
79538587|NCT05262907|Device|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
79244964|NCT03850379|Drug|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
79538588|NCT05259917|Drug|Placebo|Placebo to KVD900 Tablet
79538589|NCT05259917|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
79538590|NCT05259917|Drug|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
80010731|NCT03677583|Other|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
80010732|NCT02752958|Drug|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
80010733|NCT02185664|Procedure|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
80010734|NCT02185664|Device|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
79244966|NCT03824483|Drug|Zanubrutinib|zanubrutinib (160mg by mouth BID)
79244967|NCT03824483|Drug|Obinutuzumab|"obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter)."
79244968|NCT03824483|Drug|Venetoclax|Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
79244969|NCT03820141|Drug|Durvalumab|programmed cell death-ligand 1 inhibitor
79384009|NCT00493701|Behavioral|High Fat Diet|Daily eating
79384010|NCT00493701|Behavioral|Low Fat Diet|Life style eating habits
79384011|NCT01895829|Procedure|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
79384012|NCT01895829|Drug|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
79384013|NCT03296748|Procedure|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
79538591|NCT05251324|Other|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
79538592|NCT05242731|Device|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
79538593|NCT05242731|Device|"Video calling program Better-close"|Video calling program.
79538594|NCT05242731|Device|Researchmanager program|Case Report Form, Datamanagement program
79538595|NCT05242276|Device|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
79538596|NCT05224141|Biological|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
79538597|NCT05224141|Drug|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
79696061|NCT02906501|Procedure|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
79696062|NCT02906540|Procedure|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
80010735|NCT02185742|Behavioral|Strength Based Case Management|
80010736|NCT02181218|Drug|Romidepsin|
80010737|NCT02181218|Drug|Gemcitabine|
80010738|NCT02181218|Drug|Oxaliplatin|
80010739|NCT02181218|Drug|Dexamethasone|
80010740|NCT02181218|Drug|Pegfilgrastim|
80010741|NCT02184650|Other|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
79696063|NCT02906540|Procedure|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
79696064|NCT02906423|Other|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
79244970|NCT03820141|Drug|Trastuzumab|anti-HER2 monoclonal antibody
79696065|NCT02906462|Other|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
80010742|NCT03536234|Drug|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
79244971|NCT03820141|Drug|Pertuzumab|anti-HER2 monoclonal antibody
79244972|NCT03781804|Drug|OPN-375|OPN-375, BID
79244973|NCT03742245|Drug|Olaparib|PARP inhibitor
79384014|NCT03296748|Procedure|anterior colporraphy|
79538598|NCT05224141|Drug|Etoposide|Etoposide 100 mg/m^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
79538599|NCT05224141|Drug|Cisplatin|Cisplatin 75 mg/m^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
79696066|NCT02906462|Other|Usual practices|the centres applies their usual practices
79696067|NCT04654494|Procedure|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
79696068|NCT04654494|Procedure|Total colectomy|excision of the colon with preservation of the rectum
79384015|NCT03298776|Device|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
79384016|NCT03298776|Diagnostic Test|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
79384017|NCT03298698|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
79384018|NCT03298698|Drug|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
79384019|NCT02463942|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
79384020|NCT02463942|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
79696069|NCT04654494|Procedure|Segmental colectomy|excision of a segment of colon
79384021|NCT02463942|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
79384022|NCT03385408|Device|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
79384023|NCT03385408|Device|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
79696070|NCT02906345|Device|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
80010743|NCT03682497|Drug|AZD9977|AZD9977 capsules taken orally for 28 days.
80010744|NCT03682497|Drug|Spironolactone|Spironolactone tablets taken orally for 28 days.
79244974|NCT03742245|Drug|Vorinostat|HDAC inhibitor
79244975|NCT03732677|Drug|Durvalumab|Anti- PD-L1 Antibody
79244976|NCT03732677|Drug|Cisplatin|Chemotherapy Agent
79244977|NCT03732677|Drug|Gemcitabine|Chemotherapy agent
79244978|NCT03718312|Procedure|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
79244979|NCT03706261|Drug|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
79244980|NCT03706261|Drug|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
79244981|NCT03704662|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79384024|NCT01853163|Procedure|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.
79384025|NCT03298620|Other|Electric toothbrush|
79384026|NCT03298620|Other|Control|Manual toothbrush
79384027|NCT03360136|Behavioral|Multi-professional CBT-rehabilitation|"See Detailed description"
79384028|NCT03298542|Drug|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
79384029|NCT03298542|Drug|Placebo|Matching placebo to golimumab.
79384030|NCT03350698|Biological|Gardasil-9|3 vaccine series
79384031|NCT03296670|Drug|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
79538600|NCT05224141|Biological|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
79538601|NCT05224141|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
79538602|NCT05222178|Drug|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
79538603|NCT05215977|Drug|MW031|"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
79696071|NCT04654572|Diagnostic Test|Myotonometric measurement|Myotonometric assessment can predict the muscle stiffness, tone and elasticity
79696072|NCT02906306|Behavioral|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
80010745|NCT02950922|Drug|RVT-501 0.2% ointment|
79696073|NCT02906306|Behavioral|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
79696074|NCT04626531|Other|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
79244982|NCT03704662|Radiation|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
79384032|NCT03296670|Drug|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
79696075|NCT04626531|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
79696076|NCT02906384|Radiation|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
79696077|NCT04626414|Drug|Ferric maltol capsule|single dose of 30 mg capsule
79696078|NCT04626414|Drug|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
79696079|NCT02906267|Other|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
79696080|NCT04654611|Drug|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
79696081|NCT02906228|Radiation|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
79696082|NCT04654416|Drug|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
79696083|NCT02906189|Radiation|MRI|
79696084|NCT02906150|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
79696085|NCT02906150|Drug|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
79244983|NCT03665675|Biological|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
79696086|NCT04626453|Behavioral|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
79244984|NCT03664648|Biological|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
79244985|NCT03648450|Other|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
79384033|NCT02463864|Other|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
79384034|NCT02463864|Other|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
79384035|NCT01976260|Device|Fractional Radiofrequency|
79384036|NCT01976260|Device|1550-nm Fractional Photothermolysis|
79384037|NCT03296514|Behavioral|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
79384038|NCT03328468|Other|Breathing Exercise|Breathing exercise for stroke patients
79384039|NCT03296436|Biological|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
79384040|NCT03298464|Biological|NGM313|Subcutaneous injection
79696087|NCT00561990|Drug|Nimotuzumab|
79696088|NCT02906072|Behavioral|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
79696089|NCT02906072|Behavioral|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
79696090|NCT04654728|Procedure|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
79696091|NCT02906111|Drug|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
79696092|NCT02906111|Procedure|vaginal surgery|Control Group
79696093|NCT00562029|Procedure|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
79696094|NCT02905916|Drug|PEG-rhG-CSF|
79244986|NCT03624660|Radiation|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
80010746|NCT02950922|Drug|RVT-501 0.5% ointment|
80010747|NCT02950922|Other|Vehicle ointment|Placebo comparator
79696095|NCT04626492|Diagnostic Test|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
79696096|NCT02905994|Drug|Volasertib|Polo-Like Kinase Inhibitor
79696097|NCT02905994|Drug|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
79696098|NCT02905994|Drug|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
79696099|NCT02905994|Procedure|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
79538604|NCT05215977|Drug|Placebo|"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
79244987|NCT03624660|Radiation|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
79384041|NCT03298464|Drug|Pioglitazone|White to off-white round tablet
79696100|NCT04626336|Procedure|Cystectomy|Cystectomy
79244988|NCT03619551|Drug|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
79244989|NCT03619551|Device|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
79244990|NCT03614026|Behavioral|Teachers and Parents as Partners|Family-school partnership intervention
79244991|NCT03581448|Behavioral|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
79384042|NCT03287596|Device|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
79244992|NCT03546972|Other|Behavioral, Psychological or Informational Intervention|Take part in DDP
79244993|NCT03546972|Other|Behavioral, Psychological or Informational Intervention|Take part in HT
79384043|NCT01852071|Genetic|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
79696101|NCT02905955|Device|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
79696102|NCT04654767|Other|Tissue sampling|"Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls."
79696103|NCT02905877|Other|Behavioural study|reaching studies and other behavioural studies.
79696104|NCT04626180|Procedure|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
79696105|NCT04626180|Procedure|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
79696106|NCT02905682|Drug|Desmopressin|
79696107|NCT02905682|Drug|Placebo|
79244994|NCT03546972|Other|Questionnaire Administration|Ancillary studies
79244995|NCT03522753|Device|Metal skin staples|Routine closure methods/material for surgical wounds
79244996|NCT03522753|Device|Nylon sutures|Routine closure methods/material for surgical wounds
79244997|NCT03507686|Drug|BIIB111|Administered as specified in the treatment arm.
79384044|NCT01852071|Drug|busulfan|Busulfan is used for non-myeloablative conditioning
79384045|NCT01852071|Drug|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
79384046|NCT03219736|Procedure|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
79538605|NCT05212766|Biological|COVID infection|Infections with COVID 19
79538606|NCT05212766|Biological|COVID vaccination|Vaccination against COVID 19
79538607|NCT05212766|Diagnostic Test|Oral examination|Assessment of oral and periodontal health status
79538608|NCT05211570|Drug|AB8939|Intravenous injection (from an initial dose of 0.9 mg/m²)
79538609|NCT05211570|Drug|Azacitidine|Subcutaneous injection (75 mg/m²)
79538610|NCT05206435|Drug|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
79538611|NCT05206435|Drug|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
79696108|NCT04654377|Other|Personalised education|Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
79696109|NCT04626258|Drug|Fluconazole|Fluconazol once a month 150 mg capsule
79696110|NCT04626258|Other|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
79840521|NCT02550678|Biological|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
79840522|NCT02550678|Drug|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
79840523|NCT00293215|Drug|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
79840524|NCT00293215|Drug|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
79696111|NCT04626102|Behavioral|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
79384047|NCT03219736|Device|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
79538612|NCT05204472|Device|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
79696112|NCT04626102|Behavioral|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
79696113|NCT02905604|Device|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
79840525|NCT00822744|Drug|SSR411298|"Form: capsule~Route: oral administration with food"
79696114|NCT02905604|Device|dmPFC Sham iTBS|Sham iTBS
79840526|NCT00822744|Drug|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
79244998|NCT03506451|Other|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
79244999|NCT03471507|Drug|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
79245000|NCT03471507|Drug|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
79384048|NCT03219736|Procedure|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
79384049|NCT04084548|Drug|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
79696115|NCT04626219|Other|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
79696116|NCT04626219|Behavioral|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
79696117|NCT04626219|Behavioral|regulated meals|standardized diet from noon until 9 a.m. the next day
79840527|NCT00822744|Drug|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
79840528|NCT04102787|Other|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
79840529|NCT01065337|Biological|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
79840530|NCT01065337|Biological|bone marrow stem cells (BMC)|bone marrow stem cells
79840531|NCT00819468|Drug|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
79840532|NCT04102553|Drug|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
79840533|NCT04102553|Drug|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
79245001|NCT03459222|Biological|Relatlimab|Specified dose on specified days
79245002|NCT03459222|Biological|Nivolumab|Specified dose on specified days
79245003|NCT03459222|Drug|BMS-986205|Specified dose on specified days
79245004|NCT03459222|Biological|Ipilimumab|Specified dose on specified days
79245005|NCT03338894|Behavioral|Yoga|1 Hour yoga class
79245006|NCT03307980|Biological|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
79696118|NCT04626063|Drug|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
79696119|NCT04626063|Drug|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
79840534|NCT01067599|Other|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
79840535|NCT01067599|Other|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
79840536|NCT01067599|Other|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
79840537|NCT00822822|Behavioral|First Questionnaire|Complete questionnaire before completing health history
79840538|NCT00822822|Behavioral|Health History|Complete electronic health history
79840539|NCT00822822|Behavioral|Second Questionnaire|Complete questionnaire after completing electronic health history
79840540|NCT02601131|Biological|Platelet transfusion|
79840541|NCT00778817|Biological|IMC-A12|Given IV
79840542|NCT00778817|Drug|mitotane|Given orally
79840543|NCT00293059|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
79840544|NCT00293059|Drug|Placebo|Matching placebo to be taken orally daily.
79538613|NCT05204472|Device|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
79840545|NCT00756275|Drug|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
79840546|NCT00756275|Drug|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
79840547|NCT00756275|Behavioral|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
79840548|NCT02601053|Other|Dull movie|A dull movie (duration approximately 90 minutes)
79696120|NCT04626063|Drug|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
79840549|NCT02601053|Other|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
79840550|NCT02601053|Other|Heart rate measurement|Heart rate measurement using a actiheart device
79840551|NCT01065493|Other|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
79840552|NCT01065493|Behavioral|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
79840553|NCT00758459|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
79384050|NCT04084548|Drug|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
79384051|NCT04084548|Drug|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
79384052|NCT04084548|Drug|Placebo|Perioperative placebo infusion (normal saline)
79840554|NCT00758459|Drug|Placebo|Dosing to match AZD1236
79840555|NCT03977389|Procedure|Total wrist denervation|Study of the files
79840556|NCT05460143|Other|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
79840557|NCT05460143|Other|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
79840558|NCT04096547|Drug|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
79384053|NCT02059642|Drug|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
79384054|NCT02059642|Drug|placebo|Placebo 1400 mg administered orally once daily
79391826|NCT02404428|Dietary Supplement|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
79245007|NCT03250026|Behavioral|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
79245008|NCT03250026|Behavioral|Care Manager|Regular contact Care Manager during around 12 weeks
79245009|NCT03243734|Device|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
79840559|NCT02600975|Biological|R21 with ASO1B|R21 with ASO1B
79538614|NCT05203614|Behavioral|Household Contribution|Questionnaires
79538615|NCT05203614|Behavioral|Outside Contribution|Questionnaires
79538616|NCT05203614|Behavioral|Control|Questionnaires
79840560|NCT00298831|Drug|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
79245010|NCT03138564|Behavioral|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
79840561|NCT00298831|Drug|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
79840562|NCT02532595|Procedure|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
79840563|NCT02532595|Procedure|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
79840564|NCT00758069|Drug|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
79245011|NCT03138564|Behavioral|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
79840565|NCT00758069|Drug|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
79840566|NCT00758069|Drug|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
79840567|NCT01067677|Drug|Metaclopramide|0.5 mg/kg for rescue after PONV
79840568|NCT01067677|Drug|Ondansetron|0.1 mg/kg (max 4 mg0
79245012|NCT03137407|Biological|Botulinum Toxins, Type A|Intramuscular injection
79245013|NCT03137407|Biological|Placebo|Intramuscular injection
79538617|NCT05198570|Other|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
79538618|NCT05198479|Radiation|77 Lu-DOTA0-Tyr3-Octreotate|Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
79840569|NCT01067677|Drug|diphenhydramine|0.25 mg/kg (max 25 mg)
79840570|NCT01067677|Drug|Saline|equal volume (5 ml)as experimental rescue medications
79245014|NCT03114150|Behavioral|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
79840571|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
79840572|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
79840573|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
79538619|NCT05196308|Drug|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
79538620|NCT05196308|Drug|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
79245015|NCT03114150|Behavioral|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
79245016|NCT03063320|Other|Spice blend|Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
79384055|NCT03296358|Drug|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
79384056|NCT03296358|Drug|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
79538621|NCT05192330|Device|Virtual Reality Glasses|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
79538622|NCT05192330|Behavioral|Therapeutic Touch|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
79538623|NCT05187377|Drug|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
79538624|NCT05187377|Drug|Saline|Placebo (saline) will be administered subcutaneously once daily.
79538625|NCT05186688|Behavioral|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
79538626|NCT05186636|Other|KPI reports|Quarterly
79538627|NCT05186636|Other|Prescriber reports|Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
79538628|NCT05184478|Drug|Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|"Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing <50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing <50kg) or 2mL (participants ≥50kg) is reached."
79538629|NCT05184478|Drug|Placebo|"The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase."
79538630|NCT05182749|Biological|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
79538631|NCT05182749|Other|Placebo|Placebo orally administered with sodium bicarbonate solution
79538632|NCT05178030|Other|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
79245017|NCT02923180|Drug|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
79696121|NCT04681976|Behavioral|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
79696122|NCT04625985|Drug|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
79696123|NCT04625985|Drug|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
79245018|NCT02846103|Other|Biological samples|blood and tumor tissue samples
79384057|NCT04756323|Biological|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
79384058|NCT04756323|Biological|high dosage inactivated SARS-CoV-2 vaccine|high dosage
79384059|NCT04756323|Biological|Placebo|placebo
79245019|NCT02836717|Device|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
79245020|NCT02743494|Drug|Nivolumab|Specified dose on specified days
79245021|NCT02743494|Other|Placebo|Specified dose on specified days
79245022|NCT02722538|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
79245023|NCT02667873|Drug|SL-801|SL-801 is a small molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
79245024|NCT02531126|Drug|RPC1063|
79696124|NCT02905760|Drug|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
79696125|NCT02905760|Drug|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
79840574|NCT02600741|Other|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
79245025|NCT02401503|Drug|Bendamustine|Debulking: Cycles 1-2, d1 & 2: 70mg/m² i.v.
79245026|NCT02401503|Drug|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
79245027|NCT02401503|Drug|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
79538633|NCT05169970|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
79538634|NCT05169970|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
79538635|NCT05169359|Behavioral|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
79538636|NCT05168618|Biological|Atezolizumab|Given IV
79538637|NCT05168618|Drug|Cabozantinib S-malate|Given PO
79538638|NCT05166512|Behavioral|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
79538639|NCT05166512|Behavioral|DPP|Standard DPP
79538640|NCT05143255|Behavioral|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
79696126|NCT02905760|Drug|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
79696127|NCT02905760|Drug|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
79696128|NCT04653987|Procedure|Percutaneous biliary drainage|
79245028|NCT02399423|Behavioral|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
79245029|NCT02399423|Behavioral|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
79245030|NCT02336282|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level < 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
79245031|NCT02336282|Device|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
79384060|NCT03298386|Other|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
79384061|NCT04756713|Procedure|Uterine curettage|Manual or electric vacuum aspiration under ultrasound guidance.
79696129|NCT02905526|Behavioral|Contraceptive instant messages|Contraceptive Instant messages
79696130|NCT02905526|Other|Mobile phone app|Mobile phone app
79696131|NCT02905565|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
79696132|NCT02905565|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
79696133|NCT04654065|Drug|IN-C004|One time dose of IN-C004 taken orally.
79696134|NCT04654221|Diagnostic Test|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
79696135|NCT04654182|Drug|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
79696136|NCT02905409|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
79696137|NCT04625712|Procedure|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
79840575|NCT02600741|Other|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
79840576|NCT02600741|Drug|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
79840577|NCT02600741|Drug|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79696138|NCT02905448|Other|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
79840578|NCT02600741|Drug|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79245032|NCT02336282|Other|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
79538641|NCT05138380|Device|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist > 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
79840579|NCT02600741|Drug|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79245033|NCT02336282|Other|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
79245034|NCT02272998|Drug|ponatinib hydrochloride|Given PO
79245035|NCT02272998|Other|laboratory biomarker analysis|Correlative studies
79384062|NCT04756713|Drug|Chemotherapy|conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
79391827|NCT02404428|Dietary Supplement|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
79391828|NCT03115554|Procedure|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
79538642|NCT05138380|Device|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist > 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
79538643|NCT05133596|Other|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
79538644|NCT05133596|Other|Blood collection|12ml-blood sample
79840580|NCT02600741|Drug|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840581|NCT02600741|Drug|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840582|NCT02600741|Drug|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840583|NCT02600741|Drug|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840584|NCT02600741|Drug|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840585|NCT02600741|Drug|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840586|NCT02600741|Drug|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79245036|NCT02272842|Dietary Supplement|Vitamin B12|Vitamin B12 in a multivitamin paste.
79245037|NCT02258659|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
79245038|NCT02258659|Drug|carboplatin|Given IV
79245039|NCT02258659|Radiation|radiation therapy|Undergo radiation therapy
79245040|NCT02258659|Drug|paclitaxel|Given IV
79245041|NCT02258659|Drug|fluorouracil|Given IV
79245042|NCT02258659|Drug|hydroxyurea|Given PO
79245043|NCT02258659|Drug|cisplatin|Given IV
79245044|NCT02258659|Other|laboratory biomarker analysis|Correlative studies
79696139|NCT04653870|Other|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams & Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
79696140|NCT04653870|Other|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
79840587|NCT02600741|Drug|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840588|NCT02600741|Drug|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79245045|NCT02258659|Procedure|quality-of-life assessment|Ancillary studies
79840589|NCT02600741|Drug|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840590|NCT02600741|Drug|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79384063|NCT04489056|Genetic|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
79384064|NCT00469755|Drug|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
79840591|NCT02600741|Drug|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840592|NCT02600741|Drug|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840593|NCT02600741|Drug|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840594|NCT02600741|Drug|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840595|NCT02600741|Drug|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840596|NCT02600741|Drug|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
79840597|NCT03979573|Diagnostic Test|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
79245046|NCT02064673|Drug|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
79245047|NCT02064673|Drug|placebo|placebo orally twice a day
79245048|NCT01990300|Drug|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
79245049|NCT01909934|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion
79538645|NCT05133596|Other|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
79245050|NCT01811303|Other|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
79245051|NCT01740648|Drug|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
79245052|NCT01740648|Drug|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
79538646|NCT05133596|Other|Brushing of olfactory slits|collection of olfactory slits cells.
79538647|NCT05133596|Other|Neurological examination and neuropsychological assessment|"MOCA, BREF~CVLT~WAIS IV, MEM III~Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~Benton's Line Judgement, VOSP~Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression & anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
79538648|NCT05133596|Other|Nasal endoscopy|Nasal endoscopy
79538649|NCT05133596|Other|Assessment of olfactory and taste functions|"scales: VAS and TSS~Sniffin Stick test"
79538650|NCT05131113|Other|Physical exercise|Physical exercise
79538651|NCT05120375|Drug|BAT6021|Ⅳ infusions
79538652|NCT05115695|Other|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
79384065|NCT00469755|Drug|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
79696141|NCT02905292|Other|evaluation and treatment maneuver for BPPV|
79696142|NCT04654026|Drug|Aspirin/Clopidogrel|No intervention, only observational studies
79696143|NCT04681703|Behavioral|Nurse-led program on accuracy of blood pressure self-measurement|The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
79696144|NCT02905253|Drug|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
79840598|NCT03979573|Diagnostic Test|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
79840599|NCT03979573|Diagnostic Test|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
79538653|NCT05115695|Other|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
79696145|NCT02905253|Drug|Placebo|Placebo capsules matching AC-084 capsules
80010748|NCT04059627|Device|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
79245053|NCT01740648|Radiation|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
79245054|NCT01697566|Drug|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
79245055|NCT01697566|Other|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
79245056|NCT01697566|Procedure|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
79245057|NCT01697566|Behavioral|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
79384066|NCT00469755|Drug|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
79384067|NCT02463396|Behavioral|MBCT for ADHD|
79384068|NCT00458133|Behavioral|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching & relaxing groups.
79384069|NCT01824771|Other|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
79384070|NCT03296046|Biological|Blood test|30 ml
79538654|NCT05104866|Drug|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
79538655|NCT05104866|Drug|Capecitabine|Tablet. Oral route of administration. Active comparator
79538656|NCT05104866|Drug|Gemcitabine|IV Infusion. Active comparator
79538657|NCT05104866|Drug|Eribulin|IV Infusion. Active comparator
79538658|NCT05104866|Drug|Vinorelbine|IV Infusion. Active comparator
79538659|NCT05089409|Drug|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
79538660|NCT05089409|Drug|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
79245058|NCT01697566|Behavioral|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
79384071|NCT00453531|Procedure|Limb Ischemia|
79384072|NCT00453531|Drug|Acetylcholine|
79384073|NCT03295968|Other|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
79384074|NCT03298308|Device|Cranial Electric Stimulation|Micro amperage TCDS
79384075|NCT01812291|Behavioral|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~Diabetes problem analysis/ definition~Diabetes problem solving intervention~Cognitive restructuring of diabetes problems~Activation of personal and social resources~Goal definition and agreement"
79538661|NCT05089409|Drug|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
79245059|NCT01638442|Drug|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
79538662|NCT05089409|Drug|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
79245060|NCT01638442|Drug|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------"
79245061|NCT01368055|Radiation|70 Gy/CGE|Low Risk
79538663|NCT05089409|Drug|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
79538664|NCT05089409|Other|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
79538665|NCT05086796|Behavioral|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~Triage~Engage, Assess, and Plan~Treat~Communicate and Coordinate~Follow up~Monitor"
79245062|NCT01368055|Radiation|72.5 Gy/CGE|Intermediate Risk
79538666|NCT05085574|Drug|Famotidine|80 mg tablet, QID for 14 days
79696146|NCT04625868|Other|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
79696147|NCT02905175|Procedure|blood sample|
79696148|NCT02905175|Procedure|synovial tissue|synoviocytes from synovial tissue
79696149|NCT04653909|Other|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
79696150|NCT04625595|Drug|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
79245063|NCT01189708|Device|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
79696151|NCT04625595|Drug|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
79696152|NCT04625595|Drug|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
79245064|NCT01189708|Other|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
79384076|NCT01812291|Behavioral|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~Functional explanatory model of depression~Cognitive restructuring of negative thoughts~Practice of alternative beneficial thoughts~Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
79384077|NCT01812291|Behavioral|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
79696153|NCT04625595|Drug|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
79245065|NCT01076400|Drug|adavosertib|Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
79245066|NCT01076400|Drug|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
79245067|NCT01076400|Drug|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
79245068|NCT01076400|Drug|Placebo to adavosertib|Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
79245069|NCT01000051|Drug|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
79696154|NCT02905058|Drug|Ketoprofen|oral non-steroidal antiinflammatory drug
79696155|NCT02905058|Drug|placebo|
79696156|NCT00557661|Drug|CD-NP|24 hr intravenous infusion
79245070|NCT01000051|Drug|Placebo|Once a day, orally for 8 weeks.
79245071|NCT00953160|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
79245072|NCT00934895|Drug|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
79391829|NCT03115554|Procedure|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
79538667|NCT05085574|Drug|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
79696157|NCT02905136|Other|Fundamental research|serum, whole blood, cerebrospinal fluid
79696158|NCT03454854|Device|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
79696159|NCT02905097|Procedure|Knee Replacement|Surgical replacement of arthritic knee with an implant
79696160|NCT03454815|Procedure|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
79538668|NCT05085574|Drug|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
79696161|NCT02905019|Biological|R21 with Matrix-M1|Vaccine
79696162|NCT02905019|Biological|ChAd63 ME-TRAP|Vaccine
79538669|NCT05084729|Device|Imagio OA/US|Imagio optoacoustic
79538670|NCT05084248|Drug|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
79696163|NCT02905019|Biological|MVA ME-TRAP|Vaccine
79696164|NCT03454776|Device|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
79840600|NCT03979573|Diagnostic Test|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
79840601|NCT01325545|Other|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
79840602|NCT01067755|Device|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
79840603|NCT01065649|Drug|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
79538671|NCT05081687|Drug|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
79538672|NCT05081674|Drug|Alectinib|600mg 1OD
79840604|NCT01065649|Drug|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
79245073|NCT00934895|Drug|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
79245074|NCT00913497|Drug|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
79384078|NCT01812291|Behavioral|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~Health care and specific topics (e. g. blood pressure)~Diabetes complications~Healthy and unhealthy foods, cooking recommendations and recipes~Foot care: exercises, care and control, injuries, and diabetic neuropathy~Sports, activities and exercise~Social aspects of living with diabetes"
79384079|NCT03298230|Behavioral|REmotely SuPervised Exercise Training|As described in the Arms section.
79384080|NCT03298230|Behavioral|Supervised Exercise Training|As described in the Arms section.
79384081|NCT02461524|Device|Endurant Evo AAA Stent Graft System|
79538673|NCT05081674|Drug|Pembrolizumab|200mg every 21 days
79840605|NCT01062685|Diagnostic Test|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
79840606|NCT01065727|Other|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
79840607|NCT01065727|Other|natalizumab|monthly natalizumab during 3 years
79245075|NCT00913497|Drug|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
79384082|NCT02461524|Procedure|Endovascular aneurysm repair (EVAR)|
79384083|NCT02087163|Device|Movement Enhancement Technique|Conventional Orthodontic treatment
79384084|NCT02087163|Device|Clear Aligner|Orthodontic treatment with Clear Aligner
79384085|NCT03298152|Procedure|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
79384086|NCT03298152|Procedure|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
79384087|NCT00443001|Device|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
79384088|NCT01892592|Behavioral|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
79384089|NCT02318979|Device|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
79538674|NCT05081674|Drug|Nivolumab|6mg/kg every 4 weeks
79538675|NCT05081674|Drug|Erlotinib|150mg
79538676|NCT05077332|Drug|Famotidine|80 mg tablet, QID for 14 days
79538677|NCT05077332|Drug|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
79538678|NCT05077332|Other|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
79538679|NCT05076708|Other|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
79538680|NCT05076006|Drug|PF-06700841|Active study drug
79538681|NCT05076006|Drug|Placebo|placebo comparator
79538682|NCT05073484|Drug|BAT6021|Ⅳ infusions
79538683|NCT05073484|Drug|BAT1308|Ⅳ infusions
79696165|NCT03454776|Device|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
79696166|NCT02904941|Biological|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
79696167|NCT02904941|Device|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
79840608|NCT01067833|Drug|K201 Tablet|oral tablet, x28 days
79840609|NCT01067833|Drug|Placebo Tablet|oral tablet, x28 days
79840610|NCT01065805|Biological|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
79840611|NCT01067911|Dietary Supplement|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
79840612|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
79840613|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
79840614|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
79840615|NCT00311623|Drug|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
79840616|NCT00311623|Drug|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
79840617|NCT00311623|Procedure|Radical prostatectomy|Radical prostatectomy performed on Day 15
79840618|NCT01067989|Drug|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~Capecitabine Tab. 500mg, 1+2/day, continuously.~Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~Celecoxib Tab. 200mg, 1x2/day, continuously.~Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
79840619|NCT00528112|Drug|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
79303515|NCT03305939|Behavioral|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~simple healthy eating and moderate physical activity messages;~behavioral skills such as problem solving/goal setting/self-monitoring; and~enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
79840620|NCT00528112|Drug|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
79840621|NCT00633594|Drug|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
79840622|NCT00633594|Drug|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
80010749|NCT02184728|Device|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
79384090|NCT02318979|Device|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
79696168|NCT02904941|Procedure|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
79696169|NCT03454737|Procedure|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
79840623|NCT00633594|Drug|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
79840624|NCT03742648|Other|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
79840625|NCT00817128|Procedure|PEPT|Pain Exposure Physical Therapy
79384091|NCT02318979|Device|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
79384092|NCT03298074|Drug|Apatinib|Apatinib, 500mg,po qd for continuous administration
79384093|NCT03298074|Drug|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
79384094|NCT03295890|Procedure|Dry Needing|Dry Needling
79384095|NCT03297996|Diagnostic Test|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
79391830|NCT02561338|Drug|HMS5552|75mgQD
79391831|NCT02561338|Drug|HMS5552|100mgQD
79696170|NCT03454737|Procedure|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
79696171|NCT02904980|Behavioral|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
79696172|NCT02904980|Behavioral|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
79696173|NCT04625322|Other|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
80010750|NCT03469791|Procedure|Surgical treatment of Degenerative Spondylolisthesis|
79245076|NCT00911118|Radiation|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if < 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
79245077|NCT00693238|Radiation|Low Risk Proton Radiation|
79384096|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
80010751|NCT02184806|Procedure|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
80010752|NCT02184806|Procedure|heterotopic graft|"put under the skin~the ovarian fragments can be put under the skin of the abdomen"
79384097|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
79538684|NCT05073224|Diagnostic Test|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
79696174|NCT02904824|Biological|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
79696175|NCT02904824|Biological|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
79696176|NCT04653519|Device|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
79840626|NCT00817128|Procedure|CBO standard|Standard therapy as defined in CBO guideline 2006
79840627|NCT04840888|Drug|LY3484356|Administered orally.
79840628|NCT04840888|Drug|Omeprazole|Administered orally.
80010753|NCT02185898|Other|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
79245078|NCT00693238|Radiation|Intermediate Risk Proton Radiation|
79245079|NCT00556933|Drug|rabbit anti-thymocyte globulin - single dose|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
79303516|NCT03305861|Procedure|ThuLEP|Thulium laser enucleation of prostate
79384098|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
79384099|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
79384100|NCT01992874|Drug|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
79384101|NCT04489836|Dietary Supplement|Glutalytic®|Glutalytic® capsule
79384102|NCT04489836|Dietary Supplement|DE111®|DE111® capsule
79391832|NCT02561338|Drug|HMS5552|50mgBID
80010754|NCT02185898|Other|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
80010755|NCT02185898|Other|Electronic cigarette #1|Electronic cigarette
80010756|NCT02185898|Other|Electronic cigarette #2|Electronic cigarette
80010757|NCT02185898|Other|Electronic cigarette #3|Electronic cigarette
80010758|NCT02185898|Other|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
80010759|NCT02185976|Other|cartoon|5 different cartoons which will be recorded on a tablet PC.
80010760|NCT02186054|Device|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
79245080|NCT00556933|Drug|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
79538685|NCT05073224|Other|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
79245081|NCT00556933|Drug|rabbit anti-thymocyte globulin - 4 doses|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
79384103|NCT04489836|Other|Meal A|Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
79384104|NCT04755621|Other|Core stability training|Core stability exercises
79384105|NCT04755621|Other|Rocabado Exercises|Exercises for Temporomandibular Disorders
79384106|NCT01804179|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
79384107|NCT01804179|Other|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
79384108|NCT01804179|Other|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
79538686|NCT05073224|Other|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
79538687|NCT05073224|Diagnostic Test|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
79384109|NCT01804179|Other|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
79538688|NCT05067998|Dietary Supplement|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
79538689|NCT05067998|Drug|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
79696177|NCT02904746|Behavioral|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
79696178|NCT02904785|Device|Extracorporeal Shock Waves|
79696179|NCT02904785|Device|Sham Extracorporeal Shock Waves|
79696180|NCT02904785|Other|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
79696181|NCT01212991|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
79840629|NCT04840888|Drug|Itraconazole|Administered orally.
79840630|NCT04840888|Drug|Carbamazepine|Administered orally.
80010761|NCT02030444|Procedure|PET-MRI and EBUS-TBNA|
79245082|NCT00556933|Drug|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
79384110|NCT01804179|Other|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
79391833|NCT02561338|Drug|HMS5552|75mgBID
79696182|NCT01212991|Drug|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
79696183|NCT04625439|Behavioral|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
79840631|NCT04944160|Other|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
79245083|NCT00556933|Drug|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
79840632|NCT04944160|Other|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
79840633|NCT04707976|Device|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
79840634|NCT04707976|Other|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
79840635|NCT00755807|Drug|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
79840636|NCT00755807|Drug|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams [mg] QD for 12 weeks).
79840637|NCT03998644|Other||
79840638|NCT05372224|Drug|Cholecalciferol|4000 IU were administrated once a day for 3 months.
79245084|NCT00539162|Behavioral|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
79245085|NCT00503880|Biological|filgrastim|subcutaneously one day prior to treatment
79384111|NCT04755543|Drug|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
79384112|NCT04755543|Drug|Cisplatin|50mg/m2 IV on Day 1, Q2W
79384113|NCT04755543|Drug|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
79538690|NCT05062317|Drug|Leucovorin|Given by PO
79538691|NCT05062317|Drug|5-FLUOROURACIL|Given by IV
79538692|NCT05062317|Drug|Oxaliplatin|Given by PO
79538693|NCT05062317|Drug|Irinotecan|Given by IV
79538694|NCT05062317|Drug|Capecitabine|Given by IV
79538695|NCT05062317|Drug|Bevacizumab|Given by IV
79538696|NCT05055258|Drug|KVD824|KVD824 300 mg Modified-Release Tablets
79538697|NCT05055258|Drug|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
79538698|NCT05049577|Device|Analgesia/Nociception Index (ANI)|V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
79840639|NCT04638322|Other|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
79840640|NCT04819594|Other|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
79840641|NCT00916019|Other|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
79840642|NCT00631410|Drug|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
79245086|NCT00503880|Drug|clofarabine|single IV dose over 1 hour daily for 5 days
79245087|NCT00503880|Drug|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
79245088|NCT00503880|Genetic|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
79245089|NCT00503880|Procedure|biopsy|bone marrow biopsy
79245090|NCT00378326|Drug|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
79245091|NCT00280917|Drug|CF101|
79303517|NCT03305861|Procedure|Green LEP|Greenlight laser enucleation of prostate
79303518|NCT03305705|Drug|Iron Carboxymaltose|Single intravenous infusion within 20 min
79303519|NCT03305705|Drug|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
79384114|NCT04755543|Biological|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
79384115|NCT01993108|Drug|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
79384116|NCT01993108|Drug|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
79384117|NCT01993108|Drug|Placebo|One dose of placebo one hour before fMRI scanning.
79384118|NCT00437151|Other|More frequent than normal office visits|Mode of patient reminder
79384119|NCT00437151|Other|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
79384120|NCT00437151|Other|Parenteral involvement / intervention reminders|Mode of patient reminder
79384121|NCT00437151|Other|No intervention or reminders|Mode of patient reminder
79391834|NCT02561338|Other|Placebo|QD/BID
79696184|NCT02904551|Procedure|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
79696185|NCT02904551|Procedure|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
79696186|NCT04625400|Diagnostic Test|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
79384122|NCT02307526|Drug|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
79696187|NCT02904434|Other|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
79696188|NCT04653792|Drug|Pregabalin 75mg|75 mg capsule
79696189|NCT04653792|Device|Placebo|75 mg
79696190|NCT02904473|Other|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
79696191|NCT04625010|Other|Swaddling|Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
79840643|NCT00631410|Drug|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
79840644|NCT04097951|Drug|Combinations|Montelukast and Bepotastine Combination
79840645|NCT04096469|Behavioral|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
80010762|NCT03684681|Behavioral|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
80010763|NCT03684681|Behavioral|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
80010764|NCT03677505|Device|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
79384123|NCT02307526|Device|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
79384124|NCT02307838|Other|Assessments arm|Protocol required assessments not provided in standard of care
79840646|NCT04096469|Behavioral|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
80010765|NCT03677505|Device|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
80010766|NCT02805660|Drug|Mocetinostat - 50 mg|Participants received mocetinostat three times weekly as an oral capsule.
79384125|NCT01371201|Drug|Sunitinib|sunitinib 37.5 mg per day
79384126|NCT01371201|Drug|Placebo|Placebo 37.5 mg per day
79384127|NCT00436527|Drug|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
79384128|NCT02307916|Drug|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
79538699|NCT05048979|Other|Exercise|Telehealth-facilitated supervised exercise program. Veterans with PAD will be enrolled in a 12-week, 3 day a week, aerobic training program in a self-selected location.
79538701|NCT05033821|Behavioral|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
79384129|NCT02307916|Other|Placebo|Placebo comparator using a sterile saline solution.
79384130|NCT00433563|Radiation|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
79384131|NCT00433563|Radiation|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
79696192|NCT04625010|Other|Maternal holding|Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
79696193|NCT02904668|Other|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
79840647|NCT00822978|Drug|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
80010767|NCT02805660|Drug|Mocetinostat - 70 mg|Participants received mocetinostat three times weekly as an oral capsule.
79538702|NCT05030675|Drug|Fostamatinib|Given PO
80010768|NCT02805660|Drug|Mocetinostat - 90 mg|Participants received mocetinostat three times weekly as an oral capsule.
79384132|NCT00419367|Drug|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
79384133|NCT01994746|Drug|Nasal Glucagon|
79384134|NCT01994746|Drug|Intramuscular Glucagon|
79384135|NCT05333601|Behavioral|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
79384136|NCT01722916|Drug|Hyaluronidase|
79384137|NCT01795677|Drug|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
79538703|NCT05027490|Other|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
79538704|NCT05027490|Other|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
79538705|NCT05027490|Other|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
79538706|NCT05027490|Behavioral|QVA Questionnaire|Food quality of life questionnaire
79538707|NCT05027490|Behavioral|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
79538708|NCT05027490|Behavioral|Scratch & Snif Test|The Scratch & Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
79538709|NCT05027490|Behavioral|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
79538710|NCT05027490|Behavioral|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
79538711|NCT05027490|Behavioral|Condiment questionnaire|This questionnaire used to assess condiments consumption
79538712|NCT05027490|Behavioral|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
79538713|NCT05027490|Other|Nutrition interview|This interview will be conducted by a dietician
79696194|NCT02904707|Other|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
79696195|NCT02904395|Other|observational (no intervention)|
79384138|NCT01347177|Procedure|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
79696196|NCT04653441|Behavioral|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
79840648|NCT02599883|Radiation|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
79840649|NCT03686176|Other|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
80010769|NCT02805660|Drug|Mocetinostat - Recommended Phase 2 Dose (70 mg)|Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
80010770|NCT02805660|Drug|Durvalumab - 1500 mg|Participants received durvalumab as an intravenous infusion every 4 weeks.
80010771|NCT02186132|Drug|Atropine 0.6 mg|Atropine 0.6 mg intravenous
79384139|NCT01347177|Procedure|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
79384140|NCT04489290|Device|D005 Vaginal Mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
79384141|NCT04489290|Other|Placebo|Placebo
79384142|NCT01999192|Drug|Tregalizumab|humanized anti-CD4 mAb
79384143|NCT01999192|Drug|Placebo|identical end formulation buffer
79384144|NCT00291525|Device|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
79384145|NCT00291525|Device|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
79384146|NCT04030650|Other|Functional analyses|2-minute walking test 200-metre walking test
80010772|NCT02186132|Drug|Atropine 1.2 mg|Atropine 1.2 mg intravenous
80010773|NCT03682419|Procedure|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
80010774|NCT03682419|Procedure|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
80010775|NCT02030522|Behavioral|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
80010776|NCT02181764|Drug|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
80010777|NCT03536156|Other|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
79245092|NCT00271739|Device|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
80010778|NCT02184884|Device|MACE after OPCAB|
79245093|NCT00271739|Other|usual care|usual diabetes care, as provided by primary care providers
79245094|NCT00106600|Drug|Pixantrone IV infusion|
79245095|NCT00006478|Biological|autologous tumor cell vaccine|
79538714|NCT05017688|Procedure|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
79384147|NCT04030650|Other|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
79538715|NCT05011890|Device|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
79538716|NCT05005819|Drug|[18F] APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
79538717|NCT04988282|Drug|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
79538718|NCT04985513|Procedure|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
79538719|NCT04983654|Diagnostic Test|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~Microvascular analysis (laser doppler, TcPO2),~Neurological analysis ( sensitivity testing with thermal and mechanical test),~Analysis of physical characteristics of red blood cells and inflammatory marks,~Analysis of cytokine and metalloproteases in the wound fluid,~Assessment of healing according usual treatment"
80010779|NCT02184884|Device|without MACE after OPCAB|
80010780|NCT03536780|Drug|Avelumab and Gemcitabine|"Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
80010781|NCT02052336|Drug|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
80010782|NCT02052336|Drug|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
80010783|NCT02052336|Drug|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
79245096|NCT00006478|Biological|keyhole limpet hemocyanin|
79245097|NCT00006478|Biological|sargramostim|
79245098|NCT00006478|Procedure|adjuvant therapy|
79245099|NCT05850221|Other|weight training|weight training
79245100|NCT05850208|Biological|Transplantation of self BMSCs|Bone marrow was collected, cultured in vitro and injected back into the body
79245101|NCT05850195|Other|non invasive ventilation|compare indices and diaphragmatic ultrasonography for prediction of NIV failure in acute RF patients
79245102|NCT05850182|Behavioral|Lifestyle intervention|12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
79384148|NCT04030650|Other|Functional analyses|400-metre walking test 200-metre walking test
79384149|NCT01337349|Drug|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
79384150|NCT01337349|Drug|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
79384151|NCT03297918|Behavioral|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
79384152|NCT01895985|Drug|Latanoprostene bunod|
79384153|NCT01999348|Drug|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
79391835|NCT03172806|Diagnostic Test|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
80010784|NCT02181920|Drug|Metamizole|
79696197|NCT02904278|Other|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
79538720|NCT04983654|Diagnostic Test|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~Microvascular analysis (laser doppler, TcPO2),~Neurological analysis (sensitivity testing with thermal and mechanical test),~Analysis of physical characteristics of red blood cells and inflammatory marks"
79245103|NCT05850169|Other|Creative Dance Therapy|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
79696198|NCT02904278|Other|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
79696199|NCT00557700|Drug|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
79245104|NCT05850143|Drug|Dexamethasone|Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
79245105|NCT05850143|Drug|Prednisolone|Oral Multidose Prednisolone
79245106|NCT05850117|Drug|esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin|Tetracycline combined with levofloxacin quadruple therapy
79245107|NCT05850117|Drug|esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole|standard tincture quadruple therapy
79245108|NCT05850117|Drug|esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin|amoxicillin combined with levofloxacin quadruple therapy
79245109|NCT05850104|Other|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of classical Chopart prosthesis and silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
79245110|NCT05850104|Other|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
79538721|NCT04978727|Biological|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
79538722|NCT04978727|Biological|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
79538723|NCT04978727|Biological|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
79245111|NCT05850039|Other|Sampling|Sample collection: a small fragment of atrial wall will be collected
79245112|NCT05850026|Procedure|Septal myectomy and mitral valve repair with edge-to-edge technique|Resection of the obstructing part of the interventricular septum and mitral repair using the edge-to-edge technique (suture of leaflets free margins in the regurgitation spot)
79538724|NCT04962932|Behavioral|Internet-deliviered exposure-based CBT|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
79245113|NCT05849974|Other|Structural and fonctional phynotyping|"The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection"
79245114|NCT05849961|Device|Exactech Hip Systems|The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
79538725|NCT04962932|Behavioral|Internet-delivered stress management treatment|The intervention last for 10 weeks and include: Internet-SMT include life-style advice (e.g., exercise, sleep advice), relaxation and problem-solving skills to reduce stress. Patients are offered regular online contact with a psychologist with the same frequency and intensity as in the CBT arm.
79696200|NCT00557700|Drug|Administration of placebo|Administration of placebo
79696201|NCT00557739|Drug|mometasone furoate|Topical 0.1% mometasone furoate
79696202|NCT00557739|Drug|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
79696203|NCT00557739|Drug|Vehicle (placebo)|Topical placebo
79840650|NCT00817284|Drug|bevacizumab and Irinotecan and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15.~Irinotecan:~Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
80010785|NCT02181920|Drug|Diclofenac|
79245115|NCT05849948|Behavioral|choronobiological nutrition|Providing infant nutrition in accordance with crinobiological nutrition
80010786|NCT02181920|Drug|Diclofenac placebo|
80010787|NCT02181920|Drug|Metamizole placebo|
79696204|NCT02904122|Other|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
79245116|NCT05849883|Drug|Omeprazole 20 mg Capsules|Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
79696205|NCT02903888|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
79696206|NCT02903927|Device|Implantation of CT LUCIA IOL|
79840651|NCT00817284|Drug|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
79840652|NCT04096235|Other|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
79840653|NCT00823056|Dietary Supplement|probiotics|placebo
79840654|NCT00823056|Dietary Supplement|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
79245117|NCT05849870|Other|Frailty care pathway for older people in a rural primary care setting|This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
79538726|NCT04962230|Drug|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
79538727|NCT04962230|Drug|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
79538728|NCT04962230|Drug|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
79245118|NCT05849818|Device|full-immersive VRapeutic software gaming technology|"Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~Viblio VRapeutic fully immersive game will be used.~Manual instructions of the game will be followed and features of the game will be customized.~The child instructed to put back a pile of books on the floor into their shelves.~Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~Level III distracting tasks during book ordering~The complexity of the game depend on task duration, number of books and the nature of distractors"
79302758|NCT04997343|Other|Neurophysiological assessment|EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
79840655|NCT04096157|Drug|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
79840656|NCT04096157|Drug|Isavuconazonium sulfate capsules|Oral
79538729|NCT04947150|Behavioral|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
79696207|NCT02903927|Device|Implantation of Acrysof IQ SN60WF IOL|
79696208|NCT04624542|Device|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
79696209|NCT02904083|Behavioral|self assessment of adherence|
79696210|NCT04653168|Drug|LY3041658|Administered SC
79696211|NCT04653090|Diagnostic Test|Xray|Hip AP Xray
79696212|NCT04653012|Device|Intracranial macro-microelectrode recording|Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
79696213|NCT02903849|Behavioral|Drafting Motivational Messages|Write down three motivating messages
79696214|NCT02903849|Behavioral|Control Reminders|Receive standard reminders at three points during the challenge
79696215|NCT02903849|Behavioral|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
79696216|NCT04653129|Procedure|Autologous Fat Grafting|"The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
79696217|NCT04653129|Procedure|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
79696218|NCT04681547|Procedure|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
79696219|NCT04681547|Procedure|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
79696220|NCT04624464|Other|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
79696221|NCT04624464|Other|Examination of patient room|Only performed for cohort 2
79696222|NCT04681391|Device|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
79696223|NCT04652817|Device|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
79696224|NCT04681586|Device|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
79696225|NCT04681586|Device|dim red light|using the same device as the active group, but with an installed filter that dims light to <300 lux for 30min every morning for two weeks
79696226|NCT04624269|Drug|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
79696227|NCT02903810|Biological|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
79696228|NCT04652739|Drug|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
79696229|NCT04652739|Drug|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
79696230|NCT02904005|Other|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
79303520|NCT04490837|Diagnostic Test|ELISA and Rapid test to detect antibodies against COVID-19|Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
79696231|NCT02903498|Drug|UFT|UFT 360mg/m2 qd po d1-14, q3w
79696232|NCT04624347|Behavioral|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
79696233|NCT02903459|Other|Transversal Study so there is no intervention|
79840657|NCT00819624|Other|Interactive Voice Response System (IVRS)|Telephone based system
79840658|NCT00819624|Other|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
79303521|NCT04491149|Device|virtual reality glasses|In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
79384154|NCT02463474|Behavioral|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
79840659|NCT00823290|Drug|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
79840660|NCT00823368|Drug|STX209|
79840661|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
79840662|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
79840663|NCT00755417|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
79840664|NCT03685708|Biological|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
79840665|NCT00819702|Other|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
79840666|NCT03684928|Device|Comfilcon A (test)|Daily wear contact lenses
79245119|NCT05849792|Behavioral|Exercise and psychological intervention|"Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive."
79245120|NCT05849766|Drug|Dapagliflozin Farxiga®|Dapagliflozin 10 mg once daily
79245121|NCT05849766|Drug|Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®|Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
79245122|NCT05849701|Device|Shock wave therapy|using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.
79696234|NCT04623957|Device|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
79245123|NCT05849701|Device|Vacuum-assisted closure|Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
79696235|NCT04652427|Drug|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
79696236|NCT04652427|Drug|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
79840667|NCT03684928|Device|Senofilcon C (control)|Daily wear contact lenses
79840668|NCT00817440|Other|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
79245124|NCT05849688|Other|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied.
79245125|NCT05849688|Other|Bicycle Ergometry Training|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied + bicycle ergometry training
79245126|NCT05849675|Drug|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
79245127|NCT05849675|Drug|Placebo|Single dose placebo
79245128|NCT05849662|Drug|Trametinib|"PO or NG QD Days 1-28~For patients age < 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day"
79245129|NCT05849662|Drug|Azacitidine|"IV over 30 minutes Days 1-5~Age < 1 year or weight <10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day"
79245130|NCT05849662|Drug|Fludarabine|"IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if <12 kg)"
79245131|NCT05849662|Drug|Cytarabine|"IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if <12 kg)"
79245132|NCT05849649|Behavioral|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
79840669|NCT00817440|Other|Fasting|3 days of fasting and then the same as arm 1
79840670|NCT00777803|Drug|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
80010788|NCT02185118|Drug|oxygen|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
79245133|NCT05849649|Behavioral|Educational Brochure|An evidence-based brochure on physical activity
79303522|NCT02468219|Behavioral|cardiovascular rehabilitation program|"Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training."
79384155|NCT03297840|Behavioral|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
79384156|NCT03297762|Behavioral|gamification|incentives/rewards and contact between standard visits
79384157|NCT03297762|Behavioral|Use of Dexcom G5|Dexcom G5 continuous glucose monitor
79696237|NCT02903576|Procedure|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
79840671|NCT00777803|Drug|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
79538730|NCT04947150|Behavioral|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
79840672|NCT00819858|Dietary Supplement|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
79696238|NCT02903576|Procedure|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
79696239|NCT04623918|Other|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
79840673|NCT00819936|Procedure|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
79840674|NCT00819936|Procedure|backward walking|physiotherapy with use a backward walking type of physiotherapy
79245134|NCT05849636|Behavioral|ALERTA CANNABIS|The intervention consists of preventive messages about the benefits of not consuming cannabis, reducing the positive attitudes and encouraging the negative attitudes towards cannabis use, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject cannabis use. This information is presented through different tailored messages. In addition, the participants will be able to choose avatars to accompany them during the intervention. The intervention consists of a short story about the cannabis use by adolescents.The stories take place in three different scenarios (at home, at school leaving, and in public places).
79840675|NCT03993587|Other|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
79245135|NCT05849597|Drug|Dexmedetomidine|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h.
79245136|NCT05849597|Drug|Propofol|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h.
79245137|NCT05849571|Other|coconut oil|• The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
79696240|NCT04623918|Other|Control rice|Control rice (C4), identical in appearance
79245138|NCT05849558|Drug|Ursoplus|Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)
79245139|NCT05849558|Drug|UDCA 250mg|UDCA 250mg alone
79245140|NCT05849558|Other|Placebo|Placebo alone
79384158|NCT00280761|Drug|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
79384159|NCT00280761|Drug|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
79384160|NCT00280761|Procedure|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
79384161|NCT00280761|Radiation|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
79384162|NCT02716584|Behavioral|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
79696241|NCT02903654|Other|observational|
79696242|NCT04624308|Drug|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
79696243|NCT02903693|Other|cross sectional|
79696244|NCT04624425|Other|Segmental breathing exercises|Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
79696245|NCT04624425|Other|Buteyko breathing exercises|Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
79840676|NCT00527488|Drug|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
79840677|NCT00527488|Drug|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
79840678|NCT00527488|Drug|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
79840679|NCT00527488|Drug|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
79840680|NCT00820014|Drug|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
79538731|NCT04947150|Behavioral|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
79840681|NCT00825864|Drug|diclofenac drops|one drop 4 times a day for 3 months
79538732|NCT04947150|Behavioral|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
79538733|NCT04943445|Drug|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
79538734|NCT04943445|Radiation|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
79538735|NCT04943445|Drug|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
79538736|NCT04939883|Drug|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
79538737|NCT04939883|Drug|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
79696246|NCT02903771|Drug|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
79696247|NCT02903771|Drug|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
79696248|NCT04623879|Drug|Lumacaftor, Ivacaftor Drug Combination|
79696249|NCT04624035|Procedure|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
79840682|NCT00825864|Drug|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
79840683|NCT00916799|Device|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
79840684|NCT00825942|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
79245141|NCT05849545|Device|Garston tool|GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
79303523|NCT03303833|Other|No intervention, observational study.|
79840685|NCT00823446|Device|Revera Wound Care|Revalesio Part Number MDW0060
79840686|NCT00823446|Device|Normal Saline|Sodium Chloride for Irrigation
79840687|NCT00527332|Drug|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
80010789|NCT02185118|Drug|Sevoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
80010790|NCT02185118|Drug|Isoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
80010791|NCT02186288|Other|High-flow nasal cannula oxygen|
80010792|NCT02807376|Device|Surgeon's 'standard of care' stapler|
80010793|NCT02807376|Device|Ethicon Powered Vascular Stapler|
80010794|NCT02256566|Behavioral|emotional memory training exercise|
79538738|NCT04935528|Biological|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
79538739|NCT04935528|Biological|serology|7 mL blood sample to study the humoral response
80010795|NCT02256566|Behavioral|memory training exercise|
80010796|NCT02186366|Other|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
79538740|NCT04933695|Drug|Sotorasib|Oral tablet
79538741|NCT04931732|Biological|ctDNA analysis|ctDNA analysis of patients with suspected primary glioma tumors and in patients with suspected recurrence.
79538742|NCT04923126|Drug|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
79538743|NCT04920422|Other|No intervention|Retrospective analysis using database without any intervention assigned in the study.
79696250|NCT04624035|Procedure|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
79696251|NCT02903732|Other|observational|registry
79696252|NCT04624386|Other|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
79245142|NCT05849545|Procedure|Neuromuscular Re-education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
79245143|NCT05849519|Drug|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
79245144|NCT05849519|Drug|Conventional treatment|The control group was treated with conventional treatment
79696253|NCT04624191|Other|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
79245145|NCT05848960|Dietary Supplement|Hypercaloric, hyperproteic oral supplement|2 supplements per day
79245146|NCT05848960|Other|Mediterranean diet|Mediterranean diet
79538744|NCT04919317|Drug|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
79840688|NCT00527332|Drug|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
79538745|NCT04919317|Drug|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
79538746|NCT04915248|Drug|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
79538747|NCT04915248|Drug|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
79538748|NCT04915248|Drug|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
79538749|NCT04910841|Device|CGM GUARDIAN 2|continuous blood glucose monitoring system
79696254|NCT02903264|Other|Gestational diabetes mellitus|
79696255|NCT04624152|Behavioral|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
79696256|NCT02903225|Behavioral|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
79696257|NCT00562068|Biological|alemtuzumab|
79696258|NCT00562068|Drug|cyclophosphamide|
79696259|NCT00562068|Drug|doxorubicin hydrochloride|
79696260|NCT00562068|Drug|prednisolone|
79696261|NCT00562068|Drug|vincristine sulfate|
79840689|NCT00527332|Drug|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
79840690|NCT00527332|Drug|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
79840691|NCT00527332|Drug|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
80010797|NCT02186366|Drug|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
79245147|NCT05848479|Other|Abdominal bracing|they will perform 3 times/week of static abdominal contraction for six weeks.
79245148|NCT05848479|Other|clamshell exercise|Each women will be positioned in side lying on the floor, with the pelvis and the spine in neutral position, the hips will bent at 45° and the knees flexed to 90°. She will abduct the top knee as far as possible, while keeping the heels together, then return to the starting position , the position will be maintained for 5 seconds in an abduction state, and repeated 10 times, with rest for 1 minute to minimize muscle fatigue,they will perform 3 times/week fo 6 weeks
79245149|NCT05848271|Other|Patient Registry|Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.
79245150|NCT05848271|Other|Dry blood spots sampling|Dry blood splots require 500nl of blood.
79303524|NCT02468141|Drug|SJDBT|Sipjeondaebo-tang
79303525|NCT02468141|Drug|Placebo|Placebo
79538750|NCT04902326|Behavioral|Automated educational text messages|"During the first two weeks, participants receive a series of educational messages delivered via text message. These messages welcome participants to the study, set expectations for the next 12 months, and establish a general level of knowledge among all participants on prediabetes, the Diabetes Prevention Program (DPP), and metformin.~For the next 11.5 months, participants receive three automated text messages per week that provide evidence-based educational content about prediabetes and tips on prevention. Additionally, participants receive monthly messages reminding them about their health insurance plan's coverage of the DPP at no cost and coverage of metformin as a low co-pay medication, and monthly messages providing feedback on their participation in the DPP and use of metformin in the previous calendar month. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months."
79245151|NCT05848193|Other|MyHeadHealth online application|MyHeadHealth is an online application to be accessed through the patients smartphone. The goal of MyHeadHealth is to improve treatment compliance by providing patients with free and convenient access to resources and activities that align with their treatment plan
79538751|NCT04902326|Behavioral|Autonomy-supportive automated educational text messages|Participants receive the same text messages as in the automated educational text message intervention, but the thrice weekly messages have been modified, where applicable, to support the participant's autonomy, in accordance with principles of Self-Determination Theory. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months.
79538752|NCT04902326|Behavioral|Financial incentives|Participants in this arm have the opportunity to earn a financial incentive ranging from $50 to $250 per month for taking an evidence-based action to prevent T2DM (i.e., engagement in a DPP or fill of a metformin prescription) in the previous month.
79538753|NCT04902326|Behavioral|Tailored text messages|Participants receive twice-weekly tailored text messages that link evidence-based actions to prevent T2DM to the participant's self-identified top values, roles, and strengths. Text messages are also tailored, when possible, to participants' self-reported importance of taking action to try to prevent T2DM (i.e., participating in the DPP or taking metformin), confidence in being able to take such preventive action, and past preventive actions taken.
79245152|NCT05848193|Other|Standard of Care|Patients will receive Standard of Care from our concussion clinic as necessary as per the consultation with the physician
79538754|NCT04901494|Drug|SSRI|Selective serotonin reuptake inhibitor
79384163|NCT02716584|Behavioral|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
79384164|NCT02061748|Drug|Observational|Retrospective Chart Review
79538755|NCT04892199|Drug|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
79696262|NCT00562068|Genetic|polymerase chain reaction|
79696263|NCT00562068|Other|flow cytometry|
79696264|NCT00562068|Other|laboratory biomarker analysis|
79696265|NCT00562068|Other|pharmacological study|
79840692|NCT00527332|Drug|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
79384165|NCT03295812|Other|standard therapy|standard therapy,non-interventional study
79696266|NCT02903342|Other|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
79696267|NCT04623606|Biological|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
79696268|NCT02903303|Other|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~1st session : contact with the therapist, body scan, basic suggestions~2nd session : hypnosis induction followed by suggestions tu build a safe place~3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
79840693|NCT00527332|Drug|Morphine|5 mg is given IV (intravenously) before end of surgery
80010798|NCT02053974|Drug|Spironolactone|Spironolactone
80010799|NCT02053974|Other|Placebo|Placebo
79245153|NCT05847725|Other|Elastic bandaging|"The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally."
79245154|NCT05847725|Other|Short stretch bandaging|Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.
79245155|NCT05847725|Other|Kinesio taping|Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
79384166|NCT03999996|Biological|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV subcutaneous injection
79384167|NCT03999996|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
79384168|NCT03295656|Drug|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
79696269|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
79696270|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
79696271|NCT02903186|Behavioral|SMS|This is an intervention using short mobile messages (SMS)
79696272|NCT00562146|Procedure|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
79696273|NCT02903147|Behavioral|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
79696274|NCT02903147|Behavioral|The employer's training|
79696275|NCT02903108|Drug|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
79696276|NCT02903108|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
79696277|NCT00562185|Drug|carboplatin|
79696278|NCT00562185|Drug|doxorubicin hydrochloride|
79696279|NCT02902796|Device|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
79696280|NCT00562224|Drug|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
79696281|NCT02902718|Device|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
79696282|NCT04623645|Device|ultrasound technique|evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
79696283|NCT02902835|Behavioral|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
80010800|NCT02185196|Drug|Vitamin D3|20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
79245156|NCT05847283|Procedure|Dydrogesterone priming ovarian stiumulation protocol|Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
79245157|NCT05847283|Procedure|GnRH antagonist protocol|In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
79245158|NCT05846711|Diagnostic Test|BPPV diagnostic|Supine Roll Test and Dix-Hallpike Test
79245159|NCT05846711|Device|TRV chair|Mechanical rotational chair
79245160|NCT05846711|Device|VNG goggles|Goggles for video nystagmography
79384169|NCT02463318|Drug|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
79384170|NCT02463318|Other|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
79391836|NCT03115398|Behavioral|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
79696284|NCT02902835|Behavioral|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
79245161|NCT05846711|Device|IMU sensor|A sensor that measures triaxial acceleration and triaxial angular velocity.
79245162|NCT05846711|Procedure|Manual BPPV diagnostics|Bedside BPPV diagnostics
79245163|NCT05846126|Behavioral|RehabCovid_Telematic|A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.
79245164|NCT05846126|Behavioral|RehabCovid_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
79245165|NCT05846126|Behavioral|Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
79696285|NCT04623762|Other|Yoga|yoga application
79696286|NCT02903069|Drug|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
79696287|NCT02903069|Drug|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
79696288|NCT02903069|Radiation|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
79696289|NCT02903069|Device|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
79696290|NCT04623723|Other|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
79840694|NCT00820092|Drug|Xerecept 1.0|24 hour infusion
79840695|NCT00820092|Drug|Xerecept 2.0|24 hour infusion
80010801|NCT02185196|Drug|Placebo|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
80010802|NCT02052492|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
80010803|NCT02181998|Drug|Full dose tenecteplase|
80010804|NCT02181998|Drug|Unfractioned heparin|
79696291|NCT04623723|Other|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
79696292|NCT02902679|Drug|BMS-986177|
79696293|NCT04623840|Other|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
79696294|NCT04623840|Drug|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
79696295|NCT02902640|Drug|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
79696296|NCT02902640|Drug|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
79696297|NCT02902640|Drug|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
79696298|NCT04623528|Diagnostic Test|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
79696299|NCT04623489|Behavioral|¡Vivir Mi Vida! Lifestyle Intervention|
79840696|NCT00820092|Drug|Xerecept 3.0|24 hour infusion
79538756|NCT04892199|Drug|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
79538757|NCT04888702|Device|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
79696300|NCT04624893|Drug|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
79696301|NCT04623450|Other|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
79696302|NCT04623294|Procedure|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
79696303|NCT04623294|Procedure|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
79696304|NCT02902523|Drug|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
79696305|NCT02902523|Drug|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
79696306|NCT04623060|Other|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
79696307|NCT02902562|Procedure|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
79840697|NCT00823524|Biological|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
79840698|NCT05269810|Drug|SA001 Low dose|3 tablets b.i.d for 8 weeks
79840699|NCT05269810|Drug|SA001 Mid dose|3 tablets b.i.d for 8 weeks
79840700|NCT05269810|Drug|SA001 High dose|3 tablets b.i.d for 8 weeks
79840701|NCT05269810|Drug|Placebo|3 tablets b.i.d for 8 weeks
79840702|NCT04017156|Procedure|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
79245166|NCT05845580|Other|Red yeast rice extract initial therapy followed later on by statin therapy|Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of <2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
79245167|NCT05845580|Other|Statin therapy|Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
79391837|NCT03115320|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
79696308|NCT02902562|Procedure|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
79696309|NCT00562263|Behavioral|Lifestyle modification|Dietary modification and regular physical activity
79391838|NCT03115320|Other|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
79538758|NCT04888689|Device|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
79538759|NCT04888689|Device|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
79696310|NCT02902367|Other|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
79696311|NCT02902367|Other|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
79696312|NCT04623255|Drug|OCTAPLAS|plasma exchange
79696313|NCT02902289|Drug|Ibuprofen 200 mg/5 mL oral suspension|
79696314|NCT02902289|Drug|MOMENT 200 mg coated tablet|
79696315|NCT04623411|Behavioral|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
79696316|NCT04623411|Behavioral|Control Group|Neonatal resuscitation training with classical method
79696317|NCT02902133|Drug|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
79696318|NCT04623333|Drug|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
79696319|NCT04623021|Drug|Nafamostat Mesilate|Administered intravenously as a continuous infusion
79696320|NCT02902016|Drug|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
80010805|NCT02181998|Drug|Enoxaparin|
80010806|NCT02054052|Drug|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
80010807|NCT03810222|Other|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
79391839|NCT03172650|Diagnostic Test|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
79391840|NCT03172572|Procedure|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
79696321|NCT04622748|Behavioral|Trier Social Stress Test|8-min oral calculation and 5-min speech
79696322|NCT04622826|Biological|immune plasma|immune covid 19 plasma infusion
79696323|NCT02901977|Drug|Ramipril|Antihypertensive therapy
79696324|NCT02901977|Drug|Doxazosin|Antihypertensive therapy
79696325|NCT02902094|Device|Drug eluting balloons|
79696326|NCT02902094|Device|Non drug eluting balloons|
79696327|NCT04681235|Other|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
79696328|NCT00553553|Drug|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
79391841|NCT03172572|Procedure|Open pancreatoduodenectomy|Open resection
79696329|NCT00553553|Drug|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
79840703|NCT00823602|Drug|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
79840704|NCT00823602|Drug|suprefact|GnRH agonist, standard protocol
79840705|NCT00820326|Drug|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
80010808|NCT02186444|Other|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
80010809|NCT02186444|Other|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
80010810|NCT02051322|Device|Jet Nebulizer|
79384171|NCT01436968|Biological|Aglatimagene besadenovec + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~The second injection will be 0-3 days before initiation of radiation therapy.~The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
79538760|NCT04887129|Diagnostic Test|COVID-19 RT-PCR test|"Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests."
79696330|NCT04622982|Other|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) <30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
79245168|NCT05844956|Drug|DZD8586|Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
79245169|NCT05844696|Device|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
79538761|NCT04887129|Other|COVID-19 Vaccine Education Campaign|Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
79384172|NCT01436968|Biological|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~The second injection will be 0-3 days before initiation of radiation therapy.~The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
79391842|NCT02404506|Drug|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
79538762|NCT04882891|Device|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
79538763|NCT04876456|Drug|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
79538764|NCT04871594|Drug|Nivolumab|On day 1, 22, and 43 240mg
79538765|NCT04866147|Procedure|Cardiothoracic surgery|Cardiac & large intrathoracic vessels, respiratory, thoracic, mediastinal & diaphragmatic procedures
79538766|NCT04866147|Procedure|Breast surgery|Breast resections & mastectomies
80010811|NCT02051322|Device|Trunk Mask Nebulizer|
80010812|NCT02051322|Device|Aerobika Nebulizer|
80010813|NCT02185352|Drug|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
80010814|NCT02051400|Device|the McGrath® MAC video laryngoscope|
79538767|NCT04866147|Procedure|Gastrointestinal surgery|Digestive & spleen
79538768|NCT04866147|Procedure|Genitourinary surgery|Urinary tract, genital & retroperitoneal tissue
79538769|NCT04866147|Procedure|Orthopaedic surgery|Back & neck, shoulder & upper arm, hip & thigh, knees & lower leg
79538770|NCT04858867|Radiation|rhTSH-stimulated I-124 dosimetry|"Preparation:~Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~Ingestion of capsule with 37±10% MBq I-124~I-124 PET/CT at 24 and 96h post-ingestion~Blood draws at 2, 24 and 96h post-ingestion~Whole body counting at 2, 24 and 96h post-ingestion"
79538771|NCT04858867|Radiation|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~Blood draws at 2, 6, 24, 96 and 144h post-ingestion~Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
79538772|NCT04852471|Behavioral|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
79538773|NCT04852471|Behavioral|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
79538774|NCT04848857|Drug|Colchicine|colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
79538775|NCT04848857|Drug|Placebo|the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
80010815|NCT02051400|Device|the GlidesScope® Ranger video laryngoscope|
79538776|NCT04846556|Other|data collection|data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
79840706|NCT00820326|Drug|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
80010816|NCT02051400|Device|the Macintosh laryngoscope|
80010817|NCT02054208|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
79245170|NCT05844345|Other|Hydrocolloid barrier group|In the hydrocolloid barrier group, Comfeel Plus brand hydrocolloid tape will be used. Hydrocolloid tape is a dressing cover made of soft, flexible and economic material in the form of a semi-permeable film or foam-supported gel. Air exchange continues due to the semipermeable film on the top, while entry of harmful microorganisms to the region is prevented, healing is accelerated by creating a humid environment for the wound and exudate from the wound is absorbed. These features reduce the risk of developing infection and ensure patient comfort. There is no specific change time, though generally the tape is changed every 3-5 days; however, it may remain in place for up to 7 days.
79245171|NCT05844345|Other|Facial Massage group|Premature infants in the facial massage group will have facial massage applied by the researcher. For facial massage, physiological serum used for routine moisturizing in the clinic will be used. When performing facial massage, the fingers will be placed in the middle of the infant's forehead and massage will be performed towards the temples. The eyelids will be lightly rubbed toward the temples. Both thumbs will be placed in the center of the eyebrows and the ridge of the nose will be rubbed toward the lips. The sides of the nose will be rubbed with light pressure. The nasal septum will be rubbed toward the tip of the nose along the philtrum. The fingers will be placed on the philtrum region above the gums and the mouth will be rubbed toward the ears to make a smiling expression. The chin will be lightly massaged toward the back of the ears. The thumbs of both hands will rub from under the infant's chin toward the temples to give make a smiling face (smiling motion).
79245172|NCT05843968|Drug|Rituximab|"2 doses of rituximab 375 mg/m^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection."
79384173|NCT02461212|Procedure|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
79384174|NCT02463162|Other|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
79384175|NCT04441866|Diagnostic Test|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
79384176|NCT04441866|Diagnostic Test|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
79538777|NCT04826562|Drug|Dolutegravir/Lamivudine|single tablet antiretroviral
79696331|NCT02901938|Procedure|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
79840707|NCT04602286|Other|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
79840708|NCT00752609|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
79840709|NCT03684304|Device|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
80010818|NCT02054208|Other|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
79696332|NCT02901938|Device|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
79696333|NCT04622202|Drug|Pregabalin 150mg|oral capsule pregabalin 150 mg.
79696334|NCT04622202|Drug|multivitamin|oral placebo in the form of oral multivitamin capsule.
79840710|NCT04023539|Dietary Supplement|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
80010819|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
80010820|NCT02052726|Biological|Placebo|Placebo administered at Month 0, 1, and 3.
80010821|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
80010822|NCT02052726|Biological|placebo|Placebo administered at Day 1, 8, and 30.
80010823|NCT02185430|Drug|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
80010824|NCT02185430|Drug|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
80010825|NCT03536390|Drug|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
80010826|NCT03536390|Drug|Placebo|Placebo
80010827|NCT03561480|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
79696335|NCT02901782|Procedure|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
79245173|NCT05843968|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks"
79696336|NCT04622475|Biological|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
79696337|NCT04622358|Drug|AD-214-02|1 tablet administered before the breakfast during 7 days
79840711|NCT04023539|Other|Placebo|Placebo capsules
79840712|NCT05255068|Behavioral|OPTIMAL|A person-centered mealtime care intervention
79840713|NCT04093583|Procedure|Exodontia|Atraumatic exodontia followed by simple suture
79840714|NCT04093583|Drug|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
79840715|NCT04093583|Device|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
79696338|NCT04622358|Drug|Rabeprazole|1 tablet administered before the breakfast during 7 days
79840716|NCT00916097|Drug|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
79245174|NCT05843955|Other|Questionnaire|Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
79245175|NCT05843279|Procedure|Myofunctional therapy|In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
79245176|NCT05843175|Other|Exercise and meal testing (acute stimuli)|"Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake"
79245177|NCT05843032|Diagnostic Test|3D ultrasound, MRI, resected specimen examination by surgeon|3D ultrasound and MR scanning of the resected tongue tumor will be performed. The resected surgical specimen will also be examined by the surgeon to assess the margins. The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
79384177|NCT02462772|Drug|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
79384178|NCT02462772|Drug|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
79538778|NCT04823689|Procedure|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
79538779|NCT04817540|Drug|Herzuma|8mg/kg IVF loading dose at first cycle -> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
79538780|NCT04806165|Behavioral|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79538781|NCT04806165|Behavioral|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
79840717|NCT00629772|Drug|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
79840718|NCT00629772|Drug|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
79840719|NCT00526630|Drug|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
79840720|NCT00526630|Drug|Placebo|Participants will be given placebo instead of active MPD.
79840721|NCT00755183|Drug|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
79840722|NCT00755183|Drug|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
79245178|NCT05842369|Device|ADVOS|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
79245179|NCT05842369|Device|CVVHD|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
79696339|NCT02901665|Other|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
79840723|NCT00826254|Drug|Vitamin K|180 micrograms vitamin K daily
79245180|NCT05841134|Drug|Tislelizumab|"Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months."
79538782|NCT04806165|Behavioral|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
79538783|NCT04806165|Behavioral|Core Modules Only|A discussion with the chatbot, including only the core modules.
79245181|NCT05840731|Dietary Supplement|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
79538784|NCT04806165|Behavioral|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79696340|NCT00562341|Other|Bariatric Surgery|one time lapb-band gastric bypass surgery
79696341|NCT02901587|Drug|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
79245182|NCT05840731|Other|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
79245183|NCT05837741|Dietary Supplement|Standard hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
79245184|NCT05837741|Dietary Supplement|Leucine-enriched hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
79384179|NCT04441632|Behavioral|Positive feedback|Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
79696342|NCT02901587|Drug|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
79696343|NCT02901587|Drug|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
79696344|NCT04622397|Drug|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
79696345|NCT04622397|Drug|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
79696346|NCT02901704|Device|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
79696347|NCT02901704|Procedure|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
79840724|NCT00826254|Drug|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
79384180|NCT03295578|Other|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
79696348|NCT02901743|Other|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
79696349|NCT02901392|Procedure|AMS-800|Artificial urianry sphincter
79696350|NCT02901392|Procedure|ADVANCE/ADVANCEXP|Male sling
79696351|NCT02901392|Procedure|VIRTUE|Male sling
79696352|NCT02901392|Procedure|INVANCE|Male sling
79696353|NCT02901353|Device|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
79840725|NCT00823758|Behavioral|Focus Groups|6 to 8 participants per group.
79840726|NCT00823758|Behavioral|Personal Interviews|Conducted by phone and audiotaped.
79840727|NCT00826332|Procedure|transabdominal ultrasound|transabdominal ultrasound
79840728|NCT00826332|Procedure|transvaginal ultrasound|transvaginal ultrasound
79840729|NCT00526162|Device|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
79840730|NCT02600195|Behavioral|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
79245185|NCT05836948|Drug|SHR-9839|Weekly fixed dose injection of SHR-9839
79245187|NCT05831878|Drug|Disitamab vedotin|2.0mg/kg, iv, day1, every 2 weeks
79245188|NCT05827705|Other|need for Ephedrine hydrochloride|ephedrine dose in hypotension
79696354|NCT04621773|Procedure|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
80010828|NCT03561480|Drug|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
80010829|NCT02190188|Device|Wedge Insole 5mm|
80010830|NCT02190188|Device|Knee Brace|
80010831|NCT03561870|Drug|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
80010832|NCT02054286|Biological|THV01-1|Intramuscular injection of THV01-1 (week 0)
79384181|NCT03295578|Other|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
79384182|NCT03295578|Device|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
80010833|NCT02054286|Biological|THV01-2|Intramuscular injection of THV01-2 (week 8)
79245190|NCT05826197|Other|Radiomics|PET Radiomics
79384183|NCT03295422|Procedure|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
79384184|NCT03295422|Procedure|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
79384185|NCT03297528|Drug|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
79538785|NCT04806165|Behavioral|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79384186|NCT02062606|Device|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
80010834|NCT02054286|Biological|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
80010835|NCT02186756|Other|EMG-Biofeedback and Usual care|Please refer to arm description
79538786|NCT04806165|Behavioral|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
79696355|NCT02901119|Dietary Supplement|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
80010836|NCT02184338|Drug|BIBR 1017 BS powder|
79245191|NCT05823454|Drug|Different drug dosage|Choice of Anesthesia
80010837|NCT02184338|Drug|Placebo|PEG 400
79245192|NCT05823207|Other|sage essential oil|It will be applied 2 times a day, at the same times, at a distance of 30 cm from the nose for 5 minutes with normal breathing and 3 drops of essential oil by placing a tampon. The PMS scale and the quality of life scale are administered to the participants at the end of the 1st, 2nd and 3rd cycles of the menstrual cycle.
79245193|NCT05822115|Device|Reduction of breast hypertrophy by means of laparoscopic|"The research procedure is a breast reduction performed by means of laparoscopic surgery.~The project consists of removing a disc from the breast at the level of the base, thus causing peripheral skin slackening of 2 to 3 cm but circular. Both breasts are usually operated on at the same time. In case of asymmetry, only one side will be treated."
80010838|NCT02190344|Device|8-channel paddle coil|MRI Coil
80010839|NCT02054364|Behavioral|FBT and CRT|
80010840|NCT02054364|Behavioral|FBT and art therapy|
80010841|NCT03807648|Other|Data Inclusion|Patients in this group will be included in the project
80010842|NCT02186912|Device|Nobel Active, Nobel Procera IBO|
80010843|NCT02186990|Drug|propofol|2,5 mg/kg
80010844|NCT02186990|Drug|etomidate|0,3 mg/kg
79538787|NCT04806165|Behavioral|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
80010845|NCT02186990|Drug|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
80010846|NCT05657028|Drug|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
80010847|NCT05657028|Drug|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
80010848|NCT02187068|Drug|Dexmedetomidine|Dexmedetomidine administered intravenously
79245194|NCT05821738|Drug|Avapritinib|administered orally
79245195|NCT05816746|Drug|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
79245196|NCT05949242|Device|OMNI canaloplasty|OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal
79696356|NCT04621695|Procedure|RBL|Both arms are standard care procedures in the Netherlands
79696357|NCT04621695|Procedure|Hemorrhoidectomy|Both arms are standard care procedures in the Netherlands
79696358|NCT02901197|Behavioral|Education and Reminder Posters|See arm description
79696359|NCT02901197|Other|Policy Change|See arm description
79696360|NCT02901002|Other|Sensory testing in the two hand|spontaneous sensations while watching a hand
79696361|NCT02901002|Other|Neuropsychological evaluation|Score to anxiety-depression scale
79696362|NCT04621656|Combination Product|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
79696363|NCT04681664|Other|High fat diet|50 % fat
79696364|NCT04621461|Dietary Supplement|Zinc Sulfate 220 MG|220mg once daily for 5 days
79840731|NCT02550600|Procedure|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
79538788|NCT04806165|Behavioral|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
79696365|NCT04621461|Drug|Placebo|Once daily for 5 days
79384187|NCT02063230|Drug|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
80010849|NCT02054442|Drug|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
80010850|NCT02054442|Drug|Methotrexate|
79384188|NCT02063230|Drug|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
79384189|NCT02000908|Device|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
79245197|NCT05949242|Device|Hydrus microstent|Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
79245198|NCT05949229|Drug|Duloxetine 60 MG|Patients will recieve 2-hour preoperative duloxetine
79245199|NCT05949216|Behavioral|Musical engagement sessions|Musical engagement sessions will be 2 hours long and involve improvisation and sight-reading of sheet music. Participants will supply their own instrument of choice to play. There will be four sessions total.
79384190|NCT02000908|Other|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
79384191|NCT02000908|Other|Physiotherapy|Chiropractic massage and lymphedema treatment
79696366|NCT02901236|Procedure|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
79696367|NCT02901236|Drug|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
79245200|NCT05949164|Behavioral|Insomnia|The primary exposure is insomnia
79245201|NCT05949151|Procedure|dental implants (K1 line conical connection double thread, OXY, Italy)|Six dental implants inserted on the edentulous mandible
79245202|NCT05949151|Device|Occlusense (Bausch GmbH & Co. KG)|sensor used to evaluate the equilibration of occlusal forces.
80010851|NCT02185586|Procedure|laparoscopic cholecystectomy|
80010852|NCT02038296|Procedure|transarterial chemoembolization|
80010853|NCT02053038|Device|iFR|Treatment guided by instantaneous wave-free ratio
80010854|NCT02053038|Device|FFR|Treatment guided by Fractional Flow Reserve
79245203|NCT05949151|Device|"electromyography (EMG) (Nemus II)."|EMG recordings were accomplished by a computer electromyography-based data acquisition system
79384192|NCT02716194|Biological|BAX 826|
79384193|NCT02716194|Biological|Octocog alfa|
79384194|NCT02002702|Drug|Serelaxin|Intravenous infusion
79384195|NCT02002702|Drug|Placebo|Placebo
79391843|NCT03169140|Device|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
79538789|NCT04806165|Behavioral|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79538790|NCT04806165|Behavioral|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
79696368|NCT02901236|Drug|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
79696369|NCT02900963|Other|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
79840732|NCT02550600|Procedure|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
79245204|NCT05949151|Other|oral health-related quality of life (OHRQoL)|Oral Health-related Quality of Life (OHRQoL) was estimated by employing the Oral Health Impact Profile questionnaire which comprises nineteen multiple questions that were translated into Arabic.
79840733|NCT03875482|Drug|Risankizumab|Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
79840734|NCT03875482|Drug|Placebo solution for risankizumab|Placebo solution in prefilled syringes, self-administered subcutaneously
79840735|NCT04095767|Device|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters [DACs]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
79840736|NCT00820404|Drug|BLI-489|
79840737|NCT00820404|Drug|Placebo|
79384196|NCT02002936|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
79245205|NCT05949112|Device|soft bristle toothbrush|manual toothbrushes
79245206|NCT05949112|Device|mechanical toothbrush|sonic toothbrush
79384197|NCT02461056|Drug|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
79384198|NCT02461056|Drug|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
79384199|NCT02003404|Device|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
79384200|NCT02003404|Device|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
79696370|NCT04621422|Biological|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
79840738|NCT00820482|Drug|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
79245207|NCT05949060|Behavioral|Compassion Intervention|The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
79384201|NCT05229978|Other|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
79384202|NCT01173172|Radiation|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
79384203|NCT00003270|Biological|anti-thymocyte globulin|IV
79384204|NCT00003270|Biological|filgrastim|IV
79384205|NCT00003270|Drug|busulfan|IV
79384206|NCT00003270|Drug|cyclophosphamide|IV
79384207|NCT00003270|Drug|cyclosporine|IV
79384208|NCT00003270|Drug|methylprednisolone|IV
79384209|NCT00003270|Procedure|bone marrow ablation with stem cell support|IV
79696371|NCT04621617|Drug|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
79840739|NCT00820482|Drug|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
79840740|NCT00754793|Drug|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
79840741|NCT00754793|Drug|placebo|inactive comparator; titrated as per protocol over 12 weeks
79840742|NCT00826410|Device|Redon drain|subcutaneous suction drain after laparotomy for two days
79840743|NCT00826488|Device|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
79384210|NCT00003270|Procedure|umbilical cord blood transplantation|IV
79384211|NCT00003270|Radiation|radiation therapy|High energy X-rays
79696372|NCT04621617|Drug|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
80010855|NCT02053194|Behavioral|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
79696373|NCT04621617|Drug|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
79696374|NCT02900924|Device|BioMimics 3D Stent|
79696375|NCT00562380|Biological|ganitumab|
79384212|NCT02005354|Device|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
79538791|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
79696376|NCT00562380|Other|laboratory biomarker analysis|
79696377|NCT00562380|Other|pharmacological study|
80010856|NCT02190578|Device|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
80010857|NCT03536078|Other|home phototherapy|
80010858|NCT02804178|Drug|ATR-101|125-1000 mg twice per week
79384213|NCT02005354|Drug|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
79384214|NCT03290898|Behavioral|High Intensity Interval Training|Training (HIIT)
79384215|NCT02066740|Device|EverFlex™ stent with Entrust™ delivery system|
79384216|NCT03290820|Radiation|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
79538792|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
79384217|NCT03290820|Drug|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
79384218|NCT03290820|Drug|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
79696378|NCT00562380|Procedure|biopsy|
79696379|NCT02900612|Other|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
79696380|NCT02900612|Other|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
79696381|NCT02900612|Other|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
79696382|NCT01212757|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
79696383|NCT01212757|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
79696384|NCT01212757|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
79696385|NCT01212757|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
79696386|NCT00562419|Drug|CT-322|IV solution, weekly
79696387|NCT00562419|Drug|irinotecan hydrochloride|IV solution, biweekly
79696388|NCT02900768|Behavioral|Exercise|Combination of resistance and aerobic exercises for 100 days.
79696389|NCT00562458|Drug|anastrozole|
80010859|NCT02190734|Other|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
80010860|NCT02190734|Other|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
80010861|NCT02190734|Other|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
79245208|NCT05948995|Device|Abduction external rotation brace|Abduction external rotation brace Arm position : Abduction , External rotation
79696390|NCT02900729|Device|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
80010862|NCT02054598|Behavioral|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
80010863|NCT02190812|Device|Forearm supporter|The forearm supporter be use in tennis elbow.
80010864|NCT02190812|Device|Grip ball|
79245209|NCT05948982|Biological|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
79384219|NCT01135342|Behavioral|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
79384220|NCT01135342|Behavioral|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
79384221|NCT01135342|Behavioral|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
79384222|NCT03295188|Dietary Supplement|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
79384223|NCT03295188|Dietary Supplement|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
80010865|NCT02054676|Radiation|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
79245210|NCT05948969|Other|Decision support|"This implementation strategy will include the clinician education of the previous arm and apply audit and feedback of prior care to inform recommendations for future care. These suggestions will encompass 5 different domains based on eligibility and potential opportunity for an SGLT2i, GLP-1RA, angiotensin converting enzyme inhibitors (ACEi)/angiotensin-receptor blockers (ARB), antiplatelet or antithrombotic therapy, and statin therapy. The incorporation of clinical decision support technology will be utilized to identify tailored opportunities for each CV risk reduction based on guideline recommendations for individual patients. Clinicians will be presented prompts with patient-specific recommendation(s) for further optimization of cardioprotective agents. These prompts will be conveyed by a Study Coordinator to responsible clinicians. The follow-up clinical prompts will be based on auditing of updated clinical parameters and medication use."
79245211|NCT05948969|Other|Facilitated referral to a cardiometabolic team-based center|Each site will have access to clinicians caring for patients in structured, multidisciplinary cardiometabolic centers. Clinicians caring for patients randomized to this intervention strategy will receive a facilitated referral via the EHR together). If the clinician approves the referral, the patient will be referred to this local team-based comprehensive risk factor management clinic. All patients randomized to this group will be considered in this group whether or not a visit to the cardiometabolic center is completed.
79245212|NCT05948891|Drug|Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)|observational, prospective, multicentric, international, cohort study
79245213|NCT05948852|Procedure|metabolic surgery (SADIS and OAGB)|TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
79245214|NCT05948800|Dietary Supplement|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
79245215|NCT05948774|Drug|MT200605 for Injection|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
79245216|NCT05948774|Drug|MT200605 Placebo|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
79384224|NCT03295110|Other|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
79384225|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
79384226|NCT02066896|Device|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
79384227|NCT02066896|Device|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
79384228|NCT03773484|Behavioral|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
79384229|NCT03773484|Behavioral|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
79538793|NCT04806165|Behavioral|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79384230|NCT03773484|Behavioral|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
79840744|NCT04102397|Procedure|Vojta therapy after standard therapy|Vojta Therapy ~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
79384231|NCT02334358|Device|YVOIRE Classic s|
79384232|NCT02005510|Behavioral|Mailed in-home high-risk HPV testing kit|
79696391|NCT02900729|Drug|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
79696392|NCT00562536|Procedure|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
79840745|NCT04102397|Procedure|Standard therapy|"~50 minutes/session:~TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~Cryotherapy (5 minutes)."
79840746|NCT00826566|Dietary Supplement|Caffeine|2 times 250 mg caffeine per day
79840747|NCT00826566|Dietary Supplement|placebo|2 times 250 mg per day
79840748|NCT03999190|Drug|NPA radiotracer|"[11C]NPA radiotracer, 2 injection per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
79840749|NCT03999190|Drug|Raclopride radiotracer|"[11C]raclopride radiotracer, 2 injections per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
79840750|NCT03999190|Drug|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
80010866|NCT02054676|Procedure|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~implant drill slippage deeper than planned;~implant threads coverage;~etc."
79840751|NCT04093817|Device|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
79245217|NCT05948761|Other|Hypoxia through modified hypoxic generator|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants.
79245218|NCT05948761|Other|Normoxia through hypoxic generator without active elements|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants, without active elements.
79384233|NCT02005510|Other|Usual care|
80010867|NCT02054676|Device|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
79840752|NCT02549976|Procedure|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
79840753|NCT02549976|Procedure|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
79840754|NCT02549976|Procedure|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
79391844|NCT03169140|Device|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
79696393|NCT01190410|Drug|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
79696394|NCT01190410|Drug|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
79840755|NCT02549976|Procedure|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
79840756|NCT00586469|Biological|Fluviral|One dose, Intramuscular injection
79245219|NCT05948735|Other|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT) for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates OEP-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
79245220|NCT05948735|Other|Physical Therapy Exercise (PTE) only for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
79391845|NCT03169140|Behavioral|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
79696395|NCT01190254|Drug|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
80010868|NCT02054676|Radiation|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
79538794|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79696396|NCT01190254|Drug|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
79245221|NCT05948722|Behavioral|Motivational Interview Group (MIG)|Behavioral intervention program based on motivational interview beyond conventional treatment
79245222|NCT05948696|Behavioral|Horticultural group therapy.|Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
79245223|NCT05948631|Behavioral|MISC intervention|MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.
80010869|NCT02054676|Drug|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
80010870|NCT02054676|Procedure|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
80010871|NCT02256956|Drug|Amitriptyline|25 mg / day for 10 days
79245224|NCT05948631|Behavioral|Treatment as Usual (TAU)|TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
79245225|NCT05948527|Device|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
79245226|NCT05948514|Other|The complications related to central venous access device|The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
79245227|NCT05948488|Other|Questionnaires|The questionnaires focus on anxiety, fear and quality of life.
79245228|NCT05948449|Drug|S-1, Oxaliplatin, Cadonilimab|3 cycles of neoadjuvant therapy will be administered: S-1: 40~60mg Bid，d1~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
79538795|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
79840757|NCT00820560|Drug|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
79538796|NCT04800783|Diagnostic Test|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
79538797|NCT04799899|Behavioral|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
79696397|NCT01190254|Drug|placebo|asenapine-matched placebo tablets for sublingual administration
79696398|NCT04315987|Biological|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
79696399|NCT04315987|Biological|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
79840758|NCT05244694|Drug|Insulin|Priming dose then a constant infusion at 40 mU•m-2•min-1
79840759|NCT00820638|Device|myomo e100|use of the myomo e100 in home
79245229|NCT05948423|Other|Tisue Flossing Technique|"Experimental Group (Tissue Flossing + conventional therapy) Tissue Flossing involved active and passive movement with elbow wrapped with a floss band made from latex rubber (7m x 2 inch) Floss band was wrapped around the elbow (distal to proximal) using 25% overlapping pattern with an elongation stretch of 25%. During treatment the compression of floss band was measured with modified sphygmomanometer by placing cuff under floss band (which is applied on muscle) and note the pressure on manometer.~Control Group (Conventional Therapy) Conventional therapy was applied for 23 minutes for both groups which include hot pack for 10 minutes, PNF (hold-relax with agonist contraction): It started with a gentle stretch of bicep muscle for 10 seconds followed by isometric contraction for 6 seconds then the patient tried to flex their elbow and the therapist also assisted."
79696400|NCT04621383|Dietary Supplement|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
79538798|NCT04799899|Behavioral|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
79840760|NCT04023383|Drug|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
80010872|NCT02256956|Drug|Tolterodine|Placebo 1 mg / day for 10 days
80010873|NCT02187536|Drug|Telmisartan|
80010874|NCT02187536|Drug|Simvastatin|
79245230|NCT05948410|Behavioral|The State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.
79384234|NCT03295032|Behavioral|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
79538799|NCT04795232|Other|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
79384235|NCT03108222|Other|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
79538800|NCT04795232|Other|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
79538801|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 1|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
79538802|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 2|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
79538803|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 3|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
79840761|NCT04023383|Drug|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
79840762|NCT00626028|Drug|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
80010875|NCT02187536|Drug|Telmisartan placebo|
80010876|NCT02256722|Drug|KUC 7483 CL|
80010877|NCT02256722|Drug|Bisoprolol|
80010878|NCT02256722|Drug|Propranolol|
79538804|NCT04789577|Biological|AS03B|Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
79538805|NCT04789577|Biological|AS03A|Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
79538806|NCT04789577|Drug|Placebo|Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
79840763|NCT00626028|Drug|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
79840764|NCT00626028|Drug|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
80010879|NCT02256722|Drug|Acipimox|
80010880|NCT02256722|Drug|Salmeterol|
80010881|NCT05655624|Other|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
80010882|NCT05655624|Other|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
80010883|NCT02190890|Procedure|Dry needling|
80010884|NCT02190890|Procedure|Control|
80010885|NCT02056314|Other|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
80010886|NCT02056314|Other|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
79696401|NCT04621383|Dietary Supplement|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
79696402|NCT04621305|Other|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
79696403|NCT04621305|Drug|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
79696404|NCT04621305|Drug|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
79696405|NCT00553592|Drug|Bicifadine|600mg/day
79696406|NCT00553592|Drug|Bicifadine|placebo tablet
79696407|NCT00553592|Drug|Bicifadine|1200 mg
79384236|NCT03108144|Behavioral|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
79384237|NCT03283410|Drug|Propofol|Propofol plasmatic concentration (Marsh)
79384238|NCT04318704|Drug|Ifenprodil|Ifenprodil 20 mg TID
79696408|NCT04620954|Drug|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
79696409|NCT04620954|Drug|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
79696410|NCT04620954|Drug|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m^2 and 5 AUC (Area Under the Curve) respectively.
79696411|NCT04621032|Diagnostic Test|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
79696412|NCT04621032|Diagnostic Test|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
79696413|NCT02900261|Other|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
79696414|NCT00562692|Drug|Nesiritide|Nesiritide 4 hour infusion
79696415|NCT00562692|Drug|Placebo|Placebo infusion
79245231|NCT05948410|Behavioral|Perceived Stress Scale|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale
79384239|NCT03283332|Other|No intervention|
79696416|NCT02900534|Other|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
79696417|NCT04621110|Drug|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
79696418|NCT04621110|Drug|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
79696419|NCT04621110|Drug|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
79696420|NCT04621110|Drug|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
79840765|NCT00777257|Biological|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
79840766|NCT00777257|Biological|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
79840767|NCT00777257|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
79840768|NCT00820716|Other|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
80010887|NCT02190968|Behavioral|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
79696421|NCT04620720|Drug|capule gabapentin|neuropathic analgesic
79840769|NCT00826644|Drug|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
79840770|NCT00826644|Drug|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
79840771|NCT00826644|Drug|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
79696422|NCT02900222|Procedure|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
79245232|NCT05948410|Behavioral|Visual Analog Scale|The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
80010888|NCT02190968|Behavioral|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
80010889|NCT02056470|Device|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
79384240|NCT03283176|Diagnostic Test|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
79384241|NCT03290586|Device|Flower Cube|single use, sterile disposable fixation construct
79245233|NCT05948397|Diagnostic Test|Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale|A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.
79245234|NCT05948397|Diagnostic Test|Bladder diary|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance
79538807|NCT04772456|Drug|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) [ 13C]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize [13C]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and [13C]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as [1- 13C]pyruvate, [2- 13C]pyruvate and [1,2- 13C]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body [Koletzko et al., 1997]."
79696423|NCT04620642|Biological|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
79696424|NCT02900417|Drug|Sitagliptin|All the patients will receive sitagliptin 100mg daily
79696425|NCT04620876|Other|Bimodal high resolution imaging of the retina|The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
79384242|NCT03290430|Behavioral|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
80010890|NCT02056470|Device|Total Knee Replacement|total Knee replacement implant
80010891|NCT02056470|Device|Freedom Total Knee System|Total Knee replacement implant
80010892|NCT02187614|Drug|Diclofenac|
80010893|NCT02187614|Drug|Morphine|
80010894|NCT02187614|Drug|Paracetamol|
80010895|NCT02187614|Drug|Placebos|
80010896|NCT02030678|Drug|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
80010897|NCT02054832|Dietary Supplement|Glycosade|
79384243|NCT03290430|Behavioral|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
79384244|NCT03290430|Behavioral|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
79384245|NCT03290430|Behavioral|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
79384246|NCT03290430|Behavioral|Texting support|Texts with smoking cessation support throughout the program
79384247|NCT03290430|Drug|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
79384248|NCT03290352|Other|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
79384249|NCT03294798|Biological|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
79384250|NCT03294798|Biological|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
79696426|NCT04620408|Drug|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
80010898|NCT03677349|Procedure|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
79384251|NCT03294720|Procedure|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
79384252|NCT03294720|Device|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
79538808|NCT04756609|Procedure|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~A nasopharyngeal swab for SARS-CoV2 will be carried out.~A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
79696427|NCT02900183|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
79848978|NCT05700383|Behavioral|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
80010899|NCT02187692|Behavioral|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
79384253|NCT04488744|Drug|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
79696428|NCT02900495|Device|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
79696429|NCT04620837|Drug|Tislelizumab|Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
79696430|NCT04620837|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
79696431|NCT00562731|Drug|ARD-0403|Daily transdermal ARD-0403
79696432|NCT02900027|Drug|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
79696433|NCT02900027|Drug|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
80010900|NCT02058732|Other|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
79384254|NCT02005666|Drug|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
80010901|NCT03684603|Behavioral|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
80010902|NCT03684603|Behavioral|melody only during motor training|sequence of tones which are presented to the patient using earphones
80010903|NCT02187770|Device|IMED-4|Non invasive recording electrode used to assess lung fluid
79245235|NCT05948397|Diagnostic Test|Pad test|"One-hour pad test.~the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in <15 min- then sits or rests,~patient walks for 30 min, including climbing one flight of stairs (up and down),~patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and >50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (>75 g/24 hr) incontinence"
79384255|NCT02005666|Drug|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
79384256|NCT02005666|Drug|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
79384257|NCT03283020|Drug|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
79384258|NCT03283020|Drug|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
79384259|NCT03294642|Dietary Supplement|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
79245236|NCT05948358|Other|Menstrual Distress Questionnaire|The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
79696434|NCT04620447|Other|Intelligent Virtual Reality Therapy System (IVRTS)|The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
79245237|NCT05948319|Diagnostic Test|Doppler ultrasonography|Doppler study was performed in all cases. perinatal outcomes were evaluated.
79245238|NCT05948280|Other|Virtual reality-supported mindfulness|A single mindful stretching exercise provides a conscious stretch of VR scenario. The implementation of VR exercises will be performed by the interventionist who have received training in the application of VR scenarios and have extensive experience in VR research.
79245239|NCT05948280|Other|Mindfulness|The interventionist will guide the participant to do a mindful stretching exercise in the first week. During the second week, the interventionist will send participants an audio recording on how to do mindful stretching exercise via WeChat/WhatsApp.
79245240|NCT05948254|Procedure|Triple function scan body|The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
79245241|NCT05948241|Other|Online psychological support group|"st Session: Presentation of the participants and the objectives of the group, which are the management of depression and the promotion of self-care. Discussion on heart failure and its clinical management. Arrangements will be made with these patients about confidentiality between the participants, as it is a group intervention where each participant can expose their personal issues.~nd Session: Discussion on depression and its clinical management. From the 3rd to the 11th Session: They will aim to offer support for the emotional demands of the participants, related to the daily and future challenges inherent in the care provided with HF, seeking to promote self-care. As it is a homogeneous group, it is expected to enable enriching exchanges within the group about changes in habits or adaptations to HF, since psychological support groups have this function.~12th Session: Closing and evaluation of participants. Scheduling for reassessment of instruments"
79384260|NCT03294642|Dietary Supplement|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
79384261|NCT03294642|Dietary Supplement|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
79384262|NCT00494182|Drug|Carboplatin|Given IV
79384263|NCT00494182|Drug|Paclitaxel|Given IV
79384264|NCT00494182|Drug|Sorafenib|Given PO
79384265|NCT03294564|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
79538809|NCT04756609|Other|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
79538810|NCT04752826|Drug|BI-1808|BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intravenous (IV) infusions every 3 weeks.
79538811|NCT04752826|Drug|Pembrolizumab 25 Mg/mL Solution for Injection|Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
79840772|NCT04095533|Other|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
79384266|NCT03294564|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
79696435|NCT02900144|Behavioral|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
79538812|NCT04749368|Drug|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
79696436|NCT02900144|Behavioral|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
80010904|NCT02054988|Other|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San Diego, California]) was measured at baseline and after 10-days of coffee intake."
79696437|NCT04620018|Drug|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
79245242|NCT05948241|Other|Standard multidisciplinary care|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
79245243|NCT05948228|Drug|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
79245244|NCT05948228|Drug|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
79696438|NCT02900105|Drug|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
79245245|NCT05948215|Dietary Supplement|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
79245246|NCT05948215|Dietary Supplement|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
79245247|NCT05948202|Behavioral|Pivotal Response Treatment|Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
79245248|NCT05948150|Other|using a breastfeeding pillow|To make the breastfeeding pillow group use the breastfeeding pillow from the 8th hour in the postnatal period and to make evaluations at 24 and 48 hours
79384267|NCT03290274|Device|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
79696439|NCT02899910|Behavioral|Health education|Education on lifestyle changes for treatment of metabolic syndrome
80010905|NCT02054988|Other|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
79245249|NCT05948150|Other|not using a breastfeeding pillow|The non-breastfeeding pillow group was evaluated at 24 and 48 hours without the use of a breastfeeding pillow
80010906|NCT03682341|Genetic|endometriosis|patients with or without ovarian endometriosis
79245250|NCT05948137|Diagnostic Test|F-18 FDOPA PET/CT|Nuclear medicine imaging modalities
79245251|NCT05948124|Drug|L-carnitine|L-carnitine supplementation
79384268|NCT03290274|Device|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
79384269|NCT02006056|Drug|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
79384270|NCT03290196|Drug|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
79384271|NCT03282942|Other|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~Squatting~Leg press~Knee Extension~Knee Flexion~Supine Challenge~High Pull~Elbow flexion~Extension of elbows~Development~Abdominal"
79384272|NCT03282942|Other|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
79538813|NCT04749368|Biological|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
80010907|NCT02055066|Drug|ARGX-111|
79245252|NCT05948124|Other|isotonic saline|Intravenous 5 ml of isotonic saline
79538814|NCT04749368|Biological|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
79538815|NCT04737382|Diagnostic Test|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
79538816|NCT04737382|Diagnostic Test|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
79696440|NCT02899910|Behavioral|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
79840773|NCT04095533|Other|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
79840774|NCT04018560|Behavioral|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
80010908|NCT03684525|Procedure|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
80010909|NCT04615754|Dietary Supplement|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
79384273|NCT02006836|Dietary Supplement|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
79384274|NCT02006836|Dietary Supplement|Glucose|We dissolved 50 g of glucose in 200 ml water.
79245253|NCT05948072|Drug|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
79245254|NCT05948072|Drug|mFOLFOX 6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
79245255|NCT05948046|Behavioral|Visual training in hospital|Completion of 1 session of standardized visual training
79696441|NCT04619940|Diagnostic Test|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
79384275|NCT02006836|Other|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
79384276|NCT02006836|Drug|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
79384277|NCT02006836|Drug|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
79384278|NCT03290118|Other|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
79384279|NCT03290118|Other|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
79538817|NCT04733183|Drug|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
79538818|NCT04733183|Drug|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
79696442|NCT04619940|Diagnostic Test|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
79696443|NCT04619784|Other|Pilates Exercises|Patients will receive 12 sessions of pilates.
79696444|NCT04619784|Other|control|Their routine medical treatments were continued
79696445|NCT02899871|Other|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~serum assays of the anti-TNF administered, as well as screening for associated antibodies."
79840775|NCT00916877|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
79538819|NCT04732884|Device|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
79538820|NCT04732884|Device|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
79538821|NCT04732624|Drug|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
79840776|NCT00824148|Device|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
79840777|NCT00824148|Other|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
80010910|NCT04615754|Dietary Supplement|Placebo - use of saline infusion|Saline is infused as an comparator
80010911|NCT02058810|Device|Nasal high flow|
79696446|NCT04619667|Device|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
79538822|NCT04732624|Drug|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
79696447|NCT04619667|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
79696448|NCT02899832|Device|NIRS|Near Infra Red Spectroscopy
79840778|NCT04925050|Drug|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
79696449|NCT04619862|Drug|Gabapentin|See arm descriptions
79696450|NCT04619862|Drug|Placebo|See arm descriptions
79840779|NCT04925050|Other|Matching Placebo for VB0004|Matching Placebo
79840780|NCT00826722|Drug|Levetiracetam|1000 mg tablet
79840781|NCT04922944|Drug|COVID-19 vaccine|Two-dose COVID-19 vaccine
79245256|NCT05948033|Biological|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10^6 cells/kg) ,Dose 2(3×10^6 cells/kg) ,Dose 3 (1×10^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3."
79384280|NCT03290118|Other|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
79840782|NCT02549586|Drug|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
79696451|NCT05425121|Procedure|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
79696452|NCT05425121|Device|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
79696453|NCT01190839|Biological|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
79840783|NCT00820794|Drug|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
79840784|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
79840785|NCT00820794|Drug|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
79840786|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
79245257|NCT05947968|Other|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~anterior elevation and posterior depression~posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
79538823|NCT04722133|Drug|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
79538824|NCT04701437|Behavioral|Peer mentor|Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.
79696454|NCT01190839|Drug|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
79696455|NCT05425043|Biological|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
79696456|NCT02887261|Device|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
79840787|NCT04516876|Other|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
79840788|NCT04044378|Drug|Famitinib|famitinib with RP2D orally daily
79840789|NCT04044378|Drug|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
79840790|NCT04044378|Drug|Camrelizumab|camrelizumab 200mg infusion once Q2W
79840791|NCT04512586|Procedure|Conduction System pacing and AV node ablation|See study arm description.
79840792|NCT04512586|Procedure|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
80010912|NCT02058810|Device|Conventional nasal oxygen|
79840793|NCT04914052|Other|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
79538825|NCT04701437|Behavioral|Standard of care|Passive referral to a HCV provider
79840794|NCT00628758|Drug|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
79840795|NCT00628758|Drug|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
79840796|NCT04491604|Biological|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
79840797|NCT04491604|Other|Placebo|Matching masked inactive topical gel
79840798|NCT00824226|Dietary Supplement|magnesium|magnesium 350 mg tablets once a day for 3 weeks
79840799|NCT03999112|Other|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
79840800|NCT00821028|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
79840801|NCT00821106|Procedure|Right radial|diagnostic or interventional procedures performed through right transradial approach
79840802|NCT00821106|Procedure|left radial|diagnostic or interventional procedures performed through left transradial approach
79840803|NCT00826878|Drug|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
79840804|NCT00826956|Procedure|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
79840805|NCT00827034|Drug|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
79840806|NCT00827034|Drug|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
79840807|NCT00827034|Drug|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
79840808|NCT00754559|Drug|Tocilizumab|8mg/kg iv every 4 weeks
79538826|NCT04700046|Drug|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
79538827|NCT04700046|Drug|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
79840809|NCT02600585|Biological|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
79840810|NCT02600585|Biological|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
79840811|NCT00525148|Drug|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
80010913|NCT03677271|Behavioral|Physical Activity|
80010914|NCT02191124|Drug|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
80010915|NCT02191124|Drug|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
79538828|NCT04687956|Procedure|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
79538829|NCT04687956|Procedure|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
79538830|NCT04664829|Drug|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m^2
79840812|NCT00754325|Drug|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
79840813|NCT00754325|Drug|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
79840814|NCT00524680|Dietary Supplement|cholecalciferol|Given orally
79384281|NCT03290118|Device|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
79538831|NCT04664829|Drug|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m^2
79538832|NCT04651400|Drug|Antithrombin III|Antithrombin III
79840815|NCT04794322|Diagnostic Test|Uterine lavage, or a wash of the womb|Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
79840816|NCT04794322|Diagnostic Test|Blood sample|Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
79840817|NCT04794322|Diagnostic Test|Pap smear|Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
79538833|NCT04651374|Device|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
79538834|NCT04650984|Drug|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
79696457|NCT02887261|Device|Conventional Port|not for power injection for contrast media.
79696458|NCT04619277|Device|drug-coated balloon|drug-coated balloon
79696459|NCT01190215|Biological|FluarixTM|One Intramuscular injection
79696460|NCT01190215|Biological|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
79696461|NCT04619238|Diagnostic Test|King's Health Questionnaire|patients fulfilled questionnaire
79696462|NCT04619238|Diagnostic Test|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
79696463|NCT05424965|Other|no intervention|no intervention
79696464|NCT04619394|Other|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
79696465|NCT04619394|Other|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
79696466|NCT00553865|Drug|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
79840818|NCT00628212|Drug|Teneligliptin 10mg|
79538835|NCT04650984|Drug|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
79538836|NCT04649502|Combination Product|Metformin|Metformin in combination with doxycycline
79538837|NCT04637087|Other|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
79538838|NCT04632576|Other|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
79538839|NCT04629651|Drug|Captopril|Oral, to be administered per the dose escalation scheme.
79696467|NCT00562770|Drug|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
79696468|NCT00562770|Drug|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
79696469|NCT04619550|Other|High tibial osteotomy|Realignment surgery
79840819|NCT00628212|Drug|Teneligliptin 20 mg|
79840820|NCT00628212|Drug|Teneligliptin 40 mg|
79840821|NCT00628212|Drug|Placebo|
79840822|NCT05160610|Behavioral|Multilevel intervention|Multilevel intervention based on AACTT theory
79840823|NCT00298363|Drug|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
79840824|NCT00298363|Drug|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
79840825|NCT00298363|Drug|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
79840826|NCT00298363|Drug|TDF placebo|Placebo to match TDF QD
79840827|NCT00298363|Drug|FTC/TDF placebo|Placebo to match FTC/TDF QD
79840828|NCT00298363|Drug|ETV placebo|Placebo to match ETV QD
80010916|NCT03677193|Behavioral|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min * 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
79245258|NCT05947968|Other|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~Standing shoulder external rotation with elastic resistance.~Bilateral external rotation with scapular retraction exercise.~Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
79538840|NCT04614103|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
79538841|NCT04614103|Biological|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
79538842|NCT04614025|Biological|PLX-PAD|PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
79840829|NCT00821262|Drug|sevoflurane|
80010917|NCT02193698|Drug|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
79384282|NCT04378530|Behavioral|Personalized Anchoring Strategy|"The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm)."
79696470|NCT05424692|Drug|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
79696471|NCT04618965|Drug|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
79696472|NCT04618965|Drug|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
79840830|NCT00821262|Drug|propofol|
79840831|NCT00824694|Other|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
79840832|NCT00824694|Other|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
79840833|NCT00824694|Other|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
80010918|NCT03682185|Behavioral|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
79245259|NCT05947916|Device|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
79245260|NCT05947877|Procedure|Non-pharmacological pain management strategies|Non-pharmacological pain management strategies
79538843|NCT04604444|Behavioral|Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech|Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
79538844|NCT04601857|Drug|futibatinib and pembrolizumab|Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
79538845|NCT04601415|Diagnostic Test|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
79538846|NCT04591951|Behavioral|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
79538847|NCT04591951|Other|Usual care|Care as usual
79538848|NCT04591405|Biological|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
79538849|NCT04591405|Biological|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
79538850|NCT04591405|Biological|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
79538851|NCT04591405|Biological|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
79538852|NCT04585243|Device|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
79840834|NCT00830622|Other|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
79840835|NCT01065883|Behavioral|community health worker|community health workers will provide education in the home
79245261|NCT05947825|Drug|Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
79245262|NCT05947812|Drug|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
79538853|NCT04583878|Diagnostic Test|Blood draw (Visit 1)|Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.
79538854|NCT04583878|Diagnostic Test|Blood draw (Visits 2 and 3)|Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
79538855|NCT04578327|Device|Prosthetic hand|Different types of conventional prosthetic limbs will be used by subjects.
79538856|NCT04578327|Procedure|Peripheral Nerve Interface|Different types of peripheral nerve stimulation will take place
79538857|NCT04571502|Other|CareHeroes|CareHeroes (CH) is IT that addresses lack of caregiver support and education about ADRD care that often result in depression, burden, and low caregiving self-efficacy. The CH intervention provides caregivers with electronic and video-based educational materials, links to services, and self-assessments for depression and burden that offer feedback. It also allows the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the provider. The clinical trial evaluates the impact of the addition of an AAC interface (e-communication board) to CareHereos that relies on touchscreen technology, pictures, and text to support PWD with communication deficits so that the PWD can engage and communicate about preferences and experiences with the caregiver and provider about their daily and clinical care. The minimal intervention group will only have access to a paper version of the AAC.
79696473|NCT04618965|Drug|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
79696474|NCT04618926|Device|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
79840836|NCT01065883|Behavioral|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
79840837|NCT00830700|Other|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
79840838|NCT00830778|Procedure|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
79696475|NCT05424653|Device|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
79696476|NCT01190449|Biological|ofatumumab|Given IV
79696477|NCT00562809|Drug|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
79384283|NCT04378530|Behavioral|Non-Anchoring Strategy Control|The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
79696478|NCT01190176|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
79696479|NCT01190176|Biological|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
79840839|NCT00830778|Procedure|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
79538858|NCT04558931|Drug|CellProtect|In vitro expanded and activated autologous NK cells
79538859|NCT04558931|Drug|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
79538860|NCT04557085|Drug|Cenobamate|Cenobamate tablets
79538861|NCT04557085|Drug|Placebo|Matching placebo tablets
79538862|NCT04555694|Drug|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
79538863|NCT04555694|Drug|Loteprednol Etabonate|Used to treat inflammation of the eye
79696480|NCT01190176|Biological|Placebo control|Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
79696481|NCT04206280|Behavioral|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
79696482|NCT04206280|Behavioral|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
79696483|NCT04618848|Diagnostic Test|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
79696484|NCT04316065|Drug|YHP1906|YHP1906 Tab. 5 mg
79840840|NCT03981913|Behavioral|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
79840841|NCT02548572|Device|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
79384284|NCT04378530|Behavioral|Fixed Anchoring Strategy|The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
79840842|NCT00524368|Drug|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
79384285|NCT02068846|Drug|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
79538864|NCT04555694|Drug|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
79538865|NCT04541667|Other|Air|Air will be used for luminal inflation.
79538866|NCT04541667|Other|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
79696485|NCT04316065|Drug|YHR1902|Comparator. YHR1902 Tab. 5 mg
79696486|NCT01190098|Drug|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
79696487|NCT01190098|Drug|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
79538867|NCT04537871|Procedure|Bioelectric Impedance Analysis|Undergo bioelectric impedance analysis
79840843|NCT00524368|Drug|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
79840844|NCT00777101|Drug|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
79840845|NCT00777101|Drug|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
79840846|NCT00777101|Drug|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
79840847|NCT00830856|Drug|Fluconazole|Fluconazole 800mg po qday
79840848|NCT00830856|Drug|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
79840849|NCT00830856|Drug|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
79840850|NCT01068067|Other|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
79840851|NCT01068067|Drug|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
79538868|NCT04537871|Procedure|Biospecimen Collection|Undergo collection of blood samples
79538869|NCT04537871|Procedure|Cardiopulmonary Exercise Testing|Undergo cardiopulmonary exercise test
79538870|NCT04537871|Procedure|Echocardiography|Undergo echocardiogram
79696488|NCT04618887|Procedure|pallidotomy|deep brain nuclei lesion of GPi
79696489|NCT04618887|Procedure|deep brain stimulation|deep brain stimulation of GPi
79696490|NCT02885857|Drug|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
79696491|NCT04314739|Dietary Supplement|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
79840852|NCT00827190|Drug|ILS-920|
79840853|NCT00297427|Procedure|Acupuncture|Acupuncture twice weekly for 6 weeks.
79384286|NCT02068846|Drug|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
79538871|NCT04537871|Procedure|Physical Performance Testing|Undergo physical function tests
79538872|NCT04537871|Procedure|Pulmonary Function Test|Undergo pulmonary function test
79538873|NCT04537871|Other|Questionnaire Administration|Ancillary studies
79538874|NCT04537871|Procedure|Ultrasound|Undergo musculoskeletal ultrasound
79538875|NCT04527003|Drug|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
79696492|NCT04314739|Dietary Supplement|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
79696493|NCT00562848|Drug|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
79696494|NCT00562848|Drug|Placebo|Subjects will receive placebo.
79696495|NCT02885740|Other|Quantification assay of adenosine and methionine cycle metabolites|
79696496|NCT02885740|Genetic|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
79696497|NCT02885740|Other|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
79696498|NCT02885740|Biological|Blood sample|
79696499|NCT05309785|Drug|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
79696500|NCT00562926|Procedure|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
79538876|NCT04527003|Drug|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
79538877|NCT04527003|Other|Placebo|a substance or treatment which is designed to have no therapeutic value
79538878|NCT04515797|Drug|Glecaprevir and Pibrentasvir|4 weeks of treatment starting within 24 hrs of kidney transplant
79840854|NCT00297427|Other|Sham acupuncture|Twice a week for 6 weeks
79245263|NCT05947812|Drug|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
79245264|NCT05947799|Other|Baseline questionnaires|Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
79384287|NCT03282864|Device|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
79245265|NCT05947799|Other|Post-questionnaire|Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
79384288|NCT03282786|Other|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
79384289|NCT03289884|Other|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
79384290|NCT03289884|Other|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
79384291|NCT03289884|Other|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
79384292|NCT03289884|Other|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
79384293|NCT03289884|Other|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
79384294|NCT03289806|Procedure|Samples of fibroblasts from Tenon's capsule|
79538879|NCT04511026|Drug|Lymphoseek|Radioactive diagnostic agent
79538880|NCT04511026|Device|Single Photon Emission Computed Tomography (SPECT)|Imaging test
79538881|NCT04511026|Drug|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
79538882|NCT04511026|Device|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
79840855|NCT00830934|Procedure|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
79840856|NCT00830934|Procedure|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
79840857|NCT00524134|Drug|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
79840858|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
79840859|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
79538883|NCT04510051|Drug|Cyclophosphamide|Given IV
79538884|NCT04510051|Drug|Fludarabine|Given IV
79538885|NCT04510051|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
79538886|NCT04501185|Device|total hip arthroplasty|The indication for total hip arthroplasty is mainly osteoarthritis.
79538887|NCT04498208|Behavioral|Physical Prehabilitation|First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome & Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.
79245266|NCT05947773|Other|Learning to walk with a robot|The patients completed a 1-hour learning to walk program using a soft exoskeleton. The protocol includes several difficult parts of the walk. (Walking protocol)
79384295|NCT03294486|Drug|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
79384296|NCT05235048|Procedure|Tooth extraction|Atraumatic tooth extraction without flap elevation
79538888|NCT04498208|Behavioral|Stress Reduction Prehabilitation|Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.
79696501|NCT01190020|Drug|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
79538889|NCT04498208|Behavioral|Cognitive Prehabilitation|Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.
79696502|NCT01190020|Drug|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
79696503|NCT01189435|Drug|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
79840860|NCT00777023|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
79245267|NCT05947773|Other|Walking group|The walking protocol was performed without robotic assistance for 1 hour every day for 3 weeks.
79840861|NCT05062330|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
79840862|NCT05062330|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
79840863|NCT00297037|Drug|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
79384297|NCT05235048|Procedure|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
79840864|NCT03978065|Diagnostic Test|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
79840865|NCT04093193|Procedure|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
79840866|NCT00292981|Drug|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
79840867|NCT02598869|Drug|Triamcinolone Acetonide|injection of triamcinolone acetonide
79840868|NCT04095455|Procedure|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
79384298|NCT05235048|Procedure|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
79245268|NCT05947773|Other|Control group|The control group performed the physiotherapy treatment for 3 weeks.
79245269|NCT05947708|Device|Dialysate Flow Rate|Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
79245270|NCT05947682|Other|Adipose tissue harvesting|Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
79245271|NCT05947669|Drug|Infliximab|Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
79245272|NCT05947669|Drug|Methylprednisolone|Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
79538890|NCT04498208|Behavioral|Nutrition Prehabilitation|Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
79696504|NCT05424614|Other|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
79696505|NCT05306158|Other|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
79696506|NCT05306158|Other|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
80010919|NCT03682185|Behavioral|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
79384299|NCT05235048|Procedure|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
79384300|NCT03294252|Drug|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
79696507|NCT05306158|Other|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
79840869|NCT04095455|Drug|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
79840870|NCT04095455|Drug|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
80010920|NCT02191202|Drug|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
80010921|NCT03561168|Diagnostic Test|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
80010922|NCT02055300|Drug|LY03005|
80010923|NCT02055300|Drug|Placebo|
80010924|NCT02055300|Other|Meal|
80010925|NCT02055300|Drug|Pristiq|
80010926|NCT02056860|Procedure|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
80010927|NCT02056860|Procedure|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
79245273|NCT05947669|Drug|Prednisolone|Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 [24-27]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
79245274|NCT05947643|Drug|theophylline|capsules dissolved in intranasal irrigation
79245275|NCT05947643|Drug|Placebo|identical-appearing lactose capsules dissolved in intranasal irrigation
79245276|NCT05947630|Device|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
79245277|NCT05947630|Device|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
79384301|NCT03294252|Drug|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
79538891|NCT04480463|Drug|SCD411|IVT (intravitreal) injection
79538892|NCT04480463|Drug|Aflibercept|IVT injection
79696508|NCT05304286|Behavioral|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
79696509|NCT01165996|Other|flow cytometry|Correlative studies
79696510|NCT01165996|Other|DNA methylation analysis|Correlative studies
79840871|NCT04095299|Radiation|50.4 Gy to the tumor and elective volume|Standard radiotherapy
79840872|NCT04095299|Radiation|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
79840873|NCT04095299|Drug|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
80010928|NCT02056860|Procedure|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
79538893|NCT04470609|Biological|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
79696511|NCT01165996|Other|cytogenetic analysis|Correlative studies
79840874|NCT00296725|Drug|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.
79840875|NCT00296725|Drug|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.
79840876|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
80010929|NCT02056860|Procedure|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
79245278|NCT05947617|Drug|VIX001|"This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes."
79245279|NCT05947604|Drug|Acoziborole|Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
79384302|NCT03294252|Drug|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
79384303|NCT03282708|Other|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
79384304|NCT03294174|Drug|Ropivacaine injection|Ropivacaine administered to provide nerve block
79538894|NCT04470609|Biological|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
79538895|NCT04470609|Biological|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
79696512|NCT01165996|Drug|decitabine|Given subcutaneously
79840877|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
79840878|NCT00523978|Device|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
80010930|NCT02056860|Procedure|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
80010931|NCT02191280|Drug|Antistax®, low dose|
80010932|NCT02191280|Drug|Antistax®, high dose|
80010933|NCT02191280|Drug|Placebo|
80010934|NCT03684369|Device|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
80010935|NCT03684291|Procedure|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
80010936|NCT02193854|Device|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
79245280|NCT05947604|Drug|Midazolam|• Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
79245281|NCT05947604|Drug|Dextromethorphan|• Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
79696513|NCT01165996|Genetic|microarray analysis|Correlative studies
79696514|NCT01165996|Genetic|gene expression analysis|Correlative studies
79840879|NCT00523978|Drug|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
80010937|NCT02055378|Drug|Atropine|topical 0.125% atropine eye drops
80010938|NCT02055378|Device|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
79538896|NCT04470609|Biological|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
79538897|NCT04464759|Drug|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
79696515|NCT01165996|Other|pharmacological study|Correlative studies
79696516|NCT01165996|Genetic|polymorphism analysis|Correlative studies
79696517|NCT04619433|Drug|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
79696518|NCT04619433|Drug|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
79696519|NCT02886871|Behavioral|Step Goal Delivery by Smartphone|
80010939|NCT04558190|Drug|Intralipid, 20% Intravenous Emulsion|Lipid infusion
79696520|NCT05424536|Other|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
79245282|NCT05947565|Diagnostic Test|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
79245283|NCT05947552|Drug|Serum ferritin|Serum ferritin in CKD patients
79245284|NCT05947526|Procedure|Oocyte pick-up|With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
79696521|NCT04652388|Behavioral|Nutritional counseling|Nutritional counseling about mediterranean diet
79696522|NCT04619160|Drug|Propofol|TCI 4 µg/mL start until BIS-value of 50
80010940|NCT04558190|Dietary Supplement|MitoQ|Oral administration of MitoQ capsules
79245285|NCT05947513|Drug|Curcumin|Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
79245286|NCT05947513|Radiation|Palliative radiotherapy|As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
79538898|NCT04464759|Drug|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
79538899|NCT04464759|Drug|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
79245287|NCT05947487|Biological|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10^6 cells/kg) , Dose 2(3×10^6 cells/kg) ,Dose 3 (1×10^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;"
79245288|NCT05947461|Drug|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
79538900|NCT04462601|Other|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
79538901|NCT04443010|Drug|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
79538902|NCT04443010|Drug|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
79538903|NCT04423237|Drug|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
79538904|NCT04416750|Drug|Imatinib Mesylate|Treatment with Imatinib
79538905|NCT04412538|Biological|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
79696523|NCT04619160|Drug|Sevoflurane|start 1 MAC, until BIS-value of 50
79696524|NCT01165684|Drug|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
79696525|NCT01165684|Drug|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
79696526|NCT01165684|Drug|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
79696527|NCT04618731|Diagnostic Test|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
79696528|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
79696529|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
79696530|NCT01189201|Drug|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
79696531|NCT01189201|Drug|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
79696532|NCT04652466|Device|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
79696533|NCT05424497|Other|Vignettes|Presenting vignettes with fictive cases
79696534|NCT01188967|Drug|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
79696535|NCT01188967|Drug|Placebo|Placebo
79696536|NCT04316728|Device|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
79696537|NCT04652271|Procedure|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
80010941|NCT04558190|Drug|Salbutamol|Beta2-agonist infusion
80010942|NCT03441321|Other|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
80010943|NCT03441321|Other|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
80010944|NCT03441321|Other|Survey Administration|Ancillary studies
80010945|NCT03676959|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
80010946|NCT03676959|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
80010947|NCT03676959|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
80010948|NCT02059044|Other|ISTOP-ADE|Interactive Voice Response System + Pharmacist
79538906|NCT04412538|Biological|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
79840880|NCT02599727|Other|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
79538907|NCT04412538|Biological|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
79840881|NCT02599727|Other|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
79840882|NCT00296647|Drug|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
79840883|NCT00296647|Drug|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
79840884|NCT00296647|Drug|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
79840885|NCT00296647|Drug|bupropion|dosage according to prescription directions: 12 weeks
79840886|NCT00296647|Drug|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
79840887|NCT00296647|Drug|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
80010949|NCT04917146|Other|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
79245289|NCT05947461|Drug|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
79245290|NCT05947422|Diagnostic Test|High resolution CT Chest|"CT chest in our institution will be done with standard high resolution protocol . No I.V contrast will be given. Scans will be obtained during full inspiration in supine position from the thoracic inlet to the level of the diaphragm.~Patients with CT chest performed outside our institution will be reviewed in DICOM format and assessed for its compatibility to be integrated into the computer-based analysis software."
80010950|NCT03755973|Drug|CFA|Long-acting exogenous ovarian stimulation
79538908|NCT04412538|Biological|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
79538909|NCT04412538|Biological|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
79696538|NCT02885935|Other|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
79696539|NCT02885935|Other|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
79696540|NCT05424458|Procedure|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
79696541|NCT04618380|Diagnostic Test|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
80010951|NCT03755973|Drug|rFSH|Daily rFSH
80010952|NCT03755973|Procedure|Fixed daily rFSH dosing protocol of 200-300 IU|The dose of daily rFSH is fixed at 200 or 300 IU
80010953|NCT03755973|Procedure|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
79538910|NCT04412538|Biological|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
79538911|NCT04412538|Biological|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
79696542|NCT05424107|Other|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
79840888|NCT00754013|Drug|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
79840889|NCT00754013|Drug|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
79840890|NCT04094987|Device|inter-fascial pressure|The pressure between the fascia and the pressure line added to the catheter tip will be measured.
79840891|NCT01062919|Procedure|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
79840892|NCT01062919|Procedure|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
79840893|NCT00523744|Drug|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
79840894|NCT00523744|Drug|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
79696543|NCT04652232|Other|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
79696544|NCT04652232|Other|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
79696545|NCT04652349|Drug|HGP1910|Take it once daily for 8 weeks orally.
79696546|NCT04652349|Drug|HCP1903|Take it once daily for 8 weeks orally.
79245291|NCT05947422|Diagnostic Test|Spirometry|Spirometry will be performed using standard techniques according to ATS-ERS criteria 2019 . Spirometry device (Zan 300, NSPIRE HEALTH GMBH Co.) will be used. Percentage predicted values (%pred) will be calculated based on reference values for healthy adults. All patients will be required to undergo spirometry in a reproducible way, and the best values will be reported. Spirometry should meet international acceptability and repeatability standards
79245292|NCT05947383|Drug|Psilocybin|Psilocybin 25 mg oral capsule
79245293|NCT05947383|Drug|Placebo|Niacin 100 mg oral capsule
79245294|NCT05947370|Drug|Berberine Chloride|Traditional Chinese medicine
79245295|NCT05947370|Drug|Placebo|Placebo control
79245296|NCT05947331|Procedure|Graded Anderson procedure|In graded Anderson proceduren only recession of yoke muscles is done.
79245297|NCT05947331|Procedure|Kestenbaum procedure|In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
79538912|NCT04412538|Biological|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0,14
79840895|NCT00523744|Drug|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
79245298|NCT05947318|Device|transcranial alternating current stimulation 70 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 70 Hz"
79245299|NCT05947318|Behavioral|Training|Training of the upper limb with specific kinematic and kinetic tasks plus functional training
79538913|NCT04411732|Device|MyotonPro|Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
79538914|NCT04411732|Diagnostic Test|Six-minute walk test|The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
79696547|NCT04652349|Drug|HGP1909|Take it once daily for 8 weeks orally.
79696548|NCT04652349|Drug|HGP1911|Take it once daily for 8 weeks orally.
79696549|NCT01188811|Drug|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
79696550|NCT01188811|Drug|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
79696551|NCT01183234|Drug|SPD544|two 30mg capsules, single oral dose
79696552|NCT01183234|Drug|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
79840896|NCT00523744|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
79840897|NCT03979625|Other|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
80010954|NCT02055534|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
80010955|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
79245300|NCT05947318|Device|transcranial alternating current stimulation 7 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 7 Hz"
79245301|NCT05947318|Device|transcranial alternating current stimulation Sham|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The stimulation will be turn on for 30 seconds (at 70 Hz)"
79538915|NCT04411732|Diagnostic Test|Semiquantitative muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
79538916|NCT04411732|Diagnostic Test|Hand-held Dynamometry of muscle strength|Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
79538917|NCT04411199|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
79538918|NCT04411199|Other|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
79538919|NCT04407247|Biological|Infliximab|Given IV
79538920|NCT04407247|Biological|Vedolizumab|Given IV
79538921|NCT04402216|Behavioral|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
79538922|NCT04402216|Behavioral|MRI preparation video|A descriptive video about what to expect when undergoing MRI
79696553|NCT04618497|Drug|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
79696554|NCT04618497|Drug|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
79696555|NCT05423873|Other|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
79696556|NCT04618575|Drug|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
79696557|NCT04618575|Drug|Ursodeoxycholic acid only|Ursodeoxycholic acid only
79245302|NCT05947292|Procedure|Ultrasound-Guided Fascia Iliaca Compartment Nerve Block|Patient's who receive this intervention will have an ultrasound-guided fascia iliaca compartment nerve block performed in the Emergency Department.
79696558|NCT04618419|Diagnostic Test|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
79696559|NCT04680338|Diagnostic Test|CMR stress perfusion imaging|CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
80010956|NCT03681717|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
80010957|NCT03623451|Drug|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
80010958|NCT02056938|Drug|Anti-Thymocyte Globulins treatment|
80010959|NCT02056938|Drug|Basiliximab treatment|
80010960|NCT02059200|Behavioral|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
79245303|NCT05947253|Other|Buyteko breathing technique|group A 20 participants received Buyteko breathing technique 2 session for 3 weeks
79245304|NCT05947253|Other|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks
79245305|NCT05947240|Other|aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
79538923|NCT04402216|Behavioral|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
79538924|NCT04398680|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered
79538925|NCT04389450|Biological|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
79538926|NCT04389450|Biological|Placebo|Placebo solution for injection
79538927|NCT04364230|Drug|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
79538928|NCT04364230|Drug|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
79384305|NCT03289494|Other|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
79384306|NCT03289494|Other|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
79840898|NCT04094831|Other|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
79384307|NCT03282630|Procedure|Sphenopalatine ganglion acupuncture|"active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
79696560|NCT04618536|Other|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
79538929|NCT04364230|Drug|PolyICLC|polyICLC, local adjuvant
80010961|NCT03536000|Diagnostic Test|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
79245306|NCT05947240|Other|active alternating movements for the upper limbs|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
79538930|NCT04364230|Drug|CDX-1140|CDX-1140, local adjuvant
79538931|NCT04362722|Drug|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (~1.08 mg) and 200 µg L19TNF.
79696561|NCT04618536|Other|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
79696562|NCT04679987|Diagnostic Test|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
79696563|NCT05423795|Other|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
79696564|NCT05423795|Other|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
79696565|NCT05423561|Procedure|exchange nailing with larger, thicker nail crossing corticalization|exchange nailing with larger, thicker nail crossing corticalization
80010962|NCT02191670|Drug|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
79245307|NCT05947227|Other|Buteyko breathing technique|Group A : will be treated with manual chest physiotherapy & Buteyko Breathing exercise
79384308|NCT03289416|Combination Product|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
79384309|NCT03289416|Combination Product|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
79384310|NCT03294096|Dietary Supplement|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
79384311|NCT03294096|Other|Routine care|Routine post-op care
79384312|NCT03282552|Device|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
79384313|NCT03294018|Other|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
79384314|NCT03289338|Drug|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
79384315|NCT03289338|Drug|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
79384316|NCT03289338|Drug|Placebos|Normal saline intravenous once a month for 3 months
79384317|NCT02069704|Drug|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
79696566|NCT04651959|Drug|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
79696567|NCT04651959|Drug|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
79696568|NCT01165216|Drug|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
79696569|NCT01165216|Drug|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
79696570|NCT01165216|Drug|Paclitaxel|IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
79840899|NCT00831012|Biological|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
79696571|NCT01165216|Drug|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
79538932|NCT04350866|Other|Expert Recommendations for Implementing Change (ERIC) bundle of strategies|"Develop a formal implementation blueprint/checklist~Conduct educational meetings; Develop & distribute educational materials~Organize implementation meetings~Audit and provide feedback~Facilitation~Increase demand with marketing to patients~Promote adaptability~Involve patients and family; Use their feedback; Prepare them to be active participants"
79538933|NCT04344626|Device|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
79384318|NCT02069704|Drug|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
79538934|NCT04332341|Drug|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
79538935|NCT04325659|Device|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
79696572|NCT04651881|Drug|Reference drug|1 Cap., single oral administration under fed condition
79696573|NCT04651881|Drug|Test drug 1|1 Tab., single oral administration under fed condition
79696574|NCT04651881|Drug|Test drug 2|1 Tab., single oral administration under fed condition
79538936|NCT04325659|Drug|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
79538937|NCT04325659|Drug|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
79696575|NCT05367427|Dietary Supplement|Bifidobacterium longum consumption|Regular consumption in breakfast of inactivated B. longum
79696576|NCT05367427|Dietary Supplement|Placebo|Placebo pill with maltodextrin
79840900|NCT01068145|Drug|SCH 527123|Very low dose SCH 527123, once daily for 7 days
79840901|NCT01068145|Drug|SCH 527123|Low dose SCH 527123, once daily for 7 days
79840902|NCT01068145|Drug|SCH 527123|Medium dose SCH 527123, once daily for 7 days
79696577|NCT05423405|Other|Acupressure|selected acupoint pressure
79696578|NCT04652310|Device|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
79696579|NCT04652310|Device|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
79840903|NCT01068145|Drug|SCH 527123|High dose SCH 527123, once daily for 7 days
79840904|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
79840905|NCT01068145|Drug|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
79840906|NCT01068145|Drug|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
79840907|NCT01068145|Drug|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
79696580|NCT05423288|Procedure|Distal pancreatectomy (DP)|Any scheduled distal pancreatectomy performed for any diagnosis
79840908|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
79840909|NCT05428475|Diagnostic Test|[18F]FDG-PET Scan|185 MBq of [18F]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
79696581|NCT04652115|Drug|Defibrotide|Deibrotide via IV
79696582|NCT05423171|Other|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
79696583|NCT01580553|Drug|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
79696584|NCT01580553|Drug|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
79696585|NCT05423054|Other|Abdominal massage|"Patients will be positioned on their back while their knees will be flexed.~Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~The PR will be standed on the right side of the patient during the massage practice.~The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
79840910|NCT00824928|Procedure|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
79840911|NCT01063231|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
79840912|NCT02599103|Other|Fat-free milkshake|participants drinks a fat-free milk shakes
79840913|NCT02599103|Other|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
79840914|NCT02599103|Other|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
79840915|NCT02599103|Other|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
79840916|NCT02599103|Other|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
79840917|NCT02599103|Other|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
79840918|NCT02599103|Other|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
79840919|NCT02599103|Other|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
79696586|NCT04618107|Procedure|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
79840920|NCT02599103|Other|Tallow|participants drinks the milk shakes prepared from 60g of tallow
80010963|NCT02188082|Drug|IvabRadine hemisulfate Sustained-release Tablets|
79840921|NCT02599103|Other|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
79840922|NCT04352140|Device|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
79840923|NCT04352140|Device|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
79840924|NCT00831168|Behavioral|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
79840925|NCT02548494|Drug|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
80010964|NCT02188082|Drug|placebo|
80010965|NCT02057094|Dietary Supplement|Protein, High-Protein, and Control|
80010966|NCT02917941|Drug|Ixazomib|Ixazomib capsules
79384319|NCT02314546|Drug|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~Group 1 - Placebo - Control patients will receive intranasal saline.~Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
79384320|NCT02314546|Drug|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
79384321|NCT02314546|Drug|saline placebo|Placebo - Control patients will receive intranasal saline.
79384322|NCT02314936|Dietary Supplement|Litesse powder containing 12 g polydextrose|12 g polydextrose
79384323|NCT02314936|Dietary Supplement|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
79538938|NCT04325659|Device|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
79538939|NCT04314375|Drug|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
79538940|NCT04314375|Drug|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
79538941|NCT04314375|Drug|Placebo|Matching placebo once daily.
79840926|NCT02548494|Drug|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
79245308|NCT05947227|Other|Diaphragmatic breathing technique.|Group B : will be treated with manual chest physiotherapy & Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT & St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
79245309|NCT05947175|Biological|Vertebral bone marrow (vBMA) clot|The clotted vBMA will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
79245310|NCT05947175|Other|Bone allograft chips|Bone allograft chips will be obtained from Musculoskeletal Tissue Bank at IRCCS Istituto Ortopedico Rizzoli.
79384324|NCT02314936|Dietary Supplement|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
79538942|NCT04308278|Drug|2LEBV® / 2LXFS®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
79696587|NCT04618107|Procedure|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
79696588|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
79840927|NCT02548494|Other|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
80010967|NCT02917941|Drug|Lenalidomide|Lenalidomide capsules
80010968|NCT02917941|Drug|Dexamethasone|Dexamethasone Tablets
80010969|NCT02055690|Drug|Pazopanib|Tyrosine Kinase Inhibitor
80010970|NCT02055690|Drug|Fosbretabulin|Vascular Disrupting Agent
80010971|NCT04301258|Other|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
80010972|NCT03684135|Other|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
80010973|NCT02038608|Device|PET|
80010974|NCT02193932|Other|EEG Triggered fMRI using Micro Maglink|
80010975|NCT03741699|Drug|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
80010976|NCT03535064|Other|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
79538943|NCT04308278|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
79696589|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
79696590|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
79538944|NCT04304963|Other|NO intervention - observational study|NO intervention - observational study
79538945|NCT04303403|Drug|Trametinib|Taken orally once daily
79696591|NCT04618224|Diagnostic Test|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
79538946|NCT04303403|Drug|Ruxolitinib|Taken orally twice daily
79840928|NCT02548494|Other|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~Administer 1-3 L during the first hour.~Administer 1 L during the second hour.~Administer 1 L during the following 2 hours~Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
79840929|NCT05049148|Other|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
79538947|NCT04302103|Biological|RC18 160mg|subcutaneous injection
79538948|NCT04302103|Biological|RC18 240 mg|subcutaneous injection
79840930|NCT02548416|Procedure|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
79840931|NCT02548416|Procedure|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
79840932|NCT00752219|Drug|ceftazidime/NXL104 + metronidazole|IV TID
80010977|NCT02055846|Procedure|Realisation of blood sample, urinary sample and tumor biopsy|
79384325|NCT02314936|Dietary Supplement|Placebo|12 g Maltodextrin
79384326|NCT03289260|Drug|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
79538949|NCT04289571|Diagnostic Test|VR Motility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
79696592|NCT04618224|Diagnostic Test|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
79696593|NCT04618146|Drug|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
79696594|NCT04618146|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
79696595|NCT05422898|Behavioral|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
79696596|NCT05422898|Behavioral|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
79696597|NCT04651842|Device|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
79696598|NCT05422859|Other|MobiDig|"The application will contain the following modules:~information and knowledge about heart failure;~vital sign diary, which can be sent to the certified HFU~pedometer (individualized step-goal), cardiac home training videos~frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
79696599|NCT04651647|Procedure|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
80010978|NCT02191748|Procedure|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
79384327|NCT03289260|Drug|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
79384328|NCT03289260|Procedure|Fulguration|Surgical Excision and Fulguration of condyloma
79384329|NCT03289182|Drug|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
79384330|NCT03289104|Device|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
79696600|NCT04651686|Other|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
79538950|NCT04286178|Dietary Supplement|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
79696601|NCT05421962|Drug|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
79696602|NCT00557817|Drug|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases < 13 g/dL. If the Hb decreases to < 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
79696603|NCT00557817|Drug|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation < 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
79696604|NCT05421182|Other|Revised Impact of Event Scale|to measure the affect of routine life stress,everyday traumas and acute stress
79840933|NCT00752219|Drug|meropenem|IV TID
79696605|NCT05421182|Other|Hospital Anxiety and Depression scale|to measure anxiety and depression
79696606|NCT05421182|Other|36-Item Short Form Survey|SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
79696607|NCT05421182|Other|satisfaction survey|satisfaction survey of the trusted person about the communication with ICU personal
79840934|NCT00827268|Behavioral|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
80010979|NCT02191748|Drug|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
79538951|NCT04286178|Dietary Supplement|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
79538952|NCT04286178|Dietary Supplement|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
79538953|NCT04286178|Dietary Supplement|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
79696608|NCT05421182|Other|semi-directed interview with trusted person on the general experience of the patient's medical evacuation|interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated
79696609|NCT05421182|Other|semi-directed interview with trusted person on the general experience of hospitalization in intensive care|interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
79696610|NCT04651530|Procedure|Phaco|phacoemulsification of cataract only
79840935|NCT00825006|Device|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
79840936|NCT02599805|Device|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
79840937|NCT04774354|Diagnostic Test|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
79840938|NCT02598791|Other|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
79840939|NCT02598791|Other|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
79840940|NCT02598791|Other|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
79840941|NCT02598791|Other|OGTT|50 g oral glucose tolerance test
79840942|NCT02598791|Other|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
79840943|NCT00827346|Drug|Clopidogrel|600 mg now
79538954|NCT04286178|Behavioral|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
79538955|NCT04285853|Drug|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
79538956|NCT04285853|Drug|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
79696611|NCT04651530|Procedure|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
79840944|NCT00827346|Drug|Clopidogrel|600 mg now and 600 mg in 3 hours
79840945|NCT00827346|Drug|Clopidogrel|900 mg now
79840946|NCT00827346|Drug|Clopidogrel|600 mg now and 300 mg in 3 hours
79840947|NCT02549274|Other|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
79840948|NCT02549274|Other|physiotherapy|14 physiotherapy sessions (2 by week)
79840949|NCT00997750|Drug|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
79840950|NCT03998956|Procedure|CPVI|Circumferential PV isolation only
79538957|NCT04271007|Drug|Mometasone Furoate|mometasone furoate
79696612|NCT05420480|Procedure|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
79696613|NCT05420480|Procedure|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
79696614|NCT05420480|Procedure|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
79696615|NCT04651491|Drug|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
79696616|NCT03455231|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
79696617|NCT04617873|Procedure|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
79840951|NCT03998956|Procedure|CPVI+BOX|Circumferential PV and BOX isolation
79840952|NCT03998956|Procedure|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
79840953|NCT00622908|Drug|ISV-403|0.6% TID, 5 days
79840954|NCT00622908|Drug|Vehicle|Vehicle of ISV-403 TID, 5 days
79384331|NCT03289104|Device|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
79384332|NCT03289026|Drug|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
79384333|NCT03293940|Procedure|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
79840955|NCT00997828|Device|everolimus-eluting stent|Xience V stent
79840956|NCT00997828|Procedure|coronary artery bypass graft surgery|coronary artery bypass graft surgery
79840957|NCT02548338|Procedure|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
79840958|NCT00827424|Behavioral|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
79840959|NCT04095065|Behavioral|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking.
79840960|NCT04095065|Behavioral|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
79538958|NCT04252547|Other|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
79696618|NCT05419739|Other|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
79696619|NCT00563004|Dietary Supplement|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
79245311|NCT05947123|Behavioral|Patient health care observational follow up after 2 prophylactic tratments|Real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIDAS, HIT-6, PGIC, HAD and WPAI questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
79245312|NCT05947110|Other|Plyometric-based hydro-kinesio therapy|The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
79696620|NCT00563004|Dietary Supplement|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
79696621|NCT05419583|Diagnostic Test|Coronary computed tomography angiography|CT scan of the heart arteries
79840961|NCT04095065|Behavioral|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
79840962|NCT04095065|Behavioral|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
79840963|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
79840964|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
79840965|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
79384334|NCT03293940|Procedure|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
79696622|NCT05419583|Diagnostic Test|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
79696623|NCT05419583|Diagnostic Test|Transthoracic echocardiography|Ultrasound scan of the heart
79840966|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
79840967|NCT02598635|Drug|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels <20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
79840968|NCT02598635|Drug|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
79384335|NCT02460510|Drug|Mannitol|
79384336|NCT02460510|Drug|3% hypertonic saline|
79840969|NCT00831246|Other|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
79384337|NCT02460744|Radiation|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
79384338|NCT04137042|Drug|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
79840970|NCT00831246|Other|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
79384339|NCT04137042|Drug|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
79840971|NCT04093271|Dietary Supplement|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
79840972|NCT04093271|Drug|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
79840973|NCT04093271|Other|Placebo|No active ingredients
79840974|NCT00831402|Dietary Supplement|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
79538959|NCT04252547|Other|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
79696624|NCT05419583|Diagnostic Test|Cardiac MRI scan|An MRI scan to assess the heart structure and function
79696625|NCT05419583|Drug|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
79840975|NCT00831402|Dietary Supplement|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
79696626|NCT05419583|Drug|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
79840976|NCT00825240|Behavioral|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
79840977|NCT04090307|Behavioral|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
79840978|NCT04093115|Drug|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
79696627|NCT05419583|Drug|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
79696628|NCT05419583|Drug|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
79840979|NCT02548026|Behavioral|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
79840980|NCT02548026|Behavioral|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
79840981|NCT04092959|Behavioral|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
79840982|NCT04092959|Behavioral|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
79840983|NCT04092959|Behavioral|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
79840984|NCT00827580|Drug|Eniluracil|
79840985|NCT00827658|Procedure|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
79840986|NCT00827658|Procedure|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
79245313|NCT05947110|Other|Standard exercise therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
79245314|NCT05947097|Drug|HSK21542 Injection|1ug/kg bolus for 2min±5s
79245315|NCT05946850|Procedure|Caudal analgesia|Caudal analgesia for chronic lumbosacral pain
79245316|NCT05946291|Other|Pressure injury training|Pressure injury training with mulage application on a standardized patient
79245317|NCT05946291|Other|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
79245318|NCT05944445|Drug|Linezolid 600 mg|Linezolid 600mg injection
79384340|NCT02334436|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
79384341|NCT02334436|Other|0.9% sterile, unpreserved saline|Placebo Comparator Arm
79384342|NCT03293862|Device|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
79384343|NCT03293862|Procedure|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
79384344|NCT03293862|Device|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
79384345|NCT01958788|Behavioral|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
79384346|NCT03288870|Drug|BCD-100|monoclonal antibody to PD-1 receptor
79384347|NCT03288870|Drug|Docetaxel|Chemotherapy drug (taxane)
79384348|NCT03288792|Device|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
79538960|NCT04239911|Behavioral|mHealth app|The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
79538961|NCT04239911|Behavioral|Virtual training course|Virtual training course on heart failure for home health aides.
79840987|NCT04094909|Drug|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +[nab]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
79245319|NCT05944055|Biological|Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?|Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.
79245320|NCT05943886|Drug|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
79245321|NCT05943886|Drug|Placebo|Placebo will be administered by subcutaneous injection in the abdomen.
79245322|NCT05943067|Biological|CD45RA depleted donor lymphocyte infusion (DLI)|CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
79696629|NCT04651764|Device|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
79696630|NCT04617600|Drug|MTA|Survival rate using MTA in cariously exposed vital primary molars
79696631|NCT04617600|Drug|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
79696632|NCT05408624|Procedure|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
79696633|NCT05408624|Procedure|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
79245324|NCT05940311|Device|Affinity Mediated Transport Amplification (AMT)|Rich format single-molecule detection powered by plasmotic nanostructures of the opto-fluidific chip and proteogenomics digital readout integrated into single biotech platform.
79696634|NCT04651608|Behavioral|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
79384349|NCT02070640|Drug|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
79384350|NCT02070640|Device|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
79696635|NCT04651608|Behavioral|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
79384351|NCT03282474|Drug|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet [Sovaldi]
79840988|NCT05424731|Combination Product|DBV712 250 mcg|Daily epicutaneous delivery.
79840989|NCT02599571|Other|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
79384352|NCT02460354|Drug|Metformin|Metformin 500 mg pill dispensed once orally
79384353|NCT02071108|Device|Shockwave Lithoplasty System|
79384354|NCT03293706|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
79384355|NCT03293706|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
79538962|NCT04235322|Drug|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
79840990|NCT02599571|Other|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
79384356|NCT03293706|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
79384357|NCT03293706|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
79384358|NCT03293706|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
79696636|NCT04651608|Behavioral|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
79696637|NCT04651608|Behavioral|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
79696638|NCT05406089|Other|Medication history|The study was retrospective and did not involve the application of interventions
79696639|NCT04651335|Device|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
79696640|NCT04651335|Device|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
79696641|NCT04651023|Dietary Supplement|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
80010980|NCT03676881|Device|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
80016872|NCT03578731|Device|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~Interview during regular consultation with doctor~Web-App for gathering doctors data~Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~Well-being through a patient rating on a visual analog scale~Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
79245325|NCT05936073|Diagnostic Test|Patients co-infected HBV/HDV|Step 1: collection of SNDS data from 2016 to 2020 Snapshot of the prescription of the Delta tests and the tests usually prescribed simultaneously (HBV but also HIV and HCV) in one year. The investigator will collect the number of tests performed once for a given patient: anti-HDV, HDV RNA, HBsAg, anti-HCV, anti-HIV, and for each test, the description of the profile and the geographical distribution of prescribers in the metropolitan area; the description of age and sex of the patients screened. Step 2: collection of anti-HDV and RNA tests performed in French private and Public laboratories over the year 2019 Anti-HDV and HDV RNA are subcontracted by most private laboratories to two specialized biology companies. Number of HDV tests prescribed, technique used, number of positive tests and name of the requesting laboratory will be collected. The investigator will then go back to the prescriber of the positive tests, identify the patient, his epidemiological profile and his medical care.
79245326|NCT05934643|Device|ActivPAL accelerometer|All patient will have an accelerometer (activPAL) applied to characterise the type and quantity of movement during the inpatient postoperative period after undergoing major surgery for colorectal cancer surgery.
79245327|NCT05934643|Other|Hospital Anxiety and Depression Scale (HADS) Questionnaire|The use of the HADS questionnaire to ascertain if any correlation between level of activity and and inpatient mood.
79245328|NCT05930704|Drug|SHR-2017 injection|Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.
79696642|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
79696643|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
79696644|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
79245329|NCT05930704|Drug|Placebo|Randomized participants will receive a single SC injection dose of matching placebo.
79384359|NCT03293628|Procedure|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
79384360|NCT02008942|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
79384361|NCT02008942|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
79384362|NCT03288636|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
79696645|NCT04651062|Device|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
79384363|NCT03288636|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
79384364|NCT03288636|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
79384365|NCT03288636|Drug|Placebo|Placebo
79840991|NCT00296491|Drug|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
80010981|NCT03676881|Device|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
80010982|NCT02191826|Drug|SOM0226|Oral
80010983|NCT01333956|Drug|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
79245332|NCT05925049|Drug|Natalizumab|Administered as specified in the treatment arm.
80016873|NCT02096406|Drug|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
79696646|NCT04651062|Procedure|no endocuff|colonoscopy is performed without endocuff.
79384366|NCT02071420|Behavioral|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
79384367|NCT02071420|Behavioral|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
79696647|NCT05394779|Device|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
79384368|NCT02071420|Behavioral|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
79384369|NCT02071420|Device|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
79384370|NCT01959178|Device|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
79384371|NCT01959178|Device|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
79538963|NCT04235322|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
79538964|NCT04230395|Behavioral|CAP|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
79696648|NCT05394779|Device|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
79696649|NCT04651101|Diagnostic Test|coronary angiography|extent of coronary artery disease in invasive coronary angiography
79840992|NCT00296491|Drug|montelukast (MON)|montelukast capsule
79538965|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
79840993|NCT00296491|Drug|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
79840994|NCT00296491|Drug|placebo nasal|vehicle placebo nasal spray
79840995|NCT00296491|Drug|ADVAIR DISKUS|ADVAIR DISKUS
79840996|NCT00296491|Drug|placebo capsule|placebo capsule
79840997|NCT00296491|Drug|placebo DISKUS|placebo DISKUS
79840998|NCT00747617|Drug|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
79245333|NCT05922787|Other|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
79245334|NCT05922007|Other|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
79245335|NCT05922007|Other|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
79245336|NCT05908097|Device|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting. The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
79245337|NCT05908097|Device|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
79696650|NCT04651257|Device|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
79245338|NCT05906459|Diagnostic Test|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
79538966|NCT04224519|Biological|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
79696651|NCT05387408|Behavioral|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
79696652|NCT05380700|Device|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
79840999|NCT02599493|Drug|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
79841000|NCT02599415|Device|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
79841001|NCT04092725|Drug|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
79841002|NCT04092725|Drug|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
79841003|NCT00296335|Drug|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
79841004|NCT00296335|Drug|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
79841005|NCT04094597|Drug|Lactoferrin|lactoferrin is given orally in comparsion to placebp
79384372|NCT03107832|Procedure|thoracic epidural anesthesia procedure|general anesthesia procedure
79384373|NCT03293472|Drug|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
79384374|NCT03293472|Drug|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
79538967|NCT04224519|Biological|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
79538968|NCT04224519|Biological|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
79538969|NCT04220515|Biological|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
79538970|NCT04219332|Drug|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
79538971|NCT04219332|Drug|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
79841006|NCT04094597|Drug|Placebos|placebp is given in 2 ml saline
79841007|NCT04093037|Diagnostic Test|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
79841008|NCT04093037|Diagnostic Test|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
80010984|NCT01333956|Drug|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
80010985|NCT01333956|Drug|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
79841009|NCT04093037|Diagnostic Test|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
79841010|NCT04093037|Diagnostic Test|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
79841011|NCT04093037|Diagnostic Test|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
79245339|NCT05880914|Procedure|miRNAseq analysis|Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.
79245340|NCT05880914|Drug|Standard treatment for bone disorder|Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
79245341|NCT05865743|Drug|SDD|a 10ml suspension containing amphotericin B (50 mg/ml), colistin sulphate (10 mg/ml), and tobramycin (8 mg/ml). Patients take the oral suspension four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose
79538972|NCT04211649|Drug|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
79245342|NCT05862298|Diagnostic Test|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, >50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
80010986|NCT01333956|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
80010987|NCT03623607|Other|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
80010988|NCT02055924|Drug|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
79841012|NCT01065961|Drug|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
80010989|NCT02191904|Other|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
80010990|NCT02188238|Other|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
79245343|NCT05862168|Drug|Tislelizumab|The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
79245344|NCT05862168|Drug|Albumin paclitaxel|The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
79245345|NCT05862168|Drug|Cisplatin|The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
79245346|NCT05862168|Drug|5-Fluorouracil|The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
79245347|NCT05860829|Behavioral|Educational|Caregivers of children with ASD will be sampled that are enrolled in Autism specialized Schools or centers. Tools and group education sessions will be developed in Urdu, English and Sindhi language. A caregiver education program session will be conducted by a practicing dentist and a registered dietitian in Urdu1 and English. Considering the ease of caregivers, cost-effectiveness and managing flexible hours, tele-health will be practiced for education program. A post-test will be conducted to assess the impact of the educational program on the knowledge of caregivers.
79245348|NCT05855876|Procedure|subanesthetic ketamine infusions and bilateral cervical sympathetic blocks|Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
79245349|NCT05839483|Diagnostic Test|CXCR4|Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
79245350|NCT05838287|Drug|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
79245351|NCT05838287|Drug|Placebo|Placebo for Pioglitazone
79245352|NCT05837052|Procedure|serplulimab plus chemotherapy as conversion treatment|Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
79245353|NCT05836506|Drug|ABBV-903 Tablet Form 1|Oral Tablets
79245354|NCT05836506|Drug|ABBV-903 Tablet Form 2|Oral Tablets
79538973|NCT04210687|Procedure|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
79538974|NCT04210687|Procedure|Trapeziectomy|Simple trapeziectomy
79538975|NCT04204616|Drug|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
79841013|NCT01065961|Drug|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
80016874|NCT02096406|Drug|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
80016875|NCT00387686|Drug|rhBMP-2/CPM|
80016876|NCT00387686|Drug|rhBMP-2/CPM|
80016877|NCT00387686|Drug|rhBMP-2/CPM|
79538976|NCT04199767|Drug|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
79538977|NCT04199767|Drug|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
79538978|NCT04189939|Other|clinical assessments|"Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):"
80016878|NCT00387686|Drug|rhBMP-2/CPM|
80016879|NCT03659253|Diagnostic Test|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
79841014|NCT04092881|Device|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
79841015|NCT04092881|Device|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
79841016|NCT01068223|Drug|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
79841017|NCT01068223|Drug|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
79538979|NCT04159506|Behavioral|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
80010991|NCT02057328|Drug|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
79841018|NCT01068223|Drug|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
79841019|NCT03976609|Procedure|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
79841020|NCT02600273|Other|Usual brand cigarettes|Usual brand cigarettes
79245355|NCT05835921|Device|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
79245356|NCT05828719|Procedure|Percutaneous coronary intervention|"Revascularization indication~Diameter stenosis >90% by visual assessment~Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~Left main artery~Proximal to mid left anterior descending artery~Proximal left circumflex artery in left dominant coronary arterial system~Proximal to distal right coronary artery in right dominant coronary arterial system"
79245357|NCT05825066|Drug|Nab paclitaxel|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
79245358|NCT05825066|Drug|Gemcitabine|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
79245359|NCT05825066|Other|Radiological Assessments|CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.
79245360|NCT05825066|Drug|mFOLFIRINOX|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
79245361|NCT05813899|Dietary Supplement|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
79245362|NCT05813795|Drug|Ecnoglutide Low Dosage|Subcutaneous Injection
79538980|NCT04148066|Diagnostic Test|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
79841021|NCT02600273|Other|Lower nicotine content cigarettes|SPECTRUM research cigarettes
79841022|NCT02600273|Other|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
79841023|NCT02600273|Other|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
79841024|NCT01069393|Other|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
79538981|NCT04144231|Behavioral|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
79245363|NCT05813795|Drug|Ecnoglutide Medium Dosage|Subcutaneous Injection
79841025|NCT00747461|Device|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
79696653|NCT05376761|Drug|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
79696654|NCT04617561|Drug|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
79696655|NCT04617561|Drug|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
79696656|NCT04617483|Biological|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
79696657|NCT04617483|Biological|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
79841026|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
79841027|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
79841028|NCT01068301|Drug|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
79696658|NCT04617483|Biological|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
79696659|NCT04617288|Other|Ultrasound Therapy, SNAGs|
79696660|NCT04617249|Procedure|median anesthesia|giving median anesthesia
79841031|NCT04092491|Other|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
79841032|NCT01068379|Procedure|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
79384375|NCT03288558|Other|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.~Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
79384376|NCT02071810|Drug|BIA 9-1067|
79841033|NCT01068379|Procedure|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
79841034|NCT04866550|Other|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
79841035|NCT04092569|Behavioral|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
79841036|NCT01063465|Device|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
79696661|NCT04617249|Procedure|paramedian anesthesia|giving paramedian anesthesia
79841037|NCT03873766|Drug|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
79696662|NCT05349383|Drug|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
79841038|NCT03873766|Procedure|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
79245364|NCT05813795|Drug|Ecnoglutide High Dosage|Subcutaneous Injection
79245365|NCT05813795|Drug|Placebo|Subcutaneous Injection with matched volume
79841039|NCT03873766|Procedure|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
79841040|NCT03873766|Procedure|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
79245366|NCT05808010|Biological|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10^8) at 1 month interval
79841041|NCT03873766|Radiation|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
79245367|NCT05808010|Drug|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
79245368|NCT05799378|Drug|Hydroxychloroquine|Hydroxychloroquine 200mg capsules. Administered orally.
79384377|NCT02071810|Drug|Placebo|
79245369|NCT05799378|Drug|Placebo|Hydroxychloroquine-matching placebo capsule. Administered orally.
79245370|NCT05794958|Drug|Axicabtagene Ciloleucel|Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
79245371|NCT05780684|Other|FOX dose-escalation algorithm|Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
79245372|NCT05779995|Drug|XW001|Inhalation solution
79245373|NCT05779995|Drug|Placebo|Inhalation solution with matched volume
79384378|NCT02715258|Drug|Bexagliflozin|tablets containing 20 mg bexagliflozin
79384379|NCT02715258|Drug|Placebo|tablets matching the appearance of bexagliflozin tablets
79245374|NCT05758233|Procedure|Patients undergoing transversalis fascia plane block|The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
79245375|NCT05758233|Procedure|Patients undergoing transversus abdominis plane block|The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
79245376|NCT05754203|Radiation|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy * 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
79384380|NCT01959490|Biological|trastuzumab|Given IV
79384381|NCT01959490|Biological|Pertuzumab|Given IV
79384382|NCT01959490|Drug|docetaxel|Given IV
79384383|NCT01959490|Drug|carboplatin|Given IV
79384384|NCT01959490|Drug|doxorubicin|Given IV
79384385|NCT01959490|Drug|cyclophosphamide|Given IV
79384386|NCT01959490|Drug|paclitaxel|Given IV
79384387|NCT01959490|Drug|Bevacizumab|
79384388|NCT03282318|Drug|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
79384389|NCT03282318|Drug|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
79538982|NCT04144231|Behavioral|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
79696663|NCT05349383|Drug|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
79696664|NCT05344820|Behavioral|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
79696665|NCT04617171|Drug|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
79696666|NCT04617171|Drug|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
79696667|NCT04617054|Drug|AB-106|600mg QD for each subjects.
79245377|NCT05744427|Drug|JSKN003|JSKN003 should be given on the first day of administration every 3 weeks by intravenous drip. Before administration, JSKN003 should be redissolved with sterilized water for injection, and then diluted with 0.9% sodium chloride solution to a concentration of 0.5~5.0mg/ml. It is recommended that subjects' weight be measured on the day of each administration or one day before administration to calculate the dosage of JSKN003.
79245378|NCT05742178|Behavioral|Patient Navigation (PN) - More Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
79245379|NCT05742178|Behavioral|Educational Materials|Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
79245380|NCT05742178|Behavioral|Patient Navigation (PN) - Less Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
79841042|NCT03873766|Other|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
79841043|NCT03873766|Radiation|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
79841044|NCT03873766|Behavioral|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
79696668|NCT05337488|Other|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
79841045|NCT02598479|Other|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
79245381|NCT05718466|Drug|Bevacizumab|
79841046|NCT01069471|Biological|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
79841047|NCT04094129|Dietary Supplement|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
79841048|NCT04094129|Dietary Supplement|Placebo|placebo
79841049|NCT03683758|Other|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
79841050|NCT03683758|Other|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
79384390|NCT02714868|Behavioral|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
79384391|NCT02714868|Behavioral|Matched Comparison|Participants set goal to try a new activity in the community
79384392|NCT03288402|Other|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
79245382|NCT05718466|Drug|Chemotherapy|
79245383|NCT05718466|Radiation|Fractionated radiosurgery|
79245384|NCT05704764|Behavioral|Ending Self Stigma for Persons living with HIV and Use Substances|Group-based intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.
79245385|NCT05702723|Behavioral|Smart-3RP|9 sessions of mind-body group treatment program via Zoom platform.
79245386|NCT05702723|Behavioral|Enhanced Usual Care|14-week group-based, online support group through CancerCare.org.
79245387|NCT05680155|Drug|Ecnoglutide|Subcutaneous Injection
79245388|NCT05680155|Drug|Placebo|Subcutaneous Injection with matched volume
79384393|NCT03288246|Diagnostic Test|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
79384394|NCT02011516|Drug|Baclofen|
79384395|NCT02011516|Behavioral|Psychosocial|
79384396|NCT02011516|Drug|Placebo|
79538983|NCT04142476|Other|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
79696669|NCT00557934|Other|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
79696670|NCT04679753|Device|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
79696671|NCT04679753|Device|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
79696672|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
79538984|NCT04141358|Diagnostic Test|Advanced ultrasound measurements|"Clinical interventions and procedures:~Consent at 0 week~Clinical data collection at 0 week~Strain for native artery at 0 week~Young's modulus for native artery at 0 week~Intimal medial thickness for native artery at 0 week~Ultrasound blood volume flow measurement at 0 week~Vessel diameter at 0 week~Blood pressure at 0 week~BMI at 0 week~Intra-operative blood volume flow measurement at AVF surgery time~Strain for native artery at 6 weeks~Young's modulus native artery at 6 weeks~Intimal medial thickness native artery arteries at 6 weeks~Ultrasound blood volume flow measurement at 6 weeks~Vessel diameter at 6 weeks~Blood pressure at 6 weeks~BMI at 6 weeks"
79696673|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
79696674|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
79696675|NCT04679714|Device|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
79696676|NCT00558090|Drug|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
79841051|NCT03976921|Diagnostic Test|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
79841052|NCT03976921|Diagnostic Test|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
79841053|NCT04092023|Other|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
79841054|NCT04767958|Diagnostic Test|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
79841055|NCT02599259|Device|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
79245389|NCT05680129|Drug|Ecnoglutide high dosage|Administered subcutaneously
79245390|NCT05680129|Drug|Ecnoglutide low dosage|Administered subcutaneously
79245391|NCT05680129|Drug|Dulaglutide|Administered subcutaneously
79245392|NCT05680129|Drug|Metformin|Administered orally
79538985|NCT04125914|Behavioral|Behavioral Dietary Intervention|Record food intake
79245393|NCT05640934|Drug|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
79245394|NCT05640934|Drug|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
79384397|NCT03287934|Device|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
79384398|NCT03287934|Device|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
79384399|NCT04349410|Drug|Hydroxychloroquine, Azithromycin|FMTVDM Planar, SPECT, PET
79696677|NCT05323604|Other|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
79696678|NCT00558129|Device|X-STOP®|Surgical implantation of X-STOP IPD device
79841056|NCT02600039|Other|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
79848979|NCT05700383|Behavioral|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
79848980|NCT05696158|Device|MHNA-003|6-week digital therapy program designed to reduce the severity of tinnitus symptoms
79245395|NCT05623579|Behavioral|Pain Neuroscience Education|8 Sessions of different pain education interventions
79245396|NCT05623579|Behavioral|Exercise|12 Sessions of Aerobic Exercise
79245397|NCT05592301|Diagnostic Test|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
79245398|NCT05592301|Diagnostic Test|Transcranial Doppler (TCD)|Used to diagnose PFO
79245399|NCT05592301|Diagnostic Test|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
79245400|NCT05561920|Device|High - speed video endoscopy (HSV)|Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
79245401|NCT05561920|Device|Acoustic voice analysis|acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
79538986|NCT04125914|Other|E-mail|Receive e-mails
79696679|NCT00558129|Procedure|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
79696680|NCT04616976|Biological|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
79696681|NCT05293847|Behavioral|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
79696682|NCT04616742|Drug|[14C]SHR6390|Patients will receive single dose of orally [14C]SHR6390 on Day 1.
79696683|NCT04616703|Radiation|CT imaging|CT of abdomen
79841057|NCT02600039|Device|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
79245402|NCT05561920|Behavioral|Quality of life questionnaire|Filling out questionnaires
79245403|NCT05515055|Other|Blood test|1 blood sample extra to standard of care is taken
79384400|NCT04349410|Drug|Hydroxychloroquine, Doxycycline|FMTVDM Planar, SPECT, PET
79384401|NCT04349410|Drug|Hydroxychloroquine, Clindamycin|FMTVDM Planar, SPECT, PET
79384402|NCT04349410|Drug|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|FMTVDM Planar, SPECT, PET
80010992|NCT02057328|Drug|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
80010993|NCT02188316|Device|Jumbo forceps|comparison of different polypectomy devices
80010994|NCT02188316|Device|Hot biopsy forceps|comparison of different polypectomy devices
80010995|NCT02057484|Drug|Tacrolimus|oral
79538987|NCT04125914|Behavioral|Exercise Intervention|Undergo exercise
79538988|NCT04125914|Other|Health Promotion and Education|Receive text messages
79538989|NCT04125914|Other|Internet-Based Intervention|Join Facebook page
79696684|NCT04651140|Behavioral|aerobic exercise|Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
79245404|NCT05508009|Drug|Cyclophosphamide 1200 mg/Kg|Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
79245405|NCT05508009|Drug|Fludarabine|Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
79245406|NCT05508009|Drug|Cyclophosphamide 100 mg/Kg|Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
79245407|NCT05508009|Radiation|Total Body Irradiation|Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
79245408|NCT05508009|Drug|ATG|ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
79245409|NCT05508009|Drug|Rituximab|Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
79384403|NCT04349410|Drug|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|FMTVDM Planar, SPECT, PET
79384404|NCT04349410|Drug|Remdesivir|FMTVDM Planar, SPECT, PET
79384405|NCT04349410|Drug|Tocilizumab|FMTVDM Planar, SPECT, PET
79384406|NCT04349410|Drug|Methylprednisolone|FMTVDM Planar, SPECT, PET
79384407|NCT04349410|Drug|Interferon-Alpha2B|FMTVDM Planar, SPECT, PET
79384408|NCT04349410|Drug|Losartan|FMTVDM Planar, SPECT, PET
79384409|NCT04349410|Drug|Convalescent Serum|FMTVDM Planar, SPECT, PET
79384410|NCT03287856|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
79538990|NCT04125914|Other|Questionnaire Administration|Ancillary studies
79538991|NCT04125914|Behavioral|Telephone-Based Intervention|Receive telephone coaching
79538992|NCT04102579|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
79538993|NCT04102579|Drug|Placebo|non-active dosage form
79538994|NCT04093921|Behavioral|MET-based therapy|see previous
79538995|NCT04093921|Behavioral|Standard Care|To include all recommended outpatient treatments
79538996|NCT04093362|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
79538997|NCT04093362|Drug|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine is currently 1st line standard of care
79538998|NCT04077164|Other|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
79538999|NCT04073420|Device|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
79696685|NCT05287217|Other|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
79696686|NCT05278403|Other|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
79696687|NCT05278403|Other|Neurological physiotherapy|Application of conventional physical therapy techniques.
79841058|NCT01564810|Drug|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
79539000|NCT04073420|Device|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
79539001|NCT04070027|Procedure|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
79539002|NCT04070027|Other|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
79539003|NCT04061239|Drug|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
79539004|NCT04061239|Drug|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
79539005|NCT04061239|Drug|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
79539006|NCT04061239|Drug|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
79539007|NCT04053452|Diagnostic Test|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
79539008|NCT04053452|Diagnostic Test|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
79539009|NCT04052191|Biological|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
79539010|NCT04050163|Biological|MiSaver®|Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
79539011|NCT04037709|Procedure|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
79539012|NCT04037709|Procedure|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
79539013|NCT04036227|Drug|GS-248|GS-248 oral solution
79539014|NCT04036227|Drug|Placebo|Placebo oral solution with the same composition to match active drug
79539015|NCT04036136|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
79539016|NCT04036136|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
79539017|NCT04034004|Behavioral|Mindfulness|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
79539018|NCT04034004|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
79539019|NCT04034004|Other|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
80010996|NCT02191982|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
80010997|NCT02192060|Other|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
79245410|NCT05508009|Drug|Melphalan|Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
79841059|NCT01564810|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
79841060|NCT04091945|Drug|LT3001 Drug Product|Active comparator
80010998|NCT02192060|Other|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
80010999|NCT02188394|Drug|Anesthetic blockades with bupivacaine|
79245411|NCT05508009|Device|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is > 10 x 10^6 cells/Kg recipient weight. The minimum dose is 2 x 10^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is < 0.50 x 10^5.
79384411|NCT03287700|Other|No intervention|No intervention will be administered to any group in this observational study.
79384412|NCT03287466|Drug|Oxygen|targeted oxygen therapy
79384413|NCT03287388|Procedure|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
79384414|NCT03287388|Drug|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
80011000|NCT02188394|Drug|Isotonic saline injection|
80011001|NCT02192138|Procedure|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
80011002|NCT02192138|Device|Pleural catheter|
79539020|NCT04034004|Behavioral|Meditation|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
79384415|NCT03287388|Drug|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
79696688|NCT04650906|Behavioral|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
79696689|NCT04650750|Drug|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
79696690|NCT04650750|Drug|Placebo|Similar placebo 4g twice a day for two months
79696691|NCT05250128|Procedure|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
79841061|NCT04091945|Drug|Placebo|Placebo comparator
79841062|NCT04091789|Drug|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
79841063|NCT04091711|Device|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
79384416|NCT03293316|Device|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
79384417|NCT03293160|Other|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
79384418|NCT03293082|Device|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
79696692|NCT04650711|Diagnostic Test|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
79696693|NCT04650828|Drug|TDF|TDF combined with telbivudine (LDT) for 12 months
79841064|NCT00916955|Other|Observation|Observe development of syndrome over time
79841065|NCT04094051|Drug|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
79841066|NCT04093895|Drug|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
79841067|NCT00522418|Device|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
79841068|NCT00522418|Drug|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
79841069|NCT00624780|Drug|Pregabalin|Pregabalin 150-300 mg given twice a day
79841070|NCT00624780|Drug|Lorazepam|Lorazepam 3-4 mg given twice a day
79841071|NCT00624780|Drug|Pregabalin|Pregabalin 450-600 mg given twice a day
79245412|NCT05508009|Procedure|Kidney Transplant|In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with > 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI >18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
79245413|NCT05486676|Behavioral|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
79245414|NCT05476237|Behavioral|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
79841072|NCT00624780|Drug|Placebo|Placebo
79841073|NCT00750893|Biological|Rotarix or Rotarix liquid formulation|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
79841074|NCT01564888|Procedure|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
79841075|NCT00753623|Drug|Ramelteon|ramelteon (8 mg)
79841076|NCT00753623|Drug|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
79841077|NCT02599337|Drug|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
79848981|NCT05693766|Drug|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
79245415|NCT05476237|Behavioral|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
79539021|NCT04033029|Device|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
79539022|NCT04033029|Drug|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
79539023|NCT04026503|Other|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
79539024|NCT04022746|Procedure|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
79539025|NCT04022746|Procedure|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
79539026|NCT04020185|Drug|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
79539027|NCT04020185|Drug|Immune checkpoint inhibitor (ICI)|Administered according to product label
79539028|NCT04020185|Drug|Immuno-oncology (IO) therapy|Administered according to product label
79539029|NCT04007380|Other|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
79539030|NCT03998579|Other|The CanMoRe programme|An exercise intervention in Primary Health Care
79539031|NCT03998579|Other|Home exercise|An active control group
79539032|NCT03995641|Drug|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
79539033|NCT03977753|Drug|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
79696694|NCT04650828|Drug|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
79841078|NCT02599337|Drug|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
79245419|NCT05459298|Dietary Supplement|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
79245420|NCT05459298|Dietary Supplement|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
79245421|NCT05459298|Other|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
79245422|NCT05455034|Genetic|single-cell sequencing|Treatment is given according to the results of single-cell sequencing.
79384419|NCT03293082|Device|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
79384420|NCT03293004|Dietary Supplement|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
79384421|NCT03293004|Dietary Supplement|Vitamin C|Escalating dose of Vitamin C
79384422|NCT03293004|Dietary Supplement|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
79384423|NCT03293004|Dietary Supplement|Gummy Placebo|Gummy placebo
79384424|NCT03292848|Drug|Brexpiprazole|Tablet
79384425|NCT03292770|Device|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
79384426|NCT03292536|Drug|Merestinib|"*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
79384427|NCT03292380|Other|No intervention was included|
79384428|NCT03282162|Drug|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
79384429|NCT03282162|Drug|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
79384430|NCT03292224|Diagnostic Test|- Microscopic examination and culture of collected specimens|"Unstained wet mount with 10%-20% KOH.~Wet mounts stained with:~Lactophenol cotton blue.~India ink~Gram stain Culturing on Sabouraud´s dextrose agar ."
79384431|NCT03287076|Drug|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
79539034|NCT03977753|Drug|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
79539035|NCT03969706|Drug|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
79245423|NCT05444205|Behavioral|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
79539036|NCT03957473|Device|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
79245424|NCT05444205|Behavioral|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
79245425|NCT05444205|Behavioral|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
79245426|NCT05444205|Behavioral|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
79245427|NCT05444205|Behavioral|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
79245428|NCT05444205|Behavioral|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
79245429|NCT05444205|Behavioral|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
79245430|NCT05444127|Other|Saliva samples|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
79384432|NCT03282084|Diagnostic Test|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
79384433|NCT03282084|Diagnostic Test|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
79539037|NCT03952962|Device|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
79539038|NCT03926312|Device|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
79539039|NCT03922984|Procedure|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
79539040|NCT03893279|Behavioral|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
79384434|NCT03286920|Dietary Supplement|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
79384435|NCT03286920|Dietary Supplement|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
79384436|NCT02460276|Drug|Lenalidomide|
79384437|NCT02460276|Drug|Ibrutinib|
79384438|NCT02460276|Drug|Rituximab|
79384439|NCT02460432|Device|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
79384440|NCT02460432|Device|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
79384441|NCT03282006|Drug|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
79539041|NCT03891784|Drug|Abemaciclib|Given PO
79539042|NCT03868410|Device|New rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
79841079|NCT00831636|Drug|CP-4055|D1-5 and D8(+2)-12(+2) q4w
79841080|NCT00831636|Drug|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
79539043|NCT03868410|Device|Conventional rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
79539044|NCT03866954|Combination Product|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
79539045|NCT03862950|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
79539046|NCT03862950|Drug|Metformin|Active medication
79696695|NCT04650360|Behavioral|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
79696696|NCT05197556|Drug|HSG4112|Once-daily oral administration
79696697|NCT05197556|Drug|Placebo|Once-daily oral administration
79841081|NCT00750737|Drug|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
79245431|NCT05444127|Other|Questionnaire OHIP-14|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
79841082|NCT00750737|Drug|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
79841083|NCT04044612|Other|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
79841084|NCT04119934|Behavioral|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
79841085|NCT04093505|Drug|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
79841086|NCT04093505|Drug|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
80011003|NCT02192138|Device|Pleural manometer|
80011004|NCT01333722|Drug|Hydrocodone/Acetaminophen Extended Release|
79245432|NCT05444127|Other|Thorough dental examination|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
79245433|NCT05443698|Device|Transvaginal ultrasound|Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
80011005|NCT01333722|Drug|Placebo|Placebo tablet
80011006|NCT02188472|Drug|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
79245434|NCT05420558|Diagnostic Test|Fibroblast activation protein inhibitor PET/CT imaging|All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging
79245435|NCT05400577|Drug|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
79384442|NCT03291912|Procedure|Chuna Manual Therapy|"Unique manual therapy in traditional Korean medicine~Mandatory techniques for neck part and selective techniques for other part (if necessary)~Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
79384443|NCT03291912|Procedure|Usual care|"Physical therapy based on traditional Korean medicine theory~Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~Heat stimulation: either Hot pack or Infrared lamp~Patient education~Physical and pathological explanation of cervicogenic dizziness~Cause and risk factors of cervicogenic dizziness~Functions of muscles related to cervicogenic dizziness~Home exercising to self-manage cervicogenic dizziness"
79384444|NCT03281928|Dietary Supplement|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
79384445|NCT03281928|Dietary Supplement|Placebo|Sodium without Potassium Citrate
79384446|NCT02460120|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
79539047|NCT03846830|Device|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
79539048|NCT03846830|Behavioral|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
80011007|NCT02188472|Drug|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
80011008|NCT02188472|Drug|Placebo|Placebo: 2 tablets should be taken twice daily
80011009|NCT02188550|Drug|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
79539049|NCT03844750|Procedure|Hepatectomy|Undergo liver resection.
79539050|NCT03844750|Biological|Pembrolizumab|Given IV
79539051|NCT03844750|Drug|Vactosertib|Given orally once a day (QD) for cycle 1, and twice a day (BID) for cycle 2 and beyond
79539052|NCT03806803|Biological|Lyophilized fecal microbiota transplant|15 capsules
79539053|NCT03806803|Biological|Lyophilized sterile fecal filtrate|15 capsules
79696698|NCT04650555|Drug|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
79696699|NCT04650477|Procedure|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
79696700|NCT00553904|Dietary Supplement|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
79696701|NCT05181683|Drug|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
79696702|NCT04650516|Device|Virtual reality|20 minutes treatment in virtual reality
79696703|NCT04650516|Device|Digital control|20 minutes digital control movie on tablet without virtual reality
79696704|NCT04650321|Drug|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
79696705|NCT05153525|Drug|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
79696706|NCT05153525|Drug|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
79696707|NCT04649931|Device|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
79245436|NCT05396300|Biological|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
79245437|NCT05375136|Other|Non-interventional|No intervention will be administered.
79539054|NCT03806166|Other|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
79539055|NCT03806166|Other|Standard treatment|Standard duration of systemic antibiotic treatment
79539056|NCT03792867|Drug|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
79539058|NCT03765918|Biological|Pembrolizumab 200 mg|200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
79696708|NCT04649970|Procedure|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
79696709|NCT05127863|Behavioral|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
79841087|NCT04093505|Drug|Glasdegib|Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27
79539059|NCT03765918|Radiation|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
79539060|NCT03765918|Radiation|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
79539061|NCT03765918|Radiation|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
79539062|NCT03765918|Drug|Cisplatin 100 mg/m^2|100 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle
79696710|NCT04649892|Drug|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
79696711|NCT04649892|Drug|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
79841088|NCT04093505|Drug|Placebo Oral Tablet|Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27
79841089|NCT00622440|Drug|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
79245438|NCT05374551|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
79245439|NCT05372692|Drug|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
79245440|NCT05364450|Behavioral|Enhanced Usual Care|"Interventionists will provide a brief explanation of the intervention and coaching to the group on how to utilize the resources provided. Prior to the single session group, EUC participants will have received a workbook with the National Cancer Institute's Facing Forward: Life After Cancer Treatment booklet on maximizing quality of life during cancer survivorship and the American Society of Clinical Oncology's Guide to Cancer Survivorship."
79539063|NCT03756896|Drug|Carfilzomib|Given IV
79539064|NCT03756896|Drug|Dexamethasone|Given PO
79539065|NCT03756896|Drug|Pomalidomide|Given PO
79539066|NCT03741764|Device|Vivosorb|Resorbable implant device
79539067|NCT03737955|Drug|Gemtuzumab Ozogamicin|Receive IV
79539068|NCT03737955|Other|Quality-of-Life Assessment|Ancillary studies
79539069|NCT03737669|Biological|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
79539070|NCT03737669|Biological|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
79696712|NCT04649892|Behavioral|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
79696713|NCT04649892|Device|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~Before taking the first dose of naltrexone or placebo.~One hour after taking the first dose of naltrexone or placebo.~One week after continuous and daily use of naltrexone or placebo.~At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
79696714|NCT05125796|Drug|paracetamol|1000 mg intravenous paracetamol in 100 mL normal saline
79696715|NCT05125796|Drug|Dexketoprofen Trometamol|50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
79696716|NCT05125796|Drug|Lidocaine topical|Application of 5 gr of 5% topical lidocaine
79245441|NCT05364450|Behavioral|Acceptance Commitment Therapy|Interventionists will support participants in adopting a psychologically flexible posture toward FCR through six interdependent processes of change - acceptance, cognitive defusion, mindfulness, perspective taking, values, and committed action. During ACT sessions, participants will learn to respond adaptively to FCR by being more fully aware of thoughts, feelings, and bodily sensations without judging or attempting to control or avoid them. Participants will also clarify their deeply-held values and set action goals in alignment with their values.
79245442|NCT05364450|Behavioral|Cognitive Behavioral Therapy|Interventionists will provide psycho-education on the cognitive behavioral model of FCR and assist participants in changing unhelpful thinking patterns and maladaptive behaviors linked to FCR. Session topics will include FCR triggers, behavioral experiments to reduce FCR-perpetuating safety behaviors, and pleasant events scheduling. Interventionists will also provide evidence-based information on behaviors that may reduce recurrence risk (e.g., achieving a healthy weight, physical activity, cancer surveillance).
79696717|NCT05125796|Drug|Placebo|100 mL intravenous normal saline infusion+ placebo topical pomade application
79245443|NCT05315232|Other|survey and interview|qualitative assessment
79245444|NCT05288777|Drug|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
79245445|NCT05288777|Drug|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
79245446|NCT05288777|Radiation|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
79384447|NCT02459652|Drug|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
79384448|NCT02459652|Radiation|Radiation Therapy|Radiation therapy is delivered with >6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
79384449|NCT03281772|Other|Clinical Decision Software - provider portal|As noted in Arms
79384450|NCT03281772|Other|Clinical Decision Software - patient portal|As noted in Arms
79384451|NCT03286764|Other|Peppermint Oil|
79384452|NCT03286764|Other|Distilled water|Distilled water spray as a placebo during Colonoscopy
79384453|NCT03291678|Procedure|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
79696719|NCT04616859|Dietary Supplement|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
79384454|NCT03291678|Procedure|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
79384455|NCT03291600|Behavioral|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
79384456|NCT03291444|Biological|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
79539071|NCT03716128|Diagnostic Test|18F-PET|Bone biopsy and 18F-PET
79696720|NCT04616859|Dietary Supplement|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
79696721|NCT04616859|Dietary Supplement|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
79696722|NCT04616859|Dietary Supplement|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
79696723|NCT04616937|Dietary Supplement|GOS|Prebiotic
79696724|NCT04616937|Dietary Supplement|Placebo|Placebo
79696725|NCT05053607|Behavioral|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
79696726|NCT05053607|Device|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
79384457|NCT03291444|Biological|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
79384458|NCT03291366|Drug|UCMSCC|infusion of aUCMSC and conventional therapy
79384459|NCT03291366|Drug|conventional treatment|conventional treatment
79539072|NCT03683225|Combination Product|CTC-413|pramipexole ER, given with aprepitant
79539073|NCT03678389|Other|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
79539074|NCT03642964|Drug|CTC-501|pramipexole IR, given with ondansetron
79696727|NCT04616586|Drug|Siltuximab|11 mg/kg IV administered over 1 hour
79696728|NCT04616586|Other|Normal Saline|IV administered over 1 hour
80011010|NCT02038374|Procedure|biopsies|
79245447|NCT05288777|Radiation|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
79245448|NCT05264571|Diagnostic Test|calscreener|The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
79384460|NCT03281694|Drug|Placebo|placebo skin patch and placebo oral solution
79539075|NCT03638999|Drug|Ketorolac Trometamol 30Mg/1mL Injection|Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
79539076|NCT03638999|Drug|Normal saline|Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
79539077|NCT03636438|Other|No Intervention|No Intervention
79539078|NCT03635892|Drug|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
79539079|NCT03635892|Drug|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
79539080|NCT03629223|Drug|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
79539081|NCT03629223|Drug|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
79539082|NCT03625765|Device|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
79245449|NCT05264571|Other|Metabolic profile|"The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria"
79539083|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
79384461|NCT03281694|Drug|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
79696729|NCT04616469|Procedure|Root canal treatment using TruNaomy rotary files|Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system
80011011|NCT02059590|Drug|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
79384462|NCT03281694|Drug|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
79384463|NCT03281694|Drug|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
79384464|NCT03281616|Behavioral|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
79539084|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
79696730|NCT04616469|Procedure|Root canal treatment using race rotary instruments|Race rotary files will be used for the process of cleaning and shaping of the root canal system
79384465|NCT03286608|Other|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
79384466|NCT03281460|Device|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
79384467|NCT03281460|Procedure|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
79384468|NCT03286452|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
79539085|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
79539086|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
79539087|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
79539088|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
79696731|NCT05038787|Drug|LY3473329|Administered orally.
79696732|NCT05038787|Drug|Placebo|Administered orally.
79696733|NCT00563043|Procedure|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
79841090|NCT00622440|Drug|Placebo|Placebo twice daily for 48 weeks.
80011012|NCT02192216|Behavioral|Exercise|
80011013|NCT02056002|Other|Usual Care|- Standard CPAP educational training
79245450|NCT05264571|Other|optical microscopy|To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
79245451|NCT05264571|Other|RTqPCR|To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
79245452|NCT05254314|Drug|Semaglutide Pen Injector 2.4mg weekly|Once weekly subcutaneous injection
79245453|NCT05254314|Other|Placebo|Once weekly subcutaneous injection
79245454|NCT05235750|Behavioral|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
79384469|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
79696734|NCT00563121|Procedure|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
79696735|NCT04988321|Procedure|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
79841091|NCT04759690|Behavioral|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
79245455|NCT05167422|Behavioral|Trusted Messenger|A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
79841092|NCT04759690|Behavioral|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
79841093|NCT02597777|Other|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
79841094|NCT02597777|Other|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
79245456|NCT05156281|Drug|Remibrutinib|tablet taken orally
79245457|NCT05156281|Drug|Teriflunomide|capsule taken orally
79245458|NCT05153174|Drug|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
79539089|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
79539090|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
79539091|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
79539092|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
79696736|NCT04616508|Behavioral|motor control assessment|Basic science study of control of reaching movements
79841095|NCT00831714|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
79841096|NCT00831714|Drug|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
79841097|NCT02597699|Drug|Remifentanil + Lidocaïne|
79841098|NCT02597699|Drug|Sufentanil + Lidocaïne|
79245459|NCT05104775|Drug|GNC-035|Administration by intravenous infusion.
79245460|NCT05101746|Drug|Nitric Oxide (NO) 20 part per million (ppm)|Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
79245461|NCT05101746|Other|Standard of care cardiopulmonary bypass|Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
79841099|NCT00827736|Procedure|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
79841100|NCT00827736|Drug|ISDN ointment|application of ISDN 1% ointment 6 times a day
79841101|NCT00827736|Drug|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
79841102|NCT00744653|Procedure|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
79848982|NCT05693766|Other|Endocrine-therapy|Endocrine therapy administered
79696737|NCT04616352|Other|Resistance to cefuroxime|Non susceptibility in vitro testing
79245462|NCT05091580|Behavioral|Interpersonal Counseling|Interpersonal Counseling is a brief (4-8 sessions) psychological intervention that was developed to treat depression in primary care. In IPC, counselors provide psychoeducation about the connection of depressive symptoms to social triggers and support patients in leveraging social networks to address these stressors and reduce depressive symptoms. Since depressive symptoms are often a transient reaction to life stress (e.g. TB diagnosis), many individuals are able to achieve significant alleviation of symptoms in as few as four sessions. IPC focuses on reducing interpersonal conflict and improving social cohesion in families, which may have the advantage of strengthening the ability of families to support TB patients in completing treatment to achieve cure. All individuals will be offered 4-5 sessions (weekly), with up to 3 optional booster sessions (monthly) until TB treatment is completed.
79384470|NCT03281226|Drug|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
79539093|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
79384471|NCT03281226|Drug|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
79384472|NCT03291054|Drug|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
79696738|NCT00553943|Drug|Rituximab|375 mg/m2 D1
79696739|NCT00553943|Drug|Cytarabine|50 mg D3
79696740|NCT00563160|Drug|gemcitabine, carboplatin|
79841103|NCT00998218|Drug|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
79841104|NCT00998218|Drug|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
79384473|NCT03291054|Drug|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
79841105|NCT00825396|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
79841106|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
79841107|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
79841108|NCT04044300|Procedure|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
79841109|NCT04044300|Other|Conservative|Continued pain management and physical therapy.
79841110|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
79848983|NCT05693766|Other|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
79848984|NCT05691244|Drug|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
79539094|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
79539095|NCT03611933|Other|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
79848985|NCT05691244|Drug|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
79539096|NCT03568383|Drug|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to <30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
79539097|NCT03568383|Drug|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to <24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
79696741|NCT00563160|Procedure|surgery|
79696742|NCT00563199|Behavioral|nurse-delivered stage-matched smoking cessation counseling|
79696743|NCT00563238|Drug|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
79696744|NCT04679558|Drug|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
79696745|NCT04679558|Behavioral|Preventive protocol|Preventive protocol
79696746|NCT03454542|Device|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
79696747|NCT04934228|Drug|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Hypertension~Dose(s): 25 mg/day~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
79245463|NCT05091580|Behavioral|Enhanced treatment as usual|Depression screening and referral (as needed)
79696748|NCT04934228|Drug|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~Condition/disease indication(s): Vascular function and blood flow~Subject population: Hypertension~Dose(s): 0.1 mg (oral)~Administration: Oral~Dosing regimen: 0.1 mg twice daily by mouth"
79696749|NCT04934228|Drug|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
79696750|NCT03454503|Drug|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
79696751|NCT03454464|Procedure|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
79696752|NCT03454464|Procedure|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
79848986|NCT05681780|Biological|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
79848987|NCT05681780|Drug|Nivolumab|Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.
79539098|NCT03568383|Dietary Supplement|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
79848988|NCT05681780|Drug|Cyclophosphamide|Cyclophosphamide will be administered on days -7 and -6.
79539099|NCT03567473|Drug|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
79539100|NCT03567473|Drug|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
79539101|NCT03567473|Drug|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
79539102|NCT03567473|Drug|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
79539103|NCT03567473|Drug|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
79539104|NCT03567473|Drug|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
79539105|NCT03547908|Drug|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
79539106|NCT03547908|Drug|Placebo to match DTG|Tablet administered orally once daily, without regard to food
79539107|NCT03547908|Drug|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
79539108|NCT03547908|Drug|DTG|50 mg tablet administered orally once daily, without regard to food
79539109|NCT03547908|Drug|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
79539110|NCT03547908|Drug|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
79539111|NCT03539380|Drug|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
79539112|NCT03519685|Behavioral|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
79696753|NCT03454386|Behavioral|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
79245464|NCT05090397|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
79245465|NCT05090397|Device|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current Stimulation
79245466|NCT05089266|Drug|CAR T cells|αPD1-MSLN-CAR T Cells
79245467|NCT05027750|Behavioral|Application of The Theory of Planned Behaviour For Weight Control|The training to be imparted to the participants was applied online in groups of 5-6 people via the Google Meet program. Obesity training consisting of a total of five sessions. Each session lasted for approximately 30 minutes. After the training given to intervention group, the women will be followed-up for 6 months. The women in the intervention group will be given counseling service by the researchers, and their status will be evaluated every month.
79245468|NCT05012202|Device|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
79696754|NCT03454386|Behavioral|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
79245469|NCT04994405|Procedure|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
79245470|NCT04971733|Drug|E2814|E2814 intravenous infusion.
79841111|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
79841112|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
79841113|NCT00311311|Drug|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
79841114|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
79848989|NCT05681780|Drug|Fludarabine|Fludarabine will then be infused per institutional standard on Days -7 to -3.
79539113|NCT03519685|Behavioral|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
79848990|NCT05681780|Other|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive a dose infusion TIL cells.
79384474|NCT03290976|Other|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
79245471|NCT04938453|Drug|nintedanib 25 mg|soft gelatin capsule
79539114|NCT03517579|Device|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~A cable that connects the collar unit to the Control Unit~A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
79696755|NCT04915781|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
79696756|NCT04616157|Behavioral|ICBT-I|Cognitive-behavioral therapy for insomnia
79696757|NCT04900844|Device|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
79245472|NCT04938453|Drug|nintedanib 100 mg|soft gelatin capsule
79245473|NCT04916067|Device|Mesh Implantation|Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
79245474|NCT04876157|Diagnostic Test|Artificial intelligence-aimed point-of-care ultrasound image interpretation system|improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
79245475|NCT04874454|Diagnostic Test|ultrasound|evaluate the vocal cord movement among the stroke patients
79245476|NCT04817111|Drug|MIB-626|Two (2) 500 mg Tablets, By Mouth, Daily
79245477|NCT04802681|Device|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
79539115|NCT03510104|Drug|MRX-2843|MRX-2843 capsules
79539116|NCT03500328|Other|Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy|Early Aggressive Therapy
79245478|NCT04778982|Drug|KN026 combined with Palbociclib and Fulvestrant|HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
79539117|NCT03500328|Other|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
79539118|NCT03469674|Radiation|Vaginal brachytherapy|Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
79539119|NCT03469674|Radiation|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
79539120|NCT03469674|Other|Observation|No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
79384475|NCT03290976|Other|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
79539121|NCT03464760|Dietary Supplement|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
79696758|NCT04616391|Device|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
79841115|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
80011014|NCT02056002|Other|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP educational training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
79245479|NCT04772781|Drug|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
79245480|NCT04772781|Drug|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
79245481|NCT04768608|Drug|PD1-PSMA-CART cells|PD1-PSMA-CART cells will be given IV at split doses
79245482|NCT04767373|Biological|Clesrovimab|Clesrovimab solution
79539122|NCT03464760|Dietary Supplement|placebo|5 tablets per day of potato-based placebo
79539123|NCT03455608|Behavioral|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
79539124|NCT03455608|Behavioral|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
79539125|NCT03455608|Behavioral|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
80011015|NCT02056002|Other|Usual Care|- Educational Brochures
80011016|NCT02056002|Other|Usual Care|- Educational DVD videos mailed to participant
80011017|NCT02192294|Drug|Oral Bosutinib|a single dose of 500 mg oral bosutinib
79245483|NCT04767373|Drug|Placebo|Placebo (0.9% sodium chloride [NaCL]) solution
79539126|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
79539127|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
79539128|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
79539129|NCT03435250|Drug|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
79245484|NCT04765046|Device|Bispectral (BIS™) Complete Monitoring System|The BIS™ Complete Monitoring System is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS technology converts raw EEG data acquired from the frontal cortex into a single number to measure the level of consciousness, called the BIS index. A bilateral sensor is to be placed on the patient's forehead to collect the EEG signals and transmit them back to the system.
79245485|NCT04756648|Drug|CT0180 Cells|Five dose levels were tentatively determined.
79245486|NCT04711603|Drug|MR13A9|Intravenous administration
79245487|NCT04711603|Drug|Placebo|Intravenous administration
79245488|NCT04699877|Drug|Gilteritinib|Oral
79245489|NCT04699591|Drug|Domperidone|Domperidone taken 4 times a day, dose based on body weight
79245490|NCT04691037|Diagnostic Test|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
79245491|NCT04679948|Drug|Percoffedrinol®|Tablet
79245492|NCT04679948|Drug|Coumadin®|Tablet
79245493|NCT04679948|Drug|Antra MUPS®|Gastro-resistant tablet
79539130|NCT03435250|Drug|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
79539131|NCT03435250|Drug|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
79696759|NCT03455153|Other|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
79841116|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
80011018|NCT02192294|Drug|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
79539132|NCT03425669|Device|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
79539133|NCT03425669|Device|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
79539134|NCT03425669|Drug|Active medication|Patients will be examined with and without medication.
79539135|NCT03420014|Drug|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
79539136|NCT03420014|Combination Product|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
79696760|NCT04616430|Drug|Topical endoxifen|topical solution
79696761|NCT04616430|Drug|Placebo|topical
79696762|NCT04891796|Other|No intervention|No intervention
79696763|NCT04616040|Drug|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
79841117|NCT03854604|Other|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
79841118|NCT02599181|Other|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland.
79841119|NCT04089605|Drug|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
79841120|NCT04089605|Drug|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
79841121|NCT02597621|Other|no intervention|no intervention
79539137|NCT03395405|Drug|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
79696764|NCT04616118|Other|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
79696765|NCT04616118|Other|Video Visit|Participants randomized to this arm will receive usual care via video call
79696766|NCT00553982|Procedure|Patellar component|Resurfacing with onlay technique
79696767|NCT00553982|Procedure|No patellar component|Trimming of osteophytes when appropriate
79696768|NCT04615962|Drug|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
79696769|NCT04615962|Drug|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
79696770|NCT04615962|Drug|SNG100|A combination of low potency steroid and skin barrier repair agent
79841122|NCT02599025|Device|Innowalk cycling system|Innowalk is a unique, motorized medical device
79841123|NCT02599025|Device|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
79841124|NCT00521404|Drug|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
79539138|NCT03395405|Other|Placebo|One tablet twice daily with food for 56 consecutive doses
79539139|NCT03393520|Drug|Placebo|oral capsules
79841125|NCT00521404|Drug|gemcitabine|Gemcitabine - 1000mg/meter sq
79841126|NCT00311155|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
79848991|NCT05681780|Drug|Interleukin-2 (IL2)|Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
80011019|NCT05620134|Drug|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
79539140|NCT03393520|Drug|AVP-786|oral capsules
79539141|NCT03385005|Device|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
79696771|NCT04881929|Drug|KN026|KN026 in Combination With Docetaxel
79696772|NCT04615767|Dietary Supplement|D-chiro-inositol|as described previously
80011020|NCT02188628|Device|H-Man|H-man is a portable end-effector planar upper limb robot.
80011021|NCT02188628|Other|Additional Conventional Therapy|Repetitive goals based arm therapy
79696773|NCT04881227|Device|Chatbot on COVID-19 vaccine hesitancy|This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
79696774|NCT04881227|Other|Control intervention|This control intervention will provide to participants a brief text decribing the way vaccines works.
79841127|NCT03977077|Drug|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
79696775|NCT04615494|Procedure|Position|Pneumoperitoneum with Steep Trendelenburg position
79841128|NCT03981679|Other|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
80011022|NCT02057796|Device|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
79696776|NCT04616001|Drug|IVIG|Patients will receive IVIG daily for four days.
79696777|NCT04615611|Drug|salbutamol|inhalation of salbutamol
79696778|NCT04615611|Drug|Placebo|administration of placebo
79696779|NCT04615728|Procedure|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
79696780|NCT04832165|Other|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
79696781|NCT04798586|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
79841129|NCT03981601|Drug|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
80011023|NCT02057796|Drug|ART (Atripla, Truvada, Efavirenz, Combivir)|"ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
80011024|NCT02057796|Drug|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
80011025|NCT03681171|Other|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
80011026|NCT03676569|Biological|ADRC transplantation in autoimmune refractory epilepsy|
79539142|NCT03381248|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
79539143|NCT03381248|Other|Hyaluronic Acid Injection|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
79696782|NCT04798040|Other|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
79696783|NCT04798040|Other|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
79245494|NCT04679948|Drug|Midazolam-ratiopharm®|Oral solution
79245495|NCT04679948|Drug|BI 730357|Film-coated tablet
79245496|NCT04672616|Behavioral|Group psychotherapy|The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
79245497|NCT04653480|Drug|Surufatinib|250mg per oral, once daily
79245498|NCT04653480|Drug|Toripalimab|3mg/kg IV, once every 2 weeks
79696784|NCT04798040|Other|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
79696785|NCT00563277|Procedure|combined pterygium and cataract operation|
79696786|NCT00563277|Procedure|pterygium excision followed by cataract operation|
79696787|NCT04785053|Device|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
79696789|NCT04776551|Procedure|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
80011027|NCT02059746|Other|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
80011028|NCT02192450|Drug|Insulin aspart/glargine|
80011029|NCT02192450|Drug|Insulin aspart/degludec|
80011030|NCT03680937|Other|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
79245499|NCT04653480|Drug|chemotherapy|oxaliplatin or irinotecan based regimens, according to the first line treatment
79539144|NCT03381248|Other|Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
79539145|NCT03368625|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
79841130|NCT03981601|Procedure|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
79841131|NCT00274651|Drug|belinostat|
79841132|NCT01068691|Procedure|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~Blood pressure~Obstructive sleep apnea syndrome (OSAS)~Carotid-to-femoral pulse wave velocity (PWV)~Biological parameters"
79841133|NCT00274261|Drug|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
79384476|NCT03286374|Behavioral|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~Four weeks with an institutional stay at Muritunet (BL)~Follow-up;~Eight weeks, telephone contact between therapist at Muritunet and the participant.~16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~40 weeks, telephone contact between therapist at Muritunet and the participant.~52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
79384477|NCT03286296|Biological|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
79841134|NCT00274261|Drug|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
79841135|NCT00624468|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
79841136|NCT00624468|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
80011031|NCT03680937|Other|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
79245500|NCT04652219|Biological|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
79384478|NCT04539522|Behavioral|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
79384479|NCT04539522|Behavioral|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
79384480|NCT03281148|Device|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
79539146|NCT03357757|Drug|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
79539147|NCT03357757|Biological|Avelumab|10 mg/kg IV
79696790|NCT04614675|Procedure|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
79696791|NCT04614675|Procedure|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
79841137|NCT03976687|Drug|EYP001a|Oral tablets
79841138|NCT03976297|Other|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
79841139|NCT00827814|Drug|Dutasteride|Dutasteride 0.5 mg od.
79841140|NCT01069783|Drug|A3309|A3309 in two different dosage levels
79841141|NCT01069783|Drug|A3309|A3309 in two different dosage levels for the duration of the study
79841142|NCT01069783|Drug|Placebo|Placebo comparator once daily for the duration of the trial
80011032|NCT03535454|Other|working hours|weekly working hours
79245501|NCT04647435|Drug|APSCTC|APSCTC + Toragesic® placebo + Tramal® placebo
79245502|NCT04647435|Drug|Toragesic®|APSCTC placebo + Toragesic® + Tramal® placebo
79245503|NCT04647435|Drug|Tramal®|APSCTC placebo + Toragesic® placebo + Tramal®
79539148|NCT03354663|Device|TactiCath SE|Ablation to achieve pulmonary vein isolation.
79539149|NCT03344458|Drug|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
79539150|NCT03312465|Device|AS Domelock System|Hemi or Total Shoulder Arthroplasty
79539151|NCT03305419|Drug|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
79539152|NCT03305419|Drug|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
79245504|NCT04637529|Drug|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
79245505|NCT04637529|Drug|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
79245506|NCT04633291|Device|Novel swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
79841143|NCT00825474|Other|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
79841144|NCT03976765|Other|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
80011033|NCT03676491|Other|Music Intervention|Music intervention
79841145|NCT01068847|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
79841146|NCT00827892|Drug|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
79841147|NCT00827892|Drug|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
79539153|NCT03288103|Drug|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
79245507|NCT04633291|Device|Comparator swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
79841148|NCT00831948|Genetic|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
79841149|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
79841150|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
79245508|NCT04625803|Drug|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
79384481|NCT03281148|Device|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
79384482|NCT04443504|Behavioral|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
79384483|NCT03286140|Procedure|Early endovenous ablation|
79384484|NCT03286140|Procedure|Delayed endovenous intervention|
79384485|NCT03286062|Combination Product|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
79696792|NCT04614285|Procedure|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
79696793|NCT04614012|Other|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
79539154|NCT03287063|Other|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
79696794|NCT04713371|Drug|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
79696795|NCT04713371|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
79696796|NCT04713371|Drug|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
79696797|NCT04713371|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
79696798|NCT04713371|Drug|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
79841151|NCT04043676|Drug|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
79841152|NCT01325935|Drug|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
79841153|NCT02549742|Procedure|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
79245509|NCT04580225|Procedure|Four-Corner Arthrodesis|Participants in Group A will receive a four-corner arthrodesis (fusion of the capitate, hamate, lunate, and triquetrum) with excision of the scaphoid.
79245510|NCT04580225|Procedure|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision|Participants in Group B will receive a three-corner arthrodesis (fusion of the capitate, hamate, and lunate) or capitolunate arthrodesis (fusion of the capitate and lunate) with excision of the scaphoid and triquetrum.
79384486|NCT01776723|Drug|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
79384487|NCT01775007|Device|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
79384488|NCT03280914|Device|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
79696799|NCT04683614|Drug|Norepinephrine|5 mic/kg/hr norepinephrine
79384489|NCT03285906|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
79696800|NCT04683614|Biological|Fresh frozen plasma|early administration of fresh frozen plasma
79696801|NCT04613895|Drug|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
79696802|NCT04613895|Drug|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
80011034|NCT03680703|Behavioral|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
80011035|NCT02188940|Behavioral|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
79841154|NCT02549742|Device|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
79539155|NCT03273881|Drug|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
79245511|NCT04528823|Other|Strategy 2: Symptom screen, Genexpert and TST|Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
79245512|NCT04528823|Other|Strategy 3:Symptom screen, CXR but NO TST|Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
79384490|NCT01895205|Drug|Iron isomaltoside 1000|
79539156|NCT03273881|Drug|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
79841155|NCT02549742|Drug|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
79696803|NCT04613700|Drug|Secretin|Native hormone
79696804|NCT04613700|Other|Placebo|Saline
79696805|NCT04613544|Device|Voice Assist Arrhythmia Monitoring (VAAM)|application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
79696806|NCT00563355|Drug|erythropoietin|
79245516|NCT04469517|Other|hypoxic induced factors|hypoxic induced factors analyzed in blood sample
79245517|NCT04461171|Procedure|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
79384491|NCT01895205|Drug|Red blood cell transfusion|
79841156|NCT00521014|Biological|filgrastim|
79384492|NCT03285828|Behavioral|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :~Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~Lectures and the distribution of memory aids.~Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
79696807|NCT04672109|Device|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
79841157|NCT00521014|Biological|rituximab|
79841158|NCT00521014|Biological|sargramostim|
79696808|NCT00563394|Drug|ofloxacin|400 mg twice a day for 14 days
79696809|NCT00563394|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
79841159|NCT00521014|Drug|carmustine|
79841160|NCT00521014|Drug|cytarabine|
79841161|NCT00521014|Drug|etoposide|
79841162|NCT00521014|Drug|melphalan|
79841163|NCT00521014|Procedure|autologous hematopoietic stem cell transplantation|
79841164|NCT00825552|Drug|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
79841165|NCT00560235|Drug|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
79245518|NCT04446117|Drug|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40mg
79245519|NCT04446117|Drug|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
79696810|NCT04660877|Dietary Supplement|Cheddar Cheese|20g of protein from cheddar cheese
79245520|NCT04446117|Drug|Abiraterone Acetate|Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
79245521|NCT04446117|Drug|Enzalutamide|Supplied as 40 mg capsules; administered orally daily at 160mg
79245522|NCT04446117|Drug|Prednisone|Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
79245523|NCT04438525|Diagnostic Test|sting challenge|At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
80011036|NCT02188940|Behavioral|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
79696811|NCT04660877|Dietary Supplement|Milk|20g of protein from milk
79841166|NCT00827970|Behavioral|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
79841167|NCT00825708|Device|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
80011037|NCT02188940|Behavioral|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
79696812|NCT04653350|Other|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
79696813|NCT04653350|Other|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training & balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
79539157|NCT03245242|Other|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
79696814|NCT00563433|Drug|ofloxacin|400 mg twice a day for 14 days
79696815|NCT00563433|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
79245524|NCT04438525|Other|blood donation|To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
79245525|NCT04403919|Device|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson & Johnson) and Dermabond advanced.
79539158|NCT03245242|Other|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
79696816|NCT04652102|Biological|CVnCoV|Intramuscular (IM) injection.
79696817|NCT04652102|Biological|Placebo|Intramuscular (IM) injection.
79696818|NCT04652102|Biological|Authorized/licensed vaccines for preventing COVID-19 (AV)|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
79841168|NCT00825708|Device|shamTMS|sham TMS session
79841169|NCT00291577|Drug|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
79841170|NCT00291577|Drug|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
79384493|NCT01895283|Behavioral|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
79696819|NCT00563472|Drug|estetrol|10 mg orally per day for 28 days
79696820|NCT00563472|Drug|estetrol|20 mg orally per day for 28 days
79384494|NCT04264962|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
79384495|NCT04264962|Other|Routine medical care|Routine medical care
79384496|NCT01748175|Drug|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
79696821|NCT00563472|Drug|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
79696822|NCT00563472|Drug|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
79696823|NCT04679597|Drug|Capecitabine|comparison of two treatments
79696824|NCT00563511|Procedure|adherence intervention|
79696825|NCT00563511|Procedure|intervention without adherence advice|
79696826|NCT00563511|Procedure|control|
79696827|NCT04613856|Other|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
79696828|NCT04613856|Other|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
79841171|NCT00520936|Drug|pemetrexed|1910 milligrams per meter squared (mg/m^2) (or 60 milligrams per kilogram [mg/kg] if patient <12 months old), intravenous (IV), for 21 days x 17 cycles
79841172|NCT02549430|Drug|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
79696829|NCT04609397|Drug|Hemay005|Hemay005 tables 60mg bid p.o;
79245526|NCT04403919|Device|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
79696830|NCT04609397|Drug|Hemay005|Hemay005 tables 45mg bid p.o
79384497|NCT04261764|Device|"Fastening-mimicking diet combined with a dispelling dampness meal replacement"|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
79696831|NCT04609397|Other|Placebo|placebo to Hemay005 tables bid p.o
79696832|NCT04613193|Other|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
79841173|NCT02549430|Drug|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
79841174|NCT02549430|Drug|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
80011038|NCT02188940|Other|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
79384498|NCT04261764|Other|Normal diet|Carrying out normal diet under the guidance of a dietitian.
79696833|NCT04587947|Drug|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
79696834|NCT04613310|Diagnostic Test|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
79696835|NCT04578080|Device|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
79696836|NCT04612998|Other|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
79384499|NCT03280758|Behavioral|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
79384500|NCT04755387|Drug|Ticagrelor 90mg|Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.
79384501|NCT04755387|Drug|Ticagrelor 60/45mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
79696837|NCT04612998|Other|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
79696838|NCT04612998|Drug|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
79245527|NCT04403919|Device|Conventional Closure: Hip|"The capsule will be closed with Vicryl Plus number 1~Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson &Johnson, Somerville, NJ)~Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson & Johnson)~followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson &Johnson)."
79245528|NCT04403919|Device|Barbed suture closure: Hip|"The capsule will be closed with stratafix symmetric PDS Plus~Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson &Johnson, Somerville, NJ)~Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson & Johnson, Somerville, NJ)~Subcuticular suture with stratafix spiral monocryl plus, Ethicon~followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson &Johnson)."
79384502|NCT04046328|Drug|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
79384503|NCT04046328|Drug|Placebo|Enteric-Coated Delayed Release Placebo Capsules
79384504|NCT03285672|Drug|FP-101|Dose 1
79384505|NCT03285672|Drug|Placebo Comparator|Dose 1
79696839|NCT04612998|Drug|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate < 45 beats/minute) during surgery.
79696840|NCT04612998|Drug|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
79696841|NCT04545476|Device|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
79841175|NCT02549430|Drug|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
79696842|NCT04545476|Device|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
79841176|NCT02549430|Drug|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
79841177|NCT00828126|Procedure|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
79841178|NCT00947037|Drug|AP-CD/LD|
79848992|NCT05945160|Drug|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
79848993|NCT05945160|Drug|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
79696843|NCT04545476|Other|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
79384506|NCT03285516|Behavioral|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
79384507|NCT03280680|Other|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
79696844|NCT04545476|Other|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
79696845|NCT00563589|Drug|mycophenolate mofetil, methotrexate, cyclosporin|
79841179|NCT03867760|Behavioral|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
79841180|NCT03867760|Behavioral|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
79841181|NCT00943839|Drug|sunitinib malate|
79245529|NCT04397003|Biological|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, Ichor Medical Systems). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
79384508|NCT03280680|Other|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
79384509|NCT03280680|Other|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
79384510|NCT03285360|Combination Product|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
79384511|NCT03285360|Combination Product|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
79245530|NCT04397003|Drug|Durvalumab|-Supplied by AstraZeneca/MedImmune
79696846|NCT00563589|Drug|Methotrexate and cyclosporin|
79696847|NCT00563628|Device|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
79841182|NCT00943839|Other|laboratory biomarker analysis|
79841183|NCT00943839|Other|pharmacological study|
80011039|NCT02188940|Other|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
80011040|NCT03560856|Drug|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
79245531|NCT04397003|Device|TDS-IM v2.0 Device|-Integrated electroporation administration system
79245532|NCT04397003|Procedure|Peripheral blood draws|-Pre-treatment, Week 3 (before Cycle 2 chemotherapy), Week 6 (before Cycle 3 chemotherapy), Week 9 (before Cycle 4 chemotherapy), Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine (C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1)
79245533|NCT04266496|Other|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
79384512|NCT00160173|Drug|Estrogel|
79384513|NCT00160173|Other|Placebo|
79384514|NCT03285282|Procedure|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
79384515|NCT04046172|Procedure|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
79696848|NCT04492670|Procedure|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
79696849|NCT04492670|Drug|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
79696850|NCT00563667|Procedure|pterygium excision|
79696851|NCT04613037|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
79539159|NCT03233152|Drug|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
79539160|NCT03233152|Drug|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
79539161|NCT03190967|Drug|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
79539162|NCT03190967|Drug|TMZ|Phase I: TMZ 30, 40 or 50 mg/m^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
79245534|NCT04266496|Diagnostic Test|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
79245535|NCT04266496|Diagnostic Test|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
79245536|NCT04266496|Diagnostic Test|Blood sample|Blood collection to measure plasma sodium and osmolality.
79384516|NCT04046172|Procedure|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
79539163|NCT03188965|Drug|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
79245537|NCT04266496|Diagnostic Test|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~After awakening, when still laying dowing in bed~Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
79245538|NCT04197583|Device|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
79245539|NCT04147260|Drug|BI 730357|Film-coated tablet
79384517|NCT00136695|Drug|anastrozole|1 mg QD
79384518|NCT01896453|Procedure|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
79384519|NCT01896453|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
79384520|NCT02459730|Procedure|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
79384521|NCT02459730|Procedure|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
79384522|NCT04756167|Other|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
79539164|NCT03184571|Drug|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
79539165|NCT03176823|Device|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
79539166|NCT03176823|Other|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
79841184|NCT00832182|Drug|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
79841185|NCT00832182|Drug|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
79245540|NCT04147260|Drug|Placebo to match BI 730357|Film-coated tablet
79245541|NCT04147260|Drug|Ciprofloxacin|Film-coated tablet
79245542|NCT04134728|Biological|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
79245543|NCT04134728|Biological|Sarilumab|Sarilumab solution in PFS to be administered SC.
79245544|NCT04134728|Drug|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
79245545|NCT04134728|Drug|csDMARDs|Stable dose of csDMARD(s) as SoC.
79245546|NCT04112043|Behavioral|Walking Exercise|Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
79245547|NCT04112043|Drug|Nicotinamide Riboside (NR)|Participants randomized to this intervention will receive 1,000 mg/day of NR.
79539167|NCT03108196|Procedure|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
79539168|NCT03108196|Procedure|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
79539169|NCT03097939|Drug|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
79696852|NCT04612842|Behavioral|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
79696853|NCT04612881|Drug|fitostimoline vaginal pessaries|vaginal pessaries
79696854|NCT04612881|Other|standard of care|standard of care
79245548|NCT03997968|Drug|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
79245549|NCT03997968|Drug|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
79245550|NCT03997968|Drug|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
79384523|NCT04756167|Other|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
79384524|NCT03280602|Procedure|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
79696855|NCT04464161|Dietary Supplement|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
79384525|NCT03280602|Procedure|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
79539170|NCT03097939|Drug|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
79539171|NCT03097874|Behavioral|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
79539172|NCT03097874|Behavioral|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
79539173|NCT03096782|Biological|Anti-Thymocyte Globulin|Given IV
79539174|NCT03096782|Drug|Busulfan|Given IV
79696856|NCT04612959|Other|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
79848994|NCT05675059|Behavioral|Consultations with Moffitt Dietician|Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
79848995|NCT05675059|Behavioral|Daily Food Intake Diary with Fitbit Smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.
79245551|NCT03997968|Drug|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
79245552|NCT03995706|Drug|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
79245553|NCT03984097|Drug|TAK-079|TAK-079 subcutaneously.
79245554|NCT03984097|Drug|Lenalidomide|Lenalidomide orally.
79245555|NCT03984097|Drug|Dexamethasone|Dexamethasone orally.
79245556|NCT03984097|Drug|Bortezomib|Bortezomib subcutaneously.
79245557|NCT03984097|Drug|Pomalidomide|Pomalidomide orally.
79245558|NCT03954184|Behavioral|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
79245559|NCT03903107|Procedure|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
79384526|NCT03280524|Other|reflexology|
79384527|NCT03280524|Other|self-care guidelines with feet|
79384528|NCT04756011|Other|Health related quality of life|Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
79539175|NCT03096782|Drug|Clofarabine|Given IV
79539176|NCT03096782|Drug|Cyclophosphamide|Given IV
79539177|NCT03096782|Biological|Filgrastim-sndz|Given SC
79539178|NCT03096782|Drug|Fludarabine|Given IV
79539179|NCT03096782|Drug|Melphalan|Given IV
79539180|NCT03096782|Drug|Mycophenolate Mofetil|Given IV or PO
79539181|NCT03096782|Biological|Rituximab|Given IV
79539182|NCT03096782|Drug|Tacrolimus|Given IV
80011041|NCT03676413|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
79384529|NCT01896063|Procedure|Electroacupuncture|
79384530|NCT03280446|Device|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
79539183|NCT03096782|Radiation|Total-Body Irradiation|Undergo total body irradiation
79539184|NCT03096782|Procedure|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
79696857|NCT04612803|Drug|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
79696858|NCT02204345|Drug|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
79696859|NCT02204345|Drug|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
79696860|NCT02204345|Drug|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
79696861|NCT04612647|Other|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
79841186|NCT05280171|Other|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
79841187|NCT05280171|Other|Standard of care|Standard of care
79848996|NCT05675059|Behavioral|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
80011042|NCT03676413|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
80011043|NCT03676413|Drug|Placebo|twice daily inhalation throughout the study
80011044|NCT02257034|Other|Taichi|
80011045|NCT02257034|Other|Dance|
79539185|NCT03093831|Drug|Ibrutinib|560mg administered orally once daily.
79384531|NCT03285048|Behavioral|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
79384532|NCT04802343|Drug|BAY1817080|Oral, tablet.
80011046|NCT03561324|Device|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
79539187|NCT03055013|Procedure|Nephrectomy|Undergo nephrectomy
79539188|NCT03055013|Biological|Nivolumab|Given IV
79539189|NCT03055013|Other|Patient Observation|Undergo observation
79539190|NCT03055013|Other|Quality-of-Life Assessment|Ancillary studies
80011047|NCT03676335|Drug|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
80011048|NCT03676335|Drug|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
80011049|NCT03676335|Drug|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
79384533|NCT04802343|Drug|Placebo|Oral, tablet.
79384534|NCT02459496|Behavioral|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
79539191|NCT03055013|Other|Questionnaire Administration|Ancillary studies
79539192|NCT03052049|Device|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
80011050|NCT04841486|Other|Data collection|evaluation of women's stress
79539193|NCT03036657|Device|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
80011051|NCT02260128|Other|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
79696862|NCT04612647|Behavioral|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
80011052|NCT02192840|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
80011053|NCT03676179|Procedure|patella denervation|patella denervation
80011054|NCT03676179|Procedure|patella non-denervation|patella non-denervation
80011055|NCT02058030|Device|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
79696863|NCT02187302|Drug|CRLX101|
79696864|NCT02187302|Drug|Bevacizumab|
79696865|NCT02187302|Drug|Standard of Care (Investigator Choice)|
79696866|NCT02179151|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
79696867|NCT02179151|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
79696868|NCT02163746|Procedure|CO2 (carbon dioxide) laser|
79696869|NCT02163746|Procedure|Surgical Deroofing|
79539194|NCT03036657|Device|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
79539195|NCT03033446|Radiation|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
79696870|NCT02160665|Drug|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
79696871|NCT02160665|Drug|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
79841188|NCT00952497|Drug|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
79841189|NCT04018716|Device|MTA|Indirect capping with MTA
79841190|NCT04018716|Device|Dycal|Indirect capping with Dycal
79841191|NCT00943995|Drug|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
79539196|NCT03033446|Drug|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
79245560|NCT03903107|Procedure|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
79245561|NCT03887377|Drug|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
79539197|NCT03019536|Drug|LY3303560 - IV|Administered IV
79696872|NCT02160665|Drug|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
79696873|NCT04611984|Procedure|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
79696874|NCT04611984|Procedure|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
79696875|NCT04633707|Device|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00~9:00) for 6 weeks.
79696876|NCT04633707|Device|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.
79696877|NCT04633707|Device|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: <100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.
79696878|NCT02138630|Dietary Supplement|Capsaicin|
79696879|NCT02138630|Dietary Supplement|Placebo|Sugar capsule
79696880|NCT04612023|Other|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
79696881|NCT02137343|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
79696882|NCT02137343|Drug|Placebo|Placebo
79841192|NCT00828282|Drug|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
79841193|NCT00952575|Drug|polyclonal anti-D immunoglobulin|single injection of 300 µg
79841194|NCT00952575|Drug|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
79841195|NCT04012125|Device|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
79841196|NCT03865732|Drug|Ganaxolone|active drug
79841197|NCT03865732|Drug|Placebo|inactive
79841198|NCT00944151|Procedure|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
79841199|NCT00998452|Behavioral|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
79841200|NCT00944307|Drug|raltegravir|raltegravir 400mg orally once
79245562|NCT03887377|Other|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
79539198|NCT03019536|Drug|Placebo - IV|Administered IV
79539199|NCT03019536|Drug|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
79539200|NCT03019536|Drug|Flortaucipir F18|Administered IV during the PET scan performed during the study.
79696883|NCT02137343|Drug|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
79696884|NCT02137343|Drug|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
79696885|NCT02125253|Drug|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
79841201|NCT00944307|Drug|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
79841202|NCT00520546|Other|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq [18F]Fluoroethylcholine chloride (FEC; Eckert & Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
79841203|NCT00520546|Other|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
79841204|NCT00952887|Biological|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
79841205|NCT00952887|Biological|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
79841206|NCT00555009|Drug|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
79245563|NCT03886272|Drug|BI 730357 (Test)|tablet
79539201|NCT02966665|Other|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
79384535|NCT02459574|Procedure|AVATAR-AF ablation|Experimental ablation protocol
79539202|NCT02966665|Drug|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
79841207|NCT00555009|Drug|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
79841208|NCT04000516|Behavioral|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
79841209|NCT00944385|Drug|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
79841210|NCT01529775|Device|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
79841211|NCT01529775|Device|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
79841212|NCT00953277|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
79841213|NCT00953355|Drug|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
79245564|NCT03886272|Drug|BI 730357 (Reference)|tablet
79245565|NCT03841422|Procedure|video-assisted nasal self-packing|video-assisted nasal self-packing
79245566|NCT03821376|Drug|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
79245567|NCT03767478|Device|Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 6 months at suprathreshold (2 x motor threshold).
79245568|NCT03767478|Device|Sham Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 6 months at suprathreshold (2 x motor threshold).
79539203|NCT02966665|Drug|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
79841214|NCT00953355|Drug|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
79245569|NCT03741478|Drug|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~Cognitive arm - 5mg on Day 0, 10mg on Day 1"
79841215|NCT00944463|Drug|Gemcitabine+simvastatin|Gemcitabine and simvastatin
79841216|NCT00944463|Drug|Gemcitabine+Placebo|Gemcitabine plus Placebo
79245570|NCT03741478|Drug|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
79384536|NCT02459574|Drug|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
79384537|NCT02459574|Procedure|Conventional AF ablation|Conventional ablation procedure
79384538|NCT03284814|Dietary Supplement|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
79384539|NCT03284814|Dietary Supplement|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
79384540|NCT03284814|Dietary Supplement|Single dose intervention with Investigational product (IP)|syrup, 100 mg
79841217|NCT00947583|Biological|Osteocel Plus|biologic
79841218|NCT00956397|Drug|Rifaximin|rifaximin 550 mg TID PO x 10 days
79539204|NCT02966665|Drug|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
79696886|NCT02125253|Drug|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
79696887|NCT02125253|Drug|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
79841219|NCT00956397|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
79841220|NCT00956397|Drug|Placebo|placebo TID x 10 days
79841221|NCT00953433|Device|Endoflex tube|Size decided upon gender.
79841222|NCT00953433|Device|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
79841223|NCT00953511|Genetic|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
79245571|NCT03741478|Drug|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
79841224|NCT05300373|Diagnostic Test|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
80011056|NCT02189096|Other|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
80011057|NCT02189096|Other|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
79245572|NCT03741478|Other|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
79245573|NCT03732833|Drug|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
80011058|NCT03683979|Behavioral|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
79245574|NCT03732833|Drug|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
79245575|NCT03718494|Diagnostic Test|Brain Magnetic Resonance Imaging (MRI)|Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
79384541|NCT03284814|Dietary Supplement|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
79539205|NCT02966665|Other|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
79696888|NCT02116244|Drug|Civamide Nasal Spray|
79245576|NCT03718494|Diagnostic Test|F-18 Florbetapir Positron Emission Tomography (PET) Imaging|After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
79696889|NCT04633083|Other|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
79696890|NCT02114060|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
79696891|NCT02114060|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
79696892|NCT02114060|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79696893|NCT02114060|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79384542|NCT03284814|Dietary Supplement|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
79384543|NCT03284814|Dietary Supplement|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
79384544|NCT00047853|Device|Shock device|Electric shock stimulus
79384545|NCT00047853|Device|Acoustic startle|Acoustic startle for MEG only
79384546|NCT02459340|Other|therapeutic treatment (inpatient and outpatient setting)|
79384547|NCT03284736|Procedure|Resorbable membrane|
80011059|NCT03683979|Behavioral|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
79245577|NCT03718494|Diagnostic Test|F-18 AV-1451 Positron Emission Tomography (PET) Imaging|Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
79539206|NCT02966665|Drug|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
79539207|NCT02966665|Drug|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
79245578|NCT03718494|Other|Neuropsychological Testing|A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
79245579|NCT03702127|Device|Transcranial magnetic stimulation|NIBS is applied to the brain.
79245580|NCT03669367|Drug|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
79539208|NCT02962167|Biological|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
79539209|NCT02962167|Biological|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
79539210|NCT02945241|Drug|Vancomycin|Intravenous
79539211|NCT02945241|Other|Cystatin C dosing algorithm|Expressed in milliliters per minute
79539212|NCT02945241|Other|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
79539213|NCT02938299|Drug|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
79539214|NCT02938299|Procedure|Surgery|Surgical resection of melanoma tumor lesions
79384548|NCT03284736|Procedure|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
79384549|NCT03280368|Other|Bloodtest|
79539215|NCT02934568|Drug|LEE011|Single agent LEE011 or in combination with other treatments
79539216|NCT02924818|Other|Clinical assessment|
80011060|NCT02189174|Drug|CLR457|
80011061|NCT01370694|Drug|MK-8808|
80011062|NCT01370694|Drug|cyclophosphamide|
79384550|NCT03280368|Other|Questionnaires|
80011063|NCT01370694|Drug|vincristine|
79245581|NCT03669367|Drug|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
79245582|NCT03630081|Drug|WCK 4282 (FEP-TAZ) 4 g|WCK 4282 (FEP-TAZ) 4 g [2 g FEP and 2 g TAZ] IV q8h, infused over 90 min
79245583|NCT03630081|Drug|Meropenem|1 g IV q8h, infused over 45 min
79245584|NCT03630081|Drug|ciprofloxacin 500 mg Optional Oral Switch|ciprofloxacin 500 mg PO q12h
79539217|NCT02924818|Behavioral|questionnaires|
79539218|NCT02924818|Other|pulmonary function test|
79539219|NCT02924818|Biological|blood test|
79539220|NCT02924818|Biological|microbiology|
79539221|NCT02924818|Biological|histology|
80011064|NCT01370694|Drug|prednisolone|
80011065|NCT03680547|Other|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
80011066|NCT02256878|Drug|BIRT 2584 XX|
80011067|NCT02256878|Drug|Amitriptyline|
80011068|NCT03676101|Biological|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
80011069|NCT03676101|Biological|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
80011070|NCT02058186|Drug|oral vitamin D|
80011071|NCT02058186|Drug|Placebo|
80011072|NCT02189330|Drug|Tafamidis|20 mg of current commercial formulation.
79245585|NCT03630081|Other|Infusion of normal saline|Infusion of normal saline over 45 min
79245586|NCT03618381|Biological|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
79245587|NCT03618381|Biological|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
79384551|NCT03280290|Biological|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
79384552|NCT04168398|Drug|Combination drug|Anticoagulation
79384553|NCT00011193|Behavioral|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
79539222|NCT02924818|Other|imaging|
79539223|NCT02877316|Other|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
79539224|NCT02877316|Other|safety plan on paper|Standard treatment with safety plan on paper
79539225|NCT02847468|Other|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
79539226|NCT02847468|Other|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
79539227|NCT02804087|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
79539228|NCT02804087|Other|Sham Implantation|Sham Implantation
80011073|NCT02189330|Drug|Tafamidis|12.2 mgA free acid tablet.
79696894|NCT02114060|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
79696895|NCT02114060|Biological|Placebo|0.9% Normal Saline (NaCl)
79696896|NCT04677998|Procedure|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
79696897|NCT00560898|Drug|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
79841225|NCT00956475|Behavioral|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
79841226|NCT00956475|Other|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
79841227|NCT00956475|Procedure|assessment of therapy complications|questionnaire via telephone
79539234|NCT02763033|Drug|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
79841228|NCT00956475|Procedure|fatigue assessment and management|questionnaire via telephone
79539235|NCT02763033|Other|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
79245588|NCT03522688|Drug|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
79539236|NCT02681211|Other|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
79539237|NCT02681211|Drug|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
79696898|NCT00560898|Drug|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
79841229|NCT00956475|Procedure|psychosocial assessment and care|questionnaire via telephone
79841230|NCT00956475|Procedure|quality-of-life assessment|questionnaire via telephone
79841231|NCT00956553|Biological|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
79841232|NCT00956553|Biological|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
79841233|NCT00953589|Drug|ribavirin|Ribavirin - oral administration Subjects with body weight < 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight > 105 kg: 1400 mg/day
79841234|NCT04011501|Procedure|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
79696899|NCT00560898|Drug|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
79696900|NCT00560898|Drug|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
80011074|NCT02189330|Drug|Tafamidis|20 mg new soft gelatin capsule.
79841235|NCT00947739|Drug|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
79841236|NCT00956787|Drug|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
79841237|NCT00947817|Other|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
79841238|NCT00947895|Drug|Methylprednisolone|IV 1000 mg daily for 3 days
79841239|NCT00947895|Drug|ACTH|IM ACTH 80 mg/day for 5 days.
79841240|NCT00947895|Other|IV placebo|IV placebo (saline) daily for 3 days.
79245589|NCT03522688|Drug|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
79539238|NCT02681211|Drug|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
79696901|NCT02104388|Drug|SJP-0035 Ophthalmic Solution|
79696902|NCT02104388|Drug|Vehicle of SJP-0035 Ophthalmic Solution|
79696903|NCT04611828|Device|Philips SmartSleep|closed-loop auditory stimulation
79696904|NCT04678037|Behavioral|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
79696905|NCT04633044|Dietary Supplement|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
79696906|NCT04633044|Dietary Supplement|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
79696907|NCT02104076|Device|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
79841241|NCT00947895|Other|IM placebo|IM placebo (saline) daily for 5 days.
79841242|NCT00623766|Drug|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
79841243|NCT00623766|Drug|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
79841244|NCT00623766|Drug|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
79841245|NCT00623766|Drug|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
79841246|NCT00623766|Drug|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
79841247|NCT00623766|Drug|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
79841248|NCT00623766|Drug|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
79841249|NCT00623766|Drug|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
79841250|NCT00623766|Drug|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
79841251|NCT00623766|Drug|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
79841252|NCT00953901|Drug|Fresh Frozen Plasma Transfusion|
79841253|NCT00832494|Drug|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
79841254|NCT00953979|Drug|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
79245590|NCT03493919|Biological|rMenB+OMV NZ vaccine|Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
79539239|NCT02681211|Drug|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
79841255|NCT00832728|Other|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
79841256|NCT00832728|Device|ELAD®|ELAD therapy
79841257|NCT00956865|Other|Voucher|Vouchers given to reimburse transportation
79841258|NCT00956865|Other|Telephone Call|Telephone reminder calls
79841259|NCT00956865|Other|Contact|Contact at senior center to encourage follow up
79245591|NCT03493919|Biological|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|One dose of MenACWY vaccine were administered intramuscularly at Day 1.
79384554|NCT03280212|Drug|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
79841260|NCT00837564|Other|CBASP psychotherapy|specific psychotherapy for chronic depression
79841261|NCT00837564|Drug|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
80011075|NCT02189330|Drug|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
79841262|NCT00954135|Drug|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
79245592|NCT03431779|Procedure|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
79245593|NCT03431779|Procedure|Surgical excision|Excision of painful areas
79245594|NCT03356990|Dietary Supplement|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
79384555|NCT03536520|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79384556|NCT03536520|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79384557|NCT04784169|Device|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
79384558|NCT04784169|Device|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
79384559|NCT03280134|Procedure|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
79539240|NCT02681211|Drug|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
79539241|NCT02673775|Other|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
79841263|NCT00954135|Drug|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
79841264|NCT00832806|Behavioral|Extended IVR (integrated voice response technology)|See detailed description
79841265|NCT00832806|Drug|Varenicline (Champix)|See detailed description
79841266|NCT00832806|Behavioral|IVR treatment|See detailed description
80011076|NCT02189330|Drug|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
80011077|NCT03676023|Drug|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
79696908|NCT04632849|Behavioral|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
79539242|NCT02673775|Other|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
79696909|NCT04611438|Drug|Cannabidiol|"Intervention schedule for each patient is as follows:~Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~Maintenance: no change in medication dosage"
79696910|NCT02096666|Drug|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
79696911|NCT04632693|Procedure|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
79696912|NCT04632693|Procedure|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
79696913|NCT02093429|Drug|INCB047986|INCB047986 will be supplied as tablets.
79696914|NCT00563745|Device|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
79696915|NCT04677764|Other|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
79696916|NCT04677764|Other|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
79696917|NCT00563823|Drug|vatalanib|
79696918|NCT04677686|Behavioral|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
79384560|NCT03521466|Behavioral|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
79384561|NCT04784325|Diagnostic Test|Blood draw through TAP II|Two self-administered blood draws through TAP II device
79539243|NCT02666768|Drug|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
79384562|NCT04784325|Diagnostic Test|Blood draw through ADx cardT|One self-administered ADx card blood draw
79539244|NCT02632708|Drug|AG-120|
79539245|NCT02632708|Drug|AG-221|
79384563|NCT04784325|Diagnostic Test|Blood draw through standard venipuncture|One phlebotomist-performed standard venipuncture
79384564|NCT05228184|Drug|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
79539246|NCT02632708|Drug|cytarabine|
79539247|NCT02632708|Drug|daunorubicin|
79384565|NCT05228184|Drug|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
79539248|NCT02632708|Drug|idarubicin|
79539249|NCT02632708|Drug|mitoxantrone|
79539250|NCT02632708|Drug|etoposide|
79539251|NCT02617277|Drug|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
79539252|NCT02617277|Drug|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
79539253|NCT02611570|Other|LDCT|LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
79539254|NCT02548546|Device|ECHO|Imaging
79539255|NCT02548546|Device|ECG-gated MRA|Imaging
79539256|NCT02489617|Other|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
79539257|NCT02471144|Biological|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
79696919|NCT00563862|Procedure|Conventional RT|
79696920|NCT00563862|Procedure|Accelerated RT|
79696921|NCT00563862|Drug|Cisplatin|
79696922|NCT00563862|Drug|5-fluorouracil|
79696923|NCT04677842|Drug|ART Therapy|
79696924|NCT04632342|Drug|HL301 tablet 300mg|"Experimental group 1 : 2 tablets at once, twice a day~Experimental group 2 : 2 tablets at once, three times a day"
79696925|NCT04632342|Drug|Placebo of HL301 tablet|2 tablets at once, three times a day
79696926|NCT04611711|Drug|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
79696927|NCT04611711|Drug|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
79539258|NCT02471144|Biological|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
79539259|NCT02471144|Biological|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(<25 kg, 25- <50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
79539260|NCT02471144|Biological|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
79539261|NCT02448420|Drug|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
79245595|NCT03326128|Drug|Bupropion Hydrochloride|Antidepressant that is also effective in smoking cessation
79384566|NCT04784403|Diagnostic Test|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
79539262|NCT02448420|Drug|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
80011078|NCT02059824|Device|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
79245596|NCT03280628|Procedure|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
79539263|NCT02448420|Drug|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
79696928|NCT00554879|Procedure|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
79696929|NCT00554879|Procedure|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
79696930|NCT04632537|Drug|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
79696931|NCT04632537|Drug|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
79245597|NCT03280628|Procedure|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
79245598|NCT03280628|Procedure|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
79245599|NCT03277924|Drug|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245600|NCT03277924|Drug|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79384567|NCT03284580|Other|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
79384568|NCT03284580|Other|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
79245601|NCT03277924|Drug|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245602|NCT03277924|Drug|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245603|NCT03277924|Drug|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245604|NCT03277924|Drug|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245605|NCT03277924|Drug|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245606|NCT03277924|Drug|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
79245607|NCT03176134|Drug|Tedizolid phosphate|Tedizolid phosphate IV solution or oral suspension
79245608|NCT03176134|Drug|Comparator|Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
79384569|NCT03284580|Other|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
79696932|NCT02092922|Drug|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
79696933|NCT02092922|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
79384570|NCT04783623|Procedure|Surgical endometrioma excision|We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
79696934|NCT04611594|Behavioral|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
79696935|NCT02092454|Drug|Benzocaine|topical otic solution
80011079|NCT03633279|Drug|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
79696936|NCT02092454|Drug|Placebo|topical otic solution
79696937|NCT02083289|Drug|ONO-9054|
79245609|NCT03152786|Other|Laboratory Biomarker Analysis|Correlative studies
79245610|NCT03152786|Drug|Propranolol Hydrochloride|Given PO
79245611|NCT03152786|Other|Questionnaire Administration|Ancillary studies
79384571|NCT03279588|Diagnostic Test|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
79384572|NCT01679457|Behavioral|ACT-Focused ERP|
79245612|NCT03152786|Other|Survey Administration|Ancillary studies
79245613|NCT03089619|Drug|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
79384573|NCT01679457|Behavioral|TAU-ERP|
79384574|NCT03284346|Behavioral|Exercise Intervention|Undergo CARE
79696938|NCT02083289|Drug|Latanoprost|
79696939|NCT02081300|Drug|Oral testosterone undecanoate, LPCN 1021|
79841267|NCT00954213|Behavioral|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
79841268|NCT00832884|Drug|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
79841269|NCT00832962|Genetic|Genotyping|Whole blood sample
79841270|NCT00832962|Other|Usual prophylaxis|Prophylactic anti-RhD
80011080|NCT03633279|Drug|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
80011081|NCT02189408|Biological|Platelet rich plasma|
80011082|NCT02257190|Behavioral|Control|One hour of rest.
80011083|NCT02257190|Behavioral|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
80011084|NCT02257190|Behavioral|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
79245614|NCT03089619|Device|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
79245615|NCT03083366|Device|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
79245616|NCT03075176|Device|Wavefront optimized LASIK|Wavefront optimized laser vision correction
79245617|NCT03075176|Device|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
79384575|NCT03284346|Behavioral|Exercise Intervention|Undergo standard stretching program
79384576|NCT03284346|Other|Laboratory Biomarker Analysis|Correlative studies
79384577|NCT03284346|Device|Monitoring Device|Receive Polar heart rate monitor
79696940|NCT02081300|Drug|Topical testosterone gel 1.62 %|
79696941|NCT04611360|Other|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
79696942|NCT04611360|Other|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
79696943|NCT04677881|Other|Intervention group|intervention group: bread with sourdough control group: bread with yeast
79696944|NCT02074007|Drug|AR01|drops administered as needed for pain
79841271|NCT00947973|Behavioral|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
79841272|NCT00947973|Behavioral|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
79384578|NCT03284346|Other|Quality-of-Life Assessment|Ancillary studies
79384579|NCT03284346|Other|Questionnaire Administration|Ancillary studies
79539264|NCT02448420|Drug|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
79696945|NCT02074007|Drug|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
79696946|NCT00563979|Dietary Supplement|VitaluxPlus®|1 tablet daily
79696947|NCT00563979|Dietary Supplement|Omega 3|1 tablet daily
79696948|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
79696949|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
80011085|NCT02058342|Behavioral|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
80011086|NCT03680391|Procedure|Cesarean section|"Both groups cesarean section will be held with the same technique:~spinal anethesia~pfennenstiel imcision~lower segment cesarean section~suturing uterus in two layers while exterionezed~gentle manibulation~no towels in gutters will be used"
79696950|NCT04611204|Other|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
79696951|NCT00554918|Drug|docetaxel|
79696952|NCT00554918|Drug|prednisolone|
79245618|NCT03075176|Device|Topography-guided LASIK|Topography-guided laser vision correction
79245619|NCT03075176|Device|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
79539265|NCT02448420|Drug|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
79696953|NCT00554918|Drug|zoledronic acid|
79539266|NCT02438306|Biological|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
79696954|NCT00554918|Procedure|quality-of-life assessment|
79245620|NCT03058146|Behavioral|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
79245621|NCT03058146|Behavioral|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
79384580|NCT01673217|Drug|decitabine|Given IV
79245622|NCT02996773|Drug|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
79245623|NCT02996773|Drug|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
79384581|NCT01673217|Biological|NY-ESO-1 peptide vaccine|Given SC
79384582|NCT01673217|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
79384583|NCT01673217|Biological|sargramostim|Given SC
79384584|NCT01673217|Biological|incomplete Freund's adjuvant|Given SC
79384585|NCT01673217|Other|immunohistochemistry staining method|Correlative studies
79384586|NCT01673217|Other|liquid chromatography|Correlative studies
79384587|NCT01673217|Other|mass spectrometry|Correlative studies
79539267|NCT02438306|Other|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
79539268|NCT02420002|Drug|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
79696955|NCT00554918|Radiation|strontium chloride Sr 89|
79696956|NCT04632147|Other|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
79696957|NCT04632108|Drug|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
79696958|NCT02061332|Biological|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
79696959|NCT04631874|Drug|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
79696960|NCT02057315|Drug|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
79696961|NCT02057315|Drug|Placebo|One dose of matching placebo over 3 bilateral applications.
79709925|NCT04327362|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
79696962|NCT04610931|Behavioral|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
79696963|NCT04610931|Behavioral|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
79696964|NCT02053103|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
79841273|NCT02549118|Drug|Tenoxicam|
79841274|NCT02549118|Drug|Pethidine|
79841275|NCT00957177|Drug|Pregabalin|300mg pregabalin orally 1 hour before operation
79539269|NCT02420002|Other|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
79245624|NCT02923011|Device|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
79384588|NCT01673217|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
79245625|NCT02923011|Device|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
79384589|NCT01673217|Other|laboratory biomarker analysis|Correlative studies
79384590|NCT01673217|Genetic|DNA methylation analysis|Correlative studies
79384591|NCT01673217|Other|enzyme-linked immunosorbent assay|Correlative studies
79384592|NCT01672749|Device|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
79384593|NCT01672749|Device|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
79384594|NCT01668849|Dietary Supplement|Grape extract|Grape extract self-administered by mouth daily for 35 days
79384595|NCT01668849|Drug|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
79384596|NCT01668225|Procedure|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
79245626|NCT02918149|Other|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
79245627|NCT02918149|Device|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
79245628|NCT02909179|Other|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
79245629|NCT02851511|Behavioral|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
79384597|NCT03284190|Procedure|Surgery|Surgery
79539270|NCT02420002|Procedure|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
79539271|NCT02408471|Device|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
79539272|NCT02403674|Drug|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
79539273|NCT02403674|Drug|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
79539274|NCT02403674|Drug|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
79696965|NCT02053103|Drug|Placebo|Tablet, 0 mg, twice daily, 6 weeks
79696966|NCT02049164|Drug|AR08|
79696967|NCT02049164|Drug|Placebo|
79696968|NCT02047214|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
79696969|NCT02047214|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
79841276|NCT00957177|Drug|Placebo|Placebo
79841277|NCT00837642|Diagnostic Test|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
79841278|NCT00948051|Dietary Supplement|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
79245630|NCT02851511|Device|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
79841279|NCT00948051|Dietary Supplement|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
79841280|NCT04044066|Biological|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
79245631|NCT02851511|Device|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
79841281|NCT00954369|Drug|[F-18]W372|"The individual doses of [F-18]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
79384598|NCT03279198|Behavioral|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
79841282|NCT00828438|Drug|Lorcaserin 10mg|
79384599|NCT03279198|Behavioral|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
79539275|NCT02375802|Biological|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
79696970|NCT04632186|Device|EXOPULSE Mollii suit|"All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment)."
79696971|NCT04631991|Diagnostic Test|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
79696972|NCT04631757|Drug|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
79841283|NCT00957255|Device|OrthoADAPT|soft tissue augmentation device
79841284|NCT00957255|Procedure|Standard of care|Standard of care rotator cuff repair
79841285|NCT00828594|Drug|RAD001|
79841286|NCT00828594|Drug|RAD001, sorafenib|
80011087|NCT03680313|Procedure|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
79539276|NCT02375802|Drug|Adipose-derived stromal cells|
79696973|NCT02032277|Drug|Cyclophosphamide|Cyclophosphamide
79696974|NCT02032277|Drug|Placebo|Placebo for Carboplatin
79696975|NCT02032277|Drug|Doxorubicin|Doxorubicin
80011088|NCT02260206|Drug|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
79696976|NCT02032277|Drug|Paclitaxel|Paclitaxel
79696977|NCT02032277|Drug|Carboplatin|Carboplatin
79696978|NCT02032277|Drug|Veliparib|Veliparib
79696979|NCT02032277|Drug|Placebo|Placebo for Veliparib
79696980|NCT04611009|Behavioral|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
79696981|NCT04611009|Behavioral|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
79841287|NCT00833118|Procedure|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
79841288|NCT00550407|Drug|lamotrigine|lamotrigine 100mg/day or 200mg/day
79841289|NCT00550407|Drug|Placebo|placebo once daily
79841290|NCT00837798|Device|CRM Device|Pacemaker, ICD, or CRT device
79841291|NCT02548884|Procedure|Biliary cannulation|
79384600|NCT03279198|Behavioral|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
79539277|NCT02354781|Biological|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
79539278|NCT02352948|Drug|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
79539279|NCT02352948|Drug|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
79841292|NCT02547558|Procedure|Arterial blood gases|Measured through radial arterial catheter
79841293|NCT02547558|Procedure|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
79841294|NCT02547558|Procedure|Vital signs|As measured in clinical practice
79841295|NCT02547558|Procedure|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
79841296|NCT02547558|Procedure|Spirometry|In a daily calibrated spirometer.
79539280|NCT02352948|Drug|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
79245632|NCT02851511|Behavioral|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
79841297|NCT02547558|Drug|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
79841298|NCT00948207|Behavioral|My Living Story|"Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
80011089|NCT02192918|Behavioral|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
79245633|NCT02827370|Behavioral|Behavioral Dietary Intervention|Receive dietary counseling
79245634|NCT02781129|Other|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
79245635|NCT02727062|Device|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
79539281|NCT02352948|Drug|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
79245636|NCT02727062|Device|Accelerometer|Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
79245637|NCT02630147|Other|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
79245638|NCT02562157|Radiation|HYALURONIQUE ACIDE|Intradermal delivery of fractional CO2 laser-assisted hyaluronic acid in facial skin contouring
79539282|NCT02352948|Drug|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
79696982|NCT00560976|Drug|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
79696983|NCT02026349|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
79696984|NCT02026349|Drug|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
79245639|NCT02538484|Drug|Letrozole|Aromatase inhibitor
79245640|NCT02538484|Dietary Supplement|Fish Oil|Omega-3 free fatty acid
79841299|NCT00948207|Behavioral|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
79245641|NCT02484391|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
79245642|NCT02484391|Drug|Cytarabine|Given IV
79841300|NCT00957411|Biological|cetuximab|Given IV
79841301|NCT00957411|Drug|cisplatin|Given IV
79245643|NCT02484391|Procedure|Hematopoietic Cell Transplantation|Undergo stem cell transplant
79245644|NCT02484391|Drug|Mitoxantrone Hydrochloride|Given IV
79245645|NCT02478320|Drug|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
79245646|NCT02311998|Drug|Bosutinib|Given PO
79245647|NCT02311998|Biological|Inotuzumab Ozogamicin|Given IV
79245648|NCT02252042|Biological|Pembrolizumab|200 mg intravenous (IV) on Day 1 of each 3-week cycle.
79245649|NCT02252042|Drug|Methotrexate|40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
79245650|NCT02252042|Drug|Docetaxel|75 mg/m^2 IV on Day 1 of each 3- week cycle
79245651|NCT02252042|Biological|Cetuximab|400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
79539283|NCT02352948|Drug|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
79539284|NCT02337452|Other|Questionnaire Administration|Ancillary studies
79539285|NCT02337452|Behavioral|Web Site|Communicate via family outreach program website
79539286|NCT02331914|Procedure|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
79539287|NCT02331914|Procedure|Tumor biopsy|Tumor biopsy after disease progression
79696985|NCT04611048|Diagnostic Test|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
79841302|NCT00837954|Device|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
80011090|NCT02192918|Behavioral|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
80011091|NCT02192918|Behavioral|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
80011092|NCT03535610|Device|Uterine Embolization|Uterine Embolization with PVA Microspheres
80011093|NCT03535532|Procedure|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
80011094|NCT03535532|Drug|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
80011095|NCT02058576|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
79841303|NCT00837954|Device|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
80011096|NCT02058576|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
79384601|NCT03279198|Behavioral|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
79384602|NCT03278964|Procedure|Orbital decompression|
79539288|NCT02315326|Drug|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
80011097|NCT03675867|Other|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
80011098|NCT02192996|Dietary Supplement|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
80011099|NCT02058654|Drug|Creatine|Creatine powder (5 g)
80011100|NCT02058654|Drug|Placebo|Bulking agent powder (5 g)
80011101|NCT03680235|Other|Informational Intervention|Receive standard information about breastfeeding and pregnancy
80011102|NCT03680235|Other|Informational Intervention|Receive information about breastfeeding and cancer
80011103|NCT03680235|Other|Interview|Participate in focus groups
79245654|NCT02099058|Drug|Osimertinib|It is administered orally everyday.
79384603|NCT03107910|Behavioral|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
79245655|NCT02099058|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
79245656|NCT02099058|Drug|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
79245657|NCT02099058|Drug|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
79245658|NCT02099058|Drug|Erlotinib|It is administered orally everyday.
79245659|NCT01900847|Drug|Ketamine|0.3mg/kg ketamine
79245660|NCT01900847|Drug|Morphine|Dosage of morphine determined by treating physician
79245661|NCT01900847|Drug|placebo|saline of same volume as appropriate weight based dose of ketamine
79245662|NCT01710007|Drug|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
79245663|NCT01710007|Drug|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
79245664|NCT01633502|Device|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
79245665|NCT01633502|Device|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
79245666|NCT01608516|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
79245667|NCT01357772|Drug|Tamoxifen|
79841304|NCT00837954|Procedure|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
80011104|NCT03680235|Other|Survey Administration|Ancillary studies
80011105|NCT03535220|Combination Product|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
79245668|NCT01357772|Drug|placebo|
79384604|NCT03107910|Behavioral|Health Information Seeking|Seeking and evaluating online health information will be assessed.
79384605|NCT03277716|Procedure|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
79384606|NCT03277716|Procedure|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
79841305|NCT00948285|Procedure|MRI|magnetic resonance imaging (MRI)
79384607|NCT03277716|Device|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
79384608|NCT03277716|Drug|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
79384609|NCT01252719|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
79539289|NCT02315326|Drug|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
79539290|NCT02315326|Drug|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
79539291|NCT02315326|Drug|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
79539292|NCT02303431|Drug|Edoxaban low dose|Edoxaban low dose
79841306|NCT00954525|Drug|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
79841307|NCT00954525|Dietary Supplement|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
80011106|NCT02660424|Drug|VX-150|
80011107|NCT02660424|Drug|Placebo|
80011108|NCT02189564|Behavioral|Feedback about good performance|
79841308|NCT00833274|Behavioral|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
80011109|NCT02189564|Behavioral|Feedback about good performance + money|
80011110|NCT02189564|Behavioral|Feedback about average performance|
80011111|NCT03680079|Other|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
80011112|NCT02060448|Behavioral|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
80011113|NCT02060448|Behavioral|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
80011114|NCT03675633|Diagnostic Test|FEUrea|FEUrea in decompansated liver cirrhosis
80011115|NCT03517254|Dietary Supplement|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
80011116|NCT03517254|Other|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
80011117|NCT03517254|Other|Placebo|Maltodextrin powder to mimic glutamine,
79245669|NCT00823277|Other|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after ~ 1 Year.
79245670|NCT00811148|Procedure|Tissue Bank|Collection of clinical data and tumor tissue.
79245671|NCT00378482|Drug|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
79245672|NCT05815459|Device|OCOsense|Volunteers wear OCOsense glasses continuously during testing to monitor biobehavioural responses to tasks
79245673|NCT05813860|Drug|Azathioprine|azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
79696986|NCT04611048|Diagnostic Test|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom & Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
79841309|NCT00833352|Device|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
79841310|NCT00838032|Drug|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
79841311|NCT00838032|Drug|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
80011118|NCT03517254|Other|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
79384610|NCT01252719|Drug|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
79384611|NCT01252719|Drug|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
79384612|NCT03283956|Device|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
79539293|NCT02303431|Drug|Edoxaban high dose|Edoxaban high dose
79539294|NCT02248597|Drug|fludarabine phosphate|Given IV
79539295|NCT02248597|Drug|busulfan|Given IV
79539296|NCT02248597|Drug|cyclophosphamide|Given IV
79539297|NCT02248597|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
79539298|NCT02248597|Drug|tacrolimus|
79696987|NCT04611048|Diagnostic Test|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, & Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
79696988|NCT04611126|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
79696989|NCT04611126|Drug|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
79245674|NCT05813860|Drug|Infliximab|5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
79245675|NCT05803473|Device|Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)|"For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2."
79245676|NCT05803473|Device|FreeStyle Precision Pro Glucometer for glucose POC testing|For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
79539299|NCT02248597|Drug|mycophenolate mofetil|
79539300|NCT02227823|Drug|Pyridostigmine Bromide|
79696990|NCT04611126|Drug|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
79539301|NCT02129543|Procedure|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
79539302|NCT02125461|Drug|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
79539303|NCT02125461|Other|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
79539304|NCT02102529|Procedure|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
79539305|NCT02096042|Drug|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
79841312|NCT00954603|Drug|quetiapine|25-100 mg
79841313|NCT00954603|Drug|haloperidol|0.5-2 mg
79841314|NCT00531934|Drug|Doxycline|100mg po daily
79841315|NCT00531934|Drug|erlotinib [Tarceva]|150mg po daily
79841316|NCT02548806|Drug|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
79841317|NCT02548806|Drug|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
79841318|NCT02548806|Drug|Catapres 100μg|Catapres tablet 100μg, single dose
79696991|NCT04611126|Biological|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
79696992|NCT04611126|Drug|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
79696993|NCT04611126|Drug|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
79696994|NCT04611165|Drug|Nivolumab|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~EBRT begins 2-7 days after the first dose of nivolumab.~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
79696995|NCT02014649|Drug|20 mg laninamivir octanoate|
79384613|NCT01233531|Behavioral|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
79841319|NCT00828828|Biological|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
79841320|NCT00833508|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
79245677|NCT05799066|Diagnostic Test|Swinging Light test|The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
79696996|NCT02014649|Drug|Placebo|
79696997|NCT02014649|Drug|40 mg laninamivir octanoate|
79245678|NCT05799066|Diagnostic Test|Virtual Reality Head-Mounted Display (VR HMD)|A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
79245679|NCT05795569|Procedure|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
79245680|NCT05795569|Diagnostic Test|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
79245681|NCT05795569|Procedure|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
79384614|NCT01233531|Behavioral|B--No cash transfers|No monthly cash transfers
79696998|NCT02014142|Drug|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
79696999|NCT04631328|Other|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
79697000|NCT04631250|Drug|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
80011119|NCT02189876|Behavioral|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
79245682|NCT05795569|Diagnostic Test|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
79384615|NCT03272490|Procedure|Medartis|Surgery using the medartis implant
79384616|NCT03272490|Procedure|Synthes|Surgery using the Synthes implant
79384617|NCT02342314|Drug|LY3143753 (Part A)|Administered via SC injection
79384618|NCT02342314|Drug|LY3185643 (Part B)|Administered via SC injection
79384619|NCT02342314|Drug|Placebo (Part A and Part B)|Administered via SC injection
79384620|NCT02342314|Drug|rGlucagon (Part B)|Administered via SC injection
79384621|NCT01230411|Other|saline placebo|250 cc of placebo administered IV
79384622|NCT01230411|Drug|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
79697001|NCT02009423|Drug|Masitinib|
79697002|NCT02009423|Drug|Placebo|
79697003|NCT04610619|Other|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
79697004|NCT02006030|Drug|ADI-PEG 20|
79697005|NCT02006030|Drug|Transarterial chemoembolization|
79384623|NCT03283800|Other|Copper impregnated compression stocking|Copper impregnated compression stocking
79384624|NCT03283800|Other|Normal compression stocking|Normal compression stocking without copper
79539306|NCT02096042|Drug|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
79539307|NCT02087033|Dietary Supplement|ritmonutra|2 tablets a day by mouth for 4 weeks
79539308|NCT02087033|Dietary Supplement|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
79539309|NCT02036931|Device|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
79539310|NCT02036931|Drug|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
79841321|NCT00549939|Drug|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
79841322|NCT00549939|Drug|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
79841324|NCT00838188|Other|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
79245683|NCT05795023|Other|NeuraLight|NeuraLight software-based platform
79245684|NCT05794360|Behavioral|ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)|A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
79245685|NCT05791604|Dietary Supplement|probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG|Take probiotics, 2g each time, twice a day, for 12 weeks
79245686|NCT05791604|Dietary Supplement|Prebiotics with galactomannan and oligofructose|Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
79384625|NCT02459184|Other|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
79384626|NCT01962688|Device|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
79384627|NCT01962688|Device|Sham ultrasound|sham ultrasound to facilitate blinding
79539311|NCT02036931|Device|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
79539312|NCT02027233|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
79384628|NCT04389723|Dietary Supplement|Qualia Mind|Multi-ingredient Dietary supplement
79384629|NCT04389723|Dietary Supplement|Placebo|Multi-ingredient Placebo
79697006|NCT04631094|Other|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
79697007|NCT04631094|Other|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
79697008|NCT04631094|Other|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
79697009|NCT04631094|Other|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
79697010|NCT03455036|Other|Whole body vibration training|10 x 1 min whole body vibration exposure
79697011|NCT01998035|Drug|Romidepsin|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10, 14 mg/m2)"
79697012|NCT01998035|Drug|Oral 5-Azacitidine|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100, 200, 300 mg)"
79697013|NCT04630899|Other|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
79841325|NCT00833742|Behavioral|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
79841326|NCT00833820|Procedure|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
79384630|NCT00149487|Behavioral|Tailored Problem Solving Intervention|
79245687|NCT05788276|Drug|Dapagliflozin 10mg Tab|Dapagliflozin active tablets
79245688|NCT05788276|Drug|Placebo|Matched placebo tablets
79245689|NCT05786560|Behavioral|BABE (Body Appreciation and Better Eating)|The participants will be randomized into either a treatment or control group. For the treatment arm, girls will participate in the Body Project for 30 minutes, then will be given a 30-minute self-compassion-based nutrition education lesson. Nutrition topics will cover the basic biochemistry of nutrition, nutrition needs for teenage girls, and ways to find balance in eating, framed in the constructs of self-compassion. The control group will receive the same 30-minute Body Project class and the same 30-minute nutrition education class; however, there will be no incorporation of self-compassion.
79539313|NCT02019628|Dietary Supplement|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
79245690|NCT05785455|Other|COGMO Intervention|Group sessions in which each patient, after motivational interviewing sessions will follow a goup education in pain neuroscince program followed by a cognition targeted exercise therapy
79697014|NCT04630899|Other|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
79245691|NCT05785455|Other|Usual Care|Usual Primary Care health education and treatment for patients with chronic neck pain
79697015|NCT01991210|Drug|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
79697016|NCT01991210|Drug|PLD|PLD will be administered at a dose of 40 mg/m^2 IV every 4 weeks.
79697017|NCT04611243|Biological|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
79697018|NCT04611243|Biological|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
79697019|NCT04611243|Biological|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
79697020|NCT04611243|Biological|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
79384631|NCT00149487|Behavioral|Family Education Intervention|
79245692|NCT05776706|Diagnostic Test|AR-based navigation|"The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~Fiducial markers~Nasion~Tumor's margin (anterior, posterior, superior, inferior)"
79697021|NCT01979939|Drug|DCV/ASV/BMS-791325|
79697022|NCT04610970|Drug|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
79245693|NCT05770934|Other|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
79245694|NCT05766956|Other|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
79384632|NCT03276000|Procedure|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
79384633|NCT04058769|Device|Premedication Guide|Software with guidelines recommendations for preoperative assessment
79384634|NCT02459886|Drug|BIIB054|IV infusion
79539314|NCT01940471|Drug|TAF|25 mg tablet administered orally once daily
79539315|NCT01940471|Drug|TDF|300 mg tablet administered orally once daily
79539316|NCT01940471|Drug|TAF Placebo|Tablet administered orally once daily
79539317|NCT01940471|Drug|TDF Placebo|Tablet administered orally once daily
79539318|NCT01902693|Other|No intervention for this study|No intervention
79697023|NCT04631172|Other|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
79697024|NCT04677530|Drug|JNJ-40411813|JNJ-40411813 will be administered orally.
79245695|NCT05766956|Other|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
79384635|NCT02459886|Drug|Placebo|IV infusion
79384636|NCT02309944|Procedure|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if >2 cm deep, followed by staple or suture closure of the skin.
79697025|NCT04677530|Drug|Matching Placebo|Matching placebo will be administered orally.
79697026|NCT00564057|Drug|candesartan|tablet 8-16 mg once daily, one year
79697027|NCT00564057|Drug|lercanidipine|tablets 10-20 mg once daily, one year
79697028|NCT04630743|Behavioral|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
79539319|NCT01860456|Drug|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
79841327|NCT00833820|Procedure|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
79539320|NCT01848639|Drug|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
79245696|NCT05738694|Drug|Axitinib plus Toripalimab|Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
79245697|NCT05738694|Procedure|nephrectomy|nephrectomy
79245698|NCT05731986|Diagnostic Test|Orthostatic challenge|"Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation."
79245699|NCT05731986|Device|Biostim-5 transcutaneous spinal stimulation - Mapping|Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
79245700|NCT05731986|Device|"Biostim-5 transcutaneous spinal stimulation - Optimal testing"|Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).
79539321|NCT01848639|Drug|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
79539322|NCT01765400|Drug|Prasugrel 10 mg daily x 2 weeks|
79539323|NCT01765400|Drug|Clopidogrel 75 mg daily x 2 weeks|
79539324|NCT01751906|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
79697029|NCT04630782|Diagnostic Test|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
79697030|NCT04630704|Device|Pedra|Diffuse speckle contrast analysis perfusion system
79697031|NCT00564096|Device|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
79245701|NCT05731986|Device|"Biostim-5 transcutaneous spinal stimulation - Sham testing"|Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
79384637|NCT02309944|Device|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
79384638|NCT03271398|Behavioral|EMDR|Eye movement desensitization and reprocessing (intensive format)
79384639|NCT03271398|Behavioral|PC|Progressive counting (intensive format)
79384640|NCT02311972|Device|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
79697032|NCT00564096|Device|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
79841328|NCT00272779|Drug|ATV|300mg Oral capsules for 96 weeks
79841329|NCT00272779|Drug|RTV|100mg Oral Capsules for 96 weeks
79841330|NCT00272779|Drug|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
79384641|NCT02311972|Device|Standard of care feeding tube|
79384642|NCT03271008|Device|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
79841331|NCT00272779|Drug|LPV|400 mg (3 133mg capsules) BID for 96 weeks
79841332|NCT04011423|Other|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
79841333|NCT04011423|Other|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
79384643|NCT03271008|Device|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
79384644|NCT03271008|Device|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
79384645|NCT03274596|Drug|Vitamin E|
79384646|NCT03274596|Drug|Placebo|
79384647|NCT01963078|Drug|Oxytocin|
79697033|NCT04677452|Biological|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
79841334|NCT00828906|Drug|DuoTrav|DuoTrav Eye Drops
79245702|NCT05727111|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) implemented at the patient home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
79245703|NCT05727111|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living."
79384648|NCT01963078|Drug|Placebo|
79384649|NCT03269760|Drug|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
79384650|NCT03269916|Other|Anti Mueller hormone|used to assess ovarian reserve parameters
79384651|NCT03269916|Other|Estrogen|used to assess ovarian reserve parameters
79384652|NCT03269916|Other|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
79384653|NCT03269916|Other|Antral alveolar cell count|used to assess ovarian reserve parameters
79384654|NCT01963234|Behavioral|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
79384655|NCT02457858|Drug|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
79384656|NCT02457624|Behavioral|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
79384657|NCT02346916|Drug|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
79384658|NCT01964092|Behavioral|Individual Placement and Support|
79384659|NCT01964092|Behavioral|Ordinary employment schemes|
79539325|NCT01751906|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
79384660|NCT03274362|Behavioral|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
79384661|NCT04349176|Drug|Dose|Randomized to either 100U or 155U
79384662|NCT03274128|Radiation|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
79384663|NCT03274128|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
79384664|NCT04329546|Other|NA (no intervention)|NA (no intervention)
79539326|NCT01730937|Drug|Sorafenib|By mouth (PO)
79539327|NCT01730937|Radiation|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
79697034|NCT04677296|Other|VS002A|Amino acid based ORS/Medical food
79697035|NCT04677296|Other|WHO-ORS|WHO Oral rehydration solution, which is glucose based
79697036|NCT04610541|Drug|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
79841335|NCT00948363|Other|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
79841336|NCT00948363|Other|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
79848997|NCT05670223|Other|Fit&Strong Exercise Program|The Fit and Strong! Program (F&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F&S! exercise program assists older adults to improve strength and functioning.
79848998|NCT05661266|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
79841337|NCT00829062|Device|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
79841338|NCT03850704|Drug|Selinexor|
79841339|NCT00957879|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
79245704|NCT05727111|Behavioral|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) at the patient's home|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 1 hour per day (4 hours per week in autonomy and 1 hour per week under supervision).
79384665|NCT01966354|Procedure|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
79384666|NCT02459028|Behavioral|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
79539328|NCT01569581|Biological|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
79841340|NCT00957879|Dietary Supplement|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
79841341|NCT00838266|Drug|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
79539329|NCT01569581|Biological|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
79539330|NCT01569581|Biological|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
79841342|NCT00838266|Other|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
79841343|NCT00834054|Procedure|Double-lung transplantation|Double-lung transplanted patients
79841344|NCT00838344|Other|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
79841345|NCT04011033|Biological|iNKT cells|5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
79841346|NCT04011033|Drug|Cyclophosphamide|CTX will be administered intravenously at a dose of 750mg/m2 2 days before the first iNKT cells infusion.
79841347|NCT04011033|Drug|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
79539331|NCT01569581|Biological|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
79697037|NCT04677335|Dietary Supplement|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
79841348|NCT04011033|Procedure|TACE|TACE will be conducted to all patients at 0th week and 4th week.
79245705|NCT05727111|Behavioral|Usual care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
79384667|NCT02459028|Behavioral|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
79539332|NCT01560416|Drug|Fulvestrant|
79841349|NCT00829140|Drug|Placebo|
79841350|NCT00829140|Drug|Lorcaserin 10mg BID|
79841351|NCT00998608|Drug|risperidone|risperidone 4mg/d
79841352|NCT02547324|Radiation|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
79841353|NCT02547324|Radiation|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
79539333|NCT01560416|Drug|Ganetespib|
79539334|NCT01551823|Biological|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
79539335|NCT01551823|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
79539336|NCT01551810|Biological|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
79697038|NCT04677335|Other|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
79697039|NCT04630509|Procedure|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
79245706|NCT05725499|Device|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position."
79841354|NCT04011813|Other|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
79841355|NCT00998686|Drug|dutogliptin|400 mg
79841356|NCT00998686|Drug|sitagliptin|100 mg
79245707|NCT05725499|Diagnostic Test|Tilt-table orthostatic stress testing|"While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation."
79697040|NCT04677023|Other|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
79245708|NCT05723250|Other|Table-based Educational Intervention|Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
79245709|NCT05719103|Behavioral|With and Without Awake Prone Positioning|"HFNC flow at 60 L/min or maximum tolerable flow at supine position~HFNC flow at 60 L/min or maximum tolerable flow at prone position~CPAP with full face mask at 10 cmH2O at supine position~CPAP with full face mask at 10 cmH2O at prone position~MC at supine position~MC at prone position"
79384668|NCT03269682|Device|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
79697041|NCT04677023|Other|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
79841357|NCT00829218|Other|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
79841358|NCT00829218|Other|Placebo diet|Juice with nothing added.
79841359|NCT00948519|Device|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
79841360|NCT00948519|Device|Laser only|same only without ICG
79841361|NCT00958269|Drug|dutogliptin|100 mg QD
79841362|NCT00958269|Drug|dutogliptin|200 mg QD
79245710|NCT05708521|Drug|Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery|POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
79384669|NCT03269448|Diagnostic Test|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
79384670|NCT02458482|Device|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
79384671|NCT02458482|Drug|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
79384672|NCT03264612|Behavioral|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
79384673|NCT03264924|Behavioral|IPAIR|Motivational interview training
79841363|NCT00958269|Drug|placebo|
79841364|NCT00958269|Drug|sitagliptin|25 mg QD
79841365|NCT00958269|Drug|sitagliptin|50 mg QD
79841366|NCT02547402|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
79841367|NCT02547402|Drug|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
79841368|NCT02547402|Drug|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
79841369|NCT01068925|Drug|GSK1349572|"GSK1349572 QD x 5 days~TPV/RTV 500/200mg BID x 7 days~GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
79841370|NCT00511810|Drug|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
79841371|NCT00511810|Drug|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
79841372|NCT00834600|Drug|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
79841373|NCT00834600|Drug|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
79841374|NCT00958425|Device|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
79245711|NCT05708521|Drug|Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery|SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
79245712|NCT05707234|Device|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
79245713|NCT05707234|Drug|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
79539337|NCT01551810|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
79539338|NCT01512706|Biological|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
79539339|NCT01512706|Biological|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
79539340|NCT01512706|Biological|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
79841375|NCT00958425|Device|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
79841376|NCT02547480|Device|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
79245714|NCT05702372|Other|Glucose as reference food|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79245715|NCT05702372|Other|Cracker made by wheat flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79245716|NCT05702372|Other|Cracker made by rye flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79384674|NCT03273192|Drug|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
79384675|NCT03264846|Diagnostic Test|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
79384676|NCT02348632|Drug|JZP-110|
79384677|NCT03269604|Procedure|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
79384678|NCT03269604|Procedure|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
79384679|NCT03269604|Procedure|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
79539341|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
79539342|NCT01512706|Biological|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
79539343|NCT01512706|Biological|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
79841377|NCT00291499|Drug|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
79841378|NCT00291499|Other|Placebo|800 mg placebo/day for 6 months
79841379|NCT00838500|Drug|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
79245717|NCT05702372|Other|Cracker made by sunflower flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
79245718|NCT05702359|Other|Glucose as reference food|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g glucose diluted in 300mL water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
79245719|NCT05702359|Other|Control juice|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
79245720|NCT05702359|Other|Juice with vitamin D3|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing vitamin D3, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
79539344|NCT01512706|Biological|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
79539345|NCT01512706|Biological|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
79539346|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
79539347|NCT01512706|Biological|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
79841380|NCT00838500|Drug|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
79841381|NCT00838656|Drug|carboplatin|Given IV in one of two schedules
79841382|NCT00838656|Drug|gemcitabine hydrochloride|Given IV in one of two schedules
79841383|NCT00838656|Drug|paclitaxel|Given IV in one of two schedules
79841384|NCT03964636|Diagnostic Test|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
79384680|NCT02458872|Behavioral|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
79384681|NCT03264768|Device|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
79384682|NCT03264768|Behavioral|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
79384683|NCT03264768|Procedure|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
79384684|NCT02349178|Drug|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
79539348|NCT01512706|Biological|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
79539349|NCT01512706|Biological|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
79841385|NCT03998098|Diagnostic Test|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
79841386|NCT03998098|Diagnostic Test|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
79539350|NCT01512706|Biological|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
79539351|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
79539352|NCT01512706|Biological|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
79539353|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
79841387|NCT03998098|Diagnostic Test|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
80011120|NCT02189876|Behavioral|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
79384685|NCT02349178|Drug|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
79539354|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
79539355|NCT01345539|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
79384686|NCT02349178|Drug|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
79384687|NCT03273114|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
79384688|NCT03273114|Other|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
79384689|NCT03970356|Other|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
79384690|NCT01966900|Biological|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
79384691|NCT03269370|Behavioral|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
79539356|NCT01345539|Drug|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
79384692|NCT03269370|Behavioral|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
79384693|NCT03269370|Behavioral|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)"
79539357|NCT01288066|Procedure|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
79539358|NCT01288066|Procedure|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
79697042|NCT04630548|Device|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
79697043|NCT01975610|Drug|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
79697044|NCT01975610|Drug|Placebo|Twice daily for 28 days
79697045|NCT04610424|Behavioral|"Cooperative Parent Mediated Therapy (CPMT)"|CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
79697046|NCT04610424|Behavioral|As usual|Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
79697047|NCT04677101|Diagnostic Test|Liver Biopsy|Fine-needle liver biopsy
79697048|NCT04630470|Behavioral|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
79384694|NCT04023084|Drug|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
79841388|NCT03998098|Diagnostic Test|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
79841389|NCT00829608|Biological|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
79841390|NCT00838812|Drug|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
79841391|NCT00553605|Drug|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
79841392|NCT00553605|Drug|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
80011121|NCT03675555|Drug|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
79841393|NCT02547246|Device|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
79841394|NCT02547246|Device|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
79841395|NCT00838968|Drug|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
80011122|NCT03675555|Drug|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
79384695|NCT02349646|Device|Implantation with the commercially available Axium neurostimulator|
79384696|NCT05075460|Drug|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~Vinoresin (VDS) 4mg intravenous infusion, day 1;~Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
79384697|NCT02457234|Behavioral|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
79384698|NCT01966978|Drug|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
79384699|NCT01966978|Drug|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
79697049|NCT04630470|Behavioral|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
79697050|NCT04677062|Drug|GV-328|Patients with GV-328 treatment
79697051|NCT04610463|Diagnostic Test|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
79697052|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
79841396|NCT00829842|Other|oral hygiene|oral hygiene with 0.12% chlorexidine
79841397|NCT00829842|Other|placebo|oral hygiene placebo
79841398|NCT00954759|Procedure|Chiropractic treatment|
79841399|NCT00954759|Procedure|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
79841400|NCT02548182|Device|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults [REF]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
79848999|NCT05660525|Drug|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
80011123|NCT03675555|Drug|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
80011124|NCT02190032|Device|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
79245721|NCT05702359|Other|Juice with n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
79245722|NCT05702359|Other|Juice with probiotics|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
79539359|NCT01279850|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
79539360|NCT01257269|Other|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
79697053|NCT01972178|Drug|PRC-4016|
79697054|NCT01972178|Drug|Placebo|
79841401|NCT02548182|Other|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
79841402|NCT05352477|Other|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
79841403|NCT05352477|Other|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
79841404|NCT00835302|Procedure|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
79841405|NCT04010955|Drug|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
79841406|NCT03851328|Other|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
79245723|NCT05702359|Other|Juice with probiotics, vitamin D3, and n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, vitamin D3 and n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
79245724|NCT05702307|Other|Glucose as reference food|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79245725|NCT05702307|Other|Tagliatella control|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79245726|NCT05702307|Other|5% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79245727|NCT05702307|Other|16% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79539361|NCT01217281|Procedure|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
79697055|NCT01972178|Drug|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
79697056|NCT01972139|Device|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
79539362|NCT01068327|Drug|gemcitabine hydrochloride|Given IV
79697057|NCT01972139|Other|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
79697058|NCT01972139|Device|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
79697059|NCT01969838|Drug|Momelotinib|Momelotinib tablet administered orally once daily
79697060|NCT01969838|Drug|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
79697061|NCT01969838|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
79697062|NCT01969838|Drug|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
79841407|NCT04016688|Procedure|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
79841408|NCT00948831|Biological|Osteocel Plus|biologic
79245728|NCT05702307|Other|16% sunflower penne|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
80011125|NCT02190032|Device|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
79245729|NCT05702307|Other|16% sunflower fusilli|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79384700|NCT01966978|Drug|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
79539363|NCT01068327|Drug|leucovorin calcium|Given IV
80011126|NCT03679923|Dietary Supplement|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
79539364|NCT01068327|Drug|fluorouracil|Given IV
79697063|NCT04630314|Device|Percutaneus Coronary Intervention|Covered Stent
79697064|NCT01165177|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
80011127|NCT03679923|Dietary Supplement|Placebo|Placebo
79245730|NCT05702073|Drug|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
79384701|NCT01966978|Drug|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180
79384702|NCT05075226|Device|Vivity Extended Depth of Focus|Cataract surgery
79384703|NCT03264378|Behavioral|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
79539365|NCT01068327|Drug|nelfinavir mesylate|Given PO
79539366|NCT01068327|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
79539367|NCT01068327|Radiation|hypofractionated radiation therapy|Undergo radiotherapy
79539368|NCT01068327|Procedure|therapeutic conventional surgery|Undergo surgery
79539369|NCT01035463|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
79539370|NCT01035463|Drug|Carmustine|Given IV
79539371|NCT01035463|Drug|Cytarabine|Given IV
79539372|NCT01035463|Drug|Etoposide|Given IV
79539373|NCT01035463|Drug|Lenalidomide|Given PO
79539374|NCT01035463|Drug|Melphalan|Given IV
79539375|NCT01035463|Biological|Rituximab|Given IV
79539376|NCT00936390|Drug|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
79697065|NCT01165177|Biological|Placebo|Intramuscular injection
79697066|NCT04610385|Procedure|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
79697067|NCT01967810|Drug|ANG1005|ANG1005 at a starting dose of 650 mg/m^2 or 600 mg/m^2 by intravenous infusion once every 3 weeks
79697068|NCT01967810|Drug|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
79539377|NCT00936390|Drug|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
79697069|NCT04610268|Device|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
79697070|NCT01966601|Drug|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
79697071|NCT01966601|Drug|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
79697072|NCT01966601|Drug|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
80011128|NCT02060994|Other|No intervention|No intervention
80011129|NCT02194166|Drug|Trastuzumab|Trastuzumab IV or SC will be administered as described.
80011130|NCT02194166|Drug|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
80011131|NCT02194166|Drug|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
80011132|NCT03679845|Drug|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
79245731|NCT05702073|Drug|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
79245732|NCT05695872|Procedure|subtarsal approach|surgical approach
79841409|NCT05300061|Behavioral|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
79841410|NCT05300061|Behavioral|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
79841411|NCT05352087|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
79384704|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
79384705|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
79539378|NCT00936390|Drug|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
79539379|NCT00936390|Radiation|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
79539380|NCT00572234|Drug|bupropion SR|12 week course of bupropion SR 150 mg, BID
79539381|NCT00497926|Biological|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
79539382|NCT00411138|Radiation|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
79841412|NCT00948987|Drug|Aspirin|325 mg enteric coated single dose p.o.
79841413|NCT00954837|Procedure|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
79841414|NCT05351931|Dietary Supplement|Salovum and SPC-flakes or corresponding placebo|Salovum and SPC-flakes are foods approved for specific medical purposes.
79841415|NCT05351697|Drug|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
79245733|NCT05695872|Procedure|conventional transconjunctival approach|surgical approach
79245734|NCT05695872|Procedure|transconjunctival approach with Y- modification|surgical approach
79245735|NCT05690282|Drug|Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|Multimodal Pain Management to minimize patients' reliance on opioids.
79539383|NCT00411138|Drug|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
79539384|NCT00411138|Drug|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
79539385|NCT00411138|Drug|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
79539386|NCT00149149|Other|Zinc Carnosine coadministered with Indomethacin|
79539387|NCT00149149|Other|Placebo coadministered with Indomethacin|
79539388|NCT01469312|Other|modified pasta|50 grams carbohydrate as a single breakfast meal
79697073|NCT01966601|Drug|Placebo|Placebo continuous intravenous infusion
79697074|NCT04610073|Behavioral|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
79697075|NCT03454269|Diagnostic Test|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
79697076|NCT01165138|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
79697077|NCT01165138|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
79697078|NCT01165138|Drug|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
79245736|NCT05685914|Procedure|endoscopic surgery|Emergency or elective surgery
79245737|NCT05685576|Device|Piezotomed ridge splitting and osseodensification|Ridge expansion using piezotomed ridge splitting and osseodensification
79245738|NCT05677334|Drug|Henagliflozin|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
79245739|NCT05677334|Device|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
79841416|NCT00744497|Drug|Placebo|
79245740|NCT05676645|Drug|Artemether-lumefantrine|National policy recommendation for treatment of uncomplicated malaria in Uganda
79841417|NCT00744497|Drug|Dasatinib|
80011133|NCT02061072|Other|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
79245741|NCT05669183|Procedure|Veno-arterial extracorporeal membrane oxygenation|Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
80011134|NCT02194244|Drug|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
79245742|NCT05668845|Other|PG-ANB performed at the outset of LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.
79245743|NCT05668845|Other|PG-ANB performed at the end of the LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG>
79245744|NCT05664425|Device|Ultrasonic debridement|Ultrasonic debridement with a plastic/teflon tip (2 minutes + 1 minute irrigation)
79245745|NCT05659966|Behavioral|Plant-based diet|Participants will receive a behavioral intervention on a plant-based diet in partnership with a local restaurant.
79539389|NCT01469325|Other|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
79245746|NCT05659966|Other|Voucher only|Participants will receive vouchers to a local restaurant. Participants will not attend nutrition classes but will receive a class at the end of the 12-week study.
79245747|NCT05658224|Behavioral|Education on effects of Exercise-induced hypoalgesia from exercise|Educational session with participants
79384706|NCT02350660|Dietary Supplement|cow's milk|daily consumption of cow's milk
79539390|NCT01469325|Other|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
79841418|NCT00744497|Drug|Docetaxel|
80011135|NCT02194244|Drug|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
79841419|NCT00744497|Drug|Prednisone|
80011136|NCT03679533|Dietary Supplement|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
80011137|NCT03679533|Dietary Supplement|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
80011138|NCT02194322|Drug|BIBN 4096 BS - in single rising doses|
80011139|NCT02194322|Drug|Placebo|
80011140|NCT03675399|Other|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
80011141|NCT03675399|Other|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
80011142|NCT02195882|Procedure|Exercise program of the scapular muscle stabilizers|
80011143|NCT02193308|Drug|Telmisartan/Amlodipine FDC|
80011144|NCT02193308|Drug|Telmisartan|
80011145|NCT02193308|Drug|Amlodipine|
79245748|NCT05656586|Other|observational-- no intervention|observational
79384707|NCT02350660|Dietary Supplement|peanut powder|peanut oral immunotherapy
79384708|NCT03269214|Drug|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
79384709|NCT05075148|Other|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
79384710|NCT05075304|Drug|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
79384711|NCT05075304|Drug|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
79384712|NCT05075304|Drug|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
79539391|NCT01469338|Drug|cabazitaxel|Given IV
79539392|NCT01469338|Drug|prednisone|Given PO
79539393|NCT01469338|Drug|octreotide pamoate|Given IM
79539394|NCT01469338|Other|questionnaire administration|Ancillary studies
79539395|NCT01469338|Drug|octreotide acetate|Given SC
79697079|NCT01963598|Drug|REGN1033 (SAR391786)|
79697080|NCT01963598|Drug|placebo|
79697081|NCT00561054|Drug|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
79697082|NCT04206358|Biological|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
79841420|NCT00949065|Biological|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
80011146|NCT03683199|Procedure|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
80011147|NCT02195960|Dietary Supplement|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
80011148|NCT02195960|Dietary Supplement|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
80011149|NCT02060604|Drug|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
80011150|NCT02060604|Drug|Ranibizumab|3 monthly ranibizumab, then as needed
79245749|NCT05649449|Behavioral|Self-Directed Care|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
79245750|NCT05649449|Behavioral|Services as usual|Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
79245751|NCT05646875|Other|hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
79245752|NCT05646758|Drug|TQB2934 injection|TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
79245753|NCT05646238|Other|psychoeducation|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
79384713|NCT02457390|Procedure|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
79384714|NCT02457468|Device|coflex|
79384715|NCT05074836|Dietary Supplement|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml*2/d;~Intervention duration: 12 months"
79384716|NCT05074836|Dietary Supplement|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml*2/d;~Intervention duration: 12 months"
79384717|NCT05074836|Other|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g * 2/d grain foods~Intervention duration: 12 months"
79841421|NCT05351619|Procedure|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
80011151|NCT03679455|Drug|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
80011152|NCT02193386|Other|No intervention, no follow-up, only registration|Usual Care
79697083|NCT00561093|Drug|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
79697084|NCT00561093|Dietary Supplement|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
80011153|NCT02193386|Other|Intervention period|Predefined intervention program
79841422|NCT05351463|Procedure|papila suture technique|simple interupted vs internal horoizontal matress suture
80011154|NCT03315143|Drug|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
80011155|NCT03315143|Drug|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
80011156|NCT02194400|Biological|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
80011157|NCT02062086|Dietary Supplement|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
80011158|NCT03675165|Behavioral|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
80011159|NCT02194478|Behavioral|Meditation|30 minute, 8 week meditation
79697085|NCT00561093|Dietary Supplement|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
79697086|NCT00561093|Drug|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
79697087|NCT00561093|Dietary Supplement|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
79697088|NCT00561093|Dietary Supplement|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
79245754|NCT05646238|Other|training|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
79245755|NCT05645549|Behavioral|Centering Pregnancy with Care Navigation|Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
79245756|NCT05643768|Behavioral|Inspiratory muscle strength training (IMST)|30 breaths/day, 5 days/week, 6 weeks
79245757|NCT05639881|Behavioral|Enhancing Your Immune Health|In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
79245758|NCT05631808|Other|Epicardial adipose tissue volume and attenuation|Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.
79245759|NCT05628831|Procedure|vNOTES suspension with autologous tissue|Autologous tissue will be fixated on solid points in pelvis using vNOTES.
79384718|NCT03264144|Behavioral|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
79384719|NCT05074602|Drug|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
79384720|NCT05074602|Drug|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
79384721|NCT03264222|Other|Security screening procedure|Screening procedure with security device (model QPS 100)
79697089|NCT01960010|Drug|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
79697090|NCT01960010|Drug|Vehicle|Vehicle dosed BID
79245760|NCT05628831|Procedure|Vaginal surgery|Vaginal hysterectomy will be done with anterior and/or posterior repair depending on the judgment of the surgeon at the time of the operation. Uterosacral and cardinal ligaments will be repositioned and attached to the vaginal vault after hysterectomy at the time of vault closure. A modified McCall culdoplasty will be done in this group to prevent enterocele and further apical prolapse
79384722|NCT02457312|Drug|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
79384723|NCT02457312|Drug|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
79384724|NCT03268902|Drug|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
79384725|NCT03268902|Drug|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
79384726|NCT03268902|Dietary Supplement|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
79384727|NCT03268902|Drug|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
79697091|NCT01165021|Drug|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
79697092|NCT01165021|Drug|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
79697093|NCT01165021|Drug|Folic Acid|Administered orally.
79697094|NCT01165021|Drug|Vitamin B12|Administered Intramuscular injection.
79697095|NCT01165021|Drug|Dexamethasone|Administered orally.
79245761|NCT05622409|Other|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
79697096|NCT04314622|Drug|Supaglutide|Administered SC
79697097|NCT04314622|Drug|Placebo|Administered SC
79697098|NCT00561132|Dietary Supplement|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
79697099|NCT00561132|Other|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (<50 mg) twice daily for a period of 4 weeks
79697100|NCT02886754|Behavioral|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
79697101|NCT02886754|Behavioral|National e-learning programme only|National e-learning programme (COMPASS)
79697102|NCT02886754|Behavioral|Standard simulation|Paper based simulation cases
79697103|NCT01956812|Drug|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
79245762|NCT05613556|Device|Orpyx SI® Sensory Insole System|Orpyx SI Sensory Insole System consists of Orpyx Custom Insoles and Orpyx Sensory Technology. The Orpyx Custom Insoles are precisely fabricated for an individual's feet. The Orpyx Sensory Technology, a powered limb overload warning technology, is compatible with the Orpyx Custom Insoles. It is intended for monitoring physiological parameters, such as plantar pressure, motion and temperature, and providing real-time cues for pressure offloading as the patient goes about their daily activities
79245763|NCT05612646|Procedure|Acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
79245764|NCT05612646|Procedure|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
79245765|NCT05611021|Behavioral|Exercise|Three conditions will be tested: Walking, arm-cranking and control condition.
79245766|NCT05603286|Procedure|Home-monitoring|Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.
79245767|NCT05597202|Drug|Semaglutide, 2.0 mg/mL|Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
79245768|NCT05596903|Other|EMDR 2.0 group protocol|EMDR 2.0 group protocol
79245769|NCT05596903|Other|Mhgap stress module|Mhgap stress module
79245770|NCT05592912|Drug|HydroLenz Injection|The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
79697104|NCT01956812|Drug|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
79384728|NCT03268980|Other|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
79697105|NCT01956812|Drug|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
79539396|NCT01469351|Drug|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
79539397|NCT01469351|Drug|non-active study drug|placebo
79697106|NCT01182844|Dietary Supplement|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
79697107|NCT01164865|Device|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
79697108|NCT01164865|Device|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
79245771|NCT05592912|Other|No HydroLenz Injection|No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
79697109|NCT01164865|Device|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
79697110|NCT04630587|Procedure|Indirect restorations|see the Arm description
79697111|NCT01952990|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
79697112|NCT04314310|Drug|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
79697113|NCT04314310|Drug|Placebo|equal volume of normal saline
79697114|NCT02886793|Drug|fludeoxyglucose|
79245772|NCT05591651|Drug|Treatment of damaged nipple skin: Preparation with hyaluronic acid|The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
79245773|NCT05591651|Drug|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid|The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
79245774|NCT05590130|Device|Manual Oxygen titration with Philips oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter
79245775|NCT05590130|Device|Manual oxygen titration with Nonin oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
79245776|NCT05590130|Device|Manual Oxygen titration with Philips oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
79384729|NCT03268980|Other|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
79384730|NCT02458794|Procedure|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
79384731|NCT02458794|Device|LMA SupremeTM|
79384732|NCT02458794|Device|Ambu-Aura GainTM|
79384733|NCT05074368|Biological|ChAdOx1-nCov-19 (Astra-Zeneca)|vaccine inoculation and mixed inoculation
79384734|NCT05074368|Biological|SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine|vaccine inoculation and mixed inoculation
80011160|NCT02061228|Device|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
79841423|NCT00949143|Other|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
80011161|NCT04715204|Other|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. Formula with caloric density of >1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
80011162|NCT04715204|Other|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
79245777|NCT05590130|Device|Manual oxygen titration with Nonin oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
79245778|NCT05588895|Other|Notification|"For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician."
79245779|NCT05585502|Other|Training (minute oscillation stretching)|The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.
79384735|NCT02456922|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
79384736|NCT03263754|Behavioral|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
79539398|NCT01469403|Behavioral|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
79539399|NCT01469416|Drug|Rosuvastatin|Rosuvastatin 20 mg PO x 1
79697115|NCT04610307|Procedure|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
79841424|NCT00949143|Other|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
79539400|NCT01469416|Drug|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
79697116|NCT01952132|Drug|OMS643762|
79697117|NCT01952132|Drug|Placebo|
79697118|NCT00561171|Drug|SPP635|oral once daily
79697119|NCT01951742|Biological|ANT-1401|Active
79841425|NCT00955071|Other|Exercise: LVLI|low volume, low intensity
79841426|NCT00955071|Other|Exercise: HVLI|high volume, low intensity
79841427|NCT00955071|Other|Exercise: LVHI|low volume, high intensity
80011163|NCT04715204|Other|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
79245780|NCT05585190|Other|Control|No intervention.
79384737|NCT03263754|Behavioral|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
79384738|NCT02458716|Procedure|Robotic Assisted Radical Prostatectomy|Undergo RARP
79384739|NCT02458716|Procedure|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
79384740|NCT02458716|Other|Laboratory Biomarker Analysis|Correlative studies
79384741|NCT02458716|Other|Quality-of-Life Assessment|Ancillary studies
79697120|NCT01951742|Biological|Vehicle|Vehicle
79697121|NCT04610229|Radiation|Hypofractionation guioded by dose painting|1
79697122|NCT01951235|Drug|Imeglimin|
79697123|NCT01951235|Drug|Placebo|
79841428|NCT00955149|Drug|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
79841429|NCT00747227|Device|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
79697124|NCT04610502|Biological|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
79841430|NCT00747227|Device|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
79841431|NCT04090541|Other|Rigid Tape|Non-Elastic Tape
79841432|NCT04090541|Other|Kinesiology Tape|Tape can be elongate only one direction
79841433|NCT04090541|Other|Biomechanical Tape|Tape can be elongate only two direction
80011164|NCT02060682|Device|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
79245781|NCT05585190|Other|2-Hour Stand Group|Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 2 hours each work day.
79245782|NCT05585190|Other|3-Hour Stand Group|Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 3 hours each work day.
79384742|NCT02458716|Drug|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
79539401|NCT01469429|Other|placebo|Receive lozenge placebo PO
79841434|NCT04011657|Other|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
79245783|NCT05582759|Behavioral|teleCBT-I + SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention
79245784|NCT05582759|Behavioral|SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics and education on sleep hygiene
79539402|NCT01469429|Other|laboratory biomarker analysis|Correlative studies
79539403|NCT01469429|Other|questionnaire administration|Ancillary studies
79841435|NCT04019951|Dietary Supplement|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
79841436|NCT04019951|Dietary Supplement|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
80011165|NCT02194556|Drug|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
79539404|NCT01469429|Drug|chemoprevention|Receive LBR lozenge PO
79539405|NCT01469429|Drug|chemoprevention|Receive LBR Saliva Substitute PO
79539406|NCT01469429|Other|placebo|Receive Saliva Substitute placebo PO
79539407|NCT01469442|Procedure|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
79539408|NCT01469455|Drug|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
79245785|NCT05574504|Drug|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|"Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion"
79539409|NCT01469468|Drug|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
79539410|NCT01469468|Drug|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
79697125|NCT01949324|Biological|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
79697126|NCT01949324|Procedure|Sham procedure|Sham surgery for Sham arm
79697127|NCT01949324|Device|NT-501 Implant|NT-501 encapsulated cell implant
79697128|NCT01949324|Procedure|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
79841437|NCT04019951|Dietary Supplement|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
79245786|NCT05545670|Drug|Placebo|not containing drugs
79384743|NCT03263988|Device|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
79841438|NCT05351073|Drug|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
79841439|NCT04091399|Drug|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
79384744|NCT03263910|Drug|NPO-11|20 ml NPO-11
79384745|NCT03263910|Drug|Placebo|20 ml NPO-11(Placebo)
79384746|NCT05037396|Drug|Brolucizumab|Participants received brolucizumab injection during the index period
79384747|NCT02713542|Device|ACP|Autologous Conditioned Plasma
79384748|NCT02713542|Other|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
79841440|NCT00955227|Dietary Supplement|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
79841441|NCT00955227|Drug|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
79841442|NCT00949299|Drug|buprenorphine|intradermal injection
79841443|NCT00747149|Drug|Rosuvastatin|Oral
79841444|NCT00271609|Drug|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
79841445|NCT00548847|Biological|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
80011166|NCT02194556|Drug|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
80011167|NCT03679377|Device|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
80011168|NCT02062242|Other|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
80011169|NCT02062242|Other|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
80011170|NCT02062242|Other|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
79245787|NCT05545670|Drug|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
79384749|NCT02457078|Dietary Supplement|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
79384750|NCT02457078|Dietary Supplement|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
79384751|NCT03268512|Other|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
79697129|NCT01164475|Drug|Granulocyte-colony stimulating factor (G-CSF)|
79697130|NCT01164475|Drug|Fixed Dose Plerixafor|
79697131|NCT01164475|Drug|Weight-Based Plerixafor|
79697132|NCT04609995|Behavioral|Incentives|No financial incentive
79697133|NCT01942265|Drug|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
80011171|NCT02062242|Other|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
80011172|NCT02194634|Drug|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
80011173|NCT02194634|Other|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
79245788|NCT05541250|Biological|Autologous Human Schwann Cell|A one-time dose of 1000 μl* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.
79245789|NCT05538858|Procedure|Mechanical Ventilation|Positive pressure mechanical ventilation
79697134|NCT01942265|Drug|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
79697135|NCT01942265|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
79841446|NCT00548847|Biological|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
79841447|NCT00949377|Drug|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
80011174|NCT02194634|Procedure|Laser|Laser treatment at first month, then repeated as needed.
80011175|NCT02194634|Other|Sham laser|Sham laser at first month, then repeated as needed.
80011176|NCT03679143|Drug|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
79245790|NCT05529446|Device|Combination therapy (CT)|Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US & TENS where this approach was effective in pain modulation
79245791|NCT05514106|Drug|meta-iodobenzylguanidine (MIBG) (123I)|1 administration of 123I-MIBG for a single SPECT scan
79245792|NCT05514106|Diagnostic Test|123I-MIBG scintigraphy|SPECT scan involving 123I-MIBG as the ligand
79245793|NCT05506085|Device|Deep Brain Stimulation|Deep Brain Stimulation of Globus Pallidus interna
79245794|NCT05499767|Behavioral|HEPPI|Homebound Elderly People Psychotherapeutic Intervention
79245795|NCT05487794|Drug|Testosterone Cypionate 100 MG/ML|Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
79245796|NCT05485493|Behavioral|Internet-Based Solution Focused Short-Term Group Counseling|Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.
79245797|NCT05485493|Other|healthy nutrition education|60-minute single session healthy eating training
80011177|NCT03679143|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
80011178|NCT03679143|Drug|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
80011179|NCT03679143|Drug|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
79245798|NCT05481528|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
79245799|NCT05481528|Drug|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant
79245800|NCT05481528|Drug|Placebo|Single oral dose of placebo
80011180|NCT03679143|Drug|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
79245801|NCT05471999|Procedure|surgery|interventional or surgical treatment
79384752|NCT03268512|Other|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
79384753|NCT02458326|Other|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
79245802|NCT05457075|Diagnostic Test|Immune checkpoint measure|The measurement of soluble immune checkpoints of stage II-III rectal cancer before neoadjuvant treatment
79697136|NCT01164007|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
79697137|NCT01164007|Drug|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 28-day cycle.
79697138|NCT01941836|Drug|ETC-1002|Patients receive ETC-1002
79697139|NCT01941836|Drug|Ezetimibe|Patients receive ezetimibe
79841448|NCT00949377|Drug|Placebo|Normal saline
80011181|NCT03679143|Drug|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
80011182|NCT03679143|Drug|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
79245803|NCT05454943|Behavioral|Standardized TRE Protocol|A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
79841449|NCT00290407|Drug|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
80011183|NCT03679143|Drug|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
79841450|NCT00290407|Dietary Supplement|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
79849000|NCT05660525|Drug|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
80011184|NCT03679143|Drug|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
80011185|NCT03679143|Drug|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
79245804|NCT05454943|Behavioral|Personalized TRE Protocol|A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
79245805|NCT05454943|Behavioral|External Support for TRE|External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
79245806|NCT05454943|Behavioral|Peer Support for TRE|Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
79245807|NCT05454020|Drug|XG004|XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
79245808|NCT05454020|Drug|Placebo|Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
79384754|NCT02458326|Other|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
79384755|NCT03268278|Drug|Buprenorphine|Buprenorphine plus local anesthetic
79384756|NCT03268278|Drug|Sterile saline|Placebo 1,8 ml
79384757|NCT03268278|Drug|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
79539411|NCT01469481|Drug|PF-04991532|a single oral dose of [14C]PF-04991532 (450 mg/100 uCi suspension)
79539412|NCT01469494|Procedure|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
79539413|NCT01469494|Procedure|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
79539414|NCT01469507|Device|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
79539415|NCT01469507|Drug|Hyaluronan|3 weekly injections
80011186|NCT03679143|Drug|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
80011187|NCT03679143|Drug|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
80011188|NCT03679143|Drug|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
80011189|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
79539416|NCT01469520|Drug|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
79539417|NCT01469520|Drug|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
79697140|NCT04610151|Other|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
79697141|NCT04630041|Behavioral|211 Referral|Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
79697142|NCT04629885|Drug|Oxytocin 400 IU vaginal gel|
79245809|NCT05446792|Other|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
79245810|NCT05446792|Other|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
79384758|NCT03268434|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
79841451|NCT05350683|Procedure|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
79384759|NCT03268434|Behavioral|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
79384760|NCT05045586|Device|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
79841452|NCT01070017|Other|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
80011190|NCT03679143|Drug|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
80011191|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
80011192|NCT03679143|Drug|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
79384761|NCT05045586|Device|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
79384762|NCT03268044|Other|Hospital admission and surgery|Hospital admission and noncardiac surgery
79539418|NCT01469520|Drug|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
79539419|NCT01469533|Other|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
79697143|NCT04629885|Drug|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
79697144|NCT01939184|Drug|WC3055|12.5, 25, 50 or 75 mg dose
79697145|NCT01939184|Other|Placebo|Placebo
79697146|NCT04630119|Other|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
79697147|NCT04629768|Device|PuraStat|Purastat is applied to the EMR defect
79697148|NCT01163851|Biological|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
79697149|NCT01163851|Biological|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
79697150|NCT04609917|Procedure|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
79697151|NCT02885662|Drug|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
79697152|NCT00561210|Dietary Supplement|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
80011193|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
80011194|NCT03679143|Drug|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
80011195|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
80011196|NCT02061462|Procedure|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
80011197|NCT02030912|Drug|3 doses of amoxicillin daily for 7 days|
79245811|NCT05445505|Device|intermittent theta burst stimulation|iTBS is a new form of excitatory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
79384763|NCT03268122|Other|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
80011198|NCT02030912|Drug|2 doses of minocycline daily for five days|
80011199|NCT02030912|Other|2 doses of placebo daily for five days|
80011200|NCT03675009|Other|Educational Programming|Green Cleaning educational programming to day care staff.
79384764|NCT03268122|Other|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
80011201|NCT02196116|Other|PET|PET Scan with [18F]-Flutemetamol
80011202|NCT02196116|Other|MRI|
79245812|NCT05445505|Device|sham iTBS|The pseudo-stimulation device looks and sounds the same as the iTBS device
79245813|NCT05441722|Behavioral|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
79245814|NCT05434728|Other|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
79245815|NCT05432765|Other|Phenotypic Personalized Medicine Dosing|Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.
79245816|NCT05432765|Other|Phenotypic Personalized Medicine Dosing|Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.
79384765|NCT03267732|Biological|Pegilodecakin|Pegilodecakin Alone
79697153|NCT00561210|Dietary Supplement|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
80011203|NCT02196116|Other|neuropsychological tests|
80011204|NCT02060916|Drug|PAZ320|Single-center pilot study, open label dose escalation design
80011205|NCT02257268|Behavioral|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
79245817|NCT05431634|Drug|Experimental drug: ESK-001|Multiple doses of ESK-001
79245818|NCT05431634|Other|Placebo|Placebo
80011206|NCT02063256|Dietary Supplement|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
80011207|NCT02063256|Other|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
80011208|NCT02797080|Drug|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
80011209|NCT02196194|Drug|Tiotropium|
79245819|NCT05417321|Drug|HB0036|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
79245820|NCT05413863|Biological|Biocon's Human Insulin R U-500|Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
79697154|NCT01938599|Drug|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
79697155|NCT01938599|Drug|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
79709926|NCT04327362|Behavioral|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
79245821|NCT05413863|Biological|Humulin® R U-500 (US Reference Product)|Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
79841453|NCT00955383|Drug|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
79841454|NCT00955383|Drug|Placebo|Matching placebo
80011210|NCT03534830|Diagnostic Test|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
79245822|NCT05389865|Procedure|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
79245823|NCT05389865|Other|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
80011211|NCT02915835|Drug|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
80011212|NCT02915835|Drug|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
79245824|NCT05389085|Diagnostic Test|Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids|In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
79245825|NCT05381467|Procedure|immediate implant placement with The Dual-Zone Therapeutic Concept|After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
79245826|NCT05381467|Procedure|Immediate implant placement with the bone shielding concept|After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
79245827|NCT05374499|Drug|Liposomal bupivacaine|Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
79245828|NCT05374499|Drug|0.5% bupivacaine with 1:100,000 epinephrine|Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
79245829|NCT05363527|Biological|Endotoxin|Endotoxin
79245830|NCT05363527|Biological|Placebo|Placebo
79245831|NCT05362721|Diagnostic Test|Pressure-volume loop catheter|The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
79245832|NCT05358340|Diagnostic Test|Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)|A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
79245833|NCT05357755|Drug|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
79245834|NCT05357755|Drug|Placebo|Matching placebo will be administered orally as delayed release tablets.
79841455|NCT02597387|Drug|Mitoxantrone HCL Liposome Injection|
79841456|NCT01069081|Drug|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
79841457|NCT01069081|Drug|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
79841458|NCT01069081|Drug|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
79841459|NCT05350605|Behavioral|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
79841460|NCT04019795|Device|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
79841461|NCT04019795|Device|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
80011213|NCT02194712|Other|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
79384766|NCT03263676|Device|Icon resuable underwear|Reusable incontinence underwear
79697156|NCT04610034|Behavioral|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
79841462|NCT04019795|Device|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
80011214|NCT01370616|Drug|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
80011215|NCT01370616|Drug|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
80011216|NCT01370616|Drug|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
80011217|NCT01370616|Drug|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
80011218|NCT02196272|Behavioral|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
80011219|NCT02688881|Drug|sirolimus|Rapamune
80011220|NCT02196350|Behavioral|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
80011221|NCT02196350|Behavioral|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
80011222|NCT02196350|Behavioral|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
80011223|NCT02197208|Procedure|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
79245835|NCT05357690|Procedure|Stellate ganglion block|Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
79245836|NCT05357690|Drug|Bupivacaine|10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion
79384767|NCT03263676|Device|Disposable pad|Standard market disposable pad
79384768|NCT04736862|Device|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
80011224|NCT02197208|Procedure|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
79384769|NCT04736862|Device|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
79384770|NCT03263286|Device|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
80011225|NCT02197208|Device|ultrasound|
80011226|NCT02062476|Dietary Supplement|Lactobacillus GG|
79245837|NCT05357690|Drug|Placebo|10 mL of saline injected in the plane of the right stellate ganglion
79245838|NCT05356533|Behavioral|Drinking to Cope CBT skills|Young adults who drink to cope with negative affect will receive 8 web-based modules with cognitive behavioral skills
79245839|NCT05354882|Behavioral|Physical activity program|The single group will access to the twelve-week DEFACTO program containing one adapted physical activity session, two discussion group sessions and several motivational interviewing
79245840|NCT05351216|Other||No intervention
79245841|NCT05344352|Dietary Supplement|Multistrain Probiotic|8-week daily administration
79245842|NCT05344352|Other|Placebo|8-week daily administration
79245843|NCT05341154|Drug|Ketamine Hcl 50Mg/Ml Inj|Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
79384771|NCT03267966|Diagnostic Test|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
79384772|NCT03263520|Drug|Nandrolone Decanoate|Drug administration
79384773|NCT03263520|Drug|Dexamethasone|Drug administration
79697157|NCT04610034|Other|Care as usual|The control arm will receive usual care, which implies no systematic support.
79697158|NCT01917383|Drug|Trabodenoson|Ophthalmic eye drop
79697159|NCT01917383|Drug|Latanoprost|Ophthalmic eye drop
79697160|NCT01917383|Drug|Timolol|Ophthalmic eye drop
79697161|NCT00564135|Procedure|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
79245844|NCT05339061|Device|Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).|"Modification~Deploy the graft on the sterile, surgical table~Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch"
79384774|NCT02456844|Drug|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~BMS-986142: On Days 6 through 12."
79384775|NCT02456844|Drug|Methotrexate, Leucovorin and BMS-986142|"Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~BMS-986142 on Days 6 through 10."
79384776|NCT03269838|Diagnostic Test|ECG|Primary Percutaneous coronary intervention
79697162|NCT01163617|Device|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
79697163|NCT01163617|Device|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
79841463|NCT04019795|Device|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
79841464|NCT01581463|Drug|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
79384777|NCT03263208|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
79384778|NCT03263208|Drug|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
79384779|NCT03263208|Biological|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
79384780|NCT03259542|Drug|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
79697164|NCT01163617|Device|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
79697165|NCT01163617|Device|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
79841465|NCT00955461|Procedure|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
79841466|NCT00955461|Procedure|Fractionated Laser treatment|
79384781|NCT03259542|Drug|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
79697166|NCT01911767|Drug|Dimethyl fumarate|Administered as specified in treatment arm.
79697167|NCT01911767|Drug|Peginterferon beta-1a|Administered as specified in treatment arm.
79841467|NCT00917033|Device|GlideScope|Orotracheal intubation
79697168|NCT04629846|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
79697169|NCT04629846|Drug|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
79697170|NCT04629846|Drug|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
79697171|NCT04629846|Drug|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
79697172|NCT04629846|Procedure|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
79697173|NCT01910012|Drug|ADI-PEG 20|
79697174|NCT01182337|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
79841468|NCT00917033|Device|Macintosh direct laryngoscope|Orotracheal intubation
79841469|NCT00949455|Drug|lapatinib ditosylate|Given orally
79841470|NCT00949455|Other|Placebo|Given orally
79841471|NCT04010799|Drug|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
79841472|NCT04010799|Drug|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
79841473|NCT00749411|Drug|Placebo|matching placebo
79841474|NCT00749411|Drug|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
79697175|NCT01182337|Drug|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
80011227|NCT04243889|Device|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
79841475|NCT05342805|Procedure|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler
79245845|NCT05336474|Diagnostic Test|Ultrasonographic upper airway measurements|Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge
79245846|NCT05331170|Biological|Research Grade RG-RV|Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
79245847|NCT05330858|Drug|ESK-001|Oral tablet or liquid
79245848|NCT05330858|Drug|Rabeprazole|Oral Tablet
79245849|NCT05329389|Device|StoneMD|StoneMD - is an app from App Store (for iOS) or Google Play (for Android).
79245850|NCT05329389|Behavioral|Schools of Patients|"The Schools for Patients with Urolithiasis is an online course for patients with urinary stone disease."
79245851|NCT05329389|Behavioral|Standard recommendation|Only fluid balance recommendations given at the day of discharge.
79245852|NCT05328102|Biological|plamotamab|Biological
79245853|NCT05328102|Biological|tafasitamab|Biological
79697176|NCT04609527|Procedure|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
79697177|NCT01909427|Drug|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
79384782|NCT03267654|Drug|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
79384783|NCT03267654|Drug|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
79384784|NCT03267654|Drug|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
79384785|NCT03267342|Behavioral|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
79697178|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
79697179|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
79245854|NCT05328102|Drug|lenalidomide|Drug
79245855|NCT05323344|Other|Neuro-physiotherapy|Neuro-Physiotherapy will be done in Intervention group I
79245856|NCT05323344|Other|Combination of metacognitive behavioral therapy and Neuro-physiotherapy|Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
79245857|NCT05322785|Other|Breath collection|Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
79245858|NCT05317676|Drug|Palmitoylethanolamide|2-month supply of PEA will be given upon discharge. 300mg will be taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
79245859|NCT05317676|Drug|Placebo|2-month supply of placebo will be given upon discharge. Placebo will taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
79245860|NCT05316259|Drug|BPI-16350|Administered orally
79245861|NCT05313815|Radiation|Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
79245862|NCT05312268|Drug|Rasburicase|Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
79245863|NCT05311735|Procedure|Freeze-Dried Bone Allograft control|Bone grafting to prevent alveolar ridge collapse after tooth removal
79245864|NCT05311735|Procedure|Mineralized Dentin Graft|Mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
79697180|NCT01909427|Drug|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
79697181|NCT01909427|Drug|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
79697182|NCT01909427|Drug|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
79697183|NCT01909427|Drug|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
79841476|NCT00955539|Device|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
79841477|NCT00955539|Device|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
80011228|NCT03630497|Drug|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
79841478|NCT05296161|Drug|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
80011229|NCT02197286|Drug|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
79245865|NCT05311735|Procedure|Partial-Demineralized Dentin Graft|Partially mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
79245866|NCT05309395|Combination Product|FoodRx|Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
79384786|NCT03267342|Behavioral|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
79539420|NCT01469533|Other|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
79539421|NCT01469559|Drug|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
79384787|NCT03267342|Behavioral|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
79539422|NCT01469559|Drug|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
79697184|NCT04629573|Procedure|Lumber Epidural|Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
79841479|NCT00949611|Behavioral|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
79841480|NCT00949611|Behavioral|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
79303654|NCT05726435|Dietary Supplement|Placebo|"14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions."
79384788|NCT03267342|Behavioral|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
79841481|NCT03958149|Device|spinal collar|cervical collar to immobilise the cervical spine
80011230|NCT02197286|Drug|Placebo|Daily dose of a single gelatin placebo capsule.
80011231|NCT01378247|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
80011232|NCT03674775|Other|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
80011233|NCT02197442|Drug|Valsartan|
79841482|NCT00949689|Behavioral|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
80011234|NCT03672669|Genetic|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
80011235|NCT03672669|Genetic|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
80011236|NCT02194790|Behavioral|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
79384789|NCT03267420|Diagnostic Test|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
79539423|NCT01469572|Drug|Pasireotide|Pasireotide is given as an injection.
79539424|NCT01469572|Procedure|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
80011237|NCT02062788|Dietary Supplement|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
79539425|NCT01469572|Drug|Everolimus|Given orally every day for the duration of the study
79539426|NCT01469598|Drug|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
79539427|NCT01469611|Biological|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
79539428|NCT01469624|Drug|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
79539429|NCT01469676|Device|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
79539430|NCT01469689|Other|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
79539431|NCT01469689|Other|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
79303655|NCT03300089|Procedure|General anaesthesia|General anaesthesia
79539432|NCT01469702|Drug|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
79697185|NCT04629573|Procedure|General anesthesia|Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
79697186|NCT01909232|Device|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
79841483|NCT00955695|Drug|erlotinib hydrochloride|
79841484|NCT00955695|Drug|gefitinib|
79303656|NCT03300089|Procedure|Regional anaesthesia|Regional anaesthesia
79303657|NCT03300011|Device|stent|PTCA or PCI
79303658|NCT00702143|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
79303659|NCT02902601|Drug|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
79303660|NCT02902601|Drug|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
79303661|NCT02902601|Other|Placebo|Matching placebo to JNJ-54175446
79539433|NCT01469702|Drug|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
79539434|NCT01469702|Drug|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
79539435|NCT01469728|Procedure|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
79539436|NCT01469728|Procedure|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
79303662|NCT05307315|Other|listening to music|The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
79303663|NCT00702923|Drug|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
79539437|NCT01469741|Behavioral|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
79697187|NCT01909232|Device|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
79697188|NCT04609449|Procedure|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
79697189|NCT04609449|Procedure|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
79697190|NCT01887002|Drug|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
79697191|NCT01887002|Drug|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
79841485|NCT00955695|Other|questionnaire administration|
79841486|NCT00955695|Procedure|quality-of-life assessment|
80011238|NCT02196428|Other|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
80011239|NCT02061618|Behavioral|Bollywood Dance Exercise|
79384790|NCT03267420|Diagnostic Test|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
79539438|NCT01469793|Drug|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
79539439|NCT01469806|Device|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
79539440|NCT01469845|Device|3% hypertonic saline|4 ml dose to be administered every 6 hours
79539441|NCT01469858|Device|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
79539442|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
79539443|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
79539444|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
79539445|NCT01469884|Drug|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
79539446|NCT01469884|Drug|Cyclosporine|Trough level should be between 100 and 200ng/ml.
79697192|NCT00564174|Drug|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
80011240|NCT04102280|Device|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
79841487|NCT00955695|Radiation|whole-brain radiation therapy|
79539447|NCT01469884|Drug|Tacrolimus|Trough level should be between 5 and 10ng/ml.
79539448|NCT01469286|Device|TEA|Electroacupuncture at ST36
79539449|NCT01469286|Device|Sham-TEA|Electroacupuncture at sham-points
79697193|NCT00564174|Drug|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
79697194|NCT01878461|Drug|Vehicle|
79697195|NCT01878461|Drug|M518101|
79697196|NCT01163266|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
79303664|NCT00702923|Drug|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
79303665|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
79303666|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
79697197|NCT01163266|Drug|Placebo|Vortioxetine placebo-matching capsules
79841488|NCT00955773|Drug|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
79841489|NCT00549549|Drug|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
79841490|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
79539450|NCT01469910|Drug|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
79697198|NCT04629456|Other|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
80011241|NCT03560622|Device|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
79697199|NCT04629456|Other|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
79697200|NCT01873703|Drug|pracinostat|Histone deacetylase inhibitor (HDACi)
79697201|NCT01873703|Drug|Placebo|Placebo
79384791|NCT03267420|Diagnostic Test|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
79384792|NCT05219058|Procedure|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
79697202|NCT01873703|Drug|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
79697203|NCT04629261|Behavioral|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
79697204|NCT04629183|Other|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
80011242|NCT03534674|Dietary Supplement|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
80011243|NCT02063334|Dietary Supplement|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
79384793|NCT05219058|Procedure|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
79539451|NCT01469910|Drug|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
79697205|NCT01870505|Drug|BYL719|
79697206|NCT01870505|Drug|Letrozole|
79697207|NCT01870505|Drug|Exemestane|
79697208|NCT04629612|Procedure|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
79697209|NCT01868516|Drug|dexmecamylamine|
80011244|NCT02063334|Dietary Supplement|Placebo|
80011245|NCT02031068|Behavioral|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program~A physiotherapist will supervise the rehabilitation."
80011246|NCT02031068|Behavioral|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
79539452|NCT01469923|Drug|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
79539453|NCT01469923|Drug|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
79539454|NCT01469936|Dietary Supplement|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~First Week of intervention : 1/2 stick per day~Second to 5th Week : 1 stick per day"
79539455|NCT01469936|Dietary Supplement|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~First Week : 1/2 stick per day~Second to 5th Week : 1 stick per day"
79697210|NCT01868516|Drug|Placebo|
79697211|NCT00564213|Drug|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
79697212|NCT01861847|Drug|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
79697213|NCT01861847|Drug|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
79697214|NCT00564252|Drug|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
79539456|NCT01469949|Other|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
79697215|NCT04629144|Drug|Belimumab|"Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~60 mg/day week (W)0-W4,~40 mg/day W4-W6~30 mg/day W6-W8,~20 mg/day W8-W10,~15 mg/day W10-W12,~10 mg/day W12-W14,~7.5 mg/day W14-W16,~5 mg/day W16-W18~2.5mg/day W18-W20.~Stopping glucocorticoid therapy at W20 At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
79697216|NCT04629144|Drug|Placebo|"Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~60 mg/day week (W)0-W4,~40 mg/day W4-W6~30 mg/day W6-W8,~20 mg/day W8-W10,~15 mg/day W10-W12,~10 mg/day W12-W14,~7.5 mg/day W14-W16,~5 mg/day W16-W18~2.5mg/day W18-W20.~Stopping glucocorticoid therapy at W20 At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
79697217|NCT01855880|Biological|AbGn-168H|
80011247|NCT02194946|Drug|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
80011248|NCT02194946|Drug|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
79245867|NCT05306509|Behavioral|NiCE|Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
79245868|NCT05306509|Other|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
79245869|NCT05296980|Behavioral|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
79245870|NCT05296980|Behavioral|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
79245871|NCT05295927|Drug|EPI-7386|EPI-7386 will be administered orally once daily.
79245872|NCT05295927|Drug|Abiraterone Acetate|Abiraterone Acetate will be administered orally once daily.
79245873|NCT05295927|Drug|Prednisone or Prednisolone|Prednisone or Prednisolone will be administered orally twice daily.
79245874|NCT05295927|Drug|Apalutamide|Apalutamide will be administered orally once daily.
79245875|NCT05293002|Device|Restorer Iliac Stent System|Not applicable (only one intervention)
79245876|NCT05288673|Drug|ALXN1210|ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
79245877|NCT05288673|Drug|Placebo|Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
79245878|NCT05288660|Drug|ALXN1210|All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters [mL]/hour), excluding interruption for safety or technical reason.
79539457|NCT01469975|Drug|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
79539458|NCT01469975|Drug|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
79539459|NCT01469975|Drug|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
79539460|NCT01469988|Drug|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
79697218|NCT01855880|Biological|placebo|
79697219|NCT01851083|Biological|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
79697220|NCT01851083|Other|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
79697221|NCT04609839|Other|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
80011249|NCT02063490|Behavioral|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
80011250|NCT03792438|Diagnostic Test|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
80011251|NCT02062866|Procedure|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
79245879|NCT05288660|Drug|Placebo|All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
79245880|NCT05287243|Other|inspiratory muscle training|Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
79539461|NCT01470040|Drug|discontinuation of aspirin therapy|discontinuation of aspirin therapy
80011252|NCT02062866|Procedure|Second Intent|The wound will not be sutured, and allowed to heal on its own.
80011253|NCT02195024|Procedure|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
79245881|NCT05279560|Biological|autologous PRP (platelet rich plasma)|The required volume of PRP will be extracted from 60 ml of the patient's peripheral blood. Injecting PRP into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. After centrifugation of the whole blood, 5ml PRP will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
79384794|NCT05219058|Procedure|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
79539462|NCT01470040|Drug|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
79539463|NCT01470053|Drug|mometasone furoate plus azelastine HCl|
79539464|NCT01470053|Drug|mometasone furoate|
79539465|NCT01470053|Drug|azelastine HCl|
79384795|NCT03262818|Device|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
79697222|NCT01850381|Drug|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
79697223|NCT01850381|Drug|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
79697224|NCT00555074|Drug|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
79697225|NCT00555074|Drug|Placebo|Placebo, BID, oral route during 6 weeks
79697226|NCT04609488|Diagnostic Test|Surfactant assessment|To determine surfactant levels in lung fluid
80011254|NCT02195102|Device|Transcatheter aortic valve Replacement|
80011255|NCT03533972|Drug|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
80011256|NCT03533972|Other|Placebo|placebo capsules given twice daily after meals for 1 month
80011257|NCT02916927|Drug|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
80011258|NCT02916927|Drug|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
80011259|NCT02197598|Drug|nalmefene|
80011260|NCT02196662|Drug|IBD98-M:|single adiministration
80011261|NCT02196662|Drug|IBD98-M without HA|single adiministration
79384796|NCT03262818|Device|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
79384797|NCT03263052|Drug|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
79384798|NCT03259386|Device|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
79384799|NCT03267030|Drug|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
79384800|NCT03259230|Other|Blood Draws|
79384801|NCT03259230|Other|Data Collection|
79539466|NCT01470092|Drug|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
80011262|NCT02196662|Drug|Delzicol|single adiministration
80011263|NCT02195180|Drug|ERY001|
80011264|NCT02195180|Drug|Gemcitabine|
79539467|NCT01470157|Drug|Ketamine|5mg/kg as oral suspension
79539468|NCT01470157|Drug|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
80011265|NCT02195180|Drug|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
80011266|NCT03672591|Other|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
79697227|NCT04609605|Device|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
79245882|NCT05279560|Other|Saline solution (NaCL) Injection|Injecting NaCL into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. NaCL will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
79697228|NCT01847573|Drug|HT-100|May be administered in either fed or fasted state
79384802|NCT03262428|Other|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
79384803|NCT03259152|Drug|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
79697229|NCT01846793|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
79697230|NCT04609254|Drug|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
79697231|NCT04609254|Drug|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
79697232|NCT04609254|Drug|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
79841491|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
79539469|NCT01470209|Drug|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
79841492|NCT00549549|Drug|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
79245883|NCT05269472|Procedure|Trigeminal Electrophysiology|This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
79245884|NCT05266365|Other|Video-based exercise program|"A 8-week exercise program used in conservative treatment of degenerative meniscus tear will be performed.~A video record will be prepared by the physiotherapist to the patients where each exercise will be described in detail.~This video record will be watched in the clinic and the patients will do video-baed exercises by following th instructions in the video.~The patient will be performed the exercises without any the verbal and visual commands of the physiotherapist, who is in the clinic."
79539470|NCT01470209|Drug|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
79697233|NCT01846481|Drug|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
79697234|NCT01846481|Drug|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
79697235|NCT01846481|Drug|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
79697236|NCT01846481|Drug|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
79697237|NCT04609293|Combination Product|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
79697238|NCT01844180|Drug|ONO-2952|
79697239|NCT01844180|Drug|ONO-2952 Matching Placebo|
79841493|NCT00270205|Biological|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
79841494|NCT00270205|Biological|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
79841495|NCT00270205|Biological|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
79841496|NCT00955851|Other|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
79841497|NCT00949767|Drug|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
79841498|NCT00949767|Drug|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
79841499|NCT00949767|Drug|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
79841500|NCT00949767|Drug|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
79841501|NCT00949767|Drug|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
79841502|NCT00949767|Drug|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
79841503|NCT00949767|Drug|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
79841504|NCT00949767|Drug|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
79841505|NCT05299827|Other|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
79841506|NCT00949845|Drug|Endotoxin|
79697240|NCT04609059|Drug|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
79697241|NCT04609059|Drug|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
79697242|NCT04676750|Behavioral|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
79539471|NCT01470222|Other|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
79697243|NCT04601298|Other||
79539472|NCT01470287|Biological|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
79697244|NCT04601181|Biological|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10^6 CAR-T cells per kg body weight.~Intervention study"
79697245|NCT04676828|Diagnostic Test|Single-photon-emission CT scan|SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
79697246|NCT04676789|Drug|Pegaspargase|Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
79245885|NCT05266365|Other|Standard exercise program|"A 8-week exercise program used in conservative treatment of degenerative meniscus tear will be performed.~The patients will do exercises under control of the physiotherapist in the clinic.~The patient will be performed the exercises with the verbal and visual commands of the physiotherapist."
79384804|NCT03262506|Other|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
79384805|NCT02456142|Drug|caudal bupivacaine|
79697247|NCT04676789|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
79697248|NCT04676789|Radiation|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
79245886|NCT05266352|Other|Supervised exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises under control of the physiotherapist in the clinic."
79384806|NCT02456142|Drug|intravenous morphine|
79841507|NCT05206929|Other|Self Managed Care|Self Managed Care
79245887|NCT05266352|Diagnostic Test|Home exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises at home. Patients will visit the clinic every 2 weeks and progression of exercise program will be made."
79539473|NCT01470300|Other|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit & vegetables, decreased fat, added plain water).
79539474|NCT01470313|Drug|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
79539475|NCT01470313|Drug|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
79697249|NCT01811576|Drug|TV-1106|
79697250|NCT01811576|Drug|Recombinant human growth hormone|Subcutaneous once daily
79384807|NCT03262740|Drug|BMS-986195|Oral administration of specified dose on specified days
79697251|NCT04609371|Behavioral|self-care tools|self-care tools only
79697252|NCT04609371|Behavioral|lay telephone coaching|coaching
79697253|NCT01810484|Device|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
79245888|NCT05257577|Procedure|Breast conserving surgery|Patients receive standard of care breast surgery and subsequent whole breast irradiation
79245889|NCT05257460|Device|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
79245890|NCT05257460|Device|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
79384808|NCT03262740|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
79539476|NCT01470326|Drug|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
79697254|NCT01810484|Device|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
79841508|NCT00622284|Drug|Placebo identical to BI 1356 5mg|Placebo tablet once daily
79841509|NCT00622284|Drug|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
79697255|NCT01810484|Device|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
79245891|NCT05254626|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
79697256|NCT04600830|Procedure|Dry needling|Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
79841510|NCT00622284|Drug|BI 1356|5mg, once daily in the morning for 104 weeks
79539477|NCT01470339|Drug|duloxetine|duloxetine 60mg once a day for 5 weeks
79539478|NCT01470352|Drug|Doluxetine|30 mg/d
79539479|NCT01470352|Drug|Placebo|suger pill 30mg/d
79697257|NCT04600869|Other|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
79697258|NCT01804829|Biological|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
79245892|NCT05254626|Drug|Pioglitazone 30 mg|Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
79245893|NCT05253196|Device|Use of the foley catheter assistive device|All participants will use the foley catheter assistive device when performing their daily enema
79697259|NCT00565422|Drug|Escitalopram|10 mg/day
79841511|NCT00622284|Drug|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
79245894|NCT05252039|Behavioral|Goals in Focus|"Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training."
79384809|NCT03258918|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
79539480|NCT01470365|Procedure|quality-of-life assessment|Ancillary studies
79539481|NCT01470365|Radiation|intensity-modulated radiation therapy|Undergo IMRT
79539482|NCT01470365|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
79539483|NCT01470378|Procedure|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
79539484|NCT01470391|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
79539485|NCT01470391|Procedure|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
79539486|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
79539487|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
79539488|NCT01470456|Drug|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
79539489|NCT01470456|Drug|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
79539490|NCT01470482|Procedure|No use of tourniquet|Tourniquet is not applied i 25 pts
79539491|NCT01470482|Procedure|Tourniquet|Use of tourniquet
79539492|NCT01470495|Other|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
79539493|NCT01470495|Other|RFA|treat Recurrent HCC with RFA
79539494|NCT01470508|Behavioral|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
79539495|NCT01470508|Behavioral|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
79539496|NCT01470521|Biological|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
79697260|NCT01804088|Device|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
79697261|NCT04608747|Other|Tahini|Fifty grams of tahini were consumed by 20 healthy males
79841512|NCT00269113|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
79841513|NCT00269113|Drug|Standard chemotherapy|As prescribed
79539497|NCT01470521|Biological|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
79539498|NCT01470534|Dietary Supplement|carbohydrate drink|carbohydrate drink
79539499|NCT01470534|Procedure|Muscle biopsy|Open muscle biopsy
79539500|NCT01470534|Procedure|Blood sampling|Venopuncture
79539501|NCT01470534|Dietary Supplement|Placebo|
79841514|NCT04010487|Genetic|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
79841515|NCT00949923|Dietary Supplement|tea capsule|3 tea capsules daily for 3 weeks
79539502|NCT01470560|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
79245895|NCT05251311|Behavioral|Social Risk Screening Tool|"Investigators will use an adapted version of the evidence-based WE CARE screening tool, which assesses need in the 5 domains most frequently requested by our patient population: housing, transportation, child care, food security, and household heat and electricity. This tool was selected as it is evidence-based, takes fewer than 5 minutes to complete, is written at a 3rd grade reading level, and allows for differentiation between social risk and caregiver desire for assistance, as well as areas of emergency need."
79539503|NCT01470560|Behavioral|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
79841516|NCT01069159|Drug|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
79841517|NCT01069159|Drug|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
79841518|NCT03975205|Drug|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
79539504|NCT01470573|Procedure|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
79539505|NCT01470586|Procedure|Surgery for colorectal cancer|Surgical resection of colorectal cancer
79245896|NCT05251311|Other|Electronic Resource Map|All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha
79245897|NCT05246085|Diagnostic Test|Cortisol level|Cortisol levels will be checked in both groups to screen for adrenal insufficiency.
79245898|NCT05241925|Other|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
79245899|NCT05216653|Drug|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
79245900|NCT05216653|Drug|Oxaliplatin|130mg/m2，ivgtt，d1
79245901|NCT05216653|Drug|Capecitabine|1000mg/m2，po，bid，d1-14
79245902|NCT05216653|Radiation|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
79245903|NCT05216653|Procedure|TME surgery, total mesorectal excision|The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
79539506|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
79245904|NCT05211791|Procedure|erector spinae block|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
79539507|NCT01470690|Drug|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
79539508|NCT01470690|Drug|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
79539509|NCT01470703|Device|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure <25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level <25 cm H2O and low pressure level ≥10 cm H2O
79539510|NCT01470703|Other|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 <80% for >6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
79539511|NCT01470729|Other|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
79245905|NCT05211791|Procedure|paravertebral block anesthesia|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
79539512|NCT01470742|Drug|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
79539513|NCT01470742|Drug|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
79841519|NCT01325779|Drug|heparin|subcutaneous heparin 5000 units every 8 hours
79841520|NCT01325779|Drug|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
79841521|NCT05170659|Drug|Relatlimab|
79841522|NCT05352165|Drug|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
79697262|NCT01802723|Drug|Drug: salmeterol xinafoate|
79697263|NCT01802723|Drug|Drug: Placebo|
79697264|NCT04600908|Other|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
79245906|NCT05211791|Procedure|Thoracic epidural anesthesia|insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
79245907|NCT05181280|Other|Intervention Group|"Exposure session will consist of 15 social media ideal body message posts."
79245908|NCT05181280|Other|Control Group|Exposure will consist of 15 social media posts on infant feeding tips.
79245909|NCT05153720|Procedure|Erector spinae plane block|Ultrasound guided erector spinae plane block
79245910|NCT05153720|Procedure|Caudal block|Ultrasound guided caudal block
79841523|NCT05352165|Drug|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
79245911|NCT05151094|Other|Observation|Observation of clinical outcomes and comparison to non-treated patients
79245912|NCT05150587|Drug|Rifaximin|Rifaximin tablets
79245913|NCT05150587|Drug|Placebo|Placebo tablets
79245914|NCT05148468|Device|Active spinal cord stimulation|Spinal cord stimulation is acomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.
79384810|NCT05234814|Other|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy [6], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
79384811|NCT05234814|Other|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy [6], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
79539514|NCT01470768|Other|Amino Acid-based Formula with high DHA and ARA|
79539515|NCT01470768|Other|Amino Acid-based Formula with lower DHA and ARA|
79539516|NCT01470794|Biological|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
79539517|NCT01470794|Drug|Toca FC|
79539518|NCT01470807|Device|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
79697265|NCT01789736|Drug|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
79697266|NCT01789736|Drug|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
79697267|NCT01789736|Drug|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
79697268|NCT04600947|Drug|LP002|10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
79245915|NCT05148468|Device|Sham spinal cord stimulation|Spinal cord stimulation is acomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
79245916|NCT05143229|Drug|Alpelisib|PI3K inhibitor
79245917|NCT05143229|Drug|Sacituzumab govitecan|Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
79245918|NCT05136742|Other|aerobic exercise and diet program|It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression
79245919|NCT05136742|Other|diet program|balanced restricted diet
79245920|NCT05124522|Behavioral|MSPA eClass|An 8-week MS-HAPA Internet-based intervention
79245921|NCT05120596|Drug|Pembrolizumab+T3P-Y058-739|intravenous infusion or intratumoural injection
79245922|NCT05120596|Drug|T3P-Y058-739 (IV)|Intravenous infusion
79697269|NCT01789268|Device|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
79697270|NCT00564330|Drug|Esomeprazole|20mg bid
79697271|NCT00564330|Drug|Placebo|Placebo bid
79697272|NCT01783808|Other|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
79697273|NCT04600635|Procedure|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
79841524|NCT05352165|Drug|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
79841525|NCT05352165|Drug|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
79841526|NCT05352165|Drug|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
79245923|NCT05120596|Drug|T3P-Y058-739 (IT)|Intratumoral use
79245924|NCT05119673|Other|bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®|Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
79245925|NCT05112783|Device|Henan Tuoren Endotracheal Tube|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
79245926|NCT05112783|Device|Smiths Portex Tracheal Tubes|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
79697274|NCT00564369|Other|CDC HIV testing recommendations|Current vs. prior CDC recommendations
79697275|NCT01779947|Drug|Estradiol Vaginal Tablets 10 mcg|
79697276|NCT01779947|Drug|placebo|
79697277|NCT00564408|Drug|Carbachol|3 microgram per kg bodyweight infused intravenously
79697278|NCT01773785|Drug|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
79697279|NCT01773785|Drug|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
79841527|NCT05352165|Drug|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
80011267|NCT03623529|Drug|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
79245927|NCT05099055|Drug|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
79245928|NCT05099055|Drug|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
79384812|NCT03266718|Behavioral|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
79384813|NCT03266562|Diagnostic Test|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
79384814|NCT03266562|Diagnostic Test|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
79697280|NCT04608864|Procedure|varicocelectomy|microsurgical subinguinal varicocelectomy
79697281|NCT01758458|Biological|Aldesleukin|Given SC
79841528|NCT02548260|Device|Syndactyly without compression|three week relative immobilization by syndactyly
79841529|NCT02548260|Device|Syndactyly with compression|three week relative immobilization by syndactyly and compression
79841530|NCT02548260|Device|Rigid splint without compression|three week rigid immobilization by splint
79841531|NCT02548260|Device|Rigid splint with compression|three week rigid immobilization by splint and compression
79841532|NCT00291187|Drug|20 mg VEC-162|20 mg VEC-162
79245929|NCT05042310|Drug|LY3541860|Administered either IV or SC.
79245930|NCT05042310|Drug|Placebo|Administered either IV or SC.
79245931|NCT05041959|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours
79245932|NCT05041959|Other|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
79245933|NCT05024344|Procedure|Erector Spinae Plane Block|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
79384815|NCT03258840|Dietary Supplement|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
79384816|NCT03258840|Dietary Supplement|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
79384817|NCT03266796|Behavioral|goal setting process|goal setting process during the first consultation
79384818|NCT03266406|Drug|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
79697282|NCT01758458|Other|Laboratory Biomarker Analysis|Correlative studies
79697283|NCT01758458|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
79697284|NCT01758458|Radiation|Radiation Therapy|Undergo radiation therapy
79697285|NCT01758458|Biological|Recombinant Interferon Beta|Given intralesionally
79697286|NCT04608981|Drug|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
79697287|NCT04608981|Drug|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
79697288|NCT04608981|Drug|Placebo|Starch
79697289|NCT04600557|Behavioral|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
79697290|NCT04600557|Behavioral|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
79841533|NCT00291187|Drug|50 mg VEC-162|50 mg VEC-162
79841534|NCT00291187|Drug|100 mg VEC-162|100 mg VEC-162
79841535|NCT00291187|Drug|Placebo|Placebo
79841536|NCT00956163|Procedure|magnetic resonance imaging|Undergo whole-body MRI
79841537|NCT00956163|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
79841538|NCT00956163|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
79841539|NCT00956163|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
80011268|NCT03623529|Drug|Placebo|Placebo Arm
80011269|NCT02197676|Drug|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
80011270|NCT02916693|Drug|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
79245934|NCT05024344|Drug|Ropivacaine 0.5% Injectable Solution|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
79245935|NCT05024344|Drug|Dexamethasone|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
79539519|NCT01470820|Other|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
79245936|NCT05008900|Radiation|Salvage radiotherapy|Standard of care salvage radiotherapy to the prostate bed which may include the lymph nodes.
79539520|NCT01470833|Procedure|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
79539521|NCT01470846|Procedure|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
79245937|NCT05006391|Other|Tele-Coaching (Online) Community-Based Exercise|"PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training ~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes ~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout."
79539522|NCT01470846|Procedure|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
79245938|NCT05002842|Behavioral|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
79245939|NCT05000203|Behavioral|Online prenatal specific education|"The sessions will start around 30 weeks of gestation with the intention that around 35-37 weeks all pregnant women have had the opportunity to attend all the sessions.~Five specific online group sessions have been established for the fear of childbirth, each divided into three parts, and lasting approximately 60 minutes. In the first part, the aspects that are most relevant according to the reported experience of women with fear of childbirth will be discuss. In a second part, videos will be displayed starring midwives who will collaborate in specific intrapartum support with the aim of presenting the personnel involved in the care of women during delivery and immediate postpartum, and where the procedures and options available in the obstetric service of HUMIC. The session will end with brief therapy tasks. After each session, written documentation on the topics discussed will be made available to the participants."
79245940|NCT05000203|Behavioral|Intrapartum specific support|"At first, a group of expert midwives will be formed in support of pregnant women with fear of childbirth. The objective is that three midwives from each work group shift will include the women from the experimental group in the intrapartum support team. The working group will receive a seminar given by the researcher where the study protocol and an update on fear of childbirth will be explained, which will include information on: concept and prevalence, risk factors, consequences, diagnosis and treatment.~For the follow-up of the participants, an instant messaging group will be formed where the collaborating midwives and the main researcher will be able to find out the existence of a participant within the emergency area or in the maternity ward, facilitating continued care in the changes of guard"
79303667|NCT00702923|Drug|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
79384819|NCT03258684|Drug|Hydrocortisone, Vitamin C, and Thiamine|Intervention
79384820|NCT03258684|Other|Normal saline|Placebo
79384821|NCT02456766|Device|FibroTouch|
79384822|NCT02456766|Procedure|Liver Biopsy|
79384823|NCT03262272|Device|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
79697291|NCT04600557|Behavioral|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
79841540|NCT00956163|Radiation|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
80011271|NCT02195336|Device|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
79303668|NCT05294055|Drug|Etoposide|Etoposide 1.5-1.8g/m2, single dose
79303669|NCT05294055|Drug|Cyclophosphamide|Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
79303670|NCT05294055|Drug|Mecapegfilgrastim, day 2|Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
79303671|NCT05294055|Drug|Mecapegfilgrastim, day 5|Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
79384824|NCT03262272|Device|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
79384825|NCT03262272|Device|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
79384826|NCT03262272|Device|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
79384827|NCT03258528|Behavioral|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
79245941|NCT05000203|Behavioral|Prenatal usual education|The participants in this group will follow the development of the usual interventions by midwives and obstetricians according to the established protocol for monitoring the pregnancy and / or by the private care system, as well as additional consultations for complications in pregnancy or consultations on demand that are considered necessary Group maternal education is offered in primary care center starting at week 28 of gestation. Although its content is supported by the Affective-Sexual and Reproductive Health Care Program, midwives are responsible for preparing the sessions according to their criteria to adapt them to the population. In addition to group interventions, pregnant women in the intervention environment also receive individualized educational attention in follow-up and control visits. After delivery, an inquiry will be made about the maternal education received by pregnant women during their current pregnancy.
80011272|NCT02195336|Drug|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
79245942|NCT05000203|Behavioral|Intrapartum usual support|A routine detection of fear of childbirth or a protocolized practice for this problem is currently not contemplated in the trial setting. The different professionals who pay their attention to the pregnant woman can detect the fear of childbirth thanks to their experience or different indicators such as the expression of fears by the pregnant woman, being able to offer individualized attention and resources for the approach, according to their awareness of the problem .
79245943|NCT04997304|Combination Product|AirDuo Digihaler|"Patients will receive the AirDuo® Digihaler™ at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis."
79303672|NCT03378219|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:injection Route of administration: subcutaneous
79384828|NCT03262350|Behavioral|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
79384829|NCT03266250|Procedure|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
79539523|NCT01470898|Device|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
79539524|NCT01470911|Drug|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
79539525|NCT01470911|Drug|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
79539526|NCT01470937|Drug|Acarbose|acarbose 100 mg PO once daily
79539527|NCT01470937|Drug|Placebo|acarbose placebo
79539528|NCT01470950|Procedure|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
79539529|NCT01470963|Other|Implementation of referral template|Implementation of referral template at the GP office
79539530|NCT01470976|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~The final step will be red blood transfusion to reach a hematocrit higher than 28%."
79539531|NCT01470976|Other|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
79539532|NCT01471002|Device|Galil Medical patented 17G Cryoablation Needles|
79539533|NCT01471067|Drug|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
79841541|NCT00956163|Other|laboratory biomarker analysis|Correlative studies
80011273|NCT02195336|Drug|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
80011274|NCT03679065|Drug|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
80011275|NCT03679065|Drug|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
80011276|NCT03679065|Drug|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
79539534|NCT01471067|Drug|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
80011277|NCT02196740|Drug|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
80011278|NCT02196740|Drug|creosote|Pulp removal,Root canal irrigation and disinfection
80011279|NCT02197754|Other|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
80011280|NCT02195492|Drug|Synvisc®|
80011281|NCT02195570|Other|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
80011282|NCT02195570|Behavioral|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
80011283|NCT03678987|Diagnostic Test|P-MPA concentration|We will calculate AUC_0-12 of MPA based on 4 measurements of P-MPA
80011284|NCT03678987|Drug|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
80011285|NCT02197832|Procedure|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
80011286|NCT02197832|Procedure|control procedure|Using pipelle catheter without entering the uterine cavity.
80011287|NCT02197832|Device|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
80011288|NCT03672513|Dietary Supplement|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
79245944|NCT04997304|Combination Product|ProAir Digihaler|Patients will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
79245945|NCT04991324|Drug|Vitamin D3|24,000 IU cholecalciferol
79245946|NCT04984616|Drug|40 mg Atorvastatin/day for 120 days P.O.|Oral administration of Atorvastatin 40 mg/daily for 120 days
79245947|NCT04984616|Drug|Atorvastatin 80|Oral administration of Atorvastatin 80 mg/daily for 120 days
79245948|NCT04984616|Drug|Placebo|Oral administration of Placebo daily for 120 days
79384830|NCT03258372|Drug|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
79539535|NCT01471067|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
79539536|NCT01471067|Drug|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
79539537|NCT01471067|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
79697292|NCT04600557|Behavioral|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
80011289|NCT03672513|Dietary Supplement|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
80011290|NCT03672513|Dietary Supplement|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
79245949|NCT04980521|Other|The radon app|Participants will be asked to use the radon app.
79245950|NCT04980521|Other|Print brochure|Participants will receive print brochures.
79245951|NCT04979871|Procedure|Venous bleeding|Blood samples collected 5 times with approx. 2-4 weeks interval
80011291|NCT02195648|Other|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
80011292|NCT02919345|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
80011293|NCT02919345|Drug|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
80011294|NCT02195726|Procedure|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
80011295|NCT02195726|Procedure|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
80011296|NCT02919189|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
79539538|NCT01471067|Drug|Rituximab|375 mg/m^2 by vein on Day -10 for B cell malignancy.
79841542|NCT04016766|Behavioral|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
80011297|NCT02195804|Drug|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
80011298|NCT02195804|Drug|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
79539539|NCT01471067|Drug|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
79539540|NCT01471067|Drug|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
79245952|NCT04966481|Drug|Palbociclib|Administered on an outpatient basis
80011299|NCT02195804|Drug|Ranitidine hydrochloride|
79384831|NCT03258450|Behavioral|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
79697293|NCT01737905|Drug|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
80011300|NCT03672435|Drug|Topical Solution|proparacaine 0.5% eye drop
80011301|NCT03534128|Other|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
80011302|NCT03674463|Drug|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
80011303|NCT03674385|Dietary Supplement|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
80011304|NCT03674385|Drug|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
79384832|NCT03266328|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
79384833|NCT02456454|Drug|Risperidone|Liquid risperidone
79384834|NCT02456454|Drug|Valproic Acid|Liquid valproic acid
79384835|NCT02456454|Drug|Placebo|
79384836|NCT02456688|Drug|Imrecoxib|
79697294|NCT01737905|Drug|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
79697295|NCT03454958|Other|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer & skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
79697296|NCT01730768|Drug|AQW051|
80011305|NCT03674385|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
80011306|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
80011307|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
79245953|NCT04966481|Drug|Cetuximab|Given intravenously over approximately 60 minutes
79303673|NCT04983147|Other|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
79384837|NCT03258294|Drug|Melatonin(Circadin®)|
79384838|NCT03258294|Drug|Placebo Oral Tablet|
79384839|NCT03261648|Other|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
79384840|NCT03261648|Other|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
79384841|NCT03258216|Diagnostic Test|panendoscopy|panendoscopy
79384842|NCT03258216|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
79539541|NCT01471067|Drug|Clofarabine|30 mg/m^2 IV Day -7 to Day -4;
79539542|NCT01471067|Radiation|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
79539543|NCT01471080|Procedure|RFA|using RFA to treat cavernous hemangiomas
79539544|NCT01471080|Procedure|hepatectomy|using hepatectomy to treat cavernous hemangiomas
79697297|NCT01730768|Drug|Placebo|
79849001|NCT05660525|Behavioral|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
79697298|NCT04600245|Procedure|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
79697299|NCT04608708|Other|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
79384843|NCT03265704|Other|AGA - Control group|Data processing from Patient Medical Files
79697300|NCT01730027|Drug|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
79697301|NCT01730027|Drug|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
79841543|NCT00839046|Behavioral|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
79697302|NCT01730027|Drug|montelukast|montelukast for 12 weeks
79539545|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
79697303|NCT04600284|Drug|AD-2101|AD-2101 16/5mg
79384844|NCT03265704|Other|SGA - Control group|Data processing from Patient Medical Files
79841544|NCT00839046|Other|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
79384845|NCT03265704|Other|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
79384846|NCT03265704|Other|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
79539546|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
79539547|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
79384847|NCT03265782|Drug|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
79384848|NCT03265782|Drug|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
79384849|NCT03261726|Device|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
79539548|NCT01471119|Biological|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
79697304|NCT04600284|Drug|AD-2102|AD-2102 25mg
79697305|NCT04600284|Drug|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
79697306|NCT01715012|Biological|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
79697307|NCT01715012|Drug|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
79697308|NCT04600401|Other|Mentis Plus+ (Experimental Group)|"Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work."
79697309|NCT04600440|Biological|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
79697310|NCT00555191|Behavioral|diet restriction|each meal should contain less than 2 gm fructose
79697311|NCT04608669|Drug|Paracetamol|Give paracetamol or placebo and compare temperature
79384850|NCT03798054|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79384851|NCT03798054|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79384852|NCT03798054|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79384853|NCT03798054|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79384854|NCT03798054|Drug|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
79384855|NCT03261882|Other|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
79384856|NCT03265860|Device|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
79539549|NCT01471132|Drug|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
79539550|NCT01471132|Drug|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
79841545|NCT00839046|Other|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
79841546|NCT00956241|Procedure|j-pouch coloanal anastomosis|
79841547|NCT00956241|Procedure|side-to-end coloanal anastomosis|
79841548|NCT00835458|Procedure|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
79841549|NCT00956319|Drug|Zolpidem MR|oral
79841550|NCT00956319|Drug|Estazolam|oral
79841551|NCT02547948|Biological|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
80011308|NCT02574455|Drug|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
79245954|NCT04927533|Other|Ronnie Gardiner Method|"The Ronnie Gardiner Method (RGM), developed in 1993 by Swedish jazz drummer Ronnie Gardiner, is a promising multimodal, music-based intervention with potential to stimulate and improve several cognitive functions, motor skills, reading and speech skills and social interaction. RGM participants are required to follow (what is known as) choreoscores. This is a visual representation of the sequence of movements using four unique symbols. Each symbol represents a body half via color (red = left side, blue = right side) and the use of a body part via shape (the symbols resemble hands or feet). In addition, each movement has a specific name, based on drum sounds, which must be pronounced simultaneously. The exercises are guided by trained 'RGM-practitioners'. The course and difficulty of the session can be adapted in different ways by the RGM Practitioner, according to the capabilities of the participants."
79539551|NCT01471145|Drug|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
80011309|NCT02574455|Drug|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m^2 at North American sites and 1.23 mg/m^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m^2 and 0.67 mg/m^2 for North American and European sites, respectively).
79303674|NCT04983147|Other|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
79303675|NCT05723939|Dietary Supplement|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
79384857|NCT03265470|Drug|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
79384858|NCT03265470|Drug|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
79384859|NCT02456376|Procedure|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
79384860|NCT02456376|Procedure|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
79539552|NCT01471158|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
79841552|NCT00961779|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
79841553|NCT00961779|Drug|Placebo|Normal saline infusion
79303676|NCT05723939|Dietary Supplement|Controls|Intake of placebo capsules or regular chicken meet for three weeks
79384861|NCT02350816|Drug|HGT-1410|HGT-1410 administered according to Patient Group assignment.
79384862|NCT02456298|Behavioral|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
79539553|NCT01471158|Drug|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
79539554|NCT01471184|Device|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
79539555|NCT01471184|Device|Placebo|Placebo Eye Drops/Nasal Spray
79539556|NCT01471210|Drug|Urelumab (BMS-663513)|
79697312|NCT00555230|Drug|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
79697313|NCT00555230|Drug|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
79697314|NCT01711346|Biological|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
79697315|NCT01711346|Biological|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
79697316|NCT01710644|Drug|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
79697317|NCT01710644|Drug|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
79697318|NCT04608942|Device|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
79697319|NCT04608942|Procedure|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
79697320|NCT04600089|Drug|Saline|Saline infusion
79697321|NCT04600089|Drug|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
79245955|NCT04909216|Other|Mindful Attention Workshop|The 90-minute workshop will include a 15-minute break and include up to 15 participants. The workshop will be led by peer support staff, fire department psychologists, and/or fire department doctoral psychology practicum students. Each workshop will be facilitate by up to 3 workshop leaders. The workshop will provide (1) psychoeducation regarding common mental health concerns among firefighters, (2) introduction to the concept of mindful attention, why it is relevant to firefighters, and how it can prevent or decrease mental health symptoms, (3) 5 experiential mindful attention training exercises, and (4) discussion. Workshop co-leaders will teach 5 mindful attention exercises, and firefighters will practice each exercise and then engage in discussion about their experiences and provide feedback regarding the utility of the exercise for them personally and for firefighters, generally.
79245956|NCT04904120|Drug|[203Pb]VMT01|Diagnostic imaging radiopharmaceutical; by intravenous infusion
79245957|NCT04904120|Drug|[68Ga]VMT02|Diagnostic imaging radiopharmaceutical; by intravenous infusion
79245958|NCT04897100|Procedure|Achilles tendon tenotomy|Achilles tendon tenotomy during Ponseti treatment for clubfoot
79539557|NCT01471236|Device|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
79539558|NCT01471236|Procedure|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
79539559|NCT01471262|Procedure|Right hepatectomy|Right liver resection
79539560|NCT01471262|Procedure|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
79539561|NCT01471275|Drug|Metformin|250 mg or 500mg three times a day
79539562|NCT01471275|Drug|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
79697322|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
79697323|NCT01704365|Biological|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
79697324|NCT01704365|Biological|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
79303677|NCT05263869|Drug|MRG002|Administrated intravenously
79303678|NCT03299621|Device|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
79697325|NCT01704365|Biological|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
79303679|NCT03299621|Drug|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
79539563|NCT01471314|Behavioral|Headache day versus non-headache day|
79539564|NCT01471327|Biological|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
79539565|NCT01471327|Other|Placebo|Saline IV, single dose at Day 1
79539566|NCT01471366|Dietary Supplement|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
79539567|NCT01471366|Dietary Supplement|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
79539568|NCT01471366|Dietary Supplement|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
79539569|NCT01471366|Dietary Supplement|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
79697326|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
79697327|NCT01704365|Biological|Placebo|0.5mL IM Injection
79697328|NCT04600011|Other|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
79697329|NCT04600011|Other|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
79697330|NCT01698281|Drug|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
79841554|NCT00835848|Drug|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
79697331|NCT01698281|Drug|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
79697332|NCT01698281|Drug|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
79697333|NCT00565461|Biological|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
79697334|NCT01858883|Drug|itacitinib|
79697335|NCT01858883|Drug|Gemcitabine|
79697336|NCT01858883|Drug|nab-paclitaxel|
79697337|NCT01858883|Drug|filgrastim|
79697338|NCT01697072|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
79697339|NCT01697072|Other|Placebo|Placebo
79697340|NCT01697072|Drug|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
79841555|NCT00835848|Drug|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
79841556|NCT00961857|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
79245959|NCT04877860|Other|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
79539570|NCT01471392|Device|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
79539571|NCT01471418|Drug|PET/CT with 18-FDG|FDG uptake
79539572|NCT01471431|Other|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia <100 for >15 seconds or oxygen saturation by pulse oximetry <85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
79841557|NCT00961857|Drug|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
79539573|NCT01471470|Drug|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
79539574|NCT01471496|Procedure|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
79539575|NCT01471509|Other|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
79539576|NCT01471535|Drug|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
79539577|NCT01471548|Drug|TKI258|
79539578|NCT01471600|Procedure|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
79697341|NCT01697072|Drug|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
79697342|NCT01697072|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine.
79697343|NCT00565500|Drug|celecoxib|celecoxib capsules 200 mg bid for 1 week
79697344|NCT00565500|Drug|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
79697345|NCT00565500|Drug|placebo|placebo capsules tid for 1 week
79697346|NCT04608162|Other|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
79697347|NCT04608162|Other|Exercise Program|Exercise program to facilitate bone health
79697348|NCT04608162|Other|Placebo PEMF|Patients received placebo PEMF
79697349|NCT04608084|Biological|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
79697350|NCT04600050|Other|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
79841558|NCT00961857|Drug|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
79841559|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
79841560|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
79841561|NCT00961857|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
79841562|NCT02547792|Biological|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
80011310|NCT02574455|Drug|Capecitabine|1000 to 1250 mg/m^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
79245960|NCT04877860|Other|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
79303680|NCT03299543|Device|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
80011311|NCT02574455|Drug|Gemcitabine|800 to 1200 mg/m^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
79539579|NCT01471613|Procedure|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
79697351|NCT04600050|Other|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
79841563|NCT02547792|Biological|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
79539580|NCT01471613|Drug|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
79539581|NCT01471613|Biological|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
79539582|NCT01471613|Other|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
79539583|NCT01471652|Drug|Nutraceutical supplements|"CoEnzyme Q10: oral gel capsule bid~Acetyl L-carnitine: oral capsule bid~Alpha Lipoic Acid: oral tablet qd~Docosahexaenoic acid: oral gel capsule bid"
79539584|NCT01471652|Drug|Placebo|"Capsule form to imitate the following nutraceuticals:~Placebo 1: oral gel capsule bid~Placebo 2: oral capsule bid~Placebo 3: oral tablet qd~Placebo 4: oral gel capsule bid"
79697352|NCT01691846|Drug|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
79697353|NCT01691846|Drug|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
79697354|NCT04599543|Drug|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
79697355|NCT01670981|Biological|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
80011312|NCT02574455|Drug|Vinorelbine|25 mg/m^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
80011313|NCT02196896|Other|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
79697356|NCT01670981|Other|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
79697357|NCT01658501|Drug|50 mg PB1023|
79841564|NCT02547792|Other|Placebo Tablets|Enteric coated tablet for oral delivery
79841565|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
79841566|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
80011314|NCT02196896|Other|Information|The patients receive online information about depression once a week for 90 days.
80011315|NCT03533894|Device|colic capsule|colic polyp diagnosis
80011316|NCT02197988|Drug|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
80011317|NCT02197988|Drug|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
79303681|NCT05718167|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
79539585|NCT01471665|Drug|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
79697358|NCT01658501|Drug|70 mg PB1023|
79697359|NCT01658501|Drug|100 mg PB1023|
79697360|NCT01658501|Drug|Placebo (0.9% Sodium Chloride)|
79697361|NCT01658501|Drug|Victoza®|
79697362|NCT01658501|Other|Diet and Exercise|
79697363|NCT01658501|Drug|Metformin|
79697364|NCT01658501|Drug|Sulfonylurea|
79697365|NCT01658501|Drug|Metformin and Sulfonylurea|
79697366|NCT01656239|Drug|fedovapagon 1 mg|
79841567|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
79841568|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
79841569|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
79841570|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
79841571|NCT04009941|Drug|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
79841572|NCT00830466|Drug|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
80011318|NCT03672357|Procedure|Laparoscopic liver resection|Laparoscopic hepatectomy
80011319|NCT03672357|Procedure|Open liver resection|Traditional open hepatectomy
80011320|NCT02795832|Drug|ZPL-5212372 1% w/w Ointment BID|
80011321|NCT02795832|Drug|Placebo Ointment BID|
80011322|NCT02196974|Procedure|cryobiopsy|
80011323|NCT03678909|Procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
80011324|NCT02201030|Biological|NBP606|A single intramuscular injection into the thigh
80011325|NCT02201030|Biological|Prevnar13|A single intramuscular injection into the thigh
80011326|NCT03674073|Biological|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
80011327|NCT03674073|Procedure|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
80011328|NCT02198534|Device|Methodology of visual acuity assessment|
80011329|NCT03678597|Other|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
80011330|NCT02198066|Other|Dry Sterile Dressing|Described in Arm Description.
80011331|NCT02198066|Other|Metallic Silver Dressing|Described in Arm Description.
80011332|NCT02198066|Other|Ionic Silver Dressing|Described in Arm Description.
79697367|NCT01656239|Drug|fedovapagon 2 mg|
79697368|NCT01656239|Drug|fedovapagon 4 mg|
79245961|NCT04877860|Other|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
79245962|NCT04871412|Dietary Supplement|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
79245963|NCT04871412|Dietary Supplement|Coriolus Versicolor|1.5g twice daily for the duration of the study
79697369|NCT01656239|Drug|Placebo ( sugar pill)|
79697370|NCT01651871|Drug|S-555739 Dose 1|
79697371|NCT01651871|Drug|S-555739 Dose 2|
79697372|NCT01651871|Drug|Cetirizine HCl Dose 1|
79697373|NCT01651871|Drug|S-555739 placebo|
79697374|NCT01651871|Drug|Cetirizine HCl placebo|
79697375|NCT01647308|Drug|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
79697376|NCT01647308|Drug|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
79697377|NCT04599582|Device|Hip Arthroplasty|Patients are operated with hip replacement.
79697378|NCT04599738|Other|Wheat muffin|Participants consumed a control muffin made of wheat flour.
80011333|NCT03673995|Dietary Supplement|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
80011334|NCT03673917|Other|Educational video|The educational video on skin cancer for cosmetologists
79245964|NCT04871412|Dietary Supplement|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
79539586|NCT01471665|Drug|Placebo|Placebo will be administered once daily for up to 16 days.
79539587|NCT01471678|Drug|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
79697379|NCT04599738|Other|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
80011335|NCT03673917|Other|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
80011336|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
80011337|NCT01378091|Drug|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
80011338|NCT01378091|Drug|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
80011339|NCT01378091|Drug|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
80011340|NCT02794974|Other|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
80011341|NCT02794974|Other|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
79245965|NCT04871412|Dietary Supplement|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
79245966|NCT04871412|Dietary Supplement|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
79539588|NCT01471678|Drug|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
79539589|NCT01471678|Drug|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
79697380|NCT01643330|Genetic|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10^13 DNase Resistant Particles (DRP) MYDICAR
79697381|NCT01643330|Genetic|Placebo|Single intracoronary infusion
79697382|NCT01642550|Drug|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
79697383|NCT01642550|Drug|Placebo|
79697384|NCT04608123|Other|none (observational study)|DBS
79697385|NCT01641848|Device|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
79697386|NCT04607811|Behavioral|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
79539590|NCT01471704|Drug|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
79697387|NCT00555308|Other|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
80011342|NCT02794974|Other|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
79539591|NCT01471704|Drug|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
79697388|NCT04608006|Drug|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
79697389|NCT01640756|Device|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
79697390|NCT04599621|Diagnostic Test|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
79697391|NCT01636817|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
79697392|NCT01636817|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
79245967|NCT04871412|Dietary Supplement|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
79245968|NCT04871412|Dietary Supplement|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
79245969|NCT04871412|Other|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
79697393|NCT00564525|Drug|Amitriptyline|Medication taken for 4 weeks
79697394|NCT00564525|Drug|Placebo|Medication taken for 4 weeks
79697395|NCT01634087|Drug|Itacitinib|Itacitinib administered orally
79697396|NCT01634087|Drug|Placebo|Placebo administered orally
79841573|NCT04412265|Other|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
79245970|NCT04871412|Other|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
80011343|NCT03673839|Other|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
79245971|NCT04871412|Behavioral|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
79245972|NCT04868877|Drug|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
79245973|NCT04868877|Drug|Osimertinib|Approved, 3rd-generation EGFR-TKI
79245974|NCT04855331|Procedure|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
80011344|NCT03673839|Other|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
80011345|NCT03673839|Other|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
79245975|NCT04855331|Procedure|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
79245976|NCT04843930|Device|AKL-T01|AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
79245977|NCT04840901|Drug|Lebrikizumab|Administered SC.
79245978|NCT04826575|Other|High intensity inspiratory and expiratory muscle training|"Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks."
79384863|NCT02456298|Behavioral|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
79384864|NCT02019940|Drug|Riluzole|
79384865|NCT03258060|Procedure|Temporary pacing study|
79384866|NCT03258060|Radiation|Body Surface Mapping|
79384867|NCT03261258|Other|Questionnaire|
79384868|NCT01967836|Device|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
79384869|NCT01229943|Biological|Bevacizumab|Given IV
79384870|NCT01229943|Drug|Everolimus|Given PO
79384871|NCT01229943|Drug|Octreotide Acetate|Given IM
79539592|NCT01471704|Drug|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
79539593|NCT01471288|Drug|Carum Cravi|40mg/kg of body weight
79539594|NCT01471288|Drug|Placebo|Placebo
79539595|NCT01471717|Drug|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
79539596|NCT01471717|Drug|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
79539597|NCT01471717|Drug|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
80011346|NCT03673839|Other|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
80011347|NCT02201186|Other|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
79697397|NCT03454230|Procedure|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
79697398|NCT01632137|Drug|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
79245979|NCT04818086|Drug|Lemborexant|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
79697399|NCT01632137|Drug|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
79697400|NCT00565539|Drug|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
79539598|NCT01471717|Drug|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
79539599|NCT01471717|Drug|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
79539600|NCT01471717|Drug|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
79539601|NCT01471730|Drug|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 [mm] - MCF [mm]) * body weight [kg] / 140 [m] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
79539602|NCT01471730|Drug|Saline solution|Normal saline will be administered to control patients.
79697401|NCT01626599|Device|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~is not implantable and no surgical procedure is required for a human subject to use the devices;~is not for use in supporting or sustaining a human life; and~is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
79697402|NCT04607694|Radiation|Proton radiotherapy|Proton radiotherapy
79697403|NCT04607694|Radiation|Photon radiotherapy|Photon radiotherapy
79697404|NCT04599699|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
79697405|NCT04599114|Behavioral|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
79697406|NCT04599426|Biological|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15 ."
79697407|NCT04599348|Dietary Supplement|HRG 80 Red Ginseng|A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
80011348|NCT02063568|Drug|Oxytocin|
79245980|NCT04818086|Drug|Placebo|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which matches the intervention drug.
80011349|NCT02257502|Drug|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
80011350|NCT01380119|Biological|V7|experimental arm
80011351|NCT01380119|Other|placebo|placebo pill
80011352|NCT02063646|Dietary Supplement|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
80011353|NCT02063646|Dietary Supplement|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
79245981|NCT04818086|Drug|Buprenorphine-naloxone|Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
79841574|NCT00830544|Drug|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
79841575|NCT00830544|Drug|Chemotherapy|Neoadjuvant chemotherapy
79245982|NCT04801979|Diagnostic Test|Incremental Step Test|"Performance of the incremental step test (number of steps) for the assessment of exercise capacity. The step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
80011354|NCT02198144|Other|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
80011355|NCT03678519|Diagnostic Test|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
80011356|NCT01383941|Drug|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
79245983|NCT04799431|Drug|Neoantigen Vaccine with Poly-ICLC adjuvant|"Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
79245984|NCT04799431|Drug|Retifanlimab|500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
79245985|NCT04798235|Biological|TSHA-101|AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
79539603|NCT01471730|Drug|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds [M1] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
79539604|NCT01471743|Dietary Supplement|Impact Advance Recovery (R)|
79539605|NCT01471743|Dietary Supplement|Ensure Plus (R)|
79539606|NCT01471756|Procedure|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
79697408|NCT01516346|Drug|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
79697409|NCT01516346|Drug|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
79697410|NCT01516346|Drug|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
79697411|NCT04607304|Device|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
80011357|NCT02450123|Drug|sunitinib|
80011358|NCT02063802|Drug|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
80011359|NCT02063802|Dietary Supplement|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
80011360|NCT02063802|Drug|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
79539607|NCT01471769|Behavioral|Pain management video|6-minute video
79539608|NCT01471769|Behavioral|Falls Prevention Video|6-minute video
79539609|NCT01471808|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
79697412|NCT04599387|Other|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
79841576|NCT00830544|Drug|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
79841577|NCT04407897|Radiation|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
79841578|NCT04382235|Device|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
79245986|NCT04792853|Behavioral|Tab-G|Participants receive a tablet preloaded with Tab-G application and an accelerometer.
79539610|NCT01471808|Drug|CSII, Metformin, Pioglitazone|CSII for 2~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
79539611|NCT01471808|Drug|CSII, Sitagliptin|CSII for 2~4 weeks combined with sitagliptin 100mg/d for 3 months
79539612|NCT01471821|Drug|antiretroviral treatment|antiretroviral treatment
79697413|NCT04599387|Other|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
79697414|NCT01303796|Drug|Sapacitabine|Oral sapacitabine capsules
79697415|NCT01303796|Drug|Decitabine|Decitabine intravenous
79697416|NCT04598880|Drug|Polyethylene glycol + ascorbate|Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).
79697417|NCT04598880|Drug|Sodium picosulfate + magnesium citrate|Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.
79697418|NCT04598958|Other|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
79841579|NCT00843570|Drug|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
79539613|NCT01471847|Drug|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
79841580|NCT04010877|Biological|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
79539614|NCT01471847|Drug|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
79539615|NCT01471860|Device|BAROSTIM NEO System|
79539616|NCT01471860|Drug|Medical Management|
79539617|NCT01471873|Procedure|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
79539618|NCT01471886|Drug|Ketorolac Tromethamine|Every 8 hours for 4 days.
79539619|NCT01471886|Drug|Naproxen|Every 8 hours for 4 days.
79539620|NCT01471899|Drug|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
79697419|NCT04607655|Drug|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
80011361|NCT02063802|Behavioral|Healthy habits program|
79539621|NCT01471899|Drug|Naproxen|2 tablets every 8 hours for 4 days
79697420|NCT04607655|Drug|Placebo|Placebo is administered as inhalation once a day
79841581|NCT05169723|Behavioral|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
79841582|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
79841583|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
79841584|NCT05156463|Combination Product|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
79841585|NCT05029869|Diagnostic Test|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
79841586|NCT02547870|Drug|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
79841587|NCT02547870|Drug|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
80011362|NCT03672045|Drug|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
80011363|NCT02198300|Procedure|Coronary angioplasty with stent implantation|
79539622|NCT01471912|Procedure|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
79539623|NCT01471925|Drug|Nexium®|
79697421|NCT04607343|Device|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
79697422|NCT04607265|Diagnostic Test|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
79697423|NCT04598763|Other|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
80011364|NCT02198300|Drug|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
79697424|NCT00564564|Drug|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
79697425|NCT00564564|Drug|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
80011365|NCT03673761|Other|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
80011366|NCT03560232|Drug|Ceftriaxone|See arm description
79539624|NCT01471925|Drug|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
79539625|NCT01471951|Other|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
79539626|NCT01471964|Drug|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
79245987|NCT04785872|Other|Education|NEUMAN SYSTEMS MODEL BASED NURSING APPROACH
79539627|NCT01471977|Other|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
79539628|NCT01471990|Drug|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
79539629|NCT01471990|Drug|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
79539630|NCT01472003|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
79539631|NCT01472003|Drug|ABT-806i|ABT-806i will be administered by intravenous infusion.
79697426|NCT02894138|Drug|alteplase|
79697427|NCT02894138|Drug|Placebo|
79697428|NCT00565656|Drug|BEVACIZUMAB|Administration of Bevacizumab
79697429|NCT02894021|Procedure|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
80011367|NCT03560232|Drug|Ampicillin/sulbactam|See arm description
80011368|NCT03560232|Drug|Piperacillin/tazobactam|See arm description
80011369|NCT03560232|Drug|Cefazolin + Gentamicin|See arm description
79539632|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
79539633|NCT01472016|Drug|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
79539634|NCT01472016|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
80011370|NCT03560232|Drug|Clindamycin + Gentamicin|See arm description
80011371|NCT02196935|Other|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
80016880|NCT03659253|Procedure|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
79245988|NCT04768647|Device|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
79539635|NCT01472016|Drug|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
79539636|NCT01472016|Drug|erlotinib|Erlotinib will be taken orally daily.
79539637|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
79697430|NCT02894021|Procedure|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
79697431|NCT00564603|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
79697432|NCT00564603|Other|0.9% Saline|Saline, in same volume of 2mL
79697433|NCT00565695|Device|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
79697434|NCT02894099|Other|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
79697435|NCT02894099|Other|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
79697436|NCT02894099|Other|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
79697437|NCT02894099|Other|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
79697438|NCT00555347|Drug|Armodafinil|Dosage 150-250 mg
79697439|NCT00555347|Drug|Placebo|Placebo
79697440|NCT00564642|Drug|N Acetylcysteine|1200 mg, BD, 2weeks
79697441|NCT00555386|Dietary Supplement|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
79697442|NCT01580709|Procedure|Multiple brushings|Seven consecutive brush samples for cytology.
80011372|NCT03533192|Behavioral|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
80011373|NCT02201342|Drug|Udenafil|Drug
79245989|NCT04766424|Behavioral|Sleep extension intervention|Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.
79245990|NCT04766424|Behavioral|Health education|Participants will receive 8 weekly health education newsletters delivered via email.
79303682|NCT05718167|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
79384872|NCT02457936|Behavioral|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
79384873|NCT03257982|Procedure|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
79539638|NCT01472029|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
79539639|NCT01472029|Drug|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
79539640|NCT01472042|Other|Banyan Biomarkers|Biomarkers to detect specific proteins.
79539641|NCT01472055|Drug|Fludarabine|"Fludarabine 40 mg/m^2 once a day intravenous administration over 30 min~Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~Population pharmacokinetics analysis~Comparative analysis of population pharmacokinetics in pediatric and adult patients~Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
79384874|NCT02020018|Device|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
79697443|NCT01580709|Procedure|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
79384875|NCT02020018|Other|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
79384876|NCT03265626|Behavioral|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
79384877|NCT03265626|Behavioral|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
79697444|NCT02894294|Other|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine [SP] + Amodiaquine [AQ]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
79539642|NCT01472068|Device|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
79697445|NCT00565890|Drug|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
79841588|NCT02547870|Drug|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
79841589|NCT04251897|Device|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
79841590|NCT00836238|Behavioral|Interview|Physical Function and Symptom Assessment Interviews
80011374|NCT02063958|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
80011375|NCT03560544|Behavioral|Breaking up sitting|"A three-part behaviour change intervention, including:~Supportive organisational culture and knowledge of consequence of prolonged sitting~Environmental Modification~Behavioural Changes"
79245991|NCT04764539|Behavioral|Video Assisted Speech Therapy (VAST)|Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
79245992|NCT04738617|Behavioral|Inter and intra-individual variation in acute responses to two different warm-up types|Comparison of the acute effects of two different warm-up protocols on subsequent performance.
79245993|NCT04737317|Diagnostic Test|ECG, Echo, laboratory tests, CMR, PET-CT, Biopsy|ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging
79384878|NCT03265626|Other|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
79384879|NCT02020252|Behavioral|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
79245994|NCT04736537|Device|4DCT|CT imagining conceptually similar to time-lapse photography.
79245995|NCT04726852|Device|Concurrent comparison|Concurrent comparisons at defined procedure events
79245996|NCT04724668|Dietary Supplement|Melatonin (3hrs before DLMO)|Melatonin 3mg (3hrs before DLMO)
79245997|NCT04724668|Dietary Supplement|Placebo (3hrs before DLMO)|Placebo capsule (3hrs before DLMO)
79384880|NCT03265548|Device|Video Laryngoscope|The use of video laryngoscopy
79384881|NCT03265392|Other|Bread|Serving of wheat bread providing 50 g of carbohydrates
79539643|NCT01472133|Other|Recording of 12 lead ECG|Recording of 12 lead ECG
79539644|NCT01472133|Other|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
79539645|NCT01472133|Other|Recording of chest wall movement|Recording of chest wall movement
79539646|NCT01472133|Other|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
79539647|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
79539648|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
79841591|NCT00836238|Other|Physical Function Tests|3 physical function tests.
79245998|NCT04724668|Device|Morning light version 1|Morning light version
79245999|NCT04724668|Device|Morning light version 2|Morning light version
79303683|NCT05718167|Drug|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
79384882|NCT03265392|Other|Water|250 mL of water
79384883|NCT03265392|Other|Lemon juice|250 mL of lemon juice
79384884|NCT03265392|Other|Tea|250 mL of tea
79384885|NCT03265392|Other|Peas|20 peas
79539649|NCT01472146|Drug|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg [loading dose] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
79697446|NCT02894060|Other|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
79697447|NCT02894216|Procedure|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
79697448|NCT02894255|Device|Coronary artery bypass grafting|
79841592|NCT02547168|Device|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
79841593|NCT04016610|Device|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
79841594|NCT00836316|Drug|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
79697449|NCT02894255|Procedure|Percutaneous coronary intervention|
79539650|NCT01472159|Behavioral|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
79841595|NCT00962169|Other|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
80011376|NCT03963830|Behavioral|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
80011377|NCT02201498|Procedure|Pulpotomies with Formocresol/OZE and Biodentine|
80011378|NCT02061852|Device|Simeox|
80011379|NCT02061852|Procedure|Physiotherapy|
80011380|NCT02201576|Drug|Bortezomib|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
80011381|NCT02201576|Drug|Plasma exchanges and intravenous immunoglobulins|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
80011382|NCT02201654|Other|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
80016881|NCT03659253|Procedure|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
79384886|NCT02020408|Drug|[11C]raclopride|1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
79384887|NCT02020408|Drug|[11C]DASB|BPND of [11C]DASB.
79539651|NCT01472172|Device|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
79246000|NCT04715659|Diagnostic Test|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
79303684|NCT03299465|Behavioral|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
79539652|NCT01472211|Device|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
79539653|NCT01472211|Device|placebo filter|filter purifies water
79697450|NCT00565929|Drug|Placebo|Sterile saline (0.9%).
79303685|NCT03299387|Drug|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
79697451|NCT00565929|Biological|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10^7 or 1X10^8 TCID 50.
79697452|NCT04676516|Drug|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
79697453|NCT04606758|Procedure|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
79697454|NCT04606758|Procedure|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
79697455|NCT04676321|Other|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
79697456|NCT04598568|Device|balanSys UNI|Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
79697457|NCT04607031|Diagnostic Test|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
79384888|NCT02020408|Drug|amphetamine|The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
80016882|NCT03659253|Behavioral|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
79697458|NCT04676165|Device|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~Caregiver connect: Provides patients' caregivers with access to the app.~Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~Other: pill images, daily pill reminders, weekly dosing schedule"
79303686|NCT03299387|Drug|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
79697459|NCT04606953|Behavioral|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
79697460|NCT04675658|Behavioral|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
79384889|NCT03263832|Diagnostic Test|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
79384890|NCT03553524|Other|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
79697461|NCT04675658|Behavioral|CBPA|Classroom Based Physical Activity
79697462|NCT04598490|Device|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
79697463|NCT04598490|Device|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
79697464|NCT04675697|Drug|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
79697465|NCT04606836|Drug|Bupivacaine Hydrochloride|See group descriptions
79697466|NCT04675814|Other|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
79303687|NCT03299153|Other|barberry juice|
79384891|NCT03553524|Other|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
79539654|NCT01472211|Other|disinfection tablets|government promoted tablets disinfect water
79539655|NCT01472237|Other|Nutritional intervention|Modification of diet
79384892|NCT03257904|Procedure|intracranial pressure monitoring|measurement of intracranial pressure
79384893|NCT02352298|Device|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
79539656|NCT01472250|Drug|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
79303688|NCT03068013|Behavioral|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
79384894|NCT02352298|Device|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
79384895|NCT04782843|Other|HEP score assessement|Assessement of the HEP score between 2 physician.
79384896|NCT01219257|Biological|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
79384897|NCT01197027|Behavioral|Standard counseling|Standard HIV counseling
79384898|NCT01895439|Biological|Autologous Mesenchymal Stem Cells|
79539657|NCT01472263|Drug|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
79539658|NCT01472263|Drug|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
79539659|NCT01472276|Behavioral|Web-based program|Provided with the web-based program
79697467|NCT04598256|Procedure|Endoscopic procedure|Esophagogastroscopy and colonoscopy
79697468|NCT01163149|Drug|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
79697469|NCT01163149|Drug|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
80011383|NCT02061930|Procedure|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
79246001|NCT04685772|Drug|Methylprednisolone|"The Methylprednisolone dose pack (Medrol Dose Pack) is pre-packaged with dosing instructions. This dose pack is tapered over 7 days and administration will be the following for all patients:~Day 1 (total 24 milligrams (mg)) - 8mg before breakfast, 4mg after lunch and dinner, and 8mg at bedtime Day 2 (total 20mg) - 4mg before breakfast, after lunch and dinner, and 8mg at bedtime Day 3 (total 16mg) - 4mg before breakfast, lunch, dinner, and at bedtime Day 4 (total 12mg) - 4mg before breakfast, after lunch, and at bedtime Day 5 (total 8mg) - 4mg before breakfast and at bedtime Day 6 (total 4mg) - 4mg before breakfast Day 7 (total 0mg) - Completed"
80011384|NCT03533738|Other|Food sequence 1|Vegetables first then meat & rice together
79539660|NCT01472302|Device|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
79697470|NCT04676126|Dietary Supplement|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
80011385|NCT03533738|Other|Food sequence 2|Meat first then vegetables & rice together
79303689|NCT03068013|Behavioral|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
79697471|NCT04676126|Drug|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
79697472|NCT04676126|Other|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
79384899|NCT04782765|Drug|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
79384900|NCT01615887|Drug|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
80011386|NCT03533738|Other|Food sequence 3|Vegetables first then meat followed by rice
79384901|NCT01615887|Drug|placebo|sugar pill
79384902|NCT04389801|Drug|Desferal 500 MG Injection|iron chelating agent
79384903|NCT04782141|Procedure|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
79539661|NCT01472302|Device|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
79539662|NCT01472315|Drug|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
79697473|NCT04598373|Behavioral|interdisciplinary treatment|Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
80011387|NCT03533738|Other|Food sequence 4|Vegetables first followed by meat and rice together
80011388|NCT03533738|Other|Food sequence 5|Rice first followed by vegetables & meat together
80011389|NCT01377857|Behavioral|Monetary Incentive|$1, $5, or $10 incentive
80011390|NCT01377857|Behavioral|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
80011391|NCT01377857|Behavioral|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
79384904|NCT04782141|Procedure|hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk|motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
79539663|NCT01472315|Drug|Placebo|Placebo pills were taken in same way as active comparator
79539664|NCT01472354|Behavioral|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
79539665|NCT01472393|Dietary Supplement|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
79697474|NCT04675619|Drug|Oral pirfenidone|Treatment
79697475|NCT04675619|Drug|Standard care|Treatment
80011392|NCT02198378|Drug|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
80011393|NCT02198378|Drug|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
80011394|NCT02063100|Drug|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
79697476|NCT04675892|Procedure|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
79697477|NCT04675892|Procedure|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
79697478|NCT04598100|Behavioral|FOCUS-EC|
79246002|NCT04642053|Behavioral|Dynamic Temporal and Tactile Cuing|Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.
79246003|NCT04640337|Other|IPE applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
79539666|NCT01472393|Dietary Supplement|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
79697479|NCT01163032|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
79697480|NCT01163032|Drug|Placebo|Placebo capsules, PO daily for 6 months
79697481|NCT04675736|Procedure|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
79697482|NCT05305300|Biological|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
79697483|NCT05305300|Biological|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
79697484|NCT04606719|Procedure|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
79697485|NCT04187755|Drug|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
79697486|NCT04187755|Drug|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
79697487|NCT00555542|Drug|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
79697488|NCT04606563|Drug|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
79697489|NCT04606563|Drug|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
79539667|NCT01472406|Device|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
79539668|NCT01472406|Device|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
79539669|NCT01472406|Device|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
79697490|NCT04606563|Drug|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
79697491|NCT04606563|Drug|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
79697492|NCT04606563|Drug|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
79697493|NCT04606563|Drug|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
79697494|NCT04606563|Drug|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
79697495|NCT04606563|Drug|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
79697496|NCT02885584|Device|High frequency percussive ventilation|
79697497|NCT00565968|Drug|melphalan|
79697498|NCT00565968|Drug|sorafenib tosylate|
79697499|NCT00565968|Genetic|gene expression analysis|
79697500|NCT00565968|Genetic|protein expression analysis|
79697501|NCT00565968|Genetic|western blotting|
79697502|NCT00565968|Other|pharmacological study|
79697503|NCT01162486|Drug|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
79697504|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
79697505|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
79697506|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
79697507|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
79697508|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
79697509|NCT00555698|Device|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
79539670|NCT01472406|Device|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
80011395|NCT02063100|Drug|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
80011396|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
80011397|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
80011398|NCT02063100|Drug|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
80011399|NCT01377779|Drug|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
80011400|NCT01377779|Drug|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
80011401|NCT02198846|Device|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
80011402|NCT02198846|Drug|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
80011403|NCT01379885|Behavioral|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
80011404|NCT01379885|Behavioral|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
79384905|NCT04782141|Procedure|hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position|In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
79539671|NCT01472406|Device|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
79384906|NCT01189851|Device|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
79384907|NCT01606995|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
79384908|NCT04782453|Behavioral|ToQuit, a technology delivered tobacco cessation intervention|"The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~Psychoeducation about consequences of tobacco use and benefits of quitting;~goal setting;~managing goals and self-monitoring of behavior;~avoidance strategies;~self-awareness and reflection messages;~social and pharmacological support, and help-seeking;~identifying and managing cravings;~relapse prevention strategies."
79539672|NCT01472458|Behavioral|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
79539673|NCT01472484|Other|586/8x87 white|2 x 50 g
79539674|NCT01472484|Other|586/8x87 brown|2 x 50 g
79697510|NCT04314427|Procedure|Roux-en-Y gastric bypass|
79697511|NCT04314427|Procedure|Sleeve gastrectomy|
79697512|NCT04598607|Drug|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
79697513|NCT04598607|Drug|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
80011405|NCT02198924|Drug|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
80011406|NCT02198924|Drug|placebo|control patients are supplied with the corresponding placebo with the same instructions.
79539675|NCT01472484|Other|BAT 881|2 x 50 g
79539676|NCT01472484|Other|586/8|2 x 50 g
79539677|NCT01472497|Drug|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
79539678|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
79697514|NCT02885701|Other|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson & Johnson, New Brunswick, NJ) over the incision.
80011407|NCT02201732|Procedure|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
79697515|NCT02885701|Other|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
79697516|NCT02885701|Other|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
79697517|NCT00555737|Device|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
79697518|NCT01162135|Drug|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
79697519|NCT00555776|Drug|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
79697520|NCT00555776|Drug|placebo|placebo is given with the same definition as Gabapentin
79697521|NCT04675463|Drug|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
79697522|NCT04675463|Drug|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
79384909|NCT04782453|Behavioral|Tobacco quitting helplines|Participants from the control group will be sent the details of other functional tobacco helplines in India.
79697523|NCT04675112|Behavioral|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual [10].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
79697524|NCT01161628|Drug|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
79697525|NCT04598217|Other|anesthesiologist|non-interventional observational
79697526|NCT04675502|Other|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
79697527|NCT04675502|Other|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
79697528|NCT04314505|Drug|Opioid-Sparing Protocol|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
79384910|NCT03548220|Drug|Placebo|Placebo matching AG-348 tablets, administered to maintain the blind.
80011408|NCT02201732|Procedure|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
79246004|NCT04640337|Other|IPE applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie
79246005|NCT04640337|Other|IPE not applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th
79384911|NCT03548220|Drug|AG-348|AG-348 tablets.
79384912|NCT04050969|Procedure|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
79246006|NCT04640337|Other|IPE not applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
79246007|NCT04630015|Other|Survey Administration|Participants will complete study specific survey
79384913|NCT04050969|Procedure|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
79384914|NCT01589211|Behavioral|Brief advice|Brief advice of about 10 min accompanied by self-help material
79697529|NCT04314505|Drug|Opioid-Based Patient Controlled Analgesia|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
79697530|NCT04606641|Other|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
79697531|NCT04606641|Other|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
79697532|NCT02885467|Procedure|Total knee arthroplasty with Saphenous nerve burial|
79841596|NCT00962169|Other|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
80011409|NCT05462093|Device|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
80011410|NCT05462093|Device|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
79246008|NCT04626271|Device|"ACR | U.S. Urine Analysis Test System"|"Each study participant will test their urine sample using the ACR | U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health."
79539679|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
79246009|NCT04626271|Device|URiSCAN Optima Urine Analyzer|"Upon completion of the test using the ACR | U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer."
79246010|NCT04622644|Device|Device: clinical investigation microwave device class IIa not marked CE for stroke detection|Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
79246011|NCT04617080|Procedure|SUPRACOR Regular|SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
79246012|NCT04617080|Procedure|SUPRACOR Strong|SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
79246013|NCT04609189|Drug|Pearlium/EffectiCal|Oral administration of Pearlium/EffectiCal.
79246014|NCT04609189|Drug|Calcium carbonate/vitamin D3|Oral administration of Calcium Carbonate/Vitamin D3
79246015|NCT04604795|Drug|GSK3915393 Capsules|GSK3915393 capsules will be given orally.
79246016|NCT04604795|Drug|GSK3915393 Solution for Infusion|GSK3915393 solution for infusion will be administered intravenously.
79246017|NCT04604795|Drug|Placebo capsules|Placebo matching GSK3915393 capsules will be given orally.
79246018|NCT04604795|Drug|Itraconazole|Participants will be administered with GSK3915393 along with ITZ orally
79246019|NCT04604795|Other|Water|Participants will be administered with GSK3915393 along with water orally
79246020|NCT04604795|Other|Grape fruit juice|Participants will be administered with GSK3915393 along with GFJ orally
79539680|NCT01472536|Behavioral|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
79539681|NCT01472614|Drug|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
79539682|NCT01472627|Procedure|Blood draws|Blood draws
79539683|NCT01472640|Drug|liraglutide|1.8 mg sc QOD
79539684|NCT01472640|Drug|placebo|1 U sc QOD
79697533|NCT02885467|Procedure|Standard total knee arthroplasty|
79697534|NCT02885545|Device|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
79841597|NCT00836394|Device|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
79841598|NCT00843960|Behavioral|behavioral adaptation and symptom management|behavioral adaptation and symptom management
80011411|NCT05462093|Device|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
79539685|NCT01472653|Drug|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
79697535|NCT02885545|Drug|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
79697536|NCT04598412|Other|No intervention|Cross-sectional
79841599|NCT00962325|Behavioral|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
80011412|NCT02201888|Behavioral|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
80011413|NCT02201888|Other|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
79384915|NCT01589211|Behavioral|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
79246021|NCT04587128|Drug|Panitumumab|Epidermal growth factor receptor inhibitor, anti-neoplastic
79246022|NCT04587128|Drug|Cetuximab|Epidermal growth factor receptor inhibitor, anti-neoplastic
79246023|NCT04587128|Drug|Irinotecan|anti-neoplastic, chemotherapy drug
79246024|NCT04578314|Behavioral|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
79384916|NCT01589211|Behavioral|Standard cessation course|Cessation course over 6 dates. Group setting.
79384917|NCT03257670|Drug|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
79539686|NCT01472653|Radiation|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
79697537|NCT04675268|Diagnostic Test|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
79841600|NCT00839202|Other|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
80011414|NCT02201888|Other|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
80011415|NCT02065440|Drug|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
80011416|NCT02065440|Drug|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
79384918|NCT03257670|Device|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
79384919|NCT04781985|Procedure|cystoscopy|extraction of the bladder stone via suprapubic incision
79384920|NCT03265002|Dietary Supplement|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
79384921|NCT03265002|Dietary Supplement|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
79384922|NCT03265002|Dietary Supplement|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
79384923|NCT03265002|Dietary Supplement|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
79539687|NCT01472653|Drug|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
79697538|NCT01161472|Drug|4mg fesoterodine|4mg tablet once daily for 6 days
79697539|NCT01161472|Drug|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
79697540|NCT01161472|Drug|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
79697541|NCT01161472|Drug|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
79841601|NCT00962403|Behavioral|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
79539688|NCT01472666|Dietary Supplement|High content of MC-SFA|12 weeks dietary intervention
79539689|NCT01472666|Dietary Supplement|Whey|12 weeks dietary intervention
79539690|NCT01472666|Dietary Supplement|Low content of MC-SFA|12 weeks dietary intervention
79539691|NCT01472666|Dietary Supplement|Casein|12 weeks dietary intervention
79539692|NCT01472731|Other|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
79539693|NCT01472731|Drug|GC1008|5 mg/kg intravenous use
79539694|NCT01472744|Behavioral|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
79539695|NCT01472744|Behavioral|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
79384924|NCT04754997|Other|Traditional exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
79539696|NCT01472744|Behavioral|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
79697542|NCT04606680|Device|Heat application at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
79539697|NCT01472744|Behavioral|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
79697543|NCT04606680|Device|Medicated plaster at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~Lifestyle modification:It will be performed as the same as the heat application group."
80011417|NCT02202122|Other|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
80011418|NCT02064348|Drug|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
79246025|NCT04578314|Other|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
79384925|NCT04754997|Other|Specific exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
79384926|NCT03257592|Drug|[11C]DPA-713|[11C]DPA-713 PET imaging
80011419|NCT02064348|Drug|placebo|Solution for s.c. injection or tablets for oral administration
80011420|NCT02064348|Drug|moxifloxacin|Tablets for oral administration
80011421|NCT02202200|Drug|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
80011422|NCT02064504|Drug|GSK961081|Dry white to off white powder
80011423|NCT02064504|Drug|Fluticasone furoate|Dry white powder
80011424|NCT03790254|Other|systematic review|
80011425|NCT02202356|Drug|ALS-008176|
80011426|NCT02202356|Drug|Placebo|
80011427|NCT02065674|Drug|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
80011428|NCT03560154|Other|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
80011429|NCT01569425|Other|Dietary intervention|High Calorie breakfast and high calorie dinner
80011430|NCT02199158|Procedure|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
80011431|NCT02067936|Drug|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
79384927|NCT03265236|Diagnostic Test|Anti - modified citrullinate vimentin|patients with early and late RA
79539698|NCT01472770|Drug|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
80011432|NCT02067936|Drug|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
80011433|NCT02067936|Drug|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
80011434|NCT02067936|Drug|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
80011435|NCT05461937|Behavioral|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
80011436|NCT05461937|Behavioral|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
80011437|NCT02916446|Biological|Viaskin Peanut 250 mcg|
79539699|NCT01472783|Drug|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
79697544|NCT04606680|Device|Herb-partitioned moxibustion at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard[18]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~Lifestyle modification:It will be performed as the same as the heat application group."
79841602|NCT05010837|Other|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
79246026|NCT04574466|Behavioral|Problem Management Plus|Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
79246027|NCT04563273|Biological|BCG vaccine 1（0.025mg/0.1ml/person）|Intradermal injection of 0.025mg/0.1ml/person dose BCG.
80011438|NCT02916446|Biological|Placebo|
80011439|NCT03788928|Diagnostic Test|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
80011440|NCT01377545|Procedure|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
79246028|NCT04563273|Biological|BCG vaccine 2 （0.05mg/0.1ml/person）|Intradermal injection of 0.05mg/0.1ml/person dose BCG.
79246029|NCT04563273|Biological|BCG vaccine 3（0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
79384928|NCT02458248|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
79384929|NCT02457780|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
79384930|NCT02457780|Behavioral|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
79384931|NCT02456610|Biological|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
79539700|NCT01472796|Dietary Supplement|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
79539701|NCT01472796|Drug|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
79246030|NCT04563273|Biological|BCG vaccine 4 （0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
79246031|NCT04563273|Biological|Placebo of BCG vaccine （0.1ml/person）|Intradermal injection of 0.1ml/person dose Placebo.
79246032|NCT04560088|Behavioral|Mindfulness|Mindfulness-based mobile health intervention.
79246033|NCT04560088|Behavioral|Breathing|Breathing mobile health intervention.
79697545|NCT04675385|Drug|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
79697546|NCT04598061|Drug|Dexmedetomidine IV|Dexmedetomidine IV
79697547|NCT01161043|Device|Sensor wear|All subjects to wear sensors
79697548|NCT04606875|Diagnostic Test|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
79697549|NCT04674956|Drug|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
79697550|NCT04674956|Drug|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
79697551|NCT04674956|Drug|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
79697552|NCT00564720|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
80011441|NCT01377545|Procedure|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
79697553|NCT00564720|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
79697554|NCT00564720|Drug|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
79697555|NCT00564720|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
79697556|NCT04674917|Other|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy|"Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
80011442|NCT01379807|Drug|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
80011443|NCT02031380|Device|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
80011444|NCT02064660|Device|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
80011445|NCT02202512|Drug|Placebo|tablets
80011446|NCT02202512|Drug|Cimetidine|
79384932|NCT04778241|Procedure|Micro-osteoperforation|Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
79384933|NCT03537066|Device|CPAP|All patients included will be treated by CPAP
80011447|NCT02202512|Drug|Placebo|tablets
80011448|NCT02202512|Drug|Placebo|tablets
79246034|NCT04553211|Behavioral|EPT|Expedited Partner Therapy (EPT) involves provision of empiric oral antibiotic therapy to the recent sexual partners of an individual diagnosed with gonorrhea and/or chlamydia infection.
79384934|NCT04754919|Other|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
79384935|NCT04754919|Other|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
79697557|NCT04674917|Other|Decompression + Hot pack , TENS , Mobilization , Exercise Therapy|"Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
79841603|NCT05010837|Other|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
79841604|NCT04043754|Procedure|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
80011449|NCT02202512|Drug|BI 1060469 high dose|tablets
80011450|NCT02202512|Drug|BI 1060469 low dose|tablets
80011451|NCT02202512|Drug|Naproxen|
80011452|NCT02202512|Drug|BI 1021958|tablets
79246035|NCT04552782|Behavioral|Alcohol CBM|Trains approach or avoidance responses to alcohol cues.
79246036|NCT04552782|Behavioral|PTSD CBM|Trains approach or avoidance responses to trauma cues.
79246037|NCT04552782|Behavioral|Alcohol Sham|Will not train approach or avoidance responses.
79246038|NCT04552782|Behavioral|PTSD Sham|Will not train approach or avoidance responses.
79246039|NCT04539977|Drug|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
80011453|NCT02065752|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
79697558|NCT04674917|Other|Hot pack , TENS, Mobilization, Exercise therapy|"Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments."
80011454|NCT02065752|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
79841605|NCT04043754|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
79841606|NCT00836550|Behavioral|Video|The participants saw a 6 minute video
79841607|NCT00836550|Behavioral|in-person HIV pre-test counseling|
79841608|NCT02546778|Device|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
80011455|NCT02065752|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
79841609|NCT00546819|Biological|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
79246040|NCT04539977|Drug|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
79841610|NCT00546819|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
79246041|NCT04538911|Drug|BCG-PPD|BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
79246042|NCT04535141|Drug|Olanzapine 5 MG|It will be a de-identified pill created by investigational drug services at University of North Carolina
79246043|NCT04535141|Drug|Placebo|It will be a de-identified pill created by investigational drug services at University of North Carolina
79384936|NCT03763890|Device|Post-end-Expiratory pressure|Titrate the PEEP from 24 cmH2O to 6 cmH2O, 2 cmH2O/step and record EIT, trans-pulmonary pressure, hemodynamic parameter and Blood-gas analysis.
79384937|NCT04754841|Other|platelet cryopreservation|The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C
80011456|NCT02065752|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
80011457|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
80011458|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
79246044|NCT04534595|Other|COVID-19|To study the experience of students and their families during the COVID-19 pandemic an online questionnaire will be utilized. This COVID-19 questionnaire will be administered at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
79539702|NCT01472809|Drug|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
79539703|NCT01472809|Drug|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
79539704|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
80011459|NCT02202668|Device|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
80011460|NCT02064738|Behavioral|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
80011461|NCT02202824|Other|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
80011462|NCT05461781|Procedure|distal radial artery|primary percutaneous coronary intervention via distal radial aretry
80011463|NCT05461781|Procedure|proximal radial aretry|primary percutaneous coronary intervention via proximal radial aretry
79539705|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
79539706|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
79539707|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
79539708|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
79539709|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
79539710|NCT01472861|Procedure|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
80011464|NCT05057442|Other|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
79697559|NCT04606485|Other|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
79539711|NCT01472861|Other|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
80011465|NCT05461625|Procedure|ACL reconstruction|Anterior cruciate ligament reconstruction
79841611|NCT04010643|Behavioral|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey & O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
79841612|NCT04010643|Behavioral|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
79841613|NCT00962481|Drug|Bimosiamose|
80011466|NCT05461625|Other|ALL anatomic|anatomic anterolateral ligament reconstruction
80011467|NCT05461625|Other|ALL tenodesis|anterolateral ligament teondesis
80011468|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
80011469|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
79841614|NCT00962481|Drug|Placebo|
80011470|NCT03560076|Other|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
80011471|NCT02206490|Drug|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
79246045|NCT04534387|Other|Spanish-Language Hearing Loss Toolkit for Self-Management|The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.
79539712|NCT01472900|Device|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
79539713|NCT01472900|Drug|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
79539714|NCT01472913|Drug|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
79697560|NCT01160770|Drug|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
79841615|NCT05299437|Drug|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
79841616|NCT00621504|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
79841617|NCT00621504|Drug|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
80011472|NCT02206490|Drug|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
79246046|NCT04534387|Other|American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts|Standard of care patient education handouts developed by ASHA in the Spanish language.
79246047|NCT04534023|Drug|Idebenone|trial group
79246048|NCT04534023|Drug|Placebo|control group
80011473|NCT02068170|Drug|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
80011474|NCT02203058|Other|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
80011475|NCT02203058|Other|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
80011476|NCT02206568|Drug|URAL|
80011477|NCT02068248|Dietary Supplement|Soluble Fibre|
80011478|NCT02203136|Procedure|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
79246049|NCT04511741|Other|no intervention, it is an observational study.|no intervention, it is an observational study.
79539715|NCT01472913|Drug|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
79539716|NCT01472926|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
79697561|NCT00566007|Procedure|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
79697562|NCT00566007|Drug|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
79697563|NCT00566007|Drug|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
80011479|NCT02203136|Procedure|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
80011480|NCT02068326|Behavioral|Mentalization Based Treatment|
80011481|NCT02068326|Behavioral|Treatment As Usual|Treatment As Usual
80011482|NCT02206646|Drug|Metalyse|
79539717|NCT01472926|Drug|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
79539718|NCT01472978|Drug|metronidazole|Metronidazole, 500 mg three times a for 10 days
80011483|NCT03788148|Device|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
80011484|NCT02419417|Drug|BMS-986158|Specified dose on specified days
80011485|NCT02419417|Biological|Nivolumab|Specified dose on specified days
79246050|NCT04503317|Device|active acupuncture low level laser in addition to nasal laser irradiation|laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months
79246051|NCT04503317|Other|treadmill exercise|aerobic exercise once per day, 3 times per week for three months
79539719|NCT01473017|Behavioral|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
80011486|NCT02206724|Radiation|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
79246052|NCT04493541|Drug|BMS-986256|Specified Dose on Specified Days
80011487|NCT02203214|Device|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
79246053|NCT04493541|Other|BMS-986256 Placebo|Specified Dose on Specified Days
79246054|NCT04480918|Device|Electroconvulsive Therapy (ECT)|ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
79246055|NCT04480918|Device|Transcranial Magnetic Stimulation (TMS)|TMS for the treatment of treatment-resistant depression in an active major depressive episode
79246056|NCT04480918|Drug|Ketamine|Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
79384938|NCT03757806|Other|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
79384939|NCT04001595|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
79384940|NCT03257826|Device|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
79384941|NCT03261492|Behavioral|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
79384942|NCT03261492|Behavioral|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
79384943|NCT04781829|Diagnostic Test|BioFire Pneumonia Panel|Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
80011488|NCT02068404|Drug|Nifedipine|
80011489|NCT02257658|Drug|Doxycycyline|
80011490|NCT02257658|Behavioral|Incentive|
79246057|NCT04480918|Drug|Esketamine|Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
79246058|NCT04480918|Device|Deep Transcranial Magnetic Stimulation (dTMS)|TMS for the treatment of OCD
79246059|NCT04477109|Device|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt
79246060|NCT04477109|Other|sham laser application in addition to diet recommendations|sham laser application in addition to diet recommendations
79539720|NCT01473043|Drug|Axitinib|5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
79539721|NCT01473056|Drug|JTK-853|Tablets, twice a day for 3 days
79539722|NCT01473056|Drug|Dose 2 JTK-853|Tablets, twice a day for 3 days
79539723|NCT01473056|Drug|Dose 3 JTK-853|Tablets, three times a day for 3 days
79539724|NCT01473056|Drug|Dose 4 JTK-853|Tablets, twice a day for 3 days
79539725|NCT01473056|Drug|Placebo|Tablets, twice a day or three times a day for 3 days
80011491|NCT02068482|Drug|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
80011492|NCT02206802|Drug|5% minoxidil topical foam|5% minoxidil topical foam
80011493|NCT02065986|Drug|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
80011494|NCT02068560|Drug|dDAVP infusion|
80011495|NCT01377103|Drug|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
80011496|NCT01377103|Drug|Placebo|
79246061|NCT04471506|Other|interval training in addition to diet recommendations|Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
79246062|NCT04471506|Other|diet recommendations|the control group will follow diet recommendations for 12 weeks
79841618|NCT00621504|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
79841619|NCT00621504|Drug|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
79841620|NCT00548145|Drug|Pitavastatin|2 mg by orally/day Duration: 12 months
79841621|NCT00548145|Drug|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
79841622|NCT00547911|Drug|Droxidopa|
80016883|NCT03659253|Procedure|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
79246063|NCT04453709|Behavioral|Problem Management Plus for Immigrants at family settings|"PMP-I is a 5-week, peer-led, culturally tailored psychoeducation, behavioral activation (90 minutes), breathing and yoga intervention (90 minutes) in a family setting. PMP-I will use a structured approach, including once a week face-to-face sessions, breathing and yoga practices.~Managing Stress: Breathing and yoga practices, stress-management sessions, and behavioral activation exercises to strengthen positive coping strategies.~Managing Problems: Practice exercises to identify the problems, develop solutions, and plan a strategy to carry out those solutions.~Get Going, Keep Doing: Communication skill sessions and practice exercises to identify and carry out pleasant tasks.~Strengthening Social Support: Social skills session and practice exercise to identify social support.~Staying Well: Make a plan that helps to create supportive family environment."
79384944|NCT03261180|Other|Best Practice|Receive regular diet
79384945|NCT03261180|Other|Laboratory Biomarker Analysis|Correlative studies
79384946|NCT03261180|Dietary Supplement|Nutritional Intervention|Receive Nestle Impact AR
79384947|NCT04778319|Other|occlusion of tubes|to occlude the fallopian tubes
79384948|NCT04778319|Other|non occlusion of tubes|not to occlude the tubes
79841623|NCT00547911|Drug|Carbidopa|
79841624|NCT00547911|Drug|Entacapone|
79384949|NCT03261414|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
79841625|NCT00839280|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
79841626|NCT00839280|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
79841627|NCT00836628|Drug|Busulfan|
79841628|NCT00962637|Drug|Androxal|12.5 mg once daily
79841629|NCT00962637|Drug|Androxal|25 mg once daily
79841630|NCT00962637|Drug|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
79841631|NCT00962637|Drug|Placebo|1 capsule daily
79246064|NCT04453709|Behavioral|Talk program with Community Support Service Pamphlet (CSS)|Pamphlet including list of community support service institutions
79246065|NCT04397978|Radiation|Stereotactic radiotherapy|Local ablative therapy with SRT
79384950|NCT03261414|Procedure|usual care|Standard care before induction of anesthesia
79384951|NCT01110681|Device|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
79384952|NCT03257514|Drug|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
79384953|NCT03257514|Drug|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
79841632|NCT00839358|Drug|albumin|albumine 40 g every 15 days
79841633|NCT00839358|Drug|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
79841634|NCT00839358|Drug|Placebo|saline solution
79841635|NCT00962715|Biological|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
79841636|NCT00962715|Drug|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
79841637|NCT00962715|Drug|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
79841638|NCT00836784|Other|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
79841639|NCT00836784|Other|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
79841640|NCT04886271|Drug|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
79841641|NCT00844116|Device|spirometry|Conventional and telematic spirometry
79697564|NCT04314154|Other|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
80011497|NCT02206958|Behavioral|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
80011498|NCT02068638|Procedure|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
79697565|NCT04632719|Device|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
80011499|NCT02068638|Procedure|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
80011500|NCT02068638|Procedure|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
79246066|NCT04384861|Behavioral|Mayo Clinic SMART program (Stress Management and Resilience Training)|The SMART program included a workshop and ongoing eLearning Support. The learning objectives of the workshop are: (1) learn the neuroscience and behavioural aspects of human experience, particularly with respect to stress, resiliency, performance and wellness and (2) learn practical approaches to enhance engagement and emotional intelligence and thereby decrease stress and anxiety, increase resilience, enhance performance, and improve relationships. The goal of the eLearning support is to support and reinforce the messages and techniques delivered in the 2-hour workshop.
79246067|NCT04376346|Behavioral|Native WYSE CHOICES|Native WYSE (Women, Young, Strong, and Empowered) CHOICES (Changing High-risk alcohOl use and Increasing Contraception Effectiveness Study) is an alcohol-exposed pregnancy prevention program that translates CHOICES, an evidence-based targeted intervention, into an mHealth universal intervention for young urban American Indian/Alaska Native (AI/AN) women ages 16-20.
79697566|NCT00566046|Drug|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
79697567|NCT00566046|Drug|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
79246068|NCT04374500|Drug|Leptin infusion plus vasodilators in healthy men|This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
79246069|NCT04374500|Drug|Leptin infusion in healthy men|This applies only to protocol 1 when only leptin was given
79246070|NCT04374500|Drug|Vasodilators in CAD patients|This applies only to protocol 3
79539726|NCT01473069|Drug|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
80011501|NCT02068638|Procedure|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
80011502|NCT01377025|Drug|Placebo|two tablets in the morning and two in the evening.
80011503|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
79539727|NCT01473069|Drug|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
79539728|NCT01473082|Device|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
79539729|NCT01473082|Device|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
79539730|NCT01473095|Drug|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
79539731|NCT01473121|Other|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
79539732|NCT01473147|Drug|Exenatide|Exenatide 5 microgram bid sc.
79539733|NCT01473147|Drug|Normal saline|Normal saline 2 u bid sc.
79539734|NCT01473173|Drug|CJ-12420|
79539735|NCT01473173|Drug|Esomeprazole 40mg|
79539736|NCT01473225|Other|Calorie information|Nutrition label featuring calorie information will be provided.
79539737|NCT01473225|Other|No calorie information|No nutrition label will be provided in this condition.
79539738|NCT01473238|Other|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
79539739|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
80011504|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
80016884|NCT02096484|Behavioral|Group Metacognitive Therapy|
80011505|NCT02207036|Behavioral|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
79539740|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
79697568|NCT01160614|Drug|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
79539741|NCT01473251|Drug|Lucentis|0.5 mg monthly for 4 months
79697569|NCT00566085|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
79697570|NCT04632407|Dietary Supplement|"Flax milk"|See above
79841642|NCT00963027|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
80011506|NCT02207036|Behavioral|Smokefree.gov|referral to the NCI Smokefree.gov website
79841643|NCT00963027|Drug|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
79697571|NCT04632407|Dietary Supplement|"Oat fibre milk"|See above
79246071|NCT04368689|Other|Floatation-based reduced environmental stimulation therapy|Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
79246072|NCT04366401|Behavioral|Conventional Dietary Advice|"The education content in the control group will be centered on the acquisition of knowledge about:~- Underlying mental pathology, lifestyles and associated comorbidities~- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~- Water requirements.~- Foodstuffs.~- Culinary techniques: conservation of properties of the diet.~- Feeding in particular situations."
79697572|NCT04123639|Procedure|PTA|Percutaneous transluminal angioplasty
80011507|NCT03630757|Other|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
80011508|NCT02203292|Behavioral|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb < 9.0 g/dL
80011509|NCT02203292|Behavioral|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb < 7.0 g/dL
80011510|NCT02066064|Procedure|Standard Colonoscopy|Standard Colonoscopy
79246073|NCT04366401|Behavioral|Prebiotic/Probiotic Dietary Modulation|"The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~- Underlying mental pathology, lifestyles and associated comorbidities~- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~- Water requirements.~- Foodstuffs.~- Description and justification of prescribed prebiotic and probiotic diet.~- Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~- Optimal distribution and interchange of foods with high prebiotic and probiotic content.~- Feeding in particular situations."
79697573|NCT02885233|Behavioral|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
79841644|NCT00836940|Drug|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
80011511|NCT02066064|Procedure|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
80011512|NCT05353075|Other|Sub Occipital Muscle Inhibition|The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.
79539742|NCT01473264|Drug|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
79246074|NCT04359186|Other|Treatment Interruption Arm|Individuals with HIV on suppressive ART will interrupt their ART.
79539743|NCT01473264|Drug|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
79539744|NCT01473264|Drug|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
80016885|NCT02096484|Behavioral|Mindfulness Meditation Therapy|
79841645|NCT00837018|Other|physical exercise program|45 min, 3times a week
79841646|NCT00839592|Other|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
79697574|NCT02885233|Behavioral|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
79697575|NCT00566124|Drug|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
79697576|NCT00566124|Drug|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
79384954|NCT02456064|Behavioral|Lifestyle counseling|"Group medical visits~Telephone medical consultations~Expert patient~Training workshops"
79384955|NCT03257748|Radiation|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
80011513|NCT05353075|Other|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
79246075|NCT04352530|Other|Health Communication|Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
79246076|NCT04326283|Drug|Trametinib (0.5 mg)|0.5 mg/day
79246077|NCT04326283|Drug|Trametinib (1 mg)|1 mg/day
79246078|NCT04326283|Drug|Riluzole (100 mg)|100 mg/day (50 mg twice)
79384956|NCT03257748|Radiation|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
79384957|NCT04778007|Other|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
79539745|NCT01473277|Drug|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
79539746|NCT01473290|Dietary Supplement|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
79697577|NCT00566124|Drug|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
79697578|NCT04632563|Other|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
79384958|NCT04781751|Drug|insulin injection|Carpal tunnel syndrome sonagraphic injection
79384959|NCT04781205|Genetic|Mutation arrays, NGS panels, GWAS, WES, WGS,|DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces
79697579|NCT01159912|Drug|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
79697580|NCT01159912|Drug|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
79697581|NCT01159912|Drug|Placebo|Placebo inhalation powder
79697582|NCT04606368|Device|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
79246079|NCT04314284|Behavioral|I Can PIC|-Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.
79246080|NCT04314284|Other|Historical control survey|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
79384960|NCT04781205|Device|wearable monitors|test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
79384961|NCT05387928|Drug|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
79384962|NCT04777695|Other|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
79539747|NCT01473290|Other|placebo|Given PO
79539748|NCT01473303|Biological|ganitumab|Given IV
79539749|NCT01473303|Drug|fluorouracil|Given IV
79539750|NCT01473303|Drug|irinotecan hydrochloride|Given IV
79539751|NCT01473303|Drug|leucovorin calcium|Given IV
79539752|NCT01473303|Drug|oxaliplatin|Given IV
79539753|NCT01473303|Other|placebo|Given IV
79539754|NCT01473303|Other|questionnaire administration|Completed on paper
79539755|NCT01473316|Drug|GDC-0980|Single oral dose
79384963|NCT04488276|Other|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
79539756|NCT01473316|Drug|Ketoconazole|Repeating Oral Dose
79539757|NCT01473329|Other|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
79539758|NCT01473342|Behavioral|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors & their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting & participation. During the 9th week (Week 17), participants complete one final survey & accelerometer wear.
79246081|NCT04314284|Other|Post-intervention survey (I Can PIC participants)|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
79841647|NCT04796649|Device|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
79246082|NCT04314284|Other|Follow-Up survey (I Can PIC participants)|-19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.
79246083|NCT04309682|Procedure|crestal sinus approach technique|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
79384964|NCT03257280|Other|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
79539759|NCT01473433|Procedure|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
79539760|NCT01473433|Other|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
79697583|NCT04632368|Behavioral|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
79697584|NCT04632680|Device|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
79697585|NCT04606212|Drug|Losartan|administration of losartan (50 mg) (oral)
79697586|NCT04606212|Drug|Placebo Oral Tablet|administration of placebo (oral)
79841648|NCT04796649|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
79384965|NCT04781439|Procedure|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
79539761|NCT01473446|Procedure|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV <10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding >1000ml. By fall in blood pressure and SVV <10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
79697587|NCT04632446|Other|Early diagnosis|Early diagnosis. Upgrade program implementation.
79697588|NCT04606251|Other|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
79697589|NCT04606329|Drug|LuminoMark inj.(Conc. for fluorescence)|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
80011514|NCT02207192|Other|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
79384966|NCT03252678|Other|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
79841649|NCT00837174|Drug|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
79841650|NCT00963183|Drug|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
79539762|NCT01473459|Procedure|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
79539763|NCT01473459|Procedure|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
79841651|NCT00963183|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
79841652|NCT04042974|Drug|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
79841653|NCT04042974|Drug|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
79246084|NCT04309682|Procedure|Lateral sinus approach|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
79246085|NCT04288531|Dietary Supplement|Iodine supplementation|Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
79697590|NCT04606329|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
79246086|NCT04280965|Drug|Quetiapine Fumarate|Atypical antipsychotic
79246087|NCT04280965|Other|Standard of care meducations|SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine
79246088|NCT04276909|Combination Product|LUM Imaging System|LUM015 will be administered at the beginning of surgery. All subjects will have intraoperative imaging using the LUM imaging device.
79539764|NCT01473472|Drug|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
79697591|NCT04632251|Device|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
79697592|NCT04597749|Diagnostic Test|PSG|In-lab sleep polysomnography test
79697593|NCT04597749|Diagnostic Test|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
79697594|NCT04597749|Other|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
79841654|NCT00844272|Behavioral|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
79841655|NCT04783545|Drug|VLX-1005|VLX-1005 infusion
79841656|NCT04783545|Drug|Placebo|Placebo infusion
79841657|NCT00844350|Drug|letrozole , oxytocin,hCG,clomiphene citrate|
79246089|NCT04272450|Diagnostic Test|respiratory muscle strenght measurement|Maximum inspiratory pressure-maximum expiratory pressure. The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated.
79246090|NCT04266353|Dietary Supplement|Resveratrol (RSV)|Participants will receive Resveratrol at 150 mg daily for 6 weeks.
79384967|NCT03252678|Other|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
79384968|NCT04777773|Other|dual-task training|dual-task training
79384969|NCT03261024|Device|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
79384970|NCT03261024|Device|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
79384971|NCT04777383|Drug|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
79384972|NCT04777383|Drug|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
79384973|NCT04777383|Drug|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
79384974|NCT04777383|Drug|Atropine|Iontophoretic administration of 5 different concentrations of atropine
79384975|NCT04777383|Drug|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
79384976|NCT04777383|Drug|Sterile water|Iontophoretic administration of sterile water
79384977|NCT03260946|Other|Complementary medicine use|The prevalence of complementary medicine use
79384978|NCT03257124|Drug|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
79384979|NCT02089113|Drug|Dexamethasone|
79697595|NCT04632797|Device|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
79697596|NCT04632212|Behavioral|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
79539765|NCT01473472|Drug|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
79539766|NCT01473485|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
79697597|NCT04632212|Behavioral|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~Video: subjects will watch a video briefly explaining the food labels on the store.~My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
79539767|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
79697598|NCT04632212|Behavioral|Ordering|To order food items by Nutri-Score (high to low).
79841658|NCT00963261|Behavioral|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
79841659|NCT02547636|Other|Observational study|No intervention will be used in this study.
79841660|NCT00839670|Other|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
79539768|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
79697599|NCT04632212|Behavioral|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
79697600|NCT04606017|Drug|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
79539769|NCT01473511|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
79539770|NCT01473537|Drug|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
79697602|NCT04632095|Procedure|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
79697603|NCT04632095|Procedure|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
79841661|NCT00839670|Other|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
79841662|NCT00963339|Device|Foresee Home|Home Monitoring
79841663|NCT01563393|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
79841664|NCT01563393|Other|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
79539771|NCT01473550|Behavioral|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
79841665|NCT00844506|Drug|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
79841666|NCT00844506|Drug|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
79841667|NCT04009707|Other|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
79841668|NCT04009707|Other|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
79841669|NCT00844584|Procedure|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
79841670|NCT00963417|Other|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
80011515|NCT03579121|Other|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
79539772|NCT01473576|Dietary Supplement|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
79539773|NCT01473576|Dietary Supplement|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
79539774|NCT01473615|Behavioral|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
79697604|NCT04597788|Other|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
80011516|NCT03579121|Other|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
79697605|NCT04597788|Other|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
79697606|NCT04597983|Dietary Supplement|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
79697607|NCT04597983|Dietary Supplement|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
79697608|NCT04631822|Procedure|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
79697609|NCT04631822|Procedure|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
79697610|NCT04631822|Procedure|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
79697611|NCT04605705|Combination Product|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
79246091|NCT04253717|Other|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
79246092|NCT04231643|Drug|Dronabinol|one-time oral administration of 5 mg dronabinol
79246093|NCT04231643|Drug|Epidiolex|one-time oral administration of 600 mg Epidiolex
79246094|NCT04231643|Drug|Placebos|one-time oral administration of placebo
79246095|NCT04224974|Other|Usual Care|The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial
79246096|NCT04224974|Behavioral|EASE-psy|"All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).~-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms."
79697612|NCT00560924|Drug|estradiol, 25 mcg|
79697613|NCT04605900|Device|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
79246097|NCT04216121|Radiation|Local ablative therapy|Stereotactic body radiotherapy
79246098|NCT04216121|Procedure|Local ablative therapy|Surgery
79841671|NCT00963417|Procedure|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
80011517|NCT02203370|Device|NIRS - Near-infrared spectroscopy|
80011518|NCT05037786|Behavioral|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
80011519|NCT05037786|Behavioral|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
79246099|NCT04216004|Behavioral|Controlled-Feeding Intervention|All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
79246100|NCT04216004|Dietary Supplement|Non-dairy beverage|Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
79246101|NCT04216004|Other|Full-fat milk|3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
79246102|NCT04216004|Other|Fat-free milk|3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
79384980|NCT02089113|Procedure|Placebo Vehicle|
79697614|NCT04605900|Device|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
79841672|NCT00839826|Drug|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
79841673|NCT00839826|Drug|Enoxaparin|40 mg bid
79697615|NCT04605900|Device|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
79841674|NCT00963495|Drug|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
79384981|NCT03252990|Diagnostic Test|PET-MRI|Additional 18F-choline PET-MRI examination
79539775|NCT01473654|Behavioral|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
79539776|NCT01473667|Procedure|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
79539777|NCT01473667|Procedure|Local site infiltration|Local site infiltration using 2% lidocaine
79539778|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
79539779|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
79539780|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
79697616|NCT04605900|Behavioral|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
79697617|NCT00560963|Drug|everolimus|
79697618|NCT04597515|Procedure|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
79697619|NCT04631978|Diagnostic Test|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
79841675|NCT04042896|Behavioral|exergame|Exergame is 'exercise + game'.
79841676|NCT04042896|Behavioral|treadmill exercise|traditional aerobic exercise
79841677|NCT00844662|Drug|Fermagate|Film coated tablet 500mg
79841678|NCT00844662|Drug|Sevelamer hydrochloride|Tablet 800mg
79841679|NCT04678089|Drug|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
79841680|NCT00963573|Drug|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
79841681|NCT00963573|Drug|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
79841682|NCT05299593|Drug|tafluprost/timolol|"One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day."
80011520|NCT02203448|Device|Facet Wedge spinal system|
80011521|NCT02066142|Device|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
80011522|NCT02066142|Device|Ultrasound|
80011523|NCT02068872|Procedure|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
80011524|NCT02342275|Drug|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
79384982|NCT03252990|Procedure|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
79384983|NCT03257046|Drug|ITI-214|Oral
79384984|NCT03257046|Other|Placebo|Oral
79384985|NCT03252444|Other|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
79384986|NCT03252444|Other|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
79384987|NCT03252288|Behavioral|Reminders|Text of phone-call based reminders to mobile phones
79384988|NCT03252288|Behavioral|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs >1 week but within 4 weeks of the scheduled visit
79384989|NCT03260634|Drug|Voriconazole|
79697620|NCT04597281|Other|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
79697621|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
79841683|NCT00839904|Behavioral|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
79539781|NCT01473693|Other|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
79539782|NCT01473693|Other|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
79539783|NCT01473706|Other|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
79246103|NCT04203823|Device|Cloud-based Digital Twin and Meal Prediction algorithms|Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
79246104|NCT04199910|Other|There is no intervention, only research blood samples are collected|Research blood samples collected
79697622|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
79697623|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose open label
79697624|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose
79841684|NCT04667403|Other|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~If necessary within 24 hours of the connection if it is a weekly connection,~Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
79539784|NCT01473719|Behavioral|motivational intervention|7-session individual motivationally-based intervention
79841685|NCT00844740|Drug|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
79539785|NCT01473719|Behavioral|health education|7 individual sessions focusing on health education
79697625|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
79697626|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily low dose
79697627|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
79697628|NCT04631627|Drug|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
79697629|NCT00564759|Drug|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
79697630|NCT04632017|Diagnostic Test|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
79697631|NCT04314193|Drug|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
80011525|NCT02342275|Drug|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
79697632|NCT04314193|Drug|Prednisolone|Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
79697633|NCT04597398|Device|Evaluation of blood flow with indocyanine green|
79697634|NCT04631354|Drug|Radio-labelled S-770108|99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
79697635|NCT04631354|Device|S-770108 Inhaler A1|Dry powder inhaler
79697636|NCT01159171|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
79841686|NCT00840138|Procedure|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
80011526|NCT04988568|Other|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
79246105|NCT04197804|Other|Routine tests perform|The subjects of the Tourette group and control group are subjected to routine tests performed at Tourette Center and Extrapyramidal Diseases. Both groups are initially subjected to an evaluation that aims to identify the IQ and therefore 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) related to the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration about 3 minutes) the language field. These evaluations are in practice at the Center for Tourette patients; the tasks will be administered to both groups.
79246106|NCT04174196|Drug|CC-486|Participants will be treated with CC-486 and lenalidomide for 6 cycles
79246107|NCT04174196|Drug|Lenalidomide|Participants will be treated with CC-486 and lenalidomide for 6 cycles
79697637|NCT01159171|Drug|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
79697638|NCT01159171|Drug|oxaliplatin|40 mg/m2 iv weekly
79697639|NCT04631315|Drug|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
79697640|NCT04631315|Drug|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
79697641|NCT02885155|Other|Echocardiography|planned at regular intervals
79697642|NCT02885155|Other|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
79697643|NCT04631666|Biological|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
79697644|NCT04631666|Other|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
79697645|NCT02885194|Other|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
79697646|NCT04597203|Device|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
79697647|NCT04597203|Drug|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
79697648|NCT04313842|Device|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
79697649|NCT04631237|Other|Observational, no intervention|No intervention involved
79697650|NCT04631159|Behavioral|Health2Sync app and report blood glucose data weekly|Patients will need to download and use the Health2Sync app and report blood glucose data weekly
80011527|NCT02207270|Behavioral|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
80011528|NCT02207270|Behavioral|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
79697651|NCT04631159|Other|self-manage|Patients will be asked to self-manage and there is no intervention during the tracking process
79697652|NCT04605276|Other|No intervention|No intervention
79841687|NCT01563159|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
79841688|NCT00844818|Behavioral|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
79841689|NCT00963651|Device|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
80011529|NCT02068950|Behavioral|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
79697653|NCT04596774|Procedure|Traditional Approach|Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
79697654|NCT04596774|Procedure|Enhanced Recovery After Surgery (ERAS) Approach|Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
79697655|NCT04630691|Procedure|Implantation|Patients received narrow diameter implants in posterior mandible or maxilla
79697656|NCT04631081|Procedure|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
79709927|NCT02892474|Procedure|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
79697657|NCT04631081|Other|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
79841690|NCT02546700|Drug|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
79841691|NCT02546700|Drug|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
79841692|NCT00963729|Drug|cyclophosphamide|Given IV
79841693|NCT00963729|Drug|docetaxel|Given IV
79841694|NCT00963729|Drug|epirubicin hydrochloride|Given IV
79246108|NCT04174196|Radiation|Radiation Therapy|Radiation therapy will be initiated to the plasmacytoma after cycle 2
79246109|NCT04171895|Other|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
79384990|NCT03256890|Behavioral|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
79384991|NCT03256890|Other|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
79384992|NCT04777227|Drug|Lidocaine injection|2% (20mg/ml) lidocaine solution
79384993|NCT04777227|Drug|Physiological water injection|0.9% sterile sodium chloride water
79384994|NCT04777227|Procedure|Debridement|A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
79384995|NCT04777227|Procedure|Needle insertion|A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side
79697658|NCT04596813|Device|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
79841695|NCT00963729|Drug|fluorouracil|Given IV
79841696|NCT00963729|Drug|letrozole|Given orally
79841697|NCT00851214|Device|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
79841698|NCT00851292|Device|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
79384996|NCT03260556|Drug|Pirfenidone|Increasing doses
79384997|NCT03260556|Drug|Placebos|Increasing doses
79841699|NCT00963963|Behavioral|Healthy Futures parent education|Multi-year audio CD parent education
79384998|NCT04780737|Procedure|Cholecystectomy|Laparoscopic or laparotomic cholecystectomy
79384999|NCT04776915|Diagnostic Test|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
79841700|NCT00844974|Other|Prevalence|Mood and cognitive assessments
79841701|NCT00964041|Drug|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
79385000|NCT02712996|Drug|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
79841702|NCT00964041|Drug|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
79841703|NCT00840372|Procedure|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
79841704|NCT04009317|Drug|TQ-B3139|a multi-target protein kinase inhibitor.
79841705|NCT04009317|Drug|Crizotinib|a multi-target protein kinase inhibitor.
79841706|NCT03641547|Drug|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
79841707|NCT03641547|Drug|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 & B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
79841708|NCT03641547|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 & B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
79697659|NCT04630457|Device|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
79697660|NCT04630457|Device|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
79841709|NCT03641547|Radiation|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
79841710|NCT00851370|Drug|Omalizumab (Xolair)|Bi-weekly
79841711|NCT00851370|Drug|Placebo|Bi-Weekly
79246110|NCT04171895|Other|Communication training Part 1 (no longer recruiting)|1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
79385001|NCT02712996|Drug|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
79385002|NCT03252366|Device|GELFOAM|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~A diamond bur will be used to make a rectangular osteotomy.~The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~Implant stability will be measured by osteal device~implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
79246111|NCT04171895|Other|Enhanced usual care|"Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants."
79539786|NCT01473771|Behavioral|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
79539787|NCT01473797|Drug|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
79539788|NCT01473810|Biological|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
79539789|NCT01473810|Biological|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
79539790|NCT01473810|Biological|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
79539791|NCT01473810|Biological|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
79539792|NCT01473823|Dietary Supplement|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
79539793|NCT01473888|Drug|T89(Dantonic)|capsule, 225mg B.I.D.
79697661|NCT04630457|Device|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
79697662|NCT01158118|Drug|Sargramostim|
79697663|NCT01158118|Drug|Plerixafor|
79841712|NCT00967629|Drug|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
80011530|NCT01827553|Drug|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)
80011531|NCT01827553|Radiation|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
80011532|NCT01827553|Drug|Chemotherapy, gemcitabine|5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d
79539794|NCT01473901|Drug|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
79246112|NCT04171895|Other|Communication training Part II|Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
79539795|NCT01473901|Drug|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
79539796|NCT01473914|Dietary Supplement|Low dose: supplemental zinc, selenium and vitamin E|"ZINC 25mg (AS ZINC SULFATE)~SELENIUM 50 mcg (AS SODIUM SELENITE)~VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
79539797|NCT01473914|Dietary Supplement|Standard renal vitamin: B and C renal vitamin|"BIOTIN 300 MCG~D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~FOLIC ACID 1 MG~NIACINAMIDE 20 MG~VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~VITAMIN B12(CYANOCOBALAMIN) 6 MCG~VITAMIN B2 (RIBOFLAVIN) 1.7 MG~VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~VITAMIN C (ASCORBIC ACID) 100 MG~INERT FILLER (CORNSTARCH)"
79539798|NCT01473914|Dietary Supplement|Medium dose: supplemental zinc, selenium and vitamin E|"ZINC 50 mg (AS ZINC SULFATE)~SELENIUM 75 mcg (AS SODIUM SELENITE)~VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
79841713|NCT00967629|Drug|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
80011533|NCT01827553|Drug|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
79246113|NCT04626544|Device|Body-worn inertial sensors|The device typically includes accelerometers that capture body accelerations in three directions (anteroposteriorly, mediolaterally and vertically) and gyrometers that capture rotations (yaw, pitch and roll). The method of measuring gait using body-worn inertial sensors has been found reliable [15] and valid [20]. This project will use Opal sensors and the Mobility Lab software from the manufacturer APDM (https://www.apdm.com/wearable-sensors/).
80011534|NCT02207348|Drug|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
79246114|NCT04171167|Drug|Fluticasone Propionate|three visits: 0, after washout, after FP usage
80011535|NCT02066454|Drug|Apixaban|2.5mg x 2 per day during 6 months
79246115|NCT04166695|Device|Monolithic / facially veneered zirconia fixed partial denture|Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
79385003|NCT03252366|Device|xenograft|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~A diamond bur will be used to make a rectangular osteotomy.~The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~Implant stability will be measured by osteal device~implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
79385004|NCT04346277|Biological|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
79385005|NCT04780347|Drug|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
79385006|NCT04780347|Drug|capecitabine|capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
79539799|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
80011536|NCT03526484|Behavioral|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
80011537|NCT03526484|Behavioral|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
80011538|NCT02207426|Drug|Tobramycin|
79697664|NCT04630340|Device|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
80011539|NCT00777491|Drug|induction cisplatin|15 mg/m^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
80011540|NCT00777491|Drug|induction 5-fluorouracil|400mg/m^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
80011541|NCT00777491|Drug|induction gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
79697665|NCT04596969|Other|Soluble Fiber Dextrin|Ingredient based on resistant starch
79697666|NCT04313920|Other|Nutritional Supplement|50 g Carbohydrate
79697667|NCT00564837|Procedure|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
79841714|NCT00851448|Dietary Supplement|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
80011542|NCT00777491|Radiation|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
80011543|NCT00777491|Radiation|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
80011544|NCT00777491|Radiation|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
80011545|NCT00777491|Radiation|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
79246116|NCT04166695|Device|Completely veneered CoCr fixed partial denture|Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
79246117|NCT04162899|Drug|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
79246118|NCT04155346|Behavioral|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
79385007|NCT02455596|Drug|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
79385008|NCT01013415|Drug|HAART|
79385009|NCT01013415|Biological|T cells|
79385010|NCT03256500|Device|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
79385011|NCT03256110|Behavioral|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
79385012|NCT04780191|Device|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
79697668|NCT00564837|Procedure|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
79697669|NCT01157845|Device|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
79697670|NCT00561041|Behavioral|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
79697671|NCT00561041|Behavioral|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
79697672|NCT00566241|Drug|recombinant human IGF-1|rhIGF-1
79697673|NCT00566241|Drug|Placebo|Placebo
79697674|NCT00564915|Dietary Supplement|Ketogenic diet|Ketogenic diet
79697675|NCT00561119|Drug|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 & 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
79697676|NCT00566280|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
79841715|NCT00289783|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
79841716|NCT00289783|Biological|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
79841717|NCT00289783|Biological|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
80011546|NCT00777491|Drug|consolidation gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
80011547|NCT00777491|Drug|consolidation 5-fluorouracil|400 mg/m^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
80011548|NCT00777491|Drug|consolidation cisplatin|15 mg/m^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
80011549|NCT00777491|Procedure|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
79697677|NCT00561158|Behavioral|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~Rate Your Plate: determining high fat foods~Label Reading: reading food labels~Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~Recipe Modification: preparing old recipes in new ways to reduce fat~Eating Out: order healthier fast foods~Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~Substituting fat-modified foods for high fat foods~Avoiding fat as a seasoning or flavoring~Avoiding fried foods~Modifying meat~Replacing high fat foods with fruits, vegetables, grains and breads"
79385013|NCT03252132|Other|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
79697678|NCT00566319|Behavioral|PREPARE with pedometer|Structured educational programme with pedometer use
80011550|NCT00777491|Procedure|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
80011551|NCT00777491|Drug|adjuvant gemcitabine|1000 mg/m^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
79246119|NCT04155112|Behavioral|Physical activity|Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).
79246120|NCT04155112|Behavioral|Hypocaloric Mediterranean diet|Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
79246121|NCT04147871|Drug|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
79539800|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
79539801|NCT01473966|Dietary Supplement|coffee|patients will receive a cup of coffee at room temperature orally twice daily
79539802|NCT01473966|Dietary Supplement|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
79539803|NCT01473979|Procedure|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
80011552|NCT00777491|Drug|adjuvant cisplatin|70 mg/m^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
80011553|NCT02207582|Device|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
79539804|NCT01474005|Device|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
79539805|NCT01474031|Other|Biomechanics|"Time interval: pre-op - 3m - 6m - 12m~Assessment of all subjects:~XR~Gait analysis with surface EMG and trunk markers:~Unipodal standing: 3 trials Right and 3 trials Left on FP~Level walking: 3 trials Right and 3 trials Left on FP~Chair rise: 3 trials, both legs on FP~Stair ascent: 3 trials Right and 3 trials Left on first FP~Stair descent: 3 trials Right and 3 trials Left on first FP~Squat: 3 trials, both legs on FP~Bipodal squat: 3 trials Right and 3 trials Left on FP~Functional scores (HHS, UCLA, HOOS, SF-36)"
79246122|NCT04147871|Drug|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
79246123|NCT04140279|Drug|Latanoprostene Bunod|Ophthalmic solution
79246124|NCT04140279|Drug|Placebo|Ophthalmic solution, no active ingredient.
79539806|NCT01474044|Drug|Gastropylor Complex Capsules|3 pills, three times a day, after meal
79539807|NCT01474044|Other|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
79697679|NCT00566319|Behavioral|PREPARE|Structured educational programme
79841718|NCT00289783|Biological|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
80011554|NCT02207582|Device|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
80011555|NCT02069106|Dietary Supplement|Pro-Omega LDL|
80011556|NCT02069106|Other|Placebo|
79539808|NCT01474057|Behavioral|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
79539809|NCT01474057|Other|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
79841719|NCT00289783|Biological|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
80011557|NCT02199392|Drug|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
79539810|NCT01474070|Device|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
79539811|NCT01474096|Other|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
79246125|NCT04140032|Behavioral|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
80011558|NCT03630445|Other|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
79539812|NCT01474161|Drug|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
79539813|NCT01474161|Drug|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
80011559|NCT03630445|Other|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
80011560|NCT03630445|Other|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
80011561|NCT03630445|Other|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
79246126|NCT04131270|Behavioral|Planning + Education|"Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning."
79246127|NCT04131270|Behavioral|Education|The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
79246128|NCT04129060|Drug|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
79539814|NCT01474161|Drug|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
79539815|NCT01474161|Drug|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
79539816|NCT01474161|Drug|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
79539817|NCT01474161|Drug|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
80011562|NCT03630445|Other|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
80011563|NCT02069262|Other|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
80011564|NCT01379495|Behavioral|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
80011565|NCT05320627|Drug|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
80011566|NCT03559920|Drug|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head & neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
80011567|NCT03559920|Drug|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
79246129|NCT04119284|Device|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
79539818|NCT01474174|Biological|trivalent influenza vaccine|Given IM
79539819|NCT01474174|Other|laboratory biomarker analysis|Correlative studies
79539820|NCT01474187|Drug|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
79539821|NCT01474187|Drug|Capecitabine|625mg/m2,bid,d1-5,qw
79539822|NCT01474187|Radiation|Radiotherapy|50Gy for whole pelvis
79841720|NCT00289783|Biological|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
79841721|NCT00289783|Biological|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
79841722|NCT00840528|Other|ozone|0.4 ppm ozone for 2 hours
79246130|NCT04117763|Drug|Empagliflozin 25 MG|Empagliflozin once daily, for three months
79385014|NCT03252210|Procedure|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
79385015|NCT02455440|Drug|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
79385016|NCT02455440|Drug|Placebo|
79539823|NCT01474226|Dietary Supplement|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
79539824|NCT01474226|Dietary Supplement|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
79539825|NCT01474252|Drug|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
79539826|NCT01474265|Drug|Varenicline|0.5-2 mg per day, oral use
79697680|NCT04630223|Diagnostic Test|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
79697681|NCT04605471|Drug|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
79697682|NCT04629989|Other|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
79697683|NCT04629989|Other|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
79697684|NCT04629989|Other|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
79697685|NCT00566358|Procedure|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
79697686|NCT04629755|Behavioral|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
79697687|NCT04605042|Procedure|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
79697688|NCT04605042|Procedure|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
79697689|NCT04596696|Biological|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P[11], containing one bovine rotavirus gene P[11] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
79697690|NCT00561197|Drug|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
79246131|NCT04084119|Other|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
79246132|NCT04084119|Other|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
79246133|NCT04078880|Dietary Supplement|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
79246134|NCT04076852|Other|Administration of questionnaires|"According to clinical practice, the following questionnaires are administered:~Y-GTSS~Y-BOCS or cY-BOCS"
79246135|NCT04071574|Drug|Human Chorionic Gonadotropin (hCG)|Administration of hCG (10.000IU) for ovulation triggering
79246136|NCT04071574|Drug|Gonadotropins|Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
79539827|NCT01474265|Drug|Placebo|1-2 tablets per day, oral use
79539828|NCT01474265|Drug|Nicorette TX|10-15 mg per day, transdermal use (patches)
79539829|NCT01474278|Drug|Placebo|Single dose
79539830|NCT01474278|Drug|RO5028442|Single dose
79385017|NCT02455440|Drug|Propofol and sevoflurane|
79385018|NCT03937167|Other|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
79385019|NCT03260166|Drug|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
79385020|NCT02089191|Device|Nelfilcon A contact lenses|
79385021|NCT02089191|Device|Stenfilcon A contact lenses|
79385022|NCT03260010|Drug|Fosfomycin|Infectofos 5 g
79697691|NCT04596618|Device|Forearm cooling|forearm cooling will be performed for active cooling assessment.
79385023|NCT03260088|Diagnostic Test|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
79697692|NCT04596462|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
79539831|NCT01474304|Drug|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
79539832|NCT01474330|Drug|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
79697693|NCT04629638|Other|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
79697694|NCT04605120|Procedure|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
79697695|NCT04629560|Drug|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
79697696|NCT04605003|Device|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
79841723|NCT02546466|Procedure|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
79841724|NCT02546466|Procedure|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
79385024|NCT04779723|Procedure|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
80011568|NCT02203760|Drug|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
80011569|NCT02203760|Drug|Pazopanib|Pazopanib 800 mg orally once daily
79385025|NCT05387850|Other|no intervention|no intervention
80011570|NCT02064972|Other|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
79246137|NCT04071574|Drug|GNRH-A Triptorelin|Administration of Triptorelin (0.1mg/day)
79246138|NCT04071574|Drug|GnRH antagonist|Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
79246139|NCT04065243|Other|Overfeeding diet|Two weeks of overfeeding
79246140|NCT04065243|Other|Isocaloric diet|Two weeks of isocaloric weight maintenance
79246141|NCT04005846|Device|Transcranial Direct Current Stimulation (tDCS)|The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
79246142|NCT04002362|Drug|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) will be administered deep in the gluteal muscle by a trained registered nurse.
79246143|NCT03997071|Other|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
79385026|NCT01896219|Device|Navigation station (IMACTIS-CT®)|
79385027|NCT01896219|Device|CT|Reference method for gestures (carried out under CT) guidance
79385028|NCT04776135|Drug|MT-1186|Suspension
79539833|NCT01474330|Drug|Placebo|Placebo capsule
79539834|NCT01474343|Genetic|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
79539835|NCT01474356|Other|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
79385029|NCT03256188|Behavioral|Active classroom|30 minutes of moderate-to-vigorous physical activity
79539836|NCT01474369|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
79539837|NCT01474369|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
79539838|NCT01474369|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
79539839|NCT01474382|Drug|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
79539840|NCT01474382|Other|Sham injection|No drug administered, simulation of injection used in same manner as drug
79697697|NCT04605003|Device|Conventional Autoclave machine|The gold standard device to clean all medical instruments
79697698|NCT04629482|Other|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
79697699|NCT04596306|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
79697700|NCT04629287|Drug|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
79697701|NCT04629287|Drug|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
79697702|NCT00564993|Drug|Dobutamin|10&20 µg/kg/min
79697703|NCT04629365|Other|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
79841725|NCT02546466|Behavioral|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
79841726|NCT00840606|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
80011571|NCT03703271|Drug|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
80011572|NCT03703271|Procedure|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
79385030|NCT04775823|Procedure|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
79385031|NCT03474276|Drug|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
80011573|NCT03532802|Drug|Metoprolol Succinate|"week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~week: steady state treatment with the maximum tolerated dose of the 1.week."
80011574|NCT03532802|Drug|Placebo oral capsule|"week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~week: steady state treatment with the maximum tolerated dose of the 1. week"
79246144|NCT03995979|Other|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
79246145|NCT03982186|Drug|JNJ-73763989|JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
79246146|NCT03982186|Drug|Placebo for JNJ-73763989|Placebo for JNJ-73763989 will be administered as subcutaneous injection.
80011575|NCT03430531|Drug|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
80011576|NCT02066532|Drug|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
80011577|NCT02066532|Drug|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
79246147|NCT03982186|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
80011578|NCT03532724|Device|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
80011579|NCT02065050|Other|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
80011580|NCT04088513|Drug|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
79385032|NCT03474276|Dietary Supplement|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
80011581|NCT04088513|Drug|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
79385033|NCT03474276|Drug|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
79385034|NCT03474276|Dietary Supplement|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
79539841|NCT01474395|Drug|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
79697704|NCT04629365|Other|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
79697705|NCT04629170|Drug|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
79697706|NCT04629170|Drug|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
79709928|NCT02892474|Procedure|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
79697707|NCT04629404|Drug|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
79697708|NCT04629404|Drug|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
80011582|NCT02207660|Drug|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
80011583|NCT02069340|Drug|zoledronic acid|Given IV
80011584|NCT02069340|Other|pharmacological study|Correlative studies
79841727|NCT00840606|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
79841728|NCT00845286|Behavioral|Munich Marathon|42,195 km marathon run
79841729|NCT03850002|Other|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
79841730|NCT03975127|Other|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
79841731|NCT00840684|Drug|amsacrine|
80011585|NCT02199548|Other|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
80011586|NCT02069418|Radiation|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
80011587|NCT02069418|Radiation|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
80011588|NCT02207738|Device|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
79697709|NCT04595916|Drug|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
79697710|NCT04595916|Drug|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
79841732|NCT00840684|Drug|busulfan|
79841733|NCT00840684|Drug|cytarabine|
79841734|NCT00840684|Drug|daunorubicin hydrochloride|
79841735|NCT00840684|Drug|laromustine|
79841736|NCT00840684|Drug|melphalan|
80011589|NCT02207738|Device|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
79246148|NCT03982186|Drug|Placebo for JNJ-56136379|Placebo for JNJ-56136379 tablets will be administered orally.
79246149|NCT03982186|Drug|Nucleos(t)ide Analog (NA)|NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
79385035|NCT04779801|Behavioral|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
79385036|NCT03259776|Other|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
79697711|NCT00565071|Device|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
79841737|NCT00840684|Drug|mitoxantrone hydrochloride|
79841738|NCT00840684|Procedure|allogeneic hematopoietic stem cell transplantation|
79841739|NCT00840684|Procedure|autologous hematopoietic stem cell transplantation|
79385037|NCT04779255|Drug|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
79841740|NCT00574080|Drug|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
79841741|NCT00574080|Drug|Induction/Consolidation Dexamethasone|40 mg Days 1-4
79841742|NCT00574080|Drug|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
79841743|NCT00574080|Drug|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
79841744|NCT00574080|Drug|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
79385038|NCT04779255|Drug|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
79841745|NCT00574080|Drug|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
79841746|NCT00574080|Drug|Induction Pegfilgrastim|6 mg Days 6 and 13
79841747|NCT00574080|Drug|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
79841748|NCT00574080|Drug|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
79841749|NCT00574080|Drug|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
79841750|NCT00574080|Drug|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
79841751|NCT00574080|Drug|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
79841752|NCT00574080|Drug|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
79697712|NCT04628819|Dietary Supplement|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
79697713|NCT04604964|Other|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
79697714|NCT04604886|Diagnostic Test|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
79697715|NCT04604886|Diagnostic Test|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
79697716|NCT04595877|Drug|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
79697717|NCT04595877|Behavioral|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
79697718|NCT04595877|Biological|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
80011590|NCT04422847|Device|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
80011591|NCT02208128|Drug|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
79246150|NCT03975985|Other|Core stability exercises (CSE)|"CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process)."
79246151|NCT03975985|Other|Conventional Physiotherapy|The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
79246152|NCT03970252|Drug|Fluorouracil|Given IV
79697719|NCT04595877|Other|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
80016886|NCT03515317|Behavioral|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
79246153|NCT03970252|Drug|Irinotecan|Given IV
79246154|NCT03970252|Drug|Irinotecan Hydrochloride|Given IV
79246155|NCT03970252|Drug|Leucovorin|Given IV
79246156|NCT03970252|Drug|Leucovorin Calcium|Given IV
79246157|NCT03970252|Biological|Nivolumab|Given IV
79385039|NCT03252054|Diagnostic Test|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
79385040|NCT03256422|Drug|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
79385041|NCT04775901|Other|CT-guided lung biopsy|Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
79697720|NCT00561275|Biological|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
79246158|NCT03970252|Drug|Oxaliplatin|Given IV
79246159|NCT03970252|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79697721|NCT04595955|Other|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
79697722|NCT04628897|Behavioral|Exposures|"Total area of available floor space inside the home (m2)~Frequency that child plays outdoors~Total number of physical hazards in the home (presence of open stairwells, stove height)~Total number of fine-motor activity items available to the child~Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~Hemoglobin concentration (g/L)."
79697723|NCT00561509|Drug|SSRIs|Use within normal clinical practice
79697724|NCT00561509|Drug|Dual antidepressants|Use within clinical practice
79709929|NCT04336839|Procedure|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
79709930|NCT00107120|Drug|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
79539842|NCT01474395|Drug|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
79697725|NCT04604574|Other|Indigenous Healing and Seeking Safety|Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
79697726|NCT00561548|Procedure|rectosigmoïdal biopsies|rectosigmoïdal biopsies
79697727|NCT04604730|Procedure|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
79841753|NCT00574080|Drug|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
79841754|NCT00574080|Procedure|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
79841755|NCT00574080|Drug|Transplant 2 Carmustine|300 mg/m2 Day -5
79841756|NCT00574080|Drug|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
79841757|NCT00574080|Drug|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
79841758|NCT00574080|Drug|Transplant 2 Melphalan|140 mg/m2 Day -1
79841759|NCT00574080|Drug|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
79841760|NCT00574080|Drug|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
79841761|NCT00574080|Drug|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
80011592|NCT04411771|Behavioral|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
79385042|NCT04775901|Device|Template-guided lung biopsy|A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
79385043|NCT01968382|Drug|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
79385044|NCT01968382|Drug|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
79385045|NCT00951249|Behavioral|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
79697728|NCT04604730|Procedure|Anastomosis with protective stoma|Anastomosis with protective stoma
79697729|NCT04604535|Dietary Supplement|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
80011593|NCT04411771|Behavioral|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
80011594|NCT03119883|Other|5-Carbon C 13-labeled Glutamine|Given IV
80011595|NCT03119883|Procedure|Biospecimen Collection|Undergo collection of blood
80011596|NCT03119883|Procedure|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
80011597|NCT03119883|Other|Uniformly-labeled [13C]glucose|Given IV
79697730|NCT04604535|Dietary Supplement|Placebo|70mL concentrated nitrate deplete beetroot juice (<0.01mmol/L nitrate)
79709931|NCT00107120|Drug|Placebo|Placebo once daily for up to 8 weeks
79709932|NCT00596778|Other|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
79841762|NCT00840762|Other|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
79841763|NCT00840762|Other|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
79841764|NCT00845364|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
79841765|NCT00845364|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
79697731|NCT00566436|Procedure|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
79697732|NCT00566436|Procedure|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
79385046|NCT00951249|Behavioral|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
79539843|NCT01474395|Behavioral|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
79539844|NCT01474408|Behavioral|interval training day 1|
79539845|NCT01474408|Behavioral|Moderate exercise day 2|
79697733|NCT04628702|Behavioral|tablet training|1.5 year training period
79697734|NCT00566475|Other|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
79697735|NCT04628975|Device|transillumination dispositif|infrared light
79697736|NCT00566514|Dietary Supplement|D-ribose|5 grams administered orally TID
79697737|NCT00566514|Other|dextrose|5 grams orally TID
79697738|NCT01157377|Drug|AGN-214868|AGN-214868 injected into the bladder.
79697739|NCT01157377|Drug|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
80011598|NCT02069496|Biological|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
80011599|NCT02066610|Other|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
80011600|NCT02066610|Other|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
80011601|NCT02066610|Other|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
80011602|NCT02066610|Other|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
80011603|NCT03077711|Drug|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
80011604|NCT03077711|Drug|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
80011605|NCT03673683|Behavioral|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
79385047|NCT00951249|Behavioral|Peer health care system navigators|HIV/STI treatment and other medical and social services
79385048|NCT00951249|Behavioral|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
79385049|NCT03260244|Procedure|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.~Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
79539846|NCT01474408|Behavioral|Control day 3|
79697740|NCT02885116|Device|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
79697741|NCT02885116|Device|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
79697742|NCT02885077|Device|High-intensity IMT + combined exercise|
79697743|NCT04628312|Other|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
79697744|NCT00566553|Dietary Supplement|Grape Seed Extract|200 mg dose daily for 12 weeks.
79697745|NCT00566553|Dietary Supplement|Grape Seed Extract|400 mg dose daily for 12 weeks.
79697746|NCT00566553|Dietary Supplement|Grape Seed Extract|600 mg dose daily for 12 weeks.
79697747|NCT00566553|Dietary Supplement|Grape Seed Extract|800 mg dose daily for 12 weeks.
79697748|NCT01157182|Drug|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
79697749|NCT01157182|Drug|Activella®|1/0.5 mg Tablets
79697750|NCT04628390|Device|Laser|The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
79697751|NCT04628390|Other|Placebo|Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
79697752|NCT01157065|Drug|AL-78898A|Investigational treatment
79697753|NCT01157065|Drug|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
79697754|NCT00566592|Other|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
79697755|NCT00566592|Other|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
79697756|NCT00566592|Other|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
79539847|NCT01474447|Behavioral|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
79539848|NCT01474460|Dietary Supplement|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
79539849|NCT01474473|Device|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
79697757|NCT00566592|Other|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
79697758|NCT05268406|Device|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
79697759|NCT02885038|Other|Platelet concentrate transfusion|
79841766|NCT04043052|Other|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
79841767|NCT04043052|Other|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
79841768|NCT04043052|Biological|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
79841769|NCT04043052|Other|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
80011606|NCT03673683|Behavioral|Usual care|Usual sedation and weaning management that is not protocol based
79385052|NCT04779567|Drug|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
79385053|NCT04779567|Drug|Placebo|100 ml saline 0.9% iv 4 times a day
79697760|NCT04604457|Other|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
79841770|NCT00267865|Drug|Methotrexate|6000 mg/m^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
80011607|NCT03533426|Procedure|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
80011608|NCT03533426|Procedure|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
79385054|NCT03259854|Device|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
79385055|NCT03259854|Device|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
79697761|NCT04628351|Behavioral|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
79385056|NCT03291210|Other|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
79385057|NCT03291210|Other|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
79697762|NCT01156792|Drug|FP 100|FP 100mcg BID
79697763|NCT01156792|Drug|GSK2190915 100|GSK2190915 100mg QD (AM)
79697764|NCT01156792|Drug|GSK2190915 300|GSK2190915 300mg QD (AM)
79697765|NCT01156792|Drug|montelukast|montelukast 10mg QD (PM)
79697766|NCT01156792|Drug|placebo|placebo BID
79697767|NCT01156792|Drug|FP/SAL 100/50|FP/SAL 100/50mcg BID
79841771|NCT00267865|Drug|Rituximab|375 mg/m^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
79841772|NCT00267865|Drug|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
79841773|NCT00851760|Procedure|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
79385058|NCT04756245|Behavioral|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
80011609|NCT02069574|Procedure|non-surgical periodontal therapy|
80011610|NCT04374019|Drug|Ivermectin|"Ivermectin:~Days 1-2: Weight < 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight > 75kg: 5 tabs (15 mg total daily dose)"
80011611|NCT04374019|Drug|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
79385059|NCT04756245|Behavioral|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
80011612|NCT04374019|Dietary Supplement|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
79385060|NCT03255876|Dietary Supplement|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
79385061|NCT03255876|Dietary Supplement|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
79246160|NCT03949725|Behavioral|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
79246161|NCT03916809|Other|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
79385062|NCT02352844|Drug|Everolimus|
79539850|NCT01474473|Device|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days"
79539851|NCT01474499|Drug|Glycerine|
79539852|NCT01474499|Drug|Docusate sodium and sorbitol rectal solution|
79539853|NCT01474525|Device|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
80011613|NCT04374019|Drug|Artesunate|Days 1-14:
79539854|NCT01474564|Other|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
79841774|NCT00851760|Procedure|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
79841775|NCT00851838|Drug|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
80011614|NCT02199704|Other|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders & Turner, 1999) and up to ten sessions of support. This is a case series study."
79841776|NCT01069237|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
79385063|NCT03255642|Drug|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
79385064|NCT03255642|Drug|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
79385065|NCT03562377|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
79385066|NCT03562377|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
79841777|NCT01069237|Device|Clear Care|Lens Care Solution for contact lenses
80011615|NCT03678363|Other|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
80011616|NCT02069652|Behavioral|Lifestyle Counseling|Lifestyle Counseling
80011617|NCT02199782|Other|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
80011618|NCT02069808|Drug|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
80011619|NCT02069808|Drug|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
80011620|NCT02069808|Drug|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
79697768|NCT04604145|Diagnostic Test|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
79697769|NCT04604223|Drug|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
79697770|NCT04628624|Dietary Supplement|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
79841778|NCT00840918|Drug|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
79841779|NCT00840918|Other|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
79841780|NCT00546117|Drug|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
79385067|NCT03562377|Biological|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
79385068|NCT03562377|Biological|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
79385069|NCT02352922|Drug|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
79385070|NCT02352922|Drug|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
79385071|NCT02456220|Device|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
79385072|NCT03255330|Drug|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
79385073|NCT03255330|Drug|Metamizol|Standardized treatment
79385074|NCT03255330|Drug|Tramadol|Standardized treatment
79539855|NCT01474577|Other|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
79539856|NCT01474603|Dietary Supplement|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
79539857|NCT01474616|Other|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
79697771|NCT04628624|Dietary Supplement|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
79841781|NCT00546117|Drug|placebo|Placebo Solutab in 15 and 30 mg dosages.
79841782|NCT01582165|Drug|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
79841783|NCT01582165|Drug|Placebo.|Placebo once daily vs rosuvastatin for 6 months
79841784|NCT00851916|Radiation|CyberKnife Radiosurgery|CyberKnife Radiosurgery
79841785|NCT03975049|Radiation|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
79841786|NCT03975049|Drug|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
79841787|NCT03975049|Drug|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
79697772|NCT04628624|Dietary Supplement|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
79697773|NCT01156714|Behavioral|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
79385075|NCT01969162|Procedure|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
79385076|NCT02089659|Drug|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
79385077|NCT03259464|Drug|BI 685509|3 sequential dose groups
79385078|NCT03259464|Drug|Placebo|3 sequential dose groups
79385079|NCT03246282|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
79385080|NCT03246282|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
79385081|NCT03246282|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
79385082|NCT04754685|Drug|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
79385083|NCT02353780|Drug|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
79385084|NCT02353780|Drug|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
79385085|NCT02353780|Drug|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
79697774|NCT01156714|Behavioral|Memory training with computerized memory program|memory testing and training on computer program
79246162|NCT03915613|Drug|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
79246163|NCT03915613|Drug|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
79841788|NCT00841074|Drug|chlorhexidine|0.12% chlorhexidine mouthwash spray, ~1.3 ml, twice a day.
79841789|NCT00841074|Drug|Placebo mouthwash|Placebo mouthwash spray application of ~1.3 ml twice a day.
79841790|NCT00964197|Device|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
79841791|NCT00967707|Drug|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
79385086|NCT03246438|Behavioral|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
79385087|NCT03246438|Behavioral|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
79385088|NCT03246438|Behavioral|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
79385089|NCT04775589|Behavioral|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
79539858|NCT01474629|Dietary Supplement|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
79539859|NCT01474629|Dietary Supplement|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
79697775|NCT01156714|Behavioral|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
79697776|NCT00561314|Other|questionnaire administration|
79697777|NCT00561314|Procedure|biopsy|
79841792|NCT00967707|Drug|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
79841793|NCT00964275|Procedure|diagnostic procedure|Standard diagnostic procedures followed
79841794|NCT00964275|Radiation|fludeoxyglucose F 18|PET with flueoxyglucose F 18
79385090|NCT03251742|Device|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
79385091|NCT02022826|Device|SmartPill Monitoring System|
79539860|NCT01474642|Drug|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
79539861|NCT01474642|Drug|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
79841795|NCT00845598|Drug|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
79841796|NCT00845598|Drug|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
79697778|NCT00561314|Procedure|high-intensity focused ultrasound ablation|
79697779|NCT00561314|Procedure|magnetic resonance imaging|
79697780|NCT00561314|Procedure|quality-of-life assessment|
79697781|NCT04595643|Other|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
79697782|NCT04628273|Procedure|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
79697783|NCT04604028|Drug|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
79697784|NCT00565149|Behavioral|PROOF|dietary overfeeding with high, low or normal protein content
79246164|NCT03914157|Device|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
79697785|NCT01156675|Device|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
79697786|NCT01156675|Device|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
79841797|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
79841798|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
79841799|NCT00251719|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
79841800|NCT00968097|Drug|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
79841801|NCT02547090|Procedure|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
79841802|NCT00964587|Behavioral|Education + Problem-Solving Training Self-Study|"Education + Problem-Solving Training Self-Study~One session of Literacy-Adapted Diabetes and CVD Risk Education~Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
79539862|NCT01474655|Procedure|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
79539863|NCT01474668|Drug|GDC-0941|Single oral dose\n \n\n\n\n
79697787|NCT01156480|Drug|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
79697788|NCT01156480|Drug|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
79697789|NCT04595526|Procedure|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
79697790|NCT04595526|Procedure|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
79841803|NCT00964587|Behavioral|Education + Group Problem-Solving Training|"Education + Group Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Group problem-solving training eight, 90-minute sessions"
79841804|NCT00964587|Behavioral|Education + Individual Problem-Solving Training|"Education + Individual Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Individual problem-solving training (eight, 60-minute sessions)"
79841805|NCT00964587|Behavioral|Usual Care|"Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
80011621|NCT02069808|Drug|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
80011622|NCT02069808|Procedure|Transvaginal ultrasound guided needle aspiration of oocytes|
79246165|NCT03909893|Radiation|Adaptive Radiation Therapy|Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
79385092|NCT04775511|Other|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
79385093|NCT04775511|Other|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
79385094|NCT04775511|Other|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
80011623|NCT03678207|Other|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
79246166|NCT03907852|Biological|gavo-cel|gavo-cel
79246167|NCT03907852|Drug|fludarabine|lymphodepletion chemotherapy
79246168|NCT03907852|Drug|cyclophosphamide|lymphodepletion chemotherapy
79246169|NCT03907852|Drug|Nivolumab|immuno-oncology agent
79246170|NCT03907852|Drug|Ipilimumab|immuno-oncology agent
79246171|NCT03896633|Drug|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
79246172|NCT03896633|Drug|Azopt 1%|Azopt 1%, RLD
79697791|NCT02884960|Procedure|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
79697792|NCT04627961|Drug|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
79697793|NCT04595253|Other|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
79841806|NCT00845754|Drug|ketorolac|15mg IV every6 hours for 4doses
79841807|NCT00845754|Drug|saline|15mg IV every 6hrs for 4 doses
79841808|NCT00964665|Drug|albinterferon alfa-2b|
79841809|NCT00964665|Drug|albinterferon alfa-2b|
79841810|NCT00964665|Drug|albinterferon alfa-2b|
79841811|NCT00964665|Drug|albinterferon alfa-2b|
79246173|NCT03890731|Drug|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
79246174|NCT03873051|Behavioral|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
79391449|NCT02413164|Other|A multimodal physiotherapy programme|"Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times."
79539864|NCT01474694|Other|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
80011624|NCT02199860|Drug|SD I|
79539865|NCT01474707|Behavioral|Group one|Group 1 will view the knowledge-based video only
79539866|NCT01474707|Behavioral|Group two|Group two will view the motivational video only
79539867|NCT01474707|Behavioral|Group three|Group three will view both knowledge-based and motivational videos
79539868|NCT01474707|Behavioral|Group four|Group four will view the printed educational pamphlet and will not view either video
79539869|NCT01474720|Drug|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
79539870|NCT01474733|Other|educational intervention|series of lectures and workshops on health literacy
79539871|NCT01474759|Behavioral|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
79841812|NCT00964665|Drug|Pegasys®|
80011625|NCT02199860|Drug|SD II|
80011626|NCT02199860|Drug|Placebo|
79539872|NCT01474759|Behavioral|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
79539873|NCT01474759|Other|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
79697794|NCT00561587|Drug|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
79841813|NCT00841152|Device|Bioactive glass|Surgical implantation
79841814|NCT00841152|Device|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
79841815|NCT00841152|Procedure|Autograft|Surgical transplantation from iliac crest
79841816|NCT00841152|Procedure|Allograft (frozen femoral head)|Surgical transplantation
79841817|NCT02545686|Behavioral|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
79841818|NCT02545686|Behavioral|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
79841819|NCT02545686|Procedure|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
80011627|NCT03673605|Drug|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
80011628|NCT03673605|Drug|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
80011629|NCT02069886|Drug|deferasirox|125, 250, 500 mg dispersable tablets
80011630|NCT04311463|Drug|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
79697795|NCT04595487|Procedure|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
79697796|NCT04595487|Procedure|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
79841820|NCT02545686|Procedure|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
79539874|NCT01474759|Behavioral|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
79841821|NCT00841230|Drug|Deanxit|Deanxit 1x/day
79841822|NCT00841230|Drug|Lactose placebo|Lactose used as placebo
79841823|NCT00841308|Other|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
79246175|NCT03873051|Behavioral|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
79246176|NCT03872180|Drug|Bendamustine|Given IV
79246177|NCT03872180|Biological|Obinutuzumab|Given IV
79385095|NCT03246360|Drug|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
79391450|NCT02413086|Procedure|Early-stage amputation|Individuals with DFU were given early-stage amputation.
79539875|NCT01474785|Drug|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
79539876|NCT01474785|Other|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
79841824|NCT00852072|Procedure|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
79841825|NCT00852072|Procedure|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
79841826|NCT02545920|Other|no intervention|observational study
79246178|NCT03872180|Drug|Venetoclax|Given PO
79246179|NCT03867890|Other|no intervention|
79391451|NCT02413086|Procedure|Amputation|Individuals with DFU were given amputation.
79539877|NCT01474785|Procedure|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
79539878|NCT01474837|Behavioral|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
80011631|NCT04311463|Drug|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
80011632|NCT02203994|Device|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
79539879|NCT01474850|Procedure|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
79539880|NCT01474902|Drug|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
79539881|NCT01474928|Behavioral|patient role played community video|Group two viewed the patient role played community video
79246180|NCT03866564|Diagnostic Test|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
79539882|NCT01474928|Behavioral|both videos group|Group three viewed both the knowledge and community videos
79539883|NCT01474928|Behavioral|Pamphlet group|Group four read an educational pamphlet only
79539884|NCT01474928|Behavioral|physician-led knowledge video|Group one viewed a physician-led knowledge video
79539885|NCT01474928|Behavioral|Community video group|Group two viewed the patient role played community video
79539886|NCT01474928|Behavioral|knowledge video|Group one viewed a physician-led knowledge video
79697797|NCT01156363|Procedure|Dialysis|regular haemodialysis or peritoneal dialysis
79697798|NCT01156363|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
79697799|NCT00561626|Dietary Supplement|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
80011633|NCT03070587|Behavioral|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
79246181|NCT03866564|Diagnostic Test|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
79246182|NCT03866564|Diagnostic Test|Quantitative Sensory Testing|Clinically accepted quantitative assessment of chronic pain burden.
79246183|NCT03866564|Diagnostic Test|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
79246184|NCT03857464|Diagnostic Test|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
79539887|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
79539888|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
79697800|NCT00561626|Dietary Supplement|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
79841827|NCT00841386|Drug|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
79246185|NCT03857464|Diagnostic Test|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
79246186|NCT03848715|Biological|Endotoxin|Endotoxin
79246187|NCT03848715|Biological|Placebo|Placebo
79246188|NCT03847649|Drug|Durvalumab|1500 mg IV, 60 min, Day 1 every 4 weeks
79246189|NCT03847649|Drug|Prednisone|0.5mg/kg; PO, Daily cycles 1 & 2
79246190|NCT03847649|Drug|Prednisone|10mg, PO, Daily cycles 1 & 2
79246191|NCT03847649|Drug|Tremelimumab|Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
79246192|NCT03847311|Drug|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
79246193|NCT03847311|Drug|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
79246194|NCT03845543|Device|Luminor-14 Paclitaxel eluting balloon|Patients will be treated with the Luminor-14 paclitaxel eluting balloon
79246195|NCT03831152|Drug|ADV7103|Single group assignment
79246196|NCT03827889|Procedure|WMP of fluoride varnish|Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found
79246197|NCT03827889|Procedure|TWLP of fluoride varnish|application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
79246198|NCT03827889|Behavioral|DHP (educational intervention)|The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
79246199|NCT03826563|Drug|oral melatonin tablets (NatureMade brand)|melatonin tablets
79246200|NCT03826563|Other|Placebo|pill placebo
79539889|NCT01474941|Drug|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
79539890|NCT01474967|Drug|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
79539891|NCT01474967|Drug|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
79539892|NCT01475006|Drug|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
79539893|NCT01475019|Drug|Orlistat|Tablet, 120 mg, three times daily, for six months
79539894|NCT01475019|Drug|Sibutramine|Tablet, 10 mg, once daily, for six months
79539895|NCT01475019|Behavioral|Diet and physical exercise|Hypocaloric diet and regular physical exercise
79539896|NCT01475032|Drug|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
79539897|NCT01475032|Drug|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
79697801|NCT02884921|Drug|Paracetamol|Paracetamol
79697802|NCT02884921|Drug|Paracetamol|Paracetamol
79697803|NCT02884921|Drug|Placebo|Placebo
79697804|NCT02884882|Other|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
79697805|NCT04595214|Other|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
79539898|NCT01475032|Drug|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
79841828|NCT00841386|Drug|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
79841829|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
79841830|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
79841831|NCT03952143|Drug|LY900014|Administered SC
79841832|NCT03952143|Drug|Insulin Lispro|Administered SC
79841833|NCT03952143|Drug|Insulin Glargine|Administered SC
79841834|NCT03952143|Drug|Insulin Degludec|Administered SC
79697806|NCT00561704|Drug|losartan|losartan, 100mg daily,
79246201|NCT03823131|Device|ImmunoPulse|Intratumoral
79246202|NCT03823131|Drug|Epacadostat|Given PO
79697807|NCT01156051|Drug|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
79841835|NCT00968175|Procedure|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
79385096|NCT01969240|Other|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
79697808|NCT01156051|Drug|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
79841836|NCT03071757|Drug|ABBV-368|Intravenous infusion
79841837|NCT03071757|Drug|ABBV-181|Intravenous infusion
79841838|NCT00968331|Drug|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
79841839|NCT00852228|Drug|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
79385097|NCT02455752|Procedure|LE-TME|Retroperitoneal approach for total mesorectal excision
79385098|NCT02354092|Procedure|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
79697809|NCT04595409|Drug|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
79841840|NCT00852228|Drug|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
79246203|NCT03823131|Drug|Pembrolizumab|Given IV
79246204|NCT03823131|Biological|CORVax|Intratumoral
79385099|NCT02354092|Procedure|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
79385100|NCT02354092|Procedure|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
79385101|NCT02354092|Procedure|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
79539899|NCT01475084|Device|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
79539900|NCT01475149|Other|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
79246205|NCT03823131|Drug|Tavokinogene telseplasmid|Intratumoral
79697810|NCT04595409|Drug|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
79697811|NCT04628000|Other|Vitamin D|Clinical Correlation
79697812|NCT01156012|Drug|T2345|One drop of T2345
79697813|NCT01156012|Drug|Prostaglandin|One drop
79697814|NCT04627844|Dietary Supplement|Immediate Feeding|Standard tube feeds begun at an earlier time point
79697815|NCT04627844|Dietary Supplement|Delayed Feeding|Standard tube feeds begun at delayed time point
79697816|NCT04595136|Drug|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
79841841|NCT00852228|Drug|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
79841842|NCT00267007|Drug|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
79841843|NCT00267007|Drug|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
79697817|NCT04595136|Drug|normal saline|0.9% NS via nebulization
79697818|NCT04628117|Dietary Supplement|Oral nutritional supplementation for kidney disease|237 mls per day for 8 weeks.
79385102|NCT02354092|Behavioral|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
79385103|NCT02354092|Drug|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
79697819|NCT01155661|Drug|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
79697820|NCT01155661|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
79841844|NCT00841620|Procedure|Haemorrhoidectomy a.m. Milligan|Surgery
79841845|NCT00841620|Procedure|Stapled anopexy|Surgery
79841846|NCT00964821|Biological|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
79841847|NCT00964821|Other|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
79841848|NCT00964821|Other|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
79841849|NCT00852306|Procedure|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
80011634|NCT02065128|Other|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
80011635|NCT03678051|Behavioral|Treatment as Usual (TAU)|Standard of care residential treatment
80011636|NCT03678051|Behavioral|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
79841850|NCT01071031|Biological|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
79841851|NCT01071031|Biological|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
79841852|NCT01071031|Biological|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
79385104|NCT00907101|Drug|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
79385105|NCT03251820|Drug|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
79385106|NCT03251976|Behavioral|video|informational video
79385107|NCT03251976|Behavioral|usual care|usual physician counseling on end of life care
79385108|NCT03251664|Dietary Supplement|Food groups consumed|
79385109|NCT02455830|Biological|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
79391452|NCT02413086|Other|External herbs chitosan|Wound was given external herbs chitosan after amputation.
79391453|NCT02413086|Other|Traditional gauze|Wound was given traditional gauze after amputation.
79697821|NCT04627883|Other|Inspiratory-to-expiratory (I : E) ratio of 1:2|After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
79697822|NCT04627883|Other|Inspiratory-to-expiratory (I : E) ratio of 2:1|After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
79697823|NCT00565188|Drug|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
79841853|NCT00968409|Radiation|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
79841854|NCT00968409|Other|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
79841855|NCT00968409|Other|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
79841856|NCT00968409|Drug|F18-FFNP|injection of F18-FFNP
79841857|NCT04010019|Behavioral|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
79246206|NCT03822091|Drug|Terlipressin|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~the creatinine values decrease by <12.5%~MAP increase of <10 mmHg~urine output of <200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~A dose of 20gram/day to 60gram/day in the following days."
79246207|NCT03822091|Drug|Terlipressin and Noradrenaline|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~the creatinine values decrease by <12.5%~MAP increase of <10 mmHg~urine output of <200 ml in 4 hours."
79246208|NCT03798561|Drug|ASN008 TG|ASN008 TG
79539901|NCT01475188|Drug|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
79697824|NCT04628078|Other|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
79697825|NCT04603833|Drug|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
79539902|NCT01475188|Other|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
79539903|NCT01475201|Behavioral|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
79697826|NCT04603833|Drug|SHR3680|Participants will receive SHR3680
79697827|NCT04603833|Drug|Docetaxel|Participants will receive Docetaxel
79697828|NCT04603716|Other|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
79841858|NCT04010019|Behavioral|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
79841859|NCT00841854|Drug|pantoprazole|pantoprazole 40mg bid
79841860|NCT00841854|Drug|bismuth|bismuth 300mg qid
79841861|NCT00841854|Drug|metronidazole|metronidazole 500mg tid
79841862|NCT00841854|Drug|tetracycline|tetracycline 500mg qid
79841863|NCT05299281|Device|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
80011637|NCT01569503|Device|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
80011638|NCT04296565|Behavioral|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
79246209|NCT03798561|Drug|Placebo TG|Placebo TG
79385110|NCT03251586|Diagnostic Test|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
79246210|NCT03785730|Procedure|Non-restorative cavity control - NRCC group|The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
79697829|NCT04603716|Other|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
79539904|NCT01475201|Behavioral|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
79539905|NCT01475227|Drug|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
79697830|NCT04627532|Drug|PF-07304814|Participants will receive PF-07304814
79697831|NCT04627532|Drug|Placebo|Participants will recieve placebo
79697832|NCT01580748|Drug|Roflumilast|500 microgram once daily for 16 weeks
79697833|NCT04603872|Drug|CD19/BCMA Targeted CAR T-cells and dasatinib|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
79697834|NCT04603872|Drug|CD19/BCMA Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
79385111|NCT03251586|Diagnostic Test|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
79539906|NCT01475227|Drug|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
79246211|NCT03785730|Procedure|Restoration with resin composite - RCR group|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
79246212|NCT03779711|Biological|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
79246213|NCT03779711|Procedure|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
79246214|NCT03754322|Diagnostic Test|LAMP|LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
79697835|NCT04627688|Behavioral|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
79697836|NCT04627688|Behavioral|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
79539907|NCT01475266|Drug|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
79539908|NCT01475266|Drug|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
79246215|NCT03754322|Diagnostic Test|Microscopy/RDT|Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
79246216|NCT03747133|Radiation|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
80011639|NCT04296565|Behavioral|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
79246217|NCT03739619|Drug|Bendamustine|Given IV
79246218|NCT03739619|Drug|Gemcitabine|Given IV
79246219|NCT03739619|Biological|Nivolumab|Given IV
79246220|NCT03734393|Other|HIVD+/R+|Liver from an HIV-infected deceased donor
79246221|NCT03728504|Drug|ASN002|Daily dose of ASN002 for 32 weeks
79539909|NCT01475279|Drug|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
79539910|NCT01475292|Drug|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
79697837|NCT04603794|Drug|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
79697838|NCT04603794|Drug|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
79697839|NCT04603794|Drug|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
79697840|NCT04603794|Drug|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
79697841|NCT04603755|Device|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
79841864|NCT04043130|Behavioral|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
79539911|NCT01475292|Drug|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
79539912|NCT01475292|Drug|Placebo|Placebo administered via a nebuliser once daily for 14 days
80011640|NCT03677895|Drug|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
79539913|NCT01475318|Drug|mifepristone|200 mg mifepristone on day 1
79697842|NCT04627337|Drug|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
80011641|NCT04295005|Drug|Empagliflozin|film coated tablet
80011642|NCT04295005|Drug|DPP-4i|film coated tablets
80011643|NCT04295005|Drug|Sitagliptin|film coated tablet
80011644|NCT04295005|Drug|GLP-1-RA|subcutaneous injection or tablet
80011645|NCT03174353|Drug|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
80011646|NCT02260284|Other|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
80011647|NCT02260284|Other|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
80011648|NCT02260284|Other|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
80011649|NCT03673449|Device|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
80011650|NCT05214235|Drug|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
80011651|NCT02204306|Genetic|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
79246222|NCT03728504|Drug|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
79246223|NCT03703466|Drug|Abemaciclib|Administered orally.
79246224|NCT03691012|Diagnostic Test|Circulating tumour DNA testing|Circulating tumour DNA testing
79385112|NCT04488120|Device|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
79385113|NCT03251274|Other|machine bathing|machine bathing 20-min duration at evening
79385114|NCT03251274|Other|traditional bathing|traditional bathing
79385115|NCT04488042|Other|Stapler-less gastrectomy|After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
79539914|NCT01475318|Drug|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
79246225|NCT03677128|Other|mNavigator|Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
79246226|NCT03674697|Device|Green LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
79385116|NCT04488042|Other|Suture|No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
79539915|NCT01475318|Drug|Misoprostol|misoprostol 800mcg PV on day 3
79385117|NCT00701064|Other|Bright Light Exposure|Administered via bright light box
79539916|NCT01475344|Drug|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
79697843|NCT04627337|Behavioral|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
79697844|NCT04603638|Drug|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
79697845|NCT04603638|Drug|Isotonic|100 ml
79697846|NCT04627454|Procedure|Discectomy and insertion of dynamic cervical implant in cervical disc herniation|The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
79697847|NCT04603599|Diagnostic Test|serum soluble L1CAM (sL1CAM)|blood sample
79385118|NCT00701064|Other|Negative Ion Generator|Administered via Negative Ion Generatore
79697848|NCT04627298|Behavioral|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
79385119|NCT03245970|Drug|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
79385120|NCT03245970|Drug|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
79697849|NCT04603170|Other|DRUG|taking drug medication prescribed by psychiatrists for at least one month
79697850|NCT04627220|Diagnostic Test|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
79697851|NCT04627259|Other|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
80011652|NCT03439319|Device|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
80011653|NCT03439319|Other|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
80011654|NCT05208151|Other|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
79385121|NCT03245970|Drug|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
80011655|NCT02199938|Other|Identification and characterization of molecular markers in musculoskeletal tumors|
80011656|NCT04080947|Drug|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
79385122|NCT03255486|Biological|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
79385123|NCT02454348|Drug|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
79385124|NCT02454348|Drug|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
79385125|NCT02455908|Drug|Proleukin®|
79385126|NCT06112795|Other|Non-Interventional Study|Non-interventional study
79385127|NCT06112782|Device|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
79385128|NCT06112691|Device|taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
79385129|NCT06112665|Drug|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
79385130|NCT06112639|Device|DANCEREX-DTx|"DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context."
79697852|NCT04603092|Behavioral|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
79697853|NCT01155583|Drug|azacitidine|Given by subcutaneous injection (SC)
79697854|NCT01155583|Drug|lenalidomide|Given orally
79697855|NCT01155583|Drug|dexamethasone|Given orally
80011657|NCT04080947|Drug|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
80011658|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
80011659|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
80011660|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
80011661|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
80011662|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
80011663|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
80011664|NCT02066688|Drug|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
80011665|NCT02066688|Drug|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
80011666|NCT02066688|Drug|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
79841865|NCT00968487|Biological|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
79246227|NCT03674697|Device|White LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
79246228|NCT03664544|Drug|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
79539917|NCT01475344|Drug|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
79539918|NCT01475357|Other|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
79246229|NCT03561818|Other|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
79246230|NCT03561818|Other|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
79841866|NCT00968487|Other|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
79841867|NCT00848562|Drug|Nicorandil|Oral administration of nicorandil (15 mg/day)
79246233|NCT03534687|Behavioral|Aerobic Exercise|12-week supervised aerobic exercise
79385131|NCT06112639|Device|Multidimensional dance-based program|Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
79539919|NCT01475357|Other|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
79697856|NCT01155583|Other|DNA methylation analysis|Correlative studies
79697857|NCT01155583|Other|gene expression analysis|Correlative studies
79697858|NCT01155583|Other|bone marrow aspiration|Correlative studies
79697859|NCT01155583|Other|immunohistochemistry staining method|Correlative studies
79697860|NCT01155583|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
79697861|NCT01155583|Other|flow cytometry|Correlative studies
79697862|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
79246234|NCT03526991|Device|Spinal Cord Stimulator (SCS)|"The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
79246235|NCT03521570|Radiation|IMRT|Undergo intensity-modulated radiation therapy
79246236|NCT03521570|Biological|Nivolumab|Given IV
79246237|NCT03474185|Behavioral|Taking Charge of your Heart Health patient education classes|"Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management"
79246238|NCT03468218|Drug|Cabozantinib|Given PO
79246239|NCT03468218|Biological|Pembrolizumab|Given IV
79246240|NCT03457168|Procedure|Treatment of elevated asleep SBP mean|To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required
79246241|NCT03429816|Procedure|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
79246242|NCT03408574|Drug|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
80011667|NCT03671733|Drug|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
80011668|NCT03671733|Drug|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
79697863|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
79697864|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
80011669|NCT03671733|Drug|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
79539920|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
80011670|NCT02200016|Procedure|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
80011671|NCT02200016|Procedure|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
80011672|NCT02200016|Device|B Braun Contiplex S catheter|
79246243|NCT03404336|Behavioral|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
79246244|NCT03404336|Other|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
79385132|NCT06112639|Device|Educational Program|Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
79385133|NCT06112600|Procedure|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
79385134|NCT06112600|Procedure|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
79539921|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
79697865|NCT04603131|Biological|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
80016887|NCT03515317|Behavioral|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
80016888|NCT02286284|Device|Apheresis for extracorporal removal of sFlt-1|
79385135|NCT06112587|Behavioral|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
79539922|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
79539923|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
79539924|NCT01475396|Behavioral|exercise|
79539925|NCT01475409|Biological|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
79697866|NCT04626908|Drug|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
79697867|NCT04627181|Drug|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
79697868|NCT04627181|Drug|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
79697869|NCT04627181|Drug|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
79697870|NCT04627181|Drug|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
79841868|NCT02546154|Drug|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
79841869|NCT03943095|Other|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
79697871|NCT04626830|Other|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
79697872|NCT04626557|Procedure|biopsy|biopsy of the endometrium
79697873|NCT04602897|Other|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
79697874|NCT04626752|Drug|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
79697875|NCT04626752|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
79841870|NCT03943095|Other|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
79841871|NCT00852384|Procedure|NIPPV and IRM|"non invasive positive pressure support ventilation (NIPPV group)~alveolar recruitment maneuver (IRM group)"
79841872|NCT00841932|Procedure|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
79539926|NCT01475422|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
80011673|NCT03119363|Device|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
79246245|NCT03403933|Drug|Didrogyl|"Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study."
79385136|NCT06112574|Behavioral|Visuomotor force control training|Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
79539927|NCT01475422|Behavioral|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
79539928|NCT01475435|Procedure|non- surgical periodontal treatment|scaling and root planning
79539929|NCT01475435|Procedure|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
79539930|NCT01475448|Other|Long distance training|Long distance training during four months, 3 times per week
79539931|NCT01475448|Other|Walking training|Walking training during four months, three times per week
79539932|NCT01475526|Other|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
79697876|NCT04626752|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
79841873|NCT00852462|Behavioral|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
79841874|NCT02850939|Behavioral|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
79841875|NCT00848640|Drug|Sorafenib|400 mg twice daily
79841876|NCT00968565|Drug|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
80011674|NCT03119363|Device|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
80011675|NCT02070042|Drug|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
80011676|NCT02070042|Drug|Placebo|Placebo capsules (olive oil) twice a day
80016889|NCT03104283|Drug|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
80016890|NCT00529178|Drug|Pravastatin|
79841877|NCT04042818|Diagnostic Test|Rehabilitative Ultrasound|Ultrasound imagining
79246246|NCT03397576|Behavioral|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
79385137|NCT06112548|Procedure|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
79385138|NCT06112548|Drug|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
79385139|NCT06112548|Drug|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
79385140|NCT06112548|Drug|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
79246247|NCT03385343|Diagnostic Test|VLE imaging for staging EAC|Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
79385141|NCT06112548|Drug|Paracetamol|IV Paracetamol [Ofirmev] introduced every 6 hours after surgery
79539933|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
80011677|NCT04059081|Drug|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
79841878|NCT04010331|Dietary Supplement|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
79246248|NCT03349996|Device|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
79246249|NCT03347383|Device|Combination therapy DCB + stent|Patients will be treated with the Luminor DCB and iVolution stent
79246250|NCT03341520|Drug|Obinutuzumab Injection [Gazyva]|7x 1000mg flat dose
79246251|NCT03341520|Radiation|Low dose radiation Therapy (LDRT)|2 x 2 Gy
79246252|NCT03333551|Drug|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
79385142|NCT06112548|Drug|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
79539934|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
79385143|NCT06112548|Drug|Tramadol|IV Tramadol [Ultram] introduced when needed after surgery
79385144|NCT06112535|Device|Versius Surgical System|"Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour."
79841879|NCT04010331|Dietary Supplement|Placebo|Placebo for 8 week
79841880|NCT00965133|Other|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
79841881|NCT00848796|Drug|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
80011678|NCT03671655|Device|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
80011679|NCT03671655|Device|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
80011680|NCT02204384|Other|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
79246253|NCT03326583|Drug|Patiromer|Patiromer will be orally self-administered by participants.
79246254|NCT03286361|Device|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
79539935|NCT01475539|Biological|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
79539936|NCT01475552|Drug|Abciximab|Patients, who showed PRU >270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
80011681|NCT02204384|Dietary Supplement|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
79246255|NCT03254940|Behavioral|Charge|Text messaging-based study to determine effect of different components on weight loss.
79246256|NCT03248128|Drug|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
79246257|NCT03248128|Drug|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
79246258|NCT03222570|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
79539937|NCT01475552|Drug|control|"Patients,who showed PRU >270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
79539938|NCT01475578|Drug|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
79539939|NCT01475578|Drug|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
79697877|NCT04602663|Device|Esophageal Variceal Band ligation|Band ligation of OV
79697878|NCT04602585|Behavioral|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
79697879|NCT01155466|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
79697880|NCT01155466|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
79697881|NCT01155466|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
79697882|NCT01155466|Drug|Placebo to Preladenant Tablet|one tablet orally twice daily
79697883|NCT01155466|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
79697884|NCT01155466|Drug|Placebo to Rasagiline capsule|one capsule orally in AM
79841882|NCT00968643|Radiation|radiation therapy|Given in multiple fractions or as a single fraction
79841883|NCT02545764|Other|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
79841884|NCT05251155|Diagnostic Test|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
79841885|NCT00848874|Behavioral|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
79841886|NCT00965211|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
79841887|NCT00842166|Other|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
79841888|NCT00848952|Other|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
79841889|NCT00965289|Drug|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
79841890|NCT04042506|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
79841891|NCT04042506|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
80011682|NCT02204384|Other|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
80011683|NCT01377311|Procedure|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
80011684|NCT02208440|Procedure|Best Repair of torn Rotator Cuff|
80011685|NCT02208440|Device|InSpace™ system|
79246259|NCT03222570|Drug|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
79385145|NCT06112522|Drug|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
79385146|NCT06112509|Other|Vestibular exam|Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
79385147|NCT06112483|Behavioral|SWELE Programme|"This 16-week programme focuses on Supporting Wellness in E-Child Learning Environments (SWELE) programme by combining unstructured outdoor play with mindfulness-based interventions to promote mental health in SEN students, in the context of the COVID-19 pandemic. There is no such SWELE programme to promote mental health for SEN students in Hong Kong, especially in the context of COVID-19 pandemic.~A playful approach of unstructured play has also been found effective on promoting positive emotions and emotional competence among early adolescents (Harn & Bo, 2019). Unstructured Outdoor Play coupled with Mindfulness-based Interventions via SWELE programme to Promote Mental Health for children and adolescents with SEN during COVID-19 pandemic. Very limited unstructured outdoor play-based programme integrated into the extra-curricular activities in the special schools in Hong Kong."
79841892|NCT00251641|Drug|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
80011686|NCT03671577|Behavioral|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
80011687|NCT02200094|Drug|Low dose of Telmisartan, once daily|
80011688|NCT02200094|Drug|High dose of Telmisartan, once daily|
79246260|NCT03222570|Other|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
79246261|NCT03160456|Device|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
79841893|NCT00251641|Drug|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a <25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
79841894|NCT00842322|Behavioral|high fluid intake|fluid intake of 4 litres per day
79841895|NCT00842322|Behavioral|normal fluid intake|Fluid intake of 2 litres per day
79841896|NCT00250705|Drug|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
79841897|NCT00849030|Drug|Anastozole (Arimidex)|1mg, orally, once daily
79841898|NCT00849030|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
79841899|NCT00849030|Drug|Anastozole (Arimidex) placebo|1mg, orally, once daily
79841900|NCT00849030|Drug|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
80011689|NCT01370538|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
80011690|NCT03623295|Other|Blood sample|Blood withdrawal.
79385148|NCT06112470|Other|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
80011691|NCT03623295|Other|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
79385149|NCT06112457|Other|Survey|Anonymous self-administered questionnaire
80011692|NCT03623295|Other|MRI-imaging|MRI imaging of joints.
79697885|NCT00561860|Device|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
79697886|NCT04602351|Behavioral|Communication|policies on communication and informed consent in ICU
79841901|NCT00842400|Drug|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~2 g (four 500 mg) probenecid tablets on Day 29."
79246262|NCT03160456|Device|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
79246263|NCT03136328|Drug|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
79246264|NCT03102580|Other|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
79246265|NCT03067272|Device|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
79246266|NCT03042494|Dietary Supplement|Control|Isocaloric food without the test prebiotic.
79385150|NCT06112444|Other|scale|The scale of Short Western Ontario Rotator Cuff İndex
79385151|NCT06112418|Device|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
80011693|NCT03623295|Other|Physical examination|Physical examination of joint status.
80011694|NCT03248297|Drug|Azithromycin|Azithromycin tablet
80011695|NCT03248297|Drug|Azithromycin and amoxicillin|azithromycin and amoxicillin
79246267|NCT03042494|Dietary Supplement|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
79246268|NCT03026816|Device|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
79246269|NCT03017456|Behavioral|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
79385152|NCT06112405|Other|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
79385153|NCT06112405|Other|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
79539940|NCT01475591|Behavioral|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
80011696|NCT03248297|Drug|Placebo|Placebo tablet
80011697|NCT02208518|Procedure|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
80011698|NCT02208518|Device|EUS-elastography|
80011699|NCT02199626|Device|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
79539941|NCT01475604|Device|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
79539942|NCT01475604|Device|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
79539943|NCT01475617|Dietary Supplement|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
79539944|NCT01475617|Dietary Supplement|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
80011700|NCT02208596|Drug|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
80011701|NCT02208596|Drug|propofol|
80011702|NCT02208596|Drug|Etomidate|
79539945|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
79539946|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
79697887|NCT00561899|Drug|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
79697888|NCT00561899|Drug|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
79697889|NCT00561899|Drug|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
79697890|NCT01155388|Drug|Ferumoxytol|Experimental: Ferumoxytol
79697891|NCT01155388|Drug|Oral Iron|Active Comparator: Oral iron
79697892|NCT04313725|Device|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
79697893|NCT04313725|Other|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
79697894|NCT04626440|Procedure|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
79697895|NCT04313803|Device|CGM|Dexcom CGM system
79697896|NCT00565227|Drug|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
79697897|NCT00565227|Drug|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
79697898|NCT00561938|Procedure|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
79697899|NCT00561938|Procedure|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
79246270|NCT03011385|Behavioral|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
79385154|NCT06112366|Procedure|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
79391454|NCT02468830|Drug|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
79697900|NCT02884726|Drug|BMS-986148|Specified dose on specified days
79697901|NCT04602273|Drug|Azacitidine Injection [Vidaza]|
79246271|NCT03011385|Behavioral|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
79391455|NCT03176082|Other|Mailed Reminders with Fecal Immunochemical Testing kits|
79697902|NCT00562016|Device|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
79697903|NCT00562016|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
79391456|NCT03176082|Other|Reminder letter only|
79391457|NCT03176160|Other|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
79697904|NCT04313491|Other|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
79697905|NCT04313764|Drug|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
79697906|NCT04313764|Drug|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
79697907|NCT04602234|Diagnostic Test|Lung ultrasonography|Investigators performed lung ultrasonography on patients
79697908|NCT04313569|Procedure|Arthroscopic menisctomy|Arthroscopic medial menisctomy
79697909|NCT00624793|Other|Acupuncture|Standard Acup point protocol for treating nausea
79697910|NCT00624793|Other|Individualized Acup based on TCM diagnosis|Acup
79697911|NCT00624793|Other|Sham Acup|Sham Acup - Non-Active
79697912|NCT04626089|Drug|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
79697913|NCT04626089|Drug|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
79841902|NCT00842478|Procedure|Toothbrushing|
79841903|NCT02545296|Other|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
79841904|NCT02545374|Other|Telemedicine|
79841905|NCT02545374|Other|Control|
79246272|NCT03011385|Behavioral|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
79697914|NCT04626323|Procedure|Roux-en-Y gastric bypass|"Pneumoperitoneum closed with Veress needle~Identification of Treitz angle~Measurement of biliary loop (50 cm)~Bowel transection with linear stapler (white load)~Measurement of the alimentary limb (100 cm)~Laterolateral Entero-anastomoses (white load)~Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
79841906|NCT00266695|Drug|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
79841907|NCT00849264|Drug|chemotherapy with endostar|15mg/d×14d
79385155|NCT06112366|Procedure|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
79385156|NCT06112340|Drug|linsitinib|Study medication taken twice daily by mouth
79697915|NCT04626323|Drug|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
79385157|NCT06112301|Diagnostic Test|IdentiClone Dx IGH (IC IGH Dx) Assay|The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
79385158|NCT06112288|Other|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
79385159|NCT06112288|Other|Ankle mobilisation|ankle mobilization is manual therapy technics.
79697916|NCT04602039|Dietary Supplement|Bovine Colostrum|Bovine colostrum (Neovite)
79385160|NCT06112236|Other|no intervention|no intervention
79841908|NCT00849264|Drug|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
79841909|NCT00849264|Drug|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
79539947|NCT01475617|Dietary Supplement|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
79841910|NCT00849342|Drug|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
79841911|NCT00842556|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
80011703|NCT02070120|Drug|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
80011704|NCT02070120|Procedure|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
79246273|NCT03011385|Behavioral|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
79246274|NCT03006731|Behavioral|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
79246275|NCT03006731|Behavioral|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
79385161|NCT06112223|Drug|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
79539948|NCT01475617|Dietary Supplement|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
79539949|NCT01475630|Procedure|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
79539950|NCT01475630|Procedure|control|relaxation
79539951|NCT01475656|Drug|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
79841912|NCT00842556|Drug|Glimepiride|Tablets, Oral, 4 mg, Single Dose
79841913|NCT00842556|Drug|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
79841914|NCT00842634|Biological|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
79841915|NCT00842634|Other|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
79841916|NCT00620022|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
79841917|NCT00620022|Drug|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
79841918|NCT00852852|Behavioral|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
80011705|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
80011706|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
80011707|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
79385162|NCT06112223|Drug|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
80011708|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
79246276|NCT02968784|Device|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
79246277|NCT02966782|Drug|venetoclax|Tablet
79246278|NCT02966782|Drug|azacitidine|Powder for injection, subcutaneously or intravenous
79246279|NCT02961283|Drug|ASN003 ascending doses|
79697917|NCT04601688|Drug|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
80011709|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
79246280|NCT02961283|Drug|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
79539952|NCT01475669|Biological|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
79539953|NCT01475669|Biological|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
79539954|NCT01475695|Drug|14C GSK2251052|1500 mg iv dose GSK2251052
79539955|NCT01475708|Drug|Doxycycline|100 mg PO bid, 14 days
79697918|NCT04601688|Drug|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
80011710|NCT03673215|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
80011711|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
79246281|NCT02925650|Drug|Posiphen|oral solid dosage form capsule
79246282|NCT02925650|Drug|Placebo|oral solid dosage form capsule
79246283|NCT02914938|Drug|ME-401|60 mg
79385163|NCT06112210|Other|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
79385164|NCT06112210|Other|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
79385165|NCT06112145|Other|rehabilitation program|All fingers of the injured hand are fitted with a dorsal blocking orthosis. Early passive mobilization exercises in the form of passive flexion and extension and edema massage will be taught and it will be recommended to be applied every two hours during the day.
79539956|NCT01475760|Other|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
79539957|NCT01475760|Other|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
79697919|NCT04626011|Procedure|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
80011712|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
80011713|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
80011714|NCT02200172|Other|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
80011715|NCT02200172|Other|Placebo|
80011716|NCT03673137|Device|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
80011717|NCT03673137|Drug|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical [Hainan] Co., Ltd. Haikou, China] was administered by intravenous infusion at a dose of 1000 mg/m2.
79246284|NCT02914938|Drug|Rituximab|IV infusion 375 mg/m2
79246285|NCT02914938|Drug|Zanubrutinib|80 and 160 mg bid
79697920|NCT04601766|Drug|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
79841919|NCT00849654|Drug|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
79841920|NCT00849732|Biological|V520|Intentionally Blank
79841921|NCT00849732|Biological|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^9 vp/d given at Day 1, Week 4, and Week 26
79841922|NCT00849732|Biological|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^10 vp/d given at Day 1, Week 4, and Week 26
79841923|NCT00849732|Biological|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
80011718|NCT02066766|Other|No treatment given|Patients will fill out a questionnaire by interview.
79841924|NCT00849966|Drug|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
79841925|NCT00849966|Drug|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
79841926|NCT00853008|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
79841927|NCT00853008|Drug|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
79841928|NCT00853008|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
80011719|NCT02204540|Behavioral|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
79246286|NCT02849457|Drug|Vigabatrin|Subjects randomized to vigabatrin in Arm A will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study (Arm B) and continue to be followed until 36 months of age.
79841929|NCT00853008|Drug|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
79841930|NCT00853008|Drug|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
79841931|NCT00853008|Drug|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
79246287|NCT02849457|Drug|Placebo|Subjects randomized to placebo in Arm A will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study (Arm B) and continue to be followed until 36 months of age.
80011720|NCT02066844|Drug|Celestone|2cc
80011721|NCT02066844|Drug|Lidocaine|5cc
80011722|NCT03669783|Drug|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
80011723|NCT03669783|Drug|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
79246288|NCT02802631|Drug|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
79246289|NCT02802631|Other|Placebo|Placebo - Normal Saline
79246290|NCT02770586|Diagnostic Test|Breast PET|imaging of the breast using the Breast PET system
79385166|NCT06112119|Device|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
79385167|NCT06112067|Device|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
79841932|NCT00853008|Drug|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
79841933|NCT00853008|Drug|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
79841934|NCT00853008|Drug|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
79841935|NCT00853008|Drug|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
79841936|NCT00853008|Drug|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
79841937|NCT00853008|Drug|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
79841938|NCT00853086|Drug|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
79841939|NCT00853164|Behavioral|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
79841940|NCT00853164|Behavioral|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
79841941|NCT00853164|Behavioral|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
80011724|NCT03669783|Drug|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
80011725|NCT03669783|Drug|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
80011726|NCT03669783|Drug|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
80011727|NCT02204618|Device|cochlear implantation|
79841942|NCT00923988|Other|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
79385168|NCT06112041|Drug|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|RC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin
79841943|NCT02545530|Drug|transdermal clonidine|2.5mg/patch per week
79841944|NCT00853320|Drug|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
79841945|NCT00853320|Drug|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
79841946|NCT00853398|Procedure|surgical technique|
80011728|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
80011729|NCT02067078|Drug|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
80011730|NCT02067078|Drug|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
80011731|NCT02067078|Drug|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
80011732|NCT03673059|Drug|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
80011733|NCT03673059|Other|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
79246291|NCT02757898|Drug|Biotin-Labeled Red Blood Cells (RBCs)|"500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
79246292|NCT02754479|Device|Nd:YAG laser|Treatment of lower extremity spider veins
79246293|NCT02747888|Genetic|•Referral to Genetic Counselor, if indicated|
79385169|NCT06112028|Drug|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
79385170|NCT06112028|Other|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
79385171|NCT06112002|Other|Educational Intervention|Attend an educational session
79841947|NCT00547521|Drug|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
80011734|NCT05461235|Drug|Pembrolizumab|2mg/kg or 200mg,iv,q3w
80011735|NCT05461235|Drug|Nivolumab|3mg/kg or 240mg,iv,q2w
80011736|NCT05461235|Drug|Sintilimab|200mg,iv,q3w
80011737|NCT05461235|Drug|Toripalimab|3mg/kg or 240mg,iv,q2w
80011738|NCT05461235|Drug|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
79246294|NCT02730546|Drug|Carboplatin|Given IV
79246295|NCT02730546|Procedure|Computed Tomography|Undergo CT scan
79385172|NCT06112002|Behavioral|Health Education|Receive educational materials
79385173|NCT06112002|Other|Survey Administration|Ancillary studies
79539958|NCT01475799|Device|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
79841948|NCT00547521|Drug|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
79841949|NCT02546310|Drug|HTL0009936|
79841950|NCT02546310|Drug|HTL0009936 matching placebo|
79841951|NCT00850044|Drug|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
79841952|NCT00850044|Drug|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
79841953|NCT00850044|Drug|placebo for ABT-450|capsules, QD, one dose
79841954|NCT00850044|Drug|Placebo for ritonavir|capsules, QD, one dose
79841955|NCT00266227|Drug|placebo|Intravenous repeating dose
79841956|NCT00266227|Drug|rituximab|Intravenous repeating dose
79841957|NCT00266227|Drug|methotrexate|Oral or parenteral repeating dose
80011739|NCT05461235|Drug|Tislelizumab|200mg,iv,q3w
80011740|NCT05461235|Biological|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10^6 cells/Kg) was completed on day 14.
80011741|NCT02204696|Procedure|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
80016891|NCT03659175|Other|SIBO|SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
80011742|NCT02070198|Drug|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
79246296|NCT02730546|Drug|Fluorouracil|Given IV
79246297|NCT02730546|Other|Laboratory Biomarker Analysis|Correlative studies
79697921|NCT04601766|Drug|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
79697922|NCT04625816|Device|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
79697923|NCT01154452|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
79697924|NCT01154452|Other|Laboratory Biomarker Analysis|Correlative studies
79246298|NCT02730546|Drug|Leucovorin Calcium|Given IV
79697925|NCT01154452|Other|Pharmacological Study|Correlative studies
79246299|NCT02730546|Drug|Oxaliplatin|Given IV
79385174|NCT06111989|Behavioral|Neuropsychological testing|The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.
79385175|NCT06111989|Behavioral|On road test|The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
79385176|NCT06111976|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
79385177|NCT06111976|Procedure|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
79385178|NCT06111950|Other|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
79385179|NCT06111950|Other|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
79697926|NCT01154452|Drug|Vismodegib|Given PO
79697927|NCT04625894|Radiation|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
79697928|NCT04625894|Drug|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
79841958|NCT00266227|Drug|folate|Intravenous repeating dose
80011743|NCT02070198|Drug|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
80011744|NCT02070198|Drug|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
80011745|NCT03672981|Behavioral|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
80011746|NCT03672981|Other|Quality-of-Life Assessment|Ancillary studies
80011747|NCT03672981|Other|Questionnaire Administration|Ancillary studies
79246300|NCT02730546|Drug|Paclitaxel|Given IV
79246301|NCT02730546|Biological|Pembrolizumab|Given IV
79246302|NCT02730546|Procedure|Positron Emission Tomography|Undergo PET scan
79246303|NCT02730546|Radiation|Radiation Therapy|Undergo radiation therapy
79246304|NCT02730546|Procedure|Therapeutic Conventional Surgery|Undergo curative-intent surgery
79246305|NCT02712255|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
79385180|NCT06111950|Other|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
79385181|NCT06111937|Other|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
79385182|NCT06111924|Other|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
79391458|NCT02418858|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
79841959|NCT00968877|Drug|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
79697929|NCT01154296|Behavioral|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
79697930|NCT04601025|Dietary Supplement|Yoghurt|200 ml plain full-fat yoghurt
79697931|NCT04601025|Dietary Supplement|Chickpea+Yoghurt|80 ml plain full-fat yoghurt + 70 gr cooked chickpea
79697932|NCT04601025|Dietary Supplement|Oat+Yoghurt|80 ml plain full-fat yoghurt + 100 gr cooked oat
79697933|NCT04625855|Drug|TBPM-PI-HBr|TBPM-PI-HBr (3 x 200 mg tablets) once
79697934|NCT02884570|Other|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
79697935|NCT04313452|Other|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
79697936|NCT04313686|Behavioral|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
79697937|NCT04313686|Behavioral|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
79697938|NCT04625933|Other|No intervention|No intervention
79246306|NCT02712255|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
79385183|NCT06111924|Other|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
79385184|NCT06111911|Diagnostic Test|HPV Diagnostic Kit (Bio Farma)|Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
79841960|NCT02729727|Device|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
80011748|NCT03672981|Behavioral|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
80011749|NCT02208674|Other|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
79385185|NCT06111885|Drug|Indapamide 2.5 MG|1 indapamide 2.5 mg capsule per day for 28 days
79385186|NCT06111885|Drug|Hydrochlorothiazide 50Mg|1 hydrochlorothiazide 50 mg capsule per day for 28 days
79385187|NCT06111885|Drug|Chlorthalidone 25mg|1 chlorthalidone 25 mg capsule per day for 28 days
79385188|NCT06111872|Drug|Ketamine|Administration described in arm/ group description
79385189|NCT06111872|Drug|Midazolam|Administration described in arm/ group description
79385190|NCT06111872|Drug|Pethidin|Administration described in arm/ group description
79697939|NCT04600986|Other|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
79697940|NCT01154218|Drug|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
79697941|NCT04601142|Drug|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
79697942|NCT04625582|Behavioral|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
79697943|NCT04625582|Behavioral|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
79841961|NCT00965367|Device|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
79841962|NCT00287365|Drug|ozone|2 hour exposure to 0.4 ppm ozone
79841963|NCT00850122|Drug|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
79841964|NCT00968955|Drug|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
79841965|NCT00843258|Device|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
79246307|NCT02712255|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
79697944|NCT00565305|Behavioral|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
79697945|NCT00565305|Radiation|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
79697946|NCT04625348|Device|Ultracore Repose® mattress|residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
79697947|NCT04625348|Other|experiences and perceptions of healthcare workers|Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
79697948|NCT04625543|Drug|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
79697949|NCT04625543|Drug|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
79697950|NCT04601259|Combination Product|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
79697951|NCT04601259|Device|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
79385191|NCT06111859|Diagnostic Test|Ultrasound based Elastography and fat quantification|Correlation of ultrasound-based elastography and fat quantification on liver biopsy
79841966|NCT01072279|Other|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
79385192|NCT06111820|Behavioral|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
79385193|NCT06111768|Drug|Dapagliflozin|Receipt of 10mg oral dose of dapagliflozin once daily for three days
79391459|NCT02470234|Drug|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning
79391460|NCT02470234|Drug|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning
79539959|NCT01475812|Other|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
79539960|NCT01475864|Procedure|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
79539961|NCT01475877|Drug|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
79539962|NCT01475890|Dietary Supplement|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
79539963|NCT01475890|Dietary Supplement|Placebo|Once a day for 12 months.
79539964|NCT01475903|Procedure|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
79697952|NCT04625309|Other|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
79697953|NCT00565383|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural
79697954|NCT00565383|Procedure|Intravenous fentanyl (50mcg)|Intravenous fentanyl
79697955|NCT04625387|Other|Dry Needle and Exercise|"A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side"
79841967|NCT01072279|Other|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
79841968|NCT00850278|Other|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
79697956|NCT04625426|Device|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
79697957|NCT04625426|Device|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
79841969|NCT05279625|Device|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
79841970|NCT00853554|Drug|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
80011750|NCT03672903|Device|Weight Vest|A vest with added weights up to a maximum of 15 kg.
80011751|NCT02067156|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
80011752|NCT04058613|Drug|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
80011753|NCT04058613|Other|placebo|placebo
80011754|NCT02067234|Other|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
80011755|NCT02067234|Behavioral|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
80011756|NCT02801747|Behavioral|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
80011757|NCT03533270|Procedure|Urethroplasty|Surgical repair of Urethral injury
80011758|NCT03671499|Behavioral|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
80011759|NCT02070432|Drug|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
80011760|NCT02208752|Other|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
80011761|NCT02067312|Other|Thai massage|
79246308|NCT02712255|Behavioral|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
79385194|NCT06111716|Other|Mindfulness- Based Childbirth Education|Mindfulness- Based Childbirth Education Group includes; Women were given eight-week birth preparation training. In this training, in addition to information about birth, mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness in pregnancy and postpartum period, mindfulness breastfeeding and meditation practices were included.
79539965|NCT01475916|Behavioral|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
80011762|NCT02200406|Drug|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
79246309|NCT02691689|Other|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
79385195|NCT06111716|Other|Information-Based Birth Education|In the Information-Based Birth Education Group, women were given 4-week (4 hours per week) birth preparation training. The education given was not based on a philosophy or method.
79385196|NCT06111703|Behavioral|Knowledge assessment|Knowledge, Attitude and Practice Survey
79391461|NCT02470234|Drug|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
79391462|NCT02418702|Drug|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
80011763|NCT03782298|Device|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|Observational, post-market, clinical follow-up study
79539966|NCT01475929|Dietary Supplement|Probiotic supplement|A single strain probiotic supplement given at two doses
79539967|NCT01475942|Dietary Supplement|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
79539968|NCT01475968|Other|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
79539969|NCT01475968|Other|Filtered Air|Filtered Air
79539970|NCT01475981|Drug|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
79697958|NCT04625426|Device|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
79697959|NCT04625075|Diagnostic Test|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
79697960|NCT04625075|Diagnostic Test|Cardiac CT|Cardiac CT to assess coronaries
79697961|NCT04625075|Diagnostic Test|Electrocardiogram (ECG)|ECG to assess rhythm
79697962|NCT04625075|Diagnostic Test|Blood samples|renal function liver function full blood count, hematocrit glucose
80011764|NCT02204852|Drug|Iloprost+eptifibatide|
80011765|NCT02204852|Drug|Placebo|
80011766|NCT02071836|Behavioral|Right Turns web application|
80011767|NCT02071836|Behavioral|Treatment as usual|
80011768|NCT02204930|Drug|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
80011769|NCT02200484|Behavioral|Combined parent training and obesity prevention program|
80011770|NCT02200484|Behavioral|Wellness program (active contact control)|
80011771|NCT02070510|Drug|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
79697963|NCT04591548|Diagnostic Test|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
79697964|NCT04625192|Procedure|Trephine osteotomy|"Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
79697965|NCT04625114|Drug|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1->D5);
79697966|NCT04625114|Drug|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1->D5).
79697967|NCT04625114|Drug|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6->D10);
79697968|NCT04625114|Drug|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6->D10).
79697969|NCT04592133|Diagnostic Test|Ultrasonography|Ultrasonography Examination
79697970|NCT04624880|Device|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
79841971|NCT00853554|Drug|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
80011772|NCT02070510|Drug|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
79697971|NCT04591470|Diagnostic Test|Mar test|Study of antisperm antibodies
80011773|NCT02070510|Drug|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
80011774|NCT02070510|Drug|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
79246310|NCT02672098|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
79246311|NCT02672098|Drug|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
79246312|NCT02669797|Behavioral|In-home Visits and Food Preparation Activities|"Families will participate in twelve in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally ,a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
79385197|NCT06111690|Procedure|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
79385198|NCT06111638|Genetic|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
79539971|NCT01475994|Other|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
79697972|NCT04624841|Drug|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
79841972|NCT02586597|Device|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
80011775|NCT02258126|Other|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
79539972|NCT01475994|Other|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
79539973|NCT01476007|Drug|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
79539974|NCT01476007|Drug|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
79539975|NCT01476033|Dietary Supplement|nutraceutical group|6 capsules of supplement or placebo for 8wk
79539976|NCT01476046|Drug|GSK1995057 single dose|Single intravenous dose
79539977|NCT01476046|Drug|Placebo|Single intravenous dose
79697973|NCT04624607|Device|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
79697974|NCT04624607|Device|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
79539978|NCT01476059|Other|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
79697975|NCT00567099|Drug|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
79697976|NCT04624802|Behavioral|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
79697977|NCT00567177|Drug|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
79697978|NCT04624373|Other|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
79697979|NCT04591158|Device|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
79697980|NCT03454607|Device|FREE robot|FREE robot to hold endoscope
79539979|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
79246313|NCT02669797|Behavioral|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
79697981|NCT00567216|Drug|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
79303690|NCT05178381|Device|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates [x,y,z] = [35,50,15] for frontal pole and [x,y,z] = [56,16,22] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
79385199|NCT06111625|Drug|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
79385200|NCT06111599|Procedure|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
79385201|NCT06111560|Other|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
79391463|NCT02418702|Other|placebo|20 patients will randomly be assigned a placebo
79391464|NCT02412930|Procedure|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
79539980|NCT01476072|Other|MRI scan|MRI scan only, methodology study with no other intervention
79539981|NCT01476085|Radiation|ML10|[18F]ML10 radioligand apoptosis biomarker
79539982|NCT01476098|Drug|Placebo|SB-705498 placebo
79539983|NCT01476098|Drug|SB-705498|400 or 600mg oral SB-705498
79539984|NCT01476124|Drug|morphine Placebo|Morphine Placebo
79539985|NCT01476124|Drug|GEn 600 mg|Gabapentin enacarbil 600 mg
79539986|NCT01476124|Drug|Morphine|morphine extended release 60 mg
79697982|NCT00562055|Drug|Atomoxetine|
79697983|NCT00562055|Drug|PNU-165442G; [S,S]-reboxetine|
79539987|NCT01476124|Drug|GEn Placebo|Gabapentin enacarbil placebo
79539988|NCT01476137|Drug|GSK1120212|MEK inhibitor
79539989|NCT01476137|Drug|GSK2110183|AKT inhibitor
79539990|NCT01476163|Drug|migalastat HCl|150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
80011776|NCT02070666|Behavioral|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure < 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cmH2O"
80011777|NCT02070666|Behavioral|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~· FiO2 > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cm H2O."
80011778|NCT02070666|Other|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
80011779|NCT02200562|Drug|ipilimumab and dabrafenib|
80011780|NCT02205008|Procedure|surgery|Total or subtotal gastrectomy with D2
79246314|NCT02669797|Behavioral|Feedback on Video-recorded Family Meals|Parents will video-record and upload via an iPad (study provided) one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
79385202|NCT06111534|Behavioral|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
79385203|NCT06111521|Drug|LY3537982|Administered orally
79385204|NCT06111521|Drug|Digoxin|Administered orally
79385205|NCT06111521|Drug|Rosuvastatin|Administered orally
79539991|NCT01476176|Drug|Experimental paracetamol|experimental paracetamol with caffeine
79385206|NCT06111521|Drug|Midazolam|Administered orally
79385207|NCT06111521|Drug|Midazolam|Administered IV
79385208|NCT06111482|Device|Intense pulsed light.|The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
79539992|NCT01476176|Drug|Paracetamol marketed formulation|marketed formulation containing caffeine
79539993|NCT01476189|Drug|Experimental paracetamol formulation|experimental
79539994|NCT01476189|Drug|Marketed paracetamol|Marketed paracetamol
79539995|NCT01476189|Drug|Higher dose marketed paracetamol|Higher dose marketed paracetamol
79539996|NCT01476215|Drug|Paracetamol fast dissolution suspension|
79539997|NCT01476215|Drug|Paracetamol medium dissolution suspension|
79539998|NCT01476215|Drug|Paracetamol slow dissolution suspension|
79539999|NCT01476215|Drug|Paracetamol|
79697984|NCT04590729|Behavioral|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
79540000|NCT01476228|Device|EEG recording|EEG recording
79540001|NCT01476241|Procedure|PEG tube placement|Percutaneous endoscopic gastrostomy
79540002|NCT01476280|Drug|palonosetron|0.075mg immediately before induction of anesthesia
79540003|NCT01476280|Drug|Ramosetron|0.3mg immediately before induction of anesthesia
79697985|NCT04590729|Behavioral|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
79540004|NCT01476306|Other|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
79540005|NCT01476306|Other|Usual care|Patients in this group will receive care as they usually do with the physician.
79540006|NCT01476319|Other|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
79540007|NCT01476332|Drug|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
79697986|NCT04624022|Diagnostic Test|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
79697987|NCT04590807|Device|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
79697988|NCT04590807|Device|Anterior vertebral body tethering|Vertebral screws and cable
79697989|NCT00567294|Behavioral|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
79697990|NCT00567294|Behavioral|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
80011781|NCT02205008|Drug|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
79697991|NCT00567294|Behavioral|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
79841973|NCT00843336|Behavioral|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
80011782|NCT02205008|Drug|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
80011783|NCT02067546|Device|Experimental toilet seat|
79246315|NCT02669797|Behavioral|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
79246316|NCT02649335|Drug|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
79246317|NCT02649335|Procedure|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
79246318|NCT02602262|Other|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
79385209|NCT06111482|Device|Radiofrequency microneedling device|The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
79841974|NCT00843336|Behavioral|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
80011784|NCT02067546|Device|Standard toilet seat|
80011785|NCT02067624|Other|Thai massage|
80011786|NCT02208908|Other|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
80011787|NCT02072070|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
80011788|NCT02072070|Drug|Placebo|Placebo control(Normal Saline)
80016892|NCT03556644|Radiation|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
79246319|NCT02589496|Drug|pembrolizumab|200 mg every 3 weeks
79246320|NCT02584244|Drug|LUM015|
79246321|NCT02584244|Device|LUM 2.6 Imaging Device|
79303691|NCT05145855|Other|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
79385210|NCT06111482|Device|Radiofrequency device|The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
79385211|NCT06111482|Device|Combined energy devices|The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
79540008|NCT01476332|Drug|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
79540009|NCT01476332|Drug|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
79540010|NCT01476358|Dietary Supplement|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
79540011|NCT01476371|Behavioral|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
79540012|NCT01476384|Dietary Supplement|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
79540013|NCT01476384|Dietary Supplement|Placebo|250 ml water
79540014|NCT01476410|Drug|brentuximab vedotin|Given IV
79540015|NCT01476410|Drug|doxorubicin hydrochloride|Given IV
79540016|NCT01476410|Drug|vinblastine|Given IV
79540017|NCT01476410|Drug|dacarbazine|Given IV
79540018|NCT01476410|Procedure|quality-of-life assessment|Ancillary studies
79697992|NCT04624412|Other|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~5-10 min warm up~30 min moderate aerobic exercise (Treadmill walking exercise)~Constant intensity at 50% - 70% of max HR (3-6 METS)~5-10 min cool down"
79841975|NCT01071109|Procedure|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
79841976|NCT00853710|Other|PSA assay|rapid prostate specific antigen assay.
79841977|NCT00969033|Drug|CS-1008|CS-1008
79841978|NCT00969033|Drug|irinotecan|irinotecan
80011789|NCT02205086|Other|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
79697993|NCT04624412|Other|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~5-10 min warm up~30 min mild aerobic exercise (Treadmill walking exercise)~Constant intensity at 30-50 % of max HR (1-3 METS)~5-10 min cool down"
79841979|NCT00965601|Behavioral|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
79841980|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
79841981|NCT00573768|Drug|Placebo|Vehicle 2 times daily
79841982|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
79841983|NCT04042428|Drug|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
79841984|NCT02546076|Device|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
79841985|NCT02546076|Device|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
79697994|NCT04590924|Procedure|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
79697995|NCT00567333|Other|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
79385212|NCT06111456|Other|Questionnaire|Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
79540019|NCT01476410|Genetic|DNA analysis|Optional correlative studies
79697996|NCT00567333|Other|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
79841986|NCT02415387|Biological|typhoid vaccine|Given IM
79841987|NCT02415387|Other|Placebo|Given IM
79841988|NCT00969267|Other|ear-acupuncture A|with needle stimulation
79841989|NCT00969267|Other|stimulation B|with bread stimulation on ear acupuncture point
79841990|NCT00969267|Other|stimulation C|without needle stimulation
79841991|NCT00850434|Device|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
79841992|NCT00850434|Device|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
79841993|NCT00969345|Other|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
79841994|NCT00969345|Other|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
80011790|NCT02200640|Drug|High dose of Micardis®, once daily|
80011791|NCT02200640|Drug|Low dose of Micardis®, once daily|
80011792|NCT02200640|Drug|Low dose of COZAAR®, once daily|
79841995|NCT00850512|Drug|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
79303692|NCT04983303|Other|TICK-B group|These interventions will distract the child during venipuncture
79303693|NCT05636007|Device|Huawei Watch|pulse rate variability measured by a smartwatch
79540020|NCT01476410|Genetic|RNA analysis|Optional correlative studies
79540021|NCT01476410|Radiation|fludeoxyglucose F 18|Correlative studies
79303694|NCT02633787|Biological|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
79303695|NCT05635773|Device|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
79540022|NCT01476410|Procedure|positron emission tomography|Correlative studies
79540023|NCT01476410|Other|laboratory biomarker analysis|Optional correlative studies
79540024|NCT01476410|Other|immunohistochemistry staining method|Optional correlative studies
79540025|NCT01476410|Genetic|polymorphism analysis|Optional correlative studies
79841996|NCT00850512|Drug|Zevalin|12-week safety period for Zevalin
79841997|NCT00969423|Device|5mm videoscope|use of 5mm videoscope
79841998|NCT00969423|Device|10mm videoscope|use of 10mm videoscope
79841999|NCT00850590|Drug|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
79842000|NCT00965913|Drug|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
79842001|NCT00965913|Drug|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
80011793|NCT02200640|Drug|High dose of COZAAR®, once daily|
80011794|NCT02200640|Drug|Placebo|
80016893|NCT03077061|Procedure|Open flap debridement|Open flap debridement using saline as irrigation
80016894|NCT03077061|Device|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
80016895|NCT03556566|Biological|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
79697997|NCT04623866|Drug|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
79697998|NCT04623866|Drug|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
79697999|NCT00567372|Drug|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
79698000|NCT00562133|Drug|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
79698001|NCT00562133|Drug|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
79698002|NCT00567411|Drug|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
79698003|NCT00567411|Drug|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
79698004|NCT00562172|Drug|Insulin glargine|Once daily in the morning
79698005|NCT00562172|Drug|Glimepiride|Once daily in the morning
79842002|NCT00965913|Drug|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
79842003|NCT00853866|Drug|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
79842004|NCT00853866|Drug|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
79842005|NCT00853866|Device|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
80016896|NCT00382460|Drug|PRAVASTATIN SODIUM|
80016897|NCT00523328|Drug|BG9924|dosage administered as per Biogen-idec protocol
79246322|NCT02309580|Drug|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
79385213|NCT06111456|Other|Interview|Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
79385214|NCT06111417|Other|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~STAI-Y (State-Trait Anxiety Inventory)~Patient's Questionnaire~Practitioner's questionnaire"
79246323|NCT02266121|Device|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
79246324|NCT02213575|Drug|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
79303696|NCT05635695|Other|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
79385215|NCT06111417|Other|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
79698006|NCT00562172|Drug|Metformin|At least 1000 mg/day
79698007|NCT00567450|Drug|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
79698008|NCT00567450|Drug|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
79698009|NCT00562211|Drug|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
79698010|NCT00562211|Drug|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
79698011|NCT00567528|Drug|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
79698012|NCT00567528|Drug|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
79698013|NCT01154140|Drug|treatment|crizotinib 250mg orally continuous twice daily dosing
79698014|NCT01154140|Drug|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
79698015|NCT04623749|Procedure|US|Percutaneous Ultrasound guided FNAC
79698016|NCT04623749|Procedure|EUS|Endoscopic Ultrasound guided FNAC
79698017|NCT04590768|Other|Fermotein based meals|various meal products: bread, soup and an occasional burgers
79698018|NCT04590768|Other|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
79698019|NCT04623788|Diagnostic Test|Cardiac MRI|Cardiac MRI with contrast
79842006|NCT00853866|Device|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
79842007|NCT00855660|Drug|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
79842008|NCT00855660|Drug|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
79842009|NCT00853944|Drug|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
80016898|NCT02920983|Device|somofilcon A|contact lens
80016899|NCT02920983|Device|nelfilcon A II 2|contact lens
80016900|NCT02920983|Device|omafilcon A ll 2|contact lens
79540026|NCT01476423|Drug|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
79698020|NCT04590612|Drug|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
79698021|NCT04590612|Drug|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
79540027|NCT01476436|Other|Low carbohydrate dietary advice|Dietary advice
79842010|NCT02545452|Drug|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
79842011|NCT02545452|Drug|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
80011795|NCT02067702|Procedure|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
79246325|NCT02148796|Drug|Broncho-Vaxom (BV)|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package
79246326|NCT02148796|Other|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
79246327|NCT02139787|Other|Radio Story|
79246328|NCT02139787|Other|Control -listened to a brochure|
79246329|NCT02133872|Drug|Minocycline dose escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/> 5mm Hg BP subjects will receive minocycline 200 mg.
79698022|NCT04623476|Procedure|Pathophysiological Excision for Crohn's disease|Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
79698023|NCT04590378|Other|intensive care unit admission ratio|intensive care unit admission ratio
79698024|NCT04590339|Procedure|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
79698025|NCT04623164|Drug|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
79842012|NCT02545452|Drug|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
79842013|NCT02545452|Drug|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
79540028|NCT01476436|Other|Continue usual diet|Dietary advice
79540029|NCT01476488|Drug|tacrolimus|
79246330|NCT02095249|Drug|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
79246331|NCT02086864|Drug|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
79246332|NCT02086864|Drug|Placebo lactose/sucrose pill|
79246333|NCT02086864|Behavioral|Homeopathic consultation|
79246334|NCT02036476|Drug|Cabozantinib|oral administration
79246335|NCT02034955|Radiation|Post-operative Adaptive Radiation Therapy|
79540030|NCT01476514|Other|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
79540031|NCT01476527|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
79540032|NCT01476540|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
79842014|NCT02545452|Other|Tampon|
79842015|NCT00547365|Biological|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
80011796|NCT02200718|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
79698026|NCT04623164|Procedure|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
79698027|NCT00562250|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
79842016|NCT00854178|Drug|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
80011797|NCT02200718|Biological|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
79540033|NCT01476553|Procedure|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
79698028|NCT00562250|Drug|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
79698029|NCT00562250|Drug|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
80011798|NCT02070900|Device|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
80011799|NCT02070900|Other|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
79246336|NCT01832779|Other|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
79540034|NCT01476579|Device|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
80011800|NCT02208986|Drug|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
79540035|NCT01476592|Dietary Supplement|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
79246337|NCT01820884|Procedure|TH|Total hysterectomy
79842017|NCT00850668|Biological|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
79842018|NCT04009473|Combination Product|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
79842019|NCT00850746|Drug|YM443|Oral
79540036|NCT01476605|Procedure|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
79540037|NCT01476605|Procedure|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
79842020|NCT00850746|Drug|Placebo|Oral
79842021|NCT00850746|Drug|Moxifloxacin|Oral
79246338|NCT01820884|Procedure|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
79246339|NCT01820884|Procedure|BPLND|bilateral pelvic and para-aortic lymph node dissection
79246340|NCT01820858|Drug|Paclitaxel|175 mg/m(2), intravenously (IV)
80011801|NCT02200796|Other|Control Meal|High carbohydrate meal
79246341|NCT01820858|Drug|Paraplatin (Carboplatin Injection)|AUC=5, IV
79246342|NCT01820858|Radiation|Pelvic Radiation|45-50 Gy
79246343|NCT01820858|Radiation|Vaginal Brachytherapy 1|5 Gy, 3 times
79698030|NCT00562289|Drug|aspirin|during the follow up
79698031|NCT00562289|Drug|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
79698032|NCT00562289|Device|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
79698033|NCT01154101|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
80011802|NCT02200796|Other|Low Protein Meal|Omelet with 15 g of protein
80011803|NCT02200796|Other|Moderate Protein Meal|Omelet with 30 g of protein
80011804|NCT02200796|Other|High Protein Meal|Omelet with 45 g of protein
80011805|NCT02067780|Drug|Levofloxacin 500mg|One tablet per day for 7days.
80011806|NCT02205164|Drug|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
80011807|NCT02205164|Drug|Palonosetron|Aloxi 0.25mg
80011808|NCT02072304|Behavioral|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
80011809|NCT02072304|Behavioral|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
80011810|NCT02257814|Behavioral|Incredible Years Teacher Training|
80011811|NCT02257814|Behavioral|Preschool PATHS|
80011812|NCT02257814|Behavioral|Tools of the Mind|
80011813|NCT03559998|Other|lecture|"Empathy (1 hour)~Doctor- patient relationship (1, 5 hour)"
79246344|NCT01820858|Radiation|Vaginal brachytherapy 2|5 Gy, 2-4 times
80011814|NCT03559998|Other|Simulation using Role play|"serious illness announcement~abuse demand management~reticent patient management"
80011815|NCT03559998|Other|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
79385216|NCT06111404|Procedure|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
79698034|NCT01154101|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
79698035|NCT04313218|Drug|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
79698036|NCT04590261|Other|Blood sampling|Peripheral Blood sampling, 25 mL
79246345|NCT01802242|Radiation|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
79540038|NCT01476605|Procedure|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
79698037|NCT04590261|Other|Nasal Brushing|Nasal Brushing, facultative
80011816|NCT03559998|Other|Simulation using Simulated patient|"HIV announcement~Refuse of antibiotic prescription"
79246346|NCT01802242|Other|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
79246347|NCT01755897|Procedure|radical hysterectomy + pelvic lymph node dissection|
79246348|NCT01755897|Drug|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
79246349|NCT01755897|Drug|Cisplatin|75 mg/m(2) IV on day 2 and 3
79246350|NCT01755897|Drug|Cisplatin|35 mg/m(2) IV once a week
79246351|NCT01755897|Radiation|Pelvic RT|IMRT
79698038|NCT00624871|Drug|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
79842022|NCT00969735|Device|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
79246352|NCT01738607|Dietary Supplement|Psyllium|
80011817|NCT02076282|Other|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
80011818|NCT02200952|Drug|recombinant LH|recombinant LH twice/day for 10 days from pick up
80011819|NCT02071212|Drug|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
79246353|NCT01738607|Dietary Supplement|Gum Arabic|Gum acacia dietary fiber
79540039|NCT01476618|Other|No Intervention|No Intervention
79540040|NCT01476631|Behavioral|Walking|"7 days prior to baseline participants must wear a blinded pedometer~At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
79540041|NCT01476657|Drug|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
79540042|NCT01476670|Other|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
79540043|NCT01476683|Drug|Racecadotril|Film-coated tablet
79540044|NCT01476683|Drug|Racecadotril|Racecadotril Powder Blend
79698039|NCT00624871|Drug|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
79698040|NCT00624871|Drug|Placebo|
79698041|NCT01153984|Drug|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
79698042|NCT02884375|Other|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~comorbidities (CIRS G)~polypharmacy (number of medications)~social environment (primary caregiver, support at home, friends , family, living alone)~urinary and/or fecal incontinence"
79698043|NCT04623203|Other|No intervention|No intervention
79698044|NCT05250271|Other|15 g dextrose|15 g dextrose tablets
79698045|NCT05250271|Other|5 g dextrose|5 g dextrose tablets
79698046|NCT05250271|Other|Protein bar|5 g carbohydrates + 10 g protein
79698047|NCT04623359|Device|High resolution manometry|High resolution manometry
79709933|NCT00596856|Behavioral|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
79709934|NCT01335464|Drug|placebo|placebo matching BIBF1120, BID
79709935|NCT01335464|Drug|BIBF 1120|BIBF1120 BID (twice daily)
79698048|NCT01153633|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
80011820|NCT03396770|Procedure|Standard clinical routine|Patient management is carried out according to the usual service protocol
79698049|NCT01153633|Device|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
79698050|NCT04590183|Drug|FK-506 (Drug)|Twice a day
79698051|NCT04590183|Drug|Prednisolone Acetate 1% Oph Susp|Four times a day
79246354|NCT01738607|Dietary Supplement|carboxymethylcellulose|dietary fiber
79246355|NCT01738607|Dietary Supplement|Placebo|
79246356|NCT01728259|Drug|pomalidomide|Given PO
79540045|NCT01476683|Drug|Racecadotril|Marketed Capsule
79698052|NCT04623281|Device|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
80011821|NCT03396770|Procedure|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~If the test is negative, patient management is carried out according to the usual protocol.~A second test is realized 6 hours after the first test whatever the result of it."
80011822|NCT02072382|Drug|Metformin|metformin 850mg twice a day for eight weeks
80011823|NCT02072382|Drug|Placebo|
80011824|NCT02209220|Device|Positive airway pressure for the treatment of OSA|
79246357|NCT01728259|Drug|bortezomib|Given IV
79246358|NCT01728259|Drug|dexamethasone|Given PO
80011825|NCT02072460|Other|electromyography|
80011826|NCT02072460|Other|electroencephalography|
80011827|NCT02072460|Other|approaches from psychophysics|
80016901|NCT00523250|Drug|AR-102 0.003% Ophthalmic Solution|
79246359|NCT01728259|Other|Laboratory Biomarker Analysis|Correlative studies
79246360|NCT01722604|Drug|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
79246361|NCT01722604|Drug|Azopt 1%|Azopt 1%, RLD
79246362|NCT01714050|Behavioral|Cognitive-Behavioral Therapy (CBT)|
79246363|NCT01714050|Device|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
79246364|NCT01519843|Device|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
79246365|NCT01519843|Device|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
79246366|NCT01503073|Device|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
79246367|NCT01296022|Device|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
79246368|NCT01296022|Device|Implantation of transvenous ICD|Implantation of transvenous ICD
79246369|NCT01202994|Drug|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
79246370|NCT01075672|Behavioral|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
79246371|NCT00930943|Drug|Oxymorphone ER|40 mg qd twice
79246372|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
79246373|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
79540046|NCT01476683|Drug|Racecadotril|Marketed Film-coated Tablet
79540047|NCT01476735|Other|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
79540048|NCT01476761|Device|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
80011828|NCT02205242|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
79698053|NCT01153321|Drug|AZD2423|100mg Oral dose od
79698054|NCT01153321|Drug|AZD2423 Placebo|Oral dose od
79698055|NCT04590456|Other|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
79709936|NCT00622947|Procedure|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
79842023|NCT00969735|Device|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
79842024|NCT00850824|Behavioral|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
79842025|NCT00966069|Other|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
79842026|NCT00966069|Other|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
79246374|NCT00845208|Behavioral|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
79709937|NCT00622947|Procedure|Sham-rTMS|The coil is angled 90 degrees away from the scalp
79842027|NCT00850902|Other|High Humidity (HH)|High Humidity Level
80011829|NCT02205242|Device|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
80011830|NCT02205242|Drug|Placebo|
79246375|NCT00789607|Device|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
79246376|NCT00789607|Device|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
79391465|NCT02412930|Drug|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
79540049|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
79540050|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
79540051|NCT01476800|Drug|YM178 OCAS|oral
79540052|NCT01476800|Drug|Ketoconazole|oral
79540053|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
79842028|NCT00850902|Other|Moderate Humidity|Moderate Humidity Level
80011831|NCT02071368|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
80011832|NCT02071368|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
80011833|NCT02071368|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
80011834|NCT02071368|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
80011835|NCT02205320|Biological|DRL_PG|
80011836|NCT02205320|Biological|Pegfilgrastim Form A|
80011837|NCT02205320|Biological|Pegfilgrastim Form B|
80011838|NCT02076360|Behavioral|Preoperative Video|Patients will watch preoperative instructional video
80011839|NCT03402841|Drug|Olaparib|300 mg twice daily - oral
80016902|NCT00523250|Drug|AR-102 0.005% Ophthalmic Solution|
79246377|NCT00670670|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
79391466|NCT02412930|Drug|Bupivacaine|
79391467|NCT02412930|Device|Ultrasound|
79391468|NCT02432716|Drug|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
79391469|NCT02432716|Drug|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
79391470|NCT02421900|Other|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
79391471|NCT02418624|Drug|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
79391472|NCT02418780|Other|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
80016903|NCT00523250|Drug|AR-102 0.01% Ophthalmic Solution|
80016904|NCT00523250|Drug|AR-102 0.03% Ophthalmic Solution|
80016905|NCT00523250|Drug|AR-102 Vehicle Ophthalmic Solution|
80011840|NCT02209298|Device|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
80011841|NCT02072616|Other|Pancreatic adenocarcinoma diagnosis|
79246378|NCT00670670|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
79246379|NCT00670618|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
79246380|NCT00670618|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
79385217|NCT06111404|Procedure|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
79385218|NCT06111404|Device|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
79385219|NCT06111391|Device|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
79540054|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
79540055|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
80011842|NCT02209376|Biological|CART-EGFRvIII T cells|
80011843|NCT02072694|Other|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
79540056|NCT01476813|Drug|Comparator|comparison of different dosages of drug versus comparator
79540057|NCT01476878|Device|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
79540058|NCT01476891|Other|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
79540059|NCT01476891|Other|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
79540060|NCT01476917|Device|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
79709938|NCT04333056|Other|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
80011844|NCT02072694|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
79246381|NCT00670618|Device|Fluoride (Elmex Medical Gel)|Fluoride
79246382|NCT00643994|Radiation|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
79385220|NCT06111378|Dietary Supplement|fish oil|fish oil
79385221|NCT06111378|Dietary Supplement|linseed oil|linseed oil
79246383|NCT00643617|Radiation|CyberKnife Stereotactic Radiosurgery - Low Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate
79246384|NCT00643617|Radiation|CyberKnife Stereotactic Radiosurgery - Intermediate Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally
79246385|NCT00620425|Drug|Sumatriptan|injection
79246386|NCT00618683|Procedure|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
79540061|NCT01476930|Procedure|cupping and serkangabin syrup|wet cupping serkangabin syrup
79540062|NCT01476930|Drug|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
79540063|NCT01476956|Other|Observational study|RA patients on standard DMARD therapy
79540064|NCT01476969|Device|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
79540065|NCT01476982|Device|ClearView Scan|Assessment with ClearView device
79540066|NCT01477021|Drug|cyclophosphamide|Given IV
79540067|NCT01477021|Biological|NY-ESO-1-specific T cells|Given IV
79540068|NCT01477021|Other|laboratory biomarker analysis|Correlative studies
79540069|NCT01477034|Dietary Supplement|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
79540070|NCT01477060|Drug|Lapatinib|1250 mg/ die, os
79540071|NCT01477060|Drug|Metformin|1500 mg/die, os
79540072|NCT01477073|Drug|FSH-GEX™|
79540073|NCT01477073|Drug|recombinant FSH|
79540074|NCT01477073|Drug|urinary FSH|
79540075|NCT01477073|Drug|Placebo|
79709939|NCT00107042|Biological|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
80011845|NCT02205398|Drug|INC280|
80011846|NCT02205398|Drug|cetuximab|
80011847|NCT02071524|Drug|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
80011848|NCT02071524|Drug|Cristalloid administration|Only Ringer Lactate administration
80011849|NCT02220608|Biological|Bortezomib|
80011850|NCT02220608|Drug|G-CSF|
80011851|NCT02076438|Dietary Supplement|Probiotics|Randomized to receive probiotics or placebo
80011852|NCT02209688|Drug|ESR 1150 CL|
79540076|NCT01477099|Device|Toothbrushing with a manual brush|Toothbrushing with a manual brush
79698056|NCT04589871|Other|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
79698057|NCT04589871|Other|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
79698058|NCT04622618|Drug|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
79698059|NCT04589949|Biological|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
79698060|NCT04589949|Biological|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
79698061|NCT04622852|Device|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
79698062|NCT04589793|Behavioral|Life Style|Life Style intervention including physical activity, diet, sleep and stress
79698063|NCT04622891|Drug|Clarithromycin 500mg|clarithromycin 500
80011853|NCT02209688|Drug|Placebo|
79246387|NCT00535444|Other|Parish nurse visit|One visit with the parish nurse in 2 weeks
79246388|NCT00515281|Drug|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
79385222|NCT06111378|Dietary Supplement|walnut oil|walnut oil
79385223|NCT06111365|Device|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
80011854|NCT02076516|Device|Drug-eluting stent: CORACTO®|
80011855|NCT02220686|Behavioral|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
79246389|NCT00515281|Drug|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
79246390|NCT00504582|Drug|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
79246391|NCT00486629|Behavioral|Exercise and dietary education|Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
79385224|NCT06111352|Drug|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
79540077|NCT01477112|Dietary Supplement|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
79540078|NCT01477112|Dietary Supplement|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
79540079|NCT01476397|Other|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
79540080|NCT01476397|Other|Test infant formula|partially hydrolyzed whey formula with probiotic
79540081|NCT01477125|Behavioral|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
79540082|NCT01477138|Procedure|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
79698064|NCT04622891|Drug|Azithromycin|azithromycin group
79698065|NCT04622891|Drug|Placebo|control group
79698066|NCT04622579|Drug|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
79698067|NCT04590066|Behavioral|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
80011856|NCT03630367|Drug|Dexamethasone|Intramuscular injection 8 mg
80011857|NCT03630367|Drug|L-Carnitine 1G/5mL Injection|slow intravenous injection
79246392|NCT00353938|Drug|3,4-methylenedioxymethamphetamine (125 mg)|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
79246393|NCT00353938|Drug|3,4-methyelendioxymethamphetamine (25 mg)|Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
79246394|NCT00353938|Behavioral|Therapy|Non-directive therapy performed by a team of two co-therapists
79246395|NCT00335114|Drug|cyclosporine ophthalmic emulsion|
79698068|NCT04622501|Procedure|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
80011858|NCT02258282|Drug|Etanercept|
80011859|NCT02258282|Drug|Control|
80011860|NCT01376869|Dietary Supplement|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
79540083|NCT01477151|Drug|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
79540084|NCT01477164|Behavioral|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at ~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
79698069|NCT04590105|Device|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
79698070|NCT04590105|Other|Written Instruction|Written Instruction
79698071|NCT01153009|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
79698072|NCT01153009|Drug|Duloxetine|Overencapsulated duloxetine delayed-release capsules
79698073|NCT01153009|Drug|Placebo|Placebo-matching capsules
79698074|NCT04622111|Drug|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
79698075|NCT04622111|Drug|Placebo|matching placebo tablet
79698076|NCT04622111|Drug|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
79698077|NCT04589715|Other|electroacupuncture|the same as described in experimental arm.
79842029|NCT04041882|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
80011861|NCT01376869|Other|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
79246396|NCT00314366|Biological|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
79842030|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
79842031|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
79842032|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
80011862|NCT02076594|Drug|Docetaxel|Powder for solution for infusion
79246397|NCT00314366|Other|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
79246398|NCT00188708|Procedure|hypoxia measurement|transrectal oxygen measurement
79246399|NCT03372759|Procedure|airtamponade|airtamponade is applicated in the study group air
79540085|NCT01477164|Behavioral|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
79698078|NCT04589715|Other|sham electroacupuncture|the same as described in sham comparator.
79698079|NCT02884843|Device|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
79698080|NCT02884843|Device|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
79698081|NCT01152814|Biological|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
79698082|NCT04589442|Biological|Split thickness skin graft|standard of care graft
79698083|NCT04589442|Biological|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
79698084|NCT04621994|Other|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
79698085|NCT04621994|Other|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
79698086|NCT04205695|Procedure|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
79709940|NCT00107042|Biological|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
79709941|NCT00596895|Dietary Supplement|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
79842033|NCT00854256|Procedure|Canaloplasty|Canaloplasty surgery
79842034|NCT00854256|Procedure|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
79842035|NCT00966147|Other|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
79842036|NCT04042662|Other|no intervention|no intervention
79842037|NCT00969891|Other|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
79842038|NCT00855972|Drug|Low Dose Naltrexone|
79842039|NCT00966225|Dietary Supplement|LIP-01|comparison of different dosages of natural health product
80011863|NCT02076594|Drug|Epirubicin|Solution for infusion
79698087|NCT04205695|Procedure|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
79540086|NCT01477164|Behavioral|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
79698088|NCT04205695|Procedure|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
79698089|NCT02884531|Other|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
79698090|NCT02884531|Behavioral|Patient Education|Patient education (1/2 day)
79698091|NCT04589481|Other|Intake of 3 different candies against bad breath|Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
79698092|NCT04621721|Behavioral|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
79698093|NCT05244889|Behavioral|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
79698094|NCT05244889|Behavioral|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
79709942|NCT00596973|Procedure|Surgical Treatment|Ileal transposition with sleeve gastrectomy
80011864|NCT02076594|Drug|Oxaliplatin|Powder for solution for infusion
80011865|NCT02076594|Drug|Capecitabine|Film coated tablets
79246400|NCT03372759|Procedure|saline|saline is left in the study Group saline
79246401|NCT03137264|Drug|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
79246402|NCT03606655|Drug|Kava|Kava: 75 mg three times daily (3 capsules)
79540087|NCT01477190|Drug|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
79540088|NCT01477190|Drug|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
79540089|NCT01477203|Drug|Escitalopram|2-4 weeks, 5-10mg, max 20mg
79540090|NCT01477216|Other|ELSA 1-9|Measuring GI and II values for Finnish foods
79540091|NCT01477242|Drug|Ondansetron|2mg (5mL) in < 15 kg and 4mg (10mL) in 15kg to 30kg
80011866|NCT02258360|Other|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
80011867|NCT04175509|Drug|Rectal acetaminophen|Rectal 1300mg
80011868|NCT04175509|Drug|Intravenous acetaminophen|Intravenous 1000mg
80011869|NCT02220842|Drug|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
79246403|NCT03367221|Device|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
79246404|NCT04477148|Device|endotracheal intubation|patients were intubated with 3 different blades
79246405|NCT03606577|Drug|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
79385225|NCT06111352|Drug|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
79385226|NCT06111326|Drug|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
79385227|NCT06111326|Drug|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
79698095|NCT05244187|Device|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
79698096|NCT04589520|Behavioral|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
79698097|NCT04622033|Biological|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
79246406|NCT03606577|Drug|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 & D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
79246407|NCT03606577|Drug|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
79698098|NCT01152580|Dietary Supplement|melatonin|3mg p.o. at bedtime daily
79698099|NCT01152580|Dietary Supplement|sugar pill|lactose p.o. at bedtime daily
79698100|NCT02884453|Drug|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research & Development, LLC and Pharmacyclics Inc.
79698101|NCT02884297|Drug|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
79698102|NCT04621799|Drug|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
80011870|NCT02220842|Drug|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
80011871|NCT02220842|Drug|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
79842040|NCT00966303|Other|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
80011872|NCT02072850|Device|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
79540092|NCT01477255|Behavioral|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
79246408|NCT03606577|Drug|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
79246409|NCT03601975|Drug|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
79540093|NCT01477268|Drug|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
79540094|NCT01477281|Drug|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
79842041|NCT00854412|Other|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
79842042|NCT00619866|Drug|Elagolix|Elagolix tablets administered orally
79842043|NCT00619866|Drug|placebo|Placebo tablet administered orally
80011873|NCT02072850|Other|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (< 12 hours, days 2, 7-10 and at 6 months).
80011874|NCT02205554|Drug|Omnitram|Nine 20 mg doses administered every 6 hours
80011875|NCT02205554|Drug|Tramadol|Nine 50 mg doses administered every 6 hours.
79540095|NCT01477281|Drug|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
79540096|NCT01477294|Drug|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
79540097|NCT01477294|Drug|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
79842044|NCT00851058|Behavioral|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
79246410|NCT04982666|Other|Whole-Food, Plant-Based Diet|This diet is focused on nutritional needs with natural, minimally-processed plant foods.
79246411|NCT04982666|Other|FODMAP Diet|An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
79842045|NCT00851058|Behavioral|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
80011876|NCT02205554|Drug|Placebo|Nine doses administered every 6 hours.
79540098|NCT01477307|Other|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
79540099|NCT01477346|Other|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
79540100|NCT01477346|Other|Standard care|Continuing standard General Practitioner led care.
79698103|NCT02884336|Other|No intervention|
79540101|NCT01477372|Behavioral|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
79698104|NCT04621370|Drug|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
79698105|NCT04621370|Drug|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
80011877|NCT02076672|Drug|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
79698106|NCT04621370|Radiation|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
79842046|NCT00851058|Behavioral|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
79842047|NCT00851058|Behavioral|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
79842048|NCT02544906|Drug|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
79842049|NCT02544906|Drug|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
79842050|NCT00861276|Drug|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
79842051|NCT00861276|Drug|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
79842052|NCT00861354|Device|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
79842053|NCT02544828|Drug|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
79842054|NCT02544828|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
79842055|NCT00861432|Other|additive homeopathic treatment|These patients receive additive homeopathic treatment
79246412|NCT03137342|Behavioral|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
80011878|NCT02076750|Dietary Supplement|Vitamin D3 (cholecalciferol)|
80011879|NCT05262608|Drug|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
79246413|NCT03597841|Drug|Combination therapy|Patients who are given combination therapy will be allocated to this group.
79540102|NCT01477385|Procedure|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
79540103|NCT01477385|Procedure|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
80011880|NCT02073006|Dietary Supplement|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
79698107|NCT04621370|Radiation|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
80011881|NCT02205632|Device|MPS II|
79246414|NCT04977206|Other|Mutual Goal-Setting Education|Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
79246415|NCT03602989|Device|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
79842056|NCT00861510|Drug|ON01910 Na|
79246416|NCT03602911|Drug|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
79540104|NCT01477385|Procedure|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
79842057|NCT01095003|Drug|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
79842058|NCT01095003|Drug|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
79842059|NCT00854568|Drug|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
79842060|NCT00854568|Drug|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
79842061|NCT00854646|Drug|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
79842062|NCT00856362|Drug|Moxidectin|
79842063|NCT00856362|Drug|Midazolam|
79842064|NCT00854802|Drug|Debio 025|Debio 025 supplied in soft gel capsules
79842065|NCT00854802|Drug|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
79842066|NCT00854802|Drug|Ribavirin|Ribavirin supplied in tablets
79842067|NCT00854802|Drug|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
79842068|NCT00969969|Device|Arthrodesis|arthrodesis using screws and/or a plate
79842069|NCT00969969|Device|Cartiva|Cartiva Synthetic Cartilage Implant
79842070|NCT00854880|Drug|PDC339|
79842071|NCT00854880|Drug|Placebo|
80011882|NCT01380457|Drug|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
80011883|NCT01380457|Drug|Marinol|Capsules, 10 mg, single-dose, fasting conditions
79698108|NCT04621370|Drug|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
79540105|NCT01477385|Procedure|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
79698109|NCT01152385|Drug|AZD1656|Oral tablet administered twice daily during 4 months
79842072|NCT00966459|Procedure|Computed Tomography|1 low-dose CT is taken
79540106|NCT01477385|Procedure|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
79698110|NCT01152385|Drug|Placebo|administered twice daily during 4 months
80011884|NCT02071602|Drug|CD-NP|Randomized 1:1:1
79246417|NCT03137186|Drug|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
80011885|NCT02205710|Other|Computerized cognitive training|
80011886|NCT02205710|Other|Computerized games|
79540107|NCT01477398|Device|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
80011887|NCT05159089|Behavioral|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
79540108|NCT01477411|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
79698111|NCT04621487|Drug|Amoxicillin|14 days 1 gr bid
79842073|NCT00958503|Drug|Thiamphenicol|750 and 1500 mg/day;tablets
79540109|NCT01477411|Drug|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
79540110|NCT01477424|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
79540111|NCT01477424|Drug|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
79540112|NCT01477437|Other|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
79698112|NCT04621487|Drug|Metronidazole|14 days 500 mg bid
79842074|NCT00958503|Drug|Placebo|Matched tablets without active ingredient
79842075|NCT00861588|Drug|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
80011888|NCT05159089|Behavioral|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
80011889|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
79246418|NCT05363852|Diagnostic Test|Standard set of visual word and picture stimuli|Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
79246419|NCT03137030|Drug|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
79246420|NCT03137030|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
79698113|NCT04621487|Drug|Clarithromycin|14 days 500 mg bid
79698114|NCT04621487|Drug|Pantoprazole 40mg|40 mg bid 14 days
79698115|NCT04621487|Drug|according to antibiogram|according to antibiogram
79698116|NCT01152190|Drug|Tadalafil|Administered orally, once daily for 8 weeks
79698117|NCT01152190|Drug|Placebo|Administered orally, once daily for 8 weeks
79698118|NCT04649853|Other|Standardized nursing care|All patients will receive standardized evidence based nursing care
79842076|NCT00861588|Drug|placebo|starch placebo
79842077|NCT00970125|Behavioral|video|outline of the goals of care
79842078|NCT00966615|Other|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
79842079|NCT00966615|Other|glucose-based dialysis solution|2-L exchange; three times a day
79842080|NCT00861666|Behavioral|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
79698119|NCT04621565|Drug|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
79698120|NCT04621565|Drug|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 & 100mg at 2000), the postoperative day 1 (100mg at 0800 & 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
79842081|NCT00861822|Other|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
79842082|NCT00970437|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
79842083|NCT00970437|Behavioral|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
79842084|NCT02545218|Procedure|Perineorraphy|Surgery for improperly healed perineal tear
79842085|NCT02545218|Other|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
79842086|NCT00966771|Drug|Copper T380 IUD|copper T 380 IUD
79842087|NCT00966771|Drug|Oral levonorgestrel|1.5 mg
79842088|NCT00856440|Drug|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
79842089|NCT00856440|Drug|Colyte|Lavage preparation for colonoscopy
79842090|NCT00856440|Drug|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
79842091|NCT00958659|Other|laboratory biomarker analysis|Correlative studies
79842092|NCT00856596|Drug|Sertaconazole nitrate cream 2%|Once a day topical cream
80011890|NCT05239052|Other|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
80011891|NCT05239052|Other|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
79246421|NCT05088200|Procedure|surgery|Our study is observational and we use secondary data
79246422|NCT02237677|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
79246423|NCT03597217|Drug|PF-05221304|3, 10, 50 mg
79385228|NCT06111300|Drug|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
79385229|NCT06111274|Drug|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
79385230|NCT06111261|Drug|Albumin solution|200ml of 20% Human Serum Albumin
79385231|NCT06111261|Drug|Balanced crystalloid solution|Balanced crystalloid solution
79698121|NCT04650048|Device|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
79246424|NCT03597217|Drug|PF-05221304|50 mg multiple dose
79246425|NCT03597217|Drug|Placebo|Placebo
79246426|NCT03596749|Drug|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
79246427|NCT01595061|Drug|Cisplatin|Given IV
79246428|NCT01595061|Drug|Gemcitabine Hydrochloride|Given IV
79246429|NCT01595061|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79385232|NCT06111248|Other|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
79842093|NCT00970515|Procedure|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
79842094|NCT00970515|Procedure|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
79842095|NCT04042350|Other|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
79842096|NCT00855114|Drug|everolimus|5 mg/day x 7 days by mouth
79842097|NCT00855114|Procedure|therapeutic conventional surgery|Definitive excision of breast cancer tissue
79842098|NCT00856674|Biological|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
79842099|NCT00855192|Behavioral|mindful meditation|interpersonal and psycho-educational
79842100|NCT00855192|Behavioral|interpersonal therapy|psycho-educational
79842101|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
79842102|NCT00856752|Drug|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
80011892|NCT05138107|Other|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
80011893|NCT05138107|Other|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
80011894|NCT02071758|Biological|LEISH-F3 + SLA-SE|
79842103|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
80011895|NCT02071758|Biological|LEISH-F3 + GLA-SE|
80011896|NCT01380301|Drug|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
80011897|NCT01380301|Drug|Miltefosine alone|short course (half)
79246430|NCT01595061|Procedure|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
79246431|NCT05088122|Other|no intervention|no intervention, not applicable
79246432|NCT03601819|Drug|Pacritinib|Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
79246433|NCT04827602|Other|Drug allergy label status in electronic health records|Registered drug allergy labels in primary care and hospital electronic medical charts
79246434|NCT03596047|Device|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
79246435|NCT03596047|Device|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
79246436|NCT03367143|Drug|Lenalidomide|
79246437|NCT03367143|Drug|Ifosfamide|
79246438|NCT03367143|Drug|Carboplatin|
79246439|NCT03367143|Drug|Etoposide|
79246440|NCT02519205|Other|Survey|
79246441|NCT03376347|Device|FlotracIQ with HPI algorithm|FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
79385233|NCT06111209|Drug|Testosterone cypionate|weekly by intramuscular injection
79385234|NCT06111209|Drug|Placebo|weekly by intramuscular injection
79385235|NCT06111183|Biological|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
79385236|NCT06111183|Other|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
79385237|NCT06111170|Device|Compression dressing|Application of dressing
79385238|NCT06111118|Device|ThermaCare HeatWraps|ThermaCare HeatWraps application
79540113|NCT01477476|Drug|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
79540114|NCT01477476|Other|Placebo Comparator|A placebo will be given to 7 subjects.
79540115|NCT01477489|Drug|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
79540116|NCT01477489|Radiation|Standard radiation treatment|Limited to 60 Gy.
80011898|NCT02205866|Other|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
80011899|NCT02076828|Drug|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
80011900|NCT02076828|Drug|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
80011901|NCT02076828|Drug|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
80011902|NCT02221076|Device|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
79246442|NCT03372681|Procedure|Isoperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
79246443|NCT03372681|Procedure|Antiperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
79385239|NCT06111053|Other|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
79385240|NCT06111053|Other|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
79385241|NCT06111053|Other|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
79540117|NCT01477541|Other|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
79698122|NCT04650048|Device|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
79698123|NCT00562367|Drug|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
79698124|NCT01151410|Drug|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
79540118|NCT01477554|Other|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
79540119|NCT01477580|Biological|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79698125|NCT01151410|Drug|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
79698126|NCT04588896|Device|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
79698127|NCT04588896|Behavioral|Lifestyle modification programme|Lifestyle modification programme
79698128|NCT00562406|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
79698129|NCT00562406|Procedure|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
79246444|NCT05087654|Other|Combination of 3D VR and Hands-on Horticultural Activities|The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
79246445|NCT03376269|Biological|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
79246446|NCT03376269|Behavioral|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
79246447|NCT04762316|Drug|PP6|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
79246448|NCT04762316|Device|PP6 Placebo|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
79246449|NCT04109625|Diagnostic Test|Demonstrator MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
79246450|NCT05086718|Other|Endoscopic ear surgery|Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
79246451|NCT04074681|Behavioral|Gambling Internet-based Protocol|Gambling Internet-based protocol is a multimedia interactive and self-help program for problem and pathological gamblers, which will allow individuals to learn and practice adaptive ways to cope with this problem. The main therapeutic modules included in this program are: 1) Motivational for change; 2) Psychoeducation; 3) Stimulus control (e.g. self-prohibition and blocking of usual gambling websites with therapist confirmation) and responsible return of debts; 4) Cognitive restructuring; 5) Emotion regulation; 6) Planning of significant activities; 7) Coping skills and exposure with response prevention; 8) Relapse prevention.
79246452|NCT03372447|Drug|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
79246453|NCT03367065|Radiation|Dynamic contrast enhanced computerised tomography|
79540120|NCT01477580|Biological|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79540121|NCT01477580|Biological|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
79698130|NCT04588974|Device|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
79540122|NCT01477580|Biological|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79540123|NCT01477580|Biological|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79540124|NCT01477580|Biological|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
79698131|NCT04649658|Behavioral|Prone position|Prone position maintained at least 3 hours/day
79698132|NCT04621409|Biological|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
79246454|NCT04663256|Other|Cognitive stimulation group|Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
79540125|NCT01477580|Biological|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
79698133|NCT04621409|Biological|Placebo|IV infusion of saline, approximately 5 hours
79698134|NCT04588935|Drug|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
79698135|NCT04691258|Behavioral|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
80011903|NCT02076984|Procedure|Laparoscopic incisional or ventral hernia repair|
79698136|NCT04691258|Behavioral|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
79842104|NCT04042272|Diagnostic Test|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
79842105|NCT04041960|Other|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
79246455|NCT04656158|Other|Physical activity involving exposure to nature: Therapeutic horticulture|2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
79540126|NCT01477580|Biological|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79842106|NCT00855270|Drug|Placebo|IV saline will be used as placebo for control
79842107|NCT00855270|Drug|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
79842108|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
79246456|NCT02519283|Behavioral|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
79246457|NCT02519283|Behavioral|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:~discharge instructions;~medication reconciliation~encourage follow-up."
79385242|NCT06111053|Other|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
79385243|NCT06111027|Device|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
79385244|NCT06111001|Other|Email use data collection|Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.
79385245|NCT06111001|Other|AirEmail Tips and Tricks training|"Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool"
79385246|NCT06111001|Other|AirEmail v1 Digital Tool use|Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
79540127|NCT01477580|Biological|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79540128|NCT01477580|Biological|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79540129|NCT01477580|Biological|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79698137|NCT00562523|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
79698138|NCT00562562|Other|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
79698139|NCT04649424|Device|CanSwab|New nasopharyngeal swab design.
79842109|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
79842110|NCT03937479|Drug|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
80011904|NCT05078359|Diagnostic Test|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
79540130|NCT01477580|Biological|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
79540131|NCT01477580|Biological|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
79842111|NCT03937479|Drug|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
79842112|NCT03937479|Drug|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
80011905|NCT02221154|Dietary Supplement|Inofolic®|
79246458|NCT03366909|Behavioral|Mindfulness based relapse prevention (MBRP)|"These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis."
79246459|NCT03366909|Behavioral|classic therapy|These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
79385247|NCT06110988|Device|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
79540132|NCT01477593|Procedure|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
79540133|NCT01477593|Procedure|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
79698140|NCT00562679|Other|There is no intervention|
79842113|NCT00855348|Other|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
79385248|NCT06110949|Device|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
79385249|NCT06110923|Drug|CKD-846|once administration of Investigational Product
79698141|NCT04588779|Other|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
79842114|NCT00970671|Other|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
79842115|NCT00970671|Other|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
80011906|NCT02221154|Other|Gonadotropins; Folic Acid|standard ovarian stimulation
80011907|NCT02079870|Drug|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
80011908|NCT02079870|Drug|placebo|Solution for subcutaneous (s.c. - under the skin) injection
80011909|NCT01378897|Device|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
80011910|NCT02209844|Drug|BI 44847|
80011911|NCT02209844|Drug|Placebo|
79842116|NCT00970671|Other|No treatment|No laser treatment
79842117|NCT00967083|Behavioral|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
79698142|NCT04588779|Other|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
80011912|NCT02073084|Drug|K-877 Low Dose|K-877 Low Dose
79246460|NCT03376191|Drug|apatinib|Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
79385250|NCT06110923|Drug|D091|once administration of Investigational Product per day
79385251|NCT06110910|Drug|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
79540134|NCT01477593|Procedure|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
79540135|NCT01477606|Drug|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
79540136|NCT01477606|Drug|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
79246461|NCT03399578|Biological|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
80011913|NCT02073084|Drug|Moxifloxacin|
80011914|NCT02073084|Other|Placebo|
79385252|NCT06110884|Behavioral|music therapy, speech therapy|receive group music therapy in addition to traditional language therapy
79385253|NCT06110884|Behavioral|speech therapy|receive only traditional language therapy
79540137|NCT01477606|Drug|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
79540138|NCT01477619|Drug|Tasimelteon|20mg single dose on Day 1
79842118|NCT00967161|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
79842119|NCT00967161|Procedure|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
79842120|NCT00967239|Genetic|DNA analysis|
80011915|NCT02073084|Drug|K-877 High Dose|K-877 High Dose
80011916|NCT03899701|Procedure|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
79385254|NCT06110871|Other|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
79540139|NCT01477632|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
79540140|NCT01477632|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
79540141|NCT01477632|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
79540142|NCT01477697|Dietary Supplement|Omega-3|50 mg/kg per day of omega-3 fatty acids
79698143|NCT04621214|Device|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
80011917|NCT02221388|Drug|BI 671800 HEA, 200 mg tablets|
80011918|NCT02221388|Drug|BI 671800 HEA EC, 200 mg tablets|
79246462|NCT03376113|Behavioral|the volitional help sheet|A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
79246463|NCT03342950|Drug|Topical Solution|Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
79246464|NCT03342950|Drug|Placebos|Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
79842121|NCT00967239|Genetic|polymorphism analysis|
79842122|NCT00967239|Other|laboratory biomarker analysis|
79842123|NCT00967239|Other|pharmacogenomic studies|
80011919|NCT02221388|Drug|BI 671800 HEA, 50 mg tablets|
80011920|NCT02221388|Drug|BI 671800 ED, 100 mg capsules|
80011921|NCT02221388|Other|Standard meal|
80011922|NCT03787849|Drug|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
80016906|NCT02095080|Dietary Supplement|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
79246465|NCT03376035|Other|Temperature measurement of breast|Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
79540143|NCT01477697|Dietary Supplement|Placebo|50 mg/kg per day of placebo equivalent
79698144|NCT04649619|Procedure|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
79698145|NCT04649697|Drug|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
79698146|NCT04649697|Drug|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
79698147|NCT04649697|Drug|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
80011923|NCT03787849|Drug|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
79698148|NCT04621097|Device|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
79698149|NCT04621097|Other|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
80011924|NCT02073240|Behavioral|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~Audits and Feedback of performance~A TB IC collaborative membership~A standardized unit-level daily checklist of critical IC activities"
80011925|NCT03669705|Procedure|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
80011926|NCT03671343|Behavioral|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
80011927|NCT02205944|Other|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
80011928|NCT03671265|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
79540144|NCT01477723|Other|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
80011929|NCT03671265|Radiation|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
80011930|NCT03671265|Drug|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
79540145|NCT01477736|Drug|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
79698150|NCT04621097|Drug|Medication|regular medications
80011931|NCT02077218|Procedure|computed tomography|Undergo cardiac CT
79698151|NCT04588584|Other|Survey and Interviews|Survey and Interviews
79698152|NCT04621253|Drug|Novalgin|Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
79698153|NCT04649463|Diagnostic Test|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
79698154|NCT04620902|Other|Tear sampling|Tear sampling using Schirmer's strips
79698155|NCT04588701|Procedure|surgical procedures commonly done for anal fistula|Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
79698156|NCT00567762|Drug|FK506|Opthalmic suspension
79698157|NCT00567762|Drug|placebo|placebo eye drops
79385255|NCT06110871|Other|Working Group 2: Focusing|During IUD application
79540146|NCT01477736|Drug|Botulinum toxin A|300 U intradetrusor injection
79540147|NCT01477775|Drug|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
79540148|NCT01477775|Drug|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
79540149|NCT01477801|Drug|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
79540150|NCT01477801|Drug|PLACEBO|Standard guideline based therapy plus placebo
79540151|NCT01477814|Behavioral|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
79698158|NCT04620785|Other|methylene blue / IPL|therapeutic
79698159|NCT04620785|Other|IPL|therapeutic
79698160|NCT04620785|Other|saline|placebo
79698161|NCT00567801|Procedure|conventional embolectomy/thrombectomy|
79698162|NCT00567801|Procedure|embolectomy/thrombectomy with controlled reperfusion|
79698163|NCT04620590|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
79842124|NCT00967317|Drug|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
79246466|NCT05086640|Other|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
79246467|NCT04527159|Drug|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
79698164|NCT04649268|Device|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
79698165|NCT04649268|Other|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
79246468|NCT03366675|Drug|AZD2811|AZD2811 100mg/vial
80011932|NCT02077218|Other|cytology specimen collection procedure|Undergo collection of blood samples
79698166|NCT04691219|Dietary Supplement|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
79698167|NCT04691219|Behavioral|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
79246469|NCT03136172|Device|NIRS (near Infra-red spectroscopy)|"NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
79698168|NCT04691063|Drug|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
79698169|NCT04691063|Drug|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
79842125|NCT00967317|Drug|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
79842126|NCT00959127|Drug|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
79842127|NCT00959205|Device|CARTO 3D|CARTO (3D Electroanatomic imaging)
79842128|NCT00959205|Device|Angiography|Conventional fluoroscopically guided activation mapping
79842129|NCT00967395|Other|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
80011933|NCT02077218|Other|laboratory biomarker analysis|Correlative studies
80011934|NCT02077218|Other|questionnaire administration|Ancillary studies
80011935|NCT03729427|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
80011936|NCT03671187|Other|Exercise|8 week exercise program
80011937|NCT02073318|Other|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
80011938|NCT02073318|Other|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
79246470|NCT03366597|Drug|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
79246471|NCT03110120|Drug|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
79246472|NCT03110120|Drug|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
79246473|NCT03110120|Drug|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
79246474|NCT03110120|Drug|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
79246475|NCT04524975|Drug|CD-008-0045|CD-008-0045 20 mg capsules
79246476|NCT04524975|Drug|Placebo|Placebo capsules
80011939|NCT02209922|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
80016907|NCT02654002|Drug|Cilofexor|Tablets administered orally
79385256|NCT06110871|Other|Working Group 3 music|for a total of 30 minutes
79385257|NCT06110845|Device|QPlasia OncoReader Breast (QPORB)|Automated diagnostic algorithm
79385258|NCT06110819|Other|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
79385259|NCT06110819|Other|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
79698170|NCT04588467|Other|Medical treatment|Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
79698171|NCT04588467|Procedure|Surgical treatment|Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
79698172|NCT04620395|Diagnostic Test|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
79698173|NCT01151215|Drug|AZD8931|Tablet, oral, bd
79842130|NCT00967395|Other|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
80011940|NCT02209922|Device|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
79698174|NCT01151215|Drug|anastrozole|Tablet, oral, od
79698175|NCT01151215|Drug|Placebo|Tablet, oral
79842131|NCT00970827|Procedure|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
79842132|NCT00970905|Drug|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
79842133|NCT00970905|Drug|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
80011941|NCT03671031|Procedure|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
80011942|NCT03671031|Procedure|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
80011943|NCT02881957|Drug|Cholecalciferol|
80011944|NCT02881957|Other|Placebo|Oral syrup placebo
79385260|NCT06110806|Behavioral|MBIE|MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
79385261|NCT06110767|Device|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
79540152|NCT01477814|Behavioral|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
79540153|NCT01477814|Behavioral|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
79540154|NCT01477827|Other|None - observational study|
79540155|NCT01477840|Drug|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
79540156|NCT01477866|Dietary Supplement|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
79540157|NCT01477866|Other|conventional therapy|conventional therapy for colon-rectal cancer
79540158|NCT01477879|Other|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
79540159|NCT01477879|Other|placebo (versabase gel only)|versabase gel only
79698176|NCT04588389|Drug|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
79698177|NCT04588389|Drug|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
79698178|NCT04588389|Drug|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
79698179|NCT04620473|Drug|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
79698180|NCT04620473|Drug|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
79842134|NCT00619476|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
80011945|NCT02073396|Diagnostic Test|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
80011946|NCT02206022|Drug|Remifentanil|Pain's evaluation for Remifentanil Group
80011947|NCT02206022|Drug|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
80011948|NCT02073552|Drug|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
80016908|NCT02654002|Drug|Placebo|Tablets administered orally
80016909|NCT02286596|Device|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
80016910|NCT02286596|Device|dextran sulfate adsorption|Lipid apheresis for 3 hours
80016911|NCT02098824|Drug|Galantamine|Single administration of capsule containing 16 mg of Galantamine
79698181|NCT00637234|Drug|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
79385262|NCT06110767|Behavioral|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
79698182|NCT00637234|Drug|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
79842135|NCT00619476|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
79842136|NCT00619476|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
79842137|NCT00619476|Drug|Placebo|placebo
80011949|NCT02073552|Drug|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
80011950|NCT03022461|Other|Long term follow-up|
80011951|NCT02210156|Dietary Supplement|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
79842138|NCT00970983|Procedure|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
79385263|NCT06110741|Other|Blood and saliva sampling|Collecting blood and saliva sample
79842139|NCT00970983|Procedure|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
79842140|NCT04009083|Device|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
79842141|NCT04009083|Other|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
79842142|NCT00971061|Device|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
79842143|NCT00971061|Device|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
80016912|NCT02098824|Drug|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
80016913|NCT02098824|Drug|Placebo|Single administration of capsule containing placebo
79246477|NCT03109886|Drug|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
79246478|NCT03366519|Procedure|clinical echography (CE)|clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
79246479|NCT03110198|Drug|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
79246480|NCT03110198|Drug|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
79246481|NCT03110198|Drug|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
79385264|NCT06110741|Other|Survey|Collecting data on infectious diseases during the study period
79385265|NCT06110702|Behavioral|EMDR|Eye movement Desensitization and Reprocessing (as decribed in the 8-phases protocol), administered both online or in presence.
79385266|NCT06110676|Biological|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
79540160|NCT01477931|Drug|Bupropion extended release|300mg once a daily, PO, 8weeks
79540161|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
79698183|NCT04581720|Device|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 ~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
79246482|NCT04460781|Biological|Flublok Quadrivalent influenza vaccine RIV4|Route of administration: Intramuscular
79385267|NCT06110676|Biological|Secukinumab|Cosentyx
79698184|NCT02883985|Radiation|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
79698185|NCT02940665|Other|ERAS|Patients in the ERAS group received the ERAS protocol
79842144|NCT00973635|Other|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
79246483|NCT04460781|Biological|Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4|Route of administration: Intramuscular
80011952|NCT02210156|Other|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
80011953|NCT02080026|Biological|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
79540162|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
80011954|NCT02080026|Biological|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
80011955|NCT02080026|Drug|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
79540163|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
80011956|NCT02080026|Drug|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
80011957|NCT02206178|Drug|N-acetylcysteine combination with acetaminophen|
79246484|NCT05086328|Behavioral|Nonviolent Resistance|Six two weekly sessions of two hours, based on nonviolent resistance Questionnaires pre and post intervention
79246485|NCT02519829|Procedure|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
80011958|NCT02206178|Drug|Placebo|
79698186|NCT04588194|Drug|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
80011959|NCT02080104|Drug|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
80011960|NCT02211326|Behavioral|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
80011961|NCT02211326|Behavioral|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
80011962|NCT02077452|Drug|HMS5552|
80011963|NCT02077452|Drug|Placebo|
80011964|NCT03462979|Device|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
80011965|NCT02073630|Other|active cerebellar stimulation|
79698187|NCT04588194|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
79842145|NCT00861978|Drug|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
79842146|NCT00861978|Drug|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
80011966|NCT02073630|Other|sham cerebellar stimulation|
80011967|NCT02206256|Drug|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
79246486|NCT02519829|Procedure|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
79246487|NCT02519829|Procedure|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
79246488|NCT02519829|Procedure|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
79246489|NCT05084690|Other|Unilateral resistance training|Unilateral resistance training of the elbow flexors
79540164|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
79698188|NCT04588194|Drug|Dexamethasone|40 mg IV/PO days 1-4
79698189|NCT04587921|Device|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
79698190|NCT02940314|Drug|HIP1503|
79698191|NCT02940314|Drug|HGP1103|
79698192|NCT04581525|Device|transcranial direct current stimulation|
79698193|NCT04620083|Other|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
79698194|NCT04620044|Other|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
79698195|NCT04620044|Other|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
79540165|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
79698196|NCT04620044|Other|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
79540166|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
79540167|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
79698197|NCT04620122|Other|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
80011968|NCT02206256|Behavioral|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
80011969|NCT04749290|Other|Study Formula|Study infant formula for term infants containing OPO and CPP
79246490|NCT05084690|Other|Illusionary mirror visual feedback|Modified Ramachandran's mirror box
79698198|NCT04581213|Procedure|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
80011970|NCT02691793|Drug|Sunitinib|sunitinib 37.5mg QD
79246491|NCT03375957|Drug|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
79246492|NCT03375957|Drug|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
79540168|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
79540169|NCT01477996|Procedure|27-gauge|27-gauge needle for IVT
79540170|NCT01477996|Procedure|30-gauge|30-gauge needle for IVT
79540171|NCT01478022|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
80011971|NCT05764603|Drug|MRI|MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
80011972|NCT02073786|Device|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
80011973|NCT02073786|Device|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
80011974|NCT04747886|Behavioral|WW Only|WW is a structured behavioral weight management program that focuses on diet, physical activity and mindset skills. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories. Specifically, the WW program assigns SmartPoints values to foods based on calories, sugar, saturated fat and protein. In addition, particular foods are assigned a points value of zero (0) to encourage a healthier eating pattern (e.g. fruits, vegetables, non-fat yogurt, fish).
79246493|NCT03375879|Device|Bandage contact lens|Bandage contact lens
79540172|NCT01478022|Drug|Ibuprofen|Ibuprofen 200 mg daily, capsules
79540173|NCT01478022|Other|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
79540174|NCT01478061|Device|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
79540175|NCT01478074|Drug|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC > 1000
79540176|NCT01478074|Drug|Cytarabine|2 g/m2 daily from day -6 through -2
79540177|NCT01478074|Drug|Fludarabine|30 mg/m2 daily from day -6 through -2
79540178|NCT01478074|Biological|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10^6 cells/Kg
79540179|NCT01478074|Biological|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
80011975|NCT04747886|Behavioral|WW + PolyRules!|In addition to WW, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
79246494|NCT03366441|Other|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
79246495|NCT03366441|Other|SMS|Text messages were sent to an equal number of donors in the SMS group
79246496|NCT03138824|Procedure|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
79246497|NCT03138824|Procedure|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
79246498|NCT03366363|Other|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
79842147|NCT00971139|Behavioral|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
79698199|NCT04581291|Other|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
79540180|NCT01478126|Drug|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
79698200|NCT04620317|Dietary Supplement|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
79698201|NCT04620317|Dietary Supplement|Placebo|Non-active ingredients - Maltodextrins
79698202|NCT04620863|Other|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
79540181|NCT01478126|Drug|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2*weight/24. Infusion starts in operating room and ends next day after the surgery.
79842148|NCT00862056|Procedure|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
79698203|NCT04620863|Other|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
79698204|NCT04588155|Device|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
79698205|NCT04588155|Other|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
79698206|NCT01151137|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
79698207|NCT01151137|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
79698208|NCT02940470|Other|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
79698209|NCT02940470|Other|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
79698210|NCT01151098|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
79842149|NCT00959361|Behavioral|pharmaceutical care|consultation with the pharmacists and usual care
80011976|NCT03132415|Behavioral|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
79540182|NCT01478139|Procedure|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
79540183|NCT01478139|Procedure|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
79698211|NCT04619771|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
79698212|NCT04581252|Device|Non-invasive cardiac system|Non-invasive cardiac system
79698213|NCT04619888|Diagnostic Test|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
79842150|NCT04040712|Other|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
79842151|NCT04040712|Other|Sham FMT|Sham fecal microbiota transplantation
79842152|NCT00973713|Drug|RAD001|10mg/d
79842153|NCT00857142|Drug|oxymorphone hydrochloride|
79842154|NCT00857142|Drug|Opana|
79842155|NCT00971217|Other|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
80011977|NCT03132415|Behavioral|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
80011978|NCT02221544|Device|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
80011979|NCT02221544|Device|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
80011980|NCT02221544|Device|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
79698214|NCT04619849|Diagnostic Test|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
79698215|NCT04619849|Diagnostic Test|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
79698216|NCT04587960|Procedure|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
79698217|NCT04587960|Procedure|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
79698218|NCT04619576|Behavioral|Occupational health workers|Questionnaire online
79842156|NCT00971217|Behavioral|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
79842157|NCT00865176|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
79842158|NCT00865176|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
79842159|NCT00973791|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
79246499|NCT04345874|Behavioral|Nutrition technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
79303697|NCT05635695|Other|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
79540184|NCT01478152|Other|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
79842160|NCT00973791|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
79385268|NCT06110663|Drug|HS-10241+ Almonertinib|HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
79385269|NCT06110663|Drug|Pemetrexed + Cisplatin /Carboplatin|"The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met."
79385270|NCT06110442|Device|IbexBH Software|A software application applied to radiographs
79842161|NCT00865254|Behavioral|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
80011981|NCT02221544|Device|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
79385271|NCT06110377|Procedure|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
79385272|NCT06110377|Procedure|MMP (INJECTIONS WITH A TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
79540185|NCT01478165|Drug|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
79540186|NCT01478165|Drug|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
79540187|NCT01478230|Drug|Nicotine|Nicotine 5 mg Inhaler
79540188|NCT01478230|Drug|Nicotine|Nicotine 10 mg Inhaler
80011982|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
80011983|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
79385273|NCT06109870|Behavioral|PRECEDE-PROCEED|delivered self-sampling (CHWSS) to increase screening participation.
79385274|NCT06109129|Device|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
79540189|NCT01478282|Drug|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
79540190|NCT01478282|Drug|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
79246500|NCT04345874|Behavioral|Children's environmental health technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
79698219|NCT01151020|Device|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
79540191|NCT01478295|Behavioral|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
79540192|NCT01478295|Other|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
79246501|NCT03366285|Diagnostic Test|Attachment story completion taks (ASCT)|Bonding quality
79246502|NCT03375801|Other|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
79246503|NCT04227860|Other|Balance exercise program|"Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
79303698|NCT04895553|Other|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
79698220|NCT04619810|Other|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
79385275|NCT06108128|Other|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
79385276|NCT06108089|Diagnostic Test|[18F]MISO-PET/CT|18F]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
79385277|NCT06107829|Drug|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
79385278|NCT06107270|Device|pressure biofeedback|uninﬂated pressure sensor will be kept below the neck suboccipital
79842162|NCT00865254|Behavioral|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
79842163|NCT00865254|Behavioral|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
79385279|NCT06107270|Device|therapeutic ultra sound|continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power
79385280|NCT06107270|Device|infra red radiation|(R 125, 250watt, Philips)
79698221|NCT01150474|Drug|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
79385281|NCT06107270|Other|post isometric relaxation|sustained contraction followed by relaxation
79698222|NCT01150474|Drug|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
79842164|NCT00973869|Dietary Supplement|curcumin|
79385282|NCT06107140|Other|dual therapy|The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
79385283|NCT06106516|Device|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
79540193|NCT01478308|Drug|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
79540194|NCT01478308|Drug|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
79540195|NCT01478308|Drug|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
79698223|NCT05088044|Other|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
79698224|NCT04587804|Device|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
79540196|NCT01478334|Behavioral|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
79698225|NCT04619459|Other|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
79246504|NCT04227860|Other|Strengthening exercise program|"Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
79698226|NCT04580901|Behavioral|Group Interpersonal Psychotherapy|15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 6 weeks (acute phase) then every other week for 6 weeks (maintenance phase)
79698227|NCT04619303|Drug|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
79698228|NCT04619303|Drug|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
79698229|NCT01150357|Drug|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
79698230|NCT01150357|Drug|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
79698231|NCT01150357|Drug|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
79385284|NCT06105645|Device|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
79385285|NCT06105645|Device|Standard electrodes|Standard electrodes used usually during the SEEG
79698232|NCT04587765|Behavioral|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
79698233|NCT04619537|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
79698234|NCT04587414|Behavioral|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
79698235|NCT04587414|Behavioral|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
79698236|NCT04587414|Behavioral|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
79698237|NCT04580862|Other|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
79698238|NCT04587609|Behavioral|Free Phone Mounts|Participants will receive free phone mounts
79698239|NCT04587609|Behavioral|Commitment Contract|Participants will develop and sign a personalized commitment contract where they will create their own weekly goals for phone use reduction, and plan potential future obstacles that may hinder them from reaching their goal and how and plan to overcome that obstacle.
79842165|NCT00973869|Other|high performance liquid chromatography|
79842166|NCT00973869|Other|laboratory biomarker analysis|
79842167|NCT00973869|Other|pharmacological study|
79385286|NCT06105450|Diagnostic Test|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
79246505|NCT03371901|Other|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
79246506|NCT03371589|Drug|Dexamethasone|Solution for otic injection
79246507|NCT03375567|Procedure|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
79246508|NCT03375567|Procedure|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
79246509|NCT03365895|Procedure|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
79246510|NCT03365895|Other|Laboratory Biomarker Analysis|Correlative studies
79246511|NCT03365895|Procedure|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
79385287|NCT06104579|Other|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
79385288|NCT06101082|Biological|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10^6 CAR-T cells/kg, 3×10^6 CAR-T cells/kg, and 1×10^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
79540197|NCT01478334|Behavioral|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
79540198|NCT01478386|Other|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
79540199|NCT01478386|Device|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
79540200|NCT01478386|Device|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
79540201|NCT01478399|Drug|PB1023 Injection|90 mg Dose
79540202|NCT01478412|Other|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
79540203|NCT01478425|Device|Lipidic Microemulsion|Topical nasal, twice a day
79540204|NCT01478425|Device|Saline|Topical Nasal, twice a day
79540205|NCT01478438|Device|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
79540206|NCT01478451|Behavioral|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
79540207|NCT01478451|Other|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
79540208|NCT01478464|Other|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
79540209|NCT01478490|Drug|mirabegron|oral
79698240|NCT04587609|Behavioral|Personalized Habit Tips|Participants will receive weekly habit formation tips by text message. These messages will be tailored to encourage use of phone mounts, setting up do not disturb while driving, and include their personal obstacles and plans they developed to overcome.
79698241|NCT04587609|Behavioral|Social Gamification Feedback|"Each week of the intervention period, the participant will be notified whether they met their prior week's goal, stayed about the same, or backslid. Participants will all start with 100 points, and can gain/maintain/lose points each week in the intervention period. Levels are as follows:~Copper: 0-40 points Bronze: 50-80 points Silver: 90-120 points Gold: 130-160 points Platinum: 170-200 points~Social competition: participants will be placed in groups of 10 based on similarity of baseline phone use. Weekly leaderboard reports will be sent via email, with SMS reminder. In the leaderboard they'll see themselves as You."
79842168|NCT00973869|Procedure|diagnostic endoscopic procedure|
79842169|NCT00973869|Procedure|therapeutic conventional surgery|
79246512|NCT03365895|Other|Questionnaire Administration|Ancillary studies
79246513|NCT03365817|Drug|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
79246514|NCT03365817|Drug|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
79385289|NCT06100289|Drug|Vedolizumab IV|Vedolizumab IV injection.
79385290|NCT06100289|Drug|Vedolizumab SC|Vedolizumab SC injection.
79385291|NCT06098846|Dietary Supplement|Vitamin D phosphate|Application of a Vitamin D phosphate active patch
79385292|NCT06098846|Dietary Supplement|Placebo transdermal patch|Application of a placebo transdermal patch
79540210|NCT01478490|Drug|metoprolol|oral
79540211|NCT01478503|Drug|mirabegron OCAS|oral
79540212|NCT01478503|Drug|Placebo|oral
79540213|NCT01478516|Procedure|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
79540214|NCT01478529|Drug|mirabegron OCAS|oral administration
79540215|NCT01478529|Drug|mirabegron|iv administration
79540216|NCT01478568|Drug|mirabegron|oral
79540217|NCT01478568|Drug|desipramine|oral
79540218|NCT01478607|Drug|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
79540219|NCT01478633|Drug|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
79540220|NCT01478646|Other|conventional breathing therapy|duration: 60 minutes.
79698242|NCT04587609|Behavioral|"Contest Financial Incentives"|"Participants who finish in the platinum level will receive equal share of a prize, or a small amount will be awarded each week over the course of the intervention period to the weekly Safest Driver in each of the social competition cohorts."
79698243|NCT04619381|Behavioral|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
80011984|NCT02221622|Drug|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
80011985|NCT02221622|Drug|Placebo injection (intravenous solution)|Placebo intravenous infusion
79698244|NCT00568464|Drug|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
79842170|NCT02544672|Device|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
79842171|NCT00959439|Drug|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
79842172|NCT00959439|Drug|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
79842173|NCT04041492|Dietary Supplement|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
79246515|NCT03365739|Dietary Supplement|Active Comparator 1|Mango (pulp/flesh) (500 g)
79246516|NCT03365739|Dietary Supplement|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
79246517|NCT03365739|Dietary Supplement|Control Comparator|Vitamin C (100 mg)
79246518|NCT03365661|Biological|ALT-803|A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains > 2 x 105 α/β T cells/kg recipient weight.
79246519|NCT03365427|Other|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
79246520|NCT03363789|Biological|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
79540221|NCT01478646|Other|reflectory breathing therapy|duration: 60 minutes.
79246521|NCT03363789|Procedure|Physical Therapy|Patients will receive a prescription for physical therapy.
79246522|NCT03365349|Other|"participating in a session of living theatre"|"participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play"
79540222|NCT01478659|Dietary Supplement|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
79540223|NCT01478659|Dietary Supplement|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
79698245|NCT04618835|Diagnostic Test|40-Steps-test|40 steps performed on the spot
79698246|NCT04587063|Behavioral|Fear Appeals|Email
79698247|NCT04587063|Behavioral|Message about Future Healthcare Costs|Email
79698248|NCT04587063|Behavioral|Endorsement from a Doctor|Email
79698249|NCT04587063|Behavioral|Comparison Table|Email
79698250|NCT04587063|Behavioral|Highlighting Cost Savings and Convenience|Email
79698251|NCT00568503|Drug|QAX028|
79698252|NCT00568503|Drug|Placebo|
79698253|NCT00568503|Drug|Tiotropium bromide|
79842174|NCT00971373|Other|Vestagen scrubs|antimicrobial impregnated textile
79842175|NCT00862212|Behavioral|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
79698254|NCT00568503|Drug|QAX028|
79698255|NCT00568503|Drug|QAX028|
79698256|NCT04619030|Other|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
79698257|NCT04619030|Other|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
79698258|NCT00568542|Drug|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
79842176|NCT00973947|Other|questionnaire administration|
79842177|NCT00973947|Radiation|3-dimensional conformal radiation therapy|
79842178|NCT00973947|Radiation|radiation therapy treatment planning/simulation|
80011986|NCT02077686|Behavioral|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
80011987|NCT01380223|Drug|placebo|I.V. infusion of placebo for 8 hr
80011988|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
80011989|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
80011990|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
80011991|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
79698259|NCT00568542|Drug|placebo|35 I.E. kg body weight placebo to erythropoetin beta
79698260|NCT00568620|Procedure|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
79698261|NCT00568620|Procedure|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
79698262|NCT04587102|Other|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
79698263|NCT04587102|Other|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
79698264|NCT04619147|Other|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
79698265|NCT00568659|Procedure|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
79698266|NCT02940353|Device|TREFOIL concept|
79842179|NCT00857298|Behavioral|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be ~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
79842180|NCT00971451|Other|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
80011992|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
80011993|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
80011994|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
79246523|NCT03365349|Other|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
79246524|NCT02852005|Biological|MVA/HIV62B vaccine|1×10^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
79246525|NCT02852005|Biological|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
79246526|NCT02852005|Biological|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
79540224|NCT01478672|Procedure|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
79540225|NCT01478685|Drug|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
79540226|NCT01478685|Drug|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
79842181|NCT00971451|Other|TENS|continuous use of TENS during the exercise session
79842182|NCT00857376|Dietary Supplement|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
79842183|NCT00974025|Dietary Supplement|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
79842184|NCT00974025|Dietary Supplement|Placebo|Placebo will be administered twice daily for four weeks
79842185|NCT00618072|Drug|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
80011995|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
80011996|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
80011997|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
79246527|NCT03371433|Other|Soft drinks|Caffeine and Caffeine free soft drinks
79246528|NCT03371277|Other|Medical visit for specific questionnaires|Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
79540227|NCT01478685|Drug|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2
79540228|NCT01478711|Other|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
80011998|NCT02074020|Drug|Blisibimod|Administered via subcutaneous injection once per week
80011999|NCT02074020|Drug|Placebo|Administered via subcutaneous injection once per week
80012000|NCT05764525|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
80012001|NCT05764525|Drug|Placebo|IV infusion of 0 mg of VVZ-149
80012002|NCT02213276|Other|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
80016914|NCT03659097|Procedure|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
79246529|NCT03365271|Procedure|drainage|Applying a drain tube during TKA procedure
79246530|NCT03365271|Procedure|non-drainage|No drain tube will be applied during TKA procedure
79698267|NCT04587258|Behavioral|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
79385293|NCT06091761|Other|Auricular acupuncture|Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.
79698268|NCT00562835|Drug|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25*‡ 0.25 mg/kg/day; Days 26 to 28*‡ 0.125 mg/kg/day~*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
79698269|NCT00562835|Other|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc [prednisolone + diluting fluid], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
80012003|NCT02213276|Other|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
79540229|NCT01478724|Dietary Supplement|Milk proteins fraction|capsules, one per day, 24 months
79540230|NCT01478750|Dietary Supplement|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
79540231|NCT01478750|Procedure|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
80012004|NCT02074098|Device|Macintosh laryngoscope|Direct Laryngoscope
79540232|NCT01478776|Dietary Supplement|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
79540233|NCT01478776|Dietary Supplement|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
79842186|NCT00959517|Drug|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
79842187|NCT00959517|Drug|sulphadoxine-pyrimethamine (SP)|
79842188|NCT00959517|Drug|Chloroquine (CQ)|
79540234|NCT01478789|Dietary Supplement|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
79698270|NCT04587180|Procedure|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
79698271|NCT04587219|Biological|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
79698272|NCT00568737|Drug|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
79842189|NCT00959517|Drug|primaquine (PQ)|
79842190|NCT04008771|Device|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
79842191|NCT00959595|Drug|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
79698273|NCT00568737|Drug|Placebo|0.9% sodium chloride
79842192|NCT00959595|Drug|EMLA cream|50g applied according to description of intervention
79842193|NCT00666926|Drug|PF00562271|125 mg twice daily [BID] with food, tablet
79842194|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
79842195|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
79842196|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
79842197|NCT00974103|Other|exercise advise|Exercises
79842198|NCT00974103|Other|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
79842199|NCT00865410|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
79842200|NCT00865410|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
80012005|NCT02074098|Device|Glidescope|Videolaryngoscope-1
80012006|NCT02074098|Device|Airwayscope|Videolaryngoscope-2
79842201|NCT00974181|Device|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
79842202|NCT00974181|Device|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
79842203|NCT00971607|Drug|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
79842204|NCT00971607|Drug|Oxygen (placebo)|Control will receive oxygen only.
79540235|NCT01478789|Dietary Supplement|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
79842205|NCT00865488|Biological|ADHEXIL|Adhesions prevention
79842206|NCT00862368|Behavioral|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
80012007|NCT05764447|Behavioral|Combined qigong Baduanjin and self-administered acupressure|The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.
79246531|NCT03365193|Diagnostic Test|Transesophageal Echocardiography|Standard transesophageal echocardiography will be performed as clinically indicated by treating physicians.
79246532|NCT03601741|Other|Daily Antimicrobial Stethoscope Diaphragm Cover|Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
79385294|NCT06091761|Other|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
79385295|NCT06091761|Other|Sham Thread embedding acupuncture|Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
79540236|NCT01478789|Dietary Supplement|placebo|100g/d yogurt with no added plant sterol
79246533|NCT03601741|Other|Uncovered Stethoscopes|Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
79246534|NCT03365115|Drug|Intrathecal morphine|Intrathecal morphine 100 mcg will be injected.
79246535|NCT03365115|Drug|Intrathecal fentanyl|Intrathecal fentanyl 25 mcg will be injected.
79246536|NCT02851615|Behavioral|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
79246537|NCT03365037|Drug|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
79385296|NCT06081972|Dietary Supplement|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
79385297|NCT06081972|Dietary Supplement|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
79385298|NCT06081972|Dietary Supplement|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
79385299|NCT06078345|Other|Carbohydrate|400 Kcal glucose (100g oGTT)
79540237|NCT01478802|Device|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
79698274|NCT00562874|Dietary Supplement|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
79698275|NCT00562874|Dietary Supplement|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
79698276|NCT00562874|Dietary Supplement|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
79698277|NCT04587141|Drug|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
79698278|NCT04587141|Drug|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
79698279|NCT04587141|Drug|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
79698280|NCT04619342|Device|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
79698281|NCT04619342|Procedure|Surgical Resection|Surgical Resection of PVTT
80012008|NCT05764447|Behavioral|Wait-list Control|The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.
80012009|NCT02221856|Procedure|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
80012010|NCT02221856|Procedure|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
80012011|NCT02080182|Drug|Acetylcysteine|
80012012|NCT02080182|Drug|placebo acetylcysteine|
80012013|NCT02224898|Behavioral|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
79246538|NCT03365037|Drug|Fracture healing film|Patients with acute soft tissue injury treated with Fracture healing film
79540238|NCT01478802|Device|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
79246539|NCT04524741|Device|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
79385300|NCT06078345|Other|Fat|400 Kcal glucose rapeseed oil.
79540239|NCT01478815|Behavioral|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
79540240|NCT01478815|Other|Standard Care|Standard Care
79842207|NCT00862368|Behavioral|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
80012014|NCT02080338|Device|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
80012015|NCT02750930|Drug|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
80012016|NCT02750930|Device|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
79246540|NCT03594877|Dietary Supplement|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
79246541|NCT03364959|Other|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
79303699|NCT02719691|Drug|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
79385301|NCT06078345|Other|Protein|400 Kcal Moltein PURE (111g)
79385302|NCT06069154|Device|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
79540241|NCT01478841|Drug|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
79540242|NCT01478841|Drug|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
79540243|NCT01478867|Other|Detection of gluten in feces|Detection of Gluten in Feces
79540244|NCT01478880|Procedure|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
79698282|NCT04586790|Drug|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
79698283|NCT04586790|Drug|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
79698284|NCT04586790|Drug|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
79698285|NCT00568815|Drug|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
79698286|NCT00568893|Drug|drotrecogin alfa (activated)|
79698287|NCT00568971|Drug|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
80012017|NCT02080416|Drug|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
80012018|NCT05462665|Behavioral|theory training|theory training
79540245|NCT01478880|Procedure|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
79698288|NCT04586322|Other|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
79698289|NCT02277405|Device|Shikani Optical Stylet|Optical intubation
79698290|NCT02277405|Device|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
80012019|NCT05462665|Behavioral|theory and simulation training|theory and simulation training
80012020|NCT02080494|Drug|Tranexamic Acid|
80012021|NCT02224976|Behavioral|Intensified Training|Volunteers will increase exercise training by 30% from baseline
80012022|NCT02213744|Drug|MM-302|
80012023|NCT02213744|Drug|Gemcitabine|
80012024|NCT02213744|Drug|Capecitabine|
80012025|NCT02213744|Drug|Vinorelbine|
80012026|NCT02213744|Drug|Trastuzumab|
80012027|NCT02077764|Procedure|OCT and coronary angiography|
80012028|NCT02077764|Procedure|Right heart cat.|
79385303|NCT06069154|Procedure|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
79540246|NCT01478893|Biological|SEL-068|Sub-cutaneous injection, multiple dose
79698291|NCT00562913|Drug|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
79698292|NCT00569088|Drug|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
79698293|NCT00569088|Drug|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
79540247|NCT01478893|Biological|Saline|Sub-cutaneous injection, multiple dose
79698294|NCT02940158|Other|1/4 cup- Small red lentil|
80012029|NCT02077764|Radiation|PET|
79246542|NCT03364959|Other|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
79246543|NCT02237755|Drug|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
79246544|NCT02237755|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
79540248|NCT01477905|Device|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
79540249|NCT01477905|Device|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
79698295|NCT02940158|Other|1/4 cup- Small green lentil|
79698296|NCT02940158|Other|1/4 cup- corn|
79698297|NCT02940158|Other|1/4 cup- macaroni|
79698298|NCT02940158|Other|1/4 cup- white potato|
79698299|NCT02940158|Other|1/4 cup- white rice|
79698300|NCT02940158|Other|1/2 cup- small red lentil|
79698301|NCT02940158|Other|1/2 cup- small green lentil|
79698302|NCT02940158|Other|1/2 cup- corn|
80012030|NCT02077764|Procedure|Echocardiography|
80012031|NCT02077764|Procedure|exercise test|
80012032|NCT02077764|Other|blood samples|
79246545|NCT00642265|Procedure|osteosynthesis|operative treatment
79246546|NCT00642265|Other|sling|conservative treatment
79246547|NCT03364725|Drug|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
79698303|NCT02940158|Other|1/2 cup- macaroni|
79698304|NCT02940158|Other|1/2 cup- white potato|
79698305|NCT02940158|Other|1/2 cup- white rice|
80012033|NCT01378741|Drug|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
80012034|NCT01378741|Drug|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
80012035|NCT02080650|Device|Mesenchymal-marker based ferrofluid (c-MET)|
80012036|NCT02080650|Device|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
80012037|NCT02077842|Device|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
80012038|NCT02077842|Device|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
80012039|NCT02461849|Drug|Imatinib|Imatinib 400mg qd daily
80012040|NCT02225054|Drug|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
80012041|NCT02225054|Drug|Ropivacaine|15 ml 0.5%
80012042|NCT02225054|Drug|Normal Saline|1 mL 0.9%
79698306|NCT00569244|Drug|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
79698307|NCT00569244|Drug|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
79698308|NCT03458156|Biological|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
79842208|NCT00862368|Behavioral|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
79842209|NCT00971685|Drug|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
79540250|NCT01478945|Device|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
79540251|NCT01478984|Procedure|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
79540252|NCT01478984|Procedure|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
79698309|NCT03458156|Biological|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
79698310|NCT03458156|Other|the control group|The patients will be assigned to the control group.
79698311|NCT04586361|Combination Product|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
79842210|NCT03861052|Drug|Tirzepatide|Administered SC
79842211|NCT03861052|Drug|Dulaglutide|Administered SC
79842212|NCT00971763|Biological|rituximab|
80012043|NCT02080728|Drug|Ropivacaine 500mg/100ml Naropeine|
80012044|NCT02080728|Drug|0.9% sodium chloride BAXTER|
79246548|NCT03588247|Procedure|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
79246549|NCT04524897|Drug|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
79246550|NCT03364569|Procedure|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
79385304|NCT06069154|Device|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
79385305|NCT06069154|Procedure|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
79842213|NCT00971763|Drug|cyclophosphamide|
79842214|NCT00971763|Drug|gemcitabine hydrochloride|
79842215|NCT00971763|Drug|prednisolone|
79842216|NCT00971763|Drug|vincristine sulfate|
79842217|NCT04018170|Drug|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
79842218|NCT04018170|Drug|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
79842219|NCT00785252|Device|Powered Intraosseous device (EZIO)|EZIO
79842220|NCT00785252|Device|standard central line|placement of a central line
79842221|NCT00857688|Drug|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
79842222|NCT00857688|Other|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
80012045|NCT05136794|Other|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
79246551|NCT03594799|Other|Bed Rest Control Group|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
79246552|NCT03594799|Dietary Supplement|Cocktail intervention|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
79246553|NCT03363555|Drug|SHR-1210|A humanized monoclonal immunoglobulin.
79246554|NCT03363477|Drug|Enoxaparin|
80016915|NCT02098902|Behavioral|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
80016916|NCT03658317|Diagnostic Test|renal arterial resistive index|done by dupplex on renal arteries
79842223|NCT00959829|Other|Music and message|Experimental group: music and message Control group: silence
79698312|NCT04586361|Combination Product|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
79246555|NCT03363477|Drug|Clexane|
79842224|NCT00781196|Drug|folic acid|capsule 0.5 mg once a day
79540253|NCT01478997|Dietary Supplement|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
79540254|NCT01478997|Dietary Supplement|Placebo Capsules|Carboxy Methyl Cellulose
79842225|NCT00781196|Drug|placebo|capsule, once a day
79246556|NCT03601663|Behavioral|Physical Activity Information|Participants will receive a copy of the Canadian Physical Activity Guidelines.
79246557|NCT03601663|Behavioral|Physical Activity Monitoring|Participants will receive a wearable activity tracker (Polar A300).
79246558|NCT03601663|Behavioral|Autonomy-support|Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
79842226|NCT00865644|Drug|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
79842227|NCT00971919|Other|questionnaire administration|
79842228|NCT00971919|Procedure|assessment of therapy complications|
79842229|NCT00971919|Procedure|psychosocial assessment and care|
79246559|NCT03363399|Diagnostic Test|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
79246560|NCT03593941|Other|Standard Diet|Participants will consume the standard diet provided in care home
79246561|NCT02519049|Other|No intervention|This is an observational study
79385306|NCT06066710|Drug|Propranolol|Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
79385307|NCT06066710|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
79385308|NCT06066710|Drug|Placebo|Placebo will be given on the same schedule as the propranolol regime.
79540255|NCT01479023|Drug|64Cu-DOTA-U3-1287|
79540256|NCT01479023|Drug|U3-1287 (unlabeled)|
79698313|NCT04586361|Other|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
79698314|NCT04618952|Drug|Calcium D|calcium D supplementation given to postmenopausal females
79698315|NCT04618952|Drug|Placebo|Placebo
79698316|NCT00569283|Biological|therapeutic allogeneic lymphocytes|
79698317|NCT04619069|Radiation|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
79698318|NCT04619069|Drug|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
79842230|NCT00971919|Procedure|quality-of-life assessment|
79842231|NCT00785330|Drug|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
79842232|NCT00785330|Drug|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
79842233|NCT00974649|Behavioral|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
79842234|NCT02555150|Drug|PRC-063|Oral extended-release capsule
79842235|NCT02555150|Drug|lisdexamfetamine dimesylate|Oral capsule
79842236|NCT02555150|Drug|Placebo|Oral placebo capsule
79842237|NCT05279469|Other|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
79842238|NCT00790946|Drug|Valsartan|Valsartan 80 to 160 mg
79842239|NCT05263102|Device|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
79842240|NCT05179239|Drug|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
79246562|NCT03601585|Device|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
79246563|NCT03364413|Other|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
79246564|NCT03601429|Dietary Supplement|Lactogyn|capsules
79540257|NCT01479036|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
79540258|NCT01479036|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
79540259|NCT01479049|Drug|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
79540260|NCT01479049|Drug|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
79540261|NCT01479062|Behavioral|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
79540262|NCT01479062|Behavioral|Usual Care|Placebo Control
79698319|NCT00569322|Procedure|BG Test|
79385309|NCT06066450|Device|Genoss® DES system, Genoss® Osfit system|This is a drug-eluting stent used to improve the diameter of the coronary artery in patients with symptomatic ischemic heart disease, with de novo lesions in the native coronary artery, where the reference vessel diameter ranges from 2.25mm to 5.00mm.
79385310|NCT06064617|Device|Contact Lens|Coopervision Biofinity Multifocal Lens
79385311|NCT06062667|Other|accompany the birth|Fathers will accompany their husbands during the birth process
79385312|NCT06051500|Behavioral|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
79385313|NCT06051500|Behavioral|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
79540263|NCT01479088|Drug|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value <180 pg/mL as tolerated by the patient
79540264|NCT01479101|Other|MammaPrint 70-gene expression profile|
79540265|NCT01479101|Other|BluePrint 80 gene expression profile|
79540266|NCT01479114|Drug|rh-GCSF|10 ug/kg/day intravenously for 3 days
79842241|NCT05179239|Drug|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
79842242|NCT05179239|Drug|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
79842243|NCT04046666|Device|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
79842244|NCT04046666|Procedure|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
79842245|NCT04527874|Behavioral|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
79698320|NCT04618796|Other|vaccine|Effect of COVID-19 pandemic on vaccination compliance among children attending Assiut University Children Hospital and what is the degree of that.
79698321|NCT00569361|Procedure|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
79246565|NCT03601429|Dietary Supplement|Placebo|capsules
79246566|NCT03124095|Behavioral|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
79698322|NCT04580550|Other|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
79698323|NCT04618640|Biological|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
79842246|NCT00972075|Drug|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
79842247|NCT00972075|Drug|placebo|one tablet per day 2 hours before going to bed
79385314|NCT06039085|Device|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
79246567|NCT03593707|Drug|Metformin|Metformin
79246568|NCT03593707|Drug|PF-06865571|PF-06865571
79303700|NCT02719691|Drug|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
79385315|NCT06031194|Other|Non-Interventional Study|Non-interventional study
79385316|NCT06029530|Drug|Atropine Ophthalmic|eye drops to be administered once daily
79385317|NCT06024941|Radiation|Radiation|Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
79698324|NCT04580706|Other|this is an observational study with none intervention|this is an observational study with none intervention
79698325|NCT04586439|Drug|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
79698326|NCT02940197|Behavioral|MediterrAsian diet|no other description
79698327|NCT04585932|Drug|Apalutamide|Given PO
79698328|NCT04585932|Drug|Degarelix|Given SC
79698329|NCT04585932|Drug|Leuprolide Acetate|Given IM
80012046|NCT05095298|Drug|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
80012047|NCT02222012|Device|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
80012048|NCT02222012|Device|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
80016917|NCT03658317|Diagnostic Test|uric acid level|serum sample for doing the test
80016918|NCT03658317|Diagnostic Test|serum urea and creatinine|serum samples for doing the test
80016919|NCT03658317|Diagnostic Test|24 hours urinary proteins|urine collected over 24 hours for doing the test
79246569|NCT03364257|Diagnostic Test|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
79246570|NCT03592537|Drug|Fentanyl|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
79246571|NCT03592537|Drug|Midazolam|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
79246572|NCT03592537|Drug|Bupivacaine Hydrochloride|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
79303701|NCT04490135|Behavioral|Group psychotherapy|As described above
79385318|NCT06024707|Drug|Biological Drug|This intervention is part of regular treatment, subjects will be included if they get this treatment.
79540267|NCT01479153|Procedure|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
79540268|NCT01479179|Drug|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
79540269|NCT01479179|Drug|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
79540270|NCT01479192|Drug|Fenretinide|100mg (2cps/day) for 5 years
79540271|NCT01479192|Other|Placebo|2 cpr/day of matched placebo for 5 years
79540272|NCT01479231|Drug|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
79540273|NCT01479244|Biological|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
79540274|NCT01479244|Biological|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
79540275|NCT01479257|Behavioral|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
79540276|NCT01479257|Device|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
79698330|NCT04585932|Other|Quality-of-Life Assessment|Ancillary studies
79385319|NCT06023212|Drug|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
79698331|NCT04585932|Other|Questionnaire Administration|Ancillary studies
79698332|NCT04585932|Radiation|Radiation Therapy|Undergo RT
80016920|NCT03658317|Diagnostic Test|lipogram|serum sample for doing the test
80016921|NCT03658317|Diagnostic Test|HbA1c level|serum sample for doing the test
80016922|NCT03658317|Diagnostic Test|urine analysis|urine sample for doing the test
80016923|NCT03658317|Diagnostic Test|abdominal ultrasonography|done by the ultrasonography device
79303702|NCT04794699|Drug|IDE397|IDE397 dosed orally
79303703|NCT04794699|Drug|Docetaxel|Intravenous infusion
79303704|NCT04794699|Drug|Paclitaxel|Intravenous infusion
79385320|NCT06023212|Drug|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
79385321|NCT06019364|Other|Whole blood transfusion|Transfusion of whole blood in a situation with acute bleeding according to routine practice.
79385322|NCT06018766|Drug|LAM-001|LAM-001 administered via dry powder inhaler
79698333|NCT02940119|Device|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
79842248|NCT00974727|Other|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
79842249|NCT00785408|Drug|AC2307|subcutaneous, twice daily, low dose
79842250|NCT00785408|Drug|placebo|subcutaneous, twice daily, low dose
79842251|NCT00785408|Drug|AC2307|subcutaneous, twice daily, middle dose
79842252|NCT00785408|Drug|placebo|subcutaneous, twice daily, middle dose
79842253|NCT00785408|Drug|AC2307|subcutaneous, twice daily, high dose
79842254|NCT00785408|Drug|placebo|subcutaneous, twice daily, high dose
80012049|NCT02214758|Other|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
79540277|NCT01479257|Device|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
79842255|NCT00974805|Drug|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
79842256|NCT00781352|Drug|nitrous oxide|65% nitrous oxide administered during surgery
79842257|NCT00781352|Drug|nitrogen|Nitrogen administration during surgery
79842258|NCT00960219|Drug|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
79842259|NCT00960219|Drug|placebo|1# BID, oral, for 6 weeks
80012050|NCT03078907|Drug|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
79540278|NCT01479283|Drug|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
79698334|NCT00569400|Drug|human insulin|
79698335|NCT02939963|Procedure|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
79698336|NCT02939963|Procedure|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
79698337|NCT00569439|Drug|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
79842260|NCT02555774|Behavioral|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
79842261|NCT02555774|Behavioral|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
79842262|NCT00972231|Other|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
79842263|NCT00791024|Drug|CRC-Pharma 001|50 mg
79842264|NCT00791024|Drug|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
79842265|NCT03897244|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
79842266|NCT03897244|Drug|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
79842267|NCT03897244|Drug|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
79842268|NCT00974883|Procedure|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
79842269|NCT00974883|Procedure|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
79842270|NCT00664742|Drug|Fluvastatin XL®|Fluvastatin extended release 80 mg
80012051|NCT03078907|Drug|Placebo|Matching film coated tablets
79842271|NCT04046354|Device|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
79842272|NCT04046354|Device|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
79842273|NCT00781430|Drug|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
80012052|NCT02225210|Drug|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
79698338|NCT00569439|Drug|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
79698339|NCT00569439|Drug|NS|Normal Saline solution at 125 cc/hr
79540279|NCT01479283|Drug|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
79540280|NCT01479296|Biological|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
79540281|NCT01479296|Biological|rAd5 env A|Given intramuscularly
79246573|NCT02987582|Behavioral|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
79246574|NCT03363009|Device|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
79540282|NCT01479296|Biological|rAd5 env B|Given intramuscularly
79698340|NCT04618445|Behavioral|some risk factors that might be correlated with TMD|Fonesca questionnaire
79698341|NCT04585971|Diagnostic Test|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
79698342|NCT04618367|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
79698343|NCT04618367|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79842274|NCT00511342|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
79842275|NCT00511342|Drug|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
79842276|NCT03931785|Drug|MD-7246|Oral tablet
79246575|NCT03363009|Device|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
79385323|NCT06018766|Drug|Placebo|Placebo administered via dry powder inhaler
79540283|NCT01479296|Biological|rAd5 env C|Given intramuscularly
79540284|NCT01479296|Biological|rAd5 gag-pol|Given intramuscularly
79698344|NCT04618367|Drug|Sintilimab|200mg intravenously every 3 weeks
79698345|NCT00569478|Other|rehabilitation|Nursing consultations and physical training
79698346|NCT00569517|Behavioral|CBT|6-CBT based sesions
79698347|NCT00569517|Other|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
79698348|NCT00562952|Drug|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
79246576|NCT02850536|Biological|anti-CEA CAR-T cells|Gene modified patient T cells
79246577|NCT02238223|Drug|Alesion®|
79246578|NCT03124017|Other|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
79303705|NCT05456243|Biological|Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 1 x 10^5 cells/kg
79385324|NCT06012721|Drug|ORIC-114|Food effect healthy subjects
79385325|NCT06010251|Other|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
79385326|NCT05998395|Drug|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
79698349|NCT00562952|Drug|placebo|no intervention
79698350|NCT04585347|Drug|ALZ-801 170 mg Fasting|
79698351|NCT04585347|Drug|ALZ-801 205 mg Fasting|
79698352|NCT04585347|Drug|ALZ-801 205 mg After Food|
79698353|NCT04585347|Drug|ALZ-801 342 mg Fasting|
79698354|NCT00569556|Other|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
79698355|NCT00562991|Device|measurement of exhaled NO is used to guide treatment|exhaled NO
79842277|NCT03931785|Drug|Placebo|Matching oral tablet
79842278|NCT00666536|Drug|valsartan and amlodipine|
79842279|NCT00666536|Drug|valsartan and amlodipine|
79842280|NCT00519532|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
79842281|NCT00666458|Drug|saxagliptin|tablet, per oral, once daily
79842282|NCT00666458|Drug|sitagliptin|capsule, per oral, once daily
79540285|NCT01479296|Biological|Placebo Vaccine|Given intramuscularly
79842283|NCT00974961|Drug|bupivacaine, levobupivacaine|intrathecal injection 15~20mg(for Levobupivacaine) or 10~15mg(for Bupivacaine) once
79842284|NCT00975039|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
79842285|NCT00511108|Drug|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
79842286|NCT00511108|Drug|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
79842287|NCT00511108|Drug|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
79842288|NCT00511108|Drug|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
79842289|NCT00785642|Drug|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
79842290|NCT00781586|Dietary Supplement|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
79842291|NCT00781586|Drug|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
79842292|NCT00781586|Drug|Placebo|Placebo 1 tablet at 1st visit
79842293|NCT00785720|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
79842294|NCT00781664|Other|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
79842295|NCT00781664|Drug|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
79246579|NCT05084612|Device|standard LMA insertion|"Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed."
79842296|NCT00781664|Drug|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
79303706|NCT05456243|Biological|High dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 5 x 10^5 cells/kg infused over 5 minutes
79842297|NCT00781664|Other|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
79842298|NCT00781664|Drug|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
79842299|NCT00781664|Drug|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
79842300|NCT00781664|Drug|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
80012053|NCT02225210|Drug|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
80012054|NCT02225210|Drug|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
80012055|NCT02216942|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
80012056|NCT02216942|Drug|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
80012057|NCT02225288|Drug|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
79303707|NCT05671211|Other|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
79842301|NCT00781664|Drug|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
79842302|NCT00781664|Other|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
80012058|NCT05462275|Device|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
80012059|NCT02225444|Other|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
80016924|NCT02286752|Drug|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
79303708|NCT05671211|Other|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
79540286|NCT01479361|Drug|Atovaquone 750 mg twice daily|
79540287|NCT01479361|Drug|Atovaquone 1500 mg twice daily|
79540288|NCT01479387|Drug|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
79540289|NCT01479452|Procedure|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
79540290|NCT01479452|Other|Usual care|Non-surgical obesity treatment
79698356|NCT00569595|Behavioral|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
79698357|NCT00569595|Behavioral|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
79698358|NCT04618601|Drug|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is >5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
79698359|NCT00567918|Drug|FK506|Ophthalmic suspension
79842303|NCT00785876|Other|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
79698360|NCT00569634|Procedure|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always < 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
79698361|NCT00569712|Drug|budesonide/formoterol fumarate dihydrate inhalation aerosol|
79698362|NCT00569712|Genetic|DNA methylation analysis|
80012060|NCT05462197|Behavioral|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
80012061|NCT02217020|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
80012062|NCT03249714|Drug|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
79385327|NCT05995886|Behavioral|Wiidookaage'win Facebook Group|An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
79385328|NCT05994651|Behavioral|Tidal Model improvement model|"st interview Pre-assessment Application of measurement tools~nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
79385329|NCT05993728|Behavioral|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
79385330|NCT05993728|Behavioral|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
79385331|NCT05993039|Drug|Isoflurane Inhalant Product|1.5-2%
79385332|NCT05993039|Drug|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
80012063|NCT03249714|Drug|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
79540291|NCT01479491|Other|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
79540292|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
79698363|NCT00569712|Genetic|comparative genomic hybridization|
79698364|NCT00569712|Genetic|microarray analysis|
80012064|NCT05764291|Behavioral|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
79385333|NCT05993039|Drug|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
79385334|NCT05993039|Drug|Remifentanil Injection|0.05-2ug/kg/min adults and children
79385335|NCT05988372|Drug|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
79385336|NCT05988372|Drug|Albumin-paclitaxel + Gemcitabine|Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
79385337|NCT05984784|Drug|Placebo|Drug: Placebo Intravenous Infusion
79698365|NCT00569712|Other|bronchoalveolar lavage|
79698366|NCT00569712|Other|immunoenzyme technique|
79385338|NCT05984784|Drug|IMG-007|Drug: IMG-007 Intravenous Infusion
79385339|NCT05972564|Drug|Empagliflozin 25 MG|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.
79698367|NCT00569712|Other|laboratory biomarker analysis|
79698368|NCT00569712|Procedure|bronchoscopy|
79698369|NCT00569751|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
79698370|NCT04618562|Other|Revival Active Program|Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
79698371|NCT00569790|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
79698372|NCT00567957|Drug|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
79698373|NCT00567957|Drug|Saline|same volume iv bolus before induction followed by same volume infusion
79385340|NCT05972564|Drug|Placebo|Placebo consists of gelatin capsules.
79385341|NCT05970068|Procedure|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
79842304|NCT02554916|Behavioral|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
79842305|NCT02554916|Behavioral|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
79842306|NCT02554916|Other|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
79842307|NCT02554916|Device|Dual-Belt Treadmill|
79842308|NCT00791570|Biological|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
79385342|NCT05970068|Device|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
79385343|NCT05968508|Drug|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
79385344|NCT05964855|Device|MIT Variable Stiffness Prosthesis|Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
79385345|NCT05964855|Device|MIT Variable Equilibrium Angle Prosthesis|Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
79385346|NCT05964855|Device|MIT Sliding Beam Passive Prosthesis|Proprietary fixed-stiffness passive foot-ankle prosthesis.
79385347|NCT05964855|Device|Ossur Pro-flex XC|Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
79385348|NCT05964855|Device|Blatchford Elan Variable-Dampening Prosthesis|Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
79385349|NCT05951231|Procedure|Liver transplantation|Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
79385350|NCT05950334|Drug|FT522|FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
79540293|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
79540294|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
79540295|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
79540296|NCT01479556|Drug|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
79698374|NCT04618094|Other|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
79698375|NCT00569829|Behavioral|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
79698376|NCT02940002|Drug|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
79698377|NCT02940002|Drug|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
79540297|NCT01479556|Drug|Placebo|150mg BID p.o.
79842309|NCT00510952|Drug|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
79842310|NCT00510952|Drug|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
79842311|NCT00617604|Drug|Alefacept|IV and subcutaneous injection
79842312|NCT00617604|Drug|placebo|IV and subcutaneous injection
79842313|NCT00617604|Drug|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
79385351|NCT05950334|Drug|Rituximab|Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
79540298|NCT01479569|Procedure|Pericardiocentesis|
79540299|NCT01479582|Drug|Access to unlicensed cord blood units|
79540300|NCT01479634|Drug|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
79540301|NCT01479634|Drug|Study-Provided ART|"Study provided drugs:~Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate [TDF] and emtricitabine [FTC]) PLUS~Efavirenz [EFV]"
79540302|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
79540303|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
79540304|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
79698378|NCT02940002|Drug|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
79698379|NCT04580745|Drug|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
79698380|NCT04580745|Drug|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
79842314|NCT00617604|Drug|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
79842315|NCT00617604|Drug|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
79842316|NCT00865722|Procedure|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
79842317|NCT01012570|Drug|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
79246580|NCT05084612|Device|New technique LMA insertion|Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
79385352|NCT05950334|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
79385353|NCT05950334|Drug|Fludarabine|Fludarabine will be administered as an IV infusion at a dose of 30 mg/m^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
79385354|NCT05950334|Drug|Bendamustine|Bendamustine will be administered as an IV infusion at a dose of 90 mg/m^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
79540305|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
79540306|NCT01479647|Drug|PH-797804|Tablet, 24 mg, single dose
79540307|NCT01479660|Other|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
79698381|NCT04618328|Drug|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
79698382|NCT04585659|Other|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
79698383|NCT04617782|Combination Product|Donepezil TDS|Transdermal Delivery System
79698384|NCT04617782|Drug|Aricept|Oral
79698385|NCT04617704|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
79698386|NCT00569985|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
79698387|NCT00569985|Drug|carmustine|Given IV
79698388|NCT00569985|Drug|cyclophosphamide|Given IV
79842318|NCT01012648|Drug|Fluid resuscitation|Volume resuscitation
79842319|NCT01012648|Drug|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
79842320|NCT02544594|Device|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
79842321|NCT00858000|Other|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
79842322|NCT02544438|Drug|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~0.5 gr/m2 (0.3 age>50) 3~1.5 gr/m2(0.8age>50) 3~3.0 gr/m2(1.5 age>50) 3~4.5 gr/m2(2.3 age>50) 6~4.5 gr/m2 (no age limit) 3 up to 6~6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
79842323|NCT03843216|Other|observation|patients not treated
79842324|NCT03843216|Other|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
79842325|NCT03843216|Device|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
79842326|NCT00865878|Drug|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
79842327|NCT00865878|Other|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
79842328|NCT00661622|Drug|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
79842329|NCT00661622|Procedure|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
79246581|NCT03124173|Other|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
79540308|NCT01479660|Drug|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
79540309|NCT01479673|Dietary Supplement|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
79698389|NCT00569985|Drug|etoposide|Given IV
79842330|NCT00781820|Drug|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
79540310|NCT01479686|Procedure|iMRI|3.0TiMRI guided resection in adults with glioma
79698390|NCT00569985|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
79698391|NCT02939768|Other|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit ~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed ~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
79698392|NCT02939768|Other|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
79698393|NCT02939768|Other|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
79698394|NCT04617665|Other|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
79698395|NCT04617665|Other|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
79540311|NCT01479686|Procedure|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
79540312|NCT01479699|Dietary Supplement|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
79698396|NCT00570024|Procedure|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
79698397|NCT00570024|Procedure|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
79842331|NCT00781820|Drug|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
79385355|NCT05946265|Other|Photobiomodulation|Forty-four patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) (660nm, 100W, area 0,5cm2, 200w/cm2, 30 seconds, 3 J, 6J/cm2.
79385356|NCT05946265|Other|simulation of Photobiomodulation|Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
79842332|NCT00786110|Drug|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
79842333|NCT00786110|Drug|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
79540313|NCT01479712|Procedure|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
79540314|NCT01479738|Procedure|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
79540315|NCT01479751|Drug|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
79842334|NCT00781976|Drug|AZD7295|700mg per day maximum
79842335|NCT00781976|Drug|Placebo|matched placebo
79842336|NCT00782054|Other|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
79842337|NCT00782054|Other|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
79842338|NCT00791804|Drug|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~for nebulized administration as required by the patient.~Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
79842339|NCT00791882|Behavioral|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
79842340|NCT02544516|Other|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
79842341|NCT02544516|Other|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
79385357|NCT05945810|Drug|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
79385358|NCT05945810|Drug|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
79385359|NCT05945316|Behavioral|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
79540316|NCT01479751|Drug|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
79540317|NCT01479751|Drug|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
79540318|NCT01479790|Device|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
79246582|NCT03124173|Other|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
79698398|NCT00570102|Dietary Supplement|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
79698399|NCT00570102|Dietary Supplement|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
79842342|NCT00791960|Drug|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
79842343|NCT00791960|Other|Placebo|single dose, 10 mL normal saline, IV
79540319|NCT01479803|Procedure|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
79246583|NCT03124173|Other|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
79385360|NCT05933850|Behavioral|Strong Families Programme Intervention|This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
79842344|NCT00792194|Other|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
79842345|NCT00792350|Drug|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
79540320|NCT01479829|Drug|ESC + CBX|Escitalopram (ESC) 10 mg twice day given orally twice a day plus Celecoxib (CBX) 200 mg twice daily.
79842346|NCT04046198|Other|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
79842347|NCT00792584|Drug|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
79842348|NCT00792584|Drug|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
79842349|NCT00782366|Genetic|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
79842350|NCT02556086|Drug|Daclatasvir|
79842351|NCT02556086|Drug|Sofosbuvir|
79842352|NCT00782522|Procedure|Eccentric training program|Eccentric training program
79842353|NCT00782522|Procedure|Traditional training program|Traditional training program
79540321|NCT01479829|Drug|ESC + PBO.|• Escitalopram (ESC) 10 mg twice per day plus Placebo (PBO)administered twice daily.
79540322|NCT01479829|Drug|ESC+CBX|• Escitalopram 10 mg given twice day plus Celecoxib 200 mg twice daily.
79540323|NCT01479881|Drug|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
79540324|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
79540325|NCT01479881|Drug|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
79842354|NCT00782600|Drug|suspension IR|50 mg IR suspension once daily for one day
79540326|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
79540327|NCT01479907|Dietary Supplement|Synbiotics|12 gr in 250 cc of water once daily X 15 days
79540328|NCT01479907|Dietary Supplement|Placebo|12 gr in 250 cc of water once daily X 15 days
79540329|NCT01479920|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
79698400|NCT04617626|Drug|Azithromycin|Single dose of azithromycin suspension
79698401|NCT04585230|Drug|CBD|CBD oil Roll-On Stick
79698402|NCT04585230|Drug|Mineral Oil|Mineral Oil- Roll on Stick
79842355|NCT00782600|Drug|CR 1|50 mg shorter release CR once daily for one day
79842356|NCT00782600|Drug|CR 2|50 mg medium release CR once daily for one day
79842357|NCT00782600|Drug|CR 3|longer release SR formulation once daily for one day
79842358|NCT00786266|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
79842359|NCT00786266|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
79842360|NCT04093752|Drug|Tirzepatide|Administered SC
80012065|NCT02217098|Procedure|GIC Restorations|Restorations using Glass Ionomer Cement
80012066|NCT02217098|Procedure|Carbomer Restorations|Restorations using Glass Carbomer
79246584|NCT03124173|Other|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
79246585|NCT04189562|Other|SMS Intervention|Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
79698403|NCT04585230|Drug|Placebo|Roll- On stick with no CBD and no Mineral Oil
79698404|NCT04617899|Diagnostic Test|Intravascular imaging|Use of imaging catheter
79842361|NCT04093752|Drug|Insulin Glargine|Administered SC
79842362|NCT00865956|Behavioral|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
79246586|NCT05077514|Behavioral|Experimental: Cognitive Behavior Therapy|Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.
79698405|NCT04584840|Procedure|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~Secure a two layered waterproof closure without tension (simple or with local flaps).~Samples will be sent for Pathological and microbiological analysis.~Stitches removal after two weeks~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
79698406|NCT02939690|Device|UVC|UVC insertion depth calculated by [(3× birth weight (Kg) + 9)/2+1)]
79698407|NCT02939690|Device|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
79698408|NCT02939690|Device|Ultrasound|
79698409|NCT04580784|Radiation|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
79698410|NCT02939729|Other|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
79698411|NCT02939729|Device|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
79698412|NCT02939729|Other|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
79385361|NCT05932342|Behavioral|Integrated program of cognitive remediation, physical exercise and socially stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport."
79698413|NCT00570180|Drug|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
79246587|NCT05077514|Behavioral|Active comparator: National Crisis Line|Participants assigned to Group B received information about the VA's National Crisis Line.
79385362|NCT05924204|Radiation|Photobiomodulation|Application of photobiomodulation
79246588|NCT04527081|Biological|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
79540330|NCT01479920|Procedure|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
79540331|NCT01479920|Procedure|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
79540332|NCT01479933|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
79698414|NCT02939807|Drug|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
79698415|NCT02939846|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
79698416|NCT02939495|Drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
79698417|NCT04584879|Behavioral|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
79698418|NCT04584879|Behavioral|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
79385363|NCT05924204|Other|Simulation of Photobiomodulation|Simulation of photobiomodulation
79385364|NCT05923892|Drug|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
79698419|NCT04584879|Behavioral|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
79842363|NCT00865956|Other|Case management|Nurse case manager assigned to participant
79246589|NCT04527081|Biological|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
79246590|NCT04527081|Biological|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
79385365|NCT05923892|Drug|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
79385366|NCT05923749|Device|Biatain Ag|Biatain with silver
79385367|NCT05923749|Device|Cutimed Siltec Sorbact|comparator device
79385368|NCT05920343|Drug|Rivaroxaban 10 MG|The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
79540333|NCT01479933|Dietary Supplement|Placebo|Inactive placebo
79540334|NCT01479933|Dietary Supplement|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
79540335|NCT01479946|Drug|Electrochemotherapy|bleomycin together with electroporation
79540336|NCT01479959|Device|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
79540337|NCT01479972|Biological|VPM1002|Tuberculosis vaccine
79540338|NCT01479972|Biological|BCG|commercially available live vaccine BCG
79540339|NCT01479998|Other|standard care|standard care plus nicotine replacement therapy
79698420|NCT00570219|Drug|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
79246591|NCT03364101|Dietary Supplement|Placebo Capsule|Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.
79385369|NCT05920343|Other|Placebo control|Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
79540340|NCT01479998|Other|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
79385370|NCT05898659|Device|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
79385371|NCT05898659|Device|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
79385372|NCT05895604|Behavioral|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
79385373|NCT05893186|Other|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
79385374|NCT05893186|Other|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
79540341|NCT01480011|Drug|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
80012067|NCT02217098|Procedure|Compomer Restorations|Restorations using Compomer
79246592|NCT03364101|Dietary Supplement|POWEROFF Capsule|blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
79246593|NCT03362853|Drug|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
79246594|NCT03362853|Drug|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
79246595|NCT03362853|Drug|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
79385375|NCT05884541|Other|TipsbyText Messages|Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months
79540342|NCT01480050|Drug|temozolomide|standard of care drug
79540343|NCT01480050|Other|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
79540344|NCT01480050|Other|pharmacological study|
79540345|NCT01480050|Drug|Mibefradil|
79540346|NCT01480063|Drug|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
79540347|NCT01480102|Drug|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
79540348|NCT01480102|Other|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
79540349|NCT01480115|Other|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
79698421|NCT04584957|Device|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
79698422|NCT04610957|Drug|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
79842364|NCT02545062|Other|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
79842365|NCT00866112|Other|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
79842366|NCT00866112|Other|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
80016925|NCT02286752|Drug|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
79540350|NCT01480128|Procedure|Single-port|Single-port laparoscopic colon resection
79698423|NCT00570375|Drug|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
79385376|NCT05884333|Drug|Conditioning Chemotherapy|Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 & -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 & -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours & Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
79385377|NCT05884333|Biological|Cord blood graft|The double-unit CB graft will be infused on day 0 per standard practice.
79698424|NCT04617509|Drug|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
79540351|NCT01480128|Procedure|Multi-port|Multi-port laparoscopic colon resection
79246596|NCT03362853|Drug|Placebo oral capsule|Receive a single dose in a fasting state
79246597|NCT02849743|Drug|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
79246598|NCT02849743|Drug|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
79246599|NCT05076812|Diagnostic Test|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
79246600|NCT04523883|Radiation|postoperative radiotherapy|postoperative radiotherapy with a dose of 60-66Gy
79385378|NCT05883956|Drug|Subcutaneous azacitidine|Subcutaneous azacitidine, 75mg/m2, 7 days
79385379|NCT05883956|Drug|Oral decitabine/cedazuridine|Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
79385380|NCT05879757|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
79540352|NCT01480141|Drug|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
79246601|NCT04523883|Drug|JS001|JS001 240mg every three week
79698425|NCT04617509|Drug|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
79698426|NCT00570414|Device|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
79698427|NCT00570414|Device|Endotracheal tube|Airway management by the use of endotracheal tube
79698428|NCT04617431|Behavioral|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
79842367|NCT00862602|Behavioral|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet & nutrition and prevention.
79246602|NCT03601351|Other|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
79246603|NCT05063006|Other|Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.|Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
79540353|NCT01480167|Device|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
79540354|NCT01480167|Other|Non-operative Management|Conservative Care
79540355|NCT01480180|Drug|turoctocog alfa pegol|Administered i.v.
79540356|NCT01480193|Other|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
79540357|NCT01480193|Other|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
79540358|NCT01480245|Drug|GSK2402968|6mg/kg/week
79540359|NCT01480271|Drug|2 ng GSK2445053|2ng GSK2445053 administered intranasally
79698429|NCT00568035|Drug|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
79842368|NCT00858156|Drug|BG9928|Oral 75 mg single dose
79540360|NCT01480271|Drug|20ng GSK2445053|20ng GSK2445053 administered intranasally
79540361|NCT01480271|Drug|100ng GSK2445053|100ng GSK2445053 administered intranasally
79540362|NCT01480271|Drug|200ng GSK2445053|200ng GSK2445053 administered intranasally
79842369|NCT00858312|Other|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
79540363|NCT01480271|Drug|400ng GSK2445053|400ng GSK2445053 administered intranasally
79540364|NCT01480271|Drug|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
79842370|NCT00858312|Other|Low Dairy|less than 1 serving of dairy foods per day.
79842371|NCT00862680|Procedure|4-Dimensional Computed Tomography|Undergo 4D PET/CT
79842372|NCT00862680|Procedure|4D PET Scan|Undergo 4D PET/CT scan
79540365|NCT01480271|Drug|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
79540366|NCT01480271|Drug|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
79540367|NCT01480271|Drug|Placebo|Placebo administered intranasally
79540368|NCT01480310|Drug|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
79246604|NCT05063006|Other|Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.|During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
79698430|NCT04611113|Dietary Supplement|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
79698431|NCT04611113|Dietary Supplement|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
79246605|NCT04526457|Other|Standard of Care|Randomized to standard of care with lipid testing only.
79698432|NCT00568074|Drug|repaglinide|
80012068|NCT02218502|Other|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
79246606|NCT04526457|Other|Genetic Testing|Randomized to genetic testing.
80012069|NCT02218502|Other|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
80012070|NCT02218502|Other|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
79246607|NCT03587077|Drug|Misoprostol|vaginal application
79246608|NCT03587077|Drug|Placebos|vaginal application
79246609|NCT03587077|Drug|isosorbide mononitrate|vaginal application
79246610|NCT05090462|Device|PICO dressing|Negative Pressure Wound Therapy device
79246611|NCT04524429|Procedure|Bariatric Surgery|Bariatric surgery includes sleeve gastrectomy and gastric bypass.
79246612|NCT03601273|Procedure|Left gastric artery embolization|"450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.~30-day post-embolization endoscopic biopsy"
79246613|NCT02238457|Drug|Low dose losartan|25 mg losartan bid for 10 weeks
79246614|NCT02238457|Drug|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
79246615|NCT04524039|Device|intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive iTBS in left dorsolateral prefrontal cortex, each treatment will consist of 600 stimuli (triplet 50 Hz bursts, repeated at 5 Hz; 2 s on and 8 s off; total duration of 3 min 12 s). Simulated iTBS will be administered using Magventure static cooling MCF-B65 coil.
79540369|NCT01480310|Drug|Placebo|may receive up to 3 subcutaneous doses of placebo
79540370|NCT01480323|Drug|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
80012071|NCT02218502|Other|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
80012072|NCT05461651|Procedure|Knee arthroplasty|total or unilateral knee arthroplasty
80012073|NCT02080806|Device|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
80016926|NCT02096562|Other|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
79246616|NCT04524039|Device|sham intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive sham iTBS will undergo the same procedure to patients receiving real iTBS. Sham iTBS will be administered using Magventure static cooling MCF-P-B65 coil that shares the same mechanical outline and produces identical sound level to MCF-B65 coil without stimulating the cerebral cortex.
79540371|NCT01480323|Drug|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
79540372|NCT01480336|Drug|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
79540373|NCT01480336|Drug|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
79540374|NCT01480362|Device|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
79540375|NCT01480362|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
79698433|NCT00568074|Drug|Glurenorm®|
79698434|NCT00568074|Drug|Glucobay®|
79698435|NCT00568113|Drug|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
79698436|NCT04617392|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
79842373|NCT02544282|Drug|Levobupivacaine|Pecs II Block
79698437|NCT04617392|Other|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
79698438|NCT00568152|Dietary Supplement|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
79698439|NCT00568152|Dietary Supplement|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
79698440|NCT00568152|Drug|Aspirin|75mg dispersable aspirin taken daily for 14 days
80012074|NCT02225522|Other|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
80012075|NCT04749589|Diagnostic Test|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
79698441|NCT04610879|Drug|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
80012076|NCT02222168|Drug|BI 409306|medium dose, oral administration
80012077|NCT02222168|Drug|BI 409306|medium dose, oral administration
80012078|NCT02222168|Drug|BI 409306|medium dose, oral administration
80012079|NCT04748731|Behavioral|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
80012080|NCT04748731|Behavioral|Psycho-Educational Intervention|Reception of psycho-educational materials
80012081|NCT03283722|Device|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
80012082|NCT05236478|Other|CoviMouv' program|"An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
80012083|NCT05236478|Other|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
80012084|NCT02925117|Drug|Upadacitinib|Tablet for oral use
80012085|NCT02925117|Drug|Placebo|Tablet
80012086|NCT04634149|Drug|BMS-986036|Specified dose on specified days
79246617|NCT05090306|Diagnostic Test|Routine ultrasound examination|ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
79246618|NCT02238535|Drug|Ventavis|
79246619|NCT02238535|Drug|Warfarin|
80016927|NCT02096562|Other|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
79698442|NCT04610879|Drug|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
79698443|NCT04610879|Behavioral|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
79698444|NCT04617236|Behavioral|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
79698445|NCT04584489|Other|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
79698446|NCT00570570|Procedure|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
79698447|NCT00570570|Other|conventional physiotherapy|trice a week during 6 weeks
79698448|NCT04617119|Device|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
79698449|NCT04617119|Other|Conventional physical therapy|daily
79842374|NCT02544282|Drug|NaCl 0.9%|Placebo Pecs II block
79842375|NCT02544282|Drug|Sevoflurane|General Anesthesia
79842376|NCT02544282|Drug|Propofol|General Anesthesia
79842377|NCT02544282|Drug|Sufentanil|General Anesthesia
79842378|NCT02544282|Drug|Atracurium|General Anesthesia
79842379|NCT02544282|Drug|Paracetamol|Pain Relief
79842380|NCT02544282|Drug|Tramadol|Pain Relief
79842381|NCT02544282|Drug|Piritramide|Pain Relief
79698450|NCT00570609|Other|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
79698451|NCT00570648|Drug|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
79698452|NCT00570726|Drug|Ranibizumab (Lucentis)|
79698453|NCT04584450|Other|Questionnaire|data collection using questionnaire
79698454|NCT00570804|Behavioral|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
79698455|NCT00570804|Behavioral|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
79698456|NCT04584606|Diagnostic Test|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
79842382|NCT00866190|Drug|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
79842383|NCT00866190|Drug|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
80012087|NCT05056298|Other|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
80012088|NCT05056298|Other|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
80016928|NCT05103592|Diagnostic Test|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
79246620|NCT03362697|Dietary Supplement|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
79246621|NCT03362697|Drug|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
79246622|NCT03371199|Drug|Sodium chloride|Sodium chloride tablets, 250 mg
79246623|NCT03371199|Drug|Placebo Oral Tablet|Starch tablets
79246624|NCT05033600|Device|S.C.I.O.|The devices read, emit and entrain Electromagnetic waves of the body.
79540376|NCT01480375|Device|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
79540377|NCT01480388|Drug|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
79540378|NCT01480388|Drug|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
79540379|NCT01480388|Drug|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
79698457|NCT00570843|Drug|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
79698458|NCT00570843|Drug|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
79698459|NCT00563069|Drug|Midazolam|
79698460|NCT04584411|Diagnostic Test|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~Cine imaging using SSFP sequence for cardiac structure and function.~Tissue characterization imaging, T1 and T2.~Myocardial perfusion imaging.~Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities[5]"
79698461|NCT04580355|Procedure|One-Stage Full Mouth Debridement|Periodontal debridement
79698462|NCT04580355|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
79698463|NCT04580355|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
79698464|NCT04580355|Drug|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
79698465|NCT04580355|Drug|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
79698466|NCT00563108|Drug|Basiliximab|
79698467|NCT00563108|Drug|Placebo|
79698468|NCT00570882|Drug|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
79698469|NCT00570882|Drug|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
79698470|NCT00563147|Drug|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
79698471|NCT00570999|Drug|Palifermin|60 mg/kg/day
79698472|NCT00570999|Other|Placebo|1,2 mL once daily
79698473|NCT04616261|Behavioral|Training|6 weeks of training
79698474|NCT04616261|Drug|Formoterol|inhalation of 54 microg formoterol
79698475|NCT04616261|Drug|Placebo|inhalation of placebo
79698476|NCT04616222|Drug|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
79698477|NCT04616222|Drug|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
79698478|NCT04584177|Behavioral|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
79698479|NCT04584177|Behavioral|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
79698480|NCT00563225|Drug|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
79246625|NCT03362619|Biological|CC-EIEs|2 to 4 infusions, once a week, for 1x10^5~1x10^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time
79246626|NCT02518815|Device|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
79540380|NCT01480388|Drug|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
79246627|NCT03909074|Biological|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
79246628|NCT03909074|Biological|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
79385381|NCT05879640|Behavioral|Sleep education|Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
79540381|NCT01480388|Drug|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
79698481|NCT04580316|Behavioral|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
79246629|NCT03909074|Biological|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
79385382|NCT05878483|Device|Venipuncture Device (VD)|"The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.~During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor."
79698482|NCT04580316|Behavioral|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
79698483|NCT00563264|Behavioral|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
79698484|NCT03454490|Procedure|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
79540382|NCT01480414|Biological|4times injection|bone marrow derived mono nuclear stem cell
79540383|NCT01480414|Biological|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
79540384|NCT01480453|Device|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
79842384|NCT05227482|Radiation|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
79246631|NCT03138668|Drug|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
79540385|NCT01480466|Other|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
79540386|NCT01480492|Drug|Telbivudine|600mg,1/d,one year
79385383|NCT05873569|Behavioral|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
79698485|NCT00571077|Device|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
79698486|NCT03454373|Behavioral|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
79698487|NCT04584216|Other|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
79698488|NCT04584216|Other|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
79698489|NCT04615793|Other|PILATES EXERCISES|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
79698490|NCT04584060|Combination Product|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
79698491|NCT04584060|Combination Product|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
80012089|NCT05056298|Other|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
80012090|NCT05056298|Other|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
79698492|NCT04584060|Combination Product|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
79698493|NCT04615637|Device|MEG recordings|"Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli)."
80012091|NCT02074332|Behavioral|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight&obese students Family physical activities Parent involvement
80012092|NCT02074332|Behavioral|Health education|Knowledge of obesity prevention and control
80012093|NCT04102735|Device|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
80012094|NCT04102735|Device|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
80012095|NCT02080962|Radiation|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
80012096|NCT02080962|Radiation|40 Gy in 10 fractions|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
79698494|NCT04584021|Device|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
79698495|NCT04584021|Other|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
79246632|NCT03138668|Drug|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
79246633|NCT03371121|Other|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
80012097|NCT01379911|Other|Yogurt|
79385384|NCT05867498|Behavioral|Concurrent exercise|Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
80012098|NCT05235152|Other|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~Individual proprioceptive training."
80016929|NCT03659019|Other|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
79246634|NCT03601039|Device|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
80012099|NCT05235152|Other|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
79698496|NCT04584021|Other|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
80012100|NCT02077920|Drug|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
80012101|NCT02077920|Drug|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
80012102|NCT02077920|Device|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
79698497|NCT04584021|Other|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
79698498|NCT04584021|Other|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
79698499|NCT04584021|Other|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
79698500|NCT04584021|Other|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
79246635|NCT03371043|Other|users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
79246636|NCT05089994|Procedure|US guided injection|using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.
79246637|NCT05089838|Biological|CMV-TCR-T cells|Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
79246638|NCT03370965|Diagnostic Test|Neuro-ophtalmology examination|"Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment."
79246639|NCT05013242|Drug|Zoladex|evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
79246640|NCT05013242|Drug|Visanne|valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
79385385|NCT05867498|Behavioral|Aerobic exercise|Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
79385386|NCT05866250|Diagnostic Test|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
79385387|NCT05861050|Procedure|Biopsy|Undergo tumor biopsy
79385388|NCT05861050|Procedure|Biospecimen Collection|Undergo collection of blood samples
79385389|NCT05861050|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79385390|NCT05861050|Procedure|Computed Tomography|Undergo CT scan
79698501|NCT04615598|Behavioral|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
79698502|NCT04615598|Behavioral|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
79698503|NCT00571116|Drug|Disulfiram|Given PO
80012103|NCT02077920|Device|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
80012104|NCT03630133|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
79385391|NCT05861050|Biological|Glofitamab|Given IV
79385392|NCT05861050|Drug|Lenalidomide|Given PO
79385393|NCT05861050|Biological|Obinutuzumab|Given IV
79385394|NCT05861050|Procedure|Positron Emission Tomography|Undergo PET scan
79385395|NCT05861050|Drug|Venetoclax|Given PO
79385396|NCT05849857|Drug|Mosunetuzumab|Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
79698504|NCT00571116|Drug|Arsenic trioxide|Given IV
79698505|NCT04615676|Other|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
79540387|NCT01480505|Procedure|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
79246641|NCT03370887|Drug|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
79246642|NCT03370887|Drug|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
79698506|NCT00571155|Drug|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
79842385|NCT05227482|Radiation|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
80012105|NCT05232890|Other|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
80012106|NCT05232890|Other|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
80012107|NCT02081040|Other|Not applicable (observational study with no active intervention)|
79246643|NCT03590509|Other|Telemedicine Program|"A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits* will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home.~*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
79246644|NCT03590509|Other|Usual Comprehensive Care|Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
79246645|NCT03358173|Procedure|Conservative Treatment|Conservative Treatment
79246646|NCT03358173|Procedure|Operative Plate Fixation|Operative Plate Fixation
79246647|NCT05005832|Other|multi day walking|Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
79246648|NCT03590275|Drug|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
79385397|NCT05848895|Procedure|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.
79698507|NCT04615481|Other|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
79246649|NCT03362463|Other|Non-Interventional Study|Non-Interventional Study
79246650|NCT04993898|Other|Plyometric training with warm up and cool down|These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min
79246651|NCT04993898|Other|Conventional training with warm up & cool down|These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
79246652|NCT03370731|Procedure|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
79698508|NCT04615481|Other|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
79842386|NCT04041804|Procedure|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
79842387|NCT00858546|Device|Repetitive transcranial stimulation|Repetitive transcranial stimulation
79842388|NCT04041648|Drug|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
79842389|NCT04041648|Device|L606 Inhalation System|Single ascending dose
80012108|NCT03630523|Biological|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
80012109|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
80012110|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
79246653|NCT03370731|Other|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
79385398|NCT05848895|Behavioral|Standard of Care Repositioning|Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
79540388|NCT01480518|Genetic|DNA analysis|
80012111|NCT02225756|Drug|Placebo|Oral administration for a short time of placebo
79385399|NCT05834439|Other|flower printing activities for the elderly|Experimental group
79385400|NCT05834439|Other|Routine activities in nursing home|Control group
79385401|NCT05827536|Dietary Supplement|PKU GOLIKE|PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
79540389|NCT01480518|Genetic|comparative genomic hybridization|
79540390|NCT01480518|Genetic|gene expression analysis|
80012112|NCT02074488|Other|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
80012113|NCT02074488|Other|Informational Brochure|Informational Brochure on falls prevention
80012114|NCT02220062|Procedure|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5~10cc ethanol would be performed as bilateral injections at the celiac trunk.
80012115|NCT02220062|Procedure|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
80012116|NCT02074566|Other|Cryoballoon ablation|PVI using cryoballoon
79540391|NCT01480518|Genetic|mutation analysis|
79540392|NCT01480518|Genetic|polymerase chain reaction|
79842390|NCT04041648|Other|Placebo Solution|Single ascending dose
79842391|NCT02544360|Behavioral|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
80012117|NCT02225834|Drug|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
79246654|NCT05089448|Drug|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 6:00-10:00.
79246655|NCT05089448|Drug|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 20:00-24:00.
79246656|NCT03358095|Device|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
79385402|NCT05827536|Dietary Supplement|Standard of Care|Protein substitute
79698509|NCT04580433|Behavioral|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
80012118|NCT02077998|Radiation|carbon C 14 oxaliplatin|Given IV
80012119|NCT02077998|Drug|oxaliplatin|Given IV
80012120|NCT02077998|Other|laboratory biomarker analysis|Correlative studies
79246657|NCT04971122|Other|Trendeleburg -5 degree,-10 degree,-15 degree|Use a -5 or -10 or -15 degree trendelenburg position
79385403|NCT05824572|Other|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
79540393|NCT01480518|Genetic|polymorphic microsatellite marker analysis|
79698510|NCT04584723|Other|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
80012121|NCT05461183|Other|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
80012122|NCT02225912|Other|PrevinC|
79246658|NCT04955132|Behavioral|E-learning|The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
79246659|NCT04935944|Radiation|CBCT radiation|CBCT scanning
79246660|NCT05088824|Procedure|hernia repair by desarda technique|It involves use of undetached strip of external oblique aponeurosis to strengthen the posterior wall of the inguinal canal which is based on the physiological principles. This is a physiological repair and is tension free, can be used in strangulated hernia
80012123|NCT02225912|Drug|placebo|
80012124|NCT02074644|Procedure|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
80012125|NCT02074644|Procedure|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
79246661|NCT03362385|Other|Patients with OSA based on sleep study|Polysomnography or Polygraphy
79246662|NCT03362385|Other|Patients without OSA based on sleep study|Polysomnography or Polygraphy
79385404|NCT05824572|Other|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
79385405|NCT05818397|Behavioral|Self-Compassion for Children and Caregivers (SCCC)|A standardized, manualized adaptation of the mindful self-compassion curriculum for adults, designed for online delivery. Dyads join a group video conference call along with other caregiver-child dyads and an experienced SCCC facilitator. Sessions occur 1-hour per week for 6 weeks at a time convenient for the group.
79385406|NCT05815147|Dietary Supplement|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
79540394|NCT01480518|Other|laboratory biomarker analysis|
80012126|NCT02222324|Drug|Placebo|8 placebo tablets matching E2609
79842392|NCT00862758|Drug|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
79842393|NCT03928821|Biological|PGT121|20 mg/kg administered intravenously
79842394|NCT03928821|Biological|PGDM1400|20 mg/kg administered intravenously
79842395|NCT03928821|Biological|10-1074|20 mg/kg administered intravenously
79842396|NCT03928821|Biological|VRC07-523LS|20 mg/kg administered intravenously
79842397|NCT00666224|Drug|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
79842398|NCT00666224|Drug|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
79842399|NCT00666224|Drug|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
80012127|NCT02222324|Drug|E2609|E2609 will be administered as 8 tablets
79698511|NCT04615169|Behavioral|Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)|"2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc."
79540395|NCT01480531|Drug|Clevidipine|"Clevidipine administration begins in the ER or ICU~Clevidipine is again administered post op when blood pressure control is required.~Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
79698512|NCT04615208|Diagnostic Test|suspected of COVID-19 infection|suspected of COVID-19 infection
79698513|NCT04614857|Other|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
79698514|NCT04583865|Other|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
79698515|NCT04614818|Other|Non-intervention research|Non-intervention research
79698516|NCT04614623|Device|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
79698517|NCT04614623|Other|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
79698518|NCT00571350|Procedure|tvt-o operation|transvaginal tention free obturator tape
79246663|NCT04918160|Other|Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)|The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
79246664|NCT03362307|Device|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
79246665|NCT03362307|Device|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
79246666|NCT04445181|Drug|The physician's prescription in routine clinical practice|This is an Observational study that will not involve prescription of the drugs.
79540396|NCT01480544|Other|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
79246667|NCT05088590|Dietary Supplement|Enfagrow® Neuropro Toddler Nutritional Drink|Enfagrow® Neuropro Toddler Nutritional Drink to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
79385407|NCT05794542|Device|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
79540397|NCT01480544|Other|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
79540398|NCT01480557|Procedure|liquefaction|Cataract extraction surgery type
79540399|NCT01480557|Procedure|Torsional ip|A type cataract surgery using torsional ip technology
79540400|NCT01480609|Drug|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
79540401|NCT01480622|Drug|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
79698519|NCT00571350|Procedure|tvt o operation|transobturator vaginal tape insertion
79540402|NCT01480648|Drug|BI 144807 Placebo|Placebo that represents BI drug
79540403|NCT01480648|Drug|BI 144807|single dose (low to high dose)
79698520|NCT04583631|Procedure|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
79246668|NCT05088590|Dietary Supplement|Pediasure® Grow & Gain Protein Shake for Kids|Pediasure® Grow & Gain Protein Shake for Kids to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
79246669|NCT02849509|Drug|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
79540404|NCT01480661|Drug|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
79698521|NCT00571467|Drug|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
80012128|NCT02222324|Drug|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
80012129|NCT02220140|Behavioral|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
79246670|NCT02849509|Drug|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
79698522|NCT04583553|Diagnostic Test|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
79540405|NCT01480661|Drug|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
79698523|NCT00563303|Drug|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
79698524|NCT00563303|Drug|NaCl|48mL from Day 1 to Day 6
79698525|NCT00571506|Drug|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
79842400|NCT00866268|Device|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
79842401|NCT00866268|Device|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
80012130|NCT02074800|Drug|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
79698526|NCT00571506|Drug|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
79540406|NCT01480661|Radiation|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
79540407|NCT01480687|Dietary Supplement|DHA-EPA|1800 mg/day
80012131|NCT02074800|Drug|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
79385408|NCT05782790|Behavioral|Action Observation Theraphy Group|"In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale."
79540408|NCT01480687|Drug|Ciprofibrate|100 mg/day
79540409|NCT01480700|Other|Nutritional study|subjects consume 2 eggs per day during 4 months
79540410|NCT01480713|Drug|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
79540411|NCT01480713|Drug|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
79540412|NCT01480726|Procedure|Surgery|
80012132|NCT02074800|Drug|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
79540413|NCT01480739|Drug|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
79842402|NCT00866346|Biological|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
79842403|NCT00866424|Procedure|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
79842404|NCT00663962|Drug|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
79842405|NCT00663962|Drug|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
79842406|NCT00866502|Drug|sNN0031|Continuous ICV infusion for two weeks
79842407|NCT00866502|Drug|Placebo|Continous ICV infusion
79842408|NCT00975117|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
79842409|NCT00975117|Dietary Supplement|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
80012133|NCT04504045|Drug|Metformin|500 mg tablet
80012134|NCT04504045|Drug|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
79540414|NCT01480739|Drug|100 mg Placebo|Twice daily for 7 days
79540415|NCT01480752|Drug|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
79540416|NCT01480752|Drug|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
79540417|NCT01480752|Drug|no injection|inject nothing after inferior alveolar injection and before root canal therapy
79540418|NCT01480765|Drug|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
79540419|NCT01480765|Drug|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
79698527|NCT04614077|Other|ex vivo organ bath testing, preservation of vein sections without contact to patient|1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
79540420|NCT01480765|Drug|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
79698528|NCT00571545|Behavioral|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
79698529|NCT00571545|Behavioral|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
79698530|NCT04583397|Other|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
79842410|NCT00786344|Behavioral|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
80012135|NCT04504045|Drug|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
80012136|NCT04504045|Drug|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
79540421|NCT01480765|Drug|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
80012137|NCT04504045|Drug|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
80012138|NCT04504045|Drug|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
79385409|NCT05782790|Behavioral|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
79540422|NCT01480778|Drug|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
79698531|NCT00571584|Drug|activated recombinant human factor VII|
79698532|NCT04614272|Behavioral|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
79698533|NCT04614272|Behavioral|Reading a poem|Reading is a distraction tool for pain management
79698534|NCT04583436|Device|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
79842411|NCT00858624|Drug|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
79842412|NCT04008459|Other|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
79842413|NCT00782990|Procedure|Surgical treatment: TVT|
80012139|NCT04504045|Drug|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
80016930|NCT02095236|Behavioral|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
79385410|NCT05779072|Device|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
79540423|NCT01480778|Drug|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
79540424|NCT01480791|Drug|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
79842414|NCT00782990|Procedure|Surgical treatment: colposuspension|
79842415|NCT00960453|Drug|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
79842416|NCT00265759|Drug|anastrozole|Given PO
79842417|NCT00265759|Drug|exemestane|Given PO
79540425|NCT01480791|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
79540426|NCT01480804|Other|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
79540427|NCT01480817|Drug|Sorafenib|Sorafenib 400mg po bid
79842418|NCT00265759|Drug|letrozole|Given PO
79842419|NCT00265759|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
79842420|NCT00786500|Dietary Supplement|Gynostemma pentaphyllum tea|3 grams twice daily, orally
79842421|NCT00786500|Dietary Supplement|Placebo tea|3 grams twice daily, orally
79842422|NCT00972387|Dietary Supplement|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
79842423|NCT00972387|Dietary Supplement|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
79540428|NCT01480817|Procedure|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
79842424|NCT00972387|Dietary Supplement|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
79385411|NCT05739565|Behavioral|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
80012140|NCT02225990|Other|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
79385412|NCT05734066|Drug|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
79385413|NCT05733416|Diagnostic Test|FDG PET/CT|F-fluorodeoxyglucose positron emission/computed tomography
79385414|NCT05733416|Diagnostic Test|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
79385415|NCT05725655|Other|Thermotherapy|Hot baths directly after an exercise session
79385416|NCT05724173|Device|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
79385417|NCT05722457|Other|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, & Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
79540429|NCT01480830|Device|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
80012141|NCT02225990|Other|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
79842425|NCT00972387|Dietary Supplement|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
79842426|NCT00866580|Biological|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
79842427|NCT00866580|Biological|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
79842428|NCT00866580|Biological|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
79842429|NCT00744263|Biological|VACCINE: placebo|0.5 mL, single intra-muscular injection
79842430|NCT00744263|Biological|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
79842431|NCT00975273|Behavioral|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
79842432|NCT00975273|Behavioral|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
79540430|NCT01480856|Procedure|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
79540431|NCT01480856|Procedure|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
79540432|NCT01480869|Drug|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
79540433|NCT01480869|Drug|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level < 30 ng/mL"
79540434|NCT01480882|Procedure|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
79698535|NCT04583436|Other|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
79540435|NCT01480882|Device|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
79540436|NCT01480895|Behavioral|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
79698536|NCT04583202|Other|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
79698537|NCT04583202|Other|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
79698538|NCT04613609|Device|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
79842433|NCT00783068|Drug|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
79842434|NCT00783068|Drug|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
79842435|NCT00783068|Drug|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
79246671|NCT03362229|Procedure|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
79540437|NCT01480908|Procedure|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
79246672|NCT03362229|Procedure|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
79385418|NCT05722457|Other|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, & Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
79246673|NCT00151424|Drug|asenapine|Asenapine 5-10mgBID
79385419|NCT05721898|Diagnostic Test|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
79385420|NCT05687916|Drug|TAK-861|TAK-861 tablets.
79385421|NCT05687916|Drug|Placebo|TAK-861 placebo matching tablets.
79540438|NCT01480908|Procedure|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
79540439|NCT01480908|Procedure|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
79698539|NCT04613609|Device|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
79698540|NCT00571623|Other|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
79698541|NCT00571740|Biological|bevacizumab|Given IV
79698542|NCT00571740|Biological|cetuximab|Given IV
79698543|NCT00571740|Drug|fluorouracil|Given IV
79698544|NCT00571740|Drug|leucovorin calcium|Given IV
79698545|NCT00571740|Drug|oxaliplatin|Given IV
79698546|NCT04613687|Device|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
79246674|NCT00151424|Drug|Placebo|Matched against asenapine and olanzapine
79246675|NCT00151424|Drug|Olanzapine|10-20 mg QD
79246676|NCT03370653|Drug|Odiparcil|Investigational product: odiparcil 250 mg tablets
79246677|NCT03370653|Other|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
79246678|NCT04705532|Device|tDCS|Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA
79698547|NCT00571779|Device|AtriCure Bipolar System|
79698548|NCT00563342|Drug|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
79246679|NCT04705532|Device|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
79698549|NCT00563420|Procedure|Bronchoscopy|
79698550|NCT04580082|Behavioral|Mindfulness lessons|14 lessons on mindfulness, each lasting approximately 20 minutes.
80012142|NCT02225990|Other|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
80012143|NCT02225990|Other|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
80012144|NCT03283488|Drug|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
79246680|NCT04705532|Other|Music|Subjects will listen to their preferred music for 20 minutes
79385422|NCT05687162|Behavioral|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
79385423|NCT05687162|Behavioral|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
79385424|NCT05687162|Behavioral|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
79698551|NCT00563498|Drug|Glutamine|
79698552|NCT04583046|Drug|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
79698553|NCT04583046|Drug|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
79698554|NCT00563537|Radiation|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
79698555|NCT04613765|Behavioral|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
79698556|NCT04582929|Drug|Neuronox ® Injection|Neuronox ® 50 or 100 unit intramuscular injection
79698557|NCT04613726|Drug|ondansetron|group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
79698558|NCT04613726|Drug|Granisetron|Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
79698559|NCT04613726|Drug|Saline|Control group consisted of patients receiving IV 10 ml normal saline
80012145|NCT03283488|Drug|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
80012146|NCT02258204|Drug|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
80012147|NCT02258204|Drug|Placebo|
80012148|NCT04448743|Other|Blood sample|20 Ml blood sample
79246681|NCT04705532|Other|White noise|Subjects will listen to a white noise for 20 minutes
79246682|NCT03357783|Other|Macroscopic deciduosis|Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.
79246683|NCT03600727|Drug|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
79246684|NCT03600727|Drug|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
79246685|NCT03370575|Drug|ethiodized poppyseed oil|Hysterosalpingography using ethiodized poppyseed oil
79698560|NCT00568230|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
79698561|NCT04613804|Drug|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
79842436|NCT00866736|Drug|dasatinib|100mg QD
79842437|NCT02532049|Biological|ChAd63 Pfs25-IMX313|
79842438|NCT02532049|Biological|MVA Pfs25-IMX313|
80012149|NCT02226068|Drug|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
79246686|NCT03370575|Drug|the second-generation non-ionic monomer contrast|Hysterosalpingography using the second-generation non-ionic monomer contrast
79698562|NCT00568269|Procedure|Open repair|Open repair is according to the Lichtenstein technique
79842439|NCT04008849|Other|Safety and efficacy assessments|Long term safety and clinical outcomes
79842440|NCT00792818|Drug|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
79842441|NCT00792818|Drug|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
80012150|NCT02226068|Other|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
80012151|NCT02081274|Procedure|Surgery for congenital heart disease|
80012152|NCT05424991|Behavioral|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
80012153|NCT02081352|Other|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
80012154|NCT02081352|Other|Standard care|
79842442|NCT00972465|Drug|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
80012155|NCT02222402|Behavioral|INTRA-DIALYTIC EXERCISE TRAINING|
80012156|NCT01378585|Drug|DLBS1033|3 x 490 mg DLBS1033 daily
80012157|NCT01378585|Drug|Placebo|3 x 1 tablet daily
80012158|NCT02220218|Drug|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
79698563|NCT00568269|Procedure|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
79246687|NCT03138200|Biological|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
79698564|NCT04613258|Dietary Supplement|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
80012159|NCT02220218|Drug|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
79842443|NCT00975351|Dietary Supplement|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
80012160|NCT02220218|Drug|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
79246688|NCT03362151|Other|Regular pasta|Regular pasta (Approximately 42 grams carbohydrate per meal)
79246689|NCT03362151|Other|High protein pasta|High protein pasta (Approximately 38 grams carbohydrate per meal)
79246690|NCT03362151|Other|White rice|White rice (Approximately 43 grams carbohydrate per meal)
79246691|NCT03527654|Other|Observational|Surveys, blood and urine collected prospectively over 24 months.
80012161|NCT03559452|Procedure|Eccentric exercise|300 eccentric contractions of the knee extensors
80012162|NCT02081430|Procedure|CT Manipulation|
79246692|NCT04522011|Other|intraoperative or postoperative hyperthermic intraperitoneal chemotherapy|Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
79246693|NCT03370497|Dietary Supplement|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
79246694|NCT03370497|Dietary Supplement|Whey Protein Hydrolysate|50 g whey protein hydrolysate
79385425|NCT05687162|Behavioral|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
79385426|NCT05687162|Behavioral|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
79698565|NCT04613258|Other|Counseling|21 subjects in the control group (C) who only received dietary counseling
79698566|NCT03453957|Other|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
79698567|NCT04613102|Drug|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
79842444|NCT01071187|Drug|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
79842445|NCT01071187|Drug|Placebo|Placebo
79842446|NCT00618774|Drug|telmisartan40/amlodipine5|
79842447|NCT00618774|Drug|telmisartan80/amlodipine5|
79842448|NCT04008693|Dietary Supplement|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
79842449|NCT04008693|Other|Placebo|800 mg of maltodextrin (four capsules)
79842450|NCT00792896|Behavioral|family conference|family conference
80012163|NCT02081430|Procedure|Upper trapezius stretch|
79246695|NCT03584893|Procedure|Blood sampling for Cholestanol Analysis|Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
79246696|NCT03357705|Procedure|alveolar ridge preservation with synthetic bone|after tooth extraction
79246697|NCT03357705|Procedure|alveolar ridge preservation with bovine collagen|after tooth extraction
79698568|NCT04582851|Other|some risk factors correlated with TMD|exposure factors causing TMD
79698569|NCT04613219|Drug|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
79698570|NCT00563615|Drug|Tegaserod|
80012164|NCT02222480|Drug|Fimasartan|
80012165|NCT02222480|Drug|Hydrochlorothiazide|
80012166|NCT02222480|Drug|Placebo|
80016931|NCT03658941|Procedure|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
80016932|NCT03658941|Procedure|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
79698571|NCT04582656|Device|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
79698572|NCT00563654|Drug|Alfuzosin GITS (Xatral XL)|
79842451|NCT01071265|Procedure|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
79842452|NCT01071265|Procedure|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
79842453|NCT00792974|Behavioral|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
79842454|NCT00858936|Drug|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
80012167|NCT03669471|Other|Testing of performance|"The cross-sectional evaluation will involve assessment of:~Hip muscle function~Single leg jump performance~Self-reported hip and groin function~Evaluation of return to sport~Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
80012168|NCT02081508|Behavioral|Interference onset|Temporal duration of interference onset.
79385427|NCT05687162|Behavioral|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
80012169|NCT02258438|Behavioral|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
80012170|NCT02258438|Behavioral|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
79246698|NCT03359642|Other|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
79246699|NCT03359642|Other|stool samples|Study of the fecal microbiota
79246700|NCT03359642|Other|food questionnaire|food questionnaire on the seven days before the collection
79246701|NCT03359642|Other|colonoscopy|Only for patients with ulcerative colitis (in routine care)
79246702|NCT03359642|Other|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
79385428|NCT05687162|Behavioral|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
79698573|NCT04612985|Device|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
79698574|NCT00571896|Drug|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
79842455|NCT00858936|Drug|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
79842456|NCT03974893|Other|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
79842457|NCT00917345|Drug|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
79842458|NCT00793052|Drug|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
79842459|NCT00859092|Dietary Supplement|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
79842460|NCT01071343|Device|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
79246703|NCT03584581|Dietary Supplement|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
79246704|NCT03584581|Dietary Supplement|Control|Placebo
79385429|NCT05667779|Drug|QRL-101|Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
79246705|NCT04522245|Behavioral|Noom Healthy Weight; mobile behavior change program for weight loss.|"The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging."
79698575|NCT00571896|Drug|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
79698576|NCT04613180|Drug|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
79698577|NCT04613180|Drug|Placebo|placebo containing no active substance
79698578|NCT00571935|Drug|insulin aspart|
79698579|NCT00571935|Drug|soluble human insulin|
79246706|NCT04522245|Other|Matched Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
79698580|NCT04613063|Other|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
79698581|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
79842461|NCT02555852|Drug|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
79842462|NCT02555852|Drug|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
79842463|NCT02555852|Drug|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
79842464|NCT02555852|Drug|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
79842465|NCT02555852|Drug|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
79842466|NCT02555852|Drug|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
79842467|NCT02555852|Drug|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
79842468|NCT02555852|Drug|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
79385430|NCT05667779|Other|Placebo|A placebo comparator will be administered at all dose levels.
79385431|NCT05666960|Drug|R-3750|Probiotic
79385432|NCT05665504|Diagnostic Test|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
79385433|NCT05663463|Drug|Fluzone High-Dose Quadrivalent- 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks
79385434|NCT05663463|Drug|Fluzone High-Dose Quadrivalent- 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later
79540440|NCT01480908|Procedure|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
79698582|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
79698583|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
79698584|NCT00572052|Device|NovoFine® needle 6 mm|
79698585|NCT00572052|Device|Ultra-Fine needle 12.7 mm|
79698586|NCT04579965|Drug|medical treatment of isthmocele|comparison between different drugs
79842469|NCT02555852|Drug|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
79842470|NCT02555852|Drug|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
79842471|NCT02555852|Drug|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
79842472|NCT02555852|Drug|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
79698587|NCT04612595|Other|serum urea nitrogen to creatinine ratio|According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
80012171|NCT02258438|Behavioral|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
79246707|NCT03362073|Drug|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~Dose schedule: 0.05mg/kg/hr -> 0.10mg/kg/hr -> … -> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
80012172|NCT03670875|Dietary Supplement|Agave inulin|Will be provided in dehydrated apple cubes
79698588|NCT00568308|Drug|PI-88|160mg subcutaneous injection
79698589|NCT00568308|Drug|placebo|matched placebo
79698590|NCT04580199|Procedure|thyroidectomy|to excise the thyroid gland
79698591|NCT04612673|Drug|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
79698592|NCT00572091|Device|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
79698593|NCT04612829|Device|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
79698594|NCT04612439|Device|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
79246708|NCT03584269|Device|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
79698595|NCT04612439|Device|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
79842473|NCT02555852|Drug|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
79842474|NCT02555852|Drug|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
79842475|NCT02555852|Drug|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
79842476|NCT04091009|Drug|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
80012173|NCT03670875|Dietary Supplement|Curcumin|Will be provided in capsules
79246709|NCT03584269|Device|LTOT|Long term oxygenatory tyherapy without NIV
79246710|NCT03325634|Other|Laboratory Biomarker Analysis|Correlative studies
79246711|NCT03325634|Other|Quality-of-Life Assessment|Ancillary studies
79842477|NCT04091009|Drug|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
79842478|NCT00866892|Procedure|Irrigation|irrigation
79842479|NCT00866892|Procedure|No irrigation|no irrigation
79842480|NCT00859170|Device|Accordion device|an antiretropulsion device
79842481|NCT02597231|Dietary Supplement|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
80012174|NCT03670875|Dietary Supplement|O3FA|Will be provided in capsules
80012175|NCT03670875|Behavioral|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
80012176|NCT02078076|Device|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
80012177|NCT02226146|Biological|Bertilimumab|
79246712|NCT03325634|Other|Questionnaire Administration|Ancillary studies
80012178|NCT01379677|Drug|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
79246713|NCT03325634|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79246714|NCT03312842|Drug|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
79246715|NCT03584191|Other|No treatment given|Completion of a survey
79385435|NCT05661773|Device|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
79698596|NCT04612517|Drug|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
79698597|NCT04612517|Drug|Placebo|Placebo; corresponding volume
79698598|NCT00568347|Drug|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
79698599|NCT00568347|Drug|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
79698600|NCT00568347|Drug|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
79698601|NCT00568347|Drug|Salmeterol|salmeterol 50mcg bid X 3months
79698602|NCT00568347|Drug|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
79698603|NCT04612127|Dietary Supplement|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
79246716|NCT04523805|Behavioral|Adapted judo programme|"The judo sessions were 75 minutes in duration and were held once a week. Two judo teachers led each session, and at least four volunteer judo instructors were present to lend support. The sessions were divided into warm-up, main exercise and cool-down activities. The main exercise content of the sessions included:~Different types of movements and falling techniques (from walking in all directions to turning around, from stable movements to unstable movements).~Judo techniques and games (building up body contact with games, teaching simplified movements, essential judo movements) (blinded for review).~Ground control techniques and throws (gradually adding techniques to already known movements, scaffolding basic repetitive movements to assist in understanding to those more relevant for judo ).~Repetition of different forms of foundational directional movements (pulling, pushing, holding, lifting)."
79540441|NCT01480921|Behavioral|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~5-10 min warm-up~30 min aerobic interval training (walking or stationary bicycle)~10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
79698604|NCT04612361|Other|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
79246717|NCT02238613|Device|radioactive stent|radioactive stent carrying seed iodine 125
79698605|NCT04582071|Behavioral|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
79698606|NCT04582110|Diagnostic Test|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
79698607|NCT04612205|Device|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
79698608|NCT04612205|Other|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
79698609|NCT00572130|Genetic|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
79842482|NCT02597231|Other|Placebo|Patients in this group will receive a matching placebo pill.
79842483|NCT00866970|Biological|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
79842484|NCT00866970|Biological|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
79842485|NCT00866970|Biological|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
79842486|NCT00866970|Biological|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
79842487|NCT00545571|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
79842488|NCT00783380|Biological|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
79385436|NCT05660629|Other|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
79385437|NCT05658523|Biological|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
79842489|NCT00783380|Biological|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
79842490|NCT00793130|Dietary Supplement|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
80012179|NCT01379677|Drug|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
80012180|NCT02220296|Drug|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
80012181|NCT02220296|Drug|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
79698610|NCT00572130|Genetic|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
79842491|NCT04008225|Procedure|Bronchoalveolar lavage|
79842492|NCT00748709|Drug|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
80012182|NCT02220296|Drug|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
80012183|NCT02220296|Drug|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
79540442|NCT01480921|Behavioral|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~5-10 min of warm-up~30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~10 min of cool down~Exercise will be tracked by the participant in exercise log books."
79540443|NCT01480947|Drug|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
80012184|NCT03670719|Other|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
79698611|NCT04612088|Behavioral|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
79698612|NCT04582461|Device|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
79698613|NCT04611971|Drug|Benlysta|Benlysta injection will be administered subcutaneously.
79540444|NCT01480960|Other|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
79540445|NCT01480973|Radiation|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
79698614|NCT04611971|Drug|Candin|Candin will be administered intradermally along with NaCl solution.
80012185|NCT03670719|Other|Exercise|Exercises for the cervical spine
79246718|NCT02238613|Device|plastic stent|common plastic stent without carrying seed iodine 125
80012186|NCT02074878|Drug|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
80012187|NCT02074878|Drug|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
80012188|NCT02074878|Drug|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
79246719|NCT03361995|Device|Cooling Procedure using the ZOLL Thermogard XP3 IVTM System|Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)
79246720|NCT03361995|Device|PCI|Standard of Care for PCI
79385438|NCT05658523|Biological|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
79246721|NCT05088434|Dietary Supplement|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 CFU of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
79246722|NCT05088434|Dietary Supplement|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of ~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
79385439|NCT05655091|Drug|FLU or CZO as continuous infusion|Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
79385440|NCT05655091|Drug|standard FLU or CZO intermittent bolus administration|Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
79385441|NCT05643729|Drug|Zofin|Intravenous Infusion (IV) of Zofin
80012189|NCT02258672|Other|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
80012190|NCT01379599|Behavioral|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
80012191|NCT02220374|Other|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
80012192|NCT02081664|Behavioral|lifestyle intervention|
80016933|NCT02283164|Behavioral|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
80016934|NCT02095314|Biological|Pentavalen|Batch 5010613
80012193|NCT03075163|Procedure|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
80012194|NCT03075163|Drug|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
79698615|NCT00572208|Drug|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
79842493|NCT00793208|Biological|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
79842494|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
79842495|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
80016935|NCT00517868|Drug|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
79540446|NCT01480986|Drug|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m^2，ivgtt，90min，D1 Cisplatin 50 mg/m^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
79540447|NCT01481025|Drug|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
79540448|NCT01481025|Drug|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
79246723|NCT05088434|Dietary Supplement|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of ~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
79385442|NCT05643729|Other|Placebo|Intravenous Infusion of sterile saline
79385443|NCT05631197|Other|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
79246724|NCT03357549|Other|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
79246725|NCT03357549|Other|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
79385444|NCT05631197|Other|Sensodyne Repair & Protect|Domiciliary use twice a day
79385445|NCT05628285|Device|Sentio 1|Sound processor
79385446|NCT05628051|Procedure|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 ~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+[1.29× (HR-60)
79385447|NCT05611710|Drug|Placebo|"Drug: Placebo, with visually matched clear syringes~Adults (≥16 years) and children (12-16 years, > 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~Children (12-16 years, < 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
79540449|NCT01481025|Drug|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
79540450|NCT01481064|Behavioral|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
79540451|NCT01481090|Procedure|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
79540452|NCT01481103|Procedure|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
79698616|NCT04611386|Drug|computerized tomography|Anti Factor Xa level
79698617|NCT00572247|Behavioral|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
79540453|NCT01481142|Device|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
79842496|NCT00793286|Procedure|Mesh fixation by staples|Mesh fixation by staples
79698618|NCT04611620|Behavioral|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
79698619|NCT04611659|Behavioral|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
79842497|NCT00793286|Procedure|Mesh fixation by glue|Mesh fixation by glue
79842498|NCT00859404|Drug|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
79842499|NCT02597309|Drug|Canagliflozin|
80012195|NCT02258750|Dietary Supplement|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
80012196|NCT02258750|Other|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
80012197|NCT02220530|Drug|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
80012198|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
80012199|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
80012200|NCT02075034|Drug|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
79246726|NCT03582865|Drug|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
79540454|NCT01481155|Procedure|ablative CO2 laser therapy|CO2 laser therapy
79540455|NCT01481155|Procedure|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
79540456|NCT01481168|Device|Pacemaker implantation (Medtronic)|DDD+/-R pacing
79540457|NCT01481168|Device|Pacemaker implantation (Medtronic)|ODO pacing
79842500|NCT04008381|Biological|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
79842501|NCT00863148|Drug|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
79842502|NCT00786734|Drug|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
79842503|NCT00786734|Drug|Pitavastatin|4mg daily for 28 days after PCI
80012201|NCT03670563|Other|Short foot exercise protocol|Exercises that target intrinsic foot muscles
80012202|NCT03670563|Other|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
80012203|NCT02226380|Drug|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
80012204|NCT02078388|Drug|Doxorubicin|
80012205|NCT02222636|Drug|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
80012206|NCT02222636|Drug|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
79246727|NCT03136250|Other|Group A (Control Group - Static Stretching + Standard Treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
79246728|NCT03136250|Other|Group B (Autogenic Inhibition - PIR + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
79385448|NCT05611710|Drug|Anakinra|"Drug: Anakinra~Adults (≥16 years) and children (12-16 years, > 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~Children (12-16 years, < 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
79385449|NCT05609331|Other|Simulated Online Adaptive Planning|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
79385450|NCT05609331|Radiation|Stereotactic MRI-guided adaptive radiotherapy-SMART|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
79842504|NCT03974581|Other|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
79540458|NCT01481168|Device|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
79698620|NCT04581837|Diagnostic Test|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
79698621|NCT00563693|Device|ASV|Adaptive servo ventilator
79698622|NCT00563693|Other|without Autoset CS2|without Autoset CS2
79698623|NCT00563732|Drug|Lecozotan|
79698624|NCT00572364|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
79698625|NCT00563771|Drug|Rasburicase|
79698626|NCT00563810|Drug|MYO-029|
79698627|NCT04582032|Drug|Dexketoprofen (KETAVEL 50 mg/2 ml)|intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
79842505|NCT03974581|Other|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
79842506|NCT04089995|Other|data collection|No intervention
80012207|NCT02222636|Drug|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
79246729|NCT03136250|Other|Group C (Reciprocal Inhibition - RI + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
79246730|NCT04509375|Device|Cranial Doppler Ultrasonography|Before and after the transfusions, flow measurements of middle cerebral arteries will be obtained.
79246731|NCT04509375|Device|Near-Infrared Spectroscopy|Before, during and after the transfusions, regional cerebral oxygen saturation measurements will be obtained.
79246732|NCT03136406|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79246733|NCT03136406|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
79246734|NCT03136406|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79246735|NCT03136406|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79385451|NCT05587192|Diagnostic Test|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
79385452|NCT05581589|Procedure|Lymphadenectomy|Undergo pelvic lymph node dissection
79385453|NCT05581589|Procedure|Radical Cystectomy|Undergo radical cystectomy
79385454|NCT05581589|Biological|Sacituzumab Govitecan|Given IV
79385455|NCT05580874|Other|Massage|The babies in the massage group were given a massage once a day.
79385456|NCT05580874|Other|Swaddling|Control group
79540459|NCT01481181|Dietary Supplement|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
79540460|NCT01481194|Drug|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
79385457|NCT05571046|Drug|Glucocorticoids|Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
79385458|NCT05571046|Other|Placebo|Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
79385459|NCT05567627|Biological|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
79385460|NCT05546411|Drug|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
79540461|NCT01481194|Drug|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
79540462|NCT01481194|Drug|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
79540463|NCT01481194|Drug|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
79540464|NCT01481194|Drug|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
79540465|NCT01481220|Drug|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
79842507|NCT00960609|Procedure|Ultrasound guided liver resection|
79842508|NCT02544204|Biological|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
79246736|NCT03136406|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79246737|NCT03136406|Drug|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
79246738|NCT03136406|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
79698628|NCT04582032|Drug|Saline (Isotonic Saline Solution 0.9% )|intravenous 2 ml of saline
79698629|NCT00563849|Drug|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
79698630|NCT04581876|Drug|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
79698631|NCT04581876|Drug|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
79698632|NCT00563888|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
79698633|NCT04579458|Procedure|Collection of tears and saliva.|Saliva and ocular tears will be collected.
79698634|NCT04611932|Drug|CKD-330 Tab. and D090 Tab.|1T
79698635|NCT04611932|Drug|CKD-333 Tab.|1T
79698636|NCT00563927|Procedure|Conventional RT|
79698637|NCT00563927|Drug|Cisplatin|
79698638|NCT00563927|Drug|5-fluorouracil|
79842509|NCT02544204|Biological|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
80012208|NCT02222636|Drug|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
80012209|NCT02222636|Drug|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
79698639|NCT00572520|Behavioral|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
79246739|NCT03136406|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
79246740|NCT03136406|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79246741|NCT03136406|Biological|aNK for Infusion|NK-92 cells
79842510|NCT00263887|Drug|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
79842511|NCT00263887|Drug|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
80012210|NCT04058223|Device|Hemorrhoidopexy|stapled hemorrhoidopexy
80012211|NCT03559374|Other|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
79246742|NCT03136406|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79246743|NCT03136406|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79246744|NCT03590197|Drug|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
79246745|NCT03590197|Other|Placebo|Placebo with Valproate
79246746|NCT04521465|Device|NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)|Eye drops
79246747|NCT03136016|Behavioral|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
79246748|NCT03136016|Behavioral|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
79246749|NCT03136016|Behavioral|nudging + educational activities|Group 4 will receive both interventions
79540466|NCT01481233|Drug|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
79385461|NCT05546411|Drug|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79385462|NCT05546411|Drug|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79540467|NCT01481259|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
79540468|NCT01481259|Other|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
79540469|NCT01481311|Device|medical Body Composition Analyzer seca 514/515|Current of 100 µA
79540470|NCT01481311|Procedure|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
79698640|NCT00572520|Behavioral|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
80012212|NCT04058145|Drug|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
79246750|NCT02035579|Behavioral|Aerobic Training Intervention|
79246751|NCT02035579|Behavioral|Stretching Intervention|
79246752|NCT03357315|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
79246753|NCT03135938|Procedure|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
79246754|NCT03135938|Procedure|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
79246755|NCT03582397|Device|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
79246756|NCT05057468|Drug|Cyclosporine|2.5-5 mg orally for 3 months
79246757|NCT05057468|Drug|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks
79246758|NCT03361839|Diagnostic Test|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
79385463|NCT05546411|Drug|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79385464|NCT05546411|Drug|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
79385465|NCT05546411|Drug|NIS793|Given by intravenous infusion
79385466|NCT05546411|Radiation|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
79385467|NCT05546411|Procedure|Surgery|Surgical removal of tumor
79385468|NCT05545449|Behavioral|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
79385469|NCT05495737|Behavioral|Meaning-Centered Psychotherapy/MCP-PC Training|Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
79385470|NCT05495737|Behavioral|Meaning-Centered Psychotherapy/MCP-PC|3 sessions, completed over the course of 3-6 weeks in the participant's home
79540471|NCT01481337|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
79540472|NCT01481350|Drug|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
79540473|NCT01481363|Behavioral|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
79698641|NCT00572520|Behavioral|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
79842512|NCT00972699|Behavioral|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
79246761|NCT04509531|Behavioral|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
79698642|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- low dose|
79540474|NCT01481363|Behavioral|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
79698643|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- High dose|
79385471|NCT05495737|Behavioral|Treatment As Usual/TAU|"Research team will provide:~feedback about level of distress at time of screening~local referral for psychological care"
79385472|NCT05483868|Drug|AU-011|Administration of AU-011 intratumorally or intratumorally and intramurally
79385473|NCT05483868|Combination Product|AU-011 in Combination with Medical Laser|Administration of AU-011 intratumorally or intratumorally and intramurally with Laser application.
79385474|NCT05478954|Drug|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
79385475|NCT05478954|Drug|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
79385476|NCT05474859|Drug|XT-0528|Once Daily
79385477|NCT05471544|Drug|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
79540475|NCT01481389|Dietary Supplement|Theobromine|200 ml drink with added theobromine (no cocoa added)
79698644|NCT01150123|Biological|Placebo- Saline|
79698645|NCT00572559|Drug|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
79698646|NCT00572559|Drug|Linezolid|600 mg every 12 hours (intravenously [IV] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
79698647|NCT04611464|Drug|Misoprostol|Misoprostol is a PGE1 analog
79698648|NCT04611347|Drug|CBD|Topical CBD application for thumb basal joint osteoarthritis.
79698649|NCT04611347|Drug|Shea Butter|Placebo Shae Butter for comparison
79698650|NCT00572598|Drug|4- [F-18] fluoropaclitaxel|4- [F-18] fluoropaclitaxel, <84 micrograms, <10 mCi, IV followed by PET/CT imaging
79842513|NCT00867126|Drug|pioglitazone hydrochloride|
79842514|NCT00867126|Other|laboratory biomarker analysis|
79842515|NCT00867126|Other|questionnaire administration|
79842516|NCT00867126|Procedure|quality-of-life assessment|
79842517|NCT00748553|Drug|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
79842518|NCT00748553|Drug|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
80012213|NCT04058145|Drug|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
79540476|NCT01481389|Dietary Supplement|Cocoa|200 ml drink with cocoa (no theobromine added)
80012214|NCT02230982|Drug|nintedanib|soft gelatin capsule
80012215|NCT02075112|Drug|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
80012216|NCT02075112|Radiation|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
80012217|NCT02075112|Drug|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
79698651|NCT04611776|Drug|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
80012218|NCT03078751|Drug|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
80012219|NCT03078751|Drug|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
79246762|NCT04509531|Behavioral|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
79385478|NCT05471544|Drug|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
79385479|NCT05460273|Drug|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
79385480|NCT05456113|Biological|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
79698652|NCT04611776|Drug|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
79698653|NCT04611776|Drug|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
79385481|NCT05449665|Other|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
79385482|NCT05449665|Other|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
79540477|NCT01481389|Dietary Supplement|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
79540478|NCT01481389|Dietary Supplement|Placebo|200 ml drink (no added theobromine or cocoa)
79698654|NCT04611776|Drug|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
79842519|NCT03974815|Device|ACTIVE|"We will use 28.26cm^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
79842520|NCT03974815|Device|SHAM|"We will use 28.26cm^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
79385483|NCT05449665|Other|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
79540479|NCT01481402|Drug|Liothyronine|Liothyronine 40 microgram per day
79540480|NCT01481402|Drug|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
79540481|NCT01481441|Drug|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
79842521|NCT00661388|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
79842522|NCT00867204|Procedure|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
80012220|NCT03078751|Drug|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
80012221|NCT02223026|Drug|Linagliptin/metformin FDC|
80012222|NCT02223026|Other|high-fat, high caloric meal|
80012223|NCT02075190|Other|Therapeutic Computerized intervention|Remediation training intervention
80012224|NCT02075190|Other|Nontherapeutic computerized intervention|Online gaming intervention
80012225|NCT02226614|Device|University of Edinburgh head cooling device|head cooling
79540482|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
79540483|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
79540484|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
79246763|NCT03296462|Other|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
79246764|NCT03296462|Other|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
79246765|NCT03600571|Procedure|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
79698655|NCT04611776|Drug|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
79698656|NCT04611776|Drug|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
80012226|NCT02075268|Drug|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
80016936|NCT00517868|Drug|Placebo|Liquid formulation without active URG101 drug components
80016937|NCT02098980|Dietary Supplement|Vitamin D|
79698657|NCT04611776|Drug|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
79842523|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
79842524|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
80012227|NCT01378507|Behavioral|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
80012228|NCT02078466|Other|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
80012229|NCT01378351|Other|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
80012230|NCT02223104|Device|Flexima Active|
79540485|NCT01481454|Biological|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
79540486|NCT01481467|Behavioral|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
80012231|NCT02223104|Device|Sensura|
80012232|NCT01379443|Other|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
79540487|NCT01481480|Procedure|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
79540488|NCT01481480|Procedure|Arthroscopic repair|Arthroscopic repair
79698658|NCT00572637|Drug|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
79540489|NCT01481493|Biological|BT061|subcutaneous administration of the monoclonal antibody BT061
79540490|NCT01481493|Biological|Placebo|subcutaneous injection of placebo
79698659|NCT04611308|Other|C1q tumor necrosis factor-related protein 6 levels|C1q tumor necrosis factor-related protein 6 is a tumor marker
79540491|NCT01481506|Procedure|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
80012233|NCT02231138|Drug|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
79540492|NCT01481519|Drug|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
79540493|NCT01481519|Drug|Artificial Tears|artificial tears 1 drop, 4 times per day
79540494|NCT01481584|Dietary Supplement|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
79540495|NCT01481584|Dietary Supplement|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
79540496|NCT01481597|Drug|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
79540497|NCT01481597|Drug|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
79540498|NCT01481597|Drug|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
79540499|NCT01481597|Drug|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
79540500|NCT01481597|Drug|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
79540501|NCT01481610|Drug|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
79540502|NCT01481610|Drug|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
79540503|NCT01481623|Other|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
79540504|NCT01481623|Other|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
79698660|NCT01149655|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
79698661|NCT01149655|Drug|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
79698662|NCT00575406|Drug|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
79698663|NCT00575406|Drug|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
79698664|NCT00575406|Drug|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
79698665|NCT00575406|Drug|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
79698666|NCT00575406|Drug|Vincristin|i.v., 2mg, d1 of each treatment cycle
79698667|NCT00575406|Drug|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
79698668|NCT00564005|Other|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
79698669|NCT00564005|Other|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
79698670|NCT00564005|Other|Combined therapy (CT)|combined different treatment approaches
79698671|NCT00564005|Behavioral|Control intervention|Conventional treatment program
80012234|NCT02075424|Other|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
79842525|NCT04040478|Device|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
79842526|NCT02597465|Drug|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
79842527|NCT02597465|Drug|Reference1507|Investigators choice including chemotherapy or supportive therapy
79540505|NCT01481662|Device|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
80012235|NCT05111119|Behavioral|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~Notification-based PrEP Reminders and Adherence Self-Monitoring~HIV self-testing facilitation, interpretation of results, and testing support~HIV partner testing facilitation, interpretation of results, and testing support~Nearby HIV clinic contact information"
80012236|NCT02075502|Behavioral|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
80012237|NCT02075502|Procedure|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
80012238|NCT02075502|Procedure|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
80012239|NCT02477384|Procedure|8mm-TIPS|
80012240|NCT02477384|Procedure|Endoscopic variceal ligation|
80012241|NCT02477384|Drug|Propranolol|
79246766|NCT03600571|Procedure|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
79540506|NCT01481688|Other|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
79540507|NCT01481688|Other|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
79540508|NCT01481701|Drug|Oxaliplatin|85 mg/m² / 14days
79540509|NCT01481701|Drug|oxaliplatin|oxaliplatin
79540510|NCT01481714|Drug|Sodium picosulphate, magnesium oxid and citric acid|"A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
79540511|NCT01481714|Drug|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
79540512|NCT01481727|Device|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (>18mmHg) for at least six hours, nocturnal ventilation.
79698672|NCT01149538|Drug|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
80012242|NCT02477384|Device|8mm ePTFE-covered stent|
80016938|NCT00381602|Drug|GHRP-1/AG 70 mg depot in ESRD|
80016939|NCT00381602|Other|Placebo|
80016940|NCT05228938|Procedure|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
79246767|NCT02518503|Drug|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79246768|NCT02518503|Drug|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79698673|NCT01149538|Dietary Supplement|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
79698674|NCT02884063|Procedure|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
79698675|NCT04601207|Drug|Cannabis Preparation|Dosed as a single oral dose
79698676|NCT04601207|Drug|Cannabis Preparation|Dosed as a single oral dose
79698677|NCT01149460|Drug|Valacyclovir|Test 1000 mg Tablet
79842528|NCT00972855|Drug|Bicalutamide|50 mg Tablet
79842529|NCT00972855|Drug|Casodex®|50 mg Tablet
79842530|NCT04090931|Procedure|Orthodontic treatment|leveling and aligning stage in orthodontics
80016941|NCT05228938|Procedure|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
79698678|NCT01149460|Drug|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
79698679|NCT00575484|Drug|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium </=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
79698680|NCT00575484|Drug|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
79698681|NCT00572754|Procedure|Circumcision|Circumcision by tying a ligature around the foreskin.
79698682|NCT04600739|Procedure|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
79698683|NCT04579614|Behavioral|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
79698684|NCT04600778|Other|placebo|placebo
79698685|NCT04600778|Drug|Cavosonstat 5 mg|Cavosonstat (low dose)
79698686|NCT04600778|Drug|Cavosonstat 10 mg|Cavosonstat (medium dose)
79842531|NCT00786812|Drug|Nilotinib|
80016942|NCT03658239|Other|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
79246769|NCT02518503|Drug|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79246770|NCT02518503|Drug|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79246771|NCT02518503|Drug|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79385484|NCT05431556|Other|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
79698687|NCT04600778|Drug|Cavosonstat 25 mg|Cavosonstat (high dose)
79246772|NCT02518503|Drug|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79385485|NCT05431556|Other|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
79385486|NCT05427214|Device|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
79385487|NCT05416515|Drug|Fisetin|100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
79385488|NCT05414955|Device|Neuromodulation|Neuromodulation
79698688|NCT00572871|Other|plyometric exercise|single bout of plyometric exercise
79698689|NCT00572871|Other|resistance exercise|single bout of resistance exercise
79698690|NCT00572871|Other|No exercise|Will not do any exercise
79698691|NCT04600583|Device|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
79842532|NCT00859716|Biological|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
79842533|NCT00859716|Biological|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
79842534|NCT00743483|Drug|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
79842535|NCT00972933|Drug|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
79842536|NCT00867282|Drug|Treatment A|PF-00241939 750ug using inhaler A
79842537|NCT00867282|Drug|Treatment B|PF-00241939 750ug using inhaler B
79842538|NCT00263575|Drug|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
80016943|NCT00517790|Drug|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
79698692|NCT04600700|Device|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
79698693|NCT00575523|Drug|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
79698694|NCT00575523|Drug|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
79698695|NCT04600661|Other|Traditional exercise therapy|Neuromuscular training
79698696|NCT04600349|Behavioral|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
79540513|NCT01481727|Device|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
79698697|NCT04600349|Drug|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
79842539|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
79540514|NCT01481753|Procedure|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
80012243|NCT03709771|Diagnostic Test|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
80012244|NCT02075580|Behavioral|psychological support (interactive/cognitive strategies)|"cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
80012245|NCT05001295|Procedure|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
79246773|NCT02518503|Drug|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for <10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79540515|NCT01481753|Procedure|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
79698698|NCT01149421|Drug|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
79246774|NCT02518503|Drug|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79385489|NCT05403528|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
79385490|NCT05403528|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
79540516|NCT01481766|Dietary Supplement|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
79540517|NCT01481766|Dietary Supplement|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
79698699|NCT01149421|Drug|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
79698700|NCT00575562|Drug|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
79842540|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
79842541|NCT00748241|Device|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
79842542|NCT00863226|Device|Resonator Device|Application of Magnetic Fields Using the Resonator Device
79246775|NCT02518503|Drug|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
79385491|NCT05403528|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
79698701|NCT04600310|Device|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
79698702|NCT04600310|Device|No Intervention|Conventional skin preparation technique
79698703|NCT04600232|Diagnostic Test|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
79698704|NCT03453879|Other|no intervention|No intervention - only observation of teams delivering acute obstetric care
79698705|NCT04600193|Other|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
79842543|NCT00570128|Drug|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day [mL/day]) orally for participants with body weight (BW) 20 and less than (<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to <50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (>=) 50 kg liquid formulation (1 milligram per 1 milliliter [1 mg/1 mL]) (titrated to 0.1 to 0.2 milligram per kilogram per day [mg/kg/day] based on BW).
79246776|NCT03136874|Other|Interview and questionaires|"Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
79385492|NCT05399446|Behavioral|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
79246777|NCT02238691|Procedure|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
79246778|NCT04509297|Dietary Supplement|high protein milk|This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
79246779|NCT04509297|Dietary Supplement|Placebo|This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
79385493|NCT05399446|Behavioral|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
79385494|NCT05379400|Other|Portable air cleaner (PAC)|Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
79540518|NCT01481766|Behavioral|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
79540519|NCT01481818|Drug|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
79540520|NCT01481831|Drug|Palonosetron Hydrochloride|0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
79540521|NCT01481831|Drug|Palonosetron Hydrochloride|0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
79698706|NCT04600193|Other|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
79698707|NCT00575601|Drug|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
79698708|NCT04600271|Drug|Crystalloid Solutions|exposure
79698709|NCT04600271|Drug|Colloid Blood Volume Expanders|exposure
79698710|NCT04600271|Other|blood replacement|exposure
79698711|NCT04600271|Drug|Diuretic|exposure
79698712|NCT04600271|Drug|noradrenaline|exposure
79698713|NCT04600271|Drug|Non-Steroidal Anti-Inflammatory Analgesics|exposure
79698714|NCT00575640|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
79698715|NCT00575679|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
79698716|NCT04600388|Device|Nerivio|Nerivio Remote Electrical Neuromodulation (REN) device
79698717|NCT04579887|Other|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
79698718|NCT04599959|Diagnostic Test|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
79842544|NCT00570128|Drug|Placebo|Liquid formulation matched to active treatment for oral administration.
80012246|NCT02075736|Procedure|KTP laser|
80012247|NCT02075736|Procedure|TUR-P|device
80012248|NCT02226770|Device|Implantable Cardioverter Defibrillator (ICD)|
80012249|NCT04335253|Drug|EOS884448|Multiple Ascending Dose
79246780|NCT03600493|Drug|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
79246781|NCT03600493|Drug|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
79698719|NCT04579731|Drug|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
79698720|NCT00565487|Drug|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
79698721|NCT03453801|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
79246782|NCT03138356|Drug|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
79698722|NCT03453801|Biological|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
79698723|NCT04600115|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
80012250|NCT02231216|Procedure|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
79246783|NCT03138356|Drug|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
79385495|NCT05379400|Other|Sham Portable air cleaner (PAC)|Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
79385496|NCT05373355|Drug|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
79385497|NCT05373043|Dietary Supplement|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
79385498|NCT05373043|Dietary Supplement|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
79385499|NCT05371327|Behavioral|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
79698724|NCT04600115|Drug|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
80012251|NCT02231216|Procedure|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
80012252|NCT02231216|Procedure|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
80012253|NCT03633721|Drug|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
79698725|NCT04600115|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
79698726|NCT04600115|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
79698727|NCT04600115|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
79698728|NCT03453762|Procedure|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
79246784|NCT03138356|Drug|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
79246785|NCT03138356|Drug|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
79540522|NCT01481844|Drug|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
79540523|NCT01481844|Drug|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
79540524|NCT01481857|Other|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
79540525|NCT01481857|Other|Segmental trunk exercise|Segmental trunk exercise
79540526|NCT01481870|Drug|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
79698729|NCT03453762|Procedure|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
79698730|NCT04599998|Diagnostic Test|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
79246786|NCT03138356|Drug|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
79246787|NCT03138356|Drug|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
79246788|NCT03138356|Drug|500 mg Glucophage XR®|Used in treatments C, F and I.
79246789|NCT03577951|Procedure|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
79698731|NCT04579419|Drug|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
79849002|NCT05660525|Behavioral|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
79246790|NCT03577951|Procedure|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
79385500|NCT05367180|Other|MISOLRE prevention program on sun risks|Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt
80012254|NCT03633721|Other|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
80012255|NCT02081898|Dietary Supplement|LCD|approximate 100 kcal/d caloric deficit
80012256|NCT02226848|Drug|Erythropoeitin|
79385501|NCT05367180|Other|"Vivre avec le Soleil prevention program on sun risks"|Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months
79385502|NCT05367180|Other|Sun protection equipment|Distribution of sunscreen, caps and sunglasses
79540527|NCT01481870|Drug|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
79246791|NCT03137966|Drug|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
79698732|NCT04579419|Drug|Normal Saline|0.9 NaCl
79698733|NCT04600037|Drug|Pregabalin 150mg|"Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months"
79698734|NCT04599842|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
80012257|NCT02081976|Behavioral|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
80012258|NCT02081976|Other|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
80012259|NCT02231294|Drug|Sifrol®|
79698735|NCT04599881|Drug|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
79698736|NCT00575796|Drug|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
79246792|NCT03137966|Drug|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
79246793|NCT02035657|Biological|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
79246794|NCT03577873|Other|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
79540528|NCT01481909|Drug|Rupatadin|20 mg, 28 days over 60 days
79540529|NCT01481922|Device|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
79540530|NCT01481922|Device|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
79540531|NCT01481948|Behavioral|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
80012260|NCT04962139|Drug|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
80012261|NCT04962139|Other|Vehicle Cream|ON101 Cream Placebo
80012262|NCT02223416|Drug|RGB-10|
80012263|NCT02223416|Drug|Teriparatide|
79246795|NCT03577873|Procedure|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
79246796|NCT03357237|Other|medical device|"patients will be assigned, following an external randomization, to two groups:~Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~Control or reference group: treatment regimen with oral rehydration solution and placebo"
79246797|NCT04521387|Procedure|injection therapy|The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
79540532|NCT01481961|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
79698737|NCT04599530|Device|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
79698738|NCT04599452|Biological|Allogeneic NK cell regimen group|"10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15."
79698739|NCT00575835|Dietary Supplement|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
79698740|NCT00575835|Dietary Supplement|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
79842545|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
79842546|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
79842547|NCT00960921|Drug|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
79246798|NCT04521387|Drug|Platelet Rich Plasma|Platelet rich plasma injection in the painful area of humeral epicondyle.
79246799|NCT04521387|Drug|Corticosteroid Injection|Corticosteroid injection in the painful area of humeral epicondyle.
79246800|NCT04521387|Drug|Hyaluronic Acid Injection|Hyaluronic acid injection in the painful area of humeral epicondyle.
79246801|NCT04521387|Other|Placebo Injection|Saline injection in the painful area of humeral epicondyle.
79246802|NCT03579979|Drug|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
79246803|NCT03579979|Drug|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
79246804|NCT04967612|Other|Virtual implantation|Temporary placement of virtual optical lens in the crystalline lens plane.
79385503|NCT05359549|Device|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
79698741|NCT04579185|Device|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
79385504|NCT05350098|Other|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
79698742|NCT00565565|Drug|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
80012264|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
80012265|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
79246805|NCT03600415|Other|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
79385505|NCT05350098|Other|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
79385506|NCT05341986|Other|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
79540533|NCT01481987|Procedure|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
79246806|NCT03600415|Other|Säntis; 2500m above sea level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
79246807|NCT03361761|Other|Health education program|formalized/official Health education program
79246808|NCT03361761|Other|Health education program|non formalized/official Health education program
79246809|NCT04838444|Biological|VLA1553|Study participants previously vaccinated with VLA1553 in study VLA1553-301 will be followed up for safety and immunogenicity.
79246810|NCT04509063|Behavioral|Information about hypothetical mammography screening without benefits|We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
79246811|NCT04782362|Other|Brace Treatment|Body image and quality of life of individuals who have used brace will be evaluated
79540534|NCT01482000|Other|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
79540535|NCT01482000|Other|usual care|The control group will get the usual care with some additional tests for the study.
79540536|NCT01482013|Drug|HPP854|Oral, once a day for 28 days.
79540537|NCT01482013|Drug|Placebo|Oral, once a day for 28 days.
79540538|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
79540539|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
79842548|NCT00960921|Drug|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
79842549|NCT00863382|Device|Standard Event Monitor|Standard Event Monitor
79842550|NCT00863382|Device|Sleuth Monitor|Implantable Sleuth Recorder
79842551|NCT00743249|Device|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
79842552|NCT00743249|Device|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
79842553|NCT00973089|Other|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
79842554|NCT00863460|Radiation|cranial radiotherapy|40 Gy
79842555|NCT00863460|Drug|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
79842556|NCT00863460|Drug|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80
80012266|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
80012267|NCT02082054|Drug|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
80012268|NCT02082054|Drug|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
80012269|NCT02231372|Drug|Berodual® Respimat® solution for inhalation|
80012270|NCT04923529|Drug|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
80012271|NCT03559296|Diagnostic Test|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
80012272|NCT02884544|Drug|HLD100|Treatment
79246812|NCT03604211|Radiation|Cyberknife Radiation Therapy|Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy
79246813|NCT03600337|Behavioral|Working to Optimize Wellness in Tees with PCOS (WOW)|5 week, 75 minutes weekly, integrated mindfulness-based mental and physical health promotion intervention
79246814|NCT02518893|Other|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
79246815|NCT02518893|Other|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
79246816|NCT03601559|Dietary Supplement|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
79385507|NCT05340998|Procedure|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
79540540|NCT01482039|Procedure|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
79842557|NCT00262951|Biological|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
79842558|NCT00262951|Drug|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
79842559|NCT00262951|Drug|fluorouracil|administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
79385509|NCT05323721|Drug|Sulfadoxine pyrimethamine and amodiaquine|This is where children 3-59 months will receive SPAQ for SMC
79842560|NCT00262951|Radiation|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
79842561|NCT00262951|Procedure|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
79842562|NCT00793364|Dietary Supplement|Stanol ester spread|Stanol ester spread 20 g every day
79842563|NCT00793364|Dietary Supplement|Placebo spread|Placebo spread 20 g every day
79842564|NCT00793364|Dietary Supplement|Mediterranean Diet|Mediterranean Diet every day
79842565|NCT02597153|Drug|Mitoxantrone HCL Liposome Injection|
79842566|NCT00867438|Procedure|Sigmoidoscopy|
79842567|NCT00975741|Device|OXIMAX|
79842568|NCT00975741|Device|ASMANEX TWISTHALER|
79842569|NCT00786890|Other|observational, no intervention needed|observational, no intervention needed
80012273|NCT02226926|Drug|Aggrenox|
80012274|NCT02226926|Drug|Persantin Retard|
79385510|NCT05323721|Drug|dihydroartemisinin-piperaquine|This is where children 3-59 months will receive DP for SMC
79540541|NCT01482039|Procedure|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
79698743|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
79698744|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
79540542|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
79540543|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
79698745|NCT04599413|Other|SURVEY|Pain survey on pianists
79842570|NCT00262873|Drug|bortezomib|
79540544|NCT01482104|Drug|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
79842571|NCT00867516|Biological|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
79842572|NCT00867516|Biological|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
79842573|NCT00786968|Drug|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
80012275|NCT02226926|Drug|Acetylsalicylic acid|
79842574|NCT00975819|Drug|sirolimus|liquid dosing based on trough levels
80012276|NCT02075892|Dietary Supplement|Mushroom Blend|Scivation
79246817|NCT03601559|Dietary Supplement|Placebo|Inert placebo matched for taste and appearance
79246818|NCT03577717|Other|computerized cognitive training|participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.
79246819|NCT03577717|Other|occupational therapy|participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
79246820|NCT03110588|Drug|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
79385511|NCT05306873|Drug|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
79842575|NCT02598323|Device|ultrasound|
79246821|NCT03110588|Drug|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
79385512|NCT05306873|Drug|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
79385513|NCT05306873|Drug|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
79385514|NCT05306873|Drug|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
79385515|NCT05306873|Drug|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
79540545|NCT01482104|Drug|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
79540546|NCT01482117|Drug|Clopidogrel|single oral administration of 300mg of clopidogrel
79540547|NCT01482117|Drug|Cilostazol|single oral administration of 100mg cilostazol
79540548|NCT01482117|Drug|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
79540549|NCT01482130|Behavioral|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
79698746|NCT00573222|Drug|Symbicort|
79698747|NCT04599374|Other|no intervention|This study collected data only without any intervention.
79698748|NCT04599179|Device|self-expandable metal stent|self-expandable metal stent endoscopic positioning
80012277|NCT02075892|Dietary Supplement|Placebo|
79246822|NCT04509141|Other|acupuncture|acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
79385516|NCT05306587|Drug|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
79385517|NCT05303987|Drug|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
79385518|NCT05303987|Drug|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
79698749|NCT00575874|Drug|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
79698750|NCT00575874|Drug|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
79698751|NCT00575874|Drug|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
79698752|NCT00575874|Drug|pioglitazone HCl|30 mg capsules once daily for 12 weeks
79698753|NCT00575874|Drug|placebo|matching tablets or capsule once daily for 12 weeks
79698754|NCT03454217|Drug|Oxycodone|Postoperative pain treatment with oxycodone
79842576|NCT00793442|Diagnostic Test|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
79842577|NCT03974737|Device|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
79842578|NCT00973167|Device|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
79842579|NCT00859872|Drug|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
79842580|NCT00859872|Drug|haloperidol|haloperidol IM injection (5-20mg/d)
79540550|NCT01482130|Behavioral|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~Weight bearing activities (walking, jogging or strength training)~30 - 60 minutes, 3 - 5 times each week~A total of 2 - 3 hours each week should be achieved"
79842581|NCT02555696|Drug|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
79842582|NCT00961077|Drug|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
80012278|NCT02227004|Diagnostic Test|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
79842583|NCT00867594|Drug|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
79842584|NCT03974659|Combination Product|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
79842585|NCT02598245|Device|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
79246823|NCT03604055|Procedure|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
79246824|NCT04509219|Drug|Methylprednisolone Injection|methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
79246825|NCT03577639|Other||
79385519|NCT05302596|Drug|Semaglutide Pen Injector|semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
79842586|NCT02598245|Device|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
80012279|NCT02924883|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
80012280|NCT02924883|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
79246826|NCT04524182|Other|control group|"There was no intervention in the control group during study.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
79385520|NCT05299528|Behavioral|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
79385521|NCT05299502|Behavioral|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
79540551|NCT01482143|Drug|AFQ056|
79540552|NCT01482156|Drug|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
79698755|NCT03454217|Drug|Tramadol|Postoperative pain treatment with tramadol
79698756|NCT00575913|Drug|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
79698757|NCT04598945|Other|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
79698758|NCT04579263|Other|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
79842587|NCT00787280|Behavioral|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
79842588|NCT00787280|Behavioral|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
79842589|NCT05147493|Drug|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
80012281|NCT02924883|Other|Placebo|Placebo matched to atezolizumab
80012282|NCT02075970|Drug|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
80012283|NCT02075970|Drug|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
80012284|NCT03432325|Device|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
80012285|NCT02231450|Drug|Lu AE58054 encapsulated film-coated tablets|
79246827|NCT04524182|Other|mobilization group|"Lumbosacral mobilization for 10 minutes in the study group (pelvis forward and backward distraction, passive rotation of the lower body, short lever rotation, long lever rotation, lumbar central posterior-anterior, lumbar unilateral posterior-anterior, anterior rotation-posterior superior iliac spine- down, posterior rotation-posterior superior iliac spine-up were applied.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
79385522|NCT05290792|Biological|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
80012286|NCT02078622|Other|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
79842590|NCT05147493|Drug|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
79842591|NCT05147493|Drug|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
80012287|NCT02259062|Other|Music with brief mindfulness intervention|Music listening with mindfulness therapy
80012288|NCT02259062|Other|Music listening alone|
79385523|NCT05279846|Drug|MOB015B|Applied topically for 48 weeks
79385524|NCT05279846|Drug|Vehicle (Placebo Comparator)|Applied topically for 48 weeks
79385525|NCT05268887|Device|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
79385526|NCT05268887|Device|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
79385527|NCT05263284|Drug|8-Chloroadenosine|Given IV
79385528|NCT05263284|Drug|Venetoclax|Given PO
79385529|NCT05255003|Biological|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count < 25,000/µL: hold anticoagulation"
79540553|NCT01482234|Behavioral|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
80012289|NCT02259062|Other|Audiobook listening|
80012290|NCT02078700|Other|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
80012291|NCT05763277|Diagnostic Test|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
79385530|NCT05255003|Biological|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count < 25,000/µL: hold anticoagulation"
80012292|NCT02227082|Radiation|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
79385531|NCT05255003|Biological|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count < 25,000/µL: hold anticoagulation"
79385532|NCT05246280|Drug|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
79842592|NCT05147493|Drug|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
79842593|NCT05147493|Drug|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
79842594|NCT00573534|Drug|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
79842595|NCT03974191|Other|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
79849003|NCT05660525|Behavioral|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
80012293|NCT02227082|Drug|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
80012294|NCT03670485|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
80012295|NCT02227160|Behavioral|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
80012296|NCT02227160|Behavioral|Outpatient counseling and support groups|Usual mental health care
80012297|NCT02223494|Drug|Terbogrel|
80012298|NCT03373435|Drug|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
79385533|NCT05235620|Other|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
79385534|NCT05228899|Drug|Zofin|1mL of Zofin will be administered intravenously, containing 2-5 x 10^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
79540554|NCT01482247|Dietary Supplement|L-Arginine|Dietary Supplement
79540555|NCT01482247|Dietary Supplement|Placebo Supplement|Dietary Supplement
79540556|NCT01482260|Procedure|Biopsy|Biopsy
79540557|NCT01482273|Procedure|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
80012299|NCT03373435|Other|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
79246828|NCT04444635|Procedure|Serratus Anterior Plan Block+ Fentanyl infusion|"After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion"
79842596|NCT04090385|Device|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
79842597|NCT03974425|Drug|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
79842598|NCT00975897|Biological|bevacizumab|
79246829|NCT04444635|Drug|Fentanyl|Continuous fentanyl infusion throughout the surgical procedure.
79842599|NCT00975897|Biological|cetuximab|
80012300|NCT03670407|Procedure|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
80012301|NCT01369680|Drug|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
79385535|NCT05228899|Other|Placebo|1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
80012302|NCT03670329|Device|URGO2875|Dressing
79385536|NCT05224375|Device|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
80012303|NCT04780321|Biological|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
79842600|NCT00975897|Drug|fluorouracil|
80012304|NCT04780321|Drug|Placebo|30 patients receipt placebo intravenous infusion on day 1
80012305|NCT02078778|Device|CPAP|3 months of CPAP treatment
80012306|NCT03669393|Drug|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
80012307|NCT03670173|Drug|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
79246830|NCT03577561|Other|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
79385537|NCT05220501|Diagnostic Test|Micro-US Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
79385538|NCT05220501|Diagnostic Test|MRI Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
79385539|NCT05217966|Radiation|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
79385540|NCT05217589|Other|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
79385541|NCT05217589|Other|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
79385542|NCT05217589|Other|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
79385543|NCT05200013|Biological|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
79842601|NCT00975897|Drug|irinotecan hydrochloride|
79842602|NCT00975897|Drug|leucovorin calcium|
79842603|NCT00975897|Drug|oxaliplatin|
79842604|NCT00975897|Genetic|RNA analysis|
79842605|NCT00975897|Genetic|cytogenetic analysis|
79842606|NCT00975897|Genetic|fluorescence in situ hybridization|
79842607|NCT00975897|Genetic|gene expression analysis|
79842608|NCT00975897|Genetic|mutation analysis|
79842609|NCT00975897|Genetic|protein expression analysis|
79842610|NCT00975897|Other|diagnostic laboratory biomarker analysis|
79842611|NCT00975897|Other|immunohistochemistry staining method|
79842612|NCT00975897|Other|questionnaire administration|
79842613|NCT00975897|Procedure|cognitive assessment|
79842614|NCT00867672|Drug|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
79540558|NCT01482273|Procedure|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
79842615|NCT00867672|Drug|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
79842616|NCT00867672|Drug|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
79842617|NCT01071421|Device|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
79698759|NCT04598906|Behavioral|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
80012308|NCT02076204|Behavioral|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
80012309|NCT03670095|Drug|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
79246831|NCT03601403|Device|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
80012310|NCT03670095|Drug|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
79385544|NCT05196984|Device|GENUS device (Active Settings)|Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
80012311|NCT01378039|Drug|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
79246832|NCT04443621|Behavioral|questionnaire|Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.
79246833|NCT04443621|Behavioral|in-depth interview|Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
79540559|NCT01482299|Drug|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
79540560|NCT01482338|Drug|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
79540561|NCT01482338|Drug|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
79385545|NCT05196984|Device|GENUS device (Sham Settings)|Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
79246834|NCT03603821|Diagnostic Test|CLINICAL ASSESMENT|IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
79246835|NCT03361683|Device|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
79246836|NCT03361683|Device|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
79246837|NCT03579823|Drug|Adalimumab 100 MG/ML [Humira]|prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
79246838|NCT03579823|Drug|AVT02 100MG/ML|prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
79540562|NCT01482364|Device|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
79540563|NCT01482364|Device|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
79540564|NCT01482377|Drug|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
79540565|NCT01482377|Drug|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m^2 for the first infusion, followed by doses of 250 mg/m^2 for subsequent infusions.
79842618|NCT00917657|Procedure|Photorefractive keratectomy|
79842619|NCT05145231|Other|GÖZLEMSEL|The scales will be filled by asking the family.
79842620|NCT00783926|Biological|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
79842621|NCT01071499|Drug|Morphine|One dose of morphine (0.1 mg/kg)
79246839|NCT04444011|Drug|Anaprazole Sodium|Anaprazole Sodium isthePPI inhibitor
79246840|NCT04444011|Drug|Amoxicillin|antibiotic
79246841|NCT04444011|Drug|Clarithromycin|antibiotic
79246842|NCT04444011|Drug|Bismuth|Bismuth is to protect the gastric mucosa
79385546|NCT05196776|Device|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
79385547|NCT05196776|Device|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
80012312|NCT02078856|Drug|A3384|
80012313|NCT02473341|Drug|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
79540566|NCT01482377|Drug|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
79698760|NCT04598906|Behavioral|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
79698761|NCT04579302|Procedure|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
79698762|NCT04579302|Procedure|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
79698763|NCT04579302|Drug|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
80012314|NCT02473341|Drug|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
80012315|NCT03240679|Device|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
79246843|NCT03600181|Device|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
79246844|NCT03603743|Behavioral|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
80016944|NCT00517790|Drug|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
80016945|NCT03772392|Procedure|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
80016946|NCT02095392|Dietary Supplement|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate [1g phosphorus/d]
79246845|NCT02238769|Device|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
79246846|NCT04443387|Drug|Vitamin D|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
79303709|NCT05635539|Dietary Supplement|"Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet"|calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
79540567|NCT01482377|Drug|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
79540568|NCT01482416|Drug|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
79540569|NCT01482416|Drug|Placebo|Placebo group will use placebo once/day during 30 days
79698764|NCT04579302|Drug|Bupivacaine|bupivacaine
79698765|NCT04598867|Drug|CD-008-0045|CD-008-0045 20 mg capsules
79698766|NCT04598867|Drug|Placebo|Placebo capsules
79698767|NCT04598867|Drug|Afobazol|Afobazol 10 mg tabletes
79698768|NCT00573300|Procedure|Phlebotomy|Single blood draw
79698769|NCT04578795|Device|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
79698770|NCT00565682|Drug|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
79698771|NCT00575952|Drug|Cisplatin|Given IV or IP
79698772|NCT00575952|Drug|Doxorubicin Hydrochloride|Given IV
79698773|NCT00575952|Biological|Filgrastim|Given SC
79698774|NCT00575952|Drug|Paclitaxel|Given IV or IP
79698775|NCT00575952|Biological|Pegfilgrastim|Given SC
79698776|NCT00565799|Procedure|Omentectomy|Removing the omentum
79698777|NCT00565799|Other|No intervention|Only LAGB without Omentectomy
79698778|NCT00573417|Drug|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
79698779|NCT00573417|Drug|Placebo|
79698780|NCT00565838|Procedure|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
79698781|NCT00573456|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
79698782|NCT00565877|Other|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
79698783|NCT00573495|Biological|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
79842622|NCT01071499|Drug|Morphine|One dose of morphine (0.2 mg/kg)
79842623|NCT01071499|Drug|Morphine|One dose of morphine (0.3 mg/kg)
79849004|NCT05660525|Drug|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
79303710|NCT04779177|Drug|Lumateperone 42 mg|Lumateperone 42 mg, oral administration
80012316|NCT01377961|Drug|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
80012317|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
79385548|NCT05189353|Other|Ghrelin|Ghrelin infusion
79385549|NCT05189353|Other|Placebo|Saline infusion
79698784|NCT00565955|Drug|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
80012318|NCT01377961|Other|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
80012319|NCT01377961|Other|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
80012320|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
80012321|NCT01377961|Other|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
79303711|NCT04779177|Drug|Lumateperone 28 mg|Lumateperone 28 mg, oral administration
79385550|NCT05170984|Device|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
79385551|NCT05170828|Drug|Cyclophosphamide|pre-transplant conditioning treatment
79385552|NCT05170828|Drug|Fludarabine|pre-transplant conditioning treatment
79385553|NCT05170828|Radiation|Total Body Irradiation|pre-transplant conditioning treatment
79385554|NCT05170828|Drug|Busulfan|pre-transplant conditioning treatment
79385555|NCT05170828|Drug|Mesna|given with cyclophosphamide
79385556|NCT05170828|Drug|Sirolimus|post-transplant treatment for GVHD
79698785|NCT00565955|Drug|Placebo|The patients will receive placebo tablets.
79698786|NCT04598594|Drug|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
79698787|NCT04598594|Drug|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
79698788|NCT00575991|Dietary Supplement|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
79303712|NCT04745013|Behavioral|PRIORITY|PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
79303713|NCT04745013|Behavioral|Usual care|Only a written personalized exercise prescription will be provided.
79385557|NCT05170828|Drug|Mycophenolate Mofetil|post-transplant treatment for GVHD
79385558|NCT05170828|Drug|Filgrastim|post-transplant treatment for GVHD
79303714|NCT05428865|Other|correlation study|investigate the correlations between body mass index, spasticity, functional ability and isolated motor control in children with spastic diplegia.
79303715|NCT05635461|Drug|CVN424|150 mg of either tablet or suspension formulation
79303716|NCT05729841|Other|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
79385559|NCT05170828|Drug|Cyclophosphamide|post-transplant treatment for GVHD
79385560|NCT05170828|Procedure|Bone Marrow Transplant|Transplant with investigational bone marrow product
79385561|NCT05142800|Device|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
79698789|NCT04598243|Dietary Supplement|Smart Energy System|A nutritional /herbal combination
79698790|NCT00576030|Other|hab cof with water|habitual coffee drinker provided with water
79385562|NCT05142800|Device|SOZO device|The machine measures the amount of fluid on the arm(s)
79698791|NCT00576030|Other|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
79303717|NCT05405231|Behavioral|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
79540570|NCT01482442|Drug|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
79698792|NCT00576030|Other|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
79698793|NCT00576030|Other|non-hab cof with water|non-habitual coffee drinkers given water
79698794|NCT00576030|Other|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
79698795|NCT00576030|Other|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
79698796|NCT04579341|Dietary Supplement|probiotics|probiotics administration
79698797|NCT04598126|Other|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
79698798|NCT04598126|Other|patient education manual +traditional physical therapy|"Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
79246847|NCT04443387|Other|Placebo|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
79698799|NCT00573573|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
79698800|NCT00576108|Drug|KD7040 Topical Gel|KD7040 topical gel
79698801|NCT00576108|Drug|Placebo gel|Placebo gel
80012322|NCT02074956|Biological|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
80012323|NCT02074956|Biological|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
79540571|NCT01482442|Drug|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
79842624|NCT04040868|Device|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
79246848|NCT03601169|Dietary Supplement|Low Dose MMFS-205-SR|Twice daily, oral 500mg tablets
79540572|NCT01482468|Drug|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
79698802|NCT00565994|Procedure|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
79698803|NCT00573612|Behavioral|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
80012324|NCT03558750|Biological|Nivolumab|Given by IV
80012325|NCT03558750|Biological|Rituximab|Given by IV
80012326|NCT03558750|Drug|Lenalidomide|Given by mouth
80012327|NCT02083302|Behavioral|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
80016947|NCT02095392|Dietary Supplement|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [0,5 g calcium]
79246849|NCT03601169|Dietary Supplement|High Dose MMFS-205-SR|Twice daily, oral 500mg tablets
79698804|NCT00573612|Behavioral|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
79698805|NCT00566033|Behavioral|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
79698806|NCT00573651|Other|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
79698807|NCT00566072|Behavioral|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
79698808|NCT04597970|Drug|cTACE-HAIC|transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
79842625|NCT04040868|Device|Freehand|conventional fluoroscopy-assisted
79842626|NCT05142813|Diagnostic Test|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
79842627|NCT03974269|Procedure|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
79246850|NCT03601169|Dietary Supplement|Placebo|Twice daily, oral
79246851|NCT02932592|Device|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
79246852|NCT02518737|Other|Meal Test|
79698809|NCT00573690|Drug|carboplatin|Given IV
79698810|NCT00573690|Drug|cisplatin|Given IV
79698811|NCT00573690|Drug|etoposide|Given IV
79698812|NCT00573690|Drug|pemetrexed disodium|Given IV
79698813|NCT00573690|Drug|sorafenib tosylate|Given orally
79246853|NCT03579745|Procedure|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
79246854|NCT03603587|Procedure|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
79246855|NCT03603587|Diagnostic Test|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
79246856|NCT03603587|Diagnostic Test|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
79540573|NCT01482468|Drug|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
79698814|NCT04597814|Other|No Intervention|No Intervention
79698815|NCT00576225|Drug|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
79698816|NCT00576225|Drug|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
79698817|NCT04597853|Diagnostic Test|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
79698818|NCT00573807|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
79698819|NCT04597931|Drug|Romosozumab|SC Romosozumab 210 mg/monthly
79698820|NCT04597931|Drug|Zoledronic Acid|IV Zoledronic acid 5 mg
79698821|NCT00576459|Drug|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
79698822|NCT00576459|Drug|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
79698823|NCT00576459|Procedure|standard of care laser photocoagulation|standard of care laser photocoagulation
79698824|NCT04597736|Biological|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
79698825|NCT04597775|Drug|hydroxychloroquine|hydroxychloroquine
79698826|NCT00573885|Drug|defined green tea catechin extract|Given orally
79698827|NCT00573885|Other|placebo|Given orally
79540574|NCT01482559|Drug|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
79540575|NCT01482559|Drug|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
79540576|NCT01482572|Procedure|biopsy|percutaneous lung biopsy and aspiration
79540577|NCT01482585|Other|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
79540578|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
79540579|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
79698828|NCT00573924|Drug|Proton pump inhibitor (lansoprazole)|"120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
79698829|NCT04597229|Dietary Supplement|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
79698830|NCT04579809|Procedure|4 strand technique|4 strand technique reapir of tendin flexor injury
79246857|NCT03603587|Diagnostic Test|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
79246858|NCT03603587|Diagnostic Test|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
79246859|NCT03603587|Diagnostic Test|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
79246860|NCT03603587|Diagnostic Test|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
79246861|NCT03603587|Diagnostic Test|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
79246862|NCT02316236|Drug|dexmedetomidine|an alpha-2 receptor agonist
79246863|NCT02316236|Other|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
79246864|NCT02316236|Other|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
79303718|NCT05405231|Behavioral|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
79303719|NCT02466347|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
79303720|NCT02466347|Drug|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
79540580|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
79540581|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
79540582|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
79698831|NCT04579770|Dietary Supplement|Ketone ester|75g ketone ester in the form of a drink [96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)] will be provided.
79698832|NCT04579770|Other|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
79698833|NCT04579770|Other|Placebo|Placebo
79842628|NCT00917189|Behavioral|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
80012328|NCT02083302|Behavioral|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
79540583|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
79698834|NCT00576498|Other|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
79303721|NCT05729763|Other|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
79698835|NCT00576498|Other|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
79698836|NCT04597463|Procedure|Endometrial injury|Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
79698837|NCT04578990|Other|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
79698838|NCT04578990|Other|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
79698839|NCT04578990|Other|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
79698840|NCT04597385|Other|Long-term Follow-Up|No intervention
79698841|NCT00573963|Drug|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
79698842|NCT00573963|Drug|saline solution|2 injections of 20mL plain saline solution - one on each side.
80012329|NCT02083302|Behavioral|SCREAM Theater Dose 4|Booster Session
80016948|NCT02095392|Dietary Supplement|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [1 g calcium]
79385563|NCT05130788|Behavioral|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6-12 weeks (<30 seconds per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
79540584|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
79540585|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
79540586|NCT01482624|Device|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
79303722|NCT05729763|Other|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
79540587|NCT01482624|Procedure|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
79303723|NCT03067935|Drug|glembatumumab vedotin|
79303724|NCT03066375|Device|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
79303725|NCT02466269|Procedure|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
79303726|NCT05635149|Radiation|radiotherapy|In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
79540588|NCT01482650|Device|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
79540589|NCT01482663|Behavioral|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
79540590|NCT01482689|Dietary Supplement|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
79698843|NCT04597034|Procedure|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
79698844|NCT04597034|Procedure|AN69-Standard|Standard treatment.
79698845|NCT00576615|Drug|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
79698846|NCT00576615|Drug|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
79385564|NCT05130788|Behavioral|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
79385565|NCT05130788|Drug|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
79385566|NCT05130476|Procedure|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
79842629|NCT00961155|Drug|cyklezonid|160 mcg once daily
79540591|NCT01482689|Dietary Supplement|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
79540592|NCT01482702|Behavioral|weight loss intervention|Behavioral weight loss intervention
79540593|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
79540594|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
79540595|NCT01482728|Drug|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
79540596|NCT01482728|Drug|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
79698847|NCT00576771|Procedure|PSV|Pressure Support Ventilation
79698848|NCT00576771|Procedure|NAVA|Neurally Adjusted Ventilatory Assist
79698849|NCT00576771|Procedure|patient-controlled|assisted controlled MV through a button
79842630|NCT00961155|Drug|montelukast sodium|5 or 10 mg according to age once daily
80012330|NCT03559140|Procedure|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
80012331|NCT03559140|Procedure|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
79540597|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
79842631|NCT00961155|Drug|placebo|fluticasone placebo twice daily, montelukast placebo once daily
79246865|NCT04521075|Biological|Fecal Microbial Transplantation by capsules|"Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion."
79540598|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
79540599|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
79698850|NCT04596761|Device|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
79698851|NCT04596761|Device|Control placebo with no RF|Placebo control, toothbrush with no RF
79698852|NCT00574041|Drug|Interferon beta-1a|injected, once a week
79842632|NCT00961155|Drug|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
80012332|NCT03559140|Procedure|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
79246866|NCT03577249|Drug|Dialysis Solutions|Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
79391473|NCT02433496|Other|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
79698853|NCT04596956|Drug|sodium bicarbonate Ringer injection|Used in surgery
79698854|NCT04596956|Drug|Lactated Ringer's solution|Used in surgery
79698855|NCT04597073|Procedure|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
79698856|NCT04596722|Dietary Supplement|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
79698857|NCT04596722|Other|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
79698858|NCT00576849|Drug|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
79698859|NCT00576849|Drug|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
79842633|NCT00793676|Other|spirometry|
79842634|NCT00793676|Other|blood test|
79842635|NCT00863538|Drug|KPS-0373|
79842636|NCT00260533|Drug|atomoxetine|Flexible dose, up to 50 mg per day
79842637|NCT00260533|Drug|placebo|placebo (matching to atomoxetine)
80012333|NCT02082366|Device|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
79842638|NCT02596919|Other|photography|photography of meibomian glands
80012334|NCT02082444|Other|Skipping lunch|
79246867|NCT03601091|Drug|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
79246868|NCT03601091|Drug|DORMICUM 5MG/5 ML|Infusion therapy of the drug
79246869|NCT03549559|Drug|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
79246870|NCT03549559|Device|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
79246871|NCT04508829|Drug|Anti-EGFR monoclonal antibody|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
79246872|NCT04479176|Procedure|Transnasal Sphenopalatine Ganglion Block|In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
79246873|NCT03603431|Drug|MRG-110|Single ascending doses of MRG-110
79698860|NCT00576849|Drug|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
79698861|NCT00566189|Procedure|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
79246874|NCT03603431|Drug|Placebo|Single doses of placebo
80012335|NCT02082600|Other|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
80012336|NCT02082600|Other|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
79698862|NCT00576888|Other|no intervention|no intervention - observational only
79698863|NCT00566267|Drug|simvastatin 20 mg/ezetimibe|see protocol
79698864|NCT00574314|Other|No Intervention|Participants will be consented.
79246875|NCT03603431|Drug|MRG-110|Multiple ascending doses of MRG-110
79385567|NCT05130099|Other|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
79385568|NCT05121649|Other|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
79385569|NCT05090904|Drug|Brensocatib|Oral tablet
79698865|NCT00566306|Other|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
79698866|NCT00574353|Radiation|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
79385570|NCT05090904|Drug|Placebo|Oral tablet
79698867|NCT04596839|Drug|Remdesivir|Remdesivir INN 100 mg lyophilized powder for infusion
79698868|NCT04596839|Other|Standard of Care|Standard of Care Treatment for COVID-19 Infection
79698869|NCT00574392|Device|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
79698870|NCT04596371|Other|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
79246876|NCT03603431|Drug|Placebo|Multiple doses of Placebo
79246877|NCT02239081|Drug|CTP-730|
79246878|NCT02239081|Drug|Placebo for CTP-730|
79246879|NCT04521309|Biological|SARS-CoV-2 antibody based IVIG therapy|"Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics"
79246880|NCT03601013|Other|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
79246881|NCT02239159|Other|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
79246882|NCT03600935|Other|Vancouver Clinical Pathway|Vancouver Clinical Pathway
79246883|NCT04521153|Drug|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
79246884|NCT04521153|Drug|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
79246885|NCT04521153|Procedure|TACE treatment|TACE treatment
79246886|NCT04521153|Procedure|Radical surgery|Radical surgery
79698871|NCT00574431|Other|Data Collection|Collection of patient data before implementation of a nutritional management protocol
79698872|NCT00574431|Other|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
79698873|NCT04596683|Procedure|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
79698874|NCT00574470|Drug|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
79842639|NCT00863616|Device|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
79842640|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
79842641|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
79842642|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
79842643|NCT00973245|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
79842644|NCT00793754|Drug|Aspirin|100 mg / day for 8 weeks
79842645|NCT00793754|Drug|Atorvastatin|40 mg / day for 8 weeks
79842646|NCT00793754|Drug|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
79842647|NCT02596763|Drug|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
79842648|NCT03976141|Diagnostic Test|mri|knee mri
79842649|NCT00793832|Behavioral|supervised exercise|supervised exercise
80012337|NCT02078934|Procedure|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
80012338|NCT03558594|Behavioral|Hypnosis|Behavioral Condition
80012339|NCT03558594|Behavioral|Mindfulness|Behavioral Condition
80012340|NCT02751320|Drug|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
80012341|NCT02751320|Drug|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
79385571|NCT05089682|Device|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
79385572|NCT05084417|Other|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
79385573|NCT05062473|Behavioral|Lifestyle Modification Webinars Focused on Hypertension Control|Participation in a 12-week health education telemedicine curriculum
79385574|NCT05055128|Drug|X842|Patients will receive X842 tablets.
79698875|NCT04596527|Drug|18F-FMPP|18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
79698876|NCT00577161|Drug|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
79698877|NCT00577161|Drug|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
79698878|NCT04596332|Other|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
79698879|NCT04579497|Other|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
79842650|NCT00793832|Behavioral|Diet advice|Diet Advice
79842651|NCT00860106|Other|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
79842652|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
79842653|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
79842654|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
79842655|NCT00973323|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
80012342|NCT02751320|Drug|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
80012343|NCT02751320|Other|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
80012344|NCT02751320|Drug|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
80012345|NCT02751320|Drug|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
79385575|NCT05055128|Drug|X842 Dummy|Patients will receive matching placebo tablets for X842.
79385576|NCT05055128|Drug|Lansoprazole|Patients will receive Lansoprazole capsule.
79385577|NCT05055128|Drug|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
79385578|NCT05054504|Device|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
79385579|NCT05053100|Procedure|Biospecimen Collection|Undergo collection of blood
79385580|NCT05053100|Other|Electronic Health Record Review|Undergo electronic health record review
79385581|NCT05038020|Drug|AKST4290|Oral AKST4290
79385582|NCT05038020|Drug|Placebo|Oral Placebo
79385583|NCT05009758|Procedure|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
79842656|NCT00793988|Procedure|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
79849005|NCT05660525|Drug|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
80012346|NCT02079012|Behavioral|10-week walking program|
80012347|NCT02082756|Drug|Bifidobacterium viable pharmaceutics|
80012348|NCT02082756|Drug|Berberine Hydrochloride|
80012349|NCT02223572|Radiation|hip Xray|
79698880|NCT04579497|Other|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
79698881|NCT04579497|Other|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
79698882|NCT04579497|Other|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
79698883|NCT04596605|Other|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
79698884|NCT04596605|Dietary Supplement|Nutrof Total|2 capsules daily for 12 weeks
79698885|NCT04596488|Drug|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
79698886|NCT00574626|Procedure|PBSCT|Peripheral Blood Stem Cell Transplant
79698887|NCT00574626|Procedure|Bone Marrow Transplant|Bone Marrow Transplant
80012350|NCT04615845|Biological|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
80012351|NCT02259140|Procedure|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
80012352|NCT02259140|Procedure|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
79385584|NCT05009758|Procedure|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
79385585|NCT05009758|Procedure|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
79385586|NCT05009758|Procedure|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
79385587|NCT05009758|Procedure|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
79385588|NCT05009758|Procedure|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
79698888|NCT04596566|Other|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
79698889|NCT00574665|Other|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
79698890|NCT04578717|Procedure|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
79849006|NCT05659537|Drug|Dulaglutide|Administered SC
79849007|NCT05645146|Behavioral|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
80012353|NCT03559764|Biological|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
80012354|NCT02082834|Other|abdominal MDCT examination|
80012355|NCT02259218|Other|laboratory biomarker analysis|Correlative studies
80012356|NCT01377883|Other|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
80012357|NCT01377883|Behavioral|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
80012358|NCT02083458|Procedure|Catheterization of the axillary vein.|
80012359|NCT02231528|Device|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
80012360|NCT02231528|Device|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
79849008|NCT05645146|Drug|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
79698891|NCT04578717|Procedure|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
79698892|NCT04578717|Biological|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
79385589|NCT05009758|Procedure|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
80012361|NCT02079090|Drug|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
79385590|NCT05009758|Diagnostic Test|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
79385591|NCT05009758|Other|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
79540600|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
79698893|NCT04595942|Drug|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
79698894|NCT04595942|Drug|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
79698895|NCT04595942|Behavioral|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
79698896|NCT00566384|Drug|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
79698897|NCT00566384|Drug|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
79698898|NCT00574743|Drug|Enteric-coated Mycophenolate Sodium|
80012362|NCT02079090|Drug|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
79698899|NCT04596020|Other|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
79698900|NCT04578366|Device|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
79698901|NCT04578366|Other|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
79698902|NCT04596059|Other|Frisolac Gold Intensive HA|Regular medical care
79385592|NCT05009758|Diagnostic Test|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
79698903|NCT04596176|Other|Program Supportive Housing Services|The existing statewide SH model that included routine access to housing (voucher) and case management
79698904|NCT04596176|Other|Intensive Supportive Housing Services|an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
79698905|NCT04596137|Behavioral|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
80012363|NCT04931641|Dietary Supplement|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
80012364|NCT04931641|Other|Maltodextrin|Maltodextrin (placebo)
79385593|NCT05009758|Procedure|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
80012365|NCT04931641|Dietary Supplement|Ferrous fumarate|50 mg iron as ferrous fumarate
79385594|NCT05009758|Procedure|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
79385595|NCT05009758|Procedure|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
79698906|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
79698907|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
79698908|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
79698909|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
79698910|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
79698911|NCT03453645|Procedure|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
79698912|NCT04595708|Behavioral|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
79698913|NCT03453606|Other|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
79698914|NCT03453606|Other|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
79246887|NCT04362566|Drug|Bupivacaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
79385596|NCT05004987|Drug|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
80012366|NCT04937270|Device|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
80012367|NCT04937270|Device|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
79385597|NCT05004987|Drug|Placebo|Daily dose of placebo will mimic that of ESC.
79385598|NCT04991870|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
79385599|NCT04991870|Procedure|Resection|Undergo surgical resection
79385600|NCT04981275|Other|No intervention study|This observational study will only collect data, not provide any intervention to participants.
79385601|NCT04974736|Behavioral|iEHR + Navigator|"The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services."
79385602|NCT04968834|Genetic|Genomic profiling|Genomic profiling using CLIA assay
79385603|NCT04965935|Drug|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
79698915|NCT04595669|Behavioral|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
79698916|NCT04595552|Other|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
79385604|NCT04965935|Drug|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
79246888|NCT04362566|Other|Placebo Saline|Scalp flap: 2.5cc salinefor 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to saline used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
79698917|NCT03453411|Other|Non interventional study|Non interventional study
79698918|NCT04595357|Procedure|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
79698919|NCT04595318|Drug|Standard clinical care and varenicline|Standard clinical care includes methadone clinic-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
79698920|NCT04595318|Other|Standard clinical care|Standard clinical care includes methadone clinic-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies
79385605|NCT04957394|Behavioral|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
79385606|NCT04940286|Biological|Durvalumab|Given IV
79385607|NCT04940286|Drug|Gemcitabine|Given IV
79385608|NCT04940286|Drug|Nab-paclitaxel|Given IV
79385609|NCT04940286|Biological|Oleclumab|Given IV
79385610|NCT04933266|Procedure|Subpectoral plexus block (low dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
79698921|NCT04595396|Procedure|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
80012368|NCT04937270|Device|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
80012369|NCT04937270|Device|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
80012370|NCT02079168|Drug|RXI-109|
80012371|NCT02079168|Drug|Placebo|
80016949|NCT02095392|Dietary Supplement|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
79246889|NCT02239237|Drug|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
79385611|NCT04933266|Procedure|Subpectoral plexus block (High dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
79385612|NCT04916600|Device|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
79385613|NCT04887857|Drug|CC-486|Specified dose on specified days
79385614|NCT04887857|Drug|Venetoclax|Specified dose on specified days
79385615|NCT04878965|Device|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
79385616|NCT04862650|Drug|Carboplatin|Given IV
79385617|NCT04862650|Biological|Cemiplimab|Given IV
79385618|NCT04862650|Drug|Paclitaxel|Given IV
79698922|NCT03453333|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
79698923|NCT03453333|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
79246890|NCT02237885|Device|NeuroSky MindWave Mobile|
79385619|NCT04855578|Other|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
79698924|NCT00566423|Other|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
79698925|NCT01149343|Biological|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
79385620|NCT04855578|Other|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
79698926|NCT04595240|Diagnostic Test|semen analysis|semen analysis
79698927|NCT04578561|Procedure|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
80012372|NCT04898959|Other|Filling out Questionaire|Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
80012373|NCT02227472|Other|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
79540601|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
79540602|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
79698928|NCT04595162|Biological|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
79698929|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~Check head and cannula position~Increase mean arterial pressure~Increase pump flow~Increase systemic oxygenation~Increase PaCO2 > 45~Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~Consider PRBC transfusion for Hct < 21%"
79698930|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
79698931|NCT04594967|Other|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
79698932|NCT00624988|Procedure|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
79842657|NCT00793988|Procedure|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
79246891|NCT03354507|Dietary Supplement|Sodium bicarbonate|Sodium bicarbonate. See arms.
79246892|NCT03579589|Drug|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
79246893|NCT03357003|Other|Observational study|Comparison between O-desmethyltramadol/tramadol ratio and tramadol clinical efficiency and tolerance
79246894|NCT03600025|Biological|Typbar-TCV vaccine|vaccine will receive intramuscularly
79246895|NCT03600623|Drug|Folfirinox|SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
79246896|NCT03600623|Drug|Gemcitabine nab-Paclitaxel|SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
79246897|NCT02201810|Behavioral|Rate reduction intervention|
79246898|NCT02201810|Behavioral|Recycling Group|
79246899|NCT02201810|Behavioral|Choice Group|
79246900|NCT02201810|Behavioral|Proactive QL|
79303727|NCT03067857|Biological|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
79303728|NCT02466191|Drug|Memantine|
79698933|NCT04313101|Other|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~Euthyroid ( Normal TSH, FT3 and FT4)~Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
79698934|NCT00577668|Drug|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
79842658|NCT00973401|Other|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
79540603|NCT01482754|Drug|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
79540604|NCT01482780|Device|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
79540605|NCT01482793|Procedure|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
79540606|NCT01482806|Behavioral|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
79842659|NCT04040322|Drug|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
79540607|NCT01482806|Behavioral|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
79540608|NCT01482832|Behavioral|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
79540609|NCT01482845|Drug|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
80012374|NCT02227472|Other|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
79842660|NCT04040322|Drug|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
79842661|NCT00787358|Drug|ZT-031|80 ul subcutaneous injection per day
80012375|NCT02083536|Radiation|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
80012376|NCT02083536|Drug|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
79842662|NCT00787358|Other|placebo|80 ul daily subcutaneous injection of vehicle only
80012377|NCT03629899|Device|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
80012378|NCT02231606|Other|Free Glasses|Provide free glasses
80012379|NCT02231606|Other|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
80012380|NCT02231606|Other|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
80012381|NCT02083614|Procedure|to clamp or release the catheter for 2 days before removal|
80012382|NCT04629937|Other|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
80012383|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
80012384|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
80012385|NCT04573699|Device|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
79303729|NCT02466191|Drug|Gabapentin|
79698935|NCT04313179|Other|Music therapy|Mozart lullaby music
79246901|NCT03361527|Other|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
79698936|NCT04313179|Other|Sucrose|0.5 ml of 24% Sucrose
79842663|NCT00794066|Procedure|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
79849009|NCT05645146|Drug|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
80012386|NCT02227550|Drug|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
80012387|NCT02227550|Drug|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine >= 1.5 mg/dl (133mM), <= 60 kg body weight or age >= 80 years.
80012388|NCT02206035|Drug|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
80012389|NCT02206035|Drug|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m^2 Days +3, +6 and +11.
80012390|NCT02206035|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
79246902|NCT03600545|Other|Brain Fitness App|Brain exercises using an iPAD
80012391|NCT02227628|Dietary Supplement|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
80016950|NCT00123968|Biological|VRC-HIVDNA016-00-VP|1x10^11 per unit vaccine administered intramuscularly via Bioinjector
79246903|NCT02518347|Dietary Supplement|FDS-Strawberry|Natural frozen and dried strawberries
79246904|NCT02518347|Dietary Supplement|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
79246905|NCT03603197|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
79246906|NCT03603197|Drug|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
79246907|NCT02848729|Drug|Oral Acetaminophen|Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
79246908|NCT02848729|Drug|IV Acetaminophen|Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
79246909|NCT02848729|Drug|IV Morphine|Morphine for IV administration (0.125 mg/kg)
79246910|NCT02848729|Drug|Placebo Tablets|Placebo tablets matching oral acetaminophen
79246911|NCT02848729|Drug|Saline|Saline placebo matching IV acetaminophen
79246912|NCT02518659|Dietary Supplement|Inulin|This is the Intervention
79246913|NCT03135782|Other|Communication Skills Training|Undergo motivational interviewing training
79385621|NCT04851028|Behavioral|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons & Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
79385622|NCT04844073|Drug|TAK-186|TAK-186 IV infusion.
79385623|NCT04841096|Drug|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
79385624|NCT04841096|Drug|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
79540610|NCT01482845|Drug|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
79246914|NCT03135782|Other|Medical Chart Review|Undergo medical chart review
79246915|NCT03135782|Other|Questionnaire Administration|Ancillary studies
79246916|NCT03135782|Other|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
79540613|NCT01482871|Drug|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
79540614|NCT01482871|Drug|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
79540615|NCT01482871|Drug|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
79540616|NCT01482871|Drug|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
79540617|NCT01482897|Drug|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
79540618|NCT01482897|Drug|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
79540619|NCT01482897|Drug|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
79540620|NCT01482923|Behavioral|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
79385625|NCT04841096|Drug|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
79385626|NCT04841096|Drug|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
79385627|NCT04836000|Other|In addition to the conservative treatment, Low-level laser therapy|"For Experimental Group A Gallium-aluminum-arsenide (Ga-Al-As) diode laser instrument (Roland Serie, Elettronica Pagani, Paderno, Italy, Mod IR 27/1) will be used (wavelength 904 nm, 5500 Hz frequency, 27 W maximum power output per pulse, 13.2 mW average power, 0.8-cm2 spot size, 1.6 J of total energy will be delivered per point at each session at a power density of 16.5 mW/cm2, and the cumulative energy per point for all sessions was 16 J).~Ga-Al-As laser therapy will be applied to experimental group patients two times per week for 6 weeks in 10-min sessions. LLLT will be applied over the tuberculum majus and minus, the anterior and posterior faces of the capsule, and the subacromial regions. Each point will be treated for 120 sec. The head of the instrument will be held perpendicular to the body surface and in skin contact without pressure."
79698937|NCT04595084|Behavioral|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
79698938|NCT04595084|Behavioral|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
79698939|NCT04595084|Behavioral|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
79698940|NCT00577785|Other|tissue procurement|No intervention. Tissue procurement study.
79698941|NCT01148017|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
79698942|NCT04594928|Drug|GLPG3667|GLPG3667 capsules
79698943|NCT04594928|Drug|Placebo|Matching placebo capsules
79698944|NCT00577902|Other|Observation|Head and neck cancer patients receiving chemoradiation
79698945|NCT01147900|Biological|Boostrix™|Intramuscular, single dose
80012392|NCT02227628|Dietary Supplement|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
80012393|NCT02082990|Behavioral|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
79246917|NCT03600467|Drug|SEVI-D (Seviteronel in combination with dexamthasone)|"Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study."
79540621|NCT01482923|Behavioral|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
79698946|NCT01147900|Biological|Boostrix™-US formulation|Intramuscular, single dose
79698947|NCT04594850|Biological|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
80012394|NCT02082990|Behavioral|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
80012395|NCT02079324|Biological|GX-051|intratumoral injection
80012396|NCT02258828|Drug|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
79246918|NCT03361449|Other|Flamingo exercise|Flamingo exercise
79246919|NCT03361449|Other|training with kinesthetic ability trainer|training with kinesthetic ability trainer
79698948|NCT04594889|Procedure|angioplasty|Balloon releasing a drug inflated in the target vessel
79698949|NCT01147744|Drug|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
79698950|NCT01147744|Drug|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
79698951|NCT01147744|Drug|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
79246920|NCT03577093|Other|There is no intervention at all.|There is no intervention at all.
79246921|NCT04520919|Other|anesthesia;Radial artery puncture|we chose the patients who need to monitor invasive blood pressure to obtain high-fidelity arterial waveforms
79246922|NCT03600389|Behavioral|Patient Priorities Care|
79246923|NCT04520529|Other|Biologic Samples|"An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research."
79246924|NCT02437435|Other|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
79246925|NCT02437435|Other|Placebo Intervention|Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
79246926|NCT04508673|Other|GH provocation tst|All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).
79246927|NCT03600311|Other|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
79385628|NCT04836000|Other|In addition to the conservative treatment, Low-level laser therapy (turned off)|For Placebo Group In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions. Patients and physiotherapist will be asked to use protective eyeglasses during therapy for safety.
79385629|NCT04836000|Other|Conservative treatment solely|For Control Group All patients using an immobilization bandage up to post-operative 6th week will receive the standardized 6-week supervised rehabilitation program advocated by the same physiotherapist (CK), 7 years of experience in the clinical treatment of rotator cuff tear, after the baseline assessment. Composed of 30 treatment sessions (five days/week) of 45 to 60 minutes, the rehabilitation program will be provided individually to all participants. Physiotherapy sessions will be devoted to strength, mobilizations, stretching, perturbation, and sensorimotor training using motor control exercises, hence, to restore adequate shoulder neuromuscular control. The treatment program will also be included patient education.
79540622|NCT01482936|Drug|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
79540623|NCT01482949|Drug|AGS-003|Autologous Dendritic Cell Immunotherapy
79698952|NCT01147744|Drug|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
79698953|NCT01147744|Drug|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
79698954|NCT01147744|Drug|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
79698955|NCT01147744|Drug|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
79698956|NCT01147744|Drug|Placebo montelukast|Placebo capsule once daily in the evening
80012397|NCT02258828|Drug|Placebo|Matched placebo
80012398|NCT02746471|Device|Reveal LINQ|
79246928|NCT03600311|Dietary Supplement|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
79246929|NCT03600311|Other|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
79246930|NCT03600311|Dietary Supplement|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
79246931|NCT03600311|Dietary Supplement|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
79246932|NCT03599557|Behavioral|STOP-HPV communication intervention|This intervention will be communication skills training.
79540624|NCT01482975|Other|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
79698957|NCT01147744|Drug|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
79698958|NCT01147744|Drug|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
79698959|NCT04594460|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
79698960|NCT04594460|Device|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
79698961|NCT04594655|Procedure|surgery|colectomy
80012399|NCT02083068|Biological|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
79698962|NCT00625027|Other|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
79540625|NCT01482975|Other|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
79698963|NCT04594577|Device|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
79698964|NCT04313374|Drug|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
79385630|NCT04835961|Other|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
79698965|NCT04313374|Drug|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
79698966|NCT04313374|Drug|Placebo|the PCA will contain placebo
79246933|NCT03354351|Behavioral|Stepped-care model|The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
79385631|NCT04826874|Behavioral|Affect labeling|Short behavioral intervention teaching affect labeling
79385632|NCT04824612|Device|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
79698967|NCT04594148|Behavioral|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
79385633|NCT04824612|Drug|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
79385634|NCT04824612|Device|Sham LED|A blue LED without power and biologic effect.
79385635|NCT04804514|Drug|KH001|The study drug is applied to teeth
79385636|NCT04804514|Drug|Placebo|The placebo is applied to teeth
79385637|NCT04803201|Drug|Cyclophosphamide|Given IV
79385638|NCT04803201|Drug|Doxorubicin|Given IV
79385639|NCT04803201|Drug|Vincristine|Given IV
79385640|NCT04803201|Drug|Prednisone|Given PO
79385641|NCT04803201|Drug|Etoposide|Given IV or PO
79540626|NCT01483001|Drug|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
79698968|NCT00577980|Drug|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
79540627|NCT01483014|Drug|imatinib mesylate|
79698969|NCT05219578|Drug|RTX-224|RTX-224 monotherapy
79698970|NCT01147471|Device|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
79698971|NCT01147471|Procedure|operative rib fixation surgery|
79698972|NCT04594343|Drug|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
79698973|NCT04594343|Drug|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
79698974|NCT00578019|Procedure|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith & Nephew supracondylar nail.
79698975|NCT00578019|Procedure|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
79842664|NCT00784004|Other|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~Breathing in through the nose only and out through the mouth only~Breathing in through the mouth only and out through the nose only~Breathing in and out through the nose only~Breathing in and out through the mouth only"
79842665|NCT00867750|Device|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
80012400|NCT02083068|Biological|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
79385642|NCT04803201|Drug|Duvelisib|Given PO
79385643|NCT04803201|Drug|Oral azacitidine|Given PO
79385644|NCT04798664|Behavioral|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
79385645|NCT04798664|Behavioral|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
79385646|NCT04798664|Behavioral|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
79385647|NCT04796610|Behavioral|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
79385648|NCT04788680|Other|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
79385649|NCT04788680|Other|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
79385650|NCT04788680|Other|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
79246934|NCT03354195|Procedure|Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.|All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
79246935|NCT04562324|Drug|SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics|Medications to relieve anxiety
79246936|NCT04562324|Device|Neurofeedback system|EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
79246937|NCT03599921|Behavioral|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
79246938|NCT03599921|Behavioral|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
79246939|NCT03599921|Behavioral|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
79246940|NCT03599921|Behavioral|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
79385651|NCT04788680|Other|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
79698976|NCT04594304|Behavioral|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
79698977|NCT04578483|Other|PCA group|Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.
79698978|NCT04578483|Other|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
79698979|NCT01147393|Drug|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over ~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
79698980|NCT01147393|Biological|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
79698981|NCT00578058|Other|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
79698982|NCT02884024|Other|no intervention|there is no intervention in this study
79698983|NCT00566774|Other|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
79698984|NCT00566774|Other|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
79842666|NCT00867750|Drug|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
79698985|NCT00578097|Biological|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
79698986|NCT00578097|Drug|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
79842667|NCT00787436|Drug|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
80012401|NCT02083068|Biological|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
80012402|NCT02228018|Device|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
80012403|NCT02228252|Other|Whey protein|
79698987|NCT04593797|Diagnostic Test|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
79698988|NCT00578370|Drug|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
79698989|NCT00578370|Drug|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
79698990|NCT00578370|Drug|0.1% betamethasone|Solution 200µl once a day (26 days)
79698991|NCT00578370|Drug|0.005% calcipotriol|Solution 200µl once a day (26 days)
79698992|NCT00578370|Drug|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
79698993|NCT04593719|Other|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
79842668|NCT03945981|Drug|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
79842669|NCT00784082|Drug|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
79246941|NCT04520295|Genetic|ctDNA screening|Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
79246942|NCT04526366|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.
79246943|NCT04526366|Device|Polysomnography|Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
79540628|NCT01483040|Device|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
79698994|NCT04593836|Drug|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
79698995|NCT04593836|Drug|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
79842670|NCT03926598|Behavioral|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
79842671|NCT03926598|Behavioral|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
79842672|NCT03926598|Behavioral|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
79842673|NCT03926598|Behavioral|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
79842674|NCT03926598|Behavioral|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
79842675|NCT00784160|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
79842676|NCT00976053|Procedure|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
80012404|NCT02228252|Other|Casein|
80012405|NCT02228252|Other|Gluten protein|
80012406|NCT04525573|Device|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
80016951|NCT00123968|Biological|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
79246944|NCT03603119|Drug|Normal saline, Midazolam|2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
79385652|NCT04782258|Drug|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
79385653|NCT04782258|Drug|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
79385654|NCT04779307|Drug|Vedolizumab|Vedolizumab IV infusion.
79385655|NCT04767191|Drug|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
79246945|NCT03603119|Drug|Dexamethasone, ondansetron|8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
79698996|NCT04578405|Procedure|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
79698997|NCT04578405|Procedure|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
79698998|NCT04593368|Other|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
79698999|NCT04593524|Dietary Supplement|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
79699000|NCT04593524|Other|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
79699001|NCT00578526|Drug|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
79699002|NCT00578526|Drug|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
79699003|NCT04593446|Drug|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
79699004|NCT04593446|Drug|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
79699005|NCT00578604|Device|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
79699006|NCT00566891|Drug|tirofiban|tirofiban high dose bolus 25µ/Kg
79699007|NCT00566891|Drug|Clopidogrel|
79699008|NCT00578682|Biological|MEDI-557|Single IV dose of 3 mg/kg
79699009|NCT00578682|Biological|MEDI-557|Single IV dose of 15 mg/kg
79699010|NCT00578682|Biological|MEDI-557|Single IV dose of 30 mg/kg
79699011|NCT00578682|Biological|MEDI-557|Single IV dose of 0.3 mg/kg
79540629|NCT01483053|Drug|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
79699012|NCT04593485|Drug|Camrelizumab for injection|Carrelizumab will be administered at a fixed dose
79699013|NCT04592900|Other|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
79246946|NCT03356847|Device|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
79540630|NCT01483053|Drug|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
79699014|NCT00578760|Drug|aspirin|325mg ASA OD for the duration of the cisplatin
79246947|NCT03603041|Dietary Supplement|Whey protein|Participants in the protein arms will receive whey protein daily for 16 weeks.
79246948|NCT03603041|Dietary Supplement|Omega-3 fatty acids|Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
79246949|NCT03123627|Drug|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
79385656|NCT04767191|Drug|dihydroartemisinin piperaquine|Antimalarial Combinations
79540631|NCT01483066|Device|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
79699015|NCT00578760|Drug|placebo|OD for course of cisplatin chemotherapy
79699016|NCT00578799|Dietary Supplement|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
79699017|NCT00578799|Dietary Supplement|placebo|placebo capsules (potato starch
79699018|NCT04592705|Device|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
79699019|NCT00578838|Other|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
79246950|NCT03123627|Drug|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
79385657|NCT04765657|Drug|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
79385658|NCT04765657|Drug|Placebo|Subcutaneously injected on Day 1, 90, and 270.
79385659|NCT04764331|Device|Revian Red All LED cap|Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
79385660|NCT04754412|Other|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
79540632|NCT01483092|Dietary Supplement|inulin|20g/day for 4 weeks
79540633|NCT01483092|Dietary Supplement|maltodextrin|20g/day for 4 weeks
79540634|NCT01483131|Other|Exercise training|12 weeks of resistance training twice a week.
79540635|NCT01483131|Other|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
79699020|NCT00578838|Other|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
79699021|NCT04592822|Drug|WD-1602|dabigatran etexilate mesylate granules for oral suspension
79699022|NCT04592822|Drug|Pradaxa®|dabigatran etexilate capsules
79699023|NCT00578916|Drug|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
79699024|NCT00567047|Drug|vildagliptin|
79699025|NCT00578994|Device|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
79842677|NCT03906747|Other|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
79842678|NCT03906747|Other|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~Proportion of patients who fits criteria of EOL who died within 48 hours;~Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
79540636|NCT01483157|Other|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
79540637|NCT01483157|Other|high intensity resistance training|twelve weeks of resistance training twice a week
79842679|NCT00794300|Device|second magnetic resonance imaging scan|
79842680|NCT00979563|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
79842681|NCT00745901|Drug|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
79842682|NCT00787670|Other|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
79540638|NCT01483170|Drug|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
79540639|NCT01483170|Drug|Placebo|Placebo fexinidazole
79842683|NCT00787670|Procedure|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
79699026|NCT03454178|Diagnostic Test|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
79699027|NCT00579033|Other|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
79842684|NCT00787670|Other|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
79842685|NCT00863850|Drug|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled [14C] bendamustine will be given on day 1 of cycle 1 only.
79842686|NCT00794456|Drug|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
79842687|NCT00794456|Drug|Valeriana|1 tablet PO twice a day
79842688|NCT00860340|Drug|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
79842689|NCT00867828|Dietary Supplement|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
79842690|NCT00867828|Dietary Supplement|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
79385661|NCT04754412|Other|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
79385662|NCT04754412|Other|Best Practice|Write about facts regarding their cancer diagnosis and treatment
79540640|NCT01483196|Procedure|ultrasound imaging|Undergo TCD
79540641|NCT01483196|Other|questionnaire administration|Complete neurocognitive questionnaires
79385663|NCT04754412|Other|Quality-of-Life Assessment|Ancillary studies
79540642|NCT01483196|Procedure|assessment of therapy complications|Undergo TCD
79540643|NCT01483196|Procedure|quality-of-life assessment|Ancillary studies
79540644|NCT01483196|Procedure|magnetic resonance imaging|Undergo MRI
79699028|NCT00579033|Other|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
79699029|NCT04578171|Drug|Mepolizumab|100 mg subcutaneous injections every four weeks
79842691|NCT00867828|Dietary Supplement|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
80016952|NCT00123968|Biological|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
79385664|NCT04754412|Other|Questionnaire Administration|Ancillary studies
79385665|NCT04747522|Drug|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
79540645|NCT01483222|Device|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
79540646|NCT01483222|Device|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
79699030|NCT03454139|Procedure|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
80012407|NCT02083770|Behavioral|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
79385666|NCT04729504|Behavioral|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
80012408|NCT02228330|Procedure|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
79385667|NCT04722666|Drug|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
80012409|NCT04524715|Device|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
80012410|NCT04524715|Device|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
80012411|NCT02083848|Other|7T MRI|Ultra high field magnetic resonance imaging
79699031|NCT03454100|Behavioral|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
79699032|NCT03454061|Other|physical activity|Physical education program (PEP) of 16-week length
79699033|NCT00579267|Other|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
79699034|NCT03453983|Device|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
79699035|NCT04593017|Dietary Supplement|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
79699036|NCT04593017|Other|Placebo Probiotic|Placebo
79699037|NCT03453294|Device|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
79699038|NCT03453294|Device|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
79699039|NCT04578054|Other|Flying transport|Patient care who requires flying transport
79699040|NCT04592666|Drug|Almonertinib|the standard therapy of single agent almonertinib
79699041|NCT04592666|Drug|Pemetrexed|standard dose
79699042|NCT04592666|Drug|Carboplatin|AUC=5
79699043|NCT04577937|Diagnostic Test|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
79699044|NCT04592939|Procedure|immediate weight bearing after surgery|immediate weight bearing
79699045|NCT04592939|Procedure|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
79699046|NCT00579462|Other|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
79842692|NCT00784316|Drug|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
80012412|NCT04933370|Other|Stimulation parameters|Different device stimulation parameters
80012413|NCT02223728|Behavioral|Lifestyle|
79385668|NCT04722666|Drug|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
79385669|NCT04715555|Device|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
79385670|NCT04715555|Device|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
79385671|NCT04715555|Device|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
79385672|NCT04715555|Other|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
79385673|NCT04711109|Drug|Denosumab|Given SC
79699047|NCT00579540|Dietary Supplement|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
79699048|NCT00579540|Dietary Supplement|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
79699049|NCT00579540|Dietary Supplement|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
79699050|NCT00579618|Other|Saliva or Blood samples|Extracting sample of saliva or blood only once.
79699051|NCT04592315|Drug|Lipovirtide Injection|Single dosage of Lipovirtide Injection
79699052|NCT00579657|Other|control diet, supported by dietary supplement twice daily|control diet, see above
79699053|NCT00579657|Other|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
79699054|NCT00579657|Other|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
80012414|NCT02223728|Behavioral|Health Education|
79540647|NCT01483235|Behavioral|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
79699055|NCT00579657|Other|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
80012415|NCT02079402|Drug|Isotonic crystalloids|
79699056|NCT04592198|Drug|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
79246951|NCT03138044|Procedure|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
79699057|NCT04592198|Drug|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
79699058|NCT04592198|Drug|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
79699059|NCT04592432|Other|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
79699060|NCT04592432|Other|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
79699061|NCT00579774|Other|Low AGE Diet|Diet
79699062|NCT00579774|Other|Regular Diet|Diet
79699063|NCT04592354|Dietary Supplement|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
79699064|NCT04592081|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
79699065|NCT00579852|Procedure|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
79842693|NCT04040556|Other|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
79842694|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
79842695|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
79842696|NCT00286429|Drug|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
79842697|NCT00665444|Drug|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
79246952|NCT03602963|Device|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
79385674|NCT04711109|Drug|Placebo|Given SC
79385675|NCT04711109|Other|Quality-of-Life Assessment|Ancillary studies
79385676|NCT04705896|Biological|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
79385677|NCT04705896|Other|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
79385678|NCT04702997|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
80012416|NCT02591953|Procedure|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
79385679|NCT04702997|Drug|Placebo oral capsule|Capsule containing an inert placebo
79385680|NCT04684979|Biological|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
80012417|NCT02591953|Procedure|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
80012418|NCT02591953|Drug|Methylprednisolone|Corticosteroid used in injection (40 mg)
80012419|NCT02591953|Drug|Lidocaine 1%|Anesthesic used in injection
80016953|NCT00123968|Biological|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
79540648|NCT01483235|Behavioral|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
79540649|NCT01483248|Biological|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks."
79540650|NCT01483248|Drug|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
79699066|NCT04591964|Combination Product|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
80012420|NCT01938495|Device|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
79540651|NCT01483261|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
79540652|NCT01483274|Biological|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
79842698|NCT00860418|Behavioral|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
79842699|NCT00860418|Behavioral|Standard asthma education|Standard asthma education during 2 home visits.
79842700|NCT00867906|Biological|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
79842701|NCT00867906|Biological|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
79842702|NCT00864006|Drug|Divalproex Sodium|
79842703|NCT00864006|Drug|Depakote DR Tablets|
79842704|NCT02554448|Other|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
80012421|NCT02223806|Behavioral|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
79246953|NCT03580551|Behavioral|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
79385681|NCT04684979|Biological|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
79385682|NCT04668300|Biological|Durvalumab|Given IV
79385683|NCT04668300|Biological|Oleclumab|Given IV
79385684|NCT04666038|Drug|LOXO-305|Oral LOXO-305
79699067|NCT04592042|Behavioral|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
79699068|NCT04591769|Device|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
79699069|NCT04591847|Drug|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
79699070|NCT04591847|Drug|Placebo drug|Placebo drugs 1 tab oral weekly
79699071|NCT00580086|Other|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
79842705|NCT02544126|Device|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
80012422|NCT02223806|Behavioral|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
80012423|NCT02084004|Drug|Bifidobacterium viable pharmaceutics|
79385685|NCT04666038|Drug|Idelalisib|Oral
79385686|NCT04666038|Drug|Bendamustine|IV
80012424|NCT02084004|Drug|Berberine Hydrochloride|
80012425|NCT02223884|Drug|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
80012426|NCT02223884|Drug|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
80012427|NCT02079480|Drug|BMS-986090|
79385687|NCT04666038|Drug|Rituximab|IV
79385688|NCT04662827|Dietary Supplement|Palmithylethanolamid|PEA 3x/d
79385689|NCT04662827|Other|placebo|placebo 3x/d
79699072|NCT04591535|Drug|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
79540653|NCT01483287|Dietary Supplement|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
79699073|NCT00580242|Drug|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
79842706|NCT02544126|Behavioral|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
79842707|NCT00794612|Drug|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
79842708|NCT00794690|Drug|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
79246954|NCT03580551|Behavioral|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
79246955|NCT05737472|Dietary Supplement|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
79246956|NCT05737472|Dietary Supplement|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
79246957|NCT03602807|Device|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
79246958|NCT03356769|Drug|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
79246959|NCT03356769|Drug|AED|maintain the dosages and the drugs throughout the 3-month observation time
79246960|NCT03356769|Drug|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
79246961|NCT03136952|Device|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
79385690|NCT04662125|Drug|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
79385691|NCT04662125|Drug|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
79385692|NCT04662125|Drug|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
79540654|NCT01483300|Drug|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
79540655|NCT01483300|Drug|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
79540656|NCT01483339|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
79540657|NCT01483339|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
79540658|NCT01483365|Drug|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
79699074|NCT00580242|Drug|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
79699075|NCT00580242|Drug|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
79699076|NCT00580242|Drug|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
79699077|NCT04591496|Behavioral|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
80012428|NCT02079480|Drug|Placebo matching with BMS-986090|
80012429|NCT02079480|Drug|Keyhole limpet hemocyanin|
80012430|NCT02569489|Drug|HBI-8000|
80012431|NCT02569489|Drug|Trastuzumab|
80012432|NCT02569489|Drug|Paclitaxel|
80012433|NCT02079558|Drug|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
79699078|NCT04591496|Behavioral|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
79699079|NCT00580281|Other|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
79699080|NCT04591457|Drug|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
79699081|NCT04591457|Drug|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
79699082|NCT00580320|Drug|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
79699083|NCT00567086|Drug|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
79699084|NCT00580359|Drug|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
79699085|NCT04591340|Dietary Supplement|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
79699086|NCT04591418|Device|Rotary handpieces|Dental Caries removal
79699087|NCT04591418|Device|Er:YAG laser|Dental Caries removal
79842709|NCT00860496|Drug|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
79842710|NCT00860496|Drug|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
79842711|NCT00864162|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
79246962|NCT03602729|Other|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
79699088|NCT00580593|Device|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
79699089|NCT00580593|Other|sham-NIPPV|a sham-device
79842712|NCT00864162|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
79842713|NCT00787826|Biological|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
79842714|NCT00795314|Drug|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
79246963|NCT05737394|Procedure|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
79246964|NCT05737394|Procedure|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
79540659|NCT01483391|Behavioral|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
79699090|NCT04591145|Other|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
79540660|NCT01483391|Behavioral|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
79699091|NCT00580749|Procedure|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
79699092|NCT00580749|Procedure|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
79699093|NCT04591301|Drug|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
79699094|NCT04591301|Drug|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
79699095|NCT04577625|Dietary Supplement|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
79699096|NCT00580827|Drug|Placebo|Matched placebo.
79699097|NCT00580827|Drug|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
79540661|NCT01483404|Procedure|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
79699098|NCT00580827|Drug|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
79699099|NCT00580827|Drug|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
79842715|NCT00795314|Drug|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
79246965|NCT03356691|Other|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~Prayer: for 1 to 2 minutes.~Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~Spiritist passe, for 2-min.~Fluid therapy."
79842716|NCT03926169|Drug|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
79842717|NCT03926169|Drug|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
79842718|NCT00860808|Drug|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
80012434|NCT02079558|Drug|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
79699100|NCT00580905|Drug|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
79699101|NCT00580905|Drug|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
79699102|NCT00580905|Drug|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
79699103|NCT00581022|Procedure|Polysomnography|Overnight Sleep Study
79699104|NCT04577664|Procedure|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
79699105|NCT04577664|Procedure|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
79699106|NCT04591262|Drug|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
79699107|NCT04591262|Drug|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
79699108|NCT04591262|Drug|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
79699109|NCT00567203|Drug|PF-3463275|PF-3463275 10mg
79842719|NCT00787982|Device|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
79842720|NCT00285649|Other|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
79842721|NCT00285649|Other|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
80012435|NCT03629821|Other|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
79246966|NCT03356691|Other|Prayer|Individuals will receive prayer during 1 to 2 minutes.
79246967|NCT03356691|Other|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
79842722|NCT00285649|Other|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
79246968|NCT03356691|Other|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
79246969|NCT03356691|Other|Fluid therapy.|Individuals will receive fluid therapy.
79385693|NCT04654689|Dietary Supplement|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
79540662|NCT01483417|Procedure|Single incision Laparoscopic hysterectomy|SILS port
80012436|NCT04058379|Radiation|CT scan|3 ct scans : D0, D1 and D3
79540663|NCT01483417|Procedure|Conventional laparoscopic hysterectomy|3-4 conventional ports
79699110|NCT00567203|Drug|PF-3463275|PF-3463275 25mg
79699111|NCT00567203|Drug|Placebo|Placebo
79699112|NCT04590989|Other|Personalized Nutrition Plan|"Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~Personalized behavioral change program via electronic push notifications by ONMI"
79699113|NCT04590989|Other|Non-Personalized Nutrition Plan|"Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
80012437|NCT04057755|Drug|botulinum toxin A|
80012438|NCT04057755|Drug|NaCl|
80012439|NCT02139709|Dietary Supplement|Ganglioside|
80012440|NCT02139709|Dietary Supplement|Placebo|
79246970|NCT03356691|Other|No-fluid therapy.|Individuals will receive no-fluid therapy.
79246971|NCT03602651|Other|Hamilton-anxiety scale (HAM-A)|Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
79385694|NCT04654689|Other|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
79385695|NCT04654689|Dietary Supplement|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
79385696|NCT04654689|Drug|G04CB02|G04CB02, in a single daily dose for 4 months
79385697|NCT04654689|Other|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
79385698|NCT04606966|Other|Therapeutic Horseback Riding|Horse therapy
79385699|NCT04606966|Other|Barn Activity|Horsemanship group
79385700|NCT04606966|Other|Hybrid|Ground and riding activities
79385701|NCT04604275|Drug|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
79540664|NCT01483430|Drug|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
79540665|NCT01483430|Drug|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
79540666|NCT01483430|Drug|Placebo|1 capsule/day (starch), Duration: 8 weeks
79540667|NCT01483443|Procedure|Oophrectomy|Both oophrectomy
79699114|NCT04590638|Other|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
79699115|NCT04590638|Other|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
79699116|NCT04590950|Other|Non interventional study|Non interventional study
79699117|NCT04590677|Other|Samples required from group 1 (procedure within observational study)|"Weekly maternal blood samples to be taken~Daily urine samples to be collected~One rectal swab at the initial visit only~Weekly vaginal swabs~Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
79699118|NCT04590677|Other|Samples required from group 2 (procedure within observational study)|"Weekly maternal blood samples to be taken~Daily urine samples to be collected~One rectal swab at the initial visit only~Weekly vaginal swabs"
79699119|NCT04590755|Behavioral|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
79699120|NCT00567281|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
79699121|NCT00567281|Device|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
79842723|NCT00864240|Drug|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
79842724|NCT00795392|Other|ASA scale|ASA scale evaluation before operation
79842725|NCT00795392|Other|Full-scale psychological assessment|Full-scale psychological evaluation before operation
79842726|NCT02554370|Behavioral|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
79849010|NCT05645146|Behavioral|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
79246972|NCT05737316|Behavioral|Combat PD|CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
79246973|NCT05737316|Behavioral|Usual Care|Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
79246974|NCT02237963|Procedure|Posterolateral thoracotomy|
79246975|NCT02237963|Procedure|Axillary thoracotomy|
79246976|NCT04508439|Drug|Enoxaparin|Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
79540668|NCT01483456|Other|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~Identification of patient's fall risk,~Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~Get up workshop and morbidity and mortality conferences related to fall cases"
79540669|NCT01483469|Drug|RO4917523|orally daily, 14 days
79540670|NCT01483469|Drug|RO5011232|[11C]-RO5011232 intravenously
79540671|NCT01483482|Procedure|Conservative Treatment|Simple Sling
79540672|NCT01483482|Procedure|Surgical treatment|Superior Locking plate
79842727|NCT04018404|Other|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
79540673|NCT01483508|Other|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomer] and procyanidins [dimers to decamers]
79842728|NCT04936880|Device|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
79246977|NCT04088552|Other|"Go4Life-Physical Activity/Exercise Program Workout to Go 5"|"The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen."
79842729|NCT04936880|Drug|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
79246978|NCT04088552|Behavioral|ActuaYa Educational Sessions|The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
79385702|NCT04604275|Other|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
79385703|NCT04594876|Other|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
79385704|NCT04579848|Drug|Methotrexate Tablets|Methotrexate 2.5mg oral tablet.
79385705|NCT04579848|Drug|Placebo|Placebo capsule
79385706|NCT04579848|Drug|Folic Acid 1 MG|Folic acid
79385707|NCT04556201|Device|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
79385708|NCT04555317|Combination Product|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
79385709|NCT04548154|Other|Proximal Resistance Training|Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
79385710|NCT04523350|Device|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
79385711|NCT04523350|Other|TAE or cTACE|Bland TAE or cTACE
79385712|NCT04516538|Behavioral|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
79385713|NCT04516538|Diagnostic Test|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
79540674|NCT01483508|Other|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins [dimers to decamers]
79540675|NCT01483508|Other|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomers]
79540676|NCT01483521|Other|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
79842730|NCT00979641|Drug|Docetaxel|
79842731|NCT00864318|Drug|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
79842732|NCT00864318|Drug|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
79849011|NCT05635123|Other|No intervention|This is a prospective observational study with no intervention.
79849012|NCT05628636|Drug|AC-OLE-01-VA|formulation of tricaprilin
80012441|NCT03669315|Device|Transcranial Magnetic stimulation|Neuromodulation tool
79540677|NCT01483534|Device|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
79540678|NCT01483547|Device|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
79540679|NCT01483573|Other|neural mobilization|stretch the nerve
79540680|NCT01483573|Other|straight leg raise|stretch the hamstring
79540681|NCT01483586|Drug|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
79699122|NCT00567437|Other|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
79842733|NCT00864318|Drug|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
79842734|NCT00864318|Drug|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
79246979|NCT02237573|Other|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~a detailed report of the consultation (motive, case history, clinical examination, conclusion)~written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
79246980|NCT02237573|Other|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
79246981|NCT04508595|Diagnostic Test|RestEaze|Wearable band to detect leg movements of sleep
79246982|NCT02237651|Device|topical anesthesia multi-use device|
79246983|NCT02237651|Device|topical anesthesia Intranasal Mucosal Atomization|
79246984|NCT03356613|Other|Focus group|An researcher in psychology will lead focus group on research views for paramedical staff
79246985|NCT03356613|Other|test of the Geni tool|The GenI tool built on paramedic's view will be tested.
79246986|NCT02237729|Biological|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
79246987|NCT02237729|Biological|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
79246988|NCT02237729|Biological|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
79246989|NCT02238041|Device|GlucoClear System|
79246990|NCT04508127|Device|Spinal cord stimulation|
79385714|NCT04516538|Diagnostic Test|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
79385715|NCT04516538|Diagnostic Test|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
79540682|NCT01483586|Drug|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
79540683|NCT01483638|Drug|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
79540684|NCT01483638|Drug|placebo|will be administered orally with the same schedule of axitinib
79540685|NCT01483677|Other|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
79540686|NCT01483677|Other|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
79391474|NCT03177954|Behavioral|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
79540687|NCT01483716|Behavioral|Rehabilitation|
79540688|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
79540689|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
79246991|NCT02238119|Drug|Tiotropium + formoterol combination|
79246992|NCT02238119|Drug|Tiotropium|
79246993|NCT02238119|Drug|Formoterol|
79540690|NCT01483729|Drug|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
79540691|NCT01483729|Drug|ritonavir|Test Formulation 1, single oral dose
79540692|NCT01483729|Drug|ritonavir|Test Formulation 2, single oral dose
79699123|NCT00567515|Device|AtriCure LAA Exclusion System|Placement of clip of LAA.
79699124|NCT04577703|Drug|CT053PTSA|CT053PTSA will be administered daily in fasting state
79699125|NCT04577586|Other|oral contrast|negative oral contrast utilization in PET/CT studies
79699126|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel|
79699127|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
79699128|NCT00567554|Drug|paclitaxel|
79699129|NCT00567554|Drug|paclitaxel + everolimus (RAD001)|
79699130|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
79699131|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + lapatinib|
79842735|NCT00864318|Procedure|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
79842736|NCT00788060|Drug|Everolimus (RAD001)|5mg per day, continuously
79842737|NCT00788060|Drug|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
79842738|NCT00788138|Dietary Supplement|Vitamin D3|250,000 IU of vitamin D3
79842739|NCT00788138|Dietary Supplement|Placebo|Matching Placebo
79842740|NCT00864396|Drug|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
79849013|NCT05612412|Other|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
79842741|NCT00745823|Drug|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
79842742|NCT00745823|Drug|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
79842743|NCT00745823|Drug|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
79246994|NCT03598985|Diagnostic Test|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
79246995|NCT04508205|Drug|CGB-400|BID application
79246996|NCT03598907|Other|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
79246997|NCT03354117|Drug|Ulipristal Acetate 30 MG Oral Tablet|Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
79246998|NCT03360981|Drug|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
79391475|NCT02412774|Behavioral|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
79540693|NCT01483729|Drug|ritonavir|Reference Formulation, single oral dose
79540694|NCT01483755|Procedure|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
79540695|NCT01483755|Procedure|Percutaneaous intervention|Conventional primary percutaneaous intervention
79540696|NCT01483768|Procedure|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
79540697|NCT01483781|Drug|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
79699132|NCT04577469|Drug|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
79699133|NCT04577469|Drug|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
79699134|NCT04590911|Behavioral|Cognitive Enrichment Program (CEP)|Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
79699135|NCT04577508|Behavioral|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
79699136|NCT04577508|Other|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
79699137|NCT04590716|Other|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
79842744|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
79842745|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
79842746|NCT00979797|Other|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
79842747|NCT04090073|Procedure|Electroacupuncture|As above
79842748|NCT04090073|Other|Fast-track Perioperative program|As above
79842749|NCT00980031|Drug|Eplerenone|25mg PO daily (QD)for 6 months
79842750|NCT00980031|Drug|Lactose Tablet|Lactose tablet
79842751|NCT02595671|Other|Digital Super Coach|Receive Digital Super Coach during 12 weeks
79842752|NCT02595671|Other|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
79391476|NCT02412774|Behavioral|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
79842753|NCT02595671|Other|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
79246999|NCT03597815|Drug|Aflibercept 40 MG/ML [Eylea]|Intravitreal injection, form of anti-VEGF therapy
79247000|NCT03597815|Diagnostic Test|OSA diagnostic test - overnight sleep study|Overnight with specialist care in hospital - heart, lung and brain activity monitored.
79842754|NCT02595671|Other|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
79842755|NCT02598401|Other|observation|Observational study with no intervention
79849014|NCT05612412|Other|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
79849015|NCT05612074|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
79699138|NCT04577742|Radiation|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
79842756|NCT00976287|Procedure|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
79247001|NCT03597815|Device|CPAP therapy for OSA positive patients|positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
79247002|NCT03360825|Device|TetraGraph|The TetraGraph is a dedicated neuromuscular stimulator / recorder intended to evoke, record, and analyze muscle action potentials during surgical procedures
79247003|NCT02876315|Dietary Supplement|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
79247004|NCT02876315|Dietary Supplement|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
79247005|NCT03356457|Drug|Dichloroacetate|Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
79247006|NCT03356457|Drug|Placebo oral capsule|A Placebo oral capsule identical in shape and color to those with active ingredient.
79247007|NCT03597425|Procedure|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation (CPR) is an emergency treatment for patients with respiratory arrest and cardiac arrest in an attempt to restore the patient to spontaneous breathing and heartbeat through cardiopulmonary resuscitation
79247008|NCT03356379|Diagnostic Test|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
79247009|NCT03595241|Device|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
79247010|NCT03595085|Procedure|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
79247011|NCT03595085|Drug|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
79385716|NCT04516538|Diagnostic Test|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
79540698|NCT01483781|Drug|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
79540699|NCT01483833|Drug|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
79540700|NCT01483833|Drug|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
79540701|NCT01483846|Drug|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
79540702|NCT01483846|Drug|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
79540703|NCT01483859|Other|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
79540704|NCT01483885|Device|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
79540705|NCT01483885|Device|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
79540706|NCT01483885|Procedure|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
79540707|NCT01483911|Biological|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
79699139|NCT04590560|Diagnostic Test|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
79842757|NCT00976287|Procedure|Conserved Therapy|Conserved Therapy
79699140|NCT04590482|Drug|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
79842758|NCT00976365|Dietary Supplement|THL-P|20ml/bottle, TID, 24weeks
79540708|NCT01483911|Biological|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
79247012|NCT04507971|Biological|MET-3|Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
79540709|NCT01483976|Other|Oral medical nutritional supplement|orally over a three hour period
79540710|NCT01483976|Other|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
79842759|NCT02596529|Device|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
79247013|NCT03356301|Device|Cardiac MRI|Non injected cardiac MRI exam
79247014|NCT03356301|Device|Applanation tonometry|Applanation tonometry and ECG
79247015|NCT03594851|Behavioral|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
79385717|NCT04516538|Diagnostic Test|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
79385718|NCT04462159|Behavioral|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
79540711|NCT01483989|Other|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
79842760|NCT02596529|Other|NO Fixation|NO Fixation of the posterior malleolus.
79842761|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
79385719|NCT04449991|Procedure|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI > 3
79540712|NCT01484002|Device|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
79540713|NCT01484015|Drug|cefepime hydrochloride|Given IV
79540714|NCT01484067|Device|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
79540715|NCT01484080|Drug|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
79540716|NCT01484080|Drug|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
79842762|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
79842763|NCT00663260|Drug|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
79842764|NCT00980109|Drug|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
79842765|NCT00980109|Drug|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
79842766|NCT00980109|Drug|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
79842767|NCT00980109|Drug|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
79842768|NCT00740597|Genetic|gene expression analysis|
79540717|NCT01484106|Other|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
79540718|NCT01484106|Other|Standard of Care|Standard of Care
79540719|NCT01484145|Drug|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
79540720|NCT01484171|Drug|idarubicin|idarubicin 10-12 mg/m2 for three days
79699141|NCT04590482|Drug|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
79699142|NCT00581217|Other|Aquacel Ag|Aquacel Ag will be applied to one donor site.
79699143|NCT00581217|Other|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
79842769|NCT00740597|Genetic|polymerase chain reaction|
79842770|NCT00740597|Genetic|western blotting|
79842771|NCT00740597|Procedure|neoadjuvant therapy|
79699144|NCT00581295|Device|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
79699145|NCT04589858|Other|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
79540721|NCT01484171|Biological|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
79699146|NCT04589858|Other|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
79699147|NCT00567671|Procedure|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
79699148|NCT00567671|Procedure|Sham comparator|Sham treatment
79699149|NCT00581451|Drug|bifeprunox|oral tablet once daily
79247016|NCT03594851|Behavioral|Sleep diary|A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
79247017|NCT03594851|Behavioral|Katz Index of Independence in Activities of Daily Living|Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
79247018|NCT03594851|Behavioral|Lawton Instrumental Activities of Daily Living|"Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers."
79699150|NCT04589936|Procedure|Prone positioning|Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
79385720|NCT04445662|Behavioral|Financial incentives|Escalating financial rewards for saliva cotinine levels <30 ng/mL, assessed 10 times over 12 weeks
79385721|NCT04445662|Drug|Varenicline|"Day 1 - 3: 0.5 mg daily~Day 4 - 7: 0.5 mg twice daily~Day 8 - Week 12: 1 mg twice daily~Dose/schedule may be adjusted based on medical history and clinician judgement"
79540722|NCT01484184|Drug|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
79699151|NCT04577196|Other|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
79699152|NCT04590053|Biological|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
79699153|NCT00567710|Drug|BL - 1020|10 mg/day
79699154|NCT00567710|Drug|BL - 1020|BL 1020 20-30 mg/day
79699155|NCT00567710|Drug|Placebo|Capsules
79699156|NCT00567710|Drug|Risperidone|Capsules
79842772|NCT00740597|Procedure|therapeutic conventional surgery|
79842773|NCT00740597|Radiation|intensity-modulated radiation therapy|
79842774|NCT00976443|Drug|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
79842775|NCT00976443|Drug|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
79842776|NCT00800618|Drug|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
79385722|NCT04445662|Behavioral|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
79385723|NCT04440670|Biological|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
79385724|NCT04440670|Biological|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
79385725|NCT04435834|Drug|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
79385726|NCT04429958|Other|GDM|different degrees of hyperglycaemia during pregnancy
79385727|NCT04428190|Dietary Supplement|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
79385728|NCT04428190|Other|Placebo|Sachet manufactured to mimic 10g of HMO
79540723|NCT01484223|Behavioral|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
79247019|NCT03594851|Behavioral|Neuropsychiatric Inventory (Cummings)|"Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease."
79385729|NCT04423874|Behavioral|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
79699157|NCT04590131|Procedure|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
79842777|NCT00800618|Drug|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
79842778|NCT00800618|Drug|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
79385730|NCT04423874|Diagnostic Test|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
79540724|NCT01484249|Device|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
79842779|NCT00800618|Drug|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
79842780|NCT00800618|Drug|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
79842781|NCT00800696|Procedure|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
79842782|NCT00980187|Drug|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
79842783|NCT00980187|Drug|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
79842784|NCT00795470|Drug|Antimicrobial|Appropriate antimicrobial based on urine culture results
79247020|NCT03594851|Behavioral|Mini Zarit Caregiver Burden Scale, for the caregiver|Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
79385731|NCT04423874|Behavioral|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
79385732|NCT04423874|Diagnostic Test|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
79385733|NCT04369612|Procedure|Standard follow-up|Standard post-transplant follow-up
79540725|NCT01484262|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
79540726|NCT01484262|Drug|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
79842785|NCT00795470|Device|Catheter change|Change urine catheter
79842786|NCT00980421|Dietary Supplement|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
79842787|NCT00284089|Drug|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
79842788|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
79842789|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
79842790|NCT00984633|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
79842791|NCT00984633|Drug|Propofol|4-10 mg/kg/hr maintenance anesthesia
79842792|NCT03975751|Diagnostic Test|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
79849016|NCT05600582|Biological|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
79842793|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg [3.7 MBq/kg] (minimum dose 1mCi [37MBq] but not to exceed 5 mCi [185 MBq]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
80012442|NCT04527367|Procedure|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
80012443|NCT03669003|Biological|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
79842794|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed > 23 Gy to the kidneys, > 30 Gy to the liver, or > 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
79842795|NCT00976755|Drug|everolimus|"Everolimus:~10mg daily"
80012444|NCT03669003|Procedure|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
79247021|NCT03594851|Behavioral|Mini Mental state examination|"It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975"
79247022|NCT03594851|Behavioral|Cornell Scale for Depression in Dementia|The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
79385734|NCT04369612|Procedure|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
79385735|NCT04354012|Combination Product|methylene blue, gentian violet, and ovine forestomach wound dressings|"Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use."
79385736|NCT04352400|Drug|Nafamostat Mesilate|administered intravenously as a continuous infusion
79842796|NCT00864474|Drug|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
79842797|NCT00283387|Drug|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
79842798|NCT00283387|Drug|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
79385737|NCT04352400|Drug|Placebo|administered intravenously as a continuous infusion
79540727|NCT01484353|Behavioral|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
79842799|NCT00788216|Other|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
79842800|NCT00976833|Other|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
79842801|NCT00976833|Other|Usual Care|Usual Physical Therapy care
79842802|NCT00788294|Biological|tanezumab|Drug solution given intravenously only once at dose of 10 mg
79842803|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
80012445|NCT04429399|Other|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
80012446|NCT04429399|Other|mechanical features assessment|evaluation of the mechanical features of respiratory system
80012447|NCT04429399|Other|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
80012448|NCT05763745|Diagnostic Test|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
80012449|NCT04313959|Drug|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
80012450|NCT04313959|Drug|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
80012451|NCT03073213|Drug|Ixekizumab|Administered as subcutaneous (SC) injection
80012452|NCT03070483|Drug|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
80012453|NCT04386187|Other|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
80012454|NCT04386187|Other|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
79699158|NCT04590131|Procedure|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
79699159|NCT04589975|Procedure|laparoscopic surgery|
79699160|NCT04589429|Drug|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
79699161|NCT04589429|Drug|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
79699162|NCT04577118|Device|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
79699163|NCT04589390|Drug|Selexipag|treatment with selexipag
79699164|NCT04577040|Drug|Tadalafil 5mg|Drugs
79699165|NCT04577235|Other|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
79842804|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
79842805|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
79842806|NCT00795548|Drug|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
79842807|NCT00980577|Device|NUUS|Sonosite Micro Maxx
80012455|NCT04386187|Other|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
80012456|NCT04107727|Drug|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
80012457|NCT04107727|Drug|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
80012458|NCT04107727|Drug|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
80012459|NCT04107727|Drug|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
79699166|NCT04589000|Other|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
79699167|NCT04594668|Drug|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
80012460|NCT05763433|Other|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
80012461|NCT01074151|Drug|duloxetine|any exposure to duloxetine that occurred during pregnancy
79247023|NCT03594851|Behavioral|Quality of Life in Alzheimer's Disease|The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses & includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
79247024|NCT00158756|Biological|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
79699168|NCT04589234|Drug|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
79699169|NCT04589234|Drug|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
79842808|NCT00282919|Drug|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
79842809|NCT00800774|Procedure|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
79842810|NCT00984789|Drug|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
79842811|NCT00984789|Drug|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
79247025|NCT00158756|Biological|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
79699170|NCT04589234|Drug|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
79699171|NCT03453177|Drug|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
79699172|NCT03453177|Procedure|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
79699173|NCT03453177|Procedure|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
79540728|NCT01484366|Procedure|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
79699174|NCT04588961|Procedure|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
79699175|NCT04588961|Procedure|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
79699176|NCT04594629|Drug|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
79699177|NCT04594629|Drug|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
79699178|NCT04589078|Device|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
79699181|NCT04588844|Drug|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
79699182|NCT04588532|Drug|BAM8-22|Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
80012462|NCT05762809|Diagnostic Test|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
79247026|NCT00158756|Biological|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
79247027|NCT00158756|Biological|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
79385738|NCT04351698|Drug|Montelukast|Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.
79385739|NCT04351698|Other|Oral Placebo|Inert chewable tablet with no therapeutic value
79540729|NCT01484366|Procedure|plating|Surgical plating of both bonforearm fractures
79540730|NCT01484379|Procedure|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
79540731|NCT01484405|Procedure|posterior approach|Surgical approach for Total Hip Arthroplasty
79247028|NCT00158756|Biological|Engerix™-B|GSK Biologicals' hepatitis B vaccine
79247029|NCT00158756|Drug|Placebo|Placebo for the Rotarix™ vaccine
79247030|NCT03353883|Drug|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
79247031|NCT03360669|Other|Sequence: Clinical/Research|Participants will be assigned to a sequence of: research visit first/clinical visit second.
79247032|NCT03360669|Other|Sequence: Research/Clinical|Participants will be assigned to a sequence of: clinical visit first/research visit second.
79385740|NCT04349059|Other|Animal based diet|Food will be provided by Montefiore-Einstein Food Services
79385741|NCT04349059|Other|Plant based diet|Food will be provided by Montefiore-Einstein Food Services
79385742|NCT04341623|Other|Cetaphil Pro Eczema moisturizer|All 30 patients to receive
79385743|NCT04341623|Behavioral|Electronic interaction|10 patients to electronic surveys about moisturizer use
79385744|NCT04341623|Behavioral|GPSkin|Measuring moisture in the skin
79385745|NCT04339699|Device|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
79385746|NCT04339699|Device|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
79385747|NCT04326192|Device|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
79540732|NCT01484405|Procedure|anterolateral approach|anterolateral surgical approach
79540733|NCT01484418|Behavioral|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
79540734|NCT01484418|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
79699183|NCT04588532|Drug|Histamine|histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
79699184|NCT04588532|Drug|Cowhage (Mucuna Pruriens)|cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
79699185|NCT04588532|Drug|Doxepin|Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
79699186|NCT04594083|Device|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
79699187|NCT04594083|Device|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
79699188|NCT04588454|Other|18F-PSMA-1007 PET tracer|18F-PSMA-1007 PET/CT
79842812|NCT00864552|Drug|Kogenate (BAY14-2222)|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
79842813|NCT03975673|Procedure|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
79247033|NCT03110276|Drug|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
79385748|NCT04306952|Behavioral|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
79385749|NCT04306952|Behavioral|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
79540735|NCT01484457|Device|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose < 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
79540736|NCT01484470|Biological|StemEx|"For patients allocated to StemEx® arm:~Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~Day 1: StemEx® transplantation.~Day 2 to 3 years: Post transplant follow-up."
79540737|NCT01484522|Biological|FluMist|Administered at the manufacture's recommended dose
79540738|NCT01484522|Biological|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
79540739|NCT01484522|Biological|Fluzone|Vaccine administered at manufacturer's recommended dose
79699189|NCT03453138|Device|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
79699190|NCT03453138|Device|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
79842814|NCT04046822|Drug|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
79842815|NCT04046822|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
79842816|NCT04007835|Drug|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
79842817|NCT05226936|Diagnostic Test|Cell free DNA analysis|samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)
79842818|NCT00795626|Behavioral|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
79842819|NCT00867984|Other|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
79247034|NCT03110276|Drug|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
79247035|NCT03356067|Procedure|Gastric endoscopic peroral pyloromyotomy|"G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~Mucosal incision at the greater curvature 3-5 cm from the pylorus~Submucosal tunnelling~Finding pyloric sphincter~Myotomy (2-3 cm) of the pyloric muscle~Incision closure (endoclips or suture device)"
79247036|NCT03356067|Procedure|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope
79247037|NCT03355989|Other|Conditional Cash Transfer|Conditional cash transfer provided via mobile airtime and easypaisa along with SMS reminders to increase immunization coverage and timeliness
79247038|NCT03355989|Other|SMS Reminder|Three SMS reminders for immunization provided before, at and after the due date respectively
79699191|NCT03453099|Other|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~An abbreviated version of the Caffeine Assessment Tool (CAT)~Sleep Questionnaire (SQ)~Surgical Fear Questionnaire (SFQ)~WHO Alcohol AUDIT Tool~WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
79699192|NCT03453099|Other|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
79699193|NCT04588415|Other|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
79842820|NCT00867984|Other|Usual Care|AV optimization (VTI) only
79540740|NCT01484535|Procedure|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
79842821|NCT00800930|Biological|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
79842822|NCT00800930|Biological|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
79385750|NCT04306952|Behavioral|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
79842823|NCT00868062|Other|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
79842824|NCT00282295|Biological|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
79842825|NCT00282295|Biological|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
79842826|NCT00742781|Dietary Supplement|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
79842827|NCT00663026|Drug|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
79247039|NCT04071782|Device|Drug Coated Balloon|SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
79247040|NCT03353727|Other|Orthoptic rehabilitation|Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
79842828|NCT00663026|Drug|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
79842829|NCT00663026|Drug|placebo|Placebo subcutaneous injection once per week for 6 months
79247041|NCT04034576|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
79842830|NCT00280735|Drug|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
80012463|NCT05762809|Diagnostic Test|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
79699194|NCT04594044|Behavioral|tics training including habit reversal training and exposure response prevention|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
79699195|NCT04588493|Diagnostic Test|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
79842831|NCT00280735|Drug|docetaxel|75 mg/m² intravenously, once, every 3 weeks
79842832|NCT02555462|Device|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
79842833|NCT00979719|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
79842834|NCT00979719|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
79247042|NCT03353649|Behavioral|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
79842835|NCT01070251|Behavioral|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
79842836|NCT01070251|Behavioral|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
80012464|NCT05762809|Diagnostic Test|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
79247043|NCT03353649|Device|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
79247044|NCT04519125|Drug|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
79385751|NCT04303013|Behavioral|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
79699196|NCT04577430|Drug|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
79699197|NCT04577430|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
79842837|NCT00801008|Behavioral|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
79842838|NCT03975283|Drug|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
79842839|NCT03975283|Drug|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
79247045|NCT04519125|Other|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
79247046|NCT03353571|Device|"C3 UMBRELLA CATHETER"|The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
79247047|NCT04519281|Drug|IV of vitamin C|administration of high-dose of IV vitamin C perioperatively
79247048|NCT03353493|Behavioral|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams & Teasdale (2013).
79842840|NCT00795782|Procedure|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
79842841|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
79842842|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
79247049|NCT03353493|Other|TAU|Treatment as usual (TAU)
79385752|NCT04303013|Other|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
79385753|NCT04300556|Drug|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
79385754|NCT04300556|Drug|Prednisone|Prednisone administered orally.
79385755|NCT04300556|Drug|Prednisolone|Prednisolone administered orally.
79699198|NCT04577430|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
79699199|NCT04577430|Drug|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
79699200|NCT00567788|Drug|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
79699201|NCT00567788|Drug|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
80012465|NCT05762809|Diagnostic Test|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
80012466|NCT05762809|Diagnostic Test|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
80012467|NCT05762809|Diagnostic Test|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
79247050|NCT03360435|Dietary Supplement|Patch MD MultiVitamin Plus patch|The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
79385756|NCT04300556|Drug|Dexamethasone|Dexamethasone administered orally.
79385757|NCT04298190|Behavioral|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
79699202|NCT04588766|Other|constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
79699203|NCT04588766|Other|control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
79699204|NCT00581607|Drug|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
79699205|NCT00581607|Drug|Placebo|Placebo twice a day
80012468|NCT05762809|Diagnostic Test|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
79699206|NCT00581607|Drug|Bosentan|drug given for 16 weeks
79699207|NCT00581607|Drug|Placebo|placebo
79842843|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
80012469|NCT05203783|Other|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~Prone-lying~Prone-extension~Prone press ups~Progressive extension with pillows~Standing extension"
79247051|NCT02730195|Drug|Pioglitazone|Given PO
79247052|NCT02730195|Drug|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
79247053|NCT03360357|Procedure|Guided drills|"These residents will perform 5 set of exercises:~Needle Dance (Learning to manipulate the suture)~Loopy Loop (Learning to place needle through a loop)~Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~Dense Matter (Passing the needle through dense material without losing control of the needle)~Respect for tissue (Passing the needle through flimsy material without tearing)"
79247054|NCT04444557|Other|Beck Depression Inventory (BDI)|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
79247055|NCT03353337|Behavioral|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
79247056|NCT03353337|Behavioral|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
79699208|NCT04588571|Procedure|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
79842844|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
79842845|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
79699209|NCT04588571|Procedure|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
79699210|NCT04594122|Behavioral|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
79699211|NCT00581646|Behavioral|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
79699212|NCT04588376|Behavioral|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
79699213|NCT00581685|Drug|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
79699214|NCT04588220|Other|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
79842846|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
79842847|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 8.
79842848|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 8.
79842849|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10^10vp at week 8.
79842850|NCT00801086|Drug|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
79247057|NCT03123159|Diagnostic Test|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
79540741|NCT01484535|Procedure|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
79699215|NCT00581724|Behavioral|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
79699216|NCT04588181|Behavioral|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
79699217|NCT00566787|Device|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
79699218|NCT04588064|Diagnostic Test|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
79842851|NCT00801086|Drug|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
79842852|NCT00788606|Drug|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
79842853|NCT00801164|Drug|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
79540742|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
79540743|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
79842854|NCT00801164|Drug|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
79247058|NCT03123237|Diagnostic Test|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.
79247059|NCT03360279|Device|Regular balloon|Randomization: to use regular balloon to treat stent graft restenosis
79540744|NCT01484548|Biological|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
79540745|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
79699219|NCT04587986|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
79699220|NCT04587401|Procedure|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
79842855|NCT00801320|Procedure|Tumor collection|Tumor collected at the time of planned surgery
79842856|NCT00795860|Behavioral|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
79247060|NCT03360279|Device|DCB (paclitaxel-coated balloon)|Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
79699221|NCT04587401|Procedure|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
79842857|NCT00795860|Behavioral|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
79385758|NCT04298190|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
79540746|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
79540747|NCT01484587|Drug|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
79540748|NCT01484587|Drug|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
79842858|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
79842859|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
79385759|NCT04295564|Other|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
79385760|NCT04291105|Biological|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
79540749|NCT01484600|Drug|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
79540750|NCT01484600|Drug|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
79540751|NCT01484613|Device|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
79540752|NCT01484639|Other|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
79540753|NCT01484639|Other|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
79540754|NCT01484665|Other|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
79540755|NCT01484717|Behavioral|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
79247061|NCT03353103|Drug|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
79247062|NCT03360123|Drug|Midazolam Hydrochloride 2Mg/mL Syrup|Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
79247063|NCT03360123|Drug|Triazolam 0.125 MG|Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
79385761|NCT04291105|Biological|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
79540756|NCT01484717|Drug|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)].
79540757|NCT01484717|Behavioral|Telephone counseling|Participants receive brief twice weekly telephone counseling.
79540758|NCT01484743|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
79842860|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
79247064|NCT04523415|Other|without intervention, just retrospectively review the data about patients|without intervention
79385762|NCT04264780|Other|Neuropsychological examination|Neuropsychological follow-up examination, including questionaires
79385763|NCT04255147|Biological|Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells|Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
79540759|NCT01484756|Dietary Supplement|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
79540760|NCT01484756|Dietary Supplement|Placebo|calcium carbonate 500 mg
79699222|NCT04587401|Procedure|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
79699223|NCT04587557|Behavioral|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
79247065|NCT03360045|Drug|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
79247066|NCT03360045|Drug|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
79247067|NCT03360045|Device|Merocel|Merocel packing is applied.
79385764|NCT04250194|Device|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
79385765|NCT04250194|Device|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
79385766|NCT04233346|Drug|Ponatinib|CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily. Other patients taken 45mg orally once daily.
79540761|NCT01484782|Behavioral|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
79540762|NCT01484795|Device|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
79699224|NCT04587557|Behavioral|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
79699225|NCT04587557|Other|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
79540763|NCT01484795|Device|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
79540764|NCT01484821|Device|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
79540765|NCT01484847|Drug|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
79699226|NCT04587557|Other|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
79699227|NCT00581841|Other|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
79699228|NCT04587362|Diagnostic Test|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
80016954|NCT03556254|Drug|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
79247068|NCT03123003|Device|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
79247069|NCT03123003|Device|Wrist X-ray|Bone age assessment by Wrist X-ray
79247070|NCT03123081|Procedure|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
79699229|NCT04594317|Device|low level laser therapy|buccal application of diode laser on non-contact mode
79247071|NCT04444089|Diagnostic Test|lung ultrasound|Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
79385767|NCT04229004|Drug|Gemcitabine combined with nab-paclitaxel|"Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- >10%. If the participant's weight changes by <10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
79540766|NCT01484860|Drug|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
79540767|NCT01484886|Other|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
79540768|NCT01484886|Other|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
79540769|NCT01484964|Drug|ASP015K|oral
79540770|NCT01484990|Drug|Levodopa-Carbidopa|Intestinal Gel
79540771|NCT01485003|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
79540772|NCT01485029|Procedure|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
79540773|NCT01485042|Drug|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
79540774|NCT01485068|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
79540775|NCT01485081|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
79699230|NCT04587596|Other|Pain education|70 minute lecture about chronic pain and one focus group afterwards
79699231|NCT04587713|Drug|TD-1473 [Tablet A]|TD-1473 [Tablet A] (1 Tablet = Dose A) proposed commercial tablet formulation
79699232|NCT04587713|Drug|TD-1473 [Tablet B]|TD-1473 [Tablet B] (2 Tablets = Dose A) current clinical tablet formulation
79699233|NCT04587011|Drug|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
79540776|NCT01485107|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
79540777|NCT01485146|Drug|ETC-1002|escalating doses
79699234|NCT04587011|Drug|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
79699235|NCT04587011|Drug|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
79699236|NCT04587011|Drug|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
80012470|NCT05203783|Other|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
79699237|NCT04587206|Drug|CKD-348|QD, PO
79699238|NCT04587206|Drug|CKD-828, D097, D337|QD, PO
79699239|NCT00581880|Behavioral|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
79699240|NCT00581958|Other|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
79699241|NCT04586816|Combination Product|1% red maple leaf extract in cream base|1% red maple leaf extract is combined in a cream base
79699242|NCT04586816|Combination Product|5% red maple leaf extract|5% red maple leaf extract is combined in a cream base
79699243|NCT04586816|Combination Product|vehicle|vehicle cream base only
79699244|NCT04593849|Other|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
79385768|NCT04229004|Drug|Dose -mFOLFIRINOX|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- >10%. If the participant's weight changes by <10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.
79385769|NCT04229004|Drug|Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel|"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
79540778|NCT01485159|Procedure|Spirometry|assessment of lung function by spirometry
79540779|NCT01485185|Drug|Gabapentin lower dose|Repeat, oral dose
79540780|NCT01485185|Drug|Donepezil|Repeat, oral dose
79540781|NCT01485185|Other|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
79540782|NCT01485185|Other|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
79540783|NCT01485185|Drug|Gabapentin higher dose|Repeat, oral dose
79699245|NCT04586543|Drug|Selegiline|10 mg selegiline tablet per day
79699246|NCT04586543|Drug|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
79699247|NCT00582192|Other|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
79540784|NCT01485198|Procedure|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
79540785|NCT01485198|Drug|Acetaminophen|Acetaminophen (750mg orally TID) administration
79699248|NCT04586777|Device|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
79699249|NCT04593576|Other|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
79699250|NCT04593576|Other|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
79699251|NCT04586738|Procedure|non-perforating deep sclerectomy surgery|Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
79699252|NCT04593693|Device|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
79699253|NCT04586582|Diagnostic Test|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
79699254|NCT00581568|Other|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
79699255|NCT04586465|Drug|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
79699256|NCT04586309|Behavioral|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~First Day of Verification of Correct Practice and Further Instruction.~Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
79699257|NCT04586192|Other|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
79699258|NCT04586192|Other|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
79699259|NCT00582387|Genetic|specimen samples|blood, urine and tissue
80012471|NCT02786329|Drug|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
80012472|NCT02786329|Drug|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
79247072|NCT04507737|Other|Rapid Response Team Composition_ ICU Nurse|In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
79540786|NCT01485211|Drug|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
79540787|NCT01485224|Drug|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
79699260|NCT00582387|Behavioral|questionnaires|
79699261|NCT04586114|Drug|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
79699262|NCT00566865|Drug|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
79699263|NCT00566865|Drug|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
79699264|NCT04585997|Drug|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
79699265|NCT04585997|Drug|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
79842861|NCT00260065|Drug|Decitabine|20mg/m^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
79842862|NCT00796094|Other|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
79247073|NCT03353025|Procedure|transsphenoidal surgery treatment|transsphenoidal surgery treatment
79247074|NCT03353025|Drug|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
79247075|NCT03355755|Device|EksoGT with SmartAssist software|Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
79247076|NCT03355677|Procedure|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
79247077|NCT03355677|Procedure|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
79247078|NCT03355677|Other|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
79699266|NCT04576845|Other|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
79699267|NCT04585880|Other|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
79842863|NCT01072435|Device|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
79842864|NCT01072435|Device|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
79842865|NCT01072513|Other|Semen analysis|Semen analysis before and after proton radiation therapy.
79842866|NCT00796172|Behavioral|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
79842867|NCT00796172|Behavioral|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
80012473|NCT02786329|Drug|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
80012474|NCT02786329|Drug|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
80016955|NCT03556254|Drug|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
79247079|NCT03355599|Other|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
79247080|NCT03359967|Drug|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
79247081|NCT04506957|Device|Pulse CO-Oximetry Hemoglobin measurement transcutaneous|this is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device
79385770|NCT04229004|Drug|Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine|"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
79699268|NCT04586036|Other|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
79699269|NCT04586036|Other|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
79385771|NCT04229004|Drug|Drug: Dose -SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
79385772|NCT04228731|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
79699270|NCT04586036|Other|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
79699271|NCT04586036|Other|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
79699272|NCT04586036|Other|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
79699273|NCT00582504|Biological|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
79699274|NCT04585568|Other|Biosensors|Measures of blood flow and preassures
79699275|NCT04593108|Device|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
79699276|NCT04593108|Drug|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
79842868|NCT01071655|Drug|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
79842869|NCT01071655|Drug|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
79842870|NCT00801476|Procedure|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
79842871|NCT02531581|Drug|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output <500cc
79842872|NCT02531581|Drug|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
79842873|NCT04046510|Drug|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
79842874|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
79842875|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
79699277|NCT04577391|Other|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
79699278|NCT04577391|Other|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
79699279|NCT04585412|Drug|Palonosetron|Pharmacokinetic study under fasting conditions
79699280|NCT04592796|Device|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
79699281|NCT04592796|Other|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
79699282|NCT04592796|Other|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
79699283|NCT04592796|Other|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
79699284|NCT04592796|Other|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
79699285|NCT04592796|Other|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
79699286|NCT04592796|Other|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
79699287|NCT00567866|Drug|Quetiapine|50 or 100 mg of quetiapine orally
79842876|NCT00788840|Drug|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
79247082|NCT03355521|Other|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
79540788|NCT01485237|Other|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
79699288|NCT00567905|Dietary Supplement|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
79385773|NCT04228731|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
79699289|NCT00582543|Other|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
79842877|NCT00788840|Drug|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
79842878|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
79842879|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
79540789|NCT01485276|Procedure|DBS Surgery|
79540790|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
79540791|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
79842880|NCT00742625|Drug|daunorubicin hydrochloride|Given IV
79385774|NCT04207931|Drug|Topical steroid class I-II|applied once daily - 18 month duration of the study
79385775|NCT04207931|Drug|Triamcinolone Acetonide|Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
79385776|NCT04207931|Drug|Doxycyline|oral antibiotic twice daily for 6 months
79540792|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
79540793|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
79540794|NCT01485328|Drug|AMARGOL®|per oral solution, 40 mL single dose
79540795|NCT01485341|Dietary Supplement|gluten|gluten is administered once a day at 10g/day for 15 days
79540796|NCT01485341|Dietary Supplement|rice starch|rice starch is administered once a day at 10 g/day for 15 days
79842881|NCT00742625|Drug|cytarabine|Given IV
79842882|NCT00742625|Drug|bortezomib|Given IV
79385777|NCT04207931|Drug|Minoxidil|5% solution or foam started after month 8
79385778|NCT04207723|Other|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
79385779|NCT04207723|Drug|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
79540797|NCT01485367|Drug|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand & extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand & extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right & left forearms.
79699290|NCT00567944|Device|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
79540798|NCT01485406|Biological|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
79540799|NCT01485406|Biological|Synflorix™|1 dose administered intramuscularly
79699291|NCT00567983|Drug|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
79699292|NCT00567983|Drug|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
79699293|NCT00582582|Drug|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
79699294|NCT00582582|Drug|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
79699295|NCT04585373|Other|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
79699296|NCT04585373|Other|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
79247083|NCT03355521|Other|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
79540800|NCT01485432|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
79540801|NCT01485445|Drug|Fluticasone Furoate (200mcg unit strength)|inhalation powder
79540802|NCT01485445|Drug|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
79540803|NCT01485458|Procedure|Early surgery|Surgery within 24 hours after admission
79699297|NCT04585373|Other|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
79699298|NCT04592601|Procedure|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
79842883|NCT00801710|Device|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
79842884|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
79842885|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
79842886|NCT01070485|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
79842887|NCT00618618|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79842888|NCT00618618|Drug|Placebo|
79247084|NCT03355443|Procedure|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
79247085|NCT03355443|Procedure|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
79247086|NCT04516395|Other|Combined antibiotic regimens|Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
79540804|NCT01485458|Procedure|Delayed surgery|Surgery more than 2 weeks after injury
79540805|NCT01485510|Behavioral|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
79540806|NCT01485510|Behavioral|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
79842889|NCT00796250|Biological|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
79247087|NCT04516395|Other|Standard antibiotic regimens|Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
79842890|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
79842891|NCT00796250|Drug|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
79842892|NCT00796250|Drug|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
79842893|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
79842894|NCT00796250|Biological|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
79842895|NCT01070563|Other|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
79842896|NCT01012726|Procedure|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
79842897|NCT00788918|Drug|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
79842898|NCT02596373|Drug|Mitoxantrone Hydrochloride Liposome Injection|
79842899|NCT00246805|Device|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
79247088|NCT04507035|Drug|Anlotinib hydrochloride capsules|Using anlotinib of 2 cycles as the first-line therapy.
79247089|NCT03352947|Drug|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
79247090|NCT03352947|Drug|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
79247091|NCT02730351|Drug|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
79247092|NCT02730351|Drug|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
79247093|NCT02730351|Drug|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
79385780|NCT04207177|Drug|Mycophenolate Mofetil 500 mg Tab|Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
79385781|NCT04207177|Drug|Tacrolimus capsule|Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
79385782|NCT04177628|Behavioral|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
79385783|NCT04173494|Drug|Momelotinib|Momelotinib tablets will be self-administered orally once daily
79385784|NCT04173494|Drug|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
79699299|NCT04584944|Radiation|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
79842900|NCT00801866|Drug|Bevacizumab|Intravitreal administration
79842901|NCT00801866|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation
79247094|NCT02730351|Drug|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
79247095|NCT04516083|Diagnostic Test|Mismatch repair instability somatic and germline testing|Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
79247096|NCT03359655|Drug|Misoprostol|Rectal administration 2 jours before the procedure
79247097|NCT03359655|Drug|Hyoscine butyl bromide|Rectal administration 2 jours before the procedure
79247098|NCT03359577|Dietary Supplement|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
79247099|NCT03359577|Dietary Supplement|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
79385785|NCT04173494|Drug|Danazol|Danazol capsules will be self-administered orally twice daily
79247100|NCT03355287|Other|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
79385786|NCT04173494|Drug|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
79699300|NCT04592718|Behavioral|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
79699301|NCT04592718|Behavioral|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
79699302|NCT04584905|Dietary Supplement|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
79699303|NCT00566904|Drug|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
79247101|NCT03355287|Other|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
80012475|NCT05761327|Other|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
79247102|NCT03355287|Other|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
79247103|NCT03352869|Drug|Exenatide|Use Exenatide for 3 months to treat PCOS
79247104|NCT03352869|Drug|Metformin|Use Metformin for 3 months to treat PCOS
79247105|NCT03352791|Behavioral|DSM-H Hospice Edition performance improvement program|Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
79247106|NCT03352791|Behavioral|Usual Care|control will receive usual care from a care team who has not received the performance improvement program.
79247107|NCT03359499|Drug|Bacillus clausii|Oral suspension administered BID
79247108|NCT03359499|Drug|Trimebutine|One tablet of 200 mg of trimebutine administered BID
79247109|NCT04507113|Other|DTI sequence acquisition|DTI sequence acquisition
79385787|NCT04167631|Radiation|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
79385788|NCT04152512|Behavioral|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
79385789|NCT04150640|Drug|Nal-IRI|chemotherapy drug
79699304|NCT00566904|Drug|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
79699305|NCT00566904|Other|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
79699306|NCT04584983|Drug|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
79385790|NCT04150640|Drug|Oxaliplatin|chemotherapy drug
79385791|NCT04150640|Drug|5-FU|chemotherapy drug
79385792|NCT04150640|Drug|Trastuzumab|immunotherapy
79385793|NCT04150640|Drug|Pembrolizumab|immunotherapy
79385794|NCT04150640|Drug|Nivolumab|immunotherapy
79699307|NCT04584983|Drug|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
79699308|NCT00568100|Procedure|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
79699309|NCT04576611|Other|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
79699310|NCT04576611|Other|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
79247110|NCT03123315|Device|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
79247111|NCT04506801|Dietary Supplement|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
79385795|NCT04147780|Procedure|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
79385796|NCT04140331|Device|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
79385797|NCT04137107|Drug|Oxaliplatin|Given standard of care oxaliplatin
79699311|NCT04584515|Drug|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
79699312|NCT04584515|Drug|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
79699313|NCT04592679|Device|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
79842902|NCT04088747|Diagnostic Test|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
79247112|NCT04506801|Other|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
79247113|NCT04512183|Other|High-Fidelity Simulation|Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
79247114|NCT04512183|Other|Low-Fidelity Simulation|Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
79385798|NCT04137107|Drug|Duloxetine Hydrochloride|Given PO
79699314|NCT04592679|Other|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
79699315|NCT04592757|Device|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
79699316|NCT04584476|Procedure|superior capsular reconstuction|these patients underwent arthroscopic superior capsular reconstuction
80012476|NCT05761327|Dietary Supplement|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
79247115|NCT03352479|Other|Opioid Return|Calculate the percentage of prescribed to returned opioids
79699317|NCT04584476|Procedure|partial rotator cuff repair|these patients underwent arthroscopic partial rotator cuff repair
79247116|NCT03359265|Device|underpants|
79247117|NCT03355131|Behavioral|Adapted NASA's Mission X program|8 Weeks Adapted National Aeronautics and Space Administration's (NASA's) Mission X (MX) program
79247118|NCT03355053|Drug|Dexmedetomidine|See description of study arms
79247119|NCT03354975|Behavioral|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
79247120|NCT03354975|Behavioral|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
79247121|NCT04511559|Diagnostic Test|Circulating Tumor DNA Methylation Sequencing|Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.
79247122|NCT04511559|Diagnostic Test|tissue DNA Methylation Sequencing|Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.
79247123|NCT03359187|Other|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
79247124|NCT03359187|Other|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
79699318|NCT00582699|Behavioral|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
79699319|NCT04584437|Other|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
79699320|NCT04584593|Biological|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
79247125|NCT03359187|Other|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
79247126|NCT03352401|Other|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
79247127|NCT04506723|Procedure|Percutaneous Nephrolithotomy|PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
79247128|NCT04506723|Procedure|Partial nephrectomy|Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
79247129|NCT04506723|Procedure|Radical nephrectomy|Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
79385799|NCT04137107|Drug|Duloxetine|Given PO
79699321|NCT04584710|Drug|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
79699322|NCT04584710|Drug|Placebo|Oral matching placebo once daily for 2 weeks
79699323|NCT00582777|Behavioral|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
79699324|NCT00582777|Behavioral|HS DOSING|Take your usual BP meds at bed time
79699325|NCT00582777|Drug|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
79699326|NCT04584398|Device|Respiratory muscle training with steam inhalation|
79842903|NCT03973879|Biological|PVSRIPO|Oncolytic polio/rhinovirus recombinant
80012477|NCT05761327|Dietary Supplement|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
80012478|NCT05203549|Procedure|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
79385800|NCT04137107|Other|Quality-of-Life Assessment|Ancillary studies
79385801|NCT04137107|Other|Questionnaire Administration|Ancillary studies
79385802|NCT04137107|Other|Placebo|Given PO
79385803|NCT04125524|Diagnostic Test|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
79842904|NCT03973879|Drug|Atezolizumab|Antibody
79842905|NCT00519376|Drug|GW642444M|drug
79842906|NCT00519376|Drug|GW642444H|drug
80012479|NCT02231762|Drug|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
79540807|NCT01485523|Other|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
79540808|NCT01485562|Drug|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
79540809|NCT01485562|Other|placebo|4 tablets, administered sublingually if the woman experiences a PPH
79247130|NCT03354819|Behavioral|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion & allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
79699327|NCT03454113|Device|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
79540810|NCT01485575|Procedure|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
79540811|NCT01485653|Drug|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
79247131|NCT03354819|Behavioral|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~Overview of dementia~Pharmacological and non-pharmacological treatment of dementia~BPSD in dementia care~Person center care~Advance planning in people with dementia~Principle of mindfulness~Non-pharmacological intervention on stress reduction"
79247132|NCT04511091|Procedure|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
79247133|NCT04506489|Other|Psychological investigation|Psychological tests, psychological interviews.
79247134|NCT03359031|Other|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
79247135|NCT04506333|Device|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
79247136|NCT04506333|Device|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
79247137|NCT04443777|Other|Resistance Training|Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
79247138|NCT04511169|Behavioral|digital self-help|The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
79699328|NCT04584671|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
79699329|NCT04584671|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
79247139|NCT04523103|Behavioral|Artificial Assisted Activation|Artificial assisted activation represents an effective technique to rescue the fertilization failure.
79247140|NCT03358953|Device|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
79247141|NCT03358953|Device|Nicotine Replacement Patch|NiQuitin 21mg
79247142|NCT04509999|Drug|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily
79699330|NCT04584671|Diagnostic Test|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
79699331|NCT04584671|Diagnostic Test|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
79699332|NCT04584671|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
79842907|NCT00519376|Drug|placebo|
80012480|NCT02231762|Drug|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
80012481|NCT04540484|Other|Screening|Blood test screening for covid
80012482|NCT01687335|Other|answering questionnare in differents time of the treatment|
79247143|NCT04509999|Drug|Placebo|Placebo as formulated by mouth daily
79247144|NCT04509843|Behavioral|socioeconomic status|it is a cross-sectional study for assessment the impact of socioeconomic status on periodontal health through using a definite scale mentioned in the protocol related to the middle east people.
79247145|NCT04509921|Other|asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness|Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
79699333|NCT04584671|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
79699334|NCT04584671|Other|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
79699335|NCT00582855|Drug|AQW051|
79699336|NCT00582855|Drug|Placebo|
79699337|NCT04584359|Other|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
79699338|NCT04584359|Other|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
79699339|NCT04584359|Other|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
79699340|NCT03454074|Behavioral|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
79699341|NCT03454074|Behavioral|Education|Education about healthy brain aging behaviors provided.
79699342|NCT04584242|Drug|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
79699343|NCT04584242|Drug|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
79699344|NCT04592835|Drug|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
79699345|NCT04583696|Dietary Supplement|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
79699346|NCT04592211|Drug|olaparib+pembrolizumab+paclitaxel|olaparib, 100~200mg, PO, bid, continuous pembrolizumab 200mg, IV, q 3 weeks paclitaxel 175g/m2 IV, q 3 weeks
79247146|NCT04522869|Biological|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
79385804|NCT04119544|Other|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
79391477|NCT02435524|Behavioral|A&T infant and young child feeding intervention|"Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~Increase mother's knowledge about optimal breastfeeding and its benefits~Increase mother's self-efficacy related to breastfeeding~Improve mother's perceptions about social norms relating to breastfeeding~Community mobilisation activities to:~- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~Enhanced training of government health workers in infant and young child feeding to:~Improve their ability to support mothers and provide timely information about infant feeding"
79699347|NCT04583813|Drug|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
79699348|NCT04583813|Other|Placebo|Empagliflozin matching placebo, once daily, for 24 months
79699349|NCT04576143|Drug|Epirubicin|i.v. 90 mg/m2
79699350|NCT04576143|Drug|Cyclophosphamid|i.v. 600 mg/m2
79699351|NCT04576143|Drug|Docetaxel|i.v. 100 mg/m2
79699352|NCT04576143|Drug|Paclitaxel|i.v. 175 mg/m2
79699353|NCT04592367|Procedure|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
79247147|NCT04506021|Drug|Bicarbonate Ringer's solution|According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
79699354|NCT04576221|Device|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
79699355|NCT04576221|Device|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
79842908|NCT00860964|Drug|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
79247148|NCT04506021|Drug|Other Crystalloid|According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
79247149|NCT04509453|Device|McGRATH laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
79247150|NCT04509453|Device|Macintosh laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
79540812|NCT01485679|Other|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
79540813|NCT01485692|Drug|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
79540814|NCT01485692|Drug|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
79247151|NCT04505943|Drug|Isonicotinic Acid Hydrazide|2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
79699356|NCT04591899|Device|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
79699357|NCT04583657|Other|Eggs|Consumption of two eggs (control or test) per day during three months
79699358|NCT04583267|Drug|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
79247152|NCT04505943|Drug|dinoprostine|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
80012483|NCT01676181|Procedure|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
79247153|NCT04505943|Drug|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
79247154|NCT03358719|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intracutaneously
79247155|NCT03358719|Drug|Decitabine|Given IV
79385805|NCT04119544|Device|Intensive Visual Simulation|"First week: observation, mentalization and then attempt to perform the movements on the screen.~Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
79385806|NCT04119024|Drug|Cyclophosphamide|Given IV
79385807|NCT04119024|Drug|Fludarabine Phosphate|Given IV
79385808|NCT04119024|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
80012484|NCT01676181|Procedure|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
80012485|NCT04614051|Biological|Cellgram-DC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
79385809|NCT04119024|Drug|Recombinant Interleukin-2|Given SC
80012486|NCT03623217|Behavioral|Qualitative interviews with participants|For the development and validation of a questionnaire.
79385810|NCT04098484|Other|Control Trial|Participants will abstain from exercise throughout a 3-month period
79385811|NCT04098484|Other|Exercise Trial|Participants will execute a 3-month exercise training program
79540815|NCT01485692|Drug|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
79540816|NCT01485692|Drug|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
79540817|NCT01485705|Other|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
79540818|NCT01485718|Dietary Supplement|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
79247156|NCT03358719|Other|Laboratory Biomarker Analysis|Correlative studies
79247157|NCT03358719|Biological|Nivolumab|Given IV
79247158|NCT03358719|Drug|Poly ICLC|Given SC
79247159|NCT03358641|Other|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
79247160|NCT04505475|Procedure|Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)|single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy
79247161|NCT01376349|Drug|prasterone|Applied vaginally
79247162|NCT01376349|Other|placebo|Applied vaginally
79247163|NCT04505787|Drug|Esflurbiprofen hydrogel patch 165 mg (EFHP)|patch application with PK blood sampling
79247164|NCT04505787|Drug|Froben 100 mg comprimidos revestidos|tablet administration with PK blood sampling
79247165|NCT04445337|Procedure|Stellate Ganglion Block|An injection of local anesthetic into the front of the neck. Medication used for the block include- clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml is delivered.
79247166|NCT03351855|Biological|HPV-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg by IV each time
79385812|NCT04095247|Device|Vagus nerv stimulator|pulse triggered autostimulation
79699359|NCT04583111|Drug|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
79699360|NCT04583111|Drug|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
79699361|NCT04583345|Behavioral|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
79699362|NCT04583228|Drug|HLX71|Single-dose, intravenous infusion
79699363|NCT04583228|Other|Placebo|Single-dose, intravenous infusion
79699364|NCT00583245|Other|Gait Training|Gait training with physical therapist 2/week for 3 months
79699365|NCT04583189|Diagnostic Test|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
79699366|NCT01146652|Drug|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79842909|NCT00860964|Drug|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
79842910|NCT00745121|Device|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
79842911|NCT00864630|Behavioral|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
79842912|NCT04088903|Drug|Daratumumab|>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
79842913|NCT02545140|Other|No intervention|
79842914|NCT05395871|Behavioral|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
79842915|NCT05395871|Behavioral|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
79247167|NCT03350373|Drug|FYU-981|Single administration of FYU-981 under Fasted and fed conditions in the morning.
79247168|NCT03351777|Drug|PR022|Topical Gel
79699367|NCT04582877|Device|FFR measurement|FFR is measured sequentially with the test article and the predicate device.
79699368|NCT04576026|Behavioral|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
79842916|NCT05395871|Other|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
79842917|NCT01009372|Behavioral|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
79842918|NCT00861120|Drug|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
79842919|NCT00861120|Drug|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
79842920|NCT00864786|Drug|PF03635659|Inhaled doses of 200 mcgQD
79842921|NCT00864786|Drug|PF03635659|Inhaled doses of 600 mcg QD
79842922|NCT00864786|Drug|PF03635659|Inhaled doses of 1000 mcg QD
79247169|NCT03350295|Drug|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
79247170|NCT04523025|Diagnostic Test|NLR-ratio|The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
79699369|NCT04576026|Behavioral|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
79699370|NCT04576026|Behavioral|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
79699371|NCT04582955|Drug|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
79699372|NCT04591938|Device|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
79699373|NCT01146613|Drug|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
79699374|NCT01146613|Drug|Placebo|identical matched placebo x 2, 2xday, 13 weeks
79385813|NCT04087278|Dietary Supplement|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
79385814|NCT04087278|Dietary Supplement|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
79699375|NCT04591704|Other|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
79699376|NCT04582838|Diagnostic Test|Pulse oximeter|"In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis."
79842923|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
79842924|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
79842925|NCT03841656|Procedure|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
79842926|NCT00740051|Drug|Linagliptin|5mg once daily
79540819|NCT01485718|Dietary Supplement|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
79540820|NCT01485731|Drug|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
79540821|NCT01485731|Drug|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
79699377|NCT04582838|Diagnostic Test|ECG|ECG signal is used to monitor respiratory rate (RR).
79699378|NCT01145755|Drug|AZD2066|18 mg once daily
79699379|NCT01145755|Drug|Placebo|
79842927|NCT00740051|Drug|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
79842928|NCT00740051|Drug|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
79842929|NCT00864864|Drug|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
79842930|NCT00868686|Device|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
79842931|NCT00868686|Device|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
79540822|NCT01485731|Radiation|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
79540823|NCT01485731|Radiation|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
79247171|NCT04505241|Behavioral|Remotely-delivered physical activity promotion|Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
79247172|NCT04522635|Drug|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
79247173|NCT03350139|Device|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
79385815|NCT04083001|Device|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
79385816|NCT04068012|Other|Ventilator protocol|open loop ventilator management by a computer based protocol
79699380|NCT01145755|Drug|Duloxetine|60 mg once daily
79699381|NCT02883946|Other|Data collection|
79699382|NCT00625105|Behavioral|Biofeedback|
79699383|NCT00567060|Drug|Piracetam|
79699384|NCT00568217|Drug|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still < 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature < 38 degree Celsius
79699385|NCT00568256|Behavioral|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
79699386|NCT00583323|Drug|Lomotil|Orally 10ml of Lomotil
79699387|NCT00583323|Other|Normal saline|10 ml orally
79699388|NCT04575987|Other|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
79699389|NCT04582604|Drug|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
79699390|NCT04582760|Other|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
79699391|NCT00583401|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
79842932|NCT00868686|Device|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
79842933|NCT00868764|Drug|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
79842934|NCT00518986|Drug|armodafinil|200 mg/day
79842935|NCT00518986|Drug|placebo|placebo
79842936|NCT00870324|Device|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
79842937|NCT00870324|Device|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
79842938|NCT04089683|Other|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
79842939|NCT00864942|Drug|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
79699392|NCT04582721|Other|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~1) CON-SCS with Subcutaneous stimulation~2) HF-SCS~3) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
79699393|NCT00590928|Drug|esomeprazole|40mg once daily
79540824|NCT01485731|Procedure|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
79699394|NCT00590928|Drug|ranitidine|50mg every h hours
79540825|NCT01485731|Procedure|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
79699395|NCT00583440|Behavioral|12-step facilitation|12 weekly individual 12-step facilitation sessions
79247174|NCT03350061|Device|SENSY|The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
79699396|NCT00583440|Behavioral|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
79699397|NCT04582526|Behavioral|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
79247175|NCT03349983|Biological|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
79247176|NCT03358485|Drug|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
79247177|NCT03358485|Other|Placebo|Placebo
79247178|NCT04522401|Diagnostic Test|"consultation: Bien vieillir"|Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
79247179|NCT03349827|Procedure|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
79247180|NCT03349827|Procedure|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
79540826|NCT01485731|Procedure|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
79540827|NCT01485731|Procedure|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
79699398|NCT01145560|Drug|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
79699399|NCT01145560|Drug|Placebo|Placebo
79699400|NCT04582175|Procedure|angioplasty|angioplasty of all non-culprit lesions
79699401|NCT00591045|Drug|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
79699402|NCT01145482|Drug|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
79699403|NCT01145482|Other|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
79699404|NCT00583479|Other|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
79699405|NCT00583479|Other|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
79699406|NCT04313413|Other|Yoga|Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
79699407|NCT00568295|Drug|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
79540828|NCT01485731|Procedure|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
79540829|NCT01485731|Procedure|Proctoscopy|Optional. Pre-Treatment
79699408|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
79540830|NCT01485731|Procedure|Cytoscopy|Optional. Pre-Treatment
79540831|NCT01485731|Procedure|Renal Ultrasound|Optional. Pre-Treatment
79540832|NCT01485731|Procedure|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
79699409|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
79247181|NCT03349827|Drug|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
79540833|NCT01485731|Procedure|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
79540834|NCT01485744|Drug|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
79540835|NCT01485757|Drug|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
79540836|NCT01485822|Procedure|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
79247182|NCT03349827|Drug|Apatinib|500mg, once daily, day 1 to day 21.
79247183|NCT04504929|Device|Sham tape|Use sham type on the pitching shoulder
79247184|NCT04504929|Device|Dynamic tape|Use dynamic type on the pitching shoulder for supporting internal rotation
79247185|NCT04503915|Procedure|different estrogen supplementation modes|The different estrogen supplementation modes are randomized into two groups.
79247186|NCT04522479|Other|Change the injection time of long acting GnRH-a|The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
79540837|NCT01485822|Drug|Travoprost 0.004% ophthalmic solution|
79540838|NCT01485835|Drug|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
79540839|NCT01485835|Drug|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
79540840|NCT01485835|Drug|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
79540841|NCT01485848|Drug|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
79540842|NCT01485848|Drug|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
79699410|NCT00591084|Drug|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
79699411|NCT00591084|Drug|placebo|infusion placebo (group B)once a day and continued for 14 days
79699412|NCT00591084|Drug|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
79540843|NCT01485900|Drug|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
79699413|NCT00591162|Drug|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
79699414|NCT00591162|Radiation|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
79699415|NCT00591162|Procedure|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
79699416|NCT00568373|Device|Enterra Gastric Pacemaker|Gastric Pacemaker
79699417|NCT00583518|Drug|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
79699418|NCT04582136|Drug|Sirolimus|In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
79699419|NCT04582136|Drug|Placebo|In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
79699420|NCT04582331|Other|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
79699421|NCT04582253|Diagnostic Test|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
79699422|NCT00591201|Drug|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
79699423|NCT00591201|Drug|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
79699424|NCT04582058|Behavioral|Mobile Health of lifestyle|Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
79699425|NCT04575831|Behavioral|Exercise, Nutrition, and Palliative Symptom Management|"Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
79699426|NCT04575753|Other|Study group|"Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.~Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium"
79699427|NCT04582097|Drug|Ramipril|angiotensin-converting enzyme inhibitor
79699428|NCT04582097|Drug|placebo|same odor, color and size as the drug but without the active ingredient
79247187|NCT03351465|Behavioral|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
79699429|NCT04582019|Device|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
79247188|NCT04503837|Procedure|Personalized Mobile Phone Video Recording|Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
79247189|NCT04504851|Drug|Rosuvastatin 10mg|10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
79540844|NCT01485913|Other|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
79699430|NCT04575714|Other|Data record|Data record
79699431|NCT04581707|Device|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
79699432|NCT04581707|Device|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
79842940|NCT00864942|Drug|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
79842941|NCT00864942|Drug|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
80012487|NCT03668145|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
80012488|NCT02228486|Device|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
80012489|NCT02228486|Behavioral|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
79247190|NCT04504851|Drug|Rifampicin|Rifampicin 10mg/kg
79247191|NCT04504851|Drug|Isoniazid|Isoniazid 5mg/kg
79247192|NCT04504851|Drug|Pyrazinamide|Pyrazinamide 25mg/kg
79247193|NCT04504851|Drug|Ethambutol|Ethambutol 15mg/kg
79247194|NCT03349749|Device|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
79247195|NCT03351309|Behavioral|Telephone-based Cognitive Behavioral Therapy (CBT)|Four session telephone CBT protocol.
79247196|NCT03349671|Procedure|ultrasound|A 3D volume of the uterus will be acquired by transabdominal sonography. The sweep angle was set at 85º and the probe will be kept perpendicular to the placental plate. The placenta will be examined and the size of the volume box will be adapted in such a way that the placenta fitted into it completely. The volume will then stored for later offline analysis.
79385817|NCT04056741|Combination Product|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
79699433|NCT00591357|Drug|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
79699434|NCT00591357|Drug|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
79699435|NCT04581590|Other|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
79385818|NCT04038502|Drug|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
79385819|NCT04038502|Drug|Olaparib|Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
79385820|NCT04008147|Dietary Supplement|100mg iron fumarate|100mg iron fumarate b.i.d. for 4 consecutive days
79385821|NCT04008147|Dietary Supplement|Burgerstein Schwangerschaft & Stillzeit|contains 30 mg iron fumarate, given on 14 consecutive days
79385822|NCT03982316|Behavioral|Telehealth Behavioral Migraine Management|1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
79385823|NCT03975387|Drug|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
79842942|NCT00864942|Drug|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
79842943|NCT00870402|Drug|Spironolactone|25 mg per day for 9 months
79842944|NCT00870402|Drug|Placebo|Placebo 1 tablet per day for nine months
79305489|NCT03243929|Behavioral|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
79385824|NCT03973697|Drug|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
79385825|NCT03973697|Drug|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
79385826|NCT03973697|Drug|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
79385827|NCT03958994|Other|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
79540845|NCT01485926|Drug|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
79540846|NCT01485926|Drug|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
79385828|NCT03951142|Drug|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
79385829|NCT03937713|Drug|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
79385830|NCT03937713|Behavioral|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
79699436|NCT00591396|Drug|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
79699437|NCT04581278|Diagnostic Test|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
79842945|NCT00742391|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
79842946|NCT00742391|Drug|Vehicle gel|two day treatment
79842947|NCT05227560|Other|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
79842948|NCT02596139|Other|No Interventions|
79842949|NCT03841266|Diagnostic Test|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
79385831|NCT03920215|Drug|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
79385832|NCT03920215|Drug|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
79385833|NCT03920215|Drug|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
79385834|NCT03920215|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
79385835|NCT03917498|Radiation|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
79540847|NCT01485939|Other|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
79540848|NCT01485939|Other|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
79699438|NCT00591435|Other|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
79842950|NCT00742235|Drug|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
79842951|NCT00868920|Other|patient control of pump|Patient controls sedation pump during colonoscopy.
79842952|NCT00868920|Other|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
79842953|NCT00742079|Drug|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
79842954|NCT00742079|Behavioral|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
79540849|NCT01485952|Drug|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
79540850|NCT01485952|Drug|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
79540851|NCT01485952|Drug|Placebo|Once daily administration (immediate release capsule)
79540852|NCT01485965|Drug|SEN0014196|100 mg, immediate release tablets, once daily administration
79540853|NCT01485978|Drug|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
79699439|NCT04580966|Behavioral|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
79699440|NCT04580849|Other|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
79699441|NCT00591474|Dietary Supplement|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
79699442|NCT00591474|Dietary Supplement|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
79305490|NCT03243929|Behavioral|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
79540854|NCT01485978|Drug|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
79540855|NCT01485978|Drug|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
79540856|NCT01486004|Drug|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
79540857|NCT01486004|Drug|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
79385836|NCT03902821|Other|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
79385837|NCT03878134|Device|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
79385838|NCT03874429|Device|T2259|Sodium Hyaluronate and Trehalose
79385839|NCT03874429|Device|Vismed multi|HA
79540858|NCT01486017|Drug|ASP015K|oral
79540859|NCT01486030|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
79540860|NCT01486082|Other|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
79540861|NCT01486095|Device|AXXESS + Biomatrix Biolimus Eluting stent|NAP
79540862|NCT01486095|Device|Culotte technique with Xience V or Xience Prime stents|NAP
79540863|NCT01486108|Procedure|dorsal column stimulator|test different settings of stimulation
79540864|NCT01486121|Other|Therapy strategy|Sedation & mechanical ventilation
79699443|NCT04581239|Other|Active neural mobilization|"Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set"
80012490|NCT03668925|Radiation|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
80012491|NCT01191957|Drug|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
79305491|NCT03243851|Drug|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
79305492|NCT03243851|Drug|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
79540865|NCT01486134|Procedure|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
79540866|NCT01486147|Behavioral|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
79540867|NCT01486147|Behavioral|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
79540868|NCT01486186|Drug|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
79540869|NCT01486186|Drug|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
79540870|NCT01486225|Device|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
79540871|NCT01486225|Other|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
79540872|NCT01486251|Drug|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
79699444|NCT04581239|Other|passive neural mobilization|"Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks"
79699445|NCT04581083|Diagnostic Test|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
79699446|NCT04581083|Diagnostic Test|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
79699447|NCT04581083|Diagnostic Test|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
79699448|NCT04581083|Diagnostic Test|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
79247197|NCT04504617|Behavioral|Nutrition education intervention to enhance complementary feeding practices|The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
79305493|NCT02623959|Behavioral|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
79540873|NCT01486290|Behavioral|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
79540874|NCT01486303|Procedure|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
79540875|NCT01486329|Biological|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
79842955|NCT04730362|Device|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
79842956|NCT04730362|Device|supraglottic airway|supraglottic airway
79842957|NCT04730362|Drug|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
79842958|NCT00876096|Other|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
79540876|NCT01486329|Biological|Placebo|Drink solution
79842959|NCT00662792|Drug|Tiotropium (Tio18GEL)|18 µg Tiotropium (Tio18GEL) inhalation powder
79842960|NCT00662792|Drug|Salmeterol MDPI (Salm50DPI)|50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
80012492|NCT01191957|Drug|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
79842961|NCT00662792|Drug|Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)|18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)
79842962|NCT00662792|Drug|Tiotropium/Salmeterol (T+S_PE)|Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder
80012493|NCT01913912|Drug|LDX.|"In this study 3 different doses of LDX will be used:~30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
80012494|NCT01913912|Drug|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
80012495|NCT01913912|Device|computer task (Go/No-Go task)|
80012496|NCT01913912|Device|EEG|event-related potentials (ERP) and heart rate measurements
79699449|NCT03452241|Other|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
79699450|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
79842963|NCT01009450|Procedure|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
79842964|NCT01009450|Procedure|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
79842965|NCT00870480|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
79842966|NCT00870480|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
79842967|NCT01009528|Device|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
80012497|NCT01913912|Device|pupil size measurements (by using eye tracking)|
80012498|NCT02232230|Drug|Provenge|
80012499|NCT02276066|Other|Iohexol|Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
80012500|NCT02276066|Other|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.
79247198|NCT03351153|Radiation|X-ray|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
79247199|NCT03351153|Radiation|CT|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
79540877|NCT01486342|Radiation|PET-CT scan|"PET-CT imaging with [18F]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
79247200|NCT03351153|Other|specimen|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
79540878|NCT01486355|Biological|Measles vaccine|Edmonston-Zagreb measles vaccine
79540879|NCT01486381|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
79540880|NCT01486394|Other|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
79540881|NCT01486420|Procedure|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
79385840|NCT03871153|Device|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
79385841|NCT03871153|Drug|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
79699451|NCT04581005|Behavioral|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
79699452|NCT04575675|Drug|Dapagliflozin|Dapagliflozin 10mg once daily
79699453|NCT04575675|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan, maximal tolerated dosage
79699454|NCT04575675|Drug|Beta blocker|Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
79385842|NCT03871153|Drug|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
79385843|NCT03871153|Radiation|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
79540882|NCT01486420|Procedure|Open surgery|Open A1-pulley release
79842968|NCT00742001|Biological|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
80012501|NCT02276066|Other|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.
80012502|NCT01050855|Drug|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
80012503|NCT01050855|Drug|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
80012504|NCT01050855|Drug|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
80012505|NCT04459286|Drug|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
79247201|NCT04504461|Other|Analysis of feasibility and costs|Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
80012506|NCT04459286|Other|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
79247202|NCT03349359|Drug|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
79247203|NCT03349203|Drug|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
79247204|NCT04504539|Biological|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
79247205|NCT04504539|Biological|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
79247206|NCT04504539|Biological|Full dose IPV|FIPV (full dose injectable polio vaccine)
79540883|NCT01486433|Drug|Simvastatin|40 mg (1 tablet) simvastatin once a day
79540884|NCT01486433|Drug|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
79540885|NCT01486433|Drug|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
80012507|NCT00744081|Drug|Glivec|
80012508|NCT00744081|Drug|Mitoxantrone|
80012509|NCT00744081|Drug|Topotecan|
79247207|NCT04504539|Biological|fractional IPV|fIPV (fractional dose injectable polio vaccine)
79699455|NCT04575675|Drug|Mineralocorticoid Receptor Antagonist|Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
79699456|NCT04575675|Device|Cardiac resynchronization therapy and/or implantable cardioverter defibrillator|CRT-P, CRT-D or ICD if clinically indicated
79699457|NCT00568412|Device|Zarzenda|Topical cream, applied twice daily for three weeks
80012510|NCT00744081|Drug|AraC|
80012511|NCT03669939|Other|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
80012512|NCT03669939|Other|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
79247208|NCT03350841|Procedure|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
79247209|NCT03350841|Procedure|root canal treatment|conventional root canal treatment and obturation with guttapercha
79247210|NCT03350763|Device|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
79540886|NCT01486459|Drug|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
79699458|NCT00568412|Drug|Elidel|1% cream, applied topically twice daily for three weeks
79842969|NCT00870558|Drug|ethiodized oil|Given as an intra-arterial infusion
80012513|NCT02229110|Other|Signal|Automatic signal in the electronic medical record
80012514|NCT03023397|Biological|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
80012515|NCT02229188|Behavioral|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
80012516|NCT02229188|Behavioral|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
79247211|NCT03350763|Device|Self-expandable metallic biliary stent|ie WallFlex biliary RX
79247212|NCT03101787|Procedure|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is < 60 minutes."
79247213|NCT03349125|Behavioral|Collar On|
79247214|NCT03349125|Behavioral|Collar Off|
79385844|NCT03871153|Procedure|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
79385845|NCT03870360|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
79540887|NCT01486472|Drug|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
79540888|NCT01486485|Drug|heparinized saline priming group|
79540889|NCT01486485|Drug|nafamostat infusion after heparinized saline priming|
79842970|NCT00870558|Radiation|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
79247215|NCT03349047|Behavioral|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
79247216|NCT03349047|Behavioral|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
79540890|NCT01486511|Procedure|Liver resection|Hepatectomy including both minor and major.
80012517|NCT02229188|Behavioral|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
79247217|NCT05452863|Device|O2matic administered oxygen|Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.
79699459|NCT03452163|Device|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
79540891|NCT01486511|Radiation|Computed Tomography|Computed Tomography +/- pulmonary angiography
79540892|NCT01486550|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
79699460|NCT03452163|Device|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
79699461|NCT00568529|Drug|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
79699462|NCT00568568|Drug|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
79699463|NCT04575558|Drug|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
79699464|NCT04581161|Device|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
80012518|NCT02223962|Behavioral|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
79385846|NCT03870360|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
79540893|NCT01486550|Drug|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
79385847|NCT03870360|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
79699465|NCT03452124|Device|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
79385848|NCT03870360|Behavioral|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
79540894|NCT01486563|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
79540895|NCT01486563|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
79699466|NCT03452124|Other|Conventional cigarette|Conventional cigarette smoking continuation
79699467|NCT00568607|Drug|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
79247218|NCT05452863|Device|Manual oxygen supply and adjustments|Oxygen supply is adjusted from manual measurements of the oxygen saturation
79247219|NCT02518035|Drug|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
79247220|NCT03030261|Drug|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
79540896|NCT01486576|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
79540897|NCT01486576|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
79540898|NCT01486602|Drug|carboplatin|IV
79699468|NCT03452085|Device|artificial saliva spray (AS)|cross over design
79699469|NCT03452085|Other|maritime throat spray (TT)|cross over design
80012519|NCT02229266|Biological|NK cells|
79540899|NCT01486602|Drug|paclitaxel|IV
79540900|NCT01486602|Radiation|radiation therapy|Defined per the protocol
79540901|NCT01486641|Procedure|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
79540902|NCT01486654|Device|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
79540903|NCT01486654|Device|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
79540904|NCT01486654|Device|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
80012520|NCT02229266|Drug|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
80012521|NCT01944566|Biological|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
80012522|NCT02224040|Drug|ceftriaxone|
80012523|NCT02224040|Drug|ceftriaxone and azithromycin|
80012524|NCT02224040|Drug|azithromycin|
80012525|NCT02224040|Drug|azithromycin and cefixime|
80012526|NCT04448834|Drug|Blinatumomab|liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
80012527|NCT04429178|Other|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
79699470|NCT00568646|Drug|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
79699471|NCT03452046|Other|IVC diametres|
80012528|NCT02224118|Drug|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
80012529|NCT02224118|Drug|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
80012530|NCT02224118|Drug|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
79842971|NCT00869076|Other|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
79842972|NCT00869076|Other|Usual care|Patient was managed by their primary care physician as usual
79842973|NCT01565278|Drug|Soybean oil (Standard treatment)|1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
80012531|NCT02224118|Drug|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
80012532|NCT02224118|Drug|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
79247221|NCT03030261|Drug|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
79247222|NCT03030261|Drug|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
79540905|NCT01486667|Drug|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
79247223|NCT03348813|Behavioral|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
79699472|NCT00568763|Biological|sargramostim|
79699473|NCT00568763|Other|immunoenzyme technique|
79699474|NCT00568763|Other|immunohistochemistry staining method|
79247224|NCT03348813|Behavioral|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
79247225|NCT02176161|Drug|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
79385849|NCT03870360|Behavioral|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
79385850|NCT03845517|Drug|Placebo|Placebo
79385851|NCT03845517|Drug|PF-06700841 15 mg|PF-06700841 15 mg
79385852|NCT03845517|Drug|PF-06700841 30 mg|PF-06700841 30 mg
79385853|NCT03845517|Drug|PF-06700841 45 mg|PF-06700841 45 mg
79385854|NCT03823768|Drug|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
79385855|NCT03823768|Drug|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
79385856|NCT03799302|Behavioral|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
79385857|NCT03786094|Drug|Eribulin|Eribulin alone
79385858|NCT03786094|Drug|Balixafortide|Balixafortide + Eribulin
79699475|NCT00568763|Other|immunologic technique|
79699476|NCT00568763|Other|laboratory biomarker analysis|
79699477|NCT00568763|Procedure|biopsy|
79699478|NCT00568763|Procedure|cryosurgery|
79699479|NCT00568763|Procedure|radiofrequency ablation|
79842974|NCT01565278|Drug|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
79842975|NCT00616902|Drug|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
79842976|NCT00616902|Drug|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
79842977|NCT00869154|Behavioral|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
79842978|NCT00869154|Behavioral|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
79842979|NCT00801944|Drug|Solifenacin succinate|oral
79842980|NCT00801944|Drug|Placebo|oral
79842981|NCT00741611|Device|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
79842982|NCT00741611|Drug|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
79842983|NCT00876252|Biological|IC43|
80012533|NCT04415684|Device|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
79540906|NCT01486667|Drug|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
79540907|NCT01486680|Procedure|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
80012534|NCT04415684|Device|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
79247226|NCT04504305|Other|NeuropAWAY|2 capsules thrice daily to be taken half an hour prior to meal.
79247227|NCT04504305|Other|Microcystalline cellulose|2 capsules thrice daily to be taken half an hour prior to meal.
79247228|NCT03348735|Drug|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
79540908|NCT01486680|Procedure|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
79540909|NCT01486706|Drug|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
79699480|NCT04575480|Procedure|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with <2 sessions will be excluded from the analysis
79699481|NCT00568841|Drug|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
79699482|NCT00568841|Procedure|FDG-/FLT-PET|
79842984|NCT00876252|Drug|Placebo|NaCl
80012535|NCT02232308|Drug|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
79247229|NCT03348735|Drug|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
79385859|NCT03776747|Drug|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
79385860|NCT03776747|Drug|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
79385861|NCT03776747|Diagnostic Test|Vitals|
79385862|NCT03776747|Diagnostic Test|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
79385863|NCT03776747|Diagnostic Test|Initial protocol MRI scan|Initial scan to determine placement
79540910|NCT01486706|Drug|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
80012536|NCT02232308|Drug|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
80012537|NCT02232308|Drug|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
80012538|NCT02229500|Dietary Supplement|Inulin|
80012539|NCT02229500|Dietary Supplement|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
80012540|NCT02229500|Dietary Supplement|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
79247230|NCT03348735|Drug|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
79247231|NCT03348657|Other|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
79540911|NCT01486706|Drug|Placebo drugs|will titrate medications similar to the active drug group
79540912|NCT01486719|Procedure|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
79842985|NCT00870714|Drug|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
79842986|NCT00870714|Drug|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
79842987|NCT00796484|Drug|XL888|Administered orally
79842988|NCT02596217|Drug|ABBV-066|SC injection
79842989|NCT02596217|Drug|ABBV-066|IV infusion
79842990|NCT02596217|Drug|Placebo|SC injection (stage 1)
79842991|NCT02596217|Drug|Placebo|IV infusion (stage 2)
79842992|NCT00876330|Other|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
79842993|NCT00876330|Other|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
79699483|NCT00583869|Drug|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
79699484|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
79842994|NCT00876330|Other|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
79842995|NCT00876330|Other|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
79842996|NCT02598011|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
79842997|NCT02598011|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
79842998|NCT00869310|Drug|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
79842999|NCT00869310|Drug|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
80012541|NCT02229734|Radiation|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
80012542|NCT02229734|Drug|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
79247232|NCT03348579|Other|Guidelines publication and application|Passing recommendations on using the guidelines in the intensive care units
79385864|NCT03742089|Device|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
79540913|NCT01486732|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
79540914|NCT01486732|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
79540915|NCT01486732|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
79540916|NCT01486771|Drug|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
79843000|NCT00662558|Drug|celecoxib|200 mg capsules BID for 6 weeks
79843001|NCT00662558|Drug|tramadol HCL|50 mg capsules QID for 6 weeks
79843002|NCT00869388|Biological|rBBX-01|
79843003|NCT00870792|Behavioral|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
79247233|NCT03348579|Other|Targeted experience feedback|"Targeted experience feedback: On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi"
79247234|NCT01797003|Other|High tibial osteotomy|
79385865|NCT03734354|Drug|Brexpiprazole|Brexpiprazole , single/oral/with fasting
79385866|NCT03734302|Drug|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
79385867|NCT03734211|Drug|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
79843004|NCT00869466|Behavioral|behavioral dietary intervention|
79843005|NCT00869466|Behavioral|exercise intervention|
79540917|NCT01486797|Drug|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
79843006|NCT00869466|Other|counseling intervention|
79843007|NCT00869466|Other|educational intervention|
80012543|NCT02224196|Other|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
80012544|NCT02224196|Other|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
80012545|NCT02258516|Behavioral|CHIME 3-M|behavioral intervention for self-management in heart failure
80012546|NCT02258516|Behavioral|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
80012547|NCT04333160|Drug|JTA-004|Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
80012548|NCT04333160|Device|Hylan G-F 20|Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
80012549|NCT04333160|Other|placebo|Patients will undergo a single intra-articular injection of placebo into the knee joint
80012550|NCT02224352|Device|Functional neuromuscular electrical stimulation|
80012551|NCT04778774|Procedure|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
80012552|NCT02224430|Device|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
80012553|NCT02258906|Drug|ulinastatin|
80012554|NCT02258906|Drug|normal saline|
79540918|NCT01486823|Drug|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
79540919|NCT01486823|Drug|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
79540920|NCT01486875|Drug|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
79540921|NCT01486888|Drug|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
79699485|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
79699486|NCT00568880|Drug|bortezomib|bortezomib 1.0-1.3mg/m2 IV
79699487|NCT00568880|Drug|hydroxychloroquine|hydroxychloroquine 200 mg pill
79843008|NCT00869466|Other|laboratory biomarker analysis|
79843009|NCT00869466|Other|questionnaire administration|
79843010|NCT00869466|Procedure|quality-of-life assessment|
79843011|NCT00869466|Procedure|support group therapy|
79843012|NCT05226546|Drug|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
79843013|NCT05226546|Other|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
79843014|NCT00802022|Device|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
79843015|NCT00869700|Drug|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
79843016|NCT00788996|Behavioral|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
79699488|NCT03451968|Other|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
79699489|NCT00569036|Drug|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
79843017|NCT00869856|Drug|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
79843018|NCT00802256|Procedure|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
79385868|NCT03734211|Drug|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
79385869|NCT03733730|Device|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
79540922|NCT01486901|Drug|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
79843019|NCT00876486|Drug|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
79385870|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
79385871|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
79699490|NCT00569075|Other|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
79699491|NCT03453021|Drug|Mepolizumab|
79699492|NCT03453944|Device|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
79699493|NCT03453944|Device|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
79699494|NCT03451890|Drug|E2730|oral capsule
80012555|NCT02258984|Device|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
80012556|NCT04325906|Device|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
79540923|NCT01486914|Drug|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
79540924|NCT01486940|Drug|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
79385872|NCT03733730|Procedure|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
79540925|NCT01486940|Drug|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
79540926|NCT01486940|Drug|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
79540927|NCT01486940|Drug|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
79540928|NCT01486953|Drug|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
79699495|NCT03451890|Drug|Placebo|oral capsule
79699496|NCT02277392|Biological|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
79699497|NCT02277392|Biological|SB---485232 (Human recombinant Interleukin---18)|
79699498|NCT00569114|Drug|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
79247235|NCT03348501|Other|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
79247236|NCT04501029|Drug|Gimatecan|Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
79699499|NCT03452904|Device|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
79843020|NCT00876486|Drug|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
79540929|NCT01486953|Drug|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
79247237|NCT01700673|Drug|Azacitidine|Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
79540930|NCT01486979|Drug|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
79540931|NCT01486979|Drug|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
79247238|NCT01700673|Biological|Sargramostim|Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
79540932|NCT01486992|Drug|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
79843021|NCT00802334|Drug|generic lopinavir/ritonavir|"Screening visit~• Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~Baseline visit~• (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~Week 4~Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
79843022|NCT00876564|Other|Trauma patients|
79843023|NCT00796640|Drug|ER Paliperidone|
79843024|NCT00876642|Drug|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
79843025|NCT00796796|Drug|Temsirolimus|
79843026|NCT00796796|Radiation|Radiation therapy|
79247239|NCT00923871|Procedure|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
79540933|NCT01487018|Procedure|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
79247240|NCT03347097|Drug|TIL|
79540934|NCT01487018|Procedure|Traditional Surgery|To compare with the experamental group.
79699500|NCT03452904|Device|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
79699501|NCT00569426|Device|NovoFine® needle 6 mm|
79247241|NCT03347097|Drug|PD1-TIL|
79385873|NCT03732781|Drug|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
79699502|NCT00569426|Device|NovoFine® needle 8 mm|
79699503|NCT03451695|Drug|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
79699504|NCT03451695|Drug|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
79247242|NCT00158600|Biological|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
79247243|NCT00158600|Drug|Placebo|Placebo Comparator; qow for 78 weeks.
79699505|NCT00569465|Drug|Arginine|1200 mg, once a day
79699506|NCT00569465|Drug|Acetylcysteine|600 mg twice a day
79699507|NCT00569465|Drug|Placebo|3 vials a day
79699508|NCT00583986|Drug|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
79699509|NCT00569621|Drug|Moxaverine|intravenous administration
79699510|NCT00569621|Drug|physiological saline|intravenous administration
79699511|NCT03451617|Device|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
79699512|NCT03451617|Device|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
79699513|NCT00569699|Drug|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25 m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
79843027|NCT03794076|Drug|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
79843028|NCT03794076|Drug|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
79843029|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
79843030|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
79843031|NCT00870948|Drug|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
79843032|NCT00739973|Drug|Placebo|
79843033|NCT00739973|Drug|Aliskiren 150 mg tablet|
79540935|NCT01487031|Other|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
79699514|NCT00569738|Procedure|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
79699515|NCT00569816|Drug|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
79699516|NCT04580576|Procedure|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
79699517|NCT00569894|Biological|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
79699518|NCT00569894|Biological|TIV (Injection)|One or two injections of TIV depending on previous status.
79699519|NCT00569894|Other|Unvaccinated Control|no vaccine
79843034|NCT00739973|Drug|Aliskiren 300 mg tablet|
79843035|NCT00739973|Drug|Amlodipine 5 mg capsule|
79843036|NCT00739973|Drug|Amlodipine 10 mg capsule|
79247244|NCT03898154|Drug|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
79247245|NCT03898154|Drug|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
79385874|NCT03724695|Other|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
79699520|NCT00584064|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
79385875|NCT03723161|Device|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
79540936|NCT01487031|Other|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
79699521|NCT00569933|Behavioral|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
79699522|NCT04574661|Other|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
79699523|NCT04574661|Other|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
79699524|NCT00570011|Drug|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
79699525|NCT00570011|Drug|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
79699526|NCT04574388|Other|open label placebo|open label placebo pill
79699527|NCT04581122|Procedure|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
79699528|NCT00570050|Drug|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
79699529|NCT00570050|Drug|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
79699530|NCT00584103|Device|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
79699531|NCT00584103|Device|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
79247246|NCT02517801|Dietary Supplement|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
79247247|NCT02517801|Dietary Supplement|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
79385876|NCT03713632|Drug|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
79699532|NCT00570167|Procedure|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
79699533|NCT00570167|Procedure|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
79843037|NCT00739973|Drug|Aliskiren/amlodipine 150/5 mg tablet|
79843038|NCT00739973|Drug|Aliskiren/amlodipine 150/10 mg tablet|
79843039|NCT00739973|Drug|Aliskiren/amlodipine 300/5 mg tablet|
79843040|NCT00739973|Drug|Aliskiren/amlodipine 300/10 mg tablet|
79843041|NCT00876720|Device|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
79843042|NCT00876720|Device|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
79843043|NCT00789230|Procedure|primary suture closure|primary suture closure of hernia
79699534|NCT00584142|Behavioral|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
79699535|NCT00570206|Behavioral|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
80012557|NCT04325906|Procedure|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
80012558|NCT02229812|Drug|alteplase|
79385877|NCT03713632|Drug|Placebo|Placebo 300mg every 2 or every 4 weeks
79540937|NCT01487044|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
79540938|NCT01487070|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
80012559|NCT02229890|Drug|alteplase|
80012560|NCT02230046|Drug|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
79385878|NCT03682900|Other|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
79385879|NCT03682900|Other|Usual Tobacco Curriculum|Students complete their usual curriculum designed to prevent tobacco use.
79385880|NCT03673826|Drug|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
79385881|NCT03673826|Drug|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
79385882|NCT03673826|Drug|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
79385883|NCT03657394|Other|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
79385884|NCT03637595|Procedure|Acupuncture|3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
79540939|NCT01487096|Drug|Teriflunomide|"film-coated tablet~oral administration"
79385885|NCT03637595|Procedure|Enery Medicine Intervention|3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
79385886|NCT03637595|Procedure|Sham Energy Medicine|a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
79385887|NCT03573921|Drug|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
79385888|NCT03573921|Other|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
79385889|NCT03517436|Device|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
79385890|NCT03476330|Drug|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
79385891|NCT03458455|Diagnostic Test|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
79385892|NCT03458455|Radiation|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
79385893|NCT03458455|Drug|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
79385894|NCT03448601|Other|Culturally tailored brochure intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
79385895|NCT03448601|Other|Culturally tailored video intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational video.
79540940|NCT01487096|Drug|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
79699536|NCT00570245|Drug|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
79699537|NCT00570245|Drug|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
79699538|NCT04574544|Drug|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
79699539|NCT04574544|Behavioral|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
79699540|NCT00570284|Drug|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
79699541|NCT00570440|Drug|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
79699542|NCT00584259|Other|Coffee|3 cups of coffee over a 24 hour period
79843044|NCT00789230|Device|mesh enforced closure|mesh enforced closure of hernia
79843045|NCT00869934|Other|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
79247248|NCT02517957|Drug|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
79247249|NCT02517957|Drug|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
79247250|NCT02517957|Drug|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
79385896|NCT03430973|Behavioral|Videos|Videos depicting various aggressive driving and road rage behaviors.
79385897|NCT03430973|Behavioral|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
79385898|NCT03430973|Behavioral|Alcohol-related cues|Case of beer or water on passenger seat.
79385899|NCT03430973|Behavioral|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
79385900|NCT03430973|Behavioral|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
79385901|NCT03430973|Behavioral|Video game|Participants will play a racing or neutral video game before driving in the simulator.
79540941|NCT01487122|Radiation|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
79540942|NCT01487122|Radiation|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
79540943|NCT01487122|Procedure|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
79385902|NCT03414034|Drug|Onvansertib|Onvansertib orally
79385903|NCT03414034|Drug|Abiraterone|Abiraterone orally
79540944|NCT01487135|Drug|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
79540945|NCT01487135|Drug|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
79540946|NCT01487135|Drug|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
79699543|NCT00570479|Drug|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
79699544|NCT04574622|Device|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
79699545|NCT00584298|Drug|SMS995|
79699546|NCT00584298|Drug|Placebo|
79699547|NCT00570557|Other|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
79699548|NCT04580264|Behavioral|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
79699549|NCT00584376|Drug|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
79699550|NCT00584376|Drug|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
79699551|NCT00570830|Device|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
79699552|NCT04574349|Procedure|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
79699553|NCT00570869|Other|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
79699554|NCT04574310|Other|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
79699555|NCT00570947|Other|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
79843046|NCT00869934|Other|Behavior Therapy|Sleep restriction and stimulus control
79843047|NCT00869934|Other|Cognitive Therapy|Cognitive restructuring therapy
79843048|NCT00802568|Biological|anti-thymocyte globulin|
79843049|NCT00802568|Drug|busulfan|
79843050|NCT00802568|Drug|fludarabine phosphate|
79843051|NCT00802568|Procedure|allogeneic bone marrow transplantation|
79843052|NCT00802568|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79843053|NCT00870012|Drug|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
79843054|NCT00870012|Other|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
79843055|NCT00510874|Biological|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
79699556|NCT00584493|Drug|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
79540947|NCT01487187|Procedure|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
80012561|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
80012562|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
80012563|NCT02230202|Other|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
80012564|NCT02230202|Other|single blood draw|single blood draw of approximately 45 mL.
79247251|NCT02517957|Drug|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
79247252|NCT02517879|Other|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
79247253|NCT02517879|Other|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
79247254|NCT03137810|Procedure|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
79247255|NCT03137810|Procedure|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
79305494|NCT02623959|Drug|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
79540948|NCT01487187|Procedure|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
79540949|NCT01487213|Other|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
79540950|NCT01487226|Drug|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks * 6 cycles
79540951|NCT01487226|Drug|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks * 6 cycles"
79540952|NCT01487239|Drug|[14C]-GDC-0980|100 uCi of [14C]-GDC-0980 in total dose of 10 mg GDC-0980
79540953|NCT01487252|Behavioral|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
79540954|NCT01487278|Drug|misprostol|600 mcg misoprostol oral
79540955|NCT01487278|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
79540956|NCT01487304|Drug|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
80012565|NCT02224586|Device|light treatment|clinical routine treatment according to the doctor's advice
79540957|NCT01487317|Drug|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity < 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity < 10, the active treatment will be stopped
79699557|NCT00571025|Behavioral|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
79843056|NCT00510874|Biological|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
80012566|NCT02224742|Device|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
79305495|NCT02623959|Drug|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
79305496|NCT02623959|Other|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
79305497|NCT02623959|Drug|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
79305498|NCT02623959|Behavioral|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
79699558|NCT04573959|Device|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
79699559|NCT04580342|Drug|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
79699560|NCT04580342|Drug|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
79699561|NCT00571142|Procedure|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
79843057|NCT00802724|Behavioral|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
79843058|NCT00802724|Behavioral|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
79843059|NCT00871026|Procedure|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
79843060|NCT00871026|Procedure|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
79843061|NCT00802802|Drug|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
79843062|NCT00802802|Drug|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
79843063|NCT00870168|Drug|chemotherapy|
79843064|NCT00870168|Genetic|gene expression analysis|
79699562|NCT00571142|Procedure|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
79699563|NCT03453905|Diagnostic Test|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
79247256|NCT02517723|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
79699564|NCT03453905|Other|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
79699565|NCT00584571|Procedure|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
79699566|NCT00584571|Drug|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
79699567|NCT03451500|Drug|carbidopa-levodopa|See previous
79699568|NCT04573998|Procedure|LSG|bariatric surgery
79699569|NCT00571181|Device|Closed-loop system|Automatic delivery of propofol and remifentanil
79699570|NCT00571181|Device|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
79843065|NCT00870168|Other|laboratory biomarker analysis|
79843066|NCT00870168|Procedure|breast biopsy|
79305499|NCT02454023|Device|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
79385904|NCT03414034|Drug|Prednisone|Prednisone orally
79385905|NCT03391869|Biological|Ipilimumab|Given IV
79385906|NCT03391869|Procedure|Local Consolidation Therapy|Undergo radiation and/or surgery
79385907|NCT03391869|Biological|Nivolumab|Given IV
79385908|NCT03391869|Other|Quality-of-Life Assessment|Ancillary studies
79385909|NCT03391869|Radiation|Radiation Therapy|Undergo radiation
79385910|NCT03391869|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79385911|NCT03375619|Other|Long-Term Follow-Up of Participants who Received CAR-T cells|No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
79843067|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
79843068|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
79843069|NCT00876876|Drug|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
79843070|NCT01012804|Genetic|western blotting|
79843071|NCT01012804|Other|immunohistochemistry staining method|
79305500|NCT02454023|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
79540958|NCT01487317|Drug|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity < 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity < 10, the placebo treatment will be stopped
80012567|NCT02224742|Other|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~Formal assessment of ulcer and surrounding skin~Provision of any necessary off-loading~Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~Appropriate dressing products~Appropriate antibiotic therapy~Nutrition and self care~Optimal glycaemic control~Revascularisation if deemed clinically necessary~Continued close observation"
80012568|NCT03068455|Biological|nivolumab|Specified Dose on Specified Days
79385912|NCT03366545|Device|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
80012569|NCT03068455|Biological|ipilimumab|Specified Dose on Specified Days
79385913|NCT03344666|Behavioral|Step 1 Treatment BI+HC|Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
79540959|NCT01487330|Device|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
79699571|NCT00584610|Device|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
79699572|NCT00584610|Device|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
80012570|NCT02230280|Other|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
79699573|NCT00571220|Procedure|gastric bypass surgery|weight loss bariatric surgery
80012571|NCT03067987|Device|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
79305501|NCT04936503|Diagnostic Test|Resting electrocardiogram|An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
79699574|NCT00571220|Other|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
79699575|NCT00584649|Procedure|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
79699576|NCT00571298|Procedure|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
79843072|NCT01012804|Other|laboratory biomarker analysis|
79843073|NCT00796874|Other|active surveillance|Correlative Study
79843074|NCT00796874|Other|imaging biomarker analysis|Correlative Study
79843075|NCT00796874|Procedure|biopsy|Tissue Removal
79843076|NCT00796874|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
79843077|NCT00796874|Procedure|magnetic resonance imaging|Radiolical Medical Imaging
79843078|NCT00796874|Procedure|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
79843079|NCT00876954|Procedure|Normothermia|Warming without increase in core temperature
79843080|NCT00876954|Procedure|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
79305502|NCT04936503|Diagnostic Test|Stress test|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
79305503|NCT04936503|Diagnostic Test|Cardiac echocardiography|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
79305504|NCT04936503|Diagnostic Test|Cardiac rhythm monitoring|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
79305505|NCT04936503|Other|Questionnaire|To determine the rhythmic risk of athletes
79385914|NCT03344666|Behavioral|Step 1 Treatment BI+TM|Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
79843081|NCT01565434|Other|CR1 impact|
79843082|NCT04898036|Device|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
79843083|NCT04898036|Device|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
79843084|NCT01565512|Drug|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
79540960|NCT01487343|Behavioral|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
79699577|NCT00571298|Drug|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
79699578|NCT00571298|Drug|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
79699579|NCT00571298|Drug|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
79699580|NCT00571298|Drug|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
79699581|NCT00571298|Procedure|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
79699582|NCT04574271|Behavioral|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
79699583|NCT04574271|Behavioral|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
79540961|NCT01487356|Other|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
79699584|NCT00571337|Drug|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
79699585|NCT04575519|Drug|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
79843085|NCT01565512|Drug|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
79843086|NCT00739661|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
79843087|NCT00739661|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
79843088|NCT04895930|Drug|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
80012572|NCT02259296|Procedure|Lower eGFR for AVF construction|Lower eGFR patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
79385915|NCT03344666|Behavioral|Step 2 Treatment Responders|"Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources."
79385916|NCT03344666|Behavioral|Step 2 Treatment Non-Responders|"Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM."
79385917|NCT03340129|Drug|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
80012573|NCT02259296|Procedure|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
79385918|NCT03340129|Drug|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
79385919|NCT03340129|Radiation|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
79540962|NCT01487369|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
79540963|NCT01487382|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
79699586|NCT04575519|Drug|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
79699587|NCT04575519|Drug|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
79699588|NCT04575519|Drug|SoC TB|Standard of Care Tuberculosis treatment
79699589|NCT00571376|Other|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
79699590|NCT04573803|Drug|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
79699591|NCT04573803|Drug|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
79699592|NCT04575441|Other|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
79699593|NCT04573374|Procedure|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
79385920|NCT03340129|Other|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
79385921|NCT03333408|Drug|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
79540964|NCT01487395|Drug|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
79540965|NCT01487395|Drug|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
79540966|NCT01487408|Drug|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
79540967|NCT01487421|Drug|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
79540968|NCT01487421|Drug|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
79540969|NCT01487434|Behavioral|Check & Connect|Structured mentoring and case management
79540970|NCT01487447|Other|Customized sound|treatment with customized sound therapy
79540971|NCT01487447|Other|Regular Masker|treatment with white noise
79540972|NCT01487460|Drug|TAP311|
79699594|NCT00571454|Behavioral|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
79699595|NCT01144663|Biological|Nimenrix™|4- or 3-dose intramuscular injection
79843089|NCT04895930|Drug|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
79843090|NCT00615030|Drug|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
79247257|NCT02517723|Behavioral|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
79247258|NCT02517723|Behavioral|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
79247259|NCT02517723|Other|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
79385922|NCT03317860|Device|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
79540973|NCT01487473|Behavioral|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
79540974|NCT01487486|Drug|IVF Antagonist Protocol|"Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle >14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
79843091|NCT00615030|Drug|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
79247260|NCT03888716|Drug|KL1333|25 and 100 mg KL1333 encapsulated tablets
79540975|NCT01487512|Drug|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
79540976|NCT01487512|Drug|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
79540977|NCT01487512|Drug|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
79540978|NCT01487512|Drug|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
79540979|NCT01487551|Drug|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
79540980|NCT01487564|Drug|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
79540981|NCT01487590|Other|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
79540982|NCT01487590|Other|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
79540983|NCT01487629|Drug|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
79540984|NCT01487629|Drug|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
79699596|NCT01144663|Biological|Menjugate®|3-dose intramuscular injection
79699597|NCT01144663|Biological|NeisVac-CTM|3-dose intramuscular injection
79699598|NCT01144663|Biological|Infanrix™ hexa|4-dose intramuscular injection
79699599|NCT01144663|Biological|Synflorix™|4-dose intramuscular injection
79699600|NCT00571571|Behavioral|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
79699601|NCT00571571|Behavioral|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
79699602|NCT00584688|Drug|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
79699603|NCT00571610|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
79699604|NCT00584766|Procedure|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
79699605|NCT04573686|Drug|Erythropoietin|Erythropoietin will be given subcutenous to all patients
79699606|NCT05206708|Behavioral|Personalized psychotherapy|Strategy including personalized psychotherapy
79843092|NCT00615030|Drug|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
79843093|NCT00615030|Drug|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
79843094|NCT02596061|Behavioral|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
79843095|NCT02596061|Other|Incentives|Patients receive incentives for completing smoking cessation activities.
79247261|NCT03888716|Drug|Placebo Oral Tablet|25 and 100 mg placebo encapsulated tablets
79385923|NCT03317860|Device|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
79540985|NCT01487642|Device|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
79540986|NCT01487642|Device|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
79540987|NCT01487642|Device|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
79699607|NCT05206708|Behavioral|Standard of care|Strategy based standard intregrative psychodynamic therapy
79699608|NCT02883634|Other|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
79699609|NCT02883634|Other|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
79699610|NCT04573257|Other|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
79843096|NCT00789308|Drug|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
79843097|NCT00789308|Drug|Heparin|Anticoagulation
79699611|NCT01143337|Drug|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
79699612|NCT01143337|Drug|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
79247262|NCT03841682|Behavioral|I-CARE2|"I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity."
79699613|NCT04313023|Drug|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
79843098|NCT00789308|Drug|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
79843099|NCT00789308|Drug|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
79843100|NCT00789308|Drug|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
79843101|NCT00789308|Drug|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
79843102|NCT00789308|Drug|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
79843103|NCT00789308|Drug|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
79843104|NCT00789308|Drug|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
79843105|NCT00518284|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m^2.
79843106|NCT02595359|Drug|Moxifloxacin|Moxifloxacin intracameral
79540988|NCT01487642|Device|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
80012574|NCT02232854|Behavioral|Depression training/supervision program|"The intervention will be composed of:~Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
80012575|NCT04207736|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
79540989|NCT01487694|Drug|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
79540990|NCT01487694|Drug|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
79699614|NCT04313023|Drug|Placebo|Sterile saline for inhalation
79699615|NCT02883595|Drug|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
79699616|NCT02883595|Other|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
79699617|NCT00571766|Drug|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
79699618|NCT00571766|Drug|Placebo|Placebo 2 g twice a day for 14 weeks
79699619|NCT01143259|Drug|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
79699620|NCT01143259|Drug|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
80012576|NCT04207736|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
79247263|NCT04503369|Behavioral|Non-technical skills|"Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team."
79247264|NCT03348267|Dietary Supplement|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
79247265|NCT03348267|Dietary Supplement|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
79247266|NCT05734976|Device|electroacupuncture|This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
79843107|NCT00871104|Drug|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
79843108|NCT00871104|Drug|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
79247267|NCT05256303|Other|Home Hospital care|Patients receive hospital-level care in their home
79247268|NCT05256303|Other|Traditional Hospital care|Patients receive hospital-level care in the hospital.
79247269|NCT03136796|Drug|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
79247270|NCT05243745|Other|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
79385924|NCT03308409|Other|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
79385925|NCT03282396|Drug|Ibrutinib|Given PO
79540991|NCT01487707|Behavioral|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
79540992|NCT01487707|Behavioral|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
79540993|NCT01487707|Behavioral|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
79540994|NCT01487720|Drug|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
79843109|NCT02554292|Device|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
80012577|NCT02232932|Procedure|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
80012578|NCT02232932|Procedure|RESECTION|Intent-to-treat R0 liver resection
80012579|NCT02230358|Procedure|Regional anesthesia|Regional anesthesia
79699621|NCT04573608|Drug|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
79699622|NCT04573608|Drug|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
79843110|NCT02595515|Other|Chiropractic treatment|Procedure: chiropractic treatment.
79843111|NCT02595515|Other|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
79843112|NCT03868566|Drug|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
79843113|NCT03868566|Drug|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
79843114|NCT00796952|Behavioral|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
79843115|NCT00796952|Behavioral|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
79843116|NCT00796952|Behavioral|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
79843117|NCT02595827|Other|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
79843118|NCT00871416|Device|NovoFine® needle 6 mm|
80012580|NCT02230358|Procedure|General anesthesia|General anesthesia
79385926|NCT03280394|Diagnostic Test|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
79843119|NCT00871416|Device|NovoFine® needle 12 mm|
79843120|NCT00614874|Drug|rosiglitazone|2mg, 4mg, 8mg
79843121|NCT02553980|Behavioral|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
79843122|NCT02553980|Other|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
80012581|NCT02230358|Device|Transcranial Doppler ultrasonography|6x for 4 hours
80012582|NCT02230358|Procedure|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
79247271|NCT05243745|Other|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
79385927|NCT03271489|Other|Elagolix Placebo|Tablets
79385928|NCT03271489|Drug|E2/NETA|Capsules
79385929|NCT03271489|Other|E2/NETA Placebo|Capsules
79385930|NCT03271489|Drug|Elagolix|Tablets
79385931|NCT03240861|Other|18F-FHBG|Given IV
80012583|NCT02230358|Procedure|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
80012584|NCT02230358|Procedure|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
79247272|NCT05243745|Other|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
79247273|NCT05243745|Other|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
79247274|NCT04500717|Drug|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79385932|NCT03240861|Biological|Aldesleukin|Given SC
79385933|NCT03240861|Drug|Busulfan|Given IV
79385934|NCT03240861|Biological|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
79385935|NCT03240861|Procedure|Computed Tomography|Undergo PET/CT
79385936|NCT03240861|Biological|Filgrastim|Given SC
79385937|NCT03240861|Drug|Fludarabine|Given IV
79385938|NCT03240861|Procedure|Leukapheresis|Undergo leukapheresis
79385939|NCT03240861|Drug|Plerixafor|Given SC
79385940|NCT03240861|Procedure|Positron Emission Tomography|Undergo PET/CT
79385941|NCT03237286|Drug|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
79385942|NCT03237286|Behavioral|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
79699623|NCT00571805|Drug|varencline|2.0 mg/day varencline (1.0 mg BID)
79699624|NCT00571805|Drug|placebo|matching placebo
79699625|NCT02883556|Drug|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
79699626|NCT04580069|Procedure|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
79843123|NCT00727415|Drug|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
79843124|NCT00727415|Drug|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
79843125|NCT00727415|Drug|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
79843126|NCT00803192|Drug|Famotidine Tablets, 40 mg|
79843127|NCT00544557|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
79843128|NCT02554214|Device|Glafkos drainage device|
79843129|NCT00877110|Drug|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
80012585|NCT02230358|Behavioral|Neurological Control|perioperative, 2-3 days, as done in clinical routine
79247275|NCT04500717|Drug|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
80012586|NCT02230358|Behavioral|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
80012587|NCT02230358|Device|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
79385946|NCT03170349|Device|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
79540995|NCT01487733|Genetic|gene expression analysis|
79843130|NCT00727259|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
79247276|NCT01680458|Drug|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended."
79540996|NCT01487733|Genetic|in situ hybridization|
79540997|NCT01487733|Other|immunohistochemistry staining method|
79699627|NCT00584961|Other|non-interventional|non-interventional
79540998|NCT01487733|Other|laboratory biomarker analysis|
79843131|NCT00727259|Drug|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
80012588|NCT02230436|Other|Early drain removal|Removing drain(s) on postoperative day 3
79540999|NCT01487759|Dietary Supplement|Oligofructose enriched inulin|
79541000|NCT01487759|Dietary Supplement|Maltodextrin|
79541001|NCT01487785|Drug|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
79541002|NCT01487798|Drug|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
80012589|NCT02230436|Other|Late drain removal|Removing drain(s) on postoperative day 4 or later
80012590|NCT02230514|Drug|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
80012591|NCT02230514|Other|autologous iliac crest|Autologous iliac crest in association with surgery
79247277|NCT03348189|Other|Pulse Oximeter|Pulse Oximeter
79385947|NCT03164993|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
79385948|NCT03164993|Drug|Pegylated liposomal doxorubicin|Chemotherapy
79385949|NCT03164993|Drug|Cyclophosphamide|Chemotherapy
79385950|NCT03164993|Other|Placebo|Placebo
79541003|NCT01487798|Drug|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
79541004|NCT01487811|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
79541005|NCT01487837|Drug|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
79541006|NCT01487850|Biological|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
79699628|NCT00571844|Behavioral|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
79843132|NCT00789386|Drug|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
79843133|NCT00789386|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
80012592|NCT02230514|Procedure|Surgery|Standard surgery for non-union fractures
79247278|NCT03348111|Device|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
79385951|NCT03110822|Drug|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
79385952|NCT03110822|Drug|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
79385953|NCT03110822|Drug|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
79385954|NCT03077542|Procedure|haploidentical stem cell transplant|haploidentical stem cell transplant
79385955|NCT03077542|Drug|sirolimus|conditioning regimen
79541007|NCT01487876|Biological|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
79541008|NCT01487876|Other|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
79385956|NCT03077542|Drug|campath|conditioning regimen
79247279|NCT03136718|Other|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
79385957|NCT03077542|Drug|pentostatin|conditioning regimen
79843134|NCT05157282|Device|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
79843135|NCT05157282|Other|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
79843136|NCT05157282|Other|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
80012593|NCT04132466|Device|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
80012594|NCT02233010|Other|The level of NGAL after pre op,post op 4hr, post op 12hr|
80012595|NCT04098848|Other|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
80012596|NCT03518138|Drug|Q-122|oral capsule of Q-122
79247280|NCT03346317|Device|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
79247281|NCT03346317|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
79247282|NCT03346317|Drug|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
79385958|NCT03077542|Drug|cyclophosphamide|conditioning regimen
79385959|NCT03077542|Drug|Hydroxyurea|conditioning regimen
79385960|NCT03051256|Drug|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
79385961|NCT03051256|Drug|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
79385962|NCT02998229|Device|Artisse™|Intrasaccular Device
80012597|NCT03518138|Drug|Placebo|oral capsule of placebo
79385963|NCT02931721|Diagnostic Test|MRI|Pelvis MRI
79385964|NCT02915120|Procedure|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
79385965|NCT02915120|Procedure|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
79385966|NCT02836236|Drug|TAF|TAF 25 mg tablet administered orally once daily
79385967|NCT02836236|Drug|TDF|TDF 300 mg tablet administered orally once daily
79385968|NCT02836236|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
79541009|NCT01487889|Other|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
79699629|NCT00571844|Behavioral|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
79247283|NCT04885790|Other|"Respiratory assessment using Spiropalm 6MWT portable spirometry"|"Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry."
79247284|NCT04885790|Other|Evaluation of functional exercise capacity|Functional exercise capacity of patients will be evaluated using six-minute walk test.
79247285|NCT04885790|Other|Evaluation of peripheral muscle strength|Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.
79247286|NCT04885790|Other|Evaluation of chronic cough|The Leicester Cough Questionnaire will be used for evaluating cough.
79247287|NCT02517333|Other|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
79247288|NCT01550432|Dietary Supplement|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
79247289|NCT01550432|Dietary Supplement|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
79385969|NCT02836236|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
79385970|NCT02823821|Other|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
79385971|NCT02823821|Other|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
79541010|NCT01487902|Drug|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
79541011|NCT01487902|Drug|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
79541012|NCT01487915|Drug|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
79541013|NCT01487915|Drug|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
79247290|NCT01550432|Other|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
79385972|NCT02728531|Drug|Bendamustine|
79541014|NCT01487967|Other|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
79541015|NCT01487980|Procedure|Cord clamping|Early vs Delayed
79541016|NCT01487993|Drug|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
79541017|NCT01487993|Behavioral|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
79541018|NCT01488006|Device|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
79699630|NCT00585000|Drug|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
79699631|NCT00571883|Other|questionnaire administration|
79699632|NCT00571883|Procedure|psychosocial assessment and care|
79699633|NCT00571883|Procedure|quality-of-life assessment|
79699634|NCT00571883|Procedure|regional lymph node dissection|
79699635|NCT00571883|Procedure|therapeutic conventional surgery|
79699636|NCT00585117|Procedure|PET-imaging with CuATSM|imaging with CuATSM
79699637|NCT00585117|Procedure|PET Imaging|Imaging with CuATSM
79699638|NCT00585117|Procedure|PET CuATSM|Imaging with CuATSM
79843137|NCT05157282|Device|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
79385973|NCT02728531|Drug|Rituximab|
79385974|NCT02728531|Drug|Cytarabine|
79541019|NCT01488058|Other|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
79699639|NCT00585117|Procedure|PET imaging|imaging with CuATSM
79699640|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
79385975|NCT02728531|Drug|Pegfilgrastim|
79385976|NCT02728531|Procedure|Leukapheresis|
79699641|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
79699642|NCT00572000|Biological|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
79699643|NCT00572078|Drug|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
79699644|NCT01142791|Device|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
79699645|NCT04573218|Drug|Placebo|The placebo contains glucose
79699646|NCT04573218|Dietary Supplement|250 mg OPP|250 mg Oil Palm Phenolics
79843138|NCT00789464|Dietary Supplement|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
79699647|NCT00572312|Drug|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
79699648|NCT00585156|Drug|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
79541020|NCT01488058|Other|Waitlist Control|Waitlist will receive iCBT at week 11
79247291|NCT04502277|Drug|Fluconazole Powder|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
79247292|NCT05732090|Other|therapeutic exercise program with pulmonary training|therapeutic exercise program with pulmonary training (3 sessions/week/two months).
79247293|NCT05732090|Other|diaphragmatic myofascial release|therapeutic exercise program with pulmonary training in addition to diaphragmatic myofascial release (3 sessions/week/two months).
79247294|NCT03347019|Other|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
79385977|NCT02728531|Drug|Filgrastim|
79541021|NCT01488084|Procedure|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
79247295|NCT03347019|Other|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
79699649|NCT00572351|Other|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
79699650|NCT00572351|Other|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
79699651|NCT01142596|Drug|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
79699652|NCT01142596|Drug|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
79699653|NCT00572390|Drug|oestrogen|Cyclic oestrogen substitution therapy
79699654|NCT01142128|Drug|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
79699655|NCT01142128|Drug|Placebo to Nexium|one capsule per day for one month
79699656|NCT01142128|Drug|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
79699657|NCT01142128|Drug|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
79699658|NCT04572867|Device|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
79247296|NCT05730608|Other|18F-FDG PET/CT|Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
79247297|NCT02517255|Device|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
79247298|NCT02574026|Behavioral|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
79247299|NCT02517489|Drug|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
79385978|NCT02728531|Procedure|Autologous stem cell transplant|
79385979|NCT02710331|Drug|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
79385980|NCT02710331|Drug|Placebo|Control: no alcohol, administered for ~80 minutes.
79385981|NCT02710331|Drug|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
79385982|NCT02710331|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
79385983|NCT02677974|Device|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
79541022|NCT01488084|Procedure|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
79541023|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
79541024|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
79699659|NCT04572867|Drug|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
79699660|NCT00572429|Dietary Supplement|l-carnitine|3 gram daily dose
79699661|NCT00572507|Device|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
79699662|NCT01142089|Drug|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
79843139|NCT00789464|Drug|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
79843140|NCT03967067|Procedure|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
79843141|NCT00977067|Drug|GDC-0152|Intravenous escalating dose
79843142|NCT00797030|Drug|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
79843143|NCT00797030|Drug|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
79843144|NCT00877188|Other|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
79843145|NCT02593955|Behavioral|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
79843146|NCT02593955|Behavioral|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
79247300|NCT02517489|Drug|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
79247301|NCT04882748|Other|ADAMO|Physical therapy provided with or without the help of a robot
79385984|NCT02670525|Genetic|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
79699663|NCT01142089|Drug|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
79247302|NCT05719766|Other|education ,psycological support and social support|we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
79385985|NCT02525185|Other|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
79699664|NCT00585390|Dietary Supplement|Omega-3 Fatty Acids|"Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~Docosahexaenoic acid fish oil concentrate at 1.6 grams"
79843147|NCT00977145|Biological|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
79247303|NCT03346941|Drug|DAA treatment|Direct-acting antiviral-based treatment
80012598|NCT04066634|Device|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
80012599|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
80012600|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
79247304|NCT03351543|Biological|microbial inoculate|volunteers will regularly receive microbial inoculate that they do not use orally
79247305|NCT04850144|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant D
79247306|NCT04850144|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant E
79247307|NCT04850144|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant F
79541025|NCT01488123|Behavioral|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
79541026|NCT01488136|Drug|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
79247308|NCT04850144|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant G
79247309|NCT04850144|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant H
79385986|NCT02476435|Device|Active rTMS|Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
79385987|NCT02476435|Device|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
79541027|NCT01488136|Drug|Placebo|Lactose Ph capsules (Placebo)
79541028|NCT01488175|Procedure|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
79541029|NCT01488175|Procedure|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
79699665|NCT00585390|Other|Olive oil placebo|Olive oil capsules, 8 capsules per day
79699666|NCT00585390|Dietary Supplement|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
79699667|NCT00585390|Drug|Placebo|Olive oil capsule
79699668|NCT01141660|Device|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
79699669|NCT01141660|Device|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
79247310|NCT04850144|Drug|Tiotropium Bromide Monohydrate|Spiriva 18 µg/capsule inhaled via Handihaler
79385988|NCT02461927|Drug|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
79385989|NCT02461927|Drug|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
79385990|NCT02461927|Drug|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
79699670|NCT02883790|Dietary Supplement|Somnage|Melatonin 1mg, Zinc, Magnesium
79699671|NCT02883790|Other|Placebo|Placebo
79699672|NCT00572663|Drug|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
79699673|NCT04572672|Other|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
79541030|NCT01488201|Drug|Placebo|
79699674|NCT01140880|Drug|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
79699675|NCT00572702|Procedure|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
79699676|NCT00572702|Procedure|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
80012601|NCT03494504|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
79247311|NCT04850144|Drug|Tiotropium Easyhaler with oral activated charcoal|The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
79385991|NCT02403323|Drug|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
79541031|NCT01488201|Drug|KHK4827|
79541032|NCT01488214|Other|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
79699677|NCT01140646|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
79699678|NCT01140646|Other|questionnaire administration|Ancillary studies
79699679|NCT01140646|Procedure|quality-of-life assessment|Ancillary studies
79843148|NCT05226000|Drug|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
80012602|NCT04049864|Biological|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
79385992|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79385993|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79247312|NCT02517411|Other|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
79385994|NCT02344498|Drug|Tenofovir disoproxil|
79385995|NCT02294357|Drug|Carfilzomib|
79385996|NCT02294357|Drug|Dexamethasone|If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
79385997|NCT02294357|Drug|Prednisone|f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
79385998|NCT02294357|Drug|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
79385999|NCT02294357|Drug|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
79386000|NCT02294357|Drug|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
79386001|NCT02255422|Drug|Omaveloxolone capsules, 2.5 mg|
79386002|NCT02255422|Drug|omaveloxolone capsules, 5 mg|
79541033|NCT01488227|Dietary Supplement|Vitamin D|4000 IU of Vitamin D daily for 6 months
79541034|NCT01488227|Dietary Supplement|Placebo|Acts as a control for the Vitamin D intervention
79541035|NCT01488253|Drug|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
79541036|NCT01488253|Drug|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
79699680|NCT00572741|Dietary Supplement|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
79541037|NCT01488266|Drug|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
79699681|NCT00572741|Dietary Supplement|Placebo|cellulose
79699682|NCT00572741|Dietary Supplement|folate|Folinic acid: Dose: 400 µg twice a day (BID)
79699683|NCT00572741|Dietary Supplement|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
79386003|NCT02255422|Drug|omaveloxolone capsules, 10 mg|
79699684|NCT00572741|Dietary Supplement|vitamin C|Vitamin C 500 mg
79699685|NCT00572741|Dietary Supplement|cod liver oil|Cod liver oil 1/2 teaspoon
79843149|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
79843150|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
79843151|NCT00803348|Drug|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
79541038|NCT01488266|Drug|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
79843152|NCT00918047|Drug|SPN-804O|Open Label study
79247313|NCT02517411|Other|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
79541039|NCT01488292|Behavioral|RECAP social skills and reading program|weekly individual and group sessions
79699686|NCT00572741|Dietary Supplement|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
79699687|NCT00572741|Dietary Supplement|carnitine|Acetyl L-Carnitine Dose: 250 mg
79843153|NCT00980733|Dietary Supplement|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
79247314|NCT04543136|Device|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.
79247315|NCT04543136|Device|New intermittent Variant 1 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
79843154|NCT00980733|Dietary Supplement|Yoghurt|Plain yoghurt same as in intervention group without fortification
80012603|NCT04049864|Biological|Salmonella oral vaccine|suspension 10^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
79247316|NCT04543136|Device|New intermittent Variant 2 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
79386004|NCT02255422|Drug|Placebo capsules|
79386005|NCT02255422|Drug|omaveloxolone capsules, 20 mg|
79386006|NCT02255422|Drug|omaveloxolone capsules, 40 mg|
79386007|NCT02255422|Drug|omaveloxolone capsules, 80 mg|
79386008|NCT02255422|Drug|omaveloxolone capsules, 160 mg|
79386009|NCT02142959|Drug|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
79386010|NCT02142959|Drug|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
79386011|NCT02142959|Drug|Vehicle Lotion|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
79386012|NCT02142959|Radiation|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
79699688|NCT01140568|Drug|nilotinib|400mg po (orally) BID (twice daily)
79699689|NCT04572945|Diagnostic Test|kidney function test|laboratory and imaging
79699690|NCT00572819|Drug|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
79699691|NCT00572819|Drug|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
79699692|NCT00572858|Procedure|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
79699693|NCT00572858|Genetic|Blood test|Blood test for genetic testing
79699694|NCT00572858|Procedure|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
79699695|NCT00572858|Procedure|Saliva test|Saliva test for cotisol levels
79699696|NCT00572975|Other|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
79699697|NCT00585624|Dietary Supplement|Impact Advanced Recovery|Nutritional supplement
79541040|NCT01488305|Dietary Supplement|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
79699698|NCT00585624|Dietary Supplement|No supplement|No supplement
79699699|NCT04580186|Procedure|bladder exstrophy repair|primary complete bladder exstrophy repair
79699700|NCT04572555|Other|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
79699701|NCT03451110|Drug|lemborexant|oral tablet
79699702|NCT03451110|Drug|Loestrin|oral tablet
79699703|NCT03451110|Drug|famotidine|oral tablet
79699704|NCT03451110|Drug|fluconazole|oral tablet
79699705|NCT03453827|Other|no intervention|no intervention
79843155|NCT00877266|Procedure|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
79843156|NCT02553824|Drug|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
79843157|NCT02553824|Drug|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
79247317|NCT05585073|Other|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
79386013|NCT02128113|Drug|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
79247318|NCT04796870|Other|Online Brain and Balance Training Program|The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
79386014|NCT02128113|Drug|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
79541041|NCT01488305|Other|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
79541042|NCT01488344|Drug|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
79541043|NCT01488383|Drug|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
79843158|NCT00980889|Device|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
79843159|NCT00980889|Device|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
80012604|NCT04049864|Drug|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
79386015|NCT02128113|Drug|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
79386016|NCT02065375|Drug|Omaveloxolone Ophthalmic Suspension 1.0%|
79541044|NCT01488383|Drug|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
79541045|NCT01488396|Drug|0.05%cyclosporin eye drop|use twice daily for 6 months
79541046|NCT01488422|Behavioral|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
79541047|NCT01488435|Dietary Supplement|Cow's milk|Powdered whole cow's milk
79699706|NCT03451032|Other|Non Interventional Study|Non Interventional Study
79699707|NCT03453788|Device|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
79699708|NCT03453749|Dietary Supplement|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
80012605|NCT03475706|Drug|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
80012606|NCT03475706|Drug|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
80012607|NCT03475706|Drug|Matching Placebo|twice daily for 12 weeks.
80012608|NCT04035200|Drug|V117957 tablets|V117957 tablets taken orally at bedtime
80012609|NCT04035200|Drug|Placebo|Tablets to match V117957
79247319|NCT02517177|Other|Parabolic flight|
79386017|NCT02065375|Drug|Omaveloxolone Opthalmic Suspension 0.5%|
79386018|NCT02065375|Drug|Placebo|
79386019|NCT02036970|Drug|Bardoxolone methyl|
79386020|NCT02036970|Drug|Placebo|
79386021|NCT02013154|Drug|DKN-01 150 mg|Administered by IV infusion
79699709|NCT03450993|Other|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
79699710|NCT03450954|Procedure|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
79541048|NCT01488435|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
79541049|NCT01488461|Genetic|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
79699711|NCT03453671|Behavioral|Mindfulness|Participants will use mindfulness techniques while exercising
79699712|NCT03453671|Behavioral|Distraction|Participants will distract themselves while exercising
79699713|NCT03453671|Behavioral|Self-monitoring|Participants will use associative attentional focus while exercising
80012610|NCT03997838|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
80012611|NCT03997838|Drug|Placebo|IV infusion of 0 mg of VVZ-149
80012612|NCT03986138|Drug|gadopiclenol|Single intravenous bolus injection
80012613|NCT03986138|Drug|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
80012614|NCT02234336|Procedure|Noncontrast echocardiography|
79247320|NCT02517177|Other|Cardiovascular parameters measurements|
79386022|NCT02013154|Drug|Paclitaxel|Administered by IV infusion
79386023|NCT02013154|Drug|Pembrolizumab|Administered by IV infusion
79386024|NCT02013154|Drug|DKN-01 300 mg|Administered by IV infusion
79541050|NCT01488474|Procedure|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
79699714|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
80012615|NCT02234336|Procedure|Contrast Echocardiography|
79699715|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
79386025|NCT01909492|Procedure|Blood Draw|Patients will provide a serum sample for research.
79247321|NCT04746404|Behavioral|Emotional Skills Development Program|Emotional Skills Development Program (positive psychology)
79247322|NCT04590794|Diagnostic Test|Soluble Urokinase Plasminogen Activator Receptor|Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
79247323|NCT00709761|Drug|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
79386026|NCT01909492|Procedure|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
79386027|NCT01827787|Drug|Eribulin|
79541051|NCT01488500|Other|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
79386028|NCT01823848|Drug|Sodium phosphate enema|Rectally administered medication to treat constipation
79386029|NCT01823848|Drug|Normal saline enema|Rectally administered medication to treat constipation
79699716|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
79386030|NCT01823848|Drug|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
79699717|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
79386031|NCT01743950|Drug|Bevacizumab|10mg/kg every 2weeks.
79386032|NCT01743950|Radiation|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
79541052|NCT01488513|Drug|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
79541053|NCT01488526|Drug|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
79541054|NCT01488552|Drug|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
79699718|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
79699719|NCT00573014|Other|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
79699720|NCT00573053|Other|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
79699721|NCT00573053|Other|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
79699722|NCT00585819|Procedure|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
79699723|NCT00585819|Procedure|Freebreathing in Body fix mold|Freebreathing in Body fix mold
80012616|NCT02234336|Procedure|Cardiac magnetic resonance imaging|
80012617|NCT02234492|Drug|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
80012618|NCT01529996|Procedure|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
80012619|NCT03933410|Drug|KB195|KB195 is a novel glycan
79247324|NCT01792310|Drug|LAM561|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
79541055|NCT01488552|Drug|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
79541056|NCT01488552|Drug|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
79247325|NCT01789346|Device|532nm KTP|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
79247326|NCT01789346|Device|595nm PDL|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
79247327|NCT05584839|Other|Statistically Analysis|The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
79386033|NCT01717261|Radiation|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
79541057|NCT01488552|Genetic|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
79541058|NCT01488552|Drug|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
79541059|NCT01488552|Drug|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
79541060|NCT01488565|Drug|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
79541061|NCT01488604|Device|Polymeric Nasal Spray|Experimental nasal spray
79541062|NCT01488604|Device|Sham Nasal Spray|Sham nasal spray
79541063|NCT01488630|Other|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
79699724|NCT03450876|Other|Non-Interventional|Non-Interventional
79843160|NCT04039854|Drug|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
80012620|NCT04950842|Biological|JB-101|induced T cell with suppressive function
79247328|NCT02516943|Other|Control|The patient's ABGs were test according to a 4 - hour routine
79247329|NCT02516943|Other|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
79247330|NCT05377892|Other|Dietary protein|High protein followed by reduced protein diet
79541064|NCT01488656|Dietary Supplement|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
79699725|NCT00573209|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
79699726|NCT01140451|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
79699727|NCT03450837|Diagnostic Test|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
80012621|NCT03303170|Device|Sebacia Microparticles|Topical microparticle suspension
80012622|NCT03303170|Device|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
80012623|NCT03928184|Drug|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
80012624|NCT03928184|Drug|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
79699728|NCT03450837|Diagnostic Test|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
79699729|NCT04579913|Other|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
79699730|NCT03450798|Device|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
79843161|NCT04039854|Drug|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
79843162|NCT04045730|Drug|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
79843163|NCT00977223|Drug|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
80012625|NCT02259374|Procedure|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
79247331|NCT02516865|Device|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
79247332|NCT02516865|Device|Ankle weights|Worn during typical daily activities.
79386034|NCT01593202|Behavioral|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
79386035|NCT01593202|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
79541065|NCT01488656|Dietary Supplement|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
79541066|NCT01488669|Procedure|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
79541067|NCT01488669|Procedure|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
79843164|NCT00803426|Procedure|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
79247333|NCT04502199|Other|non interventional study|observational study
79247334|NCT04208906|Device|Masimo O3|"After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~T2: before CPB, FiO2 0.5~T3: before CPB, FiO2 0.8~T4: after CPB, FiO2 0.8~T5: after CPB, FiO2 0.5~T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2."
79247335|NCT03348033|Biological|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
79541068|NCT01488682|Procedure|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
80012626|NCT02259374|Procedure|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
80012627|NCT03204422|Other|No intervention|no any other intervention
80012628|NCT03197870|Drug|AKB-9778|Subcutaneous AKB-9778 15mg
79699731|NCT03450798|Device|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
79699732|NCT00585897|Behavioral|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
79247336|NCT03347955|Procedure|Neural implantation group|Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
79843165|NCT00977301|Drug|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
79843166|NCT00977301|Drug|olanzapine|15 mg olanzapine single dose
79843167|NCT00977301|Drug|olanzapine|10 mg olanzapine single dose
80012629|NCT03197870|Drug|Placebo|Subcutaneous Placebo
79247337|NCT03347955|Procedure|Sham surgery|Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
79247338|NCT05584761|Drug|unrelated umbilical cord blood|"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."
79247339|NCT05584605|Behavioral|Aerobic treadmill training|The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.
79247340|NCT05584605|Behavioral|Stretching exercise|Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
79247341|NCT04137458|Biological|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
79247342|NCT03346785|Behavioral|Food Photography|Participants will engage in food photography on their smart phones while eating
79247343|NCT03346785|Behavioral|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
79247344|NCT03346785|Behavioral|No Phone Use|Participants will not use their smart phones while eating
79386036|NCT01522768|Drug|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
79541069|NCT01488682|Procedure|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
79541070|NCT01488695|Device|GlideScope Groove|GlideScope Groove
79541071|NCT01488695|Device|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
79541072|NCT01488734|Dietary Supplement|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
79541073|NCT01488734|Dietary Supplement|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
79541074|NCT01488734|Dietary Supplement|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
79541075|NCT01488734|Dietary Supplement|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
79541076|NCT01488734|Drug|Placebo|Placebo for the fortified mushroom arms
79699733|NCT04579796|Other|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
79843168|NCT00803504|Procedure|ocular blood flow measurement|
79843169|NCT00735371|Drug|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
79247345|NCT02516787|Other|Parabolic flight|
79386037|NCT01484327|Drug|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
79541077|NCT01488747|Dietary Supplement|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
79699734|NCT04579796|Procedure|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
79699735|NCT00573326|Drug|Imatinib|200 mg p.o. once a day for 6 months
79699736|NCT01140061|Drug|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
79699737|NCT01140061|Drug|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
79843170|NCT00735371|Drug|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
79843171|NCT00735371|Drug|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
79843172|NCT00735371|Drug|Placebo|Placebo will be identical to test product.
80012630|NCT04921982|Drug|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
80012631|NCT04921982|Drug|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
80012632|NCT04889222|Device|INVSENSOR00050|Noninvasive pulse oximeter sensor
79699738|NCT01140061|Drug|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
79386038|NCT01484210|Drug|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
79843173|NCT00518206|Biological|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
79699739|NCT01140061|Drug|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
79699740|NCT01140061|Drug|Plain patch|Plain patch containing no MK-0873 or placebo
79541078|NCT01488747|Dietary Supplement|Coromega Nectar|660 mg EPA, 436 mg DHA
79699741|NCT04312750|Drug|Lidocaine topical system 1.8%|
79699742|NCT00573365|Device|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
79699743|NCT00573365|Radiation|Radiation|Weekly radiation treatment
79843174|NCT00518206|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
79843175|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
79843176|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
79541079|NCT01488747|Dietary Supplement|Barleans Swirl|660 mg EPA, 660 mg DHA
79699744|NCT00573365|Radiation|Radiation|Weekly radiation treatment
79699745|NCT00586014|Procedure|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
79699746|NCT01139164|Drug|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
79699747|NCT01139164|Drug|Regimen B|Other malignancies not addressed in A or C
79699748|NCT01139164|Drug|Regimen C|B-Cell Lymphomas
79699749|NCT00573404|Drug|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
79699750|NCT00573404|Drug|sunitinib malate|
79699751|NCT00573404|Other|pharmacological study|
79699752|NCT01139125|Drug|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
79843177|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
79699753|NCT03450759|Drug|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
79699754|NCT03450759|Drug|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
79843178|NCT00984945|Biological|Placebo|0.5 mL, IM, two injections 21 days apart
79843179|NCT00871650|Other|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
80012633|NCT04889222|Device|RD SET SpO2|Noninvasive pulse oximeter sensor
79386043|NCT00836823|Drug|Alfuzosin|Alfuzosin 10mg once daily for 12 months
79386044|NCT00397644|Behavioral|Prompting (survey instrument/resources list) (behavior)|
79386045|NCT00344058|Drug|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
79386046|NCT00230100|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
79541080|NCT01488747|Dietary Supplement|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
79541081|NCT01488773|Drug|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
79541082|NCT01488773|Drug|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
79699755|NCT03450759|Drug|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
79699756|NCT03450759|Drug|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
79699757|NCT01139047|Drug|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
79699758|NCT01139047|Drug|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
79699759|NCT00573482|Behavioral|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~Four group education sessions to introduce the REDE principles of eating;~Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
79843180|NCT00871650|Other|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
79843181|NCT00871650|Other|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
79843182|NCT04046588|Diagnostic Test|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
79843183|NCT04046588|Procedure|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
80012634|NCT04874324|Drug|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
80012635|NCT04874324|Other|Placebo Oral|Subjects will receive matching placebo
80012636|NCT04866056|Drug|Jaktinib|Jaktinib PO BID
79541083|NCT01488786|Device|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
79699760|NCT00573482|Behavioral|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
79699761|NCT02883829|Behavioral|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
79843184|NCT04981431|Drug|Elinzanetant (BAY3427080)|Oral administration
80012637|NCT04866056|Drug|azacitidine|Azacytidine SC
80012638|NCT03911102|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
80012639|NCT04789148|Drug|Oxytocin nasal spray|4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo
80012640|NCT03892772|Drug|SAS0421a|treatment will be given for 3 days
80012641|NCT03892772|Drug|SAS0421b|treatment will be given for 3 days
80012642|NCT03892772|Drug|SAS0421c|treatment will be given for 3 days
80012643|NCT03892772|Drug|placebo|placebo will be given for 3 days
79843185|NCT04981431|Drug|Placebo|Oral administration
80012644|NCT03172910|Drug|Ciraparantag|Ciraparantag (administered over 10 minutes)
80012645|NCT03172910|Drug|Placebo|Saline for injection
80012646|NCT03172910|Drug|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
80012647|NCT04684940|Biological|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
80012648|NCT03881852|Drug|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
80012649|NCT03881852|Drug|Placebo|Dosed orally, twice daily for up to 3 weeks
80012650|NCT03818828|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
80012651|NCT03818828|Other|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
80012652|NCT03818828|Other|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
80012653|NCT03124862|Device|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
79247346|NCT02516787|Other|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
79247347|NCT02516787|Other|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
79247348|NCT02516631|Drug|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
79247349|NCT02516631|Drug|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
79247350|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
79247351|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
79247352|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
80012654|NCT02804282|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
80012655|NCT03789656|Drug|Paltusotine|Paltusotine, capsules, once daily by mouth
79699762|NCT02883829|Behavioral|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
79699763|NCT03450720|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single dose
79699764|NCT04310878|Other|Survey among perioperative nurses and surgeons|Online survey
79699765|NCT01139008|Drug|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
79699766|NCT01139008|Drug|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
79699767|NCT03450681|Procedure|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
80012656|NCT00974870|Procedure|needling treatment|Needling treatment applied to half of the face at each study visit
79247353|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
79699768|NCT03450681|Procedure|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
79843186|NCT00879918|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
79843187|NCT00803582|Procedure|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
79843188|NCT00803582|Procedure|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
79699769|NCT00573560|Device|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
79843189|NCT01565590|Drug|Dexmedetomidine|0.2-1.5 mcg/kg/hr
79843190|NCT01565590|Drug|propofol|5-80 mcg/kg/min
79247354|NCT02516475|Dietary Supplement|zinc sulfate|1 zinc sulfate capsule for 15 weeks
79247355|NCT02516475|Other|corn starch|1 corn starch capsule for 15 weeks
79541084|NCT01488799|Behavioral|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
79843191|NCT00877422|Dietary Supplement|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
79843192|NCT00980967|Other|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
79843193|NCT04088201|Device|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
79843194|NCT04007133|Other|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
79843195|NCT00797186|Other|Intensive risk factor management|Aggressive medical and lifestyle therapy.
80012657|NCT02233244|Drug|CTX-4430|
80012658|NCT02233244|Drug|Midazolam|
80012659|NCT02259530|Behavioral|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
80012660|NCT02234648|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
79541085|NCT01488825|Behavioral|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
79541086|NCT01488838|Drug|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
79699770|NCT03450642|Other|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
79699771|NCT00573599|Drug|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
79699772|NCT00573599|Drug|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
79843196|NCT00586313|Device|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
79843197|NCT00586313|Procedure|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
79843198|NCT00871806|Drug|Commercial tablet with water|40 mg tablet, given once to each subject
80012661|NCT02234648|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
79247356|NCT05083286|Drug|OnabotulinumtoxinA|Injection of glabellar rhytids
79247357|NCT02516397|Dietary Supplement|Omnia|12weeks of treatment
79843199|NCT00871806|Drug|ODT #1 without water|40 mg tablet given once to each subject
79843200|NCT00871806|Drug|ODT #2 without water|40 mg tablet given once to each subject
79843201|NCT00871806|Drug|ODT #1 with water|40 mg tablet given once to each subject
79843202|NCT00871806|Drug|ODT #2 with water|40 mg tablet given once to each subject
79386047|NCT00230100|Behavioral|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
79541087|NCT01488838|Radiation|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
79699773|NCT04572516|Drug|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
79699774|NCT04572516|Drug|BTX A Injection|In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
79699775|NCT00573638|Device|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
79699776|NCT01138657|Biological|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
79843203|NCT02553668|Drug|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
79843204|NCT02553668|Device|Facemask|
79843205|NCT00877578|Dietary Supplement|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
79541088|NCT01488864|Behavioral|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
79843206|NCT00877578|Dietary Supplement|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
79247358|NCT02516397|Dietary Supplement|Placebo|12weeks of treatment
79843207|NCT03967145|Behavioral|Determining quality of life|Quality of Life
80012662|NCT02234726|Behavioral|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
80012663|NCT02234804|Device|Xience Prime Stent|
79247359|NCT05026424|Other|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
79247360|NCT05026424|Other|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
79699777|NCT01138657|Drug|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
79699778|NCT01138657|Drug|Placebo|Administered by subcutaneous injection
80012664|NCT02234804|Device|Medtronic Resolute Integrity stent|
80012665|NCT02234804|Procedure|Angiography|
80012666|NCT02234804|Procedure|OCT|
80012667|NCT02234882|Drug|Rosuvastatin|
80012668|NCT02234882|Drug|BMS-663068|
79305506|NCT04936503|Device|Injected Cardiac MRI|"High resolution MRIs is performed on 200 athletes :~100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)"
79699779|NCT04572282|Device|Mentora app|Remote monitoring mobile app
79699780|NCT01138501|Drug|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
79843208|NCT04007913|Behavioral|teleCBIT|Eight sessions of individual behavior therapy
79843209|NCT04046432|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
79843210|NCT04046432|Dietary Supplement|Placebo|Maltodextrin was used as a placebo.
79386048|NCT00202007|Drug|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
79386049|NCT00202007|Drug|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
79386050|NCT03245814|Behavioral|Service Dog|A service dog trained to perform tasks that are specific to PTSD
79843211|NCT02593799|Procedure|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
79843212|NCT04039698|Other|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
79843213|NCT04039698|Drug|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
79843214|NCT04006821|Drug|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
79843215|NCT04006821|Drug|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
79247361|NCT03121911|Other|Interval Training (IT)|"Each exercise session will consist of:~warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
79541089|NCT01488942|Other|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
79247362|NCT03121911|Other|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2."
79247363|NCT02239315|Other|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
79247364|NCT03423680|Drug|Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
79541090|NCT01488955|Drug|Ibuprofen|400 mg oral once a day from day 0 for 3 days
79541091|NCT01488955|Drug|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
79386051|NCT03251430|Procedure|gastrectomy|Distal gastrectomy, Total gastrectomy
79386052|NCT00897507|Other|Laboratory Biomarker Analysis|Correlative studies
79386053|NCT03254862|Procedure|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
79541092|NCT01488968|Radiation|Standard Radiation Treatment|39 radiation treatments
79541093|NCT01488968|Radiation|Hypofractionated radiation treatment|25 radiation treatments
79541094|NCT01488981|Other|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
79541095|NCT01488981|Device|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
79541096|NCT01489033|Biological|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
79541097|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
79541098|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
79699781|NCT01138501|Drug|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
79699782|NCT02883361|Behavioral|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
79699783|NCT02883361|Behavioral|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
79699784|NCT04572360|Other|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
79699785|NCT04572360|Other|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
79699786|NCT01138150|Drug|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
79843216|NCT00871884|Behavioral|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
79843217|NCT00871884|Behavioral|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
79843218|NCT00871884|Behavioral|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
79699787|NCT01138150|Drug|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
79247365|NCT03423680|Drug|Placebo of Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
79541099|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
79843219|NCT02554994|Other|Multifactorial intervention|"There are six components of intervention in this study.~For all participants:~Group exercise~Nutritional supplement(commercial liquid formula will be provided every day).~For selected participants:~Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
80012669|NCT05627726|Device|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
80012670|NCT05627726|Other|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
80012671|NCT02234960|Drug|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
80012672|NCT02235038|Behavioral|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
80012673|NCT02235038|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
80012674|NCT02235038|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
79247366|NCT02239393|Biological|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
79247367|NCT05584371|Dietary Supplement|Free Beta-hydroxybutyrate|Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
80012675|NCT02235116|Other|Survey|
79247368|NCT05094830|Procedure|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
79386054|NCT03254862|Procedure|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
79386055|NCT03245502|Biological|Blood transfusion|The transfusion of erythrocyte suspension
79386056|NCT04487730|Behavioral|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
79699788|NCT00573911|Procedure|Endoscopy and pH study|endoscopy and PH study done one time
80012676|NCT03727334|Behavioral|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
79386057|NCT04487730|Behavioral|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
80012677|NCT03727022|Drug|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
80012678|NCT03727022|Drug|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
80012679|NCT02259452|Procedure|SPECT Lung Perfusion Scan|
80012680|NCT02259452|Procedure|SPECT Heart Perfusion Scan|
80012681|NCT02259452|Procedure|Pulmonary Function Tests|
80012682|NCT02259686|Drug|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
79386058|NCT03845361|Procedure|Radial artery cannulation|Radial artery cannulation
79699789|NCT01138111|Drug|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
79386059|NCT04775121|Other|Deuterium Glucose|Oral administration of 20 g Deuterium Glucose on a 3-hour
79386060|NCT03245424|Drug|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
79386061|NCT03251040|Device|Autologous activated fibrin sealant|Application of fibrin sealant
79386062|NCT04754763|Drug|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
79541100|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
79843220|NCT02554994|Other|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
80012683|NCT02259686|Drug|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
79849017|NCT05594394|Behavioral|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, & Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
80012684|NCT02259686|Drug|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
80012685|NCT02259686|Drug|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
80012686|NCT02259686|Drug|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
80012687|NCT02259764|Drug|KUC 7483 CL - single rising dose|
80012688|NCT02259764|Drug|Placebo|
80012689|NCT02259764|Other|standardized high fat meal|
80012690|NCT02233322|Dietary Supplement|Iron|All subjects will receive iron supplementation based on iron levels in the blood
80012691|NCT02233400|Drug|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
79247369|NCT03579511|Procedure|External Pop-out|The original techniques of fetal head extraction entail the introduction of the obstetricians' hands or other instruments into the LUS. This puts the LUS at risk of damage and incision extensions with its consequences of increased blood loss, increased operative time,infection adhesions and blood transfusion.To the available, the generated good quality evidence bases practice in CS is anticipated to decrease such morbidities
79247370|NCT02516319|Drug|ICG Dye|
79386063|NCT04754763|Drug|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific & Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
79386064|NCT03254550|Other|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
79541101|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
79541102|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
79541103|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
79541104|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
79541105|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
79541106|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
79541107|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
79541108|NCT01489124|Drug|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
80012692|NCT03067441|Drug|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
80012693|NCT03687632|Biological|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
80012694|NCT02235194|Dietary Supplement|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
80012695|NCT02235194|Dietary Supplement|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
79247371|NCT04443543|Drug|Capecitabine (Xeloda) Pharmacogenetic Test Reagents|CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
79247372|NCT04443543|Drug|irinotecan|CRT:80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1
79247373|NCT04443543|Radiation|IMRT|Pelvic Radiation: 50Gy/25Fx
79247374|NCT04443543|Drug|Oxaliplatin|FOLFIRINOX: 85mg/m2 d1
79247375|NCT04443543|Drug|5Fluorouracil|FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
79247376|NCT04443543|Drug|Tislelizumab|200mg iv
79386065|NCT04774653|Other|No intervention|Associations and prevalence will be calculated
79386066|NCT03251196|Other|No Intervention, and Observational Study|Observational Study
79386067|NCT02455206|Behavioral|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
79386068|NCT02455206|Behavioral|Usual care|
79386069|NCT02454894|Drug|lidocaine|surface anesthesia with lidocaine
79386070|NCT02454894|Procedure|postoperative management|lying without the pillow for half an hour after lumbar puncture
79386071|NCT02455128|Other|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
79699790|NCT00586092|Drug|bevacizumab, ABT-510|"Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days*~Stage 2 (RPTD) ABT-510: X mg SC BID**, bevacizumab: Y mg/kg IV every 14 days**~Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~*Both agents begin on Day 1 of Cycle 1.~**At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
79843221|NCT04007679|Other|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
79247377|NCT04874948|Drug|500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043|Single oral administration of 14C-labeled radioactive 500mg BTZ-043
79386072|NCT03250962|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
79541109|NCT01489137|Drug|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
79541110|NCT01489163|Behavioral|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
79541111|NCT01489202|Device|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
79541112|NCT01489202|Device|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
79541113|NCT01489215|Behavioral|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
79541114|NCT01489215|Behavioral|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
79849018|NCT05586971|Drug|Tigulixostat|Xanthine Oxidase Inhibitor
79849019|NCT05586971|Drug|Allopurinol|Xanthine Oxidase Inhibitor
80012696|NCT03684278|Drug|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
79247378|NCT02516085|Drug|Metformin|
79386073|NCT03250962|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
79386074|NCT04778943|Other|Surgery(OLIF and MIS-TLIF)|oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
79541115|NCT01489228|Drug|E1224|100 mg tablets
79541116|NCT01489228|Drug|Benznidazole|100mg tablets
79541117|NCT01489228|Drug|Placebo|tablets
79699791|NCT01137955|Drug|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
79699792|NCT01137955|Drug|Placebo|Placebo orally three times a day for 10 days total
79247379|NCT02516085|Drug|L-Arginine|
79247380|NCT03298256|Radiation|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
79247381|NCT05069493|Procedure|simple suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
79247382|NCT05069493|Procedure|mesh|Hiatal hernia repair by tension-free mesh closure
79247383|NCT02515929|Dietary Supplement|Oligomeric Proanthocyanidins|
79247384|NCT02515929|Dietary Supplement|Placebo|
79247385|NCT03347721|Drug|lidocaine gel|2% lidocaine jelly, injected into the urethra
79247386|NCT03347721|Drug|Lubricant Gel|Lubricating gel
79247387|NCT05584215|Behavioral|Cognitive Behavioural Therapy for Psychosis Groups|Groups based on cognitive behavioural therapy for psychosis
79386075|NCT04774341|Drug|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
79386076|NCT04774263|Other|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential real time localization system
79247388|NCT03347643|Device|tDCS with real stimulation|tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
79386077|NCT04774029|Procedure|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
80012697|NCT03684278|Drug|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
79247389|NCT03347643|Device|tDCS with sham stimulation|Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
79247390|NCT03346005|Device|Aeonose|An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
79843222|NCT02592785|Drug|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
79843223|NCT00871962|Other|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
79843224|NCT00803816|Drug|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
80012698|NCT03684278|Other|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
79247391|NCT02848651|Drug|Atezolizumab|Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
79541118|NCT01489241|Procedure|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
80012699|NCT02726659|Drug|Celecoxib|Adjunct celecoxib
79247392|NCT00709059|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
79247393|NCT00709059|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg: 800 mg; 65 - 85 kg: 1000 mg; >85 kg: 1200 mg) orally for 48 weeks
79247394|NCT03345927|Other|no intervention|no intervention
79247395|NCT04500561|Drug|YY-20394|Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
79247396|NCT05094752|Device|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
79386078|NCT04774029|Drug|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
79541119|NCT01489267|Other|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
80012700|NCT02726659|Drug|Placebo|Adjunct placebo
79541120|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
80012701|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
79247397|NCT05094752|Device|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
79386079|NCT03245346|Drug|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
79541121|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
79386080|NCT03245346|Drug|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
79386081|NCT03245346|Drug|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
79386082|NCT03245346|Drug|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
79541122|NCT01489319|Drug|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
79843225|NCT00872040|Other|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
79843226|NCT04087499|Device|Acupuncture|acupuncture treatment on selected acupoint
79849020|NCT05586971|Drug|Placebo|Matching placebo
80012702|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
79843227|NCT00797264|Drug|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
79541123|NCT01489319|Drug|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
79843228|NCT00797264|Drug|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
79843229|NCT00797264|Drug|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
79843230|NCT00981201|Drug|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
79843231|NCT00981201|Drug|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
79843232|NCT00981201|Drug|Placebo|"Months 1-3:~By mouth twice daily."
80012703|NCT03660878|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
80012704|NCT05197543|Diagnostic Test|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
80012705|NCT04452578|Procedure|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
79541124|NCT01489332|Drug|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
79541125|NCT01489345|Drug|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
80012706|NCT05190211|Other|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
79247398|NCT05583825|Other|Rebozo App|It is a non-invasive, non-drug practical application made with Rebozo, a long and colorful fabric, two meters long and 70 cm wide, worn by Mexican women on their head and shoulders.
79386083|NCT03245112|Drug|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
79386084|NCT03245034|Behavioral|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
79386085|NCT03244956|Drug|Trametinib|2mg daily for a maximum of 6 weeks of treatment
79541126|NCT01489345|Drug|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
79541127|NCT01489371|Other|Laboratory Biomarker Analysis|Correlative studies
79541128|NCT01489371|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
79541129|NCT01489371|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79247399|NCT04507256|Combination Product|AZD7442|Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.
79247400|NCT04507256|Other|Placebo|Participants randomised to placebo will receive the same volume of solution as participants on active treatment.
79386086|NCT03244956|Drug|Dabrafenib|150mg twice daily
79386087|NCT03244956|Radiation|131I|5.5 GBq
79386088|NCT03244956|Drug|rhTSH|0.9mg on two consecutive days after 35 days of treatment
79386089|NCT03244878|Behavioral|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
79843233|NCT00981201|Drug|Placebo|"Months 4-6:~By mouth twice daily."
79843234|NCT04842708|Diagnostic Test|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
79843235|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
79843236|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
79843237|NCT00797342|Drug|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
79843238|NCT00872118|Behavioral|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
79843239|NCT00872118|Behavioral|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
79386090|NCT02454270|Drug|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
79541130|NCT01489397|Device|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
79541131|NCT01489410|Drug|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
79541132|NCT01489410|Drug|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
79541133|NCT01489423|Genetic|RNA analysis|
79699793|NCT00573950|Drug|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
79699794|NCT00573950|Drug|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
80012707|NCT05190211|Other|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
80012708|NCT03951961|Drug|Midostaurin|50mg Midostaurin bid for 12 months
80012709|NCT03940105|Behavioral|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
79247401|NCT05094674|Diagnostic Test|Breath Sample analysis|The participant's breath sample is taken by blowing preferably three times into a disposable tube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis. This will take place once during the study.
79247402|NCT05094596|Drug|Standart treatment group|Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
79247403|NCT05094596|Drug|Montelukast sodium 10 mg treatment|Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
79699795|NCT03452748|Device|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
79699796|NCT03452670|Behavioral|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
79699797|NCT03452670|Other|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
79699798|NCT00574106|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
79843240|NCT05279391|Drug|Dexamethasone|Dexamethasone 6-8 mg once daily
79247404|NCT05094596|Drug|Montelukast sodium 20 mg treatment|Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
79247405|NCT04500249|Drug|infiltration rescue intraoperative analgesia|in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
79247406|NCT04500249|Drug|rescue IA|in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
79247407|NCT04500249|Drug|rescue antyhypertensive medication|in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
79541134|NCT01489423|Genetic|in situ hybridization|
80012710|NCT02232542|Drug|Duloxetine - low dose|
80012711|NCT02232542|Drug|Duloxetine - high dose|
80012712|NCT02232542|Drug|Placebo|
80012713|NCT02620033|Behavioral|Yoga therapy|
79247408|NCT04500249|Drug|rescue antyemetic medication|in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
79247409|NCT04500249|Drug|rescue antyhypotensive medication|in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
79541135|NCT01489423|Genetic|polymerase chain reaction|
79541136|NCT01489423|Other|enzyme-linked immunosorbent assay|
79541137|NCT01489423|Other|flow cytometry|
79541138|NCT01489423|Other|immunohistochemistry staining method|
79843241|NCT05279391|Drug|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
79843242|NCT05279391|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
79843243|NCT05279391|Drug|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
79843244|NCT05279391|Drug|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to <60 ml/min/1.73 m2)
79843245|NCT05279391|Drug|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
79541139|NCT01489423|Other|laboratory biomarker analysis|
79699799|NCT03450564|Behavioral|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
79843246|NCT00789542|Device|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
79843247|NCT00789542|Other|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
79843248|NCT04087733|Drug|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
79386091|NCT02454270|Drug|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
79386092|NCT03244488|Drug|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
79843249|NCT00880152|Behavioral|Mindfulness-based stress reduction|An 8-week course in mindfulness training
80012714|NCT02235350|Other|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
79247410|NCT04500249|Drug|rescue antyhypotensive medication|in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
79247411|NCT04921293|Behavioral|Ketogenic diet|A diet with <50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats
79247412|NCT04921293|Dietary Supplement|Exogenous ketones|Administration of ketone monoester 25 ml t.i.d
79541140|NCT01489436|Procedure|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
79541141|NCT01489436|Procedure|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
79541142|NCT01489462|Behavioral|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
79247413|NCT04921293|Behavioral|Standard diet + placebo|A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
79247414|NCT05094518|Behavioral|Mobile phone reminders|Appointment reminders in the form of push notifications will be sent through HERA app.
79386093|NCT03244488|Drug|Mecamylamine Pill|10 or 20mg of mecamylamine orally
79386094|NCT03244332|Other|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
79386095|NCT03244332|Other|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
79386096|NCT02454738|Radiation|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
79386097|NCT03254472|Diagnostic Test|Measured concentrations of biomarkers|
79386098|NCT03244410|Diagnostic Test|complete blood picture|complete blood picture
79386099|NCT02455986|Behavioral|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
79247415|NCT04413188|Other|Warm foot bath|The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
79247416|NCT04500327|Other|Drive app|The Drive app will be used to monitor sleep metrics for users of CPAP therapy.
79247417|NCT04500327|Device|Non contact motion sensor|The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.
79247418|NCT05581017|Procedure|Preoperative biliary drainage|Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
79247419|NCT03345693|Device|MoTrack Therapy|A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
79699800|NCT03450564|Behavioral|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
79247420|NCT04401956|Other|bread|Different types of bread
79541143|NCT01489462|Behavioral|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
79699801|NCT03450564|Other|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
79541144|NCT01489462|Behavioral|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
79541145|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter [mg/mL], i.e. 16 mL) under fasting conditions
79247421|NCT05578365|Other|Pilates method|Individuals in the Pilates group will perform specific exercises online. There will be 16 sessions, lasting 60 minutes, with 10 minutes of warm-up, 30 to 40 minutes of exercises focusing on the trunk stabilizers muscles, and 10 minutes of cool-down with relaxation, stretching, or meditation. In addition, the individuals will have access to the same information of the control group.
79843250|NCT00922220|Other|stationary bike|Participants rode a stationary bike for five minutes
79843251|NCT00922220|Other|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
79843252|NCT00922220|Other|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
79843253|NCT00977847|Other|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
79699802|NCT00574223|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
79699803|NCT00574223|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
79843254|NCT02595203|Drug|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
79843255|NCT02595203|Drug|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
79843256|NCT04828746|Procedure|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
79247422|NCT05578365|Other|Pain education|Individuals in the control group will receive information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
79247423|NCT04541186|Drug|BIO89-100|BIO89-100
79247424|NCT04541186|Drug|Placebo|Placebo
79247425|NCT04500015|Drug|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
79247426|NCT04500015|Drug|Placebo Comparator|3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
79541146|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
79541147|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
79699804|NCT03450525|Other|No intervention|No intervention
79843257|NCT00789620|Drug|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
79843258|NCT00789620|Drug|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
79843259|NCT03970265|Diagnostic Test|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
79843260|NCT00803894|Drug|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
79699805|NCT00586131|Drug|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
79843261|NCT00803894|Drug|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
79843262|NCT00803894|Drug|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
79541148|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
79699806|NCT00586131|Drug|Sodium citrate/citratic acid|dictated by pH
79699807|NCT00574301|Procedure|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
79699808|NCT00574379|Drug|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
79843263|NCT05371925|Drug|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
79843264|NCT00985023|Procedure|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
79843265|NCT00985023|Procedure|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
80012715|NCT02235350|Other|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
79247427|NCT05093738|Other|Cognitive Rehabilitation|In the content of the person-centered intervention program, attention, memory, orientation, praxis (motor planning) training; metacognition (metacognition) training; visual perception; There will be cognitive training for executive functions. The intervention will consist of play activities (games, computer-assisted games) for cognitive skills; The games will be applied in a way that suits the child from simple to complex. Visual perception applications (designing blocks, recognizing and sorting the shapes in the picture, matching opposite shapes etc.); attention practices, memory practices, strategy development, space-time orientation, motor planning, games and metacognitive strategies aimed at developing skills such as planning, organization, working memory, impulse control, time management and awareness, abstract thinking, cognitive flexibility will form our intervention program.
79247428|NCT04844229|Procedure|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
79541149|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
79541150|NCT01489501|Procedure|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
79541151|NCT01489514|Other|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~Histamine control purchased from Greer.~Saline control purchased from Greer.~Standard Peanut Extract purchased from Greer.~Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A & T.~Sterile extract prepared from roasted & blanched but untreated peanuts. This is prepared by North Carolina A & T.~Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A & T. This is not classified as a drug and is~Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~Sterile extracts containing peanuts that have been treated with alcalase"
79699809|NCT00574379|Drug|Placebo|Placebo tablets twice daily for 14 days
80012716|NCT05181787|Diagnostic Test|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
80012717|NCT05181787|Diagnostic Test|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
80012718|NCT04348136|Drug|JR-141|IV infusion, 2.0 mg/kg/week
79541152|NCT01489540|Device|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
79541153|NCT01489566|Drug|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
79541154|NCT01489566|Drug|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
79699810|NCT03450408|Procedure|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
79699811|NCT00574418|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
79699812|NCT00574457|Other|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
79699813|NCT00586287|Other|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
79699814|NCT00586287|Other|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
79843266|NCT00797420|Drug|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
79843267|NCT00797420|Drug|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
79843268|NCT00981513|Biological|Trivalent live attenuated seasonal influenza vaccine|One dose
79843269|NCT00981513|Biological|Monovalent live attenuated pandemic influenza vaccine|One dose
79843270|NCT00981513|Biological|Saline|One dose
79843271|NCT00872274|Drug|sumatriptan 100mg|
79541155|NCT01489592|Drug|curcuma longa|oral administration of 6 grams of curcumin
79541156|NCT01489605|Device|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
79843272|NCT00734747|Device|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
79843273|NCT00805688|Behavioral|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
79843274|NCT00805688|Procedure|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
79541157|NCT01489605|Device|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
79843275|NCT00805688|Device|Pedometer|Worn daily to measure physical activity.
79699815|NCT00586287|Drug|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
79699816|NCT03450330|Drug|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
79699817|NCT00574574|Dietary Supplement|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
79247429|NCT04844229|Procedure|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
79699818|NCT03450291|Other|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
79843276|NCT00880308|Drug|LDE225|
79247430|NCT01678820|Drug|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
79843277|NCT00797498|Other|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
79247431|NCT01678820|Drug|Sitagliptin|Sitagliptin 100 mg tablet
79247432|NCT01678820|Drug|Simvastatin|Simvastatin 40 mg tablet
79247433|NCT01678820|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
79247434|NCT01678820|Drug|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
79247435|NCT01678820|Drug|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
79541158|NCT01489618|Biological|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
79541159|NCT01489618|Biological|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
79843278|NCT04006899|Device|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
79843279|NCT02595047|Procedure|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
79843280|NCT00872352|Procedure|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
79843281|NCT00985179|Behavioral|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
79843282|NCT00872586|Drug|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
79247436|NCT01678820|Drug|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of >= 1500 mg for at least 12 weeks prior to randomization and during the study
79247437|NCT01678820|Drug|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
79247438|NCT02515695|Drug|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
79541160|NCT01489631|Drug|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
79541161|NCT01489631|Drug|marcaine|bupivacaine 0,125%
79541162|NCT01489631|Drug|sufentanil|sufentanil 1mcg/ml
79541163|NCT01489631|Drug|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
79541164|NCT01489644|Drug|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
79541165|NCT01489644|Drug|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
79541166|NCT01489644|Drug|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
79541167|NCT01489683|Drug|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
79541168|NCT01489683|Drug|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
79541169|NCT01489696|Drug|mirabegron|oral
79843283|NCT00872586|Drug|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
79541170|NCT01489696|Drug|tamsulosin|oral
79699819|NCT04579562|Other|No intervention|This is observational, non-interventional study
79541171|NCT01489709|Drug|Vesicare|oral
79843284|NCT00726557|Biological|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
80012719|NCT04306250|Procedure|Apical prolapse fixation - anterior access|The surgery is done in anterior access
79541172|NCT01489722|Drug|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
80012720|NCT04306250|Procedure|Apical prolapse fixation - posterior access|The surgery is done in posterior access
80012721|NCT02600923|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
79247439|NCT03347487|Procedure|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
79303730|NCT05729685|Other|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
79699820|NCT04575168|Diagnostic Test|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
79541173|NCT01489761|Device|percutaneous coronary intervention|drug eluting stent implantation
79541174|NCT01489774|Drug|Placebo|single and multiple dose
79699821|NCT00574613|Drug|P144|Cream 0,3 ml once a day (3 months)
79699822|NCT00574613|Drug|placebo|Cream 0,3 ml once a day (3 months)
79699823|NCT00586365|Drug|Naproxen|500 mg Naproxen twice a day for two weeks
79699824|NCT00574652|Drug|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
79699825|NCT00574691|Device|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
79699826|NCT03450213|Device|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
79843285|NCT00726557|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
79843286|NCT00977925|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
79843287|NCT00977925|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
79843288|NCT00803972|Drug|rHuPH20|recombinant human hyaluronidase PH20
80012722|NCT02600923|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
79541175|NCT01489774|Drug|CJ-12406|single and multiple dose
79699827|NCT03450174|Dietary Supplement|Placebo|In control group, participants will receive only a placebo product
79699828|NCT03450174|Behavioral|Formative messgaes|In this group, participants will only receive daily formative messages
79699829|NCT03450174|Dietary Supplement|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
79699830|NCT03450174|Combination Product|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
79843289|NCT00803972|Drug|Insulin Human Injection|injection
79843290|NCT00803972|Drug|Insulin Lispro Injection|injection
79843291|NCT00880386|Drug|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
79843292|NCT00978081|Drug|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
80012723|NCT02232776|Drug|Losartan|Dose of Losartan : 0.7mg/kg once daily.
80012724|NCT03847519|Drug|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
80012725|NCT03847519|Drug|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
80012726|NCT02221687|Dietary Supplement|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
79699831|NCT00574769|Drug|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m^2 every 21 days"
79699832|NCT00586443|Drug|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD* RPTD* RPTD* 3b 10 RPTD** RPTD** RPTD**~Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. **Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
79699833|NCT00574808|Other|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
79541176|NCT01489787|Procedure|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
79843293|NCT00804050|Drug|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
79843294|NCT00804050|Drug|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
79541177|NCT01489787|Procedure|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
79541178|NCT01489787|Procedure|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
79541179|NCT01489800|Behavioral|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
79843295|NCT00877734|Drug|baclofen|10 mg Baclofen administered tid for 11 weeks
79843296|NCT00877734|Drug|placebo|Placebo administered tid for 11 weeks
79843297|NCT00877734|Behavioral|BRENDA counseling|
80012727|NCT02221687|Dietary Supplement|Control formula|Standard milk formula without pre and probiotic
80012728|NCT02235428|Drug|Ipratropium bromide|
80012729|NCT02235428|Drug|Placebo|
80012730|NCT02235428|Drug|Salbutamol|
80012731|NCT02235506|Procedure|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
80012732|NCT02235506|Procedure|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
79541180|NCT01489839|Other|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
79541181|NCT01489852|Drug|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
79843298|NCT00981591|Drug|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
80012733|NCT02235506|Device|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
80012734|NCT02235506|Device|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
80012735|NCT03070171|Drug|dabigatran etexilate|single dose
79843299|NCT00981591|Drug|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
80012736|NCT02262572|Drug|Telmisartan /HCTZ - compression tablet (DC)|
79843300|NCT04545216|Other|Long-distance mountain running|Impact of a mountain race on the knee cartilage
79843301|NCT00978159|Drug|esomeprazole|esomeprazole 20 mg po for 4 weeks
79843302|NCT00978159|Drug|Famotidine|Famotidine 40 mg po for 4 weeks
79843303|NCT00804206|Drug|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
80012737|NCT02262572|Drug|Telmisartan /HCTZ - dry granulation tablet (DG)|
80012738|NCT02262572|Drug|Telmisartan /HCTZ - present commercial formulation|
80012739|NCT02235584|Drug|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
80012740|NCT05174377|Diagnostic Test|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
80012741|NCT02235662|Drug|TFV IVR|
80012742|NCT02235662|Drug|TFV/LNG IVR|
80012743|NCT02235662|Other|Placebo IVR|
79305507|NCT04936503|Biological|Blood sampling for biobank|"For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers)."
79541182|NCT01489865|Drug|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
79699834|NCT03450135|Behavioral|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
79699835|NCT03450135|Behavioral|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
79699836|NCT00574925|Drug|Esomeprazole|
79305508|NCT03244007|Procedure|Vitrectomy|
79541183|NCT01489904|Biological|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
79843304|NCT00804206|Drug|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
79699837|NCT00586560|Drug|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
79699838|NCT00574964|Other|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
79699839|NCT00575003|Drug|CYT003-QbG10|6 subcutaneous injections
80012744|NCT05167981|Other|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
79843305|NCT00877812|Dietary Supplement|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
79699840|NCT00586599|Other|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
79699841|NCT03453593|Other|No intervention|No intervention
79699842|NCT03453554|Other|Digital Notebook app|Training in use of Digital Memory Notebook app
79843306|NCT00877812|Dietary Supplement|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
79843307|NCT00981903|Drug|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
79843308|NCT00738881|Drug|Erlotinib Hydrochloride|Given PO
79843309|NCT00738881|Drug|Pemetrexed Disodium|Given IV
79843310|NCT00797654|Behavioral|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
79699843|NCT03453554|Other|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
79699844|NCT00586638|Behavioral|Video game based training|36 one-hour sessions over 12 weeks
79843311|NCT00797654|Behavioral|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
79843312|NCT00877968|Dietary Supplement|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
80012745|NCT02262650|Drug|Telmisartan|
80012746|NCT02262650|Drug|Clopidogrel|
80012747|NCT02235740|Drug|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
79305509|NCT03243617|Other|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~Subjects may not wash their body with soap and water AFTER the applications"
79699845|NCT00586677|Behavioral|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
79699846|NCT00586677|Behavioral|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
79843313|NCT00877968|Dietary Supplement|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
79541184|NCT01489917|Other|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
79541185|NCT01489930|Behavioral|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
79541186|NCT01489930|Behavioral|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for ~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
79699847|NCT00586677|Behavioral|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
79699848|NCT03453476|Device|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
79843314|NCT00877968|Dietary Supplement|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
79843315|NCT00877968|Dietary Supplement|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
79843316|NCT00877968|Dietary Supplement|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
80012748|NCT02235740|Drug|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
79247440|NCT03979430|Other|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
79541187|NCT01489930|Behavioral|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
79247441|NCT02515539|Device|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
79541188|NCT01489943|Drug|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
79699849|NCT01137682|Drug|Pasireotide|"Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
79699850|NCT01137682|Drug|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
79699851|NCT01137682|Drug|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
79843317|NCT00877968|Dietary Supplement|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
79843318|NCT00877968|Dietary Supplement|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
79843319|NCT00877968|Dietary Supplement|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g"
79843320|NCT00878046|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
79843321|NCT00657020|Drug|Nicotine|Nicotine lozenge containing 4 mg of nicotine
79843322|NCT00657020|Drug|Placebo|Placebo lozenge
79843323|NCT04773288|Other|Live feedback during handwashing|Live feedback provided during handwashing on display
79843324|NCT03921723|Drug|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
79843325|NCT03921723|Drug|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
80012749|NCT03629431|Procedure|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
79541189|NCT01489943|Drug|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
79541190|NCT01489943|Drug|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
79699852|NCT03453320|Drug|Albumin solution|Infusion rate and effects
79843326|NCT03921723|Drug|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
79843327|NCT00872664|Dietary Supplement|carotenoids|beta-carotene, lycopene, lutein
79843328|NCT00872742|Behavioral|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
79699853|NCT00586755|Procedure|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
79699854|NCT00575120|Other|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
79699855|NCT03458442|Other|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
79843329|NCT00872742|Behavioral|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
79247442|NCT03888560|Device|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
79843330|NCT05056155|Other|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
79843331|NCT00878124|Dietary Supplement|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
79843332|NCT00878124|Other|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
79843333|NCT00978237|Drug|EFV|one pill QD VO.
79843334|NCT00978237|Drug|LPV/r|2 pills QD VO
79386100|NCT03243942|Drug|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
79843335|NCT00872820|Behavioral|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
79843336|NCT00872820|Behavioral|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
79843337|NCT00978315|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
79843338|NCT00978315|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
79843339|NCT00878202|Device|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
79843340|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
79843341|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
79843342|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
79843343|NCT00978393|Drug|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
79247443|NCT04500093|Procedure|Capsulotomy with Repair|Capsulotomy with Repair
79247444|NCT04500093|Procedure|Capsuloectomy|Capsuloectomy
79843344|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
79843345|NCT00978393|Drug|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
79843346|NCT04740996|Drug|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
79247445|NCT04413500|Behavioral|Reminder|A reminder to take the anti-hypertension medication with adjustable frequency.
79849021|NCT05578820|Biological|Intratumoral administration of Stimotimagene copolymerplasmid|Intratumoral administration of gene therapy drug Stimotimagene copolymerplasmid
80012750|NCT03629431|Procedure|postoperative standard care|Standard care received postoperatively
79247446|NCT04413500|Behavioral|Educational message|An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.
79247447|NCT04413500|Behavioral|Motivational messages|The motivational short messages to increase the motivational levels.
79386101|NCT03254784|Drug|BMS-986165 Capsule|Oral capsule
79386102|NCT03254784|Drug|BMS-986165 Tablet|Oral tablet
79386103|NCT03245190|Drug|Chiauranib|50mg, orally once daily
79386104|NCT01969708|Drug|aflibercept|
79386105|NCT01969708|Drug|bevacizumab|
79541191|NCT01489943|Drug|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
79699856|NCT03458442|Other|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
79541192|NCT01489943|Drug|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
80012751|NCT05163925|Device|Eurosets ECMO Life System|"ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab)."
79699857|NCT03457506|Diagnostic Test|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
79699858|NCT00575198|Other|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
79699859|NCT00575198|Other|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
79541193|NCT01489982|Device|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
79541194|NCT01489982|Behavioral|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
79541195|NCT01489982|Drug|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
79541196|NCT01489982|Device|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
79699860|NCT00586794|Drug|Sildenafil|3x per day 20 mg TID
79699861|NCT00586794|Drug|Placebo|3x per day, 20 mg TID
79699862|NCT00575237|Procedure|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
79699863|NCT00586833|Procedure|O2 consumption max bike test|Single visit exercise study
80012752|NCT04476836|Other|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
80012753|NCT02604680|Drug|BLI1100-1|BLI1100-1 Topical gel
80012754|NCT02604680|Drug|BLI1100-2|BLI1100-2 Topical gel
80012755|NCT02604680|Drug|BLI1100-3|BLI1100-3 Topical gel
80012756|NCT02604680|Drug|BLI1100-4|BLI1100-4 Topical gel
79386106|NCT03243864|Drug|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
79541197|NCT01489995|Drug|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
79541198|NCT01489995|Drug|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
79699864|NCT03453255|Drug|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
79699865|NCT00575354|Drug|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
79699866|NCT00575354|Drug|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
79699867|NCT00586911|Drug|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
79699868|NCT00586911|Drug|Identical Placebo|Placebo
79699869|NCT00575393|Drug|gold sodium thiomalate|
80012757|NCT02604680|Drug|Placebo|Placebo - Topical gel
80012758|NCT03629353|Procedure|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
79386107|NCT03250494|Drug|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
79541199|NCT01489995|Drug|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
79541200|NCT01489995|Drug|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
79541201|NCT01489995|Drug|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
79541202|NCT01490008|Drug|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
79541203|NCT01490008|Other|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
79386108|NCT03250494|Drug|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
79699870|NCT00575393|Genetic|gene expression analysis|
79699871|NCT00575393|Other|fluorine F 18 fluorothymidine|
79699872|NCT00575393|Other|mass spectrometry|
79699873|NCT00575393|Other|pharmacological study|
79247448|NCT04413500|Behavioral|showing trends|Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.
79699874|NCT00575471|Drug|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
79699875|NCT00575471|Drug|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
79699876|NCT00575471|Drug|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
79699877|NCT00575471|Drug|Placebo|Matching placebo tablets once daily for 12 weeks
79699878|NCT03454308|Behavioral|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
79699879|NCT03454308|Behavioral|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
79699880|NCT04579601|Procedure|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
79699881|NCT03452397|Drug|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
79699882|NCT03452397|Drug|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
79699883|NCT03452397|Drug|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
79699884|NCT03452397|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
79699885|NCT03453684|Drug|Administration of Vancomycin|Intravenous Vancomycin Administration
79699886|NCT00575627|Drug|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
79699887|NCT04674878|Other|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
79699888|NCT04674878|Other|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
80012759|NCT03629353|Procedure|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
80012760|NCT05762731|Diagnostic Test|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
80012761|NCT05762731|Diagnostic Test|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
79699889|NCT00586989|Procedure|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
79699890|NCT04674839|Drug|MS-20|fermented soymilk product
79699891|NCT04674839|Other|Placebo|No active ingredient
79699892|NCT03458130|Drug|AG10|TTR stabilizer
79699893|NCT03458130|Drug|Placebo Oral Tablet|Nonactive control
79699894|NCT04674488|Biological|TILs|a single center, single-arm, open label, interventional study
79699895|NCT03459690|Behavioral|Meditation|. IK is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. IK does not incorporate a spiritual or religious focus
79699896|NCT03459690|Device|Enobio 32- EEG machine|The ENOBIO 32 EEG device is an investigational device under US federal law which is a 24-bit EEG data reader which is a wearable wireless device
79699897|NCT04674605|Device|biomarkers|biomarkers
79699898|NCT03456219|Other|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
79699899|NCT03456219|Other|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
79699900|NCT02277483|Drug|LAIS®|10 X 1,000 / twice a week
79699901|NCT00555854|Behavioral|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
80012762|NCT05496686|Drug|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
80012763|NCT05496686|Drug|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
80012764|NCT05496686|Drug|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
80012765|NCT05496686|Drug|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
80012766|NCT05496686|Drug|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
79247449|NCT03346629|Drug|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
79247450|NCT04501965|Combination Product|Hydroxychloroquine/Azithromycine|Dual treatment with Hydroxychloroquine and Azythromycin
79699902|NCT04575129|Other|No intervention will be applied|No intervention will be applied
79699903|NCT00555932|Procedure|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
79699904|NCT04575402|Other|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
79699905|NCT04674332|Drug|Long acting insulin|long acting insulin analogue once daily at bed time
79247451|NCT04501965|Combination Product|Quinquina-Stevia/Azythromycin|Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
79699906|NCT04674332|Drug|multiple dose regimen|intermediate and short acting insulin
79699907|NCT00587145|Drug|S-1,Docetaxel|"S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
79699908|NCT04674449|Diagnostic Test|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
79699909|NCT04674449|Other|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
79699910|NCT04674176|Drug|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
79699911|NCT00199875|Drug|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of ^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
79386109|NCT03250494|Drug|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
79541204|NCT01490021|Procedure|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
79699912|NCT04674527|Drug|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
79541205|NCT01490021|Procedure|rTMS/Placebo TBS|rTMS/Placebo TBS
79699913|NCT04674527|Drug|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
79699914|NCT00199836|Biological|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
79699915|NCT04674293|Drug|Revelisa|Thrombolytic therapy for patients with ischemic stroke
79699916|NCT00199797|Drug|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
79699917|NCT00199797|Drug|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
79843347|NCT04040010|Dietary Supplement|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
79843348|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
79247452|NCT04501965|Combination Product|4Plants/Azythromycin|Dual treatment with 4 plant species drug and Azythromycin
79386110|NCT02354482|Behavioral|Patient Communication and Care Management|"Received the following Transitional Care strategies:~Helpful Health Care Contact OR Symptom Management~Post-discharge Care Consultation~Patient Goal/Preference Assessment~Plain Language Communication in Hospital~Plain Language Communication at Home~Transition Summary for Patients and Family Caregivers"
79247453|NCT03122067|Drug|oxytocin treatment|intranasal administration of oxytocin
79247454|NCT03122067|Drug|placebo treatment|intranasal administration of placebo
79386111|NCT02354482|Behavioral|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~Transition Team~Home visits~Plain Language Communication at Home~Promote Trust at Home~Referral to Community Services~Follow-up Appointment"
79699918|NCT00199797|Drug|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
79247455|NCT03718520|Other|no intervention, this is a purely observational study|No intervention
79247456|NCT03347409|Other|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
79541206|NCT01490034|Behavioral|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
79541207|NCT01490034|Behavioral|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
79541208|NCT01490034|Behavioral|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
79699919|NCT00199797|Drug|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
79699920|NCT04674215|Behavioral|Turning in Bed|Preoperative Turning in Bed Training
79699921|NCT04674215|Behavioral|Mobilization|Preoperative Mobilization Training
79699922|NCT04674215|Other|information|Routine Clinical Care
79699923|NCT04572087|Other|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
79699924|NCT04572087|Other|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
79699925|NCT04673903|Other|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
79699926|NCT04673903|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
79699927|NCT01137604|Drug|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
79386112|NCT02354482|Behavioral|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~Post-discharge care consultation~Identify High-Risk Patients and Intervene~Medication Reconciliation~Plain Language Communication in Hospital~Promote Trust in the Hospital~Transition Summary for Patients and Family Caregivers"
79699928|NCT01137604|Drug|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
79699929|NCT00637351|Procedure|Blood sample|One blood sample will be collected at the time of screening for subjects
79699930|NCT00637351|Procedure|Urine sample|One urine sample will be collected at the time of screening for subjects
79699931|NCT03454919|Drug|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
79541209|NCT01490034|Behavioral|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
79541210|NCT01490047|Drug|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
79541211|NCT01490047|Drug|Liposomal doxorubicin|Infusion over 60 minutes
79541212|NCT01490047|Drug|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
79541213|NCT01490047|Drug|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
79541214|NCT01490099|Drug|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
79541215|NCT01490112|Drug|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
79541216|NCT01490177|Drug|Food proteins|Oral ingestion of Food proteins
79699932|NCT00198822|Dietary Supplement|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
79699933|NCT04674059|Other|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
79699934|NCT05214976|Drug|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
79843349|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
79843350|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
79843351|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
79843352|NCT00544167|Drug|Doxorubicin|
79386113|NCT02354482|Behavioral|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~Patient Goal/Preference Assessment~Identify High-Risk Patients and Intervene~Timely Exchange of Critical Patient Information among Providers~Patient/Family Caregiver Transitional Care Needs Assessment"
79843353|NCT00544167|Drug|Cyclophosphamide|
79843354|NCT00544167|Drug|Paclitaxel|
79843355|NCT00544167|Drug|Sorafenib|
79843356|NCT00659438|Drug|ZD6474 (Vandetanib)|300mg orally, once daily
79843357|NCT00659438|Drug|Bicalutamide|150mg orally, once daily
79843358|NCT00659438|Drug|Placebo|orally, once daily
79843359|NCT00878358|Other|Hydrotherapy|
79843360|NCT00878358|Other|Physiotherapy|
79843361|NCT02553200|Device|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
79386114|NCT02354482|Behavioral|Assessment and Teach Back|"Received the following Transitional Care Strategies:~Post-discharge care consultation~Language Assessment~Teach Back for Information and Skills"
79386115|NCT02354482|Other|Standard of Care (Reference)|No specific Transitional Care Strategy
79386116|NCT03250572|Diagnostic Test|serum ferritin|serum samples and ferritin ELISA test
79386117|NCT03254628|Other|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
79386118|NCT03254628|Other|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag & mask device.
79386119|NCT03254628|Behavioral|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
79386120|NCT03254628|Behavioral|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
79699935|NCT05204134|Device|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
79699936|NCT05187832|Drug|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
79843362|NCT02553200|Device|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
79843363|NCT02553200|Device|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
79843364|NCT05225844|Drug|Camrelizumab|Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
79843365|NCT05225844|Drug|Apatinib Mesylate|Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
79843366|NCT00878514|Drug|Alprazolam|Alprazolam 1 mg tablet
79843367|NCT00878514|Drug|Xanax|Xanax 1 mg tablet
79843368|NCT00804284|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
79843369|NCT00804284|Biological|Other DTap Vaccines|0.5 mL, Intramuscular
79247457|NCT03347409|Other|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
79247458|NCT03347409|Other|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
79386121|NCT03254628|Drug|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
79699937|NCT04673747|Procedure|Total Hip Arthroplasty|Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
79843370|NCT00804440|Drug|Ibuprofen Tablets, 800 mg|
79386122|NCT03254628|Device|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
79541217|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
79541218|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
79541219|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
79699938|NCT04673747|Procedure|Manual correction of the sacroiliac joint|Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
79699939|NCT05181436|Diagnostic Test|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
79699940|NCT04674098|Device|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
79843371|NCT00880854|Drug|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
79843372|NCT00804518|Other|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
79843373|NCT00880932|Behavioral|Electronic Alert|
79386123|NCT03254706|Other|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
79386124|NCT03254706|Other|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
79843374|NCT00543855|Drug|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
79849022|NCT05578820|Drug|Intravenous administration of Ganciclovir (Cymeven®)|Intravenous administration of prodrug Ganciclovir (Cymeven®)
79849023|NCT05570058|Drug|RXC007|RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD.
80012767|NCT05496686|Drug|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
80012768|NCT05496686|Drug|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
79699941|NCT01137292|Drug|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
79699942|NCT00197496|Procedure|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
79699943|NCT04312477|Drug|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
79699944|NCT05367154|Procedure|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
79247459|NCT04502901|Drug|KX0826|investigational AR antagonist
79541220|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
79699945|NCT04673981|Diagnostic Test|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
79699946|NCT05176795|Other|Stool sample|Comparaison of the gut microbiota composition
79699947|NCT02883478|Device|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
79699948|NCT02883478|Procedure|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
79843375|NCT00543855|Drug|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
79843376|NCT00543855|Drug|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
79843377|NCT00543855|Drug|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
79843378|NCT00797810|Drug|Rituximab|
79247460|NCT04502901|Other|Placebo|Placebo of KX-826
79247461|NCT04536194|Drug|norepinephrine|to treat hypotension under general anesthesia with norepinephrine
79386125|NCT03254706|Other|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
79386126|NCT03254706|Other|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
79541221|NCT01490216|Drug|lisdexamfetamine|20mg q.d. to 70mg b.i.d
79541222|NCT01490229|Drug|Ezetimibe|os, 10 mg, once daily, 1 year
79843379|NCT03831048|Device|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
79843380|NCT03831048|Other|Cold Storage|Active comparator intervention
79247462|NCT04536194|Drug|dopamine|to treat hypotension under general anesthesia with dopamine
79247463|NCT04502511|Diagnostic Test|Standard diagnosis test|Care as usual
79247464|NCT03242720|Procedure|Cardiac Ablation for Atrial Fibrillation|Ablation of arrhythmia focus in the heart for atrial fibrillation
79247465|NCT03347175|Procedure|Volume controlled ventilation|Volume controlled ventilation mode
79247466|NCT03347175|Procedure|Pressure controlled ventilation|Pressure controlled ventilation
79541223|NCT01490229|Drug|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
79541224|NCT01490255|Drug|Ranolazine|os, 750 mg, twice per day, for 15 days
79541225|NCT01490255|Drug|Amlodipine|os, 10 mg, once daily, 15 days
79541226|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
79247467|NCT03347175|Procedure|CPAP mode|CPAP mode only
79247468|NCT04462172|Device|FNS|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
79247469|NCT04462172|Device|MCS|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
79386127|NCT01970176|Drug|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
79843381|NCT00881010|Behavioral|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
80012769|NCT05496686|Drug|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
79699949|NCT02883478|Drug|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
79699950|NCT00197145|Drug|GW873140|400 mg twice daily
79386128|NCT01970176|Drug|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
79386129|NCT03254160|Drug|DNS-3379|DNS-3379
79699951|NCT04674137|Drug|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
79699952|NCT04674137|Drug|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
79699953|NCT01136785|Device|active CPAP Therapy|7 days of active CPAP therapy
79699954|NCT01136785|Device|sham CPAP therapy|7 days of sham CPAP therapy
79699955|NCT04673864|Drug|CKD-386|QD, PO
79843382|NCT00881010|Behavioral|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
80012770|NCT05496686|Drug|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
80012771|NCT05496686|Drug|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
80012772|NCT05496686|Drug|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
80012773|NCT05496686|Drug|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
79247470|NCT03122769|Radiation|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
79247471|NCT03286088|Diagnostic Test|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
79247472|NCT03286088|Diagnostic Test|Cardiac Magnetics Resonance|imaging as standard practice
79247473|NCT03286088|Diagnostic Test|MitraClip|imaging as standard practice
79247474|NCT05376020|Device|Densah Burs|Densah Burs will be used in the intervention group
79247475|NCT05376020|Device|Conventional Burs|Conventional Burs will be used in the control group
79247476|NCT03121833|Drug|Endostar|Recombinant Human Endostatin Injection
79247477|NCT03121833|Drug|Placebo|500ml 0.9% sodium chloride
79247478|NCT03121833|Drug|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
79247479|NCT04440644|Behavioral|BBI|administration of psychometric test
79386130|NCT03254160|Drug|Placebo|Placebo
79386131|NCT02023918|Drug|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
79541227|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
79541228|NCT01490281|Behavioral|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
79541229|NCT01490281|Behavioral|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
79541230|NCT01490307|Behavioral|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
79541231|NCT01490320|Behavioral|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
79541232|NCT01490320|Behavioral|Play Nicely Program|Multimedia program available at www.playnicely.org.
79541233|NCT01490320|Other|Control Group|Standard care in primary care clinic.
79541234|NCT01490333|Dietary Supplement|Vitamin D3|The vitamin D3 will be taken daily.
79541235|NCT01490346|Drug|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
79699956|NCT04673864|Drug|D012, D326, D337|QD, PO
79699957|NCT04312321|Device|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
79843383|NCT04921605|Device|DragonFly transcatheter mitral valve clamping system|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
79843384|NCT00656474|Drug|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
79843385|NCT00656474|Drug|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
79843386|NCT00873210|Drug|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
80012774|NCT02235818|Device|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
80012775|NCT02235818|Device|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
80012776|NCT03135704|Device|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
80012777|NCT03135704|Other|Physiotherapy|Usual protocol for treatment of low back pain
80012778|NCT03644017|Device|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
79699958|NCT04312321|Device|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
79699959|NCT04312438|Diagnostic Test|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
79843387|NCT00978471|Drug|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
79843388|NCT04017416|Behavioral|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
79843389|NCT00804674|Drug|bupivacain|
79843390|NCT00804674|Drug|placebo|
80012779|NCT00158054|Behavioral|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
80012780|NCT00158054|Behavioral|Referred depression care|Physician notified of depression symptoms, usual care followed.
80012781|NCT04476524|Other|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
80012782|NCT05075044|Biological|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
80012783|NCT05078125|Device|Holter monitoring|24 hours Holter monitoring
79247480|NCT03121521|Drug|Melatonin 10 mg|melatonin 10mg daily p.o.
79247481|NCT03121521|Drug|Placebo|Placebo 10mg daily p.o.
80012784|NCT03135964|Device|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
80012785|NCT05762653|Diagnostic Test|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
80012786|NCT01413529|Behavioral|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
79386132|NCT03250728|Biological|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~the endothelial permeability~the protein C system"
79386133|NCT03243708|Behavioral|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
79699960|NCT04673474|Drug|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
79699961|NCT04673474|Drug|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
79699962|NCT00197106|Drug|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
79699963|NCT00197106|Drug|fluticasone propionate 2 x 100 mcg|comparator
79843391|NCT00881088|Drug|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
79843392|NCT00881088|Drug|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
79843393|NCT00981981|Dietary Supplement|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
79843394|NCT00981981|Dietary Supplement|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
79247482|NCT03121443|Other|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
79247483|NCT04437992|Genetic|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
79247484|NCT05590845|Other|Survey|"Patients, 65 and above, scheduled for elective total hip replacement surgery, will be invited to participate in a survey (consisting of 15 questions) testing their knowledge regarding PND.~After completion of the survey, patients will receive a standard preoperative brochure on anaesthesia-related topics and delirium.~T-MOCA scores will be collected (22 = perfect score; <18 = cutoff for cognitive impairment) (through a pre-operative telephone call).~Six weeks post-operatively patients will once again be called for T-moca scores."
79247485|NCT04538222|Other|physical activity|aerobic exercise, muscle strength and stretching, nutrition education
79247486|NCT05585931|Drug|TPN171H 10mg|Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
79247487|NCT05585931|Drug|TPN171H Placebo|Subjects were given Placebo with 240 mL warm water under fasting condition.
79247488|NCT02643056|Drug|Panitumumab|IV administration every 2 weeks
79386134|NCT02454036|Behavioral|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
79386135|NCT02024386|Drug|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
79386136|NCT03250650|Device|TTNS|Transcutaneous tibial electric stimulation
79386137|NCT03250650|Device|ES+TTNS|Transvaginal electric stimulation
79699964|NCT01136746|Drug|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
79699965|NCT01136746|Drug|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
79843395|NCT00981981|Dietary Supplement|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
79843396|NCT00981981|Dietary Supplement|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
79843397|NCT00981981|Dietary Supplement|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
79247489|NCT02515617|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
79247490|NCT02515617|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
79386138|NCT03250260|Other|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
79386139|NCT03250260|Other|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
79386140|NCT03250338|Drug|Crenolanib|Crenolanib will be administered orally
79386141|NCT03250338|Drug|Cytarabine|"HAM regimen~FLAG-Ida"
79699966|NCT01136746|Drug|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
79699967|NCT02883751|Radiation|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
79699968|NCT02883751|Procedure|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
79843398|NCT00878592|Behavioral|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
79843399|NCT00978549|Drug|docetaxel|
79843400|NCT00978549|Drug|steroid therapy|
79843401|NCT00978549|Other|questionnaire administration|
79843402|NCT00978549|Procedure|nausea and vomiting therapy|
79843403|NCT00978549|Procedure|pain therapy|
79843404|NCT00978549|Procedure|quality-of-life assessment|
79843405|NCT00978549|Procedure|standard follow-up care|
79386142|NCT03250338|Drug|Mitoxantrone|HAM regimen
79386143|NCT03250338|Drug|Placebo Oral Tablet|Placebo will be administered orally
79386144|NCT03250338|Drug|Fludarabine|FLAG-Ida regimen
79386145|NCT03250338|Drug|Idarubicin|FLAG-Ida regimen
79541236|NCT01490398|Drug|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
79541237|NCT01490411|Drug|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
79541238|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
79699969|NCT04673435|Device|PermeaDerm for temporary coverage|See above
79699970|NCT04673435|Device|FHCA for temporary coverage|See above
79699971|NCT04673435|Device|PermeaDerm over autograft|See above
79699972|NCT04673435|Device|FHCA over autograft|see above
79699973|NCT02883322|Other|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
79699974|NCT01136356|Drug|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
79843406|NCT00978549|Radiation|radiation therapy|
79843407|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
79843408|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
79843409|NCT00656084|Drug|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
79843410|NCT00656084|Drug|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
79843411|NCT00656084|Drug|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
79843412|NCT00985335|Other|Neem Based External Application Cream|Apply externally 3-4 times per day
79541239|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
79699975|NCT01136356|Drug|morphine|parenteral morphine may be administered multiple times each day
79843413|NCT00982059|Other|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
79247491|NCT05098808|Other|Acoustic features (from signals obtained during phonation)|"Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient"
79541240|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
79541241|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
79541242|NCT01490437|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
79541243|NCT01490437|Drug|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
79541244|NCT01490437|Drug|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
79541245|NCT01490437|Drug|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
79541246|NCT01490476|Drug|RAD001|10 mg per os / day or 05mg per os / day with 12 month
79541247|NCT01490489|Other|blood sample and doppler Ultrasound of uterine arteries|"36 ml of blood samples (serum and plasma) will be collected~After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
79541248|NCT01490515|Procedure|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
79541249|NCT01490515|Other|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
79699976|NCT00587379|Drug|Atorvastatin|40 mg atorvastatin pill daily
79843414|NCT00873600|Drug|chemotherapy|
79843415|NCT00873600|Other|medical chart review|
79247492|NCT04586829|Other|Diet|<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.
79247493|NCT02515461|Device|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
79541250|NCT01490554|Procedure|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
79541251|NCT01490567|Drug|Donepezil|5 mg/day
79699977|NCT00587379|Drug|placebo|40 mg pill per day
79699978|NCT04673396|Drug|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
79843416|NCT00873600|Other|questionnaire administration|
79843417|NCT00873600|Procedure|adjuvant therapy|
79843418|NCT00873600|Procedure|assessment of therapy complications|
79843419|NCT00873600|Procedure|cognitive assessment|
79843420|NCT00873600|Procedure|psychosocial assessment and care|
79247494|NCT04499703|Device|RHMS-RTM|Assessment of retinal thickness
79247495|NCT04499703|Diagnostic Test|SD-OCT|Assessment of retinal structure
79541252|NCT01490567|Drug|placebo|placebo 5mg/d
79541253|NCT01490593|Behavioral|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
79247496|NCT05079308|Device|Peripheral sealing device for surgical mask or filtering face piece|The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
79541254|NCT01490606|Other|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
79541255|NCT01490606|Other|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
79541256|NCT01490619|Behavioral|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
79541257|NCT01490619|Other|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
79699979|NCT04673396|Drug|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
79699980|NCT00637390|Drug|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
79699981|NCT00587418|Dietary Supplement|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
79699982|NCT00587418|Dietary Supplement|Placebo|Placebo powder 9.2g bid for 7 days
79699983|NCT04673669|Diagnostic Test|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
79843421|NCT00873600|Procedure|quality-of-life assessment|
79541258|NCT01490658|Drug|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
79541259|NCT01490658|Drug|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
79386146|NCT03250338|Drug|G-CSF|FLAG-Ida regimen
79541260|NCT01490658|Drug|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
79541261|NCT01490671|Drug|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
79541262|NCT01490671|Drug|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
79541263|NCT01490710|Other|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
79699984|NCT00196326|Drug|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
79699985|NCT04673318|Behavioral|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
79843422|NCT04016948|Device|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
79843423|NCT04016948|Device|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
79843424|NCT04007211|Device|ABT13107|Dose: 3mL, maximum 10mL
79843425|NCT04007211|Device|Hyalobarrier|Dose: 10mL
80012787|NCT01413529|Behavioral|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
79247497|NCT05079308|Device|IIR Surgical mask with Filtering face piece|The individuals used a IIR surgical mask with a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
79247498|NCT04169594|Diagnostic Test|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
79247499|NCT04413422|Drug|type of hypnotic used for induction of general anesthesia|
79247500|NCT02238145|Drug|Atrovent® Inhaletten|
79247501|NCT05375552|Device|Transcranial direct current stimulation|Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
79247502|NCT03579355|Behavioral|DFND Program|The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
79386147|NCT01971580|Drug|Ambrisentan|
79386148|NCT00354562|Drug|ABT-751|200mg ABT-751 daily for 14 days every 21 days
79386149|NCT00354562|Drug|Placebo|Placebo daily for 14 days every 21 days
79386150|NCT00354562|Drug|Docetaxel|Standard Docetaxel every 21 days
79386151|NCT00421564|Drug|DBT-Danggui Buxue Tang|
79386152|NCT03250104|Other|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
79541264|NCT01490710|Other|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
79541265|NCT01490736|Drug|Lemuteporfin|lemuteporfin topical solution, 1%
79541266|NCT01490749|Drug|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
79541267|NCT01490749|Drug|XELOX|Patients will receive two cycles of XELOX.
79699986|NCT04673318|Behavioral|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
79699987|NCT00587496|Drug|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
79699988|NCT00587496|Drug|placebo|lactose placebo capsule, six per day for 30 days
79699989|NCT00587496|Drug|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
79843426|NCT00881166|Drug|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
80012788|NCT01337960|Behavioral|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
79843427|NCT00881166|Drug|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
79843428|NCT00881166|Drug|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
79843429|NCT00881166|Drug|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
79843430|NCT00881166|Drug|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
79843431|NCT00804752|Drug|Adding vitamin D|Adding 1000IU/Vitamin D daily
79541268|NCT01490749|Drug|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
79541269|NCT01490749|Radiation|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
79843432|NCT00804752|Drug|Vitamin D|Addition of 1000IU/day Vitamin D
79843433|NCT05225766|Other|bupivacaine|used for peripheral block
79843434|NCT00804830|Drug|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
79843435|NCT00982215|Drug|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
79843436|NCT00982215|Drug|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
79247503|NCT05098418|Drug|Poison|standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
79843437|NCT00873678|Biological|Whole blood sample|Whole blood sample (10 ml)
79843438|NCT00798044|Behavioral|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
79843439|NCT00798044|Behavioral|Patient Feedback|Weekly feedback reports provided to counselors
79843440|NCT00978705|Drug|Autologous cultured keratinocyte cell|3x10^7 cell/ vial
79843441|NCT00805922|Other|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
79247504|NCT02512731|Device|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
79247505|NCT03345459|Other|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
79247506|NCT04550637|Drug|Oral apixaban|apixaban (5 mg bid) is given until 12 weeks after surgery
79386153|NCT03250104|Other|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
79386154|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
79386155|NCT00838383|Drug|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
79541270|NCT01490762|Drug|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
79541271|NCT01490762|Drug|Regular Human Insulin|Subcutaneous injection
79386156|NCT00838383|Drug|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
79386157|NCT03254238|Other|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
79386158|NCT01972204|Behavioral|Intensive adherence instruction|Instruction with educational brochure
79386159|NCT01972204|Behavioral|Control|Instruction as per usual practice
79541272|NCT01490775|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
79541273|NCT01490775|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
79541274|NCT01490801|Genetic|DNA analysis|
79541275|NCT01490801|Genetic|RNA analysis|
79843442|NCT00978783|Device|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
79843443|NCT00978783|Device|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
79843444|NCT00982293|Device|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
79843445|NCT00982293|Device|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
79843446|NCT02553278|Device|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
79843447|NCT02553278|Device|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
79843448|NCT00613938|Drug|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
79843449|NCT00613938|Drug|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
79843450|NCT00613938|Drug|oxycodone|10mg capsule q4-6 hrs for 3 days
79843451|NCT00613938|Drug|placebo|1 capsule q4-6 hrs for 3 days
79843452|NCT00978861|Drug|Hydrogen Peroxide|Whitening product syringe type
79843453|NCT00805064|Drug|triamcinolone and bevacizumab|
79843454|NCT04007445|Behavioral|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
79849024|NCT05570058|Drug|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD
80012789|NCT01337960|Behavioral|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
79247507|NCT03576781|Device|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
79247508|NCT03576781|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
79247509|NCT03576781|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
79386160|NCT03243240|Diagnostic Test|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.~Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
79541276|NCT01490801|Genetic|cytogenetic analysis|
79541277|NCT01490801|Genetic|in situ hybridization|
79541278|NCT01490801|Genetic|mutation analysis|
79541279|NCT01490801|Genetic|polymerase chain reaction|
79699990|NCT04610606|Behavioral|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of >1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
79699991|NCT00564044|Procedure|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm*5mm*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
79699992|NCT00564083|Procedure|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
79699993|NCT00195663|Biological|Adalimumab|
79699994|NCT00195663|Drug|Methotrexate|
79699995|NCT00195663|Biological|Adalimumab placebo|
79386161|NCT02355886|Drug|Gabapentin|Given PO
79386162|NCT02355886|Other|Placebo|Given PO
79386163|NCT02355886|Other|Questionnaire Administration|Ancillary studies
79386164|NCT03254082|Other|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
79699996|NCT00195663|Drug|Methotrexate placebo|
79699997|NCT00564122|Device|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
79699998|NCT00564122|Other|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
79699999|NCT01135498|Drug|bevacizumab [Avastin]|Intravenous repeating dose
79386165|NCT03254082|Other|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
79386166|NCT03254082|Other|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
79541280|NCT01490801|Genetic|western blotting|
79541281|NCT01490801|Other|flow cytometry|
79541282|NCT01490801|Other|immunohistochemistry staining method|
79700000|NCT01135498|Drug|eloxatin|Intravenous repeating dose
79700001|NCT01135498|Drug|capecitabine [Xeloda]|Oral repeating dose
79700002|NCT01135498|Drug|erlotinib [Tarceva]|Oral repeating dose
79700003|NCT04610567|Drug|Methotrexate-LDE phase 1|"3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE"
79247510|NCT03576781|Device|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
79247511|NCT03345381|Other|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.
79247512|NCT03345381|Other|Usual care|Treatment as usual
79541283|NCT01490801|Other|medical chart review|
79541284|NCT01490853|Drug|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
79541285|NCT01490879|Drug|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
79247513|NCT03576703|Other|Exercise with and without SSB ingestion|Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
79700004|NCT04610567|Drug|Methotrexate-LDE phase 2|44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
79700005|NCT04610567|Drug|Placebo-LDE phase 2|44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
79700006|NCT02883439|Drug|MP29-02|local nasal application
79700007|NCT02883439|Drug|Fluticasone propionate|local nasal application
79700008|NCT02883283|Procedure|Epidural loading dose|Labor epidural analgesia loading dose
80012790|NCT01337960|Behavioral|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
80012791|NCT03136042|Other|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
80012792|NCT03136042|Other|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
79247514|NCT03345303|Drug|Bortezomib|Bortezomib Injectable Solution
80012793|NCT03136042|Other|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
79247515|NCT03574909|Drug|Aspirin|Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
79247516|NCT03574909|Drug|Placebos|Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
79386167|NCT03254082|Other|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
79386168|NCT03254082|Other|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
79386169|NCT04779099|Behavioral|Brief 4-session intervention for borderline personality disorder|Intervention consists of weekly 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support. This intervention is detailed in a published manual.
79386170|NCT04779099|Behavioral|Treatment as usual|TAU comprises access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
79541286|NCT01490879|Drug|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
79541287|NCT01490879|Drug|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
79541288|NCT01490879|Drug|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
79700009|NCT02883283|Device|Epidural catheter|Epidural loading dose via epidural catheter
79700010|NCT02883283|Device|Epidural needle|Epidural loading dose via epidural needle
79700011|NCT04610255|Other|Assigned Interventions|"Hot pack for 10 minutes~TENS for 10 minutes~Trigger point release if any found.~Myofascial release~Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
79700012|NCT04610255|Other|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~Hot pack for 10 minutes~TENS for 10 minutes~Trigger point release if any found.~Myofascial release~Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
79700013|NCT04610333|Behavioral|Modified MBSR programme|1 hour group session once a week in 10 weeks
79700014|NCT00195507|Drug|Etanercept|
79700015|NCT01134562|Drug|Placebo|Single IV injection.
79700016|NCT01134562|Drug|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
79700017|NCT04610216|Device|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
79700018|NCT02883166|Drug|abiraterone|integested with a continental breakfast
80012794|NCT02571998|Drug|Omiganan (CLS001) Topical Gel|
80012795|NCT02571998|Drug|Vehicle Topical Gel|
80012796|NCT04379986|Device|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
79247517|NCT03345225|Device|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
79247518|NCT03345225|Device|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
79247519|NCT03576625|Dietary Supplement|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
79541289|NCT01490905|Other|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
79541290|NCT01490905|Drug|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
79541291|NCT01490905|Drug|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
79700019|NCT04610489|Diagnostic Test|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
79843455|NCT04007445|Other|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
79843456|NCT00881244|Drug|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
79843457|NCT00655928|Drug|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
79843458|NCT00655928|Drug|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
79843459|NCT04038762|Procedure|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
79247520|NCT03576625|Dietary Supplement|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
79247521|NCT02512653|Biological|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
79247522|NCT03579199|Device|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
79247523|NCT03579043|Other|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
79247524|NCT03579043|Other|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
79541292|NCT01490944|Drug|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
79541293|NCT01490944|Drug|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
79541294|NCT01490957|Other|Database|Database
79843460|NCT00805220|Other|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
79843461|NCT00798200|Other|Exercise program|All exercise programs will include endurance and strength exercises.
79843462|NCT00873756|Drug|FOLFOX regimen|Intravenous repeating dose
79843463|NCT00873756|Drug|bevacizumab|Intravenous repeating dose
79843464|NCT00873756|Drug|dulanermin|Intravenous repeating dose
80012797|NCT05202691|Other|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
80012798|NCT05202691|Other|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
79247525|NCT03579043|Other|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
79247526|NCT02512341|Device|Computer Aided Auscultation (CAA)|
79247527|NCT02660138|Biological|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79541295|NCT01490970|Other|Database|Database
79541296|NCT01490983|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
79541297|NCT01490983|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
79541298|NCT01490996|Drug|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
79541299|NCT01490996|Drug|Chemotherapy only|Standard care chemotherapy
79541300|NCT01491009|Drug|Remifentanil|IV infusion
79541301|NCT01491009|Drug|Midazolam|IV infusion
79700020|NCT04610021|Biological|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
79700021|NCT00195351|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
79843465|NCT00798278|Drug|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
79843466|NCT00798278|Procedure|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
79843467|NCT00873834|Drug|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
80012799|NCT02784002|Drug|Ridinilazole|
80012800|NCT02784002|Drug|Fidaxomicin|
79541302|NCT01491048|Procedure|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
79541303|NCT01491048|Procedure|No physiotherapy after THA|No physiotherapy after THA
79700022|NCT00195351|Drug|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
79843468|NCT00873834|Drug|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
80012801|NCT04362046|Procedure|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
80012802|NCT05202613|Drug|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
79386171|NCT03243162|Behavioral|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
79541304|NCT01491061|Drug|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
79247528|NCT02660138|Biological|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79541305|NCT01491061|Drug|Placebo|os, two doses 12 hours apart prior to PCI
79541306|NCT01491074|Drug|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
79541307|NCT01491074|Drug|NaCl 0.9% 100 ml|Placebo
79541308|NCT01491087|Biological|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
79541309|NCT01490385|Device|LED Phototherapy|
79541310|NCT01491100|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
79541311|NCT01491139|Drug|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
80012803|NCT02233556|Drug|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~Mismatch negativity(MMN)~P50"
80012804|NCT04932733|Other|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
79541312|NCT01491139|Drug|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
80012805|NCT04932733|Other|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
80012806|NCT05228132|Device|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
79541313|NCT01491139|Radiation|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
79541314|NCT01491152|Device|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
79541315|NCT01491165|Procedure|stem cell transplantation through interventional procedures|one time interventional procedures
79247529|NCT02660138|Drug|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79247530|NCT02660138|Drug|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
79541316|NCT01491191|Dietary Supplement|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
79700023|NCT04609982|Device|ear plugs|giving half of the patients ear plugs
79700024|NCT04609748|Drug|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
79700025|NCT04609748|Drug|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
79247531|NCT04499469|Procedure|Spreader Graft|To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose
79247532|NCT03576469|Biological|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
79247533|NCT02181751|Other|Trauma Focused Cognitive Behavioural Therapy Group|Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
79247534|NCT02239003|Drug|DAOIB|
79247535|NCT02239003|Drug|Placebo|
79247536|NCT03574831|Device|Stretta|Stretta
79700026|NCT04574934|Other|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
79843469|NCT00873990|Other|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
79843470|NCT00873990|Other|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
79843471|NCT00655850|Drug|Paclitaxel|"Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~Dexamethasone 20mg, intravenously (IV)~Diphenhydramine 50 mg IV~Ranitidine 50 mg IV~Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~Dose Level 1 ________80 mg/m2/weekly~Dose Level -1 ________70 mg/m2/weekly"
80012807|NCT04914637|Procedure|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
80012808|NCT04914637|Procedure|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
79541317|NCT01491191|Dietary Supplement|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
79247537|NCT03947918|Behavioral|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
79541318|NCT01491204|Drug|Paclitaxel+HM30181|oral, 3times for 4weeks
79541319|NCT01491217|Drug|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
79541320|NCT01491243|Drug|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
79541321|NCT01491243|Drug|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
79541322|NCT01491256|Drug|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
79541323|NCT01491256|Drug|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
79541324|NCT01491282|Other|Enabling and disabling VNS|No intervention
79843472|NCT00655850|Drug|Gemcitabine|"Premedication~Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~Prior to receiving paclitaxel chemotherapy~Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~Dose Level 2 ________300 mg/m2/weekly~Dose Level 1 ________200 mg/m2/weekly~Dose Level -1 ________150 mg/m2/weekly"
79843473|NCT00655850|Biological|Avastin|"The dose of Avastin is 10 mg/kg IV every 2 weeks~It will be administered following the administration of chemotherapy~The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~It should not be administered or mixed with dextrose solutions."
79247538|NCT03947918|Behavioral|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
79247539|NCT03905720|Procedure|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
79541325|NCT01491295|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
79541326|NCT01491295|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
79700027|NCT04609631|Behavioral|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
79700028|NCT04609631|Behavioral|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
80012809|NCT04914637|Procedure|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
80012810|NCT02235896|Behavioral|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
80012811|NCT04905433|Behavioral|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
79541327|NCT01491308|Other|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
79700029|NCT00195273|Drug|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
79700030|NCT00195273|Drug|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
79700031|NCT00195273|Drug|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
79541328|NCT01491321|Procedure|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~1st week : SC 0.2cc/day, 2days/week~2nd week : SC 0.4cc/day, 2days/week~3rd week : SC 0.8cc/day, 2days/week"
79700032|NCT00195273|Drug|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
79700033|NCT00195273|Drug|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
79700034|NCT00564200|Drug|Bortezomib|"PREACONDICIONAMIENTO:~2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~- Day -2: Velcade~POSTRANSPLANTATION:~2 cycles of 21 days : Velcade days 1, 8 and 15~5 cycles of 56 days : Velcade days 1, 8 and 15"
79849025|NCT05566834|Drug|Minnelide|at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is > 80% that a serious adverse event with at least a 16% incidence will be detected.
80012812|NCT04905433|Behavioral|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
80012813|NCT04264390|Behavioral|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
80012814|NCT02235974|Behavioral|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
79247540|NCT03905720|Behavioral|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
80012815|NCT02235974|Behavioral|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
80012816|NCT02235974|Behavioral|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
80012817|NCT02235974|Behavioral|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
80012818|NCT04240288|Other|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
79541329|NCT01491321|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
79700035|NCT00564200|Drug|dexamethasone|"PREACONDICIONAMIENTO:~- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
79700036|NCT00564200|Drug|Fludarabine|"ACONDICIONAMIENTO:~- Days -9 al -5: Fludarabine"
79700037|NCT00564200|Drug|Melphalan|"ACONDICIONAMIENTO:~- Days -4 and -3: Melphalan."
79700038|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
79700039|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions
79700040|NCT00193479|Drug|Cyclophosphamide|Cyclophosphamide
79247541|NCT05097950|Drug|Administration of 1 gr paracetamol I.V|Administration of 1 gr paracetamol I.V
79247542|NCT05375786|Biological|Vaccination completion status|the relation between vaccination completion status and the target population
79700041|NCT00193479|Drug|Mitoxantrone|Mitoxantrone
79700042|NCT00193479|Drug|Vincristine|Vincristine
79700043|NCT00193479|Drug|Prednisone|Prednisone
79700044|NCT00193479|Drug|Rituximab|Rituximab
79700045|NCT00564317|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
79843474|NCT00881322|Dietary Supplement|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
79700046|NCT00564317|Behavioral|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
79843475|NCT00881322|Dietary Supplement|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule"
79247543|NCT05097638|Diagnostic Test|spirometry|Patient do spirometry
79247544|NCT05097560|Device|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
79247545|NCT05097560|Device|Venturi mask|VM is commonly used by COPD patients during exercise training.
79247546|NCT05097248|Drug|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
79247547|NCT05097248|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
79247548|NCT05097248|Drug|Losartan|Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
79386172|NCT03243162|Other|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
79541330|NCT01491321|Procedure|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~1st week : SC 0.2cc/day, 2days/week~2nd week : SC 0.4cc/day, 2days/week~3rd week : SC 0.8cc/day, 2days/week"
79541331|NCT01491360|Procedure|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
79541332|NCT01491373|Device|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
79700047|NCT04609475|Procedure|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
79700048|NCT04609475|Procedure|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
79843476|NCT02553434|Device|Pigtail catheter|Insertion of pigtail catheter
80012819|NCT04240288|Other|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
80012820|NCT02236052|Biological|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
79247549|NCT04413812|Behavioral|FREEBASE exercise programme|"The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology."
79247550|NCT01603394|Drug|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
79247551|NCT03352778|Radiation|IMRT|66Gy by intensity-modulated radiotherapy
79247552|NCT03352778|Radiation|2DRT|66Gy by 2-dimensional radiotherapy
79386173|NCT02356198|Drug|EXPAREL|transversus abdominis plane injection
79541333|NCT01491373|Device|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
79700049|NCT00193206|Drug|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
79700050|NCT00193206|Drug|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
79386174|NCT02356198|Drug|Intrathecal hydromorphone|Intrathecal opioid administration
79386175|NCT04779021|Other|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
79700051|NCT00193206|Drug|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
79849026|NCT05564754|Device|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
79700052|NCT00587691|Biological|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
79700053|NCT04609358|Other|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
79700054|NCT00193050|Drug|Gemcitabine|Gemcitabine
79700055|NCT00193050|Drug|Epirubicin|Epirubicin
79700056|NCT00193050|Drug|Docetaxel|Docetaxel
79700057|NCT04609241|Drug|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
79247553|NCT03340844|Procedure|No Touch (NT)|Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.
79247554|NCT03340844|Procedure|Superior Mesenteric Artery First (SMA)|Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).
79386176|NCT03254004|Drug|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
79386177|NCT04778865|Dietary Supplement|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
79541334|NCT01491438|Procedure|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
79700058|NCT00587730|Device|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
79700059|NCT04609163|Other|data collection|retrospective data collection
79700060|NCT04608734|Drug|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
79843479|NCT02553122|Drug|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
79843480|NCT02553122|Device|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
79843481|NCT00874068|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
79247555|NCT03265496|Procedure|Clinical exam|Clinical exam is performed before treatment start
79247556|NCT03265496|Procedure|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
79247557|NCT03265496|Procedure|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
79843482|NCT00874068|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
79386178|NCT04778865|Dietary Supplement|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
79386179|NCT03242850|Behavioral|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
79386180|NCT02025634|Drug|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
79843483|NCT00805298|Drug|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
79843484|NCT00805298|Drug|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
79843485|NCT00805298|Drug|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
79843486|NCT00805298|Drug|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
79843487|NCT00726323|Drug|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
79247558|NCT03265496|Drug|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
79247559|NCT03265496|Procedure|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
79386181|NCT02025634|Drug|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
79386182|NCT03249948|Procedure|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
79386183|NCT03249948|Procedure|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
79541335|NCT01491438|Procedure|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
79700061|NCT04608734|Drug|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
79700062|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
79700063|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
79843488|NCT00881400|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
79700064|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
79700065|NCT00192504|Other|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
79700066|NCT00564356|Procedure|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
79700067|NCT00192114|Drug|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
79700068|NCT04608929|Behavioral|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
79700069|NCT04608929|Other|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
79541336|NCT01491477|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
79700070|NCT00192075|Drug|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
79700071|NCT00192075|Drug|avastin|5 milligrams per kilogram (mg/kg)
79700072|NCT00192075|Drug|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
79843489|NCT00881400|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
79843490|NCT00805376|Drug|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
79843491|NCT00805376|Procedure|Tumor Removal|Surgical Tumor Resection
79843492|NCT00246571|Drug|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
79843493|NCT00246571|Drug|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~Docetaxel - 75-100 mg/m2 every 3 weeks~Paclitaxel - 175-200 mg/m2 every 3 weeks~Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
79700073|NCT00192075|Drug|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
79700074|NCT00192036|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
79247560|NCT03265496|Biological|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
79541337|NCT01491477|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
79541338|NCT01491503|Drug|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
79541339|NCT01491503|Drug|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
79541340|NCT01491503|Drug|Montelukast & levocetirizine|Montelukast sodium 10mg & levocetirizine dihydrochloride 5mg PO. Single dose.
79541341|NCT01491581|Dietary Supplement|food bar|milk based food bar enriched with micronutrients
79541342|NCT01491594|Drug|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
79541343|NCT01491659|Dietary Supplement|Idoform Plus|orally once daily
79700075|NCT00192036|Drug|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
79700076|NCT00192036|Radiation|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
79247561|NCT03197090|Device|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
79247562|NCT02837432|Drug|Hydrocortisone acetate|
79247563|NCT02837432|Drug|Placebo|
79247564|NCT02729025|Drug|Evolocumab|Administered subcutaneously once a month using an autoinjector/pen.
79247565|NCT02729025|Drug|Placebo|Administered subcutaneously once a month using an autoinjector/pen.
79541344|NCT01491659|Dietary Supplement|Placebo|orally once daily
79700077|NCT04609007|Behavioral|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
79700078|NCT04609007|Behavioral|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
79541345|NCT01491698|Procedure|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
79541346|NCT01491698|Procedure|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
79700079|NCT04608461|Drug|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
79700080|NCT00191724|Drug|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
79700081|NCT00191724|Drug|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
79700082|NCT00191724|Drug|Placebo|intravenous (IV), one infusion, over 12 hours
79700083|NCT00191724|Drug|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
79700084|NCT00191724|Drug|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
79386184|NCT04773951|Biological|JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection|Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
79386185|NCT03253536|Other|observational|none (observational study)
79386186|NCT01972282|Device|WATCHMAN Left Atrial Appendage Closure|
79386187|NCT04773717|Drug|Ascorbic acid|200mg/kg/24h in four equal parts
79700085|NCT00191724|Drug|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
79700086|NCT00564473|Behavioral|questionnaire|"questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
79700087|NCT04608422|Other|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
79843494|NCT00805454|Drug|OPC-34712|Single oral dose, 0.5 to 25 mg
79386188|NCT04773717|Drug|Placebo|The same regimen as ascorbic acid.
79386189|NCT04444167|Biological|AK104|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
79386190|NCT04444167|Drug|Lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
79541347|NCT01491711|Drug|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
79541348|NCT01491711|Drug|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
79541349|NCT01491750|Behavioral|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
79541350|NCT01491750|Behavioral|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
79541351|NCT01491828|Device|Kai Strap|Medical device component that vibrates on a subject's neck.
79843495|NCT02553356|Drug|PT2385|
79843496|NCT00805610|Biological|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
79386191|NCT03243006|Drug|Paracetamol|2 tablets of 500mg of paracetamol
79386192|NCT03243006|Drug|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
79386193|NCT03243006|Drug|Placebo Oral Tablet|2 tablets of placebo
79386194|NCT04778553|Diagnostic Test|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
79386195|NCT03249402|Drug|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
79386196|NCT03249402|Drug|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
79386197|NCT03249480|Biological|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
79843497|NCT00798356|Other|Yoga training|Yoga training for 12 weeks
79843498|NCT00734591|Drug|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
79541352|NCT01491867|Drug|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
79700088|NCT00191646|Drug|Gemcitabine|"1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
79700089|NCT00191646|Drug|Paclitaxel|"175 mg/m^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
79700090|NCT00191646|Drug|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
79700091|NCT00191451|Drug|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
79843499|NCT00734591|Other|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
79541353|NCT01491880|Behavioral|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
79843500|NCT02554058|Device|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
79843501|NCT00798512|Device|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
79247566|NCT02640248|Device|Cuff ETT|
79391478|NCT02421744|Behavioral|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
79541354|NCT01491880|Behavioral|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
79700092|NCT00191451|Drug|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
79700093|NCT00191451|Drug|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
79700094|NCT04608383|Other|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~Swab from the laparoscopy filter"
79700095|NCT04608071|Procedure|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
79843502|NCT00798668|Dietary Supplement|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
79843503|NCT00798668|Dietary Supplement|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
79247567|NCT02379572|Device|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
79247568|NCT02379572|Drug|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
79247569|NCT02515149|Device|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
79247570|NCT05092334|Other|proprioceptive exercises|proprioception exercises included (a)Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.(b)Gaze stability oculomotor exercises commencing with eyes movement with the head stationary ,progressing to movement of head with visual fixation on a target. (c) Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction
79247571|NCT05092334|Other|Strengthening exercise|strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
80012821|NCT02236052|Biological|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
80012822|NCT02236052|Biological|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
80012823|NCT02236052|Biological|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
79541355|NCT01491906|Behavioral|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
79247572|NCT05377502|Diagnostic Test|OGTT|OGTT
79700096|NCT00191334|Drug|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
79700097|NCT00191334|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
79700098|NCT00191139|Drug|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
79247573|NCT02512029|Drug|18F-AV-1451|
79247574|NCT05599971|Drug|intralesional combined digoxin and furosemide|15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
79247575|NCT05599971|Drug|intralesional injection of 5- Fluorouracil|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
79247576|NCT05599971|Other|intralesional saline|15 patients will receive intralesional saline. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
79386198|NCT04342143|Device|Blood pressure and ultrasound assessment|No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
79700099|NCT00191139|Drug|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
79386199|NCT03242460|Drug|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
79700100|NCT00191139|Drug|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
79247577|NCT05093816|Behavioral|Common Elements Toolbox|The Common Elements Toolbox (COMET) is an online single-session intervention. It is entirely self-guided and lasts about 60 minutes. Participants complete a series of reading and writing exercises focused on four modules: cognitive restructuring, behavioral activation, gratitude, and self-compassion. The intervention is entirely unguided and completed in a single sitting.
79386200|NCT03242460|Drug|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
79386201|NCT03242460|Drug|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
79386202|NCT01972516|Drug|Tivozanib|
79700101|NCT00191139|Drug|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
79700102|NCT00191139|Radiation|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
79700103|NCT00564512|Biological|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
79700104|NCT00564512|Biological|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
79700105|NCT00564512|Drug|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
79700106|NCT00564512|Drug|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
79843504|NCT02553044|Dietary Supplement|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
79849027|NCT05564754|Other|High MAP|A MAP target of >85mmHg will be used. Vasopressors will be titrated to this target during 36h.
80012824|NCT02236052|Biological|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
80012825|NCT02236052|Biological|Placebo|A single dose of placebo
80012826|NCT04238494|Diagnostic Test|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
80012827|NCT03077737|Behavioral|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
80012828|NCT03077737|Behavioral|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
80012829|NCT03062449|Drug|L-Serine|Gummy containing L serine dose
80012830|NCT03062449|Other|Placebo Gummy|Gummy with no dosing of L Serine
79700107|NCT04571853|Behavioral|PNE-explained group|There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
79700108|NCT04571853|Behavioral|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
79541356|NCT01491997|Behavioral|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
79541357|NCT01491997|Behavioral|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
79700109|NCT04571853|Behavioral|TAU group|Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
79541358|NCT01492010|Dietary Supplement|whey protein|25 g whey protein
79700110|NCT00564551|Behavioral|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
79843505|NCT00569270|Drug|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
79700111|NCT00564551|Behavioral|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
79843506|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
80012831|NCT04233268|Diagnostic Test|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
79247578|NCT05086562|Other|observation study|observation study
79247579|NCT02512263|Procedure|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
79247580|NCT04263129|Procedure|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
79843507|NCT00545103|Drug|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
79541359|NCT01492010|Dietary Supplement|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
79541360|NCT01492010|Dietary Supplement|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
79541361|NCT01492023|Behavioral|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
79541362|NCT01492049|Behavioral|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
79843508|NCT00545103|Drug|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
79843509|NCT00545103|Drug|Placebo|Placebo administered Once Daily (QD)
80012832|NCT05202457|Procedure|Elective surgery|Patient undergoing elective or urgent surgery
79541363|NCT01492049|Behavioral|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
79541364|NCT01492049|Behavioral|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
79541365|NCT01492062|Device|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
79541366|NCT01492075|Drug|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
79843510|NCT00586157|Drug|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
80012833|NCT04085146|Procedure|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
80012834|NCT04085146|Procedure|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
79541367|NCT01492114|Dietary Supplement|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
79541368|NCT01492114|Dietary Supplement|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
79541369|NCT01492127|Biological|Blood test|Blood test
79700112|NCT00190983|Drug|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
79700113|NCT04607759|Dietary Supplement|nutraceutical|Subjects will consume two capsules for eight weeks
79700114|NCT04607798|Device|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
79700115|NCT00190749|Drug|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
79700116|NCT00190749|Drug|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
79700117|NCT04607720|Procedure|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
79247581|NCT05033912|Drug|CST-2032, matching placebo for CST-2032, CST-107|CST-2032 and matching placebo oral liquid; CST-107 white capsules
79386203|NCT04773561|Device|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
79386204|NCT03253380|Other|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
79386205|NCT05605743|Behavioral|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
79386206|NCT03242694|Diagnostic Test|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
79386207|NCT03242694|Procedure|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
79541370|NCT01492140|Procedure|Subdermal Injection|Injection of dermal filler
79700118|NCT04607720|Procedure|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
79700119|NCT04607447|Behavioral|low intracranial pressure strategy treatment|"Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~Abdominal belt compression"
79700120|NCT04607447|Drug|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
79700121|NCT04607213|Procedure|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
79700122|NCT04607213|Procedure|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
79700123|NCT00190671|Drug|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
79700124|NCT00190671|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
79700125|NCT00190671|Drug|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
79700126|NCT00199914|Device|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
79700127|NCT04607525|Drug|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines [5] [6] [7]."
79843511|NCT00586157|Drug|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
79843512|NCT00809432|Device|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
79849028|NCT05564754|Other|Deep sedation|Deep sedation for at least 36h
79247582|NCT02514915|Radiation|Stereotactic Radiosurgery|Radiation therapy
79386208|NCT03242616|Drug|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)"
79386209|NCT03242616|Drug|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
79386210|NCT04773327|Other|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
79700128|NCT04607525|Drug|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
79700129|NCT00198276|Combination Product|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
79541371|NCT01492140|Device|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
79700130|NCT04607642|Drug|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
79700131|NCT04607642|Radiation|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
79247583|NCT05017922|Procedure|transarterial chemoembolization combined with endoscopic therapy|TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
79541372|NCT01492153|Drug|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
79700132|NCT04607642|Drug|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
79247584|NCT02515071|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
79247585|NCT02515071|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
79247586|NCT02514759|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
79386211|NCT01748825|Drug|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
79386212|NCT03242538|Behavioral|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
79386213|NCT03249636|Diagnostic Test|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
79386214|NCT03253224|Drug|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
79386215|NCT03253224|Drug|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
79386216|NCT02028208|Diagnostic Test|Ammoniated mercury|Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.
79541373|NCT01492153|Drug|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
79541374|NCT01492153|Drug|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
79541375|NCT01492166|Drug|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
79541376|NCT01492179|Drug|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
79541377|NCT01492179|Drug|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
79541378|NCT01492179|Drug|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
79700133|NCT04607642|Other|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
79700134|NCT00587808|Procedure|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
79843513|NCT00809432|Other|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
79843514|NCT02595125|Device|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
79700135|NCT00587925|Other|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
79700136|NCT00588003|Drug|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
79700137|NCT00588003|Other|Placebo|No medication before surgery
79700138|NCT00588042|Device|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
79843515|NCT02552654|Behavioral|Stress Film|Film scene with severe physical and sexual violence.
79305510|NCT03243617|Other|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~Subjects may not wash their body with soap and water AFTER the applications"
79843516|NCT02552654|Drug|Hydrocortisone|10mg
79386217|NCT02028208|Diagnostic Test|Aluminum chloride and aluminum lactate|Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.
79700139|NCT00588042|Device|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
79700140|NCT00588081|Behavioral|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
79700141|NCT04607291|Other|Community Health Service|Receive Witness CARES services
79700142|NCT04607291|Other|Survey Administration|Ancillary studies
79305511|NCT03243773|Other|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
79843517|NCT02552654|Drug|Placebo|
79843518|NCT04045574|Procedure|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
79305512|NCT04936659|Other|neuromodulation|Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
79305513|NCT03243695|Other|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
79386218|NCT02028208|Diagnostic Test|Sodium tetrachloropalladate|Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
79386219|NCT03249324|Behavioral|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
79391479|NCT02421744|Behavioral|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
79700143|NCT00588120|Drug|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
79843519|NCT00809666|Device|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
79843520|NCT00978939|Other|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
79843521|NCT00978939|Other|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
79843522|NCT00809744|Drug|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
79843523|NCT00809822|Drug|NPB-01|Intravenous immunoglobulin
79843524|NCT00809822|Drug|Placebo|Physiological saline
79843525|NCT04006587|Device|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
79843526|NCT00246337|Drug|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
79843527|NCT00246337|Drug|MK0974|MK0974 25 mg; one orally-administered dose
79843528|NCT00246337|Drug|MK0974|MK0974 50 mg; one orally-administered dose
79843529|NCT00246337|Drug|MK0974|MK0974 100 mg; one orally-administered dose
79843530|NCT00246337|Drug|MK0974|MK0974 200 mg; one orally-administered dose
79843531|NCT00246337|Drug|MK0974|MK0974 300 mg; one orally-administered dose
79843532|NCT00246337|Drug|MK0974|MK0974 400 mg; one orally-administered dose
79843533|NCT00246337|Drug|MK0974|MK0974 600 mg; one orally-administered dose
79843534|NCT00246337|Drug|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
79843535|NCT02552576|Biological|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
79386220|NCT03249324|Other|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
79700144|NCT04574973|Device|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
79700145|NCT04574973|Behavioral|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
79700146|NCT04607057|Drug|Parenteral Nutrition Solutions|"Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + crystalloid fluid~POD#3 : Semifluid diet (SFD) + PN~POD#4-7: Soft blended diet (SBD) + PN"
79700147|NCT04575012|Procedure|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
79700148|NCT04575012|Procedure|Early invasive strategy|Primary PCI
79700149|NCT00564590|Drug|Melatonin|4 mg of Melatonin once a day for 3 months
79700150|NCT00564590|Other|omeprazole|omeprazole 20 mg once a day
79700151|NCT00564590|Drug|Placebo|Placebo once a day
79700152|NCT00564668|Drug|biphasic insulin aspart|
79700153|NCT04574817|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
79700154|NCT00564707|Behavioral|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
79700155|NCT00564707|Procedure|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
79700156|NCT04607018|Device|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
79700157|NCT04606862|Device|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
79700158|NCT00588276|Radiation|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three *IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
79700159|NCT04606667|Other|Exercise Program|Exercise program
79247587|NCT04981574|Other|Massage and stretching on neck area and thoracic thrust manipulation|"Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
79305514|NCT03243695|Other|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
79305515|NCT04957797|Procedure|round tunnel|reamed with round tunnel
79391480|NCT02439814|Drug|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
79700160|NCT03452592|Drug|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
79700161|NCT04606511|Diagnostic Test|Circumference tape measurements|centimeter and volume criterias
79700162|NCT04606511|Diagnostic Test|Indocyanine green lymphangiography|Presence of dermal backflow
79700163|NCT04606511|Diagnostic Test|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
79700164|NCT04606511|Diagnostic Test|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
79700165|NCT00564746|Drug|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"[14C] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) [14C] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of [14C]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter [14C] SB-681323 oral solution will be dosed."
79700166|NCT04606277|Other|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
79700167|NCT00588393|Drug|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
79700168|NCT04606043|Procedure|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
79305516|NCT04957797|Procedure|flat tunnel|reamed with flat tunnel
79843536|NCT00809900|Dietary Supplement|Experimental|Administration of of 480 mL cranberry juice
79700169|NCT04606043|Procedure|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
79700170|NCT04606121|Combination Product|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
79700171|NCT00588510|Other|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
79700172|NCT04606082|Drug|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
79700173|NCT04606082|Drug|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
79700174|NCT04605770|Drug|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
80012835|NCT02800915|Other|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
79247588|NCT04981574|Other|Massage and stretching on low back area and thoracic thrust manipulation|"Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
79386221|NCT03253458|Device|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
79386222|NCT02356900|Procedure|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
79386223|NCT02356900|Procedure|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
79386224|NCT02356900|Drug|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
79386225|NCT00789399|Drug|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
79386226|NCT00789399|Other|Placebo|subcutaneous equivolume isotonic saline
79541379|NCT01492192|Drug|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
79386227|NCT01720667|Drug|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
79700175|NCT00588588|Procedure|Bronchoscopy|Bronchoscopy procedure
79700176|NCT00588588|Procedure|Clinical pulmonary infection score (CPIS)|Calculate CPIS
79700177|NCT04605887|Drug|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
79843537|NCT01581853|Drug|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
80012836|NCT04908592|Drug|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
80012837|NCT04908592|Other|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
79386228|NCT01720667|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
79386229|NCT03253146|Diagnostic Test|VIM detection|VIM expression in serum and lymphocytes detection
79386230|NCT00765531|Radiation|Radiological testing|Bone mineral density
79386231|NCT00765531|Genetic|Pediatric Urologic DNA and History Repository|"All Stone Forming Patients and their families will undergo one of two groups of testing:~Testing 1 - Involves completing an in-patient evaluation at University of Texas Southwestern for patients with hypercalciuria and their families.~Testing 2 - Involves completing a simple out-patient evaluation for patients with or without hypercalciuria and their family members."
79541380|NCT01492205|Drug|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
79700178|NCT00588705|Behavioral|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
79700179|NCT04606004|Other|Stool application|Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
79700180|NCT04606004|Other|Standard of care skincare|"Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin."
79700181|NCT00588783|Device|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
79700182|NCT00588783|Device|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
79247589|NCT02511873|Drug|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
79247590|NCT02511873|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
79700183|NCT04605926|Biological|EQ001|itolizumab [Bmab600]
79247591|NCT04936490|Drug|Crocin|15 mg/d
79247592|NCT04936490|Drug|Placebo|15 mg/d
79386232|NCT03253770|Device|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
79386233|NCT04773093|Drug|Continous Intravenous Lidocaine Infusion|Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
79386234|NCT04773093|Drug|Placebo|Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
79541381|NCT01492218|Drug|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
79541382|NCT01492257|Other|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
79700184|NCT04605926|Biological|EQ001 Placebo|EQ001 Placebo
79700185|NCT00588939|Device|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
79700186|NCT04605419|Procedure|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
79700187|NCT00588978|Behavioral|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
79849029|NCT05564754|Other|Fever control without a device|Management of fever in the ICU without a device
79247593|NCT04626986|Procedure|microwave ablation|Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.
79247594|NCT04626986|Procedure|breast conserving surgery|The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
79247595|NCT02511951|Procedure|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
79247596|NCT04438070|Diagnostic Test|COVID-19 Swab|Nasal, Oral-Nasal combined or Nasopharyngeal swab
79386235|NCT01720043|Drug|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
79386236|NCT00700752|Device|senofilcon A|silicone hydrogel contact lens
79386237|NCT00700752|Device|balafilcon A|silicone hydrogel contact lens
79386238|NCT02455362|Drug|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
79541383|NCT01492270|Procedure|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
79541384|NCT01492270|Procedure|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
79541385|NCT01492270|Procedure|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
79541386|NCT01492270|Procedure|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
79541387|NCT01492283|Other|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
79541388|NCT01492283|Other|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
79700188|NCT00589095|Other|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
79700189|NCT04605575|Drug|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
79700190|NCT04605575|Drug|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
79700191|NCT04605575|Drug|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
79386239|NCT02455362|Drug|Placebo|
79541389|NCT01492296|Procedure|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
79700192|NCT00589134|Dietary Supplement|Gatorade Endurance Formula|carbohydrate electrolyte beverage
79700193|NCT00589134|Other|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
79700194|NCT00589173|Behavioral|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
79843538|NCT02594969|Other|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
79843539|NCT00798746|Behavioral|Telephone Questionnaire|Ten questions regarding symptoms of reflux
79843540|NCT01070641|Drug|Carvedilol|Carvedilol 12.5mg QD
79700195|NCT00589173|Behavioral|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
79700196|NCT00589212|Device|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
80012838|NCT02761603|Behavioral|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
79247597|NCT02511795|Drug|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
79247598|NCT02511795|Drug|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
79247599|NCT04796636|Drug|Sodium Ascorbate|As previously described
79247600|NCT04501809|Procedure|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
79386240|NCT03246789|Behavioral|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
79386241|NCT03246789|Behavioral|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
79386242|NCT01747811|Device|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
79700197|NCT04605224|Behavioral|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
79843541|NCT01070641|Procedure|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
79843542|NCT00982449|Other|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
79843543|NCT00982449|Other|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
79849030|NCT05564754|Other|Low MAP|A MAP target of >65mmHg will be used. Vasopressors will be titrated to this target during 36h.
79386243|NCT01747811|Device|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
79391481|NCT02439814|Other|Placebo|Inactive comparator
79541390|NCT01492296|Procedure|conventional fasting|patients were evaluated after fasting for 8 hours
79541391|NCT01492322|Radiation|TRODAT|Smoker will receive a TRODAT injection
79541392|NCT01492335|Behavioral|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
79849031|NCT05564754|Other|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
79541393|NCT01492335|Behavioral|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
79541394|NCT01492348|Behavioral|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, & primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
79700198|NCT00589251|Other|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
79843544|NCT02593721|Procedure|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
79247601|NCT04718636|Drug|Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)|Daily
79386244|NCT03242304|Other|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
79247602|NCT04718636|Drug|CC-99677|Daily
79700199|NCT00589368|Behavioral|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
79700200|NCT00564785|Drug|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
79700201|NCT00564785|Other|Placebo patch|placebo patch applied 20 minutes prior to epidural
79700202|NCT00564824|Drug|Caffeine|Caffeine 200 mg tablet
79843545|NCT02593721|Drug|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
80012839|NCT02761603|Behavioral|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
80012840|NCT01567033|Behavioral|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
80012841|NCT04783948|Other|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
79247603|NCT02514681|Drug|Trastuzumab|
79247604|NCT02514681|Drug|Pertuzumab|
79386245|NCT03242226|Device|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
79386246|NCT03242226|Device|single vision spectacles|Wear single vision spectacle only
79247605|NCT02514681|Drug|Docetaxel|
79386247|NCT03249246|Other|No intervention|
79386248|NCT03253068|Drug|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
79386249|NCT03241836|Diagnostic Test|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
79386250|NCT03252912|Biological|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
79247606|NCT02514681|Drug|Paclitaxel|
79247607|NCT02514681|Drug|Nab-paclitaxel|
79247608|NCT02514681|Drug|Vinorelbine|
79247609|NCT02514681|Drug|Eribulin|
79247610|NCT02514681|Drug|Capecitabine|
79247611|NCT02514681|Drug|Gemcitabine|
79247612|NCT04444700|Drug|Therapeutic anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
79247613|NCT04501575|Other|Osteopathic Consultation|A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
79247614|NCT04501575|Other|Sham Osteopathic Consultation|A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
79247615|NCT02511639|Drug|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
79247616|NCT02511639|Drug|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
79386251|NCT03253614|Diagnostic Test|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
79700203|NCT00564824|Drug|Placebo|Placebo pills
79700204|NCT00589446|Device|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
79700205|NCT00564863|Biological|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
79700206|NCT00589485|Device|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
79700207|NCT00589485|Device|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
79541395|NCT01492348|Behavioral|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
79541396|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
79700208|NCT00564941|Drug|deferasirox|
79700209|NCT00589524|Device|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
79700210|NCT00589641|Behavioral|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
79700211|NCT00589641|Behavioral|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
79700212|NCT04605068|Procedure|Transverse preputial island flap (Duckett's technique)|
79541397|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
80012842|NCT04783987|Other|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
79247617|NCT03068000|Behavioral|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
79386252|NCT03253614|Diagnostic Test|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
79386253|NCT03253614|Diagnostic Test|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
79386254|NCT03248934|Other|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
79386255|NCT03248934|Other|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
79541398|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
79386256|NCT05605041|Device|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
79391482|NCT02421822|Other|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
79700213|NCT04605068|Procedure|Double-faced preputial flap (DFPF)|
79700214|NCT04605107|Drug|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
79700215|NCT04605107|Drug|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
79700216|NCT04605341|Device|miniplate|comparison between k wires and miniplate in metacarpal fractures
79700217|NCT04605653|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
79700218|NCT00589758|Diagnostic Test|Echocardiography|2D and 3D echocardiography
79700219|NCT00589758|Other|Biomarker evaluation|Blood and urine collected
79700220|NCT00564980|Procedure|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
79247618|NCT03068000|Behavioral|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
79247619|NCT02514603|Drug|Prexasertib|Administered IV
79247620|NCT05091320|Drug|Mechanical thrombectomy|Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke
79541399|NCT01492374|Drug|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
79843546|NCT00798824|Procedure|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
79849032|NCT05550246|Drug|Atomoxetine|Treatment given for 3 nights
79700221|NCT00564980|Procedure|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
80012843|NCT05762497|Other|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
80012844|NCT04759768|Drug|Nalmefene Hydrochloride|3mg nasal spray
79247621|NCT05091320|Drug|medical treatment|medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
79247622|NCT02511483|Drug|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
79541400|NCT01492387|Other|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
79541401|NCT01492413|Behavioral|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
79541402|NCT01492452|Other|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
79541403|NCT01492465|Drug|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
79541404|NCT01492491|Device|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
79541405|NCT01492504|Drug|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention [(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)]
79541406|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
79541407|NCT01492517|Other|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
79541408|NCT01492517|Other|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
79541409|NCT01492517|Other|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
79541410|NCT01492530|Behavioral|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
79541411|NCT01492530|Behavioral|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
79541412|NCT01492543|Drug|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
79541413|NCT01492556|Drug|Etoposide|Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
79541414|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS at sham point
79541415|NCT01492569|Other|questionnaire administration|Ancillary studies
79541416|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS
79541417|NCT01492608|Drug|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
79541418|NCT01492621|Drug|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
79700222|NCT00589953|Drug|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
79700223|NCT00589953|Drug|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
79247623|NCT02511483|Drug|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
79247624|NCT02511483|Drug|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
79247625|NCT02511483|Procedure|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
79700224|NCT00589992|Drug|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
79700225|NCT00590070|Drug|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
79849033|NCT05550246|Drug|Oxybutynin|Treatment given for 3 nights
79247626|NCT02511483|Other|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
79247627|NCT02511483|Genetic|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
80012845|NCT04759768|Drug|Nalmefene|1mg intramuscular injection
80012846|NCT04754113|Other|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
79247628|NCT05091164|Procedure|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.
79247629|NCT04501341|Biological|Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10^5 - 1 x 10^6 CD34 cells/kgBW
79247630|NCT04501341|Biological|Intravenous Infusion of UC-MSC|Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10^6 cells/kgBW, twice, with three months interval
79700226|NCT00590070|Drug|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
79386257|NCT02454816|Device|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
79247631|NCT04437758|Dietary Supplement|Collagen and Vitamin C powder mix nutritional intervention|20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise
79247632|NCT04437758|Other|Maltodextrin placebo powder|20 g maltodextrin placebo daily, 60 min prior to exercise
79247633|NCT04437758|Other|Maximum power training exercise|Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)
79247634|NCT04429802|Drug|Prucalopride|Orally administered
79247635|NCT04429802|Drug|Placebo|Orally administered
79247636|NCT02511405|Drug|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
79247637|NCT02511405|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
79247638|NCT04387760|Drug|Hydroxychloroquine|"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
79247639|NCT04387760|Drug|Favipiravir|"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
79247640|NCT04387760|Other|Routine care for COVID-19 patients|Supportive care according to local guidelines
79247641|NCT02514291|Behavioral|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
79541419|NCT01492634|Other|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO < -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO > 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
79247642|NCT05375396|Dietary Supplement|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79247643|NCT05375396|Dietary Supplement|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
79700227|NCT00590070|Drug|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
79700228|NCT00565019|Drug|Triamcinolone Acetonide|"Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~Doses will range from 60-120 mg depending on extent of the disease.~Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: >10 cm2, dosage 100-120 mg"
79247644|NCT02511327|Drug|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
79700229|NCT00565097|Drug|Placebo|
79391483|NCT02421432|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
79700230|NCT00565097|Drug|Lanreotide|
79247645|NCT02511171|Other|Cranial osteopathic manipulative therapy|
79391484|NCT02440204|Procedure|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
79700231|NCT04604756|Drug|Losartan|administration of losartan (50 mg) (oral)
79700232|NCT04604756|Drug|Placebo Oral Tablet|administration of placebo (oral)
79700233|NCT00590343|Drug|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
79700234|NCT00590382|Device|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
79700235|NCT04604717|Other|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
79700236|NCT04574700|Other|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
79700237|NCT04574700|Other|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
79700238|NCT04604600|Drug|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
79700239|NCT04604678|Drug|Metformin|Metformin at 1500 mg/day
79700240|NCT04604678|Drug|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
79700241|NCT04604483|Device|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
79700242|NCT03452358|Procedure|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
79700243|NCT04604639|Diagnostic Test|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
79843547|NCT00798824|Procedure|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
79843548|NCT00798824|Device|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
79247646|NCT05091086|Drug|Denosumab|Active comparator: persistent treatment of denosumab. Experimental: alternating treatment with zoledronate and denosumab
79305517|NCT03243539|Procedure|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
79305518|NCT04936347|Procedure|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
79541420|NCT01492647|Drug|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
79700244|NCT04604327|Drug|Bemiparin sodium|Prophilactic vs full-dose for 10 days
79541421|NCT01492647|Drug|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
79700245|NCT00590616|Procedure|transthoracic examination|observational transthoracic examination
79700246|NCT00590655|Behavioral|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
79700247|NCT00590655|Behavioral|weight loss programme|
79700248|NCT04604171|Behavioral|Action Observation Training|Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
79700249|NCT04604171|Behavioral|Task Oriented Training|In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
79843549|NCT00798824|Device|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
79541422|NCT01492647|Drug|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
79843550|NCT00798902|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
79541423|NCT01492660|Device|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
79843551|NCT00798902|Other|Iliac crest autograft|autograft
79843552|NCT00979173|Drug|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
79303731|NCT05729685|Other|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
79700250|NCT04604171|Behavioral|Conventional Treatment|Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
79700251|NCT00590694|Drug|ranibizumab|0.5mg injection monthly according to protocol for one year
79700252|NCT00565175|Drug|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
79700253|NCT00565175|Drug|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
79700254|NCT04604249|Diagnostic Test|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
79843553|NCT00985647|Drug|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
79541424|NCT01492660|Device|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
79386258|NCT02454816|Device|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
79843554|NCT00806468|Drug|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
79843555|NCT00982527|Drug|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
79843556|NCT00982527|Drug|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
79843557|NCT00798980|Drug|Mirena (BAY86-5028)|Nulliparous Women
79843558|NCT00243919|Behavioral|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
79843559|NCT00243919|Behavioral|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
79843560|NCT00243919|Behavioral|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
79843561|NCT00725621|Biological|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
79843562|NCT00613626|Drug|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
79843563|NCT00613626|Drug|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
79386259|NCT03104049|Device|Neuromuscular taping|"NMT applications:~rhomboid major muscle~muscles abdominals~spinal muscles~pectoralis major muscles~gastrocnemius muscle~upper trapezius muscle~anterior muscles of the neck"
79541425|NCT01492699|Drug|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
79843564|NCT00613626|Drug|Placebo|Matched placebo oral daily
79843565|NCT00613626|Drug|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
79386260|NCT03241992|Behavioral|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
79541426|NCT01492712|Drug|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
79700255|NCT00477165|Drug|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
79843566|NCT00985803|Other|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
79843567|NCT00985803|Other|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
79843568|NCT00810056|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
79843569|NCT00810056|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
79700256|NCT00477165|Drug|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
79541427|NCT01492712|Drug|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
79700257|NCT04604054|Drug|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
79700258|NCT04604054|Drug|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
79700259|NCT00476229|Drug|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
79700260|NCT00476229|Radiation|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
79700261|NCT00476229|Procedure|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
79700262|NCT00476229|Drug|Rituximab|375 mg/m^2 by vein on days -13, -6, 1, & 8. Only those patients whose tumors express CD20 will receive Rituximab.
79700263|NCT04603976|Drug|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
79700264|NCT00476151|Drug|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
79700265|NCT00476151|Drug|placebo cream|inactive placebo cream applied two times daily
79700266|NCT04603703|Other|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
79386261|NCT03239262|Procedure|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
79541428|NCT01492725|Device|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
79386262|NCT03239262|Procedure|No intervention|No intervention was performed in patients without ganglionated plexi.
79386263|NCT01718483|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
79541429|NCT01492725|Genetic|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
79541430|NCT01492738|Procedure|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
79700267|NCT04603703|Other|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
79700268|NCT00475644|Drug|Enzastaurin|Administered orally
79700269|NCT04603664|Diagnostic Test|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
79700270|NCT04603235|Behavioral|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
79700271|NCT00474903|Drug|acetylsalicylic acid|Given orally
79700272|NCT00474903|Drug|esomeprazole magnesium|Given orally
79700273|NCT00474903|Other|placebo|Given orally
79700274|NCT01134055|Drug|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
79700275|NCT01134055|Drug|placebo|placebo eye drops
79700276|NCT01134055|Biological|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
79700277|NCT00474708|Drug|Effexor|
79386264|NCT01718483|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
79700278|NCT00474708|Drug|SSRI|
79700279|NCT04603040|Drug|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
79843570|NCT00979329|Other|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
79843571|NCT00810134|Procedure|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
79843572|NCT00810134|Procedure|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
79302759|NCT04997343|Other|clinical assessment|"Clinical evaluation, performed at each time point, will include:~The assessment of clinical disability using EDSS score~The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk [T25FW]), upper limbs (nine-hole peg test [9HPT]) and cognitive (three-second paced auditory serial addition test [PASAT3]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance"
79386265|NCT03241758|Diagnostic Test|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
79700280|NCT05366959|Other|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
79700281|NCT05366959|Other|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
79700282|NCT05366959|Other|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
79700283|NCT05366959|Other|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
79700284|NCT04603118|Procedure|Optic ultrasonography|
79700285|NCT04603118|Procedure|Lumbar puncture|
79700286|NCT02883127|Behavioral|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~Watch portion size - to be conscious about the amount of carbohydrates in each meal.~Eat mainly carbohydrates of low glycaemic index.~Reduce the intake of carbohydrate of high glycaemic index.~Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
79700287|NCT04603586|Radiation|SBRT|SBRT: in 5-6 fractions with CyberKnife
79700288|NCT04603586|Drug|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
79700289|NCT00474240|Drug|Atorvastatin 20 mg|
79700290|NCT00474240|Drug|AEGR-733 5 mg|
79700291|NCT00474240|Drug|AEGR-733 10 mg|
79700292|NCT00474240|Drug|Placebo|
79700293|NCT00474240|Drug|AEGR-733 5 mg + atorvastatin 20 mg|
79700294|NCT00474240|Drug|AEGR-733 10 mg + atorvastatin 20 mg|
79700295|NCT02277561|Procedure|diffusion tensor imaging|Undergo VB-DTI
79700296|NCT02277561|Radiation|whole-brain radiation therapy|Undergo WBRT
79700297|NCT02277561|Radiation|stereotactic radiosurgery|Undergo SRS
79700298|NCT02277561|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
79700299|NCT02277561|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
79700300|NCT00473889|Drug|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
79386266|NCT03241446|Drug|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
79700301|NCT00473889|Drug|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
79700302|NCT00473889|Drug|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
79700303|NCT00473889|Drug|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
79700304|NCT04602416|Behavioral|Training sessions|
79700305|NCT04602455|Behavioral|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
79700306|NCT00565214|Dietary Supplement|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
79700307|NCT00565214|Dietary Supplement|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
79700308|NCT00565253|Drug|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
79843573|NCT04008303|Procedure|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
79843574|NCT00806780|Procedure|on table cholangiography|x-ray imaging of common bile duct
79700309|NCT04602689|Drug|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
79700310|NCT02277600|Drug|BMS-663068|BMS-663068
79700311|NCT02277600|Drug|Darunavir|Darunavir
79700312|NCT02277600|Drug|Cobicistat|Cobicistat
79700313|NCT00575250|Behavioral|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
79700314|NCT00575250|Behavioral|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
79700315|NCT04602143|Drug|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
79700316|NCT02277678|Drug|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
79843575|NCT02592239|Device|Functional brain MRI|Functional brain MRI before and after test meal ingestion
79247647|NCT05091008|Drug|Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet|proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
79247648|NCT03346551|Behavioral|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
79247649|NCT03346551|Behavioral|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
79247650|NCT02918084|Drug|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
79247651|NCT02918084|Drug|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
79247652|NCT02514213|Biological|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
79247653|NCT02514213|Biological|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
79247654|NCT02514213|Biological|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
79247655|NCT02514213|Biological|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
79247656|NCT02514213|Device|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
79247657|NCT02514135|Other|No intervention|
79700317|NCT02277678|Drug|Opioid administration morphine|
79700318|NCT04601636|Device|Active Prewarming|Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
79247658|NCT02513979|Drug|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
79843576|NCT02592239|Dietary Supplement|A warm ham and cheese sandwich and a 200 ml fruit juice|
79247659|NCT01603082|Drug|Ticagrelor|180 mg loading dose
79843577|NCT00874146|Genetic|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
79247660|NCT01603082|Drug|Clopidogrel|600 mg loading dose
79247661|NCT02511093|Behavioral|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~BP measurements;~an educational and counselling intervention on patient adherence;~an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
79247662|NCT04499313|Drug|Dexamethasone|Injectable solution
79700319|NCT04601636|Other|Standard Care|Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
79700320|NCT04579536|Other|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
79700321|NCT04579536|Other|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
79700322|NCT04601519|Other|Cross-sectional observational study|Online questionnaire on the impact of type 1 diabetes on sleep quality
79700323|NCT04601675|Drug|Ranibizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
79700324|NCT04601675|Drug|Ranibizumab Ophthalmic only|Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
79700325|NCT02277756|Device|thermode|thermal stimulation with test thermode
79700326|NCT00565292|Drug|MK0859|
79843578|NCT00982605|Procedure|EBUS_TBNA|EBUS during bronchoscopy
79843579|NCT00874224|Procedure|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
79843580|NCT00874224|Procedure|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
79843581|NCT00725543|Biological|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
80012847|NCT04721392|Other|Mental fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
80012848|NCT04721392|Other|Control (documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
79247663|NCT04499313|Drug|Methylprednisolone|Injectable solution
79386267|NCT00736749|Procedure|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
79700327|NCT04601597|Device|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 ~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 ~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
79700328|NCT01580865|Drug|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
79700329|NCT04601441|Drug|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
79700330|NCT00473694|Drug|sugammadex|Administered as an intravenous (IV) infusion
79700331|NCT00473694|Drug|neostigmine|Administered as an IV infusion
79700332|NCT00473694|Drug|vecuronium|Administered as an IV infusion
79700333|NCT00473694|Drug|rocuronium|Administered as an IV infusion
79843582|NCT00881478|Other|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
80012849|NCT04745455|Other|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
79247664|NCT04331756|Procedure|Guiding Emergence From Anaesthesia With Tragus Pressure|Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery
79386268|NCT00736749|Other|Questionnaire Administration|Complete patient response form and Health Status Update Form
79386269|NCT04487418|Procedure|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
79700334|NCT00473694|Drug|glycopyrrolate|Administered as an IV infusion
79843583|NCT00881478|Other|Nutrition counseling|Nutrition counseling with registered dietician
79843584|NCT00985881|Device|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
79843585|NCT00985881|Device|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
79843586|NCT00917813|Drug|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
79843587|NCT00917813|Drug|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
79247665|NCT04331756|Procedure|Guiding Emergence From Anaesthesia Without Tragus Pressure|Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
79247666|NCT02514057|Other|Questionnaire|Form filling only
79247667|NCT04499625|Procedure|Sinus floor elevation|
79247668|NCT04499625|Device|Sinus floor elevation using an ultrasonic device|
79302760|NCT03199339|Drug|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
79843588|NCT00239005|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
79700335|NCT04601792|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
79700336|NCT04601792|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
79700337|NCT04601792|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
79700338|NCT04601012|Diagnostic Test|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
79700339|NCT00565331|Drug|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
79700340|NCT00565331|Drug|Placebo|saline solution
79700341|NCT00473655|Drug|rosuvastatin|10mg or 20mg
79700342|NCT04576481|Behavioral|Text Messaging|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
79700343|NCT04576481|Behavioral|Coaching|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
79700344|NCT04576481|Behavioral|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
79700345|NCT00582920|Radiation|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
79247669|NCT04094246|Procedure|Battlefield Acupuncture|Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
79247670|NCT04094246|Procedure|Standard post-surgical rehabilitation|Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
79386270|NCT04487418|Procedure|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
79386271|NCT02454582|Device|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
79247671|NCT05376956|Diagnostic Test|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
79386272|NCT01717859|Drug|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 > 3.2, dosage will be escalated to 8 mg/kg.
79386273|NCT03239184|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
79386274|NCT03239184|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
79700346|NCT00473382|Drug|Ranibizumab|Sterile solution for intravitreal injection.
79700347|NCT00473382|Drug|Sham injection|
79700348|NCT00582959|Other|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
79700349|NCT02210325|Drug|solithromycin|
79700350|NCT02210325|Drug|ceftriaxone|
79700351|NCT02210325|Drug|azithromycin|
79700352|NCT00473265|Drug|PTH|
79700353|NCT00583037|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
79700354|NCT04576286|Procedure|Holmium versus Bipolar en bloc transurethral resection|"After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B."
79700355|NCT00472641|Drug|Ziprasidone/Geodon|Ziprasidone/Geodon
79700356|NCT04576208|Drug|TAK-788|TAK-788 capsules
79386275|NCT03249168|Drug|Duloxetine 60mg|tablet
79386276|NCT03249168|Drug|Placebo|Tablet
79700357|NCT04576208|Drug|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
79700358|NCT04571151|Drug|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
79700359|NCT04571151|Drug|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
79843589|NCT00239005|Drug|Mycophenolate Mofetil (MMF)|
79843590|NCT02594891|Device|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
79843591|NCT02594891|Device|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
79843592|NCT00616434|Drug|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
79843593|NCT00616434|Drug|Placebo|Placebo IM injection, self-administered per protocol.
79843594|NCT01581697|Dietary Supplement|Oat bran|
79541431|NCT01492751|Behavioral|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.~Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
79843595|NCT00652340|Drug|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
79843596|NCT00652340|Drug|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
79843597|NCT00257725|Drug|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
79843598|NCT00544869|Drug|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
79247672|NCT05376956|Diagnostic Test|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
79247673|NCT02510937|Drug|CC-90001|
79247674|NCT05090930|Device|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
79247675|NCT05090930|Device|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
79302761|NCT03199339|Drug|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
79302762|NCT02478905|Other|Influenza|
79700360|NCT04571151|Other|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
79700361|NCT04576169|Procedure|Arthroscopic Debridement|A central or radial TFCC tear found during wrist arthroscopy is debrided with a shaver. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation.
79843599|NCT00725075|Drug|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
79843600|NCT00725075|Drug|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
79843601|NCT00725075|Drug|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
79843602|NCT00874302|Drug|Proellex|One 25mg capsule taken orally once every day.
79843603|NCT00874302|Drug|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
79843604|NCT02593643|Drug|Ketamine|
79843605|NCT02593643|Drug|Midazolam|
79386277|NCT03248856|Drug|Triamcinolone Acetonide|Intratympanic administration
79386278|NCT03241524|Other|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
79386279|NCT03241602|Drug|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
79843606|NCT02593643|Other|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
79843607|NCT05261087|Other|No intervention|Individuals will not receive any interventions
79843608|NCT00881556|Drug|Palifermin|60 mcg/kg/day for 6 days
79843609|NCT00881556|Drug|Fludarabine|30 mg/m2 IV x 1 for 6 days
79843610|NCT00881556|Drug|Busulfan|4 mg/kg/day IV divided BID for 4 days
79843611|NCT00881556|Drug|Lorazepam|0.02-0.05 mg/kg for 5 days
79843612|NCT00881556|Drug|Alemtuzumab|20 mg/m2 IV for 5 days
79700362|NCT04576169|Procedure|Placebo surgery|Diagnostic arthroscopy only. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation. The procedure is placebo surgery.
79843613|NCT00881556|Drug|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
79843614|NCT03969797|Device|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
79700363|NCT04576169|Procedure|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
79247676|NCT02510859|Other|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
79247677|NCT02510781|Drug|Epirubicin|75mg/m2 d1 evry 21days
79247678|NCT02510781|Drug|Docetaxel|75mg/m2 d1 evry 21days
79386280|NCT03241602|Procedure|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
79700364|NCT04576169|Procedure|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
79386281|NCT03241602|Combination Product|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
79386282|NCT03241680|Diagnostic Test|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
79386283|NCT01973608|Drug|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
79700365|NCT01133977|Drug|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
79700366|NCT01133977|Drug|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
79700367|NCT01133977|Drug|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
79700368|NCT04570917|Behavioral|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
79843615|NCT00874380|Other|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
79247679|NCT02510781|Drug|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
79247680|NCT02510781|Drug|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
79843616|NCT00881634|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
79843617|NCT00881634|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
79247681|NCT03578653|Behavioral|Merging Yoga and Occupational Therapy for Parkinson disease|The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
79247682|NCT03121599|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
79843618|NCT00874458|Procedure|magnetic resonance imaging|
79843619|NCT00874458|Procedure|radiomammography|
79843620|NCT00874458|Procedure|ultrasound imaging|
79700369|NCT04570917|Behavioral|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
79700370|NCT00583193|Drug|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
79700371|NCT01133821|Drug|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
79843621|NCT00878670|Drug|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
79843622|NCT00874536|Dietary Supplement|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
79843623|NCT00874536|Dietary Supplement|Placebo|
79247683|NCT03576235|Drug|PG102P|Daily dose of 1.5g
79386284|NCT01973608|Drug|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
79247684|NCT03576235|Drug|Placebo|Daily dose of placebo
79247685|NCT02510547|Procedure|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
79386285|NCT01973608|Drug|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
79386286|NCT01973608|Drug|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
79247686|NCT02510547|Procedure|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
79247687|NCT04437524|Other|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
79247688|NCT03576079|Device|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
79247689|NCT03576079|Device|anterior re-positioning splint|hard acrylic anterior re-positioning splint
79247690|NCT03576079|Device|inactive Laser therapy|sham Laser, with inactive beam
79541432|NCT01492751|Procedure|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
79247691|NCT02035735|Procedure|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
79247692|NCT02513589|Drug|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
79305519|NCT04936347|Procedure|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
79305520|NCT03243227|Other|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
79247693|NCT03575923|Behavioral|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
79541433|NCT01492751|Radiation|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
79386287|NCT01973608|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
79541434|NCT01492751|Radiation|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
79700372|NCT01133821|Drug|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
79700373|NCT00472446|Drug|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
79700374|NCT00472446|Drug|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
79700375|NCT00583232|Drug|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
79247694|NCT03575845|Behavioral|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
79247695|NCT03949868|Behavioral|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
79386288|NCT02234232|Behavioral|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
79700376|NCT00583271|Drug|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
79843624|NCT00733499|Device|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
79843625|NCT00733499|Device|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
79843626|NCT00878748|Drug|Effexor XR|
79843627|NCT00878748|Other|Effexor XR discontinue|
79843628|NCT04088045|Device|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
79843629|NCT00652028|Drug|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
79700377|NCT00583271|Drug|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
79700378|NCT04570995|Dietary Supplement|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
79843630|NCT02592473|Device|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
79843631|NCT00738101|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
79247696|NCT03949868|Behavioral|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
79247697|NCT03949868|Behavioral|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
79247698|NCT03575767|Other|Myeloablative Hematopoietic Stem Cell Transplantation|Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.
79391485|NCT02440204|Drug|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
79541435|NCT01492790|Procedure|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
79541436|NCT01492790|Procedure|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
79541437|NCT01492803|Dietary Supplement|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
79843632|NCT00810212|Procedure|PLF with autograft|6 subjects
79843633|NCT00810212|Biological|PLF with NeoFuse|6 subjects low dose
79391486|NCT02440204|Drug|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
79541438|NCT01492803|Dietary Supplement|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
79541439|NCT01492816|Behavioral|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
79700379|NCT04570995|Dietary Supplement|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
79843634|NCT00810212|Biological|PLF with NeoFuse|6 subjects medium dose
79700380|NCT04576013|Device|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
79700381|NCT04576013|Behavioral|Intensive upper extremity motor training|
79700382|NCT00472290|Drug|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
79700383|NCT01133704|Biological|sipuleucel-T|
79700384|NCT01133704|Biological|APC-Placebo|
79247699|NCT03574675|Device|Simulated Altitude (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
79247700|NCT03574675|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
79247701|NCT02513901|Drug|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
79843635|NCT00810212|Biological|PLF with NeoFuse|6 subjects high dose
79843636|NCT00799136|Drug|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
79247702|NCT04535258|Device|Blend-A|Treatment for alcohol use disorders will be offered also as an internet-based option.
79247703|NCT03575689|Device|Doyle Splint|Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
79247704|NCT02510469|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
79305521|NCT03243227|Other|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
79391487|NCT02410590|Drug|Rocuronium|
79391488|NCT02410590|Drug|Sugammadex|
79391489|NCT02410590|Drug|Cisatracurium|
79391490|NCT02410590|Drug|Neostigmine/Atropine|
79391491|NCT02410590|Drug|Succinylcholine|
79247705|NCT04090034|Procedure|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
79700385|NCT02883088|Procedure|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
79700386|NCT00583310|Behavioral|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
79700387|NCT05158582|Other|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
79700388|NCT05158582|Other|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
79700389|NCT00583349|Drug|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
79700390|NCT04571073|Procedure|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
79700391|NCT00583388|Dietary Supplement|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
79700392|NCT00583388|Device|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
79700393|NCT01133665|Drug|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
79700394|NCT04571346|Procedure|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
79849034|NCT05548491|Drug|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
79849035|NCT05546697|Other|Online- Yoga-based Intervetion|See arms description
79247706|NCT03578575|Drug|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
79247707|NCT03578575|Drug|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
79247708|NCT02513511|Procedure|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
79247709|NCT02510313|Other|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
79247710|NCT03575533|Diagnostic Test|Bayesian network 'Sherlock'|Primary objective is to validate the Bayesian Hemodynamics model 'Sherlock'. Criterion for validation is a match between Sherlock's estimate of the Hemodynamic status of a patient and a ground truth based on a cardiologist's judgement.
79247711|NCT03574519|Behavioral|Non-contingent incentives|Incentives are provided for participation
79247712|NCT03574519|Behavioral|Contingent incentives|Incentives are provided for attaining daily goals
79247713|NCT03574519|Behavioral|Weekly feedback|Text message feedback is delivered weekly summarizing the past week's progress
79247714|NCT03574519|Behavioral|Daily feedback|Text message feedback is delivered daily summarizing the current day's progress
79391492|NCT02410668|Dietary Supplement|flaxseed|
79391493|NCT02410668|Dietary Supplement|Placebo|
79391494|NCT02410668|Behavioral|Exercise recommendation|
79391495|NCT02517580|Dietary Supplement|Vitamin K2 (MK7)|
79391496|NCT02412462|Drug|AB-16B5|
79391497|NCT02412384|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
79391498|NCT02412384|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
79391499|NCT02517658|Other|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
79391500|NCT02517658|Other|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
79391501|NCT02417922|Other|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
79391502|NCT02417922|Other|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
79391503|NCT02522104|Drug|Siklos|
79391504|NCT02412150|Drug|Desflurane|Anesthesia is maintained with desflurane
79541440|NCT01492829|Behavioral|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
79541441|NCT01492855|Procedure|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
79541442|NCT01492855|Behavioral|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
79700395|NCT00583427|Drug|Sulodexide|200 mg per day in an oral gelcap form
79700396|NCT01133626|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
79700397|NCT01133626|Drug|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
79700398|NCT01133626|Drug|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
79700399|NCT01133626|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
79849036|NCT05546697|Behavioral|Online- BA|See arms description
79247715|NCT02510391|Behavioral|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
79247716|NCT03575455|Behavioral|Exercise|HR-controlled treadmill walking
79541443|NCT01492881|Drug|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
79541444|NCT01492881|Drug|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
79541445|NCT01492881|Drug|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
79700400|NCT04575974|Other|No intervention|No intervention
79541446|NCT01492894|Drug|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
79700401|NCT01133392|Drug|Insulin lispro A|20 units (U) subcutaneously (SC).
79541447|NCT01492894|Drug|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
79541448|NCT01492907|Radiation|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
79541449|NCT01492907|Procedure|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
79541450|NCT01492920|Dietary Supplement|Acetyl-L-Carnitine Hydrochloride|Given orally
79541451|NCT01492920|Other|Placebo|Given orally
79541452|NCT01492920|Other|Questionnaire Administration|Ancillary studies
79541453|NCT01492920|Other|Quality-of-Life Assessment|Ancillary studies
79541454|NCT01492959|Drug|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
79541455|NCT01492985|Biological|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
79541456|NCT01492985|Biological|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
79700402|NCT01133392|Drug|Insulin lispro B|20 U subcutaneously (SC).
79700403|NCT04575818|Drug|GLPG4059 oral suspension|GLPG4059 for oral administration
79700404|NCT04575818|Drug|Placebo|Placebo oral suspension
79700405|NCT04575818|Drug|GLPG4059 tablet|GLPG4059 for oral administration
79247717|NCT02510235|Device|Lubricin|Lubricin 150 µg/ml eye drops
79247718|NCT02510235|Device|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
79247719|NCT03575377|Other|Disposal Aid|Deterra® drug deactivation system
79247720|NCT05081336|Drug|Statin|Statin +/- ezetimib +/- Alirocumab
79247721|NCT03575299|Biological|The adoptive treatment of allogeneic γδT cells|Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
79247722|NCT03575299|Other|Control|No allogeneic γδT cells will be administered to patients with MDR-TB.
79247723|NCT03575299|Drug|Conventional treatment|Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
79247724|NCT03712982|Behavioral|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
79541457|NCT01492998|Other|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
79541458|NCT01493011|Device|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
79700406|NCT02882815|Device|IrisFIT PFO Occluder|
79700407|NCT00583505|Device|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
79700408|NCT00471354|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
79700409|NCT04575701|Other|TNF Alpha therapy|Retrospective analysis of outcome of first TNF Alpha therapy
79700410|NCT02882893|Drug|Clostridium Botulinum A Toxin|
79700411|NCT02882893|Drug|Clostridium Botulinum A Toxin|
79700412|NCT00583544|Drug|TC-2216|Multiple ascending dose groups will be explored.
79700413|NCT02210364|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
79700414|NCT02210364|Drug|capecitabine|capecitabine 150 mg tablets
79700415|NCT00583583|Device|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
79541459|NCT01493037|Device|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
79700416|NCT00471315|Drug|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
79700417|NCT00583739|Behavioral|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
79843637|NCT02592395|Drug|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
79843638|NCT02592395|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
79843639|NCT00810290|Behavioral|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
79843640|NCT00799214|Drug|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
79247725|NCT03712982|Behavioral|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
79247726|NCT03712982|Behavioral|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
79247727|NCT03712982|Other|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
79247728|NCT02239549|Device|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
79247729|NCT02239549|Device|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
79541460|NCT01493050|Drug|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
79843641|NCT00799214|Drug|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
79843642|NCT00799214|Drug|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
79843643|NCT00733421|Drug|etoricoxib|90 mg once daily
79843644|NCT00733421|Drug|tramadol|100 mg twice daily
79843645|NCT00613080|Drug|capecitabine|1650 mg/m^2/day orally 5 days/week during radiotherapy.
79247730|NCT03578497|Drug|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
79247731|NCT03710876|Biological|rAd-IFN|Adenovirus-Delivered Interferon Alpha-2b
79247732|NCT03710876|Drug|Celecoxib Oral Product|400 mg twice daily
79247733|NCT03710876|Drug|Gemcitabine|1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
79247734|NCT03578341|Biological|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
79541461|NCT01493050|Drug|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
79541462|NCT01493076|Device|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
79541463|NCT01493102|Drug|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
79541464|NCT01493102|Drug|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
79700418|NCT04575623|Diagnostic Test|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~Duration Pattern test (DPT) designed to test temporal ordering abilities.~Dichotic Digits Test (DDT) it assesses binaural integration skills.~Auditory fusion test-revised (ART-R) to measure temporal resolution.~speech in test to assess central auditory function."
79843646|NCT00613080|Drug|oxaliplatin|
79843647|NCT00613080|Procedure|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
79843648|NCT00613080|Radiation|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
79849037|NCT05545852|Procedure|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
79700419|NCT04575623|Device|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~Dual band pure tone audiometer (Orbiter 992).~Impedance audiometer (AT 235h).~Sound treated booth (industrial acoustic company IAC model 1602-A-t)~Panasonic stereo CD player SA-AK 240."
79700420|NCT00471237|Drug|Ronacaleret|100mg, 200mg, 300mg, 400mg
79700421|NCT00471237|Drug|Teriparatide|PTH (1-34)
79700422|NCT00471237|Drug|Alendronate|Bisphosphonate
79247735|NCT02513433|Drug|Bupivacaine|Local anesthetic
79843649|NCT00613080|Drug|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m^2, IV continuous infusion over 46 hours, day 1."
79843650|NCT00806858|Device|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
79247736|NCT02513433|Drug|Levobupivacaine|Local anesthetic
79386289|NCT03248778|Behavioral|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
79386290|NCT02357290|Drug|Open-label Treatment with N-Acetylcysteine|
79386291|NCT02453724|Device|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
79386292|NCT00715143|Device|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
79386293|NCT03238872|Behavioral|Cognitive Behavioural Therapy|
79700423|NCT04575545|Diagnostic Test|Serology test for COVID-19|ELISA test
79700424|NCT00583895|Drug|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
79386294|NCT03238872|Other|Treatment as usual|
79843651|NCT00917891|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
79247737|NCT02513433|Drug|Ropivacaine|Local anesthetic
79247738|NCT03567590|Procedure|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
79247739|NCT03567590|Procedure|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
79843652|NCT00917891|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
79247740|NCT03574363|Drug|KBP-5074 0.25 mg tablet|Oral administration, QD, 84 days
79247741|NCT03574363|Drug|KBP-5074 0.5 mg tablet|Oral administration, QD, 84 days
79247742|NCT03780387|Biological|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
79247743|NCT02846779|Other|Low intensity|Low intensity telepharmacy outreach
79247744|NCT02846779|Other|Moderate intensity|Moderate intensity telepharmacy outreach
79247745|NCT02846779|Other|High intensity|High intensity telepharmacy outreach
79247746|NCT02510157|Drug|Dexamethasone|active comparator
79247747|NCT02510157|Drug|Normal Saline|placebo controlled intervention
79247748|NCT02510157|Drug|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
79391505|NCT02412150|Drug|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
79391506|NCT02412150|Procedure|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
79700425|NCT00583895|Drug|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
79700426|NCT04570683|Drug|Nivolumab 10 MG/ML|Se previously
79700427|NCT04570683|Device|Ablative fractionated laser|Se previously
79700428|NCT00471081|Biological|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
79700429|NCT03453008|Other|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
79843653|NCT03871166|Other|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~[Time Frame: 01/2007 - 12/2018]"
79843654|NCT02554136|Drug|HGP0918|
79700430|NCT03452969|Other|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
79700431|NCT04570449|Drug|Fluoxetine|20 mg capsule
79700432|NCT04570449|Drug|Placebo|fluoxetine placebo capsule
79700433|NCT00470847|Drug|Lapatinib|Orally twice daily
79700434|NCT00470847|Procedure|Whole Brain Radiation|15 treatments over a period of 3 weeks
80012850|NCT05738200|Other|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
80012851|NCT05738122|Other|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
80012852|NCT05201677|Procedure|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
80012853|NCT05738044|Other|No intervention|No intervention
79247749|NCT05376332|Device|Sonomyographic Prosthesis|The sonomyographic system will include a custom-fitted test socket incorporating ultrasound transducers and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
79386295|NCT02453880|Behavioral|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
79386296|NCT04296045|Dietary Supplement|MCE|Ingestion of 15g MCE in water after min 10 hours of fasting
79700435|NCT00470847|Drug|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
79541465|NCT01493115|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79386297|NCT04296045|Dietary Supplement|Glucose|Ingestion of 15g glucose in water after min 10 hours of fasting
79541466|NCT01493115|Drug|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79541467|NCT01493154|Biological|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
80012854|NCT04676191|Device|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
79247750|NCT05376332|Device|Myoelectric direct control prosthesis|The direct control system will include a custom-fitted test socket incorporating dual-site electrodes and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
79541468|NCT01493154|Drug|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
79541469|NCT01493193|Other|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
79700436|NCT00584090|Drug|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
79843655|NCT02554136|Drug|HGP0816|
80012855|NCT04676191|Device|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
80012856|NCT02570282|Drug|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
80012857|NCT02570282|Drug|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
80012858|NCT05737888|Other|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
80012859|NCT05737888|Other|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
80012860|NCT05737888|Behavioral|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
80012861|NCT02564744|Drug|Debio 1562|Safety run in: Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Parts 2 and 3: Cohort A- Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Cohort B- Debio 1562 weekly (QW) will be given at a total dose of 0.8 milligram per kilogram (mg/kg) IV over a 21-day cycle. Participants receiving QW regimen will be allowed to switch to Q3W regimen during Coronavirus Disease 2019 (COVID-19) pandemic.
79247751|NCT05376332|Device|Myoelectric pattern recognition prosthesis|The pattern recognition system will include the subject's clinically-prescribed socket and commercially-available pattern recognition technology (IBT Sense). The pattern recognition system will not be fitted as part of this study, as subjects will already be trained users prior to enrolling in the study.
79700437|NCT00584090|Drug|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
79700438|NCT04570527|Procedure|PCI|percutaneous coronary intervention
79700439|NCT00584129|Other|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
79700440|NCT00584129|Other|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
79843656|NCT02554136|Drug|HGP0918 + HGP0816|
79700441|NCT04570566|Procedure|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
79700442|NCT00584168|Drug|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
79700443|NCT00584168|Drug|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
79700444|NCT00470535|Drug|erlotinib hydrochloride|Oral
79386298|NCT00693459|Device|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
79700445|NCT00470535|Other|immunohistochemistry staining method|Correlative Study
79843657|NCT00732875|Biological|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
79386299|NCT02454192|Behavioral|CHAMPS|
79541470|NCT01493193|Other|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
79541471|NCT01493193|Other|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
79541472|NCT01493206|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
79700446|NCT00470535|Other|laboratory biomarker analysis|Correlative Study
79700447|NCT00584207|Procedure|radiofrequency ablation|Intraoperative RFA of uterine fibroids
79843658|NCT00799370|Procedure|Early weight bearing|Weight bearing performed immediately after surgery
79843659|NCT00799370|Procedure|Delayed weight bearing|Weight bearing performed 2 months after surgery
79843660|NCT00874692|Other|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
79386300|NCT00687765|Drug|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
79700448|NCT00584324|Combination Product|BIS 40|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
79386301|NCT03248544|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
79700449|NCT00584324|Combination Product|BIS 60|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
79700450|NCT00470418|Drug|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
79700451|NCT00470418|Drug|Placebo|placebo comparator
79386302|NCT03248544|Other|control|No intervention
79843661|NCT00881790|Other|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
79843662|NCT05097456|Device|carbon dioxide laser|carbon dioxide laser
79843663|NCT05097456|Device|sham laser|sham laser
79843664|NCT00810446|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
79843665|NCT00810524|Drug|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
79843666|NCT00810524|Drug|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
79843667|NCT00810524|Drug|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
79843668|NCT00810524|Drug|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
79843669|NCT00810680|Drug|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
79843670|NCT00799448|Drug|repaglinide|
79386303|NCT03238950|Other|Porcine model|participants to conduct training on porcine model
79386304|NCT03238950|Other|Synthetic model|participants to conduct training on synthetic model
79386305|NCT03239028|Behavioral|Observational|
79843671|NCT00799448|Drug|biphasic human insulin 30|
79843672|NCT00799448|Drug|insulin NPH|
79843673|NCT00806936|Drug|human insulin|Any kind of human insulin administered at the discretion of the physician
79700452|NCT01133275|Drug|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
79700453|NCT01133275|Drug|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
79700454|NCT00470184|Drug|capecitabine|Oral
79700455|NCT00470184|Drug|oxaliplatin|IV
79700456|NCT00470184|Genetic|gene expression analysis|Correlative Study
79700457|NCT00470184|Genetic|microarray analysis|Correlative Study
79700458|NCT00470184|Genetic|reverse transcriptase-polymerase chain reaction|Correlative Study
79700459|NCT00470184|Procedure|adjuvant therapy|Metastatic growth control
79700460|NCT00470184|Procedure|biopsy|Examination of tissue type
79247752|NCT03478592|Other|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
79700461|NCT00470184|Procedure|conventional surgery|Tissue removal
79843674|NCT00806936|Drug|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
79843675|NCT00807170|Drug|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
79843676|NCT00807170|Radiation|Whole Brain Radiotherapy (WBRT)|
80012862|NCT02564744|Drug|Rituximab|Rituximab will be given on the same day as Debio 1562, Q3W IV at a dose of 375 mg/m^2 on Day 1 of a 21-day cycle in all participants.
79247753|NCT03478592|Other|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
79247754|NCT04499001|Other|Pharmacist's consultation|Information about bDMARDs management.
79386306|NCT04486794|Device|Restylane®|Hyaluronic acid
79386307|NCT03241212|Behavioral|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
79386308|NCT03238716|Other|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
79700462|NCT00470184|Procedure|neoadjuvant therapy|Tumor shrinkage
79843677|NCT00807170|Drug|ZD6474|200 mg as a once daily oral dose, 21 days
80012863|NCT05201599|Device|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
79247755|NCT03344978|Other|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found < 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
79305522|NCT03243383|Other|DiaTOHC Program|"Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~Peri-discharge coordination of care~A1c-based adjustment of diabetes therapy~Post-discharge support"
79700463|NCT00470184|Procedure|quality-of-life assessment|Correlative Study
79700464|NCT00470184|Radiation|radiation therapy|Undergoing radiation therapy
79700465|NCT00584519|Other|non-interventional|non-interventional
79700466|NCT04570254|Drug|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
79700467|NCT04570254|Drug|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
79700468|NCT04570254|Drug|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
79700469|NCT04570254|Drug|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
79700470|NCT04570254|Drug|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
79700471|NCT00584597|Drug|Saline|Saline Control
79700472|NCT00584597|Drug|Traumeel S|Traumeel S 1 mL
79700473|NCT00584597|Drug|Traumeel S|Traumeel S 2mL
79700474|NCT00584597|Drug|Traumeel S|Traumeel S 3mL
79700475|NCT00470067|Drug|carboplatin|IV
79700476|NCT00470067|Drug|pegylated liposomal doxorubicin hydrochloride|IV
79700477|NCT00584636|Drug|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
79843678|NCT00807170|Drug|ZD6474|300 mg as a once daily oral dose, 21 days
79843679|NCT00799526|Procedure|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
79700478|NCT04570137|Dietary Supplement|Dietary fiber supplementation|"16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~16g/day: mix of 50% inulin and 50% oligofructose from chicory"
79700479|NCT00584675|Device|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
79700480|NCT00479817|Drug|AMG 386|10mg/kg
79700481|NCT00479817|Drug|AMG 386|3 mg/kg
79700482|NCT00479817|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
79843680|NCT00799526|Procedure|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
79843681|NCT02553902|Device|Sleep position trainer|
79843682|NCT02553902|Device|Mandibular advancement device|
79843683|NCT02553902|Device|Continuous positive airway pressure|
79843684|NCT00615264|Drug|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
79843685|NCT00615264|Drug|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
79843686|NCT00799682|Drug|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
79247756|NCT03344978|Other|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found < 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
79247757|NCT03345147|Other|High Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
79247758|NCT03345147|Other|Normal Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
79247759|NCT03662919|Drug|Infliximab|Administered as specified in the treatment arm.
79700483|NCT00479817|Drug|AMG 386 Placebo|AMG 386 Placebo
79700484|NCT04575506|Other|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
79700485|NCT04575194|Drug|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
79700486|NCT04575194|Drug|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
79700487|NCT04570059|Behavioral|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
79700488|NCT00478179|Drug|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
79247760|NCT03662919|Drug|Adalimumab|Administered as specified in the treatment arm.
79700489|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
79700490|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
79700491|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
79700492|NCT04569825|Drug|Ophtamesone|local application intranasally as drops
79700493|NCT00476931|Biological|SB-509|60 mg dose
79700494|NCT00476931|Other|Placebo|Saline
79700495|NCT00585026|Device|D-28 bifocal lenses and frame|
79843687|NCT00799682|Drug|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
79843688|NCT00810758|Drug|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
79843689|NCT00810758|Drug|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
79843690|NCT00810758|Drug|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
79843691|NCT00732641|Drug|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
79843692|NCT03829020|Drug|Bortezomib|Given SC
79843693|NCT03829020|Drug|Metformin Hydrochloride|Given PO
79843694|NCT03829020|Drug|Nelfinavir Mesylate|Given PO
79843695|NCT00810836|Drug|BG00012|oral
79843696|NCT00810836|Drug|BG00012|Oral
79843697|NCT00810836|Drug|placebo|oral placebo
79843698|NCT00874926|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
79843699|NCT00810914|Drug|bupivicaine epidural|bupivicaine continuous epidural infusion
79843700|NCT00810914|Drug|bupivicaine epidural infusion patient epidural|bupivicaine
79843701|NCT00810914|Drug|bupivicaine|patient controlled anesthesia only
79843702|NCT00878904|Drug|epirubicin hydrochloride|
79843703|NCT00878904|Drug|panobinostat|
79843704|NCT00878904|Genetic|gene expression analysis|
79843705|NCT00878904|Genetic|protein expression analysis|
79843706|NCT00878904|Genetic|western blotting|
79843707|NCT00878904|Other|immunologic technique|
79843708|NCT00878904|Other|laboratory biomarker analysis|
79843709|NCT00878904|Other|pharmacological study|
79247761|NCT05375240|Drug|Propranolol|Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
79541473|NCT01493232|Other|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
79843710|NCT00810992|Behavioral|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
79843711|NCT00810992|Behavioral|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
80012864|NCT03110536|Diagnostic Test|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
79247762|NCT05375240|Drug|Ceftriaxone|Intravenously 2.0g/day for 7 consecutive days.
79541474|NCT01493245|Drug|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
79541475|NCT01493258|Other|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
79541476|NCT01493297|Other|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
79541477|NCT01493310|Drug|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
79541478|NCT01493310|Drug|placebo|Given orally
79541479|NCT01493310|Drug|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
79541480|NCT01493323|Behavioral|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
79541481|NCT01493323|Behavioral|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
79843712|NCT00737711|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
79843713|NCT00881946|Drug|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
79843714|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
79843715|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
79843716|NCT00807326|Drug|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
79843717|NCT00875082|Drug|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
79843718|NCT00875082|Drug|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
79843719|NCT02552342|Drug|methylprednisolone|
79247763|NCT00406393|Drug|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
79247764|NCT00406393|Drug|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
79247765|NCT00406393|Drug|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged < 12.0 years OR weighing < 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
79541482|NCT01493323|Behavioral|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
79541483|NCT01493323|Procedure|Cyber ball game|functional neuroimaging
79541484|NCT01493323|Procedure|Iowa Gambling Task|functional neuroimaging
79541485|NCT01493323|Procedure|Microcomputer|functional neuroimaging
79541486|NCT01493323|Procedure|blood sample|blood sample
79541487|NCT01493336|Drug|capecitabine RTD|single oral dose
79843720|NCT02552342|Drug|Normal saline|
79843721|NCT00811226|Drug|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
79843722|NCT00238303|Drug|vorinostat|Given orally
80012865|NCT03110536|Other|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
80012866|NCT02564588|Drug|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
80012867|NCT02564588|Drug|Placebo|Placebo once daily
79541488|NCT01493336|Drug|capecitabine [Xeloda]|single oral dose
79541489|NCT01493336|Drug|capecitabine [Xeloda]|standard treatment
79700496|NCT00585026|Device|Progressive addition computer lenses and frame|
79700497|NCT04569669|Diagnostic Test|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
79700498|NCT00479427|Drug|GW842166|100 mg once daily
79700499|NCT00479427|Drug|Placebo|once daily
79700500|NCT00585143|Drug|ABT-335|45 mg once daily for 10 consecutive days
79700501|NCT00585143|Drug|Rosuvastatin|10 mg once daily for 10 days
79386309|NCT03238716|Other|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
79700502|NCT04569981|Other|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
79247766|NCT05065892|Biological|COVAX|2 doses of Covid-19 vaccine
79247767|NCT02513355|Biological|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
79247768|NCT02513355|Drug|Changchun marina|25mg/m2,d1 and d8,q21d×4
79386310|NCT03238716|Other|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at > 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
79541490|NCT01493388|Drug|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
79541491|NCT01493401|Procedure|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
79541492|NCT01493440|Drug|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
79541493|NCT01493479|Drug|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
79541494|NCT01493479|Drug|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to <= 20% to enter the main treatment phase of the trial."
79700503|NCT04569981|Other|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
79700504|NCT00585260|Drug|mannitol|indirect mannitol challenge
79700505|NCT04569474|Device|Transparent dressing|Use of sterile transparente dressing
79700506|NCT00585299|Other|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
79700507|NCT00585299|Other|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
79700508|NCT00585416|Drug|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
79700509|NCT00475020|Drug|Busulfan|Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days
79700510|NCT00475020|Drug|Fludarabine|40 mg/m^2 by vein daily over 1 hour x 4 days
79700511|NCT00475020|Drug|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
79700512|NCT00585455|Drug|sertraline|open label 25-50 mg daily as tolerated
79700513|NCT02484456|Drug|AV 101 (4-Chlorokynurenine)|L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
79700514|NCT02484456|Other|Placebo Comparator|Placebo
79700515|NCT00585728|Procedure|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
79247769|NCT02513355|Drug|cisplatin|80mg/m2,d1, q21d×4
79247770|NCT02513355|Drug|Taxol|135-175mg/m2,d1,q21d×4
79247771|NCT02513355|Drug|parapl|AUC=5-6,d1,q21d×4
79247772|NCT03574285|Drug|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
79247773|NCT03574285|Drug|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
79247774|NCT05051930|Drug|TQC3721 suspension for inhalation|Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
79247775|NCT05051930|Drug|TQC3721 suspension placebo for inhalation|Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
79247776|NCT02509923|Drug|Z-215 10mg|Z-215 10mg, capsules
79247777|NCT02509923|Drug|Z-215 20mg|Z-215 20mg, capsules
79247778|NCT02509923|Drug|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
79247779|NCT02509923|Drug|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
79700516|NCT01132807|Biological|Bleomycin Sulfate|Given IV
79700517|NCT01132807|Drug|Doxorubicin Hydrochloride|Given IV
79700518|NCT01132807|Drug|Procarbazine Hydrochloride|Given PO
79700519|NCT01132807|Drug|Vinblastine Sulfate|Given IV
79700520|NCT01132807|Drug|Dacarbazine|Given IV
79700521|NCT01132807|Drug|Cyclophosphamide|Given IV
79700522|NCT01132807|Drug|Etoposide phosphate|Given IV
79700523|NCT01132807|Drug|prednisone|Given PO
79700524|NCT01132807|Drug|Radiation Therapy|Undergo radiation therapy
79700525|NCT01132807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
79700526|NCT01132807|Procedure|computed tomography|Undergo FDG PET/CT
79700527|NCT01132807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
79700528|NCT04569513|Biological|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
79843723|NCT00238303|Procedure|conventional surgery|Patients undergo surgery to remove tumor
79700529|NCT00585845|Biological|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.
79700530|NCT01132651|Other|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
79843724|NCT00737633|Drug|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
79247780|NCT03578263|Drug|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
79247781|NCT03578263|Drug|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
79247782|NCT03578263|Drug|ergometrine|intramuscular ergometrine 0.2 mg.
79541495|NCT01493518|Drug|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
79247783|NCT05031182|Procedure|Laparoscopy|The hysterectomy is performed by laparoscopy as described in the EMC.
79700531|NCT01132651|Other|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
79700532|NCT01089543|Drug|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
79700533|NCT01089543|Drug|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
79700534|NCT01089543|Drug|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
79700535|NCT01089543|Drug|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
79247784|NCT05031182|Procedure|vNOTES|The hysterectomy is performed by vNOTES as described Dr BAEKELANDT and this team.
79247785|NCT02507661|Drug|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
79541496|NCT01493570|Drug|BI 409306|High dose film-coated tablet
79541497|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
79700536|NCT00585962|Radiation|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
79843725|NCT00811460|Drug|Placebo|sc for 4 days
79843726|NCT00811460|Drug|taspoglutide|300micrograms/day sc for 2 days
79843727|NCT00811460|Drug|taspoglutide|800 micrograms/day sc for 2 days
79541498|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
79700537|NCT04569396|Diagnostic Test|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
79700538|NCT04569396|Diagnostic Test|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
79700539|NCT04569396|Other|BMI measurement|BMI was measured among the study subjects before and after the surgery.
79700540|NCT04569396|Diagnostic Test|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
79700541|NCT04569396|Diagnostic Test|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
79700542|NCT00586040|Procedure|tissue bonding|application of rose bengal and treatment with green light
79843728|NCT00875238|Biological|trastuzumab|
79843729|NCT00875238|Drug|doxorubicin hydrochloride|
79843730|NCT00875238|Genetic|polymorphism analysis|
79247786|NCT02507661|Drug|no-preservation of alveolar ridge - 2 months|
79247787|NCT02507661|Drug|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
79247788|NCT02507661|Drug|no-preservation of alveolar ridge - 4 months|
79247789|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
79247790|NCT02507661|Drug|no-preservation of alveolar ridge - 9 months|
79247791|NCT05009966|Drug|SYSA1801 for injection|SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
79843731|NCT00875238|Other|laboratory biomarker analysis|
79305523|NCT04957563|Behavioral|olfactory rehabilitation|treatment for improve olfactory function
79541499|NCT01493570|Drug|BI 409306 Placebo|Film-coated tablet
79541500|NCT01493570|Drug|BI 409306|Medium dose film-coated tablet
79541501|NCT01493609|Behavioral|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
79541502|NCT01493622|Drug|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
79541503|NCT01493622|Drug|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
79700543|NCT00586040|Procedure|sutures|interrupted superficial sutures
79843732|NCT00875238|Other|questionnaire administration|
79843733|NCT00875238|Procedure|assessment of therapy complications|
79843734|NCT00875238|Procedure|magnetic resonance imaging|
79843735|NCT02552498|Procedure|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
79843736|NCT00732251|Drug|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
79843737|NCT00811538|Procedure|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
79843738|NCT00811538|Procedure|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
79843739|NCT00811616|Device|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
79541504|NCT01493635|Other|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
79700544|NCT04569630|Other|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
79700545|NCT00586079|Procedure|Deep brain stimulation surgery.|Deep brain stimulation surgery.
79843740|NCT00882024|Drug|Tranilast|150 mg tranilast tablets, bid, 12 weeks
79541505|NCT01493635|Other|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
79843741|NCT00882024|Drug|Tranilast|75 mg tablets, bid, 12 weeks
79247792|NCT02509611|Other|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
79247793|NCT03174002|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
79843742|NCT00882024|Drug|Placebo|Placebo tablets, bid, 12 weeks
79541506|NCT01493648|Drug|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
79541507|NCT01493648|Drug|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
79541508|NCT01493661|Other|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
79700546|NCT04569318|Device|Treatment Beam|One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
79700547|NCT03452852|Device|PICO|NPWT with PICO (Smith and Nephew)
79843743|NCT00799760|Drug|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
79843744|NCT00799760|Drug|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
79843745|NCT00799760|Drug|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
79247794|NCT03174002|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
79247795|NCT02509533|Device|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
79247796|NCT02509533|Device|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
79541509|NCT01493674|Dietary Supplement|folic acid|two 5-mg tablets of folic acid
79541510|NCT01493700|Procedure|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
79541511|NCT01493700|Procedure|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
79541512|NCT01493713|Other|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
79541513|NCT01493726|Drug|ALKS 9072, Low dose|IM injection, given monthly
79541514|NCT01493726|Drug|ALKS 9072, Med dose|IM injection, given monthly
79700548|NCT03452852|Other|Coban 2 lite|Compression bandaging with Coban 2 lite
79700549|NCT03452735|Other|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
79700550|NCT01089504|Drug|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
79700551|NCT01089504|Drug|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
79700552|NCT03452696|Dietary Supplement|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
79700553|NCT01088997|Drug|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
79700554|NCT00586118|Drug|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
79541515|NCT01493726|Drug|ALKS 9072, High dose|IM injection, given monthly
79541516|NCT01493726|Drug|Placebo|Dosed matched placebo IM injection, given monthly
79843746|NCT00875316|Drug|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
79843747|NCT00799838|Drug|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
79843748|NCT00799838|Drug|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
79843749|NCT00799838|Drug|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
79843750|NCT00799916|Drug|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
79843751|NCT00799916|Drug|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
79843752|NCT00737477|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
79541517|NCT01493752|Dietary Supplement|beetroot juice|250mls daily beetroot juice
79843753|NCT00256867|Drug|GSK523338|
79700555|NCT00586118|Drug|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
79541518|NCT01493765|Other|Simulator training with expert scoring|Residents will be trained using surgical simulation
79541519|NCT01493791|Drug|CDB-2914|
79843754|NCT00800072|Device|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
79541520|NCT01493817|Other|laboratory biomarker analysis|Correlative studies
79247797|NCT03585933|Diagnostic Test|Cardiac magnetic resonance imaging|Echocardiography: assessment of aortic stenosis severity, evaluation of LV diastolic and systolic function; CMR: chambers quantification, LGE, T1 mapping; Intraoperative myocardial tissue biopsy for patients undergoing SAVR; DPD scintigraphy: assessment of cardiac transthyretin amyloidosis
79247798|NCT03572257|Drug|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
79247799|NCT03572257|Other|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
79247800|NCT05374850|Procedure|Cervical Interlaminar Epidural Steroid Injection|This intervention is applied mostly for cervical disc herniation.The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then combined local anesthetics and glucocorticoids is delivered to the epidural space.
79247801|NCT03572179|Device|3d printed positioning tray|3d printed positioning tray for lingual fixed retainer placement in treatment group
79247802|NCT04498143|Other|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
79386311|NCT03238404|Procedure|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
79700556|NCT04569201|Procedure|Endoscope|The use of the neuro endoscope in excision of intraventricular lesions either alone or in assistance of the surgical microscope
79700557|NCT01088529|Drug|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
79386312|NCT03238404|Procedure|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
79386313|NCT03240744|Biological|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
79386314|NCT03248466|Biological|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
79386315|NCT03248700|Other|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
79386316|NCT03238482|Drug|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
79386317|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
79541521|NCT01493830|Genetic|fluorescence in situ hybridization|
79541522|NCT01493830|Genetic|gene expression analysis|
79541523|NCT01493830|Genetic|microarray analysis|
79541524|NCT01493830|Genetic|mutation analysis|
79541525|NCT01493830|Genetic|protein analysis|
79541526|NCT01493830|Other|immunohistochemistry staining method|
79541527|NCT01493830|Other|laboratory biomarker analysis|
79541528|NCT01493830|Other|microscopy|
79541529|NCT01493843|Drug|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
79541530|NCT01493843|Drug|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
79541531|NCT01493843|Drug|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
79700558|NCT01088529|Drug|Prednisone|5 mg orally daily.
79700559|NCT01088529|Drug|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
79700560|NCT00586274|Procedure|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
79700561|NCT00586274|Drug|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m^2
79843755|NCT00882180|Drug|ALN-VSP02|IV infusion administered every two weeks
79843756|NCT00800150|Drug|fludarabine phosphate|
79843757|NCT00800150|Drug|melphalan|
79843758|NCT00800150|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79843759|NCT00800150|Radiation|intensity-modulated radiation therapy|
79843760|NCT00800150|Radiation|tomotherapy|
79843761|NCT00800150|Radiation|total marrow irradiation|
79843762|NCT00800150|Radiation|total nodal irradiation|
79700562|NCT00586274|Biological|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.~Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)"
79700563|NCT00586274|Biological|Campath 1h|10 mg iv over 4 hours day-8 through day-6
79700564|NCT00586274|Biological|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
79700565|NCT00586352|Other|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
79541532|NCT01493843|Drug|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
79700566|NCT01087944|Device|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
79700567|NCT01087944|Device|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
79700568|NCT00586430|Drug|lorazepam|single 2 mg dose of lorazepam
79700569|NCT00586430|Drug|placebo|single dose of placebo
79700570|NCT01132612|Drug|AIN457|AIN457A 150 mg powder for solution
79700571|NCT01132612|Drug|Placebo|Placebo to AIN457A 150 mg powder for solution
79700572|NCT00586547|Biological|T-Cell Infusion Dose Level -1|(1 x 10^3 T cells/Kg)
79700573|NCT00586547|Biological|T-Cell Infusion Dose Level 1|(1 x 10^4 T cells/Kg)
79700574|NCT00586547|Biological|T-Cell Infusion Dose Level 2|(1 x 10^5 T cells/Kg)
79843763|NCT04019717|Drug|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
79843764|NCT04019717|Drug|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
79247803|NCT04498143|Other|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
79247804|NCT02509299|Other|Physiotherapy program 1|The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
79541533|NCT01493843|Drug|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
79541534|NCT01493856|Drug|Cresto|tablet, rosuvastatin 20mg
79541535|NCT01493856|Drug|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
79541536|NCT01493856|Drug|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
79541537|NCT01493869|Drug|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
79541538|NCT01493882|Drug|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
79700575|NCT00586547|Biological|T-Cell Infusion Dose Level 3|(1 x 10^6 T cells/Kg)
79700576|NCT00586547|Biological|T-Cell Infusion- Dose Level 4|(5 x 10^6 T cells/Kg)
79700577|NCT04569279|Drug|Rivaroxaban|Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
79843765|NCT00879216|Drug|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
79843766|NCT00879216|Drug|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
79843767|NCT00807404|Procedure|histopathologic examination|
79843768|NCT00807404|Procedure|optical coherence tomography|
79386318|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
79386319|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
79386320|NCT02454660|Behavioral|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
79386321|NCT02454504|Drug|sugammadex|
79386322|NCT02454504|Drug|Neostigmine|
79386323|NCT03240666|Other|non applicable|non applicable
79386324|NCT03240822|Procedure|Penile Transplant|Penile Allotransplantation
79386325|NCT03240822|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
79386326|NCT03240822|Drug|Tacrolimus|
79386327|NCT03240432|Device|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
79700578|NCT04569279|Drug|Warfarin|Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
79843769|NCT02592161|Drug|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
79843770|NCT00800306|Drug|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
79541539|NCT01493882|Drug|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
79843771|NCT00800306|Drug|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
79843772|NCT01581775|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
79386328|NCT03238560|Drug|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
79843773|NCT04039152|Other|Clinical pharmacists recommendations to optimize antibiotics use|Optimal dosing, drug bug mismatch
79843774|NCT04046276|Behavioral|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
79843775|NCT04046276|Other|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
79386329|NCT04486482|Other|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
79386330|NCT04486482|Other|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
79386331|NCT02453958|Device|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
79386332|NCT04486092|Drug|Valproic Acid|
79386333|NCT03238638|Drug|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
79386334|NCT03238638|Drug|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
79386335|NCT00668655|Drug|Metronidazole Gel|Topical, Once daily for 2 weeks
79541540|NCT01493882|Drug|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
79700579|NCT01132495|Other|Stenting plus OMT|FFR guided PCI, plus OMT
79700580|NCT01132495|Other|OMT|OMT alone
79843776|NCT04046276|Behavioral|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
79386336|NCT03240354|Device|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
79386337|NCT03240354|Device|Control|Cuff of endotracheal tube inflated with air
79541541|NCT01493882|Drug|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
79541542|NCT01493895|Device|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
79541543|NCT01493895|Device|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
79700581|NCT01132495|Other|Standard of care|FFR > 0.80; treatment according to local practice
79386338|NCT03240276|Other|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
79386339|NCT03240276|Device|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
79386340|NCT03240276|Other|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
79386341|NCT02454426|Drug|Vortioxetine|open label treatment
79386342|NCT03238092|Drug|Testosterone|testosterone gel daily during the late luteal phase.
79386343|NCT03238092|Drug|Estradiol|oral estradiol during the late luteal phase.
79386344|NCT01896765|Behavioral|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
79386345|NCT01896765|Other|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
79843777|NCT00731939|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
79843778|NCT01072591|Drug|MEDI-578|intravenous infusion, once
79541544|NCT01493908|Drug|High price|Acetaminophen label as high price
79541545|NCT01493908|Drug|Low price|Acetaminophen label as low price
79843779|NCT01072591|Drug|Placebo for MEDI-578|Intravenous infusion, once
80012868|NCT03110302|Behavioral|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
79247805|NCT02509299|Other|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
80012869|NCT04665817|Diagnostic Test|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
79386346|NCT03247998|Drug|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
79386347|NCT03247998|Drug|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
79541546|NCT01493908|Drug|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
79247806|NCT02509299|Drug|Standard medical treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
79247807|NCT03140696|Dietary Supplement|Egg Alone|A chicken egg will be offered for 2 days
79541547|NCT01493908|Drug|No price|acetaminophen. No price - price issue not introduced to participants.
79700582|NCT00586586|Behavioral|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
79700583|NCT04312204|Drug|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight <40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
79247808|NCT03140696|Dietary Supplement|Egg and ready to use supplementary food (RUSF)|A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
79843780|NCT00882258|Drug|12.5 mg Proellex|12.5 mg Proellex administered orally daily
79541548|NCT01493908|Drug|Free of charge|Acetaminophen. participants aware the product is free of charge
79843781|NCT00882258|Drug|25 mg Proellex|25 mg Proellex administered orally daily
79843782|NCT00882258|Drug|Placebo|Administered orally daily
79843783|NCT00811694|Other|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
79247809|NCT03140696|Dietary Supplement|Egg and breast milk|A chicken egg and breast milk will be offered for 2 days
79247810|NCT02509377|Procedure|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
79541549|NCT01493921|Drug|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
79541550|NCT01493921|Drug|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
79843784|NCT04038606|Other|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
79843785|NCT03741595|Behavioral|Item spacing|Spatial proximity of items to one another
79843786|NCT00879294|Device|Motion sickness wristband|No drugs are involved.
79843787|NCT00879294|Dietary Supplement|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
79843788|NCT01072747|Biological|bovine heparin|5.000UI/mL bottle with 5mL
79843789|NCT01072747|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
80012870|NCT04665817|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
79247811|NCT02845375|Drug|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
79386348|NCT03248076|Drug|Fentanyl Citrate|1γ/Kg fentanyl
79541551|NCT01493934|Drug|injection of 6-DIG|Unique injection dose of 92.5 MBq
79386349|NCT01896843|Drug|STX107|
79700584|NCT04312282|Drug|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
79700585|NCT04312282|Drug|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
79700586|NCT04312282|Drug|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
79700587|NCT04312282|Drug|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
79700588|NCT04311931|Other|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
79700589|NCT01087905|Drug|Nicotine patch|"If > 10 cigs/day: one 21 mg nicotine patch per day~If < or = 10 cigs/day: one 14 mg nicotine patch per day"
79700590|NCT01087905|Drug|Nicotine gum|"If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
79843790|NCT02594657|Procedure|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
79541552|NCT01493973|Drug|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
79843791|NCT02594657|Procedure|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
79843792|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
79247812|NCT02845375|Drug|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
79247813|NCT02845375|Drug|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
79247814|NCT02979860|Behavioral|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
79247815|NCT02979860|Behavioral|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
79247816|NCT02979860|Behavioral|Sleep timing|Sleep timing: bed time kept consistent
79247817|NCT02507271|Other|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
79386350|NCT03240120|Drug|Dabigatran etexilate|Pradaxa 150 mg hard capsules
79386351|NCT03240120|Drug|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
79541553|NCT01493973|Drug|Placebo|Placebo
79541554|NCT01493986|Drug|Ropivacaine|Dosage. Onset time
79386352|NCT03240042|Procedure|nasotracheal intubation|The participants either receive intubation via nasal route.
79541555|NCT01493999|Drug|Clopidogrel reloading|Up to three times 600 mg clopidogrel
79541556|NCT01493999|Drug|Prasugrel|60 mg prasugrel in patients with HPR
79541557|NCT01494012|Radiation|stereotactic body radiation therapy|Undergo SBRT
79541558|NCT01494012|Procedure|positron emission tomography|Undergo FDG-PET/CT
79843793|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
79386353|NCT03240042|Procedure|orotracheal intubation|The participants either receive intubation via oral route.
79386354|NCT04771845|Device|Transcranial Magnetic Stimulation|Magnetic stimulation to alter neural activity
79386355|NCT03237936|Drug|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
79386356|NCT03247920|Drug|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
79541559|NCT01494012|Procedure|computed tomography|Undergo FDG-PET/CT
79386357|NCT03247920|Drug|Antibiotics|Intravenous antibiotic therapy following local protocol
79541560|NCT01494012|Other|questionnaire administration|Ancillary studies
79541561|NCT01494012|Drug|fludeoxyglucose F 18|Undergo FDG-PET/CT
79541562|NCT01494025|Behavioral|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
79843794|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
79843795|NCT00879372|Drug|tianeptine|tianeptine 12,5mg TID
79843796|NCT00879372|Drug|Placebo|Placebo 12.5 mg TID
80012871|NCT04665817|Diagnostic Test|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
80012872|NCT04049500|Other|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
80012873|NCT05759767|Drug|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
79247818|NCT02507271|Other|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
79386358|NCT04771533|Procedure|hand motor coordination in a sitting position|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
79541563|NCT01494077|Other|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
79843797|NCT00731783|Drug|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
79843798|NCT00731783|Drug|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
79843799|NCT00731783|Behavioral|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors and brushes.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
79247819|NCT02240563|Procedure|Low-level laser therapy|
79247820|NCT02240563|Procedure|Non laser ordinary red light|
79843800|NCT00879450|Other|Booklet|booklet given to parents for home exercises
79247821|NCT03344679|Drug|Bupivacaine 0.25%|Bupivacaine 0.25% for PECS block
79843801|NCT02592083|Drug|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
79843802|NCT02592083|Drug|Palbociclib|
79843803|NCT04589676|Behavioral|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
79843804|NCT00724451|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
79843805|NCT00724451|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
79247822|NCT03344679|Drug|Adenosine 12mg|Adenosine 12 mg for PECS block
79247823|NCT03344679|Drug|Magnesium Sulphate 500 mg|Magnesium sulphate 500 mg for PECS block
79247824|NCT03344601|Behavioral|physical activity|The program will consist of 18 face-to-face coaching sessions (~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
79247825|NCT02259829|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
79541564|NCT01494090|Drug|Rosuvastatin|5 or 20 mg per day during 6 months
79541565|NCT01494090|Drug|Placebo|5 or 20 mg per day during 6 months
79541566|NCT01494116|Other|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
79541567|NCT01494155|Drug|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
79843806|NCT00724451|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
79843807|NCT00724373|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
79843808|NCT00724373|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
79843809|NCT02594579|Drug|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
79843810|NCT02594579|Drug|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
79843811|NCT02593409|Drug|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
79843812|NCT00724061|Biological|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
79843813|NCT00724061|Other|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
79247826|NCT02259829|Drug|Telmisartan|
79247827|NCT02259829|Drug|Amlodipine|
79247828|NCT03344523|Drug|Iron protein succinylate oral solution|Iron protein succinylate oral solution
79247829|NCT03344523|Other|standard treatment|standard treatment
79247830|NCT02658734|Drug|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
79247831|NCT03574051|Drug|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
79247832|NCT03344445|Other|video-assisted pre anesthesia explain|Anesthesiologist will visit all study patients, and only the experimental group will read the video.
79247833|NCT03572023|Other|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
79843814|NCT00724061|Other|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
80012874|NCT05759767|Drug|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
79541568|NCT01494155|Drug|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
79700591|NCT01087905|Behavioral|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
79849038|NCT05545852|Procedure|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
79849039|NCT05544799|Other|No intervention|No intervension
80012875|NCT02561234|Drug|Co-ArgI-PEG|Administered IV
80012876|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
80012877|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
80012878|NCT04606693|Other|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
80012879|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
80012880|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
80012881|NCT02750306|Drug|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
79305524|NCT03242993|Drug|[18F]-AzaFol|[18F]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
79386359|NCT04771533|Procedure|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
79386360|NCT03238014|Device|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
79386361|NCT04771143|Drug|AFQ056|oral administration
79386362|NCT04771143|Drug|Placebo|matching placebo for oral administration
79386363|NCT04487184|Other|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
79541569|NCT01494155|Radiation|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
79541570|NCT01494168|Procedure|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
79541571|NCT01494194|Other|Air Structuring Protein|A novel food protein preparation
79541572|NCT01494194|Other|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
79541573|NCT01494207|Behavioral|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
79700592|NCT00586742|Procedure|labral repair|labral repair with suture anchors
79700593|NCT00586742|Procedure|biceps tenodesis|biceps tenodesis with suture anchor
79700594|NCT00586742|Procedure|diagnostic arthroscopy|diagnostic arthroscopy
80012882|NCT02750306|Drug|Placebo|Placebo to suvorexant
80012883|NCT03941704|Dietary Supplement|Pulse-based diet|Low Glycemic Index
80012884|NCT03941704|Dietary Supplement|Regular diet|Moderate Glycemic Index
80012885|NCT03845140|Drug|L-PZQ ODT|Participants will receive single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
80012886|NCT03845140|Drug|Biltricide®|Participants will receive single oral dose of Biltricide® 40 mg/kg crushed tablet on Day 1.
80012887|NCT03845140|Drug|L-PZQ ODT|Participant will receive single oral dose of L-PZQ ODT 60 mg/kg as decided by the IDMC.
80012888|NCT00238862|Procedure|Amniotic membrane transplantation|
79843815|NCT04936386|Behavioral|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
79843816|NCT05195424|Diagnostic Test|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
79843817|NCT02594423|Device|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
79843818|NCT02594423|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
79843819|NCT04087187|Drug|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
79843820|NCT04087187|Drug|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
79843821|NCT04087187|Drug|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
79843822|NCT04924764|Other|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
79843823|NCT02592005|Other|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
79843824|NCT00882414|Drug|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
79843825|NCT00882414|Drug|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
79843826|NCT02593487|Drug|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
79247834|NCT03572023|Other|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
79247835|NCT03346707|Device|10.5 Tesla|10.5Tesla MR scan
79386364|NCT03239964|Drug|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
79386365|NCT03239964|Other|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
79541574|NCT01494220|Device|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
79541575|NCT01494246|Other|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
79700595|NCT04311892|Diagnostic Test|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
79700596|NCT04311736|Behavioral|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
79700597|NCT04311736|Behavioral|Cycling|Cycling on a recumbent cycle ergometer
79700598|NCT04311736|Behavioral|Stretching|Stretching exercises
79843827|NCT02593487|Drug|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
79843828|NCT00875784|Drug|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
79843829|NCT00875784|Drug|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
79843830|NCT00875784|Drug|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
79843831|NCT00875784|Drug|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
79843832|NCT00875862|Procedure|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
80012889|NCT00238862|Drug|Autologous serum/BSS 20%|
79247836|NCT05098964|Device|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
79386366|NCT02453646|Device|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
79386367|NCT03239886|Other|imatinib discontinuation|imatinib discontinuation
79541576|NCT01494259|Drug|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
79541577|NCT01494259|Drug|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
79541578|NCT01494285|Drug|ARK-E021 5%|Topically applied once daily at bedtime
79541579|NCT01494285|Drug|ARK-E021 10%|Topically applied once daily at bedtime
79700599|NCT00586781|Device|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
79700600|NCT00586859|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
79700601|NCT01087788|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
79541580|NCT01494285|Drug|Placebo|Topically applied once daily at bedtime
79700602|NCT01087788|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
79700603|NCT01087788|Other|Placebo|Matching Placebo to CZP injection.
79843833|NCT00882492|Biological|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
79843834|NCT00882492|Biological|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
79843835|NCT04038450|Other|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
80012890|NCT01816165|Drug|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
80012891|NCT01816165|Drug|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
80012892|NCT03136822|Other|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
79386368|NCT03102723|Drug|Cangrelor|"Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~Or~Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
79391507|NCT02412150|Other|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
79541581|NCT01494311|Drug|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
79541582|NCT01494311|Drug|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
79541583|NCT01494311|Drug|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
79843836|NCT00879528|Other|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
79843837|NCT00879528|Other|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
79843838|NCT00731549|Drug|Aripiprazole IM Depot|300mg or 400mg
79843839|NCT00875940|Other|Diagnostic imaging procedures.|
79843840|NCT00882570|Drug|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
80012893|NCT03136822|Device|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
80012894|NCT04476680|Dietary Supplement|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
80012895|NCT04952350|Drug|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
80012896|NCT04952350|Other|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
79541584|NCT01494311|Drug|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
79700604|NCT00586937|Behavioral|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
79700605|NCT00586976|Drug|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
79700606|NCT00586976|Drug|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
79247837|NCT05098964|Other|Exercise training|Hospital based exercise training for 6 weeks
79541585|NCT01494337|Procedure|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
79700607|NCT00587015|Drug|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
79700608|NCT01086969|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
79843841|NCT00882570|Drug|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
79843842|NCT00885456|Behavioral|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
79843843|NCT00885456|Behavioral|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
79843844|NCT00882726|Drug|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
80012897|NCT03890588|Other|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
80012898|NCT04812808|Drug|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
80012899|NCT01780675|Radiation|Radiation Prophylactic Cranial Irradiation|
80012900|NCT01780675|Radiation|Radiation Hippocampal Avoidance PCI|
80012901|NCT02262884|Device|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
80012902|NCT02262884|Device|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
79247838|NCT03458299|Behavioral|Motivational Interviewing|2 hours of motivational interviewing
79247839|NCT03458299|Behavioral|Psychoeducation|2 hours of DVD viewing and discussion
79247840|NCT04501107|Drug|Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Administration of IMP1 during a 12-hour euglycaemic clamp.
79386369|NCT03237312|Procedure|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
79386370|NCT03237312|Biological|Antimullerian hormone|"In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
79391508|NCT02412150|Behavioral|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. [Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)]
79541586|NCT01494337|Procedure|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
79541587|NCT01494363|Drug|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
79700609|NCT00587093|Other|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
79843845|NCT00882726|Drug|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
79541588|NCT01494363|Drug|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
79247841|NCT04501107|Drug|Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Administration of IMP2 during a 12-hour euglycaemic clamp.
79247842|NCT04501107|Drug|Administration of US-approved Humalog® (IMP3)|Administration of IMP3 during a 12-hour euglycaemic clamp.
79247843|NCT04501107|Drug|Administration of EU-approved Humalog® (IMP4)|Administration of IMP4 during a 12-hour euglycaemic clamp.
79700610|NCT04568772|Drug|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
79700611|NCT04568772|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
79700612|NCT04568772|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
79700613|NCT04568772|Drug|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
79843846|NCT00882726|Drug|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
79843847|NCT00882726|Drug|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
79541589|NCT01494363|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
79843848|NCT00882804|Drug|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
79247844|NCT03143985|Drug|Vactosertib|Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). Vactosertib inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
79247845|NCT03143985|Drug|Pomalidomide|POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
79700614|NCT04575272|Procedure|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
79700615|NCT04575350|Genetic|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
79386371|NCT03097575|Drug|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
79386372|NCT03097575|Device|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
79700616|NCT01086423|Biological|Infanrix-IPV/Hib™|Intramuscular, three doses
79700617|NCT01086423|Biological|Infanrix Hib™|Intramuscular, three doses
79843849|NCT00882804|Drug|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
79843850|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
79843851|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
79843852|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
79843853|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
79843854|NCT00882960|Drug|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
79843855|NCT00882960|Drug|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
79843856|NCT00883038|Other|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
79843857|NCT00883038|Other|low-fat vegetarian diet|The low-fat vegetarian diet (~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
79843858|NCT00883194|Drug|PRF-108|Ropivacaine
79843859|NCT00883194|Drug|Placebo|PRF-108 Placebo
79386373|NCT05450835|Procedure|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
79386374|NCT05450835|Procedure|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
79386375|NCT03239652|Device|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
79386376|NCT03241914|Drug|Megestrol Acetate|At a dosage of 160 mg/day
79386377|NCT03241914|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
79541590|NCT01494363|Drug|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
79541591|NCT01494402|Drug|D961S|Oral gelatine capsule
79541592|NCT01494402|Drug|Esomeprazole|Oral HPMC capsule
79541593|NCT01494402|Drug|Buffered acetylsalicylic acid|Tablet
79541594|NCT01494415|Drug|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
79700618|NCT01086423|Biological|Poliorix™|Intramuscular, three doses
79700619|NCT04575389|Diagnostic Test|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
79700620|NCT04575116|Drug|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
79700621|NCT04575116|Drug|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
79700622|NCT01086150|Procedure|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
79700623|NCT01086150|Drug|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
79700624|NCT02278107|Device|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
79843860|NCT00883194|Drug|Ropivacaine|Solution
79843861|NCT00883194|Drug|PRF-110|
79700625|NCT02278107|Device|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
79700626|NCT00587249|Biological|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
79541595|NCT01494415|Drug|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
79541596|NCT01494415|Radiation|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
79700627|NCT00587249|Biological|Alhydrogel|Aluminum hydroxide gel.
79541597|NCT01494480|Procedure|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
79849040|NCT05536518|Behavioral|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
80012903|NCT03888872|Device|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
79541598|NCT01494519|Procedure|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
80012904|NCT03888872|Other|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~Wobble board training:~Active range of motion exercises (AROM):~Gentle manual stretching exercises for both UL & LL:~Graduated gait training:"
79700628|NCT00587327|Drug|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
79247846|NCT02663336|Other|Comparison ABPM with OBPM|No interventions
79247847|NCT02885714|Procedure|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
79386378|NCT03235206|Other|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
79386379|NCT00057681|Drug|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
79700629|NCT00587327|Drug|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
79700630|NCT00587327|Drug|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
79700631|NCT00587405|Procedure|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
79700632|NCT00587405|Procedure|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
79849041|NCT05534633|Other|Choice of STBBI test(s)|Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
80012905|NCT04788550|Combination Product|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
80012906|NCT04788550|Combination Product|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
79386380|NCT00057681|Drug|Valproate|Titrated until blood level is 111 to 125 ug/mL
79386381|NCT00057681|Drug|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
79700633|NCT01085682|Behavioral|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
79541599|NCT01494519|Procedure|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
79700634|NCT01085682|Behavioral|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
79386382|NCT03235362|Drug|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
79386383|NCT03235362|Drug|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
79700635|NCT00587444|Drug|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is < 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
79700636|NCT00587444|Drug|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is <600 seconds anytime during CPB
79700637|NCT00587444|Drug|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
79843862|NCT04038528|Behavioral|telemonitoring of T2DM|"Baseline record of:~Weight~Height~BMI~Abdominal circumference~Winsor Index~ECG~Retinography~Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~Blood sugar (two measurements per week).~Body weight (weekly)~Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
79849042|NCT05534100|Device|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
80012907|NCT04788550|Combination Product|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
80012908|NCT01677988|Drug|Neo-adjuvant Chemotherapy|"Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
80012909|NCT01677988|Radiation|Chemoradiation|"Chemoradiation may be administered at selected approved CTN sites.~Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~Unresectable → Off study. Subsequent treatment per patient's primary MD.~Resectable → Continue to Registration #3 for Surgical Resection"
80012910|NCT01677988|Procedure|Surgical Resection|"Meets criteria for resectable* →pancreaticoduodenectomy (POD)~At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
79386384|NCT03235362|Drug|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
79386385|NCT03234894|Device|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
79541600|NCT01494558|Other|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
79541601|NCT01494597|Drug|isavuconazole|oral
79541602|NCT01494597|Drug|cyclosporine|oral
79541603|NCT01494623|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
79541604|NCT01494636|Drug|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
79386386|NCT03234816|Drug|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
79386387|NCT03234816|Drug|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
79305525|NCT03242993|Drug|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
79305526|NCT03057249|Other|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
79305527|NCT02559323|Other|Survey|
79305528|NCT04957407|Other|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
79305529|NCT04487093|Drug|neoantigen vaccine + EGFR-TKI|"Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance."
79305530|NCT04487093|Drug|neoantigen vaccine + anti-angioge|neoantigen vaccine + anti-angioge
79386388|NCT03234816|Drug|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
79386389|NCT03234816|Drug|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
79700638|NCT00587522|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
79700639|NCT02278302|Drug|Aggrenox®|
79700640|NCT02278302|Drug|Placebo|
79541605|NCT01494636|Drug|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
79541606|NCT01494636|Drug|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
79700641|NCT02278302|Other|Ethanol|
79700642|NCT00587600|Procedure|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
79541607|NCT01494636|Drug|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
79700643|NCT00587600|Procedure|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
79700644|NCT01085214|Other|Laboratory Biomarker Analysis|Correlative studies
79700645|NCT01085214|Drug|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
79700646|NCT00587756|Procedure|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
79541608|NCT01494675|Other|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.~The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
79843863|NCT04037436|Other|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
80012911|NCT03864536|Behavioral|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
80012912|NCT04538599|Drug|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
80012913|NCT02233634|Drug|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
79541609|NCT01494688|Drug|Paclitaxel|Paclitaxel, at a dose of 80 mg/m^2 will be administered QW for up to 12 weeks.
79541610|NCT01494688|Drug|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
79541611|NCT01494701|Drug|nusinersen|Administered by intrathecal (IT) injection
79700647|NCT01085136|Drug|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
79541612|NCT01494714|Drug|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
79541613|NCT01494714|Drug|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
79541614|NCT01494714|Drug|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
79700648|NCT01085136|Drug|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
79700649|NCT00587873|Drug|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
79700650|NCT00587873|Drug|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
79700651|NCT00587873|Drug|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
79843864|NCT04037436|Other|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
80012914|NCT02233634|Other|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
80012915|NCT02233634|Other|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
80012916|NCT04692220|Other|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
80012917|NCT04508413|Other|KB295|KB295 is a novel glycan
79700652|NCT04574804|Other|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~Overweight and obesity and osteoarthritis~Overview of weight regulation, overweight and obesity~Examining weight stigma in physiotherapy and personal beliefs about weight~Communication approach for addressing weight management~Interventions for weight management~Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
79700653|NCT01084707|Drug|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
79700654|NCT01084707|Drug|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
79700655|NCT01084707|Drug|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
79700656|NCT00588107|Other|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
79700657|NCT00588107|Behavioral|print materials|tailored print materials designed to aid in smoking reduction and cessation
79700658|NCT02210520|Device|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
79700659|NCT02210520|Device|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
79700660|NCT02210520|Device|laser|1 W/cm², 2 minutes in 6 points around the back spine
79700661|NCT04574726|Other|static balance|30-second right and left unipodal static balance test
79700662|NCT04574726|Other|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~180° elevation of the arms~lowering of the arms on the side of the single-legged support to the horizontal position~180° horizontal translation of the arms~return from the horizontal to the starting point"
80012918|NCT02233712|Biological|G17DT|
79247848|NCT02885714|Procedure|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
79247849|NCT02507193|Procedure|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
79247850|NCT02507193|Procedure|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
79541615|NCT01494714|Drug|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
79541616|NCT01494714|Drug|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
79541617|NCT01494727|Drug|CJ Amlodipine/Valsartan 10/160mg|single dose
79700663|NCT02210598|Device|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
80012919|NCT04689490|Diagnostic Test|Cardiopulmonary exercise test|Only diagnostic tests
80012920|NCT04506853|Device|MED-EL Cochlear Implant System|Cochlear implant and audio processor
80012921|NCT02262962|Other|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
79700664|NCT02210598|Device|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
79700665|NCT02210598|Drug|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
79843865|NCT00888732|Drug|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
79843866|NCT00730925|Drug|BIBW2992|tablet BIBW high dose
80012922|NCT02233790|Drug|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
80012923|NCT02233790|Drug|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
80012924|NCT02547818|Drug|ALZT-OP1a|1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
79247851|NCT02646176|Behavioral|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
79541618|NCT01494727|Drug|Novartis Exforge 10/160mg|single dose
79541619|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
79541620|NCT01494740|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
80012925|NCT02547818|Drug|ALZT-OP1b|Anti-inflammatory
79247852|NCT05091944|Device|web-based birth decision aid|Women in the intervention group receive both usual care and decision support (an interactive web-based birth decision aid). The innovative interactive web-based birth decision aid comprised five components: Component 1-a communication aid video involves 2 expert's talk about how to participate in SDM and prepare self with choice talk, option talk and decision talk(10 minutes )and practice communication skills with clinician(10 minutes); Component 2-overall of the function and features of birth decision aid. Component 3-introduce the benefits and risk of vaginal birth after cesarean; Component 4- the benefits and risk of elective repeat cesarean section; Component 5 -a quit to confirm women's knowledge regarding the two choices and confirm women's values.
79247853|NCT02605148|Dietary Supplement|Gluten free diet|Gluten free diet during 18 months.
79247854|NCT02605148|Dietary Supplement|Omega 3 fatty acid|Omega 3 fatty acid
79247855|NCT02605148|Dietary Supplement|Vitamin D|Vitamin D 800 U/day
79541621|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
79541622|NCT01494766|Dietary Supplement|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
79700666|NCT00588224|Other|3D ultrasound|measurement of stomach volume by 3D ultrasound
79700667|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
79700668|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
79700669|NCT01084551|Drug|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
79700670|NCT03452657|Drug|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
79700671|NCT03452657|Procedure|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
79700672|NCT02210676|Other|PROMIS Upper Extremity|
79700673|NCT02210676|Other|Likert Pain Scale|
79700674|NCT02210676|Other|Mallet Finger Extensor Lag Measurement|
79700675|NCT03452618|Diagnostic Test|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~Age of the patient~Sex~Presence of bulbar involvement or not~Time from onset of first symptoms to diagnosis of ALS~Score ALSFRS-R~Presence of another underlying respiratory pathology (COPD, asthma ...)~FVC measurement (Forced vital capacity)~PaCO2 measurement~Measure SNIP (Sniff nasal inspiratory pressure)~Measure of Pimax (Pressure inspiratory maximal)~Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
80012926|NCT02547818|Other|Placebo ALZT-OP1a|Non-active capsules
80012927|NCT02547818|Other|Placebo ALZT-OP1b|Non-active tablets
79541623|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
79700676|NCT03452501|Drug|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
79700677|NCT00588302|Drug|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
79700678|NCT00588419|Behavioral|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
80012928|NCT04457440|Behavioral|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
79247856|NCT02605148|Dietary Supplement|Probiotics|Probiotics
79247857|NCT02462330|Drug|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
79247858|NCT02462330|Drug|Placebo comparator|injections of human albumin
79247859|NCT05100992|Procedure|Percutaneous Coronary Interbention|Percutaneous Coronary Interbention
79541624|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
80012929|NCT04457440|Behavioral|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
80012930|NCT02234024|Dietary Supplement|Supplementation of dairy-derived concentrated gangliosides.|
79541625|NCT01494792|Device|In Vitro Diagnositc aid for diagnosis|
79541626|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
79541627|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
79541628|NCT01494805|Other|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
79541629|NCT01494831|Behavioral|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
79541630|NCT01494844|Device|Respiratory monitor patient interface.|Wear each interface for 20 minutes
79541631|NCT01494857|Drug|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
79700679|NCT04568655|Device|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
79700680|NCT00588458|Procedure|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
79700681|NCT01084005|Drug|linagliptin|patients receive linagliptin 5 mg tablets once daily
79700682|NCT01084005|Drug|placebo|patients receive placebo matching linagliptin 5 mg once daily
79700683|NCT00588497|Procedure|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
79386390|NCT03247608|Behavioral|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
79386391|NCT03247842|Procedure|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
80012931|NCT02520076|Drug|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~Pre-transplant Day -1~Post-transplant Day 3~Post-transplant Day 7~Post-transplant Day 14"
79247860|NCT02395640|Drug|Epirubicin|50mg/m2 ivgtt d1
79247861|NCT02395640|Drug|Oxaliplatin|
79247862|NCT02395640|Drug|Capecitabine|1000mg/m2 po d1-14
79247863|NCT02507037|Dietary Supplement|gum+PEG|chew sugarless gum
79247864|NCT02507037|Drug|polyethylene glycol|2L PEG
79386392|NCT03247452|Other|One-day Low fiber diet|One-day low fiber diet before colonoscopy
79386393|NCT03247452|Other|Three-day low fiber diet|Three days low fiber diet before colonoscopy
79386394|NCT03247452|Drug|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
79700684|NCT00588497|Radiation|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
79700685|NCT00588497|Procedure|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
79700686|NCT00588497|Radiation|Hysterosalpingogram|Performed 3 months after micro-inserts placement
79386395|NCT03237468|Other|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
79386396|NCT03247140|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
79386397|NCT03247140|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
79541632|NCT01494870|Procedure|PCI|urgent PCI on admission
79700687|NCT04568577|Other|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
79700688|NCT04568577|Other|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
79843867|NCT00730925|Drug|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
79849043|NCT05531591|Drug|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
79849044|NCT05531591|Drug|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
80012932|NCT03752918|Drug|MDMA|A single dose of 1.5mg/kg will be administered once orally.
80012933|NCT03752918|Drug|Niacin|A single dose of 250mg will be administered once orally.
80012934|NCT04259320|Device|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
80012935|NCT04259320|Biological|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
79247865|NCT05100758|Dietary Supplement|Active Hexoses Correlated Compound|Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
79247866|NCT02501343|Drug|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
79247867|NCT02501343|Drug|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
79247868|NCT05097092|Procedure|Orthopedic immobilization|Orthopedic immobilization will be performed with a sling and swathe.
79247869|NCT05097092|Other|Unilateral resistance training|Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.
79541633|NCT01494883|Behavioral|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
79541634|NCT01494909|Dietary Supplement|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
79541635|NCT01494935|Behavioral|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
79541636|NCT01494935|Behavioral|Control diet|Normal fat, normal fat diet
79700689|NCT00588653|Device|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
79700690|NCT00588887|Device|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
79700691|NCT00588887|Device|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
79541637|NCT01494948|Other|allergen challenge|nasal challenges with antigen to which they are sensitive to
79700692|NCT01083810|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
80012936|NCT04058158|Drug|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
79247870|NCT05097092|Other|Bilateral resistance training|Bilateral resistance training will be performed by both arms in both groups during Phase 2.
79386398|NCT03237546|Procedure|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
79700693|NCT00588926|Drug|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
79700694|NCT01083771|Dietary Supplement|Olive Oil|Minimum of 3 tablespoon of olive oil per day
80012937|NCT04058158|Drug|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
80012938|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
80012939|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
80012940|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
79247871|NCT02508831|Procedure|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
79247872|NCT04949594|Device|TENS|application on muscles where pain is situated (cervical)
79247873|NCT02508909|Procedure|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
79305531|NCT03242837|Behavioral|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
79386399|NCT03237546|Procedure|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
79386400|NCT03234426|Other|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
79700695|NCT00589082|Drug|DaunoXome|
79386401|NCT03234426|Other|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
79700696|NCT00589082|Drug|Daunorubicine|
79700697|NCT00589199|Procedure|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
79700698|NCT00589238|Drug|carboplatin|
79700699|NCT00589238|Drug|cyclophosphamide|
79700700|NCT00589238|Drug|doxorubicin hydrochloride|
79700701|NCT00589238|Drug|paclitaxel|
79700702|NCT04568070|Diagnostic Test|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
79700703|NCT04568070|Diagnostic Test|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
79700704|NCT04568070|Diagnostic Test|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
79700705|NCT04568070|Diagnostic Test|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
79700706|NCT00589394|Biological|pneumococcal vaccination (Pneumovax)|pneumovax was given
80012941|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
79541638|NCT01494961|Behavioral|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
79700707|NCT01083576|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
79700708|NCT01083576|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
79700709|NCT04568265|Drug|APG-1387|Weekly intravenous infusion for 30 minutes
79700710|NCT04568265|Drug|Entecavir 0.5 mg|Taken daily by mouth
79700711|NCT00589589|Device|Endo Tool|Computer tool to help achieve glucose control
79700712|NCT04568343|Device|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
80012942|NCT02546960|Biological|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
80012943|NCT02546960|Drug|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
79247874|NCT02509143|Procedure|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
79305532|NCT03242837|Other|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
79541639|NCT01494974|Device|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
79541640|NCT01494974|Device|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
79541641|NCT01495026|Drug|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
79700713|NCT00589706|Drug|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
79700714|NCT00589745|Other|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
79700715|NCT04568304|Biological|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
79700716|NCT04568304|Drug|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
79700717|NCT04568304|Drug|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
79700718|NCT04568304|Drug|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
80012944|NCT02234102|Device|Endoscopically guided laser ablation HeartLight system|
79700719|NCT01082640|Drug|Febuxostat|Febuxostat capsules
79700720|NCT01082640|Drug|Placebo|Febuxostat placebo-matching capsules
79700721|NCT00589862|Drug|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
79700722|NCT00589901|Drug|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
80012945|NCT02263196|Other|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
79700723|NCT04568187|Device|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
80012946|NCT02263196|Other|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
80012947|NCT03343834|Biological|biological collection|"At D0:~blood samples~saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
80012948|NCT05160506|Drug|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
80012949|NCT05160506|Drug|Placebo|50ml of 0.9% NACL will serve as the placebo
80012950|NCT02236286|Behavioral|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
79700724|NCT04568187|Device|placebo|radiofrequency with 3000 Hz
79700725|NCT00590174|Drug|Aspirin|stopping clopidogrel at 1 year after DES implantation
79700726|NCT00590174|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
79700727|NCT01082367|Drug|TOBI|TOBI (tobramycin inhaled solution)
79700728|NCT01082367|Drug|Placebo|Placebo
80012951|NCT05094778|Procedure|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
79700729|NCT00590213|Drug|Casodex 150mg|
79843868|NCT00236899|Drug|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
79700730|NCT00590213|Procedure|Radiotherapy|
79700731|NCT00590213|Procedure|Haematology|
79700732|NCT04567797|Device|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
79700733|NCT04567797|Device|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
79700734|NCT04567797|Device|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
79700735|NCT04567797|Device|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
79700736|NCT01082211|Radiation|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
79700737|NCT04567758|Other|Telerehabilitation|"The home exercise program includes the following exercises:~Lumbar region and lower extremity stretching exercises;~Exercises to strengthen the abdominal muscles;~Exercises to strengthen the lumbar muscles;~Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
79843869|NCT00236899|Drug|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
79843870|NCT00236899|Drug|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
79541642|NCT01495026|Drug|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
79247875|NCT02509143|Device|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
79386402|NCT03237078|Dietary Supplement|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
79386403|NCT03247296|Drug|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
79386404|NCT03247218|Drug|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
79386405|NCT03234348|Device|Percutaneous coronary intervention|PCI + stent implantation
79386406|NCT03237624|Device|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
79541643|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
79541644|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
79541645|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
79700738|NCT04567758|Other|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~Lumbar region and lower extremity stretching exercises;~Exercises to strengthen the abdominal muscles;~Exercises to strengthen the lumbar muscles;~Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
79843871|NCT00611130|Drug|vigabatrin|Tablets twice a day for 9 weeks
79843872|NCT00611130|Drug|placebo|tablets twice daily for 9 weeks
79247876|NCT02509143|Drug|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
79247877|NCT02507115|Behavioral|TMAP|Text messages for Alcohol Risk Reduction
79386407|NCT03237624|Device|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
79386408|NCT03237624|Behavioral|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
79700739|NCT00590408|Dietary Supplement|coenzyme Q10|60mg capsule twice daily for 12 weeks
79386409|NCT03234660|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
79700740|NCT00590408|Dietary Supplement|matching placebo|matching placebo capsule twice daily for 12 weeks
79700741|NCT04574648|Device|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
79700742|NCT04567875|Other|No Intervention on patients|No Intervention on patients
79700743|NCT00590447|Drug|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
79700744|NCT00590447|Drug|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
79700745|NCT04567953|Other|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
79843873|NCT00885690|Drug|Sertindole|Sertindole 16-24 mg once daily
79843874|NCT00885690|Drug|Olanzapine|Olanzapine 10-20 mg
79843875|NCT00888810|Drug|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
79843876|NCT00888810|Drug|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
79843877|NCT02542176|Other|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
79843878|NCT02542176|Other|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
79843879|NCT00256243|Drug|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
79843880|NCT00256243|Drug|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
79247878|NCT02507115|Behavioral|Mojo Texts|Motivational texts not alcohol related
79247879|NCT05100680|Other|Multicomp|Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
79386410|NCT03234660|Other|control|0.9% normal saline continuous infusion
79541646|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
79541647|NCT01495026|Drug|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
79541648|NCT01495026|Drug|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
79843881|NCT00256243|Drug|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
79843882|NCT00256243|Drug|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
79843883|NCT00256243|Drug|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
79843884|NCT00256243|Drug|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
79541649|NCT01495026|Drug|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
79541650|NCT01495039|Drug|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
79541651|NCT01495052|Dietary Supplement|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
79541652|NCT01495065|Drug|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
79700746|NCT00590525|Procedure|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
79700747|NCT01081626|Drug|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
79843885|NCT04037202|Other|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
79700748|NCT03452423|Procedure|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
79700749|NCT03452384|Other|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
79700750|NCT01080768|Drug|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
79700751|NCT01080768|Drug|Amlodipine|Amlodipine 5 mg/day.
79386411|NCT04485780|Biological|botulinum toxin type A|In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
79700752|NCT01080768|Drug|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
79700753|NCT01080768|Drug|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
79700754|NCT03452345|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
80012952|NCT02509598|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
79247880|NCT05100680|Other|Placebo|Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
79247881|NCT05100446|Drug|Amoxicillin - high dose dual therapy|Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
79247882|NCT05100446|Drug|Pylera|Eradication with Pylera, for 10 days.
79247883|NCT05100446|Drug|Esomeprazole 40mg|Esomeprazole 40mg, twice a day.
79247884|NCT02501577|Device|SAD 1|Placement and fiberoptic control
79247885|NCT02501577|Device|SAD 2|Placement and fiberoptic control
79247886|NCT02506803|Drug|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
79386412|NCT00059475|Drug|Glycoprotein 100 (GP100): 209-217 (210M)|
79386413|NCT00059475|Drug|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
79386414|NCT00059475|Drug|Montanide ISA 51|
79386415|NCT00059475|Drug|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
79541653|NCT01495065|Drug|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
79541654|NCT01495065|Drug|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
79700755|NCT03452345|Drug|Placebo|Placebo (Normal saline)
79700756|NCT03452306|Drug|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
79700757|NCT03452306|Drug|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
79700758|NCT03452306|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
79247887|NCT02844439|Drug|Tesevatinib|
79247888|NCT02501499|Other|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
79386416|NCT00059475|Drug|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
79386417|NCT00059475|Drug|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
79386418|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
79541655|NCT01495065|Drug|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
79541656|NCT01495065|Drug|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
79700759|NCT03452306|Drug|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
79700760|NCT04567641|Dietary Supplement|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
79700761|NCT04568109|Behavioral|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
79700762|NCT01080300|Drug|Gabapentin Extended Release|Gabapentin ER 1800mg daily
79700763|NCT01080300|Drug|Placebo|Sugar pill
79700764|NCT00590603|Drug|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
79541657|NCT01495065|Drug|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
79700765|NCT01085097|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
79700766|NCT01085097|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
79843886|NCT01325857|Procedure|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
79541658|NCT01495078|Procedure|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
79541659|NCT01495104|Drug|RO4917838|Multiple doses
79843887|NCT01325857|Procedure|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
79247889|NCT05096000|Behavioral|InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Intermob is a theory- and evidence-based behavioral intervention that combines public transport/bicycle and motivational techniques (action planning, personalized transport advice, goal setting).
79541660|NCT01495104|Drug|valproate|Multiple doses
79541661|NCT01495117|Drug|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
79541662|NCT01495117|Drug|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
79843888|NCT01325857|Procedure|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
79247890|NCT05096000|Other|Active control: Air pollution information|The active control intervention is based on a discussion about air pollution, the effects of air pollution on health, the association between air pollution and transport.
79247891|NCT04559126|Drug|EDP-297|EDP-297 Oral solution
79247892|NCT04559126|Drug|Placebo|placebo to match EDP-297
79247893|NCT04531592|Drug|Valproic acid|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
79247894|NCT04531592|Drug|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
79247895|NCT03571711|Drug|Meropenem Injection|Meropenem is administered as prescribed by treating physician
79386419|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
79541663|NCT01495130|Procedure|ultrasound imaging|Undergo transrectal ultrasound
79541664|NCT01495130|Procedure|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
79541665|NCT01495143|Procedure|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
79843889|NCT00888888|Procedure|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
79843890|NCT00236197|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
79386420|NCT02453802|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
79843891|NCT00236197|Drug|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
79843892|NCT02541708|Drug|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
79247896|NCT01677182|Drug|Ramelteon|Ramelteon tablets for sublingual administration
79247897|NCT01677182|Drug|Placebo|Ramelteon placebo-matching tablets for sublingual administration
79247898|NCT02843659|Drug|BMS-931699|Specified dose on specified days
79247899|NCT02843659|Drug|BMS-986142|Specified dose on specified days
79386421|NCT02453802|Drug|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
79700767|NCT01085097|Drug|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
79700768|NCT01085097|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
79700769|NCT01085097|Drug|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
79700770|NCT00590798|Behavioral|Walking|Patient will walk within 30 minutes of vascular closure system procedure
79247900|NCT02843659|Drug|Placebo|Specified dose on specified days
79247901|NCT05099744|Behavioral|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
79386422|NCT02453802|Drug|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
79386423|NCT00060333|Radiation|radiation therapy|
79386424|NCT03234270|Device|Core temperature measurements|Core temperature measurements with coretemp pill
79700771|NCT04567446|Other|Stool|collection at diagnosis, before initiating anticancer treatment, during treatment
79700772|NCT04567446|Other|Blood sample|40 mL collection before, 3 and 6 months of treatment cancer
79843893|NCT02541708|Drug|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
79700773|NCT04567446|Other|Saliva|5 mL collection before initiation of treatment cancer
79700774|NCT00590837|Drug|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
79700775|NCT01086267|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
79247902|NCT05099744|Behavioral|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
79700776|NCT01086267|Drug|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
79700777|NCT01086267|Drug|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
79700778|NCT04567563|Device|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
79700779|NCT04574687|Other|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
79700780|NCT04574687|Other|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
79700781|NCT02277873|Behavioral|pregnancy|Observational study in order to establish relationship between moon and births
79843894|NCT00278629|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
79849045|NCT05531591|Drug|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
79247903|NCT05099744|Behavioral|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
79247904|NCT03571477|Device|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
79386425|NCT03234192|Procedure|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
79386426|NCT03234192|Procedure|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
79849046|NCT05531591|Drug|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
80012953|NCT02509598|Drug|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
79386427|NCT03234192|Procedure|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
79386428|NCT04770987|Other|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
79386429|NCT04486872|Biological|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10^6/kg, 3.00 × 10^6/kg or 5.00 × 10^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
79386430|NCT04770597|Device|Aranet4 Home CO2 monitor|The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
79700782|NCT00590915|Drug|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
79700783|NCT04574570|Device|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
79700784|NCT04571892|Biological|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
79700785|NCT04567290|Drug|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
79700786|NCT04567290|Drug|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
79700787|NCT04567329|Drug|NOV03|100% perfluorohexyloctane
79700788|NCT04567329|Drug|Saline Solution|0.6% sodium chloride solution
79700789|NCT00591071|Other|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
79700790|NCT00591071|Other|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
79700791|NCT01084161|Drug|N1539|5 mg IV once per day
79700792|NCT01084161|Drug|N1539|7.5 mg IV once per day
79843895|NCT00883350|Behavioral|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
79386431|NCT03237000|Drug|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
79843896|NCT03973567|Drug|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
79843897|NCT03973567|Other|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
79843898|NCT00883428|Other|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
79843899|NCT03975361|Other|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
79247905|NCT05104190|Other|Stabilization of teeth during debonding using fingure pressure and elastic wafer|To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
79247906|NCT03570541|Drug|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
79247907|NCT03570541|Drug|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
79247908|NCT03570541|Device|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
79247909|NCT03570541|Drug|Morphine|intravenously administered morphine via PCA-pump
79541666|NCT01495156|Drug|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
79700793|NCT01084161|Drug|N1539|15 mg IV once per day
79700794|NCT01084161|Drug|N1539|30 mg IV once per day
79843900|NCT00885924|Drug|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
79843901|NCT00885924|Drug|Placebo|NaCl 0.9%
79843902|NCT01071811|Behavioral|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
79386432|NCT02028676|Other|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
79700795|NCT01084161|Drug|placebo|IV placebo once per day
79700796|NCT01084161|Drug|Morphine|morphine 10-15 mg IV once per day
79700797|NCT01084161|Drug|N1539|60 mg IV once per day
79700798|NCT00591110|Behavioral|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
79700799|NCT00591110|Behavioral|Social-contact control|Participants receive an engaging informational session on a non-health related topic
79700800|NCT01083615|Drug|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
79700801|NCT01083615|Drug|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
79700802|NCT01083615|Drug|docetaxel|
79700803|NCT01083615|Drug|cabazitaxel|
79700804|NCT01083615|Drug|prednisone|
79700805|NCT00591188|Drug|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
80012954|NCT02509598|Procedure|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
80012955|NCT02926573|Drug|Gabapentin|
80012956|NCT02926573|Drug|Placebo|
79247910|NCT03570541|Drug|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
79247911|NCT03570541|Diagnostic Test|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
79386433|NCT02028676|Other|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
79386434|NCT02028676|Drug|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
79247912|NCT03570541|Behavioral|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
79247913|NCT03570541|Diagnostic Test|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
79386435|NCT02028676|Drug|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
79541667|NCT01495156|Drug|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
79541668|NCT01495169|Drug|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
79541669|NCT01495182|Other|Dietary fiber|A proprietary fiber will be given to subjects
79541670|NCT01495195|Drug|High-dose donepezil|Donepezil titrated to 22.5 mg daily
79541671|NCT01495195|Drug|Low-dose donepezil|Donepezil titrated to 10 mg daily
79541672|NCT01495195|Drug|Selegiline|Transdermal selegiline, 6 mg daily
79541673|NCT01495195|Drug|Placebo|microcrystalline cellulose
79541674|NCT01495208|Drug|Aflibercept|intravitreal aflibercept injection 2mg
79541675|NCT01495260|Drug|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
79541676|NCT01495260|Drug|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
79541677|NCT01495260|Drug|vitamin E|vitamin E, 150-300 mg daily for 2 months
79541678|NCT01495273|Procedure|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
79541679|NCT01495273|Procedure|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
79541680|NCT01495299|Device|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
79541681|NCT01495312|Device|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
79541682|NCT01495325|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
79541683|NCT01495325|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
79700806|NCT00591383|Drug|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
79700807|NCT00591383|Drug|erlotinib|erlotinib taken at 150 mg every morning with food.
79700808|NCT01081782|Drug|ONO-4641|0.15 mg once per day for 26 weeks
79700809|NCT01081782|Drug|ONO-4641|0.1 mg once per day for 26 weeks
79700810|NCT01081782|Drug|ONO-4641|0.05 mg once per day for 26 weeks
79700811|NCT01081782|Drug|ONO-4641 placebo|Placebo once per day for 26 weeks
79700812|NCT00591422|Drug|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
79700813|NCT04567212|Genetic|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
80012957|NCT04477018|Dietary Supplement|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
79247914|NCT05374382|Behavioral|Strengthening|3x/w, 9 wks supervised strengthening program, during prehabilitation to ACL surgery
79247915|NCT05374382|Behavioral|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
79247916|NCT00708435|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
79247917|NCT00708435|Biological|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
79247918|NCT04437290|Drug|investigational radiotracer [18F]MK6240|Brain PET scan
80012958|NCT04477018|Dietary Supplement|Iron bis-glycinate chelate|28 mg iron only
80012959|NCT04477018|Dietary Supplement|Placebo|Matched placebo
79700814|NCT04567212|Other|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
79700815|NCT01080222|Drug|telaprevir|tablet, 1125-mg, twice daily
79700816|NCT01080222|Drug|VX-222|capsule, 100-mg, twice daily
79700817|NCT01080222|Drug|ribavirin|tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
80012960|NCT02236442|Other|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~Provide a sound-proof helmet to the patient.~Provide a light-blocking google to the patient.~If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
79386436|NCT02028676|Drug|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
80012961|NCT05737654|Other|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
79247919|NCT05099354|Diagnostic Test|autonomic nervous system testing|"Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
79247920|NCT02841787|Behavioral|iCBT for late life depression|
79386437|NCT02028676|Drug|Once-daily ABC+3TC|
79386438|NCT02028676|Drug|Twice-daily ABC+3TC|
80012962|NCT02261402|Other|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
80012963|NCT03629275|Combination Product|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
80012964|NCT03629275|Drug|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
79386439|NCT02028676|Drug|Continued cotrimoxazole prophylaxis|
79386440|NCT02028676|Other|Stopped cotrimoxazole prophylaxis|
79386441|NCT03233958|Behavioral|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation [Hunger, Weinhold, Bornhäuser, Link, & Schweitzer, 2015].
79386442|NCT03247062|Other|Quality improvement - sleep bundle|implementation of a sleep bundle
79541684|NCT01495338|Drug|AC-170 0.17%|1 drop in one eye at one timepoint
79541685|NCT01495338|Drug|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
79541686|NCT01495338|Drug|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
79386443|NCT03236844|Drug|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
79386444|NCT03233880|Drug|Azithromycin 1gm|Azithromicin 1 gm oral single dose
79386445|NCT03233880|Other|PLACEBO|placebo
79541687|NCT01495338|Drug|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
79541688|NCT01495351|Drug|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
79541689|NCT01495364|Biological|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
79541690|NCT01495364|Other|placebo|matching placebo
79700818|NCT01080222|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
79700819|NCT01080222|Drug|VX-222|capsule, 400-mg, twice daily
79700820|NCT03452267|Drug|Metformin|oral, 850 mg twice daily
79700821|NCT03452267|Drug|Pioglitazone|oral, 45 mg daily
79700822|NCT03452267|Drug|Placebo|oral, once daily
79843903|NCT01071889|Drug|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
79700823|NCT03451994|Other|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
79700824|NCT01088802|Radiation|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
79700825|NCT01088802|Drug|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
79700826|NCT01088802|Drug|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
79843904|NCT01071889|Drug|Placebo|Placebo - only excipients with no API
79843905|NCT00612690|Behavioral|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
80012965|NCT05737498|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
80012966|NCT05201131|Procedure|Rezum|Rezum
79247921|NCT05104034|Behavioral|Osteoporosis and sarcopenia screening|Use DXA, BIA, and questionnaire to screen the community elderly
79247922|NCT05374226|Biological|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
79247923|NCT02508753|Drug|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
79386446|NCT03236766|Other|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
79386447|NCT04485936|Device|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
80012967|NCT02261480|Other|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
79247924|NCT02508753|Drug|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
79247925|NCT02508753|Drug|Moxifloxacin|400 mg tablet
79247926|NCT02508753|Drug|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
79247927|NCT02506647|Drug|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan & Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
79247928|NCT02506647|Drug|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan & Lee insulin glargine injection SC,
79247929|NCT02190097|Other|Paleolithic diet|see procedures section for more details
79247930|NCT02190097|Other|American Diabetes Association diet|see procedures section
79386448|NCT00061893|Drug|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. [Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.] .
79386449|NCT00061893|Drug|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
79386450|NCT00061893|Drug|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
79386451|NCT00061893|Drug|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
79386452|NCT00061893|Drug|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
79541691|NCT01495377|Drug|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
79541692|NCT01495377|Drug|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
79541693|NCT01495377|Drug|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
79541694|NCT01495377|Device|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
79541695|NCT01495429|Procedure|Central venous catheter|Placement of a peripherally inserted central venous catheter
79541696|NCT01495429|Procedure|Central venous catheter|Placement of a centrally inserted central venous catheter
79700827|NCT03451877|Genetic|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
79700828|NCT04999683|Dietary Supplement|ITIS diet|anti-inflammatory diet for 14 days
79843906|NCT00612690|Behavioral|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
79843907|NCT03973411|Drug|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
79843908|NCT03973411|Drug|Placebo|Pacients will receibe standard spinal anesthesia
79541697|NCT01495442|Device|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
80012968|NCT02261480|Other|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
80012969|NCT05759611|Other|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
80012970|NCT05759611|Other|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
80012971|NCT00158860|Drug|Valaciclovir|1g once daily
80012972|NCT00158860|Drug|Placebo|placebo
80012973|NCT02234258|Behavioral|Cognitive behavioral social skills|
79541698|NCT01495442|Device|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
79541699|NCT01495468|Biological|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
79843909|NCT00883506|Drug|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
80012974|NCT02234258|Behavioral|Psychoeducation|
79541700|NCT01495494|Device|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
79541701|NCT01495494|Device|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
79541702|NCT01495507|Procedure|MPFL- Reconstruction|
79541703|NCT01495520|Drug|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
79700829|NCT03451838|Diagnostic Test|Ultrasound|Ultrasound will be done to every pregnant lady
79843910|NCT00883506|Drug|Lisinopril 40 mg Tablet under fasting conditions.|
79843911|NCT00883506|Drug|Lisinopril 40 mg Tablet under fed conditions.|
80012975|NCT05201053|Diagnostic Test|Exploratory for different markers|Test biomarkers for development of mild, moderat or severe disease
80012976|NCT03629665|Behavioral|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
79247931|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
79247932|NCT02508519|Procedure|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
79247933|NCT02571530|Drug|Intra-arterial Cerebral Infusion of Trastuzumab|
79247934|NCT02508441|Drug|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
79541704|NCT01495520|Drug|Placebo|os, pill, b.i.d., 30 days
79541705|NCT01495546|Other|Early loading|Patients stepping down immediately after THA
79700830|NCT03451838|Diagnostic Test|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
79700831|NCT03451682|Dietary Supplement|procyanidine|Natural antioxidant
79700832|NCT04566822|Behavioral|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
79700833|NCT04566822|Behavioral|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
79843912|NCT04268784|Drug|DNL343|Single and repeating oral dose(s)
79843913|NCT04268784|Drug|Placebo|Single and repeating oral dose(s)
79843914|NCT00278473|Behavioral|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
79843915|NCT00278473|Behavioral|Supportive Therapy|Social Support Problem-Solving Group Treatment
79843916|NCT04037280|Other|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
79843917|NCT00278395|Drug|Vorinostat|Given orally
80012977|NCT03629665|Device|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
80012978|NCT02490488|Drug|Masitinib|
80012979|NCT02490488|Drug|Gemcitabine|
80012980|NCT02490488|Drug|Placebo|
79541706|NCT01495546|Other|Late loading|Patients stepping down after three weeks of HTA
79700834|NCT04566822|Behavioral|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
79700835|NCT04566822|Behavioral|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
79386453|NCT00061893|Drug|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. [Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.]
79700836|NCT03451643|Procedure|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
79843918|NCT00889044|Drug|clopidogrel by chewing|600 mg clopidogrel by chewing
79843919|NCT00889044|Drug|Placebo|Placebo p.o
79843920|NCT00889122|Behavioral|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
80012981|NCT02261558|Other|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
80012982|NCT02261558|Other|Clinical Vocal Improvisation|* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
79386454|NCT00061893|Drug|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
79541707|NCT01495624|Other|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
79541708|NCT01495624|Other|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
79541709|NCT01495650|Behavioral|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
79541710|NCT01495663|Drug|I-131-CLR1404|"Description:~Dosimetry: IV, 5 mCi, single dose, 6-day duration~Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
79541711|NCT01495715|Drug|Idebenone|
79247935|NCT05108402|Diagnostic Test|Phenotyping|"After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study."
79541712|NCT01495715|Drug|Placebo|
79541713|NCT01495728|Procedure|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
79247936|NCT05108402|Dietary Supplement|Drug intake|"After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet."
79247937|NCT02501187|Procedure|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
79247938|NCT02501187|Procedure|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
79541714|NCT01495728|Procedure|Sham Manipulation|Mid and Upper Thoracic Spine
79541715|NCT01495754|Other|coffee|Comparison of different amounts of coffee
79700837|NCT03451604|Other|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
79843921|NCT00886002|Drug|Fentanyl; Buprenorphine; Naloxone|
79843922|NCT00883584|Drug|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
79843923|NCT00883584|Drug|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
79843924|NCT00883662|Drug|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
79843925|NCT00883818|Drug|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
79843926|NCT00889356|Drug|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
79843927|NCT00889356|Drug|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
79843928|NCT00886080|Procedure|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
80012983|NCT02471222|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
80012984|NCT02471222|Other|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
79700838|NCT04566744|Other|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
79843929|NCT00889434|Dietary Supplement|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
79843930|NCT00889434|Dietary Supplement|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
79541716|NCT01495767|Other|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
79843931|NCT00889434|Dietary Supplement|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
79843932|NCT00612534|Drug|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
79843933|NCT00612534|Drug|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
79843934|NCT00612534|Drug|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
79843935|NCT00612534|Drug|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
79843936|NCT02542254|Drug|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
79843937|NCT02542254|Drug|Ipratropium|40 micrograms ipratropium administered using a pMDI
79843938|NCT02542254|Drug|RPL554|6 mg RPL554 administered using a nebuliser
80012985|NCT05094310|Device|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
79247939|NCT02501187|Procedure|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
79247940|NCT05108324|Procedure|zygomatic implant|2 zygomatic implants and 2 anterior conventional implant
79541717|NCT01495780|Behavioral|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
79843939|NCT02542254|Drug|Salbutamol matched placebo|Placebo pMDI
79247941|NCT05108324|Procedure|conventional implant|patients will receive 4 conventional dental implant
79843940|NCT02542254|Drug|Ipratropium matched placebo|Placebo pMDI
79843941|NCT02542254|Drug|RPL554 matched placebo|Nebulised placebo
79843942|NCT00883974|Behavioral|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
79386455|NCT00061893|Procedure|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
79386456|NCT00061893|Radiation|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
79541718|NCT01495806|Drug|Glucomannan|2 x 5g
79541719|NCT01495806|Drug|placebo|glucose 5 g
79541720|NCT01495832|Other|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
79541721|NCT01495832|Other|Control Group|The control group will consume comparator foods for 12 weeks.
79700839|NCT04574453|Device|Iracross|Administration of max 2ml of Iracross at first visit
79700840|NCT04574453|Device|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
79700841|NCT04566471|Other|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
79700842|NCT03451526|Procedure|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
79843943|NCT00889590|Drug|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
79843944|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
79843945|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
79843946|NCT00736853|Drug|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
79843947|NCT04037514|Drug|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
80012986|NCT02649062|Biological|NGM282|
80012987|NCT02649062|Other|Placebo|
79700843|NCT04996602|Drug|2.0 GBq of 177Lu-EB-PSMA|Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
79700844|NCT04997694|Procedure|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
79700845|NCT04574414|Diagnostic Test|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
79700846|NCT04566549|Combination Product|Test group Probiotic Shampoo|Probiotic Shampoo
79700847|NCT04566549|Combination Product|Placebo group|Shampoo base
79700848|NCT04566705|Other|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
79700849|NCT04566588|Procedure|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
79700850|NCT04566588|Procedure|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
79700851|NCT04992858|Drug|CT053PTSA|CT053PTSA will be administered orally once a day
79700852|NCT04997382|Drug|Alectinib|Alectinib Cap 600 mg po bid
79843948|NCT04037514|Drug|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
79700853|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
79305535|NCT03242681|Procedure|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
79305536|NCT03242525|Diagnostic Test|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
79700854|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
79700855|NCT02210754|Other|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
79700856|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
79700857|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
79700858|NCT02210754|Other|Marlboro Cigarette|cigarettes
79700859|NCT02210793|Procedure|transepithelial PRK|
79386457|NCT00061893|Drug|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
79386458|NCT00061893|Drug|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
79700860|NCT02210793|Procedure|LASIK|
79700861|NCT03451214|Other|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
79700862|NCT04996056|Drug|TNX-1300|TNX 1300 200 mg Intravenous injection
79700863|NCT04996056|Other|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
79700864|NCT04992078|Device|NAVIO/CORI Surgical System|Unicompartmental knee replacement with robotic assistance
79700865|NCT04992078|Procedure|Non-robotic conventional instrumentation|Unicompartmental knee replacement with non-robotic conventional instrumentation
79843949|NCT00889668|Device|GlucoTrack|comparison of different glucose monitoring devices
79843950|NCT00884130|Procedure|laparoscopic colorectal resection|
79386459|NCT02452788|Other|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
79386460|NCT03236922|Procedure|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
79386461|NCT03236922|Procedure|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
79700866|NCT02210871|Drug|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
79700867|NCT04574141|Dietary Supplement|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
79700868|NCT04573907|Drug|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
79700869|NCT04573907|Drug|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
79700870|NCT02277912|Device|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
79843951|NCT00884130|Procedure|open colorectal resection|
79843952|NCT00730847|Biological|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
79843953|NCT00573066|Drug|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
79843954|NCT00889980|Other|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
79541722|NCT01495845|Other|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
79700871|NCT02277912|Device|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
79700872|NCT02277912|Device|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
79541723|NCT01495871|Dietary Supplement|Amino Acids|15 grams amino acids two times per day for 6 weeks
79541724|NCT01495871|Dietary Supplement|Placebo of inert compounds|Placebo two times per day for 6 weeks
79700873|NCT02277951|Device|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
79700874|NCT02277951|Device|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
79843955|NCT02541552|Drug|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
79843956|NCT00886314|Drug|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
79541725|NCT01495871|Dietary Supplement|Valine|2.5 grams valine supplementation two times a day for 6 weeks
79541726|NCT01495884|Drug|non-pegylated liposomal doxorubicon (Myocet™)|
79541727|NCT01495884|Drug|Lapatinib (Tyverb™)|
79843957|NCT00886314|Other|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
79843958|NCT00890214|Drug|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
80012988|NCT05094076|Radiation|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis [ILO, 1980]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
79386462|NCT03233568|Diagnostic Test|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
79386463|NCT05383833|Dietary Supplement|Creatine Monohydrate|Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
79386464|NCT02957019|Drug|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
79700875|NCT02277951|Device|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
79700876|NCT02277951|Device|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
79700877|NCT04573790|Procedure|eFONA|Surgical Tracheotomy
79700878|NCT02278068|Device|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
79700879|NCT04573595|Device|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
79700880|NCT04566627|Behavioral|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
79700881|NCT04573361|Other|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
79700882|NCT04573361|Other|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
79843959|NCT00890214|Drug|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
79843960|NCT00890292|Drug|JNJ-31001074|
80012989|NCT05093998|Drug|AV5080|oral hard gelatin capsules
80012990|NCT05093998|Other|Placebo|Hard gelatin capsules with a white body
79700883|NCT04566354|Other|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
80012991|NCT02264756|Other|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
79386465|NCT02957019|Drug|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
79386466|NCT02957019|Drug|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
79386467|NCT02028754|Drug|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
79541728|NCT01495897|Device|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
79541729|NCT01495897|Device|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
79541730|NCT01495910|Drug|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
79700884|NCT04573400|Other|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
79700885|NCT04998981|Drug|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
79700886|NCT04998981|Drug|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
79305537|NCT03242603|Biological|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
79541731|NCT01495936|Procedure|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
79700887|NCT04998981|Drug|Placebo tablet|Placebo tablet x 2 twice daily
79700888|NCT04998981|Drug|Placebo capsule|Placebo capsule once daily
79700889|NCT04998981|Drug|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
79700890|NCT04998981|Drug|Placebo tablet|Placebo tablet twice daily
80012992|NCT03067129|Drug|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
80012993|NCT03067129|Drug|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
80012994|NCT03136120|Drug|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
80012995|NCT03136120|Procedure|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
79386468|NCT02028754|Drug|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
79386469|NCT02028754|Drug|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
79700891|NCT04573127|Other|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
79700892|NCT04573088|Behavioral|ACCEPTANCE-BASED INTERVENTION|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
79700893|NCT04566198|Other|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
79700894|NCT04573049|Drug|Levosimendan|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
79386470|NCT01897389|Drug|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
79386471|NCT01897389|Drug|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
79700895|NCT04573049|Other|Placebo|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
80012996|NCT01625390|Drug|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
79541732|NCT01495936|Procedure|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
79700896|NCT04572932|Drug|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
79386472|NCT01897389|Drug|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
79386473|NCT01897389|Drug|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
79843961|NCT02543736|Device|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
79843962|NCT00923520|Drug|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
79843963|NCT02543424|Behavioral|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
79843964|NCT00612456|Drug|Pazopanib|Pazopanib eye drops formulation
79386474|NCT01897389|Drug|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
79843965|NCT00730691|Drug|Placebo|Placebo-matching capsules
79843966|NCT00730691|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
79843967|NCT00730691|Drug|Duloxetine|Overencapsulated duloxetine capsules
79247942|NCT04495647|Other|Whole-Body Electromyostimulation|"Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention."
79386475|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
79386476|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
79386477|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
79386478|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
79386479|NCT01974700|Drug|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
79386480|NCT04753281|Other|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
79386481|NCT03236610|Drug|tenofovir monotherapy|switching to tenofovir monotherapy
79386482|NCT03236610|Drug|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
79541733|NCT01495949|Drug|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
79541734|NCT01495949|Drug|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
79541735|NCT01495962|Drug|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
79700897|NCT04572698|Drug|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
79843968|NCT02543502|Procedure|periodontal treatment|treatment of periodontal cleaning
79843969|NCT00890370|Procedure|Airway clearance technique|
79843970|NCT00890448|Other|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
79843971|NCT00235495|Biological|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
79843972|NCT00235495|Drug|Saline|equivalent volume of isotonic saline control
79843973|NCT02541474|Other|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
79843974|NCT03017105|Other|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
79843975|NCT03017105|Other|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
79541736|NCT01495962|Drug|Placebo|Placebo (Normal Saline)
79700898|NCT04572698|Drug|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
79700899|NCT02210910|Device|InSpace™ system over repair|
79700900|NCT02210910|Procedure|Best Repair of torn Rotator Cuff|
79700901|NCT04572542|Drug|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
79700902|NCT04572542|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
79843976|NCT02541630|Behavioral|Big Mind|mindfulness based intervention
79843977|NCT03968471|Behavioral|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
79541737|NCT01496001|Procedure|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
79700903|NCT04572542|Drug|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
79700904|NCT04565964|Other|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
79843978|NCT00884364|Other|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
79541738|NCT01496001|Other|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
79247943|NCT02501031|Dietary Supplement|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
79247944|NCT05103488|Other|Comprehensive palliative care|CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.
79305538|NCT04931433|Drug|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
79541739|NCT01496040|Drug|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
79541740|NCT01496053|Dietary Supplement|AndoSan|AndoSan 30 ml x 2 for 21 days
79700905|NCT04572386|Other|light cure 3m single bond universal bond|light -cure universal bond
79700906|NCT04572386|Other|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
79700907|NCT04572464|Other|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
79843979|NCT00884364|Behavioral|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
79386483|NCT02030080|Behavioral|Financial incentives|
79386484|NCT02030080|Behavioral|Teams|
79843980|NCT04088279|Diagnostic Test|MRI|Oxygen enhanced and fourier decomposition MRI
79386485|NCT02030080|Behavioral|Framing of feedback|
79843981|NCT00886860|Drug|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
79843982|NCT00886860|Drug|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
79386486|NCT02030080|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
79386487|NCT03233490|Other|web course|Web course Help Brain Heart was conducted Before CPR training.
79386488|NCT03233490|Other|CPR training|No web course was conducted
79386489|NCT02453412|Device|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
79386490|NCT05287893|Drug|Pyronaridine|Single dose
79541741|NCT01496053|Dietary Supplement|Sugar Extract|Sham comparator
79541742|NCT01496092|Drug|Keto Acid|12 tablets per day
79541743|NCT01496105|Drug|Lidocaine|
79541744|NCT01496105|Drug|saline|
79386491|NCT05287893|Biological|P. falciparum IBSM infection|Induced Blood Stage Malaria
79386492|NCT02357758|Drug|Antibiotic Prophylaxis|Approved clinical dosage or antibiotics
79541745|NCT01496144|Procedure|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
79541746|NCT01496144|Procedure|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
79541747|NCT01496170|Drug|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
79700908|NCT04572620|Drug|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
79700909|NCT04572620|Drug|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
79700910|NCT04565808|Procedure|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
79700911|NCT03451097|Radiation|echocardiography|cardiac ultrasound
79700912|NCT04994691|Other|No Message|No messages are sent
79700913|NCT04994691|Other|Standard message|2 MyChart reminders that child is overdue for well child check visit
79700914|NCT04994691|Other|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
79700915|NCT03451019|Drug|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
79700916|NCT03451019|Drug|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
79843983|NCT00884442|Drug|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
79843984|NCT00884442|Drug|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
79843985|NCT04087265|Diagnostic Test|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
79843986|NCT02543580|Other|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
79700917|NCT03450902|Combination Product|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
79700918|NCT03450902|Combination Product|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
79541748|NCT01496170|Drug|Placebo|Placebo capsules, orally, once per day for 7 days
80012997|NCT01625390|Drug|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
80012998|NCT01625390|Drug|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
79541749|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
79541750|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
79700919|NCT03450902|Combination Product|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
79843987|NCT02543580|Other|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
79843988|NCT02543034|Device|Betafoam Wound Dressing|Foam dressing including Betadine iodine
80012999|NCT01679236|Behavioral|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
80013000|NCT01679236|Behavioral|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
80013001|NCT01625234|Drug|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
79247945|NCT05103488|Other|Standard of care|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
79247946|NCT02506725|Other|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
79386493|NCT05606445|Behavioral|Elbow movement|The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
79541751|NCT01496209|Biological|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
79541752|NCT01496209|Biological|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
79541753|NCT01496235|Dietary Supplement|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
79843989|NCT02543034|Device|Petrolatum Gauze|Gauze dressing
79843990|NCT02543034|Device|Allevyn Wound Dressing|Foam dressing
79541754|NCT01496235|Dietary Supplement|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
79541755|NCT01496261|Drug|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
79541756|NCT01496261|Drug|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
79843991|NCT02594345|Other|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
79843992|NCT00278161|Biological|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
79843993|NCT00278161|Biological|Rituximab|375 mg/m^2/day on Days 1, 4, 8, 11, 45, and 52.
79843994|NCT00278161|Drug|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
79843995|NCT04038216|Procedure|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
80013002|NCT01625234|Drug|Phase II: X-396 (ensartinib)|Expanded Cohort
80013003|NCT02264834|Drug|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
80013004|NCT02264834|Drug|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
80013005|NCT02264834|Procedure|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
80013006|NCT05762419|Drug|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
79386494|NCT02357836|Drug|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
79386495|NCT03246594|Device|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
79700920|NCT03450902|Other|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
79700921|NCT04565652|Device|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
79700922|NCT03450863|Drug|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection [MDI]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion [CSII]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
79700923|NCT02211027|Biological|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
79700924|NCT02211066|Drug|Clopidogrel|
79700925|NCT02211066|Drug|Ticagrelor|
79700926|NCT03450785|Other|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
79700927|NCT04572113|Device|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
79541757|NCT01496300|Procedure|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
79700928|NCT04572191|Diagnostic Test|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
79700929|NCT04998864|Device|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
79700930|NCT04995042|Drug|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
79843996|NCT04038216|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
79843997|NCT02541396|Drug|Wafermine|35 or 70 mg ketamine in a sublingual wafer
79843998|NCT02541396|Drug|Oxycodone|5 mg oxycodone capsule
79247947|NCT04526054|Diagnostic Test|ENT exam|ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
79247948|NCT04526054|Diagnostic Test|Olfactometry|Olfactometry test using odorous pens (Sniffin's stick test).
79247949|NCT04526054|Diagnostic Test|Brain MRI|Brain MRI focused on the olfactory bulbs (3 teslas).
79386496|NCT03246594|Device|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
79541758|NCT01496300|Procedure|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
79541759|NCT01496326|Drug|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
79700931|NCT03450551|Device|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
79843999|NCT02541396|Drug|Placebo|Placebo capsule or placebo wafer
79849047|NCT05531591|Drug|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
79849048|NCT05529654|Device|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
80013007|NCT05762419|Device|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
79305539|NCT04931433|Drug|Normal saline|Group B will receive saline of similar volume and rate as Group A
79386497|NCT01897467|Behavioral|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
79386498|NCT01897467|Behavioral|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
79541760|NCT01496326|Drug|placebo|2 grams of placebo cream for 14 days
79541761|NCT01496339|Biological|MenSCs transplantation|1×10^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
79700932|NCT03450395|Other|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
79700933|NCT03450317|Drug|Aspirin 80mg|No treatment
80013008|NCT04568408|Device|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
80013009|NCT04458103|Device|Percutaneous RVAD|ProtekDuo or Impella RP
80013010|NCT02264912|Drug|antiplatelet drugs - P2Y12 antagonists|
79541762|NCT01496339|Drug|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
79700934|NCT04996563|Other|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
79541763|NCT01496378|Behavioral|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
79700935|NCT03450278|Procedure|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
79700936|NCT04565496|Drug|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
79700937|NCT03450239|Other|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
79700938|NCT04992117|Other|NO INTERVENTION|NO INTERVENTION
80013011|NCT01437722|Drug|1% SPL7013 Gel|vaginal gel
80013012|NCT01437722|Drug|3% SPL7013 Gel|vaginal gel
79541764|NCT01496404|Procedure|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
79541765|NCT01496404|Procedure|Scalpel|Incising skin (epidermis and dermis) with scalpel.
79700939|NCT04572425|Other|Guided imagery|10 minutes of guided imagery experience delivered on tablet
79700940|NCT04572425|Other|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
79700941|NCT04565340|Other|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
79700942|NCT03450200|Other|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
79700943|NCT03450200|Other|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
79844000|NCT00890526|Other|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from ~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
79844001|NCT00890526|Other|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
79247950|NCT03343275|Combination Product|Lit control pHDown|Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
79247951|NCT04379024|Drug|DUAVEE 0.45Mg-20Mg Tablet|One capsule daily for 6 months (+/- 1 month)
79844002|NCT00890526|Other|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
80013013|NCT01437722|Drug|placebo gel|vaginal gel
80013014|NCT02263352|Drug|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
80013015|NCT02263352|Device|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
80013016|NCT01435226|Drug|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
80013017|NCT01435226|Drug|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
80013018|NCT01435226|Drug|tegobuvir|tegobuvir 30 mg BID
80013019|NCT01435226|Drug|placebo to match tegobuvir|tegobuvir placebo BID
80013020|NCT01435226|Drug|placebo to match RBV|Ribovirin placebo BID
79247952|NCT02506569|Device|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
79247953|NCT02506569|Other|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
79700944|NCT03450161|Drug|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
79700945|NCT04996212|Procedure|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
79386499|NCT03107676|Other|trunk extensors endurance training|endurance training
79700946|NCT04996212|Procedure|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
79700947|NCT03458039|Behavioral|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
79700948|NCT03458039|Behavioral|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
79844003|NCT00890526|Other|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
79844004|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
80013021|NCT01435226|Drug|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
79247954|NCT04497831|Drug|Morphine hydrochloride|5 mg milligram(s) per day per two days of dosage
79247955|NCT04497831|Drug|Placebo|Inhalation use
79247956|NCT04360850|Behavioral|online survey|A brief survey for therapists to fill out
79247957|NCT04498689|Drug|Camrelizumab|Patients firstly receive camrelizumab 200 mg per time (iv, no less than 20 minutes and no more than 60 minutes, rinse time included) on Day 1 and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
79386500|NCT03233334|Behavioral|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
79386501|NCT02359006|Drug|Minocycline|Minocycline will be compared with placebo
79386502|NCT02359006|Drug|Placebo|Placebo will be compared with minocycline
79386503|NCT03236454|Device|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
79844005|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
80013022|NCT01679002|Drug|BIA 2-093|
79247958|NCT04498689|Drug|Nab paclitaxel|Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
79247959|NCT04498689|Drug|Gemcitabine Injection|At last, patients receive gemcitabine 1000 mg/m2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
79247960|NCT01376037|Device|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
79386504|NCT04486014|Procedure|Erector spinae plane block|Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
79700949|NCT03458039|Behavioral|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
79700950|NCT04565184|Drug|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
79700951|NCT04565184|Drug|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
79700952|NCT03455192|Drug|Synbiotic Supplement|
79700953|NCT03455192|Drug|Placebo Oral Tablet|
79700954|NCT04565262|Drug|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients<2years old, the drug is LAM）combined with IFN-α（when the CHB patients<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
79700955|NCT04564950|Other|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
79700956|NCT03454022|Behavioral|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
79700957|NCT03454022|Behavioral|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
79700958|NCT03452579|Drug|Nivolumab|240mg
79700959|NCT03452579|Drug|Standard Dose Bevacizumab|10mg/kg
79700960|NCT03452579|Drug|Low Dose Bevacizumab|3mg/kg
79844006|NCT00255151|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
79844007|NCT00890760|Biological|AdCh63 ME-TRAP|5 x 10*10 vp IM
79844008|NCT00890760|Biological|MVA ME-TRAP|2 x 10*8 pfu ID
79844009|NCT00890760|Other|Sporozoite challenge|Infected mosquito bite
79844010|NCT00890760|Biological|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10*10 vp MVA ME-TRAP 2 x 10*8 pfu
79844011|NCT00890838|Dietary Supplement|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
79386505|NCT04486014|Procedure|Serratus anterior plane block|Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
79386506|NCT04485702|Drug|Midazolam injection|2mg IV
79386507|NCT04485702|Drug|Ketamine Injectable Product|6mg IV
79386508|NCT04485702|Drug|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
79541766|NCT01496417|Drug|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
79541767|NCT01496443|Drug|TAK-875 and Glimepiride|
79541768|NCT01496482|Other|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
79541769|NCT01496495|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
79541770|NCT01496508|Device|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
79844012|NCT04037670|Procedure|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
79844013|NCT03973957|Device|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
79844014|NCT03973957|Drug|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
80013023|NCT01679002|Drug|Oxcarbazepine|
79541771|NCT01496521|Drug|Aspirin|100mg qd for 6 months.
80013024|NCT01428362|Drug|VI-1121|
80013025|NCT01428362|Drug|Placebo|
79386509|NCT00068367|Drug|erlotinib hydrochloride|150 mg per day, daily until disease progression
79386510|NCT03236532|Dietary Supplement|Glutamine and exercise|
79386511|NCT03236532|Dietary Supplement|Maltodextrin and exercise|
79541772|NCT01496521|Dietary Supplement|Tea Polyphenols|300mg bid for 6 months.
79700961|NCT04565223|Behavioral|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
79700962|NCT04997850|Drug|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
79700963|NCT04997850|Procedure|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
79700964|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
79700965|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
79700966|NCT04565106|Device|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
79700967|NCT04572347|Other|Observational|It is an observational study, and no intervention will be provided.
79700968|NCT04997772|Device|Digital Gaucher Platform|Digital platform specified for Gaucher patients.
79247961|NCT01376037|Device|inactive placebo laser device|non-therapeutic light application
79247962|NCT05103098|Drug|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
79386512|NCT01975090|Device|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
79700969|NCT03459014|Other|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
80013026|NCT02261870|Device|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
79386513|NCT03229434|Behavioral|Mountain hiking|Compare arm description
79541773|NCT01496534|Drug|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
79541774|NCT01496534|Drug|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
79386514|NCT03229590|Procedure|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
79386515|NCT02880891|Procedure|prothetic procedure|splinted crown
79386516|NCT03233412|Procedure|Control|Exertion of the cervix transformation zone
79541775|NCT01496547|Drug|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
79541776|NCT01496573|Other|laboratory biomarker analysis|Correlative studies
79541777|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
79541778|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
79700970|NCT03459014|Other|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
79700971|NCT03456947|Drug|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
79700972|NCT04999527|Drug|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
79700973|NCT04999527|Drug|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
79700974|NCT04995861|Procedure|Adductor canal block and IPACK block|Peripheral nerve blocks
80013027|NCT04409509|Biological|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
80013028|NCT04409509|Drug|Placebo|CSL312 diluent administered intravenously
80013029|NCT02262104|Behavioral|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
80013030|NCT02262104|Behavioral|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
79700975|NCT03456791|Diagnostic Test|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
79386517|NCT03233412|Drug|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
79700976|NCT04564638|Drug|Corticosteroid|
79386518|NCT01976416|Drug|Hydroxyurea|
79386519|NCT01976416|Drug|Placebo|
79700977|NCT02277431|Dietary Supplement|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
79700978|NCT02277431|Dietary Supplement|placebo|
79700979|NCT02277509|Behavioral|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
79386520|NCT05255133|Other|Liquid biopsies|Blood sampling will be done at regular intervals
79386521|NCT05255133|Other|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
79700980|NCT02277509|Behavioral|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
79700981|NCT01580852|Procedure|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
79700982|NCT01580852|Procedure|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
79386522|NCT02453178|Behavioral|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
79700983|NCT04564326|Procedure|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
80013031|NCT02263430|Device|Deep Brain Stimulation|
79386523|NCT02032420|Behavioral|STAR|
80013032|NCT02610296|Drug|QPI-1002|IV injection
79386524|NCT02032420|Behavioral|ART|
79386525|NCT02453100|Behavioral|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
79386526|NCT02453100|Behavioral|Education|Education on simple ways to manage incontinence
79386527|NCT03233178|Other|Non-interventional|
79386528|NCT03229044|Genetic|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
79386529|NCT03236376|Other|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
79386530|NCT03236376|Other|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
79386531|NCT03233100|Other|FMT|fecal microbiota transplantation
79386532|NCT03236298|Device|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
79386533|NCT01976572|Drug|colestilan|
79386534|NCT01976572|Drug|candesartan|
79386535|NCT03236142|Procedure|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
79386536|NCT03236142|Procedure|Standard Duodenal Switch Operation|
79386537|NCT03232866|Other|Pilates exercise|Pilates methods exercises
79386538|NCT02360488|Device|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
79386539|NCT02360488|Behavioral|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
79386540|NCT03233022|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
79386541|NCT03232944|Device|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
79386542|NCT01976650|Drug|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
79386543|NCT02361736|Drug|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
79386544|NCT02361736|Drug|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
79386545|NCT03228966|Diagnostic Test|Echocardiogram|Screening echocardiogram
80013033|NCT02610296|Other|Placebo|isotonic saline
80013034|NCT04401865|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
80013035|NCT05206903|Other|Questionnaires|Questionnaires about pandemia process
79700984|NCT04564326|Procedure|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
79844015|NCT03973957|Drug|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
79844016|NCT03973957|Device|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
79844017|NCT00658658|Biological|Panitumumab|Panitumumab administered by intravenous infusion
79844018|NCT00723203|Drug|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
79247963|NCT05103098|Drug|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
79386546|NCT01978600|Drug|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
79700985|NCT04564326|Drug|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
79700986|NCT03453164|Radiation|Radiotherapy + Nivolumab|Radiotherapy of 22.5 Gy/5 fractions/5 days will be given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1. Nivolumab will be administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) every 2 weeks to a total of 6 courses of administration.
79700987|NCT04571307|Procedure|cryotherapy|comparison between cryotherapy and surgery
79844019|NCT00723203|Genetic|gene expression analysis|Day 1 and day 28 samples
79844020|NCT00723203|Genetic|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
79844021|NCT00723203|Other|laboratory biomarker analysis|Day 1 and day 28 samples
79844022|NCT00891072|Drug|R-(-)-gossypol acetic acid|Given orally
80013036|NCT02263586|Behavioral|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
80013037|NCT02609048|Drug|Placebo Comparator|Placebo Capsule (2 taken once daily)
79247964|NCT03121287|Other|Imaging Biomarkers|Whole lung volumetric CT scans
79247965|NCT03121287|Other|Pulmonary|Pulmonary Function Tests & 6 minute hall walk
79247966|NCT03121287|Other|Imaging|Cardiac MRI
79247967|NCT03121287|Other|Specimen Collection|Blood draw
79386547|NCT01978600|Drug|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
79386548|NCT03236220|Drug|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
79386549|NCT03107598|Drug|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
79386550|NCT03107442|Behavioral|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous [40-85% of the individual's heart rate reserve] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
79386551|NCT03236064|Drug|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
79386552|NCT03232788|Procedure|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
79386553|NCT03232788|Device|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
79386554|NCT03232788|Device|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
79386555|NCT03232632|Drug|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
79386556|NCT03228810|Other|Blood draw|(2) 10 mL tubes will be collected
79386557|NCT03228810|Procedure|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
79386558|NCT03235908|Other|Observation only|Observation only
79700988|NCT03450434|Drug|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
79700989|NCT03450434|Drug|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
79700990|NCT04564716|Biological|Gam-COVID-Vac|vaccine for intramuscular injection
79700991|NCT04564716|Other|Placebo|placebo comparator
79700992|NCT00198029|Device|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
79844023|NCT00891072|Drug|paclitaxel|Given IV
79844024|NCT00891072|Drug|carboplatin|Given IV
79844025|NCT00891072|Other|pharmacological study|Correlative studies
79844026|NCT02591927|Drug|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
79844027|NCT02591927|Drug|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
79844028|NCT04037046|Behavioral|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
79700993|NCT00197054|Biological|RTS, S/AS01B|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
79700994|NCT00197054|Biological|RTS, S/AS02A|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
79700995|NCT00197054|Biological|Rabipur (Rabies) Vaccine|1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
79700996|NCT04564131|Other|Reflexology|"Hands are washed.~The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~Exercises to warm and relax the feet for five minutes.~General massage is applied to the whole foot for five minutes.~Reflexology massage is applied to the application areas for neuropathic pain.~The individual is helped to take a comfortable position.~Hands are washed."
79700997|NCT04564131|Other|Control|No intervention was performed to reduce pain in the control group
79844029|NCT04037046|Behavioral|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
79844030|NCT04037046|Behavioral|Screening HCV at primary care center|DBS for HCV screening at primary care center
80013038|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
80013039|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
79247968|NCT04272008|Drug|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
79247969|NCT04272008|Other|Tampon|Annovera with tampon use
79247970|NCT03121131|Other|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
79247971|NCT03121131|Other|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
79247972|NCT03121131|Other|No clinical exam findings|No clinical exam findings are given to the radiologists
79247973|NCT04147832|Other|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
79386559|NCT03228654|Procedure|Unipolar Electrocautery sealing of vessels|"Vaginal walls are incised by monoplar current (40 W)~A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~uterine vessels are individually secured.~Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
79700998|NCT04998435|Procedure|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
79844031|NCT00807716|Other|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
79844032|NCT00807716|Other|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
80013040|NCT02262182|Other|KP group|
80013041|NCT02262182|Other|KM group|
80013042|NCT02265068|Drug|Ticagrelor|Treatment of ACS patients with Ticagrelor
80013043|NCT02262338|Drug|AGT-182|Recombinant HIRMAb-IDS
80013044|NCT01678924|Drug|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
80013045|NCT01678924|Drug|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
80013046|NCT02265302|Drug|BIIL 284 oral solution|
80013047|NCT02265302|Drug|BIIL 284 wetability improved formulation (WIF) tablets|
79247974|NCT03120897|Device|RAM sensor|Rainbow Acoustic Monitoring sensor for measurement of respiratory rate
79247975|NCT05107622|Other|FMUD+Probiotic|Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
79247976|NCT05107622|Other|FMUD+Placebo|Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
79386560|NCT03228654|Procedure|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
79386561|NCT03228888|Other|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
79247977|NCT05107388|Device|FreeStyle Libre Pro|Measurements of interstitial glucose variations with FreeStyle Libre Pro
79305540|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
80013048|NCT02265302|Drug|Placebo|
80013049|NCT02263742|Behavioral|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
80013050|NCT02263742|Behavioral|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
80013051|NCT02265380|Device|Placement of IV catheter|
80013052|NCT02262416|Drug|leuprolide|normal saline
80013053|NCT01577654|Drug|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
79700999|NCT04998435|Procedure|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
79701000|NCT00197015|Biological|Havrix®|2 doses administered intramuscularly
79701001|NCT00197015|Biological|M-M-R®II|1 dose administered subcutaneously
79701002|NCT00197015|Biological|VARIVAX®|1 dose administered subcutaneously
79386562|NCT01747499|Drug|Azacitidine|
79701003|NCT04564248|Other|Website access|website access will be provide to families
79701004|NCT02215122|Drug|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
79844033|NCT00891150|Drug|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
79386563|NCT00071721|Drug|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
79386564|NCT00071721|Drug|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
79701005|NCT02215122|Drug|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
79701006|NCT02215122|Drug|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
79701007|NCT00196976|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
79701008|NCT00196976|Biological|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
79701009|NCT00196976|Biological|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
79844034|NCT00800462|Drug|Oxybutynin Cl|15 mg qd for 3 months
80013054|NCT01577654|Drug|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
79386565|NCT03107208|Drug|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
79701010|NCT00196976|Biological|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
79701011|NCT00196976|Biological|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
79701012|NCT04563936|Drug|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
79701013|NCT04563936|Drug|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
80013055|NCT01577654|Drug|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
80013056|NCT01577654|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
80013057|NCT02608502|Biological|RSV-F Vaccine|
80013058|NCT02608502|Biological|Phosphate Buffer Placebo|
80013059|NCT02262494|Procedure|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
79386566|NCT03107208|Device|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
79386567|NCT01717391|Drug|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
79386568|NCT03107364|Other|Hospital stay|Collection of hospital lengths of stay and readmissions
79701014|NCT04572308|Biological|CD7 CAR-T|"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"
79701015|NCT04563975|Drug|Toripalimab|Toripalimab，240mg，d1，Intravenous Infusion，q3w
79701016|NCT04563975|Drug|Docetaxel|Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
79701017|NCT04563975|Drug|nab-paclitaxel|nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
79701018|NCT00196313|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
79701019|NCT00196313|Drug|Placebo tablet|1 tablet daily by mouth
79844035|NCT00800462|Drug|Trospium Cl|20mg bid for 3 months
79844036|NCT00800462|Drug|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
79844037|NCT00233389|Drug|Rebamipide|
79844038|NCT00884520|Drug|[F-18] VM4-037|"The individual doses of [F-18]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
80013060|NCT02262494|Procedure|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
79701020|NCT04563819|Genetic|Genom-wide association study (GWAS) and biological pathway analyses|
79701021|NCT04561440|Diagnostic Test|molecular karyotyping|performed by NGS or CMA chip
79701022|NCT04561479|Other|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
79701023|NCT04561479|Other|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
79701024|NCT04563663|Procedure|Posteriorization of the talus.|Three sets of a 30-s grade IV anteroposterior mobilization.
79701025|NCT00196196|Device|Codman VPV System|Valve Positioning Verification (VPV) System
80013061|NCT02262494|Procedure|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
80013062|NCT02265458|Behavioral|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
80013063|NCT01423058|Drug|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
80013064|NCT01575470|Biological|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
79386569|NCT05606055|Drug|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
79386570|NCT01896609|Biological|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
79386571|NCT01896609|Drug|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
79701026|NCT02211885|Drug|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
79701027|NCT00195650|Biological|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
80013065|NCT02236364|Device|Contour, Bayer Healthcare, LLC|Blood glucose measurement
80013066|NCT05735782|Diagnostic Test|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
80013067|NCT05735782|Diagnostic Test|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
79386572|NCT01896609|Drug|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
79386573|NCT01896609|Drug|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
79386574|NCT03232554|Drug|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
79386575|NCT03232554|Drug|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
79386576|NCT03232554|Drug|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
79386577|NCT05605977|Behavioral|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
79386578|NCT05605977|Behavioral|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
79701028|NCT04563780|Device|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
79701029|NCT04571957|Other|No Intervention|No Intervention
79701030|NCT04560465|Drug|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
79701031|NCT00195494|Drug|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
79701032|NCT00195494|Drug|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
80013068|NCT03135392|Procedure|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
80013069|NCT03135392|Procedure|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
79701033|NCT00195494|Drug|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
79701034|NCT02211144|Drug|BIBR 796 BS|
79701035|NCT02211144|Drug|Placebo|
79701036|NCT00194987|Drug|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
80013070|NCT03135392|Procedure|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
79386579|NCT03232398|Drug|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
79386580|NCT03232398|Drug|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
79386581|NCT04753125|Behavioral|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
79701037|NCT00194987|Drug|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
79844039|NCT02551952|Device|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
80013071|NCT02265536|Drug|LY3022855|Administered IV
79701038|NCT04560855|Device|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
79386582|NCT04753125|Behavioral|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
79701039|NCT00194792|Drug|exemestane|Given PO
80013072|NCT04413292|Diagnostic Test|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
80013073|NCT01418222|Drug|5-FU|Intravenous repeating dose
79247978|NCT05103020|Drug|intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1
79386583|NCT04753125|Behavioral|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
79386584|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
79386585|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC)|See above in arm/group description
79701040|NCT00194792|Drug|triptorelin pamoate|Given IM
79701041|NCT00194792|Drug|capecitabine|Given PO
79701042|NCT00194792|Drug|methotrexate|Given IV
79701043|NCT00194792|Drug|vinorelbine tartrate|Given IV
79701044|NCT00194792|Drug|paclitaxel|Given IV
79844040|NCT01326091|Other|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
80013074|NCT01418222|Drug|FOLFOX regimen|Intravenous repeating dose
79247979|NCT05103020|Drug|IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
79386586|NCT02362048|Drug|ACP-196|
79386587|NCT02362048|Drug|ACP-196 in combination with pembrolizumab|
79386588|NCT03232242|Diagnostic Test|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
79386589|NCT03232476|Device|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
79701045|NCT00194792|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
79701046|NCT00194792|Radiation|radiation therapy|Undergo radiation therapy
79701047|NCT00194792|Other|laboratory biomarker analysis|Correlative studies
79701048|NCT02486367|Drug|Clopidogrel|Standard ADP receptor blockade
79701049|NCT02486367|Drug|Ticagrelor|High potency ADP receptor blockade
80013075|NCT01418222|Drug|Placebo|Intravenous repeating dose
80013076|NCT01418222|Drug|bevacizumab [Avastin]|Intravenous repeating dose
80013077|NCT01418222|Drug|leucovorin|Intravenous repeating dose
80013078|NCT01418222|Drug|onartuzumab [MetMAb]|Intravenous repeating dose
80013079|NCT05092906|Other|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
79701050|NCT02211183|Procedure|Best Repair of torn Rotator Cuff|
79701051|NCT02211183|Device|InSpace™ system|
79701052|NCT00194675|Drug|Dutasteride|Dutasteride 0.5 mg orally daily
79701053|NCT00194675|Drug|Testosterone gel|Testosterone gel 7.5 g daily topical
79701054|NCT00194675|Drug|Placebo dutasteride|placebo dutasteride orally daily
79701055|NCT04560387|Behavioral|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
79701056|NCT04560387|Procedure|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
79701057|NCT04560348|Other|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
79701058|NCT00194012|Drug|Aripiprazole|Addressed in arm description.
79701059|NCT00194012|Drug|Placebo|Addressed in arm description.
79701060|NCT04563351|Other|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
79844041|NCT02543190|Behavioral|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
79386590|NCT00158223|Drug|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
79844042|NCT03973801|Other|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
80013080|NCT05092906|Other|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~EMLA (Lidocain+Prilocain) Cream/Patch~Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~Nitrous oxide"
79701061|NCT00192647|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
80013081|NCT01413932|Drug|HT-2157|QD oral dosing
80013082|NCT01413932|Drug|Placebo|QD oral dosing
80013083|NCT02925793|Drug|DS107|
80013084|NCT02925793|Other|Vehicle cream|
80013085|NCT01256762|Drug|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
79701062|NCT00192647|Drug|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
79701063|NCT04563312|Procedure|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
80013086|NCT01256762|Drug|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
80013087|NCT01256762|Drug|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
80013088|NCT03135158|Other|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
79386591|NCT00158223|Drug|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
79701064|NCT00192296|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
79701065|NCT00192296|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
79701066|NCT00192296|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
79844043|NCT00887094|Behavioral|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
79701067|NCT00192296|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
79701068|NCT04563429|Dietary Supplement|Oral Vitamin A|Oral administration of 5000 EU of Vitamin A during first 28 days of life
79701069|NCT00192023|Drug|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
79701070|NCT00192023|Drug|placebo|
79701071|NCT00192023|Drug|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
79844044|NCT00887094|Behavioral|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
80013089|NCT02268188|Other|education|Attend classes as part of Harvesting Health program
80013090|NCT02268188|Other|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
80013091|NCT02268188|Behavioral|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
80013092|NCT02268188|Other|questionnaire administration|Ancillary studies
80013093|NCT02268188|Other|laboratory biomarker analysis|Correlative studies
80013094|NCT02268188|Other|quality-of-life assessment|Ancillary studies
80013095|NCT04351945|Procedure|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
79386592|NCT03228576|Combination Product|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
79701072|NCT00192023|Drug|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
79701073|NCT04563624|Drug|composite blocks|cad cam composite blocks
79701074|NCT04563624|Drug|ceramic cad cam blocks|ceramic cad cam blocks
79701075|NCT00191984|Drug|pemetrexed|400 mg/m^2, intravenous (IV), every 14 days x 12 cycles
79701076|NCT00191984|Drug|irinotecan|180 mg/m^2, intravenous (IV), every 14 days x 12 cycles
79844045|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
79844046|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
79701077|NCT04560426|Device|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
79701078|NCT04560270|Diagnostic Test|Blood samples|Blood samples to determine ctDNA levels during chemotherapy
79701079|NCT00191906|Drug|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
79701080|NCT00191906|Drug|placebo|Placebo, every day (QD), by mouth (PO)
79701081|NCT04562922|Dietary Supplement|Lifemel|
79701082|NCT00191789|Drug|gemcitabine|1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
79844047|NCT02542878|Device|Foam roller|A bout of 60 seconds of myofascial release with foam roller
79844048|NCT00884598|Drug|cilengitide|
79844049|NCT00884598|Other|pharmacological study|
79844050|NCT00884598|Radiation|radiation therapy|
79844051|NCT02552264|Behavioral|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
79844052|NCT00891306|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
79844053|NCT00891306|Drug|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
79844054|NCT00891306|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
79844055|NCT00891306|Drug|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
79844056|NCT02552108|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|
79844057|NCT00807794|Drug|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
79844058|NCT00807794|Drug|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
79844059|NCT00807794|Drug|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
80013096|NCT05761717|Drug|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
80013097|NCT01252628|Drug|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
80013098|NCT01252628|Drug|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
79386593|NCT00158379|Drug|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
79386594|NCT03235674|Other|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
79386595|NCT03228498|Drug|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
79386596|NCT03228498|Drug|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
79386597|NCT02362672|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
79386598|NCT02362672|Drug|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
79701083|NCT00191789|Drug|doxorubicin|60 mg/m^2, IV, every 21 days x 4 cycles (1-4)
79701084|NCT00191789|Drug|cisplatin|70 mg/m^2, IV, every 21 days x 4 cycles (5-8)
79701085|NCT00191789|Procedure|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
79701086|NCT00191282|Drug|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
79701087|NCT00191282|Drug|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values >8.0%
79701088|NCT00191282|Drug|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
79701089|NCT00191282|Drug|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
79701090|NCT00191282|Drug|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values >8.0%.
79701091|NCT04563156|Diagnostic Test|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
79701092|NCT04559958|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
79701093|NCT04559997|Other|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
79701094|NCT04559997|Other|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
79701095|NCT00191165|Drug|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
79701096|NCT00191165|Drug|Somatropin|In-label dosage
79844060|NCT00807794|Drug|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
79844061|NCT00807794|Drug|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
79844062|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
79844063|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
79701097|NCT04560231|Drug|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
79247980|NCT04495491|Other|pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
79701098|NCT04560153|Other|karate kata|sessions of karate kata every week during 4 months
79701099|NCT00190775|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
79701100|NCT00190775|Drug|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
79701101|NCT02211924|Drug|BI 44847|
79701102|NCT02211924|Drug|Placebo|
79701103|NCT00199901|Biological|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
79701104|NCT00199901|Biological|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
79701105|NCT00198263|Combination Product|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
79701106|NCT04562844|Other|sociale cognition|several social cognition test
79701107|NCT00198107|Drug|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
79247981|NCT04495491|Other|plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
79386599|NCT03232320|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
79386600|NCT03232320|Drug|Placebo|Placebo (Normal saline)
79541779|NCT01496651|Procedure|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
79701108|NCT00198107|Drug|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
79701109|NCT00198107|Drug|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
79701110|NCT04563000|Drug|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
79701111|NCT04563000|Drug|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
80013099|NCT01252628|Drug|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
80013100|NCT01252628|Drug|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
79247982|NCT04495491|Other|mixing mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
79247983|NCT05076188|Diagnostic Test|Emergency radiography|The intervention is to determine how the radiographer classify emergency radiography.
79247984|NCT05107076|Diagnostic Test|2D Echocardiography with color Doppler assessment & Galactin-3 level in blood|"Measurements will be~Pulsed wave (PW) Doppler~E (early diastolic)/A (late diastolic) - Using PW Doppler~IVRT (isovolumic relaxation time)~Deceleration time (DT) - from the peak of E wave to baseline.~E/e'- PW tissue Doppler imaging (TDI)~Left atrial volume and left atrial volume index (LAVI)~Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level."
79386601|NCT03232086|Other|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
79386602|NCT03232086|Other|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
79386603|NCT00158925|Device|EASYTRAK EPI lead|EASYTRAK EPI lead
79386604|NCT03235596|Device|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
79386605|NCT03232008|Dietary Supplement|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
79386606|NCT03232008|Dietary Supplement|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
79386607|NCT02364076|Drug|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
79386608|NCT02364076|Drug|Epacadostat|100mg taken by mouth twice daily
79701112|NCT04562961|Other|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
79701113|NCT00179660|Drug|Lenalidomide|Capsules for oral administration.
79844064|NCT04045418|Device|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
79844065|NCT00807872|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
79247985|NCT04495335|Device|photobiomodulation|Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
79247986|NCT04498455|Dietary Supplement|Prebiotin|Fructo-oligosaccharide dietary supplement powder
79247987|NCT03344367|Biological|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
79247988|NCT03344289|Diagnostic Test|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
79247989|NCT02657408|Drug|BI 1026706|
79247990|NCT02657408|Drug|Placebo|
79247991|NCT02841709|Drug|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
79247992|NCT02841709|Drug|Placebo|Capsules for oral administration matching the ACT-541468 capsules
79247993|NCT02506491|Other|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
79247994|NCT02506491|Other|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
79247995|NCT02506491|Other|Control Group|No exercise
79247996|NCT05374148|Behavioral|health education|health education to prevent respiratory diseases among workers
79247997|NCT02501109|Drug|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
79247998|NCT03938246|Drug|TVB-2640|Oral dose, tablet, daily dosing
79386609|NCT03235440|Behavioral|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
79386610|NCT03231930|Device|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
79386611|NCT03231930|Device|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
79247999|NCT03938246|Other|Placebo|Oral dose, tablet, daily dosing
79248000|NCT04498533|Other|forearm strap (counterforce brace)|
79248001|NCT04498533|Other|Kinesio tape application|
79541780|NCT01496651|Procedure|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
79541781|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
79541782|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
79541783|NCT01496690|Drug|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
79701114|NCT00178256|Drug|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
79701115|NCT00178256|Procedure|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
79844066|NCT00813722|Behavioral|phone call|patients received or not phone calls to give orientation abou treatment
79701116|NCT02211222|Drug|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
79701117|NCT04560192|Behavioral|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~Waiting period with TAU."
79844067|NCT00813722|Drug|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
79386612|NCT02364700|Device|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~warm up-passive stretch of hand in flexion and extension (5 minutes);~setting the EMG threshold parameters for the device;~active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~active practice of closing then hand (UFO Catcher game; 10 min)~open and closing the hand (Ball and Basket game; 10 min)~open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~cool down-passive stretch of hand in flexion and extension (5 minutes)"
79386613|NCT02453022|Drug|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
79386614|NCT02453022|Drug|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
79386615|NCT02453022|Drug|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
79386616|NCT03231852|Other|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
79386617|NCT02365714|Radiation|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
79386618|NCT03235752|Drug|TJ301 300mg|TJ301 300mg IV infusion
79386619|NCT03235752|Drug|TJ301 600mg|TJ301 600mg IV infusion
79386620|NCT03235752|Drug|Placebo|Placebo IV infusion
79386621|NCT00163293|Drug|Ciclesonide|Ciclesonide metered-dose inhaler
79386622|NCT00163293|Drug|Placebo|Ciclesonide placebo-matching metered-dose inhaler
79386623|NCT03231618|Dietary Supplement|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
79386624|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
79386625|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
79541784|NCT01496690|Drug|Pregabalin Placebo Capsules|Parallel to Active Comparator
79541785|NCT01496703|Other|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
79541786|NCT01496716|Procedure|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
79541787|NCT01496729|Procedure|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
79844068|NCT00813722|Drug|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
79844069|NCT00812318|Drug|GSK1265744 10 mg oral solution|GSK1265744
79844070|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
79844071|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
79386626|NCT02033200|Drug|Stendra 200 mg|
79386627|NCT02033200|Drug|Placebo|
79386628|NCT00076245|Behavioral|Light Therapy|Light therapy will involve exposure to bright light twice a day.
79541788|NCT01496729|Procedure|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
79541789|NCT01496742|Drug|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
79541790|NCT01496742|Drug|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
79541791|NCT01496742|Drug|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
79541792|NCT01496742|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
79541793|NCT01496742|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
79541794|NCT01496742|Drug|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
79541795|NCT01496755|Drug|Placebo|Single/multiple doses
79541796|NCT01496755|Drug|RG7667|Single/multiple ascending doses
79541797|NCT01496768|Dietary Supplement|Leucine|7,2 g/day during 3 months
79541798|NCT01496768|Dietary Supplement|Alanine|7,2 g/day during 3 months
79541799|NCT01496781|Procedure|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
79701118|NCT04560192|Other|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"Waiting period with TAU.~In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
79701119|NCT00177164|Drug|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
79844072|NCT00812396|Drug|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
79844073|NCT00812396|Drug|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
79386629|NCT00076245|Behavioral|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
79386630|NCT03231384|Device|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
79844074|NCT00812396|Drug|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
79844075|NCT00807950|Drug|Simvastatin|
79844076|NCT02552030|Device|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
79844077|NCT02552030|Device|iPhone 4s|
79844078|NCT00649220|Drug|Memantine|memantine tablets, twice a day (bid), for 20 weeks
79844079|NCT00812630|Drug|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
79844080|NCT00813878|Genetic|protein analysis|protein analysis
79844081|NCT00813878|Genetic|protein expression analysis|protein expression analysis
79844082|NCT00813878|Genetic|proteomic profiling|proteomic profiling
79844083|NCT00813878|Other|diagnostic laboratory biomarker analysis|Performed one time on study
79844084|NCT00813878|Other|immunohistochemistry staining method|Performed one time on study
79844085|NCT00813878|Other|liquid chromatography|Performed on samples collected one time on study
79386631|NCT02365870|Drug|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
79541800|NCT01496781|Procedure|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
79541801|NCT01496820|Dietary Supplement|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
79541802|NCT01496820|Dietary Supplement|Placebo|placebo 1500mg/day for 12weeks
79541803|NCT01496833|Device|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
79844086|NCT00813878|Other|mass spectrometry|Performed on samples collected one time on study
79844087|NCT00813878|Procedure|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
79844088|NCT00813878|Procedure|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
79844089|NCT00813878|Procedure|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
79844090|NCT02551640|Other|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
79844091|NCT00654368|Biological|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
79844092|NCT00654368|Drug|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
79844093|NCT04017026|Device|Implantation|Implantation of 6 mm short implants
79844094|NCT00812864|Drug|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
79844095|NCT00808184|Drug|CPT-11, Raltegravir (Isentress®), Midazolam|
79386632|NCT02365870|Drug|placebo|Participants will receive a placebo transdermal patch to be worn daily
79386633|NCT03228108|Drug|Ciprofloxacin|see study arms.
79386634|NCT03228108|Drug|Trimethoprim/Sulfamethoxazole|see study arms.
79541804|NCT01496859|Device|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
79541805|NCT01496911|Drug|Levocetirizine|a single oral dose of 5 mg
79541806|NCT01496911|Drug|Hydroxyzine|a single oral dose of 50 mg
79541807|NCT01496911|Drug|Placebo|a single oral dose
79541808|NCT01496924|Other|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
79844096|NCT02551562|Other|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
79701120|NCT04559841|Other|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
79844097|NCT02551562|Other|Placebo|Basic skin care regimen
79844098|NCT00814190|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
79844099|NCT00812942|Procedure|colonoscopy|colonoscopy screening
79844100|NCT00812942|Procedure|faecal test|faecal occult blood test for screening
79701121|NCT02487251|Behavioral|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
79701122|NCT02487251|Behavioral|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
79701123|NCT02489942|Drug|Jardiance|Empagliflozin
79844101|NCT00647426|Drug|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
79844102|NCT00647348|Drug|Simvastatin|80mg simvastatin oral once daily for 24 months
79844103|NCT00647348|Drug|Placebo|Oral placebo tablet once daily for 24 months
79844104|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
79844105|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
79844106|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
79541809|NCT01496937|Drug|GLPG0974|
79541810|NCT01496937|Drug|GLPG0974|
79844107|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
79386635|NCT03228108|Drug|Fosfomycin|see study arms.
79386636|NCT03228108|Drug|Pivmecillinam/augmentin|see study arms.
79386637|NCT01981564|Behavioral|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
79541811|NCT01496950|Device|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
79541812|NCT01496950|Device|Placebo|10Hz placebo rTMS delivered to the vertex
79248002|NCT02245399|Behavioral|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
79248003|NCT02245399|Behavioral|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
79248004|NCT05060666|Drug|Ivermectin|"2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~15 mg for 40-60 kg = 5 tablets à 3 mg~18 mg for 60-80 kg = 6 tablets à 3 mg~24 mg for > 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg."
79248005|NCT05060666|Drug|Placebo|"An analogous number of tablets is administered for placebo:~5 tablets for 40-60 kg~6 tablets for 60-80 kg~8 tablets for > 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin."
79305541|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
79386638|NCT01981564|Behavioral|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
79386639|NCT03235128|Diagnostic Test|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
79541813|NCT01496989|Biological|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
79541814|NCT01496989|Biological|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
79541815|NCT01496989|Biological|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
79541816|NCT01496989|Biological|Ad35-GRIN/ENV|(2x10^10vp) Delivered intramuscularly by standard needle injection
79701124|NCT04562493|Procedure|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
79701125|NCT04562571|Other|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
79701126|NCT04559568|Drug|LY3522348|Administered orally.
79844108|NCT00647270|Drug|Placebo|Pre-filled syringe. See arm for more detail
79844109|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
79844110|NCT00813254|Behavioral|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
79844111|NCT00645944|Drug|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
79844112|NCT00645944|Drug|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
79844113|NCT03869840|Device|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
79701127|NCT04559568|Drug|Placebo|Administered orally.
79701128|NCT04559568|Drug|Midazolam|Administered orally to some participants.
79701129|NCT02211300|Device|The OptiScanner|treatment of blood glucose per standard of care
79701130|NCT02211300|Device|YSI 2300 STAT Plus™|
79701131|NCT02211339|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
79701132|NCT02211339|Other|Usual care|Staff-led social activity
79701133|NCT00176462|Drug|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79844114|NCT00813332|Drug|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
79701134|NCT00176462|Drug|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701135|NCT00176462|Drug|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701136|NCT00176462|Drug|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701137|NCT00176462|Drug|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701138|NCT00176462|Drug|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79386640|NCT00078897|Drug|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
79701139|NCT00176462|Drug|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79844115|NCT00813332|Drug|Placebo plus Docetaxel|Placebo plus Docetaxel
79386641|NCT01746017|Drug|Placebo|Administered orally as capsules
79386642|NCT01746017|Drug|LY2922470|Administered orally as capsules
79541817|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
79541818|NCT01497002|Biological|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
79541819|NCT01497028|Procedure|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
79541820|NCT01497041|Drug|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
79541821|NCT01497041|Drug|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
79541822|NCT01497093|Drug|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
79541823|NCT01497093|Drug|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
79701140|NCT00176462|Drug|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701141|NCT00176462|Drug|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701142|NCT00176462|Drug|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
79701143|NCT00176462|Drug|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
79701144|NCT00176462|Drug|Leucovorin|
79844116|NCT04708496|Drug|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
79844117|NCT00646958|Drug|Radezolid|450mg PO QD
79844118|NCT00646958|Drug|Radezolid|450mg PO BID
79844119|NCT00646958|Drug|Linezolid|600mg PO BID
79844120|NCT00813410|Procedure|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
79701145|NCT04559295|Biological|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
79541824|NCT01497093|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
79701146|NCT02211378|Other|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
79701147|NCT02211378|Other|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
79701148|NCT00175019|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
79844121|NCT04045808|Other|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
79541825|NCT01497106|Behavioral|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
79541826|NCT01497106|Behavioral|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
79844122|NCT00817544|Drug|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
79844123|NCT00642746|Drug|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
79844124|NCT00642746|Drug|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
79844125|NCT00642746|Drug|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
79701149|NCT00175019|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
79248006|NCT02508129|Behavioral|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
79701150|NCT00175019|Drug|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
79701151|NCT04559763|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
79701152|NCT04559763|Other|Introduction of Motion conditions: tapping or rubbing|Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
79701153|NCT00174941|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
79844126|NCT00642746|Drug|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
79844127|NCT00642746|Drug|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
79386643|NCT05234502|Other|Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.
79386644|NCT05234502|Other|Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)|A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
79386645|NCT03228030|Dietary Supplement|Thiamine|Capsules
79386646|NCT03228030|Dietary Supplement|Placebo|Identical capsules
79386647|NCT02091531|Drug|MLN0128|
79386648|NCT02367430|Behavioral|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
79701154|NCT00174941|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
79844128|NCT00814268|Drug|Clopidogrel|75mg tablet, oral administration once daily
79844129|NCT00814268|Drug|Clopidogrel placebo|Matching tablet, oral administration once daily
79386649|NCT03227952|Device|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
79386650|NCT03227796|Drug|LEVI-04|LEVI-04 intravenous infusion
79386651|NCT03227796|Drug|Placebo|Placebo intravenous infusion
79386652|NCT03227718|Behavioral|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
79386653|NCT01717313|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
79386654|NCT01717313|Drug|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
79541827|NCT01497119|Drug|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
79541828|NCT01497119|Drug|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
79844130|NCT00814268|Drug|Aspirin|100mg tablet, oral administration once daily
79386655|NCT01717313|Drug|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
79541829|NCT01497119|Drug|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
79541830|NCT01497132|Drug|Vitamin D3|Oral drops 30000 IU weekly
79541831|NCT01497132|Drug|Placebo|Matching placebo
79541832|NCT01497145|Drug|KRN321|
79541833|NCT01497158|Other|Self-help brochure|Self help brochure given at baseline visit.
79541834|NCT01497158|Other|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
79541835|NCT01497223|Drug|MGCD290|1 Oral Dose Administration
79541836|NCT01497236|Dietary Supplement|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
79541837|NCT01497249|Dietary Supplement|A dietary fiber (FCHO)|15 g twice per day in beverage
79541838|NCT01497249|Dietary Supplement|Placebo|Placebo drink
79541839|NCT01497288|Drug|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
79541840|NCT01497301|Behavioral|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
79541841|NCT01497314|Other|Low Lactose Infant Formula|Low Lactose Infant Formula
79701155|NCT00174941|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
79701156|NCT04558944|Device|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
79701157|NCT04562727|Drug|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
79701158|NCT00171704|Drug|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
79701159|NCT00171704|Drug|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
79701160|NCT04559061|Device|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
79386656|NCT01717313|Drug|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
79541842|NCT01497327|Drug|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
79541843|NCT01497327|Drug|PSI-7977|PSI-7977 400mg QD for seven days
79541844|NCT01497340|Other|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
79541845|NCT01497340|Other|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
79541846|NCT01497353|Procedure|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
79541847|NCT01497353|Procedure|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
79541848|NCT01497379|Procedure|surgical implantation of subretinal device|surgical implantation of subretinal device
79701161|NCT02211963|Drug|BI 44847|
80013101|NCT05206669|Behavioral|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
79541849|NCT01497379|Procedure|surgical implantation of subretinal device|intra-individual implant OFF
79541850|NCT01497405|Behavioral|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
79541851|NCT01497405|Biological|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
79541852|NCT01497431|Dietary Supplement|Selenium|Given PO
79541853|NCT01497431|Other|Placebo|Given PO
79541854|NCT01497431|Other|Laboratory Biomarker Analysis|Correlative studies
79541855|NCT01497431|Other|Pharmacological Study|Correlative studies
79541856|NCT01497431|Drug|Methylselenocysteine|Given PO
79701162|NCT02211963|Drug|Placebo|
79701163|NCT00171314|Drug|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
79701164|NCT00171314|Drug|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
80013102|NCT01239758|Biological|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
79844131|NCT00808262|Biological|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
79844132|NCT00817622|Dietary Supplement|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
79844133|NCT00808418|Drug|Elesclomol Sodium|Chemotherapy agent
79844134|NCT00808418|Drug|Docetaxel|Chemotherapy agent
79844135|NCT00817700|Other|Sleep restriction|Sleep restriction.
79386657|NCT01717313|Drug|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
79386658|NCT03231540|Dietary Supplement|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
79386659|NCT00080535|Biological|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
79386660|NCT01897545|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
79386661|NCT01897545|Procedure|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
79386662|NCT03222804|Dietary Supplement|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
79386663|NCT05061381|Behavioral|A Lust for Life Schools Programme|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
79541857|NCT01497444|Drug|hypoxia-activated prodrug TH-302|
79541858|NCT01497444|Drug|sorafenib tosylate|
79541859|NCT01497457|Procedure|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
79541860|NCT01497470|Drug|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
79701165|NCT04562259|Radiation|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
79701166|NCT04571918|Procedure|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
80013103|NCT01239758|Biological|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
79386664|NCT01745393|Behavioral|Clinic Quality Improvement + Behavioral Counseling|
79701167|NCT04571918|Procedure|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
79701168|NCT04562454|Other|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
79701169|NCT04562337|Drug|SHR1316|Anti-PD-L1 antibody
79541861|NCT01497483|Drug|Pravastatin alone|Pravastatin 40 mg with placebo.
79701170|NCT04562337|Drug|Chemotherapy|Carboplatin
79701171|NCT04562337|Drug|Chemotherapy|etoposide
79701172|NCT04562337|Radiation|Radiation therapy|thoracic radiation therapy ,TRT
79701173|NCT00171158|Drug|imatinib mesylate|
79844136|NCT04572152|Biological|AK119|Subjects will receive AK119 by intravenous administration.
79844137|NCT04572152|Biological|AK104|On the same day subjects will receive AK104 by intravenous administration.
79844138|NCT00642668|Drug|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
79844139|NCT00817934|Drug|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
79844140|NCT00814424|Device|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
79844141|NCT00814424|Device|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
79844142|NCT00729833|Drug|CP-751,871|CP-751,871 IV, every 3 weeks
79844143|NCT00729833|Drug|Sunitinib|Sunitinib - daily dosing
79844144|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
79844145|NCT00645788|Drug|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
80013104|NCT01239758|Biological|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
80013105|NCT05206045|Other|Standard of care|Standard of care for patients with Sezary Syndrome
79541862|NCT01497483|Drug|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
79701174|NCT04562415|Device|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
79701175|NCT04562415|Device|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
79701176|NCT04562415|Device|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
79701177|NCT00170846|Drug|Everolimus (RAD001)|
79701178|NCT00170846|Drug|Calcineurin Inhibitors (CNI)|
79701179|NCT00170846|Drug|Mycophenolate acid (MPA)/Azathioprine (AZA)|
79248007|NCT02508129|Behavioral|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
79248008|NCT02508129|Behavioral|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
79248009|NCT05106842|Other|Hydrotherapy|Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
79701180|NCT00170846|Drug|Steroids|
80013106|NCT01236638|Drug|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
79248010|NCT05106842|Other|Land-based Therapy|Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
79386665|NCT01745393|Behavioral|Clinic Quality Improvement + Attention Control|
79701181|NCT04562025|Drug|UC-MSCs|3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
79386666|NCT00081861|Drug|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
79386667|NCT00081861|Drug|Rituximab|375 mg/m^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
79386668|NCT03120234|Drug|Dexmedetomidine|
79386669|NCT03120234|Drug|Ketamine|
79248011|NCT03573895|Other|Foam-Roller|Application of foam roller in the posterior part of thigh.
79386670|NCT03120234|Drug|Fentanyl|
79386671|NCT03120234|Drug|Placebos|o.9% normal saline will be used instead of ketamine
79541863|NCT01497522|Drug|Vildagliptin|vildagliptin 50 mg twice daily
79844146|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
79844147|NCT00645788|Drug|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
79844148|NCT00808496|Other|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
79386672|NCT03119922|Other|No intervention|
79386673|NCT03222726|Other|exercise group|less than 6000 steps/day or 40,000 steps/week
79386674|NCT03230760|Device|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
79386675|NCT03230682|Drug|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
79541864|NCT01497522|Drug|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
79541865|NCT01497535|Drug|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
79701182|NCT04562025|Drug|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
79701183|NCT04562142|Device|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
79701187|NCT04562103|Drug|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
79701188|NCT04562103|Drug|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
79701189|NCT02278380|Other|Low GI Standard Breakfast|Low GI Standard Breakfast
79701190|NCT02278380|Other|Medium GI Standard Breakfast|Medium GI Standard Breakfast
79701191|NCT02278380|Other|Enfamama A+|Nutritional pregnant milk supplement
79844149|NCT00808496|Other|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
79844150|NCT00808496|Other|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
79844151|NCT00814736|Drug|UK369,003|oral tablet, once a day
79844152|NCT00814736|Drug|sildenafil|single oral dose on day 14 or day 17
79248012|NCT03573895|Other|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
79248013|NCT03573895|Other|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
79248014|NCT02508051|Behavioral|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
79248015|NCT02508051|Behavioral|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
79248016|NCT04991168|Other|Questionnaire|Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
79386676|NCT03120546|Device|rigid video stylet intubation|intubation using rigid video stylet
79386677|NCT03120546|Device|video laryngoscope intubation|intubation using video laryngoscope
79386678|NCT02367820|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
79844153|NCT00814736|Drug|sildenafil matching placebo|single oral dose on day 14 or day 17
79386679|NCT03227874|Dietary Supplement|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
79386680|NCT03227874|Dietary Supplement|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
79386681|NCT03222258|Behavioral|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
79701192|NCT02278380|Other|Glucerna Triple Care|Nutritional product for diabetics
79701193|NCT02278380|Other|Dumex Precima|Pregnant and lactation women milk powder
79701194|NCT02278380|Other|Diasip|Nutritional drinks for diabetics
79844154|NCT00818090|Drug|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
79844155|NCT03869606|Device|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
79386682|NCT03222258|Behavioral|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
79701195|NCT02278380|Other|Test product|Test product not patented yet
79701196|NCT04561635|Dietary Supplement|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
79701197|NCT04561674|Other|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
79701198|NCT04558671|Other|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
79701199|NCT00479882|Drug|Comparator: simvastatin|
79701200|NCT00479882|Drug|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
79701201|NCT00479882|Drug|Placebo|
79701202|NCT00479882|Drug|MK-0524B|
79701203|NCT00479765|Drug|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
79701204|NCT04558242|Device|Genix|Low Level Light (LEDs)
79701205|NCT04558242|Device|Sham|Incandescent Bulbs Colored Red
79701206|NCT00479687|Device|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
79701207|NCT00479687|Device|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
79701208|NCT02212002|Drug|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
79701209|NCT02212080|Drug|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
79701210|NCT02212080|Drug|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
79701211|NCT00479336|Drug|OPC-41061 7.5mg|7.5mg, 1 tablet a day
79701212|NCT00479336|Drug|OPC-41061 placebo|placebo, 1 tablet a day
79701213|NCT00479336|Drug|OPC-41061 15mg|15mg, 1 tablet a day
79701214|NCT00479336|Drug|OPC-41601 30mg|30mg, 1 tablet a day
79701215|NCT02212158|Behavioral|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
79701216|NCT00478244|Drug|busulfan|Day -9 through Day -6: 1.1 mg/kg if < 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
79844156|NCT00642356|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
79844157|NCT00642356|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
79844158|NCT00642278|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
80013107|NCT04349371|Drug|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
80013108|NCT04349371|Drug|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
79541866|NCT01497535|Drug|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
79248017|NCT02507895|Device|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
79248018|NCT04935320|Drug|HTL0016878.HCl Solution 10 mg|Oral solution fasted
79248019|NCT04935320|Drug|HTL0016878.Citrate Capsule 10 mg|Oral capsule fed or fasted
79541867|NCT01497548|Drug|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
79701217|NCT00478244|Drug|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
79701218|NCT00478244|Drug|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
79701219|NCT00478244|Procedure|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
79701220|NCT02212236|Other|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
79844159|NCT00642278|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
79844160|NCT00642278|Drug|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
79844161|NCT00808574|Behavioral|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
80013109|NCT01410188|Drug|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
80013110|NCT01410188|Drug|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
80013111|NCT01410188|Drug|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
79541868|NCT01497548|Drug|Placebo|Placebo given on morning (0800) and noon (1200)daily
79541869|NCT01497561|Drug|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
79541870|NCT01497561|Drug|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
79701221|NCT04558437|Other|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
79844162|NCT00543543|Biological|Comparator: GARDASIL|GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
79844163|NCT00543543|Biological|Experimental: V503|V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
79844164|NCT00812786|Drug|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
79844165|NCT00645164|Other|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
79844166|NCT00645164|Drug|Xenaderm|20 mg under Finn chambers
79844167|NCT00815048|Drug|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
79844168|NCT00815048|Drug|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
80013112|NCT01408082|Drug|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
80013113|NCT01408082|Drug|Azasite|Azasite twice daily for 2 weeks
80013114|NCT01408082|Drug|Dexamethasone|Dexamethasone twice daily for 2 weeks
80013115|NCT01408082|Other|Vehicle|Vehicle twice daily for 2 weeks
79701222|NCT00478205|Drug|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
79701223|NCT00478205|Drug|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
79701224|NCT00477971|Biological|filgrastim|No administration information given
79701225|NCT00477971|Drug|dexamethasone|Given orally
79701226|NCT00477971|Drug|melphalan|Given IV or orally
79844169|NCT02551796|Procedure|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
79844170|NCT02551796|Procedure|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
79844171|NCT02551796|Procedure|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
79844172|NCT00808652|Other|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
79844173|NCT02551484|Device|Measurements using NIRS|
79844174|NCT02551484|Device|TCPO2 measurements|
79844175|NCT02551484|Other|2-minute walk test|
79844176|NCT00723125|Drug|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
79844177|NCT00723125|Drug|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
79248020|NCT02506335|Drug|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
79248021|NCT04498299|Diagnostic Test|echocardiogram 2D|The patient is accelerating against a workload that gradually increases at a constant rate during the exercise, images will be obtained by echocardiography. The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms.
79844178|NCT00723125|Drug|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
79844179|NCT00815126|Procedure|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
79844180|NCT02594189|Other|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
79844181|NCT04044638|Other|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G * Tech-branded automatic digital device (MASTER model).
79844182|NCT00808730|Procedure|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
80013116|NCT03071263|Drug|Patiromer|2 packets/day starting dose, administered orally
80013117|NCT03071263|Drug|Placebo|2 packets/day starting dose, administered orally
80013118|NCT03071263|Drug|Spironolactone|25 mg tablet/day starting dose, administered orally
79701227|NCT00477971|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
79701228|NCT04558086|Device|Virtual reality|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
79701229|NCT04558086|Device|Photo book|To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
79701230|NCT00477464|Drug|Lapatinib|1250mg once daily
79701231|NCT00477464|Drug|capecitabine|2000mg/m^2 twice daily (14 days out of 21 days)
79541871|NCT01497574|Drug|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
79701232|NCT02212275|Drug|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
79701233|NCT04558008|Behavioral|Online MBSR|Described previously
79701234|NCT04557774|Other|Cognitive function test|"Laboratory and imaging test~Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
79701235|NCT00477386|Drug|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
79701236|NCT02212314|Behavioral|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
80013119|NCT04462484|Behavioral|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
79541872|NCT01497574|Drug|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
80013120|NCT02268266|Device|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
79541873|NCT01497587|Drug|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
79248022|NCT04875104|Device|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
79248023|NCT04875104|Device|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
79248024|NCT04875104|Device|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
79541874|NCT01497600|Drug|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
80013121|NCT01546532|Drug|RLX030|RLX030 as intravenous infusion for 24 hours.
80013122|NCT01546532|Drug|Placebo|Intravenous infusion of Placebo over 24 hours
79248025|NCT04875104|Device|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
79248026|NCT01353859|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
79248027|NCT01353859|Drug|methotrexate|10-25 mg orally weekly
79248028|NCT03344133|Behavioral|Exercise|4-week moderate intensity exercise programme
79248029|NCT04855058|Other|online survey(or phone survey)|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over google survey(or the phone survey) for patients.
79248030|NCT02507817|Other|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
79248031|NCT02238197|Drug|Atrovent® Inhalation Solution|
79386683|NCT02036320|Device|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
79386684|NCT03232710|Drug|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
79386685|NCT03232710|Drug|abilify|Aripiprazol orodispersible tablets 10mg
79386686|NCT03227640|Procedure|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
79386687|NCT03227640|Device|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
79541875|NCT01497600|Drug|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
79541876|NCT01497626|Drug|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
79541877|NCT01497639|Device|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
79541878|NCT01497639|Device|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
79541879|NCT01497652|Drug|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
79541880|NCT01497652|Drug|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
79541881|NCT01497678|Device|Extracellular Matrix|Extracellular Matrix
79701237|NCT00477269|Drug|Imatinib mesylate|
79701238|NCT00477269|Drug|Placebo|
79701239|NCT04557852|Procedure|ATVM|Tailored anterior transvaginal mesh for pelvic organ prolapse
79701240|NCT00477152|Drug|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
79701241|NCT04557345|Diagnostic Test|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
79701242|NCT04557345|Diagnostic Test|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
79844183|NCT00722423|Behavioral|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
79844184|NCT00722423|Behavioral|Usual Care Model|
79844185|NCT02593331|Drug|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
79541882|NCT01497691|Device|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
79701243|NCT04557657|Drug|Active bio Activa|Cement that release fluoride
80013123|NCT04314115|Other|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
80013124|NCT04314115|Other|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
80013125|NCT04314115|Other|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
80013126|NCT02265614|Genetic|PGS|
79248032|NCT02500953|Drug|ASP3325|
79248033|NCT02500953|Drug|Placebo|
79541883|NCT01497691|Device|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
79541884|NCT01497691|Device|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
79541885|NCT01497717|Drug|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~Open label treatment period of 24 weeks.~Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
79701244|NCT04557657|Drug|Resin Cement|Resin Cement Convinonal
79701245|NCT00476996|Drug|Leflunomide|Oral repeating dose
79701246|NCT00476996|Drug|Methotrexate|Oral or parenteral repeating dose
79701247|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (200mg)
79701248|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (500mg)
79701249|NCT00476996|Drug|Placebo|Intravenous repeating dose
79701250|NCT04557267|Drug|low-dose|Dosage 1
79701251|NCT04557267|Drug|Middle-dose|Dosage 2
79701252|NCT04557267|Drug|Higher-dose|Dosage 3
79701253|NCT04557267|Drug|Placebo|Placebo
79701254|NCT04557579|Procedure|Clear corneal phacoemulsification and IOL implantation|Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
79701255|NCT02212353|Other|Observational study, not interventional|
79701256|NCT00476957|Device|Stent|Stent implantation
79701257|NCT00476957|Device|Stent|Stent implantation
79248034|NCT03592433|Behavioral|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
79248035|NCT05342714|Device|Remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
79248036|NCT03592355|Other|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
79248037|NCT03571243|Other|no intervention|observational study
79248038|NCT02500875|Device|PTNiA|
79701258|NCT04556955|Device|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
79701259|NCT04556955|Other|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
79701260|NCT00475865|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
79701261|NCT00475865|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
79701262|NCT00475865|Drug|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
79701263|NCT04556877|Procedure|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
79844186|NCT02593331|Other|Placebo|Participants will receive a single dose of placebo on Day 1.
79248039|NCT02500875|Device|PTNiB|
79844187|NCT00640562|Drug|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
80013127|NCT02263898|Drug|Raf kinase inhibitor LGX818|Given PO
80013128|NCT02263898|Drug|binimetinib|Given PO
80013129|NCT02263898|Other|laboratory biomarker analysis|Correlative studies
80013130|NCT01403636|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
80013131|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
80013132|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
80013133|NCT03629509|Behavioral|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
80013134|NCT05200663|Drug|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
80013135|NCT05200663|Drug|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
79701264|NCT00475709|Device|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
79248040|NCT02500875|Device|PTN|
79248041|NCT04436588|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
79248042|NCT03592199|Drug|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
79248043|NCT02245867|Drug|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
79248044|NCT02506413|Other|MamaToto Package|"The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers."
79248045|NCT03591809|Other|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
79248046|NCT02507739|Other|no possibility to walk during labor|
79701265|NCT04556994|Other|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
79701266|NCT04556994|Other|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
79248047|NCT02507739|Other|possibility to walk during labor|
79386688|NCT02451540|Radiation|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
79386689|NCT02451540|Drug|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
79386690|NCT02451540|Drug|Roflumilast|Roflumilast, once a day in the morning during 3 months
79386691|NCT03227484|Drug|Empagliflozin 25mg|Once daily over 8 weeks
79386692|NCT03227484|Drug|Placebo Oral Tablet|Once daily over 8 weeks
79386693|NCT01744691|Drug|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
79386694|NCT01982968|Procedure|Surgery|Full fundoplication surgery for the treatment of abnormal GER
79386695|NCT04485390|Other|Basic life support witn use of an AED before EMS|BLS performance with use of an AED before arrival of EMS
79386696|NCT03230448|Other|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
79701267|NCT04556721|Drug|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
79844188|NCT00640562|Drug|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
79844189|NCT00585923|Device|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
79844190|NCT00585923|Device|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
79844191|NCT04019639|Device|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
79701268|NCT00475670|Drug|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
79701269|NCT00475670|Drug|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
79701270|NCT04557072|Drug|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
79844192|NCT04019639|Device|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
79701271|NCT04557072|Drug|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
79844193|NCT00818558|Biological|ISET Methode|Sampling of blood - ISET Methode
79248048|NCT03573661|Device|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
79248049|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
79248050|NCT02506023|Drug|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
79248051|NCT04876196|Other|Selfapy for Bulimia Nervosa|Web-based intervention for Bulimia Nervosa with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
79541886|NCT01497730|Device|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
79701272|NCT04556760|Drug|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
79701273|NCT04556760|Drug|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
79701274|NCT04556760|Other|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
79701275|NCT00474968|Device|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector [SoftPAP(R)]
79701276|NCT00474968|Device|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
79844194|NCT03955679|Genetic|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
79844195|NCT00815204|Procedure|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
79248052|NCT03828461|Behavioral|Facilitated group therapy with behavioral practice; 16 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
79386697|NCT03230526|Drug|[18F]DPA-714 PET scan|"One PET scan using [18F]DPA-714 is done at M2 between two [123I]FP-CIT scan (DaTscan) done at M1 and M35.~Neuropsychological assessment is done at M0, M18 and M36"
79386698|NCT02038894|Drug|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
79541887|NCT01497743|Drug|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
79541888|NCT01497769|Biological|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10^7 pfu and intradermal saline placebo
79541889|NCT01497769|Biological|Intradermal MVA85A|Intradermal MVA85A 1 x 10^7 pfu and inhaled aerosol saline placebo
79701277|NCT04556799|Procedure|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
79701278|NCT04556799|Procedure|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
79701279|NCT00474929|Drug|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
79701280|NCT00474929|Drug|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
79701281|NCT04556604|Behavioral|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
79701282|NCT04556409|Device|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
79701283|NCT04556409|Device|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
79701284|NCT04556409|Other|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
79701285|NCT00474812|Drug|dasatinib|
79701286|NCT00474812|Procedure|laboratory biomarker analysis|Correlative study
79701287|NCT00474812|Procedure|physiologic testing|Correlative study
79844196|NCT00815204|Procedure|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
79844197|NCT00721955|Drug|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
79541890|NCT01497782|Other|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
79844198|NCT00721955|Drug|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
79302763|NCT03071523|Procedure|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
79701288|NCT04556643|Other|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
79844199|NCT00721955|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
79844200|NCT00585689|Drug|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
79701289|NCT00474383|Drug|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
79844201|NCT00585689|Drug|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
79844202|NCT00585689|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
79844203|NCT00585689|Procedure|Radical Cystectomy|
79386699|NCT02038894|Drug|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
79386700|NCT02038894|Drug|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
79541891|NCT01497821|Drug|AMG 172|AMG 172 is an antibody drug conjugate
79541892|NCT01497210|Device|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
79541893|NCT01497873|Drug|Topotecan|1.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
79541894|NCT01497873|Drug|Belotecan|0.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
79541895|NCT01497886|Behavioral|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
79386701|NCT02038894|Drug|Propofol|
79844204|NCT00721799|Drug|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
79844205|NCT00815282|Other|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
79844206|NCT02591693|Behavioral|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
79844207|NCT00818636|Behavioral|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
79844208|NCT02593019|Drug|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
79701290|NCT00474383|Drug|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
79701291|NCT04556448|Other|Aligners|Clear aligners
79701292|NCT04556448|Other|Clear braces|Clear braces
79701293|NCT00474266|Biological|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
79701294|NCT00474266|Biological|Priorix-Tetra|2-dose subcutaneous injection
79701295|NCT00474266|Biological|Meningitec|Single dose intramuscular injection
79844209|NCT00818714|Radiation|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
79844210|NCT00818792|Device|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
79248053|NCT04497441|Other|Electronic Survey questionnaire|"This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II & III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms."
79248054|NCT04395599|Other|Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.|Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
79248055|NCT02246179|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
79701296|NCT02277821|Device|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
79701297|NCT00473564|Procedure|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
79701298|NCT00472199|Drug|Pramipexole|
79701299|NCT00472199|Drug|Placebo|
79701300|NCT04556331|Behavioral|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
79701301|NCT00472082|Drug|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
79844211|NCT00729365|Drug|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
79844212|NCT00729365|Drug|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
79844213|NCT00729365|Drug|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
79844214|NCT00818870|Drug|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
79844215|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
79248056|NCT02246179|Drug|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
79386702|NCT01716533|Procedure|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
79386703|NCT01716533|Other|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
79386704|NCT01375374|Drug|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
79844216|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
79844217|NCT00922376|Device|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
79248057|NCT02246179|Drug|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
79248058|NCT02507427|Device|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
79248059|NCT02238275|Drug|Micardis® plus|
79248060|NCT03344055|Device|Endocuff Vision (ECV) second generation|"Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope"
79248061|NCT03589235|Procedure|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
79248062|NCT03589235|Device|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
79248063|NCT03589235|Device|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
79386705|NCT01375374|Drug|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
79541896|NCT01497886|Behavioral|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
79541897|NCT01497912|Drug|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
79248064|NCT04602104|Biological|low dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
79541898|NCT01497912|Drug|Placebo|Placebo tablet once daily for 8 weeks
79541899|NCT01497925|Drug|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
79541900|NCT01497951|Other|Aminolaevulinic acid|Photodynamic therapy
79844218|NCT02594267|Drug|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone"
79844219|NCT02594501|Device|COBRA PzF|
79844220|NCT02594501|Device|Drug Eluting Stent|
79248065|NCT04602104|Biological|medium dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
79248066|NCT04602104|Biological|high dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
79386706|NCT04348786|Drug|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
79386707|NCT04348786|Drug|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
79386708|NCT03222336|Behavioral|Family pedigree and data collection|"Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~Collect and analyze medical history, genetic and biochemical assessment data"
79386709|NCT03230370|Other|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
79541901|NCT01497951|Other|Methylcellulose Placebo|Methylcellulose
79541902|NCT01497964|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
79701302|NCT04556136|Device|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
79701303|NCT04556136|Dietary Supplement|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
79248067|NCT04602104|Biological|Dosage 1of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
79248068|NCT04602104|Biological|Dosage 2 of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
79248069|NCT04602104|Biological|No hMSC-derived exosomes|basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
79386710|NCT03230370|Other|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
79386711|NCT02369068|Drug|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
79386712|NCT02369068|Drug|Kenalog|Intravaginal pelvic floor injection one series
79386713|NCT03222024|Other|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
79386714|NCT03230214|Diagnostic Test|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
79386715|NCT03222180|Behavioral|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
79541903|NCT01497977|Drug|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
79541904|NCT01497977|Drug|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
79248070|NCT04495101|Biological|Prolastin|Intravenous infusion 120 mg/kg
79248071|NCT04495101|Drug|Standard Medical Treatment|Standard medical treatment per local policies or guidelines
79248072|NCT03573427|Device|Trans-atrial septal placement LV lead for CRT|
79541905|NCT01497990|Drug|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
79248073|NCT04394117|Drug|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
79248074|NCT04394117|Other|Placebo|Placebo
79541906|NCT01498003|Drug|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
79248075|NCT04745078|Other|Caboxy30|carboxy30 to periorbital dark halos
79701304|NCT04556292|Drug|SC10914|SC10914 400mg tid
79701305|NCT00471887|Biological|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
79844221|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
79844222|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
79844223|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
79844224|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
79248076|NCT04745078|Other|Caboxy60|carboxy60 to periorbital dark halos
79844225|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
79386716|NCT02370004|Procedure|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
79386717|NCT03221790|Other|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
79386718|NCT03221868|Behavioral|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
79386719|NCT03221868|Behavioral|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
79541907|NCT01498003|Drug|normal saline solution|same use as tirofiban
79541908|NCT01498016|Drug|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
79541909|NCT01498029|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
79541910|NCT01498029|Device|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
79541911|NCT01498081|Drug|AZD2115|AZD2115 administered via inhalation
79844226|NCT00254293|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
79541912|NCT01498081|Drug|Placebo|Placebo administered via inhalation
79541913|NCT01498081|Drug|Indacaterol|Indacaterol administered via inhalation
79541914|NCT01498081|Drug|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
79541915|NCT01498094|Procedure|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
79541916|NCT01498094|Other|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
79701306|NCT04556058|Drug|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
79844227|NCT00585221|Drug|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
79844228|NCT00585221|Drug|Imatinib|Continue imatinib until progression.
79541917|NCT01498107|Behavioral|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
79541918|NCT01498133|Procedure|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
79844229|NCT02594033|Drug|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
79386720|NCT01983826|Dietary Supplement|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
79541919|NCT01498159|Behavioral|Pharmacist disease/medication management|
80013136|NCT02268344|Device|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
79386721|NCT01983826|Other|Placebo|Microcrystalline cellulose (daily) for 8 weeks
79541920|NCT01498159|Behavioral|Pharmacist-patient encounters|
79541921|NCT01498159|Behavioral|Pharmacist medication intensification and adherence support|
79541922|NCT01498159|Behavioral|Pharmacist communication with primary care physicians|
79541923|NCT01498159|Behavioral|Pharmacist documentation in electronic medical record|
79541924|NCT01498159|Behavioral|Health promoter-patient encounters in-person or by phone|
79541925|NCT01498159|Behavioral|Health promoter medication and lifestyle support|
79701307|NCT04556058|Drug|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
79386722|NCT03229980|Drug|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
79701308|NCT00471536|Drug|pazopanib hydrochloride|800 mg Given orally
79386723|NCT03229980|Drug|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
79386724|NCT02452632|Drug|ASP1941|oral
79386725|NCT02452632|Drug|Placebo|oral
79386726|NCT02371252|Drug|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
79541926|NCT01498159|Behavioral|Health promoter communication with pharmacists|
79541927|NCT01498172|Biological|MAGE-A3 ASCI|5 doses every 3 weeks
79701309|NCT04556019|Procedure|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
79701310|NCT04556253|Drug|AK104|Subjects will receive AK104 by intravenous administration.
80013137|NCT05758519|Drug|QLS1128|QLS1128
79386727|NCT02452710|Other|Placebo|Open-label placebo
79541928|NCT01498172|Biological|BCG|1 intravesical dose /week for 6 weeks
79541929|NCT01498198|Procedure|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
79541930|NCT01498198|Other|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
79701311|NCT00470834|Drug|dutasteride|0.5mg dutasteride (Investigation Product)
80013138|NCT05758519|Drug|Placebo|Placebo
80013139|NCT02268422|Drug|Buprenorphine|7 day patch
80013140|NCT05758363|Dietary Supplement|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
80013141|NCT05758363|Other|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
79386728|NCT03221946|Drug|Diclofenac Sodium|tablet of 50mg,
79386729|NCT03221946|Drug|Diclofenac sodium|Transdermal patch 100 mg
79386730|NCT03221946|Drug|Diclofenac|intra muscular injection 100mg
79541931|NCT01498211|Procedure|Biopsy|3 mm punch biopsy of the skin at the distal leg.
79541932|NCT01498224|Device|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
79541933|NCT01498224|Procedure|Sutures|
79541934|NCT01498237|Device|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
79701312|NCT00470834|Drug|placebo|making placebo
79701313|NCT00470834|Drug|bicalutamide|50 mg Casodex or generic equivalent
80013142|NCT01522196|Drug|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
79541935|NCT01498237|Procedure|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
79541936|NCT01498302|Other|diagnostic laboratory biomarker analysis|
79541937|NCT01498302|Other|flow cytometry|
79701314|NCT04555746|Behavioral|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
79844230|NCT00253747|Drug|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
79701315|NCT04555824|Drug|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
79701316|NCT04555824|Other|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
79701317|NCT00470366|Biological|pegfilgrastim|
79701318|NCT00470366|Drug|cisplatin|
79701319|NCT00470366|Drug|ifosfamide|
79701320|NCT00470366|Drug|paclitaxel|
80013143|NCT01522196|Other|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
79386731|NCT02305732|Biological|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
79701321|NCT02212431|Drug|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
79701322|NCT00470093|Biological|recombinant interferon-α|
79541938|NCT01498315|Other|Ultrasound examination|Ultrasound examination following hysterectomy
79386732|NCT03229746|Drug|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
79541939|NCT01498354|Procedure|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
79701323|NCT00470093|Biological|recombinant interleukin-6|
79701324|NCT02212548|Device|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
79701325|NCT00470054|Drug|dasatinib|Given PO
79701326|NCT04555668|Other|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
79844231|NCT00253747|Drug|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
80013144|NCT01236404|Drug|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
79386733|NCT03229746|Drug|vincristine|1mg intravenous weekly for 4 weeks
79386734|NCT03229746|Drug|azathioprine|dose 100mg daily for at least 3 weeks
79386735|NCT02040298|Drug|Clemastine|4mg tablet twice daily
79386736|NCT02040298|Drug|Placebo|Placebo tablet twice daily
79386737|NCT03229668|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
79541940|NCT01498354|Procedure|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
79541941|NCT01498367|Procedure|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
79701327|NCT04555668|Other|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
79701328|NCT00478595|Drug|Rimonabant|Tablet, oral administration
80013145|NCT01236404|Drug|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
79386738|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
79386739|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
79386740|NCT03230058|Drug|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
79701329|NCT00478595|Drug|Placebo (for Rimonabant)|Tablet, oral administration
79701330|NCT00478595|Drug|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
79701331|NCT04555707|Drug|Apremilast 30mg|30mg PO BID started within 10 days of baseline
79386741|NCT01985542|Drug|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
79701332|NCT04555707|Drug|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
79701333|NCT04673279|Diagnostic Test|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
79701334|NCT04555980|Device|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
79701335|NCT04555980|Device|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
79701336|NCT04673084|Device|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
79701337|NCT02212626|Device|Rotarex S|
79701338|NCT04673201|Procedure|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
79701339|NCT04555629|Other|Advanced Cognitive Stimulation Therapy Hong Kong|A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
79701340|NCT00478088|Device|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
79701341|NCT00478088|Device|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
79701342|NCT00474188|Drug|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
79701343|NCT00474188|Drug|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
79386742|NCT03229902|Behavioral|mantra meditation|see study description
79386743|NCT03221712|Behavioral|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
79386744|NCT02371876|Device|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
79386745|NCT02372344|Drug|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
79386746|NCT03229824|Device|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
79541942|NCT01498380|Drug|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease < 20% or blood pressure decrease/increase < 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease >/= 20% or SBP/DBP/MAP decrease or increase >/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
79701344|NCT04555473|Procedure|Tumor biopsy|"Both interventions performed at baseline upon study enrolment (pre- and post-NACT for NACT+IDS patients) and at the time of recurrence.~Part of each surgical specimen will be used to obtain organoids, whereas part will be frozen for direct comparative analysis of the original tumor (1-6 organoids from each patient).~Blood samples will be collected to purify extracellular circulating RNA (cRNAs)."
79701345|NCT04555395|Other|survival rates|survival rates
79386747|NCT00081939|Drug|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m^2. Maintenance year one 1.0mg/m^2 1,4,8,11 q 28 days.
79844232|NCT00252733|Drug|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
79386748|NCT00081939|Drug|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
79541943|NCT01498406|Dietary Supplement|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
79701346|NCT00475982|Behavioral|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
79701347|NCT00475982|Other|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
79701348|NCT01089647|Drug|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
79701349|NCT01089647|Drug|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
79701350|NCT04555434|Dietary Supplement|Probiotics|"Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10^9 CFU / day)~Control group Main ingredient: Crystalline cellulose"
79701351|NCT04673240|Drug|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
79701352|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
79701353|NCT01089608|Drug|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
79701354|NCT01089608|Drug|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
79701355|NCT04554849|Other|Gender dysphoria psychosocial health|Retrospective analysis of medical records
79701356|NCT04672694|Procedure|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
79701357|NCT04672694|Procedure|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
79701358|NCT04554654|Diagnostic Test|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
79701359|NCT04554615|Drug|Insulin|insulin infusion to control postoperative hyperglycemia
79701360|NCT01089413|Drug|bevacizumab [Avastin]|As prescribed by physician
79701361|NCT04554810|Other|Medication Management Service|Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
79386749|NCT03221556|Behavioral|Engagement-Focused Care Coordination|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
80013146|NCT05758285|Other|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
80013147|NCT02268578|Device|Transcranial Direct Current Stimulation|2mA tDCS
79386750|NCT03221556|Behavioral|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
79386751|NCT02373124|Drug|infusion of NMDA antagonist|52 minute infusion
79386752|NCT03221478|Other|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
79386753|NCT03221478|Other|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
79541944|NCT01498432|Drug|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
79541945|NCT01498432|Drug|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
79541946|NCT01498497|Drug|EUR-1100|
79701362|NCT02212665|Behavioral|High intense interval training|
79844233|NCT03974035|Drug|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
80013148|NCT02268578|Procedure|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
79541947|NCT01498497|Drug|Placebo|
79541948|NCT01498510|Behavioral|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
80013149|NCT04220671|Biological|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
79701363|NCT02212665|Behavioral|Increased daily activity detected by the pedometer|
79701364|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+HIIT|
79701365|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+group intervention|
79701366|NCT01089023|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
79701367|NCT02212704|Other|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
79701368|NCT02212704|Other|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
79701369|NCT02212704|Other|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
79701370|NCT02212782|Drug|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
79701371|NCT02212782|Drug|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
79701372|NCT01088984|Drug|Bendamustine|
79701373|NCT02212821|Drug|Erythromycin|
79701374|NCT02212821|Drug|Placebo|physiological saline
79701375|NCT01088438|Behavioral|Contextualization workshop|A four-hour course on contextualization.
79701376|NCT04554537|Behavioral|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
79386754|NCT03221478|Other|Kinesio Taping with tension|Kinesio Taping with tension
79541949|NCT01498523|Other|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
79541950|NCT01498523|Other|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
79541951|NCT01498523|Other|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
79541952|NCT01498523|Other|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
80013150|NCT04220671|Other|Saline|0.9% NaCl
79541953|NCT01498536|Behavioral|aerobic exercise|3 times per week for 12-weeks
80013151|NCT01400594|Drug|HTU-520 Patch|Terbinafine hydrochloride patch
80013152|NCT01400594|Other|Placebo Patch|Treatment with Placebo Patch
80013153|NCT05049343|Drug|SAGE-904|SAGE-904 oral solution.
79386755|NCT03221634|Biological|Pembrolizumab|IV infusion
79386756|NCT03221634|Biological|Daratumumab|IV infusion
79386757|NCT03221088|Drug|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
79386758|NCT03221088|Drug|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
79391509|NCT02412150|Behavioral|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~Awake Patient anxious and agitated or restless or both!~Patient cooperative, oriented and tranquil!~Patient responds to commands only!~Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~A sluggish response to a light glabellar tap or loud auditory stimulus!~No response to a light glabellar tap or loud auditory stimulus"
79541954|NCT01498562|Drug|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
79541955|NCT01498562|Drug|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
79701377|NCT04554537|Behavioral|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
79701378|NCT04554186|Procedure|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
79701379|NCT04554186|Procedure|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
79701380|NCT04554186|Procedure|Control|Place a fentanyl patch 50 microgram
79701381|NCT01088243|Drug|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
79701382|NCT01088243|Drug|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
79701383|NCT04554342|Other|V01 candy|candy with sweetener (Isomalt) and apple flavour
79701384|NCT04554342|Other|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
79701385|NCT04554342|Other|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
79701386|NCT04554342|Other|V04 candy|candy with sweetener (Isomalt) (control group 1)
79701387|NCT04554342|Other|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
79701388|NCT04672499|Drug|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
79701389|NCT04672499|Drug|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
79701390|NCT04672499|Drug|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
79701391|NCT04554108|Other|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
79701392|NCT04554303|Drug|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
79701393|NCT04554303|Drug|Amlodipine 5mg|Oral administration, 1 tablet per day
80013154|NCT05049343|Drug|Placebo|Placebo oral solution.
79701394|NCT01088048|Drug|Idelalisib|Idelalisib tablet administered orally
79541956|NCT01498614|Behavioral|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
79701395|NCT01088048|Drug|Rituximab|Rituximab administered intravenously
79701396|NCT01088048|Drug|Bendamustine|Bendamustine administered intravenously
79701397|NCT01088048|Drug|Ofatumumab|Ofatumumab administered intravenously
79701398|NCT01088048|Drug|Fludarabine|Fludarabine administered orally
79701399|NCT01088048|Drug|Everolimus|Everolimus administered orally twice daily until disease progression
79701400|NCT01088048|Drug|Bortezomib|Bortezomib administered as a subcutaneous injection
79844234|NCT01071967|Other|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
79844235|NCT00275821|Drug|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
79844236|NCT00275821|Drug|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
80013155|NCT05049343|Drug|Ketamine|Ketamine intravenous (IV) infusion.
79248077|NCT02500485|Drug|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
79386759|NCT05003037|Drug|Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin|Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
79386760|NCT04485000|Behavioral|Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop|The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
79541957|NCT01498627|Biological|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
79541958|NCT01498627|Other|Data collection|PGRx information system
79248078|NCT04628546|Behavioral|The Parenting Young Children Check-up Initial Check-up and Text Messages|Parents assigned to the intervention condition will go through the Initial Check-up, which is a brief intervention that uses motivational content to promote use of the Parenting Young Children Check-up parenting education website. They will also receive text messages and a brochure to connect them to the parenting education website.
79701401|NCT01088048|Drug|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
79701402|NCT01088048|Drug|Lenalidomide|Lenalidomide administered orally
79701403|NCT04554498|Device|1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up|"the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands)."
79701404|NCT04554381|Biological|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
79701405|NCT04553952|Other|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
79701406|NCT04672577|Other|Observational study|No intervention is planned
79701407|NCT04553796|Device|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
79701408|NCT01087970|Drug|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
79701409|NCT01087970|Drug|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
79701410|NCT01087970|Drug|Carboplatin|Administered intravenously, for a maximum of 6 cycles
79701411|NCT01087970|Drug|Cisplatin|Administered intravenously, for a maximum of 6 cycles
79844237|NCT00275821|Drug|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
79844238|NCT01070797|Biological|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10^6 rCTLs/m2~Level Two: 1 x 10^7 rCTLs/m2~Level Three: 2 x 10^7 rCTLs/m2~Level Four: 5 x 10^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
79701412|NCT04553874|Other||observational study without intervention
79701413|NCT01087814|Drug|Efavirenz|Subject will take efavirenz for 5 days.
79386761|NCT02374060|Drug|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
79701414|NCT01087814|Drug|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
79701415|NCT02212938|Drug|BI 14332 CL|
79701416|NCT02212938|Other|high fat breakfast|
79701417|NCT04672421|Device|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
79844239|NCT03973099|Dietary Supplement|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
79386762|NCT02374060|Drug|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
79386763|NCT02374060|Drug|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
79701418|NCT04672421|Device|Placebo|No device after laparoscopic surgery
79701419|NCT04553991|Procedure|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
79701420|NCT04553991|Procedure|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
79701421|NCT01087775|Behavioral|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
79386764|NCT03221166|Drug|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
79701422|NCT02213172|Dietary Supplement|Bifidobacterium longum R0175|
79844240|NCT00275509|Drug|Thymoglobulin|
79386765|NCT03221166|Drug|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
79386766|NCT03221010|Behavioral|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
79386767|NCT03221010|Behavioral|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
79391510|NCT02412150|Other|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
79541959|NCT01498666|Dietary Supplement|L. reuteri protectis|1 tablet once daily for 4 weeks
79844241|NCT00275509|Drug|Daclizumab|
79844242|NCT00275509|Other|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
79844243|NCT00275509|Drug|Mycophenolate mofetil|2 gm/day. Standard of care
80013156|NCT01569919|Biological|TroVax®|Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
79541960|NCT01498666|Dietary Supplement|Placebo tablet|1 tablet once daily for 4 weeks
79541961|NCT01498705|Other|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
79541962|NCT01498718|Biological|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
79541963|NCT01498718|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
79701423|NCT02213172|Dietary Supplement|Lactobacillus paracasei HA-196|
79701424|NCT02213172|Other|Placebo|
79701425|NCT04554030|Behavioral|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
79701426|NCT01087502|Drug|Glimepiride|1-4 mg daily after 12 weeks
79701427|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
79701428|NCT01087502|Drug|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
79701429|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
79701430|NCT01087502|Drug|Linagliptin|5 mg once daily
79701431|NCT02213211|Drug|Artemether lumefantrine|
79701432|NCT02213367|Drug|Bilastine|20mg (8 weeks)
79844244|NCT00275509|Drug|Tacrolimus|To achieve serum level of 8-10 ng/ml.
79844245|NCT00275509|Drug|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
79701433|NCT02213367|Drug|Bilastine|40mg
79701434|NCT02213367|Drug|Bilastin|80mg
79701435|NCT01086410|Drug|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
79701436|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
79701437|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
79701438|NCT01086410|Drug|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
79701439|NCT01086410|Drug|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
79701440|NCT04553679|Behavioral|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
79701441|NCT04553601|Diagnostic Test|18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
79701442|NCT04553250|Procedure|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
79701443|NCT04553328|Device|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
79701444|NCT01085591|Drug|CB-183,315|
79701445|NCT01085591|Drug|Placebo|
79701446|NCT01085591|Drug|Vancomycin|
79701447|NCT04672265|Other|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
79701448|NCT04553055|Other|online questionnaires|questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
79701449|NCT02213406|Dietary Supplement|yogurt|Subjects will receive yogurt with varying fat concentrations
79701450|NCT04552977|Drug|fluzoparil|a PARP1 inhibitor
79701451|NCT04552977|Drug|temozolomide|an alkylating chemotherapeutic agent
79701452|NCT04672343|Other|Data collection|from D0 to hospital discharge
79386768|NCT03207828|Behavioral|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
79386769|NCT03207828|Other|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
79386770|NCT01985932|Device|MRI|
79701453|NCT04672343|Other|Querying the INSEE database|Vital status at 3 months and 12 months
79701454|NCT04552860|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
79701455|NCT01085357|Procedure|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
79844246|NCT00275509|Drug|Prednisone|Taper over three months to 5 mg daily
80013157|NCT01569919|Drug|Pemetrexed|500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
79701456|NCT01085357|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
79701457|NCT04552938|Other|pre-LVA|Venous serum samples were collected from patients before LVA.
79701458|NCT04552938|Other|post-LVA|Venous serum samples were collected from patients one-month after LVA.
79701459|NCT02277860|Behavioral|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
79701460|NCT02213523|Dietary Supplement|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
79701461|NCT02213523|Dietary Supplement|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
79844247|NCT00275509|Drug|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
80013158|NCT01569919|Drug|Cisplatin|75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
80013159|NCT01569919|Dietary Supplement|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
80013160|NCT01569919|Dietary Supplement|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
79844248|NCT01072045|Drug|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
79844249|NCT01072045|Drug|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
79844250|NCT01072123|Other|Quest for the Code|interactive asthma-based computer program
80013161|NCT01569919|Drug|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
80013162|NCT05205187|Procedure|Healthy control specimen collection|Collecting blood and feces from healthy population.
80013163|NCT05205187|Procedure|Non-Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
80013164|NCT05205187|Procedure|Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
80013165|NCT01399580|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
79701462|NCT02213523|Dietary Supplement|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
79701463|NCT02213523|Dietary Supplement|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
79701464|NCT01085201|Drug|Lexiscan|Given as an infusion
79701465|NCT02213562|Dietary Supplement|200 mg of chrysanthemum flower oil|
79844251|NCT01073059|Drug|Valproic acid and Ertapenem|
79844252|NCT00252577|Drug|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
79844253|NCT00252499|Drug|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
79844254|NCT00252499|Drug|fenofibrate|PPAR-alpha agonist, reduces triglycerides
80013166|NCT01399580|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
80013167|NCT04069585|Device|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
80013168|NCT04069585|Device|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
79386771|NCT03220932|Procedure|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
79386772|NCT03220932|Drug|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
79386773|NCT02042872|Drug|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
79386774|NCT04484688|Drug|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
79701466|NCT02213562|Dietary Supplement|300 mg of chrysanthemum flower oil|
79701467|NCT02213562|Dietary Supplement|400 mg of chrysanthemum flower oil|
79701468|NCT04671992|Device|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
79701469|NCT02213679|Dietary Supplement|Guanidinoacetic acid|Dietary supplement
79701470|NCT02213679|Other|Placebo|Placebo
79701471|NCT02213718|Drug|Desflurane|desflurane (7%-8% end-tidal concentration)
79701472|NCT02213718|Drug|propofol|propofol (TCI:3.5-4.0μg/min)
79701473|NCT02213718|Drug|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
79701474|NCT01085084|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
79701475|NCT01085084|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
79701476|NCT01085045|Drug|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
79701477|NCT01085045|Drug|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
79701478|NCT01085045|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
79844255|NCT00252499|Drug|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
79844256|NCT00252499|Drug|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
79844257|NCT00252187|Drug|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
79844258|NCT00252187|Other|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
79844259|NCT00572910|Biological|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
79844260|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
79844261|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
79844262|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
79844263|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
80013169|NCT03969433|Device|TMSi Porti|Data collections
80013170|NCT03969433|Device|Bloomlife sensor|Data collections
80013171|NCT00157196|Biological|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
80013172|NCT00157196|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
79844264|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
79248079|NCT04628546|Behavioral|The Parenting Young Children Check-up Flier and Text Messages|Parents assigned to the control condition will not go through the Parenting Young Children Check-up Initial Check-up. They will only go through assessment and then see a brief flier about the Parenting Young Children. Like the intervention condition, they will also receive text messages and a brochure to connect them to the Parenting Young Children Check-up parenting education website.
79541964|NCT01498731|Behavioral|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
79701479|NCT01085045|Drug|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
79248080|NCT03589079|Genetic|Sanger and/or Next Generation Sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS)
79701480|NCT01085045|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
79701481|NCT01085045|Drug|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
79701482|NCT02213796|Drug|Meropenem|
79701483|NCT04552392|Other|No intervention|No intervention
79701484|NCT04552626|Behavioral|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
79248081|NCT02243059|Drug|Gadofosveset trisodium (Ablavar™ )|
79701485|NCT04552626|Behavioral|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
79844265|NCT00163657|Drug|Daclizumub|anti-rejection drug
79844266|NCT00163657|Drug|Tacrolimus|anti rejection drug
80013173|NCT00157196|Other|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
80013174|NCT03066193|Drug|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
79248082|NCT02243059|Device|MRI|
79386775|NCT03207906|Drug|VBP-926|Topical VBP-926 solution
79386776|NCT00082017|Drug|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
79701486|NCT04552626|Behavioral|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
79701487|NCT01084772|Other|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
79701488|NCT01084772|Other|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
79844267|NCT00163657|Drug|Cyclosporine|anti rejection drug
79844268|NCT00163657|Drug|MMF|anti rejection drug
79844269|NCT03971149|Behavioral|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
79844270|NCT01073683|Procedure|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
79844271|NCT01073683|Drug|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
79386777|NCT02374138|Behavioral|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
79248083|NCT02500563|Other|Amino acid based infant formula|
79248084|NCT02500563|Other|Extensively hydrolyzed casein infant formula|
79248085|NCT02500563|Other|Mother's own breast milk|
79541965|NCT01498783|Drug|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
79248086|NCT02515916|Other|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
79248087|NCT02500329|Drug|Gemigliptin|Gemigliptin for 4 weeks
79248088|NCT02500329|Drug|Acarbose|Acarbose for 4 weeks
79541966|NCT01498796|Drug|Ketorolac|
79541967|NCT01498796|Drug|Normal Saline|
79701489|NCT04552158|Dietary Supplement|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
79701490|NCT00179673|Drug|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
79701491|NCT01084655|Drug|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
79701492|NCT01084655|Drug|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
79541968|NCT01498809|Drug|Midodrine|Single 10 mg dose
79701493|NCT01084655|Drug|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
79701494|NCT04552431|Drug|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
79701495|NCT04552431|Drug|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
79701496|NCT04552431|Drug|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
79844272|NCT00887172|Drug|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
79844273|NCT00887172|Drug|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
80013175|NCT02265926|Device|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
80013176|NCT03922321|Drug|RVT-1401|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
80013177|NCT02263976|Drug|BEA 2180 BR|
80013178|NCT02263976|Drug|Placebo|
80013179|NCT02263976|Device|Respimat® A 4|
80013180|NCT02263976|Drug|Methacholine Chloride|methacholine challenge test
80013181|NCT02263976|Drug|Spiriva|
79386778|NCT02374138|Other|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
79386779|NCT03227328|Drug|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~palbociclib~ribociclib~abemaciclib~Endocrine therapy:~non-steroidal or steroidal AI~fulvestrant"
79386780|NCT03227328|Drug|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~anthracycline + taxane,~taxane,~anthracycline,~capecitabine / fluoropyrimidines,~others.~Endocrine therapy:~non-steroidal or steroidal AI~fulvestrant"
80013182|NCT02264054|Drug|[14C]talsaclidine, oral|
79541969|NCT01498835|Drug|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
79541970|NCT01498848|Dietary Supplement|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
79541971|NCT01498861|Drug|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
79541972|NCT01498861|Drug|Dolutegravir|Dolutegravir is an experimental HIV drug
79541973|NCT01498861|Drug|Placebo|Placebo is a tablet with no drug in it
79541974|NCT01498874|Drug|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
79701497|NCT04552431|Drug|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
79701498|NCT01084538|Drug|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
79701499|NCT00179517|Drug|Anastrozole 1mg|
79701500|NCT00179517|Drug|Placebo Oral Tablet|
79701501|NCT01083641|Drug|Estradiol|10mg oral three times daily
79701502|NCT00179010|Drug|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
80013183|NCT02264054|Drug|[14C]talsaclidine, iv|
80013184|NCT01503944|Drug|18F-AV-133|185 MBq
80013185|NCT01503944|Drug|18F-AV-45|185-370 MBq
80013186|NCT01382654|Drug|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
80013187|NCT01382654|Drug|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
80013188|NCT01382654|Drug|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
80013189|NCT01382654|Drug|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
80013190|NCT01382654|Drug|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
80013191|NCT01378676|Drug|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
80013192|NCT01378676|Drug|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
80013193|NCT01378676|Drug|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
79701503|NCT00179010|Drug|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
79701504|NCT04552236|Device|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
79701505|NCT01083602|Drug|panobinostat|PAN 20 mg PO given TIW, weeks 1&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
79701506|NCT01083602|Drug|bortezomib|
80013194|NCT01378676|Drug|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
79844274|NCT00887172|Drug|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
79844275|NCT00609492|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
79248090|NCT02243137|Drug|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
79248091|NCT02243137|Drug|prasugrel|Administration: one loading dose (60mg)
79248092|NCT02243137|Drug|lysine acetylsalicylate|Administration: one dose (450mg iv)
79248093|NCT03343977|Drug|docetaxel 50mg/m2|50 mg/m2 of docetaxel will be given on day 1 every 14 days
79386781|NCT04821921|Other|No intervention|Care as usual
79701507|NCT01083602|Drug|dexamethasone|
79701508|NCT04552002|Dietary Supplement|Synbiotic group|Probiotics and prebiotics
79701509|NCT00178464|Drug|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
79701510|NCT04671914|Drug|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D&C
79701511|NCT04671914|Other|Dilation and curretage|After abortion in II trimester we do D&C.
79701512|NCT01083485|Drug|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
79386782|NCT03220698|Device|Tracheal ultrasonography|Tracheal ultrasonography
79386783|NCT00082329|Drug|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
79386784|NCT00082329|Drug|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
79386785|NCT03220620|Other|GDT|individualized fluid therapy
79386786|NCT02451462|Drug|Zoledronic acid|
79386787|NCT02451384|Procedure|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
79844276|NCT00609492|Biological|Infanrix™-IPV/Hib|Single dose, intramuscular injection
79844277|NCT00230971|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
79844278|NCT00230971|Drug|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
79844279|NCT02541318|Behavioral|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
80013195|NCT01378676|Drug|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
80013196|NCT01378676|Drug|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
79248094|NCT03343977|Drug|docetaxel 75mg/m2|75 mg/m2 of docetaxel will be given on day 1 every 21 days
79386788|NCT02451384|Procedure|no-touch surgery|
79844280|NCT02542722|Behavioral|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
80013197|NCT01378676|Drug|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
80013198|NCT01378676|Drug|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
80013199|NCT01378676|Drug|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
80013200|NCT01377662|Drug|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
79248095|NCT02850965|Drug|BI 695501|
79248096|NCT02850965|Drug|Humira|
79701513|NCT01083485|Drug|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
79701514|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
79386789|NCT02451384|Procedure|laparoscopic surgery|
79701515|NCT04551924|Drug|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
79701516|NCT04551924|Drug|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg [0.5%, 5mg/mL] x 30mL
79701517|NCT04671836|Drug|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
79701518|NCT04671836|Drug|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
79701519|NCT04552353|Drug|Vaway|Drug: Voriconazole. Pharmacokinetic study under fasting conditions
79701520|NCT00556088|Drug|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
79701521|NCT00177294|Drug|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
79701522|NCT00177294|Behavioral|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
79701523|NCT00177294|Behavioral|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
79701524|NCT01082081|Drug|Paracetamol 1000 mg|Paracetamol 1000 mg
79701525|NCT01082081|Drug|Paracetamol 500 mg|Paracetamol 500 mg
79701526|NCT01082081|Drug|Placebo|Placebo
79844281|NCT02542722|Behavioral|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
79844282|NCT00211081|Drug|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
79844283|NCT05278806|Other|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
80013201|NCT01377662|Other|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
80013202|NCT01371578|Drug|GS-5885 tablet|30 mg active tablet
80013203|NCT01371578|Drug|GS-9451 tablet|two active 100 mg tablets
80013204|NCT01371578|Biological|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
79386790|NCT03220386|Other|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
79386791|NCT03207204|Procedure|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
79386792|NCT03207204|Procedure|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
79386793|NCT03207204|Procedure|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
79386794|NCT03207204|Procedure|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
79541975|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
79541976|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
79541977|NCT01498900|Drug|repaglinide|Prescription according to the product labelling at the physicians' discretion
79541978|NCT01498913|Drug|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
79541979|NCT01498926|Drug|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
79541980|NCT01498926|Drug|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
80013205|NCT01371578|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
80013206|NCT01225640|Drug|PNU-100480|600 mg twice daily (BID) for 14 days
80013207|NCT01225640|Drug|PNU-100480|1200 mg once daily (QD) for 14 days
79386795|NCT03207204|Procedure|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
79386796|NCT03207204|Procedure|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
79701527|NCT00177216|Drug|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
79386797|NCT03207204|Procedure|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
79701528|NCT00177216|Drug|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
79701529|NCT00177216|Drug|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
79701530|NCT01081886|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
79701531|NCT01081886|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
79701532|NCT02213952|Drug|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
79701533|NCT02213952|Other|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
79701534|NCT01081769|Drug|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
79701535|NCT01081769|Drug|oral antipsychotics|daily treatment according to local label for maximally 24 months
79844284|NCT05278806|Other|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
79844285|NCT03971227|Device|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
79844286|NCT03971227|Device|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
80013208|NCT01225640|Drug|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
80013209|NCT01208168|Drug|NAB001|nail lacquer, once daily, 52 weeks
79386798|NCT03207204|Procedure|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
79391511|NCT02412150|Behavioral|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
79701536|NCT04551768|Drug|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
79701537|NCT04551768|Drug|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
79701538|NCT04671407|Drug|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
79701539|NCT02213991|Device|Intraoperative radiotherapy using Intrabeam®|"Operation day~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~Purse string suture pulles up tissues and wraps up the applicator.~Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~After IORT, applicator was out of the operative field, and usual wound closure will be done.~Postoperative period~Chemotherapy WBRT (46 Gy) for 4~5 weeks~Endocrine therapy or target therapy"
79701540|NCT04671641|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
79701541|NCT04551534|Drug|DNL201|Oral dose(s)
80013210|NCT01208168|Drug|Vehicle alone|nail lacquer, once daily, 52 weeks
80013211|NCT01677910|Drug|Telotristat etiprate|Telotristat etiprate tablets.
80013212|NCT01677910|Drug|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
79541981|NCT01498939|Drug|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
79844287|NCT00884676|Drug|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~Schedule B: Day 1 of each 3-week cycle."
79248097|NCT03571087|Drug|HL140 5/10|"1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
79248098|NCT03571087|Drug|HL140 10/10|"1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
79248099|NCT03571087|Drug|HL140 20/10|"1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
79386799|NCT02092311|Procedure|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
80013213|NCT01499420|Biological|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
79386800|NCT02092311|Procedure|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
79541982|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
79541983|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
79541984|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
79541985|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
79541986|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
79541987|NCT01499004|Drug|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
79541988|NCT01499017|Drug|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
79541989|NCT01499017|Drug|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
79541990|NCT01499056|Biological|stem cell injection|intra articular inection of mesenchymal stem cell
79701542|NCT04551534|Drug|Placebo|Oral dose(s)
79701543|NCT04551456|Biological|Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS|Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
79541991|NCT01499069|Drug|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
79701544|NCT01081301|Behavioral|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
79701545|NCT00174954|Procedure|MRI|Subjects underwent MRI to evaluate tophi.
79844288|NCT00884676|Drug|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
79248100|NCT03571087|Drug|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~Extension period(W9~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
79248101|NCT03571087|Drug|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
79844289|NCT02542800|Behavioral|Episodic memory task|
79844290|NCT02542800|Device|fMRI|
79844291|NCT04036812|Procedure|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
80013214|NCT01499420|Biological|Placebo|Single intravenous doses of normal saline (0.9%)
79248102|NCT03571087|Drug|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
79386801|NCT03207360|Behavioral|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
79386802|NCT03207516|Dietary Supplement|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
79541992|NCT01499108|Drug|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
79541993|NCT01499121|Drug|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop > grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
79541994|NCT01499186|Other|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
79541995|NCT01499212|Procedure|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
79541996|NCT01499225|Drug|YH14642 500mg Tab|YH14642 500mg per day(once a day)
79541997|NCT01499225|Drug|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
79541998|NCT01499225|Drug|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
79541999|NCT01499225|Drug|INSADOL[Zea mays L. extract] 35mg Tab|"[Initiation dose : 4weeks after administraion] INSADOL[Zea mays L. extract] 210mg TAB per day~[Maintain dose : Between 4weeks and 8weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day~[Maintain dose : Between 8weeks and 12weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day"
79386803|NCT03207516|Dietary Supplement|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
79386804|NCT03207126|Diagnostic Test|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
79386805|NCT02092857|Dietary Supplement|Arachidonic acid (25 mg/100 kcal )|
79386806|NCT02092857|Dietary Supplement|Arachidonic acid (34 mg/100 kcal)|
79701546|NCT04671563|Drug|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
79248103|NCT02505789|Other|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
79386807|NCT02092857|Dietary Supplement|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
79386808|NCT03220308|Other|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
79386809|NCT03220308|Other|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
79386810|NCT03207048|Device|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
79386811|NCT03207048|Device|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
79542000|NCT01499225|Drug|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA[Doxycycline hyclate] Cap 40mg per day
79542001|NCT01499225|Drug|Placebo|Placebo
79542002|NCT01499238|Device|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
79542003|NCT01499238|Device|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
79542004|NCT01499251|Drug|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
79542005|NCT01499251|Drug|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
79542006|NCT01499251|Drug|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
79542007|NCT01499264|Device|MySkin patch|Hydrogel and polyurethane film
79701547|NCT04551573|Drug|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
79701548|NCT04551573|Drug|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
79701549|NCT01081145|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
79701550|NCT01081145|Other|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
79701551|NCT00174915|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
79701552|NCT00174915|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
79701553|NCT00174915|Drug|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
79844292|NCT04036812|Other|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
79844293|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
79844294|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
80013215|NCT01498328|Drug|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
79248104|NCT04557644|Other|7-items-questionnaires addressing CI, disgust and empathy|7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.
79248105|NCT04557644|Other|Saarbrucken Personality questionnaire (SPQ) addressing empathy.|Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
79248106|NCT04557644|Other|10-items-questionnaire addressing previous dermatological conditions, intensity of itch|10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).
79248107|NCT04557644|Other|ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions|ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.
79386812|NCT03227172|Procedure|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
79386813|NCT02451306|Drug|Quetiapine|See information in arm description.
79701554|NCT00174915|Drug|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
79701555|NCT00174915|Drug|Placebo|Placebo, orally, once daily for up to 28 weeks.
79386814|NCT02451306|Drug|Placebo|See information in arm description.
79386815|NCT00167661|Drug|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
79386816|NCT03206892|Device|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
79386817|NCT03220542|Drug|Probiotics|Saccharomyces boulardii
79386818|NCT03220542|Dietary Supplement|Broccoli|Broccoli sprouts extract
79542008|NCT01499264|Device|Traditional Dressing|Gauze and Patch
79542009|NCT01499316|Procedure|High Flow oxygen|10 minute shigh flow oxygen
79542010|NCT01499316|Procedure|Room Air|Room air breathing
79542011|NCT01499407|Device|ClearWay RX catheter|
79542012|NCT01499407|Drug|Abciximab|
79542013|NCT01499433|Drug|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
79542014|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
79542015|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
79542016|NCT01499446|Drug|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
79701556|NCT04671368|Diagnostic Test|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
79542017|NCT01499446|Drug|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
79844295|NCT00887328|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
80013216|NCT01498328|Drug|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
79248108|NCT03571009|Device|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
80013217|NCT01498328|Drug|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
79248109|NCT02381522|Other|Remote Ischemic Pre-conditioning|
79248110|NCT02381522|Other|Sham RIPC|
79386819|NCT03220542|Drug|Esomeprazole|Esomeprazole
79542018|NCT01499459|Genetic|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
79542019|NCT01499472|Device|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
79248111|NCT01375959|Dietary Supplement|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
79542020|NCT01499472|Device|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
79542021|NCT01499472|Procedure|standard of care|regular care including debridement and bandaging.
79542022|NCT01499485|Drug|Acetazolamide|"Daily morning ABGA:~If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg .~If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg.~If actual bicarbonate <= 26 mmol/L: omit treatment that day."
79844296|NCT00887328|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
79844297|NCT00609336|Drug|gemcitabine hydrochloride|Given IV
79844298|NCT00609336|Drug|docetaxel|Given IV
79844299|NCT00609336|Drug|capecitabine|Given PO
79844300|NCT00609336|Radiation|intensity-modulated radiation therapy|Undergo IMRT
79844301|NCT00609336|Drug|oxaliplatin|Given IV
79844302|NCT00609336|Procedure|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
79844303|NCT00609336|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
79844304|NCT00609336|Other|laboratory biomarker analysis|Correlative studies
79844305|NCT02542566|Procedure|Physiotherapy rehabilitation|Physiotherapy rehabilitation
79248112|NCT01375959|Drug|Placebo|3 placebo capsules orally twice a day for 6 weeks
79248113|NCT03581669|Device|Cerclage and total hip arthroplasty|acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
79302764|NCT03071523|Procedure|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
79386820|NCT03220542|Drug|Amoxicillin|Amoxicillin
79386821|NCT03220542|Drug|Clarithromycin|Clarithromycin
79386822|NCT03206580|Other|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
79386823|NCT03206580|Other|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
79386824|NCT03220152|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
79844306|NCT00612066|Drug|rosiglitazone maleate|
79844307|NCT02541084|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
79844308|NCT02542488|Other|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?"
79844309|NCT02542488|Diagnostic Test|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
79844310|NCT02542488|Other|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
79844311|NCT00887406|Drug|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
79844312|NCT00887406|Drug|GSK961081 3mcg SD|single dose delivered via nebulsier
79844313|NCT00887406|Drug|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
79844314|NCT00887406|Drug|Placebo SD|single dose via nebuliser
79844315|NCT00887406|Drug|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
79844316|NCT00887406|Drug|GSK961081 200mcg SD|single dose via nebuliser
79844317|NCT00887406|Drug|GSK961081 300mcg SD|single dose via nebuliser
79844318|NCT00887406|Drug|GSK961081 100mcg RD|repeat dose via nebuliser
79844319|NCT00887406|Drug|GSK961081 300mcg RD|repeat dose vai nebuliser
79844320|NCT00887406|Drug|Placebo RD|repeat dose via nebuliser
79844321|NCT04397406|Drug|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
79844322|NCT04397406|Drug|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
80013218|NCT04537936|Behavioral|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
80013219|NCT04537936|Behavioral|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
80013220|NCT04537936|Behavioral|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
79248114|NCT03570853|Behavioral|SMART-3RP|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
79386825|NCT03227094|Diagnostic Test|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training & delivery of Jelly-Bean/75g glucose beverage
79386826|NCT03227094|Diagnostic Test|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
79386827|NCT03227094|Diagnostic Test|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
79386828|NCT03220464|Radiation|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
79542023|NCT01499485|Drug|Placebo|"Daily morning ABGA:~If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo.~If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo.~If actual bicarbonate <= 26 mmol/L: omit treatment that day."
79542024|NCT01499537|Device|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
79542025|NCT01499537|Device|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
79542026|NCT01499550|Device|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
79542027|NCT01499550|Other|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
79542028|NCT01499589|Procedure|regional anesthesia|regional anesthesia procedure
79542029|NCT01499602|Drug|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
79542030|NCT01499602|Drug|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
79542031|NCT01499615|Device|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
79248115|NCT02238353|Drug|azelastine + fluticasone|
79248116|NCT02238353|Drug|Placebo|
79386829|NCT03220464|Radiation|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
79248117|NCT04426292|Diagnostic Test|Serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
79248118|NCT02496273|Biological|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
79386830|NCT03220464|Diagnostic Test|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
79386831|NCT02395978|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
79386832|NCT02395978|Drug|placebo|Placebo contained corn starch.
79542032|NCT01499641|Drug|Methylprednisolone|Epidural methylprednisolone 40 mg or none
79542033|NCT01499693|Drug|Magnesium Pantoprazole 20 mg|oral dose, twice a day
79542034|NCT01499693|Drug|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
79386833|NCT03206658|Drug|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
79844323|NCT04397406|Drug|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
79844324|NCT02542332|Other|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
79302765|NCT03201991|Other|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
79302766|NCT03071679|Drug|Omiganan|Omignan 1%, 2.5%
79302767|NCT03071679|Drug|Imiquimod|Imiquimod 15mg
79391512|NCT02412150|Other|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
79542035|NCT01499693|Drug|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
79542036|NCT01499706|Behavioral|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
79844325|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.5%
79844326|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.2%
79844327|NCT00891540|Drug|placebo|Isotonic NaCl
79844328|NCT00887718|Biological|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
79542037|NCT01499706|Behavioral|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
79542038|NCT01499719|Behavioral|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
79542039|NCT01499745|Behavioral|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
79542040|NCT01499758|Drug|Atorvastatin|80 Mg tablets
79542041|NCT01499771|Drug|Atorvastatin|80 Mg tablets
79542042|NCT01499784|Behavioral|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
79542043|NCT01499797|Other|The CareWell programme|"The CareWell programme contains the following components:~multidisciplinary primary care teams~working with proactive care plans integrating cure, care and welfare~advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~medication review~case-management~guidelines for consultation of in-hospital geriatric experts~guidelines for transfers from primary care to home-based facilities and hospital and back~practice guidelines for management of common geriatric conditions"
79542044|NCT01499836|Other|PVB|paravertebral block
79542045|NCT01499875|Drug|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
79542046|NCT01499901|Procedure|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
79701557|NCT04671368|Diagnostic Test|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
79844329|NCT00573144|Drug|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
79844330|NCT00573144|Drug|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
79386834|NCT03206658|Drug|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
79386835|NCT00170157|Drug|Bicalutamide|Given orally
79542047|NCT01499901|Procedure|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
79542048|NCT01499914|Biological|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
79542049|NCT01499927|Other|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
79701558|NCT04671368|Diagnostic Test|Gold Standard|Firstly, the two expert pathologist(>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
79701559|NCT01080716|Biological|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
79701560|NCT01080716|Biological|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
79701561|NCT01080716|Biological|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
79701562|NCT01080716|Biological|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
79701563|NCT04551339|Dietary Supplement|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
79844331|NCT00891696|Drug|Rapamycin|Single 16-mg oral dose
79844332|NCT00891696|Other|Amino acid supplementation|Nutritional drink containing essential amino acids
79248119|NCT03570775|Device|Sleeping bag phototherapy|This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
79302768|NCT03071679|Drug|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
79302769|NCT03071679|Drug|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
79302770|NCT03071679|Drug|Placebo|Vehicle
79844333|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
79302771|NCT03199261|Drug|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
79386836|NCT00170157|Drug|Flutamide|Given orally
79386837|NCT00170157|Drug|Goserelin Acetate|Given SC
79386838|NCT00170157|Drug|Ipilimumab|Given IV
79386839|NCT00170157|Drug|Leuprolide Acetate|Given IM
79386840|NCT00170157|Other|Pharmacological Study|Correlative study
79386841|NCT03220074|Drug|Oral Tablet|study drug given and monitored for efficacy and tolerability
79386842|NCT03206346|Drug|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
79386843|NCT03206346|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
79391513|NCT02412150|Other|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
79391514|NCT02412150|Other|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
79701564|NCT04551339|Dietary Supplement|Multivitamin with 11mg of zinc|One tab taken daily for three months
79844334|NCT00891696|Drug|Sodium nitroprusside|Variable rate for 3 hours
79844335|NCT00891696|Device|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
79844336|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
79391515|NCT02412150|Drug|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
79542050|NCT01499966|Procedure|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
79542051|NCT01499979|Procedure|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
79542052|NCT01499992|Procedure|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
79542053|NCT01499992|Other|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
79542054|NCT01500005|Drug|Baby D3 drops|2000-4000 iu per day
79542055|NCT01500018|Drug|TC-5214|Single oral dose of 2 mg
79701565|NCT04671446|Diagnostic Test|Autoantibody ELISA|Serum will be tested for novel autoantibodies against eosinophil proteins by ELISA, such as those previously identified as of importance (e.g. eosinophil-peroxidase, EPX) and also novel candidate proteins specific to eosinophils (including ARFIP1, BCL2A1, PPCDC, SLC12A6 etc) as identified by FANTOM5 geneset analysis.
79701566|NCT04671134|Other|Biomimetic remineralizing agent|Self-assempling peptide
79701567|NCT04671134|Other|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
79701568|NCT04571489|Drug|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
79701569|NCT04571489|Drug|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
79844337|NCT00640328|Drug|Ofatumumab 100|100mg
79844338|NCT00640328|Drug|Ofatumumab 300|300mg
79844339|NCT00640328|Drug|Ofatumumab 700|700mg
79844340|NCT00640328|Drug|Placebo|matching placebo
80013221|NCT04537936|Behavioral|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
80013222|NCT02266082|Other|No intervention|There is no intervention in this study.
79248120|NCT03570775|Device|Conventional phototherapy|This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
79248121|NCT04482686|Drug|Ivermectin|Treatment days 1, 4, and 8
79391516|NCT02412150|Drug|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
79701570|NCT04571489|Drug|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
79701571|NCT00172185|Drug|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
79391517|NCT02523196|Drug|HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
79701572|NCT00172185|Drug|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
79844341|NCT00163189|Drug|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
80013223|NCT04537000|Diagnostic Test|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)*body weight *5.
80013224|NCT01497704|Drug|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
80013225|NCT03135626|Drug|Biodentine|
80013226|NCT03135626|Drug|ProRoot (Aggregate)|
80013227|NCT03135626|Drug|MTA Plus|
79391518|NCT02523196|Device|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
80013228|NCT03135626|Drug|Ferric Sulfate 20 % Dental Gel|
80013229|NCT02266160|Drug|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
79701573|NCT01080326|Device|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
79542056|NCT01500018|Drug|TC-5214 Placebo|Single oral dose
79701574|NCT00171951|Drug|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
80013230|NCT02266160|Other|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
80013231|NCT05731570|Behavioral|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
80013232|NCT01491932|Drug|AFQ056|AFQ056 will be supplied as oral capsules.
79701575|NCT01080131|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
80013233|NCT05731102|Diagnostic Test|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
79391519|NCT02410434|Other|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
79542057|NCT01500018|Drug|Ketamine|Single oral dose of 100 mg
79542058|NCT01500018|Drug|Phentermine|Single oral dose of 45 mg
79542059|NCT01500018|Drug|TC-5214|Single oral dose of 8 mg
80013234|NCT03911713|Drug|VX-561|VX-561 tablets for oral administration.
80013235|NCT03911713|Drug|IVA|150-mg film-coated tablet for oral administration.
80013236|NCT03911713|Drug|Placebo|Placebo matched to IVA.
80013237|NCT03911713|Drug|Placebo|Placebos matched to VX-561.
80013238|NCT05730244|Drug|Cassia alata extract|1 ml Cassia alata extract
80013239|NCT05730244|Drug|Placebo|1 ml placebo solution
79542060|NCT01500018|Drug|TC-5214|Single oral dose of 16 mg
79542061|NCT01500018|Drug|Phentermine|Single oral dose of 90 mg
79542062|NCT01500070|Device|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
79248122|NCT04482686|Drug|Doxycycline Hcl|10 day treatment
79248123|NCT04482686|Dietary Supplement|Zinc|10 Day treatment
79248124|NCT04482686|Dietary Supplement|Vitamin D3|10 day treatment
79248125|NCT04482686|Dietary Supplement|Vitamin C|10 day treatment
79248126|NCT03580889|Drug|Atropine|Comparison between atropine, glycopyrrolate and Normal Saline
79248127|NCT03580889|Drug|Glycopyrrolate|Comparison between glycopyrrolate, atropine and Normal saline
79248128|NCT03580889|Drug|Normal Saline Flush, 0.9% Injectable Solution|Comparison between Normal saline, atropine and glycopyrrolate
79248129|NCT02500017|Dietary Supplement|Melatonin|5mg rapid release melatonin capsule
79248130|NCT02500017|Other|Placebo|matching placebo capsule
79248131|NCT03415867|Drug|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
79391520|NCT02418078|Procedure|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
79542063|NCT01500122|Drug|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
79542064|NCT01500148|Device|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
79542065|NCT01500161|Drug|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
79542066|NCT01500161|Drug|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
79701576|NCT01080131|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
79701577|NCT01080131|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
79701578|NCT01080131|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
79701579|NCT04551612|Radiation|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
79701580|NCT00171873|Drug|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
79701581|NCT00171873|Drug|Placebo|Sodium chloride intramuscularly every 28 days
79701582|NCT01087151|Drug|ABT-263|Oral repeating dose
80013240|NCT02264132|Drug|Pramipexole ER tablet|
80013241|NCT02264132|Drug|Pramipexole IR tablet|
80013242|NCT01366820|Drug|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
80013243|NCT01366820|Drug|Placebo|Sodium Chloride 0.9% Injection
80013244|NCT05728762|Device|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
80013245|NCT03910153|Dietary Supplement|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
80013246|NCT03910153|Other|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
79701583|NCT01087151|Drug|rituximab|Intravenous repeating dose
80013247|NCT01192880|Drug|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
80013248|NCT01192880|Drug|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
80013249|NCT01192880|Drug|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
80013250|NCT03629197|Behavioral|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
79248132|NCT03815669|Procedure|Arthroscopic subacromial decompression|Arthroscopic subacromial decompression
80013251|NCT03629197|Other|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
80013252|NCT04540744|Drug|FDC of macitentan/tadalafil (10 mg/20 mg)|FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
80013253|NCT04540744|Drug|Macitentan 10 mg|Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
80013254|NCT04540744|Drug|Tadalafil 20 mg|Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
80013255|NCT05375734|Drug|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
80013256|NCT01489046|Drug|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
80013257|NCT01489046|Drug|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
79248133|NCT04200482|Behavioral|One Diet and Physical Activity Session|Attend 1 remote diet and physical activity session
79248134|NCT04200482|Other|Electronic (e) Health (eHealth) Communication Intervention|Receive eHealth communication intervention
79248135|NCT04200482|Behavioral|Twelve Diet and Physical Activity Group Sessions|Attend 12 remote diet and physical activity sessions in 6 months
79248136|NCT04200482|Other|Questionnaire Administration|Ancillary studies
79248137|NCT04200482|Other|Quality-of-Life Assessment|Ancillary studies
79542067|NCT01500161|Drug|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
79391521|NCT02523586|Other|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
79542068|NCT01500161|Drug|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
79542069|NCT01500161|Drug|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
79248138|NCT02505633|Device|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
79542070|NCT01500161|Drug|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
79701584|NCT04551027|Behavioral|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
80013258|NCT01489046|Drug|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
79542071|NCT01500161|Drug|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
79542072|NCT01500174|Device|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
79542073|NCT01500174|Device|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
79701585|NCT04571528|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
80013259|NCT01489046|Drug|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
80013260|NCT01489046|Drug|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
80013261|NCT01489046|Drug|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
80013262|NCT01489046|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
80013263|NCT02266238|Device|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
80013264|NCT02266238|Device|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
80013265|NCT02266238|Procedure|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
80013266|NCT05012488|Other|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
79542074|NCT01500265|Biological|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
80013267|NCT02264210|Drug|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
79542075|NCT01500291|Other|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
79542076|NCT01500304|Procedure|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
79542077|NCT01500330|Procedure|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
79542078|NCT01500330|Procedure|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
79542079|NCT01500343|Drug|Saccharomyces boulardii|1 gram per day, during 3 months
79542080|NCT01500356|Behavioral|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
79542081|NCT01500356|Behavioral|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
79542082|NCT01500356|Behavioral|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
79542083|NCT01500369|Other|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
79542084|NCT01500369|Other|standard of care|Placebo Comparator
79542085|NCT01500395|Procedure|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
79542086|NCT01500408|Drug|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
79542087|NCT01500408|Drug|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
79701586|NCT04571528|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
79701587|NCT04571528|Behavioral|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
80013268|NCT01423396|Other|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
80013269|NCT01423396|Other|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
80013270|NCT02264288|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
79248139|NCT02505633|Drug|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
79248140|NCT03580577|Device|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
79542088|NCT01500421|Device|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
79542089|NCT01500421|Device|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
80013271|NCT02264288|Biological|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
80013272|NCT02264288|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
79248141|NCT02248519|Procedure|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
79542090|NCT01500421|Device|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
79542091|NCT01500486|Device|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
79542092|NCT01500499|Genetic|gene expression analysis|
79542093|NCT01500499|Genetic|gene rearrangement analysis|
79542094|NCT01500499|Genetic|polymerase chain reaction|
79542095|NCT01500499|Genetic|protein analysis|
79542096|NCT01500499|Genetic|western blotting|
79542097|NCT01500499|Other|laboratory biomarker analysis|
79542098|NCT01500499|Other|mass spectrometry|
79542099|NCT01500512|Other|Clinical Observation|Undergo observation
79542100|NCT01500538|Drug|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
79701588|NCT00171834|Drug|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
79701589|NCT02214030|Device|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
79701590|NCT04571996|Drug|ODM-104|Capsule
79542101|NCT01500564|Device|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
79542102|NCT01500564|Device|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
79542103|NCT01500577|Drug|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
79542104|NCT01500577|Drug|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
79542105|NCT01500577|Other|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
79542106|NCT01500590|Drug|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
79701591|NCT04571996|Drug|Paracetamol|Rapidly dissolving tablet
79701592|NCT00171249|Drug|STI571 400 mg|STI571 capsules and tablets
79542107|NCT01500590|Drug|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
79701593|NCT00171249|Drug|STI571 600 mg|STI571 capsules and tablets
79701594|NCT04671056|Drug|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
79701595|NCT04671056|Drug|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
79701596|NCT01082549|Drug|gemcitabine/carboplatin|i.v.
79701597|NCT01082549|Drug|gemcitabine/carboplatin plus Iniparib|i.v.
79701598|NCT02214069|Device|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
79248142|NCT02248519|Procedure|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
79248143|NCT02500173|Radiation|Radiation|Radiation therapy
79248144|NCT03570307|Other|medical VS surgical evacuation of the uterus|mentioned above
79248145|NCT04001426|Device|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
79248146|NCT03587441|Drug|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
79248147|NCT03587441|Drug|Dextrose 5% in water|intrathecal
79542108|NCT01500603|Device|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
79248148|NCT03570151|Other|no intervention|no intervention will be done
79542109|NCT01500603|Device|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
79701599|NCT04550949|Drug|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
79701600|NCT04550949|Drug|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
79701601|NCT01085630|Drug|pemetrexed disodium|Given IV
79701602|NCT01085630|Other|clinical observation|
79701603|NCT00171210|Drug|Deferasirox|Tablets taken orally once a day.
80013273|NCT02264288|Other|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
80013274|NCT01401556|Other|case management|
79248149|NCT05102396|Drug|Topical oxybutynin spray|Participants will receive topical oxybutynin spray (10%).
79248150|NCT05102396|Drug|Topical placebo spray|Participants will receive topical placebo spray.
79248151|NCT05102396|Drug|Oral oxybutynin|Participants will receive oxybutynin (tablets).
79248152|NCT01165645|Drug|lopinavir|Given orally
79248153|NCT01165645|Drug|ritonavir|Given orally
79248154|NCT01165645|Genetic|polymerase chain reaction|Correlative studies
79248155|NCT01165645|Other|flow cytometry|Correlative studies
79248156|NCT01165645|Other|enzyme-linked immunosorbent assay|Correlative studies
79248157|NCT01165645|Other|laboratory biomarker analysis|Correlative studies
79248158|NCT03579953|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
79302772|NCT03199261|Drug|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
80013275|NCT01401556|Other|Multifaceted quality improvement intervention|
80013276|NCT01180634|Drug|MP-376 (Levofloxacin solution for Inhalation)|240 mg of MP-376 administered BID for 28 days
80013277|NCT01180634|Drug|Placebo|same volume and frequency as study drug
79701604|NCT04670861|Procedure|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
79701605|NCT00171054|Drug|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
79701606|NCT00171054|Drug|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
79701607|NCT00171054|Drug|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
79701608|NCT00174837|Drug|Tirapazamine|in combination with cisplatin and concomitant radiation
79701609|NCT00174837|Drug|Cisplatin|with concomitant radiation
79701610|NCT04670705|Other|patients' characteristics|There was no intervention.
79386844|NCT02043574|Behavioral|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
79386845|NCT02043574|Behavioral|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
79701611|NCT00179400|Drug|Pioglitazone 45 mg|
79701612|NCT00179400|Drug|Placebo|
79701613|NCT04991090|Radiation|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
79844342|NCT04036890|Drug|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
79701614|NCT04550793|Drug|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
79248159|NCT03579953|Device|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
79391522|NCT05067114|Device|Screening, detection and referral for atrial fibrillation|In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
79542110|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
79844343|NCT04036890|Drug|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
79844344|NCT00887874|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
79248160|NCT05331794|Behavioral|Training on BIOFIT-Park|"Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series."
79701615|NCT04550910|Radiation|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
79701616|NCT00479856|Drug|Lapatinib|Small molecule tyrosine kinase inhibitor
79701617|NCT00479856|Drug|Capecitabine|Chemotherapy
79391523|NCT03175926|Device|placebo Diskus®|device will be given daily for one week, two puffs per day
79391524|NCT03175926|Device|placebo Ellipta®|device will be given daily for one week, one puff per day
79701618|NCT00479856|Drug|Docetaxel|Chemotherapy
79701619|NCT00479856|Drug|nab-Paclitaxel|Chemotherapy
79701620|NCT04997759|Drug|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
79542111|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
79701621|NCT00479466|Drug|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
79701622|NCT00479466|Drug|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
79701623|NCT00479466|Drug|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
79844345|NCT00887952|Procedure|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
79844346|NCT00887952|Procedure|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
79844347|NCT02550860|Drug|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
79844348|NCT02550860|Drug|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
79844349|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
79844350|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
79386846|NCT03206502|Device|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
79386847|NCT03226860|Device|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
79248161|NCT05331794|Behavioral|Training on gym park equipament|Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
79844351|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
79248162|NCT03570073|Other|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
79542112|NCT01500044|Procedure|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
79542113|NCT01500044|Procedure|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
79844352|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
79844353|NCT02550782|Drug|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
79844354|NCT02550782|Drug|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
80013278|NCT05697250|Other|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
79386848|NCT03226860|Other|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
79386849|NCT00170625|Drug|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
79386850|NCT02043652|Drug|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
79391525|NCT03175926|Device|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
79542114|NCT01500642|Biological|Slit One|slit one sublingual immunotherapy 200 stu
79542115|NCT01500642|Biological|Slit One|slit one vestibular immunotherapy 200 stu
79701624|NCT00479466|Drug|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
79701625|NCT04991948|Drug|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
79701626|NCT04991948|Drug|FOLFOX|5-FU, leucovorin and oxaliplatin
79701627|NCT04991948|Drug|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
79844355|NCT04037982|Procedure|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
79701628|NCT04550286|Behavioral|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
79701629|NCT04550286|Behavioral|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
79701630|NCT04990778|Drug|Eprenetapopt|Given IV
79701631|NCT04990778|Drug|Venetoclax|Given PO
79844356|NCT04037982|Procedure|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
79844357|NCT00888030|Other|there are no interventions currently listed for this study|
79542116|NCT01500642|Biological|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
79844358|NCT03862820|Diagnostic Test|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
79844359|NCT00884988|Drug|Lymphomyosot|20 drops X3/day, until discharge
79248163|NCT03570073|Other|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
79248164|NCT03569995|Drug|Rituximab|500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)
79248165|NCT03569995|Drug|Methotrexate|500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory
79248166|NCT03569995|Drug|Cytarabine Injection|3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
79386851|NCT02043652|Drug|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
79386852|NCT02452164|Other|Teaching|
79386853|NCT02452164|Device|(CellScopeOTO)|
79542117|NCT01500655|Procedure|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
79386854|NCT02986204|Procedure|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~questions about your medical/contraception history~Review medical record~physical examination~urine sample for pregnancy test~Visit 2a - Radiology~Have an ultrasound of your arm~The radiologist will mark your arm at the location of the implant.~Visit 2b~ultrasound of your arm to locate the implant. This is done by feeling the area.~Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~Provide a urine sample for pregnancy test~Have the implant removal site examined"
79386855|NCT02986204|Procedure|continuation of ING implant|"the researcher(s) will ask you to:~To answer questions about your medical and contraception history~Review your medical record~Have a physical examination by the researcher~Provide a urine sample for pregnancy test~Have an ultrasound of your arm"
79542118|NCT01500655|Procedure|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
79542119|NCT01500668|Drug|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
79542120|NCT01500668|Drug|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
79542121|NCT01500707|Drug|SCH 900800|SCH 900800, one 20 mg tablet, orally
79542122|NCT01500785|Drug|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
79542123|NCT01500785|Drug|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
79542124|NCT01500811|Biological|cell injection|Intra articular injection of chondrocyte
79542125|NCT01500824|Drug|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
79542126|NCT01500837|Drug|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
79542127|NCT01500837|Drug|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
79542128|NCT01500850|Drug|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
79844360|NCT00884988|Drug|Placebo remedy|20 drops X3/day, until discharge
79248167|NCT03815162|Dietary Supplement|High Flavanol Cocoa extract|Experimental group
79248168|NCT03815162|Dietary Supplement|Alkalised cocoa|Control group
79391526|NCT02524054|Drug|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
79542129|NCT01500850|Drug|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
79391527|NCT02524054|Drug|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
79701632|NCT04993703|Other|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
79701633|NCT04993703|Other|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
79701634|NCT04993703|Other|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
79701635|NCT00479388|Drug|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
79701636|NCT00479388|Drug|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
79248169|NCT03579797|Behavioral|Screening, referral, follow-up and health management|Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
79701637|NCT00479388|Drug|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
79701638|NCT04670939|Procedure|breath exercises|diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
79701639|NCT04670276|Procedure|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
79248170|NCT05708911|Device|Pharyngeal exerciser|Pharyngo-esophageal manometry during lateral fluoroscopy
79248171|NCT02238431|Drug|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
79391528|NCT03175458|Procedure|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
79391529|NCT03175458|Procedure|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
79248172|NCT02238431|Drug|OCP|to schedule the start of the artificial cycle
79542130|NCT01500850|Drug|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
79542131|NCT01500850|Drug|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
79701640|NCT00479232|Drug|vorinostat|
79701641|NCT00479232|Drug|decitabine|
79701642|NCT00478881|Drug|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
79248173|NCT02238431|Other|Natural|to use the normal menstrual period to schedule treatment start
79248174|NCT02246335|Device|Cemented total hip arthroplasty|
79701643|NCT00478881|Drug|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
79248175|NCT02246335|Device|Cemented hemiarthroplasty|
79248176|NCT05122598|Drug|COT|The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
79248177|NCT05122598|Drug|Sham|Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
79701644|NCT02214108|Other|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
79701645|NCT04571775|Device|Qi-Shield user group|real device Qi-Shield (treatment)
79248178|NCT02238509|Drug|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
79248179|NCT02238509|Drug|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
79248180|NCT04022954|Device|Catheter ablation|Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
79248181|NCT03573271|Device|MCD|Micro-coring skin removal with automated coring device
79542132|NCT01500863|Drug|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
79542133|NCT01500863|Drug|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
79542134|NCT01500863|Drug|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
79542135|NCT01500863|Drug|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
79701646|NCT04571775|Device|Sham Qi-Shield user group|sham device (placebo)
79701647|NCT04670120|Drug|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
79701648|NCT00556127|Drug|Rituximab|375 mg/m2 on day 1
79844361|NCT00818948|Drug|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
79542136|NCT01500863|Drug|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
79844362|NCT04036734|Diagnostic Test|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
79844363|NCT04036734|Diagnostic Test|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
79844364|NCT01073215|Behavioral|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
79844365|NCT01073215|Behavioral|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
79844366|NCT05278728|Drug|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
80013279|NCT02264366|Behavioral|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
79844367|NCT05278728|Drug|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
80013280|NCT05693506|Other|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
79248182|NCT03568981|Radiation|Partial breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
79248183|NCT03568981|Radiation|Whole breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
79844368|NCT01073761|Drug|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
79844369|NCT03862664|Procedure|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
80013281|NCT02268890|Drug|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
80013282|NCT04918108|Biological|inflammatory response|laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
80013283|NCT02268968|Drug|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
80013284|NCT04480294|Drug|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
79391530|NCT03174834|Other|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
79542137|NCT01500863|Drug|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
79542138|NCT01500876|Radiation|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
79542139|NCT01500889|Procedure|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
79542140|NCT01500889|Procedure|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
79542141|NCT01500889|Procedure|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
79542142|NCT01500902|Other|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
79542143|NCT01500902|Other|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
79701649|NCT00556127|Drug|Epirubicin|110 mg/m2 on day 3
79701650|NCT00556127|Drug|Cyclophosphamide|1200 mg/m2 on day 3
79701651|NCT00556127|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
79701652|NCT00556127|Drug|Prednisone|40 mg/m2 from day 1 to 5
79844370|NCT00819104|Drug|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
79844371|NCT00819104|Drug|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
79844372|NCT00819104|Drug|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
79844373|NCT00819104|Drug|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
79844374|NCT00819104|Drug|Amlodipine 5mg|tablet,oral,OD,8 weeks
79844375|NCT02542098|Drug|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
79844376|NCT03617094|Device|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
80013285|NCT01359566|Drug|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
80013286|NCT01359566|Drug|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
80013287|NCT01359566|Drug|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
79701653|NCT00556127|Drug|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
79542144|NCT01500915|Drug|Ranibizumab|0,5mg intravitreal ranibizumab
79542145|NCT01500928|Device|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
79542146|NCT01500941|Dietary Supplement|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
79542147|NCT01500941|Other|maltodextrin|sachets
79542148|NCT01500967|Other|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
79701654|NCT00556127|Drug|Mitoxantrone|8 mg/m2 for 3-day
79701655|NCT00556127|Drug|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
79701656|NCT00556127|Drug|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
79701657|NCT00556127|Drug|Carmustine BCNU|300 mg/m2 on day -7
79701658|NCT00556127|Drug|Etoposide|100 mg/m2/12 hours
79701659|NCT00556127|Drug|Melphalan|140 mg/m2 on day -2
79701660|NCT00556127|Radiation|Radiotherapy|Involved Field Radiotherapy (IF-RT)
79701661|NCT00556127|Procedure|PBSC reinfusion|ASCT
79701662|NCT00478647|Biological|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
79701663|NCT04990934|Behavioral|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
79701664|NCT04550325|Biological|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
79701665|NCT00556205|Drug|Sunitinib|Sunitinib orally once daily
79701666|NCT00556205|Drug|Bevacizumab|Intravenously every 14 days
79701667|NCT00478608|Drug|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
79844377|NCT03617094|Device|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
79844378|NCT02541162|Behavioral|Oral information and interviews|interviews about sexuality and self experience during the disease
79844379|NCT04036656|Drug|SYHA136 0.5 mg|oral tablet
79844380|NCT04036656|Drug|SYHA136 1 mg|oral tablet
79844381|NCT04036656|Drug|SYHA136 2.5 mg|oral tablet
79844382|NCT04036656|Drug|SYHA136 5 mg|oral tablet
79844383|NCT04036656|Drug|SYHA136 10 mg|oral tablet
79844384|NCT04036656|Drug|SYHA136 20 mg|oral tablet
79844385|NCT04036656|Drug|SYHA136 35 mg|oral tablet
79844386|NCT04036656|Drug|SYHA136 50 mg|oral tablet
79844387|NCT04036656|Drug|Placebo matching SYHA136 0.5 mg|oral tablet
79844388|NCT04036656|Drug|Placebo matching SYHA136 1 mg|oral tablet
79844389|NCT04036656|Drug|Placebo matching SYHA136 2.5 mg|oral tablet
79844390|NCT04036656|Drug|Placebo matching SYHA136 5 mg|oral tablet
79844391|NCT04036656|Drug|Placebo matching SYHA136 10 mg|oral tablet
79844392|NCT04036656|Drug|Placebo matching SYHA136 20 mg|oral tablet
80013288|NCT01359566|Drug|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
79248184|NCT03584048|Other|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
79844393|NCT04036656|Drug|Placebo matching SYHA136 35 mg|oral tablet
79844394|NCT04036656|Drug|Placebo matching SYHA136 50 mg|oral tablet
79844395|NCT02541240|Other|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
79844396|NCT04036422|Device|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
79844397|NCT04036422|Other|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
79844398|NCT04036422|Other|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
80013289|NCT04904770|Device|Scoop stretcher|Already included in arm/group description
79844399|NCT00892164|Device|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
79844400|NCT00892164|Device|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
80013290|NCT04904770|Device|Vacuum mattress|Already included in arm/group description
80013291|NCT04379284|Other|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
80013292|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
80013293|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
80013294|NCT01356914|Drug|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
79248185|NCT03573193|Other|ridge preservation|"Intra operative procedures (for both groups) ridge preservation~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP)."
79248186|NCT03579407|Procedure|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
79248187|NCT03579914|Drug|intravenous Placebo|Patients receive intravenous Placebo (saline) injection
79248188|NCT03579914|Drug|Metoprolol Injectable Product|Patients receive intravenous Metoprolol injection
79542149|NCT01500967|Other|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
80013295|NCT01356914|Drug|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
79248189|NCT03579914|Device|Romote Ischemic Conditioning (RIC)|Patients receive RIC treatment
79248190|NCT03579914|Combination Product|Metoprolol & RIC|Patients receive Metoprolol & RIC treatment
79542150|NCT01500980|Biological|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
79542151|NCT01500980|Drug|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
79248191|NCT03573037|Drug|Oral anticoagulant|1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
79248192|NCT03586271|Procedure|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
79248193|NCT03586271|Procedure|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
79248194|NCT03586271|Procedure|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
79248195|NCT03586271|Procedure|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
79248196|NCT05354635|Other|Antibiotics Dosing|Dosing concerns the main antibiotics used in the unit: b-lactams, linezolid, vancomycin and aminosides
79248197|NCT03585413|Dietary Supplement|Micronutrient-probiotic-combination|Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
79248198|NCT03585413|Dietary Supplement|Micronutrient-placebo-combination|micronutrient (capsule)-placebo (powder)-supplement
79542152|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
79542153|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
79542154|NCT01500993|Drug|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
79542155|NCT01500993|Drug|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
79844401|NCT00640016|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
79844402|NCT00640016|Biological|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
79844403|NCT00640016|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
79844404|NCT00640016|Other|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
79542156|NCT01501019|Other|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
80013296|NCT04885816|Device|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
80013297|NCT04885816|Device|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
79542157|NCT01501032|Device|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
79542158|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
79542159|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
79542160|NCT01501058|Behavioral|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
79844405|NCT04036578|Device|A 12-week PFMT bio-assisted surface electromyographic program|
79844406|NCT00892242|Drug|Zoledronic acid|
79701668|NCT00556244|Procedure|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
79701669|NCT04550559|Procedure|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
79844407|NCT00885066|Drug|capecitabine|
79844408|NCT00885066|Drug|erlotinib hydrochloride|
79844409|NCT00885066|Drug|gemcitabine hydrochloride|
79844410|NCT00885144|Dietary Supplement|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
80013298|NCT03135314|Dietary Supplement|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
80013299|NCT03135314|Dietary Supplement|placebo|7 days of placebo intake
80013300|NCT04865614|Drug|Etomidate|Use of etomidate
80013301|NCT04865614|Drug|Sevoflurane|Use of sevoflurane
80013302|NCT01483898|Biological|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
79248199|NCT03449264|Biological|biological collection|"Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out."
79302773|NCT02478827|Behavioral|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
79386856|NCT03218982|Behavioral|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
79542161|NCT01501058|Behavioral|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
79701670|NCT00556283|Device|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
79701671|NCT00556283|Behavioral|Biofeedback|electromyographic-based treatment sessions
79701672|NCT00478257|Device|bright white light|Intervention: Bright white light administered for 30 minutes each morning
79701673|NCT00478257|Device|comparator red light treatment|dim red light administered for 30 minutes every morning
79701674|NCT00478140|Biological|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
79844411|NCT00885144|Dietary Supplement|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
79844412|NCT00885144|Dietary Supplement|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
80013303|NCT01483898|Other|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
80013304|NCT04847908|Other|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
79542162|NCT01501071|Device|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
79542163|NCT01501084|Drug|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
79701675|NCT00478140|Other|laboratory biomarker analysis|Correlative studies
79542164|NCT01501084|Drug|Normal saline .2cc subcutaneous injection|sterile saline injection
79701676|NCT04990739|Drug|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
79542165|NCT01501097|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
79701677|NCT00478023|Drug|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
79844413|NCT00885144|Dietary Supplement|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
79844414|NCT00885222|Device|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
80013305|NCT05377918|Other|Diary|spiritual diary group and diary gruop will write a diary
80013306|NCT02269046|Other|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
79701678|NCT00478023|Drug|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
79248200|NCT03568903|Other|Comprehensive physical therapy|Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
79248201|NCT03568825|Procedure|Osteopatic Manual Therapy (OMT)|OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
79302774|NCT05001321|Radiation|The whole abdomen contrast-enhanced CT scan|All the participants were measured by the whole abdomen contrast-enhanced CT scan.
79302775|NCT05001321|Other|H&E stained sections and slides|HE pathological examination was performed on all specimens of enrolled patients.
79302776|NCT03201679|Procedure|Repair of hip fracture|Patients undergoing hip fracture surgery
79542166|NCT01501123|Drug|Haloperidol|5mg IM
79542167|NCT01501123|Drug|Midazolam|IM midazolam
79542168|NCT01501136|Other|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
79542169|NCT01501136|Other|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
79701679|NCT00478023|Drug|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
79701680|NCT00478023|Drug|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
79701681|NCT00478023|Drug|Placebo|4 - 6 hourly; Total 72 hours
79701682|NCT04993001|Other|Open lung extubation|Before starting emergence from anesthesia, the patient will be transferred to their hospital bed or stretcher and seated at 30 degrees. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be maintained at the same level or increased to 50% (minimum FiO2) with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilation mode will be changed to pressure support. The level of pressure support will be modified by the anesthesiologist to generate the same volumes as with controlled ventilation. The PEEP will be maintained at the same level. The minimum respiratory rate will be reduced by 4 min-1. The inspiratory flow for triggering will be 2 L.min-1.
79844415|NCT00888108|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
79844416|NCT00888108|Drug|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
80013307|NCT02269046|Drug|Simvastatin|10mg/d,p.o,12 weeks.
79701683|NCT04993001|Other|Conventional extubation|Before starting emergence from anesthesia, the patient will be transferred to his hospital bed or stretcher and kept in the supine position. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be increased to 100% with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilator will be stopped with the APL valve open to atmosphere. The patient will be manually ventilated with the reservoir bag until spontaneous ventilation resumes. Then, the patient may be manually assisted if the treating anesthesiologist deems it necessary.
79844417|NCT00885300|Drug|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
79844418|NCT00885300|Drug|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
79844419|NCT00888186|Drug|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
79844420|NCT00892320|Drug|ER OROS paliperidone|
79844421|NCT00892398|Drug|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
79844422|NCT00892398|Procedure|standard care|standard post-operative care after trabeculectomy with mitomycin C
79844423|NCT00892476|Dietary Supplement|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
79844424|NCT00892476|Other|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
79844425|NCT00892554|Dietary Supplement|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
79844426|NCT00892554|Dietary Supplement|Corn/soy oil|Capsules taken once daily
79248202|NCT03569683|Procedure|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
79844427|NCT02541786|Drug|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
79844428|NCT02541786|Drug|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
80013308|NCT02269046|Other|Therapeutic Lifestyle Change|"Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg per day)~Therapeutic options for enhancing LDL lowering~Weight reduction~Increased physical activity"
79248203|NCT03569683|Device|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
79844429|NCT00888342|Drug|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 < 90%. If SpO2 < 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
79844430|NCT00888342|Drug|zopiclone|5 mg sedative given approximately 1 hour before sleep
79844431|NCT00888342|Other|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
79844432|NCT00892632|Procedure|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
79844433|NCT00608868|Drug|Gefitinib|Gefitinib tablet 250mg once daily orally
79844434|NCT00888420|Other|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
79844435|NCT00895518|Behavioral|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
79844436|NCT00888498|Other|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
79844437|NCT00888498|Other|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
80013309|NCT01483742|Drug|RO5024048|1000 mg orally bid, 24 weeks
80013310|NCT01483742|Drug|danoprevir|100 mg orally bid, 24 weeks
80013311|NCT01483742|Drug|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
79248204|NCT03569683|Other|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
79542170|NCT01501136|Other|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
79542171|NCT01501136|Other|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
79542172|NCT01501136|Radiation|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
80013312|NCT01483742|Drug|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
80013313|NCT01483742|Drug|ritonavir|100 mg orally bid, 24 weeks
80013314|NCT03065023|Drug|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
79542173|NCT01501149|Drug|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
79701684|NCT04995107|Device|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
79701685|NCT00477750|Drug|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
79701686|NCT00477750|Drug|melphalan|"Phase I - dose escalating: 5mg/m^2 dose level -1, 5 mg/m^2 dose level 0, 8 mg/m^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m^2 orally days 1-4 every 28 days until progression"
79701687|NCT00477750|Drug|prednisone|60mg/m^2, orally days 1-4 every 28 days until progression
79248205|NCT03569683|Other|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
79844438|NCT00888498|Other|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
79701688|NCT04670003|Other|users|Data of users of the web-application
79701689|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
79248206|NCT05079074|Diagnostic Test|ctDNA testing|ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
79248207|NCT03569605|Behavioral|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
79386857|NCT01898169|Other|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
79386858|NCT03227016|Drug|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
79386859|NCT03227016|Drug|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
79386860|NCT04748991|Drug|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
79386861|NCT04748991|Drug|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
79542174|NCT01501149|Drug|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
79542175|NCT01501175|Other|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
79701690|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
79701691|NCT00477672|Drug|Placebo|tablet, once daily by mouth, 6 weeks
79701692|NCT04549935|Drug|Dextenza|Dextenza 0.4mg
79701693|NCT04549935|Drug|Topical Prednisolone|Standard of care topical drop treatment
79701694|NCT00477633|Drug|Norethindrone/ethinyl estradiol|1 tablet per day
79701695|NCT04999787|Drug|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
79701696|NCT04999787|Drug|Placebo|Placebo
79701697|NCT04550091|Device|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
79701698|NCT04992767|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
79701699|NCT04992767|Behavioral|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
79701700|NCT04669847|Other|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
79701701|NCT04669847|Other|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
79844439|NCT00892788|Behavioral|contingency management|Prize-based contingency management for weight loss
79844440|NCT00892788|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
79701702|NCT04541901|Other|Massage|12 minutes of effleurage and petrissage on the upper limbs
79701703|NCT04541901|Other|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
79701704|NCT04669730|Other|usual care|Routine care
79844441|NCT00900978|Biological|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
79542176|NCT01501188|Other|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
80013315|NCT04720066|Diagnostic Test|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
79248208|NCT03569605|Behavioral|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
79542177|NCT01501188|Other|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
79542178|NCT01501214|Drug|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
79542179|NCT01501214|Drug|Normal saline|Normal saline given
79844442|NCT04036500|Drug|Estradiol Tablets|Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
79701705|NCT04669730|Behavioral|Walk|Walk 30mins
79701706|NCT04669730|Behavioral|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
79844443|NCT00895596|Drug|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
79701707|NCT04669730|Behavioral|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
79844444|NCT00901056|Device|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
79844445|NCT00895674|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
79844446|NCT00892944|Drug|AZD2516|Fractionated single oral dose
79844447|NCT04035330|Combination Product|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
79542180|NCT01501227|Device|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
79542181|NCT01501227|Other|Conventional endotracheal tube|Sham Comparator
79844448|NCT04035330|Combination Product|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
80013316|NCT04691128|Drug|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
80013317|NCT04691128|Drug|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
80013318|NCT04207918|Radiation|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
80013319|NCT04207918|Drug|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
79248209|NCT03569527|Dietary Supplement|Kiwifruit|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
79248210|NCT03569527|Dietary Supplement|Fiber|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
79542182|NCT01501253|Drug|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
79542183|NCT01501253|Drug|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
79844449|NCT02540694|Device|Endosonography|
79844450|NCT04035096|Drug|Ascorbic Acid|"Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~The final dose will be kept for 12 weeks.~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
79844451|NCT04035096|Other|Control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
79844452|NCT00608322|Drug|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
79844453|NCT00608322|Other|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
79844454|NCT04035018|Procedure|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
79844455|NCT04035018|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
80013320|NCT04207918|Drug|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
80013321|NCT02269202|Drug|Midazolam, tablet|
80013322|NCT02269202|Drug|Crobenetine, i.v. infusion|
80013323|NCT02269202|Drug|Placebo|
80013324|NCT02266316|Device|Air warming mask|Mask that warms air at the mouth
79701708|NCT04992338|Device|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
79701709|NCT04541823|Drug|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
79701710|NCT04541823|Drug|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
79701711|NCT04996043|Dietary Supplement|Collagen Peptide Drink|Testing product
79701712|NCT04996043|Dietary Supplement|Placebo drink|Blank
79844456|NCT00608244|Drug|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
79844457|NCT00608244|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
79844458|NCT00893100|Drug|Diltiazem|2%,3 times daily
79844459|NCT00895908|Behavioral|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
79248211|NCT03569527|Dietary Supplement|Prunes|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.
79542184|NCT01501253|Drug|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
79542185|NCT01501279|Procedure|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
79542186|NCT01501292|Other|Fixation and staining|Fixation and staining by MitiTracker Green FM
79248212|NCT05277428|Dietary Supplement|GTB1|2 capsule/day
79248213|NCT05277428|Dietary Supplement|Placebo|2 capsule/day
79542187|NCT01501292|Other|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
79542188|NCT01501305|Dietary Supplement|Mineral solution|Rehydration mineral solution
79542189|NCT01501305|Dietary Supplement|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
79542190|NCT01501318|Behavioral|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
79542191|NCT01501318|Behavioral|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
79248214|NCT00708201|Drug|Alvimopan|
79248215|NCT00708201|Drug|Placebo|
79542192|NCT01501331|Device|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
79542193|NCT01501344|Dietary Supplement|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
79542194|NCT01501357|Behavioral|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
79542195|NCT01501357|Behavioral|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
79542196|NCT01501370|Drug|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
79542197|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
79542198|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
79701713|NCT04541862|Other|Intensive care|intensive care for critically ill patients in the intensive care units
79701714|NCT04549584|Diagnostic Test|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
79701715|NCT04994093|Other|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
79701716|NCT04669496|Drug|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
79701717|NCT04669769|Other|interview|telephone interview
79701718|NCT04571450|Behavioral|Reintervention|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
79701719|NCT04571411|Other|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
79701720|NCT04541784|Other|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
79844460|NCT00895908|Behavioral|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
79844461|NCT00895986|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
80013325|NCT04655638|Device|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
79248216|NCT03339440|Behavioral|Hearts & Parks|The Hearts & Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
79248217|NCT03572959|Drug|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
79386862|NCT03230136|Other|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
79542199|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
79542200|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
79542201|NCT01501396|Drug|Megestrol Acetate|
79542202|NCT01501396|Drug|Mirtazapine|
79542203|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
79542204|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
79542205|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
79542206|NCT01501422|Drug|Estrogen patch|50 microgram estrogen patch weekly
79542207|NCT01501422|Drug|Placebo|Placebo patch for 8 weeks
79542208|NCT01501435|Drug|CJ-30039|single dose
79542209|NCT01501435|Drug|fenofibric acid|single dose
79386863|NCT03230136|Other|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
79248218|NCT03572959|Device|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
79248219|NCT03291002|Biological|CV8102|CV8102 alone
79542210|NCT01501448|Drug|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
79542211|NCT01501448|Drug|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
79701721|NCT04541784|Other|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
79701722|NCT04669262|Drug|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
79701723|NCT04669262|Drug|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
79701724|NCT04669262|Drug|Placebo|Placebo to match BGB-DXP593
79701725|NCT04669262|Drug|Placebo|Placebo to match BGB-DXP604
79701726|NCT04999319|Procedure|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
79542212|NCT01501461|Procedure|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
79701727|NCT04999319|Procedure|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
79701728|NCT04549818|Device|sacral neuromodulation|Sacral neuromodulation group, N=22 will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
79844462|NCT00895986|Behavioral|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
80013326|NCT04655638|Device|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
80013327|NCT02266394|Drug|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
80013328|NCT02266394|Procedure|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
80013329|NCT03614923|Biological|Etokimab|Administered by subcutaneous injection
79542213|NCT01501487|Drug|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
79542214|NCT01501487|Drug|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
79248220|NCT03291002|Biological|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
79386864|NCT03120156|Device|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
79386865|NCT03120156|Device|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
79542215|NCT01501487|Drug|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
79701729|NCT04541550|Drug|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
79701730|NCT04541550|Drug|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
79701731|NCT04541550|Drug|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
79701732|NCT00556361|Drug|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
79701733|NCT00556361|Drug|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
80013330|NCT03614923|Biological|Placebo|Administered by subcutaneous injection
79248221|NCT03568747|Device|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
79248222|NCT03568747|Device|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
79386866|NCT03120156|Other|No insoles|control group with no insoles in the shoes
79386867|NCT03218046|Behavioral|EMDR|Eye Movement Desensitisation and Reprocessing
79386868|NCT03119844|Other|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
79248223|NCT02500251|Drug|belimumab|Belimumab will be administered per study protocol.
79248224|NCT02500251|Drug|Bortezomib|Bortezomib will be administered per study protocol.
79248225|NCT02500251|Drug|Rituximab|Rituximab will be administered per study protocol.
79248226|NCT02500251|Drug|Plasmapheresis|Plasmapheresis will be administered per study protocol.
79248227|NCT03572881|Device|Endocardial mapping|An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
79386869|NCT03119844|Other|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
79701734|NCT04549350|Other|PSQI|Assessment of sleep quality using Pittsburgh Sleep Quality Index (PSQI): It is a simple tool which assess the sleep quality over one month period. It included seven components with a global PSQI score > 5 is indicative of poor sleep quality
79701735|NCT04671290|Other|Any intervention|No intervention
79701736|NCT04571606|Procedure|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
79701737|NCT04571606|Procedure|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
79701738|NCT04669613|Other|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
79701739|NCT04541160|Diagnostic Test|CR|Lung imaging evaluation performed with CR
79844463|NCT02539914|Other|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
79844464|NCT02539914|Other|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
79844465|NCT00901212|Device|Device programming|6-month period
79844466|NCT00896376|Biological|trastuzumab|
79844467|NCT00896376|Other|laboratory biomarker analysis|
79844468|NCT00896376|Other|pharmacological study|
79844469|NCT00901290|Drug|monophasic oral contraceptive|mg, oral dose
79844470|NCT00901290|Drug|AZD7325|mg, oral dose
79844471|NCT04018014|Other|CT angiography|CT angiography in detection of pulmonary embolism
79386870|NCT03119844|Other|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
80013331|NCT03614923|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
80013332|NCT01353248|Drug|GS-5885|tablet, 30 mg QD
80013333|NCT01353248|Drug|Tegobuvir|capsule, 30 mg BID
80013334|NCT01353248|Drug|GS-9451|tablet, 200 mg QD
80013335|NCT01353248|Drug|ribavirin tablet|(weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
79542216|NCT01501487|Drug|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
79542217|NCT01501487|Drug|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
79701740|NCT04541160|Diagnostic Test|ULDCT|Lung imaging evaluation performed with ULDCT
80013336|NCT01353248|Drug|GS-5885|tablet, 90 mg QD
80013337|NCT05095636|Drug|Apatinib Mesylate|oral Apatinib once everyday
80013338|NCT05095636|Drug|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
80013339|NCT05756959|Device|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
79248228|NCT03928730|Procedure|resection and removal|Surgical resection or removal for histopathological examination
79248229|NCT02505555|Device|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
79248230|NCT03568591|Procedure|Psychosensory Therapy|Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
79248231|NCT03756662|Device|ARGOS-SC suprachoroidal pressure sensor|The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
79248232|NCT03568513|Dietary Supplement|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
79248233|NCT03568513|Dietary Supplement|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
79248234|NCT02982668|Other|Initial enteral feeding|
79386871|NCT03206268|Device|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
79248235|NCT02982668|Drug|metoclopramide or mosapride|gastrointestinal (GI) motility improving
79386872|NCT03217656|Other|No intervention|
79386873|NCT03206034|Behavioral|Stylistic Memory Enhancement|
79386874|NCT03120000|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
79386875|NCT03206112|Other|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
79386876|NCT03206112|Other|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
79386877|NCT03206112|Other|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
79386878|NCT03217344|Procedure|conservative treatment|immobilization on sling of the injured arm
79701741|NCT04541277|Drug|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
79701742|NCT04541394|Device|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
79701743|NCT02210234|Dietary Supplement|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
79701744|NCT02210234|Dietary Supplement|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
79701745|NCT02214264|Behavioral|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
80013340|NCT05756959|Device|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
80013341|NCT05756959|Device|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
79248236|NCT02848313|Drug|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
79844472|NCT00893256|Drug|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
79386879|NCT00176865|Procedure|Stem Cell Transplant|IV on Day 0
80013342|NCT02264444|Other|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
79386880|NCT00176865|Drug|Fludarabine|30mg/m^2 IV Day -7 through Day -3
79386881|NCT00176865|Drug|Melphalan|140 mg/m^2 IV Day -1
79386882|NCT00176865|Drug|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
79386883|NCT00176865|Drug|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
79386884|NCT00176865|Drug|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children <40 kg) maintaining a level of >200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
79542218|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
79542219|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
79701746|NCT02214264|Behavioral|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
79542220|NCT01501487|Drug|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
79701747|NCT02214264|Behavioral|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
79701748|NCT02214264|Behavioral|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
79701749|NCT04549740|Diagnostic Test|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
79701750|NCT04571294|Procedure|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
79844473|NCT00893256|Drug|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
79844474|NCT00893256|Drug|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
79844475|NCT00893256|Drug|Placebo|Placebo: once daily
79844476|NCT00605280|Drug|Standard of Care|Clinicians decision to use optional laser therapy.
79844477|NCT00605280|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
79248237|NCT02496117|Procedure|Electrical mapping, nerve stimulation checked renal denervation procedure|
79248238|NCT02496117|Procedure|Electrial mapping, nerve stimulation guided renal denervation procedure|
79248239|NCT03071965|Biological|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
79844478|NCT00901368|Drug|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
79248240|NCT03071965|Procedure|Surgery|Surgery to implant device for NT-501
79248241|NCT03071965|Procedure|Surgery|Sham surgery
79248242|NCT03584867|Other|refresher training at six months|a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
79248243|NCT02247973|Biological|mesenchymal stem cells|Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14
79248244|NCT02247973|Biological|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
79386885|NCT00176865|Drug|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
79386886|NCT00176865|Drug|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
79386887|NCT02451072|Drug|Placebo|Capsules containing mannitol looking identical to LSD per os
79386888|NCT02451072|Drug|LSD|100µg per os, single dose
79386889|NCT02451072|Drug|Ketanserin|40mg per os, single dose looking identical to LSD per os
79386890|NCT03205878|Other|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
79386891|NCT03205878|Device|CPAP|Patients will receive CPAP according to standard care
79386892|NCT03205800|Other|Mini-screw|Placement of a mini-screw
80013343|NCT05095558|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
80013344|NCT01343966|Drug|MABT5102A|Repeating subcutaneous injection
80013345|NCT01343966|Drug|MABT5102A|Repeating intravenous infusion
79542221|NCT01501500|Drug|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
79701751|NCT04541316|Device|ProFlor inguinal hernia device|Inguinal hernia repair
79844479|NCT00901368|Drug|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
79844480|NCT00607386|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
79844481|NCT04034940|Other|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
79844482|NCT00901446|Device|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
79844483|NCT00901524|Drug|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
79844484|NCT00893412|Drug|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
79844485|NCT00893412|Procedure|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
79844486|NCT00893412|Drug|Placebo|
79844487|NCT00896688|Procedure|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
79844488|NCT00896766|Genetic|loss of heterozygosity analysis|
79542222|NCT01501500|Drug|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
79542223|NCT01501539|Procedure|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
79542224|NCT01501539|Procedure|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
79701752|NCT04541238|Diagnostic Test|MRI|Magnetic resonance imaging
79701753|NCT04997408|Device|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
79542225|NCT01501552|Other|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
79248245|NCT05001932|Procedure|Cataract surgery|Randomized Clinical Trial
79542226|NCT01501552|Other|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
79542227|NCT01501552|Other|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
79542228|NCT01501565|Procedure|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
79542229|NCT01501591|Drug|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
79701754|NCT04997408|Other|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
79701755|NCT04541199|Device|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
79844489|NCT00896766|Genetic|microarray analysis|
79844490|NCT00896766|Genetic|polymorphism analysis|
79701756|NCT04541199|Device|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
79844491|NCT00896766|Genetic|tumor replication error analysis|
79844492|NCT00896844|Behavioral|emotional disclosure|writing about emotional events from the past
79844493|NCT00896844|Behavioral|placebo writing|writing about how they spent their time the previous day
79844494|NCT04036344|Behavioral|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
79248246|NCT03572803|Other|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
79542230|NCT01501591|Other|Placebo|Matching placebo once on two different days, 72 hours apart.
79701757|NCT02210351|Device|MRI test|
79701758|NCT02214342|Other|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
79701759|NCT04549389|Device|Low intensity shockwave therapy|LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
79844495|NCT00893490|Device|Ahmed Glaucoma Valve (AGV)|AGV implantation
79844496|NCT00893490|Drug|Mitomycin C (MMC)|3 minute MMC application
79844497|NCT00893490|Procedure|amniotic membrane coverage|single layer coverage of amniotic membrane
79844498|NCT00901758|Drug|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
79844499|NCT00901758|Drug|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
79844500|NCT00893568|Other|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
79844501|NCT00896922|Genetic|microarray analysis|
79844502|NCT00896922|Other|immunohistochemistry staining method|
79844503|NCT00896922|Other|laboratory biomarker analysis|
79844504|NCT02539680|Procedure|endoscopy|duodenal biopsies
80013346|NCT01343966|Drug|placebo|Repeating subcutaneous injection
79701760|NCT04549623|Device|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
79701761|NCT04549623|Device|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
79701762|NCT04570982|Biological|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
79701763|NCT04548843|Procedure|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
79701764|NCT04548843|Procedure|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
79542231|NCT01501591|Drug|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
79386893|NCT03226782|Other|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
79542232|NCT01501604|Drug|BKM120|100 MG PO QD in cycles of 28 days
79542233|NCT01501617|Biological|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
79542234|NCT01501617|Device|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
79542235|NCT01501630|Device|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
79701765|NCT04548843|Biological|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
79701766|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
79701767|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
79701768|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
79844505|NCT00901836|Radiation|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
79248247|NCT03572803|Other|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
79701769|NCT04993586|Biological|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
79701770|NCT04993586|Biological|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
79248248|NCT03572803|Other|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
79248249|NCT03584633|Drug|Indocyanine Green|The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
79701771|NCT04992221|Procedure|arterial line|arterial line inserted for invasice mointroing and sampling
79844506|NCT00901836|Procedure|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
79844507|NCT04017780|Device|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
79844508|NCT04017780|Device|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
79844509|NCT04017780|Device|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
79248250|NCT02500095|Other|Fasting|72 hours of fasting
79248251|NCT02500095|Drug|Saline|Concomitant saline during fasting
79248252|NCT02500095|Drug|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
79248253|NCT05233215|Behavioral|GROW (Glioma Specialists Reaching Out With Support) Support Program|Follow-up survivorship care plan for patients and caregivers
79248254|NCT03577925|Diagnostic Test|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
79248255|NCT04497207|Other|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
79542236|NCT01501643|Device|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
79542237|NCT01501643|Device|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
79844510|NCT00897078|Other|laboratory biomarker analysis|
79844511|NCT00897078|Other|medical chart review|
79844512|NCT00897078|Other|metabolic assessment|
79844513|NCT00897078|Other|questionnaire administration|will be obtained at a single clinic visit
79248256|NCT02398526|Drug|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
79248257|NCT05354479|Drug|Paracetamol|babies will get expressed breast milk along with paracatamol for pain relief
79248258|NCT02505321|Other|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
79248259|NCT02505321|Procedure|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
79542238|NCT01501669|Drug|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
79542239|NCT01501695|Drug|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
79701772|NCT04548765|Behavioral|Letter|Recipients receive a letter promoting CRC screening.
79701773|NCT04548765|Behavioral|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
79542240|NCT01501695|Drug|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
79701774|NCT04548765|Behavioral|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
79844514|NCT00897078|Procedure|assessment of therapy complications|
79248260|NCT04873310|Other|Triple P online with professional support|The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found
79844515|NCT00638690|Drug|Placebo|Four tablets once daily until disease progression
79844516|NCT00638690|Drug|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
79844517|NCT00638690|Drug|Prednisone/prednisolone|5 mg twice daily until disease progression
79248261|NCT04873310|Other|Triple P online without professional support|The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
79248262|NCT03579095|Dietary Supplement|Cereboost|200mg Cereboost and Maltodextrin capsules
79248263|NCT03579095|Dietary Supplement|Placebo|200mg Maltodextrin capsules
79302777|NCT02482961|Drug|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
79542241|NCT01501695|Drug|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
79542242|NCT01501708|Drug|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
79542243|NCT01501721|Behavioral|Exercise|Home-based exercise program
79701775|NCT04548765|Behavioral|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
79844518|NCT02540928|Drug|AMG 319 hydrate|
79844519|NCT02540928|Drug|Placebo|
79844520|NCT00893646|Behavioral|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
79844521|NCT00893724|Drug|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
79844522|NCT00893724|Dietary Supplement|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine [SR] - 1[500mg] tablet bid Tocopherols [200IU], Tocotrienol [10mg], CoQ10 [50mg] - combination capsule bid Sustained Release Niacinamide - 1 [750mg] tablet bid Vitamin C - 1 [1000mg] sustained release tablet bid N-acetyl Cysteine - 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
79844523|NCT00893724|Drug|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine [SR] - 1 [500mg] tablet bid Tocopherol [200IU], Tocotrienol [10mg], CoQ10 [50mg] combination capsule bid Sustained Release Niacinamide 1 [750mg] tablet bid Vitamin C 1 [1000mg] sustained release tablet bid N-acetyl Cysteine 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 [50mg] tablet qd
80013347|NCT01343966|Drug|placebo|Repeating intravenous infusion
79542244|NCT01501721|Behavioral|Diet|Nutritional counseling aiming to reduce suggar intake
79248264|NCT05354401|Other|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
79542245|NCT01501734|Device|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
79248265|NCT04805762|Other|Your COACH Next Door|Children in the study are attending the lifestyle intervention Your COACH Next Door. A coach is supporting the child and it's family to reach their goals regarding lifestyle.
79542246|NCT01501747|Drug|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
79248266|NCT03577847|Diagnostic Test|Rural CT scanning|Rural computer tomography for acute stroke
79248267|NCT02495649|Other|[18F]-DOPA|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
79701776|NCT04548765|Behavioral|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
79701777|NCT04540926|Drug|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
79701778|NCT04540809|Other|Assessment of strength, proprioception, skill and coordination of the hand|Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
79248268|NCT02495649|Device|PET-CT|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
79701779|NCT04540965|Drug|Telaglenastat|Glutaminase inhibitor
79542247|NCT01501747|Drug|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
79542248|NCT01501760|Drug|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
79844524|NCT00893802|Other|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
79844525|NCT00819338|Dietary Supplement|Efamax|5g daily as capsules for 3 months
79844526|NCT00893880|Drug|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
79248269|NCT04749446|Other|Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)|"This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures"
79302778|NCT02478749|Procedure|arm retraction|gently pulling through the ipsilateral arm to the knee
79302779|NCT02449525|Procedure|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
79542249|NCT01501760|Drug|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
79542250|NCT01501773|Biological|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
79701780|NCT04540965|Drug|Famotidine|Histamine-H2 Receptor Antagonist
79701781|NCT04540965|Drug|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
79844527|NCT00815438|Procedure|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
79844528|NCT00815594|Drug|bevacizumab|0.05ml, 1.25mg
80013348|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
79542251|NCT01501786|Drug|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
79542252|NCT01501786|Drug|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
79701782|NCT04548687|Procedure|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
79248270|NCT03568357|Procedure|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
79701783|NCT04548687|Procedure|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
79701784|NCT02215356|Drug|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
79386894|NCT03226782|Other|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
79542253|NCT01501786|Drug|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
79386895|NCT03226626|Drug|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) & Intravenous antibiotic delivery (IVAD).
79386896|NCT03226626|Device|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
79542254|NCT01501799|Drug|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
79542255|NCT01501799|Drug|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
79542256|NCT01501799|Drug|Placebo (Vehicle Gel)|Vehicle Gel
79542257|NCT01501812|Behavioral|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
79701785|NCT02215356|Drug|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
79701786|NCT04540653|Biological|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
79701787|NCT04540653|Biological|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
79701788|NCT04999514|Behavioral|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
79701789|NCT04548960|Other|cancer patients|Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
79701790|NCT04570865|Drug|Dapagliflozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
79701791|NCT04570865|Device|CardioMEMS|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
79701792|NCT04540731|Other|This is an observational study without intervention|This is an observational study without intervention
79701793|NCT04570748|Procedure|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
79701794|NCT04570748|Procedure|capsulectomy|capsulectomy without repair
79701795|NCT04548726|Device|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
79248271|NCT02495727|Behavioral|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
79542258|NCT01501825|Device|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
79701796|NCT04548726|Device|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
79701797|NCT04548492|Other|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
79248272|NCT02495727|Behavioral|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
80013349|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
79248273|NCT02495727|Behavioral|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
79844529|NCT00897234|Other|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
79844530|NCT00815672|Behavioral|Exercise|Progressive walking and resistance exercise treatment
80013350|NCT05095480|Drug|Red Yeast Rice Pill|Taking Lesstat
80013351|NCT05095480|Drug|Placebo|Placebo receiving group
80013352|NCT04438408|Other|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
80013353|NCT06091891|Drug|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
80013354|NCT06091891|Drug|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
80013355|NCT06091852|Dietary Supplement|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
79248274|NCT02495805|Procedure|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
79248275|NCT02495805|Procedure|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
80013356|NCT06091839|Other|suturing technique in arteriovenous fistula creation for hemodialysis|End-to-side AV anastomosis was created in upper limb between cephalic vein and brachial or radial artery
79701798|NCT04540419|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
79701799|NCT04540419|Biological|Placebo|Intramuscular administration
79701800|NCT04570826|Other|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
79248276|NCT04732988|Drug|HSG4112|Once-daily oral administration
79701801|NCT04570826|Other|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
80013357|NCT06091826|Drug|NFL-101|Subcutaneous injections
79701802|NCT04540614|Other|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
80013358|NCT06091826|Drug|Placebo|Subcutaneous injections
80013359|NCT06091800|Other|biochemical analysis|GCF and serum samples were collected from the participants for biochemical analysis.
80013360|NCT06091787|Drug|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
80013361|NCT06091787|Other|Standard Medical Treatment|Standard Medical Treatment
79248277|NCT04732988|Drug|Placebo|Once-daily oral administration
79248278|NCT05354011|Other|Kinesiotape|Tape with a width of 5 cm and a thickness of 0.5 mm will be utilized. Kinesio Tex I Strip is estimated from elbow to fingertips and cut. It will be collapsed roughly two squares from the end and cut into two triangles on the overlay. The third and fourth fingers are fallen through openings and Kinesio Tex is applied on the dorsum of the hand with no strain. The situation of elbow extension, wrist extension, and radial deviation is given, and Kinesio Tex will be applied from hand to medial epicondyle with 15%-25% tension and end at medial epicondyle with no strain
79701803|NCT04561427|Other|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
79844531|NCT00897312|Biological|infliximab|
79844532|NCT00897312|Biological|pegylated interferon alfa|
79844533|NCT00897312|Biological|ticilimumab|
79844534|NCT00897312|Drug|ribavirin|
79844535|NCT00897312|Other|high performance liquid chromatography|
79844536|NCT00897312|Other|laboratory biomarker analysis|
79386897|NCT02451228|Other|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
79386898|NCT02450994|Drug|Dexamethasone|
79386899|NCT02450994|Drug|Placebo|
79386900|NCT00177255|Drug|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
79386901|NCT00177255|Drug|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
79386902|NCT03205722|Other|Non-Interventional|Non-Interventional
79386903|NCT02401048|Drug|Ibrutinib|
79386904|NCT02401048|Drug|MEDI4736|
79386905|NCT03215550|Procedure|CEA|Carotid Endarterectomy
79386906|NCT03215550|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
79844537|NCT02540460|Drug|LCB01-0371 800mg|LCB01-0371 800mg
79248279|NCT05354011|Other|Active Release Technique|This group will receive Kinesiotaping with the same method along with Active release technique will be performed on group 2. We will apply profound tension at the region of tenderness while the patient is told to effectively move the injury site from a shortened to lengthened position. The setting of a contact point close to the injury and making the patient move in a way that creates a longitudinal sliding movement of delicate tissues e.g. nerves, ligaments and muscles underneath the contact point.
79248280|NCT02505399|Drug|ticagrelor|"Ticagrelor will be administered orally, according to the following scheme:~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~90 mg the following morning (D Day before rotational atherectomy and angioplasty),~90 mg the following evening (D Day after rotational atherectomy and angioplasty),~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
79542259|NCT01501825|Device|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
79542260|NCT01501864|Behavioral|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
79701804|NCT04548531|Behavioral|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
79701805|NCT04570592|Drug|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
79386907|NCT03215550|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
79542261|NCT01501877|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
79701806|NCT04570592|Drug|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
79701807|NCT04540263|Diagnostic Test|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
79701808|NCT04570514|Procedure|PCI|percutaneous coronary intervention (PCI)
79701809|NCT04548414|Other|No.|This is an observational study with no intervention.
79701810|NCT04560959|Device|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
79701811|NCT04548336|Behavioral|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
79701812|NCT04548336|Behavioral|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
79701813|NCT04548336|Behavioral|Placebo group|This group will watch a video of nature without a human component.
79701814|NCT02211872|Drug|BI 2536 BS, intravenous|
79701815|NCT02214459|Behavioral|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
79844538|NCT02540460|Drug|LCB01-0371 800mg BID|LCB01-0371 800mg BID
79248281|NCT02505399|Drug|clopidogrel|"Clopidogrel will be administered orally, according to the following scheme:~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~75 mg the following morning (D Day before rotational atherectomy and angioplasty),~0 mg the following evening (D Day after rotational atherectomy and angioplasty),~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
79386908|NCT00178191|Other|Bladder diary|3-day bladder diary
79386909|NCT00178191|Other|Questionnaires|Incontinence Quality of Life questionnaires
79386910|NCT00178191|Procedure|Urodynamics|Urodynamics
79386911|NCT00178191|Other|Pad weight|Pad weight
79386912|NCT03215784|Dietary Supplement|Fish Oil|
79386913|NCT03215784|Dietary Supplement|Probiotic|
79386914|NCT03215784|Dietary Supplement|Placebo|
79386915|NCT02046382|Drug|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
79701816|NCT04561037|Device|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
79701817|NCT04561037|Other|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
79701818|NCT04548453|Device|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
79701819|NCT02215395|Drug|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
79844539|NCT02540460|Drug|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
79844540|NCT02540460|Drug|Placebo|Placebo
79844541|NCT00543387|Drug|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
79701820|NCT04561310|Other|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I & II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
79701821|NCT04561310|Other|Active release technique|"Active release technique with maitland mobilization Grade I & II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
79701822|NCT02215434|Drug|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
79701823|NCT02215434|Drug|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
79701824|NCT04561076|Drug|HLX70|Single-dose, intravenous infusion
79701825|NCT04561076|Other|Placebo|Single-dose, intravenous infusion
79701826|NCT02215473|Drug|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
79701827|NCT02215473|Procedure|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
79701828|NCT04560842|Device|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
79542262|NCT01501877|Behavioral|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
79542263|NCT01501890|Drug|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
79701829|NCT04560842|Device|Conventional oxygen therapy|Conventional oxygen device
79248282|NCT04814498|Drug|Geneva Cocktail|Fixed sequence use of drug cocktail
79386916|NCT02046382|Drug|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
79844542|NCT00543387|Drug|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m^2 Q12H during the first 2 days of each 21-day cycle.
79386917|NCT03205176|Drug|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
79542264|NCT01501890|Drug|Placebo|0.9% NaCl
79542265|NCT01501903|Procedure|Standard|FNA in a single plane
79542266|NCT01501903|Procedure|Fanning|FNA in multiple planes
79542267|NCT01501916|Dietary Supplement|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
79542268|NCT01501916|Dietary Supplement|Placebo|daily intake of placebo
79542269|NCT01501942|Drug|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
79542270|NCT01501942|Drug|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
79542271|NCT01501968|Drug|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
79542272|NCT01501968|Drug|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
79701830|NCT04548102|Other|Fetal movement count|Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
79844543|NCT02551250|Device|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
79844544|NCT02551250|Device|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
79248283|NCT04814498|Drug|BLD-0409|Fixed sequence use of active product
79248284|NCT03572725|Procedure|Gas tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
79248285|NCT03572725|Procedure|Air tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
79248286|NCT02728089|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
79248287|NCT04436900|Procedure|Panretinal Photocoagulation (PRP)|PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
79386918|NCT03205176|Drug|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
79386919|NCT02046772|Drug|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
79386920|NCT02046772|Drug|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
79386921|NCT02046772|Drug|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
79386922|NCT03205254|Other|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
79844545|NCT03455556|Biological|Anetumab Ravtansine|Given IV
79844546|NCT03455556|Biological|Atezolizumab|Given IV
79844547|NCT03455556|Other|Laboratory Biomarker Analysis|Correlative studies
79701831|NCT04560764|Device|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
79701832|NCT04560764|Device|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
79701833|NCT04560764|Device|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
79542273|NCT01501994|Other|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
79701834|NCT04560764|Other|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
79701835|NCT04570241|Behavioral|Malaria toolkit|Knowledge, attitude, and practice on malaria
79701836|NCT02215512|Drug|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
79701837|NCT04548258|Device|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
79701838|NCT04548258|Device|casting|casting metal framework
79844548|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
79701839|NCT02215590|Device|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
79701840|NCT04547829|Drug|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
79701841|NCT02211911|Drug|Bisacodyl|
79701842|NCT02211911|Drug|Sodium picosulfate|
79701843|NCT04540146|Diagnostic Test|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
79248288|NCT03567187|Device|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
79248289|NCT05110118|Drug|LY01008|Single intravenous injection
79248290|NCT05110118|Drug|Avastin|Single intravenous injection
79386923|NCT03205254|Other|Fast food diet|four days of participant-scaled isocaloric fast food meals
79386924|NCT00178503|Drug|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
79386925|NCT00178503|Drug|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
79386926|NCT00178503|Other|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
79386927|NCT02376010|Drug|rivaroxaban|
79386928|NCT02376010|Drug|Warfarin|
79386929|NCT03205332|Behavioral|Concreteness Training|
79248291|NCT03567967|Behavioral|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
79701844|NCT04560491|Diagnostic Test|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
80013362|NCT06091774|Device|CHD therapy through iATROS medical device|The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
80013363|NCT06091748|Drug|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
79701845|NCT01131676|Drug|BI 10773 low dose|BI 10773 tablets once daily
79701846|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
79701847|NCT01131676|Drug|BI 10773 high dose|BI 10773 tablets once daily
79248292|NCT04443075|Device|faecal sample collector|The frontline medical workers mainly exposed under the stress of fighting against 2019-nCoV
79701848|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
80013364|NCT06091709|Other|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
79248293|NCT05106530|Diagnostic Test|Holter, ECG|Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
79248294|NCT03042169|Drug|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
79248295|NCT03042169|Procedure|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
79248296|NCT03042169|Drug|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
79542274|NCT01501994|Other|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
79701849|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
79248297|NCT02495571|Other|Cough Assessment in ALS Patients|"Volitional Cough assessment by spirometer:~a) Peak Cough Espiratory Flow (PCEF)~Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
79701850|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
79248298|NCT03572647|Drug|Eritromax|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
79701851|NCT04560569|Drug|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
79701852|NCT04560569|Drug|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
79701853|NCT04547322|Other|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
79701854|NCT04539990|Behavioral|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
79701855|NCT04560530|Radiation|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
80013365|NCT06091709|Other|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
80013366|NCT06091696|Other|inspiratory muscle training|inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.
79248299|NCT03572647|Drug|Eprex|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
79248300|NCT02495493|Drug|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
79248301|NCT02495181|Drug|Intravitreal Aflibercept|
79305542|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
79701856|NCT04540029|Other|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
79701857|NCT04560374|Device|crochet octopus|Delivering crochet octopus to the hands of the neonates
79844549|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
79844550|NCT04045106|Other|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
79844551|NCT04017624|Other|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
79701858|NCT04539912|Device|angulated screw retained crown|ASC abutment was used in AG;
79701859|NCT04539912|Device|cemented crown|prefabricated Ti abutment was used in CG
79542275|NCT01501994|Procedure|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
79701860|NCT04560257|Device|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
79701861|NCT04547361|Drug|E2511|E2511 tablets.
79701862|NCT04547361|Drug|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
79701863|NCT02882971|Behavioral|Pain Assessment|To create an objective observational pain scoring system and validate.
79248302|NCT05109572|Other|Hospitalized|It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.
79248303|NCT05109572|Other|Non-hospitalized with emergency care|It is adapted from the Buss-Durkee Hostility Inventory by Buss and Perry (1992), the scale consists of 29 items and five-point Likert types. The scale is physical and verbal aggression, hostility, and anger. Questions 9 and 16 on the scale are reverse scored. The score value on the scale varies in direct proportion to the aggression, that is, the higher the score, the higher the aggression. The Cronbach Alpha internal consistency coefficients of the original version of the scale is defined as; 0.89 for physical aggression, 0.85 for physical aggression, 0.72 for verbal aggression, 0.77 for hostility, 0.83 for anger subscale.
79701864|NCT02215629|Drug|VS-4718|
79844552|NCT04017624|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
79844553|NCT00815828|Other|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
79844554|NCT04006197|Other|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
79701865|NCT01131520|Behavioral|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
79844555|NCT02540304|Behavioral|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
79844556|NCT00808964|Drug|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
79701866|NCT01131520|Behavioral|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
79701867|NCT01131325|Drug|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
79701868|NCT04547244|Other|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
79542276|NCT01502007|Other|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
79386930|NCT03205410|Procedure|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
79542277|NCT01502007|Other|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
79701869|NCT04560062|Other|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
79542278|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
79386931|NCT03205410|Procedure|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
79542279|NCT01502020|Drug|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
79701870|NCT01131130|Device|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
80013367|NCT06091683|Procedure|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|"Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy."
79542280|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
80013368|NCT06091670|Other|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
79248304|NCT05109572|Other|Non-hospitalized and non-emergency care|"Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always."
79542281|NCT01502046|Drug|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
79248305|NCT02499861|Drug|Decitabine and Genistein|intravenous Decitabine with oral genistein
79248306|NCT05106140|Other|Magnetic Resonance Imaging (MRI)|A research MRI will be performed at 6-weeks post-stroke to document stroke lesion location and size.
79248307|NCT05106140|Device|Kinarm Robotic Exoskeleton Assessment|"The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements.~The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours."
79248308|NCT05106140|Other|Clinical Assessment|The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
79248309|NCT05519319|Procedure|RFA|RFA will be performed
79248310|NCT05519319|Procedure|PDT|PDT will be performed
79248311|NCT05519319|Procedure|RFA combined with PDT|RFA and PDT will be performed
79386932|NCT02452086|Device|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
79386933|NCT02452086|Procedure|Placebo|LLLT with zero intensity
79386934|NCT00085293|Drug|Decitabine|Starting dose 6 mg/m^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
79386935|NCT00085293|Radiation|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
79701871|NCT01131130|Device|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
79386936|NCT00085293|Biological|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
79701872|NCT01131130|Device|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
79844557|NCT00982839|Procedure|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
79844558|NCT00982839|Procedure|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
79701873|NCT04547478|Diagnostic Test|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
79248312|NCT05109260|Diagnostic Test|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
79844559|NCT00897468|Other|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
79701874|NCT01130974|Device|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
79844560|NCT00897468|Other|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
79844561|NCT02551406|Device|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
79248313|NCT05505435|Drug|Depot-Medroxyprogestereone Acetate|subcutaneous depot medroxyprogesterone acetate
79248314|NCT05505435|Drug|Depot-Medroxyprogestereone Acetate|intramuscular depot medroxyprogesterone acetate
79248315|NCT05109182|Device|Innersight3D|Innersight3D generates a virtual interactive 3D model of the CT scan.
79248316|NCT02840461|Drug|Ivermectin Cream, 1%|
79248317|NCT02840461|Drug|Placebo/Vehicle cream|
79386937|NCT00085293|Radiation|Fludeoxyglucose F 18|Optional correlative studies
79386938|NCT00085293|Procedure|Positron emission tomography|Optional correlative studies
79542282|NCT01502046|Drug|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
79542283|NCT01502059|Other|Pilates|Pilates training - twice a week (one hour per class) during 90 days
79542284|NCT01502098|Procedure|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
79542285|NCT01502098|Other|Sling|Sling for 4 weeks
79248318|NCT03343821|Other|Balance and daily life questionnaire|Patients complete questionnaire
79701875|NCT01130974|Device|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
79701876|NCT04560101|Drug|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
79248319|NCT05108792|Other|NO INTERVENTION|observational study, no intervention performed
79248320|NCT03343743|Other|Oligomineral water|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
79248321|NCT03567811|Procedure|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
79386939|NCT03215628|Diagnostic Test|TCEUS|Intravenous sulphur hexafluoride microbubbles
79386940|NCT03215394|Behavioral|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
79542286|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
79542287|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
79542288|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
79542289|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
79701877|NCT02214498|Drug|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
79701878|NCT02214498|Drug|Placebo|
79844562|NCT00988299|Other|exercise|exercise sessions at 45% and 60% of maximum effort
79844563|NCT00809042|Drug|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
79844564|NCT00809042|Drug|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
79844565|NCT00809042|Drug|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
79844566|NCT00809042|Drug|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
79844567|NCT02539602|Behavioral|The Need to Know students received the N2K curriculum as described previously|
79542290|NCT01502150|Other|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
79542291|NCT01502150|Other|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
79844568|NCT00988377|Other|dietary intervention|whey protein 10-40 g
79844569|NCT00988377|Other|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
79542292|NCT01502163|Device|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
79542293|NCT01502163|Device|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
79542294|NCT01502189|Other|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
79844570|NCT02551328|Drug|sevofluorane|Continuous infusion of sevofluorane
79248322|NCT03567031|Procedure|EtCO2 modification|Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
79701879|NCT04311775|Device|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
79701880|NCT04311775|Other|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
79701881|NCT04560218|Drug|sublingual Misoprostol|apply drug by Anesthesiologist
79701882|NCT04560218|Drug|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
79248323|NCT05108714|Device|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
79386941|NCT03215394|Behavioral|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
79701883|NCT05135104|Drug|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~in combination with an aromatase inhibitor;~in combination with fulvestrant in women who have received prior endocrine therapy."
79701884|NCT04547517|Other|Evaluation of Counselling competencies|To complete a set of questionnaires
79844571|NCT00897546|Other|laboratory biomarker analysis|
79844572|NCT00982917|Behavioral|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
79844573|NCT00982917|Behavioral|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
79844574|NCT00901914|Biological|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
79391531|NCT03175770|Procedure|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
79542295|NCT01502202|Drug|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
79844575|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
79248324|NCT05108714|Device|Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device|Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
79248325|NCT05108714|Device|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
79542296|NCT01502202|Drug|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
79542297|NCT01502202|Drug|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
79844576|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
79844577|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
79844578|NCT00815906|Drug|SBI-087|IV, Single dose
79844579|NCT00815906|Drug|SBI-087|IV, Single dose
79844580|NCT00815906|Drug|SBI-087|SC, Single dose
79248326|NCT05108714|Procedure|Intravenous cannulation after without prior interventions|insertion of 18G catheter in a cubital vein without prior interventions.
79542298|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
79542299|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
79701885|NCT04559828|Other|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
79248327|NCT02505165|Behavioral|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
79386942|NCT03215394|Other|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
79386943|NCT03215394|Behavioral|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
79248328|NCT02505165|Other|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
79386944|NCT03215160|Behavioral|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
79386945|NCT03226314|Procedure|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
79386946|NCT03205098|Biological|Blood analysis|Blood test of biological markers of mesenteric ischemia
79542300|NCT01502241|Drug|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
79542301|NCT01502241|Radiation|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
79701886|NCT04579718|Other|Zeus Cloud TPS V1.0|Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
79701887|NCT04579718|Other|Eclipse|Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
79701888|NCT04540185|Biological|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
79701889|NCT04540185|Biological|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
79701890|NCT04540185|Drug|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
79701891|NCT04540185|Drug|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
79701892|NCT04540185|Combination Product|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
79701893|NCT04540185|Combination Product|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
79701894|NCT00575744|Procedure|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
79701895|NCT02214537|Other|MACS|
79844581|NCT00815906|Drug|SBI-087|SC, Single dose
79844582|NCT00988455|Radiation|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
79844583|NCT00897624|Genetic|gene expression analysis|
79248329|NCT04500626|Drug|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
79248330|NCT02495415|Drug|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
79248331|NCT05106062|Device|on remote monitoring|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
79248332|NCT02499939|Behavioral|Standard Care|Education and home exercises
79305543|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
79305544|NCT03242291|Other|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
79701896|NCT01130272|Drug|Eluxadoline|Tablets, orally, twice daily.
79701897|NCT01130272|Drug|Placebo|Matching placebo oral tablets twice daily.
79542302|NCT01502254|Other|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
79542303|NCT01502267|Drug|High dose IVIG and B cell depleting agents|"IVIG(2g/kg two times on day 1, 30)~Rituximab(375mg/m2 on day 3)~Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
79701898|NCT04559789|Behavioral|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
79701899|NCT04559789|Other|Health Education|Health education materials delivered electronically
79701900|NCT04559399|Procedure|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
79701901|NCT04539600|Drug|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
79844584|NCT00897624|Genetic|reverse transcriptase-polymerase chain reaction|
79844585|NCT00897624|Other|laboratory biomarker analysis|
79844586|NCT00815984|Procedure|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
79248333|NCT02499939|Other|Ultrasound Therapy|"Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)"
79386947|NCT02402062|Drug|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
79542304|NCT01502319|Behavioral|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
79701902|NCT00575822|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
79701903|NCT00575822|Device|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
79248334|NCT03572491|Biological|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
79248335|NCT02505009|Drug|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
79248336|NCT02505009|Drug|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
79248337|NCT02505009|Drug|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
79248338|NCT03567733|Device|XIENCE Sierra|Percutaneous coronary intervention
79386948|NCT03205020|Diagnostic Test|serum amyloid a test|"Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
79542305|NCT01502345|Biological|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
79542306|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
79844587|NCT00986037|Drug|ABT-308|Single IV doses
79844588|NCT00986037|Drug|ABT-308|Multiple SC doses x 3
79844589|NCT00986037|Drug|Placebo|Single IV dose
79844590|NCT00986037|Drug|Placebo|Multiple SC doses x 3
79844591|NCT00901992|Behavioral|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
79844592|NCT00901992|Behavioral|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
79844593|NCT00983151|Drug|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
79844594|NCT00897780|Behavioral|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
79844595|NCT00635570|Drug|Ortho Tri-cyclen Lo|Low dose oral contraceptive
79844596|NCT00635570|Device|NuvaRing|Contraceptive vaginal ring
79844597|NCT00893958|Drug|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
79386949|NCT02379442|Biological|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
79701904|NCT04546815|Drug|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
79701905|NCT01129960|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
79701906|NCT01129960|Drug|Placebo|Tablets will be used.
79701907|NCT04539756|Behavioral|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
79701908|NCT04539756|Behavioral|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
79701909|NCT01129921|Device|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
79701910|NCT01129921|Device|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
79701911|NCT04559672|Procedure|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
79701912|NCT04559672|Procedure|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
79701913|NCT04312087|Procedure|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
79701914|NCT04312087|Procedure|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
79701915|NCT04312087|Procedure|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
79701916|NCT04311814|Diagnostic Test|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
79701917|NCT04559165|Other|sericin and chitosan cream|sericin and chitosan cream
79386950|NCT02450760|Other|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
79701918|NCT04312048|Drug|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
79701919|NCT04312048|Drug|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
79701920|NCT04547127|Biological|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
79701921|NCT04547127|Drug|Standard Medical Treatment|SMT
79844598|NCT00986115|Drug|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
79844599|NCT00986115|Drug|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
79248339|NCT05105906|Diagnostic Test|cognitive tests performed|cognitive tests performed
79248340|NCT04420208|Procedure|Modified Pap test|Adding a non-painful step after the most uncomfortable phase of Pap smear
79248341|NCT05353543|Drug|SSRIs|In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
79305545|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
79701922|NCT00625222|Procedure|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
79305546|NCT04486937|Drug|S410914 tablet|S410914 tablet
79305547|NCT03242213|Behavioral|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
79386951|NCT02450838|Biological|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
79386952|NCT02450838|Biological|Alhydrogel™|Aluminum hydroxide gel adjuvant
79386953|NCT02450838|Biological|Placebo|
79542307|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
79542308|NCT01502358|Biological|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
79542309|NCT01502384|Other|neurological examination|motor and cognitive functions
79542310|NCT01502449|Behavioral|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
79542311|NCT01502449|Other|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
79542312|NCT01502488|Procedure|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
79701923|NCT04311697|Drug|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
79701924|NCT04311697|Drug|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
79701925|NCT00575861|Drug|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
79701926|NCT04547088|Drug|Camrelizumab|Anti-PD-1 targeted immunotherapy
79701927|NCT04547088|Drug|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
79701928|NCT04559360|Device|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
79701929|NCT01129882|Drug|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
79701930|NCT04546854|Behavioral|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
79701931|NCT00575900|Behavioral|dietary intervention|12 weeks of dietary intervention
79844600|NCT00983229|Procedure|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
79844601|NCT00809120|Device|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
79248342|NCT05353543|Procedure|acupuncture (strong reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
79305548|NCT04931121|Drug|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
79386954|NCT02402296|Drug|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
79701932|NCT02278419|Drug|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
79701933|NCT02278419|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
79542313|NCT01502501|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
79701934|NCT04559321|Procedure|Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.|General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
79701935|NCT02882737|Drug|Glucagon before exercise|
79542314|NCT01502514|Procedure|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
79844602|NCT04035876|Drug|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
79844603|NCT00902070|Drug|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
79844604|NCT00635492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
79844605|NCT00635492|Drug|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
79844606|NCT00543309|Drug|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
79844607|NCT00543309|Drug|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
79542315|NCT01502527|Dietary Supplement|Femarelle|Twice daily oral treatment with Femarelle
79542316|NCT01502553|Device|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
79542317|NCT01502566|Behavioral|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
79701936|NCT02882737|Drug|Glucagon after exercise|
79701937|NCT02882737|Drug|Glucagon after resting|
79701938|NCT04539171|Other|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
79701939|NCT02882698|Behavioral|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
79701940|NCT02882698|Behavioral|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
79701941|NCT02882698|Behavioral|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
79701942|NCT02882698|Behavioral|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
79844608|NCT00543309|Drug|placebo|Placebo bolus on CPB, then placebo infusion
79844609|NCT00902148|Device|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
79844610|NCT00894114|Biological|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
79701943|NCT02883010|Device|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
79701944|NCT02883010|Other|Standard Care|Care path normally used by the hospital
79701945|NCT02211950|Drug|BI 44847|
79542318|NCT01502592|Procedure|Cryoablation|"OncCore Biopsy (+ Cryo) Date*~Pre- and post- cryo MRI~Core biopsy x ≥3~Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.*"
80013369|NCT06091644|Device|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
79701946|NCT02211950|Drug|Acarbose|
79701947|NCT02211950|Other|Japanese diet|
79701948|NCT02882776|Dietary Supplement|Ginger drink|Ginger powder dissolved in water
79248343|NCT05353543|Procedure|acupuncture (weak reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
79542319|NCT01502592|Biological|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date*~MRI~Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
79542320|NCT01502605|Drug|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
79542321|NCT01502618|Behavioral|Focus Group|N/A. Protocol is the focus group
79701949|NCT04539210|Device|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
79701950|NCT02882659|Biological|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
79701951|NCT04579055|Other|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
79701952|NCT04579055|Other|1-min STS test: standardized|Standardized chair seat height of 46 cm
79844611|NCT00894114|Biological|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
79844612|NCT00986193|Procedure|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
79542322|NCT01502657|Device|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
79542323|NCT01502670|Drug|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
79542324|NCT01502683|Procedure|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
79844613|NCT00986193|Procedure|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
79844614|NCT02540382|Device|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
79701953|NCT04539288|Other||There is no intervention in this study.
79701954|NCT04559087|Procedure|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
79701955|NCT04546893|Biological|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
79701956|NCT04579289|Other|questionnaire|"A questionnaire was e-mailed to all identified institutions, with 3 reminders in one month. It included 39 questions concerning :~morbidity and mortality linked with COVID-19~structural features of the facility (location, architecture, residents characteristics)~human resources~crisis management (visits and circulation restrictions, personal protective equipment)"
79701957|NCT04579328|Behavioral|Exposure to Growth Mats|see arm/group descriptions for description of intervention
79701958|NCT04546932|Procedure|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O [24]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
80013370|NCT06091631|Procedure|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
79542325|NCT01502683|Procedure|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
79542326|NCT01502683|Procedure|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
79542327|NCT01502683|Procedure|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
79701959|NCT04578860|Other|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
79701960|NCT04578860|Other|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
79701961|NCT04578860|Other|Treatment as usual for sleep disorders|No intervention
79844615|NCT02540382|Device|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
79248344|NCT05353543|Procedure|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
79542328|NCT01502696|Biological|PEG IFN alfa-2b|3µg/kg weekly injections
79844616|NCT00986271|Procedure|EVLI was determinated by PiCCO plus system.|
79844617|NCT00988611|Other|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
79844618|NCT00897936|Genetic|DNA methylation analysis|
79844619|NCT00897936|Genetic|comparative genomic hybridization|
79542329|NCT01502722|Behavioral|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
79542330|NCT01502735|Biological|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
79542331|NCT01502735|Biological|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
79542332|NCT01502748|Other|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
79542333|NCT01502774|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
79844620|NCT00897936|Genetic|fluorescence in situ hybridization|
79844621|NCT00897936|Genetic|microarray analysis|
79844622|NCT00897936|Genetic|polymerase chain reaction|
79542334|NCT01502774|Drug|Placebo|One single intravenous bolus injection of Placebo
79542335|NCT01502774|Procedure|Echocardiography|1 year after AMI
79701962|NCT04546386|Procedure|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
79844623|NCT00897936|Other|diagnostic laboratory biomarker analysis|
79844624|NCT00897936|Other|immunologic technique|
79844625|NCT00988689|Other|Dietary Intervention|soup with or without starch
79248345|NCT02499627|Drug|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
79248346|NCT02499627|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
79248347|NCT03567655|Drug|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
79701963|NCT04546503|Procedure|Continuous Regional analgesia|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~+ General anaesthesia"
79701964|NCT04546503|Procedure|Control Group|General anaesthesia without regional analgesia
79701965|NCT04558853|Drug|autologous NK cells|Autologous ex vivo expanded and activated NK cells
79701966|NCT04546659|Other|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
79844626|NCT04006977|Dietary Supplement|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
79844627|NCT04006977|Dietary Supplement|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
79844628|NCT04332432|Drug|belapectin|intravenous
79844629|NCT00988767|Biological|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
79844630|NCT00898014|Genetic|fluorescence in situ hybridization|
79844631|NCT00898014|Other|immunologic technique|
79844632|NCT00898014|Other|laboratory biomarker analysis|
79386955|NCT02402296|Other|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
80013371|NCT06091618|Procedure|new technique of ejaculatory preserving laser prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation. Complete resection of the middle lobe to the abovementioned mark. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
80013372|NCT06091618|Procedure|conventional technique of laser vaporization of the prostate|conventional laser vaporization of the prostate
80013373|NCT06091605|Procedure|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
79844633|NCT00569582|Drug|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
80013374|NCT06091592|Other|Serum autotaxın levels|Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
80013375|NCT06091579|Drug|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
80013376|NCT06091579|Drug|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
80013377|NCT06091553|Drug|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
79386956|NCT03214302|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
80013378|NCT06091553|Drug|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
80013379|NCT06091553|Drug|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
79386957|NCT00085839|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
79386958|NCT00085839|Drug|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
79542336|NCT01502800|Drug|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
79701967|NCT04546659|Other|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
79701968|NCT04558814|Diagnostic Test|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
80013380|NCT06091527|Behavioral|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
79844634|NCT00894192|Device|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
79844635|NCT00894192|Device|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
79844636|NCT00988845|Dietary Supplement|Indole-3-carbinol|200 mg bid po X 8 weeks
79844637|NCT00894270|Procedure|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
79844638|NCT00894270|Procedure|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
79844639|NCT00894270|Device|Novofine needle|Novofine 5mm needle
79248348|NCT02505087|Drug|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
79844640|NCT00819416|Drug|5% albumin|5% albumin for the first 7 days of care in the ICU
79844641|NCT00819416|Drug|Normal Saline|Normal Saline for the first 7 days of care in the ICU
79248349|NCT02505087|Drug|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
79248350|NCT05105828|Diagnostic Test|Share wave fibro scan|Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
79248351|NCT03566875|Procedure|Total knee arthroplasty with the Stryker's MAKO™ system|The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
79248352|NCT03566875|Procedure|Total knee arthroplasty with mechanical ancillary|The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
79844642|NCT04005807|Drug|BPN-14967|BPN-14967 oral capsules
79844643|NCT04005807|Drug|Placebo|Oral capsules
79844644|NCT00898092|Genetic|microarray analysis|
79844645|NCT00898092|Genetic|molecular genetic technique|
79844646|NCT00898092|Genetic|mutation analysis|
79844647|NCT00898092|Genetic|polymerase chain reaction|
79844648|NCT00898092|Genetic|reverse transcriptase-polymerase chain reaction|
79844649|NCT00898092|Other|diagnostic laboratory biomarker analysis|
79701969|NCT04546464|Behavioral|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
79701970|NCT01129102|Drug|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
79701971|NCT01129102|Drug|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
79248353|NCT02499705|Dietary Supplement|Sucralose|2 packets
79248354|NCT02499705|Dietary Supplement|Sucrose|equisweet to sucralose
79386959|NCT03204864|Device|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
79701972|NCT01129102|Drug|Placebo|Placebo for NPC-01
79386960|NCT03204864|Device|Conventional CS lead placement|Clinical Practice
79386961|NCT02402452|Drug|Voxilaprevir|100 mg tablet administered orally
79386962|NCT03204708|Device|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
79701973|NCT04539132|Behavioral|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
79701974|NCT04538820|Drug|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
79386963|NCT03204708|Drug|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
79386964|NCT03204630|Dietary Supplement|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
79386965|NCT03204630|Dietary Supplement|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
79386966|NCT03204630|Other|Control|Standard infant formula
80013381|NCT06091527|Behavioral|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
79248355|NCT02499705|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
79248356|NCT04288544|Dietary Supplement|Microalgae|Open, monocentric intervention study in crossover design
79248357|NCT04288544|Dietary Supplement|Omega-3-fatty acid capsule|Open, monocentric intervention study in crossover design
79248358|NCT04288544|Dietary Supplement|sea fish|Open, monocentric intervention study in crossover design
79248359|NCT02499549|Drug|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
79248360|NCT02839681|Drug|Anetumab Ravtansine|Administered intravenously (IV) every 3 weeks
79248361|NCT02839681|Device|Blood test|Research blood test for eligibility
79386967|NCT02049502|Biological|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
79386968|NCT02049502|Procedure|sigmoidoscopy|
79386969|NCT03204552|Other|No intervention (observational study)|No intervention (observational study)
79386970|NCT02260869|Procedure|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
79391532|NCT03106662|Biological|mesenchymal stem cells|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
79391533|NCT03106662|Drug|cyclophosphamide administration|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
79701975|NCT04538820|Drug|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
79701976|NCT04538820|Drug|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
79844650|NCT00983697|Procedure|therapeutic conventional surgery|
79844651|NCT00983697|Radiation|fludeoxyglucose F 18|
80013382|NCT06091514|Device|CS Medical Watch|The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
80013383|NCT06091514|Other|Specific questionnaire|Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
79701977|NCT00575978|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
79248362|NCT05105204|Device|ArteVu|The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
79701978|NCT01129024|Drug|Lusutrombopag|tablet
79844652|NCT00902460|Drug|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
79844653|NCT00902460|Drug|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
79701979|NCT04546347|Radiation|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of [14C]AZD9833 Solution for Infusion
79248363|NCT02494947|Behavioral|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
79248364|NCT02494947|Other|Usual care|
79248365|NCT02504463|Drug|Samidorphan IV|Single IV administration
79248366|NCT02504463|Drug|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
79248367|NCT02504463|Drug|[14c]-Samidorphan oral|Single oral administration containing radiolabel
79248368|NCT03566719|Other|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
79248369|NCT04437212|Drug|Toripalimab|Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.
79248370|NCT03566641|Device|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
79386971|NCT02260869|Device|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
79386972|NCT03204474|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
79542337|NCT01502800|Drug|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
79701980|NCT04546347|Drug|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
79701981|NCT04546347|Drug|AZD9833 Oral Solution|AZD9833 Oral Solution
79844654|NCT00988923|Other|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
79844655|NCT00988923|Other|No intervention|the intervention tool was switched in off, only bolus was activated
79844656|NCT02539446|Behavioral|stable condition|
79844657|NCT02539446|Behavioral|unstable condition|
80013384|NCT06091488|Other|Orthopure|Reconstruction of the anterior cruciate ligament of the knee in the patient.
79248371|NCT03566641|Other|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
79248372|NCT02494635|Other|Laboratory Biomarker Analysis|Biomarker analysis
79248373|NCT04123496|Device|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
79248374|NCT03566563|Other|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
79248375|NCT03568279|Procedure|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
79248376|NCT03568279|Procedure|Control|The intubation was done without two-handed jaw thrust.
79248377|NCT03341793|Diagnostic Test|Muscle biopsy and blood test|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
79302780|NCT02478593|Behavioral|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
79391534|NCT02417610|Device|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
79701982|NCT04546347|Drug|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
79701983|NCT04546347|Drug|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
79701984|NCT04546347|Drug|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
79701985|NCT02882932|Procedure|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
79844658|NCT02539446|Behavioral|attentional focus|
79844659|NCT00989079|Drug|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
79701986|NCT04559477|Other|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
79701987|NCT04559477|Other|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
79701988|NCT04539054|Dietary Supplement|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
79844660|NCT00989079|Drug|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
79844661|NCT00809198|Other|Sodium Hyaluronate|
79844662|NCT00809198|Other|Carboxymethylcellulose sodium|
79844663|NCT00898170|Procedure|myoma removal|surgical removal of myoma by hysterectomy
79844664|NCT04006743|Behavioral|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
79302781|NCT03199417|Drug|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
79386973|NCT03204474|Drug|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
79542338|NCT01502800|Drug|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
79386974|NCT03204318|Drug|Relugolix|Relugolix 40-mg tablet administered orally once daily.
79542339|NCT01502800|Drug|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
79701989|NCT04539054|Dietary Supplement|Nutricost caffeine powder|Caffeine powder.
79701990|NCT04539054|Dietary Supplement|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
79701991|NCT00576017|Drug|Fentanyl-TTS|
79701992|NCT04558697|Drug|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
79701993|NCT04558697|Drug|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
79844665|NCT04006743|Behavioral|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
79844666|NCT04006743|Behavioral|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
80013385|NCT06091475|Drug|Other|Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
80013386|NCT06091462|Other|Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program|"Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia."
79302782|NCT03199417|Other|Placebo|An identically packaged placebo cream
79305549|NCT04931277|Procedure|cataract surgery|stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.
79386975|NCT03204318|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
79386976|NCT03204318|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
79386977|NCT03204318|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
79391535|NCT02417610|Device|Hyaluronic acid - HA - Ialart|Hyaluronic acid
79844667|NCT04006743|Behavioral|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
79542340|NCT01502826|Dietary Supplement|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
79542341|NCT01502839|Other|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
79542342|NCT01502878|Dietary Supplement|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
79542343|NCT01502878|Dietary Supplement|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
79701994|NCT04558697|Drug|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
79701995|NCT04558697|Drug|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
79701996|NCT04546269|Procedure|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
79844668|NCT04006743|Behavioral|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
79386978|NCT02402764|Drug|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m^2).
79386979|NCT03204006|Drug|Dexmedetomidine|Dexmedetomidine preinduction
79386980|NCT03204006|Drug|sterile saline|normal saline preinduction
79386981|NCT02380612|Device|ReCell Treatment|
79542344|NCT01502878|Dietary Supplement|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
79542345|NCT01502891|Other|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
79542346|NCT01502904|Device|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
79542347|NCT01502904|Device|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
79542348|NCT01502904|Drug|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
79542349|NCT01502904|Drug|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
79701997|NCT04558658|Diagnostic Test|Complete Blood Count|neutrophil to lymphocyte ratio
79701998|NCT02215707|Biological|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
79844669|NCT00986505|Drug|Lidocaine|Intravenous lidocaine once a week
79386982|NCT02380612|Procedure|Skin Graft|
79386983|NCT03204162|Other|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
79386984|NCT03226080|Drug|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
79542350|NCT01502904|Drug|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
79305550|NCT03241823|Diagnostic Test|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
79305551|NCT03241823|Diagnostic Test|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
79305552|NCT03241823|Diagnostic Test|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
79305553|NCT03241823|Diagnostic Test|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
79305554|NCT03241901|Drug|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
79305555|NCT03241901|Drug|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
79701999|NCT01128946|Drug|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
79702000|NCT01128946|Drug|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
79702001|NCT01128946|Drug|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
79702002|NCT04558580|Drug|Rufinamide|Rufinamide
79702003|NCT04546035|Device|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
79844670|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
79542351|NCT01502904|Drug|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
79248378|NCT04105712|Behavioral|Dietary Change (low in highly processed foods)|For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
79386985|NCT03226080|Drug|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
79386986|NCT03226080|Drug|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
79542352|NCT01502930|Behavioral|IRT|Internet-based IRT with therapist support during 6 weeks
79542353|NCT01502930|Behavioral|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
79702004|NCT02882620|Behavioral|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
79702005|NCT02882620|Behavioral|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
79702006|NCT02882620|Behavioral|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
79702007|NCT00625261|Other|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
79702008|NCT00625300|Device|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
79702009|NCT00625300|Device|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
79702010|NCT00576134|Device|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
79702011|NCT02215746|Drug|BI 44370 powder for oral solution|
79702012|NCT02215746|Drug|BI 44370 tablet|
79702013|NCT02215746|Other|high fat breakfast|
79702014|NCT02278458|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
80013387|NCT06091449|Other|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
79248379|NCT03566407|Procedure|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
79386987|NCT03226002|Device|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
79386988|NCT02403622|Drug|Fecal Microbiota Preparation|Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
79386989|NCT03225924|Drug|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
79386990|NCT03225924|Drug|Rituximab|cycles of 21 days - 375mg/m²
79702015|NCT02278458|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
79702016|NCT02215785|Other|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
79702017|NCT02215824|Drug|BIWH 3|
79386991|NCT03225924|Drug|Cyclophosphamide|cycles of 21 days - 750 mg/m²
79386992|NCT03225924|Drug|Doxorubicin|cycles of 21 days - 50mg/m²
79702018|NCT02215824|Drug|Placebo|
79542354|NCT01502943|Drug|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
79702019|NCT01128595|Drug|FF/GW642444M|
79702020|NCT01128595|Drug|GW642444M|
79702021|NCT01128595|Drug|Fluticasone Furoate|
79702022|NCT01128595|Drug|Placebo|
79702023|NCT01129336|Drug|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
79542355|NCT01502943|Drug|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
79702024|NCT01129336|Drug|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
79702025|NCT02882386|Other|Strength Training|
79702026|NCT02882386|Dietary Supplement|Milk 1%|
79386993|NCT03225924|Drug|Vincristine|cycles of 21 days - 1.4mg/m²
79248380|NCT04061954|Behavioral|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~Parents receive training regarding agriculture and micro credit projects, and financial assistance~One child per family receives a social skill training group preparing them for returning to school~Access to schools and school material~If needed medical assistance is provided~If needed legal assistance is provided"
79248381|NCT02499471|Other|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
79248382|NCT03566329|Drug|Magnesium sulphate|Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
79248383|NCT03566329|Drug|Lidocaine Hydrochloride|lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
79702027|NCT02882386|Dietary Supplement|Whey protein concentrate 80 (WPC-80)|
79702028|NCT02882386|Dietary Supplement|Microparticulated whey|
79386994|NCT03225924|Drug|Prednisone|cycles of 21 days - 40mg/m²
79844671|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
79248384|NCT03566329|Drug|Normal saline|Normal saline infusion with the same rate of infusion as the study drugs
79248385|NCT03824990|Behavioral|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
79248386|NCT02499315|Drug|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
79248387|NCT02499315|Drug|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
79302785|NCT02482727|Device|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
79302786|NCT03212131|Drug|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
79386995|NCT02381392|Device|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
79702029|NCT02882386|Dietary Supplement|Hydrolyzed whey|
79386996|NCT03226236|Radiation|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
79702030|NCT02882386|Dietary Supplement|Native whey|
79709943|NCT02891772|Procedure|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
79702031|NCT01128361|Behavioral|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
79702032|NCT01128361|Behavioral|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
79702033|NCT01128244|Dietary Supplement|Vitamin B6|Subjects will receive vitamin B6 supplementation.
79844672|NCT04017858|Behavioral|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
79844673|NCT04017858|Behavioral|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
79844674|NCT03687333|Drug|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
79844675|NCT00902616|Dietary Supplement|L-arginine|3gm TDS for three months
79844676|NCT00902616|Dietary Supplement|Placebo Lactose powder|3gm TDS for 3 months
80013388|NCT06091449|Other|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
79386997|NCT03226236|Biological|Autologous DC vaccine|The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
79248388|NCT03566251|Other|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
79248389|NCT03566251|Other|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
79302787|NCT03314909|Procedure|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
79305556|NCT03241901|Other|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
79542356|NCT01502943|Drug|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
79542357|NCT01502943|Drug|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
79386998|NCT03226236|Drug|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
79386999|NCT02986126|Behavioral|Resiliency Class|See Arm Description
79387000|NCT02986126|Other|Resource for Services (RS)|See Resource for Services (RS) Description
79387001|NCT03119532|Other|Receive metric feedback email|If the provider received an email about the participants performance metrics
79702034|NCT01128244|Procedure|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
79702035|NCT04545996|Other|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
80013389|NCT06091436|Drug|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
79248390|NCT03566251|Other|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
79248391|NCT03566251|Other|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
79248392|NCT02504385|Device|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
79248393|NCT02504385|Other|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
79248394|NCT05047016|Other|Virtual investigational product|The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
80013390|NCT06091436|Drug|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
80013391|NCT06091436|Biological|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79542358|NCT01502943|Drug|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
79542359|NCT01502969|Biological|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
79542360|NCT01502969|Biological|cell culture medium in absence of virus|Placebo
79702036|NCT04545996|Other|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
79702037|NCT01127893|Biological|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
79702038|NCT01127893|Biological|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
79702039|NCT01127893|Biological|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
79702040|NCT00576173|Drug|tramadol hydrochloride; acetaminophen|
79702041|NCT00625339|Drug|Entecavir|entecavir 0.5 mg QD
79702042|NCT00625339|Drug|Lamivudine|lamivudine 100 mg QD
79702043|NCT02215863|Biological|Fluad and Prevenar13|
79702044|NCT02215863|Biological|Fluad|
79702045|NCT02215863|Biological|Prevenar13|
79702046|NCT04558463|Drug|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
79844677|NCT00984087|Device|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
79844678|NCT00898326|Other|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
79702047|NCT04558463|Drug|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
79844679|NCT00989313|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
79702048|NCT04311385|Diagnostic Test|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
79702049|NCT01126879|Dietary Supplement|genistein|Given orally
79844680|NCT04035954|Other|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
79387002|NCT00180297|Device|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
79844681|NCT02539524|Other|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
79248395|NCT02499237|Drug|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
79248396|NCT02499237|Drug|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
79248397|NCT03566095|Behavioral|Coaching and Voices for Food Kit|Community Coaching and Voices for Food Kit
79248398|NCT03566095|Behavioral|Voices for Food Kit|Voices for Food Kit
79248399|NCT03565861|Drug|Placebo|Intravenous vehicle
79248400|NCT03565861|Drug|NP10679|NP10679
79387003|NCT02312986|Biological|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
79542361|NCT01502982|Drug|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
79542362|NCT01502995|Device|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
79387004|NCT02404168|Drug|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
79542363|NCT01503008|Device|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
79542364|NCT01503008|Drug|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
79542365|NCT01503047|Dietary Supplement|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
79542366|NCT01503047|Dietary Supplement|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
79702050|NCT01126879|Other|placebo|Given orally
79248401|NCT02499393|Drug|Magnesium Sulfate|intravenous infusion of magnesium sulphate
79702051|NCT01126879|Procedure|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
79702052|NCT00576212|Behavioral|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
79702053|NCT04311658|Drug|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
79702054|NCT04311658|Drug|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
79702055|NCT02882308|Drug|Olaparib|50/25 mg BD split x 5 days
79702056|NCT02882308|Drug|Cisplatin|60 mg/m^2 d1-d5
79702057|NCT02882308|Drug|Olaparib|300 mg BD x 21-28 days.
79702058|NCT02882308|Drug|Durvalumab|1500 mg d1
79702059|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
79248402|NCT04873622|Behavioral|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
79248403|NCT03341559|Device|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
79248404|NCT03565705|Procedure|Open abdominal prostatectomy|Patients undergo standardized open abdominal prostatectomy.
79248405|NCT04849598|Other|Oxygen therapy|Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
79387005|NCT02404168|Drug|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
79387006|NCT04733937|Other|a2 Platinum® stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
79248406|NCT03341481|Other|Femaltiker|Patient had taken twice a day the product
79387007|NCT04733937|Other|Conventional, A1 and A2 β-casein containing stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
79702060|NCT02211989|Drug|BI 14332 CL|
79702061|NCT02211989|Drug|Placebo|
79702062|NCT00625456|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
79387008|NCT02051452|Drug|Methylphenidate|
79702063|NCT04539444|Biological|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10*107 CART cells per kilogram of body weight.
79702064|NCT04539444|Drug|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
79702065|NCT00576329|Drug|Ketorolac|Topical use before surgery
79702066|NCT02882464|Device|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
79702067|NCT02882464|Device|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
79702068|NCT02882464|Procedure|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
79702069|NCT02882581|Radiation|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
79844682|NCT02539524|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
79844683|NCT00984243|Procedure|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2"
79844684|NCT00815750|Other|Information Gathering|An information gathering phase leading to development of a new decision aid.
79542367|NCT01503060|Behavioral|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
79542368|NCT01503060|Behavioral|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
79542369|NCT01503060|Drug|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
79542370|NCT01503060|Drug|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
79542371|NCT01503060|Drug|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
79542372|NCT01503060|Drug|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
79248407|NCT03341481|Other|Placebo|Patient had taken twice a day the placebo
79248408|NCT03565627|Device|Exercise app: 7 Minute Workout Challenge|7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
79248409|NCT03565627|Device|Running app: One You Couch to 5K|One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
79542373|NCT01503112|Other|No intervention, observational study|
79248410|NCT02504307|Device|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
79542374|NCT01503138|Behavioral|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
79248411|NCT02504307|Device|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
79302788|NCT03314909|Procedure|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
79387009|NCT02051452|Other|Saline|
79387010|NCT00180687|Drug|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
79387011|NCT00180687|Drug|Normal Saline|Nebulised Normal Saline
79702070|NCT02882347|Drug|Somatostatin|
79702071|NCT00576368|Drug|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
79702072|NCT00637468|Drug|Intravenous injection of heparin|
79702073|NCT00637468|Drug|Intravenous injection of acetazolamide|
79702074|NCT00637468|Procedure|Local intra-arterial fibrinolysis|
79702075|NCT00637468|Procedure|Globe massage|
79702076|NCT00637468|Drug|Topical use of beta-blocker|
79702077|NCT00637468|Drug|Isovolaemic haemodilution|
79702078|NCT00637468|Drug|Acetylsalicylic acid|
79702079|NCT00637507|Other|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
79844685|NCT00815750|Other|Decision Aid|To test the newly developed decision aid.
79844686|NCT00894582|Procedure|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
79844687|NCT05712681|Drug|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
79844688|NCT05712681|Drug|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
79248412|NCT03567499|Drug|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
79248413|NCT03567499|Drug|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
79387012|NCT00180687|Drug|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
79542375|NCT01503151|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
79248414|NCT04632290|Device|STIMO-BSI system implantation|Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
79248415|NCT02504229|Biological|autologous dendritic cells co-cultured with cytokine-induced killer cells|
79248416|NCT02504229|Drug|Gimeracil and Oteracil Porassium Capsules|
79248417|NCT02504229|Drug|Oxaliplatin|
79248418|NCT04625738|Biological|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg"
79248419|NCT04625738|Biological|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
79542376|NCT01503151|Behavioral|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
79542377|NCT01503151|Behavioral|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
79542378|NCT01503151|Behavioral|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
79542379|NCT01503177|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
79542380|NCT01503177|Other|laboratory biomarker analysis|Correlative studies
79248420|NCT03567343|Dietary Supplement|Proprietary Spearmint Extract Blend|Water extracted spearmint extract and green tea blend
79248421|NCT03567343|Other|Control|Placebo
79248422|NCT03567343|Dietary Supplement|Proprietary Blend And Melatonin|Water extracted spearmint extract and green tea blend and Melatonin (Proprietary Spearmint Extract Blend and Melatonin)
79248423|NCT03567343|Dietary Supplement|Melatonin|Melatonin Alone
79248424|NCT04595864|Other|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|TAI
79387013|NCT00180687|Other|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
79387014|NCT02313454|Device|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
79387015|NCT00181623|Drug|Recombinant Human Prolactin|
79387016|NCT02404792|Other|High-intensity cardiovascular and resistance exercise|
79387017|NCT02404792|Other|Moderate-intensity cardiovascular and resistance exercise|
79387018|NCT02383420|Radiation|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
79387019|NCT04708132|Procedure|Screw retained restoration|Hybrid prosthesis
79709944|NCT00106964|Biological|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
79844689|NCT00898404|Other|laboratory biomarker analysis|Correlative studies
79844690|NCT05712603|Diagnostic Test|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
79844691|NCT05712603|Diagnostic Test|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
79844692|NCT05712603|Diagnostic Test|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
79844693|NCT00898482|Other|This is a non-intervention study for all groups.|This is a non-intervention study.
79844694|NCT00898482|Other|study of socioeconomic and demographic variables|Non-intervention study.
79844695|NCT03667443|Dietary Supplement|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
79844696|NCT03667443|Dietary Supplement|Myo-inositol + folic a.|3 months of treatment
79844697|NCT00902694|Behavioral|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
79844698|NCT00902694|Other|Control|group health classes quarterly with topics not related to weight
79702080|NCT00637546|Other|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
79844699|NCT03646071|Drug|RX108|RX108
79844700|NCT00902772|Drug|Lorazepam|mg, oral dose
79542381|NCT01503177|Procedure|single photon emission computed tomography|Correlative studies
79844701|NCT00902772|Drug|AZD7325|mg, oral dose
79248425|NCT05353309|Procedure|Standard Angioplasty|Angioplasty Iliac done following standard practice
79248426|NCT05353309|Procedure|Angioplasty with D images|Angioplasty Iliac under additional 3D Images merged as surgery support
79248427|NCT03341325|Other|animal-assisted activity|a live animal (small dog and/or rabbit)
79387020|NCT04708132|Procedure|implant-retained ball overdentures|Removable prosthesis
79387021|NCT00087633|Drug|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
79387022|NCT00087633|Drug|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
79387023|NCT02384044|Device|Crest® Sensi-Stop™ Strips|
79542382|NCT01503177|Procedure|computed tomography|Correlative studies
79542383|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
79542384|NCT01503203|Other|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
79542385|NCT01503203|Other|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
79542386|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
79542387|NCT01503203|Other|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
79542388|NCT01503216|Dietary Supplement|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
79542389|NCT01503216|Dietary Supplement|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
79542390|NCT01503216|Dietary Supplement|Placebo|Placebo
79542391|NCT01503242|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
79542392|NCT01503242|Drug|Cyclosporine|Given PO
79542393|NCT01503242|Drug|Fludarabine Phosphate|Given IV
79702081|NCT02212067|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
79702082|NCT02212067|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
79702083|NCT02278575|Drug|Atenativ|intravenous transfusion
79702084|NCT01126060|Drug|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
79702085|NCT01126060|Procedure|Thyroidectomy|surgical removal of bilateral thyroid glands
79702086|NCT02882542|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
79709945|NCT00106964|Biological|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
79844702|NCT00902772|Drug|Placebo|
80013392|NCT06091436|Drug|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
79248428|NCT03341325|Other|control activity|a stuffed toy animal
79248429|NCT04583462|Drug|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
79248430|NCT04583462|Drug|Placebo|Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
79248431|NCT03564925|Procedure|Wide area circumferential ablation|Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
79248432|NCT03564925|Procedure|Cryoballoon ablation|In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
79387024|NCT02384044|Device|Colgate® Sensitivity Relief Pen|
79387025|NCT02384200|Drug|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
79387026|NCT02384200|Drug|ampicillin|IV (2 g)
79387027|NCT02384200|Drug|gentamicin|IV (5 mg/kg)
79387028|NCT02384200|Drug|vancomycin|IV (1 g)
79387029|NCT02384200|Drug|ceftriaxone|IV (2 g)
79387030|NCT02314000|Device|Precision or Precision Spectra Spinal Cord Stimulator System|
79387031|NCT02051686|Drug|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
79542394|NCT01503242|Drug|Mycophenolate Mofetil|Given IV or PO
79702087|NCT02212184|Other|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
79702088|NCT02212184|Other|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
79844703|NCT03637647|Diagnostic Test|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
79542395|NCT01503242|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
79844704|NCT00894660|Drug|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
79248433|NCT03121053|Drug|sodium bicarbonate|
79248434|NCT03121053|Drug|hypotone saline|
79248435|NCT04456322|Drug|RT plus Nimotuzumab|Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
79248436|NCT04456322|Drug|RT plus Cisplatin|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
79248437|NCT03564847|Behavioral|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
79542396|NCT01503242|Radiation|Total-Body Irradiation|Undergo TBI
79542397|NCT01503242|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
79542398|NCT01503255|Behavioral|cognitive behavioral group therapy|6 weekly 90-minute group sessions
79248438|NCT02503761|Drug|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
79248439|NCT03565549|Behavioral|Mnemonic|A mnemonic used as a memory aid
79248440|NCT03565549|Behavioral|CCHR rule|A list of the CCHR items
79248441|NCT03341169|Drug|N(2)-L-Alanine L-Glutamine dipeptide|:Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75*weight ml/h)
79542399|NCT01503255|Behavioral|health education group|6 weekly 90-minute group sessions
79542400|NCT01503268|Device|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
79542401|NCT01503268|Procedure|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
79844705|NCT00894660|Drug|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
79844706|NCT05712525|Diagnostic Test|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
79248442|NCT03341169|Drug|placebo (0.9% NaCl (normal saline))|Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75*weight ml/h)
79248443|NCT03341091|Other|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
79248444|NCT02676193|Behavioral|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
79542402|NCT01503268|Procedure|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
79542403|NCT01503281|Other|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
79542404|NCT01503320|Dietary Supplement|Enteral glutamine|Dosage of glutamine: 0.57g/kg, ~ 30g/day= 3sachets
79542405|NCT01503320|Dietary Supplement|Placebo|Similar appearing nutritional supplement without glutamine.
79702089|NCT01125748|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
79844707|NCT02539212|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
79844708|NCT02539212|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
79844709|NCT00721409|Drug|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
79844710|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
79248445|NCT05105126|Device|Transcranial Direct Current Stimulation (tDCS)|"The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA."
79248446|NCT05105126|Device|Sham tDCS|Sham tDCS
79702090|NCT01125748|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
79702091|NCT01125748|Drug|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
79702092|NCT04558268|Drug|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
79702093|NCT04558268|Drug|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
79702094|NCT04558268|Dietary Supplement|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
79702095|NCT04558268|Dietary Supplement|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
79702096|NCT04558268|Dietary Supplement|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
79702097|NCT04545918|Device|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
79702098|NCT01125514|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
79844711|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
79844712|NCT05712369|Other|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
79844713|NCT02539290|Behavioral|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
79248447|NCT03565471|Diagnostic Test|Echocardiography|Standard echocardiography.
79542406|NCT01503346|Drug|DaHuang GanTsao Tang|"Intervention group~2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~each package was given to each patient four times a day (three time after meal and one time before sleep);~each patient received the usual medication of the hospice ward at the same time;~record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
79542407|NCT01503359|Dietary Supplement|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
79542408|NCT01503372|Drug|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
79702099|NCT01125514|Drug|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
79844714|NCT02539290|Procedure|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
79844715|NCT02539290|Procedure|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
79844716|NCT02539290|Behavioral|Sexual intercourse|Sexual intercourse within 12 hours after intervention
79844717|NCT00898716|Drug|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
79248448|NCT03565471|Diagnostic Test|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
79248449|NCT03565471|Diagnostic Test|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
79248450|NCT03565471|Diagnostic Test|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
79702100|NCT01125514|Drug|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
79702101|NCT01125514|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet
79702102|NCT04538547|Radiation|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
79702103|NCT04538547|Radiation|Non Accelerated Radiotherapy|Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
79702104|NCT00576446|Biological|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
79702105|NCT04545879|Dietary Supplement|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
79702106|NCT04578782|Drug|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
79702107|NCT04538703|Behavioral|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
79702108|NCT00576485|Procedure|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
79702109|NCT04539015|Device|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
79702110|NCT00576563|Drug|FDG|contrast medium
79702111|NCT04538391|Drug|local ifiltration Bupivacaine, Meloxican and placebo|no other intervention done
79702112|NCT04558307|Diagnostic Test|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
79702113|NCT04558307|Other|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
79542409|NCT01503372|Drug|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
79542410|NCT01503385|Drug|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
79702114|NCT04545801|Drug|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
79702115|NCT04545801|Drug|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
79702116|NCT04558424|Dietary Supplement|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
79702117|NCT02214693|Drug|DA-1229|
79702118|NCT00576602|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
79702119|NCT00576602|Drug|Supportive treatment|As prescribed
79702120|NCT01125358|Drug|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
79702121|NCT01125358|Drug|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
79702122|NCT02214732|Behavioral|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
79702123|NCT02212223|Dietary Supplement|Vitamin D3|
79702124|NCT00637585|Drug|Fexofenadine|
79302789|NCT03314909|Procedure|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
79542411|NCT01503398|Drug|Olanzapine|Olanzapine Tablets, 5 mg
79542412|NCT01503424|Drug|Olanzapine|Olanzapine Tablets, 5 mg
79542413|NCT01503437|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
79542414|NCT01503450|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
79702125|NCT00576641|Biological|autologous dendritic cells|
79702126|NCT02214810|Drug|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
79702127|NCT04558385|Diagnostic Test|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
79702128|NCT02214849|Behavioral|LATCH Intervention|
79702129|NCT02214888|Drug|BIRB 796 BS, low dose|
79702130|NCT02214888|Drug|BIRB 796 BS, high dose|
79702131|NCT02214888|Drug|Placebo|
79702132|NCT04558034|Other|cryotherapy|cryotherapy will be delivered
79702133|NCT04538508|Device|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
79702134|NCT04538508|Other|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
79702135|NCT04545684|Behavioral|Motor imagery|The person will have to imagine different scenarios of manual gripping
79702136|NCT04545684|Behavioral|Placebo intervention|The placebo group will imagine a place without the presence of humans.
79702137|NCT00576719|Behavioral|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
79702138|NCT00576719|Behavioral|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
79542415|NCT01503463|Procedure|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
79542416|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
79702139|NCT00576719|Other|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
79702140|NCT01125046|Biological|bevacizumab|Given IV
79248451|NCT04988360|Device|HMD: Immersive VR|"Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function."
79702141|NCT04538937|Other|no intervention|no intervention
79248452|NCT04988360|Device|Tablet: Non-immersive VR|Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
79248453|NCT03120585|Other|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR >4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
79248454|NCT03565393|Combination Product|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
79542417|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
79702142|NCT04311346|Diagnostic Test|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
79702143|NCT04538313|Drug|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
79702144|NCT04538469|Other|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
79702145|NCT01124734|Drug|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
79702146|NCT01124734|Drug|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
79702147|NCT04538781|Device|VASCADE MVP VVCS|The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
79702148|NCT04557839|Other|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
79709946|NCT00106964|Biological|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
79709947|NCT02892435|Device|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
79709948|NCT02892435|Device|conventional dressing|positioning conventional dressing
79709949|NCT00106184|Drug|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
80013393|NCT06091436|Biological|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
80013394|NCT06091436|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
79248455|NCT02503995|Behavioral|Physical Exercise Participation|
79248456|NCT03565081|Device|PWS elastic band training group|PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
79248457|NCT02503605|Drug|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
79248458|NCT02503605|Drug|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
79702149|NCT04557839|Other|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~eyes open firm surfaces~Eyes open soft surfaces~Eyes closed firm surfaces~Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~These exercise will perform with turning the head side to side ad up and down~Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
79542418|NCT01503502|Drug|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
79248459|NCT04495023|Procedure|Left elective colectomy|Open or laparoscopic left elective colectomy with colo-rectal anastomosis
79542419|NCT01503502|Drug|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
79542420|NCT01503528|Procedure|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
79248460|NCT03341013|Drug|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
79248461|NCT03341013|Drug|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
79248462|NCT03340935|Other|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
79702150|NCT04545450|Drug|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
79702151|NCT04545450|Drug|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
79702152|NCT04579133|Drug|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min)
79702153|NCT04579133|Drug|Durvalumab|Durvalumab 1500 mg IV
79702154|NCT04545372|Other|aerobic exercise|
79702155|NCT00576914|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
79248463|NCT04097912|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
79248464|NCT04966676|Diagnostic Test|cfDNA blood test|Blood sample will be taken for cfDNA testing
79248465|NCT04966676|Drug|Nivolumab|Antineoplastic agent
79248466|NCT04966676|Drug|Ipilimumab|Antineoplastic agent
79248467|NCT04966676|Combination Product|Platinum-based Chemotherapy|May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
79248468|NCT03340857|Other|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
79248469|NCT04040816|Drug|SAP-001|SAP-001 or placebo treatment in a 4:1 randomization ratio
79248470|NCT03340779|Drug|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
79542421|NCT01503528|Procedure|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
79542422|NCT01503541|Genetic|DNA analysis|
79542423|NCT01503541|Genetic|RNA analysis|
79542424|NCT01503541|Genetic|gene expression analysis|
79542425|NCT01503541|Genetic|mutation analysis|
79542426|NCT01503541|Genetic|polymerase chain reaction|
79542427|NCT01503541|Other|laboratory biomarker analysis|
79542428|NCT01503554|Behavioral|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
79542429|NCT01503554|Behavioral|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
79542430|NCT01503567|Other|No treatment given|Subject will only fill out a questionaire
79542431|NCT01503580|Drug|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
79542432|NCT01503593|Device|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
79542433|NCT01503619|Other|laboratory biomarker analysis|Correlative studies
79702156|NCT04545645|Behavioral|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
79709950|NCT00106184|Drug|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
80013395|NCT06091436|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
80013396|NCT06091436|Drug|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
79542434|NCT01503658|Drug|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
80013397|NCT06091410|Biological|Omicron-containing COVID-19 vaccine|The COVID-19 vaccine approved for use in the 2023-2024 season
79702157|NCT04545645|Behavioral|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
80013398|NCT06091410|Biological|influenza vaccine|inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
79248471|NCT05104580|Device|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
80013399|NCT06091384|Other|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
80013400|NCT06091345|Drug|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10%
79542435|NCT01503671|Drug|Atorvastatin|Atorvastatin 40 mg/day
79542436|NCT01503684|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
80013401|NCT06091345|Biological|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is < 3.5 gm/dl
79542437|NCT01503723|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
80013402|NCT06091345|Other|Standard Medical Treatment|Standard Medical Treatment
80013403|NCT06091332|Drug|Sirolimus|Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.
80013404|NCT06091332|Drug|Starch flake|The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
80013405|NCT06091280|Device|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
79248472|NCT02503371|Other|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
79542438|NCT01503736|Drug|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
79542439|NCT01503736|Drug|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
79542440|NCT01503736|Drug|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
79542441|NCT01503762|Other|Mirror therapy|mirror therapy
79542442|NCT01503762|Other|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
79542443|NCT01503788|Drug|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
79542444|NCT01503801|Drug|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
79542445|NCT01503801|Device|respiratory support|Routine respiratory support.
79702158|NCT04545645|Behavioral|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
79702159|NCT04545645|Behavioral|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
79702160|NCT02212340|Drug|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
79709951|NCT00598923|Drug|topiramate|100 mg twice per day for 3 months
80013406|NCT06091241|Procedure|Pre-operative Erector Spinae Plane block prior to DIEP surgery|After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.
80013407|NCT06091241|Procedure|Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery|On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
80013408|NCT06091228|Other|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
80013409|NCT06091202|Behavioral|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 1 month. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 1-month follow-up, and a qualitative interview at 1-month follow-up to help inform the larger clinical trial."
80013410|NCT06091202|Behavioral|Minimally Enhanced Usual Care (MEUC)|Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 1 month. The primary outcome is a change in pain interference.
79702161|NCT02212340|Drug|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
79702162|NCT01124617|Drug|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
79702163|NCT01124617|Drug|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
79702164|NCT04205890|Drug|Ketamine|The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
79702165|NCT00577070|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
79702166|NCT00577109|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
79702167|NCT00577109|Drug|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
79702168|NCT00577109|Drug|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
79844718|NCT05277948|Other|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
79248473|NCT04040738|Procedure|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
79542446|NCT01503814|Other|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
79542447|NCT01503827|Radiation|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
79542448|NCT01503840|Drug|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
79542449|NCT01503840|Drug|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
79702169|NCT00577109|Drug|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
79702170|NCT00577109|Drug|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
79702171|NCT04538001|Device|Balloon implantation|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
79387032|NCT02051686|Drug|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
79387033|NCT02407132|Behavioral|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
79387034|NCT02407132|Behavioral|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
79387035|NCT02387008|Device|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
79387036|NCT02387008|Device|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
79542450|NCT01503892|Dietary Supplement|Metanx|Metanx- one tablet twice daily for twelve months
79542451|NCT01503892|Drug|Placebo|Placebo- one tablet twice daily for twelve months.
79387037|NCT02387008|Device|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
79387038|NCT02387476|Device|FRESCA mask first night|FRESCA nasal mask first night
79387039|NCT02387476|Device|CPAP Mask first night|CPAP Nasal Mask first night
79391536|NCT03175614|Other|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
79542452|NCT01503905|Drug|Docetaxel|75mg/m2, iv injection, day1, every 21 days
79702172|NCT04538001|Procedure|Rotator cuff repair|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
79702173|NCT01124422|Drug|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
79702174|NCT01124422|Drug|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
79702175|NCT04544982|Other|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
79702176|NCT04544982|Other|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
79702177|NCT00577187|Device|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
79702178|NCT04309591|Device|CytoSorb haemoadsorption (HA) device|CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
79702179|NCT04538196|Other|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
79702180|NCT00625495|Drug|Esomeprazole|40mg Intravenous infusion over 3 minutes
79702181|NCT00625495|Drug|Esomeprazole|40mg Oral
79702182|NCT00625534|Procedure|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
79702183|NCT00625534|Procedure|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
79844719|NCT05277948|Other|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
79702184|NCT02882425|Drug|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
79702185|NCT02882425|Drug|Selexipag for oral use|Tablet containing 200 µg of selexipag
79702186|NCT04538235|Procedure|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
79387040|NCT00182793|Biological|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
79542453|NCT01503905|Drug|epirubicin|80mg/ m2, iv injection, day1, every 21 days
79702187|NCT00577304|Drug|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
79702188|NCT00577304|Drug|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
79702189|NCT01124149|Drug|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
79702190|NCT04538118|Behavioral|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
79702191|NCT04538118|Device|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
79844720|NCT00894816|Dietary Supplement|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
79542454|NCT01503905|Drug|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
79542455|NCT01503905|Procedure|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
79542456|NCT01503905|Drug|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
79542457|NCT01503905|Drug|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
79702192|NCT04538118|Behavioral|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
79702193|NCT04545099|Drug|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
79702194|NCT04545099|Drug|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
79702195|NCT02882269|Drug|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
79702196|NCT02882269|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
79702197|NCT04545294|Device|Theta tACS|See detail in arm/group descriptions regarding the intervention.
79702198|NCT04578899|Device|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
79709952|NCT00598923|Drug|topiramate|100 twice per day for 6 days after loading dose of phenytoin
79844721|NCT00894816|Dietary Supplement|Placebo|Infant cereals without any addition
79387041|NCT00182793|Drug|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
79387042|NCT00182793|Drug|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
79387043|NCT00182793|Drug|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
79387044|NCT00182793|Drug|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
79387045|NCT00182793|Procedure|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
79391537|NCT03175614|Other|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
79542458|NCT01503905|Drug|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
79542459|NCT01503905|Radiation|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
79542460|NCT01503905|Drug|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
79702199|NCT02882503|Device|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
79702200|NCT04578704|Other|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
79702201|NCT01122862|Drug|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
79702202|NCT01122862|Other|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
79542461|NCT01503905|Drug|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
79248474|NCT04040738|Procedure|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
79702203|NCT01122862|Other|Sterile water|Sterile water
79702204|NCT04538274|Behavioral|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
80013411|NCT06091163|Behavioral|Ketogenic Diet|"A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk."
79542462|NCT01503918|Drug|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
79542463|NCT01503918|Drug|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
79542464|NCT01503957|Device|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
79844722|NCT00542997|Biological|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
79844723|NCT04035720|Other|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
79844724|NCT00903084|Drug|Tenofovir Disoproxil Fumarate|300-mg tablet
79248475|NCT05547087|Biological|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
79248476|NCT05104424|Drug|Insulin aspart|intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
79248477|NCT04497129|Device|ROMTech PortableConnect|ROMTech PortableConnect (ROMTechPC) therapy will be completed four to five times per day for 6 minutes duration for 6 weeks. The intervention will be administered using the portable rehabilitation unit.
79248478|NCT04497129|Device|Traditional Rehabilitation and CPM Device|Continuous passive motion (CPM) with standard of care HHPT and OPPT rehabilitation program (CPM with SOC). Therapy with the CPM will be completed daily from day 0 through week 3 for a total of 6 to 8 hours per day. The HHPT and OPPT rehabilitation program will be a 6-week program based on SOC goals.
79542465|NCT01503957|Device|Saline solution|Nasal spray, 2 sprays in each nostril
79542466|NCT01503970|Device|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
79542467|NCT01503983|Drug|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
79542468|NCT01503983|Drug|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
79542469|NCT01503983|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
79542470|NCT01503996|Behavioral|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
79702205|NCT04578977|Behavioral|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
79702206|NCT04537767|Drug|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
79844725|NCT00984477|Drug|AZD5122|A single dose of oral suspension
79844726|NCT00984477|Drug|Placebo|A single dose of oral suspension
79844727|NCT00984477|Drug|AZD5122|A single intravenous infusion
79542471|NCT01504009|Other|Muscle training|12 weeks of strength training 2-3 times/week
79542472|NCT01504022|Other|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
79542473|NCT01504035|Device|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
79542474|NCT01504035|Device|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
79844728|NCT02541006|Drug|Tiotropium 18 mcg|tiotropium 18 mcg once a day
79844729|NCT02591771|Drug|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
80013412|NCT06091163|Behavioral|Phytonutrient Diet|Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
80013413|NCT06091150|Procedure|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
80013414|NCT06091098|Other|Dynamic CO2|2% inspired CO2 for 2-4 breaths
80013415|NCT06091098|Other|Sham CO2|Air
80013416|NCT06091085|Drug|Acetazolamide|Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
79542475|NCT01504048|Procedure|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
79542476|NCT01504061|Other|Mederma N&I|Topical gel applied three times a day for eight weeks.
79844730|NCT00986817|Drug|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
79248479|NCT05087732|Device|STYLAGE® M Lidocaïne|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
79248480|NCT05087732|Device|STYLAGE® M|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
79542477|NCT01504061|Other|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
79542478|NCT01504074|Behavioral|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
80013417|NCT06091085|Drug|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
80013418|NCT06091072|Other|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
79248481|NCT03340701|Drug|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
79248482|NCT04758962|Biological|1 µg CoV2 SAM (LNP)|2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.
79248483|NCT02503683|Drug|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
79248484|NCT02503683|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
79248485|NCT03453866|Procedure|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
79248486|NCT03453866|Procedure|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
79702207|NCT04537767|Drug|Placebo|Placebo
79702208|NCT01122394|Behavioral|TI|Tailored intervention based on the transtheoretical model
79702209|NCT01122394|Behavioral|AP|Attention placebo
79844731|NCT00986817|Drug|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
79844732|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
79844733|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
79248487|NCT02494479|Drug|Prurisol|50mg tablet
79248488|NCT02494479|Drug|Placebo|Sugar pill designed to match Purisol tablet
79387046|NCT00182793|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
79387047|NCT00182793|Procedure|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
79702210|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
79702211|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
79248489|NCT05070494|Biological|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
79248490|NCT03340623|Device|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
79702212|NCT04578626|Device|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
79542479|NCT01504126|Drug|Chemotherapy|Undergo standard chemotherapy
79702213|NCT04544826|Drug|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
79702214|NCT04544826|Drug|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
79702215|NCT02216019|Other|Whole blood|preoparatoire whole blood and postoperative whole blood
79387048|NCT00182793|Radiation|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
79387049|NCT00183339|Drug|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
79702216|NCT04578587|Device|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
80013419|NCT06091033|Dietary Supplement|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
79248491|NCT02498535|Drug|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
79542480|NCT01504126|Drug|Propranolol Hydrochloride|Given PO
79542481|NCT01504126|Other|Quality-of-Life Assessment|Ancillary studies
79248492|NCT04497051|Diagnostic Test|CT-DSA|CTA before and after embolization
79542482|NCT01504126|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79702217|NCT00577421|Drug|risedronate|5 mg tablet of risedronate once a day for 2 years
79702218|NCT04537611|Diagnostic Test|dHb contrast and gadolinium contrast imaging|see arm description
79702219|NCT04537494|Dietary Supplement|L. reuteri|Probiotic
79702220|NCT04545255|Device|Shockwave treatment|ED 1000 shockwave generator
79702221|NCT00577616|Procedure|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
79702222|NCT04537572|Diagnostic Test|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
79248493|NCT04727138|Drug|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
79248494|NCT04727138|Drug|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
79248495|NCT04727138|Other|Midazolam|Interaction
79248496|NCT04727138|Other|Food Effect|Fed/Fasted
79542483|NCT01504139|Drug|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
79542484|NCT01504139|Drug|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
79702223|NCT00577694|Drug|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
79702224|NCT00577694|Drug|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
79702225|NCT04537533|Drug|Tranexamic acid|Intraoperative infusion
79702226|NCT04537533|Other|Normal saline|intravenous infusion
79702227|NCT02214927|Drug|BI 11634 tablet|
79702228|NCT02214927|Drug|BI 11634 drinking solution|
80013420|NCT06091033|Dietary Supplement|placebo|1,000 mg of a placebo for 8 weeks
80013421|NCT06090994|Drug|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 1-2 months after surgery. Please refer to the medication manual for specific usage. Continuous use for at least 6 months.
80013422|NCT06090981|Drug|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
79702229|NCT04544553|Other|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
79542485|NCT01504139|Drug|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
79702230|NCT04544553|Other|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
79844734|NCT02591849|Dietary Supplement|Glucagon-like peptide-1 (GLP-1)|
79844735|NCT02591849|Other|Isotonic saline|
79844736|NCT02591849|Other|Hyperglycemic clamp|
80013423|NCT06090955|Drug|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
79248497|NCT04727138|Other|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension
79248498|NCT03342885|Behavioral|Specific sleep ergonomics guidance|Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
79387050|NCT00183339|Drug|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
79387051|NCT01743989|Drug|Nilotinib|Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
79387052|NCT00183729|Drug|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
79387053|NCT00183729|Other|Placebo|Placebo distribution is planned to mimic the active drug.
79542486|NCT01504139|Drug|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
79542487|NCT01504152|Behavioral|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
79542488|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
79702231|NCT02216058|Device|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
80013424|NCT06090955|Drug|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
79387054|NCT00185679|Device|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:~Computer-controlled instrument;~Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~Wash buffer"
79387055|NCT00186069|Drug|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
79702232|NCT00577850|Drug|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
79702233|NCT00577850|Drug|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
79702234|NCT04544631|Other|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
79702235|NCT04544514|Diagnostic Test|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
79844737|NCT00898794|Biological|bevacizumab|
79844738|NCT00898794|Other|coagulation study|
79844739|NCT00898794|Other|laboratory biomarker analysis|
79844740|NCT00898794|Other|platelet aggregation test|
79844741|NCT00986895|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
79844742|NCT00898872|Other|cryopreservation|
79844743|NCT02593877|Device|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
79844744|NCT05712135|Other|supine position|The patient group whose cuff pressure was measured in the supine position
79844745|NCT05712135|Other|prone position|The patient group whose cuff pressure was measured in the prone position
79844746|NCT05712135|Other|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
79844747|NCT03948113|Other|Dialysis|
79844748|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
79844749|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
80013425|NCT06090955|Drug|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
80013426|NCT06090942|Other|Smartphone-based cognitive training|Smartphone-based cognitive training
80013427|NCT06090929|Device|STN-DBS|STN-DBS was implanted according normal process
80013428|NCT06090916|Other|Best Practice|Receive standard nutrition care
79387056|NCT00186069|Other|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
79542489|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
80013429|NCT06090916|Other|Dietary Intervention|Participate in weekly support sessions with diet prescription
80013430|NCT06090916|Other|Medical Chart Review|Ancillary studies
79542490|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
79542491|NCT01504165|Drug|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
79542492|NCT01504165|Drug|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide > 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
80013431|NCT06090916|Other|Medical Device Usage and Evaluation|Record dietary and physical activity using MyFitnessPal smartphone app
80013432|NCT06090916|Other|Nutritional Assessment|Undergo malnutrition screening
80013433|NCT06090916|Other|Questionnaire Administration|Ancillary studies
80013434|NCT06090903|Procedure|Biospecimen Collection|patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
80013435|NCT06090903|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79542493|NCT01504178|Drug|duloxetine|administration during 28 days
79702236|NCT00577967|Drug|Gabapentin|
79702237|NCT04537338|Genetic|1. Characterize the immune response after infection with SARS-CoV-2|1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
79702238|NCT00578006|Behavioral|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
79702239|NCT00578006|Behavioral|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
80013436|NCT06090903|Other|Medical Chart Review|Review Medical Chart
80013437|NCT06090890|Drug|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
80013438|NCT06090890|Drug|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
80013439|NCT06090890|Drug|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
80013440|NCT06090890|Drug|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
79248499|NCT03342885|Behavioral|General sleep ergonomics guidance|Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
79248500|NCT02498457|Other|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
79248501|NCT03340545|Other|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
79387057|NCT01898247|Other|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
79387058|NCT01898325|Device|Fibroscan|Fibroscan
79709953|NCT00598923|Drug|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
79248502|NCT04889846|Procedure|SAFE early intervention approach|SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
79248503|NCT02498301|Drug|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
79248504|NCT02498301|Drug|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
79387059|NCT01605461|Drug|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
79387060|NCT01742897|Drug|TTS-fentanyl|
79387061|NCT01715831|Drug|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
80013441|NCT06090890|Drug|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C<1.4mmol/L as the target on the basis of moderate intensity or above statins.
80013442|NCT06090877|Device|US and shear wave elstography|using B mode US to assess ulnar nerve echogenicity, measuring its cross sectional area and assess any other anatomical abnormalites Measuring ulnar nerve stiffness using shear wave elastography All measurements done at the cubital tunnel, 2 cm proximal and distal to it compare findings with electrodiagnostic studies and intra operative findings
80013443|NCT06090851|Dietary Supplement|herbal nitrate Pralines with nitrate|consumption of herbal pralines with nitrate
80013444|NCT06090851|Dietary Supplement|herbal nitrate Pralines without nitrate|consumption of herbal pralines without nitrate
80013445|NCT06090838|Procedure|Balloon Pulmonary Angioplasty (BPA)|A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
80013446|NCT06090825|Other|Observational study|Observational study
79542494|NCT01504178|Drug|placebo of duloxetine|administration during 28 days
79542495|NCT01504178|Drug|injection of apomorphine|injection performed at D28
79844750|NCT04086719|Drug|BMS-986165|Oral administration of tablet BMS- 986165
79844751|NCT04086719|Drug|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
79844752|NCT00898950|Drug|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
80013447|NCT06090812|Other|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
79248505|NCT03343665|Drug|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
79387062|NCT01715831|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
79542496|NCT01504178|Drug|injection of placebo of apomorphine|performed at D28
79542497|NCT01504178|Drug|L-Dopa|performed at D28
79702240|NCT04537455|Diagnostic Test|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
80013448|NCT06090786|Diagnostic Test|MRD assessment|Bone marrow withdrawal for MRD quantification
80013449|NCT06090760|Behavioral|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
79248506|NCT02733614|Drug|SRX246|novel V1a receptor antagonist
79387063|NCT01741259|Drug|Meperidine|
79387064|NCT01715129|Drug|Triptorelin Pamoate 11.25mg|
79387065|NCT02407756|Drug|Dupilumab|
79387066|NCT02387554|Drug|HGP0904|
79387067|NCT02387554|Drug|HGP0608|
79387068|NCT02387554|Drug|HGP1405|
79387069|NCT02408692|Drug|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of <25 kg/m2 will have completed study participation.
79542498|NCT01504178|Drug|injection of placebo of L-Dopa|performed at D28
79542499|NCT01504191|Behavioral|Internet-based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
79542500|NCT01504256|Drug|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
79702241|NCT00578045|Procedure|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
79702242|NCT04544397|Procedure|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
79844753|NCT00898950|Drug|Aspirin|300mgs/day orally for 2 weeks
79248507|NCT02733614|Drug|Placebo|matching placebo
79248508|NCT03340467|Device|CGM patch|Patient receives four CGM patches.
79248509|NCT05435001|Device|Holter ECG Monitoring|Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D[D/N]) will be computed.
79248510|NCT04805138|Other|Spectrophotometer|To objectively measure the discoloration of the peri-implant mucosa, spectrophotometric measurements of the buccal mucosa will be performed at study implant and at control tooth.
79248511|NCT03340389|Procedure|a ray-tracing aberrometry|The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
79387070|NCT02408692|Drug|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
79387071|NCT02387710|Drug|Tiagabine|GABA reuptake inhibitor
79387072|NCT02387710|Drug|Placebo|Placebo comparator
79387073|NCT02409784|Dietary Supplement|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
79387074|NCT02409784|Dietary Supplement|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
79387075|NCT02388568|Drug|Lorcaserin|Lorcaserin plus Lifestyle Modification
79387076|NCT02388568|Drug|Placebo|Placebo plus Lifestyle Modification
79844754|NCT00898950|Drug|Aspirin|aspirin 900mgs QID orally for 2 weeks
79844755|NCT00898950|Other|placebo tablet|placebo tablet with lactose and excipients.
79844756|NCT04034784|Device|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
80013450|NCT06090747|Behavioral|Hybrid lifestyle educational multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions."
79248512|NCT04760444|Behavioral|Peer Leader Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
79387077|NCT02388646|Other|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
79387078|NCT02388646|Device|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
79387079|NCT02388646|Other|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
79542501|NCT01504256|Drug|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
79542502|NCT01504282|Drug|mitomycin-C|
79702243|NCT04537221|Biological|Blood transfusion|Transfusion of red blood cells peri-operatively
79702244|NCT00578162|Behavioral|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
79702245|NCT00578201|Drug|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
79702246|NCT04537104|Device|Coala Heart Monitor|ECG monitoring
79702247|NCT00578357|Behavioral|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
79702248|NCT04544319|Drug|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
79702249|NCT04544319|Drug|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
79702250|NCT00578396|Dietary Supplement|grapes|1 pound of seedless red grapes
79702251|NCT00578396|Dietary Supplement|grapes|2/3 lb/day fresh red grapes
80013451|NCT06090747|Behavioral|Hybrid lifestyle personalized multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA"
79248513|NCT04760444|Behavioral|Virtual Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
79248514|NCT03340311|Device|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
79387080|NCT01740791|Drug|Velpatasvir|Tablets administered orally
79542503|NCT01504282|Drug|Placebo|balanced salt solution (BSS)
79542504|NCT01504295|Drug|Metadoxine|Improve Liver Function and Reduce ALcohol Use
79702252|NCT00578396|Dietary Supplement|grapes|1/3 lb/day fresh red grapes
79387081|NCT01740791|Drug|Placebo|Tablets administered orally
79387082|NCT01740323|Drug|Placebo|daily placebo for 6 weeks
79387083|NCT01740323|Drug|Curcumin|500 mg BID
79387084|NCT00090051|Drug|Rituximab|Intravenous repeating dose
79387085|NCT00090051|Drug|Fludarabine Phosphate|Intravenous repeating dose
79387086|NCT00090051|Drug|Cyclophosphamide|Intravenous repeating dose
79387087|NCT01740089|Drug|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
79542505|NCT01504308|Device|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
79702253|NCT04544085|Behavioral|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
79702254|NCT04557410|Drug|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
79702255|NCT04537182|Procedure|Lung volume reduction surgery|Lung volume reduction by surgery
79702256|NCT04537182|Procedure|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
79702257|NCT04578470|Drug|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
79702258|NCT04578470|Drug|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
79248515|NCT04496583|Other|Fluid depletion strategy|The fluid depletion strategy will be individualized depending on the response to the standardized furosemide test (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) with a urinary output (UO) cutoff of 200 ml at 2 hours. The desired depletion endpoint will be targeted by using diuretics (40 mg q6h iv initially, adjusting dose by UO) or ultrafiltration (UF) if UO <200 ml/2h
79702259|NCT00578435|Procedure|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
80013452|NCT06090708|Dietary Supplement|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
79702260|NCT04537065|Other|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
79702261|NCT04578821|Other|Educational intervention|Educational intervention
79844757|NCT04034784|Other|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
79248516|NCT03340233|Diagnostic Test|MRI (cardiac) off-label use gadolinium contrast (IND exempt)|Clinical MRI
79248517|NCT03340233|Diagnostic Test|MRI (cardiac)|MRI without contrast
79248518|NCT03342807|Drug|Insulin|Insulin infusion for subjects in Group Insulin.
79248519|NCT03342807|Device|Aphesis|Aphesis for subjects in Group Aphesis.
79844758|NCT03622515|Combination Product|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
79844759|NCT00899028|Genetic|comparative genomic hybridization|
79248520|NCT02570672|Drug|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
79248521|NCT02570672|Drug|Placebo|Subjects will randomized to placebo will receive placebo
79248522|NCT02498379|Drug|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu[64]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
79248523|NCT02503293|Device|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
79844760|NCT00899028|Genetic|fluorescence in situ hybridization|
79302793|NCT03211819|Procedure|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
79387088|NCT01740089|Drug|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
79387089|NCT01740089|Drug|Ribavirin|800-1400 mg/day orally
79387090|NCT01739933|Drug|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
79387091|NCT01739933|Drug|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
79387092|NCT00094497|Drug|Etoposide|
79387093|NCT00094497|Drug|Doxorubicin|
79387094|NCT00094497|Drug|Cisplatin|
79387095|NCT00094497|Drug|Streptozotocin|
79387096|NCT00094497|Drug|Mitotane|
79387097|NCT01738919|Procedure|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
79387098|NCT01738919|Procedure|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
79702262|NCT04543929|Behavioral|exercise|partially supervised and home-based exercise activity
79702263|NCT04537260|Behavioral|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
79702264|NCT04557332|Behavioral|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
79844761|NCT00899028|Genetic|gene expression analysis|
79844762|NCT00899028|Genetic|microarray analysis|
79844763|NCT00899028|Genetic|protein expression analysis|
79702265|NCT04544163|Drug|Magnesium sulfate- Fentanyl|drug administration before intubation
79702266|NCT04544163|Drug|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
79248524|NCT02503293|Device|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
79542506|NCT01504308|Device|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
80013453|NCT06090682|Device|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
80013454|NCT06090656|Drug|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
79248525|NCT04661306|Behavioral|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
79248526|NCT04700462|Behavioral|Sm-EMA|Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
79248527|NCT05233059|Behavioral|FitEx|FitEx is an 8 week goal-setting, behavior tracking, physical activity intervention with a low dose of social support which will be delivered virtually.
79248528|NCT05233059|Behavioral|Weekly Yoga Sessions|30 minutes of optional guided yoga online led by a 500 hour yoga teacher once a week for participants in the walking plus yoga arm. Also accompanied by a yoga based newsletter.
79248529|NCT05233059|Behavioral|Weekly Movement Sessions|30 minutes of optional guided movement online led by a 500 hour yoga teacher once a week for participants in the walking arm. Also accompanied by a movement based newsletter.
79248530|NCT03340155|Other|Photo(chemo)therapy|Treatment with photo(chemo)therapy, including UVB, UVA, PUVA and photopheresis
79248531|NCT03340077|Other|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
79248532|NCT03340077|Other|Standard of Care|Pharmacist review of ART medications
79702267|NCT04544163|Drug|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
79302794|NCT05713487|Other|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
79542507|NCT01504321|Drug|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
79542508|NCT01504321|Drug|Placebo|Encapsulated lactose powder
79542509|NCT01504334|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
79702268|NCT04544163|Drug|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
79702269|NCT04579016|Other|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
79702270|NCT04579016|Other|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
79702271|NCT04543851|Device|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
79702272|NCT00578591|Drug|Rituximab|"Rituximab 375 mg/m^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
79702273|NCT04536987|Device|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
79702274|NCT04536948|Other|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
79844764|NCT00899028|Other|immunohistochemistry staining method|
79702275|NCT04536948|Other|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
79702276|NCT04543890|Radiation|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
79844765|NCT00899028|Other|laboratory biomarker analysis|
79542510|NCT01504334|Drug|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
80013455|NCT06090656|Procedure|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
79542511|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
80013456|NCT06090643|Other|Best Practice|Recieve CRC screening usual care
80013457|NCT06090643|Other|Consultation|Recieve consultation with clinic staff
80013458|NCT06090643|Other|Educational Intervention|Recieve education and training on CRC screening
80013459|NCT06090643|Other|Electronic Health Record Review|Ancillary studies
80013460|NCT06090643|Other|Fecal Immunochemical Test|Recieve FIT kit with culturally tailored instructions
80013461|NCT06090643|Behavioral|Feedback|Recieve feedback on CRC screening
79248533|NCT04496661|Device|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
79542512|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
79542513|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
79542514|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
79702277|NCT04543890|Radiation|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
79702278|NCT04543890|Drug|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
79702279|NCT04543890|Drug|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
79702280|NCT04536831|Drug|Vitamin D|Vitamin D will be given to group A selected by Lottery method
79702281|NCT04536831|Drug|Normal saline|Vitamin D will be given to group B slected by Lottery method
79702282|NCT02214966|Drug|Telmisartan/Ramipril, fixed dose combination tablet|
79844766|NCT00899028|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
80013462|NCT06090643|Behavioral|Health Education|Recieve CRC screening recommendations
80013463|NCT06090643|Other|Support Education Activity|Utilize clinical decision support tool
79302795|NCT04990557|Drug|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
79702283|NCT02214966|Other|high fat, high caloric meal|
79844767|NCT00899028|Other|medical chart review|
79844768|NCT00899028|Procedure|diagnostic bronchoscopy|
80013464|NCT06090643|Other|Text Message-Based Navigation Intervention|Recieve text message reminders
80013465|NCT06090630|Procedure|Diffusion Weighted Imaging|Undergo DWI-MRI
80013466|NCT06090630|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
80013467|NCT06090552|Behavioral|Increasing intensity of ACP-related messaging prior to surgical visit|Behavioral interventions to observe how the different arms of advanced care planning helps participants aged 65 or older.
80013468|NCT06090526|Diagnostic Test|"pancreatic stone protein PSP measurement"|Blood samples will be collected for biomarker (PCT, CRP, and PSP) measurements in admission and 24 hours, 72 hours from admission and patients will be followed until death or discharge from the ICU or for 30 days, whichever occurred.
80013469|NCT06090487|Diagnostic Test|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
80013470|NCT06090435|Behavioral|Therapeutic exercise plus motor imagery|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a motor imagery intervention (which consists of imagining the same movements but not performing them for real).
80013471|NCT06090435|Behavioral|Therapeutic exercise plus action observation|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added an action observation intervention (which consists of observing the same movements but not performing them for real).
80013472|NCT06090435|Behavioral|Therapeutic exercise|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a sham action observation intervention (which consists of observing planets in space).
80013473|NCT06090422|Drug|Ketamine Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
79702284|NCT00578630|Other|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
79702285|NCT04536558|Drug|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
79702286|NCT04536558|Drug|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
79702287|NCT00578708|Device|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
79844769|NCT05279235|Drug|JT001|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
79844770|NCT05279235|Drug|JT001 placebo|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
79844771|NCT05279235|Drug|Favipiravir|Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
79844772|NCT05279235|Drug|Favipiravir placebo|Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
79302796|NCT04990557|Drug|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
79302797|NCT04990557|Drug|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
79387099|NCT00094887|Drug|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
79387100|NCT00094887|Drug|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
79542515|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
79542516|NCT01504386|Procedure|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
79387101|NCT01712399|Biological|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
79542517|NCT01504386|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
79702288|NCT04543656|Behavioral|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
79391538|NCT03175692|Diagnostic Test|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
79702289|NCT04543656|Other|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
79702290|NCT04557605|Other|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
79844773|NCT00903318|Behavioral|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
79844774|NCT04035252|Diagnostic Test|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
79844775|NCT03917823|Device|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
79844776|NCT03917823|Device|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
79844777|NCT00229723|Drug|gefitinib (Iressa)|250 mg oral tablet
80013474|NCT06090422|Drug|Midazolam Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
79302798|NCT02478437|Procedure|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
79702291|NCT04536753|Procedure|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
79702292|NCT04557137|Drug|Somatostatin analog|120 mg ipstyl every 28 days
79709954|NCT02892318|Drug|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
79844778|NCT00229723|Drug|cisplatin|intravenous infusion
79844779|NCT00229723|Radiation|radiotherapy|radiation therapy
79844780|NCT00229723|Drug|Gefitinib (Iressa)|500 mg oral tablet
80013475|NCT06090409|Other|Implementing free/subsidized agricultural produce to encourage a plant-based diet.|Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
80013476|NCT06090357|Other|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
79702293|NCT04536675|Drug|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
79702294|NCT04536675|Drug|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
79542518|NCT01504438|Device|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
79702295|NCT04556942|Diagnostic Test|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or > 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
79702296|NCT04556942|Other|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
79702297|NCT04556942|Other|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
79702298|NCT04556942|Other|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
79702299|NCT04556942|Biological|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
79702300|NCT04556942|Procedure|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
79702301|NCT04556942|Procedure|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
80013477|NCT06090331|Diagnostic Test|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
80013478|NCT06090318|Drug|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
80013479|NCT06090318|Drug|Atezolizumab|1680mg administered every 4 weeks
80013480|NCT06090292|Device|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
79248534|NCT04496661|Device|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
79302799|NCT02478437|Procedure|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
79387102|NCT04552301|Behavioral|Cognitive Processing Therapy|Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.
79387103|NCT04552301|Behavioral|Psychotherapy|The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.
79387104|NCT04552301|Behavioral|Targeted Asthma Education|The manualized 10-session program of asthma self-management
79387105|NCT04552301|Behavioral|General Asthma Education|A 10-session program of similar time
79387106|NCT00097695|Drug|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
79542519|NCT01504438|Device|STAR Total Ankle Replacement|STAR Total Ankle Replacement
79702302|NCT04536441|Behavioral|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley & Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
79702303|NCT04536441|Behavioral|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
79542520|NCT01504451|Device|ILR insertion|Insertion of implantable loop recorder
79542521|NCT01504451|Procedure|AF ablation|AF ablation
79542522|NCT01504464|Biological|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
79542523|NCT01504464|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
79702304|NCT04557293|Device|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
79702305|NCT04536597|Other|Quince seed jelly group|Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
79702306|NCT04536597|Other|Breast milk group|Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
79702307|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
79702308|NCT04556903|Combination Product|Bilateral Arm Training|First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
79702309|NCT04556903|Combination Product|modified constrained induce movement therapy|"BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~Block placement- 10minutes~Peg targeting- 10 minutes~Peg inversion-10miutes~Transferring objects- 10minutes"
79702310|NCT04536636|Drug|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
80013481|NCT06090292|Device|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
79248535|NCT04496661|Device|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
79702311|NCT04536636|Drug|Control-No drug|Patients received usual medical care with no DHA
80013482|NCT06090292|Device|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
79702312|NCT04556747|Other|VR - Distraction|Participants will be instructed to use any application.
80013483|NCT06090292|Device|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
80013484|NCT06090253|Behavioral|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
79248536|NCT05112068|Other|traditional skin care method|Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
79302800|NCT03201835|Drug|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
79302801|NCT03201835|Drug|Sativex|spray X 4 actuations
79702313|NCT04556747|Other|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
80013485|NCT06090253|Behavioral|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
80013486|NCT06090253|Behavioral|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
80013487|NCT06090253|Behavioral|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
80013488|NCT06090253|Behavioral|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
79387107|NCT00097695|Drug|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
79387108|NCT02096679|Drug|AZD9291|Volunteer will receive a single oral dose of 20 mg [14C]-AZD9291 as a solution on Day 1
79391539|NCT02417454|Dietary Supplement|ProbioStick|"One sachet daily, without or without meals (3 x 10^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
79391540|NCT02417454|Other|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
80013489|NCT06090214|Diagnostic Test|Liquid biopsy|For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
79702314|NCT02278653|Other|Questionnaires for the evaluation of Quality of Life|"European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~Short Form (36) health survey~EORTC CR38~Vaizey score~Low Anterior Resection Syndrome (LARS) score~International Index of Erectile Function for men~International Prostate Symptom Score for men~Female Sexual Function Index for women"
79702315|NCT02278653|Other|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
79702316|NCT00578825|Drug|Lopinavir / Ritonavir plus Ribavirin|
79702317|NCT04536129|Drug|Hydrocortisone (CORTIVIS ®)|Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
79702318|NCT00578981|Behavioral|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
79702319|NCT04556786|Behavioral|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
80013490|NCT06090201|Other|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
80013491|NCT06090188|Other|A Culture-Based Multicomponent Cognitive Training Program|Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
79702320|NCT04556825|Drug|PRP|After the arthroscopic operation was completed, a local PRP injection was performed
79702321|NCT04556825|Drug|normal saline|After the arthroscopic operation was completed, a local normal saline injection was performed
80013492|NCT06090149|Device|PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.|"The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
79248537|NCT05112068|Other|method using specialized gloves|"Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying."
79248538|NCT03339921|Drug|Botulinum toxin injections for chronic compartment syndrome|Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
79248539|NCT03339921|Procedure|surgical fasciotomy for chronic compartment syndrome|linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
79248540|NCT05112224|Behavioral|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
79702322|NCT04536246|Procedure|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
79248541|NCT03342729|Behavioral|Intervention|Participants receive the AMP 10-week program immediately
79248542|NCT03342729|Behavioral|Control|Participants will not received the AMP 10-week program immediately, rather will wait 3-months
79702323|NCT04536246|Procedure|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
79702324|NCT04556708|Other|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
79702325|NCT04556708|Other|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
79709955|NCT02892318|Drug|Guadecitabine|Guadecitabine 60 mg/m^2 SC on Days 1-5 of every 28-day cycle.
79709956|NCT01334918|Drug|regadenoson|Administered by intravenous bolus.
79702326|NCT04556708|Other|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
79387109|NCT00195039|Drug|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
80013493|NCT06090149|Device|PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator|"The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
79702327|NCT04535973|Diagnostic Test|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
79702328|NCT04535973|Other|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
79702329|NCT04536090|Drug|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
79702330|NCT04536051|Biological|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10^10 vp + paracetamol
80013494|NCT06090136|Drug|TPN171H|5 mg TPN171H tablets，single dose,oral
80013495|NCT06090123|Drug|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
80013496|NCT06090123|Drug|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
79702331|NCT04536051|Biological|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
80013497|NCT06090123|Drug|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
79387110|NCT02054338|Drug|Vinflunine+Gemcitabine|Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
79387111|NCT02054338|Drug|Paclitaxel+Gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
79387112|NCT00198081|Drug|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
79702332|NCT04536051|Biological|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10^10 vp), 4-12 weeks apart + paracetamol
80013498|NCT06090097|Device|KneeBRIGHT System|The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
79387113|NCT00198081|Drug|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
79702333|NCT04536051|Biological|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
79702334|NCT04543422|Dietary Supplement|Green tea|Green tea extract capsules
79702335|NCT04543422|Other|Placebo|Placebo containing inert material.
80013499|NCT06090097|Other|Control Exercise|The control group will complete a 10-week regimen of conventional PT exercise
80013500|NCT06090032|Device|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
80013501|NCT06090006|Other|Screening package|Y-Check is a novel intervention delivering a health check-up and where indicated will provide on-the-spot care and referral for common conditions on two occasions in adolescence (in young adolescents (10-14 year-olds) - soon after the onset of puberty - and again in older adolescents (15-19 year-olds) - when many adolescents become, or are soon to become, sexually active). It will also provide health promotion information and materials to support positive behaviours and healthy lifestyles during adolescence and beyond. Adolescents will only be screened for conditions that have an accurate, low-cost, acceptable screening test and a locally accessible, effective intervention. The conditions selected for screening will be chosen to reflect the local epidemiological contexts (e.g. screening for malaria will only take place in high malaria endemic areas).
79702336|NCT00579215|Behavioral|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
79387114|NCT02054572|Drug|[¹⁴C]Etelcalcetide|750 nCi of [¹⁴C]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
79387115|NCT00100659|Drug|Pegylated Interferon/ribavirin|
79702337|NCT00579215|Behavioral|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
79702338|NCT04536324|Procedure|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
79542524|NCT01504490|Drug|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
79702339|NCT04556669|Biological|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
79702340|NCT02215005|Drug|Telmisartan|
80013502|NCT06090006|Diagnostic Test|Psychosocial and mental health disorder screening|HEEADSSS stands for Home, Education/Employment, Eating, Activities, Drugs, Sexuality, Suicide/Depression, and Safety (Klein et al., 2014) and Patients´ Health Questionnaire - Adolescent (PHQ-A), Generalised Anxiety Disorder (GAD-9) and counselling and referral where indicated
80013503|NCT06090006|Diagnostic Test|Alcohol, tobacco and substance use screening|World Health Organization (WHO) ASSIST-Y tool (Humeniuk, 2016) and referral where indicated
80013504|NCT06090006|Behavioral|Diet and physical activity screening|HEEADSSS (Klein et al., 2014) and counselling and advice
79248543|NCT05112146|Dietary Supplement|Whey protein isolate|Oral administration
79248544|NCT05112146|Dietary Supplement|Whey protein microgel|Oral administration
79248545|NCT05112146|Dietary Supplement|Water|Oral administration
79248546|NCT04593914|Device|Cavilon Advanced Skin Protectant|"3M™ Cavilon™ Advanced Skin Protectant is a polymeric-cyanoacrylate solution intended for the protection of intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier. It is elastomeric, adhering to the contours of the skin and providing a uniform film. The film is transparent and possesses good oxygen and moisture vapor permeability.~The polymer-cyanoacrylate is dispersed in a non-stinging solvent. The film is colorless, non-cytotoxic and has a low dermatitis potential. The film adheres to dry, moist or wet skin surfaces and remains intact during conditions of continuous or repeated exposure to moisture or caustic irritants. It will wear off the skin and does not require removal."
79248547|NCT04523090|Drug|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
79542525|NCT01504503|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
79542526|NCT01504503|Drug|Aricept|Aricept 10 mg Tablets
79542527|NCT01504516|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
79542528|NCT01504516|Drug|Aricept|Aricept 10 mg Tablets
79542529|NCT01504542|Biological|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
79542530|NCT01504542|Biological|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
79542531|NCT01504542|Biological|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
79542532|NCT01504568|Other|Treatment|Adults: ≥40 kg:250mg every eight hours Children: <40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
79542533|NCT01504581|Biological|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
79542534|NCT01504581|Biological|HM10660A placebo|Single dose of HM10660A Placebo
79542535|NCT01504581|Biological|Pegasys|Single dose of Pegasys 180ug
79542536|NCT01504594|Procedure|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
79702341|NCT02215005|Drug|Ramipril|
79702342|NCT04536714|Behavioral|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
79702343|NCT02215044|Drug|BI 2536, intravenous|
79542537|NCT01504607|Procedure|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
79542538|NCT01504620|Other|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
79542539|NCT01504620|Drug|insulin infusion|i.v. infusion of insulin
79542540|NCT01504633|Dietary Supplement|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
79542541|NCT01504646|Dietary Supplement|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
79542542|NCT01504646|Dietary Supplement|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
79702344|NCT02215044|Drug|Gemcitabine, intravenous|
79709957|NCT01334918|Radiation|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
79709958|NCT01334918|Radiation|Contrast|Administered by intravenous infusion.
79702345|NCT04556318|Device|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
79702346|NCT02215083|Dietary Supplement|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
80013505|NCT06090006|Diagnostic Test|Underweight and overweight screening|MUAC (Middle Upper Arm Circumference), BMI (Body Mass Index) followed by Counselling and advice +/- referral where indicated
79702347|NCT04556279|Procedure|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
80013506|NCT06090006|Diagnostic Test|Anemia|Hemocue. Iron and folic-acid supplementation (3 months supply) if anaemic. If severely anaemic (<8g/dl) refer to health facility.
79702348|NCT04556279|Drug|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
80013507|NCT06090006|Behavioral|Oral health screening|Questions on oral health and visual inspection followed by advice, gift of toothpaste and toothbrush, fluoride varnish application +/- Silver Diamine Fluoride application +/- referral
80013508|NCT06090006|Behavioral|Circumcision screening|Question on circumcision status. Visual inspection. Referral for Voluntary Medical Male Circumcision) where uncircumcised (males only)
80013509|NCT06090006|Behavioral|Risky behaviours|Question (s) on sexual activity and other risky behaviours, followed by Risk reduction counselling, Provision of condoms, Provision of modern contraceptives (emergency contraception, depot injections, oral contraceptive pill) (females only) PreExposure Prophylaxis (PrEP) (females only)
80013510|NCT06090006|Diagnostic Test|HIV testing|HIV oral mucosal self-test +/- confirmatory blood-based rapid diagnostic test followed by Counselling + referral to treatment where indicated
80013511|NCT06090006|Diagnostic Test|STI (CT, NG, TV) testing|Chlamydia Trachomatic (CT) /Neisseria Gonorrhea (NG) test on urine sample, Trichomoniasis Vaginalis (TV) test and treatment where indicated
79248548|NCT04523090|Drug|Placebo|Placebo pills with no active ingredient.
79542543|NCT01504659|Drug|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
80013512|NCT06090006|Behavioral|Immunization screening|Question on Human Papilloma Virus (HPV) immunisation history. Review of vaccination card. Followed by referral to immunization
79542544|NCT01504659|Drug|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
80013513|NCT06090006|Diagnostic Test|Visual impairment screening|Peek Acuity or Snellen Tumbling-E and Refer to specialist if indicated
80013514|NCT06090006|Diagnostic Test|Hearing screening|"HearScreen smartphone app +/- HearTest plus Inspection for presence of wax and wax removal.~Refer to specialist if indicated"
80013515|NCT06090006|Diagnostic Test|Physical impairment screening|Questions on physical impairment. Jump or squat test Functional reach test Referral to specialist if indicated
79248549|NCT04947488|Dietary Supplement|Bioarginina C|Dietary supplement vials
79248550|NCT02727777|Drug|TAK228|Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
79248551|NCT02727777|Other|Blood Sugar Testing|Participant given a glucometer to check pre-dose blood sugar levels at home every day.
79248552|NCT04522778|Device|Wearable Central Line Securement Device (Vest)|The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
79248553|NCT04522778|Other|Traditional Securement Dressing|This is a adhesive patch that is traditionally used to secure the external portion of a central line.
79248554|NCT03342651|Other|Vitamin D|Vitamin D, general anesthesia, respiratory complications
79248555|NCT04819568|Drug|Terlipressin|Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
79248556|NCT04819568|Other|Standard of Care|Standard of Care
79248557|NCT02502981|Drug|Spironolactone|25mg orally once a day for 40 weeks
79248558|NCT02502981|Drug|Chlortalidone|25mg orally once a day for 40 weeks
79542545|NCT01504685|Procedure|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
79702349|NCT04535856|Drug|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~Low-dose group (5 x 10^7cells)~High-dose group (1 x 10^8 cells)"
79702350|NCT04535856|Other|Placebo|Control group (placebo)
79702351|NCT00579332|Dietary Supplement|brassica intervention|diet and phyto-chemical intervention
79709959|NCT01334918|Procedure|Single Photon Emission Computed Tomography|Procedure/Surgery
80013516|NCT06090006|Diagnostic Test|Uncontrolled epilepsy screening|Questions on experience of convulsions followed by referral to specialist if indicated
80013517|NCT06090006|Diagnostic Test|Pre-hypertension screening|Blood pressure measured using digital sphygmomanometer followed by counselling and advice if indicated
79702352|NCT04535622|Behavioral|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
79702353|NCT02216253|Drug|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
79844781|NCT04035798|Drug|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
79844782|NCT00894894|Drug|MP-470|escalating daily doses of amuvatinib
79844783|NCT00894894|Drug|amuvatinib (MP-470)|escalating doses of daily amuvatinib
79844784|NCT00903474|Other|questionnaire administration|
79844785|NCT00903474|Other|study of socioeconomic and demographic variables|
79844786|NCT00903474|Procedure|CAM exercise therapy|
79387116|NCT02055430|Procedure|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
79844787|NCT00903474|Procedure|psychosocial assessment and care|
79844788|NCT00903474|Procedure|quality-of-life assessment|
79844789|NCT00903474|Procedure|stress management therapy|
79387117|NCT02055430|Procedure|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
79387118|NCT02055430|Procedure|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
79542546|NCT01504685|Procedure|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
79542547|NCT01504698|Procedure|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
79844790|NCT01075477|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
79248559|NCT04230746|Drug|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
79248560|NCT04230746|Drug|Placebo oral tablet|To study effect on urinary microbiome
79248561|NCT02498223|Other|experiment protocol|"the subjects will undergo the following experiment protocol:~recruitment and medical examination day.~physiological evaluation day- the subjects will perform twice* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~biomechanical valuation day- the subjects will perform twice* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
79302802|NCT03201835|Drug|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
79542548|NCT01504698|Procedure|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
79542549|NCT01504724|Drug|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
79702354|NCT02216253|Other|Placebo|Placebo tablet twice a day 7 days before and after surgery
79702355|NCT02216292|Other|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
79709960|NCT01334918|Procedure|Multidetector Computed Tomography|Procedure/Surgery
79844791|NCT04006275|Drug|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
79844792|NCT04006275|Drug|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
79844793|NCT00987051|Procedure|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
79844794|NCT01075555|Drug|pravastatin sodium|
79844795|NCT01075555|Drug|sorafenib tosylate|
79844796|NCT03972787|Device|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
79844797|NCT00606684|Drug|GW642444 6.25|GW642444 6.25
79844798|NCT00606684|Drug|GW642444 3mcg|once daily
79844799|NCT00606684|Drug|GW642444 12.5mcg|GW642444 12.5mcg
79844800|NCT00606684|Drug|GW642444 25mcg|GW642444 25mcg
79844801|NCT00606684|Drug|GW642444 50mcg|GW642444 50mcg
79844802|NCT00606684|Other|placebo|placebo
80013518|NCT06089993|Other|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
80013519|NCT06089993|Other|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
80013520|NCT06089941|Other|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
79844803|NCT01075633|Procedure|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
79248562|NCT04681196|Other|patients shifted to nasal mask after persistent OSA with oronasal mask|In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
79542550|NCT01504737|Other|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
80013521|NCT06089902|Procedure|unroofing or other surgery if needed|unroofing of coronary artery
79387119|NCT02388880|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
79387120|NCT00101361|Drug|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
79387121|NCT00101361|Drug|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
79542551|NCT01504737|Other|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
79542552|NCT01504750|Procedure|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
79248563|NCT02494245|Other|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
79248564|NCT04633772|Drug|Angiotensin-(1-7)|Intravenous supplementation of Angiotensin-(1-7)
79248565|NCT04633772|Drug|Placebo|NaCl 0.9%
79844804|NCT01075633|Procedure|Colonoscopy with sedation|Colonoscopy with sedation
79844805|NCT00627926|Biological|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
79302803|NCT03201835|Drug|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
79844806|NCT00627926|Drug|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
79302804|NCT03201835|Drug|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
79302805|NCT03074721|Device|PCI Suite Software|PCI with PCI Suite Software
79387122|NCT01726179|Device|Resin infiltration|Proximal caries lesions that are selected for this intervention will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, local anesthesia of the gingival papila, application of rubber dam, etching of the lesion surface for 120 s using 15%HCl gel, washing the lesion with water spray for 30 s, drying the lesion with 100% ethanol for 30 s and subsequent air blowing, application of the infiltrant for 180 s using an applicator provided with the kit, removing excess material from the lesion surface by air blowing and flossing, light curing of the infiltrant for 40 s, repeated application for 60 s, light curing for 40 s, polishing, and removal of the rubber dam.
79387123|NCT01726179|Device|Control|Proximal caries lesions do not recieve a placebo treatment, but simply left untreated.
79542553|NCT01504763|Procedure|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
79844807|NCT00627926|Drug|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
79302806|NCT03074721|Other|conventional PCI|conventional PCI without PCI Software
79387124|NCT02410018|Device|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
79387125|NCT03225846|Drug|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
79387126|NCT03225846|Drug|Placebo|0.9% Sodium Chloride
79702356|NCT02216292|Other|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
79702357|NCT02216331|Drug|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
79702358|NCT02216331|Drug|rifapentine|
79542554|NCT01504776|Drug|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
79542555|NCT01504776|Drug|Bortezomib|
79844808|NCT00627926|Other|Placebo|Telaprevir matching placebo
80013522|NCT06088875|Drug|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
79542556|NCT01504828|Drug|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
79542557|NCT01504906|Drug|cyclosporine|Oral tablets, 600 mg , single dose
80013523|NCT06088875|Drug|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
79248566|NCT03339687|Behavioral|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer & Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
79248567|NCT04610840|Procedure|Puncture of the caliceal system|Puncture of the caliceal system under ultrasound/Xray control
79248568|NCT03339609|Diagnostic Test|Uroflow|Isolated uroflow measurement
79248569|NCT03339609|Diagnostic Test|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
79387127|NCT02410798|Device|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
79387128|NCT03225690|Drug|Morphine|Prevention of remifentanil induced hyperalgesia
79387129|NCT03225690|Drug|Serum physiologic|For placebo, serum physiologic will use
79248570|NCT03339609|Diagnostic Test|US|Ultrasound of post void residual urine
79387130|NCT02389738|Drug|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
79387131|NCT02389738|Drug|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
79387132|NCT02389738|Device|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
79387133|NCT03213132|Behavioral|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
79387134|NCT03213132|Behavioral|Patient Education|Educational website containing information on insomnia
79542558|NCT01504906|Drug|ticagrelor|Oral tablets, 180 mg, single dose
79542559|NCT01504932|Dietary Supplement|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
79702359|NCT02216331|Drug|rifampicin|
79702360|NCT02212418|Other|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
79702361|NCT04535817|Drug|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
79702362|NCT04577924|Other|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
79702363|NCT04543149|Diagnostic Test|Flow cytometric immunophenotyping|To evaluate T cell subsets and monocyte
79702364|NCT04555889|Device|lung recruitment maneuver (LRM) with DrageerVN500|interventions involving device that may help to gradually lung development
79702365|NCT04543266|Procedure|Surgery|Resection of tumors
79709961|NCT00598962|Drug|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
79709962|NCT00598962|Drug|Rifabutin/rifampin|
79709963|NCT00599001|Drug|SD-101|Single subcutaneous escalating dose
79709964|NCT00599001|Drug|placebo|placebo
79844809|NCT03973021|Biological|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
79844810|NCT05711589|Procedure|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
79844811|NCT05711589|Procedure|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
79702366|NCT02215239|Behavioral|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
80013524|NCT06088836|Drug|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
80013525|NCT06088836|Drug|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
79248571|NCT02502591|Drug|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
79248572|NCT05111444|Drug|Camrelizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion
79248573|NCT05111444|Drug|Pyrotinib|320mg as continuous oral once daily on every 21 days
79248574|NCT05111444|Drug|Capecitabine|1000 mg/m^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
79248575|NCT05111444|Drug|Oxaliplatin|130 mg/m^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
79248576|NCT05111444|Drug|Paclitaxel|80 mg/m^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
79248577|NCT05111444|Drug|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): <1.25 m^2 BSA =40 mg, 1.25 to <1.5 m^2 BSA=50 mg, ≥1.5 m^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
79248578|NCT03339531|Radiation|2D radiotherapy|
79248579|NCT03339375|Device|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
79248580|NCT02498691|Biological|Biological collection|Blood and saliva samples, placenta and cord blood collection
79248581|NCT05110820|Diagnostic Test|Automated quantitative pupillometer|Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
79391541|NCT03175536|Other|HDHP with PDL|Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of >$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
79248582|NCT02497989|Other|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
79302807|NCT03199495|Other|electroacupuncture|acupuncture needle with TENS device
79302808|NCT03071367|Other|Clinical Simulation|
79302809|NCT02478515|Drug|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
79302810|NCT02448199|Drug|Meloxicam and Glucosamine|Experimental
79302811|NCT02448199|Drug|Meloxicam|Active Comparator
79391542|NCT03175848|Radiation|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
79702367|NCT04578236|Combination Product|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
79702368|NCT04578236|Drug|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
79702369|NCT04555772|Other|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
79702370|NCT02215278|Dietary Supplement|10 x 55 g/ bean per arm|
79248583|NCT02497989|Other|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
79248584|NCT04598204|Drug|Treatment with oral rapmycin|To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
79248585|NCT03769688|Drug|Cervicovaginal secretions|Same as arm descriptions
79702371|NCT04578119|Procedure|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
79542560|NCT01504932|Other|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
79702372|NCT04542954|Other|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
79702373|NCT04542876|Drug|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
79844812|NCT05711511|Procedure|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
79844813|NCT05711511|Device|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
79844814|NCT02539056|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
79844815|NCT05711433|Procedure|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
79844816|NCT05278182|Drug|Naoxintong Capsule|Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
79844817|NCT05278182|Drug|Placebo|Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
79248586|NCT03769688|Drug|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
79248587|NCT03769688|Diagnostic Test|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
79302812|NCT02448199|Drug|Glucosamine|Active Comparator
79387135|NCT03225612|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
79387136|NCT00200343|Drug|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
79387137|NCT00200343|Drug|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
79844818|NCT00228553|Drug|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
79844819|NCT00922506|Drug|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
79387138|NCT00200343|Drug|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
79387139|NCT03204084|Device|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
79391543|NCT03116490|Procedure|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
79542561|NCT01504932|Other|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
79702374|NCT00579449|Behavioral|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
79702375|NCT00579449|Behavioral|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
79702376|NCT04542915|Other|No intervention|No intervention.
79702377|NCT04542759|Drug|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
79702378|NCT04542759|Drug|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
79709965|NCT04052516|Drug|Icosabutate|Icosabutate oral capsule once daily
79709966|NCT04052516|Drug|Placebo|Matching placebo oral capsule
79709967|NCT00597051|Drug|ARD-0403|
79709968|NCT00599040|Behavioral|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
79844820|NCT00816140|Drug|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
79542562|NCT01504932|Other|pharmacological study|Correlative studies
79542563|NCT01504945|Other|RBC transfusion|1 bag of packed red blood cells
79542564|NCT01504945|Other|Normal saline infusion|500 mL of normal saline infusion
79702379|NCT04556006|Other|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, FR score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
79702380|NCT04542798|Device|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
79702381|NCT04555850|Drug|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
79702382|NCT04555850|Other|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
79702383|NCT04542447|Drug|Nuvastatic|Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
79702384|NCT04542213|Drug|Linagliptin tablet|Linagliptin 5mg once daily plus a basal-bolus insulin scheme
79248588|NCT03769688|Behavioral|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
79248589|NCT03769688|Other|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
79248590|NCT02502825|Other|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
79248591|NCT02502825|Device|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
79702385|NCT04542213|Drug|Insulin|Basal-bolus insulin scheme
79248592|NCT02502825|Device|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
79387140|NCT03203928|Behavioral|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
79387141|NCT00201123|Drug|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
79702386|NCT02278406|Other|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
79702387|NCT04542252|Drug|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
79248593|NCT04572776|Drug|Resiniferatoxin|Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
79248594|NCT04572776|Other|Standard of Care|Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
79387142|NCT00201123|Drug|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
79387143|NCT00201123|Other|Placebo|
79248595|NCT03342495|Other|Patient Navigator|Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare
79248596|NCT03342495|Other|Usual Care|Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
79387144|NCT01712009|Drug|Naproxen|
79387145|NCT01712009|Drug|Loratadine|
79542565|NCT01504984|Drug|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
79542566|NCT01504984|Drug|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
79542567|NCT01505023|Dietary Supplement|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
79542568|NCT01505023|Dietary Supplement|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
79542569|NCT01505023|Dietary Supplement|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
79542570|NCT01505036|Other|SMARTCARE service|U-Healthcare service
79542571|NCT01505049|Drug|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
79542572|NCT01505075|Radiation|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
79542573|NCT01505088|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
79542574|NCT01505088|Drug|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
79542575|NCT01505088|Drug|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
79702388|NCT04542252|Drug|Cyclosporine|200 mg Capsule
79844821|NCT00816140|Drug|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
79542576|NCT01505088|Drug|Placebo Eyedrops|Placebo Eyedrops
79844822|NCT00903708|Drug|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
79844823|NCT00899184|Genetic|polymorphism analysis|
79844824|NCT00899184|Other|laboratory biomarker analysis|
79248597|NCT05110664|Drug|PYY (3-36) Peptide|oral PYY3-36 solution
79248598|NCT05110664|Drug|Placibo|oral placebo solution
79248599|NCT05104346|Procedure|appendectomy|open or laparoscopic appendectomy
79387146|NCT01712009|Biological|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
79387147|NCT01712009|Drug|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
79542577|NCT01505101|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
79542578|NCT01505101|Behavioral|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
79391544|NCT02417298|Drug|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
79391545|NCT02417298|Drug|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
79542579|NCT01505127|Drug|TAK-438|
79542580|NCT01505127|Drug|Lansoprazole|
79542581|NCT01505127|Drug|Amoxicillin|
79248600|NCT03343587|Drug|LY3375880 IV|administered IV
79542582|NCT01505127|Drug|Clarithromycin|
79542583|NCT01505140|Other|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
79542584|NCT01505153|Biological|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
79542585|NCT01505192|Device|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
79542586|NCT01505218|Drug|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:"
79702389|NCT04532775|Drug|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
79702390|NCT04532775|Drug|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
79702391|NCT04532775|Drug|Bupivacaine Hydrochloride|local anesthetic drug
79702392|NCT04532775|Drug|saline 0.9%|solution for intravenous and epidural injection
79702393|NCT04532580|Device|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
79248601|NCT03343587|Drug|LY3375880 SC|administered SC
79248602|NCT03343587|Drug|Placebo IV|administered IV
79248603|NCT03343587|Drug|Placebo SC|administered SC
79248604|NCT02502513|Behavioral|Brief computerized intervention|"Computer game Tetris"
79248605|NCT03338985|Genetic|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
79248606|NCT05100914|Other|Couple-based family nursing|Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.
79248607|NCT03338907|Drug|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
79248608|NCT03338751|Diagnostic Test|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
79248609|NCT03338751|Diagnostic Test|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
79702394|NCT04578158|Drug|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
79844825|NCT00899262|Other|immunohistochemistry staining method|
79844826|NCT00899262|Other|laboratory biomarker analysis|
79844827|NCT00899262|Other|sputum cytology|
79844828|NCT00899262|Procedure|Fourier transform infrared spectroscopy|
79844829|NCT00899262|Procedure|diagnostic bronchoscopy|
79844830|NCT00899340|Genetic|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
79702395|NCT04578158|Dietary Supplement|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
79542587|NCT01505218|Drug|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
79702396|NCT04532736|Drug|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
79387148|NCT03225768|Behavioral|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
79387149|NCT03212352|Drug|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
80013526|NCT06088511|Behavioral|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
80013527|NCT06088511|Behavioral|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
80013528|NCT06088446|Procedure|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
80013529|NCT06087510|Drug|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
79542588|NCT01505231|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.
80013530|NCT06086067|Other|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
80013531|NCT06085599|Behavioral|Progressive relaxation exercises|The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
79248610|NCT02494089|Other|distress analysis|
79248611|NCT03338517|Other|Helium Neon Laser|
79248612|NCT03338439|Device|CSII|This retrospective, observational trial will evaluate 104 diabetic patients with prior treatment with MDI initiating CSII therapy compared to 109 diabetic patients continuing MDI.
79542589|NCT01505231|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
79542590|NCT01505244|Behavioral|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
79542591|NCT01505257|Behavioral|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
79542592|NCT01505270|Other|Retrospective case study|Retrospective case study
79702397|NCT04532736|Drug|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
79702398|NCT04532736|Drug|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
79702399|NCT00579683|Other|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
79248613|NCT02498145|Other|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
79248614|NCT02498145|Other|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
79248615|NCT02497911|Procedure|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
79248616|NCT02497911|Procedure|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
79542593|NCT01505283|Drug|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
79542594|NCT01505283|Drug|Sufentanil|epidural administration of sufentanil 10 µg
79542595|NCT01505283|Drug|lidocaine|epidural administration of lidocaine 50 mg
79542596|NCT01505296|Drug|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
79702400|NCT04555733|Drug|Lemborexant|Lemborexant oral tablets.
80013532|NCT06083207|Drug|IBI3003|Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
80013533|NCT06082258|Other|Training in the management of functional disorders|Theoritical and practical training of GP in long COVID and somatic symptom disorders management
80013534|NCT06082258|Other|Reimbursement of 3 long consultations|3 long consultations (1 hour) reimbursed for each patient
80013535|NCT06080542|Procedure|Aerobic|This session will consist of an aerobic training session performed on a cycle ergometer.
80013536|NCT06080542|Procedure|High-intensity interval training|This session will consist of a HIIT performed with elastic bands
80013537|NCT06073301|Device|Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
80013538|NCT06073301|Other|Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)|Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
80013539|NCT06071143|Biological|KDSTEM Inj.|"Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10^8 cells/10mL/2 syringes)~High dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10^8 cells/30mL/6 syringes)"
80013540|NCT06068153|Drug|Sotorasib|Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
79387150|NCT03212352|Drug|Misoprostol|Regular treatment with Misoprostol 800 mcg.
79248617|NCT02497911|Drug|Ropivicaine|
79248618|NCT02497911|Drug|Bupivicaine|
79387151|NCT01175655|Other|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
79387152|NCT04633395|Other|Music|The participant can choose between 5 different soothing playlists
79387153|NCT04633395|Behavioral|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
79542597|NCT01505296|Procedure|Catheter ablation|Complete PVI
79542598|NCT01505309|Device|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
79542599|NCT01505335|Device|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
79542600|NCT01505348|Other|Overnight fast|Overnight fast from 21:00 h
79387154|NCT00201825|Drug|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
79387155|NCT00201825|Drug|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
79542601|NCT01505361|Biological|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
79542602|NCT01505361|Biological|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
79542603|NCT01505413|Drug|Erlotinib|Erlotinib 100 mg po qd daily
79542604|NCT01505413|Drug|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
79542605|NCT01505413|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
79542606|NCT01505426|Drug|ASP1941|oral
79542607|NCT01505426|Drug|metformin|oral, concomitant use
79542608|NCT01505426|Drug|Placebo|oral
79542609|NCT01505439|Drug|solifenacin|oral
79542610|NCT01505504|Drug|mirtazapine|30 mg at bedtime
79542611|NCT01505582|Other|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
79702401|NCT02216994|Drug|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
79709969|NCT00599040|Behavioral|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
79709970|NCT00599040|Behavioral|Dairy diet|participants are given a high dairy, reduced calorie diet
80013541|NCT06068153|Drug|Lenvatinib|Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
80013542|NCT06067542|Procedure|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
80013543|NCT06053463|Device|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
79248619|NCT04187300|Drug|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
79248620|NCT00707577|Behavioral|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
80013544|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & Dose 1 IBI112 through week 44
79844831|NCT00899340|Genetic|microarray analysis|microarray analysis
79387156|NCT02390050|Drug|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
80013545|NCT06049810|Drug|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & placebo through week 44 by subcutaneous injection
79702402|NCT02216994|Behavioral|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
79387157|NCT02390050|Drug|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
79387158|NCT03203538|Device|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
80013546|NCT06049810|Drug|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & placebo through week 44
80013547|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & Dose 1 IBI112 through week 44
79542612|NCT01505582|Other|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
79542613|NCT01505595|Other|Proprioceptive training|12 weeks
79542614|NCT01505595|Other|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
79387159|NCT03203538|Device|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
79387160|NCT03203538|Device|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
79387161|NCT03203538|Device|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
79387162|NCT03203538|Device|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
79542615|NCT01505621|Other|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L[ring-13C6]phenylalanine
79702403|NCT02216994|Drug|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
79702404|NCT04555928|Other|No intervention|This is a prospective cohort (survey) study. It has no intervention.
79844832|NCT00899340|Genetic|protein expression analysis|protein expression analysis
80013548|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 through week 44
79387163|NCT03203538|Device|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
79387164|NCT04563377|Biological|ChAdOx1.HTI and MVA.HTI|ChAdOx1. HTI dose 5 x 10^10 vp MVA.HTI dose 2 x 10^8 pfu
79387165|NCT03203772|Other|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
79702405|NCT02217033|Other|'R' (Electro-kinetically altered beverage)|
79702406|NCT02217033|Other|Placebo (water)|
79702407|NCT04555538|Diagnostic Test|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
79709971|NCT01332968|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
79844833|NCT00899340|Other|immunohistochemistry staining method|immunohistochemistry staining method
79844834|NCT00899340|Other|laboratory biomarker analysis|laboratory biomarker analysis
79387166|NCT01711853|Drug|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
79387167|NCT03212196|Procedure|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
79387168|NCT03212196|Procedure|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
79844835|NCT00899418|Genetic|gene expression analysis|
79844836|NCT00899418|Genetic|polymerase chain reaction|
79844837|NCT00899418|Genetic|polymorphism analysis|
79844838|NCT00899418|Other|immunohistochemistry staining method|
80013549|NCT06049810|Drug|IBI112|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 through week 44 by subcutaneous injection
79844839|NCT00899496|Other|immunological diagnostic method|
79844840|NCT00899496|Other|physiologic testing|
79844841|NCT00894972|Other|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
79542616|NCT01505660|Behavioral|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at ~9 and 12 months after enrollment.
80013550|NCT06049420|Behavioral|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
79542617|NCT01505686|Procedure|MRI scan|MRI scan with a 1,5 T MRI scanner
79702408|NCT02217072|Behavioral|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
79702409|NCT02217072|Behavioral|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
79702410|NCT02217111|Behavioral|Adventures in Voice: Pediatric Voice Therapy|
79844842|NCT04035642|Radiation|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
79387169|NCT01708187|Biological|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
79844843|NCT04035642|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
79844844|NCT04035642|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
80013551|NCT06046703|Other|Daily nutritional intake|Nutritional intake with a focus on vitamin B12, but also other micronutrients and macronutrients
80013552|NCT06046625|Other|Regular care with additional administration of a semi-structured interview|"Patients receiving regular care. In addition, a semi-structured interview is conducted.~The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement."
80013553|NCT06045221|Drug|Orforglipron|Administered orally
80013554|NCT06045221|Drug|Semaglutide|Administered orally
79387170|NCT00202449|Drug|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
79387171|NCT00202449|Drug|paroxetine|20 mg taken at 10a for duration of the study
79387172|NCT00202449|Drug|Placebo|Placebo
79387173|NCT03203304|Drug|Nivolumab|240mg every two weeks by IV infusion
79387174|NCT03203304|Drug|Ipilimumab|1mg/kg every six weeks by IV infusion
79387175|NCT03225456|Drug|Syntocinon|Intra-nasal oxytocin
79387176|NCT03225456|Drug|Placebos|Intra-nasal placebo
79702411|NCT04532697|Other|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
79844845|NCT04035642|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
79844846|NCT00895050|Other|Review of clinical records|
79844847|NCT00895128|Drug|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
79387177|NCT03119376|Other|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
79542618|NCT01505699|Genetic|RNA analysis|
79542619|NCT01505699|Genetic|cytogenetic analysis|
79542620|NCT01505699|Genetic|microarray analysis|
79542621|NCT01505699|Other|laboratory biomarker analysis|
79844848|NCT00895128|Drug|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
79844849|NCT00895206|Drug|individual adapted immunosuppression|individual adapted immunosuppression
79844850|NCT00895206|Drug|golden standard therapy|golden standard therapy
79542622|NCT01505712|Genetic|gene expression analysis|
80013555|NCT06044246|Biological|PRF membrane|Placing implant with PRF membrane treatment
80013556|NCT06038565|Device|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
80013557|NCT06038565|Device|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
79542623|NCT01505712|Other|laboratory biomarker analysis|
79387178|NCT00203229|Drug|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
79702412|NCT04532697|Other|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
79702413|NCT02212613|Drug|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
80013558|NCT06037070|Biological|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
79387179|NCT00203229|Drug|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
79844851|NCT00899652|Genetic|Southern blotting|
79844852|NCT00899652|Genetic|chromosomal translocation analysis|
79702414|NCT04532385|Dietary Supplement|Green tea extract|400 mg capsule
79844853|NCT00899652|Genetic|cytogenetic analysis|
79844854|NCT00899652|Genetic|gene rearrangement analysis|
79844855|NCT00899652|Genetic|mutation analysis|
80013559|NCT06032182|Behavioral|CRESTR Intervention|15 1-hour sessions of CRT + SRT
79248621|NCT04914650|Other|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
79248622|NCT02502279|Device|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
79248623|NCT02502279|Device|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
79248624|NCT05062694|Other|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
79387180|NCT03225300|Radiation|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
79387181|NCT03225066|Device|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
79542624|NCT01505738|Other|bacterial samples|bacterial samples taken
79542625|NCT01505777|Drug|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
79542626|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
79542627|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
79248625|NCT02497833|Dietary Supplement|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
79248626|NCT02497833|Other|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
79542628|NCT01505777|Drug|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
79542629|NCT01505777|Drug|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
79542630|NCT01505790|Drug|PRASUGREL|60 mg the first day then 10 mg per day during one month
79702415|NCT04532385|Dietary Supplement|Placebo|400 mg capsule
79702416|NCT04555460|Procedure|Hemicraniectomy|Large hemicraniectomy and duraplasty
79702417|NCT04555460|Other|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
79702418|NCT00579800|Procedure|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
79702419|NCT04532268|Drug|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
79702420|NCT00579839|Procedure|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
79702421|NCT00579839|Procedure|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
79709972|NCT01332968|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
79844856|NCT00903942|Radiation|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
79844857|NCT00903942|Drug|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
79844858|NCT05278026|Other|guideline recommended routine treatment|
79844859|NCT00899964|Behavioral|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
79844860|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
79844861|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
79844862|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
80013560|NCT06032182|Behavioral|CRESTR Control|15 1-hour sessions of SRT alone
79542631|NCT01505790|Drug|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP <50%. No more than 3 * 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
79702422|NCT04532112|Device|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
79702423|NCT04532112|Device|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
79702424|NCT04555499|Other|Standardized neurological examination|
79844863|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
79844864|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
79844865|NCT00643916|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to <6 years of age)
79542632|NCT01505803|Dietary Supplement|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
79844866|NCT00900042|Genetic|DNA ploidy analysis|
79542633|NCT01505803|Dietary Supplement|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
79248627|NCT02493933|Drug|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
79248628|NCT02494011|Other|traditional exercise|mobilization stretching exercise
79248629|NCT02494011|Other|Russian current stimulation|stimulation to wrist flexors for 15 minutes
79248630|NCT02494011|Other|closed kinetic chain exercise|wall press exercise plyometric exercise
79248631|NCT04153604|Drug|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
79248632|NCT02502201|Other|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
79387182|NCT03224988|Device|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
79387183|NCT00203931|Drug|Cetuximab|
79387184|NCT00203931|Drug|Pemetrexed|
79702425|NCT04532073|Other|Eurythmy Therapy|A mindfulness-oriented movement therapy
79702426|NCT04532073|Other|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
79387185|NCT02412982|Drug|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
79387186|NCT02412982|Drug|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
79844867|NCT00900042|Genetic|DNA stability analysis|
79844868|NCT00900042|Genetic|chromosomal translocation analysis|
79542634|NCT01505803|Dietary Supplement|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
79702427|NCT04532073|Other|Standard Care|Treatment process that a clinician should follow for a certain type of patient
79709973|NCT01332968|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
79844869|NCT00900042|Genetic|cytogenetic analysis|
79248633|NCT02502201|Other|six-minute walk study outdoors|Performance of a six-minute walk test.
79248634|NCT04102826|Device|Functional electrical stimulation (FES)|Functional electrical stimulation combined with mobile arm support to restore upper limb function.
79302813|NCT03071289|Radiation|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
79302814|NCT03071289|Drug|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
79387187|NCT03203616|Drug|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
79542635|NCT01505816|Device|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
79844870|NCT00900042|Other|flow cytometry|
79844871|NCT00900042|Other|laboratory biomarker analysis|
79844872|NCT00895362|Drug|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
79844873|NCT00895362|Drug|Cetuximab|Loading dose of 200 mg/m^2 (maintenance 125 mg/m^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
79844874|NCT02538978|Biological|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
79844875|NCT02538978|Biological|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
80013561|NCT06030505|Other|No intervention required by the protocol|No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
79387188|NCT02450370|Behavioral|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
79844876|NCT00904098|Drug|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
79844877|NCT00904098|Drug|Usual Care|Current treatment used to treat all migraine headaches
80013562|NCT06026917|Drug|Toludesvenlafaxine hydrochloride sustained-release tablets|D1~D6, 40mg/ tablet, 1 tablet per time, once a day, D7~D10, 80mg/ tablet, 1 tablet per time, once a day, D11~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11~D42, 80mg/ tablet, one tablet each time, once a day.
79542636|NCT01505842|Procedure|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
79542637|NCT01505842|Procedure|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
79844878|NCT00904176|Drug|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
80013563|NCT06022406|Biological|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
79248635|NCT03338283|Other|Electromassage|Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
79844879|NCT00904176|Drug|Warfarin|Tablets, Oral, 25 mg, Single Dose
79844880|NCT00904176|Drug|Digoxin|Tablets, Oral, 0.25, Single Dose
79844881|NCT00900276|Other|immunologic technique|
79844882|NCT00900276|Other|laboratory biomarker analysis|
80013564|NCT06022406|Biological|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
80013565|NCT06018831|Other|Urine and Ultrasound Screening|When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
79248636|NCT03338283|Other|Conservatory treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
79387189|NCT02450370|Behavioral|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
79387190|NCT03203226|Other|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
79542638|NCT01505855|Drug|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
79542639|NCT01505894|Drug|BI 409306|High dose film-coated tablet
79542640|NCT01505894|Drug|BI 409306|High dose film-coated tablet
79542641|NCT01505894|Drug|BI 409306 Placebo|Placebo film-coated tablet
79844883|NCT00900276|Other|mass spectrometry|
79248637|NCT04864964|Procedure|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
79302815|NCT03071289|Radiation|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
79305557|NCT04930575|Other|Muscle Energy Technique|A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body.
79387191|NCT02390908|Behavioral|Immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
79542642|NCT01505894|Drug|BI 409306|Low dose film-coated tablet
79702428|NCT00579917|Behavioral|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
79844884|NCT02540070|Procedure|Periarticular|
79542643|NCT01505894|Drug|BI 409306|Medium dose film-coated tablet
79248638|NCT04790240|Dietary Supplement|Inflammation (I)|"upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g"
79248639|NCT04790240|Dietary Supplement|Inflammation (II)|Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g
79542644|NCT01505907|Drug|CXB909|CXB909
79542645|NCT01505920|Procedure|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
79542646|NCT01505920|Procedure|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
79542647|NCT01505946|Other|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
79542648|NCT01505959|Device|CPAP treatment|Usual CPAP treatment
79387192|NCT02390908|Behavioral|Wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
79542649|NCT01505959|Device|CPAP treatment|CPAP treatment with telemedicine system
79542650|NCT01505985|Dietary Supplement|Oral nutritional Supplement|Specialized nutritional supplement for seniors
79542651|NCT01505985|Dietary Supplement|Placebo|placebo product with no specific nutrients
79542652|NCT01505998|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
79542653|NCT01506011|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
79542654|NCT01506024|Procedure|Total hip arthroplasty direct lateral approach|
79542655|NCT01506024|Procedure|Total hip arthroplasty posterior approach|
79542656|NCT01506024|Procedure|Total hip arthroplasty, anterior approach|
79702429|NCT00579917|Behavioral|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
79844885|NCT02540070|Procedure|Motor free|
79844886|NCT02540070|Procedure|Motor free with dex|
79844887|NCT02540070|Drug|Ropivacaine|
79387193|NCT02450214|Drug|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
79387194|NCT02450214|Drug|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
79542657|NCT01506037|Drug|Desloratadine|Desloratadine ODT 5 mg
79542658|NCT01506050|Drug|Desloratadine|Desloratadine ODT 5 mg
79542659|NCT01506063|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
79542660|NCT01506076|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
79542661|NCT01506089|Other|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
79542662|NCT01506102|Device|Thromboelastography|Thromboelastography during labor and after delivery
79542663|NCT01506115|Drug|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
79542664|NCT01506128|Other|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
79542665|NCT01506154|Drug|MRX-7EAT|Once daily application of a patch for 14 days
79542666|NCT01506167|Drug|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
79542667|NCT01506167|Drug|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
79542668|NCT01506167|Drug|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
79542669|NCT01506167|Drug|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
79542670|NCT01506167|Drug|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
79844888|NCT02540070|Drug|epinephrine|
79844889|NCT02540070|Drug|morphine|
79844890|NCT02540070|Drug|Ketorolac|
79844891|NCT02540070|Drug|Dexmedetomidine|
79844892|NCT02540070|Drug|saline|
79844893|NCT00900354|Genetic|molecular genetic technique|
79844894|NCT00900354|Other|mass spectrometry|
79702430|NCT02217189|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
79248640|NCT04790240|Dietary Supplement|Inflammation (III)|"Metabolites, abnormal fluids (PurPhl):~Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g"
79542671|NCT01506167|Drug|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
79542672|NCT01506219|Procedure|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
79702431|NCT00579956|Drug|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
79702432|NCT00579956|Drug|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
79702433|NCT04555304|Drug|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
79702434|NCT04555304|Drug|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
80013566|NCT06014697|Diagnostic Test|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
79248641|NCT04790240|Drug|Standard of care|remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab & Imdevimab.
79248642|NCT02502357|Other|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, [the participant] will feel very comfortable and [the participant] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, [the participant] will be hungry. [The participant] will be thirsty and urinate easily."
79248643|NCT04386980|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
79387195|NCT02450214|Drug|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
79387196|NCT02450682|Drug|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
79387197|NCT02450682|Drug|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
79542673|NCT01506245|Behavioral|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
79542674|NCT01506258|Procedure|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
79542675|NCT01506258|Procedure|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
79702435|NCT04531800|Procedure|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
79702436|NCT04531800|Procedure|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
79702437|NCT00579995|Drug|Oral N-Acetylcysteine|600 milligrams (mg)
79702438|NCT00579995|Drug|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
79387198|NCT01740401|Drug|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
79387199|NCT02413684|Behavioral|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
79387200|NCT03202836|Drug|progesterone|vaginal utrogestan
79387201|NCT03202836|Drug|Tocolytics|tocolysis for 48 hours
79387202|NCT03202836|Drug|Steroids|antenatal corticosteroids for 48 hours
79702439|NCT04531683|Other|electroacupuncture|same as described in experimental arm.
79702440|NCT04531683|Other|sham electroacupuncture|same as described in sham comparator.
79702441|NCT04531683|Behavioral|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
79248644|NCT04386980|Drug|Placebo|Diluent in normal saline
79248645|NCT02493699|Other|physical exercise- based intervention (Karate techniques training)|
79248646|NCT04090346|Procedure|Fecal Microbiota Transplant|Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
79702442|NCT04555421|Device|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
79702443|NCT04531371|Drug|Dexmedetomidine injection|post surgical agitation prophylaxis
79702444|NCT04531605|Behavioral|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
79702445|NCT04555382|Diagnostic Test|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
79702446|NCT00580112|Drug|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
79702447|NCT00580112|Drug|Trabectedin|Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
79542676|NCT01506284|Procedure|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
79702448|NCT04531332|Drug|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
79702449|NCT04531332|Drug|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
79702450|NCT04555148|Biological|GC5131|COVID19 Hyper-Immunoglobulin
79702451|NCT04555148|Other|Placebo|Placebo
79542677|NCT01506310|Behavioral|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
79702452|NCT04530864|Drug|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
79387203|NCT03203070|Drug|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
79702453|NCT04554875|Diagnostic Test|A scoring system|The scoring system was used to rate score patients.
79702454|NCT04531488|Procedure|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
79702455|NCT04531488|Other|Training with Powered Wheel Chair|Training with Powered Wheel Chair
80013567|NCT06014697|Other|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
80013568|NCT06012929|Drug|ONC201|ONC201 is an oral medication given once per week
79387204|NCT03203070|Procedure|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
79387205|NCT03209856|Drug|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
79542678|NCT01506310|Other|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
79387206|NCT02413918|Drug|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
79387207|NCT03209622|Procedure|Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge|when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
79387208|NCT03209622|Drug|Nicotine patch|Arm A
79387209|NCT03209622|Other|the external consultation|without patch
79387210|NCT00099021|Drug|pioglitazone hydrochloride|Given PO
79387211|NCT00354874|Drug|GW642444|drug
79387212|NCT00354874|Drug|Placebo|placebo
79542679|NCT01506310|Other|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
79542680|NCT01506336|Drug|masitinib|masitinib 12 mg/kg/day
79702456|NCT00580190|Drug|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
79702457|NCT00580190|Other|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
79702458|NCT00580190|Drug|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
79702459|NCT04531137|Dietary Supplement|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
79702460|NCT04531137|Other|Placebo|Placebo milk powder one a day for 12 weeks
79702461|NCT04531137|Other|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
79702462|NCT04530903|Drug|Clonidine|75 µg (0.5mL) per injection site
79702463|NCT04530903|Drug|Levobupivacaine|0.25% (10 ml) per injection site
79702464|NCT04530903|Drug|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
79702465|NCT00580307|Procedure|Septoplasty|Surgical straightening of nasal septum
79844895|NCT00900354|Other|pharmacological study|
79702466|NCT00580307|Procedure|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
79702467|NCT04530474|Drug|Ivermectin Pill|Ivermecin as a one-time dose
79702468|NCT04530474|Drug|Placebo|Inactive medication as a one time dose
79702469|NCT04554641|Other|Fasted breath samples|Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
79702470|NCT04554641|Other|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis.
79702471|NCT04554641|Other|Stool sample|Participants will provide stool sample pre and post Bio-kult Advanced.
79702472|NCT04530669|Device|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
79702473|NCT04530669|Other|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
79542681|NCT01506336|Drug|sunitinib|sunitinib 50 mg/day
79542682|NCT01506349|Dietary Supplement|gluten|4 grams of gluten.
79702474|NCT04554680|Drug|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day & oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- & post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
79702475|NCT00580424|Drug|Norethindrone|Norethindrone 0.35 mg orally daily
79702476|NCT04530396|Biological|Gam-COVID-Vac|vaccine for intramuscular injection
79702477|NCT04530396|Other|placebo|placebo comparator
79702478|NCT04554992|Biological|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
79844896|NCT00904254|Radiation|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
79844897|NCT00905814|Drug|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
79387213|NCT00354874|Drug|salmeterol 50mcg|salmeterol
79387214|NCT03202914|Behavioral|Usual protein and phosphorus diet|Diet intervention
79387215|NCT03202914|Behavioral|Low protein and phosphorus diet|Diet intervention
79387216|NCT03202914|Behavioral|Very low protein and phosphorus|Diet intervention
79387217|NCT05508646|Behavioral|Music therapy intervention|The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
79542683|NCT01506349|Dietary Supplement|Placebo|
79542684|NCT01506375|Biological|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
79542685|NCT01506375|Biological|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
79542686|NCT01506388|Device|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
79542687|NCT01506388|Drug|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
79542688|NCT01506388|Drug|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
79542689|NCT01506401|Device|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
79542690|NCT01506401|Procedure|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure < or = 35cmH20; Prescribed PEEP/FiO2 chart
79542691|NCT01506414|Drug|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
79542692|NCT01506427|Radiation|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
79542693|NCT01506440|Procedure|cognitive assessment|Given cognitive assessments
79542694|NCT01506440|Procedure|quality-of-life assessment|Ancillary studies
79542695|NCT01506466|Other|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
79702479|NCT04530786|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~2004-2005: A/Wyoming H3N2; B/Shanghai~2006-2007: A/New Caledonia H1N1~2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
79702480|NCT01121575|Drug|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
79709974|NCT01332968|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
79844898|NCT00905814|Drug|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
79844899|NCT00905892|Dietary Supplement|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
79844900|NCT00900432|Other|immunoenzyme technique|
79844901|NCT00900432|Other|laboratory biomarker analysis|
79542696|NCT01506492|Behavioral|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
79542697|NCT01506505|Drug|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
79702481|NCT01121575|Drug|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
79702482|NCT01121575|Drug|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
79542698|NCT01506531|Procedure|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
79702483|NCT01121575|Drug|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
79542699|NCT01506531|Procedure|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
79248647|NCT02497599|Drug|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
79248648|NCT02497599|Radiation|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
79844902|NCT00900510|Procedure|Incision and drainage|
79844903|NCT00900510|Drug|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
79844904|NCT00900510|Drug|Placebo|
79542700|NCT01506544|Drug|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
79542701|NCT01506557|Dietary Supplement|cholecalciferol|dose 800 IU/day for 6 month
79542702|NCT01506557|Dietary Supplement|placebo|oil capsules
79542703|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10^3 plaque-forming unit [PFU] of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
79542704|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
79702484|NCT04554797|Other|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
79248649|NCT02497599|Procedure|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
79542705|NCT01506570|Biological|Placebo|One SC injection at Day 0 and Day 180 of placebo
79542706|NCT01506622|Drug|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
79844905|NCT00904410|Other|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
79844906|NCT00160693|Biological|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
79844907|NCT00900588|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
79248650|NCT04314050|Drug|Tramadol|tramadol and paracetamol will perform
79248651|NCT04314050|Drug|Dexmedetomidine|dexmedetomidine and paracetamol will perform
79248652|NCT04314050|Other|control|paracetamol will perform
79248653|NCT04496193|Procedure|Quadratus Lumborum block|Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
79248654|NCT02502123|Other|No Intervention|No intervention was administered in this study.
79248655|NCT03892616|Drug|BI 1358894 (B)|Tablet formulation 2 (TF2a), fed
79542707|NCT01506622|Drug|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
79542708|NCT01506622|Drug|Administration of saline|Saline will be administered to control group at the end of anesthesia.
79542709|NCT01506635|Drug|Timolol|
79542710|NCT01506635|Drug|Placebo|artificial tear twice a day
79542711|NCT01506661|Drug|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
79542712|NCT01506687|Behavioral|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
79702485|NCT04530591|Other|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
79702486|NCT04530591|Other|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
79844908|NCT00906048|Drug|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
79844909|NCT00906126|Drug|Misoprostol|Oral misoprostol
79844910|NCT04034472|Other|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
79702487|NCT04530708|Radiation|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
79248656|NCT03892616|Drug|BI 1358894 (C)|Tablet formulation 2 (TF2a), fasted
79702488|NCT00625573|Drug|Abraxane|100mg/m2 every week X's 3
79702489|NCT04205851|Drug|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
79702490|NCT04205851|Drug|Placebo|Saline
79702491|NCT04530240|Procedure|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
79542713|NCT01506687|Behavioral|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
79702492|NCT04554758|Procedure|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
79702493|NCT04554758|Procedure|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
79542714|NCT01506700|Device|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
79542715|NCT01506713|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
79542716|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
79542717|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
79702494|NCT02882113|Drug|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
79702495|NCT04311190|Other|Family engagement|Physical exercises and simple care tasks
79702496|NCT00580541|Behavioral|variety|variety and nonvariety
79702497|NCT04311229|Device|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
79702498|NCT04311229|Other|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
79702499|NCT04530357|Biological|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
79387218|NCT05508646|Behavioral|Personalized music CD|Participants will receive a personalized music CD that they keep and can listen to as they wish.
79702500|NCT04530357|Other|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
79702501|NCT04554563|Other|Core stability training|20 sessions of specific core stability exercise with no external loading.
79702502|NCT04530045|Other|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
79702503|NCT01121536|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
79702504|NCT02217423|Other|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
79702505|NCT02217423|Other|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
79387219|NCT01711619|Device|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
79387220|NCT01711619|Other|Optimized Medical Management|Optimized medical management
79387221|NCT03209466|Drug|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
79387222|NCT03209466|Drug|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
79387223|NCT02415244|Procedure|TEE|Spinal cord segments will be imaged using the TEE
79387224|NCT05508412|Behavioral|CancerPEP|CancerPEP
79702506|NCT04311151|Procedure|own seizures visualization|At the hospital discharge, patients
79702507|NCT00580619|Other|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
79702508|NCT00580619|Other|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
79248657|NCT03892616|Drug|BI 1358894 (D)|Tablet formulation 2 (TF2b), fed
79248658|NCT03892616|Drug|BI 1358894 (E)|Tablet formulation 2 (TF2b), fasted
79248659|NCT03892616|Drug|BI 1358894 (A)|Tablet formulation 1 (TF1), fed
79248660|NCT03338127|Diagnostic Test|renal function test|2 ml blood sample to be investigated for renal function test
79248661|NCT04689542|Other|Sit-To-Stand test|The 1-minute sit-to-stand test will be realized with or without a surgical facemask covering the face of the patient with COVID-19
79542718|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
79542719|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
79248662|NCT02502045|Device|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
79248663|NCT02502045|Device|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
79542720|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
79542721|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
79702509|NCT00580619|Drug|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
80013569|NCT06004726|Other|School-based Substance abuse Prevention Programme (SSPP)|"Module 1 :Introduction~Orientation about Training Programme using PowerPoint slides~Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~Distribution of informational booklet on basics about substance abuse~Module 2:~Role play to develop a positive attitude towards the prevention of substance abuse.~Case-based scenario to increase resistance to peer pressure.~Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )"
79702510|NCT00580619|Drug|methyldopa|Aldomet oral twice a day for 12 weeks
79702511|NCT02217579|Dietary Supplement|Protein|A food containing 5 grams/serving of supplemental protein.
79702512|NCT02217579|Dietary Supplement|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
79702513|NCT02217579|Dietary Supplement|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
79844911|NCT05277870|Device|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
79844912|NCT05277870|Device|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
80013570|NCT06004284|Other|control|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
79248664|NCT02493543|Other|Blood collection|Blood collection from the subject's arm
79248665|NCT04517474|Behavioral|CANreduce|"CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised."
79248666|NCT04517474|Behavioral|psychological support|psychological support
79248667|NCT03120819|Behavioral|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
79248668|NCT03120819|Behavioral|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
79387225|NCT04485078|Diagnostic Test|Pressure pain threshold|The PPT assessments of spine will be performed over the spinous process and 2 cm right and left side of the corresponding spinous process. The regional PPT scores will be composed from sum of all PPT values for related segments at spine. The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
79542722|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
79542723|NCT01506765|Drug|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
79702514|NCT02217579|Dietary Supplement|Control|An isocaloric food not containing the test protein and fiber.
79709975|NCT01332968|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
79709976|NCT01332968|Drug|Bendamustine|Bendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
79709977|NCT01332968|Drug|Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period.
79709978|NCT00599079|Drug|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
79844913|NCT00900744|Drug|Tamoxifen|20 mg daily
79248669|NCT03343509|Drug|Metronidazole Oral|Oral Metronidazole
80013571|NCT06004284|Other|exercise group|The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
80013572|NCT06003595|Other|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
80013573|NCT05997602|Drug|FCN-159|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
80013574|NCT05995873|Device|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
80013575|NCT05984927|Genetic|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
80013576|NCT05983965|Drug|Tazemetostat|Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
79542724|NCT01506778|Device|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
80013577|NCT05978323|Behavioral|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
80013578|NCT05976490|Behavioral|Information and Support Intervention|Information guide and four one-on-one coaching sessions
79542725|NCT01506791|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
79542726|NCT01506804|Other|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
79542727|NCT01506817|Procedure|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
79702515|NCT04554524|Drug|Chemotherapy+Pembrolizumab.|Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
79702516|NCT04530084|Device|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
79702517|NCT02212652|Dietary Supplement|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
79702518|NCT02212652|Other|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
79702519|NCT02212652|Other|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
79702520|NCT02217657|Device|Thermocool Smart Touch Catheter|Physician informed to contact force
80013579|NCT05976490|Other|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
80013580|NCT05971940|Drug|Orforglipron|Administered orally.
80013581|NCT05971940|Drug|Placebo|Administered orally
80013582|NCT05971849|Drug|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
80013583|NCT05971849|Drug|GnRH|Up to one IV bolus of GnRH
80013584|NCT05970887|Biological|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
79248670|NCT03343509|Drug|Metronidazole Ointment|Metronidazole Ointment
79248671|NCT03343509|Drug|Placebo Oral Tablet|Placebo Tablet
79248672|NCT03343509|Drug|Placebo Ointment|Placebo Ointment
79302816|NCT05713409|Diagnostic Test|Intestinal ultrasound|As part of the routine care, patients will undergo ileocolonoscopy at 6 months, IUS will be performed 3, 6, 12, 18, 24, 30 and 36 months (using B-mode and CDS) and at 3 and 6 months elastography will be performed on the neo-terminal ileum. Biomarkers (CRP and fecal calprotectine) will be measured according to routine care.
79302817|NCT03199183|Radiation|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
79702521|NCT02212769|Drug|Losartan 50mg|Losartan 50mg once daily for 7 days
79248673|NCT02501889|Behavioral|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
79302818|NCT03199183|Other|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
79542728|NCT01506830|Procedure|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
79702522|NCT02212769|Drug|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
79702523|NCT02217696|Other|Computerized reading training|
79702524|NCT00580658|Device|Medtronic Activa Gpi|Activa Therapy, Gpi
79702525|NCT02212808|Other|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
79702526|NCT02212808|Other|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
79542729|NCT01506830|Procedure|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
79542730|NCT01506843|Biological|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
79542731|NCT01505972|Other|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
79542732|NCT01505972|Other|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
79542733|NCT01506895|Drug|darapladib|Experimental compound 160 mg dose
79542734|NCT01506895|Drug|placebo|Placebo to match
79542735|NCT01506921|Drug|Racemic ketamine|0.6 mg/kg
79542736|NCT01506921|Drug|S-ketamine|0.3 mg/kg
79542737|NCT01506934|Drug|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
79542738|NCT01506999|Biological|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
79702527|NCT02217774|Device|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
79542739|NCT01507012|Dietary Supplement|Berry Polyphenols|
80013585|NCT05970887|Biological|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
79302819|NCT03199183|Genetic|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
79542740|NCT01507012|Dietary Supplement|Placebo|Placebo control containing sugar and artificial flavouring.
79542741|NCT01507038|Drug|YH14617|1mg once weekly
79542742|NCT01507038|Drug|YH14617|1.6mg once weekly
79542743|NCT01507038|Drug|YH14617|2mg once biweekly
79542744|NCT01507038|Drug|Placebo|Once weekly
79542745|NCT01507064|Drug|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
79542746|NCT01507064|Procedure|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
79542747|NCT01507077|Drug|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
79702528|NCT02217852|Drug|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
79702529|NCT02217852|Drug|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
79702530|NCT02217852|Drug|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
79702531|NCT02217852|Drug|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
79702532|NCT02217930|Drug|WCK 2349|
79844914|NCT02539758|Other|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
80013586|NCT05967871|Biological|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
79387226|NCT04485078|Diagnostic Test|Temporal summation|TS will be evaluated over the trapezius muscle, sacroiliac joints, C7, T6, and L3 levels at spine with manuel algometer. TS scores will be calculated for each spine level as the sum of three values which measured over the spinous process and 2 cm right and left side of corresponding level. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
79542748|NCT01507077|Drug|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
79542749|NCT01507116|Other|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
79542750|NCT01507168|Drug|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
79542751|NCT01507168|Drug|GC33|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
80013587|NCT05963022|Drug|Tirzepatide|Administered SC
79387227|NCT04485078|Diagnostic Test|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 70C water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
79387228|NCT04485078|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
79542752|NCT01507194|Drug|Ondansetron|Single IV dose
79542753|NCT01507194|Drug|Vestipitant|Single IV dose
79542754|NCT01507207|Procedure|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
79542755|NCT01507259|Other|cocoa|70% versus 34%
79542756|NCT01507272|Drug|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
79542757|NCT01507272|Drug|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
79542758|NCT01507272|Drug|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
79542759|NCT01507272|Drug|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
79542760|NCT01507311|Drug|liraglutide|A single dose injected subcutaneously (under the skin)
79542761|NCT01507311|Drug|placebo|A single dose injected subcutaneously (under the skin)
79702533|NCT02217930|Drug|Placebo|
79702534|NCT02217930|Drug|Moxifloxacin|
79844915|NCT02539758|Device|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
80013588|NCT05963022|Drug|Placebo|Administered SC
80013589|NCT05962970|Drug|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
79248674|NCT02501889|Behavioral|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
79248675|NCT03338049|Device|Veran System|Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
79248676|NCT03337971|Dietary Supplement|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
79702535|NCT01121185|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
79702536|NCT01121185|Other|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
79702537|NCT01121146|Device|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
79702538|NCT04529733|Device|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
79844916|NCT02539758|Device|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
79844917|NCT00643760|Drug|Placebo|placebo
79844918|NCT00643760|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
79844919|NCT00643760|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
79248677|NCT03337971|Dietary Supplement|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
79542762|NCT01507337|Drug|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
79702539|NCT01120756|Behavioral|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
79702540|NCT01120756|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
79702541|NCT01120717|Drug|QVA149|capsules for inhalation, delivered by an SDDPI
79542763|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
79702542|NCT01120717|Drug|Placebo|capsules for inhalation, delivered by an SDDPI
79702543|NCT04577846|Drug|Cephalexin 500 MG|Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
79702544|NCT04577846|Drug|Placebo|A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
79702545|NCT04529811|Drug|Rifaximin Novel Formulation|Rifaximin Novel Formulation
79844920|NCT00643760|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
79387229|NCT04485078|Other|Bath Ankylosing Spondylitis Disease Activity Index|Standardized questionnaire to determine the level of disease activity in AxSpa patients
79387230|NCT04485078|Other|Ankylosing Spondylitis Quality of Life|Standardized questionnaire to investigate the quality of life in AxSpa patients
79387231|NCT04485078|Other|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability
79542764|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
79542765|NCT01507363|Drug|Placebo|Placebo tablets for 7 days, starting on the day of surgery
79542766|NCT01507376|Drug|recombinant hCG|recombinant hCG(250 µg Ovitrell)
79542767|NCT01507376|Drug|recombinant hCG|recombinant hCG(500 µg Ovitrell)
79702546|NCT04529811|Drug|Placebo|Placebo
79702547|NCT04554407|Device|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
79702548|NCT02217969|Behavioral|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
79702549|NCT02218047|Drug|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
79702550|NCT02218047|Drug|Best available therapy (BAT)|Best available therapy as selected by the investigator
79702551|NCT00580814|Drug|Methylphenidate|Methylphenidate
79844921|NCT00643760|Drug|Pregabalin|pregabalin 300mg/day
79844922|NCT00904644|Drug|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
79844923|NCT02539836|Dietary Supplement|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
79844924|NCT02539836|Diagnostic Test|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
79844925|NCT04034628|Device|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
79844926|NCT04034628|Device|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
79844927|NCT00906360|Drug|sunitinib malate|Given orally or by percutaneous gastrostomy tube
79248678|NCT04516148|Drug|Cefazolin|Dosing per hospital policy
79248679|NCT04516148|Drug|Clindamycin|Dosing per hospital policy
79248680|NCT03337893|Diagnostic Test|blood pressure|it will be done both right and left arms
79248681|NCT03342573|Drug|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
79248682|NCT03343353|Other|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
79302820|NCT04987827|Other|No intervention|No intervention
79387232|NCT04485078|Other|Beck Depression Inventory|Standardized questionnaire to investigate the depression
79387233|NCT04485078|Other|Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue
79542768|NCT01507376|Drug|urinary hCG|10,000 IU urinary hCG
79702552|NCT01120600|Drug|Odanacatib|One 50 mg tablet once weekly
79702553|NCT01120600|Drug|Placebo for Odanacatib|One 50 mg tablet once weekly
79702554|NCT01120600|Dietary Supplement|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
79702555|NCT01120600|Dietary Supplement|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
79702556|NCT04529694|Other|Psychotherapy|
79702557|NCT04577885|Drug|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
79702558|NCT02218086|Device|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
79702559|NCT02218086|Device|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
79702560|NCT02218086|Device|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
80013590|NCT05962970|Drug|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
79702561|NCT02218086|Device|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
79702562|NCT02218086|Device|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
79702563|NCT02218086|Device|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
79702564|NCT02218086|Device|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times ~15minutes within y few weeks.
79702565|NCT04554251|Other|Survey|invited questionnaire
79702566|NCT01120210|Drug|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
79702567|NCT01120210|Drug|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
79702568|NCT01120210|Drug|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
79702569|NCT01120210|Drug|Placebo|1-hour infusion of matching placebo on Day 1
79702570|NCT01120210|Drug|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
79702571|NCT04554329|Procedure|bandage contact lens|bandage contact lens
79702572|NCT02218125|Biological|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
80013591|NCT05961176|Device|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
80013592|NCT05955469|Device|FS4 then TFS4 (cochlear implant)|Cochlear implant with default fitting then with tonotopy-based fitting
79542769|NCT01507389|Drug|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
79542770|NCT01507402|Drug|REGN1033(SAR391786)|Administration method A
80013593|NCT05955469|Device|TFS4 then FS4 (cochlear implant)|Cochlear implant with tonotopy-based fitting then with default fitting
80013594|NCT05955040|Drug|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
80013595|NCT05955040|Drug|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
80013596|NCT05954104|Drug|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
80013597|NCT05944224|Drug|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
79248683|NCT03337815|Drug|Treatment of MTX and TwHF placebo|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
79542771|NCT01507402|Drug|REGN1033(SAR391786)|Administration method B
79542772|NCT01507402|Drug|Placebo|(inactive substance)
79542773|NCT01507428|Drug|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
79542774|NCT01507428|Drug|Carboplatin|Given IV
79542775|NCT01507428|Procedure|Computed Tomography|Undergo FDG PET/CT
79542776|NCT01507428|Procedure|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
79542777|NCT01507428|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
79542778|NCT01507428|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
79542779|NCT01507428|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
79542780|NCT01507428|Other|Laboratory Biomarker Analysis|Correlative studies
79702573|NCT02218125|Biological|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
79702574|NCT00580931|Drug|Nicotinamide|1500 mg twice a day for 6 months
79702575|NCT00580931|Drug|Enduramide placebo|1 tab twice a day
79702576|NCT02218281|Behavioral|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
79702577|NCT02218281|Behavioral|NCI's QuitSTART app|NCI's smoking cessation app
79702578|NCT02218281|Behavioral|Written smoking cessation materials only|Receipt of written smoking cessation materials
79702579|NCT01120093|Drug|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
79702580|NCT01120093|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
79702581|NCT01120093|Drug|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
79702582|NCT01120093|Drug|Placebo|Placebo via inhalation in the morning and evening for 7 days
79702583|NCT01120093|Drug|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
79702584|NCT00581009|Other|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
79709979|NCT04326816|Procedure|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
80013598|NCT05944224|Drug|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
80013599|NCT05943340|Other|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
79844928|NCT00906360|Other|pharmacological study|Correlative studies
79542781|NCT01507428|Drug|Paclitaxel|Given IV
79542782|NCT01507428|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
79702585|NCT00581009|Drug|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
79844929|NCT00906360|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
79844930|NCT00906360|Biological|cetuximab|Given IV
79844931|NCT00643682|Other|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
79844932|NCT00904800|Drug|AZD0837|tablet, oral, once daily, 1+5 days
79844933|NCT00904800|Drug|Placebo|Placebo
79844934|NCT00906438|Dietary Supplement|2006-RD-05|300 mg daily, once a day for 28 consecutive days
79844935|NCT00906438|Dietary Supplement|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
79844936|NCT00819494|Procedure|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
79844937|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
79844938|NCT00603798|Drug|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
79844939|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
79702586|NCT00581009|Radiation|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
79844940|NCT00819572|Biological|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
79248684|NCT03337815|Drug|Treatment of TwHF and MTX placebo|Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
79844941|NCT00819572|Drug|Placebo|
79844942|NCT00908622|Procedure|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
79844943|NCT00908622|Procedure|Cardiac revascularization|Cardiac revascularization
79844944|NCT02538588|Device|Nebulizer 1|
79844945|NCT02538588|Device|Nebulizer 2|
79844946|NCT03323502|Behavioral|ACP Specialist Program|New structured role with responsibility for ACP
79844947|NCT00630812|Drug|inhaled mannitol|400 mg BD for 26 + 26 weeks
79844948|NCT00630812|Drug|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
79844949|NCT00906516|Drug|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
79844950|NCT03299478|Other|Will look for immune infiltration|
79844951|NCT00908700|Procedure|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
79302821|NCT03314675|Device|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
79302822|NCT04987437|Device|Friendly short stem|Total Hip Arthroplasty with Friendly Short stem
79542783|NCT01507428|Procedure|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
79542784|NCT01507441|Genetic|gene mapping|
79542785|NCT01507441|Genetic|microarray analysis|
79844952|NCT00908700|Procedure|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
79387234|NCT04485078|Other|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
79387235|NCT04485078|Other|Fibromyalgia Rapid Screening Tool|Standardized questionnaire to detect fibromyalgia
79387236|NCT04485078|Other|Visual analogue scale|global pain score on a 0 to 10
79387237|NCT01710527|Drug|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
79542786|NCT01507441|Genetic|mutation analysis|
79542787|NCT01507441|Genetic|nucleic acid sequencing|
79542788|NCT01507441|Other|laboratory biomarker analysis|
79542789|NCT01507454|Drug|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
79542790|NCT01507467|Radiation|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
79387238|NCT01710527|Drug|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
79542791|NCT01507467|Radiation|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
79542792|NCT01507480|Drug|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
79702587|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
79542793|NCT01507506|Radiation|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
79387239|NCT05507242|Biological|Tezepelumab|Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
79542794|NCT01507506|Radiation|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
79702588|NCT02218359|Drug|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
79702589|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
79542795|NCT01507519|Device|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
79542796|NCT01507532|Other|pharmacokinetic monitoring|pharmacokinetic monitoring
79702590|NCT02882191|Drug|LevoCept|placement of LevoCept IUD
79702591|NCT02882035|Other|OFA|
79542797|NCT01507558|Procedure|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
79702592|NCT02212847|Other|vestibular stimulation|
79702593|NCT02218398|Drug|Albuterol|
79702594|NCT02218437|Drug|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
79702595|NCT04577768|Device|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
79702596|NCT04577768|Device|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
79702597|NCT04577768|Device|HD-tDCS sham|sham stimulation of the right primary motor cortex
79702598|NCT02218515|Procedure|Open Flap Debridement|Open Flap Debridement (Control Group)
79702599|NCT02218515|Biological|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
79702600|NCT02218515|Biological|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
79702601|NCT02218554|Genetic|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
79702602|NCT04577612|Drug|CHI-554|hemp-derived CBD in MCT oil
79702603|NCT02218671|Drug|WE 941 OD tablets|
80013600|NCT05937672|Device|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
79702604|NCT01119937|Drug|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
79702605|NCT01119937|Drug|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
79702606|NCT02278731|Other|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
79702607|NCT01119898|Drug|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
79702608|NCT01119898|Drug|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
79702609|NCT04577534|Drug|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
80013601|NCT05935410|Behavioral|DM Social Needs|6-monthly sessions of telephone delivered, manualized education and skills training on diabetes management, and problem solving and resolution of social needs.
79387240|NCT05507242|Other|Placebo|Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
79702610|NCT02278809|Behavioral|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
79702611|NCT04553900|Diagnostic Test|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
79248685|NCT03575936|Device|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
79302823|NCT03199105|Other|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
79387241|NCT03209544|Behavioral|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, & Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
79387242|NCT03202992|Drug|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
79387243|NCT00354952|Drug|Macrolides (azithromycin or clarithromycin)|
79542798|NCT01507571|Other|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~a tape-recorded session with the patient using the DT question protocol~Transcription of the interview, which is then edited~A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
79542799|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
79542800|NCT01507597|Drug|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
79702612|NCT01119859|Drug|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
79702613|NCT01119859|Drug|Adalimumab|
79702614|NCT01119859|Drug|Placebo to tocilizumab|
79702615|NCT01119859|Drug|Placebo to adalimumab|
79702616|NCT02278926|Other|Ultrasound|Ultrasound measurements
79702617|NCT02278926|Other|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
79702618|NCT01119703|Biological|Tetanus & Diphtheria booster vaccine (Td)|Tetanus & Diphtheria booster vaccine (Td), single intramuscular dose
79702619|NCT01119703|Biological|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], intramuscular, two doses of standard three dose regimen (opposite arms)
79702620|NCT01119703|Biological|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
79702621|NCT04554446|Procedure|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
79702622|NCT04554446|Procedure|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
79702623|NCT02218749|Other|Initially triaged to physiotherapist|
79702624|NCT02218749|Other|Initially triaged to physician|
79702625|NCT02882230|Drug|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
79702626|NCT00581087|Drug|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
79702627|NCT00581087|Drug|Placebo|Treatment : 200 mg/day hard gelatine capsule
79702628|NCT01119625|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
79702629|NCT01119625|Biological|Infanrix-IPV/Hib|Intramuscular injection, one dose
79702630|NCT02218827|Drug|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
79702631|NCT00581126|Drug|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
79702632|NCT04553978|Drug|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
79702633|NCT02881918|Other|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
79387244|NCT03209700|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
79702634|NCT02881762|Drug|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
79702635|NCT02218905|Behavioral|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
79702636|NCT04554017|Other|Education/Training|It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
79702637|NCT04307017|Other|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
79702638|NCT04561947|Procedure|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
80013602|NCT05935410|Behavioral|Usual Care|Diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) will be mailed monthly.
79702639|NCT04561947|Procedure|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
79248686|NCT03575936|Procedure|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
79248687|NCT03974048|Diagnostic Test|Blood samples for DNA methylation analysis|DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
79387245|NCT01706939|Radiation|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy
79387246|NCT01706939|Radiation|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy
79702640|NCT04561947|Other|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
79702641|NCT01119118|Drug|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
79702642|NCT04577339|Procedure|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
79387247|NCT01706939|Drug|Carboplatin|Day 1, every 7 days ( + 2 days)
79387248|NCT03209778|Other|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
79387249|NCT03209076|Procedure|Robotic|Robotic low anterior resection
79702643|NCT01119001|Device|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
79702644|NCT02212925|Drug|BI 14332 CL|
79702645|NCT02212925|Drug|Placebo|
79387250|NCT03209076|Procedure|Laparoscopic|Laparoscopic low anterior resection
79387251|NCT05719246|Behavioral|Yoga|The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga & Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
79387252|NCT03224910|Other|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
79387253|NCT00355810|Dietary Supplement|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
79702646|NCT01118962|Drug|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
79702647|NCT04561830|Procedure|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
79702648|NCT00581165|Drug|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
79702649|NCT05362006|Device|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
79702650|NCT05362006|Device|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
79702651|NCT05092984|Drug|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
79702652|NCT05092984|Drug|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
79702653|NCT02218944|Behavioral|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
79702654|NCT01118728|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79702655|NCT02218983|Device|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
79702656|NCT02218983|Other|Usual care|
79702657|NCT02219022|Other|Control group|
79702658|NCT02219022|Other|Experimental group|
79387254|NCT00355810|Dietary Supplement|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
79387255|NCT05719168|Device|Body Surface Gastric Mapping|64-channel electrode array placed on the outer abdomen
79387256|NCT04907500|Device|Intraocular lens|Cataract surgery
79387257|NCT03209232|Drug|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
79387258|NCT05719090|Device|Delfi Personal Tourniquet Systems|Measure within & between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
79387259|NCT04485312|Behavioral|preventive protocol|preventive protocol
79387260|NCT04485312|Behavioral|chlorhexidine added to the preventive protocol|chlorhexidine varnish added to the preventive protocol
79542801|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
79542802|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
79391546|NCT02409966|Procedure|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
79702659|NCT02213159|Drug|Dexmedetomidine|
79702660|NCT02213159|Drug|Morphine|
79702661|NCT00581282|Radiation|PET scan|positron emission tomography PET scan
79702662|NCT00581282|Other|fMRI|functional magnetic resonance imaging fMRI
79709980|NCT00597129|Biological|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
79542803|NCT01507623|Device|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
79248688|NCT02497053|Drug|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
79387261|NCT03224754|Behavioral|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
79387262|NCT03202680|Other|USDA Style Diet|USDA style healthy diet, low in saturated fats.
79387263|NCT03202680|Other|Lean Beef Diet|A lean beef containing healthy diet, low in saturated fats.
79387264|NCT01709903|Drug|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
79387265|NCT01709903|Drug|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
79387266|NCT01709903|Drug|Placebo to QVA149|Placebo to QVA149 with SDDPI
79542804|NCT01507636|Other|Occupational Therapy|Occupational therapy using a special arm function training.
79542805|NCT01507636|Other|Physical therapy|Physical therapy for arm force training.
79542806|NCT01507649|Behavioral|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
79542807|NCT01507701|Drug|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
79542808|NCT01507714|Procedure|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
79702663|NCT01118455|Device|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
79702664|NCT01118455|Drug|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
79702665|NCT02219100|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
79702666|NCT04553861|Device|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
79702667|NCT04553861|Device|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
79702668|NCT02219139|Device|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
79702669|NCT04561752|Drug|ZN-c5|ZN-c5 is the study drug.
79702670|NCT01118377|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
79702671|NCT01118377|Radiation|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
79702672|NCT04561323|Diagnostic Test|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
79248689|NCT02497053|Drug|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
79248690|NCT03120975|Other|Computerized decision support and audit & feedback|"suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~suggestion of standard antimicrobial treatment duration according to indication"
79248691|NCT03120975|Other|Audit & Feedback|* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
79248692|NCT03120975|Other|Standard antibiotic stewardship|"Infectious diseases consultation on demand~Review of positive blood cultures~Availability of a antibiotic use guidelines (on paper and as PDF)"
79387267|NCT01709903|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
79387268|NCT03202446|Drug|1% Glycated Chitosan|
79387269|NCT03202446|Device|Photothermal Laser|
79387270|NCT03202446|Drug|Placebo|
79387271|NCT03202446|Drug|Cyclophosphamide|
79387272|NCT03202446|Drug|Standard of Care|
79387273|NCT03202524|Biological|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
79702673|NCT04577222|Procedure|Technical modification during radical prostatectomy|Covering the NVB with fat
79702674|NCT02219178|Drug|lenalidomide|25mg days 1 - 14 of 21 day schedule
79702675|NCT02219178|Drug|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
79702676|NCT02219178|Drug|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
79702677|NCT02213315|Drug|100mg Mavrilimumab|100mg Mavrilimumab
79702678|NCT02213315|Drug|150mg mavrilimumab|150mg mavrilmumab
79702679|NCT02213315|Other|Placebo|Placebo
79702680|NCT02219217|Drug|Dolutegravir, Elvitegravir and Cobicistat|
79702681|NCT02213393|Dietary Supplement|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
79702682|NCT02213393|Dietary Supplement|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
79542809|NCT01507727|Drug|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
79542810|NCT01507727|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
79387274|NCT03202524|Biological|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
79542811|NCT01507740|Drug|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
79542812|NCT01507740|Drug|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
79542813|NCT01507740|Drug|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
79542814|NCT01507753|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
79542815|NCT01507753|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
79542816|NCT01507753|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
79542817|NCT01507766|Drug|early enteral nutrition|The enteral nutrition was started within 48h after admission
80013603|NCT05931471|Other|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
80013604|NCT05931367|Drug|Retatrutide|Administered SC
80013605|NCT05931367|Drug|Placebo|Administered SC
80013606|NCT05930405|Procedure|programmed intermittent epidural bolus|Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure
79248693|NCT04417556|Diagnostic Test|Sleep measurement|Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
79248694|NCT02501967|Other|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
79387275|NCT03202290|Behavioral|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
80013607|NCT05930405|Procedure|continuous epidural infusion|continuous epidural infusion
79542818|NCT01507766|Drug|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
79542819|NCT01507792|Drug|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
79542820|NCT01507792|Drug|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
80013608|NCT05930405|Drug|ropivacaine and sufentanil|0.15% ropivacaine and 0.4μg/ml sufentanil
79248695|NCT04353206|Biological|Multiple Doses of Anti-SARS-CoV-2 convalescent plasma|Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
79248696|NCT03337737|Dietary Supplement|Extreme Endurance|Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
79702683|NCT04577378|Drug|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
79248697|NCT03337737|Other|Placebo|
79387276|NCT05474092|Device|Aeson Total Artificial Heart|Heart Replacement Therapy
79387277|NCT02452242|Drug|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
79542821|NCT01507805|Device|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
79542822|NCT01507805|Device|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
79248698|NCT03337659|Other|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
79387278|NCT02452242|Other|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
79702684|NCT04577378|Drug|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
79702685|NCT02211573|Other|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
79702686|NCT04553627|Device|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
79702687|NCT02219412|Drug|ticagrelor|90 mg bid for 2 weeks
79702688|NCT02219412|Drug|Aspirin|100mg Qd for 2 weeks.
79702689|NCT04577027|Drug|Topical travoprost 0.004% solution|30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
79702690|NCT04577027|Device|Fractional CO2 laser|30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used
79702691|NCT04577027|Device|Excimer laser|30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.
80013609|NCT05930158|Other|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
80013610|NCT05930158|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
79302824|NCT05713331|Behavioral|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
79542823|NCT01507818|Device|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0>
79542824|NCT01507818|Device|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
79542825|NCT01507844|Device|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
79542826|NCT01507857|Biological|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
79542827|NCT01507857|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
79542828|NCT01507870|Procedure|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
79387279|NCT05462080|Diagnostic Test|Ceraxis product|All patients will have their symptoms evaluated using the Ceraxis product
79387280|NCT03208920|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
79387281|NCT03208920|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
79387282|NCT03208764|Drug|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
79542829|NCT01507922|Drug|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
79542830|NCT01507922|Drug|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
79542831|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
79542832|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
79702692|NCT04577027|Other|Combination therapy|30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .
79702693|NCT04577027|Other|Excimer laser and travoprost|30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months
79702694|NCT04577027|Other|fractional CO2 laser and topical travoprost|30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
79702695|NCT04553354|Procedure|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
79702696|NCT02211612|Dietary Supplement|PUFA-group|
79702697|NCT02211612|Dietary Supplement|SFA-group|
79702698|NCT04553315|Procedure|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
79702699|NCT02211690|Drug|dolutegravir 50 mg (one tablet daily)|
80013611|NCT05929079|Drug|Retatrutide|Administered SC
80013612|NCT05929079|Drug|Placebo|Administered SC
79702700|NCT02211690|Drug|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
79702701|NCT04553393|Drug|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
79702702|NCT04553393|Drug|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
79702703|NCT04553393|Drug|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
79844953|NCT00629798|Drug|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients < 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
79844954|NCT00160615|Drug|Levetiracetam|"Pharmaceutical form: Film-coating tablets~Concentration: 250 mg/ 500 mg~Route of administration: oral use"
79844955|NCT00819650|Drug|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na[131I],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
79844956|NCT00906594|Drug|latanoprost|
79844957|NCT03970759|Drug|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
80013613|NCT05929066|Drug|Retatrutide|Administered SC
80013614|NCT05929066|Drug|Placebo|Administered SC
80013615|NCT05929027|Behavioral|NoNo|"Participants in the G2 group will use the Twirlstone (knob-like) device to play a videogame called Nono's World. The Twirlstone is an electromechanical device that resembles a knob and a standard joystick (identical to the discontinued Atari CX-20 Controller). The knob can rotate or move in a push-pull fashion. To control the game's character (an axolotl called Nono), a signal about the knob motion is relayed to the computer wirelessly. This device has been certified by Johns Hopkins University's Clinical Engineering Services, where it was deemed less than minimum risk. The game has been custom built to allow participants to take control of the character using subtle manipulative finger movements to accomplish game-like tasks.~The investigators will use portable communication devices to carry out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
79248699|NCT04352816|Device|Magnetocardiogram|Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
79248700|NCT04496505|Device|Device|is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .
79387283|NCT03208608|Diagnostic Test|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
79702704|NCT04553393|Biological|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
79702705|NCT02219451|Other|exercise training|exercise training
79702706|NCT04553588|Other|Disposal pouch|Medication Disposal Pouch
79702707|NCT02211846|Drug|Mirabegron|oral
79702708|NCT02219568|Procedure|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
79702709|NCT02219568|Device|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
79702710|NCT02219646|Drug|Vardenafil|Vardenafil 10 mg twice daily for six months
79702711|NCT02219646|Drug|Placebo|Placebo two tablets daily for 6 months
79702712|NCT04553510|Drug|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
79702713|NCT04553510|Drug|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
79844958|NCT03970759|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
79844959|NCT03970759|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
79844960|NCT00905112|Other|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
79844961|NCT00905112|Other|Standard OB Care|Receive standard obstetrical care
79702714|NCT02219724|Drug|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
79702715|NCT01642017|Drug|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
79702716|NCT00581594|Procedure|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
79702717|NCT00581594|Procedure|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
79702718|NCT01642095|Other|Laboratory Biomarker Analysis|Correlative studies
79702719|NCT03453281|Drug|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
79248701|NCT04496505|Device|Sham Device|The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
79702720|NCT02219841|Procedure|radiofrequency catheter ablation|
79844962|NCT00643448|Drug|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
79844963|NCT00643448|Drug|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
79844964|NCT00643448|Drug|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
79844965|NCT03972631|Behavioral|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
79248702|NCT03337581|Drug|Dexmedetomidine|see arms
79387284|NCT03208998|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
79844966|NCT03972631|Behavioral|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
79844967|NCT03972631|Behavioral|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
79709981|NCT01332851|Behavioral|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
79844968|NCT00908778|Drug|Vitreosolve|intravitreal injection
79844969|NCT00908778|Drug|Vitreosolve|intravitreal injection
79844970|NCT00905190|Drug|Ondansetron|24 mg one time
79844971|NCT00908856|Biological|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
79391547|NCT02409966|Procedure|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
79391548|NCT02409888|Behavioral|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
79391549|NCT02409888|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
79844972|NCT00908856|Biological|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
79844973|NCT00908856|Drug|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
79844974|NCT00905502|Drug|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
79844975|NCT00905502|Drug|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
79844976|NCT00908934|Drug|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
79844977|NCT00908934|Drug|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
79844978|NCT00908934|Drug|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
79702721|NCT04553159|Biological|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
79702722|NCT01642134|Drug|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
80013616|NCT05929027|Behavioral|occupational therapy - self directed|"Participants 5 daily sessions over 3 weeks consisting of self-administered, unsupervised occupational therpay. Additionally, participants will have 2, <15 minutes telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.~The investigators will use portable communication devices for the purposes of carrying out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
79702723|NCT04552964|Other|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
79248703|NCT03041168|Device|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
79702724|NCT03453086|Procedure|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
79702725|NCT03453047|Diagnostic Test|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
79542833|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
79702726|NCT02219880|Dietary Supplement|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
79702727|NCT02219880|Dietary Supplement|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
79702728|NCT04553042|Drug|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
79542834|NCT01507948|Behavioral|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
79709982|NCT01332851|Behavioral|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
79709983|NCT00599235|Drug|sildenafil|50mg 3 times daily for 7 days
79709984|NCT00599235|Drug|hydralazine|25mg 3 times daily for 7 days
79844979|NCT00908934|Drug|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
79387285|NCT03224832|Procedure|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
79844980|NCT00604500|Drug|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
79702729|NCT01642173|Device|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
80013617|NCT05924126|Other|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
79542835|NCT01507974|Drug|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
79542836|NCT01507974|Drug|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
79702730|NCT02213432|Biological|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
79702731|NCT02219919|Other|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
79702732|NCT02219919|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
79702733|NCT01118299|Device|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
79702734|NCT04552574|Dietary Supplement|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
79702735|NCT01118143|Behavioral|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
79702736|NCT00581711|Other|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
80013618|NCT05923489|Diagnostic Test|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
79702737|NCT00581711|Other|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
80013619|NCT05923489|Diagnostic Test|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
79248704|NCT02496975|Drug|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
79248705|NCT02496975|Other|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
79542837|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
79702738|NCT00581711|Other|1-part intervention|Provision of feedback on otitis media quality indicators
79702739|NCT00581750|Other|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
79702740|NCT00581789|Drug|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
79702741|NCT01642368|Other|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
79844981|NCT00905658|Dietary Supplement|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
79248706|NCT02496897|Biological|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
79248707|NCT02496897|Other|Placebo|Placebo
79844982|NCT00905658|Procedure|standard follow-up care|Patients undergo standard monitoring
80013620|NCT05919745|Drug|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
80013621|NCT05919745|Drug|Placebo|Preoperative delivery of placebo per os.
79248708|NCT02496897|Other|IC31® Adjuvant|IC31® Adjuvant
79248709|NCT03337503|Drug|THC and CDB in a 1 to 1 ratio|capsule containing cannabis oil
79248710|NCT03337503|Drug|Experimental: THC and CBD in a 1 to 2 ratio|capsule containing cannabis oil
79248711|NCT03337503|Drug|High CBD with trace THC oil|capsule containing cannabis oil
79248712|NCT03337503|Other|placebo|carrier oil capsule
79391550|NCT02409888|Other|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
79391551|NCT02409888|Other|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
79391552|NCT03174600|Other|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
79391553|NCT03116412|Procedure|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
79391554|NCT02525536|Drug|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
79391555|NCT02525536|Drug|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
79391556|NCT02525536|Drug|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
79391557|NCT02411994|Drug|Pyronaridine-artesunate|
79391558|NCT02411994|Drug|Artemether-lumefantrine combination|
79702742|NCT02213549|Dietary Supplement|Placebo|
79702743|NCT02213549|Dietary Supplement|Ume paste and ginger powder|
79702744|NCT01642446|Procedure|Precise hepatectomy|Precise hepatectomy
79702745|NCT01642446|Other|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
79844983|NCT00906672|Device|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
79542838|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
79844984|NCT00906672|Procedure|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
79542839|NCT01507974|Drug|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
79542840|NCT01507974|Drug|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
79542841|NCT01508000|Drug|FOLFOX6|5-FU, folinic acid, oxaliplatin
80013622|NCT05919745|Drug|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
79248713|NCT02501655|Device|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
79248714|NCT02501655|Device|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
79387286|NCT03224832|Procedure|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
79387287|NCT03202368|Drug|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
79542842|NCT01508000|Biological|Bevacizumab|Targeted therapy
79542843|NCT01508000|Biological|Panitumumab|Targeted therapy
79542844|NCT01508000|Procedure|Surgery|
79542845|NCT01508039|Other|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
79542846|NCT01508065|Device|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
79702746|NCT02213588|Dietary Supplement|AOX blend|Antioxidant supplement
79702747|NCT02213588|Dietary Supplement|Placebo|
79702748|NCT01642524|Biological|hypertonic saline mixed Dextran|single dose administered intravenously
79844985|NCT00627458|Biological|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
79248715|NCT03337425|Behavioral|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
79248716|NCT03337425|Behavioral|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
79387288|NCT03202212|Procedure|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
79542847|NCT01508091|Behavioral|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
79702749|NCT01642524|Biological|Saline solution|placebo - saline solution
79702750|NCT02213705|Biological|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
79702751|NCT02217228|Device|Sebacia microparticles and laser|
79702752|NCT02217228|Device|Vehicle suspension and laser|
79702753|NCT02217228|Device|Sebacia microparticles without laser|
79702754|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
79702755|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
79702756|NCT01642563|Procedure|Platelet transfusion|One dose of pathogen reduced platelets
79702757|NCT01642563|Procedure|Platelet transfusion|One dose of standard platelets
79709985|NCT00599235|Drug|placebo|3 times daily for 7 days
80013623|NCT05917223|Dietary Supplement|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
80013624|NCT05917223|Dietary Supplement|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
80013625|NCT05917223|Dietary Supplement|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
79248717|NCT03337425|Other|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
79844986|NCT00909168|Drug|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
80013626|NCT05917223|Dietary Supplement|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
80013627|NCT05913375|Radiation|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
80013628|NCT05909761|Drug|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
80013629|NCT05900336|Drug|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
80013630|NCT05900336|Drug|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
79248718|NCT01675622|Drug|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
79248719|NCT01675622|Drug|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
79248720|NCT02496741|Drug|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
79709986|NCT04058834|Drug|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
79709987|NCT04058834|Drug|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
79248721|NCT04496037|Drug|Rituximab|See NCT03994783
79248722|NCT03777332|Drug|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
79248723|NCT02501421|Biological|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
79387289|NCT03202212|Procedure|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
79709988|NCT04055168|Drug|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
80013631|NCT05893797|Drug|Insulin Lispro|As prescribed.
80013632|NCT05893797|Device|Tempo Smart Button|Attached to the Tempo Pen
79248724|NCT02501421|Biological|Placebo|Buffer
79248725|NCT03724916|Drug|TAK-079|TAK-079 Subcutaneous injection.
79248726|NCT03724916|Drug|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection.
79248727|NCT03342339|Other|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
79248728|NCT03342339|Other|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
79248729|NCT03342339|Other|Iowa Gambling Task|Test of Iowa Gambling Task
79248730|NCT04183166|Drug|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
79248731|NCT03337347|Device|CTC/DTC count|The presence of CTCs/DTCs in the peripheral blood and/or bone marrow may identify colorectal cancer patients with high risk of disease recurrence who may benefit from adjuvant therapy.
79248732|NCT03337269|Other|Educational video|Approximately 7 minute video on the HPV vaccine
79248733|NCT03337269|Other|Educational handout|One page handout on the HPV vaccine
79248734|NCT03337269|Other|Control|Control
79248735|NCT02493465|Drug|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
79248736|NCT04161716|Device|NIRS recording|Patient has a NIRS module during their urodynamic exam.
79248737|NCT03342261|Drug|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
79387290|NCT03202056|Other|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
79387291|NCT03202056|Other|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
79542848|NCT01508091|Behavioral|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
79542849|NCT01508104|Drug|BEZ235|dose escalation 400mg- 1000mg per day
79542850|NCT01508104|Drug|Everolimus|dose escalation 2.5 to 5 mg per day
79542851|NCT01507610|Drug|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
79709989|NCT04055168|Drug|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
79709990|NCT01332305|Drug|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
80013633|NCT05893797|Device|Dexcom G6 CGM|Continuous glucose monitor
80013634|NCT05893797|Device|Glooko Research Medical App (RMA)|Installed on a study provided android phone.
80013635|NCT05891886|Drug|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
79844987|NCT00905736|Procedure|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
79844988|NCT00905736|Procedure|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
79844989|NCT00906750|Biological|FluMist|FluMist is a live attenuated intranasal influenza vaccine
79387292|NCT03208842|Radiation|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
79844990|NCT00906750|Biological|Inactivated influenza vaccine|Inactivated influenza vaccine
79387293|NCT03201822|Other|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
79387294|NCT03201822|Other|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
79387295|NCT03201822|Other|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
79844991|NCT00816218|Drug|Pioglitazone|pioglitazone, 45 mg daily
80013636|NCT05891886|Device|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
80013637|NCT05883930|Other|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change [not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
79387296|NCT03201822|Other|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
79387297|NCT03224286|Device|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
79387298|NCT00355888|Drug|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
79387299|NCT05424640|Dietary Supplement|Dietary fiber 1|Description in the arm description
79542852|NCT01508143|Drug|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
79542853|NCT01508143|Drug|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
80013638|NCT05883930|Other|no intervention|No intervention will be applied to the control group.
79387300|NCT05424640|Dietary Supplement|Dietary fiber 2|Description in the arm description
79387301|NCT05424640|Dietary Supplement|Dietary fiber 3|Description in the arm description
79387302|NCT05424640|Dietary Supplement|Dietary fiber 4|Description in the arm description
79387303|NCT03208686|Behavioral|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology - a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
79387304|NCT03224442|Procedure|PRF|soft tissue augmentation by prf
79387305|NCT03224442|Procedure|Palatal Pedicle|soft tissue augmentation by palatal pedicle
79387306|NCT05718388|Other|Physical therapy exercises|For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program
79387307|NCT05718388|Other|Isokinetic training|Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
79391559|NCT02411760|Procedure|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
79542854|NCT01508156|Drug|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
79542855|NCT01508156|Drug|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
79542856|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
79542857|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
79542858|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
79542859|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
79844992|NCT01562964|Behavioral|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
79702758|NCT01642680|Other|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
79248738|NCT03963206|Drug|Cabozantinib group|The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
79248739|NCT04495569|Biological|recombinant anti-rabies human monoclonal antibody injection (SYN023)|The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.
79248740|NCT04495569|Biological|Rabies Vaccine|The Chinese licensed Vero Cell Freeze-dried Rabies Vaccine was injected to Cohort B as per the vaccination precedure on Days 1, 4, 8, 15, 28 respectively.
79542860|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
79542861|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
79542862|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
79542863|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
79542864|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
79542865|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
79542866|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
79542867|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
79702759|NCT01642680|Other|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
79702760|NCT00582101|Behavioral|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
79542868|NCT01508208|Other|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
79542869|NCT01508247|Biological|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
79702761|NCT00582101|Behavioral|General Health Promotion|7 hour one-day workshop on general health promotion topics
79702762|NCT01642719|Behavioral|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
79542870|NCT01508247|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
79702763|NCT01642719|Behavioral|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
79702764|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
79702765|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
79702766|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
79844993|NCT01562964|Behavioral|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
79844994|NCT00819728|Drug|Docetaxel|35mg/m2 IV each week for 4 weeks
79844995|NCT00819728|Drug|Irinotecan|50mg/m2 IV each week for 4 weeks
79844996|NCT00906828|Drug|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
79844997|NCT00906828|Drug|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
79844998|NCT00906828|Drug|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
79248741|NCT04511624|Drug|IBI112 dose1|Drug: IBI112 SC dose1 Drug:placebo
79248742|NCT04511624|Drug|IBI112 dose2|Drug: IBI112 SC dose2 Drug:placebo
79702767|NCT01642758|Drug|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
79702768|NCT00582179|Procedure|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
79709991|NCT01332305|Drug|Placebo|Placebo orally once daily
79844999|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
79387308|NCT03201744|Procedure|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
79542871|NCT01508260|Procedure|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
79542872|NCT01508260|Drug|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
79542873|NCT01508273|Behavioral|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
79702769|NCT00582179|Device|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
80013639|NCT05882045|Drug|Retatrutide|Administered SC
80013640|NCT05882045|Drug|Placebo|Administered SC
80013641|NCT05875623|Other|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
80013642|NCT05874063|Drug|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
80013643|NCT05872620|Drug|Orforglipron|Administered orally
80013644|NCT05872620|Drug|Placebo|Administered orally
80013645|NCT05869903|Drug|Orforglipron|Administered orally.
80013646|NCT05869903|Drug|Placebo|Administered orally.
80013647|NCT05866432|Drug|Datopotamab deruxtecan|Will be given until PD or withdraw
80013648|NCT05856084|Biological|Low dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
80013649|NCT05856084|Biological|High dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
80013650|NCT05856084|Biological|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
80013651|NCT05856084|Biological|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
80013652|NCT05855174|Dietary Supplement|Whey protein|Weight protein provided in a shake with carbohydrate and water
79542874|NCT01508273|Behavioral|Website|Website access given that allows participant to track exercise behavior and help to set goals.
80013653|NCT05853601|Drug|Single Dose Theophylline|Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 12 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
80013654|NCT05853601|Drug|Repeat Dose Theophylline|Subjects are given a loading dose of theophylline, 5mg/kg IV, within 12 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
79387309|NCT05718310|Drug|Nitroglycerin|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
79542875|NCT01508273|Behavioral|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
79542876|NCT01508273|Behavioral|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
79702770|NCT01642797|Device|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
79702771|NCT01642797|Device|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
79709992|NCT00599274|Drug|Interferon beta-1a|injection once a week
80013655|NCT05853341|Drug|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
80013656|NCT05853341|Drug|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
80013657|NCT05851586|Procedure|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
79702772|NCT04552379|Biological|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at ~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
79845000|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
80013658|NCT05851586|Procedure|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
79542877|NCT01508273|Behavioral|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
80013659|NCT05851534|Behavioral|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
80013660|NCT05849805|Procedure|Intracalvaria bone marrow injection|Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days
80013661|NCT05849805|Other|Conventional treatment|standard treatment and management according to related guidelines
79542878|NCT01508286|Drug|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
80013662|NCT05849051|Behavioral|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
80013663|NCT05849051|Behavioral|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
79387310|NCT05718310|Drug|Saline|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
79542879|NCT01508286|Drug|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
79542880|NCT01508286|Drug|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
79542881|NCT01508299|Procedure|skin test|skin test with the Suspected raw food
79702773|NCT02215668|Procedure|Physical exercise|Exercise muscle stretching and body warming.
79702774|NCT01642836|Behavioral|MMM|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
79709993|NCT00599274|Drug|Interferon beta-1a|injection three times a week
79387311|NCT03201978|Drug|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
79542882|NCT01508338|Dietary Supplement|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
79542883|NCT01508338|Dietary Supplement|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
79542884|NCT01508338|Dietary Supplement|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
79709994|NCT01332227|Drug|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
79248743|NCT04511624|Drug|IBI112 dose3|Drug: IBI112 SC dose3 Drug:placebo
79248744|NCT04511624|Drug|IBI112 dose4|Drug: IBI112 SC dose4 Drug:placebo
79248745|NCT04511624|Drug|IBI112 dose5|Drug: IBI112 IV dose5 Drug:placebo
79248746|NCT04511624|Drug|IBI112 dose6|Drug: IBI112 SC dose6 Drug:placebo
79248747|NCT04511624|Drug|IBI112 dose7|Drug: IBI112 IV dose7 Drug:placebo
79248748|NCT03120429|Behavioral|Fish group|Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
79248749|NCT03120429|Behavioral|Control group|Control group will have hypo-energetic diet in which subjects have no seafood.
79702775|NCT01642836|Behavioral|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
79702776|NCT01117987|Drug|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
79702777|NCT01117987|Drug|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
79702778|NCT02215902|Device|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
79702779|NCT02213822|Other|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
79845001|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
80013664|NCT05848830|Dietary Supplement|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
80013665|NCT05848830|Dietary Supplement|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
80013666|NCT05848830|Behavioral|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
79387312|NCT03201978|Drug|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
79387313|NCT03224208|Drug|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
79387314|NCT03224208|Drug|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
79387315|NCT05718232|Drug|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients <60kg, and 12 mg qd for patients ≥ 60kg)
79387316|NCT05718232|Procedure|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
79387317|NCT05718232|Radiation|SBRT|SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
79387318|NCT02450448|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
79542885|NCT01508338|Dietary Supplement|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
79542886|NCT01508364|Drug|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
79542887|NCT01508377|Behavioral|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
79702780|NCT01117870|Other|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
79702781|NCT01117870|Other|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
79702782|NCT01642875|Other|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
79387319|NCT02450448|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
79845002|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
79845003|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
79845004|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
79845005|NCT00909402|Drug|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
79845006|NCT00909402|Drug|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
79845007|NCT00909402|Drug|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
79387320|NCT00355966|Drug|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
79387321|NCT00355966|Drug|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
79542888|NCT01508377|Behavioral|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
79542889|NCT01508429|Other|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
79542890|NCT01508429|Drug|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
79542891|NCT01508468|Drug|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
79542892|NCT01508468|Drug|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
79542893|NCT01508494|Drug|Galantamine|16 mg galantamine daily P/O
79542894|NCT01508494|Drug|placebo|placebo
79542895|NCT01508546|Procedure|axillary dissection|Conservative breast surgery with or without axillary dissection
79702783|NCT01642875|Other|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
79702784|NCT01117792|Device|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
79702785|NCT04552184|Other|GPOEM|gastric per oral endoscopic pyloromyotomy
79702786|NCT04552184|Other|SHAM Procedure|intrapyloric injection of saline solution
79702787|NCT02219490|Drug|ABT-450/r/ABT-267|Tablet for oral use
79702788|NCT02219490|Drug|ABT-333|Tablet for oral use
79387322|NCT03208218|Drug|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
79387323|NCT03208218|Drug|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
79387324|NCT05372380|Drug|BR1017-1|Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
79702789|NCT02219490|Drug|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing < 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
79702790|NCT04310722|Other|None intervention. This is an observational study.|None intervention. This is an observational study.
79702791|NCT04310605|Behavioral|CBT 1|CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
79387325|NCT05372380|Drug|BR1017-2|Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
79387326|NCT03201276|Drug|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
79387327|NCT05718076|Procedure|cataract surgery|Phacoemulsification combined trifocal lens implantation
79387328|NCT03224364|Procedure|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
79542896|NCT01508572|Drug|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
79542897|NCT01508585|Behavioral|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
79542898|NCT01508611|Other|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children."
79702792|NCT04310605|Behavioral|CBT 2|Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
79702793|NCT01117051|Drug|placebo|placebo
79702794|NCT01117051|Drug|prucalopride|1 or 2 mg prucalopride once daily before breakfast
79702795|NCT01642953|Dietary Supplement|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
79702796|NCT05360173|Behavioral|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
79702797|NCT05360173|Behavioral|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
79702798|NCT04577105|Diagnostic Test|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
79702799|NCT02211417|Drug|Oral DS107|
80013667|NCT05835063|Behavioral|We Chatt communication tool|This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
79248750|NCT04608890|Diagnostic Test|Eye-tracking video test|An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
79248751|NCT03337191|Drug|Levobupivacaine|% 0,125 levobupivacaine
79387329|NCT03224364|Procedure|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
79387330|NCT05370118|Behavioral|Telerehabilitation physical activity behavioral (TPAB) intervention|The intervention includes the behavior change techniques of self-monitoring of behavior, action planning, graded tasks, restructuring the physical and social environment, problem-solving, and prompts/cues.
79387331|NCT00356044|Procedure|Coronary angioplasty|
79387332|NCT03201510|Other|Observational|HPTN 075 is an observational study in sub-Saharan MSM
79387333|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
79542899|NCT01508611|Behavioral|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
79542900|NCT01508624|Other|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
79387334|NCT03201588|Dietary Supplement|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
79542901|NCT01508624|Other|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
79702800|NCT02211417|Drug|Placebo|
79702801|NCT00582413|Behavioral|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
79702802|NCT00582452|Other|Telephone survey|Telephone survey
79702803|NCT02279121|Device|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
79702804|NCT02279121|Drug|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
79702805|NCT04576520|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
79702806|NCT04576520|Procedure|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
79709995|NCT01332227|Drug|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
79709996|NCT01332227|Drug|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
79845008|NCT00821366|Behavioral|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
79845009|NCT00821366|Dietary Supplement|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
79845010|NCT00821366|Drug|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
79248752|NCT03337191|Drug|Morphine Sulfate|10 mq/kg morphine sulfate
79248753|NCT03337191|Device|Ultrasound|Ultrasound guided caudal block
79248754|NCT03854552|Drug|BI 764198|capsule
79248755|NCT03854552|Drug|Placebo|capsule
79248756|NCT04494243|Drug|AD-214 10/600mg|1 tablet administered before the breakfast during 7 days
79248757|NCT04494243|Drug|Rabeprazole 10mg|1 tablet administered before the breakfast during 7 days
79387335|NCT02979106|Other|Test meal|Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
79845011|NCT02538120|Other|Microvascular assessment|Microvascular assessment
80013668|NCT05835063|Behavioral|Usual/standard care|Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
80013669|NCT05830955|Other|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
80013670|NCT05830955|Other|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
79387336|NCT03201432|Device|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
79387337|NCT03201432|Device|Bare metal stent (BES)|Bare metal stent
79248758|NCT03337035|Drug|intranasal oxytocin|4-24 IU per day, dosage gradually increases
79387338|NCT05717998|Procedure|Biospecimen Collection|Undergo blood sample collection
79248759|NCT03337035|Dietary Supplement|oral probiotics|200 million cfu per day
79248760|NCT03337035|Dietary Supplement|oral placebo|2 pills per day
79248761|NCT03547076|Diagnostic Test|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
79387339|NCT05717998|Procedure|Computed Tomography|Undergo cardiac PET/CT
79387340|NCT05717998|Procedure|Magnetic Resonance Imaging of the Heart|Undergo CMR
79387341|NCT05717998|Procedure|Positron Emission Tomography|Undergo cardiac PET/CT
79387342|NCT03201354|Procedure|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
79387343|NCT03201354|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
79387344|NCT03201354|Procedure|Cataract extraction|Cataract surgery and IOL implantation
79387345|NCT02451774|Drug|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
79387346|NCT02451774|Drug|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
79542902|NCT01508624|Behavioral|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
79709997|NCT01332227|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
79709998|NCT00599352|Dietary Supplement|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
79542903|NCT01508624|Behavioral|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
79542904|NCT01508637|Other|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
79542905|NCT01508637|Other|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
79542906|NCT01508637|Drug|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
79542907|NCT01508637|Drug|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
80013671|NCT05830955|Other|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
80013672|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
80013673|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
80013674|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
80013675|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
79542908|NCT01508663|Device|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
80013676|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
79702807|NCT02218164|Drug|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
80013677|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
79248762|NCT02493387|Other|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
79542909|NCT01508663|Drug|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
79542910|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
79542911|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
79702808|NCT02218164|Drug|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
79709999|NCT00599391|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
80013678|NCT05821426|Device|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
80013679|NCT05817643|Drug|BMS-984923|Oral capsule
80013680|NCT05814705|Dietary Supplement|Protein supplement|Ready-to-drink protein beverage consumed once daily for 28 days
80013681|NCT05814705|Dietary Supplement|Protein supplement with Urolithin A|Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
80013682|NCT05807997|Other|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
79248763|NCT02493387|Other|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
79387347|NCT03119220|Device|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
79542912|NCT01508715|Other|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
79542913|NCT01508728|Device|ORTHOSENS orthosis|with active vibration
79542914|NCT01508728|Device|ORTHOSENS orthosis|with placebo vibration
79845012|NCT03862118|Other|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
80013683|NCT05805215|Combination Product|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to < 100 Hz."
79248764|NCT02491905|Drug|HL tablet|
79248765|NCT02491905|Drug|Placebo|
79248766|NCT03539666|Other|diet|dietary patterns
79248767|NCT05232747|Diagnostic Test|Diagnostic Test|Diagnostic Test
79248768|NCT03526172|Procedure|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
79248769|NCT03526172|Device|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
79248770|NCT03526172|Device|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
79542915|NCT01508741|Dietary Supplement|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
79542916|NCT01508741|Dietary Supplement|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
79542917|NCT01508754|Procedure|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
79387348|NCT03201120|Behavioral|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
79391560|NCT02411838|Other|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI <28 will follow a regimen of fasting for two days per week while patients with BMI>28 will follow a regimen of fasting for three days per week."
79845013|NCT02537964|Other|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
79845014|NCT00819884|Drug|AZD1656|Oral suspension
79845015|NCT00821444|Drug|ziprasidone|40 mg capsule, single dose x 3
79845016|NCT00821444|Drug|B16 Fasted|40 mg tablet, single dose X 3
79248771|NCT03526172|Other|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
79248772|NCT03331029|Device|transesophageal investigation|Comparison of 3D ultrasound with transesophageal echocardiography
79542918|NCT01508767|Other|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
79845017|NCT00821444|Drug|B16 Fed|40 mg tablet, single dose X 3
79845018|NCT00909558|Biological|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
79845019|NCT00819962|Drug|Bupivacaine|Local anesthetic
79845020|NCT00819962|Other|TAP|
79845021|NCT00927342|Other|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
79845022|NCT00927342|Other|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
79845023|NCT00542919|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
79248773|NCT03640988|Device|dermaPACE|Shockwave application
79248774|NCT05464797|Procedure|Pulp therapy|partial or complete removal of inflamed pulp tissue
79248775|NCT05464797|Diagnostic Test|Cytokines level in pulpal blood.|Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
79248776|NCT05464641|Other|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
79248777|NCT03330873|Device|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
79248778|NCT03330873|Device|Foley catheter|Foley catheter can partly separate the sides of uterus wall.
79248779|NCT04596254|Other|Pomegranate Juice|Collection of Mother's milk before and after juice consumption
79248780|NCT05073536|Device|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
79248781|NCT05073536|Device|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
79248782|NCT02496819|Other|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
79248783|NCT02496819|Other|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
79702809|NCT02218164|Drug|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
79702810|NCT01643109|Other|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
79702811|NCT04552106|Dietary Supplement|3 caps x3/day|3 capsules 3 times daily for 28 days
79702812|NCT04552106|Dietary Supplement|3 caps x2/day|3 capsules 2 times daily for 28 days
79702813|NCT04552106|Dietary Supplement|2 caps x3/day|2 capsules 3 times daily for 28 days
79702814|NCT04552106|Dietary Supplement|2 caps x2/day|2 capsules 2 times daily for 28 days
79702815|NCT04552106|Dietary Supplement|3 caps x1/day|3 capsules 1 times daily for 28 days
79702816|NCT04552067|Drug|Lovenox|patients given curative dose of Lovenox
79702817|NCT04552067|Drug|Enoxaparin|patients given curative dose of Enoxa
79702818|NCT01643187|Dietary Supplement|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
79702819|NCT01643187|Dietary Supplement|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
79702820|NCT01643265|Dietary Supplement|Whey Milk Protein|20 grams of Whey Milk Protein
79702821|NCT01643265|Dietary Supplement|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
79845024|NCT03861962|Other|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
79845025|NCT00820118|Drug|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~atazanavir : 300 mg/d~ritonavir : 100 mg/d~abacavir 600 mg and lamivudine 300 mg : once a day~tenofovir 245 mg and emtricitabine 200 mg : once a day"
79845026|NCT00927498|Drug|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
79391561|NCT02417220|Behavioral|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
79391562|NCT02417220|Other|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
79542919|NCT01508780|Device|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
79702822|NCT04551833|Drug|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
79702823|NCT01643304|Behavioral|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
79702824|NCT00582686|Procedure|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
79702825|NCT00582686|Procedure|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
79845027|NCT00927498|Drug|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
79542920|NCT01508780|Device|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
79248784|NCT02496819|Other|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
79391563|NCT02530294|Drug|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
79391564|NCT02530294|Other|Vehicle|Vehicle (placebo) topical wipes
79542921|NCT01508793|Behavioral|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
79542922|NCT01508806|Drug|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
79542923|NCT01508819|Other|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
79542924|NCT01508845|Dietary Supplement|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
79702826|NCT04551755|Drug|Ivermectin and Doxycycline|"Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
79248785|NCT03255590|Behavioral|Configuration task|Training the impaired hand on a configuration task
79702827|NCT04551755|Other|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
79542925|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
79702828|NCT01640106|Dietary Supplement|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
79248786|NCT02496507|Other|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
79248787|NCT03125798|Device|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
79248788|NCT03125798|Device|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
79542926|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
79542927|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
79542928|NCT01508858|Drug|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
79542929|NCT01508858|Drug|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
79542930|NCT01508858|Drug|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
79542931|NCT01508871|Other|Observational study, no intervention|No intervention
79542932|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
79542933|NCT01508884|Drug|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
79702829|NCT01640106|Dietary Supplement|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
79702830|NCT01643421|Other|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
79702831|NCT04552028|Other|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
79702832|NCT01643499|Drug|oxaliplatin|Given IV
79702833|NCT01643499|Drug|irinotecan hydrochloride|Given IV
79702834|NCT01643499|Drug|leucovorin calcium|Given IV
79702835|NCT01643499|Drug|fluorouracil|Given IV
79702836|NCT01643499|Other|laboratory biomarker analysis|Correlative studies
79702837|NCT00582725|Drug|R-CHOP+GM-CSF|addition of GM-CSF
79702838|NCT01643538|Behavioral|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
79702839|NCT01643538|Behavioral|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
79702840|NCT01643538|Behavioral|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
79702841|NCT01643538|Behavioral|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
79702842|NCT00582764|Other|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
79542934|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
79542935|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
79542936|NCT01508884|Biological|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
79542937|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
79542938|NCT01508923|Drug|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
79702843|NCT01640145|Dietary Supplement|Protein|Whey protein intake
79702844|NCT01640145|Other|Exercise|Unilateral low intensity exercise
79542939|NCT01508923|Drug|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
79248789|NCT03342183|Other|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
79702845|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
79702846|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
79702847|NCT04551794|Behavioral|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
79845028|NCT00820196|Drug|Nexagon®|
79845029|NCT00820196|Drug|Nexagon® vehicle|
79845030|NCT00909636|Drug|ABT-333|See arm description for more information
79845031|NCT00909636|Drug|Placebo|See arm description for more information
79845032|NCT05711355|Procedure|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
79845033|NCT05711355|Procedure|meningomyelocele sac repair|meningomyelocele sac repair without Platelet-Rich Plasma
79845034|NCT00816296|Other|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
79845035|NCT00816296|Other|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
80013684|NCT05805215|Combination Product|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to < 100 Hz."
80013685|NCT05805215|Combination Product|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
80013686|NCT05803421|Drug|Orforglipron|Administered orally once daily
80013687|NCT05803421|Drug|Insulin Glargine|Administered SC once daily
79248790|NCT03342183|Other|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
79248791|NCT03342105|Procedure|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
79387349|NCT03201120|Behavioral|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
79542940|NCT01508975|Other|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
79542941|NCT01508988|Drug|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
79542942|NCT01508988|Drug|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
80013688|NCT05803408|Other|gluten-free oats|Early vs late introduction of gluten free oats
79391565|NCT03177720|Drug|Ciprofloxacin|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
79542943|NCT01508988|Drug|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
79542944|NCT01508988|Drug|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
79542945|NCT01508988|Drug|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
79542946|NCT01508988|Drug|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
79542947|NCT01508988|Drug|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
79845036|NCT00816296|Other|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
80013689|NCT05800717|Behavioral|SCI Self-Management for AIS D|An individually administered, self-management intervention for Veterans with AIS D spinal cord injury.
80013690|NCT05800288|Drug|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
79542948|NCT01509001|Drug|Metformin|750 to 2500 mg/day, two times a day during 4 months
79542949|NCT01509001|Drug|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
79845037|NCT00816296|Other|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
79702848|NCT04551794|Behavioral|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
79542950|NCT01509014|Behavioral|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
79702849|NCT01643577|Procedure|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
79702850|NCT01643577|Procedure|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
79542951|NCT01509027|Behavioral|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
79702851|NCT01117012|Drug|Ivacaftor|
79702852|NCT01640262|Other|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
79702853|NCT04551209|Procedure|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
79702854|NCT01640418|Device|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
80013691|NCT05799729|Drug|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
80013692|NCT05797441|Behavioral|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
79248792|NCT03342105|Procedure|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
79248793|NCT02891096|Procedure|inspiratory muscle strength|"Measurements:~in- and expiratory muscle strength (5min)~lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~ISCoS core data-set~ISCoS pulmonary function data sets~ISCoS quality of life questionnaire~questionnaire on individual respiratory muscle training, regular physical exercise and therapies~individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
79387350|NCT02448342|Device|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
79387351|NCT00355576|Drug|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
79387352|NCT00355576|Drug|Creatine|10 g BID for either study arm
79542952|NCT01509027|Behavioral|Standard care|standard care
79542953|NCT01509027|Behavioral|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
79387353|NCT00355576|Drug|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
79387354|NCT03195582|Drug|Corsodyl|following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
79542954|NCT01509066|Other|Diet|Dietary approaches for PCOS
79542955|NCT01509092|Procedure|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
79542956|NCT01509131|Drug|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
79542957|NCT01509131|Drug|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
79542958|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
79542959|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
79542960|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
79542961|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
79702855|NCT01116739|Device|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
79702856|NCT01116739|Behavioral|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
79702857|NCT01116739|Other|Dental services delivered by the Indian Health Service.|
79845038|NCT00909714|Device|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
79845039|NCT00909714|Device|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
80013693|NCT05797441|Other|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
79702858|NCT01116544|Device|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
79702859|NCT01640496|Drug|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
79845040|NCT00816374|Other|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~The American Cancer Society~The American Academy of Dermatology~The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~Sun protection practices~Risk factors for melanoma~Information about what melanoma looks like~How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
79845041|NCT00816374|Other|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~Melanoma and skin cancer protection guidelines~The benefits of skin screening practices~Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
80013694|NCT05796778|Procedure|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
80013695|NCT05796778|Procedure|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
80013696|NCT05794828|Drug|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
80013697|NCT05784350|Drug|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
79387355|NCT05334940|Other|not applicable, observational study|Patients do not receive intervention
79702860|NCT01640496|Other|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
80013698|NCT05776160|Drug|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
80013699|NCT05775185|Radiation|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
80013700|NCT05773976|Device|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~Afomill Refreshing Soothing~Afomill Anti-redness Eye Drops~Iridil"
80013701|NCT05773963|Device|Irilens; Iridina; Afomill Lubricating Eye Drops|"Irilens (with 0.4% HA as key ingredient);~Iridina (with 0.4% HA as key ingredient);~Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
80013702|NCT05769010|Drug|SHR-A1811|SHR-A1811: intravenous
79387356|NCT02448264|Drug|BCX7353|
79387357|NCT02448264|Drug|Placebo to match BCX7353|
79702861|NCT04551443|Biological|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
79702862|NCT04551443|Biological|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
80013703|NCT05769010|Drug|Pyrotinib|Pyrotinib: oral
80013704|NCT05769010|Drug|Bevacizumab|Bevacizumab: intravenous
80013705|NCT05767021|Drug|Mirikizumab|Administered IV
80013706|NCT05767021|Drug|Mirikizumab|Administered SC
80013707|NCT05762146|Drug|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
79387358|NCT02451852|Drug|AZD9291|AZD9291 80mg tablet once daily, open label
79387359|NCT02448186|Behavioral|ESTEEM|10-session cognitive behavioral treatment
79387360|NCT03201042|Diagnostic Test|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
79845042|NCT00816374|Other|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~knowledge of melanoma~current and past skin cancer screening practices~current and past sun protection practices~attitudes about skin cancer and sun protection~feelings about relative's melanoma diagnosis and treatment"
79702863|NCT01643655|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
79702864|NCT04551248|Biological|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
79702865|NCT04551248|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
79702866|NCT04551248|Biological|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
79702867|NCT01643733|Device|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
79702868|NCT02214056|Other|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
79702869|NCT02214056|Procedure|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
79702870|NCT04529382|Diagnostic Test|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
79702871|NCT04550819|Procedure|intraintestinal extended biliary stents|The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
79702872|NCT04550819|Procedure|ordinary plastic biliary stents|The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
79702873|NCT01640535|Drug|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
79845043|NCT00906906|Device|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
79845044|NCT00159913|Drug|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
79387361|NCT03201042|Diagnostic Test|Serology based assay|"The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~The Immunetics C6 Lyme ELISA assay.~A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
79387362|NCT03201042|Diagnostic Test|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
79542962|NCT01509144|Biological|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
79542963|NCT01509157|Device|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
79542964|NCT01509157|Procedure|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
79542965|NCT01509196|Drug|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
79702874|NCT01640535|Drug|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
79702875|NCT01640535|Drug|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
79702876|NCT04550936|Drug|Isavuconazole|antifungal agent
79702877|NCT04550858|Drug|Rebamipide|rebamipide use for ttt of h.pylori infection
79845045|NCT00159913|Drug|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
79845046|NCT00159913|Drug|Placebo|oral; 3 times a day(TID)
79845047|NCT00159913|Drug|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
80013708|NCT05762146|Drug|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
79702878|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
79702879|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
79702880|NCT01640574|Drug|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
79702881|NCT01640574|Drug|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
79845048|NCT05498259|Drug|Orelabrutinib|Orelabrutinib 150mg qd PO
79845049|NCT05498259|Biological|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
80013709|NCT05762146|Drug|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
79845050|NCT05498259|Drug|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
79845051|NCT00820274|Procedure|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
79248794|NCT02496429|Device|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
79542966|NCT01509209|Drug|Pseudoephedrine / Levocetirizine|tablet, BID everyday
79845052|NCT00821600|Drug|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
79845053|NCT00987207|Drug|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
79248796|NCT02496351|Device|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
80013710|NCT05756023|Procedure|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
79248797|NCT03336957|Procedure|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
79387363|NCT00421642|Drug|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
79542967|NCT01509222|Behavioral|Personalized nutrition counseling|
79542968|NCT01509235|Procedure|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
79702882|NCT04550975|Other|Advanced Cognitive Stimulation Therapy|An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
79845054|NCT00987207|Other|No injection|No cyclosporine A is administered before aortic cross-declamping.
79845055|NCT04044326|Procedure|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
79845056|NCT00604188|Drug|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
79845057|NCT00604188|Drug|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
79845058|NCT03913377|Device|Spectacles|Subjects' own habitual spectacles
80013711|NCT05747690|Device|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
80013712|NCT05741918|Diagnostic Test|Fick's method|Cardiac output measurement by Fick method
79248798|NCT03330717|Procedure|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
79248799|NCT03330717|Procedure|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
79248800|NCT03330717|Procedure|General anesthesia with preoperative session of hypnosis|Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
79248801|NCT02655224|Drug|Relugolix|Relugolix Tablets
79248802|NCT02655224|Drug|Relugolix placebo|Relugolix placebo-matching tablets
79248803|NCT04494477|Behavioral|The IN•clued program|The INclued program as previously described.
79248804|NCT04494321|Drug|Budesonide|Inhaled corticosteroid
79248805|NCT04494321|Drug|Formoterol|Long Acting Beta Agonist (LABA)
79387364|NCT05278468|Other|PCR test for covid-19|real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
79387365|NCT02979028|Device|TEAS|Transcutaneous electrical acupoint stimulation
79387366|NCT03200964|Other|anesthesia given as required for surgical procedure|
79387367|NCT03223818|Other|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
79387368|NCT04730518|Behavioral|Yoga-based group therapy|see above
79542969|NCT01509261|Drug|Ilaprazole|20mg/Tap, QD
79542970|NCT01509261|Drug|Lansoprazole|30mg/Tap, QD
79542971|NCT01509274|Biological|Plasma|3 ml plasma injected once into the plantar fascia
79542972|NCT01509274|Biological|Saline|3 ml of saline injected once into the plantar fascia
79542973|NCT01509274|Other|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
79542974|NCT01509300|Biological|anti-thymocyte globulin|On days -10 to -9
79542975|NCT01509300|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
79542976|NCT01509300|Radiation|Total body irradiation|2Gy D-6 to D-4
79542977|NCT01509300|Drug|Fludarabine|30mg/M2 once daily IV on days -8 to -4
79702883|NCT01643811|Procedure|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
79702884|NCT01643811|Procedure|Endoscopic submucosal dissection|endoscopic submucosal dissection
79702885|NCT01116427|Biological|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
79702886|NCT01116427|Drug|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
80013713|NCT05741918|Diagnostic Test|Echocardiography|Cardiac output measurement by echocardiography
79702887|NCT04550897|Drug|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
79702888|NCT04529226|Drug|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
79702889|NCT04529226|Drug|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
79702890|NCT04310683|Other|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
79845059|NCT03913377|Device|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
79845060|NCT00820352|Drug|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
79248806|NCT04494165|Other|massage with frankincense and myyrh essential oil|In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
79248807|NCT04494165|Other|massage with carrier oil|In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
79248808|NCT01675544|Procedure|Electrocardiogram|EKG voltage changes between admission and discharge
79248809|NCT01675544|Procedure|Six minute walk test|
79542978|NCT01509300|Drug|cyclophosphamide|60 mg/kg IV on day-3 and -2
79542979|NCT01509300|Drug|Tacrolimus|begin on 0
79542980|NCT01509300|Drug|Mycophenolate mofetil|begin on 0
79542981|NCT01509300|Drug|Rituximab|375mg/m2 on day +21
79702891|NCT04310683|Other|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
79542982|NCT01509313|Device|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
79542983|NCT01509313|Device|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
79702892|NCT04550702|Drug|Mirabegron 25mg|Mirabegron 25 mg per day
79702893|NCT01116232|Biological|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
79702894|NCT01116232|Biological|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
79702895|NCT01116232|Drug|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
79702896|NCT01116232|Drug|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
79702897|NCT01116232|Other|laboratory biomarker analysis|laboratory biomarker analysis
79702898|NCT01116232|Procedure|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
79702899|NCT01116232|Procedure|management of therapy complications|management of therapy complications
79702900|NCT01116232|Procedure|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
79702901|NCT04310527|Drug|Enasidenib|Enasidenib
79702902|NCT04550663|Drug|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
79845061|NCT00820352|Drug|placebo|placebo twice a day for 12 weeks
79845062|NCT00927654|Drug|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
79845063|NCT00927654|Drug|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
79845064|NCT05709327|Other|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
80013714|NCT05741047|Other|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
79542984|NCT01509326|Other|chiropractic treatment|12 sessions over 4 weeks
79542985|NCT01509326|Device|Dr. Zaxx pillow|Daily use of an acupressure pillow
79542986|NCT01509352|Procedure|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
79542987|NCT01509352|Procedure|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
79702903|NCT01115998|Other|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
79702904|NCT01115998|Other|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
79702905|NCT04528914|Other|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
79845065|NCT02550704|Procedure|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
80013715|NCT05741047|Other|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
80013716|NCT05740514|Behavioral|Exercise|Exercise training.
80013717|NCT05740514|Behavioral|De-training|Exercise de-training via unilateral knee immobilization.
79542988|NCT01509365|Drug|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
80013718|NCT05739162|Device|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
79542989|NCT01509365|Drug|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
79702906|NCT02214095|Drug|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
79702907|NCT02214095|Drug|lactose capsules|
79702908|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79845066|NCT00927732|Drug|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
79845067|NCT00927732|Drug|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
79845068|NCT04423575|Other|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
80013719|NCT05739162|Behavioral|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
79542990|NCT01509391|Drug|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
79542991|NCT01509417|Other|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
79542992|NCT01509417|Other|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
79845069|NCT00227539|Drug|cisplatin|
79845070|NCT00227539|Drug|pemetrexed disodium|
79845071|NCT00227539|Procedure|adjuvant therapy|
80013720|NCT05737199|Drug|MK-3475 (pembrolizumab)|MK-3475 (pembrolizumab) 200mg IV every 3 weeks [Q3W] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
80013721|NCT05732376|Behavioral|Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator."
79248810|NCT03330327|Biological|HM12470|HM12470 is a long-acting insulin analogue
79248811|NCT03336879|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
79248812|NCT05116124|Other|dosing of inflammatory parameters|View and register the dosing of inflammatory parameters
79387369|NCT02449980|Procedure|Primary Surgery Group|Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
79387370|NCT02449980|Procedure|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
79387371|NCT04484844|Drug|TOKUYAMA SHIELD FORCE PLUS|Self-reinforcing (SR) monomer technology
79387372|NCT04484844|Drug|Sodium Fluoride 5% Dental Varnish|5% NaF
79387373|NCT03119454|Drug|Diprospan|Intramuscular
79542993|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
79542994|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
79542995|NCT01509443|Other|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
79542996|NCT01509456|Dietary Supplement|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
79845072|NCT00227539|Procedure|therapeutic conventional surgery|
79845073|NCT00227539|Radiation|fludeoxyglucose F 18|
79845074|NCT00816530|Device|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
79845075|NCT00927966|Drug|RAD001|Taken orally once a day.
79845076|NCT00927966|Drug|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
79248813|NCT03330171|Biological|Measles vaccine|All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
79702909|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79248814|NCT03330171|Biological|Hepatitis-A vaccine|Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
79702910|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
79702911|NCT02214173|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
79702912|NCT02214173|Dietary Supplement|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
79248815|NCT03330171|Biological|Varicella vaccine|Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
79702913|NCT01640691|Biological|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~Administration route: Intramuscular Injection~Dosing schedule: 2 injections - at Day 1 and Day 22 separately~Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
79702914|NCT01205230|Drug|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
79702915|NCT04550390|Diagnostic Test|Saliva collection|2 saliva samples are self-collected by participants
79702916|NCT04549961|Other|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
79702917|NCT01643889|Drug|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
79702918|NCT01643889|Drug|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
79702919|NCT01643889|Drug|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
79702920|NCT01643889|Drug|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
79845077|NCT00227305|Drug|quetiapine fumarate|Oral dosing, flexible dosing
79845078|NCT00720941|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
79845079|NCT00720941|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
79845080|NCT00821756|Behavioral|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
79248816|NCT05118542|Drug|Propylthiouracil|PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
79387374|NCT04673656|Dietary Supplement|BKR-017|Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
79387375|NCT04485156|Drug|High-dose rifampicin|30mg/kg
79702921|NCT04550078|Dietary Supplement|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
79845081|NCT00924222|Drug|Sevoflurane|Sedation with sevoflurane
79845082|NCT00924222|Drug|Propofol|Sedation on intensive care unit with propofol
79845083|NCT03866642|Device|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
79845084|NCT00987285|Behavioral|CASM +|Computer Assisted Self Management plus Social Support
79845085|NCT00987285|Behavioral|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
79248817|NCT05118542|Drug|Methimazole|methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
79845086|NCT03972319|Dietary Supplement|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
79845087|NCT00928122|Device|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
79248818|NCT03336801|Procedure|Back Surgery|All patients undergo basic back surgery.
79248819|NCT03336801|Drug|Propofol|Anesthesia on propofol alone.
79248820|NCT03336801|Drug|Sevoflurane|Anesthesia on sevoflurane alone.
79387376|NCT04485156|Drug|Isoniazid|300mg
79387377|NCT04485156|Drug|Pyrazinamide|20-30mg/kg
79387378|NCT04485156|Drug|Ethambutol|15-20mg/kg
79387379|NCT04485156|Drug|Rifampicin|10mg/kg
79387380|NCT04666012|Biological|AdCLD-CoV19|Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
79391566|NCT03177720|Drug|Imipenem|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
79845088|NCT00928122|Device|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
79845089|NCT00928122|Device|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
79845090|NCT00928122|Device|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
79845091|NCT00928122|Device|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
79248821|NCT05115578|Drug|Remifentanil 1 MG Injection [Ultiva]|Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
79845092|NCT01075711|Drug|Prednisone|According to SPC
79845093|NCT00820508|Drug|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
80013722|NCT05732376|Behavioral|Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator."
80013723|NCT05732363|Device|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
80013724|NCT05732363|Radiation|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
79387381|NCT02448030|Other|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
79248822|NCT05115578|Drug|Midazolam 1 MG/ML Prefilled Syringe|Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
79248823|NCT05115578|Drug|Saline solution|Group III Control
79391567|NCT02411682|Other|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
79248824|NCT05115578|Device|Algometry|The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
79702922|NCT04550078|Dietary Supplement|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
79248825|NCT03325179|Other|Thread-embedding Therapy|
79248826|NCT03336723|Device|Dental Implant|Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
79391568|NCT02411682|Other|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
79702923|NCT04550078|Dietary Supplement|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
79702924|NCT01640730|Drug|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
79702925|NCT02214251|Device|PK-16CH EXG system|
79702926|NCT01643967|Other|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
79702927|NCT01643967|Other|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
79845094|NCT00907062|Dietary Supplement|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
79248827|NCT05115500|Drug|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
79248828|NCT02490891|Device|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
79845095|NCT01073371|Drug|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
79248829|NCT05115344|Drug|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79248830|NCT05115344|Drug|flonoltinib 50mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
79845096|NCT00820586|Procedure|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
79542997|NCT01509469|Dietary Supplement|Casein|Ileal infusion of low dose casein (5 gram)
80013725|NCT05721378|Procedure|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
80013726|NCT05721378|Procedure|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
79248831|NCT05115344|Drug|flonoltinib 100mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
79702928|NCT04549805|Diagnostic Test|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
79702929|NCT01640769|Procedure|Image guided delivery of cardiac pacing leads.|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).
79845097|NCT00928278|Drug|Treatment A|Inhaled, 300/150, single dose
79845098|NCT00928278|Drug|Treatment B|Inhaled, 300/150, single dose
79845099|NCT00928278|Drug|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
79845100|NCT00928278|Drug|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
79845101|NCT03970369|Behavioral|Usual care|Personalized goals and an activity prescription.
79845102|NCT03970369|Behavioral|Monitor|Participants wear a step counter to track activity goals.
79845103|NCT04034394|Other|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
79248832|NCT05115344|Drug|flonoltinib 150mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
79248833|NCT05115344|Drug|flonoltinib 225mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
79248834|NCT05115344|Drug|flonoltinib 325mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
79391569|NCT02411604|Drug|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
79391570|NCT02530450|Device|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
79391571|NCT02411370|Behavioral|phonetic tests|
79391572|NCT03175380|Biological|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
79391573|NCT02411214|Other|survey|questionnaire survey sent by regular mail for 3 groups
79542998|NCT01509469|Dietary Supplement|Casein|Ileal infusion of high dose casein (15 gram)
79542999|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
79543000|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
79543001|NCT01509469|Other|Saline|Ileal infusion with saline (180mL in total)
79543002|NCT01509469|Dietary Supplement|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
79543003|NCT01509482|Other|blood samples|blood samples to test for primary and secondary outcome measures
79543004|NCT01509482|Other|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
79543005|NCT01509495|Device|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
79543006|NCT01509508|Drug|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
79543007|NCT01509508|Other|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~WHO clinical stage 3 or 4 irrespective of CD4 count~MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
79543008|NCT01509521|Drug|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
79391574|NCT02530528|Drug|CHG|Varied application times
79543009|NCT01509521|Drug|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
79702930|NCT01640769|Procedure|Standard delivery of cardiac pacing leads.|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
79702931|NCT04550273|Behavioral|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
79702932|NCT01644006|Procedure|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
79702933|NCT01205152|Biological|asfotase alfa|
79702934|NCT01640847|Drug|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
79702935|NCT04549727|Other|Organoids creation|Organoids are created from discarded tissue
79702936|NCT01205035|Drug|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
79845104|NCT04034394|Other|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
79845105|NCT04005573|Dietary Supplement|VD3|VD3 50000 IU/ week for 8 weeks
79845106|NCT04005573|Dietary Supplement|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
79845107|NCT04005573|Dietary Supplement|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
79845108|NCT04005573|Other|no intervention|no intervention is given
79845109|NCT03970213|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
79845110|NCT03970213|Drug|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
79845111|NCT00821834|Drug|clopidogrel (SR25990)|"Form: tablets~Route: oral"
79845112|NCT00821834|Drug|ticlopidine|"Form: tablets~Route: oral"
79845113|NCT00821834|Drug|Placebo|"Form: tablets~Route: oral"
79702937|NCT01644045|Device|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
79702938|NCT04549844|Drug|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
79702939|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
79845114|NCT00924534|Drug|Placebo|Placebo
79845115|NCT00924534|Drug|SLV337|SLV337 400 mg/day
79387382|NCT02448030|Other|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
79387383|NCT04637620|Drug|NMDAE|Use of an NMDA enhancer for the treatment of MDD
80013727|NCT05721092|Other|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
80013728|NCT05716789|Procedure|CPR|CPR in cardiac arrest patients
79387384|NCT04637620|Drug|Sertraline|Use of SSRI as an active comparator
79387385|NCT04637620|Drug|Placebo Cap|Use of placebo as a comparator
79387386|NCT02448108|Behavioral|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT."
79702940|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
79845116|NCT00924534|Drug|SLV337|SLV337 800 mg/day
79845117|NCT00924534|Drug|SLV337|SLV337 1400 mg/day
79845118|NCT04005417|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
80013729|NCT05715021|Procedure|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
79702941|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
79702942|NCT04549883|Other|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
79702943|NCT01204918|Drug|Riluzole|Riluzole 100mg PO
79702944|NCT01204918|Drug|placebo|placebo
79702945|NCT04528797|Drug|Levothyroxine|
79702946|NCT04528797|Drug|Methylprednisolone|
79845119|NCT04005417|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
79845120|NCT04005417|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
79845121|NCT01073839|Drug|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
79845122|NCT00820742|Drug|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
79845123|NCT00928356|Procedure|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
79845124|NCT00928356|Procedure|Off Pump CABG|Standard of Care Off Pump CABG
79845125|NCT03743454|Other|No intervention|No intervention will be applied.
79702947|NCT00624481|Drug|Teriparatide|20ug subcutaneous injection daily for 24 weeks
79702948|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
79845126|NCT05698251|Behavioral|Uncertainty distress model|Psychological therapy intervention based on elements of traditional Cognitive Behaviour Therapy (CBT) for anxiety, illness uncertainty and intolerance of uncertainty.
79845127|NCT00585533|Drug|Erlotinib (Tarceva)|Erlotinib
79543010|NCT01509560|Drug|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
79543011|NCT01509573|Behavioral|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
80013730|NCT05706493|Other|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
80013731|NCT05705726|Device|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
79702949|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
80013732|NCT05705726|Drug|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
80013733|NCT05705479|Procedure|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
80013734|NCT05705479|Procedure|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
80013735|NCT05703360|Device|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
80013736|NCT05702463|Drug|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
80013737|NCT05702463|Drug|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
79248835|NCT05115266|Behavioral|Animal-assisted therapy (AAT|The activity program consists of 10 sessions with a duration of about 60 minutes. During the 10 sessions the animal is presented, in this case a dog. They caress it, dress it, educate it ...
79248836|NCT05115266|Behavioral|Usual treatment|receive usual treatment (group activities)
79702950|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
80013738|NCT05702463|Drug|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
80013739|NCT05700747|Behavioral|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
79387387|NCT02448108|Other|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
79387388|NCT00355108|Drug|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
79387389|NCT03200652|Dietary Supplement|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
79391575|NCT02411136|Drug|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
79391576|NCT02411136|Drug|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
79702951|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
79702952|NCT04549766|Other|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
79702953|NCT04318054|Other|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
79702954|NCT01644162|Device|iVAPS ventilation|3 months of ventilation on iVAPS mode
79248837|NCT03329859|Procedure|High resolution standardized laparoscopic cholecystectomy|High resolution standardized laparoscopic cholecystectomy
79248838|NCT02636036|Biological|enadenotucirev|
79248839|NCT02636036|Biological|nivolumab|
79702955|NCT04549649|Other|Dual triggering|Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
80013740|NCT05697783|Drug|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
79845128|NCT00924690|Other|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
80013741|NCT05681611|Drug|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
80013742|NCT05676684|Drug|Dapagliflozin|A: Dapagliflozin 10 mg once daily
79845129|NCT00924690|Other|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
79543012|NCT01509599|Procedure|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
79845130|NCT04719741|Other|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
79845131|NCT04085861|Behavioral|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
80013743|NCT05676684|Drug|Spironolactone|B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
79248840|NCT03336567|Other|Telephonic interview|Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
79702956|NCT01644201|Dietary Supplement|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
79845132|NCT04085861|Behavioral|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
79702957|NCT01644201|Dietary Supplement|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
79702958|NCT02214329|Device|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
79702959|NCT02214329|Other|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
79845133|NCT00628862|Drug|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
79845134|NCT00628862|Drug|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
79845135|NCT00628862|Drug|Turbuhaler® placebo|placebo inhaled twice daily
79845136|NCT00907140|Procedure|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
79845137|NCT05420727|Drug|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
79248841|NCT03329781|Dietary Supplement|BCM-95|Consuming 1 capsule of BCM-95 per day.
79248842|NCT03329781|Dietary Supplement|Placebo|Consuming 1 placebo capsule per day
79391577|NCT02411058|Behavioral|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
79391578|NCT02411058|Behavioral|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
79543013|NCT01509599|Procedure|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
79845138|NCT05420727|Drug|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
79845139|NCT04085783|Procedure|PRP|Platelet Rich Plasma
79845140|NCT00987363|Other|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
79845141|NCT04086563|Other|Action observation|look at a clip of a hand doing neurodynamic exercises.
79845142|NCT04086563|Other|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
79845143|NCT04086563|Other|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
79845144|NCT04086563|Other|Strength|Execute a short strength training for the dominant hand
79845145|NCT00820820|Biological|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
79845146|NCT00820820|Biological|placebo|Vehicle (water for injection), 0.5 ml, once
79248843|NCT02437604|Drug|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
79248844|NCT02437604|Drug|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
79248845|NCT02437604|Drug|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
79845147|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
80013744|NCT05676684|Drug|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
80013745|NCT05672680|Drug|0.25% Bupivacaine|received during TAP block
80013746|NCT05672680|Drug|Placebo|placebo equivalent
80013747|NCT05672680|Procedure|TAP block|The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
80013748|NCT05668676|Drug|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
79845148|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
79845149|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
79387390|NCT03200730|Behavioral|Family Dignity Intervention group|A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
79387391|NCT04614766|Drug|Lutathera|intravenous administration
79845150|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
79387392|NCT04614766|Drug|Azedra|intravenous administration
79845151|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
79845152|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
79387393|NCT00355186|Procedure|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
79387394|NCT03200886|Device|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
79702960|NCT04529187|Drug|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
79702961|NCT04529187|Drug|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
79702962|NCT04549415|Drug|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
79702963|NCT04549415|Other|lifestyle modification|Lifestyle modification Standard Principles
79543014|NCT01509651|Drug|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
79702964|NCT04549064|Diagnostic Test|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
79702965|NCT02214368|Other|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
79387395|NCT03200886|Drug|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
79702966|NCT02214368|Device|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
79702967|NCT02214368|Drug|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
79845153|NCT00928824|Dietary Supplement|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
79845154|NCT00816686|Biological|AGS-16M18|IV Infusion
79845155|NCT00924768|Biological|20K EU CCRE|Inhalation of CCRE
79845156|NCT00584987|Drug|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
79845157|NCT00584987|Drug|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
80013749|NCT05668676|Other|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
80013750|NCT05667376|Other|Local drug delivery|Local application of curcumin gel into the periodontal pocket
79248846|NCT02437604|Drug|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
79248847|NCT03325023|Dietary Supplement|Dietary and life style modification and probiotic Sanprobi Super Formula|Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
79248848|NCT03325023|Other|Placebo|Placebo
79248849|NCT02315144|Drug|TV48108|TV48108 15, 60, 120 μg
79248850|NCT02315144|Drug|Placebo|Placebo Comparator
79248851|NCT03324945|Behavioral|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
79845158|NCT00584987|Drug|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
79845159|NCT00584987|Drug|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
79845160|NCT00924846|Procedure|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
79845161|NCT00924924|Behavioral|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
79845162|NCT00924924|Behavioral|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
80013751|NCT05667376|Drug|curcumin gel|curcumin gel
80013752|NCT05661981|Device|GLYCAR Pericardial Patch|The Glycar patches are intended to be used by surgeons specialized in the field of cardiovascular surgery. The patch is intended to be used for pericardial closure, or repair and/or reconstruction of cardiovascular structures by replacing missing tissue, reinforcing weakened tissue and providing extra strength to repair tissue during healing.
80013753|NCT05651828|Drug|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
79702968|NCT02214368|Other|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
79387396|NCT04614532|Diagnostic Test|cognitive assessment|"global cognitive assessment :~Mini Mental State~Evaluation of manual laterality~Hospital Anxiety and Depression scale~5 words of Dubois~Trail Making Test~short battery of the praxies~neuropathic pain scale (DN4 in french)~Analog Visual Scale for pain~Fast Front End Efficiency Battery"
79702969|NCT04529148|Drug|Ginkgo biloba dropping pills，best western medicine treatment|oral
79543015|NCT01509690|Other|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access [arteriovenous (AV) fistula or graft] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
79543016|NCT01509703|Procedure|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
79543017|NCT01509729|Procedure|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
79387397|NCT04614532|Other|Cold Pressor Test|"consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test."
79543018|NCT01509729|Procedure|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
79845163|NCT00727961|Drug|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
79845164|NCT00568958|Behavioral|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
79845165|NCT00568958|Drug|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
79845166|NCT00568958|Drug|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
79845167|NCT03540771|Other|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~Patient/caregiver understanding of diagnosis, illness and prognosis~Symptom assessment and management~Psychosocial assessment and management~Distress screening and management~Discussion of goals of care~Advanced directives"
80013754|NCT05631938|Drug|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
79702970|NCT04529148|Drug|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
80013755|NCT05631327|Drug|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
80013756|NCT05624957|Drug|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
80013757|NCT05624957|Drug|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
80013758|NCT05624775|Behavioral|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
79248852|NCT05118464|Other|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
79387398|NCT04614532|Other|digital sensor of Nociception Level Index|placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
79543019|NCT01509755|Drug|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
79543020|NCT01509755|Drug|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
79543021|NCT01509755|Drug|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
79702971|NCT04548908|Diagnostic Test|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
79845168|NCT02590835|Procedure|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
79845169|NCT02590835|Procedure|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
79845170|NCT00821912|Drug|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
79845171|NCT00821912|Drug|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
79845172|NCT05690997|Other|Intensive treatment|If the mean home SBP preceding clinic follow-up is >130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is <120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.
79845173|NCT05690997|Other|Standard treatment|If the mean home SBP preceding clinic follow-up is >140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is <130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
79248853|NCT03329703|Behavioral|Project UPLIFT|A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.
79387399|NCT05717764|Drug|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
79387400|NCT05717764|Drug|Capecitabine|Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
79387401|NCT05717608|Other|high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects|oral ingestion of food supplement for 4 weeks
79387402|NCT03118830|Drug|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
79543022|NCT01509781|Procedure|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
79543023|NCT01509781|Procedure|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
79543024|NCT01509794|Other|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
79543025|NCT01509794|Other|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
79543026|NCT01509833|Drug|rFSH|Administration of rFSH for ovarian stimulation.
79543027|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
79543028|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
79543029|NCT01509859|Device|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
79702972|NCT04548635|Device|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
79702973|NCT01204294|Drug|Linagliptin|Linagliptin once daily
79702974|NCT01204294|Drug|Linagliptin|Linagliptin once daily
79702975|NCT01204294|Drug|Metformin|Metformin twice or three time per day
79391579|NCT02530996|Drug|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
79702976|NCT01204294|Drug|Metformin|Metformin twice or three time per day
79702977|NCT01204294|Drug|Linagliptin|Linagliptin once daily
79702978|NCT01204294|Drug|Linagliptin|Linagliptin once daily
79702979|NCT01204294|Drug|Linagliptin|Linagliptin once daily
79702980|NCT01641276|Device|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
79702981|NCT01182181|Drug|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
79702982|NCT01182181|Drug|Anastrozole (Arimidex®)|1 mg Tablets
79543030|NCT01509859|Device|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith&Nephew INTERTAN proximal femur nail device"
79702983|NCT04548674|Other|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
79702984|NCT04548674|Device|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
79845174|NCT02593253|Other|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
79845175|NCT02593253|Other|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
79845176|NCT00816764|Biological|AGS-8M4|IV Infusion
79845177|NCT05325905|Diagnostic Test|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
79248854|NCT05117216|Behavioral|Parental Vigilant Care (Parental training)|
79248855|NCT05117216|Behavioral|Technological Parental Monitoring|
79248856|NCT03329625|Behavioral|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
79543031|NCT01509898|Device|Water jet|use of water jet for a month
79543032|NCT01509911|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
79387403|NCT03118830|Drug|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
79845178|NCT00820976|Drug|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
79845179|NCT00727649|Drug|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
79543033|NCT01509911|Drug|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
79543034|NCT01509924|Other|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
79702985|NCT04548674|Other|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
79702986|NCT04548674|Other|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
79702987|NCT01181986|Drug|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
79845180|NCT00727649|Drug|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
79845181|NCT00987597|Behavioral|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
79845182|NCT00987597|Behavioral|conventional follow-up|nicotinic substitutes
79845183|NCT00568334|Biological|Varilrix (inactivated varicella vaccine)|subcutaneously injection
79845184|NCT04006041|Drug|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
79845185|NCT04006041|Drug|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
79248857|NCT03329625|Behavioral|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
79845186|NCT04006041|Radiation|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
79248858|NCT05114954|Device|CardioPulsesTM pulsed field ablation system|Using pulsed field ablation (PFA) catheter, steerable sheath and pulsed field generator to treat atria fibrillation.
79248859|NCT02493309|Other|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
79387404|NCT03118830|Drug|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
79387405|NCT03223506|Drug|Paracetamol|
79391580|NCT02530996|Diagnostic Test|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
79845187|NCT04006041|Procedure|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
79543035|NCT01509937|Device|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
79543036|NCT01509937|Device|Device|participants in control arm will not receive BCM measurement.
79845188|NCT00727571|Other|Observations|This is a non-interventional, observational study; no investigational product is being used
79845189|NCT00225277|Drug|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
79845190|NCT00225277|Drug|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
79845191|NCT00821054|Drug|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
79387406|NCT03223740|Other|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
79387407|NCT03223740|Other|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
79845192|NCT04391673|Behavioral|Vestibular rehabilitation|Vestibular rehabilitation (treatment as usual).
79845193|NCT00567996|Drug|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
79845194|NCT00567996|Drug|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
79387408|NCT03223896|Drug|Naloxone hydrochloride 20mg/ml|Nasal spray
79387409|NCT03195504|Device|HFNC|High flow nasal oxygen (60 l) under GA
79845195|NCT00567996|Drug|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
79845196|NCT00567996|Drug|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
79543037|NCT01509963|Other|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
79543038|NCT01509976|Other|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
79543039|NCT01510002|Procedure|Total thyroidectomy|Extracapsular total thyroidectomy
79543040|NCT01510002|Procedure|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
79543041|NCT01510015|Drug|Risperidone|variable dose
79387410|NCT03195504|Device|CON (control)|Standard oxygen (10-15 l) under GA
79543042|NCT01510041|Other|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
79543043|NCT01510041|Other|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
79845197|NCT00821990|Drug|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
79543044|NCT01510080|Behavioral|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
79845198|NCT00821990|Other|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
79845199|NCT04388319|Drug|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
79845200|NCT04388319|Drug|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
79845201|NCT04388319|Other|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
79845202|NCT04085627|Drug|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg& Amlodipine 5mg
79845203|NCT00821210|Device|Sham CPAP|CPAP with pressure of 3cm H2O
79845204|NCT00821210|Device|CPAP of optimal pressure|CPAP of optimal pressure
79845205|NCT03970135|Other|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose < 3mmol/L) or symptoms of hypoglycemia
79845206|NCT04086173|Dietary Supplement|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
79845207|NCT04086173|Other|Placebo|Placebo
79845208|NCT04005261|Diagnostic Test|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
79543045|NCT01510080|Behavioral|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
79845209|NCT00821288|Behavioral|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
79845210|NCT00821288|Behavioral|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
79543046|NCT01510093|Drug|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
79543047|NCT01510132|Drug|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
79248860|NCT02493309|Other|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
79248861|NCT03329547|Drug|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
79543048|NCT01510171|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
79543049|NCT01510171|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
79543050|NCT01510223|Dietary Supplement|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
79702988|NCT01181986|Drug|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
79702989|NCT01181986|Drug|Placebo SC|Placebo sc BID/10days
79702990|NCT01181986|Drug|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
79248862|NCT03329547|Drug|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
79248863|NCT05107232|Other|MRI|MRI
79387411|NCT03118908|Dietary Supplement|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
79387412|NCT03118908|Dietary Supplement|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
79387413|NCT03118908|Dietary Supplement|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
79387414|NCT03200418|Other|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
79387415|NCT03200418|Other|P-4|This patch is made of new adhesive
79387416|NCT03200418|Other|P-15|This patch is made of new adhesive
79387417|NCT03200418|Other|P-16|This patch is made of new adhesive
79387418|NCT02447796|Drug|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
79387419|NCT02447796|Drug|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
79387420|NCT05225116|Drug|Sintilimab|Sintilimab will be at a dose of 200mg,Q3W
79702991|NCT01181986|Drug|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
79702992|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
79702993|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
79702994|NCT04315909|Drug|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
79702995|NCT04315909|Dietary Supplement|Vitamin E and C|Vitamin E and vitamin C
79702996|NCT04315909|Other|Placebo|Placebo
79702997|NCT04548362|Other|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
79702998|NCT04548362|Other|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
79702999|NCT01181167|Drug|edoxaban|
80013759|NCT05619432|Device|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
79703000|NCT01181167|Drug|enoxaparin sodium|
79703001|NCT04550507|Behavioral|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
80013760|NCT05619289|Drug|Ergocalciferol|One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
79387421|NCT05225116|Drug|Lenvatinib|On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).
79703002|NCT04550507|Behavioral|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory & Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
80013761|NCT05619289|Drug|Placebo|One-time, oral dose of 6 inert capsules matched to the active comparator
79248864|NCT05463627|Drug|Metformin|All participants among the three groups were treated with metformin
79248865|NCT01975298|Drug|Laquinimod|Oral Administration
79248866|NCT01975298|Drug|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
79248867|NCT03336177|Other|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
79387422|NCT05225116|Radiation|radiotherapy|Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction
79387423|NCT02447640|Drug|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
79387424|NCT02447640|Radiation|[18F]FPEB|radiotracer used for PET scanning
79387425|NCT04503772|Procedure|Preoperative SRS|Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.
79703003|NCT01644630|Procedure|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
79703004|NCT01644630|Procedure|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
79703005|NCT04548557|Biological|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
79248868|NCT05114642|Device|Skeletal Class III Malocclusion Treatment with Face Mask Group|Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
79248869|NCT03324867|Drug|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
79387426|NCT03195348|Other|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
79387427|NCT03200496|Drug|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
79387428|NCT03200496|Drug|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
79387429|NCT03200496|Drug|TALION®|Reference drug : Talion®
79387430|NCT04492618|Drug|Ruxolitinib|Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
79387431|NCT03195036|Behavioral|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
79845211|NCT00224887|Behavioral|In home nutrition counseling|In home family-based behavioral counseling
79845212|NCT00224887|Other|standard nutrition education curriculum|video and lesson plans based on USDA Food Guide Pyramid
79543051|NCT01510223|Dietary Supplement|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
79845213|NCT04085393|Drug|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
79845214|NCT00987675|Other|pharmacological study|
79845215|NCT00987675|Other|questionnaire administration|
80013762|NCT05614024|Other|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
80013763|NCT05614024|Other|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
80013764|NCT05610306|Other|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
80013765|NCT05604690|Biological|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
79248870|NCT03324867|Drug|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
79248871|NCT03329391|Behavioral|Nurse-led cognitive-behavioral-based group intervention|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
79703006|NCT04548323|Behavioral|Motor imagery|Subjects will perform motor imagery tasks on the motor gestures of running and walking.
79703007|NCT01181128|Drug|Factor VIII (rFVIIIFc)|
79703008|NCT01181128|Drug|Advate®|
79703009|NCT04548401|Drug|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
79703010|NCT04548284|Drug|Glucocorticoids|Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
79703011|NCT04547894|Drug|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
79703012|NCT01641315|Biological|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
79703013|NCT04548011|Other|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
79845216|NCT00987675|Procedure|assessment of therapy complications|
79845217|NCT00987675|Procedure|high-intensity focused ultrasound ablation|
79845218|NCT00987675|Procedure|quality-of-life assessment|
79845219|NCT00928902|Drug|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
79845220|NCT00928902|Biological|melanoma vaccine|six melanoma vaccines given over a 6-week period
80013766|NCT05604690|Combination Product|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
80013767|NCT05604690|Other|Placebo|Placebo will be administered via intranasal route.
80013768|NCT05600296|Drug|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
80013769|NCT05600296|Procedure|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
80013770|NCT05600296|Procedure|IINB+ Spermatic cord block|IINB+ Spermatic cord block
80013771|NCT05594225|Behavioral|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
80013772|NCT05592275|Drug|LY3540378|Administered SC
80013773|NCT05592275|Drug|Placebo|Administered SC
80013774|NCT05590338|Drug|GSK1070806|Participants will receive GSK1070806
80013775|NCT05590338|Drug|Placebo|Participants will receive placebo
79703014|NCT01641393|Drug|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
79703015|NCT01641393|Drug|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
79845221|NCT00816920|Other|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
80013776|NCT05585580|Drug|Serplulimab|300mg d1 q3w
80013777|NCT05585580|Drug|Lenvatinib|8mg po qd
80013778|NCT05585580|Drug|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
80013779|NCT05580068|Device|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
80013780|NCT05577819|Diagnostic Test|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
80013781|NCT05577533|Behavioral|O-Kidia game battery|Children will be playing on a series of games with a touch screen tablet while video and digit trajectories data will be collected from this mobile device to analyze eye-, face-, sound-recognition.
80013782|NCT05577533|Behavioral|O-Brain|Electrical recordings and measurements - A mobile EEG headset will be used during the visit - 30 min
79248872|NCT05084534|Drug|Midodrine|"Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age)"
79387432|NCT04485234|Diagnostic Test|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance|Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
79387433|NCT03200106|Device|Alfapump|Alfapump implant
79387434|NCT05713942|Diagnostic Test|The Sport Concussion Assessment Tool 5th Edition (SCAT5)|The SCAT5 is a standardized tool for use by healthcare professionals in the evaluation of individuals 13 years old or older, who are suspected of having sustained a sports-related concussion. It comprises a neuropsychological test battery that assesses attention and memory function through 8 different domains 1) Symptom number, 2) Symptom severity, 3) Orientation, 4) Immediate memory, 5) Concentration, 6) Neurological examination, 7) Balance errors, 8) Delayed recall.
79703016|NCT04547933|Diagnostic Test|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
79710000|NCT01332149|Drug|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
79710001|NCT01332149|Drug|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
79710002|NCT00599430|Dietary Supplement|Placebo|Inert excipient
80013783|NCT05565742|Drug|LY3819469|Administered SC
80013784|NCT05565742|Drug|Placebo|Administered SC
80013785|NCT05564299|Diagnostic Test|Rapid 30-minute Desktop Assay|"Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter.~Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay.~Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols."
80013786|NCT05564039|Drug|Tirzepatide|Administered SC
80013787|NCT05564039|Drug|Dulaglutide|Administered SC
80013788|NCT05561985|Drug|Itacitinib|
79710003|NCT00599430|Dietary Supplement|Lactobacillus acidophilus NCFM|1e10 CFU/day
79845222|NCT04004949|Other|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores & scapular balance angle test (SBA).
79845223|NCT00148759|Drug|LPV/r|LPV/r 800/200 mg once daily
79845224|NCT00925080|Device|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
80013789|NCT05560958|Device|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
79248873|NCT05084534|Other|Standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~To continue restriction of sodium to < 2meq/kg/day~To continue maximum tolerable dose of diuretics~Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~Albumin infusion for serum albumin <2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
79248874|NCT03329235|Drug|PRP|platelet rich plasma
79248875|NCT03329235|Drug|HA|hyaluronic acid
79845225|NCT00717275|Drug|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
79845226|NCT00822068|Device|anodal tDCS|anodal transcranial direct current stimulation
79543052|NCT01510223|Dietary Supplement|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
79845227|NCT00822068|Device|cathodal tDCS|cathodal transcranial direct current stimulation
79248876|NCT03336099|Other|Spa Treatment|"Bath with immersion shower~Overall shower, penetrating shower~Multiple local application cataplasm~Single local application cataplasm~Inhalation or collective steam bath~Individual physiotherapy technique"
79248877|NCT05046548|Biological|Vaccine for intramuscular injection|Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
79543053|NCT01510223|Dietary Supplement|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
79387435|NCT05713942|Diagnostic Test|The Immediate Post-Concussion Assessment and Cognitive Testing tool version 4 (ImPACT)|The ImPACT is a computer-based neurocognitive test battery that provides an objective measure of neurocognitive functioning as an assessment aid in the management of concussion in individuals ages 12-80 years
79387436|NCT04470934|Device|SeQuent® SCB drug-coated balloon catheter|"treatment of coronary artery disease with SeQuent® SCB of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
79703017|NCT01641432|Behavioral|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
79703018|NCT01641432|Behavioral|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
79703019|NCT04547972|Other|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with ~80% of their one repetition maximum
79703020|NCT04547972|Other|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with ~30% of their one repetition maximum
79703021|NCT01644825|Drug|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
79845228|NCT00822068|Device|sham stimulation|sham stimulation
79845229|NCT04006353|Drug|ABT|320 mg, Intravenous infusion
79845230|NCT04006353|Drug|RIF|600mg q.d.
79845231|NCT00925158|Procedure|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
79845232|NCT01075789|Drug|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
79248878|NCT05046548|Other|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
79248879|NCT03336021|Other|FAS program|Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
79387437|NCT03195114|Diagnostic Test|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
79387438|NCT03200028|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
79387439|NCT05711836|Genetic|HLA-genotyping|HLA genotyping in DNA samples from peripheral blood of patients and controls
79387440|NCT02449824|Other|magnetic resonance imaging|early MRI
79387441|NCT03223116|Procedure|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
79703022|NCT01644825|Drug|pazopanib|orally, 800 mg orally daily
79710004|NCT00599430|Dietary Supplement|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
79845233|NCT01075789|Drug|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
79845234|NCT04515849|Drug|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
79845235|NCT04515849|Drug|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
79845236|NCT04515849|Drug|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
79845237|NCT04515849|Drug|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
79845238|NCT04515849|Drug|Placebo|Placebo administered subcutaneously
79845239|NCT03972241|Device|foot insole|arch support and toe extension
79845240|NCT04085159|Biological|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
79845241|NCT00928980|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
79248880|NCT02491281|Drug|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
79703023|NCT04547660|Biological|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
79703024|NCT04547660|Other|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
79248881|NCT02491281|Drug|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
79248882|NCT04645316|Drug|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
79703025|NCT01644864|Drug|0.375% ROPIVACAINE|
79703026|NCT01644864|Drug|placebo|
80013790|NCT05559437|Drug|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
79703027|NCT04547855|Drug|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
79703028|NCT01641510|Drug|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
79703029|NCT01641510|Drug|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
79703030|NCT01644942|Other|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
79703031|NCT04547621|Device|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
79387442|NCT03200184|Drug|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
79703032|NCT04547621|Device|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
79703033|NCT04547621|Drug|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
79845242|NCT00928980|Drug|Optimal Medical Care|Therapeutic dose of antidepressant medication
79248883|NCT04645316|Drug|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
79703034|NCT01644981|Other|blood sampling|blood sampling
79703035|NCT01641549|Procedure|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
79248884|NCT04645316|Drug|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
79703036|NCT01641549|Drug|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
79248885|NCT05114408|Other|4 week trimodal prehabilitation course|"trimodal prehabilitation in mixed: stationary and at-home structure"
79703037|NCT04547348|Drug|Denosumab Injection|Injections made subcutaneously per standard description
79703038|NCT04547426|Other|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
79703039|NCT01641588|Behavioral|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
80013791|NCT05556525|Other|Fluorescein|Given IV
80013792|NCT05556525|Device|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
80013793|NCT05556525|Procedure|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
79387443|NCT04438564|Other|Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer|Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
79387444|NCT03223038|Other|No intervention|No intervention - exposure is mechanical ventilation in PICU
79387445|NCT05711680|Device|Device|To develop an e-health system to remotely monitor patients with chronic HIV infection and conduct early screening for COVID-19 through a telemonitoring, teleconsultation and periodic remote visit system.
79387446|NCT03222960|Drug|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
79387447|NCT03222960|Drug|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
79703040|NCT04547387|Device|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
79703041|NCT01641627|Procedure|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
79710005|NCT02892240|Other|No intervention. Observational study|
79710006|NCT04326270|Device|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
79710007|NCT04054427|Device|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
79710008|NCT00599469|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
79710009|NCT04054505|Dietary Supplement|EZPAK|One packet with breakfast for three months
79710010|NCT04054505|Dietary Supplement|Placebo|One packet with breakfast for three months
80013794|NCT05552664|Genetic|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
79543054|NCT01510236|Behavioral|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
79703042|NCT04547231|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|"Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
79703043|NCT01641666|Drug|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
79703044|NCT01641666|Drug|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
79703045|NCT01641666|Drug|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
79703046|NCT02214485|Behavioral|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
79703047|NCT02214485|Behavioral|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
79703048|NCT01645215|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
79703049|NCT04547270|Other|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
79248886|NCT03324789|Other|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
79248887|NCT03324789|Other|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
79248888|NCT03335943|Drug|CDA-2 (Cell Differentiation Agent 2)|CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
79248889|NCT01843634|Drug|ODSH|
79248890|NCT03324555|Drug|ORIC-101|Oral suspension
79248891|NCT03328923|Dietary Supplement|500mg brown seaweed powder|
79248892|NCT03328923|Dietary Supplement|Placebo|
79248893|NCT02491515|Drug|Denosumab|every 6 month injection
79248894|NCT05113628|Diagnostic Test|methylene blue identification|"After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl."
79248895|NCT05113472|Biological|Pfizer-BioNTech COVID-19 vaccine|Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
79387448|NCT03831802|Device|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
79387449|NCT03831802|Device|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
79387450|NCT02447484|Behavioral|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education & Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
79387451|NCT02447484|Behavioral|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
79703050|NCT01203787|Drug|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
79703051|NCT01203787|Drug|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
79703052|NCT01641744|Behavioral|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
79703053|NCT01641744|Behavioral|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
79703054|NCT02887768|Device|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
79703055|NCT02887768|Procedure|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
79703056|NCT04547504|Drug|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
79845243|NCT03972085|Other|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
79845244|NCT03972085|Other|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
79845245|NCT00826046|Drug|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
79248896|NCT05464485|Procedure|ACL hamstring reconstructions using semitendinosus (ST) tendon only|ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
79248897|NCT05464485|Procedure|ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith & Nephew, London, UK).
79248898|NCT04445090|Drug|BI 1569912|BI 1569912
79248899|NCT04445090|Drug|Placebo|Placebo
79703057|NCT04547504|Drug|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
79703058|NCT01645254|Drug|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
79703059|NCT01181011|Drug|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
79710011|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
79845246|NCT00584909|Drug|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
79845247|NCT02551172|Drug|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
79845248|NCT02551172|Drug|HGP0816|Rosuvastatin
79845249|NCT02551172|Drug|Placebo of HCP1105|Soybean Oil
79845250|NCT02551172|Drug|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
79248902|NCT03335709|Behavioral|ADL intervention|Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
79248903|NCT03324399|Dietary Supplement|probiotic|a proprietary probiotic formulation
79248904|NCT04247750|Drug|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
79248905|NCT03335631|Behavioral|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
79703060|NCT04528602|Procedure|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
79845251|NCT03947099|Drug|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
79710012|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
79710013|NCT00597324|Procedure|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
79845252|NCT00147823|Device|Vitoss Alone|Synthetic bone graft material
79845253|NCT00147823|Device|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
79845254|NCT05361915|Drug|Abivertinib|Abivertinib is a small molecule inhibitor
79845255|NCT05361915|Drug|Abiraterone|Hormone-based chemotherapy
79845256|NCT00929058|Drug|Bevacizumab|Intra-arterial infusion during 6 minutes
79845257|NCT03860246|Diagnostic Test|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
79845258|NCT00925314|Biological|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
79248906|NCT05117606|Device|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
79248907|NCT03328767|Behavioral|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
79845259|NCT00822146|Device|CRT|classified
79248908|NCT02493231|Drug|Nefopam|
79248909|NCT02493231|Drug|Ketamine|
79845260|NCT00816998|Procedure|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
79248910|NCT02493231|Drug|Saline|
79248911|NCT04075682|Other|Inserts with efficacy messages|Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.
79248912|NCT04075682|Other|Pictorial warnings on packs|Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
79248913|NCT03328689|Other|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
79845261|NCT00816998|Procedure|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
79845262|NCT00907452|Drug|melphalan-prednisone-thalidomide|
79387452|NCT05704504|Behavioral|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
79845263|NCT00907452|Drug|lenalidomide-dexamethasone|
79845264|NCT00822224|Drug|MEOPA|inhalation of MEOPA during the painful care
80013795|NCT05552430|Device|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
80013796|NCT05548517|Behavioral|Time Restricted Eating (TRE)|9-hour eating window
80013797|NCT05548517|Behavioral|Calorie Restriction|daily calorie restriction
79845265|NCT00907530|Drug|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
79845266|NCT00907530|Drug|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
79845267|NCT05331885|Biological|Suvratoxumab|Monoclonal antibody
79845268|NCT05331885|Drug|Placebo|Placebo contains only excipients
79703061|NCT04528602|Procedure|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~Common procedure steps~The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed.~The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~Tapes of the clean diaper will be fastened.~Hands will be washed after the procedure.~Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
79703062|NCT04546997|Diagnostic Test|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
79703063|NCT01180777|Device|etafilcon A (A)|Daily wear contact lens
79703064|NCT01180777|Device|etafilcon A (B)|Daily wear contact lens
79703065|NCT01180777|Device|etafilcon A (C)|Daily wear contact lens
79703066|NCT01641783|Drug|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
79703067|NCT02214524|Device|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
79703068|NCT02214602|Drug|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
79703069|NCT01646580|Drug|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
79703070|NCT04546802|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
79703071|NCT04528875|Device|Ultrasound imaging|Imaging of low back with ultrasound
79703072|NCT04546880|Other|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
79845269|NCT00717197|Drug|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
79845270|NCT00929136|Biological|USP endotoxin|Continuous intra-arterial infusion
80013798|NCT05543265|Behavioral|Default appointment scheduling|Default primary care appointment scheduling
79248914|NCT03328689|Other|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
79248915|NCT02993107|Biological|AR101|AR101 powder provided in capsules & sachets
79248916|NCT05112692|Drug|Dydrogesterone Tablets|first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
79391581|NCT02530996|Drug|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (~22°C) laboratory conditions.
79703073|NCT04546880|Other|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
79703074|NCT01645293|Genetic|Genetically modified T cells # 1138|
79248917|NCT05112692|Drug|cetrorelix 0.25mg|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
79845271|NCT00925392|Drug|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
79845272|NCT00925392|Drug|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
80013799|NCT05543265|Behavioral|Targeted messaging|Patient-specific messages about the importance of postpartum care transition
80013800|NCT05543265|Behavioral|Nudge Reminders|Primary care appointment reminders
80013801|NCT05541952|Biological|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
80013802|NCT05540457|Device|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
80013803|NCT05523817|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
79248918|NCT05112692|Drug|human menopausal gonadotropin|(150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
79248919|NCT05112692|Drug|triptorelin 0.1 mg|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
79391582|NCT03174756|Drug|Hypochlorous Acid|Mouthwashes of antiplaque agents
79703075|NCT04546919|Other|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
79703076|NCT01648023|Device|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
79703077|NCT01648023|Drug|Gem-Cis or Gem-Carbo|
79703078|NCT04547114|Diagnostic Test|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
79703079|NCT01580033|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
79845273|NCT05315271|Drug|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
79845274|NCT05315271|Drug|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
79845275|NCT00147745|Drug|Colesevelam|Colesevelam 3.8g for 12 weeks
79845276|NCT00147745|Drug|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
79845277|NCT00147745|Drug|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
79845278|NCT04542486|Procedure|"Excision of gingival hyperplasia using Soft tissue trimmer ."|Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.
79845279|NCT04542486|Procedure|Excision of gingival hyperplasia using the conventional scalpel technique|Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
79845280|NCT00929292|Other|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
79845281|NCT00929292|Other|Modilac 1|Infant formula used for non breastfed children
79845282|NCT01326169|Behavioral|Brief intervention|Telephone-delivered counseling
79845283|NCT01326169|Behavioral|Standard care|No intervention
79845284|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
79248920|NCT05112692|Drug|human chorionic gonadotropin|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
79391583|NCT03174756|Drug|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
79703080|NCT01580033|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
79703081|NCT01580033|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
79703082|NCT01580033|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
79703083|NCT04547036|Device|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
79703084|NCT01645332|Drug|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
79703085|NCT01645332|Drug|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
79703086|NCT01645332|Other|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
79703087|NCT04546763|Device|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
79703088|NCT04546763|Device|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
79710014|NCT01330628|Device|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
79845285|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
79391584|NCT03174756|Other|Placebo|Sterile water as placebo
79391585|NCT03174678|Drug|Dexmedetomidine|1µg/kg dexmedetomidine oral
79391586|NCT03174678|Other|apple juice|apple juice
79845286|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
79845287|NCT00642902|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
79845288|NCT05313477|Drug|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If <10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If >20 ng/mL, 20000U of Ergocalciferol capsule per week
79845289|NCT05313477|Drug|Calcium carbonate|1000mg of Calcium carbonate daily
79710015|NCT01330628|Procedure|Balloon angioplasty|standard balloon catheters for PTA
79710016|NCT02892279|Other|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
79845290|NCT02531815|Biological|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
79845291|NCT02531815|Drug|Placebo|Placebo for PF-06741086, single dose
79845292|NCT00826124|Procedure|Epidural steroid injection|Injection based solely on history and physical exam
79845293|NCT00826124|Procedure|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
79845294|NCT00826124|Procedure|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
79703089|NCT02757222|Radiation|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
79703090|NCT02757222|Radiation|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
79703091|NCT04546490|Other|Pressure Release technique|Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
79543055|NCT01510262|Behavioral|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
79703092|NCT04546490|Other|Ischemic pressure technique|Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
79703093|NCT04546373|Drug|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
79387453|NCT05704504|Behavioral|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
79845295|NCT00224107|Drug|Silodosin|8 mg daily for 12 weeks
79845296|NCT00224107|Other|Placebo|1 capsule daily for 12 weeks
79845297|NCT00822302|Drug|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
79387454|NCT02447562|Device|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
79845298|NCT00822302|Drug|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
79387455|NCT02447562|Other|Phone-based care group|
79387456|NCT02447562|Other|Usual care group|
79845299|NCT04004871|Drug|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
79845300|NCT04004871|Radiation|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
79845301|NCT00826358|Drug|ABT-143|Once, please see Arm Description for more details.
79845302|NCT00826358|Drug|ABT-335|Once, see Arm Description for more detail
79248921|NCT05112692|Procedure|cryopreservation|All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
79387457|NCT00355654|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
79387458|NCT00355654|Biological|DT3aP-HBs-IPV|0.5 mL, IM
79387459|NCT03199716|Other|Parent mentors|Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
79387460|NCT03195192|Other|biomarker study|This is a biomarker study
79387461|NCT03118440|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
79387462|NCT03118440|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
79391587|NCT02409498|Drug|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
79391588|NCT02409498|Drug|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
79845303|NCT00826358|Drug|rosuvastatin|once, see Arm Description for more detail
79543056|NCT01510262|Behavioral|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
79703094|NCT01645410|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
79703095|NCT04546334|Drug|Medical treatment|routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
79703096|NCT04546334|Procedure|Real Erector Spinae block|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
79703097|NCT04546334|Procedure|Real Erector Spinae block with magnesium sulphate|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
79703098|NCT04546334|Procedure|Sham Erector Spinae block|Ultrasound guided Erector spinae plane block with injection ofnormal saline
79703099|NCT04546256|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
79703100|NCT04546256|Drug|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
79703101|NCT01645449|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
79703102|NCT04546100|Other|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
79703103|NCT01645761|Drug|Endonase|PPI- based triple therapy with endonase
79703104|NCT04546646|Other|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
79703105|NCT02759640|Drug|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
79845304|NCT03972007|Device|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
79845305|NCT00987909|Biological|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
79248922|NCT05112692|Drug|Estradiol Valerate and progesterone|Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
79248923|NCT03328611|Device|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
79248924|NCT03328533|Drug|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
79248925|NCT03328533|Drug|Norepinephrine|Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
79248926|NCT03328533|Drug|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
79248927|NCT05105594|Other|survey application|Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
79703106|NCT04546529|Device|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
79703107|NCT04546529|Device|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
79703108|NCT04546022|Drug|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
79703109|NCT01645800|Drug|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
79703110|NCT01645800|Drug|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
79703111|NCT01645878|Behavioral|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
79703112|NCT01645878|Behavioral|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
79703113|NCT01645878|Behavioral|routin breast feeding education|
79703114|NCT04546607|Other|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
79703115|NCT01645917|Device|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
79703116|NCT02278445|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
79845306|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
79845307|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
79845308|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
79703117|NCT02278445|Device|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
79248928|NCT03324321|Other|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
79387463|NCT05681260|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
79703118|NCT02278523|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
79387464|NCT05681260|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
79543057|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
79543058|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
79703119|NCT02214680|Drug|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
79845309|NCT00822380|Dietary Supplement|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
79845310|NCT00822380|Dietary Supplement|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
79845311|NCT00822380|Dietary Supplement|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
79703120|NCT02214680|Drug|Timolol|0.5% eye drop
79710017|NCT02892162|Procedure|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
79845312|NCT00822380|Dietary Supplement|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
79845313|NCT00822380|Dietary Supplement|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
79248929|NCT05117372|Other|treatment with immunotherapy and diffuse infiltrative lung disease|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
79248930|NCT05117372|Other|Patients requiring carcinologic lobectomy|Patients requiring carcinologic lobectomy
79248931|NCT05353777|Device|Levita Robotic Platform|Levita Robotic Platform
79248932|NCT03324243|Drug|Crenolanib|66.7 mg/m2 three times a day (TID)
79248933|NCT03324243|Drug|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
79248934|NCT03324243|Drug|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
79248935|NCT05117138|Biological|AMT-116 CAR-T cells|"Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled."
79248936|NCT05117138|Biological|AMT-253 CAR-T cells|"1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 ~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10^8 cells.~3.3 ~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum)."
79710018|NCT01330433|Device|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~Patients weighing < 3kg will receive 1ml of CoSeal~Patients weighing 3-10kg will receive 1-2ml of CoSeal~Patients weighing >10kg will receive 2-4ml of CoSeal"
79845314|NCT00720083|Drug|cisplatin|Given IV
79845315|NCT00720083|Drug|vandetanib|Given orally
79845316|NCT00720083|Radiation|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
79845317|NCT00209131|Drug|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
79845318|NCT00209131|Drug|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
79845319|NCT00925626|Procedure|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
79845320|NCT00925626|Procedure|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
79845321|NCT04044950|Biological|E7 TCR|The injection will be approximately 3x10^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
79845322|NCT00907608|Drug|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
80013804|NCT05521048|Drug|Doxycycline Injection [Doxy]|Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
79703121|NCT02214875|Other|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
79703122|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
80013805|NCT05506150|Behavioral|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
80013806|NCT05504083|Drug|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
80013807|NCT05504083|Drug|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
79248937|NCT05353699|Other|Implementation strategies|We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
79387465|NCT05681260|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
80013808|NCT05500508|Drug|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
79387466|NCT03193086|Drug|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
79387467|NCT03118206|Device|lumbar traction|
79387468|NCT03118206|Procedure|spinal manipulation|
79543059|NCT01510288|Drug|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
79703123|NCT02756208|Biological|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
80013809|NCT05500508|Drug|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
80013810|NCT05498597|Drug|AMT-151|Administered intravenously
79387469|NCT03118206|Procedure|surgery|
79387470|NCT03199950|Drug|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
79387471|NCT03199950|Drug|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
79387472|NCT03118284|Other|urine collection|
79387473|NCT03118284|Other|Blood collection|
79387474|NCT03118284|Behavioral|NRS|
79387475|NCT05156632|Biological|Medium-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection.
79543060|NCT01510301|Device|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
80013811|NCT05493189|Other|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
80013812|NCT05485532|Device|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
80013813|NCT05483621|Drug|Beta-hCG|Treatment of spermatogenesis
79703124|NCT02756208|Biological|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
79703125|NCT02756208|Biological|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
79703126|NCT02756208|Biological|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
79703127|NCT04545788|Drug|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
80013814|NCT05482880|Other|Regular care with additionally administration of questionnaires|"Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~after the multidisciplinary consultation, a baseline questionnaire*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital."
79248938|NCT03324165|Other|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
79248939|NCT02493153|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
79248940|NCT02493075|Behavioral|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
79248941|NCT03564769|Behavioral|Intervention Arm|Individuals randomized to the intervention group will receive skin cancer screening educational materials.
79248942|NCT03564769|Other|AAD SPOTmeⓇ skin cancer screening|All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
79387476|NCT05156632|Biological|High-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd.1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
79387477|NCT05156632|Biological|Placebo-comparator group|The composition is aluminium hydroxide with no antigen ,0 SU/0.5 mL,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
79387478|NCT03118362|Drug|Plasmalyte|"Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
79387479|NCT03118362|Drug|Ringer lactate|"Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
79387480|NCT02446938|Procedure|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
79387481|NCT05132374|Other|I-T CHILD|This study will evaluate the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs
79543061|NCT01510314|Biological|C-reactive protein and procalcitonin dosages|
79543062|NCT01510340|Behavioral|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
79543063|NCT01510353|Device|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
79543064|NCT01510392|Device|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
79543065|NCT01510405|Other|Tissue Collection|Tissue sample collection
79543066|NCT01510431|Drug|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
79543067|NCT01510483|Behavioral|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
79543068|NCT01510483|Behavioral|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
79703128|NCT02756013|Drug|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
79703129|NCT02756013|Drug|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
79703130|NCT01680003|Drug|Hepar-P|
79703131|NCT01680003|Drug|Placebo for Hepar-P|
79703132|NCT01680042|Drug|Phenytoin paste|
79703133|NCT01680042|Drug|Placebo|
79703134|NCT01646229|Other|Polymyxin-B hemoperfusion|
79703135|NCT01646229|Other|Control|
79703136|NCT01680081|Other|Adenosine stress dynamic CT perfusion|
79543069|NCT01510496|Procedure|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
79845323|NCT00224029|Drug|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
80013815|NCT05475418|Procedure|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
79703137|NCT04545203|Other|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
79703138|NCT04545086|Behavioral|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
79703139|NCT01646307|Drug|Atorvastatin|
79703140|NCT01646307|Drug|Rosuvastatin|
80013816|NCT05471492|Drug|Investigational Product|PF-06480605 150 mg
79248943|NCT02492919|Device|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
79248944|NCT05101226|Behavioral|Yoga attended in person|One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
79387482|NCT03195738|Other|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
79387483|NCT03199404|Device|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
79387484|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/rilpivirine|
79387485|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/efavirenz|
79387486|NCT02447094|Drug|Alteplase|Intravenous (i.v.) tPA per the standard of care
79703141|NCT04548089|Behavioral|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
79387487|NCT02446860|Drug|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
79845324|NCT00826592|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
79387488|NCT05676346|Genetic|LUTS|Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
79543070|NCT01510496|Procedure|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
79543071|NCT01510496|Procedure|Thoracotomy .|Thoracotomy (non laparoscopic).
79543072|NCT01510509|Device|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
79543073|NCT01510509|Device|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
79543074|NCT01510522|Drug|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
79543075|NCT01510522|Drug|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: > 1.700mg/day for 6 month"
79543076|NCT01510535|Drug|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
79543077|NCT01510535|Drug|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
79543078|NCT01510535|Drug|LBSA0103|at third week LBSA0103(60mg) once in experimental group
79845325|NCT04085081|Other|E-mail|Receive brief motivational text or email messages
79845326|NCT04085081|Behavioral|Exercise Intervention|Receive personalized walking program plus strength exercises
79845327|NCT04085081|Other|Quality-of-Life Assessment|Ancillary studies
80013817|NCT05471492|Drug|Placebo|Placebo
80013818|NCT05464537|Other|Unipolar Polarity Switch Left|10-15 Left veins are randomized to Unipolar Polarity Shift, right veins are randomized to CAI-OPR-LAAP
80013819|NCT05464537|Other|Unipolar Polarity Switch Right|10-15 cases randomized to CAI-OPR-LAAP on left veins, and Unipolar Polarity Switch on right veins
80013820|NCT05462730|Drug|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
80013821|NCT05462730|Drug|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
79543079|NCT01510548|Biological|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
79248945|NCT05101226|Behavioral|Yoga attended online|One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
79248946|NCT03324087|Diagnostic Test|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
79248947|NCT03324009|Diagnostic Test|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
79703142|NCT04545359|Behavioral|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
79248948|NCT02838901|Drug|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
79703143|NCT04545359|Behavioral|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
79703144|NCT01680276|Behavioral|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
79703145|NCT01680276|Other|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
79845328|NCT04085081|Other|Questionnaire Administration|Ancillary studies
79845329|NCT04085081|Behavioral|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
79845330|NCT04085081|Other|Text Message|Receive brief motivational text or email messages
79845331|NCT03969979|Diagnostic Test|Shear wave elastography|shear wave elastogrophy will be performed
80013822|NCT05459948|Device|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
80013823|NCT05457933|Drug|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
79248949|NCT02838901|Drug|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
80013824|NCT05457933|Drug|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
79543080|NCT01510561|Drug|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
80013825|NCT05456724|Drug|TO-O-1001|TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
80013826|NCT05456724|Other|Placebo|The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
80013827|NCT05450159|Behavioral|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
80013828|NCT05450159|Behavioral|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
80013829|NCT05447312|Other|Adaptive Music Intervention|Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.
80013830|NCT05447312|Other|Traditional Music Intervention|Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
79248950|NCT03328377|Diagnostic Test|Metagenomic analysis of gut microbiota|All patients have rectal swaps/fecal samples subjected to metagenomic analysis
79248951|NCT05098106|Diagnostic Test|Bronchoscopy, blood sampling; testing.|BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
79248952|NCT03328299|Drug|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
79248953|NCT03328299|Drug|bupivacaine|20 ml of 0.5 % bupivacaine
79248954|NCT05097872|Other|Diet|Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
79248955|NCT05091554|Procedure|intraoral ice pack application|Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
79543081|NCT01510561|Drug|90Y-hPAM4|
79543082|NCT01510561|Drug|90Y-hPAM4 + gemcitabine|
79543083|NCT01510574|Drug|Misoprostol|3 x 200mcg tablets of oral misoprostol
79543084|NCT01510574|Drug|placebo|3 x placebo tablets resembling misoprostol taken orally
79703146|NCT02214914|Drug|BI 11634 drinking solution|
79703147|NCT02214914|Drug|BI 11634 tablet|
80013831|NCT05442840|Combination Product|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
79248956|NCT03564301|Drug|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
79248957|NCT03564301|Drug|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
79248958|NCT03335397|Device|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
79248959|NCT03335397|Other|Traditional learning process|Traditional content available in university library.
79387489|NCT02449746|Biological|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
79387490|NCT02449746|Biological|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
79543085|NCT01510587|Behavioral|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
79387491|NCT03199560|Drug|Tc 99m tilmanocept|lymphatic mapping agent
79387492|NCT03199560|Drug|Tc 99m filtered sulfur colloid|lymphatic mapping agent
79387493|NCT02446782|Drug|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
79543086|NCT01510587|Behavioral|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
79543087|NCT01510600|Genetic|DNA analysis|
79543088|NCT01510600|Genetic|polymerase chain reaction|
79248960|NCT03328143|Drug|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
79387494|NCT02446782|Other|saline|100 mL normal saline 15-30 minutes before the start of the procedure
79543089|NCT01510600|Other|laboratory biomarker analysis|
79543090|NCT01510600|Other|medical chart review|
79543091|NCT01510613|Drug|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
79543092|NCT01510626|Dietary Supplement|Food proteins|Food proteins
79703148|NCT02214914|Drug|Placebo|
79710019|NCT00597363|Device|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH & Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
80013832|NCT05438953|Biological|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
79248961|NCT05079854|Drug|Intraocular Instillation Solution|Intracameral Moxifloxacin 0.5%
79248962|NCT05079854|Drug|Moxifloxacin Ophthalmic|Topical Moxifloxacin 0.5%
79387495|NCT06076512|Behavioral|Behavioral therapy|Behavioral and supportive therapy
79387496|NCT06076486|Drug|Elagolix|Elagolix 200 mg tablets administered orally BID
79387497|NCT06076486|Drug|Elagolix placebo|Elagolix placebo administered orally BID
79543093|NCT01510626|Drug|Omalizumab|Drug
79543094|NCT01510639|Biological|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
79543095|NCT01510665|Dietary Supplement|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
79543096|NCT01510665|Dietary Supplement|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
79703149|NCT04544969|Drug|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
79710020|NCT00597363|Other|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
79845332|NCT00817154|Behavioral|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
79248963|NCT03323931|Behavioral|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
79248964|NCT03323931|Behavioral|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
79387498|NCT06076460|Other|Early Total Enteral Feeding|This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
79543097|NCT01510665|Behavioral|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
79248965|NCT05116436|Procedure|Blood sample|It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
79248966|NCT05116436|Procedure|Spine X-ray|To determine the scoliosis
79248967|NCT03335319|Other|Periodized Exercise Training Regime|MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or > 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
79387499|NCT06076460|Other|Conventional Enteral Feeding|This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
79543098|NCT01510730|Drug|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
79543099|NCT01510743|Procedure|Catheterization of subclavian vein|Catheterization of subclavian vein
79543100|NCT01510743|Procedure|Catheterization of internal jugular vein|Catheterization of internal jugular vein
79543101|NCT01510782|Drug|Placebo to BI 655064|intravenous infusion of escalating doses
79543102|NCT01510782|Drug|Placebo to BI 655064|subcutaneous injection of escalating doses
79543103|NCT01510782|Drug|BI 655064|intravenous infusion of escalating doses
79543104|NCT01510782|Drug|BI 655064|subcutaneous injection of escalating doses
79543105|NCT01510795|Drug|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
79543106|NCT01510808|Procedure|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
79543107|NCT01510821|Other|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
79543108|NCT01510821|Other|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
79543109|NCT01510847|Drug|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
79703150|NCT01646463|Behavioral|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
79248968|NCT03335319|Other|Non Periodized Exercise Training Regime|To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
79710021|NCT00599508|Dietary Supplement|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
79387500|NCT06076434|Other|The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region|The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
79710022|NCT00599508|Dietary Supplement|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
79845333|NCT02591381|Procedure|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
79845334|NCT00929370|Drug|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
79845335|NCT00817232|Device|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
79543110|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|250 mg
79845336|NCT03967795|Drug|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
79543111|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|500 mg
79845337|NCT04086251|Other|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
79845338|NCT00907764|Drug|regadenoson|400 ug, IV
79845339|NCT02550314|Drug|fiblast,gelatin sponge,fibrin glue|
79248969|NCT05116358|Device|Phototherapy device|The active phototherapy device will emit light
79248970|NCT03327987|Biological|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
79248971|NCT03335241|Drug|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
79543112|NCT01510873|Other|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
79543113|NCT01510899|Drug|RO4917838|Single dose of RO4917838
79543114|NCT01510899|Drug|RO4917838|Single dose of RO4917838
79845340|NCT00987987|Procedure|donor lymphocyte infusion|regulatory T cells depletion
79845341|NCT01073527|Drug|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
79845342|NCT01073527|Drug|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
79845343|NCT00822458|Drug|vismodegib|Given orally
79845344|NCT00822458|Other|laboratory biomarker analysis|
79845345|NCT00822458|Other|pharmacological study|
79845346|NCT00223795|Device|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
79845347|NCT02538432|Drug|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
79248972|NCT03335241|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
79302825|NCT03074799|Other|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
79703151|NCT01646463|Behavioral|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
79703152|NCT01680354|Procedure|ReLEx|
79703153|NCT01680354|Procedure|LASIK|
79703154|NCT04544657|Other|no intervention|No intervention for enrolled patients
79845348|NCT02538432|Drug|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
79845349|NCT01563627|Other|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
79845350|NCT01563627|Device|Magnetic Resonance Imaging|
79845351|NCT00826670|Drug|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
79845352|NCT00826670|Drug|Placebo (Decolonization)|Placebo
80013833|NCT05434130|Behavioral|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
80013834|NCT05433584|Drug|Tirzepatide|Administered SC
80013835|NCT05433584|Drug|Antihyperglycemic medication|As prescribed
80013836|NCT05426057|Behavioral|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
79387501|NCT06076382|Procedure|endoscopic ultrasound guided colorectal ESD surgery|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
79387502|NCT06076382|Procedure|the traditional colorectal ESD surgery|The control group underwent injection and dissection directly.
79543115|NCT01510938|Dietary Supplement|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
79543116|NCT01510938|Dietary Supplement|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
79703155|NCT01646502|Biological|Esp protein|
79703156|NCT01646502|Other|Standard wound care|
79703157|NCT01680393|Device|Sequential compression device|a sequential compression device will be applied to the legs
79703158|NCT01680393|Other|TED stockings|TED stockings will be applied to the patients legs during surgery
79703159|NCT04544579|Device|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
79703160|NCT04541732|Other|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
79703161|NCT04541732|Other|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
79703162|NCT04541732|Drug|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
79703163|NCT04541732|Drug|Muscle Relaxant|Atracurium : 0.5mg/Kg.
79703164|NCT04541732|Drug|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
79703165|NCT04544774|Drug|AIT|AIT for airborn allergens (SCIT/SLIT)
79845353|NCT00719849|Biological|anti-thymocyte globulin|30mg/Kg Days -6 to -4
79845354|NCT00719849|Drug|cyclophosphamide|50 mg/Kg Day -6
80013837|NCT05416307|Drug|ELA026|Single or multiple daily doses of ELA026
80013838|NCT05415085|Procedure|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
79543117|NCT01510951|Drug|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
79703166|NCT04544774|Diagnostic Test|NAPT|NAPT test with airborn allergens ( HDM, Threes, Grasses)
79703167|NCT01680432|Dietary Supplement|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
79845355|NCT00719849|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
79845356|NCT00719849|Drug|fludarabine phosphate|40mg/m2 Days -6 to -2
79845357|NCT00719849|Drug|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
79845358|NCT00719849|Procedure|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
79845359|NCT00719849|Radiation|total body irradiation|200 cGy Day -1
79845360|NCT02549612|Device|Moniri Otovent|Please see arm description.
79302826|NCT03074799|Other|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
79845361|NCT03775239|Behavioral|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing & Exploring Week 3: Avoidance & Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
79387503|NCT06076369|Procedure|The tubular adenoma group|Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
79387504|NCT06076343|Behavioral|DBT skills-training and Family Connections interventions|"DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills."
79387505|NCT06076330|Biological|20% Albumin|S. albumin > 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin < 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr
79387506|NCT06076330|Biological|5% Albumin|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP >65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
79387507|NCT06076330|Drug|Plasmalyte|Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
79387508|NCT06076278|Procedure|resistance exercise|Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
79543118|NCT01510964|Behavioral|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
79703168|NCT01680432|Dietary Supplement|Regular Cheese|
79387509|NCT06076265|Procedure|Radical Gastric Cancer Surgery|Laparoscopic (robotic) radical surgery for gastric cancer
79387510|NCT06076252|Procedure|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
79387511|NCT06076252|Procedure|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
79703169|NCT04541927|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
79703170|NCT04542044|Other|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
79703171|NCT02279277|Behavioral|Supervised physical therapy program prior to total knee replacement surgery|
79703172|NCT04544423|Other|Block group|Patients received lumbar erector spinae plane Block before operation
79703173|NCT01680471|Drug|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
79710023|NCT00599508|Dietary Supplement|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
79391589|NCT02409420|Behavioral|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
79543119|NCT01510964|Behavioral|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
79543120|NCT01510977|Drug|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
79543121|NCT01510977|Drug|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
79543122|NCT01510990|Drug|Gefitinib|gefitinib 250mg/day daily
79543123|NCT01511003|Drug|Tacrolimus|oral
79387512|NCT06076239|Other|ESWT Group|EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (<0.28 mJ/mm2).
79703174|NCT01680471|Drug|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
79703175|NCT01680471|Drug|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
79703176|NCT02215304|Dietary Supplement|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
79845362|NCT03775239|Behavioral|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
79845363|NCT00907842|Device|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
79845364|NCT00822536|Drug|Aspirin and Clopidogrel|Aspirin <= 325 mg/j Clopidogrel = 75 mg /j
79387513|NCT06076239|Other|Control Group|Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
79387514|NCT06076226|Other|No intervention, observation study|No intervention, observation study
79387515|NCT06076200|Drug|Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
79387516|NCT06076187|Other|Dual isotope method|Dual isotope method
79387517|NCT06076148|Device|Virtual reality games|three individual games (physical, cognitive and relaxation) and two multiplayer games will be tested.
79387518|NCT06076122|Dietary Supplement|Food supplement based on Salicornia extracts|Freshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain [https://evesa.com/]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain [https://www.bio-dis.com/]), experts in food supplements and certified for such procedures.
79387519|NCT06076122|Dietary Supplement|Placebo|Placebo capsules physically equal to the Salicornia extracts capsules
79543124|NCT01511029|Drug|Dexpramipexole|300 mg - Oral Tablets
79543125|NCT01511029|Drug|Dexpramipexole|600 mg Oral Tablets
79543126|NCT01511029|Drug|Dexpramipexole Placebo|Placebo - Oral Tablet
79543127|NCT01511029|Drug|Moxifloxacin|400 mg - Oral Tablet
79543128|NCT01511094|Procedure|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
79543129|NCT01511120|Drug|Tetraspan|
79845365|NCT00822536|Drug|Aspirin|Aspirin : <= 325 mg/j
79845366|NCT04015752|Diagnostic Test|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
79543130|NCT01511120|Drug|acetated Ringer's solution|
79845367|NCT00826826|Procedure|Catheter ablation|(Pulmonary vein isolation)
79845368|NCT00826826|Drug|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
79845369|NCT00826826|Drug|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
79845370|NCT00925860|Procedure|non positive pressure mechanical ventilatory support|
79543131|NCT01511133|Procedure|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
79543132|NCT01511133|Procedure|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
79543133|NCT01511146|Drug|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
79543134|NCT01511146|Drug|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
79543135|NCT01511159|Drug|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
79543136|NCT01511159|Drug|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
79543137|NCT01511159|Drug|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
79543138|NCT01511159|Drug|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
79703177|NCT02215304|Dietary Supplement|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
79703178|NCT02215304|Dietary Supplement|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
79703179|NCT02215304|Dietary Supplement|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
79703180|NCT02279316|Drug|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
79703181|NCT02279316|Other|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
79703182|NCT02279316|Other|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
79845371|NCT02592941|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
79845372|NCT00817388|Other|No intervention|No intervention
79845373|NCT05013996|Behavioral|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
79845374|NCT05013996|Behavioral|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
79387520|NCT06076109|Other|Prone position|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
79845375|NCT00822614|Drug|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
79845376|NCT00822614|Drug|Opioid|Current optimized BTP treatment
79845377|NCT00907920|Other|laboratory biomarker analysis|Correlative studies
79845378|NCT04087967|Drug|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~16,intravenous infusion; Aclarubicin:10mg/d, d3~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
79845379|NCT04087967|Drug|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
79845380|NCT03735693|Diagnostic Test|Ulstrasound|measurement of right femoral cross-section
79387521|NCT06076109|Other|Standard treatment|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
79387522|NCT06076096|Other|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
79387523|NCT06076057|Diagnostic Test|vital signs monitoring|Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
79543139|NCT01511159|Drug|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
79845381|NCT02549456|Procedure|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
80013839|NCT05412758|Dietary Supplement|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
80013840|NCT05412277|Other|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
79543140|NCT01511159|Drug|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
79543141|NCT01511159|Drug|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
79543142|NCT01511172|Drug|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
79543143|NCT01511172|Drug|metformin|1000 mg daily, administered orally
79543144|NCT01511172|Drug|placebo|Metformin placebo administered orally. 1000 mg daily
79543145|NCT01511172|Drug|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
79543146|NCT01511172|Drug|glimepiride|Individually adjusted dose, administered orally
79543147|NCT01511185|Drug|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
79543148|NCT01511185|Drug|placebo|A single dose administered subcutaneously in random order
79543149|NCT01511198|Drug|liraglutide|Injected subcutaneously once daily
79703183|NCT04544306|Other|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
79703184|NCT01680588|Drug|[18F]NAV4694|
80013841|NCT05409833|Diagnostic Test|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
80013842|NCT05408962|Other|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
79248973|NCT03525860|Procedure|Acupuncture|"The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~."
79248974|NCT03327831|Drug|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
79248975|NCT03120663|Drug|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
79387524|NCT06076031|Behavioral|Streaming Media|The aim of this study is to conduct a cross-over randomized clinical trial to compare the effects of with using streaming media (video and audio) on reducing pain medication use, anxiety, pain intensity, and factors related to pain during dressing changes for second-degree burn patients.
79387525|NCT06075992|Other|experimental group|An experimental application will not be made to premature babies in this group.
79387526|NCT06075940|Device|MAGNITUDE BRS|Treatment with the MAGNITUDE Scaffold
79387527|NCT06075927|Biological|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10^7 cells/m2 Level Two: 2 x 10^7cells/m2 Level Three: 5x 10^7 cellss/m2"
79387528|NCT06075914|Other|Ketogenic Intervention|Participants will receive ready-to-eat Ketogenic Diet meals.
79387529|NCT06075914|Other|Mediterranean Intervention|Participants will receive ready-to-eat Mediterranean Diet meals.
79387530|NCT06075914|Dietary Supplement|Placebo|Participants will receive twice-daily placebo servings to be consumed once in the morning and once before sleep.
79387531|NCT06075914|Dietary Supplement|Ketone Ester|Participants will receive twice-daily ketone ester servings to be consumed once in the morning and once before sleep.
79387532|NCT06075901|Device|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
79387533|NCT06075901|Device|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
79387534|NCT06075901|Other|Training Protocol|The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
79387535|NCT06075680|Procedure|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
79387536|NCT06075641|Procedure|Gingival depigmentation|Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
79387537|NCT06075628|Other|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
79387538|NCT06075602|Device|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
79543150|NCT01511198|Drug|metformin|1000 mg twice daily, administered orally
79710024|NCT00599508|Dietary Supplement|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
79710025|NCT00599508|Dietary Supplement|berry placebo powder|berry placebo powder administered daily for 16 weeks
79710026|NCT01330316|Drug|BI 201335|BI 201335 for 24 weeks
79710027|NCT01330316|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
79710028|NCT00599547|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
79710029|NCT01316198|Dietary Supplement|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
79703185|NCT04544228|Procedure|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
79703186|NCT04544228|Procedure|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
79703187|NCT04544228|Drug|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
79703188|NCT04544228|Drug|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
79703189|NCT04544228|Drug|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
79703190|NCT04544540|Other|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
79703191|NCT02279433|Drug|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
79703192|NCT04544345|Device|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
79703193|NCT04544345|Device|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
79387539|NCT06075563|Radiation|Total lymphoid irradiation|Total lymphoid irradiation (TLI) 6Gy by tomotherapy as part of conditioning treatment before haploidentical hematopoietic stem cell transplant
79387540|NCT06075550|Other|single cone technique using TotalFill BC Sealer|Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
79543151|NCT01511211|Drug|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
80013843|NCT05408611|Other|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
79703194|NCT01680627|Behavioral|CASI|
79703195|NCT01680744|Other|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
79703196|NCT01646697|Other|cytology specimen collection procedure|Undergo cytopathologic sample collection
79703197|NCT04541771|Drug|Lactobacillus Reuteri DSM 17938|The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
79703198|NCT04541771|Drug|Placebo|expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
79703199|NCT01646736|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
79703200|NCT01646736|Drug|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
79703201|NCT01646736|Drug|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
80013844|NCT05408611|Other|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
80013845|NCT05406531|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
79387541|NCT06075550|Other|warm vertical compaction technique using TotalFill BC Sealer HiFlow|TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
79387542|NCT06075524|Procedure|Biospecimen Collection|Undergo blood and optional stool/tissue sample collection
79387543|NCT06075524|Other|Electronic Health Record Review|Medical records are reviewed
79543152|NCT01511211|Drug|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
79387544|NCT06075485|Other|Ketocal|ketogene diet
79387545|NCT06075472|Other|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.
79387546|NCT06075472|Other|Balance Exercises|Balance exercises involve functional movements at the individual's maximum level of independence.
79387547|NCT06075446|Behavioral|ACT Raising Safe Kids|American Psychological Association ACT Raising Safe Kids
79543153|NCT01511237|Drug|Nevirapine, zidovudine, lamivudine|"Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~3TC syrup 2 mg/kg every 12 hours for four weeks."
79703202|NCT04542005|Behavioral|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
79543154|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
79543155|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year."
79703203|NCT01646775|Drug|epidural fentanyl|withold epidural fentanyl
79703204|NCT01680978|Drug|aleglitazar|150 mcg orally daily, 6 weeks
80013846|NCT05406531|Behavioral|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
80013847|NCT05406531|Behavioral|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
79543156|NCT01511276|Behavioral|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
79543157|NCT01511276|Behavioral|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
80013848|NCT05400694|Other|Food|Dairy products with reduced sugar content
79703205|NCT01680978|Drug|placebo|orally daily, 6 weeks
79387548|NCT06075381|Combination Product|Pulmonary Expansion Device (PED)|The Pulmonary Expansion Device constitutes an innovative instrumental technique for lung expansion, designed for use in patients with or without an artificial airway. This device is attached to the artificial airway, the oronasal mask, or the patient's mouth. It enables voluntary control through a system of one-way valves that restrict the air's escape from the lungs to the outside. This creates an environment conducive to retaining air within the lungs, thereby increasing intrapulmonary pressure. Additionally, it reduces the risk of pulmonary complications associated with conventional management, employing a strategy free from exogenous application of positive pressure to the airway. This approach doesn't necessitate expensive equipment or electrical power.
80013849|NCT05400590|Procedure|Peripheral venous blood sample|2.5% of body weight
79543158|NCT01511289|Drug|Imatinib|400mg/Tab, QD
79703206|NCT04541576|Device|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
79703207|NCT01646853|Radiation|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
79703208|NCT01646853|Drug|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
79543159|NCT01511289|Drug|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
79703209|NCT04541459|Device|new device against ambient electromagnetic radiation|New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
79703210|NCT04541459|Device|sham device against ambient electromagnetic radiation|Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
79703211|NCT01647165|Drug|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
79703212|NCT01647165|Drug|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
79703213|NCT01647165|Drug|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
80013850|NCT05400590|Procedure|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
80013851|NCT05392075|Biological|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
80013852|NCT05392075|Biological|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
80013853|NCT05390840|Drug|MG-O-1002|MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
79543160|NCT01511302|Drug|RNS60|RNS60, 2ml, nebulized twice daily.
79543161|NCT01511302|Drug|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
79543162|NCT01511302|Drug|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
79703214|NCT01681056|Behavioral|Autosuggestion for 30 days|
79703215|NCT01681134|Drug|Advagraf®|oral
79703216|NCT01681134|Drug|Prograf®|oral
79703217|NCT04543916|Drug|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
79703218|NCT04543916|Drug|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
80013854|NCT05390840|Other|Placebo|The placebo is 0.9% saline ocular administration 3 drops in study eye
79543163|NCT01511341|Behavioral|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
79703219|NCT04543916|Drug|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
79703220|NCT04543916|Drug|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
80013855|NCT05389644|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
80013856|NCT05388760|Drug|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment).
79703221|NCT04543916|Drug|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
79703222|NCT04543916|Drug|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
79703223|NCT04543916|Drug|Venetoclax (RP2D)|orally, once per day
80013857|NCT05386927|Other|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
80013858|NCT05376371|Other|CJC-TraC|CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
80013859|NCT05362916|Drug|Letermovir|Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.
80013860|NCT05358925|Other|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 10-12 minutes long, for a total of ~120 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: the history of the diagnosis of BPD and current diagnostic criteria, challenging BPD-related stigma, developmental pathways to BPD and biological predisposition, prevalence of BPD and its common comorbid disorders, the naturalistic course of BPD without treatment, available psychotherapeutic treatment options for BPD, current research on the neurobiological and genetic markers related to BPD, the interpersonal hypersensitivity model of BPD, lifestyle changes that are beneficial for people with BPD"
79703226|NCT01681173|Dietary Supplement|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
79703227|NCT01681173|Dietary Supplement|Placebo|200ml Placebo, BID, over 24 months
79703228|NCT02214953|Drug|BI 11634 ER formulation A|
79543164|NCT01511367|Drug|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
79543165|NCT01511367|Drug|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
79543166|NCT01511367|Drug|Flixotide|50ug 2 puffs twice daily
79703229|NCT02214953|Drug|BI 11634 ER formulation B|
79703230|NCT02214953|Drug|BI 11634 ER formulation M|
79703231|NCT02214953|Drug|BI 11634 ER formulation C|
79703232|NCT02214953|Drug|BI 11634 IR tablet|
79703233|NCT01647204|Other|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
79703234|NCT04541303|Drug|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
79703235|NCT04541303|Drug|normal saline|0.9% sodium chloride
79703236|NCT01647243|Other|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
79703237|NCT02214992|Drug|Telmisartan/Ramipril|Fixed dose combination tablet
79703238|NCT02214992|Drug|Telmisartan|
79703239|NCT02214992|Drug|Ramipril capsule|
79703240|NCT02214992|Drug|Ramipril tablet|
79703241|NCT01647321|Behavioral|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
79703242|NCT01647321|Behavioral|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
79703243|NCT04544150|Other||
79703244|NCT01681290|Drug|CBX129801|
79703245|NCT04543721|Device|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
79703246|NCT04528095|Drug|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
79703247|NCT04528095|Device|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
79703248|NCT04528095|Device|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
79703249|NCT04541264|Diagnostic Test|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
79703250|NCT04543604|Behavioral|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
79703251|NCT04543604|Behavioral|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
79703252|NCT04528056|Drug|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
79703253|NCT04528056|Drug|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
79703254|NCT04528056|Drug|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
79703255|NCT04528056|Drug|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
79710030|NCT01316198|Dietary Supplement|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
80013861|NCT05358925|Other|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from all time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
80013862|NCT05358925|Other|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, lifestyle changes to combat stress, what is psychotherapy?, prevalence of depression and anxiety in the general population, healthy sleep habits.
79710031|NCT00599586|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
79710032|NCT01316237|Drug|GS-6620|GS-6620 tablet, 50 mg QD
80013863|NCT05355623|Procedure|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
80013864|NCT05347667|Other|Unilateral Resistance Exercise Leg|One leg will perform unilateral resistance exercise
80013865|NCT05347667|Other|Control Leg|One leg will serve as a non-exercise control
80013866|NCT05344534|Behavioral|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
79387549|NCT06075381|Procedure|Conventional management|The conventional management includes: Adequate postoperative pain control, global postural reeducation, reeducation of breathing pattern, airway hygiene, early mobilization, respiratory and scapular waist exercises, and in patients with evidence of lung atelectasis or mild persistent hypoxemia, conventional management will involve the use of intermittent positive pressure ventilation in the airway.
79387550|NCT06075342|Behavioral|exercise|Exercise intervention according to the training program
79710033|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD
80013867|NCT05338892|Other|Non-Interventional|No study treatment will be administered on this study.
79387551|NCT06075303|Behavioral|Modified Cycles|
79387552|NCT06075238|Drug|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
80013868|NCT05335408|Device|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
79387553|NCT06075225|Drug|Ruxolitinib|Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
79387554|NCT06075212|Drug|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
79387555|NCT06075186|Other|A survey to assess anesthesiologists' secondary victim experience and quality of support resources.|cross-sectional descriptive questionnaire
79710034|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD
79710035|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
79710036|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
79710037|NCT01316237|Drug|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
79248976|NCT03327753|Behavioral|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
79387556|NCT06075173|Diagnostic Test|Resting full-cycle ration (RFR) measurments|RFR and FFR measurements in main vessel and side branch lesions
80013869|NCT05335408|Device|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
79387557|NCT06075160|Diagnostic Test|Resting full-cycle ratio (RFR)-guided revascularization|The decision of coronary intervention is based on an RFR cut-value of 0.89. If RFR ≤ 0.89, target lesion will be revascularized, and if RFR > 0.89, PCI will be deferred. However, even if RFR ≤ 0.89, PCI can be deferred if the RFR gradient of the lesion ≤ 0.02, or if the diffused type of stenosis, because physiological gain is expected to be very low.
79387558|NCT06075160|Diagnostic Test|Fractional flow ratio (FFR)-guided revascularization|Study participants of FFR-guided PCI arm will be selected from a large-scaled, ongoing FFR registry. The decision of coronary intervention is based on an FFR cut-value of 0.80. If FFR ≤ 0.80, target lesion will be revascularized, and if RFR > 0.80, PCI will be deferred.
79387559|NCT06075134|Procedure|Botox injection|Botox injection
79387560|NCT06075134|Device|EMG|Quantitative Electromyography
79543167|NCT01511380|Behavioral|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
79543168|NCT01511380|Behavioral|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
79703256|NCT04541342|Procedure|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
79703257|NCT04543565|Drug|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
79703258|NCT04543565|Drug|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
79703259|NCT01681329|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
79703260|NCT01681329|Other|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
79703261|NCT02215343|Dietary Supplement|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R&D Centre Europe).
79703262|NCT02215343|Dietary Supplement|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
79703263|NCT01647477|Behavioral|interview|25 minutes of semi directive interview
79703264|NCT01647477|Behavioral|questionnaires|questionnaires to answer at baseline 45 minutes
79703265|NCT04540991|Procedure|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
80013870|NCT05323734|Drug|Ganaxalone|GNX will be administered
79710038|NCT01316237|Drug|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
79710039|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900mg , BID
79710040|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900 mg
80013871|NCT05323734|Drug|Placebo|Placebo will be administered
80013872|NCT05317000|Drug|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
79387561|NCT06075134|Drug|Zinc Supplement|To increase efficacy of Botox
79387562|NCT06075121|Other|Abdominal massage|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
79387563|NCT06075108|Other|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
79387564|NCT06075082|Device|LEFT smartwatch app|The LEFT smartwatch app is an app on the Apple Watch which measures body sleep position and gently vibrates when the body is in the right lateral decubitus position. In this way, patients with nocturnal gastroesophageal reflux symptoms learn to avoid the right lateral sleep position as they will avoid the annoying vibrations. Measurements while using the smartwatch app will be compared to measurements at baseline.
79387565|NCT06075069|Device|Feeding appliance|A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
79387566|NCT06075056|Other|No Intervention|No intervention is planned as part of this study, this is a feasibility/pilot study
79387567|NCT06074991|Other|musıc therapy|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
79387568|NCT06074965|Device|Medtronic Extended Infusion Set|Each subject will be given 2 types of infusion sets to wear and change sets per label use (3 days for Medtronic Quick-set™ and 7 days for Medtronic Extended).
79845382|NCT02549456|Procedure|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
80013873|NCT05317000|Drug|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
79387569|NCT06074952|Other|Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)|Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.
79387570|NCT06074913|Other|infrared thermography (IRT)|Temperatures and infrared thermograms were recorded in the region of the extremities of three groups of subjects by using an infrared thermographic camera.
79387571|NCT06074913|Procedure|Basal therapy+EA|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen. 2. Acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject.
79387572|NCT06074913|Other|Basal therapy|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen.
79387573|NCT06074900|Other|prospective cohort study|"This study is observational in nature and does not involve any experimental treatments or additional radiographs, diagnostic tests or clinical interventions beyond what is regularly prescribed within the context of standard of care for each patient.~Outcomes for participants will be measured and captured primarily during regularly scheduled clinic/hospital visits, which include standard of care clinical examinations. Participants will be asked to complete study questionnaires as per the visit schedule and participant data will be recorded on applicable study CRFs at the appropriate time points. CRFs detailing patient, injury, and treatment variables of interested will be collected at the time of recruitment."
79703266|NCT04540991|Procedure|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
79703267|NCT04540991|Diagnostic Test|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
79703268|NCT01647555|Drug|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
79703269|NCT01647555|Radiation|Radiotherapy|Curative dose: 66 to 70 Gy
79710041|NCT02892084|Device|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
80013874|NCT05317000|Drug|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
80013875|NCT05315713|Drug|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
80013876|NCT05315713|Drug|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
79248977|NCT03327753|Behavioral|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
79248978|NCT05042180|Behavioral|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
80013877|NCT05315713|Drug|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
80013878|NCT05315713|Other|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
79845383|NCT04087577|Other|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
80013879|NCT05299086|Drug|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
80013880|NCT05298345|Other|Anthem Strong Families TYRO Champion Program Primary Services|Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula. Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs.
80013881|NCT05293145|Other|Building Futures Program Primary Services|Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops, or 16 hours of Survival Skills for Healthy Families curricula delivered over one weekend followed by 2 hours of a Reflections Workshop delivered two weeks later. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
79248979|NCT05042180|Behavioral|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
79248980|NCT04493307|Diagnostic Test|Phlebotomy|Serial assessment of hemostasis by blood and urine collection
79248981|NCT02578394|Drug|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
79387574|NCT06074887|Behavioral|transtheoretical model-based intervention|"Pretest data are collected for patients in the intervention group in a face-to-face interview in the hospital setting.~The training prepared according to the behavior change phase will be conducted one week later in the patients' home environment and the required data will be collected.~In the fourth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the eighth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the twelfth week of the study, the patient will be visited at home and final tests will be collected."
79387575|NCT06074874|Other|Intestinal tissue analysis|Intestinal tissue analysis
79387576|NCT06074848|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.
79543169|NCT01511406|Behavioral|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
79248982|NCT02578394|Drug|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
79248983|NCT04493229|Drug|Oxytocin|IM Oxytocin
79248984|NCT04493229|Drug|Placebo|Placebo IM
79248985|NCT04984148|Diagnostic Test|CT|Contrast-enhanced thoracic computed tomography
79543170|NCT01511432|Drug|telaprevir formulation A|A single 1125-mg dose administered orally
79543171|NCT01511432|Drug|telaprevir Formulation B|A single 1125-mg dose administered orally
79543172|NCT01511432|Drug|telaprevir Formulation C|A single 1125-mg dose administered orally
79543173|NCT01511432|Drug|telaprevir Formulation D|A single 1125-mg dose administered orally
79845384|NCT04087577|Other|mirror therapy|mirror therapy
79248986|NCT03323775|Diagnostic Test|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
79387577|NCT06074848|Behavioral|Motor Training|Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7*age). Just for the arms of fatigue and pain.
79845385|NCT04196751|Other|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6&12 month with pre-specified tools.
79248987|NCT03120273|Drug|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
79248988|NCT03120273|Drug|Lansoprazole Injection|30 mg q12h for 5 days.
79845386|NCT00926016|Drug|Pioglitazone (Actos)|pioglitazone 45 mg a day
79248989|NCT02122718|Drug|Allopurinol|
79248990|NCT02122718|Drug|Placebo|
79248991|NCT04244084|Drug|MMH-407|Oral use.
79703270|NCT04541615|Procedure|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
79703271|NCT04541615|Procedure|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
80013882|NCT05292963|Other|Intervention #1: Fatherhood Works Program Delivered to Participants|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
80013883|NCT05284240|Device|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
80013884|NCT05283330|Drug|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
79248992|NCT04244084|Drug|Placebo|Oral use.
79248993|NCT04979156|Procedure|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
79248994|NCT04974476|Other|HIIT Exercise Training|The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, >80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
79703272|NCT04541615|Procedure|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
79387578|NCT06074848|Behavioral|Cognitive Training|an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
79703273|NCT04541615|Procedure|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
79248995|NCT04513652|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
79248996|NCT04513652|Drug|Placebo|Placebo Topical Ophthalmic Solution
79387579|NCT06074822|Other|Residual neuromuscular biopsy|recovery of residual neuromuscular biopsy (nerve ans muscle)
79387580|NCT06074809|Drug|Modified Guizhi Fuling granules|Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
79387581|NCT06074809|Other|Placebo|Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
79391590|NCT02409576|Biological|Expanded , Activated NK cells|"Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
79703274|NCT01647594|Behavioral|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
79703275|NCT01647594|Behavioral|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
79703276|NCT04543448|Other|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
79845387|NCT04017104|Diagnostic Test|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
79845388|NCT04017104|Diagnostic Test|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
80013885|NCT05279495|Device|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
80013886|NCT05279495|Device|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
79248997|NCT04234802|Other|Heat Education and Awareness Tools|HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
79248998|NCT02060162|Other|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
79248999|NCT00706797|Drug|etanercept (EnbrelTM)|
79249000|NCT00706797|Drug|methotrexate|
79249001|NCT03323697|Other|SZ-05|2.5g a day (3 capsules twice a day)
79387582|NCT06074783|Biological|Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)|50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
79387583|NCT06074770|Other|no intervention|Natural exposure of iodine
79387584|NCT06074757|Drug|Fulvestrant injection|phosphate ester of fulvestrant for test arm
79387585|NCT06074744|Other|SSNB + IPACK|already included in arm/group description
79387586|NCT06074744|Other|FNB + IPACK|already included in arm/group description
79387587|NCT06074731|Diagnostic Test|SS-OCT system Plex Elite 9000|We will use a commercially available SS-OCT system (Plex Elite 9000; Carl Zeiss Meditec).
79387588|NCT06074718|Other|pricking therapy and wheat grain moxibustion|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
79387589|NCT06074705|Drug|DS-1471a|Intravenous administration on Day 1 of each 28-day cycle
79543174|NCT01511471|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
79543175|NCT01511484|Behavioral|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
79543176|NCT01511484|Behavioral|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
79703277|NCT04543448|Other|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
79845389|NCT04017104|Diagnostic Test|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
79703278|NCT04543370|Drug|Edasalonexent 2000 mg TID|CAT-1004 capsules
79703279|NCT04543370|Drug|Midazolam 2 MG/ML|2 mg/ml syrup
79249002|NCT03323697|Drug|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
79387590|NCT06074679|Procedure|Open cholecystectomy|The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
79387591|NCT06074601|Diagnostic Test|Mirvie Predictive Test for Adverse Pregnancy Outcomes|This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
79387592|NCT06074575|Behavioral|Emotion induction|The participants will receive different emotion inductions through short video clips.
79703280|NCT04543370|Drug|Deflazacort 36Mg Tab|36 mg tablets
79703281|NCT01681524|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
79249003|NCT02491593|Device|fecal occult blood test|
79387593|NCT06074536|Procedure|patient-centered approach training|face to face training of general practitioner of interventional arm
79387594|NCT06074523|Behavioral|Behavioral Measurement and self-report|Measurements of behavioral performance and self-report
79387595|NCT06074497|Drug|KGX101- Cohort 1|Single dose of 0.003 mg/kg of KGX101 every 3 weeks
79387596|NCT06074497|Drug|KGX101- Cohort 2|Single dose of 0.006 mg/kg of KGX101 every 3 weeks
79387597|NCT06074497|Drug|KGX101- Cohort 3|Single dose of 0.012 mg/kg of KGX101 every 3 weeks
79387598|NCT06074497|Drug|KGX101- Cohort 4|Single dose of 0.025 mg/kg of KGX101 every 3 weeks
79387599|NCT06074497|Drug|KGX101- Cohort 5|Single dose of 0.05 mg/kg of KGX101 every 3 weeks
79387600|NCT06074497|Drug|KGX101- Cohort 6|Single dose of 0.1 mg/kg of KGX101 every 3 weeks
79703282|NCT04528485|Other|Sea swimming|8 sessions of swimming activities in the sea
79703283|NCT04543487|Other|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
79703284|NCT01681563|Drug|Pentostatin|Lyophilized powder for intravenous administration.
79703285|NCT01681563|Drug|Cyclophosphamide|IV
79703286|NCT01681563|Drug|Ofatumumab|Liquid concentrate for solution for infusion.
79703287|NCT04543292|Device|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
79703288|NCT01681641|Other|A psycho-social intervention|
79703289|NCT04543214|Other|Enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response after surgery. It benefits patient by reducing complications and enhancing recovery and saves resources for the health care system. In this concept, surgeons work collaboratively with anesthesiologist, nurses, nutritionists and physical therapists to develop and manage the perioperative care.
79703290|NCT01681680|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
79703291|NCT04543175|Other|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
79703292|NCT01647633|Other|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
79710042|NCT02892084|Device|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
79249004|NCT00706641|Drug|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
79249005|NCT00706641|Procedure|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
79249006|NCT05465499|Procedure|ERAS|This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
79387601|NCT06074497|Drug|KGX101- Cohort 7|Single dose of 0.2 mg/kg of KGX101 every 3 weeks
79703293|NCT04541069|Behavioral|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
79249007|NCT02491203|Other|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
79703294|NCT01647672|Drug|Abraxane|Abraxane for neoadjuvant chemotherapy
79703295|NCT04540562|Other|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
79249008|NCT03335085|Drug|Oxytocin|
79703296|NCT01681719|Device|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
79710043|NCT00597480|Drug|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
79249009|NCT03335085|Other|Placebo|
79845390|NCT04015206|Other|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
79845391|NCT04799223|Other|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
79249010|NCT03327363|Device|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
79249011|NCT03323619|Procedure|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
79249012|NCT03323541|Drug|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils >1 giga/l)
79387602|NCT06074497|Drug|KGX101- Cohort 8|Single dose of 0.3 mg/kg of KGX101 every 3 weeks
79387603|NCT06074484|Drug|RC48-ADC|4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）
79387604|NCT06074484|Drug|AK104|4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
79543177|NCT01511484|Behavioral|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
79543178|NCT01511497|Biological|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
79543179|NCT01511497|Other|Normal saline|Intravenous, normal saline
79543180|NCT01511510|Drug|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
79543181|NCT01511510|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
79845392|NCT04799223|Other|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
79249013|NCT03335007|Drug|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
79249014|NCT03335007|Other|Placebo|Placebo tablet given one hour before starting the root canal treatment
79249015|NCT03327285|Biological|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
79249016|NCT01362530|Drug|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
79249017|NCT01362530|Drug|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
79249018|NCT01362530|Drug|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
79249019|NCT01362530|Drug|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
79249020|NCT01362530|Drug|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
79249021|NCT01362530|Drug|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
79387605|NCT06074445|Other|No intervention|No intervention
79387606|NCT06074432|Other|Emergency Colorectal Resection|Patients underwent resection due to colorectal carcinoma in emergency surgery
79387607|NCT06074419|Device|Occulus quest 2 virtual reality glasses|Patients will be shown nature videos via the specified virtual reality connection.
79543182|NCT01511510|Drug|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
79543183|NCT01511510|Drug|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
79543184|NCT01511510|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
79543185|NCT01511523|Dietary Supplement|RGMA001|3 capsules administered BID once a day.
79543186|NCT01511523|Dietary Supplement|Sugar Pill|Placebo
79703297|NCT01681719|Device|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
79703298|NCT01681719|Device|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
79703299|NCT04543058|Device|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
79249022|NCT01362530|Drug|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
79703300|NCT04543058|Other|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
79703301|NCT04543058|Other|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
79703302|NCT01647789|Drug|CFG920|
79703303|NCT02215031|Drug|BI 44370|
79249023|NCT01362530|Drug|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
79543187|NCT01511549|Drug|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
79543188|NCT01511549|Drug|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
79543189|NCT01511562|Drug|carmustine|Given IV
79543190|NCT01511562|Drug|cytarabine|Given IV
79543191|NCT01511562|Drug|etoposide|Given IV
79543192|NCT01511562|Drug|thiotepa|Given IV
79703304|NCT02215031|Drug|Placebo|
79249024|NCT02492685|Device|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
79249025|NCT03327207|Other|Non Interventional|Non Interventional
79387608|NCT06074016|Drug|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
79387609|NCT06074016|Drug|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
79391591|NCT03174444|Behavioral|Small Media|Bilingual brochures and access to bilingual website
79391592|NCT03177564|Procedure|Protective ventilation 1|Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
79543193|NCT01511562|Procedure|stem cell transplant|
79543194|NCT01511562|Drug|G-CSF|
79543195|NCT01511575|Genetic|RNA analysis|
79543196|NCT01511575|Genetic|reverse transcriptase-polymerase chain reaction|
79543197|NCT01511575|Other|laboratory biomarker analysis|
79703305|NCT01681758|Other|IV fluid according to PPV|intravenous fluids
79703306|NCT01681758|Other|fluids according to standard care|
79703307|NCT04540679|Other|VIP4SCI|Technology-enabled self-management & rehabilitation solution
79703308|NCT01647867|Other|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
79703309|NCT04540367|Device|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
79703310|NCT01682070|Biological|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
79703311|NCT01682070|Biological|Placebo|
79703312|NCT04542941|Biological|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
79249026|NCT04494399|Drug|Interferon beta-1b|5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
79387610|NCT06073886|Device|Active cTBS|600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
79387611|NCT06073886|Device|Inactive/Sham cTBS|600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
79387612|NCT06073886|Behavioral|Imaginal exposure|Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
79543198|NCT01511627|Drug|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:~Tylenol® 975mg per os~Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~Bupivacaine 0.5% 10 mg~Fentanyl 10ug~Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~Midazolam 1 - 2 mg intravenously~Fentanyl 1 - 2 ug/kg intravenously~Propofol 1-3 mg/kg intravenously~Rocuronium 0.3 - 0.9mg/kg intravenously~followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~Dexamethasone 4mg and Ondansetron 4mg intravenously~Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
79703313|NCT01647984|Dietary Supplement|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
79703314|NCT01647984|Dietary Supplement|placebo|
79703315|NCT04540328|Other|Non-surgical periodontal treatment|
79703316|NCT01648062|Behavioral|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
79703317|NCT04540640|Device|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
79703318|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
79703319|NCT01648179|Drug|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
79703320|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
79703321|NCT01648179|Drug|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
79703322|NCT02215382|Drug|sugammadex|sugammadex 2 mg/kg
79703323|NCT02215382|Drug|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
79703324|NCT04540601|Other|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
79703325|NCT01682109|Drug|Valacyclovir|
79703326|NCT02215148|Drug|Tolvaptan|
79249027|NCT04494399|Drug|Ribavirin|5-day course of oral ribavirin 400mg twice daily
79249028|NCT01758614|Procedure|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
79249029|NCT01758614|Drug|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
79249030|NCT01758614|Drug|Clopidogrel|
79249031|NCT03334929|Device|Virtual Reality headset|The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
79249032|NCT03334773|Behavioral|Nutrition education|
79249033|NCT05120726|Biological|Dehydrated human amnion/chorion membrane|Dehydrated human amnion/chorion membrane (dHACM) has been commercially available for nearly 15 years. dHACM has been shown to elute growth factors including platelet-derived growth factors, fibroblast growth factors (PDGF), fibroblast growth factors (FGF), transforming growth factor beta 1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF). Additionally, dHACM exerts immunomodulatory effects by releasing anti-inflammatory interleukins and factors which help regulate the matrix metalloproteinase (MMP) activity. Furthermore, dHACM has also been shown to stimulate mesenchymal stem cell migration and recruitment. dHACM is routinely utilized in the management of chronic wounds including diabetic ulcer and venous ulcers.
79387613|NCT06073522|Other|Artificial Intelligence for combining multi-domain data acquisition|Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
79703327|NCT01682265|Other|Stretta procedure|
79703328|NCT01682265|Other|Sham procedure|No radiofrequency delivered
79703329|NCT01682343|Dietary Supplement|Calcium|Milk-calcium supplement
79710044|NCT00597480|Drug|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
79710045|NCT01326702|Drug|Bendamustine Hydrochloride|Given IV
79249034|NCT02490657|Drug|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
79249035|NCT02490657|Drug|normal saline (Saline 0.9%)|
79249036|NCT05120492|Procedure|bariatric surgery followed by total knee replacement|The only intervention is the randomization of the priority of the 2 procedures.
79703330|NCT04542746|Procedure|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
79249037|NCT03326973|Behavioral|EuroQoL EQ-5D-3L|Overall QOL
79249038|NCT03326973|Behavioral|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
79249039|NCT03326973|Other|PRO-CTCAE|Additional potential immune-specific symptoms
79703331|NCT01648257|Drug|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
79703332|NCT01648257|Drug|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
79703333|NCT01648257|Drug|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
79249040|NCT03326973|Behavioral|Fatigue severity score questionnaire|Fatigue severity
79249041|NCT03326973|Behavioral|The COST|Financial toxicity; satisfaction with ability to work
79703334|NCT04540250|Other|questionnaire|conventional intra-oral examination and questionnaire
79703335|NCT01648335|Device|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
79845393|NCT04765449|Drug|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
79249042|NCT03326973|Behavioral|Physician information|Details on outside health providers
79703336|NCT01648335|Device|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
79703337|NCT02215460|Procedure|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703338|NCT02215460|Procedure|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703339|NCT02215460|Drug|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703340|NCT02215460|Drug|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703341|NCT02215460|Drug|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79710046|NCT01326702|Other|Pharmacological Study|Correlative studies
79845394|NCT00827138|Drug|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
79845395|NCT00907998|Drug|APL180|
79845396|NCT00907998|Drug|APL180|
79845397|NCT00907998|Drug|Placebo|
79845398|NCT02549378|Device|confocal microscopy|microvessel diameter measured by confocal microscopy
79845399|NCT03907683|Behavioral|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
79845400|NCT00929604|Other|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
79249043|NCT03334383|Device|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
79249044|NCT03326817|Other|Control Group|Patients receive standard care
79249045|NCT03326817|Device|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
79387614|NCT06073275|Dietary Supplement|Beetroot juice ingestion|Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
79387615|NCT06073275|Dietary Supplement|Placebo ingestion|Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
79391593|NCT03177564|Procedure|Protective ventilation 2|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
79249046|NCT05120414|Other|balanace exercises|Balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
79543199|NCT01511627|Drug|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:~Tylenol® 975mg per os~Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~Midazolam 1 - 2 mg intravenously~Fentanyl 1 - 2 ug/kg intravenously~Propofol 1-3 mg/kg intravenously~Rocuronium 0.3 - 0.9mg/kg intravenously~followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~Dexamethasone 4mg and Ondansetron 4mg intravenously~Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
79543200|NCT01511666|Device|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
79543201|NCT01511666|Other|Standard care|Standard care as per recent guidelines will be provided.
79543202|NCT01511692|Drug|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
79543203|NCT01511692|Drug|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
79543204|NCT01511692|Drug|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
79543205|NCT01511692|Drug|glimepiride|Dose individually adjusted, administered orally for 4 weeks
79543206|NCT01511705|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
79703342|NCT02215460|Drug|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703343|NCT02215460|Drug|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703344|NCT02215460|Drug|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703345|NCT02215460|Drug|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703346|NCT02215460|Drug|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
79703347|NCT02215499|Drug|Placebo|
79703348|NCT02215499|Drug|Sodium Oxybate|
79703349|NCT02215499|Drug|JZP-386|
79703350|NCT01648608|Drug|Exemestane|Exemestane for neoadjuvant chemotherapy
79703351|NCT02215538|Drug|OROS methylphenidate|
79845401|NCT02549534|Procedure|Axon Reflexes|"*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33*C.~Heat Ramp: Increasing the heat in the heat probe to 42*C at approx. 0.1*C/10 sec.~Skin Heating: Heating the skin of the toe for 30 minutes 42*C.~Heat Ramp: Increasing the heat in the heat probe to 44*C at 0.1*C/10 sec..~Skin Heating: Heating the skin for an additional 5 minutes at 44*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
79249047|NCT05120414|Other|Balance Exercises plus Ankle strategy|ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.While balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
79387616|NCT06073249|Other|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.
79387617|NCT06073249|Other|Tibial Nerve Stimulation|The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).
79391594|NCT03177564|Procedure|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
79391595|NCT02409186|Drug|Nimotuzumab|400mg/w，d1, week 1-7
79543207|NCT01511705|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
79543208|NCT01511718|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
79543209|NCT01511718|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
79543210|NCT01511731|Drug|Famotidine|Famotidine Tablets 40 mg
79543211|NCT01511731|Drug|Pepcid|40mg tablets
79703352|NCT02215538|Drug|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
79703353|NCT01682421|Drug|Weak steroid (Flurolon, Allergan)|
79543212|NCT01511744|Biological|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
79703354|NCT01682421|Drug|Potent steroid (Maxidex, Alcon)|
79703355|NCT04540172|Behavioral|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
79387618|NCT06072261|Other|kinesio tape application|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
79703356|NCT04540172|Behavioral|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
79703357|NCT01682499|Drug|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
79703358|NCT04540055|Procedure|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
79703359|NCT04540055|Procedure|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
79703360|NCT02215655|Behavioral|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
79703361|NCT01202773|Drug|LY2127399|Administered Subcutaneously (SC)
79703362|NCT01202773|Drug|Placebo Q4W|Administered SC
79703363|NCT01202773|Drug|Placebo Q2W|Administered SC
79703364|NCT01648686|Procedure|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
79249048|NCT04494087|Other|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
79249049|NCT04494087|Other|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
79249050|NCT04442841|Biological|Hepatitis B vaccine|It may be GSk or MSD vaccine
79249051|NCT03323229|Diagnostic Test|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
79387619|NCT06071923|Device|Fibroscan|Scan the liver for metabolic fatty changes
79387620|NCT06071455|Other|Platelet-rich fibrin|injected distal to the canine on the experimental side.
79387621|NCT06071455|Other|Vitamin D3|injected distal to the canine on the experimental side.
79387622|NCT06071429|Device|MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold|CLTI patients treated with MAGNITUDE BRS
79387623|NCT06071429|Device|Percutaneous Transluminal Angioplasty (PTA)|CLTI patients treated with PTA
79543213|NCT01511757|Drug|Fluconazole|Fluconazole Tablets, 200 mg
79543214|NCT01511757|Drug|Fluconazole|fluconazole 200 mg
79543215|NCT01511770|Drug|Fluconazole|Fluconazole Tablets, 200 mg
79543216|NCT01511770|Drug|Fluconazole|Fluconazole 200 mg tablets
79543217|NCT01511783|Drug|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
79543218|NCT01511783|Drug|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
79703365|NCT02215694|Dietary Supplement|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
79703366|NCT02215694|Dietary Supplement|placebo|2g of powder daily without probiotics
79703367|NCT01648725|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
79703368|NCT01648725|Procedure|usual care|Standard care before induction of anesthesia
79703369|NCT04539782|Other|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
79249052|NCT03323073|Other|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
79249053|NCT03334227|Device|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 > 92% and with, at least, 30 liters of total flow.
79249054|NCT02491125|Dietary Supplement|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
79249055|NCT02491125|Dietary Supplement|Placebo|12 weeks daily intake of 15g of maltodextrin
79387624|NCT06071156|Drug|Anakinra|Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
79391596|NCT02409186|Radiation|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
79391597|NCT02409186|Drug|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
79391598|NCT02409186|Drug|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
79391599|NCT02409186|Other|placebo|400mg/w，d1, week 1-7
79391600|NCT00701766|Drug|BI 2536|
79391601|NCT02410746|Other|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
79543219|NCT01511796|Other|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
79543220|NCT01511822|Drug|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
79249056|NCT02492607|Other|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy"
79249057|NCT02492607|Device|digital mammography|annual mammography
79543221|NCT01511822|Drug|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
79543222|NCT01511822|Drug|placebo|
79543223|NCT01511835|Dietary Supplement|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
79703370|NCT01180660|Drug|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
79703371|NCT01180660|Drug|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
79703372|NCT04539860|Device|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
79703373|NCT01648881|Radiation|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
79703374|NCT01202227|Drug|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
79703375|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
79703376|NCT01682694|Dietary Supplement|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
79703377|NCT01682694|Dietary Supplement|placebo|
79703378|NCT04539587|Other|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
79703379|NCT01682733|Drug|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
79249058|NCT02492607|Radiation|radiotherapy|according local policy
79249059|NCT04326686|Other|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
79249060|NCT04501484|Procedure|Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy|Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
79391602|NCT02410746|Other|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
79391603|NCT02410746|Other|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
79391604|NCT03177174|Drug|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
79391605|NCT03177174|Drug|Docetaxel|Docetaxel
79391606|NCT03175146|Radiation|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
79543224|NCT01511835|Dietary Supplement|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
79543225|NCT01511835|Drug|Folic Acid|Folic Acid 400mcg; 1 cp/die
79543226|NCT01511848|Drug|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
79543227|NCT01511848|Drug|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
79543228|NCT01511874|Drug|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
79703380|NCT01682733|Device|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
79703381|NCT01682772|Drug|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
79703382|NCT01682850|Behavioral|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
79703383|NCT01682850|Other|Usual Care|
79710047|NCT01326702|Biological|Rituximab|Given IV
79710048|NCT01326702|Drug|Veliparib|Given PO
79710049|NCT05654129|Other|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
79249061|NCT04323566|Drug|Rituximab|"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~administered iv over a course of max 180 minutes~at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"
79249062|NCT02491047|Device|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
79249063|NCT02491047|Other|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
79249064|NCT03326739|Procedure|Arterial Line Placement|arterial line placement
79391607|NCT02409108|Device|Exatherm-TBH system|One treatment of Total Body Hyperthermia
79543229|NCT01511887|Drug|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
79543230|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
79543231|NCT01511900|Drug|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
79543232|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
79543233|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
79703384|NCT01649037|Drug|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.[ No response defined as MAP < 10, or 4 hr Urine output < 200 ml] with maximum dose upto 3 mg/h."
79845402|NCT02549534|Procedure|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
80013887|NCT05279326|Behavioral|Virtual SMAs|18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
80013888|NCT05267236|Other|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
80013889|NCT05267236|Other|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
80013890|NCT05262777|Device|GP0112|Injectable gel
79387625|NCT06070168|Other|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
79543234|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
79387626|NCT06070051|Biological|VRON-0200-AdC6|VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
79543235|NCT01511900|Drug|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
79703385|NCT01649037|Drug|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response [< 25% decrease in s.creatinine] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
80013891|NCT05262777|Device|Restylane Lyft Lidocaine|Injectable gel
79249065|NCT03322917|Biological|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
80013892|NCT05261802|Other|Intervention 1: AVANCE-Houston FRAMEWorks Program Weekly Workshops Spread Across 7 Weeks (spaced out format)|Participants in this arm receive 14 hours of Survival Skills for Healthy Families curricula over 7 weeks. Participants also receive employment supports and case management services.
80013893|NCT05261802|Other|Intervention #2: AVANCE-Houston FRAMEWorks Program Weekend Workshops in 16-Hour Retreat (compressed format)|Participants in this arm receive 14 hours of Survival Skills for Healthy Families in a compressed format during a 16-hour weekend retreat, followed by a 2-hour reflections workshop two weeks later. Participants also receive employment supports and case management services.
80013894|NCT05256992|Other|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
80013895|NCT05253846|Drug|Irinotecan|chemotherapy treatment
79249066|NCT04864184|Behavioral|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
80013896|NCT05253846|Drug|Oxaliplatin|chemotherapy treatment
79249067|NCT04864184|Behavioral|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
79387627|NCT06070051|Biological|VRON-0200-AdC7|VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
79387628|NCT06069349|Other|Early Rehabilitation|Early Rehabilitation for patients after cardiac surgery
79387629|NCT06069349|Other|usual treatment|Patients are not allowed to exercise Early Rehabilitation
79387630|NCT06068517|Device|Closed incision negative pressure wound therapy|After the completion of abdominal surgery and standardised skin closure with staples, ciNPWT will be applied, using a commercially available device.
79703386|NCT04539119|Drug|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1*10^3/L.
79703387|NCT04539119|Drug|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
79703388|NCT02279511|Drug|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
79703389|NCT02279511|Drug|PLACEBO|Infusion of 500 mL of saline solution. (IV)
79543236|NCT01511952|Other|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
79249068|NCT03334071|Behavioral|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last <1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
79703390|NCT04538885|Biological|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
79703391|NCT01682889|Dietary Supplement|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
79543237|NCT01511952|Other|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
79543238|NCT01511965|Other|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
79703392|NCT01682889|Dietary Supplement|Placebo|NaCl 0.9% intravenously for 24h
79703393|NCT04538963|Device|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
79703394|NCT04538807|Diagnostic Test|electromyography|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
79703395|NCT04542902|Biological|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
79703396|NCT04542902|Procedure|Blood sampling|An amount of a person's blood taken from their body for use in medical.
79249069|NCT03109119|Drug|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
79249070|NCT03109119|Drug|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
79249071|NCT02490969|Procedure|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
79703397|NCT04542902|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
79249072|NCT03333993|Other|Pilates Exercise|The Mat Pilates exercise will be performed twice a week and the duration of the sessions will be 60 minutes, consisting of 5 minutes of warm-up exercises, 50 minutes of strengthening exercises followed by 5 minutes of relaxation and stretching.
79249073|NCT03333993|Other|Home exercises|Exercises for upper limbs according to the institutional routine.
79249074|NCT05119946|Behavioral|Suicide prevention video|The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
79249075|NCT05119946|Other|Standard suicide treatment|The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
79249076|NCT03326661|Procedure|Aspiration|Needle aspiration of pus from the peritonsilar abscess
79249077|NCT03326661|Procedure|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
79249078|NCT03326661|Drug|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
79387631|NCT06068517|Device|Standard dressing|After the completion of abdominal surgery and standardised skin closure with staples, standard dressings will be applied.
79703398|NCT02279628|Drug|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
79703399|NCT02279628|Drug|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
79703400|NCT04538924|Other|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
80013897|NCT05253846|Drug|Lederfolin|treatment
80013898|NCT05253846|Drug|5-Fluorouracil|chemotherapy treatment
80013899|NCT05253846|Radiation|Short-course radiotherapy|RT
80013900|NCT05253846|Procedure|TME|surgery
79387632|NCT06068309|Other|CareAide App Usage|The study participant uses the CareAide app in addition to prescribed usual therapeutic care
79387633|NCT06067204|Device|Automatic ventilation|"The FDA-approved device used is Meditech MICROVENT RESUSCITATOR, which is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. It is powered by the airflow from the oxygen tank and provides ventilation in fixed interval. It has a pressure valve which will release the pressure once the airway pressure exceeds its threshold. In the current study, the threshold is set at 60 mmH2O. The tidal volume is set at 600 ml."
79387634|NCT06067204|Device|Manual ventilation|The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.
79387635|NCT06062914|Drug|oral nutritional supplements|Only ONS was used as enteral nutrition
79387636|NCT06058845|Dietary Supplement|Tamarindus indica fruit juice_A|The participants will be exposed to 10% Tamarind pulp juice
80013901|NCT05253443|Behavioral|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
79703401|NCT02279706|Other|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
79703402|NCT04538612|Device|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~Veinous vascular occlusion test (30mmHg),~Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
79387637|NCT06058845|Dietary Supplement|Tamarindus indica fruit juice_B|The participants will be exposed to 30% Tamarind pulp juice
79703403|NCT04528524|Other|Questionnaire|QoR-15Dt
79703404|NCT04542629|Drug|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
79703405|NCT01683006|Drug|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
79703406|NCT01683006|Drug|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
79845403|NCT02549534|Procedure|Self-Reported Signs & Symptoms of CIPN|Self-reported signs & symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
79249079|NCT03322839|Behavioral|Multifaceted implementation strategies|The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
79249080|NCT03322839|Behavioral|Single implementation strategy|The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
79387638|NCT06054191|Drug|Dabrafenib + Trametinib|Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）
79387639|NCT06054191|Drug|Capmatinib|Capmatinib 400mg BID/（2 cycles）
79543239|NCT01511991|Drug|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
79543240|NCT01512004|Drug|Propiverine Hydrochloride|drug of oral capsule
79543241|NCT01512004|Drug|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
79543242|NCT01512017|Device|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
79387640|NCT06053489|Other|general anesthesia with remimazolam|general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery
79391608|NCT02409264|Other|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
79391609|NCT03177252|Drug|Lidocaine|-2% lidocaine will be given
79543243|NCT01512017|Device|Vaseline|External use
79543244|NCT01512043|Behavioral|Breathing control|Practice of device guided breathing control twice a day for four weeks.
79543245|NCT01512056|Drug|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
79703407|NCT04542668|Other|Cycling then running|Ergometer cycling Treadmill running
79703408|NCT04542668|Other|Running then cycling|Treadmill running Ergometer cycling
79703409|NCT04542668|Other|Inotropy|Adrenaline induced inotropy
79703410|NCT04542668|Other|Resting|Subjects must be minimally physically active
79703411|NCT01683045|Device|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
79703412|NCT01683162|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
79703413|NCT01683162|Drug|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
79703414|NCT01683162|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
79703415|NCT02215733|Drug|ARB|other than telmisartan
79703416|NCT02215733|Drug|ACEI|
79703417|NCT02215733|Drug|Beta-blockers|
79703418|NCT02215733|Drug|Diuretics|
79703419|NCT02215733|Drug|Telmisartan|
79845404|NCT04173195|Other|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
79845405|NCT00929682|Drug|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
79703420|NCT01683201|Procedure|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
79703421|NCT01683201|Procedure|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
79703422|NCT02215772|Drug|BI 44370 BS|
79703423|NCT01202188|Drug|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
79703424|NCT01202188|Drug|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
79703425|NCT01202188|Drug|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
79703426|NCT01202188|Drug|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
79703427|NCT01202188|Drug|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
79703428|NCT01649115|Other|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
79703429|NCT02215811|Biological|Mesenchymal stromal cells|
79845406|NCT03659721|Behavioral|FACAM|Support person
79845407|NCT03659721|Behavioral|Care as Usual|Usual care
79845408|NCT03659721|Behavioral|COS-P|Attachment based therapy
79845409|NCT04015674|Other|Exercise group|Aerobic exercise on a stationary bicycle
79845410|NCT04015674|Other|Control group|In a rest
79845411|NCT00929760|Behavioral|specialised renal care|"Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
79845412|NCT00817466|Drug|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1) 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
79249081|NCT04363814|Biological|Bactek-R|BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10^9 bacteria / mL)
79249082|NCT05119634|Other|whole body vibration training|participants will receive whole body vibration training 3 days in a week and for 8 weeks
79249083|NCT05119634|Other|home based exercises|participants will receive a home based exercise program for 8 weeks
79249084|NCT03322761|Combination Product|Systematic exercise training|Combination of standard medical treatment and systematic early exercise training in persons with MS.
79249085|NCT03322761|Behavioral|Educational program|Informations regarding health benefits of physical activity and exercise.
79387641|NCT06052904|Behavioral|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
79391610|NCT03177252|Drug|Sodium chloride|-Normal saline will be given
79391611|NCT03177252|Drug|Bupivacaine|-0.5% bupivacaine will be given
79703430|NCT01580046|Drug|iodixanol|"coronary angiography, 32gI/100ml, 40～60 ml once injection~left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
79703431|NCT01580046|Drug|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
79703432|NCT02215850|Drug|SLC-0111|
79703433|NCT01683318|Procedure|Thermal Pulsation therapy|
79703434|NCT01201915|Drug|Vismodegib|Vismodegib was supplied in gelatin capsules.
79703435|NCT01649154|Procedure|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
79703436|NCT04542122|Behavioral|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
79703437|NCT04124770|Other|Movement|Re-positioning of neck
79703438|NCT04532879|Device|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
79703439|NCT01649193|Other|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
79703440|NCT04318288|Other|Observational|Observational
79845413|NCT00817466|Drug|Isotonic saline|2ml NaCl 9mg/ml.
79845414|NCT00926250|Dietary Supplement|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
79845415|NCT00926250|Dietary Supplement|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
79845416|NCT04582370|Behavioral|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
79845417|NCT00908154|Drug|Placebo|Tablets to match GSK1014802
79845418|NCT00908154|Drug|GSK1014802|Sodium channel blocker
79845419|NCT00830648|Biological|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
80013902|NCT05253443|Behavioral|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
79845420|NCT00926406|Drug|lead chelation therapy|Patients with lead poisoning (BLL> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL < 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
79703441|NCT01179919|Drug|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
79703442|NCT01649310|Other|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
79703443|NCT01201798|Drug|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
79543246|NCT01512069|Behavioral|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
79845421|NCT04708899|Behavioral|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
79845422|NCT04708899|Behavioral|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
79845423|NCT00930072|Drug|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
79845424|NCT00626522|Drug|Aclidinium bromide and formoterol|once daily
79845425|NCT00626522|Drug|Aclidinium bromide and formoterol placebo|once daily
79845426|NCT00926562|Drug|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
79543247|NCT01512069|Behavioral|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
79543248|NCT01512082|Device|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
79543249|NCT01512082|Device|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
79543250|NCT01512134|Device|Deep Brain Stimulation Device|Deep brain stimulation surgery
79845427|NCT00926562|Drug|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
79845428|NCT04366791|Radiation|Low Dose Radiation Therapy|Undergo low-dose radiation therapy
79845429|NCT00926640|Drug|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
79543251|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
79703444|NCT01201798|Drug|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
79387642|NCT06052904|Behavioral|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
79387643|NCT06048471|Other|HiTop|High tone transcutaneous electrical stimulation
79387644|NCT06041919|Drug|RESP301|Nitric Oxide agent
79703445|NCT04539353|Other|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
79703446|NCT04539353|Other|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
79387645|NCT06041919|Drug|HRZE|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
79387646|NCT06028672|Drug|Toripalimab|200mg q2w intravenous
79387647|NCT06028672|Drug|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
79387648|NCT06028451|Other|Record the information data|Record the information data
79387649|NCT06028321|Drug|Part 1 Group 1 Regime A (ACM-001.1)|"Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B."
79387650|NCT06028321|Drug|Part 1 Group 2 Regimen C (Pindolol)|Drug: Pindolol tablets for oral use.
79703447|NCT02887456|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
79703448|NCT02887456|Drug|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
79845430|NCT00926640|Drug|Cisplatin|6 cycles at 60mg/m2 IV on day 2
79703449|NCT01201759|Drug|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
79703450|NCT01201759|Drug|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
79703451|NCT04315597|Drug|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
79249086|NCT03333759|Device|Alma - Harmony XL Laser|The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.
79703452|NCT04315597|Drug|Placebo|1 x daily, 1 tablet, 900 mg
79703453|NCT01683396|Drug|Placebo|Solution for subcutaneous injection
79703454|NCT01683396|Drug|gevokizumab|Solution for subcutaneous injection
79845431|NCT00926640|Drug|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
79845432|NCT04656171|Radiation|MRI of the hand and forearm,|MRI of the hand and forearm,
79845433|NCT00830726|Drug|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
79845434|NCT00830726|Procedure|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
79845435|NCT00830726|Procedure|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
79249087|NCT02703116|Behavioral|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
79249088|NCT02703116|Behavioral|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
79543252|NCT01512173|Drug|propranolol gel|Topical administration twice daily
79249089|NCT02490579|Behavioral|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
79249090|NCT02490579|Behavioral|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
79703455|NCT04532840|Device|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
79387651|NCT06028321|Drug|Part 2 Group D (Pindolol)|Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
79387652|NCT06028321|Drug|Part 2 Group E (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
79387653|NCT06028321|Drug|Part 2 Group F (ACM-001.1 )|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
79391612|NCT03174912|Procedure|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
79391613|NCT02408640|Behavioral|Cannabishjalpen.se|
79543253|NCT01512173|Drug|Placebo|Topical administration twice daily
79543254|NCT01512199|Drug|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
79543255|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
79543256|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
79543257|NCT01512199|Drug|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
79703456|NCT04532840|Other|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
79703457|NCT01649349|Device|two-piece nasogastric tube|one week period
79703458|NCT04538846|Other|Culinary art therapy|Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
79845436|NCT00830726|Procedure|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
79845437|NCT00931398|Drug|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
79845438|NCT00931398|Drug|Placebo|Matched placebo for all Concerta doses.
80013903|NCT05244447|Other|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 10 weeks. Participants also receive life coaching and ongoing job readiness support.
79703459|NCT01683435|Other|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
79703460|NCT04532684|Drug|Duloxetine|
79703461|NCT04532684|Drug|Pregabalin|
79845439|NCT00827216|Drug|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
80013904|NCT05244421|Other|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
79703462|NCT01683474|Device|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
80013905|NCT05240742|Other|no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts|(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.
79249091|NCT02490579|Behavioral|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
79249092|NCT03326505|Biological|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
79703463|NCT04538768|Procedure|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
79703464|NCT04538768|Procedure|Direct suture|direct fascia suture
79703465|NCT01683513|Drug|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
79703466|NCT01649466|Drug|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
79703467|NCT01649466|Drug|Protaphane|Protaphane will be used as commercially available injection pens
79845440|NCT00827216|Drug|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
79845441|NCT00931476|Drug|somatropin|
79703468|NCT01200589|Biological|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
79845442|NCT00931476|Drug|placebo|
79845443|NCT00827294|Behavioral|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
80013906|NCT05239754|Other|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
79249093|NCT03326505|Other|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
79249094|NCT05122520|Other|Questionnaire|The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.
79249095|NCT05122442|Other|Patients with inherited retinal disease|Patients with inherited retinal disease
79387654|NCT06028321|Drug|Part 2 Group G (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
79391614|NCT02703324|Drug|LY900014|Administered subcutaneously (SC)
79703469|NCT01200589|Biological|Rituximab|sourced locally from commercial stock
79703470|NCT01200589|Biological|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
79845444|NCT03760692|Device|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
79845445|NCT03760692|Device|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
79845446|NCT05097729|Device|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
79845447|NCT00822848|Drug|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
79703471|NCT01200589|Biological|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
79703472|NCT04532762|Device|nasal spray|Application of a nasal spray
79543258|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
79543259|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
79543260|NCT01512199|Drug|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
79845448|NCT00822848|Drug|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
79845449|NCT00822848|Drug|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
79845450|NCT00822848|Other|immunoenzyme technique|
79845451|NCT00822848|Other|immunohistochemistry staining method|
79845452|NCT00822848|Other|laboratory biomarker analysis|
79249096|NCT02654054|Drug|Elagolix|Film-coated tablets
79845453|NCT00822848|Procedure|adjuvant therapy|Preoperative administration has been the preference at our institution.
79845454|NCT00822848|Procedure|neoadjuvant therapy|
79845455|NCT00822848|Procedure|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
79845456|NCT00822848|Radiation|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. *Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
79249097|NCT02654054|Drug|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
79249098|NCT02654054|Drug|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
79249099|NCT02654054|Drug|Placebo for Elagolix|Film-coated placebo tablets
79249100|NCT03326427|Behavioral|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
79543261|NCT01512212|Procedure|biopsy|fnab
79543262|NCT01512238|Other|Pharmaceutical care|Information about medicine, sideeffect, adherence
79543263|NCT01512277|Biological|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
79543264|NCT01512290|Other|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
79543265|NCT01512303|Behavioral|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
79387655|NCT06028321|Drug|Part 1 Group 1 Regimen B (Pindolol)|Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
79387656|NCT06028321|Other|Part 1 Group 1 Regimen A (Placebo)|Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
79387657|NCT06028321|Other|Part 2 Group E (Placebo)|"Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D."
79387658|NCT06028321|Other|Part 2 Group F (Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
79249101|NCT03326427|Other|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
79249102|NCT03186404|Drug|Atorvastatin|Atorvastatin 40mg OD
79249103|NCT03186404|Drug|Placebo oral tablet|Placebo
79249104|NCT02492373|Drug|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
79387659|NCT06028321|Other|Part 2 Group G ( Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
79387660|NCT06028113|Behavioral|THRIVE 2.0|Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment & responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines & Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
79387661|NCT06024733|Drug|Target Controlled Infusion|the patient's age and weight will be entered into the Target Controlled Infusion unit enabling target propofol concentrations to be set and the infusion to be started. Target induction concentrations will be 4-6 mcg/ ml. and anesthesia will be maintained with Target Controlled Infusion propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
79543266|NCT01512303|Behavioral|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
79703473|NCT01683552|Drug|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
79703474|NCT01683552|Drug|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
79703475|NCT01683552|Drug|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
79703476|NCT04532723|Device|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
79703477|NCT01200511|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
79703478|NCT04532567|Drug|GLPG1205|GLPG1205 film-coated tablets
79703479|NCT04532567|Drug|Placebo|placebo film-coated tablets
79249105|NCT02492373|Device|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
79543267|NCT01512329|Behavioral|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
79543268|NCT01512329|Behavioral|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
79543269|NCT01512342|Behavioral|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
79543270|NCT01512342|Behavioral|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
79543271|NCT01512355|Drug|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
79543272|NCT01512355|Drug|placebo group|normal saline_02mcg/kg/hr
79543273|NCT01512381|Device|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
79543274|NCT01512381|Device|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
79543275|NCT01512394|Procedure|standard bowel prep|standard bowel prep
79543276|NCT01512394|Procedure|no bowel prep|no bowel prep
79543277|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
79543278|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
79543279|NCT01512433|Procedure|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
79543280|NCT01512433|Procedure|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
79543281|NCT01512459|Drug|Venlafaxine|Venlafaxine MR Capsules 150 mg
79543282|NCT01512472|Drug|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
79543283|NCT01512485|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
79543284|NCT01512511|Procedure|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
79543285|NCT01512524|Other|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
79543286|NCT01512537|Radiation|Narrowband UVB|UVB 3 times a week
79543287|NCT01512537|Dietary Supplement|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
79249106|NCT05119322|Diagnostic Test|GlutenDetect home urine test|GFD compliance self-asessment using a home rapid test for GIP detection in urine.
79387662|NCT06024733|Drug|Target Controlled Infusion and maintenance by sevoflurane|patients will be induced with intravenous propofol 1.5 mg/kg and fentanyl 1- 2 μg/kg. Tracheal intubation will be performed after adequate neuromuscular blockade with rocuronium 0.6 mg/kg. Anesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
79387663|NCT06024733|Drug|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure and 1mg/kg/h for 24 h postoperative.
79387664|NCT06023316|Device|mGain system|passive, noninvasive surface electromyography measurement device and gaming mobile application
79543288|NCT01512550|Procedure|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
79543289|NCT01512550|Procedure|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
79543290|NCT01512550|Device|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
79543291|NCT01512563|Device|Biliary stent|palliative treatment for malignant patients
79543292|NCT01512576|Other|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
79543293|NCT01512576|Behavioral|relaxation|1 treatment session of 30 minutes
79543294|NCT01512602|Behavioral|DBT|16 weeks DBT treatment
79543295|NCT01512602|Behavioral|CAMS|CAMS-informed psychotherapy
79543296|NCT01512615|Other|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
79543297|NCT01512615|Other|Control group|Usual care, clinical control as provided by treating heart centre
79249107|NCT03326349|Other|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
79543298|NCT01512628|Drug|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
80013907|NCT05237466|Behavioral|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
79543299|NCT01512641|Other|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
79249108|NCT03326349|Other|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
79387665|NCT06020105|Behavioral|NURLIFE|After the first consultation with the surgeon, the patients will be referred to the case manager, who will carry out the first face-to-face consultation, with consequent monitoring and clarification of identified needs, following the flowchart in figure 3, being referred to the different specialties, psychology, nutrition and nursing, fostering the case manager as the central pillar of the process, which will monitor each process individually, namely the number of consultations and necessary referrals.
79543300|NCT01512641|Other|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
79543301|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
79543302|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
79703480|NCT04528368|Biological|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
79703481|NCT01683591|Procedure|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
79703482|NCT02216981|Behavioral|Cognitive Behavioural Therapy (CBT)|
79703483|NCT01683708|Dietary Supplement|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
79703484|NCT01649544|Device|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
79703485|NCT01649544|Drug|Amiodarone|
79703486|NCT04538729|Behavioral|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
79387666|NCT06013059|Procedure|three levels of TMJ arthroscopy|Group I: 10 patients will be treated with Lysis and lavage
79387667|NCT06013059|Procedure|three levels of TMJ arthroscopy|Group II: 10 patients will be treated with operative arthroscopy
79387668|NCT06013059|Procedure|three levels of TMJ arthroscopy|Group III: 10 patients will be treated with operative arthroscopy + discopexy
79387669|NCT06011408|Other|TDtect|Collecting video data on abnormal movement
79387670|NCT06006442|Behavioral|Vaping|Subjects will be smoking the vapnig products that they admitted to using at baseline in the personal life prior to this study
79391615|NCT02703324|Drug|Insulin Lispro|Administered SC
79391616|NCT02408718|Behavioral|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
79391617|NCT02408562|Other|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
79249109|NCT03073070|Drug|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
79249110|NCT03326271|Procedure|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
79703487|NCT04528290|Drug|Ozanimod|Ozanimod capsule formulation of 0.92mg
79703488|NCT04528290|Drug|Ozanimod|Ozanimod, granule formulation of 0.92mg
79703489|NCT04538690|Other|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
79703490|NCT04538690|Other|Electrotherapy|TENS, US
79703491|NCT01179334|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
79703492|NCT01179334|Drug|Placebo|Placebo for 12 weeks
79703493|NCT01179334|Drug|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
79703494|NCT01649583|Device|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
79703495|NCT04532450|Device|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
79703496|NCT02886481|Device|perioperative monitoring|
79703497|NCT02886520|Device|PVDF transobturator tape|
79703498|NCT02886520|Device|Polypropylene transobturator tape|
79703499|NCT01649622|Drug|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
79703500|NCT04538300|Diagnostic Test|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
79703501|NCT04538300|Diagnostic Test|Degree of nausea|Degree of postoperative nausea was evaluated.
79543303|NCT01512680|Behavioral|Education to Functional Insulin Therapy|"Intake of Continuous Glucose Monitor for 5 to 7 days~Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~3 months after the training: Blood sampling, vital signs and data on diabetes~6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~9 months after the training: Blood sampling, vital signs and data on diabetes~1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
79543304|NCT01512719|Procedure|POEM|Per Oral Endoscopic Myotomy for achalasia
79703502|NCT04538300|Diagnostic Test|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
79845457|NCT00931554|Procedure|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
79845458|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
79845459|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
79845460|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
79543305|NCT01512771|Other|CPAP|6 weeks of CPAP
79703503|NCT04538300|Diagnostic Test|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
79703504|NCT04538300|Diagnostic Test|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
79703505|NCT04538300|Other|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
79703506|NCT02886676|Drug|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
79703507|NCT04315753|Other|LDCT (Low Dose CT)|validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
79703508|NCT02886598|Drug|degarelix|
79703509|NCT01683747|Drug|Tranexamic Acid|
79703510|NCT01683747|Drug|Control Intervention (Carrier fluid only)|
79703511|NCT04538027|Procedure|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
79703512|NCT04538027|Procedure|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
79703513|NCT04538027|Procedure|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
79703514|NCT01178671|Drug|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
79703515|NCT01178671|Drug|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
79703516|NCT01178671|Other|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
79703517|NCT02886637|Other|None intervention|
79703518|NCT04532216|Procedure|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
79703519|NCT04532216|Procedure|Traditional surgery|Tendon transfer
79703520|NCT01649700|Biological|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.
79703521|NCT04532060|Drug|Nystatin|
79703522|NCT04532060|Procedure|Antimicrobial Photodynamic Therapy|
79703523|NCT01649739|Drug|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
79703524|NCT04532138|Device|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
79703525|NCT04532138|Device|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
79249111|NCT03326271|Procedure|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
79249112|NCT05122364|Behavioral|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
79387671|NCT06004804|Behavioral|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
79703526|NCT04527822|Other|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
79543306|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
79703527|NCT01178125|Drug|DR-102|
79703528|NCT01649778|Drug|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
79249113|NCT05122364|Behavioral|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
79703529|NCT04532333|Drug|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
79703530|NCT04532333|Drug|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
79703531|NCT04538183|Other|WO 5000|WO 5000
79703532|NCT04538183|Other|WO 5001|WO 5001
79249114|NCT03322683|Procedure|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
79703533|NCT04538105|Other|Control|Saline Articular Nerve Branch Block
79703534|NCT04538105|Other|Articular Branch Block (ABB)|0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
79703535|NCT01649895|Drug|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
79703536|NCT01649895|Drug|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
79703537|NCT04527939|Procedure|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
79845461|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
79249115|NCT03322683|Procedure|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
79249116|NCT05119244|Other|blood and hair sampling|3.5 ml blood sample Hair sample
79249117|NCT03333681|Biological|Autologous mesenchymal stem cells|A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
79249118|NCT05099432|Procedure|CARMA technique|Once standard polyp resection and assessment of the polypectomy site without magnification is completed, the CARMA technique will be applied. This will involve an assessment of the entire polypectomy margin using cap assisted magnification endoscopy with the ability to also use NBI (at the endoscopist's discretion) and documentation of any residual polyp noted.
79387672|NCT06004804|Behavioral|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
79387673|NCT06004804|Behavioral|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
79387674|NCT06001359|Other|No intervention|No intervention
79703538|NCT04527783|Other|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
79703539|NCT04527783|Other|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
79845462|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
79387675|NCT06000709|Drug|6% aqueous phenol|1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance
79391618|NCT02408562|Other|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
79249119|NCT03326115|Behavioral|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
79703540|NCT04537754|Device|bleaching device|activated bleaching
79543307|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
79703541|NCT02217215|Device|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
79249120|NCT02905214|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
79249121|NCT03333603|Drug|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
79543308|NCT01512823|Behavioral|Education|"Interactive educational intervention:~4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)~Emailed notes from second session~Telephonic/email follow-up (reminders)~Didactic educational intervention:~- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
79387676|NCT06000709|Drug|MethylPREDNISolone 40 MG|40 mg of methylprednisolone diluted in 5 mL of 0.9% normal saline will be injected inside the knee joint capsule under ultrasound guidance
79543309|NCT01512836|Behavioral|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~Formulation and implementation of care plans together with the patient~Monitoring of individual status and care plan effectuation~Overall coordination between health care providers~Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~Regular telephone consultations and home visits~Promote disease-self management through coaching"
79543310|NCT01512862|Drug|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
79543311|NCT01512862|Drug|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
79543312|NCT01512901|Drug|Betamethasone Microsphere (DE-102） Low Dose|
79543313|NCT01512901|Drug|Betamethasone Microsphere (DE-102） High Dose|
79543314|NCT01512901|Drug|Sham|
79703542|NCT04537676|Other|No intervention, this is an observational study|No intervention
79703543|NCT01649505|Drug|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
79703544|NCT01649505|Procedure|breast reconstruction|Undergo sharp dissection technique
79249122|NCT02701556|Device|Complete MPS|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
79249123|NCT02701556|Device|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
79387677|NCT06000709|Drug|Intraarticular Knee Placebo|Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance
79845463|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
79845464|NCT00823004|Drug|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
79387678|NCT06000709|Drug|Genicular Nerve Placebo|1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance
79387679|NCT05984966|Behavioral|Supported Employment|PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
79387680|NCT05983393|Procedure|Erector spinae plane block|Erector spinae plane block was performed
79543315|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
79703545|NCT01649505|Procedure|breast reconstruction|Undergo electrocoagulation dissection technique
79703546|NCT02279784|Device|Freeway PTA|angioplasty with Freeway drug-eluting balloon
79703547|NCT02279784|Device|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
79845465|NCT00823004|Drug|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
79543316|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
79703548|NCT02217254|Procedure|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
79387681|NCT05983393|Procedure|Control|Erector spinae plane block was not applied.
79703549|NCT01178086|Drug|Rituximab|Rituximab IV
79703550|NCT04531865|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
79387682|NCT05980468|Other|music therapy|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
79703551|NCT04531865|Drug|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.
79703552|NCT04531865|Drug|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.
79703553|NCT01683981|Drug|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
79387683|NCT05973500|Dietary Supplement|Mediterranean Diet|Mediterranean Diet for 42 Days
79387684|NCT05969535|Behavioral|Birth preparation education according to travelbee human-human relations theory|human-to-human communication and psychoeducation-assisted birth preparation training
79543317|NCT01512914|Drug|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
79703554|NCT01177969|Behavioral|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
79703555|NCT01177969|Behavioral|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
79387685|NCT05965960|Device|TUS Active|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa
79387686|NCT05965960|Device|TUS Sham|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
79387687|NCT05961696|Drug|Mosunetuzumab|Subcutaneous (SQ or Sub-Q) injection under the skin
79249124|NCT03333525|Other|Calculation of insulin dosages for different meals|Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
79387688|NCT05961098|Drug|RBD1016|RBD1016 with NAs background treatment will be explored.
79387689|NCT05961098|Drug|RBD1016+PegIFN-α|RBD1016 with PegIFN-α and NAs background treatment will be explored.
79387690|NCT05957055|Behavioral|parental training in behavior management|Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.
79387691|NCT05957055|Drug|Lisdexamfetamine|Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).
79387692|NCT05957055|Drug|Methylphenidate|Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
79387693|NCT05951465|Drug|Esketamine|esketamine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
79387694|NCT05951465|Drug|Esketamine|esketamine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
79543318|NCT01512914|Drug|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
79703556|NCT01643070|Drug|Capecitabine, Oxaliplatin|Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.
79703557|NCT01643070|Radiation|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
79703558|NCT02216006|Procedure|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
79710050|NCT05654129|Other|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
79710051|NCT00599625|Drug|Pravastatin|80mg administered daily for 6 consecutive weeks
79710052|NCT05661474|Drug|Fitostimoline ® hydrogel group|Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
79387695|NCT05951465|Drug|Propofol|propofol
79387696|NCT05949645|Device|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
79387697|NCT05948085|Drug|Zavegepant 10 mg IN|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
79387698|NCT05941689|Device|AI-assisted colonoscopy|AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.
79387699|NCT05941065|Other|Balancing gel cream|Skin balancing gel cream will be applied onto clean skin morning and night
79391619|NCT02408250|Procedure|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
79249125|NCT05045300|Procedure|Ultrasound guided Selective trunk block|High definition ultrasound images that were acquired during USG SeTB are routinely stored in the hard disk of ultrasound machine in DICOM (Digital Imaging and Communications in Medicine) format will be used for this review. The images of principal investigator's previous research studies with Clinical trial registration: NCT04752410 and NCT04773405 will also be retrieved. The ultrasound imaging was performed before (scout scan), during and immediately after the USG SeTB. As is the principal investigator's standard practice, all ultrasound scan was performed in a sequential manner (SUIT: Sequential Ultrasound Imaging Technique) with the orientation marker of the transducer directed laterally so as to obtain a transverse oblique view of the brachial plexus block at the supraclavicular fossa. Approximate 50 cases who had undergone USG SeTB for surgical anesthesia during upper extremity surgery since January 1 2020 to June 30, 2021 will be evaluated by two anesthesiologists.
79387700|NCT05940649|Procedure|Continuous norepinephrine administration|In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure < 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
79387701|NCT05938803|Behavioral|PASEO|The intervention consists of community-based accompaniment intervention aimed at facilitating the transition to adult HIV care for adolescents living with HIV in Lima, Peru.The intervention includes the following activities: health systems navigation and accompaniment to clinic visits, monthly check-ins with an entry-level health worker, social support provided through peer support groups, education sessions, resolution of acute needs, and individualized adherence support.
79387702|NCT05932329|Behavioral|Dietary Advice|Dietary Advice provided
79387703|NCT05924750|Drug|BL-M11D1|Administration by intravenous infusion
79387704|NCT05923528|Device|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
79543319|NCT01512940|Procedure|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.~Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
79543320|NCT01512953|Drug|Lansoprazole|Lansoprazole 30 mg once a day
79543321|NCT01512966|Biological|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
79543322|NCT01512992|Procedure|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~Personalised care plan~Education on self-management~Access to a personalized online health folder~Access to Call center~Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~Daily videoconferences for the 1st week after discharge~Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~Remote monitoring for respiratory parameters.~One monthly phone call from the call centre to promote and assess patient self-management."
79543323|NCT01513005|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~position of 4 trocars and insertion of a nasogastric tube~dissection and mobilization of the greater curvature of the stomach~preparation of the stomach for division~gastric partition~extraction of the gastric remnant~postoperative surveillance"
79703559|NCT02216006|Procedure|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
79703560|NCT04532021|Diagnostic Test|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
79703561|NCT04531787|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
79387705|NCT05923528|Device|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
79387706|NCT05923528|Device|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
79387707|NCT05923528|Device|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
79387708|NCT05921305|Drug|MTX|MTX (5mg/m^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
79387709|NCT05921305|Drug|Corticosteroid|Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
79387710|NCT05918575|Device|Noninvasive ventilation alternating with high flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.
79845466|NCT00823004|Drug|GnRH agonist (buserelin)|50 µg SC twice daily
80013908|NCT05237466|Behavioral|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
79387711|NCT05918575|Device|High flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
79703562|NCT05140707|Other|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
79703563|NCT01684059|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
79703564|NCT04531748|Drug|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
79703565|NCT04531748|Drug|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
79543324|NCT01513018|Other|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
79543325|NCT01513018|Other|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
79543326|NCT01513031|Other|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
79543327|NCT01513044|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
79543328|NCT01513044|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
79543329|NCT01513057|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
79543330|NCT01513057|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
79543331|NCT01513070|Drug|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
79543332|NCT01513070|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
79543333|NCT01513070|Drug|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
79543334|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
79543335|NCT01513070|Drug|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
79543336|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
79543337|NCT01513083|Drug|trastuzumab emtansine|Multiple intravenous doses
79543338|NCT01513096|Drug|itopride|itopride, 10mg, twice per day, for 1 day
79703566|NCT04531748|Other|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
79703567|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
79387712|NCT05918510|Diagnostic Test|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
79543339|NCT01513109|Biological|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
79703568|NCT01177813|Drug|BI 10773|BI 10773 low dose tablet once daily
79703569|NCT01177813|Drug|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
79845467|NCT00823004|Drug|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
79387713|NCT05911061|Biological|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
79543340|NCT01513135|Biological|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
79543341|NCT01513135|Biological|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
79703570|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
79703571|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
79703572|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
79703573|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
79703574|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
79845468|NCT00823004|Drug|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
79703575|NCT01177813|Drug|BI10773|BI 10773 high dose tablets once daily
80013909|NCT05232045|Drug|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
80013910|NCT05229874|Drug|carbon nanoparticles|Endoscopic injection
80013911|NCT05229874|Drug|Indocyanine green|Endoscopic injection
79543342|NCT01513161|Drug|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
79249126|NCT05121818|Procedure|PCI|Primary percutaneous coronary intervention
79543343|NCT01513161|Drug|Placebo|
79543344|NCT01513174|Drug|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
79543345|NCT01513174|Drug|Gefitinib plus olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
79543346|NCT01513200|Drug|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
79543347|NCT01513200|Drug|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
79543348|NCT01513200|Drug|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
79543349|NCT01513226|Other|Cycled light|lights on at daytime, lights off at nighttime
79543350|NCT01513252|Behavioral|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
79543351|NCT01513265|Other|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
79703576|NCT01177813|Drug|Sitagliptin|Sitagliptin tablets 100 mg once daily
79703577|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
79703578|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
79703579|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
79703580|NCT04537481|Other|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
79703581|NCT04531826|Other|5-strand hamstring graft preparation|Five-strand hamstring graft preparation
79703582|NCT01684137|Dietary Supplement|Joalis Bambi Analerg|
79249127|NCT03333447|Other|MRI|
79249128|NCT03322371|Device|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
79249129|NCT03333369|Drug|200 mg levodopa/50 mg benserazide|
79387714|NCT05911061|Biological|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
79387715|NCT05911061|Biological|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
79387716|NCT05911061|Biological|Placebo group|saline
79703583|NCT01684137|Dietary Supplement|Joalis Bambi Bronchi|
79703584|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
79703585|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
79703586|NCT04315831|Drug|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
79703587|NCT04531436|Other|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
79845469|NCT00930150|Behavioral|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
79249130|NCT03333369|Drug|Dextrose|
79249131|NCT03326037|Genetic|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
79249132|NCT03333291|Dietary Supplement|fecal suspension|helathy donor fecal suspension administered by duodenal scope
79249133|NCT03333213|Other|Gua Sha|
79249134|NCT03325803|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
79387717|NCT05911048|Biological|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)|boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
79387718|NCT05911048|Biological|Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)|boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
79845470|NCT00930150|Behavioral|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
79387720|NCT05892887|Drug|Bupivacaine 0.25% Injectable Solution|Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
79387721|NCT05861674|Biological|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
79703588|NCT01684176|Behavioral|Complex tailored intervention|
79703589|NCT01684176|Behavioral|Usual care|
79703590|NCT02216045|Drug|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
79703591|NCT02216045|Drug|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
79703592|NCT04531358|Device|nasal spray|application of nasal spray
79703593|NCT04531358|Other|no treatment|no treatment
79543352|NCT01513278|Drug|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
79543353|NCT01513278|Drug|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
79543354|NCT01513304|Procedure|Manual therapy|
79543355|NCT01513356|Drug|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
79543356|NCT01513369|Drug|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
79543357|NCT01513369|Drug|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
79543358|NCT01513382|Procedure|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
79249135|NCT03325803|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
79543359|NCT01513395|Behavioral|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
79543360|NCT01513421|Procedure|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
79543361|NCT01513434|Procedure|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
79543362|NCT01513434|Procedure|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
79249136|NCT03325803|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
79249137|NCT03325803|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
79249138|NCT03325803|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
79249139|NCT02653664|Behavioral|PsychoEducation|Condition #1
79249140|NCT02653664|Behavioral|Self-Hypnosis Training|Condition #2
79249141|NCT02653664|Behavioral|Mindfulness Meditation|Condition #3
79249142|NCT05465343|Drug|Furmonertinib|Furmonertinib 160mg orally QD
79249143|NCT04494009|Drug|INCMGA00012|INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
79249144|NCT05465187|Other|Non applicable|Non applicable
79249145|NCT03325725|Device|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
79249146|NCT02623244|Procedure|Laparoscopic oophorocystectomy or oophorectomy|
79387722|NCT05861674|Biological|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
79387723|NCT05861674|Drug|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
79391620|NCT03171870|Diagnostic Test|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
79391621|NCT03171948|Behavioral|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
79703594|NCT01684293|Behavioral|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
79703595|NCT01684293|Behavioral|Psychoeducation/games|Psychoeducation/games
79703596|NCT02216084|Drug|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
79845471|NCT00930150|Behavioral|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
79845472|NCT00930150|Behavioral|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
79387724|NCT05845281|Procedure|Bupivakain + deksametazon Adjuvant|In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
80013912|NCT05227352|Behavioral|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
80013913|NCT05221970|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
79387725|NCT05842915|Behavioral|Questionnaire|Baseline and 3 month questionnaire
79387726|NCT05842538|Device|Triathlon|Total knee arthroplasty
79387727|NCT05834348|Drug|lorlatinib|As provided in real world practice
79387728|NCT05834348|Drug|crizotinib|As provided in real world practice
79543363|NCT01513434|Procedure|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
80013914|NCT05221970|Behavioral|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
80013915|NCT05221970|Behavioral|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
80013916|NCT05215730|Device|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
79249147|NCT03325569|Diagnostic Test|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
79543364|NCT01513486|Behavioral|immobilization|
79703597|NCT01684332|Other|Strawberry Jam|
79543365|NCT01513499|Drug|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
79543366|NCT01513499|Drug|Placebo|Intranasal Placebo single-dose administration
79543367|NCT01513525|Drug|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
79703598|NCT01684371|Other|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
79249148|NCT03924362|Procedure|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
79703599|NCT04531397|Drug|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
79710053|NCT05661474|Drug|Saline gauze group|Treatment of DFUs with saline gauze every day for 12 weeks.
79845473|NCT00827450|Dietary Supplement|Ctl|Control, isocaloric diet; no coffee
79845474|NCT00827450|Dietary Supplement|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
79845475|NCT00827450|Dietary Supplement|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
79249149|NCT03332901|Other|this is an observational study, no intervention required|this is an observational study, no intervention required
79249150|NCT03325491|Dietary Supplement|Acipimox|Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
79249151|NCT03325491|Dietary Supplement|Placebo|Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
79387729|NCT05834348|Drug|brigatinib|As provided in real world practice
79387730|NCT05834348|Drug|ceritinib|As provided in real world practice
79845476|NCT00827450|Dietary Supplement|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
79845477|NCT00827450|Dietary Supplement|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
79845478|NCT00827528|Procedure|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
79387731|NCT05834348|Drug|alectinib|As provided in real world practice
79543368|NCT01513564|Drug|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
79543369|NCT01513564|Drug|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
79543370|NCT01513577|Other|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
79703600|NCT04531397|Drug|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
79703601|NCT04531475|Drug|X842|X842 capsules
79703602|NCT04531475|Drug|X842 Placebo|X842 placebo-matching capsules
79543371|NCT01513577|Other|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
79703603|NCT04531475|Drug|Lansoprazole|Lansoprazole capsules
79845479|NCT00827528|Procedure|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
80013917|NCT05204446|Behavioral|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
79249152|NCT04150562|Drug|rhIL-15|Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
79249153|NCT04150562|Biological|Avelumab|avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
79249154|NCT04442529|Behavioral|Mothers and Babies (MB)|Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
79249155|NCT03325413|Behavioral|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
79249156|NCT03325413|Behavioral|Preoperative information|Detailed preoperative information about delirium prevention and procedures
79249157|NCT03325413|Behavioral|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
79249158|NCT03325413|Dietary Supplement|Dietary supplements|Dietary supplements if necessary
79249159|NCT03325413|Other|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
79543372|NCT01513603|Drug|CLAG-M|IV times 5 days
79543373|NCT01513603|Drug|CLAG-M|Chemotherapy
79543374|NCT01513616|Other|Pulmonary rehabilitation|8-week program, 3 supervised session per week
79703604|NCT04531475|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
79703605|NCT01684449|Drug|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
79703606|NCT01684527|Other|Respiratory secretions obtained|
79249160|NCT03325413|Procedure|Regional anesthesia|Regional anesthesia whenever possible
79249161|NCT03325413|Other|Personal aids|Personal orientation aids until anesthesia induction
79249162|NCT03325413|Device|Temperature management|Perioperative warming
79249163|NCT03325413|Device|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
79249164|NCT03325413|Procedure|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
79249165|NCT03332823|Behavioral|SME Ambassadors training & program|"Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc."
79387732|NCT05834348|Drug|atezolizumab|As provided in real world practice
79387733|NCT05834348|Drug|bevacizumab|As provided in real world practice
79387734|NCT05834348|Drug|paclitaxel|As provided in real world practice
79387735|NCT05834348|Drug|carboplatin|As provided in real world practice
79387736|NCT05834348|Drug|docetaxel|As provided in real world practice
79387737|NCT05834348|Drug|erlotinib|As provided in real world practice
79387738|NCT05834348|Drug|gefitinib|As provided in real world practice
79387739|NCT05834348|Drug|afatinib|As provided in real world practice
79249166|NCT05002790|Diagnostic Test|Data collection group|"Magnetic resonance imaging (MRI) allows measurement of the axes described to suggest which head and neck position would provide best anatomical alignment to reduce anterior impingement.~All the MRI scans will be conducted using 3.0 Tesla (Optima 750w, GE Medical, Milwaukee, WI, USA) using the cervical spine section of the coil. T2-weighted images in the sagittal plane will be acquired using a fast recovery fast spin echo (FRFSE) technique. The scans will take around two and half minutes and a member of the anaesthetic investigator team will be present to facilitate positional changes and maintain consistency. MRI scanning will be performed in following 3 head and neck positions:~Neutral position, Sniffing position and the Extension position."
79249167|NCT03325335|Drug|Midazolam premedication|Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
79543375|NCT01513616|Other|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
79543376|NCT01513642|Behavioral|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
79543377|NCT01513655|Device|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
79543378|NCT01513668|Drug|Acetaminophen|Extended release Gel tabs 650 mg
79543379|NCT01513681|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
79543380|NCT01513681|Drug|Lamictal®|Lamictal® 200 mg Tablets
79543381|NCT01513694|Procedure|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
79543382|NCT01513720|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
79543383|NCT01513720|Drug|Lamictal®|Lamictal® 200 mg Tablets
79543384|NCT01513733|Drug|tasquinimod|tasquinimod 0.25 mg continuously
79249168|NCT03325335|Drug|Remifentanil infusion|Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
79249169|NCT03325335|Drug|Propofol infusion|Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
79387740|NCT05834348|Drug|dacomitinib|As provided in real world practice
79387741|NCT05834348|Drug|osimertinib|As provided in real world practice
79543385|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
79543386|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
79543387|NCT01513772|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
79543388|NCT01513772|Drug|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
79387742|NCT05834348|Drug|pembrolizumab|As provided in real world practice
79387743|NCT05834348|Drug|nivolumab|As provided in real world practice
79387744|NCT05834348|Drug|entrectinib|As provided in real world practice
79387745|NCT05832814|Behavioral|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
79391622|NCT03171948|Behavioral|Nut Free group|continue their diet without any nut consumption.
79543389|NCT01513785|Drug|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
79543390|NCT01513785|Drug|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
79543391|NCT01513798|Behavioral|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
79543392|NCT01513798|Behavioral|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
79543393|NCT01513811|Drug|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
79543394|NCT01513811|Drug|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
79703607|NCT01684605|Drug|NESP 60μg|Administrated NESP 60μg once intravenously
79703608|NCT01684605|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
79710054|NCT00599664|Drug|OMS201|OMS201 irrigation solution during surgery
79543395|NCT01513811|Drug|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
79703609|NCT04531319|Diagnostic Test|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
79703610|NCT01580085|Other|polysomnography|full night supervised laboratory polysomnography
79703611|NCT04537442|Drug|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
79703612|NCT01684683|Drug|Theophylline|Theophylline 0.1 bid
79249170|NCT05121116|Behavioral|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
79249171|NCT03322059|Behavioral|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
79249172|NCT03322059|Behavioral|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
79249173|NCT02279030|Other|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
79249174|NCT02044328|Drug|Icotinib|Icotinib is administered 125 mg three times per day.
79249175|NCT03325257|Other|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
79387746|NCT05832814|Behavioral|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
79387747|NCT05818943|Drug|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
79543396|NCT01513824|Behavioral|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
79703613|NCT01684683|Drug|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
79249176|NCT03332511|Drug|Nilotinib|Nilotinib 300mg twice-daily
79249177|NCT05114720|Drug|standard adjuvant chemotherapy plus moxifloxacin|docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1 cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days
79543397|NCT01513850|Drug|Hepabulin IV|I.V.
79703614|NCT04537325|Device|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
79703615|NCT01684761|Biological|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
79703616|NCT01684761|Biological|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
79710055|NCT00599664|Drug|Vehicle|Vehicle irrigation solution during surgery
79387748|NCT05808959|Behavioral|Education group|After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health.
79387749|NCT05794568|Device|OITcontrol app monitoring|App to monitor OIT patients
79543398|NCT01513863|Drug|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
79543399|NCT01513863|Drug|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
79391623|NCT02701764|Drug|Pregabalin|
79543400|NCT01513863|Drug|Placebo|Placebo applied to affected area once a day for 70 days
79391624|NCT02701764|Drug|Placebo|
79543401|NCT01513915|Other|Group cognitive behavioral intervention|A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
79543402|NCT01513928|Drug|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
79543403|NCT01513928|Drug|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
79543404|NCT01513928|Drug|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
79249178|NCT05114720|Drug|standard adjuvant chemotherapy plus placebo|docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1 cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
79703617|NCT04537091|Procedure|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
79249179|NCT04493775|Device|Brainwave Entrainment|Alpha frequency visual and auditory stimulation delivered through a smartphone application, with the use of a virtual reality headset and earphones respectively.
79543405|NCT01513941|Drug|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
79249180|NCT05113550|Other|Surgical remove|liver hydatid cyst (LHC) treated by total or partial pericystectomy
79543406|NCT01513941|Drug|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
79543407|NCT01513941|Drug|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
79249181|NCT04493697|Device|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
79249182|NCT04493697|Device|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
79543408|NCT01513980|Procedure|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
79543409|NCT01513980|Procedure|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
79249183|NCT02488629|Drug|SCB01A|This study is a single arm, open-label, Phase II trial
79543410|NCT01513993|Procedure|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
79543411|NCT01514019|Drug|Acebutolol|Acebutolol
79703618|NCT04537091|Procedure|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
79703619|NCT01684800|Drug|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
79703620|NCT01684800|Drug|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
79703621|NCT01684800|Drug|C: Placebo|1 orally disintegrating tablet every night during study period
79703622|NCT04531163|Drug|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
79249184|NCT05111054|Other|Resistance Exercise|Acute leg-based resistance exercise bout (3 sets performed to volitional failure on leg extension and leg curl machines)
79249185|NCT04493463|Drug|Methylprednisolone 40 mg + Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
79387750|NCT05789940|Procedure|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
79710056|NCT04326699|Procedure|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
79703623|NCT04537169|Procedure|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
79387751|NCT05789940|Procedure|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
79387752|NCT05788588|Drug|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
79703624|NCT01684995|Behavioral|Brief physician advice|Brief physician advice to quit smoking
79703625|NCT01684995|Drug|nicotine patch|nicotine patch
79703626|NCT01684995|Behavioral|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
79703627|NCT04530851|Procedure|ERAS|"Counseling~H2- antagonist and metroclopramide for prevent aspiration~Drink clear liquid until 2 hour before surgery~First generation cephalosporin in 60 minute before surgery~Clorhexidine for skin cleansing and Povidine for vaginal cleansing~Regional anesthesia~Keep warming~Blunt expansion of uterine incision~Do not peritoneal suture and subcuticular suture if less than 2 cm~Local wound anesthesia.~Paracetamol and NSAIDs for for pain control~Early remove catheter and ambulation~5-HT3 antagonist for prevent nausea"
79543412|NCT01514019|Drug|Placebo|Placebo capsule(Capsules filled up with lactose)
79703628|NCT04536896|Other|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
79387753|NCT05788588|Drug|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
79249186|NCT04493463|Drug|Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
79543413|NCT01514032|Procedure|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
79249187|NCT04493073|Procedure|Trabectulectomy|decrease IOP
79249188|NCT04493073|Drug|Mitomycin|Decrease bleb failure
79249189|NCT04493073|Device|Ologen Collagen Implant|Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
79249190|NCT04493073|Device|Mitomycin-C Kyowa®|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
79543414|NCT01514032|Procedure|Retrograde intrarenal surgery|Retrograde intrarenal surgery
79703629|NCT04536896|Other|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
79703630|NCT01685190|Radiation|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
79703631|NCT01685190|Radiation|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
79249191|NCT04492761|Behavioral|qualitative study|The qualitative approach will be based on content analysis of - Isemi-structured nterviews of families
79249192|NCT00748904|Drug|Rifaximin|400 mg orally
79249193|NCT00748904|Drug|Lactulose|20 grams titrate to 2-3 bowel movements in one day
79249194|NCT03332433|Device|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
79703632|NCT01685346|Behavioral|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
79387754|NCT05777278|Drug|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
79387755|NCT05777278|Drug|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
79387756|NCT05774327|Other|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
79543415|NCT01514058|Procedure|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
79543416|NCT01514058|Procedure|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
79249195|NCT00219830|Behavioral|home-based walking program|Home-based walking program; included use of pedometer and daily walk diary
79543417|NCT01514071|Behavioral|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
79703633|NCT04531124|Other|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
79249196|NCT05071742|Genetic|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
79391625|NCT03171714|Device|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
79703634|NCT01685385|Other|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
79703635|NCT04530968|Other|No intervention|No intervention
79703636|NCT01200394|Drug|PF-00489791|Tablet, 20 mg once daily for 12 weeks
79703637|NCT01200394|Drug|Placebo|Tablet, placebo once daily for 12 weeks
80013918|NCT05204446|Behavioral|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
79249197|NCT03321903|Device|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
79305558|NCT04930575|Other|Mulligan Technique|"The patient will be in a supportive low back chair, thus cervical region will be in a vertical position (Weight-bearing position) with the therapist position will be behind the patient.~Then the therapist will move the spinous process up in the direction that must follow the apophyseal joint plane under treatment, that is, toward the eye ball. While sustaining this pain-free accessory glide, the patient will be instructed to actively perform the physiological movement gradually until the end ROM with over pressure at the end of the range."
79391626|NCT03171714|Device|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
79391627|NCT03116256|Dietary Supplement|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
79845480|NCT04015284|Procedure|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
80013919|NCT05198349|Drug|M1069|Participants will receive escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
80013920|NCT05197959|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires ~ 11.5 minutes in total.
79543418|NCT01514110|Drug|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
79543419|NCT01514123|Drug|VGX-100|VGX-100 will be administered by IV infusion once every week
79543420|NCT01514123|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
79543421|NCT01514175|Drug|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
79543422|NCT01514175|Drug|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
79543423|NCT01514188|Drug|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
79543424|NCT01514188|Drug|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
79543425|NCT01514214|Device|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
79543426|NCT01514214|Device|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
79543427|NCT01514227|Drug|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
79543428|NCT01514227|Drug|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
79703638|NCT04527354|Drug|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
79703639|NCT04527354|Drug|Placebo|Participants will receive Placebo once a day during 4 weeks
80013921|NCT05197959|Other|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take ~ 30 minutes to complete.
79703640|NCT04531280|Other|Home hospital care|Patients receive hospital-level care in their home.
79387757|NCT05774327|Other|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
79703641|NCT01685502|Drug|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
79703642|NCT04537130|Biological|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
79703643|NCT04527276|Other|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
79703644|NCT04537052|Procedure|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
79249198|NCT03321903|Other|EPR Oximetry Measurement|An oximetry measurement visit consists of ~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
79249199|NCT04993430|Drug|HRS8807|HRS8807 monotherapy
79249200|NCT04993430|Drug|HRS8807|HRS8807 monotherapy
79703645|NCT01200355|Drug|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
79249201|NCT04993430|Device|HRS8807、SHR6390|HRS8807 in combination with SHR6390
80013922|NCT05196191|Biological|VIAGENEX Max|Collagenous membrane derived from umbilical cord
79387758|NCT05772299|Radiation|Er:Yag laser|Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.
79387759|NCT05772299|Device|EMS ultrasound|Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
79387760|NCT05768425|Diagnostic Test|Real-time quaking-induced conversion (RT-QuIC)|RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
79543429|NCT01514253|Drug|Glucose 25%|1 ml glucose 25%, once
79543430|NCT01514253|Dietary Supplement|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
79703646|NCT01200355|Drug|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
79703647|NCT04527705|Procedure|Non-surgical root canal retreatment|Non-surgical root canal retreatment
79703648|NCT04530929|Dietary Supplement|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
79249202|NCT04993430|Drug|HRS8807、SHR6390|HRS8807 in combination with SHR6390
79249203|NCT02492061|Behavioral|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
79249204|NCT04411550|Drug|HLX11|healthy volunteers receive HLX11 (420mg) once
79387761|NCT05768425|Diagnostic Test|Cognitive test|Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
79387762|NCT05768425|Diagnostic Test|Motor examination|Unified Parkinsons Rating Scale (UPDRS)
79387763|NCT05767294|Other|Observation|clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
79543431|NCT01514253|Other|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
79543432|NCT01514266|Drug|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
79543433|NCT01514266|Drug|Placebo|
79543434|NCT01514331|Other|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
79703649|NCT04530929|Dietary Supplement|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
79703650|NCT04536818|Procedure|Laparotomy|Exploratory laparotomy.
79387764|NCT05763303|Other|educational program|interventional program consists of educational part and training part in case of agreement of participants
79703651|NCT04527666|Drug|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
79703652|NCT04530500|Genetic|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
79703653|NCT01685580|Device|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
79703654|NCT01685658|Drug|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
79703655|NCT01685658|Drug|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
79249205|NCT04411550|Drug|CN-Perjeta(Pertuzumab)|healthy volunteers receive CN-Perjeta (420mg) once
79249206|NCT04411550|Drug|EU-Perjeta(Pertuzumab)|healthy volunteers receive EU-Perjeta (420mg) once
79703656|NCT04530578|Drug|Heparin sodium|Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
79703657|NCT04530578|Drug|Enoxaparin|Subcutaneous Enoxaparine every 24 hours
79387765|NCT05761925|Behavioral|COMA-F|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc.) to the comatose patient's caregiver. These sessions will take place in person or on Zoom, depending on the participant's preference.
79387766|NCT05761431|Drug|SYHX2008 injection|Subcutaneous administration on Day 1.
79703658|NCT01200238|Drug|STA-9090|
79703659|NCT01685853|Drug|Bisacodyl plus PEG-CS|"the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
79703660|NCT01685853|Drug|PEG 4 litres split|"the day before colonoscopy: 2 litres of PEG~the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
79845481|NCT04015284|Procedure|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
79249207|NCT04411550|Drug|US-Perjeta(Pertuzumab)|healthy volunteers receive US-Perjeta (420mg) once
79249208|NCT03320499|Procedure|echo doppler at the bed|we practise the echo doppler at the patient 's bed
79543435|NCT01514331|Other|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
79543436|NCT01514409|Dietary Supplement|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
79543437|NCT01514409|Dietary Supplement|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
79543438|NCT01514435|Device|Electroconvulsive therapy|treatment for major depression
79543439|NCT01514435|Device|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
79543440|NCT01514487|Drug|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
79543441|NCT01514500|Drug|somapacitan|Administered s.c. (subcutaneously, under the skin)
79543442|NCT01514500|Drug|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
79543443|NCT01514526|Drug|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
79845482|NCT00930306|Drug|AZD2066|12 doses, Given as capsule, 2 mg & 8 mg
79249209|NCT03320499|Procedure|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
79249210|NCT04984382|Behavioral|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
79249211|NCT03321825|Device|Belotero® Volume Lidocaine|Mode of application: subdermal injection
79249212|NCT03332199|Other|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
79249213|NCT03322449|Other|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
79249214|NCT03322449|Other|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
79387767|NCT05761431|Drug|Octreotide Acetate Microspheres for Injection injection|Intramuscular administration on Day 1.
79387768|NCT05761431|Drug|Sandostatin ® injection|Subcutaneous administration on Day 1.
79387769|NCT05761431|Drug|Placebo to SYHX2008 injection|Subcutaneous administration on Day 1.
79387770|NCT05759663|Procedure|MIRRAD|Repair of the diastasis with MIRRAD technique
79387771|NCT05759663|Procedure|Plication of the entire diastasis arm|Plication of the entire diastasis
79387772|NCT05755178|Behavioral|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
79543444|NCT01514539|Other|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
79703661|NCT04317976|Other|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
79845483|NCT00930306|Drug|Caffeine|2 doses, Given as Tablet, 2x50 mg
80013923|NCT05196191|Procedure|Hibiclens wash|Antiseptic skin cleanser
80013924|NCT05194007|Drug|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
80013925|NCT05194007|Drug|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
80013926|NCT05186077|Other|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
80013927|NCT05186077|Other|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
79249215|NCT05230160|Other|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
79543445|NCT01514578|Drug|TRV130A|Intravenous infusion of 1 hour duration
79543446|NCT01514578|Drug|Dextrose in Water|Intravenous infusion of 1 hour duration
79543447|NCT01514617|Procedure|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.~During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
79543448|NCT01514695|Drug|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
79703662|NCT04317976|Other|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
79305559|NCT03242057|Other|NAVA|Infant will be extubated to NAVA, settings based per protocol
79305560|NCT03242057|Other|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
79305561|NCT04957017|Behavioral|Training|"After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training"
79387773|NCT05748236|Drug|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
79387774|NCT05748236|Drug|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
79387775|NCT05739669|Device|EEG recording with the comparator device Micromed Brain Quick|Each patient will undergo a visit in a clinic, during which a 15 minutes long EEG trace with a CE-certified wet electrode EEG Device (Micromed Brain Quick) will be recorded by specialized staff.
79703663|NCT04530422|Drug|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~Oseltamivir 150 mg q 12 hours for 10 days ;~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
79703664|NCT02887573|Drug|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
79845484|NCT00930306|Drug|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
79845485|NCT00930306|Drug|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
79845486|NCT00930306|Drug|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
79845487|NCT00830882|Drug|levosalbutamol|2 puffs four times a day for 2 weeks
79845488|NCT00830882|Drug|racemic salbutamol|2 puffs four times a day for 2 weeks
79845489|NCT00830882|Drug|placebo|2 puffs four times a day for 2 weeks
80013928|NCT05186077|Other|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
80013929|NCT05186077|Other|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
80013930|NCT05176132|Other|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
80013931|NCT05176132|Other|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
80013932|NCT05176132|Other|No intervention|Control groups (BMI 20-25 and BMI 25-30)
80013933|NCT05175521|Other|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
80013934|NCT05175521|Other|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
79387776|NCT05739669|Device|"EEG recording with the investigational device Atlas with dry electrodes clinic/specialized staff"|"During the same visit when the wet electrode EEG is recorded, the patient will be subjected to a second 15 minutes long EEG recording with the investigational device Atlas with dry electrodes, which will be conducted by specialized staff"
80013935|NCT05170334|Drug|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
79387777|NCT05739669|Device|"EEG recording with the investigational device Atlas with dry electrodes home/lay people"|"The patients will record their own EEGs at home daily for 14 days, using the investigational device Atlas with dry electrodes"
79703665|NCT02887573|Drug|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
79845490|NCT04044092|Other|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
79845491|NCT04044092|Other|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
79845492|NCT00823160|Procedure|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
79845493|NCT00823160|Procedure|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
79845494|NCT03584724|Drug|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
79845495|NCT03584724|Drug|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
79845496|NCT00823238|Drug|ceftazidime and tobramycin|
80013936|NCT05170334|Drug|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
80013937|NCT05169424|Device|Trelegy Ellipta|Trelegy Ellipta
80013938|NCT05169424|Device|Stiolto Respimat|Stiolto Respimat
80013939|NCT05169424|Drug|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
79302827|NCT03199027|Other|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
79543449|NCT01514695|Drug|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
79543450|NCT01514695|Other|Placebo|One dose of saline (2ml)
79703666|NCT02887573|Procedure|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
79845497|NCT00823238|Drug|inhaled tobramycin|
79845498|NCT00931788|Drug|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
79302828|NCT02482649|Behavioral|EAA/T|bi-weekly for 12weeks
79387778|NCT05739058|Device|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
79387779|NCT05729061|Device|Assist-Knee|Investigational prosthetic knee-ankle device
79387780|NCT05729061|Device|Prosthetic Knee|Commercially available prosthetic knee devices
79387781|NCT05729061|Device|Prosthetic Ankle|Commercially available prosthetic ankle devices
79543451|NCT01514708|Biological|AdimFlu-S Influenza Vaccine|Suspension for injection
79543452|NCT01514721|Drug|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
79543453|NCT01514799|Procedure|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
79543454|NCT01514812|Drug|YM150|oral - modified release formulation of YM150
79703667|NCT02887573|Drug|2L PEG|2L PEG are laxatives for experiment group.
79703668|NCT02887573|Drug|4L PEG|4L PEG are laxatives in the control group.
79703669|NCT02887573|Drug|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
79703670|NCT02887573|Drug|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
79845499|NCT00931788|Other|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
79845500|NCT00831038|Procedure|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
79845501|NCT00827684|Drug|Irinotecan|
79845502|NCT00827684|Drug|Temsirolimus|
79845503|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
79845504|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
80013940|NCT05169424|Drug|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
80013941|NCT05165576|Behavioral|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
80013942|NCT05165186|Other|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
79543455|NCT01514812|Drug|placebo|oral
79543456|NCT01514812|Drug|digoxin|oral
80013943|NCT05155046|Drug|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
80013944|NCT05150691|Biological|DB-1303|Administered IV
79249216|NCT04109378|Procedure|Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE|For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
79249217|NCT03320421|Radiation|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
79249218|NCT02492217|Drug|Adalimumab|
79249219|NCT05229926|Device|CareCube|modular, disposable, negative pressure, isolation patient care system
79249220|NCT03332043|Device|HIRREM|HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.
79387782|NCT05729061|Device|Prosthetic Foot|Commercially available prosthetic foot devices
79387783|NCT05729061|Device|Ankle-Foot Orthosis|Commercially available ankle-foot orthosis devices
79387784|NCT05724004|Radiation|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
79543457|NCT01514825|Drug|YM150|oral
79543458|NCT01514825|Drug|Placebo|oral
79703671|NCT01685892|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
79543459|NCT01514838|Drug|ASP1941|oral
79703672|NCT01685892|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
79703673|NCT02887534|Drug|SPARC1401-low dose|SPARC1401- low dose
80013945|NCT05150691|Drug|Pertuzumab Injection|Administered IV
79543460|NCT01514838|Drug|acarbose|oral
79543461|NCT01514838|Drug|Placebo|oral, used only during placebo run-in period
79703674|NCT02887534|Drug|SPARC1401-mid dose|SPARC1401- mid dose
79703675|NCT02887534|Drug|SPARC1401-high dose|SPARC1401-high dose
79703676|NCT02887534|Drug|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
79703677|NCT02887534|Drug|Placebo1401|Placebo
79387785|NCT05707975|Other|Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents|Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
79387786|NCT05706298|Behavioral|Active Breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm
79543462|NCT01514851|Drug|Lanthanum carbonate (BAY77-1931)|
79703678|NCT01685931|Drug|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
79703679|NCT04530461|Diagnostic Test|Serological test|Positive serological test of SARS Cov2
79703680|NCT01685970|Drug|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
79703681|NCT01685970|Drug|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
79703682|NCT04530617|Drug|Camostat Mesilate|Tablets
79703683|NCT04530617|Drug|Artemisia Annua Leaf|Tea bags
80013946|NCT05150691|Drug|Ritonavir|Administered oral
80013947|NCT05150691|Drug|Itraconazole|Administered oral
80013948|NCT05139160|Dietary Supplement|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
79387787|NCT05699499|Other|KeryFlex|KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
79543463|NCT01514851|Drug|Calcium carbonate|
79543464|NCT01514877|Drug|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
79543465|NCT01514916|Device|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
79543466|NCT01514929|Drug|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
79543467|NCT01514929|Drug|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
79543468|NCT01514929|Drug|Moxifloxacin|400mg oral pill given once
79543469|NCT01514929|Drug|Placebo|Placebo oral pill given once
79703684|NCT01686009|Drug|Intra-nasal ketamine|
80013949|NCT05132491|Other|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
79703685|NCT01686243|Other|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
79703686|NCT01686243|Other|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
79703687|NCT04530695|Other|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
79703688|NCT01686282|Dietary Supplement|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
79703689|NCT01686282|Dietary Supplement|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
79703690|NCT04536389|Procedure|Office Hysteroscopy|"The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment."
80013950|NCT05129527|Device|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
79845505|NCT00927030|Drug|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
80013951|NCT05129527|Other|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
80013952|NCT05126784|Biological|Denosumab|AVT03 (denosumab) or Prolia (denosumab) will be given as 1 time subcutaneous injection)
79249221|NCT03332043|Other|Ambient Nature Sounds|Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
79249222|NCT05229848|Procedure|3D electroanatomical mapping alone guided CTI ablation|3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
79302829|NCT02482649|Drug|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
79302830|NCT02482649|Drug|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
79302831|NCT03198637|Drug|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
79302832|NCT03198637|Drug|clinical assessment|
79305562|NCT03241433|Other|High intensity interval training|exercise by use of stationary cycles
79387788|NCT05682547|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
79387789|NCT05682547|Drug|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
79387790|NCT05675865|Device|cryoablation procedure|ablation procedure for VT using the investigational device
79387791|NCT05675657|Other|No Block|The patients will receive general anesthesia.
79387792|NCT05675657|Procedure|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
79543470|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
79543471|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
79543472|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
79543473|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
79543474|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
79543475|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
79543476|NCT01514955|Radiation|Gold seeds insertion to detect movements at pelvis|
79543477|NCT01514955|Radiation|Image guided MRI based RT (IMRT+Brachytherapy)|
79543478|NCT01514968|Drug|cyclosporine|Single oral dose
79543479|NCT01514968|Drug|danoprevir|Single oral dose
79543480|NCT01514968|Drug|ritonavir|Single oral dose
79543481|NCT01514981|Drug|AMG 761|Single dose of AMG 761 on study day 1.
79703691|NCT04536662|Drug|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
79703692|NCT04536662|Drug|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
79703693|NCT04536662|Drug|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
79703694|NCT01686321|Drug|Bendamustine and subcutaneous rituximab|
79703695|NCT01199731|Drug|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
79703696|NCT01199731|Drug|GSK2248761 200 mg once daily|2 100mg capsules OAD
79703697|NCT01199731|Drug|Etravirine|2 100mg tablets twice daily
79703698|NCT01686360|Behavioral|Decision Aid|
79703699|NCT04530266|Diagnostic Test|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
79703700|NCT01686399|Behavioral|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
79703701|NCT01686555|Drug|ABT-199|Tablet
79703702|NCT01686555|Other|Placebo|Tablet
79845506|NCT00927030|Drug|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
79543482|NCT01514981|Drug|Placebo|Single dose of placebo on study day 1.
79543483|NCT01514994|Device|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
79543484|NCT01515020|Drug|vancomycin monotherapy|intravenous therapy by vancomycin
79845507|NCT00827762|Drug|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
79845508|NCT00931866|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
79845509|NCT00931866|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
80013953|NCT05122806|Genetic|RNAseq|"Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples"
80013954|NCT05121961|Procedure|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
79543485|NCT01515020|Drug|daptomycin monotherapy|intravenous therapy by daptomycin
80013955|NCT05114187|Other|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~Ten selected multimedia e-learning lessons;~A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
79703703|NCT01686672|Behavioral|Web Intervention|Behavioral
79845510|NCT00831116|Device|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
79387793|NCT05675657|Procedure|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
79387794|NCT05672836|Drug|Enavogliflozin|0.3 mg 1 tablet once daily
79387795|NCT05672836|Drug|Standard-of-Care|Standard-of-Care medical therapy plus Enavogliflozin matching placebo
79387796|NCT05672017|Behavioral|Dietary Instructions|Dietary Instructions
79387797|NCT05656807|Behavioral|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
79391628|NCT03116256|Other|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
79543486|NCT01515033|Other|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
79543487|NCT01515085|Procedure|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
79543488|NCT01515163|Behavioral|Exercise training|Aerobic exercise training, two times a week
79703704|NCT02217371|Other|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
79703705|NCT05393596|Behavioral|Virtual Reality Software Intervention|Virtual Reality Software Intervention
79703706|NCT02217488|Drug|DG3173|
79703707|NCT02217488|Drug|Placebo|
79710057|NCT02891655|Other|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
79710058|NCT05653310|Drug|Tradipitant|Tradipitant Capsule
79710059|NCT05653310|Drug|Placebo|Placebo Capsule
79845511|NCT04885452|Other|biobank|"Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
79845512|NCT00823394|Behavioral|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
79845513|NCT00823394|Other|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
79845514|NCT00823394|Behavioral|Self-help Materials|Information on how to lower risk for developing cancer.
79249223|NCT05229848|Procedure|ICE plus 3D electroanatomical mapping guided CTI ablation|ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
79710060|NCT05649878|Drug|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
79845515|NCT00831194|Behavioral|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
79845516|NCT04366544|Other|Part A1: Survey|Online
79845517|NCT04366544|Other|Part A2: Sample collection|Blood and Stool
79845518|NCT04366544|Other|Part B:|EEG and fMRI
79845519|NCT00930462|Device|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
79543489|NCT01515202|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
79845520|NCT00827840|Drug|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
79249224|NCT02488395|Other|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
79305563|NCT03241433|Other|Moderate intensity continuous training|exercise by use of stationary cycles
79845521|NCT00827840|Drug|Risperidone|1 to 6 mg of risperidone once or twice a day
79845522|NCT05280288|Device|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
79387798|NCT05656807|Behavioral|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
79387799|NCT05636319|Biological|ABO1020|Vaccine
79387800|NCT05636319|Biological|Placebo|Placebo
79543490|NCT01515202|Drug|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
79387801|NCT05619809|Dietary Supplement|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
79387802|NCT05619809|Dietary Supplement|Protein supplement|Daily ingestion of protein supplement.
79387803|NCT05619809|Dietary Supplement|Placebo supplement|Daily ingestion of a placebo dietary supplement.
79543491|NCT01515202|Drug|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
79543492|NCT01515202|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
79543493|NCT01515202|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
79387804|NCT05614843|Device|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
79387805|NCT05614843|Device|Sham placebo|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
79387806|NCT05608499|Drug|Duobrii|topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks
79543494|NCT01515215|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
79543495|NCT01515228|Device|Xience Prime|everolimus-eluting stent implantation
79543496|NCT01515228|Device|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
79543497|NCT01515254|Behavioral|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
79543498|NCT01515293|Procedure|Single Incision Laparoscopic Appendectomy|
79543499|NCT01515293|Procedure|Conventional appendectomy|
79845523|NCT00927108|Other|Progenitor Stem Cell Culture|
79845524|NCT02549300|Other|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
79387807|NCT05608499|Drug|Placebo|Topical does not contain active properties of study drug
79543500|NCT01515358|Drug|Placebo|Administered orally
79543501|NCT01515358|Drug|LY3000328|Administered orally
79543502|NCT01515371|Drug|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
79543503|NCT01515371|Drug|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
79543504|NCT01515384|Drug|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
79543505|NCT01515397|Drug|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
79543506|NCT01515397|Drug|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
79543507|NCT01515436|Other|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
79543508|NCT01515436|Other|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
79543509|NCT01515501|Procedure|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
79543510|NCT01515553|Drug|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
79543511|NCT01515579|Drug|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
79543512|NCT01515579|Drug|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
79543513|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
79543514|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
79543515|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
79543516|NCT01515592|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
79543517|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin I
79543518|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin II
79543519|NCT01515644|Other|Powder based infant formula|Powder based infant formula without Inulin
79543520|NCT01515683|Behavioral|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
79543521|NCT01515683|Behavioral|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
79543522|NCT01515683|Behavioral|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
79543523|NCT01515683|Behavioral|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
79543524|NCT01515722|Behavioral|Health education intervention (HEI)|"<Part 1> Understanding OAB~<Part 2> Behavioral/lifestyle modification~<Part 3> Bladder training~<Part 4> Understanding antimuscarinics"
79387808|NCT05608499|Drug|Bryhali|Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
79543525|NCT01515761|Procedure|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
79543526|NCT01515761|Procedure|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
79543527|NCT01515774|Drug|Mirapex ER|Change Requip or Mirapex to Mirapex ER
79543528|NCT01515800|Behavioral|Text message reminder|Receive text message
79845525|NCT00930618|Drug|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
79845526|NCT00930618|Drug|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
79845527|NCT00827996|Drug|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
79387809|NCT05578807|Procedure|without reverse ureteral catheter insertion|In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
79543529|NCT01515813|Drug|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
79543530|NCT01515813|Drug|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
79543531|NCT01515813|Drug|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
79543532|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
79387810|NCT05576662|Drug|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours
79387811|NCT05576662|Drug|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
79387812|NCT05576662|Drug|Ritonavir|One 100 mg capsule taken by mouth every 12 hours
79387813|NCT05575674|Device|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
79387814|NCT05564650|Biological|Navitoclax|Given PO
79387815|NCT05564650|Drug|Venetoclax|Given PO
79387816|NCT05564650|Drug|Decitabine|Given IV
79703708|NCT04536740|Device|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
79703709|NCT01686789|Drug|Pegylated interferon alpha-2a|
79845528|NCT00936780|Device|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
79845529|NCT00823550|Drug|Entecavir|entecavir 0.5 mg QD
79845530|NCT00823550|Drug|Lamivudine|lamivudine 100 mg QD
79249225|NCT02488395|Other|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
79845531|NCT00937014|Other|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
79845532|NCT00937014|Other|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
80013956|NCT05114187|Other|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~One selected multimedia e-learning lesson;~A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
80013957|NCT05105919|Drug|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
80013958|NCT05098509|Drug|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
80013959|NCT05098509|Drug|Placebo|Matching Placebo for RAD011
79249226|NCT02488395|Other|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
80013960|NCT05092451|Drug|Cyclophosphamide|Given by IV
79249227|NCT05229536|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
79249228|NCT05229536|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
79543533|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
79543534|NCT01515839|Dietary Supplement|Multivitamin Supplement intervention|"We recommend the following protocol:~2 tablets of a high quality multivitamin BID~2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~Weight loss"
79543535|NCT01515852|Procedure|general anesthesia in stereotactic biopsy|stereotactic biopsy
79543536|NCT01515852|Procedure|local anesthesia in stereotactic biopsy|stereotactic biopsy
79845533|NCT00828152|Behavioral|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
79845534|NCT00828152|Behavioral|On line discussion group|Placebo. On line discussion group.
79845535|NCT00932100|Drug|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
80013961|NCT05092451|Drug|CAR.70/IL15-transduced CB-NK cells|Given by IV
79703710|NCT02217605|Dietary Supplement|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
79845536|NCT00932100|Drug|Heparin|IV dose per standard of care at the local institution
79845537|NCT00828230|Drug|budesonide|One application of 2mg budesonide once daily for 8 weeks
79845538|NCT00828230|Drug|Placebo foam|One application of placebo foam once daily for 8 weeks
79845539|NCT02548988|Other|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
79845540|NCT04469556|Drug|Folfirinox|Chemotherapy
80013962|NCT05092451|Drug|Fludarabine phosphate|Given by IV
79249229|NCT02490735|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
79249230|NCT03331887|Procedure|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
79249231|NCT03331887|Procedure|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
79845541|NCT04469556|Drug|Gemcitabine/nab-paclitaxel|Chemotherapy
79845542|NCT00540423|Drug|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
79845543|NCT00540423|Drug|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
79845544|NCT00540423|Drug|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
79543537|NCT01515878|Device|Hemocontrol|Blood Volume Tracking system using biofeedback
79703711|NCT01686867|Device|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
79703712|NCT02217644|Drug|BI 653048 H3PO4 solution|
79703713|NCT02217644|Drug|BI 653048 H3PO4 low dose capsule|
79703714|NCT02217644|Drug|BI 653048 H3PO4 high dose capsule|
79703715|NCT02217644|Drug|Placebo|
79703716|NCT04536311|Procedure|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
79703717|NCT02217683|Drug|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
79703718|NCT04536233|Biological|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
79703719|NCT04536233|Other|physiological saline|The physiological saline was injected on the wound
79845545|NCT00540423|Drug|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
79845546|NCT00932178|Behavioral|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
79543538|NCT01515917|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
79845547|NCT04014504|Diagnostic Test|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
79703720|NCT02217722|Other|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
79703721|NCT02217722|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
79703722|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
79703723|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
79703724|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
79703725|NCT01686945|Drug|placebo|Placebo semaglutide. For oral administration.
79845548|NCT03710850|Dietary Supplement|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
79845549|NCT00932256|Drug|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
79845550|NCT00932334|Behavioral|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
79845551|NCT00932334|Behavioral|TALK Standard|Participants receive and educational video and booklet about living kidney donation
79845552|NCT00932334|Behavioral|Usual Care|Participants receive their usual care
79845553|NCT00937092|Drug|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
79845554|NCT00937092|Drug|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
79845555|NCT04124601|Radiation|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
79845556|NCT04124601|Drug|Ipilimumab|Infusion
79249232|NCT04830956|Other|FID123238|Lubricant applied to the ocular surface
79249233|NCT04830956|Other|Systane Hydration|Drops applied to the ocular surface
79249234|NCT02488161|Other|No intervention|
79249235|NCT04810910|Biological|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
79543539|NCT01515917|Drug|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
79543540|NCT01515917|Other|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
79703726|NCT01686945|Drug|placebo|Placebo semaglutide with carrier. For oral administration.
79703727|NCT04536506|Other|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
79703728|NCT04536506|Other|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
79703729|NCT01686984|Other|Altered breath|
79845557|NCT04124601|Drug|Nivolumab|Infusion
79845558|NCT00930696|Procedure|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
79845559|NCT00930696|Procedure|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
79543541|NCT01515917|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
79703730|NCT02217839|Drug|DG3173|
79703731|NCT02217839|Drug|DG3173+Octreotide|
79703732|NCT02217839|Drug|Octreotide|
79703733|NCT02217839|Drug|DG3173 Placebo|
79703734|NCT02217839|Drug|DG3173 Placebo+Octreotide Placebo|
79703735|NCT02217839|Drug|Octreotide+DG3173 Placebo|
79703736|NCT02217917|Drug|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
79703737|NCT02217917|Drug|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
79703738|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
79703739|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
79703740|NCT02217917|Drug|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
79703741|NCT01687062|Other|FeSO4|
79703742|NCT01687062|Other|reduction of phytate|
79703743|NCT01687062|Other|NaFeEDTA|
79703744|NCT02217956|Drug|Cisplatin|
79703745|NCT02217956|Drug|Bevacizumab|
79703746|NCT01687140|Drug|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
79703747|NCT01687140|Drug|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
79703748|NCT04535960|Drug|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
79703749|NCT04535960|Drug|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
79845560|NCT00937170|Device|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
79845561|NCT00937170|Device|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
79249236|NCT04810910|Other|GM-CSF|GM-CSF: 40 mcg
79249237|NCT03331809|Procedure|Two-handed jaw thrust|The assistant applied two-handed jaw thrust when intubating with double-lumen tube endotracheal tube.
79249238|NCT03331809|Procedure|Conventional intubation|The attending anesthesiologist provided intubation with double-lumen tube endotracheal tube without two-handed jaw thrust.
79703750|NCT02270463|Drug|SL-401|
79703751|NCT04536428|Device|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~The tip of endoscope is accessed to a bleeding site.~The accurate visualization of bleeding site is done.~A sheath of delivery system of clip is inserted through a working channel of endoscope.~The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~The both ends of clip are placed on both sides of a bleeding site.~If bleeding is still continued, additional placements of clip are tried until bleeding stops."
79703752|NCT01687374|Drug|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
79703753|NCT01687374|Drug|Placebo|Saline injection daily for 8 weeks.
79703754|NCT04530188|Drug|Sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
79703755|NCT04530188|Drug|Propofol|Intravenous sedation with propofol, as already used in our ICU
79703756|NCT01687452|Biological|Blood samples|
79703757|NCT02216162|Other|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
79703758|NCT02216162|Other|No intervention|Usual clinical follow-up
79703759|NCT01687491|Drug|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
79703760|NCT01687491|Drug|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
79703761|NCT01687530|Procedure|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
79703762|NCT04530227|Drug|Biological: Camrelizumab|PD-1
79703763|NCT04530227|Drug|Pemetrexed|chemotherapy
79703764|NCT04530227|Drug|Nab-paclitaxel|chemotherapy
79703765|NCT01687569|Other|Control Cracker Snack|Base cracker snack
79703766|NCT01687569|Other|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
79703767|NCT01687569|Other|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
79703768|NCT01199263|Other|Laboratory Biomarker Analysis|Correlative studies
79703769|NCT01199263|Drug|Paclitaxel|Given IV
79703770|NCT01199263|Biological|Pelareorep|Given IV
79703771|NCT01687647|Other|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
79703772|NCT02217995|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams & Teasdale, 2002)."
79703773|NCT01687725|Device|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
79249239|NCT04791722|Behavioral|Adaptive Intervention|The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
79249240|NCT02488083|Device|Ultrashape|circumference reduction
79249241|NCT03320265|Drug|PC-mAb|Monthly treatment for 3 months (4 administrations)
79249242|NCT03320265|Drug|Placebo|Monthly treatment for 3 months (4 administrations)
79249243|NCT04631588|Drug|Botox|Intradermal (ID) injection
79703774|NCT02218034|Drug|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
80013963|NCT05072977|Procedure|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
80013964|NCT05072977|Procedure|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
79249244|NCT04631588|Drug|Placebo|Intradermal (ID) injection
79249245|NCT02492139|Device|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
79249246|NCT02492139|Device|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
79387817|NCT05564650|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79703775|NCT02218034|Drug|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
79703776|NCT02218034|Drug|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
79703777|NCT02218034|Drug|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
80013965|NCT05068752|Drug|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
79387818|NCT05564650|Procedure|Biospecimen Collection|Undergo collection of blood
79387819|NCT05564650|Other|Laboratory Biomarker Analysis|Correlative studies
79387820|NCT05564650|Other|Quality-of-Life Assessment|Ancillary studies
79845562|NCT00937170|Device|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
80013966|NCT05068752|Drug|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
80013967|NCT05064410|Behavioral|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
80013968|NCT05051293|Other|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
80013969|NCT05049044|Other|Quality of Life Questionnaire-Core 30 (QLQ-C30)|The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
80013970|NCT05042505|Drug|Dapagliflozin 10Mg Tab|Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
80013971|NCT05042505|Drug|Sitagliptin 100mg|Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
79249247|NCT04591886|Behavioral|mind. body. voice.|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
79249248|NCT02490501|Procedure|SC0806 and rehabilitation|
79249249|NCT02490501|Other|Rehabilitation only|
79249250|NCT03331653|Other|Dry Needling and Ischemic Compression at the Trigger Point|The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
79305564|NCT03241433|Other|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
79387821|NCT05564169|Drug|Placebo|treatment per os
79387822|NCT05564169|Drug|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
79387823|NCT05564169|Drug|Standard of care|Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
79387824|NCT05561816|Drug|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
79387825|NCT05561816|Drug|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
79703778|NCT01687764|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
79703779|NCT01687764|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
79703780|NCT01687764|Behavioral|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
79703781|NCT01687764|Behavioral|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
79703782|NCT04529759|Other|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
79703783|NCT04529759|Other|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
79703784|NCT01687803|Behavioral|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
79703785|NCT01687803|Behavioral|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
79703786|NCT01687842|Other|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
79845563|NCT00932412|Drug|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
79845564|NCT00932412|Drug|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
79845565|NCT05046639|Drug|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
79845566|NCT05046639|Drug|10 mL preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
80013972|NCT05036876|Drug|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
80013973|NCT05036876|Drug|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
79703787|NCT01687959|Other|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
80013974|NCT05031962|Device|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
79249251|NCT03331653|Other|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point|The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
79703788|NCT02216240|Other|Paramedic|
79703789|NCT02216240|Other|Standard care|
79703790|NCT01688115|Procedure|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
79249252|NCT03321669|Procedure|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
79249253|NCT05229380|Drug|Saccharin test|Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
79387827|NCT05558462|Drug|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
79703791|NCT01688115|Other|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
80013975|NCT05014282|Drug|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
80013976|NCT05014282|Behavioral|Counseling|Phone counseling with the state tobacco quitline.
80013977|NCT05014282|Drug|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
80013978|NCT05014282|Behavioral|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
80013979|NCT05010200|Biological|PGV-001|personalized genomic peptide vaccine
79249254|NCT02490423|Other|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
80013980|NCT05010200|Biological|Poly-ICLC|immune modulator
80013981|NCT05010200|Biological|CDX-301|soluble recombinant human protein to work on stem cell
80013982|NCT05010174|Drug|MDR product|Observation of patients previously receiving MDR product(s)
79703792|NCT04529486|Other|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
79543542|NCT01515930|Behavioral|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding monitoring diabetes care.
79543543|NCT01515930|Behavioral|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding diabetes care.
79543544|NCT01515930|Behavioral|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
79543545|NCT01515969|Drug|Erlotinib hydrochloride|Given PO
79703793|NCT01688154|Dietary Supplement|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
79703794|NCT01688154|Other|2 empty capsules|
79703795|NCT02216279|Drug|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
79703796|NCT04529681|Device|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
80013983|NCT05007327|Other|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
79249255|NCT03320187|Drug|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
79249256|NCT03320187|Drug|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
79543546|NCT01515969|Drug|Dovitinib lactate|Given PO
79543547|NCT01515982|Behavioral|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
79543548|NCT01515982|Behavioral|Control Group|All participants were asked not to commence any new exercise regimen.
79543549|NCT01516021|Dietary Supplement|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
79543550|NCT01516047|Drug|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
79543551|NCT01516047|Drug|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
79543552|NCT01516060|Drug|Efavirenz|400mg qd; 2 x 200mg
79543553|NCT01516060|Drug|Efavirenz|600mg qd; 3 x 200mg qd
79543554|NCT01516099|Other|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
79703797|NCT04529681|Other|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
79703798|NCT04529642|Diagnostic Test|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
79710061|NCT05649878|Drug|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
80013984|NCT04984850|Other|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
79302833|NCT02635347|Procedure|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
79543555|NCT01516099|Other|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
79703799|NCT01688349|Other|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
79703800|NCT02216318|Other|blue light|
79845567|NCT04565613|Dietary Supplement|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
79845568|NCT04014036|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
79845569|NCT05007951|Biological|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
79845570|NCT05007951|Biological|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
79845571|NCT05007951|Biological|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
79845572|NCT04014816|Other|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
79543556|NCT01516138|Drug|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
79845573|NCT04014816|Other|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
79387828|NCT05557721|Procedure|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
79543557|NCT01516138|Drug|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
80013985|NCT04983615|Drug|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
79845574|NCT00932490|Behavioral|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
79845575|NCT00932724|Drug|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
79845576|NCT00932724|Drug|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
79845577|NCT00931008|Drug|SID530, Taxotere|75mg/m2
80013986|NCT04983615|Drug|midazolam-based sedation|midazolam-based sedation
80013987|NCT04975308|Drug|Imlunestrant|Administered orally.
80013988|NCT04975308|Drug|Exemestane|Administered orally.
80013989|NCT04975308|Drug|Fulvestrant|Administered IM.
80013990|NCT04975308|Drug|Abemaciclib|Administered orally.
79249257|NCT04511156|Other|Foundational Helping Skills|Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
79249258|NCT03320109|Other|Vitamin D|
79387829|NCT05557721|Procedure|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
79387830|NCT05546788|Procedure|scaling and root planing|subgingival Depridement
79543558|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
80013991|NCT04962698|Behavioral|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
80013992|NCT04962698|Behavioral|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
80013993|NCT04962698|Behavioral|Robotic-Hand Interaction with MI|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
79249259|NCT04530812|Other|Best Practice|Maintain usual diet
79249260|NCT04530812|Dietary Supplement|Kefir|Consume commercial kefir beverage
79249261|NCT04530812|Other|Quality-of-Life Assessment|Ancillary studies
79845578|NCT01563705|Procedure|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
79249262|NCT04530812|Other|Questionnaire Administration|Ancillary studies
79249263|NCT04529876|Drug|Tofacitinib|Tofacitinib claim is used as the reference group.
80013994|NCT04962698|Behavioral|Robotic-Hand Interaction without MI|Subjects will perform the Robot-Hand Interaction without MI.
79703801|NCT04822389|Device|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
79703802|NCT02218073|Drug|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
79845579|NCT01563705|Procedure|Manual dexterity assessment|Purdue pegboard test
79845580|NCT00932802|Drug|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
79845581|NCT03439449|Device|CLEOS software program|Computer-assisted history taking program
79845582|NCT03439449|Procedure|Physician taken history|Conventional history taking by physicians
79845583|NCT00932880|Drug|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
79845584|NCT00932880|Drug|Norvasc|10 mg dose (Pfizer, USA)
79845585|NCT05360199|Behavioral|PROMs|evaluate the impact of recall bias on post proms scores
79845586|NCT00937482|Drug|cediranib maleate|Given orally
79845587|NCT00937482|Radiation|whole-brain radiation therapy|Undergo whole-brain radiotherapy
79845588|NCT01563861|Genetic|RNA analysis|
79845589|NCT01563861|Genetic|gene expression analysis|
79845590|NCT01563861|Other|immunohistochemistry staining method|
79845591|NCT01563861|Other|laboratory biomarker analysis|
79845592|NCT00931086|Drug|belimumab|IV 10mg/kg q28days
79845593|NCT00933036|Device|Crosstrees Pod system for PVA|Minimally invasive spine surgery
80013995|NCT04962698|Behavioral|Virtual-Hand Interaction|Subjects will interact with visual feedback of virtual robot actions on a monitor.
79249264|NCT04529876|Drug|Abatacept|Abatacept claim is used as the exposure group.
79249265|NCT03320031|Drug|Linagliptin|Take linagliptin 5mg a day.
79249266|NCT03320031|Drug|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
79845594|NCT04453839|Drug|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
79845595|NCT04004559|Other|No interventions|As this is a patient registry, there are no interventions.
79845596|NCT00566982|Drug|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
79249267|NCT04510922|Drug|Droxidopa 100 MG [Northera]|droxidopa taken three times a day titrated up to a maximum of 600 mg.
79249268|NCT05465031|Drug|Sacubitril-valsartan|Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
79302834|NCT02635347|Device|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
79387831|NCT05546788|Drug|hydroxylated poly methoxy flavones|Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
79387832|NCT05546788|Drug|chlorhexidine|Received chlorhexidine gel
79387833|NCT05546788|Drug|placebo|Received placebo gel
79387834|NCT05544916|Drug|XC221|200 mg/day, for 5 days
79387835|NCT05544916|Drug|Placebo|2 tablets/day, for 5 days
79387836|NCT05534802|Drug|Ulinastatin|On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
79387837|NCT05534802|Other|saline|On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
79703803|NCT02218073|Drug|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
79845597|NCT00566982|Drug|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
79845598|NCT00624338|Drug|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
79845599|NCT00624338|Drug|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
80013996|NCT04962698|Behavioral|Robotic Action Observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
80013997|NCT04962698|Behavioral|Rest|Subjects will rest without a task.
79845600|NCT00624338|Other|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
79387838|NCT05534256|Behavioral|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
79387839|NCT05510089|Drug|Etoposide|D1~D2: 75mg/m^2
79703804|NCT02218073|Drug|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
79703805|NCT05138523|Combination Product|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
79703806|NCT02218112|Procedure|bariatric surgery (gastric bypass)|
79703807|NCT04535570|Other|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
79249269|NCT04510844|Drug|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
79249270|NCT04510844|Other|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
79249271|NCT03319875|Device|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
79249272|NCT04103996|Diagnostic Test|Ultrasound|Sonographic measurements (diaphragm, abdominal muscle, and quadriceps thickness) will be acquired when listed for lung transplantation. Sonographic measurements will be recorded on a daily basis for up to 1 week after transplantation (while the patient remains intubated).
79305565|NCT03058731|Device|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
79387840|NCT05510089|Drug|Cytarabine|D1~D2: 300mg/m^2, q12h
79387841|NCT05510089|Drug|PEG-rhG-CSF|D6: 6mg
79387842|NCT05497492|Drug|propofol|single administration of propofol
79387843|NCT05497492|Drug|propofol and sufentanil|administration of propofol and sufentanil in combination
79387844|NCT05497492|Drug|propofol and esketamine|administration of propofol and esketamine in combination
79387845|NCT05497492|Drug|propofol and lidocaine|administration of propofol and lidocaine in combination
79387846|NCT05453500|Procedure|Bone Marrow Aspiration and Biopsy|Ancillary studies
79387847|NCT05453500|Drug|Cyclophosphamide|Given IV
79387848|NCT05453500|Drug|Doxorubicin|Given IV
79387849|NCT05453500|Drug|Etoposide|Given IV
79387850|NCT05453500|Drug|Prednisone|Given PO
79387851|NCT05453500|Biological|Rituximab|Given IV
79387852|NCT05453500|Biological|Tafasitamab|Given IV
79387853|NCT05453500|Drug|Vincristine|Given IV
79387854|NCT05438576|Other|Artificial Intelligence enabled electrocardiogram (AI-ECG)|An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
79387855|NCT05434312|Drug|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
79387856|NCT05426954|Other|Rehabilitation utilizing blood flow restrictive therapy|BFR therapy
79387857|NCT05416086|Device|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
79387858|NCT05414136|Drug|BAT1006|Intravenous fluids
79387859|NCT05410496|Drug|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
79387860|NCT05410210|Other|Pharmaceutical care|The clinical pharmacists will conduct medication reviews, patient education, and counseling. Moreover, the clinical pharmacists will identify drug-related problems (DRPs) and provide the information through written pharmacist notes to physicians at the clinic.
79387861|NCT05408754|Device|Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.|Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
79387862|NCT05391126|Drug|Irinotecan|Usual dosing per package insert.
79387863|NCT05388643|Diagnostic Test|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
79387864|NCT05388643|Diagnostic Test|Routine Gestational Diabetes Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
79387865|NCT05384938|Biological|Benralizumab|Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
79387866|NCT05371132|Procedure|Positron Emission Tomography|Undergo PET
79387867|NCT05371132|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79387868|NCT05371132|Drug|Zirconium Zr 89-Df-Crefmirlimab|Given IV
79387869|NCT05371132|Radiation|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
79703808|NCT05138484|Drug|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
80013998|NCT04958252|Drug|BI 1569912|BI 1569912
80013999|NCT04958252|Drug|Placebo|Placebo
79249273|NCT04103996|Diagnostic Test|Respiratory function measurements|Maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) will be acquired after listing for lung transplantation. After transplant, MIP will be recorded once patients are eligible for a trial of spontaneous breathing and weekly thereafter. MEP will also be recorded at ICU discharge.
79543559|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
79249274|NCT05464953|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
79387870|NCT05370937|Procedure|ARTROSCOPİC SURGERY WITH ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS
79387871|NCT05370937|Procedure|ARTROSCOPİC SURGERY WITHOUT ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS WITH ELEVATOR SYSTEM
79543560|NCT01516151|Dietary Supplement|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
79543561|NCT01516151|Drug|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
79543562|NCT01516151|Dietary Supplement|CaPre™|4 capsules of 1 g total per day for 8 weeks.
79543563|NCT01516164|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
79543564|NCT01516229|Drug|somatropin|Prescription of somatropin at the discretion of the physician
79543565|NCT01516242|Other|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
79543566|NCT01516255|Drug|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
79543567|NCT01516255|Drug|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
79703809|NCT04535804|Drug|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
79845601|NCT00933114|Procedure|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
80014000|NCT04948333|Drug|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
79249275|NCT05464953|Drug|Formulated Triamcinolone|Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
79249276|NCT02491749|Procedure|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
79387872|NCT05359237|Procedure|Biospecimen Collection|Undergo collection of blood samples
79387873|NCT05359237|Drug|Vincristine|Given IV
80014001|NCT04948333|Drug|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
80014002|NCT04948333|Drug|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
80014003|NCT04943965|Diagnostic Test|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~Pre-induction.~Post-induction / Pre-PAC~Post-induction / Post-PAC"
80014004|NCT04940663|Behavioral|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
80014005|NCT04931810|Behavioral|All Nations Breath of Life|Same.
79387874|NCT05357508|Behavioral|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
79387875|NCT05357508|Behavioral|Control brochure|Provide participants with general information about options for colorectal cancer screening.
79387876|NCT05346029|Behavioral|Lifestyle intervention|Resistance training and nutritional counseling
79387877|NCT05345990|Drug|Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)|"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"
79543568|NCT01516255|Drug|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
79543569|NCT01516255|Drug|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
79543570|NCT01516255|Procedure|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
79543571|NCT01516255|Procedure|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
79543572|NCT01516294|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
79543573|NCT01514903|Drug|HIP0908|SINGLE DOSE , CROSS OVER
79543574|NCT01514903|Drug|viagra|single dose, cross over
79543575|NCT01516320|Procedure|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
80014006|NCT04931173|Other|IVA+OA versus IVA+MBP+OA|Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
79703810|NCT04535765|Other|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
79703811|NCT04535765|Other|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
79387878|NCT05343143|Device|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
79543576|NCT01516320|Procedure|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
79845602|NCT00933192|Device|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
79845603|NCT03977454|Procedure|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
79845604|NCT03977454|Procedure|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
79845605|NCT03977454|Drug|Ropivacaine|60 ml 0.2% ropivacaine
79845606|NCT03977454|Drug|Dex|10 mg DEX/ 80 mg MPA
79845607|NCT00828386|Procedure|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
80014007|NCT04927897|Diagnostic Test|Ultrasound|3D endorectal ultrasound.
80014008|NCT04927897|Diagnostic Test|Rectoscopy|Rigid rectoscopy.
80014009|NCT04927897|Other|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
79249277|NCT04443296|Drug|CCRT+TIL|Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
79543577|NCT01516320|Procedure|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
79249278|NCT03331575|Radiation|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
79249279|NCT03321435|Other|placenta previa patient|women had placenta previa either major or minor degree
79249280|NCT03321435|Other|normal women|those women had not placenta previa
79249281|NCT04243070|Diagnostic Test|3-channel Holter ECG recording|3-channel Holter ECG recording for patients undergoing an EPS
79249282|NCT04243070|Diagnostic Test|12-channel Holter ECG recording|12-channel Holter ECG recording for patients undergoing a routine follow-up
79249283|NCT03756740|Other|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
79249284|NCT03756740|Other|control|subjects will receive the LBP exercises as printed pictures on paper
79543578|NCT01516333|Other|High GL 107|Three meals a day
79249285|NCT02727699|Drug|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
79249286|NCT02727699|Drug|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
79387879|NCT05342012|Dietary Supplement|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
79387880|NCT05342012|Dietary Supplement|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
79387881|NCT05324306|Device|combat application tourniquets (CAT)|"CAT tourniquets have been indicated for use in emergency situations revolving around a wounded limb, such as hemorrhage control.22-23 CAT tourniquets are the official tourniquet of the US Army since in 2005.~We will deploy well-studied and FDA approved combat application tourniquets (CAT) on both thighs of volunteer healthy adult subjects while measuring blood pressure in the upper extremities."
79543579|NCT01516333|Other|Medium GL 76|Three meals a day
79543580|NCT01516333|Other|Medium GL 68|Three meals a day
79543581|NCT01516333|Other|Low GL 48|Three meals a day
79543582|NCT01516372|Drug|GEn 1200mg|1200 mg of Gen administered as a single dose
79703812|NCT05138445|Behavioral|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
79845608|NCT02549066|Procedure|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
79845609|NCT02549066|Drug|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) < 12 %."
79845610|NCT00831350|Drug|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
79845611|NCT00933348|Drug|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
79845612|NCT00933348|Drug|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
79845613|NCT00823628|Drug|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
79845614|NCT00823628|Drug|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
80014010|NCT04922983|Drug|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
80014011|NCT04922983|Behavioral|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
80014012|NCT04922983|Behavioral|Placebo|Used as placebo
80014013|NCT04918173|Drug|Atenativ|Antithrombin concentrate
79703813|NCT05138445|Behavioral|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
79845615|NCT00937872|Drug|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
79845616|NCT00937872|Drug|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
79845617|NCT00938184|Drug|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
80014014|NCT04917679|Drug|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10^9/L as follows: (1) if platelet count is less than 150 × 10^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10^9/L to 250 × 10^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10^9/L.
80014015|NCT04917679|Drug|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10^9/L to 150 × 10^9/L.
79543583|NCT01516372|Drug|Gen 6000 mg|6000 mg of Gen administered as a single dose
79543584|NCT01516372|Drug|GEn Placebo|Placebo to match GEn Tablets
79543585|NCT01516372|Drug|Moxifloxacin Placebo|Placebo to match Moxifloxacin
79543586|NCT01516372|Drug|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
79543587|NCT01516411|Behavioral|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
79543588|NCT01516450|Drug|GSK1550188 IV|Single IV dose of belimumab 200 mg
79543589|NCT01516450|Drug|GSK1550188 SC|Single SC dose of belimumab 200mg
79703814|NCT04529603|Device|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
79703815|NCT04535739|Radiation|prophylactic cranial irradiation|25Gy/2.5Gy/10f were given for PCI patients
79703816|NCT04529525|Drug|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
79845618|NCT00938184|Drug|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
79845619|NCT00938184|Drug|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
79845620|NCT00938262|Drug|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
79305566|NCT03058731|Device|Control|Paraesophageal hernia repair with other biologic mesh
79305567|NCT03241511|Other|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
79387882|NCT05321719|Behavioral|Comparison Condition|In this Phase II project, BR2S will be evaluated for efficacy relative to a usual care control. Investigators expect BR2S to improve outcomes on behavioral change, self-efficacy, establishment of a dental home, knowledge, and attitudes in real settings relative to the usual care condition. The outcome measures include a direct clinical dental measure as well as observational measures of parental behavior. The study will also provide important information regarding the various types and combinations of BeReady2Smile product components for dissemination. The long-term goal of the program is to help parents provide the foundation for a lifetime free from preventable oral disease.
79543590|NCT01516463|Drug|Collagenase Santyl|Applied topically (2 mm thickness once daily)
79543591|NCT01516463|Biological|Bacitracin|Applied topically (2 mm thickness) once daily
79543592|NCT01516489|Behavioral|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
79543593|NCT01516489|Behavioral|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
79845621|NCT00933426|Drug|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
79845622|NCT00933426|Drug|Paclitaxel|50 mg/m^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
79703817|NCT04529525|Drug|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
79703818|NCT02218346|Drug|AG221|AG221 in fed and fasted conditions
79703819|NCT04535427|Drug|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
79703820|NCT04535427|Drug|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
79703821|NCT05138367|Procedure|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10^7cells, 1×10^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
79703822|NCT02218385|Device|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
79703823|NCT02216409|Drug|Hu5F9-G4|
79703824|NCT02218580|Other|Massage therapy|
79703825|NCT02218580|Other|Standard care|
80014016|NCT04905316|Drug|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
79543594|NCT01516502|Other|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
79543595|NCT01516515|Drug|Vehicle gel|placebo
79543596|NCT01516515|Drug|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
79543597|NCT01516528|Procedure|Spirometry|Assessment of lung function by spirometry
79543598|NCT01516554|Drug|Testosterone undecanoate|40 mg twice daily
79543599|NCT01516554|Drug|placebo|twice daily
79543600|NCT01516567|Drug|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
79543601|NCT01516580|Drug|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
79543602|NCT01516580|Drug|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
79543603|NCT01516645|Drug|KHK2898|injection
79703826|NCT05126121|Drug|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
79703827|NCT02218658|Drug|WE941 OD tablets|
79703828|NCT02218658|Drug|Brotizolam|
79703829|NCT05125653|Procedure|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
80014017|NCT04905316|Drug|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
79543604|NCT01516658|Device|Hydrogel coil|at least one Hydrogel coil have to use for embolization
79543605|NCT01516658|Device|Bare platinum coil|only bare platinum coil have to use for embolization
79543606|NCT01516697|Procedure|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
79543607|NCT01516697|Procedure|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
79543608|NCT01516710|Procedure|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
79543609|NCT01516710|Procedure|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
79543610|NCT01516723|Device|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
79543611|NCT01516762|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
79543612|NCT01516775|Other|clear fluid ingestion|drinking of clear fluid in preoperative period
79543613|NCT01516788|Other|Phototesting|Single MED dose on Day 2
79543614|NCT01516801|Other|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
79543615|NCT01516814|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
79543616|NCT01516814|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
79543617|NCT01516814|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
79703830|NCT05125653|Procedure|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
79703831|NCT02278679|Procedure|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
79845623|NCT04014582|Behavioral|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
80014018|NCT04905316|Radiation|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
79543618|NCT01516827|Behavioral|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
80014019|NCT04905316|Drug|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
80014020|NCT04902833|Procedure|Blood Draw|Blood specimen 2-4 teaspoons
80014021|NCT04892134|Other|blood sample|40-50 ml of blood is taken
79543619|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
79543620|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
79543621|NCT01516840|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
79543622|NCT01516840|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
79543623|NCT01516853|Device|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
79543624|NCT01516866|Procedure|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
79703832|NCT01199068|Drug|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice daily
79703833|NCT01199068|Drug|Erlotinib|Erlotinib 150 mg once daily
79703834|NCT05103891|Drug|Binimetinib Oral Tablet|two-period, crossover study
79703835|NCT04535375|Diagnostic Test|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
79249287|NCT05228600|Drug|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
79703836|NCT01198873|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
79703837|NCT01198873|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
79703838|NCT04535297|Other|exposure|Exposure to social distancing due to COVID-19
79703839|NCT04535388|Device|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
80014022|NCT04878185|Other|Exercise|Preoperative exercise
79249288|NCT04408898|Genetic|ADP-A2M4 in combination with pembrolizumab.|Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
79543625|NCT01516905|Drug|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
79845624|NCT04014582|Behavioral|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
79845625|NCT04013958|Drug|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
79845626|NCT04013958|Drug|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
79543626|NCT01516931|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
79703840|NCT01198795|Drug|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
79703841|NCT04535024|Radiation|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
79543627|NCT01516931|Behavioral|counseling|Placebo monthly by general counseling for 12 months.
79543628|NCT01516983|Drug|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
79543629|NCT01516983|Radiation|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
79543630|NCT01516996|Drug|docetaxel and cisplatin|"The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
79703842|NCT04535024|Drug|Sintilimab|Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
79703843|NCT04535336|Other|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
79703844|NCT04535336|Other|Control|Participants maintained their daily activities.
79703845|NCT04535154|Other|No interventions|No interventions
79703846|NCT04535180|Diagnostic Test|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
79845627|NCT00933504|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks.
80014023|NCT04877041|Behavioral|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
79703847|NCT02216448|Other|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
79703848|NCT02216448|Other|OR Training|Training on diagnostic knee arthroscopy in the OR
79703849|NCT02278757|Other|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
79845628|NCT00933582|Drug|JNJ-39439335; Placebo; Naproxen|
80014024|NCT04875702|Drug|Allopurinol|"For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial."
80014025|NCT04875702|Drug|Naproxen 250 MG|Naproxen 250 mg p.o. twice daily
80014026|NCT04875702|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg p.o. once daily
80014027|NCT04875702|Drug|Colchicine 1.2 mg|Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
80014028|NCT04875702|Drug|Naproxen 500 Mg|dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
79249289|NCT03747926|Drug|BI 705564|single-rising oral dose
80014029|NCT04875702|Drug|Prednisone 40 mg|For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
80014030|NCT04859985|Device|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30% or FFR < 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
79249290|NCT03747926|Drug|Placebo|single-rising oral dose
79543631|NCT01516996|Radiation|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13~GTV（primary tumor）：68-70Gy/35~38 F，once a day, 5 times per week~CTV（Clinical target）：56-66Gy/30~36f，once a day, 5 times per week~GTV-ln（positive neck region）：66-70Gy/33~36 F，once a day, 5 times per week~CTV-ln（negative neck region）：50-54Gy/28~30F, once a day, 5 times"
79543632|NCT01516996|Biological|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13~14 weeks
79703850|NCT02278757|Other|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
79703851|NCT04534946|Other|This is not an intervention study|This is not an intervention study
79543633|NCT01517009|Drug|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
80014031|NCT04859985|Device|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
80014032|NCT04859218|Procedure|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
80014033|NCT04855435|Drug|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
80014034|NCT04847921|Drug|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
80014035|NCT04842890|Radiation|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
80014036|NCT04839523|Device|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
80014037|NCT04839523|Device|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
80014038|NCT04837573|Behavioral|Sister Circle protocol|The intervention is an 8-week, therapeutically-informed protocol.
80014039|NCT04832321|Other|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
80014040|NCT04805203|Other|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
79543634|NCT01517009|Drug|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
79543635|NCT01517009|Drug|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
79543636|NCT01517009|Procedure|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
79249291|NCT03331419|Behavioral|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
79249292|NCT03543722|Behavioral|National Career Coach Program|Intensive employment services as described above.
79387883|NCT05321719|Behavioral|BeReady2Smile video only|"The video will be viewed at the Head Start site after informed consent and T1 questionnaires and plaque assessment. The video will include concrete demonstrations and feature diversity in settings and actors in video content derived from actual peer-based parenting education sessions. Parents' ability to see themselves in the content makes them more likely to engage in discussions about dental health. Supporting these conversations has been identified as an important need. For example, in a recent environmental scan prepared by the Association of State and Territorial Dental Directors the lack of communication strategies was identified as a gap in oral health educational resources. Specifically mentioned was the lack of oral health curricula that support interactive communication between families and home visitors. Families struggle with such dialogues."
79391629|NCT03116256|Other|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
79543637|NCT01517022|Drug|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
79543638|NCT01517035|Procedure|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
79703852|NCT02278913|Drug|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
79703853|NCT02278913|Drug|Human Insulin|NPH twice a day + Regular insulin before meals
79845629|NCT00933660|Other|ERC-training by instructor|Standard way of training with an instructor
79249293|NCT03543722|Behavioral|Local Community Resources Program|Usual employment services as described above.
79249294|NCT02490345|Drug|gabapentin|gabapentin usage as adjunctive treatment for pain control
79249295|NCT02490345|Drug|Placebo|Identical placebo
79391630|NCT03174210|Device|liquid oxygen device (LOD)|This oxygen Supplementation is used in special order
79391631|NCT03174210|Device|portable oxygen concentrator (POC)|This oxygen Supplementation is used in special order
79249296|NCT03319641|Diagnostic Test|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
79845630|NCT00933660|Other|Web-based training only|Experimental way of training with a web based training application
79845631|NCT00933660|Other|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
79845632|NCT00938418|Radiation|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
79543639|NCT01517165|Drug|Pioglitazone|
80014041|NCT04804098|Procedure|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
80014042|NCT04804098|Procedure|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
80014043|NCT04802655|Other|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
79543640|NCT01517165|Drug|Placebo|
79387884|NCT05321719|Behavioral|BeReady2Smile video and BeReady2Smile app completely self-guided|In addition to the BeReady2Smile video as described above, the BeReady2Smile app includes: (a) presentation of concepts, behaviors, and examples via video and text, (b) electronically presented check-in questions recorded to a database for review, (c) capture of a 5-minute video of parent-child interactions uploaded for later review by the parent, using a mobile application, (d) daily dental activities (homework), and (e) program feedback recorded to the database. BeReady2Smile will be designed such that before the parent can go on to a new area of learning, the parent must complete the previous lesson. Participants can go back and review previous material in a non-linear format. The database and log-files record all computer activities to track use of each intervention component.
79543641|NCT01517204|Device|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
79543642|NCT01517204|Device|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
79543643|NCT01517217|Procedure|No girdle|No girdle is used for the first five postoperative days
79845633|NCT00938574|Drug|Atu027|
79387885|NCT05321719|Behavioral|"Complete BeReady2Smile video and BeReady2Smile app guided by a Coach"|"In addition to the BeReady2Smile video and BeReady2Smile app described above, the complete intervention includes support via phone and text from a trained facilitator/coach who builds supportive one-on-one relationships with the parent and gives feedback on parent-recorded videos of parent-child interactions of tooth-brushing, designed to facilitate learning and promote engagement with their oral health professional; and tools to create a long-term follow-up plan. Dental behaviors will be tailored for children's developmental level (e.g. twice daily tooth brushing for preschoolers and limiting sugar sweetened beverages or milk in bottles at bed for infants)."
79845634|NCT00938730|Drug|YM150|oral
79845635|NCT00938730|Drug|Warfarin|oral
79845636|NCT00933816|Drug|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
79845637|NCT00538785|Biological|Motavizumab|15 mg/kg IM administered at monthly intervals
79387886|NCT05318690|Device|PlayGait|PlayGait is a dynamic energy storing and returning lower-limb exoskeleton.
79391632|NCT03174288|Other|Exercise|24 weeks of exercise treatment
79543644|NCT01517217|Procedure|Girdle|Girdle the first five postoperative days
79543645|NCT01517230|Behavioral|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
79845638|NCT00538785|Biological|Palivizumab|15 mg/kg IM administered at monthly intervals
79845639|NCT02058459|Device|Holaira™ Lung Denervation System with energy delivery|
79845640|NCT02058459|Device|Holaira™ Lung Denervation System without energy delivery|
79845641|NCT00990015|Drug|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
79845642|NCT00990015|Drug|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
79845643|NCT04237545|Device|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
79845644|NCT04237545|Device|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
80014044|NCT04802655|Other|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
79249297|NCT05228054|Procedure|laser procedure|In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen
80014045|NCT04801953|Drug|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
80014046|NCT04801953|Other|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
80014047|NCT04797000|Drug|Eltrombopag|Eltrombopag comes in 12.5 mg & 25 mg tablets and is taken orally once per day (QD)
80014048|NCT04797000|Drug|Placebo|Placebo comes in 12.5 mg & 25 mg tablets and is taken orally once per day (QD)
79543646|NCT01517256|Behavioral|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
79249298|NCT05228054|Procedure|sclerotherapy|In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol
79249299|NCT02487927|Behavioral|weaning|T piece
79249300|NCT03991286|Dietary Supplement|Astaxanthin 8 mg|experimental
79249301|NCT03991286|Other|placebo|Matching placebo pill
79249302|NCT03331263|Drug|Chlorhexidine Gluconate|2% CHG
80014049|NCT04795427|Drug|asciminib|Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
80014050|NCT04795427|Other|best available treatment|Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
80014051|NCT04789707|Behavioral|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
79249303|NCT04111016|Behavioral|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
79387887|NCT05318690|Other|Baseline|Baseline condition with no prescribed or intervention lower-limb devices.
79387888|NCT05308264|Drug|R906289 Monosodium (R289 Na)|Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd,500 mg PO qd, 750 mg PO qd, 1000 mg PO qd)
79387889|NCT05302011|Drug|Pembrolizumab|Pembrolizumab 200mg i.v. day 1-22-43-64
79387890|NCT05302011|Drug|Carboplatin or Cisplatin|Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64
79387891|NCT05302011|Drug|Docetaxel|75mg/m2 i.v. day 1-22-43-64
79387892|NCT05296746|Drug|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
79387893|NCT05296746|Drug|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
79387894|NCT05296746|Drug|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
79387895|NCT05291260|Procedure|Cast immobilization|A cast to immobilize the MCP, in 10-30 degrees (slight) flexion (neutral position), and the CMC joint, in 30-40 degrees palmar abduction, is applied (IP joint is free).
79387896|NCT05291260|Procedure|Surgical treatment|"In general, two surgical techniques are described in literature and used in daily clinical practice:~If the UCL is ruptured in the middle of the ligament, sutures are used to reattach the ligament remnants together.~When no viable UCL ligaments are present, the UCL is reattached directly to the bone using suture anchors."
79387897|NCT05289570|Drug|Voxelotor|500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
79387898|NCT05287399|Drug|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
79387899|NCT05287399|Drug|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
79387900|NCT05287399|Drug|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
79387901|NCT05287399|Drug|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
79387902|NCT05287399|Drug|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
79387903|NCT05279872|Drug|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
79387904|NCT05265338|Drug|KC1036|60mg QD
79387905|NCT05253820|Procedure|distal radial approach|coronary diagnosis and intervention via distal vs conventional radial approach
79387906|NCT05253820|Procedure|conventional radial access|conventional radial access
79387907|NCT05245552|Biological|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
79391633|NCT03174288|Drug|Spironolactone|24 weeks of spironolactone
79703854|NCT04846530|Device|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
79543647|NCT01517256|Other|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
79543648|NCT01517269|Behavioral|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
80014052|NCT04781231|Device|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
80014053|NCT04781231|Device|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
80014054|NCT04781231|Other|Usual management of anxiety|No specific intervention
79387908|NCT05245552|Biological|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
79387909|NCT05245552|Biological|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
79543649|NCT01517269|Behavioral|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
79249304|NCT02487693|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
79249305|NCT02487693|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
79249306|NCT03943082|Behavioral|Cancer Educational Materials|Receive FRP brochure
79543650|NCT01517308|Drug|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
79249307|NCT03943082|Other|Follow-Up Care|Receive follow-up phone call
79249308|NCT03943082|Behavioral|Questionnaire|Ancillary studies
79249309|NCT02490033|Device|Ablation Catheter|
79543651|NCT01517321|Drug|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
80014055|NCT04771130|Drug|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
80014056|NCT04771130|Drug|Azacitidine|Intravenous or subcutaneous administration for 7 days.
79249310|NCT02490267|Other|Quality of Life questionnaire|
79249311|NCT02490189|Behavioral|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
79543652|NCT01517321|Drug|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
80014057|NCT04771130|Drug|Posaconazole|Oral administration for 8 days on second cycle only.
79249312|NCT02490189|Behavioral|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
79249313|NCT04436120|Procedure|De novo tumor tissue biopsy|De novo tissue biopsy performed following disease progression
79249314|NCT04436120|Procedure|Research blood draws|Blood biospecimens collected following disease progression
79249315|NCT02491827|Other|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
79387910|NCT05245552|Biological|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
79543653|NCT01517334|Drug|Minocycline HCl Microspheres|
79543654|NCT01517347|Drug|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
79543655|NCT01517360|Drug|Oxytocin|Oxytocin 40 IU, intranasal inhalation
79543656|NCT01517360|Other|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
79703855|NCT02278991|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
79703856|NCT02216474|Other|Transcranial direct current stimulation|
79703857|NCT02216513|Drug|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
79249316|NCT03319563|Drug|Local anesthetic-epinephrine|"Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~Lidocaine 5 mg/Kg.~Epinephrine 5 mcg/ml of the total volume.~Add normal saline to a total volume of 100 ml/10 cm of the wound length."
79249317|NCT03319563|Drug|Saline|normal saline 100 ml/10 cm of the wound length
79249318|NCT02485119|Drug|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
80014058|NCT04771130|Drug|BGB-11417|Oral administration for 28 days on a 28-day cycle.
80014059|NCT04771130|Drug|BGB-11417|Oral administration for 10 or 21 days on a 28-day
79543657|NCT01517360|Behavioral|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
79543658|NCT01517386|Procedure|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
79543659|NCT01517399|Drug|tivantinib|three oral 120 mg tablets administered twice a day
79703858|NCT02216513|Drug|placebo|normal saline IV for 4 hours for 5 consecutive days
79703859|NCT04534998|Procedure|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
79703860|NCT02218775|Drug|LY2456302|Mood and Anxiety Disorders
79249319|NCT03153020|Other|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
79249320|NCT04060940|Behavioral|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
79302835|NCT03314597|Other|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
79703861|NCT02216552|Dietary Supplement|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
79387911|NCT05237583|Behavioral|Prehabilitation|All participants will be offered a multimodal prehabilitation program. This program will include an individualized and supervised aerobic and resistance exercise training program, nutritional optimization, and psychological support. The program will last 6 months or until liver transplantation, whichever comes first.
79543660|NCT01517399|Drug|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
80014060|NCT04765709|Combination Product|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
80014061|NCT04765709|Combination Product|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
79387912|NCT05236335|Dietary Supplement|Ketone ester|Commercially available ketone supplement
79387913|NCT05236335|Dietary Supplement|Placebo drink|Isocaloric placebo
79387914|NCT05218213|Other|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~Dual-task walking with the auditory stroop task.~Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~Navigational and dual-task walking (condition 1 and 2 together)"
79387915|NCT05217212|Radiation|Radiochemotherapy|Primary radiotherapy of the primary tumor and nodal basin with curative intent with or without concomitant chemotherapy with cisplatin, carboplatin, or cetuximab weekly.
79543661|NCT01517399|Drug|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
79543662|NCT01517399|Drug|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
79543663|NCT01517399|Dietary Supplement|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
79543664|NCT01517399|Drug|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
79703862|NCT02216552|Dietary Supplement|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
79703863|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
80014062|NCT04765709|Biological|durvalumab|Consolidation treatment with durvalumab
80014063|NCT04764175|Behavioral|Telephone All Nations Breath of Life|Same as described above.
80014064|NCT04764175|Behavioral|Comparison Program|Same as described above.
80014065|NCT04761328|Behavioral|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
80014066|NCT04752020|Drug|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
80014067|NCT04740333|Other|No intervention- observational study|No intervention- observational study
80014068|NCT04738097|Drug|Ticagrelor 90mg|ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
79387916|NCT05211284|Drug|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of study (72 weeks).
79543665|NCT01517399|Drug|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
79543666|NCT01517438|Behavioral|agitation|agitation score after desflurane anesthesia
79543667|NCT01517464|Genetic|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
79543668|NCT01517490|Other|Insulin pump|Insulin pump therapy
79543669|NCT01517490|Other|Multiple daily insulin injections|Multiple daily insulin injections
79543670|NCT01517490|Procedure|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
79543671|NCT01517490|Other|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
79543672|NCT01517503|Behavioral|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
79543673|NCT01517503|Behavioral|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
79543674|NCT01517542|Other|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
79543675|NCT01517555|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
79543676|NCT01517555|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
79543677|NCT01517555|Drug|paracetamol|One single dose of 1 g. Tablet
79543678|NCT01517568|Drug|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
79543679|NCT01517607|Other|Mesalazine|Patient's treated with oral Mesalazine
79543680|NCT01517620|Drug|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
79543681|NCT01517633|Device|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
79543682|NCT01517646|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79387917|NCT05211284|Drug|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (72 weeks).
79387918|NCT05206227|Behavioral|Aerobic Exercise|Subjects will complete a single bout of aerobic exercise.
79387919|NCT05206227|Drug|alpha-FMH|Subjects will undergo either local heating with diathermy or whole body heating with far-infrared sauna.
79387920|NCT05206227|Behavioral|Resistance and Aerobic Exercise|Subjects will complete bouts of resistance and aerobic exercise.
79387921|NCT05206227|Drug|Antihistamine|Subjects will complete a single bout of aerobic exercise under placebo vs antihistamine conditions.
79249321|NCT04060940|Behavioral|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
79249322|NCT02490111|Drug|DWJ1319|
79249323|NCT02490111|Drug|Placebo|
79387922|NCT05204251|Behavioral|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
79387923|NCT05199948|Other|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
79387924|NCT05199948|Other|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
79387925|NCT05199350|Other|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
79387926|NCT05159570|Dietary Supplement|Ketone ester|Commercially available ketone supplement
79387927|NCT05159570|Dietary Supplement|Placebo drink|Isocaloric placebo
79543683|NCT01517672|Behavioral|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
79543684|NCT01517685|Dietary Supplement|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
79543685|NCT01517685|Dietary Supplement|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
79543686|NCT01517724|Drug|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
79703864|NCT01198756|Biological|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
80014069|NCT04738097|Drug|Clopidogrel 75 mg|ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
79703865|NCT01198756|Biological|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
79543687|NCT01517789|Device|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
79249324|NCT03316365|Other|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
79703866|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
79703867|NCT04534647|Diagnostic Test|different serum and urine biomarkers|urine exosomes and serum biomarkers
79249325|NCT05190224|Other|Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.|In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
79249326|NCT02484573|Drug|Propanolol|
79387928|NCT05156762|Procedure|Bariatric surgery|Patients randomized to the bariatric surgery study arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass - this decision would be a joint decision made between the study participant and the bariatric surgeon after consideration of the patient's overall goals with weight loss and discussion of the risks and benefits of each procedure.
79387929|NCT05156762|Behavioral|Medical weight loss|Study participants randomized to the medical weight loss study arm will have consultations with nutritionists, dieticians, and endocrinologists, and will make dietary and lifestyle changes in an effort to lower their BMI to ≤ 40 kg/m2. Patients may also be placed on pharmacotherapy to assist with weight loss.
79543688|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
79543689|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
79543690|NCT01517828|Drug|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
79703868|NCT04534868|Other|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~A table containing the useful information about the patient for the lesion's analysis will be completed.~The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~The photo is anonymized via a serial number assigned by the Handyscope application.~Sending photos and information via a secure email address to the dermatologists.~Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
79703869|NCT02216487|Drug|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
79703870|NCT01198600|Device|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
79703871|NCT01198600|Device|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
79845645|NCT05360121|Other|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
79249327|NCT02489955|Drug|Amikacin|
79249328|NCT02489955|Drug|Tobramycin|
79249329|NCT02489955|Drug|Colomycin|
79249330|NCT03784430|Procedure|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
79249331|NCT03784430|Procedure|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
79703872|NCT01198600|Device|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
79703873|NCT02218814|Procedure|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
79543691|NCT01517828|Drug|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
79703874|NCT02218814|Procedure|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
79703875|NCT04317898|Procedure|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
79703876|NCT04317898|Procedure|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
79703877|NCT02216565|Other|Hospitalization in specialized neuro-vascular unit|
79703878|NCT02216565|Drug|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
79703879|NCT02216565|Other|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
79387930|NCT05156762|Other|Patient research surveys|Patients will have a telemedicine visit every 3 months with an orthopaedic surgery physician assistant to review their latest BMI and to complete a patient research survey to assess the patient's feelings regarding their progress. The telemedicine visits every 3 months are unique to the clinical trial and these visits would not otherwise occur if the patient was not enrolled in the trial. If patients are found to not be advancing toward the BMI goal of ≤ 40 kg/m2, these patient research surveys can be used to make individualized adjustments, based on recommendations from dieticians and the medical nutritionist.
79703880|NCT02216565|Procedure|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
79703881|NCT02218931|Behavioral|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
79387931|NCT05156762|Procedure|Total joint arthroplasty (TJA)|Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.
79387932|NCT05156762|Other|Usual standard of care|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics. They will be urged to make an appointment or to seek any other interventions they choose to help lower their BMI, but no appointments will be made for them. A follow up visit in 6 months and 1 year will be made for them in the arthroplasty clinic to reassess their progress. Referral information will again be provided at 6 months if no progress has been made."
79543692|NCT01517854|Drug|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
79703882|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
79703883|NCT04534790|Radiation|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
79703884|NCT02216630|Drug|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
79703885|NCT02218970|Behavioral|strength training|
79703886|NCT02218970|Behavioral|no training (control)|
79543693|NCT01517854|Drug|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
79543694|NCT01517906|Behavioral|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
79543695|NCT01517906|Behavioral|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
79543696|NCT01517919|Behavioral|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
79703887|NCT04534803|Drug|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
79703888|NCT04534803|Other|Placebo|.1 nL of diluent (saline) given intradermally at baseline
79703889|NCT02219126|Other|Dietary intervention|
79703890|NCT04534569|Other|Experts consensus|Consensus opinion using Delphi Methodology
79703891|NCT04534634|Combination Product|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10^7/kg, intravenously infusion."
79249332|NCT03321357|Diagnostic Test|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.~(1) Jones et al."
79249333|NCT03319485|Device|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
79703892|NCT01198132|Dietary Supplement|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
79703893|NCT01198132|Dietary Supplement|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
79845646|NCT05360121|Other|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
79845647|NCT05360121|Other|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
80014070|NCT04726891|Behavioral|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
79703894|NCT01198132|Drug|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
79703895|NCT02219165|Drug|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
80014071|NCT04717596|Other|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
80014072|NCT04712565|Device|Astra Tech Implant System Profile EV|dental implant with a sloped neck configuration
79249334|NCT03319485|Device|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
79249335|NCT02484495|Other|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
79249336|NCT03734744|Dietary Supplement|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
79249337|NCT03316287|Device|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
79249338|NCT03316287|Device|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
79249339|NCT03316287|Device|Sensor|Wearable biosensor for the collection of physiological data
79249340|NCT03731546|Procedure|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
79305568|NCT04936737|Dietary Supplement|Beta-alanine supplementation|The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.
80014073|NCT04712565|Device|Astra Tech Implant System EV|dental implant with a conventional neck configuration
79845648|NCT05360121|Other|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
79703896|NCT02219165|Drug|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
79703897|NCT02887690|Device|Modular Prosthetic Limb|
79387933|NCT05154981|Behavioral|Education communication skills (ECS) training|Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
79387934|NCT05154981|Behavioral|Partners in School|Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
79845649|NCT05360121|Other|Back strengthening exercises|"Supine Abdominal Draw In~Supine Butt Lift with Arms at Side~Abdominal Draw In with Heel Slide~Abdominal Draw In with Knee to Chest~Abdominal Draw In with feet on the ball~Abdominal Draw In with feet on the ball- add movement"
79845650|NCT05360121|Other|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
79845651|NCT01563939|Drug|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
79543697|NCT01517932|Drug|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
79845652|NCT04004715|Dietary Supplement|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
79249341|NCT03319329|Device|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein & Coulter, 2014);(P. Singer & Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
79543698|NCT01517932|Drug|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
79543699|NCT01517958|Other|Respiratory Distress Group|Diagnostic lung ultrasound.
79543700|NCT01517958|Other|Control Group|Lung ultrasound
79703898|NCT02216604|Behavioral|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
79703899|NCT04534439|Drug|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
79845653|NCT04004715|Dietary Supplement|Whey Protein|commercially available whey protein isolate
79845654|NCT04004715|Dietary Supplement|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
80014074|NCT04707716|Other|conometric concept Acuris system|implant crown retention type using friction only
79249342|NCT04715126|Other|Oxyjun|One capsule to be taken after breakfast with water.
79249343|NCT04715126|Other|Placebo|One capsule to be taken after breakfast with water.
79249344|NCT02487537|Dietary Supplement|custom-made soft drink|
79249345|NCT02484105|Behavioral|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
79543701|NCT01517971|Other|laboratory biomarker analysis|Correlative studies
79703900|NCT04534439|Drug|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
79703901|NCT04534478|Drug|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
79845655|NCT05360043|Device|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
80014075|NCT04707716|Other|screw retention|screw retained implant crown
80014076|NCT04707716|Other|cementation|cement retained implant crown
80014077|NCT04670432|Drug|Hydroxyethylrutoside|500 mg film-coated tablet
79387935|NCT05134402|Diagnostic Test|Sleepiz One Connect|Sleepiz One Connect measurements over 10 nights
79703902|NCT02216669|Drug|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
79703903|NCT03881748|Other|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
79703904|NCT03881748|Other|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
79703905|NCT02219204|Procedure|Acupuncture|
79703906|NCT02219204|Other|Herbal treatment|
79387936|NCT05123807|Other|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
79703907|NCT03772158|Drug|Cetirizine 10mg|Chewable tablet
79703908|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
79543702|NCT01517997|Procedure|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
79703909|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
79387937|NCT05118672|Drug|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine [09] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one [01] film-coated tablet every eight [08] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
79387938|NCT05118672|Drug|Placebo|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine [09] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one [01] film-coated tablet every eight [08] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
79387939|NCT05100212|Biological|cord blood-RBC concentrates|Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 31 weeks of postmenstrual age (31+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).
79703910|NCT03653988|Procedure|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
79387940|NCT05100212|Biological|adult donor RBC concentrates|Patients in the comparator arm are candidates to receive adult donor-RBC units
79387941|NCT05088603|Device|Clear Mask|The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
79387942|NCT05084066|Other|Repeated remote ischemic preconditioning|"An automated device performs four 5-minute episodes of upper limb ischemia in which the cuff pressure in the experimental group remains at 200 mmHg for 5 minutes, causing and ensuring ischemia. Ischemic episodes alternate with 5-minute reperfusion. The intervention lasts a total of 35 minutes. The participant places the device on his upper arm and presses the Start button, starting the intervention. The intervention takes place at rest in the patient's home environment daily for 28 days. During the first visit to the research center, the research assistant teaches the participant how to use the device. The device measures the patient's blood pressure at the start of the intervention. If the patient's blood pressure is above 200 mmHg, the device will not perform the intervention."
79543703|NCT01517997|Procedure|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
79543704|NCT01518010|Behavioral|Play game|Participants engage in non-game activity (establish baseline) 7 * 1 hr weekly; play single-player game 7 * 1 hr weekly; play multi-player game 7 * 1 hr weekly.
79543705|NCT01518023|Other|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
79543706|NCT01518036|Drug|somatropin|2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
79543707|NCT01518036|Drug|somatropin|4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
79543708|NCT01518062|Drug|somatropin|4 IU/m^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
79543709|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
79703911|NCT03653988|Procedure|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
79703912|NCT01197508|Drug|TC-5214|Twice daily for 8 weeks.
79703913|NCT01197508|Drug|Placebo|Twice daily for 8 weeks.
79703914|NCT02219243|Behavioral|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
79703915|NCT02219243|Behavioral|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
79703916|NCT04534764|Device|etafilcon A with cosmetic pattern|TEST
79703917|NCT04534764|Device|1-Day Acuvue DEFINE Vivid Style|CONTROL
79249346|NCT02484105|Behavioral|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
79845656|NCT04004637|Drug|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10^6/kg."
79387943|NCT05084066|Other|Simulation of repeated remote ischemic preconditioning (sham)|The automated device simulates the intervention of the experimental group with the difference that the device does not apply pressure to the upper limb and, therefore, no ischemia occurs.
79387944|NCT05082584|Drug|Vadadustat|Vadadustat tablet orally once a day for 52 weeks
79845657|NCT03287271|Drug|VS-6063|"Phase 1:~First 3 patient cohort: VS-6063 200 mg PO twice daily~IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
80014078|NCT04666623|Drug|esketamine nasal spray|unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
79543710|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface, the second year and finally 8 IU/m^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
79387945|NCT05067101|Procedure|Capsule Sparing Cystectomy (CSC)|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
79543711|NCT01518062|Drug|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
79543712|NCT01518075|Other|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
79543713|NCT01518075|Other|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
79543714|NCT01518088|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to study foods
79543715|NCT01518101|Drug|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
79543716|NCT01518101|Drug|Liraglutide|1.2 mg once daily by commercially available injection pens
79543717|NCT01518101|Drug|Metformin|1000 mg tablets twice daily
79703918|NCT04534062|Other|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
79249347|NCT02487459|Biological|BPX-501|T cells transduced with CaspaCIDe suicide gene
79249348|NCT02487459|Drug|AP1903|dimerizer drug administered to treat GVHD
79387946|NCT05067101|Procedure|Conventional Radical Cystoprostatectomy (CRC)|According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
79387947|NCT05053633|Procedure|Combined spinal epidural anesthesia|The Anxiety (Visual Analogue Scale for Anxiety), pain (Visual Analogue Scale), and the Analgesia Nociception Index (ANI) assessments are conducted at four specific time points: lateral position, local anesthesia, epidural needle puncture and 2 minutes after puncture.
79387948|NCT05047835|Diagnostic Test|electrocardiogram|Prone position electrocardiogram
79543718|NCT01518114|Behavioral|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
79703919|NCT02219399|Dietary Supplement|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
79703920|NCT02219399|Dietary Supplement|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
79703921|NCT02219399|Dietary Supplement|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
79703922|NCT02887378|Device|hot clamps|reusable hot biopsy forceps
79703923|NCT02887378|Device|normal clamps|
79305569|NCT04936737|Other|High intensity interval exercise|The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
79543719|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
79543720|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
79543721|NCT01516944|Drug|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
79543722|NCT01518127|Other|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
79543723|NCT01518140|Device|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
79543724|NCT01518140|Behavioral|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
79543725|NCT01518166|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
79249349|NCT03319095|Device|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
79543726|NCT01518166|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
79543727|NCT01518166|Drug|atorvastatin|One single dose of 40 mg. Tablet
79249350|NCT03321279|Behavioral|Social Incentive|Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
79387949|NCT05045482|Drug|Saroglitazar Magnesium 1 mg|Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
79387950|NCT05045482|Drug|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
79387951|NCT05039411|Biological|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
79387952|NCT05030558|Behavioral|Web-assisted patient education intervention designed according to the common-sense model|Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
79249351|NCT02489643|Procedure|Individualized practical training|
79249352|NCT03315819|Procedure|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
79543728|NCT01518166|Drug|lisinopril|One single dose of 20 mg. Tablet
79543729|NCT01518166|Drug|griseofulvin|One single dose of 500 mg. Tablet
79249353|NCT03315819|Procedure|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
79543730|NCT01518166|Drug|digoxin|One single dose of 1 mg. Tablet
79543731|NCT01518179|Device|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
79543732|NCT01518179|Other|Routine follow up and treatment|Control
79703924|NCT04534244|Device|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
79703925|NCT04534140|Dietary Supplement|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
79249354|NCT03576716|Drug|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
79249355|NCT02489721|Device|PICC and Midline|Peripherally inserted central venous catheter
79387953|NCT05030558|Behavioral|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
79543733|NCT01518205|Device|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
79543734|NCT01518231|Procedure|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
79543735|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
79543736|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial);
79543737|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
79703926|NCT04534140|Other|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
79703927|NCT03596697|Drug|CRV431|Single or multiple dose(s) of CRV431
79703928|NCT03596697|Drug|Placebo|Single Placebo dose
80014079|NCT04666623|Drug|placebo nasal spray|unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
79249356|NCT03319017|Procedure|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
79249357|NCT04505072|Behavioral|PR-ESSENCE|Manual-based training of mutual problem-solving
79249358|NCT04505072|Behavioral|Treatment as usual|General support in daily structure and activities that is given to all youth staying at the treatment homes
79249359|NCT02484183|Device|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher & Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer & Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer & Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
79249360|NCT04620434|Device|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
79249361|NCT04620434|Device|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
79249362|NCT02487381|Drug|delta-9-tetrahydrocannabinol|
79387954|NCT05015088|Other|No interventions will be performed in this study|This study will not include any intervention
79387955|NCT05008484|Device|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
79703929|NCT03596697|Drug|TDF|Single or multiple dose(s) of TDF
79703930|NCT01196416|Drug|Cisplatin|Given IV
79387956|NCT05008484|Drug|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
79387957|NCT05008484|Procedure|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
79387958|NCT04998162|Procedure|SVF injection|Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
79703931|NCT01196416|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
79703932|NCT01196416|Other|Laboratory Biomarker Analysis|Correlative studies
79703933|NCT01196416|Other|Pharmacological Study|Correlative studies
79703934|NCT01196416|Drug|Temozolomide|Given PO
79703935|NCT01196416|Drug|Vinblastine Sulfate|Given IV
79703936|NCT02219555|Drug|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
79703937|NCT02219555|Procedure|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
79703938|NCT03272178|Device|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
79703939|NCT03272178|Device|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
79703940|NCT04534166|Other|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis
79703941|NCT04534088|Behavioral|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
79703942|NCT04534088|Behavioral|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
79703943|NCT01196104|Drug|Technosphere® Insulin Inhalation Powder|
79845658|NCT03287271|Drug|Paclitaxel|"Phase 1:~First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
79249363|NCT02487381|Drug|Cannabidiol|
79249364|NCT02487381|Drug|Placebo|
79703944|NCT01196104|Drug|Insulin Aspart|Usual Care
79703945|NCT01196104|Drug|Insulin Glargine|
79387967|NCT04980495|Biological|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
79703946|NCT04534322|Drug|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
79387968|NCT04980495|Biological|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
79387969|NCT04978090|Device|3D printed EAF management device|Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
79543738|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt.
79543739|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
79703947|NCT04534322|Drug|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
79543740|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial)
79703948|NCT04534179|Procedure|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
79703949|NCT04534179|Other|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
79703950|NCT02219594|Device|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
79703951|NCT02219633|Drug|LEO 39652 cream|Applied for 21 days
79703952|NCT02219672|Drug|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
79703953|NCT02219672|Drug|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
79845659|NCT03287271|Drug|Carboplatin|"Phase 1:~First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
79543741|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
79703954|NCT03113955|Device|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
79703955|NCT04533971|Other|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
79703956|NCT02219750|Drug|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
79845660|NCT00538629|Other|no intervention|no intervention
79845661|NCT00538629|Other|no intervention|no intervention
79845662|NCT03163095|Device|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
79249365|NCT04606706|Other|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
79387970|NCT04972383|Combination Product|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
79387971|NCT04972383|Combination Product|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
79387972|NCT04953754|Dietary Supplement|Melatonin|The melatonin group will receive 5mg melatonin nightly
79249366|NCT02487849|Procedure|HIPEC|secondary cytoreductive operation
79249367|NCT02487849|Drug|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
79305570|NCT04956861|Behavioral|Individualized Targeted Sleep|The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
79387973|NCT04953754|Device|Phillips Actiwatch Spectrum Plus|Both groups will be monitored by the FDA-cleared Actigraph
79387974|NCT04945239|Behavioral|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
79543742|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt
79543743|NCT01518283|Drug|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
79703957|NCT04534374|Behavioral|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
79845663|NCT03163095|Other|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
79543744|NCT01518296|Device|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
79543745|NCT01518335|Procedure|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
79543746|NCT01518335|Procedure|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
79543747|NCT01518348|Biological|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
79543748|NCT01518387|Drug|Lanthanum Carbonate (BAY77-1931)|
79543749|NCT01518413|Drug|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
79543750|NCT01518413|Drug|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
79543751|NCT01518426|Device|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
79543752|NCT01518439|Device|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
79543753|NCT01518439|Device|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
80014080|NCT04654117|Other|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
79387975|NCT04945239|Behavioral|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
79387976|NCT04942028|Behavioral|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
79387977|NCT04942028|Behavioral|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
79543754|NCT01518439|Device|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
79703958|NCT04534374|Behavioral|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
79703959|NCT04534452|Drug|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
79703960|NCT04533789|Other|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
79703961|NCT04533776|Behavioral|Celiac Disease Definition, Symptoms and Treatment|"Adolescents share their knowledge about the disease~Emphasizing the definition and symptoms of celiac disease~Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
79703962|NCT04533776|Behavioral|Difficulties Due to Celiac Disease|"Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
79845664|NCT04232163|Behavioral|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
79845665|NCT00990405|Drug|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
80014081|NCT04649398|Drug|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
79703963|NCT04533776|Behavioral|Gluten Free Diet in Celiac Disease|"Evaluating dietary information~Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
79703964|NCT04533776|Behavioral|Difficulties Related to Disease in School and Social Life|"Assessment of difficulties encountered in school and social life~Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
79703965|NCT04533776|Behavioral|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"Evaluation of the effects of the disease on academic success~Evaluation of the effects of the disease on peer relationships in the school enviroment~Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
79703966|NCT04533776|Behavioral|Celiac Diseae anf Future Goals|"General summary of all sessions so far~Summarizing the topics discussed in the previous session~Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
79845666|NCT00990639|Drug|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
79845667|NCT04211727|Diagnostic Test|Capillary finger prick blood sample|Patients will have a blood finger prick sample
79249368|NCT04435730|Diagnostic Test|serum level of Mac 2 binding protein|"Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment."
79543755|NCT01518439|Device|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
79703967|NCT04533776|Other|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
79703968|NCT04533828|Drug|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
79845668|NCT03742947|Diagnostic Test|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
79845669|NCT04003935|Other|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
79845670|NCT04003935|Dietary Supplement|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
79249369|NCT04435730|Device|musculoskeletal ultrasound|MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.
79249370|NCT04504448|Drug|HNC664 capsules Single dose|HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
79543756|NCT01518439|Other|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
79703969|NCT02219789|Drug|Alisertib|Given PO
79703970|NCT02219789|Drug|Fulvestrant|Given IM
79703971|NCT02219789|Other|Laboratory Biomarker Analysis|Correlative studies
79703972|NCT04533633|Procedure|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
79703973|NCT04533932|Diagnostic Test|Elastography|Endosonographic shear wave elastography
79703974|NCT02219828|Drug|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
79703975|NCT02219828|Drug|Placebo|Placebo
79703976|NCT04533867|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
79703977|NCT04533867|Drug|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
79703978|NCT04533867|Drug|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
79249371|NCT04504448|Drug|HNC664 placebos Single dose|HNC664 placebos single ascending doses,PO,Single dose, matching placebo
79249372|NCT04504448|Drug|HNC664 capsules FED|HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
79249373|NCT02484339|Drug|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
79249374|NCT02484339|Other|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)->->conventional or high dose radiotherapy
79543757|NCT01518452|Behavioral|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
79543758|NCT01518452|Behavioral|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
79543759|NCT01518465|Drug|dalteparin|Given SC
79543760|NCT01518465|Drug|lenalidomide|Given PO
79703979|NCT01196026|Biological|Fluarix™|One or two intramuscular injections
79703980|NCT01196026|Biological|Havrix™ Junior|Two intramuscular injections
79703981|NCT02216708|Other|Rapid dehydration|
79249375|NCT04021550|Device|Continuous Positive Airway Pressure CPAP|All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
79703982|NCT02216708|Other|Slow rehydration|
79703983|NCT02219867|Drug|Ketamine|Drug (including placebo)
79703984|NCT04533906|Device|Coldamaris lozenges|sucking carageenan containing lozenge
79703985|NCT02219906|Dietary Supplement|Resveratrol|1000mg tid
79703986|NCT02219906|Dietary Supplement|Placebo|1000mg tid placebo
80014082|NCT04648189|Drug|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
79845671|NCT00990717|Biological|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~Level I: 1x10^9 cells/m^2~Level II: 3x10^9 cells/m^2~Level III: 5x10^9 cells/m^2"
79703987|NCT04533893|Other|Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores|Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
79703988|NCT02219945|Other|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
79845672|NCT04004013|Dietary Supplement|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
79387978|NCT04942028|Behavioral|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
79387979|NCT04913285|Drug|KIN-2787|KIN-2787 will be administered orally twice daily in 28-day cycles
79703989|NCT01620918|Procedure|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
80014083|NCT04622514|Other|Village doctor-led telemedicine integrated care|1. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
80014084|NCT04622514|Other|Enhanced usual care|1. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
80014085|NCT04622085|Device|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
80014086|NCT04622085|Device|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
79249376|NCT04021550|Drug|Telmisartan 80mg|Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
79249377|NCT04021550|Dietary Supplement|Alpha-Lipoic Acid 600mg|Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
79249378|NCT04021550|Other|Microcrystalline Cellulose|Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
79387980|NCT04913285|Drug|KIN-2787 and binimetinib|KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles
79387981|NCT04893681|Other|Fluoridated bottled drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
79387982|NCT04893681|Other|Non-fluoridated drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
79387983|NCT04867343|Drug|HR020602 injection|HR020602 injection
79387984|NCT04867343|Drug|fentanyl injection ； remifentanil injection|fentanyl injection + remifentanil injection
79387985|NCT04866771|Other|Transcranial Direct Current Stimulation (tDCS)|Noninvasive brain stimulation
79387986|NCT04866771|Other|Sham tDCS + anodal tDCS|Fake noninvasive brain stimulation or anodal noninvasive brain stimulation
79543761|NCT01518465|Drug|dexamethasone|Given PO
79543762|NCT01518465|Other|laboratory biomarker analysis|Correlative studies
79703990|NCT01620918|Procedure|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
79703991|NCT04533516|Other|Manual therapy technics|Manual therapy technics
79703992|NCT04533516|Other|Inspiratory Muscle Training|Inspiratory Muscle Training
79703993|NCT04533243|Drug|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
79703994|NCT04533243|Drug|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
79703995|NCT04533620|Radiation|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
79703996|NCT04533620|Radiation|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
79845673|NCT04004013|Dietary Supplement|Placebo|"Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
79845674|NCT05359497|Diagnostic Test|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
80014087|NCT04616326|Drug|Galcanezumab|Administered SQ
80014088|NCT04616326|Drug|Placebo|Administered SQ
80014089|NCT04613375|Diagnostic Test|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
80014090|NCT04613375|Diagnostic Test|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
79703997|NCT02210585|Other|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
79703998|NCT04533321|Drug|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
79845675|NCT05359497|Device|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
79845676|NCT05359497|Device|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
79845677|NCT05359497|Diagnostic Test|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
79845678|NCT05359497|Diagnostic Test|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
80014091|NCT04612231|Behavioral|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
79249379|NCT02489565|Other|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
79387987|NCT04818853|Other|Observation to monitor patients for these infections|We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
79387988|NCT04795869|Drug|Brentuximab Vedotin|Given IV
79387989|NCT04795869|Biological|Pembrolizumab|Given IV
79543763|NCT01518478|Drug|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
79543764|NCT01518491|Drug|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
79543765|NCT01518491|Other|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
79387990|NCT04772131|Device|Desara® One Single Incision Sling|Single incision sling
79387991|NCT04772131|Device|Desara® Blue Transobturator Sling|Standard mid-urethral sling
80014092|NCT04612231|Behavioral|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
80014093|NCT04609514|Device|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
79387992|NCT04737122|Drug|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
79703999|NCT04533191|Procedure|Bilateral implantation of light adjustable intraocular lens and subsequent adjustment to binocular custom vision|Subjects will receive bilateral implantation of a commercially available Light Adjustable Intraocular lens at the time of cataract surgery. Subsequently, they will undergo light adjustment of the lens to target binocular custom vision.
79704000|NCT01004367|Other|Experimental|Environmental- and individual based components carried out in the school.
79704001|NCT02211599|Other|15% protein|Meal to provide 15%en from protein.
79704002|NCT02211599|Other|30% protein|Meal to provide 30%en from protein.
79704003|NCT02211599|Other|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
79704004|NCT00734019|Device|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
80014094|NCT04609514|Behavioral|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
80014095|NCT04609514|Drug|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
80014096|NCT04609514|Behavioral|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
80014097|NCT04608149|Device|Carpediem System|Continuous renal replacement therapy
79249380|NCT04009850|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
79249381|NCT04009850|Other|E-cigarette Flavor|Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
79249382|NCT02489253|Other|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
79249383|NCT02489487|Drug|VM-1500|VM-1500 40 mg
79249384|NCT02489487|Drug|Darunavir|Darunavir 600 mg
79387993|NCT04737122|Drug|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
79704005|NCT01195948|Drug|B27PD|
79387994|NCT04732325|Device|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
79704006|NCT01195948|Drug|Placebo|Capsule with no active ingredients to mimic B27PD
79704007|NCT02213354|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
79704008|NCT02213354|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
79704009|NCT04533048|Combination Product|MW33 injection|a recombinant fully human antibody to coronavirus
79704010|NCT04533048|Combination Product|MW33 injection placebo|Placebo
79704011|NCT01195831|Drug|Xamiol® gel|Once daily application
79704012|NCT01195831|Drug|Calcipotriol scalp solution|Twice daily application
79704013|NCT02210273|Device|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
79704014|NCT02210273|Device|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
79704015|NCT01195675|Drug|BI 10773 (low)|single oral dose
80014098|NCT04603261|Diagnostic Test|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
80014099|NCT04599335|Device|2% HA|2% HA
79387995|NCT04732091|Procedure|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
79543766|NCT01518504|Other|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
80014100|NCT04598516|Diagnostic Test|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
80014101|NCT04597892|Diagnostic Test|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
79543767|NCT01518504|Other|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
79543768|NCT01518569|Drug|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
80014102|NCT04597307|Combination Product|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
80014103|NCT04562532|Device|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
79249385|NCT02489487|Drug|Ritonavir|Ritonavir 100 mg
79704016|NCT01195675|Drug|Moxifloxacin|single oral dose
79704017|NCT01195675|Drug|BI 10773 Placebo|2 times single dose
79249386|NCT02489487|Drug|Raltegravir|400 mg Raltegravir
79249387|NCT04503746|Drug|ALH-L1005 600mg/day|ALH-L1005 300mg 2 tablet and placebo 2 tablet
79249388|NCT04503746|Drug|ALH-L1005 1,200mg/day|ALH-L1005 300mg 4 tablet
79249389|NCT04503746|Drug|Placebo|Placebo 4 tablet
79249390|NCT03318705|Device|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
79249391|NCT02096354|Drug|RRx-001|
79543769|NCT01518569|Drug|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
79543770|NCT01518582|Device|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
79249392|NCT02096354|Drug|Regorafenib|
79249393|NCT02096354|Drug|Irinotecan|To be dosed after RRx-001 or regorafenib
79249394|NCT03177746|Drug|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
79387996|NCT04731207|Device|Optovue®|Optical coherence tomography and optical coherece tomography angiography
79387997|NCT04727398|Device|Wide-field optical coherence tomography (Optovue®)|Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images
79387998|NCT04720417|Drug|Defactinib Hydrochloride|Given PO
79387999|NCT04720417|Drug|Raf/MEK Inhibitor VS-6766|Given PO
79388000|NCT04720417|Procedure|Biopsy|Undergo tumor biopsy
79543771|NCT01518595|Drug|bosentan|pts. will receive bosentan for 3 months
79543772|NCT01518595|Drug|Placebo|pts. will receive placebo for 3 months
79704018|NCT01195675|Drug|BI 10773 (high)|single oral dose
79704019|NCT04532931|Other|Standard of care (Paracetamol)|SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
79704020|NCT04532931|Drug|Artesunate-amodiaquine|SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
79704021|NCT04532931|Drug|Pyronaridine-artesunate|SOC plus pyronaridine-artesunate (PA) Weight 45 to <65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
79704022|NCT04532931|Drug|Favipiravir plus Nitazoxanide|SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
79704023|NCT04532931|Drug|Sofosbuvir/daclatasvir|"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"
79704024|NCT02210975|Device|LES-Stimulation Device|
80014104|NCT04562532|Device|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~Sirolimus eluting stents (Orsiro- Biotronik)"
79704025|NCT01195636|Drug|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
79249395|NCT02484027|Drug|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
79845679|NCT05359497|Device|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
79249396|NCT04318496|Other|Press Tack Acupuncture|PYONEX Φ0.20×0.6 mm made by Seirin Corporation
79249397|NCT04318496|Other|Press Tack Placebo|PYONEX placebo sticker made by Seirin Corporation
79249398|NCT02483715|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
79388001|NCT04719949|Behavioral|Behavioral Activation (BA) Therapy|Brief BA is a manualized individual psychotherapy adapted to a four-session structure for this pilot study. The first session provides psychoeducation about the value and reinforcement of various behaviors and treatment rationale. Three additional sessions include reviewing the youth's log of the activities they planned each week, assessing youths' values and planning further valued activities, and reviewing progress.
79388002|NCT04719949|Behavioral|Problem Solving Therapy (PST)|Brief PST is a manualized individual psychotherapy adapted to a four-session structure for this study. The first session provides psychoeducation on links between mood and managing social problems, as well as defining and identifying individual problems. Three additional sessions focus on generating solutions, decision making, implementing solutions, and evaluation and assessment of the outcomes of these solutions.
79388003|NCT04677504|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
79543773|NCT01518608|Drug|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
79543774|NCT01518621|Radiation|Radiation|Whole brain radiation
79543775|NCT01518621|Drug|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
79543776|NCT01518634|Drug|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
79704026|NCT01195636|Drug|Placebo|Twice daily application of Placebo ointment
79704027|NCT04533113|Procedure|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
79704028|NCT01195363|Drug|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
79704029|NCT01195363|Drug|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
79704030|NCT04317625|Diagnostic Test|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
79845680|NCT05359497|Device|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
79845681|NCT05279079|Diagnostic Test|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
79249399|NCT02483715|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
79388004|NCT04677504|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
79388005|NCT04677504|Other|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
79543777|NCT01518634|Drug|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
79543778|NCT01518647|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
79543779|NCT01518660|Behavioral|Training|Bi-weekly progressive resistance training
79543780|NCT01518686|Device|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
79845682|NCT00990795|Drug|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
80014105|NCT04558879|Behavioral|CT|12 weeks of exercise Cardiovascular Training
80014106|NCT04558879|Behavioral|RT|12 weeks of exercise Resistance Training
79249400|NCT03090230|Device|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
79249401|NCT02483793|Drug|Tamsulosin|
79249402|NCT02483793|Drug|Oxybutynin|
79249403|NCT02483949|Behavioral|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
79704031|NCT04315870|Other|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
79704032|NCT04533269|Other|Arnica montana, Ledum palustre|Homeopathic
79704033|NCT01195090|Drug|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
79845683|NCT00990795|Drug|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
79845684|NCT00622700|Drug|Teriflunomide|Film-coated tablet Oral administration
79845685|NCT00622700|Drug|Placebo|Film-coated tablet Oral administration
79845686|NCT00538473|Biological|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
79845687|NCT00538473|Biological|Fluarix™|Single dose, intramuscular injection
80014107|NCT04547374|Other|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
80014108|NCT04533646|Drug|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
80014109|NCT04533646|Device|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
80014110|NCT04525196|Other|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
80014111|NCT04523064|Drug|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
79543781|NCT01518712|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
79543782|NCT01518712|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
79704034|NCT01195090|Drug|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
79704035|NCT04533282|Diagnostic Test|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
79704036|NCT04533282|Diagnostic Test|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
79704037|NCT04533282|Diagnostic Test|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
79845688|NCT04004091|Biological|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
79845689|NCT00990873|Genetic|gene expression analysis|
79845690|NCT00990873|Genetic|microarray analysis|
79845691|NCT00990873|Genetic|reverse transcriptase-polymerase chain reaction|
79845692|NCT00990873|Other|laboratory biomarker analysis|
79845693|NCT04025229|Behavioral|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
79845694|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
79845695|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
79845696|NCT00831506|Drug|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
79845697|NCT02548130|Other|MELD score|introduction of MELD score
79845698|NCT00990951|Drug|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
79845699|NCT00828620|Other|Imaging study|PET-CT
80014112|NCT04497584|Drug|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
80014113|NCT04489771|Drug|Belzutifan|Oral administration
80014114|NCT04488861|Other|Non-interventional cohort study|Non-interventional cohort study
79845700|NCT02842359|Drug|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
80014115|NCT04488757|Diagnostic Test|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
80014116|NCT04488757|Other|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
80014117|NCT04486209|Device|transcutaneous spinal cord stimulation|electrical stimulation of the lumbosacral spinal cord through surface electrodes
80014118|NCT04480840|Drug|PLN-74809|PLN-74809
79543783|NCT01518725|Dietary Supplement|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
79704038|NCT04533282|Diagnostic Test|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
80014119|NCT04480840|Drug|Placebo|Placebo
80014120|NCT04467840|Drug|Opaganib|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
80014121|NCT04467840|Drug|Placebo|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
80014122|NCT04466059|Diagnostic Test|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
80014123|NCT04456699|Drug|Olaparib|300 mg BID, oral until progressive disease or end of study
79704039|NCT02211287|Other|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q&A form and can help answer frequent family questions.
79704040|NCT02211287|Other|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
79704041|NCT04524546|Diagnostic Test|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
79704042|NCT02213081|Drug|Ulipristal|Patients will take 15mg every other day, or every 4 days per week.
79704043|NCT02216760|Device|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
79704044|NCT02216760|Device|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
79704045|NCT02213627|Drug|Corifollitropin alfa|
79704046|NCT02213627|Drug|Recombinant FSH|
79704047|NCT02213627|Drug|HP-hMG|
79249404|NCT03200288|Device|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
79543784|NCT01518725|Dietary Supplement|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
79704048|NCT02216799|Drug|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
79704049|NCT02216799|Drug|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
79704050|NCT04532996|Behavioral|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
79704051|NCT02216877|Drug|Mablet 360 mg|
79543785|NCT01518738|Behavioral|breath attention training|4 week training
79845701|NCT02842359|Drug|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
79845702|NCT02842359|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
79249405|NCT03200288|Device|Placebo|2 ml intra-articular single injection
79249406|NCT03318471|Drug|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
79543786|NCT01518738|Behavioral|working memory attention training|4 week training
79543787|NCT01518764|Dietary Supplement|Red Wine Polyphenols 600mg/day|
79845703|NCT00823784|Procedure|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
79845704|NCT00823784|Procedure|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
79704052|NCT02216877|Drug|Placebo|
79704053|NCT02214563|Dietary Supplement|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
79704054|NCT02214563|Dietary Supplement|Olive oil|
79704055|NCT01194973|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
79704056|NCT02218619|Drug|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
79704057|NCT02218619|Drug|Sugar Pill (placebo)|Placebo
79704058|NCT04524234|Diagnostic Test|Echocardiography|Echocardiography for assessment of cardiac function
79704059|NCT02218697|Biological|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
79704060|NCT02218697|Biological|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
79704061|NCT02218697|Biological|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
79704062|NCT02216916|Drug|HM781-36B|
79845705|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
79845706|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
79249407|NCT03318471|Drug|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
79845707|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
79845708|NCT01564017|Biological|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
79845709|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
80014124|NCT04456699|Drug|5-FU|2400 mg/m^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5FU (400mg/m2) can be added prior to infusional 5FU, per local standards and at the investigator's discretion
79249408|NCT03175796|Behavioral|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
79388006|NCT04677504|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
79704063|NCT02279069|Device|4-roll canne|
79704064|NCT02216747|Drug|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
79704065|NCT02216747|Drug|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
79845710|NCT01564017|Biological|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
79845711|NCT00828698|Other|No intervention|
80014125|NCT04456699|Drug|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
79388007|NCT04677504|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
79388008|NCT04650178|Other|Quality-of-Life Assessment|Ancillary studies
79388009|NCT04650178|Other|Questionnaire Administration|Complete questionnaire
79388010|NCT04635631|Drug|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
79388011|NCT04620538|Diagnostic Test|Breath Analysis|Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
79704066|NCT02216747|Drug|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
79845712|NCT04044014|Device|Gellan sheet|Gellan sheet.
80014126|NCT04456699|Drug|Capecitabine|1000mg/m^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
79249409|NCT02489409|Drug|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
79249410|NCT02489409|Drug|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
79249411|NCT02489409|Drug|Navelbine|40 mg/d, iv, d1, 8
79249412|NCT02489409|Drug|Platinum|30 mg/m2, iv 3h, d1-3
79249413|NCT02489409|Drug|Xeloda Tablets:|2 000 mg/m2, po, d1-14
79249414|NCT02797574|Procedure|Punch Biopsy at a Lesional Site|
79704067|NCT04521933|Other|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
79704068|NCT02216786|Drug|AZD2014|Oral tablet
79704069|NCT02216786|Drug|Everolimus|Oral tablet
79704070|NCT02216786|Drug|Fulvestrant|Im injection
79704071|NCT02279147|Drug|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
79704072|NCT02216825|Dietary Supplement|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
79704073|NCT02216825|Dietary Supplement|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
79704074|NCT04518384|Procedure|colon or rectum resection|surgical procedure to resect the colon or rectum
79704075|NCT02279186|Drug|Tranexamic Acid|Intravenous Injection
79845713|NCT04044014|Device|Gellan fluid gel|Gellan fluid gel.
79845714|NCT04044014|Device|Mepitel One|Control dressing-- Mepitel One.
79845715|NCT00991107|Drug|HE3286|HE3286 20 mg (10 mg BID) for 28 days
79845716|NCT00828776|Biological|Heparin sodic - Cristália|5000UI/mL
79845717|NCT00828776|Biological|heparin - Liquemine (Roche)|5000UI/mL
79704076|NCT04471350|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
79704077|NCT01177540|Drug|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
79388012|NCT04566172|Behavioral|Inspiratory Muscle Training (IMT)|Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
79704078|NCT01177540|Drug|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
79704079|NCT04516707|Other|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
79704080|NCT04317469|Diagnostic Test|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
79704081|NCT04468737|Behavioral|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
79704082|NCT01177384|Drug|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
79704083|NCT01177384|Drug|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
79704084|NCT01177384|Drug|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
79845718|NCT00622466|Drug|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
79845719|NCT00622466|Drug|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
79845720|NCT02617251|Other|No intervention|
79845721|NCT02550158|Procedure|Educational program EDU-MICI|
80014127|NCT04456699|Drug|Leucovorin/ levoleucovorin|400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) may be added to Bevacizumab + 5FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
80014128|NCT04452877|Drug|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
79249415|NCT02797574|Procedure|Punch Biopsy at a Non- Lesional site|
79249416|NCT03930602|Drug|BMS-986165|Participants will receive BMS-986165.
79249417|NCT03930602|Drug|Fluvoxamine|Participants will receive fluvoxamine.
79249418|NCT02489175|Device|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
79388013|NCT04543396|Other|Resistance exercise|A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
79388014|NCT04540302|Device|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
79388015|NCT04540302|Device|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
79388016|NCT04534309|Behavioral|Written Weight Loss Material|Participants will receive written weight loss material by email.
79388017|NCT04534309|Behavioral|Weight Loss App|Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
79388018|NCT04534309|Behavioral|Behavioral Lifestyle Weight Loss Intervention (Coaching)|Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
79388019|NCT04524832|Drug|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
79388020|NCT04502745|Device|Minimally Invasive Cortical Access System (MICAS)|Temporary surgical tool that provides access to the sub-dural space through the cranium.
79388021|NCT04499534|Biological|Seasonal influenza vaccine|To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination
79388022|NCT04487327|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
79388023|NCT04483102|Device|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
79543788|NCT01518764|Dietary Supplement|placebo|
79543789|NCT01518777|Other|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
79543790|NCT01518790|Drug|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
79543791|NCT01518803|Dietary Supplement|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
79704085|NCT01177384|Drug|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
79704086|NCT04315714|Other|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
79704087|NCT01640015|Other|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
79704088|NCT04315519|Other|Exercise|Aerobic Exercise
79249419|NCT02729636|Device|multi-pad functional electrical stimulation (FES)|"Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait."
79249420|NCT02729636|Other|Conventional therapy|2. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
79543792|NCT01518803|Dietary Supplement|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
79704089|NCT01641887|Other|Decision Aid|Patients will use a decision aid administered on a computer.
79704090|NCT01640093|Drug|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
79704091|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
79704092|NCT01640093|Drug|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
79704093|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
79704094|NCT04512807|Diagnostic Test|AMH|AMH & PREGNANCY
79704095|NCT01641965|Device|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 < 45 mmHg and improve symptoms.
79704096|NCT04466124|Radiation|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
79249421|NCT02943980|Device|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
79249422|NCT02943980|Device|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
79249423|NCT02483871|Drug|Rosuvastatin|
79249424|NCT02489019|Drug|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
79249425|NCT02489019|Drug|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
79249426|NCT02604446|Drug|Tapentadol|
79249427|NCT02604446|Drug|Oxycodone|
79249428|NCT02604446|Drug|Placebo|
79543793|NCT01518842|Biological|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
79388024|NCT04483102|Procedure|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
79704097|NCT01642121|Other|laboratory biomarker analysis|Correlative studies
79704098|NCT01194154|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
79704099|NCT01194154|Drug|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
79710062|NCT01327703|Drug|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
79249429|NCT02604446|Drug|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
79388025|NCT04477772|Biological|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
79388026|NCT04477772|Biological|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
79543794|NCT01518855|Drug|Nifedipine (Adalat, BAYA1040)|
79543795|NCT01518855|Drug|Amlodipine (Norvasc)|
79704100|NCT01640210|Device|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
79704101|NCT01642160|Behavioral|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
79543796|NCT01518855|Drug|Diovan|
79543797|NCT01518881|Drug|TKM-100201|IV Infusion
79543798|NCT01518881|Drug|Placebo|IV infusion
79543799|NCT01518894|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
79704102|NCT01642160|Behavioral|Standard of care|participants will receive education from staff nurses as needed.
79704103|NCT01640405|Drug|modified FOLFOX6 + bevacizumab|"Bevacizumab 5 mg/kg iv, day 1, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
79704104|NCT01640405|Drug|FOLFOXIRI + Bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
79845722|NCT04043858|Drug|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
79845723|NCT05359419|Combination Product|aminolevulinic acid hydrochloride gel, 10%|10% ALA with Red Light
79845724|NCT05359419|Combination Product|aminolevulinic acid HCl topical solution, 20%|20% ALA with Blue Light
79845725|NCT00823862|Drug|SD-101|Intramuscular (IM)
79845726|NCT00823862|Drug|ribavirin|oral, 2 times per day, for 2 months
79845727|NCT00991263|Genetic|gene expression analysis|
79845728|NCT00991263|Genetic|polymerase chain reaction|
79845729|NCT00991263|Other|laboratory biomarker analysis|
79249430|NCT02847637|Drug|Emicizumab|Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week [QW], 3 mg/kg once every 2 weeks [Q2W], or 6 mg/kg once every 4 weeks [Q4W]) and continue on that dosing regimen until discontinuation from the study.
79388027|NCT04471597|Drug|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
79543800|NCT01518894|Drug|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
79543801|NCT01518894|Drug|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
79543802|NCT01518894|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
79543803|NCT01518907|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
79543804|NCT01518920|Drug|PF-04958242|PF-04958242 0.35 mg oral solution
79543805|NCT01518920|Drug|PF-04958242|PF-04958242 0.27 mg oral solution
79543806|NCT01518920|Drug|Placebo|Placebo oral solution
79543807|NCT01518933|Drug|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
79543808|NCT01518933|Drug|Saline|Placebo
79543809|NCT01518959|Drug|Cholecalciferol|180.000 IU monthly
79543810|NCT01518959|Drug|oleum neutralicum|Placebo comparator, 9 ml monthly
79543811|NCT01518985|Drug|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
79543812|NCT01518985|Drug|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
79543813|NCT01518985|Other|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
79845730|NCT02548598|Procedure|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
79845731|NCT00828932|Drug|Lorcaserin|
79845732|NCT00537771|Drug|Anastrozole|1 mg once daily oral dose
79845733|NCT00537771|Drug|Tamoxifen|20 mg once daily oral dose
79845734|NCT00829088|Drug|AZD2066|1 dose oral solution
79249431|NCT02847637|Drug|Factor VIII (FVIII)|FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
79249432|NCT05399199|Procedure|virtual reality distraction|study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
79249433|NCT02483559|Other|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (~470 nm) to be worn prior to desired sleep onset time.
79388028|NCT04471597|Drug|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
79543814|NCT01518998|Drug|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
79543815|NCT01519011|Drug|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
79845735|NCT00831740|Other|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
79249434|NCT02483559|Other|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
79249435|NCT05345353|Behavioral|Fat For Fight (FFF), The Aarhus Protocol|A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum
79249436|NCT05345353|Behavioral|The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol|A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
79249437|NCT05352607|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
79388029|NCT04469920|Drug|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
79704105|NCT04465929|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
79704106|NCT02279225|Radiation|Group Phototherapy|
79704107|NCT02279225|Radiation|Phototherapy + Physical activity|
79845736|NCT00831740|Other|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
79845737|NCT00831896|Biological|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
79845738|NCT00823940|Drug|GSK1362885|5 - 100mg of GSK1362885 or placebo
79845739|NCT00823940|Drug|GSK1362885|100 - 600mg or placebo
79845740|NCT00823940|Drug|Glucagon|0.5mg IV bolus
79845741|NCT00823940|Drug|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
79845742|NCT03857828|Other|semen sample|• seminal sample for measuring clusterin level.
79388030|NCT04469920|Drug|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
79388031|NCT04456413|Biological|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
79388032|NCT04456413|Other|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
79388033|NCT04454411|Drug|Brixadi|Extended release injectable Buprenorphine
79388034|NCT04454411|Drug|Vivitrol|Extended release injectable Naltrexone
79543816|NCT01519011|Drug|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
79704108|NCT02279225|Other|Physical activity|
79704109|NCT02279225|Other|Placebo|
79704110|NCT01640444|Drug|FOLFIRI + bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
79704111|NCT01640444|Drug|FOLFIRI + cetuximab|"Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~FOLFIRI:~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
79249438|NCT05352607|Other|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
79543817|NCT01519037|Drug|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
79543818|NCT01519037|Drug|Placebo oral tablet|one tablet of placebo
79845743|NCT04043546|Behavioral|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
79543819|NCT01519050|Behavioral|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
79704112|NCT04464096|Other|non|non
79249439|NCT02314910|Other|Sample histology|
79704113|NCT04509804|Other|non-interventional|non-interventional
79845744|NCT00831974|Drug|masitinib (AB1010)|3 mg/kg/day
79845745|NCT00831974|Drug|masitinib (AB1010)|6 mg/kg/day
79249440|NCT03564535|Device|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
80014129|NCT04452877|Drug|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
80014130|NCT04445883|Behavioral|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
79388035|NCT04446507|Drug|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
79543820|NCT01519076|Device|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
79543821|NCT01519102|Device|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
79543822|NCT01519115|Other|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
79543823|NCT01519115|Other|usual care|one physical therapy visit in hospital following ACF surgery
79845746|NCT00829322|Drug|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
79845747|NCT00829322|Drug|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
79845748|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
79388036|NCT04396288|Device|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
79388037|NCT04387500|Drug|Sintilimab injection plus Inlyta treatment|Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
79391634|NCT02532010|Drug|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
79543824|NCT01519128|Drug|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
79845749|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
79543825|NCT01519128|Drug|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
79543826|NCT01519154|Drug|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
79704114|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
79845750|NCT02513667|Drug|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
80014131|NCT04444869|Drug|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
79388038|NCT04384263|Behavioral|Tai Chi|Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
79388039|NCT04369846|Drug|GM-XANTHO onitment|Onitment application
79388040|NCT04369846|Drug|Placebo onitment|Onitment application
79543827|NCT01519154|Drug|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
79543828|NCT01519193|Behavioral|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
79543829|NCT01519219|Radiation|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
79543830|NCT01519232|Radiation|Liver Irradiation|Patients already scheduled to undergo radiation treatment
79543831|NCT01519258|Other|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
79543832|NCT01519258|Device|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
80014132|NCT04430569|Drug|Alteplase|Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
79845751|NCT02513667|Radiation|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
79388041|NCT04290130|Other|Measurement of brain activity using electrodes.|We will present audiovisual speech and record neural responses.
79388042|NCT04269395|Drug|MAL Cream|No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
79388043|NCT04269395|Drug|Vehicle cream|No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
79388044|NCT04258566|Device|Optical Molecular Imaging|Tracks and localizes intrahepatic lesions
79388045|NCT04258566|Radiation|Indocyanine Green|Fluorescent dye used for visualization of cells and tissue
79543833|NCT01519297|Drug|Irbesartan|150mg orally for one dose
79543834|NCT01519310|Other|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
79704115|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
79845752|NCT00829400|Behavioral|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
79845753|NCT00829400|Behavioral|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
79388046|NCT04250402|Procedure|Resection|Radical resection.
79388047|NCT04232917|Drug|2LPAPI®|Treatment
79388048|NCT04232917|Drug|Placebo|Placebo
79388049|NCT04205734|Diagnostic Test|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
79388050|NCT04162665|Radiation|MR guided radiation therapy|-Image-based treatment planning and intensity modulated radiotherapy (IMRT) is permitted.
79543835|NCT01519336|Drug|danoprevir|100 mg q12h
79543836|NCT01519336|Drug|darunavir|600 mg q12h
79543837|NCT01519336|Drug|ritonavir|100 mg q12h
79704116|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
79704117|NCT01642316|Other|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
79845754|NCT00829478|Behavioral|Decision Aid for Atrial Fibrillation|Single contact educational session
79845755|NCT00829478|Other|Usual Care|Usual Care
80014133|NCT04430569|Drug|Placebo|Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
80014134|NCT04421924|Procedure|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
80014135|NCT04421924|Procedure|standard of care|2) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
79249441|NCT03564535|Device|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
79543838|NCT01519388|Other|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
79543839|NCT01519388|Device|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
79543840|NCT01519401|Drug|3 mg drospirenone and 20 µg ethinyl-estradiol|
79543841|NCT01519401|Drug|3 mg drospirenone and 30 µg ethinyl-estradiol|
79543842|NCT01519479|Other|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
79543843|NCT01519479|Other|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
79388051|NCT04162665|Procedure|Blood for ctDNA|-Prior to start of radiation, after the completion of radiation therapy and prior to starting chemotherapy (2-4 weeks after radiation completion), at the completion of chemotherapy and prior to surgery (2-4 weeks after chemotherapy completion), and 6 months after surgery
79388052|NCT04162665|Drug|Standard of care chemotherapy regimen|The recommendations are CAPOX, FOLFOX, or FLT.
79543844|NCT01519492|Drug|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
79543845|NCT01519505|Behavioral|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
79543846|NCT01519531|Drug|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
79543847|NCT01519531|Drug|VIA-3196|Oral, daily dosing for 14 days
79704118|NCT01642316|Other|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
79704119|NCT01642355|Behavioral|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
79845756|NCT00991419|Drug|[18F]AZD4694|[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
79845757|NCT00829556|Device|Integuseal|
79249442|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m^2 for normal hepatic function.
79543848|NCT01519544|Drug|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
79543849|NCT01519544|Drug|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
79543850|NCT01519557|Drug|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
79543851|NCT01519557|Drug|Placebo|Placebo
79249443|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m^2 for mild hepatic impairment (Child-Pugh A)
79543852|NCT01519596|Procedure|quality-of-life assessment|Ancillary studies
79543853|NCT01519596|Other|counseling intervention|Receive lifestyle-related counseling
79543854|NCT01519596|Behavioral|exercise intervention|Undergo physical activity intervention
79543855|NCT01519596|Other|educational intervention|Receive educational materials
79704120|NCT01642355|Behavioral|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
79704121|NCT04529330|Procedure|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
79249444|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m^2 for moderate hepatic impairment (Child-Pugh B)
79249445|NCT02486913|Other|Enhanced Health Check|National Health Service Health Check enhanced by risk report
79388053|NCT04157608|Device|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
79388054|NCT04157608|Device|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
79388055|NCT04153019|Other|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
79543856|NCT01519596|Procedure|standard follow-up care|Undergo usual care
79543857|NCT01519609|Drug|bowel prep before endoscopy|bowel prep before colonoscopy
79543858|NCT01519622|Other|Questionnaire|Questionnaire to be distributed among sick elderly in the community
79543859|NCT01519687|Drug|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
79543860|NCT01519726|Drug|Midazolam|
79543861|NCT01519739|Device|MediGuide™|MediGuide™ system will be used to guide CRT implants
79845758|NCT03823911|Drug|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
79543862|NCT01519752|Drug|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
79704122|NCT04508556|Device|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
79704123|NCT04508556|Diagnostic Test|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
80014136|NCT04383223|Behavioral|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
80014137|NCT04362748|Drug|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
79704124|NCT04508556|Diagnostic Test|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
80014138|NCT04361240|Radiation|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
80014139|NCT04353622|Device|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~10 minutes elbow flexion/extension~10 minutes forearm supination/pronation~10 minutes wrist flexion/extension~10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
79249446|NCT05352841|Diagnostic Test|Salivary sample analysis|The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.
79704125|NCT01642433|Drug|Placebo|Placebo capsules, 3x daily
79704126|NCT01642433|Drug|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
79704127|NCT04529213|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
79249447|NCT02486835|Device|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
79704128|NCT01642472|Drug|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
79704129|NCT04507191|Diagnostic Test|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
79249448|NCT02486835|Device|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
79249449|NCT05708287|Device|HFNC|The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation >90%, were commenced on HFNC therapy
79249450|NCT01084382|Dietary Supplement|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
79249451|NCT00584246|Drug|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
79388056|NCT04143594|Drug|Oral Lenacapavir|Tablets administered without regard to food
79388057|NCT04143594|Drug|F/TAF|Tablets administered without regard to food
79388058|NCT04143594|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
79543863|NCT01519752|Drug|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
79543864|NCT01519752|Drug|Placebo|Placebo applied to affected area once a day for 28 days
80014140|NCT04353622|Other|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
79249452|NCT00584246|Drug|Placebo|50 - 150 mg po qhs for 2 months
80014141|NCT04335656|Dietary Supplement|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
80014142|NCT04335656|Other|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
80014143|NCT04308109|Behavioral|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
80014144|NCT04300335|Other|Individual Exercise|Supervised body weight & resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
79388059|NCT04143594|Drug|TAF|Tablets administered without regard to food
79388060|NCT04143594|Drug|BIC|Tablets administered without regard to food
79388061|NCT04143594|Drug|B/F/TAF|Tablets administered without regard to food
79388062|NCT04132323|Procedure|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
79543865|NCT01519830|Drug|Iron carboxymaltose (Ferinject)|Intravenous iron
79543866|NCT01519830|Drug|Placebo|0.9% NaCl solution
79543867|NCT01519856|Drug|piribedil (Clarium)|oral tablets, 50 mg
79543868|NCT01519895|Behavioral|Telephone intervention|counseling and education support
79543869|NCT01519908|Device|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
79845759|NCT03823911|Procedure|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
79249453|NCT03321123|Drug|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
79388063|NCT04102228|Device|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
79249454|NCT03564457|Other|No interventions will take place (observational)|No interventions will take place (observational)
79543870|NCT01519973|Radiation|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
79249455|NCT05124314|Drug|Mifepristone, Oral, 200 Mg|Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
79388064|NCT04102228|Device|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
79388065|NCT04102228|Behavioral|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
79704130|NCT04460196|Other|survey|Each admitted patient will complete a questionnaire
79704131|NCT01640639|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
79704132|NCT01640639|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
79704133|NCT01640678|Procedure|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
79704134|NCT01640678|Procedure|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
79704135|NCT01642628|Other|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
79845760|NCT00829634|Drug|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
79845761|NCT00829634|Drug|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
79845762|NCT05277753|Biological|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
80014145|NCT04300335|Other|Group Exercise|Supervised body weight & resistance band resistance exercises in a Group setting plus home based aerobic exercise
80014146|NCT04295499|Device|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
79249456|NCT05124314|Drug|Misoprostol Pill|Regular treatment with vaginal Misoprostol 800 mcg
79388066|NCT04084067|Drug|Indocyanine Green|IV
80014147|NCT04280562|Device|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
79388067|NCT04082988|Diagnostic Test|18F-FDG PET-CT|18F-FDG PET-CT scan
79388068|NCT04068376|Other|Control excercise|Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).
79391635|NCT02532010|Drug|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
79391636|NCT02532010|Drug|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
79543871|NCT01519986|Dietary Supplement|Vitamin D3|Supplement of vitamin D3
79543872|NCT01519986|Dietary Supplement|Placebo|Placebo
79543873|NCT01519999|Behavioral|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
79543874|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
79543875|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
79249457|NCT04413032|Device|DreaMS|The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
79249458|NCT02486991|Procedure|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
79388069|NCT04068376|Other|"Mind and Movement for Cognitive Health in the Older Adult"|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health profesional certified to coach SSE. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).
79845763|NCT00824096|Procedure|Bronchoscopy|The patients in our ICU intubated for > 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3~4 days even with CLV <24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
80014148|NCT04280562|Device|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
79704136|NCT04459143|Behavioral|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
79704137|NCT01642667|Drug|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
79704138|NCT01642667|Drug|Placebo|
79704139|NCT04458012|Diagnostic Test|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
79704140|NCT04456179|Device|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
79845764|NCT00991497|Device|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
80014149|NCT04274296|Device|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
80014150|NCT04273516|Drug|Rivaroxaban 2.5 Mg Oral Tablet|Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
80014151|NCT04273516|Drug|Rivaroxaban placebo tablets|Placebo tablets add to ASA 80 mg daily that is standard treatment
80014152|NCT04267926|Drug|20 mg MitoQ|a third of subject will receive 20mg of oral MitoQ
80014153|NCT04267926|Drug|Placebo|Subject will receive Placebo
80014154|NCT04267926|Drug|40mg of MitoQ|a third of subjects will receive 40mg of MitoQ
79391637|NCT03176862|Diagnostic Test|cardiac magnetic resonance scan|An MRI scan of the heart
79391638|NCT03176862|Diagnostic Test|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
79543876|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
79543877|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
79543878|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
79704141|NCT04456179|Device|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
79704142|NCT01640912|Drug|RXI-109|Single intradermal injection of RXI-109 at incision sites
79704143|NCT01640912|Drug|Placebo|Single intradermal injection of placebo at incision sites
79704144|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
80014155|NCT04255433|Drug|Tirzepatide|Administered SC
79704145|NCT01642745|Drug|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
79704146|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
79704147|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
79845765|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
79845766|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
79845767|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
79845768|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
80014156|NCT04255433|Drug|Dulaglutide|Administered SC
79388070|NCT04068376|Other|Double-task exercise by older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
79388071|NCT04068051|Drug|AXS-07|AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
79388072|NCT04065971|Drug|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
79388073|NCT04065971|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
79388074|NCT04046549|Drug|Belatacept|Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
79543879|NCT01520025|Radiation|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
79543880|NCT01520051|Drug|Mepolizumab|3 monthly intravenous infusions of 750 mg
79704148|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
79704149|NCT04502238|Other|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
79704150|NCT01640990|Drug|Saline|30mins run-in period
79704151|NCT01640990|Drug|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
79845769|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
79845770|NCT00824174|Behavioral|Questionnaire|1 questionnaire, about 15-20 minutes.
79845771|NCT04003467|Drug|EBP05|tablets
80014157|NCT04236128|Other|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
79388075|NCT04046549|Drug|VIB4920|"Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48."
79391639|NCT03176862|Diagnostic Test|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
79704152|NCT01640990|Drug|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
79704153|NCT01641029|Other|No intervention|There is no intervention
79704154|NCT01641068|Other|Cognitive Intervention|Participate in memory and thinking skills workshop
79704155|NCT01641068|Other|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
79704156|NCT01641068|Procedure|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
79845772|NCT04003467|Drug|Placebo of EBP05|tablets
79845773|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
79845774|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
79845775|NCT05361057|Drug|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
79845776|NCT05361057|Drug|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
79845777|NCT00832286|Drug|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
79845778|NCT00991653|Procedure|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
80014158|NCT04231110|Biological|Fecal microbiota transplantation|Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
79704157|NCT01641068|Other|Memory Intervention|Participate in memory and thinking skills workshop
79249459|NCT02486991|Procedure|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
79249460|NCT04436354|Procedure|vaginoscopic office hysteroscopy|comparison of procedural time and pain scores of patients in different gynecologycal positions
79845779|NCT00829946|Behavioral|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of ~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
79704158|NCT01641068|Other|Quality-of-Life Assessment|Ancillary studies
79704159|NCT01641068|Other|Questionnaire Administration|Ancillary studies
79249461|NCT02837731|Device|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
79704160|NCT04454385|Diagnostic Test|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
79704161|NCT04529057|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
79704162|NCT01642862|Drug|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
79704163|NCT04501263|Behavioral|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
79388076|NCT04046549|Drug|Thymoglobulin|"Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4."
79704164|NCT04529369|Procedure|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
79704165|NCT04529369|Procedure|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
79704166|NCT01641146|Behavioral|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
79710063|NCT01327703|Drug|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
79845780|NCT02548520|Other|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
79845781|NCT04016792|Drug|Placebo|Placebo will be administered once daily
80014159|NCT04225819|Dietary Supplement|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
80014160|NCT04225819|Other|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
79249462|NCT03320967|Diagnostic Test|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
80014161|NCT04219904|Other|Fludeoxyglucose F-18|Given IV
80014162|NCT04219904|Drug|Gadobutrol|Given IV
80014163|NCT04219904|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
80014164|NCT04219904|Procedure|Positron Emission Tomography|Undergo PET/MRI
79249463|NCT03315663|Other|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
79249464|NCT03315663|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
79249465|NCT02483325|Drug|Allogeneic transplant conditioning|Allogeneic transplant
79249466|NCT02486679|Drug|Prostin (PGE2) tablets|
80014165|NCT04217330|Behavioral|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
80014166|NCT04217330|Behavioral|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
79249467|NCT02486679|Device|Foley catheter|
80014167|NCT04199871|Other|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
79249468|NCT04211090|Drug|Camrelizumab|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
79249469|NCT04211090|Drug|Pemetrexed|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
79249470|NCT04211090|Drug|Carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
79249471|NCT02486445|Drug|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
79543881|NCT01520051|Drug|Placebo|3 monthly intravenous infusions with saline
79543882|NCT01520077|Drug|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
79704167|NCT01641146|Behavioral|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
79704168|NCT01642940|Drug|Prasugrel|Prasugrel 10mg/day
79249472|NCT02836873|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
79249473|NCT02836873|Drug|Placebo|Placebo (inactive) tablet to match the active comparator
79249474|NCT04538534|Drug|Nicardipine|To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
79249475|NCT03318159|Drug|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
79249476|NCT03740984|Other|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
79249477|NCT03315585|Device|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
79704169|NCT01642940|Drug|Ticagrelor|Ticagrelor 90mg twice a day
79704170|NCT01643018|Procedure|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
79704171|NCT01643018|Procedure|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
79704172|NCT01641185|Procedure|radiation|radiation with protons or carbon ions
79249478|NCT03318081|Behavioral|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
79249479|NCT03315507|Drug|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
79704173|NCT04497519|Drug|inhaled hydroxychloroquine|ascending dose of iHCQ
79388077|NCT04046549|Drug|Methylprednisolone|"Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit."
79391640|NCT03176862|Diagnostic Test|12-lead ECG|Can be done immediately by the bedside.
79543883|NCT01520103|Drug|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
79543884|NCT01520103|Drug|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
79543885|NCT01520116|Drug|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
79543886|NCT01520116|Drug|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
79543887|NCT01520116|Drug|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
79543888|NCT01520116|Drug|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
79543889|NCT01520116|Drug|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
79543890|NCT01520116|Drug|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
79543891|NCT01520116|Drug|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
79543892|NCT01520116|Drug|Timoptic|0.5%
79704174|NCT01641224|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
79704175|NCT01641224|Device|Atractylodes|Atractylodes (~10-15g)
79704176|NCT01641224|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
79704177|NCT01641224|Device|Tangerine Peel|Tangerine Peel (~10g)
79704178|NCT01641224|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
79704179|NCT01641224|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
79704180|NCT01641224|Drug|Radix curcumae|Radix curcumae (~10g)
79845782|NCT04016792|Drug|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
79388078|NCT04034511|Other|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
80014168|NCT04196556|Behavioral|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
79249480|NCT05123924|Other|Evaluation of respiratory capacity, respiratory muscle strength and fatigue|"The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time."
79388079|NCT04031118|Device|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
79704181|NCT01641224|Drug|Fingered citron|Fingered citron (~10g)
79704182|NCT01641224|Drug|Tuckahoe|Tuckahoe (15g)
79704183|NCT01641224|Drug|Placebo|Placebo is blindly given to patients.
79704184|NCT01641263|Behavioral|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
79704185|NCT01641263|Behavioral|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
79704186|NCT04451733|Procedure|Endotracheal intubation|Perform the endotracheal intubation during CPR
79704187|NCT01643057|Device|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
79704188|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
79704189|NCT01643096|Other|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
79845783|NCT04044170|Drug|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
79845784|NCT00832364|Drug|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
79845785|NCT00832364|Drug|Placebo|Placebo capsules
79845786|NCT00832364|Biological|Etanercept|Injectable Biologic
79249481|NCT03320889|Other|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
79845787|NCT00832442|Drug|Beta blocker|as determined by individual study
79249482|NCT03315429|Diagnostic Test|stress echocardiography|stress testing of patients with functional mitral regurgitation
79388080|NCT03975231|Drug|Dabrafenib|Given PO
79388081|NCT03975231|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79388082|NCT03975231|Drug|Trametinib|Given PO
79388083|NCT03964753|Drug|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
79388084|NCT03964753|Procedure|surgery|surgery
79388085|NCT03933384|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
79388086|NCT03933384|Drug|Entecavir|Entecavir 0.5mg/tab once daily
79388087|NCT03915431|Biological|NCS-01|single infusion
79704190|NCT01643135|Drug|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
79704191|NCT01643135|Drug|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
79704192|NCT01641419|Drug|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
79845788|NCT00832442|Other|Placebo|in addition to usual care
79845789|NCT00824330|Behavioral|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
79845790|NCT00830414|Drug|medroxyprogesterone acetate|IM Injection
79704193|NCT01641419|Drug|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
79704194|NCT01641419|Drug|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
79704195|NCT04449081|Behavioral|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
79704196|NCT01643252|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
79704197|NCT01643252|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
79704198|NCT01641458|Other|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G>A, c.1679T>G, HapB3/c.1129-5923C>G and c.2846A>T).
79704199|NCT01641458|Other|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
79704200|NCT01641497|Radiation|3D conformational radiation|25 * 1.8 Gy in 5 weeks (=45 Gy)
79704201|NCT01641497|Radiation|IMRT|25 * 1.8 Gy in 5 weeks (=45 Gy)
79704202|NCT01641536|Genetic|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
79704203|NCT01641575|Drug|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
79704204|NCT01643369|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
79249483|NCT02724410|Drug|home intravenous ertapenem|see arm description
79704205|NCT01643369|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
79249484|NCT02724410|Drug|home oral amoxicillin-clavulanate|see arm description
79704206|NCT01643369|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
79704207|NCT01641731|Other|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
79704208|NCT01643447|Drug|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
79704209|NCT01643447|Drug|Diammonium glycyrrhizinate|
79704210|NCT01643486|Other|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
79704211|NCT01643486|Other|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
79704212|NCT04491669|Diagnostic Test|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~Stage1 in which GFR>90 mil/min but evidence of kidney damage.~Stage 2 GFR 60-89 mil/min.~Stage 3 GFR 30-95 mil/min.~Stage 4 GFR 15-29 mil/min.~Stage 5 GFR<15 mil/min."
79845791|NCT00830414|Drug|medroxyprogesterone acetate|IM injection
79845792|NCT00830492|Drug|clomiphene citrate|100 mg from cycle day 3 through 7
79249485|NCT02724410|Device|peripheral inserted central Catheter|All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
79249486|NCT03320811|Other|Data record|
79388088|NCT03879018|Behavioral|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
79704213|NCT01641770|Other|Nutritional beverage 10003RF|2 sachets per day
79388089|NCT03877640|Device|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
79543893|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
79543894|NCT01520142|Drug|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
79543895|NCT01520142|Drug|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
79543896|NCT01518218|Behavioral|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
80014169|NCT04196556|Other|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
79388090|NCT03835117|Drug|Wide-spectrum nutritional supplement|Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
79543897|NCT01520181|Drug|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
79543898|NCT01520194|Other|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
79543899|NCT01520194|Other|medical records|medical chart review of patients assisted January 2009 to December 2010
79543900|NCT01520220|Drug|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
79543901|NCT01520233|Genetic|RNA analysis|
80014170|NCT04192773|Drug|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
79388091|NCT03835117|Other|Placebo|Inactive placebo comparator
79388092|NCT03821714|Drug|Glucocorticoid combination therapy|Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.
79543902|NCT01520233|Genetic|gene expression analysis|
79543903|NCT01520233|Other|laboratory biomarker analysis|
79543904|NCT01520246|Genetic|gene expression analysis|
79543905|NCT01520246|Other|laboratory biomarker analysis|
79543906|NCT01520285|Drug|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
79543907|NCT01520285|Drug|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
79704214|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
80014171|NCT04182464|Other|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
79704215|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
79704216|NCT01600911|Other|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
79704217|NCT01643603|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
79388093|NCT03821714|Drug|Glucocorticoid|The glucocorticoid group was defined as the use of hydrocortisone alone.
79704218|NCT01643603|Other|laboratory biomarker analysis|Correlative studies
79388094|NCT03783715|Drug|Ketoprofen|Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
79543908|NCT01520298|Drug|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
79388095|NCT03725436|Drug|MDM2/MDMX Inhibitor ALRN-6924|Given IV
79388096|NCT03725436|Drug|Paclitaxel|Given IV
79388097|NCT03703050|Drug|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
79543909|NCT01520298|Drug|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
79845793|NCT00830492|Procedure|Ultrasound|cycle day 8
79845794|NCT00830492|Drug|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
80014172|NCT04182464|Other|Placebo|Cornstarch without significant physiological effects
79249487|NCT02486523|Behavioral|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
79388098|NCT03703050|Drug|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
79704219|NCT02279238|Procedure|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest [Washout time] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of [HR, SPO2, PSG RPE scale, Distance walked, BP] the participants are collected before, during and after the completion of each lap [according to American Thoracic Society [ATS] protocol]."
79704220|NCT02488863|Other|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
79704221|NCT02488863|Other|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
79704222|NCT02488863|Other|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
79704223|NCT02488863|Other|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
79704224|NCT02755844|Drug|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
79845795|NCT00830492|Drug|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
79845796|NCT00830492|Drug|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
79845797|NCT00830492|Drug|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
79845798|NCT00830570|Other|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
79845799|NCT00837356|Drug|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
80014173|NCT04158635|Drug|Bosentan|Given PO
80014174|NCT04158635|Drug|Gemcitabine|Given IV
80014175|NCT04158635|Drug|Nab-paclitaxel|Given IV
79388099|NCT03691350|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
80014176|NCT04158635|Other|Quality-of-Life Assessment|Ancillary studies
80014177|NCT04158635|Other|Questionnaire Administration|Ancillary studies
79388100|NCT03691350|Drug|Cigarette|Smoke usual brand
79388101|NCT03691350|Other|Electronic Cigarette|Smoke SREC with nicotine
79388102|NCT03691350|Other|Electronic Cigarette|Smoke SREC without nictoine
79249488|NCT02486523|Device|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
79388103|NCT03691350|Other|Laboratory Biomarker Analysis|Correlative studies
79249489|NCT02486523|Behavioral|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
79388104|NCT03691350|Drug|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
79388105|NCT03691350|Other|Questionnaire Administration|Ancillary studies
79388106|NCT03657342|Drug|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
79391641|NCT03176862|Diagnostic Test|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
79391642|NCT03176862|Biological|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
79704225|NCT02755844|Drug|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
79704226|NCT02755844|Drug|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
79704227|NCT01643642|Other|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
79704228|NCT01643642|Other|Treatment As Usual|Other: Treatment As Usual
79704229|NCT04490070|Behavioral|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
79704230|NCT01600989|Other|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
79704231|NCT01600989|Other|blood sampling|Blood samples will be taken twice at a 7 day interval
79845800|NCT00837356|Drug|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
79845801|NCT00832754|Device|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
79704232|NCT01643681|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
79845802|NCT00832754|Other|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
79845803|NCT00824486|Behavioral|Injury prevention education (TIPP)|using TIPP materials
79704233|NCT04489914|Device|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
79704234|NCT06032195|Drug|Custodiol-N|heart will preserved in and will be treated with Custodiol-N solution
79845804|NCT00824486|Behavioral|Injury prevention education (safe home)|using safe home model
80014178|NCT04148482|Other|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
79249490|NCT02486523|Behavioral|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
79249491|NCT02486523|Procedure|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
79249492|NCT04435886|Dietary Supplement|Probiotic|Probiotic mixture with maltodextrin as a carrier.
79249493|NCT04435886|Dietary Supplement|Placebo|Placebo comparator with maltodextrin as a carrier.
79249494|NCT02486601|Drug|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
79388107|NCT03657342|Drug|standard of care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
79388108|NCT03656926|Drug|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
79845805|NCT00832832|Other|Eyelid closure|Eyelid will be closed after eye drop instillation
79845806|NCT00832832|Other|No intervention will be assigned|No intervention will be assigned to this arm
79845807|NCT00824642|Device|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
79845808|NCT00824642|Device|placebo|placebo TENS applied prior to exercise
79845809|NCT00837746|Drug|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
79845810|NCT04043702|Drug|The intervention being studied|Intervention Other Names have not been specified
79845811|NCT00832988|Other|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
79845812|NCT02550080|Drug|Dapsone|For the HLA-B*1301 positive subjects, dapsone will not be administrated.
79845813|NCT02550080|Genetic|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
79845814|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
80014179|NCT04141761|Dietary Supplement|Visbiome|This group will receive Visbiome probiotic in powder form.
79249495|NCT02486601|Drug|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
79249496|NCT02487069|Procedure|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
79249497|NCT02487069|Procedure|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
80014180|NCT04141761|Other|Placebo|This group will receive a placebo in powder form.
79704235|NCT06032195|Drug|Custodiol|heart will preserved in and will be treated with Custodiol solution
79543910|NCT01520311|Device|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
79704236|NCT06032078|Device|Cutera laser machine|1064nm Nd: YAG laser
79704237|NCT06032065|Behavioral|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
79704238|NCT06032065|Behavioral|Home-Based Exercise|This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
79704239|NCT06032065|Dietary Supplement|Nitrate-rich beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
79704240|NCT06032039|Drug|Triamcinolone|Standard treatment for osteoarthritis knee pain
79704241|NCT06032039|Other|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
79704242|NCT06031987|Device|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
79845815|NCT00833066|Biological|Placebo|placebo entero-coated capsules
79249498|NCT02487069|Procedure|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
79704243|NCT06031987|Device|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
79249499|NCT02487069|Drug|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
79249500|NCT02487069|Drug|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
79388109|NCT03656926|Drug|Standard of Care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
79704244|NCT06031961|Drug|melatonin|We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
79704245|NCT06031948|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
79704246|NCT06031948|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
79704247|NCT06031948|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
79704248|NCT06031948|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
79704249|NCT06031935|Behavioral|Yoga|The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
79704250|NCT06031922|Device|Microprocessor controlled knee|Microprocessor controlled knee
79543911|NCT01520337|Device|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
79543912|NCT01520350|Drug|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
79704251|NCT06031909|Diagnostic Test|Multimodal frailty assessment|"Different domains are assessed during hospital stay, these include:~Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle."
79704252|NCT06031896|Other|No interventions|No interventions
79704253|NCT06031883|Drug|Ketamine|Total intravenous anesthesia in craniotomy
79704254|NCT06031870|Device|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
79845816|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
79845817|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
79845818|NCT02547272|Procedure|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
79845819|NCT00838058|Drug|CE-224,535|one 250mg tablet, once in the morning in fasted state
79249501|NCT02487069|Drug|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
79249502|NCT02487069|Drug|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
79249503|NCT02949830|Drug|givosiran (ALN-AS1)|givosiran by subcutaneous (SC) injection
79249504|NCT03317925|Procedure|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
79249505|NCT05123456|Procedure|Radiography|Comparative X-ray of the single knee at 30 ° flexion.
79249506|NCT03564379|Drug|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
79543913|NCT01520350|Drug|placebo|Placebo
79543914|NCT01520376|Behavioral|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
79543915|NCT01520389|Drug|MM-151|MM-151
79704255|NCT06031870|Behavioral|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
79704256|NCT06031870|Procedure|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
79704257|NCT06031857|Other|kinesio tape|kinesio tape was applied over the specific muscle of rotator cuff
79543916|NCT01520389|Drug|MM-151 + irinotecan|MM-151 + irinotecan
79704258|NCT06031857|Other|Dry needling|dry needling was applied over the affected muscles
79704259|NCT06031831|Other|airway anomalies|with or without airway anomalies
79704260|NCT06031792|Procedure|Endodontic Microsurgery|Osteotomy will be done with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
79543917|NCT01520415|Drug|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
79710064|NCT01380080|Drug|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
79710065|NCT01380080|Drug|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
79249507|NCT03564379|Drug|Placebo|Matching placebo tablet will be administered orally.
79249508|NCT03317847|Drug|Bromfenac 0.09 % Ophthalmic Solution|Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
79388110|NCT03639623|Drug|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
79543918|NCT01520415|Drug|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
79249509|NCT03317847|Drug|Dexamethasone 0.1% ophthalmic suspension|Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
79710066|NCT01380080|Drug|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
79249510|NCT02675192|Other|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
79249511|NCT03315351|Procedure|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
79388111|NCT03617458|Drug|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
79249512|NCT03315351|Other|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:~the first one is additional to the brachytherapy~the second one is realized 4 months after the brachytherapy"
79249513|NCT01342081|Drug|DE-111 ophthalmic solution|
79249514|NCT01342081|Drug|Tafluprost ophthalmic solution 0.0015%|
79249515|NCT01342081|Drug|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
79388112|NCT03617458|Drug|Placebo|A treatment with no active ingredients or therapeutic effect.
79388113|NCT03617458|Device|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
79388114|NCT03617458|Device|Usual Care|Our HIPPA compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
79543919|NCT01520428|Behavioral|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
79543920|NCT01520441|Drug|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
79543921|NCT01520467|Drug|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
79543922|NCT01520467|Drug|Placebo|1 placebo tablet /day administered orally for 18 months.
79543923|NCT01520493|Other|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
79543924|NCT01520571|Procedure|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
79543925|NCT01520571|Procedure|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
79543926|NCT01520584|Dietary Supplement|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
79249516|NCT03320733|Diagnostic Test|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
79388115|NCT03617263|Drug|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
80014181|NCT04132362|Behavioral|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
80014182|NCT04132362|Behavioral|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
79388116|NCT03617263|Drug|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
79388117|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
79388118|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
80014183|NCT04132362|Behavioral|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
80014184|NCT04119258|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
80014185|NCT04113863|Drug|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
80014186|NCT04113863|Drug|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
80014187|NCT04086745|Drug|Baricitinib|Administered orally.
80014188|NCT04086745|Drug|TNF Inhibitor|Administered SC
80014189|NCT04073979|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
79388119|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
79388120|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
79543927|NCT01520623|Other|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
79710067|NCT01380080|Drug|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
80014190|NCT04071652|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
80014191|NCT04026048|Behavioral|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
80014192|NCT04023110|Drug|Carvedilol|Individually dosed carvedilol
80014193|NCT04021290|Drug|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
80014194|NCT04021290|Drug|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
80014195|NCT04010708|Diagnostic Test|Urinary Iodine Concentration Measurement|UIC
79249517|NCT02518087|Device|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [oXiris® (Baxter Gambro)].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
79388121|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
79388122|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
79388123|NCT03580499|Dietary Supplement|Vitamin B6|Given PO
79388124|NCT03580499|Other|Questionnaire Administration|Ancillary studies
79704261|NCT06031766|Dietary Supplement|Dietary supplement|The participation of the patients in the study will consist of performing the screening for malnutrition that is usually used in the hospital (CIPA) to which the GLIM test will be added, considered as the gold standard for this work. Subsequently, the sample of patients with a positive CIPA (as it is currently considered the screening test used in the hospital) will be implemented the therapeutic measures according to the usual protocol, while the subjects with a negative CIPA test but a positive GLIM will be studied. and constant monitoring taking the appropriate measures according to optional criteria. The patients will be followed up for the study of prognostic factors based on the variables obtained.
79388125|NCT03471845|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
79704262|NCT06031753|Behavioral|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
79845820|NCT00838058|Drug|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
79845821|NCT00838058|Drug|CE-224,535|4x250mg tablets, once in the morning, in fasted state
79845822|NCT00838058|Drug|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
79845823|NCT00838058|Drug|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
79845824|NCT00838058|Drug|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
79845825|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
80014196|NCT03998618|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
79249518|NCT05123378|Behavioral|Liberia National Community Health Assistant Program|Through the National Community Health Assistant Program (NCHAP), members of remote communities select Community Health Assistants (CHAs). Once selected, CHAs are trained to deliver direct services which include; treatment of diarrhea, ARI, and malaria following Integrated Community Case Management (iCCM) protocols, referrals for patients with clinical danger signs, family planning for women of childbearing age and birth preparedness and education for pregnant women. CHAs are also trained to deliver indirect services which include; health education, active surveillance, referral for mental health and other special conditions for all age groups. Since 2020 COVID-education has also been included in the CHAs work.
79543928|NCT01520636|Procedure|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
79704263|NCT06031714|Other|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
79249519|NCT03315273|Other|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
79249520|NCT03563833|Other|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
79388126|NCT03466476|Device|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
79388127|NCT03466177|Diagnostic Test|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
79543929|NCT01520636|Procedure|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
79543930|NCT01520649|Drug|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
79845826|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
79845827|NCT02550392|Behavioral|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
79845828|NCT02547350|Drug|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
79845829|NCT00838214|Drug|budesonide|3mg capsule, 3x per day for 6 months
79845830|NCT00838214|Drug|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
79845831|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
79845832|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
79845833|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
79845834|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
79845835|NCT00838292|Dietary Supplement|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
79845836|NCT00838292|Other|nutrition counseling|
79704264|NCT06031714|Other|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
79704265|NCT06031714|Other|Interviews|V2 and/or V3
79704266|NCT06031714|Other|Clinical examination|V2 and/or V3
79845837|NCT00838370|Drug|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD*2A. Patients heterozygous or homozygous mutant for DPYD*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
79543931|NCT01520649|Drug|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
79249521|NCT03563833|Other|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
79249522|NCT03317769|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets social cognition for 2 hours per week.
79845838|NCT00838448|Behavioral|Exercise|Exercise performed on a treadmill for 20-30 minutes
80014197|NCT03998618|Behavioral|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
79388128|NCT03466151|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
79845839|NCT00510718|Drug|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
80014198|NCT03984084|Other|no intervention|no intervention
79388129|NCT03466151|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
79388130|NCT03425422|Device|VITARIA System|Chronic stimulation of the right cervical vagus nerve
79388131|NCT03423953|Device|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
79845840|NCT00537381|Drug|Docetaxel|Docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks.
79845841|NCT00537381|Drug|Prednisone|Prednisone 5 mg orally twice daily.
79388132|NCT03403205|Drug|ALXN1840|ALXN1840 administered orally in 15 mg tablets
79388133|NCT03403205|Drug|SoC Therapy|Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
80014199|NCT03973281|Device|Materna Prep Device|Materna Prep Device
79249523|NCT03317769|Other|Commercially available computerized training|Training on computerized, casual video games for 2 hours per week.
79845842|NCT00537381|Biological|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
80014200|NCT03973281|Other|Standard of Care (SOC)|Standard of Care (SOC)
79249524|NCT03317769|Other|Optimized social skills training|Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
79249525|NCT03317769|Other|Unstructured support group sessions|Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
79249526|NCT03563989|Device|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
79249527|NCT03318627|Device|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
79249528|NCT03317691|Diagnostic Test|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
79388134|NCT03375112|Procedure|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
79249529|NCT02310620|Behavioral|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
79249530|NCT02483169|Drug|cilostazol|Cilostazol 100mg bid
79249531|NCT02483169|Drug|Probucol|Probucol 250mg bid
79249532|NCT02483169|Drug|Aspirin|Aspirin 100mg qd
79543932|NCT01520662|Other|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
79543933|NCT01520675|Procedure|surgery|Drainage procedure
79543934|NCT01520675|Procedure|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
79543935|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
79249533|NCT02483169|Drug|placebo of cilostazol|same shape and size of active cilostazol
79388135|NCT03375112|Drug|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
79388136|NCT03375112|Drug|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
79388137|NCT03278509|Drug|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
79543936|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
80014201|NCT03971591|Behavioral|Immediate Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
79543937|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
79543938|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
79543939|NCT01520753|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
79543940|NCT01520766|Device|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
79543941|NCT01520766|Device|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
79543942|NCT01520792|Drug|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
79543943|NCT01520805|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
79543944|NCT01520818|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m^2 will receive BIAsp 50
79543945|NCT01520818|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m^2 will receive BIAsp 70
79543946|NCT01520818|Drug|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
79543947|NCT01520831|Drug|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
79249534|NCT02483169|Drug|Placebo of aspirin|same size and shape of active aspirin 100mg
79249535|NCT02483169|Device|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
79249536|NCT02483091|Behavioral|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
79249537|NCT02489097|Drug|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
79249538|NCT02489097|Other|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
79388138|NCT03278509|Drug|Bisoprolol|Please see the section above.
79391643|NCT02532556|Device|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
79391644|NCT02406300|Procedure|Subarachnoid Anesthesia|
79391645|NCT02406300|Procedure|PNB/GA|
79391646|NCT02406300|Drug|ropivacaine|
79391647|NCT02406300|Drug|sevoflurane or desflurane|
79391648|NCT02406300|Drug|bupivacaine or levobupivacaine|
79391649|NCT02533726|Other|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
79543948|NCT01520831|Drug|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
79543949|NCT01520831|Drug|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
79710068|NCT01380080|Drug|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
79543950|NCT01520831|Drug|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
79704267|NCT06031675|Other|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
79704268|NCT06031649|Device|MyotonPRO device|It is a valid and reliable device for measuring the muscular mechanical properties
79704269|NCT06049147|Drug|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
79704270|NCT06049147|Drug|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
79704271|NCT06049147|Drug|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
79704272|NCT06049121|Other|moderately rough surface|treated surface
79704273|NCT06049121|Other|implantoplasty|threads removal and polishing
79704274|NCT06049069|Diagnostic Test|physical activity in stroke|physical activity in stroke
79249539|NCT02488707|Procedure|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
79704275|NCT06049030|Drug|HS-10516|Oral HIF-2α inhibitor
79704276|NCT06048939|Other|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
79704277|NCT06048939|Other|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
79249540|NCT02488707|Procedure|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
79704278|NCT06048926|Drug|Carrelizumab|200 mg/time, iv, Q3W
79704279|NCT06048926|Drug|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
79249541|NCT02203682|Drug|Doxycycline hyclate|Tab. Doxycycline 50 mg PO per day for 12 weeks
79249542|NCT02203682|Drug|Placebo|Tablet placebo for 12 weeks
79249543|NCT02483013|Other|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
79388139|NCT03268668|Other|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase > 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
79388140|NCT03206710|Other|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
79704280|NCT06048926|Drug|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
79704281|NCT06048926|Radiation|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
79388141|NCT03198026|Drug|Ibrutinib|Given PO
79710069|NCT01380080|Drug|Isoniazid|INH 300 mg orally once daily
79249544|NCT02483013|Other|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
79388142|NCT03198026|Biological|Obinutuzumab|Given IV
79388143|NCT03198026|Other|Laboratory Biomarker Analysis|Correlative studies
79388144|NCT03187951|Behavioral|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
79388145|NCT03187951|Behavioral|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
79388146|NCT03187951|Other|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
79543951|NCT01520844|Biological|blood sampling|blood sampling
79543952|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
79543953|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
79543954|NCT01520896|Drug|NKTR-118|Oral 25 mg
79543955|NCT01520896|Drug|Ketoconazole|Oral 400 mg
79543956|NCT01520935|Other|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
79543957|NCT01520948|Behavioral|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
80014202|NCT03959098|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
79543958|NCT01520948|Behavioral|Behavioral control|Mirrored star drawing
79704282|NCT06048913|Drug|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of Taixinsen is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
79249545|NCT02256800|Genetic|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
79388147|NCT03187951|Behavioral|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
79543959|NCT01520974|Other|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
79845843|NCT00537381|Drug|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
79845844|NCT00833300|Drug|Haloperidol|"2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
79845845|NCT00833300|Drug|Olanzapine|"2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
79845846|NCT00833378|Drug|Eltrombopag|Eltrombopag 100 mg single oral dose
79845847|NCT00833378|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
79845848|NCT00833378|Drug|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
79845849|NCT05359341|Drug|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
79845850|NCT05359341|Drug|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
79704283|NCT06048913|Drug|Tigio|Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy.
79710070|NCT01379768|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
79710071|NCT01379768|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
79249546|NCT02256800|Genetic|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
79388148|NCT03187951|Behavioral|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
79391650|NCT02533726|Other|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
80014203|NCT03959098|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
79543960|NCT01520974|Other|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
80014204|NCT03959098|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
80014205|NCT03959098|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
79543961|NCT01521000|Device|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
79543962|NCT01521013|Behavioral|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
79543963|NCT01521013|Behavioral|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
79704284|NCT06048913|Radiation|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord < 40 Gy and lung V20<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
79704285|NCT06048900|Device|ultrasound guided optic nerve sheath diameter measurement|First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
79704286|NCT06048887|Drug|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
79704287|NCT06048887|Drug|Placebo Oral Solution|Placebo
79704288|NCT06048861|Device|KForce Sens|The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.
79704289|NCT06048861|Device|Baseline Electrıgoniometer|The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
79704290|NCT06048835|Device|Blood sample|For each patient, a 15 ml EDTA blood sample will be collected at different time-points
79704291|NCT06048796|Other|Early cessation of sedation and TTM|Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
79845851|NCT05359341|Drug|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
80014206|NCT03959098|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79845852|NCT05359341|Drug|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
79845853|NCT00824954|Procedure|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
80014207|NCT03959098|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
80014208|NCT03959098|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
80014209|NCT03959098|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
79391651|NCT02533726|Other|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
79391652|NCT03176940|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
79391653|NCT00363922|Behavioral|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
79391654|NCT00363922|Behavioral|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
79249547|NCT02256800|Genetic|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
79249548|NCT02256800|Genetic|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
79249549|NCT02256800|Drug|bevacizumab (Avastin)|bevacizumab as target therapy
79388149|NCT03187951|Behavioral|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
79704292|NCT06048770|Biological|RBI-4000|RBI-4000 intramuscular injection.
79704293|NCT06048770|Biological|RabAvert|RabAvert intramuscular injection.
79704294|NCT06048757|Device|Diactive-1 application|Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
79704295|NCT06048705|Drug|GSK3901961|GSK3901961 was administered.
79845854|NCT05398731|Other|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
79845855|NCT00838760|Drug|TMC558445; TMC310911; Darunavir; Placebo|
79845856|NCT05384301|Other|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
79388150|NCT03163368|Radiation|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
79388151|NCT03163368|Procedure|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
79543964|NCT01521052|Device|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
79249550|NCT02256800|Drug|irinotecan|irinotecan as escalating dose according to UGT1A1 genotyping
79249551|NCT02256800|Drug|Leucovorin|combined with 5-FU
79249552|NCT02256800|Drug|5-FU|combined with irinotecan
79388152|NCT03162432|Drug|Vitamin D3|Oral Vitamin D3 therapy.
79388153|NCT03133923|Biological|≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but <3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
79543965|NCT01521065|Device|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
79543966|NCT01521078|Behavioral|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
79388154|NCT03133923|Biological|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
79388155|NCT03133923|Biological|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
79388156|NCT03122106|Biological|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
79388157|NCT03122106|Device|TDS-IM Electrode Array System|-Ichor Medical Systems
79388158|NCT03122106|Procedure|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
79543967|NCT01521130|Drug|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
79543968|NCT01521156|Other|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
79704296|NCT06048705|Drug|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
79704297|NCT06048705|Drug|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
79704298|NCT06048692|Drug|Cefepime 1000 MG|Cefepime is a fourth-generation cephalosporin antibiotic
79704299|NCT06048692|Drug|Ampicillin-sulbactam|Broad-Spectrum Antibiotic
79704300|NCT06048679|Device|Endovascular pulmonary artery flow-limiting covered stent implantation|selective reduction of flow in the pulmonary arteries affected by anomalous pulmonary venous drainage using a modified flow-limiting covered stent
79710072|NCT01379768|Device|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
79710073|NCT04444505|Other|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
79543969|NCT01521156|Other|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
79704301|NCT06048666|Biological|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
79704302|NCT06048653|Other|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~Patients will receive training for four weeks, two sessions per week.~Each patient will assume a comfortable sitting position on a chair in front of the screen.~A report will be generated at the end of the session. It will be used for follow up.~Session duration will range from 45 to 60 min. including rest period."
79704303|NCT06048653|Device|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
79543970|NCT01521169|Other|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
79543971|NCT01521169|Other|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
79543972|NCT01521169|Other|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
79543973|NCT01521182|Other|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
79543974|NCT01521182|Other|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
79543975|NCT01521195|Device|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
79543976|NCT01521208|Device|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
79543977|NCT01521208|Other|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
79543978|NCT01521221|Other|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
79543979|NCT01521234|Behavioral|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
79543980|NCT01521247|Other|Asthma Transition Program|Asthma Education.
79543981|NCT01521273|Other|Bean varieties|10 x 50 g/ arm
79543982|NCT01521286|Other|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
79543983|NCT01521299|Drug|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
79543984|NCT01521312|Drug|saxagliptin|5mg a day for 11-14 weeks
79543985|NCT01521312|Other|placebo pill|one tablet a day for 11-14 weeks
79543986|NCT01521325|Drug|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
79543987|NCT01521377|Drug|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
79543988|NCT01521377|Drug|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
79704304|NCT06048601|Diagnostic Test|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
79704305|NCT06048575|Procedure|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
79704306|NCT06048562|Diagnostic Test|echocardiography|evaluation idm for cardiomyopathy by echo
79543989|NCT01521377|Drug|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
79543990|NCT01521377|Drug|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
79543991|NCT01521377|Drug|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
79543992|NCT01521377|Drug|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
79543993|NCT01521390|Drug|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
79543994|NCT01521390|Drug|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
79704307|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
79704308|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
79704309|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
79704310|NCT06048536|Drug|MR-130A-01 Transdermal patch|MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
79704311|NCT06048523|Procedure|Patient cohort|"For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~Biological samples offered to patients in the context of research:~Annual blood sample~Annual urine sample~Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
79543995|NCT01521390|Drug|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
79543996|NCT01521390|Drug|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
79543997|NCT01521390|Drug|Placebo|Placebo, no active ingredient
79845857|NCT00825032|Procedure|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
79704312|NCT06048523|Procedure|Control cohort|"controls without LP: 1 visit for blood, urine and optional skin biopsy~controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
79388159|NCT03118531|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
79704318|NCT06048458|Diagnostic Test|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
79704319|NCT06048458|Diagnostic Test|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
79704320|NCT06048458|Diagnostic Test|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
80014210|NCT03956277|Device|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
80014211|NCT03937726|Other|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
80014212|NCT03937726|Other|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
80014213|NCT03927638|Behavioral|sit/stand|Subjects will be asked to both sit and stand during a single trial.
80014214|NCT03924791|Drug|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
79249553|NCT03320655|Other|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
79388160|NCT03076203|Drug|Niraparib|Given orally
79388161|NCT03076203|Radiation|Radium Ra 223 Dichloride|Given intravenously
79388162|NCT03075423|Drug|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
79388163|NCT03075423|Drug|Standard Therapy|Standard of Care therapy is administered according to the physician´s decision.
79388164|NCT03033914|Drug|doxorubicin|Doxorubicin: 25 mg/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
79388165|NCT03033914|Drug|Bleomycin|Bleomycin: 10 units/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
79388166|NCT03033914|Drug|vinblastine|Vinblastine: 6 mg/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
79388167|NCT03033914|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
79388168|NCT03033914|Drug|Nivolumab|nivolumab 240mg q14 days
79388169|NCT03007095|Behavioral|Evaluation of the children's social cognitive development|standardized neuropsychological tests
79388170|NCT03001986|Biological|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
79704321|NCT06048458|Diagnostic Test|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
79704322|NCT06048458|Diagnostic Test|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
79845858|NCT00825032|Procedure|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
79845859|NCT03791398|Drug|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
79845860|NCT03791398|Drug|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
79845861|NCT03791398|Drug|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
80014215|NCT03924791|Drug|Methylprednisolone Acetate|In combination with lidocaine
80014216|NCT03924791|Drug|Dexamethasone|In combination with lidocaine
80014217|NCT03916237|Other|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
80014218|NCT03916237|Other|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
80014219|NCT03916237|Other|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
79543998|NCT01521416|Other|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
79704323|NCT06048445|Device|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
79704324|NCT06048432|Other|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
79704325|NCT06048393|Drug|SA55 nasal spray|"The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus."
79704326|NCT06048380|Drug|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
79704327|NCT06048380|Other|Placebo|Saline eye drops
79704328|NCT06048367|Drug|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
79249554|NCT03320655|Other|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
79249555|NCT03315195|Dietary Supplement|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
79845862|NCT00838838|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
79704329|NCT06048367|Drug|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
80014220|NCT03916237|Other|Regular School Based Health Asthma Care|Regular care in the School Health Program
80014221|NCT03915548|Behavioral|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
80014222|NCT03915548|Behavioral|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
79388171|NCT02957032|Drug|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles."
79249556|NCT00821522|Procedure|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
79249557|NCT01341457|Drug|LY2603618|Administered intravenously
79388172|NCT02957032|Drug|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
79388173|NCT02923739|Biological|Bevacizumab|Given IV
79388174|NCT02923739|Biological|Emactuzumab|Given IV
79388175|NCT02923739|Other|Laboratory Biomarker Analysis|Correlative studies
79388176|NCT02923739|Drug|Paclitaxel|Given IV
79388177|NCT02923739|Other|Pharmacological Study|Correlative studies
79388178|NCT02920892|Drug|AFQ056|12.5 mg - 100 mg oral suspension (liquid)
79543999|NCT01521442|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
79704330|NCT06048367|Drug|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned [based on Fe(II)]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
79704331|NCT06048354|Dietary Supplement|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
79249558|NCT01341457|Drug|Gemcitabine|Administered intravenously
79249559|NCT02488473|Drug|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
79249560|NCT02488473|Drug|Ropivacaine|20 ml Ropivacaine 5mg/ml
79249561|NCT02488473|Drug|Isotonic Saline|Placebo
79249562|NCT05128292|Dietary Supplement|CoQ10 plus Selenium|400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks
79249563|NCT04492137|Procedure|Cannulation technique|"Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed"
79388179|NCT02920892|Drug|Placebo|Placebo oral suspension (liquid)
79704332|NCT06048354|Dietary Supplement|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
79388180|NCT02920892|Other|Language Intervention|"All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children."
79388181|NCT02897375|Drug|Carboplatin|Given IV
79388182|NCT02897375|Drug|Cisplatin|Given IV
79704333|NCT06048354|Dietary Supplement|Placebo|The study foresees the intake of 2 capsules per day during 84 days
79704334|NCT06048315|Drug|Anlotinib|Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
79710074|NCT04444739|Other|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
80014223|NCT03879447|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
79249564|NCT01736618|Device|S-ICD System|
79249565|NCT05458791|Device|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
79249566|NCT02480127|Procedure|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
79388183|NCT02897375|Drug|Palbociclib|Given PO
79388184|NCT02841618|Other|High Linoleic Acid Healthy Cookies|
79388185|NCT02841618|Other|High Oleic Acid Healthy Cookies|
79388186|NCT02781792|Drug|Temozolomide|-Given standard of care
79391655|NCT00363922|Behavioral|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
79391656|NCT03176706|Other|no intervention|this is a completely observational study, NO INTERVENTION
79544000|NCT01521442|Behavioral|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
79544001|NCT01521455|Drug|HCP0910|250/50, BID for 2 weeks
79544002|NCT01521455|Drug|Seretide Diskus|250/50, BID for 2 weeks
79544003|NCT01521481|Other|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
79704335|NCT06048315|Drug|Penpulimab|On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
79704336|NCT06048224|Drug|HS628+MTX|Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
79704337|NCT06048224|Drug|Actemra +MTX|Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
79704338|NCT06048211|Other|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
79704339|NCT06048198|Other|No intervention|No intervention
79704340|NCT06048172|Behavioral|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
79249567|NCT03979742|Biological|Umbilical Cord Blood Mononuclear Cell|Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)
79704341|NCT06048081|Drug|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
79704342|NCT06048068|Behavioral|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
79704343|NCT06048055|Other|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
79704344|NCT06048055|Other|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
79710075|NCT02894333|Behavioral|behavioral observation|
79845863|NCT00838994|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
79845864|NCT05360979|Drug|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
79845865|NCT00991731|Behavioral|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
79249568|NCT03979742|Other|Locomotor Training|Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
79710076|NCT01379573|Drug|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
79249569|NCT03317301|Drug|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
79249570|NCT03317301|Drug|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
79249571|NCT05463471|Drug|Compound sodium acetate ringer injection|Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
79710077|NCT01379534|Drug|TKI258|
79710078|NCT01371851|Drug|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
79249572|NCT05463471|Drug|Albumin|Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
79249573|NCT03317145|Device|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
79249574|NCT03317145|Device|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
79249575|NCT03971708|Drug|Lidocaine|Local anesthetic
79249576|NCT03971708|Drug|Ropivacaine|Local anesthetic
79249577|NCT02480205|Device|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~On conventional NIPPV device with the clinically prescribed settings (30 min)~With NeuroPAP and no change of Pmin (=peep) (60 min)~With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~During CPAP delivered with NeuroPAP device (15 min)~Again with original NIPPV device and settings for 30 minutes"
79249578|NCT02832037|Drug|BI 425809 dose 1|
79249579|NCT02832037|Drug|BI 425809 dose 2|
79249580|NCT02832037|Drug|BI 425809 dose 3|
79249581|NCT02832037|Drug|BI 425809 dose 4|
79249582|NCT02832037|Drug|Placebo|
79249583|NCT03970226|Drug|Tocilizumab|"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."
79845866|NCT00991731|Behavioral|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
79845867|NCT00833534|Biological|rituximab|Given IV
80014224|NCT03879447|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
79249584|NCT02480361|Device|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
79388187|NCT02781792|Other|Functional Assessment of Cancer Therapy - Brain|"23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire [2] that includes 27 items.~Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
79249585|NCT02482857|Drug|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
79249586|NCT04202276|Other|diet assessment|Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
79249587|NCT03316755|Behavioral|Exposure|Exposure to pamphlet
79249588|NCT02480049|Drug|Asmakast|1 tablet contains 10 mg of montelukast
79249589|NCT02480049|Drug|Singulair|1 tablet contains 10 mg of montelukast
79249590|NCT02479971|Drug|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
79388188|NCT02781792|Other|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
79388189|NCT02753283|Drug|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
79388190|NCT02753283|Drug|Placebo|Semi-annual saline injection
79388191|NCT02753283|Dietary Supplement|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
79544004|NCT01521481|Other|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
79544005|NCT01521520|Drug|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
79544006|NCT01521533|Drug|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
79544007|NCT01521572|Drug|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
79388192|NCT02753283|Drug|Zoledronic Acid|One time safety treatment dose: 5 mg infusion
79388193|NCT02735746|Radiation|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
79388194|NCT02735746|Radiation|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
79845868|NCT00833534|Drug|lenalidomide|Given orally
79845869|NCT00833612|Device|Counterpulsation with IAB|IABC pre-reperfusion PCI
79845870|NCT00517192|Drug|Tipranavir|
79391657|NCT03174054|Procedure|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
79249591|NCT02479971|Drug|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
79249592|NCT02482701|Device|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
79249593|NCT02486055|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
79249594|NCT03314883|Diagnostic Test|D-US ARF|Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
79249595|NCT02486289|Drug|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
79544008|NCT01521585|Drug|SEN0014196|50 mg oral once daily tablet
79544009|NCT01521585|Drug|SEN0014196|200 mg oral once daily tablet
79544010|NCT01521585|Drug|Placebo|oral once daily tablet
79544011|NCT01521611|Radiation|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
79704345|NCT06048042|Biological|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
79704346|NCT06048042|Biological|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
79704347|NCT06048029|Procedure|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
79845871|NCT00517192|Drug|Darunavir|
79845872|NCT00517192|Drug|Ritonavir|
79544012|NCT01521624|Drug|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
79249596|NCT02486289|Drug|Placebo|NBMI Placebo
79249597|NCT03314727|Other|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
79249598|NCT02485821|Drug|Estradiol|
79249599|NCT02485821|Drug|Placebo|
79388195|NCT02735746|Radiation|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
79388196|NCT02735746|Device|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy"
79388197|NCT02660255|Drug|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
79544013|NCT01521637|Procedure|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
79544014|NCT01521637|Procedure|Sham-treatment: no NMES|Sham comparator
79544015|NCT01521650|Dietary Supplement|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
79704348|NCT06048016|Diagnostic Test|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
79704349|NCT06047990|Device|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
79704350|NCT06047964|Device|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
79704351|NCT06047964|Device|POBA|Intracranial PTA balloon catheter
79710079|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
79249600|NCT02485821|Drug|Misoprostol|
79388198|NCT02605369|Behavioral|Intervention arm: An integrated package|See description in previous column
79845873|NCT05283369|Device|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
79845874|NCT05283369|Other|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
79845875|NCT00625820|Drug|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
79845876|NCT00625820|Dietary Supplement|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
79845877|NCT00145327|Drug|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
79845878|NCT00145327|Drug|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
79845879|NCT05408793|Device|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
79845880|NCT00833768|Drug|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
79249601|NCT02479737|Device|Blood drainage post cardiac surgery using PleuraFlow System|
79249602|NCT02485977|Device|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
79249603|NCT03314649|Other|Observational study|Lavage of the Peritoneal Cavity
79249604|NCT05127668|Device|Airglove (TM)|A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
79249605|NCT05127668|Device|Warm-water Immersion|The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
79388199|NCT02596685|Procedure|Bronchoscopy|Undergo bronchoscopy
79544016|NCT01521676|Genetic|molecular alteration|research of molecular alteration
79544017|NCT01521689|Drug|Rituximab|Low doses of sub cutaneaous rituximab
79544018|NCT01521702|Drug|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
79544019|NCT01521702|Procedure|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
79845881|NCT00833768|Drug|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
79704352|NCT06047925|Procedure|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid composite) material.The 3d printed crown is cemented with resin cement.
79544020|NCT01521715|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
79544021|NCT01521728|Other|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
79544022|NCT01521728|Other|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
79704353|NCT06047925|Procedure|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
79704354|NCT06047873|Device|Endoscopy|clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
79704355|NCT06047860|Radiation|Radiotherapy|hypofractionated radiotherapy/SBRT
79845882|NCT01009606|Other|Usual strategy|Usual strategy
79845883|NCT01009606|Other|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
79845884|NCT05590611|Other|Dietary Intervention with Brown Bread|The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
79249606|NCT02485665|Device|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
79388200|NCT02596685|Other|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
79388201|NCT02596685|Other|Laboratory Biomarker Analysis|Correlative studies
79388202|NCT02596685|Other|Questionnaire Administration|Ancillary studies
79704356|NCT06047860|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
79704357|NCT06047860|Drug|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
79704358|NCT06047860|Drug|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
79388203|NCT02555189|Drug|Enzalutamide|Given PO
79388204|NCT02555189|Drug|Ribociclib|Given PO
79388205|NCT02509052|Other|Laboratory Biomarker Analysis|Correlative studies
79704359|NCT06047860|Drug|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
79388206|NCT02509052|Drug|Leflunomide|Given PO
79388207|NCT02509052|Other|Pharmacological Study|Correlative studies
79388208|NCT02365597|Drug|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
79388209|NCT02365597|Drug|Midazolam|Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
79388210|NCT02365597|Drug|Metformin|Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
79388211|NCT02361320|Procedure|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
79704360|NCT06047808|Behavioral|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
79845885|NCT05590611|Other|Dietary Intervention with Sourdough Bread|The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
80014225|NCT03879447|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
79391658|NCT02538016|Drug|Tolvaptan|
79544023|NCT01521728|Other|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
79544024|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of extended release capsules
79544025|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
79544026|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
79544027|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
79544028|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
79845886|NCT05358405|Other|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
80014226|NCT03879447|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
80014227|NCT03879447|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79249607|NCT02479815|Dietary Supplement|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
79544029|NCT01521793|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
79704361|NCT06047795|Other|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions * 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
79704362|NCT06047795|Other|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
79388212|NCT02361320|Behavioral|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
79388213|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
79710080|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
79710081|NCT01371734|Drug|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
79249608|NCT05404568|Procedure|Total knee arthroplasty|We included patients with knee osteoarthritis who planned to take total knee arthroplasty
79388214|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
79544030|NCT01521806|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to snack foods
79544031|NCT01521819|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
80014228|NCT03879447|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
80014229|NCT03879447|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
80014230|NCT03879447|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
79388215|NCT02223923|Drug|AZD6738|
79544032|NCT01521819|Drug|Lucentis|Intravitreal injection of Lucentis as needed.
79249609|NCT02482545|Dietary Supplement|Meal replacement|
79249610|NCT05037110|Behavioral|Physical activity|For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
79388216|NCT02223923|Radiation|Palliative radiotherapy|
79388217|NCT02220894|Biological|pembrolizumab|
79388218|NCT02220894|Drug|carboplatin|
79388219|NCT02220894|Drug|paclitaxel|
79388220|NCT02220894|Drug|pemetrexed|
79388221|NCT02124733|Procedure|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
79388222|NCT02068092|Drug|Hydroxytyrosol|
79388223|NCT02063165|Dietary Supplement|High Linoleic Safflower Oil|2 tsp per day (~10g of oil)
79388224|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10^5 cells/kg~Dose Level 2: 1×10^6 cells/kg~Dose Level 3: 5×10^6 cells/kg"
79391659|NCT02406144|Drug|MLN9708|
79544033|NCT01521832|Drug|SEN0014196|5 mg single oral dose
79544034|NCT01521832|Drug|SEN0014196|25 mg single oral dose
79544035|NCT01521832|Drug|SEN0014196|75 mg single oral dose
79544036|NCT01521832|Drug|SEN0014196|150 mg single oral dose
79544037|NCT01521832|Drug|SEN0014196|300 mg single oral dose
79544038|NCT01521832|Drug|SEN0014196|600 mg single oral dose
79544039|NCT01521832|Drug|SEN0014196|300 mg single oral dose (females)
79544040|NCT01521832|Drug|SEN0014196|100 mg multiple oral dose
79388225|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10^5 cells/kg~Dose Level 2: 5x10^5 cells/kg~Dose Level 3: 1x10^6 cells/kg"
80014231|NCT03860883|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
80014232|NCT03860883|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
80014233|NCT03859466|Device|Shockwave Therapy|The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
79388226|NCT02023463|Drug|Enzalutamide|Given PO
79249611|NCT05037110|Other|Smell training|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
79249612|NCT02485743|Other|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
79388227|NCT02023463|Drug|Goserelin acetate|Given SC
79544041|NCT01521832|Drug|SEN0014196|300 mg multiple oral dose
79544042|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose
79544043|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose (females)
79544044|NCT01521910|Dietary Supplement|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
79544045|NCT01521910|Dietary Supplement|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
79704363|NCT06047769|Other|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes & Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
79704364|NCT06047730|Procedure|operation ways|nothing
79704365|NCT06047652|Device|e-CPD user testing|nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
79704366|NCT06047600|Other|Uroconnect Follow Up Group|Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
79704367|NCT06047587|Behavioral|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
79704368|NCT06047587|Other|Care as Usual|Care as usual as provided in prison.
79704369|NCT06047574|Other|This study does not involve any interventions|This study does not involve any interventions
79704370|NCT06047561|Radiation|PET-CT|PET combined with CT or MRI
79704371|NCT06047535|Drug|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
79704372|NCT06047522|Device|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
79704373|NCT06047483|Drug|HRF2105 patch|HRF2105 patch ，external use，once a day
79845887|NCT05590533|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
79845888|NCT00510484|Drug|Pancrelipase Delayed Release|24000 unit Capsule
79845889|NCT00510484|Drug|Placebo Comparator|Placebo
79388228|NCT02023463|Drug|Leuprolide acetate|Given IM or SC
79388229|NCT02023463|Radiation|Radiation therapy|Undergo image-guided radiation therapy
79388230|NCT01959672|Procedure|4-Dimensional Computed Tomography|Correlative studies
79388231|NCT01959672|Drug|Fluorouracil|Given IV
79388232|NCT01959672|Drug|Gemcitabine Hydrochloride|Given IV
79388233|NCT01959672|Other|Laboratory Biomarker Analysis|Correlative studies
79388234|NCT01959672|Drug|Leucovorin Calcium|Given IV
79388235|NCT01959672|Drug|Nelfinavir Mesylate|Given PO
79544046|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (lower dose)
79704374|NCT06047483|Drug|Loxoprofen patch|Loxoprofen patch ，external use，once a day
79704375|NCT06047483|Drug|placebo|placebo ，external use，once a day
79845890|NCT00839228|Drug|Perhexiline|100mg o bd for 3 months
79845891|NCT00839228|Drug|Placebo|Placebo one tablet bd for 3 months
79544047|NCT01521936|Other|pharmacological study|Correlative studies
79845892|NCT00839384|Device|Advisa IPG|Implantable Pulse Generator will be implanted
79845893|NCT05408481|Diagnostic Test|Serum cortisol level|Biochemical test
79845894|NCT00839462|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
79544048|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (higher dose)
79704376|NCT06047431|Drug|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
79845895|NCT00839462|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
79845896|NCT01009996|Procedure|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
79704377|NCT06047418|Procedure|Blepharoplasty|This is an cross-sectional, retrospective observational study, to evaluate the clinical characteristics and surgical outcome of blepharoptosis patients who undergone the surgery
79704378|NCT06047340|Device|G:DATA, dementia screen videogame|A videogame for screening
79845897|NCT05590143|Drug|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
79704379|NCT06047327|Diagnostic Test|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
79704380|NCT06047327|Diagnostic Test|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
79704381|NCT06047249|Behavioral|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
79704382|NCT06047249|Behavioral|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
79704383|NCT06047210|Other|Blood Draws Data Collection|
79704384|NCT06047197|Biological|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
79704385|NCT06047184|Drug|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
79845898|NCT05590143|Drug|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
80014234|NCT03854799|Drug|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
79544049|NCT01521936|Other|laboratory biomarker analysis|Correlative studies
79544050|NCT01521962|Drug|Alogliptin|Alogliptin tablets
79544051|NCT01521962|Drug|Insulin|Insulin injection
79544052|NCT01521975|Drug|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
79544053|NCT01521988|Procedure|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
79845899|NCT01789983|Behavioral|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
79391660|NCT02406144|Drug|Lenalidomide|
79391661|NCT02406144|Drug|Dexamethasone|
79391662|NCT04341142|Diagnostic Test|Serological tests will be applied on patients blood sampling|Application of tests on patients' serum
79391663|NCT02416752|Drug|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
79391664|NCT02416752|Drug|choice of intra-operative opioids were left to the discretion of anesthesiologist|
79391665|NCT02405910|Drug|Nab-paclitaxel|
79391666|NCT02405910|Drug|Gemcitabine|
79391667|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
79704386|NCT06047184|Drug|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
79704387|NCT06047184|Drug|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
79704388|NCT06047158|Drug|Omega-3 fish oil fat emulsion|Use omega-3 fish oil fat emulsion
79845900|NCT01789983|Other|Collect Blood, GA and Other Survey Tools|"Geriatric Assessment (GA) (Version 5)~Functional Assessment of Cancer Therapy-General (FACT)~Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~Outcome Expectations for Exercise (OEE) scale29~Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
79845901|NCT00622388|Drug|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
79845902|NCT01156389|Drug|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
79845903|NCT01156389|Drug|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
79388236|NCT01959672|Biological|Oregovomab|Given IV
79544054|NCT01521988|Procedure|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
79845904|NCT04043624|Drug|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
79845905|NCT04043624|Drug|Saline|IV bolus of saline, followed by continuous infusion of saline
79845906|NCT01105767|Drug|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
80014235|NCT03854799|Drug|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
80014236|NCT03854799|Radiation|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
80014237|NCT03851380|Behavioral|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
80014238|NCT03851380|Other|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
80014239|NCT03851380|Device|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
80014240|NCT03851380|Device|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
79388237|NCT01959672|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79544055|NCT01522001|Behavioral|Shared Care model|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
79544056|NCT01522014|Device|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
80014241|NCT03840668|Device|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
80014242|NCT03829787|Device|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
79544057|NCT01522014|Device|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
79544058|NCT01522027|Procedure|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
79544059|NCT01522040|Drug|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
79544060|NCT01522040|Drug|Placebo|Simple saline drip, without active drug
79544061|NCT01522053|Procedure|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
79388238|NCT01959672|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79388239|NCT01958593|Drug|Placebo|Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
79388240|NCT01958593|Drug|Midomafetamine|Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
79388241|NCT01958593|Behavioral|Psychotherapy|Psychotherapy before and after experimental sessions.
79388242|NCT01949857|Biological|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
79391668|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
79544062|NCT01522053|Procedure|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
79544063|NCT01522066|Procedure|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
80014243|NCT03806283|Procedure|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
79544064|NCT01522066|Procedure|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
79544065|NCT01522079|Procedure|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
80014244|NCT03802877|Behavioral|Resource bank|See intervention arm descriptions
79249613|NCT02485743|Other|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
79388243|NCT01949857|Biological|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
79388244|NCT01949857|Biological|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
80014245|NCT03802877|Behavioral|ePlatform|See intervention arm descriptions
80014246|NCT03802877|Behavioral|Health coach|See intervention arm descriptions
80014247|NCT03800914|Other|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
80014248|NCT03800914|Other|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
80014249|NCT03757091|Device|Laryngoscopy|Undergo video laryngoscopy
79249614|NCT04119830|Biological|Pembrolizumab|Given IV
79249615|NCT04119830|Other|Questionnaire Administration|Ancillary studies
79388245|NCT01949857|Biological|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose.
79388246|NCT01760005|Drug|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
79388247|NCT01760005|Drug|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
79544066|NCT01522092|Drug|escitalopram|5mg-20mg, tablet, od, 12 months
79544067|NCT01522105|Drug|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
79704396|NCT06047015|Combination Product|IRE plus checkpoint inhibitor|Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.
80014250|NCT03757091|Procedure|Tracheal Intubation|Undergo flexible scope intubation
80014251|NCT03733197|Behavioral|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
80014252|NCT03733197|Behavioral|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
79388248|NCT01760005|Drug|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
80014253|NCT03724136|Procedure|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
79388249|NCT01760005|Drug|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
79388250|NCT01760005|Drug|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
79388251|NCT01760005|Drug|E2814|Administered intravenously in a blinded fashion
79388252|NCT01760005|Drug|Lecanemab|Administered intravenously
79249616|NCT04119830|Drug|Rintatolimod|Given IV
79249617|NCT03314571|Other|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
79249618|NCT04049786|Procedure|Digestive biopsy|All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
79249619|NCT04049786|Drug|Carvedilol 25mg|Single-dose of carvedilol 25 mg are being administrated orally.
79704397|NCT06047015|Combination Product|IRE plus Checkpoint Inhibitor plus CpG-ODN|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
79704398|NCT06046989|Behavioral|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
79704399|NCT06046963|Drug|Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.
79704400|NCT06046963|Other|Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected|"Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable."
79704401|NCT06046924|Other|Fruits and vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.
79249620|NCT04049786|Procedure|Serial blood sampling for PK analysis|Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
79249621|NCT04049786|Drug|Metoprolol 100 mg for CYP2D6 phenotyping|Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
79704402|NCT06046924|Drug|NaHCO3 Tablets|Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.
79704403|NCT06046924|Other|Usual Care|Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
79704404|NCT06046911|Other|Tai Chi|In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.
79704405|NCT06046911|Other|Daily activity group|The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
80014254|NCT03724136|Procedure|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
80014255|NCT03724136|Procedure|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
80014256|NCT03714204|Behavioral|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
79249622|NCT04049786|Drug|Simvastatin 40mg|Single-dose of simvastatin 40 mg are being administrated orally.
79249623|NCT04049786|Drug|Midazolam 2 mg for CYP3A4 phenotyping|Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
79249624|NCT04049786|Other|Genotyping|Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
79249625|NCT04039100|Other|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
79249626|NCT03316677|Procedure|Intraoperative testing of colorectal anastomoses|"Insert a Foley catheter through the anus into the rectum.~Insufflate the Foley balloon with 5 cc of air.~Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~Remove the saline from the pelvic space.~Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
79704406|NCT06046885|Device|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
79249627|NCT03316677|Procedure|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
79544068|NCT01522118|Device|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
79704407|NCT06046872|Behavioral|Report-back training|Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
79704408|NCT06046859|Drug|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
79704409|NCT06046859|Drug|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
79845907|NCT01105767|Other|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
79704410|NCT06046846|Device|Asensei app|The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
79845908|NCT00834002|Biological|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
79845909|NCT05589987|Device|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
79845910|NCT00834158|Procedure|TACE|1 time
79845911|NCT00834158|Procedure|PVE|1 time
79845912|NCT05589909|Diagnostic Test|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
79845913|NCT03693430|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
79845914|NCT03693430|Drug|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
79845915|NCT00625742|Behavioral|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
79845916|NCT00625742|Behavioral|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
79845917|NCT00625742|Drug|Melatonin|20 mg by mouth (PO) Daily
79845918|NCT00625742|Dietary Supplement|Juven|90 calories of Juven, twice a day.
79249628|NCT02482077|Drug|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
79249629|NCT02482077|Drug|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
79388253|NCT01760005|Drug|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
79704411|NCT06046807|Other|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
79704412|NCT06046781|Other|physical exercise|The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
79704413|NCT06046768|Other|Psychological care|Psychological consultations (interviews, scales), participation in a discussion group for parents in Visio via Zoom, a speech therapy assessment and possible complementary multidisciplinary consultations)
79704414|NCT06046755|Other|Very low calorie ketogenic diet (VLCKD)|Weight loss therapies in patients with excess body weight based on a ketogenic diet
79544069|NCT01522144|Behavioral|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
79544070|NCT01522157|Dietary Supplement|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
79544071|NCT01522157|Dietary Supplement|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
79544072|NCT01522157|Dietary Supplement|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
79544073|NCT01522209|Procedure|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
79544074|NCT01522209|Device|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
79544075|NCT01522209|Radiation|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
79544076|NCT01522209|Radiation|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
79544077|NCT01522222|Procedure|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
79544078|NCT01522261|Other|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
79704415|NCT06046755|Behavioral|Group educational intervention program (IGOBE)|Balanced hypocaloric diet plus structured groupal program of habits change and exercise
80014257|NCT03702920|Biological|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
80014258|NCT03702920|Other|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
80014259|NCT03698877|Diagnostic Test|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
79249630|NCT02482077|Drug|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
79249631|NCT03316599|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
79249632|NCT03316599|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
79249633|NCT03316599|Drug|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
79249634|NCT02482155|Drug|Ibuprofen|ibuprofen 400 mg single dose oral solution
79249635|NCT01675154|Drug|SLx-4090 placebo|Given for 4 weeks
79388254|NCT01712906|Biological|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
79388255|NCT01712906|Biological|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
79388256|NCT01712906|Biological|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
79388257|NCT01712906|Biological|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
79388258|NCT01712906|Biological|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
79388259|NCT01712308|Biological|Sotatercept|Given SC
79388260|NCT01712308|Drug|Ruxolitinib|
79388261|NCT01655836|Radiation|Brachytherapy|Undergo high dose rate brachytherapy
79388262|NCT01655836|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
79388263|NCT01655836|Procedure|Quality-of-life assessment|Ancillary studies
79388264|NCT01655836|Other|Questionnaire administration|Ancillary studies
79388265|NCT01556256|Other|Caregiver-Related Intervention or Procedure|Undergo TMV+P
79388266|NCT01556256|Procedure|Music Therapy|Undergo TMV
79544079|NCT01522261|Other|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
79544080|NCT01522274|Behavioral|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
79704416|NCT06046716|Behavioral|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
79704417|NCT06046677|Other|No intervention|No intervention
79710082|NCT01365494|Biological|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
79704418|NCT06046664|Diagnostic Test|ONCOTYPE DX DCIS test|"The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK."
79249636|NCT01675154|Drug|Orlistat Placebo|Given for 4 weeks
79845919|NCT00625742|Drug|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
79249637|NCT01675154|Drug|Orlistat|Given for 4 weeks
79249638|NCT01675154|Drug|Slx-4090|Given for 4 weeks
79249639|NCT03316521|Drug|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
79249640|NCT02485431|Drug|Deflazacort|
79388267|NCT01556256|Procedure|Music Therapy|Undergo TMV+P
79388268|NCT01556256|Other|Quality-of-Life Assessment|Ancillary studies
79388269|NCT01556256|Other|Questionnaire Administration|Ancillary studies
79388270|NCT01420250|Drug|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
79388271|NCT01420250|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
79388272|NCT01420250|Drug|Anti-Androgen Therapy: Bicalutamide|"Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~Will continue once daily until the final day of IMRT"
79249641|NCT02485509|Drug|VM-1500/Placebo|VM-1500 or Placebo
79388273|NCT01420250|Genetic|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~Will continue for 24 months after IMRT~Total administered duration and agent used must be documented on the case report form"
79388274|NCT01133951|Drug|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
79388275|NCT01133951|Drug|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
79388276|NCT00666731|Other|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
79249642|NCT02744755|Biological|Adalimumab - GP2017|Adalimumab - GP2017
79249643|NCT02744755|Biological|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
79249644|NCT03314493|Drug|Spironolactone 25Mg Tablet|Patients with coronary calcium score > 30 were treated with spironolactone for 12 months
79249645|NCT02485587|Behavioral|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
79249646|NCT02485587|Behavioral|Treatment as usual|counseling, psychoeducation
79249647|NCT02479893|Procedure|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
79249648|NCT03924752|Device|Powered hip exoskeleton|The study team will test a powered hip exoskeleton and its capability to improve locomotion.
79388277|NCT00666731|Other|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
79388278|NCT00666731|Other|study of socioeconomic and demographic variables|Repository
79388279|NCT00666731|Procedure|Excess human biological tissue|Tissue procurement.
79388280|NCT00666731|Procedure|quality-of-life assessment|Cancer care.
79388281|NCT00617799|Biological|aldesleukin|
79388282|NCT00617799|Genetic|gene expression analysis|
79388283|NCT00617799|Genetic|mutation analysis|
79388284|NCT00617799|Other|flow cytometry|
79388285|NCT00607945|Drug|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
79388286|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
79388287|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
79388288|NCT00574509|Radiation|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
79388289|NCT00574509|Drug|BEAM|Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
79388290|NCT00571818|Procedure|Oral glucose tolerance test|test done over 2 hours
79388291|NCT00571818|Procedure|IV Glucose Tolerance Test|Done over 4 hours
79388292|NCT00071760|Drug|GW433908|Fosamprenavir suspension bid
79388293|NCT00071760|Drug|ritonavir|Ritonavir solution bid
79544081|NCT01522274|Behavioral|Health education|Videos
79704419|NCT06046638|Drug|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
79845920|NCT00625742|Drug|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
79845921|NCT00834314|Procedure|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
79704420|NCT06046638|Drug|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
79704421|NCT06046612|Drug|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
79704422|NCT06046560|Drug|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
79388294|NCT04745260|Drug|Intranasal Fentanyl Spray and Intranasal Midazolam Spray|Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
79388295|NCT04745260|Drug|Intranasal Midazolam Spray|Intranasal Midazolam 0.3mg/kg
79388296|NCT03195426|Procedure|distal nerves blocks group|"ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
79388297|NCT03195426|Procedure|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
79388298|NCT05123872|Device|tDCS|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
79388299|NCT03199482|Drug|Dexamethasone Oral Tablet|single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
79388300|NCT03199482|Drug|Placebo|Placebo will be administrated 30 minutes before start of root canal treatment
79391669|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
79544082|NCT01522287|Behavioral|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
79544083|NCT01522300|Other|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
79544084|NCT01522300|Other|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
79544085|NCT01522326|Drug|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
79544086|NCT01522326|Drug|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
79544087|NCT01522352|Procedure|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
79544088|NCT01522378|Drug|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
79544089|NCT01522430|Procedure|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
79704423|NCT06046560|Behavioral|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
79704424|NCT06046508|Other|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
79704425|NCT06046469|Diagnostic Test|CT with contrast|CT abdomen and pelvis with IV contrast
79704426|NCT06046469|Diagnostic Test|MRI pelvis|MRI pelvis with contrast
79845922|NCT00834314|Procedure|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
79544090|NCT01522430|Procedure|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
79704427|NCT06046469|Procedure|TURBT|transurethral resection of bladder tumor
79704428|NCT06046404|Procedure|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
79704429|NCT06046404|Procedure|no closed reduction|no reduction will be performed
79704430|NCT06046391|Biological|LP-003 dose 1|Liquid in vial
79704431|NCT06046391|Biological|LP-003 dose 2|Liquid in vial
79704432|NCT06046391|Biological|Placebo|Liquid in vial
79704433|NCT06046378|Other|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
79544091|NCT01522482|Dietary Supplement|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
79845923|NCT05589441|Drug|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
79845924|NCT05589441|Drug|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
79845925|NCT00825188|Drug|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
79544092|NCT01522482|Dietary Supplement|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
79544093|NCT01522482|Dietary Supplement|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
79544094|NCT01522495|Device|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
79544095|NCT01522495|Device|SPY Imaging|SPY Imaging to assess tissue perfusion
79845926|NCT00825188|Drug|eplerenone|Eplerenone 25-50mg daily x 8 weeks
79249649|NCT02479659|Other|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
79845927|NCT00825188|Drug|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
79845928|NCT00825188|Drug|amlodipine|amlodipine 5-10mg daily for 8 weeks
79845929|NCT00834392|Behavioral|Exercise|Walking exercise
79845930|NCT00834470|Drug|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
79845931|NCT03997864|Drug|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
79388301|NCT05650372|Other|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
79388302|NCT05650372|Other|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
79544096|NCT01522508|Procedure|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
79845932|NCT03997864|Drug|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
79845933|NCT05407467|Dietary Supplement|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
79845934|NCT04043468|Other|Audit and feedback|Audit and feedback (A&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
79249650|NCT02479659|Other|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
79388303|NCT02446704|Drug|Olaparib|
79388304|NCT02446704|Drug|Temozolomide|
79544097|NCT01522521|Drug|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
79710083|NCT00637169|Other|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
79710084|NCT04443218|Device|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
79845935|NCT01010152|Drug|Codeine Sulfate|30 mg Tablet
79845936|NCT00834548|Procedure|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
79544098|NCT01522521|Drug|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
79544099|NCT01522534|Drug|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
79544100|NCT01522534|Drug|Morphine|Morphine alone with a placebo nerve block
79544101|NCT01522547|Drug|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
79704434|NCT06046378|Other|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
79704435|NCT06046365|Diagnostic Test|lymphoscintigraphy|lymphoscintigraphy
79704436|NCT06046365|Diagnostic Test|circumference measurement|circumference measurement
79704437|NCT06046365|Diagnostic Test|sonography|B-mode sono and elastography
79704438|NCT06046365|Diagnostic Test|DXA body composition analysis|DXA body composition analysis
79845937|NCT05589129|Dietary Supplement|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
79845938|NCT05589129|Dietary Supplement|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
79845939|NCT00839774|Other|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
79845940|NCT00839774|Other|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
79845941|NCT00839774|Other|White wheat flour|White wheat flour will be administered at 50 g/day
79249651|NCT02479659|Other|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
79388305|NCT06243016|Behavioral|High-Intensity Interval Training (HIIT) Breaks to Sitting|HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
79388306|NCT06243016|Behavioral|Light-Intensity Interval Training (LIIT) Breaks to Sitting|LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
79391670|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
79391671|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
79391672|NCT02406066|Drug|Placebo|Each cohort will have 2 subjects receiving placebo
79544102|NCT01522560|Other|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
79544103|NCT01522560|Other|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
79544104|NCT01522573|Procedure|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
79544105|NCT01522586|Drug|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
79544106|NCT01522586|Drug|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
79845942|NCT02549846|Drug|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
79391673|NCT02408328|Drug|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
79704439|NCT06046352|Procedure|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
79710085|NCT04443140|Diagnostic Test|PCR, lung ultrasound|PCR for Covid-19
79845943|NCT01888653|Behavioral|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
79845944|NCT01888653|Behavioral|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
79845945|NCT00840008|Other|Educational intervention|As per detailed protocol.
79704440|NCT06046339|Other|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
79704441|NCT06046326|Behavioral|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
79704442|NCT06046313|Drug|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
79704443|NCT06046313|Drug|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
79704444|NCT06046196|Drug|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
79704445|NCT06046196|Drug|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
79704446|NCT06046183|Behavioral|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
79388307|NCT06242990|Behavioral|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
79388308|NCT06242977|Drug|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
79388309|NCT06242977|Other|Control cream|This intervention will be for the control group, a simple lotion cream.
79391674|NCT02408328|Device|Home monitor|Use of home monitor until 44 weeks postmenstrual age
79391675|NCT02408328|Other|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
79544107|NCT01522599|Other|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
79544108|NCT01522599|Other|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
79544109|NCT01522612|Drug|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
79544110|NCT01522612|Drug|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
79704447|NCT06046144|Diagnostic Test|Fluorescence-Advanced videodermatoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
79704448|NCT06046144|Diagnostic Test|Reflectance confocal microscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
79544111|NCT01522612|Drug|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
79544112|NCT01522625|Drug|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
79544113|NCT01522625|Drug|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
79544114|NCT01522664|Drug|DEDN6526A|Multiple ascending doses
79544115|NCT01522677|Drug|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
79544116|NCT01522690|Other|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
79544117|NCT01522716|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
79544118|NCT01522729|Drug|Fentanyl|Single-dose of intrathecal fentanyl [25ug] Duration of fentanyl : 3.5 hours
79544119|NCT01522729|Drug|Placebo comparator|placebo [NaCl]
79544120|NCT01522794|Drug|NOX-H94|single i.v. infusion
79544121|NCT01522794|Drug|Placebo solution|single i.v. infusion
79544122|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
79704449|NCT06046144|Diagnostic Test|Super-high magnification dermoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
79704450|NCT06046131|Other|Standard care|"Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire"
79704451|NCT06046118|Device|Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)|"Each session consists of:~1st phase: 300 seconds of continuous Yellow light (eyes closed) + 60 seconds of pulsed Yellow light (eyes opened)~2nd phase: 300 seconds of continuous Red light(eyes closed) + 60 seconds of pulsed Red light (eyes opened).~Cycle 1: 8 sessions (two PBM per week for 4 weeks); Cycle 2: 6 sessions (two PBM per week for 3 weeks)."
79704452|NCT06046118|Device|Sham Mask|Low light emission mask (Sham Mask, Espansione group, Bologna, Italy)
79704453|NCT06046105|Drug|Administering intraperitoneal bupivacaine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
79704454|NCT06046105|Drug|Administering intraperitoneal bupivacaine plus Dexmedetomidine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Dexmedetomidine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
79704455|NCT06046105|Drug|Administering intraperitoneal bupivacaine plus Ibuprofen for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Ibuprofen injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
79249652|NCT02479659|Other|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
79249653|NCT02479659|Other|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
79249654|NCT03912350|Drug|Balovaptan|Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
79388310|NCT06242964|Behavioral|Promoting Resilience in Stress Management - Social Needs (PRISM-SN)|The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts <60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
79388311|NCT06242938|Procedure|Early intensive antihypertensive treatment|"Treatment starts within 1 hour after randomization~SBP target:130-140 mmHg within 1 hour after treatment~The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.)."
79544123|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
79544124|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
79544125|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
79544126|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
79544127|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
79544128|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
79544129|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
79544130|NCT01522820|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
79544131|NCT01522820|Other|Laboratory Biomarker Analysis|Correlative studies
79544132|NCT01522820|Other|Pharmacological Study|Correlative studies
79544133|NCT01522820|Drug|Sirolimus|Given PO or PEG
79544134|NCT01522846|Drug|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
79845946|NCT05407155|Combination Product|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
80014260|NCT03674346|Other|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~The time of return. It is time that allows the patient to regain his classic state of consciousness."
79544135|NCT01522859|Device|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
80014261|NCT03674346|Other|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
79249655|NCT03563755|Other|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
79388312|NCT06242912|Behavioral|QOL|QOL assessments using EQ5D +/- ESAS +/- CPC every 4-8 weeks +/- 2 weeks
79388313|NCT06242912|Diagnostic Test|Radiographic or laboratory evaluation|Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
79544136|NCT01522872|Drug|TH-302|
79544137|NCT01522872|Drug|TH-302 and Dexamethasone|
79704456|NCT06046066|Drug|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
79704457|NCT06046027|Device|Accupressure band|The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
80014262|NCT03672643|Drug|Crizotinib|receive crizotinib orally
79249656|NCT01849627|Behavioral|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
79388314|NCT06242899|Other|Exercise|"Exercise with a cycle ergometer in three phases:~Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes."
79704458|NCT06045975|Drug|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting|"Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by IRE procedure at Day 30+/-7 days~11 monthly Durvalumab 1500 mg infusions."
79845947|NCT00840242|Drug|Nicotine gum|8-12 pieces per day, maximum 24 daily
79845948|NCT00840242|Drug|Placebo gum|8-12 pieces per day, maximum 24 daily
80014263|NCT03658967|Drug|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
80014264|NCT03658967|Drug|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
79388315|NCT06242886|Behavioral|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
79544138|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
79544139|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
79388316|NCT06242886|Behavioral|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
79845949|NCT00840242|Drug|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
79544140|NCT01522885|Device|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
79544141|NCT01522885|Procedure|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
79544142|NCT01522898|Procedure|AV nodal ablation|Percutaneous catheter ablation of the AV node.
79544143|NCT01522898|Drug|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
79704459|NCT06045936|Drug|Lidocaine|2 teaspoons of 2% lidocaine injection
79704460|NCT06045936|Drug|Placebo|Saline injection
79704461|NCT06045897|Device|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
79704462|NCT06045897|Device|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
79544144|NCT01522911|Device|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
79544145|NCT01522989|Drug|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
79544146|NCT01522989|Drug|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
79704463|NCT06045897|Behavioral|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
79704464|NCT06045897|Biological|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
79704465|NCT06045897|Behavioral|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
79249657|NCT01849627|Behavioral|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
79249658|NCT03314415|Device|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
79704466|NCT06045897|Device|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
79704467|NCT06045871|Procedure|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
79704468|NCT06045858|Drug|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
79845950|NCT00840242|Drug|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
79845951|NCT00621296|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
79845952|NCT00840320|Drug|1278863|15mg, 25mg, 50mg, 150mg
79845953|NCT00840320|Drug|Placebo|matching placebo
79845954|NCT00840398|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
79388317|NCT06242873|Other|Gait training with/without TSCS|To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
79388318|NCT06242860|Device|ELM|Treatment of dry eye with ELM device
79845955|NCT00840398|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
79249659|NCT03801200|Drug|Apatinib|radiotherapy with Apatinib
79388319|NCT06242834|Procedure|Biospecimen Collection|Undergo blood sample collection
79388320|NCT06242834|Procedure|Computed Tomography|Undergo CT scan
79544147|NCT01522989|Drug|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
79544148|NCT01523015|Other|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
79544149|NCT01523015|Procedure|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
79544150|NCT01523028|Other|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~200 mL coffee or~200 mL coffee + 2 bread rolls + honey~200 mL coffee + 1 bread roll + peanut butter"
79544151|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
79704469|NCT06045832|Device|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
79704470|NCT06045832|Device|Water|Water
79704471|NCT06045780|Other|nothing|disease
79704472|NCT06045728|Other|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
79704473|NCT06045728|Behavioral|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
79704474|NCT06045715|Other|follow-up with different time intervals|After radical surgery, patients are followed up with different time intervals
79704475|NCT06045624|Drug|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
79249660|NCT03563911|Behavioral|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
79388321|NCT06242834|Procedure|Echocardiography|Undergo echocardiography
79704476|NCT06045624|Drug|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
79704477|NCT06045624|Drug|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
79704478|NCT06045624|Drug|Placebo|Participants will receive matching placebo across Part A and C of the study
79704479|NCT06045585|Biological|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10^6 TU/kg、 1-5 x10^7 TU/kg、 5-10 x10^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
79704480|NCT06045546|Procedure|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
79704481|NCT06045546|Procedure|10-10-10-5 technique|the standard technique of 10-10-10-5 for laparoscopic cholecystectomy
79388322|NCT06242834|Biological|Pembrolizumab|Given IV
79845956|NCT00537303|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
79845957|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
79845958|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
79388323|NCT06242834|Procedure|Positron Emission Tomography|Undergo PET scan
79388324|NCT06242834|Drug|Tazemetostat|Given PO
79388325|NCT06242821|Other|Observation|Patients who chose to be part of the study, but do not wish to participate in PT or Yoga, will be monitored with routine imagine, and survey follow up.
79388326|NCT06242821|Other|Physical Therapy|Patients will either be randomized or self select to participate in Physical Therapy as per standard of care for non-operative AIS.
79388327|NCT06242821|Other|Yoga|Patients will either be randomized or self select to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week for 6 months. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
79388328|NCT06242795|Drug|7% Hypertonic Saline via nebulization|Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
79544152|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
79704482|NCT06045429|Drug|Oroxid®|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash."
79704483|NCT06045429|Drug|Chlorhexidine mouthwash|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine"
79388329|NCT06242782|Procedure|VRA + d-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
79388330|NCT06242782|Procedure|VRA + e-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
79845959|NCT00840554|Other|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
79845960|NCT00840554|Other|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
79845961|NCT02548286|Drug|Candesartan 8mg|PO, 1day or 22day
79845962|NCT02548286|Drug|Amlodipine 5mg|PO, 1day or 22day
79845963|NCT02548286|Drug|CKD-330 8/5mg|PO, 1day or 22day
79845964|NCT00834704|Drug|PEGPH20|PEGylated recombinant human hyaluronidase
79388331|NCT06242782|Procedure|VRA + customised Ti-mesh|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
79845965|NCT05360433|Drug|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
79845966|NCT00834782|Procedure|IOP measurement|Measuring IOP
79845967|NCT00989391|Drug|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
79845968|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
79249661|NCT03563911|Behavioral|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
79544153|NCT01523041|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
79388332|NCT06242782|Procedure|VRA + RPM|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
79388333|NCT06242769|Drug|Stannous Fluoride Toothpaste (SnF)|test
79388334|NCT06242769|Drug|Colgate Fluoride Toothpaste (CDC)|negative control
79388335|NCT06242743|Other|Scalpel blade needles|Patients were assigned to IANB injection by double scalpel blade bevel needles.
79388336|NCT06242743|Other|standard blade needles|Patients were assigned to IANB injection by standard blade bevel needles.
79544154|NCT01523054|Drug|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
79544155|NCT01523054|Drug|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
79544156|NCT01523067|Drug|Vasomera (PB1046)|Single dose of Vasomera
79544157|NCT01523067|Drug|0.9% Sodium Chloride|Placebo injection
79544158|NCT01523080|Drug|Acetaminophen|Extended release Gel tabs 650 mg
79544159|NCT01523093|Drug|Ondansetron|Orally Disintegrating Tablets 8mg
79544160|NCT01523106|Drug|L-carnitine|dietary supplement
79544161|NCT01523106|Other|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
79388337|NCT06242704|Behavioral|Working Memory Training|A multi-session computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
79388338|NCT06242704|Behavioral|Working Memory|A multi-session control computer training condition that is designed to not engage working memory among at-risk adolescents in a traditionally underserved area.
79388339|NCT06242691|Biological|MK-1200|IV Infusion
79544162|NCT01523119|Drug|Ondansetron|Orally Disintegrating Tablets 8 mg
79544163|NCT01523145|Behavioral|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
79544164|NCT01523145|Other|Control Group|usual follow-up Standard follow-up at the participating heart center
79704484|NCT06045403|Behavioral|The electrocardiography(ECG) and blood pressure monitoring|The electrocardiography (ECG) and blood pressure indicators will be monitored every day during the study period in the monitoring group.
79845969|NCT00989391|Drug|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
80014265|NCT03648918|Other|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
80014266|NCT03641924|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
79704485|NCT06045390|Other|App|"App features (App will be used during the office visit):~Pictorial representation of drops (color-coded) and schedule.~Quiz to assess understanding of the regimen.~Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~Graphical print-out of the regimen."
79845970|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
79249662|NCT02485197|Other|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
79249663|NCT04234178|Drug|Epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
79544165|NCT01523158|Biological|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
79544166|NCT01523197|Device|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
79544167|NCT01523210|Other|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
79544168|NCT01523236|Drug|Mometasone furoate|50 mcg/actuation Nasal Spray
79544169|NCT01523236|Drug|Nasonex®|50 mcg/actuation Nasal Spray
79704486|NCT06045377|Dietary Supplement|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
80014267|NCT03630705|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
79704487|NCT06045364|Drug|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
79704488|NCT06045364|Drug|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
79704489|NCT06045338|Behavioral|Mind Body Intervention #1|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
79704490|NCT06045312|Other|education|Comparison of the effectiveness of peer or adult education to adolescents with asthma
80014268|NCT03630705|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
80014269|NCT03630705|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
80014270|NCT03630705|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
80014271|NCT03630705|Biological|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
80014272|NCT03630705|Biological|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
80014273|NCT03630705|Biological|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
80014274|NCT03630705|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
80014275|NCT03614949|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
80014276|NCT03614949|Drug|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
79249664|NCT04234178|Drug|Intrathecal+Epidural|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
79249665|NCT02485041|Drug|Dapoxetine 30mg|Tablet, Orally administered
79249666|NCT02485041|Drug|Mirodenafil 100mg|Table, Orally administered
79249667|NCT02422160|Other|No interventions are planned|No interventions are planned
79249668|NCT02481843|Other|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
79249669|NCT01246297|Other|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
79249670|NCT01246297|Other|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
79704491|NCT06045286|Radiation|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
79704492|NCT06045286|Drug|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
79704493|NCT06045260|Drug|177Lu-DOTATOC|Administration of 4 cycles of therapy with a 2 months interval between each cycle of therapy
79704494|NCT06045208|Other|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
79704495|NCT06045208|Other|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
79704496|NCT06045195|Drug|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and an eBEACOPP variant without bleomycin (P-EACOPP). Response to induction therapy will be measured after P-mono (PET-1; only for scientific purposes) and after completion of 1x P and 2x P-EACOPP (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two cycles of P-EACOPP while participants with a positive PET-3 will receive four cycles of P-EACOPP. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
79704497|NCT06045182|Procedure|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
79704498|NCT06045182|Procedure|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
79704499|NCT06045182|Procedure|Electrotherapy|Hot pack and TENS for 10 min
79704500|NCT06045169|Procedure|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
79388340|NCT06242691|Drug|Antiemetic|One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
79249671|NCT03563599|Drug|Telacebec (Q203)|High, Mid, Low dose of telacebec
79388341|NCT06242678|Device|SCS trial lead|placement of spinal cord stimulator trial leads to see if effective in the management of symptoms associated with stiff person syndrome
79704503|NCT06045091|Drug|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
79704504|NCT06045065|Other|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
79704505|NCT06045052|Drug|Eltrombopag|Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
79249672|NCT03563599|Drug|Rifafour e-275|RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
79249673|NCT04282694|Diagnostic Test|Low-dose computed tomography (LDCT)|Early detection of lung cancer by LDCT and smoking cessation counselling
79388342|NCT06242652|Drug|608 Dose A|608 subcutaneous (SC) injection.
79388343|NCT06242652|Drug|608 Dose B|608 subcutaneous (SC) injection.
79249674|NCT02484963|Drug|Zolpidem|
79388344|NCT06242652|Drug|608 Dose C|608 subcutaneous (SC) injection.
79388345|NCT06242652|Drug|Adalimumab|Adalimumab subcutaneous (SC) injection.
79388346|NCT06242652|Drug|Placebo|Placebo subcutaneous (SC) injection.
79388347|NCT06242639|Other|Clinical examination|clinic and radiographic evaluation
79388348|NCT06242626|Other|observation|analysis of clinical, laboratory and haemodynamics parameters
79388349|NCT06242613|Procedure|Robot-Assisted Gastrectomy|Gastrectomy performed with a robotic system.
79249675|NCT02484963|Drug|placebo|
79388350|NCT06242613|Procedure|Laparoscopic Gastrectomy|Gastrectomy performed with conventional laparoscopic approach.
79388351|NCT06242587|Device|Pericoccygeal nerve block|The coccygeal corneas are visualised with a linear probe under ultrasound guidance. The pericoccygeal nerves are located medial to the cornu and a combination of local anaesthetic and dexamethasone is injected.
79388352|NCT06242587|Procedure|Impar ganglion block|The sacrum is visualised with fluoroscopy. A needle is inserted through the sacrococcygeal junction. The optimal image is obtained by administering contrast material. A combination of local anaesthetic and dexamethasone is injected.
79388353|NCT06242574|Other|Survey|Each group will have to complete a questionnaire online, taking about 30 minutes.
79388354|NCT06242561|Behavioral|Data collection from sepsis management|observational study
79544170|NCT01523236|Drug|Placebo|Nasal Spray
79544171|NCT01523249|Device|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
79544172|NCT01523262|Procedure|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
79544173|NCT01523262|Procedure|Normal surgery, with sham intervention without inflating arm cuff|
79249676|NCT03316443|Device|Glidescope|"The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter).~For endotracheal intubation with glidescope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.~Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation."
79249677|NCT03316443|Device|Macintosh|The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first. The laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced.Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation.Maximal arterial blood pressure and heart rate changes will be recorded
79249678|NCT04116242|Other|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
79249679|NCT04116242|Other|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
79388355|NCT06242548|Other|physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic)|"organisation of 4 physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic).~During each of of the 4 physical activity outings, collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise)."
79388356|NCT06242522|Other|Telephone interview|Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
79388357|NCT06242509|Diagnostic Test|Biological samples|"Plasma sampling ans stool sampling~at inclusion~at 1 month~at 3 months~at progression within the 3 months"
79388358|NCT06242496|Other|Retrospective follow-up|Data collection
79388359|NCT06242483|Other|Elfie Solution|"The Elfie solution was designed to improve knowledge, adherence, and the quality of care for patients with cardiovascular diseases. The Elfie solution comprises a mobile phone app with the following features related to hypertension:~Personalized monitoring plan based on health conditions to guide frequency of monitoring of blood pressure, weight, and step count~Digital pillbox with daily medication-taking reminders and refill reminders~Clinical measurements graphs~Newsfeed with short videos and texts related to cardiovascular diseases~Digital coach - Artificial intelligence technology that provides information via a chatbox as well as feedback information via personalized videos. This feature does not provide medical advice.~Connection with a health app or wearable for step count~Possibility of family peer support~Gamification through the Elfie rewards scoring system"
79704507|NCT06045013|Drug|5% dextrose injection|Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
79704508|NCT06045013|Drug|5% dextrose injections with methylprednisolone acetate 40 mg/ml|Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
79704509|NCT06045000|Drug|DC-806|Oral tablets
79704510|NCT06045000|Drug|[14C]-DC-806|Oral capsules
79704511|NCT06044987|Procedure|Trans Obturator Tape Procedure (TOT)|Done under Spinal anesthesia in the dorsal lithotomy position.
79704512|NCT06044987|Procedure|Cystocele Repair|Done under Spinal anesthesia in the dorsal lithotomy position..
79704513|NCT06044974|Device|Nd-YAG Fotona|four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
79388360|NCT06242470|Biological|MGC026 Dose Escalation|Escalating doses of MGC026
79388361|NCT06242470|Biological|MGC026 Dose for Expansion|MGC026 recommended dose for expansion
79388362|NCT06242444|Drug|Experimental Dentifrice|Dentifrice containing 1150 ppm fluoride and 5% KNO3.
79388363|NCT06242444|Drug|Placebo Control Dentifrice|Dentifrice containing 0 ppm fluoride and 5% KNO3.
79388364|NCT06242444|Drug|Reference Dentifrice|Dentifrice containing 1100 ppm fluoride as SnF2.
79388365|NCT06242392|Genetic|homologous recombination deficiency|Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
79544174|NCT01523314|Drug|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
79544175|NCT01523314|Other|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
79704514|NCT06044974|Drug|Epidermal Growth Factor|"Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle"
79704515|NCT06044961|Radiation|CT scan|All pre-operative CT scan collected
79704516|NCT06044922|Device|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
80014277|NCT03606746|Biological|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
79704517|NCT06044883|Procedure|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
79704518|NCT06044883|Diagnostic Test|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
79249680|NCT04116242|Other|Health-related Questionnaires|Health-related Questionnaires (Questionnaire_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
79704519|NCT06044870|Procedure|Modified laterally stretched technique with a connective tissue graft.|Modified laterally stretched technique with a connective tissue graft.
79704520|NCT06044844|Drug|Tofacitinib|tofacitinib efficacy
79704521|NCT06044792|Other|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
79704522|NCT06044766|Procedure|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
80014278|NCT03605654|Biological|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
80014279|NCT03605654|Drug|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
80014280|NCT03603730|Device|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
80014281|NCT03591510|Drug|Midostaurin|midostaurin 30mg/m2 bid
80014282|NCT03591510|Drug|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
80014283|NCT03591510|Drug|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
79249681|NCT04116242|Other|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
79388366|NCT06242379|Biological|GMP compliant-BM-MSC derived sEVs|The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
80014284|NCT03591510|Drug|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
80014285|NCT03591510|Drug|Mitoxantrone|10mg/m2/day D3 and D4
80014286|NCT03591510|Drug|Etoposide|100mg/m2/day D1 to D5
80014287|NCT03577418|Behavioral|Clinician-facilitated educational intervention|People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
80014288|NCT03577418|Behavioral|Enhanced usual care|In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
80014289|NCT03545386|Other|Fecal microbiota transplantation|Stool from healthy donor administered via enema
80014290|NCT03545386|Other|Placebos|Saline with food coloring administered via enema
79388367|NCT06242353|Diagnostic Test|Coagulopathy parameters|"Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.~Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.~Protein expression profile (mass spectroscopy)~Ultrasound of catheterised neck veins to detect clots"
80014291|NCT03543969|Drug|Encorafenib|450 mg encorafenib daily by mouth
79249682|NCT05713773|Drug|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
79544176|NCT01523327|Other|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
79544177|NCT01523353|Behavioral|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
79544178|NCT01523379|Drug|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
79544179|NCT01523379|Drug|Placebo|NaCl i.v. two times a day, two days in an row
79544180|NCT01523418|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) & 5 weeks (THR)
79544181|NCT01523431|Drug|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 *1/*1 or heterozygous UGT1A1*1/*28 or *1/*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1*28/*28, *6/*6 or *28/*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
79544182|NCT01523431|Drug|5-fluorouracil|The 5-FU dosage will remain the standard.
79544183|NCT01523431|Drug|Leucovorin|The LV dosage will remain the standard.
79544184|NCT01523470|Device|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
79704523|NCT06044753|Device|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
79704524|NCT06044714|Procedure|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
79704525|NCT06044714|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
79544185|NCT01523483|Drug|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
79544186|NCT01523483|Drug|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
79544187|NCT01523509|Device|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
79544188|NCT01523522|Other|Myoblast injection|Autologous myoblast injection in the anal sphincter
79704526|NCT06044701|Other|Hologram Distraction Technique|Hologram fan application during blood collection process
79704527|NCT06044701|Other|Bubble Machine Distraction Technique|Bubble machine application during blood collection
80014292|NCT03543969|Drug|Binimetinib|45 mg binimetinib daily by mouth
80014293|NCT03543969|Drug|Nivolumab|240 mg Nivolumab IV every 2 weeks
80014294|NCT03539458|Device|Tendyne Mitral Valve System|Mitral valve replacement
79388368|NCT06242340|Other|Preterm group bathing 24 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
79388369|NCT06242340|Other|Preterm group bathing 48 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
79388370|NCT06242340|Other|Early term group bathing 24 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
79544189|NCT01523522|Procedure|saline solution injection|saline solution injection in anal sphincter
79544190|NCT01523535|Behavioral|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
79544191|NCT01523548|Drug|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
79704528|NCT06044688|Device|EyeQue VisionCheck|Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.
79704529|NCT06044688|Device|Phoropter|Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
80014295|NCT03534180|Other|Laboratory Biomarker Analysis|Correlative studies
80014296|NCT03534180|Drug|Romidepsin|Given IV
80014297|NCT03534180|Drug|Venetoclax|Given PO
80014298|NCT03519945|Drug|Mirikizumab|Administered SC.
80014299|NCT03494166|Behavioral|Start with SMSH+TIPC|See arm/group descriptions
80014300|NCT03494166|Behavioral|Start with SMSH alone|See arm/group descriptions
80014301|NCT03477591|Other|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
80014302|NCT03477591|Other|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
80014303|NCT03477591|Other|Sham information|Educational information not specific to PSA testing or cancer screening
79544192|NCT01523561|Behavioral|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
79704530|NCT06044675|Drug|MDMA assisted psychotherapy|This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
79704531|NCT06044675|Behavioral|Psychotherapy|A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
79704532|NCT06044597|Device|SyncAV function on|CRT-D with SyncAV plus activated
80014304|NCT03477539|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
80014305|NCT03477539|Biological|Daratumumab|Given IV
79704533|NCT06044584|Other|No intervention|Observational study with no intervention - Monitoring
80014306|NCT03477539|Drug|Lenalidomide|Given PO
80014307|NCT03476837|Behavioral|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
80014308|NCT03476837|Behavioral|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
80014309|NCT03476642|Drug|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
80014310|NCT03476642|Drug|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
80014311|NCT03474913|Device|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
80014312|NCT03474913|Device|Standard MRI|standard of care closed 3T MRI
80014313|NCT03432286|Drug|Galcanezumab|Administered SQ
79704534|NCT06044545|Diagnostic Test|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
79704535|NCT06044532|Other|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
79704536|NCT06044519|Biological|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
79704537|NCT06044506|Drug|Autologous Natural Killer Cell Therapy|The therapy will be administered intravenously
80014314|NCT03432286|Drug|Placebo|Administered SQ
80014315|NCT03378167|Biological|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
80014316|NCT03378167|Biological|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
79704538|NCT06044506|Device|Clinimacs Plus|The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology. It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
80014317|NCT03377816|Behavioral|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
80014318|NCT03377816|Behavioral|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
80014319|NCT03367156|Drug|Dexamethasone|Given PO
80014320|NCT03367156|Other|Placebo|Given PO
80014321|NCT03367156|Other|Questionnaire Administration|Ancillary studies
80014322|NCT03363945|Biological|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
80014323|NCT03346772|Biological|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
79704539|NCT06044480|Drug|Dexamethasone|Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
79704540|NCT06044480|Other|Placebo|Administration of the same amount of saline solution instead of dexamethasone
79704541|NCT06044467|Drug|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
79704542|NCT06044467|Drug|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
79704543|NCT06044467|Drug|Placebo - Study Part One|Placebo Comparator
80014324|NCT03302299|Drug|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
79704544|NCT06044467|Drug|Placebo - Study Part Two|Placebo Comparator
79704545|NCT06044428|Device|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
79704546|NCT06044415|Drug|JWH018|A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants
79704547|NCT06044415|Other|non-active control (no substance)|Participants will inhale from a vaporizer with an empty chamber.
79704548|NCT06044402|Other|group L (Vt 6 ml/kg)|low tidal volume ventilation (tidal volume was set to 6 ml/kg)
79704549|NCT06044402|Other|group I (Vt 8 ml/kg)|intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
79704550|NCT06044389|Device|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
79704551|NCT06044376|Combination Product|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10^7 CFU/serving).
79704552|NCT06044376|Other|Formula milk|Formula milk without any addition of probiotic strain
79388371|NCT06242340|Other|Early term group bathing 48 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
79704553|NCT06044350|Drug|BAT4406F Injection|Intravenous infusion; Dosage:500mg/time
79704554|NCT06044350|Drug|BAT4406F Placebos|Intravenous infusion; Dosage:500mg/time
79845971|NCT00989391|Drug|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
80014325|NCT03302299|Drug|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
80014326|NCT03297125|Device|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
79388372|NCT06242314|Procedure|L_PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
80014327|NCT03297125|Device|Advanced MRI.|Perfusion and diffusion MRI.
79388373|NCT06242314|Procedure|A-PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
79388374|NCT06242314|Procedure|Palatal stent|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
79544193|NCT01523574|Drug|Vitamin E|Vitamin E 400mg PO orally
79544194|NCT01523574|Drug|Placebo|Placebo, given orally
79704555|NCT06044272|Other|Factors associated|Factors associated with the type of resistance by microorganisms.
79704556|NCT06044259|Procedure|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
79704557|NCT06044259|Procedure|Conventional hemiarch replacement|Coventional open hemiarch replacement
79704558|NCT06044207|Diagnostic Test|Pittsburgh sleep quality index|The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
79704559|NCT06044207|Diagnostic Test|Self-rating depression scale|The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
79704560|NCT06044207|Diagnostic Test|Montreal Cognitive Assessment|The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
79704561|NCT06044194|Drug|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
79704562|NCT06044181|Procedure|Diode laser photocoagulation.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
79704563|NCT06044129|Device|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
79704564|NCT06044103|Drug|PDB + PCS|Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
79704565|NCT06044090|Drug|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
79704566|NCT06044090|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
79704567|NCT06044077|Biological|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
79704568|NCT06044077|Biological|control pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Merck Sharp & Dohme Corp
79845972|NCT00989391|Drug|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
79845973|NCT00834860|Drug|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
79845974|NCT00834938|Other|No intervention|No intervention
79845975|NCT00835016|Behavioral|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
79845976|NCT00825422|Drug|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
80014328|NCT03276962|Biological|RTS,S/AS01E (Full dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
79704569|NCT06044051|Other|Blood sample|An additionnal volume of blood will be collected at inclusion and at each follow-up visit
79704570|NCT06044051|Other|Expectoration|Expectoration will be collected at inclusion and at each follow-up visit
79704571|NCT06044051|Other|Nasopharyngeal swab|A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
79704572|NCT06044038|Behavioral|Physical activity|Bi-weekly supervised physical activity intervention
79704573|NCT06044038|Behavioral|Cognitive rehabilitation program|weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
79249683|NCT05713773|Drug|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
79704574|NCT06044012|Procedure|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
79249684|NCT05713773|Drug|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
79249685|NCT05713773|Drug|coated beads glucose (8 g)|After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
79249686|NCT05713773|Drug|uncoated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
79249687|NCT02830087|Procedure|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
79704575|NCT06043999|Procedure|Radical total mesorectal excision|Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
79710086|NCT04442360|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
79845977|NCT04003545|Radiation|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
79249688|NCT02481765|Device|High definition transcranial direct current stimulation|
80014329|NCT03276962|Biological|RTS,S/AS01E (1/5th dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
79388375|NCT06242301|Other|The collective person-centered dialogue intervention|"Educate and train the interdisciplinary team and staff.~Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions."
79845978|NCT04003545|Other|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
79704576|NCT06043999|Other|Salavge Adjuvant Chemoradiotherapy|Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
79704577|NCT06043973|Drug|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
79704578|NCT06043960|Other|Humac Norm İsokinetic Machine|Tecno Body Prokin Isokinetic Balance System CSMI (CYBEX) Humac Norm Isokinetic Testing and Exercise System Romberg Test Mini Mental Test (MMSE) Fugl-Meyer Assessment of the lower limb
79704579|NCT06043934|Other|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
79710087|NCT04442204|Other|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
79710088|NCT04441268|Procedure|primary IOL implantation|implant IOL in capsular bag after cataract extraction
79845979|NCT00835250|Procedure|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
80014330|NCT03276962|Biological|Rabies vaccine|Subjects will receive intramuscular injection of rabies vaccine (0.1 ml).
79845980|NCT00835250|Procedure|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
79845981|NCT03853226|Procedure|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
80014331|NCT03275805|Other|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
80014332|NCT03275805|Other|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
80014333|NCT03262935|Drug|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
79249689|NCT05126654|Dietary Supplement|Partially Hydrolyzed Guar Gum (PHGG)|Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
79845982|NCT05358015|Procedure|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
80014334|NCT03262935|Drug|Physician's choice|See drug label
80014335|NCT03225625|Procedure|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
80014336|NCT03225625|Procedure|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
80014337|NCT03225625|Procedure|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
80014338|NCT03206762|Device|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
80014339|NCT03200847|Drug|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
79249690|NCT02481921|Behavioral|Group medical visits|Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.
79249691|NCT05126498|Other|no intervention|no intervention was applied
79249692|NCT05713617|Behavioral|PODER Familiar|Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
79544195|NCT01523600|Behavioral|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
79544196|NCT01523600|Behavioral|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
79544197|NCT01523626|Other|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
79544198|NCT01523626|Other|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
79544199|NCT01523639|Drug|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
79544200|NCT01523678|Drug|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
79544201|NCT01523678|Drug|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
79544202|NCT01523678|Drug|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
79544203|NCT01523691|Behavioral|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
79544204|NCT01523691|Behavioral|Control sleep|Regular amounts of sleep across study protocol
79544205|NCT01523730|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
79544206|NCT01523730|Device|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
79544207|NCT01523769|Procedure|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
79544208|NCT01523795|Other|Motion-controlled video gaming|Play of motion-controlled video games for one hour
79544209|NCT01523795|Other|Traditional video gaming|Participants played traditional video games for one hour
80014340|NCT03190317|Other|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
80014341|NCT03190317|Other|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
79388376|NCT06242249|Biological|Anti-BCMA CAR-NK|"Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~Dose Level 1: 1×10^7/Kg~Dose Level 2: 5×10^7/Kg~Dose Level 3: 1×10^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease."
79544210|NCT01523795|Other|Television watching|Participants watched television for one hour
79544211|NCT01523847|Drug|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
79704580|NCT06043934|Other|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
79704581|NCT06043921|Other|No intervention|There is no intervention associated with this observational study.
79704582|NCT06043908|Drug|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
79704583|NCT06043908|Drug|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
79544212|NCT01523860|Drug|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
79845983|NCT04043780|Device|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
79544213|NCT01523912|Device|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
79845984|NCT04043780|Device|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
79544214|NCT01523925|Behavioral|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
79544215|NCT01523925|Behavioral|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
79544216|NCT01523925|Behavioral|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
79704584|NCT06043843|Combination Product|Focused diabetes tele-education and medication adjustment based on guidelines with remote monitoring from trial of fasting from before to throughout Ram|"Ramadan-focused online education by physician, specialist nurse, and dietitian via video conferencing~Fasting and exemptions~Self-monitoring of blood glucose~Acute diabetes complications and treatment~Ramadan nutritional plan~Safe physical activity You will be taught to record~Meal plans~Physical activities~Blood glucose monitoring, and~Monitoring for diabetes complications Perform a trial fasting day prior to Ramadan.~Medication adjustments will be made according to the Diabetes and Ramadan Alliance guideline as well as individualized modifications based on their HbA1c as follows Baseline HbA1c Recommended dose reduction < 8% 30% 8 to 10% 15% > 10% None~2) Glucose monitoring~up to 4 times daily Before Ramadan for 1 week During Ramadan After Ramadan for 1 week~uploaded into an online portal for data collection, without remote monitoring."
79704585|NCT06043804|Other|Doppler ultrasound measurement of changes in uterine artery blood flow|Doppler ultrasound measurement of changes in uterine artery blood flow
79710089|NCT04328870|Other|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
79710090|NCT04328870|Other|General anesthsia|General anesthesia alone.
79845985|NCT00505414|Drug|Tapentadol in the Titration Phase|
79845986|NCT00505414|Drug|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
79845987|NCT00505414|Drug|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
79544217|NCT01523925|Behavioral|Functional electrical stimulation|
79544218|NCT01523938|Behavioral|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
79845988|NCT00505414|Drug|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
79544219|NCT01523990|Drug|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
79544220|NCT01523990|Drug|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
79544221|NCT01524003|Procedure|cryotherapy|cryotherapy treatment of the uterine cervix
79249693|NCT02829775|Drug|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
79249694|NCT02829775|Drug|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
79845989|NCT00505414|Drug|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
80014342|NCT03190317|Other|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
79544222|NCT01524003|Procedure|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
79249695|NCT02476539|Drug|Hemay022|
79704586|NCT06043778|Behavioral|Community care for People with Schizophrenia in India (COPSI)|This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
79704587|NCT06043778|Behavioral|mindLAMP Mobile Application|Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
79704588|NCT06043765|Device|repetitive transcranial magnetic stimulation (rTMS)|real rTMS versus sham rTMS
79704589|NCT06043765|Behavioral|cognitive strategy training|7 weekly sessions with a trained neuropsychologist.
80014343|NCT03184545|Device|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
80014344|NCT03184545|Other|Physical therapy|Standard physical therapy exercises
80014345|NCT03168815|Device|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
80014346|NCT03102632|Other|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
79249696|NCT02476695|Device|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
79249697|NCT02476695|Device|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
79249698|NCT02476695|Device|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
79249699|NCT02476773|Biological|Na-GST-1/Alhydrogel plus GLA-AF|
79249700|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel|
79249701|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
79544223|NCT01524016|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
79544224|NCT01524042|Procedure|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
79544225|NCT01524055|Device|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
79544226|NCT01524055|Device|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
79544227|NCT01524068|Drug|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
79544228|NCT01524068|Drug|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
79249702|NCT02476773|Biological|Sterile Saline Placebo|
79249703|NCT05126420|Procedure|biopsy|biopsy to identify the lesion in the oral mucosa
79544229|NCT01524081|Drug|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~- Cefuroxime in 100ml saline~- Metronidazole in 500ml saline"
79544230|NCT01524081|Drug|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~- 2x amoxicillin in 100ml saline~- Fluconazole in 500ml saline"
79544231|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~- 100ml saline solution~- 500ml saline solution"
79704590|NCT06043752|Drug|Remsima|The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is >80 kg, 2 injections will be given.
79704591|NCT06043726|Diagnostic Test|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
79704592|NCT06043687|Drug|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
79704593|NCT06043648|Device|Endotracheal tube cuff pressure monitoring|The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
79704594|NCT06043622|Other|Optical coherence tomography angiography|Optical coherence tomography angiography
79704595|NCT06043622|Other|ophthalmological exam|ophthalmological exam
79704596|NCT06043583|Procedure|Intrauterine device|The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.
79704597|NCT06043583|Procedure|Uterine artery embolization|The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
79704598|NCT06043570|Device|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
79704599|NCT06043544|Device|Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe|Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
79704600|NCT06043544|Drug|Corticosteroid injection|Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
79704601|NCT06043518|Diagnostic Test|MRI|We will examine patients with congenital upper-limb amputations using functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
79704602|NCT06043518|Diagnostic Test|MRI|We will examine healthy patients using functional and structural MRI in both the brain and the spinal cord and questionnaires.
79845990|NCT00840788|Procedure|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
79845991|NCT00840788|Procedure|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
79845992|NCT02549924|Drug|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
79845993|NCT02549924|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
79845994|NCT01813227|Drug|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
79249704|NCT05126186|Other|haplo-SCT with PTCy|"Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide >100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1).~Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient~GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 200 à 300ng/l) Mycophenolate mofetyl at 15mg/Kg x2/day from day+5~Prevention of EBV reactivation Rituximab : 150mg/m2 intravenously at Day+5 post Haplo-SCT Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic."
79388377|NCT06242236|Other|The respiratory effort parameters guide sedative dosage.|The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
79388378|NCT06242223|Other|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
79388379|NCT06242223|Other|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
79704603|NCT06043505|Other|Echographic hemodynamic algorithm guiding fluid resuscitation|"Ultrasound Hemodynamic Algorithm (UHA):~st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~E/Ea >14 and/or E/A >2~YES => No filling test => Bilateral anterior B lines on lung ultrasound => YES => Consider administration of diuretics~NO => Step 2~nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase >15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~YES => consider 250ml bolus filling~NO => stop vascular filling~rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~YES => depletion~NO => stop vascular filling"
79845995|NCT01813227|Drug|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
79704604|NCT06043479|Other|Fever Management Education|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
79704605|NCT06043466|Biological|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
79704606|NCT06043453|Other|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
79544232|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~- 2x 100ml saline solution~- 500ml saline solution"
79704607|NCT06043401|Other|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
79704608|NCT06043375|Dietary Supplement|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
79704609|NCT06043349|Combination Product|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
79704610|NCT06043349|Drug|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
79704611|NCT06043336|Drug|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
79704612|NCT06043310|Drug|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
79704613|NCT06043310|Drug|Acetylcholine|ACh will be infused locally through microdialysis catheters.
79845996|NCT01813227|Drug|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
79544233|NCT01524094|Drug|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
79544234|NCT01524094|Procedure|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
79544235|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
79704614|NCT06043310|Drug|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
79704615|NCT06043284|Device|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
79544236|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
79544237|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
79704616|NCT06043271|Behavioral|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
79704617|NCT06043258|Other|Bond Apatite|composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1
79704618|NCT06043258|Other|Bio-Oss|xenograft bone substitute
79249705|NCT05403164|Procedure|Modified Widman flap|"Administration of anaesthesia~First incision (reversed bevel incision), scalpel is placed at 45 degree, 2mm apical to gingival margin in coronal-apical direction until touching the bone and moved continuously around the teeth without any vertical releasing incisions~Partial mobilization of the mucoperiosteal flap (full thickness flaps both facially and orally) within the attached gingiva to the alveolar crest~Second incision (sulcular incision)~Third incision (horizontal incision), also interdentally to remove the delineated tissue and all granulation tissue which is used later for analysis.~Root surface debridement~Flap adaptation, complete coverage interdentally and suturing."
79704619|NCT06043245|Procedure|Duodenal Switch|Classic Duodenal Switch
79845997|NCT00825578|Device|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
79845998|NCT01012882|Biological|sublingual immunotherapy with allergen extract|sublingual application
79845999|NCT01012882|Biological|sublingual immunotherapy with placebo|sublingual application
79846000|NCT00841022|Other|Information with comics|Information of children with comic leaflet
79388380|NCT06242210|Other|pursed lip|pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups
79388381|NCT06242210|Other|Stacked Breathing|The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
79388382|NCT06242197|Other|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
79846001|NCT00989469|Drug|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
79846002|NCT04709458|Biological|TBX-2400|Hematopoietic stem cells transplantation
79544238|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
79846003|NCT02546882|Biological|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
79846004|NCT02546882|Drug|saline|1 ml saline was injected for 1 cm2 area.
79544239|NCT01524146|Procedure|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
79846005|NCT00989547|Other|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
79544240|NCT01524159|Dietary Supplement|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
79704620|NCT06043245|Procedure|SADI-S|SADI-S with a 300cm common channel
79704621|NCT06043245|Procedure|Minigastric Bypass|Classic minigastric bypass
79704622|NCT06043232|Biological|DC vaccine|DC vaccine produced by the Team
79704623|NCT06043219|Other|Action Observation|"Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
79710091|NCT04329026|Device|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
79846006|NCT01010308|Drug|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
79846007|NCT04002687|Drug|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
79846008|NCT02548052|Drug|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
79544241|NCT01524159|Dietary Supplement|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
79704624|NCT06043219|Other|Motor Imagery|"Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
79704625|NCT06043219|Other|Traditional Teaching|Traditional anatomical teaching via a powerpoint slide deck
79704626|NCT06043206|Procedure|Bariatric Surgery|Bariatric Surgery
79704627|NCT06043180|Procedure|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
79704628|NCT06043167|Diagnostic Test|The predictive value russian rendition the FOUR score.|"It is planned to include at least 200 adult OAR patients and all those transferred to the rehabilitation department for evaluation.~To maintain accounting documentation, an individual registration card is offered for registration. The paper version of the IRC records the age of the patient, the diagnosis according to the International Classification of diseases of the tenth revision (ICD-10), the day of hospital stay and ICU. The level of consciousness is assessed according to the unified interdisciplinary scale of disorders of consciousness, Glasgow Coma Scale (GCS), Full Outline of Unresponsiveness (FOUR) and Richmond Agitation-Sedation Scale (RASS). After each inspection, the data is entered into the electronic version of the IRC."
79704629|NCT06043115|Other|covid-19 survival cohort|consists of surviving patients
79704630|NCT06043115|Other|covid-19 mortality cohort|consists of deceased patients
79704631|NCT06043102|Device|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
79704632|NCT06043076|Device|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
79704633|NCT06043076|Device|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
79704634|NCT06043024|Device|Stabilization occlusal splint|Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance. OS will be made by the same dental technician in the dental laboratory.
79704635|NCT06042998|Procedure|Robotic radical gastrectomy|Laparoscopic gastrectomy
79704636|NCT06042985|Drug|The absorption effect between calcium citrate and calcium carbonate|Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
79704637|NCT06042959|Other|Laughter therapy|We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
79704638|NCT06042868|Other|Nursing protocol|Emergency nursing protocol
79704639|NCT06042829|Device|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
79704640|NCT06042829|Device|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
79704641|NCT06042816|Procedure|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
79846009|NCT02548052|Drug|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
79846010|NCT02548052|Drug|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
79544242|NCT01524172|Behavioral|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
79544243|NCT01524172|Behavioral|Standard Mental Health Treatment|Trauma and evidence informed therapy
79704642|NCT06042816|Procedure|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
79710092|NCT04329026|Device|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
79710093|NCT00591539|Procedure|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
79710094|NCT00591617|Other|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
79846011|NCT02548052|Drug|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
79704643|NCT06042803|Other|Human milk collection|Every time the mother would normally feed the child, we ask to collect the total milk volume for the feed from both breasts by an electric pump. For each collection, the volume and time will be noted, the container will be inverted and 5 to 10ml of that volume will be transferred in a polypropylene test tube or other tube type depending on the type of compounds (=sample to determine drug concentration in milk) for analysis (max 10% of the collected volume of each feed). The participant decides how the remainder of the collected milk is used. The milk samples will immediately be stored in the refrigerator (4°C) after being labeled. The samples will be collected by one of the investigators within 24 hours, will be transported on ice and frozen at -80°C until analysis.
79704644|NCT06042803|Other|Optionally: maternal blood sample|Blood collection to determine the drug concentration in plasma (6 to 10mL EDTA or other tube type, depending on the type of compound) will be performed at least within 1 hour interval with the first feeding (pumping) after medication intake, and 24 hours after medication intake (with preferable milk collection within 1 hour of blood sampling). The sample label, date and time of sampling will be noted.
79704645|NCT06042803|Other|Optionally: child blood sample|Blood collection of the infant to determine systemic exposure of child(1-5% of the total blood volume, according to the FDA guidelines, in an EDTA or other tube type, depending on the type of compound,) will be performed at the same day as the maternal sampling, if parental consent is obtained. The sample label, date and time of sampling will be noted.
79704646|NCT06042777|Behavioral|Acupuncture and TCM-based lifestyle management|Non-pharmacological treatment based on traditional Chinese medicine.
79846012|NCT02548052|Drug|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
79846013|NCT02548052|Drug|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
79710095|NCT04328987|Procedure|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
79249706|NCT05403164|Procedure|Gingivectomy|"Administration of anaesthesia~Marking the base of the sulcus with pocket marker tweezer.~First incision (gingivectomy incision), scalpel blade placed 1mm apical to the bleeding points and the incision should be beveled 45 degrees coronally.~Second incision (interdental) to free the tissue which is used for analysis later.~Debriding the area and applying periodontal pack."
79249707|NCT05501613|Diagnostic Test|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
79388383|NCT06242158|Procedure|arthroscopic assisted mini-open 5 step repair|"First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair"
79249708|NCT04500860|Drug|Low dose tadalafil 5 mg|Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
79249709|NCT04500860|Drug|Tolterodine 4 Mg Oral Capsule, Extended Release|To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
79249710|NCT04500860|Drug|Placebo|Placebo drugs
79544244|NCT01524185|Behavioral|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
79544245|NCT01524185|Behavioral|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
79544246|NCT01524237|Drug|LY2979165|Capsules administered orally
79544247|NCT01524237|Drug|LY2140023|Tablets administered orally
79846014|NCT04590417|Drug|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
79846015|NCT00825656|Drug|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
79846016|NCT01010386|Procedure|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
79249711|NCT05125874|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
79249712|NCT05402696|Procedure|Endoscopic tissue resection|Endoscopic resection techniques for removal of large polyps
79249713|NCT05430789|Behavioral|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~Ask: Smoking patients will be asked about their smoking status.~Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~Assist: Those who are ready to quit will be assisted in setting a quit plan.~Arrange: Refer to smoking cessation services."
79249714|NCT05430789|Behavioral|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~Highlights of the absolute risk of death due to smoking;~Smoking and diseases management;~Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~Benefits of quitting;~Methods to quit and handle. withdrawal symptoms."
79249715|NCT05430789|Behavioral|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
79544248|NCT01524237|Other|Placebo|Administered orally
79544249|NCT01524237|Other|Ketamine|Administered intravenously (IV)
79544250|NCT01524250|Drug|corticosteroids|1250mg of oral prednisone daily for 3 days
79704647|NCT06042764|Drug|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
79704648|NCT06042738|Combination Product|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
79704649|NCT06042634|Behavioral|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
79704650|NCT06042634|Behavioral|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
79704651|NCT06042530|Diagnostic Test|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
79704652|NCT06042530|Diagnostic Test|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
79704653|NCT06042530|Diagnostic Test|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
79704654|NCT06042530|Diagnostic Test|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
79846017|NCT01010386|Procedure|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
79249716|NCT05430789|Behavioral|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
79249717|NCT02479503|Procedure|Antibiotic prophylaxis in adult heart transplantation|
79249718|NCT02479581|Procedure|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
79704655|NCT06042439|Behavioral|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
79388384|NCT06242145|Drug|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
79388385|NCT06242145|Drug|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
79704656|NCT06042439|Behavioral|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
79710096|NCT04432844|Procedure|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
79710097|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
79846018|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
79846019|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
79846020|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
79846021|NCT02548208|Device|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
79249719|NCT02479581|Procedure|ERAS group|"No routine bowel preparation;~Normal eating 1 days before the operation;~No drinking 2h and solid food 6h before the operation;~Drink 10% glucose 250ml 3h before operation ;~Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
79249720|NCT02479581|Procedure|ERAS group|Emphasize the preoperative psychological preparation for patients.
79249721|NCT02479581|Procedure|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
79249722|NCT02479581|Procedure|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
79249723|NCT02479581|Procedure|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
79249724|NCT02479581|Procedure|ERAS group|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~Goal-directed fluid management."
79846022|NCT02548208|Device|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
79704657|NCT06042283|Behavioral|Metacognitive Training-Silver|"The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period."
79704658|NCT06041958|Device|Extracorporeal shock wave therapy|2 times/week for 12 weeks
79544251|NCT01524250|Drug|corticosteroids|1000mg IV methylprednisolone daily for 3 days
79544252|NCT01524315|Drug|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
79704659|NCT06041958|Device|Pulse electromagnetic field therapy|2 times/week for 12 weeks
79544253|NCT01524315|Drug|Placebo|100 ml normal saline, intravenous, preoperative
79704660|NCT06041958|Other|Rehabilitation|2 times/week for 12 weeks
79704661|NCT06041854|Procedure|Freeze-dried bone allograft combined with Enamel Matrix derivative|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex."
79704662|NCT06041854|Procedure|Freeze-dried bone allograft|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed."
79704663|NCT06041737|Other|consultation|nephrology consultation during 2020
79704664|NCT06041685|Procedure|local warming|local warming on the site for arterial catheterization using forced air warmer
79704665|NCT06040749|Other|Virtual group-based handcycling|Virtual group-based handcycling
79704666|NCT06040645|Other|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
79846023|NCT01010464|Procedure|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
79704667|NCT06040645|Other|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
79704668|NCT06040242|Other|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
79710098|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
79249725|NCT02479581|Procedure|ERAS group|"Infusion of Human Albumin Grifol®20% 50ml;~Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~Shorten the Cardio-pulmonary Bypass line；~Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
79544254|NCT01524341|Drug|KAE609|KAE609 was supplied as capsules for oral use.
79544255|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
79544256|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
79544257|NCT01524367|Drug|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
79544258|NCT01524367|Drug|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
79544259|NCT01524380|Drug|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
79544260|NCT01524380|Drug|Placebo|twice a day, 10 weeks
79544261|NCT01524406|Drug|HPP593|Oral, twice a day.
79544262|NCT01524406|Drug|Placebo|Oral, twice a day.
79544263|NCT01524432|Drug|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
79544264|NCT01524432|Drug|Placebo|No drug loaded microcapsules socks
79544265|NCT01524445|Other|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
79704669|NCT06040203|Biological|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
79704670|NCT06040203|Biological|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
79704671|NCT06040203|Drug|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
79544266|NCT01524458|Procedure|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
79846024|NCT00841256|Biological|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
79846025|NCT00841256|Drug|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
79846026|NCT05360355|Procedure|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
79846027|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
79704672|NCT06038799|Behavioral|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
79704673|NCT06038682|Drug|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
79846028|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
79704674|NCT06038682|Drug|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
79846029|NCT00989703|Drug|placebo|oral solution, daily for 14 days
79846030|NCT00989703|Drug|GLPG0259|oral solution
79544267|NCT01524471|Procedure|Per Oral Endoscopic Myotomy|
79704675|NCT06038669|Device|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
79846031|NCT00989703|Drug|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
79846032|NCT01012960|Drug|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
79249726|NCT02479581|Procedure|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
79249727|NCT02479581|Procedure|ERAS group|Protective ventilation strategy：Low tidal volume about 6~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
79249728|NCT02479581|Procedure|ERAS group|"Bilateral thoracic paravertebral block before induction of anesthesia;~Fast channel anesthesia:~Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1~0.4ug/kg·min, Propofol Injection 2~6mg/kg·h, Sevoflurane 0.5~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
79249729|NCT02479581|Procedure|ERAS group|"Drink water after 6h, 200ml once, 2~3 times / day，~early ambulation，mobilization within 48 h,~Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~Intravenous the lansoprazole 30mg q12h."
79249730|NCT02479581|Procedure|Conventional control group|Routine preoperative psychological preparation for patients.
79544268|NCT01524497|Drug|Trazodone|75mg tablet/150 mg tablet
79544269|NCT01524497|Drug|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
79846033|NCT04572009|Other|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
79846034|NCT04572009|Other|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
79544270|NCT01524510|Radiation|CT scan|low dose radiation scan without contrast without and with MRA
79544271|NCT01524510|Device|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
79704676|NCT06038669|Other|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
79704677|NCT06038656|Dietary Supplement|Galactooligosaccharides (GOS)|"10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS."
79846036|NCT01683825|Drug|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
79544272|NCT01524575|Drug|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
79544273|NCT01524601|Drug|Rosuvastatin|20 mg rosuvastatin for 4 weeks
79544274|NCT01524614|Procedure|nasal mask|nasal mask use instead of face mask
79704678|NCT06038500|Other|Multicomponent intervention of resistance exercises, dancing sessions and nutritional education|The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
79704679|NCT06038448|Procedure|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
79710099|NCT02893748|Device|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
79249731|NCT02479581|Procedure|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
79249732|NCT02479581|Procedure|Conventional control group|"Routine bowel preparation;~Liquid food eating 2 days before the operation;"
79249733|NCT02479581|Procedure|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
79388386|NCT06242132|Drug|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
79388387|NCT06242132|Drug|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
79388388|NCT06242106|Device|Glucometer|A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
79388389|NCT06242093|Device|whole body vibrator|• WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform
79249734|NCT02479581|Procedure|Conventional control group|"Induction use Sufentanil 0.5~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2~0.6mg/kg,Midazolam0.05~0.1mg/kg ;~Maintain use Sufentanil 1~2ug/kg·h, Propofol 4~12mg/kg·h, Sevoflurane 1~3(minimal alveolar concentration)， Vecuronium 0.06~0.12mg/kg·h;"
79249735|NCT02479581|Procedure|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
79249736|NCT02479581|Procedure|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
79249737|NCT02479581|Procedure|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
79388390|NCT06242093|Other|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
79388391|NCT06242067|Drug|Trifluridine/tipiracil|patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
79388392|NCT06242054|Diagnostic Test|Motor Function Assessment System|Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
79388393|NCT06242041|Drug|sodium zirconium cyclic silicate|On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
79388394|NCT06242015|Other|Carbohydrate-first meal|Rice (150 grams) eaten first, followed by broccoli (150 grams) and chicken (100 grams)
79388395|NCT06242015|Other|Carbohydrate-last meal|Broccoli (150 grams) and chicken (100 grams) eaten first, followed by rice (150 grams)
79388396|NCT06242002|Procedure|Set up of sensor|Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
79544275|NCT01524640|Biological|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
79710100|NCT02893748|Procedure|Colonoscopy|Screening colonoscopy as per standard of care.
79710101|NCT02893748|Drug|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
79710102|NCT01357850|Drug|GSK716155|GSK716155
79544276|NCT01524640|Biological|Placebo|1.5 ml oral administration on day 0 and day 14
79544277|NCT01524653|Drug|Rosuvastatin|20 mg po od
79544278|NCT01524653|Drug|Placebo|20 mg po od
79544279|NCT01524718|Radiation|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
79544280|NCT01524731|Drug|Saline|Normal Saline
79544281|NCT01524731|Drug|Dexamethasone|4 mg
79544282|NCT01524731|Drug|Dexamethasone|8 mg
79544283|NCT01524744|Drug|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
79704680|NCT06037993|Dietary Supplement|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
79704681|NCT06037408|Drug|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
79704682|NCT06037408|Other|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
79544284|NCT01524744|Drug|Adcortyl|triamcinolone acetonide 0.1% in orabase
79544285|NCT01524757|Drug|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
79544286|NCT01524809|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
79544287|NCT01524809|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
79710103|NCT01357850|Drug|Placebo|Placebo
79249738|NCT05389592|Procedure|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
79544288|NCT01524848|Drug|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
79249739|NCT05389592|Procedure|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
79710104|NCT01357655|Drug|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
79249740|NCT02479347|Drug|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
79710105|NCT01357655|Drug|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
79710106|NCT01357616|Drug|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
79710107|NCT01357616|Drug|Brinzolamide 1% ophthalmic suspension|
79249741|NCT02479347|Drug|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
79388397|NCT06241989|Other|health education supported by motivational interviewing|The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
79388398|NCT06241976|Other|Glucose drink|75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)
79544289|NCT01524861|Drug|Placebo|a placebo tablet bis in die for 12 months
79544290|NCT01524861|Drug|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
79249742|NCT05125718|Drug|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
79249743|NCT05125718|Drug|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
79249744|NCT01355497|Drug|GTx-024|subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
79249745|NCT01355497|Drug|placebo|subject will receive matching placebo for the duration of the trial
79249746|NCT04859972|Diagnostic Test|Diagnosis of IBS|Diagnosis of IBS according to ICD-10
79249747|NCT02481609|Drug|N-acetyl cysteine (NAC)|
79249748|NCT04076540|Drug|AZD4041|Administration by Oral syringe
79249749|NCT04076540|Drug|Placebo|Administration by Oral syringe
79388399|NCT06241976|Other|Pure orange juice|300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
79388400|NCT06241950|Genetic|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
79388401|NCT06241950|Biological|imlifidase|IV infusion of Imlifidase
79544291|NCT01524861|Drug|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
79544292|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
79544293|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
79544294|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
79544295|NCT01524939|Drug|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
79544296|NCT01524952|Device|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
79544297|NCT01524965|Procedure|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
79388402|NCT06241937|Behavioral|Expanded Clinical Firearm Safety Counseling Training|Members of the DGSOM class of 2027 will participate in a mandatory 3.5 hour training session as a part of the regular curriculum that will include: (1) didactic information on firearm violence epidemiology; (2) suicide epidemiology and introduction to lethal means restriction; (3) firearm safety counseling techniques; (4) a panel of firearm violence survivors / trauma interventionists; and (5) a small group session with discussions of the aforementioned topics and a demonstration of a patient encounter using a standardized patient actor depicting a clinical scenario warranting firearm safety counseling. The training will be taught by faculty members, invited subject matter experts, senior medical students, and the DGSOM Standardized Patient Program.
79388403|NCT06241924|Procedure|High Resolution Electroencephalogram (EEG-HR)|Local field potentials (LFP) recording using EEG-HR
79704683|NCT06037369|Behavioral|customized standardized educational program sent by LINE software.|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
79544298|NCT01524965|Procedure|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
79544299|NCT01524965|Device|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
79704684|NCT06036459|Other|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
80014347|NCT03030417|Drug|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand DNA breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
80014348|NCT02956447|Drug|Kisspeptin 112-121|0.313 ug/kg IV or 0.313 ug/kg - 13.19 ug/kg SC
79704685|NCT06036303|Device|Nasr fascial closure device|Nasr fascial closure device is a novel device for fascial closure
79704686|NCT06036303|Device|Berci Fascial Closure Device|Berci Fascial Closure Device is a known device for fascial closure
79704687|NCT06035302|Procedure|Madany Closure|Madany Closure is a new technique for the porte site closure
80014349|NCT02956447|Drug|GnRH|0.075 ug/kg IV
80014350|NCT02948426|Biological|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
80014351|NCT02942927|Other|Medication reduction|Systematic approach to reduction in polypharmacy.
80014352|NCT02936024|Procedure|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
80014353|NCT02936024|Procedure|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
79249750|NCT05373225|Device|Acetic acid shockwave phonophoresis therapy|This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
79704688|NCT06035302|Procedure|Standard closure|Standard closure technique of the port site from ecternal
79388404|NCT06241924|Procedure|Stereo-electro-encephalography (SEEG)|Local field potentials (LFP) recording using sEEG
79249751|NCT05373225|Device|Shock wave Therapy|This group composed of subjects and represented the control group who will receive shock wave therapy
79249752|NCT05373225|Other|conventional physical therapy program|"Exercise program:~Standing calf-stretching exercise~Towel stretch: stretching exercise~Ice bottle~Towel pickup exercise~Marble pickups exercise~Calf raises exercises -Static and dynamic balance exercise"
79249753|NCT02479191|Device|Ovation Abdominal Stent Graft Platform|
79249754|NCT01355575|Drug|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
79704689|NCT06034899|Drug|BMS-986196|Specified dose on specified days
79846037|NCT00841334|Behavioral|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
79704690|NCT06034873|Drug|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
79388405|NCT06241911|Device|transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
79544300|NCT01525004|Drug|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
79846038|NCT00841334|Behavioral|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
79544301|NCT01525004|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
79544302|NCT06053606|Device|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
79846039|NCT02547116|Drug|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
79249755|NCT05125640|Drug|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Orally, with 240 mL of water at dosing in sitting position
79704691|NCT06034873|Drug|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
79704692|NCT06034535|Biological|CD62L depleted donor lymphocyte infusion|Intravenous infusion of CD62L depleted donor lymphocytes
79704693|NCT06034379|Device|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
79704694|NCT06034379|Drug|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
79846040|NCT05377047|Radiation|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
79249756|NCT05125640|Drug|Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Orally, with 240 mL of water at dosing in sitting position
79846041|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
79249757|NCT03314259|Drug|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
79249758|NCT03314259|Drug|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
79388406|NCT06241898|Drug|BB-1709|Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
79388407|NCT06241885|Procedure|Intervention group I|The women in this group will be covered with a gynaecological drape on the gynaecological table by the same researcher before vaginal examination. This cover will be prepared as disposable, terikoton fabric and 80x200 cm in size.
79544303|NCT06053606|Device|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
79544304|NCT06053580|Drug|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
79544305|NCT06053580|Drug|Placebo|Placebo twice daily for 24 weeks.
79544306|NCT06053528|Drug|Antibiotic|Effect if treatment
79544307|NCT06053346|Behavioral|Pay For Performance (PFP)|Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.
79544308|NCT06053346|Behavioral|Usual Care (UC)|Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
79704695|NCT06034249|Behavioral|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
79704696|NCT06034249|Behavioral|Audio|The mindfulness-based audio files for six weeks.
79846042|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
79846043|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
79846044|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
79846045|NCT00835562|Procedure|Non-surgical management|Non-surgical management (physiotherapy and self-training)
80014354|NCT02910700|Drug|Binimetinib|Given PO
80014355|NCT02910700|Drug|Dabrafenib|Given PO
79846046|NCT00835562|Procedure|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
79846047|NCT00835562|Procedure|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
79846048|NCT05359107|Behavioral|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
79846049|NCT05359107|Behavioral|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
80014356|NCT02910700|Drug|Encorafenib|Given PO
80014357|NCT02910700|Other|Laboratory Biomarker Analysis|Correlative studies
80014358|NCT02910700|Biological|Nivolumab|Given IV
80014359|NCT02910700|Other|Pharmacological Study|Correlative studies
80014360|NCT02910700|Drug|Trametinib|Given PO
79388408|NCT06241885|Procedure|Intervention group II|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
79388409|NCT06241872|Other|Dry needling group|Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
79544309|NCT06053333|Other|Non-Interventional Study|Non-interventional study
79704697|NCT06034158|Drug|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
79249759|NCT05125406|Behavioral|Exposure therapy with Virtual Reality.|Experimental arm patients will be offered Exposure therapy with Virtual Reality (ETRV) support with a virtual reality headset. A scenario with progressively increasing stress levels linked to the ICU environment and different situational contexts (alarms, etc.) will be presented to patients. This habituation to the potentially anxiety context of ICU will reduce the occurrence of psycho-cognitive disorders by progressive extinction phenomenon.
79704698|NCT06034158|Drug|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
79704699|NCT06034158|Drug|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
79704700|NCT06034158|Drug|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
79704701|NCT06034158|Drug|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
79704702|NCT06034158|Drug|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
79704703|NCT06033950|Drug|Finerenone|Oral finerenone.
79846050|NCT03971695|Drug|BI 706321|Capsule or Oral Solution
79388410|NCT06241859|Device|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
79846051|NCT03971695|Drug|Placebo|Capsule or Oral solution
79846052|NCT02549690|Drug|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
79846053|NCT02549690|Drug|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
79388411|NCT06241859|Device|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
79388412|NCT06241833|Drug|PPI|use of PPI concomitant with DAPT
79704704|NCT06033950|Drug|Placebo|Matching oral placebo.
79704705|NCT06033625|Procedure|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
79704706|NCT06033495|Device|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
79704707|NCT06032650|Other|Calisthenics exercise and High intensity interval training|"The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
79710108|NCT01357616|Drug|Timolol 0.5% ophthalmic solution|
80014361|NCT02876185|Other|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
79249760|NCT03563443|Diagnostic Test|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
79249761|NCT02479269|Other|Aerobic exercise|Aerobic exercise for 8 weeks
79846054|NCT05357937|Behavioral|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
79846055|NCT02549768|Drug|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
79846056|NCT02549768|Drug|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
79846057|NCT04551651|Device|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
79846058|NCT04551651|Device|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
80014362|NCT02850575|Device|Mpact Double Mobility cup|
80014363|NCT02763917|Device|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
79704708|NCT06032455|Behavioral|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
80014364|NCT02763917|Device|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
80014365|NCT02748408|Device|SMS femoral stem|
79846059|NCT00841646|Biological|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
79846060|NCT04464213|Other|Single dose experiments|In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
79846061|NCT04464213|Other|Multi-dose experiments|In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
79388413|NCT06241755|Drug|BCG for Therapeutic Use|"Specification: 60 mg (6.0×10^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10^6 CFU.~Usage & dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
79846062|NCT00841724|Drug|Fludarabine, Busulfan, Thymoglobuline|
79846063|NCT00843362|Drug|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
79846064|NCT00843362|Drug|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
80014366|NCT02603562|Biological|ATYR1940|Concentrate for solution for infusion
80014367|NCT02586727|Drug|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
80014368|NCT02579239|Biological|ATYR1940|Concentrate for solution for infusion
80014369|NCT02579239|Biological|Placebo|Concentrate for solution for infusion
79544310|NCT06053320|Device|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
79249762|NCT03929042|Device|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
79544311|NCT06053320|Device|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
79846065|NCT04003233|Device|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
79846066|NCT04003233|Device|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
79846067|NCT00841802|Drug|Prednisone|Prednisone 30mg once daily x 5 days
79846068|NCT05300295|Behavioral|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
79846069|NCT00989859|Device|Plethysmographic monitoring|Plethysmographic monitoring
79846070|NCT00621140|Drug|linagliptin|active
79846071|NCT00621140|Drug|placebo|placebo
79249763|NCT02481687|Other|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
79249764|NCT03823742|Other|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
79704709|NCT06032455|Behavioral|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
79846072|NCT00207727|Drug|CNTO 1275|
80014370|NCT02567201|Other|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
79249765|NCT03823742|Other|Low FODMAP Diet|Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
79249766|NCT02479425|Procedure|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
79249767|NCT02826421|Device|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
79249768|NCT02826421|Device|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
79544312|NCT06053320|Other|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
79544313|NCT06053203|Other|Exposure of interest - Moderate or High-risk Preeclampsia|No intervention
79544314|NCT06053190|Behavioral|Sentence stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
79388414|NCT06241755|Drug|BCG for Therapeutic Use|"Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10^6 CFU/mg.~Usage & dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
79544315|NCT06053190|Behavioral|Speaking style|The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
79388415|NCT06241716|Procedure|Ultrasound-assisted localization, US-AS|In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.
79544316|NCT06053151|Behavioral|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
79544317|NCT06053138|Dietary Supplement|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
79704710|NCT06031558|Drug|SY-5007|a RET selective Inhibitor
79846073|NCT00841880|Drug|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
79846074|NCT00841880|Drug|Ramipril|10 mg once a day
79846075|NCT00841880|Drug|Ramipril|5mg once a day
79846076|NCT03971851|Other|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
80014371|NCT02567201|Other|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
79249769|NCT02826421|Device|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
79249770|NCT02826421|Device|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
79846077|NCT00835874|Drug|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
79846078|NCT03969745|Behavioral|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
79846079|NCT03969745|Behavioral|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
79846080|NCT00835952|Drug|ATX-101|ATX-101 single doses
79544318|NCT06053138|Dietary Supplement|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
79704711|NCT06031337|Diagnostic Test|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
79704712|NCT06030466|Other|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
79704713|NCT06030466|Other|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
79544319|NCT06053112|Other|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
79544320|NCT06053112|Other|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
79704714|NCT06027788|Device|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
79704715|NCT06027788|Device|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
80014372|NCT02555358|Drug|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
79249771|NCT02476461|Drug|xiapex|
79388416|NCT06241716|Procedure|Real-time ultrasound guidance, US-RTG|In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
79544321|NCT06053099|Other|Plasma ctDNA|"Plasma ctDNA before surgery (optional)~Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)~Plasma ctDNA every 6 months~Plasma ctDNA at relapse"
79544322|NCT06053099|Other|FFPE blocks|"Surgery FFPE blocks~FFPE blocks at relapse (optional)"
79544323|NCT06053086|Radiation|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
79846081|NCT03971773|Other|hypnosis|patient with cancer will undergo sessions of hypnosis
79846082|NCT00843440|Drug|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
79846083|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet once daily
79846084|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet once daily
79846085|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet two times a day
80014373|NCT02555358|Drug|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
80014374|NCT02532231|Other|Laboratory Biomarker Analysis|Correlative studies
79249772|NCT02476461|Procedure|percutaneous needle fasciotomy|
79544324|NCT06053086|Radiation|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
79249773|NCT05224765|Other|Fall prevention class|Participants attend fall prevention discharge class per hospital protocols
79249774|NCT05466357|Procedure|Excision of pituitary tumor outside pseudocapsule|Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
79544325|NCT06053073|Device|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
79846086|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet two times a day
79846087|NCT00504556|Drug|warfarin|warfarin tablets
79846088|NCT05274009|Other|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
80014375|NCT02532231|Biological|Nivolumab|Given IV
80014376|NCT02497365|Drug|Besifloxacin|
80014377|NCT02497365|Drug|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
80014378|NCT02476396|Procedure|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
79846089|NCT05274009|Other|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (~23°C, ~50% relative humidity), and then return to the heat for a final 3 hours.
80014379|NCT02458690|Behavioral|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
80014380|NCT02458690|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
80014381|NCT02458690|Drug|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
79249775|NCT04703816|Other|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
79388417|NCT06241703|Procedure|ICCAUT|For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM after the bladder is empty. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
79544326|NCT06053073|Device|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
79544327|NCT06053060|Other|Randomisation Standard Dynacup or Dynacup One C|Randomisation
79544328|NCT06053034|Device|Solio alpha cure plus|The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
79249776|NCT04642274|Other|Nutrition|Correct the patient's low nutritional status before surgery.
79388418|NCT06241703|Procedure|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
79249777|NCT04642274|Other|Control Blood Glucose|Control the patient's blood glucose before surgery, fasting blood glucose level ≤ 8mmol/L or HbA1c ≤ 7%.
79249778|NCT04642274|Drug|Fasting|Take 10% glucose water 6ml/kg 2 to 4 hours before operation (except for diabetes).
79544329|NCT06053008|Other|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
79544330|NCT06052995|Drug|Elidel 1% Topical Cream|Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
79544331|NCT06052982|Procedure|Drainage|At the end of the knee arthroplasty, a drain is placed or not at the surgical site depending on randomization result
79544332|NCT06052930|Device|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
79704716|NCT06027411|Device|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
79249779|NCT04642274|Behavioral|Smoking and Alcohol|Quit smoking and alcohol before surgery
79249780|NCT04642274|Other|Control Anemia|Correct anemia before surgery
79704717|NCT06027190|Device|Repetitive transcranial magnetic stimulation|"Intervention Name and Specification~Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced."
79544333|NCT06052917|Other|DECIdE|DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
80014382|NCT02458690|Other|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
80014383|NCT02446457|Other|Laboratory Biomarker Analysis|Correlative studies
79704718|NCT06027190|Device|Sham|Placebo coil (Magstim Company, Whitland, UK):
79704719|NCT06025513|Device|Embrace Patch|Tension offloading skin patch
80014384|NCT02446457|Drug|Lenalidomide|Given PO
80014385|NCT02446457|Biological|Pembrolizumab|Given IV
79388419|NCT06241690|Other|the cold applications in post-suture pain reduces the child's pain|The experimental groups was applied cold applications immediately after 20 minutes the suture. Later, The experimental groups was applied cold applications again for 20 minutes 1 hour, 2 hours and 6 hours after the suture.
79388420|NCT06241651|Device|Conduction system pacing|Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.
79388421|NCT06241651|Device|Biventricular pacing|Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
79388422|NCT06241638|Drug|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
79544334|NCT06052865|Behavioral|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
79704720|NCT06021444|Device|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
80014386|NCT02446457|Biological|Rituximab|Given IV
79704721|NCT06021444|Device|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
79704722|NCT06018688|Drug|Osimertinib|Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
79704723|NCT06018688|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.
79704724|NCT06018480|Other|Creatine Monohydrate|The supplementation is the intervention.
79704725|NCT06018480|Other|Maltodextrin (Placebo)|Placebo to Creatine Monohydrate
79704726|NCT06017505|Diagnostic Test|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
79704727|NCT06016322|Dietary Supplement|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
79704728|NCT06012058|Diagnostic Test|ROTA assessment by AI|The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.
79704729|NCT06012058|Diagnostic Test|Optic disc assessment by AI|The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
79710109|NCT01357577|Behavioral|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
80014387|NCT02445222|Genetic|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
80014388|NCT02404402|Other|LED|Low Level Light Therapy
79249781|NCT04642274|Other|Blood Transfusion|Use strict blood transfusion indications and blood protection strategy during surgery.
79249782|NCT04642274|Other|GDFT|Use goal-directed fluid therapy during surgery.
79249783|NCT04642274|Other|Remove the tracheal tube|Remove the tracheal tube as soon as possible after surgery.
79249784|NCT04642274|Behavioral|Eating and Drinking|Eat and drink as soon as possible after extubation after surgery.
79249785|NCT04642274|Other|Prevent Thrombosis|Actively prevent thrombosis after surgery.
79249786|NCT02476227|Procedure|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
79249787|NCT02476305|Device|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
79704730|NCT06011226|Other|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
79704731|NCT06011226|Other|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
79704732|NCT06010810|Drug|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
79704733|NCT06010810|Drug|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
79704734|NCT06009653|Behavioral|Standard Care|Participants will meet with community health workers to receive general health information through individual check-ins.
79704735|NCT06009653|Behavioral|Culturally-tailored dietary and behavioral intensive lifestyle intervention|Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
79704736|NCT06009653|Drug|Placebo|Participants will receive placebo subcutaneous injections.
79704737|NCT06009653|Drug|Tirzepatide|Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
79388423|NCT06241638|Drug|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
79544335|NCT06052865|Behavioral|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
79544336|NCT06052865|Other|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
79544337|NCT06052826|Other|Best Practice|Undergo standard of care
79544338|NCT06052826|Other|Cognitive Intervention|Receive delirium prevention education
79544339|NCT06052826|Other|Comprehensive Geriatric Assessment|Undergo geriatric assessment
80014389|NCT02404402|Other|sham LED|Inactive (sham) LED treatment
79704738|NCT06009302|Procedure|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
79704739|NCT06009302|Procedure|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
79704740|NCT06009107|Biological|HY004|A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
80014390|NCT02369562|Procedure|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
79388424|NCT06241625|Diagnostic Test|Virtual Reality (VR) Contrast Function Test|Patients perform a new Virtual Reality (VR) Contrast Function Test
79544340|NCT06052826|Other|Nutritional Intervention|Undergo nutritional optimization
79704741|NCT06009107|Drug|Cyclophosphamide|Administered intravenously.
79704742|NCT06009107|Drug|Fludarabine Phosphate|Administered intravenously.
79704743|NCT06007846|Drug|Namenda|Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
79704744|NCT06006611|Drug|Azvudine|Received antiviral treatment with azvudine
79710110|NCT01351025|Drug|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
79710111|NCT01351025|Drug|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
79710112|NCT01351025|Drug|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
79544341|NCT06052826|Procedure|Physical Therapy|Undergo physical function optimization
79544342|NCT06052826|Other|Questionnaire Administration|Ancillary studies
79710113|NCT01349036|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
79710114|NCT01348763|Drug|Maraviroc|Maraviroc 150 mg daily
79710115|NCT01348763|Drug|Truvada|daily until 10. day then stop
79710116|NCT01348763|Drug|Darunavir|daily until 10. day then stop
79388425|NCT06241612|Radiation|Individualized Elective Neck Irradiation|Individualized Elective Neck Irradiation
79544343|NCT06052748|Drug|AD-223A|PO, Once daily(QD), 8weeks
79544344|NCT06052748|Drug|AD-223B|PO, Once daily(QD), 8weeks
79544345|NCT06052748|Drug|AD-223C|PO, Once daily(QD), 8weeks
79544346|NCT06052748|Drug|AD-223A Placebo|PO, Once daily(QD), 8weeks
79544347|NCT06052748|Drug|AD-223B Placebo|PO, Once daily(QD), 8weeks
79544348|NCT06052748|Drug|AD-223C Placebo|PO, Once daily(QD), 8weeks
79544349|NCT06052735|Other|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
79544350|NCT06052722|Other|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
80014391|NCT02339909|Behavioral|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
79704745|NCT06006338|Other|3D Printed Model for preoperative planning|Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
79704746|NCT06005649|Biological|HY004|"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10^6/kg CAR+T-cells"
79704747|NCT06005129|Behavioral|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, [low] conscientiousness, [low] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
79704748|NCT06003205|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
79704749|NCT06001333|Procedure|fecal microbiota transplantation|Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
79544351|NCT06052709|Other|Occupational balance assessment|There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.
79704750|NCT05998759|Biological|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
79249788|NCT04547738|Drug|TB treatment according to national guidelines|National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
79388426|NCT06241599|Drug|GP/PFLL+AK104|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks)."
79544352|NCT06052696|Drug|Gardasil 9 Suspension for Injection|"After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
79544353|NCT06052696|Drug|Placebo|"After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
79544354|NCT06052683|Radiation|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
79544355|NCT06052683|Radiation|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
79544356|NCT06052670|Diagnostic Test|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|pressure wire-based fractional flow reserve (FFR); intravascular ultrasound (IVUS)-based ultrasonic flow ratio (UFR)
79704751|NCT05998759|Drug|Placebo|subcutaneous placebo weekly for 24 weeks.
79704752|NCT05992844|Other|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
79710117|NCT01346969|Drug|EXC 001|Single-dose administered by injection four different times
79544357|NCT06052605|Behavioral|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
79846090|NCT05274009|Other|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (~23°C, ~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
79249789|NCT02476149|Procedure|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
79249790|NCT02481453|Drug|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
79249791|NCT02481453|Drug|Placebo|Comparator: placebo
79249792|NCT02481531|Other|Previously marketed infant formula|
79249793|NCT02481531|Other|Previously marketed formula using a similar protein|
79249794|NCT02476383|Procedure|spinal manipulative therapy|refer to arm descriptions
79704753|NCT05992844|Other|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
79704754|NCT05992688|Other|Sucrose sweetened beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
79846091|NCT00836030|Other|No treatment given|No treatment given
79846092|NCT00206323|Drug|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
79249795|NCT04492527|Behavioral|Telehealth coaching sessions|Participants will be receiving a 2-month coaching session intervention that will be delivered via telephone or video-conferencing. Each of the 6 sessions will be 30-45minutes long and one-on-one with a student coach. In each session, coaches will review the participants' health behaviours and assess their knowledge about behavioural risks factors for chronic diseases and their current behaviours. The coaches will then provide information about the health risks of poor health behaviours, and benefits of change. Health behavioural goals will be established through a collaborative process. The coaches will then assist participants to develop readily achievable action plans that participants will follow in between coaching sessions as a means to realize their health goals. Adherence and modifications to the action plans will be discussed at the follow-up coaching session to promote health accountability.
79544359|NCT06052345|Device|Garmin smartwatch|"Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~Meal detection and meal characteristics (accelerometry and gyroscope data)~Oxygen saturation (pulse oximetry)~Number of steps (pedometer)~Stress level indicators (based on heart-rate analytics)~Sleep patterns (sleep and wake-up time, sleep quality)"
79544360|NCT06052345|Other|REBECCA Mobile application|"GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
79544361|NCT06052345|Other|REBECCA PC plug-in|"the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
79391676|NCT02539342|Drug|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
79544362|NCT06052332|Radiation|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
79544363|NCT06052332|Drug|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
79544364|NCT06052332|Procedure|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch & wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
79704755|NCT05992688|Other|Stevia sweetened beverages|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
79704756|NCT05992688|Other|Calorie free flavored water beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
79704757|NCT05992597|Drug|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
80014392|NCT02339909|Behavioral|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
79704758|NCT05992038|Procedure|Osteotomy with putty|Synthetic ceramic putty
79704759|NCT05992038|Procedure|Conventional osteotomy|conventional osteotomy
79846093|NCT00206323|Drug|placebo/sugar pill|placebo
79846094|NCT00841958|Procedure|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
80014393|NCT02339909|Behavioral|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
79704760|NCT05991310|Other|Telemedicine Assessment by Remote Neurologist|Use of a telemedicine platform for a neurologist, remotely located, to assess a MSU patient, review imaging, and decide on the required treatments.
79704761|NCT05991310|Other|In-Person Assessment by an Onboard Neurologist|Traditional in-person assessment of a patient by a neurologist located onboard the MSU
79704762|NCT05986331|Drug|BCD-201|up to 8 treatment cycles
79704763|NCT05986331|Drug|Keytruda|up to 8 treatment cycles
80014394|NCT02336217|Other|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
80014395|NCT02336217|Other|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
80014396|NCT02308280|Drug|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
79846095|NCT03903159|Behavioral|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
79704764|NCT05984446|Device|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
79388427|NCT06241599|Drug|GP/PFLL+placebo|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks)."
79704765|NCT05984446|Device|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
79704766|NCT05984238|Device|ReCET|Investigational product.
79704767|NCT05984238|Drug|Semaglutide, 1.0 mg/mL|Already registered medicine for type 2 diabetes
79388428|NCT06241586|Procedure|The novel PMMI surgical strategy|"Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals."
79704768|NCT05984238|Other|Sham procedure|The sham control for the ReCET procedure.
79704769|NCT05983705|Behavioral|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
79249796|NCT05713539|Other|Metal block|Small sheet of copper will be used when cooled to the designated temperature
79249797|NCT05335005|Drug|MK-2060|MK-2060 administered via IV infusion
79249798|NCT02825251|Drug|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
79388429|NCT06241586|Procedure|The conventional step-up strategy|Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
79704770|NCT05982600|Diagnostic Test|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
79704771|NCT05982600|Diagnostic Test|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
79704772|NCT05982600|Diagnostic Test|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
79704773|NCT05982600|Diagnostic Test|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
79704774|NCT05979064|Procedure|Laparoscopically harvested omental tissue autograft|"Standard neurosurgical removal of recurrent GBM,~removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~the omental fat will be transferred and implanted into brain tumor cavity,~standard closure of surgical resection cavity."
79710118|NCT01346969|Drug|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
79710119|NCT01346969|Drug|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
79710120|NCT01346969|Drug|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
79846096|NCT04043000|Dietary Supplement|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
79846097|NCT02546804|Procedure|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
79249799|NCT02825251|Drug|insulin aspart|Injected s.c. /subcutaneously (under the skin)
79249800|NCT05449197|Other|HEMOPHAR e-learning program|training on professional practice by following HEMOPHAR e-learning program
79249801|NCT05415111|Procedure|Subepithelial connective tissue|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) in addition to bone grafting of periimplantitis-affected implants.
79249802|NCT05415111|Procedure|Volume stable Collagen Matrix|Study specific intervention is the placement of a soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants.
79846098|NCT02546804|Procedure|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
79388430|NCT06241573|Drug|Spesolimab|Spesolimab
79846099|NCT02546804|Procedure|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
80014397|NCT02210715|Drug|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
79388431|NCT06241547|Device|electrical stimualtion via EmeTerm bracelet|We planned to exert electrical stimulation via the bracelet.
80014398|NCT02210715|Other|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
79388432|NCT06241547|Drug|antimetic drugs（ dexamethasone，ondansetron）|Antimetic drugs (dexamethasone ondansetron) are used to prevent postoperative nausea and vomiting.
79388433|NCT06241534|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
79388434|NCT06241534|Behavioral|Relaxation-therapeutic recordings|"8 sessions of relaxation-therapeutic recordings in the non-sleep deep rest concept.~The content of the recording is based on the 'body scanning technique', which constitutes the core of the therapy. This approach aims to quiet the overactive sympathetic part of the autonomic nervous system. During therapy, the patients take a 'journey' through their own body from feet to head. Following the voice of the narrator, the patient focuses on specific body parts, tries to feel this place and then relaxes tense muscles. Relaxation of individual body parts (muscle groups) is combined with breathing exercises. Conscious and mindful breathing deepens the state of relaxation. Additionally, the recording includes therapeutic suggestions related to making a choice between: overload and relief, holding on and letting go, acting and sensing. Furthermore, suggestions focus the patient on inner wisdom that allows them to make the best decisions."
79544365|NCT06052332|Combination Product|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~SCRT (5 fractions of 5 Gy), followed by~Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~SCRT (5 fractions of 5 Gy), followed by~Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
79710121|NCT04424498|Procedure|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
79846100|NCT00205855|Device|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
79846101|NCT01013038|Procedure|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
79846102|NCT01013038|Procedure|conventional PCI|balloon angioplasty and/or stent implantation
79846103|NCT04526704|Drug|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
79846104|NCT00842114|Biological|R+CVP+IFN|Immunochemotherapy
80014399|NCT02124421|Procedure|Cytoreductive Surgery (CRS)|Cytoreductive surgery
80014400|NCT02124421|Drug|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
79249803|NCT05415111|Procedure|No soft tissue augmentation|Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed.
79249804|NCT04491981|Procedure|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).
79249805|NCT04491981|Procedure|Composite resin|Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
79249806|NCT02478801|Dietary Supplement|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
79391677|NCT02539342|Drug|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
80014401|NCT02124421|Other|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
80014402|NCT02124421|Procedure|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
80014403|NCT02124421|Drug|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
80014404|NCT02124421|Drug|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
79249807|NCT02478957|Drug|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
79249808|NCT02478957|Drug|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
79388435|NCT06241534|Device|Virtual reality therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
79544366|NCT06052280|Other|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
79388436|NCT06241534|Behavioral|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
79388437|NCT06241508|Device|Transcranial magnetic stimulation|A standard 600-pulse TBS [16] will be administrated using a MagPro X100 stimulator (MagVenture, Denmark) and a 65-mm figure-of-eight coil. The measurement of the motor hotspot and individual RMT will be in accordance with our established methodology [3, 9]. For patients with stroke, the intensity of real stimulation will be 55% or 70% RMT of the unaffected M1 [17], depending on their assigned condition. Sham stimulation will be delivered using the same coil with 20% RMT of the unaffected M1 [4, 6]. The priming and conditioning sessions will be delivered to the ipsilesional M1 sequentially. In line with previous works, the interval between them will be 10 minutes [2, 3]. For healthy adults, the stimulation will be applied exclusively to the non-dominant (right) M1.
79388438|NCT06241495|Other|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
79388439|NCT06241495|Other|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
79388440|NCT06241469|Drug|Sintilimab,nab-paclitaxel and tegio|Immunotherapy combined with chemotherapy
79388441|NCT06241443|Other|hybrid simulation|"During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices."
79704775|NCT05978895|Other|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
79704776|NCT05976685|Procedure|Left atrial appendage Occlusion|Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
79704777|NCT05976685|Drug|DOAC|Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
79704778|NCT05976464|Drug|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
79704779|NCT05975684|Drug|Baclofen|0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
79704780|NCT05975684|Drug|Placebo|Placebo three times a day for 4 weeks
79704781|NCT05975151|Drug|Pseudomonas aeruginosa|A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
79704782|NCT05971784|Other|Telerehabilitation Group|The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities
79704783|NCT05971784|Other|Control Group|The group that will receive an exercise program consisting of balance and walking activities
79388442|NCT06241443|Other|video-modeling|"The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance."
79704784|NCT05968469|Device|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
79704785|NCT05968469|Other|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
79704786|NCT05966935|Combination Product|Fenugreek Cumin Powder|Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
79704787|NCT05966376|Device|Hemostatic device for distal radial approach.|Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
79704788|NCT05964452|Drug|Methimazole Tablets|Testing dosing algorithm for efficacy.
79704789|NCT05961748|Other|Multi-disciplinary assessment|Multi-disciplinary assessment
79846105|NCT00842192|Drug|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
79846106|NCT00536991|Dietary Supplement|Calcitriol|Given PO
79846107|NCT00536991|Drug|Ketoconazole|Given PO
79544367|NCT06052280|Other|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
79846108|NCT00536991|Other|Laboratory Biomarker Analysis|Correlative studies
79544368|NCT06052254|Drug|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
79846109|NCT00536991|Other|Pharmacological Study|Correlative studies
79846110|NCT00536991|Drug|Therapeutic Hydrocortisone|Given PO
79544369|NCT06052254|Drug|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
79544370|NCT06052254|Drug|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
79544371|NCT06052241|Drug|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
79846111|NCT00842270|Drug|AB1010|3 mg/kg/day
79846112|NCT00842270|Drug|AB1010|4,5 mg/kg/day
79846113|NCT00842270|Drug|AB1010|6 mg/kg/day
79846114|NCT00842270|Drug|placebo|matching placebo to AB1010 dosages
79846115|NCT00836108|Behavioral|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
79846116|NCT00504166|Drug|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
80014405|NCT02124421|Drug|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
79388443|NCT06241430|Device|CardioMEMS|Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
79846117|NCT00504166|Other|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
79388444|NCT06241404|Procedure|trigger point therapy|patients who have been treated for shoulder tendinopathy by trigger point therapy
79388445|NCT06241404|Procedure|Exercise therapy|patients who have been treated for shoulder tendinopathy by exercise therapy
79846118|NCT02547584|Procedure|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
79846119|NCT04342520|Other|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
79846120|NCT01013116|Biological|modified allergen extract of house dust mites|subcutaneous injections
79846121|NCT01013116|Biological|placebo|subcutaneous injections
79544372|NCT06052215|Behavioral|Online Information Cards Education|Providing family planning education to women through online information cards
79704790|NCT05959915|Device|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
79249809|NCT02481063|Other|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
79249810|NCT02481063|Other|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
79249811|NCT03563365|Other|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
79249812|NCT03563365|Drug|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
79249813|NCT02475993|Other|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
79388446|NCT06241378|Device|perineometer device for physiotherapy|measuring the vaginal pressure for stress urinary incontinence patients
79388447|NCT06241313|Drug|Atogepant|Oral Tablet
79544373|NCT06052202|Behavioral|CRC mHealth|Participants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
79544374|NCT06052202|Behavioral|Control|Participants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
79846122|NCT04002765|Diagnostic Test|pulmonary function tests|"Lung function tests (standard of care)~Dynamic and static volumes (FVC, FEV1, TPC, RV)~Lung diffusion capacity for CO (DLCO)~Chest Xrays~High resolution CT scanner (HRCT)"
79846123|NCT02546648|Drug|Tranexamic Acid|
79846124|NCT02546648|Drug|Tranexamic Acid Placebo|
79846125|NCT02546648|Drug|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
79388448|NCT06241313|Drug|Placebo for Atogepant|Oral Tablet
79544375|NCT06052189|Procedure|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
79710122|NCT04424342|Other|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
79846126|NCT03997942|Other|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
79846127|NCT00843596|Procedure|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
79249814|NCT02259907|Drug|KUC 7483 CL|
79249815|NCT02259907|Drug|Placebo|
79249816|NCT02259907|Other|High fat meal|
79249817|NCT02475915|Drug|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
79249818|NCT02475915|Drug|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
79249819|NCT02475915|Drug|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
79249820|NCT02475915|Drug|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
79388449|NCT06241300|Behavioral|Chicago Parent Program|Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
79391678|NCT02416986|Behavioral|6 hour smoking abstinence|
79710123|NCT04424342|Other|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
79710124|NCT01346774|Drug|Cranberry powder capsules|2 cranberry powder capsules twice a day
80014406|NCT02124421|Drug|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
79704794|NCT05958615|Behavioral|Reimagining Us in the Context of Bariatric Surgery (ReConnect)|ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
79704795|NCT05957445|Device|active continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
79704796|NCT05957445|Device|sham continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
79704797|NCT05956340|Behavioral|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
79704798|NCT05953597|Behavioral|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
79704799|NCT05953415|Device|active iTBS|Participants in this group will receive two sessions of 1800-pulse active stimulation per day, with an intersession interval of 50 minutes. The stimulation will be administered on workdays over a period of 3 weeks, totaling 15 days.
79704800|NCT05953415|Device|sham iTBS|Participants in this group will receive two sessions of 1800-pulse sham stimulation per day, with an intersession interval of 50 minutes. The stimulation will be comprehensively mimic the active condition, and also administered on workdays over a period of 3 weeks, totaling 15 days.
79704801|NCT05950581|Device|Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
79704802|NCT05950581|Device|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
79704803|NCT05944510|Drug|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
79704804|NCT05944510|Drug|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
79710125|NCT01346774|Drug|Placebo powder capsules|2 placebo capsules twice a day
79710126|NCT01346696|Device|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
79846128|NCT00842426|Behavioral|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
79846129|NCT00842426|Behavioral|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
79846130|NCT01010620|Behavioral|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
79846131|NCT00842504|Drug|Micafungin|3 mg/kg IV once over 1 hour
79846132|NCT00842582|Drug|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
79846133|NCT00842582|Drug|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
79388450|NCT06241287|Behavioral|Better Living with Non-memory led Dementia programme|an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.
79388451|NCT06241287|Other|Waiting list|Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
79704805|NCT05940675|Behavioral|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
79704806|NCT05940675|Behavioral|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
79704807|NCT05940675|Behavioral|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
79704808|NCT05940675|Behavioral|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
79704809|NCT05940493|Drug|Abemaciclib|Tablet
79704810|NCT05940493|Drug|Placebo|Tablet
79710127|NCT01346540|Drug|BIBF 1120|VEGF inhibitor
79846134|NCT00842582|Drug|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
79544376|NCT06052163|Drug|Bumetanide|Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
79249821|NCT02475915|Drug|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
79249822|NCT02475915|Drug|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
79544377|NCT06052163|Drug|Placebo|A placebo has no active properties and is taken orally.
79544379|NCT06052124|Device|Augmented Reality Device|AR device will be used to determine where to place SEPS drain
79544380|NCT06052111|Drug|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
79544381|NCT06052111|Drug|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
79544382|NCT06052085|Other|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
79846135|NCT00843908|Device|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
79846136|NCT00843908|Device|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
79846137|NCT00842660|Drug|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
79249823|NCT02475915|Drug|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
79249824|NCT02480985|Other|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~Thyroid-stimulating hormone, free T4 and T3~Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~Adrenocorticotropic hormone stimulation test~Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~Demographic data~Daily data (clinical exam, secondary brain injuries)~Hormone levels on day 1, 3 and 7~Biomarkers on day 1, 3 and 7~Brain CT-Scan on day 1~Pituitary MRI on day 7~Outcome measures at 6 and 12 months~Neurological recovery (GOSe)~Independent functioning (FIM)~Quality of life (EQ-5D-5L)~Life satisfaction (LISAT-11)~Depression (PHQ-9)"
79249825|NCT03833323|Combination Product|Implantable System for Remodulin (treprostinil)|All patients will be implanted with the Implantable System for Remodulin (treprostinil).
79249826|NCT02475525|Dietary Supplement|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
79388452|NCT06241274|Other|Moxibustion|Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
79388453|NCT06241274|Other|Symptomatic supportive treatment|Symptomatic supportive treatment.
79249827|NCT03110575|Drug|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
79249828|NCT02475603|Procedure|Total knee arthroplasty|Total knee arthroplasty
79249829|NCT02479035|Dietary Supplement|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
79249830|NCT02479035|Dietary Supplement|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
79249831|NCT02479035|Dietary Supplement|Control meal|0 g red raspberry
79544383|NCT06052085|Other|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
79704811|NCT05938907|Other|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
79704812|NCT05938907|Other|bone substitute|Implanting bone substitute into the area of root apical bone defect
79704813|NCT05938907|Combination Product|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
79704814|NCT05935982|Behavioral|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
79704815|NCT05934253|Drug|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
79249832|NCT03563287|Drug|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
79388454|NCT06241248|Diagnostic Test|Rapid sepsis diagnostic test|The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
79544384|NCT06052085|Other|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
79544385|NCT06052007|Behavioral|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
79704816|NCT05932888|Drug|QLM3003|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
79704817|NCT05932888|Drug|QLM3003 Placebo|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
79704818|NCT05925959|Other|Preoperative Weight Management Program|The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
79704819|NCT05925400|Device|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 30 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
79249833|NCT05384847|Drug|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
79704820|NCT05924854|Other|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
79704821|NCT05921916|Drug|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
79704822|NCT05921916|Drug|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
79249834|NCT05384847|Other|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
79704823|NCT05918822|Drug|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
79704824|NCT05918822|Drug|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
79704825|NCT05918822|Drug|Rabeprazole|Rabeprazole tablet.
79710128|NCT01346540|Drug|Placebo|BIBF 1120 placebo
79710129|NCT01342913|Drug|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
79710130|NCT01342913|Drug|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
79846138|NCT00509236|Drug|Sitagliptin|25 mg (one 25-mg tablet) once daily
79846139|NCT00509236|Drug|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
79846140|NCT00836420|Procedure|no intervention|the value of the clinical use of microdialysis monitoring of the brain
79249835|NCT02480907|Behavioral|Workshop Group|Workshop support group
79704826|NCT05916300|Other|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
79846141|NCT00842738|Behavioral|Mindfulness meditation|Mindfulness meditation
79846142|NCT00842738|Other|No meditation|Health care services as usual
79846143|NCT00842738|Other|Controls|No intervention
80014407|NCT02076113|Procedure|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
80014408|NCT02076113|Procedure|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
79544386|NCT06052007|Behavioral|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
80014409|NCT02076113|Procedure|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
80014410|NCT01989143|Drug|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
80014411|NCT01989143|Drug|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
80014412|NCT01989143|Drug|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
80014413|NCT01989143|Drug|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
79249836|NCT02480907|Behavioral|Internet-based support group|Internet based support group with E-mail coaching
79544387|NCT06051981|Drug|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
79249837|NCT05378217|Diagnostic Test|AMR LFIA Assay|AMR LFIA will be performed in parallel to routine testing on appropriate sample types retrieved from routine testing : Blood, urine, BronchoAlveolar Lavage (BAL), Tracheal Aspirate (TA), Rectal swab
79249838|NCT02479113|Procedure|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
79846144|NCT00842816|Drug|ST101|10 mg; administered once/day
79846145|NCT00842816|Drug|ST101|60 mg; administered once/day
79846146|NCT00842816|Drug|ST101|120 mg; administered once/day
80014414|NCT01989143|Drug|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
80014415|NCT01989143|Drug|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
80014416|NCT01927250|Behavioral|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
80014417|NCT01914900|Drug|docetaxel, cisplatin, 5 fluorouracil|
80014418|NCT01703455|Drug|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
80014419|NCT01599559|Other|observation|observation
79249839|NCT02478567|Other|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
79249840|NCT02478567|Other|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
79544388|NCT06051981|Drug|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
79544389|NCT06051981|Drug|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
79544390|NCT06051981|Drug|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
79704827|NCT05906394|Procedure|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
79846147|NCT00842816|Drug|Placebo|placebo tablets to match ST101 tablets
79846148|NCT00842894|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
79846149|NCT00842894|Drug|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
79846150|NCT02546726|Behavioral|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
79704828|NCT05900856|Other|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
79249841|NCT04856527|Behavioral|Physical therapist support|Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
79704829|NCT05900856|Device|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
79704830|NCT05899582|Procedure|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
79704831|NCT05899582|Other|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
79704832|NCT05895838|Drug|Dexamethasone|Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
79704833|NCT05895838|Procedure|Backrest elevation|Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
79846151|NCT02546726|Behavioral|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
79249842|NCT05714787|Other|Chest CT Scan examination|Double examination of chest CT scan on sagittal section after multiplanar reconstruction
79249843|NCT02478411|Procedure|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
79249844|NCT02478411|Procedure|Conventional physiotherapy|30 minutes of conventional physiotherapy
79249845|NCT02478879|Drug|ZP-PTH|Patch applied daily for 30 minutes, 14 days
79249846|NCT02478879|Drug|FORTEO|Subcutaneous injection administration daily for 14 days
79249847|NCT03563053|Combination Product|EryDex System|EryDex System is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which is infused into the patients
79388455|NCT06241235|Drug|ZG005 Powder for Injection|ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
79704834|NCT05895838|Procedure|Early wakeup call|Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
79704835|NCT05895838|Drug|Olanzapine|Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
79704836|NCT05894291|Other|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
79704837|NCT05894291|Other|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
79704838|NCT05888896|Other|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
80014420|NCT01599559|Radiation|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
79388456|NCT06241235|Drug|Paclitaxel|IV infusion
79388457|NCT06241235|Biological|Bevacizumab|IV infusion
79388458|NCT06241235|Drug|Cisplatin|IV infusion
79704839|NCT05888896|Other|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
79846152|NCT04043390|Diagnostic Test|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
79249848|NCT02478645|Drug|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
79249849|NCT02478645|Drug|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
79249850|NCT02478645|Drug|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
79249851|NCT02475447|Drug|Asimadoline|kappa-opioid receptor agonist
79249852|NCT02475447|Drug|Placebo|placebo-matched control
79249853|NCT05871957|Drug|Vitamin D Drops|Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
79249854|NCT05871944|Other|KAlternborn Joint Mobilization|This is a join mobilization technique to reduce the joint stiffness and help in improving joint range of motion
79388459|NCT06241235|Drug|Carboplatin|IV infusion
79544391|NCT06051955|Other|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
79704840|NCT05886582|Drug|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
79704841|NCT05886582|Drug|Placebo|Placebo drug
79704842|NCT05885932|Procedure|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
79388460|NCT06241222|Drug|Probiotic Blend Oral Tablet|In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
79704843|NCT05885932|Drug|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
79704844|NCT05885932|Procedure|mono anti-platelet therapy|mono anti-platelet therapy
79704845|NCT05885763|Drug|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
79704846|NCT05884684|Other|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
79704847|NCT05884671|Drug|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
79704848|NCT05884671|Drug|Placebo|All participants will receive placebo during one of the sessions.
79704849|NCT05881863|Other|No intervention|This is an observational study
79704850|NCT05880667|Radiation|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
79704851|NCT05876286|Other|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
79704852|NCT05873179|Other|role-playing for learning the clinical interview|role-playing for learning the clinical interview
79704853|NCT05872581|Behavioral|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
79704854|NCT05872581|Behavioral|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
80014421|NCT01586910|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
79710131|NCT04423250|Other|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|- Failure to trace, Lack of product information, absence of product in the operating room
79846153|NCT04043390|Diagnostic Test|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
80014422|NCT01586910|Procedure|Surgical Aortic Valve Replacement (SAVR)|
80014423|NCT01586910|Device|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
79388461|NCT06241209|Other|PowerPoint program visual stimulation|Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
79388462|NCT06241196|Device|implant|Implant will be placed through the surgical guide in the extraction socket
79388463|NCT06241196|Procedure|Vestibular Socket Therapy|tunnel incision will be made in labial vestibule
79388464|NCT06241196|Drug|Alloderm|allogenic soft tissue substitute
79846154|NCT04043390|Diagnostic Test|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
79846155|NCT04043390|Diagnostic Test|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
79846156|NCT00843128|Device|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
79846157|NCT00843128|Device|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
79846158|NCT00508924|Drug|Argatroban|
80014424|NCT01496976|Drug|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
80014425|NCT01496976|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
80014426|NCT01496976|Drug|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
80014427|NCT01438034|Drug|kisspeptin 112-121|0.24 nmol/kg
80014428|NCT01438034|Drug|GnRH|75 ng/kg
80014429|NCT01409161|Drug|Arsenic Trioxide|Given IV
80014430|NCT01409161|Drug|Gemtuzumab Ozogamicin|Given IV
80014431|NCT01409161|Other|Laboratory Biomarker Analysis|Correlative studies
80014432|NCT01409161|Drug|Tretinoin|Given PO
79704855|NCT05871151|Device|taVNS|Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
79544392|NCT06051929|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
79544393|NCT06051916|Other|residual urine|The study includes two group, A and B. Se previously
79544394|NCT06051851|Drug|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
79544395|NCT06051851|Drug|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
79544396|NCT06051851|Drug|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
79544397|NCT06051851|Drug|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
79544398|NCT06051838|Procedure|surgery|if the patients is TD positive, we recommond careful surgery and pathological examination.
79704856|NCT05871151|Behavioral|Exercise|All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations; 3) a home program, which consists of exercises and tasks that the patient can do on their own and performed nightly; and 4) group exercise sessions. The exercise intervention proposed involves the supervision of a trained exercise specialist at all times during the treatment session. Exercise will be provided in a clinical setting, 60 minutes per session, up to 3 sessions/week, for 4 weeks total.
80014433|NCT01401907|Other|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
79544399|NCT06051825|Diagnostic Test|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
79710132|NCT01342796|Biological|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
79846159|NCT00508924|Drug|Argatroban|
79846160|NCT00508924|Drug|Argatroban|
79846161|NCT00508924|Drug|Heparin|
79846162|NCT00836576|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
79846163|NCT00836576|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
79249855|NCT05871944|Other|Post stretch Facilitation Technique|This is a PNF techniques used to relax the muscles and help in getting more free range of restricted joint
79249856|NCT05871918|Drug|TCbHP VS ddEC-THP|The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
79388465|NCT06241196|Drug|Xenogenic bone membrane shield|xenogenic bone membrane
79388466|NCT06241196|Procedure|Connective tissue graft|soft tissue harvesting from palate
79388467|NCT06241183|Drug|Intravenous Famotidine|Patients in this group will receive 20mg IV Famotidine.
79388468|NCT06241183|Drug|Oral Maalox/ Mylanta|Patients in this group will receive 30 ml Maalox/ Mylanta.
79388469|NCT06241170|Procedure|mesentery-guided resection margin|The research team positions the proximal margin of the anastomosis in a way that the mesentery reaches the point of being palpable and where the fat appears entirely normal under direct visual observation, in contrast to the mesentery near the proximal and distal ends of the anastomosis.
79544400|NCT06051799|Other|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
79846164|NCT00836654|Biological|Catumaxomab (Removab)|Puncture free survival
79846165|NCT00836654|Procedure|paracentesis|
79846166|NCT00836732|Procedure|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
79846167|NCT00844064|Drug|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
79846168|NCT04003077|Device|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm^2; power density, 300mW/cm^2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm^2.
79846169|NCT05221593|Drug|Lithium Carbonate|400 mg tablet in controlled released formula
80014434|NCT01140516|Drug|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
80014435|NCT01140516|Other|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
80014436|NCT01138020|Behavioral|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
79704857|NCT05868876|Drug|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
79704858|NCT05867316|Behavioral|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
79704859|NCT05866341|Dietary Supplement|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
79249857|NCT05871879|Diagnostic Test|The 5-item modified frailty index|The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
79388470|NCT06241157|Other|Pediatric Quiz Game|"Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily."
79388471|NCT06241144|Device|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
79704860|NCT05866341|Dietary Supplement|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
79704861|NCT05863702|Behavioral|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
79704862|NCT05855161|Other|Rebound therapy|Participants will receive exercise-based training on a trampoline
79704863|NCT05855161|Other|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
79704864|NCT05848739|Drug|ST316|IV
79704865|NCT05846568|Biological|GR1801|The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.
79704866|NCT05846568|Biological|Human Rabies Immunoglobulin(HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.
79544401|NCT06051799|Other|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
79544402|NCT06051786|Drug|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
79544403|NCT06051786|Drug|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
79704867|NCT05846568|Biological|Rabies Vaccine|The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .
79704868|NCT05845450|Drug|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
79704869|NCT05845450|Drug|Durvalumab|durvalumab 1500 mg IV on day 1
79704870|NCT05845450|Drug|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
79704871|NCT05845450|Drug|Botensilimab|botensilimab 1 mg/kg on day 1
79704872|NCT05845450|Drug|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
79704873|NCT05845450|Drug|Sotorasib|sotorasib 960 mg orally once daily from day 1 to 28
79249858|NCT05871866|Procedure|"minimally invasive internal fixation device infix"|An INFIX involves the insertion of spinal pedicle screws in the anterior pelvis (supra-acetabular entry) and the placement of a connecting rod in the subcutaneous tissue of the patient
79249859|NCT05871827|Procedure|Intraoperative Fluoroscopic Computer Navigation|Computer technology used during surgery
79704874|NCT05842213|Biological|AVT05 (proposed biosimilar to golimumab)|AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection
79704875|NCT05842213|Biological|Simponi (Golimumab)|Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
79704876|NCT05830942|Behavioral|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
79704877|NCT05830942|Device|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
79704878|NCT05830942|Device|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
79710133|NCT01342796|Biological|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
79544404|NCT06051773|Other|muscle involvement|evaluation of muscle involvement
79544405|NCT06051760|Biological|NV-001|NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
79704879|NCT05826418|Dietary Supplement|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
79704880|NCT05826418|Dietary Supplement|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
79704881|NCT05821842|Device|Sonu|Acoustic energy delivery
79704882|NCT05816083|Behavioral|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
79704883|NCT05811377|Drug|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
79704884|NCT05811377|Drug|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
79704885|NCT05809427|Device|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
79704886|NCT05802225|Drug|BCD-178|at an initial dose of 840 mg (1 cycle), then 420 mg
79704887|NCT05802225|Drug|Perjeta|at an initial dose of 840 mg (1 cycle), then 420 mg
79704888|NCT05801835|Drug|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m^2 on days 1 and day3 of the first cycle of induction.
79846170|NCT00844142|Drug|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
79704889|NCT05801835|Drug|Vyxeos|Be given intravenously at 65U/m^2 on days 1 and day3 of the first cycle of induction.
79704890|NCT05801835|Drug|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m^2 on days 1 and day3 of the second cycle of induction.
79704891|NCT05801835|Drug|Vyxeos|Be given intravenously at 65U/m^2 on days 1 and day3 of the second cycle of induction.
79846171|NCT00844142|Drug|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
79846172|NCT00837044|Drug|Treximet|Treximet
79846173|NCT00837044|Drug|Migraine rescue medication of choice|Migraine rescue medication of choice
79846174|NCT01013272|Drug|Entecavir|Entecavir 0.5mg orally daily
79846175|NCT01013272|Drug|Lamivudine|Lamivudine 100mg orally, daily
79846176|NCT02546024|Drug|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
79846177|NCT01010698|Drug|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
79846178|NCT00851162|Biological|Trinity multipotent stem cells|Enough to fill voids which vary in size
79846179|NCT00851162|Biological|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
79846180|NCT03541486|Drug|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
80014437|NCT01138020|Behavioral|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
80014438|NCT01068210|Behavioral|Exercise Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
79388472|NCT06241131|Drug|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
79544406|NCT06051747|Procedure|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
79544407|NCT06051708|Other|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
79544408|NCT06051708|Other|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
79846181|NCT03541486|Drug|Gemcitabine|600 mg/m2 once weekly for up to weeks
79846182|NCT03541486|Radiation|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
79846183|NCT00851240|Drug|BTT-1023|intravenous
79846184|NCT00851240|Drug|Placebo|Intravenous
79249860|NCT05871788|Diagnostic Test|identify biomarkers|Identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma
79249861|NCT05871775|Behavioral|Personalized exercise|After selective functional movement evaluation, customized interventions for each patient
79249862|NCT05871775|Behavioral|Stabilization exercise|Neck stabilization exercise and sensorimotor program
79249863|NCT05871775|Behavioral|General exercise|General mobility exercise and strength exercise program
79249864|NCT05871723|Other|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
79704892|NCT05799482|Other|Qualitative Interview|Qualitative, semi-structured interview
79704893|NCT05797545|Diagnostic Test|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
79704894|NCT05790681|Drug|Insulin icodec|Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
79704895|NCT05784662|Behavioral|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
79704896|NCT05781386|Drug|SIM1811-03 or in combination with Sintilimab injectiont|"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"
80014439|NCT01068210|Behavioral|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
79249865|NCT05871723|Other|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
80014440|NCT00984399|Drug|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
80014441|NCT02915016|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
80014442|NCT02915016|Biological|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
79249866|NCT05871710|Other|Turkish version of the Tele-Pulmonary Rehabilitation Acceptance Scale|The Tele-Pulmonary Rehabilitation Acceptance Scale is a measuring tool that assesses the level of acceptance towards telerehabilitation programs among healthcare providers and patients in the field of pulmonary rehabilitation. It is used to evaluate the attitudes, beliefs, and perceptions of potential users towards telerehabilitation, which is a form of healthcare delivery that utilizes telecommunication technology to provide remote rehabilitation services to patients. The scale is intended to provide a standardized data collection tool that can be used to measure the level of acceptance of telerehabilitation programs among different groups of potential users. This scale will be translated into Turkish by a researcher who has an advanced level of knowledge in English and whose native language is Turkish.
79388473|NCT06241118|Drug|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79388474|NCT06241118|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79388475|NCT06241118|Drug|Topical corticosteroids|Pharmaceutical form: Various Topical formulation Route of administration: Topical
79388476|NCT06241118|Drug|Topical tacrolimus or pimecrolimus|Pharmaceutical form: Various Topical formulation Route of administration: Topical
79388477|NCT06241105|Drug|Lenvatinib+Toripalimab.|Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
79388478|NCT06241092|Other||
79388479|NCT06241079|Other|non-intervention|non-intervention
79388480|NCT06241066|Other|no-Intervention|no-Intervention
79704897|NCT05780216|Drug|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
79249867|NCT05871710|Other|Scale Evaluation Form|The healthcare providers and the patients will be asked about their opinions on the scale's construction, usefulness, and scope using a 100 mm visual analog scale.
79704898|NCT05780216|Drug|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
79388481|NCT06241053|Other|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball."
79388482|NCT06241053|Other|Multimodal therapy without McConnell taping|Multimodal therapy without McConnell taping
79388483|NCT06241040|Other|Aerobic Exercises with core Muscle strengthening|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
79704899|NCT05778162|Diagnostic Test|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments [CLIA] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
79704900|NCT05775627|Behavioral|Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
79704901|NCT05770570|Behavioral|Counseling|In-person individual diet and physical activity (PA) counseling
79704902|NCT05770570|Behavioral|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
80014443|NCT02915016|Biological|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
79544409|NCT06051682|Device|Artificial intelligence|Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.
80014444|NCT02915016|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
79249868|NCT05871697|Other|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|To measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
79388484|NCT06241040|Other|Aerobic Exercise without Core Muscle Strengthening|Aerobic Exercise without Core Muscle Strengthening
80014445|NCT03859414|Drug|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
79544410|NCT06051682|Procedure|Emergency physician|the emergency physician analyzes the x-rays
79544411|NCT06051630|Drug|Lidocaine intravenous|Perioperative lidocaine intravenous administration
79544412|NCT06051630|Drug|Serum saline intravenous|Perioperative serum saline intravenous administration
79544414|NCT06051461|Dietary Supplement|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
79704903|NCT05770570|Behavioral|Phone calls|Weekly telephone support
79704904|NCT05770570|Behavioral|Self-monitoring tools|Self-monitoring tools
79704905|NCT05768529|Drug|U16|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
79710134|NCT01342640|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
79710135|NCT01342484|Drug|placebo|comparison of different dosages of drug (low vs high) vs placebo
79710136|NCT01342484|Drug|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
79710137|NCT01342484|Drug|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
80014446|NCT03859414|Drug|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
80014447|NCT03859414|Drug|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
80014448|NCT03859414|Drug|Placebo|CHF 5993 placebo pMDI
80014449|NCT01170650|Drug|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
80014450|NCT01170650|Drug|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
79704906|NCT05766631|Behavioral|DynamiCare Health|"Participants earn incentives for:~CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
79704907|NCT05766631|Drug|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
79704908|NCT05761847|Other|Pediatric Medication Therapy Management (pMTM)|The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
79704909|NCT05759078|Drug|Ferinject|The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin <100 ng/mL or/and TSAT <20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
79704910|NCT05759078|Drug|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
79704911|NCT05757882|Other|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
79704912|NCT05757882|Other|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
79704913|NCT05755776|Drug|TMF|switch ETV to TMF
79704914|NCT05753306|Procedure|Biospecimen Collection|Undergo stool and blood sample collection
79704915|NCT05753306|Drug|Cisplatin|Given via HIPEC
79704916|NCT05753306|Procedure|Computed Tomography|Undergo CT scan or PET/CT
79704917|NCT05753306|Drug|Docetaxel|Given via HIPEC
79704918|NCT05753306|Procedure|Gastrectomy|Undergo robotic gastrectomy
79704919|NCT05753306|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
79704920|NCT05753306|Procedure|Magnetic Resonance Imaging|Undergo MRI
80014451|NCT01170650|Drug|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
79249869|NCT05871697|Other|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56.
79544415|NCT06051370|Procedure|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
79704921|NCT05753306|Procedure|Positron Emission Tomography|Undergo PE/CT
79704922|NCT05753306|Other|Questionnaire Administration|Complete questionnaire
79704923|NCT05752734|Drug|Group D|"Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
79704924|NCT05752734|Drug|Group C|"Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
79710138|NCT01342445|Drug|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
79710139|NCT01342445|Drug|Placebo|
79710140|NCT01342211|Biological|Placebo|Intravenous placebo monthly during treatment phase.
80014452|NCT01170650|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
80014453|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
80014454|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
80014455|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
79544416|NCT06051370|Procedure|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
80014456|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
80014457|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
80014458|NCT01168310|Drug|Formoterol Fumarate|Inhalation Solution
80014459|NCT01168310|Drug|Placebo|Inhalation Solution
79249870|NCT05871671|Behavioral|Pulmonary Rehabilitation|A 16-week PR programme shall be delivered twice weekly to the active group. This shall be followed by a 36-week maintenance home exercise programme which shall be monitored every 4 weeks via a phone call from the researcher herself for 36 weeks. The subjects shall self-document their adherence to the home exercise programme on a diary which shall be returned to the researcher at week 52.
79388485|NCT06241027|Other|Nerve flossing technique|The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
79704925|NCT05748522|Other|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
79704926|NCT05748522|Procedure|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
79704927|NCT05744661|Other|Mechanical Method|Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
80014460|NCT04464928|Other|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
79388486|NCT06241027|Other|Myofascial release|Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
79704928|NCT05744661|Other|Chemomechanical Method|Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
79846185|NCT00620750|Drug|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
79704929|NCT05744310|Device|Long term mechanical ventilation support|Patients that choose life prolonging treatment with long term mechanical ventilation support
79846186|NCT04884243|Drug|CBT-006|Cyclodextrin
79846187|NCT02547896|Drug|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
79846188|NCT02547896|Drug|Diclofenac|The patients will receive only diclofenac
80014461|NCT04464928|Other|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
80014462|NCT01472198|Drug|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
80014463|NCT01472198|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
79249871|NCT05871671|Other|Control|The control group shall not receive the 16-week PR programme and the following 36-week maintenance home exercise programme until completion of the study.
79249872|NCT05871658|Behavioral|electroacupuncture|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
79846189|NCT04002999|Device|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, [24] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
80014464|NCT01472198|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
80014465|NCT04575610|Drug|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
80014466|NCT04575610|Drug|Placebo|Matching placebo tablets will be administered.
79249873|NCT05871645|Procedure|Jakarta Surgical Uterine Conservation (JSICA) Technique|a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction
79704930|NCT05744310|Device|No long term mechanical ventilation support|Patients that decline life prolonging treatment with long term mechanical ventilation support
79704931|NCT05741905|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
79704932|NCT05741905|Drug|Levofloxacin simulant|Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
79704933|NCT05737966|Other|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
79388487|NCT06241014|Other|Mulligan Mobilization and Sling Exercises|Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
79704934|NCT05736445|Behavioral|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
79704935|NCT05733832|Other|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
79704936|NCT05733585|Device|Purabond|hemostatic efficacy of PuraBond
79704937|NCT05732974|Other|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
79704938|NCT05728866|Procedure|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
79704939|NCT05728034|Behavioral|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
79704940|NCT05728034|Behavioral|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
79704941|NCT05726656|Other|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
79249874|NCT05871645|Procedure|Standard Hysterectomy|The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
79704942|NCT05726656|Other|wii console based exercise|execise session using the wii console video games
79704943|NCT05725018|Biological|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets [LEAES]"
80014467|NCT02269358|Drug|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
79388488|NCT06241014|Other|Mulligan Mobilization|Mulligan Mobilization
79704944|NCT05724160|Other|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
79704945|NCT05724160|Other|Physiotherapy Protocol|Routine physiotherapy protocol
79704946|NCT05723471|Other|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
79704947|NCT05722496|Other|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
79704948|NCT05719883|Device|Maurora® Sirolimus Eluting Stent System|The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
80014468|NCT04504240|Drug|Famotidine 20 MG|Famotidine; tablet Famotac 20mg oral form.
80014469|NCT02266550|Drug|[14C] BILL 284 BS|
80014470|NCT04464304|Device|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
80014471|NCT04464304|Device|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
80014472|NCT02269436|Drug|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
79249875|NCT05871593|Genetic|Molecular genetic diagnostic|With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
79249876|NCT05871554|Behavioral|Mind-OP+|"Mind-OP is an online program designed to cultivate mindfulness and self-compassion developed by Beshai and his team. Mind-OP is self-guided, with four modules administered at a pace of one module per week (four weeks total). The version used for this study, Mind-OP+, is five weeks total, containing an extra module focused on connectedness.~The modules contain psychoeducational videos, guided audio meditations, goal-setting and motivational interviewing inspired exercises. Participants also have opportunities to engage with meditations and other exercises embedded within each module.~The first module (Week 1) introduces the concept of mindfulness. The second module (Week 2) focuses on attention to bodily sensations and thoughts. The third module (Week 3) introduces the concept of self-compassion. The fourth module (Week 4) focuses on the self-kindness component of self-compassion. The fifth module (Week 5) focuses on the concept of connectedness."
79704949|NCT05719883|Device|APOLLO™ Intracranial Stent System|The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
79704950|NCT05717491|Other|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
79704951|NCT05717491|Other|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
79704952|NCT05717049|Drug|Theophylline Tablets|12 week oral treatment
79704953|NCT05714280|Behavioral|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
79704954|NCT05714033|Procedure|Ventilatory Strategy To Prevent Atelectasis|Given
79704955|NCT05714033|Procedure|Lateral Decubitus Strategy (LADS)|Given
79704956|NCT05711888|Behavioral|Semantic Recognition Procedure|A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
79704957|NCT05711056|Behavioral|Sociobehavioral Intervention|"Utilizes two primary evidence-based strategies:~Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation."
79846190|NCT04002999|Device|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
79249877|NCT05871502|Device|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). This device will be selected from those currently available on the market, with CE marking, and with previous studies documenting its safety and feasibility for radiological procedures.
79388489|NCT06241001|Other|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
79388490|NCT06241001|Other|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
79388491|NCT06240988|Device|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy
79388492|NCT06240988|Other|Motor Imagery Technique|Motor Imagery Technique
79388493|NCT06240975|Other|Theragun Technique|Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks
79704958|NCT05708105|Diagnostic Test|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
79710141|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
79846191|NCT04002999|Device|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
79846192|NCT01564251|Drug|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
79846193|NCT01564251|Drug|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m^2 and/or 500 mg/m^2.
79388494|NCT06240975|Other|Dry Needling Technique|Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
79388495|NCT06240962|Other|Strength Training|They will receive the strength training only (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
79388496|NCT06240962|Other|Mindfulness Exercise|They will receive mindfulness-exercise for 6-week mindfulness intervention in addition to the strength training protocol.
79388497|NCT06240949|Device|Positional Release Technique|Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
79710142|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
80014473|NCT02264522|Other|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
80014474|NCT02264522|Other|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
80014475|NCT02264522|Other|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
80014476|NCT02264522|Other|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
79704959|NCT05708105|Diagnostic Test|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and < 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
79249878|NCT05871463|Biological|MSC-derived exosomes|Patients will receive standard medication plus MSC-derived exosomes at a final dose of 40mg in three weeks. Standard medication includes: a) treatment of the underlying cause of cirrhosis such as drug treatment of hepatitis B and C. b) symptomatic treatment of port complications such as ascites, prevention of variceal bleeding, treatment and prevention of hepatic encephalopathy.
79544417|NCT06049004|Other|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
80014477|NCT02084316|Behavioral|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
79704960|NCT05708105|Diagnostic Test|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
79704961|NCT05704387|Procedure|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
79704962|NCT05704387|Procedure|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
79704963|NCT05703568|Other|virtual reality|14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
79249879|NCT05871450|Behavioral|Inclusive events|Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
79544418|NCT06048289|Other|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
79544419|NCT06047743|Other|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
79544420|NCT06047743|Other|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
79544421|NCT06046261|Other|ACP board game for life|The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
79544422|NCT06046248|Drug|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
79544423|NCT06046248|Drug|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
79704964|NCT05703568|Other|Virtual reality|14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
79249880|NCT05871359|Device|Transcranial Direct Current Stimulation|The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.
79249881|NCT05871359|Procedure|Dual task|The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
79704965|NCT05700708|Diagnostic Test|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
79704966|NCT05698888|Drug|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
79846194|NCT00844220|Procedure|CT/MR|CT/MRI-directed clinical management strategy
79846195|NCT00844220|Procedure|Catheterization|Standard clinical management directed by conventional coronary angiography
79846196|NCT00508144|Drug|Alimta|500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks
79846197|NCT00844454|Procedure|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
80014478|NCT02084316|Behavioral|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
80014479|NCT02269514|Other|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
79249882|NCT05871294|Device|Acoustic stimulation|The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.
79249883|NCT05871294|Device|Repetitive transcranial magnetic stimulation|The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
79249884|NCT05871281|Procedure|Pelvic floor muscle exercises|Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
79249885|NCT05871229|Device|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
79249886|NCT05871229|Other|Standard treatment for peri-implantitis|Standard treatment for peri-implantitis as per international, national and clinic guidelines
79249887|NCT05871216|Diagnostic Test|Clinical tests and balance evaluation using the Delos Proprioceptive System|Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
79249888|NCT05871203|Other|Gene sequencing|Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery
79388498|NCT06240949|Device|Manual Pressure Technique|Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
79388499|NCT06240936|Other|Active Cycle of breathing|Active Cycle of Breathing Techniques will be given to group A. In Active cycle of breathing exercises, breathing control, thoracic expansion and forced expiration technique will be applied. 3-4 sets of exercise ,10-15 mint, 4 times per week for 4 weeks.
79544424|NCT06045702|Procedure|Epididymal sample|During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
79544425|NCT06045637|Behavioral|Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)|The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
79544426|NCT06045481|Drug|administration of single dose of doxycycline|Postexposure prophylaxis with Single Dose doxycycline
79704967|NCT05698368|Behavioral|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
79704968|NCT05698368|Other|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
79704969|NCT05698147|Drug|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
79846198|NCT00844454|Procedure|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
79846199|NCT02545712|Other|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
79846200|NCT02545712|Other|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
79846201|NCT02545712|Other|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
79846202|NCT02545712|Other|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
79846203|NCT02545712|Other|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
80014480|NCT02269514|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
80014481|NCT02269514|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
80014482|NCT02269514|Other|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
79544427|NCT06045143|Device|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
80014483|NCT02269514|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
79704970|NCT05698147|Drug|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
79704971|NCT05698147|Drug|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
79704972|NCT05696236|Device|Transepidermal water loss (TEWL) monitor and stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
79704973|NCT05696236|Device|Monitor (TEWL) without stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
79704974|NCT05693818|Other|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
79704975|NCT05689333|Device|Vista Vitrectomy Probe|Vitrectomy will be performed through 27 GA Vista Ophthalmics vitrector
79710143|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
79710144|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
80014484|NCT03465982|Procedure|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
80014485|NCT03465982|Procedure|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
79249889|NCT05871190|Other|İnjectable platelet rich fibrin|I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
79544428|NCT06044727|Procedure|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
79544429|NCT06044727|Procedure|Conventional subgingival instrumentation|Conventional subgingival instrumentation
79544430|NCT06044220|Behavioral|Intervention|The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.
79710145|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
79710146|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
79846204|NCT02545712|Other|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
79846205|NCT02545712|Other|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
79249890|NCT05871190|Procedure|Gingivectomy anad gingivoplasty|leveling and regulation of the gingiva
79249891|NCT05871112|Other|Use of dynamic tensioner|Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
79544431|NCT06044220|Other|Control|Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
79846206|NCT02545712|Other|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
79846207|NCT02545712|Other|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
80014486|NCT01332812|Drug|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
80014487|NCT01332812|Other|control group|General anesthesia, without additional interventions
80014488|NCT02079792|Procedure|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
80014489|NCT02079792|Procedure|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
80014490|NCT03408652|Drug|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
80014491|NCT01332656|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
80014492|NCT01332656|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
79249892|NCT05871099|Procedure|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Experimental group receive HIPEC two times after laproscopic gastrectomy
79249893|NCT05871073|Drug|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
79544432|NCT06043388|Biological|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
79544433|NCT06043388|Biological|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
79846208|NCT02545712|Other|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
79249894|NCT05871073|Drug|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
80014493|NCT01332656|Drug|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
80014494|NCT01332656|Drug|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
80014495|NCT02084472|Other|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
80014496|NCT02084472|Other|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
80014497|NCT02084472|Other|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
80014498|NCT02266784|Behavioral|Contingency Management (CM)|
79388500|NCT06240936|Other|Active Cycle of breathing with Acapella|"Acapella device will be used along active cycle of breathing techniques to group B. 3-4 sets ,10 mints foe acapella training ,15 -20 munts ,4 times per week for 4 weeks.~This technique is active form of therapy in which patient uses its own energy on request to aid in treatment."
79388501|NCT06240923|Device|Maxillary molars distalization|Maxillary molars distalization by using a nickel titanium open coil spring as an posterior displacement device.
79388502|NCT06240910|Other|Neurodynamics|Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per ~3-4 s. The participants rested for 60 s between each exercise.
79544434|NCT06040801|Behavioral|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~Functional status~Nutrition~Comorbidity~Mobility/Falls~Mood~Cognition~Polypharmacy~Social support."
79704976|NCT05689268|Diagnostic Test|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
79704977|NCT05685251|Other|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
79704978|NCT05685251|Other|Home Blood Pressure Monitoring|Participants will be provided an A&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
80014499|NCT02266784|Drug|Transdermal nicotine skin patches (i.e. Habitrol)|
80014500|NCT02266784|Other|Supportive Counseling|
80014501|NCT02090790|Drug|iv dexamethasone|2 ml 8 mg iv dexamethasone
80014502|NCT02090790|Drug|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
79249895|NCT05871047|Device|tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application|Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.
79249896|NCT05871034|Procedure|phacoemulsification|cataract extraction
79249897|NCT05871021|Radiation|Dose escalation of radiation dose beyond the therapeutic standard|Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab
79249898|NCT05870969|Behavioral|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
79249899|NCT05870969|Behavioral|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
79249900|NCT05870969|Behavioral|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
79249901|NCT05870904|Other|Dry Needling|"Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied"
79704979|NCT05684653|Drug|Orelabrutinib Tablets|50 mg, single oral dose
79704980|NCT05684510|Device|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
80014503|NCT02090790|Drug|serum physiologic|2 ml iv serum physiologic
80014504|NCT04959916|Behavioral|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
80014505|NCT02084550|Dietary Supplement|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
80014506|NCT02084550|Other|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
80014507|NCT04946110|Device|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
80014508|NCT01443728|Drug|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
80014509|NCT01443728|Drug|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
79249902|NCT05870878|Other|Standard care|Individual lifestyle consultation
80014510|NCT02088138|Device|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
79544435|NCT06030388|Other|Strength training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
79388503|NCT06240910|Other|Aerobic training|Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
79388504|NCT06240897|Device|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
79388505|NCT06240897|Device|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
79544436|NCT06030388|Other|High-intensity aerobic training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
79544437|NCT06024785|Procedure|Vertebropexy|"microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side.~Stabilization of the spine will be achieved with a biological ligament (for instance semitendinosus donor allograft) which will be pulled through a drilled hole in the spinous process of two adjacent vertebra in a looping technique and tendon ends fixed by an anchor knot after baseball stitches in a standardized fashion. Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia). Passive stability in clinically important directions of motion such as flexion-extension and shear movements will be provided, yet without stiffening other directions of motion."
79704981|NCT05684510|Device|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
79544438|NCT06018961|Other|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
79846209|NCT01011010|Drug|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
80014511|NCT02088138|Device|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
79249903|NCT05870878|Other|Lifestyle program|Lifestyle program focusing on lifestyle advice, coping with stress and adherence to a healthy(er) lifestyle. This program consists of 3 group sessions and an online platform.
79249904|NCT05870852|Device|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
79704982|NCT05682677|Device|iTBS|iTBS over the left dorsolateral prefrontal cortex
79249905|NCT05870852|Other|PNF|PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
79704983|NCT05682677|Device|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
79704984|NCT05682677|Behavioral|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
79704985|NCT05676736|Other|No intervention|No intervention to be done for the group
79846210|NCT01011010|Drug|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
80014512|NCT05092048|Other|questionnaire|PHQ-9 and GAD-7 questionnaire
80014513|NCT01324466|Drug|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
80014514|NCT01324466|Drug|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
80014515|NCT04740346|Diagnostic Test|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
80014516|NCT05479188|Device|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
80014517|NCT05479188|Device|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
79704986|NCT05672550|Drug|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
79544439|NCT06015490|Other|Conditioned Stimulus: Sucrose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79704987|NCT05672550|Drug|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
79846211|NCT01011010|Drug|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
79846212|NCT01011010|Other|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
79846213|NCT01011010|Other|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
80014518|NCT05479188|Device|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
80014519|NCT05479188|Device|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
79388506|NCT06240884|Procedure|Infraspinatus-teres minor interfascial block|After palpating the posterior-lateral angle of the acromion, the probe is tilted so that it is perpendicular to the muscle, which allows identification of the tendinous units of the infraspinatus and teres minor in the region of the humeral head on the ultrasound image. The probe is then moved medially, allowing the interfascial structures of the infraspinatus and teres minor muscles to be traced along the glenohumeral joint and scapular neck region. After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected.
79388507|NCT06240884|Procedure|interscalene block|In the interscalene block group, the probe was placed perpendicular to the neck to check for clear visualization of the C5 and C6 nerve roots. The probe was moved distally until just before identifying the upper trunk. Approximately 1 ml of 1% lidocaine was injected into the selected puncture site, and then the needle was advanced from lateral to medial using an in-plane technique under ultrasound guidance. The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.
79544440|NCT06015490|Other|Conditioned Stimulus: Glucose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79704988|NCT05672407|Drug|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
79704989|NCT05672407|Drug|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
79704990|NCT05667246|Other|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
79846214|NCT05357391|Device|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
79846215|NCT00851708|Drug|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
79846216|NCT01011088|Other||Not any artificial interventions were given
79846217|NCT01011166|Drug|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
79846218|NCT01011166|Drug|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
79846219|NCT01011166|Biological|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
79846220|NCT01011166|Drug|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
80014520|NCT02090868|Other|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
80014521|NCT01312454|Drug|AL-59412C injectable solution|Concentration 1 and Concentration 2
80014522|NCT01312454|Drug|Travoprost injectable solution|
80014523|NCT01312454|Drug|AL-59412C Vehicle|Inactive ingredients used as placebo
80014524|NCT01310114|Biological|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
80014525|NCT01310114|Drug|Placebo|Thawed placebo
79704991|NCT05667246|Other|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
79704992|NCT05663515|Drug|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
79704993|NCT05663515|Drug|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
79704994|NCT05659394|Other|Standard Wound Care Alone|gold standard compression therapy
79846221|NCT00621842|Drug|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
80014526|NCT04090918|Diagnostic Test|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
80014527|NCT02088294|Behavioral|Lifestyle Education (LS)|See arm description
80014528|NCT02088294|Behavioral|LS + Stress Reduction Guided Imagery|See Arm Description
79544441|NCT06015490|Other|Conditioned Stimulus: Fructose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
80014529|NCT02088294|Behavioral|LS + Activity/Eating Guided Imagery|See arm description
79249906|NCT05870774|Procedure|Soft tissue augmentation with CTG|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~Placement of the Astra Tech dental implant (Dentsply, Germany)~Harvesting of free connective tissue graft from the maxilla tuberosity area~Fixation of the graft to the vestibular mucosal-periosteal flap~Suturing the wound tightly"
79249907|NCT05870774|Procedure|Soft tissue augmentation with CM|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~Placement of the Astra Tech dental implant (Dentsply, Germany)~Modeling of sterile collagen matrix according to the shape of the recipient bed~Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~Suturing the wound tightly"
79249908|NCT05870696|Diagnostic Test|PrecogColo Dx test|the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer
79249909|NCT05870644|Other|Cycling exercise in room temperature at 25 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 25 degree Celsius.
79388508|NCT06240871|Other|Pulmonary artery pressure measurements|The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
79544442|NCT06015490|Other|Conditioned Stimulus: Sucrose (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79704995|NCT05659394|Device|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
79704996|NCT05654805|Dietary Supplement|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
79704997|NCT05654623|Drug|ARV-471|orally, once daily on a 28-day continuous dosing schedule
79704998|NCT05654623|Drug|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
79710147|NCT01342211|Drug|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
80014530|NCT01305824|Drug|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
80014531|NCT01305824|Drug|Placebo|Placebo administered at the time of AVF creation.
79249910|NCT05870644|Other|Cycling exercise in room temperature at 34 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 34 degree Celsius.
79249911|NCT05870631|Biological|vaccinate with DTaP|vaccinate with DTaP
79388509|NCT06240845|Other|High-level laser therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
79388510|NCT06240845|Other|Low-level laser therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
79388511|NCT06240832|Other|Physical therapy exercise|Endurance, strength and stretching training in Chronic liver disease children
79388512|NCT06240819|Other|Sleeper Stretch|They will receive three sessions a week for four weeks. In a session three sets with three repetitions of sleeper stretch in a side lying position
79249912|NCT05870631|Biological|vaccinate with DT|vaccinate with DT
79710148|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
80014532|NCT01305824|Drug|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
80014533|NCT03323749|Combination Product|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
80014534|NCT03323749|Combination Product|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
80014535|NCT03323749|Combination Product|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
80014536|NCT02084784|Drug|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
80014537|NCT02084784|Drug|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
79704999|NCT05654363|Procedure|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
80014538|NCT02266862|Radiation|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
80014539|NCT02091024|Dietary Supplement|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
80014540|NCT02091024|Dietary Supplement|Placebo|Placebo 200mg, twice a day
80014541|NCT03135236|Behavioral|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
79388513|NCT06240819|Other|Cross Body Stretch|They will receive three sessions a week for four weeks. In a session, three sets with three repetitions of cross-body stretch will be done in sitting position.
79388514|NCT06240806|Other|Manuka Honey|Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
80014542|NCT02084862|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
80014543|NCT02084862|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
80014544|NCT03240601|Device|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
79388515|NCT06240806|Other|Saline mouthwash|Saline mouthwash will be used 3 times per day for one month
79544443|NCT06015490|Other|Conditioned Stimulus: High Fructose Corn Syrup (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of high fructose corn syrup in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79388516|NCT06240793|Procedure|unilateral transforaminal epidural steroid block|unilateral transforaminal epidural steroid block
79388517|NCT06240793|Procedure|bilateral transforaminal epidural steroid block|bilateral transforaminal epidural steroid block
79249913|NCT05870618|Biological|vaccinate with DTap|vaccinate with DTap
79249914|NCT05870618|Biological|vaccinate with DT|vaccinate with DT
79249918|NCT05870501|Drug|Ketamine|0.5mg/kg IV infusion
79249919|NCT05870501|Drug|Midazolam|0.045mg/kg IV infusion
79249920|NCT05870475|Drug|Ruxolitinib|Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
79388518|NCT06240780|Other|Activated Incrediwear Products|Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation.
79388519|NCT06240780|Other|Sham Incrediwear Products|Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
79388520|NCT06240767|Biological|Granulocyte infusion|The number of single granulocytes per infusion was 2.0-5.0×10^10, with an interval of 2±1 day and 5 continuous infusions.
79388521|NCT06240754|Drug|Enasidenib|Provided by BMS.
79388522|NCT06240741|Drug|[68Ga]Ga-DOTA-TATE|Single intravenous injection of [68Ga]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
79388523|NCT06240741|Drug|68Ge/68Ga Generator|Radionuclide generator
79388524|NCT06240715|Procedure|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
79388525|NCT06240689|Drug|Sintilimab|Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
79388526|NCT06240689|Drug|Placebo|Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
79710149|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
79710150|NCT01342094|Drug|DE-111 ophthalmic solution|
79846222|NCT00621842|Drug|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
79846223|NCT05356143|Drug|Rupatadine|Oral single dose 10 mg tablet
79846224|NCT01013428|Other|Ultrasound|Ultrasound will be used to evaluate tendons.
79846225|NCT04849455|Drug|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
79391679|NCT02416986|Behavioral|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
79249921|NCT05870475|Drug|Pegylated interferon α-2b|Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
79249922|NCT05870449|Device|tunneled PICC|Tunneled PICC is a type of PICC catheterization technique that involves establishing a subcutaneous tunnel to keep the outlet of the catheter away from the puncture site
79249923|NCT05870449|Device|routine PICC|Peripherally inserted central venous catheterization is a technique that involves inserting PICC through the peripheral vein and infusing drugs into the central vein through a catheter.
79710151|NCT01342094|Drug|Timolol ophthalmic solution 0.5%|
79710152|NCT01342094|Drug|Placebo ophthalmic solution|
79846226|NCT04849455|Drug|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
79846227|NCT04849455|Drug|Spinal Morphine|200-300 mcg of spinal morphine
79846228|NCT02545010|Drug|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
79846229|NCT02545010|Radiation|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
79710153|NCT01340768|Drug|Sitagliptin|One 100 mg tablet taken orally once daily
79710154|NCT01340768|Drug|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
79710155|NCT01340768|Drug|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
79710156|NCT01340651|Drug|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
79710157|NCT04423016|Device|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
79710158|NCT04423016|Device|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
79710159|NCT01340495|Radiation|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
79710160|NCT01340300|Behavioral|Exercise training|Two supervised exercise sessions per week
79710161|NCT01340300|Drug|Metformin|Oral metformin QD for two weeks, then BID
79710162|NCT01340300|Other|Educational information|educational information
79710163|NCT01340066|Drug|UISH001|sublingual dosing, 1 drop 3 times a day
79710164|NCT01340066|Drug|matching placebo|sublingual dosing,1 drop 3 times a day
79710165|NCT02893904|Device|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
79710166|NCT02893904|Device|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
79710167|NCT04397627|Procedure|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
79705000|NCT05654363|Procedure|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
79705001|NCT05653401|Drug|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
79705002|NCT05653401|Drug|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
79705003|NCT05653401|Drug|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
79705004|NCT05648162|Device|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily
79705005|NCT05648162|Device|Acupuncture|Electrical acupuncture (no electricity) once daily
79846230|NCT05356065|Other|survey administration|Outcome Measures
79846231|NCT01013506|Drug|IGF-1R inhibitor OSI-906|Given orally
79846232|NCT01013506|Drug|erlotinib hydrochloride|Given orally
79846233|NCT01013506|Drug|goserelin|Given subcutaneously
79846234|NCT01013506|Drug|letrozole|Given orally
80014545|NCT03135080|Other|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
80014546|NCT03135080|Other|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
80014547|NCT02091180|Drug|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
79388527|NCT06240676|Behavioral|AWARENESS-BASED COGNITIVE THERAPY|A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
79388528|NCT06240663|Behavioral|Exercise|Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
79846235|NCT00855452|Procedure|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
79846236|NCT00844688|Drug|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease.~The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs.~Withdrawal of consent for any reason."
79388529|NCT06240650|Device|modified Health- Dx™ (mHDx) study capsule|The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.
79705006|NCT05648162|Device|tDCS|tDCS (1mA) once daily
79705007|NCT05648162|Device|sham tDCS|tDCS (no electricity) once daily
79705008|NCT05645276|Drug|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
79705009|NCT05634538|Device|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
79705010|NCT05634538|Procedure|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
79846237|NCT00844688|Drug|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 & 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
79544444|NCT06015490|Other|Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)|Participants will consume flavored beverage solutions containing a non-nutritive sweetener and 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79705011|NCT05630404|Drug|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
79705012|NCT05630404|Drug|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
79705013|NCT05621161|Drug|Postoperative analgesia management|Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
79705014|NCT05620849|Behavioral|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
79705015|NCT05619653|Drug|Prednisolone|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
79705016|NCT05619653|Drug|Losartan|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
79705017|NCT05615701|Diagnostic Test|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
79710168|NCT04309825|Procedure|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
79710169|NCT05010850|Device|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
79710170|NCT05010850|Procedure|Stoma Creation|Protective ileostomy
79388530|NCT06240650|Device|modified Health- Dx™ (mHDx) control capsule|The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
79544445|NCT06000254|Device|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
79710171|NCT05010655|Device|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
80014548|NCT02091180|Drug|Control|Saline infusion
80014549|NCT03949738|Diagnostic Test|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
80014550|NCT03134924|Behavioral|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
80014551|NCT03134924|Behavioral|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
79544446|NCT06000254|Other|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
79544447|NCT06000254|Device|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
79388531|NCT06240637|Other|Telemonitoring|A networked platform that enables the telemonitoring of both compliance data and the patient's ventilatory pattern, allowing the assessment of flow/pressure curves as well as leaks or events related to the upper airway.
79388532|NCT06240624|Other|No intervention|No intervention will be given.
79388533|NCT06240585|Other|presence of gastroparesis as an early sign for sepsis (bacteremia)- measurement of gastric residual volume|presence of gastroparesis as an early sign for sepsis (bacteremia)-measurement of gastric residual volume
80014552|NCT02084940|Drug|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
80014553|NCT05755321|Other|Skin biopsy|Skin biopsy performed during surgery.
80014554|NCT02269748|Procedure|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
79249924|NCT05870436|Diagnostic Test|Methacholine Choline Provocation Test|Perform methacholine choline provocation test according to the protocol
79705018|NCT05614882|Behavioral|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
80014555|NCT02269748|Procedure|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
80014556|NCT02269748|Drug|Analgesic Therapy|Ibuprofen 600 mg TID
80014557|NCT02269826|Device|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
80014558|NCT02269826|Device|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
80014559|NCT02269904|Drug|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
79249925|NCT05870423|Drug|olaparib|18 days olaparib during each cycle of PRRT
80014560|NCT02269904|Drug|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
80014561|NCT04540198|Behavioral|GamePlan4Care|GamePlan4Care; Experimental
79249926|NCT05870397|Diagnostic Test|HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times|Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
79249927|NCT05870371|Behavioral|Feldenkrais Awareness Through Movement technique|10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique
79388534|NCT06240572|Other|no intervention|no intervention
79388535|NCT06240546|Drug|LPM6690176|Administered orally
79388536|NCT06240520|Drug|Panobinostat 20 MG Oral Capsule|Panobinostat 20mg will be administered once orally
80014562|NCT04540198|Behavioral|Resources4Care|R4C; Active Comparator
80014563|NCT03557112|Drug|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
80014564|NCT03557112|Drug|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
80014565|NCT01300208|Drug|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
79388537|NCT06240520|Drug|Pyrimethamine 200mg Oral Tablet|Pyrimethamine 200mg will be administered once orally
80014566|NCT01300208|Other|Placebo|
80014567|NCT02085018|Drug|Omeprazole|Drug
80014568|NCT02085018|Drug|Matched placebo|Matched placebo
80014569|NCT05091814|Radiation|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
80014570|NCT02091336|Drug|Metformin|patients treatment
80014571|NCT02091336|Drug|Glyburide|patients treatment
79249928|NCT05870371|Behavioral|Acupuncture|10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.
79249929|NCT05870371|Behavioral|Stretching|10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
79249930|NCT05870358|Drug|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
79249931|NCT05870332|Device|GI Genius (GIG)|"GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG"
79388538|NCT06240520|Drug|Lenalidomide 25 MG Oral Capsule|Lenalidomide 25mg will be administered once orally
79388539|NCT06240507|Procedure|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
79249932|NCT05870306|Procedure|pulmonary vein isolation and targeted radiofrequency ablation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins. Extra radiofrequency ablation will be performed on the targeted areas
79249933|NCT05870306|Procedure|pulmonary vein isolation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins.
79705019|NCT05614882|Behavioral|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
79544448|NCT05999214|Diagnostic Test|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
79705020|NCT05611073|Diagnostic Test|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
79705021|NCT05611073|Diagnostic Test|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
79705022|NCT05611073|Other|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
79705023|NCT05610657|Drug|Mitapivat|Mitapivat tablets
79705024|NCT05607537|Drug|E7386 Tablet|E7386 40 mg tablet.
79705025|NCT05607537|Drug|(14C)E7386 Capsule|(14C)E7386 40 mg capsule.
80014572|NCT03805204|Procedure|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
80014573|NCT01442090|Drug|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
80014574|NCT01442090|Drug|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
79388540|NCT06240507|Procedure|fluoroscopy-guided intralesional radiofrequency thermocoagulation|The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
79705026|NCT05607537|Drug|(14C)E7386|(14C)E7386 administered intravenously.
79846238|NCT04541680|Drug|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
79705027|NCT05602506|Drug|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
79705028|NCT05600114|Drug|Cannabidiol oral solution|CBD 150 mg BID
79846239|NCT04541680|Other|Placebo|Placebo
79846240|NCT00855530|Drug|amibegron (SR58611A)|oral administration of 300 mg twice daily
79846241|NCT03883191|Other|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
79249934|NCT05870163|Device|RefluxStop implantation|Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
79249935|NCT05870163|Procedure|Nissen fundoplication|Standard of care Nissen fundoplication surgery
79249936|NCT05870137|Device|HoloLens2TM|Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).
79544449|NCT05990751|Biological|GD2 CAR T cells|The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.
79544450|NCT05990075|Behavioral|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
79544451|NCT05968638|Other|Regular Diet|Regular Diet
79544452|NCT05968638|Other|Ketogenic Diet|Ketogenic Diet
79705029|NCT05600114|Drug|Cannabidiol oral solution|CBD 300 mg BID
79705030|NCT05600114|Drug|Placebo|Placebo BID
79705031|NCT05599841|Procedure|PI solution|3,000 cc of <2% concentrated povidone iodine solution will be used as irrigation solution at primary hip/knee arthroplasty. The PI solution was left in the joint for 3 minutes.
79705032|NCT05599841|Procedure|Saline Solution|3,000 cc of 0.9% saline solution will be used as irrigation solution at primary hip/knee arthroplasty. The saline solution was left in the joint for 3
79705033|NCT05599139|Behavioral|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake < 50 mcg per day and thereby depleting the overall iodine store in the body.
80014575|NCT02085096|Behavioral|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
80014576|NCT04475042|Drug|Dapagliflozin|10mg od
80014577|NCT04475042|Drug|Placebo|Placebo
79705034|NCT05595434|Procedure|Acute Maastricht Stress Test (MAST), active condition.|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
79705035|NCT05595434|Procedure|Acute Maastricht Stress Test (MAST), placebo condition|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
79705036|NCT05593276|Behavioral|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
79705037|NCT05589220|Other|Music Intervention|Music therapy carried out with MUSIC CARE©
79705038|NCT05589220|Drug|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
79705039|NCT05588960|Device|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
79249937|NCT05870137|Other|Standard care|The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
79249938|NCT05870111|Drug|Citicoline (cytidine diphosphate-choline)|2000mg/day citicoline, administered orally, for 4 weeks
79544453|NCT05954949|Procedure|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
79249939|NCT05870111|Drug|Placebo oral capsule|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
79249940|NCT05870085|Behavioral|Neuro-linguistic program|"Intervention: Neuro-linguistic program developed by three specialists (a clinical psychologist, a social worker, and one education specialist).~4 (45 minutes) sessions for teachers, and 2 for children (total of 6 sessions)"
79544454|NCT05935618|Behavioral|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
79544455|NCT05930587|Other|Cold water immersion|Cold water immersion (15 degree celsius, 20 minutes)
79544456|NCT05905094|Other|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
79544457|NCT05891262|Drug|BMS-986196|Specified dose on specified days
79544458|NCT05891262|Drug|Loestrin|Specified dose on specified days
79705040|NCT05588960|Device|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
79846242|NCT03883191|Other|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
79846243|NCT00855608|Drug|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
79846244|NCT00851864|Drug|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
79544459|NCT05888454|Other|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
79544460|NCT05888454|Other|Conventional treatment for T2DM|Conventional medical treatment for T2DM
79705041|NCT05581186|Other|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
79846245|NCT00851942|Drug|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
79846246|NCT04190186|Device|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
79846247|NCT02545790|Procedure|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
79846248|NCT02545790|Biological|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
80014578|NCT02088450|Drug|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
80014579|NCT03688828|Drug|Saccharomyces boulardii|500mg bid
80014580|NCT03688828|Drug|Esomeprazole|20mg bid
79705042|NCT05581186|Other|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
79705043|NCT05581186|Other|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
79249941|NCT05870072|Other|Dual task training|In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.
79544461|NCT05878587|Other|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
79705044|NCT05580679|Other|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
79705045|NCT05579704|Behavioral|My Viva Plan (www.myvivaplan.com)|A web-based platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.
79705046|NCT05579704|Behavioral|Online support group with health professionals|Participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, psychologist, and exercise specialist). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
79705047|NCT05569811|Drug|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
79705048|NCT05569811|Drug|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
79705049|NCT05569811|Drug|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
79705050|NCT05566899|Procedure|esophagogastroduodenoscopy (EGD)|"After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC"
79705051|NCT05560789|Behavioral|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
79705052|NCT05556876|Dietary Supplement|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
79846249|NCT00503776|Behavioral|exercise intervention|Patients undergo low weight resistance training.
79846250|NCT00503776|Drug|amifostine trihydrate|Given subcutaneously
80014581|NCT03688828|Drug|Amoxicillin|1.0g bid
80014582|NCT03688828|Drug|Clarithromycin|0.5g bid
79544462|NCT05878587|Other|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
79544463|NCT05877469|Other|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
79846251|NCT00503776|Procedure|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
79846252|NCT00852020|Dietary Supplement|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
79846253|NCT04002531|Other|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
79846254|NCT04002531|Other|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
79846255|NCT04002531|Procedure|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
79846256|NCT04002531|Procedure|Echocardiogram|A non-invasive sonogram of the heart
80014583|NCT03688828|Drug|Bismuth potassium citrate|0.22g bid
79705053|NCT05546528|Device|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
79705054|NCT05546528|Device|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
79846257|NCT04002531|Procedure|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
79249942|NCT05870072|Other|Kinesthetic motor imagery training|Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.
79249943|NCT05870072|Other|Balance exercises|Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
79544464|NCT05877469|Other|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
79544465|NCT05877183|Device|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
79705055|NCT05539326|Other|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
79705056|NCT05538962|Diagnostic Test|Sensor skin|Skin sensor to detect inflammatory molecules in sweat
79705057|NCT05525546|Biological|Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation|One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
79846258|NCT04002531|Procedure|Urine collection|Urine will be collection to evaluate renal function (kidney health)
79846259|NCT04002531|Procedure|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
79846260|NCT04002531|Other|Brief Pain Inventory questionnaire|A questionnaire about daily pain
79846261|NCT04002531|Other|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
79846262|NCT02545634|Dietary Supplement|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
79846263|NCT02545634|Other|Placebo|
79846264|NCT00852098|Procedure|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
79846265|NCT00852098|Procedure|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
79846266|NCT05356689|Other|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
79846267|NCT00855686|Drug|Memantine|20mg once daily oral dose
79846268|NCT00855686|Drug|Placebo|Daily oral dose
79846269|NCT04041908|Other|Experimental Product|2 sachets per day
79846270|NCT04001283|Drug|Sodium Nitrite|Intravenous drug infusion
79846271|NCT04001283|Drug|0.9% Sodium-chloride|Matched placebo
79846272|NCT02546414|Other|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
80014584|NCT03960476|Behavioral|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
80014585|NCT02091492|Drug|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
79705058|NCT05525546|Biological|Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation|One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
79705059|NCT05525546|Biological|Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation|One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
79846273|NCT00991965|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
79846274|NCT00844922|Drug|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
79846275|NCT00844922|Drug|Placebo|Placebo
79249944|NCT05870059|Drug|Propolis mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
79249945|NCT05870059|Drug|Chlorhexidine mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
79249946|NCT05870020|Other|Questionnaire (DBS-QoLs)|"The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~the inclusion~15 days after the inclusion~1 year after the inclusion"
79249947|NCT05870007|Drug|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg
79249948|NCT05870007|Drug|Sodium Bicarbonate 600 Mg Oral Tablet|Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
79249949|NCT05869253|Behavioral|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
79249950|NCT05868460|Device|High intensity laser|patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
79249951|NCT05868460|Other|traditional physical therapy exercise program|passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
79249952|NCT05868460|Device|placebo High intensity laser|patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
79249953|NCT05866653|Drug|lidocaine transdermal patch|The topical pain-relieving treatment 5% lidocaine transdermal patch has been registered in the USA since 1999
79249954|NCT05861804|Procedure|Rhomboid Intercostal Nerve Block|Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
79544466|NCT05877183|Device|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
79544467|NCT05874570|Drug|Esomeprazole|Proton pump inhibitor
79544468|NCT05874570|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
79544469|NCT05874570|Drug|Tetracycline|Antibiotics for H. pylori eradication
79544470|NCT05874570|Drug|Doxycycline|Antibiotics for H. pylori eradication
79544471|NCT05874570|Drug|Metronidazole|Antibiotics for H. pylori eradication
79544472|NCT05874531|Diagnostic Test|End-expiratory occlusion test|15 seconds end-expiratory occlusion
79705060|NCT05525546|Other|Placebo|One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
79705061|NCT05525247|Drug|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
79705062|NCT05525247|Combination Product|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
79705063|NCT05521321|Behavioral|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
79705064|NCT05520814|Drug|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg * q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
79544473|NCT05854316|Diagnostic Test|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
79544474|NCT05853081|Diagnostic Test|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
79705065|NCT05520814|Radiation|chemoradiotherapy|"Chemotherapy：~GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~* Treatment courses every 3 weeks~Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min * Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
79705066|NCT05518045|Drug|LM-108|Administered intravenously
79705067|NCT05518045|Drug|Toripalimab|Administered intravenously
79705068|NCT05516329|Drug|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60~120 min after the injection.
79846276|NCT04534335|Device|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
79846277|NCT00619112|Drug|temozolomide|single arm study
79846278|NCT00845156|Dietary Supplement|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
79544475|NCT05848076|Other|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
79846279|NCT04001985|Other|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
79544476|NCT05848076|Other|core stability|McGill exercises for the low back.
79544477|NCT05840276|Device|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
80014586|NCT02091492|Drug|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
80014587|NCT02266940|Drug|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
80014588|NCT02266940|Drug|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
80014589|NCT04011358|Other|Sleeping Monitor|to evaluate obstructive sleep apnea
79544478|NCT05840276|Other|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
80014590|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
80014591|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
80014592|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
79705069|NCT05515796|Drug|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
79705070|NCT05515796|Drug|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
79705071|NCT05515796|Drug|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
79705072|NCT05515796|Radiation|Radiotherapy|25 Gy/5 fractions
79705073|NCT05515783|Drug|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
79705074|NCT05515783|Drug|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
79705075|NCT05514366|Procedure|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
79710172|NCT01107535|Biological|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
79710173|NCT02881294|Drug|SUVN-G3031|
80014593|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
79705076|NCT05514366|Procedure|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) < 97% is detected."
79544479|NCT05834114|Other|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
79705077|NCT05514366|Procedure|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs > 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is >10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
79705078|NCT05513846|Device|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
79705079|NCT05513846|Device|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
79846280|NCT04001985|Other|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
79846281|NCT00856154|Biological|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~Gag150 RLLNAWVKV~Gag433 FLGKIWPV~Env 67 NIWATHACV~Pol606 KLGKAGYVV~Vpu66 ALVEMGHHV~Vif101 GLADQLIHL~Vif23 SLVKHHMYV~Gag298 KRWIILGLNKIVRMY~gp41 VWGIKQLQARVLAVERYLKD~Padre AKXVAAWTLKAAA"
79705080|NCT05513209|Procedure|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
79705081|NCT05513209|Procedure|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
79705082|NCT05511610|Procedure|Sevoflurane uptake and supply|"Phase sevo 1)~Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels >> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels>> increase SEVOdel by 0.25-0.5%."
79705083|NCT05511610|Procedure|Washout phase|The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2>5>10 liters per minute (LPM), until the etSEVO% is <0.2 MAC.
79710174|NCT02881216|Device|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
79846282|NCT00852332|Dietary Supplement|Curcumin|
79846283|NCT00852332|Drug|Taxotere|
80014594|NCT03981952|Other|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
80014595|NCT02269982|Device|AR-v7 assays|
80014596|NCT02091570|Other|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
79249955|NCT05861700|Other|Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L|A change Dbic in a middle of hemodialysis
79249956|NCT05861700|Other|Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L|A change Dbic in a middle of hemodialysis
79391680|NCT02416986|Behavioral|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
79705084|NCT05511610|Procedure|Desflurane uptake and supply|"Phase desflu 1)~Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels >> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels>> increase DESFLUdel by 0.25-0.5%."
79846284|NCT00992043|Dietary Supplement|creatine|
79846285|NCT00992043|Other|Exercise training|
80014597|NCT03838120|Other|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
80014598|NCT02091648|Behavioral|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
79388541|NCT06240494|Procedure|Maxillary nerve and mandibular nerve pulsed radiofrequency|"For maxillary nerve pulsed radiofrequency, the lineer transducer is placed distal and parallel to the zygomatic arch, bridging the coronoid and condylar processes and a 22 gauge 6 mm RF cannula was inserted into the target area. With sensory stimulation, patients experienced a distinct sensation in upper jaw, teeth, and palate. Then, PRF treatment was performed at 42 °C for 240 seconds.~For mandibular nerve pulsed radiofrequency, the transducer was placed distally and parallel to the zygomatic arch, bridging the coronoid and condylar processes. The pterygopalatine fossa was visualized and the needle was inserted to target area. With sensory stimulation, patients experienced a distinct sensation in the lower jaw and teeth. With motor stimulation, a throwing movement of the jaw was observed with contraction of the masseter and temporal muscles. PRF treatment was performed at 42 °C for 240 s."
79249957|NCT05859867|Other|Promotion of Healthy Nutrition and Physical Activity|Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
79249958|NCT05857176|Other|COVID-19 Vaccine questionnaire|An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).
79388542|NCT06240481|Drug|Test Regimen|toothpaste & mouthwash
79388543|NCT06240481|Drug|Control Regimen|toothpaste
79388544|NCT06240468|Other|not have|not have
79388545|NCT06240442|Other|Fasted exercise|Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
79388546|NCT06240442|Other|Fed exercise|Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
79388547|NCT06240429|Dietary Supplement|Collagen|Daily doses of 10 g collagen peptide supplementation
79544480|NCT05834114|Other|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
79544481|NCT05824650|Other|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
79544482|NCT05811260|Other|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
79544483|NCT05811260|Other|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
79544484|NCT05808608|Drug|AK104|Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
79544485|NCT05808608|Drug|Axitinib|An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
79388548|NCT06240416|Procedure|Low speed drilling without irrigation|Low-speed drilling (50 rpm) irrigation to perform the osteotomy
79388549|NCT06240416|Procedure|High speed drilling with irrigation|High-speed drilling (800 rpm) irrigation to perform the osteotomy
79388550|NCT06240403|Drug|Digoxin 0.125 MG|One capsule containing digoxin per day for three months
79391681|NCT02405988|Drug|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
79705085|NCT05511610|Procedure|Final phase|"From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% < 0.2 MAC."
79705086|NCT05511584|Procedure|VO2 estimation|"st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) * minute volume (Volmin)~nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
79544486|NCT05803200|Drug|No intervention|No intervention was given as this is an observational study.
79388551|NCT06240390|Device|Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
79388552|NCT06240390|Drug|pharmacological treatment by Opioids|Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
79544487|NCT05790031|Device|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
79544488|NCT05782309|Drug|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
79544489|NCT05782309|Drug|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
79544490|NCT05781321|Radiation|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
80014599|NCT02091648|Behavioral|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
79544491|NCT05781321|Procedure|Computed Tomography|Undergo CT simulation
79544492|NCT05781321|Drug|Fluorodopa F 18|Given IV
79705087|NCT05511584|Procedure|SEVOup estimation|"st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) * Volmin~nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
79705088|NCT05510531|Behavioral|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
79705089|NCT05509569|Drug|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
79705090|NCT05506605|Drug|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
79705091|NCT05506566|Drug|68Ga-FAP-CHX|The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
79544493|NCT05781321|Procedure|Magnetic Resonance Imaging|Undergo MRI
79544494|NCT05781321|Procedure|Positron Emission Tomography|Undergo PET
79544495|NCT05781321|Other|Quality-of-Life Assessment|Ancillary studies
79705092|NCT05506566|Drug|68Ga-FAP-CHX|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
79705093|NCT05505825|Drug|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
79705094|NCT05503732|Other|Energy Drink|Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
79705095|NCT05503732|Other|Placebo Drink|Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
79544496|NCT05781321|Other|Questionnaire Administration|Complete questionnaires
79544497|NCT05781321|Radiation|Radiation Therapy|Undergo standard course RT
79544498|NCT05781321|Drug|Temozolomide|Given PO
79544499|NCT05781243|Drug|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
79544500|NCT05781243|Drug|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
80014600|NCT04475120|Drug|liposomal lactoferrin|oral and intra-nasal formulation
80014601|NCT04475120|Drug|SOC therapy|oral administration
80014602|NCT03821038|Biological|CYT107|IV twice a week at 10µg/kg for 3 weeks
80014603|NCT03821038|Drug|Placebos|IV twice a week at the same volume for 3 weeks
80014604|NCT02208024|Radiation|Stereotactic Body Radiation Therapy|
79249959|NCT05852015|Behavioral|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy for substance use disorder
79249960|NCT05852015|Behavioral|Digital Mindfulness Treatment|The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
79705096|NCT05500482|Biological|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
79544501|NCT05774509|Biological|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
80014605|NCT03664804|Other|No Study Drug was Administered in this Study|No study drug was administered in this study
79544502|NCT05768035|Biological|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
79249961|NCT05851664|Device|intubation by direct laryngoscopy|intubation using a direct laryngoscopy type macintosh
79249962|NCT05851664|Device|Intubation by videolaryngoscopy|Intubation using a videolaryngoscope type McGrath
79249963|NCT05848856|Behavioral|Cancer Risk Screening and Follow up|Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement
79249964|NCT05845879|Other|delivery|delivery
79249965|NCT05842252|Procedure|greater trochanter transfer, subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
79249966|NCT05841628|Device|532 nm laser treatment|The port wine birthmark will be treated with the DermaV 532 nm laser.
79249967|NCT05840484|Other|Active Surveillance|Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.
79249968|NCT05820828|Diagnostic Test|Volume control|Volume control in venous reservoir during extracorporeal circulation.
79388553|NCT06240377|Device|Transcranial direct current stimulation (tDCS)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
79388554|NCT06240377|Device|Ultrasound-guided percutaneous neuromodulation (NMP)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
79544503|NCT05739890|Other|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
79544504|NCT05739890|Other|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
79544505|NCT05735847|Procedure|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
79544506|NCT05735847|Procedure|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
79705097|NCT05500170|Dietary Supplement|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
79705098|NCT05500170|Dietary Supplement|Placebo|The placebo pill will contain micro cellulose powder.
79249969|NCT05816460|Other|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be delivered through an online platform called Sleepio (BigHealth Ltd)
79249970|NCT05816460|Other|Sleep Hygiene Education (SHE)|Sleep Hygiene Education (SHE) will be provided electronically
79249971|NCT05805176|Device|ADHD Therapy|investigational game-play therapy
79249972|NCT05802030|Other|Plyometric training|Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
79249973|NCT05802030|Other|Routine training|Regular tennis training, including normal fitness training, and injury prevention drills
79249974|NCT05790577|Drug|Metformin and Nicotinamide vs Kligman Formula|Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
79705099|NCT05499390|Drug|AK112|Subjects receive AK112 intravenously.
79705100|NCT05499390|Drug|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
79705101|NCT05497908|Procedure|TAP block via lateral approach|TAP block via lateral approach
79705102|NCT05497908|Procedure|TAP block via posterior approach|TAP block via posterior approach
79705103|NCT05492773|Device|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
79705104|NCT05492773|Device|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
79705105|NCT05492162|Other|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~Well-being (Workshops)~Smoking prevention (Conference)~Balanced diet (Workshop)~Optimal organization for daily healthy living (Conference)"
79705106|NCT05490615|Behavioral|Virtual Mindfulness|Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
79705107|NCT05486559|Other|ECMO-free protocol|"All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial)."
79705108|NCT05486559|Other|Usual Care|All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
79705109|NCT05486520|Device|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
79705110|NCT05477186|Biological|CV0501 (3 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705111|NCT05477186|Biological|CV0501 (6 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705112|NCT05477186|Biological|CV0501 (12 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705113|NCT05477186|Biological|CV0501 (25 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705114|NCT05477186|Biological|CV0501 (50 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705115|NCT05477186|Biological|CV0501 (75 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705116|NCT05477186|Biological|CV0501 (100 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705117|NCT05477186|Biological|CV0501 (150 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705118|NCT05477186|Biological|CV0501 (200 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
79705119|NCT05464147|Device|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
79705120|NCT05463263|Drug|STP938|Small molecule
79705121|NCT05462951|Radiation|Standard|Radiation then brachytherapy
80014606|NCT01155362|Biological|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
79544507|NCT05729984|Behavioral|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
79388555|NCT06240364|Dietary Supplement|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
80014607|NCT01155362|Drug|Vehice Control|
79544508|NCT05729984|Behavioral|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
79249975|NCT05778838|Drug|Midodrine Oral Tablet|Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
79388556|NCT06240364|Dietary Supplement|Placebo|Daily intake of one tablet for 84 days.
79391682|NCT02405988|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
79391683|NCT02539654|Drug|EXE844 Sterile Otic Suspension, 0.3%|
79391684|NCT02539654|Procedure|Tympanostomy Tube Insertion|
79391685|NCT02402010|Behavioral|Adjunctive Yoga|
79391686|NCT02402010|Behavioral|Enhanced Treatment as Usual|
79391687|NCT04482348|Other|Explanation|Explanation provided to patients for more pain than expected
79544509|NCT05700396|Behavioral|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
79544510|NCT05695131|Device|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
79544511|NCT05694741|Drug|AZD0186|Subjects will receive AZD0186 orally.
79544512|NCT05694741|Drug|Placebo|Subjects will receive placebo orally.
79544513|NCT05675709|Behavioral|Training and Education|Undergo group and online trainings
79544514|NCT05672121|Drug|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
79249976|NCT05771701|Device|Pain pressure threshold measurement|"Pain pressure threshold (PPT) is used to measure deep muscular tissue sensitivity. The test determines the amount of pressure over a given area in which a steadily increasing nonpainful pressure stimulus turns into a painful pressure sensation. A varying pressure is applied from 0.5 to 1 kg/sec in a perpendicular direction relative to the muscle. PPT has no standard protocol on administration and placement. Equipment used varies with many handheld electric algometers.~PPT has been used on a wide variety of patients and conditions, including musculoskeletal and neuromuscular disorders (eg, Parkinson disease, tension headaches, pelvic pain, low back pain, myofascial trigger points, sacroiliac joint pain, knee osteoarthritis, skin humidity, shoulder pain, lateral epicondylitis)."
79249977|NCT05769413|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
79705122|NCT05454891|Drug|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
79705123|NCT05454891|Drug|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
79705124|NCT05452564|Drug|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
79705125|NCT05452564|Drug|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
79705126|NCT05448274|Biological|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
79705127|NCT05448274|Biological|Ruminococcus torques|10^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
79846286|NCT00845234|Behavioral|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
79249978|NCT05769400|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
79388557|NCT06240325|Behavioral|SPP|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
79705128|NCT05447091|Behavioral|LOH game- high dose|Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
79249979|NCT05768737|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
79705129|NCT05447091|Behavioral|LOH game- low dose|Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
79705130|NCT05447091|Behavioral|LOH sham game|Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
79249980|NCT05763615|Other|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
79249981|NCT05760248|Drug|10XB-101 Solution for Injection, 6.0%|The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
79705131|NCT05445167|Drug|KLH-2109|Oral administration
79705132|NCT05445167|Drug|Placebo|Oral administration
79705133|NCT05443945|Device|Nasal Spray|3 sprays in each nostril 3 times per day
79846287|NCT00852410|Drug|1% lidocaine with 1:100,000 adrenaline|high dose
79846288|NCT00852410|Drug|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
79846289|NCT00992121|Drug|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
79249982|NCT05760248|Drug|Placebo Solution for Injection (no active ingredient)|Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
79846290|NCT00992121|Drug|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
79705134|NCT05440383|Drug|KLH-2109|Oral administration
79705135|NCT05440383|Drug|Leuprorelin|Subcutaneous administration
79846291|NCT00992121|Drug|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
79846292|NCT00852488|Procedure|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
79388558|NCT06240325|Behavioral|Sleep Psychoeducation|Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
79846293|NCT04002609|Other|oxygen|oxygen supplementation during brronchoscopy
79705136|NCT05434689|Drug|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
79705137|NCT05434689|Drug|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
79705138|NCT05434689|Drug|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
79249986|NCT05757544|Drug|IV Ganaxolone|IV Ganaxolone will be administered.
79249987|NCT05757544|Drug|IV Placebo|IV Placebo will be administered
79705139|NCT05434689|Drug|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
79249988|NCT05748392|Device|Wound and per-wound assessments While using Device|3D imaging and wound and per-wound skin characteristics will be conducted initially, at dressing changes and at end of treatment/study.
79388559|NCT06240312|Device|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
79388560|NCT06240286|Behavioral|Sitting workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
79705140|NCT05432297|Behavioral|Preventive physical exercise|Daily physical activity depending on daily condition
79249989|NCT05740943|Drug|Lorlatinib|Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
79705141|NCT05431920|Dietary Supplement|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
79705142|NCT05431920|Dietary Supplement|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
79705143|NCT05431478|Device|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
79705144|NCT05431478|Device|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
79249990|NCT05738785|Other|Document review and scanning|Osteoporosis risk and osteoporotic fracture risk will be calculated by examining the patients' files.
79249991|NCT05732220|Behavioral|EMA assessment|Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
79388561|NCT06240286|Behavioral|Standing workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
79388562|NCT06240286|Behavioral|Stepping workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
79388563|NCT06240286|Behavioral|Walking workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
79388564|NCT06240273|Dietary Supplement|Corn silk powder|Corn silk (CS) is abundant in phenolic compounds, especially flavonoids. It also contains proteins, vitamins, carbohydrates, calcium, potassium, magnesium, sodium salts, volatile oils, sterols like sitosterol and stigmasterol, alkaloids, and saponins. Numerous studies have explored the pharmacological activities associated with CS.
79391688|NCT02542150|Drug|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
79705145|NCT05431478|Device|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
79710175|NCT02881216|Device|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
79846294|NCT02545946|Device|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I&D
79846295|NCT02545946|Other|traditional I&D with or without packing|abscess will be drained with a traditional I&D with or without packing (as deemed appropriate by ER doctor)
79846296|NCT03131193|Other|Physician|Study primary health centers will be staffed with an additional physician
79846297|NCT03131193|Other|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
79846298|NCT03131193|Behavioral|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
79846299|NCT04420299|Drug|Bemiparin|Bemiparin at therapeutic dose for 10 days
79846300|NCT04420299|Drug|Bemiparin|Bemiparin at prophylactic dose for 10 days
79846301|NCT00619502|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
79846302|NCT00992199|Drug|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
79846303|NCT04041986|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
79846304|NCT00992277|Procedure|Ablation and skin resurfacing|
79846305|NCT00856310|Biological|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
79846306|NCT02773485|Radiation|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
79846307|NCT02773485|Drug|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
79846308|NCT04042220|Drug|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
79846309|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1%|
79846310|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
79846311|NCT02545556|Procedure|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
79846312|NCT04341909|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
79846313|NCT00852566|Drug|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
79249992|NCT05732220|Behavioral|EMA-based cessation counselling|Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.
79705146|NCT05428618|Other|e-BariS app group|"During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online."
79705147|NCT05428618|Other|Self-Monitoring Group|"Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients."
79705148|NCT05427890|Behavioral|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
79705149|NCT05427890|Behavioral|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
79544515|NCT05671887|Procedure|Double Lung Transplantation|To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
79705150|NCT05427890|Behavioral|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
79705151|NCT05427760|Drug|Oxygen|After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
79705152|NCT05421793|Other|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
79705153|NCT05420233|Diagnostic Test|MRE|Magnetic Resonance Enterography at year 1 (in some patients)
79705154|NCT05418244|Other|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
79705155|NCT05418244|Drug|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
79846314|NCT00852566|Drug|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
79846315|NCT00852722|Other|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
79846316|NCT00856622|Drug|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
79846317|NCT00856622|Drug|timolol 0.5% ophthalmic solution|one drop in the morning and evening
79846318|NCT00856622|Drug|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
79846319|NCT00856700|Drug|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
79249993|NCT05732220|Behavioral|Usual peer counselling|Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
79249994|NCT05715645|Procedure|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
79388565|NCT06240260|Device|TENS (transcutaneous electrical nerve stimulation) unit|"Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of a mild electrical current.~A TENS machine is a small, battery-operated device that has leads connected to sticky pads called electrodes."
79388566|NCT06240260|Other|Standard care|Paracervical block only or participant declines analgesia for IUD insertion
79388567|NCT06239987|Behavioral|Care-oriented Practical Training|The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
79544516|NCT05663112|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy will be performed.
79249995|NCT05715645|Procedure|Analgesia|Analgesic management by adductor canal block
79544517|NCT05663112|Procedure|Breast massage|Breast massage will be performed for a duration of 5 minutes.
79846320|NCT00618956|Drug|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.
79846321|NCT00618956|Drug|Placebo|Placebo
80014608|NCT03279718|Procedure|Periodontal Treatment|Scaling and root planing
79544518|NCT05663112|Procedure|Blue dye injection|Isosulfan blue dye will be injected in the subareolar region of the breast
79544519|NCT05661344|Drug|BI 1015550|BI 1015550
79544520|NCT05643183|Other|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
79705156|NCT05418244|Other|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
79705157|NCT05415670|Diagnostic Test|Whole-genome Methylation Sequencing(GM-seq)|A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
79705158|NCT05411991|Diagnostic Test|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
79705159|NCT05411991|Drug|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (>145 mmol/L) or metabolic acidosis (bicarbonate <22 mmol/L) is present at the moment of the scheduled administration.
79705160|NCT05411991|Drug|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR >45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR <30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), a dose of 4 mg TID is used.
79705161|NCT05411991|Drug|Oral chlorthalidone OD|In case of hypernatremia (>145 mmol/L) or low eGFR (<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration <135 mmol/L.
79705162|NCT05411991|Drug|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration <135 mmol/L or if serum potassium levels are >5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
79249996|NCT05709600|Dietary Supplement|Fasting mimicking diet|"Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.~The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet."
79249997|NCT05709600|Dietary Supplement|Ketogenic diet|"Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.~The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption"
79388568|NCT06239792|Behavioral|Sleep Promotion Program|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
79391689|NCT02542150|Drug|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
79544521|NCT05616949|Behavioral|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
79846322|NCT00852800|Drug|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
79846323|NCT00852800|Drug|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
79846324|NCT00845546|Drug|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
79846325|NCT00852878|Behavioral|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
79846326|NCT00852878|Behavioral|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
80014609|NCT02088528|Device|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
80014610|NCT02088528|Procedure|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
79388569|NCT06239766|Diagnostic Test|Breast Cancer Risk Assessment|Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
79388570|NCT06239571|Behavioral|Resilient Families (R-FAM)|Dyadic, resiliency intervention that aims to reduce depression, anxiety, and posttraumatic stress among parents of babies in the NICU
79705163|NCT05411991|Other|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are <4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration <130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
79544522|NCT05616949|Behavioral|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
79544523|NCT05603702|Drug|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
79544524|NCT05558865|Behavioral|somnovia|Participants receive access to the digital health application somnovia
79705164|NCT05411991|Drug|Oral potassium supplements|If serum potassium levels are <3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels >4 mmol/L
79705165|NCT05411991|Other|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration <125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
79705166|NCT05411991|Other|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa <80 mmol/L, intravenous diuretics are switched to an oral schedule including:~Loop diuretics with dose & frequency at the discretion of the treating physician~Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
80014611|NCT02272010|Other|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
79249998|NCT05709600|Dietary Supplement|Dietary restriction of sulfur containing amino acids|"Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.~A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption."
80014612|NCT02272010|Other|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
80014613|NCT02091804|Behavioral|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
80014614|NCT02091804|Behavioral|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
79249999|NCT05709600|Dietary Supplement|Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)|Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.
79388571|NCT06238921|Radiation|Stereotactic Radiation|Stereotactic Radiation to intact brain metastases or post-operative cavity.
79388572|NCT06238921|Drug|Zimberelimab|One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
79388573|NCT06238921|Drug|Sacituzumab govitecan|SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
79544525|NCT05548036|Device|OPEP|OPEP (Aerobika (tm)
79705167|NCT05411991|Other|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
79250000|NCT05688943|Drug|Spinal Anesthesia|Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.
79705168|NCT05411263|Diagnostic Test|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
79846327|NCT00852956|Drug|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
79250001|NCT05688943|Drug|General Anesthesia|General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out.
79250002|NCT05673915|Device|ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)|Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
79544526|NCT05546606|Device|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
79544527|NCT05526313|Drug|Prilinostat Mesylate 1.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
79705169|NCT05410951|Diagnostic Test|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
79705170|NCT05410860|Drug|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
79705171|NCT05410860|Drug|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
79705172|NCT05409612|Biological|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
79846328|NCT00853034|Dietary Supplement|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
79846329|NCT00853034|Dietary Supplement|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
79846330|NCT00716417|Drug|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
79846331|NCT00716417|Drug|BIBW 2992|low to high dose, daily
79846332|NCT02592863|Drug|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
79846333|NCT02592863|Drug|Placebo|Patients will take placebo 3 times per day for 12 weeks
79846334|NCT00719537|Drug|Aspirin|Aspirin 81 mg once a day
79846335|NCT00719537|Drug|Placebo Oral Tablet|Placebo 1 tab Daily
79846336|NCT00719537|Drug|Progesterone|Oral Progesterone 200 mg Twice Daily
79846337|NCT02591459|Other|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
79846338|NCT00853190|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
79250003|NCT05673915|Device|ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)|Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
79250004|NCT05663216|Other|Blood sampling|6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.
79250005|NCT05661539|Device|Transvaginal Ultrasonography|The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.
79250006|NCT05657561|Other|early mobilization|Mobilization training was given to the intervention group.
79544528|NCT05526313|Drug|Prilinostat Mesylate 2.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
79544529|NCT05526313|Drug|Prilinostat Mesylate 4.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
80014615|NCT03634150|Biological|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
80014616|NCT02085330|Device|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
79705173|NCT05409612|Biological|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
80014617|NCT01148498|Drug|solanezumab|400mg administered once intravenously
80014618|NCT05090956|Other|mri|
80014619|NCT02092038|Drug|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
80014620|NCT02092038|Radiation|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
79250007|NCT05648617|Dietary Supplement|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
79250008|NCT05638919|Drug|Oral Antiviral|Nirmatrelvir plus ritonavir or molnupiravir
79250009|NCT05637879|Drug|Glecaprevir/pibrentasvir|Direct-acting antiviral, Food & Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
79250010|NCT05637879|Other|Placebo|Compounded, inactive pill equal in appearance to active study drug
79846339|NCT00853190|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
79250011|NCT05634031|Radiation|PET imaging|PET imaging visit, which will take approximately 1-2 hours.
79250012|NCT05634031|Radiation|Coronary CT angiogram|A coronary CT angiogram if the participant has not had one recently.
79250013|NCT05634031|Procedure|Functional Angiography|"A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications."
79250014|NCT05634031|Procedure|Treadmill exercise stress study|A treadmill exercise stress study
79544530|NCT05526313|Drug|Prilinostat Mesylate 6.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
79544531|NCT05526313|Drug|Prilinostat Mesylate 8.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
79846340|NCT02591225|Drug|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
79846341|NCT02591225|Drug|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
79846342|NCT03962153|Diagnostic Test|Obstetric Ultrasonography|Obstetric Ultrasonography
80014621|NCT02092038|Procedure|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
79250015|NCT05631405|Drug|Dexamethasone|Patients treated with dexamethasone
79544532|NCT05526313|Drug|Prilinostat Mesylate 11.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
79544533|NCT05526313|Drug|Prilinostat Mesylate 15mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
79544534|NCT05515159|Other|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
79544535|NCT05513716|Other|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
80014622|NCT02092038|Procedure|craniotomy and tumor resection|maximal safe resection
80014623|NCT02272166|Drug|propofol|
80014624|NCT02272166|Drug|Sevoflurane|
80014625|NCT04438252|Diagnostic Test|ICDAS II|Index for caries detection
80014626|NCT04438252|Device|CariScan Pro|Device for early caries detection
80014627|NCT04438252|Radiation|Digital Radiograpgy|Device for digital x-ray imaging
80014628|NCT02085564|Procedure|Peritoneal washing cytology|The methode is describes in the detailed study description
80014629|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
80014630|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
80014631|NCT01139216|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
80014632|NCT03246568|Procedure|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
80014633|NCT03246568|Procedure|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
80014634|NCT01138436|Drug|MEBO Wound Ointment (MEBO)|Topical application once a day
80014635|NCT01138436|Procedure|Standard of Care|Application of Profore multilayer compression bandage system
80014636|NCT03115450|Device|Ultrasound|Type of imaging technology to look at organs and structures inside the body
80014637|NCT03115450|Device|Pupilometer|A device that measures pupil size and how it changes.
80014638|NCT02088684|Drug|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
80014639|NCT02088684|Drug|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
79705174|NCT05408507|Behavioral|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
79705175|NCT05407662|Other|sMRA therapies|No drug will be provided to participants. Patients follow routine clinical practice/administration.
79544536|NCT05509101|Other|commercially available control algorithm|Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.
79544537|NCT05509101|Other|experimental control algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
79705176|NCT05403385|Drug|inupadenant|Adenosine 2a receptor antagonist
79705177|NCT05403385|Drug|Placebo|matched placebo capsule to inupadenant
79705178|NCT05403385|Drug|Carboplatin|standard of care chemotherapeutic, alkylating agent
79705179|NCT05403385|Drug|Pemetrexed|standard of care chemotherapeutic, anti-metabolite
79846343|NCT04085003|Procedure|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
79846344|NCT02590679|Device|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
79544538|NCT05508854|Genetic|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
79544539|NCT05498883|Other|Score completion|completion of the SRI score
79846345|NCT05302895|Device|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
79544540|NCT05494593|Drug|ELAPRASE|Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
79250016|NCT05631405|Drug|Placebo|Patients treated with placebo
79250017|NCT05628207|Other|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
79846346|NCT04085939|Other|Online survey|Anonymous survey using the online survey tool, JotForm
79250018|NCT05628207|Other|Observational-control|There is no intervention, the hospitals will not use the CDS system.
79846347|NCT03951389|Other|Non-interventional|Non-interventional
79846348|NCT02590445|Device|deep brain stimulation system|
79250019|NCT05625477|Biological|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
79250020|NCT05625477|Biological|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
79250021|NCT05625477|Biological|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
79250022|NCT05625477|Biological|HTIG|Single dose of HTIG administered by intramuscular injection
79250023|NCT05625477|Biological|Placebo|Single dose of placebo administered by intramuscular injection
79388574|NCT06238362|Other|TPAP|Algorithm for modification of CPAP therapy where pressure is reduced during the inspiratory phase though much of the expiratory phase, then is returned to full pressure near the end of the expiratory phase. Note that the same device that delivers CPAP can also deliver TPAP
79388575|NCT06238362|Device|CPAP|Gold standard for treating sleep apnea.
79388576|NCT06238011|Drug|Dexmedetomidine|Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
79388577|NCT06238011|Drug|Normal saline|Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
79544541|NCT05494593|Drug|Rituximab|Participants will receive 375 milligram per square meter per dose (mg/m^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
79544542|NCT05494593|Drug|Methotrexate|Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
79544543|NCT05494593|Drug|Intravenous Immunoglobulin (IVIG)|Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
79544544|NCT05491356|Drug|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
79544545|NCT05491356|Drug|Placebo|0.9% saline solution, intra-catheter administration, sterile
79705180|NCT05402280|Behavioral|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
79705181|NCT05401084|Other|Diet|Macronutrient diet changes.
79705182|NCT05400863|Behavioral|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
79846349|NCT04086095|Device|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
80014640|NCT02088684|Drug|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
80014641|NCT02088684|Drug|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
80014642|NCT01137968|Drug|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
80014643|NCT01137968|Drug|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
80014644|NCT03557814|Device|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
79250024|NCT05625230|Behavioral|Behavioral Activation plus Dynamic Mental Imagery|This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
79250025|NCT05625230|Behavioral|Behavioral activation|"The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity."
79250026|NCT05621655|Biological|Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
79250027|NCT05621655|Biological|High dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
79250028|NCT05621655|Biological|Placebo|0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.
79250029|NCT05594329|Other|Instant noodle soup containing containing the equivalent of 2 servings (18.78g) of powdered Pleurotus oyster mushroom.|Ingredients: celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
79391690|NCT03173820|Genetic|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5*1/*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5*1/*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5*3/*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
79544546|NCT05481151|Drug|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
79705183|NCT05400863|Behavioral|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
79705184|NCT05400720|Behavioral|Mentoring|At least one meeting between the mentor and mentee will occur to share experiences and see if the mentee would like to continue meeting with a mentor
79705185|NCT05398198|Drug|GSK3923868|GSK3923868 dose and administration as per study intervention.
80014645|NCT03557814|Device|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
79250030|NCT05594329|Other|Instant noodle soup containing containing the equivalent of 1 serving (9.39g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
79250031|NCT05594329|Other|Instant noodle soup containing containing the equivalent of 0.5 serving (4.70g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
79250032|NCT05594329|Other|Control instant noodle soup|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
79250033|NCT05590780|Other|Clinical Attachment level|1-year
79544547|NCT05481151|Drug|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
80014646|NCT03557814|Device|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
80014647|NCT02249910|Drug|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
79391691|NCT03173820|Genetic|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
79391692|NCT03173742|Drug|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
79544548|NCT05473013|Behavioral|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
79544549|NCT05473013|Behavioral|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
79705186|NCT05398198|Drug|Placebo|Placebo matching GSK3923868 will be administered.
79705187|NCT05396833|Drug|M1774|M1774 will be administered orally once daily over a defined period of time in Part A1 and Part B1 until disease progression, death, discontinuation, or end of study.
79705188|NCT05396833|Drug|M4076|M4076 will be administered orally once daily over a defined period of time in Part A1 until disease progression, death, discontinuation, or end of study.
80014648|NCT02249910|Drug|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
79250034|NCT05581095|Behavioral|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
80014649|NCT02249910|Drug|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
79250035|NCT05581095|Behavioral|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
79705189|NCT05396833|Drug|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
79705190|NCT05395052|Drug|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
79705191|NCT05395052|Drug|Cyclophosphamide|Lympho-conditioning agent
79705192|NCT05395052|Drug|Fludarabine|Lympho-conditioning agent
79705193|NCT05395052|Drug|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
79705194|NCT05395052|Combination Product|Avelumab|Monoclonal antibody
80014650|NCT02249910|Drug|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
79388578|NCT06237972|Procedure|4-week Perturbation-based balance training|Participants will be asked to walk over a six by two meters computer-controlled movable platform at a self-selected speed. Slip-like perturbations will be induced by the device software that moves the platform 12 inches forward at 0.46 m/s with an acceleration of 9.4 m/s2. Participants will be secured in a safety harness which will be attached to the overhead arch of the platform. Participants will be asked to go to the experimental study cite 11 times. A baseline screening, 8 training sessions, a post-training screening, and a 2 months folow up screening
79388579|NCT06237972|Device|Neuromuscular electrical stimulation|NMES will be applied on tibialis anterior and quadriceps muscles during perturbation-based balance training.
79388580|NCT06237881|Drug|KSQ-001EX|Given by IV
79388581|NCT06237881|Drug|Interleukin-2|Given by IV
79388582|NCT06237881|Drug|Cyclophosphamide|Given by IV
79544550|NCT05473013|Behavioral|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
79388583|NCT06237881|Drug|Fludarabine|Given by IV
79705195|NCT05395052|Combination Product|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
79388584|NCT06237842|Diagnostic Test|Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)|Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
79388585|NCT06237803|Other|storage of biological samples|collect and store biological samples
79705196|NCT05395052|Combination Product|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
79544551|NCT05473013|Behavioral|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
79705197|NCT05395052|Combination Product|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
79705198|NCT05395052|Combination Product|Trastuzumab|Monoclonal antibody
79705199|NCT05395052|Combination Product|Cetuximab|Monoclonal antibody
79705200|NCT05395052|Combination Product|Amivantamab|Monoclonal antibody
79705201|NCT05395052|Drug|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
79705202|NCT05389657|Behavioral|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
79705203|NCT05389657|Behavioral|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
79705204|NCT05389527|Drug|Pembrolizumab+Lenvatinib|"After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight <60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year."
79705205|NCT05389423|Drug|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
79705206|NCT05389423|Drug|Prednisone|60 mg/m2/day administered orally on days 1 to 5
79705207|NCT05389423|Drug|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
80014651|NCT02936596|Drug|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
80014652|NCT02936596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid
80014653|NCT02088762|Procedure|surgical excision|comparison of safety margin 1 versus 2 cm
80014654|NCT02267018|Device|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
80014655|NCT03557736|Behavioral|Training mode|type of exercise training completed for 12 weeks
80014656|NCT02267096|Behavioral|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
79544552|NCT05470400|Biological|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
79846350|NCT05325827|Procedure|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
79705208|NCT05389423|Drug|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
79705209|NCT05389423|Drug|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
79544553|NCT05470400|Biological|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
79544554|NCT05470400|Biological|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
79705210|NCT05389423|Drug|Cyclophosphamide|750 mg/m2 administered IV on day 5
79388586|NCT06237244|Diagnostic Test|triglyceride to glucose ratio|Ratio of triglyceride level to glucose
79705211|NCT05389423|Drug|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
80014657|NCT02267096|Behavioral|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
79705212|NCT05384704|Behavioral|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
79705213|NCT05384145|Other|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
79705214|NCT05383092|Other|Adapted Physical Activity Strong|Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
79846351|NCT00715949|Other|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
79846352|NCT04084535|Other|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
79846353|NCT04084535|Other|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
79846354|NCT00503698|Drug|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
80014658|NCT02085642|Other|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
79388587|NCT06237244|Diagnostic Test|triglycerdie to HDL ratio|Ratio of triglyceride to HDL cholesterol
79388588|NCT06236841|Drug|XH-S004 tablet|XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
79388589|NCT06236841|Drug|XH-S004 placebo tablet|XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
79388590|NCT06236685|Device|Electric impedance tomography|EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
79705215|NCT05376488|Other|One meal|One meal given to assess impact on ammonia levels serially
79705216|NCT05376176|Drug|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
79705217|NCT05376176|Drug|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
79705218|NCT05376176|Drug|Placebo (Vehicle) BID|Placebo (vehicle) BID
79705219|NCT05370235|Drug|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
79846355|NCT00503698|Drug|placebo|Placebo injected s.c (under the skin)
79846356|NCT02589899|Other|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
79846357|NCT00573794|Biological|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
79846358|NCT00715793|Drug|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
80014659|NCT02085642|Other|Sham needle|Retractable needle with no skin puncture
79705220|NCT05364541|Device|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
79705221|NCT05362071|Other|Remote Exercise Group|The intervention will have a weekly frequency of two sessions on non-consecutive days during the first six weeks and three sessions on non-consecutive days for the remaining six weeks. The exercise intervention will consist of four 3-week mesocycles. The session's structure will consist of a warm-up, the main part, in which a combined training program will be carried out, consisting of three distinct blocks, and at the end, stretching. Blocks 1 and 2 will consist of three strength exercises with bodyweight and alternative materials and aerobic training. Between blocks 1 and 2, and later in block 3, participants will take a free walk with displacement in the space they have available in their own home. The session will end with stretching exercises for the main muscle groups. The sessions will last 37 to 57 minutes over 12 weeks, with approximately 5 min of warm-up and stretching, and the main part ranging from 27 min to 47 min throughout the intervention.
79846359|NCT00715793|Drug|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
79846360|NCT00715793|Procedure|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
79846361|NCT04085549|Device|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
79846362|NCT04085549|Other|Reference Cream|Commercial refence cream not containing berry and plant oils.
79846363|NCT00924014|Drug|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
79846364|NCT00924014|Drug|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
79846365|NCT00924014|Drug|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
79250036|NCT05579743|Other|Remote wound monitoring technology|Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
79388591|NCT06235788|Behavioral|Experimental Group ICEMS verbal feedback with pause group|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
79391693|NCT03173742|Drug|T1,T3,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
79544555|NCT05470400|Biological|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
79544556|NCT05470400|Biological|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
79544557|NCT05470400|Biological|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
79544558|NCT05451862|Device|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
79544559|NCT05451862|Device|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
79544560|NCT05438836|Radiation|online adaptive radiotherapy|Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
79544561|NCT05433948|Diagnostic Test|Simultaneous EEG and CRT|"EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal."
79544562|NCT05427578|Other|fNIRS measurement|measurement using functional near-infrared spectroscopy
79544563|NCT05423184|Other|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
79544564|NCT05423184|Other|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
79544565|NCT05415787|Other|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
79705222|NCT05362071|Other|Group control|"Participants allocated to the GC will receive recommendations for the practice of physical activity based on information from three specific chapters of the Physical Activity Guide for the Brazilian Population (2021). The GC will receive through Whatsapp the information that is available in chapters 1, 4, and 5, which address the following topics: Understanding Physical Activity, Physical Activity for Adults, and Physical Activity for the Elderly. If sending via Whatsapp is not possible, the booklet will be printed and delivered to the participant. At the end of the 12 weeks, the same booklet will be made available to IG participants."
79705223|NCT05361720|Drug|Cabozantinib|Given PO
79705224|NCT05361720|Biological|Ipilimumab|Given IV
79705225|NCT05361720|Biological|Nivolumab|Given IV
79544566|NCT05415787|Other|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
79705226|NCT05361590|Device|Lumoral device|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
79705227|NCT05359653|Drug|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
79705228|NCT05359653|Drug|Placebo|Matched sugar tablet
79705229|NCT05358704|Drug|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
79705230|NCT05350826|Other|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
79388592|NCT06235788|Behavioral|Experimental Group ICEMS audio feedback with pause and expert video|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
79544567|NCT05415397|Drug|Celecoxib 400mg|Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
79544568|NCT05415397|Drug|Placebo|Placebo add-on to treatment as usual (standard antidepressant treatment)
79544569|NCT05414201|Drug|Adalimumab|Subcutaneous Injection
79705231|NCT05349968|Drug|Lipovirtide for injection|Multiple dosing of Lipovirtide
79705232|NCT05347238|Drug|Dopamine|Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
79705233|NCT05347238|Drug|Norepinephrine|Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
79705234|NCT05339776|Behavioral|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
79705235|NCT05336760|Diagnostic Test|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
79705236|NCT05336760|Diagnostic Test|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
79705237|NCT05336760|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
79705238|NCT05336760|Diagnostic Test|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
79705239|NCT05331755|Drug|Dupilumab|start medication in cohort
79705240|NCT05327946|Drug|BI 770371|BI 770371
79544570|NCT05413733|Behavioral|Digital care pathway|"Sessions of the digital neuropsychological program:~Subjective functional ability and goals~Fatigue after ABI~Attention and concentration~Memory~Memory strategies~Working memory and executive functions~Emotional reactions~Summary and future goals"
79705241|NCT05327946|Drug|ezabenlimab|ezabenlimab
79705242|NCT05319184|Other|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
79705243|NCT05318417|Device|The Cochlear™ Nucleus® Cochlear Implant (CI) System|"The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®."
79705244|NCT05316168|Drug|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
79846366|NCT02591303|Other|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
79846367|NCT00853268|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
79250037|NCT05569538|Drug|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
80014660|NCT02398396|Biological|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
80014661|NCT02092194|Procedure|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
80014662|NCT02092194|Procedure|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
80014663|NCT03096808|Radiation|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
79250038|NCT05564312|Device|Transabdominal ultrasonographic guidance at embryo transfer.|During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.
79250039|NCT05551052|Diagnostic Test|Next-Gen CRC Screening Test|The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.
79544571|NCT05413733|Behavioral|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
79391694|NCT03173742|Drug|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
80014664|NCT04476056|Other|Intensified Nutritional Therapy|Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
79250040|NCT05517148|Device|Therapeutic VR|Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
79391695|NCT03173742|Drug|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
79391696|NCT03173742|Drug|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
79391697|NCT03173742|Drug|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
79391698|NCT02542462|Drug|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
79391699|NCT02542462|Drug|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
79705245|NCT05316168|Drug|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
79544572|NCT05410288|Device|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
79544573|NCT05410288|Other|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
79544574|NCT05410288|Other|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
79705246|NCT05316168|Procedure|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
79705247|NCT05316168|Drug|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
79705248|NCT05306964|Procedure|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
79705249|NCT05306964|Procedure|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
79705250|NCT05300191|Diagnostic Test|Effluent dialysate|Effluent dialysate samples evaluated for evidence of peritonitis
79705251|NCT05297487|Device|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
79705252|NCT05293509|Drug|Fludarabine|40 mg/m2/day i.v.- by vein
79250041|NCT05586724|Drug|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
79250042|NCT05586724|Drug|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
79250043|NCT05515952|Device|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
79250044|NCT05515952|Device|Transcranial Magnetic Stimulation (Sham)|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used.
79250045|NCT05505045|Behavioral|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
79705253|NCT05293509|Drug|Dexamethasone|25 mg/m2/day i.v.-by vein
79705254|NCT05293509|Drug|Cyclophosphamide|100 mg/m2 IV-by vein
79705255|NCT05293509|Drug|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
79705256|NCT05293509|Drug|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
79705257|NCT05293509|Drug|Busulfan|110 mg/m2 i.v-by vein
79705258|NCT05293509|Drug|Cyclophosphamide (Cy)|by vein
79705259|NCT05293509|Drug|Tacrolimus (or cyclosporine)|by vein
79705260|NCT05293509|Drug|Mycophenolate mofetil (MMF)|given by PO
79391700|NCT02542462|Drug|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
79391701|NCT02542462|Drug|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
79705261|NCT05293509|Drug|Rabbit ATG|by vein
79705262|NCT05288790|Dietary Supplement|Probiotic|Dietary supplement
79705263|NCT05288790|Dietary Supplement|Placebo|Placebo sachet
79710176|NCT04309747|Procedure|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
79710177|NCT02881060|Dietary Supplement|Alcohol|
79710178|NCT02881060|Dietary Supplement|Placebo|
79391702|NCT03173898|Procedure|PDL anesthesia versus local infiltration|Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
79391703|NCT02401932|Other|Hemophagocytosis|Best supportive care and immunosuppressive treatments
79250046|NCT05505045|Behavioral|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
79705264|NCT05286892|Other|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
79705265|NCT05286892|Other|Enhanced Education|See control group description above
79705266|NCT05284643|Radiation|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
79705267|NCT05284643|Drug|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
79705268|NCT05273736|Behavioral|5 Behavioral Change Techniques|"Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
79710179|NCT00592085|Behavioral|Questionnaires|Participants will use a computer to complete a series of questionnaires.
79710180|NCT00592085|Behavioral|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
79846368|NCT00853268|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
79846369|NCT01011244|Biological|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
79846370|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
79846371|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
79846372|NCT00845780|Drug|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
79846373|NCT00853424|Procedure|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
79846374|NCT00853424|Other|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
79250047|NCT05500651|Other|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
79846375|NCT00853502|Drug|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
79250048|NCT05485558|Drug|N-acetyl cysteine|10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
79846376|NCT00853736|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
79846377|NCT00853736|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
79846378|NCT00857168|Drug|Testosterone MD-Lotion|
80014665|NCT03090022|Procedure|Strattice|Intra-abdominally Fixation
80014666|NCT03090022|Procedure|Single running suture of abdominal fascia|Intra-abdominal suture
79250049|NCT05485558|Drug|Placebo|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
80014667|NCT02267174|Behavioral|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
79705269|NCT05270369|Behavioral|digital CBTI|The app-based intervention will consists of 6 weekly sessions and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
79705270|NCT05270369|Behavioral|group CBTI|The group-based CBT-I intervention will consist of 6 weekly sessions (90-min, 5-8 adolescents in each group) and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
79705271|NCT05266911|Behavioral|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
79705272|NCT05266911|Behavioral|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
79705273|NCT05265000|Device|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
79705274|NCT05263362|Other|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
79705275|NCT05263206|Drug|Dupilumab|Injection solution subcutaneous
79705276|NCT05263206|Drug|Placebo|Injection solution SC
79705277|NCT05263206|Drug|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
79705278|NCT05263206|Drug|Moisturizer|Topical
79705279|NCT05256472|Drug|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
79705280|NCT05256472|Drug|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
79705281|NCT05240014|Device|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
79705282|NCT05238558|Biological|FMPV-1|Intradermal administration
79705283|NCT05238558|Biological|GM-CSF (as adjuvant)|Intradermal administration
79705284|NCT05236192|Behavioral|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
79705285|NCT05236192|Behavioral|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
79705286|NCT05235880|Other|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
79705287|NCT05235880|Other|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
79705288|NCT05227937|Drug|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
79250050|NCT05485558|Drug|NAc|40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
79250051|NCT05479058|Drug|Filgotinib|Tablets administered orally once daily
79250052|NCT05479058|Drug|Placebo|Tablets administered orally once daily
79250053|NCT05468034|Behavioral|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
79250054|NCT05446857|Drug|Glecaprevir / Pibrentasvir Pill|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
79544575|NCT05410288|Other|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
79705289|NCT05227144|Drug|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
79705291|NCT05219968|Drug|LYR-210|LYR-210 drug matrix (mometasone furoate)
79705292|NCT05219968|Drug|Sham procedure control|Sham procedure control
79705293|NCT05219968|Other|Background Therapy|Daily Saline Irrigation
79705295|NCT05212181|Device|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
79705296|NCT05209750|Diagnostic Test|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
79544576|NCT05397665|Drug|AT-007|AT-007, aldose reductase inhibitor
79705297|NCT05208879|Biological|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
79705298|NCT05208879|Other|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
79705299|NCT05201313|Drug|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
79705300|NCT05201313|Drug|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
79705301|NCT05200988|Drug|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
79705302|NCT05199766|Drug|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
79705303|NCT05199753|Drug|LM-108|Administered intravenously
80014668|NCT02085798|Other|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
79250055|NCT05443074|Other|Face to face intervention group|"Participants of this group will participate in a one 15 minutes face to face session where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge urinary incontinence (UI)."
79391704|NCT02543398|Procedure|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
80014669|NCT04474574|Device|Simultaneous recording of nocturnal SpO2|The intervention will consist in performing a simultaneous recording of nocturnal SpO2 and pulse rate for at least 4 hours with 3 different devices.
79391705|NCT02408172|Drug|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
79391706|NCT02408172|Drug|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
79391707|NCT02401776|Dietary Supplement|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
79391708|NCT02401776|Dietary Supplement|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
79705304|NCT05199753|Drug|An Anti-PD-1 Antibody|Administered intravenously
79705305|NCT05198934|Drug|Sotorasib|Sotorasib will be administered orally
79705306|NCT05198934|Drug|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
79705307|NCT05198934|Drug|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
79705308|NCT05198934|Drug|Regorafenib|Regorafenib will be administered orally
80014670|NCT05377138|Other|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
80014671|NCT05628584|Combination Product|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
80014672|NCT05628584|Combination Product|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
80014673|NCT05628506|Drug|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
79544577|NCT05397665|Drug|Placebo|Liquid oral suspension
79544578|NCT05386810|Biological|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
79705309|NCT05192382|Drug|Paltusotine|Paltusotine, tablets, once daily by mouth
79705310|NCT05192382|Drug|Placebo|Placebo, tablets, once daily by mouth
79705311|NCT05188872|Diagnostic Test|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
79705312|NCT05184348|Radiation|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
79705313|NCT05184348|Drug|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
79705314|NCT05184348|Combination Product|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
79705315|NCT05184270|Device|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
79705316|NCT05183412|Device|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
79705317|NCT05183412|Procedure|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
79705318|NCT05183412|Procedure|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
80014674|NCT02427490|Behavioral|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
80014675|NCT02427490|Other|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
80014676|NCT05626946|Other|Observation|Observation
80014677|NCT02088918|Drug|Nateglinide|
80014678|NCT02088918|Drug|Nateglinide/Metformin|
79705319|NCT05182125|Biological|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS [tris(hydroxymethyl)aminomethane], pH 8.0 formulation buffer to a concentration of 1.2 x 10^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
79705320|NCT05182125|Biological|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS [tris(hydroxymethyl)aminomethane], pH 8.0 formulation buffer to a concentration of 1.2 x 10^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
79391709|NCT02401776|Dietary Supplement|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
79391710|NCT02401776|Dietary Supplement|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
79391711|NCT02543554|Procedure|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
79391712|NCT02547064|Procedure|Glidescope guided intubation|
79391713|NCT02547064|Device|GlideScope®|
79705321|NCT05182125|Biological|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
79544579|NCT05386810|Biological|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
79544580|NCT05386810|Biological|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
80014679|NCT02088918|Drug|Metformin|
79544581|NCT05376345|Biological|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
79705322|NCT05182125|Biological|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
79705323|NCT05182125|Biological|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
79705324|NCT05181371|Procedure|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS|Programmed Intermittent Bolus (PIB) of Levobupivacaine
79705325|NCT05181371|Procedure|Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS|Continuous Infusion (CI) of Levobupivacaine
79705326|NCT05174988|Procedure|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
79705327|NCT05172648|Other|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
79705328|NCT05172648|Other|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
79705329|NCT05166629|Behavioral|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
79705330|NCT05166629|Behavioral|Usual Care|Please see above description of usual care.
79705331|NCT05165238|Behavioral|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
79705332|NCT05159908|Drug|NBI-921352|Tablets for oral administration
79705333|NCT05159908|Drug|Placebo|Matching placebo tablets for oral administration
79705334|NCT05156957|Other|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
79250056|NCT05443074|Other|Remote intervention group|"Participants of this group will be referred to a room with a computer (inside the rehabilitation center) to participate in a one 15 minutes real time remote session, where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge UI."
79705335|NCT05156944|Other|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
79705336|NCT05147675|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79705337|NCT05147376|Drug|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
79705338|NCT05147376|Drug|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
79705339|NCT05140083|Drug|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
80014680|NCT02419378|Drug|Alemtuzumab|
80014681|NCT05628272|Other|Intravenous infusion of cord blood mononuclear cells|On the basis of the application of granulocyte stimulating factor, the research group was given intravenous infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10^8, once a week
80014682|NCT05628272|Drug|application of granulocyte stimulating factor|application of granulocyte stimulating factor
80014683|NCT02092272|Behavioral|instructional exercise video source|instructional exercise video source
79705340|NCT05139264|Other|Observational|Observation of diet, physical activity, sleep and interstitial glucose
79705341|NCT05135169|Drug|Definity Suspension for Injection|Administration of Definity
79705342|NCT05131100|Drug|Somavert|As provided in real world practice
79705343|NCT05127174|Drug|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
79705344|NCT05126563|Biological|HB-adMSCs (allogeneic)|HB-adMSCs allogenic
79705345|NCT05126563|Other|Placebo|Placebo comarator
79705346|NCT05126472|Drug|2141-V11|All subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks, at weeks 1 (±3 days), 2 (±3 days), and 3 (±3 days) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points. Dose escalation of 2141-V11 will proceed incrementally from the initial dose of 0.7 mg to doses of 2 mg, 7 mg, 21 mg, and 70 mg using an MCRM design to assess AEs/DLTs (according to CTCAE version 5.0) and to determine the MTD and/or a RP2D. There will be no intra-patient dose escalations or dose reductions of 2141-V11. Subjects with evidence of HG disease at the week 25 evaluation will not continue on treatment, but be followed on study for survival data.
79705347|NCT05122247|Other|Machine learning algorithm|machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization
79705348|NCT05118854|Drug|AMG 510|Given by IV
79705349|NCT05118854|Drug|Cisplatin|Given by IV
79846379|NCT00857324|Drug|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
80014684|NCT05375500|Device|telemedicine digital therapeutic|digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
80014685|NCT01097096|Biological|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
80014686|NCT01097096|Biological|Placebo|Identical placebo to CAD106 administered via intramuscular injection
79544582|NCT05368090|Procedure|EUS-RFA of left adrenal gland|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
79705350|NCT05118854|Drug|Carboplatin|Given by IV
79705351|NCT05118854|Drug|Pemetrexed|Given by IV
79705352|NCT05116007|Drug|AK112|IV infusion
79705353|NCT05116007|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
79705354|NCT05116007|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
79710181|NCT00592085|Behavioral|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
79710182|NCT04328168|Procedure|ROM exercises, stretching, positioning, gait training|
79710183|NCT04328168|Procedure|by two physiotherapist under the supervision of a doctor|
80014687|NCT01097096|Biological|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
80014688|NCT01097096|Biological|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
80014689|NCT02085876|Other|2 additional MRI sequences|
80014690|NCT02085876|Other|An additional blood sample|
80014691|NCT05375422|Other|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
80014692|NCT05375422|Other|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
80014693|NCT02092428|Other|Image Quality|"The following procedures may be conducted as part of this study:~Coronary MRI scan with no contrast~Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~MRI scan with an oral beta blocker (metoprolol)~Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
80014694|NCT02092428|Other|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
80014695|NCT02783404|Drug|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
80014696|NCT02783404|Drug|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
79705355|NCT05114161|Other|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP > 60mg/L will be deemed 'appreciable risk' while patients with CRP < 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of <95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
79705356|NCT05114005|Behavioral|Rhythmic Auditory Stimulation|Rhythmically-entrained sensorimotor activity.
79705357|NCT05114005|Behavioral|Evidence-Based Exercise|This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
79705358|NCT05112289|Diagnostic Test|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
79705359|NCT05107726|Behavioral|TRE Group|This group will practice time-restricted eating
79705360|NCT05104476|Drug|Lu AF82422|Solution for infusion
79705361|NCT05104476|Drug|Placebo|Solution for infusion
79705362|NCT05095376|Drug|Lomustine|Given PO
79705363|NCT05095376|Radiation|Photon Beam Radiation Therapy|Undergo radiation therapy
79705364|NCT05095376|Other|Quality-of-Life Assessment|Ancillary studies
79705365|NCT05095376|Other|Questionnaire Administration|Ancillary studies
79846380|NCT04043078|Other|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
79846381|NCT00857402|Dietary Supplement|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
80014697|NCT05503290|Behavioral|Lullaby Project|Our proposed intervention is the randomized participation of pregnant individuals with epilepsy in the Lullaby Project coordinated by a musical institution in Toronto. The Lullaby Project is an initiative first created by Carnegie Hall's Weill Music Institute. In this program, pregnant women and/or new mothers are paired with professional musicians to compose and write personal lullabies for their child(ren). Since its inception in 2011, the project has expanded globally and have helped numerous families write original lullabies for their newborns. The Lullaby intervention is unlike traditional music therapy as patients are actively participating in the creative song-writing process, not singularly in passive listening. Through sessions, participants will be given an opportunity to share experiences, experiment with musical arrangements, write lyrics, and receive positive feedback from the musician.
79388593|NCT06234267|Behavioral|Eat, Play, Sleep|The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
79544583|NCT05368090|Procedure|adrenalectomy|Patients in the adrenalectomy group will be admitted in the Dept. of Endocrine surgery. They will undergo laparoscopic transabdominal total adrenalectomy according to routine. The patients will be monitored in the postoperative unit 4-6 hours before returning to the ward. If no complications occur, the patients are usually discharged day 2 after surgery.
79705366|NCT05095376|Drug|Temozolomide|Given PO
79705367|NCT05090696|Device|Mechanical In-Exsufflator (MI-E)|The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
79705368|NCT05090358|Dietary Supplement|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
79846382|NCT00857402|Dietary Supplement|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
79846383|NCT00853814|Behavioral|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
80014698|NCT05096806|Other|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
80014699|NCT05096806|Device|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
79388594|NCT06232603|Other|Education of medication management|Video and handout materials will be provided
79391714|NCT02407860|Other|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
79391715|NCT02407860|Other|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
79544584|NCT05364788|Other|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
79846384|NCT00853892|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
79846385|NCT00853892|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
79705369|NCT05090358|Dietary Supplement|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
79705370|NCT05090358|Drug|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
79250057|NCT05443074|Other|Control group|Participants of this group will be assessed in the same time points of the participants of the two other groups. They will not receive any intervention or information about pelvic floor anatomy, functions and dysfunctions of the pelvic floor, however after the last assessment (20 days after) for ethical reasons they will receive the same intervention.
79705371|NCT05090358|Drug|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
79846386|NCT02546336|Device|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
79846387|NCT00854126|Drug|GDC-0980|Escalating repeating dose
79846388|NCT00857480|Drug|NRL972|Single intravenous administration of 2 mg NRL972
79846389|NCT00857480|Drug|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
79846390|NCT00857480|Drug|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
80014700|NCT01097018|Drug|Capecitabine|1000 mg/m2 BID/ Days 1-14
80014701|NCT01097018|Drug|Perifosine|50 mg daily x 21 days
80014702|NCT01097018|Drug|Placebo|1 pill daily x 21 days
80014703|NCT05096650|Procedure|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
80014704|NCT02088996|Device|longwave diathermy on high power and interferential therapy|
79250058|NCT05441774|Device|Active transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the active condition, stimulator electrodes deliver a mild electrical current to the tragus. Stimulation parameters: stimulation of left tragus via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
79705372|NCT05090358|Drug|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
79705373|NCT05087888|Procedure|Biospecimen Collection|Undergo collection of blood samples
79705374|NCT05087888|Procedure|Magnetic Resonance Imaging|Undergo functional MRI
79705375|NCT05087888|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
79705376|NCT05087888|Other|Questionnaire Administration|Complete questionnaires
79705377|NCT05084560|Drug|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
79705378|NCT05084560|Drug|Placebo|Placebo
79705379|NCT05083546|Drug|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
80014705|NCT02088996|Device|longwave diathermy on low power|
80014706|NCT05096572|Device|VIM Stimulation|Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
80014707|NCT05096572|Device|PSA Stimulation|Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
80014708|NCT05096572|Device|VIM+PSA Stimulation|Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
80014709|NCT01096862|Drug|peficitinib|oral
80014710|NCT01096862|Drug|Placebo|oral
80014711|NCT02092506|Drug|10 day triple therapy|10 day triple therapy
79250059|NCT05441774|Behavioral|Active self-compassion imagery|Self-compassion imagery is both a meditative technique and a component of compassion-focused cognitive therapy. Here, self-compassionate imagery is delivered as standardized audio-recorded instructions.
79391716|NCT02405832|Dietary Supplement|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
79391717|NCT02405832|Dietary Supplement|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
79391718|NCT02401698|Other|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
79846391|NCT00857558|Drug|saxagliptin|orally administration at 1 mg once a day for 12 weeks
79846392|NCT00857558|Drug|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
79846393|NCT00857558|Drug|saxagliptin|orally administration at 5 mg once a day for 12 weeks
79846394|NCT00857558|Drug|placebo|orally administration once a day for 12 weeks
79846395|NCT00857636|Behavioral|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
79846396|NCT00718523|Drug|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
80014712|NCT02092506|Drug|10 day sequential therapy|10 day sequential therapy
80014713|NCT02092506|Drug|10 day concomitant therapy|10 day concomitant therapy
80014714|NCT02089074|Behavioral|Drug use counselling|
80014715|NCT01092104|Drug|TBR-652|TBR-652 25 mg
79250060|NCT05441774|Device|Sham transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the sham condition, stimulator electrodes deliver a mild electrical current to the earlobe. Stimulation parameters: stimulation of left earlobe via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
79705380|NCT05083546|Other|Placebo|sugar pill
79705381|NCT05083312|Drug|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
79388595|NCT06232200|Other|ACUPUNCTURE|"Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week."
79705382|NCT05083312|Drug|Placebo oral tablet|Placebo orally disintegrating tablet
79705383|NCT05080920|Dietary Supplement|Rosmalip®|Nutritional Supplement+Usual Care
79846397|NCT00718523|Drug|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
79388596|NCT06231797|Diagnostic Test|AI algorithm conducted on 12-lead ECG and transthoracic echocardiography|12-lead ECG is performed for each patient. For 12-lead ECG, AITIALVSD (AI algorithm) analysis will be performed through a separate server.
79388597|NCT06231706|Other|Prebiotic-like nut and seed mix|A mixture of nuts, seeds and other plant based ingredients. To be consumed as 2 x 15g portions per day for 6 weeks
79544585|NCT05345951|Behavioral|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
79388598|NCT06231706|Other|Bread Crouton|A commercially available bread crouton product. To be consumed as 2 x 14g portions per day for 6 weeks.
79705384|NCT05080920|Other|Placebo|Placebo+Usual Care
79388599|NCT06231706|Dietary Supplement|Probiotic capsule|Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule. To be consumed as one capsule per day for 6 weeks.
80014716|NCT01092104|Drug|TBR-652 Matching Placebo|Matching Placebo
79250061|NCT05441774|Behavioral|Sham mental imagery|Draw-a-face-in-imagination is the sham/ control imagery condition. Here, control imagery instructions are delivered as a standardized audio-recording, well-matched to self-compassion imagery for number of words, complexity of language, and duration of the audio instructions.
79250062|NCT05436834|Biological|mRNA-1273.214|Sterile liquid for injection
79388600|NCT06231355|Drug|Performing paravertebral nerve block with lipo-bupivacaine|Paravertebral block is performed using liposomal bupivacaine.
79705385|NCT05079698|Drug|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
79705386|NCT05079698|Procedure|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
79705387|NCT05078138|Drug|Epoetin Alfa|Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
79705388|NCT05073874|Other|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
79846398|NCT02590367|Drug|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks."
79846399|NCT02590367|Drug|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
79846400|NCT02590367|Drug|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
79846401|NCT02590913|Dietary Supplement|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
79846402|NCT02590913|Dietary Supplement|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
79846403|NCT02589743|Device|Sealant|Application of preventive agent
79388601|NCT06231355|Drug|Performing paravertebral nerve block with bupivacaine|Paravertebral block is performed using bupivacaine.
79846404|NCT02589743|Device|Adhesive and Sealant|Application of preventive agent and technique for control moisture
79388602|NCT06230354|Drug|Tezepelumab|Tezepelumab subcutaneous injection
79388603|NCT06230354|Drug|Placebo|Placebo subcutaneous injection
79388604|NCT06227286|Device|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
79388605|NCT06227286|Device|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
79705389|NCT05072210|Other|Mobile Intervention|Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
79705390|NCT05069935|Drug|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
79705391|NCT05069935|Drug|Cyclophosphamide|Lympho-conditioning agent
79705392|NCT05069935|Drug|Fludarabine|Lympho-conditioning agent
80014717|NCT01092104|Drug|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
80014718|NCT01092104|Drug|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
80014719|NCT01092104|Drug|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
79705393|NCT05069935|Combination Product|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
80014720|NCT01092104|Drug|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
79705394|NCT05069935|Combination Product|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
79705395|NCT05067478|Drug|Vibegron|Vibegron to be administered.
79705396|NCT05064696|Other|Non-stick gauze dressing|Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
79705397|NCT05064696|Device|PICO dressing|Group 2 (Treatment group): surgical site will be dressed with PICO dressing
79544586|NCT05345951|Behavioral|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
79544587|NCT05328440|Drug|Pyrotinib Maleate|once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine
79544588|NCT05328440|Drug|Dalpiciclib Isethionate Tablets|400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle
79544589|NCT05328440|Drug|Inetetamab|the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.
79705398|NCT05062902|Device|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
79544590|NCT05328440|Drug|Fulvestrant|fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
79705399|NCT05062902|Drug|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
79705400|NCT05059678|Other|Best Practice|Receive standard of care
80014721|NCT02092584|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
80014722|NCT02092584|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
80014723|NCT01128530|Drug|JNJ-32729463|250 mg tablet twice daily
80014724|NCT01128530|Drug|linezolid|600 mg tablet twice daily
80014725|NCT01128530|Drug|JNJ-32729463 placebo|1 placebo tablet twice daily
80014726|NCT01128530|Drug|linezolid placebo|1 placebo tablet, twice daily
80014727|NCT02660086|Behavioral|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
80014728|NCT02086032|Drug|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
79705401|NCT05059678|Other|Educational Intervention|Receive educational materials and attend videoconference sessions
79705402|NCT05059678|Other|Questionnaire Administration|Ancillary studies
79705403|NCT05058859|Drug|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
79705404|NCT05056818|Other|Electronic Health Record Review|Review of medical records and past imaging examinations
80014729|NCT02086032|Drug|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
80014730|NCT02086032|Drug|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
79705405|NCT05056779|Drug|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
79705406|NCT05056779|Drug|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
80014731|NCT01128452|Drug|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
80014732|NCT01128452|Drug|Placebo|HPMC Placebo capsules, once daily for 28 days
80014733|NCT02092818|Drug|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
80014734|NCT05626868|Device|Intra abdominal pressure measurement|Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
80014735|NCT02267408|Other|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
80014736|NCT02267408|Other|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
80014737|NCT05376826|Behavioral|Nurse Led Physical Therapy|Nurse Led Physical Therapy in Form of Range of Motion Exercises
80014738|NCT03777618|Procedure|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
80014739|NCT03902444|Device|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
79705407|NCT05050500|Drug|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
79705408|NCT05050500|Drug|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
79705409|NCT05049590|Biological|Acute normovolemic hemodilution (ANH)|A blood conservation technique that removes whole blood (~8-10cc/kg) from a patient in the operating room prior to incision.
79705410|NCT05044026|Other|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
79705411|NCT05043870|Drug|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
79705412|NCT05043870|Drug|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
79705413|NCT05036083|Procedure|Contrast-Enhanced Mammography|Undergo CEM
79705414|NCT05036083|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
79705415|NCT05036083|Other|Electronic Health Record Review|Medical records reviewed
79705416|NCT05036083|Drug|Iodinated Contrast Agent|Given IV
79705417|NCT05035654|Drug|LYR-220 Design 1|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
79705418|NCT05035654|Drug|LYR-220 Design 2|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
79705419|NCT05035654|Drug|Bilateral sham procedure control|Bilateral sham procedure control
79705420|NCT05034731|Device|Remote Fitting|Processors will be programmed using remote fitting application.
79705421|NCT05034731|Device|In-Office Fitting|Processors will be programmed using standard Target CI application.
80014740|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
79705422|NCT05033288|Other|Electronic Health Record Review|Medical records are reviewed
79705423|NCT05033288|Other|Quality-of-Life Assessment|Complete quality of life questionnaires
79705424|NCT05030350|Drug|PH94B|Nasal spray
79705425|NCT05029596|Drug|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
79705426|NCT05029596|Drug|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
79705427|NCT05027386|Drug|Apatinib, Irinotecan, Temozolomide|The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
79705428|NCT05018767|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79705429|NCT05016622|Biological|BNT162b2 vaccine|administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
80014741|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
80014742|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
80014743|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
79705430|NCT05015803|Combination Product|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
79705431|NCT05015803|Behavioral|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
79705432|NCT05015803|Behavioral|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
79705433|NCT05013073|Other|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
79705434|NCT05010824|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
79705435|NCT05010434|Drug|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
79705436|NCT05009381|Device|Stylage XXL at enrollment|Injection in the chin at enrollment
79705437|NCT05009381|Device|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
79705438|NCT05008315|Other|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
79705439|NCT05008315|Other|Direct focused scar release technique|Direct focused scar release technique
79705440|NCT05008315|Other|Direct manipulations to visceral structures|Direct manipulations to visceral structures
79705441|NCT05008315|Other|pelvic anatomy education|pelvic anatomy education
79846405|NCT00715559|Drug|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
79846406|NCT00620282|Drug|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
79846407|NCT00620282|Drug|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
79846408|NCT00620282|Drug|glimepiride|Tablets, 1 - 4 mg daily
79846409|NCT05684861|Drug|Isotretinoin|systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
79846410|NCT05684861|Diagnostic Test|ELISA Assays of Serum TWEAK.|: From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
79846411|NCT02591069|Device|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
79846412|NCT04042688|Drug|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
79388606|NCT06226155|Behavioral|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
79544591|NCT05304858|Procedure|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
79544592|NCT05300087|Drug|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
79544593|NCT05300087|Drug|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
79544594|NCT05296577|Drug|anlotinib and vinorelbine|anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
79544595|NCT05296577|Drug|Vinorelbine injection|vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
79544596|NCT05296564|Drug|CYCLOPHOSPHAMIDE and FLUDARABIN|1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
79544597|NCT05296564|Drug|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
79705442|NCT05008315|Other|sham|sham
79705443|NCT05006807|Device|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
79705444|NCT05006807|Device|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
79705445|NCT05006807|Device|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
79388607|NCT06226155|Other|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
79388608|NCT06225453|Other|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at more than -20% of the baseline values of each patient.
79388609|NCT06225453|Other|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
79388610|NCT06222515|Diagnostic Test|Bladder diary|3-day bladder diary record including fluid intake, urine amount, urgency and incontinence.
79388611|NCT06222398|Device|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
79544598|NCT05296564|Biological|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
79705446|NCT05006807|Device|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
79705447|NCT05006807|Device|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
79705448|NCT05006807|Other|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
79705449|NCT04997265|Other|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
79846413|NCT02590133|Drug|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
79846414|NCT02590133|Drug|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
79705450|NCT04997265|Other|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
79705451|NCT04994639|Device|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
79250063|NCT05435469|Other|Questionnaires|Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
80014744|NCT05096026|Behavioral|Standard PCP Outreach|These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
79388612|NCT06221800|Diagnostic Test|Microbiome|Stool and saliva samples will be collected
79388613|NCT06221488|Diagnostic Test|TB infection testing|Diagnostic testing with existing and novel tests to evaluate for TB infection and disease
79544599|NCT05296564|Drug|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
79705452|NCT04986696|Device|FLASH therapy|Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
79250064|NCT05433909|Diagnostic Test|Blood, fecal, vaginal and endometrial liquid samples|"During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling."
79250065|NCT05425524|Procedure|Care Bundle|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
79250066|NCT05397223|Biological|mRNA-1273|Sterile liquid for injection
79250067|NCT05397223|Biological|mRNA-1010|Sterile liquid for injection
79250068|NCT05397223|Biological|mRNA-1345|Sterile liquid for injection
79250069|NCT05397223|Biological|FLUAD®|adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine
79388614|NCT06219018|Other|Medical grade honey formulation (MGH) (L-Mesitran®)|daily application of 5 grams (with applicator)
79388615|NCT06218563|Other|vibration-induced illusion of movement|Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same.
79388616|NCT06218212|Dietary Supplement|Renastart formula|"Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~Readjusting dosage ratio according to serum electrolytes levels especially potassium."
79705453|NCT04985214|Other|Questionnaire|Questionnaire on the quality of life
79705454|NCT04984993|Device|MED3000 (Male)|Gel formulation
79705455|NCT04984993|Drug|Tadalafil 5mg (Male)|Tablets
79705456|NCT04984993|Device|MED3000 (Female)|Gel formulation
79705457|NCT04984993|Drug|Tadalafil 5mg (Female)|Tablets
79250070|NCT05397223|Biological|mRNA-1647|Sterile lyophilized product
79250071|NCT05383196|Drug|Onvansertib|oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
79250072|NCT05383196|Drug|Paclitaxel|once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
79250073|NCT05340582|Drug|Acetaminophen Injection|Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
79250074|NCT05340582|Drug|Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)|Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
79250075|NCT05340582|Other|Sodium chloride 0.9% injection|Placebo- IV q6h for 3 days
79250076|NCT05319548|Other|Purple-Red Carrot Juice|Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins
79250077|NCT05319548|Other|Red Carrot Juice|Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..
79544600|NCT05290025|Drug|Nicotine patch|> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
79544601|NCT05290025|Drug|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
79544602|NCT05290025|Drug|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
79705458|NCT04979611|Drug|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
79705459|NCT04975646|Behavioral|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
79705460|NCT04971577|Drug|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
79705461|NCT04970225|Other|1 blood sample|4 tubes of 7 ml per sample (a single sample)
79388617|NCT06218212|Drug|calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.|calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
80014745|NCT05096026|Behavioral|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
80014746|NCT02092974|Procedure|tDCS|
79388618|NCT06213103|Procedure|Patient cohort|Collection of 6 blood tubes at the inclusion visit.
80014747|NCT02092974|Drug|Citalopram|
79250078|NCT05319548|Other|Purple Carrot Juice|Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
79544603|NCT05290025|Behavioral|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
79544604|NCT05290025|Other|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
79705462|NCT04970225|Other|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
79705463|NCT04967248|Other|Alpelisib|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
79705464|NCT04967248|Other|Fulvestrant|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
80014748|NCT02092974|Other|sham-tDCS + placebo|
79250079|NCT05313295|Other|Home-based physiotherapy|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
79705465|NCT04957901|Drug|modified BFM-95 protocol|Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol. The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
79705466|NCT04952792|Drug|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
79705467|NCT04952389|Device|Acupuncture Therapy|Consists of two treatments per week for five weeks
79388619|NCT06213103|Procedure|Control cohort|Collection of 6 blood tubes at the inclusion visit.
79388620|NCT06212154|Biological|ThisCART19A|Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.
79388621|NCT06205186|Behavioral|Army Health|A whole health mobile application for Soldiers
79705468|NCT04952389|Drug|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
80014749|NCT02093052|Behavioral|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
80014750|NCT02093052|Behavioral|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
79388622|NCT06194864|Drug|Itraconazole|itraconazole 200 mg QD Days 6 to 16
79250080|NCT05313295|Other|Usual Physiotherapy|Usual care provided for the management of neurological disorders in children
79250081|NCT05310448|Device|Optune device|Wear Optune device
79250082|NCT05302505|Other|simulation-based training|Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
79250083|NCT05285605|Drug|Ulipristal Acetate|Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
79544605|NCT05290025|Other|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
79544607|NCT05274321|Device|Nanodropper|Device used for administering eye drops
79544608|NCT05274321|Device|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
79544609|NCT05259475|Other|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
79544610|NCT05259475|Other|Diet Intervention|Calorie-restricted meals (lunch and dinner)
79544611|NCT05259475|Other|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
79544612|NCT05255835|Device|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
79705469|NCT04952389|Other|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
79705470|NCT04950582|Diagnostic Test|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
79388623|NCT06194864|Drug|rifampicin|rifampicin 600 mg QD Days 6 to 20
79705471|NCT04947631|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
80014751|NCT05097508|Drug|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
79250084|NCT05268289|Drug|Iptacopan (part 1)|Taken for 52 Weeks
79250085|NCT05268289|Drug|Iptacopan (part 2)|Taken for 52 Weeks
79250086|NCT05268289|Drug|Placebo + standard of care|Taken for 52 Weeks
79250087|NCT05268289|Drug|Iptacopan + placebo|Taken for 52 Weeks
79388624|NCT06194864|Drug|Ecopipam|89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
79250088|NCT05244083|Other|Mirror Therapy|Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.
79388625|NCT06194331|Behavioral|iCHART/cASAP|When patients disclose suicidal ideation on the PHQ-9, the intervention of iCHART/cASAP will be implemented in the pediatrician's office, and in collaboration with parents, which includes safety planning, teaching skills to improve distress tolerance and emotion regulation all on the teen's smart device. iCHART/cASAP will include: Screening Wizard, a digital screening tool that will guide the provider to gauge patient satisfaction with current treatment and making further personalized treatment recommendations; cASAP, a computerized version of the As Safe As Possible intervention that focuses on psychoeducation in safety planning, distress tolerance, and emotion regulation skills; BRITE, a safety planning app with distress monitoring that a teen can be guided through with automated onboarding manuals; Text2Connect, an automated text messaging sent centrally to patients and parents to enhance treatment adherence.
79388626|NCT06194331|Behavioral|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
79544613|NCT05255835|Device|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
79544614|NCT05252429|Drug|Docetaxel|Docetaxel 75mg/m2; q21
79388627|NCT06191315|Drug|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79544615|NCT05252429|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
79544616|NCT05249309|Drug|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
79388628|NCT06191315|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79388629|NCT06190652|Drug|Chemotherapy combined with immunotherapy|chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
79388630|NCT06190652|Radiation|radiotherapy|Intensity-modulated radiation therapy
79388631|NCT06183229|Drug|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
79388632|NCT06183229|Drug|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
79388633|NCT06179628|Drug|Low and standard concentrations and volumes|Compare low and standard concentrations and volumes of bupivacaine boluses for continuous adductor block
79250089|NCT05244083|Other|Program without Mirror Therapy|Bimanual exercises performed with both upper limbs.
79388634|NCT06179511|Drug|AZD9829|AZD9829 will be administered by IV infusion
79388635|NCT06177652|Other|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
79544617|NCT05224271|Other|Electronic Health Record Review|Medical records are collected
79544618|NCT05224271|Other|Medical Device Usage and Evaluation|Fitbit information is collected
79544619|NCT05224271|Other|Survey Administration|Complete surveys
79544620|NCT05220202|Behavioral|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
79544621|NCT05199480|Other|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
79544622|NCT05199480|Other|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
79544623|NCT05198336|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
79544624|NCT05193019|Other|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
79544625|NCT05186337|Behavioral|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
79705472|NCT04947631|Drug|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
79544626|NCT05176964|Radiation|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
79705473|NCT04947631|Drug|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
79705474|NCT04947631|Drug|DKF-313 placebo|Once daily for 48 weeks
79846415|NCT02590133|Drug|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
79846416|NCT00854204|Drug|TMC114; TMC41629|
79846417|NCT02590991|Other|Prebiotics|To study the long term effect of supplementation in early life
79846418|NCT02590991|Other|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
80014752|NCT05097508|Drug|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
80014753|NCT05097508|Device|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
80014754|NCT05097508|Device|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
79250090|NCT05219448|Behavioral|Education and self-efficacy coaching|"Children and their caregiver(s) in the intervention communities will receive a culturally-adapted, 5-session program consisting of video-based health education and self-efficacy coaching delivered by an indigenous Community Health Worker. Families will be introduced to sugar-free water enhancers that are commercially available and come in the same flavors as regular Tang and Kool-Aid. The sessions will include conversations on related topics, interactive hands-on activities, and homework assignments. Additionally, four brief check-ins will keep families engaged. Local stores in the intervention communities only will carry the sugar-free water enhancers that are highlighted in the health education."
79388636|NCT06177652|Other|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
79388637|NCT06175286|Other|POWERBreath Plus Medium Resistance training device|30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
79388638|NCT06175273|Dietary Supplement|Oral Nutrition Supplement|8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
79388639|NCT06175273|Dietary Supplement|Tube Feed|EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
79544627|NCT05176964|Drug|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
79544628|NCT05176964|Drug|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
79705475|NCT04947631|Drug|Dutasteride placebo|Once daily for 48 weeks
79846419|NCT00854282|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
79388640|NCT06175273|Drug|Cyproheptadine|0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
79388641|NCT06175273|Drug|Dronabinol|5mg BID (before breakfast and lunch). May titrate by 2.5mg increments to max of 20mg/day
79388642|NCT06175273|Other|Standard of Care|Diet education on high protein, high calorie food consumption
79544629|NCT05174702|Radiation|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
79705476|NCT04947631|Drug|Tadalafil placebo|Once daily for 48 weeks
79705480|NCT04931069|Other|Microbiota analysis|Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
79705481|NCT04930822|Other|Table Top Visual Intervention|Table top visual interventions and exercises.
79705482|NCT04930822|Device|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
79544630|NCT05150028|Behavioral|Patient participation|Questionnaire
79544631|NCT05150028|Other|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
79544632|NCT05149040|Other|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
79705483|NCT04929951|Biological|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
79705484|NCT04929951|Biological|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
79705486|NCT04914910|Device|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
79705487|NCT04913610|Drug|ABBV-4083|Oral Capsule
79705488|NCT04913610|Drug|Placebo for ABBV-4083|Oral Capsule
79705489|NCT04913610|Drug|Albendazole|Oral encapsulated tablets
79705490|NCT04913610|Drug|Placebo for Albendazole|Oral Capsule
79705491|NCT04913610|Drug|Placebo for Ivermectin|Oral Capsule
79705492|NCT04913610|Drug|Ivermectin|Encapsulated Oral Tablet
79250091|NCT05210088|Drug|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
79250092|NCT05210088|Other|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
79388643|NCT06174701|Behavioral|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
79388644|NCT06174168|Other|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
79388645|NCT06173596|Drug|ALXN2080|Participants will receive ALXN2080 orally.
79544634|NCT05116644|Other|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
79544635|NCT05095571|Dietary Supplement|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
79544636|NCT05090111|Drug|ALG-055009|Single or multiple doses of ALG-055009
79544637|NCT05090111|Drug|Placebo|Single or multiple doses of Placebo
79705493|NCT04910217|Procedure|Conventional rehabilitation|Patients will undergo conventional rehabilitation
79705494|NCT04910217|Procedure|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
79705495|NCT04910217|Procedure|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
79705496|NCT04904835|Diagnostic Test|Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
79705497|NCT04903197|Drug|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
79705498|NCT04903197|Drug|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
79705499|NCT04903197|Drug|CC-99282|Cereblon (CRBN) E3 Ligase Modulator that induces the recruitment, ubiquitination and destruction of key target substrates (e.g. Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3)
79705500|NCT04898010|Device|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
79705501|NCT04893161|Drug|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
79705502|NCT04891757|Drug|FHD-286|FHD-286 administered orally
79705503|NCT04891757|Drug|Low Dose Cytarabine|LDAC administered subcutaneously (SC)
79705504|NCT04891757|Drug|Decitabine|Decitabine administered intravenously
79705505|NCT04890470|Drug|Oxytocin|intranasal administration of oxytocin (24 IU)
79705506|NCT04890470|Drug|Vasopressin|intranasal administration of vasopressin (20 IU)
79705507|NCT04890470|Drug|Placebo|intranasal administration of placebo
79544638|NCT05077098|Drug|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
79388646|NCT06173596|Drug|Itraconazole|Participants will receive Itraconazole orally.
79388647|NCT06173596|Drug|Fluconazole (AxMP)|Participants will receive Fluconazole orally.
79544639|NCT05063916|Drug|AK104|Given By IV
79705508|NCT04888338|Other|Data Capture|Treatment related data is collected
79705509|NCT04888338|Other|Electronic Medical Record|Medical records are reviewed
79705510|NCT04882137|Behavioral|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
79705511|NCT04881201|Procedure|blood sample|blood sample
80014755|NCT02089152|Other|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
79544640|NCT05034458|Dietary Supplement|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
79705512|NCT04880161|Biological|Ampion|Inhaled Ampion
79544641|NCT05017025|Drug|Aurora A Kinase Inhibitor LY3295668|Given PO
79705513|NCT04880161|Other|Placebo|Inhaled Placebo
79544642|NCT05017025|Drug|Osimertinib|Given PO
79544643|NCT05003739|Procedure|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
79544644|NCT04992208|Biological|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
79544645|NCT04987320|Drug|Olpasiran|Subcutaneous injection
79544646|NCT04979728|Other|At Home Self-Collections|Directly observed at home self-collection of blood samples
79705514|NCT04875221|Combination Product|Connectivity-based neurofeedback|Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
79705515|NCT04873778|Device|Kinesio taping|Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
79705516|NCT04873778|Device|Dynamic taping|Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
79705517|NCT04870788|Behavioral|Mindfulness Relaxation|Participate in mindfulness program
79705518|NCT04870788|Other|Quality-of-Life Assessment|Ancillary studies
79705519|NCT04870788|Other|Questionnaire Administration|Ancillary studies
79705520|NCT04865159|Drug|Tipifarnib|Cardiac Safety of Tipifarnib
79705521|NCT04864210|Drug|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
79705522|NCT04864210|Drug|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
79705523|NCT04853966|Behavioral|Physical activity counseling|Physical activity counseling will be performed using physical activity behavior steps of the transtheoretical model.
80014756|NCT02093130|Dietary Supplement|Pomegranate Juice|
80014757|NCT02093130|Dietary Supplement|Placebo|
80014758|NCT02089308|Drug|Test treatment : V0116 transdermal patch|
80014759|NCT02089308|Drug|Reference treatment : Nicotine transdermal patch|
79388648|NCT06173596|Drug|Carbamazepine (AxMP)|Participants will receive Carbamazepine orally.
79388649|NCT06167317|Drug|GS-0201|Pill administered orally
79388650|NCT06167317|Drug|Sacituzumab Govitecan|Administered intravenously
79388651|NCT06162728|Drug|Briquilimab|Subcutaneous Administration
79388652|NCT06162728|Other|Placebo|Placebo Comparator
79544647|NCT04966000|Behavioral|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
79544648|NCT04959240|Drug|Velmanase Alfa|
79544649|NCT04941664|Drug|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
80014760|NCT01678144|Device|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
80014761|NCT02086266|Other|PILATES|
80014762|NCT02086266|Other|PFMT and AES|
80014763|NCT02086344|Procedure|PBS|TLH plus PBS
79544650|NCT04918420|Device|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
79544651|NCT04911790|Biological|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
79705524|NCT04843488|Procedure|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
79705525|NCT04843488|Procedure|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
79846420|NCT02590211|Behavioral|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
79705526|NCT04837625|Other|no interventions|no interventions
79846421|NCT00854438|Other|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
79705527|NCT04837040|Drug|Paltusotine|Paltusotine, tablets, once daily by mouth
79705528|NCT04837040|Drug|Placebo|Placebo, tablets, once daily by mouth
79705529|NCT04835857|Device|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
79846422|NCT00857870|Drug|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
79846423|NCT00857870|Drug|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
79846424|NCT00848432|Drug|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
79250093|NCT05179733|Drug|six courses of zanubrutinib, rituximab and lenalidomide|Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
79250094|NCT05179733|Drug|six courses of rituximab combined with low-dose CHOP|Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
79388653|NCT06160986|Behavioral|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
79705530|NCT04835857|Device|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
79705531|NCT04835857|Device|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
79705532|NCT04831541|Drug|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
79544652|NCT04899908|Radiation|Stereotactic Radiation|Focused radiation beams to treat tumors
79544653|NCT04899908|Drug|AGuIX gadolinium-based nanoparticles|Intravenous injection
79544654|NCT04899908|Other|Placebo|Intravenous infusion
79705533|NCT04831034|Drug|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
79705534|NCT04829760|Dietary Supplement|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
79846425|NCT00854516|Procedure|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
79846426|NCT04043156|Radiation|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
79846427|NCT00854750|Drug|ACTHAR|SQ weekly injections
79250095|NCT05178797|Other|Kinesiology taping technique with exercise therapy|Kinesiology tape is a latex-free fiber that stretches longitudinally & elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.
79705535|NCT04829760|Dietary Supplement|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
79705536|NCT04829760|Dietary Supplement|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (~2 tablespoons) in two doses each day for 8 weeks
79846428|NCT00854750|Drug|ACTHAR|SQ weekly injections
79846429|NCT00854750|Drug|ACTHAR|SQ weekly injections
79846430|NCT00854750|Drug|ACTHAR|SQ weekly injection
79846431|NCT00858026|Other|Breastmilk|Exclusively breastfed babies
79846432|NCT00858026|Other|Standard milk|Weaning babies fed with the standard formula
79846433|NCT00858026|Other|Fermented milk|Weaning babies fed with the fermented formula
80014764|NCT02086344|Procedure|TLH _adnexal preservation|TLH without PBS
79705537|NCT04828863|Behavioral|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
80014765|NCT00153920|Drug|bortezomib|
79846434|NCT00848666|Drug|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
79846435|NCT00858104|Procedure|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
79250096|NCT05178797|Other|Compression decongestive therapy|"It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma."
79846436|NCT00858182|Drug|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
79846437|NCT00858182|Drug|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
79846438|NCT00854984|Behavioral|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
79846439|NCT04123340|Diagnostic Test|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
79846440|NCT02545244|Dietary Supplement|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
79846441|NCT02545244|Dietary Supplement|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
79846442|NCT02545244|Drug|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
79710184|NCT02880943|Drug|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
79846443|NCT00858260|Genetic|blood sample|Searching for Klotho variants in DNA
79846444|NCT00858338|Procedure|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
79846445|NCT00858338|Drug|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
80014766|NCT05095714|Other|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
80014767|NCT05095714|Other|Liver ultrasound|Half-yearly liver ultrasound
80014768|NCT02086422|Drug|ivabradine|
80014769|NCT02086422|Drug|Placebo|
80014770|NCT02086422|Other|Exercise|
80014771|NCT05376436|Diagnostic Test|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
80014772|NCT01073228|Drug|EVP-6124|
80014773|NCT01073228|Drug|Placebo|
80014774|NCT03558282|Other|Recession Observation|Soft tissue measurements
80014775|NCT03558282|Diagnostic Test|Crown Contour Observation|Ultrasound measures of implant crown contour.
80014776|NCT02660242|Drug|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
80014777|NCT02660242|Other|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
79388656|NCT06150937|Behavioral|AEGIDA intervention arm|The intervention arm has 4 sessions facilitated one-on-one by trained staff and lasting ~40 minutes. The first session focuses on establishing rapport, assessing HIV risk, and educating/training participants on HIV self-testing/PEP/PrEP. The second session on peer education/training, barriers to and facilitators of testing, and supporting peers in receiving reactive and/or indeterminate HIV test results, as well as self-care. The third session on stigma and discrimination and techniques to cope with and resist stigma. The final session is a culminating one focused on reviewing key skills and health promotion planning conducted in first three sessions. The intervention arm applies anti-intersectional stigma, empowerment, and harm reduction approaches. All participants will receive/have access to HIV self-test kits every three months.
79846446|NCT00858338|Procedure|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
79846447|NCT00855140|Other|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
79388657|NCT06150937|Behavioral|AEGIDA control arm|The control arm has 4 sessions via one-on-one facilitation by a trained facilitator and lasting ~40 minutes. It includes basic information on self-screening for common adverse health conditions among women in Kazakhstan, including STIs and HIV, as well as information on testing and risk reduction. All participants will receive/have access to HIV self-test kits every three months.
79846448|NCT00848900|Behavioral|Outdoor activity|Adding 1 hour outdoor time into school curricula
79846449|NCT00858416|Device|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
79846450|NCT00858416|Device|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
80014778|NCT02660242|Other|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
79388658|NCT06148792|Drug|Tafenoquine|oral treatment
79388659|NCT06148792|Drug|Primaquine|oral treatment
79388660|NCT06147505|Biological|XS005 Cell Injection|"Treatment on this study includes eight XS005 cell infusions over an 16 week period.~Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D)."
79388661|NCT06147505|Drug|Temozolomide（TMZ）|Patients were given temozolomide on day 1 to day 5 of each cycle, 28 days per cycle, for a total of 4 cycles.
79544655|NCT04890002|Device|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
79846451|NCT00848978|Behavioral|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity ~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
79846452|NCT00858572|Drug|STA-9090 (ganetespib)|Chemotherapy agent
79846453|NCT00858650|Other|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
79846454|NCT00515086|Drug|Everolimus|Tablets taken once a day with a full glass of water.
79846455|NCT00515086|Procedure|Surgery|Salvage surgical resection
79846456|NCT00849134|Drug|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
79846457|NCT00861224|Other|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
79846458|NCT00861302|Behavioral|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
80014779|NCT02089386|Drug|Tamoxifen|
80014780|NCT02089386|Procedure|Endoscopy|
80014781|NCT03557580|Drug|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
80014782|NCT03557580|Drug|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
79388662|NCT06145854|Drug|Cabotegravir Injection [Apretude]|Apretude for PrEP
79388663|NCT06139692|Drug|Dexmedetomidine|Patients receive perioperative sedation with dexmedetomidine
79846459|NCT01011322|Drug|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
79846460|NCT01011322|Drug|placebo|placebo
80014783|NCT03557580|Drug|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
80014784|NCT05627960|Drug|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
79388664|NCT06139692|Drug|Midazolam|Patients receive perioperative sedation with midazolam
79388665|NCT06137560|Device|Single vision spectacle lens|Standard single vision spectacle lens
79388666|NCT06137560|Device|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
80014785|NCT02089542|Other|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
79705538|NCT04828031|Drug|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
79544656|NCT04890002|Device|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
79544657|NCT04888858|Drug|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
79544658|NCT04873687|Device|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
79705539|NCT04826861|Behavioral|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
79705540|NCT04825496|Genetic|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
79705541|NCT04825496|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
79846461|NCT00858806|Drug|Imatinib|"Intermittent Imatinib administration.~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
79846462|NCT02545088|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
79846463|NCT02545088|Other|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
79846464|NCT02545088|Other|2nd control group|The 2nd control group will not receive an intervention.
79544659|NCT04859842|Other|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
79250097|NCT05154825|Other|Imaging-Observational|Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
79250098|NCT05152303|Drug|Remimazolam Tosilate|Loading dose: 0.08mg/kg IV of Remimazolam Tosilate, Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1mg/kg/h
79250099|NCT05152303|Drug|Remimazolam Tosilate|Loading dose: 0.08mg/kg, Drug: Propofol Injection Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.2mg/kg/h IV of Propofol Injection
79250100|NCT05149664|Device|Therapeutic ultrasound (TUS)|As described elsewhere, a sleeve is wrapped around the subject's targeted calf such that the inner lining with attached transducers are positioned around the calf muscle, with a gel-skin interface. The ultrasound energy is transmitted from these transducers to the deeper layers of the muscle.
79250101|NCT05096273|Behavioral|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
79250102|NCT05083247|Drug|mFOLFIRINOX or Gemcitabine nab-paclitaxel|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
79705542|NCT04825496|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
79846465|NCT00849368|Drug|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
79846466|NCT02544932|Drug|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
79846467|NCT02544932|Drug|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
79846468|NCT02544932|Drug|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
79846469|NCT02544854|Drug|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~First 15 minutes: 15 mg/kg/min~16 to 30 minutes: 13 mg/kg/min~31 to 60 minutes: 11 mg/kg/min~61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~5, 15 and 25 minutes of starting infusion,~1, 3, 5, 7, 9 and 12 minutes of bolus and,~5, 25, 60 and 120 minutes of infusion ended."
79846470|NCT00861458|Drug|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
79250103|NCT05083247|Radiation|Isotoxic High-Dose (iHD)-SBRT|Radiation therapy
79705543|NCT04815239|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
79705544|NCT04815239|Behavioral|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
79705545|NCT04809220|Drug|Dulaglutide|Administered SC
79846471|NCT00861536|Drug|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
80014786|NCT01295060|Drug|Octreotide|84 mg Octreotide Implant
79705546|NCT04809220|Drug|Oral antihyperglycemics|Administered orally
79705547|NCT04804969|Device|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
79705548|NCT04798755|Drug|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
79544660|NCT04859842|Other|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
79544661|NCT04859842|Other|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
79705549|NCT04798755|Drug|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
79846472|NCT00861536|Drug|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
79846473|NCT00849446|Device|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
79846474|NCT02544776|Drug|Clomifene citrate ( clomid 50 mg )|
79250104|NCT05083247|Procedure|Surgery|Surgery
79250105|NCT05076110|Drug|Oxycodone|5 mg tablets every 4 hours postoperatively as needed for pain control
79250106|NCT05076110|Drug|Ibuprofen|800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
79846475|NCT02544776|Drug|Amlodipine|
79846476|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
79846477|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
79846478|NCT00859196|Drug|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
79846479|NCT00859196|Drug|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
79846480|NCT00849602|Drug|Placebo|Placebo bid for three days
79250107|NCT05076110|Drug|Gabapentin|300 mg three times a day for 5 days then wean off by day 10 postoperatively
79250108|NCT05076110|Drug|Acetaminophen|1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
79250109|NCT05076110|Drug|Methocarbamol|500 mg three times a week for 2 weeks postoperatively
79544662|NCT04854291|Other|Administration of donor FMT|Intracaecal infusion of FMT
79250110|NCT05070390|Drug|MK-0616|10 mg capsule administered orally
79544663|NCT04854291|Other|Administration of placebo|Intracaecal infusion of carrier solution
79544664|NCT04803734|Drug|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
79544665|NCT04803734|Drug|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
79250111|NCT05069584|Procedure|Biopsy|patient must have a biopsy for his prostate cancer
79544666|NCT04799964|Device|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
79544667|NCT04799964|Device|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
79705550|NCT04798755|Drug|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
79705551|NCT04794816|Other|Questionnaire Administration|Complete questionnaire
79705552|NCT04787783|Other|Web based preoperative assessment|Preoperative assessment conducted through a web based application
79710185|NCT02881021|Other|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
79846481|NCT00849602|Drug|Chloroquine|Chloroquine bid for three days
79846482|NCT00859274|Drug|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
79250112|NCT05063838|Other|Pharmacogenomic optimisation of anaesthetic medications|Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.
79250113|NCT05048680|Procedure|Hypoxia and/or Exercise|Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
79250114|NCT05174650|Drug|Atezolizumab|Infusion i.v. of atezolizumab on day 1 of a 3-week cycle, first infusion rate over 60 minutes, subsequent infusion rates 30 minutes if tolerated for a maximum of 16 cycles in total
79250115|NCT05174650|Drug|Derazantinib|Oral intake of 300 mg derazantinib continuously on day 1 to day 21 of a 3-week cycle for a maximum of 16 cycles in total
79544668|NCT04784247|Drug|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
79544669|NCT04784247|Drug|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
79846483|NCT00859352|Drug|AZD1981|oral tablets during 14 consecutive days.
79846484|NCT00859352|Drug|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
79846485|NCT00861770|Other|Ultrafiltration|Ultrafiltration based on standard of care.
79846486|NCT00861770|Other|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
79846487|NCT00618410|Device|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
79846488|NCT00618410|Other|Placebo|Nasal placebo
79846489|NCT00861926|Drug|Ventolin|Ventolin : salbutamol sulfate 100µg
79846490|NCT00861926|Drug|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
79846491|NCT04041518|Procedure|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
79846492|NCT04041752|Behavioral|SOLID|condition with a classical meal served using solid food items
79388667|NCT06137560|Device|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
80014787|NCT05374876|Other|Hand Therapy Until CIPN|Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
80014788|NCT02086656|Drug|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
79250116|NCT05020353|Device|OraQuick® HIV Self-Test|OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.
79250117|NCT05006339|Device|Dental Monitoring|Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
79250118|NCT05006339|Other|Clinic Review|Patients in this arm are required to attend in clinic appointments for their retention review
79250119|NCT04998357|Other|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
79388668|NCT06137560|Device|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
79388669|NCT06137560|Device|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
79388670|NCT06137118|Drug|AZD0486|Investigational Product administered via intervenous infusion.
79846493|NCT04041752|Behavioral|LIQUID_P|condition with a liquid meal served using a powder solution
79388673|NCT06131983|Drug|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
79388674|NCT06131983|Drug|Placebo|calculated volume to match active treatment by IV infusion
79544670|NCT04771650|Other|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
79544671|NCT04766073|Procedure|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
79544672|NCT04730570|Behavioral|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
79544673|NCT04714086|Drug|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
79544674|NCT04681287|Drug|inetetamab and PD-1 inhibitor combined with chemotherapy.|"Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
79705554|NCT04778371|Other|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
79705555|NCT04778371|Other|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
79250120|NCT04986579|Device|Paxman Scalp Cooling System|Cap attached to coolant lines connected to a refrigeration unit placed on scalp
79250121|NCT04986579|Drug|Eribulin|Intravenous Infusion
79705556|NCT04775550|Drug|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
79705557|NCT04775550|Drug|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
79705558|NCT04775550|Drug|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
79705559|NCT04775550|Drug|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
79710186|NCT02881021|Device|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
79250122|NCT04986579|Drug|Sacituzumab govitecan|Intravenous Infusion
79250123|NCT04986579|Drug|Trastuzumab deruxtecan|Intravenous Infusion
79388675|NCT06131840|Drug|SGN-CEACAM5C|Given into the vein (IV; intravenous)
79388676|NCT06126328|Device|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
79391719|NCT02548312|Other|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
79391720|NCT04481100|Drug|itraconazole|Oral administration of itraconazole twice daily concurrent with chemoradiation
79391721|NCT02405754|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
79544675|NCT04681131|Biological|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
79705560|NCT04775082|Drug|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
79705561|NCT04775082|Drug|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
79705562|NCT04774991|Drug|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1 to <12 months of age, weight-based dosing will be used~For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
79846494|NCT04041752|Behavioral|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
79846495|NCT04041206|Device|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated [Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)]. The acupoint microcirculation will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
79846496|NCT00849992|Drug|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
79846497|NCT00849992|Procedure|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
79846498|NCT00862004|Procedure|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
79846499|NCT03846128|Biological|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
79846500|NCT00859664|Other|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
79544676|NCT04681131|Biological|PD-1 inhibitor|PD-1 inhibitor
79846501|NCT00859742|Procedure|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
79846502|NCT00618722|Drug|Deoxycholic Acid Injection|
79846503|NCT00618722|Drug|Placebo|
79250124|NCT04967703|Procedure|Group A|Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
79250125|NCT04967703|Procedure|Group B|Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
79250126|NCT04967703|Procedure|Group C|Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
79250127|NCT04967222|Behavioral|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Participants meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique. .
79250128|NCT04967222|Behavioral|Control Downregulate Condition|Participants either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
79302836|NCT03314597|Other|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
79544678|NCT04641741|Drug|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
79544679|NCT04626141|Drug|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
79544680|NCT04626141|Drug|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
79544681|NCT04625959|Behavioral|Behavioral Therapy for Eating Disorders|Change behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
79544682|NCT04625959|Behavioral|MABT: Mindful Awareness|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically mindful awareness, designed to enhance self-regulation. Mindful awareness strategies include developing inner and outer wisdom, formal meditation, and shifting awareness to the present moment. Mindful awareness skills also include increasing awareness of thoughts, feelings, physical sensations, and hunger and fullness cues.
79705563|NCT04773600|Drug|Roflumilast (ARQ-151) cream|Roflumilast (ARQ-151) cream 0.15% - Active
79705564|NCT04773600|Drug|Vehicle cream|Vehicle cream
79710187|NCT04328519|Other|observation|observation
79710188|NCT02893982|Radiation|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
79846504|NCT02546180|Other|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
79388677|NCT06125483|Procedure|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, TBI/Flu/Bu/Mel combined with UCBT is safe and feasible for the treatment of patients with malignant hematological diseases who experienced post-transplant relapse, which has enormous potential to improve patient outcomes.
79388678|NCT06124404|Drug|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
79705565|NCT04769024|Device|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~The facilitator announces the immersion theme of the session~Participants are equipped with virtual reality head-mounted displays.~Participants watch the content.~The head-mounted displays are removed.~A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
79705566|NCT04769024|Behavioral|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes…). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
79388679|NCT06124404|Drug|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
79544683|NCT04625959|Behavioral|MABT: Values|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically values, designed to enhance self-regulation. Values skills include identifying and clarifying values, living a values life, making values-consistent decisions, addressing competing values, values awareness, and using values to address negative moods.
79544684|NCT04625959|Behavioral|MABT: Emotion Modulation|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically emotion modulation, designed to enhance self-regulation. Emotion modulation skills include long-term habits for emotion regulation, coping strategies, crisis management, and cognitive reappraisal.
79705567|NCT04768621|Other|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
79705568|NCT04764162|Dietary Supplement|Choline capsule|Participants will consume 1000 mg (2 x 500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. They will continue to consume 1000 mg of choline bitartrate during the post-testing period.
79705569|NCT04764162|Dietary Supplement|Placebo capsule|Participants will consume 1000 mg (2 x 500 mg) of placebo (maltodextrin) for 28 consecutive days. They will continue to consume 1000 mg of placebo during the post-testing period.
79846505|NCT02546180|Other|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
79846506|NCT02544698|Biological|One dose of PCV13a vaccine|
79846507|NCT02544698|Biological|One dose of PCV13a vaccine|
79544685|NCT04625959|Behavioral|MABT: Distress Tolerance|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically distress tolerance, designed to enhance self-regulation. Distress tolerance skills include psychological acceptance, uncoupling, willingness, and dealing with dirty distress.
79846508|NCT02544698|Biological|three doses of PCV13a vaccine|
79846509|NCT02544698|Biological|three doses of PCV13a vaccine|
79846510|NCT03845816|Behavioral|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
79250129|NCT04954391|Procedure|Pulsed radiofrequency neuromodulation of the suprascapular nerve only|"PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg"
79302837|NCT03211429|Behavioral|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
79302838|NCT03211429|Other|Tai chi|Tai Chi training in the Yang style of 24 movement
79302839|NCT03211429|Other|Postural control exercise|Individually adjusted progressive and specific postural control training,
79846511|NCT00862160|Device|ROCsafeTM|using minimized perfusion circuit while CABG
79302840|NCT02478281|Drug|Methylene Blue|
79302841|NCT02482337|Procedure|POEM|POEM procedure in the OR
79846512|NCT00850148|Procedure|Anwar|Anwar surgical method
79846513|NCT00850148|Procedure|Melles|Melles surgical method
79705570|NCT04762290|Other|Dance|The intervention is a series of expressive dance movements.
80014789|NCT01294202|Drug|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
79544686|NCT04613440|Other|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
79250130|NCT04954391|Procedure|Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves|Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
79250131|NCT04951687|Dietary Supplement|Ecologic Barrier©|5x10^9 CFU/ 2g per day of Ecologic Barrier©
79250132|NCT04951687|Dietary Supplement|Placebo powder|matched placebo
79388680|NCT06124404|Drug|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
79388681|NCT06123715|Drug|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
79388682|NCT06123715|Drug|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
79388683|NCT06117982|Drug|Neupogen|Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days
79544687|NCT04613440|Other|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
79544688|NCT04613440|Other|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
79705571|NCT04761120|Device|Abbott SJM Rigid Saddle Ring|The Abbott SJM Rigid Saddle Ring is a rigid, polyester-velour-covered, titanium alloy mitral annuloplasty ring with a saddle shape intended to mimic the shape of a healthy mitral annulus during systole.
79705572|NCT04761120|Device|Abbott SJM Séguin Ring|The Abbott SJM Séguin Ring is a semi-rigid, polyester-velour-covered, polyethylene mitral annuloplasty ring that varies in thickness and flexibility over its circumference, with the posterior portion of the ring having greater flexibility than the anterior portion.
79846514|NCT00862238|Behavioral|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
79846515|NCT00862238|Other|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, & C
80014790|NCT05098990|Drug|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
80014791|NCT05098990|Drug|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
79710189|NCT04417010|Procedure|Radiofrequency ablation|Both groups of patients underwent radiofrequency ablation
79710190|NCT04425941|Other|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
80014792|NCT02093442|Procedure|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
79846516|NCT00860054|Dietary Supplement|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
80014793|NCT01071902|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79250133|NCT04939441|Drug|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF [Vemlidy® 25mg QD] monotherapy
79250134|NCT04937738|Drug|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
79388684|NCT06115967|Drug|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
79388685|NCT06115967|Drug|Placebo|Placebo will be administered as a single sub-cutaneous dose.
79250135|NCT04937738|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
79250136|NCT04937738|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
79388686|NCT06115330|Device|Press Needle Acupuncture|Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
79388687|NCT06115278|Other|survey|survey
79388688|NCT06112379|Drug|Dato-DXd|Experimental drug IV infusion
79388689|NCT06112379|Drug|Durvalumab|Experimental drug IV Infusion
79388690|NCT06112379|Drug|Pembrolizumab|IV Infusion Active comparator
79544689|NCT04613440|Other|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
79250137|NCT04937738|Drug|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
79250138|NCT04937738|Drug|Capecitabine|1000 mg/m² two times per day (BID), d1-14
79250139|NCT04937738|Drug|Oxaliplatin|130 mg/m² d1 i.v. every 3 weeks
79544690|NCT04609852|Drug|E8001|Intravenous infusion.
79705573|NCT04761120|Device|Abbott SJM Tailor Ring|The Abbott SJM Tailor Ring is a flexible, polyester-velour-covered, silicone annuloplasty ring indicated for use in surgical repair of the mitral or tricuspid valve. The Tailor Ring can be implanted as a full annuloplasty ring, or the surgeon can remove the ring's cut zone with a scalpel and use the partial Tailor Ring as a posterior annuloplasty band.
79846517|NCT00850226|Behavioral|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
79705574|NCT04761120|Device|Abbott SJM Tailor Band|The Abbott SJM Tailor Band is a flexible, polyester-velour-covered, silicone band for posterior annuloplasty indicated for use in surgical repair of mitral or tricuspid valve. The Tailor Band is identical to the Tailor Ring with the cut zone removed, save that the polyester covering is sewn closed at the ends of the band during manufacturing.
79846518|NCT00850226|Behavioral|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
79705575|NCT04760652|Behavioral|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
79846519|NCT00862316|Device|Oxford Unicompartmental Knee|Knee Arthroplasty
79846520|NCT02544620|Other|Does fulfil of discharge criteria on the day of the surgery|
79846521|NCT02544620|Other|Does not fulfil of discharge criteria on the day of the surgery|
79846522|NCT02546258|Device|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
79250140|NCT04890925|Behavioral|Community Support Network (CSN) intervention|The SOAR Community Support Network (CSN) intervention is a multi-pillar, interdisciplinary system platform focused on improving higher order cognitive functions through aerobic exercise, mindfulness meditation, counselling, quality of life tracking, and cognitive exercises. The goal is to improve cognitive functions such as executive function, reasoning, and memory among those experiencing the effects of brain injury. Individually tailored protocol is administered to each participant. Goals are set daily, weekly, and monthly, and accomplishments tracked in a database. The CSN seeks to test and evaluate the success of the program when applied, and tailored, to survivors of brain injury in intimate partner violence.
79250141|NCT04890925|Behavioral|Usual care|Participants in this group will receive dose-equivalent usual care based on the findings of a recent survey of the Canadian Rehabilitation Clinicians for concussion management, scoping review and clinical studies. Based on the evidence, usual care in this study will consist of education and aerobic exercises. Education includes information about the injury, recovery, management, nutrition, hydration, sleep, reassurance and goal setting that will be adapted to make appropriate to the population of this study. Aerobics include stationary cycling and treadmill exercises.
79846523|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
79846524|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
79846525|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
79846526|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
79388691|NCT06112379|Drug|Doxorubicin|IV infusion Experimental/Active Comparator
79388692|NCT06112379|Drug|Epirubicin|IV Infusion Experimental/Active Comparator
80014794|NCT01071902|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79302842|NCT03074565|Device|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
79388693|NCT06112379|Drug|Cyclophosphamide|IV infusion Experimental/Active Comparator
79388694|NCT06112379|Drug|Paclitaxel|IV infusion Experimental/Active Comparator
79388695|NCT06112379|Drug|Carboplatin|IV infusion Experimental/Active Comparator
79388696|NCT06112379|Drug|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
79388697|NCT06112379|Drug|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
79388698|NCT06109818|Drug|ICP-488 Tablets|ICP-488 will be administered as tablet
79388699|NCT06109818|Drug|ICP-488 Placebo|ICP-488 Placebo will be administered as tablet
79846527|NCT02544542|Device|Rectum cooling system|
79388705|NCT06109194|Other|Joint mobilization|Grade III manual joint mobilization as standard-of-care physical therapy intervention
79388706|NCT06105983|Drug|Sisunatovir|Single Dose
79388707|NCT06105983|Drug|Rabeprazole|Tablets once daily for 7 days
79388708|NCT06098677|Dietary Supplement|Carotenoids supplementation|Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
79388709|NCT06098677|Dietary Supplement|Placebo|Daily oral supplementation of a soft gel capsule containing only placebo oil
79388710|NCT06096779|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
79544691|NCT04609852|Drug|Placebo|Intravenous infusion.
79544692|NCT04603495|Drug|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
79544693|NCT04603495|Drug|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
79705576|NCT04760613|Drug|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
79250142|NCT04884178|Device|Trifocal Preloaded IOL Delivery System|UV and blue-light filtering foldable trifocal IOL with a +2.2 diopter (D) addition power of intermediate visual acuity and a +3.3 D addition power of near visual acuity. This device is approved in Taiwan.
79388711|NCT06096779|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
79388712|NCT06094972|Behavioral|Adolescent Community Reinforcement Approach, A-CRA|A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.
79391722|NCT03171792|Other|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
79544694|NCT04603495|Drug|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
79250143|NCT04868968|Drug|DFV890|DFV890
79544695|NCT04597619|Other|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
79250144|NCT04860505|Drug|Doxycycline|Doxycycline (DOX [200 mg]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
79250145|NCT04860505|Drug|Biktarvy|Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
79250146|NCT04840680|Other|No Intervention|This is a non-interventional study.
79544696|NCT04593940|Drug|Infliximab|study drug or matching placebo
79544697|NCT04593940|Drug|Abatacept|study drug or matching placebo
79544698|NCT04593940|Drug|Remdesivir|Standard of Care
79250147|NCT04836858|Biological|CMK389|Active
79250148|NCT04836858|Biological|Placebo|Placebo Comparator
79250149|NCT04829539|Behavioral|Behavioral Intervention|Receive BBT-CI
79250150|NCT04829539|Behavioral|Behavioral Intervention|Receive HEAL
79705577|NCT04760613|Drug|Placebo|identical capsules containing placebo (taken daily by mouth)
79705578|NCT04751292|Other|Exposure to high altitude|permanence at high (>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
79544699|NCT04593940|Drug|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
79544700|NCT04584294|Behavioral|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~Questions to capture reproductive goals and orientations towards a potential pregnancy~Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~A feature for adding free-text questions that patients may have for their provider~An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
79705579|NCT04740827|Drug|Atogepant 60 mg|Atogepant tablets.
79705580|NCT04740827|Drug|Placebo|Atogepant matching placebo tablets.
79705581|NCT04740697|Other|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
79846528|NCT02544542|Device|Hyper-hypothermia blanket|
79846529|NCT00862472|Drug|DuoTrav APS|DuoTrav APS QD AM
79250151|NCT04829539|Other|Quality-of-Life Assessment|Ancillary studies
79250152|NCT04829539|Other|Questionnaire Administration|Ancillary studies
79544701|NCT04566900|Behavioral|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
79250153|NCT04809870|Procedure|surgery|retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
79250154|NCT04809792|Radiation|SBRT on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
79250155|NCT04800341|Other|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
79250156|NCT04784390|Device|Binocular video games|Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
79250157|NCT04784390|Device|Patching of the sound eye|Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
79302843|NCT03074565|Device|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
79250158|NCT04742465|Other|Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
79705582|NCT04739124|Other|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~Biological sampling at the start and end of the education program (glycated hemoglobin).~Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
79388713|NCT06094972|Behavioral|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.
79388714|NCT06094010|Drug|Baloxavir Marboxil|Baloxavir marboxil will be administered as oral suspension either as 2 milligrams per kilograms (mg/kg) (if weight less than 20 kg), or 40 mg (if weight more than or equal to 20 kg to less than 80 kg) or 80 mg (if weight more than or equal to 80 kg).
79544702|NCT04566900|Other|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
79388715|NCT06092970|Drug|RBT-1|Intravenous administration
79705583|NCT04739124|Other|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
79705584|NCT04732494|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
79705585|NCT04732494|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
79705586|NCT04732494|Drug|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
79705587|NCT04732273|Other|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
79705588|NCT04732273|Other|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
79705589|NCT04725240|Drug|Setmelanotide|Setmelanotide for SC injection
79544703|NCT04562831|Dietary Supplement|EH301 (Nicotinamide Riboside/Pterostilbene)|Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.
79544704|NCT04548648|Drug|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
79544705|NCT04548648|Drug|Isavuconazole|Prophylactic treatment with isavuconazole includes loading dose of 372 mg (2 capsules) administered orally every 8 hours for 6 doses (48 hours), followed by maintenance administration of 372 mg (2 capsules) once daily as long as the subject is on study treatment.
79705590|NCT04721132|Biological|Atezolizumab|Given IV
79705591|NCT04721132|Biological|Bevacizumab|Given IV
79705592|NCT04721132|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79705593|NCT04721106|Drug|Vizimpro|treatment group
79705594|NCT04721067|Device|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
79846530|NCT00862472|Drug|DuoTrav|DuoTrav QD AM
79846531|NCT00860210|Device|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
79846532|NCT00850304|Drug|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
80014795|NCT01071902|Other|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79846533|NCT00850304|Drug|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
80014796|NCT01071902|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
80014797|NCT05082766|Drug|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
80014798|NCT02086734|Other|Perfusion-CT|"Baseline Perfusion CT-Scan (before AAT)~Follow-Up I Perfusion-CT Scan 7 days after start with AAT~Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
79544706|NCT04544111|Drug|Trametinib|"2mg by mouth daily~*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"
80014799|NCT01284530|Drug|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
79388716|NCT06092970|Drug|Placebo|Intravenous administration
79544707|NCT04544111|Drug|Dabrafenib|150 mg twice daily (OR at dose the patient previously tolerated)
79544708|NCT04544111|Drug|PDR001|400mg IV every 4 weeks
79544709|NCT04539483|Drug|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
79544710|NCT04539483|Drug|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
79544711|NCT04539483|Behavioral|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
79846534|NCT00850382|Drug|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
79250159|NCT04724018|Drug|Sacituzumab Govitecan (SG)|Intravenous infusion
79544712|NCT04539483|Behavioral|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
79705595|NCT04721067|Behavioral|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
79544713|NCT04539483|Procedure|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
79846535|NCT00850382|Drug|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
79846536|NCT00850382|Drug|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
79846537|NCT00860366|Drug|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
79846538|NCT00860366|Other|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
79846539|NCT02544464|Drug|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
79544714|NCT04539483|Procedure|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
79544715|NCT04531969|Other|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
79544716|NCT04524208|Drug|Cabozantinib|Cabozantinib is administered orally at the dose of 60 mg per day..
79388717|NCT06091566|Device|UCon-Bar|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for either 4 weeks or 12 weeks using UCon with the Bar electrode
79544717|NCT04522739|Drug|Spironolactone|The initial dose of spironolactone will be 25mg and will be increased to 50 mg after 2 weeks provided the following criteria are present: 1) systolic blood pressure (SBP) >110 mm Hg, 2) diastolic blood pressure (DBP) > 60 mm Hg, and no reported symptoms of hypotension (dizziness or weakness). Participants will take one capsule by mouth per day.
79544718|NCT04522739|Drug|Placebo|A placebo to match spironolactone will be taken orally once per day.
79544719|NCT04517487|Biological|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
79544720|NCT04517487|Biological|Placebo|Placebo
79388718|NCT06088095|Other|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
79846540|NCT02544464|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
79846541|NCT00862550|Other|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
79846542|NCT00862628|Drug|Rebamipide|100mg tid, 4 or 8 weeks
79250160|NCT04724018|Drug|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
79250161|NCT04719910|Other|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
79250162|NCT04719910|Other|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
79250163|NCT04713592|Drug|Risankizumab|Subcutaneous (SC) Injection
79250164|NCT04713592|Drug|Placebo for Risankizumab|Subcutaneous (SC) Injection
79388719|NCT06084676|Drug|Immunotherapy|Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
79391723|NCT02405598|Drug|Salbutamol|"Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)"
79391724|NCT03171402|Diagnostic Test|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
79391725|NCT03173664|Device|KAMRA Inlay|Unilateral implantation of the KAMRA inlay in the corneal stroma.
79705596|NCT04717843|Other|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
79391726|NCT03173586|Other|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
79705597|NCT04717843|Other|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
79544721|NCT04517370|Device|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
79544722|NCT04487041|Biological|Standard dose influenza vaccination|Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
79544723|NCT04487041|Biological|High dose influenza vaccination|4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
79705598|NCT04717843|Other|Holter ECG|48 hours ECG recording
79705599|NCT04717843|Other|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
79705600|NCT04717843|Biological|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
79250165|NCT04704401|Other|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
79250166|NCT04687176|Drug|Oral Arsenic Trioxide Formulation|"Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin or idarubicin will only be used during induction in patients <65 with presenting white blood cell count (WBC) ≥ 10 x 10^9/L. In patients not receiving daunorubicin, hydroxyurea if WBC ≥ 5 x 10^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.~Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).~Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week)."
79250167|NCT04676815|Procedure|NBI and interventional bronchoscopy|NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
79250168|NCT04667065|Other|Physical activity|Physical activity with the remotely guidance of physical activity teachers
79250169|NCT04653831|Drug|Pirfenidone|Treatment with Pirfenidone as mentioned in the experimental arm description.
79250170|NCT04653831|Other|Standard of care|Treatment with SoC as mentioned in the control arm description.
79250171|NCT04635800|Drug|MHU650|MHU650 powder for solution for injection
79388720|NCT06083987|Behavioral|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
79391727|NCT03173274|Behavioral|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
79391728|NCT03173274|Behavioral|Contingency Management|Contingent Reinforcement for negative breath CO samples
79544724|NCT04478708|Biological|AMG 133|Participants will receive AMG 133 as a single dose in Part A and multiple doses in Part B and C.
79705601|NCT04717843|Other|Standard MRI|Acquisitions of MR imagining
79705602|NCT04715035|Other|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
79705603|NCT04713150|Other|No Intervention|No Intervention
79250172|NCT04627610|Other|Rectal prolapse, rectocele and elytrocele|Recurrence of dyschesia on rectal prolapse, rectocele and elytrocele
79391729|NCT03173274|Behavioral|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value [CM control]
79544725|NCT04478708|Drug|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
79544726|NCT04478006|Genetic|RNA-seq|Gene expression and fusion transcripts analysis
79705604|NCT04713124|Behavioral|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
79705605|NCT04713124|Other|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
79846543|NCT00507442|Drug|VELCADE (bortezomib)|bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
79846544|NCT00507442|Drug|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
79846545|NCT00507442|Drug|cyclophosphamide|cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
79250173|NCT04597632|Drug|brolucizumab|brolucizumab 6 mg/0.05 mL solution for intravitreal injection
79302844|NCT03211039|Genetic|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
79544727|NCT04478006|Genetic|whole exon sequencing|Genetic alternation analysis
79544728|NCT04478006|Other|Cytogenetics test|Remission and relapse are monitored by cytogenetic analyses.
79250174|NCT04579198|Behavioral|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|The intervention, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), consists of four components: First, all caregivers of PTI patients (ages 0-11) will be given brief education in the hospital related to children's and caregivers' emotional recovery. Second, all families will receive an in-hospital risk-reduction session. These sessions will address avoidance and trauma triggers; scheduling of pleasurable activities; and coping strategies. Third, all caregivers will receive the CAARE app-based components before discharge. The app will engage caregivers for 30 days via an automated SMS system. MHealth components of care will reinforce risk-reduction strategies. Fourth, 30 days post-discharge, a brief behavioral health screen will be completed by caregiver and child to assess need for more intensive screening by a mental health provider. Caregivers/children reporting elevated symptom levels will receive a comprehensive screening and referral process.
79705606|NCT04701476|Drug|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
79250175|NCT04517500|Behavioral|Home-based pulmonary rehabilitation program|Subjects will wear an activity monitor while doing at home exercises using a computer tablet
79250176|NCT04517500|Behavioral|Mindful breathing module|Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.
79250177|NCT04517500|Behavioral|Health coaching|Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
79250178|NCT04512638|Drug|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
79250179|NCT04512638|Drug|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
79250180|NCT04512638|Procedure|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
79388721|NCT06083987|Behavioral|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
79391730|NCT02401386|Behavioral|The Eight Brocades|Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
79391731|NCT02407938|Other|Rice meal|
79544729|NCT04461899|Biological|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
79544730|NCT04455048|Other|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
79544731|NCT04455048|Other|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
79705607|NCT04701476|Drug|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
79705608|NCT04701476|Drug|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
79705609|NCT04678427|Other|6 Minute Walk Functional Test|Complete 6-minute walk test
79705610|NCT04678427|Behavioral|Behavioral Intervention|Participate in walking and other activities
79705611|NCT04678427|Other|Survey Administration|Complete survey
79705612|NCT04678427|Behavioral|Timed Get Up and Go Test|Complete timed get up and go test
79846546|NCT00507442|Drug|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
79250181|NCT04512638|Procedure|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
79250182|NCT04510428|Drug|Ocular Surface Immune Globulin (OSIG)|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
79250183|NCT04510428|Drug|Placebo|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
79250184|NCT04485416|Drug|Eltrombopag|Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
79250185|NCT04473599|Behavioral|Uniform random message delivery|In this arm, the categories and timings of text-messages will be delivered to participants using a random schedule
79302845|NCT02482415|Other|Psycho-educational|
79846547|NCT00850616|Biological|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
79705613|NCT04678271|Behavioral|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
79705614|NCT04675424|Device|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
79250186|NCT04473599|Behavioral|Reinforcement learning message delivery|In this arm, the categories and timings of text-messages will be chosen by a reinforcement learning algorithm
79388722|NCT06083987|Behavioral|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
79846548|NCT00850616|Biological|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
79391732|NCT03173508|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79846549|NCT00862706|Drug|Telbivudine/LDT600A|Oral once daily
79846550|NCT00860444|Behavioral|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
79846551|NCT00860444|Behavioral|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
79846552|NCT00860522|Drug|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
79846553|NCT00860522|Drug|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
79250187|NCT04473599|Behavioral|Mood ratings only|In this arm, participants will monitor their mood daily and receive feedback on that mood randomly
79250188|NCT04437303|Drug|Continuation of oral anticoagulants|Oral anticoagulant treatment will not be interrupted before the procedure.
79250189|NCT04437303|Drug|Interruption of oral anticoagulants|"Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m^2 96 hours before procedure.~For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician."
79391733|NCT03173508|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79544732|NCT04442828|Diagnostic Test|Use of 3D echocardiography in patient follow-up|Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
79544733|NCT04419818|Behavioral|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
79250190|NCT04431063|Procedure|Distal Stump Suturing|in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
79705615|NCT04672811|Device|Study App and Apple Watch|Study App and Apple Watch
79846554|NCT02544386|Procedure|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
79846555|NCT04041362|Biological|UB-421|Monoclonal antibody by IV infusion plus standard ART
79846556|NCT04041362|Other|Antiretroviral Therapy (ART)|Standard ART
79544734|NCT04402346|Procedure|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
79846557|NCT02546102|Biological|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
79846558|NCT02546102|Biological|Placebo|Control, autologous monocytes-enriched PBMC.
79846559|NCT00860678|Other|Physical activity|
79846560|NCT00860678|Other|no Intervention|
80014800|NCT03556878|Behavioral|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
79544735|NCT04402346|Procedure|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
79705616|NCT04663074|Diagnostic Test|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
79705617|NCT04651192|Other|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
79705618|NCT04646434|Procedure|Electroencephalography|Undergo EEG
79846561|NCT00860756|Other|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
79846562|NCT00850772|Dietary Supplement|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
79846563|NCT00850850|Drug|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
79846564|NCT00850850|Drug|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
79846565|NCT03845426|Other|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
79846566|NCT00860834|Behavioral|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
79846567|NCT00860834|Behavioral|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
79846568|NCT00860912|Procedure|Collagen Matrix|surgical/reinforcing material
79388723|NCT06083987|Behavioral|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
79388724|NCT06083987|Behavioral|Control Group - No Interventions|Control Group - Will be given no interventions
79544736|NCT04397484|Drug|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
79705619|NCT04646434|Procedure|Electromyography|Undergo EMG
79705620|NCT04646434|Other|Questionnaire Administration|Complete questionnaire
79705621|NCT04645420|Procedure|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
79705622|NCT04638088|Other|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
79705623|NCT04636177|Behavioral|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
79705624|NCT04633551|Dietary Supplement|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
79705625|NCT04633096|Behavioral|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
79705626|NCT04633096|Behavioral|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
79705627|NCT04620746|Drug|Penicillin Major Determinant (PrePen) Skin Testing|Skin testing followed by oral challenge with amoxicillin 250 mg single dose
79705628|NCT04620746|Drug|Direct Oral challenge|Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
79705629|NCT04614909|Drug|Pamiparib|60mg administered orally BID for 4 days prior to surgical resection
79705630|NCT04614909|Drug|Olaparib|200mg administered orally BID for 4 days prior to surgical resection
79846569|NCT00860990|Other|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
79846570|NCT00619892|Drug|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
79846571|NCT00619892|Drug|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
79846572|NCT04040972|Other|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
79705631|NCT04614909|Radiation|Radiation therapy|Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
79846573|NCT00507130|Biological|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
79846574|NCT00507130|Biological|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
79846575|NCT00507130|Biological|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
79846576|NCT00507130|Other|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
79250191|NCT04420728|Combination Product|Early auto-mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
79846577|NCT00863096|Biological|Gardasil|HPV vaccine
79846578|NCT00863174|Drug|SPARC147709|SPARC147709 injection
79846579|NCT00863174|Drug|Reference147709|Reference147709 injection
79846580|NCT00870272|Drug|Misoprostol|400mcg misoprostol taken sublingually or buccally
79846581|NCT00863252|Drug|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
79388725|NCT06081166|Drug|Obicetrapib|obicetrapib 10 mg daily
79705632|NCT04614909|Drug|Temozolomide|Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
79705633|NCT04614636|Drug|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
79705634|NCT04614636|Drug|Cyclophosphamide|Lympho-conditioning Agent
79705635|NCT04614636|Drug|Fludarabine|Lympho-conditioning Agent
79705636|NCT04614636|Drug|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
79846582|NCT00863252|Drug|angiotensin blockade|Continuation of angiotensin blockade
79846583|NCT00503308|Procedure|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
79846584|NCT00870350|Biological|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
79846585|NCT00870350|Biological|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
79846586|NCT04040894|Biological|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
79846587|NCT00863564|Dietary Supplement|Caseine|
79846588|NCT00863564|Dietary Supplement|Cod|
79846589|NCT00863564|Dietary Supplement|Gluten|
79846590|NCT00863564|Dietary Supplement|Whey Isolate|
79250192|NCT04420728|Combination Product|Delayed auto mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
79250193|NCT04411693|Drug|Dexamethasone implant|A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.
79250194|NCT04411693|Drug|Aflibercept|A single dose, 2mg, drug administered by intravitreal injection.
79388726|NCT06081166|Drug|Atorvastatin Calcium|Atorvastatin 80 mg
79388727|NCT06081166|Drug|Rosuvastatin Calcium|Rosuvastatin 40 mg
79846591|NCT03893565|Drug|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
79846592|NCT03893565|Drug|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
79846593|NCT03893565|Drug|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
79846594|NCT00863642|Procedure|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
79388728|NCT06077188|Other|Gum group|Group chewing gum with xylitol
79391734|NCT03171558|Procedure|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
79705637|NCT04614636|Drug|Elotuzumab|Monoclonal Antibody
79705638|NCT04609943|Drug|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
79705639|NCT04609280|Radiation|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
79705640|NCT04588246|Drug|Memantine|Given PO
79846595|NCT00863642|Procedure|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
79846596|NCT00865358|Behavioral|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
79846597|NCT00502996|Drug|Methotrexate|>=15 mg po/week
79846598|NCT00502996|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
79846599|NCT00865436|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
79846600|NCT00865436|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
79846601|NCT00870506|Behavioral|video|5-minute video compared (intervention) to no video and no other intervention (control)
79846602|NCT00870662|Device|AFS System|AFS System with patient specific flow rate
79846603|NCT00715403|Drug|BIBF 1120|
79544737|NCT04397484|Drug|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
79705641|NCT04588246|Other|Quality-of-Life Assessment|Ancillary studies
79705642|NCT04588246|Other|Questionnaire Administration|Ancillary studies
79544738|NCT04396600|Behavioral|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
79705643|NCT04588246|Radiation|Stereotactic Radiosurgery|Undergo salvage SRS
79544739|NCT04372641|Drug|p97 Inhibitor CB-5339 Tosylate|Given PO
79846604|NCT01013584|Dietary Supplement|cholecalciferol|daily dose
79846605|NCT00863954|Device|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
79846606|NCT00864110|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
79846607|NCT00864110|Radiation|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
79846608|NCT00864110|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
79846609|NCT00864188|Dietary Supplement|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
79846610|NCT00864188|Dietary Supplement|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
79846611|NCT00864188|Dietary Supplement|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
79846612|NCT00864188|Dietary Supplement|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
80014801|NCT05069116|Other|Training in surgery|The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
79544740|NCT04352296|Procedure|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
80014802|NCT01126970|Drug|Velneperit 400 mg|Velneperit 400 mg q.d.
80014803|NCT01126970|Drug|Orlistat 120 mg|Orlistat 120 mg t.i.d
79250195|NCT04399967|Behavioral|Chat-based support|Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
79250196|NCT04399967|Behavioral|AWARD plus COVID-specific advice|Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
79705644|NCT04588246|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT
79705645|NCT04568824|Other|GraphoLearn reading intervention|This is an Edtech reading intervention
79705646|NCT04568824|Other|Vektor math control intervention|This is an Edtech math/cognition intervention
79705647|NCT04564755|Drug|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
79705648|NCT04557787|Device|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
79705649|NCT04557787|Device|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
79705650|NCT04557787|Device|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
80014804|NCT01126970|Drug|Orlistat Placebo|Orlistat Placebo t.i.d.
79250197|NCT04399967|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
79250198|NCT04399967|Behavioral|COVID-19 related health warning leaflet|The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
79250199|NCT04399967|Behavioral|Health warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
79250200|NCT04399967|Behavioral|SMS-based support|Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
79705651|NCT04553666|Drug|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
79705652|NCT04551885|Drug|FT516|Experimental Interventional Therapy
79705653|NCT04551885|Drug|Avelumab|Monoclonal antibody
79705654|NCT04551885|Drug|Cyclophosphamide|Lympho-conditioning agent
79705655|NCT04551885|Drug|Fludarabine|Lympho-conditioning agent
79705656|NCT04551885|Drug|IL-2|Biologic response modifier
79705657|NCT04547998|Device|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
79544741|NCT04352296|Procedure|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure <140 mm Hg, and treatment of hypertension defined by a systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
79705658|NCT04547998|Device|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
79705659|NCT04545502|Device|Gelsoft Plus Vascular Graft|Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
79705660|NCT04545502|Device|Vascular Bypass Graft|Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
79705661|NCT04545502|Device|Cardiovascular Patch|Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
80014805|NCT01126970|Drug|Velneperit Placebo|Velneperit Placebo q.d
79705662|NCT04545502|Device|Gelweave Vascular Graft|The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
79705663|NCT04545502|Device|Gelweave Valsalva Vascular Graft|This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
79544742|NCT04313881|Drug|Magrolimab|Administered intravenously
79544743|NCT04313881|Drug|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
80014806|NCT01126970|Other|Reduced Calorie Diet|Reduced calorie diet
80014807|NCT03557424|Drug|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
80014808|NCT03557424|Drug|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
80014809|NCT03557424|Drug|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
80014810|NCT05626400|Biological|Senl-T7|Patients will be treated with CD7 CAR-T cells
80014811|NCT05057572|Drug|Carvedilol|- Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP>90, HR >55.
79250201|NCT04399967|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
79705664|NCT04540536|Other|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
79250202|NCT04399967|Behavioral|COSH Self-help smoking cessation booklet|A general smoking cessation self-help booklet
79250203|NCT04380740|Drug|Placebo|During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
79250204|NCT04380740|Drug|Abatacept|Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
79250205|NCT04377100|Behavioral|Computer task questionnaires|MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
79705665|NCT04540536|Other|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
79705666|NCT04538482|Behavioral|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
79705667|NCT04538482|Behavioral|standard American diet|Participants will receive foods following the standard American diet for 28 days.
79705668|NCT04532970|Behavioral|Cessation Counseling|Two different types of smoking cessation counseling
79705669|NCT04532047|Drug|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
79705670|NCT04531670|Behavioral|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
79705671|NCT04531670|Other|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
79250206|NCT04360460|Other|Immersive virtual reality + related functional translation into real-life|The experimental group will perform tasks in an immersive virtual reality setting designed to encourage functional task performance for 30 minutes. The patient will then be brought to a real-life setting and evaluated on similar task performances for an additional 30 minutes for a total of 60 minutes per day, 3 times a week for 2 weeks.
79544744|NCT04313881|Drug|Placebo|Placebo to match magrolimab administered intravenously
79544745|NCT04304911|Behavioral|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
79544746|NCT04304911|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
79705672|NCT04524858|Drug|ATI-450|Oral, small molecule MK2 inhibitor
79705673|NCT04521179|Drug|KN026 combination|30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
79705674|NCT04516447|Drug|ZN-c3|Investigational drug
79705675|NCT04516447|Drug|Carboplatin|Carboplatin is an approved drug
79705676|NCT04516447|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin (PLD) is an approved drug
79705677|NCT04516447|Drug|Paclitaxel|Paclitaxel is an approved drug
79705678|NCT04516447|Drug|Gemcitabine|Gemcitabine is an approved drug
79705679|NCT04515459|Other|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~2 OTE will be performed before the surgery,~6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
79846613|NCT05325749|Genetic|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
80014812|NCT05057572|Drug|Standard Medical Treatment|"Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)"
79250207|NCT04360460|Other|Immersive virtual reality + non-related translation into real-life|The control group will also be asked to perform tasks in an immersive VR setting for 30 minutes, however tasks will be unrelated to the tasks performed in the real-life setting in the following 30 minutes. The control group will also receive 60 minutes of therapy a day, 3 times a week, for 2 weeks.
79250208|NCT04274335|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|1 gram of tranexamic acid to be administered intravenously
80014813|NCT01124708|Drug|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
79544747|NCT04288635|Biological|Whole blood samples|Whole blood samples at admission, from day one to three after admission
79544748|NCT04262843|Drug|Cyclophosphamide|Given IV
80014814|NCT01124708|Drug|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
79250209|NCT04274335|Drug|Tranexamic Acid Oral Solution|4 grams of tranexamic acid given as an oral solution
79250210|NCT04274335|Drug|Tranexamic Acid Injectable Product|1 gram of tranexamic acid given as 2 separate intramuscular injection
79846614|NCT05325749|Genetic|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
79846615|NCT05325749|Other|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
79846616|NCT05325749|Genetic|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
80014815|NCT02089620|Drug|Yasmin|will be used every 21 days for three months by the patient
80014816|NCT02089620|Dietary Supplement|Calver|Calver will be given daily for 3 months
79391735|NCT03171558|Procedure|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
79544749|NCT04262843|Drug|Fludarabine|Given IV
79544750|NCT04262843|Drug|Fludarabine Phosphate|Given IV
79544751|NCT04262843|Biological|Granulocyte Colony-Stimulating Factor|Growth factor therapy
79544752|NCT04262843|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
79544753|NCT04262843|Procedure|Intensity-Modulated Radiation Therapy|Undergo TMLI
79544754|NCT04262843|Drug|Mycophenolate Mofetil|Immunosuppressive therapy
79391736|NCT03171324|Drug|Iron Supplement|2 mg/kg/day elemental iron
79391737|NCT03173430|Drug|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
79391738|NCT03172962|Behavioral|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
79391739|NCT03172962|Behavioral|Usual care (control)|Will receive the usual care at the hospital
79544755|NCT04262843|Drug|Tacrolimus|Immunosuppressive therapy
79705680|NCT04505254|Drug|Acalabrutinib|Given PO
79705681|NCT04505254|Biological|Obinutuzumab|Given IV
79705682|NCT04502693|Combination Product|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine is administered intramuscularly to the non-dominant arm as 3 doses in a 0,2,6-M schedule or as 2 doses in a 0,6-M schedule to participants in the MenB_0_2_6 Group, as 2 doses in a 0,6-M schedule to participants in the MenB_0_6 Group and as 2 doses at Day 181 and Day 211 to participants in the ACWY Group.
79705683|NCT04502693|Biological|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine is administered intramuscularly to the non-dominant arm as 1 dose at Day 211 to participants in the MenB_0_2_6 Group, as 1 dose at Day 61 to participants in the MenB_0_6 Group and as 1 dose at Day 1 to participants in the ACWY Group.
79705684|NCT04502693|Combination Product|Placebo|Placebo is administered intramuscularly to the non-dominant arm as 1 dose at Day 211 to participants in the MenB_0_6 Group, 2 doses at Day 61 and Day 211 to participants in the ABCWY groups and as 1 dose at Day 61 to participants in the ACWY Group.
79705685|NCT04502693|Combination Product|MenABCWY-1|Lot 1 of the MenABCWY vaccine is administered intramuscularly to the non-dominant arm as 2 doses at Day 1 and Day 181 to participants in the ABCWY-1 Group.
79705686|NCT04502693|Combination Product|MenABCWY-2|Lot 2 of the MenABCWY vaccine is administered intramuscularly to the non-dominant arm as 2 doses at Day 1 and Day 181 to participants in the ABCWY-2 Group.
80014817|NCT02089620|Drug|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
80014818|NCT02089620|Drug|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
80014819|NCT02093598|Drug|Temsirolimus|
80014820|NCT01124552|Drug|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
79705687|NCT04502693|Combination Product|MenABCWY-3|Lot 3 of the MenABCWY vaccine is administered intramuscularly to the non-dominant arm as 2 doses at Day 1 and Day 181 to participants in the ABCWY-3 Group.
79705688|NCT04502121|Behavioral|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
79846617|NCT05325749|Genetic|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
79846618|NCT00864266|Drug|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
79846619|NCT00918515|Drug|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
79250217|NCT04262414|Device|Functional Electrical Stimulation|"The device used was a prototype closed-loop FES system to improve standing balance by activating the ankle plantar flexors and dorsiflexors (i.e. A-FES system). As a closed-loop system, the body's position and velocity are continually monitored, and the level of stimulation adjusted accordingly on a moment-to-moment basis. This differs from currently available FES units, which do not monitor body movement and therefore, provide a constant level of stimulation unless manually adjusted by the user/PT. The control strategy used in the A-FES system mimics the physiological control system in able-bodied people, meaning it has the potential to re-educate normal movement patterns."
79250218|NCT04252950|Behavioral|CB-SET|Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed
79250219|NCT04252950|Procedure|Revascularization|Endovascular revascularization is a primary treatment option for patients with PAD
79250220|NCT04248283|Device|Adjustable Continence Therapy for Women (ACT)|Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
80014821|NCT01124552|Drug|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
79250221|NCT04238767|Drug|Dolutegravir|Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
80014822|NCT01124552|Other|Vehicle|Vehicle Control
79250222|NCT04235972|Other|Follow-up consultation|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
79544756|NCT04215679|Other|Three-dimensional immersive virtual reality application|In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
79705689|NCT04496479|Biological|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
79705690|NCT04496323|Other|EE Golf|Exercise in Golf and Playing 9 holes
80014823|NCT01124552|Drug|Placebo|Placebo Comparator
80014824|NCT02087124|Other|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
79705691|NCT04485559|Drug|Everolimus|Given PO
79705692|NCT04485559|Drug|Trametinib|Given PO
79846620|NCT00865592|Drug|dutogliptin|dutogliptin 400 mg, once daily tablet
79846621|NCT04084223|Other|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
80014825|NCT05627882|Diagnostic Test|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
79250223|NCT04207203|Combination Product|sodium zirconium cyclosilicate and healthy diet|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
79302846|NCT03209947|Diagnostic Test|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
79846622|NCT00865670|Drug|Azithromycin Monohydrate 600 mg Tablets|
79846623|NCT00865670|Drug|Zithromax (azithromycin dihydrate) 600 mg Tablets|
79846624|NCT00864344|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
80014826|NCT04925830|Behavioral|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
80014827|NCT02087202|Drug|Magnesium Sulfate|magnesium sulfate is added to the patients
79544757|NCT04215679|Other|Motor imagery|Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
79705693|NCT04474834|Genetic|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40 %).
79705694|NCT04466345|Biological|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
79705695|NCT04466345|Biological|Placebo|Semaglutide placebo capsules
79705696|NCT04466150|Drug|Ocrelizumab|open label biomarker study
79846625|NCT00864344|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
80014828|NCT02087202|Drug|ketamine|ketamine is added to the patients.
79250224|NCT04206735|Other|Interprofessional Education (IPE)|We will use the training stated in the arm description above. In addition, prerecorded webinars that include evidence-based practice management of COPD will be released every month for the champions and clinicians to watch at their leisure.
79250225|NCT04206735|Other|Usual care|Usual care of patients hospitalized with severe COPD exacerbation
79250226|NCT04203004|Procedure|HOPE with cytokine filtration by CytoSorb|Cytokine filtration during HOPE
79250227|NCT04200872|Other|biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
79388729|NCT06077175|Other|hand massage group|Each individual will receive a 10-minute hand massage, 5 minutes for each hand. Since the speed and number of repetitions of the massage movements should be at normal frequency, the massage will be performed at a speed that does not disturb the individual, is not stimulating and has a calming effect, and will not tire the practitioner. In the massage, effleurage (stroking) and friction (circular rubbing) movements will be used, which have a circulation-supporting and tissue-relaxing effect. Evaluations will be made within 30 minutes after the hand massage.
79250228|NCT04200872|Other|no biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
79388730|NCT06076304|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
79388731|NCT06076304|Drug|Placebo antibiotic|Placebo antibiotic, oral, twice daily for 7 days
79544758|NCT04215679|Other|Conventional physiotherapy|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
79544759|NCT04185935|Other|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
79544760|NCT04185935|Other|Questionnaire Administration|Ancillary studies
79544761|NCT04150497|Biological|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
79544762|NCT04150497|Biological|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
80014829|NCT01283594|Drug|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
79544763|NCT04116723|Device|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
79544764|NCT04116164|Drug|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
79544765|NCT04112173|Behavioral|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
80014830|NCT01283594|Drug|Placebo|White-coated, modified-oval placebo tablets.
80014831|NCT01283594|Drug|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
80014832|NCT01283594|Drug|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
79250229|NCT04180059|Combination Product|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1*04:01 and with a HLA-DPB1*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
80014833|NCT01283594|Drug|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
79250230|NCT04177355|Biological|BG505 SOSIP.664 gp140|Administered by IM injection
79250231|NCT04177355|Biological|Placebo|Administered by IM injection
79250232|NCT04177355|Biological|3M-052-AF|Administered by IM injection
79250233|NCT04177355|Biological|CpG 1018|Administered by IM injection
79250234|NCT04177355|Biological|GLA-LSQ|Administered by IM injection
79250235|NCT04177355|Biological|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
79250236|NCT04177355|Biological|Trimer 4571|Administered by IM injection
79250237|NCT04166110|Drug|Predetermined treatment duration|Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
79544767|NCT04074746|Biological|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
79388732|NCT06076304|Drug|Budesonide nasal spray|Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
79544768|NCT04074746|Drug|Cyclophosphamide|Given IV
79544769|NCT04074746|Drug|Fludarabine|Given IV
79544770|NCT04074746|Drug|Fludarabine Phosphate|Given IV
79705697|NCT04465721|Behavioral|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
79250238|NCT04166110|Drug|Variable treatment duration|"Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment."
79250239|NCT04158180|Diagnostic Test|Questionnaire|A battery of questionnaires will be propose to the participants
79250240|NCT04154514|Device|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
79250241|NCT04125277|Other|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
79250242|NCT04063865|Drug|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
79250243|NCT04063865|Drug|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
79250244|NCT04053764|Drug|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
79250245|NCT04053764|Drug|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
79250246|NCT04046562|Behavioral|PAW|Pain and Weight Treatment plus standard of care
79250247|NCT04046562|Behavioral|Pain Education|Pain Education plus standard of care
79250248|NCT04015700|Biological|Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.
79250249|NCT04015700|Device|CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
79544771|NCT04074746|Biological|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
79544772|NCT04053075|Other|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
79544773|NCT04053075|Other|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
79544774|NCT04038619|Procedure|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
79544775|NCT04038619|Drug|Loperamide|Given PO
79250250|NCT04015700|Drug|Plasmid encoded IL-12|The INO-9012 vials will be supplied by Geneos Therapeutics
79250251|NCT04001205|Drug|Anticoagulation Therapy|Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
79250252|NCT03994211|Drug|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
79544776|NCT04033497|Device|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
79250253|NCT03994211|Drug|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
79388733|NCT06076304|Other|C-reactive protein|Measurement of C-reactive protein level in capillary blood
79388734|NCT06076304|Other|Mid-turbinate swab (optional)|Optional collection of mid-turbinate nasal swab sample
79388735|NCT06072911|Behavioral|Pelvic floor exercise program|General exercises will be prescribed along with a specialized pelvic floor program
79388736|NCT06072911|Behavioral|General exercise|A general progressive resistance exercise program
79388737|NCT06072911|Behavioral|Physical Activity Counseling|Advice on increasing physical activity
79544777|NCT04030507|Device|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
79544778|NCT03987386|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79544779|NCT03987386|Other|Quality-of-Life Assessment|Ancillary studies
79544780|NCT03987386|Other|Questionnaire Administration|Ancillary studies
79544781|NCT03987386|Radiation|Radiation Therapy|Undergo conventional radiation therapy
79544782|NCT03983577|Other|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
79544783|NCT03967834|Other|Patient with Soft Tissue Sarcoma|"Tumor specimens will be collected for the study at diagnosis.~A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
79544784|NCT03960723|Other|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
79250254|NCT03994211|Drug|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
79705698|NCT04465721|Behavioral|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
79705699|NCT04464265|Other|Functional Magnetic Resonance Imaging (fMRI)|"Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze."
79705700|NCT04462419|Radiation|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
79250255|NCT03994211|Drug|rifampin|600 mg rifampin once a day from days 3 to 11
79250256|NCT03994211|Drug|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
79846626|NCT00870974|Drug|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
79846627|NCT00864422|Behavioral|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
79250262|NCT03916562|Behavioral|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
79388738|NCT06066502|Other|Precision ventilation|The intervention arm prioritizes mitigation of ventilator-induced-lung-injury by individualizing support to patient-specific mechanics in an integrated approach to limit overdistension and atelectrauma. This is accomplished in this arm by titration of tidal volume to limitation of driving pressure at 12 centimeters of water (cmH2O) or less and using esophageal manometry to titrate PEEP to a transpulmonary pressure of 0 cmH2O with adjustments in respiratory rate to allow for permissive hypercapnia and FiO2 adjustments to assure adequate oxygenation.
79388739|NCT06066502|Other|Guided usual care ventilation|The comparison arm allows clinician discretion when titrating PEEP and tidal volume, while setting general targets for allowable PEEP/FiO2 combinations, target range for SpO2, and target range for tidal volume. This arm applies routine best-practice guidelines. This includes maintenance of tidal volumes of 6-8 cc/kg of ideal body weight, limiting plateau pressures to 30 cmH2O or less and application of PEEP-FiO2 combinations which include a wide range of typical usual care with esophageal manometry only for data collection and not clinical adjustment.
79544785|NCT03951831|Drug|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
79544786|NCT03951831|Drug|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
79544787|NCT03951831|Drug|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
79544788|NCT03951831|Drug|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
79544789|NCT03911687|Behavioral|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
79705701|NCT04462419|Other|Fluciclovine F18|Given IV
79846628|NCT00864422|Behavioral|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
79846629|NCT00864500|Drug|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
79846630|NCT00864500|Drug|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
79846631|NCT02588963|Other|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
79250263|NCT03914872|Biological|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
79250264|NCT03914872|Device|Integrated electroporation device|"Ichor Medical Systems~All study injections will be given intramuscularly using an integrated electroporation device"
79302847|NCT02478125|Drug|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
79705702|NCT04461808|Diagnostic Test|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
79388740|NCT06064851|Device|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 30 minutes of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
79544790|NCT03897270|Procedure|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
79705703|NCT04461808|Diagnostic Test|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
79544791|NCT03884972|Drug|Trabectedin|Given IV
79391740|NCT03173040|Drug|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
79544792|NCT03884972|Drug|Venetoclax|Given PO
79544793|NCT03872453|Drug|Zavegepant|A single dose of zavegepant
79544794|NCT03872453|Drug|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
79705704|NCT04448184|Drug|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
79705705|NCT04437888|Drug|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
79705706|NCT04423302|Dietary Supplement|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
79544795|NCT03872453|Device|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
79544796|NCT03869463|Other|Computerized Cognitive Training|Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
79705707|NCT04423302|Dietary Supplement|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
79544797|NCT03869463|Other|Control|This group will not receive computerized cognitive training.
79544798|NCT03819517|Dietary Supplement|Resveratrol|Over the counter supplementation
79705708|NCT04423302|Dietary Supplement|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
79302848|NCT02478125|Drug|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
79705709|NCT04417062|Drug|Olaparib|Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
79544799|NCT03819517|Other|Placebo|Empty white colored soft vegetarian capsule
79544800|NCT03803761|Drug|Copanlisib|Given IV
79544801|NCT03803761|Drug|Fulvestrant|Given IM
79544802|NCT03772834|Behavioral|Exercise Intervention|Undergo resistance training and walking
79544803|NCT03772834|Drug|Methylphenidate|Given PO
79544804|NCT03772834|Other|Placebo|Given PO
79705710|NCT04417062|Drug|Ceralasertib|Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
80014834|NCT01283594|Drug|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
79302849|NCT02478125|Drug|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
79302850|NCT03070197|Other|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
79544805|NCT03772834|Other|Quality-of-Life Assessment|Ancillary studies
79544806|NCT03772834|Other|Questionnaire Administration|Ancillary studies
79544807|NCT03772834|Other|Stretching|Undergo stretching
79544808|NCT03739073|Other|OCTA (angiography by tomography in optical coherence)|The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
79544809|NCT03735095|Drug|Porfimer Sodium|Given IV
79544810|NCT03735095|Procedure|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
79544811|NCT03726879|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
79544812|NCT03726879|Drug|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
79544813|NCT03726879|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
79544814|NCT03726879|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
79250265|NCT03910660|Drug|BXCL701 plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle."
79705711|NCT04406389|Drug|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
79705712|NCT04406389|Drug|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
79705713|NCT04406389|Drug|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~If greater than or equal to 100 kg: 10 mg daily~If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~If less than 50 kg: 5 mg daily"
79705714|NCT04406389|Drug|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
79250266|NCT03910660|Drug|BXCL701 monotherapy|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day."
79705715|NCT04401462|Procedure|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
79705716|NCT04401462|Behavioral|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
79705717|NCT04379544|Other|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
79705718|NCT04378751|Behavioral|Decision aid video|Decision aid video
79705719|NCT04378751|Behavioral|Genetic counseling informational brochure|Genetic counseling informational brochure
79705720|NCT04358458|Biological|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
79846632|NCT02588963|Other|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
79250267|NCT03875378|Drug|Transdermal estrogen|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
79250268|NCT03875378|Drug|Placebos|Placebo weekly patch
79388741|NCT06063538|Combination Product|CardiaMend in Combination with Amiodarone|"The first three patient will receive 600 mg amiodarone into the intact pericardial space. Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.~The CardiaMend patch will saturated per the instructions and be sutured into place. Amiodarone will be dripped directly over the heart."
79391741|NCT02401074|Biological|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
79544815|NCT03726879|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
79544816|NCT03726879|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
79544817|NCT03726879|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
79544818|NCT03726879|Drug|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
79544819|NCT03723187|Other|normal saline|experimental group use normal saline sealing tube
79544820|NCT03723187|Other|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
79544821|NCT03721835|Device|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
79705721|NCT04358458|Biological|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
79846633|NCT02588963|Other|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
79846634|NCT00864734|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
79705722|NCT04356924|Behavioral|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
79250269|NCT03872154|Other|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
79250270|NCT03837756|Drug|Saline|Placebo
79250271|NCT03837756|Drug|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
79705723|NCT04356924|Behavioral|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
79250272|NCT03837756|Drug|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
79250273|NCT03829644|Device|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
79250274|NCT03818607|Drug|ABP 959|intravenous infusion
79388742|NCT06059495|Drug|Dostarlimab|"After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, <3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and >2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with <3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)"
79388743|NCT06056830|Drug|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
79388744|NCT06053268|Device|Headspace|The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
79388745|NCT06052306|Drug|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
79388746|NCT06052306|Drug|BAY2616505|Each participant in the substudy will receive the BAY2616505 administered at baseline (Day 1) by intravenous (i.v.), after completion of the screening period and before the first dose of BAY3546828 in Cycle 1.
79388747|NCT06052306|Drug|BAY2315493|If the planned dose of total antibody is more than 1 mg, BAY2315493 will be administered by intravenous (i.v.), starting one hour prior to the i.v. injection of BAY2616505.
79388748|NCT06050785|Drug|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
79388749|NCT06044740|Drug|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the two drug conditions, subjects will first receive low-dose sevoflurane (0.4% corresponding to 0.2 Minimum Alveolar Concentration) and then a higher dose sevoflurane condition (0.8% corresponding to 0.4 Minimum Alveolar Concentration).
79544822|NCT03716843|Other|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
79705724|NCT04356729|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
79705725|NCT04356729|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
79846635|NCT00864734|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
79846636|NCT04084691|Other|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
79846637|NCT04084691|Other|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
79250275|NCT03818607|Drug|Eculizumab|intravenous infusion
79250276|NCT03811275|Behavioral|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
79250277|NCT03811275|Behavioral|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
79250278|NCT03797963|Device|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
79250279|NCT03797963|Device|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
79250280|NCT03796156|Drug|Aspirin|75mg low dose non enteric coated or dispersible
79302851|NCT03070197|Other|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
79705726|NCT04345393|Behavioral|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
79705727|NCT04343716|Behavioral|Low-carbohydrate diet|A diet low in daily carbohydrates (<40 grams/day) provided as prepared meals.
79705728|NCT04339894|Other|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
79250281|NCT03767595|Device|ProACT Adjustable Continence Therapy for Men|The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
79250282|NCT03737292|Drug|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
79544823|NCT03712462|Behavioral|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
79388750|NCT06044740|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
79544824|NCT03712462|Behavioral|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
79250283|NCT03737292|Drug|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
79388751|NCT06042751|Behavioral|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
79388752|NCT06042751|Behavioral|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
79388753|NCT06042413|Other|Personalized CPC Prehabilitation|Patients for elective surgery randomized to the intervention group will be scheduled for a preoperative evaluation (3-6 weeks prior to the surgical date) and will receive standardized and personalized assessment and prehabilitation according to UPMC's established disease-specific algorithms.
79544825|NCT03697096|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
79544826|NCT03697096|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
79544827|NCT03697070|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
79544828|NCT03697070|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
79544829|NCT03691051|Drug|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
79544830|NCT03653598|Other|Atrial Fibrillation|Data collection on Atrial Fibrillation
79544831|NCT03630042|Drug|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
79544832|NCT03630042|Drug|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
79705729|NCT04336826|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
79250284|NCT03732586|Dietary Supplement|Omega 5 fatty acid supplement|Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
79250285|NCT03732586|Other|PLACEBO|Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
79705730|NCT04335721|Drug|Voxelotor|Voxelotor 1500mg once a day
79705731|NCT04333810|Device|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
79705732|NCT04329650|Drug|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
79705733|NCT04329650|Drug|Dexamethasone|A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
79705734|NCT04327310|Drug|Meplazumab for Injection|humanized mAb against CD147
79250286|NCT03724929|Procedure|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
79250287|NCT03724929|Device|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
79250288|NCT03713450|Device|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
79705735|NCT04327310|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
79705736|NCT04326231|Device|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
79705737|NCT04308499|Behavioral|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions accessed using either a computer or a smartphone
79250289|NCT03713450|Device|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
79544833|NCT03565991|Drug|Avelumab|IV treatment
79250290|NCT03710460|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
79250291|NCT03710460|Drug|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
79544834|NCT03565991|Drug|Talazoparib|Oral treatment
79250292|NCT03710460|Drug|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
79250293|NCT03650894|Drug|Nivolumab|Nivolumab 240 mg IV every 2 weeks
79544835|NCT03535142|Procedure|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
79250294|NCT03650894|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
79250295|NCT03650894|Drug|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
79250296|NCT03606694|Drug|Dihydromyricetin|The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.
79544836|NCT03504488|Biological|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
79544837|NCT03504488|Biological|PD-1 inhibitor|PD-1 inhibitor
79705738|NCT04308499|Behavioral|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions comprised of comprise a website and a downloadable booklet
79250297|NCT03606694|Drug|Metformin|The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
79250298|NCT03546881|Procedure|fusion imaging guidance technology|Imaging fusion guidance overlay used during PAOD endovascular revascularisation
79544838|NCT03465813|Behavioral|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
79544839|NCT03461276|Biological|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminium hydroxide as adjuvant.
79544840|NCT03461276|Biological|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminium hydroxide) without the conjugate.
79544841|NCT03391362|Radiation|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
79544842|NCT03364868|Drug|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
79705739|NCT04308135|Diagnostic Test|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
79705740|NCT04308135|Diagnostic Test|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
79705741|NCT04308135|Diagnostic Test|lab investigations|Each patient will undergo full lab investigations:[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes]
79544843|NCT03364868|Other|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
79705742|NCT04308135|Diagnostic Test|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
79705743|NCT04308135|Diagnostic Test|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
79705744|NCT04308135|Diagnostic Test|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~.Freezing of gait questionnaire~Berg balance scale.~10 meter walk test .~Timed up and go test."
79705745|NCT04308135|Diagnostic Test|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
79705746|NCT04308135|Diagnostic Test|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
79705747|NCT04308135|Diagnostic Test|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
79705748|NCT04308135|Other|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
79250299|NCT03546881|Procedure|2D X-ray screen|2D X-ray screen during PAOD endovascular revascularisation
79250300|NCT03544281|Drug|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as an infusion.
79250301|NCT03544281|Drug|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
79250302|NCT03544281|Drug|Dexamethasone|Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
79388754|NCT06042413|Behavioral|Cognitive Training|Participants will be provided with access to the Lumosity (Lumos Labs) software for installation on a home device. They will be trained to navigate the touchscreen tablet and guided through an introductory series of brain exercise games focused on 5 main categories: memory, speed, attention, flexibility, and problem-solving. Patients will be asked to complete a cognitive exercise dosage of a minimum of 20 minutes a day for ≥5 days prior to their date of surgery. Research coordinators and volunteers from UPMC's Hospital Elder Life Program (HELP) will reach out to participants daily for a quick social check-in and to remind them to perform their training. Compliance data will be retrieved from the Lumosity app.
79250303|NCT03544281|Drug|Bortezomib|Bortezomib will be administered as 1.3 mg/m^2, as SC or IV, with belantamab mafodotin and dexamethasone.
79250304|NCT03529045|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
79250305|NCT03512002|Device|HIRREM|Technology
79250306|NCT03512002|Other|Continued Current Care|Continue their current clinical care.
79250307|NCT03481530|Device|Continuing Glucose Monitor System|glucose monitoring
79250308|NCT03467906|Other|In-laboratory assessment|Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
79388755|NCT06042413|Behavioral|Meditation|A single guided meditation session with instructions will be provided using a smart device. The meditation session will last for at least 10 minutes daily starting at least 1-week prior to surgery. If the subject does not own a smart device, one will be provided or meditation will be completed in-person or over the phone.
79391742|NCT03173196|Device|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
79391743|NCT02407782|Drug|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
79391744|NCT02407782|Drug|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
79391745|NCT02405364|Drug|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
79544844|NCT03354897|Drug|Torasemide 5Mg Tablet|16 weeks treatment
79544845|NCT03332251|Device|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
79705749|NCT04308135|Other|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
79705750|NCT04308135|Other|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
79705751|NCT04300764|Behavioral|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
79705752|NCT04296071|Other|Research study|Blood and tracheal aspirates will be collected
79705753|NCT04289415|Behavioral|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
79705754|NCT04283370|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
79705755|NCT04283370|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
80014835|NCT04861870|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
80014836|NCT02089698|Device|Mini-flared|Mini-flared Kelman tip
80014837|NCT02089698|Device|Reversed tip|Reversed Kelman tip
79705756|NCT04282187|Drug|Decitabine|Given IV
79705757|NCT04282187|Drug|Ruxolitinib|Given PO
79705758|NCT04282187|Drug|Fedratinib|Given PO
79705759|NCT04282187|Other|Questionnaire Administration|Ancillary studies
79705760|NCT04282187|Drug|Pacritinib|Given PO
79846638|NCT04084691|Other|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
80014838|NCT04437784|Procedure|Laparoscopic Trans-Abdominal Pre-Peritoneal|Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
80014839|NCT04437784|Procedure|Open pre-peritoneal repair|Open pre-peritoneal single mesh repair with suture fixation
80014840|NCT04437784|Procedure|Bilateral Lichtenstein repair|Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
80014841|NCT01282346|Device|SOLX Gold Shunt|Single use implant
79544846|NCT03308929|Device|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
79544847|NCT03186638|Drug|Ibuprofen|Given PO
79544848|NCT03186638|Other|Placebo|Given PO
80014842|NCT02093676|Behavioral|"experimental protocol treatment The New Authority"|
80014843|NCT04826458|Device|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
80014844|NCT04826458|Other|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
79250312|NCT03387579|Drug|Smoflipid 20% Lipid Emulsion for Injection|Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
79250313|NCT03387579|Drug|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
79544849|NCT03186638|Other|Questionnaire Administration|Ancillary studies
79544850|NCT03165292|Radiation|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
79544851|NCT03165292|Drug|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
79544852|NCT03165292|Drug|Thiotepa|Day 1-3 Thiotepa
79544853|NCT03165292|Procedure|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
79705761|NCT04275336|Drug|EMLA application|A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.
79846639|NCT04084691|Other|Normal meal|- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
79705762|NCT04275336|Behavioral|Distraction techniques|Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
79705763|NCT04275336|Other|EMLA cream and distraction techniques|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
79705764|NCT04269005|Other|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
79846640|NCT04084691|Other|Normalized meal|"- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
79250314|NCT03387579|Drug|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
79846641|NCT04084691|Other|Fasting|non meal in the hour before exercise
79250315|NCT03339635|Drug|Androgel (Testosterone gel)|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
79250316|NCT03339635|Drug|Placebo gel|Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
79250317|NCT03322215|Drug|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
79250318|NCT03322215|Drug|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
79250319|NCT03322215|Drug|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
79250320|NCT03260387|Procedure|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
79250321|NCT03218475|Other|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
79250322|NCT03174327|Diagnostic Test|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
79250323|NCT03119597|Dietary Supplement|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
79250324|NCT03119597|Dietary Supplement|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
79302852|NCT02448121|Procedure|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
79391746|NCT02405286|Other|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
79391747|NCT02405130|Other|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
79391748|NCT02405130|Other|no intracoronary epinephrine|patients will receive standard therapy only
79544854|NCT03075072|Radiation|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
79544855|NCT03075072|Radiation|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
79544856|NCT03045744|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
79544857|NCT03010657|Other|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
79544858|NCT02998385|Drug|Cisplatin|intravenous, concomitant to irradiation
79544859|NCT02998385|Radiation|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
79544860|NCT02958007|Behavioral|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
79705765|NCT04266886|Other|Best Practice|Receive usual care
79705766|NCT04266886|Procedure|Hypnotherapy|Receive self-hypnosis guided relaxation
79705767|NCT04266886|Other|Quality-of-Life Assessment|Ancillary studies
79705768|NCT04266886|Other|Questionnaire Administration|Ancillary studies
79846642|NCT00864812|Drug|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
79846643|NCT00864812|Drug|tiotropium|COPD patients treated with tiotropium
79846644|NCT02590055|Drug|gemcitabine/docetaxel combination|
79846645|NCT00864890|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
79846646|NCT00864890|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
79846647|NCT00919295|Drug|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
79846648|NCT00919295|Drug|placebo|placebo
79846649|NCT00865748|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
79705769|NCT04266717|Behavioral|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
79705770|NCT04266717|Behavioral|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
79250325|NCT03094884|Radiation|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
79705771|NCT04265625|Device|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
79705772|NCT04256915|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux)."
79846650|NCT00865748|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
79846651|NCT00865826|Other|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
80014845|NCT01281254|Drug|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
80014846|NCT01281254|Drug|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
79391749|NCT04896450|Procedure|Guided tissue regeneration (GTR)|GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
79391750|NCT04896450|Device|Orthodontic tooth movement (OTM)|An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
80014847|NCT02093754|Procedure|MRI and biopsy|
80014848|NCT02087436|Device|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
80014849|NCT02087436|Device|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
80014850|NCT05104138|Drug|Eplerenone|The patients underwent eplerenone treatment for 6 months
79544861|NCT02958007|Behavioral|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
79544862|NCT02876302|Drug|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
79544863|NCT02876302|Drug|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
79544864|NCT02876302|Drug|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
80014851|NCT05104138|Device|The patients underwent half fluence photodynamic therapy for 6 months|Half fluence photodynamic therapy for 6 months
79544865|NCT02876302|Drug|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
79544866|NCT02853747|Behavioral|Physical Activity, 20-meter shuttle run|cross-sectional physical activity assessment and medical screeening
80014852|NCT05627804|Other|Low-moderate intensity exercise|The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia
79250326|NCT03094884|Drug|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
79544867|NCT02846623|Drug|Atezolizumab|Given IV
79544868|NCT02846623|Other|Laboratory Biomarker Analysis|Correlative studies
79705773|NCT04256915|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (<50 lux)."
79705774|NCT04255745|Behavioral|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
79705775|NCT04254575|Other|None, observational study only (no interventions)|None, observational study only (no interventions)
79705776|NCT04251910|Drug|Sublingual film containing Dexmedetomidine|Sublingual film containing Dexmedetomidine
79705777|NCT04251910|Drug|Sublingual Placebo Film|Sublingual placebo film that matches BXCL501
79705778|NCT04248582|Device|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
79705779|NCT04248491|Device|BTL Emsella chair|Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
79388756|NCT06042413|Behavioral|Daily Exercise|Participants in the intervention group will meet with an occupational or physical therapist approximately 1-6 weeks before surgery who will discuss the potential benefits of exercise and give directions for an easy strength training exercise. Participants will then be provided with a video link for a guided exercise and encouraged to walk or perform a seated strength exercise for ≥ 5 minutes each day for at least 1 week before surgery and after surgery. Patient reported frequency, fitness app compliance and exercise duration with REDCap email or mobile link or over telephone will be collected before and after surgery. Patients will be cleared by an occupational or physical therapist to perform the upper-extremity exercises and will confirm the exercises are not contraindicated after surgery. An occupational or physical therapist will see subject again post-surgery to mitigate risk of injury.
79388757|NCT06042413|Behavioral|Enhanced Social Support|"Research coordinators and volunteers from HELP will reach out to patients daily prior to their surgery to discuss concerns they may have, provide daily social touchpoints, and remind them to perform their cognitive exercises. In addition, the importance of social support will be discussed with family members and other caregivers and they will be encouraged to participate.~e. Proactive depression treatment: All patients will receive preoperative interventions to manage their depression under their CPC prehabilitation program."
79705780|NCT04248192|Biological|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
79705781|NCT04246151|Drug|Vancomycin|Vancomycin capsules
79846652|NCT00865982|Drug|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
80014853|NCT05627804|Other|Sprint interval training|The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.
79705782|NCT04246151|Dietary Supplement|Culturelle|Culturelle capsules
79250327|NCT03094884|Drug|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
79705783|NCT04246151|Drug|Vancomycin Placebo|sugar pill manufactured to mimic the vancomycin 125 mg capsule
79846653|NCT00866060|Drug|Memantine|20mg memantine
79250328|NCT03076489|Other|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
79705784|NCT04246151|Drug|Probiotic Placebo|sugar pill manufactured to mimic 10 billion unit probiotic capsules.
79846654|NCT00866060|Drug|Donepezil|10mg donepezil
79846655|NCT00866060|Drug|Placebo donepezil|Placebo donepezil
79846656|NCT00866060|Drug|Placebo memantine|Placebo memantine
79846657|NCT00871052|Drug|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
79846658|NCT00866138|Drug|masitinib (AB1010)|masitinib 9 mg/kg/day per os
79846659|NCT00502840|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
79391751|NCT03169374|Device|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
80014854|NCT05627804|Other|Functional exercise|The participants will perform bodyweight exercises under moderate hypoxia.
80014855|NCT05627804|Other|Control|No exercise will be performed.
80014856|NCT04437082|Device|optical coherence tomography|imaging structural and vascular features of the eye
79705785|NCT04236882|Other|Focus Group|Attend focus group
79846660|NCT00515008|Behavioral|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
79250329|NCT03076489|Other|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
79250330|NCT03076489|Device|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
79388758|NCT06042413|Other|Proactive Bundle Interventions|Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines. For example, increasing mean arterial pressure can stabilize SSEP (Fig. 6). If persistent focal changes in SSEP and EEG, (i.e., changes in one hemisphere) occur efforts will be made to increase brain perfusion by ensuring and maintaining hematocrit >30, MAP >70, and anesthetic BIS >50-60; soon after surgery, patients will get stroke management and thrombectomy if indicated.
79388759|NCT06042413|Procedure|Pre-operative Standard of Care|Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
80014857|NCT03072043|Drug|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
80014858|NCT03072043|Drug|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m^2.
80014859|NCT05626010|Drug|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
80014860|NCT05626010|Drug|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
79544869|NCT02846623|Biological|Obinutuzumab|Given IV
80014861|NCT04766398|Drug|KHK7791|oral administration
80014862|NCT04766398|Drug|Placebo|oral administration
80014863|NCT02093832|Other|There are no specific Intervention|are no specific Intervention
79250331|NCT03059108|Procedure|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
79250332|NCT03059108|Procedure|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
79250333|NCT03046199|Other|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
79250334|NCT03046199|Other|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
79391752|NCT02405052|Other|No intervention|Validation of the Panic Screening Score
79544870|NCT02846623|Drug|Venetoclax|Given PO
79705786|NCT04236882|Behavioral|Health Education|Receive educational material on healthy homes
79705787|NCT04236882|Other|Internet-Based Intervention|Receive web-based sleep intervention
79705788|NCT04236882|Other|Internet-Based Intervention|Receive web-based health coaching sessions
79705789|NCT04236882|Other|Internet-Based Intervention|Receive web-based counseling sessions
80014864|NCT02089854|Drug|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
79705790|NCT04236882|Other|Interview|Complete interview
80014865|NCT02093910|Drug|Monosialotetrahexosylganglioside|
79544871|NCT02691663|Dietary Supplement|Oral bicarbonate supplementation|
79544872|NCT02691663|Dietary Supplement|Placebo|
79544873|NCT02649868|Procedure|TAE|Transarterial embolization
79705791|NCT04236882|Other|Questionnaire Administration|Ancillary studies
79705792|NCT04236791|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79544874|NCT02649868|Radiation|RFA|Thermal ablation
79544875|NCT02649868|Device|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
79544876|NCT02639065|Drug|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
80014866|NCT04636216|Behavioral|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
80014867|NCT03557346|Device|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
79705793|NCT04236791|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
79846661|NCT00515008|Behavioral|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
79846662|NCT03326830|Device|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher&Paykel, New-Zealand).
79846663|NCT03326830|Device|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
79846664|NCT01013662|Procedure|glycemic control|exogenous insulin
79846665|NCT01011790|Behavioral|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
79846666|NCT00514540|Drug|Docetaxel|75 mg/m^2 IV over 60 Minutes on Day 1 of 21 day cycle.
79705794|NCT04236479|Biological|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
79846667|NCT00514540|Drug|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
79846668|NCT00514540|Drug|Etoposide|120 mg/m^2 daily for 3 days of 21 day cycle.
79846669|NCT00514540|Drug|Cisplatin|25 mg/m^2 for 3 days of 21 day cycle.
79846670|NCT03121534|Drug|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
79250335|NCT03029390|Dietary Supplement|Berberine|"Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg"
79250336|NCT03029390|Drug|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
79250337|NCT02975674|Device|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
79250338|NCT02975674|Device|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
79388760|NCT06042413|Procedure|Intra-operative Standard of Care|This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
79388761|NCT06042205|Device|TISSIUM™ Adhesive Hernia Repair System (TAHRS)|The TAHRS is intended for fixation of prosthetic material to soft tissue
79388762|NCT06038968|Drug|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
79846671|NCT03121534|Drug|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
79846672|NCT03121534|Drug|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
79846673|NCT03121534|Drug|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
79705795|NCT04235140|Drug|LUM/IVA|LUM/IVA granules for oral administration
79705796|NCT04220684|Drug|Cytarabine Hydrochloride|Given IV
79705797|NCT04220684|Drug|Fludarabine|Given IV
79705798|NCT04220684|Biological|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
79705799|NCT04216589|Drug|Semaglutide|Administered subcutaneously
79846674|NCT01012102|Biological|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
79846675|NCT01012102|Biological|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
79544877|NCT02620072|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
79846676|NCT01012102|Biological|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
79846677|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
79250339|NCT02975245|Procedure|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
79250340|NCT02923063|Behavioral|Combined Aerobic and Resistance Exercise via videoconferencing|Combined aerobic and resistance exercise session thrice weekly for 12 weeks
79846678|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
79846679|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
79846680|NCT01013818|Drug|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
79846681|NCT01013896|Behavioral|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
80014868|NCT04437160|Drug|Epirubicin or Pirarubicin|Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d*4cycls
80014869|NCT04437160|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 IV, q21d*4cycls
80014870|NCT01265264|Drug|ulodesine|Oral dose administered daily for 84 days.
80014871|NCT01265264|Drug|Placebo|Oral dose administered daily for 84 days.
80014872|NCT02089932|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
80014873|NCT02089932|Drug|Placebo|
80014874|NCT05761483|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography, placement of stents using a duodenoscope and making an access through the papilla of Vater
79250341|NCT02889458|Other|Not Provided|
79250342|NCT02822144|Drug|Etomidate|
79388763|NCT06038968|Procedure|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
79846682|NCT01013896|Other|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
79846683|NCT01013974|Drug|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
79846684|NCT01013974|Drug|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
79846685|NCT01013974|Drug|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
80014875|NCT05374486|Device|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
80014876|NCT02093988|Drug|Topical TXA|
80014877|NCT02093988|Drug|Intravenous TXA|
80014878|NCT05221996|Behavioral|Resistance training|Resistance circuit training
79250343|NCT02822144|Drug|Succinylcholine|
79250344|NCT02822144|Drug|Propofol|
79250345|NCT02822144|Drug|Remifentanil|
79250346|NCT02822144|Drug|Lidocaine|
79250347|NCT02802397|Other|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
79250348|NCT02725060|Drug|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every ~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
79388764|NCT06035705|Other|Patient acuity tool|A tool for measuring patient acuity as a part of daily management will be implemented in four somatic in-patient care units.
79388765|NCT06025708|Device|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
79391753|NCT03170934|Behavioral|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
79544878|NCT02620072|Other|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
79250349|NCT02725060|Drug|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every ~3 min until heart rate increases by 25 bpm. This intervention is optional.
79544879|NCT02589106|Device|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
79705800|NCT04204915|Procedure|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
79705801|NCT04204798|Drug|Dexmedetomidine|"Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
79705802|NCT04204798|Drug|Placebo|"Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~Propofol sedation is administered when considered necessary."
79705803|NCT04197869|Drug|Polyethylene Glycol Powder|Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
79705804|NCT04193293|Drug|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
79846686|NCT01013974|Drug|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
80014879|NCT01037036|Drug|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
79250350|NCT02725060|Radiation|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
79250351|NCT02725060|Procedure|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
79250352|NCT02725060|Procedure|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
79250353|NCT02725060|Procedure|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
79544880|NCT02566785|Other|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
79250354|NCT02725060|Procedure|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
79544881|NCT02532257|Drug|Ibrutinib|Given PO
79544882|NCT02532257|Other|Laboratory Biomarker Analysis|Correlative studies
79544883|NCT02532257|Drug|Lenalidomide|Given PO
79544884|NCT02532257|Biological|Rituximab|Given IV
79705805|NCT04193293|Biological|Pembrolizumab|Immunotherapy (programmed cell death protein 1 [PD-1] inhibitor)
79705806|NCT04191876|Other|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
79846687|NCT04615624|Drug|Furosemide|Furosemide, a loop diuretic
79846688|NCT04615624|Other|Placebo|Normal saline
79846689|NCT00713609|Drug|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
79846690|NCT00713609|Drug|Clindamycin gel|1% clindamycin phosphate applied topically once a day
79846691|NCT00713609|Drug|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
79846692|NCT00713609|Drug|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
79846693|NCT00713609|Drug|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
80014880|NCT01037036|Drug|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
80014881|NCT04360694|Procedure|Incremental hemodialysis|58 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
80014882|NCT04360694|Procedure|Conventional hemodialysis|58 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
80014883|NCT02250066|Other|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
80014884|NCT03069313|Dietary Supplement|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
79705807|NCT04188990|Dietary Supplement|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
79705808|NCT04188990|Dietary Supplement|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
79705809|NCT04188990|Dietary Supplement|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
79705810|NCT04188457|Other|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
79250355|NCT02725060|Other|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
79544885|NCT02441101|Device|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
79705811|NCT04188457|Other|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
79705812|NCT04187118|Other|Quality of life|Quality of life one year post chemo-therapy
79250356|NCT02725060|Other|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
79250357|NCT02725060|Procedure|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
79705813|NCT04171843|Genetic|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
79250358|NCT02684955|Device|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
79250359|NCT02684955|Device|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
79250360|NCT02565680|Drug|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
79250361|NCT02565680|Drug|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
79250362|NCT02558946|Behavioral|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
79250363|NCT02558946|Behavioral|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
79250364|NCT02487160|Device|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
79250365|NCT02487160|Device|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
79250366|NCT02422615|Drug|Ribociclib|Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
79250367|NCT02422615|Drug|Fulvestrant|Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
79388766|NCT06023498|Other|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
79250368|NCT02422615|Drug|Placebo|Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
79250369|NCT02382406|Drug|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
79544886|NCT02441101|Device|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
80014885|NCT02267486|Other|Standard therapy of Alzheimer Dementia (AD)|
80014886|NCT02267486|Other|Observation|
79544890|NCT02398786|Other|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
79705814|NCT04171843|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
79705815|NCT04171843|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
79705816|NCT04171843|Drug|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
79705817|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
79705818|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
79705819|NCT04165993|Drug|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
79250370|NCT02382406|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
79388767|NCT06023498|Other|Intramuscular Electroacupuncture|As described previously
79388768|NCT06021457|Drug|RBT-1|Intravenous administration
79388769|NCT06021457|Drug|Placebo|Intravenous administration
79705820|NCT04165993|Drug|KN026 monotherapy|30 mg/kg Q3W KN026
79705821|NCT04165993|Drug|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
79705822|NCT04141501|Drug|Psilocybin|single dose of psilocybin (25mg). orally in form of a capsule
80014887|NCT02094066|Drug|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
79250371|NCT02382406|Drug|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
79544891|NCT02344537|Behavioral|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
79250372|NCT02382406|Drug|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
79250373|NCT02203669|Other|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
79388770|NCT06018376|Drug|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
79250374|NCT02203669|Other|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
79250375|NCT02186587|Device|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
79250376|NCT02134327|Drug|Combination of Dexmedetomidine with Midazolam|
79250377|NCT02112331|Other|Raw human milk|
79544892|NCT02236429|Biological|vaginal flora transplant|
79544893|NCT02113657|Drug|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
79250378|NCT02112331|Other|Pasteurized human milk|
79388771|NCT06015724|Drug|Daratumumab|anti-CD38 monoclonal antibody (mAb)
79388772|NCT06015724|Biological|KRAS vaccine|Stimulon QS-21 and Targovax TG01
79388773|NCT06015724|Drug|Nivolumab|anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
79388774|NCT06014853|Drug|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
79388775|NCT06014853|Drug|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
79388776|NCT06013865|Drug|Empagliflozin|SGLT2 Inhibitor
79388777|NCT06013501|Behavioral|puppet show|puppet show to the child before and during subcutaneous application
79388778|NCT06012669|Dietary Supplement|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
79388779|NCT06012669|Dietary Supplement|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
79388780|NCT06012669|Dietary Supplement|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
79544894|NCT02004704|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
79544899|NCT01415882|Drug|Cyclophosphamide|Given PO
79544900|NCT01415882|Biological|Daratumumab|Given IV
79705823|NCT04141501|Drug|Placebo oral capsule|single dose of mannitol (100%)
79705824|NCT04127604|Behavioral|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
79705825|NCT04127604|Behavioral|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
79705826|NCT04126187|Device|Panoptix|Panoptix trifocal intraocular lens (IOL)
79705827|NCT04106167|Genetic|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
80014888|NCT02094066|Drug|serum physiologic|preoperative 100 cc ıv serum physiologic
80014889|NCT02090010|Procedure|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel."
79250379|NCT02112331|Other|Pasteurized-homogenized human milk|
79250380|NCT02112331|Other|Gastric samples|
79250381|NCT02101268|Drug|Momelotinib|Momelotinib tablet administered orally once daily
79544901|NCT01415882|Drug|Dexamethasone|Given PO or IV
79544902|NCT01415882|Drug|Ixazomib Citrate|Given PO
79544903|NCT01415882|Other|Laboratory Biomarker Analysis|Correlative studies
79544904|NCT01303341|Other|Laboratory Biomarker Analysis|Correlative studies
79544905|NCT01303341|Other|Pharmacological Study|Correlative studies
79544906|NCT01303341|Drug|Riluzole|Given PO
79705828|NCT04101318|Device|Non-Conformité Européene marked product|New Baseplate is not named at this point
79705829|NCT04101318|Device|Conformité Européene marked competitor products|The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
79705830|NCT04091672|Procedure|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
79705831|NCT04091672|Device|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
79544907|NCT01303341|Drug|Sorafenib Tosylate|Given PO
79250382|NCT02101268|Drug|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
79544908|NCT01254942|Other|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
80014890|NCT02090010|Procedure|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
79250383|NCT02063113|Other|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
79250384|NCT02045446|Radiation|Stereotactic Body Radiation Therapy|
79250385|NCT02045446|Drug|Maintenance chemotherapy|Maintenance chemotherapy
79250386|NCT01898650|Other|MR scan|
79250387|NCT01880515|Drug|Tetracycline|The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
79544909|NCT01254942|Other|Usual Care|
79544910|NCT01092702|Drug|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
79705832|NCT04091490|Drug|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
80014891|NCT01033292|Drug|BSI-201|IV infusion, 5.6 mg/kg
79705833|NCT04090125|Behavioral|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
79705834|NCT04090125|Behavioral|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
79705835|NCT04088318|Drug|OQL011|OQL011 is an ointment containing active ingredient.
80014892|NCT03068767|Dietary Supplement|Vitamin D|
79250388|NCT01817517|Device|Medtronic Activa Deep Brain Stimulation System|
79250389|NCT01780883|Drug|melatonin|
79544911|NCT01057134|Device|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
79250390|NCT01780883|Drug|Placebo|Placebo tablets of Circadin®
79250391|NCT01668719|Drug|Bortezomib|Given SC or IV
79250392|NCT01668719|Drug|Dexamethasone|Given PO or IV
79250393|NCT01668719|Biological|Elotuzumab|Given IV
79250394|NCT01668719|Other|Laboratory Biomarker Analysis|Correlative studies
79250395|NCT01668719|Drug|Lenalidomide|Given PO
79250396|NCT01642901|Drug|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
79250397|NCT01642901|Drug|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
79250398|NCT01488045|Drug|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
79250399|NCT01488045|Drug|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
79250400|NCT01488045|Drug|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
79250401|NCT01090479|Drug|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
79544912|NCT00926848|Behavioral|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
79544913|NCT00690352|Behavioral|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
79544914|NCT00667121|Drug|citalopram hydrobromide|
79544915|NCT00667121|Drug|escitalopram oxalate|
79544916|NCT00667121|Drug|gabapentin|
79544917|NCT00667121|Drug|sertraline hydrochloride|
79544918|NCT00667121|Drug|tamoxifen citrate|
79544919|NCT00667121|Drug|venlafaxine|
80014893|NCT02094144|Other|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
79250402|NCT01045525|Procedure|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
79705836|NCT04088318|Drug|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
79705837|NCT04087057|Other|Interview|Participate in interview
79705838|NCT04087057|Other|Medical Chart Review|Patients' medical records are reviewed
79705839|NCT04087057|Behavioral|Questionnaire|Complete questionnaires
79846694|NCT00513682|Drug|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
79846695|NCT00493012|Dietary Supplement|vitamin D|6 drops of a vitamin D containing oil
79846696|NCT00918593|Drug|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
79846697|NCT00918593|Radiation|Radiotherapy|Radiotherapy according to hospital procedures.
79250403|NCT01045525|Behavioral|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
80014894|NCT02094144|Other|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
79846698|NCT00918593|Drug|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
80014895|NCT02267720|Procedure|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
79846699|NCT04084847|Dietary Supplement|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
79846700|NCT04084847|Dietary Supplement|Placebo|Placebo powder
80014896|NCT02267720|Procedure|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
80014897|NCT02090166|Other|Blood test|a blood test will be taken from each patient
80014898|NCT01110902|Drug|Agomelatine (AGO178C)|
79250404|NCT00946712|Biological|Bevacizumab|Given IV
79250405|NCT00946712|Drug|Carboplatin|Given IV
79544920|NCT00667121|Genetic|molecular genetic technique|
79544921|NCT00667121|Other|high performance liquid chromatography|
79544922|NCT00667121|Other|laboratory biomarker analysis|
79544923|NCT00667121|Other|pharmacological study|
79705840|NCT04084704|Device|Cingal|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
79705841|NCT04082780|Drug|Rifamycin SV MMX|Intervention arm
79846701|NCT04084457|Dietary Supplement|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
79846702|NCT04084457|Dietary Supplement|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
80014899|NCT01110902|Drug|Placebo|
79544924|NCT00667121|Procedure|adjuvant therapy|
79846703|NCT05163431|Device|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
79846704|NCT04083833|Drug|Tetrodotoxin|A single TTX dose in a dose ascending study
80014900|NCT05204173|Drug|sintilimab, paclitaxel and S-1|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
80014901|NCT05204095|Device|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
80014902|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
80014903|NCT01025648|Drug|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
80014904|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
79250406|NCT00946712|Biological|Cetuximab|Given IV
79250407|NCT00946712|Other|Laboratory Biomarker Analysis|Correlative studies
79250408|NCT00946712|Drug|Paclitaxel|Given IV
79250409|NCT00772200|Procedure|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
79250410|NCT00772200|Other|Quality-of-Life Assessment|Ancillary studies
79544925|NCT00658879|Drug|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
79544926|NCT00591851|Drug|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
79705842|NCT04082780|Other|Placebo|Placebo arm
79705843|NCT04082117|Behavioral|Educational video|Educational genetic counseling video
79846705|NCT04083833|Drug|Placebos|matching placebo comparator
79846706|NCT05155241|Behavioral|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
79846707|NCT05155241|Behavioral|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
79250411|NCT00656669|Drug|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
80014905|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
79250412|NCT00656669|Drug|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
79250413|NCT00656669|Drug|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
79250414|NCT03829423|Diagnostic Test|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
79250415|NCT03829579|Drug|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
79250416|NCT03070951|Drug|OBE2109|OBE2109 100mg tablets for oral administration once daily
79544927|NCT00336024|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC resuce
79544928|NCT00336024|Drug|Carboplatin|Given IV
79544929|NCT00336024|Drug|Cisplatin|Given IV
79544930|NCT00336024|Drug|Cyclophosphamide|Given IV
79544931|NCT00336024|Drug|Etoposide|Given IV
79544932|NCT00336024|Biological|Filgrastim|Given IV or SC
79544933|NCT00336024|Other|Laboratory Biomarker Analysis|Correlative studies
79544934|NCT00336024|Drug|Leucovorin Calcium|Given IV or orally
79544935|NCT00336024|Drug|Methotrexate|Given IV
79544936|NCT00336024|Other|Quality-of-Life Assessment|Ancillary studies
79544937|NCT00336024|Drug|Thiotepa|Given IV
79705844|NCT04080284|Drug|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
79705845|NCT04078373|Behavioral|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
79705846|NCT04078373|Behavioral|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
79705847|NCT04067115|Drug|Trabectedin 1 MG [Yondelis]|Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
79705848|NCT04067115|Drug|Irinotecan|Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
79705849|NCT04067115|Diagnostic Test|tumor biopsy|Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
79705850|NCT04067115|Other|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
79705851|NCT04065347|Device|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
79705852|NCT04054375|Drug|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
79705853|NCT04051593|Other|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
79705854|NCT04048668|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
79705855|NCT04039386|Device|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
79705856|NCT04039386|Other|Control|Subjects in the control group will receive standard care.
79544938|NCT00336024|Drug|Vincristine Sulfate|Given IV
79544939|NCT00133705|Drug|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
79544940|NCT00133705|Drug|Inert Capsule|sugar pill
79544941|NCT01525017|Biological|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
79544942|NCT01525043|Drug|Naproxen|Naproxen 500mg BID for the first 2 weeks
79544943|NCT01525043|Drug|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
79544944|NCT01525043|Drug|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
79544945|NCT01525043|Drug|Naproxen|500mg bid
79705857|NCT04034433|Procedure|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
80014906|NCT01025648|Drug|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
80014907|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
79544946|NCT01525043|Drug|Synera|Topical appication of single patch to elbow for 12hrs/day
79250417|NCT03070951|Drug|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
79846708|NCT05144477|Behavioral|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
80014908|NCT03020745|Drug|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
80014909|NCT03020745|Drug|Placebo|Placebo is available as a Clear colorless solution.
79250418|NCT03070951|Drug|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
79544947|NCT01525043|Drug|Synera|Single patch applied to elbow for 4hrs/twice daily
79250419|NCT03070951|Drug|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
79250420|NCT04759339|Drug|AG-920|AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
79388781|NCT06003608|Device|Fluid biopsy capsule|Ingestion of two SIMBA capsules
79388782|NCT06003608|Drug|Levodopa-Carbidopa Immediate Release|Single dose, Levodopa-Carbidopa Immediate Release
79544948|NCT01525056|Radiation|ct and mri scans|ct and mri scan preradiation and postradiation
79544949|NCT01525056|Radiation|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
79544950|NCT01525056|Radiation|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
79544951|NCT01525108|Behavioral|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
79705858|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
79705859|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
79705860|NCT04023708|Drug|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
79705861|NCT04023422|Behavioral|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
79705862|NCT04023422|Behavioral|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
79705863|NCT04021641|Diagnostic Test|Speech recognition in noise|Measurement of speech recognition performance in noise
79705864|NCT04017442|Drug|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
79705865|NCT04017442|Drug|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
79705866|NCT04015622|Drug|Enzalutamide|Enzalutamide 160 mg PO OD
79705867|NCT04015622|Drug|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks
79705868|NCT04010578|Dietary Supplement|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
79705869|NCT04010578|Other|Placebo|Patients will receive a placebo each day.
79705870|NCT04005521|Behavioral|Preventive intervention|Preventive, structured exercise protocol
79705871|NCT04003389|Drug|fezolinetant|administered orally
79705872|NCT04003389|Drug|placebo|administered orally
79544952|NCT01525108|Other|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
79544953|NCT01525121|Other|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
79705873|NCT04000282|Drug|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
79705874|NCT03996018|Other|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
79705875|NCT03994055|Other|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
79705876|NCT03994055|Other|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
79705877|NCT03994055|Other|Soluble fiber|Diet will include foods rich in soluble fiber.
79705878|NCT03994055|Other|Probiotics|Diet will include foods rich in probiotics.
79705879|NCT03994055|Other|Lactose restriction|Diet will be restricted to 5g lactose/day
79705880|NCT03994055|Other|Fiber restriction|Diet will be restricted to 20g fiber/day
79705881|NCT03994055|Other|Fat restriction|Diet will be restricted to 20% total energy intake
79705882|NCT03991104|Drug|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
79705883|NCT03991104|Drug|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
79705884|NCT03991104|Radiation|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
79705885|NCT03989349|Drug|Placebo|Placebo
79705886|NCT03989349|Drug|Nemolizumab|Nemolizumab
79544954|NCT01525134|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
79846709|NCT05135663|Drug|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
79705887|NCT03988595|Other|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
79705888|NCT03985943|Drug|Placebo|Placebo
79705889|NCT03985943|Drug|Nemolizumab|Nemolizumab
80014910|NCT04960891|Drug|Tebentafusp|Concentrate solution for intravenous infusion
80014911|NCT01110746|Drug|Viaject 7|100IU/mL administered subcutaneously
79544955|NCT01525134|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
79544956|NCT01525147|Biological|YHB1411-2: Level 2|IV infusion
79544957|NCT01525147|Biological|YHB1411-2: Level 3|IV infusion
79705890|NCT03983473|Other|Microbiota Sequencing|virome, bacteriome, fungome NGS sequencing
79705891|NCT03968913|Drug|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
79705892|NCT03968913|Procedure|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
80014912|NCT01110746|Drug|LISPRO|100IU/mL administered subcutaneously
80014913|NCT05208775|Procedure|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
80014914|NCT05208775|Procedure|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
79388783|NCT05999097|Dietary Supplement|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
79388784|NCT05999097|Dietary Supplement|Placebo Group|This group will receive 12 g of corn starch as a control group.
79544958|NCT01525147|Biological|YHB1411-2: Level 4|IV infusion
79705893|NCT03968315|Procedure|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
79705894|NCT03968315|Procedure|Magnetic Resonance Imaging|Undergo MRI
79705895|NCT03962712|Other|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
79705896|NCT03962712|Other|No Increase in Minimum Wage|No increase in minimum wage
79705897|NCT03960437|Drug|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
80014915|NCT05623280|Drug|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
79388785|NCT05995652|Procedure|elastography|elastography
79388786|NCT05986084|Drug|Cabotegravir Injection [Apretude]|Injection
79388787|NCT05985057|Other|Artificial intelligence|Prediction of carbapenem resistance via deep machine learning model
79388788|NCT05978180|Device|Medical Device : HO-1|The injection will be performed at Day 1.
79388789|NCT05978180|Device|Medical Device : HS-3|The three injections will be performed at Days 1, 8 and 15.
79388790|NCT05978180|Device|Medical Device : SINOVIAL® ONE|The injection will be performed at Day 1.
79544959|NCT01525147|Biological|YHB1411-2: Level 5|IV infusion
79388791|NCT05974787|Behavioral|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the barriers and facilitators encountered during the (pre-)admission process. The second part will focus on the timeline that led to an emergency department (ED) visit. It will be established when and which symptoms were first detected. The third part is regarding the number and type of health care workers that were contacted before visiting the ED. The fourth part will be about the actions and considerations taken before the ED visit.
79544960|NCT01525147|Biological|Placebo|IV infusion
79544961|NCT01525147|Biological|YHB1411-2: level 1|IV infusion
79544962|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
79544963|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
79544964|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
79544965|NCT01525212|Drug|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
79544966|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
79544967|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
79544968|NCT01525264|Behavioral|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
79705898|NCT03959488|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
79705899|NCT03959488|Drug|Palivizumab|Approved anti-RSV monoclonal antibody
80014916|NCT02946853|Procedure|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
80014917|NCT02946853|Device|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
79250421|NCT01338493|Procedure|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
79250422|NCT01362296|Drug|GSK1120212|Oral once daily
79544969|NCT01525264|Behavioral|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
79250423|NCT01362296|Drug|docetaxel|IV once every 3 weeks
79250424|NCT01338415|Drug|Bosentan|Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
79250425|NCT04353128|Drug|Melatonin 2mg|2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
79250426|NCT04353128|Drug|Placebo oral tablet|Identically looking placebo tablets P.O. before bedtime for 12 weeks
79388792|NCT05974605|Behavioral|MM+HighC|In this intervention, participants will be trained on a available mindfulness meditation app, followed by a working memory updating game, developed by Dr. Chandramallika Basak. This game requires high degree of attentional control (Unpredictable Bird Watch), also known as High-C. The app and the game are delivered through an Android tablet for this home-based training.
79544970|NCT01525290|Drug|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
79544971|NCT01525290|Drug|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
79544972|NCT01525303|Behavioral|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
79544973|NCT01525368|Behavioral|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
79388793|NCT05971979|Other|No intervention|No intervention
79388794|NCT05971108|Diagnostic Test|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
79388795|NCT05957406|Device|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
79544974|NCT01525433|Behavioral|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
79544975|NCT01525433|Behavioral|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
79705900|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
79705901|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
79705902|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
79705903|NCT03948984|Behavioral|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
79705904|NCT03948100|Other|Educational Intervention|Undergo dyadic education program
79705905|NCT03948100|Other|Quality-of-Life Assessment|Ancillary studies
79705906|NCT03948100|Other|Questionnaire Administration|Ancillary studies
79705907|NCT03948100|Procedure|Yoga|Undergo dyadic yoga
80014918|NCT02267798|Other|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
79705908|NCT03942250|Biological|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
79846710|NCT05135663|Drug|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
79250427|NCT05334823|Biological|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
79846711|NCT05684237|Procedure|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
80014919|NCT02267798|Device|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
79250428|NCT05125172|Other|Focus of Attention|Focus of attention instruction and feedback. Focus of attention refers to what people are thinking about during motor tasks. An external focus refers to thinking about an outside outcome or target. An internal focus of attention refers to thinking about how someone is moving their body.
79250429|NCT05320549|Behavioral|Community Programme|Participants have the opportunity to engage in face-to-face and/or online exercise classes. Attendance will be recorded.
79250430|NCT05125094|Device|TACE,Ablation|Transcatheter arterial chemoembolization
79250431|NCT04312490|Diagnostic Test|endomyocardial biopsy|Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
79250432|NCT04609891|Drug|Avatrombopag|10×109/L<PLT<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
79250433|NCT04263350|Drug|Atazanavir/Cobicistat|Specified Dose on Specified Days
79250434|NCT04263350|Drug|Reyataz Atazanavir|Specified Dose on Specified Days
79250435|NCT04263350|Drug|Cobicistat|Specified Dose on Specified Days
79250436|NCT05258149|Device|JJVC Investigational Multifocal Contact Lenses|TEST
79250437|NCT05258149|Device|Dailies Total 1® Multifocal Contact Lenses|CONTROL
79388796|NCT05955053|Other|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
79388799|NCT05947188|Other|prostate cancer diagnosis|prostate cancer diagnosis
79544976|NCT01525446|Radiation|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
79544977|NCT01525459|Procedure|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
79544978|NCT01525459|Other|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
79544979|NCT01525511|Drug|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~Dosage: 2 tablets~DHA-PQP:~1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~Dosage: 3 tablets"
79705909|NCT03936894|Drug|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
79705910|NCT03934268|Genetic|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
79846712|NCT02589587|Procedure|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
79846713|NCT02589587|Other|no intervention|lean control group
79846714|NCT05246813|Other|Blood and bone marrow cell collection|Collection of blood and bone marrow
79846715|NCT05238233|Drug|Tropicamide|One drop will be given to participants
79846716|NCT05238233|Drug|1% Pilocarpine|One drop will be given to participants
79846717|NCT05238233|Drug|Proparacaine Hydrochloride|One drop will be given to participants
79846718|NCT05238233|Device|Tono pen AVIA|Participant intraocular pressures measured
79846719|NCT05238233|Device|VG4 Gonio|Participant iridocorneal angle measured
79846720|NCT05238233|Device|Reichert phoropter|Participant screened for hyperopia >+1 diopter
79846721|NCT05685017|Diagnostic Test|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
79705911|NCT03931707|Genetic|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
79705912|NCT03926507|Procedure|Computed Tomography|Undergo PET/CT scan
79705913|NCT03926507|Other|Fluciclovine F18|Given IV
79705914|NCT03926507|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79705915|NCT03913195|Drug|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
79705916|NCT03912038|Other|No intervention.|No intervention
79705917|NCT03907124|Drug|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
79705918|NCT03907124|Drug|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
79705919|NCT03894059|Other|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
79250438|NCT03490682|Other|Ultrasound assessment of gastric emptying of a flavoured yoghourt.|Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
79705921|NCT03888040|Other|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
79705922|NCT03885622|Device|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
79705923|NCT03884790|Device|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
79846722|NCT00918905|Device|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
79705924|NCT03884374|Behavioral|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
79705925|NCT03884374|Behavioral|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
80014920|NCT02895841|Other|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
80014921|NCT02267876|Device|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
79705926|NCT03884374|Device|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
79705927|NCT03884374|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
79705928|NCT03873818|Biological|Ipilimumab|Given IV
79705929|NCT03873818|Biological|Pembrolizumab|Given IV
80014922|NCT02267876|Procedure|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
80014923|NCT05762185|Device|nursing consultation|nursing consultation
79705930|NCT03848676|Diagnostic Test|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
79705931|NCT03847194|Behavioral|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
79846723|NCT04083443|Other|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
79250439|NCT03562585|Diagnostic Test|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
79544980|NCT01525511|Drug|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~Dosage: 2 tablets~DHA-PQP:~1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~Dosage: 3 tablets"
79388800|NCT05946551|Drug|Cetirizine|Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
79846724|NCT04083677|Device|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
79846725|NCT00919373|Procedure|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
79250440|NCT03463850|Radiation|Dual Energy CT (DECT)|Dual Energy CT (DECT)
79846726|NCT00919373|Procedure|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
79846727|NCT00919373|Procedure|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
79250441|NCT03463850|Radiation|DEXA|Dual-energy x-ray absorptiometry for measurement of bone mineral density
79846728|NCT05314439|Drug|ION904|ION904 will be administered by SC injection.
79250442|NCT05124938|Diagnostic Test|Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.|a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
79846729|NCT05314439|Drug|Placebo|Placebo will be administered by SC injection.
79846730|NCT00617708|Biological|cixutumumab|Given IV
80014924|NCT02267954|Other|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
80014925|NCT05622968|Device|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
80014926|NCT05622968|Drug|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
80014927|NCT03667989|Diagnostic Test|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
80014928|NCT01020968|Biological|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
80014929|NCT01020968|Other|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
79250443|NCT03187028|Behavioral|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
79250444|NCT03187028|Behavioral|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
79388801|NCT05946551|Drug|Famotidine|Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
79388802|NCT05946551|Drug|Cetirizine Placebo|The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
79544981|NCT01525524|Device|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
80014930|NCT02268032|Drug|DHEA|DHEA 2.2 g in vaginal ring
80014931|NCT02268032|Drug|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
80014932|NCT02268032|Drug|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
80014933|NCT03019965|Drug|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
80014934|NCT03019965|Drug|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
80014935|NCT03019965|Drug|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
80014936|NCT03019965|Drug|Extended Imipenem|Imipenem administered in 6 hours infusion.
80014937|NCT03019965|Drug|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
80014938|NCT03019965|Drug|Extended Meropenem|Meropenem administered in 8 hours infusion.
79544982|NCT01525537|Drug|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
80014939|NCT02268110|Other|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
79705932|NCT03843294|Biological|TAA-T cells|The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
79705933|NCT03843294|Drug|Nivolumab|Nivolumab: For patients <18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
79846731|NCT00617708|Drug|erlotinib hydrochloride|Given PO
80014940|NCT02268110|Other|Abdominal binding|Wearing an abdominal binder for 12 weeks
79544983|NCT01525537|Drug|sufentanil|sufentanil was given at standard practise
79388803|NCT05946551|Drug|Famotidine Placebo|The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
79544984|NCT01525576|Behavioral|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
79705934|NCT03836443|Other|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
79705935|NCT03828747|Drug|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
80014941|NCT03623061|Diagnostic Test|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
79388804|NCT05941650|Dietary Supplement|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
79544985|NCT01525654|Behavioral|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
79705936|NCT03828747|Drug|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
79846732|NCT00617708|Drug|gemcitabine hydrochloride|Given IV
79544986|NCT01525680|Other|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
79846733|NCT04083209|Behavioral|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
79846734|NCT02589119|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
79846735|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
79846736|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
80014942|NCT01468831|Drug|Minocycline|100 mg of minocycline in a pink opaque capsule
79250445|NCT02259985|Drug|Itasetron tablet|
79250446|NCT02259985|Drug|Itasetron infusion|
79250447|NCT02259985|Other|high fat breakfast|
79250448|NCT04010396|Other|Blood sampling|Blood sampling: 1 EDTA and 1 Serum vial
79250449|NCT05124626|Procedure|MIRPE with two bars|Minimally invasive repair of pectus excavatum utilizing two metallic bars
79250450|NCT05124626|Procedure|MIRPE with one bar|Minimally invasive repair of pectus excavatum utilizing one metallic bar
79250451|NCT01371643|Drug|Octreotide LAR|
79250452|NCT01371643|Procedure|transsphenoidal surgery|
79388805|NCT05941650|Other|Corn Starch|This group will receive 12 g of corn starch as a control group.
79544987|NCT01525680|Other|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
79705937|NCT03828747|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
79705938|NCT03825315|Biological|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
79705939|NCT03825315|Biological|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
79705940|NCT03825315|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
79705941|NCT03821402|Biological|DAXI for injection 250 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
79846737|NCT05227586|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
80014943|NCT01468831|Other|Placebo|Pill with inactive ingredients in a pink opaque capsule
80014944|NCT01468831|Drug|Bevacizumab|1.25 mg bevacizumab injection
80014945|NCT03667911|Other|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
80014946|NCT05627414|Drug|Disitamab Vedotin|2.5mg/kg，IV，Q3W
80014947|NCT05627414|Drug|Sintilimab|200 mg，IV，Q3W
80014948|NCT05627414|Drug|S-1|40~60mg / m2, bid, d1-14, repeated every 3 weeks.
80014949|NCT05627414|Procedure|Intraperitoneal chemotherapy with paclitaxel|Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）
79705942|NCT03821402|Biological|DAXI for injection 375 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
79388806|NCT05935007|Device|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
79705943|NCT03821402|Biological|DAXI for injection 500 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
79388807|NCT05933941|Other|Virtual reality|"This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility."
79705944|NCT03821402|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
79705945|NCT03816176|Drug|Isavuconazonium sulfate|Intravenous (IV) infusion
79544988|NCT01525706|Drug|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL [3mg/ml diluted in normal saline from original concentration of 6mg/mL] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
79544989|NCT01525719|Drug|Everolimus|10 mg everolimus
79846738|NCT05227586|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
79250453|NCT03056222|Device|Ablation catheter|Ablation of paroxysmal atrial fibrillation
79250454|NCT04390477|Dietary Supplement|Probiotic|Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
79388808|NCT05933941|Other|Exercises|The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
79388809|NCT05931289|Behavioral|Enhanced Crisis Response Planning (ECRP)|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
79391754|NCT03171090|Other|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
79544990|NCT01525732|Procedure|Per Oral Endoscopic Myotomy|
79250455|NCT04046809|Other|Food for special medical purposes: Neurotidine®|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
79250456|NCT04046809|Other|Placebo|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
79250457|NCT03719456|Procedure|Retrograde Intrarenal Surgery|
79705946|NCT03816176|Drug|Isavuconazonium sulfate|Oral capsule
79705947|NCT03804606|Other|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
79705948|NCT03774758|Diagnostic Test|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
79846739|NCT00871130|Procedure|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
79846740|NCT00876044|Drug|aflibercept (AVE0005)|Intravenous route
79846741|NCT00876044|Drug|placebo|Intravenous route
79846742|NCT04040114|Device|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
79250458|NCT03819439|Other|Microbiome and Autism Questionnaire|The questionnaire will be administered to collect demographic data (i.e. sex, age, race, and ethnicity) of the volunteers. Additionally, it will ask for the volunteers to identify whether or not they have autism spectrum disorder and what other medical conditions they have and what medications (e.g. prescribed, over the counter, herbal; etc.) that they take.
79250459|NCT03023462|Drug|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
79250460|NCT03023462|Drug|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
79250461|NCT03023462|Drug|Ropivacaine|Local anesthetic for the block
79250462|NCT04412798|Other|orange juice concentrate|250mL of 100% orange juice made from concentrate
79250463|NCT04412798|Other|Sugar-sweetened orange-flavoured beverage|Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition
79250464|NCT04412798|Other|Whole orange juice with skin removed|Whole orange pieces with skin removed, energy-matched to the orange juice condition
79250465|NCT02824952|Drug|Tagrisso|taking orally everyday for 6 or 12 weeks.
79250466|NCT01371565|Drug|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
79388810|NCT05931289|Behavioral|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
79544991|NCT01525758|Drug|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
79250467|NCT03714854|Device|transcranial magnetic stimulation|TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
79250468|NCT03662906|Other|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
79705949|NCT03765541|Drug|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV [10 minutes])~Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV [10 minutes])~In combination with azacitidine:~Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV [10 minutes]).~Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV [10minutes])."
79250469|NCT03662906|Other|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
79250470|NCT04093843|Device|TMS|NeuroStar TMS Therapy
79388811|NCT05931016|Diagnostic Test|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
79388812|NCT05931016|Diagnostic Test|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
79388813|NCT05926817|Device|Placebo-VR headsets|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
79250471|NCT03598478|Behavioral|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
79250472|NCT03598478|Behavioral|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
79388814|NCT05926817|Device|QTC-VR headsets|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
79388815|NCT05922683|Drug|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
79544992|NCT01525758|Drug|microcrystalline cellulose|identical number of tablets to active drug groups
79544993|NCT01525771|Other|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~Cisplatin 60mg/m2 IV (D1) every 21 days"
79544994|NCT01525810|Drug|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention [subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)]
79705950|NCT03765541|Drug|Amsacrine|"Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV [3 hours])~Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV [3 hours])"
79250473|NCT03598478|Behavioral|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
79250474|NCT05347940|Other|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
79250475|NCT05347940|Other|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
79250476|NCT02035969|Behavioral|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
79250477|NCT05121584|Procedure|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
79250478|NCT05089136|Device|transcatheter paravalvular leak closure|Transcatheter paravalvular leak closure (PVLc) was first described in 1992 and has since then emerged as an attractive alternative to repeat surgery. Many implantable devices that can be used for transcatheter PVLc have been marketed, although few are specifically designed for this purpose. It consist in implanting an occluder in the paravalvular leak to stop or reduce the regurgitant flow.
79250479|NCT02821819|Other|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
79250480|NCT02821819|Drug|Gonadotrophins|Urinary FSH 150-225 IU/d
79388816|NCT05922683|Device|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
79544995|NCT01525823|Drug|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
79544996|NCT01525823|Drug|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
79250481|NCT02821819|Drug|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
79250482|NCT02821819|Drug|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
79250483|NCT04500548|Procedure|Biospecimen Collection|Undergo collection of tissue samples
79250484|NCT04500548|Biological|Ipilimumab|Given IV
79250485|NCT04500548|Biological|Nivolumab|Given IV
79250486|NCT05707819|Drug|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
79250487|NCT02273336|Other|cytology specimen collection procedure|Undergo tissue and blood sample collection
79250488|NCT02273336|Other|laboratory biomarker analysis|Correlative studies
79250489|NCT03034538|Drug|Zonegran|100mg
79250490|NCT03034538|Drug|Zonegran|200mg
79250491|NCT02766998|Procedure|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
79250492|NCT02468180|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
79388817|NCT05921994|Other|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
79544997|NCT01525836|Drug|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 29th day)
79544998|NCT01525836|Drug|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
79544999|NCT01525888|Procedure|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
79545000|NCT01525914|Drug|Dutasteride|dutasteride 0.5mg daily
79388818|NCT05921435|Drug|CKD-341, D958|A single dose of 1tablet under fasting condition
79388819|NCT05919264|Drug|FOG-001|FOG-001 will be administered IV once weekly at assigned doses in continuous cycles of 28 days
79705951|NCT03765541|Drug|Cytarabine|"Patients < 60 years of age:~Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV [2 hours])~Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV [2 hours]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
79705952|NCT03765541|Drug|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle [or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle] (SC)
79846743|NCT00876122|Drug|GDC-0941|Escalating oral dose
79705953|NCT03753334|Combination Product|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
79846744|NCT00866216|Drug|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
79250493|NCT02468180|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
79250494|NCT02468180|Drug|N-butyl-2-cyanoacrylate|
79545001|NCT01525940|Device|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
79388820|NCT05919264|Drug|FOG-001|FOG-001 will be administered IV once weekly at the RP2D dose in continuous cycles of 28 days
79250495|NCT02468180|Drug|Lauromacrogol|
79250496|NCT01836068|Drug|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
79250497|NCT05053880|Drug|ACT001|Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
79250498|NCT05053880|Drug|ACT001 + Pembrolizumab|Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
79388821|NCT05918523|Biological|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
79388822|NCT05918224|Drug|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
79250499|NCT04973540|Device|Iron Bioresorbable Scaffold System (IBS Angel)|Subjects in this arm will be implanted with IBS Angel.
79545002|NCT01525953|Drug|Chemotherapy|Chemotherapy according to standard
79388823|NCT05918224|Drug|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
79545003|NCT01525953|Radiation|Radiotherapy|Radiotherapy according to local standard
79545004|NCT01525979|Behavioral|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
79250500|NCT00094016|Drug|beclomethasone dipropionate|
79250501|NCT05134376|Other|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
79705954|NCT03753334|Dietary Supplement|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
79705955|NCT03752242|Drug|BMX-010 0.3%|Safety and efficacy of BMX-010 in topical treatment of acne.
79705956|NCT03748667|Diagnostic Test|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
79705957|NCT03748667|Diagnostic Test|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
79846745|NCT00866216|Drug|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
79250502|NCT03926611|Drug|LOU064 Arm 1|10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
79250503|NCT03926611|Drug|LOU064 Arm 2|35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
79388824|NCT05909085|Device|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
79388825|NCT05909085|Device|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
79846746|NCT00871208|Drug|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
79846747|NCT00871208|Drug|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
79846748|NCT04039802|Procedure|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
79250504|NCT03926611|Drug|LOU064 Arm 3|100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
79250505|NCT03926611|Drug|LOU064 Arm 4|10mg bid of LOU064 orally, twice daily from Day 1 to 85
79250506|NCT03926611|Drug|LOU064 Arm 5|25 mg bid of LOU064 orally, twice daily from Day 1 to 85
79250507|NCT03926611|Drug|LOU064 Arm 6|100 mg bid of LOU064 orally, twice daily from Day 1 to 85
79250508|NCT03926611|Drug|Placebo arm|Matching placebo, orally, twice daily from Day 1 to 85
79388826|NCT05908084|Biological|HAV|HAV implantation
79545005|NCT01525979|Behavioral|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
79545006|NCT01525979|Behavioral|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
79705958|NCT03747887|Behavioral|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
79705959|NCT03747887|Other|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
79705960|NCT03738748|Other|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
79705961|NCT03738748|Other|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
80014950|NCT03668691|Device|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
80014951|NCT01675882|Biological|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
80014952|NCT01675882|Biological|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
80014953|NCT01675882|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
80014954|NCT01675882|Biological|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
80014955|NCT05617508|Other|Placebo|Placebo capsules administered twice daily for a total of 12 weeks.
80014956|NCT05617508|Dietary Supplement|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside supplementation 1000mg daily in total
80014957|NCT05617508|Dietary Supplement|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)|Nicotinamide Riboside supplementation up to 3000mg daily in total
80014958|NCT03018249|Drug|Entinostat|Given PO
80014959|NCT03018249|Procedure|Hysterectomy|Undergo hysterectomy
80014960|NCT03018249|Other|Laboratory Biomarker Analysis|Correlative studies
80014961|NCT03018249|Drug|Medroxyprogesterone Acetate|Given IM
79250509|NCT05134298|Drug|Piperacillin/tazobactam, Meropenem|This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
79250510|NCT05134220|Diagnostic Test|Serum Calcium|"Serum calcium level.~Serum phosphorus level. will be measured to all study population"
79250511|NCT01423682|Behavioral|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
79388827|NCT05908084|Other|AVF|AVF creation procedure
79388828|NCT05906810|Procedure|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
79388829|NCT05889052|Drug|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
79388830|NCT05887492|Drug|TNG260|CoREST inhibitor, administered orally
79388831|NCT05887492|Drug|Pembrolizumab|Pembrolizumab, an anti-PD-1 antibody, administered intravenously
79388832|NCT05887401|Behavioral|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
79388833|NCT05887401|Behavioral|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
79388834|NCT05887401|Behavioral|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
80014962|NCT01018550|Drug|AMG 853|AMG 853 5 mg (BID)
80014963|NCT01018550|Drug|AMG 853|AMG 853 200 mg (QD)
80014964|NCT01018550|Drug|AMG 853|AMG 853 25 mg (BID)
80014965|NCT01018550|Drug|AMG 853|AMG 853 100 mg (BID)
80014966|NCT01018550|Drug|Placebo|Placebo
80014967|NCT05380154|Drug|Botulinum Toxin A type for injection (Botulax®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
80014968|NCT05380154|Drug|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
79250512|NCT01272999|Other|No intervention|Non interventional
79545007|NCT01525979|Behavioral|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
79705962|NCT03736590|Behavioral|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
79705963|NCT03712956|Drug|Caelyx®|Caelyx® every two weeks for 8 courses
79705964|NCT03712098|Drug|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
79705965|NCT03712098|Drug|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
79705966|NCT03712098|Behavioral|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
79705967|NCT03710772|Drug|Cyclophosphamide|Given IV
79250513|NCT05129852|Other|Sage oil group|Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.
79705968|NCT03710772|Drug|Cytarabine|Given IV
79388835|NCT05887401|Behavioral|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
79705969|NCT03710772|Drug|Dexamethasone|Given PO or IV
79705970|NCT03710772|Drug|Doxorubicin Hydrochloride|Given IV
79705971|NCT03710772|Drug|Ibrutinib|Given PO
79705972|NCT03710772|Drug|Methotrexate|Given IV
79705973|NCT03710772|Biological|Rituximab|Given IV
79250514|NCT05129852|Behavioral|Reiki group|Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
79705974|NCT03710772|Drug|Venetoclax|Given PO
79705975|NCT03710772|Drug|Vincristine Sulfate|Given IV
79705976|NCT03706014|Behavioral|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
79250515|NCT05707585|Diagnostic Test|Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)|Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs
79388836|NCT05887401|Behavioral|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
79705977|NCT03706014|Behavioral|Control|Contact-equivalent attention control program in which students play educational games
80014969|NCT05378984|Other|before - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
79250516|NCT05129774|Procedure|Radical surgery with PALND|sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach
79388837|NCT05887401|Behavioral|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
79388838|NCT05887401|Behavioral|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
79388839|NCT05887401|Behavioral|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
79545008|NCT01525992|Behavioral|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
79705978|NCT03704688|Drug|Trametinib 0.5 mg|0.5mg PO q daily
79705979|NCT03704688|Drug|Trametinib 1 MG|1.0 mg PO q daily
79705980|NCT03704688|Drug|Trametinib 1.5 MG|1.5mg PO q daily
79705981|NCT03704688|Drug|Trametinib 2 mg|2 mg PO q daily
79705982|NCT03704688|Drug|Ponatinib 15 MG|15mg PO q daily
79705983|NCT03704688|Drug|Ponatinib 30 MG|30mg PO q daily
79705984|NCT03686332|Drug|Arm A: Atezolizumab and Radiotherapy|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
79705985|NCT03686332|Drug|Arm B: Atezolizumab|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
80014970|NCT05378984|Other|after - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
80014971|NCT05374252|Drug|PD-1 inhibitor|Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
80014972|NCT05374252|Radiation|concurrent chemoradiotherapy|Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
80014973|NCT00912158|Other|standard therapy (ST)|standard medical therapy
80014974|NCT00912158|Device|CPAP|Non-invasive mechanical ventilation (CPAP)
79846749|NCT04039802|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
79846750|NCT00876278|Device|*AT.Smart 46LC|Primary implantation of *AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
79846751|NCT04083521|Dietary Supplement|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10^9 CFU once a day for 90-days.
79846752|NCT00871364|Drug|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
79250517|NCT05129774|Procedure|Radical surgery without PALND|surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
79846753|NCT00871364|Drug|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
79250518|NCT03954379|Drug|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2"
79388840|NCT05887401|Behavioral|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
79388841|NCT05885737|Drug|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
79846754|NCT00876356|Dietary Supplement|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
79846755|NCT00876356|Dietary Supplement|Olive oil|Olive oil 4.5g/day x 12 weeks
79846756|NCT04083053|Procedure|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
79846757|NCT04083053|Procedure|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
79388842|NCT05885737|Drug|Placebo Injection|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
79545009|NCT01525992|Other|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
79545010|NCT01526005|Drug|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
79545011|NCT01526005|Drug|Transdermal Placebo Patch|1 patch per day; 8 weeks total
79250519|NCT03954379|Drug|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~IV dexmedetomidine~IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~injection of freezing medication through the tube in the thigh x 2~IV dexamethasone 8 mg 1 day after surgery"
79391755|NCT03171090|Other|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
79545012|NCT01526018|Behavioral|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
79705986|NCT03684486|Behavioral|rehabilitation by effort|
79705987|NCT03683394|Behavioral|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
79705988|NCT03683394|Behavioral|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
79705989|NCT03677102|Other|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
79705990|NCT03677102|Other|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
79705991|NCT03671746|Drug|Ketorolac|Participants will receive Ketorolac at 30 mg IV every 6 hours for their first 5 days of hospitalization
79705992|NCT03671746|Drug|Saline Solution|Participants will receive 10 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
79705993|NCT03667092|Biological|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
79705994|NCT03658278|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
79705995|NCT03656510|Drug|JNJ-53718678|Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
79705996|NCT03656510|Drug|Placebo|Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
80014975|NCT00912158|Device|BIPAP|Non-invasive mechanical ventilation (BIPAP)
79545013|NCT01526031|Procedure|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
80014976|NCT04438096|Drug|100 mg|One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
79545014|NCT01526031|Procedure|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
79545015|NCT01526031|Procedure|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
79250520|NCT03954379|Procedure|Periarticular Local Anesthetic Infiltration|INTERVENTION DURING SURGERY
79705997|NCT03652545|Biological|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
79705998|NCT03646175|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
79705999|NCT03646175|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
80014977|NCT04438096|Drug|200 mg|Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
79388843|NCT05882344|Procedure|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
79388844|NCT05882344|Device|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
80014978|NCT04438096|Drug|300 mg|Three 100 mg pills (QD) will be orally administered for 12 weeks
79388845|NCT05879835|Device|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
79250521|NCT03954379|Drug|IV Dexamethasone 8mg at the end of surgery as standard of care|INTERVENTION DURING SURGERY
79388846|NCT05879835|Device|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
79706000|NCT03642795|Other|Questionnaire|Patients are asked to complete several questionnaires
79706001|NCT03637816|Drug|Anamorelin Hydrochloride|Given PO
79706002|NCT03637816|Other|Placebo|Given PO
79706003|NCT03637816|Other|Questionnaire Administration|Ancillary studies
79706004|NCT03630991|Drug|Edetate Calcium Disodium|Given IV
79706005|NCT03630991|Dietary Supplement|Multivitamin|Given PO
79706006|NCT03630991|Drug|Succimer|Given PO
80014979|NCT04438096|Drug|Placebo|Three placebo pills (QD) will be orally administered for 12 weeks
79250522|NCT05134064|Device|total-body PET/CT|PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.
79250523|NCT02036125|Device|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
79250524|NCT02036125|Drug|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
79250525|NCT05403866|Drug|LT3001 Drug Product|Administered by intravenous infusion
79388847|NCT05875571|Drug|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
79388848|NCT05875571|Drug|Placebo|Patients will get IV placebo during IUD placement under sedation
79391756|NCT02404740|Device|Pulse oximetry|Pulse oximetry
79706007|NCT03622528|Radiation|Chest CT scan|Standard dose chest CT scan
79706008|NCT03620188|Other|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
79706009|NCT03616886|Drug|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
80014980|NCT01015430|Drug|Placebo (for RO4917523 ascending doses)|Placebo daily po
80014981|NCT01015430|Drug|Placebo (for RO4917523 fixed dose)|Placebo daily po
80014982|NCT01015430|Drug|RO4917523|RO4917523 ascending doses daily po
80014983|NCT01015430|Drug|RO4917523|RO4917523 fixed dose daily po
79250526|NCT05403866|Drug|Placebo|Administered by intravenous infusion
79250527|NCT05707507|Other|Place of treatment|Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
79250528|NCT05133752|Drug|Nemonoxacin|500 mg, oral administration, once daily for 7-10 days.
79250529|NCT05129072|Device|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D|kalifilcon A Daily Disposable Toric LD213001 lens
79846758|NCT05227274|Other|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
79706010|NCT03616886|Drug|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
79846759|NCT00866450|Dietary Supplement|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
80014984|NCT02923245|Other|point-of-care ultrasound|
80014985|NCT05103748|Behavioral|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
80014986|NCT05103748|Behavioral|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
80014987|NCT04399486|Other|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
80014988|NCT03668535|Procedure|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
79388849|NCT05874453|Other|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
80014989|NCT03668535|Procedure|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
80014990|NCT00908648|Procedure|Narrow Band Imaging|Narrow Band Imaging
79388850|NCT05873959|Biological|HAV implantation|HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.
79388851|NCT05871008|Other|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
79706011|NCT03616886|Drug|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
79706012|NCT03616886|Drug|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
79706013|NCT03609840|Drug|Thiotepa|Given IV
79706014|NCT03601897|Drug|rebastinib|25 mg tablets or 75 mg tablets
79706015|NCT03601897|Drug|Paclitaxel|Paclitaxel administered by IV infusion at 80 mg/m2
79706016|NCT03594981|Biological|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
79846760|NCT00866450|Dietary Supplement|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
80014991|NCT04437940|Diagnostic Test|Vaginal fluid Covid-19 PCR test|Vaginal fluid samples are tested for Covid-19
80014992|NCT01014806|Biological|Influenza VLP Vaccine|Single dose; 0.5mL
80014993|NCT01014806|Biological|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
80014994|NCT03667833|Other|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
79302853|NCT02478047|Drug|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
79388852|NCT05871008|Other|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
79706017|NCT03586583|Device|FBP|Old processing
79706018|NCT03586583|Device|ISR|New processing
79706019|NCT03581461|Behavioral|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
79706020|NCT03573349|Drug|Ketamine|We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
79706021|NCT03562507|Drug|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
79706022|NCT03562507|Drug|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
79706023|NCT03552705|Drug|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
79846761|NCT03894969|Biological|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
79846762|NCT03894969|Biological|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
79846763|NCT00876434|Drug|Sirolimus|
80014995|NCT05102968|Behavioral|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
79846764|NCT00871442|Other|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
80014996|NCT05102968|Behavioral|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd~12th week and once two weeks at post-operative 13th~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
80014997|NCT03667755|Procedure|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
79250530|NCT04847102|Biological|SARS-CoV-2 mRNA Vaccine|"The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000)."
79545016|NCT01526031|Procedure|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~transcutaneous electrical nerve stimulation (TENS) for 15 minutes~transcutaneous infrared thermotherapy (TDP) for 15 minutes~manual physical therapy for 15 minutes~simple home exercise program"
79250531|NCT04847102|Biological|Placebo|0.9% sodium chloride solution, 0.5 mL/vial
79250532|NCT02818777|Drug|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
79388853|NCT05862285|Drug|Ipatasertib|Ipatasertib will be administered as a monotherapy or in combination with other agent(s) or comparator agent(s) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
79388854|NCT05857475|Device|CPAP therapy|Continous positive airway pressure therapy
79388855|NCT05857475|Other|Control|No CPAP
79706024|NCT03552705|Drug|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
79545017|NCT01526044|Device|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
79706025|NCT03543371|Diagnostic Test|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A & B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
79706026|NCT03539081|Diagnostic Test|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
79545018|NCT01526070|Drug|Intravitreal injection of Aflibercept|
79545019|NCT01526083|Other|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
79545020|NCT01526083|Other|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose"
79846765|NCT00871442|Other|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
79846766|NCT00871442|Drug|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
79846767|NCT00871520|Other|no specific interventions|There are no specific interventions in this observational study
80014998|NCT01014572|Behavioral|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
80014999|NCT01014572|Drug|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
80015000|NCT01014572|Behavioral|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
80015001|NCT04437316|Device|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
80015002|NCT01013324|Drug|XL147 (SAR245408)|dosed as capsules taken orally daily
80015003|NCT04437550|Other|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
80015004|NCT00905606|Drug|Topiramate Tablets|
80015005|NCT00905606|Drug|Topamax® Tablets|
80015006|NCT01002950|Drug|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
80015007|NCT01002950|Drug|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
79388856|NCT05856357|Drug|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
79250533|NCT05128916|Biological|intralesional platelet rich plasma|Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
79706027|NCT03539081|Other|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
79250534|NCT05128916|Drug|Oral terbinafine|Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
79250535|NCT02036047|Device|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
79706028|NCT03539081|Other|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
79706029|NCT03539081|Other|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
79706030|NCT03539081|Other|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
79706031|NCT03539081|Other|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
79706032|NCT03539081|Other|Anthropometric Measurements|Height and weight will be obtained.
79706033|NCT03539081|Behavioral|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
79706034|NCT03539081|Behavioral|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
79706035|NCT03534713|Drug|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
79706036|NCT03534713|Drug|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
79706037|NCT03534713|Drug|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
79706038|NCT03534713|Radiation|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
79706039|NCT03534076|Other|Cohort Observational study|Cohort Observational study - there is no intervention
79706040|NCT03518203|Drug|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
79388857|NCT05846581|Device|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
79388858|NCT05844826|Device|SIMBA Capsule|Participants will swallow capsule
79388859|NCT05840510|Drug|Adagrasib|KRAS G12C inhibitor
79388860|NCT05840510|Drug|nab-Sirolimus|mTOR inhibitor
79388861|NCT05838417|Behavioral|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
79388862|NCT05827055|Drug|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
79388863|NCT05827055|Drug|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
79388864|NCT05827055|Drug|Proglumide|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
79846768|NCT02588729|Other|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
79846769|NCT05355597|Drug|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
80015008|NCT01676896|Behavioral|Asthma in-school class|
80015009|NCT01676896|Behavioral|Asthma Day Camp|
80015010|NCT01676896|Behavioral|Health Promotion in-school class|
79706041|NCT03507062|Other|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
79846770|NCT05355597|Drug|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
79545021|NCT01526109|Behavioral|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
79545022|NCT01526109|Behavioral|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
80015011|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
79846771|NCT05684003|Other|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
79846772|NCT00866528|Drug|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
80015012|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
80015013|NCT00905372|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
80015014|NCT00905372|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
79706042|NCT03507062|Other|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
80015015|NCT05208788|Diagnostic Test|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
80015016|NCT03017079|Dietary Supplement|semi-solid agent with standard enteral feeding|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
79706043|NCT03507062|Other|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
79846773|NCT00866528|Drug|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
79706044|NCT03501693|Device|DBT plus S-View|DBT plus S-View images
79706045|NCT03501693|Device|FFDM Alone|FFDM alone images
79706046|NCT03500172|Behavioral|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
79846774|NCT05355519|Other|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
79846775|NCT05355519|Other|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
79846776|NCT00871598|Drug|BTT1023|intravenous, three infusions over three weeks
79706047|NCT03500172|Behavioral|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
79706048|NCT03493932|Drug|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
79706049|NCT03493932|Drug|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
79706050|NCT03487809|Drug|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
79706051|NCT03485963|Biological|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
79706052|NCT03470922|Biological|Relatlimab|Specified dose on specified day
79706053|NCT03470922|Biological|Nivolumab|Specified dose on specified days
79846777|NCT00871598|Drug|Placebo|intravenous, three infusions over three weeks
79846778|NCT00871598|Drug|BTT1023|Test challenge
79846779|NCT04082741|Drug|BMS-986318|Specified dose on specified days
80015017|NCT03017079|Other|standard enteral feeding|Intermittent enteral feeding is applied less than 60 minutes
80015018|NCT05048134|Drug|HRS2300|HRS2300 monotherapy
80015019|NCT05048134|Drug|HRS2300、 SHR-1316|HRS2300 combined with SHR-1316
80015020|NCT05048134|Drug|HRS2300、SHR-1701|HRS2300 combined with SHR-1701
80015021|NCT05048134|Drug|HRS2300、trametinib|HRS2300 combined with trametinib
80015022|NCT05048134|Drug|HRS2300、Almonertinib|HRS2300 combined with Almonertinib
79846780|NCT04082741|Other|Placebo|Placebo Matching BMS-986318
80015023|NCT04438928|Dietary Supplement|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
80015024|NCT04438928|Other|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
80015025|NCT03667677|Drug|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
80015026|NCT03667677|Drug|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
79846781|NCT00992667|Drug|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
79706054|NCT03469024|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
79706055|NCT03469024|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
79706056|NCT03465774|Drug|Doxycycline|Receive via IPC
79846782|NCT00992745|Drug|123-I-MIP-1072|Single 10 mCi intravenous injection
79846783|NCT00992745|Drug|111-In capromab pendetide|Single 5 mCi intravenous injection
79846784|NCT00992745|Drug|123-I-MIP-1072|Single 5 mCi intravenous injection
79846785|NCT05171972|Drug|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
79706057|NCT03465774|Device|Indwelling Catheter|Receive IPC
79706058|NCT03465774|Procedure|Quality-of-Life Assessment|Ancillary studies
79846786|NCT00992823|Drug|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
79846787|NCT00992823|Biological|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
79846788|NCT00871676|Behavioral|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
79846789|NCT00871676|Behavioral|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
79846790|NCT00876746|Procedure|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
80015027|NCT03667677|Drug|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
80015028|NCT03667677|Drug|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
79706059|NCT03465774|Other|Questionnaire Administration|Ancillary studies
79846791|NCT03894813|Drug|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
79846792|NCT03894813|Drug|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
79250536|NCT02036047|Device|Regular polypectomy snare (Snare Master, SD-210U-10)|
79706060|NCT03465774|Other|Survey Administration|Ancillary studies
79846793|NCT00615992|Drug|Tiotropium|
79846794|NCT04001361|Procedure|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
79846795|NCT02588183|Device|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
79846796|NCT00876824|Drug|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
79846797|NCT00876824|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
79250537|NCT05128760|Diagnostic Test|characterization of aPL|characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
79250538|NCT05133050|Drug|Ramipril|We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
79250539|NCT05132972|Biological|Normoxic Allogenic UCMSC|Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
79250540|NCT05132972|Other|Normal saline solution|Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
79250541|NCT04835480|Drug|OrsHSA|OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
79250542|NCT04835480|Drug|HSA|Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
79388865|NCT05827055|Drug|Placebo|Placebo given in vegan. capsules orally three times a day
79388866|NCT05806216|Device|EarliPoint Diagnosis|Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
79706061|NCT03451292|Drug|Albutein 20% Injectable Solution|Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
79706062|NCT03451292|Other|Standard medical treatment|Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
80015029|NCT04437472|Other|CareSignal|The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
80015030|NCT04392856|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
79250543|NCT04495634|Device|Stationary Head CT (s-HCT)|The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
79545023|NCT01526109|Behavioral|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
80015031|NCT04392856|Behavioral|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
80015032|NCT00818480|Drug|YM155|continuous infusion
80015033|NCT04176718|Drug|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
80015034|NCT04176718|Drug|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
80015035|NCT04176718|Drug|Pomalidomide|predetermined dose, orally, daily per cycle
80015036|NCT04176718|Drug|Dexamethasone|predetermined dose, orally, given 8 times per cycle
80015037|NCT03134534|Procedure|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
80015038|NCT03134534|Procedure|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
79545024|NCT01526122|Drug|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg & Aspirin 100mg in 1 capsule), PO
79545025|NCT01526122|Drug|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets & Aspirin 100mg 2 capsules, PO
79706063|NCT03440814|Drug|DCCR|Once daily oral administration
79706064|NCT03440814|Drug|Placebo for DCCR|Once daily oral administration
79706065|NCT03439228|Device|Lumbar brace|3 months of lumbar brace wear
79706066|NCT03427814|Drug|Pamiparib|60 mg orally twice daily
80015039|NCT04154020|Procedure|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
80015040|NCT02880371|Drug|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
80015041|NCT02880371|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
79388867|NCT05806216|Behavioral|Clinically Certain Expert Clinician Diagnosis (CC-ECD)|Diagnosis by an expert clinician using gold standard developmental assessment tools.
79388868|NCT05805371|Biological|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
80015042|NCT00813956|Drug|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
79388869|NCT05805371|Procedure|Biopsy|Undergo tumor biopsy
79388870|NCT05805371|Procedure|Biospecimen Collection|Undergo blood, stool, and urine sample collection
79388871|NCT05805371|Procedure|Bone Scan|Undergo bone scan
79388872|NCT05805371|Procedure|Computed Tomography|Undergo CT scan
79388873|NCT05805371|Radiation|External Beam Radiation Therapy|Undergo radiation
79388874|NCT05805371|Procedure|Leukapheresis|Undergo leukapheresis
79388875|NCT05805371|Procedure|Lymphodepletion Therapy|Undergo lymphodepletion
79388876|NCT05798793|Drug|Camrelizumab plus TP|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
79388877|NCT05798793|Drug|TP|The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
79388878|NCT05796752|Drug|Memantine|Cognition-enhancing medication
79388879|NCT05796752|Behavioral|ComB Behavioral Therapy|Therapy for BFRBs
79706067|NCT03427814|Drug|Placebo|60 mg orally twice daily
79706068|NCT03420651|Other|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
79706069|NCT03420651|Other|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
79846798|NCT00992979|Procedure|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
80015043|NCT03667209|Other|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
80015044|NCT03667209|Other|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
80015045|NCT01002248|Drug|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
80015046|NCT01002248|Drug|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
79250544|NCT04160078|Behavioral|Mindfulness-based stress reduction (MBSR) Intervention|"1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~Sleep log diary: self report of sleep records~Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks"
79250545|NCT02817841|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
79388880|NCT05796557|Biological|Platelet Transfusion|Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.
79388881|NCT05790278|Other|Survey|Completion of a Purpose in Life Survey
79388882|NCT05789797|Drug|Remaxol|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
79388883|NCT05789615|Drug|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) [R+] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
79545026|NCT01526161|Drug|inhaled fluticasone propionate|100 micrograms
79545027|NCT01526161|Drug|salmeterol|50 m
79545028|NCT01526161|Drug|Montelukast|Double blind double dummy
79545029|NCT01526174|Drug|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
79545030|NCT01526200|Procedure|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
79250546|NCT04805840|Device|CoV-SCAN rapid COVID-19 antigen test|SARS-CoV-2 rapid antigen screening test
79250547|NCT05132894|Other|Osteopathic Assessment|As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.
79250548|NCT02036905|Other|Cervical and thoracic mobilization|Described in arm description
79250549|NCT02036905|Other|cervical and thoracic manipulation|described in arm description
79388884|NCT05786547|Drug|Varenicline|Per package dosing, tablet taken orally
79545031|NCT01526226|Device|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
79545032|NCT01526226|Device|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
79545033|NCT01526239|Other|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
79545034|NCT01526265|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
79706070|NCT03418493|Drug|LY3316531 - IV|Administered IV.
79706071|NCT03418493|Drug|LY3316531 - SC|Administered SC.
79706072|NCT03418493|Drug|Placebo - IV|Administered IV.
79706073|NCT03396731|Device|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
79706074|NCT03383016|Other|Lifestyle questionnaires|
79706075|NCT03383016|Diagnostic Test|Prostate Biopsy|Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
79545035|NCT01526265|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
79250550|NCT05128448|Other|Cross-body stretch (CBS)|CBS is a self administered stretch that aims to stretch posterior shoulder structures
79706076|NCT03382249|Combination Product|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
79706077|NCT03382249|Combination Product|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
79706078|NCT03380559|Drug|Injection, botulinum toxin + corticoid|"Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
79388885|NCT05786547|Behavioral|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
79250551|NCT05128448|Other|Mobilisation with movement (MWM)|WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
79250552|NCT05120102|Device|Diode laser|K2 diode laser of 980nm wavelength
79250553|NCT05403788|Device|Intervention with virtual reality|"VR intervention with OCULUS QUEST2 (OCULUS VR, USA) consiste on a VR helmet positioned over subject head. The software consisted of a 3D environment with exercises of upper limbs and visual feedback for the treatment of cognitive and motor dysfunction. The therapist have real-time access to the activities in the 3D environment vby real-time video transmission of the helmet activity.~The program include a single session. Each session is monitored on safety aspects of the subjects with emphasis on possible side effects of virtual reality."
79250554|NCT03764761|Device|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
79388886|NCT05786547|Behavioral|Standard Care|Brief cessation advice plus referral to local tobacco quitline
79388887|NCT05785832|Device|t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ technology 1.5 is derived from the commercially available t:slim X2 with Control-IQ, with additional features. It will be used with the Dexcom G6 CGM.
79388888|NCT05785832|Device|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
79545036|NCT01526265|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
79545037|NCT01526265|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
79250555|NCT03764761|Device|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
79545038|NCT01526265|Behavioral|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
79388889|NCT05780463|Drug|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
79388890|NCT05780463|Drug|Placebo|Commercially available 0.9% sodium chloride solution
79545039|NCT01526278|Drug|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
79706079|NCT03380559|Drug|Injection, placebo of toxin + corticoid|"Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
79706080|NCT03380559|Drug|Injection, botulinum toxin + placebo corticoid|"Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
79706081|NCT03379909|Drug|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
79706082|NCT03376984|Combination Product|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
79706083|NCT03376984|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
79706084|NCT03368664|Drug|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
80015047|NCT01002248|Drug|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
79388891|NCT05780463|Biological|Remdesivir|Antiviral agent
80015048|NCT01002248|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
80015049|NCT02837029|Other|Laboratory Biomarker Analysis|Correlative studies
80015050|NCT02837029|Biological|Nivolumab|Given IV
80015051|NCT02837029|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
80015052|NCT04130932|Other|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
80015053|NCT04097236|Other|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
80015054|NCT04097236|Other|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
79545040|NCT01526304|Other|no intervention|No intervention, only observational study
80015055|NCT03667131|Drug|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
80015056|NCT03667131|Drug|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
80015057|NCT04532710|Drug|Eye Drops, Solution in Single-Dose Container|Application of eye drops
79250556|NCT03764761|Device|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
79388892|NCT05780424|Biological|BRII-196|BRII-196 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2C-1F11 that was isolated directly from human B cells of a convalescent COVID-19 patient.
79388893|NCT05780424|Biological|BRII-198|BRII-198 is a fully human IgG-1 mAb derived from antibody P2B-1G5 that was isolated directly from human B cells of a convalescent COVID-19 patient.
79706085|NCT03368664|Drug|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
79388894|NCT05780424|Biological|Placebo|Commercially available 0.9% sodium chloride solution
79706086|NCT03368664|Drug|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
79706087|NCT03368664|Drug|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
79388895|NCT05780424|Biological|Remdesivir|Antiviral agent
79706088|NCT03368664|Drug|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
80015058|NCT05174000|Drug|Test Euthyrox®|Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
80015059|NCT05174000|Drug|Reference Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
79388898|NCT05775718|Drug|Zoster Vaccine Recombinant|Injection
79388899|NCT05769842|Drug|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1~2mg/kg before extubation when the patient recovered spontaneously.
79388900|NCT05769842|Drug|normal saline|Same dose as propofol.
79706089|NCT03368664|Drug|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
79706090|NCT03368664|Drug|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
79706091|NCT03368664|Drug|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
79706092|NCT03368664|Drug|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
79706093|NCT03368664|Drug|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
79706094|NCT03368664|Drug|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
79706095|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
79706096|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
79706097|NCT03360422|Other|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
79706098|NCT03360422|Other|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
79706099|NCT03360422|Other|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
79706100|NCT03345485|Drug|Tinostamustine (EDO-S101)|The study is designed as an open label, Phase 1/2 trial of single agent EDO-S101. The Phase 1 portion of the study is designed to define the MTD by evaluating toxicities during dose escalation until MAD. The Phase 2 portion of the study is designed to evaluate ORR and SD that persists for at least 4 months of the RP2D.
79706101|NCT03343054|Drug|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
79545041|NCT01526317|Drug|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
79545042|NCT01526330|Drug|YH14618|A mg/disc
79545043|NCT01526330|Drug|YH14618|B mg/disc
79545044|NCT01526330|Drug|YH14618|C mg/disc
79545045|NCT01526330|Drug|Placebo|0mg/disc
79545046|NCT01526369|Drug|Trastuzumab|
79545047|NCT01526369|Drug|Paclitaxel|
79545048|NCT01526369|Drug|Lapatinib|
79545049|NCT01526382|Device|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
79706102|NCT03339596|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
79706103|NCT03339596|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
79706104|NCT03322358|Other|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
79706105|NCT03322358|Device|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
79706106|NCT03322358|Other|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
79545050|NCT01526382|Procedure|central venous catheter|patients in this arm can receive central venous catheter
79250557|NCT05132738|Drug|Ripretinib treatment|"Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen."
79250558|NCT02036203|Device|SCu300A IUB|Spherical copper contraceptive
79250559|NCT02036203|Device|TCu380A IUD|T-shaped copper IUD
79250560|NCT04640714|Behavioral|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|Video visit by nurse practitioner within 3 business days of hospital discharge.
79302854|NCT02478047|Other|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
79706107|NCT03315975|Biological|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
79706108|NCT03309878|Biological|Mogamulizumab|Given IV
79706109|NCT03309878|Biological|Pembrolizumab|Given IV
79706110|NCT03303248|Behavioral|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
79706111|NCT03298295|Device|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
80015060|NCT03666585|Other|mobile application actuated rehabilitation exercise guidance|Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
79846799|NCT00992979|Procedure|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
79846800|NCT00866684|Drug|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
80015061|NCT03666585|Other|routine rehabilitation exercise guidance|the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
80015062|NCT05024656|Other|AmnioExcel Plus Amniotic Membrane|AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
80015063|NCT05024656|Other|Standard of Care|The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
79388901|NCT05761223|Drug|Phase Ia dose-escalation part of FB849 Monotherapy|At a given level dose once daily
79388902|NCT05761223|Drug|Phase Ib dose-expansion of FB849 monotherapy|At recommended dose for expansion cohort once daily
79388903|NCT05761223|Drug|Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab|At recommended dose for expansion cohort once daily in combination with pembrolizumab
79388904|NCT05761223|Drug|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
79388905|NCT05761223|Drug|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
79388906|NCT05761223|Drug|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
79388907|NCT05756764|Drug|Semaglutide|Medication for weight loss
79388908|NCT05756764|Drug|Phentermine-Topiramate combination|Medication for weight loss
79388909|NCT05756764|Drug|Phentermine|Medication for weight loss
79388910|NCT05756764|Drug|Tirzepatide|Medication for weight loss
79388911|NCT05756764|Drug|Topiramate|Medication for weight loss
79388912|NCT05756764|Drug|Diethylpropion|Medication for weight loss
79706112|NCT03293264|Behavioral|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
79706113|NCT03291158|Drug|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
79706114|NCT03282890|Other|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
79706115|NCT03264989|Drug|crizanlizumab|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion
79706116|NCT03264196|Procedure|Open Reduction and Internal Fixation|Surgical treatment of fracture
79706117|NCT03259867|Drug|Nivolumab Injectable Product|a PD-1 immune check inhibitor
79706118|NCT03259867|Combination Product|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
79706119|NCT03256539|Behavioral|Sleep intervention|Behavioral sleep intervention program
79706120|NCT03256539|Behavioral|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
79706121|NCT03226691|Drug|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
79706122|NCT03219502|Other|Best Practice|Receive standard of care
79706123|NCT03219502|Other|Quality-of-Life Assessment|Ancillary studies
79706124|NCT03219502|Other|Questionnaire Administration|Ancillary studies
79706125|NCT03219502|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
79388913|NCT05756764|Drug|Naltrexone/Bupropion|Medication for weight loss
79388914|NCT05756764|Drug|Liraglutide|Medication for weight loss
79706126|NCT03219502|Procedure|Sham Intervention|Undergo sham rTMS
79302855|NCT02478047|Other|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
79545051|NCT01526395|Drug|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
79545052|NCT01526421|Other|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
79706127|NCT03218761|Diagnostic Test|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
79706128|NCT03218761|Diagnostic Test|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
79706129|NCT03218761|Diagnostic Test|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
79388915|NCT05755984|Diagnostic Test|3D printed model|scan
79388916|NCT05755711|Device|Shockwave Medical Coronary IVL System|Coronary Intravascular Lithotripsy (IVL)
79388917|NCT05751759|Drug|Mitiperstat|Participants receive mitiperstat orally.
79388918|NCT05746767|Behavioral|Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
79545053|NCT01526447|Procedure|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
79545054|NCT01526447|Procedure|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
79545055|NCT01526460|Drug|Atorvastatin|80 mg
79545056|NCT01526460|Drug|Rosuvastatin|40 mg
79545057|NCT01526460|Drug|Placebo|no statin loading dose
79250561|NCT05132426|Procedure|Osteopathic Manipulative Treatment (OMT)|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
79545058|NCT01526473|Biological|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
80015064|NCT05764187|Other|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
79250562|NCT05132348|Diagnostic Test|Immunological markers|Markers of blood samples of patients suffering from osteoporosis will be analyzed
79545059|NCT01526486|Procedure|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
79250563|NCT05132270|Drug|hydroxyurea and thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
79250564|NCT02814565|Drug|Cyclobenzaprine HCl|Cyclobenzaprine HCl extended-release capsules
79250565|NCT02814565|Drug|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules
79250566|NCT05132192|Procedure|living donor liver transplantation|Living donor liver transplantation
79250567|NCT05132192|Procedure|Thrombectomy or interposition graft|Portal flow restoration due to PVT in any manner
79250568|NCT05121038|Drug|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
79388919|NCT05746767|Behavioral|Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
79388920|NCT05746520|Other|Antibiotic|Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
79545060|NCT01526486|Procedure|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
79706130|NCT03202628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79706131|NCT03202628|Drug|Dexamethasone|Given PO
79706132|NCT03202628|Drug|Ixazomib Citrate|Given PO
79706133|NCT03202628|Other|Laboratory Biomarker Analysis|Correlative studies
79706134|NCT03202628|Drug|Pomalidomide|Given PO
79846801|NCT00866684|Drug|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
80015065|NCT05019352|Device|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
80015066|NCT05019352|Device|CRRT|continuous renal replacement therapy
79250569|NCT05121038|Drug|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
79250570|NCT05121038|Drug|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
79250571|NCT05106374|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
79388921|NCT05742893|Diagnostic Test|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
79388922|NCT05733975|Other|Decision Making Guide|The tool will be used by parent(s) to help guide them in discussion with their infant's clinicians.
79388923|NCT05733624|Drug|SCAI-001 0.01% eyedrop|BID for 12weeks
79545061|NCT01526499|Drug|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
79545062|NCT01526499|Drug|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
79545063|NCT01526512|Drug|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
79545064|NCT01526525|Drug|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
79545065|NCT01526525|Drug|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
79545066|NCT01526525|Drug|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
79846802|NCT00866684|Drug|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
80015067|NCT01377155|Drug|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
79545067|NCT01526525|Drug|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
79545068|NCT01526525|Procedure|sedation|If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
79250572|NCT05106374|Procedure|Cognitive Assessment|Complete thinking test
79250573|NCT05106374|Other|Physical Performance Testing|Complete walking test
79545069|NCT01526525|Procedure|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
79250574|NCT05106374|Other|Quality-of-Life Assessment|Ancillary studies
79706135|NCT03200704|Combination Product|IC2000 and SPY-PHI|Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
79545070|NCT01526525|Drug|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
79250575|NCT05106374|Other|Questionnaire Administration|Complete questionnaire
79250576|NCT05705713|Radiation|chest computed tomography (CT)|Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
79250577|NCT05097794|Drug|BR1015-1|- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
79545071|NCT01526525|Drug|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
79545072|NCT01526564|Drug|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or >4 hours for 8 weeks
79250578|NCT05097794|Drug|BR1015-2|- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
79250579|NCT05097794|Drug|BR1015-1 + BR1015-2|- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
79250580|NCT02036281|Drug|Substance P-Saporin|
79250581|NCT02036359|Drug|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
79250582|NCT02036359|Drug|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
79250583|NCT04884386|Device|robot-assisted gait training|RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
79250584|NCT04884386|Behavioral|conventional locomotion therapy|locomotion exercise, postural control training, balance training, electrotherapy
79388924|NCT05733624|Drug|SCAI-001 0.02% eyedrop|BID for 12weeks
79388925|NCT05733624|Drug|Restasis 0.05% eyedrop|BID for 12weeks
79388926|NCT05728658|Drug|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
79388927|NCT05721105|Other|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
79388929|NCT05718245|Device|HEPA filter|HEPA filters with the capacity to reduce PM2.5 levels
79388930|NCT05718245|Device|Sham filter|sham filters without the capacity to reduce PM2.5 levels
79545073|NCT01526564|Drug|Placebo|3 t.i.d, two plates per time
79545074|NCT01526590|Drug|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
79706136|NCT03200704|Combination Product|Tc-99m radioactive colloid and Gamma Probe|Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
79846803|NCT00866684|Drug|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
79388931|NCT05705622|Other|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
79388932|NCT05703971|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
79846804|NCT00866684|Drug|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
79846805|NCT05356455|Behavioral|motivational interview technique|Difference between pre-test and post-test
79388933|NCT05703971|Biological|atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
79388934|NCT05701345|Device|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
79391757|NCT02407470|Drug|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
80015068|NCT04976374|Drug|Dexmedetomidine and Gabapentin|Administration of intravenous dexmedetomedine for post operative analgesic purposes in combination with gabapentin
79388935|NCT05701345|Other|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
80015069|NCT04976374|Other|Saline|Intravenous Saline 0.9% for placebo purposes
79388936|NCT05698329|Drug|AIV007|Periocular injection
80015070|NCT04473560|Device|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate <100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
79388937|NCT05688982|Behavioral|General information provision|Patients will receive information with general oral health and aSDoH resources.
79545075|NCT01526616|Drug|Metformin|Metformin 850 mg twice a day for six months
79545076|NCT01526616|Drug|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
79846806|NCT05225948|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
80015071|NCT03984058|Behavioral|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
80015072|NCT00809510|Drug|ABT-089|20 mg ABT-089 taken once-daily for 6 months
79250585|NCT02036437|Drug|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
79250586|NCT02036437|Drug|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
79250587|NCT02650466|Device|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
79250588|NCT02036593|Behavioral|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
79250589|NCT03562429|Drug|TGF|TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
79250590|NCT03562429|Drug|TGFP|TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
79545077|NCT01526642|Device|Non Invasive Ventilation|NIV during night
79545078|NCT01526655|Procedure|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
79545079|NCT01526655|Procedure|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
79545080|NCT01526694|Drug|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
79545081|NCT01526694|Drug|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
79545082|NCT01526694|Drug|Dexamethasone|It's a corticosteroid.
79846807|NCT05225948|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
79846808|NCT00993057|Drug|Insulin|Adjustable insulin infusion scale with loading doses
79846809|NCT00866762|Drug|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
79250591|NCT02036671|Device|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
79250592|NCT05697445|Other|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
79250593|NCT05697445|Other|Conventional Treatment|Cervicogenic headache exercises
79388938|NCT05688982|Behavioral|Geographic information provision|Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.
79250594|NCT02815735|Device|comfilcon A|contact lens
79250595|NCT02815735|Device|lotrafilcon B|contact lens
79250596|NCT04677218|Procedure|Arthroscopic ACL reconstruction with retensioned hamstring autograft|After diagnostic arthroscopy, an oblique, 5-cm oblique skin incision is made below the joint line over the proximal edge of the pes anserine.Then fascia will be incised the fascia in an L-shaped fashion. After the releasing the distal end of tendons ,tendons will be harvested in their direction via tendon strippers.During the graft preparation phase firstly femoral tunel will be drilled from AM portal with knee flexed to 120 degrees. The drill will be aligned parallel to the tibial plateau and exit through LFC.Then tibial guide wire will be sent from graft incision to the tibial tunel and drilled for desired direction.Once the adjustable loop button is deployed to the graft, it will be pulled through the tunnels and the button is slipped on lateral femoral cortex. Then tibial fixation will be provided with one bioabsorbable screw and staple.After tibial fixation, the femoral loop will be retensioned in group 2 patients.
79250597|NCT04677218|Procedure|Arthroscopic ACL reconstruction with retensioned and knotted hamstring autograft|After the same preparation procedure as in retensioned autograft group, after tibial fixation of graft, femoral loop will be retensioned and knotted in 3. group .
79388939|NCT05688982|Behavioral|Navigational assistance|Patients will receive phone-based navigational assistance from the study navigator.
79388940|NCT05686551|Drug|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks
79250598|NCT05027360|Drug|SNP - Sodium Nitroprusside|The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
79250599|NCT02036983|Procedure|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
79250600|NCT02036983|Procedure|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
79250601|NCT02036983|Procedure|Opioid IV medications (Control)|Standard anesthetic technique.
79250602|NCT04990310|Drug|[14C]-CORT113176|[14C]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
79388941|NCT05686551|Drug|Placebo|Matching placebo administered intrathecally every 16 weeks
79388942|NCT05686551|Drug|Tominersen 100 mg|100 mg tominersen administered intrathecally every 16 weeks
79388943|NCT05675371|Behavioral|Assessment by Expert Clinician During Behavioral Intervention (ABA or similar)|Assessment (e.g., responder vs. non-responder status) utilizing gold-standard clinical reference assessments performed by expert clinicians as the subject undergoes Applied Behavioral Analysis (ABA) or similar intervention for autism spectrum disorder and related developmental delays
79388944|NCT05675371|Device|Assessment by the EarliPoint Assessment For Autism Spectrum Disorder|Assessment by The EarliPoint™ Evaluation for Autism Spectrum Disorder (ASD), a medical device which employs Dynamic Quantification of Social-Visual Engagement (DQSVE) to aid clinicians in the diagnosis, assessment, and treatment monitoring of ASD related developmental delays, is a diagnostic tool which measures an individual's visual preferential attention to social information in the environment relative to normative age-specific benchmarks.
79250603|NCT03814681|Other|Colorectal Surgery|elective Colorectal Surgery
79250604|NCT05020652|Drug|TQ05105 tablets|TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
79250605|NCT05020652|Drug|Hydroxycarbamide tablets|Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
79250606|NCT03562351|Other|Verbal Instructions Educational Intervention|Caregivers will undergo training with verbal instructions
79388945|NCT05669430|Drug|GV20-0251|Increasing doses of GV20-0251 given intravenously as monotherapy.
79846810|NCT04001907|Behavioral|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
79846811|NCT04001907|Dietary Supplement|β-hydroxy-β-methylbutyrate|
79846812|NCT04001907|Dietary Supplement|placebo|
79846813|NCT00876902|Drug|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
79846814|NCT00876902|Drug|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
79846815|NCT04039646|Combination Product|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
79846816|NCT00993135|Drug|methotrexate|
79846817|NCT00993135|Other|medical chart review|
79250607|NCT03562351|Other|Video Educational Intervention|Caregivers will undergo training with an educational video
79250608|NCT03562351|Other|Mannequin Educational Intervention|Caregivers will undergo training with a mannequin
79706137|NCT03180216|Biological|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
79250609|NCT04853498|Drug|TQB3720|This is an androgen receptor antagonists.
79250610|NCT05689177|Biological|Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)|Booster dose administration
79250611|NCT05108012|Biological|NK cell therapy|Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
79250612|NCT02036749|Procedure|nerve block|quadratus lumborum block
79250613|NCT04818320|Drug|Favipiravir|Day 1: 1800mg BD, day 2-5: 800mg BD
79388946|NCT05669430|Drug|GV20-0251|GV20-0251 RP2D given intravenously as monotherapy.
79388947|NCT05666518|Drug|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
79388948|NCT05666518|Drug|Standard of care|Dosage at the discretion of the treating physician
79388949|NCT05661331|Device|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
79388950|NCT05660070|Behavioral|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
79388951|NCT05646836|Drug|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
79250614|NCT02475135|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
79545083|NCT01526707|Drug|inhaled steroid|inhaled budesonide for 7 days
79388952|NCT05646836|Drug|XmAb24306|XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
79388953|NCT05646836|Drug|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
79388954|NCT05645029|Other|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
79388955|NCT05645029|Other|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
79388956|NCT05645029|Other|glass ionomer|glass ionomer will be used without any additives
79388957|NCT05636852|Drug|Altropane (123I) Injection|Each subject will receive a single IV administration of 5 mCi (185 MBq) Altropane.
79388958|NCT05633706|Device|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
79388959|NCT05630482|Behavioral|Healthy Family Foundations|Healthy Family Foundations Curriculum
79388960|NCT05630482|Other|Standard of Care|Standard of Care
79388961|NCT05630066|Drug|60 mg QD Alogabat|"Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.~I"
79388962|NCT05630066|Drug|40 mg QD Alogabat|Participants aged 10-14 years receiving the equivalent of the adult 60 mg alogabat dose.
79545084|NCT01526746|Drug|Tasimelteon|20mg capsule, once
79250615|NCT02475135|Drug|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
79250616|NCT02475135|Drug|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
79388963|NCT05630066|Drug|7 mg QD Alogabat|Participants aged 5-9 years receiving the equivalent of the adult 20 mg alogabat dose.
79388964|NCT05630066|Drug|Part 2 Adult Alogabat High Dose (aged 15-17)|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
79388965|NCT05630066|Drug|Alogabat|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
79388966|NCT05630066|Drug|Alogabat|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, additional participants may be recruited in any of the of the 3 age-groups in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
79545085|NCT01526746|Drug|Tasimelteon|20mg, once
79545086|NCT01526759|Dietary Supplement|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
79545087|NCT01526759|Dietary Supplement|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
79545088|NCT01526772|Procedure|Endoscopy|Transoral endoscopy versus transoral endoscopy
79545089|NCT01526798|Device|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
79545090|NCT01526798|Device|Conventional high-flux dialyzer|
79545091|NCT01526811|Device|Endurant Stent graft|Endurant Stent graft implantation
79545092|NCT01526824|Dietary Supplement|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
79706138|NCT03176472|Drug|ricolinostat|120 mg per dose in 12 mL liquid formulation
79706139|NCT03176472|Drug|Placebo|12 mL liquid formulation placebo
79545093|NCT01526837|Drug|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
79250617|NCT02475135|Drug|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
80015073|NCT03856684|Behavioral|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
79250618|NCT02475135|Drug|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
79250619|NCT02475135|Other|High-fat Breakfast|High-fat breakfast will be administered.
80015074|NCT03856684|Behavioral|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
79250620|NCT02475135|Other|Standardized Regular Breakfast|Standardized regular breakfast will administered.
79250621|NCT05707429|Other|The Arabic version of The International Index of Erectile Function (IIEF-5)|The Arabic version of The International Index of Erectile Function A self-administered questionnaire that assesses 5 dimensions of sexual function over the most recent 4 weeks. It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection. A total score of < 22 is defined as ED .
79250622|NCT05707429|Other|The Sexual Quality of Life Questionnaire Male/Female (SQoL M/F)|was developed by Symonds et al.,(14) which assesses subjects' feelings toward their sexuality (ranging from 0% to 100%, with higher scores indicating higher SQoL). The SQoL M/F was developed as a condition-specific QoL questionnaire to test the relationship between sexual symptoms and other aspects of general health and sexual QoL.
79250623|NCT05707429|Other|Assessment of depression and anxiety|Arabic version of Hamilton depression and anxiety rating scale (15): used to measure the severity of anxiety and depressive symptoms, and is widely used in both clinical and research settings.
79250624|NCT05707429|Other|The Fatigue assessment scale (16)|It is a 10-item self-report scale evaluating symptoms of fatigue. The FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale evaluates all aspects of fatigue, it measures both physical and mental symptoms. The total score ranges from 10 to 50, with a higher score indicating more severe fatigue.
79250625|NCT05707429|Other|• Quality of life assessment|Health related quality of life (HRQoL measure): using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (17), which assesses physical, social, and emotional domains of IBD patients' lives (scores range from 10-70, with higher scores indicating better HRQoL) The SIBDQ reflects relevant clinical changes in both CD and UC.
79250626|NCT05707429|Other|The Female Sexual Function Index (FSFI)|The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
79545094|NCT01526850|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
79545095|NCT01526850|Drug|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
79545096|NCT01526863|Dietary Supplement|HA egg|Daily dose of HA egg or placebo for 6 months
79545097|NCT01526876|Drug|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
79545098|NCT01526915|Procedure|Bone curettage + PRF|Bone curettage and PRF insertion
79545099|NCT01526915|Procedure|Bone curettage alone|Bone curettage without PRF insertion
79545100|NCT01526941|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
79706140|NCT03141060|Drug|Delamanid|Administered orally; dosing will be based on participants' age and weight.
79706141|NCT03141060|Drug|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
79706142|NCT03136146|Drug|Bortezomib|Given SC
79706143|NCT03136146|Drug|Clofarabine|Given IV
79706144|NCT03136146|Drug|Cyclophosphamide|Given IV
79706145|NCT03136146|Drug|Dexamethasone|Given IV or PO
79706146|NCT03136146|Drug|Etoposide|Given IV
79545101|NCT01526941|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
79545102|NCT01526954|Device|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
79706147|NCT03136146|Biological|Ofatumumab|Given IV
79706148|NCT03136146|Biological|Pegfilgrastim|Given SC
79706149|NCT03136146|Biological|Rituximab|Given IV
79706150|NCT03136146|Drug|Vincristine Sulfate Liposome|Given IV
79846818|NCT00993135|Procedure|assessment of therapy complications|
80015075|NCT03856684|Behavioral|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
79706151|NCT03129828|Drug|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
79706152|NCT03127631|Behavioral|Nutrition|Standardized advice on healthy diet practices.
79706153|NCT03127631|Behavioral|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
79846819|NCT00876980|Device|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
79846820|NCT00993213|Procedure|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
80015076|NCT03856684|Behavioral|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
79846821|NCT00993213|Other|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
80015077|NCT00894530|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
79706154|NCT03127631|Behavioral|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
80015078|NCT00894530|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
80015079|NCT01377077|Procedure|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
79706155|NCT03127631|Drug|Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
79846822|NCT00877136|Device|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
79250627|NCT02478723|Device|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
79545103|NCT01526980|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
79545104|NCT01526980|Drug|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
79706156|NCT03127631|Drug|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >130mmHg, or other blood pressure lowering medication as applicable.
79846823|NCT00993369|Other|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
79846824|NCT00866996|Drug|Methylphenidate extended-release; Atomoxetine|
79846825|NCT02588495|Other|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
79846826|NCT00871910|Drug|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
79846827|NCT00871910|Drug|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
79846828|NCT00871910|Drug|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
79846829|NCT00871910|Drug|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
79846830|NCT00871910|Drug|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
79846831|NCT00871910|Drug|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
80015080|NCT01377077|Procedure|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
79846832|NCT00871910|Drug|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
79545105|NCT01526980|Drug|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
79545106|NCT01527019|Drug|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
79545107|NCT01527019|Drug|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
79545108|NCT01527019|Drug|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
79388967|NCT05630066|Drug|Part 2 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, participants from any of the 3 age-groups may enroll in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2"
79846833|NCT01564329|Drug|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
79250628|NCT02478333|Drug|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
79250629|NCT02478333|Drug|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
79250630|NCT02478333|Drug|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
79545109|NCT01527032|Drug|melphalan, thalidomide and dexamethasone|
79388968|NCT05629962|Drug|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
79388969|NCT05629962|Drug|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
79388970|NCT05618028|Drug|ABBV-525|Oral; Tablet
79388971|NCT05612594|Drug|Bexagliflozin 20 mg|15mg once daily
79388972|NCT05612594|Drug|Placebo|matching placebo once daily
79388973|NCT05605054|Behavioral|UCSD RELINK|UCSD RELINK coach-guided health literacy intervention and in-person service navigation assistance
79388974|NCT05605054|Behavioral|Self-study|Self-studying of programmatic information and list of service referrals
79545110|NCT01527058|Drug|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
79545111|NCT01527084|Procedure|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
79545112|NCT01527097|Drug|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
80015081|NCT04093336|Biological|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
79388975|NCT05601453|Procedure|Elective redo transcatheter aortic valve implantation (redo-TAVI)|Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)
79388976|NCT05591742|Dietary Supplement|FEMIDUR®|"Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin"
79388977|NCT05591742|Other|Placebo Z Cap V-3 Pla|Consist mainly of maltodextrin. One tablet a day.
79388978|NCT05585619|Other|Pain treatment|Any pain treatment to include medications, procedures, or referrals
79388979|NCT05585606|Drug|Placebo|Volume Matched Placebo
79545113|NCT01527097|Drug|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
79545114|NCT01527123|Drug|GSK2585823|CLDM1%/BPO3%
79545115|NCT01527175|Other|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
79846834|NCT05213481|Drug|Tepotinib Hydrochloride Hydrate|Participants will receive Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
80015082|NCT04093336|Biological|Placebo|Placebo
80015083|NCT04093336|Other|standardized treatment|standardized treatment
80015084|NCT05552534|Other|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
80015085|NCT01376999|Drug|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
79250631|NCT02478333|Other|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
79250632|NCT05118620|Drug|Active bupivacaine 0.375% PENG block|A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
79250633|NCT05118620|Drug|Placebo normal saline PENG block|A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
79250634|NCT02814643|Drug|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
79250635|NCT02814643|Drug|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
79250636|NCT02814643|Drug|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
79250637|NCT05105516|Procedure|Ablation|Ablation of ectopic foci causing PVCs
79388980|NCT05585606|Drug|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg"
79545116|NCT01527188|Biological|100IR|100IR sublingual tablet of
79545117|NCT01527188|Biological|300IR|300IR sublingual tablets of
79545118|NCT01527188|Biological|500IR|500IR sublingual tablet of
79545119|NCT01527188|Other|Placebo|Placebo sublingual tablet of
79250638|NCT05368233|Other|ERAS protocol|ERAS protocol whch helps to optimise the length of hospital stay.
79250639|NCT05080790|Drug|Dinutuximab Beta, Zoledronic acid, Interleukin-2|Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
79388981|NCT05585606|Drug|scp776 (3.8 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 3.8 mg/kg"
79545120|NCT01527201|Procedure|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
79545121|NCT01527214|Radiation|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
79706157|NCT03112200|Procedure|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
79706158|NCT03112200|Procedure|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
79706159|NCT03103139|Procedure|Transpapillary Stent|ERCP with placement of short stent
79706160|NCT03103139|Procedure|Stent across bile leak|ERCP with long stent
80015086|NCT03010527|Drug|Bimekizumab|Subjects will receive bimekizumab injections every four weeks (Q4W)
80015087|NCT03010527|Other|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
80015088|NCT05763095|Behavioral|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
80015089|NCT00892970|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
79706161|NCT03100487|Device|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
79706162|NCT03067571|Biological|Daratumumab|Given IV
79250640|NCT02036827|Drug|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
79250641|NCT02475213|Biological|Enoblituzumab|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
79250642|NCT02475213|Biological|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
79250643|NCT02475213|Biological|MGA012|anti-PD-1 monoclonal antibody
79846835|NCT05213481|Drug|Carbamazepine|Participants will receive Carbamazepine tablet with break-line twice daily at the same time each day in the morning and evening from Day 8 to Day 32.
80015090|NCT00892970|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
80015091|NCT05340257|Drug|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
80015092|NCT03759808|Behavioral|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
80015093|NCT03667521|Procedure|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
79388982|NCT05583526|Drug|Ritlecitinib|50 mg capsule
79388983|NCT05583526|Drug|Placebo|Matching capsule
79388984|NCT05577507|Drug|Cholestyramine Resin 4000 MG [Questran]|cholestyramine 4 gram sachets (questran) will be administered orally on 150 ml water three times daily for 8 weeks period trial
79388985|NCT05577507|Drug|Calcium Carbonate 500 MG Oral Tablet|control group will administer standard therapy calcium carobonate as calcium based phosphate binder 500 mg three times daily within meals
79388986|NCT05576350|Behavioral|Smartphone Based Alcohol Monitoring (SAM)|Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
79388987|NCT05576350|Behavioral|Tracking and Reducing Alcohol Consumption (TRAC)|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
79391758|NCT02407470|Procedure|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
79545122|NCT01527227|Other|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
79706166|NCT03052985|Procedure|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
79545123|NCT01527240|Drug|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
80015094|NCT02201381|Drug|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
80015095|NCT00803114|Drug|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
80015096|NCT00803114|Drug|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
80015097|NCT05519384|Drug|JK500 cell injection，cyclophosphamide，Fludarabine|After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
80015098|NCT03489382|Other|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
80015099|NCT00799292|Drug|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
80015100|NCT00794924|Dietary Supplement|VSL#3|one sachet per day, for 45 consecutive days
80015101|NCT00794924|Dietary Supplement|placebo|one sachet per day, for 45 consecutive days
79250644|NCT02474979|Device|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
79846836|NCT00872066|Device|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
80015102|NCT02914275|Biological|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
80015103|NCT02914275|Biological|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
79250645|NCT02474979|Other|Control|
79250646|NCT05256056|Drug|Bupivacain|efficacy of bupivacaine in different volumes
79250647|NCT02480673|Dietary Supplement|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
79250648|NCT02480673|Dietary Supplement|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
79250649|NCT02480673|Behavioral|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
79545124|NCT01527240|Drug|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
79706169|NCT06081075|Other|Genetic testing|Rapid whole genome sequencing
79706170|NCT06081062|Biological|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
79846837|NCT00872066|Device|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
79846838|NCT00993525|Drug|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
80015104|NCT05359978|Behavioral|To with significance activities|activities with purpose with people who are diagnosed of dementia 2 days at week during 30 minutes
80015105|NCT05139056|Biological|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
79250650|NCT02724111|Drug|sufficient dose of rocuronium|
79250651|NCT02724111|Drug|sugammadex 10 min after position change|
79250652|NCT02649218|Biological|Ligelizumab|QGE031 240 mg s.c. q4w
79250653|NCT02480751|Drug|Beraprost|
79250654|NCT02480751|Drug|Placebo|
79250655|NCT04930016|Behavioral|Quality of life diagnosis and therapy during the completed RCT DIQOL|Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
79846839|NCT00993603|Behavioral|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
79846840|NCT00993681|Biological|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
79846841|NCT00993681|Biological|TD Vaccine System|placebo
79545125|NCT01527253|Other|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
79250656|NCT04227314|Drug|Apremilast|Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
79388988|NCT05576350|Behavioral|TRAC-ER|Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
79388989|NCT05574946|Procedure|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
79388990|NCT05568927|Other|SEARCH algorithm|The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
79545126|NCT01527266|Dietary Supplement|Carbohydrate drink|sucrose beverage
79706171|NCT06081062|Drug|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
79250657|NCT04227314|Drug|Placebo oral tablet|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
79250658|NCT02480517|Device|Ultrasound|
79388991|NCT05567952|Drug|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
79388992|NCT05567952|Drug|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
79388993|NCT05567952|Drug|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
79706172|NCT06081036|Other|Questionnaire|Questionnaire about children development
79706173|NCT06081023|Behavioral|Psycho-educational weight reduction program|This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
79706174|NCT06081010|Behavioral|Community Health Worker Intervention|After receiving the training, Community Health Workers (CHW) will conduct home visits using a locally adapted CHW's manual for hypertension management. They will visit households in their catchment area and measure BP. Each CHW will take the high BP clients (>=140/90) to the nearest health center. They will enlist the individuals with preHTN and HTN and conduct three follow-up visits to these participants, every four months. In the first visit (tentative 90 minutes), CHWs will explain the purpose of the home visit and discuss HTN and its consequences. CHWs will apply inductive questioning techniques to initiate dialogue and reflection regarding lifestyle modifications and choose lifestyle goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent visits (approximately 60 minutes), the CHWs will measure BP and address ongoing problems.
79846842|NCT03892707|Drug|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
79388994|NCT05557110|Drug|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
79388995|NCT05556616|Drug|Modakafusp alfa|Modakafusp alfa intravenous infusion.
79388996|NCT05556616|Drug|Lenalidomide|Lenalidomide capsules orally.
79388997|NCT05556616|Drug|Bortezomib|Bortezomib injection subcutaneously.
79545127|NCT01527266|Dietary Supplement|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
79846843|NCT05132049|Drug|DA-5211|single dose administration (DA-5211 one tablet once a day)
79846844|NCT05132049|Drug|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
79846845|NCT00993759|Drug|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
79846846|NCT00513604|Biological|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
79846847|NCT00513604|Biological|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10^11 lymphocytes (minimum of 1 x 10^9), day 0
79250659|NCT02480517|Device|Sham Ultrasound|
79388998|NCT05556616|Drug|Carfilzomib|Carfilzomib intravenous infusion.
79388999|NCT05556616|Drug|Daratumumab|Daratumumab injection subcutaneously.
79389000|NCT05556616|Drug|Pomalidomide|Pomalidomide capsules orally.
79389001|NCT05555290|Combination Product|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
79389002|NCT05555290|Combination Product|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
79389003|NCT05552339|Drug|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
79545128|NCT01527279|Drug|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
79846848|NCT00513604|Drug|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
80015106|NCT05139056|Procedure|Resection|Undergo surgical resection
79846849|NCT00513604|Drug|Fludarabine phosphate|Given intravenously 25 mg/m^2/day over 15-30 minutes, day -5 to -1
79846850|NCT00513604|Radiation|Total body irradiation|600 cGy
79846851|NCT00872144|Drug|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
79846852|NCT05355129|Drug|TT-00920|Tablets
79846853|NCT05355129|Drug|TT-00920 Placebo|Tablets
80015107|NCT01941875|Drug|Progesterone Effervescent Vaginal Tablets|Experimental
80015108|NCT03667287|Procedure|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
80015109|NCT05210777|Device|observation|no intervention
80015110|NCT03666429|Device|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
79846854|NCT00872222|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
79846855|NCT00877526|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
79389004|NCT05552339|Drug|Type 2 DM drugs|Following the physicians' decision
79846856|NCT00867152|Drug|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
79846857|NCT00867152|Drug|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
79846858|NCT00867152|Drug|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
80015111|NCT03666429|Device|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
79389005|NCT05547321|Drug|OMTX705|The investigational product is OMTX705 administered as monotherapy.
79389006|NCT05547321|Drug|Pembrolizumab|The investigational product is OMTX705 administered in combination with pembrolizumab.
79389007|NCT05546866|Drug|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
79389008|NCT05546476|Drug|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
79389009|NCT05546476|Drug|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
79389010|NCT05538130|Drug|PF-07799544|Tablet
79389011|NCT05538130|Drug|PF-07799933|Tablet
79389012|NCT05538130|Drug|encorafenib|Capsule
79389013|NCT05537766|Biological|Brexucabtagene Autoleucel|Administered intravenously
79706175|NCT06080984|Drug|Oncolytic Virus SDJ001|"Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10^11 and 1x10^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter >2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters <0.5 cm, with a maximum of 4 mL)."
79706176|NCT06080984|Drug|Oncolytic Virus YD06-1|Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10^6 pfu/mL to 10^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
79706177|NCT06080945|Other|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
79706178|NCT06080932|Other|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
79706179|NCT06080932|Other|NIH Toolbox|IPAD-based assessments that examines cognitive function
79846859|NCT00867152|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
80015112|NCT03775408|Device|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
80015113|NCT01814657|Drug|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
80015114|NCT01814657|Drug|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
80015115|NCT03666975|Device|LIV 30 Hz|LivMD LIV platform
80015116|NCT00792116|Behavioral|Gum Chewing|
80015117|NCT04050033|Device|Evoke Device|Subjects will undergo treatment with Evoke Device
80015118|NCT01773395|Biological|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
80015119|NCT01773395|Biological|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
79706180|NCT06080932|Other|gradCPT|The gradCPT contains grayscale photographs of mountain scenes and city scenes. Scene images gradually transition from one image to the next
79389014|NCT05537766|Drug|Cyclophosphamide|Administered intravenously
79389015|NCT05537766|Drug|Fludarabine|Administered intravenously
79706181|NCT06080932|Other|Resting-state fMRI|Whole brain echo-planar imaging (EPI) volumes sensitive to the BOLD signal will be acquired. Images will be re-aligned, un-warped, and normalized. Confounding effects of white matter, CSF signal, and head motion will be regressed from the functional time series, followed by bandpass filtering, linear detrending and smoothing, and whole brain resting state networks will be identified (e.g., default mode network, salience network, etc).
79706182|NCT06080932|Other|Task-fMRI|During whole brain EPI data acquisition, participants will be presented with words and pictures and asked to make judgements about the stimuli, such as indicating whether a particular stimulus (e.g., face-name association, word, number, or letter) has been previously presented, if a presented stimulus is a city or mountain scene, the direction an arrow is pointing (left or right), if a pair of stimuli match (e.g., faces with neutral or emotional expressions; word with a face). Behavioral responses will be recorded with an MRI compatible button box.
79250660|NCT04223648|Drug|tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy|"Subjects will receive 1 cycle of tremelimumab/durvalumab~Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
79250661|NCT04165148|Device|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
79250662|NCT04165148|Device|conventional laparoscopy|conventional laparoscopy
79250663|NCT04165148|Other|Visual Analog Scale (VAS) for Pain|"The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS."
79545129|NCT01527279|Drug|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
79706183|NCT06080932|Other|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day.
79545130|NCT01527305|Drug|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
79545131|NCT01527318|Drug|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
79706184|NCT06080932|Biological|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
79389016|NCT05535855|Drug|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
79545132|NCT01527331|Behavioral|video decision aid|cpr video decision aid
79706185|NCT06080932|Other|Sleep Monitoring|Sleep will be assessed by ring-based acceleration with cloud technology (Oura Ring). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands. Worn daily throughout intervention
79706186|NCT06080932|Biological|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
79706187|NCT06080932|Other|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
79706188|NCT06080932|Behavioral|PHQ-9|It is a self-assessment tool used to screen and assess the severity of depression in individuals. The PHQ-9 consists of nine questions based on the nine criteria for diagnosing major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
79706189|NCT06080932|Behavioral|WHO-5|The WHO-5, also known as the World Health Organization-Five Well-Being Index, is a self-assessment tool used to measure subjective well-being and mental health. It was developed by the World Health Organization (WHO) as a brief and reliable instrument to evaluate well-being in clinical and research settings.
79389017|NCT05532735|Biological|ANXV|ANXV (Human recombinant Annexin A5 protein)
79389018|NCT05526300|Device|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
79389019|NCT05526300|Other|The standard care|The standard care
79389020|NCT05526248|Drug|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
79389021|NCT05526248|Drug|Enzalutamide|tablet, oral
79389022|NCT05511038|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
79389023|NCT05504018|Procedure|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
79389024|NCT05500534|Device|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
79389025|NCT05500534|Other|Laser lithortripsy|Standard laser lithotripsy
79389026|NCT05497778|Drug|Gemcitabine|Given by IV (vein)
79706190|NCT06080932|Behavioral|SKID|The SKID refers to the Structured Clinical Interview for DSM Disorders (SCID). It is a widely used diagnostic tool in the field of psychiatry and clinical psychology. The SCID is a semi-structured interview designed to assess and diagnose various mental disorders according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the American Psychiatric Association.
79706191|NCT06080880|Drug|Ondansetron every 3 weeks|Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
79250664|NCT04165148|Other|Saint-Antoine Pain Questionnaire (QDSA)|"The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire."
79250665|NCT04165148|Other|post-operative questionnaire|The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
79706192|NCT06080880|Drug|Aprepitant|aprepitant, Po, 125mg/d, 1day' application every 3 weeks
79706193|NCT06080880|Drug|Dexamethasone|dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
79846860|NCT00867152|Drug|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
79250666|NCT02814175|Drug|methotrexate (MTX)|
80015120|NCT01773395|Procedure|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
79706194|NCT06080880|Drug|Ondansetron weekly|Ondansetron, Po, 24mg/d, 3 days' application weekly
79706195|NCT06080854|Drug|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
79846861|NCT00993837|Procedure|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
79706196|NCT06080854|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1 & 8 of every 3 weeks
79846862|NCT00867230|Drug|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
80015121|NCT01773395|Drug|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
79250667|NCT02814175|Biological|adalimumab (ADA)|
79250668|NCT04696484|Behavioral|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.
79250669|NCT05714397|Device|Cingal|A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
79250670|NCT04511858|Other|maximum effort test on a cycloergometer|5 h test on cycloergometer
79250671|NCT04511858|Other|maximum effort test on a treadmill|5 h test on treadmill
79250672|NCT02475057|Drug|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
79389027|NCT05497778|Drug|Nab paclitaxel|Given by IV (vein)
79389028|NCT05497778|Drug|IM156|Given by PO
79389029|NCT05496868|Drug|Reparixin 600mg|Reparixin will be administered through a nasogastric tube at the dose of 1200 mg (2 x 600 mg tablets) TID every 8 hours (6 tablets daily) for 14 days. All patients will receive therapy in line with current standard-of-care as it pertains to ARDS management (protocolized ventilator management will be made available to all sites in accordance with currently accepted standard of care).
79389030|NCT05496868|Other|Matching Placebo|Placebo will be administered through a nasogastric tube at the dose of 1200 mg (2 x 600 mg tablets) TID every 8 hours (6 tablets daily) for 14 days. All patients will receive therapy in line with current standard-of-care as it pertains to ARDS management (protocolized ventilator management will be made available to all sites in accordance with currently accepted standard of care).
79391759|NCT02407470|Procedure|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
79706197|NCT06080854|Drug|Nab paclitaxel|Nab paclitaxel 125 mg/m^2 administered intravenously on Days 1 & 8 of every 3 weeks.
79846863|NCT05093543|Behavioral|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
79706198|NCT06080854|Other|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy*10 fractions, Planning target volume (PTV) 3Gy*10 fractions
79706199|NCT06080841|Dietary Supplement|Curcumin|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
79846864|NCT05014841|Behavioral|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
80015122|NCT01773395|Drug|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
79250673|NCT02475057|Drug|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
79250674|NCT02475057|Device|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
79846865|NCT04039958|Drug|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
79706200|NCT06080841|Dietary Supplement|Curcumin + Piperine|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
79846866|NCT04039958|Drug|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
79706201|NCT06080815|Device|CAD/CAM Complete denture|four implant-supported CAD/CAM complete overdenture
79846867|NCT04039958|Drug|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
79846868|NCT00534105|Other|Total Cholesterol|
79846869|NCT00534105|Other|Triglyceride|
79846870|NCT00534105|Other|HDL|
79706202|NCT06080802|Drug|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
79846871|NCT00534105|Other|LDL|
79846872|NCT00872378|Drug|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
79846873|NCT00872378|Drug|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
79846874|NCT00994071|Drug|Temozolomide|
79846875|NCT00994071|Drug|ABT-888|
79846876|NCT00877682|Procedure|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
79846877|NCT05084885|Other|Online therapy|Standard counseling provided over the internet.
79846878|NCT00994149|Drug|Diazoxide|10mg/kg/d divide every 8 hours
80015123|NCT01773395|Drug|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
79706203|NCT06080776|Drug|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
79706204|NCT06080776|Drug|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
79250675|NCT04906070|Device|HB-001|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79302856|NCT02478047|Other|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
79389031|NCT05496829|Behavioral|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
79389032|NCT05496829|Other|Usual Care|Receipt of usual care from providers
79389033|NCT05490680|Drug|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
79389034|NCT05490680|Drug|Placebo|Placebo Oral Film
79706205|NCT06080763|Procedure|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
79846879|NCT00994149|Drug|Ora-plus|placebo, give every 8 hours.
79846880|NCT00573248|Drug|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
79846881|NCT00573248|Other|Placebo|Placebo Patch
79846882|NCT00994227|Procedure|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
79846883|NCT04039880|Drug|Olorofim|single oral dose (120 mg, 3.7 MBq)
79846884|NCT04083989|Other|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
79846885|NCT00994305|Drug|N-acetylcysteine|600 mg bid po 0-7 PO
79846886|NCT00994305|Drug|control|No treatment: standard care provided. No N-acetylcysteine administration.
79846887|NCT00877760|Drug|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
79846888|NCT00877760|Drug|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
79846889|NCT04083911|Drug|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~9,intravenous infusion; Aclarubicin:10mg/d, d3~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
79389035|NCT05489588|Device|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
80015124|NCT01773395|Drug|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
80015125|NCT04437394|Diagnostic Test|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
79389036|NCT05486234|Behavioral|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
79389037|NCT05486234|Behavioral|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
79391760|NCT02549014|Drug|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
79706206|NCT06080750|Genetic|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
79706207|NCT06080750|Diagnostic Test|ELISA and colorimeter|IL-6 and total LDH
79706208|NCT06080724|Drug|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
79706209|NCT06080711|Other|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
79706210|NCT06080620|Procedure|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
79706211|NCT06080620|Procedure|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
79706212|NCT06080620|Procedure|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
80015126|NCT04437394|Diagnostic Test|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
80015127|NCT01000922|Drug|Regular Human Insulin|Individual dose of RHI administered subcutaneously
80015128|NCT01000922|Drug|Lispro|Individual dose of lispro administered subcutaneously
80015129|NCT01000922|Drug|VIAject|Individual dose of VIAject administered subcutaneously
80015130|NCT01000922|Drug|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
80015131|NCT01000922|Drug|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
80015132|NCT01000922|Drug|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
79706213|NCT06080490|Drug|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
79706214|NCT06080438|Drug|Botulinum toxin|15 units of botulinum toxin administered one time to the eye via eye drops
80015133|NCT03666039|Behavioral|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
80015134|NCT04727606|Drug|Ure-Na|"Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~Treatment will continue for approximately 1 month."
79250676|NCT02047435|Behavioral|Information, event and workshops at a cartoon museum|"An event at the Storm P. Museum consisting of:~A guided tour at the museum~A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~The museum serves a refreshment and offer participants a season pass to the museum.~And~Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
79706215|NCT06080438|Other|Saline solution|1 cc of saline solution eye drops administered one time to the eye via eye drops
79846890|NCT05354895|Device|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
79846891|NCT00877838|Drug|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
79389038|NCT05481593|Behavioral|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
79250677|NCT02047435|Behavioral|Information and event at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~A guided tour at the museum~A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~The museum serves a refreshment and offer participants a season pass to the museum."
79389039|NCT05481593|Behavioral|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
79389040|NCT05481593|Behavioral|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
79389041|NCT05481593|Behavioral|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
79389042|NCT05480462|Biological|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
79389043|NCT05480462|Biological|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
80015135|NCT03671434|Behavioral|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
80015136|NCT03671434|Behavioral|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
80015137|NCT03666195|Combination Product|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
79706216|NCT06080386|Diagnostic Test|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
79250678|NCT04929470|Device|cochlear implantation|patients receive a cochlear implantation within clinical routine
79250679|NCT02037139|Other|Screening|Standard care screening
79250680|NCT02037139|Other|Brochure|Participants are given an illustrated educational brochure
79389044|NCT05478018|Behavioral|High Intensity Interval Training|Supervised high-intensity interval training for 12 weeks three times per week
79389045|NCT05470621|Behavioral|PlayOn! playground curriculum|A staff and student training to implement a playground curriculum in after-school and recess settings
79389046|NCT05460832|Drug|MBS2320 5 mg|Oral capsule
79389047|NCT05460832|Drug|MBS2320 20 mg|Oral capsule
79389048|NCT05460832|Drug|MBS2320 40 mg|Oral capsule
79389049|NCT05460832|Drug|Placebo|Oral capsule
79706217|NCT06080373|Behavioral|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
79846892|NCT00877838|Drug|Placebo|Gelatin capsules resembling the ones containing the active substance
79846893|NCT00995241|Drug|Raltegravir|Raltegravir 800 mg / 24 hours.
79846894|NCT00867542|Other|no intervention|no intervention
79846895|NCT00872612|Procedure|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
79846896|NCT00872612|Procedure|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
79250681|NCT02037139|Behavioral|Education|Participants undergo a in-person educational intervention
79250682|NCT02474667|Drug|ANG-3777|
79250683|NCT02474667|Other|Placebo|
79250684|NCT02047669|Behavioral|Biopsychosocial|
79250685|NCT02047669|Behavioral|Reference|
79250686|NCT03096080|Drug|Tesevatinib|One dose of the study drug in liquid form
79250687|NCT02037217|Device|ExAblate Transcranial MRgFUS System|
79302857|NCT04996485|Drug|Secukinumab Injection|Pathogenetic therapy with biologic drugs
79302858|NCT04996485|Drug|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
79389050|NCT05450380|Device|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
79846897|NCT00994383|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
79846898|NCT00877994|Behavioral|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
80015138|NCT00889382|Drug|OSI-906|Administered orally
80015139|NCT00889382|Drug|Paclitaxel|Administered intravenously
80015140|NCT00489827|Drug|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
79706218|NCT06080373|Behavioral|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
79706219|NCT06080334|Device|Dry needling|Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
79706220|NCT06080334|Device|Electrolysis|Electrolysis on the Achilles tendon using ultrasound-guided technique.
79706221|NCT06080321|Other|WhatsApp reminders|"Patients will receive active oral hygiene reminders in the form of WhatsApp messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
79706222|NCT06080321|Other|Instagram reminders|"Patients will receive active oral hygiene reminders in the form of Instagram messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
79706223|NCT06080321|Other|Phone calls|"Patients will receive active oral hygiene reminders in the form of phone calls one weekday each week. The structured phone call will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
79250688|NCT02474745|Procedure|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
79846899|NCT00877994|Behavioral|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
79250689|NCT02474745|Procedure|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
79545133|NCT01527409|Behavioral|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
79846900|NCT02588417|Drug|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
79846901|NCT02588417|Drug|Levobupivacaine|levobupivacaine 2.5 mg
79846902|NCT00532935|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an ~32 wk treatment period
79846903|NCT00532935|Drug|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an ~32-wk treatment period.
79250690|NCT02047825|Other|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
79250691|NCT02047825|Other|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
79389051|NCT05423262|Biological|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
79389052|NCT05423262|Biological|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
79389053|NCT05423262|Biological|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
79389054|NCT05423262|Drug|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
79389055|NCT05421065|Drug|Psilocybin|1 25mg oral dose
79389056|NCT05421065|Drug|Ketamine|1 200mg oral dose
79389057|NCT05399485|Drug|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
79389058|NCT05399485|Drug|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
80015141|NCT00489827|Other|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
79706224|NCT06080321|Other|Application alerts|"Patients will download an app on their mobile phones which has cleaning tips, demonstrations and alerts. The structured message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
79706225|NCT06080308|Other|No intervention|No intervention
79706226|NCT06080269|Device|technology based intervention along with conventional therapy|Technology based intervention are training session given to the participants through devices which has software installed to train cognitive functions for patients with cognitive deficit.
79250692|NCT01335997|Drug|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
79545134|NCT01527409|Behavioral|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
79250693|NCT01335997|Drug|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
79545135|NCT01527422|Drug|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
79706227|NCT06080269|Other|conventional therapy alone|Participants in the control group will receive only conventional therapy
79706228|NCT06080256|Drug|Alirocumab|alirocumab (75 mg every 2 weeks)
79706229|NCT06080256|Drug|Atorvastatin|Atorvastatin 20-40mg
79706230|NCT06080243|Biological|R21/Matrix-M1|10 µg of R21 and 50 µg of Matrix-M1
79706231|NCT06080243|Biological|Saline and R21/Matrix-M1|Saline and 10 µg of R21 and 50 µg of Matrix-M1
79706232|NCT06080243|Other|Sterile isotonic (0.9%) normal saline|Saline
79250694|NCT01335997|Drug|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
79250695|NCT01335997|Drug|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
79389059|NCT05399004|Other|Survey Administration|Complete surveys
79389060|NCT05397067|Behavioral|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
79389061|NCT05395624|Drug|18F-OP-801|18F Hydroxyl Dendrimer
79389062|NCT05386576|Drug|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
79389063|NCT05385926|Radiation|Radiotherapy|Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
79389064|NCT05380544|Device|Extracorporeal Shockwave Therapy|ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
79389065|NCT05376462|Diagnostic Test|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
79706233|NCT06080230|Behavioral|Participants in the 8-week program|Psychological resilience program based on positive psychotherapy was applied to nurses
79706234|NCT06080152|Device|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
79706235|NCT06080087|Behavioral|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
80015142|NCT03629314|Other|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
80015143|NCT04052607|Drug|LH Suppression|Stimulation protocols
80015144|NCT00888914|Drug|RT001|RT001
80015145|NCT00888914|Drug|RT001|RT001
79250696|NCT01335997|Drug|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
79250697|NCT03947294|Device|Q-NRG®|Energy expenditure measurements
79250698|NCT02472561|Other|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
79250699|NCT02472561|Other|mHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
79389066|NCT05376462|Diagnostic Test|Standard Laboratory Tests|Laboratory tests that provide information about a patient's coagulation status.
79391761|NCT02549014|Drug|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
79391762|NCT01696643|Drug|CB-5945|
79391763|NCT01696643|Drug|Placebo|
79391764|NCT02407626|Drug|Propofol|Total intravenous anesthesia is a clinical standard procedure
79389067|NCT05370469|Other|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
79250700|NCT02472561|Other|mHealth Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
79389068|NCT05370469|Device|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
79706236|NCT06080074|Device|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
79706237|NCT06080035|Other|Topical Cetyl Tranexamate Mesylate|Topical product will be applied onto clean skin morning and night.
79545136|NCT01527448|Drug|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
79545137|NCT01527474|Drug|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
80015146|NCT00888914|Drug|RT001|RT001
79545138|NCT01527539|Drug|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
79545139|NCT01527552|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
79389069|NCT05370469|Device|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
79545140|NCT01527565|Drug|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
79545141|NCT01527604|Other|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
79706238|NCT06079996|Other|CAFFEINE GUM|Observing the effect of chewing gum on the performance of female softball players.
79706239|NCT06079983|Drug|JSKN003|Administered intravenously according to protocol.
79706240|NCT06079983|Drug|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
80015147|NCT00888914|Drug|RT001|RT001
80015148|NCT00888914|Other|Vehicle Comparator|Vehicle Comparator
79250701|NCT02048137|Device|Transcranial direct current stimulation|
79250702|NCT03784118|Diagnostic Test|Ultrasonography|Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children
79389070|NCT05370469|Other|Surveys|Electronic and paper surveys will be administered throughout the study.
79302859|NCT04996485|Drug|Dupilumab Injection|Pathogenetic therapy with biologic drugs
79302860|NCT04996485|Other|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
79389071|NCT05368246|Device|UCon|The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
79391765|NCT02407626|Drug|Sevoflurane|Volatile anesthesia is a clinical standard procedure
79302861|NCT02447965|Drug|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
79391766|NCT02407392|Drug|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
79545142|NCT01527604|Other|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
79545143|NCT01527617|Other|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
79545144|NCT01527617|Other|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
79706241|NCT06079983|Drug|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
79706242|NCT06079983|Drug|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
79846904|NCT00878150|Behavioral|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
80015149|NCT05135936|Behavioral|Hyperthermia Group|The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
80015150|NCT05135936|Behavioral|Sham-Group|The number of treatments is equal to the number of treatments in the intervention group.
79250703|NCT02048215|Drug|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
79250704|NCT02048215|Drug|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
79250705|NCT02048215|Drug|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
79545145|NCT01527630|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
79250706|NCT02048215|Other|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
80015151|NCT04059003|Drug|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
80015152|NCT05160701|Other|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
80015153|NCT05375188|Drug|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
79250707|NCT04849832|Dietary Supplement|SIC|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
79250708|NCT04849832|Dietary Supplement|SIC + tea|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
79389072|NCT05359835|Drug|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
79389073|NCT05347485|Drug|Cilta-cel|Cilta-cel will be administered as an IV infusion.
79389074|NCT05347485|Drug|Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)|Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
79389075|NCT05342077|Behavioral|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
79391767|NCT02407392|Procedure|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
79545146|NCT01527643|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
79545147|NCT01527656|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
79545148|NCT01527669|Drug|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
79545149|NCT01527669|Drug|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
79706243|NCT06079983|Drug|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
79706244|NCT06079983|Drug|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
79706245|NCT06079983|Drug|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
79846905|NCT00878150|Behavioral|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
79846906|NCT00994539|Drug|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
79389076|NCT05342077|Behavioral|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
79389077|NCT05338060|Other|prospective collection of surgical exudates (SEs)|prospective collection of surgical exudates (SEs) from patients who are hospitalized for post-operative recovery from esophagectomy or gastrectomy for gastroesophageal cancer
79389078|NCT05327816|Biological|RSV preF-based Vaccine|RSV preF-based vaccine will be administered as intramuscular injection.
79250709|NCT04849832|Dietary Supplement|FeSO4|Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
79250710|NCT04849832|Dietary Supplement|FeSO4 + tea|Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
79250711|NCT02048293|Drug|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
79706246|NCT06079957|Procedure|Ergonomic training|"1. Individuals will be given a copy of ergonomic guidelines to follow which includes:~Organize workstation according to the primary , secondary and tertiary zones.~Place frequently used items within the reach of an arm.~Don't move head while reading documents instead raise or lower the eyes to read.~Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~Keep reference material upright at desk.~Avoid slouched postural habits, sit upright.~Adjust chair height in such a way that it shouldn't compress the thigh.~Arm rest should be at elbow flexion of 90 degrees.~Phone must be cradled between neck and shoulder to avoid forward head posture."
79706247|NCT06079957|Procedure|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
79706248|NCT06079944|Procedure|Progressive resistance training|"6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~Speed of movement will be 2 seconds for both the eccentric and concentric phases.~To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system."
79706249|NCT06079944|Procedure|Traditional physical therapy|"TENS+ Hot pack~Pendulum exercises and stretching exercises"
79706250|NCT06079905|Other|Nonoperative treatment|Nonoperative treatment
79706251|NCT06079905|Other|Operative treatment|Operative treatment
79706252|NCT06079892|Procedure|radiofrequency|haemorrhoidal removal using radiofrequency
79389079|NCT05327816|Drug|Placebo|Placebo will be administered as intramuscular injection.
79389080|NCT05321251|Drug|Insulin|see arm description
79389081|NCT05321251|Procedure|Tarsorrhaphy|see arm description
79706253|NCT06079866|Device|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
79706254|NCT06079866|Device|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
79250712|NCT02048293|Drug|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
79250713|NCT02048293|Drug|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
79250714|NCT05712993|Procedure|V2 thermal radio frequency|V2 targeted thermal radio frequency safely without sustained V3 stimulation
79250715|NCT05252247|Other|Immobilisation|Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.
79250716|NCT05252247|Other|Exercise|Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
79389082|NCT05297617|Drug|Anti-aromatase inhibitor|"Treatment will be either:~Letrozole, given per os, 2.5 mg daily~Anastrozole, given per os, 1 mg daily~Exemestane, given per os, 25 mg daily"
79389083|NCT05294952|Genetic|real time PCR|diagnostic test
79389084|NCT05292950|Drug|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
79545150|NCT01527695|Drug|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
79545151|NCT01527695|Drug|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
79545152|NCT01527695|Drug|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
79545153|NCT01527695|Drug|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
79706255|NCT06079853|Behavioral|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
79706256|NCT06079814|Other|virtual reality intervention|Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
79706257|NCT06079788|Drug|Adrenocorticotrophic Hormone|"For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area > 1.0m2) and 2.5mg qod (body surface area < 1.0m2) and maintain the dose until study completion."
79706258|NCT06079788|Drug|Steroid|For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area > 1.0m2) and 2.5mg qod (body surface area < 1.0m2) and maintain the dose until study completion.
80015154|NCT05375188|Drug|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
79250717|NCT02050009|Drug|metformin hydrochloride|Given PO
79250718|NCT02050009|Drug|carboplatin|Given IV
79250719|NCT02050009|Drug|paclitaxel|Given IV
79250720|NCT02050009|Other|laboratory biomarker analysis|Correlative studies
79250721|NCT02474823|Other|polysomnogram|all participants will undergo PSG for assessment of OSA
79706259|NCT06079762|Behavioral|AGE SELF CARE group visit program|"AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World."
79846907|NCT00872846|Device|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
79846908|NCT00878306|Drug|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
79389085|NCT05292950|Drug|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
79846909|NCT00878306|Drug|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
79846910|NCT00878306|Drug|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
79389086|NCT05291754|Device|PEEK Cranioplasty|3D printed PEEK skull implant
80015155|NCT05113589|Device|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
79389087|NCT05288816|Drug|ALXN1210|Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
79389088|NCT05288595|Device|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
79545154|NCT01527708|Procedure|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
79545155|NCT01527721|Procedure|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
79389089|NCT05288166|Drug|Abemaciclib|Administered orally.
79706260|NCT06079749|Procedure|Simultaneous BTKA|Simultaneous BTKA
79846911|NCT00878306|Drug|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
80015156|NCT05113589|Device|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
79706261|NCT06079749|Procedure|Staged BTKA|Staged BTKA
80015157|NCT04058535|Biological|Eylea|Aflibercept
80015158|NCT04058535|Biological|ALT-L9|Aflibercept biosimilar
80015159|NCT05375110|Device|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
80015160|NCT00994292|Drug|YM150|oral
80015161|NCT00994292|Drug|Placebo|oral
80015162|NCT05387915|Radiation|Radiation Therapy|Undergo reduced dose radiation therapy
80015163|NCT02604433|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
80015164|NCT02604433|Other|Placebo|Placebo, Subcutaneous, every 21 days.
80015165|NCT04306744|Device|Vorso PROTECT System|The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
79389090|NCT05288166|Drug|Abiraterone|Administered orally.
79389091|NCT05288166|Drug|Prednisone or Prednisolone|Administered orally.
80015166|NCT04306744|Device|Vorso PROTECT System - Sham (OFF)|Identical device to experimental arm, but the device will not deliver stimulation
80015167|NCT03630419|Dietary Supplement|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
79706262|NCT06079684|Device|Intermittent vacuum therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days."
79706263|NCT06079658|Behavioral|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
79706264|NCT06079619|Other|Analysis of photos of pigmented tumours by the three groups|Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.
79706265|NCT06079606|Other|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
79846912|NCT00878384|Drug|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of <80bpm and <110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
79846913|NCT00878384|Procedure|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
79846914|NCT04082975|Drug|NVP-1203|Oral dose for 7 days
79846915|NCT04082975|Drug|NVP-1203-R|Oral dose for 7 days
79846916|NCT04082975|Drug|NVP-1203 placebo|Oral dose for 7 days
79846917|NCT04082975|Drug|NVP-1203-R placebo|Oral dose for 7 days
79846918|NCT00994617|Drug|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
79389092|NCT05288166|Drug|Placebo for Abemaciclib|Administered orally.
79846919|NCT00994617|Drug|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
79706266|NCT06079528|Device|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
79706267|NCT06079528|Other|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
79846920|NCT00995397|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
80015168|NCT03630419|Other|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
79846921|NCT00995397|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
79706268|NCT06079528|Other|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
79846922|NCT00919451|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
79846923|NCT05684393|Other|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
79846924|NCT04968743|Device|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
79846925|NCT03016312|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
79250722|NCT02474823|Other|home sleep test|all participants will undergo HST for assessment of OSA
79250723|NCT02474823|Other|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
79250724|NCT02050087|Device|Simple sling.|
79250725|NCT02050087|Device|Neutral brace|
79250726|NCT03095768|Other|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
79389093|NCT05279651|Drug|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
79391768|NCT02551432|Drug|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
79846926|NCT03016312|Drug|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
79846927|NCT05061953|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
79846928|NCT05059223|Drug|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
79250727|NCT02050165|Dietary Supplement|KIND Bars|Consumption of KIND Bars for 12 weeks
79846929|NCT05059223|Drug|Placebo|Placebo tablets, taken twice daily
79846930|NCT00919607|Drug|quetiapine fumarate extended-release|200mg,oral,single dose
79846931|NCT00919607|Drug|quetiapine fumarate extended-release|300mg,oral,single dose
79846932|NCT01014052|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
79846933|NCT05188391|Diagnostic Test|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
79846934|NCT01014130|Radiation|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
79846935|NCT01014130|Radiation|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
80015169|NCT04437004|Drug|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
80015170|NCT05763017|Other|Relative Motion Splint|Six weeks relative motion splint wear.
79389094|NCT05279651|Drug|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
80015171|NCT05763017|Other|Metacarpophalangeal Joint Blocking Splint|Six weeks metacarpophalangeal joint blocking splint wear.
79250728|NCT02050165|Dietary Supplement|Typical American Snack|Consumption of typical American snacks for 12 weeks
79389095|NCT05274243|Drug|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
79389096|NCT05274243|Other|Placebo|Placebo (provided as three capsules) three times a day for 4 weeks
80015172|NCT03264508|Behavioral|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
79250729|NCT04800614|Drug|sitravatinib|100 mg sitravatinib on Day 1 of each of 3 periods
79389097|NCT05265845|Behavioral|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
79846936|NCT05187221|Behavioral|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
79846937|NCT02587637|Device|Dorsal Root Ganglion Stimulation|
79846938|NCT00512902|Drug|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
79846939|NCT00512902|Drug|Imatinib|Up to 600 mg QD PO for up to 1 year.
80015173|NCT03264508|Behavioral|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature >0.2°C.
80015174|NCT05762939|Behavioral|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
80015175|NCT05762939|Behavioral|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
80015176|NCT03665883|Procedure|Monopolar energy|Monopolar energy in TEP for inguinal hernia
80015177|NCT03665883|Procedure|Blunt dissection|Blunt dissection in TEP for inguinal hernia
80015178|NCT00992732|Drug|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
80015179|NCT00992732|Drug|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
79250730|NCT02050243|Drug|5ALA|20mg/kg of oral suspension of 5ALA
79250731|NCT02050399|Other|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
79250732|NCT03357380|Drug|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
79302862|NCT02447965|Drug|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
79389098|NCT05265845|Behavioral|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
79706269|NCT06079528|Other|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
79846940|NCT01014364|Drug|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
79846941|NCT01014364|Drug|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
79846942|NCT04082351|Dietary Supplement|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
79846943|NCT04082351|Dietary Supplement|ordinary water|Ordinary bottled water
79846944|NCT01015300|Drug|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
79846945|NCT04082507|Diagnostic Test|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
79846946|NCT01015378|Procedure|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
79846947|NCT01015456|Drug|mycophenolate sodium|per oral, twice daily, for 12 months
79846948|NCT01015456|Drug|cyclophosphamide|intravenous, monthly, for 6 months
79250733|NCT03357380|Drug|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
79250734|NCT02050477|Procedure|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
79250735|NCT02472483|Behavioral|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
79250736|NCT02472483|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
79846949|NCT00919841|Other|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
79250737|NCT04717154|Biological|Ipilimumab|4 courses of 1mg/kg q3w
79250738|NCT04717154|Biological|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
79250739|NCT02050555|Dietary Supplement|Placebo|
79389099|NCT05265247|Drug|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
79389100|NCT05265247|Drug|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
79391769|NCT02407548|Dietary Supplement|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
79391770|NCT02407548|Dietary Supplement|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
79846950|NCT02589041|Procedure|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
79846951|NCT02589041|Drug|Ropivacaine 1%|
79846952|NCT00919139|Other|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
79846953|NCT00492232|Drug|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
79846954|NCT00492232|Drug|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
79250740|NCT02050555|Dietary Supplement|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
79250741|NCT02474511|Other|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
79250742|NCT03608540|Device|Endomina|Suturing system with sutures apposition then bulging then cutting
79250743|NCT03561961|Radiation|Moderate Hypo-fractionation|66-68Gy in 25#
79250744|NCT03561961|Radiation|Extreme Hypo-fractionation|35-36.25 Gy in 5#
79250745|NCT03108963|Drug|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
79250746|NCT03108963|Drug|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
79250747|NCT04697654|Drug|TLC19|Hydroxychloroquine Liposome Inhalation Suspension
79846955|NCT02587871|Drug|Cytarabine|Given IV
79846956|NCT02587871|Other|Laboratory Biomarker Analysis|Correlative studies
79846957|NCT02587871|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
79846958|NCT02587871|Biological|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
79846959|NCT02587871|Biological|G-CSF mobilized peripheral blood cells|microtransplantation
79846960|NCT05683379|Diagnostic Test|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
79846961|NCT02587793|Other|not interventional study|
79846962|NCT04082273|Device|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
79846963|NCT04082273|Other|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
80015180|NCT02659150|Drug|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
80015181|NCT00884234|Other|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
80015182|NCT00884234|Drug|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
80015183|NCT03006393|Drug|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
80015184|NCT03006393|Other|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
79545156|NCT01527721|Procedure|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
80015185|NCT03028480|Drug|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
80015186|NCT00991172|Drug|REGN475|Single Subcutaneous injection dose level 1
80015187|NCT00991172|Drug|REGN475|Single subcutaneous injection dose level 2
80015188|NCT00991172|Drug|Placebo Injection|Placebo Subcutaneous injection
80015189|NCT05762861|Other|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
79250748|NCT04697654|Drug|TLC19 Vehicle|Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
80015190|NCT02950012|Dietary Supplement|OPTI-BIOME™ Bacillus subtilis MB40|
80015191|NCT02950012|Other|Placebo|
79545157|NCT01527734|Drug|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
79545158|NCT01527734|Drug|placebo|1ml once or twice a day for 1 or 2 days.
80015192|NCT01376921|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
80015193|NCT01383109|Drug|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
79545159|NCT01527760|Drug|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
79545160|NCT01527786|Drug|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
79545161|NCT01527812|Procedure|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
80015194|NCT02903992|Radiation|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
80015195|NCT04966871|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
80015196|NCT04966871|Biological|PfSPZ Challenge (7G8) for CHMI|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
80015197|NCT04966871|Other|Normal Saline|normal saline placebo control
80015198|NCT00882440|Drug|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
80015199|NCT00882440|Drug|Placebo|Placebo capsule to losartan
80015200|NCT00882440|Drug|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
80015201|NCT03665805|Other|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
80015202|NCT02864290|Drug|ASP1235|intravenous (IV) infusion
79250749|NCT02474433|Drug|Misoprostol (Cytotec)|
79250750|NCT04812002|Drug|PD-1 inhibitor， bevacizumab|Both drugs are given intravenously
79250751|NCT02050711|Behavioral|Pulmonary rehabilitation|
79250752|NCT02050711|Other|Usual care|
79250753|NCT02474277|Other|30 sec chair stand test|diagnostic test for functional impairment
79545162|NCT01527825|Biological|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~An A/California/7/2009 (H1N1)pdm-like virus~An A/Perth/16/2009 (H3N2)-like virus*~A B/Brisbane/60/2008-like virus * A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
79545163|NCT01527825|Biological|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
79846964|NCT00919919|Drug|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
79846965|NCT00919919|Drug|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
79545164|NCT01527838|Biological|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
79706270|NCT06079515|Procedure|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
79846966|NCT04082195|Other|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
79706271|NCT06079515|Procedure|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
79706272|NCT06079489|Other|Brochure-Based Exercise Program|Simple posture exercises
79706273|NCT06079489|Other|Telerehabilitation-Based Structured Exercise Program|Progressive physical fitness and posture exercises
79545165|NCT01527864|Drug|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
79389101|NCT05254990|Drug|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
79389102|NCT05254990|Other|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
79545166|NCT01527864|Drug|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
79706274|NCT06079463|Other|progressive relaxation exercise|"Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises)."
79389103|NCT05254002|Drug|Finerenone (BAY94-8862 ) 10 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: <60 mL/min/1.73 m2
79389104|NCT05254002|Drug|Empagliflozin|oral administration, once daily
79389105|NCT05254002|Drug|Empagliflozin Placebo|Matching placebo to empagliflozin oral administration, once daily
79545167|NCT01527877|Drug|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
79545168|NCT01527890|Drug|Fentanyl|intravenous patient-controlled analgesia
79545169|NCT01527903|Drug|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
79706275|NCT06079450|Other|artificial intelligence based mobile application|Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
79706276|NCT06079437|Procedure|Cheer|Maximum isometric contraction was performed with cheering.
79706277|NCT06079437|Procedure|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
79706278|NCT06079424|Other|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
79706279|NCT06079411|Device|virtual reality non-embodied|the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
79706280|NCT06079411|Device|virtual reality embodied|the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
79706281|NCT06079411|Other|treatment as usual|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises"
79706282|NCT06079346|Drug|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
80015203|NCT05214391|Drug|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
79389106|NCT05254002|Drug|Finerenone (BAY94-8862 ) 20 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
79389107|NCT05254002|Drug|Finerenone Placebo|Matching Placebo to Finerenone oral administration once daily
79391771|NCT02407548|Dietary Supplement|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
79706283|NCT06079346|Drug|FOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
79706284|NCT06079333|Drug|dabrafenib/trametinib|braf/mek-inhibition
79846967|NCT04082195|Other|Uno board game|A popular board game which is not a mobile app.
79706285|NCT06079255|Device|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
79706286|NCT06079203|Behavioral|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
79389108|NCT05250466|Procedure|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
79389109|NCT05250466|Procedure|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\C\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
79846968|NCT04807595|Other|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
79846969|NCT02587091|Behavioral|Portable obstetric ultrasound|This intervention was advertised at the cluster level
79389110|NCT05243836|Device|S.T.O.P® F2|Ocufilcon D, 55% water
79389111|NCT05243836|Device|S.T.O.P® DT|Ocufilcon D, 55% water
79846970|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
80015204|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
79389112|NCT05243836|Device|MiSight®|Omafilcon A (60% water)
79389113|NCT05231421|Behavioral|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
79389114|NCT05228821|Drug|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
79389115|NCT05225857|Drug|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
79389116|NCT05225857|Drug|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
80015205|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
80015206|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
80015207|NCT00880490|Drug|Inhaled placebo|single dose, inhaled
80015208|NCT00880490|Drug|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
79391772|NCT01695317|Drug|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
79545170|NCT01527903|Drug|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
79545171|NCT01527929|Drug|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
79545172|NCT01527955|Other|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
79545173|NCT01527968|Drug|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
79545174|NCT01527968|Drug|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
79545175|NCT01527968|Drug|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
79545176|NCT01527981|Behavioral|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
79545177|NCT01527994|Drug|Aprepitant|Aprepitant 125 mg oral tablets
79545178|NCT01527994|Drug|Placebo pill|Placebo oral pill- inactive compound
79545179|NCT01528007|Drug|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
79545180|NCT01528007|Drug|Placebo|Placebo pill with no active ingredients.
80015209|NCT05332990|Diagnostic Test|HFO analysis|We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centers.
79706287|NCT06079203|Behavioral|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call ~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
79706288|NCT06079203|Behavioral|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within ~5 days of index ED visit. One home visit and three telephone encounters over 30 days
79250754|NCT04557254|Device|graft|evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
79250755|NCT05712915|Other|RRT operation|"A retrospective observational study was conducted at a 990-bed tertiary care referral teaching hospital from April 2014 to December 2020. The RRT implemented in April 2017 as a part-time RRT operating 8 hours on weekdays. In March 2018, operation time was extended to 15 hours on weekdays and finally, extended to 24 hours a day, 7 days a week in February 2019.~Impact of RRT operation on CPR incidence was retrospective analyzed without any prospective intervention."
79846971|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
79250756|NCT02051491|Device|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
79706289|NCT06079151|Device|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
79846972|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
79706290|NCT06079138|Device|Transcranial direct current stimulation (Active)|"Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application.~In the experimental group, participants will receive real tDCS at 2.0 mA for 20 minutes, with a 30-second ramp-up and ramp-down period."
79846973|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
79846974|NCT00491764|Drug|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
79846975|NCT00491764|Drug|Placebo|Placebo for 24 weeks.
79389117|NCT05214118|Behavioral|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
79846976|NCT04082039|Other|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
79846977|NCT04082039|Other|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
79846978|NCT02586311|Drug|CKD-330 16/5mg|Once a day, 8 weeks
80015210|NCT05214157|Procedure|active gas aspiration|sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
80015211|NCT04957433|Diagnostic Test|Blood Specimen|Blood and Sputum Specimen Samples
80015212|NCT04284124|Other|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
79389118|NCT05214092|Behavioral|Speech sound stimulation|Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
79389119|NCT05211895|Drug|Durvalumab|Durvalumab IV (Intravenous infusion)
79846979|NCT02586311|Drug|Amlodipine 5mg Placebo|Once a day, 8 weeks
80015213|NCT03628963|Device|Concerto+|a user-centered, multifunctional and personalized eHealth platform
79846980|NCT02586311|Drug|CKD-330 16/5mg Placebo|Once a day, 8 weeks
79846981|NCT02586311|Drug|Amlodipine 5mg|Once a day, 8 weeks
79389120|NCT05211895|Drug|Domvanalimab|Domvanalimab IV (Intravenous infusion)
79389121|NCT05211895|Other|Placebo|Placebo IV (Intravenous infusion)
79391773|NCT04480866|Device|Colli-Pee® (FV5000 and Small Volumes)|"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."
80015214|NCT03665727|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
79250757|NCT02051491|Device|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
79389122|NCT05209386|Behavioral|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
79250758|NCT03424460|Biological|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
79250759|NCT03424460|Biological|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
79389123|NCT05204992|Procedure|ultrasound guided hydrodissection|Injection of steroids, saline and bupivicaine ultrasound guided
79389124|NCT05202860|Biological|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
79389125|NCT05202860|Biological|PLACEBO vaccine|Isotonic saltwater sham vaccine
79389126|NCT05202301|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
79389127|NCT05202301|Drug|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
79389128|NCT05202301|Drug|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
79389129|NCT05195008|Drug|BIIB113|Administered as specified in the treatment arm.
79389130|NCT05195008|Drug|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
79389131|NCT05195008|Drug|11^C]BIO-1819578|Administered as specified in the treatment arm.
79706291|NCT06079138|Device|Transcranial direct current stimulation (Sham)|Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application. The sham group will receive sham tDCS, where the current will only be delivered for the first 30 seconds and automatically stopped, while the electrodes remain in place for 20 minutes.
79250760|NCT03424460|Genetic|RNA extraction|RNA extraction from liver tissue
79250761|NCT05712837|Drug|25% TRICHLOROACETIC ACID|Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
79250762|NCT05712837|Drug|30% salicylic acid|Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
79250763|NCT02050789|Behavioral|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
79250764|NCT03267914|Other|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
79250765|NCT03267914|Other|Brush|Patients will brush with the fluoride for 2 minutes each day.
79389132|NCT05194072|Drug|SGN-B7H4V|Given into the vein (IV; intravenously)
79389133|NCT05179824|Other|Observation|No Intervention
79706292|NCT06079138|Other|Telerehabilitation exercise|Telerehabilitation exercise will be provided via tele-conference meeting program. The program will consist of 3 parts. First part, there will be a limb exercise program for 20 minutes to prepare the joint range of motion and muscles. Second part, participants will receive functional balance training for 15 minutes to promote their postural balance during changing positions and static positions. Each exercise will perform 10 repetitions for each set and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. Final part, participants will receive 20 minutes of functional training of wheelchair/bed transferring exercise. Each wheelchair and bed transfer exercise will perform 10 repetitions for each completely transfer and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. After finishing all the programs, they will be asked to cool down by doing breathing exercises with torso stretching for 5 minutes.
79389134|NCT05169567|Drug|Abemaciclib|Administered orally.
79706293|NCT06079125|Procedure|Posterior fossa decompression with duraplasty|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
79389135|NCT05169567|Drug|Fulvestrant|Administered IM.
79389136|NCT05169567|Drug|Placebo|Administered orally.
79389137|NCT05145816|Drug|Belantamab mafodotin 2.5 mg/kg (8 weeks)|2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
79389138|NCT05145816|Drug|Belantamab mafodotin 1.9 mg/kg (8 weeks)|1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
79389139|NCT05145816|Drug|Belantamab mafodotin 1.4 mg/kg (12 weeks)|1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
79389140|NCT05145816|Drug|Belantamab mafodotin 1.9 mg/kg (12 weeks)|1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
79389141|NCT05145816|Drug|Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
79389142|NCT05145816|Drug|Belantamab mafodotin 1.0 mg/kg (12 weeks)|1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
79706294|NCT06079125|Procedure|PFDD with tonsillar resection/reduction|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
79706295|NCT06079112|Drug|9MW2821|1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
79706296|NCT06079112|Drug|Toripalimab|240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
79706297|NCT06079086|Device|Breast Implants Lifesil|The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
79846982|NCT02586467|Behavioral|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
80015215|NCT03665727|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
79302863|NCT05713175|Device|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
79389143|NCT05144620|Diagnostic Test|3D Mapping|3D model will be made from diagnostic imaging for pre-surgical planning
79389144|NCT05139121|Drug|MR-100A-01|Transdermal contraceptive delivery system
79389145|NCT05138133|Drug|Anifrolumab|Anifrolumab intravenous infusion (IV)
79706298|NCT06079073|Behavioral|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
79846983|NCT02586467|Behavioral|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
79389146|NCT05138133|Drug|Placebo|Placebo intravenous infusion (IV)
79389147|NCT05125302|Drug|Ubrogepant|Oral Tablet
79389148|NCT05125302|Drug|Placebo-Matching Ubrogepant|Oral Tablet
79389149|NCT05123586|Drug|LY3361237|Administered SC
79706299|NCT06079034|Procedure|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
79706300|NCT06079034|Procedure|Venoarterial ECMO|Initial support type of venoarterial ECMO
79389150|NCT05123586|Drug|Placebo|Administered SC
79389151|NCT05116202|Drug|Nivolumab|Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
80015216|NCT03665727|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
80015217|NCT04215640|Device|Microfidelity (MIFI) catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
80015218|NCT04215640|Device|Conventional ablation catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
80015219|NCT05214079|Device|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
79302864|NCT05713175|Device|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
79389152|NCT05116202|Drug|Ipilimumab|Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
79389153|NCT05116202|Drug|RO7247669 2100 mg|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
79389154|NCT05116202|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
79389155|NCT05116202|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
79389156|NCT05116202|Drug|RO7247669 600 mg|RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
79389157|NCT05114070|Other|Decision of hypothermia|Decision of hypothermia thanks to EEG signal
79389158|NCT05112965|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
79389159|NCT05112965|Drug|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
79389160|NCT05112965|Drug|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
79706301|NCT06079008|Other|calcified cardiac valve|patients have cardiac cardiac valve before surgery
79706302|NCT06078995|Drug|Tenecteplase|Thrombolysis wtih rhTNK-tPA
79706303|NCT06078995|Drug|Alteplase|Thrombolysis wtih rt-PA
79706304|NCT06078982|Drug|Disitamab Vedotin|2.0mg/kg, intravenously D1, once every 14 days (Q2W)
79706305|NCT06078982|Drug|Toripalimab|3.0 mg/kg, once every 14 days (Q2W)
79250766|NCT05712213|Procedure|Intraperitoneal onlay mesh reinforcement with defect closure before placement of mesh (pIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. The laparoscopic closure of the hernia defect was performed with non-reabsorbable detached stitches of prolene 1/0 suture at a distance of 1.5 cm from stich to stich using a Reverdin' needle. The final fixation of the mesh took place with a non-resorbable tacks.
79302865|NCT05713175|Device|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
79545181|NCT01528020|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
79706306|NCT06078956|Device|Measuring of analytes|Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
79846984|NCT02586467|Behavioral|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
79846985|NCT02586467|Behavioral|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
79846986|NCT02586467|Behavioral|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
79846987|NCT00491608|Biological|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
79389161|NCT05112965|Drug|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
79389162|NCT05112965|Drug|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
79389163|NCT05107908|Behavioral|Active Implicit Priming|Approximately 10-minute behavioral intervention
79389164|NCT05107908|Behavioral|Control Implicit Priming|Approximately 10-minute behavioral intervention
79706307|NCT06078943|Device|method comparison|to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
79706308|NCT06078930|Diagnostic Test|Tongue imaging, tougue coating, saliva, and feces|Tongue images, coating, saliva, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
79706309|NCT06078891|Biological|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
79389165|NCT05107908|Behavioral|Food Exposure Task|Approximately 10-30 minute behavioral intervention
79389166|NCT05100316|Other|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
79706310|NCT06078878|Device|HF-OCT Imaging System with Vis-M Micro-Imaging Catheter|Subjects undergo HF-OCT imaging of the desired intravascular segement
79706311|NCT06078865|Device|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
80015220|NCT02926144|Device|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
79389167|NCT05081999|Other|Medical Assessment|medical hx, events inquiry, adherence to treatment arm periodically over 4 years
79389168|NCT05081999|Other|Quality of Life Assessment|online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
79389169|NCT05074355|Drug|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
79391774|NCT02551744|Drug|histamine-2 receptor antagonist group|famotidine tab 40 mg qd for 6 months.
79706312|NCT06078852|Diagnostic Test|Diaphragmatic ultrasound|Each patient will undergo a diaphragmatic ultrasound using a MyLab TM 50 Gold Cardiovascular ultrasound machine (Esaote Spa, Rome, Italy), both in a semi-recumbent position (45° inclined bed) and in sitting position. If the patient is unable to maintain the supine position, the examination will be assessed only in the sitting position. Diaphragmatic thickness (DT) and diaphragmatic contractility will be assessed bilaterally with a 10 MHz linear probe. The amplitude of the diaphragm excursion will also be calculated with a 5 MHz convex probe in order to evaluate the cranio-caudal excursion of the diaphragm.
79706313|NCT06078839|Drug|Nafamostat mesilate|Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
79706314|NCT06078839|Drug|5% glucose|Add 50ml of 5% glucose into a 50ml syringe
79706315|NCT06078826|Other|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
79706316|NCT06078826|Other|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
79389170|NCT05074355|Drug|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
79846988|NCT01018888|Device|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
79250767|NCT05712213|Procedure|Standard intraperitoneal onlay mesh repair (sIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. In sIPOM, the defect was not closed. The final fixation of the mesh took place with a non-resorbable tacks.
79545182|NCT01528020|Behavioral|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
79846989|NCT04678583|Procedure|Resection of colorectal liver metastases|Comparison of two liver surgery methods
79846990|NCT03996928|Other|Exercise|
79846991|NCT04675775|Other|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
80015221|NCT02926144|Device|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
80015222|NCT03630341|Drug|Clomiphene Citrate 50mg|oral 50 mg tablets
80015223|NCT03630341|Drug|L-carnitine|1000 mg oral tablet
79250768|NCT02472327|Behavioral|Pre-operative support|
79250769|NCT02464202|Other|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
79250770|NCT02472249|Radiation|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
79250771|NCT02472249|Drug|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
79250772|NCT02313194|Device|Epidural Stimulation|Determine if epidural stimulation can improve motor function
79250773|NCT02313194|Drug|Buspirone|Determine if the pharmacological agent in combination with the stimulator can improve motor function.
79250774|NCT02332226|Behavioral|Representational approach|Representational approach to patient education
79250775|NCT01733420|Drug|Biodentine pulpotomy|
79250776|NCT01733420|Drug|White MTA pulpotomy|
79391775|NCT02551744|Drug|proton pump inhibitor group|pantoprazole tab 40 mg qd for 6 months.
79391776|NCT03169218|Other|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
80015224|NCT03630341|Drug|Placebo Oral Tablet|oral tablets identical to L-carnitine
80015225|NCT02632396|Drug|Ixazomib|Given PO
79706317|NCT06078800|Drug|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
80015226|NCT02632396|Biological|Rituximab|Given IV
79250777|NCT01733420|Drug|Tempophore pulpotomy|
79389171|NCT05067712|Procedure|Open Surgical Exposure Technique|"A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~Follicular tissue is removed from the exposed crown area~The flap is repositioned back and sutured~The area over the exposed canine crown is excised leaving a window with the crown uncovered.~If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
79391777|NCT03169218|Other|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
79846992|NCT04675775|Dietary Supplement|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
79846993|NCT04675775|Behavioral|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
79846994|NCT02586545|Other|Shared care|
80015227|NCT01872169|Other|Disordered eating screening questionnaire|
80015228|NCT04078516|Diagnostic Test|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
80015229|NCT04078516|Diagnostic Test|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
80015230|NCT04078516|Diagnostic Test|Heart rate variability|4 measurements of heart rate.
80015231|NCT04078516|Diagnostic Test|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
79250778|NCT02474121|Device|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
79250779|NCT04435652|Drug|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
79250780|NCT04435652|Drug|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
79250781|NCT04435652|Drug|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
79250782|NCT02474043|Behavioral|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
79391778|NCT04743544|Drug|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
79706318|NCT06078787|Drug|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
79706319|NCT06078735|Device|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
79846995|NCT04932785|Other|Regular diet|Regular diet
79846996|NCT04932785|Other|Clear Liquid Diet|Clear Liquid Diet
79846997|NCT02587715|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
79846998|NCT02587715|Other|Liberation therapy|
80015232|NCT04078516|Diagnostic Test|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
80015233|NCT04078516|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
80015234|NCT04078516|Diagnostic Test|Questionnaires|Questionnaires for detecting painful neuropathy
80015235|NCT04078516|Diagnostic Test|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
79250783|NCT02474043|Behavioral|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
79250784|NCT02473887|Drug|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
80015236|NCT05473754|Behavioral|SUPER digital platform|SUPER digital platform was implemented to ensure synergy between ASD families, health services, and schools through different tools to share rehabilitative and educational objectives and strategies. It was designed following the ASD International Guidelines and the recommendations of the ICF-CY and was organized into two areas: General (to promote scientific knowledge on ASD) and Personalized (restricted virtual space for groups of users following an individual with ASD).
80015237|NCT05208229|Diagnostic Test|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
80015238|NCT05207995|Biological|Autologous tolerogenic dendritic cells|Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.
80015239|NCT05207995|Other|Standard treatment according to the clinical protocols|Standard treatment of type 1 diabetes mellitus according to the clinical protocols
80015240|NCT05102422|Drug|Propofol 1 % Injectable Suspension|Induction and maintenance of general anesthesia using the intravenous anesthetic
79250785|NCT02478021|Other|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
80015241|NCT05102422|Drug|Sevoflurane inhalant product|Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
80015242|NCT03005067|Drug|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
79250786|NCT01952522|Behavioral|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
79250787|NCT01952522|Behavioral|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
79250788|NCT02477865|Drug|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
79250789|NCT02477865|Drug|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
79250790|NCT02477865|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
79389172|NCT05067712|Procedure|Closed Surgical Exposure Technique|"A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~Follicular tissue is removed from the exposed crown area.~An attachment with a chain is bonded to the exposed canine crown.~The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~The extraction of the primary canine (if present) made before or in connection with the surgical exposure~Ten to fifteen days later the sutures are removed.~Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
79389173|NCT05067088|Other|CPAP (all patients receive CPAP as part of routine clinical care)|Continuous positive airway pressure
79389174|NCT05055206|Diagnostic Test|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
79389175|NCT05053503|Device|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
79389176|NCT05053503|Drug|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
79389177|NCT05053503|Drug|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
79389178|NCT05047250|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
79389179|NCT05043090|Drug|savolitinib|Tablets : 3 × 200 mg tablets once daily
79250791|NCT04441190|Behavioral|Digital Action Observation Therapy (Digital AOT)|The participants will be asked to observe videos and then practice what the participants observed.
79250792|NCT04441190|Behavioral|Digital Mirror Therapy (Digital MT)|The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
79250793|NCT04441190|Behavioral|Conventional Occupational Therapy|The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
79250794|NCT05419245|Other|Guided Health History for Freeman-Burian Syndrome Questionnaire|Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
79250795|NCT05419245|Other|Freeman-Burian syndrome Semi-Structured Quality of Life Interview|Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
79250796|NCT05419245|Other|Medical Records Review|Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
79389180|NCT05043090|Drug|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
79545183|NCT01528059|Procedure|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
79545184|NCT01528085|Drug|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
79545185|NCT01528137|Biological|talactoferrin|Given PO
79545186|NCT01528137|Other|laboratory biomarker analysis|Correlative studies
79846999|NCT04777721|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
80015243|NCT03005067|Other|Placebo|Reference product containing vehicle without carbomer 980 gel
79545187|NCT01528163|Drug|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
79545188|NCT01528163|Drug|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
80015244|NCT01088789|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.|"A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months."
79389181|NCT05043090|Drug|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
79847000|NCT00615836|Drug|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
79389182|NCT05033743|Drug|Secnidazole 2 GM Oral Granules|Once weekly 2g oral secnidazole for 18 weeks
79389183|NCT05027269|Drug|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
80015245|NCT00979004|Drug|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
80015246|NCT05207839|Dietary Supplement|Milk powder|one sachet per day dissolved in 200 ml of water
80015247|NCT00788528|Drug|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
80015248|NCT05331274|Other|exercise group|"1 stage~In a sitting position, pull the leg up and extend the knee forward~Standing, bending forward and bending the knee~Supine, tucked legs~Maintaining spinal smoothness in crawling~Prone heel pull to buttock~Stage 2~Prone on forearms-hands~Extending the supine hands to the knees~Rounding and hollowing the waist in crawling~Progressive sit-stand~Standing up from sitting and putting on and taking off socks~Reaching up while standing and maintaining the straightness of the spine~Squatting~Climbing and descending stairs~Stage 3~Maintaining standing, arms forward~Slipping hands on the bed while standing~Initiating the standing throw and maintaining the position until the final interval~Putting on and taking off socks while standing~Taking weight towards the ground from a certain height~Picking up different weights from the ground~Push-pull items~Crossing obstacles of certain height~Walking a certain distance"
79250797|NCT05419245|Other|PTSD Checklist for DSM-5|"Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms."
79250798|NCT05419245|Other|Modified Flanagan Quality of Life Scale|"Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life."
79389184|NCT05027269|Drug|Placebo|Placebo will be administered by intravenous (IV) infusion.
79389185|NCT04995523|Drug|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
79847001|NCT05139212|Procedure|Optimum time for intravenous cannulation in children premedicated with dexmedetomidine|The optimum time for intravenous cannulation after the induction of anesthesia with sevoflurane, oxygen, and nitrous oxide in children with intranasal dexmedetomidine premedication will be searched in children undergoing elective surgery.
79847002|NCT04040270|Behavioral|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
80015249|NCT05331274|Other|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
79389186|NCT04993027|Drug|Vancomycin Powder|Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
79389187|NCT04984278|Drug|Nabiximols|oromucosal spray
79545189|NCT01528176|Drug|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
79545190|NCT01528202|Dietary Supplement|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
79545191|NCT01528202|Dietary Supplement|Fruit juice cordial|fruit flavoured juice concentrate
79545192|NCT01528241|Drug|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
79545193|NCT01528267|Other|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
79545194|NCT01528267|Other|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
79545195|NCT01528280|Biological|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
79250799|NCT05419245|Other|Center for Epidemiologic Studies Depression Scale|"Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms."
79389188|NCT04984278|Drug|Placebo|oromucosal spray
79391779|NCT04481802|Device|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
79545196|NCT01528280|Other|No Intervention|No Intervention
79545197|NCT01528306|Biological|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
79847003|NCT04040270|Behavioral|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
79847004|NCT00872924|Drug|sumatriptan 100mg|
79847005|NCT00867776|Behavioral|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
80015250|NCT03665259|Procedure|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
79250800|NCT05419245|Other|Review of Systems|Completed during the interview. A review of systems is a checklist of medical problems.
80015251|NCT03665259|Procedure|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
79250801|NCT05419245|Other|"FACE-Q | Craniofacial - Appearance of the Face"|"Completed by patients. The FACE-Q | Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face."
80015252|NCT05213767|Drug|TQB2916 injection|TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
79389189|NCT04972318|Procedure|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
80015253|NCT03533517|Device|AccuCinch® Ventricular Restoration|AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
79250802|NCT05419245|Other|"FACE-Q | Craniofacial - Appearance Distress"|"Completed by patients. The FACE-Q | Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face."
79389190|NCT04972318|Procedure|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
79545198|NCT01528306|Other|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
79545199|NCT01528371|Drug|Midazolam|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~Investigators inject an additional sedative agent and the dental treatment is started."
79706320|NCT06078696|Drug|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
79706321|NCT06078696|Procedure|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level < 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
79706322|NCT06078696|Procedure|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
79847006|NCT00878540|Drug|mirtazapine|30 mg mirtazapine once daily for 7 days
79847007|NCT04039334|Other|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
79847008|NCT04039334|Other|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
79847009|NCT04018274|Drug|PF-06651600|50 mg by mouth (PO) once daily (QD)
79847010|NCT04018274|Drug|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
79389191|NCT04966520|Other|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be ~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
79389192|NCT04962126|Drug|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 & Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
79545200|NCT01528371|Drug|Normal Saline Solution (NSS)|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~Investigators inject an additional sedative agent and the dental treatment is started."
79545201|NCT01528384|Drug|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
79706323|NCT06078696|Procedure|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
79706324|NCT06078696|Drug|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing > 125% ideal body weight (IBW).
79706325|NCT06078696|Drug|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
79706326|NCT06078696|Drug|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
79706327|NCT06078696|Drug|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
79847011|NCT00873002|Drug|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
79847012|NCT00873002|Drug|sorafenib tosylate|400 mg PO BID
79847013|NCT00491530|Drug|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
79250803|NCT05419245|Other|"FACE-Q | Craniofacial - Facial Function"|"Completed by patients. The FACE-Q | Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning."
79250804|NCT04497350|Device|Transcranial Magnetic Stimulation|5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).
79250805|NCT04497350|Device|Theta Burst Stimulation|One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
79250806|NCT02472093|Other|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
79302866|NCT03070275|Biological|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
79389193|NCT04962126|Drug|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
79389194|NCT04962126|Radiation|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
79389195|NCT04949360|Behavioral|Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies|The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
79545202|NCT01528397|Procedure|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
79545203|NCT01528410|Device|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
79545204|NCT01528410|Procedure|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
79706328|NCT06078683|Dietary Supplement|C8 Ketone Supplement|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch."
79706329|NCT06078683|Dietary Supplement|Placebo|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil."
79706330|NCT06078683|Dietary Supplement|Ketone Ester Acute|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein."
79706331|NCT06078683|Dietary Supplement|Placebo Acute|Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
79706332|NCT06078670|Drug|CVL218|Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
79847014|NCT00491530|Drug|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
79847015|NCT00491530|Drug|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
79847016|NCT00491530|Drug|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
79545205|NCT01528423|Procedure|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
79545206|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
79545207|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
79847017|NCT04040660|Drug|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
79847018|NCT04313062|Behavioral|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
80015254|NCT01166737|Procedure|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
80015255|NCT00785954|Drug|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
80015256|NCT05102032|Procedure|mini invasive approach|using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
80015257|NCT05102032|Procedure|Conventional approach|laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
79250807|NCT02472093|Other|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
79250808|NCT02472093|Other|Control group|The control group did brief educational sessions.
79250809|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
79250810|NCT02472171|Dietary Supplement|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
79250811|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
79250812|NCT00071552|Drug|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
79250813|NCT00071552|Drug|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
79250814|NCT05164263|Drug|Empagliflozin|Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
79250815|NCT05136014|Other|Collection of surgical waste|collection of a fragment of healthy and tumorous lung tissue taken as part of the operating theatre procedure and normally destined to be destroyed
79250816|NCT04767711|Dietary Supplement|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri with cholecalciferol compared to cholecalciferol only.
79250817|NCT04767711|Drug|Prednisolone|Oral glucocorticoid 25 mg daily for 7 days.
79250818|NCT04273178|Drug|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
79706333|NCT06078657|Drug|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
79706334|NCT06078605|Other|Nicotinamide(Mitovita)|Nicotinamide(VitaminB3)
79250819|NCT02473809|Drug|Liraglutide|Once daily
79389196|NCT04949360|Behavioral|Regular Cognitive Behavioural Therapy for Insomnia|This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
79389197|NCT04949360|Behavioral|Sleep hygiene - minimal intervention|It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by regular mail and email.
79389198|NCT04936139|Behavioral|Art Therapy|"During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes)."
79545208|NCT01528475|Behavioral|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
79545209|NCT01528488|Other|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
79847019|NCT00867854|Other|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
79847020|NCT00873158|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
80015258|NCT03665181|Other|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
80015259|NCT05326906|Drug|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
79250820|NCT02473809|Drug|Placebo|Once daily
79250821|NCT02725671|Device|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
79545210|NCT01528488|Other|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
79545211|NCT01528501|Drug|Panobinostat (LBH589)|
79545212|NCT01528514|Dietary Supplement|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
79250822|NCT05131334|Device|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
79250823|NCT02446990|Drug|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
79250824|NCT02446990|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
79545213|NCT01528514|Other|Placebo|Placebo in capsule form, 4 capsules 4 times/day
79545214|NCT01528540|Drug|Placebo|This group will include placebo.
79706335|NCT06078605|Other|Placebo|Placebo
80015260|NCT05101954|Procedure|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
79706336|NCT06078592|Drug|BRIDIN-plus Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
79706337|NCT06078592|Drug|Combigan Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
79706338|NCT06078527|Device|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
80015261|NCT05101954|Procedure|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
79250825|NCT04272632|Drug|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
79389199|NCT04933968|Biological|ALVR106|Infusion, visually identical to placebo
79250826|NCT04272632|Drug|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
79250827|NCT04272632|Drug|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
79545215|NCT01528540|Drug|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
79545216|NCT01528553|Device|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
79250828|NCT02471703|Device|Total hip arthroplasty|Total hip arthroplasty
79250829|NCT04269824|Behavioral|Behavioral intervention package|"Community mobilization and commitment events~Update factual beliefs~Establish public commitment~Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~Update empirical expectations of improved sanitation behaviors in their community~Motivate improved sanitation practices~Build capacity to achieve exclusive toilet use~Stickers/decals~- Signal adoption of promoted behaviors to community members~Individual-level~Update empirical expectations of improved behaviors among similar others~Set goals, track progress and maintain improved behavior"
79250830|NCT04413110|Device|Polysomnography|PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
79250831|NCT03976934|Drug|Tamsulosin|administration of tamsulosin tablets
79389200|NCT04933968|Biological|Placebo|Infusion, visually identical to ALVR106
79250832|NCT03976934|Drug|Placebo oral tablet|sugar pills
79389201|NCT04929223|Drug|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
79389202|NCT04929223|Drug|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
79389203|NCT04929223|Drug|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
79389204|NCT04929223|Drug|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
79250833|NCT02725515|Biological|XmAb5871|
79250834|NCT02725515|Biological|Placebo to match XmAb5871|
79545217|NCT01528553|Device|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
79706339|NCT06078527|Procedure|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
79706340|NCT06078527|Other|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
79706341|NCT06077942|Device|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
79847021|NCT00919685|Biological|blood sample|from rest of blood sample collected for other measurements
79389205|NCT04929223|Drug|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
79389206|NCT04929223|Drug|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
79389207|NCT04929223|Drug|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
79389208|NCT04929223|Drug|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
79389209|NCT04929223|Drug|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
79389210|NCT04925193|Drug|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
79389211|NCT04925193|Drug|Pomalidomide|Oral Table
79389212|NCT04925193|Drug|Daratumumab|Injection
79389213|NCT04925193|Drug|Carfilzomib|Injection
79389214|NCT04925193|Drug|Dexamethasone|Oral tablet or injection
79389215|NCT04910048|Other|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
79389216|NCT04910048|Other|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
79389217|NCT04906408|Device|Prevena|Incisions will be dressed with closed incisional negative pressure wound therapy
79545218|NCT01528566|Behavioral|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
79847022|NCT00617240|Drug|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
79847023|NCT00617240|Drug|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
79847024|NCT04775927|Other|education|premarital education
79847025|NCT04039490|Device|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
79545219|NCT01528566|Behavioral|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
79706342|NCT06077123|Device|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
79545220|NCT01528579|Other|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
79706343|NCT06076980|Drug|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
79545221|NCT01528579|Behavioral|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
79545222|NCT01528579|Other|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
79847026|NCT00878618|Drug|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
80015262|NCT04765475|Behavioral|Motivational Interviewing|A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
80015263|NCT04765475|Behavioral|COVID-19 Symptom Monitoring System|A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.
79545223|NCT01528618|Drug|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
79706344|NCT06076980|Drug|Normal saline|as placebo
79706345|NCT06076733|Device|high definition-transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
79706346|NCT06076733|Device|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
79250835|NCT05130554|Procedure|XEN45 gel stent implantation|The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
79250836|NCT04912024|Device|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
79847027|NCT00878618|Drug|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
79389218|NCT04906408|Device|Prineo|Incisions will be dressed with Prineo
79389219|NCT04906408|Drug|Traditional|Incisions will be dressed with bacitracin/xeroform
79389220|NCT04886518|Drug|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
79389221|NCT04886518|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
79545224|NCT01528618|Drug|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
79545225|NCT01528631|Other|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
79545226|NCT01528631|Other|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
79545227|NCT01528644|Dietary Supplement|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
79706347|NCT06076655|Other|EXERCISE AND MOBILIZATION PROGRAM|"EXERCISE AND MOBILIZATION PROGRAM The Hallux Valgus exercise program determined by the physiotherapist will be applied twice a week in the rehabilitation unit under the supervision of a physiotherapist. Each exercise and mobilization will be planned as 2 sets of 10 repetitions and 15 seconds between sets, and will be carried out throughout the interval for 12 weeks. In addition, home exercises will be given twice a day, and each exercise will be followed in 2 sets of 10 repetitions with a 15-second interval between sets.~The exercise and mobilization program planned to be implemented in this study for children with diplegic cerebral palsy is an exercise and mobilization program that has yielded positive results in various studies in adults. We created a sample protocol with exercise and mobilization practices that were found effective in these studies."
79706349|NCT06075784|Other|reiki|placebo reiki
79706350|NCT06075329|Behavioral|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
79545228|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
79706351|NCT06074653|Other|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
79706352|NCT06074653|Other|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
79250837|NCT04912024|Device|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
79250838|NCT02473653|Biological|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
79250839|NCT02416180|Device|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
79389224|NCT04876950|Combination Product|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
79250840|NCT02416180|Device|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
79389225|NCT04872400|Drug|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
79250841|NCT02416180|Device|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
79389226|NCT04872400|Drug|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
79389227|NCT04871477|Other|Communication Intervention|Audio record part of clinic visit
79389228|NCT04871477|Other|Questionnaire Administration|Ancillary studies
79389229|NCT04868539|Other|Artificial Light At Night|90 lux lighting for 19hr/day
79250842|NCT02471937|Biological|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
79250843|NCT05130320|Other|Not Interventional their treatments are their routine NHS care|Not Interventional their treatments are their routine NHS care
80015264|NCT04765475|Behavioral|Motivational Interviewing and COVID-19 Symptom Monitoring System|A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
79250844|NCT05130242|Procedure|Cement-augmented Pedicle Screws (CPS)|Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine
79389230|NCT04868539|Behavioral|Sleep Restriction|5-hr of sleep/night
79250845|NCT05130242|Procedure|Hybrid Construct (HC)|Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
79250846|NCT02473510|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
79250847|NCT02473510|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
79250848|NCT05135780|Other|Osteopathic manual treatment|Between 5 and 8 sessions of osteopathy will be carried out, and the time interval between sessions may vary depending on the need and individual evolution of each child, assessed by the team of osteopaths.
79250849|NCT05135780|Other|Social education|"Intervention in children:~During the school year there will be activities of two days per week with a duration of 2.5 hours per session in the afternoon.~The activities will focus on school reinforcement, facilitating snacks and having a recreational space.~Groups will be made by age ranges (from 4 to 6 and from 7 to 12) of maximum 10 children, due to the current COVID situation. The number could vary in the event of a change in measures at the institutional level.~Family intervention:~Quarterly tutoring spaces between the coordinators and the team of social educators to evaluate needs, specify objectives and assess evolution.~Monthly group spaces for mothers managed by the team of educators where they will exchange experiences and create an informal support network.~Monthly spaces shared between parents and children accompanied by the educational team, where family ties will be worked through play."
79250850|NCT02473575|Dietary Supplement|caffeine gum|Gum is consumed 30 minutes before commencement of run
79250851|NCT02473575|Dietary Supplement|placebo gum|Gum is consumed 30 minutes before commencement of run
79250852|NCT02473731|Biological|KTN3379|
79545229|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
79545230|NCT01528644|Dietary Supplement|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
79250853|NCT03952286|Drug|ED-Dispensing home and school supervision|"Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~360 ug of budesonide inhalation powder once-daily for at-home use, and~albuterol sulfate as needed for relief of acute respiratory symptoms."
79389231|NCT04860791|Other|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
79389232|NCT04858880|Radiation|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
79545231|NCT01528657|Other|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
79545232|NCT01528657|Other|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
79250854|NCT02471625|Device|ClearView Scanning|
79250855|NCT05135234|Behavioral|Muscular Exercise|Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
79545233|NCT01528683|Radiation|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
79545234|NCT01528722|Drug|Bupivacaine|0.25% 20ml administered intraperitoneal
79545235|NCT01528722|Other|Normal saline|sodium chloride 0.9% solution
80015265|NCT04765475|Other|Supportive Services|Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
80015266|NCT00875108|Drug|VIAject™|Subcutaneous injection 25 IU/mL
80015267|NCT05100940|Procedure|Cardiac Catheterization|Cardiac Catheterization
79250856|NCT05092724|Procedure|fetal blood transfusion|transfusion of fetal blood
79545236|NCT01528748|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
79706353|NCT06074640|Other|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
79706354|NCT06074640|Other|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
79706355|NCT06074393|Behavioral|Tailored Support Group|Participants engage in a secure, confidential environment, sharing caregiving insights and knowledge. Expert-led sessions, lasting 90 minutes, occur biweekly for 16 weeks, held via Zoom and at the University of Calgary's Cumming School of Medicine. These sessions take place twice annually, emphasizing the structured nature of the support group. Weekly themes include self-care, adaptation, coping skills, emotions, anticipatory grief, forgiveness, mindfulness, boundaries, and closure. Care partners actively participate by sharing experiences and asking questions in each session.
79706356|NCT06074289|Behavioral|Family connections program|Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
79545237|NCT01528761|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
79706357|NCT06073405|Device|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
79706358|NCT06073002|Other|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
79847032|NCT05102942|Behavioral|Attentional Control Training Program|The 317 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 106), Group B: ACTP sham training delivered via a smartphone application + TAU (n = 106), or Group C: TAU only (n = 106). Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks). Patients in Group C will receive only the primary treatment for AUD.
79847033|NCT02587559|Procedure|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
79847034|NCT00615290|Drug|tipranavir|
80015268|NCT04044209|Drug|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
80015269|NCT04044209|Drug|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
80015270|NCT00874796|Drug|GS-9450|Taken as one capsule by mouth once daily
80015271|NCT00874796|Drug|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
80015272|NCT05100784|Biological|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
80015273|NCT02658448|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
79250857|NCT05682885|Procedure|Lymphatic Bypass Supermicrosurgery|Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
79250858|NCT03770546|Biological|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
79706359|NCT06072456|Procedure|laparoscopic lateral suspension|Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
79706360|NCT06072456|Procedure|laparoscopic pectopexy|Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
79706361|NCT06072456|Procedure|Sacrospinous ligament fixation|Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
79706362|NCT06072287|Diagnostic Test|Living with LTC Questionnaire|A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
79706363|NCT06072209|Behavioral|Behavioral Activation|- instruction to create a list of individual positive activities. - instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
79706364|NCT06072209|Behavioral|Mindfulness and Gratitude|- instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with
79847035|NCT02587169|Drug|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
79389233|NCT04858100|Procedure|Surgical excision of the lesion|"The surgical removal of the lesion will follow these steps:~local anesthesia~excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having 5 mm-free margins~silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case."
79389234|NCT04858100|Other|Wait and see approach|The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.
79250859|NCT03770546|Drug|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
79250860|NCT05077046|Other|Ergonomic handwriting pen|An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
79250861|NCT03137576|Procedure|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
79250862|NCT03137576|Procedure|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
79250863|NCT05134844|Other|Hydrotherapy- Snoezelen|Multi sensory approach in water
79389235|NCT04857138|Drug|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
79389236|NCT04857138|Drug|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
79389237|NCT04855981|Other|whole body vibration|All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
79706365|NCT06072209|Behavioral|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
79706366|NCT06070961|Diagnostic Test|Cellular immunity vs SARS-CoV-2|Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
79706367|NCT06070961|Diagnostic Test|Humoral immunity vs SARS-CoV-2|Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
79706368|NCT06070961|Diagnostic Test|Cellular immunity vs Varicella Zoster Virus|Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
79706369|NCT06070961|Diagnostic Test|Humoral immunity vs Varicella Zoster Virus|Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
79706370|NCT06070961|Diagnostic Test|Diphtheria toxin-binding IgG|Evaluation of diphtheria toxin-binding IgG by ELISA assay
79706371|NCT06070961|Diagnostic Test|Tetanus toxoid-binding IgG|Evaluation of tetanus toxoid-binding IgG by ELISA assay
80015274|NCT00872300|Drug|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
79250864|NCT05134844|Other|Snoezelen|Multu Sensory approach on land
79250865|NCT05134766|Other|Observation only|Based on type of SOC applied and the type of CAM products by subject's own decison
79389238|NCT04855981|Other|aerobic exercise|the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
79389239|NCT04855981|Other|supplementation|the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
79706372|NCT06070961|Diagnostic Test|T-cell populations and markers characterization|Characterization of T-cell populations and markers by flow cytometry
79847036|NCT00873236|Biological|bevacizumab|Given IV
79847037|NCT00873236|Biological|recombinant interferon alpha-2a|Given SC
79847038|NCT04039724|Drug|HCP0605 + HGP0816|
79847039|NCT04039724|Drug|HCP1305|
79250866|NCT05110989|Device|AtriCure Cryo Nerve Block (cryoNB) Device Family|Use of Atricure Cryo Nerve Block Device Family to generate cryoanalgesia for the management of post operative pain.
79545238|NCT01528761|Other|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
79250867|NCT05107635|Device|AtriCure Isolator® Synergy™ Surgical Ablation System|A sinoatrial (SA) node sparing, endoscopic epicardial and endocardial hybrid ablation approach used to treat the IST or POTS using the AtriCure Isolator® Synergy™ Surgical Ablation System and Isolator® pen devices as applicable.
79250868|NCT03734042|Biological|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
79250869|NCT03734042|Biological|Normal saline|Intrauterine infusion of normal saline at day 11
79389240|NCT04844749|Drug|VERU-111|Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent
79389241|NCT04844749|Drug|Enzalutamide, Abiraterone|Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
79389242|NCT04838977|Behavioral|RESET|Therapy
79389243|NCT04835428|Device|Treatment Group: AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
79389244|NCT04835428|Device|Control Group: PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
79389245|NCT04832399|Drug|Natalizumab|As described in the treatment arm.
79389248|NCT04816149|Behavioral|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
79389249|NCT04816149|Behavioral|Treatment for Relationships and Safety Together (TR&ST)|TR&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
79389250|NCT04811729|Behavioral|Motivational interview|The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
79545239|NCT01528774|Other|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
79545240|NCT01528800|Drug|Vitamin K1|10mg orally three times a week for 12 months
79545241|NCT01528800|Drug|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
79545242|NCT01528813|Device|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
79706373|NCT06070350|Biological|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
79706374|NCT06070350|Drug|Placebo|Placebo will be made by the research pharmacy at each of the clinical sites
79706375|NCT06070350|Drug|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure.
79706376|NCT06070350|Biological|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
79706377|NCT06069596|Combination Product|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
79302867|NCT03070275|Procedure|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
79302868|NCT02450695|Device|rTMS|
79706378|NCT06068660|Behavioral|The Goal-Oriented Care program|The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.
79706379|NCT06068660|Behavioral|The routine health education|The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
79706380|NCT06068582|Behavioral|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
79706381|NCT06068582|Behavioral|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
79706382|NCT06066190|Other|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
79706383|NCT06065007|Other|No intervention|This is a cross-sectional observational study, no intervention will be implemented or exposure studied. Data for outcomes of interest will be collected via questionnaires
79706384|NCT06064448|Drug|Sildenafil|Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
80015275|NCT05208853|Biological|Anti CD30 CAR-T Cell Injection|"After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10^7 cells，1.5×10^8 cells，5× 10^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
79250870|NCT03704168|Device|CRYOABLATION|The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
79250871|NCT02477943|Device|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
79389251|NCT04811729|Behavioral|Medical advice|Usual care
79250872|NCT02477943|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
79389252|NCT04806919|Drug|Progesteron TID|increasing the dose
79389253|NCT04804826|Procedure|Pelvic Reconstructive Surgery|Pelvic Reconstructive Surgery including total vaginal hysterectomy
79389254|NCT04788953|Drug|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
79545243|NCT01528813|Drug|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
79302869|NCT03070041|Other|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
79389255|NCT04788953|Drug|Placebo|Control subjects will receive placebo tablets for oral use.
79389256|NCT04786210|Combination Product|Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil|Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
79389257|NCT04786210|Combination Product|Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide|Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
79545244|NCT01528826|Drug|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
79706385|NCT06064448|Drug|Ningmitai capsule|The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
79706386|NCT06064448|Drug|Ningbitai capsule + sildenafil|The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
79389258|NCT04772989|Drug|AB308|Administered intravenously (IV) as specified in the treatment arm
79389259|NCT04772989|Drug|Zimberelimab|Administered IV as specified in the treatment arm
79545245|NCT01528839|Drug|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
79545246|NCT01528839|Drug|Placebo|
79545247|NCT01528865|Drug|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
79545248|NCT01528865|Drug|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
79545249|NCT01528930|Drug|Amikacin|500 mg, once daily for 2 years
79545250|NCT01528943|Drug|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
79545251|NCT01528943|Drug|Isotonic saline|same volume as the group that are allocated to prostacycline
79545252|NCT01528956|Genetic|DNA methylation analysis|
79545253|NCT01528956|Genetic|RNA analysis|
79847040|NCT00878696|Procedure|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
79847041|NCT00878774|Biological|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
79847042|NCT00878774|Biological|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
79847043|NCT00868010|Drug|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
79847044|NCT00868010|Drug|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
79250873|NCT03383900|Device|Inspiratory muscle training|"The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value."
79250874|NCT05341323|Drug|Ketamine.|Peritonsillar infiltration of ketamine
79250875|NCT05341323|Drug|Bupivacaine|peritonsillar infiltration of Bupivacaine
79250876|NCT05115734|Diagnostic Test|Serum acylcarnitine profiling|"Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA)."
79389260|NCT04770896|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
79847045|NCT05683301|Drug|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
79847046|NCT05683301|Drug|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
79389261|NCT04770896|Drug|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of < 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
79389262|NCT04770896|Drug|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
79847047|NCT05683301|Drug|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
79847048|NCT05081648|Procedure|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
79847049|NCT05081648|Procedure|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
79847050|NCT05068856|Drug|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
79847051|NCT04770467|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
79847052|NCT04770467|Drug|Placebo|Placebo given by intravenous administration
79847053|NCT00873314|Behavioral|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
79847054|NCT00873314|Behavioral|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
79847055|NCT00878852|Behavioral|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
79847056|NCT00878852|Behavioral|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
80015276|NCT00977522|Drug|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
80015277|NCT00977522|Drug|Placebo|Placebo tablet BID
80015278|NCT05324176|Radiation|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
80015279|NCT01561651|Other|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
80015280|NCT00870818|Diagnostic Test|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
80015281|NCT00870818|Behavioral|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
79847057|NCT05226806|Other|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
79847058|NCT05226806|Other|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
79847059|NCT00868088|Procedure|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
79847060|NCT00873392|Drug|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
79545254|NCT01528956|Genetic|gene expression analysis|
80015282|NCT00870818|Diagnostic Test|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
79389263|NCT04770779|Drug|Placebo Matching Mitapivat|Tablets
80015283|NCT03817463|Drug|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
80015284|NCT03817463|Drug|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
80015285|NCT05101642|Procedure|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
80015286|NCT05207683|Other|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
80015287|NCT05100550|Dietary Supplement|Zinc|Zinc is given as written in the arm description, two hours after lunch
80015288|NCT05100550|Other|Control|This group will not receive zinc
79250877|NCT02471859|Drug|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
79250878|NCT02471859|Drug|Placebo|Placebo at various doses, depending on the cohort and treatment period
79250879|NCT05080400|Dietary Supplement|White rice|Jasmine rice 179g of cooked weight
79250880|NCT05080400|Dietary Supplement|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
79545255|NCT01528956|Genetic|nucleic acid sequencing|
79545256|NCT01528956|Genetic|polymorphism analysis|
79389264|NCT04770779|Drug|Mitapivat|Tablets
79250881|NCT02473419|Drug|Vayarin|
79389265|NCT04762602|Drug|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
79391780|NCT04481802|Device|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
79391781|NCT02551822|Device|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
79391782|NCT02407158|Device|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
79545257|NCT01528995|Device|Medtronic Interstim II-3058|impulse generator
79545258|NCT01528995|Procedure|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
79545259|NCT01529073|Drug|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
79545260|NCT01529099|Device|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
79545261|NCT01528436|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
79545262|NCT01528436|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
79250882|NCT02473419|Drug|Placebo|
79250883|NCT04622865|Drug|Masitinib|Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.
79250884|NCT04622865|Drug|Isoquercetin|Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.
79250885|NCT04622865|Drug|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
80015289|NCT00970424|Drug|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
79389266|NCT04733118|Drug|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~Cohort B: T-DM1 ± ET for 10 cycles~Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
79847061|NCT00873392|Other|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
79847062|NCT04039256|Device|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
79389267|NCT04730258|Drug|CFI-400945|The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
80015290|NCT00970424|Drug|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
79545263|NCT01528436|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
79847063|NCT02587013|Procedure|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
79847064|NCT02587013|Procedure|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
79847065|NCT04040036|Behavioral|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
80015291|NCT03075761|Device|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
80015292|NCT03075761|Behavioral|30-minute education session|
79545264|NCT01529125|Drug|zidovudine, lamivudine, nevirapine|
79545265|NCT01529138|Drug|Axitinib|Combination treatment with temsirolimus and axitinib
79545266|NCT01529138|Drug|Temsirolimus|Combination treatment with temsirolimus and axitinib
79545267|NCT01529151|Other|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
79847066|NCT03933371|Device|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
79847067|NCT00879008|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
79847068|NCT04081181|Procedure|Microwave ablation|CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
79847069|NCT00873470|Procedure|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
79847070|NCT00873548|Device|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~Positioning of the patient~Definition of the CCD-angle~Fracture reduction~Determination of the nail diameter~Incision~Insertion of the device"
80015293|NCT05106790|Behavioral|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
80015294|NCT05106790|Behavioral|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
80015295|NCT05106790|Behavioral|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
80015296|NCT03000075|Drug|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
80015297|NCT03000075|Drug|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
80015298|NCT03883516|Other|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
80015299|NCT03883516|Other|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
79250886|NCT02471781|Device|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
79706387|NCT06064032|Behavioral|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
79545268|NCT01529151|Other|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
79706388|NCT06064032|Behavioral|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
79706389|NCT06061250|Dietary Supplement|Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia|To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
79847071|NCT02586935|Drug|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
79847072|NCT02586935|Other|Placebo|Administered orally after dispersion in approximately 100 ml of water
79847073|NCT00868400|Dietary Supplement|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
79847074|NCT00868400|Dietary Supplement|flavored water|will be given in doses equal to those of high-carbohydrate beverage
79847075|NCT00868478|Drug|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
79847076|NCT04079699|Diagnostic Test|Liquid Biopsy|Measuring biomarkers in blood and urine samples
79250887|NCT02473185|Drug|Methylphenidate|Cross-over
79250888|NCT02477787|Biological|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
79250889|NCT02445586|Drug|Docetaxel|Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
79389268|NCT04730258|Drug|Azacitidine|Azacitidine will be given at its labeled dose and schedule
79545269|NCT01529164|Drug|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
79545270|NCT01529164|Drug|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
79545271|NCT01529164|Drug|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
79545272|NCT01529164|Drug|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
79847077|NCT04079699|Diagnostic Test|Standard biopsy|Histological examination of tissue biopsies
79847078|NCT00879164|Drug|bupivacaine hydrochloride|
79847079|NCT00879164|Other|questionnaire administration|
80015300|NCT03883516|Other|No Pre-briefing|no instruction of the study participants prior to the simulation training
79389269|NCT04717388|Other|acoustics tests, Questionaries,|"acoustics tests at V1 Questionaries at V1~cognitive~emotional~auditory"
79389270|NCT04717388|Radiation|MRI|Anatomical and functional MRI at V2
79389271|NCT04715191|Genetic|CARE T cells|"Three different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 1x10^8/m2 DL2: 3x10^8/m2 DL3: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
79389272|NCT04715191|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
79389273|NCT04715191|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
79545273|NCT01529177|Drug|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
79545274|NCT01529177|Drug|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
79545275|NCT01529190|Drug|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
79545276|NCT01529190|Drug|Placebo|placebo
79847080|NCT00919997|Genetic|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
79847081|NCT00919997|Genetic|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
79847082|NCT00919997|Other|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
79847083|NCT00919997|Other|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
79847084|NCT00919997|Other|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
79847085|NCT00919997|Procedure|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
79847086|NCT02586779|Other|whatsApp|whatsApp application will be used for consultations.
79847087|NCT02586779|Other|without whatsApp|whatsApp application will be not used for consultations.
79706390|NCT06054893|Drug|Omaveloxolone|One dose of omaveloxolone will be taken orally. Dosage to be determined based on age and PK data from prior Parts.
79706391|NCT06041269|Drug|Rosnilimab|PD-1 agonist antibody
79706392|NCT06041269|Drug|Placebo|Placebo
79706393|NCT06040697|Device|Thermal Anisotropy|Usability assessment observation.
79706394|NCT06036147|Behavioral|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
79706395|NCT06036147|Behavioral|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
79706396|NCT06036147|Behavioral|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
79545277|NCT01529216|Device|DIAMOND System|Electrical stimulation to the fundus
79706397|NCT06034210|Device|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
79706398|NCT06028035|Dietary Supplement|BB01|20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
79847088|NCT04079777|Drug|Clinical treatment|Liquid Resuscitation, Anti-infection
79847089|NCT04079543|Other|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
79545278|NCT01529229|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
79706399|NCT06026254|Drug|IMSA101|Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
79706400|NCT06026254|Drug|Immune Checkpoint Inhibitor|Administered according to product label
79706401|NCT06018818|Device|Amvia/Solvia pacemaker family|Implantation of a pacemaker or CRT-P devices
79706402|NCT06016478|Dietary Supplement|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
79250890|NCT02445586|Drug|Pertuzumab|Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
79706403|NCT06016478|Dietary Supplement|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
79706404|NCT06006741|Biological|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
79706405|NCT06000774|Other|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
79847090|NCT04079543|Other|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
79847091|NCT02585687|Device|liver Perfusion MRI|
79250891|NCT02445586|Drug|Trastuzumab|Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
79545279|NCT01529229|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
79847092|NCT00920543|Drug|Placebo|Twice daily dosing
79545280|NCT01529242|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
79847093|NCT00920543|Drug|FP 100mcg|Twice daily dosing
79847094|NCT00920543|Drug|FP 500mcg|Twice daily dosing
79847095|NCT00920543|Drug|FP 250mcg|Twice daily dosing
79847096|NCT00920543|Drug|FSC 100/50mcg|Twice daily dosing
79545281|NCT01529242|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
79847097|NCT00920543|Drug|FSC 250/50mcg|Twice daily dosing
79847098|NCT00920543|Drug|FSC 500/50mcg|Twice daily dosing
79847099|NCT04731155|Drug|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
79250892|NCT02471547|Other|BWT with Mitomycin-C prior TURBT|"Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes"
79250893|NCT02477631|Drug|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
79706406|NCT05997329|Other|App for diet record (MyFood)|Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
79389274|NCT04709601|Drug|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
79389275|NCT04699786|Other|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A & C participants will receive their risk estimate about two weeks after consent is signed and Arms B& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing & demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A & C will have extra surveys at twenty-four months post disclosure.
79847100|NCT04731155|Drug|standard medications|standard medications was giving to subjects according guidelines
79847101|NCT04080011|Device|NP-PWD|Application of NP-PWD device.
79847102|NCT02584439|Drug|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
79545282|NCT01529255|Drug|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
79706407|NCT05988697|Drug|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
79847103|NCT02584439|Drug|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
80015301|NCT00869726|Drug|dirucotide|500mg, intravenous, dosed once every six months for 18 months
80015302|NCT00869726|Drug|Placebo|intravenous, once every six months for 18 months
79250894|NCT01674062|Drug|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
80015303|NCT05213065|Other|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
80015304|NCT05213065|Other|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
80015305|NCT03846076|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
79250895|NCT01674062|Drug|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
79250896|NCT02473029|Radiation|Vascular tomodensitometry|
79250897|NCT02473029|Other|Magnetic resonance angiography|
79250898|NCT02473029|Other|Vascular ultrasonography|
79250899|NCT02473029|Other|Retinal angiography|
79250900|NCT02473029|Other|Retinal optical coherence tomography|
79389279|NCT04698499|Other|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
79389280|NCT04696861|Behavioral|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
79389281|NCT04696861|Behavioral|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
79706408|NCT05978791|Procedure|collection of venous blood or arterial blood|"Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
79706409|NCT05977192|Behavioral|Standard MI|One phone-based MI session
79389282|NCT04690504|Other|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
79847104|NCT04729049|Procedure|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
79545283|NCT01529255|Drug|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
79545284|NCT01529281|Dietary Supplement|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with ~300 ml of water.
79250901|NCT02472873|Procedure|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
79250902|NCT02472873|Procedure|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
79250903|NCT02472873|Drug|Ethanol|
79250904|NCT02472886|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
79250905|NCT02472886|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79389283|NCT04684524|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79389284|NCT04684524|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
79389285|NCT04663308|Drug|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
79389286|NCT04663308|Drug|Placebo|Capsules matched to study drug minus active substance
79389287|NCT04659343|Other|Measurement of concentration of active metabolite in cancer treatment.|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab and nivolumab.
79389288|NCT04657679|Drug|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
79389289|NCT04656535|Drug|AB122|AB122 is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1 immune checkpoint.
79389290|NCT04656535|Drug|AB154|AB154 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT immune checkpoint.
79389291|NCT04656535|Drug|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
79545285|NCT01529281|Dietary Supplement|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with ~300 ml of water.
79545286|NCT01529294|Drug|Iloperidone|
79545287|NCT01529307|Drug|TAS266|TAS266 IV infusions given weekly
79545288|NCT01529320|Drug|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
79847105|NCT04729049|Drug|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
79847106|NCT04722107|Drug|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
79847107|NCT02585765|Drug|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
79847108|NCT02585765|Drug|Placebo|8 weeks of daily placebo capsules.
79250906|NCT05283356|Drug|Ticagrelor 60mg|Ticagrelor 60mg BID after TAVI
79250907|NCT05067465|Dietary Supplement|Selected food groups|"Food groups~Milk and dairy products~Whole-grain products (rich in soluble fibers)~Sausage and processed meat (pork)~Meat-free sausage and meat alternatives (based on egg, soy)"
79250908|NCT03351218|Behavioral|Behavioral testing - computerized tasks|Cognitive behavioral testing and cerebral MRI
79706410|NCT05977192|Behavioral|Intensive MI|Four phone-based MI sessions
79706411|NCT05977192|Behavioral|MOTIVACC|mHealth-based MI
79706412|NCT05977192|Behavioral|Ecological momentary assessment (EMA) messages|EMA messages focused on vaccinations and health
79706413|NCT05975450|Drug|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~- Abatacept 125 mg subcutaneous weekly"
79706414|NCT05974592|Other|Education|Diabetic Foot Self-Management Training Program will be implemented.
79706415|NCT05949619|Drug|BL-M02D1|Administration by intravenous infusion
79706416|NCT05945966|Other|Unilateral training group (UTG)|stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
79847109|NCT02584361|Procedure|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
79847110|NCT02584361|Procedure|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
79847111|NCT02584283|Procedure|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
79847112|NCT02584283|Device|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
79847113|NCT02584283|Procedure|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
79847114|NCT02584283|Drug|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
79847115|NCT04080401|Device|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
79847116|NCT04080401|Other|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
79847117|NCT04634669|Drug|AXS-05 (dextromethorphan-bupropion)|- AXS-05 tablet, taken daily (up to 15 months)
79250909|NCT02472652|Drug|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
79250910|NCT04410848|Other|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
79302870|NCT03209557|Other|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
79302871|NCT02482103|Procedure|Renal denervation|Catheter based renal nerve ablation
79389292|NCT04639050|Drug|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
79545289|NCT01529333|Device|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
79545290|NCT01529359|Dietary Supplement|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
79847118|NCT02585531|Drug|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
79389293|NCT04639050|Drug|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
79389294|NCT04636190|Device|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
79389295|NCT04632498|Behavioral|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
79545291|NCT01529359|Dietary Supplement|Placebo|Placebo 2 gelules per days for 6 weeks
79545292|NCT01529372|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
79545293|NCT01529398|Other|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
79706417|NCT05945966|Other|Bilateral training group (BTG).|stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
79706418|NCT05944471|Other|Providing breastfeeding support with Telehealth|After discharge, training videos on the importance of breast milk and breastfeeding prepared in line with the literature and explained by experts, and written documents (e-brochure, plain text version of breastfeeding trainings) were sent to individual mothers once a week between 10.00-14.00 hours via telehealth application. At the same time intervals, visualised messages explaining breastfeeding and that breast milk is sufficient for the baby were sent via telehealth application five days a week. In addition, if the mothers requested at 10.00-17.00 on weekdays, they were given live support by the researcher for the issues they were curious about breastfeeding by calling the researcher via telehealth application.
79706419|NCT05943821|Drug|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
79706420|NCT05943821|Drug|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels >5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
79706421|NCT05940610|Biological|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. Once a week for 4 weeks.
79706422|NCT05939362|Other|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
79706423|NCT05938543|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
79250911|NCT05276336|Procedure|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
79250912|NCT05276336|Drug|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
79545294|NCT01529398|Other|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
79545295|NCT01529398|Other|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
79545296|NCT01529411|Drug|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min).
79545297|NCT01529411|Other|Undefined (standard care)|All the current interventions used by each institution for the study disease.
79706424|NCT05934708|Behavioral|Downhill Running|Participants will complete a 20 minute downhill running protocol on a -12% grade, at ~6 mph. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump and maximal voluntary isometric contraction. After the running protocol, the same tests will be performed again. The metrics will be collected a third and fourth time at 24 hours and 48 hours post exercise, respectively.
79706425|NCT05911074|Diagnostic Test|The Abbott Panbio™ COVID-19 Ag Rapid Test|This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
79250913|NCT05274698|Behavioral|muscle energy technique|It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
79706426|NCT05900947|Other|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
79706427|NCT05898412|Drug|Andexanet alfa|Patients treated with andexanet alfa
79706428|NCT05891327|Dietary Supplement|Maca|2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks
79706429|NCT05891327|Dietary Supplement|Placebo|Placebo
79706430|NCT05887934|Device|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
79706431|NCT05881668|Biological|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
79706432|NCT05878951|Drug|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
79706433|NCT05878080|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
79545298|NCT01529437|Drug|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
79545299|NCT01529437|Drug|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
79545300|NCT01529476|Drug|Levofloxacin|levofloxacin 500 mg,QD,7~10 days
79545301|NCT01529476|Drug|Nemonoxacin|Nemonoxacin 500mg,QD,7~10 days
79250914|NCT05274698|Behavioral|conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.|"Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel"
79250915|NCT02910752|Drug|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
79389301|NCT04598646|Behavioral|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
79389302|NCT04598646|Behavioral|Support|Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
79389303|NCT04596995|Drug|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
79389304|NCT04595747|Procedure|Biopsy|Undergo biopsy
79545302|NCT01529489|Other|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
79545303|NCT01529489|Other|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
79706434|NCT05877027|Other|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
79706435|NCT05877027|Other|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
79706436|NCT05877027|Other|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
79706437|NCT05870748|Drug|Luveltamab tazevibulin|antibody-drug conjugate
79706438|NCT05870748|Drug|Pegfilgrastim|pegylated G-CSF
79706439|NCT05861115|Device|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
79706440|NCT05857592|Diagnostic Test|Adaptive functioning self-report questionnaire|A self-report questionnaire for assessing level of adaptive functioning
79706441|NCT05857592|Diagnostic Test|Adaptive functioning self-report questionnaire - adapted|A self-report questionnaire for assessing level of adaptive functioning, adapted to the communication level of the participant
79706442|NCT05855369|Device|Trigeminal Nerve Stimulation (TNS)|Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
79706443|NCT05855369|Other|Active Smell Training (ST)|Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
79250916|NCT02807857|Procedure|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
79250917|NCT04568798|Device|Sana Sham Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
79250918|NCT05268146|Behavioral|Lifestyles|Co-creation process and participatory research; lifestyles
79545304|NCT01529489|Other|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
79250919|NCT05243186|Device|Treadmill workstation|walking on a treadmill workstation next to desk with computer and screen
79250920|NCT05243186|Drug|Methylphenidate|Using prescription drug
79250921|NCT02856074|Biological|prise de sang|
79250922|NCT02856074|Other|quality of life questionnaire|
79250923|NCT02808182|Drug|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
79389305|NCT04595747|Procedure|Biospecimen Collection|Undergo blood sample collection
79389306|NCT04595747|Procedure|Computed Tomography|Undergo CT scan and PET/CT scan
79389307|NCT04595747|Procedure|Magnetic Resonance Imaging|Undergo MRI
79545305|NCT01529489|Other|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
79545306|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
79545307|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
79545308|NCT01529528|Drug|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
79545309|NCT01529541|Drug|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
79545310|NCT01529541|Drug|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
79545311|NCT01529554|Drug|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
79545312|NCT01529554|Drug|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
79545313|NCT01529567|Behavioral|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
79706444|NCT05855369|Other|Placebo Smell Training (PBO)|Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
79250924|NCT02808182|Other|[7,7,8,8-2H]-palmitate|using i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to +360 min
79389308|NCT04595747|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79389309|NCT04595747|Drug|Rogaratinib|Given PO
79545314|NCT01529567|Behavioral|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
79706445|NCT05850533|Behavioral|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
79706446|NCT05850312|Device|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
79250925|NCT02808182|Other|[U-13C]-palmitate|oral administration of [U-13C]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
79250926|NCT02808182|Procedure|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
79706447|NCT05850312|Device|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
79706448|NCT05848180|Other|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
79706449|NCT05848180|Other|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
79706450|NCT05838742|Drug|GSK3858279|GSK3858279 will be administered.
79706451|NCT05838742|Drug|Placebo|Placebo will be administered.
79250927|NCT02808182|Other|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
79250928|NCT04695704|Drug|Montelukast|10 mg oral montelukast once daily for 28 days
79250929|NCT04695704|Other|placebo|10 mg oral placebo once daily for 28 days
79389311|NCT04574765|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
79389312|NCT04574765|Other|Questionnaire collection|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
79389313|NCT04574765|Other|Optional blood completion|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
79389314|NCT04574765|Other|Optional questionnaire completion|Fill out an optional mental health questionnaire.
79391783|NCT03169452|Device|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
79706452|NCT05837806|Drug|tislelizumab+disitamab-vedotin|patients in group will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin 120 mg intravenously.
79706453|NCT05828654|Behavioral|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
79706454|NCT05828654|Behavioral|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
79706455|NCT05827874|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
79706456|NCT05827874|Biological|Tdap|Tdap will be administered as an IM injection.
79706457|NCT05827874|Biological|PPSV23|PPSV23 will be administered as an IM injection.
79706458|NCT05824728|Drug|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
79706459|NCT05821959|Combination Product|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
79706460|NCT05821582|Other|Stool Collection and Survey Completion|Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact. The biospecimens collected from participants on this study are stool samples.
79250930|NCT02051569|Dietary Supplement|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
79250931|NCT02048527|Other|Global|Single medium for the culture of embryos from Day1 to Day 5
79250932|NCT02048527|Other|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
79250933|NCT04497272|Other|COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
79389315|NCT04574037|Other|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
79389316|NCT04573439|Dietary Supplement|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
79389317|NCT04572841|Drug|SAR441344|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
79389318|NCT04572841|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
79389319|NCT04570956|Drug|Tamoxifen|Oral Tamoxifen 10 mg/day
79706461|NCT05818137|Biological|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
79706462|NCT05816343|Drug|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
79706463|NCT05816343|Drug|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
79706464|NCT05813314|Combination Product|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
79706465|NCT05813314|Drug|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
79706466|NCT05799963|Device|BioMatrix Alpha|Patient will be treated with BioMatrix Alpha
79250934|NCT02048605|Behavioral|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
79389320|NCT04570956|Drug|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
79389321|NCT04570956|Drug|Placebo|placebo pill or placebo gel
79389322|NCT04559529|Drug|Levetiracetam (LEV) 500 mg|The levetiracetam pill will look just like the placebo pill.
79706467|NCT05789173|Drug|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
79847119|NCT02585531|Drug|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
79847120|NCT04572503|Procedure|Barbed Suture Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
79250935|NCT02048605|Behavioral|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
79250936|NCT02648438|Drug|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
79250937|NCT02648438|Drug|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
79250938|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
79389323|NCT04559529|Drug|Placebo|The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
79389324|NCT04558138|Other|Discharge timing|Patients will be discharged home on the day of surgery as opposed to POD #1
79389325|NCT04544449|Drug|Fenebrutinib|Participants will receive fenebrutinib.
79389326|NCT04544449|Drug|Ocrelizumab|Participants will receive ocrelizumab.
79706468|NCT05789173|Drug|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
79706469|NCT05773755|Device|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
79706470|NCT05773170|Drug|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
79389327|NCT04544449|Drug|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
79706471|NCT05764785|Behavioral|MentorPRO|MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
79706472|NCT05763199|Drug|AHCC|AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.
79706473|NCT05763199|Drug|Chemotherapy|Chemotherapy will be administered per standard of care.
79706474|NCT05763199|Other|Placebo|Dextrin
79389328|NCT04544449|Drug|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
79706475|NCT05762276|Drug|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
79706476|NCT05762276|Biological|Placebo|Normal saline
79706477|NCT05753774|Biological|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses
79706478|NCT05749835|Other|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
79545315|NCT01529580|Behavioral|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
79706479|NCT05749835|Other|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\her head is cradled between your body and your right forearm (when you stand at his\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
79847121|NCT00920153|Biological|bleomycin sulfate|Given IV
79847122|NCT00920153|Drug|ABVD regimen|Given IV
79250939|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
79250940|NCT02648438|Drug|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
79250941|NCT02051725|Other|Active life-style intervention|
79250942|NCT02591420|Biological|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
79250943|NCT02591420|Biological|Placebo for VRC01|Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
79250944|NCT02591420|Drug|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
79250945|NCT02050945|Behavioral|Resistance training|
79250946|NCT02050945|Behavioral|Endurance training|
79389329|NCT04534777|Other|repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery|Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
79389330|NCT04516746|Biological|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
79706480|NCT05743517|Behavioral|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
79389331|NCT04516746|Biological|Placebo|Commercially available 0.9% (n/V) saline for injection.
79389332|NCT04516070|Other|Questionnaire Administration|Ancillary studies
79389333|NCT04516070|Radiation|Stereotactic Radiosurgery|Undergo SRS
79389334|NCT04515667|Behavioral|Mindfulness|Participants will view a brief mindfulness video
79545316|NCT01529619|Drug|Rivastigmine transdermal patch|
79847123|NCT00920153|Drug|carmustine|Given IV
79847124|NCT00920153|Drug|cisplatin|Given IV
79847125|NCT00920153|Drug|cytarabine|Given IV
79847126|NCT00920153|Drug|dacarbazine|Given IV
79847127|NCT00920153|Drug|dexamethasone|Given orally
79847128|NCT00920153|Drug|doxorubicin hydrochloride|Given IV
79847129|NCT00920153|Drug|etoposide|Given IV
79250947|NCT05218538|Diagnostic Test|Fibroscan (non interventional)|An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
79389335|NCT04515667|Behavioral|Video|Participants will view a control video
79389336|NCT04506775|Device|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
79389337|NCT04506775|Procedure|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
80015306|NCT04423471|Diagnostic Test|Sociodemographic variables|"Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~Result variables: Changes in PASI or MADRS scores"
79250948|NCT02051803|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
79706481|NCT05743387|Other|T2D care package|T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
79706482|NCT05743387|Other|Referral to the responsible health facility|CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
79706483|NCT05737160|Biological|Telitacicept|Administered as an SC infusion
79706484|NCT05737160|Drug|Placebo|Administered as an SC infusion
79706485|NCT05736497|Other|Digital Care Plans|Investigators will develop digital care plans for 10 common Cancer Predisposition Syndromes for patients diagnosed within 3 years.
79250949|NCT02051803|Behavioral|Health Education (HE)|
79250950|NCT05217758|Drug|Mifepristone|1200 mg/day, once daily, 7 days
79706486|NCT05725733|Other|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
79706487|NCT05724953|Behavioral|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
79706488|NCT05721755|Drug|Carboplatin|Given IV
79706489|NCT05721755|Drug|Cisplatin|Given IV
79250951|NCT05217758|Drug|Placebo|Placebo, once daily, 7 days
79250952|NCT05135390|Drug|HSK21542|three times per week
79250953|NCT05135390|Drug|Placebo|three times per week
79250954|NCT03723512|Device|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
79250955|NCT02051023|Drug|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
79250956|NCT02051023|Drug|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
79250957|NCT02415556|Drug|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
79250958|NCT02415556|Drug|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
79545317|NCT01529658|Procedure|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
79545318|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
79545319|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
79545320|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
79545321|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
79389338|NCT04502407|Radiation|Cisplatin-based Radiation Therapy|"High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."
79389339|NCT04502407|Drug|Cisplatin Chemotherapy|"High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."
79389340|NCT04475939|Drug|Niraparib|Niraparib will be administered
79389341|NCT04475939|Drug|Pembrolizumab|Pembrolizumab will be administered
79389342|NCT04475939|Drug|Placebo|Matching placebo will be administered
79545322|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension BID
79545323|NCT01529684|Drug|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
79706490|NCT05721755|Procedure|Computed Tomography|Undergo CT and/or PET/CT
79706491|NCT05721755|Drug|Fluorouracil|Given IV
79706492|NCT05721755|Procedure|Magnetic Resonance Imaging|Undergo MRI
79706493|NCT05721755|Drug|Paclitaxel|Given IV
79706494|NCT05721755|Biological|Pembrolizumab|Given IV
79847130|NCT00920153|Drug|gemcitabine hydrochloride|Given IV
79847131|NCT00920153|Drug|ifosfamide|Given IV
79250959|NCT03812341|Other|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
79847132|NCT00920153|Drug|melphalan|Given IV
79706495|NCT05721755|Procedure|Positron Emission Tomography|Undergo PET/CT
80015307|NCT03834532|Other|Breast reconstruction decision aid|The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.
80015308|NCT03834532|Other|Educational website|The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
79250960|NCT05138198|Behavioral|Mediterranean Diet & Physical Activity|"At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~Discuss optimal dietary pattern (Med Diet pyramid handout)~Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals"
79389343|NCT04471532|Behavioral|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
79389344|NCT04470726|Drug|AIV001|Intradermal/intratumoral
79545324|NCT01529684|Drug|OSI-906|Part B: oral tablets OSI-906
79545325|NCT01529697|Behavioral|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
79545326|NCT01529710|Drug|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
79706496|NCT05721755|Other|Quality-of-Life Assessment|Ancillary studies
80015309|NCT03665649|Procedure|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
80015310|NCT04610450|Device|HEARO|Robotic system for otological procedures
79389345|NCT04469959|Drug|L-Dopa|"Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."
79389346|NCT04469959|Drug|Placebo|Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
79545327|NCT01529788|Drug|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
79706497|NCT05721755|Radiation|Radiation Therapy|Undergo radiation therapy
79706498|NCT05719805|Drug|Mavacamten|Specified dose on specified days
79706499|NCT05719623|Other|CUEVAS MEDEK EXERCISES|stretchings/strengthening
79706500|NCT05719623|Other|BALANCE AND POSTURAL|BALANCE AND POSTURAL
79706501|NCT05717166|Radiation|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
80015311|NCT04610450|Device|OTOPLAN|Otological surgical planning software
80015312|NCT03664635|Biological|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
79389347|NCT04457622|Other|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
79706502|NCT05717166|Drug|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
79706503|NCT05717166|Drug|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
79706504|NCT05717166|Drug|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
79706505|NCT05717166|Drug|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
79706506|NCT05717166|Other|Observation|Pre-specified based on the standard of care approach for that patient.
79250961|NCT05138198|Behavioral|Usual Care|As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
79706507|NCT05717166|Radiation|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
79706508|NCT05717166|Procedure|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
80015313|NCT04414033|Device|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
80015314|NCT04406545|Other|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
79250962|NCT02471235|Behavioral|Physiotherapy|Pulmonary rehabilitation
79250963|NCT02051881|Other|Taking intestinal biopsies|
79706509|NCT05717166|Other|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
79250964|NCT02051959|Device|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
79250965|NCT02051959|Device|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
79389348|NCT04451291|Biological|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
79389349|NCT04450329|Drug|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
79389350|NCT04450329|Drug|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
79706510|NCT05717166|Radiation|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
79706511|NCT05689099|Drug|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
79706512|NCT05689099|Drug|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
79847133|NCT00920153|Drug|methylprednisolone|Given IV
79847134|NCT00920153|Drug|mitoguazone|Given IV
79847135|NCT00920153|Drug|vincristine sulfate|Given IV
79847136|NCT00920153|Drug|vindesine|Given IV
79847137|NCT00920153|Drug|vinorelbine tartrate|Given IV
79847138|NCT00920153|Procedure|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
79847139|NCT00920153|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
80015315|NCT00969722|Biological|MAb-3F8|
79250966|NCT02051959|Device|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
79250967|NCT02051959|Device|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
79250968|NCT05418621|Drug|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
79250969|NCT05418621|Other|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
79250970|NCT02048683|Drug|Short term sedation with sevoflurane in ICU|
79250971|NCT04516694|Behavioral|Financial incentive (gain)|Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
79847140|NCT04080713|Drug|Budesonide|Budesonide 9 mg prolonged release tablet
79847141|NCT04080557|Other|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
79847142|NCT02585453|Device|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
79250972|NCT04516694|Behavioral|Financial incentive (loss)|Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
79250973|NCT03108807|Diagnostic Test|D-dimer test|D-dimer test
79389358|NCT04427761|Behavioral|Measurement of Transitions in Cancer Scale (MOT-CA) Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
79389359|NCT04427761|Behavioral|Distress Thermometer Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
79389360|NCT04424316|Biological|RSVpreF|RSV vaccine (RSVpreF)
79706513|NCT05687539|Dietary Supplement|Mastiha water|10ml of mastiha water before every meal for one month
79706514|NCT05687539|Dietary Supplement|Mastiha capsules|2x350mg mastiha capsules before every meal for one month
79706515|NCT05684055|Drug|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
79545328|NCT01529788|Drug|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
79545329|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
79706516|NCT05684055|Other|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
79847143|NCT02585453|Device|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
79847144|NCT02585453|Device|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
79250974|NCT02048761|Drug|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
79545330|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
79545331|NCT01529892|Drug|A single oral 5 mg of duterium labeled methamphetamine|
79545332|NCT01529918|Other|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
79706517|NCT05682612|Other|outcome|hospital survivors and nonsurvivors
79706518|NCT05682612|Other|Subtype of COVID-19|Different subtype of COVID-19
79706519|NCT05681559|Behavioral|Medi for All|Please see description of Medi for All arm
79250975|NCT02048761|Drug|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
79250976|NCT04491903|Procedure|REBOA|Endovascular balloon occlusion of the aorta
79250977|NCT03108729|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
79250978|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
79250979|NCT02048917|Drug|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
79250980|NCT02048917|Drug|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
79250981|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
79847145|NCT02586701|Other|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
79847146|NCT04079309|Behavioral|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
79250982|NCT02048917|Drug|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
79250983|NCT02048917|Drug|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
79250984|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
79250985|NCT02048917|Drug|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
79250986|NCT02048917|Drug|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
79250987|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
79250988|NCT02048917|Drug|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
79545333|NCT01529931|Device|Hair2Go|Hair2Go treatment once a month for 6 months
79706520|NCT05681559|Dietary Supplement|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
79250989|NCT02048917|Drug|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
79847147|NCT02583503|Radiation|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
80015316|NCT00969722|Biological|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
79250990|NCT04492982|Behavioral|Yoga|1 hour of group format, guided yoga practice
79389361|NCT04424316|Biological|Placebo|Placebo
79250991|NCT04492982|Behavioral|Distress Tolerance|1 hour didactic group format, to develop distress tolerance skills
79250992|NCT02472951|Other|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
79250993|NCT02472951|Other|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
79250994|NCT02472717|Drug|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
79250995|NCT02472717|Other|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
79545334|NCT01529957|Drug|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
79545335|NCT01530022|Drug|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
79706521|NCT05680480|Biological|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
79706522|NCT05680480|Biological|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
79250996|NCT02037373|Biological|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
79250997|NCT02037373|Biological|Plasma|Plasma as prescribed by the treating physician.
79250998|NCT04427150|Behavioral|Auditory Training|A series of psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
79250999|NCT04427150|Behavioral|Non-auditory training|A series of non-psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
79251000|NCT04491747|Diagnostic Test|functional capacity|Six minute walk test used assessment of functional capacity.
79251001|NCT02049073|Drug|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
79251002|NCT02049073|Drug|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
79251003|NCT04518345|Drug|Azacitidine|Given IV
79251004|NCT04518345|Drug|Dubermatinib|Given PO
79251005|NCT02260063|Drug|Epinastine syrup|
79389362|NCT04423718|Drug|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
79389363|NCT04423718|Drug|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
79389364|NCT04370691|Device|JETi Peripheral Thrombectomy System|The JETi System is is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
79389365|NCT04355611|Other|Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)|Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
79545336|NCT01530022|Drug|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
79251006|NCT02260063|Drug|Epinastine tablets|
79251007|NCT05151302|Diagnostic Test|computer vision symptom scale (CVSS) questionnaire|Subjects working at VDT for >20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
79545337|NCT01530035|Other|physical training|training
79545338|NCT01530048|Drug|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
79706523|NCT05680480|Drug|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
79847148|NCT02584205|Device|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
79847149|NCT04550039|Device|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
79847150|NCT04550039|Device|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
79847151|NCT02585297|Other|no intervention|
79847152|NCT02584127|Behavioral|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
80015317|NCT00969722|Biological|13-cis-Retinoic Acid|
79847153|NCT02584127|Behavioral|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
79847154|NCT00501046|Drug|Placebo|9g /day (3 times a day)
79847155|NCT00501046|Drug|AST-120|9g /day (3 times a day)
79847156|NCT01018966|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
80015318|NCT03665571|Diagnostic Test|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
80015319|NCT05099614|Combination Product|Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system|1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
80015320|NCT00968942|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
80015321|NCT00968942|Drug|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
80015322|NCT05207449|Other|Questionnaire|"The questionnaire will include:~The demographic data of the patients~Chronic disease related questions~Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
79389366|NCT04345718|Drug|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
79389367|NCT04345718|Drug|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
80015323|NCT02418689|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
79545339|NCT01530074|Procedure|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
79545340|NCT01530126|Biological|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
79545341|NCT01530126|Biological|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
79545342|NCT01530126|Biological|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
80015324|NCT05207371|Biological|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
80015325|NCT05212987|Drug|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
80015326|NCT03234790|Other|Filtered Air Exposure|Exposure to Filtered air
80015327|NCT03234790|Other|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
79545343|NCT01530139|Behavioral|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
80015328|NCT00869336|Drug|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
80015329|NCT00869336|Drug|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
80015330|NCT00869336|Drug|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
80015331|NCT00869336|Drug|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
80015332|NCT05212675|Other|Short daily dialysis|7 days 2hours dialysis
80015333|NCT05090410|Drug|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
79389368|NCT04331769|Device|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
79389369|NCT04331769|Drug|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
79389370|NCT04331041|Device|MR-guided stereotactic body radiation therapy|"Will be administered using MRIdian or MRIdian Linac system~50 Gy in 5 fractions"
79389371|NCT04331041|Drug|Defactinib|-Oral drug 400 mg twice a day
79389372|NCT04331041|Procedure|Tumor biopsy|-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
79389373|NCT04331041|Procedure|Research blood draw|-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
79389374|NCT04324619|Other|Online interactive learning activities|"3-hour video-storyline-based interactive learning program~Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
79389375|NCT04305587|Drug|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
79389376|NCT04305587|Other|Placebo|Placebo once daily for up to 42 days.
79389377|NCT04305587|Drug|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
79545344|NCT01530139|Behavioral|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
79545345|NCT01530139|Behavioral|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
79847157|NCT01019044|Procedure|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
79847158|NCT04546061|Behavioral|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
79847159|NCT04078685|Procedure|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
79706524|NCT05675891|Other|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
79706525|NCT05675085|Diagnostic Test|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~Two-view tomosynthesis of both breasts~Calculation of volumetric breast density (VBD)~Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
79706526|NCT05668897|Drug|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
79706527|NCT05668897|Drug|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
79706528|NCT05665166|Genetic|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
79706529|NCT05664815|Biological|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
79251008|NCT02037685|Behavioral|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:~Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
79251009|NCT02037685|Other|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
79251010|NCT03561727|Procedure|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
79389378|NCT04299464|Drug|Placebo|Participants will receive oral placebo for approximately 12 weeks.
79389379|NCT04299464|Drug|RO7017773|Participants will receive oral RO7017773 for approximately 12 weeks.
79389380|NCT04279964|Behavioral|Boot Camp Translation|Practices in the intervention arm will participate in the Boot Camp Translation process, where BCT Community Advisory group members will come together to develop and implement practice relevant materials to promote adolescent vaccination.
79389381|NCT04279964|Other|Control|No intervention. Practices will continue to behave as usual.
79389382|NCT04252625|Drug|Q-Urol|Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
79545346|NCT01530139|Behavioral|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
79545347|NCT01530152|Procedure|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
79545348|NCT01530165|Behavioral|Life style counseling|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat <30 proportion of total energy, saturated fat <10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
79545349|NCT01530204|Procedure|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
79389383|NCT04252625|Drug|Placebo|placebo capsule
79389384|NCT04231851|Drug|Glasdegib|Given PO
79389385|NCT04231851|Drug|CPX-351|Given IV
79389386|NCT04227847|Drug|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
79389387|NCT04227847|Drug|azacitidine|75mg/m^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
79545350|NCT01530204|Behavioral|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
79847160|NCT04078685|Procedure|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
79847161|NCT03928223|Other|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
79847162|NCT05519189|Drug|Ropivacaine|Peri-anal infiltration of Ropivacaine
79251011|NCT03561727|Procedure|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
79251012|NCT04398914|Drug|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
79251013|NCT04398914|Drug|Trastuzumab|"Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab"
79389388|NCT04224948|Device|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
79389389|NCT04222972|Drug|Pralsetinib|Administered orally
79389390|NCT04222972|Drug|Carboplatin|Administered IV
79389391|NCT04222972|Drug|Cisplatin|Administered IV
79847163|NCT05519189|Other|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
79251014|NCT04398914|Drug|Pertuzumab|"Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab"
79251015|NCT04398914|Drug|Nab-paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
79389392|NCT04222972|Drug|Pemetrexed|Administered IV
79389393|NCT04222972|Drug|Pembrolizumab|Administered IV
79389394|NCT04222972|Drug|Gemcitabine|Administered IV
79389395|NCT04222972|Drug|Paclitaxel|Administered IV
79389396|NCT04222972|Drug|Nab-Paclitaxel|Administered IV
79389397|NCT04197934|Procedure|Biospecimen Collection|Undergo collection of blood samples
79389398|NCT04197934|Procedure|Biospecimen Collection|Undergo collection of CSF samples
79389399|NCT04197934|Procedure|Computed Tomography|Undergo CT
79389400|NCT04197934|Drug|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
79389401|NCT04197934|Procedure|Magnetic Resonance Imaging|Undergo MRI
79389402|NCT04197934|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79389403|NCT04191304|Biological|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
79389404|NCT04191304|Biological|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
79389405|NCT04176523|Drug|Carglumic Acid|Maintenance therapy with carglumic acid
79847164|NCT04080323|Drug|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
79847165|NCT04080323|Drug|placebo|1 vaginal tablet of placebo 60 minutes before surgery
79389406|NCT04141475|Dietary Supplement|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
79389407|NCT04141475|Dietary Supplement|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
79389408|NCT04137900|Drug|TAB004|Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
79389409|NCT04137900|Drug|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
79545351|NCT01530204|Other|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
79847166|NCT03930017|Biological|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
79847167|NCT00533949|Biological|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
79389410|NCT04137224|Biological|IgPro20|Human normal immunoglobulin for subcutaneous administration
79389411|NCT04137224|Biological|IgPro10|Human normal immunoglobulin for intravenous administration
79389412|NCT04125927|Drug|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
79847168|NCT00533949|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
79847169|NCT00533949|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
79847170|NCT00533949|Radiation|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
79706530|NCT05664815|Other|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
79706531|NCT05657184|Drug|REGEND001 Autologous Therapy Product|Transplantation of REGEND001 Autologous Therapy Product for dosage re-escalation.
79706532|NCT05656560|Behavioral|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
79706533|NCT05656560|Other|Clinician education|Brief, online education module for primary care clinicians
79706534|NCT05656560|Behavioral|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
79706535|NCT05656443|Drug|GST-HG171/Ritonavir|dose of 150 mg GST-HG171 with 100 mg ritonavir
79847171|NCT00533949|Radiation|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
79847172|NCT00485134|Biological|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
79847173|NCT00485134|Biological|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
79847174|NCT00485134|Biological|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
79847175|NCT00485134|Other|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
79847176|NCT05514353|Drug|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
79389413|NCT04116151|Combination Product|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
79389414|NCT04116151|Combination Product|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
79389415|NCT04105166|Biological|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
79389416|NCT04092777|Behavioral|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
79545352|NCT01530217|Drug|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
79545353|NCT01530230|Drug|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
79545354|NCT01530269|Drug|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
79706536|NCT05656443|Drug|Placebo|Placebo
79706537|NCT05653323|Drug|VX-993|Suspension for oral administration.
79706538|NCT05653323|Drug|Placebo|Suspension for oral administration.
79545355|NCT01530282|Other|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
79706539|NCT05650918|Biological|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
79706540|NCT05650918|Biological|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
79706541|NCT05649410|Other|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
79706542|NCT05649410|Other|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
79706543|NCT05643755|Other|Preoperative image-based education|Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
79706544|NCT05643430|Device|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
79847177|NCT05514353|Drug|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
79847178|NCT02585141|Device|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
79545356|NCT01530282|Other|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
79706545|NCT05643365|Radiation|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
79706546|NCT05641701|Device|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
79706547|NCT05641701|Device|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
79706548|NCT05630755|Drug|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
79545357|NCT01530295|Drug|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
79706549|NCT05630755|Drug|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
79706550|NCT05630755|Drug|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
79706551|NCT05630755|Drug|Placebo to DOR/ISL|0 mg oral tablets once daily
79706552|NCT05621486|Biological|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
79706553|NCT05621174|Drug|Dexamfetamine|Magisterial Dexamfetamine
79706554|NCT05621174|Drug|Dexamfetamine|Tentin
79706555|NCT05617911|Device|Blood Flow Restriction Cuff|Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
79251016|NCT04398914|Drug|EC chemotherapy|Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
79389417|NCT04092777|Other|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
79389418|NCT04078152|Drug|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
79389419|NCT04071236|Drug|Avelumab|Given IV
79389420|NCT04071236|Drug|Peposertib|Given PO
79389421|NCT04071236|Other|Quality-of-Life Assessment|Ancillary studies
79389422|NCT04071236|Other|Questionnaire Administration|Ancillary studies
79545358|NCT01530308|Drug|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
79545359|NCT01530308|Drug|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
79706556|NCT05617911|Procedure|Sham and standard of Care Therapy|SoC PT + non-inflated BFR cuff
79706557|NCT05610189|Drug|Tavapadon|Oral tablets
79706558|NCT05579977|Drug|PF-07081532|Oral glucagon-like peptide-1 receptor agonist
79706559|NCT05579977|Other|Placebo|No drug
79706560|NCT05579977|Drug|Rybelsus|Oral Semaglutide
79251017|NCT04398914|Drug|Physician's choice|Physician decided chemotherapy for 0-4 cycles.
79251018|NCT04398914|Drug|T-DM1|T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
79251019|NCT04398914|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
79389423|NCT04071236|Radiation|Radium Ra 223 Dichloride|Given IV
79389424|NCT04057807|Drug|LPS|LPS (0.4 ng/kg)
79545360|NCT01530321|Other|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
79545361|NCT01530321|Other|Light Massage|5 minutes of light pressure massage to the neck and upper back
79545362|NCT01530347|Device|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
79706561|NCT05576584|Drug|GST-HG121 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
79706562|NCT05576584|Drug|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
79706563|NCT05553145|Diagnostic Test|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
79706564|NCT05549648|Other|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
79706565|NCT05538624|Drug|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
79706566|NCT05538624|Drug|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
79847179|NCT02585141|Procedure|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
79847180|NCT02585141|Drug|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
79251020|NCT03561649|Drug|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
79251021|NCT03108651|Other|Case|Motivational message will be administrated.
79389425|NCT04054648|Other|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
79847181|NCT04443101|Other|different types of intracular lens|different types of intracular lens
80015334|NCT05090410|Drug|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
80015335|NCT02371889|Drug|Topiramate|Max therapeutic dose of 200mg/day
79389426|NCT04040296|Other|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
79251022|NCT05138042|Other|Cryotherapy (frozen glove)|"In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes."
79389429|NCT04029688|Drug|Idasanutlin|Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
79389430|NCT04029688|Drug|Venetoclax|Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
79389431|NCT04029688|Drug|Cyclophosphamide|Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m^2) as an intravenous (IV) infusion.
79389432|NCT04029688|Drug|Topotecan|Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m^2 as an IV infusion.
79389433|NCT04029688|Drug|Fludarabine|Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m^2 as an IV infusion.
79389434|NCT04029688|Drug|Cytarabine|Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m^2 as an IV infusion.
79389435|NCT04029688|Drug|Intrathecal Chemotherapy|All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
79389436|NCT04022850|Behavioral|A non-reflective decision assistance strategy|A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
79389437|NCT04022850|Behavioral|A both reflective and non-reflective decision information strategy|"This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients."
79389438|NCT04022850|Behavioral|A reflective decision structure strategy|The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
79389439|NCT04009109|Drug|Lenalidomide|Induction and Maintenance
79389440|NCT04009109|Drug|Ixazomib|Induction and Only Maintenance Arm B
79389441|NCT04009109|Drug|Daratumumab Injection|Induction and Only Maintenance Arm B
80015336|NCT02371889|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
80015337|NCT02371889|Drug|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
79389442|NCT04009109|Drug|Dexamethasone|Induction and Only Maintenance Arm B
79389443|NCT04008836|Device|T-PLUS Meter|Blood Glucose Monitoring System (BGMS)
79389444|NCT03980769|Drug|Thiotepa|Given IV
79847182|NCT02583347|Device|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
79847183|NCT04079231|Drug|Brolucizumab|Intravitreal Injection
80015338|NCT00867698|Drug|AST-120|AST-120
80015339|NCT05099458|Biological|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
80015340|NCT05207215|Other|Home Base Exercises|The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
80015341|NCT05099302|Other|divert attention|In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
80015342|NCT00860288|Drug|Vildagliptin|
79545363|NCT01530360|Device|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
79389445|NCT03980769|Drug|Treosulfan|Given IV
79251023|NCT02807623|Drug|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
79389446|NCT03980769|Drug|Fludarabine Phosphate|Given IV
79389447|NCT03980769|Biological|Rabbit Anti-Thymocyte Globulin|Given IV
79389448|NCT03980769|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
79545364|NCT01530386|Drug|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
79706567|NCT05537064|Behavioral|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
79706568|NCT05537064|Behavioral|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
79545365|NCT01530412|Other|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
79706569|NCT05531604|Behavioral|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
79706570|NCT05524649|Dietary Supplement|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
79545366|NCT01530438|Other|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~Imaging : fMRI at rest and anatomical MRI~Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
79545367|NCT01530451|Drug|Desmopressin|120mg OD
79847184|NCT04079231|Drug|Aflibercept|Intravitreal injection
79847185|NCT00994695|Biological|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
79847186|NCT05350293|Other|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
79389449|NCT03980340|Behavioral|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
79389450|NCT03980340|Behavioral|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
79389451|NCT03969901|Drug|IMI/REL|"Age-based dosing:~12 to <18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~2 to <12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~3 months to <2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~Birth to <3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
79847187|NCT05350293|Other|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
80015343|NCT00860288|Drug|Metformin|
80015344|NCT00860288|Drug|Placebo|
79545368|NCT01530451|Drug|Placebo|one tab OD
79545369|NCT01530490|Drug|Cabergoline and Hydroxyethyl Starch|0.5mg
79545370|NCT01530490|Drug|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
80015345|NCT00860288|Drug|Sitagliptin|
80015346|NCT03941275|Diagnostic Test|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
79847188|NCT02584985|Procedure|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
79847189|NCT02584985|Procedure|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
79251024|NCT02807623|Behavioral|Compound Exercise of Push-ups|The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
79847190|NCT04521803|Drug|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
79847191|NCT00920465|Drug|mifegyne and cytotec|One day dosage versus two days dosage
79847192|NCT04078919|Dietary Supplement|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
79251025|NCT02807623|Drug|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
80015347|NCT05099224|Behavioral|Mindfulness meditation|similar to the information included in arm/group descriptions
79251026|NCT05137964|Diagnostic Test|Vitamin D|Serum Biochemical routine lab workup and gynaecological ultra sound AFC
79251027|NCT02471469|Drug|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
79251028|NCT05137340|Other|Nasal continuous positive airway pressure and Non-invasive positive pressure ventilation|After transfer to NICU ward, infants were randomly assigned to NCPAP group and NIPPV group. Patients diagnosed with NRDS on non-invasive respiratory support (NIPPV or NCPAP) were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth.
79545371|NCT01530503|Drug|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
79545372|NCT01530503|Drug|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
80015348|NCT03630029|Drug|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
80015349|NCT03072875|Device|CAMS-RAS|
79251029|NCT04386590|Other|Manual Therapy Plus Pulmonary Rehabilitation|Manual therapy combined with Pulmonary Rehabilitation
79251030|NCT04386590|Other|Sham Intervention|Detuned US plus Pulmonary Rehabilitation
79251031|NCT02471157|Other|Observation|
79251032|NCT02052037|Dietary Supplement|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
79389452|NCT03969901|Drug|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
79545373|NCT01530516|Device|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
79545374|NCT01530516|Device|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
79545375|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
79847193|NCT04078919|Other|Low calorie diet|Low calorie diet
79847194|NCT02583035|Other|Nurse telephone contact|Nurse will contact patient 3 days before consultation
79847195|NCT00994773|Drug|Simvastatin|daily doses for 14 days
79847196|NCT00994773|Drug|Tenofovir|
80015350|NCT05212597|Drug|Sacubitril-valsartan|50mg~100mg twice daily
79847197|NCT00994773|Drug|Entecavir|Entecavir
79847198|NCT05405543|Drug|MYK-224|Specified dose on specified days
79847199|NCT05405543|Other|Placebo|Specified dose on specified days
80015351|NCT05212597|Drug|Amlodipine-losartan|amlodipine/losartan 2.5/25mg ~ 5/100mg once daily
80015352|NCT02450812|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
80015353|NCT03629717|Procedure|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
80015354|NCT03629717|Drug|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
79706571|NCT05524649|Dietary Supplement|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
80015355|NCT03629717|Procedure|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
80015356|NCT03629717|Drug|Calcium|1200mg daily
79545376|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
79545377|NCT01530529|Drug|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
80015357|NCT03629717|Drug|Vitamin D|800 IU daily
79251033|NCT02052037|Dietary Supplement|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
79251034|NCT04374578|Drug|Dulaglutide 1.5 MG/ML|Dulaglutide 1.5Mg qw sc injection for 4 weeks
79251035|NCT02470923|Drug|Nicotine replacement therapy|
79251036|NCT02470923|Behavioral|Intensive counseling|
79706572|NCT05524649|Dietary Supplement|Placebo|5 drops/day for 3 months of sunflower oil
79706573|NCT05521074|Device|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
79251037|NCT02470923|Behavioral|Medical advice|
79251038|NCT02037841|Other|Nursing-driven clinical pathway for management of inpatient asthma|
80015358|NCT05212519|Other||For observational research
79251039|NCT04358198|Diagnostic Test|Artificial intelligence|The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
79251040|NCT04345952|Behavioral|Calm Meditation Mobile App|The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
80015359|NCT04473404|Dietary Supplement|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
79251041|NCT02049229|Device|percutaneous coronary intervention|Optimax-stent implantation
79389453|NCT03969212|Drug|Baloxavir Marboxil|IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
79389454|NCT03969212|Drug|Placebo|IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
79389455|NCT03944772|Drug|Osimertinib|Osimertinib given orally at 80 mg once daily
79545378|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
79545379|NCT01530542|Drug|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
79545380|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
79545381|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
79706574|NCT05521074|Device|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
79251042|NCT02049229|Device|percutaneous coronary intervention|Synergy stent implantation
79251043|NCT02052115|Behavioral|12 month exercise and weight loss intervention|
79251044|NCT02471001|Biological|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
79251045|NCT02805907|Drug|Calcifediol|
79251046|NCT02805907|Drug|Placebo|
79545382|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
79545383|NCT01530542|Drug|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
79545384|NCT01530555|Drug|Rabbit ATG, Thymoglobuline (Genzyme)|"Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
79545385|NCT01530568|Other|Xpert|This arm receives the GeneXpert test
79706575|NCT05519475|Drug|ALN-HSD|Administered by subcutaneous injection (SC)
79706576|NCT05519475|Drug|Placebo|Administered by SC injection
80015360|NCT04473404|Dietary Supplement|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
80015361|NCT04473404|Other|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
80015362|NCT04250077|Behavioral|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
79545386|NCT01530568|Other|Smear|This arm receives smear microscopy
79706577|NCT05509257|Drug|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
79706578|NCT05509257|Drug|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
79706579|NCT05507541|Procedure|Biospecimen Collection|Undergo correlative studies
79706580|NCT05507541|Procedure|Computed Tomography|Undergo PET/CT or CT scans of the chest, abdomen, and pelvis
79706581|NCT05507541|Drug|Ontorpacept|Given IV
79706582|NCT05507541|Biological|Pembrolizumab|Given IV
79545387|NCT01530581|Procedure|G-PB Transplant|G-PB Transplant
79706583|NCT05507541|Procedure|Positron Emission Tomography|Undergo PET/CT scans
79706584|NCT05507541|Drug|Maplirpacept|Given IV
79706585|NCT05489562|Device|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
79706586|NCT05463965|Biological|QM1114-DP|Intramuscular injection
79706587|NCT05463965|Biological|OnabotulinumtoxinA|Intramuscular injection
79706588|NCT05463965|Biological|Placebo|Intramuscular injection
79706589|NCT05438680|Dietary Supplement|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
79706590|NCT05438680|Dietary Supplement|Placebo|distilled water with no bovine colostrum
79706591|NCT05436041|Behavioral|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
79847200|NCT00995631|Procedure|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
79389456|NCT03944772|Drug|Savolitinib|Savolitinib will be given orally at 300 mg or 600mg once daily
79389457|NCT03944772|Drug|Gefitinib|Gefitinib given orally at 250 mg once daily
79389458|NCT03944772|Drug|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
79389459|NCT03944772|Drug|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
79389460|NCT03944772|Drug|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
79389461|NCT03944772|Drug|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
79389462|NCT03944772|Drug|Alectinib|Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
79545388|NCT01530581|Procedure|G-BM Transplant|G-BM Transplant
79706592|NCT05434078|Device|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
79706593|NCT05417854|Device|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
79706594|NCT05414565|Device|Vivity IOL|Commercially available extended vision IOL
79389463|NCT03944772|Drug|Selpercatinib|Selpercatinib given orally at 160mg twice daily
79545389|NCT01530594|Drug|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
79545390|NCT01530594|Drug|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
79545391|NCT01530594|Drug|Lenalidomide|Lenalidomide/Low dose Dex (LLD
79545392|NCT01530607|Drug|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
79545393|NCT01530607|Drug|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
79545394|NCT01530620|Drug|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
79545395|NCT01530620|Drug|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
79545396|NCT01530646|Behavioral|Weight loss|-750kcal/d
79545397|NCT01530646|Dietary Supplement|Soy|2 x 25g/d SPC
79706595|NCT05414565|Device|Aspheric monofocal IOL|Commercially available aspheric IOL
79706596|NCT05407012|Other|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
79706597|NCT05400707|Diagnostic Test|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
79706598|NCT05400707|Diagnostic Test|Assessment of impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
79706599|NCT05400707|Diagnostic Test|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
79706600|NCT05400707|Diagnostic Test|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
79847201|NCT00995787|Drug|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
79847202|NCT00995787|Drug|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
79847203|NCT04079153|Device|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
79847204|NCT00994851|Drug|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
79847205|NCT00994851|Drug|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
79847206|NCT04411745|Other|No intervention, observational study|
79706601|NCT05400707|Diagnostic Test|Assessment of current living situation in patients of 65 years and older|Questionnaire to assess living situation (living at home independently, living at home with help by family members or professional services, and living in a retirement or nursing home)
79847207|NCT04001127|Other|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
79251047|NCT04308902|Other|VLBW|Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
79545398|NCT01530646|Dietary Supplement|Whey|2 x 25g/d WPI
79545399|NCT01530672|Device|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
79251048|NCT04308902|Other|Term-born Comparison|Children born >=37 weeks gestation and weighing more than 2500g
79545400|NCT01530685|Dietary Supplement|Glycabiane|2 gelule per day for 4 months
79545401|NCT01530685|Dietary Supplement|placebo|2 gelules per day for 4 months
79251049|NCT02470845|Drug|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
79545402|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
79545403|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
79545404|NCT01530711|Drug|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
79545405|NCT01530724|Other|Weight-loss diet strategy (+) exercise (PA)|Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
79251050|NCT02470845|Drug|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm*1cm round size.Each patch will be applied on one acupoint.
79389464|NCT03944772|Drug|Selumetinib|Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
79389465|NCT03944772|Drug|Etoposide|Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
79545406|NCT01530724|Other|weight loss (-) exercise (PA)|Weight-loss diet strategy without exercise
79389466|NCT03944772|Drug|Cisplatin|Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
79545407|NCT01530737|Drug|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
79706602|NCT05400707|Diagnostic Test|Assessment of elder abuse (EA)|The ED Senior AID tool is a questionnaire with 15 questions to identify elder abuse
79545408|NCT01530737|Other|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
79545409|NCT01530763|Drug|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children < 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
79706603|NCT05400707|Diagnostic Test|Assessment of caregiver burden:|"The caregiver will be asked 4 questions about caregiver burden: do you feel emotionally burdened by caring for your relative?, is caring for your relative a physical strain for you?, has the care of the relative negatively affected the relationship with someone close (family, care recipient)?, is caring for your relative a financial burden for you?."
79251051|NCT05137106|Other|Active Dry Needling|All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
79389467|NCT03944772|Drug|Datopotamab deruxtecan|Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
79389468|NCT03927157|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
79389469|NCT03927157|Other|Placebo|Placebo subcutaneous injection
79389470|NCT03914326|Drug|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
79389471|NCT03914326|Drug|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
79706604|NCT05398640|Biological|Lifileucel|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
79706605|NCT05395091|Biological|denosumab|AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed as a subcutaneous injection.
79706606|NCT05388864|Behavioral|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
79706607|NCT05387759|Drug|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
80015363|NCT04250077|Behavioral|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
79251052|NCT05137106|Other|Sham Dry needling|All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
80015364|NCT00781742|Drug|AZD6765|IV once per dosing day, multiple times during the treatment period
79251053|NCT03562039|Procedure|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
79389472|NCT03883165|Other|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
79545410|NCT01530763|Drug|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
79545411|NCT01530763|Drug|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
79545412|NCT01530776|Behavioral|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
79251054|NCT02477397|Drug|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
79706608|NCT05387759|Drug|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
80015365|NCT00781742|Drug|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
79251055|NCT02477397|Drug|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
79389473|NCT03883165|Other|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
79389474|NCT03872128|Drug|Pregnenolone300|300mg
79389475|NCT03872128|Drug|Pregnenolone500|500mg
79706609|NCT05387759|Drug|Placebo|Placebo will be administered orally.
79706610|NCT05387759|Drug|Moxifloxacin|Moxifloxacin capsule will be administered orally.
79706611|NCT05380921|Device|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
79706612|NCT05380921|Device|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
79706613|NCT05380180|Other|OneClick Social Engagement Intervention|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.
79847208|NCT04078607|Behavioral|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
80015366|NCT03538223|Other|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
80015367|NCT03538223|Radiation|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
79389476|NCT03872128|Drug|Placebo|placebo
79847209|NCT04078607|Behavioral|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
79251056|NCT05131724|Other|Treadmill training with virtual reality|The virtual environment will be composed of obstacles, different paths, and narrow and deviated corridors. Walking through this environment will require the infant to coordinate walking behaviour and adjust the length, height, and width of steps to negotiate the obstacles on the television screen placed at the infant's eye level in front of the treadmill. The speed, orientation, size, frequency of appearance, and shape of the obstacles will be manipulated according to individual performance following a standardized protocol. The virtual system will provide visual and auditory feedback on the success or failure of the activity to enhance motor learning. In addition, the characteristics of the environment (e.g., visibility, configuration, and distractions) will be adjusted to increase the complexity of the training.
79251057|NCT05131724|Other|Treadmill training|The RAM870A of the Medisoft treadmill will be used. Two treadmill training sessions will be held before the onset of the intervention to familiarize the children with the equipment. During these two sessions, the treadmill training and speed will be set according to the following procedures: the ground walking speed of each child will be determined through the baseline 6MWT, then the training velocity will be set at 50% of the maximum ground speed established during the 6MWT and increased gradually based on the tolerance of each child (i.e., no complaint of fatigue, heart rate not exceeding 70% of the maximum heart rate, and a lack of gait shuffling, buckling or dragging steps more than 5 seconds during walking).
79251058|NCT02037451|Procedure|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
79251059|NCT02469675|Device|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
79251060|NCT02469675|Device|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
79251061|NCT02469675|Device|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
79251062|NCT04365777|Other|OAA/S=5|Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
79389477|NCT03869190|Drug|Atezolizumab|"For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
79545413|NCT01530802|Procedure|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
79545414|NCT01530815|Drug|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
79706614|NCT05380180|Other|OneClick Social Engagement Intervention Extension|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
79710191|NCT00597792|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
79847210|NCT05198505|Drug|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
79847211|NCT04078841|Dietary Supplement|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
79847212|NCT04078841|Other|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
79847213|NCT03742869|Combination Product|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
79389478|NCT03869190|Drug|Enfortumab Vedotin|Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
79389479|NCT03869190|Drug|Niraparib|Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
79389480|NCT03869190|Drug|Magrolimab (Hu5F9-G4)|Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
79389481|NCT03869190|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
79847214|NCT02583191|Drug|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
79706615|NCT05379556|Diagnostic Test|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
79847215|NCT02583191|Drug|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~Enoxaparin 1 mg/kg BW twice daily~Tinzaparin 175 I.E./kg BW once daily~Dalteparin 200 I.E./kg BW once daily"
79847216|NCT04000893|Other|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
79847217|NCT04078217|Device|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
80015368|NCT04474340|Drug|COVID-19 Convalscent Plasma|The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
79251063|NCT04365777|Other|OAA/S=3|Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
79251064|NCT04365777|Other|OAA/S=1|Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
79251065|NCT05096078|Other|Diet|Special diet program for gestational diabetes
79251066|NCT05096078|Other|Exercise|The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
79545415|NCT01530841|Device|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
79545416|NCT01530893|Dietary Supplement|Flavanone - supplement|acute single optimal dose
79545417|NCT01530893|Other|Flavanone - food|acute single dose
79545418|NCT01530893|Other|Flavanone - placebo|acute single dose (flavanone free)
79545419|NCT01530893|Dietary Supplement|Isoflavone - supplement|acute single optimal dose
79710192|NCT00597948|Behavioral|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
79847218|NCT04078217|Other|Booklet|Home-based exercise program using a paper booklet (not the technology).
79847219|NCT02582723|Other|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
79251067|NCT02052271|Device|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
79251068|NCT04280276|Diagnostic Test|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
79251069|NCT03561571|Other|butter based breakfast|ingestion of proteins : 5 g, lipids 20 g, glucides 57 g
79251070|NCT03561571|Other|Chocolate spread based breakfast|ingestion of proteins 7 g, lipids 20 g, glucides 56 g
79545420|NCT01530893|Other|Isoflavone - food|acute single optimal dose
79545421|NCT01530893|Other|Isoflavone - placebo|acute single dose (isoflavone free)
79545422|NCT01530893|Dietary Supplement|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
79545423|NCT01530893|Dietary Supplement|Flavan-3-ol - supplement|acute single optimal dose
79545424|NCT01530893|Other|Flavan-3-ol - food|acute single optimal dose
79545425|NCT01530893|Other|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
79545426|NCT01530893|Dietary Supplement|Anthocyanin - supplement|acute single optimal dose
79545427|NCT01530893|Other|Anthocyanin - food|acute single optimal dose
79545428|NCT01530893|Other|Anthocyanin - placebo|acute single dose (anthocyanin free)
79545429|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
79545430|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
79545431|NCT01530919|Procedure|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
79545432|NCT01530958|Behavioral|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~identify patients with CKD~notify PCPs of a patients' CKD status~provide PCP outreach with NKDEP guidelines and patient educational materials"
79706616|NCT05379556|Diagnostic Test|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
79847220|NCT02582723|Other|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
79847221|NCT02582723|Other|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
79847222|NCT05347329|Dietary Supplement|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
79847223|NCT02582567|Other|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
79251071|NCT02723175|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
79251072|NCT02052349|Drug|ABT-333|Dose of ABT-333
79847224|NCT05347017|Procedure|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
79847225|NCT05347017|Procedure|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
79847226|NCT04403009|Other|no intervention|no intervention
79251073|NCT05058326|Diagnostic Test|Portable endoanal manometry|Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
80015369|NCT05108350|Drug|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
80015370|NCT05108350|Drug|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
80015371|NCT05108350|Drug|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
80015372|NCT05108350|Drug|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
79545433|NCT01530958|Behavioral|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
80015373|NCT05108272|Procedure|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
80015374|NCT05108272|Procedure|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
79251074|NCT05058326|Diagnostic Test|Endoanal ultrasound|To assess the integrity of the anal canal.
79251075|NCT05058326|Other|Incontinence severity scale questionaires|Wexner and St. Mark's scales.
79251076|NCT02051413|Drug|Venlafaxine extended release|antidepressant drug
79545434|NCT01530958|Behavioral|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
79545435|NCT01530971|Drug|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
79706617|NCT05379556|Diagnostic Test|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
79706618|NCT05379556|Diagnostic Test|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
79706619|NCT05377827|Biological|WU-CART-007|Provided by Miltenyi Biotec
79706620|NCT05373186|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
79706621|NCT05373186|Drug|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
79706622|NCT05373186|Drug|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
79706623|NCT05366010|Device|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
79706624|NCT05361746|Device|Scotchbond Universal Plus Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
79706625|NCT05361746|Device|Scotchbond Universal Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
79706626|NCT05349227|Behavioral|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
79706627|NCT05349227|Device|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
79706628|NCT05337007|Other|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
79706629|NCT05337007|Other|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
79847227|NCT00998907|Device|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
79847228|NCT00998907|Device|PDS II|polyglactin 910 suture material for abdominal wall closure
79847229|NCT03084237|Biological|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
79251077|NCT05305976|Other|Telerehabilitation|The 8 week exercise program with telerehabilitation
79251078|NCT02470767|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
79251079|NCT02477241|Procedure|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
79251080|NCT02477241|Device|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
79251081|NCT02049541|Drug|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
79251082|NCT02049541|Biological|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
79251083|NCT02049541|Other|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
79389482|NCT03869190|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
79389483|NCT03869190|Drug|Tocilizumab|Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
79389484|NCT03869190|Drug|Cisplatin|Cisplatin will be administered at a dose of 70mg/m^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
79545436|NCT01530984|Drug|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
79545437|NCT01530984|Drug|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
79545438|NCT01531010|Device|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
79545439|NCT01531036|Device|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
79545440|NCT01531049|Drug|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
79706630|NCT05321758|Biological|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
79706631|NCT05321758|Drug|Immunosuppressive Agents|hormones, azathioprine, thalidomide
79706632|NCT05321745|Other|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
79706633|NCT05314933|Drug|2-Deoxyglucose|Intranasal administration
79706634|NCT05314933|Other|Placebo|Intranasal administration
79847230|NCT03084237|Biological|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
79847231|NCT03084237|Drug|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
79847232|NCT02584907|Other|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
79847233|NCT04615715|Behavioral|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
79847234|NCT04615715|Behavioral|Stress Reduction Messaging|Stress Reduction Messaging
79389485|NCT03869190|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000mg/m^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
79389486|NCT03867201|Biological|Erenumab|Administered by pre-filled syringe
79847235|NCT00996021|Drug|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
79847236|NCT00996021|Drug|Placebo Suspension|Placebo is a liquid with no drug in it.
79847237|NCT00996021|Drug|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
79706635|NCT05309187|Biological|IO-202|IO-202 given as monotherapy
79706636|NCT05309187|Biological|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
79706637|NCT05309187|Biological|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
79706638|NCT05306743|Other|CONQUEST Quality Improvement Program|"CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations."
79706639|NCT05300425|Other|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
79706640|NCT05300425|Other|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
79706641|NCT05289544|Behavioral|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
79706642|NCT05276622|Other|Comprehensive Geriatric Assessment|"A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)"
79706643|NCT05276622|Other|Qualitative patient-care partner interviews|Semi-structured Interviews: Baseline and again at 3 months.
79706644|NCT05276622|Other|Surveys on well-being and function|Care partner's Surveys on well-being and function: Baseline and again at 3 months
79545441|NCT01531049|Drug|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
79706645|NCT05262595|Drug|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
79706646|NCT05262595|Drug|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
79706647|NCT05262595|Drug|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
79706648|NCT05262595|Drug|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
79706649|NCT05260424|Other|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
79706650|NCT05260047|Behavioral|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
79847238|NCT00996099|Device|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
79847239|NCT00996099|Other|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
79847240|NCT02582645|Procedure|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
79545442|NCT01531049|Drug|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
79545443|NCT01531049|Other|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
79389487|NCT03867201|Other|Placebo|Administered by pre-filled syringe
79389488|NCT03851237|Drug|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
79389489|NCT03851237|Device|PET/CT|-Standard of care
79545444|NCT01531062|Drug|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
79545445|NCT01531062|Dietary Supplement|black sticky rice|300 mg capsule bid, 56 days
79545446|NCT01531075|Biological|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
79389490|NCT03842033|Behavioral|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
79706651|NCT05260047|Behavioral|Telehealth MAT|Describe what is the Telehealth MAT briefly
79706652|NCT05260047|Behavioral|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
79706653|NCT05250258|Other|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
79706654|NCT05248659|Drug|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
79706655|NCT05248646|Drug|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
79706656|NCT05248646|Drug|Placebo|Placebo s.c. q 4 weeks
79251084|NCT02049541|Other|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
79706657|NCT05248204|Device|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
79706658|NCT05248204|Device|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
79706659|NCT05223010|Drug|Melatonin 5 MG/15 ML Oral Solution 0.05 mg/kg|will be administered 1 hour before arrival to operating room
79706660|NCT05223010|Drug|Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg|will be administered 1 hour before arrival to operating room
79706661|NCT05223010|Drug|Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg|will be administered 1 hour before arrival to operating room
79706662|NCT05223010|Drug|Sevoflurane|for anaesthesia induction 3-8 MAC
79847241|NCT02582645|Procedure|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
79251086|NCT05026112|Diagnostic Test|ECG-Imaging|ECG imaging acquisition
79251087|NCT05026112|Diagnostic Test|Cardiac MRI scan|Cardiac MRI scan
79251088|NCT02052427|Device|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
79251089|NCT02052427|Device|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (<1mL) of autologous blood
79251090|NCT02470611|Drug|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% sodium alendronate gel
79251091|NCT02470611|Other|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% placebo gel
79251092|NCT02049619|Device|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
79251093|NCT02470689|Drug|Diacerin cream|Diacerin tablet solubule in ultraphil cream
79251094|NCT05305898|Drug|Metformin|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
79251095|NCT02049697|Drug|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
79389491|NCT03842033|Behavioral|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
79545447|NCT01531075|Biological|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
79545448|NCT01531088|Behavioral|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
79545449|NCT01531101|Behavioral|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
79545450|NCT01531114|Drug|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
79545451|NCT01531114|Drug|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
79545452|NCT01531140|Drug|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
79545453|NCT01531140|Drug|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
79545454|NCT01531140|Drug|Sennosides|Sennosides 1tbl/8kg for 2 days
79545455|NCT01531166|Drug|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
79545456|NCT01531179|Drug|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
79545457|NCT01531179|Drug|Placebo|Placebo for 3 months
79706663|NCT05208112|Drug|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
79706664|NCT05203471|Other|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
79706665|NCT05181592|Drug|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
79706666|NCT05180032|Drug|Romoszumab|Monthly SQ injections
79706667|NCT05180032|Drug|Denosumab|2 injections 6 months apart SQ
79706668|NCT05180032|Drug|Placebo|Monthly Placebo Injections
79847242|NCT02584751|Drug|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
79706669|NCT05178706|Other|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
79706670|NCT05178706|Diagnostic Test|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
79251096|NCT03561493|Other|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
79706671|NCT05178589|Device|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
79706672|NCT05178589|Device|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
79706673|NCT05169554|Drug|Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.|Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
79706674|NCT05169554|Drug|Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.|"On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily."
79706675|NCT05161390|Drug|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
79706676|NCT05156320|Drug|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
79706677|NCT05156320|Drug|Placebo|Placebo will be administered every 4 weeks by intravenous (IV) infusion.
79706678|NCT05154994|Drug|Belinostat|Given IV
79706679|NCT05154994|Biological|Durvalumab|Given IV
79389492|NCT03842033|Behavioral|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
79545458|NCT01531192|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
79545459|NCT01531192|Drug|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
79251097|NCT05005676|Diagnostic Test|acceleromyography|Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
79389493|NCT03834168|Other|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
79545460|NCT01531218|Drug|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
79545461|NCT01531218|Drug|Placebo|
79545462|NCT01531244|Biological|dactinomycin|Given via ILI
79391784|NCT02552368|Device|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
79391785|NCT02401152|Other|Sports drink 1|Sports drink with a specific source of CHO.
79545463|NCT01531244|Drug|melphalan|Given via ILI
79545464|NCT01531244|Biological|Conditionally replicative adenovirus 3/5-delta|Given via ILI
79545465|NCT01531283|Drug|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
79545466|NCT01531283|Drug|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
79545467|NCT01531283|Drug|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
79545468|NCT01531283|Drug|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
79706680|NCT05152342|Behavioral|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
79706681|NCT05152342|Behavioral|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
79389494|NCT03824158|Behavioral|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
79847243|NCT02584751|Device|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
79847244|NCT02584751|Procedure|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
79847245|NCT02584751|Procedure|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
79847246|NCT02584751|Procedure|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
79251098|NCT02052505|Procedure|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
79389495|NCT03824158|Behavioral|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
79545469|NCT01531309|Drug|AGO178|AGO178 is administered as a sublingual tablet.
79545470|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
79545471|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
79545472|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
79545473|NCT01531348|Other|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
79847247|NCT02584751|Procedure|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
79847248|NCT02584751|Procedure|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
79847249|NCT00999219|Drug|FK199B|oral
79251099|NCT02469831|Drug|Rocuronium|
79251100|NCT05305742|Other|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
79251101|NCT02049775|Procedure|NBI|
79545474|NCT01531361|Drug|Crizotinib|Given PO
79545475|NCT01531361|Other|Laboratory Biomarker Analysis|Correlative studies
79251102|NCT02469909|Other|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
79251103|NCT02469909|Other|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
79389496|NCT03813654|Behavioral|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
79545476|NCT01531361|Other|Pharmacological Study|Correlative studies
79545477|NCT01531361|Drug|Sorafenib Tosylate|Given PO
79545478|NCT01531361|Drug|Vemurafenib|Given PO
79545479|NCT01531400|Other|self-selected music|Investigators played self-selected background music in the music group
79706682|NCT05138003|Diagnostic Test|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
79706683|NCT05138003|Diagnostic Test|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
79710193|NCT02892006|Behavioral|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
79710194|NCT00598104|Drug|QAX576|
79847250|NCT00999219|Drug|Zolpidem|oral
79847251|NCT00996177|Drug|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
79847252|NCT00996177|Drug|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
79847253|NCT04079933|Other|Oral tobacco-derived nicotine product (OTDN)|
79847254|NCT02584595|Device|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
79847255|NCT00996255|Drug|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
79706684|NCT05138003|Diagnostic Test|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate > 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
79706685|NCT05138003|Diagnostic Test|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
79847256|NCT04080089|Combination Product|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
79251104|NCT02469909|Other|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
79251105|NCT02469909|Procedure|immediate decannulation|the tracheostomy tube is removed at once
79389497|NCT03813654|Behavioral|8-h Free Sleep|8 consecutive hours time in bed at any time.
79847257|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
79251106|NCT02469909|Procedure|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
79389498|NCT03811561|Drug|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
79389499|NCT03811561|Drug|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
79389500|NCT03807765|Drug|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
79545480|NCT01531413|Other|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
79545481|NCT01531426|Device|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
79706686|NCT05130047|Drug|Aldafermin|1 mg solution
79706687|NCT05130047|Drug|Placebo|Aldafermin placebo solution
79251107|NCT04999904|Other|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
79251108|NCT04999904|Other|Standard of Care Physical Therapy|Standard of Care Physical Therapy
79251109|NCT02049853|Device|"NTproBNP measurement with point of care device Cobash232 in the POCT group"|
79391786|NCT02401152|Other|Sports drink 2|Sports drink with a specific source of CHO
79391787|NCT02401152|Other|Placebo|iso-caloric sports drink with maltodextrin as CHO source
79391788|NCT02407314|Procedure|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
79545482|NCT01531452|Drug|Oxaliplatin|130mg/m2 d1,repeated q21d
79545483|NCT01531452|Drug|s1|80mg/m2/d, d1-14,repeated q21d
79545484|NCT01531465|Other|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
79706688|NCT05127616|Behavioral|Minimal Contact-Cognitive Behavior Therapy|This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.
79706689|NCT05127616|Behavioral|Patient Education/Support|This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
79706690|NCT05121558|Other|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
79706691|NCT05121558|Other|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN) , how yoga may help with CIPN, and how different therapies may help with CIPN.
79706692|NCT05121558|Other|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive a voucher for sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
79251110|NCT04985084|Behavioral|The intervention group|The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
79251111|NCT04985084|Other|Usual care|General dietary advice provided as routine by the ward nurses before discharge from the hospital.
79251112|NCT04211246|Procedure|Titration of fraction of inspired oxygen (FiO2) guided by SpO2|Titration of fraction of inspired oxygen (FiO2) guided by SpO2
79706693|NCT05113563|Device|Transcranial Electric Stimulation Therapy|TEST is a form of brain stimulation.
79706694|NCT05112952|Drug|Lazertinib|Lazertinib tablet will be administered orally.
79706695|NCT05106426|Behavioral|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
80015375|NCT04596449|Other|study intervention|"The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator."
79251113|NCT04211246|Procedure|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
80015376|NCT00859430|Drug|Levetiracetam|1000 mg Tablet
80015377|NCT00859430|Drug|Keppra®|1000 mg Tablet
80015378|NCT04240483|Other|Intracutaneous sterile water injections (ISWI) group|ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
79251114|NCT02995005|Drug|Tenofovir Disoproxil Fumarate|300 mg daily
79251115|NCT05305274|Other|screening|This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.
79251116|NCT02052817|Device|Optimal Medical Therapy Debridement + Toad Brace|
79251117|NCT02052817|Other|Optimal Medical Therapy - Debridement|
79251118|NCT04182386|Procedure|Portal vein embolization|Selective preoperative portal vein embolization
79706696|NCT05106426|Behavioral|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
79706697|NCT05101356|Biological|Antineoplastic Vaccine|Given LabVax 3(22)-23 ID
79706698|NCT05101356|Biological|Sargramostim|Given SC
79706699|NCT05101356|Biological|Pembrolizumab|Given IV per standard of care
79706700|NCT05101018|Drug|Romosozumab|Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
79706701|NCT05101018|Drug|Denosumab|Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
79251119|NCT03561415|Other|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
79251120|NCT03561415|Other|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
79251121|NCT02477007|Drug|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
79251122|NCT02477007|Drug|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
79706702|NCT05088876|Drug|Placebo|Blinded withdrawal of regular co-medication with paracetamol
79706703|NCT05088876|Drug|Paracetamol|Paracetamol in the dose already used
79706704|NCT05074186|Device|neurological thrombectomy device is an investigational device.|Revascularization device is an investigational device.
79706705|NCT05070767|Device|Neurolens spectacle lens|spectacle lens
79706706|NCT05070767|Device|Placebo spectacle lens|spectacle lens for refractive error correction
79706707|NCT05059158|Radiation|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
79706708|NCT05054348|Biological|IO-108|IO-108 given as monotherapy
79706709|NCT05054348|Biological|IO-108 + pembrolizumab combination therapy|IO-108 and fixed dose pembrolizumab combination therapy
79847258|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
79847259|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
80015379|NCT04240483|Other|Intracutaneous dry injections (IDI) group|Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
80015380|NCT05212285|Device|Inbody 570|Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up
79847260|NCT02582801|Drug|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
79706710|NCT05054348|Biological|IO-108 + cemiplimab combination therapy|IO-108 and fixed dose cemiplimab combination therapy
79706711|NCT05046431|Drug|BAT2506|50mg/0.5mL
80015381|NCT05212285|Device|JAMAR Dynamometer|Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up
80015382|NCT05212285|Radiation|CT scan|Chest and abdominal CT scan during each follow-up
80015383|NCT00959114|Biological|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
79251123|NCT02477007|Drug|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
79251124|NCT02477007|Drug|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
79251125|NCT04173182|Diagnostic Test|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
79389501|NCT03807765|Radiation|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
80015384|NCT00959114|Biological|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
80015385|NCT00857090|Drug|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
80015386|NCT00857090|Drug|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
79389502|NCT03800693|Drug|Fluorouracil|Given IV
79706712|NCT05046431|Drug|EU Simponi|50mg/0.5mL
79706713|NCT05039671|Behavioral|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
79706714|NCT05039164|Behavioral|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
80015387|NCT04182919|Drug|Phlai|Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
79710195|NCT00598104|Drug|Placebo|
79847261|NCT05388695|Biological|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
79847262|NCT04078451|Procedure|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
79847263|NCT00583115|Drug|Gleevec|260 mg/M2/day, given once daily by mouth
79847264|NCT04079075|Other|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
80015388|NCT04182919|Drug|Placebo oral capsule|Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
80015389|NCT00856934|Biological|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
80015390|NCT00856934|Biological|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
80015391|NCT00856934|Other|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
80015392|NCT05212051|Biological|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
80015393|NCT05212051|Biological|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
80015394|NCT00855764|Drug|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
80015395|NCT00959036|Drug|ATN-103|10 mg every 4 weeks until week 12
79706715|NCT05039164|Behavioral|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
79706716|NCT05039164|Behavioral|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
79706717|NCT05039164|Behavioral|Initial Training (CC)|School personnel will participate in an initial live remote training.
79706718|NCT05039164|Behavioral|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
79706719|NCT05039164|Behavioral|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
79706721|NCT05001347|Drug|TJ004309|Antibody to CD73
79251126|NCT02052973|Other|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
79251127|NCT02477085|Other|all women with an induced labor|all women who have an induced labor
79389503|NCT03800693|Drug|Leucovorin|Given IV
79389504|NCT03800693|Drug|Oxaliplatin|Given IV
79545485|NCT01531465|Other|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
79706722|NCT04996654|Behavioral|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
79706723|NCT04996654|Behavioral|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
79706724|NCT04996433|Behavioral|inpatient CBASP individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
79706725|NCT04996433|Behavioral|inpatient CBASP group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
79389505|NCT03798145|Procedure|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
79389506|NCT03784248|Other|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
79706726|NCT04996433|Behavioral|inpatient CBASP nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
79847265|NCT04079075|Behavioral|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
80015396|NCT00959036|Drug|ATN-103|10 mg every 8 weeks until week 12
80015397|NCT00959036|Drug|ATN-103|30 mg every 4 weeks until week 12
79251128|NCT02053519|Drug|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
79251129|NCT02053519|Drug|Mygliol Oil|Matched placebo comparator
79389507|NCT03760744|Procedure|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
79545486|NCT01531478|Other|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
79545487|NCT01531491|Procedure|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
79251130|NCT02053597|Drug|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
79251131|NCT02053597|Drug|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
79251132|NCT02801617|Drug|PRO-067|1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
79706727|NCT04996433|Behavioral|inpatient CBASP exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
79706728|NCT04996433|Behavioral|outpatient CBASP group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
79251133|NCT02801617|Drug|GAAP Ofteno®|1 drop QD during 30 days Active comparator, reference medication.
79251134|NCT02056015|Drug|[68Ga]MLN6907|IV Administration of [68Ga]MLN6907 on Day 1
79251135|NCT02056093|Device|PSV mode|Application of PSV in all patients
79706729|NCT04996433|Behavioral|inpatient BA individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
79545488|NCT01531491|Procedure|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
79706730|NCT04996433|Behavioral|inpatient BA group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
79251136|NCT02056093|Device|PAV mode|Application of PAV mode in all patients
79251137|NCT02056093|Device|NAVA|
79706731|NCT04996433|Behavioral|inpatient BA nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
79706732|NCT04996433|Behavioral|inpatient BA exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
79251138|NCT02056249|Other|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
79251139|NCT02056327|Device|A novel monitoring suite of sensors will be inserted into the standard oral device.|
79847266|NCT04079075|Behavioral|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
79251140|NCT04140968|Drug|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
79545489|NCT01531504|Device|ViKY UP|laparoscopic-assisted hysterectomy procedure
79545490|NCT01531517|Drug|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~Assessment of the patient for inclusion/exclusion criteria~Informed consent process~Medical history of the patient~Blood withdrawn for investigation~Drainage of the ulcer if there is a collection~Revascularization as needed and indicated by APSV done at visit 0.~Swab from the ulcer for culture and micro-organism count: on detailed visits only.~Debridement as needed.~Dressing:~Inspection and assessment of the ulcer~Irrigation using 500 ml of saline or as required.~Drying of the ulcer (leave to dry)~Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~Fix the dressing to the ulcer"
79706733|NCT04996433|Behavioral|outpatient BA group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
79706734|NCT04996433|Drug|algorithm-based study medication|"All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~1st line dose escalation (if appropriate)~2nd line lithium augmentation~3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~4th line change of antidepressant."
79847267|NCT04079075|Behavioral|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
79847268|NCT04079075|Diagnostic Test|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
79251141|NCT05042804|Other|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
79251142|NCT02896556|Device|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
79251143|NCT04383938|Drug|APR-246 (eprenetapopt) + Pembrolizumab|APR-246 D1-4 + Pembrolizumab D3
79251144|NCT04933760|Diagnostic Test|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
79251145|NCT01334515|Biological|hu14.18-IL2 fusion protein|Given IV
79251146|NCT01334515|Drug|isotretinoin|Given PO
79251147|NCT01334515|Biological|sargramostim|Given SC
79251148|NCT01334515|Other|laboratory biomarker analysis|Correlative studies
79251149|NCT02802319|Device|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
79251150|NCT02802319|Device|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
79251151|NCT02053129|Other|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
79251152|NCT02053129|Other|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
79251153|NCT02415400|Drug|Apixaban|
79251154|NCT02415400|Drug|vitamin K antagonist|
79251155|NCT02415400|Drug|Acetylsalicylic acid|
79251156|NCT02415400|Other|Acetylsalicylic acid placebo|
79251157|NCT02053675|Drug|Vasopressin infusion|
79847269|NCT05370443|Behavioral|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
79847270|NCT02582411|Device|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
79251158|NCT02037997|Drug|docetaxel|docetaxel 75mg/m2 ivgtt D1
79706735|NCT04966169|Device|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
79847271|NCT02582411|Device|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
79847272|NCT00532779|Drug|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
79706736|NCT04957082|Behavioral|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
80015398|NCT00959036|Drug|ATN-103|80 mg every 4 weeks until week 12
79251159|NCT02037997|Drug|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
79706737|NCT04957082|Behavioral|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
79847273|NCT00532779|Drug|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
79251160|NCT02037997|Drug|Erlotinib|Erlotinib 150mg qd
79251161|NCT02056405|Drug|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
79251162|NCT02056405|Drug|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
79251163|NCT02056483|Other|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
79389508|NCT03760744|Procedure|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
79545491|NCT01531517|Drug|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~Assessment of the patient for inclusion/exclusion criteria~Informed consent process~Medical history of the patient~Blood withdrawn for investigation~Drainage of the ulcer if there is a collection~Revascularization as needed and indicated by APSV done at visit 0.~Swab from the ulcer for culture and micro-organism count: on detailed visits only.~Debridement as needed.~Dressing:~Inspection and assessment of the ulcer~Irrigation using 500 ml of saline or as required.~Drying of the ulcer (leave to dry)~Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~Fix the dressing to the ulcer"
79847274|NCT00532779|Drug|Placebo|
79847275|NCT00532779|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
79545492|NCT01531530|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
79847276|NCT02583737|Procedure|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
79389509|NCT03740698|Device|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
79545493|NCT01531530|Other|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
79706738|NCT04949958|Other|Exercise Based Manual (Supervised)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
79847277|NCT02583737|Procedure|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
79847278|NCT04489355|Procedure|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
80015399|NCT00959036|Drug|ATN-103|80 mg every 8 weeks until week 12
80015400|NCT00959036|Drug|Placebo|Placebo every 4 weeks
80015401|NCT00959036|Drug|Methotrexate|
80015402|NCT04129723|Other|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
79706739|NCT04949958|Other|Exercise Based Manual (Home Based)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
80015403|NCT03628729|Other|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
79706740|NCT04949958|Other|Control|General advice to be active
79706741|NCT04940650|Diagnostic Test|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
79706742|NCT04940650|Diagnostic Test|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
79706743|NCT04932421|Behavioral|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
79706744|NCT04932421|Other|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
80015404|NCT03628729|Other|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
80015405|NCT03619759|Drug|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
80015406|NCT04474262|Biological|Albumin|Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
80015407|NCT04474262|Drug|Midodrine Oral Tablet|Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
80015408|NCT04474262|Other|Placebo|Placebo
80015409|NCT05211817|Behavioral|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
80015410|NCT05211817|Dietary Supplement|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
79251164|NCT05655637|Other|Exercise|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
79545494|NCT01531543|Device|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
79545495|NCT01531569|Other|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
79545496|NCT01531595|Drug|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
79545497|NCT01531621|Other|Biomarker sampling|Blood samples every 8-12 weeks
79251165|NCT02053207|Behavioral|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
79251166|NCT02056717|Drug|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
79545498|NCT01531634|Behavioral|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
79706745|NCT04929236|Drug|Panzyga|PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
80015411|NCT04418648|Drug|Toripalimab|Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
79706746|NCT04921631|Behavioral|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
79706747|NCT04914429|Drug|Guselkumab|Guselkumab 100 mg will be administered as a SC injection.
79706748|NCT04914429|Drug|Placebo|Matching placebo will be administered as a SC injection.
79706749|NCT04910139|Device|Soniflow System|Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
79706750|NCT04897945|Behavioral|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
79706751|NCT04886856|Behavioral|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
80015412|NCT03628183|Other|Hydrolysate Infant Formula 1|Feed ad lib
79545499|NCT01531647|Drug|danoprevir|100 mg q12h Days 8-21
79706752|NCT04886856|Behavioral|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
79706753|NCT04879368|Drug|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
79706754|NCT04879368|Biological|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
79251167|NCT02056717|Drug|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
79706755|NCT04879368|Drug|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
79706756|NCT04879368|Drug|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
79710196|NCT02891928|Device|Rocker sole shoes|Measure of walk testing Measure of standing position
79710197|NCT02891928|Device|Normal shoes|Measure of walk testing Measure of standing position
79545500|NCT01531647|Drug|raltegravir|400 mg q12h Days 1-4 and 18-21
79251168|NCT04194801|Drug|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
79389510|NCT03740698|Device|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
79389511|NCT03736863|Drug|Apatinib+ SHR-1210（Camrelizumab）|Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
79545501|NCT01531647|Drug|ritonavir|100 mg q12h Days 8-21
79545502|NCT01531660|Behavioral|step-up jogging program|
79545503|NCT01531686|Procedure|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
79545504|NCT01531712|Drug|Gemcitabine|1000mg/m2 / / 40mg/m2
80015413|NCT03628183|Other|Hydrolysate Infant Formula 2|Feed ad lib
80015414|NCT00781118|Device|Guardian System|There is no intervention in this study. The device is a diagnostic only.
80015415|NCT05211583|Diagnostic Test|Serum progesterone levels|In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
79389512|NCT03736863|Drug|Apatinib+ SHR-1316（Adebrelimab）|Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
79389513|NCT03718533|Drug|Eltrombopag|Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
79391789|NCT02407314|Device|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
79545505|NCT01531712|Radiation|Radiotherapy|50.4 Gy
79545506|NCT01531712|Drug|Tarceva|100mg/day
79545507|NCT01531712|Drug|Oxaliplatin|100mg/m2 (only in QT)
80015416|NCT04031599|Device|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
80015417|NCT04031599|Device|Insulin pump|Tandem Diabetes Care
79706757|NCT04879368|Drug|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
79389514|NCT03672695|Combination Product|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
80015418|NCT04031599|Device|Continuous glucose monitoring system|Dexcom G6
79389515|NCT03671928|Other|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
79545508|NCT01531751|Device|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
79251169|NCT04194801|Drug|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
79545509|NCT01531751|Drug|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
79545510|NCT01531764|Drug|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 & 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
79545511|NCT01531777|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
79545512|NCT01531777|Drug|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
79545513|NCT01531790|Drug|Carboplatin|d1, AUC 5, i.v.
79545514|NCT01531790|Drug|Pemetrexed|d1, 500 mg/m2, i.v.
80015419|NCT04031599|Drug|Aspart or Lispro|Aspart or lispro will be infused with the infusion pump
79251170|NCT04194801|Drug|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
79389516|NCT03671928|Other|additional blood sample|for le group control, another blood sample is taken outside the usual care.
80015420|NCT04031599|Other|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
80015421|NCT04031599|Other|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
80015422|NCT04031599|Other|3-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
80015423|NCT04031599|Other|1-hour postprandial exercise (sub-study)|60 minute exercise will be started one hour after the meal time.
79389517|NCT03650114|Biological|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
79545515|NCT01531790|Drug|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
79545516|NCT01531790|Drug|Centrum|1 tablet/day
79545517|NCT01531816|Device|Early Rehabilitation intervention|"Passive mobility: cycle ergometer~Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
79545518|NCT01531829|Drug|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
79545519|NCT01531829|Drug|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
79545520|NCT01531842|Procedure|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
80015424|NCT04031599|Other|2-hour postprandial exercise (sub-study)|60 minute exercise will be started two hours after meal time
79545521|NCT01531855|Other|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
79545522|NCT01531868|Other|Video|Video of physician
79389518|NCT03650114|Biological|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
79389519|NCT03650114|Biological|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
79706758|NCT04879368|Drug|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
79706759|NCT04878757|Behavioral|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
79706760|NCT04876599|Behavioral|IN FOCUS|Adapted Resiliency Group Intervention
79706761|NCT04876599|Behavioral|Usual Care|Referral to Virtual Group Support
79706762|NCT04868604|Drug|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
79706763|NCT04868604|Drug|67Cu-SAR-bisPSMA|67Cu-SAR-bisPSMA
79847279|NCT04078763|Behavioral|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
80015425|NCT04031599|Other|Exercise announcement and meal bolus reduction (sub-study)|Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
80015426|NCT00954590|Drug|Dimebon (latrepirdine)|20 mg orally three times daily
80015427|NCT00954590|Drug|Placebo|Placebo orally three times daily
80015428|NCT02913105|Drug|LMB763|Hard Gelatin Capsules
80015429|NCT02913105|Drug|Placebo|Hard Gelatin Capsule
80015430|NCT04724759|Drug|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
80015431|NCT00771446|Biological|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
80015432|NCT00771446|Other|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
80015433|NCT05186467|Drug|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
80015434|NCT05186467|Drug|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
79389520|NCT03650114|Biological|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
79389521|NCT03650114|Biological|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
79389522|NCT03650114|Biological|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
79545523|NCT01531868|Other|Video|Video of physician
79545524|NCT01531868|Other|Video|Video of physician
79545525|NCT01531868|Other|Video|Video of physician
79545526|NCT01531868|Other|Video|Video of physician
79710198|NCT04207632|Drug|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
79710199|NCT00598260|Procedure|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
79710200|NCT00598338|Drug|Prucalopride|4 mg o.d.
79710201|NCT00598338|Other|Placebo|o.d.
79389523|NCT03642067|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
79389524|NCT03642067|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
79389525|NCT03642067|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
79389526|NCT03642067|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
79389527|NCT03611335|Behavioral|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
79389528|NCT03575611|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79545527|NCT01531868|Other|Video|Video of physician
79545528|NCT01531907|Other|Study visit procedures|"Anthropometric measurements to include:~Weight, height, and BMI.~Waist and hip circumference~Triceps skinfold thickness~Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
79710202|NCT04326348|Drug|TQ05105|TQ05105 is a JAK2 inhibitor.
79710203|NCT00598416|Behavioral|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
79847280|NCT04078763|Behavioral|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
79847281|NCT04078763|Behavioral|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
79847282|NCT04078763|Behavioral|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
79847283|NCT04078763|Behavioral|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
79847284|NCT04001673|Behavioral|Pharmacist's intervention|Information about bDMARDs management.
80015435|NCT00771134|Drug|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
79545529|NCT01531920|Drug|alcohol + placebo|Part A alcohol + placebo
80015436|NCT00771134|Drug|Placebo|B.I.D. for 8 weeks
80015437|NCT00771134|Drug|Quetiapine|300mg/day for 8 weeks
79251171|NCT02056795|Device|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
79545530|NCT01531920|Drug|alcohol + perampanel|Part A: alcohol + perampanel
79251172|NCT02056795|Device|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
79251173|NCT02802865|Drug|Clomiphene|
79545531|NCT01531920|Drug|perampanel + alcohol|Part B: perampanel + alcohol
79251174|NCT02802865|Drug|Letrozole|
79251175|NCT02414932|Drug|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
79545532|NCT01531920|Drug|placebo + alcohol|Part B: placebo + alcohol
79545533|NCT01531933|Drug|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
79545534|NCT01531933|Drug|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
79706764|NCT04867798|Drug|Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet|PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels <1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
79710204|NCT00598572|Drug|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
80015438|NCT00768482|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
80015439|NCT00768482|Drug|Sublingual Buprenorphine|16 mg/day, QD
80015440|NCT00766688|Drug|AVE5530|"one tablet in the evening with dinner~in addition to high doses of statin treatment"
80015441|NCT00766688|Drug|Placebo|"one tablet in the evening with dinner~in addition to high doses of statin treatment"
80015442|NCT00840866|Drug|cefprozil|500 mg Tablet
80015443|NCT00840866|Drug|Cefzil®|500 mg Tablet
79251176|NCT02414932|Drug|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
79251177|NCT02476929|Device|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
79251178|NCT02476929|Device|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
79251179|NCT02038387|Behavioral|normocaloric low cholesterol diet|
79847285|NCT00500266|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
79706765|NCT04867122|Behavioral|Problem-Solving Therapy|Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.
79706766|NCT04867122|Other|Attention-matched Control|"Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team."
79706767|NCT04867122|Other|In-depth interviews|The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.
79710205|NCT04326426|Drug|Tradipitant|Neurokinin-1 antagonist
79710206|NCT04326426|Drug|Placebo|Matching placebo
79847286|NCT00996411|Drug|Salvinorin A|This is an initial dose ranging study
79251180|NCT02056951|Procedure|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~health education~exercise therapy~back school~physical treatments~psychological interventions in groups and individual counselling~rehabilitation/social counselling."
79251181|NCT02056951|Procedure|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~education about low back pain~behavioural exercise therapy~coping with pain~relaxation~work related informations"
79847287|NCT00996567|Drug|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
79847288|NCT02583581|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
79847289|NCT02583581|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
79251182|NCT02057029|Behavioral|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
79847290|NCT02852655|Drug|MK-3475|
80015444|NCT05106556|Other|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
79251183|NCT02555319|Device|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
79251184|NCT02470533|Radiation|Radiation therapy|6 fractions of 8-9Gy
79251185|NCT02470533|Device|chemoembolization|Up to 4 sessions
79251186|NCT02053987|Other|Intensive rehabilitation in the home.|
79251187|NCT02054065|Other|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
79251188|NCT02054143|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
79251189|NCT02054143|Drug|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
79251190|NCT05313867|Dietary Supplement|Nutri VX 1|1 sequence of 10 tablets (one intake)
79251191|NCT05313867|Dietary Supplement|Placebo|1 sequence of 10 tablets (one intake)
79389529|NCT03541642|Behavioral|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
79389530|NCT03541642|Behavioral|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
79847291|NCT00500110|Drug|Docetaxel|30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
79847292|NCT00500110|Drug|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
79847293|NCT00500110|Drug|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
79847294|NCT00500110|Drug|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
79389531|NCT03534284|Behavioral|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
79847295|NCT02582333|Other|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
79389532|NCT03534284|Drug|Trazodone|trazodone tablet
79389533|NCT03534284|Drug|Placebo|Inactive pill manufactured to mimic trazodone tablets.
79389534|NCT03534271|Device|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
79389535|NCT03533543|Device|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
79389536|NCT03509012|Drug|Durvalumab|IV (intravenous)
79706768|NCT04858230|Device|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
79389537|NCT03509012|Drug|Tremelimumab|IV
79389538|NCT03509012|Drug|Cisplatin (dose level 4)|IV
79706769|NCT04852224|Drug|Androgen deprivation therapy|Prostate cancer survivors in the ADT+ group will have been prescribed androgen deprivation therapy for a period of 6-months or more by their treating oncologist prior to consent for this study.
79706770|NCT04833114|Drug|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
79251192|NCT02054221|Procedure|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
79847296|NCT05335551|Diagnostic Test|Patients monitored with TruGraf and TRAC Liver testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.
79847297|NCT04358159|Device|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
79847298|NCT04358159|Device|Progrip|Repair of the hernia by a Progrip mesh in onlay position
79389539|NCT03509012|Drug|Cisplatin (dose level 3)|IV
79389540|NCT03509012|Drug|Carboplatin (dose level 1)|IV
79251193|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
79251194|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
79251195|NCT02058667|Radiation|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
79545535|NCT01531946|Procedure|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
79389541|NCT03509012|Drug|Carboplatin (dose level 2)|IV
79389542|NCT03509012|Drug|Etoposide (dose level 1)|IV
79545536|NCT01531972|Drug|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
79706771|NCT04833114|Drug|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
79706772|NCT04833114|Drug|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
79706773|NCT04833114|Drug|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
79389543|NCT03509012|Drug|Etoposide (dose level 2)|IV
79389544|NCT03509012|Drug|Paclitaxel|IV
79389545|NCT03509012|Drug|Pemetrexed|IV
79389546|NCT03509012|Radiation|External beam radiation (dose level 1)|radiation therapy
79389547|NCT03509012|Radiation|External beam radiation (dose level 2)|radiation therapy
79545537|NCT01531972|Drug|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
79847299|NCT03925649|Biological|HB-adMSCs|single infusion of HB-adMSCs
79847300|NCT05304533|Drug|MYK-224|Specified dose on specified days
79847301|NCT05304533|Drug|Itraconazole|Specified dose on specified days
79847302|NCT05304533|Drug|Verapamil|Specified dose on specified days
79847303|NCT00534495|Biological|Rilonacept|2.2 mg/kg subcutaneously
79847304|NCT04077827|Drug|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
79847305|NCT00999375|Behavioral|Education|
79389548|NCT03509012|Radiation|External beam radiation (hyperfractionated)|radiation therapy
79389549|NCT03509012|Drug|Cisplatin (dose level 1)|IV
79389550|NCT03509012|Drug|Cisplatin (dose level 2)|IV
79389551|NCT03509012|Radiation|External beam radiation (standard)|radiation therapy
79389552|NCT03496402|Other|Sampling on blood, bone marrow and cerebrospinal fluid|biological sampling during treatment and follow-up
79389553|NCT03459079|Drug|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
79545538|NCT01532011|Drug|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
79545539|NCT01532011|Drug|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
79847306|NCT00999375|Behavioral|Problem Solving|
79706774|NCT04833114|Drug|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
79847307|NCT00999375|Behavioral|Social Learning|
79847308|NCT00999375|Behavioral|Behavior Modification|
79847309|NCT00996645|Other|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
79847310|NCT00996723|Drug|vandetanib and dasatinib|Two oral investigational agents (vandetanib [VEGFR2, RET, and EGFR inhibitor] and dasatinib [bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
79251196|NCT02470455|Drug|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
79251197|NCT02057263|Drug|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
80015445|NCT05106556|Other|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
80015446|NCT00840632|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
79389554|NCT03459079|Other|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
79251198|NCT02057263|Drug|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
79251199|NCT02057263|Drug|Placebo|Participants will receive 4 doses of placebo during the course of the study.
79251200|NCT02058745|Behavioral|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
79251201|NCT02058745|Behavioral|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
79251202|NCT02058745|Behavioral|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
79251203|NCT05550909|Drug|Artesunate-amodiaquine combination|Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
79251204|NCT05550909|Drug|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
79251205|NCT05550909|Drug|Artemether-lumefantrine|Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
79389555|NCT03444298|Drug|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
79389556|NCT03444298|Drug|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
79389557|NCT03428828|Behavioral|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
79545540|NCT01532024|Other|Microdose of NAP|Delivery of NAP at microdose (<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
79545541|NCT01532037|Other|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
79545542|NCT01532037|Other|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
79545543|NCT01532050|Device|Mandibular Advancement Device ( MAD)|
79545544|NCT01532063|Procedure|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
79545545|NCT01532076|Procedure|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
79706775|NCT04829045|Device|SEIRIN PYONEX Acupuncture Needles|10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
79706776|NCT04829045|Other|PYONEX Placebo|Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
79710207|NCT00598728|Behavioral|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
79847311|NCT00999453|Other|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
79847312|NCT01019122|Radiation|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
79847313|NCT05332587|Drug|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
79847314|NCT04078529|Other|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
79847315|NCT04078529|Other|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
79847316|NCT04078529|Other|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
79706777|NCT04821440|Device|Water displacement volumetry|The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
79706778|NCT04821440|Device|Three dimension volumetry|The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
79706779|NCT04812535|Drug|IFX-1|IFX-1 Monotherapy
79706780|NCT04812535|Drug|IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
79706781|NCT04806516|Device|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~Research Lab Programmer (RLP), Model 4NR010: 1 unit~Research Software Development Kit (RDK), Model 4NR013: 2 units~Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
79706782|NCT04806516|Other|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
79706783|NCT04805320|Procedure|Dental Extraction|Extraction
79847317|NCT00996879|Drug|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
79847318|NCT00996879|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
79847319|NCT02581397|Drug|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
79847320|NCT02581397|Drug|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
79847321|NCT02581397|Drug|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
79847322|NCT02582177|Drug|Candicort®|Apply on the affected area and around it twice a day
79251206|NCT05550909|Drug|Amodiaquine|Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.
79251207|NCT04008615|Other|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
79251208|NCT02054299|Drug|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
79389558|NCT03428828|Behavioral|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
79545546|NCT01532076|Procedure|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
79545547|NCT01532102|Drug|AP611074|
79545548|NCT01532102|Drug|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
79847323|NCT02582177|Drug|Nizoral®|Apply on the affected area and around it twice a day
79847324|NCT02582177|Drug|Baycuten N®|Apply on the affected area and around it twice a day
79847325|NCT02582177|Drug|Canesten®|Apply on the affected area and around it twice a day
79847326|NCT00999531|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
80015447|NCT00840632|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
79251209|NCT02054299|Drug|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
79251210|NCT02054299|Drug|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
79251211|NCT02054299|Drug|Drug application Proguanil|Proguanil: 200mg, single oral application
79251212|NCT02054299|Drug|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
79251213|NCT02054299|Drug|Drug application Thiamine|Thiamine: 200mg, single oral application
79251214|NCT05232591|Diagnostic Test|The teeth diagnosed with chronic apical periodontitis|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
79545549|NCT01532115|Drug|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
79545550|NCT01532115|Drug|Placebo|single-dose
79545551|NCT01532115|Drug|moxifloxacin|400 mg moxifloxacin (single-dose)
79545552|NCT01532154|Drug|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
79706784|NCT04739254|Diagnostic Test|CardioFlux|Magnetocardiography
79706785|NCT04730947|Drug|Dapagliflozin|10 mg orally once a day
79545553|NCT01532180|Device|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
79706786|NCT04730947|Drug|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
79706787|NCT04725331|Biological|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A]; one dose lower and at Recommended Dose for Part B [Phase I, Part B] by intra-tumoral (IT) route.
79545554|NCT01532193|Other|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
79706788|NCT04725331|Drug|Pembrolizumab [KEYTRUDA®]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
79706789|NCT04716725|Drug|68Ga-PSMA-11|Given IV
79847327|NCT00999531|Drug|Placebo|Inhaled Placebo, sterile saline
79251215|NCT02054377|Other|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
79706790|NCT04716725|Procedure|Positron Emission Tomography (PET)|Undergo PET
79706791|NCT04700488|Diagnostic Test|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
79706792|NCT04688255|Behavioral|MSTEP|Aerobic exercise that is advanced weekly
79706793|NCT04688255|Behavioral|Stretching|Stretching exercises that are advanced weekly
79706794|NCT04680468|Drug|Belantamab mafodotin|2.5 mg/kg IV
79251216|NCT03311061|Other|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
79251217|NCT02038231|Behavioral|Parenting Mindfully Program|see Arm Description.
79706795|NCT04673409|Diagnostic Test|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
79706796|NCT04660799|Drug|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m^2 (milligram per square meter).
79706797|NCT04660799|Drug|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
79706798|NCT04660799|Drug|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m^2.
79706799|NCT04660799|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m^2
79545555|NCT01532206|Other|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
79706800|NCT04660799|Drug|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m^2
79706801|NCT04660799|Drug|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m^2
79706802|NCT04660799|Drug|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
79706803|NCT04660799|Drug|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
79847328|NCT00996957|Biological|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
79251218|NCT02038231|Other|Parent Education Program|See Arm Description.
79251219|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
79251220|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
79545556|NCT01532219|Behavioral|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
79545557|NCT01532219|Behavioral|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
79706804|NCT04660799|Drug|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
79706805|NCT04648033|Drug|Atovaquone Oral Suspension|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
79706806|NCT04648033|Drug|Standard of care chemotherapy|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 & 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 & 29.
79706807|NCT04648033|Radiation|Standard of care radiotherapy|Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
79706808|NCT04640779|Drug|Choline Salicylate|Given PO
79706809|NCT04640779|Drug|Selinexor|Given PO
79847329|NCT04099667|Drug|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
79847330|NCT04099667|Drug|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
79847331|NCT04099667|Drug|Phase 2; Placebo|Intramuscular injections on Day 1
79847332|NCT04099667|Drug|Phase 3; MYOBLOC|Intramuscular injections on Day 1
79251221|NCT02058823|Drug|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
79251222|NCT02058823|Drug|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
80015448|NCT00840476|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
79251223|NCT00704535|Drug|Ezetimibe|1 tablet of 10 mg once daily
80015449|NCT00840476|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
80015450|NCT03665103|Other|Laser-assisted ICSI|Laser opening of the zona pellucida.
79251224|NCT02290119|Device|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
79847333|NCT04099667|Drug|Phase 3; Placebo|Intramuscular injections on Day 1
80015451|NCT03665025|Other|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
79706810|NCT04625517|Procedure|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
79706811|NCT04625517|Drug|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
79706812|NCT04601987|Behavioral|Breastfeeding|Counseling about the maternal health benefits of lactation.
79847334|NCT00997191|Procedure|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
79847335|NCT00997191|Drug|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
79847336|NCT00997191|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
80015452|NCT00765830|Drug|vildagliptin|50mg qd
80015453|NCT00765830|Drug|Placebo|qd
79251225|NCT02290119|Procedure|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
79251226|NCT03964467|Device|transcranial direct current stimulation|see arm/group descriptions
79706813|NCT04601987|Behavioral|Smokefree Homes|Counseling about the importance of smoke-free homes.
79706814|NCT04599192|Other|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
79706815|NCT04598321|Drug|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
79847337|NCT02581319|Procedure|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
79847338|NCT05315739|Device|Non-invasive transcutaneous vagus nerve stimulation (tVNS)|tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
79847339|NCT05315739|Device|Sham vagus nerve stimulation|"The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period."
80015454|NCT03664947|Other|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
80015455|NCT03664869|Drug|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
80015456|NCT03664869|Drug|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
79251227|NCT02058901|Drug|Sunitinib|
79251228|NCT02057731|Genetic|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
79251229|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
79251230|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
79251231|NCT02058979|Drug|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
79706816|NCT04594616|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
79706817|NCT04592523|Other|No Intervention|This is a non-interventional study.
80015457|NCT03961009|Biological|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
79847340|NCT00997269|Dietary Supplement|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
79847341|NCT00997269|Dietary Supplement|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
79847342|NCT02582099|Drug|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
79847343|NCT02582099|Drug|Normal saline nasal irrigation|Nasal wash with normal saline solution
79847344|NCT00997347|Drug|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
79847345|NCT00997581|Drug|apremilast|apremilast 20 mg taken twice daily by mouth
80015458|NCT00953420|Drug|Docetaxel|60 mg/m2 IV on Day 1
79847346|NCT00997581|Drug|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
79706818|NCT04577352|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
79251232|NCT02058979|Drug|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
79251233|NCT03108183|Diagnostic Test|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
79251234|NCT01915797|Other|blood and tumor samples|all tumor pathology associated with anomaly of development
79251235|NCT02059369|Procedure|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
79251236|NCT02059369|Procedure|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
79706819|NCT04577352|Drug|Placebo|Placebo will be administered per schedule specified in the arm.
79706820|NCT04571684|Other|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
79391790|NCT02407314|Other|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
79706821|NCT04561661|Procedure|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
79706822|NCT04561661|Procedure|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
80015459|NCT00953420|Drug|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
80015460|NCT00953420|Drug|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
80015461|NCT00953420|Biological|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
79251237|NCT03310827|Behavioral|Personalized Nutrition|Diet plan based on nutrition-related gene test results
79251238|NCT02057887|Drug|HM10660A|
79251239|NCT02057887|Drug|Pegasys|180 mcg Pegasys SC once weekly
79251240|NCT03108417|Device|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
79251241|NCT03561337|Dietary Supplement|PROTEIN-CARBOHYDRATE|PRO before and PRO-CHO after training
79251242|NCT03561337|Dietary Supplement|CARBOHDYRATE|CHO before and after training
79251243|NCT01740687|Device|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
79251244|NCT01740687|Procedure|NovaSure|Nova Sure Endometrial Ablation
79251245|NCT03893955|Drug|ABBV-927|Intravenous (IV) Infusion
79706823|NCT04553471|Radiation|Stereotactic body radiotherapy|Treatment will take approximately 2 weeks.
79847347|NCT04001439|Drug|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
80015462|NCT00953420|Biological|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for > 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC > 2500 cells/ul x 2 days after nadir.
79251246|NCT03893955|Drug|ABBV-368|Intravenous (IV) Infusion
79251247|NCT03893955|Drug|ABBV-181|Intravenous (IV) Infusion
79251248|NCT03893955|Drug|Carboplatin|Intravenous (IV) Infusion
79251249|NCT03893955|Drug|Nab-paclitaxel|Intravenous (IV) Infusion
79251250|NCT02648204|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
79251251|NCT02648204|Drug|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
79251252|NCT05232513|Other|Hand massage|Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
80015463|NCT01602562|Drug|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
80015464|NCT00765518|Biological|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
80015465|NCT00765518|Other|Standard of Care|Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
79251253|NCT03310749|Drug|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
79545558|NCT01532232|Drug|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
79706824|NCT04553471|Procedure|Research blood draw|-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
79706825|NCT04542616|Device|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
80015466|NCT03135002|Other|Other|
80015467|NCT04367636|Behavioral|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
79706826|NCT04540068|Drug|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
79706827|NCT04523701|Drug|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
79391791|NCT02407314|Other|Six minute walk distance|Assessment of the walking distance in 6 minutes.
79391792|NCT02407314|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
79706828|NCT04491422|Combination Product|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
79706829|NCT04490356|Behavioral|Legacy Intervention|The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
79251254|NCT03310749|Drug|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
80015468|NCT04367636|Behavioral|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
80015469|NCT04367636|Other|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
80015470|NCT01945775|Drug|talazoparib|Until progression or unacceptable toxicity develops
80015471|NCT01945775|Drug|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
80015472|NCT00839930|Drug|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
80015473|NCT00839930|Drug|Pletal®|1 x 50 mg, single-dose tablet
80015474|NCT05108038|Drug|CKD-382, D860, D027|QD, PO for 7days
80015475|NCT05051332|Drug|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm^3 defect
80015476|NCT05051332|Procedure|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
79251255|NCT03310749|Drug|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
79847348|NCT05301153|Diagnostic Test|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
79847349|NCT05183139|Drug|Ixazomib|Ixazomib capsules
79847350|NCT05183139|Drug|Pomalidomide|Pomalidomide capsules
79847351|NCT05183139|Drug|Lenalidomide|Lenalidomide capsules
79847352|NCT05183139|Drug|Dexamethasone|Dexamethasone tablets
79847353|NCT00999843|Drug|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
79847354|NCT03830567|Other|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
79847355|NCT03830567|Other|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
80015477|NCT03875365|Procedure|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
80015478|NCT05211349|Other|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
79847356|NCT00997659|Dietary Supplement|chromium picolinate|1000 mg per day
80015479|NCT05211349|Other|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
80015480|NCT05211349|Other|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
80015481|NCT05211349|Other|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
80015482|NCT05211349|Other|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
80015483|NCT00838136|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
80015484|NCT00838136|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
80015485|NCT00944294|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
80015486|NCT00944294|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
79251256|NCT03310671|Procedure|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~Mean transvalvular pressure gradient~Aortic valve~Aortic valve opening area~Aortic valve opening area adjusted for body mass index~Bicuspid or tricuspid aorta~Thickness of the upper valve> 3 mm"
79251257|NCT02470221|Other|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system|Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
79251258|NCT02470221|Other|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
79251259|NCT02799745|Drug|Enzalutamide|Oral
79251260|NCT02799745|Other|Active Surveillance|
79389561|NCT03420118|Procedure|Tumour tissue collection|"Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~A previous surgery for the disease,~A biopsy for diagnosing the disease,~Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens."
79545559|NCT01532232|Drug|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
79545560|NCT01532245|Other|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
79545561|NCT01532245|Other|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
79389562|NCT03420118|Procedure|Blood draws|"Blood samples will be collected at the following different times points:~All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~Before starting a new line of treatment for the disease,~One week after starting a new line of treatment for the disease,~During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~At the time the disease worsens or relapses (comes back)~During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
79706830|NCT04484831|Behavioral|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
79706831|NCT04484831|Other|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
79706832|NCT04477850|Drug|Luspatercept|Specified dose on specified days
79706833|NCT04471233|Other|Multimodal analgesia including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
79706834|NCT04471233|Other|Multimodal analgesia not including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
79706835|NCT04449510|Other|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
80015487|NCT00758966|Drug|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
80015488|NCT00758966|Drug|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
79847357|NCT00997737|Device|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
79847358|NCT05300919|Other|Measurement based care|Measurement-based care based on arm.
79847359|NCT03827213|Drug|Exparel|A shot of long acting local anesthetic for post operative pain management
79847360|NCT03827213|Device|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
79545562|NCT01532245|Other|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
79847361|NCT00999999|Procedure|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
79847362|NCT00997815|Drug|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
79847363|NCT00997815|Drug|Normal saline injection|Using normal saline 2.5 ml injected in control side
79847364|NCT04078139|Drug|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
79847365|NCT04078139|Drug|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
79847366|NCT04077983|Drug|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
79251262|NCT00949221|Device|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~group 2: intensive strategy using continuous glucose monitoring for 12 months;~group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
79545563|NCT01532284|Other|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
79545564|NCT01532297|Device|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
79545565|NCT01532297|Device|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
79251263|NCT00658671|Drug|ENMD-2076|Capsules, daily dosing in 28 day cycles
79251264|NCT04903340|Procedure|PET/CT Exam|PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear
79251265|NCT02057965|Drug|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight
79251266|NCT05304884|Combination Product|combined oxygen-ozone and corticosteroid|Subacromial injection using Ultrasound
79251267|NCT03310593|Drug|Cannabidiol|Cannabidiol as active intervention.
79251268|NCT03310593|Drug|Placebo|Placebo intervention.
79251269|NCT02054455|Dietary Supplement|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
79251270|NCT02054455|Dietary Supplement|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
79545566|NCT01532323|Other|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
79545567|NCT01532336|Drug|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
79545568|NCT01532336|Drug|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
79545569|NCT01532375|Dietary Supplement|Kochujang|Kochujang (32g/day) for 12weeks.
79706836|NCT04445571|Procedure|Thin catheter technique or standard ET-tube for surfactant administration|Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
79710208|NCT00598884|Behavioral|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
79710209|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
79545570|NCT01532375|Dietary Supplement|placebo|placebo(32g/day) for 12weeks
79545571|NCT01532401|Other|sodium chloride|sodium chloride 500mg
79545572|NCT01532401|Other|Methylcellulose crystalline|Methylcellulose 37 ml
79545573|NCT01532466|Drug|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
79847367|NCT00997971|Other|Modilac Rose 1|Infant formula used for non-breastfed children
79251271|NCT04878536|Dietary Supplement|Collagen drink|Testing product
79847368|NCT03823469|Behavioral|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
79847369|NCT03823469|Behavioral|Nutritional counseling|Two 30-minute nutritional counseling sessions
79847370|NCT04000191|Procedure|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
79847371|NCT04000191|Other|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
80015489|NCT00758966|Drug|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
80015490|NCT03750877|Procedure|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
80015491|NCT03750877|Procedure|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
80015492|NCT05107804|Other|Exercise+CR|Exercise with caloric-restriction
80015493|NCT05107804|Other|Light Conditioning|Light Conditioning Exercise
79545574|NCT01532531|Device|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
79545575|NCT01532544|Drug|Ilomedin and Integrilin|Continuous infusion
80015494|NCT04336124|Drug|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
80015495|NCT03734497|Other|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
79545576|NCT01532544|Drug|low molecular weight heparin.|
79545577|NCT01532583|Other|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
79545578|NCT01532596|Behavioral|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
79545579|NCT01532622|Dietary Supplement|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
79706837|NCT04426019|Behavioral|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
79251272|NCT04878536|Dietary Supplement|Blank|Placebo drink
79251273|NCT03310515|Behavioral|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
79251274|NCT03310515|Other|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
79706838|NCT04426019|Behavioral|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
79251275|NCT03310515|Other|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
79251276|NCT02054611|Other|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
79251277|NCT02054611|Other|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
80015496|NCT03734497|Other|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
79251278|NCT03310437|Procedure|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
79545580|NCT01532622|Other|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
79545581|NCT01532661|Other|observational study|data collected by investigators
79847372|NCT03822845|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
79706839|NCT04421235|Behavioral|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
79706840|NCT04415281|Device|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
79847373|NCT01000233|Dietary Supplement|Phytine (phytate)|300 mg tid * 24 months
79847374|NCT01000233|Dietary Supplement|Placebo|Phytine (Phytate)
79545582|NCT01532674|Device|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~All the periodontal pockets will be treated subgingivally~Elimination of the photosensitive by irrigation"
79545583|NCT01532674|Procedure|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
79847375|NCT04075955|Drug|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
79847376|NCT04075955|Drug|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
79251279|NCT05304650|Device|iTEAR100|Controlled Stimulation External Nasal Nerve to stimulate tear production
79251280|NCT02260141|Dietary Supplement|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
79545584|NCT01532713|Procedure|oxygen administration|nasal O2 5L/min via nasal cannula
79545585|NCT01532726|Drug|ESL|ESL 400/800/1200 mg tablets once daily
79545586|NCT01532739|Behavioral|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
79545587|NCT01532765|Procedure|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
79706841|NCT04415281|Device|sham THOR® laser system|sham THOR® laser system
79847377|NCT04076033|Other|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
80015497|NCT03734497|Other|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
80015498|NCT04841122|Device|Camera observation|Supplemental camera observation directly linked to the nurse's phone
79251281|NCT05304338|Drug|Chlorhexidine|Gargling with 10 mL 0.2% Chlorhexidine
79251282|NCT05304338|Other|Oil Pulling|In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes
79251283|NCT05304338|Other|Distilled Water|Gargling with 10 mL distilled water
80015499|NCT00941486|Drug|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
79251284|NCT02059447|Other|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
79706842|NCT04401267|Drug|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
79706843|NCT04401267|Drug|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
79706844|NCT04401267|Other|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
79706845|NCT04401267|Other|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
79847378|NCT03814187|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
79847379|NCT00484198|Drug|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
79389563|NCT03411356|Behavioral|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
79389564|NCT03411356|Behavioral|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
79847380|NCT00484198|Drug|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
80015500|NCT00941486|Drug|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
79251285|NCT02059447|Behavioral|Mindfulness Based Cognitive Therapy|
79545588|NCT01532765|Procedure|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
79545589|NCT01532765|Procedure|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
80015501|NCT04836364|Other|No Intervention|There is no intervention; observation only.
79545590|NCT01532804|Drug|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
79706846|NCT04398966|Device|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
79251286|NCT02059447|Behavioral|Relaxation Therapy|
79251287|NCT03314103|Biological|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
79251288|NCT03314103|Biological|one shot of placebo|one shot of placebo with no live virus
79251289|NCT02058121|Behavioral|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
79251290|NCT02058121|Behavioral|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
79251291|NCT05304260|Other|clinical and radiographic examination|Prevalence of dental anomalies in deciduous dentition and risk factors associated with non-syndromic oral clefts patients: A cross-sectional study.
79545591|NCT01532804|Drug|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
79545592|NCT01532843|Drug|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
79706847|NCT04394676|Procedure|Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
79706848|NCT04370509|Drug|Axitinib (VEGF-TKI)|Given PO
79706849|NCT04370509|Procedure|Cytoreductive Nephrectomy (CN)|Undergo CN
79706850|NCT04370509|Procedure|Metastasectomy (MET)|Undergo MET
79706851|NCT04370509|Biological|Pembrolizumab|Given IV
79847381|NCT00484198|Drug|Rivoglitazone|1.0 mg tablet administered orally, once daily
79847382|NCT00484198|Drug|Rivoglitazone|1.5 mg tablet administered orally, once daily
79847383|NCT04077905|Drug|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
79847384|NCT04077905|Drug|Etoposide|100mg/m² ivgtt on day 1
79847385|NCT04077905|Drug|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
79847386|NCT04076501|Procedure|Oxygen application|Oxygen application Supplemental oxygen via mask
79847387|NCT04076501|Procedure|Sham room air|Room air applied via mask
80015502|NCT00937352|Drug|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
80015503|NCT01566175|Device|Neovac coronary sinus reducer|reducer
80015504|NCT03072719|Drug|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
80015505|NCT03072719|Drug|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
80015506|NCT04665700|Drug|BI 764198|BI 764198
80015507|NCT04665700|Drug|Placebo|Placebo
79706852|NCT04355572|Drug|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
79706853|NCT04355572|Drug|Placebo|Randomized to placebo daily
79706854|NCT04331444|Device|CGM|Using the CGM during the entire study period of 12 months.
79706855|NCT04331444|Behavioral|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
79706856|NCT04331444|Behavioral|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
79706857|NCT04312659|Drug|Infliximab|Participants will be observed who were treated with Infliximab.
79847388|NCT04077749|Biological|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
79847389|NCT04077749|Other|Normal Saline|50 mL normal saline at room temperature
80015508|NCT05107414|Procedure|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
79706858|NCT04308590|Drug|relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
79706859|NCT04308590|Other|Placebo|Placebo is supplied as 100 mg capsules for oral dosing.
79251292|NCT02058199|Drug|rivaroxaban|Single dose pharmacodynamic study
79251293|NCT05304026|Device|Technique 1|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.
79251294|NCT05304026|Device|Technique 2|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.
79251295|NCT05304026|Device|Technique 3|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.
79389566|NCT03391479|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
79706860|NCT04308512|Device|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
79706861|NCT04300894|Device|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
79389567|NCT03391479|Other|Best Supportive Care|As required.
79389568|NCT03376659|Drug|Durvalumab|750mg IV q2 weeks
79389569|NCT03376659|Biological|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
79389570|NCT03376659|Drug|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
79706862|NCT04300894|Other|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
79847390|NCT01015846|Other|Exercise|Redcord (sling exercise) and traditional exercise
79847391|NCT01015846|Other|Core stability exercise|Traditional core stability exercise
79847392|NCT04471246|Drug|Cephalexin|1000 mg PO QID for 7 days
79847393|NCT04471246|Drug|Cephalexin|500 mg PO QID plus oral placebo for 7 days
79389571|NCT03376659|Drug|Bevacizumab|5mg/kg IV q2weeks
79389572|NCT03375463|Drug|Tirzepatide|Administered SC
79389573|NCT03375463|Drug|Tirzepatide|Administered IV
79389574|NCT03375463|Drug|Placebo|Administered SC
79389575|NCT03375463|Drug|Tirzepatide|Administered IV
79389576|NCT03366337|Drug|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
79389577|NCT03358875|Drug|Tislelizumab|Intravenous injection (Anti-PD-1 monoclonal antibody)
79389578|NCT03358875|Drug|Docetaxel|Intravenous injection (Antineoplastic, cytotoxic, taxane)
79389579|NCT03347838|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
79389580|NCT03324373|Drug|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
79847394|NCT04278521|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
79847395|NCT03797651|Drug|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
80015509|NCT04594265|Dietary Supplement|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
80015510|NCT04594265|Dietary Supplement|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
79847396|NCT03797651|Drug|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
79706863|NCT04287647|Device|Transpyloric stent|See arm/group descriptions
79251296|NCT05304026|Device|Technique 4|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
80015511|NCT05107258|Diagnostic Test|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
80015512|NCT05106400|Drug|ZTlido (Lidocaine Topical System) 1.8%|1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
79251297|NCT02468973|Behavioral|Life style counseling|Life style counseling for chronic patients by medical students
79251298|NCT02058277|Drug|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
79706864|NCT04287647|Other|Sham|Sham
79706865|NCT04276701|Biological|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
79251299|NCT04813562|Biological|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
79389581|NCT03324373|Drug|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
79251300|NCT04813562|Biological|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
79251301|NCT04813562|Biological|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
79545593|NCT01532856|Drug|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
79545594|NCT01532856|Drug|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
79251302|NCT04813562|Biological|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
79251303|NCT04813562|Biological|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
79251304|NCT04813562|Biological|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
79251305|NCT04813562|Biological|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
79389582|NCT03324373|Procedure|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
79389583|NCT03291522|Procedure|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
79389584|NCT03278925|Procedure|Biopsy|Undergo biopsy
79389585|NCT03278925|Procedure|Biospecimen Collection|Undergo collection of blood samples
79251306|NCT04813562|Biological|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
79389586|NCT03278925|Procedure|Computed Tomography|Undergo CT
79389587|NCT03278925|Drug|Defined Green Tea Catechin Extract|Given PO
79389588|NCT03278925|Other|Laboratory Biomarker Analysis|Correlative studies
79706866|NCT04276701|Other|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
79706867|NCT04276701|Behavioral|questionnaires|Food and exercise questionnaires validated by the American heart Association
79706868|NCT04274465|Diagnostic Test|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
79706869|NCT04270188|Other|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
79706870|NCT04258462|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
79706871|NCT04258462|Procedure|Magnetic Resonance Imaging|Undergo MRI
79389589|NCT03278925|Procedure|Magnetic Resonance Imaging|Undergo MRI
79389590|NCT03278925|Other|Pharmacological Study|Correlative studies
79389591|NCT03278925|Other|Questionnaire Administration|Ancillary studies
79847397|NCT05062109|Behavioral|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~Muscle rehabilitation developed with a physiotherapist or physical activity monitor~Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~Cognitive and physical stimulation Exergame~Psychological support by a psychologist~Information in the form of videos on the main risks and important points to know and prepare before and after surgery~Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
80015513|NCT05106400|Drug|Salonpas (Lidocaine Patch 4%)|1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
79251307|NCT02470143|Behavioral|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
79389592|NCT03278925|Procedure|Ultrasound|Undergo ultrasound
79389593|NCT03237780|Drug|Atezolizumab|Given IV
79389594|NCT03237780|Procedure|Biopsy|Undergo biopsy
79389595|NCT03237780|Procedure|Biospecimen Collection|Undergo blood sample collection
79389596|NCT03237780|Procedure|Computed Tomography with Contrast|Undergo CT scan
79251308|NCT02058355|Behavioral|Consequences List Feedback|
79251309|NCT02058355|Behavioral|Personalized Normative Feedback|
79389597|NCT03237780|Drug|Eribulin Mesylate|Given IV
79389598|NCT03209401|Drug|Niraparib|an oral PARP inhibitor
79545595|NCT01532856|Drug|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
79545596|NCT01532882|Drug|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
79545597|NCT01532882|Drug|Placebo|tablet, PO, 1 per day during 28 days
79545598|NCT01532895|Drug|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
79706872|NCT04258462|Drug|Hyperpolarized 13C,15N2-urea|Given IV
79706873|NCT04253977|Behavioral|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
79251310|NCT03310359|Dietary Supplement|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
79251311|NCT03310359|Other|Placebo|Matching placebo pill
79389599|NCT03209401|Drug|Carboplatin|a platinum-based injection
79706874|NCT04253977|Behavioral|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
79706875|NCT04247100|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
79706876|NCT04247100|Device|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
79706877|NCT04245397|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
79389600|NCT03197350|Diagnostic Test|cMR|cardiac MRI done to complete the diagnosis
79389601|NCT03197350|Biological|biomarker|Biomarker correlation with cMR parameters Prognostic information
79389602|NCT03193151|Procedure|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
79389603|NCT03190278|Biological|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
79706878|NCT04245397|Drug|Decitabine|Decitabine is a hypomethylating agent.
79706879|NCT04228991|Radiation|Locoregional radiation treatment - Conventional fractionation|40 Gray in 15 daily fractions over 3 weeks
79706880|NCT04228991|Radiation|Locoregional radiation treatment - Hypofractionation|26 Gray in 5 daily fractions over 1 week
79251312|NCT02054767|Drug|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
79389604|NCT03181516|Biological|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
79389605|NCT03181516|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
79389606|NCT03144674|Drug|Parsaclisib|Parsaclisib at the protocol-defined dose.
79389607|NCT03127722|Procedure|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
79389608|NCT03127722|Device|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
79389609|NCT03127722|Procedure|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
79545599|NCT01532947|Procedure|post placement|placement of an endocanalar post
79545600|NCT01532960|Biological|poly-ICLC|poly-ICLC
79706881|NCT04195347|Drug|CM4620|IV
79706882|NCT04169529|Device|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
79706883|NCT04166851|Behavioral|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
79706884|NCT04166851|Behavioral|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
79847398|NCT00499486|Drug|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
80015514|NCT05106400|Drug|Aspercreme (Lidocaine Patch 4%)|1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
79545601|NCT01532960|Biological|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA & CTA derived breast cancer proteins.
79545602|NCT01532960|Biological|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
79545603|NCT01533012|Procedure|Pressure difference|Peak inspiratory pressures difference between two lungs
80015515|NCT05106400|Drug|IcyHot (Lidocaine 4% + Menthol 1% Patch)|1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
79251313|NCT03310281|Device|HOLD: Videogame|Videogame-like digital therapy
79251314|NCT02054845|Behavioral|Body awareness therapy|"Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.~Specifically the following techniques will be applied:~Body scan~Psychoeducation~Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)~Body Awareness Training~Exposure training (imaginary exposure to induce response fluctuations)~Training in cueing techniques to overcome problems with initiation and freezing~Visual Feedback training~Relaxation techniques"
79251315|NCT02054845|Other|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
80015516|NCT01433315|Behavioral|sleep restriction|restricted sleep
80015517|NCT00754988|Drug|Metformin|As prescribed
80015518|NCT00754988|Drug|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
80015519|NCT00754988|Drug|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
79251316|NCT05303948|Device|Videolaryngoscopy / Direct Laryngoscopy|First pass success analysis
79251317|NCT04489082|Device|Near Infrared Laser Stimulation|10 minutes of transcranial near infrared laser stimulation
79251318|NCT03314025|Drug|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
79251319|NCT03314025|Drug|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
79251320|NCT03314025|Device|Foley catheter|Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
79389610|NCT03066843|Drug|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
79389611|NCT03066843|Device|Blue light therapy|Subjects will be exposed to blue light
79389612|NCT03057002|Diagnostic Test|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized [1-13C]pyruvate flux during magnetic resonance spectroscopic imaging.
79389613|NCT03006172|Drug|Inavolisib|Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
79389614|NCT03006172|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
79545604|NCT01533025|Procedure|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
79706885|NCT04165018|Procedure|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
79706886|NCT04153890|Behavioral|FamPALcare|"Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care. FamPALcare intervention will be delivered by community-based nurses. FamPALcare intervention involves coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions.~The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines."
79710210|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
80015520|NCT00754988|Drug|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
80015521|NCT00754988|Drug|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
80015522|NCT01416935|Other|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
80015523|NCT05106322|Other|intraoperative spectrometer scan|intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
80015524|NCT03547843|Behavioral|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
79545605|NCT01533090|Drug|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
79251321|NCT02054923|Procedure|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
79251322|NCT02054923|Behavioral|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
79389615|NCT03006172|Drug|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
79389616|NCT03006172|Drug|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
79706887|NCT04151342|Drug|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
79389617|NCT03006172|Drug|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
79706888|NCT04151342|Other|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
79706889|NCT04136652|Procedure|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
79706890|NCT04136626|Device|Perspectives OCD|The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
79706891|NCT04136626|Device|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
79706892|NCT04116112|Drug|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
79706893|NCT04116112|Drug|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
79706894|NCT04116112|Drug|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
79706895|NCT04077684|Drug|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
79706896|NCT04063787|Device|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
79710211|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
79710212|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
79545606|NCT01533090|Drug|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
80015525|NCT03547843|Behavioral|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
79389618|NCT03006172|Drug|Trastuzumab|Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
79389619|NCT03006172|Drug|Pertuzumab|Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
79389620|NCT02887859|Biological|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
79389621|NCT02836574|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC).
79389622|NCT02789345|Drug|Ramucirumab|Administered IV
79389623|NCT02789345|Drug|Necitumumab|Administered IV
79389624|NCT02789345|Drug|Osimertinib|Administered orally
79545607|NCT01533129|Drug|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
79545608|NCT01533129|Drug|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
79545609|NCT01533142|Procedure|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
79545610|NCT01533142|Procedure|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
79847399|NCT03794375|Other|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
79847400|NCT03794375|Other|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
79847401|NCT01019278|Radiation|proton beam radiation therapy|Undergo external proton beam radiation
79545611|NCT01533155|Drug|Nektar 118|Oral 25 mg tablet
79545612|NCT01533155|Drug|Quinidine|Oral 200 mg tablet
79847402|NCT01019278|Radiation|radiation therapy treatment planning/simulation|
79389625|NCT02759419|Drug|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
79389626|NCT02755896|Radiation|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
79389627|NCT02755896|Radiation|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
79706897|NCT04051346|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
79706898|NCT04051346|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
79389628|NCT02747927|Drug|Placebo|TDV placebo-matching SC injection.
79389629|NCT02747927|Biological|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
79706899|NCT04040400|Radiation|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
79389630|NCT02722525|Procedure|Magnetic Resonance Imaging|Undergo treadmill stress CMR
79389631|NCT02722525|Behavioral|Exercise Intervention|Complete treadmill exercise
79545613|NCT01533155|Drug|Quinidine placebo|Oral Tablet
79706900|NCT04027972|Drug|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
79847403|NCT01019278|Drug|cisplatin|Given IV
79251323|NCT03313947|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
79251324|NCT03313947|Other|Questionnaire|"The following 6 questions will be asked during the preoperative visit:~While sleeping, does your child snore more than half the time?~While sleeping, does your child always snore?~Have you ever seen your child stop breathing during the night?~Does your child occasionally wet the bed?~Did your child stop growing at a normal rate at any time since birth?~Is your child overweight"
79251325|NCT02055079|Drug|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
79389632|NCT02722525|Procedure|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
79389633|NCT02722525|Behavioral|Exercise Intervention|Complete resistive lower extremity exercise
79389634|NCT02722525|Procedure|Spectroscopy|Undergo skeletal muscle PMRS
79389635|NCT02722525|Other|Laboratory Biomarker Analysis|Correlative studies
79389636|NCT02714881|Drug|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
79389637|NCT02714881|Radiation|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
79389638|NCT02650414|Biological|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB|
79389639|NCT02647437|Drug|Levetiracetam|
79389640|NCT02647437|Drug|Placebo|
79389641|NCT02644941|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
79389642|NCT02644941|Device|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
79389643|NCT02628067|Biological|pembrolizumab|intravenous infusion
79389644|NCT02628067|Biological|pembrolizumab|intravenous infusion
79389645|NCT02612831|Procedure|Early bariatric surgery|
79389646|NCT02612831|Procedure|Delayed bariatric surgery|
79545614|NCT01533155|Drug|Morphine|10 mg/ml, intravenously
79545615|NCT01533168|Genetic|cytogenetic analysis|
79545616|NCT01533168|Genetic|nucleic acid sequencing|
79545617|NCT01533168|Other|diagnostic laboratory biomarker analysis|
79545618|NCT01533168|Other|laboratory biomarker analysis|
79545619|NCT01533168|Other|medical chart review|
79545620|NCT01533194|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79545621|NCT01533194|Biological|Wild-type Reovirus|Given IV
79706901|NCT04027972|Device|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
79710213|NCT00599742|Behavioral|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
79847404|NCT02581241|Device|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
79847405|NCT01014520|Drug|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
80015526|NCT03547843|Other|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
80015527|NCT05106166|Behavioral|Occupational Therapy|occupational therapy sessions are based on the joint attention
80015528|NCT05107024|Device|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
80015529|NCT05107024|Device|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
79545622|NCT01533220|Drug|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
79545623|NCT01533220|Drug|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
79545624|NCT01533233|Procedure|thoracoscopic lobectomy and mediastinal lymph node dissection|
79389647|NCT02556567|Other|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
79389648|NCT02529462|Genetic|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
79706902|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
79706903|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
80015530|NCT03529981|Other|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
80015531|NCT03529981|Other|no active intervention|No intervention will be administered
79706904|NCT04026009|Drug|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
79847406|NCT04040699|Biological|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
79847407|NCT01015924|Procedure|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
79847408|NCT01015924|Procedure|ESIN|Elastiv stable intramedullary nailing
79251326|NCT02055079|Drug|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
79545625|NCT01533272|Drug|Tenofovir, emtricitabine, maraviroc|experimental drug
79545626|NCT01533272|Drug|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
79545627|NCT01533285|Biological|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
79545628|NCT01533285|Biological|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
79545629|NCT01533298|Drug|CombiflexOmega peri|intravenously over 3 days infusion
79706905|NCT04013854|Drug|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
79847409|NCT04267367|Behavioral|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process[27]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
79251327|NCT02470065|Drug|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
79251328|NCT02470065|Procedure|Immediate surgery|anatomical resection and systematic lymph node dissection
79251329|NCT03313869|Dietary Supplement|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
79251330|NCT03313869|Dietary Supplement|control diet|habitual diet to be followed
79251331|NCT02055391|Behavioral|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
79545630|NCT01533298|Drug|SmofKabiven peripheral|intravenously over 3 days infusion
79389649|NCT02529462|Drug|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
79389650|NCT02467881|Behavioral|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
79391793|NCT02407314|Drug|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
80015532|NCT05012566|Device|Juvederm|"Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
79545631|NCT01533324|Drug|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
79545632|NCT01533363|Procedure|Stapled hemorrhoidopexy|
79545633|NCT01533363|Procedure|Milligan Morgan|
79545634|NCT01533376|Drug|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
79847410|NCT04266574|Device|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
79706906|NCT04013854|Drug|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
80015533|NCT05012566|Drug|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
79847411|NCT04266574|Device|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
80015534|NCT05202665|Procedure|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
79710214|NCT00599742|Behavioral|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
79251332|NCT02055391|Behavioral|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
79251333|NCT00705159|Drug|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
79251334|NCT00705159|Drug|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
79545635|NCT01533376|Drug|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
79545636|NCT01533389|Drug|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
79251335|NCT00705159|Drug|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
79545637|NCT01533389|Drug|Placebo|dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
79710215|NCT00599820|Drug|Intravitreal Bevacizumab|
79251336|NCT00705159|Drug|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
79251337|NCT01673984|Drug|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 & month 6 (+/- 7 days).
79251338|NCT01673984|Drug|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
79545638|NCT01533402|Behavioral|therapist support|Weekly therapist support without CBT-interventions
79545639|NCT01533402|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
79710216|NCT00599898|Drug|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
80015535|NCT05202665|Procedure|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
80015536|NCT04268342|Other|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
80015537|NCT05106010|Other|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
79545640|NCT01533415|Device|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of <1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
79706907|NCT03995316|Behavioral|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
79389651|NCT02467881|Behavioral|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
79389652|NCT02467881|Other|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
79545641|NCT01533415|Device|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
79706908|NCT03995316|Behavioral|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
80015538|NCT04473638|Procedure|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
80015539|NCT05210647|Device|robotic surgery|by da Vinci Xi
79545642|NCT01533441|Dietary Supplement|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
79847412|NCT01016002|Drug|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
79847413|NCT01016080|Drug|glutathione|250 mg capsules, twice daily, orally
79847414|NCT01016080|Drug|placebo|250 mg capsules, twice daily, orally
79847415|NCT01019434|Drug|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
79847416|NCT01019434|Drug|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
79847417|NCT01016158|Drug|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
79251339|NCT03313791|Dietary Supplement|Whey protein concentrate|see arm description
79847418|NCT04024631|Other|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
79847419|NCT04024631|Other|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
79847420|NCT00499252|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
79847421|NCT00499174|Procedure|conventional surgery|Radical prostatectomy
79847422|NCT00499174|Radiation|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
79847423|NCT00499174|Radiation|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
80015540|NCT05106868|Device|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
79251340|NCT03313791|Dietary Supplement|Yoghurt|see arm description
79251341|NCT03313791|Dietary Supplement|50%whey-50% casein (Standard)|see arm description
79847424|NCT00499174|Procedure|Biopsies|Periodic repeat biopsies
80015541|NCT05764577|Procedure|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
80015542|NCT04438772|Other|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
80015543|NCT04560634|Drug|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
80015544|NCT04560634|Device|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
80015545|NCT00927914|Drug|Ranirestat|Ranirestat 40 mg tablets
79847425|NCT01019512|Other|questionnaire administration|Ancillary studies
79847426|NCT01019512|Other|lymphedema management|
79847427|NCT01019590|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
79847428|NCT01019590|Drug|Benicar HCT ® Tablets 40 mg/25 mg|
79847429|NCT03775421|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
79847430|NCT04130620|Diagnostic Test|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
79847431|NCT01016314|Device|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
79847432|NCT01016314|Device|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
79847433|NCT01014676|Dietary Supplement|Probiotic|
79847434|NCT01014676|Other|Placebo|
79389653|NCT02450708|Genetic|KIR genotyping|
79847435|NCT00532155|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
79847436|NCT00532155|Drug|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
80015546|NCT00927914|Drug|Placebo|Placebo tablets
80015547|NCT04438616|Procedure|dome magnetic attachment|"All patients will receive complete denture before implant installation .~The CBCT examination should be take~patients received infiltration local anesthesia~A crestal incision is made using No. 15 c blade .~Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~Patient satisfaction measure"
79251342|NCT03313791|Dietary Supplement|50%whey-50% casein (Alternative)|see arm description
79251343|NCT03313791|Dietary Supplement|Micellar Casein Isolate- WPH|see arm description
79251344|NCT03313791|Dietary Supplement|Micellar Casein Isolate - Na-caseinate|see arm description
79251345|NCT03313791|Dietary Supplement|Micellar Casein Isolate|see arm description
79251346|NCT03313791|Dietary Supplement|UHT milk|see arm description
79251347|NCT03313791|Dietary Supplement|Recombined milk|see arm description
79251348|NCT03313791|Dietary Supplement|Recombined 50%whey milk|see arm description
79251349|NCT03313791|Dietary Supplement|Ca-caseinate|see arm description
79251350|NCT03313791|Dietary Supplement|Milk protein isolate|see arm description
79251351|NCT03313713|Dietary Supplement|Beta-glucans|Placebo consumption at breakfast (3 g per day)
79389654|NCT02450708|Genetic|HLA genotyping|
79389655|NCT02425046|Behavioral|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
80015548|NCT04438616|Procedure|flat magnetic attachment|"All patients will receive complete denture before implant installation .~The CBCT examination should be take~patients received infiltration local anesthesia.~A crestal incision is made using No. 15 c blade~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire"
79706909|NCT03951012|Procedure|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
79706910|NCT03927690|Drug|LKA651|LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
79706911|NCT03927690|Drug|Lucentis|Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
79706912|NCT03833921|Drug|Abiraterone Acetate|1000 mg orally daily until disease progression
79706913|NCT03833921|Drug|Prednisone|5 mg oral low dose prednisone, twice daily
80015549|NCT05764499|Other|Physiotherapy Scoliosis Specific Exercise (PSSE)|Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
80015550|NCT05261464|Drug|Metoprolol tartrate|Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
79545643|NCT01533454|Other|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
80015551|NCT05261464|Drug|Ivabradine|Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
80015552|NCT05261464|Drug|Diltiazem|Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
79251352|NCT03313713|Dietary Supplement|Placebo|Placebo consumption at breakfast (3 g per day)
79251353|NCT03310203|Diagnostic Test|Iron|Labelled iron
79251354|NCT03304977|Other|questionnaire via smartphone|questionnaire via smartphone
79251355|NCT04782674|Diagnostic Test|Saliva Testing|Saliva EBV-DNA Detection comparing with PBMC and plasma EBV-DNA
79545644|NCT01533467|Device|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
79545645|NCT01533480|Drug|Zirgan|0.15% ganciclovir gel(Zirgan)
79545646|NCT01533480|Drug|genteal gel|0.3% Hypromellose gel
79545647|NCT01533506|Drug|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
79545648|NCT01533519|Drug|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
79545649|NCT01533532|Drug|KLH-2109|
79545650|NCT01533532|Drug|KLH-2109|
79706914|NCT03821246|Drug|Atezolizumab|Given IV
79706915|NCT03821246|Drug|Tocilizumab|Given IV
80015553|NCT04438694|Biological|Convalescent Plasma|Convalescent Plasma
80015554|NCT04438694|Drug|Standard of Care|Standard of Care drugs administered as per Cairo University ICU protocol
80015555|NCT05210491|Other|Review of eyelid positioning in increasing brightness levels|Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
80015556|NCT05379998|Other|Neural mobilization|Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
79545651|NCT01533532|Drug|KLH-2109|
79706916|NCT03821246|Drug|Etrumadenant|Given Orally
79706917|NCT03806985|Drug|Placebo oral capsule|microcrystalline cellulose capsule
79706918|NCT03806985|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
79706919|NCT03806985|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
79706920|NCT03793842|Other|Usual care|Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.
79706921|NCT03793842|Device|PEEP titration by EIT|PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
79706922|NCT03763604|Drug|Abemaciclib|Administered orally.
79706923|NCT03739411|Radiation|Hyperpolarized Carbon C 13 Pyruvate|Given IV
79251356|NCT03310047|Drug|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
79251357|NCT03310047|Drug|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
79251358|NCT04760834|Other|Questionnaire|Complete a questionnaire to look for signs of concussion in the past. The questions also seek to collect data on participants' knowledge, concussion management and potential confounding factors
79251359|NCT03313635|Diagnostic Test|Men presenting with low-T|Evaluation of prealbumin levels.
79545652|NCT01533532|Drug|placebo|
79545653|NCT01533545|Drug|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
79545654|NCT01533545|Drug|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
79706924|NCT03739411|Procedure|Magnetic Resonance Imaging|Undergo MRI
79706925|NCT03739411|Radiation|Radiation Therapy|Undergo radiation therapy
79706926|NCT03739411|Drug|Temozolomide|
79706927|NCT03721653|Drug|Bevacizumab|5 mg/kg iv over 30 minutes day 1
79706928|NCT03721653|Drug|Irinotecan|165 mg/sqm iv over 60 minutes day 1
79706929|NCT03721653|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
80015557|NCT05379998|Other|PNF hold relax technique|Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
80015558|NCT04461730|Device|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
80015559|NCT02928887|Other|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
79847437|NCT00532155|Drug|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
80015560|NCT05210335|Other|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
80015561|NCT00835796|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
80015562|NCT00835796|Drug|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
80015563|NCT05106712|Drug|Vitamin D3|4000IU per day for around 12 weeks.
80015564|NCT05106712|Drug|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
80015565|NCT05106712|Drug|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
80015566|NCT05106712|Other|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
80015567|NCT00835718|Drug|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
80015568|NCT00835718|Drug|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
80015569|NCT00835718|Drug|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
79251360|NCT03313557|Drug|Wee-1 kinase inhibitor AZD1775|Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
80015570|NCT00835718|Drug|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
80015571|NCT05463185|Other|Stretching exercises|Stretching exercises along with manual lymphatic drainage
79251361|NCT03313479|Drug|Dexmedetomidine|Dexmedetomidine will be given with GS
79545655|NCT01533558|Drug|caspofungin|normal dosage for caspofungin, not adapted for the study
79706930|NCT03721653|Drug|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
79706931|NCT03721653|Drug|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
80015572|NCT05463185|Other|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
80015573|NCT05105698|Drug|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
80015574|NCT05105698|Drug|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
80015575|NCT00835640|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
79706932|NCT03721653|Drug|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
79706933|NCT03709992|Drug|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
79706934|NCT03709992|Drug|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
79706935|NCT03699345|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
79706936|NCT03696225|Behavioral|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
80015576|NCT00835640|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
80015577|NCT05098678|Dietary Supplement|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
80015578|NCT05098678|Dietary Supplement|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
80015579|NCT00752570|Drug|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
80015580|NCT00752570|Drug|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
79847438|NCT00532155|Drug|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
79847439|NCT01019668|Drug|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
80015581|NCT00752570|Drug|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
79545656|NCT01533571|Procedure|Immediate implant placement with simultaneous bone grafting|"Flapless surgery is used for surgical implant installation.~Implant is placed in the cingulum position of adjacent teeth incisal edge.~After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
80015582|NCT05083000|Drug|Topotecan|Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
79706937|NCT03696225|Behavioral|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
80015583|NCT05764421|Behavioral|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
79706938|NCT03658694|Procedure|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
79706939|NCT03658694|Procedure|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
79706940|NCT03658694|Procedure|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
79706941|NCT03658694|Procedure|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
79706942|NCT03606499|Drug|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
79706943|NCT03601286|Drug|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
79706944|NCT03597100|Device|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
79847440|NCT01019668|Drug|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
79251362|NCT02813252|Genetic|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
79251363|NCT03304899|Drug|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
79545657|NCT01533610|Procedure|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
79545658|NCT01533623|Device|Mandibular Advancement Device|Nightly wearing time
79251364|NCT03313401|Drug|Aflibercept|Intravitreal aflibercept injection
79251365|NCT03313401|Device|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
79545659|NCT01533649|Behavioral|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
79545660|NCT01533649|Behavioral|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
79545661|NCT01533662|Drug|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
79545662|NCT01533662|Drug|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
79706945|NCT03587688|Procedure|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
79545663|NCT01533675|Other|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
79545664|NCT01533675|Other|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
79706946|NCT03570632|Drug|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
80015584|NCT00752258|Drug|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
79706947|NCT03555695|Behavioral|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
80015585|NCT02942017|Drug|Placebo|Intravenous infusion of matching placebo for SAGE-547.
79706948|NCT03555695|Behavioral|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
80015586|NCT02942017|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547
80015587|NCT04447781|Biological|INO-4800|- Manufacturer: Inovio Pharmaceuticals Inc.
80015588|NCT04447781|Device|CELLECTRA® 2000|- Manufacturer: Inovio Pharmaceuticals Inc.
79251366|NCT03304743|Diagnostic Test|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
79251367|NCT05302622|Other|There is no intervention planning|There is no intervention planning
79251368|NCT03309891|Drug|GX-H9|subcutaneous injection (weekly or twice-monthly)
79251369|NCT03309891|Drug|Genotropin|subcutaneous injection (daily)
79251370|NCT05431868|Other|AT LISA tri 839MP (Carl Zeiss Meditec AG)|This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
79251371|NCT05431790|Device|Absorbable interface screws manufactured by Natong Biotechnology|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
79389656|NCT02425046|Behavioral|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
80015589|NCT04447781|Other|Saline-sodium citrate (SSC) buffer|- Manufacturer: Inovio Pharmaceuticals Inc.
80015590|NCT00835484|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
79251372|NCT05431790|Device|Absorbable interface screws manufactured by INION.|Reconstruction of anterior cruciate ligament using Inion Oy absorbable interface scews from INION, Finland
79251373|NCT03304509|Other|Telematic follow-up|Telematic follow-up by using a platform with videoconference
79251374|NCT03313323|Biological|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
79251375|NCT03313245|Other|No Intervention/Observational Study|No Intervention/Observational Study
79251376|NCT05302232|Diagnostic Test|depomedrone 40mg/ml + 1% lidocaine|Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
80015591|NCT00835484|Drug|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
79389657|NCT02359565|Procedure|Biospecimen Collection|Undergo CSF and blood sample collection
79389658|NCT02359565|Procedure|Conventional Magnetic Resonance Imaging|Undergo standard MRI
80015592|NCT04442555|Dietary Supplement|HVMN Ketone Ester|Commercially available ketone supplement
80015593|NCT04442555|Dietary Supplement|Maltodextrin|Commercially available maltodextrin supplement
80015594|NCT05105464|Drug|SYHA1815|Subjects will receive SYHA1815 orally.
80015595|NCT05202431|Behavioral|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
80015596|NCT04999618|Drug|Haemoblock|Delivering with transdermal patches
80015597|NCT04999618|Other|Placebo|Delivering with transdermal patches
80015598|NCT00835406|Drug|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
80015599|NCT00835406|Drug|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
80015600|NCT04973098|Biological|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
79251377|NCT05302232|Diagnostic Test|depomedrone 40mg/ml+ 0.9% saline|Response to intra-articular injection of steroid only as a placebo
79251378|NCT05302232|Other|painDETECT questionnaire|painDETECT questionnaire
79251379|NCT02468661|Drug|INC280 single agent|
79389659|NCT02359565|Procedure|Diffusion Tensor Imaging|Undergo DTI
79389660|NCT02359565|Procedure|Diffusion Weighted Imaging|Undergo MR diffusion imaging
79389661|NCT02359565|Procedure|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
79389662|NCT02359565|Procedure|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
79389663|NCT02359565|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
79389664|NCT02359565|Biological|Pembrolizumab|Given IV
79389665|NCT02332668|Biological|Pembrolizumab|IV infusion
79706949|NCT03555695|Behavioral|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
79706950|NCT03538691|Drug|Brexpiprazole|Administered as tablets.
80015601|NCT05202275|Drug|Olanzapine|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
79251380|NCT02468661|Drug|erlotinib|
79251381|NCT03304431|Drug|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
79251382|NCT04741334|Drug|direct anticoagulant|exposure to direct anticoagulant
79389666|NCT02318849|Behavioral|Web intervention|interactive website using social media and gamification
79389667|NCT02255435|Drug|Omaveloxolone Capsules, 2.5 mg|
79251383|NCT04741334|Drug|antiplatelet drugs|exposure to antiplatelet drugs
79251384|NCT04741334|Drug|Dicumarols|exposure to dicumarols
79251385|NCT03309735|Drug|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
79251386|NCT03309735|Drug|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
79251387|NCT03309735|Drug|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
79251388|NCT05302076|Device|Low-intensity electrical current (LIEC)|Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
79389668|NCT02255435|Drug|Omaveloxolone Capsules, 5 mg|
79389669|NCT02255435|Drug|Omaveloxolone Capsules, 10 mg|
79389670|NCT02255435|Drug|Placebo|
79389671|NCT02255435|Drug|Omaveloxolone Capsules, 20 mg|
79389672|NCT02255435|Drug|Omaveloxolone Capsules, 40 mg|
80015602|NCT05105386|Device|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
80015603|NCT00749216|Drug|Solanezumab|
79251389|NCT05302076|Device|Traditional fixed orthodontic appliance|"The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction."
79251390|NCT02469363|Device|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
79251391|NCT02469363|Device|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
79251392|NCT02469363|Device|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
79389673|NCT02255435|Drug|Omaveloxolone Capsules, 80 mg|
79389674|NCT02255435|Drug|Omaveloxolone Capsules, 160 mg|
79389675|NCT02255435|Drug|Omaveloxolone Capsules, 300 mg|
79389676|NCT02255435|Drug|Omaveloxolone Capsules, 150 mg|
79389677|NCT02229123|Drug|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
79389678|NCT02216864|Procedure|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
79251393|NCT02469363|Device|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
79251394|NCT02469207|Other|Removal of tissue post-mortem|
79251395|NCT05430776|Radiation|Photobimodulation|laser therapy application
79389679|NCT02180711|Drug|acalabrutinib|
79389680|NCT02180711|Drug|rituximab (IV)|
79389681|NCT02180711|Drug|Lenalidomide|
79389684|NCT02159755|Drug|Ibrutinib|Given PO
79389685|NCT02159755|Other|Laboratory Biomarker Analysis|Correlative studies
79389686|NCT02159755|Drug|Palbociclib|Given PO
79706951|NCT03538691|Drug|Antidepressant therapy|"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."
79706952|NCT03490760|Drug|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks
80015604|NCT05104684|Other|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
80015605|NCT05104684|Other|routine medical treatment|medical treatment
80015606|NCT00748124|Device|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
80015607|NCT00748124|Procedure|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
79706953|NCT03490760|Radiation|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
79706954|NCT03407417|Other|virtual technology - highly tailored|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
79847441|NCT04076345|Diagnostic Test|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
79251396|NCT03304353|Other|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
79706955|NCT03407417|Other|virtual technology - tailored minimally|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Minimally tailored patient reminders will be customized using 4 randomly selected constructs.
79706956|NCT03398135|Drug|risankizumab|subcutaneous (SC) injection
79706957|NCT03398135|Drug|placebo for risankizumab|subcutaneous (SC) injection
79706958|NCT03383874|Combination Product|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
79847442|NCT01019746|Drug|propofol|propofol administration
79847443|NCT00205777|Drug|Bazedoxifene Acetate|BZA 20mg, daily, oral
79847444|NCT00205777|Other|Placebo|Placebo, daily, oral
79847445|NCT03762395|Drug|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
79847446|NCT03762395|Drug|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
79251397|NCT03304353|Other|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
79389687|NCT02159755|Other|Pharmacological Study|Correlative studies
79251398|NCT03313167|Other|Non-interventional|Non-interventional
79389688|NCT02125149|Other|Exercise Intervention|
79389689|NCT02061423|Biological|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
79847447|NCT01000389|Device|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
79251399|NCT03304275|Behavioral|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
79251400|NCT04724330|Behavioral|Healthy for Two/Healthy for You|~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
79251401|NCT03304197|Dietary Supplement|Hypotonic|N/A: see arm description
79251402|NCT03304197|Dietary Supplement|Isotonic|N/A: see arm description
79389690|NCT01948882|Device|ESS505 (BAY1454033)|
79389691|NCT01881048|Dietary Supplement|Omega-3 fatty acid|Given PO
79389692|NCT01881048|Drug|Celecoxib|Given PO
79391794|NCT02555098|Device|Sapphire contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
79545665|NCT01533701|Other|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
79545666|NCT01533727|Drug|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
79545667|NCT01533727|Drug|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
79706959|NCT03383874|Other|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
79706960|NCT03370016|Procedure|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
79706961|NCT03364803|Other|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
79847448|NCT05674097|Other|no intervention|no intervention
79389693|NCT01822652|Genetic|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~Dose Level 1 = 1 x 10^7~Dose Level 2 = 1 x 10^8~Dose Level 3 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
79389694|NCT01822652|Genetic|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~Dose Level 1 = 1 x 10^8~Dose Level 2 = 1.5 x 10^8~Dose Level 3 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
79251403|NCT03304197|Dietary Supplement|Placebo|N/A: see arm description
79389695|NCT01822652|Drug|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients <12 kg = 16.7 mg/kg/day x 2 days)
79389696|NCT01822652|Drug|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients <12 kg = 1 mg/kg/day x 3 days)
80015608|NCT05201963|Procedure|Serratus Anterior Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).
79545668|NCT01533740|Drug|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
79706962|NCT03364803|Other|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
79706963|NCT03364803|Other|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
79706964|NCT03364803|Other|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
79847449|NCT01004055|Device|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
79847450|NCT01004055|Drug|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
79251404|NCT03304197|Other|Dehydrated|N/A: see arm description
79847451|NCT01004055|Drug|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
79251405|NCT04072874|Drug|Experimental topical (Curaleish Topical)|Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
79251406|NCT05184387|Other|Blood samples|Collection of blood samples and completion of an electronic Diary (eDiary)
79251407|NCT02926586|Drug|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
79251408|NCT02926586|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
79251409|NCT03313089|Behavioral|"Papas más nutritivas (PSAN)"|"Activities of the project Papas más nutritivas"
79251410|NCT04233008|Device|Foley catheter length|see arm description
79251411|NCT04490967|Combination Product|Silymarin|Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
79251412|NCT04490967|Procedure|Salicylic acid|Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
79389697|NCT01822652|Drug|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
79545669|NCT01533766|Drug|CombiflexOmega|intravenously over 5 days infusion
79545670|NCT01533766|Drug|SmofKabiven|intravenously over 5 days infusion
79545671|NCT01533792|Procedure|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
79545672|NCT01533792|Procedure|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
79545673|NCT01533805|Other|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
79706965|NCT03364803|Other|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
79706966|NCT03364803|Other|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
79706967|NCT03364803|Other|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
79847452|NCT03748511|Other|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
79847453|NCT00483652|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
79847454|NCT00483652|Drug|Placebo|placebo (sugar pill)
79389698|NCT01822652|Genetic|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~Dose Level 1 = 1.5 x 10^8~Dose Level 2 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
79545674|NCT01533805|Other|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
79847455|NCT04000425|Combination Product|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
79545675|NCT01533818|Drug|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
79847456|NCT03742791|Drug|TS-134|5 mg to 80 mg oral solution
80015609|NCT05201963|Procedure|Erector Spinae Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
80015610|NCT04911400|Other|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
80015611|NCT04911400|Other|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
80015612|NCT05201573|Other|Observational|This is an observational study of long term follow up data for patients who previously received the DIAM implant
79706968|NCT03364803|Other|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
79251413|NCT03312855|Drug|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
79251414|NCT03312855|Drug|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
79251415|NCT03312855|Drug|Placebo|single dose, intravenous application of Placebo solution
79706969|NCT03364803|Other|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
79706970|NCT03364803|Other|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
79847457|NCT03742791|Drug|Placebo|Matched Placebo oral solution
79847458|NCT04245683|Procedure|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
80015613|NCT05462327|Procedure|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
79389699|NCT01792583|Drug|Modafinil/armodafinil|
79389700|NCT01777802|Radiation|SBRT|
79389701|NCT01777802|Radiation|IMRT|
79389702|NCT01777802|Radiation|Brachytherapy|
79545676|NCT01533818|Drug|Sugar Syrup|It will be given 2 times/day for 7 days
79545677|NCT01533857|Dietary Supplement|hot water|Hot water and placebo capsule
79251416|NCT03304041|Dietary Supplement|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
79251417|NCT03304041|Dietary Supplement|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
79251418|NCT05430620|Drug|Oxygen|Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
79251419|NCT03312777|Drug|Omnitram|Omnitram tablets overencapsulated
79251420|NCT03312777|Drug|Tramadol|Tramadol tablet overencapsulated
79251421|NCT03312777|Drug|Placebo|Microcrystalline powder overencapsulated
79251422|NCT04209998|Diagnostic Test|transcutaneous oximetry|Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
79389703|NCT01721798|Device|Mirena levonorgestrel IUD|Intrauterine contraception system
79706971|NCT03364803|Other|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
79706972|NCT03341689|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
79706973|NCT03341689|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
79389704|NCT01721798|Device|Copper T-380a IUD|intrauterine contraception system
79847459|NCT04245683|Other|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
79847460|NCT00998283|Drug|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
80015614|NCT05462327|Procedure|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
80015615|NCT00744926|Drug|placebo|sc, once weekly
80015616|NCT00744926|Drug|taspoglutide|10mg sc, once weekly
79251423|NCT02332928|Drug|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
79251424|NCT02332928|Drug|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
79251425|NCT04490733|Behavioral|dual-task walking|Participants will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
79251426|NCT03312621|Behavioral|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
79251427|NCT03856424|Procedure|Modality 1|Pressure support ventilation (PSV) modality
79389705|NCT01492036|Other|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
79389706|NCT01492036|Behavioral|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
79389707|NCT01291953|Procedure|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
79389708|NCT01291953|Procedure|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
79389709|NCT01241864|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
79389710|NCT01241864|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
79389711|NCT01038778|Biological|Aldesleukin|Given IV
79389712|NCT01038778|Procedure|Computed Tomography|Undergo FDG-PET/CT
79389713|NCT01038778|Drug|Entinostat|Given PO
79847461|NCT00998283|Drug|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
79389714|NCT01038778|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
79389715|NCT01038778|Other|Laboratory Biomarker Analysis|Correlative studies
79389716|NCT01038778|Other|Pharmacological Study|Correlative studies
79389717|NCT01038778|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
79847462|NCT00998283|Drug|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
79847463|NCT00998283|Drug|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
79847464|NCT00998283|Drug|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
79847465|NCT00998283|Drug|Placebo|Subcutaneously administrate at 0 hour on Day 1
80015617|NCT00744926|Drug|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
79251428|NCT03856424|Procedure|Modality 2|T-Piece modality
79251429|NCT03856424|Procedure|Modality 3|High-flow oxygen
79251430|NCT03309501|Drug|Tong-Luo-Qu-Tong Plaster|for 14 days as two period of treatment, daily 1 time.
79389718|NCT00980954|Drug|carboplatin|Given IV
79389719|NCT00980954|Drug|cisplatin|Given IV
79389720|NCT00980954|Drug|paclitaxel|Given IV
79389721|NCT00716066|Biological|Anti-Thymocyte Globulin|Given IV
79706974|NCT03341689|Drug|Placebo|microcrystalline cellulose capsule
79847466|NCT01014832|Drug|Intensive insulin therapy|Intensive insulin therapy
79847467|NCT03996473|Drug|Radium-223 dichloride (Xofigo, BAY 88-8223)|Intravenous (IV) injection, every 6 weeks for up to 6 administrations
79847468|NCT03996473|Drug|Pembrolizumab|IV infusion, every 3 weeks for a maximum of up to 35 administrations
80015618|NCT03840772|Drug|Eribulin|Treatment with eribulin
80015619|NCT03838744|Drug|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy
80015620|NCT03838744|Drug|Experimental arm: Trabectedin + Olaparib|Trabectedin given in combination to olaparib
80015621|NCT05327348|Drug|Intravenous Ascorbate|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
79706975|NCT03307746|Drug|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
79545678|NCT01533857|Dietary Supplement|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
79847469|NCT04075565|Behavioral|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
79251431|NCT03309501|Drug|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two period of treatment, daily 1 time
79251432|NCT03738878|Drug|Valsartan|oral valsartan
79251433|NCT03738878|Drug|LCZ696|oral LCZ696
79251434|NCT03738878|Drug|Bradykinin|Intra-arterial bradykinin at three graded doses
79389722|NCT00716066|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
79251435|NCT03738878|Drug|Substance P|Intra-arterial substance P at three graded doses
79545679|NCT01533870|Drug|NKTR-118|Oral 25 mg
79545680|NCT01533870|Drug|Rifampin|Oral 600 mg
79847470|NCT04075565|Behavioral|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
79251436|NCT03738878|Drug|BNP|Intra-arterial BNP at three graded doses
79251437|NCT03738878|Drug|Sitagliptin|oral sitagliptin
79251438|NCT03309423|Diagnostic Test|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
79251439|NCT03154671|Other|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
79251440|NCT01070342|Device|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
79251441|NCT04441827|Other|breathing exercise|Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
79389723|NCT00716066|Drug|Carmustine|Given IV
79251442|NCT04699682|Other|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
79389724|NCT00716066|Drug|Cytarabine|Given IV
79389725|NCT00716066|Drug|Etoposide|Given IV
79706976|NCT03294954|Genetic|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~Dose Level 1 = 3 x 10^6~Dose Level 2 = 1 x 10^7~Dose Level 3 = 3 x 10^7~Dose Level 4 = 1 x 10^8~Dose Level 5 = 3 x 10^8~Dose Level 6 = 1 x 10^9"
79706977|NCT03287908|Drug|AMG 701|Subjects will receive IV infusions of AMG 701.
79389726|NCT00716066|Other|Laboratory Biomarker Analysis|Correlative studies
79389727|NCT00716066|Drug|Melphalan|Given IV
79389728|NCT00716066|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
79389729|NCT00716066|Drug|Prednisone|Given PO
79389730|NCT00716066|Procedure|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
79389731|NCT00704288|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
79389732|NCT00085930|Biological|EBV specific CTLs|CTLs: 2x10e7 cells/m2
79389733|NCT00031512|Other|Placebo|Placebo.
79389734|NCT00031512|Drug|Pleconaril|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
79545681|NCT01533896|Behavioral|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
79545682|NCT01533961|Drug|SCYX-7158|
79545683|NCT01533961|Drug|Placebo|
79545684|NCT01533987|Dietary Supplement|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
79545685|NCT01534000|Procedure|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
79545686|NCT01534026|Drug|Aspirin|Current dose
79545687|NCT01534026|Other|withdrawal of aspirin|Stopping current dose of aspirin
79545688|NCT01534039|Device|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
79545689|NCT01534039|Device|FormaFlex|Hollister skin barrier for ostomy patients
79251443|NCT04699682|Other|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~- stool samples taken at different times:~every 7 days during the first month (M1)~every 14 days for the following months until the end of the patient's participation (M2 to M12)."
79251444|NCT02647658|Behavioral|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
79545690|NCT01534091|Behavioral|Pedometer with supervision|
79706978|NCT03287908|Drug|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
79706979|NCT03287908|Drug|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
79706980|NCT03286257|Behavioral|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
79389735|NCT05104606|Other|TEE|"The intervention within the framework of the protocol will consist, for the needs of the study, in performing 2 TEE and 5 TTE in 24 hours after~For TEE:~The first TEE will allow us to evaluate the right ventricle, to look for the existence of a acute cor pulmonale, to evaluate the patient's blood volume as recommended during the management of ARDS. If the patient is included in the study, our intervention will consist in leaving this TEE in place in order to perform measurements at H0, 30min, H1 and H2 after iNO administration.~The second TEE will be performed at H24 to performed new measurements."
79545691|NCT01534091|Behavioral|Pedometer without supervision|
79545692|NCT01534117|Biological|Platelets|1 unit of platelets
79706981|NCT03266991|Drug|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
79706982|NCT03266991|Drug|Isoniazid|Treatment with daily isoniazid in 6 months
79847471|NCT01004211|Procedure|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
79391795|NCT02555098|Device|senofilcon A contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
79545693|NCT01534117|Drug|DDAVP|Desmopressin 0.3mcg/kg IV x 1
79706983|NCT03191266|Device|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
79706984|NCT03191266|Device|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
79847472|NCT01004211|Procedure|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
79847473|NCT02580461|Behavioral|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
79847474|NCT01004289|Procedure|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
79847475|NCT01004289|Procedure|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
79847476|NCT03745079|Other|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
79251445|NCT02647658|Behavioral|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
79251446|NCT00703677|Drug|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
79545694|NCT01534130|Device|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
79545695|NCT01534130|Device|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
79545696|NCT01534169|Drug|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
79545697|NCT01534221|Device|Biomatrix drug eluting stent|Biomatrix drug eluting stent
79706985|NCT03180398|Device|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
79706986|NCT03120949|Drug|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
79706987|NCT03120949|Drug|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
79706988|NCT03120949|Drug|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
79706989|NCT03104855|Drug|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
79706990|NCT03089905|Drug|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
79706991|NCT03089905|Drug|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
79706992|NCT03089905|Drug|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
79706993|NCT03077347|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
79706994|NCT03035448|Behavioral|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
79706995|NCT03035448|Other|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
79545698|NCT01534234|Device|PARADYM RF SONR|SonR CRT Optimization
79545699|NCT01534234|Device|PARADYM RF SONR|Echocardiography Optimization
79706996|NCT02981329|Drug|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
79706997|NCT02981329|Behavioral|Questionnaires|Questionnaires will be completed to assess the impact quality of life
79706998|NCT02921256|Drug|Capecitabine|Given PO
79706999|NCT02921256|Drug|Fluorouracil|Given IV
79707000|NCT02921256|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
79707001|NCT02921256|Drug|Leucovorin|Given IV
79707002|NCT02921256|Drug|Oxaliplatin|Given IV
79707003|NCT02921256|Biological|Pembrolizumab|Given IV
79707004|NCT02921256|Drug|Veliparib|Given PO
80015622|NCT05327348|Drug|Normal Saline 10 mL Injection|Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
79389736|NCT05104606|Other|TTE|"For TTE:~• The TTEs will allow us to evaluate the anatomy of the right ventricle, to estimate the systolic pulmonary artery pressure, to calculate the cardiac output and to measure the conventional parameters of the right ventricular systolic function. This noninvasive examination will be repeated at 30 min, H1, H2, and H24 after iNO administration"
79707005|NCT02757885|Procedure|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.
79707006|NCT02757885|Drug|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing >125% ideal body weight.
79707007|NCT02757885|Drug|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing >125% ideal body weight.
79251447|NCT03303807|Device|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
79707008|NCT02757885|Drug|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing > 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
79847477|NCT03745079|Other|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
79847478|NCT03745079|Other|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
79847479|NCT01000545|Drug|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
80015623|NCT05201417|Other|adapted physical activity|The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
79391796|NCT02407080|Drug|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
79545700|NCT01534247|Drug|CAZ-AVI|Infusion
79545701|NCT01534247|Drug|metronidazole|Infusion
79545702|NCT01534247|Drug|CAZ-AVI + metronidazole|Infusion
79545703|NCT01534286|Drug|Theramine|Theramine 2 capsules 3 times per day
79545704|NCT01534286|Drug|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
79545705|NCT01534312|Drug|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
79545706|NCT01534312|Drug|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
79847480|NCT01000545|Drug|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
80015624|NCT04695106|Drug|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
80015625|NCT04695106|Drug|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
79251448|NCT00888680|Drug|BGC20-1531|BGC20-1531 administered orally
80015626|NCT04695106|Drug|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
79251449|NCT00888680|Drug|Lactose|Placebo administered orally
79251450|NCT02468505|Behavioral|STEPS|time-limited behavioral counseling, online materials, training
79251451|NCT01506986|Drug|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
79389737|NCT03199248|Procedure|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
79707009|NCT02757885|Drug|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
80015627|NCT04695106|Drug|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
80015628|NCT05104372|Other|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
80015629|NCT04032665|Diagnostic Test|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
79251452|NCT01506986|Drug|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
79251453|NCT03309345|Other|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
79251454|NCT03312387|Other|Exercise|Aerobic exercise performed 3/d per week during intervention
79389738|NCT04745338|Device|3max cool shaping device|cryolipolysis sessions are applied on abdomen area each session for 40 min. each
79389739|NCT04745338|Dietary Supplement|low calolric diet|low caloric diet (1200cal/day)
79251455|NCT03312387|Dietary Supplement|Essential Amino Acids|Mixture of 10g of essential amino acids ingested throughout intervention
79251456|NCT03312387|Dietary Supplement|Placebo|10g of maltodextrin ingested throughout intervention
79251457|NCT02469051|Device|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
79251458|NCT02469051|Device|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
79251459|NCT02469051|Device|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
79251460|NCT03993938|Device|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
79251461|NCT04491513|Diagnostic Test|Computed tomography angiography|Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI
79389740|NCT01605227|Drug|cabozantinib|Tablets taken orally once-daily
79389741|NCT01605227|Drug|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
79847481|NCT03992729|Drug|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
80015630|NCT04516720|Other|data collection|Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
79251462|NCT02714894|Drug|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
79251463|NCT03303729|Dietary Supplement|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
79389742|NCT02446548|Drug|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
79707010|NCT02757885|Other|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
80015631|NCT05201261|Device|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
80015632|NCT03629639|Drug|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
80015633|NCT03577288|Behavioral|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
80015634|NCT03577288|Behavioral|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
80015635|NCT03577288|Behavioral|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
79847482|NCT03992729|Drug|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
79251464|NCT03303729|Dietary Supplement|Cluster Dextrin|75 grams of Cluster Dextrin
79251465|NCT03303729|Dietary Supplement|Placebo|75 grams of Glucose
79251466|NCT03390140|Behavioral|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
79251467|NCT03390140|Behavioral|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
79251468|NCT03390140|Behavioral|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
79391797|NCT02407080|Drug|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
79707011|NCT02757885|Radiation|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
79251469|NCT03303651|Procedure|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
79545707|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
79707012|NCT02729480|Device|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
79389743|NCT02446548|Drug|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
79707013|NCT02703623|Drug|Abiraterone Acetate|Given PO
79847483|NCT00483574|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
79847484|NCT00483574|Biological|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
79847485|NCT00483574|Biological|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
79847486|NCT00483574|Biological|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
79847487|NCT01000623|Drug|venlafaxine|Given orally
79847488|NCT01000623|Drug|placebo|Given orally
79389744|NCT02446548|Other|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
79251470|NCT03303651|Procedure|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
79251471|NCT03312153|Drug|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
79251472|NCT03312153|Drug|2.5% sodium hypochlorite|anti bacterial root canal irrigant solution
79389745|NCT04291768|Other|Shortened antibiotic treatment|Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
79545708|NCT01534325|Device|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
79707014|NCT02703623|Drug|Apalutamide|Given PO
79707015|NCT02703623|Drug|Cabazitaxel|Given IV
79707016|NCT02703623|Drug|Carboplatin|Given IV
79707017|NCT02703623|Biological|Ipilimumab|Given IV
79707018|NCT02703623|Other|Laboratory Biomarker Analysis|Correlative studies
79707019|NCT02703623|Drug|Prednisone|Given PO
79847489|NCT01000623|Procedure|hypnotherapy|Practice hypnosis
79251473|NCT03309267|Procedure|Intercostal block|Intercostal block +patient controlled analgesia
79251474|NCT03309267|Procedure|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
79251475|NCT03303573|Drug|recombinant human erythropoietin|Subcutaneous rhEPO injection
79251476|NCT03312075|Other|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
79707020|NCT02670811|Dietary Supplement|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
79251477|NCT03303495|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
79251478|NCT03303495|Drug|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
79251479|NCT03303495|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
79251480|NCT03303495|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
79251481|NCT03303495|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
79707021|NCT02670811|Dietary Supplement|Acidified milk|150 mL daily of artificially acidified milk
79707022|NCT02654119|Drug|Cyclophosphamide|Given IV
79707023|NCT02654119|Other|Laboratory Biomarker Analysis|Correlative studies
79847490|NCT01000623|Procedure|mind-body intervention procedure|Practice focused attention
79847491|NCT00998361|Procedure|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
79847492|NCT00483184|Biological|Veldona,|Very low dose oral natural human interferon alpha lozenges
79847493|NCT00998439|Device|SeQuent® Please|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
79847494|NCT00998439|Device|SeQuent® II|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
79847495|NCT01000779|Drug|Propranolol|upto 320mg/day maximum
79251482|NCT03309111|Biological|ISB 1342|ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
79707024|NCT02654119|Drug|Paclitaxel|Given IV
79847496|NCT01000779|Device|multi band ligator for esophageal varices|to obliterate esophageal varices
79707025|NCT02654119|Biological|Trastuzumab|Given IV
79847497|NCT00998595|Other|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
79847498|NCT04075643|Drug|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
79389746|NCT04291768|Other|Standard antibiotic treatment|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
79389747|NCT02446470|Procedure|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
79847499|NCT04075643|Drug|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
79847500|NCT01000857|Drug|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
79847501|NCT01004445|Drug|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
79251483|NCT03308955|Drug|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
79251484|NCT03308955|Procedure|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
79707026|NCT02635867|Procedure|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
79389748|NCT02446470|Procedure|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
79707027|NCT02635867|Procedure|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
79707028|NCT02635867|Procedure|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
79389749|NCT03199326|Other|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
80015636|NCT03577288|Behavioral|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
79847502|NCT01004445|Drug|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
79847503|NCT01004445|Drug|Placebo|Two aerosol treatments per day (one treatment every 12hr)
79847504|NCT02580695|Biological|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
79847505|NCT02580695|Drug|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
79251485|NCT03308955|Procedure|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
79847506|NCT04075019|Behavioral|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
79389750|NCT03199170|Drug|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
79847507|NCT03672929|Device|RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years.
79847508|NCT02581553|Drug|lesinurad/allopurinol 200/300 FDC tablets|
79847509|NCT02581553|Drug|lesinurad 200 mg|
79251486|NCT03311685|Device|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
79251487|NCT03303183|Device|Standard Impression technique|Silicone impression technique
79707029|NCT02635867|Procedure|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
79707030|NCT02635867|Procedure|Direct Pulp capping-Calcium hydroxide - Dycal|\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
79707031|NCT02565446|Procedure|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
79707032|NCT02433054|Device|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
79847510|NCT02581553|Drug|allopurinol 300 mg|
79847511|NCT02581553|Drug|lesinurad/allopurinol 200/200 FDC tablets|
79847512|NCT02581553|Drug|allopurinol 200 mg|
79847513|NCT04077203|Behavioral|Biofeedback / No biofeedback|Biofeedback / No biofeedback
79251488|NCT03303183|Device|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
79251489|NCT03311607|Drug|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
79389751|NCT03199170|Drug|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
79389752|NCT03199170|Drug|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
79847514|NCT03944915|Drug|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
79847515|NCT03944915|Drug|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
79847516|NCT03944915|Drug|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
79847517|NCT03944915|Radiation|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
79251490|NCT03303027|Device|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
79847518|NCT03944915|Drug|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
79847519|NCT03944915|Drug|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
79847520|NCT03944915|Drug|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
79545709|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
79707033|NCT02426658|Other|Laboratory Biomarker Analysis|Correlative studies
79847521|NCT03944915|Drug|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
79847522|NCT05674019|Other|MRI exam|Brain MRI Morphometric exam
80015637|NCT05210023|Other|NUTRIGENETIC DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
79389753|NCT04229056|Behavioral|Computer-based cognitive rehabilitation (CBCR)|CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
79389754|NCT04229056|Behavioral|General computer-based cognitive stimulation|For this trial we have developed a webpage for cognitive sham-training, which is designed to provide general computer-based cognitive stimulation.
79389755|NCT02446392|Other|No intervention.|
79389756|NCT03118128|Drug|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
79545710|NCT01534338|Behavioral|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
79545711|NCT01534338|Behavioral|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
79545712|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
79545713|NCT01534377|Behavioral|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
79545714|NCT01534377|Behavioral|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
79545715|NCT01534390|Device|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
79545716|NCT01534429|Procedure|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
79707034|NCT02426658|Drug|Pemetrexed Disodium|Given IV
79707035|NCT02426658|Other|Quality-of-Life Assessment|QOL studies
79847523|NCT00482170|Device|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
79847524|NCT00482170|Device|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
79847525|NCT05228249|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
79545717|NCT01534442|Drug|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
79847526|NCT05228249|Drug|Carmustine|Given IV
79847527|NCT05228249|Drug|Cytarabine|Given IV
79847528|NCT05228249|Drug|Etoposide|Given IV
79847529|NCT05228249|Biological|Loncastuximab Tesirine|Given IV
79847530|NCT05228249|Drug|Melphalan|Given IV
79847531|NCT02580383|Procedure|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
79847532|NCT02580227|Drug|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
79847533|NCT02580227|Other|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
79847534|NCT04076267|Other|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
79847535|NCT03883113|Biological|MVA-NP+M1|Trial Vaccine
79707036|NCT02400242|Drug|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
79707037|NCT02400242|Drug|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
79707038|NCT02400242|Drug|Dexamethasone|40 mg qd on days 1, 8, 15, 22
79707039|NCT02369575|Other|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
79707040|NCT02338687|Dietary Supplement|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
79847536|NCT03883113|Biological|Saline|Sodium Chloride Placebo
79545718|NCT01534442|Drug|Placebo|
79545719|NCT01534455|Drug|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
79707041|NCT02338687|Behavioral|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
79707042|NCT02318472|Device|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
79707043|NCT02318472|Device|Plaster cast|Lower limb plaster cast
79707044|NCT02158091|Drug|IPI-145|oral PI3K delta/gamma inhibitor
79707045|NCT02158091|Drug|Fludarabine|intravenous chemotherapy
79707046|NCT02158091|Drug|Cyclophosphamide|intravenous chemotherapy
79707047|NCT02158091|Drug|Rituximab|intravenous immunotherapy
80015638|NCT05210023|Other|CONVENTIONAL DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
79847537|NCT03883113|Biological|H3N2 (A/Belgium/2417/2015)|Challenge Agent
79847538|NCT04218695|Drug|Ceftriaxone|Antibiotic
79847539|NCT04218695|Drug|Normal saline|50cc intravenous once daily
80015639|NCT00835172|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
79251491|NCT03303027|Device|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
79251492|NCT03311529|Behavioral|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
80015640|NCT00835172|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
80015641|NCT04941755|Drug|BMS-986256|Specified dose on specified days
79545720|NCT01534455|Drug|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
79545721|NCT01534468|Biological|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
79545722|NCT01534546|Drug|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
79707048|NCT02057133|Drug|LY2835219|Administered orally.
79707049|NCT02057133|Drug|Letrozole|Administered orally.
79707050|NCT02057133|Drug|Anastrozole|Administered orally.
79707051|NCT02057133|Drug|Tamoxifen|Administered orally.
80015642|NCT04941755|Drug|Famotidine|Specified dose on specified days
79251493|NCT04490889|Diagnostic Test|NiPGT-A|NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
79251494|NCT05232435|Other|pilate mat exercise will be performed|pilate group:1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist plus standard treatment(stretch hamstring -stretch lower back - strength abdominal muscles - electrical heat pad)
79251495|NCT05232435|Other|MET|Will receive MET for hamstring and erectorspinae plus standard treatment
79251496|NCT05232435|Other|control group receive standard treatment|electrical heat pad - stretch hamstring - stretch lower back muscles - stregth abdominal muscles
79545723|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
79545724|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
79707052|NCT02057133|Drug|Exemestane|Administered orally.
79707053|NCT02057133|Drug|Everolimus|Administered orally.
79707054|NCT02057133|Drug|Trastuzumab|Administered IV infusion.
79707055|NCT02057133|Drug|LY3023414|Administered orally.
79707056|NCT02057133|Drug|Fulvestrant|Administered IM.
79707057|NCT02057133|Drug|Pertuzumab|Administered IV infusion.
79707058|NCT02057133|Drug|Loperamide|Administered orally.
79707059|NCT02057133|Drug|Endocrine therapy|Endocrine therapy administered orally.
79707060|NCT02054429|Drug|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
79707061|NCT01940757|Biological|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
79707062|NCT01460654|Drug|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
79707063|NCT01460654|Drug|Alendronate|Alendronate (Fosamax) 70mg every week.
79847540|NCT01000935|Other|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
79847541|NCT03967639|Procedure|Elective cardiac surgery|Elective cardiac surgery
80015643|NCT05093218|Dietary Supplement|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: <5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
79707064|NCT01460654|Drug|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
79707065|NCT01460654|Drug|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
79707066|NCT01408225|Procedure|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
79707067|NCT01224275|Other|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
79707068|NCT01093326|Drug|Ponesimod 10 mg|Ponesimod 10 mg oral use
79707069|NCT01093326|Drug|Ponesimod 20 mg|Ponesimod 20 mg oral use
79707070|NCT01093326|Drug|Ponesimod 40 mg|Ponesimod 40 mg oral use
79707071|NCT01091038|Other|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
79707072|NCT01091038|Other|Routine Care|Routine Care
79707073|NCT00752531|Behavioral|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
79707074|NCT00497952|Biological|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
79847542|NCT05674331|Procedure|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
79847543|NCT05674331|Device|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
79847544|NCT05674331|Procedure|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
79707075|NCT03039439|Procedure|Biospecimen Collection|Previously collected tumor tissue and blood samples
79707076|NCT03039439|Other|Laboratory Biomarker Analysis|Correlative studies
79707077|NCT03021460|Drug|Ibrutinib|Given PO
79847545|NCT00998673|Device|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
79847546|NCT00998673|Device|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
79847547|NCT03967561|Other|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
79545725|NCT01534559|Other|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
79251497|NCT03308643|Drug|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
79251498|NCT03308643|Other|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
79251499|NCT03302871|Drug|Botulinum toxin type A|
79545726|NCT01534572|Dietary Supplement|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
79545727|NCT01534572|Dietary Supplement|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
79545728|NCT01534585|Drug|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
79251500|NCT03302871|Device|transcranial direct current stimulation|
79251501|NCT03302871|Other|hybrid training model of CIMT and BIT|
79545729|NCT01534585|Radiation|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
79251502|NCT03302871|Other|usual care|
79251503|NCT03311295|Device|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
79251504|NCT03311217|Behavioral|Healthy retail strategies|
79251505|NCT04490811|Other|no intervention. observational cohort study|blood sampling is part of care
79251506|NCT00703911|Drug|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
79251507|NCT03302715|Genetic|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
79707078|NCT03021460|Other|Laboratory Biomarker Analysis|Correlative studies
79847548|NCT03967561|Other|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
79545730|NCT01534585|Drug|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
79707079|NCT03021460|Biological|Pembrolizumab|Given IV
79707080|NCT02996266|Device|Targeted Temperature Management|Prophylactic normothermia
79707081|NCT02996266|Other|Standard Care|No intervention to control temperature unless fever occurs
79707082|NCT02954497|Device|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
79707083|NCT02954497|Procedure|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
79707084|NCT02952248|Drug|BI 754091|
79847549|NCT01001013|Drug|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
80015644|NCT05093218|Other|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
79251508|NCT03311139|Drug|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
79251509|NCT03308487|Dietary Supplement|vitamin D3 (1000 IU)|
79545731|NCT01534585|Other|Quality of life|The EORTC QLQ-C30 and H&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
79707085|NCT02939755|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
79707086|NCT02939755|Behavioral|Enhanced Usual Care|usual care from health providers
79847550|NCT01004523|Genetic|fluorescence in situ hybridization|
79847551|NCT01004523|Genetic|loss of heterozygosity analysis|
79847552|NCT01004523|Genetic|polymerase chain reaction|
79847553|NCT01004523|Other|flow cytometry|
79847554|NCT01004523|Other|immunohistochemistry staining method|
79251510|NCT03308487|Dietary Supplement|Vitamin D3 (2000 IU)|
79251511|NCT03302637|Other|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
79251512|NCT03308331|Other|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
80015645|NCT05209945|Procedure|vibration|whole-body vibration, heel and soleus tendon vibrations were applied to the human body
79251513|NCT02055547|Drug|MK-8521 35μg|Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
79251514|NCT02055547|Drug|MK-8521 100μg|Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
79251515|NCT02055547|Drug|MK-8521 125μg|Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
79389757|NCT03199092|Behavioral|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
79545732|NCT01534585|Genetic|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
79707087|NCT02933736|Drug|Ribociclib|
79707088|NCT02926859|Drug|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
79707089|NCT02926859|Drug|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
79707090|NCT02912312|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
79707091|NCT02912312|Other|Laboratory Biomarker Analysis|Correlative studies
79707092|NCT02912312|Other|Quality-of-Life Assessment|Ancillary studies
79707093|NCT02912312|Other|Questionnaire Administration|Ancillary studies
79707094|NCT02912312|Radiation|Radiation Therapy|Undergo standard RNI
79707095|NCT02903420|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
79707096|NCT02876107|Drug|Carboplatin|Given IV
79707097|NCT02876107|Other|Laboratory Biomarker Analysis|Correlative studies
79707098|NCT02876107|Drug|Paclitaxel|Given IV
79847555|NCT00490282|Radiation|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
79847556|NCT00490282|Radiation|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
79847557|NCT03646877|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
79847558|NCT03646877|Other|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
79847559|NCT00998751|Drug|oral masitinib|7.5 mg/kg/day
79707099|NCT02876107|Biological|Panitumumab|Given IV
79707100|NCT02874885|Procedure|Biospecimen Collection|Undergo collection of blood sample
79707101|NCT02872259|Drug|BGB324+pembrolizumab|Combination
79707102|NCT02872259|Drug|BGB324+dabrafenib and trametinib|Combination
79707103|NCT02872259|Drug|pembrolizumab|Monotherapy
79707104|NCT02872259|Drug|dabrafenib and trametinib|Combination
79707105|NCT02859467|Other|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
79707106|NCT02859467|Other|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
79707107|NCT02831933|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
79251516|NCT02055547|Drug|MK-8521 150μg|Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
79251517|NCT02055547|Drug|MK-8521 175μg|Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
79251518|NCT02055547|Drug|MK-8521 200μg|Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
79251519|NCT02055547|Drug|MK-8521 300μg|Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
79389758|NCT03199092|Behavioral|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
79389759|NCT03198936|Dietary Supplement|Cognizin® SynapsaTM|2 capsules to be taken twice a day with meals with a glassful of water
79389760|NCT03198936|Dietary Supplement|Placebo|2 capsules to be taken twice a day with meals with glassful of water
79389761|NCT03199014|Device|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
79389762|NCT03199014|Device|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
79389763|NCT05642650|Device|novel wearable device|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
79389764|NCT03198780|Other|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
79389765|NCT05087914|Drug|Carbidopa-Levodopa (100mg/25mg):|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
79389766|NCT05087914|Drug|Naproxen|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
79545733|NCT01534702|Drug|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (< 60 years vs. ≥ 60 years).~Medication:~Patients < 60 years:~idarubicin 7.5 mg/m2 iv, days 1 + 3~cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~idarubicine 6 mg/m2 iv, days 1 + 3~cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~level -1: 15 mg/m2 iv, days 1 to 5~level 1: 20 mg/m2 iv, days 1 to 5~level 2: 25 mg/m2 iv, days 1 to 5~level 3: 30 mg/m2 iv, days 1 to 5~level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
79545734|NCT01534715|Drug|IMGN529|
79545735|NCT01534741|Other|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
79545736|NCT01534741|Device|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
79707108|NCT02831933|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
79707109|NCT02831933|Radiation|SBRT|Low-dose SBRT
79707110|NCT02831933|Drug|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
79707111|NCT02821741|Device|The Twin Stim Plus, 3rd Edition|Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
79707112|NCT02821741|Device|Medoc Pathway System|Device used to apply Thermal stimulation to both arms.
79707113|NCT02813668|Behavioral|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
79707114|NCT02805803|Other|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
79847560|NCT02580929|Radiation|radiotherapy|radiotherapy before surgery
79251520|NCT02055547|Drug|MK-8521 50/72μg|MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
79251521|NCT02055547|Drug|MK-8521 72/125μg|MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
79389767|NCT03198624|Drug|HTL0018318|Part A single dose Part B five doses
79389768|NCT03198624|Drug|Placebo oral capsule|Part B only
79389769|NCT03194724|Other|Vitamin A supplementation|Bi annual vitamin A supplementation programme
79707115|NCT02792881|Procedure|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
79707116|NCT02789228|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
79707117|NCT02763566|Drug|Abemaciclib|Administered orally
79707118|NCT02763566|Drug|Anastrozole|Administered orally
79389770|NCT03194802|Behavioral|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
79707119|NCT02763566|Drug|Letrozole|Administered orally
79847561|NCT01016470|Dietary Supplement|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
79251522|NCT02055547|Drug|MK-8521 100/150μg|MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
79545737|NCT01534754|Drug|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
79847562|NCT01016470|Dietary Supplement|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
79545738|NCT01534754|Drug|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
79545739|NCT01534754|Drug|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
79545740|NCT01534754|Drug|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
79545741|NCT01534780|Procedure|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
79545742|NCT01534780|Device|Protack|fixation of mesh with protack
79545743|NCT01534780|Device|Securestrap|fixation of mesh with Securestrap
79545744|NCT01534780|Device|Glubran|fixation of mesh with Glubran
79251523|NCT02055547|Drug|MK-8521 125/150μg|MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
79389771|NCT03194802|Behavioral|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
79545745|NCT01534793|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
80015646|NCT04921735|Drug|Cisatracurium|0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
79251524|NCT02055547|Drug|Placebo|Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
79251525|NCT02468817|Procedure|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
79389772|NCT03198858|Procedure|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
79707120|NCT02763566|Drug|Placebo|Administered orally
79707121|NCT02763566|Drug|Fulvestrant|Administered intramuscularly
79707122|NCT02760849|Other|Laboratory Biomarker Analysis|Correlative studies
79707123|NCT02760849|Procedure|Oophorectomy|Undergo ISDO
79251526|NCT02468817|Procedure|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
79251527|NCT04442451|Other|Control Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
79251528|NCT04442451|Other|Blood Flow Restriction Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
79389773|NCT03198858|Procedure|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
79389774|NCT01709513|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets.
79389775|NCT01709513|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet.
79707124|NCT02760849|Other|Quality-of-Life Assessment|Ancillary studies
79707125|NCT02760849|Procedure|Salpingectomy|Undergo ISDO
79389776|NCT01709513|Drug|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
79389777|NCT01709513|Drug|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
79545746|NCT01534806|Drug|Ketorolac|Ketorolac(0.5mg/kg) IV push
79545747|NCT01534806|Drug|Placebo|Sodium Chloride 0.9% - 10 mL IV push
79545748|NCT01534832|Device|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
79707126|NCT02760849|Procedure|Salpingo-Oophorectomy|Undergo RRSO
79707127|NCT02760433|Drug|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
79707128|NCT02760433|Drug|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
79847563|NCT01004601|Drug|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
79545749|NCT01534845|Drug|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
79707129|NCT02760407|Drug|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
79707130|NCT02760407|Drug|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
79707131|NCT02760407|Drug|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
79707132|NCT02760407|Drug|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
79707133|NCT02760368|Drug|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
79707134|NCT02760368|Drug|Placebo|sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
79707135|NCT02754752|Procedure|Electroacupuncture Therapy|Undergo electroacupuncture therapy
79707136|NCT02754752|Procedure|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
79707137|NCT02754752|Other|Laboratory Biomarker Analysis|Correlative studies
79707138|NCT02754752|Other|Quality-of-Life Assessment|Ancillary studies
79707139|NCT02754752|Other|Questionnaire Administration|Ancillary studies
79707140|NCT02752750|Other|MRI|MR imaging (MRI) at 3 Tesla
79707141|NCT02747004|Drug|Abemaciclib|Administered orally
79707142|NCT02747004|Drug|Tamoxifen|Administered orally
79707143|NCT02747004|Drug|Prophylactic Loperamide|Administered orally
79707144|NCT02741570|Biological|Nivolumab|
79707145|NCT02741570|Biological|Ipilimumab|
79707146|NCT02741570|Drug|Cetuximab/Erbitux|
79707147|NCT02741570|Drug|Cisplatin/Platinol|
79707148|NCT02741570|Drug|Carboplatin/Paraplatin|
79707149|NCT02741570|Drug|Fluorouracil/Adrucil|
79707150|NCT02741180|Other|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
79707151|NCT02741180|Other|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
79707155|NCT02730416|Drug|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
79707156|NCT02723760|Drug|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
79707157|NCT02706197|Device|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
79707158|NCT02703610|Drug|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
79251529|NCT05031585|Device|Roncoliv|The medical device with nasal spray solution should be used 1 time a day, before bedtime, for 30 days.
79251530|NCT05031585|Device|Placebo|The medical device with placebo should be used 1 time a day, before bedtime, for 30 days.
79251531|NCT02414854|Drug|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
79707159|NCT02703610|Drug|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
79707160|NCT02685566|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
79707161|NCT02685566|Device|FFDM|FujiFilm Aspire Cristalle System
79251532|NCT02414854|Drug|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
79251533|NCT02414854|Drug|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
79251534|NCT02414854|Drug|Albuterol/Salbutamol|Oral inhalation as needed
79251535|NCT02414854|Drug|Levalbuterol/Levosalbutamol|Oral inhalation as needed
79251536|NCT04442139|Other|Mini-Gastric Bypass|Mini-Gastric Bypass bariatric surgery
79707162|NCT02683824|Diagnostic Test|Computed Tomography|Undergo CT scan
79707163|NCT02683824|Other|Laboratory Biomarker Analysis|Correlative studies
79707164|NCT02683824|Diagnostic Test|PET/MRI scan|Undergo PET/MRI scan
79707165|NCT02683824|Drug|[18F]FP-R01-MG-F2|radioactive tracer
79707166|NCT02681185|Other|Virtual Care|"Virtual Care consists of the following services and resources:~Have a virtual consult through online methods or telephone with one of the study endocrinologists~Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
79707167|NCT02681185|Other|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
79707168|NCT02675231|Drug|Abemaciclib|Administered Orally
79707169|NCT02675231|Drug|Trastuzumab|Administered IV
79707170|NCT02675231|Drug|Fulvestrant|Administered IM
79707171|NCT02675231|Drug|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
79707172|NCT02661035|Drug|Allopurinol|300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
79707173|NCT02661035|Drug|Fludarabine|30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
79707174|NCT02661035|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
79707175|NCT02661035|Drug|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
79707176|NCT02661035|Radiation|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
79707177|NCT02661035|Drug|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
79707178|NCT02661035|Drug|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated."
79847564|NCT01004601|Drug|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
79847565|NCT03640793|Device|Implantation|Implantation of 6 PPIS implants
79847566|NCT00998829|Other|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
79251537|NCT03308253|Device|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
79847567|NCT01001247|Drug|TMC278; Omeprazole|
79847568|NCT03923543|Diagnostic Test|Neutrophil to lymphosit ratio|
79847569|NCT04205357|Drug|Sulfasalazine|Sulfasalazine combined with stereotactic radiosurgery
79847570|NCT01004757|Other|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
79545750|NCT01534858|Device|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
79389778|NCT05637190|Other|Expressive Arts Therapy group intervention|Art is helpful to reduce negative emotions and boost self-worth during the creative process. During the Expressive Arts Therapy workshops, participants experience different art forms, including visual art, body movement, writing, music, and guided imagery to identify the inner self and get in touch with the self to release suppressed emotions and stress.
79847571|NCT01004757|Other|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
79847572|NCT02580773|Drug|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
79389779|NCT02449590|Dietary Supplement|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
79847573|NCT02580773|Drug|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
79251538|NCT03308253|Drug|Vancomycin|0.5 g Vancomycin per patient
79251539|NCT03308253|Drug|Tobramycin|120 mg tobramycin per patient
79251540|NCT03308253|Other|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
79389780|NCT02449590|Dietary Supplement|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
79251541|NCT02055625|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
79251542|NCT02467023|Device|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
79389781|NCT04152148|Biological|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
79389782|NCT04152148|Biological|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
79389783|NCT04152148|Biological|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
79545751|NCT01534884|Biological|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
79545752|NCT01534923|Behavioral|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
79545753|NCT01534949|Biological|rituximab|375 mg/m2 by intravenous [IV] infusion
79389784|NCT04152148|Biological|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
79545754|NCT01535027|Drug|teriparatide|teriparatide 20 ug/day, sc.
79707179|NCT02661035|Biological|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
79707180|NCT02661035|Biological|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
79707181|NCT02641483|Other|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
79847574|NCT05032937|Drug|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
79847575|NCT01008813|Biological|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A
80015647|NCT01676116|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
79707182|NCT02627846|Device|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
79707183|NCT02627846|Device|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
79847576|NCT01008813|Biological|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)
80015648|NCT01676116|Drug|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
79389785|NCT02446158|Drug|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
80015649|NCT01676116|Drug|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
79251543|NCT02467023|Device|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
79389786|NCT02446002|Drug|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
79389787|NCT04125316|Other|Observation, no intervention|Observational study, no intervnetion
80015650|NCT04930796|Drug|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
80015651|NCT05200793|Drug|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
79545755|NCT01535027|Drug|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
79545756|NCT01535027|Drug|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
79545757|NCT01535079|Drug|Placebo|Single administration
79545758|NCT01535079|Drug|Ibuprofen 35 mg|Single administration
79545759|NCT01535079|Drug|Ibuprofen 25 mg|Single administration
79545760|NCT01535079|Drug|Ibuprofen 15 mg|Single administration
79545761|NCT01535079|Drug|Strefen|Single administration
79545762|NCT01535092|Drug|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
79545763|NCT01535092|Drug|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
79707184|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
79707185|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
79707186|NCT02627846|Drug|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
79707187|NCT02627846|Drug|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
79707188|NCT02603887|Other|Laboratory Biomarker Analysis|Correlative studies
79707189|NCT02603887|Biological|Pembrolizumab|Given IV
79707190|NCT02581787|Biological|Fresolimumab|Given IV
79707191|NCT02581787|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
79707192|NCT02576496|Drug|Tinostamustine|
79707193|NCT02573766|Procedure|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
79847577|NCT01001481|Other|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
79707194|NCT02573766|Procedure|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
79707195|NCT02573766|Behavioral|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
79707196|NCT02573766|Behavioral|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
79847578|NCT03999645|Procedure|Early laparoscopic cholecystectomy|within 72h from symptom onset
80015652|NCT05200793|Drug|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
79389788|NCT05072626|Combination Product|high MCT formula|Alfaré(Nestlé Health Science China, including 39% of MCT) with breast milk (or infant formula). Alfaré can be fed with moderate concentration(3.45 tablespoons of 90ml water - 4 tablespoons of 90ml water), and the total energy can be increased by 7.3-16.8kcal/kg/day.
79707197|NCT02554279|Drug|menotropin|
79707198|NCT02554279|Drug|recombinant FSH|
79707199|NCT02535988|Radiation|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
79707200|NCT02535988|Drug|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
79707201|NCT02515773|Drug|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
80015653|NCT05200793|Drug|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
79389789|NCT05072626|Dietary Supplement|MCT powder|MCT supplement 1-2g/kg/day combined with breast milk (or infant formula), the total energy can be increased by 7.3-14.6kcal/kg/day.
79389790|NCT02446080|Dietary Supplement|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
79389791|NCT02446080|Dietary Supplement|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
79389792|NCT05627830|Procedure|Prolotherapy|Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
79389793|NCT04118764|Device|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
79389794|NCT04118764|Drug|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
79707202|NCT02515773|Behavioral|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
79707203|NCT02511730|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
79707204|NCT02511730|Device|FFDM|FujiFilm Aspire Cristalle System
79707205|NCT02510417|Biological|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
79707206|NCT02484248|Drug|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
79707207|NCT02484248|Drug|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
80015654|NCT00917306|Drug|PEP005 Gel|0.05% two day treatment
79707208|NCT02478788|Drug|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
79707209|NCT02478788|Drug|Placebo|Pills with no medication in it
79707210|NCT02456194|Device|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
79707211|NCT02439450|Biological|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
79847579|NCT03999645|Procedure|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
79707212|NCT02439450|Drug|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
79707213|NCT02439450|Drug|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
79707214|NCT02439450|Drug|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
79707215|NCT02437136|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACs)
79707216|NCT02437136|Drug|pembrolizumab|A selective humanized monoclonal antibody (mAb)
79707217|NCT02435758|Procedure|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
79707218|NCT02403778|Drug|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
79707219|NCT02403778|Drug|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
79707220|NCT02386826|Drug|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
79707221|NCT02386826|Biological|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
79707222|NCT02378272|Other|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
79707223|NCT02365454|Device|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
79707224|NCT02326402|Device|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
79707225|NCT02312258|Drug|Placebo|Ixazomib placebo-matching capsules.
79707226|NCT02312258|Drug|Ixazomib|Ixazomib capsules.
79707227|NCT02276274|Drug|SYR-322-MET|Oral administration of SYR-322-MET
79707228|NCT02221700|Procedure|Massage Therapy|Undergo massage therapy
79251544|NCT02467023|Procedure|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
79707229|NCT02221700|Other|Quality-of-Life Assessment|Ancillary studies
79389795|NCT04118764|Other|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
79389796|NCT04118764|Other|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
79389797|NCT04118764|Other|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
79389798|NCT01605071|Drug|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
79389799|NCT02710422|Biological|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
79707230|NCT02221700|Other|Questionnaire Administration|Ancillary studies
79707231|NCT02203903|Biological|Tumor associated antigen lymphocytes (TAA-T)|TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
79707232|NCT02203240|Other|Cocoa|
79707233|NCT02203240|Other|Placebo|
79707234|NCT02199184|Drug|Cyclophosphamide|Given IV
79707235|NCT02199184|Drug|Doxorubicin Hydrochloride|Given IV
79707236|NCT02199184|Drug|Etoposide|Given IV
79545764|NCT01535144|Device|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
79545765|NCT01535144|Device|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
79707237|NCT02199184|Biological|Ofatumumab|Given IV
80015655|NCT05191303|Device|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
80015656|NCT03453502|Behavioral|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
79707238|NCT02199184|Drug|Prednisone|Given PO
79707239|NCT02199184|Biological|Rituximab|Given IV
80015657|NCT02264899|Other|in Memento-VASCOD|"Pulse wave velocity assessment~Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~Neuropsychological testing and behaviorial and mood scales~Urinary albumin excretion measurement"
79847580|NCT05195801|Device|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
80015658|NCT05763485|Procedure|Anti reflux mucosal ablation (ARMA)|"In patients fulfilling the inclusion criteria and being randomized for ARMA, the procedure using argon plasma coagulation involves two semicircular ablations of the mucosa of the EGJ in a butterfly shape of a width of 2 cm. The approximate duration of the procedure is 30min.~Follow includes objective evaluation of reflux disease by reflux questionnaires, esophagogastroduodenoscopy, esophageal manometry, pH metry."
80015659|NCT05763485|Procedure|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, the procedure involves esophagogastroduodenoscopy with the same set of movements and duration as the ARMA procedure without the actual ablation.
79707240|NCT02199184|Drug|Vincristine Sulfate|Given IV
79847581|NCT01005069|Drug|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
80015660|NCT03383224|Other|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
79847582|NCT01005069|Drug|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
79251545|NCT02467023|Drug|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
79251546|NCT02467023|Drug|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
80015661|NCT03383224|Drug|Nicotine patch|
79847583|NCT01005069|Drug|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
79847584|NCT01005069|Drug|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
79847585|NCT01005069|Drug|Placebo capsule|Placebo capsules once daily and lifestyle modification
80015662|NCT03383224|Behavioral|Smoking cessation counseling|
80015663|NCT05200637|Device|Orsiro stent|Orsiro stent
80015664|NCT05200637|Device|Xience stent|Xience stent
80015665|NCT05200637|Device|Any drug-eluting stent|Any drug-eluting stent
79545766|NCT01535157|Drug|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
79545767|NCT01535170|Dietary Supplement|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17].
79545768|NCT01535183|Drug|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
79545769|NCT01535196|Drug|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
79707241|NCT02196376|Other|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
79707242|NCT02196376|Other|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
80015666|NCT05200169|Drug|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
79707243|NCT02196376|Other|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
79847586|NCT01009125|Other|$2 cash|$2 cash incentive will be included in the mailed survey
79847587|NCT01009125|Other|$5 cash|$5 cash incentive will be included in the mailed survey
79847588|NCT02580851|Other|diagnostic test - cardiac magnetic resonance imaging|
79847589|NCT02580851|Other|diagnostic test - coronary angiography|
79847590|NCT01005147|Drug|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
79545770|NCT01535209|Radiation|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
79707244|NCT02196376|Behavioral|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
80015667|NCT03219658|Behavioral|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
80015668|NCT05762081|Procedure|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
80015669|NCT05762081|Procedure|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
80015670|NCT04699357|Drug|Atropine|different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
80015671|NCT00737516|Biological|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
79847591|NCT01005147|Other|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
80015672|NCT04651387|Dietary Supplement|Ozonized oil (HOO|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations."
79251547|NCT02467023|Drug|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
79251548|NCT02467023|Other|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
79847592|NCT01001793|Device|Levacor Ventricular Assist Device|Surgical procedure
79847593|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
79847594|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
79389800|NCT02710422|Behavioral|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
79707245|NCT02185755|Other|Internet-Based Glucose Monitoring System|
79707246|NCT02185755|Drug|Normal Medication Positive Control|
79847595|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
80015673|NCT05198531|Drug|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
80015674|NCT05198531|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
80015675|NCT05198531|Drug|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
80015676|NCT05198531|Drug|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
80015677|NCT02986516|Other|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
80015678|NCT02986516|Radiation|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
79545771|NCT01535209|Radiation|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
79545772|NCT01535300|Procedure|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
79545773|NCT01535313|Device|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
79847596|NCT01001871|Dietary Supplement|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
79545774|NCT01535352|Behavioral|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
79545775|NCT01535352|Behavioral|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
79707247|NCT02165007|Drug|peripheral blood stem cell graft that are CD34+ selected|The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.
79707248|NCT02164734|Device|Endotracheal intubation|
79707249|NCT02164734|Device|Laryngeal mask airway|
79707250|NCT02164734|Drug|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
79707251|NCT02135133|Drug|Idelalisib|150 mg BID Oral Daily
79707252|NCT02135133|Drug|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
79707253|NCT02131805|Radiation|Electronic Skin Surface Brachytherapy|
80015679|NCT03628651|Other|Blood Sample Collection|HCC subjects will have one blood sample collected.
79251549|NCT02467023|Device|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
79251550|NCT02055703|Drug|E2609|
79251551|NCT02055703|Drug|itraconazole|
79251552|NCT02055703|Drug|rifampin|
79707254|NCT02131805|Behavioral|Quality of life assessment|
79707255|NCT02110069|Drug|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
79707256|NCT02110069|Drug|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
79707257|NCT02049515|Drug|IPI-145|PI3K Inhibitor
80015680|NCT03628651|Other|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
80015681|NCT02743520|Device|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
79251553|NCT02055703|Drug|digoxin|
79251554|NCT02055703|Drug|donepezil|
79251555|NCT03302481|Other|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
79707258|NCT02049515|Drug|Ofatumumab|Monoclonal antibody
79707259|NCT02046460|Drug|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
79707260|NCT02046460|Drug|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
79707261|NCT02039401|Biological|VM202|
79707262|NCT02004522|Drug|Duvelisib|PI3K Inhibitor
79707263|NCT02004522|Drug|Ofatumumab|monoclonal antibody
79251556|NCT02058433|Other|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
79251557|NCT02058433|Other|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
79389801|NCT02710422|Other|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
79389802|NCT02710422|Behavioral|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
79389803|NCT04345198|Procedure|Adrenal Artery Ablation|Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
79389804|NCT03192618|Procedure|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
79707264|NCT01956084|Drug|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
79847597|NCT01001871|Dietary Supplement|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
79389805|NCT03192618|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
79389806|NCT01706159|Drug|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
79389807|NCT01706159|Drug|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
80015682|NCT05186207|Other|abnormal pre-pregnancy test results that need clinical intervention|The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
80015683|NCT05176613|Device|HF-rTMS|HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
79251558|NCT03561181|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
79251559|NCT03561181|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
79251560|NCT03308175|Device|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
79251561|NCT03308175|Device|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
79251562|NCT02060149|Drug|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
79251563|NCT02060149|Drug|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
79251564|NCT02060149|Drug|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
79251565|NCT02060149|Drug|No nebulization|No nebulization will be given to the patients.
79389808|NCT03198312|Device|CathiportTM|fully implanted
79389809|NCT03198312|Device|Implant Port|fully implanted
79389810|NCT04113226|Drug|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
79389811|NCT04113226|Drug|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
79389812|NCT04113226|Other|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,…) on which treatment may impact.
79707265|NCT01956084|Drug|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
79389813|NCT04113226|Other|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
79251566|NCT03302403|Genetic|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
79251567|NCT03302403|Genetic|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
79251568|NCT03302403|Genetic|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
79251569|NCT03302403|Genetic|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
79251570|NCT03302403|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
79251571|NCT03302403|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
79251572|NCT02038621|Drug|Paclitaxel|
79251573|NCT02038621|Drug|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\PR\SD,then randomized into this clinical trial.
79251574|NCT04902651|Device|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
79251575|NCT04902651|Device|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
79251576|NCT02055859|Radiation|Radiosurgery|
79707266|NCT01945814|Drug|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
80015684|NCT05176613|Behavioral|ML|Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
80015685|NCT05176613|Device|Sham-rTMS|Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
80015686|NCT04473170|Biological|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
79389814|NCT05060302|Other|transthoracic echocardiography (TTE)|the included patients have a TTE preoperatively in order to evaluate the RV systolic function. TTE will also be done at day 2 and day-15 during the follow-up surgical consultation.
79389815|NCT04552145|Procedure|surgery|standard decompression surgery
80015687|NCT04473170|Drug|COVID-19 standard care|UAE National Guidelines for Clinical Management and Treatment of COVID-19.
79251577|NCT04891341|Other|Technology Supported Task-Oriented Circuit Training|"Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.~Sit to stand~Standing and trunk training~Standing and lower limb training~Stepping~Walking~Walking with object manipulation~Climbing and descending stairs~Unilateral upper extremity activity training (VR)~Bilateral upper extremity activity training (VR)~Upper extremity reaction time training (VR) Virtual reality games will be played using the USE-IT intelligent physiotherapy game system. The system offers unilateral, bilateral and bimanual upper extremity training to individuals with a 55 inch touch screen and 7 computer games (balloon popping, car washing, plumbing, arithmetic, apartment, drum and matching)."
79389816|NCT04552145|Behavioral|Physiotherapy|3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
79389817|NCT02444208|Behavioral|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
79389818|NCT02444208|Behavioral|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
79545776|NCT01535391|Drug|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
79545777|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
79707267|NCT01945814|Drug|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
79707268|NCT01932697|Drug|Docetaxel|Given IV
79707269|NCT01932697|Radiation|Hyperfractionation|Undergo hyperfractionated IMRT
79251578|NCT04891341|Other|Home-based Telerehabilitation|Strengthening, balance and coordination exercises will be sent to the participants via a mobile application. Patients will do the exercises at home and send a notification to their physiotherapist. Intervention will be applied for 1 hour, 3 days a week for 8 weeks.
79251579|NCT03332498|Drug|Pembrolizumab|200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
79389819|NCT05044000|Device|Deep propioceptive stimulation|Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
79389820|NCT02444364|Drug|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
79389821|NCT05039476|Dietary Supplement|Retinol face cream|Retinol face cream
79389822|NCT05039476|Dietary Supplement|Placebo face cream|Placebo face cream
79707270|NCT01932697|Radiation|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
79707271|NCT01932697|Other|Laboratory Biomarker Analysis|Correlative studies
79707272|NCT01932697|Other|Quality-of-Life Assessment|Ancillary studies
79389823|NCT02445846|Device|dual HIV/syphilis rapid diagnostics tests|
79389824|NCT05031598|Other|Long-term fasting according to the Buchinger Wilhelmi fasting program|the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
79545778|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
79707273|NCT01820182|Device|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
79707274|NCT01752049|Drug|Topical timolol maleate|"Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 3 cutaneous telangiectasias per patient"
79707275|NCT01752049|Drug|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
79707276|NCT01747447|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
79707277|NCT01747447|Dietary Supplement|Fish oil placebo|Fish oil placebo
79707278|NCT01747447|Dietary Supplement|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79847598|NCT02580071|Dietary Supplement|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
79251580|NCT03332498|Drug|Ibrutinib|Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
79251581|NCT01334125|Drug|Metformin|Metformin 1000 mg once daily by mouth for 9 months
79251582|NCT01334125|Drug|Placebo|2 capsules once daily by mouth for 9 months
79251583|NCT03302325|Procedure|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
79251584|NCT02414152|Drug|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
79707279|NCT01747447|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
79707280|NCT01739309|Drug|Abemaciclib|Administered orally
79707281|NCT01724346|Drug|Post-Chlorambucil Therapy Follow-up|Patients remain in this Arm for continued follow-up until PD, unacceptable toxicity, or other reason for treatment discontinuation. All patients in this Arm have completed Chlorambucil therapy. Patients who have progression will exit the study.
79707282|NCT01724346|Drug|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily.
79707283|NCT01724346|Drug|Second-line Ibrutinib|Patients in this arm who were previously eligible to receive Second-line Ibrutinib will exit the study with option to roll-over to another long-term Ibrutinib study, if eligible.
79707284|NCT01724346|Drug|Alternative Anticancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion.
79707285|NCT01724346|Drug|Alternative Anti-cancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion. Patients originally randomized to Chlorambucil will exit the study. Patients originally randomized to Ibrutinib will continue on study.
79707286|NCT01659658|Drug|IXAZOMIB|Ixazomib capsules
79707287|NCT01659658|Drug|Dexamethasone|Dexamethasone tablets
80015688|NCT02872948|Genetic|Diagnostic|
79251585|NCT03308019|Device|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
79389825|NCT00355732|Procedure|Weaning from mechanical ventilation|
79389826|NCT02445612|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
79545779|NCT01535417|Drug|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
79545780|NCT01535417|Drug|Celebrex|
79545781|NCT01535456|Procedure|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
79389827|NCT00356356|Drug|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
79545782|NCT01535469|Drug|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
79707288|NCT01659658|Drug|Melphalan|Melphalan tablets
79707289|NCT01659658|Drug|Cyclophosphamide|Cyclophosphamide tablets
79707290|NCT01659658|Drug|Thalidomide|Thalidomide capsules
79707291|NCT01659658|Drug|Lenalidomide|Lenalidomide capsules
79707292|NCT01591356|Drug|EphA2-targeting DOPC-encapsulated siRNA|Given IV
79707293|NCT01591356|Other|Laboratory Biomarker Analysis|Correlative studies
80015689|NCT01869829|Drug|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
80015690|NCT02683018|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
80015691|NCT02683018|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
80015692|NCT04472624|Other|Fasting|Acute fasting for 72 hours
80015693|NCT04472624|Other|Ketogenic diet|Intake of a ketogenic diet for 14 days
79251586|NCT03308019|Procedure|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
79847599|NCT05673941|Other|Creative physical training|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
79847600|NCT01001949|Dietary Supplement|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
79847601|NCT01001949|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
79389828|NCT03194412|Dietary Supplement|Diet /nutritional|"• Duration:~the first stage - 3 months: 12 weeks~second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~make a diet modification to include the products recommended in frailty~modifying eating habits~The diet modification is mainly focused on adequate supply:~vitamin D (according to Central Europe guidelines -2013 for seniors)~protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
79545783|NCT01535482|Behavioral|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
80015694|NCT03982576|Other|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
80015695|NCT03982576|Behavioral|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
80015696|NCT03982576|Behavioral|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
80015697|NCT03982576|Behavioral|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
80015698|NCT03982576|Behavioral|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
79545784|NCT01535482|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
79545785|NCT01535495|Drug|Propranolol|Propranolol XL 120mg by mouth once daily
79545786|NCT01535521|Device|Sleep Position Trainer (SPT)|
79251587|NCT02413996|Device|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
79251588|NCT02413996|Behavioral|Functional activities|Stairs, walking
79389829|NCT03194412|Behavioral|Physical activity|"Duration:~the first stage - 3 months: 12 weeks~second stage - 3 months: 12 weeks~Frequency: twice a week~Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~resistance exercises and strength training, which aim to improve muscle strength in the limbs~exercises aimed at improving motor coordination, flexibility and speed~stretching exercises."
79389830|NCT03194412|Combination Product|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~the first stage - 3 months- 12 weeks~the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
79389831|NCT03194412|Behavioral|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~the first stage - 3 months: 12 weeks~the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
79545787|NCT01535547|Drug|isavuconazole|oral
79545788|NCT01535547|Drug|tacrolimus|oral
79545789|NCT01535586|Device|CPAP versus MAD|Cross over design
79545790|NCT01535612|Device|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
79545791|NCT01535625|Device|Momo stent|Patients with PCI
79545792|NCT01535651|Behavioral|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
79707294|NCT01591356|Other|Pharmacological Study|Correlative studies
79707295|NCT01586767|Radiation|Proton radiation therapy|Daily proton radiation therapy
79707296|NCT01586767|Radiation|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
79251589|NCT02413996|Other|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
79251590|NCT02413996|Other|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
79707297|NCT01523977|Drug|Everolimus|Orally, daily days 1-32 per assigned dose level
79707298|NCT01523977|Drug|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
79707299|NCT01523977|Drug|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
79707300|NCT01523977|Drug|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
79707301|NCT01523977|Drug|Doxorubicin|30 mg/m2 IV on days 4 and 5
79707302|NCT01523977|Drug|Dexrazoxane|300 mg/m2 IV on days 4 and 5
79707303|NCT01517243|Drug|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
79707304|NCT01517243|Drug|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
79707305|NCT01407510|Drug|Mapracorat|Application of the investigational product on the affected skin areas
79707306|NCT01357161|Drug|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
80015699|NCT05167721|Biological|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
80015700|NCT05167721|Other|Placebo|Placebo administered intrathecally
80015701|NCT05081518|Drug|Lu AG06466|Lu AG06466 - capsule
80015702|NCT05081518|Drug|Placebo|Placebo - capsule
80015703|NCT05127005|Procedure|Trapeziectomy|Surgical excision of trapezoideum
80015704|NCT05127005|Procedure|Sham|Skin incision only
79545793|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
79545794|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
79545795|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
79545796|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
79545797|NCT01535690|Other|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
79545798|NCT01535716|Behavioral|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) & cardiac index (CI).~goals:~SVV < 11%~IC > 2,2 ml/min/m²~During the anesthesia"
79707307|NCT01357161|Drug|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
79707308|NCT01357161|Drug|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
79707309|NCT01357161|Drug|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
79707310|NCT01321073|Device|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
80015705|NCT00798265|Biological|Gardasil|.5 mL dose injected IM at 0, 2 and 6 months
80015706|NCT00798265|Behavioral|Survey|Administration of online risk behavior and knowledge survey done at week 0.
79707311|NCT01308203|Drug|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
79707312|NCT01308203|Drug|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
79707313|NCT01289171|Drug|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
79707314|NCT01276704|Drug|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
79707315|NCT01276704|Drug|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
79707316|NCT01190930|Drug|Cyclophosphamide|Given IV
79707317|NCT01190930|Drug|Cytarabine|Given IT, IV, or SC
79707318|NCT01190930|Drug|Dexamethasone|Given orally (PO) or IV
79707319|NCT01190930|Drug|Doxorubicin Hydrochloride|Given IV
79707320|NCT01190930|Other|Laboratory Biomarker Analysis|Correlative studies
79707321|NCT01190930|Drug|Leucovorin Calcium|Given PO
79707322|NCT01190930|Drug|Mercaptopurine|Given PO
79707323|NCT01190930|Drug|Methotrexate|Given IT, PO, or IV
79707324|NCT01190930|Drug|Pegaspargase|Given IV
79707325|NCT01190930|Other|Quality-of-Life Assessment|Ancillary studies
80015707|NCT04882124|Drug|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
80015708|NCT04882124|Drug|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
80015709|NCT03976960|Other|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
80015710|NCT03628573|Device|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
80015711|NCT03628573|Device|Intermittent Theta burst stimulation ( iTBS)|
79847602|NCT01002027|Behavioral|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
79847603|NCT01005381|Dietary Supplement|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
79847604|NCT01005381|Dietary Supplement|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
79847605|NCT01005381|Dietary Supplement|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
79847606|NCT01005381|Dietary Supplement|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
80015712|NCT05125913|Diagnostic Test|FMD|Measurements will be made by using ultrasound system with a 12-Mhz probe. All vasoactive medications will be withheld for 24 h before the procedure. The participants will remain at rest in the supine position for at least 15 minutes before the examination. Each subject's right arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. If an arteriovenous fistula is present, the contralateral arm will be used for assessment. Three adjacent measurements of end-diastolic brachial artery diameter will be made from single 2D frames. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively.
80015713|NCT05125913|Diagnostic Test|Arterial stiffness|Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference-acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
80015714|NCT05125913|Diagnostic Test|Assessment of IMT|A high-resolution B-mode ultrasound of the common carotid arteries with scanning of the longitudinal axis until the bifurcation and of the transversal axis will be performed using ultrasonic pulse with a middle frequency of 12 MHz. For each carotid artery, two longitudinal measurements will be obtained by rotating the vessels at 180o increments along their axis. IMT will be measured at 1 cm proximal to the bifurcation on each side.
79251591|NCT03302169|Procedure|Radical prostatectomy with posterior rhabdosphincter reconstruction|To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
79251592|NCT03302169|Procedure|Radical prostatectomy without posterior rhabdosphincter reconstruction|Standard technique with a running suture to perform the urethrovesical anastomosis
79251593|NCT05727813|Device|cryoablation|cryoablation of breast cancer smaller than 2 cm
79251594|NCT02467725|Other|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
79251595|NCT01333501|Drug|Fingolimod|0.5 mg in capsules for oral administration once daily
79251596|NCT01333501|Drug|Interferon beta 1b|250 μg injected s.c. every other day
79251597|NCT01362140|Drug|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
79251598|NCT01362140|Drug|Placebo|Administered by subcutaneous injection every 3 weeks
79251599|NCT03307941|Drug|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
79251600|NCT03307941|Drug|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
79251601|NCT03307941|Drug|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
79251602|NCT03307941|Radiation|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
79545799|NCT01535716|Behavioral|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~Diuresis > 0,5ml/kg/h~Blood pressure , PAM > 65 mmHg~Pulse pressure variation~CVP 8 to 12 cmH20~Visual aspect of the heart~Overload signs During the anesthesia"
79545800|NCT01535742|Device|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
79545801|NCT01535742|Device|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
79545802|NCT01535742|Device|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
79545803|NCT01535742|Device|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
79545804|NCT01535755|Device|protocol|In this group, the patients were weaned as the protocol.
79707326|NCT01190930|Other|Questionnaire Administration|Ancillary studies
79707327|NCT01190930|Drug|Thioguanine|Given PO
79707328|NCT01190930|Drug|Vincristine Sulfate|Given IV
79707329|NCT01169259|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
79707330|NCT01169259|Drug|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79707331|NCT01169259|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
79707332|NCT01169259|Dietary Supplement|Fish oil placebo|Fish oil placebo
79707333|NCT01163682|Device|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
79707334|NCT01163682|Device|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
79707335|NCT01047007|Drug|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
79707336|NCT01047007|Drug|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
79847607|NCT05080335|Other|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~TRANS- vs CIS-gender female instructors~With or without short videos of transgender youth embedded into the didactic [TV or CV]; for the group with no embedded videos [NV], the same videos will be shown AFTER completion of the post measures)~No-intervention control, in which TV will be delivered *after* collection of pre/post measures."
79847608|NCT01002183|Drug|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
79847609|NCT05734209|Behavioral|Virtual food|Virtual food eaten using immersive virtual reality equipment
79847610|NCT05734209|Behavioral|Real food|Real food eaten using regular utensils
79847611|NCT05154279|Drug|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
79847612|NCT05734131|Other|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up&Go test (TUG).
79389832|NCT04032730|Device|Wisepill device|"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."
79847613|NCT01005537|Biological|aldesleukin|Given IV and orally
79847614|NCT01005537|Biological|therapeutic autologous lymphocytes|Given IV
79847615|NCT01005537|Drug|cyclophosphamide|Given IV
79847616|NCT01005693|Other|questionnaire administration|
79847617|NCT01005693|Procedure|cognitive assessment|
79847618|NCT01005693|Procedure|examination|
79847619|NCT01005693|Procedure|management of therapy complications|
79545805|NCT01535755|Other|physician's orders|In this group, the patients were weaned as the clinicians' order.
79707337|NCT01047007|Drug|CDDP|CDDP 60 mg/m^2 to 100 mg/m^2 administered as an IV infusion on Day 1.
79707338|NCT01047007|Drug|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
79707339|NCT01007578|Device|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
79847620|NCT01002417|Drug|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
80015715|NCT05125913|Diagnostic Test|Echocardiography|Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
79847621|NCT01002417|Drug|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
79847622|NCT01002417|Drug|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
79847623|NCT01002495|Biological|VM202|Endocardial injections on Day 0.
79847624|NCT01005771|Drug|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
79847625|NCT01005771|Drug|Placebo|Matching placebo
79847626|NCT01005849|Dietary Supplement|Protecflor|1 Capsule to be taken once a day during the entire study period
79847627|NCT01005849|Dietary Supplement|Placebo|1 Capsule to be taken once a day during the entire study period
79847628|NCT01005927|Dietary Supplement|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
79847629|NCT03742713|Drug|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
79847630|NCT01002651|Dietary Supplement|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
79847631|NCT01002651|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
79847632|NCT05733429|Other|eye cervical re-education|patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
79707340|NCT01002872|Drug|Lanthanum Carbonate (Fosrenol)|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus <3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is <3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus <3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
79847633|NCT05733429|Other|motor imagery therapy|the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
79707341|NCT01002872|Drug|placebo|Initial dose of placebo will be 1 pill three times a day
79707342|NCT01000350|Drug|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
79707343|NCT01000350|Other|Placebo|Placebo x1 lactose tablet
79707344|NCT00815815|Behavioral|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
79847634|NCT05733429|Other|conventional physical therapy|the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
79847635|NCT01002729|Other|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI < 30 given Oseltamivir
79847636|NCT01002729|Other|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI > 40 given Oseltamivir
79847637|NCT01002807|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
79847638|NCT01002807|Drug|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
79847639|NCT01002807|Drug|Glucophage|Tablets, Oral, 1000 mg, Single Dose
79847640|NCT01002963|Drug|PF-04418948|solution, 30 mg, single
79847641|NCT01002963|Drug|PF-04418948|solution, 100 mg, single
79251603|NCT03307941|Other|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
79251604|NCT03307941|Procedure|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
79545806|NCT01535768|Drug|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
79707345|NCT00707473|Drug|Carboplatin|Given IV
79707346|NCT00707473|Other|Chemoradiotherapy|Undergo chemoradiotherapy
79847642|NCT01002963|Drug|PF-04418948|solution, 300 mg, single
79847643|NCT01002963|Drug|PF-04418948|solution, 1000 mg, single
79847644|NCT01002963|Drug|PF-04418948|solution, 3000 mg, single
79847645|NCT01002963|Drug|PF-04418948|solution, 4500 mg, single
79847646|NCT01002963|Drug|PF-04418948|solution, 6000 mg, single
79847647|NCT01006161|Drug|SCH 527123|Low dose
79847648|NCT01006161|Drug|SCH 527123|Medium dose
79847649|NCT01006161|Drug|SCH 527123|High dose
79847650|NCT01006161|Drug|SCH 527123|Placebo to match SCH 527123
79251605|NCT03307863|Drug|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
79251606|NCT03307863|Drug|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
79251607|NCT03307863|Drug|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
79251608|NCT02467803|Other|Scapula mobilization|
79251609|NCT02467803|Other|Shoulder ROM exercises|
79251610|NCT03302013|Procedure|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
79545807|NCT01535781|Drug|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
79707347|NCT00707473|Drug|Cisplatin|Given IV
79707348|NCT00707473|Procedure|Definitive Surgical Resection|Undergo surgery
79707349|NCT00707473|Drug|Docetaxel|Given IV
79707350|NCT00707473|Drug|Fluorouracil|Given IV
79847651|NCT05733195|Other|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
79847652|NCT05733117|Drug|Vitamin D|cholecalciferol
79847653|NCT01003119|Behavioral|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
79847654|NCT01006239|Other|No study intervention|The is no study related intervention.
79847655|NCT01006317|Behavioral|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
79847656|NCT01006317|Behavioral|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
79847657|NCT01006317|Other|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
79847658|NCT01006395|Drug|Zoledronic acid|yearly infusion
79847659|NCT01006395|Drug|Placebo|yearly infusion
79847660|NCT03999801|Genetic|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab
79847661|NCT01003353|Behavioral|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
79251611|NCT03302013|Procedure|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
79251612|NCT01333189|Other|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
79545808|NCT01535781|Drug|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
79545809|NCT01535820|Drug|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
79545810|NCT01535820|Drug|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
79545811|NCT01535833|Procedure|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
79545812|NCT01535846|Behavioral|Conscious food tasting intervention|Six weekly 2-hour workshops
79545813|NCT01535859|Drug|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
79545814|NCT01535859|Drug|Placebo|1 tablet daily for 8 days.
79545815|NCT01535872|Dietary Supplement|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
79545816|NCT01535885|Biological|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
79707351|NCT00707473|Procedure|Quality-of-Life Assessment|Correlative studies
79707352|NCT00707473|Radiation|Radiation Therapy|Undergo radiation therapy
79707353|NCT00692471|Device|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
79707354|NCT00648648|Drug|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
79707355|NCT00648648|Drug|gemcitabine|Gemcitabine administered at 1000 mg/m^2 by IV infusion in a 28-day cycle.
79707356|NCT00648648|Drug|cisplatin|Cisplatin administered at 75 mg/m^2 by IV infusion in a 21-day cycle.
79707357|NCT00648648|Drug|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
79707358|NCT00625638|Behavioral|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
79707359|NCT00625638|Other|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
79707360|NCT00614172|Radiation|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
79707361|NCT00608725|Radiation|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
79707362|NCT00608725|Procedure|QSweat|Quantitative Sweat Testing
79707363|NCT00608725|Drug|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
79707364|NCT00581633|Other|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
79707365|NCT00581373|Other|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
79707366|NCT00581321|Dietary Supplement|water|water 500 ml x 1
79707367|NCT00580996|Other|water high dose|water 16 oz PO x 1
79707368|NCT00580996|Other|water tiny dose|water 1 oz PO x 1
79707369|NCT00546351|Drug|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
79707370|NCT00542373|Other|Cytology Specimen Collection Procedure|Undergo oral tissue collection
79707371|NCT00542373|Procedure|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
79707372|NCT00542373|Procedure|Diagnostic Procedure|Undergo standard white light headlamp oral examination
79707373|NCT00542373|Procedure|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
79707374|NCT00542373|Procedure|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
79847662|NCT05732805|Biological|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
79847663|NCT05732805|Biological|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
79847664|NCT05732805|Biological|Placebo|Placebo
79847665|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous [IV] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
79707375|NCT00536172|Drug|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
79707376|NCT00536172|Drug|Placebo|Placebo distribution matches the active medication.
79707377|NCT00477100|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and stool
79707378|NCT00477100|Other|Interview|Participate in interview
79707379|NCT00477100|Other|Medical Chart Review|Undergo collection of medical data
79707380|NCT00477100|Other|Questionnaire Administration|Ancillary Studies
79707381|NCT00386906|Procedure|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
79707382|NCT00003838|Procedure|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg.
79707383|NCT00003838|Drug|Methotrexate|IV MTX on days +1, +3, and +6 will be given
79707384|NCT00003838|Drug|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade > II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade > II GVHD will have CSA discontinued regardless of chimerism results.
79707385|NCT00003838|Drug|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
79707386|NCT06031636|Drug|Oncolytic Adenovirus H101|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
79707387|NCT06031636|Drug|Programmed death receptor-1 inhibitor|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
79545817|NCT01535898|Other|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
79545818|NCT01535989|Drug|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
79707388|NCT06031610|Procedure|carotid artery stenting|Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.
80015716|NCT05125913|Diagnostic Test|LUS|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
79545819|NCT01535989|Drug|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
79545820|NCT01536002|Drug|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
79707389|NCT06031545|Other|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
79707390|NCT06031545|Other|Midline catheter|Midline catheters for use during the perioperative period in obese patients
79710217|NCT00599898|Drug|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
79710218|NCT00599976|Procedure|Pulmonary vein isolation|Pulmonary vein isolation
80015717|NCT05125913|Diagnostic Test|BIS analysis|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device using specific electrodes. Based on a fluid model using 50 discrete frequencies (5-1000kHz), the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
80015718|NCT05125913|Other|Biomarkers determination|Biomarkers by ELISA: IL-1, IL-6, VCAM1, Endoglin, NO and ADMA
80015719|NCT04472780|Device|Hyperbaric oxygen Therapy HBOT|HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
80015720|NCT03768622|Procedure|surgery for pertrochanteric femoral fracture|surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
79545821|NCT01536028|Drug|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
79545822|NCT01536028|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
79545823|NCT01536028|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
79847666|NCT00615056|Drug|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous [IV] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
79847667|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
79847668|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion [IV] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
79847669|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
79847670|NCT00615056|Drug|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
79545824|NCT01536028|Drug|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
80015721|NCT03768622|Procedure|surgery for femoral neck fracture|surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
80015722|NCT04472546|Other|in-vivo mesure|"for acne of the face subgroup and its associated control : face and inner side of the forearm~for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
80015723|NCT04472546|Other|Scotch|"for acne of the face subgroup and its associated control : face and inner side of the forearm~for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
79251613|NCT01333189|Other|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
80015724|NCT04472546|Other|Lipid index|"for acne of the face subgroup and its associated control : face~for seborrheic dermatitis of scalp subgroup and its associated control: scalp~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face"
79251614|NCT04662008|Behavioral|Tele-coaching|This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
79251615|NCT04662008|Behavioral|Website|This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
79389833|NCT03194178|Other|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :~Kidscreen 52 (generic quality of life questionnaire)~Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~MDI-C (composite depression scale for minors)"
79389834|NCT02444052|Device|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
79707391|NCT06031519|Procedure|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
79545825|NCT01536054|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
79707392|NCT06031506|Device|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
79545826|NCT01536054|Drug|sirolimus|Given PO
79545827|NCT01536054|Other|laboratory biomarker analysis|Correlative studies
79545828|NCT01536054|Biological|sargramostim|Given SC
79545829|NCT01536106|Other|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
79707394|NCT06031480|Drug|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
79707395|NCT06031389|Drug|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
79707396|NCT06031389|Drug|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
80015725|NCT04472546|Other|Absorbant paper|"for acne of the face subgroup and its associated control : face~for seborrheic dermatitis of scalp subgroup and its associated control: scalp~for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead"
79251616|NCT04656470|Drug|Dexmedetomidine|Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
79251617|NCT03301701|Procedure|Radical prostatectomy|Radical prostatectomy
79251618|NCT03301701|Radiation|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
80015726|NCT04472546|Other|Hydratation Index|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
80015727|NCT04472546|Other|TransEpidermal Water Loss|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
80015728|NCT02675842|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
79389835|NCT02444052|Device|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
79389836|NCT02443974|Device|Brace (Fisiotensor®)|
79389837|NCT02443974|Device|Sleeve (Fisiotensor®)|
79389838|NCT02443818|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
80015729|NCT02675842|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
79251619|NCT05391074|Dietary Supplement|postbiotics (IGENH35.3A)|postbiotics to induce microbiota epigenetic factors
79707397|NCT06031376|Drug|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
79251620|NCT05391074|Dietary Supplement|vitamins (AREDS formulation and recommended daily dose)|vitamins (AREDS to prevent AMD progression
79251621|NCT05311358|Device|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
79251622|NCT03301545|Procedure|Fast-Track to Bariatric Surgery|30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
79251623|NCT02467647|Drug|Thalidomide|
79251624|NCT02467647|Drug|HLJDT|
79251625|NCT04614116|Other|External cooling|water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.
79251626|NCT04614116|Diagnostic Test|FDG PET/CT|o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.
79251627|NCT04614116|Diagnostic Test|13C-Glucose injection|0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
79389839|NCT01705691|Drug|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
79389840|NCT01705691|Drug|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
79707398|NCT06031376|Drug|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
79707399|NCT06031376|Drug|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
79707400|NCT06031376|Drug|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
79707401|NCT06031363|Drug|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
79707402|NCT06031350|Diagnostic Test|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
80015730|NCT05116553|Behavioral|SDT|Standard 2 SDT (Self Determination Theory) psychological interviews.
79389841|NCT01705691|Drug|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
79389842|NCT01705691|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
79389843|NCT04016974|Drug|Oral semaglutide|Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
80015731|NCT05116553|Device|APP + CA|An APP with a CA (Conversational Agent).
80015732|NCT05187247|Device|Virtual Reality glasses|use of virtual reality glasses to reduce anxiety and pain levels
79251628|NCT01333111|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
79251629|NCT01333111|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
80015733|NCT04528108|Drug|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
80015734|NCT04528108|Drug|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
80015735|NCT04602559|Device|MOBIDERM Panty group|"In the MOBIDERM Panty group, patients wear the MOBIDERM Panty during day and night for 3 months with the possibility to add the PAD.~The protocol includes 3 visits.~Visit 1 at day 0, corresponding to the inclusion visit, includes device delivery and some clinical evaluations (clinical examination, characteristics of lymphedema, self questionnaires, pain assessment, perimeter data).~Visit 2 at 30 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).~Visit 3 at 90 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance)."
80015736|NCT03701776|Behavioral|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
80015737|NCT03701776|Behavioral|Balance Training|Standard of care
80015738|NCT05216731|Procedure|Femoro-popliteal bypass|Under general anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
79251630|NCT01333111|Drug|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
80015739|NCT05216731|Procedure|Endovascular procedure|Preparing the artery with suitable balloon angioplasty followed with stenting (using the preferred material: bare/covered/drug-coated) or drug-coated balloon angioplasty.
80015740|NCT04436614|Dietary Supplement|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
80015741|NCT04436614|Dietary Supplement|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
80015742|NCT04436614|Dietary Supplement|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
79251631|NCT04613570|Diagnostic Test|Upper gastrointestinal endoscopy|"In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~Antrum, incisura and corpus fragments should be sent in 3 separate vials;"
79389844|NCT04016974|Drug|Placebo|Placebo tablets once daily throughout the treatment period (day 1 to 84)
79545830|NCT01536106|Other|Placebo control|Intracoronary infusion of autologous peripheral blood.
79389845|NCT02449668|Device|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
79545831|NCT01536132|Drug|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
79707403|NCT06031298|Biological|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
79707404|NCT06031285|Drug|Sintilimab|Perioperative Sinitilimab, bevacizumab biosimilar and TACE-HAIC
79707405|NCT06031246|Procedure|Selective Lymph Node Dissection|For patients with NSCLC with CTR>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
79707406|NCT06031233|Drug|Nivolumab|Gradual shortening of infusion times
79251632|NCT04612322|Device|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
79389846|NCT02449668|Device|Sham Acupuncture|
79389847|NCT02445534|Biological|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
79545832|NCT01536132|Drug|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
79545833|NCT01536158|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
79545834|NCT01536158|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
79707407|NCT06031233|Drug|Pembrolizumab|Gradual shortening of infusion times
79707408|NCT06031233|Drug|Ipilimumab|Gradual shortening of infusion times
79707409|NCT06031233|Drug|Durvalumab|Gradual shortening of infusion times
79707410|NCT06031233|Drug|Atezolizumab|Gradual shortening of infusion times
79707411|NCT06031233|Drug|Bevacizumab|Gradual shortening of infusion times
79707412|NCT06031233|Drug|Trastuzumab|Gradual shortening of infusion times
79707413|NCT06031168|Other|Metformin gel coated implants|Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.
79707414|NCT06031168|Other|uncoated hydrophilic dental implants|Patients treated by uncoated implants
79707415|NCT06031142|Device|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
79707416|NCT06031129|Drug|Butorphanol|The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
79707417|NCT06031129|Drug|normal saline|normal saline contain 0.9% NaCl sodium.
79707418|NCT06031116|Procedure|depigmentation|gingival depigmentation
79847671|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous infusion [IV] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
79707419|NCT06031103|Procedure|mini-PCNL procedure|"Mini-PCNL~. A 12 Fr rigid nephroscope and a Holmium:YAG laser as energy source was used for surgery Percutaneous renal puncture was achieved with an 18 Ga needle after displaying renal collecting system with contrast material. and tract dilatation was achieved using Amplatz dilators up to 16-18 Fr according to patient age"
79707420|NCT06031103|Procedure|RIRS procedure|RIRS Technique the 9.5 Fr ureteral access sheath (UAS). UAS was inserted over the guide wire under fluoroscopy control. A flexible ureteroscope was passed through the UAS. If the UAS did not pass over the guide wire, the investigator moved the flexible ureteroscopy over the guide wire without access sheat
79707421|NCT06031090|Drug|Clonidine Injection|intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
79707422|NCT06031090|Drug|Granisetron Injection|intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.
79707423|NCT06031090|Drug|Normal Saline 10 mL Injection|intravenous 10 ml normal saline 20 minutes before spinal anesthesia
79707424|NCT06031051|Device|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
79847672|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
79847673|NCT01003431|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
79707425|NCT06031038|Other|TECCU Software|patient monitoring by software application
79707426|NCT06031012|Drug|glutamine combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
79847674|NCT01003431|Biological|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
80015743|NCT04299503|Drug|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
80015744|NCT04299503|Drug|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
79707427|NCT06031012|Drug|glutamine alone|Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
79707428|NCT06030986|Diagnostic Test|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
79707429|NCT06030973|Behavioral|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
79707430|NCT06030960|Device|Virtual Reality (VR)|Virtual Reality (VR) Stabilization Exercises
79389848|NCT02450058|Drug|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
79389849|NCT02450058|Drug|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
79389850|NCT02450058|Drug|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
79707431|NCT06030960|Other|Regular Exercises|Regular Stabilization Exercises
79707432|NCT06030960|Other|patient instructions and education|a unified form of patient instructions and education in regards of LBP
79707433|NCT06030934|Drug|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
79847675|NCT01003431|Biological|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
79847676|NCT01006473|Other|Exercise training|
80015745|NCT05033470|Device|Dabir Mattress Overlay System|Dabir Surface mattress overlay system consists of a controller and a low-profile alternating pressure (AP) surface (placed over a non-powered mattress) with hundreds of air-filled geometric nodes arranged in rows. . The multiple rows of nodes inflate and deflate in alternating sequence every five minutes. During deflation phase, the skin and soft tissues experience reduced pressure/loading and enhanced perfusion. In conjunction with Standard of Care: Debridement, Proper moisture balance, off-loading, reduce bacterial burden and nutritional counseling.
79545835|NCT01536210|Drug|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
79389851|NCT02450058|Drug|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
79389852|NCT02450058|Drug|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
79389853|NCT02445300|Other|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
79847677|NCT01006551|Drug|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
80015746|NCT05178433|Combination Product|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
80015747|NCT04251689|Drug|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
79545836|NCT01536210|Drug|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
80015748|NCT04251689|Drug|Placebo|0.9% normal saline 100 ml
80015749|NCT05164393|Drug|AVX001|Topical gel treatment for once daily application
80015750|NCT04232423|Drug|Olanzapine 10 Mg ORAL TABLET|"Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
80015751|NCT04232423|Drug|Olanzapine 5 Mg ORAL TABLET|"Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
80015752|NCT04232423|Drug|Placebo ORAL TABLET|"Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
80015753|NCT04436770|Other|Non-immersive virtual reality therapy|"Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used."
79251633|NCT03301389|Other|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
79251634|NCT03263936|Drug|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
79251635|NCT03263936|Drug|Vorinostat|Age <18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
79545837|NCT01536223|Drug|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
79545838|NCT01536223|Drug|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
79545839|NCT01536236|Device|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
79545840|NCT01536236|Device|Placebo|Placebo
79545841|NCT01536249|Drug|Dexpramipexole|Single Oral Dose
79545842|NCT01536249|Drug|Cimetidine plus Dexpramipexole|Multiple Oral Doses
79545843|NCT01536288|Drug|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
79545844|NCT01536288|Drug|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
79847678|NCT00873626|Drug|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
79847679|NCT01003509|Procedure|modified shouldice and double|one arm modified shouldice, other one is double repair
79847680|NCT00879242|Drug|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
79847681|NCT05732493|Drug|Serplulimab|Serplulimab 300mg, d1, q3w
79847682|NCT05732493|Radiation|short-term radiotherapy|radiation: 25Gy/5Fx
79847683|NCT05732493|Drug|Oxaliplatin|130mg/m2 d1 q3w
79847684|NCT05732493|Drug|Capecitabine|1000mg/m2 d1-14 q3w
79847685|NCT00873704|Other|supplemental postoperative oxygen|
79251636|NCT03263936|Drug|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
79251637|NCT03263936|Drug|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
79251638|NCT03263936|Drug|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
79251639|NCT03307629|Drug|NOX66|NOX66 delivered as rectal suppository.
79389854|NCT02445300|Other|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
79389855|NCT04971070|Other|Observation and follow-up|Observation and follow-up study
80015754|NCT04436770|Other|Standard Physiotherapy|"Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used."
80015755|NCT05104294|Diagnostic Test|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
79545845|NCT01536301|Drug|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
79847686|NCT01003587|Behavioral|District health information package|"The intervention package consists of:~A report on disease burden, disease control priorities and health system performance in India~Condensed fact sheet based on the report~District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~Customized speech for district level officials detailing key actions to reduce deaths~Reminder materials including poster version of the DRCs and video on key points and actionable messages"
79545846|NCT01536301|Drug|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
79545847|NCT01536314|Drug|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
79545848|NCT01536314|Drug|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
79545849|NCT01536353|Drug|AGSAV301|tablet, q.d.
79707434|NCT06030921|Other|Osteopathic Structural Exam, State - Trait Anxiety Questionnaire|During a single patient encounter they will fill out the State-Trait Anxiety Questionnaire , and undergo a Osteopathic Structural Exam
79251640|NCT03307629|Radiation|Irradiation Therapy|Radiation per selected tumour lesion.
79251641|NCT02055937|Procedure|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
79545850|NCT01536353|Drug|Exforge 10/160|Tablet, q.d.
79707435|NCT06030895|Drug|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
79707436|NCT06030856|Device|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
79707437|NCT06030856|Behavioral|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
79847687|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
79847688|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
79847689|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
79251642|NCT03307551|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
79251643|NCT03307551|Drug|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
79389856|NCT02445378|Procedure|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
79389857|NCT02445378|Other|Placebo|Undergo placebo intervention using rose water
79389858|NCT02445378|Other|Questionnaire Administration|Ancillary studies
79389859|NCT02445066|Dietary Supplement|Vitamin D3|
79389860|NCT02443662|Other|Catheterization|Routine catheterization during follow up.
79389861|NCT05549908|Biological|rabies vaccine|The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
79389862|NCT02443584|Other|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
79389863|NCT03197610|Procedure|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
79389864|NCT03197298|Drug|Clopidogrel|
79389865|NCT03197298|Drug|Ticagrelor|
79847690|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
79847691|NCT00868634|Drug|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
79847692|NCT05232357|Drug|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
79847693|NCT00879476|Drug|Ramipril 10mg capsules|
79847694|NCT01003743|Device|endolumenal tissue approximation|
79251644|NCT05212376|Other|Foot massage|"Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days."
79251645|NCT02059603|Procedure|Electroacupuncture|
79251646|NCT02059603|Procedure|Fast-track program|
79251647|NCT03307473|Behavioral|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
79545851|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
79545852|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
79545853|NCT01536431|Drug|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
79545854|NCT01536444|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
79545855|NCT01536470|Other|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
79545856|NCT01536470|Other|Ephedryne chorydrate|
79707438|NCT06030830|Behavioral|SMaRT Mom|"SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention."
79707439|NCT06030817|Diagnostic Test|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
79707440|NCT06030791|Diagnostic Test|MRI|MRI of operated knee
79707441|NCT06030752|Drug|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
79707442|NCT06030674|Other|Secondhand cannabis emissions/smoke exposure|This is an environmental exposure performed in public places where people are consuming cannabis.
79847695|NCT04925102|Other|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
79847696|NCT00879554|Biological|CVX-045|Weekly, intravenous dose
79847697|NCT00868946|Drug|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
79847698|NCT00874016|Device|Airtraq|Intubation using Airtraq
79847699|NCT00874016|Device|Direct Laryngoscopy|Intubation using direct laryngoscopy
79847700|NCT00482014|Drug|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
79847701|NCT00482014|Drug|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
80015756|NCT05104294|Diagnostic Test|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
79707443|NCT06030648|Biological|Mesenchymal stem cells (IV-MSC)|Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
80015757|NCT04367467|Other|Kidney Function Test|Cystatin-C measurement
80015758|NCT04178993|Drug|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
79707444|NCT06030609|Drug|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
79707445|NCT06030609|Drug|Normal saline|The patient will receive NSS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
79707446|NCT06030570|Other|Rehabilitation program (Revita)|Multidisciplinary programs in an outpatient hospital setting are coordinated by specialists in Physical and Rehabilitation Medicine. These programs combine a physical part (e.g., specific exercises, manual techniques) with at least one other element (psychological, social, educational or occupational intervention). In a multidisciplinary spine rehabilitation program, a maximum of 36 sessions over a maximum time period of 6 months is offered. Afterwards, a (monodisciplinary) follow-up trajectory (K15) is possible, consisting of maximum 104 sessions a year.
79707447|NCT06030557|Drug|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
79707448|NCT06030544|Dietary Supplement|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
79847702|NCT00482014|Drug|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles"
79707449|NCT06030544|Dietary Supplement|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
79847703|NCT00482014|Radiation|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
79847704|NCT00879788|Drug|Ramipril 10mg capsules|
80015759|NCT04178993|Drug|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
80015760|NCT04178993|Drug|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
80015761|NCT04178993|Drug|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
79251648|NCT05189132|Diagnostic Test|Periodontal Diagnosis|All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
79251649|NCT05189132|Diagnostic Test|Microbiological analysis|"Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum."
79389866|NCT05723224|Procedure|elective endoscopic gallbladder treatment|Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (≥15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure
79389867|NCT03197220|Other|fish|300 gr/week fish
79389868|NCT03197220|Other|walnut|18 walnut per week
79847705|NCT03595553|Drug|Ridinilazole|ridinilazole (200 mg bid)
79389869|NCT03197220|Other|fish-walnut|150 gr fish and 9 walnut per week
79847706|NCT03595553|Drug|Vancomycin|vancomycin (125 mg qid)
79847707|NCT00874172|Drug|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
79847708|NCT00874172|Drug|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
79847709|NCT04119154|Diagnostic Test|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
80015762|NCT04795804|Dietary Supplement|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
80015763|NCT04795804|Dietary Supplement|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
80015764|NCT04795804|Dietary Supplement|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
80015765|NCT04436848|Other|This is a non-interventional study|This is a non-interventional study
80015766|NCT05104216|Biological|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
80015767|NCT04671472|Drug|NPC-09|The drug will be administered by the oral route with the same manner
80015768|NCT04671472|Drug|NPC-09 placebo|The drug will be administered by the oral route with the same manner
80015769|NCT04436536|Other|Treadmill walking training with random speed changes|Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
79707450|NCT06030531|Other|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
79251650|NCT05189132|Diagnostic Test|Inflammatory mediators|"The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α."
79707451|NCT06030531|Other|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
79710219|NCT00600054|Biological|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
79847710|NCT00614822|Drug|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
79847711|NCT04861298|Drug|standard of care for COVID-19 as per the hospital guidelines|Hospital standard of care treatment for COVID-19
80015770|NCT04436536|Other|Treadmill walking training with blocked speed changes|Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
80015771|NCT04086017|Other|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
80015772|NCT04570618|Device|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
79251651|NCT02060305|Drug|Bevacizumab intra-articular injection|Bevacizumab, 20~40mg, intra-articular injection every 28 days for 4 times
80015773|NCT04570618|Other|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
79251652|NCT03307395|Procedure|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
79251653|NCT05102786|Other|40007388|A non-combusted cigarette used with heated tobacco device 20020064
79251654|NCT05102786|Other|40007385|A non-combusted cigarette used with heated tobacco device 20020064
79389870|NCT02443506|Drug|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
79389871|NCT02443506|Drug|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
79389872|NCT03197688|Other|Notapplicable|Not applicable as non-interventional study
79545857|NCT01536483|Drug|Butyrate enemas|"Seven enemas~Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~The study remains blinded for the investigation team through the intervention of a clinical research nurse~According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~Installation time and retention is setted at 15 minutes~Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
79389873|NCT03903484|Other|Deprescribing toolbox and intervention|Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
79847712|NCT04861298|Dietary Supplement|Quercetin Phytosome (QP)|Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week
79389874|NCT02443272|Procedure|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
79847713|NCT00869102|Drug|GLP-1|intravenous, 124,5 pmol/kg body weight
79847714|NCT03582917|Drug|Alphacalcidol|Alphacalcidol 0,5mg tablet
79847715|NCT05226728|Drug|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
79847716|NCT00869180|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
79847717|NCT00869180|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
79847718|NCT00874328|Drug|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
79847719|NCT00874328|Drug|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
79847720|NCT00874328|Drug|TS-1 (S-1)|TS-1 po D1~D14 q 3 weeks until maximum 6 cycles
80015774|NCT03008980|Other|Diagnostic Test|
79251655|NCT05102786|Other|40007387|A non-combusted cigarette used with heated tobacco device 20020064
79389875|NCT02443272|Procedure|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
79251656|NCT05102786|Other|40007386|A non-combusted cigarette used with heated tobacco device 20020064
79847721|NCT00879866|Biological|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
79251657|NCT03307239|Other|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application."
79847722|NCT00879944|Other|Blood pressure|Blood pressure will be measured once while patient is seated
79847723|NCT00879944|Other|Height|Height will be measured in centimeters at the time of enrollment
79847724|NCT00879944|Other|Weight|Weight will be measured in kilograms at enrollment
79847725|NCT00879944|Other|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
79251658|NCT03307239|Other|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application."
79847726|NCT00879944|Other|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
79847727|NCT00874406|Drug|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
79847728|NCT00874406|Drug|folfox4|folfox4 will be done within 28 days after liver resection
79847729|NCT04840628|Other|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
79847730|NCT00880178|Drug|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
79847731|NCT00880178|Drug|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
79251659|NCT03561025|Diagnostic Test|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
79251660|NCT03561025|Diagnostic Test|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
79251661|NCT03307161|Other|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
79251662|NCT02059759|Drug|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
79251663|NCT02059759|Drug|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
79251664|NCT02059759|Drug|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
79251665|NCT03378362|Procedure|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
79251666|NCT03103022|Drug|Acetaminophen|Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
79251667|NCT03103022|Drug|ibuprofen|Oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
79251668|NCT02929082|Radiation|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
79251669|NCT00702507|Drug|0.25 % Miconazole Nitrate Ointment|Topical Application
79389876|NCT05723146|Behavioral|Spatial cognition assessment|The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
79389877|NCT00357448|Biological|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
79389878|NCT00357448|Procedure|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
79389879|NCT00357448|Other|laboratory biomarker analysis|Correlative studies
79389880|NCT00357448|Other|enzyme-linked immunosorbent assay|Correlative studies
79389881|NCT00357448|Other|flow cytometry|Correlative studies
79389882|NCT03192384|Behavioral|Educational programme|Educational programme for ward staff
79847732|NCT04038866|Other|rehabilitation gait with dual task|
79847733|NCT04038866|Other|rehabilitation gait without dual task|
79847734|NCT00529659|Drug|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
79847735|NCT00529659|Drug|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
80015775|NCT05762003|Drug|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
79847736|NCT05726565|Other|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
80015776|NCT04660708|Behavioral|manual physical therapy|Previously described in the arm description
79847737|NCT04076969|Behavioral|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
80015777|NCT03001557|Drug|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
80015778|NCT03001557|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablets
80015779|NCT03001557|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablets
80015780|NCT03001557|Drug|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
80015781|NCT03001557|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
80015782|NCT03587480|Procedure|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
80015783|NCT03587480|Procedure|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
79251670|NCT05727033|Behavioral|Participatory teaching group|"The intervention will be called FEDE-ITS® methodology. This methodology is self-designed and self-developed and draws on previous work in equivalent populations. It is based on teaching in a participatory way knowledge and healthy attitudes related to the five most prevalent STIs in the province of Barcelona and Lleida, the methods to avoid contagion, and the health resources that can be consulted in case of infection, contact with an infected person or concerns. In addition, a gender perspective is incorporated to contribute to freer and more egalitarian relationships and reduce the likelihood of violence against women which develops in adolescence.~The cross-cutting themes of the training are: health, pleasure, self-esteem, knowledge-based freedom of choice, equality between people and respect for sexual freedom. Therefore, the ultimate goal is to prevent abusive power relations and macho violence."
79251671|NCT05727033|Behavioral|Sham control group|"The Health and School program was implemented to promote health in schools, and for this reason the program's nurse attends annually to address problems related to sexual affective health within the curricular itinerary of each school, but not specifically on sexually transmitted infections or gender perspective."
79707452|NCT06030518|Diagnostic Test|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
79389883|NCT05715658|Drug|Dabigatran etexilate capsule|Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
79389884|NCT02443194|Drug|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
79707453|NCT06030492|Drug|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics & a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
79707454|NCT06030492|Drug|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics & a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
80015784|NCT03776669|Procedure|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
79389885|NCT02443194|Drug|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
80015785|NCT03776669|Procedure|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
80015786|NCT05112094|Device|peripheral magnetic stimulation|peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
80015787|NCT05112094|Other|physical therapy|regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
79389886|NCT03194022|Other|Blood sample|measurement of electrolytes and blood count
79389887|NCT03772288|Drug|TAK-659|Tablets.
79389888|NCT03772288|Drug|NKTR-214|Intravenous infusion.
79389889|NCT03196908|Dietary Supplement|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
79389890|NCT03196908|Dietary Supplement|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
79389891|NCT03196908|Other|Placebo|Lime juice, water, and cherry flavoring
80015788|NCT04003220|Procedure|blood sample|The extra samples will be taken Blood sampling
79707455|NCT06030479|Drug|Topical adrenaline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution."
79545858|NCT01536509|Behavioral|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
79707456|NCT06030479|Drug|Warm saline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees)."
79847738|NCT04077125|Drug|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
79847739|NCT05707689|Behavioral|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
79847740|NCT05172401|Device|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
79847741|NCT05167877|Other|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
79847742|NCT01006785|Drug|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
80015789|NCT04003220|Procedure|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
80015790|NCT03134612|Drug|Ondansetron 8 mg|
80015791|NCT03134612|Drug|Lidocain 40 mg|
80015792|NCT05203757|Procedure|ArthroCT scan|Conventional CT arthrogram as routine care
80015793|NCT05203757|Procedure|CBCT|Cone Beam CT scan.
80015794|NCT05112016|Procedure|Total mesorectal excision for rectal cancer|
80015795|NCT00831662|Drug|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
80015796|NCT00831662|Drug|Placebo|One to two drops in each eye QID for 6 weeks
79251672|NCT03307083|Other|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
79251673|NCT03301233|Drug|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
79251674|NCT05726955|Other|Exercise training program|an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
80015797|NCT05111938|Behavioral|Friends, Family, and Food App (F3A-App)|
80015798|NCT04365985|Drug|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
80015799|NCT04365985|Drug|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
79251675|NCT03301077|Other|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
79251676|NCT02581748|Drug|HLX02|
79251677|NCT02581748|Drug|Herceptin|
79251678|NCT05726877|Other|ventilation strategy|Titrating positive end-expiratory pressure
79251679|NCT02466633|Other|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
79251680|NCT05726799|Procedure|Cryo myectomy|Extended septal myecotmy using cryo energy
79251681|NCT05726799|Procedure|Myectomy|Classic surgical myectomy
79389892|NCT00357526|Drug|OCPs|
79389893|NCT00357526|Device|vaginal ring|
79389894|NCT03193944|Drug|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
79389895|NCT03193944|Drug|Placebo vitamin D3|vitamin D as a placebo
79251682|NCT05726643|Other|resistive training|"5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times."
79251683|NCT05726643|Other|kinesiotaping|Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
79251684|NCT03306771|Diagnostic Test|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
79251685|NCT03306693|Behavioral|Emotional skills|2-hour 3 group sessions
79545859|NCT01536509|Behavioral|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
79251686|NCT03306693|Behavioral|Relaxation and talking group|2-hour 3 group sessions
79251687|NCT03113942|Drug|Pomalidomide 2 MG Oral Capsule [Pomalyst]|Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
79251688|NCT03300999|Dietary Supplement|ginger tea|"1. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
79545860|NCT01536548|Procedure|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
79707457|NCT06030453|Combination Product|SMART HOME strategy|Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).
79707458|NCT06030453|Combination Product|PADIS nursing intervention|pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
79707459|NCT06030401|Device|Transthoracic Ultrasound|Sonar of The Chest
79847743|NCT01006785|Drug|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
79251689|NCT04490577|Other|Pilates exercises|Pilates exercises are a combined exercise procedure including strengthening and stretching. Pilates exercises are performed with different equipment for example; therabands, mats, reformer, etc.
79251690|NCT04490577|Other|Whole body vibration|Whole-body vibration gives vibration to the body with a platform at different frequencies (Power-plate). The participant performed exercises on the platform.
79545861|NCT01536548|Procedure|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
79545862|NCT01536600|Drug|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
79545863|NCT01536613|Drug|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
79545864|NCT01536626|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
79545865|NCT01536639|Drug|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
79545866|NCT01536652|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
79545867|NCT01536665|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
79707460|NCT06030375|Drug|KAND567|Continuous intravenous infusion for 6 hours
79707461|NCT06030375|Other|Placebo|Continuous intravenous infusion for 6 hours
79847744|NCT00143455|Drug|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
79847745|NCT00143455|Drug|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
79847746|NCT05166551|Procedure|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
79847747|NCT05166551|Procedure|Placebo Acupressure|Placebo Acupressure
79251691|NCT03306537|Device|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
79847748|NCT01006863|Drug|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
80015800|NCT04365985|Other|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
80015801|NCT05111860|Drug|Bevacizumab+mFOLFOX6|Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
80015802|NCT00830336|Drug|Azithromycin|Oral Suspension
80015803|NCT00830336|Drug|Zithromax®|Oral Suspension
79251692|NCT03104270|Drug|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
79545868|NCT01536665|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
79251693|NCT03104270|Drug|Pomalidomide|Pomalidomide PO at 3mg
80015804|NCT05111704|Other|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
80015805|NCT04316689|Biological|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
79251694|NCT03104270|Drug|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
79251695|NCT03104270|Drug|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
79251696|NCT03300765|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
79251697|NCT03300765|Radiation|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
79251698|NCT03306459|Diagnostic Test|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
79545869|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
79707462|NCT06030323|Other|No intervention|This is not an interventional study. The study is classified as 'pre-clinical device development or performance testing'. The purpose of the study is to develop and validate the AI models using data collected from people affected by stroke in a hospital environment, to test the accuracy of the optimised models, and to ascertain patient preference for sensor location.
79545870|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
79545871|NCT01536691|Drug|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
79545872|NCT01536691|Drug|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
79545873|NCT01536717|Drug|Articaine hydrochloride 2% solution|"4 ml/h periosteal wound infusion~duration of 72 h"
79545874|NCT01536717|Drug|Sodium Chloride|Placebo Sodium chloride 0,9%
79545875|NCT01536730|Behavioral|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
80015806|NCT04316689|Biological|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
80015807|NCT05111470|Other|Arm throws with his dominant arm|Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
79545876|NCT01536743|Drug|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
79707463|NCT06030310|Other|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
79545877|NCT01536756|Other|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
79545878|NCT01536756|Other|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
79707464|NCT06029179|Drug|sodium zirconium cyclosilicate (SZC)|30 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 4 weeks.
79707465|NCT06029179|Drug|sodium polystyrene sulfonate|30 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 4 weeks.
79707466|NCT06028490|Biological|GR1802 injection-1|subcutaneous，dose*1
79847749|NCT01006863|Drug|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
79847750|NCT01006863|Drug|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine [group 5 (n=30)] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
79847751|NCT05688189|Device|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
79847752|NCT03967093|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
80015808|NCT03567551|Other|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
80015809|NCT03567551|Other|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
80015810|NCT03567551|Other|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
80015811|NCT00830258|Drug|Pravastatin sodium 80 mg tablets|1 x 80 mg
79707467|NCT06028490|Biological|GR1802 injection-2|subcutaneous，dose*2
79707468|NCT06028490|Biological|Placebo|subcutaneous，dose*2
80015812|NCT00830258|Drug|Pravachol® 80 mg tablets|1 x 80 mg
79707469|NCT06028386|Device|AC5® Advanced Wound System|This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
79251699|NCT04064918|Other|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
79251700|NCT04064918|Other|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
79251701|NCT03306381|Other|Dietary intervention|Elimination of certain products.
79389896|NCT03192228|Other|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
79389897|NCT03766906|Behavioral|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
79251702|NCT02467946|Drug|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
79251703|NCT02468349|Other|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
79251704|NCT04714424|Device|Virtual Reality Headset|Virtual reality (VR) - a 3-D reality right in a headset
79847753|NCT01006941|Biological|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
79847754|NCT03534167|Behavioral|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
79707470|NCT06028386|Device|Fibracol Plus Collagen Dressing|This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
79707471|NCT06028100|Procedure|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
79847755|NCT02531347|Behavioral|Telemedical home blood pressure measurements|
80015813|NCT05111158|Diagnostic Test|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
80015814|NCT04334291|Combination Product|Observational (registry)|Observational study.
80015815|NCT03664479|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
80015816|NCT00724334|Drug|SAR302503 (TG101348)|orally administered, once a day
80015817|NCT03664401|Device|Kerecis Oral™|
80015818|NCT03664401|Other|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
80015819|NCT05110768|Drug|Triferic AVNU|Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy
80015820|NCT05110768|Other|Placebo|normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
79251705|NCT04057976|Diagnostic Test|Probabilistic diffusion tensor tractography|Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
79251706|NCT04688294|Drug|Sacubitril-Valsartan|30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
79251707|NCT04688294|Drug|Valsartan|30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
79251708|NCT03102944|Diagnostic Test|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
79251709|NCT04042298|Other|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
79389898|NCT03193164|Device|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
79707472|NCT06027892|Radiation|Two-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments
79707473|NCT06027892|Radiation|Five-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
79707474|NCT06027567|Drug|Semaglutide|Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
79707475|NCT06027567|Dietary Supplement|Very Low Calorie Diet|Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
79707476|NCT06027567|Behavioral|Dietician counselling|Counselling by a dietician on weight loss through behavioural changes and life style intervention
79707477|NCT06027528|Procedure|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
79707478|NCT06027528|Procedure|dentin graft|extracted tooth will be grafted in the socket
79707479|NCT06027099|Drug|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
79847756|NCT02531347|Behavioral|Conventional blood pressure monitoring|
79847757|NCT04075175|Drug|S315|Human monoclonal antibody against Diphtheria Toxin
79847758|NCT04075175|Drug|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
79847759|NCT05550051|Procedure|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
80015821|NCT05215483|Behavioral|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
80015822|NCT05215483|Behavioral|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
80015823|NCT05215483|Behavioral|LFT available|LFT availability: Enough lateral flow tests available at home
80015824|NCT05215483|Behavioral|No LFT available|LFT availability: No lateral flow tests available at home
80015825|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
79847760|NCT03967015|Other|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
79847761|NCT05012007|Other|Reminder Phone|Standard reminder via phone (audiocare)
79847762|NCT05012007|Other|Reminder Text|reminder via text (VEText)
79847763|NCT03741439|Device|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
79847764|NCT03741439|Device|Sham|Sham treatment
79251710|NCT04042298|Other|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
79251711|NCT04042298|Other|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
79251712|NCT04042298|Other|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
79545879|NCT01536782|Procedure|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
79707480|NCT06027099|Behavioral|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
79707481|NCT06027099|Drug|Placebo|1 tablet three times a day for 5 weeks after surgery
79707482|NCT06027099|Behavioral|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide & Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
79707483|NCT06027021|Diagnostic Test|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
79707484|NCT06026800|Biological|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
79707485|NCT06026774|Biological|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
79707486|NCT06026683|Device|Pacemaker implant|Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
79707487|NCT06026358|Drug|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
79707488|NCT06020001|Dietary Supplement|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
79707489|NCT06020001|Dietary Supplement|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
79847765|NCT03529955|Drug|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
79251713|NCT03300687|Drug|FX-322|intratympanic injection
79251714|NCT03300687|Drug|Placebo|intratympanic injection
79251715|NCT03300609|Biological|Panitumumab|Given IV
79251716|NCT03300609|Drug|Oxaliplatin|Given IV
79251717|NCT03300609|Drug|Leucovorin Calcium|Given IV
79251718|NCT03300609|Drug|Fluorouracil|Given IV
79251719|NCT03300609|Drug|Capecitabine|Given PO
79251720|NCT03300609|Other|Quality-of-Life Assessment|Ancillary studies
79389899|NCT03193164|Other|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
79847766|NCT00142909|Drug|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
79847767|NCT00142909|Drug|Placebo|Lofexidine Placebo
79847768|NCT03885245|Drug|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
79389900|NCT03196830|Biological|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
79389901|NCT04745182|Behavioral|MASTERY|A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
79251721|NCT03300609|Other|Laboratory Biomarker Analysis|Correlative studies
79251722|NCT03007940|Other|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
79545880|NCT01536782|Procedure|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
79847769|NCT03885245|Drug|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
79847770|NCT01007019|Drug|YH4808 30mg|YH4808 30mg (single dose)
79847771|NCT01007019|Drug|YH4808 50mg|YH4808 50mg (single dose)
79847772|NCT01007019|Drug|YH4808 100mg|YH4808 100mg (single dose)
79847773|NCT01007019|Drug|YH4808 200mg|YH4808 200mg (single dose)
79251723|NCT03007940|Other|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
79251724|NCT03007940|Other|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
79251725|NCT03007940|Other|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
79389902|NCT00357604|Drug|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
79707490|NCT06020001|Other|Placebo|Twice a day
79389903|NCT00357604|Drug|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
79389904|NCT02442960|Drug|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
79389905|NCT02443038|Other|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
79389906|NCT02959294|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
79707491|NCT06019702|Biological|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
79707492|NCT06016010|Drug|USL|500mg of Achyranthis Radix Extract
79707493|NCT06016010|Drug|USL Placebo|USL Placebo
79707494|NCT06014073|Biological|TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10^6 cells/kg) , dose 2 (3 × 10^6 cells/kg), dose 3 (1 × 10^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
79847774|NCT01007019|Drug|YH4808|YH4808 400mg (single dose)
79847775|NCT01007019|Drug|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
79847776|NCT01007019|Drug|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
79847777|NCT01007019|Drug|YH4808 600mg|YH4808 600mg
79847778|NCT01007019|Drug|YH4808 800mg (single dose)|YH4808 800mg (single dose)
79847779|NCT01007019|Drug|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
79847780|NCT01007019|Drug|Placebo|10 volunteers will be administered matched placebo.
79847781|NCT01007019|Drug|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
79847782|NCT05673863|Behavioral|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
79847783|NCT02579993|Procedure|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
79847784|NCT02579993|Procedure|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
79847785|NCT04075097|Behavioral|Aerobic exercise|1 session
79847786|NCT04075097|Behavioral|Iyengar yoga|1 session
79847787|NCT01007175|Biological|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
79847788|NCT01007175|Biological|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
79847789|NCT01007175|Biological|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
79847790|NCT01007175|Biological|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
79545881|NCT01536782|Device|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
79545882|NCT01536808|Other|Cardiac RMI|Cardiac RMI
79545883|NCT01536808|Other|Analysis telomere|Analysis telomere
79847791|NCT01007175|Biological|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
79847792|NCT04076189|Procedure|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
79847793|NCT04076189|Procedure|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
79847794|NCT03508739|Drug|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
79847795|NCT03508739|Drug|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
79847796|NCT03882437|Biological|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
79847797|NCT00205699|Drug|risperidone|randomized to begin 12 week trial of risperidone
79251726|NCT03007940|Other|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
79545884|NCT01536808|Other|Stress test|Stress test
79251727|NCT00583778|Drug|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
79251728|NCT04491435|Diagnostic Test|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
79251729|NCT04491435|Diagnostic Test|Sialometry|unstimulated whole saliva (UWS) flow measurement
79389907|NCT02959294|Device|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
79545885|NCT01536808|Other|echocardiography|echocardiography
79545886|NCT01536834|Device|Medical Device|
79545887|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
79545888|NCT01536847|Other|Dietary Intervention|300 mL of liquid food product
79545889|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
79545890|NCT01536873|Drug|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
79545891|NCT01536977|Other|quality-of-life assessment|Ancillary studies
79545892|NCT01536977|Other|questionnaire administration|Ancillary studies
79545893|NCT01536977|Behavioral|management of therapy complications|Undergo BBT-I
79545894|NCT01536977|Behavioral|cognitive assessment|Ancillary studies
79545895|NCT01536977|Behavioral|educational intervention|Undergo BBT-I
79545896|NCT01537003|Device|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
79847798|NCT00205699|Drug|olanzapine|randomized to begin 12 week trial of olanzapine
79847799|NCT00205699|Drug|aripiprazole|randomized to 12 week trial of aripiprazole
79389908|NCT02959294|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
79389909|NCT02444598|Device|Vaccum Assisted Closure device|Negative-pressure wound therapy
79389910|NCT02444598|Procedure|Conventional wound dressings|Conventional wound dressings
79389911|NCT05715424|Other|Six interventions for children and adolescents|"Vision Health Record Establishment and Myopia Risk Assessment.~Evaluation of vision care behavior and development of reasonable eye use behavior.~Health education for teachers and parents.~Action to improve the reading and writing environment at home and school.~One hour of outdoor activities in and out of school during the day.~Myopia grading management and medical correction action."
79545897|NCT01537003|Device|Coban 2 layer|Compression bandage
79545898|NCT01537016|Device|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
79847800|NCT03503513|Drug|Gentamicin Sulfate|Gentamicin will be compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Participants will do daily instillations of 30 milliliters of solution
79847801|NCT03882801|Drug|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
79847802|NCT03882801|Drug|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
79847803|NCT01073917|Other|Spontaneous Breathing|
79847804|NCT01073917|Other|Pressure Controlled Ventilation|
79847805|NCT01073917|Other|Pressure Support Ventilation|
79847806|NCT01582399|Drug|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
79847807|NCT03880227|Device|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
79847808|NCT03880227|Device|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
79707495|NCT06014073|Drug|Fludarabine|Intravenous fludarabine 30~50 mg/m^2/day on days -5, -4, and -3.
79389912|NCT03196752|Procedure|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
79389913|NCT03196752|Other|simple palpation|conventional
79389914|NCT03193788|Drug|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
79707496|NCT06014073|Drug|Cyclophosphamide|Intravenous cyclophosphamide 500~1000 mg/m^2/day on days -5, -4, and -3.
79707497|NCT06013319|Drug|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
79707498|NCT06012110|Device|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
79251730|NCT04398758|Drug|SanaCutan Basiscreme|In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
79251731|NCT03300531|Biological|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
79389915|NCT03193788|Drug|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
79545899|NCT01537016|Device|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
79389916|NCT03193788|Drug|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
79707499|NCT06007417|Drug|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
80015826|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
79251732|NCT03300531|Biological|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
79389917|NCT03193788|Drug|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
79389918|NCT02444520|Behavioral|Integrated GP Care|"The overall aims of the intervention are to help the patient:~develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~understand factors that may be maintaining the problem;~learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
79389919|NCT05722912|Drug|Ruxolitinib|Ruxolitinib Cream
79389920|NCT02443116|Biological|NGM282|
79389921|NCT02443116|Other|Placebo|
79389922|NCT00356668|Device|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
79389923|NCT05715190|Other|Education|"Education- topics of the sessions are the following:~Discover and understand patient's trajectory with psoriasis~Knowledge of the etiology and pathophysiology of psoriasis (genetic and environmental risk factors)~Knowledge about treatment and its management (acquisition and maintenance of self-care skills, empowerment and enhancement of coping skills)~Disease management and patient adaptation to different situations~Educational goals setting~Maintenance and updating of the goals"
79251733|NCT03300531|Drug|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
79389924|NCT03196596|Other|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
79545900|NCT01537055|Drug|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
79545901|NCT01537055|Drug|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
79545902|NCT01537094|Dietary Supplement|Placebo|
79545903|NCT01537094|Dietary Supplement|Vitamin C 250 mg once daily|
79545904|NCT01537094|Dietary Supplement|Vitamin C 1,000 mg once daily|
79545905|NCT01537107|Drug|vismodegib|Given PO
79545906|NCT01537107|Drug|sirolimus|Given PO
79707500|NCT06007417|Drug|Genotropin|Genotropin
79707501|NCT05990231|Drug|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
79707502|NCT05989906|Behavioral|Sprint Interval Training (SIT)|Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
79707503|NCT05989906|Behavioral|Usual Care|Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
79847809|NCT04000113|Device|laser acupuncture|low level laser emission on specific acupuncture points
79847810|NCT04000113|Device|Sham laser|Sham laser
80015827|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
79389925|NCT00358072|Behavioral|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
79545907|NCT01537107|Procedure|positron emission tomography|Correlative studies
79251734|NCT04491201|Other|Customized questionnaire|A customized questionnaire will be delivered by the social software WeChat to the specific hospital which has been randomly sampled, and all physicians of Obstetrics and Gynecology in this hospital will fill the questionnaire anonymously.
79251735|NCT04817163|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
79707504|NCT05989906|Behavioral|Home Ergometer (ERGO)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
79707505|NCT05989906|Behavioral|Motivational Interviewing (MI)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
79251736|NCT04817163|Behavioral|Professionally-administered booster face-to-face CBT-I sessions|"Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment."
79545908|NCT01537107|Procedure|computed tomography|Correlative studies
79545909|NCT01537107|Other|pharmacological study|Correlative studies
79847811|NCT03999567|Other|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
79847812|NCT03999567|Other|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
80015828|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
79251737|NCT03300453|Drug|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
79389926|NCT02442726|Device|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
79545910|NCT01537107|Other|laboratory biomarker analysis|Correlative studies
79545911|NCT01537107|Radiation|fludeoxyglucose F 18|Correlative studies
79545912|NCT01537146|Drug|Ropivacaine|Bolus infusion via catheter/6H for 24H
79545913|NCT01537146|Drug|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
79545914|NCT01537159|Device|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
79545915|NCT01537172|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
79545916|NCT01537172|Drug|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
79545917|NCT01537224|Other|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
79545918|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
79545919|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
79707506|NCT05985005|Other|online simulation of high alert medication safety training|online simulation of high alert medication safety training
79847813|NCT02580149|Drug|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
79707507|NCT05980247|Device|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
79707508|NCT05977933|Device|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
79847814|NCT02580149|Drug|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
79707509|NCT05975060|Biological|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent [5 μg/50 μg] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
79707510|NCT05975060|Biological|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent [5 μg/50 μg] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
79707511|NCT05961306|Diagnostic Test|SCID 5|"SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone."
79707512|NCT05951985|Behavioral|HIFT|Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity. Exercises will be tailored/modified to meet the needs of each participant.
79707513|NCT05943249|Procedure|magnetic resonance|
79847815|NCT01007331|Behavioral|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10^10 colony forming units pr day of probiotics
79707514|NCT05931965|Dietary Supplement|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
79847816|NCT04996017|Drug|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
79707515|NCT05931965|Dietary Supplement|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
79707516|NCT05931965|Dietary Supplement|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
79707517|NCT05921578|Diagnostic Test|Pre-operative planning based on CBCT|Pre-operative planning based on CBCT
79707518|NCT05921084|Behavioral|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
79847817|NCT04996017|Drug|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
79545920|NCT01537250|Drug|Nemonoxacin 3 tablets|oral form,once daily,7~10 days
79389927|NCT02442648|Drug|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
79545921|NCT01537263|Device|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
79389928|NCT02442648|Drug|Rituximab|Rituximab will be administered for desensitization per study protocol.
79389929|NCT00356824|Drug|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
79389930|NCT00356824|Drug|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
79389931|NCT02442570|Biological|recombinant human alpha B-crystallin|intravenous injections
79389932|NCT02442570|Other|Placebo comparator|intravenous injection
79389933|NCT05722756|Other|craniosacral therapy|subtle form of applied touch, type of osteopathy
79389934|NCT01705145|Drug|Ivacaftor|
79389935|NCT03716934|Device|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
79389936|NCT03716934|Drug|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
79389937|NCT03716934|Device|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
79389938|NCT05722600|Other|Grape juice|Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
79545922|NCT01537276|Procedure|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
79545923|NCT01537289|Device|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
79545924|NCT01537289|Device|chest tube (28-French)|inserting chest tube to decompress pneumothorax
79707519|NCT05921084|Behavioral|General dietary advice|General dietary advice
79707520|NCT05917964|Drug|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
79707521|NCT05915806|Dietary Supplement|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
79707522|NCT05915806|Dietary Supplement|Control|Control with no or low-dose DHA.
79707523|NCT05911763|Drug|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
79707524|NCT05908955|Procedure|PVI|pulmonary vein isolation
79707525|NCT05908955|Procedure|PVI+ quantitative SVCI|pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
79847818|NCT03483935|Other|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
79707526|NCT05908487|Behavioral|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
79251738|NCT05057390|Dietary Supplement|New Human Milk Fortifier (NHMF)|"The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use."
79251739|NCT02467335|Drug|BMS-663068|BMS-663068
79251740|NCT05722275|Diagnostic Test|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
79251741|NCT03104660|Device|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
79707527|NCT05907707|Device|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
79707528|NCT05907707|Device|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
79389939|NCT05722600|Other|Placebo drink|Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
79389940|NCT03196674|Other|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
79707529|NCT05907707|Device|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
79707530|NCT05907707|Device|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
79707531|NCT05898672|Drug|Rosuvastatin|Single oral dose of rosuvastatin tablets
79545925|NCT01537328|Other|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
79707532|NCT05898672|Drug|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
79707533|NCT05897554|Drug|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
79707534|NCT05883566|Behavioral|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
79545926|NCT01537341|Behavioral|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
79545927|NCT01537341|Behavioral|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
79251742|NCT02809820|Drug|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
79251743|NCT02809820|Drug|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
79545928|NCT01537354|Drug|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
79545929|NCT01537354|Drug|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
79251744|NCT04491357|Drug|Calcium Gluconate|Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
79251745|NCT04491357|Drug|Normal saline|Normal saline within 4 hours of skin closure after total thyroidectomy
79545930|NCT01537380|Drug|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
79545931|NCT01537406|Radiation|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
79545932|NCT01537471|Drug|Placebo|Placebo
79545933|NCT01537471|Drug|Meclizine|Meclizine 12.5 mg
79545934|NCT01537471|Drug|Meclizine|Meclizine 25 mg
79545935|NCT01537484|Procedure|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
79707535|NCT05864482|Other|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
79847819|NCT00530439|Other|Lifestyle intervention|Dietician counselling and physical training
79847820|NCT00530439|Other|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
79707536|NCT05856994|Drug|Tacrolimus ointment|For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
80015829|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
80015830|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
79251746|NCT03102788|Behavioral|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
79251747|NCT03102788|Behavioral|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
79545936|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
79251748|NCT05052554|Drug|QR-504a|Intravitreal (IVT) injection
79251749|NCT03306147|Behavioral|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
79251750|NCT03300375|Other|Home exercise program|Home-based, progressive exercise program using resistance bands
79251751|NCT03300375|Other|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
79251752|NCT01673594|Drug|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
79389941|NCT03632200|Other|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
79545937|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
79545938|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
79545939|NCT01537497|Drug|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
79545940|NCT01537510|Behavioral|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
79707537|NCT05846399|Drug|Amoxicillin/clavulanate|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
79707538|NCT05846399|Drug|Ciprofloxacin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
79707539|NCT05846399|Drug|Clindamycin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
79251753|NCT01673594|Drug|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
79251754|NCT03306069|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
79251755|NCT03306069|Other|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~2 sessions per week~5x1 min at 80-95% HRmax~time-effort per week: ~30 min"
79389942|NCT04483830|Drug|Sulodexide|an oral dose of 2 capsules each day for 21 days
79389943|NCT04483830|Drug|Placebo|an oral dose of 2 capsules each day for 21 days
79389944|NCT05712382|Behavioral|Parent handbook|Handbook motivating parents to discuss alcohol use with their college student.
79545941|NCT01537523|Procedure|community-care program|community nurse care, physiotherapy
79707540|NCT05846399|Other|Placebo (microcrystalline cellulose)|Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
79847821|NCT00530439|Behavioral|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
79847822|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
79847823|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
80015831|NCT03665415|Behavioral|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
80015832|NCT03349775|Drug|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
79545942|NCT01537536|Drug|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
79545943|NCT01537562|Other|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
79707541|NCT05846399|Procedure|Wound management|Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
79707542|NCT05842759|Procedure|Monitoring|Continuous blood pressure monitoring
79847824|NCT04994223|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
80015833|NCT03349775|Drug|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
80015834|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
80015835|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
80015836|NCT04810780|Device|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
80015837|NCT05203211|Procedure|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
80015838|NCT05215249|Procedure|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
80015839|NCT04806412|Diagnostic Test|meassurement of PD-L1, ALK, EGFR|"PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).~ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies Origene clone: OT1A4. Sample quality is assessed as for PD-L1.~EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)"
80015840|NCT00829868|Drug|Zaleplon 10 mg Capsules|1 x 10 mg
80015841|NCT00829868|Drug|SONATA® 10 mg capsules|1 x 10 mg
79545944|NCT01537575|Biological|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
79545945|NCT01537575|Biological|Saline solution|Placebo
79545946|NCT01537588|Other|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
79545947|NCT01537588|Other|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
79545948|NCT01537614|Drug|COLIMYCINE inhalation|2 MILLION UI
79545949|NCT01537614|Drug|COLIMYCINE injectable|2 MILLIONS UI
79707543|NCT05842759|Procedure|Norepinephrine preparation|Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)
79847825|NCT04962633|Other|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
80015842|NCT05215015|Biological|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
79847826|NCT04962633|Other|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
79847827|NCT01007565|Procedure|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
80015843|NCT05110066|Procedure|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
79389945|NCT05712382|Behavioral|Coping with negative emotions|Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
79251756|NCT03306069|Other|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~2 sessions per week~5x1 min at 65-79% HRmax~time-effort per week: ~30 min"
79389946|NCT05712382|Behavioral|Problem-solving risky situations|Identifying and planning for barriers to change are encouraged.
79251757|NCT03306069|Other|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~2 sessions per week~session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~time-effort per week: ~30 min"
79251758|NCT02721147|Behavioral|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
79545950|NCT01537627|Other|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
79847828|NCT00497146|Drug|paricalcitol|2 µg capsule
79389947|NCT05712382|Behavioral|Recovering from slips|Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
79389948|NCT04484064|Behavioral|Adherence program|This program combines adherence evaluation using an electronic monitor (MEMS®) and feedback with repeated medication adherence interviews with the pharmacist.
80015844|NCT05110066|Procedure|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
80015845|NCT05214703|Other|cold therapy application|cold therapy
79251759|NCT02721147|Behavioral|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
79251760|NCT02721147|Behavioral|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
79251761|NCT02721147|Behavioral|Behavioral, Psychological or Informational Intervention|Receive educational information and support
79389949|NCT02442492|Drug|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
79389950|NCT02442492|Drug|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
79389951|NCT05712304|Diagnostic Test|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
79545951|NCT01537627|Other|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
79545952|NCT01537640|Biological|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
79389952|NCT02442258|Drug|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
79847829|NCT00497146|Drug|placebo|placebo capsule
79847830|NCT01016548|Biological|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
79847831|NCT01019824|Drug|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
80015846|NCT00721760|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
79847832|NCT01016626|Drug|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
79707544|NCT05842759|Procedure|Propofol administration|Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds
79545953|NCT01537640|Biological|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
79707545|NCT05842759|Procedure|Alarm adjustment|Lower mean arterial pressure alarm threshold will be set to 75 mmHg
79707546|NCT05842759|Procedure|Intervention threshold|Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
79707547|NCT05794165|Drug|Thrombate infusion|Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
79707548|NCT05794165|Drug|Placebo|Normal Saline will be given as one time IV after the 3rd dose of Enoxaparin. The dose will be based on patient weight.
79545954|NCT01537653|Drug|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
79707549|NCT05784545|Dietary Supplement|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
79707550|NCT05784545|Dietary Supplement|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
79707551|NCT05781178|Dietary Supplement|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
79707552|NCT05779007|Drug|Pirfenidone|Pirfenidone
79707553|NCT05779007|Drug|Nintedanib|Nintedanib
79251762|NCT04690478|Device|Electronic remote blood pressure monitor|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
79545955|NCT01537653|Drug|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
79545956|NCT01537679|Behavioral|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
79251763|NCT04690478|Device|Ordinary household electronic sphygmomanometer|One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
79251764|NCT04690478|Device|Office electronic sphygmomanometer|One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
79847833|NCT01016626|Drug|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
79847834|NCT01016704|Behavioral|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
79545957|NCT01537679|Behavioral|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
79847835|NCT00489970|Procedure|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
79847836|NCT00489970|Biological|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
80015847|NCT00721760|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
79545958|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
79545959|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
79251765|NCT02720757|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
79251766|NCT02786498|Drug|Vitamin D3|
79251767|NCT02786498|Other|Placebo|
79251768|NCT03300297|Other|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
79251769|NCT03300297|Other|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
79251770|NCT03300297|Other|Home Program|therapeutic exercise program and education
79251771|NCT03300297|Other|Suboccipital Release|suboccipital soft tissue mobilization
79545960|NCT01537692|Drug|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
79545961|NCT01537705|Drug|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
79545962|NCT01537718|Device|REPLY 200|REPLY 200 pacemaker
79545963|NCT01537731|Procedure|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
79707554|NCT05764252|Device|BioEP|All patient's EEG will have the BioEP score conducted on it
79707555|NCT05761600|Other|Ethnographically-informed group observation|The chief investigator will visit each art therapy group 3-6 times; there will be up to 5 groups recruited. They will record observational data and insights; making use of visual reflective journaling where appropriate. These will later be written up as full field notes.
79707556|NCT05761600|Other|Semi-structured Interviews|Individual interviews will take place with all three key stakeholders in group art therapy at different stages of the study. Each interview will have a topic guide to structure the discussion and will combine arts-based methods with conversation to maximise accessibility. Interview location, timing and format (online or in-person) are flexible, and the chief investigator will adapt to the needs of the participants.
79707557|NCT05761600|Other|Focus Group|After data collection and initial analysis (likely 3-5 months after final observation and/or interview) a focus group will be held with the art therapist participants. This session will use arts-based engagement to support member checking of the initial results and triangulation of the findings, which is likely to include potential active ingredients in group art therapy and principles of practice with this client group.
79847837|NCT00489970|Biological|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
80015848|NCT00721760|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
79847838|NCT01020058|Procedure|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
79847839|NCT02798471|Drug|Edoxaban|15 or 30 mg tablets for participants 12 years of age to <18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
79847840|NCT02798471|Drug|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
79847841|NCT03443765|Diagnostic Test|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
79847842|NCT03443765|Diagnostic Test|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
79251772|NCT03891914|Drug|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
80015849|NCT05109832|Drug|14C-IMP4297|14C marked IMP4297
79251773|NCT03891914|Drug|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
79251774|NCT02467569|Drug|Hemay020|
79545964|NCT01537744|Drug|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~Each cycle will last 28 days.~Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
79545965|NCT01537757|Drug|MK-8931|Single dose, administered as oral capsules
79545966|NCT01537770|Procedure|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
79847843|NCT03441893|Diagnostic Test|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
79251775|NCT02742506|Other|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
79847844|NCT03441893|Drug|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
79847845|NCT03441893|Drug|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
79847846|NCT03441893|Drug|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
79847847|NCT03441893|Drug|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
79847848|NCT03848663|Behavioral|Traditional Remapping|Shifting text outside of scotoma
80015850|NCT05194891|Diagnostic Test|Specular Microscopy|Phacoemulsification
80015851|NCT04943068|Drug|Bremelanotide|Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
79251776|NCT02721134|Other|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
79251777|NCT03300219|Behavioral|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
79251778|NCT02683616|Device|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
79251779|NCT02597660|Drug|Somatropin|Active drug
79251780|NCT02597660|Drug|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
80015852|NCT04943068|Drug|Placebo|Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
79389953|NCT02442258|Drug|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
79389954|NCT02442024|Behavioral|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
79389955|NCT02442024|Behavioral|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
79389956|NCT01704755|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
79389957|NCT01704755|Drug|Ribavirin (RBV)|Capsule
79389958|NCT02449122|Procedure|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
79707558|NCT05744856|Behavioral|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
79251781|NCT02597660|Other|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
79847849|NCT03848663|Behavioral|Personalized Remapping|Shifting text based on individual letter-based perimetry
79847850|NCT03440177|Drug|Ramipril|Patients are tested for their normal prescription ramipril medication
79251782|NCT02597660|Procedure|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
79251783|NCT03101852|Dietary Supplement|Plumpy Nut|
79251784|NCT03101852|Dietary Supplement|Plumpy Sup|
79847851|NCT00489736|Drug|dronedarone (SR33589)|oral administration
79847852|NCT00489736|Drug|amiodarone|oral administration
79251785|NCT03848858|Behavioral|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
79251786|NCT04368260|Device|Control swab|FDA-cleared nasopharyngeal swab
79389959|NCT05165550|Drug|Elsulfavirine|Elsulfavirine (Elpida®) 20 mg capsules for oral administration
79847853|NCT02774759|Device|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
79847854|NCT02774759|Behavioral|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
79251787|NCT04368260|Device|Prototype swab|Injection molded polypropylene flocked nylon nasopharyngeal swab
79251788|NCT04435262|Other|Remote Monitoring|Remote Monitoring Follow-up
79545967|NCT01537770|Procedure|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
79545968|NCT01537796|Behavioral|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
79847855|NCT02774759|Behavioral|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
79847856|NCT02774759|Behavioral|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
79251789|NCT02523248|Procedure|tonsillectomy|Tonsillectomy with cold steel
79251790|NCT02523248|Procedure|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
79389960|NCT04166669|Drug|APX001|Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
79389961|NCT04166669|Drug|Itraconazole|Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
79389962|NCT04166669|Drug|Rifampin|Cohort 2 Days 15-33: rifampin 600 mg oral QD.
79389963|NCT03193710|Drug|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
79389964|NCT03193710|Drug|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
79389965|NCT03193710|Drug|Remifentanil|Remifentanil will be used for analgesia in both groups.
80015853|NCT03628105|Behavioral|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger & Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
80015854|NCT03628105|Behavioral|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
79707559|NCT05743153|Behavioral|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support."
80015855|NCT04780282|Other|Scapular Stabilization Group|Participants will apply the 5 exercises given.
79251791|NCT02419664|Drug|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
79251792|NCT02646566|Drug|APD421|
79251793|NCT02646566|Drug|Placebo|
79707560|NCT05732935|Behavioral|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
79707561|NCT05732935|Behavioral|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
79847857|NCT02774759|Behavioral|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
80015856|NCT03628027|Device|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
80015857|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5mL oral dose
79251794|NCT04351880|Other|Medically Tailored Meals|Compare 2 and 4 weeks of meal delivery
79251795|NCT03102476|Drug|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
79251796|NCT04482530|Other|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
79389966|NCT03193632|Diagnostic Test|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
79545969|NCT01537796|Behavioral|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
80015858|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
80015859|NCT03207815|Drug|Filgotinib|Tablet(s) administered orally
80015860|NCT03207815|Drug|Placebo to match filgotinib|Tablet(s) administered orally
80015861|NCT03207815|Drug|Prednisone|Tablet(s) administered orally
80015862|NCT05110534|Behavioral|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
80015863|NCT02911935|Drug|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
80015864|NCT02911935|Drug|Placebo|Placebo suspension
79251797|NCT03104582|Procedure|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
79707562|NCT05731323|Drug|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
79707563|NCT05731323|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
79710220|NCT00600210|Drug|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
79847858|NCT02774759|Behavioral|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
80015865|NCT05193487|Other|inferior alveolar nerve block|inferior alveolar nerve block using Articaine 4% with 1/200000 Adrenaline and a traditional needle injection
80015866|NCT05193487|Other|intra-osseous mandibular anaesthesia|intra-osseous mandibular anaesthesia using Articaine 4% with 1/200000 Adrenaline and a special intra-osseous injection device
80015867|NCT04294108|Other|Prolong in-hospital stay|Patients have a longer length of hospital stay than the common recommendation.
80015868|NCT03479762|Drug|Liraglutide|No treatment given
80015869|NCT05100394|Radiation|Laser Therapy|Therapeutic laser therapy was applied.
79251798|NCT03104582|Procedure|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
79251799|NCT04435574|Drug|Lactoferrin|Bovine Lactoferrin 100mg sachets.
79389967|NCT03193632|Diagnostic Test|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
79545970|NCT01537796|Behavioral|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
79545971|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
79545972|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
79251800|NCT04435574|Drug|Ferrous Sulfate|6mg/kg of ferrous sulfate.
79251801|NCT03102164|Procedure|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
79251802|NCT03104426|Drug|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
79389968|NCT01704599|Drug|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
79389969|NCT03196362|Drug|Pioglitazone + Metformin|One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
79545973|NCT01537822|Procedure|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
80015870|NCT05100394|Other|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
80015871|NCT03391635|Device|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
79251803|NCT04435106|Drug|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
79251804|NCT04435106|Drug|Standard of Care|Study participants received Standard of Care
79251805|NCT04015856|Behavioral|Full TP intervention|CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
79251806|NCT04015856|Behavioral|Light TP intervention|The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
79389970|NCT03196362|Drug|Placebo Oral Tablet|One tablet of placebo will be given twice daily
79707564|NCT05700981|Diagnostic Test|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
79847859|NCT02774759|Behavioral|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
79847860|NCT00617084|Device|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
79847861|NCT00617084|Device|Abbott Xience V|Abbott Xience V
79847862|NCT02758847|Device|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
79847863|NCT02758847|Device|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
79847864|NCT01016860|Drug|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
79847865|NCT01016860|Drug|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
79847866|NCT04075877|Behavioral|FOCUS|See prior section.
79847867|NCT00874484|Drug|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
79847868|NCT00869492|Drug|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
79545974|NCT01537822|Procedure|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
79847869|NCT00869492|Drug|nadifloxacine|Nadifloxacine 1% cream twice dailly
79251807|NCT03104348|Diagnostic Test|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
79251808|NCT03989180|Device|C-Scan System|"Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~The recorder will be secured to their lower back to test its functionality"
79545975|NCT01537848|Procedure|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
79545976|NCT01537861|Drug|Filgrastim|
79847870|NCT00489424|Drug|Placebo|
79389971|NCT03193320|Other|Fluid therapy protocol|Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
79545977|NCT01537861|Drug|Bortezomib|
79847871|NCT00489424|Drug|Acetaminophen|
79847872|NCT00489424|Drug|Fluvastatin|
79847873|NCT05325359|Behavioral|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
79847874|NCT00869570|Drug|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
79847875|NCT00869570|Drug|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
79847876|NCT00869570|Radiation|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
79847877|NCT00880412|Drug|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
79847878|NCT00880412|Drug|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
79847879|NCT05673707|Diagnostic Test|Thyromental Height|its measure between thyroid and mentum
79847880|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
79251809|NCT03104894|Procedure|Meibomian Glands Massage|Meibomian gland expression
79251810|NCT03104894|Procedure|Sham Meibomian Glands Massage|Touching the eyelids gently
79707565|NCT05684159|Drug|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
79847881|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
79251811|NCT03104894|Device|Meibomian Massage device|Meibomian glands expression with applicator
79545978|NCT01537861|Drug|Carfilzomib|
79389972|NCT02449278|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
79389973|NCT02449278|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
79389974|NCT02449278|Drug|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
79545979|NCT01537861|Drug|Dexamethasone|
79545980|NCT01537861|Drug|Cyclophosphamide|
79545981|NCT01537861|Drug|Thalidomide|
79545982|NCT01537861|Drug|Lenalidomide|
79847882|NCT03412643|Drug|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
79847883|NCT03412643|Drug|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
79251812|NCT02229344|Other|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
79545983|NCT01537861|Drug|Pomalidomide|
79707569|NCT05674422|Drug|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
79707570|NCT05658705|Procedure|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
79707571|NCT05658705|Procedure|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
79707572|NCT05636306|Drug|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
79847884|NCT03412643|Drug|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
79847885|NCT03412643|Drug|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
79847886|NCT03412643|Drug|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
79847887|NCT03412643|Diagnostic Test|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
79251813|NCT03824756|Other|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
79251814|NCT03824756|Other|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
79545984|NCT01537874|Behavioral|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
79251815|NCT02163356|Drug|Fenretinide/LXS Oral Powder|Oral Powder
79251816|NCT02163356|Drug|Ketoconazole|Oral Tablet
79251817|NCT02163356|Drug|Vincristine|IV
79251818|NCT02004080|Other|Intensive Care treatment|intensive care treatment
79251819|NCT04412564|Drug|TQ-B3101|TQ-B3101 is a ALK inhibitor.
79545985|NCT01537874|Behavioral|Usual best practices|Standard care delivered using informational materials
79545986|NCT01537939|Behavioral|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
79545987|NCT01537965|Device|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~elastography with Fibroscan®~ultrasound elastography in supersonic mode with Aixplorer®~ultrasound analysis of the surface liver with QRS software,~quantification of acoustic structure with Aplio XG,~elastography ARFI with Acuson S2000."
79545988|NCT01537978|Other|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
80015872|NCT03391635|Device|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
79545989|NCT01537991|Radiation|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
80015873|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
79545990|NCT01538017|Drug|Xiapex|Collagenase Clostridium Histolyticum
79545991|NCT01538017|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
79707573|NCT05636306|Drug|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
79707574|NCT05629260|Drug|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
79707575|NCT05629260|Drug|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
79707576|NCT05621694|Behavioral|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
79707577|NCT05616208|Biological|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
80015874|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
79251820|NCT04412642|Drug|Methoxyflurane, MEOF|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
79251821|NCT04412720|Other|Aerobic and Breathing Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
79251822|NCT04412720|Other|Aerobic and Stretching Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
79251823|NCT03101618|Other|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
79251824|NCT03101618|Other|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
79707578|NCT05615012|Drug|BMS-986322|Specified dose on specified days
79707579|NCT05615012|Drug|Rosuvastatin|Specified dose on specified days
79707580|NCT05615012|Drug|Metformin|Specified dose on specified days
80015875|NCT04306211|Device|SuperNO2VA|SUPERNO2VA is nasal PAP device for oxygen delivery
80015876|NCT05079802|Drug|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
80015877|NCT05079802|Drug|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
79251825|NCT03101384|Other|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
79389975|NCT02449278|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
79389976|NCT02449278|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy
79389977|NCT02449278|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy
79389978|NCT02441868|Behavioral|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
79545992|NCT01538043|Other|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
79707581|NCT05615012|Dietary Supplement|Glucose|Specified dose on specified days
79707582|NCT05615012|Drug|Methotrexate|Specified dose on specified days
79707583|NCT05615012|Drug|Leucovorin|Specified dose on specified days
79707584|NCT05609240|Drug|Cefuroxime|See arm/group description
79707585|NCT05606198|Other|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
79707586|NCT05597033|Behavioral|Exercise|walking and handgrip exercise
79707587|NCT05597033|Behavioral|Control|seated rest
79707588|NCT05588141|Drug|Zotiraciclib|Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
79707589|NCT05544526|Biological|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
80015878|NCT05050669|Other|No Intervention for this observational study|No Intervention for this observational study
79707590|NCT05535439|Procedure|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
79707591|NCT05534763|Behavioral|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
79707592|NCT05534763|Other|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
79707593|NCT05531643|Device|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
79707594|NCT05531643|Device|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
79707595|NCT05529628|Diagnostic Test|Cytokine levels|Preoperative cytokine levels of the patients
79707596|NCT05523973|Other|Lingual Endurance Exercise|Participants will participate in 3 training sessions per day for 8 weeks. Group 1 will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session.
79707597|NCT05523973|Other|Lingual Endurance + Transference Exercise|"Group 2 will complete lingual endurance exercise for 2 sessions, and for the 3rd training session participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva. The TongueometerTM will provide biofeedback on performance and will be instructed to generate more pressure during this effortful swallow than during a natural, saliva swallow."
79707598|NCT05519397|Diagnostic Test|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
79707599|NCT05517382|Other|supportED|suicide prevention videogame
79707600|NCT05517382|Other|Control|non-health related videogame
79707601|NCT05511623|Drug|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
79707602|NCT05511623|Other|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
79847888|NCT05125744|Diagnostic Test|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
79847889|NCT00614744|Procedure|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
79847890|NCT00614744|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
79847891|NCT01017094|Drug|silversulfadiazine|apply once a day
79847892|NCT04074239|Other|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
79847893|NCT01020214|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
79847894|NCT01020214|Drug|Benicar HCT® Tablets 40 mg/25 mg|
79847895|NCT02733029|Drug|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
79847896|NCT02733029|Device|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
79251826|NCT03104114|Behavioral|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
79251827|NCT03104114|Behavioral|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
79251828|NCT03867110|Drug|Placebo|
79251829|NCT03867110|Drug|Ezetimibe 10 mg|
79251830|NCT03867110|Drug|Atorvastatin 10 mg|
79251831|NCT03867110|Drug|Atorvastatin 20 mg|
79251832|NCT03867110|Drug|Atorvastatin 40 mg|
79389979|NCT02441790|Behavioral|Early Active Range of Motion|3-9 days
79389980|NCT02441790|Behavioral|Standard Immobilization|21-27 days
79389981|NCT02449200|Other|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
79389982|NCT03196128|Other|Digital communication|Communicating with patients via email and text message.
79389983|NCT03196128|Other|Non digital|Communicating with patients via telephone and written appointment letters.
79389984|NCT04484298|Diagnostic Test|Reference position patient is put in a 30 degree supine position during 5 minutes|Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)
79389985|NCT04484298|Diagnostic Test|nitroglucerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
79389986|NCT02441712|Device|PENS|
79389987|NCT03196050|Device|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
79389988|NCT02441556|Device|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
79847897|NCT01017172|Other|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
79847898|NCT02715323|Other|Cross-sectional study|
79251833|NCT03867110|Drug|Atorvastatin 80 mg|
80015879|NCT05187091|Radiation|Swallowing and submandibular sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures & submandibular gland sparing by SWOAR-IMRT
80015880|NCT04473248|Device|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
80015881|NCT05203055|Drug|Peginterferon alpha-2b|180μg/w
80015882|NCT05203055|Drug|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
80015883|NCT05203055|Drug|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
80015884|NCT05108662|Procedure|Surgery method|Patients were subdivided into two groups according to their prostate volume
79251834|NCT03865082|Drug|Tilsotolimod|9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
79251835|NCT03865082|Drug|Nivolumab|Specified dose on specified days.
79251836|NCT03865082|Drug|Ipilimumab|Specified dose on specified days.
79251837|NCT03102398|Drug|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
79251838|NCT03103802|Device|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
79251839|NCT03103958|Dietary Supplement|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water"
79251840|NCT03103958|Dietary Supplement|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water"
79389989|NCT02441556|Other|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
79389990|NCT03162978|Other|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
79389991|NCT03162978|Other|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
79389992|NCT03157362|Other|Near Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
79389993|NCT03157362|Other|Near Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated, and converse with a confederate represented by an avatar.
79251841|NCT01187810|Drug|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
79251842|NCT01187810|Drug|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
79389994|NCT03157362|Other|Far Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces a different room.
79389995|NCT03157362|Other|Far Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces another room, and converse with a confederate represented by an avatar.
79389996|NCT03599518|Drug|DS-1205c|DS-1205c 200 mg capsule for oral administration
79389997|NCT03599518|Drug|Gefitinib|Gefitinib 250 mg tablet for oral administration
79389998|NCT03099486|Drug|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
79707603|NCT05499650|Behavioral|Supervised Exercise Regiment|Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
79707604|NCT05465538|Drug|[11C]UCB-J PET|Single PET scan using the radioligand [11C]UCB-J
79707605|NCT05465317|Drug|Empagliflozin|Empagliflozin
79707606|NCT05465317|Drug|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
79707607|NCT05465317|Drug|Sodium glucose co-transporter-2 inhibitors|Sodium glucose co-transporter-2 inhibitors
79707608|NCT05465317|Drug|Glucagon-like Peptide-1 Receptor Agonists|Glucagon-like Peptide-1 Receptor Agonists
80015885|NCT05186155|Procedure|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
80015886|NCT03899636|Drug|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
80015887|NCT03899636|Device|NanoKnife System|IRE using NanoKnife System
80015888|NCT03813862|Other|Non-interventional (observational only)|
80015889|NCT05184751|Other|colonoscopy|
80015890|NCT03773380|Combination Product|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
80015891|NCT03457766|Device|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
79847899|NCT02578433|Behavioral|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
80015892|NCT05168371|Behavioral|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
80015893|NCT05168371|Behavioral|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
79847900|NCT02578433|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
79847901|NCT04919993|Behavioral|Cognitive Behavioral Therapy-Insomnia|Group presentation
80015894|NCT05105620|Diagnostic Test|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
80015895|NCT05105620|Diagnostic Test|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
80015896|NCT04237181|Device|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
80015897|NCT05157139|Drug|Oral Capsule|Oral Capsule of vanillin & wheat germ oil
80015898|NCT03386942|Drug|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
80015899|NCT04527094|Diagnostic Test|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
80015900|NCT05136937|Biological|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection for 3 dose cohorts: 1×10^7 TCID50/mL, 1×10^8 TCID50/mL and 7×10^8 TCID50/mL
79251843|NCT01187810|Drug|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
79251844|NCT03104036|Other|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
79251845|NCT03104036|Drug|Mesalazine 4G Enema|Standard mesalazine enema
79251846|NCT01124942|Device|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
79847902|NCT00565812|Drug|SD-6010|200 mg tablets once a day for 2 years
79847903|NCT00565812|Drug|SD-6010|50 mg tablets once a day for 2 years
79847904|NCT00565812|Drug|Placebo|Placebo tablets once a day for 2 years
79251847|NCT01124942|Device|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
79251848|NCT03101306|Other|MR scans|Additional imaging using MR scans.
79251849|NCT03449888|Procedure|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
79251850|NCT03449888|Procedure|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
79847905|NCT03974334|Behavioral|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
79847906|NCT03970824|Biological|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
79847907|NCT03970824|Biological|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
79847908|NCT03970824|Biological|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
79707609|NCT05457322|Behavioral|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
79707610|NCT05457322|Behavioral|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
79707611|NCT05451823|Device|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
80015901|NCT05015569|Device|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
80015902|NCT05015569|Other|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
80015903|NCT04910230|Drug|nicotinamide|In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
80015904|NCT03069989|Drug|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
79389999|NCT03099486|Drug|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
79390000|NCT03099486|Drug|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
79707612|NCT05446597|Procedure|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
79707613|NCT05446597|Other|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
79707614|NCT05446597|Behavioral|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
79847909|NCT00933894|Drug|Telaprevir; Escitalopram|
80015905|NCT03069989|Drug|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
80015906|NCT03069989|Drug|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
79847910|NCT00933972|Drug|RO4998452|20mg po single dose
79847911|NCT00564486|Drug|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
79847912|NCT00564486|Drug|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
79847913|NCT00564486|Drug|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
80015907|NCT04894474|Drug|BI 767551 intravenous|BI 767551 intravenous
80015908|NCT04894474|Drug|BI 767551 inhalation|BI 767551 inhalation
79251851|NCT03449888|Procedure|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
79251852|NCT03449888|Procedure|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease > 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
79251853|NCT03308396|Drug|Guadecitabine|Days 1-5 Dose 0: 60 mg/m^2 Dose -1: 45 mg/m^2
79251854|NCT03308396|Drug|Durvalumab|Day 8 Durvalumab (1500 mg IV)
79390001|NCT04483986|Procedure|Rectus muscle re-approximation|Study group: we are going to re-approximate rectus muscle wirth minimum 3 stiches.
79390002|NCT03192072|Diagnostic Test|Host Gene Expression|comparison to retrospective clinical adjudication
79390003|NCT02448966|Procedure|open esophagectomy|
79390004|NCT02448966|Procedure|Minimally invasive esophagectomy|
79390005|NCT02441478|Radiation|functional magnetic resonance imaging exam|
79390006|NCT00358228|Drug|Rimonabant|
79390007|NCT02441400|Device|EndoStim LES Stimulation System|
79390008|NCT03192930|Other|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
79390009|NCT05710198|Drug|Citicoline eye drops 2%|Eye drops containing Citicoline 2%
79390010|NCT05710198|Drug|Placebo|Eye drops containing placebo matching product
79390011|NCT02448888|Other|Adapted exercise|2 months, 3 times/week
79847914|NCT00564486|Drug|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
79847915|NCT00481078|Drug|vorinostat|Given PO
79847916|NCT00481078|Drug|paclitaxel|Given IV
79847917|NCT00481078|Drug|carboplatin|Given IV
79847918|NCT00481078|Other|placebo|Given PO
79847919|NCT00481078|Other|laboratory biomarker analysis|Correlative studies
79847920|NCT00934206|Behavioral|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
79847921|NCT00934284|Other|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
80015909|NCT04894474|Drug|Placebo intravenous|Placebo intravenous
80015910|NCT04894474|Drug|Placebo inhalation|Placebo inhalation
80015911|NCT03438682|Device|Essure|Essure hysteroscopic sterilization
80015912|NCT03438682|Procedure|Laparoscopic sterilization|Laparoscopic sterilization via electrocautery, ring, or clip.
80015913|NCT03438682|Device|Intrauterine Device (IUD)|Intrauterine Device (IUD)
80015914|NCT04764136|Device|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
79545993|NCT01538069|Other|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
79707615|NCT05445869|Device|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
79707616|NCT05443633|Behavioral|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
79707617|NCT05443633|Behavioral|standard language intervention|Participants will undergo standard speech-language naming therapy
79707618|NCT05428891|Procedure|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
79707619|NCT05405270|Drug|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
79847922|NCT00934284|Other|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
79251855|NCT01072682|Device|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
79251856|NCT03102086|Procedure|Scaling|Scaling of dental calculus
79251857|NCT03102008|Behavioral|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
79390012|NCT02448888|Other|General exercise recommendations|2 months, 3 times/week
79390013|NCT04344496|Other|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
79707620|NCT05405270|Diagnostic Test|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
79390014|NCT02448732|Drug|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
79390015|NCT05722054|Other|Diagnostic tests|"Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination."
79390016|NCT05722054|Other|Equilibrate diet|Nutritionally-balanced Alimentation
79707621|NCT05405270|Other|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
79390017|NCT01787682|Dietary Supplement|BOOST High Protein|
79390018|NCT01687920|Drug|BAY94-8862 (1.25mg)|
79390019|NCT01687920|Drug|BAY94-8862 (2.5mg)|
79847923|NCT00938808|Dietary Supplement|day formula diet|The Cambridge Programme. Formula diet
79847924|NCT00480532|Drug|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
79390020|NCT01687920|Drug|BAY94-8862 (5mg)|
79390021|NCT01687920|Drug|BAY94-8862 (7.5mg)|
79390022|NCT01687920|Drug|BAY94-8862 (10mg)|
79847925|NCT00480532|Drug|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
80015915|NCT03619915|Diagnostic Test|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
79847926|NCT00480532|Drug|Oracea|40-mg tablet daily for 84 days
79707622|NCT05405270|Diagnostic Test|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
79251858|NCT00985400|Behavioral|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
79707623|NCT05394376|Other|Level of noise and environment (public vs private) while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
79707624|NCT05372328|Other|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
79707625|NCT05343650|Device|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
79707626|NCT05343650|Device|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
79707627|NCT05338346|Drug|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
79707628|NCT05338190|Drug|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
79707629|NCT05338190|Drug|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
79707630|NCT05330637|Other|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
79251859|NCT00985400|Behavioral|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
79251860|NCT00985400|Other|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
79251861|NCT00985400|Other|Questionnaire administration|
79251862|NCT00985400|Behavioral|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
79251863|NCT02720523|Drug|Placebo|Tablet; Oral
79251864|NCT02720523|Drug|Upadacitinib|Tablet; Oral
79251865|NCT00779168|Drug|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
79251866|NCT00779168|Other|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
79390023|NCT01336530|Drug|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
79390024|NCT01336530|Drug|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
79390025|NCT01336530|Drug|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
79390026|NCT01336530|Other|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
79390027|NCT02441244|Drug|Visbiome|Visbiome probiotic
79390028|NCT02441244|Other|Placebo|Placebo
79707631|NCT05325840|Other|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
79707632|NCT05319691|Behavioral|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
79707633|NCT05305586|Device|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
79847927|NCT00480532|Drug|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
79847928|NCT00480532|Drug|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
79847929|NCT00480532|Drug|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
79251867|NCT00779168|Other|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
79707634|NCT05305586|Device|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
79707635|NCT05296109|Diagnostic Test|Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)|The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
79707636|NCT05287503|Drug|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
80015916|NCT03619915|Other|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
79251868|NCT00779168|Other|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
79251869|NCT00779168|Other|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
79251870|NCT00779168|Other|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
79251871|NCT02646332|Drug|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
79390029|NCT02441166|Procedure|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
79390030|NCT00356902|Procedure|titration of oxygen during resuscitation|
79545994|NCT01538069|Other|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
79251872|NCT02646332|Drug|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
79545995|NCT01538069|Other|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
79545996|NCT01538095|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
79390031|NCT00777348|Drug|Combination DSCG and Reproterol|1:
79390032|NCT04484454|Dietary Supplement|ProdromeNeuro Omega 3 Oil Nutritional Supplement|ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
79390033|NCT03836560|Drug|Nicotine patch|nicotine patch given for 8 weeks
79390034|NCT03836560|Drug|Nicotine gum|nicotine gum given as requested
79390035|NCT02448498|Behavioral|Exercise Intervention|
79390036|NCT05721820|Procedure|TAVR|Transcatheter aortic valve replacement
79545997|NCT01538095|Other|Laboratory Biomarker Analysis|Correlative studies
79545998|NCT01538095|Other|Pharmacological Study|Correlative studies
79545999|NCT01538095|Biological|Trebananib|Given IV
79707637|NCT05287503|Drug|Placebo|Excipients
79707638|NCT05271617|Diagnostic Test|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
79707639|NCT05271344|Dietary Supplement|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
79251873|NCT02471716|Biological|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks
79707640|NCT05263908|Drug|nirmatrelvir / ritonavir|The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
79251874|NCT00015002|Drug|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
79546000|NCT01538108|Device|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
79546001|NCT01538108|Procedure|Plain Balloon angioplasty (PBA)|PBA
79546002|NCT01538160|Drug|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
79546003|NCT01538173|Drug|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
79546004|NCT01538173|Drug|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
79546005|NCT01538225|Drug|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
79546006|NCT01538225|Drug|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
79707641|NCT05259371|Drug|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
79707642|NCT05227001|Biological|PF-07852352 Influenza saRNA 1|Intramuscular injection
79546007|NCT01538238|Drug|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
79707643|NCT05227001|Biological|PF-07836391 Influenza saRNA|Intramuscular injection
79707644|NCT05227001|Biological|PF-07836394 Influenza saRNA|Intramuscular injection
79546008|NCT01538251|Drug|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
79546009|NCT01538251|Drug|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
79707645|NCT05227001|Biological|PF-07836395 Influenza saRNA|Intramuscular injection
79707646|NCT05227001|Biological|PF-07836396 Influenza saRNA|Intramuscular injection
79707647|NCT05227001|Biological|PF-07867246 Influenza saRNA|Intramuscular injection
79707648|NCT05227001|Biological|Placebo|Intramuscular injection
79707649|NCT05227001|Biological|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
79707650|NCT05227001|Biological|PF-07871987 Influenza saRNA|Intramuscular injection
80015917|NCT05202977|Device|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
80015918|NCT04995094|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
80015919|NCT04995094|Biological|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
80015920|NCT04924387|Procedure|Exercise|All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercises of 2-3 minutes.
79251875|NCT01370863|Drug|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
79546010|NCT01538277|Procedure|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
79546011|NCT01538277|Other|Standard ablation procedure|Standard ablation procedure
79546012|NCT01538316|Dietary Supplement|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
80015921|NCT05202821|Drug|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
79251876|NCT01370863|Drug|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
79251877|NCT03103724|Drug|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
79251878|NCT03560947|Other|Manual Therapy and Exercise (Physiotherapy Intervention)|Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.
79546013|NCT01538316|Dietary Supplement|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
79546014|NCT01538316|Dietary Supplement|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
80015922|NCT05202821|Drug|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
79251879|NCT03560947|Other|Usual Care (Physiotherapy Intervention)|Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
79251880|NCT03305913|Drug|TAS 102|TAS-102 tablet
79546015|NCT01538329|Drug|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
79707651|NCT05227001|Biological|PF-07914705 Influenza saRNA|Intramuscular injection
79707652|NCT05227001|Biological|PF-07915048 Influenza saRNA|Intramuscular injection
79707653|NCT05212571|Drug|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
79707654|NCT05212571|Drug|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
79707655|NCT05209763|Procedure|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
79707656|NCT05209763|Dietary Supplement|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~inclusion of probiotics in standard doses"
79707657|NCT05209269|Other|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
79707658|NCT05201001|Drug|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
79707659|NCT05198050|Drug|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
79707660|NCT05198050|Drug|Misoprostol Tabets|a synthetic prostaglandin medication
80015923|NCT05202821|Drug|MI paste|Third group will be receiving MI paste
79847930|NCT00480532|Drug|placebo daily|Placebo daily for the first 84 days of the study
79251881|NCT03305913|Drug|Regorafenib|Regorafenib tablet
79251882|NCT02444182|Dietary Supplement|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
79847931|NCT04013880|Drug|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
80015924|NCT04958902|Behavioral|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
80015925|NCT02951416|Other|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
80015926|NCT05201651|Dietary Supplement|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
79251883|NCT02444182|Dietary Supplement|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
79707661|NCT05198050|Drug|Placebo tablets|Placebo tables with a similar appearance to letrozole
79251884|NCT03103412|Drug|TD-3504|TD-3504
79546016|NCT01538329|Drug|placebo|200mg / day once daily in the morning and at noon - oral administration -
79546017|NCT01538355|Other|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
79546018|NCT01538355|Other|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
79546019|NCT01538355|Other|Control diet|Patients stay on their regular diet.
79546020|NCT01538381|Drug|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
79707662|NCT05189223|Behavioral|Brief, values based intervention for early buprenorphine treatment|The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
79707663|NCT05189223|Behavioral|Treatment as Usual|Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
79251885|NCT03103412|Drug|15N2-tofacitinib|15N2-tofacitinib
79251886|NCT03103412|Drug|Placebo|Placebo
79251887|NCT02061007|Drug|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
79707664|NCT05176418|Drug|low dose Nicotine|IV nicotine infused over different delivery rates
79847932|NCT04013880|Drug|IDH-1 Inhibitor FT-2102|Given by mouth
79251888|NCT02061007|Drug|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
79251889|NCT02061007|Procedure|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
79546021|NCT01538381|Other|Observation|Observation
79546022|NCT01538394|Drug|Varenicline|
79546023|NCT01538394|Drug|Nicotine patches|
79546024|NCT01538394|Drug|Placebo (nicotine patches)|
79251890|NCT03305757|Drug|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
79251891|NCT03305757|Procedure|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
79251892|NCT03305757|Procedure|Conventional|Conventional closure after mastectomy
79251893|NCT02780648|Radiation|Stereotactic Body Radiation|
79707665|NCT05176418|Drug|high dose Nicotine|IV Nicotine infused over different delivery rates
79847933|NCT00934518|Radiation|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
79847934|NCT00934518|Drug|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
79847935|NCT00496366|Drug|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
79847936|NCT00496366|Drug|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
79847937|NCT00934674|Drug|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
80015927|NCT05201651|Dietary Supplement|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
80015928|NCT04826731|Other|Incentive Spirometer/Respiratory Exerciser|"A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device."
80015929|NCT04853914|Device|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
79707666|NCT05171894|Drug|Hemopfin+PDT|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
80015930|NCT04231409|Device|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
79390037|NCT02440152|Device|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
79707667|NCT05171894|Drug|Vehicle+PDT|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
80015931|NCT04684810|Behavioral|Community Lay Therapist-Administered EBT|Community Therapists Used CBT and EMDR Interventions
80015932|NCT02698163|Device|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
79707668|NCT05166642|Device|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
79707669|NCT05166642|Device|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
79707670|NCT05161780|Drug|Lactated Ringer's Irrigation|Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
79847938|NCT00934752|Device|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
79251894|NCT02059837|Procedure|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
80015933|NCT02698163|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
80015934|NCT04680676|Drug|BI 730357|BI 730357
79251895|NCT02086604|Drug|Brentuximab vedotin|
79251896|NCT02086604|Drug|Lenalidomide|
79251897|NCT02467101|Other|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
79251898|NCT05100225|Biological|PTP-001|Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.
79251899|NCT05100225|Other|Placebo control|The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
79251900|NCT03101540|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
79251901|NCT02061085|Drug|Eribulina|
79251902|NCT03300063|Other|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
79251903|NCT03103568|Drug|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
79251904|NCT03103568|Drug|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
79251905|NCT03103568|Drug|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
79847939|NCT01020292|Drug|Nelfinavir|
79847940|NCT01017406|Device|PSU heel cushion and plantar fascia specific stretching exercise|"Wear heel cushion during daily activity~Plantar fascia stretching exercise 3 times per day"
80015935|NCT04680676|Drug|Placebo|Placebo
79251906|NCT03103568|Drug|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
79251907|NCT03103568|Drug|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
79251908|NCT03103568|Drug|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
79251909|NCT03299985|Other|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
79251910|NCT03299985|Other|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
80015936|NCT04631731|Diagnostic Test|Blood screening|Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
79251911|NCT03101072|Other|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
80015937|NCT04631731|Diagnostic Test|Tissue screening|Archival tumor tissue (FFPE) will be spatially analysed in order to define tissue heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and correlate it with the occurrence/development of immune-related adverse events.
79707671|NCT05161780|Drug|Normal Saline|Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
80015938|NCT02941276|Device|Active Electrostimulator device|Patients who will receive a fully functioning device
80015939|NCT02941276|Device|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
80015940|NCT03817190|Drug|DS107|DS107 Capsule
80015941|NCT03817190|Drug|Placebo|Placebo capsule
79390038|NCT04483596|Drug|melatonin effect on the Abbreviated Mental Test|"Questionnare~Age~Time (to nearest hour)~Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~Year~Name of hospital~Recognition of two persons (e.g. doctor, nurse)~Date of birth~Year of any famous event e.g: the last Egyptian revolution~Name of the present monarch~Count backwards from 20 to 1"
79707672|NCT05159414|Device|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
79847941|NCT04014426|Other|Blood sample|"Exposed group:~15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
80015942|NCT05666245|Behavioral|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
79390039|NCT05721586|Other|Self Assembling Peptide P11-4 (CURODONTTM REPAIR) + Fluoride varnish (DURAFLOR|The WSL was Acid etched with phosphoric acid gel 35-37% for 20 seconds, the tooth surface was rinsed with water and then dried afterwards application of CURODONTTM REPAIR
79390040|NCT05721586|Other|Fluoride varnish (DURAFLOR|A very thin coat of the DURAFLOR varnish was applied by a thin brush which was then allowed to dry for 10 seconds. The varnish hardens on contact with saliva or moisture
79390041|NCT03190512|Other|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
79390042|NCT03322306|Genetic|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
79390043|NCT02441010|Device|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
79390044|NCT02441010|Other|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
79707673|NCT05134740|Biological|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10^7/m2"
79847942|NCT04014426|Other|Urinary sample|"Exposed group:~15 to 30 min before the PIPAC procedure (T0)~2hours after the end of the procedure (T1)~The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)"
79847943|NCT03117582|Other|Stool specimen|"The following stool specimen will be collected for this study:~4, 3mL stool specimen from patient~1, 25mL stool aliquot from donor"
79847944|NCT00488644|Drug|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
79847945|NCT00488644|Drug|Liothyronine|15 mcg PO Daily for 8 Weeks
79847946|NCT00934830|Drug|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
79847947|NCT00934830|Other|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
79847948|NCT00934908|Dietary Supplement|Green Tea|Green tea capsules taken twice a day.
80015943|NCT05666245|Behavioral|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
79251912|NCT03101072|Other|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
79707674|NCT05133076|Biological|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
79847949|NCT00934908|Other|Placebo|"Non-active sugar pill."
79707675|NCT05133076|Biological|Placebo|Placebo
79707678|NCT05130060|Biological|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
79707679|NCT05130060|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79847950|NCT02575404|Drug|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
79847951|NCT02575404|Drug|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
79847952|NCT00564018|Drug|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
79847953|NCT00564018|Drug|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
80015944|NCT05666245|Behavioral|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
79847954|NCT00564018|Drug|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
79847955|NCT04013724|Behavioral|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
79847956|NCT00934986|Other|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~Stage A patient who does not require a treatment: one sample the day of enrollment.~Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
79251913|NCT03101072|Other|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
79847957|NCT00935142|Drug|[18F]VM4-037|Bolus IV injection of [18F]VM4-037
79847958|NCT04013412|Dietary Supplement|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
79847959|NCT00935298|Drug|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*1 type and CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d).
79847960|NCT04014192|Drug|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
80015945|NCT05666245|Behavioral|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
80015946|NCT04615936|Other|Methylene-Blue Photodisinfection|Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
80015947|NCT04887415|Device|Respiratory strength training|Devices will be set to 70% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 5 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
80015948|NCT04544254|Procedure|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
79390045|NCT02441010|Device|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
80015949|NCT04544254|Procedure|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
79251914|NCT02061163|Device|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
79251915|NCT02061163|Drug|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
79251916|NCT03103646|Drug|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
79251917|NCT03103646|Drug|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
79251918|NCT03103646|Drug|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
79390046|NCT02440932|Dietary Supplement|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
79390047|NCT02440932|Other|Normal (control) diet|Breakfast, lunch and open buffet dinner
79390048|NCT02978482|Drug|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
79847961|NCT04014192|Drug|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
79847962|NCT04014192|Drug|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
79847963|NCT00935376|Behavioral|Sleep Education Program|Treatment as usual.
80015950|NCT01569971|Other|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
79251919|NCT02061241|Procedure|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
79707680|NCT05121493|Other|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
79390049|NCT02978482|Drug|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
79707681|NCT05121493|Other|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
79707682|NCT05120973|Procedure|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
79707683|NCT05120973|Procedure|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
80015951|NCT05175833|Combination Product|Oral probiotics|Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
79251920|NCT02061241|Procedure|Pacing in other suitable vein|Pacing in other suitable vein
79390050|NCT03191994|Behavioral|Exercise|a structured, supervised eight week moderate intensity exercise intervention
79546025|NCT01538407|Other|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
79707684|NCT05114486|Combination Product|Pilocarpine Ophthalmic administered with the Optejet dispenser|Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
79707685|NCT05114486|Combination Product|Placebo administered with the Optejet dispenser|Vehicle ophthalmic solution administered with the Optejet dispenser
79847964|NCT00935376|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
80015952|NCT05175833|Other|Oral placebo|Oral gel containing placebo
80015953|NCT04799392|Device|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
79847965|NCT00935376|Behavioral|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
79251921|NCT03709238|Behavioral|Thermal stimulation|Thermal stimulation
79251922|NCT03305679|Procedure|Direct provisional technique|The method of implantation will be accomplished directly.
79251923|NCT03305679|Procedure|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
79251924|NCT01554410|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
79251925|NCT01554410|Drug|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
79251926|NCT01554410|Drug|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
79251927|NCT03299907|Diagnostic Test|Spirometry|
79390051|NCT04344808|Device|Dynamic navigation system|The navigation system allows clinicians, using a specific software, to visualize the position of the surgical drill (tip location and shaft axis direction) on the reconstructed 3D image of the pre-acquired CBCT. The software guides the surgeon, in real-time, to the preoperative planned position.
79390052|NCT04344808|Device|Freehand implant placement|Dental implants will be placed without any guidance once a virtually planning of the ideal position on the CBCT is done
79546026|NCT01538420|Drug|GLPG0492|Oral solution
79546027|NCT01538420|Drug|Placebo|Placebo oral solution
79707686|NCT05108506|Behavioral|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
79707687|NCT05108506|Behavioral|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
79707688|NCT05105048|Biological|mRNA-1647|Lyophilized product that is reconstituted with saline
79707689|NCT05105048|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79251928|NCT03305601|Other|application on smarthphone|application on smarthphone
79251929|NCT03299829|Drug|Trientine|Trientine is a chelating agent for removing the copper from the body
79251930|NCT04968158|Drug|Etoricoxib 90 mg / Tramadol 50 mg|One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
79251931|NCT04968158|Drug|Acetaminophen 325 mg / Tramadol 37.5 mg|One tablet, every 8 hours of 325 mg/ 37.5 m
79251932|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
79251933|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
79251934|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
79251935|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
79847966|NCT00935454|Procedure|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
80015954|NCT04507321|Drug|GSK3640254 Oral tablet|GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
79251936|NCT03305523|Device|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
79251937|NCT05607823|Other|Core Stabilization Training|Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.
79251938|NCT05607823|Other|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
79390053|NCT02448576|Radiation|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
79707690|NCT05103384|Other|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
79707691|NCT05082675|Procedure|HLA Matched allogeneic transplant|
79390054|NCT05721508|Other|Combined physical and cognitive program|All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.
79390055|NCT02978560|Device|fluorescence-mediated photoplethysmography|Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
79707692|NCT05074953|Other|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
79847967|NCT00935610|Dietary Supplement|Immunocal|20 grams per day of Immunocal for 135 days.
79546028|NCT01538446|Drug|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
79546029|NCT01538446|Drug|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
79546030|NCT01538446|Device|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
79707693|NCT05073419|Other|Standard of Care|Routine monitoring of post AMI patient with clinic visits
79707694|NCT05073419|Device|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
79707695|NCT05064839|Procedure|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
79847968|NCT00935610|Dietary Supplement|Casein|20 grams per day for 135 days
79847969|NCT04013646|Drug|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
80015955|NCT04507321|Drug|[14C]-GSK3640254 intravenous infusion|[14C]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
80015956|NCT04507321|Drug|[14C]-GSK3640254 powder|[14C]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
79707696|NCT05058976|Drug|Romosozumab|Monthly dose: 210 mg subcutaneous injection
79707697|NCT05058976|Drug|Placebo|Monthly saline injection
79707698|NCT05058976|Drug|Zoledronic acid|5 mg IV infusion at Month 12 Visit
79707699|NCT05058976|Dietary Supplement|Calcium and Vitamin D|Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
79707700|NCT05041647|Drug|25:1 CBD/THC|"1 dose (1 mL) of HIGH CBD~50 mg/ml CBD and 2 mg/ ml THC"
79707701|NCT05041647|Drug|5:1 CBD/THC|"1 dose (1 mL) of LOW CBD~10 mg/ml CBD and 2 mg/ ml THC"
79707702|NCT05041647|Other|Placebo|"1 dose (1 mL) of PLACEBO~No active ingredients"
79847970|NCT04013646|Drug|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
79847971|NCT04013646|Drug|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
79847972|NCT04013646|Drug|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
79847973|NCT04013646|Procedure|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
79847974|NCT03381287|Drug|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
79847975|NCT03381287|Drug|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
79847976|NCT03381287|Drug|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
79847977|NCT03381287|Drug|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
79847978|NCT03381287|Drug|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
79847979|NCT03381287|Drug|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
79546031|NCT01538459|Drug|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
79847980|NCT04074473|Drug|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
79847981|NCT04074473|Procedure|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
79847982|NCT04074473|Other|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
79847983|NCT03093480|Biological|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
79847984|NCT00616928|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
79546032|NCT01538459|Drug|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
79546033|NCT01538485|Drug|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
79546034|NCT01538511|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
79847985|NCT00616928|Biological|Placebo|Two intramuscular injections at Days 0 and 21.
79546035|NCT01538511|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
79707703|NCT05021237|Radiation|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
79847986|NCT00939042|Procedure|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
79847987|NCT00939042|Procedure|BMNC therapy|Injection of BMNC after common PCI
79251939|NCT05607823|Other|Conventional Physiotherapy|Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
79251940|NCT02468037|Procedure|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
79390056|NCT03272932|Other|No intervention|No intervention
79390057|NCT02978950|Other|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
79707704|NCT05014815|Drug|Ociperlimab|Ociperlimab intravenous injection
79707705|NCT05014815|Drug|Tislelizumab|Tislelizumab intravenous injection
79707706|NCT05014815|Drug|histology-based chemotherapy|Administered intravenously
79707707|NCT05014815|Drug|Placebo|Administered as an intravenous injection
79707708|NCT05012384|Other|Vergence exercises (Orthoptic exercises)|Vergence exercises as described by the Convergence Insufficiency Treatment Trials Group (CITT)
79847988|NCT02578511|Drug|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
79847989|NCT00935688|Other|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
79847990|NCT00869648|Procedure|Extension|After anaesthesia induction the head is placed in extension
79847991|NCT00869648|Procedure|Neutral head position|After anaesthesia induction the head is placed in neutral position
79390058|NCT02978950|Other|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
79390059|NCT05721352|Behavioral|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
79707709|NCT05012384|Genetic|Placebo|Generic management plan with non-visual elements
79847992|NCT00869648|Procedure|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
79847993|NCT00563784|Drug|Erlotinib|150 mg by mouth daily for 7 Weeks
79847994|NCT00563784|Drug|Carboplatin|2 AUC by vein weekly for 7 Weeks
79847995|NCT00563784|Drug|Paclitaxel|45 mg/m^2 by vein weekly for 7 Weeks
79847996|NCT00563784|Radiation|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
79546036|NCT01538537|Drug|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
79707710|NCT05003674|Device|Focused stimulation strategy|Investigational focused stimulation strategy
79847997|NCT00869882|Procedure|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
79847998|NCT00869882|Procedure|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~Central stenosis: decompression is performed including medial facectomy, laminectomy;~Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
79251941|NCT04803812|Other|"Remote SMS (short message service, also known as text message) delivery"|Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
79707711|NCT05003674|Device|ACE stimulation strategy|Standard of care stimulation strategy
79707712|NCT05002465|Drug|68Ga-PSMA-11|Injection of 68Ga PSMA-11
79707713|NCT05002465|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
79707714|NCT04983264|Drug|GBT021601|Tablets and capsules which contain GBT021601 drug substance
79847999|NCT03291509|Behavioral|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
79848000|NCT03291509|Behavioral|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
79848001|NCT03291509|Behavioral|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
79848002|NCT03291509|Behavioral|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
79251942|NCT02467257|Dietary Supplement|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
79251943|NCT02060617|Behavioral|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
79546037|NCT01538550|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
79546038|NCT01538550|Procedure|iFOBT|Biennial screening with iFOBT
79251944|NCT02060617|Procedure|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
79251945|NCT02060617|Procedure|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
79546039|NCT01538563|Drug|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
79546040|NCT01538576|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
79546041|NCT01538589|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
79707715|NCT04966299|Dietary Supplement|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit"
79707716|NCT04966299|Dietary Supplement|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
79707717|NCT04966299|Dietary Supplement|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
79707718|NCT04966299|Dietary Supplement|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
79707719|NCT04953858|Other|Social network strategy (SNS)|SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
79848003|NCT00203047|Drug|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
79546042|NCT01538641|Drug|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
79707720|NCT04943848|Biological|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
79546043|NCT01538654|Procedure|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
79707721|NCT04943848|Drug|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
79390060|NCT03240640|Procedure|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
79848004|NCT00203047|Drug|Placebo|Placebo for prednisone given daily
79848005|NCT00203047|Drug|Prednisone|Prednisone 1250 mg taken daily
79848006|NCT00870038|Device|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
79848007|NCT00870038|Device|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
79707722|NCT04943848|Drug|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
79848008|NCT00870038|Device|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
79707723|NCT04942860|Drug|1% Methotrexate gel|1% methotrexate gel applied onto a predefined limb
79707724|NCT04942860|Drug|0.5% Methotrexate gel|0.5% methotrexate gel applied onto a predefined limb
79848009|NCT04074551|Drug|HCP1701|HCP1701
79390061|NCT03240640|Procedure|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
79390062|NCT03229564|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
79546044|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
79546045|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
79707725|NCT04942535|Behavioral|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
79848010|NCT04074551|Drug|Losartan|Losartan
79848011|NCT04074551|Drug|Amlodipine|Amlodipine
79848012|NCT04074551|Drug|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
79848013|NCT00870116|Radiation|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
79848014|NCT00870116|Radiation|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
79848015|NCT00870116|Radiation|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
79848016|NCT02608385|Radiation|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
79848017|NCT02608385|Drug|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
79848018|NCT00142519|Drug|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
79848019|NCT00142519|Drug|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
79848020|NCT03714776|Drug|Placebo|Placebo matching solution administered as SC injection.
79848021|NCT03714776|Drug|ISIS 757456|Administered as SC injection.
79848022|NCT00141817|Drug|pantoprazole for approximately 9 weeks.|
79848023|NCT00573170|Drug|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
79848024|NCT00573170|Drug|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
79848025|NCT00573170|Drug|placebo|placebo
79848026|NCT03967171|Other|before uterine incision oxytocin|blood loss during elective cesarean section
79848027|NCT03967171|Other|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
79848028|NCT03971383|Drug|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
79848029|NCT03971383|Drug|Placebo|3 tablets one time, 3 times a day(tid)
79546046|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
79546047|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
79546048|NCT01538680|Drug|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
79707726|NCT04942535|Behavioral|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
79848030|NCT01077349|Procedure|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
79251946|NCT02060617|Procedure|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
79707727|NCT04942535|Behavioral|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
79251947|NCT03623594|Procedure|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
79251948|NCT04491279|Procedure|Home 'General' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
79251949|NCT04491279|Procedure|Home 'Neuropilates' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
79251950|NCT04491279|Procedure|Supervised Neuropilates Group Class|Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).
79390063|NCT03229564|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
79251951|NCT04491279|Procedure|Supervised General Exercises Group Class|Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
79251952|NCT02471404|Drug|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
79251953|NCT02471404|Drug|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
79251954|NCT02471404|Drug|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
79251955|NCT02471404|Drug|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
79390064|NCT00357682|Drug|Esomeprazole|20mg per day
79390065|NCT00357682|Drug|Esomeprazole|80mg per day
79546049|NCT01538693|Drug|escitalopram oxalate|10 mg 4.5 hours prior to testing
79546050|NCT01538693|Drug|Cyproheptadine|8mg 4.5 hours prior to testing
79390066|NCT00357682|Drug|Aspirin|300mg per day
79390067|NCT00356980|Biological|colloidal gold-bound tumor necrosis factor|
79390068|NCT00356980|Other|pharmacological study|
79390069|NCT00105027|Other|Standard Care|CRVO: observation; BRVO: standard care
79390070|NCT00105027|Drug|intravitreal triamcinolone injection|1 mg dose
79390071|NCT00105027|Drug|intravitreal triamcinolone injection|4 mg
79390072|NCT00357136|Behavioral|password usage|
79546051|NCT01538693|Drug|sugar pill|4.5 hour prior to testing
79546052|NCT01538693|Other|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
79546053|NCT01538706|Other|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
79546054|NCT01538732|Drug|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
79848031|NCT01077349|Procedure|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR~Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~Or serum urea > 36 mmol/l OR~Or life threatening hyperkalemia"
80015957|NCT04119089|Other|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
79707728|NCT04930328|Drug|Oxbryta® (voxelotor) 500-mg Tablets|Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
79707729|NCT04902820|Other|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
80015958|NCT03797222|Dietary Supplement|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if >17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive <600 IU daily, or for any subjects who prefer liquid medication to capsules.
79251956|NCT02471404|Drug|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
79707730|NCT04902820|Other|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
79707731|NCT04900740|Device|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
79707732|NCT04900740|Device|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
79848032|NCT03966937|Other|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
79848033|NCT03966937|Other|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
80015959|NCT04725760|Device|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
80015960|NCT04118231|Other|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
80015961|NCT04783324|Behavioral|E-Mobile Health Application|The e-mobile health application prepared by the researcher will be used. E-mobile health application include information about postpartum care.
80015962|NCT02742818|Device|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
80015963|NCT02742818|Device|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
80015964|NCT04708990|Device|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
80015965|NCT04876105|Other|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
79251957|NCT02471404|Drug|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
79251958|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
79848034|NCT00880646|Dietary Supplement|Oolong tea containing L-arabinose and indigestible dextrin|
79848035|NCT00880646|Dietary Supplement|Oolong tea (Placebo)|
79251959|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
79251960|NCT02061475|Drug|Lidocaine Patches|
79251961|NCT02468115|Drug|VIS410|Single fixed IV dose of VIS410
79251962|NCT02468115|Drug|Placebo|Single IV dose of placebo
79251963|NCT03100994|Drug|Bupivacaine|injecting anesthetics to different local
79251964|NCT03100994|Device|Ultrasound|Ultrasound guided nerve block
79251965|NCT02060071|Other|Blood test|Blood test
79251966|NCT03101228|Behavioral|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
79848036|NCT00880724|Device|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
79848037|NCT03967327|Drug|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
79848038|NCT03967327|Drug|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
79848039|NCT01075945|Drug|Dihydroartemisinin- piperaquine|three tablets per day
79848040|NCT01075945|Drug|artemether- lumefantrine|twenty tablet in eight doses
79848041|NCT00882752|Procedure|molecular analysis|bowel disease
79848042|NCT00874562|Drug|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
79848043|NCT00874562|Drug|Rapamycin|Taken orally mixed with water or orange juice
79848044|NCT00874640|Biological|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
79848045|NCT00882830|Procedure|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
79848046|NCT00874718|Behavioral|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
79848047|NCT00874718|Behavioral|General education|Non-specific educational program for general health.
79848048|NCT00201643|Drug|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
79848049|NCT00201643|Drug|Placebo|Course of Placebo (NS)
79251967|NCT03100916|Drug|BI 690517|once daily
79251968|NCT03100916|Drug|Placebo|once daily
79251969|NCT03100916|Drug|BI 690517 (Reference)|Fasting
79390073|NCT05720962|Procedure|uninterrupted accompanying support|"When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm."
79707733|NCT04880473|Device|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
79251970|NCT03100916|Drug|BI 690517|Non- fasting
79390074|NCT03145012|Drug|Ranitidine|Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
79251971|NCT04160936|Drug|Marcaine Injectable Product|Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
79546055|NCT01538758|Other|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
79546056|NCT01538758|Other|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
79390075|NCT00106119|Drug|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
79390076|NCT03832660|Behavioral|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
79848050|NCT03798314|Biological|Nivolumab|Given IV
79848051|NCT03798314|Drug|Pomalidomide|Given PO
79848052|NCT01077427|Device|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course~* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
79848053|NCT01077427|Drug|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
79848054|NCT05204654|Other|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
79707734|NCT04852055|Behavioral|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
79707735|NCT04836182|Drug|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
80015966|NCT03069365|Drug|Glecaprevir/pibrentasvir|Film-coated tablet
79707736|NCT04836182|Drug|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
79848055|NCT05204654|Device|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
79848056|NCT00883064|Drug|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
79848057|NCT00883064|Drug|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
79546057|NCT01538771|Drug|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
79546058|NCT01538771|Drug|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
79848058|NCT01077505|Biological|albiglutide|albiglutide 50mg weekly subcutaneous injection
79848059|NCT01077505|Drug|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
79848060|NCT01073995|Drug|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
79848061|NCT01074073|Drug|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
79848062|NCT00883220|Behavioral|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
79848063|NCT00874874|Drug|sorafenib tosylate|
80015967|NCT04480411|Behavioral|Doctorgram Patient Kit|Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.
79251972|NCT03103334|Other|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
79390077|NCT03832660|Drug|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
79546059|NCT01538784|Drug|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A & B were dosed alternately, at weekly intervals"
79546060|NCT01538797|Drug|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
79848064|NCT01076257|Behavioral|Modified Constraint-induced Movement Therapy|"Home based CIT~Restriction of the less affected limb~Intensive practice using affected limb~Positive experience~Functional task (task)"
79848065|NCT01076413|Behavioral|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
79848066|NCT01076413|Behavioral|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
79848067|NCT05204264|Behavioral|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
79848068|NCT05204264|Behavioral|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
79848069|NCT04017884|Combination Product|Remin Pro Forte|a combination of chemicals with natural products cream .
79848070|NCT04017884|Combination Product|Remin Pro|a combination of chemicals
80015968|NCT04471675|Drug|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion.
80015969|NCT04461028|Drug|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
80015970|NCT04461028|Drug|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
80015971|NCT00716534|Drug|ABT-869|12.5 mg ABT-869
79251973|NCT03103334|Drug|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
79251974|NCT03305367|Dietary Supplement|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
79251975|NCT02471014|Drug|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
79251976|NCT02471014|Other|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
80015972|NCT00716534|Drug|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
80015973|NCT00716534|Drug|ABT-869|7.5 mg ABT-869
80015974|NCT00716534|Drug|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
80015975|NCT00716534|Drug|Paclitaxel|Paclitaxel (200 mg/m2)
80015976|NCT01024829|Radiation|Radiotherapy|Radiotherapy
79707737|NCT04788511|Drug|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
79707738|NCT04788511|Drug|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
79848071|NCT00880880|Other|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
79707739|NCT04781673|Drug|Ketamine|Will receive titratable infusion.
79707740|NCT04781673|Drug|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
79707741|NCT04750642|Device|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)
79546061|NCT01538797|Drug|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
79251977|NCT02471014|Other|Questionnaires|"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
79390078|NCT00006411|Other|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors >=66 and <66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
79546062|NCT01538836|Behavioral|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
79546063|NCT01538836|Behavioral|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
79707742|NCT04750642|Device|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
79546064|NCT01538849|Drug|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
79546065|NCT01538849|Drug|YH4808 A mg|1 tablet = YH4808 A mg
79546066|NCT01538849|Drug|YH4808 B mg|1 tablet = YH4808 B mg
79848072|NCT00880958|Dietary Supplement|Mixture of various probiotics and fermentation products|
79848073|NCT00880958|Dietary Supplement|Placebo|
79848074|NCT04489628|Drug|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
79251978|NCT00795158|Drug|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
79251979|NCT03299595|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
79251980|NCT02063269|Drug|Rivastigmine|9-18mg/rivastigmine for 52 weeks
79546067|NCT01538849|Drug|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
79546068|NCT01538875|Drug|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
79546069|NCT01538875|Drug|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
79546070|NCT01538888|Procedure|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
79546071|NCT01538901|Other|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
79546072|NCT01538901|Drug|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
79546073|NCT01538914|Procedure|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
79546074|NCT01538914|Procedure|PCA|Postoperative pain is controlled with intravenous PCA.
79546075|NCT01538927|Drug|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
79546076|NCT01538927|Drug|Suture|Black silk 000
79546077|NCT01538940|Biological|Intradermal vaccine|15ug
79546078|NCT01538940|Biological|Intramuscular vaccine|15ug
79546079|NCT01538953|Other|handwashing|participants received weekly in-home handwashing promotion and soap as needed
79546080|NCT01538953|Other|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
79546081|NCT01538953|Other|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
79707743|NCT04749667|Other|MSCs|Autologous bone-marrow derived mesenchymal stem cells
79707744|NCT04749667|Drug|Saline|Isotonic saline
79707745|NCT04724291|Device|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
79848075|NCT04489628|Device|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
79848076|NCT00130039|Drug|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
79707746|NCT04713683|Device|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
79707747|NCT04691323|Other|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
79848077|NCT00130039|Drug|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
79848078|NCT00875030|Drug|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
80015977|NCT04623736|Behavioral|quitSTART|"All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location."
80015978|NCT04352881|Other|Questionary patient|Assessing pain reduction using a 4-step questionary
79251981|NCT03305289|Procedure|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
79546082|NCT01538979|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
79546083|NCT01538979|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
79251982|NCT03305289|Procedure|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
79251983|NCT00794846|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
79251984|NCT00794846|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
79251985|NCT03560713|Device|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
79546084|NCT01538979|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
79546085|NCT01538992|Device|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
79546086|NCT01539018|Drug|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
79546087|NCT01539018|Drug|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
79546088|NCT01539044|Drug|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
79546089|NCT01539044|Drug|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
79546090|NCT01539057|Drug|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
79707748|NCT04688411|Behavioral|MED-Go App|A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
79707749|NCT04670471|Drug|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
79707750|NCT04670471|Drug|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
79707751|NCT04652804|Behavioral|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
79707752|NCT04652804|Behavioral|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
79848079|NCT00875030|Drug|Arsuamoon|single dose 50 mg arsuamoon tablet
79251986|NCT03560713|Other|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
79848080|NCT00883298|Drug|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 & 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 & 5 every 28-day cycle
79848081|NCT03969277|Other|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
79848082|NCT03969277|Other|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
79707753|NCT04652804|Behavioral|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
79848083|NCT03969277|Other|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
80015979|NCT03360500|Other|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
79251987|NCT00794768|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
79251988|NCT00794768|Drug|fexofenadine|Allegra 180 mg daily x 7 days
79251989|NCT02060851|Other|standard PN|Group 1: a control group who received standard PN
79251990|NCT02060851|Drug|Vifor|iron sucrose, 200 μg/kg per day, was given everyday with PN,
79251991|NCT02060851|Drug|Vifor and EPO|EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
79251992|NCT00779636|Drug|Desloratadine|Desloratadine 10 mg daily x 28 days
79251993|NCT00779636|Drug|Placebo|Placebo daily x 28 days
79251994|NCT05624073|Device|Air-QTM Blocker|The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes
79251995|NCT05624073|Device|LarySealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
79546091|NCT01539057|Drug|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
79546092|NCT01539096|Procedure|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
79707754|NCT04620213|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
79848084|NCT03969277|Other|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
79546093|NCT01539096|Behavioral|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
79707755|NCT04620213|Other|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
79707756|NCT04615273|Drug|Lonapegsomatropin|Due to the different hGH dose requirements, depending on subject's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
79251996|NCT02060929|Drug|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
79707757|NCT04615273|Other|Placebo|The placebo for lonapegsomatropin drug product will contain the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution will be administered by SC injection via syringe and needle. Due to the different hGH dose requirements, depending on subject's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo will receive the same dose volume as if they would have been randomized to once-weekly lonapegsomatropin.
79546094|NCT01539096|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
79707758|NCT04615273|Drug|Somatropin|Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on subject's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
79546095|NCT01539109|Behavioral|Rehabilitation|Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.
79707759|NCT04608955|Drug|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
79707760|NCT04608955|Drug|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
79707761|NCT04608955|Drug|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
79707762|NCT04608955|Drug|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
79707763|NCT04595682|Drug|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
79707764|NCT04595682|Drug|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
79848085|NCT04038788|Device|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
79848086|NCT00881114|Drug|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
79848087|NCT00881114|Drug|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
79848088|NCT00875186|Other|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
79251997|NCT00757562|Drug|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects >=2 to <6 years, 2.5 mg (5 mL) for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
79251998|NCT00757562|Drug|Placebo|placebo syrup: 2.5 mL for subjects >=2 to <6 years, 5 mL for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
79707765|NCT04593277|Other|Internet Mobile Technology|Use INSPIRE mobile application
79848089|NCT00875186|Other|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
79848090|NCT04687436|Device|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
79848091|NCT00475852|Drug|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
79848092|NCT00475852|Drug|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
80015980|NCT03360500|Other|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
79251999|NCT03299517|Drug|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
79707766|NCT04593277|Other|Internet-Based Intervention|Access to a study-specific control website
79848093|NCT00875264|Drug|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
79848094|NCT01017484|Other|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
79390079|NCT04374747|Behavioral|Dietary Counseling|The counseling approach will employ strategies shown to be successful in previous and ongoing dietary modification studies including supportive and motivational interviewing techniques. Each woman in the diet intervention group will be assigned a trained nutrition coach/counselor. Counselors will focus on helping participants identify and address barriers to achieving the goal of consuming at least 8 to 10 servings of nutrient dense fruits and vegetables each day (e.g., modifying recipes and food preparation). Participants will also receive weekly boxes of fruits and vegetables .
79390080|NCT00030147|Drug|Raloxifene|60 mg a day orally administered
79848095|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
79848096|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
79848097|NCT00141271|Drug|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
79848098|NCT01017640|Other|Laboratory Biomarker Analysis|Correlative studies
79848099|NCT01017640|Drug|Mitomycin|Given IV
79848100|NCT01017640|Drug|Veliparib|Given PO
79848101|NCT00614120|Drug|liraglutide|0.6 mg/day, s.c. (under the skin) injection
79848102|NCT00614120|Drug|placebo|Glimepiride placebo, capsules
79848103|NCT00614120|Drug|liraglutide|1.2 mg/day, s.c. (under the skin) injection
79848104|NCT00614120|Drug|liraglutide|1.8 mg/day, s.c. (under the skin) injection
80015981|NCT03360500|Other|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
79252000|NCT03299517|Drug|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
79252001|NCT03796741|Other|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
79390081|NCT00030147|Drug|Rimostil|1000 mg twice a day administered orally
79390082|NCT00030147|Drug|Transdermal Estradiol|100 microgram per day transdermal estradiol
79390083|NCT00030147|Drug|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
79390084|NCT02709486|Drug|Tanezumab|2.5 mg
79390085|NCT02709486|Drug|Tanezumab|5 mg
79707767|NCT04593277|Other|Questionnaire Administration|Ancillary studies
79252002|NCT00651404|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
79252003|NCT00651404|Drug|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
79252004|NCT02413372|Drug|BMS-986036|
79252005|NCT02413372|Drug|BMS-986036|
79252006|NCT02413372|Drug|Placebo|
79390086|NCT02709486|Drug|Placebo|Placebo
79390087|NCT00106431|Drug|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
79390088|NCT03195816|Behavioral|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
79707768|NCT04593277|Procedure|Supportive Care|Receive telehealth stepped care
79707769|NCT04593277|Other|Informational Intervention|Receive printed SCP materials
79707770|NCT04588116|Behavioral|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
79848105|NCT00614120|Drug|glimepiride|Capsules, 4.0 mg/day
79848106|NCT00614120|Drug|metformin|Tablets, 1.5-2.0 g/day
79848107|NCT00614120|Drug|placebo|Liraglutide placebo, s.c. (under the skin) injection
79848108|NCT00496054|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 & P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
79848109|NCT00881192|Procedure|IABP|preoperative IABP placement
79252007|NCT00651014|Drug|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
79707771|NCT04587024|Other|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
79848110|NCT00495820|Drug|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
79848111|NCT00495820|Other|Placebo|Standard inactive pill.
79848112|NCT04387240|Drug|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
79252008|NCT00651014|Drug|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
79252009|NCT03305211|Other|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
79848113|NCT04387240|Other|placebo|placebo or sham drug will be given to the second arm
79848114|NCT05203328|Device|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
79252010|NCT04435418|Drug|Apixaban|The decision to treat with apixaban and the timing of initiation will be at the attending physicians' discretion, independent of enrolment in EASSE.
79252011|NCT03305133|Other|Immunohistochemistry|The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
79390089|NCT02440074|Other|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
79390090|NCT03191838|Other|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
79252012|NCT04601558|Behavioral|The letters with the Cochrane abstracts in the form of blog-shots|"The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
79390091|NCT03191448|Procedure|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
79390092|NCT03191448|Device|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
79390093|NCT03191448|Device|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
79546096|NCT01539109|Procedure|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
79546097|NCT01539109|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
79546098|NCT01539161|Device|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
79707772|NCT04587024|Other|standard of care|Subjects will receive standard of care observation for 12 weeks
79707773|NCT04559893|Behavioral|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
79707774|NCT04546633|Drug|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
79848115|NCT05203328|Device|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
79848116|NCT00495586|Drug|Placebo|One pill to be taken every eight hours for 8 days
79848117|NCT00495586|Drug|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
79848118|NCT00881270|Drug|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
79848119|NCT00881348|Drug|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
79848120|NCT00613730|Drug|Gemcitabine|Intravenous administration
79848121|NCT00613730|Drug|panitumumab|Intravenous administration
79390094|NCT02439996|Drug|IVIG (1g/kg,once)|"Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
80015982|NCT03627949|Behavioral|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
80015983|NCT04554706|Behavioral|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
80015984|NCT05761067|Procedure|Percutaneous Coronary Intervention (PCI)|Alternative treatment
80015985|NCT02283398|Other|without RIPC|the cuff will be placed around the left arm without being inflated
79252013|NCT04601558|Behavioral|The letters with remainder on cardiovascular risk factors|"The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
79546099|NCT01539161|Procedure|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
79707775|NCT04546633|Drug|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
79707776|NCT04546633|Drug|Coartem|Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
79848122|NCT05200754|Other|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
79848123|NCT00613574|Drug|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
79546100|NCT01539174|Biological|rituximab|Given IV
79546101|NCT01539174|Drug|cyclophosphamide|Given IV
79546102|NCT01539174|Drug|doxorubicin hydrochloride|Given IV
79848124|NCT00881426|Drug|Cefprozil 500 mg Tablets (Sandoz GmbH)|
79848125|NCT00881426|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
79252014|NCT02413294|Device|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
79546103|NCT01539174|Drug|vincristine sulfate|Given IV
79546104|NCT01539174|Drug|prednisone|Given PO
79546105|NCT01539174|Other|laboratory biomarker analysis|Correlative studies
79546106|NCT01539174|Other|pharmacological study|Correlative studies
79546107|NCT01539187|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
79848126|NCT00883532|Drug|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 < 30% or is extubated
79848127|NCT00883532|Drug|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
79848128|NCT00875498|Procedure|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
79848129|NCT00875498|Procedure|sham iTBS|iTBS placebo (placebo coil)
80015986|NCT02283398|Procedure|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
80015987|NCT03981731|Other|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
80015988|NCT02283476|Drug|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
79546108|NCT01539200|Dietary Supplement|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
79546109|NCT01539200|Dietary Supplement|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
79546110|NCT01539213|Drug|secukinumab (AIN457)|anti-IL-17 antibody
79546111|NCT01539252|Procedure|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
79546112|NCT01539252|Procedure|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
79546113|NCT01539265|Drug|silodosin|
79546114|NCT01539265|Drug|silodosin|
79707777|NCT04512144|Behavioral|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
79707778|NCT04476173|Drug|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
79707779|NCT04476173|Drug|Morphine|ACS patients who received intravenous morphine as analgesic treatment
79707780|NCT04475328|Drug|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
79546115|NCT01539265|Drug|placebo|
79546116|NCT01539278|Procedure|Adenotonsillectomy|Tonsils and adenoids are surgically removed
79546117|NCT01539278|Other|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
79707781|NCT04475328|Drug|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
79707782|NCT04475328|Other|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
79707783|NCT04467723|Drug|Atezolizumab|Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
79707784|NCT04466579|Other|BIS monitor|BIS monitor is used to control and monitor the depth of general anesthesia.
79707785|NCT04466579|Other|Standard care|Standard anesthesiology care according to the protocol of the study
79848130|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
79848131|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
79252015|NCT03299361|Other|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
79546118|NCT01539304|Drug|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
79546119|NCT01539304|Drug|Placebo|Placebo dry syrup, b.i.d
79546120|NCT01539330|Drug|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
79252016|NCT03560479|Drug|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79252017|NCT03560479|Other|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79546121|NCT01539330|Other|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
79707786|NCT04464070|Dietary Supplement|niacin|induce biosynthesis of PGD2
79707787|NCT04464070|Drug|aspirin|inhibition of cyclooxygenase
79707788|NCT04464070|Other|PGD2|labeled precursor
79707789|NCT04462536|Drug|Placebo|Vehicle only
79707790|NCT04462536|Drug|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
79707791|NCT04459234|Drug|Ketamine use in CLCC sites (indication and administration protocol)|"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~Administration protocol: route, posology, duration, administration sequence, premedication~Antalgic efficacy~Tolerance profile~Quality of life, anxiety and depression evaluations"
79707792|NCT04444479|Other|ECG verification|The correct positioning of the PICC catheter tip will be verified using ECG.
79707793|NCT04444479|Other|X-ray verification|The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
79707794|NCT04441138|Drug|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
79707795|NCT04440189|Device|GID SVF-2 Device System|The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
79707796|NCT04428177|Device|Intravascular lithotripsy|Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel
79707797|NCT04428177|Device|Standart therapy|conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
79707798|NCT04311502|Drug|Clofazimine (CFZ)|Administered orally once daily
79707799|NCT04311502|Drug|Rifapentine (RPT)|Administered orally once daily
79707800|NCT04311502|Drug|Isoniazid (INH)|Administered orally once daily
79707801|NCT04311502|Drug|Pyrazinamide (PZA)|Administered based on weight orally once daily
79546122|NCT01539343|Drug|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
79707802|NCT04311502|Drug|Ethambutol (EMB)|Administered based on weight orally once daily
79707803|NCT04311502|Drug|Rifampicin (RIF)|Administered orally once daily
79707804|NCT04311502|Dietary Supplement|Pyridoxine (vitamin B6)|All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
79848132|NCT04262258|Dietary Supplement|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
79848133|NCT00881582|Drug|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
79848134|NCT00875654|Genetic|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke
79848135|NCT00881738|Drug|Clarithromycin 250 mg Tablets (Geneva, USA)|
79848136|NCT00881738|Drug|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
79848137|NCT00613106|Drug|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
79848138|NCT00613106|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
79848139|NCT00883844|Drug|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
79848140|NCT00883844|Drug|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
79390095|NCT02439996|Drug|IVIG (1g/kg,twice)|"Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
79546123|NCT01539369|Other|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
79707805|NCT04311073|Drug|Tranexamic Acid|IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
79707806|NCT04311073|Drug|Placebos|IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
79707807|NCT04298827|Other|Unimodal|Patients will receive physical therapy alone.
79848141|NCT00875732|Device|Bi Ventricular Pacing|
79848142|NCT00875732|Device|Right Ventricular Pacing|
79848143|NCT00881816|Drug|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
79848144|NCT03712904|Radiation|Stereotactic Body Radiation Therapy|Undergo radiation
79848145|NCT03712904|Biological|Ziv-Aflibercept|Given IV
79848146|NCT00875888|Device|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
79848147|NCT00881972|Behavioral|Exercise|walking/running/cycling
79848148|NCT04038554|Diagnostic Test|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
79707808|NCT04298827|Other|Trimodal|Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
79848149|NCT00875966|Drug|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
79848150|NCT00875966|Drug|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
79848151|NCT04142294|Dietary Supplement|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
79707809|NCT04283669|Drug|Crizotinib|Oral
79707810|NCT04276883|Drug|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
79707811|NCT04276883|Drug|Placebo Film|Placebo Film for BXCL501
79707812|NCT04271930|Behavioral|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
80015989|NCT02283476|Drug|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
79707813|NCT04271930|Behavioral|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
79252018|NCT03560479|Drug|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79546124|NCT01539382|Procedure|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow >2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
79252019|NCT03560479|Drug|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79252020|NCT05588349|Other|Dry needling|Dry needling + stretching exercise
79252021|NCT05588349|Other|Stretching exercise|Stretching exercise only
79252022|NCT02062255|Drug|Aspirin|
79252023|NCT02062255|Dietary Supplement|Omega 3 FFA|
79546125|NCT01539395|Other|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
79707814|NCT04271085|Other|Observational study|No intervention involved
79707815|NCT04267107|Other|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
79546126|NCT01539408|Drug|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
79546127|NCT01539408|Procedure|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
79252024|NCT03299283|Diagnostic Test|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
79252025|NCT02739542|Drug|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
79252026|NCT02739542|Drug|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
79252027|NCT02466477|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
79252028|NCT02466477|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
79252029|NCT02466477|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
79390096|NCT02439996|Drug|IVIG (2g/kg.once)|"Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
79390097|NCT03195972|Other|Drug diary filling|patient will fill every day a drug diary
79390098|NCT03833596|Drug|Prednisone|All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
79390099|NCT03833596|Dietary Supplement|Exclusive Enteral Nutrition|2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
79546128|NCT01539421|Behavioral|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
79546129|NCT01539434|Behavioral|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
79707816|NCT04262609|Radiation|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
80015990|NCT02283476|Drug|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
80015991|NCT02283476|Drug|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
79848152|NCT00141037|Drug|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
80015992|NCT04054570|Other|No intervention|No Intervention
80015993|NCT05156879|Drug|Aspirin|75mg, one time/day
80015994|NCT05156879|Drug|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
79252030|NCT03103178|Other|Quality of life questionnaire|Measurement of quality of life
79252031|NCT02466945|Device|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
79252032|NCT05547243|Biological|SARS-CoV-2 mRNA Vaccine, Bivalent Low dose|50μg/dose
79546130|NCT01539434|Behavioral|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
79546131|NCT01539460|Procedure|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
79546132|NCT01539473|Drug|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
79546133|NCT01539473|Drug|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
79546134|NCT01539551|Other|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
79546135|NCT01539564|Drug|Minocycline HCl Microspheres|
79546136|NCT01539577|Drug|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
79707817|NCT04261790|Drug|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
80015995|NCT02283554|Procedure|open flap debridement (OFD)|
79252033|NCT05547243|Biological|SARS-CoV-2 mRNA Vaccine, Bivalent High dose|100μg/dose
79707818|NCT04238546|Device|sirolimus-coated balloon catheter|angioplasty with sirolimus-coated balloon catheter
79707819|NCT04238546|Device|uncoated balloon catheter|angioplasty with uncoated balloon catheter
79707820|NCT04212416|Drug|Leflunomide|Given PO
79707821|NCT04187105|Device|Arm1|Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2
79707822|NCT04187105|Drug|Arm1|"All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2"
79252034|NCT05547243|Drug|Placebo|Saline solution
79252035|NCT03100604|Drug|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
79252036|NCT03100604|Drug|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
79707823|NCT04187105|Drug|Arm1|IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
80015996|NCT02283554|Other|Platelet rich fibrin (PRF)|
80015997|NCT02283554|Drug|Metformin|
80015998|NCT03957070|Device|Liver Incyte|Ultrasound elasticity imaging
79252037|NCT02719353|Device|comfilcon A Extended Range test lens|contact lens
80015999|NCT03629405|Other|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
80016000|NCT03629405|Other|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
80016001|NCT00641732|Drug|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
80016002|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
80016003|NCT00641732|Drug|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
80016004|NCT00641732|Drug|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
80016005|NCT00641732|Drug|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
80016006|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
79252038|NCT02719353|Device|comfilcon A control lens|contact lens
79252039|NCT05244824|Other|Adaptation into Turkish, Examining The Reliability and Validity for People with RA|Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis
79546137|NCT01539603|Device|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
79546138|NCT01539603|Device|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
79546139|NCT01539616|Drug|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
79546140|NCT01539616|Drug|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
79546141|NCT01539616|Drug|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
79546142|NCT01539616|Drug|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
79546143|NCT01539629|Device|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
79546144|NCT01539655|Drug|vandetanib|Oral tablets, 300 mg, single dose
79707824|NCT04187105|Device|Arm 1|Total body irradiation 2Gy on day -1.
79707825|NCT04187105|Other|Arm1|Stem cell infusion on day 0.
79707826|NCT04187105|Drug|Arm1|Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
80016007|NCT00641732|Drug|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
79707827|NCT04187105|Drug|Arm1|Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
79707828|NCT04108117|Procedure|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
79707829|NCT04099992|Behavioral|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
80016008|NCT03845842|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
79848153|NCT00141037|Drug|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
79848154|NCT00141037|Drug|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in subjects weighing >40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
79848155|NCT00141037|Drug|Tacrolimus|Taken orally from immediately preoperatively to those>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects <age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) &5-7 ng/mL >= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 & 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
79848156|NCT00141037|Drug|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
79848157|NCT00141037|Drug|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
80016009|NCT05761769|Other|no intervention|no intervention
80016010|NCT03770494|Drug|LY3405105|Administered orally.
80016011|NCT00790829|Drug|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
80016012|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
80016013|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
79252040|NCT03101774|Device|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
79546145|NCT01539655|Drug|omeprazole|Oral capsules, 40 mg, multiple doses
79546146|NCT01539655|Drug|ranitidine|Oral tables, 150 mg, multiple doses
79546147|NCT01539681|Drug|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
80016014|NCT00640484|Drug|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
80016015|NCT00640484|Drug|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
80016016|NCT04382248|Other|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
80016017|NCT04382248|Behavioral|Tailored education|in-person coaching
80016018|NCT03949361|Diagnostic Test|Indirect calorimetry|Resting energy expenditure
79546148|NCT01539707|Drug|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
79546149|NCT01539733|Drug|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
80016019|NCT03949361|Diagnostic Test|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
80016020|NCT03949361|Diagnostic Test|Dual energy X-ray Absorptiometry (DXA)|Body composition
79252041|NCT03101774|Device|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
79546150|NCT01539733|Drug|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
79546151|NCT01539785|Procedure|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
79707830|NCT04099992|Behavioral|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
79848158|NCT00141037|Drug|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
79252042|NCT03101774|Other|Control group|Conventional therapy without any inspiratory muscle training program
79252043|NCT00398294|Drug|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
79546152|NCT01539785|Procedure|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
79848159|NCT04612946|Behavioral|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
79848160|NCT04612946|Behavioral|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
79848161|NCT04602884|Diagnostic Test|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
79848162|NCT00140413|Drug|Nutropin AQ|Daily injection. Dosage dependent on weight.
79848163|NCT04039178|Device|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
79848164|NCT04039178|Device|Sham|Sham BQ device
79546153|NCT01539798|Other|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
79848165|NCT04038398|Procedure|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
79252044|NCT05449509|Diagnostic Test|Abdominal aortic Duplex ultrasound|All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.
79546154|NCT01539798|Other|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
79546155|NCT01539824|Biological|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
79252045|NCT03517592|Other|EMDR|The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
80016021|NCT03949361|Diagnostic Test|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
79848166|NCT01582555|Drug|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
80016022|NCT03949361|Diagnostic Test|FDG-PET|Dynamic PET scanning of the neck-region
80016023|NCT03949361|Diagnostic Test|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
80016024|NCT03949361|Diagnostic Test|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
80016025|NCT03065933|Drug|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
80016026|NCT00630656|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
80016027|NCT00630656|Drug|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
80016028|NCT04256629|Drug|Verinurad|Randomized subjects will receive oral dose of verinurad
80016029|NCT04256629|Drug|Placebo|Randomized subjects will receive oral dose of placebo
80016030|NCT04256629|Drug|Allopurinol|Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
80016031|NCT04225936|Drug|BMS-986263|Single Dose
79252046|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
79546156|NCT01539824|Radiation|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
79546157|NCT01539850|Device|OMS102|Subjects will receive implanted OMS102 System.
79546158|NCT01539876|Procedure|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
80016032|NCT05206721|Other|Open tracheal suction system flushing with chlorhexidine|After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
80016033|NCT04183270|Other|Questionnaires|The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
79252047|NCT04823403|Drug|Nivolumab|Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.
79252048|NCT04823403|Drug|Ipilimumab|"Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels*.~(D1) Starting dose : 50 mg; n=3 to 6~(D2) 2nd dose-level : 100 mg; n=3 to 6~(D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) *Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (>1/3 DLT at D1)"
79546159|NCT01539889|Radiation|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
79546160|NCT01539902|Biological|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
79546161|NCT01539902|Drug|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
79707831|NCT04099992|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous Vagus Nerve Stimulation (tVNS) is delivered using gammaCore (Electrocore), a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
79848167|NCT01582555|Drug|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
80016034|NCT05206019|Drug|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
80016035|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
80016036|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
80016037|NCT00696332|Other|placebo|capsules, placebo, 3 times a day, for 52 weeks
80016038|NCT05133401|Device|Ultrasound-guided tracheal width measurement|Ultrasound measurements will be made with a 5-10 MegaHertz linear probe positioned in the horizontal plane at the midline of the anterior neck. After identifying the vocal cords as paired hyperechoic linear structures, the probe was moved caudally to visualize the cricoid arch. The transverse air column diameter was measured at the lower border of the cricoid cartilage.
80016039|NCT04163926|Procedure|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
80016040|NCT04163926|Procedure|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
80016041|NCT05125523|Drug|Sirolimus for Injection (Albumin Bound)|Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
80016042|NCT00625664|Drug|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
79252049|NCT03497390|Other|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
79252050|NCT03497390|Other|Usual care|Usual care without any workshop or program
79252051|NCT03493646|Drug|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
79252052|NCT03493646|Drug|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
79546162|NCT01539915|Drug|BCT194|Topically applied BCT194 cream (0.5%)
79390100|NCT03191682|Drug|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
79390101|NCT03188562|Other|PET/CT|Positron Emission Tomography (PET/CT)
79546163|NCT01539928|Other|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
79546164|NCT01539941|Behavioral|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
79546165|NCT01539967|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~position of 4 trocars and insertion of a nasogastric tube~dissection and mobilization of the greater curvature of the stomach~preparation of the stomach for division~gastric partition~extraction of the gastric remnant~postoperative surveillance"
79546166|NCT01540006|Other|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
79546167|NCT01540019|Drug|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
79546168|NCT01540032|Behavioral|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
79546169|NCT01540032|Behavioral|Normal diet|Patients will eat their usual diet.
79707832|NCT04099992|Device|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
79707833|NCT04099888|Drug|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
79707834|NCT04099888|Drug|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
79707835|NCT04081389|Drug|Celecoxib|Given PO
79707836|NCT04081389|Drug|Cyclophosphamide|Given IV
79707837|NCT04081389|Drug|Doxorubicin|Given IV
79707838|NCT04081389|Drug|Doxorubicin Hydrochloride|Given IV
79707839|NCT04081389|Drug|Paclitaxel|Given IV
79707840|NCT04081389|Biological|Recombinant Interferon Alfa-2b|Given IV
79707841|NCT04081389|Drug|Rintatolimod|Given IV
79707842|NCT04078854|Behavioral|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
79848168|NCT03966313|Device|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~After anesthetic induction~Before starting the device~2h, 6h and 48h after starting the device"
80016043|NCT00625664|Drug|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
79707844|NCT04033081|Device|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
79707845|NCT04032080|Combination Product|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
79707846|NCT04022005|Drug|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
79707847|NCT04020276|Radiation|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
80016044|NCT00625664|Drug|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
79546170|NCT01540058|Other|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
79848169|NCT03741361|Other|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
79546171|NCT01540058|Other|No test Empiric strategy|Empiric strategy
79546172|NCT01540084|Drug|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
79546173|NCT01540110|Drug|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
79546174|NCT01540123|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
79707848|NCT04016142|Drug|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
79848170|NCT00884000|Drug|Genotropin|
79848171|NCT00884000|Drug|Zomacton|
80016045|NCT03628495|Device|compression|compression will be delivered using compression garment
80016046|NCT03628495|Device|occlusion|occlusion will be delivered using silicone gel sheeting
80016047|NCT04762264|Device|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
79546175|NCT01540123|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
79546176|NCT01540136|Drug|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
79546177|NCT01540136|Drug|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
79546178|NCT01540175|Other|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
79848172|NCT00884078|Other|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
79848173|NCT00885716|Behavioral|patient training in shared decision making|
79848174|NCT00885716|Behavioral|cognitive training|
80016048|NCT04519528|Other|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
79252053|NCT05519865|Drug|Tucidinostat|30mg orally BIW
79252054|NCT05519865|Drug|Tislelizumab|200 mg intravenously (IV) Q3W
79848175|NCT03948932|Device|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
79848176|NCT03948932|Device|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
79848177|NCT02543684|Other|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
79848178|NCT02543684|Other|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
79848179|NCT02543684|Other|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
79848180|NCT02543684|Other|oral glucose load|glucose load providing 50g of carbohydrates
79848181|NCT02543762|Procedure|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
79848182|NCT00923312|Biological|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
79848183|NCT04038710|Drug|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
79848184|NCT00923390|Genetic|2G-1 TCR Retroviral Vector-Transduced lyn|
79848185|NCT00923390|Drug|Aldesleukin|
80016049|NCT04519528|Other|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
79848186|NCT00923390|Drug|Cyclophosphamide|
80016050|NCT04498858|Other|Patient interview|"Patient will be interviewed :~tobacco consumption~reported question asked by the dentist about his/her tobacco consumption~presence and nature of reported advices given by the dentist~presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~contact with the general practioner~Fagerstrom score (2 questions)~demographic variables, age, sex, level of education~satisfaction"
80016051|NCT05062655|Other|Drug reconciliation|Drug reconciliation information transmission to pharmacist interview with the patient
79848187|NCT00923390|Drug|Fludarabine|
79848188|NCT00923390|Drug|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
79848189|NCT00882596|Device|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
79848190|NCT00882674|Drug|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
79848191|NCT00888524|Procedure|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
79848192|NCT00888524|Procedure|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
79848193|NCT04038242|Other|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
79848194|NCT00885794|Drug|Ranibizumab|3 intravitreal injection every 5 weeks
80016052|NCT03585322|Drug|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
80016053|NCT02947165|Drug|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
80016054|NCT02947165|Drug|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
80016055|NCT02280746|Other|Gluten challenge|Intervention will be continued for at least 6 months
79390102|NCT03188562|Procedure|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
79848195|NCT00888602|Dietary Supplement|3.4 g psyllium|3.4 g psyllium served with meal
79848196|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium served with a meal
79848197|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium
79848198|NCT00888602|Other|Meal|meal
79848199|NCT02543450|Other|Cardiovascular and task-oriented training|
79848200|NCT02543450|Other|Upper limb strength training program|
79848201|NCT00885872|Drug|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
79848202|NCT00888758|Device|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
79848203|NCT00888758|Device|everolimus|200 patients with STEMI will be treated with PROMUS DES.
79848204|NCT04037150|Diagnostic Test|Circulating tumor DNA|Circulating tumor DNA
79848205|NCT02542436|Other|No intervention|No intervention administered in this study
79546179|NCT01540188|Behavioral|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
79707849|NCT04004936|Other|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
79707850|NCT04004936|Other|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
79546180|NCT01540201|Other|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
79707851|NCT03985800|Other|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
80016056|NCT02283632|Procedure|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
80016057|NCT03528382|Behavioral|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
80016058|NCT04739839|Other|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
80016059|NCT03629093|Drug|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
80016060|NCT02283710|Drug|Pentoxifylline|Pentoxifylline 600 mg BD
79252055|NCT03100526|Behavioral|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~Improve Veteran and staff satisfaction~Objectives:~Maintain the patient in the home setting as much as possible~Secure appropriate home environment to facilitate health and well-being~Utilize comprehensive team-based care~Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
79252056|NCT05244356|Behavioral|Health message exposure|Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
79252057|NCT05244200|Other|Pharmaceutical care and insulin staging.|Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
79390103|NCT03188562|Procedure|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
79546181|NCT01540201|Other|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
79546182|NCT01540214|Other|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).~At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).~At time of surgery: additional cystoscopy."
79546183|NCT01540227|Drug|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
79546184|NCT01540240|Drug|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
79546185|NCT01540240|Drug|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
79546186|NCT01540292|Biological|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
79848206|NCT00888836|Procedure|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
79546187|NCT01540305|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
79546188|NCT01540305|Device|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
80016061|NCT02283710|Behavioral|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
80016062|NCT04739293|Drug|ON123300|ON 123300 hard gelatin capsules
80016063|NCT04425304|Behavioral|Group counseling|4 times
79252058|NCT03100448|Device|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
79546189|NCT01540318|Procedure|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
79252059|NCT05032352|Drug|Adjuvant|Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
79390104|NCT03188328|Drug|AvidinOX|"AvidinOX vial containing 22.5 mg AvidinOX~+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
79390105|NCT03188328|Drug|177Lu-ST2210|177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
79390106|NCT03188328|Drug|177Lu-ST2210|Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
79707852|NCT03985800|Other|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
80016064|NCT04425304|Behavioral|Intensive group counseling|14 times
79707853|NCT03970720|Drug|Metoclopramide|10 mg metoclopramide four times a day
79707854|NCT03970720|Drug|Placebo|10 mg matching placebo capsules four times a day
79707855|NCT03957382|Device|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
79707856|NCT03943498|Drug|Fingolimod|Given PO daily for 4 weeks
79707857|NCT03943498|Drug|Fingolimod Hydrochloride|Given PO
80016065|NCT04425304|Behavioral|Persuasive ICT support|Weekly reminders for 12 months
80016066|NCT05055947|Drug|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
80016067|NCT00506792|Drug|QAU145|
80016068|NCT00506792|Drug|Placebo|
79252060|NCT05032352|Other|Observation|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
79252061|NCT03103256|Drug|YHP1701|PO, Once daily (QD), 8 weeks
79707858|NCT03943498|Other|Questionnaire Administration|Ancillary studies
79707859|NCT03912818|Drug|Carboplatin|Given IV
79707860|NCT03912818|Drug|Cisplatin|Given IV
79707861|NCT03912818|Procedure|Cystectomy|Undergo cystectomy
79390107|NCT02434224|Procedure|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
79390108|NCT02440542|Other|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
79707862|NCT03912818|Drug|Doxorubicin|Given IV
79707863|NCT03912818|Biological|Durvalumab|Given IV
79707864|NCT03912818|Drug|Gemcitabine|Given IV
79707865|NCT03912818|Drug|Methotrexate|Given IV
79707866|NCT03912818|Drug|Vinblastine|Given IV
79707867|NCT03865277|Radiation|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm.~Radiotherapy is always applied with 5 fractions per week."
80016069|NCT04697797|Other|Device Programming|Intervention includes (1) pacemaker reprogramming (2) echocardiographic parameters acquisition (3) ECG recording
80016070|NCT03507010|Radiation|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
80016071|NCT03507010|Other|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
80016072|NCT05043311|Biological|SCTV01C|intramuscular injection
79252062|NCT03103256|Drug|YHR1703|PO, Once daily (QD), 8 weeks
79252063|NCT03103256|Drug|YHR1704|PO, Once daily (QD), 8 weeks
79252064|NCT01362062|Drug|Tocilizumab|
79848207|NCT00888836|Procedure|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
79848208|NCT00888836|Behavioral|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (<30% total fat and <10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
79848209|NCT00888992|Behavioral|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
79252065|NCT02114450|Behavioral|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
79252066|NCT02114450|Behavioral|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
79252067|NCT05243498|Other|Assessment of the Allogenomic Mismatch Score (AMS)|Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
79390109|NCT03189966|Procedure|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
79546190|NCT01540331|Device|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
79546191|NCT01540344|Procedure|CRS|complete macroscopic cytoreduction (CC-0/1)
79546192|NCT01540344|Drug|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
79546193|NCT01540357|Behavioral|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
79546194|NCT01540357|Behavioral|Treatment after waiting time|Treatment was performed after completion of the active arm.
79546195|NCT01540383|Behavioral|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, >=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
79546196|NCT01540383|Behavioral|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
79546197|NCT01540396|Behavioral|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
79546198|NCT01540435|Drug|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
79707868|NCT03865277|Radiation|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
79707869|NCT03865277|Radiation|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
79707870|NCT03853733|Radiation|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
79707871|NCT03852498|Genetic|Lenti-D|Participants received a single IV infusion of Lenti-D Drug Product.
79707872|NCT03781934|Drug|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
79707873|NCT03781934|Drug|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
79707874|NCT03781323|Drug|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
79707875|NCT03779854|Radiation|Total-Body Irradiation|Undergo TBI
79707876|NCT03779854|Drug|Thiotepa|Given IV
79546199|NCT01540448|Procedure|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
79707877|NCT03779854|Drug|Fludarabine|Given IV
79707878|NCT03779854|Drug|Cyclophosphamide|Given IV
79707879|NCT03779854|Drug|Busulfan|Given IV
79252068|NCT05243498|Other|Assessment of the optimised Allogenomic Mismatch Score (AMS)|Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
79707880|NCT03779854|Procedure|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
79707881|NCT03779854|Drug|Tacrolimus|Given IV
79707882|NCT03779854|Drug|Methotrexate|Given IV
79707883|NCT03779854|Procedure|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
79707884|NCT03771261|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
79707885|NCT03771261|Dietary Supplement|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
79707886|NCT03742687|Radiation|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
79848210|NCT00888992|Behavioral|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
79252069|NCT05073770|Device|Titan Condom|"The test condoms have the following specifications throughout the study:~The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
79707887|NCT03729362|Biological|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
79707888|NCT03729362|Drug|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
79707889|NCT03729362|Biological|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
80016073|NCT05043311|Other|Placebo|intramuscular injetion
79707890|NCT03729362|Drug|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
79707891|NCT03677440|Behavioral|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
79707892|NCT03677440|Behavioral|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
79707893|NCT03653884|Diagnostic Test|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
79707894|NCT03630211|Drug|Cyclophosphamide|Stem Cell Mobilization
79707895|NCT03630211|Drug|Mesna|Stem Cell Mobilization
79707896|NCT03630211|Drug|Rituximab|Transplantation Conditioning
79707897|NCT03630211|Drug|Alemtuzumab|Transplantation Conditioning
79707898|NCT03630211|Drug|Thiotepa|Transplantation Conditioning
79707899|NCT03630211|Drug|GM-CSF|Transplantation Conditioning
79848211|NCT04038320|Drug|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients <75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
79252070|NCT04034420|Other|Online training platform|Self-paced training and learning materials in relation to family services
79707900|NCT03630211|Drug|Intravenous immunoglobulin|Transplantation Conditioning
79707901|NCT03630211|Radiation|Total Body Irradiation|Transplantation Conditioning
79707902|NCT03630211|Drug|Anti Thymocyte Globulin|Transplantation Conditioning
79707903|NCT03629106|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
79707904|NCT03623984|Drug|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
79707905|NCT03587961|Drug|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
79707906|NCT03580772|Device|Persona TKR|Persona® TKR (Zimmer Biomet)
79707907|NCT03580772|Device|Attune TKR|Attune® TKR (Depuy synthes)
79707908|NCT03551665|Behavioral|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
79707909|NCT03534453|Drug|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
80016074|NCT03258164|Biological|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
80016075|NCT03258164|Biological|Standard Lipofilling|Non-ASC enriched fat grafts
79390110|NCT03189966|Procedure|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
79390111|NCT02959372|Other|lung ultrasound|
79390112|NCT02959372|Other|placebo|lung ultrasound. The attending physician will not know the result
79707910|NCT03453385|Behavioral|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
79848212|NCT00563706|Drug|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
79390113|NCT02439528|Genetic|Genetic analysis|"One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis."
79390114|NCT02831998|Drug|ZuraPrep|Apply topically.
79546200|NCT01540448|Procedure|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
79546201|NCT01540448|Procedure|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
79546202|NCT01540461|Drug|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
79707911|NCT03426293|Other|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
79707912|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 1|54/ 59,4 Gy
79707913|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 2|48,8/ 55 Gy
79707914|NCT03396718|Radiation|Standard radio(chemotherapy)|60/ 66 Gy
79707915|NCT03387423|Drug|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
79707916|NCT03378739|Procedure|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
79707917|NCT03340766|Drug|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
80016076|NCT03943342|Drug|Ibrutinib|Given PO
80016077|NCT03943342|Drug|Venetoclax|Given PO
80016078|NCT02280824|Procedure|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
80016079|NCT02280824|Device|Amplatzer Duct Occluder|
80016080|NCT01569893|Other|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
79707918|NCT03340766|Drug|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
79707919|NCT03302949|Dietary Supplement|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
79707920|NCT03290534|Device|CivaSheet|implanting CivaSheet for localized radiation dose delivery
79848213|NCT00563706|Drug|risperidone|
79707921|NCT03267589|Drug|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
79546203|NCT01540500|Drug|Tasimelteon|5.66 mg dose on Day 1 and Day 8
79848214|NCT00563706|Other|placebo|
79848215|NCT02543606|Drug|Esomelone|powder for injection/ infusion Esomeprazole 40mg
79252071|NCT03991832|Drug|Olaparib|Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
79252072|NCT03991832|Drug|Durvalumab|Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
79252073|NCT01361594|Other|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
79252074|NCT01361594|Other|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
79707922|NCT03226106|Behavioral|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
79252075|NCT04435028|Drug|Ketotifen 1 MG|Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
79707923|NCT03226106|Other|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
79252076|NCT02642432|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
79252077|NCT05072834|Procedure|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
79390115|NCT02831998|Drug|ChloraPrep|Apply topically.
79390116|NCT02831998|Drug|ZP Vehicle|Apply topically.
79546204|NCT01540500|Drug|Fluvoxamine|50 mg Dose on Days 2-8
79546205|NCT01540526|Drug|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
79546206|NCT01540539|Drug|REGN1154 or placebo|Participants will receive active drug or placebo
79546207|NCT01540552|Other|medical chart review|
79546208|NCT01540552|Procedure|computed tomography|
79848216|NCT02543606|Drug|Nexium|powder for injection/ infusion Esomeprazole 40mg
79848217|NCT04038632|Other|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
79848218|NCT00935844|Drug|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
79848219|NCT02543372|Behavioral|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
79848220|NCT02543372|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
79848221|NCT00939588|Drug|Aliskiren/ Valsartan|
79848222|NCT00939588|Drug|Telmisartan/ Ramipril|
79848223|NCT02543138|Device|Trocar|Closed thoracostomy using the new trocar
79848224|NCT00935922|Dietary Supplement|Flaxseed|Flaxseed omega-3 fatty acids and lignans
79390117|NCT02434614|Drug|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
79390118|NCT02434614|Radiation|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
79390119|NCT02434614|Drug|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
79546209|NCT01540552|Procedure|computer-aided detection/diagnosis|
79546210|NCT01540578|Other|laboratory biomarker analysis|Correlative studies
79546211|NCT01540591|Drug|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
79707924|NCT03208452|Drug|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
79707925|NCT03208452|Drug|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
79707926|NCT03190265|Drug|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
79707927|NCT03190265|Drug|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
79848225|NCT00936000|Dietary Supplement|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
79848226|NCT00889148|Drug|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
80016081|NCT03837964|Drug|BI 1291583|Tablet
80016082|NCT00694928|Drug|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
80016083|NCT00694928|Drug|butoconazole nitrate|semi-solid, single dose
80016084|NCT04424368|Device|The remote monitoring system|Usage of remote monitoring system
79252078|NCT04434950|Behavioral|Promoting and implementing repeated HIV self-testing and online real-time counseling|At baseline, Month 6 and Month 12, participants will view an online video clip promoting the needs for HIV testing in general and HIV self-testing with online real-time counseling. A free HIV self-testing kit will be sent to participants. An HIVST administrator will provide online real-time pre-test and post-test counseling.
79252079|NCT05060198|Drug|Artemether-lumefantrine (AL)|AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
79252080|NCT05060198|Drug|Dihydroartemisinin-piperaquine (DP)|DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
79390120|NCT02439606|Device|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
79546212|NCT01540591|Drug|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
79546213|NCT01540604|Drug|CRD007|
79546214|NCT01540643|Device|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
79848227|NCT00889148|Other|Placebo|Half the patients will be randomized to placebo
79390121|NCT02439606|Device|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
80016085|NCT03737591|Diagnostic Test|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
80016086|NCT04758754|Other|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
79390122|NCT04345042|Other|Classic Massage (Swedish Technique)|Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
79390123|NCT02829190|Device|Magnetic Resonance Imaging (MRI),|Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
79390124|NCT05720260|Drug|Goserelin|Hormone therapy
79390125|NCT05720260|Drug|Fulvestrant|Hormone therapy
79390126|NCT05720260|Drug|Capivasertib|AKT inhibitor
79390127|NCT05720260|Drug|Durvalumab|immunotherapy
79390128|NCT03191604|Other|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
79546215|NCT01540656|Device|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
79546216|NCT01540669|Dietary Supplement|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
80016087|NCT00694382|Drug|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
80016088|NCT00694382|Drug|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
80016089|NCT05116228|Drug|500mg RTX Group|Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
80016090|NCT05116228|Drug|1000mg RTX Group|Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
80016091|NCT05205395|Diagnostic Test|Transperineal ultrasound|Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
80016092|NCT05116150|Dietary Supplement|Grape seed extract|Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
79546217|NCT01540669|Dietary Supplement|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
79546218|NCT01540669|Dietary Supplement|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
79546219|NCT01540669|Dietary Supplement|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
79546220|NCT01540682|Drug|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
79707928|NCT03190265|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
79707929|NCT03190265|Drug|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
79707930|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
79707931|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
79252081|NCT05060120|Diagnostic Test|biomakers for ovarian torsion|Blood biomarkers analysis using multiplex ELISA: The Luminex system is a magnetic bead-based multiplex ELISA that enable to measure simultaneously multiple proteins within the same sample. Human magnetic Luminex assay will be used for the following analytes: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml). Plasma samples stored at -70°C will be sent to accredited lab at BioTest (Israel) for performing the multiplex ELISA readout assay test using MagPix system.
79390129|NCT03188250|Behavioral|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
79848228|NCT00936156|Drug|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
79390130|NCT02440698|Behavioral|Genetic test for personalized nutrition|
79546221|NCT01540682|Drug|Cetuximab|~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
79707932|NCT03160612|Behavioral|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
79848229|NCT00129961|Drug|sirolimus|
79848230|NCT00129961|Drug|cyclosporine or tacrolimus|
79848231|NCT00528567|Drug|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
79546222|NCT01540682|Radiation|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of ~70 Gy.
79707933|NCT03124186|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
79707934|NCT03109041|Device|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
79848232|NCT00528567|Drug|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
79848233|NCT00936234|Drug|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
79707935|NCT03103880|Device|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device, mobile application, and mobile spirometry designed for use with iOS and Android operating systems. Using Bluetooth to connect, the devices sync with the mobile application to facilitate the collection of controlled medication adherence, rescue medication usage, lung function data, and asthma control.
79707936|NCT03057119|Behavioral|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
79848234|NCT00886028|Drug|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
79848235|NCT00886028|Drug|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
79848236|NCT00889304|Device|Position HTO system|open wedge high tibial osteotomy
79848237|NCT00936468|Biological|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
79848238|NCT02543216|Dietary Supplement|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
79390131|NCT02978170|Procedure|Cone-Beam Computed Tomography|Undergo CBCT
79707937|NCT03057119|Behavioral|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
79707938|NCT03057119|Behavioral|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
79546223|NCT01540708|Drug|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
79707939|NCT03057119|Behavioral|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
79707940|NCT03057119|Behavioral|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
79707941|NCT02998983|Drug|Racotumomab|
79707942|NCT02974647|Drug|Ruxolitinib|
80016093|NCT05116150|Dietary Supplement|Placebo|Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
79252082|NCT05060120|Diagnostic Test|peritoneal fluid proteins analysis|"Western blot for peritoneal fluid proteins analysis~We will look for the relative abundance of proteins involved in the protection of cells against oxidative stress and the regulation of reactive oxygen species (ROS) using western blot. Superoxide dismutase 1 (SOD1, 16kDa) scavenges superoxides (O-2) within cells. Catalase (60kDa) is hydrogen peroxide (H2O2) scavenging enzyme regulate ROS concentrations within cells by reducing H202 into O2 and water. Thioredoxin (12kDa) facilitates the reduction of proteins via cysteine thiol-disulfide exchange. Alpha smooth muscle actin (42kDa) will be used as a loading control. These four proteins will be resolved by western blot given their different molecular weights using western blot cocktail antibodies (abcam # ab179843)."
80016094|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
80016095|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
80016096|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
80016097|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
80016098|NCT04989101|Drug|Nigella|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
80016099|NCT04200664|Diagnostic Test|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
79252083|NCT05059574|Behavioral|Breast Crawling|The mother's first breast-feeding of her baby is not routine biological breast-feeding, but as a cradle to the breast.
79252084|NCT02640482|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
79390132|NCT02440386|Behavioral|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~send a text message to the study team to let us know they have started ART;~Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
79707943|NCT02882282|Other|Laboratory Biomarker Analysis|Correlative studies
79707944|NCT02882282|Other|Patient Observation|Undergo observation
80016100|NCT04200664|Diagnostic Test|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
79252085|NCT02640482|Drug|Placebo for ABT-493/ABT-530|tablet
79252086|NCT04478084|Biological|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form:freeze-dried Route of administration: intradermal
79390133|NCT02959216|Other|Aerobic Exercise|Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
79707945|NCT02882282|Biological|Pembrolizumab|Given IV
79707946|NCT02875158|Procedure|Cyclophotocoagulation protocol|"Intravenous route is installed~Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~Pars plana measurement using transillumination (if needed)~Laser treatment applied approximately 1mm post to limbus~Dexamethasone 0,5 mg subconjunctival injection~Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
79707947|NCT02875158|Procedure|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
79707948|NCT02875158|Procedure|Modified cyclophotocoagulation|2000 mW for 2 seconds.
79707949|NCT02843945|Device|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
79707950|NCT02816099|Biological|Prise de sang|
79707951|NCT02711852|Drug|Duvelisib|Administered as oral capsules
79707952|NCT02703597|Behavioral|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
79848239|NCT00939666|Procedure|Wait&see or TEM with intensive follow-up|Wait&see or TEM with intensive follow-up
79848240|NCT03835364|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
79848241|NCT00936546|Drug|Rituximab|Mabthera, Rituximab 1000 mg I.V.
79848242|NCT00889460|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
80016101|NCT04200664|Other|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
79252087|NCT04478084|Biological|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried Route of administration: intradermal
79252088|NCT04478084|Biological|Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)|Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular
79252089|NCT04478084|Biological|Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)|Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular
79252090|NCT05072756|Other|Applying a questionnaire|The participants have to answer a questionnaire addressing their opinion on menopausal hormone replacement therapy
79252091|NCT03098888|Procedure|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
79252092|NCT05072522|Drug|SKLB1028|SKLB1028 capsules, oral, once daily in continuous 28-day cycles
79252093|NCT03098810|Drug|Zinc sulphate|Oral syrup zinc sulphate
79252094|NCT03098810|Other|Placebo|Oral syrup placebo
79252095|NCT03098732|Device|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
79390134|NCT02959216|Other|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
79390135|NCT03188016|Behavioral|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
79390136|NCT03188016|Behavioral|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
79546224|NCT01540708|Drug|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
79546225|NCT01540721|Drug|Marketed paracetamol|marketed formulation
79546226|NCT01540721|Drug|Experimental paracetamol formulation|Experimental formulation
79546227|NCT01540734|Drug|Marketed paracetamol|Marketed formulation
79546228|NCT01540734|Drug|Experimental paracetamol formulation|Experimental formulation
79707953|NCT02703597|Behavioral|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
79707954|NCT02703597|Behavioral|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
79707955|NCT02688114|Procedure|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
79707956|NCT02688114|Procedure|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
79707957|NCT02688114|Procedure|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
79848243|NCT00889460|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
79848244|NCT00936624|Drug|SOTB07|SOTB07 100mg
79848245|NCT00936624|Drug|SOTB07|SOTB07 200mg
79848246|NCT00936624|Drug|placebo|placebo
79848247|NCT00936624|Drug|montelukast|montelukast 10mg po, bid, 12week
79848248|NCT00889538|Drug|placebo|50 mL of 1/2 normal saline IV
79252096|NCT03098732|Device|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
79848249|NCT00889538|Drug|glutathione|glutathione 600 mg IV
80016102|NCT04200664|Diagnostic Test|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
79546229|NCT01540747|Dietary Supplement|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
79848250|NCT00889538|Drug|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
79848251|NCT04012476|Drug|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
79848252|NCT00138151|Biological|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
79848253|NCT00138151|Drug|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
79848254|NCT00138151|Drug|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
79848255|NCT02543060|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
79848256|NCT02543060|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
79546230|NCT01540747|Dietary Supplement|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
79252097|NCT03702842|Device|Soterix Medical tsDCS stimulator|tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.
79252098|NCT03702842|Other|Locomotor training|Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
79546231|NCT01540760|Drug|MCAF5352A|Multiple ascending doses
79848257|NCT04012788|Dietary Supplement|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
79848258|NCT04012788|Other|Placebo comparator|Placebo powder
79848259|NCT00889616|Drug|BSAM2/Alhydrogel + CPG 7909|
80016103|NCT04200664|Genetic|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
79252099|NCT02719743|Biological|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
79252100|NCT02464761|Drug|Visudyne|
79848260|NCT00138073|Device|Web-based waveform interpretation guide|Use of an educational website.
79252101|NCT04790019|Behavioral|Low energy availability|Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.
79390137|NCT05720026|Drug|SYSA1901|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
79546232|NCT01540760|Drug|Placebo|Matching MCAF5352A, multiple doses
79546233|NCT01540786|Procedure|High resolution urodynamic assessment|
79546234|NCT01540786|Procedure|Conventional urodynamic assessment|
79546235|NCT01540799|Device|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
79546236|NCT01540812|Drug|Vincristine in induction|
79546237|NCT01540812|Drug|Daunorubicin in induction|
79546238|NCT01540812|Drug|Prednisone in induction|
79546239|NCT01540812|Drug|Metotrexato in induction|
79848261|NCT04038164|Behavioral|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
79848262|NCT04013490|Dietary Supplement|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
79848263|NCT04037306|Behavioral|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
79848264|NCT04037306|Behavioral|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
79848265|NCT02581631|Biological|Nivolumab|
79848266|NCT02581631|Drug|Brentuximab Vedotin|
79848267|NCT00884546|Drug|BMS-833923|Capsule, Oral, Once daily, 6 months
79390138|NCT05720026|Drug|Pertuzumab|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
79390139|NCT05720026|Drug|Trastuzumab|loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
79390140|NCT05720026|Drug|Docetaxel|75 mg/m^2 IV, q3w/cycle, total 4cycle
79390141|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|
79390142|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|
79390143|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|
79390144|NCT02439294|Device|CPAP|
79546240|NCT01540812|Drug|Cytarabine in induction|
79848268|NCT00884546|Drug|Lenalidomide|Capsule, Oral, Once daily, 6 months
79848269|NCT00884546|Drug|Dexamethasone|Capsule, Oral, Once a week, 6 months
79848270|NCT00884546|Drug|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
79848271|NCT04970277|Other|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
79848272|NCT04970277|Other|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
79707958|NCT02688114|Procedure|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
79707959|NCT02688114|Procedure|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
79707960|NCT02615691|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
79707961|NCT02615691|Biological|ITI|Immune tolerance induction therapy
79707962|NCT02579460|Other|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
79707963|NCT02429570|Drug|Meclofenamate|
79848273|NCT05444049|Device|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
79848274|NCT00886106|Drug|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
79252102|NCT04790019|Behavioral|High impact jumping|Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
79848275|NCT00886106|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
79390145|NCT03187938|Diagnostic Test|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
79390146|NCT04483674|Drug|50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide|"Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~complete physical examination~register concomitant medication~blood test~concomitant medications~assessment od adverse events~assessement of compliance~PSQI and CESTA questionnaire (week 4 and 48)~Recommendation in contraception methods~Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL"
79546241|NCT01540812|Drug|Hydrocortisone in induction|
79390147|NCT05719870|Behavioral|Educational training|The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
79390148|NCT03191214|Device|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery >30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
79546242|NCT01540812|Drug|Idarubicin in induction-2|
79546243|NCT01540812|Drug|Fludarabine in induction-2|
79546244|NCT01540812|Drug|Ara-C in induction-2|
79546245|NCT01540812|Drug|G-CSF in induction-2|
79848276|NCT00939978|Drug|rhEPO|recombinant human erythropoietin(rhEPO)
79848277|NCT00889694|Drug|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
79390149|NCT03190980|Other|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
79390150|NCT03190980|Other|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
79390151|NCT03190980|Other|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
79390152|NCT05638750|Other|Rehabilitation Intervention|12-week treatment intervention & home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
79546246|NCT01540812|Drug|Dexamethasone in consolidation-1|
79546247|NCT01540812|Drug|Vincristrine in consolidation-1|
79546248|NCT01540812|Drug|Metotrexato in consolidation-1|
79546249|NCT01540812|Drug|PEG-ASP in consolidation-1|
79546250|NCT01540812|Drug|Dexamethasone in consolidation-2|
79546251|NCT01540812|Drug|ARA-C in consolidation-2|
79546252|NCT01540812|Drug|PEG-ASP in consolidation-2|
79546253|NCT01540812|Drug|Dexamethasone in consolidation-3|
79546254|NCT01540812|Drug|Vincristine in consolidation-3|
79546255|NCT01540812|Drug|Metotrexato in consolidation-3|
79546256|NCT01540812|Drug|PEG-ASP in consolidation-3|
79546257|NCT01540812|Procedure|allogeneic HSCT|
79707964|NCT02342613|Biological|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
79707965|NCT02221934|Device|Altius|Electrical signal
79707966|NCT02204072|Drug|BI 836845|
79707967|NCT02204072|Drug|Enzalutamide|
79707968|NCT02204072|Drug|Enzalutamide|
79707969|NCT02163525|Procedure|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
79848278|NCT00889694|Drug|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
79848279|NCT00889694|Drug|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
79848280|NCT04012320|Other|No intervention, observational study|No intervention, observational study
79390153|NCT05719792|Procedure|Transforaminal Epidural Steroid Injection|In the TFESI group, all patients were positioned prone. The injection site was cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) was applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle was inserted just below the pedicle. It was advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position was confirmed through a lateral view. Using lateral views, the needle was placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 2 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride was injected.
79707970|NCT02163525|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
79707971|NCT02163525|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
79848281|NCT05278910|Other|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
79848282|NCT05278910|Dietary Supplement|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
79848283|NCT05278910|Dietary Supplement|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
79848284|NCT05278910|Dietary Supplement|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
79848285|NCT00940212|Drug|AZD2423|oral, single administration
79848286|NCT00940212|Drug|Placebo|oral administration and single dose
79848287|NCT00529035|Drug|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
79848288|NCT04421664|Drug|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
79848289|NCT04421664|Drug|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
80016104|NCT04940351|Procedure|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
79707972|NCT02143128|Other|Efficacy Safety Score|Evaluation using the score for postoperative patients
79707973|NCT02143128|Other|Verbal Numeric Rating Scale|Patients assessed for postoperative pain using VNRS (0-10)
79707974|NCT01977417|Drug|Salsalate|
79707975|NCT01977417|Drug|Placebo|
79707976|NCT01969578|Drug|bicalutamide + triptorelin|
79707977|NCT01969578|Drug|Cisplatin + Doxorubicin|
79707978|NCT01969578|Drug|Carboplatin + Paclitaxel|
79848290|NCT02578043|Drug|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
79848291|NCT02578043|Drug|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
79707979|NCT01951885|Drug|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
79707980|NCT01951885|Drug|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient < 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
79707981|NCT01951885|Drug|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients >40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients < 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
79707982|NCT01951885|Drug|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
79707983|NCT01810588|Device|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
79707984|NCT01810588|Drug|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
79848292|NCT02578043|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
79848293|NCT04037384|Behavioral|Eye yoga|Eye yoga exercises at home given by a trained instructor
79848294|NCT04037384|Behavioral|Passive Reading|Passive reading at home
79390154|NCT05719792|Procedure|Erector Spina Plane Block|Patients are placed in the prone position to determine the vertebrae in the middle of the involved area. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a high-frequency (8 MHz) linear ultrasound (USG) probe. The transverse process is, then, visualized approximately at the 3 cm lateral from the midline and the erector spinae muscle is visualized on it. The 22-gauge 50 mm block needle is advanced towards the in-plane section craniocaudally and the transverse process is touched. Then the needle is then withdrawn minimally to confirm that it is between the erector spinae muscle and the transverse process through hydrodissection. Following that, 5 mL from 0.5% bupivacaine hydrochloride, 8 mg dexamethasone and 3 ml saline is administered and local anesthetic spread is confirmed by USG.
79848295|NCT00940056|Procedure|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
79848296|NCT00940056|Drug|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
79848297|NCT00889850|Drug|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
79848298|NCT00889850|Drug|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
79848299|NCT04074317|Drug|PRAM9|SC injection
79848300|NCT04074317|Drug|Regular Insulin + Pramlintide|Separate SC injections
79848301|NCT04074317|Drug|Regular Insulin|SC injection
79546258|NCT01540812|Procedure|Allo HSCT with reduced-intensity conditioning|
79848302|NCT00941148|Drug|Insulin Glargin|
79546259|NCT01540877|Procedure|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
79546260|NCT01540877|Procedure|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
79390155|NCT02438982|Drug|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
79546261|NCT01540877|Procedure|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
79390156|NCT02438982|Drug|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3, it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
79390157|NCT03187704|Other|HEPA air filtration|Air filters were placed in participant homes
79390158|NCT02425774|Procedure|Vagus stimulation|
79390159|NCT02425774|Procedure|Sham stimulation|
79390160|NCT02425774|Drug|Prucalopride|
79390161|NCT02425774|Drug|Placebo|
79390162|NCT03190902|Behavioral|Attention Processing Training program (APT)|
79390163|NCT03190902|Behavioral|nonspecific computer training (n-ST)|
79390164|NCT03191136|Drug|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
79546262|NCT01540877|Procedure|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
79390165|NCT03191136|Drug|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
79390166|NCT03187782|Diagnostic Test|ANSWatch|
79390167|NCT03187626|Drug|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
79390168|NCT03187626|Drug|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
79390169|NCT03190746|Diagnostic Test|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
79546263|NCT01540903|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
79546264|NCT01540903|Biological|Saline|Saline
79546265|NCT01540916|Other|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
79546266|NCT01540916|Other|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
79546267|NCT01540942|Dietary Supplement|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;[W=weight（Kg）；H=height（cm）；A=age（year）]
79546268|NCT01540942|Other|surgery|bowel resection
79707985|NCT01810588|Drug|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
79707986|NCT01810588|Drug|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
79707987|NCT01810588|Drug|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
79707988|NCT01810588|Radiation|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
79546269|NCT01540955|Behavioral|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
79546270|NCT01540968|Behavioral|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
79707989|NCT01810588|Drug|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
79707990|NCT01810588|Drug|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
79707991|NCT01627301|Device|Device-Guided Breathing (DGB)|The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to < 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
79707992|NCT01627301|Device|Sham DGB|The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
79707993|NCT01627301|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
79707994|NCT01627301|Device|Sham tVNS|Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
79252103|NCT04490187|Behavioral|Motor Learning|"Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995)."
79252104|NCT02466711|Drug|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
79546271|NCT01540994|Radiation|radiation therapy|Stereotactic Body Radiation Therapy
79546272|NCT01541007|Drug|Cabazitaxel|25 mg/m2 every three weeks
79546273|NCT01541007|Drug|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
79546274|NCT01541046|Biological|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
79546275|NCT01541046|Biological|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
79848303|NCT00941148|Drug|NPH insulin|
79848304|NCT00941148|Drug|Insulin detemir|
79848305|NCT00941148|Drug|metformin|metformin (2000 mg/day)
79848306|NCT02541500|Drug|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
79848307|NCT04073849|Drug|EPOGEN® (epoetin alfa)|Active drug
79848308|NCT04073849|Other|Normal Saline|Placebo
79252105|NCT02466711|Drug|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
79252106|NCT02462889|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection
79252107|NCT02462889|Drug|Placebo|Sham injection
79546276|NCT01541059|Drug|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
79546277|NCT01541059|Drug|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
79546278|NCT01541072|Drug|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
79546279|NCT01541072|Drug|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils >= 0.5 G/L)
80016105|NCT04940351|Procedure|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
79707995|NCT01499888|Procedure|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
79707996|NCT01499888|Drug|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
79707997|NCT01499888|Drug|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
79707998|NCT00745316|Drug|Tonapofylline|Oral Tonapofylline - 2 capsules bid
80016106|NCT05115916|Behavioral|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
80016107|NCT05115526|Other|PEEP setting|PEEP setting according to various methods
80016108|NCT05115448|Other|Bevel Position|During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
79252108|NCT02463123|Device|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
79252109|NCT04489407|Device|Remote Photoplethysmography (rPPG) vital sign acquisition|Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
79390170|NCT03117894|Drug|Ropivacaine 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
79390171|NCT03117894|Drug|Remifentanil 50 microg/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
79390172|NCT03117894|Drug|Betamethason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
79390173|NCT03117894|Drug|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
79390174|NCT03117894|Drug|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
79546280|NCT01541098|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
79546281|NCT01541098|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
79546282|NCT01541111|Drug|Magnesiun|75mg pills; each 12h; 12wk
79546283|NCT01541124|Drug|Opioid|10 mg/pill, po, each 6h, during 6m
79546284|NCT01541137|Drug|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
79546285|NCT01541137|Drug|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
79707999|NCT00745316|Drug|Placebo|Oral placebo - 2 capsules bid
79708000|NCT00709865|Drug|tonapofylline|IV
79708001|NCT00709865|Drug|Placebo|IV
79708002|NCT00682318|Drug|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
79708003|NCT00682318|Dietary Supplement|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
79708004|NCT00682318|Dietary Supplement|Ethanol|"Part 1 & Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
79708005|NCT00682318|Dietary Supplement|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
80016109|NCT00136903|Drug|Prochymal® - 2 Million cells/kg|2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
80016110|NCT00136903|Drug|Prochymal®- 8 Million cells/kg|8 million hMSCs/kg actual body weight IV on study Days 1 and 4
80016111|NCT00136903|Drug|Methylprednisolone|Methylprednisolone 2 mg/kg administered intravenously.
80016112|NCT00136903|Drug|Prednisone|Prednisone 2.5 mg/kg administered orally.
80016113|NCT00136903|Drug|Cyclosporine|Administered as prescribed by the caregiver.
79252110|NCT02462733|Behavioral|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
79390175|NCT03117894|Drug|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
79708006|NCT00682318|Dietary Supplement|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (<130 mg/day EPA/DHA)"
79848309|NCT05280210|Other|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
79390176|NCT03117894|Drug|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
79390177|NCT03117894|Drug|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
79848310|NCT05221203|Behavioral|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
80016114|NCT00136903|Drug|Tacrolimus|Administered as prescribed by the caregiver.
80016115|NCT00136903|Drug|Mycophenolate Mofetil|Administered as prescribed by the caregiver.
80016116|NCT04917029|Drug|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
80016117|NCT04917029|Drug|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
79546286|NCT01541137|Device|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
79546287|NCT01541150|Behavioral|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
80016118|NCT04917029|Drug|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
79546288|NCT01541176|Other|Absence of corticotherapy post-transplantation|No study treatment
79546289|NCT01541176|Drug|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~D1 to D14 : 20 mg/day,~D15 to M1 : 15 mg/day,~M1 to M3 : 10 mg/day,~M3 to M12 : 5 mg/day."
79546290|NCT01541189|Drug|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
79252111|NCT02462733|Behavioral|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
79546291|NCT01541202|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
79546292|NCT01541202|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
79708007|NCT00626990|Drug|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
79708008|NCT00626990|Genetic|DNA methylation analysis|O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
79708009|NCT00626990|Other|laboratory biomarker analysis|Prognostic factor analyses
79708010|NCT00626990|Procedure|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
79708011|NCT00626990|Procedure|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
79708012|NCT00626990|Radiation|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
79708013|NCT00107198|Procedure|Conventional Surgery|Undergo surgery
79252112|NCT04783311|Biological|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
79252113|NCT04783311|Other|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
79708014|NCT00107198|Drug|Cyclophosphamide|Given IV
79708015|NCT00107198|Drug|Doxorubicin Hydrochloride|Given IV
79708016|NCT00107198|Drug|Prednisone|Given IV or PO
79708017|NCT00107198|Radiation|Radiation Therapy|Undergo IFRT
79848311|NCT05221203|Behavioral|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
79848312|NCT03263429|Drug|Glutaminase Inhibitor CB-839|Given by mouth
79848313|NCT03263429|Biological|Panitumumab|Given by vein
79390178|NCT00357292|Drug|Azithromycin (T1225)|
79390179|NCT02438670|Device|PID control algorithm|
79390180|NCT02438670|Device|MPC control algorithm|
79390181|NCT05719480|Diagnostic Test|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
79390182|NCT04483752|Other|CHEST CT SCAN|Chest CTscan at 3 and 12 months
79390183|NCT02438748|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
79390184|NCT03187548|Drug|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
79390185|NCT03190044|Dietary Supplement|PACR|Daily assumption of PACR for a 3-month period
79390186|NCT03190044|Dietary Supplement|Placebo|Daily assumption of placebo
79708018|NCT00107198|Drug|Vincristine Sulfate|Given IV
79708019|NCT01601106|Drug|liposomal prednisolone|Two weekly dosages with 150 mg.
79708020|NCT01601106|Drug|Placebo|
79708021|NCT04529018|Combination Product|[18F]CETO|[18F]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
79848314|NCT03263429|Drug|Irinotecan Hydrochloride (phase I only)|Given by vein
79848315|NCT03263429|Other|Laboratory Biomarker Analysis|Correlative studies
79848316|NCT03263429|Other|Pharmacological Study|Correlative studies
80016119|NCT04189510|Device|Artificial Pancreas|The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
80016120|NCT04189510|Other|Multiple Daily Injections|Multiple Daily Injections as standard of care post kidney transplant.
79390187|NCT05719402|Procedure|non-interventional prospective cross-sectional observational study|to investigate the feasibility of using intestinal motility quantified by intestinal ultrasound (US) to evaluate disease activity. The outcomes of intestinal motility detected by ultrasound will be compared with endoscopic and histopathological reference standards in adult patients with IBD
79708022|NCT01601145|Dietary Supplement|consumption of lozenges|Each subject two lozenges a day for 6 weeks
79708023|NCT04488588|Other|Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
79708024|NCT01601184|Drug|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
79708025|NCT01601184|Drug|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
79708026|NCT01643759|Drug|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
79546293|NCT01541228|Device|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
79708027|NCT04488237|Drug|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
79708028|NCT02754557|Other|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
79708029|NCT02754557|Device|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
79848317|NCT03263429|Device|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
79848318|NCT00609674|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
79848319|NCT00609674|Drug|Placebo|Placebo
79848320|NCT00940134|Biological|PYY 3-36|0.8 pmol/kg/min x 3 hours
79848321|NCT00940134|Biological|GLP-1|1.0 pmol/kg/min x 3 hours
79848322|NCT00940134|Biological|saline infusion|saline infusion x 3 hours
80016121|NCT04098952|Other|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
79848323|NCT00941382|Drug|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
80016122|NCT04098952|Other|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
79848324|NCT00941382|Drug|Sibutramine|15 mg per day for 180 days
79848325|NCT00941382|Drug|Metformin|Metformin 850 mg per day for 180 days
79848326|NCT00137839|Drug|Erlotinib|
79848327|NCT02542982|Device|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
80016123|NCT03654131|Device|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
80016124|NCT03654131|Radiation|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
80016125|NCT00500084|Drug|Liprotamase|Administered orally
80016126|NCT05115214|Device|SpherePVI™ Catheter|Affera SpherePVI™ Multi-Ablation System
79390188|NCT03190122|Procedure|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. [NCT ID not yet assigned]
79390189|NCT02977936|Dietary Supplement|Cartimotil Fort|1 to 4 capsules per day during 90 days
79390190|NCT03189888|Device|apheresis|
79848328|NCT00941460|Drug|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
79848329|NCT00941460|Drug|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
79848330|NCT02542904|Procedure|mesenteric excision|
79848331|NCT04013178|Behavioral|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
79848332|NCT04013178|Behavioral|Conventional resistance training|A conventional approach to resistance training
79848333|NCT00886184|Procedure|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
79848334|NCT00886184|Procedure|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
79546294|NCT01541228|Procedure|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
79546295|NCT01541267|Drug|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
79708030|NCT04528979|Other|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
79708031|NCT04528979|Other|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
79708032|NCT01601262|Device|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
79708033|NCT02279849|Other|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
79708034|NCT02279849|Other|Pricing|The pricing incentives were used to help promote sales of healthier food items.
79708035|NCT02279849|Other|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
79708036|NCT04488549|Other|Survey|International E-survey
79390191|NCT02042326|Drug|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
79390192|NCT02434068|Other|CT|followup
79848335|NCT02542670|Genetic|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
79848336|NCT00890240|Drug|JNJ-31001074|
79390193|NCT02438514|Other|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.~Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.~Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
79390194|NCT05718544|Drug|Esketamine|Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
79390195|NCT05718544|Drug|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
79390196|NCT05718544|Drug|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
79390197|NCT03187470|Device|Different programming of a CRT defibrillator|Different programming of a CRT defibrillator using pacing modalities of a quadripolar left ventricular lead
79390198|NCT03190824|Drug|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
79390199|NCT05616598|Drug|Sofosbuvir +daclatasvir+ simeprevir+Ribavirin|Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
79390200|NCT03190356|Device|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
79390201|NCT05717296|Other|anxiety survey|surgery and anesthesia anxiety questionnaire
79708037|NCT01680029|Device|PBASE-system 2.0|
79708038|NCT04528628|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
79708039|NCT04528628|Drug|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
79708040|NCT04528628|Combination Product|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
79848337|NCT00890318|Drug|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
79848338|NCT00890318|Other|ketoconazole|Tablet, see Arm Description for intervention information.
79848339|NCT00890318|Drug|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
79848340|NCT00563316|Drug|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
79848341|NCT00563316|Drug|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
79848342|NCT04037774|Drug|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
79848343|NCT04037774|Other|placebo|addition of placebo with local anesthetic to create a control group
79848344|NCT00890474|Procedure|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
79848345|NCT01529736|Procedure|High torque insertion|Osseotite implant placed with high insertion torque forces
79708041|NCT04528940|Diagnostic Test|PD-1/PDL-1 staining|Every endometrial or ovarian carcinoma will be stained for PD-1/PDL-1. The stage and grade of the tumor will be determined and correlation between tumor grade and stage and PD-1/PDL-1 staining will be made.
79708042|NCT01601340|Drug|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
79546296|NCT01541280|Drug|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of >15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of >1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
79708043|NCT01601340|Drug|Placebo|Placebo tablets, twice daily for 48 weeks
79708044|NCT04528862|Behavioral|Nature slides|participants will view a presentation of nature slides
79708045|NCT04528862|Behavioral|Urban slides|participants will view a presentation of urban slides
79708046|NCT01600248|Behavioral|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
79708047|NCT01680068|Procedure|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
79708048|NCT01641341|Drug|Bifidobacterium infantis|once a day for seven to eight weeks
79708049|NCT01641341|Drug|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
79848346|NCT01529736|Procedure|Low torque insertion|Osseotite implant placed with low insertion torque forces
80016127|NCT05761535|Radiation|Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses|"Regarding the neurological MR protocol, the following may be acquired:~3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~diffusion sequences for the evaluation of the connection between different areas within a specific organ;~perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~susceptibility sequences for noninvasive assessment of vasculature and deposits of iron."
80016128|NCT03471520|Behavioral|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
79546297|NCT01541280|Other|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of >grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
79546298|NCT01541293|Drug|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
79708050|NCT01641341|Drug|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
79848347|NCT02542748|Drug|Norepinephrine|norepinephrine injection
79848348|NCT02542748|Drug|Ephedrine|Ephedrine injection
79708051|NCT01641341|Drug|Placebo|Placebo capsule will not contain active treatment ingredients.
79708052|NCT01601418|Drug|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
79708053|NCT01601418|Drug|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
79708054|NCT01680107|Drug|d-cycloserine|
79708055|NCT01680107|Drug|placebo|
79708056|NCT01680107|Behavioral|cognitive-behaviour therapy|
79708057|NCT01680146|Dietary Supplement|PRO+FAT|
79708058|NCT01680146|Dietary Supplement|PRO|
79708059|NCT01643915|Behavioral|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
79848349|NCT00941616|Biological|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
79848350|NCT00941616|Biological|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
79708060|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
79708061|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
79708062|NCT01680185|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
79708063|NCT01680185|Drug|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
79708064|NCT01680185|Other|Standard of care|all covered above
79708065|NCT01680263|Device|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
79708066|NCT01680263|Procedure|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
79848351|NCT04037540|Procedure|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
79848352|NCT04037540|Procedure|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
79848353|NCT00941694|Behavioral|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
79848354|NCT00941694|Behavioral|placebo group|3 phone calls not related to asthma self-management
79848355|NCT02542592|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
79848356|NCT02542592|Drug|Isotonic Sodium Chloride|Placebo
79848357|NCT00941772|Other|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
79848358|NCT03178487|Drug|Upadacitinib|Tablet
79848359|NCT03178487|Drug|Placebo|Tablet
79848360|NCT02542826|Other|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
79390202|NCT05717296|Other|scale of satisfaction|scale of satisfaction of multimedia
79390203|NCT05717296|Other|Multimedia Information|"Patients randomized to the with multimedia support arm will have access to educational videos focused on the vascular surgery they are to receive."
79848361|NCT04430036|Drug|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
79848362|NCT04430036|Drug|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
79848363|NCT04430036|Drug|Cisplatin|Alkylating antineoplastic agent
79546299|NCT01541293|Drug|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
79848364|NCT04430036|Drug|Gemcitabine|Antimetabolite antineoplastic agent
79848365|NCT00528957|Drug|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
79848366|NCT00528957|Drug|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants < 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
79848367|NCT00528957|Drug|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m^2 every 8 hours; pediatric participants > 12 years of age: 300 mg twice daily).
79390204|NCT03190434|Device|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
79390205|NCT03187392|Drug|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
79848368|NCT00890630|Procedure|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
79848369|NCT00890630|Drug|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
79848370|NCT00890708|Drug|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
79390206|NCT03187392|Drug|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
79390207|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
79390208|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
79390209|NCT02430324|Other|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
79546300|NCT01541332|Drug|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
79546301|NCT01541332|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
79546302|NCT01541332|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
79390210|NCT05717218|Device|Ultra-protective mechanical ventilation monitored by electrical impedance tomography|"A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored."
79848371|NCT00890786|Drug|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
79848372|NCT00890786|Drug|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
79848373|NCT00890786|Drug|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
79848374|NCT00560508|Drug|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
79848375|NCT00560508|Drug|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
79848376|NCT05127759|Drug|HLX208|HLX208 450mg bid po
79848377|NCT00890864|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
79848378|NCT00890942|Drug|naloxone|naloxone 0.4mg.(1 ml) intramuscular
79848379|NCT00890942|Drug|normal saline|normal saline 1 ml IM
79390211|NCT02438124|Behavioral|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
79546303|NCT01541410|Device|Vascutek Hybrid Graft|Single Group Assignment
80016129|NCT03060902|Behavioral|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
79708067|NCT01601574|Behavioral|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
79546304|NCT01541436|Device|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
79252114|NCT04769505|Behavioral|digital mindfulness-based intervention (MBI)|The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.
79390212|NCT05608798|Device|ODI-Tech medical device|"The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes."
79546305|NCT01541462|Other|Weaning|Decrease assistance provided by the ventilator
79546306|NCT01541475|Drug|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
79546307|NCT01541475|Drug|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
79546308|NCT01541488|Drug|BI 1021958|tablet
79546309|NCT01541488|Drug|BI 1021958|drinking solution / tablet
79546310|NCT01541488|Drug|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
79708068|NCT01601574|Other|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
79708069|NCT01643993|Other|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
79708070|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
79708071|NCT01601613|Drug|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
79848380|NCT05125887|Other|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
79848381|NCT04037852|Device|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
80016130|NCT03632759|Drug|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
79390213|NCT02430246|Dietary Supplement|Urex Plus|Probiotic
80016131|NCT03632759|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
79390214|NCT02430246|Other|Placebo|capsule without active ingredient
79390215|NCT02430246|Dietary Supplement|Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14|
79390216|NCT00214539|Procedure|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
79390217|NCT00214539|Drug|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
79390218|NCT00215787|Drug|lansoprazole|Lansoprazole 30 mg BID for 1 year
79546311|NCT01541501|Device|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
79546312|NCT01541527|Biological|blood test|One blood test entering in the usual follow-up of the patient
80016132|NCT03047083|Other|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
80016133|NCT03047083|Other|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
80016134|NCT00498914|Drug|YM155|Continuous IV infusion
79708072|NCT01601613|Drug|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
79708073|NCT01601730|Drug|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
79708074|NCT01601730|Drug|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
79708075|NCT01601730|Drug|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
79708076|NCT01601730|Drug|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
79708077|NCT01644032|Other|Teleconsultation|Teleconsultation between paramedics and an EMS physician
79546313|NCT01541540|Behavioral|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
79708078|NCT01644071|Drug|cipralex|one time 10 mg, tablet
79252115|NCT04768725|Behavioral|Dietary intervention combined with physical-cognitive exergaming|Intermittent Fasting (IF) [self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)] combined with physical-cognitive exercise [60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)].
79708079|NCT04528589|Other|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
79708080|NCT01601769|Device|Vitom|Patients treated and diagnosed by vitom
79848382|NCT04037852|Procedure|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
79708081|NCT01601769|Device|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
79708082|NCT01680536|Drug|maraviroc|
79708083|NCT01601808|Drug|Placebo|Orally once a day, continuously throughout the study
79848383|NCT04037852|Procedure|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
79848384|NCT00941850|Procedure|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
79848385|NCT04938986|Diagnostic Test|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
79848386|NCT00942006|Drug|doxycycline|100 mg bid, 14 days
79252116|NCT04768725|Behavioral|Dietary intervention|Intermittent Fasting (IF) [self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)].
79848387|NCT00942006|Drug|ceftriaxone|2g x 1 iv, 14 days
79848388|NCT00886418|Drug|muscle relaxant|muscle relaxant administration throughout anesthesia
79848389|NCT00886418|Drug|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
79848390|NCT00942240|Drug|ACU-4429|administered orally once a day for 14 days
79390219|NCT00955552|Drug|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
79708084|NCT01601808|Drug|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
79708085|NCT01680614|Behavioral|CASI|
79708086|NCT04482153|Device|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
79848391|NCT00942240|Drug|matching placebo tablet|administered orally once a day for 14 days
80016135|NCT02953093|Drug|Acarbose|see arm description
79390220|NCT00955552|Drug|Cosamin DS® (Nutramax)|oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
79390221|NCT05716906|Dietary Supplement|Melatonin|5mg gummy 30 min before bedtime for 2 consecutive nights
79390222|NCT00216099|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
79390223|NCT00216099|Dietary Supplement|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
79708087|NCT01644383|Behavioral|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
79708088|NCT01680692|Drug|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
79708089|NCT01680692|Device|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
79708090|NCT01680692|Device|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
79708091|NCT01601925|Other|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
79708092|NCT04481880|Diagnostic Test|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
79708093|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
79848392|NCT02542124|Biological|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
79848393|NCT00942318|Drug|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
79848394|NCT04037618|Drug|[14C]-EYP001a|Oral drinking suspension
79848395|NCT00942396|Device|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
79848396|NCT00891098|Behavioral|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
79848397|NCT00891098|Behavioral|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
79848398|NCT00944580|Biological|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
79708094|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
79708095|NCT01644422|Other|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
80016136|NCT02953093|Other|Placebo|See arm description
80016137|NCT04518280|Drug|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
79390224|NCT00216099|Dietary Supplement|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
79390225|NCT04344652|Device|Photoscreening -|external picture taken with a an phone based app
79390226|NCT05716828|Other|Balint group activities|A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
79848399|NCT05280054|Drug|AV-101|360 mg capsules
79848400|NCT05280054|Drug|Probenecid|1000 mg oral
79848401|NCT00891254|Device|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
79390227|NCT00039195|Biological|filgrastim|
79390228|NCT00039195|Biological|rituximab|
79390229|NCT00039195|Drug|carboplatin|
79390230|NCT00039195|Drug|cyclophosphamide|
79390231|NCT00039195|Drug|doxorubicin hydrochloride|
79390232|NCT00039195|Drug|etoposide|
79390233|NCT00039195|Drug|ifosfamide|
79390234|NCT00039195|Drug|prednisone|
79390235|NCT00039195|Drug|vincristine sulfate|
79390236|NCT00039195|Procedure|peripheral blood stem cell transplantation|
79390237|NCT00039195|Radiation|radiation therapy|
79390238|NCT05591170|Drug|Cholecalciferol 120 000 IU|single, oral administration of high dose of vitamin D
79390239|NCT00218439|Drug|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
79390240|NCT00218439|Drug|Placebo|
79390241|NCT04344730|Drug|Dexamethasone injection|Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
79390242|NCT04344730|Drug|placebo|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
79390243|NCT04344730|Procedure|conventional oxygen|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
79390244|NCT04344730|Procedure|CPAP|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
79390245|NCT04344730|Procedure|HFNO|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
79708096|NCT01602003|Drug|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
79848402|NCT00942474|Device|Facilitate nerve stimulation lead placement with the nerve access tool|
79848403|NCT03999099|Drug|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
79848404|NCT03999099|Drug|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
80016138|NCT04518280|Drug|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
80016139|NCT04518280|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
80016140|NCT04518280|Radiation|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
80016141|NCT00498836|Drug|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
80016142|NCT00498836|Drug|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
80016143|NCT02283866|Drug|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
80016144|NCT02283866|Drug|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
80016145|NCT03502187|Behavioral|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about ~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
79546314|NCT01541540|Behavioral|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
79390246|NCT04344730|Procedure|mechanical ventilation|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
79390247|NCT05716672|Drug|Lazertinib|Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
79546315|NCT01541579|Other|Cx601|120 million cells administered by intralesional injection.
79546316|NCT01541579|Other|Saline solution|24 mL saline solution by intralesional injection
79546317|NCT01541592|Other|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of ~1 tablespoon per hour so that the total infusion time will be 6 hours.
79546318|NCT01541605|Drug|methylphenidate|tablets for oral use
79708097|NCT01602003|Drug|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
79708098|NCT01602003|Drug|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
79708099|NCT01680926|Dietary Supplement|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
79708100|NCT04481529|Other|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
79390248|NCT01898559|Other|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
79546319|NCT01541605|Drug|Placebo|tablets for oral use
79546320|NCT01541618|Other|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
79708101|NCT01644461|Other|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
79708102|NCT01681043|Behavioral|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~nurse nearby~no visits after 10 p.m.~decreased alarm sound in ventilator and monitor~decreased light intensity~no unnecessary conversations around the patient~medication should be limited to max 1-2 times in this time period~no unnecessary therapeutic or diagnostic procedures in this time period~earplugs and sleep masks"
79708103|NCT01644539|Dietary Supplement|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
79708104|NCT01644539|Dietary Supplement|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
79708105|NCT01644539|Dietary Supplement|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
79708106|NCT01602081|Device|reinforce soft tissue|reinforce soft tissue
79708107|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
79708108|NCT01193920|Other|Saline solution|Subjects received two injection of saline solution.
79708109|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
79708110|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
79848405|NCT03999099|Drug|Placebo oral tablet|Placebo
79390249|NCT02977858|Other|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
79546321|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
79546322|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
79546323|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
79848406|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
79252117|NCT04768725|Behavioral|Physical-cognitive intervention|Physical-cognitive exercise [60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)].
79546324|NCT01541657|Other|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
79546325|NCT01541657|Other|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
79546326|NCT01541657|Other|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
79546327|NCT01541670|Drug|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
79708111|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
79848407|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
79848408|NCT05323695|Behavioral|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
79848409|NCT04013022|Behavioral|Exercise History|The groups will be divided based on their exercise history
80016146|NCT03502187|Device|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back & abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
79252118|NCT02462655|Other|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
79708112|NCT01193920|Other|saline solution|Subjects received one injection of saline solution.
79252119|NCT02462655|Other|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
79390250|NCT02977858|Other|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
79708113|NCT04480983|Device|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
79848410|NCT01007799|Dietary Supplement|vitamin D placebo|12 weeks of placebo
79848411|NCT01007799|Dietary Supplement|Vitamin D|12 weeks supplementation based on serum vitamin D levels
79848412|NCT01007877|Other|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
79252120|NCT02462577|Drug|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
79708114|NCT01681082|Behavioral|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
79252121|NCT02462499|Drug|Inspra (eplerenone)|
79252122|NCT02462343|Other|walk tests|
79252123|NCT02464683|Dietary Supplement|VitaminD|200 International Units (oral dose) daily of 60 days
79252124|NCT02464605|Biological|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
79390251|NCT00108303|Other|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
79390252|NCT05716594|Combination Product|Plant enteral-extended anti-reflux stents|Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts
79390253|NCT05716594|Combination Product|Plant traditional stents|Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
79390254|NCT05723302|Diagnostic Test|MIP/MEP|MIP/MEP
79708115|NCT04315480|Drug|Tocilizumab|single intravenous administration 8mg/Kg
79708116|NCT01193686|Other|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
79848413|NCT00609518|Drug|pemetrexed|500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
79848414|NCT00609518|Dietary Supplement|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
79848415|NCT00609518|Dietary Supplement|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
79848416|NCT00609518|Dietary Supplement|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
79252125|NCT02641730|Drug|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
79252126|NCT02641730|Drug|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
79252127|NCT02797171|Biological|VRC01|Administered by intravenous (IV) infusion
79252128|NCT02797171|Biological|VRC01LS|Administered by intravenous (IV) infusion
79252129|NCT03100136|Drug|[11C]PF-06809247|PET Tracer
79252130|NCT02061631|Drug|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
79252131|NCT02061631|Drug|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
79252132|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
79252133|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
79252134|NCT03100292|Other|Sleeve gastrectomy or Roux-en-Y gastric bypass|
79390255|NCT04344418|Device|Nurse-performed Focused cardiac ultrasound (FoCUS)|A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
79390256|NCT04344418|Other|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
80016147|NCT03502187|Behavioral|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
79390257|NCT00358384|Drug|Pazopanib|Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
79390258|NCT00358384|Drug|Pazopanib vehicle|Pazopanib vehicle will be given to subjects.
79390259|NCT00358384|Drug|Betamethasone valerate|Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
79390260|NCT00358384|Drug|Calcipotriol|Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
79390261|NCT05716438|Radiation|Forearm anteroposterior and lateral plain radiograph|2 view plain film of forearm after valving a short arm cast.
79252135|NCT02061709|Biological|Ragweed-SPIRE|
79252136|NCT02061709|Biological|Placebo|
79252137|NCT03100214|Other|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
79252138|NCT03100214|Other|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
79252139|NCT03098342|Procedure|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
79390262|NCT02959060|Drug|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
79390263|NCT02959060|Drug|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
79708117|NCT04480515|Other|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
79708118|NCT01681160|Other|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
79708119|NCT01681160|Other|conventional therapy|patients receive ordinary treatment for diabetic foot
79708120|NCT02886442|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
79708121|NCT02886442|Other|New adhesive strip|This is a newly developed adhesive strip
79546328|NCT01541683|Other|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
79546329|NCT01541683|Other|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
79708122|NCT01644773|Drug|Crizotinib|"Starting dose level:~Initial Treatment Plan: 130 mg/m^2 per dose~Modified Treatment Plan per Amendment 1.0: 165 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
79708123|NCT01644773|Drug|Dasatinib|"Starting dose level: 50 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
79708124|NCT01602159|Procedure|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
79708125|NCT01602159|Procedure|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
79708126|NCT01681199|Drug|Fluvastatin extended release tablet|
79708127|NCT04479345|Other|Questionnaire|Online questionnaire
79708128|NCT01681316|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
79708129|NCT01681316|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
79708130|NCT01681316|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
79708131|NCT01602276|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
79708132|NCT04528394|Radiation|Photon|Photon combined with Carbon ion in Arm 1
79708133|NCT04528394|Radiation|Proton|Proton combined with Carbon ion in Arm 2
79708134|NCT04528394|Radiation|Carbon ion|Same dose and fractionation will be used in both arms.
79708135|NCT04479462|Procedure|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
79708136|NCT04528316|Behavioral|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~Stage I: Warm-up: consists of four Pilates motions:~Breathing:~Rolling back:~Coccyx-curl:~Hundred breathing:~Stage II: Work-out: consists of twelve Pilates motions:~Single leg stretch:~Straight leg raise:~Basic bridge:~Bridging variation:~Quadruped:~Clap with seal motion~Mermaid twist:~Swimming:~Double leg stretch:~Shoulder bridge:~Swan dive:~Leg full front:~Stage III: Cool-down: consists of three Pilates motions:~Rest position:~Cat with arm/leg extension:~Breathing:"
79848417|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
79848418|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
79848419|NCT01008033|Drug|IDP-108|Topical application once a day for 48 weeks
79848420|NCT01008033|Drug|Vehicle|Topical application once a day for 48 weeks
79848421|NCT01008111|Drug|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
79848422|NCT01008111|Drug|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
79848423|NCT00886496|Biological|recombinant human mannose-binding lectin|
79848424|NCT00884858|Drug|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
79390264|NCT00109005|Drug|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
79848425|NCT05272293|Biological|NK cell infusions|Three doses of expanded haploidentical NK cells (30-100 x 10^6 cells /kg).
79390265|NCT05716360|Diagnostic Test|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
79390266|NCT05716360|Procedure|Aneurysm Treatment with Flow-Diversion Therapy|Aneurysm Treatment with Flow-Diversion Therapy
79390267|NCT05716360|Procedure|Aneurysm Treatment with Metalic Bare Stent|Aneurysm Treatment with Metalic Bare Stent
79390268|NCT00357916|Drug|PEP005 Topical Gel (0.01% concentration)|
79390269|NCT02978014|Device|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
79708137|NCT04528316|Behavioral|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
79848426|NCT00891332|Drug|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
79708138|NCT04528316|Behavioral|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
79708139|NCT01644812|Behavioral|Aerobic exercise|
79848427|NCT02541344|Device|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
79848428|NCT02541344|Device|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
79848429|NCT02541344|Device|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
79848430|NCT00609362|Drug|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
79848431|NCT00609362|Drug|Placebo pill|One encapsulated placebo pill a day for 14 weeks
79848432|NCT02541266|Other|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
79848433|NCT05278832|Drug|QLS31905|QLS31905 injection
79848434|NCT00886574|Drug|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
79848435|NCT00886574|Drug|Aspirin|100 mg once a day
79252140|NCT03098342|Drug|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
79708140|NCT01644812|Behavioral|Stretching|
79252141|NCT02797951|Drug|Galcanezumab|Administered SC
79252142|NCT05070962|Other|clinical population|or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
79252143|NCT05059496|Other|Hamstring stretching with Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
79708141|NCT01681355|Other|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
79708142|NCT04477902|Other|none - observational|online survey
79708143|NCT01602588|Drug|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
79708144|NCT01602588|Radiation|Radiotherapy|Short Course radiotherapy
79708145|NCT01681394|Dietary Supplement|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
79848436|NCT00886652|Other|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
79848437|NCT00891566|Procedure|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
79708146|NCT01681394|Dietary Supplement|Chocolate cream|
79708147|NCT04477824|Diagnostic Test|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
79708148|NCT01681550|Drug|Incretin-based therapy|
79708149|NCT01645085|Drug|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
79708150|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
79708151|NCT01645085|Drug|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
79708152|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
79708153|NCT01602627|Drug|Hsp90 inhibitor AUY922|Given IV
79252144|NCT05059496|Other|Hamstring stretching with out Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
79252145|NCT05059730|Other|Zero Degrees Cold Environment|Participants will be exposed to zero degrees celsius environment.
79252146|NCT05059730|Other|Eight Degrees Cold Environment|Participants will be exposed to eight degrees celsius environment.
79252147|NCT05059730|Other|Ten Degrees Cold Environment|Participants will be exposed to Ten degrees celsius environment.
79252148|NCT05059730|Other|40 degrees Hot Environment|Participants will be exposed to 40 degrees celsius hot environment.
79252149|NCT02061865|Drug|REGN2176-3|
79252150|NCT05059418|Drug|Clonazepam 0.5 MG|Topical treatment of oral mucosa with lozenge pill
79252151|NCT05059418|Drug|Capsaicin Topical|Topical treatment of oral mucosa with capsaicin rinse
79708154|NCT01602627|Other|pharmacological study|Correlative studies
79708155|NCT01602627|Other|laboratory biomarker analysis|Correlative studies
79708156|NCT01602783|Other|11C Acetate Imaging|Single scan
79708157|NCT01645124|Drug|Hydroxyurea|
79708158|NCT01645124|Procedure|Phlebotomy|
79708159|NCT01602861|Drug|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
79708160|NCT01602861|Drug|placebo|
79708161|NCT01681667|Drug|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
79848438|NCT00885014|Behavioral|CBT|Telephone cognitive-behavioral therapy
79848439|NCT00885014|Behavioral|EAP|Employees Assistance Program
79848440|NCT00611858|Drug|Cetuximab|
79848441|NCT00611858|Drug|5-Fluorouracil|
79848442|NCT00611858|Radiation|Radiation|
79848443|NCT00137449|Drug|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
79708162|NCT04474977|Other|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
79708163|NCT01645163|Behavioral|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
79708164|NCT01600365|Drug|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
79708165|NCT01600365|Drug|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
79390270|NCT05716126|Drug|[14C]Iruplinalkib (WX-0593)|Volunteer will receive a single oral dose of 120 mg [14C]Iruplinalkib (WX-0593) as a solution on Day 1
79390271|NCT04745494|Other|OT administration|OT nasal administration
79708166|NCT01602900|Drug|GSK356278|Investigational Medicinal Product
79708167|NCT01602900|Drug|Rolipram|Challenge Agent
79848444|NCT00886730|Behavioral|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
80016148|NCT03058705|Drug|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
80016149|NCT03058705|Device|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
80016150|NCT04517110|Drug|Pregabalin 300 mg|Pregabalin 300 mg, capsule
80016151|NCT04517110|Drug|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
80016152|NCT04517110|Drug|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
79252152|NCT05059418|Other|Placebo|Mouth rinse with no capsaicin
80016153|NCT04517110|Drug|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
79252153|NCT02062333|Drug|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
79252154|NCT02062333|Drug|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
79252155|NCT02062411|Behavioral|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
79252156|NCT02062411|Behavioral|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
79252157|NCT02063425|Drug|Fluoxetine|1 pill of 20mg / day, during 3 months
79390272|NCT04745494|Other|Placebo administration|Placebo nasal administration
79390273|NCT05552950|Biological|BioBlock® antiviral nasal spray|SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
79546330|NCT01541774|Device|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
80016154|NCT04517110|Other|Usual Care|Usual Care
80016155|NCT00498212|Biological|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
80016156|NCT00498212|Biological|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
80016157|NCT02798263|Other|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
79252158|NCT02063425|Drug|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
79252159|NCT05071118|Drug|Pregabalin 150mg|pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
79252160|NCT05071118|Drug|Placebo|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
79390274|NCT00359866|Radiation|IMRT with tomotherapy|
79390275|NCT05547100|Drug|LYBALVI|5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
79390276|NCT00109473|Drug|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
79546331|NCT01541852|Drug|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
79546332|NCT01541852|Drug|Placebo|One tablet twice daily
79546333|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
79708168|NCT01645202|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
79708169|NCT01645241|Drug|gonadotropins plus GnRH antagonists|
79708170|NCT01645241|Drug|ganirelix|
79708171|NCT01602939|Drug|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
79708172|NCT04528745|Diagnostic Test|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
79708173|NCT04528784|Device|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
79252161|NCT00701805|Drug|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
79252162|NCT02063503|Other|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
79252163|NCT05059106|Biological|Half dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
80016158|NCT02798263|Other|Acupuncture|30 minutes of classical acupuncture using predefined points.
79252164|NCT05059106|Biological|Standard dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
79252165|NCT05059184|Other|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
79252166|NCT05070416|Device|Lithium disilicate crowns|The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
80016159|NCT02798263|Other|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
79546334|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
79546335|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
80016160|NCT02280980|Other|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
79252167|NCT04412408|Drug|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
79252168|NCT05070182|Diagnostic Test|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
79546336|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
79546337|NCT01541904|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
79546338|NCT01541085|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
79390277|NCT00109473|Drug|cortecosteroid|As prescribed by the referring gastroenterologist
79390278|NCT04344106|Procedure|Prone positioning|The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.
79546339|NCT01541085|Drug|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
79390280|NCT00040443|Drug|CX516|
79390281|NCT00040443|Drug|Placebo|
79390282|NCT05321992|Behavioral|eCHEC program|The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
79546340|NCT01541943|Drug|Atorvastatin|Once daily, administered orally, 8 week
79546341|NCT01541943|Drug|Losartan|Once daily, administered orally, 8 week
79546342|NCT01541943|Drug|Placebo|Once daily, administered orally, 8 week
80016161|NCT04882553|Procedure|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
80016162|NCT04882553|Procedure|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
80016163|NCT04882553|Diagnostic Test|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
79546343|NCT01541943|Drug|HL-040XC|Once daily, administered orally, 8 week
79546344|NCT01541956|Drug|Metformin|500 mg twice daily
79546345|NCT01541956|Drug|vildagliptin|Vildagliptin 50 mg twice daily
79546346|NCT01542008|Behavioral|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
79708174|NCT01600404|Drug|antimuscarinic treatment|
79708175|NCT01600443|Device|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
79708176|NCT01600443|Device|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
79708177|NCT01600443|Device|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
80016164|NCT02281058|Drug|Abatacept|self-injected subcutaneous biologic medication
80016165|NCT05760911|Behavioral|Outdoor activities motivation with smartwatches|Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
80016166|NCT01568723|Genetic|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
79252169|NCT05070182|Diagnostic Test|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
79708178|NCT01681823|Dietary Supplement|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
79708179|NCT01603017|Device|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
79708180|NCT01603017|Device|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
79708181|NCT01681862|Behavioral|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
79708182|NCT04474782|Diagnostic Test|There is not an intervention|There is not an intervention
79708183|NCT01681901|Procedure|ultrasound imaging|Undergo ultrasound
79546347|NCT01542008|Behavioral|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
79546348|NCT01542047|Drug|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
79708184|NCT01681940|Drug|Lamazym|ERT, i.v. infusions weekly
79708185|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
79708186|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
79708187|NCT01603173|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
79708188|NCT01603173|Drug|Quetiapine Fumarate|25 mg tablet once a day
79708189|NCT01645358|Device|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
79708190|NCT01645358|Device|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
79708191|NCT01603212|Drug|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
79708192|NCT01603212|Drug|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
79708193|NCT01603212|Drug|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
79708194|NCT01645436|Other|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
79708195|NCT01645748|Drug|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
79390283|NCT05136430|Behavioral|Self-Regulation strategies + large changes (SR)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on teaching self-regulation and efforts to produce a 10 lb weight loss to buffer against anticipated post-cessation weight gain. Participants will be taught the core self-regulation skills for controlling their weight. In order to produce an initial weight loss buffer, they will be instructed to self-monitor their intake, given a daily calorie goal, and taught strategies for reducing caloric intake. Structured physical activity, such as brisk walking will also be prescribed and self-monitored. During smoking cessation treatment (weeks 9-16), participants will be asked to continue to use self-regulation skills for monitoring their weight and to use a color zone system (red, yellow, green) to determine what course of action to follow based on whether changes in weight have occurred.
79546349|NCT01542047|Drug|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
79546350|NCT01542060|Drug|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
79546351|NCT01542073|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
79546352|NCT01542086|Procedure|Myocardial SPECT|
79546353|NCT01542086|Procedure|64-channel coronary CT angiography (CCTA)|
79708196|NCT01645748|Drug|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
80016167|NCT02784262|Drug|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
80016168|NCT05205317|Drug|Metformin Hydrochloride Sustained-release Tablets|drug
79546354|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
79252170|NCT04672863|Behavioral|Dietary Intervention|Modified Mediterranean diet approved by the Nutrition Team at the Transplant Center and it emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt (2-2.4g/day), moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats. The modifications to the traditional Mediterranean diet are: no alcohol consumption and fewer added fats. In addition, close scheduled followup on diet and progress with study team.
79252171|NCT02731508|Device|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
79252172|NCT02705924|Behavioral|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:~Latest knowledge in oncogenetics~Recommendations and morbidity of prophylactic breast surgeries and annexectomy~Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~How to perform the periodic breast screening~Assisted medical procreation and embryo selection~Importance of nutrition and physical activity as risk modulator~Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
80016169|NCT05205317|Procedure|Vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
79252173|NCT03270189|Device|prism glasses|orthoptic treatment by wearing prisms when writing
79252174|NCT05069870|Drug|SKLB1028|SKLB1028, capsule, oral
79252175|NCT05069870|Drug|Itraconazole|Itraconazole, capsule, oral
79252176|NCT05069870|Drug|Gemfibrozil|Gemfibrozil, capsule, oral
79252177|NCT05069870|Drug|Rifampicin|Rifampicin, capsule, oral
79252178|NCT02715765|Device|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
79390284|NCT05136430|Behavioral|Healthy Lifestyle Education (LE)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on living a healthy lifestyle. Information provided will include education on why weight gain happens while quitting smoking, principles of healthy eating (e.g., simple versus complex carbohydrates), physical activity guidelines, and other topics related to living a healthy lifestyle. Participants can choose to use the healthy lifestyle information and education provided however they would like. Participants will not be asked to use self-regulation strategies during either part of the 16-week program.
79390285|NCT05136430|Other|Smoking Cessation Treatment|The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
79390286|NCT00044655|Drug|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
79390287|NCT00044655|Drug|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
79390288|NCT00044655|Drug|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
79390289|NCT00044655|Drug|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
79390290|NCT00044655|Drug|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
79546355|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
79390291|NCT05130892|Drug|Colchicine|1 tablet (0.5mg) / time, once a day
79390292|NCT05130892|Drug|Tranilast|1 capsule (0.1g) / time, 3 times a day
79390293|NCT05130892|Drug|Oridonin|2 tablets (0.5g) / time, 3 times a day;
79390294|NCT02958904|Other|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
79546356|NCT01542112|Other|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
79546357|NCT01542112|Other|No treatment|Patients in this arm receive the usual routine in the department.
79546358|NCT01542138|Drug|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
79546359|NCT01542138|Drug|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
79546360|NCT01542138|Drug|Placebo|Humectant placebo cream
79708197|NCT01645748|Drug|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
79708198|NCT02484924|Drug|Ticagrelor|No intervention- purely observational
79848445|NCT00886730|Behavioral|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
79848446|NCT00886730|Behavioral|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
79848447|NCT00886808|Drug|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
80016170|NCT04087330|Other|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
80016171|NCT04087330|Other|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
79546361|NCT01542151|Other|Time of labor induction|Assigned time of labor induction - morning or evening
79848448|NCT00891644|Other|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
80016172|NCT04471298|Drug|Qishenyiqi dripping pills, 6 bags|28 consecutive days
80016173|NCT04471298|Drug|Qishenyiqi dripping pills, 9 bags|28 consecutive days
80016174|NCT04471298|Drug|Qishenyiqi dripping pills, 12 bags|28 consecutive days
80016175|NCT04471298|Drug|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
80016176|NCT04471298|Drug|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
80016177|NCT04471298|Drug|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
79546362|NCT01542190|Drug|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
79546363|NCT01542216|Behavioral|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
79708199|NCT01645826|Drug|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
79708200|NCT01645826|Drug|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
79708201|NCT01645865|Behavioral|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
79708202|NCT01645865|Behavioral|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
79708203|NCT01645904|Behavioral|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
79546364|NCT01542216|Behavioral|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
79546365|NCT01542242|Drug|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
79546366|NCT01542268|Drug|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
79546367|NCT01542268|Drug|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
79252179|NCT02715765|Device|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
79848449|NCT00891644|Other|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
79252180|NCT02715765|Device|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
79390295|NCT02093793|Device|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
79390296|NCT05130346|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
79390297|NCT02093949|Procedure|Routine substrate ablation without pulmonary vein Isolation|
79390298|NCT02093949|Procedure|Routine conventional ablation with pulmonary vein Isolation|
79390299|NCT00223665|Drug|Flutamide|Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
79546368|NCT01542281|Dietary Supplement|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
79708204|NCT01645904|Behavioral|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
79708205|NCT01645904|Behavioral|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
79390300|NCT00223665|Drug|Leuprolide Acetate|Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
79708206|NCT01645904|Behavioral|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
79390301|NCT05311540|Drug|Zinc Sulfate|
79390302|NCT05122390|Other|Contraction Coper|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.
79390303|NCT05122390|Other|Contraction Coper Plus|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind. Clinical guidance from a midwife during two different occasions is added to the group.
79390304|NCT00223821|Drug|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
79390305|NCT00223821|Behavioral|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
79546369|NCT01542281|Other|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
79546370|NCT01542294|Drug|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
79546371|NCT01542294|Drug|Oxaliplatin|130mg/m2 d1 repeated every 21 days
79546372|NCT01542320|Dietary Supplement|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
79546373|NCT01542320|Other|Placebo|Solution without active Lactobacillus reuteri
79546374|NCT01542333|Genetic|gene expression analysis|
79546375|NCT01542333|Genetic|proteomic profiling|
79546376|NCT01542333|Genetic|reverse transcriptase-polymerase chain reaction|
79546377|NCT01542333|Genetic|western blotting|
79546378|NCT01542333|Other|immunohistochemistry staining method|
79546379|NCT01542333|Other|laboratory biomarker analysis|
79708207|NCT01645943|Procedure|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
79708208|NCT01600521|Drug|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
79546380|NCT01542333|Procedure|spectroscopy|
79546381|NCT01542346|Procedure|subcutaneous adaption|
79546382|NCT01542359|Other|Yogic practice|breathing, meditation, physical postures
79546383|NCT01542359|Other|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
79848450|NCT00891644|Other|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
79708209|NCT01646060|Device|CM-1500|Blood Volume Monitor
79546384|NCT01542385|Procedure|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
79708210|NCT01607034|Drug|Dexpramipexole|150 mg single dose
79848451|NCT00886886|Drug|MDMA|125 mg, single dose
79546385|NCT01542424|Drug|biphasic insulin aspart 30|Prescribed at the discretion of the physician
79848452|NCT00886886|Drug|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
80016178|NCT05205239|Diagnostic Test|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
80016179|NCT00691964|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
80016180|NCT00691964|Biological|etanercept|SQ injection 50 mg BIW
79390306|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds [light dose of 25 J/cm2]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
80016181|NCT00691964|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
80016182|NCT03474887|Other|Physical Consultation|Regular physician consultation at the primary care clinic.
79390307|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
79390308|NCT00359164|Drug|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
79390309|NCT00359242|Behavioral|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
79546386|NCT01542424|Drug|insulin detemir|Prescribed at the discretion of the physician
80016183|NCT03474887|Other|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
80016184|NCT05761457|Other|Cryopreserved autologous platelet transfusion|Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20*10E9/L or severe bleeding occurred.
80016185|NCT04522180|Drug|IONIS-GHR-LRx|IONIS-GHR-LRx will be administered by SC injection.
79546387|NCT01542450|Drug|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
79546388|NCT01542450|Drug|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
79546389|NCT01542463|Drug|insulin detemir|Prescribed at the discretion of the physician
79546390|NCT01542476|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
79546391|NCT01542489|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
79546392|NCT01542489|Drug|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
79546393|NCT01542489|Drug|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
79546394|NCT01542515|Procedure|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
79546395|NCT01542554|Other|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
79848453|NCT00886886|Drug|Placebo|capsules identical to MDMA or Reboxetine
79708211|NCT01646099|Behavioral|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
79708212|NCT01603251|Drug|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
79708213|NCT01603251|Drug|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
79708214|NCT01603251|Drug|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
79848454|NCT04036760|Behavioral|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
79848455|NCT04036916|Other|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
79848456|NCT00891722|Other|biologic sample preservation procedure|
79848457|NCT00891722|Other|laboratory biomarker analysis|
79848458|NCT00891722|Other|questionnaire administration|
79848459|NCT00891800|Device|Brachytherapy|SIR-Sphere contains radiation of Y-90.
79546396|NCT01542554|Other|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
79546397|NCT01542567|Drug|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
79546398|NCT01542567|Drug|Placebo|Placebo suppositories
79546399|NCT01542593|Device|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
79546400|NCT01542606|Device|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
79848460|NCT00891800|Device|SIR-Sphere|Brachytherapy Radiation seeds
79848461|NCT00886964|Biological|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
79546401|NCT01542619|Biological|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
79708215|NCT01646294|Drug|YM178 modified release (OCAS)|oral
79708216|NCT01646294|Drug|YM178 immediate release (IR)|oral
79848462|NCT00886964|Biological|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
79848463|NCT00887042|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, & -6)
79848464|NCT00892112|Drug|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
79848465|NCT00892112|Drug|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
79848466|NCT00887120|Drug|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"BW 6-7.9 kg: 1.5 mL oral q 12 hr~BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~BW > 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
79848467|NCT00887120|Drug|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"BW 6-7.9 kg: 1.0 mL oral q 12 hr~BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~BW > 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
79848468|NCT00892190|Drug|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
79848469|NCT00892190|Drug|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
79848470|NCT00887276|Drug|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~20 ml physiologic saline solution (placebo) (over 30 min)~20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2 capsules Placebo~2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
80016186|NCT02281214|Other|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
79848471|NCT00887276|Drug|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
79848472|NCT00528879|Drug|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
79848473|NCT00528879|Drug|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
79848474|NCT00528879|Drug|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
79848475|NCT00608894|Drug|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
79848476|NCT00608894|Drug|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
79848477|NCT00892268|Procedure|acupuncture therapy|Undergo acupuncture
79848478|NCT00892268|Procedure|pain therapy|Receive standard care
79848479|NCT00892346|Procedure|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
79848480|NCT00892424|Drug|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
79848481|NCT02541032|Procedure|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
79848482|NCT02541032|Procedure|Standard dental treatment|Supragingival mechanical scaling and polishing.
79252181|NCT05315037|Other|Resistance Training|"Bench press: Exercise performed with participant lying supine with hands in prone position. Barbell is lowered vertically from fully extended elbow position to sternum, then returned to starting position. Barbell will be weighted with plates dependent on their strength and workout demands.~Deadlift: Consists of gripping bar while in a squat position. Extension of ankles, knees, and hips while gripping the bar brings the weight up until joints are locked completing the exercise concentric portion. The eccentric lowering of the weight follows and consists of flexion of joints.~Seated overhead press machine: This multi-joint exercise, deltoid and trapezius are the prime movers and triceps are secondary movers, with hands on the grips and a position allowing back and buttocks to be completely supported. They push against a load vertically until glenohumeral joint fully extends, then load is returned to starting position and process continues until all repetitions desired are achieved"
79546402|NCT01542619|Biological|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
79546403|NCT01542671|Behavioral|Intervention|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months~Structured eating plan~Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~Monthly Motivational phone calls with Lifestyle Counselor for the first year~4 informational DVDs over the two year period~Feedback on submitted food and exercise journals"
79252182|NCT04626843|Other|Intermittent fast|16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
79546404|NCT01542671|Behavioral|Control|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months~Structured eating plan~5 informational NIDDK mailings over the two year period"
79252183|NCT04605939|Device|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
79252184|NCT04605939|Device|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
79546405|NCT01542697|Drug|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
79546406|NCT01542710|Drug|Ganfort|Bimatoprost/Timolol fixed combination
79546407|NCT01542710|Drug|Duotrav|Fixed combination of Travoprost and Timolol
79546408|NCT01542723|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
79546409|NCT01542762|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
79546410|NCT01542775|Behavioral|Aerobic Exercise Group|12 weeks Aerobic exercise
79546411|NCT01542775|Behavioral|Control Group|maintaining usual activities
79710221|NCT00600210|Drug|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
79848483|NCT02541032|Drug|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
79848484|NCT00557856|Drug|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
79848485|NCT00892502|Drug|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
79848486|NCT00892502|Drug|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
79848487|NCT01008189|Behavioral|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
79848488|NCT01008189|Behavioral|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
79848489|NCT00885404|Drug|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
79848490|NCT00892580|Drug|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
79848491|NCT00191113|Drug|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
79252185|NCT04619121|Device|NIR-tPBM|The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
79252186|NCT04619121|Device|Sham device|The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
79848492|NCT00191113|Drug|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
79848493|NCT00191113|Drug|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
79848494|NCT00608582|Device|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
79252187|NCT05291715|Device|Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)|Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)
79390310|NCT00359242|Behavioral|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
79390311|NCT00224289|Drug|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
79390312|NCT01897623|Other|ultrasound of aorta|
79390313|NCT00045435|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
79252188|NCT05275491|Diagnostic Test|Calcium|Free calcium serum levels
79252189|NCT05275491|Diagnostic Test|Fibroblast growth factor 23|Serum level
79252190|NCT05275491|Diagnostic Test|Sclerostin|Serum level
79252191|NCT05275491|Diagnostic Test|parathyroid hormone|serum level
79390314|NCT00045435|Drug|fludarabine phosphate|Given IV
79390315|NCT00045435|Radiation|total-body irradiation|Undergo TBI
79390316|NCT00045435|Drug|cyclosporine|Given PO
79390317|NCT00045435|Drug|mycophenolate mofetil|Given PO
79390318|NCT00045435|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
79390319|NCT05529238|Behavioral|biofeedback training|participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
79390320|NCT01897155|Other|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
79546412|NCT01542801|Drug|Norfloxacin|Norfloxacin 400 mg per day
79546413|NCT01542801|Drug|ciprofloxacin|Ciprofloxacin 750 mg per week
79546414|NCT01542814|Device|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
79546415|NCT01542814|Device|2D FFDM|Standard of care screening mammogram.
79546416|NCT01542827|Other|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
79708217|NCT01603329|Other|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
79708218|NCT01193608|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
79708219|NCT01193608|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
79708220|NCT01193608|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
79708221|NCT01193608|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
79708222|NCT01193608|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
79708223|NCT01193608|Other|Placebo|Placebo, IV
79708224|NCT01646333|Behavioral|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
79708225|NCT01646333|Behavioral|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
79708226|NCT01603446|Drug|L-Arginine|NOW® L-Arginine powder
79848495|NCT03965052|Drug|PRO 179|"Generic name: Travoprost~Distinctive denomination: Bristrio® (PRO-179)~Active principles: Travoprost 0.004%.~Pharmaceutical form: Ophthalmic solution~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Sophia Laboratories, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
79848496|NCT03965052|Drug|Travatan 0.004 % Ophthalmic Solution|"Generic name: Travoprost~Distinctive denomination: Travatan®~Active ingredients: Travoprost 0.004%~Pharmaceutical form: Ophthalmic solution.~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Alcon Laboratories Inc.~Description of the solution: transparent solution, free of visible particles.~Consult information to prescribe."
80016187|NCT04520854|Other|Telehealth Protocol|"The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate."
80016188|NCT04520854|Other|Usual Care|The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
79708227|NCT01607151|Other|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
79848497|NCT05265117|Procedure|HIPEC|HIPEC is given after primary or interval debulking surgery.
79848498|NCT03964974|Behavioral|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
80016189|NCT05756075|Behavioral|Aerobic exercise training|Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
80016190|NCT02281292|Biological|LKA651 ophthalmic solution|
80016191|NCT02281292|Biological|Ranibizumab ophthalmic solution|
79708228|NCT01607151|Other|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
79708229|NCT01646372|Other|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
79708230|NCT01646372|Other|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
79708231|NCT01603563|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
80016192|NCT02281292|Biological|Sham injection|Mock injection administered as an empty hub without needle
80016193|NCT04044742|Drug|Resiniferatoxin|Receiving Resiniferatoxin injection
80016194|NCT04044742|Drug|Placebo|Receiving Placebo injection
80016195|NCT00690716|Drug|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
80016196|NCT00690716|Drug|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
80016197|NCT03942484|Device|rPMS device|Pelvic floor muscle contractions will be induced by the device.
79708232|NCT01603563|Behavioral|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
79708233|NCT01646450|Drug|Icotinib|Icotinib: 125mg, oral administration, three times per day.
79708234|NCT01607229|Other|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
79708235|NCT01646489|Drug|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
79708236|NCT01646489|Drug|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
79708237|NCT01603719|Dietary Supplement|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
79708238|NCT01646528|Procedure|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
79708239|NCT01603758|Drug|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
79708240|NCT02279264|Device|RightSpot Infant pH Indicator|pH indicator
79708241|NCT01603797|Behavioral|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
80016198|NCT05205083|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
79252192|NCT02976753|Drug|efmoroctocog alfa|extended half-life factor VIII product
79390321|NCT01897155|Other|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
79708242|NCT02279303|Behavioral|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
79708243|NCT02279303|Behavioral|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
79708244|NCT01177228|Drug|Vedolizumab|Vedolizumab for intravenous infusion
79708245|NCT01177228|Drug|Placebo|Placebo intravenous infusion
79708246|NCT01607268|Procedure|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
79708247|NCT02279342|Drug|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
79708248|NCT01193530|Other|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
79708249|NCT01193530|Other|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
79708250|NCT01193530|Behavioral|Questionnaires|Weekly
79708251|NCT01193530|Behavioral|Study Diaries|Daily logs
80016199|NCT02998671|Biological|CJM112|
80016200|NCT02998671|Other|Placebo|
79252193|NCT02976753|Drug|Factor VIII|conventional factor VIII product
79252194|NCT04603053|Behavioral|mHealth app|Participants will receive access to CBot-A app for 12 weeks.
79252195|NCT04490421|Drug|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
79252196|NCT02462031|Drug|KD101|200mg, 400mg, 800mg, 1400mg
79252197|NCT02462031|Drug|placebo|200mg, 400mg, 800mg
79252198|NCT04542291|Drug|Dapagliflozin|Dapagliflozin will be provided for this trial
79252199|NCT04542291|Device|BIOSENSE meters|-Being used in this trial to evaluate utility for assessing breath ketones
79390322|NCT00047619|Procedure|Pulsatile Lavage|pulsatile lavage to wound bed
79390323|NCT00047619|Other|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
79546417|NCT01542827|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
79546418|NCT01542866|Other|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
79546419|NCT01542892|Other|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
79546420|NCT01542892|Dietary Supplement|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
79546421|NCT01542905|Dietary Supplement|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
79546422|NCT01542905|Other|Placebo|Placebo Capsule (1g/day) for 8 Weeks
79708252|NCT01193530|Device|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
79708253|NCT01193530|Device|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
79708254|NCT01607307|Drug|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
79708255|NCT01607307|Drug|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
79708256|NCT02279381|Drug|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
79708257|NCT02279381|Other|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
79708258|NCT02279381|Other|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
79708259|NCT01607385|Drug|GSK2330672|BID, repeat doses
79252200|NCT02462109|Drug|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
79252201|NCT02464527|Behavioral|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
79252202|NCT02464527|Other|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
79252203|NCT02466165|Behavioral|Physical exercise|
79252204|NCT02795767|Drug|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
79252205|NCT02597439|Drug|Omega-3 fatty acids|
79252206|NCT02597439|Other|Placebo|
79708260|NCT01607385|Drug|Placebo|BID, repeat doses
79708261|NCT01607385|Drug|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
79252207|NCT02576925|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
79252208|NCT03560401|Device|Knight-Taylor [chairback] brace|Knight-Taylor [chairback] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
79708262|NCT01646567|Drug|SHP-141C|Topical Cream
79708263|NCT01646567|Drug|Placebo to SHP-141C|Placebo Topical Cream
79708264|NCT01646567|Drug|Betamethasone Valerate|Topical cream, 0.02%
79708265|NCT01646567|Drug|Calcipotriol|Topical cream, 0.005%
79708266|NCT01607424|Behavioral|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
79708267|NCT01646606|Procedure|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
79708268|NCT01646606|Procedure|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
79708269|NCT01681979|Drug|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
79708270|NCT01646684|Drug|SOM230|
79708271|NCT01607580|Drug|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
79252209|NCT04476849|Drug|fezolinetant|Oral
79252210|NCT04397211|Procedure|Angiography-derived FFR|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm~*Criteria for revascularization: Angiography-derived FFR ≤ 0.80"
79708272|NCT01646723|Behavioral|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
79708273|NCT01607619|Dietary Supplement|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
79708274|NCT01646801|Device|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
79708275|NCT01647152|Drug|Ustekinumab|
79708276|NCT01682018|Device|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
79708277|NCT01607697|Behavioral|Mindfulness Training|Mindfulness Training
79708278|NCT01682057|Device|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
79708279|NCT01682057|Device|ROX Anastomotic Coupler System (ACS)|
79708280|NCT01604187|Drug|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
79708281|NCT01604187|Drug|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
79708282|NCT01682096|Radiation|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
79390324|NCT05102188|Combination Product|Assessment of sleep and related factors|Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
79848499|NCT03964974|Behavioral|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
79848500|NCT00892658|Drug|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
79848501|NCT00892736|Other|Laboratory Biomarker Analysis|Correlative studies
79848502|NCT00892736|Other|Pharmacological Study|Correlative studies
79848503|NCT00892736|Drug|Veliparib|Given PO
79848504|NCT03966235|Drug|Melatonin 3 mg|Melatonin was taken daily for 6 months.
80016201|NCT00688766|Drug|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
80016202|NCT00688766|Drug|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
79252211|NCT04397211|Procedure|IVUS|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3< MLA ≤ 4mm2 & Plaque burden > 70%"
79390325|NCT05292820|Other|Validated and non-validated questionnaire for exploration of sexuality and satisfaction after surgical procedure|Validated questionnaire : Female Sexual Function Index (FSFI), Female Genital Self-Imaging Scale (FGSIS), Body Image Scale (BIS), Non-validated questionnaire exploring post-surgery satisfaction, self-esteem scale, sexology.
79708283|NCT01682096|Procedure|Exercise stress echocardiography|Limited by symptoms
79710222|NCT00600210|Radiation|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
79710223|NCT00600366|Drug|biphasic insulin aspart|
79710224|NCT00600444|Procedure|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
79710225|NCT00600444|Procedure|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
79252212|NCT03443635|Behavioral|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
79252213|NCT02062021|Other|No intervention|
79252214|NCT04490265|Behavioral|Problem-solving treatment|included in arm descriptions
79390326|NCT00111657|Biological|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
79252215|NCT04490265|Behavioral|Supportive Psychotherapy|included in arm descriptions
79546423|NCT01542918|Drug|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
79546424|NCT01542918|Drug|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
79546425|NCT01542931|Drug|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
79390327|NCT05292586|Drug|Beclomethasone Dipropionate/Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF 200/6 µg
79390328|NCT05292586|Drug|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP 100 µg
79546426|NCT01542944|Drug|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
79546427|NCT01542970|Dietary Supplement|Placebo|Olive oil
79390329|NCT02097303|Drug|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
79390330|NCT00703326|Biological|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
79390331|NCT00703326|Drug|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
79390332|NCT00703326|Other|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
79390333|NCT02097537|Drug|Methacholine Chloride (SK-1211)|
79546428|NCT01542970|Dietary Supplement|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
79546429|NCT01542970|Dietary Supplement|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
79546430|NCT01542970|Dietary Supplement|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
79708284|NCT01607736|Behavioral|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
79708285|NCT01682174|Other|Control Drink|
79708286|NCT01682174|Other|Experimental Drink|
79710226|NCT04326114|Device|Inspiratory training device|Inspiratory training by a Power-breath device
79710227|NCT04326114|Device|Expiratory training device|Expiratory training a Winner-flow device
80016203|NCT00688766|Other|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
79390334|NCT02097849|Drug|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
79390335|NCT02097849|Biological|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
79252216|NCT02063581|Drug|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
79252217|NCT02063581|Drug|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
79252218|NCT02063815|Procedure|Fissure sealant application|
79390336|NCT02097849|Biological|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
79390337|NCT02097849|Biological|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
79390338|NCT02097849|Drug|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
79252219|NCT02056899|Drug|Gabapentin|
79252220|NCT02462265|Drug|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) & Oshadi R (180mg TID) will be administrated;
79252221|NCT02462265|Drug|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
79252222|NCT02461953|Device|hemoperfusion apparatus|
79252223|NCT02461953|Device|low flux dialyzer|
79546431|NCT01542983|Behavioral|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
79708287|NCT01647191|Behavioral|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
79708288|NCT01647191|Behavioral|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
79708289|NCT01604304|Procedure|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
79708290|NCT01604304|Procedure|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
79708291|NCT01682291|Behavioral|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
79708292|NCT01682291|Dietary Supplement|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
79708293|NCT01607931|Behavioral|Exercise|1 hour of cycling at 50% of maximum power output
79708294|NCT01604382|Drug|General Anesthesia|General Anesthesia as described above
79708295|NCT01604382|Drug|Neuraxial anesthesia|Neuraxial anesthesia as described above
79708296|NCT01604421|Procedure|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
79708297|NCT01604421|Procedure|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
79708298|NCT01647269|Procedure|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
79708299|NCT01682369|Biological|TIV (Aggripal)|
79708300|NCT01682369|Biological|ATIV (Fluad)|
79252224|NCT02461953|Device|high flux dialyzer|
79252225|NCT02461797|Other|healthy controls|biopsy of nasal mucosa for healthy controls
79252226|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
79252227|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
79546432|NCT01542983|Behavioral|treatment as usual|Standard treatment for fatigue and insomnia
79546433|NCT01543009|Other|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
79546434|NCT01543022|Device|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
79708301|NCT01604460|Procedure|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
79848505|NCT03966235|Drug|Placebo|Placebo tablet was taken daily for 6 months.
80016204|NCT03390725|Behavioral|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
80016205|NCT03723772|Drug|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
80016206|NCT03723772|Drug|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
80016207|NCT00495014|Drug|GSK376501|
79252228|NCT02464215|Procedure|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
79252229|NCT02464215|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
79252230|NCT02461875|Drug|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
79390339|NCT00358540|Drug|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
79390340|NCT04752423|Other|Pre operative assessment|"Anxiety assessment : Numeric rating scale (patient and caregiver), APAIS scale (patient), Covi Scale (Caregiver)~Verbalization : anesthesia-related concerns (expressed by patient and considered by caregiver)"
79546435|NCT01543022|Procedure|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
79546436|NCT01543035|Drug|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
79848506|NCT00892814|Radiation|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
79848507|NCT00892814|Radiation|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
79252231|NCT02461875|Drug|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
79252232|NCT02461719|Drug|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
79252233|NCT02461719|Drug|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
79252234|NCT04489953|Other|Viral Load|For the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time
79708302|NCT01604460|Procedure|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
79708303|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
79708304|NCT01682408|Drug|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
79708305|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
79708306|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
79708307|NCT01682408|Drug|Ranitidine|150 mg ranitidine
79708308|NCT01607970|Drug|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
79708309|NCT01608009|Drug|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
79708310|NCT01647347|Drug|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
79708311|NCT01647347|Other|Water|
79848508|NCT03966469|Other|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
79848509|NCT03966469|Other|Patient Present Only|Patient presents to their preoperative appointment without a support person.
79848510|NCT01077661|Drug|Nebivolol|patients administrated Nebivolol according to the prescribing information
79546437|NCT01543048|Other|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
79708312|NCT01604499|Behavioral|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
79708313|NCT01604499|Behavioral|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
79708314|NCT01682447|Other|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
79708315|NCT01604577|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
79848511|NCT00606320|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
79848512|NCT03966079|Drug|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
80016208|NCT00495014|Drug|Placebo|
80016209|NCT05204771|Other|Ultrasound exam|Ultrasound exam
79252235|NCT05174247|Other|FFRct analysis|Software analysis of Cardiac CT to show extent of pericardial stenoses
79252236|NCT04345497|Other|Diabetes-Specific Formula|Diabetes-Specific Formula and Standard of Care
79252237|NCT04345497|Other|Standard Of Care|Standard of Care
79546438|NCT01543061|Device|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
79848513|NCT02540486|Other|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
79848514|NCT02540486|Other|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
79546439|NCT01543061|Procedure|No treatment|One month of contact lens wear with no eye drop use
79546440|NCT01543061|Device|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
79848515|NCT03966859|Drug|Atorvastatin 20mg|oral dose, once daily for 7 days
79848516|NCT03966859|Other|Lactose placebo|oral dose, once daily for 7 days
79848517|NCT00528411|Drug|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
79848518|NCT00528411|Drug|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
79848519|NCT00528411|Drug|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
79848520|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
80016210|NCT05204771|Other|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
80016211|NCT05204771|Other|Pediatric Follow up|Pediatric Follow up
79708316|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
79252238|NCT02464293|Other|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
80016212|NCT05112328|Drug|Exocrine Pancreatic Enzyme|Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
80016213|NCT05112328|Drug|Placebo|Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
79708317|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
79848521|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
80016214|NCT00684944|Drug|TRx0014|Gelatin capsule, tid
79252239|NCT02796391|Drug|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
79546441|NCT01543100|Other|blood and bone marrow samples|"Specific tests of the study will be realized from :~Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
79252240|NCT02796391|Behavioral|One on One Counseling|All participants will receive One on One Counseling.
79252241|NCT02063971|Other|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
79390341|NCT03187158|Diagnostic Test|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
79390342|NCT05101720|Procedure|Ultrasound Guided Axillary Venous Access|Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
79708318|NCT01604031|Biological|B-CLL Vaccine|Patients will receive a fixed dose (2X10^7) of IL-2 secreting B-cells together with (2X10^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
79708319|NCT01604031|Drug|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
80016215|NCT05112250|Device|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
80016216|NCT04515537|Dietary Supplement|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
79390343|NCT05101720|Procedure|Fluoroscopy-Guided Axillary Venous Access|Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
79390344|NCT00047697|Drug|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
79390345|NCT00047697|Drug|Placebo|Placebo used in placed of Donepezil HCL
79546442|NCT01543139|Drug|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
80016217|NCT04515537|Procedure|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
79252242|NCT02064049|Drug|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
79252243|NCT03560089|Device|Serious game|Serious game with movements
79252244|NCT03560089|Device|Placebo serious game|Serious game without movement
79546443|NCT01543139|Drug|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
79546444|NCT01543139|Drug|Valproate|Valproate: Week0-8: 300mg/day
79546445|NCT01543165|Drug|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
80016218|NCT00492596|Device|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
80016219|NCT00492596|Procedure|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
80016220|NCT03663699|Behavioral|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
80016221|NCT04202146|Behavioral|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
80016222|NCT02660827|Device|Insulin Pump|Closed Loop Algorithm
80016223|NCT03664557|Device|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
80016224|NCT00491738|Drug|bevacizumab|Intravenous repeating dose
80016225|NCT00491738|Drug|sunitinib|Oral repeating dose
80016226|NCT00491738|Drug|placebo|Intravenous repeating dose
80016227|NCT03664323|Biological|Evaluate the improvement in response from the end of anti-PD-1 monotherapy|Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
79546446|NCT01543165|Drug|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
79708320|NCT01682525|Other|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
79708321|NCT02279927|Device|Ureteroscopy|Ureteroscopy with laser stone fragmentation
79708322|NCT01682564|Drug|Candemore tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
79708323|NCT01682564|Drug|Atacand tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
79708324|NCT01608048|Device|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
79708325|NCT01647425|Behavioral|physician assessment|"Socio-economic conditions and general features: educational level, professional status...~Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~Assessment of current use of cannabis using the Cannabis Abuse Screening Test~Psychiatric assessment using the MINI 5.0"
79252245|NCT05576233|Procedure|disinfection of the surface that the blood culture is taken|lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
79390346|NCT02430168|Procedure|Percutaneous nephrolithotomy|
79390347|NCT02430168|Procedure|Retrograde intrarenal surgery|
79708326|NCT01604655|Procedure|Coronary CT Angiography|CCTA
79708327|NCT01604655|Procedure|Stress Test|Stress Test
79708328|NCT01604694|Procedure|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
79708329|NCT01682798|Dietary Supplement|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
79708330|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
79708331|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
80016228|NCT05114200|Procedure|Erector spinae plane block|"Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread."
80016229|NCT03414489|Drug|ABC294640|
80016230|NCT02281370|Drug|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
79252246|NCT02064283|Procedure|Diffusion MRI|
79252247|NCT02064751|Device|CRT with MultiPoint Pacing|
79252248|NCT02064751|Procedure|Hemodynamic measurements for CRT device programming|
79252249|NCT02064829|Drug|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
79252250|NCT02064829|Drug|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
79252251|NCT02064361|Other|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
79252252|NCT02064517|Device|MTA|Creation of a barrier apicale in the MTA
79252253|NCT02064517|Device|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
79390348|NCT02430012|Behavioral|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
79390349|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
79390350|NCT00112125|Device|OPTIMIZER System|
79390351|NCT00359320|Procedure|pancreaticojejunostomy|
79390352|NCT02437812|Drug|Metformin|Metformin with standard chemotherapy
79546447|NCT01543165|Drug|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
79546448|NCT01543191|Drug|PUR118|low dose and high dose for 3 doses, BID
79546449|NCT01543217|Other|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
79708332|NCT01608126|Procedure|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
79708333|NCT04528550|Biological|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
79708334|NCT04528550|Drug|Placebo|Included patients will receive the same amount of saline through lumbar injection.
79708335|NCT04528472|Other|Acupuncture Treatment|stimulate acupoints to accelerate recovery
79708336|NCT04528472|Other|Regular Treatment|Oral Medicine and Rehabilitation Treatment
79708337|NCT01647620|Drug|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
79708338|NCT01647620|Drug|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
79708339|NCT01608243|Biological|SLIT tablets of house dust mite allergen extracts|10 dosing days
79708340|NCT01608243|Biological|Matching placebo|10 dosing days
79708341|NCT04527692|Other|Questionnaire|semi-structured interviews on the quality of life
79708342|NCT01608282|Behavioral|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
79252254|NCT01370317|Drug|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
79390353|NCT02437812|Drug|Paclitaxel|Standard chemotherapy
79708343|NCT01608360|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
79252255|NCT01370317|Drug|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
79252256|NCT02064595|Procedure|External fixator|Treatment with external fixation
79390354|NCT02437812|Drug|Carboplatin|Standard chemotherapy
79390355|NCT00359398|Procedure|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
79390356|NCT02438046|Procedure|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
79546450|NCT01543217|Other|Ususal care|Routine respiratory care.
79546451|NCT01543230|Device|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
79546452|NCT01543243|Device|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
79546453|NCT01543243|Device|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
79708344|NCT01608360|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
79708345|NCT01647659|Drug|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
79708346|NCT01647659|Drug|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
79708347|NCT01608399|Behavioral|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
79708348|NCT01682993|Other|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
79708349|NCT01682993|Other|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
79708350|NCT01604811|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
79252257|NCT02064595|Procedure|Intramedullary nail|Fracture treated with intramedullary nail
79252258|NCT02260219|Procedure|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
79252259|NCT02067871|Other|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
79252260|NCT02067871|Other|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
79252261|NCT02065531|Other|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
79708351|NCT01604811|Drug|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
79708352|NCT01604811|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
79708353|NCT01604811|Drug|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
79708354|NCT01683032|Drug|MPH|a capsule containing 20 mg
79708355|NCT01604928|Drug|YM178|Oral
79708356|NCT01604928|Drug|tolterodine|Oral
79708357|NCT01604928|Drug|Placebo|Oral
79708358|NCT01647776|Other|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
79708359|NCT01647776|Procedure|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors [levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression] as markers of risk of developing adenoma.
79708360|NCT01647776|Other|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
79546454|NCT01543269|Drug|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
79708361|NCT01683110|Drug|cabozantinib|
79252262|NCT02065531|Other|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
79708362|NCT01608438|Device|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
79546455|NCT01543269|Drug|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
79708363|NCT01647815|Procedure|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
79708364|NCT01605045|Other|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
79848522|NCT00136357|Behavioral|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
79848523|NCT00895700|Behavioral|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
79848524|NCT00129649|Behavioral|Telephone reminder call|
79848525|NCT00895778|Other|Neuromuscular blockade with rocuronium and reversal with sugammadex|
79848526|NCT00895856|Other|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
79848527|NCT00896246|Drug|Klean-Prep®|Four litres of solution administered orally as a divided dose.
79848528|NCT00896246|Drug|Moviprep®|Two litres of solution administered orally as a divided dose
79848529|NCT00187135|Drug|Fentanyl|"Fentanyl - 1 mcg/kg in 3 ml normal saline~Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
79848530|NCT00187135|Drug|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
80016231|NCT02281370|Drug|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
79252263|NCT02067949|Drug|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
79390357|NCT05085886|Behavioral|DepCare|Primary Care Provider (1) One-time presentation or video with education and motivational messaging around collaborative care, functionality of the DepCare patient tool and optimal management of depression and comorbid anxiety (2) Quality improvement/ implementation team meetings on optimizing mental health treatment in primary care and DepCare (i.e., multi-level, multi-component intervention) implementation (3) Automatically-generated decisional support on individual patient treatment preferences (i.e., for every patient who receives the DepCare patient tool) Patient: Tool comprised of enhanced depression and anxiety screening (includes option for voice-over questions, point-and-click responses), and for those who screen positive for depressive symptoms (with or without comorbid anxiety), diagnosis recognition support, psycho-education, videos promoting patient engagement in treatment, and personalized medication selection support.
79546456|NCT01543282|Device|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
79546457|NCT01543321|Drug|Tetrabenazine|"Treatment with tetrabenazine consists in:~5-week titration to a maximum dose of 200 mg / day~5 weeks at stable dose~2 weeks in wash-out~The treatment will be blinded for patients and investigators"
80016232|NCT05114122|Procedure|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
80016233|NCT05114122|Procedure|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
79546458|NCT01543321|Drug|Placebo|"Treatment with placebo consists in:~5-week titration to a maximum dose of 200 mg / day~5 weeks at stable dose~2 weeks in wash-out~The treatment will be blinded for patients and investigators"
79708365|NCT01605045|Other|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
79708366|NCT01683149|Drug|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
79252264|NCT02068105|Drug|ALKS 5461|Sublingual tablet
79252265|NCT02068105|Drug|Placebo|Sublingual tablet
79708367|NCT01683149|Drug|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
79708368|NCT01608555|Drug|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
79708369|NCT01647854|Procedure|Teleconsultation|Teleconsultation in prehospital emergencies
79708370|NCT01647893|Drug|CTB-001|IV bolus or IV infusion
79708371|NCT01608633|Other|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
79708372|NCT01648010|Device|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
79708373|NCT01648010|Device|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
79708374|NCT01605201|Biological|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
79708375|NCT01683461|Behavioral|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
79708376|NCT01683461|Behavioral|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
79708377|NCT01608711|Biological|AGS-1C4D4|Intravenous Infusion
79708378|NCT01608711|Biological|gemcitabine|Intravenous Infusion
79708379|NCT01648049|Behavioral|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein & Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, & Dick, 1995).
80016234|NCT00680342|Drug|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
79390358|NCT05085886|Behavioral|Enhanced Usual Care|Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization
79546459|NCT01543334|Biological|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
80016235|NCT00680342|Drug|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
79708380|NCT01648049|Behavioral|Treatment as usual|Standard Care - Treatment as usual
79848531|NCT00187135|Drug|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
80016236|NCT00680342|Other|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
79390359|NCT02437968|Behavioral|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
79390360|NCT05500222|Drug|Resmetirom|Randomized 80 mg
79390361|NCT05500222|Drug|Placebo|randomized matching placebo
79390362|NCT02437734|Procedure|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
79390363|NCT05083468|Drug|SR750 tablet|The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
79546460|NCT01543347|Drug|Temocillin|Antibiotic treatment
79708381|NCT02482623|Behavioral|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
79708382|NCT01683500|Device|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
79708383|NCT01605357|Drug|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
79708384|NCT01605357|Drug|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium < 135 mmol/L) is to be corrected at the discretion of the provider.
80016237|NCT03664167|Dietary Supplement|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
80016238|NCT05114044|Other|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
79252266|NCT02068261|Behavioral|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
79390364|NCT05083468|Drug|matching placebo|The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
79390365|NCT00112593|Drug|fludarabine phosphate|Given IV
79708385|NCT01648127|Drug|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
79708386|NCT01605474|Other|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
79708387|NCT01605474|Other|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
79708388|NCT01683539|Behavioral|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
79708389|NCT01683539|Behavioral|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
79708390|NCT01608750|Drug|Pantoprazol|40mg/day, oral, 28 days
79390366|NCT00112593|Radiation|total-body irradiation|Undergo TBI
79708391|NCT01608750|Drug|Folic Acid|5 mg/day, oral, 28 days
79708392|NCT01605513|Drug|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
79708393|NCT04528277|Drug|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
79708394|NCT01605591|Procedure|the DLT bending to the right|bending the bronchial lumen of DLT 60~90 degrees in the same side with the tracheal lumen
79708395|NCT01605591|Procedure|the DLT bending to the left|bending the bronchial lumen of DLT 60~90 degree opposed to the tracheal lumen
79708396|NCT01683617|Behavioral|Coping skills and relaxation training with new technologies|
79708397|NCT01683617|Behavioral|Traditional coping skills and relaxation training|
79708398|NCT01605630|Behavioral|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
79708399|NCT01605630|Behavioral|Control|standard of care
79848532|NCT00187135|Drug|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
80016239|NCT05114044|Other|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
79252267|NCT02068261|Behavioral|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
79390367|NCT00112593|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
79390368|NCT00112593|Drug|cyclosporine|Given IV or PO
79390369|NCT00112593|Drug|mycophenolate mofetil|Given IV or PO
79252268|NCT02068339|Drug|Oltipraz 1 (90mg)|
79252269|NCT02068339|Drug|Placebo|
79390370|NCT00112593|Other|laboratory biomarker analysis|Correlative studies
79390371|NCT02437422|Biological|SANGUINATE|Single two-hour infusion of SANGUINATE
79546461|NCT01543360|Procedure|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
79546462|NCT01543360|Procedure|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
79252270|NCT02068339|Drug|Oltipraz 2 (120mg)|
79252271|NCT02068417|Device|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
79546463|NCT01543373|Device|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
79546464|NCT01543373|Device|Bare Metal Stent|Bare metal coronary stent
79546465|NCT01543386|Drug|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
79546466|NCT01543399|Drug|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
79546467|NCT01543399|Drug|Placebo|patients of the placebo group will use placebo one a day for 30 days
79546468|NCT01543412|Drug|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
79546469|NCT01543438|Other|Video Prescription (additional education)|receives video prescriptions
79546470|NCT01543464|Drug|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
79708400|NCT01683656|Drug|niacin/laropiprant|
79708401|NCT01683656|Drug|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
79708402|NCT01605747|Dietary Supplement|Culturelle|one capsule 2x per day per feeding tube
79708403|NCT01605747|Dietary Supplement|Placebo|one placebo 2x per day per feeding tube
79708404|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
79708405|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
79708406|NCT01605786|Other|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
79708407|NCT01683695|Drug|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
80016240|NCT00617552|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
79252272|NCT02065843|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
79708408|NCT01683695|Drug|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
79390372|NCT05280106|Procedure|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
79546471|NCT01543529|Drug|RO4917838|Single dose of RO4917838
79546472|NCT01543529|Drug|Placebo to RO4917838|Single dose of placebo to RO4917838
79708409|NCT01605864|Drug|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
79710228|NCT01326546|Biological|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
80016241|NCT00617552|Drug|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
80016242|NCT00617552|Drug|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
80016243|NCT00617552|Drug|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
80016244|NCT00617552|Drug|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
80016245|NCT00617552|Drug|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
79390373|NCT05280106|Procedure|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
79546473|NCT01543529|Other|Alcohol|Standard alcoholic drink
79546474|NCT01543542|Radiation|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
79546475|NCT01543555|Drug|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
79546476|NCT01543555|Drug|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
79710229|NCT01326546|Drug|entecavir|0.5mg,per day,oral intake.
79710230|NCT01326546|Other|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
80016246|NCT00617552|Drug|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
80016247|NCT00617552|Drug|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
80016248|NCT05113888|Drug|Qizhi weitong granules(High）|take orally before meals, 1 bag each time, 3 times a day.
80016249|NCT05113888|Drug|Qizhi weitong granules(Low）|take orally before meals, 1 bag each time, 3 times a day.
80016250|NCT05113888|Drug|Placebo|take orally before meals, 1 bag each time, 3 times a day.
80016251|NCT05113654|Diagnostic Test|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
80016252|NCT04057365|Drug|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
80016253|NCT04057365|Drug|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
79252273|NCT02065843|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
79252274|NCT02065843|Drug|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
79252275|NCT02065843|Drug|midazolam|15 mg/single dose/1 hour before dental surgery
79252276|NCT02068573|Device|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
79546477|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
79546478|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
80016254|NCT00616148|Drug|YKP3089|Oral dosage form
80016255|NCT00616148|Drug|Placebo|
80016256|NCT02283944|Device|TMS|Pulsed non-invasive brain stimulation using electromagnets
79546479|NCT01543724|Drug|Lithium|10mg/kg/day for 12 weeks
79708410|NCT01648244|Other|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
79708411|NCT01608789|Device|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
79708412|NCT01683773|Biological|AERAS-402|Intramuscular needle injection 1x10^11 vp
79708413|NCT01683773|Biological|MVA85A|Intradermal needle injection 1x10^8 pfu
79708414|NCT01608867|Biological|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
79708415|NCT01648478|Other|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~A basal period (from T-30 to T0)~The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~The infusion of glucose at variable rate (so as to maintain euglycemia)"
79390374|NCT03187314|Drug|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
79390375|NCT03187314|Drug|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
79390376|NCT00360022|Other|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
79390377|NCT00112671|Drug|sorafenib tosylate|Given orally 400mg orally twice daily
79848533|NCT00896324|Behavioral|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
79390378|NCT00112671|Other|laboratory biomarker analysis|Correlative studies
80016257|NCT03622827|Combination Product|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
79390379|NCT05279092|Drug|Bupivacaine-Liposomal Bupivacaine|Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
79390380|NCT05279092|Drug|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
79390381|NCT02437656|Drug|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day"
79390382|NCT05273632|Drug|Oxytocin|trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
79546480|NCT01543737|Device|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
79546481|NCT01543737|Device|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
79546482|NCT01543750|Drug|4-Aminopyridine|
79546483|NCT01543750|Drug|Placebo|Placebo
79546484|NCT01543802|Drug|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
79546485|NCT01543815|Behavioral|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
79708416|NCT01608945|Drug|Hydrocortisone sodium succinate|100mg/day
79708417|NCT01608984|Procedure|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
79708418|NCT01608984|Procedure|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
79252277|NCT02068573|Device|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
79252278|NCT02068651|Behavioral|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
79252279|NCT02066077|Drug|Etomidate|
79708419|NCT01608984|Procedure|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
79708420|NCT01648517|Drug|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
79708421|NCT01648517|Drug|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
79708422|NCT01609101|Device|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
79708423|NCT01609101|Device|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
79708424|NCT01609101|Device|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
79708425|NCT01609101|Device|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
79708426|NCT01609101|Device|King Vision® videolaryngoscope|King Vision® videolaryngoscope
79708427|NCT01609101|Device|Venner® videolaryngoscope|Venner® videolaryngoscope
79708428|NCT01609101|Device|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
79708429|NCT01683929|Other|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
79708430|NCT01683929|Other|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
79708431|NCT01609179|Drug|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
79708432|NCT01648556|Other|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
79708433|NCT01605981|Drug|AMN107|
79708434|NCT01648595|Drug|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
79708435|NCT01606020|Other|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
79708436|NCT01606020|Other|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
79708437|NCT01648634|Drug|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
79708438|NCT01648634|Drug|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
79708439|NCT04527848|Drug|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
79708440|NCT01606059|Drug|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
79708441|NCT01606059|Drug|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
79708442|NCT01606293|Behavioral|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
79708443|NCT04527809|Device|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
79708444|NCT04527809|Device|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
79708445|NCT01606332|Procedure|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
79708446|NCT01606371|Drug|Placebo|Administered orally
79708447|NCT01606371|Drug|LY2409021|Administered orally
79708448|NCT04527653|Device|Tixel|Non-invasive thermo-mechanical treatment
79708449|NCT01606410|Other|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
79708450|NCT01648712|Device|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
79708451|NCT01648712|Device|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
79708452|NCT01606449|Procedure|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
79252280|NCT02066077|Drug|Propofol|
79252281|NCT02066077|Device|Bilateral temporal MECT|
79708453|NCT04527536|Diagnostic Test|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
79708454|NCT05140629|Other|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
79708455|NCT05140629|Other|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
79546486|NCT01543815|Behavioral|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
79708456|NCT01608165|Procedure|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
79708457|NCT01608165|Procedure|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
79708458|NCT01608165|Procedure|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
79546487|NCT01543815|Other|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
79708459|NCT01688544|Drug|Ilaprazole|Ilaprazole 10 mg for 7 days
79708460|NCT01688583|Drug|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
80016258|NCT00486512|Drug|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
79708461|NCT01648829|Drug|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
79252282|NCT02066077|Device|The right temporal MECT|
79252283|NCT02066077|Device|Bilateral frontal MECT|
79546488|NCT01543854|Drug|RLX030|Intravenous infusion of RLX030 over 20 hrs
79708462|NCT01648829|Drug|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
80016259|NCT00486512|Drug|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
80016260|NCT00486512|Drug|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
79252284|NCT02068807|Dietary Supplement|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
79252285|NCT02068807|Dietary Supplement|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
79252286|NCT02066155|Behavioral|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
79252287|NCT02066155|Behavioral|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
79252288|NCT01370083|Behavioral|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
79252289|NCT01370083|Behavioral|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
79390383|NCT02429622|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
79390384|NCT02429622|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
79390385|NCT02429622|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
79546489|NCT01543854|Drug|Placebo|Intravenous infusion of placebo over 20 hours
79252290|NCT03350815|Drug|150 mg open-label secukinumab|All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
79546490|NCT01543867|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
79546491|NCT01543880|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
80016261|NCT00486512|Drug|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
80016262|NCT00486512|Procedure|Colonoscopy|
80016263|NCT04057989|Drug|ketamine|
79390386|NCT02429622|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
79390387|NCT02429544|Behavioral|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
79390388|NCT02429544|Behavioral|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
80016264|NCT04093882|Diagnostic Test|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
79708463|NCT01688622|Behavioral|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
79708464|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
79708465|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
80016265|NCT03687580|Device|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
79390389|NCT02429544|Device|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
79390390|NCT02429544|Other|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
79390391|NCT02429544|Behavioral|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
80016266|NCT03687580|Device|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
80016267|NCT00486200|Drug|ASP2151|Oral administration.
79252291|NCT03350815|Drug|150 mg double-blinded secukinumab|Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
79390392|NCT05075746|Device|enVista Toric|enVista Toric IOL
79390393|NCT05075746|Device|enVista non-Toric (spherical)|enVista non-Toric (spherical) IOL
79390394|NCT03186924|Behavioral|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
79390395|NCT02429154|Other|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
79390396|NCT02429154|Other|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
79390397|NCT05494996|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet and the five-item relationship satisfaction scale(RS5) .
79546492|NCT01543893|Behavioral|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
79252292|NCT03350815|Drug|300 mg double-blinded secukinumab|Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
79708466|NCT01688700|Drug|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
79708467|NCT01684085|Behavioral|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
79708468|NCT01684085|Behavioral|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
79252293|NCT02065063|Drug|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
79252294|NCT02065063|Drug|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
79252295|NCT02069197|Other|Ketogenic diet|ketogenic diet will consist of 3:1[fat]:[protein+carbohydrate]weight ratio with 1600 kcal restriction. Diet will last 9 months.
79252296|NCT02069197|Drug|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
79252297|NCT02069197|Other|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
79252298|NCT02069275|Other|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
79390398|NCT05075278|Behavioral|Survey|A survey will be completed by the participants at the conclusion of each day.
79390399|NCT02429466|Drug|Guadecitabine (SGI-110)|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
79390400|NCT02977390|Other|Passive leg raise|By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
79390401|NCT03184896|Procedure|Hip Fracture Surgery|Hip Fracture Surgery
79546493|NCT01543893|Behavioral|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
79708469|NCT01684085|Drug|Lorazepam|Lorazepam 1 mg
79708470|NCT01648985|Other|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
80016268|NCT00486200|Drug|valacyclovir|Oral administration of active comparator.
80016269|NCT00486200|Drug|Placebo|Oral administration of placebo.
80016270|NCT02284022|Device|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
80016271|NCT04079062|Biological|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
79708471|NCT01688817|Other|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
79708472|NCT01688817|Other|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
79708473|NCT01684241|Biological|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
79708474|NCT01688934|Drug|V116517 50-mg tablets|Taken orally twice daily
79708475|NCT01688934|Drug|V116517 30-mg tablets|Taken orally twice daily
79708476|NCT01688934|Drug|Naproxen 500-mg capsules|Taken orally twice daily
79708477|NCT01688934|Drug|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
79848534|NCT00896324|Behavioral|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
79390402|NCT02429388|Drug|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
79390403|NCT02429232|Drug|Pioglitazone|Pioglitazone 30mg/tablet once daily
79390404|NCT02429232|Drug|Linagliptin|Linagliptin 5mg/tablet once daily
79390405|NCT04343950|Behavioral|SMS reminders to enhance colorectal cancer screening|"Cluster randomization instead of individual randomization will be used. The cluster will be invitation week.~Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis)."
79390406|NCT04343950|Behavioral|SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|"Cluster randomization instead of individual randomization will be used. The cluster will be invitation week.~Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis)."
79848535|NCT00896324|Behavioral|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
79848536|NCT00528021|Drug|Placebo|Vehicle Only
79390407|NCT04343950|Behavioral|Invitation by SMS to previous participants in breast cancer screening:|Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
79390408|NCT03189498|Drug|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250 mg tablets) on Day 1.
79390409|NCT02437266|Other|Scapular mobilization|
79390410|NCT03186768|Behavioral|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
79390411|NCT03186690|Other|Biodentine|
79390412|NCT03186690|Other|Mineral Trioxide Aggregate|
79546494|NCT01543906|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
79546495|NCT01543932|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
79546496|NCT01543932|Drug|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
79546497|NCT01543932|Drug|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
79546498|NCT01543945|Drug|Dexamethasone|4 mg iv before induction for high and extremely high risk
79546499|NCT01543945|Drug|Ondansetron|4 mg iv before ended surgery 30 min
79708478|NCT01684319|Dietary Supplement|Formula milk free of cow's milk protein|
79708479|NCT01684319|Dietary Supplement|Placebo|Infant formula milk
79708480|NCT02279576|Drug|Pazopanib|Pazopanib 800mg/day continuously administered.
79708481|NCT02279576|Drug|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
79708482|NCT02279615|Drug|Mirabegron|50mg of mirabegron per day will be given.
79708483|NCT02279615|Drug|Tamsulosin|0.4mg of flomax per day.
79708484|NCT01689051|Other|human glucagon-like peptide 1 (7-36)amide|
79708485|NCT01689051|Other|human glucagon-like peptide 1 (9-36)amide|
79708486|NCT01684358|Device|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
79708487|NCT05140395|Diagnostic Test|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
79708488|NCT01684475|Drug|CJH1 (CLR4001)|
79708489|NCT05140356|Device|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
79708490|NCT05140356|Device|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
79708491|NCT04528121|Other|CoDuSe balance training and step square exercises|"The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed."
79708492|NCT04528121|Other|conventional balance training|static and dynamic balance training exercises from sitting, standing and ambulation activities
79708493|NCT01689090|Other|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
79546500|NCT01543945|Drug|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
79708494|NCT01689090|Other|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
79708495|NCT01689090|Other|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
79708496|NCT01684553|Behavioral|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
79708497|NCT01684553|Behavioral|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
79708498|NCT01689129|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
79708499|NCT01689129|Drug|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
79708500|NCT01684631|Device|Total Hip arthroplasty|
80016272|NCT04079062|Biological|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
79708501|NCT01689168|Behavioral|Counseling|Tobacco cessation counseling
79708502|NCT01689168|Procedure|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
79708503|NCT01689285|Drug|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
80016273|NCT04079062|Biological|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
79252299|NCT02069275|Other|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
79708504|NCT01689285|Drug|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
79708505|NCT01649102|Device|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~Palindroom~Hemoglide Bard"
79848537|NCT00528021|Drug|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
79848538|NCT00896402|Drug|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
79252300|NCT00854295|Device|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
79546501|NCT01543971|Drug|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
79546502|NCT01543971|Drug|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
79546503|NCT01543984|Other|Tailored Physical Activity|Tailored Physical Activity (3*50 min/week in 10 weeks)
79546504|NCT01543984|Behavioral|Health Counselling|Health guidance (1,5h)
79546505|NCT01543997|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
79546506|NCT01543997|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
79546507|NCT01544010|Behavioral|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
79546508|NCT01544010|Behavioral|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
79546509|NCT01544010|Behavioral|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
79546510|NCT01544010|Behavioral|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
79708506|NCT01606527|Drug|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
79708507|NCT01684670|Behavioral|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
79708508|NCT01609335|Drug|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
79708509|NCT01609335|Drug|C-11 PiB|One time intravenous administration of 10-20 mCi
79848539|NCT00896402|Drug|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
80016274|NCT04079062|Biological|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
80016275|NCT04079062|Biological|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
79708510|NCT01609374|Device|M6-C Artificial Cervical Disc|Total disc replacement
79708511|NCT01609374|Device|Anterior plate system with corticocancellous allograft bone|Cervical fusion
79546511|NCT01544010|Behavioral|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
79546512|NCT01544036|Drug|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
79546513|NCT01544075|Behavioral|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
79390413|NCT03189654|Device|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
79708512|NCT01684709|Behavioral|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
79708513|NCT01649141|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
79708514|NCT01609413|Dietary Supplement|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
79708515|NCT01609413|Dietary Supplement|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
79708516|NCT02279966|Drug|Vortioxetine 10 mg|
79708517|NCT02279966|Drug|Paroxetine 20 mg|
79708518|NCT02279966|Drug|Placebo|
79708519|NCT01606644|Procedure|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
79848540|NCT00560352|Drug|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
79848541|NCT00560352|Drug|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m^2 QD, 1.3 mg/m^2 QD
79848542|NCT00560352|Drug|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
79848543|NCT00892892|Drug|Rilmenidine|1 mg Rilmenidine per day versus
79848544|NCT00892892|Drug|Nitrendipine|20 mg Nitrendipine per day
79848545|NCT04037696|Behavioral|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
79390414|NCT03186846|Device|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
79390415|NCT03186846|Device|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
79390416|NCT03189732|Drug|Metformin Oral|
79390417|NCT03189732|Drug|Metformin local in AT|
79390418|NCT03189732|Other|Exercise|
79390419|NCT02433756|Device|CRTD|
79546514|NCT01544075|Behavioral|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
79546515|NCT01544101|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
79546516|NCT01544101|Dietary Supplement|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
79546517|NCT01544140|Drug|Midazolam|Oral syrup 7.5 mg, single dose
79546518|NCT01544140|Drug|vandetanib|Oral tablets, 800 mg, single dose
79708520|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
79708521|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
79708522|NCT01606683|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
79708523|NCT01606683|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
79708524|NCT01606683|Other|No intervention|
79708525|NCT01649219|Behavioral|Exercise|
79708526|NCT01609452|Biological|Blisibimod|
79708527|NCT01609452|Other|Placebo|
79708528|NCT01649258|Drug|granisetron transdermal system|Given granisetron transdermal system patch
79708529|NCT01649258|Drug|fosaprepitant dimeglumine|Given IV
79708530|NCT01649258|Other|laboratory biomarker analysis|Correlative studies
79708531|NCT01649336|Drug|MEK162, MEK inhibitor; oral|multiple dose, escalating
79708532|NCT01649336|Drug|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
80016276|NCT02936050|Procedure|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
79708533|NCT01609491|Drug|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
79708534|NCT01609491|Drug|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
79848546|NCT04037696|Behavioral|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
79848547|NCT00944736|Dietary Supplement|VSL#3|1 packet BID
79252301|NCT02792959|Device|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
79252302|NCT02792959|Device|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
79390420|NCT05057728|Behavioral|Social-Emotional Prevention Program enhanced version|The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
79390421|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 8 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
79390422|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 12 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
79546519|NCT01544192|Drug|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
79546520|NCT01544192|Drug|α-tocopherol|2x300 mg α-tocopherol
79546521|NCT01544192|Drug|Placebo|control group did not receive oral neuroprotective agent
79546522|NCT01544192|Drug|Antioxidant formula|2x1 tablet AOF
79546523|NCT01544205|Other|fMRI-based neurofeedback|5 sessions lasting one hour each
79546524|NCT01544231|Biological|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
79546525|NCT01544244|Procedure|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
79546526|NCT01544244|Procedure|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
79546527|NCT01544257|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
79546528|NCT01544257|Procedure|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
79546529|NCT01544270|Dietary Supplement|Yogurt-like snacks|twice a day 120 g for four weeks
79708535|NCT01606917|Other|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
79708536|NCT01684865|Drug|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
79848548|NCT00944736|Dietary Supplement|Placebo|1 inactive packet BID
79848549|NCT00887900|Procedure|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
79848550|NCT00887900|Procedure|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
79848551|NCT00944814|Dietary Supplement|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
80016277|NCT00481520|Drug|SAM-531|
80016278|NCT00481520|Other|placebo|
80016279|NCT05206526|Behavioral|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
79252303|NCT02464371|Other|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
79252304|NCT02069431|Drug|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
79252305|NCT02069431|Other|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
80016280|NCT05206526|Behavioral|Home-based Exercise|12 weeks of home-based training composed by 10 exercises.
79252306|NCT01652872|Biological|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
79252307|NCT01652872|Other|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
79252308|NCT02065219|Drug|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
79252309|NCT02065219|Drug|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
79390423|NCT02433600|Other|Cow's milk-based infant formula|
79390424|NCT02433600|Other|Cow milk-based infant formula with enriched protein fractions|
79390425|NCT05243056|Other|Best Practice|Receive enhanced usual care
79390426|NCT05243056|Other|Educational Intervention|Receive Y-AMBIENT
79390427|NCT05243056|Other|Quality-of-Life Assessment|Ancillary studies
80016281|NCT05113420|Drug|Detralex|Diosmin+ Hesperidin
79390428|NCT05243056|Other|Questionnaire Administration|Ancillary studies
79390429|NCT02437032|Drug|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
79708537|NCT01606956|Procedure|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
79708538|NCT01606956|Procedure|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
79708539|NCT01649453|Device|Pathwork® Tissue of Origin Test|
79708540|NCT01580163|Drug|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
79848552|NCT00944814|Dietary Supplement|LNS without zinc|LNS containing no zinc
79848553|NCT00527787|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
79848554|NCT00527787|Drug|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
79848555|NCT00893048|Drug|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
79252310|NCT02065297|Other|1 blood sample|
79252311|NCT02065297|Other|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
79390430|NCT02437032|Drug|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
79546530|NCT01544283|Drug|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
79390431|NCT02437032|Drug|hMG|Controlled ovarian stimulation with 150-300 UI hMG
79390432|NCT02433444|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
79390433|NCT02436564|Genetic|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
79390434|NCT05232994|Drug|Esomeprazole 20mg|Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
79390435|NCT02436642|Device|AVERT Plus System|
79390436|NCT00359554|Biological|VAXIGRIPPE|
79708541|NCT01580163|Drug|Methadone|Oral Solution，1mg/ml
79708542|NCT01580163|Drug|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
79708543|NCT01609647|Drug|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
79848556|NCT00893048|Drug|Placebo Oral Tablet|Placebo
79848557|NCT00940368|Dietary Supplement|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
79252312|NCT03299127|Behavioral|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
79390437|NCT02436798|Drug|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
79390438|NCT05231044|Drug|KX01 ointment 1%|The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
79390439|NCT05231044|Drug|Placebo|Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
79390440|NCT03185130|Drug|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
79390441|NCT03185130|Drug|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
79848558|NCT00608426|Behavioral|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
79848559|NCT00557076|Behavioral|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
79848560|NCT00557076|Behavioral|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
79390442|NCT03185130|Drug|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will recieve prochlorperazine 0.15 mg/kg up to 10mg IV slow push
79708544|NCT01609647|Drug|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
79708545|NCT01649492|Dietary Supplement|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
79708546|NCT01580202|Drug|Entecavir|Entecavir 0.5mg daily per os
79708547|NCT01580202|Drug|Lamivudine|lamivudine 100mg daily per os
79708548|NCT01649570|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
79708549|NCT01685294|Behavioral|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
79708550|NCT01685450|Device|Echodia® hand-held equipment|
79708551|NCT01609764|Behavioral|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
79546531|NCT01544283|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
79708552|NCT01609803|Other|laboratory biomarker analysis|Correlative studies
79708553|NCT01649648|Biological|Autologous cord blood|Baby's own umbilical cord blood
79252313|NCT03298971|Other|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
79546532|NCT01544296|Drug|KHK6188|
79546533|NCT01544296|Drug|Placebo|
79546534|NCT01544322|Drug|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
79546535|NCT01544374|Other|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
79546536|NCT01544387|Other|Bed Rest|"Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~Subjects may have limited bathroom privileges"
79546537|NCT01544387|Other|Activity|"Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
79546538|NCT01544413|Procedure|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
79708554|NCT01609881|Drug|Acuvail|Dosing of drug 3 days prior to surgery
79708555|NCT01609881|Other|Placebo|Artificial tears qid for 3 days preoperatively
79708556|NCT01649687|Biological|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells
79252314|NCT02069587|Dietary Supplement|pomegranate|
79252315|NCT03560011|Drug|immunoglobulin IV|5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
79252316|NCT02464137|Radiation|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
79708557|NCT01609920|Drug|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
79708558|NCT04527458|Other|Patient Characteristics|Characteristics of the patients
79708559|NCT04527458|Other|COVID-19 treatments|Specific treatments used on COVID-19 patients
79708560|NCT04527458|Other|Differences in triage|Triage criteria for treating COVID-19 patients
79708561|NCT04527458|Other|Surge capacity|Capacity of hospitals
79708562|NCT01609959|Drug|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
79708563|NCT01609959|Drug|Valsartan|Valsartan 160 mg per day
79708564|NCT01649726|Procedure|Apnea test - control|
79708565|NCT01649726|Procedure|Apnea test - CPAP|
79708566|NCT01609998|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
79708567|NCT01609998|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
79708568|NCT04527263|Diagnostic Test|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
80016282|NCT05113420|Drug|Troxevasin|Troxerutin
79708569|NCT01649882|Procedure|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
79708570|NCT01685528|Behavioral|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
79708571|NCT01685645|Device|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
79708572|NCT01649921|Drug|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
79708573|NCT01649921|Other|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
79390443|NCT03185130|Drug|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
79708574|NCT01606566|Drug|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
79708575|NCT01644968|Drug|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
79848561|NCT00942864|Drug|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
79848562|NCT00943020|Dietary Supplement|Nutricia PreOp nutritional supplement|nutritional supplement
79848563|NCT00943020|Dietary Supplement|Lipid|Drink
80016283|NCT00479492|Drug|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
80016284|NCT00479492|Drug|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
79708576|NCT01644968|Drug|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
79252317|NCT03785197|Other|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
79252318|NCT04251273|Other|This is Quitting|Text message-based intervention for quit vaping support.
79708577|NCT01644968|Drug|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
79252319|NCT04251273|Other|Assessment only Control|Assessment only
79252320|NCT02069665|Other|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
79252321|NCT02069665|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
79252322|NCT02069665|Drug|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
79252323|NCT02069665|Drug|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
79390444|NCT02428920|Behavioral|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
79390445|NCT00358618|Drug|Propofol|See Detailed Description.
79390446|NCT02428764|Drug|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
79390447|NCT02428764|Drug|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
79708578|NCT01644968|Biological|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
79708579|NCT01644968|Biological|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
79708580|NCT01644968|Biological|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
79708581|NCT01644968|Biological|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
79708582|NCT01605708|Drug|REGN846|Dose 1
79390448|NCT02428764|Drug|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
79390449|NCT02428764|Procedure|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
79708583|NCT01685723|Behavioral|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
79708584|NCT01685723|Behavioral|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
79708585|NCT01605162|Drug|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
79848564|NCT00943020|Dietary Supplement|Glutamine|Drink
79848565|NCT04017728|Device|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
79848566|NCT04017728|Device|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
79848567|NCT00945048|Device|electrical velocimetry|determination of cardiac output by electrical velocimetry
79848568|NCT00945048|Device|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
79848569|NCT00945048|Device|spirometry|spirometry for testing the ventilatory function
80016285|NCT00479492|Drug|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
80016286|NCT00479492|Drug|placebo|placebo administered QD for 84 days
79708586|NCT01605162|Drug|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
79708587|NCT01649999|Drug|peficitinib|oral
79708588|NCT01649999|Drug|Placebo|oral
79708589|NCT01604889|Drug|Epacadostat|
79708590|NCT01604889|Drug|Placebo|Placebo
79708591|NCT01604889|Drug|ipilimumab|ipilimumab 3 mg/kg IV
79708592|NCT01604889|Drug|ipilimumab|Doses to be determined following the completion of Phase I of the study
79708593|NCT01685762|Drug|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
79708594|NCT01685879|Other|Rice|Rice portion containing 50 g total carbohydrate
79708595|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
79848570|NCT00945048|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
79848571|NCT00896558|Drug|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
79848572|NCT00896558|Drug|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
79848573|NCT00943176|Drug|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
79848574|NCT00896636|Procedure|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
79848575|NCT00896636|Other|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
80016287|NCT05112796|Procedure|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
80016288|NCT05112796|Procedure|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
80016289|NCT05112718|Biological|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
79390450|NCT00358696|Drug|tenofovir|See Detailed Description.
79390451|NCT05466214|Behavioral|Conjoint Behavioral Consultation (CBC)|Within the treatment group, CBC will be integrated into how a school-based specialist works with families and teachers of children with or at risk of severe emotional disturbance.
79708596|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
79708597|NCT01685879|Other|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
79708598|NCT01602822|Drug|3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
79708599|NCT01602822|Drug|Ritonavir, Atazanavir, Truvada|
79708600|NCT01644344|Other|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
79708601|NCT01644344|Other|Xray|
79708602|NCT02273154|Drug|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
79708603|NCT02273154|Drug|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
79708604|NCT01644656|Device|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
79708605|NCT01607541|Behavioral|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
79848576|NCT00129259|Biological|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
79848577|NCT00129259|Other|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
79848578|NCT00129259|Dietary Supplement|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
79848579|NCT00896714|Device|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
79708606|NCT01607541|Behavioral|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
79848580|NCT00943254|Other|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
80016290|NCT05112718|Other|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
79252324|NCT02069665|Drug|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
79252325|NCT02069665|Drug|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
79390452|NCT05222308|Other|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
79390453|NCT05445544|Other|Observational studies, The diagnosis was preeclampsia|Observational studies, The diagnosis was preeclampsia
79390454|NCT05218018|Dietary Supplement|Lipid drink|100 mls of heavy cream
79390455|NCT05429476|Drug|Tissue Plasminogen Activator (Alteplase)|"Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA"
79390456|NCT02977546|Device|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
79390457|NCT02977546|Device|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
79390458|NCT00360100|Drug|Zmax|
79390459|NCT04999696|Procedure|radical hysterectomy|To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
79390460|NCT04995406|Diagnostic Test|ISIT-TB prototype|Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
79390461|NCT00358774|Procedure|homeopathic nasal spray|
79708607|NCT01644851|Behavioral|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
79708608|NCT01603836|Biological|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
79708609|NCT01645046|Drug|Coenzyme A|Coenzyme A 200mg per day.
80016291|NCT00479258|Drug|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
79390462|NCT04343794|Device|BIOVITALS|Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
79708610|NCT01645046|Drug|Coenzyme A|Coenzyme A 400mg per day.
79708611|NCT01645046|Drug|Placebo|Capsule without coenzyme A.
79708612|NCT01605006|Device|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
79708613|NCT01606215|Drug|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
79708614|NCT01606215|Drug|Placebo|Placebo
80016292|NCT00479258|Drug|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
79252326|NCT02069665|Drug|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
79252327|NCT02069665|Drug|Ibuprofen Suspension|taken under prescription
79252328|NCT02069665|Drug|salbutamol|taken under prescription
79252329|NCT04938856|Drug|Lamotrigine tablet|Lamotrigine 100 mg immediate release Tablet
79390463|NCT00360178|Drug|Valsartan plus Hydrochlorothiazide|
79390464|NCT00360178|Drug|Candesartan plus Hydrochlorothiazide|
79390465|NCT00360178|Drug|Amlodipine|
79390466|NCT00421720|Drug|Sufentanil|
79390467|NCT00421720|Drug|Remifentanil|
79390468|NCT05388214|Behavioral|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
79390469|NCT00358852|Other|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
79390470|NCT05008276|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
79708615|NCT01607775|Device|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
79708616|NCT01607775|Device|PMMA-cage|The in-house produced cervical cage will be implanted
79848581|NCT00943254|Other|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
79848582|NCT04017572|Procedure|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
79390471|NCT05008276|Drug|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
79546539|NCT01544439|Procedure|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
79848583|NCT00896792|Other|counseling intervention|
79848584|NCT00896792|Other|questionnaire administration|
79848585|NCT00896792|Other|survey administration|
80016293|NCT05112562|Behavioral|Computerized attentional bias modification training|In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
80016294|NCT05112562|Behavioral|Placebo attention control training|This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
80016295|NCT05107180|Diagnostic Test|drug screen|urine sample
79390472|NCT05008276|Drug|Dextran 40|Diagnostic aid/agent used to measure glomerular size and selectivity
79390473|NCT04877080|Biological|Fast Dual CAR-T Injection|Fast Dual CAR-T injection is a autologous dual CAR-T targeted CD19 and BCMA. A single infusion of CART cells will be administered intravenously.
79390474|NCT05381662|Biological|CD19 CAR-T cells and CD19 positive feeder T cells|Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
79708617|NCT01685957|Behavioral|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
79708618|NCT01685957|Behavioral|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
79848586|NCT00896792|Procedure|end-of-life treatment/management|
80016296|NCT00612170|Drug|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
80016297|NCT00612170|Drug|Placebo|0 mg oral tablet once a day dosing
80016298|NCT00612170|Drug|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
80016299|NCT00612170|Drug|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
80016300|NCT05104996|Behavioral|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
79848587|NCT00896792|Procedure|psychosocial assessment and care|
79848588|NCT00940524|Drug|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) *continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) *continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
79252330|NCT02461641|Other|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
79252331|NCT02461641|Other|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
79252332|NCT02461641|Other|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
79252333|NCT02069821|Drug|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
79252334|NCT04938778|Other|PNF|PNF Participants will engage in 8 weeks of 14 hours per night fasting
79252335|NCT02461329|Drug|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
79252336|NCT02461329|Drug|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
79708619|NCT01685957|Behavioral|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
79708620|NCT01602393|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
79708621|NCT01602393|Drug|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
79708622|NCT01602393|Drug|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
79848589|NCT00186901|Drug|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
80016301|NCT05099146|Behavioral|pictures|pictures with brushing technique demonstrated technique for proper brushing
80016302|NCT05099146|Behavioral|video|video of brushing technique demonstrated technique for proper brushing
80016303|NCT05099146|Behavioral|control|oral hygiene instructions provided
80016304|NCT00612014|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
80016305|NCT00612014|Drug|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
80016306|NCT00612014|Drug|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
79708623|NCT02273076|Device|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
80016307|NCT00612014|Drug|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
80016308|NCT00612014|Drug|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
80016309|NCT00612014|Drug|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
80016310|NCT05098288|Behavioral|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
79708624|NCT02271789|Other|problematic tooth|problematic tooth
79708625|NCT01645787|Drug|4-aminopyridine|10 mg/twice daily
79708626|NCT01645787|Drug|Placebo|Crossover study involving one trial with sugar pill (placebo)
79708627|NCT02270034|Drug|Crizotinib|Crizotinib is added to Stupp method
79708628|NCT01686113|Other|NEFA|
79708629|NCT01686113|Other|Sucrose|
79708630|NCT02270190|Device|Percutaneous Tibial Nerve Stimulation (PTNS)|
79708631|NCT01686230|Other|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
79848590|NCT00186901|Other|Placebo|Placebo
79848591|NCT00893126|Procedure|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
80016311|NCT05068336|Diagnostic Test|desflurane anesthesia|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
80016312|NCT05068336|Diagnostic Test|sevoflurane anesthesia|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
80016313|NCT00607256|Drug|[S,S]-reboxetine|S_S reboxetine dosed daily.
80016314|NCT02774590|Drug|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
80016315|NCT00606476|Drug|Bapineuzumab (AAB-001)|IV q13w
80016316|NCT02419456|Drug|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
79252337|NCT03655990|Device|Treatment with the JUVORA™ Dental Disc|treatment with the JUVORA™ Dental Disc
79252338|NCT02463825|Drug|Pimozide 2 mg per day|
79390475|NCT00358930|Drug|ARQ 501|
79390476|NCT02977078|Behavioral|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
79390477|NCT02977078|Device|Inhaler casing|Monitors inhaler use
79390478|NCT02977078|Device|Mobile application|Mobile application software linked to inhaler casing
79390479|NCT04492306|Other|Dimethyl Sulfoxide|DMSO [(CH3)2SO] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
79390480|NCT04492306|Other|3M ESPE Single bond 2|Total etch adhesive bond
79390481|NCT04492306|Other|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
79390482|NCT04492306|Other|3m ESPE etch|32% phosphoric acid
79848592|NCT00945126|Other|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
80016317|NCT02419456|Drug|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
80016318|NCT01069341|Drug|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
80016319|NCT00468806|Drug|GSK598809, using [11C]-(+)-PHNO|
80016320|NCT00676832|Drug|Placebo|Placebo solid capsule dosage form administered orally once daily.
79708632|NCT01686230|Drug|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
79708633|NCT01686269|Procedure|blood collecting|
79708634|NCT02273271|Other|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
79708635|NCT01688414|Procedure|photoacoustic imaging|Undergo PAI
79708636|NCT01688414|Procedure|fluorescence imaging|Undergo fluorescence imaging
79546540|NCT01544439|Procedure|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
79848593|NCT00888056|Procedure|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
79546541|NCT01544452|Procedure|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
79848594|NCT00943332|Procedure|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
79848595|NCT04036370|Procedure|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
79708637|NCT01688414|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
79252339|NCT02463825|Drug|Pimozide 4 mg per day|
79390483|NCT04486924|Device|Globe Mapping and Ablation System|Prospective, non-randomized, open-label clinical study.
79708638|NCT02273349|Device|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
79708639|NCT01686308|Procedure|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
79708640|NCT01686308|Procedure|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
79708641|NCT02270268|Dietary Supplement|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
79848596|NCT04036370|Other|Control group|Standard pain follow up and monitorization will be performed.
79848597|NCT00943410|Radiation|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
79848598|NCT00943410|Drug|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
79848599|NCT00896948|Genetic|Southern blotting|
79848600|NCT00896948|Genetic|TdT-mediated dUTP nick end labeling assay|
79848601|NCT00896948|Genetic|gene expression analysis|
79390484|NCT04482400|Behavioral|NEAT!2|8 week sedentary reduction program
79390485|NCT04482400|Behavioral|MyKneeGuide|8 week surgery recovery education program
79708642|NCT02270268|Dietary Supplement|maltodextrin|
79848602|NCT00896948|Genetic|protein expression analysis|
79252340|NCT02463825|Drug|Placebo (Lactose tablet)|
79252341|NCT04936828|Other|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
79252342|NCT02069977|Drug|Aripiprazole|
79252343|NCT04490031|Drug|Ketamine Hydrochloride|patient in Ketamine group will be given Ketamine as sedative agent
79252344|NCT02066935|Other|kidney transplant patient|kidney transplanted patients for at least one year
79252345|NCT05108961|Procedure|Acupuncture|one session with precise acupunture points
79708643|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
79708644|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
79708645|NCT02270307|Drug|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
79708646|NCT02270307|Biological|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
79708647|NCT05140772|Drug|Dipeptiven|IV administration daily for 7 days
79708648|NCT05140772|Drug|normal Saline|IV administration daily for 7 days
79708649|NCT02270385|Behavioral|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
79546542|NCT01544452|Procedure|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
79252346|NCT05108961|Behavioral|A digital stress scale|The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
79390492|NCT00361426|Device|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
79390493|NCT04868500|Device|AMAZE™ Application|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
79390494|NCT04868500|Device|AMAZE™ Dashboard|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
79390495|NCT04454086|Other|Aerobic Exercise|Undergo aerobic exercise
79390496|NCT04454086|Other|Exercise Counseling|Receive behavioral activity counseling
79708650|NCT02270385|Behavioral|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
79708651|NCT02270424|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
79848603|NCT00896948|Other|flow cytometry|
79848604|NCT00896948|Other|fluorescent antibody technique|
79848605|NCT00896948|Other|immunoenzyme technique|
79848606|NCT00896948|Other|immunohistochemistry staining method|
79848607|NCT00896948|Other|immunologic technique|
79848608|NCT00186121|Drug|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
80016321|NCT00676832|Drug|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
80016322|NCT04057443|Other|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
80016323|NCT04057443|Other|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
80016324|NCT04057443|Drug|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
79546543|NCT01544465|Behavioral|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
79252347|NCT05108961|Behavioral|a relaxation questionnaire|The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
79252348|NCT05108961|Diagnostic Test|Bispectral Index|BIS is based on an EEG analysis algorithm
79252349|NCT02443402|Drug|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) < 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
79252350|NCT02443402|Drug|Placebo|One pill daily until discharge
79252351|NCT02443402|Drug|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG > 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
79390497|NCT04454086|Other|Nutritional Assessment|Receive nutritional counseling
79546544|NCT01544465|Behavioral|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
79546545|NCT01544504|Drug|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
79546546|NCT01544517|Drug|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
79708652|NCT02270424|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
79708653|NCT02270424|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
79708654|NCT02270424|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
79708655|NCT02270424|Drug|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
79390498|NCT04454086|Other|Quality-of-Life Assessment|Ancillary studies
79390499|NCT04454086|Other|Questionnaire Administration|Ancillary studies
79848609|NCT00186121|Drug|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
79848610|NCT00897026|Drug|cyclophosphamide|
79252352|NCT02443402|Drug|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate >2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~If fasting and pre-dinner BG is > 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~If fasting and pre-dinner BG is < 100 mg/dL in the absence of hypoglycemia: stop glargine"
79390500|NCT04454086|Other|Resistance Training|Undergo resistance exercises
79390501|NCT04932694|Other|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
79390502|NCT04448158|Diagnostic Test|Genotypic Resistance Test|"A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~If M184V is still present no additional test will be performed.~If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing."
79390503|NCT04442464|Device|Scleral Lens|15.0 mm diagnostic spherical rigid contact lens
79390504|NCT04833010|Other|Cardiopulmonary Exercise Test|Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
79390505|NCT04833010|Other|Cognitive Performance Test|Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
79390506|NCT02977312|Drug|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
79390507|NCT00360802|Behavioral|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
79390508|NCT00360802|Behavioral|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
79390509|NCT02976610|Device|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
79546547|NCT01544530|Other|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
79546548|NCT01544569|Genetic|DNA analysis|
79390510|NCT04907110|Dietary Supplement|Niagen|Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day
79848611|NCT00897026|Drug|doxorubicin hydrochloride|
79848612|NCT00897026|Drug|paclitaxel|
79390511|NCT04907110|Other|Exercise|During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.
79390512|NCT04807738|Device|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"The 110 outpatients will be randomized into groups: First arm, individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in a second, interventional group, uses virtual reality and new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality."
79390513|NCT04807738|Other|"Neuroproprioceptive facilitation and inhibition"|The first arm of the study will consist of a physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
79390514|NCT02977234|Drug|Isoamyl 2-Cyanoacrylate|
79546549|NCT01544569|Genetic|fluorescence in situ hybridization|
79546550|NCT01544569|Genetic|gene expression analysis|
79546551|NCT01544569|Genetic|gene mapping|
79546552|NCT01544569|Genetic|microarray analysis|
79546553|NCT01544569|Genetic|polymerase chain reaction|
79546554|NCT01544569|Genetic|protein expression analysis|
79546555|NCT01544569|Other|laboratory biomarker analysis|
79546556|NCT01544569|Other|medical chart review|
79546557|NCT01544621|Other|Smoking cessation|Smoking cessation
79848613|NCT00897026|Genetic|fluorescence in situ hybridization|
79848614|NCT00897026|Other|immunohistochemistry staining method|
79848615|NCT00897182|Genetic|microarray analysis|
79848616|NCT00897182|Genetic|polymerase chain reaction|
79848617|NCT00186043|Drug|Quetiapine/Seroquel|Quetiapine/Seroquel
79848618|NCT00186043|Drug|Placebo|Placebo
79708656|NCT02270424|Drug|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
79708657|NCT02270424|Drug|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
79708658|NCT01686347|Drug|ropivacaine|
79708659|NCT02270541|Other|Telemedicine|In-ambulance telemedicine
79708660|NCT01686425|Procedure|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
79708661|NCT05140655|Drug|Fulvestrant|Medicine for Advanced breast cancer
79708662|NCT02270619|Biological|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
79708663|NCT02270619|Behavioral|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
79708664|NCT02270619|Other|Placebo|0.9% saline as IV bolus
79708665|NCT02270619|Other|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
79708666|NCT05140616|Drug|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
79708667|NCT01688570|Drug|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
79546558|NCT01544634|Drug|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
79708668|NCT01688570|Drug|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
79708669|NCT01688570|Drug|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
79546559|NCT01544634|Drug|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
79708670|NCT02270697|Device|Array|Applications of oligonucleotide array in diagnosis.
79708671|NCT01686464|Drug|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
79708672|NCT01686464|Device|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
79708673|NCT01686542|Procedure|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
79252353|NCT02443402|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
79708674|NCT01686542|Procedure|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
79708675|NCT02270931|Device|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
79390515|NCT02976454|Behavioral|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
79546560|NCT01544634|Drug|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
79390516|NCT02976454|Behavioral|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
79390517|NCT04394416|Drug|Imatinib|Therapeutic
79390518|NCT04394416|Drug|Placebo oral tablet|Placebo
79390519|NCT02976844|Procedure|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
79546561|NCT01544634|Drug|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
79546562|NCT01544647|Other|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
79546563|NCT01544647|Other|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
79546564|NCT01544673|Drug|linezolid|600 mg oral tablet twice daily for 4.5 days
79546565|NCT01544673|Drug|Placebo|500 mg oral placebo twice daily for 4.5 days
79546566|NCT01544686|Device|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
79546567|NCT01544712|Procedure|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
79546568|NCT01544712|Procedure|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
79708676|NCT02270970|Biological|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
79848619|NCT00897260|Drug|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~Fludarabine dose adjustment:~70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
79848620|NCT00897260|Radiation|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
79848621|NCT00897260|Procedure|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
79848622|NCT00897338|Other|flow cytometry|laboratory analysis
79848623|NCT00897338|Other|fluorescence activated cell sorting|laboratory analysis
79252354|NCT02443402|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin aspart~BG between 221-260 mg/dL; 3-5 units of insulin aspart~BG between 261-300 mg/dL; 4-6 units of insulin aspart~BG between 301-350 mg/dL; 5-7 units of insulin aspart~BG between 351-400 mg/dL; 6-8 units of insulin aspart~BG > 400 mg/dL; 7-9 units of insulin aspart"
79848624|NCT00897338|Other|immunohistochemistry staining method|laboratory analysis
79848625|NCT00897338|Other|immunologic technique|laboratory analysis
80016325|NCT02685358|Behavioral|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
80016326|NCT02685358|Behavioral|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
79252355|NCT02260297|Device|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
79252356|NCT02067013|Drug|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
79390520|NCT04796506|Other|Progressive Resistance Training (PRT)|PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by >24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with <24 minutes increase in SWS will transition to endurance training (ET).
79546569|NCT01544725|Drug|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
79252357|NCT02067013|Other|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
79708677|NCT05140733|Procedure|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
79708678|NCT05140733|Procedure|Fusion surgery|Fusion surgery for patients with foraminal stenosis
79708679|NCT01688648|Drug|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
79708680|NCT01688648|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
79708681|NCT02271009|Drug|AllerT|Ultrafast immunotherapy
79708682|NCT02271009|Drug|Placebo|placebo control
79708683|NCT01686659|Device|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin [SpHb] and Pleth Variability Index [PVI]) to the clinicians in the operating room
79708684|NCT02271048|Device|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
79708685|NCT01686698|Dietary Supplement|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
79708686|NCT01686698|Other|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
79708687|NCT01688687|Procedure|Endoscopic submucosal dissection|
79708688|NCT02271126|Device|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
79708689|NCT02271126|Device|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
79848626|NCT00897338|Other|biomarker analysis|laboratory analysis
80016327|NCT04057521|Other|Care Coordination|Comprehensive care coordination.
79708690|NCT02271126|Drug|Heparin|Anticoagulation provided to patients in ECMO
79546570|NCT01544725|Drug|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
79708691|NCT05140577|Other|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
79546571|NCT01544738|Other|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
79708692|NCT02271165|Drug|Immunoglobulin (Hizentra)|
79546572|NCT01544738|Other|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
79708693|NCT01686737|Behavioral|Iyengar Yoga|"12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
79708694|NCT01686737|Behavioral|Walking|"12 weeks of walking~2 weekly sessions of 60 minutes"
79708695|NCT02271204|Drug|Ibandronic acid|As prescribed by physician
79708696|NCT05140460|Behavioral|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
79708697|NCT05140460|Behavioral|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
79546573|NCT01544751|Drug|Low dose metformin|500 mg twice a day
79546574|NCT01544751|Drug|Metformin|1000 mg twice a day
79708698|NCT02271282|Drug|Toremifene|
79708699|NCT02271282|Drug|Placebo|
79708700|NCT02271282|Drug|GHRH/Ghrelin combined Injection|
79708701|NCT02271321|Other|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
79708702|NCT01686893|Device|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
79708703|NCT01686893|Device|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
79708704|NCT01580111|Biological|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
80016328|NCT01909414|Biological|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
79252358|NCT02461407|Drug|Anlotinib|Anlotinib p.o. qd
79252359|NCT02461407|Drug|Placebo|Placebo p.o. qd
79546575|NCT01544751|Drug|Atorvastatin|20 mg/day
79708705|NCT01688804|Behavioral|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
79708706|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 1
79708707|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 2
79252360|NCT02067091|Device|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
79390521|NCT04796506|Other|Delayed Exercise Training (DE)|PD subjects randomized to the exercise control group (1:1) will not exercise during the first 12 weeks of the study. During that time, they will be asked not to change their physical activity levels or dietary habits. All participants in the delayed-exercise group will begin PRT at completion of the 1st 12-week period.
79708708|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 3
79708709|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 1
79708710|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 2
79708711|NCT02271360|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
79708712|NCT02271360|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
79708713|NCT01687049|Drug|Red yeast rice|
79848627|NCT00185965|Drug|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
79848628|NCT00607880|Procedure|vascular access device placement|
80016329|NCT01909414|Biological|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10^8 TCID50 dose IM.
79708714|NCT02271399|Drug|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
79848629|NCT01076491|Drug|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
79848630|NCT02541890|Behavioral|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
79848631|NCT01076569|Other|laboratory biomarker analysis|Correlative studies
79848632|NCT00893282|Device|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
79848633|NCT00893282|Device|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
79848634|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
79848635|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
79848636|NCT00127933|Drug|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
79848637|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
79848638|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
79848639|NCT03875313|Drug|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
79848640|NCT03875313|Drug|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
79252361|NCT04193709|Device|Spinal Cord Epidural Stimulation|For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
79546576|NCT01544764|Other|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
79848641|NCT01008345|Drug|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
79546577|NCT01544777|Device|Study IOL|Aspheric IOL for correction of aphakia
79546578|NCT01544777|Device|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
79546579|NCT01544777|Device|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
79546580|NCT01544790|Procedure|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
79546581|NCT01544803|Behavioral|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
79708715|NCT02271399|Drug|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
79708716|NCT01689038|Drug|F17464|Single dose
79848642|NCT06089811|Dietary Supplement|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
79708717|NCT02271438|Drug|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6*140 mg capsules) of ibrutinib in Treatment B.
79708718|NCT02271438|Drug|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
79708719|NCT02271438|Drug|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
79708720|NCT02271438|Drug|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
79708721|NCT02271516|Radiation|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
79708722|NCT02272595|Other|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
79848643|NCT06089811|Dietary Supplement|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
79848644|NCT06089811|Dietary Supplement|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
79848645|NCT06089785|Device|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
79848646|NCT06089772|Other|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
79848647|NCT06089746|Other|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
79848648|NCT06089733|Drug|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
79848649|NCT06089733|Drug|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
80016330|NCT01909414|Biological|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
79708723|NCT02272595|Other|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
79708724|NCT02271555|Drug|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
79708725|NCT02271555|Drug|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
79708726|NCT02271555|Drug|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
79708727|NCT02271672|Device|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
79708728|NCT02271672|Device|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
79708729|NCT01687205|Drug|1% Tenofovir Gel|
79708730|NCT02271711|Other|Laboratory Biomarker Analysis|Correlative studies
79708731|NCT02271711|Biological|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
79848650|NCT06089720|Device|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans & lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
79546582|NCT01544803|Behavioral|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
79848651|NCT06089720|Device|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans & lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
80016331|NCT01909414|Biological|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
79390522|NCT04796506|Other|Endurance Training (ET)|Non-responders to PRT will transition too ET during 2nd 12 weeks of the study. This intervention is supervised endurance training, 3 times per week for 12 weeks. Each session lasts approximately 75 min., comprised of warm-up, stimulus phase for 50-60 min., and cool-down. Sessions are split between cycle ergometer and treadmill exercise. Participant heart rate is monitored to maintain target exercise intensity of 60-80% (±5%) of heart rate reserve (HRR).
79390523|NCT04792528|Other|Computerized cognitive training.|COGMED RM program (Pearson Inc., UK)
79390524|NCT04792528|Other|Generalized brain training / Active control|Solitaire
79390525|NCT04782232|Other|No intervention|No intervention due to observational design
79390526|NCT04388332|Procedure|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
79546583|NCT01544816|Other|Snack Product|control food product
79708732|NCT01689194|Drug|genexolPM + cisplatin|
79708733|NCT02271750|Procedure|lumbar puncture|for spinal fluid
79708734|NCT01687361|Dietary Supplement|branched-chain amino acids (BCAA) supplementation|
79708735|NCT01687361|Drug|PLACEBO|
79708736|NCT02271828|Procedure|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
79708737|NCT01689272|Procedure|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
79708738|NCT02271867|Procedure|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
79708739|NCT01687439|Drug|Endostar|7.5mg/m2, D1-14
79708740|NCT01687439|Drug|Vinorelbine|25-30mg/m2, D1,8
79708741|NCT01687439|Drug|Cisplatin|25 mg/m2, D1-3
79708742|NCT01687439|Radiation|Radiotherapy|
79390527|NCT04388332|Device|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
79390528|NCT04372186|Drug|Placebo|Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
79546584|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 1
79546585|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 2
79546586|NCT01544829|Dietary Supplement|Theobromine|Single dose of theobromine
79546587|NCT01544829|Dietary Supplement|Theobromine|Multiple doses of theobromine
79546588|NCT01544829|Dietary Supplement|Placebo|Placebo capsules
79546589|NCT01544842|Drug|0.1 % tacrolimus ointment|applied topically to oral mucosa
79546590|NCT01544842|Drug|0.1 % triamcinolone paste|applied topically to oral mucosa
79546591|NCT01544842|Drug|Orabase paste|applied topically to oral mucosa
79708743|NCT01588704|Drug|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
79708744|NCT01687634|Behavioral|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
79708745|NCT01687634|Behavioral|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
79708746|NCT01588743|Drug|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
79708747|NCT01689311|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
79708748|NCT01689311|Drug|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
79848652|NCT06089707|Drug|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
79848653|NCT06089655|Device|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
80016332|NCT00467402|Drug|agomelatine|
80016333|NCT00467402|Drug|placebo|
79708749|NCT01689311|Drug|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
79708750|NCT01689311|Drug|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
79708751|NCT01588782|Drug|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
79708752|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
79708753|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
79708754|NCT02272062|Other|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
79708755|NCT02276456|Behavioral|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
79708756|NCT02273427|Drug|BIIL 284 BS|
79708757|NCT02273427|Other|high fat meal|
79708758|NCT02273427|Other|low fat meal|
79708759|NCT02272101|Dietary Supplement|Vitamin D versus placebo|Cross-over design
79708760|NCT01689467|Dietary Supplement|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
79708761|NCT01689467|Dietary Supplement|Placebo|Placebo (1g/day)
79708762|NCT02272218|Procedure|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
79708763|NCT02272335|Behavioral|Group Sessions|"10 weekly sessions:~CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
79708764|NCT02278133|Drug|WNT974|
79708765|NCT02278133|Drug|LGX818|
79708766|NCT02278133|Biological|Cetuximab|
79252362|NCT03298581|Drug|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
79708767|NCT02277704|Drug|TNX-102 SL|
79252363|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
79252364|NCT01370005|Drug|BI 10773|BI 10773 high dose once daily
79252365|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
79252366|NCT01370005|Drug|BI 10773|BI 10773 low dose once daily
79390529|NCT04372186|Drug|Tocilizumab|Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
79390530|NCT04360174|Drug|OTX-TIC|OTX-TIC implant is injection in the anterior chamber of the eye
79390531|NCT02976298|Other|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
79390532|NCT04358224|Biological|Dupilumab Prefilled Syringe|open-label
79546592|NCT01544855|Dietary Supplement|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
79708768|NCT02277704|Drug|Placebo|
79708769|NCT00107172|Procedure|surgery|
79708770|NCT00107172|Radiation|brachytherapy|
79708771|NCT01687868|Drug|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
79708772|NCT01687907|Behavioral|Music|
79708773|NCT02272374|Procedure|AVF creation|
79708774|NCT02272374|Procedure|TCC placement|
79252367|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
79252368|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
79390533|NCT04357132|Other|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora Application
79390534|NCT04357132|Other|VR-Distraction|Participants will be instructed to use one of four applications
79708775|NCT02272374|Procedure|AVG creation|
79708776|NCT01688024|Drug|Mitomycin C|
79708777|NCT01688024|Drug|Normal saline|
79708778|NCT01689506|Drug|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
79708779|NCT01689506|Drug|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
79708780|NCT02272452|Device|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
79708781|NCT01689545|Behavioral|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
79708782|NCT01689545|Behavioral|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
79708783|NCT01689545|Behavioral|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
79708784|NCT01689545|Behavioral|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
79708785|NCT04059861|Diagnostic Test|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
79708786|NCT01689623|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
79848654|NCT06089655|Behavioral|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
79848655|NCT06089642|Device|Virtual reality|Virtual reality based on distraction and Virtual Reality based on focussed attention
80016334|NCT02996097|Device|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
79252369|NCT02070055|Other|No intervention|
79252370|NCT03782077|Procedure|Deflation of pneumatic tourniquet|Deflation of pneumatic tourniquet
79252371|NCT02070133|Drug|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
79252372|NCT02070133|Drug|Placebo|Placebo once a day during 12 weeks
79252373|NCT02067169|Biological|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
79390535|NCT04357054|Diagnostic Test|Darwish test|Infertile women planned for combined laparoscopy and hysteroscopy as an integral part of infertility wok-up.
79390536|NCT02976376|Other|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
79708787|NCT01689623|Drug|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
79252374|NCT02070211|Dietary Supplement|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
79390537|NCT02977000|Drug|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
79708788|NCT01689623|Drug|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
79708789|NCT04055142|Procedure|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
79708790|NCT04055142|Drug|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
79848656|NCT06089629|Procedure|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
79848660|NCT06089590|Other|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
80016335|NCT02996097|Drug|Intralesional Triamcinolone Acetonide|
79390538|NCT02975986|Other|123I-BMIPP|Uptake of radioactive isotope by the kidney
79390539|NCT02975986|Other|99mTc-MAG3|Uptake of radioactive isotope by the kidney
79390540|NCT00112827|Radiation|total marrow irradiation|Undergo irradiation
79390541|NCT00112827|Drug|melphalan|Given IV
79390542|NCT00112827|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
79390543|NCT00112827|Biological|filgrastim|Given IV
79390544|NCT00112827|Genetic|fluorescence in situ hybridization|Correlative studies
79390545|NCT00112827|Genetic|cytogenetic analysis|Correlative studies
79708791|NCT04055142|Drug|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
79708792|NCT02272569|Device|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
79708793|NCT01688258|Procedure|Diagnostic swab|
79708794|NCT02272608|Other|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
79390546|NCT00112827|Drug|cyclophosphamide|Given IV
79390547|NCT00112827|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
79390548|NCT00112827|Drug|lenalidomide|Given orally
79390549|NCT04317040|Drug|Efprezimod alfa|Efprezimod alfa is given on Day 1.
79390550|NCT04317040|Drug|Placebo|Placebo is given on Day 1.
79708795|NCT01688297|Biological|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
79708796|NCT01688297|Biological|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
79708797|NCT04054323|Behavioral|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
79252375|NCT02070211|Other|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
79708798|NCT05138354|Other|Low Level laser therapy|MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
79708799|NCT05138354|Other|Myofascial release|Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
79708800|NCT05138354|Other|Standard care|"Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~Lateral movements of the jaw (3 sets of 10 repetitions).~Jaw relaxation exercise (3 sets of 10 repetitions).~Chin tuck (10 repetitions, holding 10s each).~Resisted opening of the mouth (3 sets of 10 repetitions).~Resisted closing of the mouth (3 sets of 10 repetitions).~Stretching exercise for mandibular muscles."
79390551|NCT01897701|Biological|Monovalent Avian Influenza VLP (H7N9)|
79390552|NCT01897701|Biological|Adjuvant 1|
79708801|NCT02272647|Drug|IM Saline Placebo (0.25 ml)|
79708802|NCT02272647|Drug|IM Estradiol valerate (2.5 mg)|
79708803|NCT02272647|Drug|IM Saline Placebo (0.5 ml)|
79708804|NCT02272647|Drug|IM Estradiol valerate (5.0 mg)|
79708805|NCT02272647|Drug|Oral Micronized Progesterone|
79390553|NCT01897701|Biological|Placebo|
79708806|NCT02272647|Drug|Oral Placebo|
79708807|NCT02272647|Drug|Ghrelin (0.3 ug/kg)|
79708808|NCT02272647|Drug|Medroxyprogesterone - Acetate|
79390554|NCT04752345|Other|Pharmacoinvasive strategy|Pharmacoinvasive treatment [full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
79390555|NCT04752345|Other|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(<3 hours)]
79390556|NCT04314076|Other|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
79390557|NCT04314076|Other|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
79708809|NCT02272647|Drug|Oral Placebo|(in lieu of Medroxyprogesterone)
79708810|NCT01689818|Other|exercise training|exercise training program which included aerobic exercise for 3 times per week.
79708811|NCT02272764|Drug|Itraconazole|Administered orally in a crossover design
79708812|NCT02272764|Drug|ALKS 5461|Administered sublingually in a crossover design
79252376|NCT02070211|Dietary Supplement|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
79390558|NCT04752111|Drug|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
79390559|NCT04313140|Diagnostic Test|Diagnostic test|"The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:~Cinicial MRI (50 minutes)~Research MRI (Phosphorus Spectroscopy, Sodium Imaging)"
79708813|NCT01689896|Drug|Testosterone Gel|
79708814|NCT01689896|Drug|Placebo Gel|
79708815|NCT01316094|Drug|ASP1941|oral
79708816|NCT01316094|Drug|placebo|oral
79708817|NCT01689935|Drug|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
79708818|NCT01689935|Device|Red light only|Red Light therapy
79708819|NCT01689935|Device|Blue light only|Blue light only
79708820|NCT01316133|Drug|tacrolimus|oral
79708821|NCT01684826|Radiation|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
79708822|NCT01684826|Radiation|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
79708823|NCT01316172|Behavioral|5 Cs|education on consultation
79708824|NCT05654064|Drug|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
79708825|NCT05654064|Drug|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
79708826|NCT01689233|Drug|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
79252377|NCT02067247|Device|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
79708827|NCT01689233|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
79708828|NCT02272881|Procedure|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
79708829|NCT02272881|Procedure|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
79708830|NCT01687985|Drug|BLI801 laxative - low dose|BLI801 laxative - oral solution
79708831|NCT01687985|Drug|BLI801 laxative - high dose|BLI801 laxative - oral solution
79708832|NCT01686620|Drug|BIOD-123|
79708833|NCT01686620|Drug|Lispro (Humalog)|
79708834|NCT01685255|Drug|Epacadostat|
79708835|NCT01685255|Drug|tamoxifen|
79708836|NCT01684163|Drug|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
79390560|NCT02976688|Other|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
79390561|NCT00226239|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV over 1 hour, day 1
79390562|NCT00226239|Drug|Cisplatin|Cisplatin 75 mg/m^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
79390563|NCT00226239|Drug|Cetuximab|Cetuximab dose will be 250 mg/m^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
79708837|NCT01684163|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
79708838|NCT01684163|Drug|Placebo|Intravenous administration of normal saline into arm.
79708839|NCT05653284|Drug|AK130|IV infusion, specified dose on specified days.
79252378|NCT02070289|Drug|PF-06372865|Tablets, 2.5 mg BID, 14 days
79252379|NCT02070289|Drug|Placebo|Tablets, BID, 14 days
79390564|NCT00226239|Procedure|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies>6 MV may be utilized when appropriate to boost target localized centrally.
79390565|NCT04033822|Procedure|cholecystectomy|If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
79390566|NCT04729972|Combination Product|NT-501 CNTF implant|Single implantation of CNTF-secreting NT-501 device into one eye
79708840|NCT01680965|Drug|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
79708841|NCT02272920|Procedure|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
79708842|NCT02272959|Behavioral|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
79708843|NCT02272959|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
79252380|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
79252381|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
79252382|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
79252383|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
79252384|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
79252385|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
79252386|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
79252387|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
79252388|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
79252389|NCT02067325|Other|Thai massage|
79252390|NCT02070367|Other|Somatosensory rehabilitation|
79252391|NCT02070367|Other|Usual treatment: physiotherapy|
79390567|NCT00227019|Drug|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
79390568|NCT00227019|Drug|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
79708844|NCT05140304|Device|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
79708845|NCT01683188|Drug|vemurafenib + HD IL-2|
79708846|NCT01339923|Biological|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
79708847|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
79708848|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
79708849|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses 2 months apart
79708850|NCT01339923|Biological|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
80016336|NCT04054713|Diagnostic Test|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
79708851|NCT01339923|Biological|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
80016337|NCT04054713|Diagnostic Test|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
79252392|NCT02071927|Drug|CB-839|Single-agent CB-839
79252393|NCT02071927|Drug|CB-Aza|CB-839 in combination with standard dose azacitidine
79252394|NCT02070523|Drug|VDCLD regimen|
79252395|NCT02072005|Other|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
79252396|NCT02072083|Drug|Dexmedetomidine|via intranasal route 1 mcg/kg
79252397|NCT02072083|Drug|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
79252398|NCT02442778|Drug|AVP-786-18|18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
79546593|NCT01544868|Other|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
79546594|NCT01544881|Drug|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
79546595|NCT01544881|Drug|Rapid Acting Analog|Subcutaneous Injection
79546596|NCT01544894|Drug|Raloxifene|60 mg/d for one year
79546597|NCT01544894|Drug|Strontium ranelate|2 g/d, for one year
79546598|NCT01544907|Device|Conventional PTA|Use of conventional balloon for angioplasty only
79546599|NCT01544907|Device|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
79546600|NCT01544946|Drug|88% sucrose po|88% sucrose solution (Syrup B.P.)
79708852|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
79708853|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
79708854|NCT04615832|Device|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
79708855|NCT05652036|Biological|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
79708856|NCT05651334|Device|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
79708857|NCT05651334|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
79708858|NCT05650905|Device|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
80016338|NCT03314181|Drug|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
80016339|NCT03314181|Drug|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
80016340|NCT03314181|Drug|Venetoclax|Tablet; Oral
80016341|NCT03314181|Drug|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
79252399|NCT02442778|Drug|Placebo|Administered as capsules.
79252400|NCT02442778|Drug|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
79252401|NCT02442778|Drug|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
79390569|NCT00227019|Drug|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
79390570|NCT00227019|Drug|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
79390571|NCT00227019|Drug|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
79390572|NCT00113217|Drug|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
79252402|NCT02067403|Other|Pressure-support Eadi optimization|
79252403|NCT02070679|Drug|Vitamin E|
79252404|NCT02067481|Behavioral|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
79546601|NCT01544946|Drug|placebo po|sterile water
79708859|NCT05650905|Device|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
79848661|NCT06089564|Behavioral|Skit video, Pictorial, Sign language|Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.
79252405|NCT02067559|Behavioral|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
79252406|NCT02067559|Behavioral|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
80016342|NCT03133832|Drug|Companion Tablet|Chinese-made drug for schistosomiasis treatment
80016343|NCT00603668|Biological|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
80016344|NCT03663309|Diagnostic Test|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~Bring 4-day food diary (attached)~Fill symptoms and complaints questionnaire (attached)~Provide 24 h diet recall in case a food diary absents~Fill Biagi score questionnaire (attached)~Perform blood test of TTG~Provide stool and urine samples"
79252407|NCT02412436|Drug|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
79252408|NCT02067715|Drug|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
79252409|NCT02072239|Device|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
79252410|NCT02072317|Drug|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
79252411|NCT02072317|Drug|taxol|taxol 135 mg/m2, every three weeks for a cycle
79390573|NCT02976064|Behavioral|PreHabilitation|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~Work plan execution & 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
79546602|NCT01544959|Drug|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
79546603|NCT01544959|Drug|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
79708860|NCT05650905|Device|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
79708861|NCT05650905|Device|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
79708862|NCT05650905|Diagnostic Test|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
79546604|NCT01544972|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
79546605|NCT01544972|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
79546606|NCT01544985|Drug|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
79546607|NCT01544985|Drug|placebo po|sterile water
79546608|NCT01545011|Other|Inspiratory muscle training|Inspiratory muscle training
79546609|NCT01545024|Drug|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
79708863|NCT05140109|Other|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
79708864|NCT05140109|Other|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
80016345|NCT00675116|Drug|GW823296|
79252412|NCT02072395|Procedure|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
79546610|NCT01545037|Dietary Supplement|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
79252413|NCT02072473|Procedure|Coronary sinus / left-sided slow pathway ablation|"Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:~coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by~left-sided slow pathway ablation, using trans-septal approach."
79252414|NCT03781453|Behavioral|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
79708865|NCT05140109|Other|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
79708866|NCT04195919|Drug|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
79708867|NCT04195919|Drug|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
79848662|NCT06089538|Diagnostic Test|mEEG battery|The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
79848663|NCT06089512|Procedure|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
79848664|NCT06089512|Procedure|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
79252415|NCT01651000|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
79390574|NCT02976064|Behavioral|Rehabilitation in chronic stable patients in primary care|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~Work plan execution & 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk & patients with mild disease."
79390575|NCT02976064|Behavioral|Rehabilitation in mild chronic patients and citizens at risk|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~Work plan execution & 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
79390576|NCT04718116|Drug|Group tapentadol 50 mg|patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
79390577|NCT04718116|Drug|group tapentadol 75 mg|patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
79708868|NCT01380093|Drug|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
79848665|NCT06089512|Procedure|Control group|Only general anesthesia was applied to the patients.
79848666|NCT06089499|Behavioral|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
79390578|NCT04718116|Drug|group tramadol 100 mg|patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
79390579|NCT00115869|Behavioral|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
79390580|NCT04276792|Behavioral|TCU Opioid-Treatment Linkage Model (O-TLM)|The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
79708869|NCT01380093|Drug|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
79848667|NCT06089473|Other|Intervention Group: Exercise, Nutritional, and Psychological Support|"Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session.~Nutritional Intervention: this will include a comprehensive nutrition assessment by a dietitian, followed by a visit with a nutritionist to address individual needs and convey recommendations (in-person for those in Quebec, and online for those in Alberta).~Psychological Intervention: this will include an initial in-person consultation to identify participants' needs. If anxiety or depression are identified, participants will be referred to a web-based resource with evidence-bases strategies and resources to help develop coping skills. Some participants may be referred to a psychiatrist if this has not already been done by the transplant team."
79848668|NCT06089473|Other|Usual Care Only|Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.
79252416|NCT01651000|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
79252417|NCT04911322|Device|ultrasonography|"A full obstetric ultrasound scan will be performed to assess signs of placental invasion, to document fetal biometry, estimated fetal weight, amniotic fluid index, assess fetal lung maturity parameters as pulmonary artery Doppler waveforms, amniotic fluid free floating particles, bowel echogenicity, fetal epiphyseal ossific centers, liver/lung echogenicity and kidney length.~Pulmonary artery Doppler: Fetal echocardiography will be done. Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time ratio will be measured in the main pulmonary artery."
79546611|NCT01545037|Other|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
79708870|NCT01380093|Drug|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
79708871|NCT01686854|Behavioral|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
79708872|NCT01686854|Other|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
79708873|NCT04099199|Diagnostic Test|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
79390581|NCT00053703|Drug|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
79708874|NCT04083326|Device|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
79708875|NCT04059926|Other|insert apossing lumen metal stent|insert apossing lumen metal stent
80016346|NCT05011240|Behavioral|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
80016347|NCT05011240|Behavioral|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
80016348|NCT03663465|Other|Hawthorn|Hawthorn tablet
80016349|NCT03663465|Drug|SGAs|SGAs tablet
80016350|NCT00461006|Drug|Actos|45mg po daily
79390582|NCT00053703|Drug|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
79252418|NCT02072629|Other|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
79546612|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
79390583|NCT00053703|Drug|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
79390584|NCT02975440|Drug|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
79390585|NCT02975440|Drug|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
79390586|NCT02975440|Drug|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
79390587|NCT04269772|Behavioral|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
79546613|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
79546614|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
79546615|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
79252419|NCT02469610|Other|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
79546616|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
79252420|NCT02071069|Drug|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
79252421|NCT02071069|Drug|irinotecan|180 mg/m2 IV every 2 weeks
79546617|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
79546618|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
79546619|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
79546620|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
79546621|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
79252422|NCT02071069|Drug|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
79252423|NCT02076373|Drug|recombinant human Erythropoietin|i.v. administration
79252424|NCT02076373|Drug|Placebo|i.v. administration
79252425|NCT02072707|Procedure|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
79252426|NCT02072707|Procedure|Endocardial VT Ablation|Endocardial Only VT ablation
79252427|NCT02072785|Drug|Vincristine Sulfate Liposome|
79252428|NCT02072785|Drug|Vincristine Sulfate|
79390588|NCT04269772|Other|Treatment As Usual|Treatment as usual, unrestricted, as provided by prison and community providers.
79390589|NCT00231309|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
79390590|NCT05440162|Diagnostic Test|electrolyte|follow up NA
79390591|NCT04267120|Drug|Lenvatinib|Lenvatinib will be provided by Merck.
79390592|NCT04267120|Drug|Pembrolizumab|Merck will provide pembrolizumab
79390593|NCT04267120|Procedure|Research blood collection|-Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
79708876|NCT04826705|Device|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
79708877|NCT04829084|Behavioral|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
79708878|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
79708879|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
79708880|NCT01379937|Biological|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
79708881|NCT01379937|Biological|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
79708882|NCT03720392|Drug|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
79708883|NCT03720392|Drug|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
79708884|NCT01379781|Behavioral|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
79708885|NCT04820972|Drug|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
79708886|NCT03558854|Drug|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
79708887|NCT03558854|Drug|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
79708888|NCT03545126|Other|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
79708889|NCT01335477|Drug|placebo|placebo matching BIBF 1120 BID
79848669|NCT06089447|Behavioral|A story based intervention called 'The Shadow of Tallystick Valley'|'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.
79252429|NCT02071147|Other|No Clinical Follow up|
79252430|NCT02071147|Other|Quality of Life questionnaire|
79252431|NCT02071147|Other|Patient satisfaction Questionnaire|Conducted at Research clinic.
79252432|NCT02469298|Drug|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
79708890|NCT01335477|Drug|BIBF 1120|BIBF 1120 BID (twice daily)
79708891|NCT03389438|Biological|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
79708892|NCT04829474|Other|Survey|It is a survey that the patient and doctor must complete.
79708893|NCT04828850|Procedure|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
79708894|NCT01371825|Drug|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
79708895|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
79708896|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
79708897|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
79708898|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
79708899|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
79252433|NCT02469298|Drug|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
79252434|NCT02469298|Drug|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
79252435|NCT02469298|Drug|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
79252436|NCT02076451|Drug|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
79252437|NCT02071303|Drug|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
79252438|NCT02071303|Drug|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
79708900|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
79708901|NCT01371747|Drug|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
79708902|NCT01371747|Drug|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
79708903|NCT03321617|Drug|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
79708904|NCT01371708|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
79708905|NCT01335399|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708906|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708907|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708908|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708909|NCT01335399|Drug|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708910|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708911|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
79708912|NCT03176615|Dietary Supplement|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
79252439|NCT02071303|Drug|Placebo|A placebo will be given to 70 women before the procedure.
79252440|NCT02260453|Other|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
79390594|NCT00116337|Procedure|Spinal Cord Stimulation to restore cough|Participants will have small electrodes (metal discs) placed - by a routine surgical procedure - over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
79390595|NCT00116337|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
79848670|NCT06089421|Other|Genetic Information Assistant|Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
79252441|NCT02260453|Other|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
79390596|NCT04252846|Drug|Perampanel|Perampanel oral tablets or oral suspension.
79390597|NCT00232479|Drug|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
79390598|NCT04713202|Drug|Telotristat ethyl|Telotristat Ethyl, 250mg
79390599|NCT04713202|Drug|Peptide Receptor Radionuclide Therapy|Peptide Receptor Radionuclide Therapy
79390600|NCT04713202|Other|Placebo|Placebo
79252442|NCT02076529|Drug|Ramosetron 0.3mg|
79708913|NCT01366521|Biological|Mepolizumab|Monoclonal antibody
79390601|NCT01897311|Device|transcutaneous electrical nerve stimulation|
79390602|NCT00233103|Drug|Sertraline|Sertraline arm
79252443|NCT02076529|Drug|Ramosetron 0.45mg|
79252444|NCT02076529|Drug|Ramosetron 0.6mg|
79252445|NCT04163991|Drug|VIB4920|liquid for IV infusion following dilution in normal saline
79390603|NCT00233103|Drug|Placebo|Placebo
79708914|NCT04825262|Drug|Tacrolimus|Starting dose based on CYP3A5 genotype
79708915|NCT04825145|Other|Pregnancy|Pregnancies complicated by preeclampsia
79708916|NCT01335009|Biological|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
79708917|NCT04824365|Drug|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
79708918|NCT04824365|Other|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
79708919|NCT01366443|Procedure|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
79708920|NCT01366443|Procedure|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
79708921|NCT01366443|Procedure|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
79848671|NCT06089421|Other|Telegenetics with UVA genetic counselor|Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
79848672|NCT06089408|Other|Best Practice|Use a regular blanket
79848673|NCT06089408|Other|Supportive Care|Use a weighted blanket
79252446|NCT04163991|Drug|Placebo|0.9% saline for IV infusion
79252447|NCT02073019|Drug|BL-8040|
79252448|NCT02073019|Drug|Placebo|
79252449|NCT02442622|Other|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
79252450|NCT02442622|Device|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
79252451|NCT02071381|Drug|DW330SR 45mg|
79252452|NCT02071381|Drug|DW1030 75mg|
79252453|NCT02073175|Drug|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
79708922|NCT01332630|Drug|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
79708923|NCT01332630|Drug|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
79708924|NCT01332630|Drug|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
79708925|NCT01332630|Drug|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
79708926|NCT04822961|Drug|Placebo|Senaparib-matched placebo capsules
79708927|NCT04822961|Drug|Senaparib|20 mg capsules
79708928|NCT01366209|Drug|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
79708929|NCT01366209|Drug|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
79708930|NCT01600001|Drug|KWA-0711|
79252454|NCT02073253|Other|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
79708931|NCT01600001|Drug|Placebo|
79708932|NCT01365546|Biological|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
79252455|NCT02411578|Drug|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment~BG is 50-69 mg/dl, treatment is 150 µg of glucagon~BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~BG is 60-69 mg/dl, no treatment~BG is 50-59 mg/dl, treatment is 150 µg of glucagon~BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~BG is >=70, no treatment~BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)"
79252456|NCT02411578|Other|Glucose Tablets|"1st BG check, 1st treatment~BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~BG is 60-69 mg/dl, no treatment~BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~BG is >=70, no treatment~BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
79708933|NCT04828421|Dietary Supplement|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
79848674|NCT06089408|Other|Survey Administration|Ancillary studies
79848675|NCT06089382|Drug|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）
79252457|NCT02076607|Procedure|Arthrodesis|Posterior approach to toracolumbar spine fusion.
79252458|NCT02076607|Device|Brace|Toracolumbar imobilization
79390604|NCT04000750|Other|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
79390605|NCT04000750|Other|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
79390606|NCT04000750|Other|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
79390607|NCT04000750|Dietary Supplement|Whey Protein|Consumed on all exercise days.
79848676|NCT06089382|Drug|Lenvatinib|8mg orally once a day for 1 year
79390608|NCT04704076|Other|ESVS|Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
79708934|NCT04828421|Dietary Supplement|Placebo|Placebo
79708935|NCT01600040|Radiation|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
79708936|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
79708937|NCT02995694|Drug|Estradiol|Estradiol Vaginal Cream
79848677|NCT06089382|Procedure|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
79848678|NCT06089369|Biological|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
79848679|NCT06089369|Procedure|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
79848680|NCT06089356|Drug|zolmitriptanee|zolmitriptane tablet daily
79390609|NCT04704076|Other|Exclusive breastfeeding|Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
79390610|NCT00117585|Other|Treatment Phase 1|"Patient Education~Physical Therapy Exercises~Increased Salt Intake~Elevation of head of bed with 2-4 inch wedge~Medication Review by MD, Pharma"
79390611|NCT00117585|Drug|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~Fludrocortisone~Salt tablet"
79708938|NCT02995694|Drug|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
79708939|NCT02995694|Drug|Reference|Estrace Vaginal Cream
79708940|NCT01365468|Drug|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
79708941|NCT04827836|Procedure|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
79708942|NCT01357980|Biological|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
79708943|NCT01357980|Drug|Placebo|Intra detrusor injection on Day 1 (single dose)
79708944|NCT01332318|Drug|XP13512|XP13512 once daily for 16 days
79848681|NCT06089356|Drug|topiramate|topiramate once daily
79848682|NCT06089356|Drug|Valproate|valproate once daily
79848683|NCT06089343|Diagnostic Test|Coronary CT angiography|Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.
80016351|NCT00461006|Drug|aleglitazar|0.6mg po daily
79252459|NCT03298503|Other|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
79708945|NCT01332318|Drug|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
79708946|NCT01332318|Drug|Placebo|XP13512 placebo once daily for 16 days
79708947|NCT02071901|Drug|eltrombopag olamine|Given PO
79708948|NCT01331109|Drug|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
79390612|NCT00117585|Other|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
79390613|NCT00703014|Drug|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
79252460|NCT02076685|Drug|isoniazid|dose adjustment according to the pharmacogenomic results
79546622|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
79546623|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
79390614|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79390615|NCT00703014|Drug|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
79546624|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
79708949|NCT01865396|Behavioral|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
79708950|NCT01865396|Behavioral|Standard oncologic care|Patients will receive standard oncologic care.
79848684|NCT06089330|Drug|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
79546625|NCT01545089|Other|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
79546626|NCT01545089|Other|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
79546627|NCT01545154|Device|Transperineal Ultrasound|
79546628|NCT01545167|Genetic|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
79708951|NCT01357551|Behavioral|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
79708952|NCT01640483|Other|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
79708953|NCT01357239|Drug|AFQ056|
79252461|NCT05077917|Drug|Cromolyn Sodium|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
79252462|NCT05077917|Other|Placebo|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
79252463|NCT02071459|Drug|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
79252464|NCT02071459|Drug|placebo|initial period (4 weeks) followed by 8 weeks
79252465|NCT02463747|Drug|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
79708954|NCT01357239|Drug|Placebo|
79708955|NCT04820582|Other|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
79708956|NCT00903500|Behavioral|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
79708957|NCT00737321|Procedure|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
79708958|NCT01351350|Drug|MLN0128|MLN0128 capsules
79708959|NCT01351350|Drug|paclitaxel|paclitaxel intravenous infusion
79708960|NCT01351350|Drug|trastuzumab|trastuzumab intravenous infusion
79708961|NCT02271503|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
79708962|NCT02271503|Drug|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
79708963|NCT02271503|Drug|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
79708964|NCT02271503|Drug|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
79708965|NCT02271503|Drug|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
79708966|NCT04526405|Diagnostic Test|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
79848685|NCT06089330|Drug|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
79848686|NCT06089330|Drug|Irinotecan|180mg/m^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
80016352|NCT02452840|Other|No Intervention|No Intervention
80016353|NCT04161430|Drug|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
79708967|NCT01350999|Drug|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
79708968|NCT01350999|Drug|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
79708969|NCT02275559|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
79546629|NCT01545219|Dietary Supplement|Prebiotic|8g/day xylo-oligosaccharide
79546630|NCT01545219|Dietary Supplement|Bi-07|10^9 CFU B. lactis / day
79708970|NCT02275559|Behavioral|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
79708971|NCT04526522|Other|No intervention|No intervention
79708972|NCT02270021|Other|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
79708973|NCT02270021|Other|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
79252466|NCT02463747|Drug|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
79546631|NCT01545219|Dietary Supplement|Synbiotic|8g/day xylo-oligosaccharide + 10^9 CFU Bi-07
79546632|NCT01545219|Dietary Supplement|Placebo|8g/day maltodextrin
79546633|NCT01545258|Other|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
79708974|NCT01350804|Biological|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
79390616|NCT00703014|Drug|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79390617|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
79708975|NCT01350804|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
79708976|NCT01350804|Biological|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
79252467|NCT02463747|Drug|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
79546634|NCT01545284|Drug|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
79546635|NCT01545297|Drug|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
79546636|NCT01545297|Drug|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
79546637|NCT01545297|Drug|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
79546638|NCT01545310|Drug|SLV354|One dose of ABT-354
79546639|NCT01545323|Genetic|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
79546640|NCT01545349|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
79546641|NCT01545349|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
79546642|NCT01545349|Biological|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
79546643|NCT01545362|Procedure|Total knee arthroplasty|Total knee arthroplasty
79708977|NCT04526249|Device|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
79708978|NCT02274818|Behavioral|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
79848687|NCT06089330|Drug|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
79252468|NCT02463747|Drug|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
79252469|NCT02465775|Device|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
79252470|NCT02071537|Drug|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
79390618|NCT00703014|Drug|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
79546644|NCT01545401|Other|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~Global CV Risks Self-Management Booklets~CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
79848688|NCT06089304|Device|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
79848689|NCT06089252|Drug|walnut extract|Four times a day over a 10-day period
79848690|NCT06089213|Other|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
80016354|NCT04161430|Drug|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
80016355|NCT04161430|Drug|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
79252471|NCT02071537|Drug|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
79252472|NCT02071537|Drug|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
79390619|NCT00703014|Biological|hCG|In the Base Trial P05787, when 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
79390620|NCT00703014|Biological|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
79708979|NCT04448418|Other|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
79708980|NCT01350492|Behavioral|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
79708981|NCT02270957|Biological|Abatacept|
79708982|NCT02270957|Other|Placebo|
79708983|NCT01350414|Device|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
79708984|NCT04523753|Procedure|emergency endoscopy|emergency endoscopy for gastrointestinal bleeding situation before or after surgery
79708985|NCT01350336|Device|Alair System|Treatment of airways with the Alair System
79848691|NCT06089200|Procedure|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
79848692|NCT06089200|Procedure|Spinal Morphine|100 µg was administered intrathecally preoperatively
79848693|NCT06089174|Other|Ultra-trail|Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
79848694|NCT06089148|Diagnostic Test|contrast enhanced digital mammography, tomosyntheis and MRI|
79252473|NCT03298425|Device|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
79252474|NCT03298425|Device|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
79252475|NCT02076841|Device|interferon beta-1a|Administered as specified in the treatment arm
79708986|NCT04827290|Behavioral|Low-AGE diet|Low-AGE diet during 24 months
79708987|NCT04827290|Behavioral|High-AGE diet|High-AGE diet during 24 months
79708988|NCT04826315|Behavioral|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
79708989|NCT04823702|Biological|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
79708990|NCT01349049|Drug|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
79708991|NCT01349049|Drug|PLX3397|The drug product is available in capsule form, to be taken orally.
79708992|NCT04522700|Procedure|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
79848695|NCT06089122|Biological|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
79848696|NCT06089109|Behavioral|Kentucky Violent Death Reporting System|The Kentucky Violent Death Reporting System (KYVDRS) addresses the need for accurate surveillance and data analysis by combining data from death certificates, coroner/medical examiner reports, police reports, crime laboratory reports, toxicology reports, and child fatality review team reports.
80016356|NCT03663153|Other|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
79252476|NCT02442310|Drug|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
79252477|NCT02442310|Drug|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
79252478|NCT02077075|Behavioral|Web-based weight loss program|A 4-week web-based wellness program.
79252479|NCT02077075|Behavioral|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
79252480|NCT02073721|Other|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
79708993|NCT04829864|Behavioral|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
79708994|NCT01348854|Device|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
79708995|NCT04522310|Other|MR-Pro-ADM|Dosage of MR-pro-ADM
79848697|NCT06089109|Behavioral|Implementation and Effectiveness of VIP Corps Training|Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
79848698|NCT06089096|Diagnostic Test|Home Sleep Apnea test (HSAT)|Patient will received HSAT at baseline
79848699|NCT06089044|Drug|Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.
79848700|NCT06089031|Diagnostic Test|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
79848701|NCT06089005|Device|Instrument Assisted Soft Tissue Mobilization device|Application of IASTM tool on specific muscle areas twice daily for intervention protocol of 7 days
79252481|NCT02073721|Other|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
79390621|NCT04246216|Procedure|Percutaneous Electrical Nerve Stimulation|Experimental: Percutaneous Electrical Nerve Stimulation The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
79390622|NCT04246216|Procedure|Endoscopic surgery of the carpal tunnel|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
79546645|NCT01545414|Behavioral|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
79546646|NCT01545414|Behavioral|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
79546647|NCT01545427|Drug|Imatinib mesylate|200 mg bid for 6 months
79848702|NCT06088953|Diagnostic Test|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
79252482|NCT02071615|Drug|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
79252483|NCT02071615|Drug|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
79252484|NCT02071615|Drug|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
79252485|NCT02071615|Drug|placebo|
79390623|NCT02433522|Drug|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
79390624|NCT02433522|Drug|Placebo|
79546648|NCT01545427|Other|Placebo|Placebo coated to match appearance of Gleevec identically.
79546649|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
79546650|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
79546651|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
79546652|NCT01545440|Drug|placebo|subcutaneous dose every 4 weeks
79708996|NCT01348776|Device|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
79708997|NCT01348698|Procedure|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
79708998|NCT01348698|Procedure|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
79252486|NCT02073799|Procedure|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
79252487|NCT02411110|Combination Product|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
79252488|NCT02411110|Combination Product|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
79546653|NCT01545466|Behavioral|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
79708999|NCT04520477|Diagnostic Test|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
79709000|NCT04520477|Diagnostic Test|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
79709001|NCT04520477|Dietary Supplement|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
79709002|NCT04520477|Diagnostic Test|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
79709003|NCT01348542|Drug|Trazodone|50 mg once a day, for 3 months
79709004|NCT01348542|Behavioral|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
79709005|NCT04827758|Procedure|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~SARC-F questionnaire,~measurement of muscle strengh by a grip test,~measurement of muscle mass by impedancemetry (ASM/size2),~4-meter walking speed test,~Timed-Up and Go (TUG) test,~ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
79709006|NCT04447677|Other||
79848703|NCT06088940|Dietary Supplement|Multistrain Probiotic|The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.
79848704|NCT06088940|Other|Placebo|Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
79848705|NCT06088927|Device|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
79848706|NCT06088849|Procedure|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
79848707|NCT06088810|Other|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
79252489|NCT02077153|Behavioral|Reminiscence therapy|
79390625|NCT03997630|Device|High flow Oxygenation|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
79390626|NCT03997630|Device|Standard oxygen|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
79390627|NCT02433912|Procedure|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
79848708|NCT06088810|Other|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
79848709|NCT06088797|Other|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
79390628|NCT02433912|Procedure|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
79390629|NCT02433912|Drug|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
79390630|NCT02433912|Drug|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
79546654|NCT01545479|Drug|captopril 25mg|renal blood oxygenation after captopril
79546655|NCT01544426|Procedure|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
79546656|NCT01544426|Procedure|Office hysteroscopy|Office hysteroscopy
79546657|NCT01545505|Behavioral|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
79709007|NCT04447638|Procedure|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
79709008|NCT04826471|Device|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
79709009|NCT04447248|Device|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
79709010|NCT04519190|Diagnostic Test|Prolonged continuous single-lead ECG monitor|We use Smartpatch, a listed ambulatory electrocardiographic system that can continuously record and save patients' cardiac rhythm for up to 45 days.
79252490|NCT02077153|Behavioral|Active participation in group setting|
79252491|NCT02077231|Drug|Vitamin A|use one drop in the eye
79252492|NCT02077231|Drug|carbomer eye gel|use one drop in the eye
79252493|NCT02077309|Drug|Linagliptin|
79252494|NCT02077309|Drug|Placebo|
79252495|NCT01369849|Drug|Akt Inhibitor MK2206|Given PO
79252496|NCT01369849|Drug|Bendamustine Hydrochloride|Given IV
79252497|NCT01369849|Other|Laboratory Biomarker Analysis|Correlative studies
79709011|NCT04519190|Diagnostic Test|Intermittent ECG monitor|When using Smartpatch, we can set time markers by pressing the button on the device. We ask our subjects to press that button twice a day and also when they feel any discomfort. Analyzing the ECG 1 minute after those time markers can serve as a surrogate for intermittent ECG monitor.
79709012|NCT04519190|Diagnostic Test|Routine practice|Perform pulse palpation and also ECG if irregular rhythm is found.
79709013|NCT04822766|Procedure|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
79709014|NCT04822766|Drug|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
79709015|NCT05139953|Other|No intervention|No intervention
79848710|NCT06088797|Other|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
80016357|NCT03663153|Other|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
80016358|NCT00673478|Drug|Tiotropium+Salmeterol|
80016359|NCT00673478|Drug|Salmeterol|
79390631|NCT00361660|Behavioral|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
79390632|NCT00361660|Behavioral|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
79390633|NCT02436486|Drug|Placebo|Capsules, orally, single dose
79546658|NCT01545531|Drug|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration [13]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
79546659|NCT01545570|Drug|GSK2376497|GSK2376497 Active Comparator
79546660|NCT01545570|Drug|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
79709016|NCT04445961|Diagnostic Test|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
79709017|NCT04445961|Diagnostic Test|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
79709018|NCT04828265|Biological|Aldafermin|Single dose of aldafermin
79709019|NCT01346592|Biological|Trivalent split influenza vaccine (TIV)|
80016360|NCT00673478|Drug|Tiotropium|
80016361|NCT02203474|Drug|Tiotropium HFA BAI 5 mcg|
79252498|NCT01369849|Biological|Rituximab|Given IV
79252499|NCT02077387|Behavioral|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
79252500|NCT02077387|Behavioral|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
79252501|NCT02077543|Device|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
79252502|NCT02716779|Drug|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
79252503|NCT02716779|Drug|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
79709020|NCT01346592|Biological|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
79709021|NCT01346592|Biological|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
79709022|NCT05139758|Diagnostic Test|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
79709023|NCT04822610|Procedure|interscalene block|peripheral nerve block
79709024|NCT04822610|Procedure|suprascapular block + axillary block|peripheral nerve block
80016362|NCT02203474|Drug|Tiotropium 18 mcg Capsule|
80016363|NCT02203474|Drug|Placebo|Placebo
80016364|NCT04053699|Drug|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
80016365|NCT00672386|Drug|JNJ16269110|5 mg twice daily for 12 weeks
80016366|NCT00672386|Drug|JNJ16269110|10 mg twice daily for 12 weeks
80016367|NCT00672386|Drug|JNJ16269110|15 mg twice daily for 12 weeks
80016368|NCT00672386|Drug|Placebo|twice daily for 12 weeks
79848711|NCT06088797|Other|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
79709025|NCT04516928|Diagnostic Test|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
79709026|NCT04516928|Other|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
79252504|NCT02716779|Drug|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
79252505|NCT02074189|Drug|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
79546661|NCT01545596|Behavioral|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
79546662|NCT01545609|Other|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
79546663|NCT01545635|Drug|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
79546664|NCT01545635|Drug|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 <7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
79848712|NCT06088797|Other|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
79848713|NCT06088797|Other|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
79848714|NCT06088797|Other|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
79848715|NCT06088797|Other|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
79848716|NCT06088771|Biological|Dupilumab|Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
79252506|NCT02463591|Drug|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
79546665|NCT01545661|Procedure|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
79546666|NCT01545661|Procedure|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
79848717|NCT06088771|Biological|Cemiplimab|Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
79252507|NCT02079961|Dietary Supplement|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
79252508|NCT02079961|Behavioral|BCC|"Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
79546667|NCT01545687|Dietary Supplement|Lactobacillus brevis CD2 lozenge|Dissolved orally
79546668|NCT01545687|Other|placebo|Dissolved orally
79252509|NCT02463903|Behavioral|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
79546669|NCT01545726|Drug|QAW039|QAW039 was supplied as capsules for oral administration.
79546670|NCT01545726|Drug|Placebo|Placebo was supplied as capsules for oral administration.
79546671|NCT01545739|Device|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
79848718|NCT06088758|Device|Normothermic machine perfusion (NMP) of steatotic liver|Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
79252510|NCT02080039|Device|Electrical Stimulation|
79546672|NCT01545752|Other|teaching by non-interactive CD|teaching book with non-interactive CD
79546673|NCT01545752|Other|Interactive CD|Teaching book with interactive CD
79709027|NCT01346514|Behavioral|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
79709028|NCT01346514|Behavioral|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
79709029|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
79709030|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
79252511|NCT03298347|Drug|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
79252512|NCT03298347|Drug|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
79709031|NCT02893995|Drug|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
79709032|NCT02893995|Drug|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
79848719|NCT06088745|Biological|Recombinant Herpes Zoster Vaccine|The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
79848720|NCT06088745|Biological|Recombinant Herpes Zoster Vaccine Placebo|Alumina adjuvant
79848721|NCT06088719|Procedure|axillary surgery|one group undergoes axillary surgery
79848722|NCT06088706|Procedure|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
79848723|NCT06088654|Drug|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
79848724|NCT06088628|Diagnostic Test|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
79848725|NCT06088589|Behavioral|Mismatch negativity|"Event related potentials are compared between frequent and infrequent speech sounds (i.e., ba vs da)."
80016369|NCT00672386|Drug|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
79252513|NCT02074423|Dietary Supplement|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
79546674|NCT01545778|Drug|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
79546675|NCT01545778|Drug|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
79546676|NCT01545791|Drug|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
79546677|NCT01545804|Drug|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
79709033|NCT01342887|Drug|cyclosporine|Given IV
79709034|NCT01342887|Drug|pravastatin sodium|Given PO
79709035|NCT01342887|Drug|mitoxantrone hydrochloride|Given IV
79709036|NCT01342887|Drug|etoposide|Given IV
79709037|NCT01342887|Procedure|bone marrow aspiration|Correlative studies
79709038|NCT04445415|Diagnostic Test|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
79709039|NCT01342341|Drug|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
79252514|NCT02074423|Dietary Supplement|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
79252515|NCT02461485|Other|Fermented milk product containing Probiotics|2 pots/day during 28 days
79252516|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
79252517|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
79252518|NCT02461485|Other|Non fermented Milk Product|2 pots/day during 28 days
79390634|NCT02436486|Drug|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
79390635|NCT02436486|Drug|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
79390636|NCT02436486|Drug|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
79390637|NCT04342858|Drug|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
79390638|NCT04342858|Drug|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
79390639|NCT04342858|Other|Oral health education|Standard oral hygiene instructions every 3 months
79390640|NCT02428998|Dietary Supplement|Korean Red Ginseng|
79390641|NCT02428998|Dietary Supplement|Placebo|
79390642|NCT04243096|Behavioral|Exercise-based Physical Therapy|Exercises for pain modulation, strengthening, and neuromuscular control
79709040|NCT01340664|Drug|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
79848726|NCT06088576|Other|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
79848727|NCT06088550|Dietary Supplement|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine & 1.25 gm valine).
79848728|NCT06088550|Other|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
79848729|NCT06088524|Other|Social Media Fatigue|Mental Fatigue creation protocol: It has been reported that at least 30 minutes of social media use causes mental fatigue and impairs lower extremity and decision-making performance (Fortes et al., 2021). For mental fatigue with social media, participants will be created with 45 minutes of continuous use of social media (instagram, facebook, twitter, youtube) on smartphones by concentrating with headphones.
79546678|NCT01545830|Dietary Supplement|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
79252519|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
79252520|NCT02465697|Behavioral|Reappraisal Training|
79390643|NCT02429076|Drug|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
79546679|NCT01545856|Drug|levodopa|levodopa use
79546680|NCT01545869|Procedure|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
80016370|NCT00672386|Other|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
79252521|NCT02077699|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
79252522|NCT02463669|Device|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
79252523|NCT02077777|Drug|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
79252524|NCT02463201|Behavioral|Weight loss|
79252525|NCT05036421|Drug|Empagliflozin 10 milligram|antihyperglycemic medication
79252526|NCT03094819|Behavioral|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
79252527|NCT03094819|Behavioral|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
79252528|NCT03298191|Drug|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
79252529|NCT03298191|Drug|Ritodrine|Those women will be given Ritodrine for tocolysis
79252530|NCT03298191|Drug|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
79252531|NCT02080117|Procedure|kidney transplantation, living or deceased donor|
79252532|NCT02074657|Biological|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
79546681|NCT01545882|Drug|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
79390644|NCT02429076|Drug|Placebo|normal saline
79546682|NCT01545908|Other|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
79390645|NCT02429076|Drug|Sevoflurane|Inhaled anesthetic
79390646|NCT02429076|Drug|Propofol|IV anesthetic
79546683|NCT01545908|Other|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
79546684|NCT01545921|Other|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
79709041|NCT01340664|Drug|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
79709042|NCT01340664|Drug|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
79709043|NCT01340664|Drug|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
79709044|NCT01340625|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
79709045|NCT01340625|Drug|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
79709046|NCT04823468|Dietary Supplement|Abbott®Ensure|Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy
79709047|NCT04823468|Radiation|Intensity Modulated Radiation Therapy|The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
79709048|NCT04823468|Drug|cisplatin|80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.
79709049|NCT04511273|Drug|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
79848730|NCT06088498|Behavioral|Updating Existing Smartphone App|Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 1-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-10 cues, and each cue will be presented for 30-60 seconds (average amount of extinction per day will be about 17 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
79848731|NCT06088498|Behavioral|Quitline Services|Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
79848732|NCT06088498|Behavioral|Quitline Services and Smartphone App|In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
79848733|NCT06088472|Biological|TIL injection|Autologous tumor infiltrating lymphocyte injection
79848734|NCT06088459|Biological|1mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
79252533|NCT01369615|Drug|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
79546685|NCT01545947|Drug|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
79546686|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
79546687|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
79848735|NCT06088459|Biological|4mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
79848736|NCT06088459|Biological|8mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
79252534|NCT02080351|Behavioral|Simple cognitive task|
79709050|NCT01340196|Drug|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
79709051|NCT04827212|Behavioral|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
79252535|NCT02074813|Other|Inspiratory muscle training|Inspiratory muscle training
79546688|NCT01545960|Other|not applicable in this study|No actual interventions will be administered for this study.
79252536|NCT02260375|Biological|Mesenchymal Stromal Cells|
79302872|NCT03070977|Other|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
79546689|NCT01545973|Other|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
79709052|NCT04826744|Other|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
79546690|NCT01545986|Behavioral|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
79546691|NCT01546012|Device|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
79546692|NCT01546012|Device|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
79546693|NCT01546025|Behavioral|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
79546694|NCT01546025|Behavioral|Relaxation training|One hour training in relaxation techniques
79546695|NCT01546051|Drug|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
79546696|NCT01546051|Drug|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
79546697|NCT01546051|Drug|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
79546698|NCT01546051|Drug|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
79546699|NCT01546064|Device|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
79546700|NCT01546064|Device|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
79709053|NCT04137315|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
79709054|NCT02893332|Radiation|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
79709055|NCT02893332|Drug|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
79709056|NCT04443699|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
79709057|NCT04328493|Drug|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
79848737|NCT06088433|Drug|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD * 1 month, followed by clopidogrel 75mgQD)
79848738|NCT06088433|Drug|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD * 1 month, followed by clopidogrel 75mgQD)
80016371|NCT05119114|Diagnostic Test|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
79390647|NCT04236544|Behavioral|PExMS and DECIMS-Wiki|The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.
79390648|NCT04236544|Behavioral|DECIMS-Wiki|The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
79709058|NCT02893449|Behavioral|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
79848739|NCT06088433|Drug|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD * 1 month, followed by clopidogrel 75mgQD)
80016372|NCT04056897|Biological|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
79709059|NCT02893449|Behavioral|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
79709060|NCT02893449|Procedure|Deep brain stimulation|
79709061|NCT04508270|Behavioral|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
79709062|NCT05139641|Behavioral|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
79709063|NCT04443231|Device|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
79709064|NCT01600118|Device|Extracorporeal shockwave therapy|1000 impulses
79709065|NCT01600118|Device|No extracorporeal shockwave|0 impulses, acoustic effect
79546701|NCT01546077|Procedure|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
80016373|NCT04056897|Drug|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
79546702|NCT01546090|Drug|Alprazolam|preoperative administration of an orally 0.50 mg single dose
79546703|NCT01546090|Drug|placebo|placebo capsules were filled with starch
79709066|NCT04504799|Device|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
79709067|NCT04395963|Device|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
80016374|NCT04056897|Drug|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
79709068|NCT05139524|Other|Evidence of past or recent RVF exposure|Detection of RVF exposure.
79302873|NCT03209635|Dietary Supplement|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
79302874|NCT03209635|Dietary Supplement|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
79302875|NCT05713097|Diagnostic Test|TSI|TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
79302876|NCT03198481|Behavioral|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
79390649|NCT02433132|Other|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
79390650|NCT04676854|Device|PRIMA Bionic Vision System|Implantation of PRIMA, Vision training, follow up
79390651|NCT00255177|Drug|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
79709069|NCT04442217|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
79709070|NCT04395651|Device|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
79709071|NCT01327599|Drug|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
79709072|NCT05139407|Diagnostic Test|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
79709073|NCT04502147|Procedure|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
79709074|NCT04328415|Radiation|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
79709075|NCT04395534|Procedure|Complete mesocolic excision|
79709076|NCT04395066|Diagnostic Test|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
80016375|NCT04056897|Biological|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
80016376|NCT04436302|Device|Exergame device|motor-cognitive training
80016377|NCT02281682|Drug|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
80016378|NCT02281682|Drug|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
79302877|NCT03198481|Behavioral|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
79302878|NCT05713019|Device|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
79390652|NCT00255177|Drug|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
79390653|NCT04670224|Other|QLB anesthesia|The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
79390654|NCT04670224|Other|Intravenous anesthesia without QLB|only intravenous anesthesia
79390655|NCT00360958|Procedure|ultrafiltration|
79546704|NCT01546103|Dietary Supplement|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
79546705|NCT01546103|Dietary Supplement|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
79546706|NCT01546116|Drug|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
79546707|NCT01546129|Device|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
79709077|NCT04498871|Drug|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
79709078|NCT02893215|Other|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
80016379|NCT02281682|Drug|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
80016380|NCT02281682|Procedure|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
80016381|NCT04057053|Drug|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
80016382|NCT04589338|Other|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
80016383|NCT04589338|Other|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
80016384|NCT04056975|Biological|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
79546708|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
79546709|NCT01546233|Behavioral|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
79546710|NCT01546233|Behavioral|standard education|standard education before and after chemotherapy
79546711|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
79709079|NCT04439877|Behavioral|Peri-implant disease diagnosis|Diagnosis of peri-implant disease
79390656|NCT04223986|Diagnostic Test|Ultrasound|decide between the need for intervention or not (Percutaneous coronary intervention)
79390657|NCT04223986|Diagnostic Test|Troponin- T quick test|Quick test for Troponin T blood assessment
79390658|NCT02976142|Procedure|neoadjuvant chemoimmunotherapy|
79390659|NCT00361036|Device|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
79390660|NCT00361036|Device|Uterine fibroid embolization Embosphere®|Embosphere - control arm
79709080|NCT04497896|Other|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
79709081|NCT05139329|Diagnostic Test|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
80016385|NCT02281916|Drug|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
80016386|NCT03663075|Behavioral|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
80016387|NCT03663075|Behavioral|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
80016388|NCT04963504|Diagnostic Test|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
80016389|NCT04963504|Diagnostic Test|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
80016390|NCT02284100|Behavioral|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
80016391|NCT03662763|Drug|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
80016392|NCT03662763|Drug|Placebo oral capsule|
79390661|NCT03955432|Device|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
79709082|NCT04497194|Other|not applicable (observational study)|not applicable (observational study)
80016393|NCT02141932|Procedure|Bed-side pocket size ultrasound imaging|
79390662|NCT00361114|Drug|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
79709083|NCT01193257|Drug|Orteronel|Orteronel tablets
79709084|NCT01193257|Drug|Prednisone|Prednisone tablets
79709085|NCT01193257|Drug|Orteronel Placebo|Orteronel placebo-matching tablets
79709086|NCT04495595|Other|No intervention|There is no intervention due to the observational, cross-sectional design of the study
79709087|NCT02886559|Drug|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
79709088|NCT05138978|Drug|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
79709089|NCT05138978|Drug|Colgate Cavity Protection|Toothpaste
80016394|NCT02141932|Device|GE Ultrasound Vscan|
80016395|NCT00458978|Drug|Cediranib Maleate|Given orally
79390663|NCT00361114|Drug|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
79390664|NCT00361114|Drug|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
79390665|NCT04342936|Drug|Camrelizumab|A humanized monoclonal immunoglobulin
79390666|NCT04342936|Drug|Investigator's choice of Chemotherapy|"Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin."
80016396|NCT00458978|Other|Laboratory Biomarker Analysis|Correlative studies
79709090|NCT04495049|Device|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
79709091|NCT04391400|Diagnostic Test|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
79709092|NCT04391400|Diagnostic Test|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~At least 2mL to 5mL of peripheral blood.~Collected in EDTA tubes.~Shipped to ambient LabPMM, LLC within 2 days.~Specimen Collections:~Collected at the same time as the NP specimen sent for COVID-19 testing.~Collected two to three weeks post the original patient's COVID-19 testing."
79709093|NCT04391166|Other|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
79709094|NCT04436484|Diagnostic Test|Peripheral blood sampling|Non-interventional study
80016397|NCT04514224|Other|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
80016398|NCT04514224|Other|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
80016399|NCT00458276|Drug|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
80016400|NCT00458276|Drug|placebo|Placebo (i.e., normal saline) for i.v. use.
80016401|NCT03661749|Other|clean catch|clean catch technique applied to collect urine for PR/CR ratio
80016402|NCT04520074|Drug|Etoposide, Cyclophosphamide, Carboplatin/Cisplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
80016403|NCT03661671|Diagnostic Test|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
80016404|NCT00600782|Biological|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
79709095|NCT05138861|Drug|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
79709096|NCT05138744|Other|Behavioral activation using virtual reality|The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
79709097|NCT04390659|Procedure|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
79709098|NCT04493294|Radiation|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
79709099|NCT02893176|Drug|macitentan|
79709100|NCT02893176|Drug|placebo (for macitentan)|
80016405|NCT05118958|Drug|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
80016406|NCT05118958|Drug|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
80016407|NCT05118958|Drug|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
80016408|NCT05118958|Drug|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
80016409|NCT05118958|Drug|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
80016410|NCT00672074|Drug|Ipamorelin|IV
79709101|NCT05138627|Other|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
79252537|NCT02077933|Drug|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
79709102|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
79709103|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
80016411|NCT00672074|Drug|placebo|IV
80016412|NCT03662451|Procedure|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
79546712|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
79546713|NCT01546272|Device|Insorb resorbable staples|Subcutanous suture using resorbable staples
79546714|NCT01546272|Device|Monocryl resorbable wire|Subcutanous suture using resorbable wire
79546715|NCT01546298|Other|Patch tests|Patch tests for allergic reaction
79546716|NCT01546311|Device|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
79709104|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
80016413|NCT05118880|Other|Peer Bullying Counseling Program based on the Interpersonal Relationship Model|"The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques."
80016414|NCT04056507|Procedure|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
80016415|NCT00455156|Drug|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
79252538|NCT02077933|Drug|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
79252539|NCT02077933|Drug|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
79709105|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
79709106|NCT01193218|Drug|BI 10773|BI 10773 tablets low dose once a day
79709107|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
79709108|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
79390667|NCT04201288|Behavioral|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
79546717|NCT01546324|Procedure|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
79546718|NCT01546350|Genetic|PGD|array CGH after blastocyst biopsy
79546719|NCT01546350|Procedure|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
79546720|NCT01546363|Other|Blood draw|phlebotomy
79546721|NCT01546376|Radiation|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
79709109|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
79709110|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-high dose once a day
79709111|NCT01193218|Drug|BI 10773|BI 10773 tablets high dose once a day
79546722|NCT01546376|Other|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
79709112|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
79709113|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
79546723|NCT01546389|Biological|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
79546724|NCT01546389|Drug|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
79848740|NCT06088420|Drug|intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .|Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .
79848741|NCT06088407|Drug|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
79848742|NCT06088394|Device|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~CV3,4 &5-40 mm needles at a depth of 1 cun perpendicular insertion.~ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~SP6 & 9, K13&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
80016416|NCT05118646|Device|sublingual microcirculation,|Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.
80016417|NCT05118646|Device|hemodynamic monitoring|Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
80016418|NCT03661593|Other|Cataract guideline|The patients gets an IOL according to cataract guideline correcting the ametropia
80016419|NCT04513834|Other|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
80016420|NCT04513834|Other|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
80016421|NCT03661515|Drug|Selinexor|"According to escalation level:~Level -1: Selinexor 40 mg/day, once weekly~Level 1: Selinexor 60 mg/day, once weekly~Level 2: Selinexor 80 mg/day, once weekly~Level 3: Selinexor 100 mg/day, once weekly"
80016422|NCT03661515|Drug|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
80016423|NCT03661515|Drug|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
80016424|NCT03661515|Drug|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
79252540|NCT02078011|Device|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
79252541|NCT02080429|Procedure|Passive Descent|
79252542|NCT02080429|Procedure|Pushing|
79390668|NCT04201288|Behavioral|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
79546725|NCT01546415|Drug|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
79546726|NCT01546428|Drug|INC280|
80016425|NCT03661515|Drug|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
80016426|NCT02284256|Drug|Fibrocaps|
80016427|NCT02284256|Drug|TachoSil|
79390669|NCT04200274|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
79546727|NCT01546441|Behavioral|interprofessional assessment|assessment by interprofessional team
79546728|NCT01546441|Behavioral|usual care|usual care in primary care clinic
79546729|NCT01546467|Behavioral|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
79252543|NCT02078089|Drug|Morphine|Morphine will be given to patients as part of their standard care
79252544|NCT02078089|Drug|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
79252545|NCT02074891|Drug|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
79252546|NCT02080585|Behavioral|Physical Activity advice.|Subjects receive advice regarding physical activities.
79252547|NCT02074969|Device|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
79709114|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
79709115|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
79709116|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-low dose once a day
79709117|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
79709118|NCT04389645|Diagnostic Test|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
79709119|NCT00592098|Drug|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
79709120|NCT00592098|Drug|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
79709121|NCT01193101|Drug|LCZ696|LCZ696
79709122|NCT01193101|Drug|Placebo|matching placebo to LCZ696
79709123|NCT04472078|Diagnostic Test|Serological Assay or IgG for SARS-CoV-2|Serological Assay for detection of IgG for SARS-CoV-2
79709124|NCT02887846|Device|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 < 0,40, Pa CO2 < 65 mmHg, pH> 7.20, MAP (mean airway pressure) <7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 < 0.30 at 24 hours and above, free oxygen will be introduced.
79709125|NCT04328805|Drug|Ibuprofen tablets|oral tablet
79709126|NCT02886364|Behavioral|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
79709127|NCT01192516|Behavioral|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
79709128|NCT01192516|Behavioral|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
79709129|NCT04471883|Procedure|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
79252548|NCT02074969|Device|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
79252549|NCT02078167|Other|nutraceutical combination (red yeast rice, policosanols and berberine)|
79546730|NCT01546506|Drug|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
79546731|NCT01546558|Drug|Metformin|Metformin 1000 mg bid on Days 1-10
79546732|NCT01546558|Drug|Ranolazine|Ranolazine 500 mg bid on Days 6-10
79709130|NCT04329000|Drug|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
79709131|NCT04329000|Drug|Esomeprazole|Continuous Esomeprazole 40 mg QD
79709132|NCT01192399|Biological|Eculizumab|
79709133|NCT01176916|Drug|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
80016428|NCT01624480|Drug|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
80016429|NCT00670592|Drug|HCD122|
79709134|NCT04328922|Other|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
79709135|NCT04328922|Other|Placebo capsuls|capsules of glycerol and saline (placebo).
79709136|NCT01192204|Drug|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
80016430|NCT05115682|Behavioral|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
79709137|NCT01192204|Drug|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
79252550|NCT02080663|Procedure|Proximal row carpectomy|
79252551|NCT02078323|Drug|Linaclotide|
79252552|NCT02078323|Drug|Placebo|
79302879|NCT05713019|Diagnostic Test|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
79546733|NCT01546597|Drug|Metformin|"Metformin 500 mg bid on Days 1-5~Metformin 850 mg bid on Days 6-10~Metformin 500 mg bid on Days 11-15~Metformin 850 mg bid on Days 16-20"
79546734|NCT01546597|Drug|Ranolazine|"Ranolazine 1000 mg bid on Days 11-15~Ranolazine 1000 mg bid on Days 16-20"
79546735|NCT01546610|Other|insoles intervention|EVA insole with arch support and bar retrocapital
79546736|NCT01546610|Other|placebo insole|EVA insole flat
79546737|NCT01546662|Dietary Supplement|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
79546738|NCT01546662|Dietary Supplement|Placebo|1/ 2 capsules, twice daily for 12 weeks
79546739|NCT01546701|Drug|Buprenorphine|2 mg sublingual tablet
79546740|NCT01546701|Drug|Morphine|0.1 mg/kg IV morphine
79709138|NCT01192126|Device|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
79709139|NCT01192126|Device|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
79709140|NCT04433403|Other|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
79848743|NCT06088394|Other|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
79709141|NCT04433286|Other|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
80016431|NCT02992899|Device|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
79546741|NCT01546727|Behavioral|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
79709142|NCT04468802|Other|Case fatality rate|Mortality rate caused by SARS CoV-2
79709143|NCT02894268|Drug|Doxycycline|Doxycycline 100g po bid
79546742|NCT01546727|Behavioral|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
79709144|NCT02894268|Drug|Furazolidone|Furazolidone 100mg po bid
79848744|NCT06088368|Procedure|in-plane needle guidance|Ultrasound -guided lumbar plexus block with in-plane needle guidance using the Shamrock method
79848745|NCT06088368|Procedure|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block with out-of-plane needle guidance using Shamrock method
79252553|NCT02075437|Behavioral|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
79390670|NCT03931174|Behavioral|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
79546743|NCT01546779|Device|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
79546744|NCT01546792|Behavioral|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
79546745|NCT01546805|Drug|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
79546746|NCT01546805|Drug|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
79546747|NCT01546818|Biological|SAV001-H|A whole-killed HIV
79709145|NCT02894268|Drug|Esomeprazole|Esomeprazole 20mg po bid
79709146|NCT02894268|Drug|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
79709147|NCT02894268|Drug|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
79709148|NCT02893683|Other|Paris Visual Learning Test|
79709149|NCT01600625|Drug|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
79709150|NCT04386954|Procedure|observational study|observation study
79848746|NCT06088316|Drug|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal & esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal & Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
79848747|NCT06088316|Drug|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal & Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
79848748|NCT06088264|Drug|BMS-986322|Specified dose on specified days.
79848749|NCT06088251|Behavioral|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
79546748|NCT01546844|Other|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
79546749|NCT01546896|Drug|buspirone+alprazolam|day 1~7: buspirone 10mg/d + alprazolam 0.5mg / day 8~28: buspirone 20mg/d + alprazolam 0.5mg / day 29~56: buspirone 20~30mg/d + alprazolam 0.5mg
79709151|NCT01600664|Behavioral|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
79848750|NCT06088251|Behavioral|Standard Nutrition Education|Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
79848751|NCT06088225|Device|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
79546750|NCT01546896|Drug|alprazolam|0.5mg/d
79252554|NCT02075437|Behavioral|Treatment Strategies|"identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~incorporate caregivers as role models and facilitators based on attachment research."
79546751|NCT01546909|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
79546752|NCT01546935|Drug|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
79546753|NCT01546961|Drug|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
79546754|NCT01546974|Device|HME filter Twin Star 55, Drager Medical, Germany|
79546755|NCT01546974|Device|Heated humidification|
79546756|NCT01547026|Behavioral|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
79546757|NCT01547052|Behavioral|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
79546758|NCT01547052|Behavioral|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
79546759|NCT01547078|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
79546760|NCT01547078|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
79546761|NCT01547091|Biological|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
79546762|NCT01547091|Drug|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
79546763|NCT01547091|Biological|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
79546764|NCT01547104|Drug|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
79546765|NCT01547104|Drug|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
79546766|NCT01547143|Drug|IST and/or alloHCT|"1) Patients will be categorized by their initial serum ferritin level.~Mild ( ferritin<3,000 μg/L): close observation~Moderate (ferritin: 3,000-10,000 μg/L):~Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~Severe (ferritin>10,000 μg/L):~initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~2) AlloHCT for refractory or reactivated cases."
79252555|NCT02075749|Drug|Triamcinolone Acetonide|
79546767|NCT01547156|Device|Intervention group|
79546768|NCT01547169|Drug|Placebo Comparator|saline, taken twice per day for a 3 week duration
79252556|NCT02075749|Drug|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
79252557|NCT05527327|Device|traxi® Panniculus Retractor|This is an adhesive medical device designed to retract a pannus during cesarean section. It will be applied to prospective participants according to manufacturer instructions, just prior to the detailed anatomic ultrasound.
79546769|NCT01547169|Drug|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
79546770|NCT01547169|Drug|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
79546771|NCT01547182|Behavioral|Caloric restriction|Caloric restriction
79252558|NCT02075827|Behavioral|Competitive video game|1 hour playing video game
79546772|NCT01547182|Behavioral|Aerobic Training|Walking
79546773|NCT01547182|Behavioral|Resistance Training|Lifting weights
79709152|NCT01600664|Behavioral|Convertible PC|Participants will be using the convertible PC without the interactive computer game
79709153|NCT02893839|Other|Prick to prick test|
79709154|NCT01600742|Drug|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
79252559|NCT02075827|Behavioral|Little Big Planet|1 hour playing video game
79848752|NCT06088121|Device|ATNC MDD-V1 (Real TMS + Real Cog)|Synchronized TMS and cognitive stimulation to 6 brain areas.
79709155|NCT01600742|Drug|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
79709156|NCT04431804|Other|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
79709157|NCT04430829|Diagnostic Test|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
79709158|NCT04430829|Diagnostic Test|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
79709159|NCT01327482|Drug|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
79709160|NCT04430205|Procedure|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
79709161|NCT04490291|Other|chronic pain team|enrollment in chronic pain team at study site
79709162|NCT04490291|Other|chiropractic team|enrollment in chiropractic team/intervention at study site
79709163|NCT04385823|Device|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
79390671|NCT03931174|Behavioral|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
79709164|NCT04429386|Procedure|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
79709165|NCT02893488|Drug|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
79709166|NCT02893488|Drug|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
79709167|NCT02893488|Drug|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
79709168|NCT04328883|Drug|Aspirin|Oral and inhaled ASA formulations
79709169|NCT04464356|Device|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
79709170|NCT04385472|Radiation|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
79546774|NCT01547195|Procedure|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
79546775|NCT01547195|Procedure|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
79390672|NCT00702624|Drug|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
79390673|NCT00702624|Biological|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
79390674|NCT00702624|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
79546776|NCT01547208|Procedure|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
79546777|NCT01547208|Procedure|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
79546778|NCT01547221|Drug|clotrimazole|single application of 1%clotrimazole ear drop
79709171|NCT01600196|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
79709172|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
79709173|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
79709174|NCT04464083|Diagnostic Test|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
79709175|NCT01600235|Drug|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
79709176|NCT02893254|Drug|IBI303|12 cycles. IBI303: 40 mg, iH
79546779|NCT01547221|Drug|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
79546780|NCT01547273|Procedure|bone graft inside socket only|bone graft inside socket only
79709177|NCT02893254|Drug|Adalimumab|12 cycles. Adalimumab: 40mg, iH
79709178|NCT02893137|Device|Optune|For further information see www.optune.com
79709179|NCT02893137|Procedure|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
79709180|NCT04429581|Other|Anthropometry|
79252560|NCT02080975|Other|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
79252561|NCT02075983|Biological|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
79252562|NCT02078479|Procedure|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
79252563|NCT02078479|Procedure|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
79546781|NCT01547273|Procedure|bone graft inside and outside socket|bone graft inside and outside socket
79546782|NCT01547273|Procedure|no bone graft|no bone graft
79252564|NCT02081053|Device|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
79252565|NCT02078635|Behavioral|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
79252566|NCT02078635|Behavioral|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
79252567|NCT02081131|Procedure|Open surgery|pancreatic head resection by open method
79252568|NCT02081131|Procedure|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
79546783|NCT01547312|Drug|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
79546784|NCT01547312|Procedure|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
79546785|NCT01547312|Procedure|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
79546786|NCT01547312|Procedure|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
79546787|NCT01547312|Drug|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
79709181|NCT04462991|Diagnostic Test|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
79848753|NCT06088121|Device|ATNC MDD-V1 (Sham TMS + Real Cog)|Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
79252569|NCT02081209|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79390675|NCT00702624|Biological|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
79390676|NCT00702624|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
79390677|NCT00702624|Drug|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
79390678|NCT00702624|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
79546788|NCT01547312|Drug|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
79709182|NCT04383171|Device|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
79709183|NCT04382508|Other|Questionnaire|A weekly questionnaire will be filled in
79709184|NCT04460339|Other|Swimming participants in the 25-km|The 25-km race was the French national Open Championship event and participants were the swimmers registered for the race who volunteered to participate in this study
79252570|NCT02081287|Drug|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
79252571|NCT02081287|Drug|Lamotrigine|Dose up to 200 mg per day over 10 weeks
79252572|NCT02078791|Drug|Botox infiltration|botox cervical infiltration in a group
79252573|NCT02078791|Behavioral|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
79252574|NCT02078791|Other|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
79252575|NCT02076139|Dietary Supplement|Nyaditum resae® 10e4|
79252576|NCT02076139|Dietary Supplement|Nyaditum resae® 10e5|
79252577|NCT02076139|Other|Distilled water|
79546789|NCT01547312|Drug|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
79709185|NCT04425954|Procedure|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
79709186|NCT04482491|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
79709187|NCT04379622|Other|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
79709188|NCT04458701|Device|Hemodynamic monitoring|This is a comprehensive hemodynamic management strategy that would-be initiated in the operating room post-bypass and then continued for the first 12 hours in the intensive care unit
79709189|NCT04328220|Diagnostic Test|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
79709190|NCT04379232|Biological|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
79709191|NCT04424277|Other|diaphragm ultrasound|respiratory loading
79709192|NCT04378491|Other|Collection of clinical measurements|"Collection of clinical measurements:~Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
79709193|NCT04378491|Other|Collection of data for muscle strength|"Collection of data for muscle strength:~Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
79709194|NCT04378491|Other|Collection of EMG Data|"Collection of EMG Data:~Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
79709195|NCT04378491|Other|Collection of Clinical Scores|"Collection of Clinical Scores:~patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
79709196|NCT04378491|Other|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
79709197|NCT04457024|Other|classification statistics|Without any intervention
79709198|NCT04328454|Other|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19
79709199|NCT04423497|Other|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
79252578|NCT02811913|Other|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~session 1 - High frequency rTMS targeting contralesional sensory cortex~session 2 - Low frequency rTMS~session 3 - sham rTMS"
79709200|NCT00592137|Dietary Supplement|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
79252579|NCT02811913|Other|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
79252580|NCT02083237|Behavioral|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
79252581|NCT02468674|Drug|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
79252582|NCT02468674|Drug|Placebo|"Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
79252583|NCT03558763|Device|Telemonitoring|During the telemonitoring treatment period the subjects will register; vital functions (blood pressure, heart rate, weight, SpO2) twice a week, physical movement daily by using a fitness device, have video calls with a nurse weekly the first 4 weeks and thereafter every fourth week the last 5 months. Twice a week (± 2 days) questionnaires (CAT and MRC) should be filled out at home.
79252584|NCT03558763|Other|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
79709201|NCT00592137|Dietary Supplement|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
79709202|NCT00592137|Dietary Supplement|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
79709203|NCT04455776|Drug|Propofol|Sedation by propofol
79709204|NCT04135092|Biological|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
79546790|NCT01547312|Procedure|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
79709205|NCT04135092|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
79546791|NCT01547325|Drug|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
79709206|NCT04135092|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
79709207|NCT04135092|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
79709208|NCT04135092|Drug|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
79709209|NCT00592215|Drug|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
79252585|NCT04918069|Drug|Capsaicin|Topical capsaicin ointment
79546792|NCT01547325|Drug|placebo hydrogel|placebo hydrogel
79546793|NCT01547351|Other|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
79546794|NCT01547364|Drug|Saline|Injection of 10 ml of normal saline into the caudal epidural space
79546795|NCT01547364|Drug|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
79252586|NCT04918069|Drug|Placebo|Topical placebo ointment
79252587|NCT02081521|Behavioral|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
79252588|NCT02467192|Device|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
79546796|NCT01547377|Dietary Supplement|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
79546797|NCT01547377|Other|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
79709210|NCT04479137|Diagnostic Test|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
79709211|NCT00592332|Drug|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
79709212|NCT00592332|Other|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
79709213|NCT04422444|Diagnostic Test|Questionnaires|Participants will answer questionnaires in three areas: physical/functional, emotional status and cognitive status
79709214|NCT04477382|Dietary Supplement|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
79252589|NCT02083315|Drug|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
79252590|NCT02083315|Drug|TRV130 3 mg|TRV130 3 mg IV x 1 dose
79252591|NCT02083315|Drug|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
79252592|NCT02083315|Drug|Morphine 10 mg|Morphine 10 mg IV x 1 dose
79252593|NCT02083315|Drug|Placebo|Dextrose 5% in water IV x 1 dose
79390679|NCT00702624|Biological|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
79390680|NCT03915496|Drug|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
79390681|NCT03915496|Drug|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
79390682|NCT03915496|Drug|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
79390683|NCT00702546|Drug|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
79390684|NCT00702546|Biological|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
79390685|NCT00702546|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
79390686|NCT00702546|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
79390687|NCT00702546|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
79390688|NCT00702546|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
79390689|NCT00702546|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
79390690|NCT00702546|Biological|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
79390691|NCT02428530|Other|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
79390692|NCT02976532|Other|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
79709215|NCT04375644|Other|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
79709216|NCT04454021|Procedure|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
79848754|NCT06088108|Device|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
79252594|NCT04922242|Behavioral|Welch Emotional Connection Screen for Neonatal Intensive Care Unit|The Welch Emotional Connection Screen (WECS) is an investigational developmental screening tool, developed to rate the quality of the emotional connection that formed between mother and child. The screen is administered in 2-3 minutes by observing a mother and child interact, and requires the rater to critically assess 4 sub-domains of emotional connection. The NICU WECS is a clinical tool adapted for use with neonates in the NICU. Reliability of NICU staff WECS scoring will be calculated via intra-class correlations with key scores. The WECS is scored on intervals of 0.5, with a minimum of 1 (rarely--low level of connection) and maximum of 3 (mostly--high connection). Scores are used to determine the level of need for intervention.
79252595|NCT04922242|Other|NICU WECS Training|"WECS Training is an educational module consisting of an introduction of the concepts of emotional connection and autonomic co-regulation as studied by The Nurture Science Program, as well as an illustration of how these experiential constructs differ from traditional care plans that focus on educating parents to encourage bonding as opposed to autonomic emotional connection within the NICU. An introduction to the domains of the WECS screen as well as illustrations of these domains through video will augment the training designed for NICU staff."
79252596|NCT03559387|Drug|ANF-RHO™|"Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml"
79252597|NCT03559387|Drug|Neulasta®|"Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe."
79252598|NCT03558685|Behavioral|Weight loss diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
79390693|NCT02709330|Drug|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
79390694|NCT02709330|Other|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
79546798|NCT01547416|Drug|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
79390695|NCT02976766|Drug|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
79390696|NCT02976766|Drug|Placebo|Participants will receive placebo three times a day for 10 days.
79546799|NCT01547416|Drug|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
79546800|NCT01547455|Drug|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
79390697|NCT02436174|Device|novel device|novel device being used to measure shivering
79390698|NCT02709096|Drug|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
79390699|NCT02709096|Drug|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
79390700|NCT04638712|Other|Microbiopsy sample|before and after chemotherapy
79390701|NCT04638712|Other|Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level|before and after chemotherapy
79546801|NCT01547455|Drug|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
79848755|NCT06088082|Drug|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
79848756|NCT06088056|Drug|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
79848757|NCT06088017|Drug|CKD-391(2)|QD, PO
79848758|NCT06088017|Drug|CKD-331, D337|QD, PO
79709217|NCT04453592|Other|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
79848759|NCT06087965|Drug|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
79848760|NCT06087952|Other|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
79848761|NCT06087952|Diagnostic Test|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
79848762|NCT06087952|Diagnostic Test|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
79848763|NCT06087952|Other|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
79848764|NCT06087952|Other|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
79848765|NCT06087939|Device|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
79252599|NCT02410954|Device|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
79546802|NCT01547494|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
79709218|NCT04477226|Diagnostic Test|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
79848766|NCT06087913|Drug|TAF/EVG vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
79848767|NCT06087913|Drug|Matching Placebo vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
79848768|NCT06087900|Other|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
79848769|NCT06087900|Other|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
79848770|NCT06087900|Other|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
79848771|NCT06087900|Other|Control|The CON group did not have any intervention but usual care.
79848772|NCT06087887|Other|no interventions|no interventions
79390702|NCT04177264|Procedure|Occipito-Atlantal Decompression (OA DC)|The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
79390703|NCT04177264|Procedure|Sham Occipito-Atlantal Decompression (Sham OA DC)|The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
79390704|NCT04177264|Procedure|Splenic Lymphatic Pump Technique (SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
79546803|NCT01547494|Dietary Supplement|mixture of omega3 and vitamins|mixture of omega3 and vitamins
79546804|NCT01547507|Device|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
79546805|NCT01547520|Drug|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
79546806|NCT01547520|Drug|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
79546807|NCT01547546|Drug|GDC-0084|Multiple doses
79546808|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
79546809|NCT01547559|Drug|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
79709219|NCT04453397|Drug|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
79709220|NCT01600274|Drug|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
79709221|NCT01600274|Drug|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
79546810|NCT01547559|Drug|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
79709222|NCT01176565|Drug|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
79546811|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
79252600|NCT03558607|Drug|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~If Age < 55 years and ECOG PS < 2 : 7+3 regimen~If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
79252601|NCT02083471|Dietary Supplement|Specific Oral Tolerance Induction with Egg or Cow's milk|
79252602|NCT03559777|Other|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~The widening drills can be sequentially used to widen the osteotomy site to the same level~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~The osteotome will be tapped gently to fracture up the sinus floor.~Xenograft will be added to the osteotomy as the grafting material.~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
79390705|NCT04177264|Procedure|Sham Splenic Lymphatic Pump Technique (Sham SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
79390706|NCT04177264|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
79390707|NCT04177264|Device|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
79546812|NCT01547559|Drug|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
79709223|NCT04374123|Diagnostic Test|Serological screening for IgG and IgM antibodies against COVID-19|Serum evaluation for IgG and IgM antibodies against COVID-19 in patients in the endoscopy unit during the COVID 19 pandemic
79709224|NCT01600313|Dietary Supplement|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
79848773|NCT06087874|Dietary Supplement|Vivomixx®|The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
79848774|NCT06087874|Dietary Supplement|Placebo|A maltose- containing product with a similar phenotype with Vivomixx®.
79390708|NCT02975752|Genetic|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
79390709|NCT01372410|Drug|GSK573719|125 mcg once daily
79546813|NCT01547572|Procedure|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
79546814|NCT01547572|Procedure|The control group will receive a leaflet only|The control group will receive a leaflet only
79546815|NCT01547585|Other|Standardized soy containing muffin|Standardized muffin containing two levels of soy
79709225|NCT01176292|Device|Rotating Platform High-Flex Cruciate Substituting TKA|
79709226|NCT01176292|Device|Rotating Platform Cruciate Substituting TKA|
79709227|NCT04315675|Behavioral|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
79709228|NCT04315675|Behavioral|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
79848776|NCT06087848|Biological|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
79848777|NCT06087809|Behavioral|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
80016432|NCT02992899|Device|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
80016433|NCT02992899|Drug|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2[15O] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2[15O]. Subjects will receive a 20 mCi intravenous bolus of H2[15O] for each of the 14 scans during exposure to neutral and traumatic scripts.
80016434|NCT02281994|Device|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
79252603|NCT03559777|Other|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~Change the drill motor to reverse- densifying Mode~with the densah bur (2.5mm) until 1 mm short of the sinus floor.~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~densah burs (3.5mm) advance in the osteotomy.~Xenograft will be added to the osteotomy .~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
79252604|NCT02079103|Device|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
79252605|NCT02079103|Behavioral|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
79390710|NCT01372410|Drug|GSK573719|62.5 mcg once daily
79546816|NCT01547611|Other|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
79546817|NCT01547611|Other|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
79709229|NCT04315675|Behavioral|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
80016435|NCT00448058|Drug|GSK372475|daily administration during the 10-week treatment phase
80016436|NCT00448058|Drug|venlafaxine|daily administration during the 10-week treatment phase
80016437|NCT00448058|Drug|placebo|daily administration during the 10-week treatment phase
80016438|NCT01081210|Other|Ultrasound examination|Screening with bedside ultrasound examination
79390711|NCT01372410|Drug|GSK573719|31.25 mcg once daily
79390712|NCT01372410|Drug|GSK573719|15.6 mcg once daily
79390713|NCT01372410|Drug|GSK573719|31.25 mcg twice daily
79390714|NCT01372410|Drug|GSK573719|15.6 mcg twice daily
79390715|NCT01372410|Drug|Tiotropium|18 mcg once daily
79390716|NCT01372410|Drug|Placebo|once or twice daily
79390717|NCT02975830|Radiation|Three dimensional CT based images|Right bronchial angle, left bronchial angle
79709230|NCT01600469|Drug|DAOI-B|250-1500 mg/day, oral, for 24 weeks
79709231|NCT01600469|Other|Placebo|placebo, oral, for 24 weeks
79709232|NCT01113541|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
79709233|NCT04417608|Procedure|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
80016439|NCT03662373|Radiation|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
80016440|NCT03662373|Radiation|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
80016441|NCT02282072|Device|Deep brain stimulation：PINS Stimulation System|
79709234|NCT04451252|Procedure|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
79709235|NCT04451252|Procedure|Fluoroscopically guided lumbar facet joint injection.|With the patient in prone position and guided by fluoroscopy, lumbar facet joints are identified. The 22 french needles are then advanced aiming to the lumbar facet joints. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous facet joint infiltration. The selection of target facet joints is made based on clinical and radiological findings.
79709236|NCT04451252|Procedure|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
79709237|NCT04451252|Procedure|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
79848778|NCT06087809|Behavioral|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
79848779|NCT06087796|Drug|Betamethasone Valerate 0.1% Cream|Topical treatment modality for alopecia areata.
79848780|NCT06087796|Drug|Pentoxifylline|Topical treatment modality for alopecia areata.
79848781|NCT06087796|Drug|Metformin|Topical treatment modality for alopecia areata.
79848782|NCT06087783|Dietary Supplement|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
79848783|NCT06087783|Other|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
79848784|NCT06087744|Behavioral|NeuroN-QI|Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
80016442|NCT01602484|Device|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
80016443|NCT01602484|Device|Bulk splint supplies|Applying splint by using the bulk splint supplies
79546818|NCT01547624|Other|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
79546819|NCT01547637|Procedure|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
79546820|NCT01547637|Procedure|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
79546821|NCT01547650|Other|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
79546822|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
79546823|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
79546824|NCT01547689|Biological|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
79546825|NCT01547702|Behavioral|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~Session 5: Help to use instructional interventions for ADHD~Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
79546826|NCT01547897|Drug|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
79546827|NCT01547910|Dietary Supplement|Fish Oil|Fish oil given in supplementary dose
79709238|NCT04451252|Procedure|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
79709239|NCT04451252|Procedure|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
79709240|NCT04450823|Other|no intervention|no intervention study, survey amongst health workers
79709241|NCT04372368|Biological|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
79709242|NCT04417413|Device|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
79709243|NCT04372173|Diagnostic Test|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
79709244|NCT04450277|Procedure|Emergency surgery|Emergency surgery vs conservative management
79709245|NCT01113502|Drug|Eltrombopag|Oral formulation taken daily
79709246|NCT04474652|Other|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
79709247|NCT04416789|Other|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
79709248|NCT01113463|Drug|TPI 287|Starting dose of 160 mg/m^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
79709249|NCT02886403|Other|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
79848785|NCT06087744|Behavioral|SSC alone|Skin-to-skin contact (SSC) lasting 2 hours
80016444|NCT03662295|Behavioral|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
79252606|NCT03559309|Diagnostic Test|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
79252607|NCT02079337|Drug|Rocuronium|
79709250|NCT02886403|Other|New adhesive strip|A newly developed adhesive strip
79709251|NCT01112917|Device|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
79709252|NCT01112917|Procedure|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
79709253|NCT00591708|Dietary Supplement|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
79709254|NCT00591708|Dietary Supplement|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
79709255|NCT01176058|Drug|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
79709256|NCT01606982|Drug|MDV3100|oral
79709257|NCT04328766|Drug|DWC202005, alone|DWC202005, as a single dose
79709258|NCT04328766|Drug|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
79709259|NCT04328766|Drug|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
79709260|NCT01600781|Dietary Supplement|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
80016445|NCT04441736|Device|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation
80016446|NCT05118100|Drug|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
79252608|NCT02079337|Drug|sugammadex|
79252609|NCT02079337|Drug|placebo|
79252610|NCT02079415|Other|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
79709261|NCT01600820|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
79709262|NCT01600820|Other|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
79709263|NCT01600820|Other|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
79709264|NCT01600859|Drug|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
79709265|NCT01600859|Drug|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
79709266|NCT04328142|Other|Qigong group|Traditional Chinese Medicine exercise programme
79709267|NCT04328142|Other|Physiotherapy|Physiotherapy exercise programme
79709268|NCT01607099|Procedure|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
79709269|NCT02273765|Drug|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
79709270|NCT02273765|Drug|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
79709271|NCT04370184|Procedure|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
79709272|NCT00591747|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
79709273|NCT00591747|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
79709274|NCT01607177|Behavioral|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
79709275|NCT02279888|Device|CardioMEMS HF System|Pulmonary artery pressure sensor
79848786|NCT06087718|Device|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size < 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
80016447|NCT05118100|Drug|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
80016448|NCT03662529|Behavioral|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
80016449|NCT03662529|Behavioral|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
80016450|NCT00447980|Drug|NT-501|High Dose
79252611|NCT02083549|Other|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
79252612|NCT02083627|Drug|rosuvastatin|Oral
79252613|NCT02083627|Drug|fidaxomicin|Oral
79252614|NCT02083705|Procedure|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
79252615|NCT02083705|Procedure|3:1 CPR|CPR using 3:1 ratio (control group)
79252616|NCT02084017|Device|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
79252617|NCT02084017|Device|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
79252618|NCT02079493|Device|Total Knee Arthroplasty|Knee replacement
79252619|NCT02079571|Dietary Supplement|Coconut water|250 ml Coconut water for each subject
79252620|NCT02079571|Dietary Supplement|ginger tea|250 ml for each subject
79709276|NCT04414332|Other|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
79709277|NCT02489591|Device|Oral appliance|Patients will bring their prescribed oral appliance.
79709278|NCT02489591|Device|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
79709279|NCT01607333|Drug|Lamotrigine use|Lamotrigine prescription during the study period
79709280|NCT02892981|Other|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
79709281|NCT01601015|Other|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
79252621|NCT02079727|Drug|chondroitin sulfate|
79252622|NCT02079727|Drug|celecoxib|
79252623|NCT02079727|Drug|placebo|
79709282|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
79709283|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
79848787|NCT06087705|Device|Intra-articular injection of hyaluronic acid|"The injection must necessarily be performed by a practitioner in compliance with the rules of asepsis.~Procedure of use:~Before the injection, a rigorous prior disinfection of the area to be treated will be carried out.~Check the integrity of the sterility protector.~Take the syringe and remove the protective tip.~Hold the syringe body and insert a sterile intra-articular injection needle into the Luer-Lock system.~Gently turn the needle clockwise to secure the needle in the Luer-Lock system.~A visual check of the attachment of the needle will be carried out.~Remove the needle cap.~Inject slowly."
79848788|NCT06087666|Procedure|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
79848789|NCT06087653|Drug|Lenalidomide|Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
79252624|NCT02081989|Procedure|Renal denervation|Renal denervation
79252625|NCT02084173|Behavioral|MET + CRA|
79709284|NCT01601015|Other|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
79709285|NCT02893098|Drug|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
79252626|NCT02082067|Procedure|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
79252627|NCT02082067|Procedure|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
79848792|NCT06087575|Device|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
79848793|NCT06087562|Drug|Ropivacaine 0.5% Injectable Solution 20mL|Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine
80016451|NCT00447980|Drug|NT-501|Low Dose
79252628|NCT02082067|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
79848794|NCT06087562|Drug|0,9% normal saline 20mL|Ultrasound-guided placebo block with 20mL of 0,9% normal saline
79848795|NCT06087341|Other|NKG2D-CAR memory T cell|Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
80016452|NCT03660891|Diagnostic Test|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
80016453|NCT02284334|Other|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
80016454|NCT05116696|Procedure|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
80016455|NCT02284412|Drug|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
80016456|NCT02284412|Drug|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
80016457|NCT02284412|Drug|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
80016458|NCT02284490|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
80016459|NCT00583154|Drug|BLI-801|Dose 1
80016460|NCT00583154|Drug|BLI-801|Dose 2
80016461|NCT00583154|Drug|BLI-801|Dose 3
79546828|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
80016462|NCT00583154|Drug|BLI-801|Dose 4
80016463|NCT02207218|Drug|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
79546829|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
79546830|NCT01547949|Dietary Supplement|tart cultivar Montmorency cherry juice|
79546831|NCT01547949|Dietary Supplement|placebo cherry fruit drink|
79546832|NCT01547962|Device|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
79848796|NCT06086821|Diagnostic Test|Periodontal Re-Evaluation|Recording of the periodontal charting
79546833|NCT01547962|Other|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
79709286|NCT02893098|Drug|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
79709287|NCT01601054|Device|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
79709288|NCT01607528|Dietary Supplement|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
79709289|NCT01607528|Dietary Supplement|Placebo|A similar looking and tasting powder with no active substances
79848797|NCT06086535|Procedure|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
79848798|NCT06086015|Device|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
79848799|NCT06085729|Drug|ADI-PEG 20|Given by Injection
79848800|NCT06085729|Drug|Cabazitaxel|Given by IV (vein)
79848801|NCT06085729|Drug|Carboplatin|Given by IV (vein)
79848802|NCT06085651|Procedure|Selective thoracolumbar fusion (STLF) surgery|Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
80016464|NCT02273570|Drug|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
80016465|NCT02273570|Drug|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
79709290|NCT01601093|Drug|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
80016466|NCT01676818|Drug|eribulin mesylate|Given IV
80016467|NCT02282150|Drug|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
80016468|NCT02282150|Drug|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
80016469|NCT01354210|Behavioral|SMS Text Message Reminder|Daily
80016470|NCT00583076|Drug|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
79848803|NCT06084832|Biological|blood microsampling|blood microsampling for the measure of Phosphatidylethanol
79848804|NCT06084377|Genetic|Preimplantation Genetic Screening|Non-invasive technique to investigate the presence of genetic disorders.
79252629|NCT02082067|Procedure|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
79252630|NCT02082067|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
79252631|NCT02082067|Drug|Ropivacaine 0,75%|
79546834|NCT01547988|Other|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
79546835|NCT01548001|Drug|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
79546836|NCT01548001|Drug|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
79546837|NCT01548014|Dietary Supplement|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
79709291|NCT01601093|Drug|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
79709292|NCT01601093|Drug|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
79709293|NCT04328571|Dietary Supplement|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
79709294|NCT04328571|Dietary Supplement|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
79848805|NCT06083922|Drug|Cyclophosphamide|Days 1, 8 and 15, Cycles 1-8
79848806|NCT06083922|Drug|Bortezomib|Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
79848807|NCT06083922|Drug|Dexamethasone|Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
79848808|NCT06083922|Drug|Daratumumab|Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
79848809|NCT06082947|Device|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
79848810|NCT06082908|Diagnostic Test|Diagnostic test|Subjective and objective measurement will be performed in older adults.
79848811|NCT06082830|Behavioral|Intervention|"The intervention arm includes five components:~Personalized goal: Participants will complete an interview with a registered dietitian to review their baseline diet quality data and establish their personalized dietary goals.~Meal timing: Participants will receive information on why eating later at night is detrimental and specific strategies on how to limit eating past 8pm in the evening.~Nutrition skills: Participants will receive nutrition education and cooking skills text messages, using adolescent specific guidance from the Dietary Guidelines for Americans.~Home food environment: Participants will receive text messages on how to better select and prepare foods in the home environment (e.g., fruit and vegetable availability).~Engagement strategies: Researchers will design and implement text messages that recognize participant time and effort (e.g., text badges in recognition of completing the first study week)."
79848812|NCT06082544|Other|mini-screw implant|JEIL SCREW 1.6* 8 MM 16-G2-008 or JEIL SCREW 1.6*10 MM 14-G2-010
79848813|NCT06082544|Device|removable partial denture|Acrylic removable partial denture
79252632|NCT02082067|Drug|Levobupivacaine 0,5%|
79252633|NCT02082067|Drug|Levobupivacaine 0,125%|
79252634|NCT02082067|Drug|Ketorolac 30mg|
79252635|NCT02082067|Drug|Morphine|
79252636|NCT02082067|Device|stimulong sono, Pajunk, Germany|
79252637|NCT02084251|Drug|PB-119|
79709295|NCT04328571|Dietary Supplement|OLE|OLE (Olive leaf extract) + maltodextrin
79252638|NCT06131918|Drug|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
79252639|NCT06131918|Drug|Resveratrol|Tab Resveratrol 1500 mg BD
79252640|NCT06131918|Drug|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD
79252641|NCT06131918|Drug|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD
79252642|NCT06131879|Device|Laser acupuncture|Biostimulation of temporalis and masseter muscles
79252643|NCT06131879|Behavioral|Modified physical therapy|Progressive muscle relaxation of temporalis and masseter muscles
79252644|NCT06131814|Other|2 groups|up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
79252645|NCT06131749|Other|No intervention|No intervention, observational cohort study
79709296|NCT04366830|Drug|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
79709297|NCT01175824|Drug|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
79709298|NCT01175824|Drug|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
79709299|NCT01175824|Drug|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
79709300|NCT02482532|Biological|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
79709301|NCT01607684|Device|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
79709302|NCT01601210|Drug|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
79709303|NCT01175707|Drug|Daptomycin|
79848814|NCT06080204|Drug|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
79848815|NCT06079307|Other|Oxygenated Mouthwash|Will be comparing the impact of using oxygenated mouthwash with other groups.
79252646|NCT06131736|Other|Tabata Training|This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.
79546838|NCT01548027|Procedure|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
79848816|NCT06079307|Other|Oxygenated mouth foam|will be comparing the impact of using oxygenated foam to other groups.
79252647|NCT06131736|Other|Cluster Training|The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.
79252648|NCT06131697|Other|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.
79252649|NCT06131697|Other|McKenzie Exercises with Mulligan Mobilization|"McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks."
79252650|NCT06131684|Device|Intrauterine pressure catheter (IUPC) present|Amniotic fluid will be analyzed every 3 hours for the duration of labor for patients who require an IUPC through the standard of care.
79252651|NCT06131684|Device|Intrauterine pressure catheter (IUPC) absent|Patients that do not require an IUPC through the standard of care will not have amniotic fluid analyzed.
79390718|NCT03184818|Other|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
79546839|NCT01548027|Procedure|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
79709304|NCT01175707|Drug|Vancomycin|
79390719|NCT02428686|Drug|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
79390720|NCT00362050|Drug|Treatment with 3 dose groups of RBx11160 over 7 days|
79709305|NCT01601249|Procedure|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
79546840|NCT01548027|Other|No intervention|No intervention
79546841|NCT01548053|Other|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
79709306|NCT02892903|Device|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
79709307|NCT01112059|Drug|Doxycycline|100 mg twice a day for 8 days
79709308|NCT01112059|Other|placebo|placebo
79709309|NCT01175668|Drug|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores <8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
79709310|NCT01175668|Drug|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
79709311|NCT01601327|Drug|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
79848817|NCT06077929|Other|No intervention done|No interventions done
79848818|NCT06075732|Behavioral|Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
79848819|NCT06075433|Device|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79848820|NCT06075420|Device|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79252652|NCT06131606|Behavioral|experimental group|Patients in the experimental group were told how to use the stress ball before the procedure. The patient was then taken to the angiography unit. The stress ball was placed on the palms of the patients according to the procedure position. During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes. After the procedure, the NRS and STAI were filled out as a post-test 10 minutes after the patient was taken to the ward. The answers given by the patients were recorded by the researcher by marking them on the forms.
79252653|NCT06131580|Drug|Intervention/Treatment|"Drug: osilodrostat~- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint."
79252654|NCT06131567|Procedure|Implantoplasty|Implantoplasty as surface decontamination method
79546842|NCT01548066|Drug|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
79546843|NCT01548066|Drug|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
79709312|NCT01601327|Drug|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
79709313|NCT01601327|Drug|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
79709314|NCT01607723|Other|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
79709315|NCT01607723|Other|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
79709316|NCT01601366|Device|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
79709317|NCT01601366|Drug|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
79709318|NCT04412226|Device|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
79709319|NCT04412226|Device|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
79709320|NCT01607762|Drug|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
79709321|NCT01607762|Drug|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
79709322|NCT01607762|Drug|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
79709323|NCT01607762|Drug|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
79709324|NCT01607762|Drug|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
79709325|NCT04412031|Other|non applicable|non applicable
79709326|NCT04327869|Device|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
79848821|NCT06072768|Drug|Oral prednisone Taper|The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
79252655|NCT06131554|Biological|batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
79252656|NCT06131554|Biological|batch 2 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
79546844|NCT01548079|Drug|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
79546845|NCT01548092|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
79546846|NCT01548105|Other|Blood draw for the study participants|"These will include:~Procollagen 1-N propeptide levels (PINP)~Matrix metalloproteinase (MMP9)~Plasma Vitamin C levels"
79546847|NCT01548118|Biological|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
79709327|NCT01601405|Drug|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
79709328|NCT01601405|Drug|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
79709329|NCT01607840|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
79709330|NCT04327947|Other|Hyaluronic acid - Research product 1|Health care product (intimate gel)
79709331|NCT04327947|Other|Hyaluronic acid - Research product 2|Health care product (intimate gel)
79709332|NCT04327947|Other|Hyaluronic acid - Comparator product|Health care product (intimate gel)
79709333|NCT01601444|Device|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
79546848|NCT01548118|Biological|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
79709334|NCT01601483|Drug|MC-1101|1% Ophthalmic Solution TID
79709335|NCT01601483|Drug|MC-1101 Vehicle|Ophthalmic solution, TID
79546849|NCT01548118|Biological|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
79546850|NCT01548118|Biological|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
79709336|NCT01607918|Drug|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
79709337|NCT01607918|Drug|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
79709338|NCT04363125|Diagnostic Test|Pathology result|Pathology result of rectal biopsy
79709339|NCT04362774|Device|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
79252657|NCT06131554|Biological|batch 3 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
79252658|NCT06131554|Biological|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
79252659|NCT06131489|Other|Segmental bowel resection combined with the DEP regimen|Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
79546851|NCT01548131|Behavioral|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
79546852|NCT01548144|Drug|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
79546853|NCT01548144|Drug|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
79546854|NCT01548144|Drug|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
79546855|NCT01548157|Drug|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
79546856|NCT01548170|Drug|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
79546857|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
79252660|NCT06131476|Drug|Blink® Tears eye drops|Control Drops
79252661|NCT06131476|Drug|Investigational lipid eye drops|Test Drops
79546858|NCT01548170|Drug|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
79709340|NCT01607996|Procedure|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
79709341|NCT01607996|Drug|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
79709342|NCT01601561|Drug|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
79709343|NCT04361682|Procedure|Surgical Drain Management|
79709344|NCT01601717|Drug|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
79709345|NCT01601717|Drug|Placebo|Matching placebo pill administered once per day for 10 days.
79709346|NCT01601756|Device|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
79546859|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
79546860|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
79252662|NCT06131411|Other|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
79252663|NCT06131411|Other|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
79252664|NCT06131359|Diagnostic Test|Fine wire EMG and Force Frame muscle strength testing|Insertion of fine wires for EMG study of tibialis posterior and assessment of muscle strength using a force frame
79546861|NCT01548183|Behavioral|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
79546862|NCT01548196|Procedure|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
79546863|NCT01548209|Drug|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
79546864|NCT01548209|Drug|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
79546865|NCT01548235|Drug|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
79546866|NCT01548248|Drug|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
79546867|NCT01548248|Drug|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
79709347|NCT01601756|Device|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
79709348|NCT04327830|Other|Decisional needs assessment|Assessment of decision-making needs
79709349|NCT01601795|Drug|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
79709350|NCT01601795|Drug|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
79709351|NCT04360590|Device|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
79546868|NCT01548261|Procedure|Donating oral mucosal cells|Donating oral mucosal cells
79546869|NCT01548274|Drug|Sarpogrelate|Sarpogrelate 300mg/day
79546870|NCT01548326|Drug|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
79546871|NCT01548326|Drug|placebo|one Placebo tablet orally per day for 10 days
79709352|NCT01608035|Procedure|Sciatic catheter|presurgical sciatic catheter insertion
79709353|NCT01608035|Procedure|Stump catheter|intraoperative placed stump catheter
79709354|NCT01601912|Drug|Atomoxetine|40 mg, 1 application
79709355|NCT01601912|Drug|Citalopram|20 mg, 1 application
79709356|NCT02489201|Drug|donafenib tosilate tablets|200mg,bid
79709357|NCT04410939|Diagnostic Test|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
79709358|NCT01601951|Other|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
79709359|NCT01111825|Drug|Temsirolimus|"28 day treatment cycle Phase 1~Weekly intravenously (IV) on days 1, 8, 15, and 22~Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
79709360|NCT01111825|Drug|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
79709361|NCT01608191|Behavioral|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
79252665|NCT06131346|Other|Evaluation of clinical and paraclinical data.|Retrospective data collection from available medical files of patient.
79252666|NCT06131333|Procedure|Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation|PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.
79546872|NCT01548365|Other|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
79546873|NCT01548378|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
79709362|NCT01175590|Drug|Besivance|Ocular administration to affected eye for 7 days
79709363|NCT01175590|Drug|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
79709364|NCT01601990|Drug|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
79709365|NCT01601990|Drug|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
79709366|NCT01175473|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
79709367|NCT01175473|Device|Pen auto-injector|
79709368|NCT01175473|Drug|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
79709369|NCT01175473|Device|Pre-filled pen injector|
79709370|NCT01175473|Drug|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
79709371|NCT01602107|Other|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
79252667|NCT06131320|Diagnostic Test|PVSE Test|Completion of the PVSE test
79252668|NCT06131320|Other|Cerebral MRI|Cerebral MRI scan
79252669|NCT06131307|Procedure|Education|Paternalistic leadership training will be given to clinical manager nurses.
79390721|NCT02432976|Drug|Exenatide|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
79546874|NCT01548378|Genetic|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
79546875|NCT01548378|Genetic|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
79546876|NCT01548378|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
79546877|NCT01548391|Drug|HX-1171|20mg, 200mg, 500mg
79546878|NCT01548430|Drug|TTP4000|
79546879|NCT01548430|Drug|Placebo|
79546880|NCT01548443|Device|Medifoam H dressing|"Cover medifoam H on the wound for a week."
79546881|NCT01548443|Device|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
79546882|NCT01548456|Procedure|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
79546883|NCT01548456|Procedure|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
79546884|NCT01548469|Other|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
79546885|NCT01548469|Other|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
79546886|NCT01548482|Other|Laboratory Biomarker Analysis|Correlative studies
79546887|NCT01548482|Other|Pharmacological Study|Correlative studies
79546888|NCT01548482|Drug|Temsirolimus|Given IV
79546889|NCT01548482|Biological|Trebananib|Given IV
79546890|NCT01548508|Other|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
79709372|NCT01602146|Other|ultramarathon running|"blood samples before and after ultramarathon~urinary samples before and after ultramarathon~voluntary ant electrically muscular forces measuring before and after ultramarathon~Broadband ultrasound Attenuation before and after ultramarathon"
79252670|NCT06131294|Device|Fluoride Application (Experimental Fluoride Application and Fluor Protector S)|Both Fluoride containing applications are used to treat white spot lesions. (for more information see Description Arms)
79252671|NCT06131268|Drug|Venlafaxine|we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
79546891|NCT01548508|Other|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
79546892|NCT01548521|Drug|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
79546893|NCT01548534|Dietary Supplement|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
79546894|NCT01548534|Dietary Supplement|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
79709373|NCT01111552|Drug|Escitalopram|Escitalopram oral capsules.
79546895|NCT01548547|Other|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
79546896|NCT01548560|Drug|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
79546897|NCT01548560|Drug|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
79546898|NCT01548586|Device|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
79546899|NCT01548612|Drug|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
79546900|NCT01548612|Drug|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
79546901|NCT01548664|Other|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
79546902|NCT01548664|Other|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
79546903|NCT01548677|Drug|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
79546904|NCT01548703|Drug|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
79546905|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
79546906|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
79546907|NCT01548729|Procedure|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
79709374|NCT01111552|Drug|Aripiprazole|Aripiprazole oral capsules.
79709375|NCT01111552|Drug|Placebo|Study drug matching placebo capsule.
80016471|NCT05122468|Procedure|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
79848822|NCT06072768|Drug|150-day taper prednisone|The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
79709376|NCT01602185|Drug|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
79709377|NCT01602185|Drug|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
79390722|NCT02432976|Drug|Insulin|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
79390723|NCT02428452|Behavioral|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
79390724|NCT02975596|Other|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
79390725|NCT02975596|Other|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
79390726|NCT02975596|Other|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
79709378|NCT01602185|Drug|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
79848823|NCT06072703|Device|Magstim Rapid2 System|"The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction."
79848824|NCT06071741|Procedure|Percutaneous Coronary Intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
79390727|NCT02975596|Other|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
79390728|NCT02428374|Drug|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
79546908|NCT01548781|Behavioral|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
79546909|NCT01548794|Procedure|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
79546910|NCT01548794|Procedure|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
79546911|NCT01548794|Procedure|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
79546912|NCT01548807|Drug|Everolimus (RAD001)|
79848825|NCT06070220|Behavioral|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
79848826|NCT06070220|Behavioral|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
79546913|NCT01548846|Radiation|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
79546914|NCT01548859|Drug|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
79709379|NCT02886208|Behavioral|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
79709380|NCT05062720|Radiation|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
79709381|NCT01602302|Drug|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
79709382|NCT05098171|Biological|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10^8-1x10^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
79709383|NCT02893956|Procedure|echocardiography with postural support|
79709384|NCT02893956|Procedure|echocardiography with standard condition (usual)|
79709385|NCT01602458|Procedure|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
79709386|NCT01602458|Procedure|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
79252672|NCT06131255|Drug|Citalopram|Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
79252673|NCT06131229|Behavioral|Structured emotional education program (PEE)|The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.
79390729|NCT02428374|Drug|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
79390730|NCT02428374|Drug|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
79390731|NCT02428374|Drug|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
79546915|NCT01548859|Drug|Sevoflurane|end tidal concentration of % 0,5-8
79546916|NCT01548872|Drug|HTK solution|50 ml/kg bolus in 2 minutes
79546917|NCT01548872|Drug|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
79546918|NCT01548898|Device|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
79546919|NCT01548911|Drug|gemtuzumab ozogamicin|Given IV
79546920|NCT01548911|Other|laboratory biomarker analysis|Correlative studies
79709387|NCT02893722|Drug|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
79709388|NCT02893722|Drug|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
79709389|NCT01602497|Device|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
79848827|NCT06069882|Behavioral|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
79546921|NCT01548924|Drug|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
79546922|NCT01548924|Drug|Dovitinib + Paclitaxel|"Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
79546923|NCT01548937|Drug|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
79546924|NCT01548950|Drug|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
79546925|NCT01548963|Procedure|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
79709390|NCT01602497|Device|sham rTMS|Patients will undergo ten session of sham rTMS.
79709391|NCT01608269|Drug|Abacavir/Lamivudine|one tablet once a day
79709392|NCT04407156|Other|acute kidney injury|AKI in COVID positive cases
79848828|NCT06066476|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79390732|NCT03186612|Behavioral|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
79390733|NCT03184740|Device|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
79546926|NCT01549015|Other|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
79546927|NCT01549028|Behavioral|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
79546928|NCT01549054|Drug|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
79546929|NCT01549054|Drug|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
79546930|NCT01549054|Drug|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
79546931|NCT01549054|Drug|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
79709393|NCT01602536|Behavioral|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
79709394|NCT01602536|Behavioral|Twitter|Twitter quit-smoking group
79709395|NCT04407117|Behavioral|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
79709396|NCT01602575|Behavioral|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
79709397|NCT01608347|Drug|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
79709398|NCT01608347|Drug|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
79546932|NCT01549080|Drug|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
79546933|NCT01549093|Drug|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
79709399|NCT04404933|Other|Treatment algorithm for OIC|Treatment Algorithm for OIC
79709400|NCT01608386|Procedure|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
79709401|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
79709402|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
79709403|NCT01602770|Drug|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
79709404|NCT04405284|Other|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
79709405|NCT01603004|Other|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
79848829|NCT06060470|Behavioral|Virtual reality based dance group|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
80016472|NCT05122468|Procedure|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
80016473|NCT05122312|Drug|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
80016474|NCT05122312|Drug|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
80016475|NCT00579020|Drug|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
80016476|NCT00579020|Drug|Moxifloxacin ophthalmic solution 0.5%|
80016477|NCT00579020|Drug|Dexamethasone phosphate solution, 0.1%|
79390734|NCT03184740|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
79390735|NCT02436018|Device|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
79390736|NCT02436018|Device|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
79390737|NCT02435862|Drug|1.0mg Luminate®|
79390738|NCT02435862|Drug|2.0mg Luminate®|
79390739|NCT02435862|Drug|3.0mg Luminate®|
79709406|NCT04328610|Procedure|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
79709407|NCT01608464|Drug|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
79709408|NCT01608464|Drug|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
79709409|NCT01603160|Behavioral|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
79848830|NCT06060470|Behavioral|Active Comparator: Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
79848831|NCT06058455|Behavioral|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS & SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
79848832|NCT06058455|Behavioral|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
79390740|NCT02435862|Other|Balanced Salt Solution for intravitreal injection in 0.10cc|
79546934|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
79546935|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
79546936|NCT01549106|Drug|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
79546937|NCT01549106|Drug|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
79546938|NCT01549119|Biological|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
79546939|NCT01549119|Biological|Placebo|Comparison with experimental vaccine
79546940|NCT01549145|Device|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
79546941|NCT01549158|Drug|torasemide-PR|Single oral dose of torasemide PR 10 mg
79546942|NCT01549158|Drug|Furosemide-IR|Single oral dose of furosemide IR 40 mg
79546943|NCT01549158|Drug|torasemide-IR|Single oral dose of torasemide IR 10 mg
79546944|NCT01549171|Drug|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
79546945|NCT01549171|Other|normal saline|Supplement with vehicle only no Iloprost.
79546946|NCT01549236|Drug|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
79546947|NCT01549249|Device|optical coherence tomography|spectral-domain optical coherence tomography
79848833|NCT06058130|Drug|Anticoagulant Oral|Anticoagulation alone
79390741|NCT04343014|Device|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
79390742|NCT04343014|Device|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
79848834|NCT06058130|Drug|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
79848835|NCT06057467|Drug|Anticoagulation Agents|Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
79390743|NCT02435784|Other|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
79390744|NCT02435784|Other|Treatment as usual|Patients will attend a psychiatric consultation as usual.
79546948|NCT01549262|Device|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
79546949|NCT01549262|Device|Observe embryo development|Observe embryo development in the traditional manner
79546950|NCT01549288|Behavioral|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
79546951|NCT01549288|Other|no dietetic input|continuation of anti-epileptic medication without any dietetic input
79546952|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
79709410|NCT04404699|Diagnostic Test|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
79709411|NCT01608503|Procedure|lung deflation|lung was deflated during respiration cycle
79709412|NCT01608503|Procedure|lung inflation|lung was inflated during respiratory cycle
79546953|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
79848836|NCT06057155|Diagnostic Test|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
80016478|NCT04530604|Drug|Defibrotide|"All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~Patients who have not responded to study therapy by day 7 of therapy, evidenced by <20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~Patients who have evidence of a partial pulmonary response by day 7 (>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course)."
79390745|NCT03186222|Diagnostic Test|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
79546954|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
79546955|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
79709413|NCT04404270|Diagnostic Test|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
79709414|NCT04404270|Behavioral|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~medical data (height, weight, smoking, history of intense stress);~socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~use of care, hospitalization, work stoppage in the last 3 months;~contact with people who are symptomatic or proven COVID-19."
79709415|NCT04404270|Diagnostic Test|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
79709416|NCT01608542|Drug|Fostamatinib 100mg|oral tablet
79709417|NCT01608542|Drug|Fostamatinib 200mg|oral tablet
79709418|NCT01608698|Drug|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
79709419|NCT01608698|Drug|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
79709420|NCT04133805|Dietary Supplement|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
79709421|NCT01603199|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
79709422|NCT01603238|Drug|[14C]-LC15-0444|A single oral administration of [14C]-LC15-0444 50 mg, containing 4.9 MBq [14C]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
79709423|NCT01175083|Biological|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
79709424|NCT01175083|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
79709425|NCT01175083|Biological|Polio Sabin|4 oral doses
79709426|NCT02489708|Behavioral|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
79709427|NCT04403061|Diagnostic Test|Cytokines measurement|Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).
79709428|NCT04403061|Diagnostic Test|Cellular response|SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).
79546956|NCT01549327|Other|Oncology Interactive Navigator|
79546957|NCT01549327|Other|Routine Care|
79546958|NCT01549353|Behavioral|gum chewing|
79546959|NCT01549366|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
79546960|NCT01549366|Device|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
80016479|NCT04471142|Device|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
80016480|NCT04169698|Drug|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
80016481|NCT04169698|Drug|Alendronate 70Mg Tab|Bisphosphonates
80016482|NCT04470752|Drug|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
79390746|NCT03184350|Radiation|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
79390747|NCT02428218|Drug|dimethyl fumarate|enteric-coated microtablets
79390748|NCT02428218|Drug|Placebo|enteric-coated microtablets
79390749|NCT03186300|Device|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
79546961|NCT01549379|Radiation|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
79390750|NCT04606576|Other|Placebo|Fish Oil
79546962|NCT01549418|Drug|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
79546963|NCT01549418|Drug|Placebo|
79546964|NCT01549431|Drug|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~Standard 3+3 design~3 out of 4 weeks"
79546965|NCT01549431|Drug|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~Standard 3+3 design~Days 1/2, 8/9 and 15/16 every 4 weeks"
79546966|NCT01549431|Drug|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
79390751|NCT04606576|Drug|ORMD-0801 QD|Oral Insulin once per day
79390752|NCT04606576|Drug|ORMD-0801 BD|Oral Insulin, twice per day
79390753|NCT02428140|Device|Medtronic Reveal LINQ|
79546967|NCT01549444|Other|presence of maternal risk factor for hypertension|
79546968|NCT01549457|Other|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
79546969|NCT01549470|Biological|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
79546970|NCT01549470|Biological|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
79546971|NCT01549496|Drug|Amlodipine|amlodipine 2.5 mg QD
79546972|NCT01549496|Drug|Diltiazem|diltiazem 120 mg qd
79709429|NCT04403061|Diagnostic Test|TLRs activation measurement|After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).
79709430|NCT04403061|Diagnostic Test|KIR phenotype evaluation|Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
79709431|NCT02881333|Genetic|Blood samples|
79709432|NCT04310254|Procedure|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
79709433|NCT04310254|Procedure|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
79709434|NCT04310254|Procedure|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
79709435|NCT02480972|Procedure|magnetic resonance imaging|"multiparametric MRI as follows:~diffusion weighted imaging using multiple b-values~Fat quantification sequence~perfusion MRI using ECCM agent~MR elastography~------------------------------------~routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
79709436|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
79709437|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
79709438|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
79709439|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
79709440|NCT01608737|Drug|BI 201335|BI 201335 once daily low dose for 24 weeks
79709441|NCT02886130|Dietary Supplement|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
80016483|NCT04470752|Drug|InOrpha Solution|glycerol based suspension vehicle
80016484|NCT02273804|Drug|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
79546973|NCT01549509|Biological|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
79546974|NCT01549522|Behavioral|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
79709442|NCT02886130|Dietary Supplement|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
79709443|NCT02881606|Device|Naso-alveolar molding (NAM)|
79709444|NCT02881606|Device|Computer aided design NAM (CAD/NAM)|
79709445|NCT01608776|Device|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
79709446|NCT01608776|Other|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
79709447|NCT04402554|Behavioral|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
79709448|NCT01111474|Other|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
79709449|NCT01111474|Radiation|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
79709450|NCT01608932|Procedure|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
79709451|NCT01603433|Device|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
79709452|NCT01603511|Device|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
79709453|NCT04400955|Diagnostic Test|Audiometry tablet diagnostic tool and web-based test|as above
79709454|NCT01603550|Other|Sleep Deprivation|Sleep Deprivation
80016485|NCT02273804|Drug|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
80016486|NCT04142944|Device|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
80016487|NCT04142944|Device|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
79390754|NCT02428140|Device|Sorin Spiderflash-t|
79390755|NCT02428062|Procedure|Hemodynamic target|"The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~intravenous fluids~patient's positioning~reduction of depth of anesthesia"
79390756|NCT02428062|Drug|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
79390757|NCT02428062|Drug|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
79546975|NCT01549522|Behavioral|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
79546976|NCT01549535|Device|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
79546977|NCT01549548|Drug|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
79546978|NCT01549561|Behavioral|Parent Training|16 weeks of parent training led by a trained group facilitator
79546979|NCT01549561|Behavioral|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
79709455|NCT01603550|Other|Energy Restriction|Energy Restriction
79709456|NCT04399590|Other|Interficial Intelligence|Interficial Intelligence
80016488|NCT00578474|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
80016489|NCT00578474|Drug|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
80016490|NCT00578474|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
80016491|NCT03909490|Other|Preference elicitation tool|Ranking tool to assess patient preferences for trigger finger treatment
80016492|NCT03909490|Other|handout|handout with information about trigger fingers
80016493|NCT00577148|Drug|Rimonabant|Tablet, oral administration
80016494|NCT00577148|Drug|Placebo (for Rimonabant)|Tablet, oral administration
80016495|NCT03700918|Device|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
79252674|NCT06131229|Behavioral|Incidental tutorial action based on the school's regular curriculum (PCO)|One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
79390758|NCT02428062|Procedure|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
79546980|NCT01549574|Drug|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
79546981|NCT01549574|Drug|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
79546982|NCT01549600|Dietary Supplement|psyllium|1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
79546983|NCT01549600|Dietary Supplement|Microcrystalline Cellulose|1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
79546984|NCT01549626|Dietary Supplement|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
79709457|NCT01603667|Drug|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
79709458|NCT01603667|Drug|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
79709459|NCT01603745|Drug|Zoely|1 pill every day
79848838|NCT06056557|Device|VARIPULSE™ catheter ablation|"Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation"
79709460|NCT01603745|Drug|Yasmin|1 pill every day
79390759|NCT02428062|Procedure|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
80016496|NCT05203796|Device|Transcutaneous pulsed electrical stimulation (NuEyne 02)|Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
79546985|NCT01549626|Dietary Supplement|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
79546986|NCT01549626|Dietary Supplement|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
79546987|NCT01549665|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
79546988|NCT01549678|Other|Total contact insole|EVA insole shaped on patient´s foot.
79546989|NCT01549678|Other|placebo insole|EVA insole flat
79546990|NCT01549691|Drug|Zopiclone|7.5 mg before sleep, the evening before surgery
79546991|NCT01549691|Drug|Alprazolam|0.5 mg at awakening, the day of surgery
79546992|NCT01549691|Drug|placebo|given night before surgery and at awakening, the day of surgery
79709461|NCT02691585|Other|Music Intervention|A raga will be played for 10 minutes & data collected.
79848839|NCT06054880|Drug|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
79848840|NCT06054880|Other|Saline injection 0.9%|Placebo
79848841|NCT06053021|Drug|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
79252675|NCT06131216|Drug|SHR-2022 Injection|SHR-2022 Injection is administered by intravenous (IV) infusion
79546993|NCT01549704|Drug|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
79546994|NCT01549704|Drug|Saline|please see intervention description for ropivacaine
79709462|NCT01174264|Other|Pharmacological Study|Correlative studies
79709463|NCT01174264|Drug|Vismodegib|Given PO
79252676|NCT06131190|Behavioral|mindfulness training|it focuses on attention and has gained empirical support as a complementary or alternative intervention
79252677|NCT06131177|Dietary Supplement|Nutritional supplement|Protein supplement
79252678|NCT06131151|Other|Nerve block|Nerve block in percutaneous nephrolithotomy
79390760|NCT02428062|Drug|Ephedrine|Ephedrine 5-25 mg intravenous bolus
79390761|NCT02428062|Drug|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
79390762|NCT02428062|Drug|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
79390763|NCT02428062|Drug|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
79709464|NCT01603784|Behavioral|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at ~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
79252679|NCT06131138|Other|Aquatic exercises|This include aquatic exercises thrice as week for 6 weeks.
79252680|NCT06131138|Other|Core strengthening|This include core strengthening exercises thrice a week for 6 weeks
79390764|NCT03189264|Procedure|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
79546995|NCT01549717|Device|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
79546996|NCT01549743|Drug|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
79546997|NCT01549743|Drug|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
79546998|NCT01549743|Drug|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
79546999|NCT01549756|Behavioral|bulletin board and teleophone depth interview|qualitative based research
79547000|NCT01549782|Dietary Supplement|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
79547001|NCT01549782|Dietary Supplement|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
79547002|NCT01549795|Procedure|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
79547003|NCT01549795|Radiation|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
79547004|NCT01549795|Radiation|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
80016497|NCT05203796|Device|Sham stimulation|Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
79252681|NCT06131125|Other|Plyometric training exercises|This includes plyometric training exercises thrice a week for 6 weeks
79252682|NCT06131125|Other|Explosive strength training exercises|this includes explosive strength training exercises thrice a week for 6 weeks
79252683|NCT06131086|Other|stabilization exercises|this include stabilization exercise thrice a week for six weeks
79252684|NCT06131086|Other|stabilization exercises along with pectoralis minor stretching|this include stabilization exercise with pectoralis minor thrice a week for six weeks
79252685|NCT06131073|Other|speed endurance production (SEP) training along with conventional training.|this include speed endurance training for 3 days in a week for 8 weeks.
79547005|NCT01549795|Drug|Capecitabine|Capecitabine - administered till liver transplantation
79547006|NCT01549795|Procedure|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
79547007|NCT01549808|Other|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
79547008|NCT01549808|Other|mobilization|sitting, standing and walking
79547009|NCT01549847|Drug|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
79547010|NCT01549847|Drug|Placebo|Placebo PO BID
79547011|NCT01549899|Behavioral|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education & hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
79848842|NCT06049940|Biological|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
79848843|NCT06049940|Biological|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
79252686|NCT06131073|Other|conventional training|this include conventional training for 3 days in a week for 8 weeks.
79252687|NCT06131060|Other|Progressive eccentric exercises|This include progressive eccentric exercises thrice a week for 6 weeks.
79252688|NCT06131060|Other|Bodyweight exercises|This include bodyweight exercises thrice a week for 6 weeks
79390765|NCT02435550|Genetic|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
79709465|NCT01603784|Behavioral|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
79848844|NCT06048510|Diagnostic Test|Pregnant women|"Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin."
79848845|NCT06048159|Device|HD-tACS|High definition tACS will be applied during speech therapy.
79848846|NCT06048159|Device|Sham HD-tACS|Sham high definition tACS will be applied during speech therapy.
79252689|NCT06131047|Other|High intensity Traditional Resistance Traning without Blood Flow Restriction|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement
79547012|NCT01549899|Behavioral|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
79547013|NCT01549938|Dietary Supplement|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
79547014|NCT01549938|Dietary Supplement|Placebo|Microcellulose capsule identical in appearance to treatment
79547015|NCT01549990|Drug|Sevoflurane|maintenance of general anesthesia with sevoflurane
79547016|NCT01549990|Drug|desflurane|maintenance of general anesthesia with desflurane
79547017|NCT01550016|Other|Observation|Clinical follow-up and laboratory investigations.
79547018|NCT01550029|Behavioral|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
79547019|NCT01550029|Behavioral|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
79547020|NCT01550055|Drug|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
79709466|NCT01603784|Behavioral|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
79848847|NCT06045819|Biological|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
79848848|NCT06032715|Behavioral|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
79848849|NCT06025305|Diagnostic Test|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
79390766|NCT04596202|Behavioral|Supine position|After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
79390767|NCT04596202|Behavioral|Prone position|After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
79709467|NCT01603784|Behavioral|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
79709468|NCT01174186|Drug|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
79709469|NCT01609049|Drug|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
79547021|NCT01550055|Drug|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
79709470|NCT01609049|Drug|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
79709471|NCT02893566|Behavioral|Mi Band Step Challenge|
80016498|NCT03673228|Behavioral|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
80016499|NCT03673228|Behavioral|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
80016500|NCT03673228|Drug|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
80016501|NCT00664664|Drug|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
80016502|NCT00664664|Drug|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
80016503|NCT00664664|Drug|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
80016504|NCT05122234|Biological|Injection of secretome - mesenchymal stem cell|Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
80016505|NCT05122234|Other|Placebo|Normal saline
80016506|NCT05122234|Drug|Standard treatment of Covid-19|Standard treatment of Covid-19 based on national protocol.
80016507|NCT00439634|Drug|AVE1625|oral administration
80016508|NCT00439634|Drug|placebo|oral administration
79547022|NCT01550068|Diagnostic Test|Echocardiography|
79547023|NCT01550081|Other|Rate of perceived exertion|Exercise intensity controlled by Borg scale
79547024|NCT01550081|Other|Heart rate monitor|Exercise intensity controlled by heart rate monitors
79547025|NCT01550107|Drug|Allopurinol|300mg b.d for 24 weeks
79547026|NCT01550107|Drug|Lactose tablets|matched placebo tablets b.d
79547027|NCT01550146|Drug|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
79547028|NCT01550146|Drug|Placebo|iv. Normal Saline 0.1 ml/kg
79547029|NCT01550172|Behavioral|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
79709472|NCT02893527|Behavioral|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
79709473|NCT01609088|Dietary Supplement|Erythritol-containing beverage|Orange flavored beverage containing erythritol
79709474|NCT01173718|Device|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
79709475|NCT01603862|Procedure|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
79709476|NCT01609127|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
79709477|NCT01609127|Drug|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
79709478|NCT01609127|Drug|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
79709479|NCT01603901|Device|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
79709480|NCT01603979|Biological|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
79709481|NCT00592020|Procedure|Short Transverse Incision|Short Transverse Incision for kidney transplantation
79709482|NCT00592020|Procedure|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
80016509|NCT03161626|Drug|Coagadex|Plasma-driven blood coagulation factor X concentration
80016510|NCT02282228|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
80016511|NCT02282306|Behavioral|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
80016512|NCT02277236|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
79709483|NCT01609166|Drug|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
79547030|NCT01550172|Behavioral|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
79709484|NCT01609166|Drug|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
79848850|NCT06017440|Behavioral|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
79848851|NCT06017440|Behavioral|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
79848852|NCT06016959|Other|Dietetic intervention|Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition & also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
79848853|NCT06016959|Other|Diet sheet (placebo)|Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton & Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
80016513|NCT02277236|Radiation|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
79547031|NCT01550211|Device|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
79547032|NCT01550250|Behavioral|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
79547033|NCT01550250|Behavioral|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
79547034|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
79547035|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
79547036|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
79547037|NCT01550276|Other|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
79709485|NCT01609205|Biological|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
79709486|NCT01604057|Drug|ZT-034 Low Dose Nasal Spray|Nasal Spray
79709487|NCT01604057|Drug|ZT-034 Mid Dose Nasal Spray|Nasal Spray
79709488|NCT01604057|Drug|ZT-034 High Dose Nasal Spray|Nasal Spray
79709489|NCT01604057|Drug|Teriparatide|20 mcg subcutaneous daily
79709490|NCT01604057|Drug|Placebo|Nasal Spray
79709491|NCT04331223|Other|Observation|observational
79709492|NCT01604096|Other|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~posters (same distribution as brochures)~short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~radio-spots transmitted in local radio stations~advertisements in local newspapers~banners on websites of local newspapers~newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
79709493|NCT01604174|Other|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
79848854|NCT06014775|Drug|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
79848855|NCT06007651|Drug|LY3885125|Administered SC
79547038|NCT01550302|Procedure|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
79848856|NCT06007651|Drug|Placebo|Administered SC
80016514|NCT05116306|Drug|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
79390768|NCT04596202|Behavioral|Lateral position|After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
79390769|NCT03186066|Device|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
79390770|NCT03186066|Procedure|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
79390771|NCT02432586|Behavioral|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
79390772|NCT02975518|Biological|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
79547039|NCT01550302|Drug|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
79547040|NCT01550354|Drug|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
79547041|NCT01550354|Drug|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
79547042|NCT01550354|Drug|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
79709494|NCT01604174|Other|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
79709495|NCT04330014|Behavioral|vaccine|affect vaccination on children
79709496|NCT01609244|Device|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
79848857|NCT06005038|Behavioral|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
79848858|NCT06005038|Behavioral|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
79848859|NCT06001814|Behavioral|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
79848860|NCT06001814|Other|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
80016515|NCT05116306|Drug|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
80016516|NCT00570986|Drug|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
79547043|NCT01550380|Drug|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
79547044|NCT01550393|Genetic|proteomic profiling|
79547045|NCT01550393|Other|enzyme-linked immunosorbent assay|
79547046|NCT01550393|Other|laboratory biomarker analysis|
79709497|NCT01609244|Device|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
79848861|NCT05999994|Drug|Ramucirumab|Administered IV
79848862|NCT05999994|Drug|Cyclophosphamide|Administered orally
79848863|NCT05999994|Drug|Vinorelbine|Administered IV
79848864|NCT05999994|Drug|Gemcitabine|Administered IV
79848865|NCT05999994|Drug|Docetaxel|Administered IV
79848866|NCT05999994|Drug|Abemaciclib|Administered orally
79848867|NCT05999994|Drug|Irinotecan|Administered IV
80016517|NCT00570986|Biological|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
79848868|NCT05999994|Drug|Temozolomide|Administered orally
80016518|NCT00570986|Biological|ABT-874|100mg every 12 weeks.
80016519|NCT00570752|Other|Placebo|
80016520|NCT00570752|Drug|BMS-582949|
80016521|NCT00570752|Drug|Atorvastatin|
80016522|NCT00570752|Drug|Statin|
79709498|NCT01609283|Biological|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~Group 1: single intrathecal dose of 1 x 107 cells~Group 2: single intrathecal dose of 5 x 107 cells~Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~Group 4: single intrathecal dose of 1 x 108 cells~Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
79709499|NCT00592566|Drug|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
79709500|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
79709501|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
79709502|NCT01609322|Behavioral|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
79709503|NCT01609322|Behavioral|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
79709504|NCT04310800|Procedure|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
79709505|NCT00592644|Procedure|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
79709506|NCT00592644|Procedure|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
79709507|NCT01604330|Drug|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
79709508|NCT01604330|Drug|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
79709509|NCT00622830|Drug|SB-480848 (Darapladib)|
79709510|NCT01609361|Other|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
79709511|NCT01173679|Drug|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
79709512|NCT01173679|Drug|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
79709513|NCT01173679|Drug|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
79709514|NCT02881528|Drug|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
79709515|NCT02881528|Drug|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
79709516|NCT01609439|Drug|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
79709517|NCT01609439|Drug|Placebo|Placebo
79709518|NCT01110382|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
80016523|NCT00569972|Drug|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
80016524|NCT00569972|Drug|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
79252690|NCT06131047|Other|High intensity Traditional Resistance Traning with Blood Flow Restriction|Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
79547047|NCT01550393|Other|medical chart review|
79547048|NCT01550406|Device|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
79547049|NCT01550406|Device|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
79547050|NCT01550419|Drug|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
79547051|NCT01550419|Drug|Placebo|The smell and shape of placebo are the same as atorvastatin
79709519|NCT01110382|Drug|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
79709520|NCT01110382|Drug|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
79709521|NCT01110382|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
79848869|NCT05993091|Other|mirror therapy (MT)|Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
79848870|NCT05993091|Other|augmented reality (AR)|The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
79848871|NCT05993091|Other|Control intervention|Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
79252691|NCT06131034|Other|Music|Participant in the intervention group will receive music interventions perioperatively.
79252692|NCT06131021|Drug|Amoxicillin|Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
79390773|NCT02435628|Other|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
79390774|NCT03851926|Radiation|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
79390775|NCT02435394|Behavioral|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
79390776|NCT02435394|Behavioral|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
79390777|NCT02435394|Behavioral|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
79390778|NCT04594798|Drug|Polatuzumab vedotin|IV 1.8 mg/kg per cycle
79547052|NCT01550445|Drug|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
79547053|NCT01550497|Other|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
79547054|NCT01550523|Drug|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
79709522|NCT01110382|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
79709523|NCT01604369|Procedure|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
79252693|NCT06131021|Drug|Metronidazole|Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.
79252694|NCT06131021|Other|Placebo|Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
79390779|NCT04594798|Drug|Rituximab|IV 375 mg/m2 per cycle
79390780|NCT04594798|Drug|Cyclophosphamide|IV 400 mg/m2 per cycle
79390781|NCT04594798|Drug|Doxorubicin|IV 25 mg/m2 per cycle
79390782|NCT04594798|Drug|Prednisone|PO 40 mg/m2 per cycle
79390783|NCT04592770|Behavioral|Nature based walk therapy|10 minutes stretching exercises followed by walk in nature for 50 minutes
79390784|NCT04592770|Behavioral|Sit in nature|Sit in nature for 60 minutes
79390785|NCT02432508|Device|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
79390786|NCT02432508|Device|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
79390787|NCT04590976|Other|Semi-Structured Interview Healthcare Professional|Interview
79390788|NCT04590976|Other|Semi-Structured Interview Patients|Interview
79390789|NCT04590976|Other|Think Aloud Interview Patients|Interview
79390790|NCT04590976|Other|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
79390791|NCT03184584|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
79547055|NCT01550523|Device|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
79547056|NCT01550588|Device|Device closure|PFO Amplatzer device closure
79547057|NCT01550588|Drug|Standard medical treatment|Standard Medical management using anti-coagulant therapy
79709524|NCT00592917|Dietary Supplement|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
79709525|NCT01609517|Drug|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
79709526|NCT04309903|Other|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 * 10 repetitions, 20 sec of per reps and 10 sec of interval.
79709527|NCT02881489|Other|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
79709528|NCT01604447|Procedure|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
79848872|NCT05985382|Other|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
79848873|NCT05985382|Other|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
79848874|NCT05984316|Other|Exercise|"Dual task exercises are defined as the appropriate direction of attention during two activities performed at the same time. Dual task performance is required during many activities in daily life. Multitasking is complicated to understand because it is divided into social, physical, and psychological branches.~The simultaneous occurrence of movement and cognitive processes is seen as a part of social participation. Considering that one task affects the other, dual task is defined as the simultaneous performance of two tasks that can be performed independently, can be evaluated separately, and have different purposes.~Each task must be incompatible and measurable, achievable alone or in different combinations. The increased need for information processing alone does not constitute dual-tasking."
79848875|NCT05981768|Drug|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
79848876|NCT05980793|Procedure|PIP joint denervation|Surgical denervation of the PIP joint
79848877|NCT05980793|Procedure|Patient education plus exercise|An education plus exercise program
79848878|NCT05973019|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
79848879|NCT05966948|Drug|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
80016525|NCT00569972|Drug|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
80016526|NCT00569972|Drug|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
80016527|NCT00569972|Drug|Placebo|Matched oral placebo for weeks 2-7.
79848880|NCT05966948|Drug|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
79252695|NCT06131008|Diagnostic Test|Diastology|We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.
80016528|NCT05106946|Biological|ThisCART22 cells|0.2-60 x 10^6 CAR T cells per kg body weight
79252696|NCT06131008|Behavioral|Diastology-Guided Diuresis|If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.
79252697|NCT06131008|Behavioral|Usual Care|Clinicians will rely on usual care metrics and parameters to guide diuresis.
79547058|NCT01550601|Procedure|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
79547059|NCT01550614|Genetic|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
79547060|NCT01550627|Other|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
79848881|NCT05966688|Drug|SPR720|Multiple oral doses of SPR720 capsules.
80016529|NCT04250740|Other|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
80016530|NCT04250740|Other|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
80016531|NCT04250740|Other|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
80016532|NCT00565760|Drug|Q8003|Capsules
80016533|NCT00565760|Drug|Placebo|Capsules
80016534|NCT05121610|Procedure|The procedures include PCI, CABG and HCR|The procedures include PCI, CABG and HCR
79709529|NCT01604447|Procedure|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
79709530|NCT00593073|Behavioral|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
79709531|NCT00593073|Behavioral|General Reminder Message|General CRC health education message and reminder to get screened.
79709532|NCT02892669|Other|non interventional study|non interventional study
79303732|NCT02466113|Other|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
79848882|NCT05966688|Drug|Azithromycin|Multiple oral doses of azithromycin.
79547061|NCT01550627|Other|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
80016535|NCT02282384|Drug|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
80016536|NCT02282384|Other|Placebo|
80016537|NCT02989389|Drug|LY3323795|Administered orally
79547062|NCT01550640|Drug|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
79547063|NCT01550653|Drug|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
79547064|NCT01550653|Drug|Placebo|
79547065|NCT01550666|Behavioral|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
79547066|NCT01550718|Behavioral|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
79547067|NCT01550718|Behavioral|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
79709533|NCT01609595|Drug|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
79709534|NCT00593151|Other|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
79709535|NCT00593151|Biological|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
79709536|NCT01609634|Other|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
80016538|NCT02989389|Drug|Itraconazole|Administered orally
79547068|NCT01550770|Drug|propofol|peripheral IV of propofol at increasing dose levels
79547069|NCT01550783|Other|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
79547070|NCT01550783|Other|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
79547071|NCT01550783|Other|Questionnaire Administration|Ancillary studies
79709537|NCT01609634|Other|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
79709538|NCT01609634|Other|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
79709539|NCT00593190|Drug|Gas SF6 (Sulfur Hexafluoride)|ONCE
79709540|NCT01604525|Behavioral|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
79709541|NCT01604525|Behavioral|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
79709542|NCT01604525|Other|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
79709543|NCT04327128|Device|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
79848883|NCT05966688|Drug|Ethambutol|Multiple oral doses of ethambutol.
79848884|NCT05960513|Behavioral|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
80016539|NCT02989389|Drug|Placebo|Administered orally
80016540|NCT02653300|Biological|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
79709544|NCT02485496|Device|Endovascular abdominal repair|
79709545|NCT04327167|Behavioral|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
79709546|NCT00593307|Other|high GI|high GI and high carb breakfast
79709547|NCT00593307|Other|Low GI|low GI, high carb breakfast
79848885|NCT05956405|Behavioral|AIR + Mindfulness|AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
79848886|NCT05956405|Behavioral|Relaxation condition|Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
80016541|NCT00436670|Biological|AMG 317 75 mg|75 mg SC weekly injection
79252698|NCT06130982|Behavioral|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
80016542|NCT00436670|Biological|AMG 317 150 mg|150 mg SC once weekly injection
79252699|NCT06130982|Behavioral|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
79252700|NCT06130982|Behavioral|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
79547072|NCT01550783|Procedure|Screening Method|Undergo standard of care Pap test screening
79547073|NCT01550783|Procedure|Screening Method|Undergo home-based HPV screening
79547074|NCT01550796|Behavioral|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
79547075|NCT01550822|Other|HEALS|
79547076|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
79547077|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
79547078|NCT01550848|Drug|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
79709548|NCT00593307|Other|Low GI Low Carb|low GI low carb breakfast
79709549|NCT00593307|Other|High GI Low carb|high GI low carb breakfast
79709550|NCT01173601|Drug|LY2216684|
80016543|NCT00436670|Biological|AMG 317 300 mg|300 mg weekly SC injection
79709551|NCT01173601|Drug|Placebo|
79709552|NCT01173601|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
79709553|NCT01609673|Drug|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
79709554|NCT01604642|Other|blood tests and muscular biopsies|blood tests and muscular biopsies
79709555|NCT01604681|Dietary Supplement|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
80016544|NCT00436670|Biological|Placebo|Placebo SC once weekly injection
80016545|NCT02284646|Other|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
80016546|NCT04055337|Procedure|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
79547079|NCT01550874|Behavioral|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
79709556|NCT01604681|Dietary Supplement|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
80016547|NCT03187509|Drug|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
80016548|NCT03187509|Other|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
79252701|NCT06130982|Behavioral|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
79252702|NCT06130956|Dietary Supplement|Vegan diet|Vegan diet for 2 weeks before surgery
79252703|NCT06130956|Dietary Supplement|Omnivorous diet|Omnivorous diet for 2 weeks before surgery
79390792|NCT03184662|Other|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
79390793|NCT03184662|Other|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
79390794|NCT03184506|Other|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
79547080|NCT01550887|Other|No intervention|No intervention will be performed on this study
79547081|NCT01550900|Drug|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
79547082|NCT01550900|Other|Placebo|Placebo tablets by mouth 1 time a day.
79848887|NCT05955326|Drug|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
80016549|NCT05121532|Diagnostic Test|Interleukin-15 and Interleukin-22|Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
80016550|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
79390795|NCT03184506|Other|no warming|patients were covered only with two layers of cotton blanket
79390796|NCT03184272|Procedure|baseline alert 1|measurement in supine position
79390797|NCT03184272|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
79390798|NCT03184272|Procedure|ATB in narcosis|measurement under ATB in narcosis
79390799|NCT03184272|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
79390800|NCT03184272|Procedure|passive leg raising|measurement under passive leg raising
79547083|NCT01550913|Behavioral|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
79709557|NCT01173523|Drug|STA-9090|
79709558|NCT01609712|Procedure|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
79709559|NCT00593424|Other|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
79709560|NCT00593424|Other|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
79709561|NCT01173055|Drug|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
79709562|NCT01173055|Drug|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
79709563|NCT04327440|Biological|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
79709564|NCT04327440|Other|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
79709565|NCT01609829|Procedure|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
79709566|NCT00593502|Drug|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
80016551|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
80016552|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
79848888|NCT05955326|Other|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
79848889|NCT05948007|Device|Neurofeedback training|12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
79848890|NCT05948007|Device|Sham-neurofeedback training|The Sham group has the same training dosage as the neurofeedback group.
79252704|NCT06130917|Other|Multisystem Exercise|"Proprioception: Seated ankle ball. Single leg stance (hip ﬂexion) with support and with ﬂexion and extension of knees. Single leg stance (hip extension) with support and with ﬂexion and extension of knees.~Muscle strengthening: Seated alternate double knee lifts with weights. Modiﬁed chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward)."
79547084|NCT01550913|Other|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
79848891|NCT05948007|Behavioral|Pain management protocol|The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
79390801|NCT03184272|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
79390802|NCT03184272|Procedure|baseline in narcosis 2|measurement in supine position
79390803|NCT03184272|Procedure|start capnoperitoneum|measurement in supine position
79390804|NCT03184272|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
79547085|NCT01550926|Drug|120 mg orlistat|2 X60 mg capsule
79547086|NCT01550926|Drug|60 mg orlistat|60 mg orlistat
79848892|NCT05941494|Drug|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
79390805|NCT03184272|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
79390806|NCT03184272|Procedure|ATB loss of capnoperitoneum|measurement under ATB
79390807|NCT03184272|Procedure|baseline|measurement in supine position
79390808|NCT03184272|Procedure|baseline alert 2|measurement in supine position
79390809|NCT03184272|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
79390810|NCT03184272|Procedure|torso position rising 30° at the end|measurement in the recovery unit
79547087|NCT01550926|Drug|orlistat experimental dose|experimental
79547088|NCT01550939|Device|Ophthalmic Biometer|One complete biometry examination
79547089|NCT01550978|Device|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
79547090|NCT01551004|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
79709567|NCT00593502|Drug|placebo|The dosage of placebo will be similar to the active drug
79709568|NCT01609868|Dietary Supplement|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
79709569|NCT01609868|Dietary Supplement|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
79709570|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
79848893|NCT05941494|Drug|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
79252705|NCT06130917|Other|Conventional Treatment|"ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. Modiﬁed chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle"
79390811|NCT02435004|Device|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
79848894|NCT05941494|Drug|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
79390812|NCT02432430|Behavioral|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
79390813|NCT02432430|Behavioral|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
79547091|NCT01551004|Other|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
79390814|NCT02432664|Drug|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
79390815|NCT02432664|Drug|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
79547092|NCT01551043|Biological|CART-19|
79848895|NCT05941494|Drug|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
79848896|NCT05937893|Other|Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans|Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.
79848897|NCT05932238|Other|Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)|commercially available eye drops
79848898|NCT05932238|Other|Polyethylene glycol 400 and propylene glycol solution/drops - Preserved|commercially available eye drops
79390816|NCT02432664|Drug|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
79390817|NCT02432664|Drug|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
79390818|NCT02432664|Drug|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
79390819|NCT02432664|Drug|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
79390820|NCT02432352|Behavioral|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
79547093|NCT01551069|Drug|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
79547094|NCT01551069|Drug|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
79547095|NCT01550458|Drug|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
79547096|NCT01550458|Other|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
79547097|NCT01551108|Behavioral|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
79709571|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
79709572|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
80016553|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
80016554|NCT04221880|Drug|Bupivacaine Hcl 0.25% Inj|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine
80016555|NCT04221880|Drug|Saline Solution for Block|Ultrasound-guided erector spinae plane block with 20 ml saline
80016556|NCT04221880|Drug|Saline Solution intravenously|Same volume saline solution bolus and infusion as Group Lidocaine
79547098|NCT01551108|Behavioral|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
79252706|NCT06130904|Behavioral|Academic detailing|"Eligible dentists/oral surgeons will have one visit (30 minutes or less) at the dentist's office. During the initial visit, the detailers will discuss the evidence against routine opioid prescribing to adolescents and young adults for most common surgeries performed by dentists and oral surgeons, the harms of dental opioid exposure in adolescents and young adults, and the benefits and feasibility of relying on non-opioids as a first line option for routine dental procedures among adolescents and young adults. A survey will be completed to assess the satisfaction regarding the intervention. A professionally designed packet of information on reducing use of opioids for routine procedures will also be given.~There may also be a second optional follow-up visit conducted virtually for any participants that wish to discuss further with the detailer. The second visit may occur any time between the initial visit and March 31, 2024."
79390821|NCT03189186|Drug|Pembrolizumab Injection [Keytruda]|Same as arm description
79709573|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
79709574|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
79709575|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
79709576|NCT00593580|Drug|placebo|placebo
79709577|NCT00593580|Drug|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
79709578|NCT01604759|Device|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
79709579|NCT01609946|Device|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
79709580|NCT01609946|Procedure|Cytology (FNAB) or Surgery|
79709581|NCT04327011|Biological|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
79709582|NCT04327011|Drug|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
79709583|NCT00593619|Drug|Iron dextran|300mg in 250cc normal saline given over 2 hours
79848899|NCT05931432|Other|Comprehensive Well-Being Intervention|The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
79390822|NCT03189186|Procedure|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
79303733|NCT02466113|Other|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
79390823|NCT03189186|Procedure|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
79390824|NCT03820492|Diagnostic Test|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
79390825|NCT02435160|Biological|Fecal Microbiota Transplantation|
79709584|NCT00593619|Drug|Iron sucrose|300mg in 250cc normal saline given over 2 hours
79709585|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
79709586|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
79709587|NCT00593658|Drug|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
79709588|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)"
79390826|NCT03189030|Biological|pLADD|via IV infusion
79390827|NCT02432118|Procedure|Lumpectomy|Undergo lumpectomy
79390828|NCT02432118|Other|Questionnaire Administration|Ancillary studies
79252707|NCT06130891|Other|Cognitive sensory motor relearning|"Cognitive Exercises:~Orientation: Checking awareness of date, time, and weather.~Attention: Tasks like connecting dots or spotting differences.~Shape Sorting: Sorting objects by size, color, etc.~Calculation Training: Counting money, beads, basic arithmetic.~Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~Discrimination: Identifying textures, shapes, sizes, and temperatures.~Tactile Recognition: Recognizing objects through touch.~Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
79252708|NCT06130891|Other|Sensory motor relearning|"Sensory Relearning:~Discrimination: Identifying textures, shapes, sizes, and temperatures.~Tactile Recognition: Recognizing objects through touch.~Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
79252709|NCT06130891|Other|Motor Relearning|"Motor Relearning:~Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
79547099|NCT01551121|Other|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
79547100|NCT01551134|Procedure|Fundoplication|Primary fundoplication
79547101|NCT01551134|Procedure|Fundoplication|Primary fundoplication
79390829|NCT02432118|Procedure|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
79547102|NCT01551147|Drug|ONO-6950|200 mg QD for 8 days
79547103|NCT01551147|Drug|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
79709589|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
79709590|NCT02892747|Behavioral|Educational Program|
79848900|NCT05930730|Biological|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
79547104|NCT01551147|Drug|Montelukast|10 mg Montelukast QD for 8 days
79709591|NCT01604954|Behavioral|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
79709592|NCT01604954|Behavioral|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
79709593|NCT01604954|Behavioral|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
79848901|NCT05930730|Biological|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
79848902|NCT05929482|Behavioral|Infección de Amor (Infectious Love)|"Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
79848903|NCT05928091|Other|Phone call to an expert team|Patients will be treated as the expert said when the investigator called him
79252710|NCT06130878|Other|Rhythmic exercise|"A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow [46] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined."
79252711|NCT06130852|Behavioral|Behavioral Parent Training|10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
79390830|NCT04574440|Device|multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
79390831|NCT02427828|Device|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
79390832|NCT03186144|Genetic|Blodd punction for genetic analysis|
79390833|NCT03811600|Diagnostic Test|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
79709594|NCT04327050|Procedure|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
79709595|NCT02892786|Other|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
79709596|NCT01601522|Procedure|Peanut protein|500 mg
79709597|NCT01601522|Procedure|Oat flour|500 mg Oat flour
79709598|NCT01601522|Drug|Antihistamine|Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
79547105|NCT01551160|Other|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
79709599|NCT02892552|Radiation|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
79709600|NCT02892552|Radiation|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
79709601|NCT00593775|Procedure|assisted hatching|assisted hatching with laser
79709602|NCT01604993|Other|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
79709603|NCT01604993|Other|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
79848904|NCT05926453|Other|Maximal cardiorespiratory exercise test|previously described
79252712|NCT06130839|Other|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
79252713|NCT06130839|Other|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
79390834|NCT02427594|Drug|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
79547106|NCT01551225|Drug|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
79547107|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
79547108|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
79709604|NCT04329507|Diagnostic Test|Breath test|collection of an exhaled breath sample
80016557|NCT04221880|Drug|Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
79709605|NCT00593853|Drug|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
79709606|NCT00593853|Drug|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
79848905|NCT05924191|Device|Photobiomodulation|Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
79848906|NCT05924191|Drug|Placebo Corticosteroid|Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
79848907|NCT05924191|Device|Simulation Photobiomodulation|The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
79848908|NCT05924191|Drug|Corticosteroid|The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
79848909|NCT05923606|Device|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
79848910|NCT05923606|Device|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
79390835|NCT02427594|Other|Controlled diet|Diet without sodium bicarbonate supplementation
79390836|NCT00361738|Drug|AVE2268|
79390837|NCT02427438|Other|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
79390838|NCT02427438|Other|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
79390839|NCT00361894|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
79390840|NCT00361894|Drug|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
79390841|NCT02427282|Device|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
79709607|NCT01607294|Drug|ETC-1002|ETC-1002 Daily for 4 weeks
79709608|NCT01607294|Drug|Placebo|Placebo Daily for 4 weeks
79709609|NCT01601600|Drug|BYM338|BYM338
79709610|NCT01601600|Drug|Placebo|BYM338 Placebo
79709611|NCT00593931|Other|fMRI|Functional Magnetic Resonance Imaging without contrast
79709612|NCT01605110|Drug|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
79709613|NCT01605110|Drug|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
79709614|NCT00594048|Device|Resperate|Use of the device 15 minutes a day for 9 weeks
79709615|NCT00594048|Device|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
79709616|NCT00594087|Drug|eszopiclone|eszopiclone 2mg or 3mg at bedtime
79709617|NCT00594087|Other|placebo|2 mg or 3 mg at bedtime
79709618|NCT01605305|Drug|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
79709619|NCT00594126|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
79709620|NCT00594243|Behavioral|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
79709621|NCT00594243|Other|Wait-list control|No treatment given.
79709622|NCT01605344|Drug|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
79709623|NCT01605344|Drug|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
79709624|NCT04358211|Biological|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
79709625|NCT01605383|Biological|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
79709626|NCT01605383|Procedure|Standard treatment|Isolated core decompression
79709627|NCT00594282|Device|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
79709628|NCT00594321|Device|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
79709629|NCT00594321|Device|standard vertebroplasty|standard vertebroplasty
79709630|NCT01605422|Other|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
79709631|NCT01607372|Drug|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
79709632|NCT01607372|Device|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
79709633|NCT01607372|Other|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
79848911|NCT05923593|Dietary Supplement|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
79390842|NCT02427282|Device|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
79390843|NCT02434692|Device|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after cataract surgery on day 0 (V01)
79547109|NCT01551277|Other|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
79390844|NCT04556578|Procedure|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
79547110|NCT01551277|Other|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
79709634|NCT01608581|Other|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
79709635|NCT04130568|Diagnostic Test|INO survey|Garvin's Learning organisation tool
79709636|NCT00594360|Behavioral|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
79709637|NCT01605578|Procedure|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
79390845|NCT03185910|Behavioral|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
79390846|NCT03185910|Behavioral|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
79709638|NCT00593463|Drug|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
79709639|NCT00593463|Drug|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
79709640|NCT00593463|Drug|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
79709641|NCT00593463|Drug|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
79709642|NCT00593463|Drug|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
79709643|NCT00593463|Drug|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
79709644|NCT00593463|Drug|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
79709645|NCT00593463|Device|Saline|Saline: I.M. injection may possibly be given
79709646|NCT00593463|Drug|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
79709647|NCT00594438|Device|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
80016558|NCT04055415|Biological|adipose derived mesenchymal stem cells|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
79709648|NCT00594438|Device|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
79709649|NCT02270138|Behavioral|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
79709650|NCT02270216|Procedure|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
79709651|NCT02270216|Procedure|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
79709652|NCT00592410|Drug|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
79709653|NCT01605656|Behavioral|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
79709654|NCT01605656|Behavioral|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
79302880|NCT05713019|Device|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
79547111|NCT01551290|Drug|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
79547112|NCT01551290|Drug|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
80016559|NCT04055415|Drug|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
79547113|NCT01551316|Drug|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
79547114|NCT01551316|Drug|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
80016560|NCT05218759|Drug|Anlotinib|anlotinib administration at a dose of 10 mg daily
79390847|NCT03804814|Behavioral|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
79390848|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
79390849|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
79709655|NCT01605656|Behavioral|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
79390850|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
79390851|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
79709656|NCT00594477|Radiation|IMRT|
79709657|NCT02270294|Other|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
79709658|NCT02270294|Other|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
79252714|NCT06130761|Procedure|Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block|"For PENG block transducer is placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved inferiorly to visualize the pubic ramus. The femoral artery and iliopubic eminence are visualized, and then, using an in-plane technique, a 22-gauge 50 mm needle is advanced from lateral to medial then 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it.~For LFCN the transducer is placed immediately inferior to the anterior superior iliac spine (ASIS), parallel to the inguinal ligament. The tensor fasciae lata muscle (TFLM) and sartorius muscle (SaM) are then identified. The nerve appears as a small hypoechoic oval structure with a hyperechoic rim between the TFLM and SaM in a short-axis view or superficial to the SaM. A 22-gauge 50 mm needle is inserted in-plane in a lateral-to-medial orientation through the subcutaneous tissue. A fascial pop may be felt as the needle tip enters the plane."
79390852|NCT00361192|Procedure|biopsy of temporal artery|
79848912|NCT05916144|Behavioral|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
79848913|NCT05912088|Behavioral|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
79848914|NCT05912088|Behavioral|Control Group|Subjects will receive the usual care advice
79848915|NCT05910268|Behavioral|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
79848916|NCT05882305|Biological|(Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate|Patients will receive approximately （2.5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
79848917|NCT05869266|Device|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
79547115|NCT01551329|Drug|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
79709659|NCT00592449|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
79848918|NCT05866835|Other|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~digital recording of the maxillary and mandibular dental arches~mandibular wedging performed with an inter-arch piece~digital recording of the inter-arch position"
79848919|NCT05866835|Other|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~At rest, standing still.~During a 4 minute run on a treadmill at 50% of MAS.~During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
79848920|NCT05866835|Other|Evaluation of comfort level:|Collection from participants (self-questionnaire)
79848921|NCT05863819|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
79848922|NCT05860439|Procedure|Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Patients previously treated were reassessed for long-term follow-up.
79848923|NCT05858710|Drug|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
79848924|NCT05852873|Drug|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
79547116|NCT01551368|Drug|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
79547117|NCT01551368|Drug|Placebo|Identical inactive tablets.
79547118|NCT01551381|Drug|EV-077|twice daily oral administration
79848925|NCT05852873|Drug|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
79848926|NCT05849259|Other|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) seven modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
80016561|NCT01922752|Drug|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
80016562|NCT03662217|Other|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
79547119|NCT01551381|Drug|Placebo|twice daily oral administration
79547120|NCT01551394|Drug|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
79547121|NCT01551394|Drug|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
79709660|NCT00592449|Behavioral|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
79848927|NCT05845359|Drug|Methadone|One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
79848928|NCT05838222|Behavioral|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
79848929|NCT05838222|Other|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
80016563|NCT03662217|Other|ADA- based diet|The American standard of care dietary guidelines for diabetes.
80016564|NCT03661359|Other|Social Determinants of Health Referrals|Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
80016565|NCT00427856|Drug|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
80016566|NCT00427856|Drug|Rituximab|Rituximab
80016567|NCT00427154|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
79390853|NCT02431962|Procedure|Computed Tomography|Low dose chest CT screening annually x 3
79709661|NCT04328064|Drug|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
79709662|NCT04328064|Drug|Placebo oral tablet|40 mg placebo for 12 months
79709663|NCT01605734|Procedure|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
79709664|NCT01605734|Drug|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
80016568|NCT00427154|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
79302881|NCT05713019|Procedure|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
79390854|NCT02431962|Behavioral|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
79390855|NCT02431962|Behavioral|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
79390856|NCT03184116|Behavioral|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning & Rehabilitation
79390857|NCT04072432|Drug|RBT-3|intravenous administration
79390858|NCT03189342|Behavioral|Single task training|The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
80016569|NCT00427154|Drug|metformin|Tablets, 2000 mg/day.
80016570|NCT00427154|Drug|glimepiride|Tablets, 8 mg/day.
80016571|NCT03627871|Behavioral|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
80016572|NCT03627871|Behavioral|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
79547122|NCT01551407|Drug|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
79547123|NCT01551433|Device|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
79547124|NCT01551459|Drug|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
79547125|NCT01551459|Drug|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
79547126|NCT01551485|Drug|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
79547127|NCT01551485|Drug|Placebo|Pacebo tablet, blinded given on the first night after surgery
79390859|NCT03189342|Behavioral|dual task training|The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
79547128|NCT01551498|Dietary Supplement|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
79547129|NCT01551498|Dietary Supplement|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
80016573|NCT03627871|Behavioral|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
79547130|NCT01551511|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
79547131|NCT01551511|Drug|Placebo|Identical step-up approach to the Namisol arm.
79547132|NCT01551524|Biological|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
79547133|NCT01551537|Other|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
79547134|NCT01551537|Other|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
79709665|NCT02270372|Biological|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
79709666|NCT01605773|Drug|repaglinide|Dose individually adjusted and conducted according to labeling
79709667|NCT01605773|Drug|glyburide|Dose individually adjusted and conducted according to labeling
79709668|NCT00592527|Drug|insulin detemir|
79709669|NCT01605851|Device|Closure, Foramen Ovale|
79709670|NCT02270528|Behavioral|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (~5 minutes)
79709671|NCT02270528|Behavioral|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
80016574|NCT03627871|Behavioral|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
79547135|NCT01551576|Device|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
80016575|NCT03627871|Behavioral|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
79547136|NCT01551589|Radiation|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33~35F，once a day, 5 times per week.
79547137|NCT01551589|Drug|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
79709672|NCT00594555|Drug|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
79709673|NCT00594555|Drug|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
80016576|NCT02988219|Drug|Bupivacaine-fentanyl|Local anesthetic
80016577|NCT02988219|Device|Holter ECG monitor|3-chanel, CM5 leads
80016578|NCT02988219|Procedure|Open kidney cancer surgery|Lateral position
80016579|NCT02988219|Procedure|General anesthesia|
80016580|NCT02988219|Procedure|Epidural Anaesthesia|
79391846|NCT04481646|Diagnostic Test|Face mask sampling|Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.
79547309|NCT01553513|Procedure|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
79547310|NCT01553513|Other|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
79547311|NCT01553565|Procedure|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
79547312|NCT01553578|Other|questionnaire administration|Ancillary studies
79547313|NCT01553578|Procedure|therapeutic touch|Receive healing touch therapy
79547314|NCT01553578|Behavioral|management of therapy complications|Receive healing touch therapy
79547315|NCT01553578|Behavioral|management of therapy complications|Receive guided imagery audiotapes
79547316|NCT01553578|Procedure|standard follow-up care|Receive standard care
79391847|NCT03168828|Drug|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
79547317|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the first postoperative day
79547318|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
79547319|NCT01553617|Drug|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
79547320|NCT01553617|Drug|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
79547321|NCT01553630|Procedure|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
79547322|NCT01553630|Procedure|Surgery without bone graft|Plating of fracture without bone graft
79547323|NCT01553643|Drug|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
79547324|NCT01553643|Drug|placebo|at a rate of 3g two times per day
79547325|NCT01553656|Drug|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
79547326|NCT01553656|Drug|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
79547327|NCT01553669|Behavioral|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
79547328|NCT01553682|Behavioral|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
79547329|NCT01553682|Behavioral|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
79739716|NCT04295616|Behavioral|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
79547330|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
79391848|NCT03115866|Behavioral|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
79391849|NCT03116178|Other|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi<4 fluid rate is 50-60ml/hr and pvi>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
79391850|NCT03116178|Other|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
79391851|NCT03115944|Device|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
79391852|NCT02562898|Drug|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
79391853|NCT02562898|Drug|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
79391854|NCT02562898|Drug|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
79391855|NCT03168594|Drug|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
79391856|NCT03168594|Drug|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
79391857|NCT04482192|Combination Product|Thoracic paravertebral block|After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
79391858|NCT04482192|Drug|Systemic analgesia|Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
79391859|NCT02563834|Drug|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
79391860|NCT02563834|Drug|Saline|Saline infusion for control
79391861|NCT02563834|Drug|Insulin|Insulin infusion for insulin/glucose clamp procedure
79391862|NCT02563990|Procedure|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
79391863|NCT02563990|Procedure|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
79391864|NCT02564926|Drug|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
79391865|NCT02564926|Drug|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
79391866|NCT02700984|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
79391867|NCT02700984|Procedure|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
79391868|NCT02567968|Drug|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
79391869|NCT02567968|Drug|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
79391870|NCT02404584|Genetic|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
79391871|NCT02404584|Biological|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.*~*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
79391872|NCT02404272|Other|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
79391873|NCT02571634|Drug|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
79547331|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
79547332|NCT01553721|Drug|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
79547333|NCT01553721|Drug|placebo|Phase IIa - placebo Phase IIb - placebo
79547334|NCT01553760|Procedure|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
79547335|NCT01553760|Procedure|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
79547336|NCT01553773|Drug|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
79391874|NCT02404194|Behavioral|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
79391875|NCT02404194|Behavioral|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
79391876|NCT02404038|Drug|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
79391877|NCT02404038|Device|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
79391878|NCT02404038|Drug|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
79391879|NCT03172728|Behavioral|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
79391880|NCT02574598|Drug|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
79391881|NCT02574598|Drug|Docetaxel|Use on both arms as standard of care.
79391882|NCT03116022|Drug|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
79391883|NCT03116022|Drug|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
79391884|NCT03116022|Drug|Vaginal Gel|Women using a base water gel lubricant during intercourse
79391885|NCT02400840|Procedure|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
79391886|NCT02400840|Drug|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
79391887|NCT02574832|Drug|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
79391888|NCT02400606|Other|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
79391889|NCT02400606|Other|Solving VP cases|See above
79391890|NCT02400684|Biological|blood samples|Evolution of AMH before and after deep endometriosis surgery
79875122|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
79391891|NCT02400528|Behavioral|quality of life questionnaires|
79391892|NCT02406534|Behavioral|HRQoL surveys|
79391893|NCT02406690|Other|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
79391894|NCT02406456|Other|Neurofeedback|
79391895|NCT02400138|Other|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
79391896|NCT02400138|Other|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
79391897|NCT02575300|Drug|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
79391898|NCT04440696|Drug|Lanthanum Polystyrene Sulphonate Powder|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
79391899|NCT04440696|Drug|Lanthanum Carbonate 500 MG|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
79391900|NCT04440696|Drug|Placebo|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
79547337|NCT01553773|Drug|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
79547338|NCT01553786|Drug|Lenalidomide|Lenalidomide
79547339|NCT01553838|Device|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
79547340|NCT01553877|Dietary Supplement|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
80031411|NCT00858728|Behavioral|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
79547341|NCT01553877|Dietary Supplement|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
79547342|NCT01553877|Dietary Supplement|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
79547343|NCT01553890|Other|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
79547344|NCT01553903|Drug|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
79547345|NCT01553903|Drug|Exemestane|Exemestane 25mg/day during 5 years
79547346|NCT01553903|Drug|Anastrozole|Anastrozole 1 mg/day during 5 years,
79547347|NCT01553903|Drug|Letrozole|Letrozole 2.5 mg/day during 5 years,
79547348|NCT01553929|Other|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
79252715|NCT06130761|Procedure|trans muscular quadratus lumborum block|With the patient in the lateral position, after standard sterilization of skin and probe identify 3 layers of the abdomen. The transversus abdominis is traced more posteriorly until the transversus aponeurosis. usually we can find the peritoneum curves away from the muscles from anterior to posterior . Tilting the probe slightly caudal into the pelvis thus improves the view of the retroperitoneal fat and the tapered end of transversus aponeurosis. QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine.
79252716|NCT06130748|Device|Hybrid Hyrax|these patents will be treated using Two mini-screws supported hybrid hyrax
79547349|NCT01553929|Other|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
79547350|NCT01553929|Other|control group|no physical training and no cognitive activity
79547351|NCT01553942|Drug|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
79547352|NCT01553942|Radiation|Radiation|Daily, Monday-Friday
79547353|NCT01553942|Drug|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
79547354|NCT01553942|Drug|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
79547355|NCT01553942|Procedure|Surgery|Surgery to remove tumor
79547356|NCT01553955|Procedure|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
79547357|NCT01553968|Other|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
79252717|NCT06130735|Behavioral|Cognitive Computerized Training|Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
79252718|NCT06130722|Drug|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15[N72D]/IL-15Rα-sFc).
79252719|NCT06130709|Procedure|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
79252720|NCT06130696|Other|Clamshell exercises|Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.
79252721|NCT06130696|Other|Isometric and muscle strengthen exercise|"group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given"
79547358|NCT01553981|Drug|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
79547359|NCT01553981|Drug|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
79547360|NCT01554007|Other|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
79547361|NCT01554020|Dietary Supplement|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
79547362|NCT01554020|Dietary Supplement|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
79547363|NCT01554059|Drug|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
79547364|NCT01554059|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly * 6 doses 3-4 weeks after radical resection
79547365|NCT01554059|Drug|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
79547366|NCT01554059|Radiation|Radiotherapy|2GY daily *20次
79547367|NCT01554072|Other|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
79547368|NCT01554085|Drug|ALS-002158|ALS-002158
79547369|NCT01554085|Drug|Placebo|placebo
79580929|NCT01930617|Procedure|Burr hole surgery with various drainage techniques|"Surgical technique~Continuous irrigation and drainage~Passive subdural drain~Active subgaleal drain"
79547370|NCT01554098|Procedure|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
79547371|NCT01554098|Procedure|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
79547372|NCT01554111|Drug|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
79547373|NCT01554111|Drug|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
79547374|NCT01554111|Drug|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
79547375|NCT01554124|Drug|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
79547376|NCT01554137|Other|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
79547377|NCT01554137|Other|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
79580930|NCT01930630|Device|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
79710231|NCT00600522|Procedure|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
79252722|NCT06130657|Procedure|Lateral Maxillary Sinus Floor Elevation using surgical guide|The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
79252723|NCT06130657|Procedure|Lateral Maxillary Sinus Floor Elevation without surgical guide|The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
79252724|NCT06130618|Other|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
79252725|NCT06130618|Drug|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
79252726|NCT06130605|Other|Data collection|Data collection
79252727|NCT06130592|Diagnostic Test|ultrasound muscle imaging technique|ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
79252728|NCT06130540|Drug|Secukinumab|Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8
79252729|NCT06130488|Behavioral|KMC|KMC implementation as per protocol
79252730|NCT06130475|Other|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
79252731|NCT06130475|Other|Water|Participants will be administered water during one of the study visits
79252732|NCT06130462|Diagnostic Test|Aluminum|Different concentrations of aluminium added to the blood test in vitro
79252733|NCT06130462|Diagnostic Test|Tetanus toxoid|Used as control substance
79252734|NCT06130449|Drug|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
79252735|NCT06130449|Drug|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
79252736|NCT06130436|Device|Sham-Remote Ischemic Conditioning|Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
79252737|NCT06130436|Device|Remote Ischemic Conditioning Once Daily|"Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg."
79252738|NCT06130436|Device|Remote Ischemic Conditioning Twice Daily|Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
79252739|NCT06130397|Other|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Participants must review 500 X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period - Time allowed: 4 weeks, to mitigate the effects of recall bias.~Phase 2 - Time allowed: 2 weeks~- Review 500 X-rays together with an AI report for each case and express their clinical opinion through the same structured reporting template used in Phase 1."
79252740|NCT06130397|Other|Ground truthing|Two consultant musculoskeletal radiologists will independently review the images to establish the 'ground truth' findings on the XRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior musculoskeletal radiologist's opinion (>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
79252741|NCT06130345|Biological|SPIKEVAX|Intramuscular injection
79252742|NCT06130332|Drug|PD-1 with chemotherapy|"Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
79252743|NCT06130332|Procedure|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
79252744|NCT06130306|Procedure|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.
79252745|NCT06130306|Procedure|pelvic floor muscle training combined with transanal electrical stimulation|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system [AM1000B; Shenzhen Creative Industry Co. Ltd, China]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of < 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
79252746|NCT06130293|Device|VR game intervention|Using self-paced VR game to train.
79252747|NCT06130267|Other|Endocare|Virtual paradigm (calming environnement)
79252748|NCT06130241|Procedure|sentinle lymphnode biopsy|intraoperative sentinle lymphnode biopsy
79252749|NCT06130228|Dietary Supplement|Multi-ingredient supplement (PDT-MIS)|Supplementation with active PDT-MIS daily
79252750|NCT06130228|Dietary Supplement|Placebo (PLA)|Supplementation with inactive placebo
79252751|NCT06130202|Device|Echocardiographic findings|Echocardiographic findings as Markers of Subclinical Cardiac dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
79252752|NCT06130176|Procedure|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
79252753|NCT06130176|Procedure|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
79547378|NCT01554150|Behavioral|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
79391901|NCT02974348|Drug|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
79547379|NCT01554189|Drug|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
79547380|NCT01554189|Drug|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
79547381|NCT01554202|Behavioral|assessment of memory|
79547382|NCT01554202|Biological|circulating tPA dosage|
79547383|NCT01554202|Genetic|ApoE4|
79547384|NCT01554202|Other|Brain imaging examination MRI and PET examinations|
79547385|NCT01554215|Behavioral|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
79547386|NCT01554215|Behavioral|Mom Power Attentional Control Group|at home control, weekly mailings
79547387|NCT01554228|Other|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
79547388|NCT01554254|Drug|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
80031412|NCT00858728|Behavioral|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
79710232|NCT00600600|Drug|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
80031413|NCT04906798|Drug|CKD-385|Test Drug
80031414|NCT04906798|Drug|D744|Reference Drug
79252754|NCT06130176|Procedure|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
79252755|NCT06130163|Procedure|endoscopic retrograde cholangiopancreatography|endoscopical clearance of the common bile duct
79391902|NCT02974348|Drug|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
79547389|NCT01554267|Device|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
79547390|NCT01554280|Device|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
80031415|NCT05039138|Other|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
79252756|NCT06130111|Procedure|Mastectomy|Mastectomy as a surgical procedure for breast cancer (regardless of perioperative treatment).
79252757|NCT06129045|Behavioral|One-time educational video|Sleep hygiene educational tips provided through a video participants watch on their own.
79252758|NCT06129045|Behavioral|Educational video plus repeated education|Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
79391903|NCT02974348|Drug|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
79547391|NCT01554293|Drug|Matching placebo|Matching Placebo, single dose
79547392|NCT01554293|Drug|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
79547393|NCT01554332|Device|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
79547394|NCT01554345|Drug|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
79710233|NCT00600678|Dietary Supplement|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
79710234|NCT00623064|Drug|cisplatin|
79710235|NCT00623064|Drug|gemcitabine hydrochloride|
80031416|NCT05039138|Other|traditional training exerises|traditional strength training exercises in group I
79391904|NCT02974348|Drug|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
79710236|NCT00623064|Drug|lapatinib ditosylate|
79710237|NCT00623064|Other|pharmacological study|
79710238|NCT00623142|Drug|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
79710239|NCT00623220|Other|N2O|EMONO
79710240|NCT00623220|Other|oxygen|oxygen
79547395|NCT01554358|Behavioral|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------"
79252759|NCT06129032|Procedure|Wound infiltration (LWI) + Intraperitoneal local anaesthetic (IPLA) instillation|"a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia.~A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision"
79547396|NCT01554384|Procedure|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
79547397|NCT01554384|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
79547398|NCT01554397|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
79547399|NCT01554397|Drug|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
79547400|NCT01554423|Other|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
79547401|NCT01554423|Behavioral|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
79547402|NCT01554423|Behavioral|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
79547403|NCT01554436|Behavioral|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
79547404|NCT01554449|Procedure|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
79547405|NCT01554449|Procedure|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
79547406|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
79547407|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
79547408|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
79547409|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
79547410|NCT01554319|Drug|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
79710241|NCT00600912|Drug|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
79710242|NCT00600912|Drug|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
79710243|NCT00600990|Drug|GW597599|
79252760|NCT06129032|Procedure|Group QUADRATUS LUMBORUM BLOCK (QLB)|quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance
79252761|NCT06128928|Behavioral|REDES|Training on motivational interviewing (MI) led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.
79252762|NCT06128928|Behavioral|Control|Brief CHW-led training about the safety and efficacy of the COVID-19 vaccine. Participants will have the opportunity to ask clarifying questions from the CHWs during the training.
79252763|NCT06128317|Other|no intervention is intended.|no intervention is intended.
79252764|NCT06128031|Other|questionaire|"Psychiatric interview: this will be assessed by (SCID-5)semi structural clinical interview based on Diagnostic and Statistical manual of Mental disorders-5 criteria~-Psychometric assessment include; Hamilton depression rating scale(7) and Hamilton anxiety rating scale(8) , used to score the symptoms of anxiety or depression Quality of life assessment: will be assessed by the Patient assessment of constipation-quality of life questionnaire"
79547411|NCT01554319|Drug|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
79547412|NCT01554540|Drug|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
79547413|NCT01554553|Procedure|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
79547414|NCT01554566|Dietary Supplement|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
79547415|NCT01554592|Drug|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
79547416|NCT01554592|Drug|Statin therapy|Participants will continue on stable statin therapy.
79849049|NCT05527405|Device|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
79252765|NCT06128018|Procedure|Surgical gastrojejunostomy (S-GJ)|Surgical gastro-jejunostomy
79252766|NCT06128018|Procedure|EUS-guided gastrojejunostomy (EUS-GJ)|Endoscopic Ultrasound guided gastro-jejunostomy
79547417|NCT01554631|Drug|Acarbose (Glucobay ODT, BAYG5421)|
79252767|NCT06128005|Behavioral|knowledge translation in nursing for pressure injury care|Pressure injury's knowledge and healing of wound.
79547418|NCT01554631|Drug|Acarbose (Glucobay, BAYG5421)|
79547419|NCT01554644|Device|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
79710244|NCT00601068|Other|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
79710245|NCT00601224|Behavioral|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
79710246|NCT00601224|Behavioral|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
79710247|NCT00601302|Drug|Amlodipine|
79710248|NCT00601536|Drug|Lithium|
79252768|NCT06127992|Device|Cold stimulation tests / critical temperature threshold|ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage & Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
79391905|NCT02974348|Drug|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
79391906|NCT02974348|Drug|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
79391907|NCT03170622|Diagnostic Test|Intervention group|This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
79391908|NCT02400372|Device|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
79391909|NCT03170310|Drug|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
79391910|NCT02577640|Dietary Supplement|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
79391911|NCT02404116|Other|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
79391912|NCT02404116|Other|Wait List|Individuals are on a waiting list
79547420|NCT01554644|Device|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
79710249|NCT02891460|Device|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
79710250|NCT02891460|Device|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
79710251|NCT02891694|Other|in vitro immuno-histo-chemical analysis of corneal epithelium|
79710252|NCT00601614|Drug|temozolomide|
79710253|NCT00601614|Drug|vandetanib|
79710254|NCT00601614|Other|immunoenzyme technique|
79710255|NCT00601614|Other|laboratory biomarker analysis|
79547421|NCT01554657|Other|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
79849050|NCT05522036|Combination Product|Metvix + Dermaris|Photodynamic Therapy
79849051|NCT05508594|Drug|CT001|Intranasal
79547422|NCT01554657|Other|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
79391913|NCT00364000|Drug|Calcium acetate|Calcium acetate in 240 chronic HD patients
79391914|NCT00364000|Drug|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
79391915|NCT02400450|Dietary Supplement|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
79391916|NCT02400450|Dietary Supplement|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
79547423|NCT01554670|Procedure|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
79547424|NCT01554709|Device|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
79849052|NCT05508594|Drug|Placebo|Intranasal
79849053|NCT05508594|Drug|Sufentanil|Intranasal
79849054|NCT05508594|Drug|Ketamine|Intranasal
79849055|NCT05505630|Drug|Ketamine|A single dose of IV ketamine will be administered.
79849056|NCT05505630|Drug|Midazolam|A single dose of IV midazolam will be administered
79849057|NCT05505630|Drug|Dexmedetomidine|A single dose of IV dexmedetomidine will be administered
79391917|NCT00422188|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
79252769|NCT06127966|Procedure|Erector Spinae Plane Block|The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
79391918|NCT00422188|Drug|Placebo|Administered via intralipomal injection.
79391919|NCT03172260|Device|E Balance Pro Therapy|Micro-current treatment
79391920|NCT03172182|Behavioral|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
79391921|NCT02581384|Radiation|Stereotactic Body Radiotherapy (SBRT)|
79547425|NCT01554722|Procedure|Needle placement|In plane versus out of plane needle placement techniques
79391922|NCT03170466|Behavioral|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
79391923|NCT02403960|Dietary Supplement|probiotic|the patients used probiotic tablets in addition to scaling and root planning
79391924|NCT02403960|Dietary Supplement|placebo|the patients used placebo tablets in addition to scaling and root planning
79710256|NCT00601692|Drug|cisplatin|Given IV
79710257|NCT00601692|Drug|docetaxel|Given IV
79710258|NCT00601692|Drug|irinotecan hydrochloride|Given IV
79710259|NCT00601692|Radiation|radiation therapy|Given 5 days a week for 3 weeks
79710260|NCT04208022|Other|Respiratory evaluation|Hypermobility and Respiratory evaluation
79710261|NCT00601770|Biological|IC41|injection
79710262|NCT00602004|Drug|losartan|losartan 50 mg a day
79710263|NCT00602082|Drug|capecitabine|
79710264|NCT00602082|Drug|cisplatin|
79710265|NCT00602082|Drug|streptozocin|
79849058|NCT05505630|Drug|Saline|A single dose of IV saline will be administered
79849059|NCT05500885|Device|PEMF device, Quantum Tx, Singapore|The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
79710266|NCT00602082|Genetic|DNA analysis|
79710267|NCT00602082|Genetic|RNA analysis|
79849060|NCT05500885|Other|Standard rehabilitation and sham PEMF therapy for CAI|Balance training and muscle strengthening
79849061|NCT05498441|Device|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
79547426|NCT01554735|Behavioral|Exercise and diet|24 weeks of exercise and diet counselling
79277275|NCT02288923|Drug|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
79391925|NCT02403882|Behavioral|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
79547427|NCT01554748|Procedure|Total joint arthroplasty|
79547428|NCT01554761|Procedure|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
79547429|NCT01554761|Device|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
79547430|NCT01554787|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
79547431|NCT01554787|Other|Placebo|at a rate of 2.8g three times per day
79547432|NCT01554800|Drug|ACP-501|A single dose infusion
79547433|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
79547434|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
79547435|NCT01554813|Biological|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
79547436|NCT01554826|Biological|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
79547437|NCT01554826|Biological|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
79547438|NCT01554839|Behavioral|"Family of Heroes"|One hour online educational tool
79547439|NCT01554839|Behavioral|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
79547440|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
79547441|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
79547442|NCT01554852|Drug|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1 & 2, 8 & 9, 15 & 16 - carfilzomib 20*/36 mg/m2** IV (*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; **carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 & 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
79547443|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
79547444|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
79391926|NCT02403882|Behavioral|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
79710268|NCT00602082|Genetic|protein analysis|
79710269|NCT00602082|Genetic|proteomic profiling|
79391927|NCT02403882|Behavioral|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
79547445|NCT01554852|Drug|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 & 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 & 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
79547446|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
79710270|NCT00602082|Other|laboratory biomarker analysis|
79710271|NCT01325532|Device|Active CES|CES current
79710272|NCT01325532|Device|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
79710273|NCT04327752|Other|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
79710274|NCT04126356|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
79710275|NCT05063695|Other|Multimodal Erector spinae catheter protocol|Patients either received multimodal epidural or ESP protocol
79710276|NCT01171963|Biological|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
79710277|NCT01171963|Biological|Placebo|Oral administration
79710278|NCT01171963|Biological|Infanrix™|Intramuscular administration
79252770|NCT06127966|Procedure|0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).|The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
79252771|NCT06127953|Procedure|intermediate cleft rhinoplasty|intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
79547447|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 & 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
79547448|NCT01554852|Drug|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
79547449|NCT01554865|Dietary Supplement|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
79547450|NCT01554865|Behavioral|Conventional diet counseling|
79252772|NCT06127940|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
79547451|NCT01554878|Procedure|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
79547452|NCT01554917|Drug|Iguratimod|taken orally, 2 tablets/day (bid)
79547453|NCT01554930|Drug|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
79547454|NCT01554930|Drug|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
79547455|NCT01554943|Other|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
79547456|NCT01554969|Drug|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
79547457|NCT01554995|Drug|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
79547458|NCT01554995|Drug|Linezolid|Linezolid 600 mg (Cohort 9) none
79547459|NCT01555008|Drug|LX4211|Subjects will receive LX4211 once daily for 7 days
79547460|NCT01555008|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
79580931|NCT01930669|Other|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
79252773|NCT06127940|Drug|Temporary Stopping|Temporary stop of sotorasib during SBRT
79252774|NCT06127927|Device|Impella|interventional implant impella for cardiogenic shock patients
79252775|NCT06127914|Behavioral|Learning Early Infant Feeding Cues|"The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods."
79252776|NCT06127901|Procedure|Any surgery under any type of anaesthesia.|Any surgery under any type of anaesthesia.
79252777|NCT06127784|Other|Motivational interviewing counselling session|Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist
79252778|NCT06127758|Other|virtual reality glasses application|The experimental group will be given classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower). After 15 minutes video containing nature images and sounds will be shown through virtual glasses.
79252779|NCT06127758|Other|classical training|Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.
79252780|NCT06127745|Device|Discure System|All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
79547461|NCT01555021|Genetic|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
79547462|NCT01555034|Behavioral|movement therapy|exercise, nutrition, movement therapy
79547463|NCT01555034|Other|exercise plus nutrition|exercise, nutrition
79547464|NCT01555047|Procedure|IUI|intrauterine insemination
79547465|NCT01555047|Procedure|IUI|intrauterine insemination
79710279|NCT01171963|Biological|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
79252781|NCT06127693|Drug|Tetravalent Influenza Vaccine|All participants will receive the tetravalent influenza vaccine
79547466|NCT01555060|Dietary Supplement|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
79252782|NCT06127693|Behavioral|High-frequency electrical stimulation|All participants will receive High-frequency electrical stimulation
79252783|NCT06127680|Behavioral|Brief Health Promotion Advice|Brief Health Promotion advice on exercise and nutrition (protein intake) delivered by a health care professional during routine consultations
79547467|NCT01555086|Procedure|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
79547468|NCT01555086|Procedure|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
79710280|NCT04315207|Behavioral|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
79849062|NCT05498441|Drug|Antipsychotics, mood stabilizers, etc.|During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
79252784|NCT06127654|Device|Healthy lung sparing treatment plan|CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
79252785|NCT06127641|Other|Standard care plus pulmonary rehabilitation|A 12-week rehabilitation program, 3X/week. Each outpatient session will last 2 hours including: guidance on the care of inhalation techniques and/or oxygen therapy, when prescribed; aerobic training on a cycle ergometer supervised by a physiotherapist (30 min each: 5 min warm-up, 20 min training and 5 min cool-down) at constant load calculated with Hill's equation (HILL et al., 2008). Optional components of RP will include: inspiratory muscle conditioning using a threshold-loading device, inspiratory muscle training with powerbreathe, breathing exercises, airway clearance, psychological support, relaxation and nutritional counseling. Patients will participate in two group educational sessions, managed by a respiratory physiotherapist, on lifestyle, physical activity and maintenance programs (VISCA et al., 2019; FUGAZZARO et al., 2017; TENCONI et al., 2021).
79252786|NCT06127641|Other|Standard Care|Participants will receive standard care (SC): a therapeutic education session upon admission, as well as pulmonary rehabilitation (PR) taught by a physical therapist. This therapeutic educational session will involve counseling and self-care management, emphasizing breathing exercises and sputum clearance and self-care techniques. It will consist of smoking cessation education (if this is the case, as tobacco is associated with TB), respiratory retraining (pursed lip breathing, diaphragmatic breathing and segmental breathing) and secretion removal training (coughing exercise, huffing , assisted cough and postural drainage).
79252787|NCT06127628|Procedure|Ultrasound-guided scalp block with ropivacaine 0.375%|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
79252788|NCT06127628|Procedure|Ultrasound-guided scalp block with placebo|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, normal saline placebo will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
79252789|NCT06127615|Device|ClearFit|Implantation of ClearFit Longeviti Craniectomy Cover
79277276|NCT02288923|Drug|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight >70kg 2 hourly.
79277277|NCT02288923|Drug|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
79547469|NCT01555099|Drug|AZD5423|oral inhaled
79547470|NCT01555099|Drug|Budesonide|oral inhaled
79547471|NCT01555099|Drug|Placebo|oral inhaled
79547472|NCT01555112|Drug|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
79547473|NCT01555190|Drug|myo-inositol 1500 gr|
79547474|NCT01555190|Drug|myo-inositol 2000 gr + folic acid 200 mcg|
79580932|NCT01930682|Drug|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
79252790|NCT06127602|Behavioral|Reactive balance training with Neuromuscular Electrical Stimulation|REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have < 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
79547475|NCT01555203|Behavioral|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
79547476|NCT01555216|Drug|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
79547477|NCT01555216|Drug|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
79547478|NCT01555229|Device|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
79547479|NCT01555229|Device|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
79547480|NCT01555242|Drug|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
79547481|NCT01555307|Other|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
79710281|NCT04315207|Behavioral|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
79710282|NCT01171183|Drug|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
79849063|NCT05492201|Drug|LY3873862|Administered orally.
79277278|NCT02288923|Drug|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
79277279|NCT02369445|Behavioral|Moisture Pager Intervention for Toilet Training|
79277280|NCT02369445|Behavioral|Standard of Care|
79277281|NCT02195375|Drug|Flutiform 500/20 µg BID|
79391928|NCT02403882|Behavioral|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
79391929|NCT02403882|Behavioral|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
79391930|NCT05249296|Other|Nature based solution for stress reduction|participation in nature activities: daily 30 min walking in nature
79710283|NCT01171183|Drug|Placebo|Placebo
79710284|NCT04315441|Diagnostic Test|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
79710285|NCT04315051|Drug|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
79710286|NCT04315051|Other|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
79849064|NCT05492201|Drug|Placebo|Administered orally.
80031417|NCT03785912|Behavioral|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
79277282|NCT02195375|Drug|Flutiform 250/10 µg BID|
79277283|NCT02195375|Drug|Seretide Accuhaler 50/500 µg BID|
79391931|NCT05249218|Other|Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
79391932|NCT05249218|Other|Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
79391933|NCT05249218|Other|Phase D - Extra 1 Phe exchange from milk or yoghurt|Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
79391934|NCT05249218|Other|Phase E - Extra 2 Phe exchanges from milk or yoghurt|Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
79391935|NCT02400294|Other|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
79547482|NCT01555307|Other|Typical group|Seven typical exercises, 10 times each, 3 times a day
79547483|NCT01555320|Drug|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
79547484|NCT01555320|Drug|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
79547485|NCT01555333|Drug|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
79547486|NCT01555372|Device|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
79547487|NCT01555372|Device|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
79547488|NCT01555385|Dietary Supplement|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
79547489|NCT01555398|Dietary Supplement|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
79547490|NCT01555424|Dietary Supplement|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
79547491|NCT01555424|Dietary Supplement|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
79547492|NCT01555450|Other|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
79547493|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
79710287|NCT04315129|Diagnostic Test|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
79710288|NCT01169779|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
79391936|NCT05248906|Diagnostic Test|Giant cell arteritis|Ultrasound 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Temporal artery biopsy
79710289|NCT01169779|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
80031418|NCT04891744|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
80031419|NCT04891744|Drug|Thalidomide|100mg/d, Po. on day1-28
79252791|NCT06127602|Behavioral|Reactive balance training without Neuromuscular Electrical Stimulation|REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have < 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
79391937|NCT02399904|Other|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
79547494|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
79547495|NCT01555515|Procedure|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
79547496|NCT01555515|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
79547497|NCT01555580|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
79710290|NCT01169779|Device|Pen auto-injector|
80031420|NCT04891744|Drug|Dexamethasone|20 mg/d Po. on day 1, 2,8,9,15,16,22,23
79710291|NCT01169779|Drug|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
79547498|NCT01555593|Device|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
79252792|NCT06127589|Behavioral|Brief cessation advice (AWARD)|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
79252793|NCT06127589|Drug|Nicotine Replacement Therapy (NRT)|1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
79252794|NCT06127589|Behavioral|Instant messaging Support (IM)|Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.
79547499|NCT01555606|Other|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
79391938|NCT04481022|Other|proximal control exercises|"study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010)."
79547500|NCT01555619|Device|CRT-D System|Implantation of a CRT-D System
79547501|NCT01555645|Behavioral|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
79547502|NCT01555658|Drug|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
79547503|NCT01555658|Drug|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
79547504|NCT01555684|Procedure|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
79547505|NCT01555710|Drug|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
79547506|NCT01555710|Drug|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
79547507|NCT01555710|Drug|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
79547508|NCT01555710|Drug|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
79710292|NCT01169779|Drug|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c <8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
79391939|NCT05248048|Biological|CAR-T infusion|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
79391940|NCT02399826|Device|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
79391941|NCT02399826|Procedure|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
79391942|NCT05247736|Diagnostic Test|Infrared Thermography|Non-contact body thermometry
79391943|NCT02399982|Other|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
79391944|NCT02399982|Other|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
79391945|NCT02403804|Dietary Supplement|Phosphatidylcholine|Phosphatidylcholine 3600 mg qam and 2700 mg qpm
79391946|NCT02403804|Dietary Supplement|Betaine (588 mg qam and 412 mg qpm)|Betaine anhydrous 588 mg qam and 412 mg qpm
79391947|NCT02403804|Dietary Supplement|Betaine (1000 mg BID)|Betaine anhydrous 1000 mg BID
79710293|NCT01169701|Drug|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
79252795|NCT06127589|Behavioral|Financial Incentive (FI)|A financial incentive (vouchers) of HK$ 500 will be provided for biochemically validated smoking abstinence at 3- and 6-month follow-up. Considering a possibly low engagement rate of the smokers in mHealth-based support (17% in our previous trial, non-engagement mostly due to busy work), additional HK$ 200 will be provided for participants who actively engaged in the mHealth counselling (defined by have discussed quitting process for >2 times) at 3-month follow-up.
79547509|NCT01555736|Drug|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
79252796|NCT06127589|Behavioral|Self-help smoking cessation booklet|A well-designed self-help booklet will be provided to guide and provide detailed information on smoking cessation. The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
79547510|NCT01555749|Drug|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
79547511|NCT01555749|Drug|placebo|One injection administered subcutaneously (s.c., under the skin)
79547512|NCT01555775|Dietary Supplement|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
79710294|NCT01169701|Drug|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
79252797|NCT06127589|Behavioral|Environmental assessment derived intervention|"In a selected subgroup of 50 families with an additional signed consents, four home visits will be done to: 1. Setup an indoor air quality (IAQ) monitor to collect 24hr air quality data (2 weeks), 2. Collect the monitor for data retrieval, 3. Setup the monitor at 6 months follow-up (2 weeks), 4. Collect the monitor for data retrieval.~Environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
79252798|NCT06127537|Behavioral|Therapeutic Intervention Group|"The therapeutic group factors that are worked on in the group session with a psychologist are:~Altruism.~Cohesion: feeling of belonging and acceptance in a group.~Universality: identification with the feelings, ideas or problems of the other group members.~Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~Counselling.~Identification: assumption of behavioural patterns of other members as one's own.~Reactualisation of the family experience.~Understanding of one's own internal motivations.~Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~Existential factors: empowerment of the individual."
79252799|NCT06127511|Other|Food (peanut)|After the recruitment, the participants will follow a peanut-free diet for two weeks.
79277284|NCT03531931|Drug|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
79391948|NCT03169764|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79391949|NCT03169764|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
79391950|NCT03169764|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79391951|NCT03169764|Biological|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
79391952|NCT03169764|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79391953|NCT03169764|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79391954|NCT03169764|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79391955|NCT03169764|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
79391956|NCT03169764|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79391957|NCT03169764|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79547513|NCT01555775|Dietary Supplement|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
79547514|NCT01555788|Device|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
79710295|NCT01169701|Drug|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
79710296|NCT01168999|Other|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
79710297|NCT01168999|Other|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
79710298|NCT01168999|Other|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
79710299|NCT01167907|Device|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
79710300|NCT01167907|Drug|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
79710301|NCT01166659|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
79547515|NCT01555801|Device|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
79547516|NCT01555801|Device|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
79547517|NCT01555814|Drug|Amisulpride|4-week open label amisulpride treatment
79547518|NCT01555827|Other|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~Wide-field colour and autofluorescence imaging (Optomap)~Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~Age, gender~educational level~smoking~cardiovascular diseases, current medications~scores at neuropsychological tests"
79547519|NCT01555840|Device|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
79547520|NCT01555853|Drug|Abraxane|
79547521|NCT01555866|Drug|isavuconazole|IV
79547522|NCT01555879|Drug|Abatacept|As prescribed by a doctor for patient medical care.
79547523|NCT01555918|Drug|Isavuconazole|oral
79547524|NCT01555918|Drug|Isavuconazole (IV)|intravenous (IV)
79547525|NCT01555970|Drug|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
79547526|NCT01555970|Drug|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
79849065|NCT05491551|Behavioral|Mindfulness-Based Treatment-Regulation of Craving|"Participants will be trained in using the MBT-based mindfulness strategy as described above (notice craving and accept the feeling without judgment or reaction). Participants will then be instructed to think of accepting and non-reactive responses when they see the instruction ACCEPT during ROC-T. On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see ACCEPT and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale."
79710302|NCT02886169|Other|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
79710303|NCT02886169|Other|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
79547527|NCT01556022|Device|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
79391958|NCT03169764|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
79547528|NCT01556022|Device|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
79710304|NCT01115491|Drug|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
79391959|NCT03169764|Drug|Lovaza|Omega-3-acid ethyl esters
79547529|NCT01556035|Drug|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
79547530|NCT01556048|Behavioral|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, & Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
79710305|NCT01115491|Drug|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
79710306|NCT01113931|Drug|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
79710307|NCT01113931|Drug|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
79710308|NCT04310761|Procedure|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
79391960|NCT03169764|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
79391961|NCT03169764|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex]
79391962|NCT03169764|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen (CEA) vaccine
79391963|NCT03169764|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 (HER2) vaccine
79391964|NCT03169764|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79710309|NCT02881879|Biological|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
79710310|NCT02881177|Drug|Oxytocin|40 IU
79252800|NCT06127498|Biological|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
79547531|NCT01556074|Behavioral|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
79277285|NCT02031263|Procedure|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
79277286|NCT03531775|Diagnostic Test|Upright MRI|Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
79547532|NCT01556087|Behavioral|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
79547533|NCT01556087|Behavioral|Health Education|7 individual sessions with didactic health education information
79547534|NCT01556113|Other|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
79710311|NCT02881177|Drug|Placebo|40 IU
79710312|NCT04187677|Procedure|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
79710313|NCT04187677|Other|classical hand therapy|classical hand therapy
79710314|NCT02881723|Procedure|Surgery|
79710315|NCT02881723|Radiation|Radio- chemotherapy|
79710316|NCT04187599|Device|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
79710317|NCT02880787|Drug|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
79710318|NCT02880787|Device|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
79710319|NCT02880709|Dietary Supplement|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
79391965|NCT03169764|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1) vaccine
79710320|NCT04309435|Behavioral|Self-esteem intervention|See relevant study arm for description
79391966|NCT03169764|Biological|GI-4000|Ras yeast vaccine
79391967|NCT03169764|Biological|GI-6207|CEA yeast vaccine
79391968|NCT03169764|Biological|GI-6301|Brachyury yeast vaccine
79547535|NCT01556126|Device|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
79710321|NCT04309435|Behavioral|Self-stigma intervention|See relevant study arm for description
79710322|NCT04309435|Behavioral|Jumping to conclusions intervention|See relevant study arm for description
79710323|NCT04309435|Behavioral|Control procedure (assessment only)|See relevant study arms for description
79710324|NCT01107379|Device|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
79710325|NCT01106911|Device|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
79710326|NCT01106677|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
79710327|NCT01106677|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
79710328|NCT01106677|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
79710329|NCT01106677|Drug|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
79710330|NCT04309045|Behavioral|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
79391969|NCT03169764|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
79547536|NCT01556152|Drug|GRC 17536 (Medium Dose)|1 BD for 28 days
79547537|NCT01556152|Drug|GRC 17536 (Low Dose)|1 BD for 28 Days
79547538|NCT01556152|Drug|Placebo|Matching Placebo for 28 Days
79547539|NCT01556191|Drug|Gefitinib|250 mg per day (oral)
79547540|NCT01556191|Drug|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
79547541|NCT01556191|Drug|Erlotinib|150 mg per day (oral)
79547542|NCT01556217|Drug|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
79252801|NCT06127498|Other|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
79547543|NCT01556217|Drug|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
79277287|NCT02197793|Behavioral|Community Mobilization Program|
79277288|NCT03534557|Diagnostic Test|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
79547544|NCT01556282|Device|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
79391970|NCT03858712|Other|Active Care Team Alert|"2) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."
79547545|NCT01556308|Procedure|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
79547546|NCT01556321|Dietary Supplement|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
79547547|NCT01556321|Dietary Supplement|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
79547548|NCT01556334|Drug|Azithromycin|Azithromycin 1g po
79547549|NCT01556334|Drug|Erythromycin|Erythromycin IV then PO
79547550|NCT01555528|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
79547551|NCT01556373|Other|NA : non interventional study|NA : non interventional study
79547552|NCT01555996|Behavioral|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
79547553|NCT01555996|Behavioral|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
79547554|NCT01556464|Device|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
79547555|NCT01556477|Drug|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
79710331|NCT04309045|Behavioral|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
79710332|NCT04309045|Other|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
79710333|NCT04309357|Drug|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
79710334|NCT04309279|Behavioral|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
79710335|NCT02880397|Drug|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
79710336|NCT02880397|Drug|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
79710337|NCT01106287|Drug|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
79710338|NCT01106287|Drug|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
79391971|NCT03858712|Other|Passive Care Team Alert|"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."
79252802|NCT06127485|Procedure|Neuropilates+occupational therapy and physiotherapy conventional|Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.
79252803|NCT06127485|Procedure|Occupational Therapy and Physiotherapy conventional|Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
80031421|NCT04891900|Drug|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
79547556|NCT01556477|Drug|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
79547557|NCT01556503|Device|VivaScope System|VivaScope System, Model#s 1500 and 2500
79710339|NCT04309123|Device|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
79710340|NCT04308343|Drug|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
79710341|NCT04308343|Drug|Letrozole|Drugs to treat undisturbed ectopic pregnancies
79710342|NCT04308343|Drug|cetrotide|Drugs to treat undisturbed ectopic pregnancies
79849066|NCT05491551|Behavioral|Cognitive-Based Therapy-Regulation of Craving|"Participants will be trained in using the CBT strategy by first considering and reading about the negative consequences of drinking. Participants will then be instructed to think of those negative consequences (Focus on the negative consequences associated with drinking) when they see the instruction REFRAME during ROC-T.On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see REFRAME and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale"
79849067|NCT05487820|Device|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
79849068|NCT05483062|Other|galla chinensis|toothpaste
79391972|NCT02396706|Drug|Ivy Leaves Cough Liquid|
79391973|NCT02396706|Drug|Placebo|
79849069|NCT05483062|Other|Stannous fluoride|Toothpaste
79849070|NCT05481034|Device|SMA bolus option|SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
79849071|NCT05481034|Device|Exactly estimated carbohydrate content bolus option|The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
79391974|NCT02399592|Drug|Bevacizumab|10 mg/kg q3w
79391975|NCT02399592|Drug|Tocotrinol|300 mg tid
79391976|NCT03801304|Drug|Atezolizumab|Atezolizumab in IV infusions
79849072|NCT05477134|Other|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
79849073|NCT05474989|Drug|LSD|Moderate to high dose LSD
79391977|NCT03801304|Drug|Vinorelbine|Vinorelbine capsules
79391978|NCT04480398|Drug|Guduchi Ghan Vati|Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
79391979|NCT04708522|Behavioral|Breath Control - Equal Breathing Technique|The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
79391980|NCT04708522|Behavioral|Guided Mindfulness Exercise|The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
79547558|NCT01556529|Procedure|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
79547559|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
79547560|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
79710343|NCT01104493|Biological|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
79710344|NCT01104493|Other|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
79710345|NCT01104415|Drug|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
79710346|NCT01099579|Drug|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
79547561|NCT01556542|Device|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
79547562|NCT01556542|Device|nitinol stent implantation|nitinol stent implantation
79547563|NCT05847660|Drug|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
79252804|NCT06127472|Other|Training in detection and diagnosis of ASD|To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
79391981|NCT04708522|Behavioral|Control|The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
79547564|NCT05847660|Drug|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
79547565|NCT05847595|Other|Implicit motor training program|The implicit motor training aims to create a learning situation in which the learner is not (or minimally) aware of the underlying rules of the practiced motor skill. Cognitive-motor dual-task training will be used, which involves practicing hand-reaching and grasping in different locations in space while performing cognitive tasks associated with attention, memory, and executive function. The cognitive tasks include naming words, counting backwards, counting tones, counting days and months backwards, listening to a number and counting backwards by twos and threes, telling daily stories, spelling words backward, continuous subtraction of 7 from 100, and the Stroop task. The training will be tailored to the participant's abilities.
79849074|NCT05474989|Drug|Active placebo|Low dose LSD
79849075|NCT05469802|Biological|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
79849076|NCT05469802|Other|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
79391982|NCT02396628|Drug|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
79391983|NCT02396628|Drug|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
79391984|NCT02396550|Behavioral|Positive Expectations|Give positive expectation of the treatment efficacy to patients
79391985|NCT02396550|Procedure|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
79710347|NCT01099579|Drug|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
79710348|NCT01099579|Drug|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
79710349|NCT01099579|Drug|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
79710350|NCT01103713|Drug|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
79391986|NCT03559816|Other|Classification of perineal tears based on new classification|Classifications according to the American College of Obstetricians and Gynaecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) and sub classification of second-degree lacerations based on the assumption that episiotomy involves the same anatomic structures of a second-degree laceration (perineal muscle, mucosa and skin), and divides them in two sub-groups, named A (if spontaneous vaginal tear is smaller than episiotomy) and B (if spontaneous vaginal tear is bigger than episiotomy).
79710351|NCT01103479|Behavioral|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
79710352|NCT01103479|Behavioral|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
79849077|NCT05459376|Other|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
79849078|NCT05458674|Drug|Tucatinib|taken orally
79849079|NCT05458674|Drug|Eribulin|taknen intravenously
79849080|NCT05458674|Drug|Trastuzumab|taken intravenously
79849081|NCT05456477|Other|Beef|Beef entrees
79849082|NCT05456477|Other|Poultry|Poultry entrees
80031422|NCT03687320|Device|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
80031423|NCT03687320|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
79849083|NCT05445414|Device|"SteWARdS Antibiotic Defense app"|"The SteWARdS Antibiotic Defense app is an evidence-based serious game app developed by the study team. The app uses gamification theories to increase user engagement and to deliver bite-sized information to participants. For example, players will learn about the uses of antibiotics through the messages delivered through the game and the cost of tackling antibiotic-resistant infections through purchasing an expensive antibiotic with the virtual currency earned from the games."
79849084|NCT05438940|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
79849085|NCT05438940|Behavioral|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
79849086|NCT05438940|Behavioral|Survey|Participants will take a survey at baseline and weeks 4,8,12 & 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
79849087|NCT05438927|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
79849088|NCT05438927|Behavioral|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
79252805|NCT06127472|Other|PE program|An adapted PE program for older adults with a recent diagnosis of ASD. The PE program consists of seven, two-hour group meetings on a weekly basis.
79710353|NCT01103323|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
79710354|NCT01103323|Drug|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
79710355|NCT01103323|Other|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
79252806|NCT06127433|Drug|Insulin Glargine|Insulin Glargine
79252807|NCT06127433|Drug|Metformin|Metformin
79391987|NCT03559816|Procedure|Selective use of Episiotomy|Standardized selective use of Episiotomy as recommended by guidelines.
79391988|NCT02696850|Drug|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
79391989|NCT02696850|Drug|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
79391990|NCT00365092|Procedure|Insertion of tympanostomy tubes|
79391991|NCT02403726|Procedure|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
79391992|NCT02403726|Procedure|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
79547566|NCT05847595|Other|Explicit motor training program|"The explicit motor training aims to create a learning situation in which the learner is very aware of the learning process by providing detailed explicit instructions on each exercise. The Motion Guidance Shoulder Kit will be used for this intervention, which involves four exercises: Around the clock in flexion and abduction, Locate the Target in active range of motion, Butterfly in tracing small and large butterfly patterns, and Test your positional awareness in locating circles with eyes open and closed. The kit involves a strap around the forearm with a laser to guide the movement of the arm during the exercises."
79547567|NCT05847595|Other|Selected physical therapy program|The selected physical therapy program, which includes shoulder joint mobilization, graduated active exercises for shoulder muscles, hand weight bearing exercises, Approximation of the upper limb joints. While, the conventional physical therapy program for the lower extremity which includes gait training, strengthening exercises and balance training .
79547568|NCT05847491|Diagnostic Test|IGRA/Tuberculin skin test|"All patients will receive:~Clinical evaluation;~Chest x-ray.~IGRA (or tuberculin skin test if immunocompromised)~Therapeutic proposal if eligible"
79547569|NCT05847413|Drug|Verapamil|Subjects will receive oral verapamil for 12 weeks
79710356|NCT01103245|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
79710357|NCT01103245|Drug|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
79710358|NCT01103245|Drug|Spironolactone (SPL 25)|spironolactone 25mg daily
79710359|NCT01103245|Drug|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
79849089|NCT05438927|Behavioral|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
79849090|NCT05438927|Behavioral|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
79849091|NCT05438927|Behavioral|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
79252808|NCT06127433|Drug|Dapagliflozin|Dapagliflozin
79252809|NCT06127433|Drug|Insulin aspart|Insulin aspart
79252810|NCT06127407|Drug|Ivosidenib 500mg|Provided as tablets, taken orally as two 250mg tablets once daily.
79252811|NCT06127407|Drug|Placebo|Provided as tablets, taken orally once daily.
79252812|NCT06127381|Drug|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
79252813|NCT06127355|Drug|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
79252814|NCT06127355|Other|500 mg of Placebo|Administration of 500 mg of placebo /day
79391993|NCT00365170|Drug|human insulin|
79391994|NCT00365170|Drug|insulin aspart|
79547570|NCT05847335|Behavioral|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
79547571|NCT05847257|Drug|Letrozole tablets|letrozole 2.5mg twice weekly for 3 months
79547572|NCT05847257|Dietary Supplement|Coenzyme Q10 table|Coenzyme Q10 400 mg per day for 3 months
79547573|NCT05847218|Drug|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
79849092|NCT05436808|Radiation|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
79849093|NCT05425615|Device|Transcranial Magnetic Stimulation|Deymed DuoMag XT-35 rTMS
79849094|NCT05422339|Device|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
79849095|NCT05388604|Device|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
79849096|NCT05388604|Device|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
79391995|NCT02403648|Drug|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
79391996|NCT02403648|Drug|Lilly Glucagon|
79391997|NCT02403648|Drug|Novo Glucagon|
79391998|NCT02403570|Other|Brain MRI|
79391999|NCT03446092|Behavioral|Mindfulness for health|A course of mindfulness using the mindfulness for health programme.
79392000|NCT02396472|Behavioral|Order by time and topic|
79547574|NCT05847218|Drug|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
79710360|NCT01103245|Drug|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
79710361|NCT04307875|Diagnostic Test|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
79710362|NCT04307875|Diagnostic Test|Blood glucose measurement|measuring blood glucose using standard measurement devices
79710363|NCT04307875|Other|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
79710364|NCT02878837|Drug|Dexmedetomidine|
79392001|NCT02396472|Behavioral|Order by information relevance|
79392002|NCT02396472|Behavioral|Order by social relationship|
79392003|NCT02396472|Behavioral|Order by help giving|
79392004|NCT02396472|Behavioral|Order by self-disclosure|
79392005|NCT03400150|Device|ProSpace|ProSpace balloon implantation
79392006|NCT03400150|Other|Control|Control - Marking & IMRT are standard of care for prostate cancer - there is no study-specific intervention
79392007|NCT02396862|Drug|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
79392008|NCT02399514|Other|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
79392009|NCT03317314|Diagnostic Test|Lung Biopsy during LVAD Implantation|Lung Biopsy during LVAD Implantation
79547575|NCT05847205|Drug|r-Hirudin|100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
79392010|NCT02403492|Device|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
79392011|NCT02403492|Device|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
79547576|NCT05847192|Diagnostic Test|[18F]-PI2620 PET scan|The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer [18F]-PI2620.
79710365|NCT02878837|Drug|Midazolam|
79710366|NCT02880007|Radiation|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
79710367|NCT02880007|Radiation|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
79710368|NCT02880007|Drug|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
79710369|NCT01098487|Drug|Eltrombopag olamine|Thrombopoietin receptor agonist
79710370|NCT02880085|Drug|Local anesthetic|local injection
79710371|NCT00591890|Drug|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
79710372|NCT02878993|Device|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
79710373|NCT01098097|Biological|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
79710374|NCT01098097|Drug|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
79710375|NCT01097863|Device|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
79849097|NCT05379946|Drug|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
79710376|NCT01097863|Device|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
79392012|NCT02403492|Device|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
79547577|NCT05847179|Drug|Progerinin|"This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase."
79547578|NCT05847101|Procedure|Tracheoesophageal fistula repair|Tracheoesophageal fistula repair
79547579|NCT05847088|Drug|Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:|Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
79547580|NCT05847075|Other|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
79849098|NCT05379946|Drug|IN10018|IN10018 orally once daily at approximately the same time each day
79849100|NCT05347914|Behavioral|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
79392013|NCT00365248|Drug|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
79547581|NCT05847075|Other|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last ~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
79547582|NCT05847075|Other|Sedentary Control|Participants will not receive any intervention during 12 weeks.
79710377|NCT01097863|Device|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
79710378|NCT04407572|Other|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
79710379|NCT04406090|Other|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
79710380|NCT04404920|Other|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
79710381|NCT04405232|Other|Non-interventional|Observational study
79710382|NCT04404452|Device|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
79710383|NCT04328636|Drug|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
79849101|NCT05338879|Other|Non-Interventional|No study treatment will be administered on this study.
79849102|NCT05334381|Behavioral|Adapted-STAT ED|Patient navigator assigned to provide culturally informed motivational interviews, brief case management, psychoeducation and telephone contacts
79849103|NCT05334381|Behavioral|Standard Enhanced Treatment|Follow up phone calls following discharge from the emergency department to confirm mental health treatment referral recommendations
80031424|NCT04891588|Drug|Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)|"switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months"
80031425|NCT04900012|Procedure|Distal pancreatectomy|We are going to collect all cases
80031426|NCT03050866|Drug|Cabazitaxel|25mg/m2 q3w
79392014|NCT02440360|Behavioral|PSH|Please see arm description.
79392015|NCT02440360|Behavioral|Usual Care|Please see arm description.
79392016|NCT02399436|Behavioral|School-Based Healthy Snacking Campaign|"The school-based healthy snacking campaign includes the following activities:~Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;~The installation of new filtered water fountains outfitted with water-filling stations;~The distribution of re-usable water bottles to students at participating schools; and~A social marketing campaign to support adoption of the healthy snacks and water consumption by students."
79392017|NCT02399436|Behavioral|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
79710384|NCT04328636|Drug|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
79710385|NCT04403828|Other|Survey|a cross-sectional, online survey-based study administered to Dentist in Egypt. A 20-item questionnaire developed and distributed using Google Forms.
79710386|NCT02893826|Drug|EG-1962 (nimodipine microparticles)|
79710387|NCT02893826|Drug|Enteral Nimodipine|
80031427|NCT03050866|Other|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
79392018|NCT02377492|Drug|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
79392019|NCT02396394|Behavioral|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
79547583|NCT05847062|Procedure|reverse shoulder arthroplasty|The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
79547584|NCT05847049|Other|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
79547585|NCT05847023|Behavioral|LUNA|see description above
79547586|NCT05846997|Diagnostic Test|Liquid biopsy and imaging|Liquid biopsy and imaging
79547587|NCT05846971|Other|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
79547588|NCT05846958|Device|laser acupuncture|"Each patient in experimental group will receive laser acupuncture for 10 s with at least 4J/point for each point.10 minutes, three times per week for 4 weeks (total of 12 sessions)~nieght splint for 4 weeks ."
79547589|NCT05846958|Device|night splint|wearing night splint for 4 weeks
79392020|NCT01763320|Procedure|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
79392021|NCT01763320|Drug|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
79392022|NCT02396238|Device|Celution Device|ADRCs prepared using the investigational Celution Device
79392023|NCT02396238|Other|Placebo|Placebo
79547590|NCT05846945|Other|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
79547591|NCT05846945|Other|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
79547592|NCT05846945|Other|Chest physiotherapy|Conventional chest physiotherapy
79547593|NCT05846867|Drug|AK119|AK119 IV every 2 weeks.intravenous infusion
79547594|NCT05846867|Drug|AK112|AK112 IV every 2 weeks.intravenous infusion
79547595|NCT05846867|Drug|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
79547596|NCT05846867|Drug|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
79710388|NCT00591968|Device|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
79710389|NCT00592046|Drug|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
79710390|NCT02893280|Drug|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
79710391|NCT02893436|Procedure|Surgery with tracheal intubation curarisation|
80031428|NCT03050866|Other|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
80031429|NCT03050866|Other|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
79277289|NCT02195453|Drug|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
79277290|NCT02195453|Drug|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
79277291|NCT03531697|Drug|Generic Loteprednol Etabonate|Drug
79277292|NCT03531697|Drug|Reference Listed Drug (RLD)|Drug
79547597|NCT05846867|Drug|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
79547598|NCT05846867|Drug|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
79547599|NCT05846854|Other|Assessment for bleeding disorder with tailored post-operative care|Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.
79547600|NCT05846828|Other|Stanford Binet IQ test|"The Fourth Edition Stanford-Binet test which is based upon a four-factor model of intelligence, and its 15 subtests are partitioned into :~Verbal ability.~Abstract/Visual ability.~Quantaitive potential.~Short-Term Memory Scales"
80031430|NCT03050866|Other|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
79547601|NCT05846737|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg.
79392024|NCT01614106|Behavioral|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
79710392|NCT02893358|Drug|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
79252815|NCT06127329|Procedure|BAI combine with DEB-BACE|"First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 ~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 ~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
79547602|NCT05845736|Drug|Antihypertensive Agents|number of hypertensive drugs
79547603|NCT05843942|Other|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
79547604|NCT05842148|Other|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
79547605|NCT05842148|Other|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
79547606|NCT05842148|Other|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
79547607|NCT05841173|Dietary Supplement|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~Apple juice concentrated 2.5% - 7,5 g;~Potassium beta-hydroxybutyrate - 4,5 g;~Magnesium beta-hydroxybutyrate - 500 mg;~E211 sodium benzoate - no more than 5 mg;~E202 Potassium sorbate - no more than 3,6 mg;~Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
79547608|NCT05841173|Behavioral|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
79252816|NCT06127303|Drug|Toripalimab|Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
79252817|NCT06127303|Other|Cryoablation|The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
79710393|NCT02893358|Drug|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
79739717|NCT01004406|Device|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
79739718|NCT01004406|Drug|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
79252818|NCT06127277|Behavioral|Next4You|Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
79252819|NCT06127264|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
79392025|NCT02399280|Behavioral|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
79252820|NCT06127238|Drug|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
79252821|NCT06127225|Drug|Proliverenol|1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
79392026|NCT02399280|Behavioral|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
79392027|NCT01113736|Biological|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
79392028|NCT03169920|Procedure|Modified-Minimally Invasive Surgical Technique + PRF|
79392029|NCT03169920|Procedure|Modified-Minimally Invasive Surgical Technique|
79252822|NCT06127225|Drug|Placebo caplets of Proliverenol|2 caplets of Proliverenol Placebo daily
79547609|NCT05841173|Other|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
79392030|NCT02594644|Device|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
80031431|NCT03471806|Behavioral|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
79547610|NCT05841173|Behavioral|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
79252823|NCT06127212|Drug|Dapagliflozin 10 mg film-coated tablet|One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
79547611|NCT05840757|Device|HemoSphere ClearSight Module|The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
79252824|NCT06127212|Drug|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
79392031|NCT02594644|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
79392032|NCT02594644|Radiation|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
79392033|NCT03168204|Behavioral|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
79392034|NCT02596750|Device|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
79252825|NCT06127160|Drug|Cephalexin|Cephalexin 1000 mg by mouth 3 times daily for 10 days
79252826|NCT06127160|Drug|Cephalexin or placebo|Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.
79392035|NCT02596750|Device|Sham microneedle Roller|Flat roller without microneedles
79392036|NCT02403336|Other|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
79547612|NCT05840744|Diagnostic Test|complete blood count|Investigations done for identifying the risk factor which lead to thrombosis.
79710394|NCT04390802|Drug|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
79739719|NCT04210804|Dietary Supplement|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
79739720|NCT04210570|Device|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
79252827|NCT06127134|Procedure|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
79252828|NCT06127121|Behavioral|Digital Art Activity|"complete a symptom questionnaire~complete another activity such as listening to meditative music for 10 minutes~fill out the symptom questionnaire and engage in the digital art activity again"
79252829|NCT06127056|Device|High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
79252830|NCT06127056|Device|sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
79392037|NCT02403336|Behavioral|Behavioral group intervention|Intervention on patients (educational workshop).
79392038|NCT02403336|Other|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
79392039|NCT02403414|Device|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
79547613|NCT05840705|Procedure|Small curved incision with apex lateral|Small curved incision with apex lateral
79547614|NCT05840692|Drug|Escitalopram 20 mg|Antidepressant
79547615|NCT05840692|Drug|Placebo|
79547616|NCT05840679|Drug|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
79547617|NCT05840653|Other|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
79547618|NCT05840640|Drug|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
79547619|NCT05840640|Drug|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
80031432|NCT03471806|Behavioral|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
79252831|NCT06126978|Device|Vibration Therapy (Galileo Dela Interface)|Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
80031433|NCT04455308|Diagnostic Test|Biological sample collection|10mL blood sample
79252832|NCT06126978|Device|Mirror Therapy ( Mirror Box)|Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).
79252833|NCT06126965|Drug|KX-826-（5%） BID|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
79252834|NCT06126965|Other|Placebo|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
79392040|NCT02403258|Other|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
79392041|NCT02403258|Behavioral|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
79392042|NCT02601976|Drug|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
79392043|NCT02601976|Drug|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
79392044|NCT03168126|Device|Pro-AQT|Use of the device for advanced hemodynamic monitoring
79392045|NCT02396082|Behavioral|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
79547620|NCT05840640|Drug|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
79547621|NCT05840627|Other|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
79739721|NCT04210570|Drug|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
79392046|NCT02396082|Other|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
79392047|NCT04742218|Drug|K-877|K-877 Tablet
79392048|NCT02396004|Device|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
79547622|NCT05840614|Behavioral|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
79547623|NCT05840601|Device|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
79547624|NCT05840601|Device|Comparator|Unmodified commercially available prosthetic hand.
79739722|NCT01187368|Device|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
79739723|NCT01187368|Device|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
79739724|NCT00620152|Behavioral|1|Low glycemic load diet by telephone counseling
79739725|NCT00620152|Behavioral|2|Low fat diet by telephone counseling
79392049|NCT02603926|Drug|Allopregnanolone|Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
79392050|NCT02399202|Drug|osilodrostat|
79849104|NCT05332639|Behavioral|Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool|We will develop a web-based, personalized risk estimation for CD (PRE-CD) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI), smoking history, NSAID use, intake of fruit, vegetables, and fiber, oral contraceptive use (females), and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
79849105|NCT05332639|Behavioral|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-CD tool as well.
79849106|NCT05332379|Diagnostic Test|Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.
79849107|NCT05312632|Drug|Safinamide Mesilate|Safinamide Mesilate oral tablets.
80031434|NCT03051880|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
79392051|NCT00365404|Behavioral|Diet and exercise promotion|
79392052|NCT03168048|Other|mobile application|Oncologic therapy support by means of a mobile application
79252836|NCT06126913|Other|Community Antiretroviral Therapy|Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
79252837|NCT06126900|Other|Smartphone medication intake reminder + educational and motivational text messaging|The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
79277293|NCT02197871|Dietary Supplement|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
79739726|NCT04210648|Device|Mobile app|Mobile app for self-managing emotional dysregulation
79739727|NCT02687308|Procedure|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
79392053|NCT02605876|Device|Whole body vibration|
79392054|NCT02605876|Device|Local muscle vibration|
79392055|NCT04933422|Drug|CM93|oral capsule of CM93 administered once daily
79547625|NCT05840588|Drug|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
79547626|NCT05840588|Dietary Supplement|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
79739728|NCT02687308|Procedure|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
79739729|NCT03900832|Other|Without Heating|Subject will complete walking protocol without any heating procedure
79547627|NCT05840536|Drug|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
79547628|NCT05840536|Drug|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
79875123|NCT04320628|Device|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
80031435|NCT03051880|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
79392056|NCT02606500|Drug|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age > 38 years."
79392057|NCT02403024|Behavioral|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
79392058|NCT02403024|Behavioral|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
79547629|NCT05840523|Other|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
79547630|NCT05840523|Other|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
79547631|NCT05840497|Other|Resistance exercise|"The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~."
79710395|NCT04328480|Drug|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~In patients not receiving Lopinavir/Ritonavir~Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~The next day 0.5 mg bid for 14 days or until discharge.~In patients receiving Lopinavir/Ritonavir~Loading dose of 0.5 mg (day 1)~After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
79710396|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
79710397|NCT04382222|Procedure|prenatal ultrasound|prenatal cardiac ultrasound
79710398|NCT00592202|Device|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
79710399|NCT04375358|Biological|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
79710400|NCT04374266|Diagnostic Test|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
79710401|NCT02893124|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
79875124|NCT04320628|Other|NSS|NSS
79252838|NCT06126874|Other|Patient Education|Individuals in both study groups will be provided with patient education through verbal and visual presentations. In the content of patient education; information about the importance of the research topic and the content of the study through anatomical models and short animations, lifestyle recommendations for urinary incontinence symptoms (avoiding bladder irritants such as alcohol, caffeine, tea, spicy foods, acidic foods and chocolate, regulating water / fluid consumption, recommendations for attention to bowel regularity and increasing physical activity levels) and recommendations for sexual functioning (coitus positions that facilitate erection, recommendations for reshaping the sexual schema, recommendations for the physical dimension of sexual health) will be given.
79392059|NCT02606734|Device|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
79392060|NCT03106506|Procedure|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
79392061|NCT04340674|Other|Telerehabilitation based on aerobic exercise|To perform different whole body aerobic exercises moderately intense according to Borg scale.
79392062|NCT03106584|Dietary Supplement|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose"
79849108|NCT05301114|Behavioral|Community Health Worker support|Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
79849109|NCT05287594|Behavioral|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
79849110|NCT05282212|Diagnostic Test|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
79849111|NCT05272813|Drug|MS-553|MS-553
79547632|NCT05840458|Procedure|PENG Block|Patient will be placed in the supine position and the ultrasound probe will be placed in the transverse plane over the anterior inferior iliac spine (AIIS) and aligned with the pubic ramus by rotating the probe counterclockwise by approximately 45 degrees. A 22-gauge, 100 mm needle will be inserted using the plane approach from lateral to medial, between the psoas tendon anteriorly and the pubic ramus posteriorly. Following a negative aspiration, 20 mL of 0.375% ropivacaine will be injected. The needle position will be confirmed by visualizing the separation of layers with the dispersion of the injected volume.
79710402|NCT04370678|Behavioral|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
79849112|NCT05267587|Radiation|Hypofractionated Stereotactic Radiosurgery|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected.
80016956|NCT04350658|Procedure|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
80016957|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
80016958|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
80016959|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
80016960|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
79710403|NCT04369508|Radiation|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
79392063|NCT03106584|Dietary Supplement|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose"
79392064|NCT00365560|Drug|tiotropium|
79710404|NCT04327778|Procedure|Music Therapy|Automate music therapy every two weeks
79710405|NCT02892968|Procedure|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
79392065|NCT00365560|Drug|placebo|
79392066|NCT03167736|Other|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
79547633|NCT05840445|Drug|Onabotulinum toxin A|Intramuscular application of onabotulinum toxin-A in the upper facial third.
79710406|NCT02892968|Procedure|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
79849113|NCT05265364|Radiation|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
80016961|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
79252839|NCT06126874|Other|Pelvic Floor Muscle Training|In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program. In the first 2 weeks of PFMT, individuals will perform 3 sessions of exercise per day. In each 2-week control, the number of sessions will be increased by 1 session and PFMT application will be completed with 5 sessions per day in the study.
79277294|NCT04424979|Device|High power prisms|High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
79547634|NCT05840445|Drug|Prabotulinumtoxin A|Intramuscular application of prabotulinum toxin-A in the upper facial third.
79547635|NCT05840419|Device|Laparoscopic appendectomy|Laparoscopic appendectomy with Airseal or with standard insufflation
79547636|NCT05840406|Drug|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
79547637|NCT05840406|Procedure|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
79547638|NCT05840406|Procedure|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
79547639|NCT05840406|Drug|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
79547640|NCT05840406|Drug|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
79547641|NCT05840406|Drug|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
79580933|NCT01930682|Procedure|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
79710407|NCT04368338|Diagnostic Test|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
79710408|NCT04368338|Procedure|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
79710409|NCT02893046|Other|No intervention|
79710410|NCT04359992|Other|Extra blood sample|3 extra blood samples at day 0, 2 and 7
79710411|NCT04358042|Other|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
79710412|NCT04358042|Other|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
79739730|NCT03900832|Other|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP >20 mmHg), the subject will be removed from the bath even if the time is <30 min."
79849114|NCT05263180|Biological|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
79277295|NCT05724979|Other|ZP-binding|The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
79277296|NCT02375763|Other|Software instruction|
79392067|NCT03167736|Other|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
79392068|NCT02395770|Other|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching & Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
79392069|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
79392070|NCT02395926|Drug|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
79392071|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
79392072|NCT02607124|Drug|Ribociclib|
79392073|NCT02402868|Drug|Ketamine and saline|Ketamine intravenous and intranasal
79392074|NCT02399046|Device|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
79849115|NCT05260671|Drug|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
80016962|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
79849116|NCT05253924|Diagnostic Test|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
79710413|NCT04358042|Other|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
79710414|NCT04358042|Other|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
79710415|NCT04327856|Procedure|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
79710416|NCT04352426|Other|Exercise Test|Tests were conducted to evaluate exercise capacity.
79710417|NCT04349540|Other|no intervention|no intervention
79710418|NCT04348682|Diagnostic Test|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
79710419|NCT04343456|Procedure|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
79547642|NCT05840393|Other|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
79849117|NCT05253924|Diagnostic Test|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
79849118|NCT05233527|Procedure|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
80016963|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
80016964|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
79547643|NCT05840367|Behavioral|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
79547644|NCT05840341|Drug|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
79710420|NCT04340648|Device|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
79710421|NCT04340726|Procedure|One time abutment|
79710422|NCT04336280|Other|Symptom questionnaire|Arabic version of the International Prostate Symptom Score: Known and validated questionnaire to quantify and qualify the severity of symptoms of the lower urinary tract
79710423|NCT04336280|Diagnostic Test|Urodynamics|Urodynamics: the standard diagnostic tool, it includes invasive recording of the pressure that is produced when the bladder muscle contracts via pressure sensors introduced in the urinary bladder through special types of urethral catheters.
79710424|NCT04334252|Other|Questionnaire|Questionnaire
79710425|NCT02892812|Biological|Pneumococcal conjugate vaccine|
79710426|NCT00592670|Drug|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
79710427|NCT00592670|Drug|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
80016965|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
80016966|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
79547645|NCT05840328|Drug|Dexmedetomidine Injection [Precedex]|interventional drug will be administred either intravenously or epidurally
79547646|NCT05840328|Drug|Bupivacaine Injection|intervention drug will be administred epidurally
79547647|NCT05840315|Dietary Supplement|Basic intervention and nutritional intervention|"The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories."
79580934|NCT01930682|Procedure|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
79710428|NCT00622856|Behavioral|psychological intervention|Psychological intervention
79849119|NCT05233371|Other|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
79849120|NCT05233371|Other|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~Frequency and duration of rehabilitation sessions by type of health professionals,~Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
79849121|NCT05233371|Other|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
79849122|NCT05223413|Device|RIPC|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.
79849123|NCT05223413|Device|Simulated RIPC (Sham)|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
79849124|NCT05221931|Procedure|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent [Boston Scientific, USA], Prevail [Medtronic, USA], or SeQuent Please, SeQuent Please NEO [B-Braun, Germany])
79849125|NCT05212727|Device|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
79849126|NCT05212428|Procedure|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
79849127|NCT05212428|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79849128|NCT05212428|Other|Genetic Counseling|Receive genetic counseling
79849129|NCT05212428|Other|Questionnaire Administration|Complete family history
79849130|NCT05212428|Other|Questionnaire Administration|Ancillary studies
79849131|NCT05198245|Drug|Rimegepant|Rimegepant 75mg
79849132|NCT05198245|Drug|Various|Various
79849133|NCT05198245|Other|No intervention|No intervention
79580935|NCT01930708|Drug|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
79580936|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 60 degrees.
79580937|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
79580938|NCT01930734|Drug|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
79580939|NCT01930734|Drug|Normal Saline|Normal Saline solution 0.9% Placebo Arm
79710429|NCT00622856|Behavioral|Diabetes education|5 sessions with diabetes nurse
79710430|NCT00592748|Radiation|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
79710431|NCT04327232|Drug|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
79710432|NCT04327232|Drug|Placebo oral tablet|Placebo
80016967|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
80016968|NCT05228782|Other|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
80016969|NCT02095470|Device|video laryngoscope|newly developed innovatory device
80016970|NCT02095470|Device|traditional laryngoscope|traditional way for intubation
80031436|NCT04891276|Other|Data collection|Data collection on the national PMSI database
80031437|NCT05390996|Other|dental implant placement|dental implant placement by using a different drilling techniques
79277297|NCT05161871|Device|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
79710433|NCT00593138|Drug|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
79710434|NCT00593216|Device|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
79710435|NCT04326998|Procedure|solvent|using solvent (GuttaClear) in procedure
79392075|NCT02399046|Device|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
79392076|NCT02609308|Other|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
79849134|NCT05197595|Behavioral|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
79710436|NCT04326998|Procedure|non-solvent|non-solvent
79547648|NCT05840315|Procedure|Sit-to-stand|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height."
79849135|NCT05197595|Behavioral|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
79849136|NCT05186948|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
79252840|NCT06126874|Other|Aerobic Exercise Training|Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).The intensity of aerobic exercise training will be planned according to the Maximal Heart Rate (MHR) method and Modified Borg Scale (MBS). In the first 2 weeks in the clinic, training will be started with 50 min (+10 min warm-up and cool-down) at 60% of the MHR, the exercise intensity will be increased by 5% every 2 weeks, and the program will be terminated by providing exercise training at 85% of the MHR in the 10th-12th week. Patients will be asked to adjust the intensity of aerobic exercise outside the clinic to correspond to the 12-14 (slightly difficult) degree of perceived fatigue according to the MBS.
79277298|NCT05161871|Device|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
79392077|NCT02609308|Procedure|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
79392078|NCT02402946|Behavioral|Biofeedback|
79392079|NCT02402946|Drug|Placebo|
79547649|NCT05840315|Procedure|Leg press|"Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press."
79547650|NCT05840315|Procedure|Hip abduction|"Third subtrial (participants 21-30):~In addition to interventions described in sub-trials 1 and 2, progressive strength training of the gluteal muscles is carried out in the form of hip abduction from a sitting position, using a hip abduction machine, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press."
79547651|NCT05840172|Device|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
79710437|NCT00593294|Behavioral|Physical exercise|45 minutes each day for three times/week for 6 months
79710438|NCT00593294|Drug|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
79710439|NCT00593294|Dietary Supplement|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
79710440|NCT00593528|Device|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
79392080|NCT02398968|Dietary Supplement|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
79392081|NCT02402712|Drug|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
79710441|NCT00593528|Device|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
79849137|NCT05184569|Drug|Verdiperstat|Oral, extended release (ER) tablet
79849138|NCT05180422|Drug|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
79849139|NCT05180422|Drug|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
79849140|NCT05161533|Drug|Carboplatin|Given IV
79849141|NCT05161533|Drug|Cisplatin|Given IV
79392082|NCT02402712|Drug|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
79392083|NCT02402712|Drug|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
79392084|NCT02398812|Other|Medication assessment and treatment plan based on it|"Intervention~Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
79710442|NCT00593528|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
79277299|NCT02375607|Device|Algometer|Algometer performed patients
79277300|NCT03529747|Other|Online self-help|As detailed in experimental arm description.
79277301|NCT02369133|Drug|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
79277302|NCT02369133|Drug|Placebo|
79392085|NCT02402634|Other|Mechanical ventilatory lung care|
79392086|NCT02395458|Drug|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
79392087|NCT02395458|Drug|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
79277303|NCT02195609|Dietary Supplement|Omega-3|600 mg oral twice a day
79277304|NCT02195609|Dietary Supplement|Soy Isoflavones|54.4 mg oral twice a day
79277305|NCT02377635|Dietary Supplement|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
79392088|NCT02398890|Other|routine care|routine care
79392089|NCT02395380|Other|C-reactive protein dosage|
79392090|NCT02402400|Drug|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
79392091|NCT02402556|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
79392092|NCT02398578|Device|Amphora OAB Device|Cystoscopic procedure to treat OAB
79710443|NCT04327076|Device|Using robot system of endotracheal intubation and airway cleaning|"Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
79710444|NCT02892578|Other|electrocardiogram|
79710445|NCT00593996|Other|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
79710446|NCT00594074|Other|white wine|3.25 ounces of white wine twice a day with lunch and dinner
79710447|NCT00594152|Drug|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
79710448|NCT00594698|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
79710449|NCT00594776|Device|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
79710450|NCT00595010|Behavioral|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
79710451|NCT00595166|Device|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
79710452|NCT00595244|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
79710453|NCT00595322|Other|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
79710454|NCT00595712|Procedure|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
79710455|NCT00595712|Procedure|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
79710456|NCT00596024|Dietary Supplement|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
79710457|NCT00596024|Dietary Supplement|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
79710458|NCT00596180|Drug|HBOT|total body exposure to greater than atmospheric pressure oxygen
79710459|NCT00596258|Drug|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
79710460|NCT02892266|Other|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
79710461|NCT00596336|Drug|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
79710462|NCT00596336|Drug|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
79392093|NCT02398344|Device|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
79710463|NCT00596414|Procedure|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
79710464|NCT00596414|Drug|placebo|
79710465|NCT00596414|Drug|midazolam|
79849142|NCT05161533|Biological|Durvalumab|Given IV
79849143|NCT05161533|Drug|Etoposide|Given IV
79849144|NCT05161533|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79392094|NCT02398344|Device|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
79849145|NCT05161533|Other|Quality-of-Life Assessment|Ancillary studies
79392095|NCT02610868|Drug|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
79547652|NCT05840172|Device|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
79710466|NCT00596414|Drug|midazolam + pethidine|
79849146|NCT05161533|Other|Questionnaire Administration|Ancillary studies
79849147|NCT05156606|Drug|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
79849148|NCT05132439|Drug|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
79849149|NCT05132439|Drug|placebo|Matched to active study drug
79392096|NCT02394990|Behavioral|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
79392097|NCT02394990|Behavioral|ABI|
79392098|NCT02395068|Drug|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
79547653|NCT05840172|Device|Control NRL condom|IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
79710467|NCT00596492|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
79710468|NCT00596492|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
79710469|NCT00596570|Procedure|PCI|Percutaneous coronary interventiom
79710470|NCT00596648|Drug|XL184|Capsules administered orally daily
79710471|NCT00596648|Drug|erlotinib|Tablets administered orally daily.
79710472|NCT00596726|Device|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
79710473|NCT00596804|Drug|veltuzumab|once weekly intravenous dosing for 4 weeks
79710474|NCT00622934|Drug|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
79710475|NCT00622934|Drug|placebo|placebo
79849150|NCT05113667|Other|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
79710476|NCT00596882|Other|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
79710477|NCT00596882|Other|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
79875125|NCT01065064|Procedure|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
79875126|NCT03983902|Procedure|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
80031438|NCT05163236|Diagnostic Test|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
79710478|NCT00597194|Procedure|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
79710479|NCT00597350|Dietary Supplement|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
79710480|NCT02892032|Behavioral|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
79710481|NCT02892032|Behavioral|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
79849151|NCT05113316|Behavioral|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
79849152|NCT05108298|Other|Questionnaires|Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms. The patients will be asked to rank the 15 types of PROs according to their importance. The participants randomized to the choice arm will be asked to choose 5 of the 15 PROs to complete. The participants randomized to the fixed arm will be given a fixed 5 of the 15 PROs at each time point.
79849153|NCT05100069|Drug|Brigatinib|Brigatinib Tablets
79849154|NCT05087550|Procedure|Liver Transplantation|Patients who underwent liver transplantation at Methodist Dallas Medical Center
79849155|NCT05086250|Drug|Ketamine|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
79849156|NCT05086250|Drug|Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
79849157|NCT05086250|Drug|Placebo|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
79849158|NCT05086250|Drug|Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
79849159|NCT05083923|Drug|Diroximel fumarate|Administered as specified in the treatment arm
79849160|NCT05070403|Drug|Afatinib 40 MG|Participants will receive 40 mg Afatinib, once daily.
79849161|NCT05064423|Behavioral|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
79849162|NCT05064085|Drug|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
79849163|NCT05064085|Drug|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m^2 and 1000 mg/m^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
79849164|NCT05044832|Behavioral|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
79849165|NCT05036629|Device|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~NIRS Oxymon artinis medical system~tES (transcranial electrical stimulation, Neuroelectrics)"
79849166|NCT05035511|Device|tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
79849167|NCT05030493|Drug|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79392099|NCT02395068|Drug|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
79710482|NCT00597662|Device|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
79710483|NCT00597662|Device|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
79710484|NCT00597974|Procedure|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
79710485|NCT00597974|Device|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson & Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson & Johnson), Wallstent® (Boston Scientific Medi-Tech)
79710486|NCT00597974|Other|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
79710487|NCT00597974|Procedure|Angiography|(non-experimental) Coronary angiography
79710488|NCT00598052|Drug|Escitalopram|10mg/day
79710489|NCT04207814|Biological|biological sample|biological samples will be taken from the subjects included
79710490|NCT00598130|Biological|Fleece|Fibrin Patch
79710491|NCT00598286|Drug|[18F]FMPEP-d2|
79710492|NCT04326296|Drug|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
79710493|NCT04328324|Procedure|Endoscopy|Diagnostic upper Git endoscopy
79710494|NCT00598676|Device|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
79710495|NCT00598676|Device|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
79710496|NCT00598676|Device|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
79710497|NCT04326218|Other|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~anti-PLA2R1 and anti-THSD7A antibodies~anti-PLA2R1 and anti-THSD7A epitopes~HLA typing"
79710498|NCT00598910|Drug|Omacor|n-3 PUFA
79710499|NCT00598910|Drug|Placebo|Placebo
79710500|NCT04326374|Drug|TransCon hGH|Once weekly subcutaneous injection
79710501|NCT04326374|Drug|daily hGH|Once daily subcutaneous injection
79710502|NCT04326140|Device|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
79710503|NCT04326140|Device|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
79710504|NCT04326140|Device|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
79849168|NCT05030493|Drug|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79849169|NCT05026814|Other|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
79849170|NCT05023382|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection
79849171|NCT05021991|Drug|100 mg PRAX-944|Once daily oral treatment with titration
79849172|NCT05021991|Drug|60 mg PRAX-944|Once daily oral treatment with titration
79849173|NCT05021991|Drug|Placebo|Once daily oral treatment
79849174|NCT05021991|Drug|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
79849175|NCT05018247|Procedure|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
79849176|NCT05014672|Drug|Setanaxib|Oral tablets, 400mg per tablet
79849177|NCT05014672|Drug|Placebo|Oral tablets
79849178|NCT05014438|Drug|BMS-986166|Specified dose on specified days
79710505|NCT00599066|Device|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
79710506|NCT00599144|Procedure|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
79710507|NCT00599144|Procedure|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
79710508|NCT00599144|Procedure|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
79710509|NCT00599222|Biological|ranibizumab|0.5 mg intravitreal injection
79710510|NCT00599222|Procedure|TTT|Transpupillary thermotherapy (TTT)
79710511|NCT00599222|Procedure|Sham TTT|Sham Transpupillary thermotherapy (TTT)
79710512|NCT01326962|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
79710513|NCT01326728|Biological|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
79710514|NCT00599378|Behavioral|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
79710515|NCT01097707|Drug|LY500307|Administered orally, daily for 24 weeks
79710516|NCT01097707|Drug|Placebo|Administered orally, daily for 24 weeks
79710517|NCT00599456|Dietary Supplement|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
79710518|NCT00599456|Dietary Supplement|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
79710519|NCT00599534|Drug|Montelukast|4 mg oral tablets
79710520|NCT00599534|Drug|Placebo|5mg tablets
79710521|NCT00599612|Drug|GW856553|A dose of 10mg GW856553 containing 50µCi of [14C]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
79849179|NCT05014438|Drug|Branebrutinib|Specified dose on specified days
79849180|NCT05014438|Other|Placebo|Specified dose on specified days
79849181|NCT05014048|Dietary Supplement|Vitamin D3|20 mikrog vitamin D3 daily
79849182|NCT05014048|Dietary Supplement|Placebo|Placebo
79849183|NCT05010577|Drug|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
79849184|NCT05010577|Drug|Placebo|Nebulized placebo
79849185|NCT05008783|Drug|AK104|AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
79849186|NCT05008783|Drug|Placebo|Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
79875127|NCT03983902|Procedure|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
79252841|NCT06126874|Other|Resistance Exercise Training|Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training. These exercises are leg press, leg extension, leg curl, squat, seated row, lateral pull down, biceps curl, triceps extension, dumble fly, lateral raises, bench press and abdominal crunch. Exercises will be performed with free weights (dumbbells), resistance bands (therabands) or body weight.
79392100|NCT02398422|Behavioral|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
79392101|NCT02614222|Device|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
79392102|NCT02614924|Device|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
79392103|NCT02614924|Device|Pentax AWS videolaryngoscope|Patient intubated using Pentax AWS videolaryngoscope
79547654|NCT05840146|Other|Kinesiotaping|"Two I-strips were used:~The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
79547655|NCT05840146|Other|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
79547656|NCT05840133|Diagnostic Test|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
79547657|NCT05840094|Drug|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
79710522|NCT00599690|Procedure|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
79710523|NCT00599768|Other|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
79547658|NCT05840094|Device|MR STIR|The overall scanning time of MR is about 13min.
79710524|NCT02878759|Device|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
79710525|NCT00600002|Biological|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
79710526|NCT02891720|Device|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
79710527|NCT00600158|Drug|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
79710528|NCT00600158|Drug|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
79710529|NCT00600236|Procedure|blood sample|
79710530|NCT04325984|Drug|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
79710531|NCT02891642|Device|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
79710532|NCT00600470|Behavioral|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
79710533|NCT00600470|Behavioral|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
79710534|NCT04326062|Other|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
79875128|NCT03983902|Procedure|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
79875129|NCT00317356|Drug|OPC-6535(Tetomilast)|
80031439|NCT05163236|Diagnostic Test|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
79547659|NCT05840094|Procedure|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
79547660|NCT05840081|Other|Milk or yogurt beverage|Commercially available milk or yogurt (depending on experimental arm) will be incorporated into flavored drinks/smoothies to minimize perceived differences among these items, preserving the double-blind nature of the study design.
79547661|NCT05840029|Procedure|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
79547662|NCT05840003|Radiation|Ultra-Low-Dose thoraco-abdominopelvic scan|In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
79547663|NCT05839977|Other|Individual telerehabilitation|The exercise will consist of strength and balance exercises using the Homebalance ® system
79547664|NCT05839977|Other|Home exercises based on videos|intervention include 12 video recordings of exercises created by a physiotherapist for home exercises, according to which they will also exercise
79710535|NCT04326062|Other|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
79710536|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
79710537|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
79710538|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
79710539|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
79710540|NCT00600626|Drug|biphasic insulin aspart|
79710541|NCT00600626|Drug|insulin NPH|
79710542|NCT00600626|Drug|insulin aspart|
79710543|NCT00623090|Behavioral|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
79710544|NCT00623090|Behavioral|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
79710545|NCT00623090|Behavioral|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
79710546|NCT00623168|Drug|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
79710547|NCT00623246|Behavioral|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
79710548|NCT00623246|Behavioral|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
79710549|NCT00600860|Other|No interventions|Only registration of clinical practice
79710550|NCT00601016|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
79710551|NCT00601094|Biological|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
79710552|NCT00601328|Drug|Calcitriol|
79710553|NCT00601406|Genetic|gene expression analysis|
79710554|NCT00601406|Genetic|gene rearrangement analysis|
79710555|NCT00601406|Genetic|polymorphism analysis|
79710556|NCT00601406|Other|laboratory biomarker analysis|
79710557|NCT00601406|Radiation|radiation therapy|
79710558|NCT02891486|Procedure|Spinal surgery|Elective spinal surgery performed
79710559|NCT00601562|Drug|Zidovudine|
79710560|NCT00601874|Drug|Pilocarpine|
79710561|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
79710562|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
79710563|NCT01097629|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
79710564|NCT01097629|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
79710565|NCT01097629|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
79849187|NCT05004090|Diagnostic Test|DNA methylation analysis|Genomic DNA will be extracted from 0.4 ml aliquots of each saliva sample using the kit manufacturer's suggested protocol, quantified with Qubit 2.0 (Invitrogen), and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed as described. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated and tabulated.
79849188|NCT05004090|Diagnostic Test|Proteomics analysis|Urine samples are collected using non-invasive methods and are prepared according to a procedure preparatory to quantitative recovery of exosomes: once thawed and centrifuged at 17,000 x g for 10 min at 4°C, the recovered supernatants are separated and centrifuged at 200,000 x g for 1 hr at 4°C. Exosome pellets are separated, washed repeatedly and resuspended in buffer (NH4HCO3, 0.1 mM ph=7.8). Protein concentration is estimated with the SPNTM Protein Assay kit and each sample (50 ± 0.5 μg protein) is digested with trypsin using a 1:50 (w/w) enzyme/substrate ratio at 37 °C over night (o/w). A second tryptic digestion is performed with an enzyme:substrate ratio of 1:100 (w/w) for 4h. Digested samples, centrifuged at 13,000 × g for 10 min, are purified and concentrated using PepClean C-18 columns. The samples obtained are analyzed by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry.
79849189|NCT05004090|Diagnostic Test|Still Face Paradigm|During an observational session, a short video recording of the mother-child interaction of approximately 10 minutes will be made in a semi-structured setting to assess the child's emotional regulation and social behavior. The interaction will be structured in 5 different phases according to the Still Face paradigm (Tronick et al., 1978): Play, Still#1, Reunion#1, Still#2, Reunion#2. Play: Mothers will be invited to interact with their babies for 10 minutes; Still: mothers will be asked to remain still while maintaining an unresponsive expressionless face and not to smile, touch, or talk to the child for 2 minutes (Still#1: 2 minutes; Still#2: 2 minutes); Reunion: mothers will be asked to resume the play activity with their own for an additional 2 minutes (Reunion#1: 2 minutes; Reunion#2: 2 minutes).
79849190|NCT05000931|Device|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
79710566|NCT00602108|Procedure|adjuvant therapy|
79849193|NCT04993235|Behavioral|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
79849194|NCT04993235|Behavioral|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
79849195|NCT04993235|Behavioral|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
79849196|NCT04982367|Device|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
79849197|NCT04982367|Device|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
79849198|NCT04979442|Drug|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
79849199|NCT04979442|Drug|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
79875130|NCT00331006|Drug|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
79277306|NCT02377635|Dietary Supplement|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
79547665|NCT05839964|Dietary Supplement|CBN and CBD|CBN and CBD in Gummy Format
79547666|NCT05839834|Diagnostic Test|Blood test|RNA sequencing of peripheral blood cells
79547667|NCT05839821|Behavioral|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
79710567|NCT00602108|Procedure|conventional surgery|
79710568|NCT00602108|Radiation|hypofractionated radiation therapy|
79710569|NCT00602108|Radiation|intraoperative radiation therapy|
79710570|NCT04325516|Behavioral|Daily activities|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
79710571|NCT04308031|Drug|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
79547668|NCT05839821|Behavioral|F-noRAS|finger-tapping without listening to RAS
79547669|NCT05839821|Behavioral|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
79547670|NCT05839821|Behavioral|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
79547671|NCT05839821|Behavioral|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
79547672|NCT05839821|Behavioral|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
79710572|NCT04308031|Drug|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60 Max dose: 0.25 once daily (QD)
79710573|NCT01324622|Device|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
79710574|NCT01324622|Procedure|laminectomy|standard procedure
79710575|NCT01096849|Drug|levofloxacin|
79710576|NCT01096849|Drug|plazomicin|
79710577|NCT01096849|Drug|placebo|
79710578|NCT02878447|Radiation|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
79710579|NCT04307173|Drug|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
79710580|NCT04307173|Drug|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
79849200|NCT04969887|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
79392104|NCT02615158|Behavioral|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
79710581|NCT04915261|Behavioral|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
79710582|NCT04915261|Behavioral|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
79252842|NCT06126848|Device|Ambient sensor system|Main study: A contactless non-intrusive ambient sensor system including infrared motion sensors combined with a contactless Emfit bed sensor will be installed in the home of single living study patients by using a commercially available System (Domo Health®, Lausanne) after informed consent has been obtained. Sensor data are prospectively followed over 3-6 months for predefined indicators of health deterioration. If indicators for health deterioration are present, patients will be called in to the hospital for cardiology consult by the study team including blood analysis for follow-up of BNP values and if necessary, therapy adaption.
79392105|NCT02615158|Behavioral|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
79547673|NCT05839782|Procedure|Mitral valve repair (PLM)|A mitral valve plasty is performed to treat mitral regurgitation
79547674|NCT05839782|Procedure|Mitral valve replacement|A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
79547675|NCT05839704|Procedure|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
79875131|NCT00302458|Drug|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
79875132|NCT00302458|Drug|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
79547676|NCT05839704|Procedure|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
79547677|NCT05839652|Drug|Midodrine Hydrochloride|Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
79547678|NCT05839613|Diagnostic Test|Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)|Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
79710583|NCT01324388|Biological|LY2189265|Administered subcutaneously
79547679|NCT05839587|Procedure|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
79547680|NCT05839587|Procedure|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
79710584|NCT01324388|Drug|Metoprolol|Administered orally
79710585|NCT01324388|Drug|Lisinopril|Administered orally
79710586|NCT01324388|Drug|Placebo|Administered subcutaneously
79547681|NCT05839548|Drug|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
79547682|NCT05839548|Drug|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
79710587|NCT01102777|Behavioral|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
79710588|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
79710589|NCT02878681|Drug|Ranibizumab|0.5 mg intravitreal injections
79710590|NCT02878681|Drug|Aflibercept|2 mg intravitreal injections
79710591|NCT02879461|Procedure|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
79710592|NCT01324310|Drug|Romidepsin|Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
79710593|NCT01324310|Drug|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
79710594|NCT05645666|Behavioral|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
79849201|NCT04969887|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
79849202|NCT04968132|Other|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
79849203|NCT04968132|Other|Standard care|Standard perioperative care, surgical treatment, and pain medications.
79849204|NCT04968054|Drug|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
79849205|NCT04968054|Drug|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
79849206|NCT04951804|Procedure|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
79849207|NCT04951804|Procedure|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
79849208|NCT04941469|Device|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
79849209|NCT04941469|Device|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
79849210|NCT04940299|Biological|Ipilimumab|Given IV
79710595|NCT04325672|Biological|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.
79849211|NCT04940299|Biological|Nivolumab|Given IV
79849212|NCT04940299|Biological|Tocilizumab|Given SC
79849213|NCT04936204|Device|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
79849214|NCT04936204|Device|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
79547683|NCT05839535|Behavioral|BDJ|BDJ is a mind-body intervention
79547684|NCT05839535|Device|tDCS|tDCS is a brain stimulation method.
79710596|NCT01102231|Drug|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
79547685|NCT05839535|Device|sham tDCS|sham tDCS
79547686|NCT05839535|Other|exercise|exercise including stretching and other activities.
79547687|NCT05839522|Diagnostic Test|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
79547688|NCT05839522|Diagnostic Test|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
79547689|NCT05839522|Diagnostic Test|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
79547690|NCT05839522|Diagnostic Test|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
79547691|NCT05839522|Diagnostic Test|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
79710597|NCT01102231|Drug|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
79710598|NCT01102231|Radiation|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
79710599|NCT04308733|Device|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
79710600|NCT02879539|Device|MP3000 sound coding strategy or ACE strategy with lower stimulation|
79710601|NCT01094743|Device|galyfilcon A prototype lens|Silicone hydrogel contact lens
79710602|NCT01094743|Device|lotrafilcon B lens|Silicon Hydrogel contact lens
79849215|NCT04931771|Device|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
79875133|NCT00302458|Drug|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
79547692|NCT05839522|Behavioral|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
79547693|NCT05839509|Drug|GH001|GH001 administered via inhalation
79547694|NCT05839327|Diagnostic Test|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
79252843|NCT06126835|Drug|Ozanimod|Women with UC exposed to ozanimod during pregnancy
79392106|NCT02615158|Behavioral|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
79547695|NCT05839275|Drug|Surufatinib|In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
79547696|NCT05839275|Drug|Sintilimab|200mg, d1, q3w
79547697|NCT05839275|Radiation|Radiotherapy|"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."
79547698|NCT05839262|Other|Conventional physical rehabilitation (CPR) / Active video games (AVG)|"In each session a routine of conventional exercises and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility).~AVG: Set of interactive video games available for the Nintendo Switch console."
79547699|NCT05839262|Other|Conventional physical rehabilitation (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
79547700|NCT05839249|Other|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
79547701|NCT05839236|Combination Product|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
79547702|NCT05839223|Other|Education|"educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped."
79710603|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
79710604|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
79252844|NCT06126835|Drug|Conventional therapy|Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
79392107|NCT02616250|Drug|Brimonidine 0.33% gel (Br)|
79710605|NCT01095835|Drug|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
79710606|NCT02878525|Procedure|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
79710607|NCT02878525|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
79710608|NCT04308577|Other|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
79710609|NCT04308811|Biological|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
79710610|NCT04308811|Combination Product|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
79710611|NCT04308811|Device|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
79710612|NCT02879773|Radiation|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
79710613|NCT04908865|Drug|Belimumab|Belimumab will be administered.
79710614|NCT04908865|Drug|Standard therapy|Standard therapy will be continued.
79710615|NCT04308421|Device|Red light|Low irradiation 650 nm +/- 5 nm red light
79392108|NCT02616250|Other|CD07805/47 (Br) placebo gel|
79710616|NCT01324232|Drug|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
79849216|NCT04931771|Device|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
79392109|NCT02616250|Drug|Ivermectin 1% cream (IVM)|
79392110|NCT02616250|Other|CD5024 (IVM) placebo cream|
79392111|NCT02974192|Other|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
79392112|NCT05443204|Other|Fortimel energy|Standard nutritional oral supplement
79710617|NCT01324232|Drug|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
79252845|NCT06126835|Drug|Advanced therapy|Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
79252846|NCT06126822|Drug|Zabdeno® booster|A single Zabdeno® booster vaccination
79252847|NCT06126822|Drug|Ervebo® booster|A single Ervebo® booster vaccination
79277307|NCT03534479|Drug|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
79277308|NCT00162253|Drug|BMS 587101|
79392113|NCT05443204|Other|Nutrision Advanced Diason Energy HP|Specifc nutritional oral supplement in diabetics patients
79392114|NCT02698410|Drug|Lanreotide (Autogel formulation) and Temozolomide|
79849217|NCT04915131|Device|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes."
79849218|NCT04897334|Device|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
79849219|NCT04897334|Device|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
79849220|NCT04897334|Behavioral|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
79547703|NCT05839197|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
79849221|NCT04887337|Procedure|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
79392115|NCT05731648|Device|Intrathecal balofen pump|Management of spasticity
79392116|NCT04340518|Device|Scleral lens|Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
79547704|NCT05839197|Drug|Camrelizumab plus Apatinib|"Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC."
79392117|NCT05731414|Behavioral|Cognitive Behavioural Therapy for Psychosis (CBTp)|Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness. This approach has demonstrated moderate to large improvements on symptoms and small to moderate effects on functioning. The first four sessions are devoted to building therapeutic rapport and developing collaborative treatment goals. The following phase focuses on developing formulations of why difficulties persist and using cognitive and behavioural change strategies. A longitudinal formulation is then offered to better understand how their difficulties developed. The final 2-4 sessions focus on consolidating the learning that occurred during treatment so that participants can maintain their improvement. Therapy homework is collaboratively assigned at the end of sessions to promote new learning in between sessions.
79277309|NCT02377557|Drug|Topical Steroids|
79547705|NCT05839171|Behavioral|music and mandala coloring|Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
79710618|NCT01324232|Drug|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
79277310|NCT02195765|Drug|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
79710619|NCT01324232|Drug|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
79710620|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
79710621|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
79710622|NCT04841083|Device|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
79710623|NCT04306783|Other|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
79710624|NCT05350891|Procedure|endoscopic surgery|endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
79710625|NCT01094119|Device|heated blanket|heated blanket
79710626|NCT01094119|Device|heated pad|patients will be warmed with a heated pad during surgery.
79710627|NCT01323920|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 IV
79710628|NCT01323920|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
79277311|NCT02195765|Procedure|Open flap debridement|Open flap debridement
79710629|NCT01323920|Drug|Methotrexate|Methotrexate 15 mg/m^2 IV
79710630|NCT01093885|Drug|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
79710631|NCT02878369|Procedure|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
79277312|NCT02368977|Device|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
79392118|NCT05731414|Behavioral|Cognitive Remediation Therapy (CR)|Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials. ABCR involves practicing computerized training exercises with difficulty level dynamically titrated to improve neurocognitive abilities. Then participants engage in strategy discussions with other group members to develop new cognitive strategies. Finally, participants complete role-play simulations of real-world activities to practice their cognitive strategies in simulations of everyday life. ABCR is more effective for improving functioning than traditional approaches to CR. Homework consists of additional cognitive training and practicing cognitive strategies in everyday life.
79849222|NCT04887337|Other|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
79849223|NCT04879199|Diagnostic Test|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
79849224|NCT04879199|Diagnostic Test|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
79849225|NCT04868565|Drug|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
80016971|NCT04088656|Other|Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization|The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
80016972|NCT03556176|Behavioral|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
80016973|NCT03556176|Behavioral|Quiet rest|Quiet rest during 30 min
79547706|NCT05839132|Procedure|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
79547707|NCT05839080|Behavioral|Gardens to Bellis|In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.
79547708|NCT05839080|Behavioral|No intervention|Pupils are not receiving any intervention
79710632|NCT01101997|Device|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
79710633|NCT00597597|Drug|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
79710634|NCT02891967|Other|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
79710635|NCT02891967|Other|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
79710636|NCT00598065|Other|PET/CT|Synchronized PET/CT Imaging
79710637|NCT02892045|Device|MMG|neuromuscular monitoring device
79710638|NCT04326621|Other|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
79710639|NCT04326621|Other|Control|exercises
79710640|NCT04207827|Behavioral|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
79710641|NCT04207827|Behavioral|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
79710642|NCT04207827|Other|Usual Care|Usual postnatal care
79710643|NCT00598299|Procedure|venous puncture|venous puncture
79710644|NCT00598299|Other|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
79710645|NCT00598377|Drug|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
79710646|NCT04326543|Diagnostic Test|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
79710647|NCT04326387|Diagnostic Test|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
80016974|NCT00372944|Drug|AZD6244|oral capsule
79849226|NCT04858776|Combination Product|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
79849227|NCT04858776|Combination Product|Perivascular sham|Saline delivery around target vein segment(s)
79849228|NCT04849416|Drug|LOXO-305|Administered orally.
79849229|NCT04831476|Other|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
79849230|NCT04825847|Device|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
79849231|NCT04825847|Other|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at [0.8-1.2] MAC.
79849232|NCT04815473|Procedure|Valvulotomy|Valvulotomy of the venous valves
79849233|NCT04806373|Drug|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
79849234|NCT04806373|Drug|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
79849235|NCT04804280|Genetic|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
79710648|NCT04326387|Diagnostic Test|Public Health England Gold Standard|Reverse Transcription PCR
79710649|NCT04326387|Diagnostic Test|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
79710650|NCT04326387|Diagnostic Test|Radiological Detection|Chest X-ray & CT Scan detection of viral infection in the lungs
79849236|NCT04804280|Diagnostic Test|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
79849237|NCT04796415|Behavioral|the DEMA-Pro intervention|Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
79849238|NCT04786340|Drug|Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution|WST-057
79849239|NCT04786340|Drug|Placebo: WST-057 4mL topical solution|Placebo
79849240|NCT04763577|Other|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
80016975|NCT00372944|Drug|capecitabine|oral tablet
79547709|NCT05839067|Behavioral|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
79710651|NCT00598533|Device|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
79252848|NCT06126809|Device|Steep-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
79252849|NCT06126809|Device|Flat-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
79252850|NCT06126809|Device|Sham-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
79710652|NCT00598533|Device|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
79710653|NCT00598845|Procedure|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
79710654|NCT04207671|Procedure|Complete omission of chest tube|No chest tube implacement
79392119|NCT05731414|Behavioral|Befriending|Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth. Befriending consists of 1-hour individual sessions once per week and involves a series of conversations similar to those one might have with a social acquaintance. These conversations involve discussion of neutral topics without problem-solving, coping strategies, or exploration of emotion. If emotional or mental health-related topics are brought up therapists redirect back to a neutral topic.
79392120|NCT05731414|Behavioral|Sham Cognitive Remediation|Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion. Participants practice similar computerized exercises to ABCR, however, the exercises do not increase in difficulty. Participants then discuss enjoyment of the exercises but any discussion of cognitive strategies is redirected back to a neutral topic. We have previously found this condition to be an effective control for CR, with similar engagement to the active training group.
79392121|NCT02395146|Procedure|Monitoring|intraoperative EBSLN monitoring
79547710|NCT05839054|Device|Virtual Reality audio and visual glass (Roller Coasters, group 1)|During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
79547711|NCT05839054|Device|Virtual Reality audio and visual glass (Wild Dolphins, group 2)|During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
79547712|NCT05839015|Behavioral|mHealth Intervention Based on Self-Compassion|Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
79547713|NCT05839015|Behavioral|Psychoeducation Intervention|Psychoeducational intervention promotes the learning of emotions, thoughts and behaviors through the description and explanation of psychological dimensions.
79547714|NCT05839002|Procedure|nCRT|ESCC patients that recieved surgery and nCRT.
79547715|NCT05838989|Device|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
79547716|NCT05838989|Other|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
79547717|NCT05838989|Other|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
79547718|NCT05838976|Diagnostic Test|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
79547719|NCT05838950|Other|high-intensity interval training intervention|Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
79547720|NCT05838924|Other|PHYSICAL ACTIVITY + VIRTUAL REALITY|"The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
79710655|NCT04207671|Procedure|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
79710656|NCT00599703|Other|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
79710657|NCT00599781|Genetic|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
79710658|NCT00599859|Dietary Supplement|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
79710659|NCT00599859|Dietary Supplement|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
79392122|NCT02394678|Device|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
79710660|NCT00599937|Drug|ATRA|early introduction of ATRA
79849241|NCT04739358|Drug|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
80016976|NCT05228704|Behavioral|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
79392123|NCT00365638|Drug|simvastatin|
79392124|NCT02699892|Drug|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
79392125|NCT04481178|Other|Laser (QS, Picosecond laser)|QS-Nd Yag Laser, Picosecond laser
79252851|NCT06126744|Biological|MVR-C5252|MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
79252852|NCT06126731|Drug|Enzalutamide 40mg|Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
79392126|NCT05731258|Drug|Liposomal doxorubicin containing regimen|Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
79252853|NCT06126731|Drug|Amoxicillin 500mg|"Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder"
79392127|NCT04340908|Drug|Dapagliflozin 10 MG|10 mg tablet, oral, once daily, 1-year treatment, postoperation
79547721|NCT05838924|Other|PHYSICAL ACTIVITY|"The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
79547722|NCT05838898|Device|Specular microscopy|Non-contact Specular microscopy is a non-invasive method that allows for in vivo study of corneal endothelium.
79547723|NCT05838872|Device|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
79547724|NCT05838846|Drug|Inhaled Milrinone|Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization (21-23), inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
79710661|NCT00599937|Drug|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
79710662|NCT02891421|Behavioral|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
79849242|NCT04734743|Other|cystic fibrosis|Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
79547725|NCT05838846|Drug|IV Milrinone|Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
79547726|NCT05838833|Drug|INV-001|Patient will be assigned to one of three arms.
79547727|NCT05838820|Diagnostic Test|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
79547728|NCT05838820|Diagnostic Test|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
80016977|NCT02099136|Procedure|UV Light Therapy|Undergo UV-irradiation
80016978|NCT02099136|Other|Placebo|Given PO
80016979|NCT02099136|Drug|Celecoxib|Given PO
80016980|NCT02099136|Procedure|Biopsy|Undergo skin biopsy
79252854|NCT06126731|Drug|Metronidazole 400mg|"Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 & break line on one side and plain on other"
79392128|NCT04340908|Drug|Placebos|matching placebo tablet, oral, once daily, 1-year treatment, postoperation
79392129|NCT02398110|Procedure|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
79392130|NCT02398110|Procedure|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
79392131|NCT04480320|Procedure|pericapsular nerve group block|Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
79849243|NCT04730167|Other|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
79849244|NCT04728048|Procedure|Dural puncture epidural|already described
79849245|NCT04728048|Procedure|Standard epidural|already described
79710663|NCT02891421|Other|Standard Care|Standard Care: Participants received standard care
79710664|NCT00600093|Drug|Amantadine|IV Amantadine 200mg *1/d at the beginning of surgery and 24 hours following surgery
79849246|NCT04717635|Biological|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
79849247|NCT04714411|Drug|Omadacycline|Omadacycline monotgherapy
79849248|NCT04713735|Dietary Supplement|Control: Placebo|Placebo
79849249|NCT04713735|Dietary Supplement|bovine lactoferrin supplement|600 mg
79849250|NCT04678557|Combination Product|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
79849251|NCT04652752|Device|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
79849252|NCT04647656|Device|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
79849253|NCT04647656|Device|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
79849254|NCT04636905|Other|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
79849255|NCT04620551|Device|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
79849256|NCT04599946|Dietary Supplement|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
79849257|NCT04599946|Dietary Supplement|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
79849258|NCT04591808|Drug|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
79849259|NCT04591808|Drug|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
79849260|NCT04591808|Drug|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
79849261|NCT04589065|Device|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
79849262|NCT04588545|Radiation|Radiation Therapy|Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
79849263|NCT04588545|Drug|Pertuzumab|Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
79710665|NCT00600249|Drug|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
79710666|NCT00600249|Drug|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
79710667|NCT00600327|Device|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
79849264|NCT04588545|Drug|Trastuzumab|Participants will be treated at a fixed dose of 80 mg trastuzumab.
79849265|NCT04551053|Drug|parsaclisib|parsaclisib will be administered QD orally
79849266|NCT04551053|Drug|ruxolitinib|ruxolitinib will be administered BID orally
79849267|NCT04551053|Drug|placebo|placebo will be administered QD orally
79849268|NCT04545489|Behavioral|Intervention group|This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)
79849269|NCT04545489|Behavioral|Education control group|This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
79849270|NCT04544202|Drug|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~Dabrafenib, 150 mg, twice daily (BID);~Trametinib, 2.0 mg, once daily (QD)"
79849271|NCT04544202|Drug|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
79849272|NCT04544202|Drug|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
79392132|NCT02398266|Drug|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
79710668|NCT00600327|Device|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
79392133|NCT05730790|Other|Cognitive-motor dual task training (DTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage > 80%."
79710669|NCT00600405|Drug|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
79710670|NCT00600405|Drug|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
79710671|NCT00600561|Behavioral|MBSR|Mindfulness-Based Stress Reduction Intervention
79710672|NCT01324830|Drug|day 1 to day 5|low to high dose
79710673|NCT01324830|Drug|day 1 to day 14|low to high dose
79710674|NCT02891577|Procedure|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
79710675|NCT00600639|Device|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
79547729|NCT05838040|Other|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
79547730|NCT05838040|Other|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
79710676|NCT00600639|Drug|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
79710677|NCT00600639|Drug|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
79710678|NCT00623025|Drug|Creon 25000|6 to 9 capsules Creon 25000 per day
79710679|NCT00623025|Drug|Placebo|6 to 9 capsules placebo per day
79710680|NCT00600795|Other|CSF collection|CSF collection at time of VPS insertion
79710681|NCT00602160|Drug|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
79710682|NCT00600873|Drug|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
79710683|NCT04325997|Device|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
79710684|NCT04325997|Device|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
79710685|NCT01324440|Biological|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
79710686|NCT01324440|Biological|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
79710687|NCT00598611|Drug|desloratadine|singel dose, oral, 20 mg
79710688|NCT00598611|Drug|desloratadine|single dose, oral, 5 mg
79849273|NCT04543097|Behavioral|Vocational Support|"Participants randomised to receive vocational advice will all be offered:~Step 1, contact by phone to undertake an assessment with a trained Vocational Support Worker (VSW) to identify obstacles to Return to Work (RTW) and support RTW planning.~Step 2, face-to-face (in person or by videoconference) in-depth discussion of obstacles to RTW and further support for RTW planning.~Step 3, contact by the VSW (with participant consent) with the participants' workplace.~The frequency of contact will be individualised to the needs of participants and the offer of support continued until sustained RTW (defined as return to any work for at least 4 weeks) or until 6 months of absence, after which participants will be signposted to other services."
79710689|NCT04325724|Other|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
79710690|NCT04325724|Other|Dermatological evaluation|treatment and evaluation
79710691|NCT04325724|Other|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
79710692|NCT04325724|Other|para clinical data|biological data, medical imaging data
79710693|NCT04325724|Other|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
79710694|NCT00601185|Procedure|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
79849274|NCT04536038|Behavioral|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
79849275|NCT04496154|Dietary Supplement|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
79849276|NCT04490655|Behavioral|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
79849277|NCT04490655|Behavioral|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
79849278|NCT04450797|Device|US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).|"US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance."
79849279|NCT04450797|Device|Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).|"Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet."
79849280|NCT04446273|Device|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
79849281|NCT04441203|Device|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
79849282|NCT04415333|Drug|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
79849283|NCT04415333|Drug|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
79849284|NCT04409457|Other|fasting state|16 hours of fasting
79392134|NCT05730790|Other|Cognitive single task training (CSTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage > 80%."
79392135|NCT05730790|Other|Motor single task training (MSTT)|For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
79392136|NCT02394522|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
79547731|NCT05837702|Procedure|ESPB|Erector spinae plane block
79547732|NCT05837702|Procedure|PVB|Paravertebral Block
79547733|NCT05837702|Procedure|CONTROL|No block has been done
79547734|NCT05837650|Behavioral|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
79710695|NCT00598143|Behavioral|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
79710696|NCT00598143|Behavioral|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
79710697|NCT00601263|Drug|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
80016981|NCT02099136|Other|Imaging Biomarker Analysis|Correlative studies
79392137|NCT02394522|Device|Active Ingredient|Transfluthrin (Active ingredient)
79392138|NCT02394522|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
79392139|NCT05730634|Drug|Atorvastatin 40 Mg Oral Tablet|Atorvastatin 40mg once daily for three months
79392140|NCT02394366|Other|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
79392141|NCT02394366|Other|OHS base only|Olive and beeswax salve base
79547735|NCT05837403|Procedure|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
79547736|NCT05837403|Drug|Nitroglycerin ointment|application of the ointment twice daily
79547737|NCT05837208|Other|RV4369A cosmetic product|"The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician."
79547738|NCT05836935|Radiation|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
79547739|NCT05836935|Radiation|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
79547740|NCT05836610|Drug|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
79547741|NCT05835804|Drug|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
79547742|NCT05833048|Procedure|Rectus sheath block|Participants will receive an ultrasound guided rectus sheath block with local anesthetic
79547743|NCT05832944|Device|ultrasound guided hyomental distance|measuring the hyomental distance by ultrasound guidance
79547744|NCT05832866|Other|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
79547745|NCT05832866|Other|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
79547746|NCT05830630|Drug|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
79547747|NCT05830630|Drug|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
79547748|NCT05827367|Device|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
79547749|NCT05827367|Other|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
79710698|NCT04325490|Drug|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
79710699|NCT04325490|Drug|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
80016982|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
79849285|NCT04409457|Other|fed state|fed a standardized meal
79849286|NCT04409457|Other|magnetic resonance imaging|neuroimaging with computational modeling
79849287|NCT04400253|Behavioral|SAATH Intervention|SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
80016983|NCT00117650|Biological|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
79392142|NCT03167814|Dietary Supplement|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
79392143|NCT05705830|Device|Pulse magnetic therapy|Pulse magnetic therapy SM-II (2019102133903)
79392144|NCT05705830|Drug|Selective serotonin reuptake inhibitors （SSRI）|Anti-anxiety Drugs
79392145|NCT05705830|Device|Shame magnetic therapy|Shame magnetic therapy
79710700|NCT00601341|Other|lumbosacral joint manipulation|lumbosacral joint manipulation
79710701|NCT00601341|Other|lumbar passive range of motion|lumbar passive range of motion
79710702|NCT00601341|Other|No active intervention|Lie on exam table for 3 minutes
79710703|NCT00601497|Device|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
79710704|NCT00601575|Drug|Lithium|
79710705|NCT00601653|Behavioral|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
79710706|NCT00601653|Behavioral|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
79710707|NCT00601809|Other|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
79849288|NCT04388761|Drug|Allogeneic adipose derived mesenchymal stem cells|Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
79849289|NCT04338893|Procedure|Device: Persona Total Knee|The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice
79849290|NCT04338893|Procedure|Device: NexGen Total Knee|The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice
79849291|NCT04338893|Procedure|Device: Vanguard Total Knee|The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
79849292|NCT04293939|Diagnostic Test|Functional Magnetic Risonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (~15 cm area) with a soft brush at a velocity of ~5 cm/s Stimulus blocks will last for ~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
79849293|NCT04293523|Drug|ELOCTA|Extended half-life factor VIII product
79849294|NCT04280978|Diagnostic Test|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
79849295|NCT04279587|Behavioral|Residential camp|Intensive education at a residential camp.
79849296|NCT04253821|Other|muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index|The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
79404259|NCT05229276|Other|Sternum Guard|"The intervention being assessed is a surgical drape used as a cover of sternal bones and the neighboring structures exposed during median sternotomy named Sternum Guard.~Sternum guard® is a single use, sterile surgical drape with modified cellulose designed specifically to reduce the risk of surgical site infection (SSI).~It is made of 4 parts, the main part is in contact with the retractors and the sternum edge. It is made of carboxymethylated cellulose (CMC) spunlace which makes direct contact with the sternum edges. It contributes to blood absorption, to decreasing of pH environment, and to haemostatic action through a physical effect (compression); another part was made from hydrophilic spunbond (swabs) allowing blood absorption, comfort and protection"
79547750|NCT05827367|Other|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
79547751|NCT05826132|Other|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
79547752|NCT05826132|Other|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
79710708|NCT00601809|Drug|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
79710709|NCT00601887|Drug|Meloxicam|
79710710|NCT02891499|Procedure|Low-level laser therapy|"Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
79547753|NCT05823753|Drug|Cannabidiol|"The CBD product to be used in this study is Epidiolex (Jazz Pharmaceuticals/Greenwich), a plant-derived, highly purified CBD oral solution that is FDA approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.~Doses will be 300 mg/d or 900 mg/d according to participants' assigned condition. Participants will receive CBD or placebo oral solution twice daily (evenly split doses at morning and evening meals) for three days (to achieve steady state) following the baseline assessment (day 0), and in the morning of day 4 (before the post-test)."
79547754|NCT05823753|Drug|Placebo|Placebo solution (excipients only, also by Jazz Pharmaceuticals/Greenwich).
79710711|NCT02891499|Procedure|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
79547755|NCT05823402|Diagnostic Test|SPECT/CT|SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
79547756|NCT05822388|Procedure|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
79547757|NCT05820464|Diagnostic Test|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
79849297|NCT04249622|Other|Best Practice|Given standard of care pertuzumab-based chemotherapy
79252855|NCT06126731|Drug|Vancomycin 125mg|"Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass"
79252856|NCT06126731|Drug|Ciprofloxacin 500g|"White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side"
79392146|NCT05745792|Other|Description of clinical, immunological and tumor features of patients harboring Hu Abs|This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
79392147|NCT02398032|Device|CPAP nasal|During the night
79392148|NCT02398032|Device|sham CPAP nasal|During the night
79392149|NCT02397798|Behavioral|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
79392150|NCT02397798|Behavioral|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
79392151|NCT05681494|Procedure|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
79392152|NCT05681494|Procedure|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
79392153|NCT05745714|Drug|Ruxolitinib|oral
79392154|NCT05745714|Drug|Venetoclax|oral
79392155|NCT05745714|Drug|Dexamethasone|oral/intravenous
79547758|NCT05813158|Drug|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
79547759|NCT05813158|Drug|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
79547760|NCT05805683|Drug|Calcitonin|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
79547761|NCT05805683|Drug|Placebo|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
79547762|NCT05803057|Device|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
79547763|NCT05803057|Device|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
79547764|NCT05799651|Biological|Glycovax-002|Intramuscular injection of vaccine against SARS-CoV-2
79547765|NCT05797051|Diagnostic Test|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
79547766|NCT05793996|Drug|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
79710712|NCT01325493|Drug|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
79849298|NCT04249622|Other|Questionnaire Administration|Ancillary studies
79392156|NCT05745714|Drug|Cyclophosphamide|intravenous
79849299|NCT04249622|Drug|Rifaximin|Given PO
79547767|NCT05793996|Other|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
79849300|NCT04249544|Drug|Pramipexole|1mg of pramipexole
79547768|NCT05793762|Device|Left virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual left hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
79849301|NCT04249544|Drug|Placebo|1mg equivalent of placebo
79849302|NCT04230980|Drug|Gabapentin|Gabapentin 600mg tablet
79849303|NCT04230980|Drug|Placebo|Placebo tablet
79849304|NCT04218968|Drug|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
79849305|NCT04216381|Diagnostic Test|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
79849306|NCT04208464|Drug|Baricitinib|4mg daily for 24 weeks from baseline
79849307|NCT04208464|Drug|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
79252857|NCT06126718|Drug|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
79252858|NCT06126718|Drug|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
79547769|NCT05793762|Device|Right virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual right hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
79547770|NCT05779826|Other|Play dough|In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
79252859|NCT06126705|Drug|Radiation: 18F-AlF-FAPi-04|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
79849308|NCT04201223|Behavioral|FLARE Intervention|[See arm/group descriptions]
79849309|NCT04195685|Procedure|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
79252860|NCT06126705|Drug|Radiation: 18F-FDG|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
79392157|NCT05745714|Drug|Cytarabine|intravenous
79392158|NCT05745714|Drug|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
79392159|NCT04840030|Behavioral|Multimodal intervention (MM-int)|"Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication"
79392160|NCT02974270|Drug|Leuprolide|
79547771|NCT05757856|Drug|NDX-3315 and NDX-3324|Oral solution
79547772|NCT05749029|Behavioral|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~The Foundations of Self-Compassion~Developing your Compassionate Self~Deepening the Compassionate Relationship with Yourself~Self-compassion in Everyday Life."
79547773|NCT05748496|Behavioral|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
79710713|NCT01325493|Drug|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
79710714|NCT01323972|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
79710715|NCT01325337|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79849310|NCT04192344|Drug|ABSK021|ABSK021 oral capsule
79849311|NCT04188236|Device|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
79547774|NCT05746845|Biological|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
79547775|NCT05743491|Other|Standard Care|Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
79547776|NCT05743491|Behavioral|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
79547777|NCT05731791|Radiation|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
79849312|NCT04184882|Drug|Bocidelpar|Oral
79547778|NCT05730933|Behavioral|Intervention|Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
79710716|NCT01325337|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79710717|NCT01325337|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79710718|NCT01325337|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
79710719|NCT01325337|Drug|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
79710720|NCT01324947|Drug|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
79710721|NCT01101841|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
79849313|NCT04184882|Drug|Placebo|Oral
79710722|NCT01101841|Drug|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
79710723|NCT04952545|Drug|ALXN2050|Oral tablet.
79710724|NCT04952545|Drug|Placebo|Oral tablet.
79710725|NCT01324401|Drug|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
79849314|NCT04164225|Behavioral|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
79849315|NCT04164225|Behavioral|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
79849316|NCT04147819|Drug|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
79710726|NCT02877511|Drug|BAY987517|Applied liberally to the skin (Formulation: Y73-161
79710727|NCT02877511|Drug|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
79710728|NCT05645679|Device|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
79710729|NCT01323660|Drug|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
79710730|NCT01323660|Drug|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
79710731|NCT01323660|Drug|GSK573719 125|125mcg QID
79710732|NCT01323660|Drug|GSK573719 62.5|62.5mcg QID
79710733|NCT01323660|Drug|GW642444 25|25mcg QID
79710734|NCT01323660|Device|placebo|Comparator QID
79710735|NCT01324323|Drug|Romidepsin|14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
79710736|NCT01324323|Drug|Rifampin|600 mg oral once daily on Days 4-8
80016984|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
79392161|NCT02394444|Other|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
79392162|NCT02394288|Procedure|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
79392163|NCT03167424|Device|Treatment of restenosis|Treatment of in-stent restenosis
79392164|NCT02397876|Other|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
79392165|NCT00366808|Procedure|LASIK surgery|
79849317|NCT04147819|Drug|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
79547779|NCT05725239|Device|Vagus Nerve Stimulation|All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.
79547780|NCT05725239|Device|Transcranial Magnetic Stimulation|Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
79252861|NCT06126679|Procedure|1-year dietary and physical activity intervention of childhood obesity|"The 1-year lifestyle intervention includes intensive, family-based diet and physical activity counselling. Children with their parents meet the pediatrician two times, the specialist nurse five times and the clinical nutritionist three times during the 1-year intervention. One of the meetings with the clinical nutritionist is only for parents and the child is with the nurse at the same time.~The participants in the intervention group are advised and motivated to increase their regular daily physical activity and to reduce sedentary habits. They have one group session for the training in the gymnasium with physical education instructor. The physical education instructor gives a voluntary lecture for parents about increasing physical activity and reducing sedentary time."
79252862|NCT06126640|Drug|SHR-A1811|Lyophilized powder injection, 100mg / bottle, intravenous drip
79547781|NCT05720689|Other|using relaxing music|music diffusion during dental care under MEOPA
79547782|NCT05720689|Other|No relaxing music|dental care under MEOPA without music
79547783|NCT05701085|Other|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
79547784|NCT05700799|Behavioral|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
79547785|NCT05693792|Other|Observational|No treatment regimen will be deployed in this follow-up study.
79547786|NCT05686005|Drug|Oral tranexamic acid|4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
79547787|NCT05686005|Drug|Intravenous tranexamic acid|15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
79547788|NCT05682950|Radiation|online adaptive radiotherapy|CTV covers pelvis.
79547789|NCT05681923|Other|Questionnaires|Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
79547790|NCT05681923|Other|Biospecimen collection|urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
79547791|NCT05681923|Other|Neurodevelopmental assessment visit|"Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, between 60 and 66 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment."
79547792|NCT05681923|Other|DNA collection|If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
79710737|NCT05344963|Drug|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
79710738|NCT05645601|Biological|CD19-CAR-NK|The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10^6/kg, 2x10^7/kg) after FC chemotherapy.
79710739|NCT02879227|Drug|Cisplatin|Arm cisplatin : 75mg/m2, day n*1 and day n*22, And radiotherapy 50 Gy, 2Gy/f
79710740|NCT02879227|Drug|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
79710741|NCT05645445|Device|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
79849318|NCT04140448|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
79849319|NCT04140448|Device|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
79849320|NCT04125589|Behavioral|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
79849321|NCT04125589|Behavioral|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
79849322|NCT04120493|Genetic|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
79710742|NCT01323582|Drug|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
79739731|NCT03900832|Other|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
79710743|NCT01323582|Drug|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
79710744|NCT00626041|Other|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
79392166|NCT04480788|Biological|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
79710745|NCT05367765|Drug|Flumatinib|Flumatinib 600mg orally daily
79710746|NCT05367765|Drug|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
79392167|NCT04053192|Procedure|BAV|BAV
79392168|NCT04053192|Procedure|BAV + TAVR|BAV + TAVR
79392169|NCT04053192|Procedure|SAVR|Surgical aortic valve replacement (SAVR)
79547794|NCT05658757|Other|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
79710747|NCT05645367|Other|No intervention|This is a post-hoc analysis of a cross-sectional study.
79710748|NCT01323621|Drug|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
79710749|NCT01323621|Drug|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
79849323|NCT04120493|Other|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
79849324|NCT04106570|Other|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
79710750|NCT01323621|Drug|Double-dummy placebo|inhalation powder
79710751|NCT01323621|Drug|Salbutamol as needed|inhalation powder
79710752|NCT00623298|Behavioral|Narrative Exposure Therapy|
79710753|NCT00623298|Behavioral|group IPT|
79710754|NCT00623298|Other|6 months-baseline|
79710755|NCT01323192|Drug|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
79710756|NCT01323192|Drug|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
79710757|NCT01323387|Device|Interbody Fusion|allograft spacer + anterior plate
79710758|NCT05645289|Drug|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
79710759|NCT05645289|Drug|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
79710760|NCT00623259|Biological|MVA-mBN120B|
79710761|NCT02891343|Other|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
79710762|NCT01321749|Procedure|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
79710763|NCT01320033|Drug|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
79710764|NCT01320033|Drug|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
79849325|NCT04100174|Radiation|focal brachytherapy boost to SBRT|As above
79849326|NCT04087096|Drug|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
79849327|NCT04087096|Drug|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
79849328|NCT04087096|Drug|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
79849329|NCT04075435|Drug|high CBD/low THC sublingual solution|Hemp derived solution to be administered sublingually twice daily.
79392170|NCT03167580|Procedure|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
79392171|NCT03167580|Procedure|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
79392172|NCT03167268|Drug|Lycopene|
79392173|NCT03167268|Other|Placebo|
79392174|NCT03167502|Other|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
79392175|NCT03167502|Other|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
79392176|NCT02393898|Drug|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
79392177|NCT02393898|Drug|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
79710765|NCT01320033|Drug|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
79710766|NCT01101061|Drug|Romosozumab|Administered by subcutaneous injection
79849330|NCT04069299|Drug|68Ga-DOTATATE|The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection
79710767|NCT01101061|Drug|Placebo|Administered by subcutaneous injection
79710768|NCT04325295|Procedure|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached > 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
79710769|NCT04325295|Drug|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
79710770|NCT02891187|Behavioral|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
79849331|NCT04069299|Diagnostic Test|Positron Emission Tomography (PET) Scan|PET scan is an imaging test using radioactive tracers.
79849332|NCT04067297|Other|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of ~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
79849333|NCT04052828|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
80016985|NCT00117650|Other|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
80016986|NCT02099214|Device|3Tesla cardiac MRI|
79252863|NCT06126640|Drug|Trastuzumab Emtansine|Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
79392178|NCT02393898|Drug|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
80016987|NCT02099214|Device|Electrocardiogram (EKG)|
79392179|NCT04394962|Device|Virtual reality|Patients randomized to the study group, will be provided with the VR headset and sensors. The VR exposure will take place before the ET procedure, during their routine pre-transfer waiting period, in a private room. The patient will be able to choose between three different calming VR environments (3 scenes: beach sunset, palm tree patio or redwood forest) and will be exposed to the chosen VR environment for a continuous duration of 15-30 minutes. The VR exposure will be passive, and the patient can control her observation inside the environment by herself, simply by moving her head. During this period, at any time and for any reason, the patient can discontinue the use of the VR session simply by self-removing the helmet
79392180|NCT02393820|Drug|pazopanib|treatment will be given until progression or unacceptable toxicity .
80016988|NCT02099214|Biological|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
80016989|NCT02099214|Biological|Pregnancy test|Beta-hCG
79252864|NCT06126627|Behavioral|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
79252865|NCT06126601|Other|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
79547795|NCT05658757|Other|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
79252866|NCT06126588|Drug|Everolimus|Patient will be treat during 7 months of Everolimus
79710771|NCT02891187|Behavioral|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
79710772|NCT05644743|Device|gemcitabine + cisplatin|Gemcitabine intravenous drip, day 1, 8； Cisplatin intravenous drip, day 1； 3 weeks is a cycle, and 6 cycles are used continuously.
79710773|NCT01317615|Drug|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
79710774|NCT01317615|Drug|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
79710775|NCT01317615|Drug|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
79710776|NCT02891109|Biological|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
79710777|NCT05644509|Biological|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
79710778|NCT01078675|Drug|rosuvastatin calcium|5 mg, oral, once daily, 24 months
79710779|NCT01078675|Drug|rosuvastatin calcium|10 mg, oral, once daily, 24 months
79710780|NCT01078675|Drug|rosuvastatin calcium|20 mg, oral, once daily, 24 months
79392181|NCT04741048|Device|CI624 Slim 20 Electrode|Cochlear Ltd CI624 cochlear implant with Slim 20 Electrode
79547796|NCT05658757|Other|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
79710781|NCT04301791|Other|nutritional status|impact of nutritional status on clinical outcome of children admitted in PICU
79710782|NCT02878135|Procedure|fast application|
79547797|NCT05654519|Drug|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
79710783|NCT02878135|Procedure|slow application|
79710784|NCT04875793|Diagnostic Test|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
79710785|NCT02877199|Other|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
79710786|NCT02879149|Device|AUGMENT® Bone Graft|AUGMENT® Bone Graft
79710787|NCT02879149|Procedure|Standard of Care|Autologous Bone Graft
79710788|NCT02877277|Dietary Supplement|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
79710789|NCT02877277|Dietary Supplement|Placebo|Oral intake of placebo tablet daily for 56 days
79849334|NCT04047563|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
79392182|NCT04740970|Drug|JNJ-64304500|JNJ-64304500 injection will be administered subcutaneously.
79392183|NCT04740970|Drug|Placebo|Matching placebo injection will be administered subcutaneously.
79392184|NCT04309084|Biological|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
79392185|NCT04340128|Drug|Meglumine antimoniate|Intra-lesional injection once a week, 0.1/cm2
79392186|NCT04340128|Drug|Meglumine antimoniate|Intra-lesional injection twice a week, 0.1/cm2
79392187|NCT04740502|Procedure|Parahtyroidectomy|Parathyroidectomy
79392188|NCT04145674|Drug|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
79392189|NCT04145674|Other|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
79710790|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
79710791|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
79710792|NCT04306705|Drug|Tocilizumab|Administered as an intravenous infusion.
79710793|NCT04306705|Other|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
79710794|NCT04306705|Procedure|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
79710795|NCT01322490|Biological|PROSTVAC-V|
79710796|NCT01322490|Biological|PROSTVAC-F|
79710797|NCT01322490|Drug|GM-CSF|
79710798|NCT01322490|Other|GM-CSF Placebo|
79710799|NCT01322490|Biological|Placebo|PROSTVAC V/F Placebo
79710800|NCT02877355|Drug|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
79710801|NCT01314261|Drug|ABT-267|5 mg or 25 mg tablets
79710802|NCT01314261|Drug|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
79710803|NCT01314261|Drug|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
79547798|NCT05643196|Device|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
79710804|NCT01314261|Other|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
79849335|NCT04047563|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
79849336|NCT04037397|Drug|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
79710805|NCT02891616|Drug|fludeoxyglucose F 18|
79710806|NCT02891616|Device|Positron emission tomography-computed tomography|
79849337|NCT04037397|Procedure|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
79392190|NCT00366964|Device|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
79392191|NCT00366964|Device|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
79392192|NCT02698176|Drug|Birabresib|Administered as an oral capsule in a fasted state
79392193|NCT02393976|Dietary Supplement|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
79392194|NCT02393976|Dietary Supplement|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
79392195|NCT02394054|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
79392196|NCT02394054|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
79547799|NCT05643196|Device|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
79547800|NCT05643196|Device|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
79710807|NCT02891616|Drug|18F-fluorothymidine|
79710808|NCT02891616|Device|Positron emission tomography-magnetic resonance imaging|
79849338|NCT04029974|Device|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
79252867|NCT06126575|Drug|Elacestrant dihydrochloride|A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
79849339|NCT04029233|Device|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
79252868|NCT06126510|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)|VG161:1.0×10^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
79252869|NCT06126497|Drug|Ropanicant|Tablet
79710809|NCT01321710|Behavioral|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
79710810|NCT01321710|Behavioral|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
79849340|NCT04023045|Device|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
79849341|NCT04023045|Device|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
79252870|NCT06126484|Procedure|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
79252871|NCT06126458|Other|shooting performance|collecting total points after 72 target shootings done
79849342|NCT04006769|Drug|Entacapone|Entacapone tablet
79392197|NCT03167190|Procedure|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
79392198|NCT03167190|Procedure|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
79392199|NCT02393742|Drug|Sodium nitrite|
79392200|NCT02393742|Drug|Placebo|
79392201|NCT02393664|Drug|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
79392202|NCT02393664|Drug|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
79547801|NCT05624294|Drug|CS0159|Tablets administered orally
79849343|NCT04006769|Drug|Imatinib Mesylate|Imatinib Mesylate tablet
79849344|NCT03999138|Diagnostic Test|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of < 3 minutes.
79849345|NCT03974061|Behavioral|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
79252874|NCT06126432|Dietary Supplement|Yugart|Yugart 2 bottles per day for 1 month
80016990|NCT02099214|Device|Echocardiography at rest|Transthoracic echocardiograph
80016991|NCT02099214|Biological|Urinary pregnancy test|
79392203|NCT02393352|Other|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
80016992|NCT02099214|Device|3Tesla abdominal MRI|
79392204|NCT02393352|Other|Electrical Stimulation Therapy|
79392205|NCT02397642|Procedure|IVF/ICSI|
79392206|NCT02397642|Drug|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
79392207|NCT02393508|Other|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
79392208|NCT02393508|Other|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
79392209|NCT03167658|Behavioral|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
79392210|NCT02397486|Drug|Pentoxifylline|
79547802|NCT05624294|Drug|Placebo|Tablets administered orally
79547803|NCT05590273|Behavioral|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
79547804|NCT05585112|Drug|Lidocaine 2%|The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale
79547805|NCT05585112|Drug|Articaine 4%|The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale
79547806|NCT05560477|Drug|AM3101|Injectable drug product.
79547807|NCT05560477|Drug|Saline Placebo|2 mL 0.9% normal saline
79547808|NCT05559515|Behavioral|NDPP-Flex|NDPP + patient-centered goal setting
79547809|NCT05559515|Behavioral|NDPP|Usual care NDPP only
79547810|NCT05555004|Other|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
79547811|NCT05555004|Other|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
79547812|NCT05552443|Drug|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
79547813|NCT05552443|Drug|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
79547814|NCT05552443|Drug|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
79547815|NCT05552443|Drug|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
79547816|NCT05552443|Drug|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
79547817|NCT05552443|Drug|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
79547818|NCT05552443|Drug|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
79547819|NCT05552443|Drug|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
79547820|NCT05551195|Device|WB001|WB001 is a digital therapeutic for postpartum depression.
79547821|NCT05551195|Device|ED001|ED001 is a digital therapeutic for postpartum depression.
79547822|NCT05531253|Other|Data collection using the Optical Gas Analyser|To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
79547823|NCT05529641|Other|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
79547824|NCT05529641|Other|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
79547825|NCT05527483|Drug|[68Ga]PSMA|Patients will receive up to 6 mCi of [Ga-68]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
79547826|NCT05527483|Drug|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of [F-18]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
80031440|NCT05163236|Diagnostic Test|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
80031441|NCT04899466|Device|ActiGraft|Whole blood clot (WBC) gel
79392211|NCT02397486|Drug|Vitamin E|
79392212|NCT02397486|Drug|Cisplatin|
79392213|NCT02397486|Radiation|Radiation therapy|
79392214|NCT02393586|Drug|Faropenem|Single oral dose
79392215|NCT02393586|Drug|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
79392216|NCT02393586|Drug|Rifampicin|Single oral dose
79547827|NCT05527483|Diagnostic Test|PET/CT|Patients will receive [68Ga]PSMA with a PET/CT and Flourine-18 [F-18] Sodium Fluoride (NaF) with a PET/CT
79710811|NCT01321710|Drug|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
79710812|NCT01321008|Radiation|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
79710813|NCT01321008|Drug|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
79710814|NCT01321008|Drug|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
79710815|NCT01321008|Drug|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
79710816|NCT01321008|Drug|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
79710817|NCT05661396|Behavioral|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
79392217|NCT03503812|Behavioral|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity"
79710818|NCT01323530|Drug|Eribulin mesylate|Intravenous (IV) bolus or infusion.
79710819|NCT01323530|Drug|Capecitabine|Oral film-coated tablets.
79710820|NCT05645198|Drug|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
79710821|NCT05645198|Drug|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
79710822|NCT04325438|Other|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
79710823|NCT02891252|Procedure|outpatient procedure|
79710824|NCT01313637|Drug|GSK573719/GW642444 125/25mcg|125/25mcg
79404260|NCT05229276|Other|Bone Wax|patients in this group were given Bone Wax as the hemostatic material during sternotomy. Midline sternotomy with an oscillating saw was conducted after standard aseptic surgical techniques. Bone wax was applied to both spongiosa surfaces of resected sternal bones until bleeding had ceased.
79710825|NCT01313637|Drug|GSK573719 125mcg|125mcg
79849346|NCT03974061|Behavioral|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
79849347|NCT03936998|Combination Product|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
79710826|NCT01313637|Drug|GW642444 25mcg|25mcg
79849348|NCT03936998|Combination Product|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
79710827|NCT01313637|Drug|Placebo only|Placebo
79710828|NCT01320722|Drug|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
79710829|NCT01320722|Drug|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
79710830|NCT01320722|Drug|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
79710831|NCT01320722|Drug|Placebo|Placebo soft gel once per week for 8 weeks
79710832|NCT01320722|Drug|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
79710833|NCT01313559|Drug|Pasireotide|Given IM
79710834|NCT01313559|Drug|Everolimus|Given PO
79710835|NCT01313559|Other|Laboratory biomarker analysis|Correlative studies
79710836|NCT02891330|Behavioral|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
79710837|NCT00623337|Behavioral|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy & 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify & refer sick babies
79710838|NCT02891031|Drug|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
79710839|NCT02891031|Drug|Placebo|500 mg twice daily after meal for 6 weeks
79710840|NCT04325750|Procedure|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
79710841|NCT04325750|Other|Placebo|simulated TECAR Therapy (machine off)
79710842|NCT04325360|Procedure|Cathodal Transcranial Direct Current Stimulation|20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
79710843|NCT04325360|Procedure|Sham Transcranial direct current stimulation|Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
79849349|NCT03936998|Combination Product|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
79849350|NCT03936998|Combination Product|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
79710844|NCT02890953|Drug|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
79710845|NCT02890953|Drug|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
79252875|NCT06126380|Drug|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
79710846|NCT05644652|Other|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~Flexibility exercises to restore joint mobility of soft tissues.~Static and dynamic balance exercises~Functional strengthening exercises.~Functional gait training."
79710847|NCT05644652|Other|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
79710848|NCT02890875|Other|Ethanol lock|
79849351|NCT03917407|Drug|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
80016993|NCT03324958|Device|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
80016994|NCT03324958|Other|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
80016995|NCT02095548|Drug|SM04690, 0.03mg/2mL|
80016996|NCT02095548|Drug|SM04690, 0.07mg/2mL|
80016997|NCT02095548|Drug|SM04690, 0.23mg/2mL|
80016998|NCT02095548|Drug|Placebo|
79392218|NCT03503812|Behavioral|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity~ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~Reduce indoor particle levels by using air cleaners."
79392219|NCT03503812|Behavioral|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity"
79392220|NCT03503812|Behavioral|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity~ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~Reduce indoor particle levels by using air cleaners."
79547828|NCT05527470|Drug|Gemcitabine,Cisplatin|Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
79710849|NCT02890875|Other|Heparin lock|
79710850|NCT04324970|Device|Tookie Vest|Tookie Vest
79392221|NCT04480632|Biological|Convalescent plasma|ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
79710851|NCT01312779|Device|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
79710852|NCT01312467|Drug|metformin hydrochloride|
79392222|NCT02393430|Drug|Rebamipide|Rebamipide is a
79710853|NCT01310127|Drug|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
79710854|NCT01310127|Drug|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
80031442|NCT05163002|Behavioral|Nutritional education & carbohydrate counting|Nutrition Education with a multidisciplinary team
79392223|NCT02393430|Behavioral|optimization of life style|
80031443|NCT03052660|Drug|Midazolam|Oral administration preoperatively
79547829|NCT05527470|Radiation|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
79252876|NCT06126380|Drug|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
79547830|NCT05527470|Drug|Cisplatin|Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
79710855|NCT01309893|Device|Investigational Lens|Lenses worn on a daily wear basis for one week
79710856|NCT01309893|Device|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
79710857|NCT01318902|Drug|Ixazomib|Ixazomib capsules.
79710858|NCT01318902|Drug|Dexamethasone|Dexamethasone tablets.
79710859|NCT05644938|Procedure|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
79710860|NCT05644938|Procedure|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
79710861|NCT05644860|Combination Product|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
79710862|NCT05644860|Combination Product|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
79277313|NCT03531541|Device|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
79392224|NCT03453892|Drug|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
79710863|NCT01313858|Drug|Simponi®|
79710864|NCT01313858|Drug|Methotrexate|Given concomitantly with Simponi®
79710865|NCT05644704|Other|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
79710866|NCT05644548|Other|No intervention|No intervention
79710867|NCT01090765|Drug|TRC105|
79710868|NCT01313780|Drug|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
79710869|NCT01313780|Drug|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
79710870|NCT01090453|Biological|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
79875134|NCT03982264|Procedure|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
80031444|NCT03052660|Drug|Placebo oral capsule|Oral administration preoperatively
79392225|NCT03453892|Drug|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
79392226|NCT03453892|Radiation|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
79392227|NCT03453892|Drug|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
79392228|NCT02393274|Device|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
79392229|NCT04340440|Procedure|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
79392230|NCT04340440|Procedure|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
79392231|NCT00367042|Device|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
79392232|NCT00367042|Device|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
79392233|NCT00367120|Drug|Azithromycin Extended Release|
79392234|NCT00367120|Drug|Amoxicillin/Clavulanate|
80031445|NCT05159180|Device|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
79392235|NCT00367198|Dietary Supplement|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
79710871|NCT01090453|Biological|Prevenar 13®|3 co-administered doses
79710872|NCT01090453|Biological|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
79710873|NCT01090453|Biological|Menjugate®|3 co-administered doses
79710874|NCT01090453|Biological|Rotarix™|Oral, two doses
79710875|NCT01171534|Device|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
79710876|NCT01171534|Device|Vessel loop|Vessel loops and staples for fasciotomy closure
79710877|NCT01170598|Other|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
79404261|NCT03581773|Drug|Folic Acid|5 mg pr day for 12 weeks
79710878|NCT01170364|Drug|Sibutramine|1 week of active sibutramine (15mg)
79710879|NCT01170364|Drug|Placebo|2 weeks of placebo
79710880|NCT01170208|Device|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
79710881|NCT01313624|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
79710882|NCT01313624|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
79710883|NCT05324410|Drug|VX-840|Solution for oral administration.
79710884|NCT05324410|Drug|Placebo|Placebo matched to VX-840 for oral administration.
79710885|NCT02877043|Procedure|resection pulmonaire|
79710886|NCT02891018|Device|paclitaxel controlled release balloon catheter Vasoguard TM|
79710887|NCT02891018|Device|paclitaxel release coronary balloon catheter SeQuent Please|
79710888|NCT01169350|Radiation|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
79710889|NCT01169350|Other|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
79710890|NCT01169350|Procedure|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
79710891|NCT01169350|Procedure|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
79710892|NCT01169350|Other|laboratory biomarker analysis|Correlative studies
79710893|NCT00623324|Drug|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
79710894|NCT00623324|Drug|Placebo|Placebo tablets to match the number of active tablets
79710895|NCT01169038|Drug|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
79710896|NCT04315012|Other|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
79710897|NCT01167634|Behavioral|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
79710898|NCT01167634|Behavioral|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
79849352|NCT03917407|Drug|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
79547831|NCT05519631|Other|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
79710899|NCT01167634|Behavioral|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
79710900|NCT00624754|Drug|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
79710901|NCT00624754|Drug|lactose|Lactose 2 puffs b.i.d for 1 month
79849353|NCT03901534|Device|Auto-CPAP|Use of Auto-CPAP
79710902|NCT02886052|Behavioral|Therapist guided Internet-CBT for insomnia|
79710903|NCT02886052|Other|Active control|
79710904|NCT01166386|Behavioral|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
79710905|NCT01166386|Behavioral|FANCI|Watching DVDs chosen by participants on various topics.
79849354|NCT03901534|Other|Withdrawal of Auto-CPAP|Withdrawal of Auto-CPAP
79849355|NCT03897673|Dietary Supplement|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
79849356|NCT03897673|Dietary Supplement|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
79392237|NCT02693418|Drug|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
79392238|NCT02693418|Drug|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
79392239|NCT02693418|Drug|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
79392240|NCT02693418|Drug|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
79392241|NCT05745324|Procedure|Scaling and root planing|SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
79392242|NCT03166956|Dietary Supplement|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
79392243|NCT02397330|Drug|bupivacaine|
79392244|NCT02397330|Device|ultrasound|ultrasound guided nerve blocks
79392245|NCT02397330|Drug|morphine|
79392246|NCT03081052|Drug|iNO|Subject will receive inhaled Nitric Oxide in this intervention
79392247|NCT03081052|Drug|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
79392248|NCT02693106|Dietary Supplement|Control|Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.
79392249|NCT02693106|Dietary Supplement|Leucine|Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.
79404262|NCT03581773|Drug|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
79547832|NCT05492435|Device|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
79710906|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
79710907|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
79710908|NCT01313312|Biological|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
79710909|NCT01114672|Drug|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
79710910|NCT01114672|Drug|Placebo|oral placebo once weekly
79710911|NCT01114516|Drug|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
79849357|NCT03873805|Biological|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
79849358|NCT03873805|Drug|Cyclophosphamide|Given IV
79252877|NCT06126367|Diagnostic Test|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
79849359|NCT03873805|Drug|Fludarabine|Given IV
79252878|NCT06126367|Diagnostic Test|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
79252879|NCT06126354|Drug|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
79547833|NCT05483920|Behavioral|One-time educational video|One-time educational video
79849360|NCT03873805|Drug|Fludarabine Phosphate|Given IV
79849361|NCT03853564|Behavioral|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
80031446|NCT04891120|Diagnostic Test|Treadmill test (Bruce protocol)|Treadmill test performed with and without a mask.
79252880|NCT06126354|Drug|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
79252881|NCT06126354|Drug|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
79547834|NCT05483920|Behavioral|One-time educational video plus automated text messaging|Educational video plus automated text messaging
79547835|NCT05475730|Procedure|bone and soft tissue augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
79547836|NCT05473988|Other|Admission to General Ward|Admission to General Ward
79547837|NCT05473988|Other|Admission to Intensive Care Unit|Admission to Intensive Care Unit
79710912|NCT01114438|Device|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
79547838|NCT05473988|Other|30 Day Mortality|30 Day Mortality
79710913|NCT01313078|Drug|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
79710914|NCT00625690|Other|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
79710915|NCT00625690|Procedure|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
79849362|NCT03853564|Other|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
79849363|NCT03836482|Device|Selective Cytopheretic Device|Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
79849364|NCT03812302|Diagnostic Test|68-Ga HA-DOTATATE PET/CT|See arm description.
79710916|NCT00625690|Procedure|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
79547839|NCT05472545|Behavioral|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
79710917|NCT00625690|Procedure|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
79710918|NCT01114360|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
79710919|NCT01114360|Drug|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
79710920|NCT01310036|Drug|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
79710921|NCT01309100|Device|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
79710922|NCT01309100|Device|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
79710923|NCT01309100|Device|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
79710924|NCT01075321|Drug|everolimus|Given orally
79710925|NCT01075321|Drug|lenalidomide|Given orally
79710926|NCT01075321|Other|laboratory biomarker analysis|Correlative studies
79710927|NCT01075321|Genetic|polymorphism analysis|Correlative studies
79710928|NCT01075321|Other|immunohistochemistry staining method|Optional correlative studies
79710929|NCT01075321|Genetic|microarray analysis|Optional correlative studies
79710930|NCT01075321|Genetic|fluorescence in situ hybridization|Optional correlative studies
79710931|NCT01114204|Drug|Ferumoxytol|IV Ferumoxytol
79710932|NCT01114204|Drug|Iron Sucrose|IV Iron Sucrose
80031447|NCT05006456|Device|Catheter ablation|Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
79252882|NCT06126354|Drug|Human Growth Hormone|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
79547840|NCT05471921|Behavioral|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
79710933|NCT01075243|Drug|Paracetamol 1000 mg|Paracetamol 1000mg
79710934|NCT01075243|Drug|Paracetamol 650 mg|Paracetamol 650 mg
79710935|NCT01075243|Drug|Placebo|Placebo
79710936|NCT01308476|Procedure|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
79252883|NCT06126354|Drug|Dexamethasone Oral|Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
79252884|NCT06126354|Other|[6,6-2H2] D-glucose|"Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)"
79252885|NCT06126354|Drug|20% D-glucose (aq)|"20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)"
79392250|NCT02693106|Dietary Supplement|Butyrate -|Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.
79392251|NCT02693106|Dietary Supplement|Butyrate +|Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.
79392252|NCT02693106|Dietary Supplement|Octanoate -|Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.
79392253|NCT02693106|Dietary Supplement|Octanoate +|Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.
79710937|NCT01308476|Procedure|control group|no daily SMS to remind of treatment with tiotropium
79710938|NCT01078441|Drug|liposomal doxorubicin|Given IV
79710939|NCT01078441|Drug|bortezomib|Given subcutaneously.
79710940|NCT01078441|Drug|dexamethasone|Given orally
79710941|NCT01078441|Drug|cyclophosphamide|Given IV
79710942|NCT01308008|Behavioral|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
79710943|NCT01308008|Behavioral|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
79710944|NCT04325048|Device|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
79710945|NCT02890706|Device|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
79252886|NCT06126354|Dietary Supplement|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)"
79392254|NCT02693106|Dietary Supplement|Carnitine|Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.
79392255|NCT02693106|Dietary Supplement|Butter fraction|Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.
79392256|NCT02393196|Drug|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
79547841|NCT05471921|Behavioral|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
79849365|NCT03803852|Device|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL on the axis according to the steep meridian of the cornea"
79392257|NCT02393196|Drug|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
79547842|NCT05467111|Other|Acute Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
79547843|NCT05466188|Diagnostic Test|CPC|CPC
79547844|NCT05465070|Device|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
79547845|NCT05465070|Device|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
79547846|NCT05462340|Drug|[18F]ASEM|[18F]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. [18F]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR [18F]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with [18F]ASEM, which will be highly significant for understanding these receptors in SCZ.
79547847|NCT05462340|Drug|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-[18F]FA. Because 2-[18F]FA exhibits very slow brain kinetics, the investigators developed [18F]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize [18F]AZAN to determine α4β2-nAChR [18F]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with [18F]ASEM, which will be highly significant for understanding these receptors in SCZ.
79547848|NCT05452278|Other|Product A|Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
79547849|NCT05452278|Other|Product B|Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
79710946|NCT00626665|Drug|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
79710947|NCT05644106|Device|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
80031448|NCT04958174|Device|web-application|web application for monitoring children's development
79547850|NCT05452278|Other|Product C|Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
79547851|NCT05452278|Other|Product D|Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
79710948|NCT01113892|Device|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
79252887|NCT06126354|Device|Harvard Apparatus PHD ULTRA CP syringe pump|"Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)"
79392258|NCT02392962|Procedure|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
79392259|NCT02392962|Procedure|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
79547852|NCT05451485|Diagnostic Test|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
79547853|NCT05451485|Diagnostic Test|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
79547854|NCT05451485|Diagnostic Test|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
79547855|NCT05451485|Diagnostic Test|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
79547856|NCT05439356|Drug|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
79547857|NCT05439356|Drug|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
79710949|NCT02877979|Drug|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
79710950|NCT02877979|Drug|Placebo|
79849366|NCT03792841|Drug|acapatamab|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
79849367|NCT03792841|Drug|Pembrolizumab|Combined with acapatamab for investigational treatment of mCRPC
79252888|NCT06126354|Device|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|"Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)"
79710951|NCT00626353|Other|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
79392260|NCT02397018|Biological|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
79547858|NCT05425004|Drug|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
79547859|NCT05413421|Drug|ORIC-944|ORIC-944 oral once daily for 28 days
79710952|NCT00626353|Other|Standard care|Standard care during hospital stay and in the municipality after discharge
79710953|NCT04305847|Other|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
79710954|NCT02881684|Device|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
79710955|NCT02881684|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
79710956|NCT02876731|Device|PET-CT|NaF PET-CT
79547860|NCT05413252|Other|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
79710957|NCT02876731|Device|MRI|DWMRI
79849368|NCT03792841|Drug|Etanercept|Prophylaxis for acapatamab-related cytokine release syndrome.
79547861|NCT05412979|Drug|ST-1891|ST-1891
79547862|NCT05412979|Drug|Levothyroxine|Levothyroxine
80016999|NCT00113438|Drug|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
79547863|NCT05396846|Behavioral|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
79710958|NCT04310332|Drug|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
79710959|NCT04310332|Drug|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
79710960|NCT01090063|Drug|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
79710961|NCT00625768|Drug|AS1409|Study drug
79710962|NCT01113580|Biological|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
80031449|NCT04753814|Diagnostic Test|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
79547864|NCT05396846|Behavioral|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
79252889|NCT06126354|Other|Normal saline|Normal saline (0.9% NaCl, aq), variable rate (as needed)
79252890|NCT06126354|Other|Human albumin|Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
79252891|NCT06126341|Other|Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM|Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
79710963|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
79710964|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
79710965|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
79710966|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
79710967|NCT01306214|Drug|BI 10773|BI 10773 low dose once daily
79710968|NCT01306214|Drug|BI 10773|BI 10773 high dose once daily
79710969|NCT00623402|Drug|Sorafenib|2x 400 mg orally per day (4 tablets)
79710970|NCT00623402|Drug|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
79710971|NCT01077739|Drug|fluorouracil (5FU)|standard FOLFOX regimen
79710972|NCT01077739|Drug|leucovorin|standard FOLFOX regimen
79849369|NCT03792841|Drug|Cytochrome P450 (CYP) Cocktail|Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
79849370|NCT03727724|Drug|Afatinib|Tablet
79849371|NCT03727724|Drug|Cetuximab|Injection
79252892|NCT06126341|Behavioral|Hospital Anxiety and Depression Scale|Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
79392261|NCT00422344|Drug|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
79547865|NCT05396846|Behavioral|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
79710973|NCT01077739|Drug|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
79710974|NCT01077739|Drug|capecitabine [Xeloda]|standard XELOX regimen
79710975|NCT01077739|Drug|oxaliplatin|standard XELOX or FOLFOX regimen
79710976|NCT02876497|Other|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
79710977|NCT01306058|Drug|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
79710978|NCT01306058|Drug|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
79710979|NCT00626509|Drug|sunitinib malate|
79710980|NCT00626509|Procedure|adjuvant therapy|
79547867|NCT05385458|Behavioral|ACT Intervention|Acceptance and Commitment Therapy
79547868|NCT05385458|Other|Usual Care|Usual Care Services
79547869|NCT05373836|Diagnostic Test|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
79547870|NCT05373511|Other|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
79710981|NCT00626509|Procedure|neoadjuvant therapy|
79710982|NCT00626509|Procedure|therapeutic conventional surgery|
79710983|NCT02876653|Other|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
79710984|NCT02876965|Procedure|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
79710985|NCT02876965|Procedure|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
79710986|NCT02877901|Drug|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
79710987|NCT02877901|Drug|placebo|one tablet at bed time
79710988|NCT04306159|Procedure|Subcostal TAP|Subcostal transversus abdominis plane block
79710989|NCT04306159|Procedure|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
79710990|NCT04306159|Other|General anesthesia|Traditional general anesthesia management
79710991|NCT01305200|Drug|supersaturated calcium phosphate rinse|Mouth rinse
80017000|NCT04087408|Drug|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~Quantative BHCG will be performed 14 days after OPU."
79252893|NCT06126341|Behavioral|Duke-UNC Functional Social Support Questionnaire|A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
79252894|NCT06126341|Behavioral|Distress Thermometer|The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
79710992|NCT01305200|Other|placebo|Mouth rinse
79710993|NCT01305200|Other|questionnaire administration|Ancillary studies
79252895|NCT06126341|Behavioral|FACT-BMT|The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
79392262|NCT02393118|Device|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
79392263|NCT02952352|Behavioral|Diabetes Prevention Program|Culturally adapted diabetes prevention program
79710994|NCT01305200|Procedure|quality-of-life assessment|Ancillary studies
79710995|NCT01305044|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
79710996|NCT01305044|Behavioral|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
79710997|NCT01304498|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
79710998|NCT01304498|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
79710999|NCT01077193|Procedure|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
79711000|NCT05644028|Behavioral|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
79711001|NCT04299139|Other|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
79711002|NCT02876029|Other|Reference|the reference product used
79711003|NCT02876029|Other|Test product|The test Product used
79392264|NCT02397252|Device|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
79711004|NCT05661110|Other|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
79711005|NCT01074931|Drug|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
79711006|NCT04306003|Other|ERAS pathway|See ERAS pathway arm description.
79392265|NCT02397252|Device|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
79711007|NCT04306003|Other|Standard Perioperative Care|See control arm description.
79392266|NCT02397252|Procedure|Physician-collected sampling|Routine colposcopy sample collected by a physician.
79392267|NCT02397174|Other|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
79392268|NCT02397174|Other|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
79392269|NCT02396940|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
79711008|NCT00626587|Device|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
79711009|NCT04774159|Drug|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
79711010|NCT04774159|Drug|Colchicine-Placebo|Colchicine-Placebo tablet
79711011|NCT02877745|Other|Stratification, no intervention|
80017001|NCT02099292|Drug|Rituximab and DexaBEAM|combination treatment
80017002|NCT02283242|Drug|Galantamine|Oral use for 12 weeks
80017003|NCT02283242|Drug|Placebo (for galantamine)|Oral use for 12 weeks
80017004|NCT02283320|Drug|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
80017005|NCT05228392|Other|listening to music|listening to lullaby or other music types
79392270|NCT02396940|Device|2D HD laparoscopy|Placebo
79392271|NCT00367276|Drug|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
79392272|NCT02546986|Drug|CC-486|CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
79392273|NCT02546986|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
79392274|NCT02546986|Drug|Placebo|Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
79392275|NCT02196844|Behavioral|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
79392276|NCT02196844|Behavioral|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
79392277|NCT02196844|Other|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
79392278|NCT02689206|Drug|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
79392279|NCT02689206|Drug|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
79392280|NCT01695239|Drug|Ixekizumab|Administered SC
79547871|NCT05348538|Other|Medication review with follow up or MaJ? for the acronym in french|"MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service."
79252896|NCT06126341|Behavioral|Psychosocial Assessments of Candidates for Transplantation|The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
79711012|NCT01303172|Biological|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
79711013|NCT01303172|Drug|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
79711014|NCT01302938|Drug|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
79711015|NCT01302938|Drug|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
79711016|NCT05643872|Drug|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
79711017|NCT01302548|Device|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
79711018|NCT01302548|Procedure|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
79711019|NCT01302392|Drug|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days [Days 1, 2, 8, 9, 15, 16] for individual subjects).
79711020|NCT01302392|Drug|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
79711021|NCT01076647|Drug|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
79547872|NCT05344872|Other|Weaning from mechanical ventilation|Weaning from mechanical ventilation post congenital cardiac surgery
79547873|NCT05344274|Diagnostic Test|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
79711022|NCT01076647|Drug|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
79711023|NCT04306081|Drug|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
79252897|NCT06126302|Other|Birth year|we divided the patients according to patients' birth year
79711024|NCT04306081|Other|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
79252898|NCT06126263|Drug|Linezolid|Adjunctive antitoxin therapy
79252899|NCT06126263|Drug|Clindamycin|Adjunctive antitoxin therapy
79252900|NCT06126250|Device|Power sonic toothbrush|Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.
79252901|NCT06126250|Device|Manual toothbrush|Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.
79252902|NCT06126237|Biological|CM313 injection|CM313, subcutaneous injection
79252903|NCT06126198|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
79252904|NCT06126172|Diagnostic Test|Multiparametric magnetic resonance imaging (mpMRI)|Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
79252905|NCT06126159|Diagnostic Test|multiparametric and fat-detection magnetic resonance imaging (MRI)|Differentiating of renal AMLs with minimal fat and RCCs
79252906|NCT06126133|Device|Near Infrared Spectroscopy|Two NIRS probes will be attached to the extremity to be operated on and to the other lower extremity on the opposite side, at a level approximately coinciding with the midline above the quandriceps femoris muscle.
79252907|NCT06126107|Behavioral|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
79252908|NCT06126107|Behavioral|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
79252909|NCT06126107|Behavioral|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
79252910|NCT06126094|Dietary Supplement|Myrkl|The subject of the test will be supplementation with precise probiotic for hangovers (Myrkl, De Fair) in the form of one pill of 800 mg
79392281|NCT01695239|Drug|Placebo|Administered SC
79547874|NCT05344274|Biological|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
79547875|NCT05344274|Diagnostic Test|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
79849372|NCT03724110|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
79547876|NCT05340179|Procedure|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
79547877|NCT05340179|Procedure|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
79547878|NCT05325996|Diagnostic Test|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.
79547879|NCT05325996|Diagnostic Test|visuALL H|visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.
79547880|NCT05325996|Diagnostic Test|iCare Home Tonometer|iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.
79849373|NCT03714555|Diagnostic Test|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
79849374|NCT03714555|Other|AE Assessment|Assessment of Adverse Events (AE)
79711025|NCT01074307|Drug|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
79392282|NCT01695239|Drug|Adalimumab|Administered SC
79392283|NCT01984762|Procedure|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
79392284|NCT01984762|Procedure|sleeve gastrectomy|SG = sleeve gastrectomy
79711026|NCT01074307|Drug|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
79547881|NCT05325996|Diagnostic Test|Spectralis Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
79547882|NCT05323487|Drug|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
79547883|NCT05307640|Behavioral|CG-Well|CG-Well is a web & phone based psychosocial intervention that teaches caregivers how to obtain information, education & support
79849375|NCT03714555|Other|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
79849376|NCT03714555|Other|Concomitant Medication Review|Prior and Concomitant Medication Review
79849377|NCT03714555|Diagnostic Test|Tumor Imaging|Tumor CT or MRI
79849378|NCT03714555|Drug|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
79392285|NCT00975520|Other|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
79547884|NCT05307640|Behavioral|Information Support & Referral (ISR)|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
79547885|NCT05307523|Device|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
79547886|NCT05307523|Other|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
79849379|NCT03714555|Drug|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
79849380|NCT03714555|Drug|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
79849381|NCT03701295|Drug|Azacitidine|Given IV or SC
79849382|NCT03701295|Drug|Pinometostat|Given IV
79392286|NCT00975520|Radiation|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
79252911|NCT06126094|Dietary Supplement|dextrin|The subject of the test will be supplementation with placebo (maltodextrin) in the form of two pills (each 400 mg)
79252912|NCT06126081|Device|LBBP+GDMT|LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.
79252913|NCT06126081|Drug|GDMT|GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
79252914|NCT06126055|Device|Band Ligation|Placing bands in distal esophagus
79252915|NCT06126042|Drug|Test Product|DRL_AB, Pre Filled Syringe; Solution for injection
79392287|NCT04449250|Drug|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
79252916|NCT06126042|Drug|Reference product|USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection
79392288|NCT04344028|Behavioral|True Cognitive Training Program|The training program is a personal device-based adaptive version of a visual N-back task.
79392289|NCT04344028|Behavioral|Control Cognitive Training Program|The training program is a personal device-based adaptive version of a knowledge task (control).
79392290|NCT04344028|Behavioral|Positive Expectation Induction|The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.
79547887|NCT05307302|Diagnostic Test|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
79547888|NCT05307302|Diagnostic Test|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
79547889|NCT05307302|Diagnostic Test|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
79547890|NCT05307302|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
79547891|NCT05307302|Diagnostic Test|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
79849383|NCT03698552|Biological|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
79392291|NCT04344028|Behavioral|Negative Expectation Induction|The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
79547892|NCT05300685|Drug|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
79547893|NCT05300685|Drug|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
79547894|NCT05300685|Drug|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
79711027|NCT01076335|Drug|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
79711028|NCT01076335|Drug|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
79849384|NCT03697720|Drug|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
79849385|NCT03635983|Biological|NKTR-214|Specified dose on specified days
79849386|NCT03635983|Biological|Nivolumab|Specified dose on specified days
79849387|NCT03626662|Drug|AMG 890|Ascending Single Doses of AMG 890
79849388|NCT03626662|Drug|Placebo|Calculated volume to match experimental drug.
79849389|NCT03610971|Drug|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
79849390|NCT03610971|Drug|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
79252917|NCT06126042|Drug|Reference Medicinal Product|EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
79252918|NCT06126029|Drug|Metformin 500 Mg extended release Oral Tablet|34 patients of experimental group will get metformin 500mg extended release oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
79252919|NCT06126029|Drug|Placebo oral tablet|34 patients of placebo group will get placebo oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
79252920|NCT06126003|Other|Observation|No Intervention
79252921|NCT06125990|Other|Experimental: Study Group (SGr)|For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
79252922|NCT06125990|Other|Sham Comparator: Control Group (CGr)|Only institutional conventional rehabilitation was implemented.
79277314|NCT03531541|Device|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
79392292|NCT04317430|Drug|Niclosamide|Niclosamide tablets 1 gram once daily
79711029|NCT01309737|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
79711030|NCT01309737|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
79711031|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
79849391|NCT03596385|Drug|Beta blocker|long-term maintenance beta-blocker therapy
79849392|NCT03564197|Other|18F-PD-L1|18F-PD-L1 PET/CT scan
79849393|NCT03549000|Other|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
79547895|NCT05276817|Device|Epic Diode|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
79392293|NCT04317430|Drug|Placebo oral tablet|lactose tablets
79547896|NCT05276817|Drug|HP|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
79711032|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
79711033|NCT01074229|Drug|Placebo|placebo injection
79711034|NCT01074229|Drug|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
79711035|NCT01074229|Drug|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
79252923|NCT06125964|Behavioral|Intensity-Based Goals|On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.
79392294|NCT04277884|Drug|Firibastat|Oral administration 2×250 mg capsules bid
79711036|NCT01106014|Drug|Selexipag|Selexipag 200 µg tablets
79711037|NCT01106014|Drug|Placebo|Placebo tablets matching selexipag
79711038|NCT01073605|Drug|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
79849394|NCT03549000|Other|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
79392295|NCT04277884|Drug|Placebo|Oral administration 2 capsules bid
79392296|NCT04129840|Other|dual combination|Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
79711039|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
79711040|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
79711041|NCT01073293|Biological|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
79711042|NCT01073293|Biological|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
79711043|NCT01073293|Biological|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
79711044|NCT01105936|Drug|Paracetamol|665 mg sustained release paracetamol caplets
79711045|NCT01105936|Drug|Placebo|Placebo caplets
79711046|NCT01309659|Drug|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
79711047|NCT01309659|Drug|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
79849395|NCT03549000|Drug|NIR178|NIR178 Specified dose on specified days, Orally
79849396|NCT03517449|Drug|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
79547897|NCT05276817|Device|Sham|The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
79547898|NCT05266807|Drug|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
79547899|NCT05266807|Drug|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
79547900|NCT05254418|Drug|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
79711048|NCT04989166|Dietary Supplement|Nano-curcumin|Nano-curcumin soft gels
79711049|NCT04989166|Drug|Placebo|Placebo
79711050|NCT04870411|Biological|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
79711051|NCT05320705|Drug|Intra Operative Dexmedetomidine|Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
79711052|NCT04305535|Dietary Supplement|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~Bifidobacterium animalis subsp. lactis BPL1,~Lactobacillus rhamnosus BPL15,~Lactobacillus rhamnosus CNCM i-4036~Bifidobacterium longum ES1"
79711053|NCT04305535|Dietary Supplement|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
79849397|NCT03517449|Drug|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
79849398|NCT03517449|Drug|Paclitaxel|80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
79849399|NCT03517449|Drug|Doxorubicin|60 mg/m^2 administered by IV on Day 1 of each 21-day cycle.
79711054|NCT04305535|Dietary Supplement|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
79711055|NCT04305223|Procedure|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
79711056|NCT04305223|Other|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
79277315|NCT03531541|Device|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
79849400|NCT03480360|Drug|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
80017006|NCT05228236|Dietary Supplement|Plant based protein|A single dose of ~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
80017007|NCT05228236|Dietary Supplement|Whey protein|A single dose of ~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
80017008|NCT03556098|Drug|glucose-dependent insulinotropic peptide|Infusion of GIP
80017009|NCT03556098|Drug|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP[3-30]
80017010|NCT03556098|Drug|Saline Solution|Infusion of Saline
80017011|NCT02096640|Procedure|Type of surgical teqnique for tracheostomy|
80017012|NCT02286986|Drug|Cannabidiol|
79392297|NCT04129840|Other|triple combination|Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
79547901|NCT05250284|Behavioral|WellBQ|National Institue for Occupational Safety and Health Worker Well-Being Questionnaire is comprised of 21 scales (multiple items assessing a single construct) and 31 single items that cover worker well-being. Domains include (i) work evaluation and experience, (ii) workplace policies and culture, (iii) workplace physical environment and safety climate, (iv) health status, and (v) home, community, and society.
79547902|NCT05250284|Behavioral|PROMIS|Patient-Reported Outcomes Measurement Information System is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
79547903|NCT05233267|Other|Blood sample|Dosage of neopterin
79547904|NCT05233072|Other|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
79547905|NCT05227079|Device|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
79711057|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
79711058|NCT01104766|Drug|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
79849401|NCT03480360|Drug|Fludarabine|30 mg/m2 daily for 5 days
80017013|NCT04995874|Dietary Supplement|KOKOPlus protein and micronutrient powder|KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
79849402|NCT03480360|Radiation|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
79711059|NCT01104766|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
79711060|NCT04305379|Procedure|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
80017014|NCT02095626|Drug|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
79711061|NCT04305379|Procedure|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
79711062|NCT02880280|Drug|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
79711063|NCT02880280|Drug|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
79711064|NCT04304287|Procedure|Preoperative autologous blood donation, 14 days before surgery|
79849403|NCT03480360|Drug|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
79849404|NCT03480360|Drug|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
80017015|NCT02095626|Drug|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
80031450|NCT04412278|Other|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
79711065|NCT04304287|Procedure|Preoperative autologous blood donation, 72 hours before surgery|
79392298|NCT04129840|Other|Standard of care|Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
79711066|NCT04304287|Procedure|Without preoperative blood donation|
79252924|NCT06125964|Behavioral|Affect-Based Goals|"On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon."
79392299|NCT04085848|Other|music therapy|4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
79392300|NCT04023058|Procedure|Mitral surgery|Guidelines approved mitral surgery
79392301|NCT03921814|Device|Treatment with IPL device|Exposure of body parts to the IPL device
79392302|NCT03680794|Other|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
79711067|NCT02879968|Other|Non-interventional study|
79252925|NCT06125964|Behavioral|TYPE/CONTEXT Enhancement|The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
79547906|NCT05227079|Device|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
79547907|NCT05222477|Behavioral|pelvic floor exercise|pelvic floor exercises(intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
79711068|NCT04743271|Other|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
79711069|NCT04743271|Other|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
80031451|NCT05162612|Diagnostic Test|abtominal CT|standard basic Abdominal Ct scan
79392303|NCT03595540|Other|Prolon|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
79392304|NCT03353116|Procedure|the mandible first|the mandible osteotomy is going to be done and fixed first
79392305|NCT03353116|Procedure|the maxilla first|the maxilla osteotomy is going to be done and fixed first
79392306|NCT00367822|Drug|Lisuride|
79392307|NCT00367822|Drug|Ropinirole|
79392308|NCT00367822|Drug|Placebo|
79392309|NCT03185026|Behavioral|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
79392310|NCT03185026|Other|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
79392311|NCT02937688|Device|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
79547908|NCT05222477|Behavioral|Abdominal muscles exercise|abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
79547909|NCT05213520|Other|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
79547910|NCT05213520|Other|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
79711070|NCT01104376|Drug|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
79711071|NCT01104376|Drug|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
79711072|NCT02875873|Drug|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
79711073|NCT02875873|Drug|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
79711074|NCT02875873|Other|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
79711075|NCT02875873|Other|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
79711076|NCT02880202|Other|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
79392312|NCT01694849|Drug|GFT505 80mg|
79392313|NCT01694849|Drug|GFT505 120mg|
79711077|NCT02880124|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
79711078|NCT02880124|Behavioral|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
79711079|NCT02880124|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
79711080|NCT02880124|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
79711081|NCT02880124|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
79711082|NCT02880124|Other|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
79392314|NCT01694849|Drug|Placebo|
79711083|NCT02880124|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
79711084|NCT02880124|Behavioral|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
79711085|NCT01072357|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
79711086|NCT01072357|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
79711087|NCT01072201|Drug|Triclosan and Fluoride|Brush twice daily
79711088|NCT01072201|Drug|Fluoride|Brush twice daily
79711089|NCT01103362|Drug|flibanserin|all patients will receive open-label flibanserin 100mg
79711090|NCT00591929|Other|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
79392315|NCT02535286|Drug|Umbralisib|A once daily oral agent
79392316|NCT02535286|Biological|ublituximab|IV anti-CD20 monoclonal antibody
79711091|NCT04412993|Other|withdraw blood samples|withdraw blood sample from gorup O donors
79711092|NCT04412135|Other|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
79711093|NCT04208009|Behavioral|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
79711094|NCT01103284|Drug|DiaPep277|1.0 mg dose in 0.5 mL of solution
79711095|NCT01103284|Drug|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
79711096|NCT04409249|Diagnostic Test|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
79711097|NCT04134221|Diagnostic Test|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
79392317|NCT02535286|Biological|TG-1501|IV immunotherapy for cancer
79392318|NCT02249572|Radiation|gamma knife radiosurgery|Leksell Perfection model gamma knife.
79392319|NCT05441800|Other|Observational Study|observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases
79392320|NCT01834924|Other|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
79711098|NCT02893709|Drug|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
79711099|NCT04972396|Drug|ALT-801|Injected subcutaneously (SC)
79711100|NCT04972396|Drug|Metformin|Taken by mouth (PO)
79392321|NCT01126840|Behavioral|Telephone Interview|The phone interview should take 30-45 minutes to complete.
79392322|NCT01126840|Behavioral|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
79392323|NCT00610402|Other|blood sample tear drop sample|blood sample tear drop sample
79392324|NCT00556114|Device|Optical Coherence Tomography|Optical Coherence Tomography
79392325|NCT02643862|Drug|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
79711101|NCT04972396|Drug|Atorvastatin|Taken by mouth (PO)
79711102|NCT04972396|Drug|Warfarin|Taken by mouth (PO)
79711103|NCT04972396|Drug|Digoxin|Taken by mouth (PO)
79711104|NCT04972396|Drug|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
79849405|NCT03480360|Drug|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) > 1000/mcL for 3 days.
79849406|NCT03480360|Procedure|Peripheral Blood Transplant|cell dose goal: < 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
79849407|NCT03452826|Device|Antibiotic therapy according to the result of mPCR (device)|"Phone call at D28 and D90, unless the patient is still hospitalized;~Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~Collection of an additional respiratory tract sample for biological banking in both arms."
79252926|NCT06125964|Behavioral|SAVOR Enhancement|The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
79252927|NCT06125665|Drug|Aminophylline-Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
79392326|NCT02643862|Drug|Placebo|Placebo
79392327|NCT02646826|Other|Placebo|Subjects are treated with Placebo tablets
79547911|NCT05202418|Behavioral|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
79711105|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
79711106|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
79711107|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
79711108|NCT04407533|Other|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
79711109|NCT02877589|Other|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
79711110|NCT04309162|Other|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
80031452|NCT05162534|Other|effect of COVID-19 exposure|effect of COVID-19 exposure
79392328|NCT02646826|Drug|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
79711111|NCT04328597|Procedure|Inguinal hernia repair|Inguinal hernia repair (open, laparo-endoscopic, robotic)
79711112|NCT01089361|Drug|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
79849408|NCT03444948|Device|EUS-RFA using Habib Tm as a probe|3 EUS-RFA interventions at 1-month interval
79849409|NCT03444948|Procedure|EUS|Standard intervention
79392329|NCT02646826|Drug|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
79392330|NCT02646826|Drug|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
79392331|NCT02648230|Device|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
79392332|NCT02648230|Device|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
79392333|NCT02649322|Device|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
80031453|NCT04890808|Dietary Supplement|Inosine|Patients will be dosed with two 500 mg capsules of Inosine twice daily for 36 months
80031454|NCT04890808|Dietary Supplement|IP6|Patients will be dosed with two 500 mg capsules of IP6 twice daily for 36 months
80031455|NCT05162456|Diagnostic Test|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
79711113|NCT01089361|Drug|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
79711114|NCT04399811|Diagnostic Test|Near-infrared Vision Photograph|The near-infrared image will be recorded (by a infrared camera connected to a laptop) for each enrolled patient
79392334|NCT02649322|Device|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
79849410|NCT03434548|Radiation|PET imaging|"PET imaging Radiation: Radioligand [¹¹C]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand [¹¹C]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand [¹¹C]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain."
79849411|NCT03434548|Other|Multi-modal MRI imaging|Multi-modal MRI imaging
79711115|NCT01102972|Drug|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
79711116|NCT01102972|Drug|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
79711117|NCT02893319|Behavioral|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
79711118|NCT04328753|Drug|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
79392335|NCT01694771|Drug|Tiotropium|Marketed dose
79252928|NCT06125665|Drug|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
79252929|NCT06125626|Dietary Supplement|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
79711119|NCT04328753|Drug|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
79392336|NCT01694771|Drug|Placebo matching Olodaterol|One dose
79711120|NCT04328753|Other|Distilled water|act as a negative control in this study
79392337|NCT01694771|Drug|Olodaterol|One dose
79392338|NCT01694771|Drug|Tiotropium|Marketed dose
79392339|NCT02649556|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
79392340|NCT02649556|Other|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
79711121|NCT04328363|Behavioral|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
79547912|NCT05182359|Other|SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
79711122|NCT04963894|Other|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
79711123|NCT04963894|Other|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
79711124|NCT02879500|Other|Diet beverages|
79711125|NCT04388579|Other|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
79711126|NCT01088503|Drug|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
79252930|NCT06125626|Other|Placebo|A daily sachet of placebo will be given to this groups
79252931|NCT06125574|Other|Osteopathic Manipulative Medicine|Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
79392341|NCT02651272|Drug|macitentan|10mg macitentan tablets
79392342|NCT01582061|Drug|Pasireotide sub-cutaneous|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
79547913|NCT05156996|Device|Supersaturated O2 Therapy of the Therox Downstream System®|SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient's left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
79547914|NCT05156996|Procedure|PCI alone|Percutaneous Coronary Intervention for treatment of acute MI
79252932|NCT06125340|Drug|Placebo|5 days of placebo to be given after 3-5 days of antibiotics
79392343|NCT01693523|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day).
79392344|NCT01693523|Other|Placebo|Matching placebo capsules by mouth twice a day.
79392345|NCT01693523|Behavioral|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
79711127|NCT01087489|Drug|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
79392346|NCT03924323|Drug|Escitalopram|8-weeks of treatment followed by 1-week taper down period
79849412|NCT03422783|Device|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
79252933|NCT06125340|Drug|Amoxicillin|Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
79392347|NCT03924323|Other|Placebo|Matching oral administration of inactive substance once daily
79392348|NCT01581593|Biological|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
79392349|NCT01581281|Drug|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
79849413|NCT03422783|Diagnostic Test|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
79849414|NCT03422783|Diagnostic Test|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
79252934|NCT06125236|Other|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
79252935|NCT06124703|Drug|Prednisone tablet|Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
79392350|NCT01581281|Drug|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
79392351|NCT01581281|Drug|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
79392352|NCT02692716|Drug|semaglutide|For oral use once daily.
79392353|NCT02692716|Drug|placebo|For oral use once daily.
79547915|NCT05154786|Other|Early Mobilization and endurance training|The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
79547916|NCT05154786|Other|Usual Care|The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
79711128|NCT01087489|Drug|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
80031456|NCT05162456|Diagnostic Test|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
79252936|NCT06124703|Drug|Ginkgo Biloba Extract|Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
79547917|NCT05153330|Drug|BMF-219|BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
79547918|NCT05141162|Behavioral|case and control group|randomized controlled experimental study
79392354|NCT05745012|Procedure|endoscopic mucosal resection|The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
79392355|NCT05745012|Procedure|sham|The procedure consists of performing endoscopic exploration, no mucosal resection
79392356|NCT01580969|Drug|Bevacizumab|Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.
79392357|NCT01580969|Drug|Minocycline|Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
79392358|NCT01580969|Radiation|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
79392359|NCT02392884|Behavioral|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
79392360|NCT01693367|Device|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
79711129|NCT04306627|Drug|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
79711130|NCT04306471|Drug|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
79277316|NCT03531541|Device|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
79711131|NCT04306471|Other|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
80017016|NCT02287064|Drug|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
79277317|NCT02198027|Drug|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
79849415|NCT03422783|Biological|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
79392361|NCT01693367|Device|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
79392362|NCT03165162|Behavioral|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
79277318|NCT02198027|Other|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
79392363|NCT02696226|Drug|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
79392364|NCT02696226|Drug|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
79547919|NCT05123989|Behavioral|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
79547920|NCT05123989|Behavioral|Constant move goals|Static move goal delivered by the Welltory mobile app
79547921|NCT05117866|Drug|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
79547922|NCT05117177|Drug|Inupadenant|Oral administration
79547923|NCT05114031|Other|FB101|Microbial intervention using product FB101
79547924|NCT05114031|Other|Placebo|Saline water
79547925|NCT05107284|Behavioral|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
79547926|NCT05107284|Behavioral|Delayed feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
79547927|NCT05106686|Dietary Supplement|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
79547928|NCT05106686|Dietary Supplement|placebo group|Placebo 300 mg/day for 12 weeks
79547929|NCT05102136|Drug|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
79547930|NCT05102136|Drug|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
79392365|NCT02696226|Drug|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
79711132|NCT04758481|Radiation|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
79711133|NCT04758481|Radiation|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
79711134|NCT04758481|Radiation|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
79711135|NCT04296253|Genetic|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
79711136|NCT04304989|Other|mHealth program|mobile health applications
79711137|NCT04304989|Other|usual care|usual care
79711138|NCT02877667|Device|planar acoustic wave device|accessory to laser treatment
79711139|NCT01082965|Drug|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
79711140|NCT01082965|Drug|Placebo|matching placebo
79711141|NCT01102426|Drug|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
79711142|NCT01102426|Drug|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
79711143|NCT04304365|Other|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
79711144|NCT04304365|Other|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
79711145|NCT04304365|Other|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
79849416|NCT03410836|Drug|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
79849417|NCT03410836|Other|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
79252937|NCT06124183|Behavioral|The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals|The program is based on the emotional intelligence skills model (Mayer & Salovey, 1997; Salovey & Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
79252938|NCT06124105|Diagnostic Test|arterial blood gases|measurement of partial oxygen pressure in urine by arterial blood gas device
79252939|NCT06124066|Drug|Mirabegron 50 MG|The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
79277319|NCT02257463|Drug|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
79277320|NCT02257463|Other|peripheral muscles exercise training|
79547931|NCT05095259|Drug|insulin human|Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of ~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
79547932|NCT05095259|Drug|Epinephrin|Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
79849418|NCT03390595|Combination Product|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~Intravenously every 2 weeks for two cycles.~During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~Intravenously every 2 weeks until progressive disease or intolerance.~Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
80017017|NCT02095704|Drug|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
79392366|NCT02696226|Drug|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
79392367|NCT02393040|Other|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
79547933|NCT05095259|Procedure|Muscle biopsy|With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( ~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
79711146|NCT04308772|Behavioral|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
79711147|NCT02879422|Genetic|genetic analysis|
79711148|NCT02879656|Procedure|non-operative treatment|conservative treatment with 5 weeks cast immobilization
79711149|NCT02879656|Procedure|operative treatment|surgery with volar locking plate with modified Henry's volar approach
79711150|NCT02881138|Drug|RC48-ADC|
79711151|NCT04308460|Procedure|arthrocentesis|lavage of the temporomandibular joint was done
79711152|NCT04308460|Procedure|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
79711153|NCT02879734|Other|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
79711154|NCT02879344|Other|Blood draw|
79392368|NCT02392728|Behavioral|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
79392369|NCT02392728|Behavioral|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
79547934|NCT05095259|Procedure|Adipose tissue biopsy|With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( ~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
79711155|NCT02879266|Biological|TetraVax-DV TV005|Contains 10^3 plaque-forming units (PFUs) of rDEN1Δ30, 10^4 PFUs of rDEN2/4Δ30(ME), 10^3 PFUs of rDEN3Δ30/31-7164, and 10^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
79711156|NCT02879266|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
79711157|NCT04308850|Drug|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
79711158|NCT04308538|Procedure|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
79252940|NCT06123949|Device|Galvanic Vestibular Stimulation|Galvanic Vestibular Stimulation (GVS) is a non-invasive technique that uses low-level electrical currents to stimulate the vestibular system, affecting balance, posture, and eye movements. It has applications in research, clinical assessment, and rehabilitation of vestibular and balance-related issues, as well as potential applications in cognitive and motor function enhancement.
79252941|NCT06123936|Other|Reminder|"At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient."
79404263|NCT04425174|Procedure|Quadratous lumborum block|Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.
79711159|NCT04308538|Procedure|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
79711160|NCT02880904|Other|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
79711161|NCT02880670|Drug|BMS-986142|
79711162|NCT01101334|Drug|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
79711163|NCT01101334|Drug|erlotinib|Erlotinib; One 150mg tablet administered once daily
79711164|NCT02880748|Other|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
79711165|NCT02880748|Other|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
79711166|NCT01327547|Drug|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
79711167|NCT01327547|Drug|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
79711168|NCT04387643|Dietary Supplement|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
80017018|NCT02095704|Drug|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
79711169|NCT04386785|Device|Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins|The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
79711170|NCT01308567|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
79711171|NCT01308567|Drug|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
79711172|NCT01308567|Drug|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
79849419|NCT03390595|Combination Product|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
79849420|NCT03387761|Drug|Ipilimumab|"For Cohort 1:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~Day 1: Ipilimumab 1 mg/kg~Days 22: Ipilimumab 1 mg/kg"
79849421|NCT03387761|Drug|Nivolumab|"For Cohort 1:~Day 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~Days 1 and 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg"
79849422|NCT03367312|Drug|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
79252942|NCT06123871|Other|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
79277321|NCT02257463|Device|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
79547935|NCT05095259|Drug|Glucagon|Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
79277322|NCT00162175|Drug|Muraglitazar|
79547936|NCT05095259|Device|IPRO 2 Medtronic Minimed|All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
79547937|NCT05095259|Procedure|7 Tesla (7T) Magnetic Resonance Imaging|Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
79547938|NCT05095259|Procedure|Indirect Calorimetry using Jaeger Oxycon Champion|Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
79547939|NCT05095259|Procedure|Core temperature and thermography using Thermovision SC645|Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
79547940|NCT05095259|Device|Freestyle Libre 2|All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
79711173|NCT00592163|Drug|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
79711174|NCT00592241|Device|"Adi Insulin Pump Usability"|no intervention
79711175|NCT04375007|Other|Routine care|Physiotherapy intervention in routine care
79711176|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
79711177|NCT02890719|Drug|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
79711178|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
79711179|NCT02890719|Drug|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
79711180|NCT02890719|Drug|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
79711181|NCT04373681|Other|patient-administered questionnaires|patient-administered questionnaires
79739732|NCT03900832|Other|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches ~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
79849423|NCT03354169|Behavioral|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
79711182|NCT04324983|Other|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
79711183|NCT05644197|Other|Multidisciplinary program|"Multidisciplinary program:~APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~Psychological intervention:~5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
79739733|NCT03900832|Other|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at ~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
79849424|NCT03325946|Behavioral|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
79849425|NCT03288545|Drug|enfortumab vedotin (EV)|Intravenous (IV) infusion on days 1 and 8 every 21 days
79849426|NCT03288545|Drug|pembrolizumab|IV infusion on day 1 every 21 days
79849427|NCT03288545|Drug|cisplatin|IV infusion on day 1 every 21 days
79252943|NCT06123442|Behavioral|Cognitive Resilience Intervention|Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period [22]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
79252944|NCT06123416|Behavioral|Expressive Writing|Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
79849428|NCT03288545|Drug|carboplatin|IV infusion on day 1 every 21 days
79849429|NCT03288545|Drug|gemcitabine|IV infusion on days 1 and 8 every 21 days
79849430|NCT03274414|Drug|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m^2 (dose reductions after the first cycle allowed for toxicity)
79849431|NCT03274414|Radiation|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
79849432|NCT03274414|Procedure|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
79849433|NCT03274414|Drug|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
79849434|NCT03267316|Biological|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
79849435|NCT03267316|Drug|Cisplatin|Standard of care treatment
79252945|NCT06122974|Device|Drug Eluting Temporary Spur Stent System|The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
79252946|NCT06122974|Device|Percutaneous Transluminal Balloon Angioplasty|A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
79252947|NCT06122623|Other|Health Education|As previously mentioned, the intervention for this study will be a gaming education program that will be conducted once with each participant. Implementation of the program will occur at different times. Each performance will include a maximum of 60 participants who will be divided into small groups within the same room. Seven to 10 participants will comprise a small group, and each group will have one facilitator. The facilitator will be either a member of the research team or a Health lecturer who will be recruited and trained by the Japanese and Indonesian research teams.
79547941|NCT05068284|Drug|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
79547942|NCT05068284|Drug|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
79849436|NCT03267316|Drug|Gemcitabine|Standard of care treatment
79849437|NCT03267316|Drug|Nab-paclitaxel|Standard of care treatment
79849438|NCT03267316|Drug|Carboplatin|Standard of care treatment
79849439|NCT03267316|Drug|Pemetrexed|Standard of care treatment
79547943|NCT05068284|Drug|ABBV-154|Subcutaneous Injection
79547944|NCT05068284|Drug|Placebo|Subcutaneous Injection
79547945|NCT05049278|Drug|Norepinephrine|"Continuous drug: norepinephrine 4mg * 1@ + D5W 200 mL (20 μg/mL)~Range: 0.03 ~ 0.09 μg/kg/min (= 0.1 ~ 0.3 mL/kg/h)"
79547946|NCT05049278|Drug|Phenylephrine|"Continuous drug: phenylephrine 10mg * 5@ + D5W 200 mL (250 μg/mL)~Range: 0.42 ~ 1.26 μg/kg/min (= 0.1 ~ 0.3 mL/kg/h)"
79547947|NCT05032963|Behavioral|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
80017019|NCT02287142|Procedure|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
80017020|NCT02102412|Biological|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
80017021|NCT04820140|Procedure|Lymphatic drainage|Lymphatic drainage
80017022|NCT02287220|Device|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
79252948|NCT06122506|Procedure|Laparoscopic cerclage|Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
79547948|NCT04995237|Behavioral|PPP|Participants will be provided with a weekly bag of produce, information about how to cook the produce, assistance in setting quality of life goals, and individualized teaching to support meeting participant's set goals.
79252949|NCT06122506|Procedure|Vaginal cerclage|Transvaginal cerclage in pregnant women.
79252950|NCT06122415|Diagnostic Test|Plasma Amyloid Probability Score 2 (APS 2) score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252951|NCT06122415|Diagnostic Test|Plasma ptau217/nptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252952|NCT06122415|Diagnostic Test|Plasma ptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252953|NCT06122415|Diagnostic Test|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252954|NCT06122415|Diagnostic Test|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79392370|NCT01692275|Other|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
79404264|NCT04425174|Procedure|Epidural anesthesia|Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
79547949|NCT04994054|Dietary Supplement|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
79547950|NCT04994054|Dietary Supplement|Placebo group|Placebo 2,400 mg/day for 12 weeks
79711184|NCT02893007|Other|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
79711185|NCT04325061|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
79547951|NCT04993729|Drug|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
79547952|NCT04993729|Drug|Placebo capsule|Placebo capsules, p.o. TID.
79547953|NCT04982354|Drug|CPX-351|For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
79711186|NCT02893085|Biological|bile sample analysis|tumor mutation profile tumor genotype
79711187|NCT02893085|Biological|biochemical markers, VEGF and MMPs, in bile samples|
79711188|NCT01307319|Drug|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
79711189|NCT01307319|Drug|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
79711190|NCT04367519|Diagnostic Test|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
79711191|NCT05644119|Device|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
79711192|NCT05644119|Device|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
79711193|NCT04365725|Drug|Remdesivir|Compassionate provision
79711194|NCT04365335|Behavioral|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
80017023|NCT01675492|Device|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
80017024|NCT02250690|Device|experimental group - tDCS|
80017025|NCT02250690|Device|Control group (tDCS sham)|
79252955|NCT06122155|Device|Transcranial direct current stimulation (Anodal)|20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
79252956|NCT06122155|Device|Transcranial direct current stimulation (Sham)|20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
79277323|NCT02198105|Device|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~PTA with Cutting-Balloon (60-120 seconds).~PTA with DC-Balloon (60 seconds).~Technical success is defined as~no recoil >30%~no dissection >Type B~no stenting >30% of lesion length."
79711195|NCT04365335|Biological|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
79711196|NCT04365335|Other|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
79711197|NCT04365335|Behavioral|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
79277324|NCT02375685|Biological|Gevokizumab|
79277325|NCT04371081|Device|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
79392371|NCT01692275|Other|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
79711198|NCT02892929|Behavioral|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
79711199|NCT02892929|Behavioral|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
79711200|NCT04328051|Other|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
79711201|NCT01080391|Drug|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
79711202|NCT01080391|Drug|Lenalidomide|25 mg orally on days 1-21
79711203|NCT01080391|Drug|Carfilzomib|20 mg/m², 27 mg/m² intravenously
79711204|NCT04359407|Other|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
79711205|NCT00592397|Other|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
79711206|NCT04356365|Other|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
79711207|NCT04327817|Device|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
79711208|NCT04747483|Other|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
79711209|NCT04747483|Other|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
79711210|NCT04351451|Procedure|thyroidectomy|total thyroidectomy
79711211|NCT04350983|Behavioral|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
79711212|NCT04348721|Other|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
80017026|NCT00095030|Drug|muraglitazar|
79849440|NCT03257631|Drug|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
79547954|NCT04982354|Drug|Midostaurin|The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
79849441|NCT03257631|Drug|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
80017027|NCT02099604|Drug|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
80031457|NCT04890964|Device|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
80031458|NCT04890886|Diagnostic Test|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
79252957|NCT06121752|Procedure|Endoscopic submucosal dissection|Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.
79277326|NCT03534089|Other|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
79392372|NCT03167112|Drug|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
79392373|NCT03167112|Drug|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
79392374|NCT03167112|Drug|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
79392375|NCT03167112|Drug|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
79392376|NCT02692560|Behavioral|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
79392377|NCT02692560|Other|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
79547955|NCT04982354|Drug|Busulfan|0.8 mg/kg/dose every six hours x 12 doses administered intravenously
79547956|NCT04982354|Drug|Melphalan|70 mg/m2/day x 2 doses administered intravenously
79392378|NCT02688192|Behavioral|Exercise Intervention|Participate in fitness program
79547957|NCT04982354|Drug|Fludarabine|25 mg/m2/day x 5 doses administered intravenously
79711213|NCT04327739|Other|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
79547958|NCT04982354|Biological|CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor|Allogeneic stem cell transplant infused intravenously
79547959|NCT04981834|Other|Quality-of-Life Assessment|Ancillary studies
79392379|NCT02688192|Behavioral|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
79711214|NCT04327739|Other|Intervention 2 Exercise and INIT|"Exercise programme same as Intervention Group 1 and~Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
79711215|NCT04327739|Other|Intervention 3 Exercise and SMT|"Exercise programme same as Intervention Group 1 and~Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
79711216|NCT04327739|Other|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
79711217|NCT01070329|Drug|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
79711218|NCT01070329|Drug|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
79711219|NCT04327661|Drug|Tradipitant High Dose|Oral Capsule
79711220|NCT04327661|Drug|Tradipitant Low Dose|Oral Capsule
79711221|NCT04327661|Drug|Placebo|Oral Capsule
79392380|NCT02688192|Device|Monitoring Device|Wear an electronic accelerometer
79392381|NCT02688192|Other|Quality-of-Life Assessment|Ancillary studies
79547960|NCT04981834|Other|Questionnaire Administration|Ancillary studies
79547961|NCT04981834|Procedure|Radical Prostatectomy|Undergo RARP
79547962|NCT04981834|Procedure|Vesicopexy|Undergo vesicopexy
80017028|NCT03075046|Device|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
80017029|NCT03075046|Other|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
79252958|NCT06121752|Device|EFTR|"Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4)."
79252959|NCT06121544|Diagnostic Test|Plasma tau|Plasma levels of different p-tau and np-tau species
79392382|NCT01579565|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
79252960|NCT06121544|Diagnostic Test|Plasma Ab42/Ab40|Plasma levels of Ab42/Ab40 ratio
79392383|NCT01579565|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
79392384|NCT01578785|Drug|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
79392385|NCT01578785|Drug|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
79392386|NCT02692482|Device|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
79547963|NCT04975633|Device|Bodyport Cardiac Scale|Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
79547964|NCT04959461|Behavioral|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
80017030|NCT02099760|Device|STD testing (GC/Ct/trich)|
79711222|NCT01069861|Drug|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
80017031|NCT04751110|Other|ultrasound guided rhomboid intercostal block|A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
80017032|NCT02099916|Drug|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
80031459|NCT04890886|Diagnostic Test|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
79547965|NCT04959461|Behavioral|Usual Care|6 hours of driver education
79547966|NCT04935606|Behavioral|Usual Care|Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
79547967|NCT04935606|Behavioral|QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|"QUIT's core components include:~patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~face-to-face brief clinician advice on reducing drug use (2-3 minutes);~video doctor reinforcing the clinician message;~drug use reduction brochure;~2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes)."
79711223|NCT04344197|Other|global survey|surgery questionnaire
79711224|NCT02892851|Device|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~Parameter setting~Cross-over double-bind (ON/OFF)~Open Phase (ON)"
79711225|NCT04304521|Procedure|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
79252961|NCT06121544|Diagnostic Test|Flutemetamol F18 Injection|Positron emission tomography (PET) imaging of amyloid-β plaques
79547968|NCT04935606|Behavioral|QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)|"The QUIT-Mobile intervention includes QUIT's core components and adds:~SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms."
79547969|NCT04932382|Drug|Misoprostol|will be used 3 h before IUD insertion
79252962|NCT06121544|Diagnostic Test|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
79252963|NCT06121544|Diagnostic Test|Magnetic resonance imaging (MRI)|Different MRI sequences relevant for brain imaging
79252964|NCT06121414|Device|laserpuncture|laserpuncture use continous wave,dose 2 Joule, 785nm, 50mw
79547970|NCT04932382|Device|IUD|a copper T380A IUD
79547971|NCT04921475|Device|Regional oxygen saturation monitoring|Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
79547972|NCT04910256|Drug|HuaTuo Zaizao pill|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
80017033|NCT02099916|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
80017034|NCT02102646|Drug|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
79252965|NCT06121414|Device|Sham Laserpuncture|Sham laser using laserpuncture in off condition
79711226|NCT04327427|Other|Aspirin|Outcome Analysis of Aspirin in liver transplantation
80017035|NCT02102646|Procedure|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
79252966|NCT06121206|Other|Altitude-like hypoxia (12% O2)|Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (≈ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
79252967|NCT06121206|Other|Normoxia (20% O2)|Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours
79392387|NCT02692482|Procedure|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
79392388|NCT03167034|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79392389|NCT03167034|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79547973|NCT04910256|Other|basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
79547974|NCT04909060|Device|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children between 1 and 3 years old, scheduled for elective adeno-tonsillectomy, tonsillectomy or adenoidectomy and with no neurological or cardiac congenital deficits, no cardiac arrythmias (non-sinus rhythm), no implanted pacemakers, nor with a history of prolonged resuscitation at birth, and chronic therapy with drugs that have known effects on sympathetic and parasympathetic activity, ASA physical status III or higher and parent/guardian refusal will have a NIPE placed on their electrocardiogram, at least 20 minutes before the expected end of the surgery, the NIPE monitor will be connected to the anesthesia monitor at the end of the surgery, when the patient is considered ready to be transferred to the PACU, the NIPE will be disconnected and reconnected to the patient monitor once in PACU. Values will be recorded until the patient meets the discharge criteria from PACU not before 2hours
79547975|NCT04901715|Drug|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
79711227|NCT02875405|Procedure|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
79711228|NCT04306549|Other|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
79711229|NCT04338347|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
79711230|NCT02875717|Drug|Acetylsalicylic acid|
79711231|NCT02875717|Drug|low molecular weight heparin|
79711232|NCT04337957|Other|geriatric nephrology|Collection of the geriatrician's opinion
79711233|NCT02875639|Drug|Yiqi prescription|
79711234|NCT02875639|Drug|Huoxue prescription|
79711235|NCT02875639|Drug|Buyang huanwu decoction|
79711236|NCT02875639|Drug|QISHEN YIQI DRIPPING PILLS|
79711237|NCT02875639|Drug|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
79711238|NCT02875639|Drug|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
79711239|NCT04334837|Diagnostic Test|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
79739734|NCT03900832|Other|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
79547976|NCT04901715|Diagnostic Test|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.
79252968|NCT06121206|Behavioral|Cognitive training|The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
79849442|NCT03256812|Device|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
79849443|NCT03256812|Device|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
79849444|NCT03164460|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
79849445|NCT03164460|Radiation|Proton Radiation|Undergo IMRT/IMPT
79849446|NCT03164460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79849447|NCT03152058|Drug|Certolizumab Pegol|"Certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
79252969|NCT06121206|Behavioral|Sham training|Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.
79252970|NCT06121102|Procedure|Supervoltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage pulsed RF(60-75 volt according to patient tolerability will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
79547977|NCT04895592|Drug|Dexamethasone|Given PO or IV
79547978|NCT04895592|Procedure|Resection|Undergo surgical resection
79547979|NCT04895592|Radiation|Stereotactic Radiosurgery|Undergo SRS
79711240|NCT04741711|Procedure|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
79711241|NCT04741711|Procedure|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
79849448|NCT03129139|Drug|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
79849449|NCT03122639|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
79849450|NCT03122639|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
79849451|NCT03117920|Drug|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
79547980|NCT04879927|Other|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
79711242|NCT04327349|Biological|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
79849452|NCT03098459|Other|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
79277327|NCT03534089|Other|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
79547981|NCT04879927|Other|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
79711243|NCT04333121|Other|weight|we can monitoring the growth of the infants by weight gain degree
79711244|NCT04331015|Diagnostic Test|Pure tone audiometry|pure tone audiometry
79711245|NCT00593099|Drug|Bupropion|BUP [as the intermediate-release (IR) formulation] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg [as BUP SR formulation] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
79711246|NCT00593099|Drug|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
79711247|NCT00593177|Drug|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
79711248|NCT00593255|Drug|soluble human insulin|
79711249|NCT00593255|Drug|insulin aspart|
79711250|NCT00593255|Drug|insulin NPH|
79711251|NCT02892773|Device|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times per therapy session.~Each I.S. therapy session will last about 15 minutes, 3 times per day.~Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
79711252|NCT02892773|Device|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times.~Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
79711253|NCT00593723|Radiation|IMRT|
79711254|NCT00593801|Drug|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
79711255|NCT00593801|Drug|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
80017036|NCT00366704|Drug|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
79252971|NCT06121102|Procedure|Standard voltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage8 pulsed RF will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
79252972|NCT06120907|Other|Data collection|The data include phenotypic data, treatments administered, response to treatment, Three-dimensional total body images, biopsies and blood plasma.
79392390|NCT02392338|Procedure|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
79547982|NCT04876053|Behavioral|Healthy Food Delivery Intervention|Each weekly food box will include ~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
79547983|NCT04861103|Drug|Lovenox|Three times a day dosing and measuring Xa peak and trough levels
79547984|NCT04855123|Other|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
79547985|NCT04855123|Other|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
79547986|NCT04843761|Biological|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
79547987|NCT04843761|Drug|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
79547988|NCT04843761|Biological|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
79252973|NCT06120842|Drug|Bimatoprost Implant System (High Dose)|Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
79252974|NCT06120842|Drug|Bimatoprost Implant System (Low Dose)|Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
79392391|NCT01578551|Drug|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
79404265|NCT05119452|Other|Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)|The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
79547989|NCT04843761|Drug|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
79547990|NCT04843761|Drug|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
79711256|NCT00593879|Drug|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
79711257|NCT00594113|Other|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
79711258|NCT00594113|Other|Touch screen intervention|Touch screen intervention
79711259|NCT00594191|Drug|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
79711260|NCT00594191|Drug|Placebo|Placebo with the same characteristics of the drug and at the same dose
79711261|NCT00594269|Drug|Risperidone|Discontinuation
79711262|NCT00594269|Drug|Escitalopram|Discontinuation
79711263|NCT00594269|Drug|Citalopram|Discontinuation
79711264|NCT00594269|Drug|Sertraline|Discontinuation
79711265|NCT00594269|Drug|Paroxetine|Discontinuation
79711266|NCT00594347|Biological|Pneumo 23|Vaccine (Pneumo 23)
79711267|NCT00594347|Biological|Prevnar|Vaccine (Prevnar)
80017037|NCT00366704|Drug|risperidone|4mg, QD, 8 week treatment
79711268|NCT04326959|Biological|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
79711269|NCT04326959|Biological|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
79711270|NCT04326959|Biological|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
79711271|NCT01306929|Drug|pridopidine|45mg bid
79711272|NCT02892617|Other|Bacteriological analysis of disc|
79711273|NCT02892695|Biological|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
79711274|NCT02892539|Radiation|Coronary Angiography|
79711275|NCT00594503|Drug|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
79711276|NCT00594581|Drug|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
79849453|NCT03096054|Drug|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
79547991|NCT04797572|Device|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
79547992|NCT04795635|Device|CMM + Axon Therapy|transcutaneous magnetic stimulation (tMS)
79547993|NCT04766190|Behavioral|Group 2: The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
79547994|NCT04766190|Behavioral|Group 1: Usual Care|Patients randomized to this arm will receive usual care.
79547995|NCT04766190|Behavioral|Group 3: The DISCO App + Booster|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
79547996|NCT04742881|Procedure|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
79711277|NCT00594737|Drug|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
80017038|NCT03924622|Device|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
80031460|NCT04890886|Diagnostic Test|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
79547997|NCT04742881|Procedure|Low pressure + standard instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of standard instruments (5mm and 10mm instruments)
79711278|NCT00594893|Procedure|Mini Incision Approach|Mini Incision Approach
79711279|NCT00594893|Procedure|2 Incision Approach|2 Incision Approach
79711280|NCT00594971|Other|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
80031461|NCT04890886|Diagnostic Test|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
79252975|NCT06120842|Drug|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol Maleate Ophthalmic Solution 0.5% BID
79252976|NCT06120842|Device|Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL|Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
79547998|NCT04721925|Behavioral|Social media messaging|A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
79711281|NCT00594971|Other|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
79711282|NCT00595049|Drug|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
79711283|NCT00595205|Other|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
79711284|NCT00595283|Behavioral|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
79711285|NCT00595283|Behavioral|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
79711286|NCT04326881|Drug|SHR-1314|single dosing
79711287|NCT00595673|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
79711288|NCT02892461|Procedure|Umbilical cord milking|As same as that in arm descriptions.
79711289|NCT00595829|Drug|XL019|XL019 capsules administered orally
79711290|NCT00595985|Drug|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
79711291|NCT00596063|Biological|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
79711292|NCT00596063|Biological|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
79711293|NCT00596141|Device|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
79711294|NCT00596219|Drug|celecoxib|celecoxib
79849454|NCT03094793|Other|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
79849455|NCT03055767|Drug|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
79392392|NCT01578551|Drug|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
79849456|NCT03055767|Other|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
79849457|NCT03025308|Drug|Filgotinib|Tablet(s) administered orally once daily
79849458|NCT03025308|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
79849459|NCT02998567|Drug|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
79711295|NCT00596297|Drug|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
79849460|NCT02998567|Drug|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
80017039|NCT03924622|Device|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
79547999|NCT04720313|Drug|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
79548000|NCT04699604|Drug|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) or placebo to their current asthma regimen.
79392393|NCT01578551|Drug|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
79392394|NCT01578551|Drug|Metformin|1000 mg twice daily with food.
79392395|NCT02392182|Other|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
79548001|NCT04699604|Drug|Placebo|Placebo
79711296|NCT00596297|Procedure|pars plana vitrectomy|4 weeks after baseline
79711297|NCT00596375|Procedure|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
79548002|NCT04677660|Biological|TAK-919|TAK-919 intramuscular injection
79548003|NCT04677660|Biological|Placebo|Placebo intramuscular injection
79548004|NCT04664842|Other|Diaphragmatic Stretch Technique|Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
79548005|NCT04664842|Other|Breathing Exercise Training|During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
79548006|NCT04648215|Other|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
79849461|NCT02998567|Drug|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
79252977|NCT06120842|Device|SpyGlass IOL|SpyGlass Intraocular Lens
79252978|NCT06120361|Diagnostic Test|Plasma APS 2 score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252979|NCT06120361|Diagnostic Test|Plasma p-tau217/np-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252980|NCT06120361|Diagnostic Test|Plasma p-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252981|NCT06120361|Diagnostic Test|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252982|NCT06120361|Diagnostic Test|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
79252983|NCT06120361|Diagnostic Test|MRI and CT of the brain|Structural brain imaging
79711298|NCT00596375|Drug|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
79711299|NCT00596531|Drug|Acamprosate|Oral administration, 666 mg, tid, for 4 months
79711300|NCT00596531|Drug|Placebo|Oral administration of 2 pills, tid, for 4 months
79392396|NCT03106350|Other|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
79392397|NCT03106428|Drug|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
79392398|NCT02392260|Device|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
79548007|NCT04648215|Other|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
79548008|NCT04644419|Other|none (observational study)|This is an observational study and does not include intervention delivery.
79548009|NCT04633928|Biological|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
79548010|NCT04605445|Procedure|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
79548011|NCT04605445|Procedure|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
79849462|NCT02918864|Drug|Oxytocin|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
80017040|NCT02099994|Biological|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
79392399|NCT03166878|Biological|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
79548012|NCT04587167|Other|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
79548013|NCT04587167|Other|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
79711301|NCT00596609|Drug|Intrathecal Morphine|"In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
79711302|NCT00596765|Behavioral|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
79711303|NCT00596843|Behavioral|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
79711304|NCT00596843|Behavioral|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
79711305|NCT00622973|Other|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
79711306|NCT00622973|Other|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
79711307|NCT04326647|Other|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
79711308|NCT04326647|Other|Exercise|Exercises about balance and gait
79711309|NCT00596999|Procedure|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
79711310|NCT00597077|Other|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
79849463|NCT02918864|Behavioral|Social Cognitive Skills Training|Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
79392400|NCT01692197|Drug|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
79392401|NCT01692197|Drug|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
80017041|NCT02099994|Biological|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
80017042|NCT02099994|Biological|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
79548014|NCT04587167|Other|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
79711311|NCT00597077|Other|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
79711312|NCT04326803|Biological|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
79711313|NCT02892227|Procedure|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
79711314|NCT00597233|Drug|insulin aspart|
79711315|NCT00597233|Drug|soluble human insulin|
79711316|NCT00597233|Drug|insulin NPH|
79711317|NCT00597311|Radiation|radiotherapy|"Short term radiotherapy 5x5 Gy during 5 days~Chemoradiotherapy 50 Gy + 5Fu/Lv"
79711318|NCT01064401|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
79711319|NCT01064401|Drug|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
79711320|NCT01064401|Biological|Interferon beta-1a|Interferon beta-1a for intramuscular injection
79548015|NCT04581616|Procedure|Intrathoracic Intercostal Nerve Block|Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
79392402|NCT01692197|Drug|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age <60 years) or Days 9 - 11 (age > 60 years).
79711321|NCT01064401|Drug|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
80017043|NCT02099994|Biological|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
80017044|NCT02097186|Procedure|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
80031462|NCT04890886|Diagnostic Test|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
79252984|NCT06120361|Diagnostic Test|Different cognitive tests|Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
79392403|NCT01692197|Drug|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
79392404|NCT01692119|Behavioral|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
79548016|NCT04581616|Procedure|Erector Spinae Plane Block|Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
79711322|NCT00597389|Drug|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
79711323|NCT02892071|Drug|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
79711324|NCT02892071|Device|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
79711325|NCT02892071|Device|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
79711326|NCT00597467|Device|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
79711327|NCT00597467|Device|Acuvue 2 Soft Contact Lens|Control device
79711328|NCT01306617|Drug|ABT-450|tablets
79711329|NCT01306617|Drug|ABT-333|tablets
79252985|NCT06120348|Device|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
79252986|NCT06120348|Device|Sham Stimulation|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
79252987|NCT06118957|Drug|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
79404266|NCT02788591|Drug|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
79548017|NCT04573582|Drug|Enasidenib|100 mg enasidenib (CC-90007)
79711330|NCT01306617|Drug|ribavirin|tablets
79711331|NCT01306617|Drug|ritonavir|capsules
79711332|NCT00597623|Other|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
79711333|NCT00597623|Other|Placebo|syringes under cutaneous vol = 8 ml
79711334|NCT00597779|Device|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
79711335|NCT04326569|Other|Blood sample|Blood sample to quantify copeptin
79711336|NCT02874625|Procedure|Dental restoration|
79711337|NCT02875795|Procedure|automatic speech processing tool|
80017045|NCT05725850|Other|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
79711338|NCT00597857|Drug|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
79711339|NCT00597857|Drug|placebo|receipt of a placebo pill for 16 days
79392405|NCT03165552|Other|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
79711340|NCT00627133|Drug|levetiracetam|2 gram iv load, 500mg bid
79711341|NCT01306305|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
79711342|NCT00598013|Drug|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
79252988|NCT06118606|Other|Case-manager led multidisciplinary follow-up after intensive care|Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
79252989|NCT06117904|Drug|MEBO ointment|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
79252990|NCT06117904|Drug|Symptomatic treatment only|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
79392406|NCT01691885|Drug|Fluticasone Furoate|100mcg Once daily
79711343|NCT04303429|Drug|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
79711344|NCT00598091|Drug|gemcitabine|1000mg/m2, Days 1, 8, 15
79711345|NCT00598091|Drug|dasatinib|50mg, PO, QD
79711346|NCT00598091|Drug|gemcitabine|1000mg/m2, days 1, 8, 15
79711347|NCT00598091|Drug|dasatinib|50mg, PO, BID
79711348|NCT00623415|Drug|Flupirtine|300 mg daily (divided in two doses)
79711349|NCT00623415|Drug|Placebo|twice daily
79711350|NCT02874703|Other|Cardiac MRI/MRS|
79711351|NCT04326725|Drug|Plaquenil 200Mg Tablet|health workers under risk who took this medications
79711352|NCT01038427|Drug|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
79711353|NCT01038427|Drug|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
79711354|NCT01038427|Drug|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
79711355|NCT00598169|Biological|rituximab|375mg/m2 on Day 1
79711356|NCT00598169|Drug|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
79711357|NCT00598169|Drug|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x [creatinine clearance + 25]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
79711358|NCT00598169|Drug|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
79711359|NCT00598169|Drug|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
79711360|NCT00598169|Drug|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
79711361|NCT00598169|Genetic|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
79711362|NCT00598169|Genetic|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
79711363|NCT00598247|Drug|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
79711364|NCT00598325|Biological|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
79711365|NCT00598403|Drug|cefditoren pivoxil|400 mg, oral, single dose during 3 days
79711366|NCT00598403|Drug|Ciprofloxacin|250 mg, oral, twice a day for 3 days
79711367|NCT00598637|Device|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
79711368|NCT00598637|Device|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
79711369|NCT00598715|Device|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
79711370|NCT00598715|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
79849464|NCT02918864|Behavioral|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
79392407|NCT01691885|Drug|Vilanterol|25mcg Once daily
79849465|NCT02916979|Drug|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
79849466|NCT02916979|Drug|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
79849467|NCT02916979|Biological|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
79849468|NCT02916979|Drug|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
79849469|NCT02716116|Drug|TAK-788|TAK-788 capsules.
79849470|NCT02702414|Biological|Pembrolizumab|Intravenous (IV) infusion
79849471|NCT02548559|Drug|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
79849472|NCT02548559|Drug|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
79849473|NCT02548559|Drug|Placebo|Placebo solution.
79849474|NCT02491632|Drug|Dexamethasone|Given PO
79849475|NCT02491632|Behavioral|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
79711371|NCT00598793|Drug|biphasic insulin aspart|
79252991|NCT06116578|Drug|Pembrolizumab|cf Arm A
79252992|NCT06116578|Drug|Pembrolizumab and Olaparib|cf Arm B
79252993|NCT06116578|Drug|Pembrolizumab adjuvant|After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year
79252994|NCT06115382|Behavioral|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
79711372|NCT00598793|Drug|insulin glargine|
79711373|NCT00598793|Drug|metformin|
79711374|NCT00598793|Drug|pioglitazone|
79711375|NCT04325945|Device|Low level laser therapy|808nm low level laser therapy on acupuncture points
79252995|NCT06115382|Behavioral|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
79392408|NCT03166800|Drug|Mitoquinone|This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
79392409|NCT03166800|Drug|Mitoquinone|This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
79392410|NCT03166800|Drug|Placebo|This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
79392411|NCT03166254|Drug|Pembrolizumab|-Pembrolizumab will be given intravenously over the course of 30 minutes
79392412|NCT03166254|Biological|NEO-PV-01 vaccine|-Generation of the vaccine is expected to take approximately 12 weeks
79711376|NCT00599105|Procedure|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
79711377|NCT01037413|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
79711378|NCT01037413|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
79711379|NCT00599183|Other|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
79711380|NCT01326845|Drug|Deferasirox|
79711381|NCT02873845|Other|Preliminary validation of the COBQoL questionnaire|
79711382|NCT01062763|Drug|spironolactone|25 to 50 mg once daily
79711383|NCT01062763|Drug|placebo|addition of placebo 1 to 2 tablets daily
79711384|NCT00599261|Procedure|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
79711385|NCT00599417|Drug|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
79711386|NCT00599417|Drug|placebo|placebo controlled
79711387|NCT00599573|Drug|ondansetron|Ondansetron 4mg BID for six weeks
79711388|NCT00599651|Device|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
79849476|NCT02491632|Other|Laboratory Biomarker Analysis|Correlative studies
79849477|NCT02491632|Other|Quality-of-Life Assessment|Ancillary studies
79849478|NCT02491632|Other|Questionnaire Administration|Ancillary studies
79849479|NCT02270580|Behavioral|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
79849480|NCT02270580|Behavioral|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
79849481|NCT02086188|Drug|Mirabegron|see detailed information in associated Arm Description
79849482|NCT02086188|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
79849483|NCT01854229|Device|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
79849484|NCT01675440|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
79849485|NCT01361399|Drug|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
79849486|NCT01361399|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
79849487|NCT01361399|Drug|Lidocain|Single oral application of Lidocain (as lozenge)
79849488|NCT01361399|Drug|Placebo|Single oral application of Placebo (as lozenge)
79849489|NCT01332682|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
79392413|NCT03166254|Procedure|Biopsy|-Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
80017046|NCT05725850|Other|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
79392414|NCT03166254|Drug|Poly ICLC|-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
80017047|NCT02097264|Drug|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
79252996|NCT06114914|Diagnostic Test|Tap Talk online program|Online hand and speech motor testing
79392415|NCT03166254|Procedure|Leukapheresis|-Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
79252997|NCT06114498|Diagnostic Test|Echocardiography|Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, intensity of mitral regurgitation.
79392416|NCT03166254|Procedure|Peripheral blood samples|-Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
79392417|NCT02391870|Behavioral|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
79392418|NCT02651428|Drug|Neutrolin|Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
79392419|NCT02651428|Drug|Heparin|Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
79404267|NCT02788591|Drug|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
79548018|NCT04571164|Drug|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
79548019|NCT04571164|Drug|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
79711389|NCT00599651|Other|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
79711390|NCT01048099|Procedure|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
79711391|NCT01048099|Drug|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
79711392|NCT01048099|Drug|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
79711393|NCT00599807|Dietary Supplement|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
79711394|NCT00599885|Drug|telmisartan|telmisartan 40-80mg once per day for 8 months
80017048|NCT02097264|Drug|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
80017049|NCT02097264|Drug|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
79252998|NCT06114498|Diagnostic Test|Bioimpedance|Bioelectrical impedance analysis research
79252999|NCT06114498|Diagnostic Test|Immunoassay|Enzyme immunoassay of heat shock proteins in blood serum
79253000|NCT06114498|Diagnostic Test|Routine biochemistry|Measuring of routine biochemical parameters (glucose, total protein, creatinine, urea, uric acid, total bilirubin, direct bilirubin, total cholesterol, triglycerides, low and high density lipoprotein cholesterol, Lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium and special (C-reactive protein, N-terminal pro b-type natriuretic peptide)
79253001|NCT06113497|Drug|Cocktail injection|Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
79253002|NCT06112184|Other|SK-M11/3A1 Digital health program|Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
79404268|NCT02785471|Behavioral|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
79548020|NCT04559880|Drug|Tranexamic Acid Injection [Cyklokapron]|Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
79711395|NCT00599885|Drug|valsartan|valsartan 80-160mg once per day for 8 months
79711396|NCT00599963|Drug|paricalcitol|paricalcitol 1 mg/day
79711397|NCT01303965|Drug|Sirolimus|Start on Day -3 and continue for 1 year
79711398|NCT01303965|Drug|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
79253003|NCT06108570|Other|Cosmetic Product TOPIALYSE Baume Protect+|One or two application.s of TOPIALYSE Baume Protect+ daily on one side for 28±3 days and the Neutral Product daily on the other side for 28±3 days. The side will be decided before by randomisation.
79253004|NCT06107361|Device|B. Braun 6.35cm 20 gauge ultralong intravenous catheter|B Braun Medical Inc, 6.35cm 20 gauge ultralong intravenous catheter
79392420|NCT03166566|Device|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
79711399|NCT01303965|Drug|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
79711400|NCT00600041|Drug|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
79711401|NCT00600041|Drug|Placebo|Identical infusion manner like experimental arm
79392421|NCT01587703|Drug|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
79392422|NCT01577381|Biological|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
79392423|NCT01577381|Biological|Placebo|Intravenous, 11 doses, 30 minute infusion
79392424|NCT02686164|Drug|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
79392425|NCT02686164|Drug|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
79548021|NCT04559867|Procedure|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
79392426|NCT03167970|Device|Pill cam|Patient is asked to swallow the esophageal capsule.
79548022|NCT04559867|Procedure|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
79711402|NCT01045993|Device|Heat Device|8-Hour Heatwrap
79711403|NCT01045993|Device|Sham Device|Inactive wrap worn for 8 hours
79711404|NCT01045993|Drug|marketed analgesic|2 x 200 mg ibuprofen tablets
79711405|NCT01045993|Drug|Placebo|2 x placebo tablets
79392427|NCT03167970|Other|EGD|Patient will undergo standard EGD
79392428|NCT02651584|Drug|CAM2038 SC injection|
79548023|NCT04548193|Behavioral|Behavioral Dietary Intervention|Receive live phone call
79711406|NCT00600197|Behavioral|back school|A kind of educational program for low back pain
79711407|NCT02890563|Device|Class II Compression Stockings|
79711408|NCT04325867|Other|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
79253005|NCT06107361|Device|BD 5.71 cm 20 gauge Accucath|Bard Access Systems, Inc, BD 5.71 cm 20 gauge ultralong intravenous catheter with guide wire
79253006|NCT06105749|Device|contrast-enhanced mammography|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
79253007|NCT06105476|Other|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
79253008|NCT06105476|Other|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
79253009|NCT06105476|Other|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
79253010|NCT06105476|Other|Retinol|Test drink with 1000 μg retinol in water
79253011|NCT06104332|Device|ProRhinel Naturel spray nasal/ Allergic rhinitis|ProRhinel Naturel spray nasal: 21 days; 1 spray per nostril; 3 to 6 times per day
79548024|NCT04548193|Behavioral|Behavioral Dietary Intervention|Receive IVR phone messages
79548025|NCT04548193|Other|Educational Intervention|Receive educational materials
79548026|NCT04548193|Other|Questionnaire Administration|Ancillary studies
79548027|NCT04542369|Drug|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
79711409|NCT05643963|Other|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
79711410|NCT00600509|Drug|Levetiracetam|
79711411|NCT01303419|Device|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
79711412|NCT01303419|Device|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
79711413|NCT01326533|Drug|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
79711414|NCT01326533|Other|Placebo|Thirteen weeks of oral placebo provided as capsules
79711415|NCT00600587|Drug|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
79711416|NCT00600587|Drug|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
79711417|NCT01045447|Drug|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
79711418|NCT01045447|Drug|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
79711419|NCT00600665|Behavioral|PAINReportIt|A pain assessment data collection tool
79711420|NCT00600665|Behavioral|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
79711421|NCT00600665|Behavioral|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
79711422|NCT04324827|Device|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
79711423|NCT04324827|Other|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
79253012|NCT06104332|Device|ProRhinel EXTRA Eucalyptus spray nasal|ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum
79392429|NCT02651584|Drug|SL BPN/NX tabs|
79392430|NCT02651584|Drug|placebo SC injections|
79392431|NCT02651584|Drug|SL placebo tablets|
79253013|NCT06104332|Device|RESPIMER Enfant|RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
79392432|NCT01691105|Other|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
79548028|NCT04533334|Procedure|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
79548029|NCT04518995|Drug|CTP-543 matching placebo|Administered as tablets.
79548030|NCT04518995|Drug|CTP-543|Administered as tablets.
79253014|NCT06104332|Device|Phytosun Aroms spray nasal MAX|Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
79253015|NCT06104332|Device|PHYSIOMER RHUME TRIPLE ACTION|PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
79253016|NCT06104332|Device|Phytosun Aroms spray nasal decongestionnant|Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum
79253017|NCT06104332|Device|ProRhinel Naturel spray nasal/ URTI|ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
79277328|NCT03534089|Other|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
79277329|NCT02369289|Other|bone mineral density test|
79392433|NCT02685072|Drug|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
79711424|NCT00623051|Procedure|Male Circumcision|
79711425|NCT00623129|Other|questionnaire administration|
79711426|NCT00623129|Procedure|electroacupuncture therapy|
79711427|NCT00623129|Procedure|management of therapy complications|
79711428|NCT00623129|Procedure|quality-of-life assessment|
79711429|NCT02875249|Other|patients stool collection|patients stool collection
79711430|NCT00623207|Drug|Atropine|I.V Atropine 0.5mg up to 2 mg
79711431|NCT00600899|Procedure|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
79711432|NCT00600899|Procedure|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
79711433|NCT04205617|Other|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
79711434|NCT00600977|Drug|Doxorubicine|9mg/m² J1 J4 2 COURSES
79277330|NCT00160147|Drug|bifeprunox|One week titration with dose adjustments
79392434|NCT02685072|Drug|Placebo|TNP + Placebo
79392435|NCT02652208|Behavioral|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
79392436|NCT02652208|Behavioral|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
79392437|NCT04339192|Procedure|Minimally Invasive Tricuspid Surgery|minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
79548031|NCT04518995|Drug|CTP-543|Administered as tablets.
79548032|NCT04496596|Drug|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
79548033|NCT04496596|Drug|Placebo|Placebo
79548034|NCT04485286|Drug|[68Ga]CBP8|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
79711435|NCT00600977|Drug|Doxorubicine pegylated|40 MG/M² J1 2 courses
79711436|NCT01301625|Device|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
79711437|NCT00601055|Behavioral|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
79711438|NCT00601055|Behavioral|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
79711439|NCT00601133|Other|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
80017050|NCT03530618|Device|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
79849490|NCT01332682|Behavioral|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
79253018|NCT06104176|Behavioral|CBT in group|"All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
79392438|NCT02653144|Drug|Ropivacaine|local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
79849491|NCT01116622|Drug|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
79392439|NCT02653144|Drug|Dexmedetomidine|local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
79849492|NCT01116622|Drug|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
79849493|NCT01064479|Drug|Carboplatin|Given IV
80017051|NCT03530618|Device|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
79392440|NCT02653144|Drug|Dexamethasone|local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
79392441|NCT00118365|Other|placebo|Given orally
79392442|NCT00118365|Drug|eflornithine|Given orally
80017052|NCT02097342|Drug|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
79253019|NCT06104176|Other|Virtual reality exposure|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
79277331|NCT00160147|Drug|Placebo|Placebo
79392443|NCT00118365|Drug|sulindac|Given orally
79392444|NCT00118365|Other|laboratory biomarker analysis|Correlative studies
79392445|NCT02695524|Other|Scapula-focused exercises|
79392446|NCT02695524|Other|Motor control exercises|
79392447|NCT01576367|Biological|ACZ885|
79548035|NCT04474691|Behavioral|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
79849494|NCT01064479|Drug|Cisplatin|Given IV
79392448|NCT02653456|Device|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
79392449|NCT05744622|Other|KetacTM Universal AplicapTM|chemically cured conventional GICs
79711440|NCT00601133|Other|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
79711441|NCT00601133|Behavioral|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
79711442|NCT00601133|Behavioral|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
79711443|NCT00601211|Drug|Pilocarpine|
79711444|NCT00601289|Drug|temozolomide|
79711445|NCT00601289|Genetic|DNA methylation analysis|
79711446|NCT00601289|Genetic|microarray analysis|
79849495|NCT01064479|Drug|Docetaxel|Given IV
79849496|NCT01064479|Drug|Erlotinib Hydrochloride|Given PO
79849497|NCT01064479|Other|Laboratory Biomarker Analysis|Optional correlative studies
80017053|NCT02097342|Drug|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
80017054|NCT02097342|Drug|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
80017055|NCT03530540|Device|low-intensity extracorporeal shockwave therapy|Active shockwaves
80017056|NCT03530540|Device|Placebo LI-ESWT|Placebo shockwaves
80017057|NCT03530540|Device|Penile pump|both groups will be treated with a penile pump
80017058|NCT04294498|Drug|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
80031463|NCT03469154|Other|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
79392450|NCT05744622|Other|KetacTM Universal AplicapTM with light cure|chemically cured conventional GICs with light curing enhancement
79392451|NCT01689857|Device|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
79849498|NCT01064479|Other|Pharmacological Study|Optional correlative studies
79849499|NCT01064479|Other|Placebo|Given PO
79392452|NCT01689857|Device|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
79392453|NCT03165240|Drug|BI 690517|Film-coated tablet
79392454|NCT03165240|Drug|Eplerenone|Film-coated tablet
79548036|NCT04474691|Behavioral|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
79548037|NCT04453462|Procedure|Endoscopic carpal tunnel release under local direct median nerve block|local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
79548038|NCT04453462|Procedure|Endoscopic carpal tunnel release under brachial plexus block|brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
79548039|NCT04453007|Behavioral|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
79711447|NCT00601289|Genetic|protein expression analysis|
79711448|NCT00601289|Genetic|proteomic profiling|
79711449|NCT00601289|Other|laboratory biomarker analysis|
79711450|NCT04301947|Other|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
79711451|NCT04301947|Other|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
79711452|NCT02891525|Dietary Supplement|50g glucose|
79711453|NCT02891525|Dietary Supplement|25g fructose|
79711454|NCT02891525|Dietary Supplement|220mg acesulfame-K|
79711455|NCT02891525|Dietary Supplement|250mL tap water|
79711456|NCT04304053|Drug|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
79711457|NCT04304053|Other|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
79711458|NCT00601445|Behavioral|Amount of sleep and wake|4 groups with different patterns of sleep and wake
79711459|NCT00601679|Other|NT-proBNP guided care|knowledge of NT-proBNP results
79711460|NCT00601757|Behavioral|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
79711461|NCT00601757|Behavioral|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
79392455|NCT03165240|Drug|Placebo|Film-coated tablet
79392456|NCT05746494|Device|tDCS|active anodal tDCS and sham tDCS
79711462|NCT00601913|Drug|erlotinib hydrochloride|
79711463|NCT00601913|Genetic|protein analysis|
79711464|NCT00601913|Genetic|western blotting|
79711465|NCT00601913|Other|immunohistochemistry staining method|
79711466|NCT00601913|Other|laboratory biomarker analysis|
79711467|NCT00601913|Other|liquid chromatography|
79711468|NCT00601913|Other|mass spectrometry|
79711469|NCT00601913|Procedure|neoadjuvant therapy|
79849500|NCT01064479|Other|Quality-of-Life Assessment|Ancillary studies
79849501|NCT00640978|Drug|RAD001|30 mg orally weekly for 4 weeks
79711470|NCT00601913|Procedure|therapeutic conventional surgery|
79711471|NCT00601991|Biological|VEGF Trap|Drug under investigation
79711472|NCT00601991|Procedure|Bone marrow biopsy|To determine response to treatment
79711473|NCT00601991|Procedure|bone marrow aspiration|To determine response to treatment
79711474|NCT00601991|Procedure|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
79711475|NCT01301391|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
79711476|NCT00602069|Behavioral|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
79711477|NCT00602069|Behavioral|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
79711478|NCT01036321|Drug|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
79711479|NCT01036321|Drug|Methyl cellulose blend|Placebo - Take 2 capsules daily
79849502|NCT00640978|Drug|Erlotinib|150 mg by mouth daily for 28 Days
79849503|NCT00449748|Drug|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
79849504|NCT00241098|Drug|valsartan|
79711480|NCT04325633|Drug|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
79711481|NCT04325633|Drug|2: Standard of care|Standard of care
79711482|NCT04126889|Other|questionnaire survey|questionnaire survey
79711483|NCT04324749|Other|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
79253020|NCT06104176|Behavioral|individual CBT|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
79392457|NCT03165084|Behavioral|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
79392458|NCT03165084|Other|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
79392459|NCT03165084|Other|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
79392460|NCT03165318|Device|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
79392461|NCT03165318|Device|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
79392462|NCT01587079|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
79392463|NCT01587079|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
79392464|NCT01587079|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
79392465|NCT01587079|Drug|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
79392466|NCT03028909|Drug|Oseltamivir|Standard of care for influenza caused by Type A strains
79392467|NCT03028909|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
79548040|NCT04453007|Behavioral|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
79548041|NCT04451057|Device|high flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
79548042|NCT04451057|Device|low flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
79548043|NCT04441619|Behavioral|Delayed onset muscle soreness.|Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
79392468|NCT03028909|Drug|Placebo|Salt-water solution containing no active ingredients.
79548044|NCT04391374|Procedure|an arterial reconstructive procedure|
79548045|NCT04352452|Procedure|laparoscopic surgery|differences in musculoskeletal and cognitive stress
79548046|NCT04343521|Biological|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start May-June and extend for 1-2 months. Residents will be asked to temporarily leave the house during treatment and wait 0.5-1 h for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed in CDC-Emory-UADY collaboration.
79548047|NCT04332783|Behavioral|psychophysics of sequential biases (no drug or patient work)|Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
79548048|NCT04315883|Behavioral|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~at baseline (time of treatment) and~1 month post treatment~6 months post treatment~12 months post treatment~5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
79711484|NCT04324749|Other|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
79711485|NCT04324749|Other|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
79711486|NCT01061359|Drug|Epirubicin: Observational Study|Observational: Chemotherapy
79711487|NCT05643417|Drug|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
79711488|NCT02891369|Other|No intervention. Descriptive study|
79711489|NCT04303975|Other|clinical measurements|Only clinical parameters were recorded, no intervention was made.
80031464|NCT03469154|Other|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
79548049|NCT04315883|Radiation|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~Resection Rate following treatment~Transplant Rate following treatment~Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~Review of clinical course post-treatment-rehospitalization rate"
79548050|NCT04312958|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79711490|NCT05643339|Diagnostic Test|microvascular flow imaging|microvascular flow imaging
79711491|NCT00602147|Other|laboratory biomarker analysis|Blood or cheek cells wil be collected.
79711492|NCT04303741|Drug|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
79253021|NCT06102122|Dietary Supplement|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
79392469|NCT02654860|Drug|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
79392470|NCT02654860|Drug|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
79253022|NCT06101667|Drug|Best medical management|Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
79392471|NCT02654860|Drug|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
79711493|NCT04303741|Drug|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
79711494|NCT04303741|Drug|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
79392472|NCT01587001|Dietary Supplement|N-acetyl-cysteine|900mg three times daily for 8 weeks
79392473|NCT01587001|Drug|Placebo|Matching placebo three times daily for 8 weeks.
79392474|NCT02656420|Drug|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
79392475|NCT02656420|Drug|Placebos|Placebo as comparison to broccoli sprout-derived beverages
79392476|NCT04739644|Device|Specific wrist rehabilitation by WRISTBOT device|The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.
79392477|NCT04739644|Other|Specific wrist rehabilitation performed by the physiotherapist|Passive, active and assisted mobilization
79548051|NCT04312503|Drug|Lurasidone|Patients are treated with dosages according clinical practice
79711495|NCT05643261|Other|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
79711496|NCT00626977|Drug|ropivacaine|15 ml of ropivacaine 0.125% peridural once
79711497|NCT00626977|Drug|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
80031465|NCT04080700|Procedure|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
80031466|NCT04906252|Diagnostic Test|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
79548052|NCT04312503|Drug|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
79711498|NCT04302883|Diagnostic Test|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
79711499|NCT04302883|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
79711500|NCT00623571|Other|Treatment of elderly patients in a GMW|
79711501|NCT00623571|Other|Treatment of elderly patients in GHHS|
79711502|NCT00627211|Procedure|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
79849505|NCT00171015|Drug|valsartan plus hydrochlorothiazide|
80017059|NCT02260518|Behavioral|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
79392478|NCT04739644|Other|General rehabilitation|Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
79253023|NCT06101667|Procedure|Endovascular treatment|The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® [Medtronic, USA], Trevo® [Stryker, USA], EMBOTRAP® [Johnson & Johnson, USA], Captor® [HeartCare, China] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® [Penumbra, USA], Afentta® [HeMo, China] and other aspiration systems)) balloon angioplasty (e.g., Gateway® [Stryker, USA], Neuro RX® [SinoMed, China], FocuStar® [HeMo, China] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® [Stryker, USA], Apollo® [MircoPort, China], Enterprise® [Johnson & Johnson, USA], Neuroform EZ® [Stryker, USA] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
79253024|NCT06100276|Drug|AMT-162|AMT-162, the investigational product (IP), is a non-replicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
79253025|NCT06099041|Device|Nd-YAG Laser for iris depigmentation|Nd-YAG Laser for iris depigmentation
79253026|NCT06098521|Behavioral|CONSENT|The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
79392479|NCT01568047|Drug|Placebo|once-daily
79392480|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
79392481|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
80031467|NCT04906252|Diagnostic Test|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
80031468|NCT05137886|Drug|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
79392482|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
79548053|NCT04305444|Drug|DTRM-555|Oral once-daily administration
79548054|NCT04290975|Other|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
79548055|NCT04290975|Other|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
79711503|NCT04303819|Drug|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
79711504|NCT01301079|Drug|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
79711505|NCT01301079|Drug|Saline|Patients in group N (placebo) was administrated saline during surgery.
79711506|NCT04303039|Drug|ABP-671|ABP-671 Tablet 1.0 mg
79392483|NCT01568047|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
79711507|NCT05271721|Drug|epidural transforaminal injection of magnesuim sulfate|transforaminal fluroscopic guided
79392484|NCT01568047|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
79392485|NCT04739488|Device|Inhaler training|This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.
79392486|NCT04739488|Behavioral|Breathing exercises|"This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness."
79392487|NCT01688999|Drug|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
79392488|NCT02658994|Behavioral|Thinking Healthy Program Peer Delivered Plus|
79392489|NCT02658994|Other|Enhanced Usual Care|
79548056|NCT04288375|Radiation|Intensity-modulated radiation therapy (IMRT)|The prescribed dose of radiations for all patients will be 50 Gy in 25 fractions. 6MV energy photons will be used. Multi-beam IMRT plans, utilizing dynamic multileaf collimation, will be created based on the target tissue coverage and normal tissue avoidance.
79711508|NCT05271721|Drug|epidural transforaminal injection of dexmedtemodine|transforaminal fluroscopic guided
79711509|NCT05271721|Drug|transforaminal epidural injection of dexamethasone|transforaminal fluroscopic guided
79711510|NCT01036165|Device|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
79711511|NCT05642871|Radiation|DKI and APT|DKI and APT in patients with ovarian malignancy before and after treatment
79711512|NCT01301001|Drug|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
79711513|NCT01301001|Drug|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
79711514|NCT01300923|Drug|Acamprosate|
79711515|NCT05642559|Other|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
79711516|NCT01300767|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
79392490|NCT01541917|Behavioral|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
79392491|NCT01541917|Behavioral|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
79711517|NCT01300767|Device|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
79392492|NCT05746338|Device|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
79392493|NCT05746338|Device|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
79711518|NCT01300767|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
79392494|NCT02660788|Other|Standard Reminder Postcard|
79392495|NCT02660788|Other|Family Physician Reminder Letter|
79548057|NCT04282343|Behavioral|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
79548058|NCT04282343|Behavioral|Usual Care|Patients randomized to this arm will receive usual care.
79548059|NCT04278131|Drug|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
79548060|NCT04273841|Dietary Supplement|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
79548061|NCT04273841|Dietary Supplement|Placebo Gum|Pellet form placebo gum
79548062|NCT04267029|Diagnostic Test|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~hemolytic~allergic~cardiorenal~inflammatory~leukoagglutinating~exploratory bioarchive"
79548063|NCT04256889|Device|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
79548064|NCT04249063|Drug|Xylocaine 1 % and Normal Saline|3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
79392496|NCT03166410|Procedure|Cell injection|
79392497|NCT01688921|Biological|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
79392498|NCT01688921|Device|Needle-Syringe|
79392499|NCT01688921|Device|Stratis needle-free injection device|
79392500|NCT00118755|Drug|capecitabine|850 mg/m^2 po bid on Days 1-14 of each 3-week cycle
79392501|NCT00118755|Drug|Oxaliplatin|130 mg/m^2 IV on Day 1 of each 3-week cycle
79392502|NCT00118755|Drug|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
79392503|NCT00118755|Drug|capecitabine|1500 mg/m^2 po bid on Days 1-7 of each 2-week cycle
79392504|NCT00118755|Drug|Oxaliplatin|85 mg/m^2 IV on Day 1 of each 2-week cycle
79392505|NCT00118755|Drug|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
79548065|NCT04249063|Drug|Normal Saline|3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
79548066|NCT04239040|Procedure|Tissue collection|Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure
79548067|NCT04239040|Biological|GVAX vaccine|Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
79548068|NCT04239040|Drug|Nivolumab|"Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
79548069|NCT04239040|Drug|Ipilimumab|Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
79548070|NCT04237753|Behavioral|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
79711519|NCT05642481|Diagnostic Test|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
79711520|NCT02890173|Drug|CS-3150|
79711521|NCT02890173|Drug|Eplerenone|
79711522|NCT01300455|Drug|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
79711523|NCT01300455|Drug|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
79739735|NCT00639106|Procedure|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
79739736|NCT00639106|Procedure|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
79739737|NCT01182350|Drug|Bevacizumab|
79849506|NCT03999255|Procedure|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
79392506|NCT03165006|Procedure|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
79392507|NCT03165006|Procedure|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
79548071|NCT04237753|Behavioral|MyHealtheBladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
79711524|NCT05642169|Behavioral|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
79392508|NCT02661256|Device|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
79711525|NCT05642169|Behavioral|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
79392509|NCT02661256|Dietary Supplement|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
79392510|NCT03166488|Device|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
79711526|NCT05642169|Behavioral|CON|This group will not suffer any changes in their lifestyle
80017060|NCT02260518|Behavioral|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
80017061|NCT04288648|Diagnostic Test|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
79253027|NCT06093529|Diagnostic Test|complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.|"Full history~Thorough clinical examinations~Laboratory investigations will include:~complete blood count with focus on platelet count, platelet distribution width and mean platelet volume. Platelet count will be confirmed by direct blood film and blood smear.~Measurements of CD3+, CD4+, CD8+ and natural killer cells (CD16+, CD56+) will be conducted using flow cytometry.~Serum IFN-γ levels will be determined using an ELISA kit.~Response to the treatment will be assessed according to The International Working Group criteria which defines Response as platelet count ≥ 30 x 10⁹/L and >2-fold increase in platelet count from baseline and absence of bleeding, measured on 2 occasions greater than 7 days apart. No response is characterized by a platelet count <30 x 10⁹/L or a less than 2-fold increase in platelet count from baseline, or the presence of bleeding."
79253028|NCT06091956|Drug|Deucravacitinib|6 milligram (mg) orally administrated, twice daily
79253029|NCT06088212|Other|Disease management program|"The components of our DMP include:~Intensive post-discharge education~Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer.~Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period.~Exercise program delivered by an exercise physiologist~Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly."
79392511|NCT01541371|Drug|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
79392512|NCT00121173|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
79392513|NCT02662036|Drug|Bupivicaine HCL|
79392514|NCT02662036|Drug|Liposomal bupivacaine|
79392515|NCT01687673|Drug|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
79392516|NCT01687673|Drug|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
79392517|NCT00121251|Drug|Capecitabine|Given PO
79392518|NCT00121251|Drug|Gemcitabine Hydrochloride|Given IV
79548072|NCT04229017|Procedure|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
79711527|NCT01107418|Drug|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
79392519|NCT00121251|Drug|Sorafenib Tosylate|Given PO
79392520|NCT04546139|Other|footwork|six-point footwork
79711528|NCT01107418|Drug|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
79711529|NCT01107418|Drug|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
79711530|NCT01107418|Drug|RO5185426|960 mg orally twice daily, from day 22 onward
79739738|NCT01182350|Drug|Erlotinib|
79392521|NCT02664220|Drug|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
79392522|NCT02664220|Procedure|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
79392523|NCT02664532|Other|Miller group|Miller blade was used for laryngoscopy
79548073|NCT04229017|Device|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
79392524|NCT02664532|Other|Macintosh group|Macintosh blade was used for laryngoscopy
79392525|NCT04339348|Drug|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
79548074|NCT04209127|Procedure|Microwave treatment via needle antenna|Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
79548075|NCT04209127|Procedure|Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)|Embolization via percutaneous catheter
80017062|NCT02102958|Behavioral|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
79548076|NCT04204252|Drug|Alpha 1-Antitrypsin|Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
79548077|NCT04204252|Drug|Placebo|Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
79548078|NCT04203433|Drug|DLX105-DMP|1mg applied to target lesion
79548079|NCT04192955|Drug|Acetyl Salicylate|Tablets
79548080|NCT04184869|Drug|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A & B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
79548081|NCT04184869|Drug|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
79711531|NCT01107418|Drug|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
79711532|NCT05642091|Device|ultrasound Elastography|application of shear wave force by ultrasound elastography
79711533|NCT05641779|Device|pigtail|pigtail catheter insertion in chest in the pleural cavity
79711534|NCT01101178|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
79711535|NCT01101178|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
79711536|NCT05639205|Diagnostic Test|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
79739739|NCT01182350|Drug|Temozolomide|•
79739740|NCT01182350|Radiation|Radiation|
80017063|NCT02102958|Behavioral|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
80017064|NCT00366080|Drug|GSK189254|
80017065|NCT02097498|Other|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
79253030|NCT06088147|Drug|Methotrexate|A standard derma pen 12 pins with of 0,5 mm depth was used, dermapen as a tool of infusion of our treatments works in a few ways to target hair loss, firstly by breaking down the scar tissue that covers or compromises the hair follicles which are not growing, stimulating new hair growth and also by enhancing infusion of mesotherapy ingredients to increase hair follicle size and therefore hair volume ,here we will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2
79392526|NCT04339348|Drug|Lidocaine-Prilocaine Topical cream|Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
79739741|NCT02886416|Other|Non interventional study|
80017066|NCT02097498|Other|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
79253031|NCT06088147|Drug|Triamcinolone Acetonide|A standard derma pen 12 pins with of 0,5 mm depth was used, will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution
79392527|NCT04339348|Drug|placebo|inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
79548082|NCT04175262|Drug|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
79253032|NCT06084104|Drug|DZD9008|A single oral dose of 200mg DZD9008
79548083|NCT04156997|Other|No intervention is involved in this study|No intervention is involved in this study
79392528|NCT02664922|Drug|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
79392529|NCT02664922|Drug|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
79253033|NCT06084104|Drug|DZD9008|A single oral dose of 200mg DZD9008
80017067|NCT02097576|Other|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
79253034|NCT06081114|Dietary Supplement|Micronutrient Supplement|A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
79392530|NCT02664922|Drug|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
79392531|NCT02664922|Drug|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
79392532|NCT02665468|Behavioral|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
79548084|NCT04149899|Drug|WB007 0.05%|WB007 Ophthalmic Solution 0.05%
79548085|NCT04149899|Drug|WB007 0.15%|WB007 Ophthalmic Solution 0.15%
79548086|NCT04149899|Drug|WB007 0.4%|WB007 Ophthalmic Solution 0.4%
79548087|NCT04149899|Drug|Timolol 0.5%|Timolol Maleate 0.5% Ophthalmic Solution
79711537|NCT05637645|Procedure|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
79711538|NCT05637645|Procedure|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
80017068|NCT02097576|Other|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
79253035|NCT06077253|Procedure|Iridotomy|Peripheral iridotomy (size >200µm)
80017069|NCT00359450|Drug|BMS-275183 (oral taxane)|
80017070|NCT02097654|Other|SENATOR software generated pharmacotherapy advice report.|
79392533|NCT02665468|Behavioral|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
79548088|NCT04137536|Drug|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~First 3 participants, twice weekly infusions of 10^10 EGFR BATs infusions~If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10^10.~If >/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10^9 per infusion~If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10^9 or 10^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
79548089|NCT04119115|Device|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
79548090|NCT04119115|Other|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
79392534|NCT02666560|Device|Auditory Cueing|Auditory cueing set at different frequency rates
79392535|NCT02666950|Drug|Cytarabine|Given SC
79392536|NCT02666950|Other|Laboratory Biomarker Analysis|Correlative studies
79548091|NCT04111029|Diagnostic Test|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
79711539|NCT05637645|Procedure|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
79711540|NCT05637021|Other|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
79849507|NCT05225961|Drug|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
79849508|NCT05225961|Drug|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
79711541|NCT00623649|Drug|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
79849509|NCT00556998|Drug|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
79849510|NCT00528801|Behavioral|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
79849511|NCT00528801|Procedure|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
79849512|NCT01564563|Drug|standard therapy|Standard treatment of bleeding
79849513|NCT01564563|Drug|placebo|Placebo
79849514|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
79849515|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
79849516|NCT00945204|Other|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
79849517|NCT00945360|Drug|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
80017071|NCT03530462|Drug|rituximab|375 mg/m2 weekly for 4 weeks
80017072|NCT03530462|Drug|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
79711542|NCT00623649|Drug|Placebo|Dose escalation study with a full review of all safety data following each cohort.
79711543|NCT01101022|Drug|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
79253044|NCT06076161|Dietary Supplement|Spirulina supplementation and calorie restriction in obese men|The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
79253045|NCT06069414|Other|Type of anesthesia induction|Patients will receive inhalatory or intravenous anesthesia at their choice; both groups will be evaluated with lung ultrasound after induction to detect ultrasonografic signs of atelectasis
79253046|NCT06067399|Diagnostic Test|Glycated hemoglobin (HbA1C)|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
79253047|NCT06067399|Diagnostic Test|RDW|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
79253048|NCT06067399|Diagnostic Test|Lipid profile|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
79711544|NCT01101022|Other|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
79711545|NCT05627193|Other|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
79711546|NCT05627193|Other|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
79711547|NCT05622435|Device|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
79711548|NCT01299909|Behavioral|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
79849518|NCT00943566|Drug|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
79849519|NCT00943566|Drug|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
79849520|NCT00943644|Device|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
79849521|NCT00943644|Device|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
79849522|NCT01008657|Procedure|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
79711549|NCT01299909|Behavioral|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
79849523|NCT00940680|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
79849524|NCT00940680|Drug|Losartan|losartan 100mg q.d.
79849525|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
79849526|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
79849527|NCT01564719|Behavioral|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
79849528|NCT00940758|Drug|PEP02|Dose escalation: 50-100 mg/m2 biweekly
79392537|NCT02666950|Other|Pharmacological Study|Correlative studies
79711550|NCT01299909|Behavioral|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
80017073|NCT03530462|Drug|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
79711551|NCT02879110|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
79711552|NCT02879110|Other|Placebo|Placebo tablet is composed of starch.
79711553|NCT04207515|Procedure|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
79739742|NCT04315844|Device|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
79849529|NCT01792752|Behavioral|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
79849530|NCT01792752|Behavioral|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
80017074|NCT03530462|Drug|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
80017075|NCT02250456|Procedure|Echo doppler|vascular ultrasound explorations
80017076|NCT04044664|Drug|Placebo oral capsule|Matching placebo capsules.
80017077|NCT04044664|Drug|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
80017078|NCT03555474|Procedure|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
79392538|NCT02666950|Other|Quality-of-Life Assessment|Ancillary studies
79392539|NCT02666950|Other|Questionnaire Administration|Ancillary studies
79392540|NCT02666950|Drug|WEE1 Inhibitor AZD1775|Given PO
79392541|NCT02668198|Device|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
79392542|NCT02668198|Device|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
79392543|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
79849531|NCT01792752|Behavioral|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
79711554|NCT04207515|Procedure|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
79392544|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine the area of prior EMR site.
79392545|NCT02668198|Procedure|Biopsy|Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
79849532|NCT01792752|Behavioral|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
79849533|NCT01792752|Behavioral|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
79849534|NCT00945516|Device|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
79392546|NCT02668432|Drug|Amiodarone|Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
79253049|NCT06063850|Genetic|AAV9-hSyn1-miGRIK2|AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
79253050|NCT06058962|Drug|Suramin Sodium|Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
79711555|NCT04324515|Procedure|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
79711556|NCT02880826|Behavioral|Measure the culture of safety in the reanimation units|
79849535|NCT00945516|Device|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
79849536|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
79849537|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
79253051|NCT06058533|Other|Previsit Imagery Picturebook|This picturebook will include pictures of the dental operatory and materials the patient can expect to see during their dental treatment appointment. The pictures included will be generalized pictures of a dental operatory and dental materials. The picture book will also include some words to describe what is happening during the appointment. It is important to note that pictures of the local anesthetic / needle will not be shown in the picture book but will be used during the appointment. The procedures described are standard protocol at both clinics. The traditional picture book shown will be a hard copy.
79253052|NCT06056310|Drug|Xevinapant|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
79253053|NCT06056310|Drug|Cisplatin|Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).
79253054|NCT06056310|Radiation|intensity-modulated radiation therapy (IMRT)|Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
79253055|NCT06056219|Device|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
79392547|NCT01687595|Drug|HerpV and QS-21|HerpV (recombinant human heat shock protein 70 [rh-Hsc70] polyvalent peptide complex) in combination with adjuvant QS-21
79392548|NCT01687595|Drug|Placebo|phosphate buffered saline
79392549|NCT01687283|Drug|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
79392550|NCT01687283|Drug|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
79392551|NCT02684370|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
79253056|NCT06056219|Device|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
79548092|NCT04100122|Procedure|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
79548093|NCT04087421|Device|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
79548094|NCT04087421|Drug|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
79253057|NCT06056219|Other|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
79253058|NCT06054620|Dietary Supplement|Collagen and Vitamin C|Collagen-modelled crystalline amino acids (30g total, 8g glycine) and vitamin C (500 mg).
79392552|NCT02684370|Drug|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
79548095|NCT04081883|Other|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
79548096|NCT04077073|Device|ReIn-Hand|ReIn-Hand assists the hand opening
79711557|NCT02879188|Other|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
79849538|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
79849539|NCT00943956|Drug|bicalutamide|
79849540|NCT00943956|Drug|everolimus|
79253059|NCT06054620|Dietary Supplement|Carbohydrate Placebo|Iso-caloric Placebo (30g maltodextrin).
79253060|NCT06053476|Procedure|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
79253061|NCT06053476|Procedure|Single-shot paravertebral block|At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
79392553|NCT02684370|Drug|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
79253062|NCT06053476|Procedure|Late chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~The patient is lucid and capable of sitting up straight in bed on his/her own~No air leakage indicated by the Thopaz+ system during at least 4 hours, or <15 mL/min air leakage during at least 6 hours~Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~Absence of bloody drainage by the Thopaz+ system"
79392554|NCT02684370|Drug|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
79392555|NCT02669914|Drug|MEDI4736|
79548097|NCT04077073|Device|Robot|Robot supports the shoulder load
79849541|NCT00943956|Drug|leuprolide acetate|
79849542|NCT00943956|Radiation|external beam radiation therapy|
79849543|NCT01564797|Behavioral|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
80017079|NCT03555474|Procedure|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
79392556|NCT01686581|Drug|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
79392557|NCT04739410|Drug|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
79548098|NCT04073485|Procedure|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
79580940|NCT01930760|Behavioral|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
79711558|NCT02879188|Other|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
79711559|NCT01298661|Other|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
79849544|NCT00945828|Behavioral|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
79849545|NCT00945828|Behavioral|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
79253063|NCT06053476|Procedure|Early chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~The patient is lucid and capable of sitting up straight in bed on his/her own~No air leakage indicated by the Thopaz+ system during at least 4 hours, or <15 mL/min air leakage during at least 6 hours~Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~Absence of pure blood drainage by the Thopaz+ system"
79253064|NCT06052137|Device|Active TBS-DLPFC|"Participants will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
79392558|NCT03166176|Drug|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
79849546|NCT01564875|Drug|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
79849547|NCT01564875|Drug|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
79849548|NCT00944112|Biological|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
79849549|NCT00944112|Biological|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
79849550|NCT04012086|Other|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
79849551|NCT01529814|Device|Implant with new abutment connection|New abutment connection implant system
80017080|NCT03555474|Procedure|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
80017081|NCT02100306|Behavioral|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
79253065|NCT06052137|Device|TBS-DMPFC|"Participants will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
79253066|NCT06049953|Drug|Antipsychotics|Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
79253067|NCT06049953|Drug|Non-antipsychotic medication|Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
79253068|NCT06049953|Other|No Medication|Non-psychotropic medications
79253069|NCT06048146|Drug|Experimental: FOLFOXIRI and Lateral lymph node dissection|Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
79253070|NCT06048146|Drug|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
79253071|NCT06046742|Biological|M1-c6v1|Intravenous drip administration
79392559|NCT03165864|Drug|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
79392560|NCT03165864|Other|Placebo|Saline .9%
79849552|NCT01529814|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
79849553|NCT00944190|Behavioral|Self-management intervention|Brief counseling technique, self-management,
79849554|NCT00944190|Behavioral|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
79849555|NCT00945984|Procedure|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
80017082|NCT02100306|Behavioral|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
79392561|NCT02672176|Behavioral|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
79392562|NCT02672176|Behavioral|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
79849556|NCT00944268|Drug|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
79849557|NCT00944346|Drug|Metformin HCl|
79849558|NCT00527319|Drug|VT-122 low dose|VT-122 low dose, dose escalated
80017083|NCT05202184|Procedure|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
79253072|NCT06046417|Drug|Pramlintide|Pramlintide delivered in a basal-bolus manner.
79253073|NCT06046417|Drug|Insulin Lispro|Insulin Lispro delivered in a basal-bolus manner.
79849559|NCT00527319|Drug|VT-122 high dose|VT-122 high dose, dose escalated
79711560|NCT01100944|Drug|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
79392563|NCT04545749|Biological|UB-612|UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
79580941|NCT01930760|Behavioral|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
79711561|NCT01100320|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
79711562|NCT01100320|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
79849560|NCT00562302|Device|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
79849561|NCT00946062|Other|orientation and mobility training|orientation and mobility training
79849562|NCT04012632|Other|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
79253074|NCT06046417|Drug|Insulin aspart|Insulin Aspart delivered in a basal-bolus manner.
79253075|NCT06046417|Device|Automated Insulin Delivery (AID) system|The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.
79849563|NCT00134719|Biological|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
79849564|NCT00134719|Biological|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
79849565|NCT00134719|Biological|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
79849566|NCT00134719|Biological|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
79849567|NCT00134719|Biological|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
80017084|NCT02103036|Procedure|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
80017085|NCT02103036|Procedure|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
79392564|NCT02691936|Device|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
79253076|NCT06044948|Device|Delefilcon A contact lenses|Daily disposable, silicone hydrogel spherical contact lenses
79392565|NCT02691936|Drug|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
79849568|NCT00134719|Biological|M-M-R®II|One subcutaneous dose at 12-15 months of age
79392566|NCT02675764|Other|Vibration|peripheral vibration at the wrist skin at an imperceptible level
79711563|NCT04309708|Device|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
79711564|NCT01100086|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
79711565|NCT01100086|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
79711566|NCT01297959|Drug|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
79711567|NCT01297959|Drug|Saline solution|Saline solution matched to E-101
79849569|NCT00134719|Biological|Varivax®|One subcutaneous dose at 12 to 15 months of age
79392567|NCT02675764|Other|Placebo (for vibration)|No peripheral vibration at the wrist skin
79849570|NCT00134719|Biological|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
79849571|NCT00940836|Drug|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
79849572|NCT00940836|Drug|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
79849573|NCT00940836|Drug|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
79392568|NCT02675764|Behavioral|therapy|standardized hand therapy program
79253079|NCT06042972|Other|Questionnaire including Edinburgh postnatal depression scale, Patient Health Questionnaire 2 and background variables|"Patients meeting the inclusion criteria will be recruited by health professionals who have agreed to participate in the study.~Patients must fill out an anonymous self-questionnaire which will consist of 2 tests aimed to help diagnose postpartum depression, recommended in France by the Haute Autorité de Santé (HAS), and background variables.~The self-questionnaire will be given back by the patient in a sealed envelope. Each questionnaire will only be filled out once per patient."
79711568|NCT04187716|Drug|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
79849574|NCT03999177|Behavioral|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
79392569|NCT04739332|Behavioral|The Newborn behavioral observations system|The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
79849575|NCT05104827|Other|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
79849576|NCT00940914|Drug|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
79253080|NCT06041971|Device|AIDANET system|The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
79849577|NCT00944424|Drug|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
80017086|NCT02103036|Device|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
80017087|NCT02103036|Device|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
79253081|NCT06039449|Drug|VYD222|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
79253082|NCT06039449|Drug|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
79253083|NCT06037798|Other|cranio-cervical flexion test with NOD|testing the anterior neck muscles during a nodding movement and by using a dynamometer
79253084|NCT06036173|Other|diagnosis of lymphedema|being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
79392570|NCT04339114|Other|Breakfast: control meal|The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
79392571|NCT04339114|Other|Breakfast: Cinnamon meal|The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
79392572|NCT04339114|Other|Breakfast: Italian herbs meal|The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
79253085|NCT06036173|Other|breast cancer surgery|be diagnosed and undergo surgery
79253086|NCT06032975|Other|Questionnaires|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
79392573|NCT04339114|Other|Breakfast: pumpkin spice|The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
79392574|NCT04707898|Device|Single Bond Universal|Adhesive system
79392575|NCT04707898|Device|G-Premio Bond|Adhesive system
79580942|NCT01930773|Device|Genotyping|Patients harboring CYP2C19 *2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
79580943|NCT01930773|Device|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
79580944|NCT01930786|Drug|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
79580945|NCT01930812|Procedure|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
79711569|NCT00626080|Drug|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
79711570|NCT00626080|Drug|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
79711571|NCT04309240|Drug|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
79849578|NCT00944424|Drug|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
80017088|NCT02100384|Procedure|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
79253088|NCT06025227|Drug|Etrasimod|tablets
79253089|NCT06022757|Drug|XNW5004|XNW5004 an EZH2 inhibitor, BID, administered in continuous
79253090|NCT06022757|Drug|KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection|KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
79392576|NCT04707820|Diagnostic Test|ELISPOT|"The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein."
79548099|NCT04038684|Behavioral|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
79548100|NCT04038684|Behavioral|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
79548101|NCT04014075|Drug|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
79548102|NCT03983993|Drug|Niraparib|Given PO
79548103|NCT03983993|Biological|Panitumumab|Given IV
79548104|NCT03950661|Other|Walking|
79548105|NCT03944616|Behavioral|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
79849579|NCT00944502|Drug|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
79849580|NCT04754295|Other|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
79849581|NCT04754295|Other|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
79253091|NCT06016452|Drug|Chlorophyllin|Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.
79253092|NCT06015178|Other|Intelligent Language Model|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
79253093|NCT06015178|Other|control|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
79253094|NCT06012812|Drug|SHR-1819 injection|SHR-1819 injection 300 mg Q2W
79392577|NCT04707742|Drug|Betadine© bucal 100 mg/ml|15 ml 2% povidone-iodine, one minute rinse.
79253095|NCT06011889|Drug|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
79392578|NCT04707742|Drug|Oximen® 3%|15 ml 1% hydrogen peroxide, one minute rinse.
79253096|NCT06011889|Drug|Placebo|treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
79253097|NCT06010017|Behavioral|STEPP Intervention|Peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, via virtual platform. If participants do not have a smart device, one will be provided by the study team.
79253098|NCT06006026|Drug|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
79253099|NCT06004271|Other|exercise|"Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching"
79392579|NCT04707742|Drug|Clorhexidine Dental PHB©|15 ml 0,12% clorhexidine, one minute rinse.
79392580|NCT04707742|Drug|Vitis Xtra Forte©|15 ml 0,07% cetylpyridinium chloride, one minute rinse.
79392581|NCT04707742|Drug|Distilled Water|15 ml distilled water, one minute rinse.
79392582|NCT02679976|Device|etafilcon A|Marketed Multifocal Contact Lens
79711572|NCT02878954|Other|No intervention (Observational study)|"160 patients will be recruited to:~Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~Perform a six-minute walk test Comparison between men and women will be performed."
79711573|NCT02878954|Other|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
79253100|NCT06004271|Other|exercise and taping|When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.
79253101|NCT06004271|Other|placebo|In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
79548106|NCT03944616|Behavioral|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
79580946|NCT01930812|Procedure|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
79580947|NCT01930812|Drug|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
79580948|NCT01930838|Procedure|Gastric bypass operation|
79711574|NCT02878954|Other|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
79711575|NCT04309318|Procedure|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
79711576|NCT04309318|Procedure|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
79711577|NCT01035229|Drug|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
79711578|NCT01035229|Drug|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
79739743|NCT05367518|Dietary Supplement|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79849582|NCT00946140|Procedure|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
79849583|NCT00949962|Drug|antiandrogen therapy|Given systemically
79849584|NCT00949962|Drug|leuprolide acetate|Given subcutaneously
79849585|NCT00949962|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
79849586|NCT04115007|Radiation|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients~Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~Long term ADT +/- intermittent treatment~Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
80017089|NCT03922126|Other|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
79277332|NCT03533777|Procedure|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
79392583|NCT02680054|Drug|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
79392584|NCT02681458|Other|Direct Examination|It was an observational study and subjects received their routine treatment.
79392585|NCT00367978|Drug|Amlodipine/benazepril|
79392586|NCT00368056|Drug|Eszopiclone|eszopiclone 3 mg
79392587|NCT00368056|Drug|Placebo|Placebo tablet
79392588|NCT02683174|Device|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
79392589|NCT02683174|Biological|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
79392590|NCT01685801|Drug|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
79392591|NCT01685801|Drug|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
79849587|NCT04115007|Drug|Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients~Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~Long term ADT +/- intermittent treatment~Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
79849588|NCT04012866|Behavioral|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
79849589|NCT04012866|Behavioral|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
79849590|NCT04012866|Behavioral|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
79548107|NCT03921801|Other|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
79849591|NCT00950040|Behavioral|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
79849592|NCT00950040|Behavioral|General health education|The intervention will consist of information about several general health behaviors.
79253102|NCT06003842|Other|exercise|Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.
79849593|NCT00946374|Drug|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
79849594|NCT00946374|Drug|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
79849595|NCT00946374|Other|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
79253103|NCT06003842|Other|taping|After the Kinesio® Tex application, it will remain in the body for 4 days, and then it will be applied 6 times in total, with a 3-day break. It will be stated that the area to be banded should not contain substances such as cream, hair or oil. Upper Trapeze taping will be performed by applying one end of the Y tape to the upper trapeze and the other end to the lower part of the spina scapula, by affixing the tape to the head of the shoulder while standing upright, and keeping the participant's ear tilted towards the other ear as much as possible. Before attaching the rest of the tape, the participant will be asked to bring the shoulder blades closer together and stand upright. In this position, using a mechanical correction technique along the medial line of the scapula along the spine, the rest of the tape will be adhered as an I tape with 35-50% tension.
80017090|NCT03922126|Diagnostic Test|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
79392592|NCT01353222|Biological|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
79392593|NCT01353222|Other|Standard of Care|Observation only until documentation of disease recurrence.
80017091|NCT02103192|Other|Anti-Oxidant Drink|
79580949|NCT01930851|Procedure|Gastric bypass operation|
80017092|NCT03555864|Device|infrared transluminescent device|use of infra red for venous access for second intravenous access
79580950|NCT01930864|Drug|metformin|metformin up to 2500mg/d
79580951|NCT01930864|Drug|irinotecan|Irinotecan 350 mg/m² IV q21d
79580952|NCT01930877|Drug|Lidocaine|Lidocaine iv bolus followed by infusion
80017093|NCT02097810|Drug|Entrectinib|
79580953|NCT01930877|Other|Placebo (normal saline)|Normal saline bolus followed by infusion
80017094|NCT04153552|Dietary Supplement|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
80017095|NCT01918930|Biological|MGA271|MGA271 anti-B7-H3 monoclonal antibody
80017096|NCT03555162|Other|fMRI|Imaging examination
80017097|NCT05179798|Device|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
80017098|NCT03555786|Other|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
80017099|NCT02100462|Drug|Chlorthalidone 12.5 mg|
79548108|NCT03921801|Other|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
79548109|NCT03909152|Drug|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
79253104|NCT06002152|Drug|Bupivacaine|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
79548110|NCT03909152|Drug|Onapristone ER + Anastrozole|Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
79548111|NCT03874169|Device|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
79548112|NCT03840174|Biological|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
79711579|NCT01035229|Other|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
79849596|NCT04529577|Device|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
79849597|NCT00950196|Drug|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
79849598|NCT01565031|Procedure|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
79849599|NCT04012554|Procedure|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
79849600|NCT04012554|Procedure|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
79849601|NCT01565109|Drug|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
79253105|NCT06002152|Drug|Placebo|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
79253106|NCT06001515|Device|Dual scan protocol|one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone
79253107|NCT06001515|Device|triple scan protocol|3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
79277333|NCT03533777|Other|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
79849602|NCT01565109|Radiation|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
79849603|NCT00526071|Drug|migalastat HCl|
79849604|NCT00525915|Drug|5-Fluorouracil|"Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15."
79849605|NCT00525915|Drug|Oxaliplatin|"Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m^2 IV on Day 1 and 15"
79849606|NCT00525915|Radiation|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
79849607|NCT00525915|Procedure|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
79849608|NCT05191329|Diagnostic Test|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
79849609|NCT00521079|Device|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
79849610|NCT00521079|Device|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
79849611|NCT03107117|Behavioral|Computer Counseling|two computer counseling online programs for a teen and a parent
79548113|NCT03840174|Other|Placebo|Saline solution (0.9% sodium chloride [NaCl] administered as a 0.5 mL IM injection
79548114|NCT03811873|Diagnostic Test|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
79849612|NCT03107117|Behavioral|Standard Care|A referral for substance use counseling
79711580|NCT02880436|Other|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
79711581|NCT01106404|Device|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
79849613|NCT02579837|Device|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
79253108|NCT06000761|Procedure|Standardized oral Care|One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.
79849614|NCT02579837|Device|Zeiss Cirrus|optical coherence tomographer (OCT)
79253109|NCT06000397|Other|Enhanced reminders|"The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit"
79253110|NCT06000397|Other|Standard CANImmunize notifications|"Push notifications at two time points:~two weeks prior to the immunization due date~one week after the immunization due date"
79253111|NCT05999981|Procedure|Transversalis Fascia Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance between transversus abdominis muscle and transversalis fascia bilaterally
79392594|NCT04544735|Behavioral|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
79849615|NCT00521001|Drug|everolimus|
79849616|NCT00521001|Drug|temozolomide|
79392595|NCT04475315|Device|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
79392596|NCT04475315|Procedure|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
79548115|NCT03811873|Other|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
79548116|NCT03810898|Radiation|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
80017100|NCT02100462|Drug|Hydrochlorothiazide 25 mg|
79548117|NCT03810898|Radiation|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
79580954|NCT01930903|Device|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
79711582|NCT02880592|Other|Affinity Allograft|fresh hypothermically stored human amniotic membrane
79711583|NCT02880592|Other|Standard of care|offloading, debridement, infection management using appropriate dressings
79849617|NCT04887701|Device|Non-hormonal vaginal device therapy|Experimental Active Therapy
79849618|NCT04887701|Device|Sham vaginal device therapy|Sham Comparator
79849619|NCT00134563|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
79849620|NCT00134563|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
79849621|NCT04019171|Behavioral|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
79849622|NCT03966547|Procedure|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
80017101|NCT02100462|Drug|Aspirin 81 mg|
79711584|NCT01059799|Drug|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
79711585|NCT01059799|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
80017102|NCT00150176|Drug|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
80017103|NCT00150176|Drug|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
80017104|NCT00150176|Drug|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
80017105|NCT02100540|Drug|I placebo capsule|I placebo capsule
80017106|NCT02100540|Drug|II RDC 0.3mg capsule|II RDC 0.3mg capsule
80017107|NCT02100540|Drug|III RDC 0.6mg capsule|III RDC 0.6mg capsule
79849623|NCT03966547|Procedure|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
79253112|NCT05999981|Procedure|Transversus Abdominis Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally
79711586|NCT02874547|Behavioral|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
79711587|NCT01106248|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
79711588|NCT01059175|Device|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
79711589|NCT01059175|Device|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
79711590|NCT04301869|Drug|Antibiotics|Oral versus intravenous therapy
79711591|NCT04301479|Drug|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
79711592|NCT04301479|Drug|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
79711593|NCT01297491|Drug|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
79711594|NCT04303585|Procedure|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
79711595|NCT04303585|Procedure|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
79253113|NCT05997290|Biological|BNT162b2 (Omi XBB.1.5)|BNT162b2 monovalent (Omicron XBB.1.5)
79253114|NCT05996523|Biological|PRGN-2009|PRGN-2009 5x10^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart
79711596|NCT04324593|Device|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
79711597|NCT01106092|Biological|GSK2036874A vaccine|Intramuscular, single dose
79711598|NCT01106092|Biological|Zilbrix™/Hib vaccine|Intramuscular, single dose
79849624|NCT01326325|Drug|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
79849625|NCT01326325|Drug|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
80017108|NCT02100618|Procedure|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
80017109|NCT05201768|Other|balance tests,questionnaire|Individuals will be tested and recorded.
80017110|NCT04435912|Drug|Hydrocortisone 200mg IV|single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
79253115|NCT05996523|Drug|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
79253116|NCT05996497|Behavioral|behavioral measures|behavioral measures
79253117|NCT05996497|Other|Electrophysiological measures|Electrophysiological measures
79253118|NCT05996497|Other|Training 1|Training 1
79253119|NCT05996497|Other|Training 2|Training 2
79253120|NCT05995769|Drug|Psilocybin|Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
79253121|NCT05994937|Device|PAC with HEPA filter intact|A commercially available PAC with a true HEPA filter will be used. Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
79253122|NCT05994937|Device|PAC with HEPA filter removed|Uses the same model as the experimental PAC that is identical in appearance and sound with the HEPA filter removed . Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
79277334|NCT03533777|Device|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
79580955|NCT01930916|Device|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
79580956|NCT01930916|Other|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
79580957|NCT01930929|Procedure|Bariatric surgery|
79580958|NCT01930942|Radiation|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
79711599|NCT01106092|Biological|Poliorix™|Intramuscular, single dose
79711600|NCT01097668|Biological|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
79711601|NCT04307290|Drug|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
79711602|NCT04902430|Procedure|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
80017111|NCT02287298|Procedure|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
80017112|NCT00321958|Device|CSA System (CryoSpray AblationTM System)|10 second spray times
80017113|NCT00321958|Device|CryoSpray Ablation|10 second spray times
80017114|NCT02100852|Drug|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
79711603|NCT04902430|Procedure|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
79711604|NCT01325207|Radiation|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
79711605|NCT01324349|Device|Veriset Hemostatic Patch|Topical hemostat
79711606|NCT01324349|Device|Fibrin Sealant (TachoSil®)|Topical hemostat
79711607|NCT01095250|Drug|AIN457|
79711608|NCT01095250|Drug|AIN457|
79711609|NCT01095250|Drug|AIN457|
79711610|NCT01095250|Drug|Placebo|
79711611|NCT01324271|Device|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
79711612|NCT04325711|Drug|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
79711613|NCT01095094|Drug|ritonavir|Given orally
79711614|NCT01095094|Drug|lopinavir|Given orally
79711615|NCT01323647|Biological|PoliorixTM|Single dose, intramuscular administration
79711616|NCT01323647|Biological|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
79711617|NCT01094782|Other|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
80017115|NCT00057980|Drug|celecoxib|
80017116|NCT00057980|Drug|epirubicin hydrochloride|
79392597|NCT05746104|Drug|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
79392598|NCT02684188|Behavioral|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
79392599|NCT01684943|Other|Multiplex pharmacokinetic profiling|
79392600|NCT01684943|Other|Continuous insulin monitoring|
79392601|NCT03115242|Other|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
79711618|NCT01094782|Other|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
79711619|NCT05645315|Drug|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
79711620|NCT04325555|Drug|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
79711621|NCT05645237|Radiation|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
79711622|NCT00623285|Drug|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
79711623|NCT00623285|Drug|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
79711624|NCT02878720|Device|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
79711625|NCT01097044|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
79711626|NCT01097044|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
79711627|NCT01322009|Drug|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
79711628|NCT01322009|Drug|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
79711629|NCT01321697|Procedure|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
79711630|NCT01320683|Drug|oxaliplatin|Given IV
79711631|NCT01320683|Drug|leucovorin calcium|Given IV
79711632|NCT01320683|Drug|fluorouracil|Given IV
79711633|NCT01320683|Biological|bevacizumab|Given IV
80017117|NCT02985879|Drug|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
79253123|NCT05991791|Other|Early Start Denver Model (ESDM)|"Phase A~4 individual sessions (1 per week)~Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM~Satisfaction Evaluation - Parent~Satisfaction Evaluation - Therapist~Phase B :~11 sessions (1 per week)~Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM with the help of the robot Pepper~Satisfaction Evaluation - Parent~Satisfaction Evaluation - Therapist~Phase C :~4 sessions (1 per week)~Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM without the help of the robot Pepper~Satisfaction Evaluation - Parent~Satisfaction Evaluation - Therapist~All sessions will also be filmed and recorded"
79253124|NCT05991076|Other|Latin Dance|The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
79253125|NCT05990920|Biological|SNK02|SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.
79253126|NCT05987306|Behavioral|Weight loss plus self-compassion|A novel weight loss approach combining a standard weight loss based on the Diabetes Prevention Program and internalized weight bias intervention with self-compassion exercises.
79711634|NCT01320683|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
79711635|NCT01320683|Other|laboratory biomarker analysis|Correlative studies
79711636|NCT01320683|Other|pharmacological study|Correlative studies
79711637|NCT01320683|Drug|irinotecan hydrochloride|Given IV
79711638|NCT01320293|Drug|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
79711639|NCT05661383|Device|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
79711640|NCT05661383|Device|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
79711641|NCT01318811|Drug|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
79849626|NCT01326403|Drug|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
79849627|NCT00520845|Drug|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
79711642|NCT01318811|Drug|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
79849628|NCT00520845|Drug|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
79849629|NCT00520845|Drug|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
79849630|NCT00520845|Other|laboratory biomarker analysis|Blood collection
79849631|NCT00185731|Drug|Atorvastatin|80 mg orally once daily
79849632|NCT00582491|Drug|Modafinil|Modafinil 400mg orally every day for 16 days
79849633|NCT00582491|Drug|Placebo|Placebo orally everyday for 16 days
79849634|NCT00520767|Drug|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
79548118|NCT03808766|Other|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
79548119|NCT03789721|Other|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
79849635|NCT00520767|Drug|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
79849636|NCT00520767|Drug|melphalan|Melphalan 9 mg/m2/day days 1-4
79849637|NCT00520767|Genetic|microarray analysis|≤28 days prior to enrollment
79849638|NCT00520767|Other|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
79849639|NCT00520767|Other|laboratory biomarker analysis|≤28 days prior to enrollment
79253127|NCT05987202|Other|DA closure in a population of premature infants|Evaluate the incidence of DA closure in a population of premature infants treated with BTM per os for bronchopulmonary dysplasia
79253128|NCT05981963|Drug|[14C]-BMS-986196|Specified dose on specified days
79253129|NCT05978206|Drug|Nandrolone Decanoate|Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
79548120|NCT03789721|Other|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
79711643|NCT05644847|Other|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
79711644|NCT05644847|Procedure|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
79849640|NCT00520767|Procedure|quality-of-life assessment|Start of each cycle
79849641|NCT02390453|Behavioral|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
79849642|NCT02390453|Behavioral|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
79849643|NCT02390453|Behavioral|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
79253130|NCT05978206|Behavioral|Physiotherapy Intervention|"The physiotherapeutic intervention includes the following components:~Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate."
79849644|NCT02390453|Behavioral|Active Control|Control modules provide social contact for group discussion of health and successful aging.
79849645|NCT04074707|Dietary Supplement|Labeled iron solution (60mg and 120mg Ferrous Sulfate)|3 doses of 60mg iron as FeSO4 are given on 3 consecutive days (e.g., days 1-3); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 100ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with daily, alternate-day or every-third day dosing.
79253131|NCT05978206|Behavioral|Nutritional Intervention|An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.
79253132|NCT05978206|Drug|Placebo|Placebo
79253133|NCT05977595|Other|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
79253134|NCT05976867|Behavioral|Parents as Teachers (PAT) as usual|Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.
79548121|NCT03786718|Other|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
79253135|NCT05976867|Behavioral|Parents as Teachers (PAT) + Smart Parents|"Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (~60 min). Parents return to PAT as usual following this session."
79548122|NCT03778424|Drug|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
79548123|NCT03776864|Biological|Pembrolizumab|Given IV
79548124|NCT03776864|Drug|Umbralisib|Given PO
79548125|NCT03773575|Device|PREVENA™ PEEL & PLACE™ Dressing Kit|In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
79711645|NCT05644769|Other|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
79548126|NCT03762759|Procedure|Computed Tomography|Undergo PET/CT
79548127|NCT03762759|Drug|Fluciclovine F18|Given IV
79548128|NCT03762759|Radiation|Gallium Ga68-labeled PSMA-11|Given IV
79548129|NCT03762759|Procedure|Positron Emission Tomography|Undergo PET/CT
79849646|NCT04679051|Behavioral|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
79849647|NCT03873987|Drug|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
79849648|NCT03873987|Drug|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
79849649|NCT03018587|Device|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
79849650|NCT02359253|Other|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
79849651|NCT02359253|Other|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
79711646|NCT05644769|Drug|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
79711647|NCT05644691|Other|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
79711648|NCT05644691|Other|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
79849652|NCT02359253|Other|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
79849653|NCT02359253|Other|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
79849654|NCT04072913|Other|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
79849655|NCT02579213|Other|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
79392603|NCT01683383|Device|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
79392604|NCT01683383|Other|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
79392605|NCT03114852|Diagnostic Test|blood collection|They will have blood tested to renal genetic diseases
79392606|NCT05428462|Other|Psychoeducation day on borderline personality disorder|Transmission of latest knowledge on borderline personality disorder
79392607|NCT05744388|Device|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
79392608|NCT05746026|Behavioral|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~Session 1: introduction and basic information about Climate Change~Session 2: causes and factors that contribute to climate change by humans and nature~Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
79392609|NCT04739566|Drug|Dabrafenib|Given PO twice daily
79392610|NCT04739566|Drug|Trametinib|Given PO once daily
79392611|NCT05425108|Device|Binocular CP1|Binocular active projection of defocused image in the peripheral visual field
79392612|NCT02694744|Drug|patiromer|8.4 g/day starting dose, administered orally
79711649|NCT01093846|Drug|AIN457|300mg every 4 weeks
79711650|NCT01093846|Drug|AIN457|300mg every 2 weeks
79711651|NCT01093846|Drug|Placebo AIN457|Placebo to AIN457
79711652|NCT01315847|Drug|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
79711653|NCT01315847|Drug|[11C]MK-4232|Single intravenous doses of ~300 MBq [11C]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
79711654|NCT05644535|Diagnostic Test|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
79849656|NCT04072679|Drug|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
80017118|NCT02985879|Drug|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
80017119|NCT02103426|Drug|ASP0113|intramuscular injection
80017120|NCT02103426|Drug|Placebo|intramuscular injection
80017121|NCT05039320|Dietary Supplement|Bactoblis|dissolve the tablets in the mouth once a day for 4 weeks
80017122|NCT05039320|Dietary Supplement|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
79849657|NCT02579291|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
79849658|NCT02579291|Other|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
79849659|NCT00474760|Drug|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
79849660|NCT02579681|Drug|dimethyl fumarate|dimethyl fumarate administered as per the arm description
79849661|NCT00528645|Drug|saracatinib|Given orally
79849662|NCT04072757|Behavioral|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~seasonal fruits & vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~choose healthier foods Session Five: Taste Bud Rehab~reduce foods high in sugar and salt.Mind-body connection Session Six: Batch & One Ingredient Cooking~making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~prepare healthier desserts Session Eight: Family Meal Practices~healthy eating habits in children Session Nine: Snacks as Mini Meals~make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~healthy up favorite recipes"
79849663|NCT04072757|Behavioral|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
79849664|NCT00524745|Biological|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
79849665|NCT04073693|Dietary Supplement|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
79849666|NCT01017796|Drug|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
79849667|NCT01783535|Drug|vincristine|Given via minibag/gravity flow.
79849668|NCT01783535|Drug|topotecan|Given IV over 30 minutes.
79849669|NCT01783535|Drug|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
79548130|NCT03675412|Dietary Supplement|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
79548131|NCT03672877|Behavioral|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
79548132|NCT03664180|Drug|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
79548133|NCT03664180|Drug|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
79548134|NCT03664180|Drug|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
79711655|NCT05644535|Diagnostic Test|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
79849670|NCT01783535|Drug|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
80017123|NCT05718518|Drug|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
79548135|NCT03664180|Drug|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
79711656|NCT05644535|Diagnostic Test|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
79711657|NCT04325399|Other|Volitional help sheet|
79711658|NCT01093534|Drug|Placebo|Matching solifenacin placebo tablet
79711659|NCT01093534|Drug|solifenacin|Tablet for oral administration
79849671|NCT01783535|Drug|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
79849672|NCT01783535|Other|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
79849673|NCT01783535|Drug|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
79849674|NCT01783535|Drug|cyclophosphamide|Given IV.
79849675|NCT01783535|Drug|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
79849676|NCT01783535|Drug|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
79849677|NCT01783535|Procedure|enucleation|Eye removal due to advanced disease in Strata C and D participants.
79392613|NCT04738630|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
79548136|NCT03664180|Drug|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
79548137|NCT03664180|Drug|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
79849678|NCT01783535|Radiation|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
79253136|NCT05973006|Biological|NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
79253137|NCT05973006|Biological|Prototype/XBB.1.5 Bivalent Vaccine (5 µg)|A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
79849679|NCT05001646|Device|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
79849680|NCT00495040|Radiation|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
79849681|NCT04073537|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
79849682|NCT04073537|Drug|Placebos|Anlotinib blank analog capsule.
79849683|NCT04073537|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV on Day 1 of each 21-day cycle.
79849684|NCT04073537|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
79849685|NCT03998631|Procedure|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
79849686|NCT03998631|Procedure|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
79711660|NCT01314911|Drug|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
79711661|NCT01314911|Drug|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
79711662|NCT02891057|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-036)
79711663|NCT01093222|Drug|Erlotinib Hydrochloride|Given PO
79711664|NCT01093222|Drug|Sorafenib Tosylate|Given PO
79849687|NCT01020760|Behavioral|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
79849688|NCT04085133|Diagnostic Test|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
79849689|NCT01020916|Procedure|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
79849690|NCT01020916|Procedure|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
80017124|NCT05718518|Drug|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
80017125|NCT05718518|Drug|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
80017126|NCT02103504|Device|DePuy Attune posterior stabilized fixed bearing total knee replacement|
80017127|NCT04253782|Other|Team Intervention|"The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~treatment with buprenorphine/naloxone (BUP),~inpatient, 12-step, or methadone regimens, or~education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option."
79392614|NCT03106194|Other|case management|
79392615|NCT05339542|Other|platelet rich plasma|derived from patient own blood
79392616|NCT05339542|Drug|MethylPREDNISolone 40 MG|active comparative intervention
79392617|NCT03162900|Drug|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
79392618|NCT03162900|Drug|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
79392619|NCT03162900|Drug|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
79548138|NCT03662841|Procedure|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
79548139|NCT03652870|Drug|Nortriptyline|A medication used to treat conditions such as depression
80031469|NCT04905394|Procedure|subchondroplasty|subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
79253138|NCT05971641|Other|progressive relaxation exercise|Patients who undergo total knee replacement surgery in the experimental group will be taught progressive relaxation exercises. The exercise will last for 30 minutes and will be applied twice a day. Patients will wear a smart wristband. Patient Information Form, Numeric Rating Scale, Richard Campbell Sleep Quality Survey, and Postoperative Recovery Index Scale will be administered. The scales will be filled out for 5 days and will take approximately 10-15 minutes.
79253139|NCT05970354|Drug|EMLA Cream|Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
79548140|NCT03652870|Drug|Escitalopram|A medication used to treat conditions such as depression
79392620|NCT03162900|Other|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
79392621|NCT04338568|Diagnostic Test|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
79548141|NCT03652870|Drug|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
79548142|NCT03652389|Behavioral|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
79548143|NCT03652389|Behavioral|Usual Care|Standard Diabetes Treatment
79711665|NCT02878018|Drug|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
79711666|NCT02878018|Drug|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
79711667|NCT01313663|Drug|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
79711668|NCT01313663|Drug|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
80031470|NCT05135624|Drug|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
80031471|NCT05135624|Other|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
80031472|NCT05135624|Drug|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
79253140|NCT05970354|Drug|VersaPro Cream Base for Compounding|Placebo
79253141|NCT05968521|Behavioral|Cardiac Rehabilitation (CR): Experimental|CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.
79253142|NCT05968521|Behavioral|Treatment as usual: Control|Treatment as usual will include routine clinical outpatient management.
79253143|NCT05967052|Drug|Pregabalin|Pregabalin pharmacotherapy
79253144|NCT05967052|Behavioral|Independent walking training|Independent walking training
79253145|NCT05967052|Drug|Placebo|Placebo
79253146|NCT05967052|Behavioral|Gradual movement therapy in the ward|Gradual movement therapy in the ward
79253147|NCT05967052|Behavioral|Telerehabilitation|Telerehabilitation
79253148|NCT05967052|Behavioral|Psychotherapy|Psychotherapy
79392622|NCT05291806|Other|Reference Product|This intervention is based on white rice.
79392623|NCT05291806|Other|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
79392624|NCT05291806|Other|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
79392625|NCT05291806|Other|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
79548144|NCT03635060|Procedure|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
79548145|NCT03635060|Procedure|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
79548146|NCT03634852|Drug|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
79548147|NCT03634852|Drug|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
79253149|NCT05966090|Biological|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
79253150|NCT05966090|Biological|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
79253151|NCT05964920|Drug|Saline|Two placebo injections one at baseline and one week 3.
79580959|NCT01931007|Drug|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
79253152|NCT05964920|Drug|Testosterone Undecanoate|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
79711669|NCT05644457|Genetic|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
79849691|NCT02664363|Biological|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
79849692|NCT01020994|Drug|LAS41003|Once daily, topically
79849693|NCT01020994|Drug|LAS189962|Once daily, topically
80031473|NCT03469076|Other|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
79253153|NCT05964920|Drug|Saline + Resistance exercise training|Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
79253154|NCT05964920|Drug|Testosterone Undecanoate + Resistance exercise training|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
79253155|NCT05963568|Drug|Polycap|Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
79253156|NCT05953974|Other|Clinical score of Granillo and al.|Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
79392626|NCT05273788|Device|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
79580960|NCT01931007|Drug|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
79711670|NCT01092832|Drug|voriconazole|"Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
79849694|NCT01020994|Drug|LAS189961|Once daily, topically
79849695|NCT00494026|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
79849696|NCT00494026|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
79849697|NCT00494026|Procedure|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
79253157|NCT05953961|Device|Therasphere 90Y|Transarterial Radioembolization
79253158|NCT05953961|Device|Microwave Ablation|Microwave Ablation
79580961|NCT01931020|Drug|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
79580962|NCT01931020|Drug|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
79849698|NCT01018108|Procedure|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
79849699|NCT01018108|Procedure|Acupuncture Therapy|Undergo acupuncture
79849700|NCT01018108|Other|Questionnaire Administration|Ancillary study
79849701|NCT01018108|Other|Laboratory Biomarker Analysis|Correlative Study
79849702|NCT00524589|Dietary Supplement|calcitriol|IV
79849703|NCT00524589|Drug|dexamethasone|Oral
79849704|NCT00524589|Genetic|protein expression analysis|Correlative Study
79849705|NCT00524589|Other|laboratory biomarker analysis|Correlative Study
79253159|NCT05952323|Other|Teach-back|According to the prepared educational materials for medical devices, students will be trained using the teach-back method.
79711671|NCT05661305|Other|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
79849706|NCT04074837|Drug|NNI-362|NNI-362 small molecule in liquid suspension.
79849707|NCT04074837|Drug|Placebo|Placebo liquid suspension
79849708|NCT01015066|Drug|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
79711672|NCT02878564|Drug|Praziquantel|40 mg/kg, PO (orally administered tablets)
79849709|NCT01015066|Drug|Naltrexone|Oral tables, 50 mg/d, once a day for six months
79849710|NCT01021072|Drug|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
79849711|NCT00472030|Drug|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
79849712|NCT00472030|Drug|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
79849713|NCT00127855|Biological|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
79849714|NCT00127855|Biological|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
79253160|NCT05952323|Other|Video-assisted teaching|Students will be sent educational videos related to medical devices and asked to watch them.
79849715|NCT00127855|Biological|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
79849716|NCT00127855|Biological|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
79849717|NCT00127855|Biological|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
79849718|NCT00127855|Biological|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
79849719|NCT00127855|Biological|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
79253161|NCT05952141|Behavioral|Clinic Outreach|A member of the pathology team will contact the referring clinic to communicate the readiness of results.
79253162|NCT05952141|Behavioral|Enhanced Outreach|A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.
79253163|NCT05952141|Behavioral|Low-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.
79711673|NCT04325477|Device|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
79849720|NCT00493636|Drug|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
79849721|NCT00493636|Drug|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
79849722|NCT00493636|Drug|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
79849723|NCT00493636|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
79711674|NCT02891135|Other|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
79849724|NCT00524121|Drug|erlotinib hydrochloride|Oral
79849725|NCT00524121|Other|immunohistochemistry staining method|Correlative Study
79849726|NCT00524121|Radiation|radiation therapy|Radiation Treatment
79849727|NCT03996382|Diagnostic Test|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
79849728|NCT01018342|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
79849729|NCT01018342|Drug|Macrobid® Capsules 100 mg|
79849730|NCT01074385|Behavioral|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
79849731|NCT03965767|Drug|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
79849732|NCT00470626|Device|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
79849733|NCT03966001|Other|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
79849734|NCT03966001|Other|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
79849735|NCT01074541|Radiation|UVB|0.375 SED x 4 in a week
79849736|NCT01074541|Radiation|UVB|0.75 SED x 4 in a week
79849737|NCT01074541|Radiation|UVB|1.5 SED x 4 in a week
79849738|NCT01074541|Radiation|UVB|3.0 SED x 4 in a week
79849739|NCT00132769|Drug|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
79849740|NCT00132769|Drug|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
79849741|NCT00520299|Drug|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
79849742|NCT02518269|Procedure|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
79253164|NCT05952141|Behavioral|High-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
79392627|NCT05273788|Device|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
79711675|NCT04308070|Device|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
79711676|NCT04308070|Device|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
79711677|NCT02890979|Other|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
79711678|NCT02890979|Other|Laboratory Biomarker Analysis|Correlative studies
79711679|NCT02890979|Other|Quality-of-Life Assessment|Ancillary studies
79711680|NCT02890979|Device|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
79849743|NCT02478255|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
79849744|NCT02478255|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
79849745|NCT00132691|Drug|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
79849746|NCT00132691|Drug|oral corticosteroid with immunosuppressive agents as needed|Prednisone
79253165|NCT05950724|Drug|Etanercept Injection [Enbrel]|25 mg subcutaneous injection
79253166|NCT05949970|Procedure|Radiofrequency denervation of the lumbar facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the lumbar facet joint with a three-tined expandable needle.
79392628|NCT05273788|Device|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
79392629|NCT05229094|Device|Eva Nexus|Eva Nexus vitrectomy device
79392630|NCT05227534|Device|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
79711681|NCT01313273|Drug|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
79711682|NCT01313273|Drug|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
79253167|NCT05949853|Other|the respiratory parameters (AHI) and time spent|interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
79711683|NCT01091974|Drug|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
79711684|NCT01091974|Drug|Placebo Comparator|Placebo for 47 days
79253168|NCT05949268|Device|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
79711685|NCT01091974|Behavioral|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
79711686|NCT01313117|Drug|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
79711687|NCT01313039|Drug|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
79711688|NCT05644379|Drug|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
79711689|NCT05644379|Drug|Regorafenib|Regorafenib 80mg, po, orally once daily
79711690|NCT01091662|Drug|Eslicarbazepine acetate 1600 mg|1600 mg once per day
79711691|NCT01091662|Drug|Eslicarbazepine acetate 1200 mg|1200 once per day
79711692|NCT01312961|Drug|Dupilumab|Solution for injection, one subcutaneous injection.
79253169|NCT05948904|Diagnostic Test|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
79711693|NCT01312961|Drug|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
79711694|NCT01312961|Drug|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
79711695|NCT01312961|Drug|Fluticasone monotherapy|Oral inhalation twice daily.
79392631|NCT05218252|Procedure|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
79849747|NCT00125359|Drug|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
79711696|NCT01312961|Drug|Albuterol|Oral inhalation as needed.
79849748|NCT00524043|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
79849749|NCT00524043|Drug|Placebo|Once daily for 6 weeks
79849750|NCT00524043|Drug|Paliperidone ER|6 mg tablet once daily for 6 weeks
79849751|NCT03966703|Behavioral|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
79849752|NCT01076725|Device|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
79849753|NCT01076725|Device|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
79849754|NCT01076803|Drug|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
80017128|NCT02287454|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
79849755|NCT01076881|Behavioral|exercise training|
79849756|NCT00523419|Drug|Pemetrexed|500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
80017129|NCT02097966|Drug|Daclatasvir|
79277335|NCT03533777|Drug|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
79277336|NCT02198261|Drug|5% minoxidil topical foam|5% minoxidil topical foam
79392632|NCT00368602|Drug|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
79392633|NCT00368602|Other|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
79392634|NCT01683071|Drug|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
79392635|NCT01683071|Drug|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
79392636|NCT01683071|Drug|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
80017130|NCT02097966|Drug|Sofosbuvir|
80017131|NCT02097966|Drug|Ribavirin|
79392637|NCT01683071|Drug|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
79392638|NCT00368680|Device|Early Bubble CPAP|
79392639|NCT04707508|Drug|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
79392640|NCT04707508|Drug|Metformin|Metformin monotherapy
79711697|NCT01312961|Drug|Levalbuterol|Oral inhalation as needed.
79711698|NCT00626158|Drug|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
79711699|NCT00626158|Drug|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
79711700|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
79711701|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
79711702|NCT01310777|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
79711703|NCT01310777|Drug|Brinzolamide 1% ophthalmic suspension|
79711704|NCT01310777|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
79849757|NCT03868059|Drug|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
79849758|NCT03998865|Device|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
79849759|NCT04028115|Drug|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
79849760|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
79849761|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
79849762|NCT00522951|Drug|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
79849763|NCT03865953|Drug|LAT8881|LAT8881 oral capsule
79849764|NCT03865953|Drug|Placebo|Placebo oral capsule
79711705|NCT01310699|Device|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
79849765|NCT06028061|Procedure|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
79849766|NCT06028061|Procedure|Quadratus lumborum block III with Adjuvant|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
79711706|NCT01310075|Device|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
79849767|NCT06027970|Drug|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
79849768|NCT06027970|Other|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
79253170|NCT05948592|Biological|TP-102|Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (>1x108 PFU/mL and <1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
79849769|NCT06027957|Biological|anti-CD19 CAR T-cells|"For Biological: CD19 CAR T-cells~Dose: 1-2.10e6 cells/kg of weight~Route: intravenous infusion~For Chemotherapy Drug:~Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after."
79849770|NCT06027944|Other|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
79849771|NCT06027866|Device|SRAVI (Speech Recognition Application for the Voice Impaired)|Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
79849772|NCT06027853|Drug|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
79849773|NCT06027827|Procedure|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
79849774|NCT06027775|Drug|Targeted agent|The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
79849775|NCT06027736|Other|pharmacist-led education|A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
79849776|NCT06027710|Procedure|Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft|Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
79849777|NCT06027697|Device|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
79849778|NCT06027658|Behavioral|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
79392641|NCT05189080|Other|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
79392642|NCT05189080|Other|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
79392643|NCT05189080|Other|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
79711707|NCT01310075|Device|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
79711708|NCT01309997|Drug|imatinib mesylate|Given PO
79711709|NCT01309997|Biological|rituximab|Given IV
79711710|NCT01309919|Device|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
79711711|NCT01309919|Other|Diary|Subjects will keep a bleeding diary for three months
79711712|NCT04325165|Device|DBS Implantation|Bilateral implantation of PPN DBS electrodes
79711713|NCT01309841|Drug|NKTR-118|12.5 mg oral tablet once daily
79711714|NCT01309841|Drug|NKTR-118|25 mg oral tablet once daily
79711715|NCT01309841|Drug|Placebo|Oral tablet once daily
79711716|NCT01308749|Drug|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
79711717|NCT01308749|Drug|Placebo|Placebo Nasal Spray
79849779|NCT06027593|Behavioral|Mixed methods intervention|"Investigators will implement the intervention at the completion of the rapid user-centered design process and consultation with CDC collaborators.~During the rapid user-centered design process, the team will engage key stakeholders to create and optimize feedback reports that will fit the prescribing context, and determine appropriate implementation supports that will be needed to accompany the introduction of the feedback reports to each setting.~Following the initial awareness-building activities, investigators will circulate the antibiotic prescribing feedback reports. After the first 3 months (approximately) of report dissemination, the team will assess the feasibility and acceptability of the reports and implementation activities by administering a brief survey to prescribers and also conducting interviews with them. No direct identifiers will be collected."
79849780|NCT06027580|Device|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
79253171|NCT05948592|Other|Placebo|Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
79253172|NCT05944835|Other|Analyzed on the post-operative scanner|Analyzed on the post-operative scanner
79849781|NCT06027541|Procedure|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
79711718|NCT01307891|Drug|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
79392644|NCT05140642|Other|Automated annotation of the left ventricle through deep learning|A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
79711719|NCT01307891|Drug|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
79253173|NCT05944822|Other|pro-inflammatory cytokines|compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
79711720|NCT05644301|Drug|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
79711721|NCT05644301|Drug|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
79253174|NCT05942885|Other|anxiety questionnaire|Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
79253175|NCT05942677|Procedure|proportion of colorectal lesions|Evaluation of the proportion of colorectal lesions detected by a computer-aided detection system (CADe) compared with experienced endoscopists.
79253176|NCT05941702|Behavioral|Body Signal Integration Training|Information and protocol uploaded to documents.
79392645|NCT05140642|Other|Sonographer Measurement of LVEF|Standard practice sonographer measurement of left ventricle and assessment of LVEF
79392646|NCT05099068|Biological|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
79711722|NCT05644301|Drug|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
79849782|NCT06027515|Behavioral|Prehabilitation Program|Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
79253177|NCT05939570|Other|Interview|Prospective, semi-structured, qualitative interview.
79253178|NCT05939453|Other|Sham Light|Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.
79253179|NCT05939453|Other|Bright Light Therapy|Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
79253180|NCT05937399|Behavioral|Intervention video|This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.
79253181|NCT05937399|Behavioral|Control video|This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
79392647|NCT01567865|Biological|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
79392648|NCT01567865|Biological|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
79711723|NCT04324931|Other|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
79711724|NCT04324931|Other|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
79711725|NCT02890745|Drug|Empagliflozin|
79711726|NCT02890745|Drug|Placebo|
79711727|NCT01307579|Drug|Caspofungin Acetate|Given IV
79711728|NCT01307579|Drug|Fluconazole|Given IV or PO
79711729|NCT01307579|Other|Laboratory Biomarker Analysis|Correlative studies
79711730|NCT01057693|Drug|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
79711731|NCT01057693|Drug|Placebo|Placebo is supplied as capsules and given 3 times daily.
79711732|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
79711733|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
79392649|NCT05049226|Biological|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 10^10 viral particles (vp)~*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
79548148|NCT03634852|Drug|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
79253182|NCT05937256|Procedure|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
79253183|NCT05937256|Procedure|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
79711734|NCT02875171|Drug|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
79711735|NCT01307501|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
79711736|NCT04325009|Drug|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
79711737|NCT04325009|Drug|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
79711738|NCT01034137|Drug|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
79277337|NCT02368899|Other|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
79392650|NCT05049226|Biological|Pfizer/BioNTech BNT162b2 vaccine (PF) full dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
79580963|NCT01931046|Drug|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
79580964|NCT01931072|Behavioral|High-intensity interval training|Interval training 3 times a week for 8 weeks
79711739|NCT01034137|Drug|placebo MTX|orally weekly
79711740|NCT01034137|Drug|placebo TCZ|iv every 4 weeks
79711741|NCT01034137|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
79711742|NCT04302805|Drug|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
79711743|NCT04302805|Drug|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
79711744|NCT04302805|Other|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
79711745|NCT02874469|Other|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
79711746|NCT02874079|Other|Blood sample and cotton skin swabs|
79711747|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
79392651|NCT05049226|Biological|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 10^10 viral particles (vp)~*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
79711748|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
79711749|NCT01056289|Drug|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
79711750|NCT01039675|Drug|500mcg/25mcg once daily|GSK573719/GW642444
79711751|NCT01039675|Drug|Placebo once daily|Inactive, excipients only
79711752|NCT02875093|Drug|ADI-PEG 20|Investigational Medicine
79548149|NCT03634852|Drug|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
79548150|NCT03593811|Diagnostic Test|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
79711753|NCT02875093|Drug|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
79711754|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
79711755|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
79849783|NCT06027502|Behavioral|Passive Heating|20 minutes of baseline data collection, up to 45 minutes of immersion in the hot tub to achieve a core temperature of 38.5 degrees celsius, followed by up to 90 minutes of recovery.
79849784|NCT06027450|Other|NHIg prescription|Analysis of NHIg prescription
79392652|NCT05049226|Biological|Pfizer/BioNTech BNT162b2 vaccine (PF) half dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
79711756|NCT01033825|Drug|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
79548151|NCT03593811|Diagnostic Test|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
79849785|NCT06027424|Other||observational study, no intervention
79849786|NCT06027398|Diagnostic Test|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
79392653|NCT05006872|Device|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
79849787|NCT06027385|Diagnostic Test|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
79548152|NCT03593811|Diagnostic Test|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
79548153|NCT03593811|Diagnostic Test|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
79548154|NCT03593811|Diagnostic Test|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
79849788|NCT06027372|Device|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
79849789|NCT06027346|Biological|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
79711757|NCT01033825|Drug|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
79849790|NCT06027294|Procedure|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
79392654|NCT05005546|Behavioral|Yoga|Yoga will be applied to mothers in the yoga group
79711758|NCT01033825|Drug|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
79711759|NCT01033825|Drug|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
79711760|NCT01033825|Drug|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
79711761|NCT01033747|Drug|Deferasirox|10 mg/kg or 30 mg/kg orally daily
79711762|NCT01033747|Drug|Deferasirox|5 mg/kg or 30 mg/kg orally daily
79711763|NCT00627055|Drug|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
79711764|NCT00627055|Drug|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
79711765|NCT02875015|Drug|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
79711766|NCT02875015|Drug|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
79711767|NCT02875015|Procedure|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
79849791|NCT06027281|Other|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
79849792|NCT06027281|Other|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
79548155|NCT03593811|Drug|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
79849793|NCT06027281|Other|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
79548156|NCT03593811|Drug|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
79548157|NCT03560453|Behavioral|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
79548158|NCT03552575|Drug|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
79548159|NCT03552575|Drug|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
79548160|NCT03535623|Other|remote ischemic preconditioning (RIPC)|RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
79548161|NCT03535623|Other|Sham-RIPC|Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion.
79548162|NCT03528902|Drug|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
79548163|NCT03528902|Drug|Placebo Oral Tablet|Placebo
79548164|NCT03522714|Device|Fluid Immersion Simulation System|Dolphin Fluid Immersion Simulation® System Mattress will be used
79548165|NCT03522714|Device|Air Fluidized Bed System|Air Fluidized Bed (Clinitron) will be used.
79548166|NCT03511339|Device|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
79548167|NCT03463408|Drug|nivolumab|240 mg every 2 weeks
79548168|NCT03463408|Drug|ipilimumab|1 mg/kg every 6 weeks
79548169|NCT03462238|Procedure|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
79548170|NCT03462238|Radiation|CT Scan|A scanner will be performed
79548171|NCT03420144|Drug|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
79548172|NCT03420144|Drug|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
79548173|NCT03415425|Other|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
79548174|NCT03415425|Other|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
79548175|NCT03409744|Drug|evinacumab|Intravenous (IV) administration
79548176|NCT03408314|Other|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
79548177|NCT03408314|Other|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
79548178|NCT03400943|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
79548179|NCT03400943|Drug|Placebo|Matching placebo was administered to group B1 and B2.
79548180|NCT03384784|Drug|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
79548181|NCT03384784|Drug|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
79548182|NCT03383094|Drug|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
79548183|NCT03383094|Radiation|Radiation therapy|70 Gy in 33-35 fractions
79548184|NCT03383094|Drug|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
79548185|NCT03374475|Drug|JNJ-42847922 20mg|Participants will swallow 20 mg (2*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
79548186|NCT03374475|Drug|JNJ-42847922 40mg|Participants will swallow 40 mg (2*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
79548187|NCT03374475|Drug|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
79580965|NCT01931072|Behavioral|Moderate training|Moderate training 3 times a week for 8 weeks
79711768|NCT01091428|Drug|Alisertib|Alisertib tablets
79711769|NCT01091428|Drug|Paclitaxel|Paclitaxel intravenous infusion
79711770|NCT04307758|Other|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
79711771|NCT04307758|Other|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
79711772|NCT04307680|Device|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
79711773|NCT04307524|Procedure|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
79711774|NCT04307524|Drug|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
79711775|NCT04307602|Other|Exercise - High Intensity Interval Training (HIIT)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
79711776|NCT04307602|Other|Exercise - Submaximal Steady State Training (SST)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
79711777|NCT01096342|Drug|dinaciclib|Given IV
79711778|NCT01096342|Other|laboratory biomarker analysis|Correlative studies
79849794|NCT06027281|Other|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
79548188|NCT03373032|Other|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
79548189|NCT03373032|Other|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
79849795|NCT06027281|Other|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
79849796|NCT06027281|Other|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
79548190|NCT03373032|Other|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
79548191|NCT03373032|Other|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
79548192|NCT03373032|Other|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
79548193|NCT03344419|Drug|CI-581a|Medication infusion intravenously over 1 hour.
79548194|NCT03344419|Drug|CI-581b|Medication infusion intravenously over 1 hour.
79548195|NCT03344419|Behavioral|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
79548196|NCT03344419|Behavioral|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
79548197|NCT03321526|Drug|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
79711779|NCT01039519|Drug|Ganetespib|Ganetespib 200 mg/m^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
79711780|NCT04874740|Other|No intervention|No intervention
79711781|NCT01096186|Drug|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
79849797|NCT06027281|Other|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
79849798|NCT06027203|Procedure|prostate biopsy|Prostate biopsy by either transrectal or transperineal technique
79849799|NCT06027164|Device|Portable Ultrasound System|EchoNous KOSMOS
79849800|NCT06027151|Drug|1ml of 1% metronidazole gel|1ml of 1% metronidazole gel subgingivally at baseline visit
79849801|NCT06027151|Drug|1ml of 2% minocycline gel|1ml of 2% minocycline gel sub gingivally at baseline visit
79849802|NCT06027151|Drug|1ml of combination of 1% metronidazole gel and 2% minocycline|1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
79849803|NCT06027138|Other|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
79711782|NCT01096186|Drug|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
79711783|NCT01096186|Drug|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
79849804|NCT06027138|Other|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
79849805|NCT06027073|Biological|omalizumab|adding omalizumab to anti asthmatic therapy
79849806|NCT06026995|Drug|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
79548198|NCT03321526|Drug|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
79849807|NCT06026995|Drug|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
79392655|NCT05005546|Behavioral|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
79392656|NCT01567163|Biological|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
79392657|NCT01567163|Drug|Docetaxel|docetaxel 75 milligrams/square meter (mg/m^2) intravenous infusion administered on Day 1 of each 3-week cycle
79392658|NCT05002114|Drug|Cannabidiol|Topical CBD cream - special formulation
79392659|NCT05002114|Other|Placebo|Not the drug
79392660|NCT02986061|Device|Urinary catheter|
79548199|NCT03321526|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
79711784|NCT01096186|Drug|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
79849808|NCT06026982|Dietary Supplement|probiotic and pickle|probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
79849809|NCT06026969|Other|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
79849810|NCT06026956|Other|Tele-Assessment|Tele-Assessment
79849811|NCT06026943|Device|DaRT seeds insertion|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
79392661|NCT00368758|Drug|Probiotic bacteria (Trevis R)|
79548200|NCT03321526|Drug|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
79548201|NCT03321526|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
79849812|NCT06026930|Device|low-level laser therapy|LLLT and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
79548202|NCT03321526|Drug|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
79548203|NCT03297593|Drug|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
79548204|NCT03297593|Drug|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
79548205|NCT03240653|Other|Stratified response to Enzyme Therapy|Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
79548206|NCT03217669|Drug|Epacadostat|Epacadostat tablet: 100mg or 300mg
79548207|NCT03217669|Drug|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
79711785|NCT01032889|Drug|Deoxycholic acid injection|
79392662|NCT04597840|Procedure|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
79711786|NCT01032889|Drug|Placebo|Phosphate buffered saline placebo for injection
79392663|NCT04597840|Procedure|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
79392664|NCT04567810|Drug|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
79392665|NCT04567810|Drug|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
79711787|NCT04301713|Other|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
79711788|NCT04307368|Other|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
79711789|NCT04307368|Other|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
79711790|NCT04307368|Other|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
79711791|NCT01049503|Other|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
79711792|NCT04292353|Other|Cognitive tests and Patient Reported Outcome|
79711793|NCT01029925|Drug|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
79711794|NCT04302415|Drug|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
79711795|NCT02873533|Other|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
79711796|NCT04302649|Drug|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
79711797|NCT04301557|Drug|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
80017132|NCT05716958|Radiation|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) is a type of 3D mammography that creates detailed images of the breast tissue. It uses X-rays to take multiple images at different angles and combines them to create a clear, layered view of the breast tissue. DBT is used for breast cancer screening and diagnosis and provides a more accurate view of the breast tissue compared to traditional 2D mammography.
79392666|NCT04556344|Behavioral|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
79711798|NCT04301557|Drug|Oxaliplatin|Oxiliplatin 130mg/m^2 (100mg/m^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
79711799|NCT04301557|Drug|Capecitabine|Capecitabine 1000mg/m^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
79711800|NCT04301557|Radiation|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
79711801|NCT04301557|Procedure|Total mesorectal excision|Total mesorectal excision
79711802|NCT02874313|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
79711803|NCT02874313|Drug|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
79711804|NCT02874313|Other|Conventional anti-diabetic diet recommendations|
79253184|NCT05935111|Behavioral|Physical Activity Self-efficacy (PAS) intervention|The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
79253185|NCT05932693|Other|E-liquid coolant (WS-3, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.1%.
79711805|NCT01029691|Device|Positive Airway Pressure|Women will use positive airway pressure until delivery
79253186|NCT05932693|Other|E-liquid coolant (WS-3, 0.25%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.25%.
79392667|NCT04556344|Behavioral|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
79392668|NCT04338802|Drug|Nintedanib 150 MG|Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
79392669|NCT04338802|Other|Placebo|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
79548208|NCT03196427|Drug|Vedolizumab|Vedolizumab intravenous infusion
79548209|NCT03185819|Drug|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
79548210|NCT03185819|Drug|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
79548211|NCT03185819|Drug|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
79548212|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
79548213|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
79548214|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
79548215|NCT03153111|Drug|Macitentan|macitentan 10 mg; film-coated tablet; oral use
79548216|NCT03153111|Drug|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
79711806|NCT02874157|Biological|blood draw|
79711807|NCT01029535|Device|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
79711808|NCT04290481|Other|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
79711809|NCT04301167|Behavioral|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
79739744|NCT05367518|Dietary Supplement|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
79739745|NCT01163474|Other|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
79392670|NCT04455022|Other|Bedside blood culture bottles weighing combined with educational interventions.|Educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
79711810|NCT04302571|Behavioral|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
79849813|NCT06026904|Device|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
79849814|NCT06026878|Drug|gemcitabine,nimotuzumab, toripalimab|same as before
79253187|NCT05932693|Other|E-liquid coolant (WS-3, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.5%.
79253188|NCT05932693|Other|E-liquid coolant (WS-3, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 1.0%.
79253189|NCT05932693|Other|E-liquid coolant (WS-3, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 2.0%.
79392671|NCT04453150|Other|Standard hypocaloric die|Standard hypocaloric diet
79392672|NCT04453150|Other|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
79253190|NCT05932693|Other|E-liquid coolant (menthol, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.1%.
79392673|NCT04453150|Other|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
79711811|NCT04302571|Behavioral|sham exercise|general recommendation to perform regular aerobic physical activity
79392674|NCT04453150|Other|Alternate-day fasting|Alternate-day fasting
79392675|NCT04453150|Other|Ketogenic diet|Ketogenic diet
79392676|NCT04439656|Diagnostic Test|Eye movement analysis|Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
79392677|NCT04395508|Drug|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
79548217|NCT03151629|Other|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
79711812|NCT02874235|Behavioral|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
79849815|NCT06026878|Drug|gemcitabine, cisplatin|same as before
79849816|NCT06026865|Dietary Supplement|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
79849817|NCT06026865|Other|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
79849818|NCT06026787|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
79253191|NCT05932693|Other|E-liquid coolant (menthol, 0.25%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.25%.
79849819|NCT06026748|Drug|XJ103 Injection|XJ103 is a humanized monoclonal antibody.
79253192|NCT05932693|Other|E-liquid coolant (menthol, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.5%.
79253193|NCT05932693|Other|E-liquid coolant (menthol, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 1.0%.
79253194|NCT05932693|Other|E-liquid coolant (menthol, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 2.0%.
79253195|NCT05932537|Procedure|Preoperative visualization techniques|describe techniques for pre-operative visualization of subcutaneous contraceptive implants
79253196|NCT05929716|Drug|Magrolimab|Given by IV (vein)
79253197|NCT05929716|Drug|Rituximab|Given by IV (vein)
79392678|NCT00368914|Drug|sirolimus|
79392679|NCT00368914|Other|laboratory biomarker analysis|
79392680|NCT00368914|Other|pharmacological study|
79392681|NCT00368914|Procedure|biopsy|
79253198|NCT05929716|Drug|CAR T leukapheresis|Given by IV (vein)
79253199|NCT05929716|Drug|Radiation|Given by IV (vein)
79548218|NCT03144921|Behavioral|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
79548219|NCT03126435|Drug|EndoTAG-1|twice weekly
79548220|NCT03126435|Drug|Gemcitabine|once weekly
79548221|NCT03123809|Device|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
79253200|NCT05920629|Behavioral|Alcohol consumption|After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 12 months. We will perform a first echocardiography at randomization and a second at 12 months' follow-up.
79392682|NCT04357990|Device|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
79548222|NCT03084939|Biological|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
79548223|NCT03084939|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
79392683|NCT04357990|Other|Placebo|The placebo will be a similar spray containing saline only.
79548224|NCT03084939|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
79548225|NCT03011684|Drug|Tamoxifen|For ER Positive Randomization
79548226|NCT03011684|Drug|Letrozole|For ER Positive Randomization
79548227|NCT03003299|Device|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
79253201|NCT05914194|Drug|NLS-2|Participants will receive NLS-2 tablets orally.
79253202|NCT05914194|Drug|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
79548228|NCT02968108|Drug|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects <40 kg or 130 mg for subjects >= 40 kg in Group 1 and 9 mg/kg for subjects < 40 kg or 390 mg for subjects >= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at Week 8.
79548229|NCT02957149|Other|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
79548230|NCT02957149|Device|Angel Concentrated Platelet Rich Plasma System|
79548231|NCT02947347|Drug|ibrutinib|ibrutinib 560mg administered orally
79548232|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
79548233|NCT02947347|Drug|rituximab|rituximab 375mg/m^2 IV
79548234|NCT02870907|Other|Observation|no post operative chemotherapy
79548235|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
79548236|NCT02870907|Drug|Vincristine|1, 5 mg/m²/d, IV at D1.
79548237|NCT02870907|Radiation|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
79548238|NCT02870907|Drug|Carboplatin|160 mg/m²/d, IV from D1 to D5.
79548239|NCT02870907|Drug|Vincristine|1,5 mg/m²/d, IV at D22 and D26
79548240|NCT02870907|Drug|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
79849820|NCT06026748|Drug|Placebo|Placebo contains only excipients.
79849821|NCT06026735|Other|lung cancer with brain /leptomeningeal metastasis|Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
79392684|NCT01567085|Drug|Eculizumab|
79392685|NCT04344184|Drug|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
79392686|NCT04344184|Other|Placebo|Dextrose 5% Water
79392687|NCT04290754|Behavioral|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
79548241|NCT02870907|Drug|Carboplatin|560 mg/m²/d, IV at D1.
79548242|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV from D1 to D5
79548243|NCT02870907|Drug|Carboplatin|160 mg/m²/d,IV from D1 to D5
79253203|NCT05913687|Diagnostic Test|AIDP|Machine learning algorithm of imaging data
79548244|NCT02870907|Drug|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
79548245|NCT02870907|Drug|Vincristine|1,5 mg/m²/d), IV at D22
79548246|NCT02870907|Drug|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
79548247|NCT02870907|Procedure|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
79548248|NCT02870907|Drug|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
79548249|NCT02870907|Drug|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
79548250|NCT02870907|Drug|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
79548251|NCT02870907|Procedure|Peripheral bood stem cell transplantation|at D0
79548252|NCT02823574|Biological|Nivolumab|
79548253|NCT02823574|Biological|Ipilimumab|
79548254|NCT02823574|Other|Placebo|
79548255|NCT02746809|Device|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut 34R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
79548256|NCT02641028|Drug|CERC-501|CERC-501
79548257|NCT02641028|Drug|Placebo|Placebo
79548258|NCT02525796|Drug|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
79548259|NCT02525796|Drug|amiloride|amiloride, titrated up to a maximum of 10mg BID
79548260|NCT02525796|Drug|Placebo|
79580966|NCT01931085|Drug|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
79849822|NCT06026722|Behavioral|cognitive behavioral therapy for insomnia|CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
79711813|NCT02874235|Behavioral|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
79253204|NCT05912101|Procedure|Pericapsular Nerve Group Block|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
79253205|NCT05912101|Procedure|Suprainguinal Fascia Compartment Block|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
79711814|NCT04301635|Procedure|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
79392688|NCT04290754|Behavioral|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
79711815|NCT01028053|Drug|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
79849823|NCT06026709|Behavioral|MindWellness|"The online intervention MindWellness integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
79849824|NCT06026696|Other|follow-up|Long term follow-up
79849825|NCT06026631|Procedure|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
79392689|NCT01566773|Drug|PT001 MDI|Administered as two puffs BID for 14 days
79392690|NCT01566773|Drug|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
79849826|NCT06026605|Drug|WTX212A|WTX212A infusion once every 21 days
79849827|NCT06026592|Genetic|determination of circulating biomarkers of renal origin circulating biomarkers of renal origin|The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).
79849828|NCT06026566|Drug|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
79849829|NCT06026566|Drug|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
79849830|NCT06026566|Drug|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
79849831|NCT06026566|Drug|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
79849832|NCT06026566|Drug|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
79849833|NCT06026566|Drug|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
79849834|NCT06026566|Drug|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
79849835|NCT06026566|Drug|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
79849836|NCT06026566|Drug|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
79392691|NCT01566773|Drug|PT001 Placebo MDI|
79392692|NCT04276714|Other|Socket without Revofit system|All the tests are evaluate during one week with the classical type of fittings
79849837|NCT06026553|Drug|Ketorolac (Toradol)|IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
79849838|NCT06026553|Other|Placebo (saline)|IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
79849839|NCT06026527|Drug|Magnesium sulfate|50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
79849840|NCT06026527|Drug|Normal Saline|100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
79392693|NCT04276714|Other|Socket with Revofit system|All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
79548261|NCT02525796|Drug|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
79548262|NCT02360280|Drug|ketamine|sedative
79548263|NCT02360280|Drug|midazolam|sedative
79548264|NCT02201251|Drug|Topiramate|Topiramate weight based dosing for participants 2 to <10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
79548265|NCT02201251|Drug|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
79548266|NCT02174575|Drug|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
79548267|NCT02174575|Drug|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
79580967|NCT01931098|Drug|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
79849841|NCT06026501|Drug|PE0116,PE0105|"PE0116: 4-1BB Agonist Antibody Drug~PE0105: PD-1 Monoclonal Antibody Drug"
79711816|NCT04301245|Other|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
79711817|NCT04607317|Behavioral|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
79711818|NCT04607317|Behavioral|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
79711819|NCT04607317|Behavioral|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
79548268|NCT02153814|Procedure|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
79711820|NCT04300621|Drug|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
79253206|NCT05912101|Procedure|3-1 Block|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
79711821|NCT04300621|Drug|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
79711822|NCT04300621|Drug|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
79711823|NCT04300621|Drug|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
79711824|NCT01023217|Drug|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
79849842|NCT06026488|Other|Other|real world treatment and survival of DLBCL patients in China
79849843|NCT06026475|Procedure|Goal directed Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining SVV below 11
79253207|NCT05910775|Behavioral|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
79392694|NCT04134442|Drug|Bupivacaine Liposome Injection|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
79392695|NCT04134442|Other|Standard Therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
79392696|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
79548269|NCT02153814|Procedure|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
79580968|NCT01931098|Drug|pazopanib|600 mg orally, daily until progression, up to one year.
79580969|NCT01931124|Behavioral|High Intensity Training|
79711825|NCT01023217|Drug|Entecavir|Entecavir 1 mg/day orally
79711826|NCT01023217|Drug|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
79711827|NCT01095796|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
79849844|NCT06026475|Procedure|Conventional Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining CVP between 8-12 cms H20
79849845|NCT06026280|Behavioral|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
79711828|NCT01095796|Drug|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
79711829|NCT01095796|Drug|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
79711830|NCT01095796|Drug|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
79711831|NCT01023061|Drug|abiraterone acetate|Given PO
79711832|NCT01023061|Drug|prednisone|Given PO
79711833|NCT01023061|Drug|leuprolide acetate|Given via injection
79711834|NCT01023061|Other|laboratory biomarker analysis|Correlative study
79711835|NCT01023061|Radiation|external beam radiation therapy|Undergo radiotherapy
79711836|NCT01023061|Drug|goserelin acetate|Given via injection
79711837|NCT01027897|Drug|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
79711838|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
79849846|NCT06026280|Other|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
79253208|NCT05909150|Drug|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
79253209|NCT05909150|Drug|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
79253210|NCT05908526|Behavioral|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
79392697|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
79253211|NCT05908526|Device|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
79253212|NCT05908526|Drug|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
79253213|NCT05908526|Other|Placebo|An inactive substance that looks like the drug or treatment being tested.
79253214|NCT05904691|Drug|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
79392698|NCT04068064|Procedure|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days."
79548270|NCT02027545|Behavioral|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
80017133|NCT05716178|Behavioral|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
79548271|NCT02027545|Behavioral|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
79548272|NCT02027545|Behavioral|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
79548273|NCT02027545|Behavioral|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
79548274|NCT01937039|Procedure|Sample collection|Blood, tissue, urine, and other samples may be collected
79548275|NCT01889810|Dietary Supplement|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
79548276|NCT01888198|Behavioral|(EORTC QLQ-C30) questionnaire|
79548277|NCT01888198|Behavioral|EuroQol EQ-5D 7-item questionnaire|
79548278|NCT01867242|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
79548279|NCT01867242|Other|Snus|Winterchill or Robust flavors
79548280|NCT01860560|Device|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
79548281|NCT01860560|Device|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
79548282|NCT01858688|Device|Multiparametric MRI|an MRI of the prostate will be performed
79548283|NCT01858688|Procedure|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
79548284|NCT01840592|Drug|Sorafenib|
79548285|NCT01840592|Drug|Doxorubicin|
79548286|NCT01831895|Device|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
79548287|NCT01734694|Drug|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
79548288|NCT01734694|Drug|Ceftaroline|"Dose based on package insert labeling~CrCL > 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL < 15mL/min: 200 mg q12h;"
79548289|NCT01734694|Drug|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL < 30 mL/min: 6 - 10 mg/kg IV q48h"
79548290|NCT01734694|Drug|Linezolid|600 mg IV/PO q12h
79548291|NCT01599234|Drug|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
79548292|NCT01599234|Drug|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
79711839|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
79392699|NCT04068064|Procedure|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
79392700|NCT04341922|Behavioral|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes [e.g. becoming unemployed]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
79548293|NCT01393301|Behavioral|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
79392701|NCT01565993|Device|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
79711840|NCT04300465|Behavioral|10 week MySlainte Program|"The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí."
79711841|NCT02873611|Device|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
79711842|NCT02873611|Procedure|genicular ablation procedure|
79711843|NCT02873299|Other|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
79711844|NCT02873299|Other|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
79711845|NCT01027273|Behavioral|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
79277338|NCT02368899|Other|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
79277339|NCT00147277|Device|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
79711846|NCT01027273|Behavioral|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
79711847|NCT04300933|Behavioral|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
79392702|NCT01565993|Device|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
79392703|NCT01565291|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
79711848|NCT01022203|Behavioral|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
79548294|NCT01393301|Behavioral|Control|Enhanced standard smoking cessation treatment and NRT.
79548295|NCT01339546|Other|no intervention|
79548296|NCT00716625|Drug|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
79548297|NCT00713817|Drug|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
79548298|NCT00713817|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
79711849|NCT01022203|Other|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
79392704|NCT03417388|Drug|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
79548299|NCT00713323|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
79849847|NCT06026241|Other|Collecting data from the medical record|Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
79849848|NCT06025838|Behavioral|positive feedback|The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
79548300|NCT00713193|Drug|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
79548301|NCT00713193|Drug|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
79849849|NCT06024044|Behavioral|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
79548302|NCT00710554|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
79711850|NCT01296711|Biological|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
80017134|NCT02103582|Other|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
79711851|NCT04324281|Other|Investigation|cadaveric dissection
79849850|NCT06023628|Other|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
79849851|NCT06023550|Other|Treatment with surgery and/or conservative measures|Patients will be treated according to established clinical practice with surgery and/or conservative measures.
80017135|NCT00052598|Biological|therapeutic allogeneic lymphocytes|Given IV
79392705|NCT03417388|Drug|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
79392706|NCT03417388|Drug|Aspirin|Will be recommended to IMT women without contraindications or bleeding risk.
79392707|NCT03417388|Behavioral|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
79392708|NCT03417388|Behavioral|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
79392709|NCT02691702|Drug|BIIB118|Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
79711852|NCT05661045|Procedure|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
79711853|NCT01294917|Device|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
79711854|NCT01294917|Device|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
79849852|NCT06023420|Drug|4 Herbs Formula|4 herbs formula dose: 5g/day
79849853|NCT06023147|Procedure|E-TACE|The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
79849854|NCT06022068|Drug|Sirolimus|7 mg taken once per week during 26 weeks.
80017136|NCT00052598|Biological|aldesleukin|Given SC
80017137|NCT00052598|Other|laboratory biomarker analysis|Correlative studies
79392710|NCT02691702|Drug|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
79548303|NCT00710554|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
79548304|NCT00710424|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
79548305|NCT00710424|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
79548306|NCT00674609|Drug|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
79580970|NCT01931124|Behavioral|Moderate Intensity Training|
79711855|NCT01294917|Device|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
79711856|NCT01294683|Drug|Simvastatin|
79711857|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
79711858|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant (N/LRPT)|
79711859|NCT01294683|Drug|Placebo|
79392711|NCT02975128|Device|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
79253215|NCT05900284|Drug|Metformin low dose|If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
79253216|NCT05900284|Drug|Metformin high dose|If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
79392712|NCT02974894|Dietary Supplement|Probiotic (Lactobacillus Plantarum)|
79548307|NCT00674609|Drug|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
79277340|NCT02191917|Procedure|Respiratory muscle strength measurements by different techniques.|
79548308|NCT00674609|Drug|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
79548309|NCT00562549|Drug|SLx-2101|
79711860|NCT01294449|Device|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
79711861|NCT01294449|Device|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
79711862|NCT01293123|Drug|Raltegravir|raltegravir 400 mg PO twice daily
79711863|NCT01293123|Drug|Efavirenz|efavirenz 600 mg PO once daily
79711864|NCT01292187|Drug|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
79392713|NCT02974894|Dietary Supplement|Placebo|
79392714|NCT02974816|Device|Glooko's mobile application|Standard of care and Remote monitoring
79392715|NCT05742204|Other|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
79392716|NCT05742204|Other|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
79548310|NCT00289107|Device|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
79548311|NCT00289107|Device|Total knee replacement|Fixed Cruciate Substituting Knee System
79548312|NCT00118846|Dietary Supplement|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
79711865|NCT01292187|Drug|Oral placebo at dinnertime|Oral placebo at dinnertime.
79711866|NCT01292187|Drug|Oral calcitonin at bedtime|Oral calcitonin at bedtime
79711867|NCT01292187|Drug|Oral placebo at bedtime|Oral placebo at bedtime
79711868|NCT01026493|Drug|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
80017138|NCT00052598|Other|flow cytometry|Correlative studies
79548313|NCT00118846|Other|Placebo|Milk protein administered twice daily
79548314|NCT01556568|Drug|MEK162|
79548315|NCT01556607|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
79548316|NCT01556607|Drug|Placebo|
79548317|NCT01556646|Drug|Tolvaptan|15 to 30mg qd titrated to sodium concentration
79548318|NCT01556659|Drug|Absence of Acenocoumarol|Dual anti-platelet therapy without the addition of Acenocoumarol.
79580971|NCT01931137|Drug|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
79711869|NCT01026493|Drug|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
79711870|NCT01026493|Drug|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
79711871|NCT01026493|Drug|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
79711872|NCT01026493|Drug|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
79711873|NCT01026493|Drug|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
79711874|NCT01026103|Device|Tri Staple Technology stapler|This is a single arm study.
79392717|NCT05742048|Diagnostic Test|traumatic patient suspect to have long bone fracture between 18 - 65 years old|Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
79711875|NCT02873767|Drug|PR1|"Active substance: UCB4019~Route of Administration: subcutaneously"
79849855|NCT06021743|Diagnostic Test|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
79849856|NCT06021743|Diagnostic Test|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
79849857|NCT06021743|Diagnostic Test|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
79253217|NCT05900284|Drug|Placebo|If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
79253218|NCT05900258|Drug|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
79253219|NCT05893030|Procedure|anesthesia guided by sedation and analgesia monitoring|"Anesthesia guided by sedation and analgesia monitoring The level of sedation will be monitored by~Monitoring System BIS™ : Bispectral index (BIS) between 45 and 60 AND Suppression Ratio (SR) at 0;~or SedLine® Sedation Monitor : Patient State Index (PSi) between 25 and 50;~or Entropy Sensor™: State entropy (SE) between 45 and 60 AND Burst Suppression Ratio (BSR) at 0;~and the level of nociception by :~Nociception monitor PMD-200® : Nociception Level (NoL) between 10 and 25."
79548319|NCT01556672|Drug|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
79548320|NCT01556672|Device|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
79711876|NCT02873767|Other|PL1|"Active substance: Placebo~Concentration: 0.9 % saline~Route of Administration: subcutaneously"
79711877|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
79277341|NCT03657745|Device|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
79277342|NCT03533699|Drug|Propranolol|
79548321|NCT01556685|Other|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
79392718|NCT05740644|Device|CM-1600|Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
79392720|NCT01564277|Drug|rasburicase|Given IV
79392721|NCT01564277|Drug|allopurinol|Given PO
79548322|NCT01556685|Other|Blood Sample|For evaluation of interferon-related Nab
79548323|NCT01556685|Genetic|Blood Sample|genetic evaluation - predisposition to Nab generation
79548324|NCT01556698|Drug|NVN1000|
79548325|NCT01556698|Drug|Vehicle|Placebo
79548326|NCT01556737|Dietary Supplement|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
79548327|NCT01556737|Dietary Supplement|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
79548328|NCT01556789|Biological|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
79711878|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
79711879|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
79711880|NCT01291173|Drug|Placebo|Placebo capsule taken once daily for up to 11 weeks
79711881|NCT02873455|Other|Short video clip including the circumstance of operation theater, and surgeon's interview|
79711882|NCT02872519|Drug|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
79711883|NCT02872519|Procedure|Positron Emission Tomography|Undergo scan
79711884|NCT02872519|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
79711885|NCT01291017|Drug|PD0332991|PD0332991 125 mg PO days 1 - 21
79711886|NCT01290315|Drug|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
79711887|NCT01290315|Drug|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
79711888|NCT01289847|Biological|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
79711889|NCT04830748|Other|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
79253220|NCT05893030|Procedure|anesthesia performed according only to the clinical judgment of the anesthetist as usual practice|Administration of anesthesia will be performed according to the clinical judgment of the anesthetist as usual practice without sedation and analgesia monitoring
79711890|NCT04830748|Other|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
79253221|NCT05893004|Diagnostic Test|Headache Screening Questionnaire|The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
79711891|NCT02877784|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
79711892|NCT02877784|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
79711893|NCT02877784|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
79711894|NCT01021813|Drug|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
79711895|NCT01021813|Drug|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
79711896|NCT01025635|Drug|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
79711897|NCT01025635|Drug|Vehicle foam|Applied topically twice daily for 12 weeks
79711898|NCT04300387|Behavioral|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
79711899|NCT01021423|Drug|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
79711900|NCT01021423|Other|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
79711901|NCT02872207|Drug|BAY 987516 (Y65-122)|5 µL in one eye
79711902|NCT02872207|Drug|BAY 987516 (Y65-118)|5 µL in one eye
79711903|NCT02872207|Drug|Control|5 uL in other eye
79711904|NCT02873143|Other|No intervention|No intervention
79253222|NCT05891977|Other|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
79392722|NCT05553912|Behavioral|QBSafe|an intervention comprised of (a) a set of conversation cards (QBSafe ASK) designed to enable patients to identify aspects of life with diabetes important to them and to share them with their clinician to obtain their input; and (b) materials that help clinicians respond to patient concerns.
79392723|NCT02679222|Dietary Supplement|Coconut oil|20 g of coconut oil
79392724|NCT02679222|Dietary Supplement|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
79392725|NCT02679222|Dietary Supplement|MCT|20 g of MCT (60 of C8+40 of C10)
79392726|NCT02679222|Dietary Supplement|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
79548329|NCT01556802|Drug|Minocicline|Minocicline 100mg oral twice a day for 5 days
79711905|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
79711906|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
79711907|NCT01020799|Drug|AZD7268|15 mg, oral, twice daily (BID)
79392727|NCT02679222|Dietary Supplement|Tricaprylin|20 g tricaprylin
79392728|NCT02679222|Dietary Supplement|Tricaprin|20 g tricaprin
79392729|NCT02679222|Dietary Supplement|Control|No supplement taken on this visit
79392730|NCT03354910|Behavioral|House Call|60 to 90 minute home based educational intervention which will be administered by a health educator.
79548330|NCT01556802|Drug|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
79548331|NCT01556815|Procedure|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
79580972|NCT01931176|Biological|rDEN2Δ30-7169 vaccine|Administered at a dose of 10^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
79711908|NCT01020799|Drug|Escitalopram|20 mg, oral, once daily (QD)
79711909|NCT01020799|Drug|Placebo capsules|Placebo capsules to match AZD7268
79711910|NCT01020799|Drug|Placebo tablets|Placebo tablets to match encapsulated escitalopram
79711911|NCT02872597|Drug|Ipratropium|
79711912|NCT02872597|Drug|0.9% Sodium Chloride|
79849858|NCT06021743|Diagnostic Test|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
79849859|NCT06021431|Device|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness,reappraisal, and savoring techniques to address OUD.~Combination Product: Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD). Usual addictions treatment with medications such as buprenorphine or methadone plus psychological counseling."
79849860|NCT06021431|Other|Treatment as Usual|Participants will receive their usual treatment for OUD, including medications such as buprenorphine or methadone and any counseling they might already be receiving
79849861|NCT06021392|Procedure|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
79849862|NCT06020807|Diagnostic Test|Bladder EpiCheck|Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
79849863|NCT06019910|Other|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
79849864|NCT06018415|Behavioral|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories in early 8h eating window,
79548332|NCT01556815|Other|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
79580973|NCT01931176|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
79253223|NCT05891977|Other|Intervention B - Control|Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
79253224|NCT05881798|Device|Celect Platinum Vena Cava Filter|Inferior vena cava filter
79392731|NCT03354910|Behavioral|Peer Mentorship|A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
79392732|NCT01563185|Drug|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
79580974|NCT01931189|Biological|NI-071|100mg/vial
79711913|NCT02872597|Drug|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
79849865|NCT06018415|Behavioral|Late time-restricted eating (lTRE)|The lTRE group is instructed to consume all calories in late 8h eating window.
79849866|NCT06017115|Device|Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)|Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
79849867|NCT06012071|Device|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
80017139|NCT05037994|Procedure|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
79392733|NCT02974660|Drug|Protamine sulfate|
79711914|NCT02872597|Drug|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
80017140|NCT03555084|Device|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
79253225|NCT05872958|Drug|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
79711915|NCT04299919|Procedure|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
79711916|NCT04299919|Procedure|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
79849868|NCT06008951|Other|Listening to music|All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
79253226|NCT05872958|Other|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
79277343|NCT03533699|Drug|Placebo Oral Tablet|oral tablets with no active drug
79277344|NCT00135421|Drug|Pexacerfont|Tablets & Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
79392734|NCT02974660|Drug|0.9% NaCl|
79392735|NCT05735496|Drug|TQB2102 injection|TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
79392736|NCT04771169|Other|vestibular Training Group|this Group will receive vestibular Adaptation & Balance exercises
79580975|NCT01931189|Biological|Infliximab|100mg/vial
79711917|NCT01288989|Biological|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
79711918|NCT01020487|Drug|Paricalcitol|Paricalcitol capsules taken with water.
79849869|NCT06008951|Other|Listening to a podcast|ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
80017141|NCT03555084|Device|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
79392737|NCT04771169|Other|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
79392738|NCT04410029|Other|Healthwise Decision Aid|Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.
79392739|NCT04410029|Other|Control informational handout|Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
79711919|NCT01020487|Drug|Placebo|Placebo capsules taken with water
80017142|NCT03658161|Behavioral|Communicating About Sexual Concerns and Dysfunction Effectively|The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
79392740|NCT03316300|Combination Product|NT-501|Surgery to receive one NT-501 device implant.
79392741|NCT03316300|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
79392742|NCT03305848|Drug|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure > 100 mmHg.
80017143|NCT00052520|Biological|therapeutic allogeneic lymphocytes|Given IV
79392743|NCT01563029|Drug|Fluticasone Furoate|current asthma medicine
79392744|NCT01563029|Drug|Fluticasone Propionate|Fluticasone propionate
79392745|NCT01563029|Drug|Placebo|placebo
79392746|NCT03293368|Biological|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
79392747|NCT03293368|Drug|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
79392748|NCT01562873|Drug|Ruxolitinib|
79392749|NCT03273712|Radiation|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
79392750|NCT03273712|Diagnostic Test|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
79392751|NCT03273712|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
79392752|NCT04113317|Drug|G-CSF (Filgrastim)|Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
79548333|NCT01556841|Biological|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
79548334|NCT01556841|Biological|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
79711920|NCT02872675|Dietary Supplement|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
79711921|NCT02872675|Dietary Supplement|Maltodextrin|Placebo Comparator: Maltodextrin.
79253227|NCT05871892|Diagnostic Test|18F-FDGal PET/CT or PET/MRI|All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
79253228|NCT05871814|Device|Colon preparation guided by an artificial intelligence device|Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing
79392753|NCT04341844|Drug|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
79392754|NCT04341844|Drug|Placebo|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
79711922|NCT04299217|Dietary Supplement|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
79392755|NCT01562327|Drug|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
79392756|NCT01561313|Biological|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
79392757|NCT01561079|Drug|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
79711923|NCT04299217|Other|Placebo|Placebo comparator (carrier)
79711924|NCT02873065|Drug|Ilaprazole|
79392758|NCT01559675|Drug|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
79392759|NCT01559675|Drug|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
79548335|NCT01556867|Other|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
79548336|NCT01556867|Other|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
79711925|NCT02873065|Drug|Esoprazole|
79711926|NCT00628225|Behavioral|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
79392760|NCT03028493|Behavioral|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
79392761|NCT03028493|Behavioral|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
79392762|NCT01374906|Drug|pasireotide LAR|Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still >1.5xULN unless titration was precluded by safety reasons).
79392763|NCT01374906|Drug|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
80017144|NCT00052520|Biological|aldesleukin|Given SC
79711927|NCT00628225|Behavioral|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
79392764|NCT01374906|Drug|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
79392765|NCT00362518|Dietary Supplement|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
79711928|NCT01024855|Device|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
79277345|NCT00135421|Drug|Escitalopram|Tablets & Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
79392766|NCT00362518|Dietary Supplement|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
79392767|NCT00362518|Dietary Supplement|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
79548337|NCT01556880|Behavioral|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
79277346|NCT00135421|Drug|Placebo|Tablets & Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
79277347|NCT02200991|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
79392768|NCT00362518|Dietary Supplement|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
79392769|NCT00362596|Drug|acyclovir|
79392770|NCT03139786|Other|Study the natural history of bicuspid|Study the natural history of bicuspid
79711929|NCT01014013|Drug|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
79711930|NCT01014013|Drug|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
79739746|NCT00603538|Drug|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
80017145|NCT00052520|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
80017146|NCT00052520|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
79277348|NCT02200991|Drug|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
79277349|NCT02200991|Drug|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
79277350|NCT02201069|Behavioral|health coaching|
79548338|NCT01556893|Device|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
79548339|NCT01556919|Procedure|Standard of care endoscopy|standard of care endoscopy
79548340|NCT01556945|Biological|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
79548341|NCT01556945|Biological|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
79548342|NCT01556945|Other|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
79548343|NCT01556945|Other|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
79392771|NCT02974504|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
79392772|NCT02974504|Drug|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
79548344|NCT01556971|Drug|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
79392773|NCT04744948|Device|Treadmill exercise|high intensity interval training
79392774|NCT04744948|Other|low caloric diet|low caloric diet (1200ca/lday)
79548345|NCT01556971|Drug|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
79548346|NCT01556984|Other|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
79548347|NCT01557010|Drug|DWP05195|Tablets, oral administration, 100mg
79548348|NCT01557010|Drug|DWP05195|Tablets, oral administration, 200mg
79548349|NCT01557010|Drug|DWP05195|Tablets, oral administration, 300mg
79548350|NCT01557010|Drug|Control|Tablets, oral administration, Placebo
79849870|NCT06007430|Drug|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
79849871|NCT06007430|Other|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
79392775|NCT04341688|Drug|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
79392776|NCT03065686|Genetic|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
79392777|NCT03029806|Other|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
79548351|NCT01557023|Drug|barrier methods|
79548352|NCT01557023|Drug|barrier methods|
79548353|NCT01557036|Device|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
79548354|NCT01557049|Other|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
79548355|NCT01557049|Other|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
79548356|NCT01557062|Other|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
79548357|NCT01557062|Other|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
80017147|NCT00052520|Other|laboratory biomarker analysis|Correlative studies
79392778|NCT03029806|Other|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
79392779|NCT03029806|Other|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
79392780|NCT03028948|Other|Internet-Based Intervention|Access ITW
79392781|NCT03028948|Other|Questionnaire Administration|Ancillary studies
79548358|NCT01557062|Other|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
79711931|NCT02872051|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
79711932|NCT02872051|Other|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
79711933|NCT01013701|Drug|fluticasone furoate|nasal steroid spray
79548359|NCT01557075|Drug|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Atorvastatin 40 mg daily for 12 months after randomization"
79711934|NCT01013701|Other|placebo|nasal steroid vehicle without drug
79711935|NCT00628303|Biological|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
79711936|NCT00628303|Other|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
79711937|NCT01020019|Drug|Dronabinol|Dronabinol: 20 mg/TID
79711938|NCT01020019|Drug|Placebo|Placebo control
79849872|NCT06006325|Device|electroacupuncture treatment|"Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min."
79548360|NCT01557075|Drug|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
79711939|NCT01020019|Drug|Lofexidine|Lofex: .6 mg/ TID
79392782|NCT03028948|Other|Survey Administration|Ancillary studies
79849873|NCT06006325|Device|sham electroacupuncture treatment|"The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized."
79849874|NCT06005012|Drug|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
79392783|NCT03013504|Drug|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
79392784|NCT03013504|Drug|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
79849875|NCT06005012|Drug|Placebo|Placebo
79392785|NCT03013504|Drug|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
79392786|NCT03013504|Drug|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
79392787|NCT03013504|Drug|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
79392788|NCT04744792|Other|Short Form - 36|"Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients"
79548361|NCT01557088|Other|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
79548362|NCT01557088|Procedure|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
79548363|NCT01557101|Procedure|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
79548364|NCT01557101|Procedure|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
79580976|NCT01931215|Other|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
79711940|NCT00627835|Drug|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
79849876|NCT06002724|Other||
79849877|NCT05997199|Dietary Supplement|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
79849878|NCT05995002|Other|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
79711941|NCT00627835|Drug|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
79711942|NCT00627835|Drug|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
79849879|NCT05992649|Other|physical therapy|Aquatic physiotherapy in warm water
80017148|NCT00052520|Genetic|gene expression analysis|Correlative studies
80017149|NCT00052520|Other|immunologic technique|Correlative studies
79711943|NCT00627835|Drug|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
80017150|NCT00052520|Other|flow cytometry|Correlative studies
80017151|NCT00052520|Genetic|polymerase chain reaction|Correlative studies
79253229|NCT05871255|Other|Zantogin® Gel|Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
79548365|NCT01557114|Drug|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
79711944|NCT00627835|Drug|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
79849880|NCT05989776|Behavioral|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
79849881|NCT05987891|Diagnostic Test|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
80017152|NCT00052520|Genetic|cytogenetic analysis|Correlative studies
79392789|NCT04744792|Other|WHODAS-II|"The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients."
79392790|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
80017153|NCT00052520|Other|staining method|Correlative studies
79253230|NCT05871242|Dietary Supplement|Probiotic Lactobacillus crispatus M247|Patient who have received probiotic Lactobacillus crispatus M247
79253231|NCT05870891|Other|Food|Food
79253232|NCT05869734|Behavioral|Sleep health promotion|We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.
79392791|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
79392792|NCT02683746|Drug|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
79548366|NCT01557114|Radiation|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
79548367|NCT01557127|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
79548368|NCT01557140|Drug|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
79548369|NCT01557153|Drug|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
79253233|NCT05869734|Behavioral|Urologic health promotion|We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).
79580977|NCT01931215|Other|TAP-block with ropivacaine and clonidine|
79253234|NCT05869734|Behavioral|Pelvic floor muscle training|We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
79253235|NCT05862649|Other|NeuraLight|NeuraLight software-based platform
79253236|NCT05861427|Drug|Atogepant|Oral Tablet
79253237|NCT05861427|Drug|Placebo for Atogepant|Oral Tablet
79711945|NCT01024465|Device|ReShape Duo Balloon|ReShape Duo Balloon
79711946|NCT02872363|Other|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
79253238|NCT05857241|Dietary Supplement|Fasting mimicking diet (FMD)|"D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period."
79253239|NCT05849194|Diagnostic Test|POCUS examination|Point of care ultrasound examination
79253240|NCT05841784|Behavioral|MBCT-T|MBCT-T is an 8-week group-based program that combines training in mindfulness and cognitive-behavioral therapy to reduce psychological distress and negative emotions. Each weekly 1-hour session will consist of a check-in, discussion, teaching, mindfulness or cognitive behavioral practice or exercise, inquiry by the facilitator, and summary of the at-home practice.
79711947|NCT02872363|Other|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
79711948|NCT04299607|Diagnostic Test|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
79548370|NCT01557153|Drug|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
79548371|NCT01557179|Device|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
79849882|NCT05987488|Biological|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
79548372|NCT01557179|Device|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
79849883|NCT05987488|Other|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
79849884|NCT05980702|Drug|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
79849885|NCT05980702|Drug|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
79548373|NCT01557192|Device|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
79849886|NCT05977634|Behavioral|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
79711949|NCT04205461|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
79711950|NCT04300699|Other|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
79849887|NCT05977634|Device|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
79711951|NCT01024387|Drug|AMG 479|
79711952|NCT01019317|Drug|Cytarabine|0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
79711953|NCT01019317|Drug|Fludarabine|15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
79253241|NCT05841784|Behavioral|Booster Mindfulness Sessions|Following the standard 8-week MBCT-T program, participants in certain arms will receive monthly MBCT-T booster sessions for 4 months of follow up. Each booster session will be 1 hour long. The sessions will include a concise review and summary of the main MBCT-T sessions.
79253242|NCT05841784|Behavioral|Website Support|Participants in certain arms will receive continuous intervention support via the use of an online study website. The website will provide quick access to intervention materials and support to encourage participants to complete the at-home practice and apply the content of the MBCT-T program to real life situations.
79392793|NCT02683746|Drug|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
79392794|NCT03883529|Other|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
79392795|NCT02691468|Device|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
79392796|NCT02691468|Device|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
79392797|NCT02678676|Other|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
79392798|NCT02678676|Other|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
79548374|NCT01557218|Other|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
79711954|NCT01024309|Procedure|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
79711955|NCT01024309|Procedure|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
79739747|NCT03854734|Behavioral|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
80017154|NCT05041816|Device|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to ~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
80017155|NCT05036434|Drug|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
80017156|NCT00051038|Drug|Entecavir|
80017157|NCT05035186|Drug|Amoxicillin|Anti-H. pylori regimens
79253244|NCT05840432|Device|Postoperative hypotension prediction index|Performance of the hypotension prediction index (HPI) in predicting hypotension episodes in the first 12 h of cardiac surgery postoperative
79253245|NCT05839717|Procedure|Blood sampling|A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
79253246|NCT05837637|Diagnostic Test|The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)|"The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12"
79253247|NCT05836597|Device|Virtual reality|Virtual reality
79253248|NCT05835466|Drug|reparixin|reparixin at 1200mg TID three times per day.
79253249|NCT05833867|Drug|Sacituzumab govitecan|8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
79253250|NCT05833867|Radiation|Adaptive Radiotherapy|Concurrently, participants will receive an individualized tailored plan for radiation therapy.
79253251|NCT05830877|Other|the acupuncture group|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
79548375|NCT01557218|Other|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
79548376|NCT01557218|Other|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
79548377|NCT01557218|Other|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
79548378|NCT01557218|Other|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
79253252|NCT05830877|Other|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
79392799|NCT03162276|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
79548379|NCT01557218|Other|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
79548380|NCT01557218|Other|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
79548381|NCT01557218|Other|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
79548382|NCT01557257|Drug|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
79548383|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
80017158|NCT01067469|Drug|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
80017159|NCT01067469|Drug|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
80017160|NCT01067469|Drug|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
79392800|NCT03162276|Behavioral|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
79548384|NCT01557257|Drug|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
79711956|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
79711957|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
79711958|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
79277351|NCT03531385|Diagnostic Test|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
79277352|NCT03531385|Diagnostic Test|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
79392801|NCT01558739|Drug|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
79392802|NCT03162120|Drug|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
79392803|NCT03162120|Drug|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
79392804|NCT03162198|Other|Cirrhosis with HCC|Cirrhosis with Hepatocellular Carcinoma
79392805|NCT03162198|Other|Cirrhosis without HCC|Cirrhosis without Hepatocellular Carcinoma
79392806|NCT03162042|Procedure|Tumor removal|Surgery
79392807|NCT02683668|Combination Product|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
79392808|NCT02683668|Combination Product|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
79392809|NCT02683668|Combination Product|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
79392810|NCT03114228|Drug|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
79392811|NCT02678286|Drug|N1539|
79548385|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
79548386|NCT01557257|Drug|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
79548387|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
79548388|NCT01557270|Drug|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
79548389|NCT01557270|Drug|saline|ropivacaine + saline placebo, single shot perineural application
79548390|NCT01557296|Dietary Supplement|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
79548391|NCT01557296|Radiation|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
79548392|NCT01557296|Other|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
79548393|NCT01557296|Biological|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
79548394|NCT01557335|Drug|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
79548395|NCT01557335|Drug|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
79548396|NCT01557361|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
79548397|NCT01557361|Other|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~Serum potassium ≥6.0 mmol/L, or~Serum bicarbonate ≤ 10 mmol/L, or~Evidence of severe respiratory failure, based on a PaO2/FiO2 <200 and bilateral infiltrates on the chest x-ray, or~By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
79548398|NCT01557374|Drug|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
79580978|NCT01931228|Procedure|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
79392812|NCT02678286|Drug|Intravenous Placebo|
79849888|NCT05976815|Behavioral|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
79392813|NCT03115008|Behavioral|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
79711959|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
79711960|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
79849889|NCT05974748|Drug|Sodium hypochlorite 5.25%|The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
79849890|NCT05974748|Drug|Propolis 20%|In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
79849891|NCT05973279|Other|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
79849892|NCT05973279|Other|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
79849893|NCT05973279|Other|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
79392814|NCT03115164|Other|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
79392815|NCT03164850|Device|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
79392816|NCT03166020|Other|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
79392817|NCT03165786|Behavioral|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
79548399|NCT01557374|Drug|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~If DAS 28 > 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~If DAS 28 > 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
79711961|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
79392818|NCT03165630|Behavioral|Transportation incentives|Free transportation only for the first 3 months post-discharge.
79392819|NCT03165630|Behavioral|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
79392820|NCT03164694|Drug|Apatinib|Apatinib was given 850 mg per day orally.
79711962|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
79392821|NCT03164694|Drug|Pemetrexed|pemetrexed (500 mg/m2)
79392822|NCT03164694|Drug|Carboplatin|carboplatin (AUC =5)
79392823|NCT02682264|Drug|CB-03-01 cream, 1%|Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
79392824|NCT02930902|Drug|Gemcitabine Hydrochloride|Given IV
79392825|NCT02930902|Other|Laboratory Biomarker Analysis|Correlative studies
79392826|NCT02930902|Drug|Nab-paclitaxel|Given IV
79392827|NCT02930902|Drug|Paricalcitol|Given IV
79548400|NCT01557387|Other|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
79392828|NCT02930902|Biological|Pembrolizumab|Given IV
79392829|NCT02930902|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
79849894|NCT05965739|Other|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
79392830|NCT02926066|Drug|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
79711963|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
79849895|NCT05965739|Other|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
79849896|NCT05965739|Other|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention with demonstrated efficacy in improving attention and executive functions, among other cognitive domains.
79849897|NCT05965739|Device|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
79849898|NCT05965739|Device|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
79849899|NCT05960318|Device|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
79849900|NCT05960318|Device|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
79849901|NCT05960292|Procedure|Laparoscopic and Vaginal Hysterectomy|To make a comparison between the Vaginal Vault complications after Hysterectomy
79392831|NCT02900482|Other|Sampling saliva|
79392832|NCT02817802|Device|Magmaris|PCI (Magmaris)
79392833|NCT02767804|Drug|X-396 (ensartinib)|oral ALK inhibitor
79392834|NCT02767804|Drug|crizotinib|oral ALK inhibitor
79392835|NCT02741128|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
79392836|NCT02741128|Biological|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
79392837|NCT02721316|Other|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
79392838|NCT02660554|Other|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
79392839|NCT01566721|Drug|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
79392840|NCT01541215|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
79392841|NCT01541215|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
79392842|NCT01541215|Drug|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
79392843|NCT01540981|Device|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
79392844|NCT01540981|Other|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
79392845|NCT01585987|Biological|Ipilimumab|
79392846|NCT01585987|Other|Best Supportive care (BSC)|
79392847|NCT01585831|Drug|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
79711964|NCT02877472|Device|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
79711965|NCT02877472|Procedure|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
79711966|NCT02877238|Drug|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
79711967|NCT02877238|Drug|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
79711968|NCT01288911|Drug|enzalutamide|capsules
79711969|NCT01288911|Drug|bicalutamide|tablets
79711970|NCT01288443|Drug|Alirocumab|Two SC injections in the abdomen only.
79711971|NCT01288443|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
79711972|NCT01288443|Drug|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
79711973|NCT04324203|Other|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
79392848|NCT01585831|Drug|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
79392849|NCT04409899|Diagnostic Test|Blood tests|RT-PCR, D-dimer, CRP, procalcitonin, ferritin, complete haemogram
79548401|NCT01557413|Procedure|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
79548402|NCT01557413|Procedure|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
79548403|NCT01557426|Other|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
79849902|NCT05959850|Drug|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
80017161|NCT02098200|Device|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
80017162|NCT00050102|Drug|MDX-010 (CTLA-4)|
79548404|NCT01557439|Drug|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
79711974|NCT01288209|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
79711975|NCT01288209|Drug|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
79711976|NCT01288209|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
79711977|NCT01288053|Biological|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
79392850|NCT03028207|Procedure|Medical tests|During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
79392851|NCT03028207|Other|Questionnaire|During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
79392852|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
80017163|NCT04873336|Device|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
79392853|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
79548405|NCT01557478|Drug|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
79711978|NCT02889783|Other|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
79392854|NCT03027895|Device|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
79392855|NCT03027895|Device|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
79392856|NCT01558271|Drug|LY2189265|
79392857|NCT01558271|Drug|Placebo|
79392858|NCT01558271|Drug|Liraglutide|
79548406|NCT01557478|Drug|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
79548407|NCT01557491|Procedure|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
79548408|NCT01557491|Procedure|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
79548409|NCT01557543|Other|Cell Therapy|Intramyocardial Injection of BMSCs
79711979|NCT01287195|Drug|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
79711980|NCT01287195|Drug|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
79711981|NCT01287117|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
79711982|NCT01287117|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
79711983|NCT01287039|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
79849903|NCT05959850|Drug|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
79253254|NCT05828849|Behavioral|Navigation, compensation, and personalization|The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
79392859|NCT01565707|Drug|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
79548410|NCT01557608|Procedure|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
79253255|NCT05828589|Drug|BGB-21447|BGB-21447 will be administered orally
79253256|NCT05827432|Device|Field-cycling imaging (FCI)|FCI scan
79548411|NCT01557608|Procedure|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
79548412|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
79548413|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
79739748|NCT03854734|Behavioral|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
79739749|NCT04545580|Drug|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
79849904|NCT05955768|Procedure|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
79253257|NCT05826314|Other|Boxing training|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
79253258|NCT05826314|Other|Exercise|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
79253259|NCT05824338|Drug|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
79253260|NCT05824338|Drug|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
79253261|NCT05824338|Drug|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
79739750|NCT04545580|Drug|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
79739751|NCT04185766|Dietary Supplement|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
79739752|NCT04185766|Dietary Supplement|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
79253262|NCT05823818|Device|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
79253263|NCT05821309|Drug|PEG 3350|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
79253264|NCT05821309|Drug|PEG-3350 with electrolytes|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
79580979|NCT01931228|Procedure|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
79711984|NCT01287039|Drug|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
79739753|NCT04185766|Dietary Supplement|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
79849905|NCT05955768|Procedure|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
79739754|NCT04185766|Dietary Supplement|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
79392860|NCT01565707|Drug|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
79580980|NCT01931241|Drug|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
79580981|NCT01931267|Behavioral|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
79580982|NCT01931267|Behavioral|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
79739755|NCT02537938|Drug|NGP 555|
79739756|NCT04033900|Device|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
79580983|NCT01931280|Behavioral|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
79580984|NCT01931293|Dietary Supplement|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
79739757|NCT00639184|Other|Early intervention counseling|Bi-monthly home visits by counselor
79739758|NCT00639184|Other|Health education counseling|World Health Education health education counseling program at home visits,twice per month
79739759|NCT02537860|Other|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
79739760|NCT02537860|Other|Placebo at T11 and L3|Two injections that contain saline are performed
79739761|NCT02537860|Other|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
79739762|NCT02537860|Procedure|Herniorrhaphy|Unilateral inguinal hernia repair
79739763|NCT02537860|Drug|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
79739764|NCT02537860|Drug|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
79739765|NCT02687230|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
79739766|NCT02687230|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
79739767|NCT04210102|Diagnostic Test|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
79739768|NCT04210102|Diagnostic Test|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
79739769|NCT02885792|Other|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
79739770|NCT02885792|Other|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
79739771|NCT02885792|Other|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
79739772|NCT02885792|Procedure|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
79739773|NCT01162304|Drug|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
79739774|NCT01162304|Drug|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
79711985|NCT02889939|Other|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
79711986|NCT05584527|Other|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
79711987|NCT05584527|Other|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
79548414|NCT01557621|Behavioral|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
79711988|NCT05584527|Other|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
79711989|NCT05575245|Device|Drug-eluting Stent|Drug-eluting Stent angioplasty
79711990|NCT05575245|Device|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
79711991|NCT05572203|Dietary Supplement|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
79711992|NCT01285401|Drug|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day [mcg/day]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
79711993|NCT01285401|Drug|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
79711994|NCT01285401|Biological|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
79711995|NCT01285323|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
79711996|NCT01285323|Drug|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
79711997|NCT02889705|Other|Ultrasonographic examination|
79711998|NCT01284621|Drug|BI 10773|medium dose, oral administration
79711999|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
79392861|NCT01565707|Behavioral|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
79392862|NCT01557569|Drug|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
79392863|NCT01557569|Drug|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
79392864|NCT04756271|Biological|SARS-Cov-2 neutralizing antibody titer|Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
79392865|NCT01538719|Drug|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
79548415|NCT01557634|Procedure|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
79548416|NCT01557647|Drug|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
79712000|NCT01284621|Drug|BI 10773|medium dose oral administration
79712001|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
79712002|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
79712003|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
79712004|NCT04323813|Diagnostic Test|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
79712005|NCT02890017|Other|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
79712006|NCT02890017|Other|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
79392866|NCT01538719|Other|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
79392867|NCT01537783|Drug|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
79253265|NCT05821309|Drug|Glycerin|Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
79253266|NCT05815680|Drug|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
79548417|NCT01557647|Drug|Placebo|placebo inhalation solution
79253267|NCT05815680|Drug|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
79849906|NCT05946954|Procedure|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
79392868|NCT01537783|Drug|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
79392869|NCT01556165|Drug|rasagiline|1 mg/day, tablets, once daily, orally
79548418|NCT01557660|Drug|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
79548419|NCT01557673|Dietary Supplement|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
79548420|NCT01557673|Dietary Supplement|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
79712007|NCT01283139|Biological|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
79712008|NCT01283139|Biological|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
79712009|NCT01283139|Biological|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
79712010|NCT01283139|Other|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
79849907|NCT05946954|Procedure|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
79580985|NCT01931306|Drug|Afatinib|BIBW2992 low to medium dose once daily
79253268|NCT05815680|Drug|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
79253269|NCT05815680|Drug|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
79253270|NCT05815680|Drug|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
79253271|NCT05803551|Drug|Ketamine Hydrochloride|Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
79253272|NCT05803551|Drug|Placebo|Intravenous 0.9% saline infusions for three consecutive days.
79253273|NCT05800860|Drug|GH001|GH001 administered via inhalation
79253274|NCT05800860|Drug|Placebo|Placebo administered via inhalation
79253275|NCT05799157|Drug|VDMN-21 Patch Low Dose|Microneedle patch containing 125 mcg of active drug
79392870|NCT01556165|Drug|placebo|tablets, once daily, orally
79392871|NCT01537549|Drug|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
79580986|NCT01931319|Drug|Intravenous baclofen|
79712011|NCT01281969|Drug|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
79712012|NCT01281969|Drug|Placebo|Normal saline, IV (in the vein), over 2 days
79712013|NCT01281813|Drug|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
79712014|NCT01281813|Drug|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
79712015|NCT04325139|Other|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
79712016|NCT01090414|Drug|Idelalisib|Idelalisib tablets or capsules administered orally
79712017|NCT01090102|Drug|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
79712018|NCT01090102|Drug|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
79253276|NCT05799157|Drug|VDMN-21 Patch High Dose|Microneedle patch containing 250 mcg of active drug
79253277|NCT05799157|Drug|Vehicle Patch|Placebo microneedle patch containing no active drug (i.e., placebo)
79849908|NCT05944900|Procedure|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
79849909|NCT05938699|Drug|NCX 470|NCX 470 0.1% vs Placebo
79849910|NCT05938699|Drug|Placebo|NCX 0.1% vs Placebo
79849911|NCT05931315|Dietary Supplement|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
79849912|NCT05931315|Dietary Supplement|Placebo|One capsule to be taken immediately post-dinner / with dinner
79849913|NCT05926349|Drug|Andexanet alfa|Andexanet is a recombinant version of human FXa
79849914|NCT05926349|Drug|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
79849915|NCT05923775|Procedure|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
79849916|NCT05921396|Procedure|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
79849917|NCT05921396|Procedure|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
79849918|NCT05919862|Procedure|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
79849919|NCT05919862|Procedure|Freehand surgery|Freehand implant placement by experienced surgeon.
79849920|NCT05911724|Other|Group I|Healthy Subjects
79849921|NCT05911724|Other|Group II|Stable Angina Patients
79253278|NCT05798130|Other|No intervention group.|No intervention group.
79392872|NCT01555931|Drug|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
79392873|NCT01583179|Drug|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
79392874|NCT01582945|Drug|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
79712019|NCT02877160|Drug|AL-794 suspension|
79712020|NCT02877160|Drug|AL-794 tablet|
79712021|NCT02878096|Drug|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
79849922|NCT05911724|Other|Group III|Heart Failure Patients
79849923|NCT05911451|Procedure|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
79849924|NCT05911451|Procedure|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
79253280|NCT05796817|Device|Ventilator modification|The ventilator modification will be fitted to a ResMed Lumis 150, Breas® Nippy 4+ or Vivo 1, 2 or 3 ventilator. The participants oxygen level will be measured with and without the modification in place at their baseline ventilation, and with 1, 2 and 3 litres oxygen extra to their baseline. the researcher will then leave the modification on and slowly reduce the oxygen going into the ventilator, maintaining the participants SP02 at an acceptable level (>95%)
79712022|NCT01287897|Drug|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
79712023|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
79392875|NCT01565083|Drug|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
79392876|NCT01565083|Drug|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
79392877|NCT01565083|Drug|Vinorelbine|A dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
79392878|NCT01582789|Device|enfilcon A|enfilcon A daily wear soft contact lens
79712024|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
79712025|NCT02877940|Device|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
79253281|NCT05795738|Behavioral|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
79392879|NCT01582789|Device|senofilcon A|senofilcon A daily wear soft contact lens
79712026|NCT02877940|Device|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
79849925|NCT05911451|Procedure|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
79253282|NCT05795738|Behavioral|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
79253283|NCT05794204|Drug|RMP-A03 - Dose 1|Patients will randomized to dose 1 of RMP-A03
79849926|NCT05907694|Procedure|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
79849927|NCT05907694|Drug|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
79849928|NCT05907252|Behavioral|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
79849929|NCT05907252|Behavioral|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
79253284|NCT05794204|Drug|RMP-A03 - Dose 2|Patients will be randomized to dose 2 of RMP-A03
79253285|NCT05794204|Drug|RMP-A03 Placebo|Patients will be randomized to RMP-A03 Placebo
79253286|NCT05792670|Procedure|Changing mechanic ventilatation parameters|The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
79712027|NCT02877940|Device|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
80017164|NCT02287532|Device|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
79253287|NCT05792228|Other|nurse-led standardized intervention|Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
79277353|NCT03531385|Other|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
79392880|NCT01537393|Biological|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
79392881|NCT01537393|Biological|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
79712028|NCT04306978|Other|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
79712029|NCT04306978|Other|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
79712030|NCT01090024|Drug|BI 671800|BI 671800
79712031|NCT01090024|Drug|Placebo|Placebo matching BI 671800
79277354|NCT03531385|Other|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
79277355|NCT02368743|Drug|mesalazine|
79392882|NCT01555151|Drug|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
79392883|NCT01555151|Device|Concept 1|A single dose dry powder inhaler (SDDPI)
79253288|NCT05790824|Other|Spa therapy|"The RH2 rheumatology treatment protocol will propose treatments that can be carried out with water from the SL5 borehole and will be composed of:~54 treatments among the following treatments:~Swimming pool, 15 minutes (code 201)~Bath with aerobath, 10 minutes (code 205)~Bath with immersion shower, 10 minutes (code 206)~Cataplasm in multiple local application, 10 minutes (code 408)~18 sessions of mobilization pool, 15 minutes (code 601)"
79253289|NCT05789342|Drug|GP681|GP681, tablet, oral
79392884|NCT01555151|Device|Twisthaler|A single dose dry powder inhaler (SDDPI)
79548421|NCT01557686|Behavioral|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
79548422|NCT01557712|Drug|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~Intravenous injection on day 0 to 0.5 mg / kg of ketamine~D0 to D4: 75 mg of venlafaxine~D4 to D14: 150 mg per day of venlafaxine~D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
79548423|NCT01557712|Drug|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~D0 to D4: 75 mg of venlafaxine~D4 to D14: 150 mg per day of venlafaxine~D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
79712032|NCT04868890|Biological|Ampion|Inhaled Ampion
79712033|NCT04868890|Other|Placebo|Inhaled Placebo
79712034|NCT01281189|Drug|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
79712035|NCT01281189|Drug|Placebo|Oral tablet twice daily for up to 18 months.
79253290|NCT05789342|Drug|Rosuvastatin|Rosuvastatin, tablet, oral
79253291|NCT05789342|Drug|Digoxin|Digoxin, tablet, oral
79392885|NCT01537081|Drug|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
79548424|NCT01557738|Dietary Supplement|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
79548425|NCT01557738|Dietary Supplement|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
79548426|NCT01557738|Dietary Supplement|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
79548427|NCT01557738|Dietary Supplement|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
79548428|NCT01557764|Drug|lapatinib ditosylate|Given PO
79548429|NCT01557764|Biological|trastuzumab|Given IV
79548430|NCT01557816|Drug|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
79548431|NCT01557816|Drug|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
79548432|NCT01557829|Device|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
79712036|NCT02877862|Behavioral|mAGIC app|7-day app to encourage uptake of genetic counseling
79712037|NCT04306666|Other|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
79712038|NCT04818892|Diagnostic Test|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
79712039|NCT02877628|Other|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
79712040|NCT01280955|Drug|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
79712041|NCT00623883|Procedure|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
79712042|NCT00623883|Procedure|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
80017165|NCT02103660|Drug|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
80017166|NCT02103660|Drug|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
79253292|NCT05789342|Drug|Itraconazole|Itraconazole, capsule, oral
79253293|NCT05789342|Drug|Oseltamivir|Oseltamivir, capsule, oral
79253294|NCT05786443|Drug|Empagliflozin 10 MG|Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
79253295|NCT05786443|Drug|Placebo|Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
79253296|NCT05786209|Other|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
79392886|NCT01537081|Drug|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
79392887|NCT01537081|Drug|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
79548433|NCT01557829|Device|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
79548434|NCT01557855|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
79548435|NCT01557907|Device|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
79253297|NCT05786209|Other|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
79253298|NCT05784129|Drug|Guselkumab|Guselkumab will be administered subcutaneously.
79253299|NCT05784129|Drug|Placebo|Placebo will be administered subcutaneously.
79253300|NCT05783765|Behavioral|Heightened Drive to Eat|Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
80017167|NCT03658005|Other|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and >6h, between two doses of ticagrelor (taken at 0 and 12 hours).
79712043|NCT01280721|Drug|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
79712044|NCT04323969|Behavioral|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
79712045|NCT04323969|Behavioral|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
79712046|NCT02889471|Procedure|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
80017168|NCT04704232|Drug|ACD440|Double blind, parallel within subject comparison
79253301|NCT05783180|Drug|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
79392888|NCT03196024|Behavioral|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
79548436|NCT01557907|Device|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
79548437|NCT01557933|Other|No interventions will be used|No interventions will be used
79253302|NCT05783180|Drug|Placebo|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
79253303|NCT05777512|Procedure|Gastric Feeds|The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
79253304|NCT05777512|Procedure|Jejunal Feeds|The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
79253305|NCT05770531|Procedure|Biospecimen Collection|Undergo blood sample collection for banking
79253306|NCT05770531|Procedure|Computed Tomography|Undergo CT
79253307|NCT05770531|Procedure|Magnetic Resonance Imaging|Undergo MRI
79548438|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
79548439|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
79548440|NCT01557985|Drug|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
79712047|NCT02889471|Procedure|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
79739775|NCT04515394|Drug|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
79739776|NCT04515394|Biological|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
79739777|NCT04206176|Drug|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
79739778|NCT01175018|Drug|Anakinra|Anakinra 100 mg s.c. daily for 14 days
79739779|NCT01175018|Drug|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
79739780|NCT02685514|Device|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
79739781|NCT04314986|Drug|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
79739782|NCT04314986|Drug|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
79739783|NCT04314986|Drug|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
79739784|NCT04314986|Drug|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
79739785|NCT02685280|Device|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
79739786|NCT03754972|Diagnostic Test|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
79739787|NCT01174784|Device|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
79739788|NCT02686918|Other|Advanced Practice Nurse consultation|
79875135|NCT03982264|Procedure|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
79253308|NCT05770531|Procedure|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
79253309|NCT05770531|Biological|Sacituzumab Govitecan|Given by IV
79253310|NCT05764005|Behavioral|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
79253311|NCT05764005|Behavioral|MUSIC website|Standard of care educational materials {add more detail}
79253312|NCT05749588|Drug|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
79548441|NCT01557998|Behavioral|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
79712048|NCT05560581|Behavioral|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
79253313|NCT05749588|Drug|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
79253314|NCT05749588|Drug|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
79253315|NCT05749588|Drug|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
79253316|NCT05749588|Drug|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
79253317|NCT05749588|Drug|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
79253318|NCT05749588|Drug|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
79392889|NCT03196024|Behavioral|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
79392890|NCT01564459|Drug|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
79253319|NCT05749588|Drug|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
79253320|NCT05749588|Drug|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
79253321|NCT05749588|Drug|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
79392891|NCT01564459|Drug|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
79392892|NCT01555073|Drug|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
79392893|NCT01555073|Drug|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
79548442|NCT01557998|Drug|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
79548443|NCT01557998|Behavioral|Control - No intervention|
79548444|NCT01558011|Drug|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
79548445|NCT01558050|Dietary Supplement|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
79253322|NCT05749588|Drug|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
79392894|NCT01555073|Drug|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
79392895|NCT01555073|Drug|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
79392896|NCT01582243|Drug|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
79392897|NCT01536535|Drug|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
79392898|NCT01536535|Drug|IV Corticosteroid|Treatment with IV Corticosteroid
79712049|NCT05560581|Behavioral|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
79712050|NCT01087762|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
79712051|NCT01087762|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
79712052|NCT01087762|Other|Placebo|Matching Placebo to CZP injection.
79712053|NCT04306354|Drug|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
79712054|NCT04306354|Drug|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
79253323|NCT05749588|Drug|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
79548446|NCT01558141|Other|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
79253324|NCT05747079|Other|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
79253325|NCT05747079|Procedure|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
79849930|NCT05907252|Behavioral|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
79253326|NCT05747079|Procedure|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
79253327|NCT05742568|Drug|Esomeprazole|High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
79392899|NCT01536535|Drug|Oral Corticosteroids|Treatment with oral corticosteroids
79392900|NCT01536535|Other|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
79392901|NCT01536535|Procedure|Colectomy|Colectomy
79392902|NCT01554527|Procedure|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
79712055|NCT04306276|Drug|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
79712056|NCT01078168|Drug|Acitretin|30mg per day from Day 1 to Day 28
79849931|NCT05907031|Device|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
79849932|NCT05907031|Device|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
79392903|NCT01554527|Other|No CPAP treatment|Children randomized to the comparison group will receive routine care
79392904|NCT04767763|Diagnostic Test|Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF|blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
79392905|NCT01563913|Drug|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
79392906|NCT01563913|Drug|Placebo|Sugar Pill, taken for 1.5 years
79392907|NCT01553747|Drug|Eluxadoline|Oral tablets twice daily
79548447|NCT01558141|Other|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
79548448|NCT01558154|Drug|Chinese herbs|Chinese herbs special for depression
79548449|NCT01558154|Procedure|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
79548450|NCT01558154|Other|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
79548451|NCT01558154|Device|Transcranial magnetic stimulation|Give magnetic stimulation at head
79712057|NCT01078168|Drug|Placebo|Placebo
79712058|NCT01086358|Drug|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
79712059|NCT01086358|Drug|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
79712060|NCT01277601|Drug|TDF|TDF 300 mg tablets administered orally once daily
79712061|NCT01277601|Drug|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
79712062|NCT01277523|Drug|tiotropium high dose|2 actuations once daily
79712063|NCT01277523|Drug|placebo|2 actuations once daily
79712064|NCT01277523|Drug|tiotropium low dose|2 actuations once daily
79712065|NCT01081834|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
79712066|NCT01081834|Drug|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
79712067|NCT01081834|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
79712068|NCT01276509|Drug|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
79849933|NCT05892406|Device|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
79849934|NCT05892406|Device|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
79849935|NCT05892406|Device|Robotic system|Implant will be placed under robotic arm and human collaboration.
79849936|NCT05891990|Procedure|immediate implant augmented with sticky tooth|"Topical anesthesia will be administered using an infiltration technique.~Atraumatic extraction will be done with the aid of periotome and Luxators.~The extraction socket will be debrided to remove any residual debris or granulation tissue.~Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~Finally, the flap will be repositioned and sutured."
79849937|NCT05891990|Procedure|immediate implant augmented with autogenous tooth graft|"Topical anesthesia will be administered using an infiltration technique.~Atraumatic extraction will be done with the aid of periotome and Luxators.~The extraction socket will be debrided to remove any residual debris or granulation tissue.~Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~Finally, the flap will be repositioned and sutured."
79849938|NCT05867420|Biological|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
79875136|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
79253328|NCT05742568|Drug|Amoxicillin|High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
79392908|NCT01553747|Drug|Placebo|Oral tablets twice daily
79392909|NCT01536379|Drug|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
79548452|NCT01558167|Drug|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~Dose level 5: maximal tolerated dose"
79548453|NCT01558180|Behavioral|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
79253329|NCT05742568|Drug|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
79253330|NCT05742568|Drug|Esomeprazole|BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
79392910|NCT01536379|Drug|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
79392911|NCT04409977|Diagnostic Test|MRI examination|Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.
79392912|NCT01536145|Drug|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
79392913|NCT01536067|Biological|ofatumumab|Given IV
79548454|NCT01558180|Behavioral|Usual Care|educational handouts on pediatric insomnia
79392914|NCT01536067|Drug|bortezomib|Given SC
79392915|NCT01536067|Other|laboratory biomarker analysis|Correlative studies
79548455|NCT01558193|Dietary Supplement|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
79712069|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
79712070|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
79712071|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
79712072|NCT01079962|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
79712073|NCT01079962|Drug|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
79712074|NCT01274637|Drug|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
79712075|NCT01079806|Drug|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
79712076|NCT01079806|Drug|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
79712077|NCT00626314|Biological|myoblast|autologous myoblast
79253331|NCT05742568|Drug|Amoxicillin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
79277356|NCT02201147|Procedure|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
79712078|NCT00626314|Biological|sham|sham injection procedure
79253332|NCT05742568|Drug|Clarithromycin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
79849939|NCT05860738|Other|sterilization|autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
79849940|NCT05860387|Diagnostic Test|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
79849941|NCT05859386|Behavioral|Mindfulness maintenance program|"Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
79548456|NCT01558193|Dietary Supplement|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
79548457|NCT01558193|Dietary Supplement|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
79849942|NCT05852587|Drug|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
79849943|NCT05852587|Drug|Sucralose|The placebo in this trial will be sucralose. Sucralose is alternate SA that is poorly absorbed and non-microbially metabolized by bacteria in the microbiome including C. difficile. Because this is a double-blind, controlled trial, the control will be presented in capsules that are identical in size, smell, texture, and appearance to those of the xylitol capsules. These will be produced by the BWH investigational drug service. Sucralose will be ordered from MEDISCA as well and will be 100% pure.
79849944|NCT05845216|Device|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
79849945|NCT05845216|Device|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
79849946|NCT05828095|Biological|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
79849947|NCT05828095|Biological|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
79849948|NCT05824364|Other|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
79849949|NCT05824364|Other|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
79849950|NCT05821283|Procedure|exercise program consisting of supervised exercise and physical activity|The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
79849951|NCT05821283|Procedure|exercise program consisting of only supervised exercises.|The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
79849952|NCT05817877|Other|phone use|There is no intervention.
79849953|NCT05816356|Drug|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
79548458|NCT01558193|Dietary Supplement|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
79548459|NCT01558206|Other|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
79548460|NCT01558206|Other|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
79548461|NCT01558219|Drug|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
79548462|NCT01558232|Device|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
79253333|NCT05742386|Behavioral|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
79277357|NCT02201147|Procedure|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
79277358|NCT02201147|Device|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
79548463|NCT01558245|Drug|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
79548464|NCT01558258|Behavioral|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
79849954|NCT05816356|Drug|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
79712079|NCT04299178|Device|X-PLO2R POC|Portable Oxygen Concentrator (POC)
79712080|NCT00626470|Procedure|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
79849955|NCT05815498|Biological|mRNA-1283.222|Sterile liquid for injection
79849956|NCT05815498|Biological|mRNA-1273.222|Sterile liquid for injection
79849957|NCT05808595|Dietary Supplement|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
79392916|NCT04410211|Drug|Sevoflurane|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~Time taken from the point that the procedure ended to the first OAAS score of 5~Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator"
79712081|NCT02876770|Dietary Supplement|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
79253334|NCT05742386|Behavioral|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
79849958|NCT05808595|Other|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
79849959|NCT05805709|Other|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
79849960|NCT05805709|Other|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
79849961|NCT05805709|Other|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
79849962|NCT05805709|Other|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
79849963|NCT05801757|Drug|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
79849964|NCT05801757|Drug|Propofol|propofol 2-3mg/kg/h
79849965|NCT05799755|Drug|Nintedanib|Nintedanib 150 mg BID
79849966|NCT05799755|Drug|Placebo|Placebo comparator
79849967|NCT05799755|Drug|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
79849968|NCT05796089|Radiation|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
79875137|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
79875138|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
79875139|NCT00391053|Biological|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
79253335|NCT05742139|Other|Non intervention|Non intervention
79253336|NCT05739136|Drug|Relugolix + Estradiol + Norethindrone Acetate|Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
79253337|NCT05739123|Drug|Relugolix-Containing Product|Any relugolix-containing therapy
79277359|NCT02201147|Device|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
79277360|NCT02365311|Procedure|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
79712082|NCT02876770|Dietary Supplement|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
79712083|NCT01077622|Drug|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
79712084|NCT01313676|Drug|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
79548465|NCT01558284|Drug|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
79548466|NCT01558284|Drug|Placebo|Placebo
79253338|NCT05731362|Other|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
79392917|NCT04410211|Drug|Midazolam injection|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~Time taken from the point that the procedure ended to the first OAAS score of 5~Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator."
79548467|NCT01558310|Drug|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
79548468|NCT01558310|Drug|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
79712085|NCT01313676|Drug|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
79548469|NCT01558323|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
79712086|NCT01313676|Drug|vilanterol|25mcg given once daily via novel dry powder inhaler
79253339|NCT05729594|Drug|Bimatoprost Ophthalmic|eyedrops
79712087|NCT01313676|Other|Placebo|placebo comparator once daily via novel dry powder inhaler
79849969|NCT05796089|Drug|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
79849970|NCT05796089|Drug|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
79849971|NCT05795881|Other|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
79849972|NCT05794464|Procedure|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
79849973|NCT05775081|Other|Regenerative endodontic procedues|Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
79849974|NCT05774366|Drug|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
79849975|NCT05774366|Drug|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
79392918|NCT01582009|Drug|panobinostat|Given orally
79392919|NCT01582009|Drug|everolimus|Given orally
79392920|NCT01582009|Other|laboratory biomarker analysis|Correlative studies
79548470|NCT01558336|Drug|praziquantel|praziquantel 40 mg/kg oral tablets
79712088|NCT02891304|Other|Quarterly Feedback|Learning curves received quarterly vs. annually
79712089|NCT05661318|Other|Risk assessment|Collect clinical, laboratoary and genetics data from the participants after informed consent
79849976|NCT05763082|Drug|roflumilast cream 0.3%|test product
79849977|NCT05763082|Drug|Zoryve|RLD product
79849978|NCT05763082|Drug|Placebo|placebo
79392921|NCT01582009|Other|pharmacological study|Correlative studies
79392922|NCT01582009|Other|liquid chromatography|Correlative studies
79712090|NCT02890914|Other|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
79849979|NCT05745870|Dietary Supplement|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
79712091|NCT00623376|Drug|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
79712092|NCT00623376|Drug|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
79712093|NCT01313286|Drug|LY2608204 Reference|Administered orally
79712094|NCT01313286|Drug|LY2608204 Test|Administered orally.
79712095|NCT05644392|Drug|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
79712096|NCT05644392|Drug|Regorafenib|Regorafenib 80mg, po, orally once daily
79712097|NCT01313208|Drug|etanercept|Administered by subcutaneous injection once weekly.
79712098|NCT01313208|Drug|Placebo|Placebo subcutaneous injection
79712099|NCT01313208|Drug|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
79712100|NCT01312428|Device|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
79712101|NCT01312428|Device|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
79712102|NCT01075984|Drug|Posaconazole|
79548471|NCT01558362|Drug|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
79253340|NCT05727527|Procedure|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
79712103|NCT01075984|Drug|Dextrose 5% in water|
79712104|NCT04306198|Device|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
79548472|NCT01558375|Drug|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
79849980|NCT05736484|Behavioral|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
79253341|NCT05727527|Procedure|Local Anesthesia 2|Local anesthesia injection after applying sterile water
79253342|NCT05727475|Procedure|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
79253343|NCT05727475|Procedure|Fluoride gel application|Fluoride gel application 1.23%
79253344|NCT05722782|Drug|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
79548473|NCT01558375|Drug|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
79548474|NCT01558388|Drug|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
79712105|NCT04306198|Device|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
79253345|NCT05722782|Drug|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
79253346|NCT05722782|Drug|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
79253347|NCT05722327|Drug|MRTX849|Given by PO (mouth)
79253348|NCT05722327|Drug|Irinotecan|Given by IV (vein)
79548475|NCT01558388|Drug|Placebo|One vaginal tablet daily for 10 days.
79712106|NCT02876536|Device|TENS|The effect of TENS device will be compared in case and control groups.
79712107|NCT01024231|Drug|BMS-936558 (MDX1106-04)|
79712108|NCT01024231|Drug|Ipilimumab|
79253349|NCT05722327|Drug|Cetuximab|Given by IV (vein)
79253350|NCT05716490|Device|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
79253351|NCT05716490|Other|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
79253352|NCT05710978|Other|Work Protocol|Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
79253353|NCT05708755|Device|Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)|Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).
79253354|NCT05708755|Diagnostic Test|Donor-Derived Cell-Free DNA (dd-cfDNA) Assay|Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.
79253355|NCT05708755|Drug|Valganciclovir|Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
79253356|NCT05699642|Behavioral|Tai chi + wearable|The tai chi intervention will be delivered remotely via Zoom Enterprise. Participants will access classes on a phone, tablet, laptop, or desktop computer. Participants will attend 3 classes/week (each lasting 60 min) during weeks 1-12, 2 classes/week during weeks 13-16, and then 1 class every other week during weeks 17-24. Classes include tai chi warm-up exercises, breathing exercises, review and practice of tai chi forms, and cool-down exercises. Participants will be asked to practice tai chi at home 3x per week during the 6 month intervention period using an instructional video provided to them. The Fitbit fitness tracker will be given to each participant along with instructions on how to use the tracker and the Fitbit app on their personal device.
79392923|NCT01582009|Other|mass spectrometry|Correlative studies
79392924|NCT01582009|Other|enzyme-linked immunosorbent assay|Correlative studies
79392925|NCT01582009|Other|immunohistochemistry staining method|Correlative studies
79392926|NCT01553591|Drug|Eluxadoline|Oral tablets twice daily
79392927|NCT01553591|Drug|Placebo|Oral tablets twice daily
79392928|NCT01581931|Drug|Linagliptin/metformin|FDC
79392929|NCT01581931|Drug|Metformin|single tablet Metformin
79392930|NCT01581931|Drug|Linagliptin|single tablet Linagliptin
79392931|NCT01581619|Radiation|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
79253357|NCT05692453|Diagnostic Test|Arterial blood gas with co-oximetry|1 mL blood sample for ABG-CoOx analysis to obtain co-oximetry measured arterial oxygen saturation (SaO2C) and standard ABG derived arterial oxygen saturation (SaO2S).
79712109|NCT01077544|Drug|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
79548476|NCT01558401|Other|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
79548477|NCT01558414|Procedure|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
79712110|NCT04297969|Diagnostic Test|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
79712111|NCT04543201|Behavioral|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
79712112|NCT02871583|Procedure|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
79712113|NCT02871583|Procedure|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
79712114|NCT02871817|Other|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
79712115|NCT04299763|Dietary Supplement|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
79712116|NCT02871427|Drug|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
79712117|NCT01012999|Drug|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
79712118|NCT00628381|Dietary Supplement|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
79392932|NCT01581307|Drug|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
79392933|NCT01581307|Device|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
79712119|NCT00628381|Dietary Supplement|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
79712120|NCT04297813|Combination Product|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
79712121|NCT04297813|Procedure|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
79712122|NCT00637663|Drug|Entecavir|entecavir 0.5 mg QD
79712123|NCT00637663|Drug|Lamivudine|lamivudine 100 mg QD
79712124|NCT04299529|Diagnostic Test|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
79712125|NCT01017601|Biological|Seneca Valley virus-001|Given IV
79253358|NCT05685394|Drug|Dapagliflozin|Dapagliflozin 10mg P.O. daily
79253359|NCT05677633|Drug|Sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
79253360|NCT05676476|Drug|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
79253361|NCT05668091|Drug|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours.
79253362|NCT05668091|Drug|Ritonavir|One 100 mg capsule taken by mouth every 12 hours.
79253363|NCT05668091|Drug|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
79712126|NCT01017601|Other|placebo|Given IV
79253364|NCT05667727|Drug|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
79712127|NCT04297735|Other|Standard of care group|Visits every 6 months is standard of care.
79712128|NCT04297735|Behavioral|Telemedicine group|Conduct monthly telemedicine 'skype' visit
79712129|NCT04297735|Behavioral|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
79712130|NCT01016977|Drug|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
79712131|NCT01016977|Drug|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
79253365|NCT05667727|Drug|Salbutamol|Patient will receive salbutamol as 4th nebulization.
79253366|NCT05667181|Device|Surform|Da Vinci linear cutting stapler
79712132|NCT02871661|Drug|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
79712133|NCT02871661|Other|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
79712134|NCT02871661|Device|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
79253367|NCT05651737|Behavioral|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
79253368|NCT05649085|Device|Cobalt-Chromium (CoCr) prosthetic abutments|Cobalt-Chromium (CoCr) prosthetic abutments in single-unit implant-supported prostheses
79253369|NCT05637567|Drug|Acetylsalicylic acid|100 mg per os once daily
79548478|NCT01558414|Procedure|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
79548479|NCT01558414|Procedure|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
79548480|NCT01558440|Dietary Supplement|Infant Formula|A diet that is being fed to the young infants.
79548481|NCT01558440|Dietary Supplement|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
79253370|NCT05637567|Drug|Placebo|Placebo pill per os once daily
79253371|NCT05630638|Drug|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
79548482|NCT01558440|Dietary Supplement|Diluted F-100|300 ml of water is added to 1000 ml of f-100
79548483|NCT01558453|Drug|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
79548484|NCT01558466|Drug|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
79548485|NCT01558466|Drug|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
79712135|NCT01012765|Drug|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
79712136|NCT01012765|Drug|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
79712137|NCT01012765|Drug|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
79875140|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg twice daily
79253372|NCT05630638|Drug|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
79548486|NCT01558505|Device|PEB|paclitaxel-eluting balloon angioplasty
79548487|NCT01558505|Device|POBA|conventional balloon angioplasty
79875141|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg once daily
79253373|NCT05627323|Biological|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
79253374|NCT05627206|Behavioral|Problem Management + For Moms|Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
79253375|NCT05625789|Behavioral|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
79253376|NCT05625789|Behavioral|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
79392934|NCT01580995|Drug|Valacyclovir|Valacyclovir 500 mg po bid
79392935|NCT01580995|Drug|Placebo|Placebo tablet twice daily
79392936|NCT01535599|Drug|AL-60371, 0.3% Otic Suspension|
79392937|NCT01535599|Other|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
79392938|NCT01553279|Biological|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate [meningococcal outer membrane protein complex], and Hepatitis B [recombinant] vaccine administered via 0.5 mL intramuscular injection.
79392939|NCT01553279|Biological|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
79392940|NCT01553279|Biological|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
79712138|NCT00628459|Dietary Supplement|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
79875142|NCT00317044|Drug|Placebo|Placebo twice daily
79875143|NCT00301834|Biological|alemtuzumab|
79548488|NCT01558531|Device|DEB|paclitaxel-eluting balloon angioplasty
79849981|NCT05733962|Device|Use of the device DBL-4pen|"During the treatment period, the patient will use~the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
79548489|NCT01558531|Device|POBA|conventional balloon angioplasty
79849982|NCT05730543|Drug|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
79849983|NCT05716451|Device|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
79849984|NCT05712772|Other|Blue Light|Blue light exposure
79849985|NCT05712772|Other|Red Light|Red light exposure
79849986|NCT05711095|Dietary Supplement|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
79849987|NCT05711095|Dietary Supplement|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
79849988|NCT05711095|Dietary Supplement|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
79849989|NCT05708586|Behavioral|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
79849990|NCT05708586|Device|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
79849991|NCT05705609|Other|Mandala art therapy|A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.
79849992|NCT05692167|Drug|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
79849993|NCT05692167|Drug|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
79849994|NCT05690594|Other|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~General questionnaire (to collect socio-demographic data)~ICIQ score to evaluate urinary continence~FLQI score to evaluate fecal continence~FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
79849995|NCT05682261|Dietary Supplement|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
79849996|NCT05682261|Dietary Supplement|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
79849997|NCT05682261|Other|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
79849998|NCT05671965|Dietary Supplement|Xylitol|33.5g xylitol dissolved in 300mL tap water.
79849999|NCT05671965|Dietary Supplement|Sucrose|33.5g sucrose dissolved in 300mL tap water.
79850000|NCT05671965|Dietary Supplement|Acesulfame Potassium|0.1675g Ace-K dissolved in 300mL tap water.
79850001|NCT05671965|Dietary Supplement|Water|300mL tap water.
79850002|NCT05670041|Behavioral|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure.
79850005|NCT05658718|Procedure|refractive surgery|refractive surgery
79850006|NCT05650775|Drug|Concerta|3-week trial of oral methylphenidate extended release
79850007|NCT05650775|Drug|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
79850008|NCT05646030|Diagnostic Test|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
79850009|NCT05646030|Diagnostic Test|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
79850010|NCT05646030|Diagnostic Test|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
79548490|NCT01558557|Other|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
79548491|NCT01558570|Procedure|Blood Draw|One time blood draw
79548492|NCT01558583|Other|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
79548493|NCT01558583|Other|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
79850011|NCT05645458|Other|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
79850012|NCT05631132|Procedure|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
79850013|NCT05630222|Drug|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
79850014|NCT05630222|Drug|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
79392941|NCT01553279|Biological|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
79850015|NCT05630222|Drug|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
79850016|NCT05618730|Device|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
79850017|NCT05618730|Drug|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
79850018|NCT05605249|Device|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
79850019|NCT05603494|Device|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
79850021|NCT05598619|Dietary Supplement|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
79850022|NCT05598619|Other|placebo|Colon delivered placebo once a day for 12 weeks
79850023|NCT05597891|Device|Viper Catheter System|Treatment with the Viper Catheter System for thromboembolectomy
79850024|NCT05595317|Device|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
79850025|NCT05595317|Device|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
79392942|NCT01553279|Biological|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
79392943|NCT01553279|Biological|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
79392944|NCT01562743|Drug|SPM 962|Tansdermal patch
79548494|NCT01558583|Other|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
79548495|NCT01558622|Drug|dexketoprofen trometamol|50mg intravenous infusion
79548496|NCT01558622|Drug|tramadol hydrochloride|100mg intravenous infusion
79548497|NCT01558622|Drug|pethidine hydrochloride|50mg intravenous infusion
79548498|NCT01558622|Drug|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
79548499|NCT01558622|Drug|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
79548500|NCT01558622|Drug|vitamin c|500mg intravenous infusion
79548501|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
79850026|NCT05590767|Procedure|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
79392945|NCT03028571|Drug|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
79850027|NCT05588752|Other|TAP block|TAP block under ultrasound
79850028|NCT05580939|Other|Intervention group|They use Web-based Simulation Application for 4 weeks
79850029|NCT05579899|Drug|EVO101|Topical Cream
79850030|NCT05576012|Biological|SOL-116|Participants will receive SC injection in a double-blind manner
79850031|NCT05576012|Biological|Placebo|Participants will receive SC injection in a double-blind manner
79850032|NCT05565768|Drug|HZN-457|HZN-457 will be given in one subcutaneous administration
79875144|NCT00301834|Drug|busulfan|
79712139|NCT00627913|Procedure|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
79712140|NCT00627913|Procedure|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
79712141|NCT01010503|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
79712142|NCT00628537|Device|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
79712143|NCT00627991|Drug|Valsartan|
79712144|NCT05006053|Other|Interviews/Focus groups|Qualitative study (no intervention delivered)
79850033|NCT05565768|Drug|Placebo|Placebo will be given in one subcutaneous administration
79712145|NCT04297657|Other|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
79548502|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
79580987|NCT01931332|Procedure|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
79850034|NCT05564806|Drug|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
79850035|NCT05564793|Device|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
79580988|NCT01931332|Procedure|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
79580989|NCT01931345|Behavioral|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
79712146|NCT04472845|Radiation|1 week RT|RT will be delivered over 1 week
79712147|NCT04472845|Radiation|2 week RT|RT will be delivered over 2 week
79712148|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
79712149|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
79712150|NCT01006291|Drug|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
79850036|NCT05564793|Device|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
79850037|NCT05561127|Combination Product|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
79850038|NCT05561127|Other|Control|Standard of Care Endoscopic Dilation
79850039|NCT05561114|Combination Product|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
79850040|NCT05561114|Other|Control|Standard Endoscopic Dilation
79850041|NCT05553119|Behavioral|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
79850042|NCT05553119|Behavioral|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
79850043|NCT05552638|Other|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
79850044|NCT05546554|Drug|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
79850045|NCT05546554|Drug|Placebo|Matching Placebo given orally
79850046|NCT05540574|Drug|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
79850047|NCT05540574|Drug|Placebo|Matching Placebo given orally
79850048|NCT05538234|Diagnostic Test|Laboratory values - baseline|Baseline laboratory values will be obtained
79875145|NCT00301834|Drug|cyclosporine|
79875146|NCT00301834|Drug|fludarabine phosphate|
79850049|NCT05538234|Other|Medical information 12 hours before organ harvesting|"average hourly diuresis~hypotension MAP<65 Torr longer than 30 minutes (YES/NO)~Furosemide administration (YES/NO)~Mannitol administration (YES/NO)~administration of anti-diuretic hormone (YES/NO)~administration of vasopressors (YES/NO)~polyuria >3ml/kg/h (YES/NO)~nephrotoxic agents during hospitalization (YES/NO)"
79850050|NCT05538234|Diagnostic Test|Laboratory values - 12 hours after reperfusion|Laboratory values will be obtained 12 hours after reperfusion
79548503|NCT01558687|Drug|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
79548504|NCT01558687|Other|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
79548505|NCT01558713|Drug|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
79712151|NCT02871349|Drug|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
79850051|NCT05538234|Diagnostic Test|Laboratory values - 48 hours after reperfusion|Laboratory values will be obtained 48 hours after reperfusion
79850052|NCT05538234|Diagnostic Test|Laboratory values - 7 days after reperfusion|Laboratory values will be obtained 7 days after reperfusion
79850053|NCT05538234|Diagnostic Test|Laboratory values - 90 days after reperfusion|Laboratory values will be obtained 90 days after reperfusion
79850054|NCT05538234|Other|Medical information during organ harvesting/transplantation|"Medical information during organ harvesting/transplantation~hypotension MAP 65 Torr > 5 minutes (YES/NO)~vasopressor support (YES/NO, duration in minutes)"
79850055|NCT05538234|Procedure|Organ harvesting|Organ harvesting for transplant
79850056|NCT05538234|Procedure|Organ transplantation|Transplantation of the harvested organ
79850057|NCT05528471|Other|Dietary intervention|To compare an iso-caloric, low fructose diet (~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
79850058|NCT05527574|Other|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
79850059|NCT05527171|Behavioral|Virtual Reality Mindfulness Meditation|Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.
79548506|NCT01558713|Drug|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
79392946|NCT03028571|Other|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
79392947|NCT01535443|Drug|Bromfenac|Drug: Bromfenac Other names: PRO-155
79392948|NCT03028259|Other|lab results|Comparison of lab results
79392949|NCT04108403|Other|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
79392950|NCT04108403|Other|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
79392951|NCT04108403|Other|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
79392952|NCT04108403|Other|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
79712152|NCT02871349|Drug|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
79712153|NCT02871349|Device|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
79850060|NCT05527171|Behavioral|Virtual Reality Sham|Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
79850061|NCT05527041|Device|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~Gaze coordinates~Pupil sizes~Accelerometer data~Gyroscopic data~Rotation data~Blink data"
79850062|NCT05526664|Other|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
79850063|NCT05525390|Behavioral|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
79850064|NCT05525390|Behavioral|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
79850065|NCT05523986|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
79850066|NCT05523986|Other|Placebo|Placebo
79850067|NCT05521789|Drug|ESB Thoracic|Erector spinae thoracic block with bupivacaine
79850068|NCT05520255|Drug|18F-PSMA-1007|18F-PSMA-1007 intravenous injection
79850069|NCT05509855|Genetic|Genetic: WU-CART-007|No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
79850072|NCT05501678|Drug|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
79850073|NCT05501678|Drug|Placebo|Matching Placebo given orally
79850074|NCT05501522|Biological|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
79850075|NCT05501522|Other|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
79253377|NCT05624346|Other|Deep-Breathing Exercises|In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
79253378|NCT05623748|Procedure|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
79253379|NCT05618002|Drug|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
79253380|NCT05615649|Device|MED-EL BONEBRIDGE Bone Conduction Implant|Subjects will be implanted with the MED-EL BONEBRIDGE Bone Conduction Implant System. Subjects will be fit with the appropriate external audio sound processor.
79548507|NCT01558713|Drug|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
79253381|NCT05604976|Device|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
79277361|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
79548508|NCT01558713|Drug|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
79548509|NCT01558713|Drug|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
79548510|NCT01558713|Drug|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
79548511|NCT01558726|Behavioral|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
79548512|NCT01558726|Behavioral|Usual Treatment|The usual treatment used for regular patients of CAPSad
79548513|NCT01558765|Other|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
79548514|NCT01558778|Procedure|management of therapy complications|Undergo mechanical stimulation
79548515|NCT01558778|Procedure|musculoskeletal complications management/prevention|Undergo mechanical stimulation
79548516|NCT01558817|Behavioral|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
79548517|NCT01558817|Behavioral|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
79548518|NCT01558830|Drug|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
79548519|NCT01558830|Drug|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
79548520|NCT01558856|Procedure|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
79580990|NCT01931345|Behavioral|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
79580991|NCT01931358|Biological|ALVAC-HIV|1 mL intramuscular injection containing 10^6 CCID50/dose
79850076|NCT05497596|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
79850077|NCT05497596|Other|Placebo|Placebo
79850078|NCT05495204|Drug|Ibalizumab|Participation in clinical trials vs. routine care in OPERA
79850079|NCT05494723|Drug|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
79850080|NCT05491603|Biological|DBI-001|Topically administered
79850081|NCT05491603|Biological|DBI-002|Topically administered
79850082|NCT05491603|Biological|Aqueous Gel|Topically administered
79850083|NCT05489120|Other|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
79850084|NCT05488405|Drug|Mesalamine Oral Product|Mesalamine oral suspension for oral use
79850085|NCT05470140|Biological|WU-NK-101|WU-NK-101 administered on Day 1, Day 8, and Day 15.
79850086|NCT05464602|Other|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
79875147|NCT00301834|Drug|methotrexate|
79875148|NCT00301834|Drug|methylprednisolone|
79392953|NCT01535287|Drug|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
79850087|NCT05464602|Other|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
79850088|NCT05463380|Other|standard of care|The patient will be treated following the satndard of care in the participating units
80017169|NCT04704232|Drug|PLAC|Double blind, parallel within subject comparison
79253382|NCT05604820|Behavioral|Progressive Muscle Relaxation Exercise|Training on progressive muscle relaxation exercises will be given to the experimental group in the chemotherapy unit. Before going to sleep in the evening and during the day, they will be asked to do progressive muscle relaxation exercises in line with the instruction of the video. They will be asked to do the application every day for 8 weeks. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. Only routine care will be applied to the control group and no intervention will be made. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. After the evaluations, information about progressive muscle relaxation exercises will be given.
79253383|NCT05590507|Behavioral|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
79253384|NCT05587244|Device|Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners|Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
79850089|NCT05456152|Drug|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
79253385|NCT05585034|Biological|XmAb®808|Monoclonal bispecific antibody
79253386|NCT05585034|Biological|Keytruda® (pembrolizumab)|Monoclonal antibody
79392954|NCT02985775|Biological|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
79392955|NCT01551173|Drug|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
79392956|NCT01549613|Drug|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
79392957|NCT01549613|Drug|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
79392958|NCT04739189|Behavioral|Con : control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
79392959|NCT04739189|Behavioral|Def-EX : Condition with an exercise-induced energy deficit|Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
79548521|NCT01558856|Procedure|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
79548522|NCT01558869|Drug|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
79548523|NCT01558869|Drug|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
79548524|NCT01558869|Drug|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
79850090|NCT05454033|Device|JUVÉDERM® VOLITE™|Injection, intradermal
79850091|NCT05454033|Other|Control|No-treatment control
79850092|NCT05441332|Other|EOS Radiation|One EOS exam of lower extremities
79850093|NCT05441332|Behavioral|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
79875149|NCT00301834|Procedure|allogeneic bone marrow transplantation|
79875150|NCT00301834|Procedure|allogeneic hematopoietic stem cell transplantation|
79875151|NCT00301834|Procedure|peripheral blood stem cell transplantation|
79875152|NCT00301834|Procedure|umbilical cord blood transplantation|
80017170|NCT02098356|Other|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
80017171|NCT03363256|Behavioral|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
80017172|NCT03363256|Behavioral|TAU|Standard outpatient addiction treatment
79875153|NCT00301366|Drug|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
79875154|NCT00330928|Device|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
79875155|NCT00330928|Device|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
79875156|NCT01062334|Procedure|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
79875157|NCT00330616|Drug|323U66 SR|
79875158|NCT00466440|Drug|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
79875159|NCT00466440|Drug|placebo|Loading dose, then po QD until unblinding
80017173|NCT02101086|Other|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
80017174|NCT00358982|Drug|MGCD0103|MGCD0103 administered orally three times per wek
79253387|NCT05579769|Drug|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
79253388|NCT05579769|Drug|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
79392960|NCT04739189|Behavioral|Def-EI : Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
79712154|NCT01012609|Other|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
79712155|NCT04297501|Drug|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
79850094|NCT05441241|Device|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
79712156|NCT04298749|Drug|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
79712157|NCT04298749|Drug|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
79712158|NCT04298749|Drug|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
79712159|NCT04298515|Diagnostic Test|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
80017175|NCT02101164|Biological|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
80017176|NCT02101164|Drug|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
79392961|NCT01548599|Other|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
79392962|NCT01548287|Drug|AZD5213|AZD5213 doseA daily
80017177|NCT00036608|Drug|Entecavir|
80017178|NCT03657927|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
79253389|NCT05579769|Drug|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
79277362|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
79392963|NCT01548287|Drug|AZD5213|AZD5213 doseB daily
79392964|NCT01548287|Drug|AZD5213|AZD5213 doseC daily
79392965|NCT01548287|Other|Placebo|Placebo tablet daily
79392966|NCT04410185|Behavioral|Meditation|Meditation sessions will take place over 12 weekly sessions of 1.5 hours
79392967|NCT01546883|Drug|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
79392968|NCT01546649|Drug|TAP-144-SR(6M)|
79392969|NCT01546649|Drug|TAP-144-SR(3M)|
79712160|NCT01012219|Drug|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
79712161|NCT01012219|Drug|Comparator: aspirin|81 mg oral tablet once daily for 7 days
79712162|NCT01012219|Drug|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
79712163|NCT01012219|Drug|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
79712164|NCT01012219|Drug|Comparator: placebo|placebo oral tablet once daily for 7 days
79712165|NCT04298125|Behavioral|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
79712166|NCT01011907|Drug|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
79712167|NCT01011907|Drug|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
79712168|NCT01011673|Drug|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
79712169|NCT01011673|Drug|Ketorolac|ketorolac 30mg IVSS
79712170|NCT01011439|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
80017179|NCT03657927|Device|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
79712171|NCT01311024|Biological|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
79712172|NCT01311024|Biological|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
79712173|NCT02871193|Drug|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
79712174|NCT02871193|Drug|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
79712175|NCT02871193|Other|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
79712176|NCT01310868|Drug|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
79712177|NCT01310868|Drug|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
79712178|NCT01310868|Radiation|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
79712179|NCT01310868|Drug|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
79712180|NCT01310868|Drug|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
80017180|NCT02098434|Behavioral|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
80017181|NCT03223480|Device|EUS-guided gastrojejunstomy|As listed in the arms description
79253390|NCT05579769|Drug|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
79253391|NCT05579769|Drug|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
79548525|NCT01558882|Device|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
79253392|NCT05579769|Drug|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
79253393|NCT05579769|Drug|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
79253394|NCT05579769|Radiation|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be < 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
79253395|NCT05579769|Drug|Bone marrow infusion|Day 0
79253396|NCT05579769|Drug|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
79392970|NCT02985983|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 66.
79392971|NCT02985983|Drug|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered KHK4827 by SC injection from week 17 until week 66.
79392972|NCT01544309|Drug|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society [JAS] Guidelines [GL] after 3 months, had the atorvastatin [ATV] dose of 20 mg.)"
79392973|NCT01544309|Drug|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)"
79392974|NCT01544153|Behavioral|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
79392975|NCT01544153|Behavioral|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
79548526|NCT01558895|Radiation|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
79548527|NCT01558895|Other|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
79548528|NCT01558908|Biological|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
79548529|NCT01558934|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
79580992|NCT01931358|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
79580993|NCT01931358|Biological|ALVAC-HIV Placebo|1 mL per injection
79580994|NCT01931358|Biological|AIDSVAX B/E Placebo|1 mL per injection
79712181|NCT01273155|Drug|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
79850095|NCT05441241|Other|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
79712182|NCT05557851|Combination Product|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
79712183|NCT01005901|Drug|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
79712184|NCT01005901|Drug|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
79712185|NCT02889549|Drug|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
79712186|NCT02889549|Drug|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
79253397|NCT05579769|Drug|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
79253398|NCT05575869|Other|(online) PRONEtect educational material|This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
79850096|NCT05440903|Behavioral|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
79712187|NCT04968925|Device|ACUVUE Oasys 1-Day|TEST
79712188|NCT04968925|Device|Precision 1|CONTROL
79712189|NCT01266993|Biological|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
79712190|NCT01266993|Biological|Menjugate|Intramuscular, 1 dose
79712191|NCT04282525|Other|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
79712192|NCT01309386|Drug|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
79712193|NCT01309386|Drug|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
79253399|NCT05575869|Other|Classic (normal) one hour lesson/lecture|As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
79712194|NCT04295317|Drug|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
79392976|NCT01544153|Behavioral|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
79392977|NCT01543685|Drug|Indomethacin|40 mg TID capsules
79712195|NCT04295317|Drug|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
79277363|NCT02201225|Dietary Supplement|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
79392978|NCT01543685|Drug|Indomethacin|40 mg BID capsules
79392979|NCT01543685|Drug|Indomethacin|20 mg TID capsules
79392980|NCT01543685|Drug|Celecoxib|200 mg capsules
79392981|NCT01543685|Drug|Placebo|Capsules
79712196|NCT01266603|Drug|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
79712197|NCT01266603|Biological|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
79712198|NCT04295551|Drug|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
79712199|NCT04295551|Drug|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
79712200|NCT01309308|Procedure|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
79712201|NCT01309308|Other|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
79850097|NCT05440903|Behavioral|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
79850098|NCT05439941|Drug|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
79548530|NCT01558947|Drug|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery.
79548531|NCT01558947|Drug|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4~6 weeks after surgery.
79548532|NCT01558960|Drug|IVit Melphalan|IVit injections of Melphalan
79548533|NCT01558986|Procedure|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
79548534|NCT01558986|Procedure|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
79548535|NCT01559025|Drug|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
79850099|NCT05434598|Device|ChromoSeq|Novel, streamlined whole genome sequencing approach
79850100|NCT05430438|Other|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
79850101|NCT05430438|Other|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
79850102|NCT05421078|Drug|Obicetrapib|tablet
79712202|NCT01266291|Drug|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
79712203|NCT00628771|Behavioral|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
79712204|NCT00628771|Behavioral|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
79392982|NCT01541969|Device|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
79712205|NCT01004263|Drug|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
79712206|NCT01308762|Biological|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
79548536|NCT01559051|Procedure|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
79712207|NCT01308762|Biological|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
79850103|NCT05421078|Drug|Obicetrapib|No active ingredient
79850104|NCT05413174|Behavioral|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
79850105|NCT05408663|Drug|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
79850106|NCT05408663|Other|Placebo|matching placebo administered via subcutaneous injection
79850107|NCT05402449|Other|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
80017182|NCT02103738|Other|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
79850108|NCT05402449|Dietary Supplement|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
80017183|NCT02985021|Drug|Carboplatin|Chemotherapy
80017184|NCT02985021|Drug|Docetaxel|Chemotherapy
80017185|NCT03902704|Device|Cleverscope|the device is used in patients without difficult airways predictors
80017186|NCT03902704|Device|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
79253400|NCT05574764|Behavioral|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
79253401|NCT05562999|Drug|Rocuronium Bromide|Moderate NMB (TOF 1-2)
79253402|NCT05562999|Drug|Rocuronium Bromide|Deep NMB (PTC 1-2)
79253403|NCT05558293|Procedure|Scaling and root planing|Full mouth or quadrant SRP
79253404|NCT05558267|Dietary Supplement|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
79253405|NCT05558267|Dietary Supplement|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
79548537|NCT01559077|Drug|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
79548538|NCT01559077|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79253406|NCT05556174|Other|periodic lung recruitment maneuvers|lung recruitment maneuvers repeated every 30 minutes
79277364|NCT02201225|Dietary Supplement|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
79548539|NCT01559103|Biological|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
79548540|NCT01559103|Biological|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
79548541|NCT01559142|Drug|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
79548542|NCT01559142|Drug|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
79253407|NCT05554861|Device|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
79253408|NCT05554861|Device|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
79253409|NCT05554861|Device|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
79548543|NCT01559168|Device|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
79548544|NCT01559194|Behavioral|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
79548545|NCT01559194|Behavioral|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
79548546|NCT01559220|Device|Deep Brain Stimulation|Implanted device
79548547|NCT01559233|Device|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
79548548|NCT01559272|Drug|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
79548549|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
79548550|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
79548551|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
79548552|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
79548553|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
79548554|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
79548555|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
79548556|NCT01559272|Drug|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
79548557|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
79548558|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
79548559|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
79548560|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
79548561|NCT01559285|Drug|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
79548562|NCT01559285|Drug|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
79548563|NCT01559285|Drug|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
79712208|NCT01308762|Biological|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
79850109|NCT05396495|Device|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
79712209|NCT01265823|Biological|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
79392983|NCT01541969|Device|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
79392984|NCT04767737|Other|Topically Administered Lavender Aromatherapy|3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
79392985|NCT04767737|Other|Topically Administered Water|3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
79253410|NCT05554653|Dietary Supplement|Leucine enriched amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
79253411|NCT05554653|Dietary Supplement|Carbohydrate Placebo|iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
79253412|NCT05551117|Biological|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
79850110|NCT05396040|Procedure|LOLLI METHODE|WEEKLY SCREENING WITH POOLED SALIVA PCR TEST
79850111|NCT05369871|Device|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
79392986|NCT01540565|Other|Laboratory Biomarker Analysis|Correlative studies
79392987|NCT01540565|Drug|Veliparib|Given PO
79253413|NCT05551117|Biological|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
79392988|NCT01540487|Drug|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
79392989|NCT01540487|Drug|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
79392990|NCT03027947|Device|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
79392991|NCT01539317|Drug|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
79712210|NCT02890836|Drug|Antihypertensiva, mainly Metyldopa|
79392992|NCT01539317|Drug|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
79392993|NCT01539239|Device|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
79392994|NCT01539239|Procedure|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
79392995|NCT01539083|Drug|Thalidomide|Thalidomide 100 mg tablet, orally.
79392996|NCT01539083|Drug|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m^2) solution for injection subcutaneously (SC).
79548564|NCT01559298|Drug|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
79548565|NCT01559298|Drug|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
79548566|NCT01559324|Device|ECT|Bifrontal ECT, low dosage
79548567|NCT01559324|Device|ECT|Right unilateral electrode position, high dosage
79548568|NCT01559337|Procedure|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
79712211|NCT01004185|Drug|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM & 2 Asacol 400mg PM; 33-<54kg = 5 Asacol 400 mg AM & 4 Asacol 400mg PM; 54-<90kg = 6 Asacol 400mg AM & PM
79712212|NCT01004185|Drug|Asacol 400 mg|17-<33kg = 2 Asacol 400mg & 1 placebo AM, 1 Asacol 400mg & 1 placebo PM; 33-<54kg = 3 Asacol 400mg & 2 placebo AM, 2 Asacol 400mg & 2 placebo PM; 54-<90kg = 3 Asacol 400mg & 3 placebo AM & PM
79850112|NCT05369871|Device|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
79277365|NCT02365155|Other|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
79548569|NCT01559350|Procedure|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
79712213|NCT01265511|Drug|Placebo|Oral tablets given bid for 28 days
79712214|NCT01265511|Drug|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
79712215|NCT01265511|Drug|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
79712216|NCT01265511|Drug|Copegus|tablets given bid for up to 48 weeks
79712217|NCT04325178|Other|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
79712218|NCT04325100|Behavioral|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
79712219|NCT04325100|Behavioral|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
79712220|NCT04324788|Other|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
79392997|NCT01539083|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m^2 orally.
79253414|NCT05547607|Diagnostic Test|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
79850113|NCT05361902|Radiation|Adaptive radiotherapy according to UPRATE protocol|According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
79712221|NCT04324788|Other|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
79712222|NCT01264965|Drug|long acting oxycodone|10mg twice daily
79392998|NCT01539083|Drug|Dexamethasone|Dexamethasone 20 mg orally.
79392999|NCT01539083|Drug|Prednisolone|Prednisolone 50 mg orally.
79393000|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
79393001|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
79712223|NCT01264965|Drug|extra strength acetaminophen|1,000 mg twice daily
79548570|NCT01559350|Procedure|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
79548571|NCT01559402|Procedure|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
79548572|NCT01559402|Procedure|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
79548573|NCT01559402|Procedure|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
79393002|NCT01537133|Drug|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
79548574|NCT01559415|Other|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
79548575|NCT01559415|Other|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
79850114|NCT05351749|Behavioral|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
79393003|NCT01537133|Drug|Placebo|Dry Powder Inhaler: Placebo
79393004|NCT01536587|Drug|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
79548576|NCT01559428|Dietary Supplement|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
79253415|NCT05547373|Behavioral|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
79253416|NCT05547165|Device|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
79253417|NCT05547165|Combination Product|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
79253418|NCT05547165|Diagnostic Test|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
79393005|NCT01536119|Behavioral|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
79393006|NCT02985905|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
79393007|NCT01535261|Drug|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
79548577|NCT01559428|Dietary Supplement|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
79548578|NCT01559428|Dietary Supplement|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
79548579|NCT01559441|Dietary Supplement|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
79548580|NCT01559441|Dietary Supplement|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
79548581|NCT01559467|Other|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
79548582|NCT01559467|Other|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
79548583|NCT01559480|Drug|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
79548584|NCT01559480|Drug|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
79548585|NCT01559519|Drug|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
79548586|NCT01559545|Drug|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
79548587|NCT01559545|Drug|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
79548588|NCT01559545|Drug|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
79548589|NCT01559558|Procedure|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
79548590|NCT01559584|Radiation|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
79548591|NCT01559584|Drug|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
79548592|NCT01559597|Biological|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
79548593|NCT01559610|Other|Intervention Group|The patients were instructed by a nurse
79548594|NCT01559623|Procedure|retrospective data analysis|retrospective data analysis
79548595|NCT01559636|Biological|bivalent oral polio vaccine|vaccine given during immunization campaigns
79548596|NCT01559662|Dietary Supplement|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
79580995|NCT01931371|Procedure|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
79712224|NCT05644236|Other|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
79712225|NCT02890680|Procedure|Platelet-rich fibrin|
79712226|NCT02890680|Procedure|Control group|
79712227|NCT01264887|Drug|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
79393008|NCT01534637|Drug|aprepitant|Given PO
79712228|NCT01306968|Drug|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
79850115|NCT05351749|Behavioral|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
79393009|NCT01534637|Drug|gemcitabine hydrochloride|Given IV
79850116|NCT05351749|Behavioral|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
79393010|NCT01534637|Drug|capecitabine|Given PO
79548597|NCT01559688|Behavioral|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
79548598|NCT01559688|Behavioral|Waitlist|Fitness assessment or career counseling
79548599|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
79548600|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
79548601|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
79253419|NCT05541887|Other|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content <0.5% with addition of 50ppm of sodium metabisulfite for preservation
79253420|NCT05541887|Other|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
79253421|NCT05540899|Radiation|Hypofractionated Postoperative Radiotherapy|Hypofractionated Postoperative Radiation Therapy
79253422|NCT05535114|Other|Yoga-resistance exercise|Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation & meditation (10 minutes).
79548602|NCT01559740|Drug|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
79580996|NCT01931371|Procedure|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
79580997|NCT01931384|Drug|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
79580998|NCT01931384|Drug|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
79580999|NCT01931410|Drug|Misoprostol|
79393011|NCT01534637|Drug|fluorouracil|Given IV
79253423|NCT05533138|Behavioral|Therapist Guided Internet-CBT for antenatal depression|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression.
79277366|NCT02365155|Other|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
79393012|NCT01534637|Procedure|radiation therapy|Undergo radiation therapy
79393013|NCT01534637|Other|questionnaire administration|Ancillary studies
79393014|NCT01534637|Procedure|quality-of-life assessment|Ancillary studies
79393015|NCT01534637|Procedure|nausea and vomiting therapy|Receive aprepitant
79393016|NCT01534637|Procedure|management of therapy complications|Receive aprepitant
79393017|NCT02655016|Drug|Niraparib|Niraparib will be administered.
79393018|NCT02655016|Drug|Placebo|Placebo will be administered.
79393019|NCT01533935|Drug|Placebo|placebo matching tiotropium + olodaterol
79393020|NCT01533935|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
79393021|NCT01533935|Drug|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
79393022|NCT01533935|Drug|Tiotropium|tiotropium
79393023|NCT01533935|Drug|Olodaterol|Olodaterol 5 mcg once daily
79393024|NCT01533935|Device|Respimat|Respimat inhaler
79393025|NCT01532999|Behavioral|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
79393026|NCT01532999|Behavioral|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
79581000|NCT01931423|Behavioral|Placental cord drainage|
79581001|NCT01931449|Procedure|Modified method of digestive tract reconstruction|
79850117|NCT05351749|Behavioral|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
79850118|NCT05333783|Behavioral|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
79850119|NCT05324020|Behavioral|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
79850120|NCT05320393|Drug|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
79850121|NCT05320393|Drug|OnabotulinumtoxinA|One treatment of 20 units
79850122|NCT05320393|Drug|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
79850123|NCT05301803|Device|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
79253424|NCT05533138|Behavioral|Therapist Guided Internet-CBT for antenatal depression and perinatal extra support.|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression. Additionally, up to three supportive contacts with a midwife or perinatal mental health nurse to support ICBT treatment and adress general pregnancy related health problems.
79253425|NCT05533138|Behavioral|Diagnostic assessment by telephone, video or face-to face - Allocation by chance|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation by chance.
79253426|NCT05533138|Behavioral|Diagnostic assessment by telephone, video or face-to face - Allocation by choice|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation based on patient preference.
79253427|NCT05525949|Device|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
79393027|NCT02652676|Procedure|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
79393028|NCT02652676|Procedure|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
79393029|NCT02554630|Other|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
79393030|NCT02554630|Other|Blood Collection|Blood collection will be performed on all groups.
79253428|NCT05525949|Other|No-treatment Control|No-treatment is administered during control period.
79393031|NCT01532921|Procedure|Tricuspid valve repair|
79581002|NCT01931449|Procedure|Routine digestive tract reconstruction|
79581003|NCT01931488|Other|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
79581004|NCT01931488|Device|SPECT imaging|
79581005|NCT01931501|Drug|Torrent's Montelukast Sodium Chewable Tablets 5mg|
79581006|NCT01931501|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
79581007|NCT01931514|Drug|Torrent's Montelukast Sodium chewable Tablets 5mg|
79581008|NCT01931514|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
79581009|NCT01931540|Behavioral|Exercise Training|Three times a week, for four months.
79581010|NCT01931553|Other|Standardized attending morning rounds|
79581011|NCT01931579|Device|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
79850124|NCT05283980|Drug|0.25% Bupivacaine|The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
79277367|NCT02365155|Other|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
79850125|NCT05273658|Drug|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
79850126|NCT05273658|Drug|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
79850127|NCT05273190|Device|Vibrotactile Stimulation|Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
79850128|NCT05272501|Behavioral|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
79850129|NCT05272254|Drug|10% povidone iodine + FV|applied to children's teeth
79850130|NCT05272254|Other|Placebo +FV|applied to children's teeth
79548603|NCT01559753|Drug|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~Beta-Lactams:~Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~Ceftriaxone : 2 g OD during 3 days, then 1 g OD~Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
79850132|NCT05269498|Device|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
79850133|NCT05264896|Drug|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
79277368|NCT02365155|Other|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
79277369|NCT02365155|Other|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
79393032|NCT01532921|Procedure|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
79393033|NCT01532921|Device|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
79393034|NCT04341610|Drug|Stem Cell Product|100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
79393035|NCT04767425|Radiation|Brachytherapy|• 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
79393036|NCT01532687|Drug|Gemcitabine|Given IV
79850134|NCT05264896|Drug|XELOX|XELOX 8 cycles post radical gastrectomy
79850135|NCT05259306|Device|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
79393037|NCT01532687|Drug|Gemcitabine Hydrochloride|Given IV
79393038|NCT01532687|Other|Laboratory Biomarker Analysis|Correlative studies
79393039|NCT01532687|Drug|Pazopanib|Given PO
79393040|NCT01532687|Drug|Pazopanib Hydrochloride|Given PO
79850136|NCT05259176|Device|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
79850137|NCT05259176|Device|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
79850138|NCT05259176|Device|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
79850139|NCT05248919|Drug|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
79850140|NCT05248802|Drug|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
79850141|NCT05248802|Drug|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
79875160|NCT00466440|Drug|docetaxel|75 mg/m^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
79875161|NCT00466440|Drug|prednisone|5 mg po BID, six 21-day cycles
79393041|NCT01532687|Other|Placebo Administration|Given PO
79393042|NCT04409717|Procedure|Type II endoleak treatment|Type II endoleak endovascular treatment
79393043|NCT02677116|Drug|Olaratumab|Olaratumab administered IV.
79393044|NCT02677116|Drug|Doxorubicin|Doxorubicin administered IV.
79850142|NCT05240924|Behavioral|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
79393045|NCT02677116|Drug|Vincristine|Vincristine administered IV.
79850143|NCT05240924|Other|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
79393046|NCT02677116|Drug|Irinotecan|Irinotecan administered IV.
79548604|NCT01559753|Drug|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~Ceftriaxone : 2 g OD during 3 days, then 1 g OD~Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
79548605|NCT01559831|Biological|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
79548606|NCT01559883|Other|no intervention is being made|This is a Non-Interventional Study (NIS)
79548607|NCT01559896|Dietary Supplement|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
79548608|NCT01559909|Device|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
79548609|NCT01559961|Drug|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
79548610|NCT01559974|Drug|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
79548611|NCT01559974|Drug|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
79548612|NCT01559987|Other|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
79712229|NCT01306968|Other|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
79712230|NCT04323423|Behavioral|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
79548613|NCT01559987|Other|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
79548614|NCT01559987|Other|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
79548615|NCT01560117|Drug|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
79548616|NCT01560533|Behavioral|Interviews|Interviews will be done with patients
79548617|NCT01560845|Procedure|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
79548618|NCT01560845|Procedure|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
79548619|NCT05570669|Drug|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose|Taking the colonoscopy preparation drug (Clensia) in a single administration
79548620|NCT05570669|Drug|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose|Taking the colonoscopy preparation drug (Clensia) in two stages of administration
79548621|NCT05570643|Drug|LPS|This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
79393047|NCT02677116|Drug|Ifosfamide|Ifosfamide administered IV.
79393048|NCT03161730|Other|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
79393049|NCT03161730|Other|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
79393050|NCT03161730|Other|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
79548622|NCT05570643|Drug|Placebo|Injection of NaCl 0.9%.
79712231|NCT05644158|Procedure|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
79712232|NCT05644158|Other|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
79393051|NCT03161886|Device|Pan-enteric Capsule Endoscopy (PCE)|Second generation of colon capsule endoscopy (Medtronic)
79393052|NCT05274204|Drug|CA102N|
79850144|NCT05228574|Dietary Supplement|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
79850145|NCT05228574|Dietary Supplement|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
79712233|NCT01264419|Device|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
79712234|NCT04323345|Dietary Supplement|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
79712235|NCT04323345|Other|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
79712236|NCT01263873|Device|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
79548623|NCT05570552|Behavioral|mHealth based behavioral change communication intervention|We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
79712237|NCT01263873|Device|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
79712238|NCT01263639|Other|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
79712239|NCT01263639|Other|Standard of care - No biosketch card|Standard of care
79712240|NCT01011283|Drug|decitabine|decitabine 20 mg/m^2 /day intravenous (IV) infusion for 5 days every 28 days
79712241|NCT01011283|Drug|azacitidine|azacitidine 75 mg/m^2 /day subcutaneous (SC) injection for 7 days every 28 days
79850146|NCT05228574|Drug|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
79712242|NCT01263561|Procedure|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
79712243|NCT01263561|Procedure|trabeculectomy|trabeculectomy filtering surgery
79712244|NCT01009099|Other|breathing retraining|breathing retraining using a metronome
79712245|NCT01009099|Other|exercise training|treadmill exercise training
79712246|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
79712247|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
79712248|NCT01263483|Drug|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
79712249|NCT01306890|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
79850147|NCT05214443|Procedure|POEM + F|POEM would first be performed as per usual technique. Upon completion of the myotomy, a 2cm incision would be created over the adventitial layer at the level of gastro-esophageal junction (GEJ), allowing scope entry into the peritoneal cavity. The anterior part of the gastric fundus would be located, grasped with endoscopic forceps and pulled towards the esophageal myotomy site. The intended anterior fundus would then be anchored to the edge of the muscle at the GEJ, with the use of X-TackTM system. After confirming adequate hemostasis and secure anchorage of fundus to the esophagus, the mucosal entry site for the submucosal tunnel would be closed with endoscopic clips as per usual POEM technique.
79850148|NCT05195541|Drug|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
79850149|NCT05177107|Biological|Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
79393053|NCT02689518|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
79548624|NCT05570474|Dietary Supplement|Protein drink supplementation|Daily drink containing 20 grams of whey protein, dissolved in 200mL water.
79548625|NCT05570474|Dietary Supplement|Placebo|Daily placebo drink
79712250|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
79712251|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
79712252|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
79712253|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
79712254|NCT02871973|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
79850150|NCT05177107|Other|Placebo|Placebo (normal saline)
79850151|NCT05176873|Drug|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
79277370|NCT02365155|Other|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
79277371|NCT02201303|Drug|Danirixin|Powdered form for in-vitro administration to blood sample
79277372|NCT02201303|Other|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
79850152|NCT05176873|Drug|Placebo|A single oral dose of placebo will be given.
79253429|NCT05523843|Other|Tulsa Life Chart (TLC)|The TLC is a self-administered, interactive assessment of patient history. Participants are asked to provide information from birth to their current age in developmental epochs (i.e., ages 0 to 5; 6 to 10; 11 to 14; 15 to 18; 19 to 25; 26 to 35; and so on in 10-year increments). Participants are first asked to rate their average mood during the epoch. They are then asked about locations lived, schools attended, people they were close to, hobbies, medical conditions, medications, hospitalizations, direct and indirect substance use exposure, mental health symptoms, mental health treatment, and important life events. The information is then displayed in an interactive, graphic of the individual's life that is reviewable by the patient and the healthcare providers enrolled in the study that the patient consents to having access.
79548626|NCT05570461|Other|Modified Constraint-Induced Movement Therapy|Experimental group will receive Modified Constraint-Induced Movement Therapyand traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the mCIMT group will be constrained by wearing a mitten during the treatment session and for 3 hours/day outside the therapy hours, 6(six) days/week for two weeks by an experienced Physical therapist.The time duration for Group A will be 40 minutes.
79850153|NCT05176509|Drug|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
79712255|NCT02871973|Behavioral|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
79850154|NCT05176509|Drug|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
79850155|NCT05176509|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
79850156|NCT05176288|Drug|Axitinib|Taken Orally
79850157|NCT05176288|Drug|Palbociclib|Taken Orally
79850158|NCT05176288|Drug|Avelumab|Intravenous infusion
79712256|NCT01263093|Drug|Clopidogrel|
79850159|NCT05173415|Device|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
79850160|NCT05173415|Device|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
79850161|NCT05167565|Other|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
79850162|NCT05167565|Other|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
79850163|NCT05167565|Other|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
79850164|NCT05167565|Other|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
79712257|NCT01263093|Drug|LY2216684|
79253430|NCT05522556|Drug|Ritlecitinib|capsules
79712258|NCT01010971|Drug|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
79712259|NCT01010971|Drug|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
79712260|NCT01010971|Drug|Placebo|Placebo HFA Nasal Aerosol once daily
79850165|NCT05167565|Other|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
79253431|NCT05520086|Drug|Single Dose|Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
79712261|NCT01306656|Drug|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
79712262|NCT01306656|Other|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
79712263|NCT01306656|Dietary Supplement|Vitamin D|Daily multivitamin with 400 IU vitamin D.
79712264|NCT04327908|Other|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
79712265|NCT01008943|Biological|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
79712266|NCT02871271|Dietary Supplement|IQP-AS-121|
79712267|NCT04205071|Drug|Lorcaserin|Given PO
79712268|NCT04205071|Drug|Lorcaserin Hydrochloride|Given PO
79712269|NCT04205071|Other|Questionnaire Administration|Ancillary studies
79712270|NCT01003639|Drug|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
79850166|NCT05167565|Other|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
79850167|NCT05167565|Other|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
79850168|NCT05167565|Other|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
79393054|NCT03165474|Other|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
79393055|NCT03165474|Other|Didactic health information|Didactic health information and resources by email and/or text
79393056|NCT03114774|Device|The bispectral index (BIS) monitoring|
79548627|NCT05570448|Procedure|ARAT|For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
79548628|NCT05570448|Procedure|Sham intervention (control)|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
79850169|NCT05162326|Biological|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
79548629|NCT05570383|Drug|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
79850170|NCT05154448|Device|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
79850171|NCT05154448|Other|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
79253432|NCT05520086|Drug|Double Dose|Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
79253433|NCT05515874|Drug|Feraheme|"Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use."
79393057|NCT03114774|Behavioral|Ramsay Sedation Scale (RSS) Score monitoring|
79393058|NCT02681094|Drug|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
79393059|NCT02681094|Drug|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
79393060|NCT02681094|Drug|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
79393061|NCT02681094|Drug|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
79548630|NCT05570370|Other|This is an observational study|This is an observational study
79548631|NCT05570357|Dietary Supplement|Berberine+Cinnamon|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract, and trace amounts of vitamins and minerals
79712271|NCT01003639|Drug|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
79712272|NCT01003639|Behavioral|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
79850172|NCT05150340|Drug|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
79850173|NCT05150184|Other|Non-interventional|observational study, thus no different arm/groups
79850174|NCT05127681|Radiation|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
79850175|NCT05127681|Biological|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
79850176|NCT05127681|Radiation|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
79850177|NCT05127681|Other|medical data collection|Data of healthy men is already available
79253434|NCT05513703|Biological|Telisotuzumab Vedotin|Intravenous (IV) Infusion
79393062|NCT03164304|Drug|Magnesium Sulfate|intravenous
79393063|NCT02689284|Biological|Margetuximab 10 mg/kg|Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
79393064|NCT02689284|Biological|Margetuximab 15 mg|Margetuximab treatment is administered IV once every 21-day cycle
79393065|NCT02689284|Biological|Pembrolizumab|Pembrolizumab treatment is administered IV once every 21-day cycle
79393066|NCT03165396|Drug|Propofol|Propofol is the most common clinical anesthetics.
79393067|NCT03165396|Drug|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
79548632|NCT05570357|Other|Placebo|Placebo contains Maltodexterin
79548633|NCT05570331|Diagnostic Test|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
79548634|NCT05570318|Drug|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
79548635|NCT05570318|Device|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
79850179|NCT05099341|Other|HDRS-17 depression scale|Measuring the severity of depression
79850180|NCT05099341|Biological|Blood sampling|3 tubes of 5 ml
79253435|NCT05510700|Device|Acupuncture|All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
79548636|NCT05570201|Other|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
79253436|NCT05510700|Device|Sham acupuncture|"The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out."
79253437|NCT05510297|Device|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
79253438|NCT05509231|Behavioral|High-intensity exercise|Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.
79253439|NCT05509231|Device|Wearable glove and arm sleeve device to measure movement|Sign language and other fine motor skills activities using wearable technology.
79253440|NCT05507658|Drug|Tislelizumab combined with Oxaliplatin and Capecitabine|"Drugs:~Tistelizumab 200mg, iv.gtt, D1, Q3W;~Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~Tislelizumab combined with XELOX, Q3W, for 2~3 cycles;~D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~From 4 to 8 weeks after surgery, the treatment dose was the same as above;~Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3~8 cycles;~Tumor evaluation performed every 3 cycles;~The maximum duration of adjuvant therapy was not more than 8 cycles."
79393068|NCT03164382|Drug|FOLFOX regimen|Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
79548637|NCT05570175|Behavioral|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
79548638|NCT05570110|Drug|Enoxolone|one capsule of active or placebo in the evening
79548639|NCT05570084|Drug|Silodosin|Cap silodosin for medical expulsion therapy
79548640|NCT05570084|Drug|Tamsulosin|Cap tamsulosin
79548641|NCT05570019|Procedure|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
79548642|NCT05569993|Drug|Glutamine|.3 mg/kg of glutamine
79548643|NCT05569993|Other|Placcebo|Patients will recieve placcebo
79548644|NCT05569967|Other|Spinal stabilization training through telerehabilitation|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
79548645|NCT05569967|Other|Spinal stabilization training face-to-face|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
79548646|NCT05569850|Other|Brushing|Brushing the teeth 2x a day for 4 weeks.
79548647|NCT05569824|Diagnostic Test|Lateral-flow Device|An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
79850181|NCT05098028|Drug|Low Dose Rifaximin ER|Low Dose Rifaximin Extended Release Twice Daily
79850182|NCT05098028|Drug|Low Dose Rifaximin DER|Low Dose Rifaximin Delayed Extended Release Twice Daily
79850183|NCT05098028|Drug|High Dose Rifaximin ER|High Dose Rifaximin Extended Release Twice Daily
79850184|NCT05098028|Drug|High Dose Rifaximin DER|High Dose Rifaximin Delayed Extended Release Twice Daily
79850185|NCT05098028|Drug|Placebo|Placebo Twice Daily
79850186|NCT05091918|Device|MotionSense|MotionSense Wearable: Remote patient monitoring
79850187|NCT05082753|Drug|Ivermectin tablets (3 mg Ivermectin)|Two Ivermectin tablets were administered orally.
79850188|NCT05082753|Drug|Stromectol ® tablets|Two Ivermectin tablets were administered orally.
79850189|NCT05081986|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
79850190|NCT05081986|Drug|Cycloserine|Cycloserine 100mg
79253441|NCT05498662|Device|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
79253442|NCT05496543|Device|acupuncture|All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.
79393069|NCT03164382|Drug|Sorafenib 200Mg Tab|Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
79393070|NCT03161340|Drug|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
79393071|NCT03164148|Device|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
79581012|NCT01931592|Drug|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
79850191|NCT05081986|Drug|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
79850192|NCT05079451|Drug|3BNC117-LS|3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
79393072|NCT04714320|Drug|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
79850193|NCT05079451|Drug|10-1074-LS|10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
79850194|NCT05064540|Device|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
79253443|NCT05496543|Device|sham acupuncture|"The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle."
79253444|NCT05488665|Device|Crush technique|Treatment for bifurcation with the Crush technique
79393073|NCT04714320|Drug|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
79850195|NCT05064540|Device|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
79850196|NCT05053737|Drug|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
79850197|NCT05053737|Radiation|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
79850198|NCT05048004|Procedure|QMODE intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).
79850199|NCT05048004|Procedure|QMODE+ intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
79875162|NCT00465972|Drug|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
79875163|NCT00465972|Drug|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
79253445|NCT05488665|Device|Culotte technique|Treatment for bifurcation with the culotte technique
79253446|NCT05488535|Device|cochlear implant headpiece|investigational cochlear implant headpiece
79253447|NCT05479994|Drug|BGB-11417|Administered orally
79393074|NCT03161262|Behavioral|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
79393075|NCT02676882|Dietary Supplement|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
79393076|NCT03161418|Drug|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
79393077|NCT03161418|Drug|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
79393078|NCT03161496|Genetic|detection of genotype|detection of genotype by next generation sequencing
79393079|NCT03161574|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
79393080|NCT03163914|Drug|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
79850200|NCT05047003|Diagnostic Test|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
79850201|NCT05043987|Drug|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
79393081|NCT03163914|Drug|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
79393082|NCT03163914|Drug|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
79850202|NCT05040932|Drug|YH004|IV infusion once every 3 weeks (Q3W).
79393083|NCT03163914|Drug|Saline|saline infusion will apply till the end of the surgery
79850203|NCT05038735|Drug|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
79850204|NCT05038735|Drug|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
79850205|NCT05038735|Drug|Alpelisib-matching placebo|Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
79850206|NCT05021484|Drug|Felzartamab|Intravenous infusion in regular intervals over 6 months
79850207|NCT05021484|Drug|Placebo|Intravenous infusion in regular intervals over 6 months
79850208|NCT05019885|Drug|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
79548648|NCT05569785|Other|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
79850209|NCT05019274|Other|Culinary Medicine Intervention|Participants randomized to the Culinary Medicine intervention will complete a series of 6 virtual culinary medicine cooking classes (1 class per month for 6 months). Virtual sessions will be delivered via Zoom using a combination of large group instruction and small group break-out sessions in which participants prepare a recipe in their home kitchen with the virtual assistance from trained group facilitators. After preparing the dish, participants will enjoy the dish they prepared and report-back to the large group about their dish and experience. Classes will be conducted in English and Spanish with language-concordant instructors and facilitators.
79850210|NCT05019274|Other|Standard of Care Nutrition Visits|Participants randomized to standard of care nutrition visits will complete a series of 6 nutrition visits (1 session per month for 6 months) led by bilingual (English/Spanish) dieticians. Sessions will consist of a mix of individual and small group sessions per standard of care in the clinic.
79850211|NCT05006443|Diagnostic Test|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
79850212|NCT05005429|Drug|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
79393084|NCT05676138|Other|Measuring PK and PD indices in patients who receive conventional treatment|Measuring plasma concentration of commonly used antibiotics in NTM-PD
79393085|NCT04700202|Other|Observational|Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
79393086|NCT04693650|Device|NeuroBlock UHF stimulation|NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
79393087|NCT04676724|Drug|GSK3228836|Participants will be administered GSK3228836.
79393088|NCT04676724|Drug|PegIFN|Participants will be administered PegIFN.
79393089|NCT04676724|Drug|NA therapy|Participants will continue to receive their NA therapy for the duration of the study.
79393090|NCT03160950|Device|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany)."
79393091|NCT03160872|Diagnostic Test|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
79393092|NCT03163680|Drug|Omeprazole 40 MG|Omperazole 40 mg twice daily
79850213|NCT05002270|Drug|JAB-21822 (KRAS G12C inhibitor)|Administered orally
79850214|NCT05002270|Drug|JAB-21822 (KRAS G12C inhibitor)|Administered orally
79850215|NCT05002270|Drug|JAB-21822 (KRAS G12C inhibitor)|Administered orally
79850216|NCT05002270|Drug|Cetuximab (EGFR inhibitor)|Administered IV
79850217|NCT04995588|Other|Blood test|Unique blood draw of 45mL for all the participants
79393093|NCT05180448|Behavioral|Coach Share On|If an index participant is randomized to have Coach Share ON, the coach will have continuous access to objective, real-time, detailed device data, and address data directly in all individual interactions with index participants (groups, individual weigh-ins, phone calls, texts), conveying that they are closely monitoring progress.
79712273|NCT01003249|Drug|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
79850218|NCT04989647|Radiation|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
79850219|NCT04989647|Radiation|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
79393094|NCT05180448|Behavioral|Group Share On|If Group Share is ON, participants in a given LM group will view and respond to aspects of each other's self-monitoring device data in their small-group text messages. Each small group participant's data will be highlighted one day of the month, and content from the Group Share Off message library also will be sent.
80017187|NCT05714540|Drug|Ketamine Hydrochloride ,Magnesium sulphate and saline 0.9%|The Effect of Oropharyngeal Pack Soaked with Ketamine or Magnesium Sulphate on Post Operative Sore Throat after Nasal Surgeries
79875164|NCT00465972|Drug|Placebo|Placebo capsule nightly for duration of study
80017188|NCT04385667|Device|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
79393095|NCT05180448|Behavioral|Friend/Family Share On|Index participants who are randomized to have Friend/Family Share ON will give their friend or family member access to their self-monitoring data. Text messages sent by the program bot, which includes the index participant and friend/family member, will use a similar format as described in Group Share ON. The friend or family member will be trained to respond to data in ways that enhance the participant's motivation and self-regulation.
80017189|NCT04385667|Drug|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
79875165|NCT03926754|Drug|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
79253448|NCT05478720|Drug|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
79548649|NCT05569720|Drug|ApTOLL|"ApTOLL will be administered as follows:~Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."
79548650|NCT05569707|Device|Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag|In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® & DiffMag) in combination with SPIO particles (Magtrace®).
79548651|NCT05569668|Drug|Paclitaxel- and platinum-based chemotherapy|Neoadjuvant Chemotherapy
79548652|NCT05569655|Drug|Tolvaptan|Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.
79548653|NCT05569655|Drug|Furosemide|Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
79712274|NCT01003249|Drug|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
79875166|NCT00465894|Drug|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
79875167|NCT00465894|Drug|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
79875168|NCT00330460|Drug|Alendronate|ALN; 70 mg; oral; once weekly
80017190|NCT02103894|Drug|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an [18F]MNI-777 PET imaging visit. For individuals with AD or CTE, [18F]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by [18F]florbetapir imaging) and tau protein uptake (measured by [18F]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, [123I]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
80017191|NCT04441346|Radiation|Echocardiography|test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
79875169|NCT00330460|Drug|Denosumab|60 mg; SC; every 6 months
79253449|NCT05478720|Drug|Placebo|Single intravenous dose of saline
79253450|NCT05478720|Drug|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
79253451|NCT05474755|Drug|GP681 40mg|2X20mg tablets taken orally
79253452|NCT05474755|Drug|Placebo|Placebo tablets matching GP681 40mg
79253453|NCT05473975|Procedure|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
79393096|NCT05180448|Behavioral|Coach Share Off|Among index participants who are randomized to have Coach Share OFF, the coach will have no access to their device data. Index participants will be explicitly told their coach does not have data access. During groups and phone calls, the participant will self-report progress, and goal setting will be based on that self-report. Text messages from the coach will be personalized in the OFF condition, as they are when coach data sharing is ON, though these messages will not be informed by device data. Instead, text messages will provide a reminder of key goals and strategies discussed in the previous phone call and provide encouragement for participant efforts.
79393097|NCT05180448|Behavioral|Group Share Off|Among index participants randomized to have Group Share OFF, supportive accountability will not be the target of participant interactions and no data will be shared with LM program peers. Instead, once weekly prompts for small group text exchanges will encourage index participants to provide social support (primarily of the informational type) to each other. Index participants will be explicitly told that they should not include information on goal progress such as weight change or minutes of PA.
79253454|NCT05472792|Radiation|Accelerated Partial Breast Irradiation (APBI)|Radiation treatment delivered to the lumpectomy cavity.
79850222|NCT04965064|Drug|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
79850223|NCT04952584|Biological|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
79393098|NCT05180448|Behavioral|Friend/Family Share Off|If an index participant is randomized to Friend/Family Share OFF, the text messages from the bot will prompt the participant and friend/family member to communicate about the LM program; those messages will be standardized, except for names, and will not be tailored to index participant progress. Index participants will be instructed to refrain from sharing any device data with friends or family members.
79850224|NCT04938024|Dietary Supplement|Vitamin C|Vitamin C is a commercially available over-the-counter food supplement.
79393099|NCT05180448|Behavioral|Behavioral Weight Loss Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
79850225|NCT04912895|Device|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
79548654|NCT05569616|Other|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
79850226|NCT04899778|Drug|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
79850227|NCT04892706|Drug|IDP-126 Gel|Gel applied to face once daily in the evening.
79253455|NCT05472792|Drug|tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene|Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
79253456|NCT05472714|Other|Educational Video|We will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
79548655|NCT05569616|Other|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
79712275|NCT04297033|Drug|Lovastatin|lovastatin 40mg/d 12m
79253457|NCT05465161|Device|Sting Mark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
79712276|NCT04297033|Drug|Placebo|placebo
79712277|NCT01001767|Drug|Lovaza|Lovaza one gram twice a day for 24 weeks
79712278|NCT01001767|Drug|Placebo|Placebo
79712279|NCT04338295|Device|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
79253458|NCT05463783|Drug|Biktarvy|microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
79253459|NCT05463783|Drug|Symtuza|microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
79253460|NCT05463224|Drug|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
79712280|NCT04294537|Procedure|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
79850228|NCT04892706|Drug|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
79253461|NCT05461794|Drug|Sitravatinib|administered orally
79850229|NCT04892706|Drug|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
79850230|NCT04880772|Other|Prehabilitation|exercise & multivitamin (nutritional/dietary advice)
79850231|NCT04872517|Device|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
79850232|NCT04870762|Other|Best Practice|Receive standard of care
79850233|NCT04870762|Other|Medical Device Usage and Evaluation|Wear 3D printed oral stent
79393100|NCT03163836|Procedure|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
79393101|NCT03163836|Procedure|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
79548656|NCT05569603|Behavioral|Chronobiology-guided lifestyle interventions|1) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
79548657|NCT05569590|Drug|Propolis|Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
79548658|NCT05569590|Drug|hydrogen peroxide 35%|hydrogen peroxide 35%
79548659|NCT05569590|Other|fluoride varnish|fluoride varnish
79548660|NCT05569577|Drug|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
79850234|NCT04862208|Dietary Supplement|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
79850235|NCT04862208|Dietary Supplement|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
79253462|NCT05461794|Drug|Tislelizumab|administered intravenously
79253463|NCT05461794|Drug|Docetaxel|administered intravenously
79253464|NCT05461794|Drug|Irinotecan|administered intravenously
79253465|NCT05457244|Device|single-port robotic surgery|Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
79548661|NCT05569577|Drug|estrogen and dydrogesterone|estrogen and dydrogesterone
79253466|NCT05456308|Procedure|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
79253467|NCT05453604|Device|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
79548662|NCT05569564|Procedure|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
79548663|NCT05569564|Procedure|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
79548664|NCT05569473|Procedure|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
79548665|NCT05569460|Other|No intervention|No intervention
79548666|NCT05569434|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
79712281|NCT04294537|Procedure|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
79712282|NCT04294537|Procedure|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
79850236|NCT04862208|Dietary Supplement|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
79850237|NCT04862208|Dietary Supplement|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
79253468|NCT05446194|Device|Non invasive neuromodulation device pattern 1|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
79393102|NCT04440306|Procedure|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
79393103|NCT03114696|Dietary Supplement|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
79548667|NCT05569369|Procedure|angioplasty and stenting|dilatation of stenotic arteries and insertion of stent
79548668|NCT05569356|Biological|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
79875170|NCT03979768|Other|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
79253469|NCT05446194|Device|Non invasive neuromodulation device pattern 2|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
79253470|NCT05441345|Other|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
79548669|NCT05569356|Other|Retrospective|None (only data collection)
79548670|NCT05569343|Other|No intervention|This is an observational study without any intervention
79548671|NCT05569330|Other|Air purification|Aerosol particles are removed from room air by several methods
79548672|NCT05569304|Procedure|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
79850238|NCT04860128|Behavioral|Sports technology application|Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
79393104|NCT03114696|Dietary Supplement|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
79253471|NCT05432999|Device|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
79393105|NCT05676060|Combination Product|quasi|block facet joint in back pain due to afacet cause
79253472|NCT05427981|Drug|Belbuca Buccal Product|Buprenorphine Buccal Films
79850239|NCT04858789|Behavioral|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
79850240|NCT04857658|Procedure|extraction orthodontic treatment plan|patients will be referred for extraction of the upper and lower first premolars then orthodontic treatment will follow.
79850241|NCT04855903|Device|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
79850243|NCT04843982|Drug|Esketamine hydrochloride|After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
79393106|NCT05675982|Other|CAR-T cells monitoring|monitoring of circulating DNA by blood sample
79393107|NCT05675904|Procedure|Colon oncological resection|Scheduled colon cancer surgery
79712283|NCT04294537|Drug|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
79850244|NCT04836390|Drug|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
79253473|NCT05427981|Other|Placebo|Placebo Buccal Films
79850245|NCT04833699|Other|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
79253474|NCT05424718|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
79253475|NCT05424315|Drug|Dapagliflozin 10mg|10mg Tab once daily
79393108|NCT03114540|Drug|GBT440|Oral
79393109|NCT03163524|Other|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
79875171|NCT01062490|Drug|Treosulfan|14 g/m2/d, day -6 to -4
79875172|NCT00454116|Drug|Vandetanib|once daily oral tablet two doses
79393110|NCT03163524|Other|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
79548673|NCT05569239|Biological|OVX836 480µg|One single administration intramuscularly at Day 1.
79548674|NCT05569239|Biological|Saline Solution|One single administration intramuscularly at Day 1.
79548675|NCT05569213|Diagnostic Test|motor evoked potentials|see previous descriptions
79253476|NCT05424315|Drug|Glucose Tab|Placebo Oral Tablet
79253477|NCT05424146|Dietary Supplement|Prebiotic Bar +CPT|Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.
79253478|NCT05424146|Behavioral|Non-Prebiotic Bar +CPT|Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.
79548676|NCT05569200|Device|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
79548677|NCT05569135|Device|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
79548678|NCT05569109|Device|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
79850246|NCT04827940|Other|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
79850247|NCT04824599|Procedure|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
79253479|NCT05420740|Device|Aerobika OPEP|Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
80017192|NCT03657615|Device|hearing aid fitting|All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
79850248|NCT04824599|Procedure|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
80017193|NCT04413136|Behavioral|Web-ORLA|
79850249|NCT04824599|Procedure|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
79850250|NCT04824599|Drug|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
79850251|NCT04824599|Device|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
79850252|NCT04817800|Drug|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
79850253|NCT04807218|Behavioral|Virta Health|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
79850254|NCT04804839|Other|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
79850255|NCT04804839|Other|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
79850256|NCT04804839|Other|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
79850257|NCT04804813|Drug|Cabozantinib|Cabozantinib tablets
79850258|NCT04802408|Combination Product|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
79850259|NCT04802408|Combination Product|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
80017194|NCT04413136|Behavioral|Control|
80017195|NCT02101320|Device|TRECAM|using the camera during the surgery
80017196|NCT04441424|Biological|Convalescent plasma|400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
79404269|NCT02785471|Behavioral|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
79548679|NCT05569096|Diagnostic Test|ELIZA , Flowcytometry|CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.
79875173|NCT00454116|Drug|FOLFIRI|Intravenous infusion
79253480|NCT05419531|Other|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
79253481|NCT05419466|Dietary Supplement|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm|dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
79253482|NCT05418101|Drug|VIS171|Participants will receive VIS171 via SC route of administration.
79253483|NCT05418101|Drug|Placebo|Participants will receive Placebo via SC route of administration
79253484|NCT05417282|Drug|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
79875174|NCT00465816|Biological|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
79875175|NCT00465816|Biological|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
79875176|NCT00465738|Drug|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
79712284|NCT04296721|Behavioral|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
79548680|NCT05569031|Drug|Venlafaxine|patients with tramadol abuse will use venlafaxine for 10 days.
79850260|NCT04802408|Combination Product|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
79548681|NCT05569031|Drug|Lofexidine|patients with tramadol abuse will use lofixidine for 10 days.
79548682|NCT05568875|Other|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
79850261|NCT04802408|Combination Product|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
79850262|NCT04776720|Behavioral|Yoga Practice Program|3 month group yoga classes
79850263|NCT04776720|Behavioral|Physical Conditioning Program|3 month group physical conditioning classes
79253487|NCT05412121|Device|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
79548683|NCT05568875|Other|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
79712285|NCT04296721|Behavioral|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
79712286|NCT04294615|Other|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
79850264|NCT04749693|Device|DBLG1 System|Use of DBLG1 System in real life condition
79548684|NCT05568823|Other|Blood sampling|Measurement of markers of disease evolution
79712287|NCT04294615|Other|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
79712288|NCT02871037|Drug|PF-05221304|Single or repeated, escalating dose of PF-05221304
79712289|NCT02871037|Other|Placebo|single or repeated dose of placebo
79581013|NCT01931592|Drug|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
79581014|NCT01931605|Device|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
79712290|NCT04295629|Procedure|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
79253488|NCT05410145|Drug|D3S-001|Oral
79253489|NCT05409274|Other|No Intervention|No Intervention
79850265|NCT04740593|Other|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
79850266|NCT04740593|Other|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
80017197|NCT04441424|Drug|Hydroxychloroquin with Azithromycin|The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
79253490|NCT05400915|Drug|Variltinib, Paclitaxel|Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
79850267|NCT04740593|Other|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
79850268|NCT04725890|Device|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
79548685|NCT05568771|Other|Core Exercises Assisted Injury Prevention Training Program|After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
79548686|NCT05568732|Procedure|Root coverage procedure will be done with VCMX|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
79253491|NCT05399992|Other|Inclisiran|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive inclisiran are eligible to enroll into this study.
79253492|NCT05391230|Other|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
79850269|NCT04712318|Procedure|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
79253493|NCT05391230|Other|Untreated lesu|Water soaked baby wraps (lesus)
79581015|NCT01931618|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
79712291|NCT04295629|Procedure|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
79712292|NCT04282681|Other|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
79875177|NCT00400179|Drug|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
79253494|NCT05386706|Behavioral|Digital Intervention|This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
79253495|NCT05386706|Drug|Metformin|Traditional metformin monotherapy.
79253496|NCT05383469|Other|Exercise Training|Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises
79253497|NCT05383469|Other|Massage|Classical massage including superficial and deep stroking and friction methods for the lower extremity.
79253498|NCT05383469|Other|Neuromuscular Electrical Stimulation|Symmetrical biphasic current at a frequency of 30-85 Hz
79253499|NCT05383469|Other|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
79253500|NCT05380531|Diagnostic Test|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
79253501|NCT05377554|Drug|ALM-488|ALM-488 will be infused during the pre-operative period.
79253502|NCT05377554|Other|Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay|Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.
79253503|NCT05377554|Other|Intra-operative Visualization using White Light Reflectance (WLR)|Intra-operative real time nerve visualization will be undertaken using WLR.
79253504|NCT05377281|Procedure|Peripheral Nerve Tissue Implantation|At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epinerium is removed, fascicles are cut, and (~5 pieces per side; ~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
79253505|NCT05376319|Drug|Obinutuzumab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
79253506|NCT05376319|Drug|Rituximab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
79393112|NCT02674386|Drug|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
79393113|NCT04574232|Drug|knee intra-articular infiltration with Triamcinolone acetonide|knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
79393114|NCT03163290|Other|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
79393115|NCT03163290|Other|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
79875178|NCT00400179|Drug|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
79548687|NCT05568732|Procedure|Root coverage procedure will be done with CTG|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
79548688|NCT05568693|Biological|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
80017198|NCT03657537|Drug|Ketone infusion|β-hydroxybutyrate is infused intravenously.
79548689|NCT05568628|Device|ultrasound|screening of breast lesions by ultrasonography
79393116|NCT05071716|Drug|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
79393117|NCT05071716|Drug|Placebo|Placebo Twice Daily
79393118|NCT05064618|Drug|Am80|medicine taken internally
79393119|NCT02680002|Biological|7.5 mcg H5N1 (stored as monobulk)|
79393120|NCT02680002|Biological|15 mcg H5N1 (stored as monobulk)|
79581016|NCT01931618|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
79712293|NCT01306032|Drug|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
79712294|NCT01306032|Drug|Cyclophosphamide|
79712295|NCT01263015|Drug|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
79712296|NCT01263015|Drug|Atripla|Atripla once daily on an empty stomach
79712297|NCT01263015|Drug|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
79712298|NCT01263015|Drug|Abacavir/Lamivudine Placebo|matching placebo taken once daily
79712299|NCT01263015|Drug|Dolutegravir placebo|matching placebo taken once daily
79712300|NCT01263015|Drug|Atripla placebo|matching placebo taken once daily on an empty stomach
79712301|NCT04323267|Device|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
79712302|NCT04323267|Behavioral|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
79712303|NCT04322877|Procedure|Temporary pacing Study|Temporary delivery of CRT
79712304|NCT04322877|Radiation|Thoracic CT|As part of non-invasive mapping protocol
79712305|NCT04322877|Diagnostic Test|Acute hemodynamic study|Measurement of invasive dP/dTmax
79712306|NCT04322877|Diagnostic Test|Non-invasive body surface mapping|Cardioinsight body surface mapping
79712307|NCT04322877|Diagnostic Test|Invasive catheter-based mapping|Invasive electroanatomical mapping
79712308|NCT04322799|Procedure|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
79712309|NCT04322175|Drug|Meloxicam|Meloxicam Eye Drops
79875179|NCT00465270|Device|AMPLATZER PFO Occluder|patent foramen ovale closure device
79875180|NCT00465270|Other|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
79875181|NCT00464568|Drug|GSK256066|
79277373|NCT05724745|Diagnostic Test|1. Standard spirometry|Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
79277374|NCT05724745|Diagnostic Test|2. 3D dynamic lung MRI at UTE in prone and supine positions|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
79277375|NCT05724745|Drug|3. Reversibility test with salbutamol|Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
79277376|NCT05724745|Diagnostic Test|4. 3D dynamic lung MRI at UTE in supine and prone position|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
79393121|NCT02680002|Biological|90 mcg H5N1 (stored as monobulk)|
79393122|NCT02680002|Biological|90 mcg H5N1 (stored in vials)|
79393123|NCT02680002|Other|MF59|
79393124|NCT02680002|Other|MF59 (stored as monobulk)|
79875182|NCT00464490|Drug|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
79393125|NCT04557384|Drug|Ramucirumab|Administered SC
79393126|NCT02673684|Device|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
79393127|NCT02673684|Device|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
79393128|NCT05063448|Behavioral|DadSpace|A group educational support and mentoring program for perinatal fathers.
79404270|NCT01670305|Procedure|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
80017199|NCT03657537|Drug|Saline infusion|saline is infused intravenously.
80017200|NCT02103972|Dietary Supplement|GM080|
80017201|NCT02103972|Dietary Supplement|Maltodextrin|
79253507|NCT05371834|Device|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
79253508|NCT05371834|Device|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
79548690|NCT05568251|Device|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
79253509|NCT05369585|Dietary Supplement|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
79548691|NCT05568251|Procedure|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
79548692|NCT05568108|Procedure|masseteric nerve to central branch facial nerve|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
79850270|NCT04712318|Procedure|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
79850271|NCT04695054|Device|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
79850272|NCT04695054|Drug|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
79850273|NCT04694482|Other|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
79850274|NCT04693663|Procedure|Relex-Smile surgery|surgery using Relex-Smile
79850275|NCT04675151|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
79850276|NCT04675151|Drug|Pilocarpine|Pilocarpine ophthalmic solution
79850277|NCT04675151|Other|Placebo|Topical sterile ophthalmic solution
79875183|NCT01022034|Procedure|sacral rectopexy with sutures or meshes|
79253510|NCT05367609|Diagnostic Test|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
79253511|NCT05367271|Drug|Botulinum Toxin A|20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
79253512|NCT05367271|Drug|Dexamethasone|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
79253513|NCT05365594|Device|Controlled Ankle Movement Boot|Walking boot used for orthopaedic foot injuries
79253514|NCT05365594|Device|EVENUp Lift|Orthotic shoe lift worn on contralateral foot to increase leg length
79393129|NCT03161184|Behavioral|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
79404271|NCT01670305|Procedure|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
79404272|NCT01670305|Procedure|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
79404273|NCT01670305|Procedure|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
79548693|NCT05568108|Procedure|Masseteric nerve to free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
79548694|NCT05567445|Diagnostic Test|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
79548695|NCT05566249|Device|ArtiSential|Articulating laparoscopic instrument
79548696|NCT05564975|Other||
79548697|NCT05564741|Drug|Norepinephrine 1 MG/ML|As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
79875184|NCT01022034|Procedure|full rectal mobilization from the sacrum without sacral rectopexy|
79875185|NCT03849300|Other|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
79875186|NCT03849300|Other|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
79712310|NCT01305564|Device|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
79712311|NCT04322331|Other|no intervention|no intervention
79712312|NCT04322253|Drug|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
79712313|NCT04324671|Device|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
79712314|NCT04322409|Device|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
79712315|NCT04322409|Device|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
79712316|NCT04321785|Other|Placebo|placebo capsule (mannitol)
79712317|NCT04321785|Other|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
79712318|NCT05648175|Behavioral|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
79712319|NCT05648175|Behavioral|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
79548698|NCT05560880|Behavioral|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
79548699|NCT05560880|Behavioral|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
79712320|NCT05648175|Behavioral|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
79253515|NCT05364606|Device|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
79253516|NCT05364554|Drug|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
79548700|NCT05556382|Radiation|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
79548701|NCT05531084|Device|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
79712321|NCT01305408|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
79712322|NCT01305408|Drug|Placebo|Matching placebo tablets, taken orally, once daily in the morning
79712323|NCT01261611|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
79712324|NCT01261611|Biological|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
79253517|NCT05357222|Behavioral|Straw phontion|"Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection."
79253519|NCT05354830|Other|Foot Massage|Foot Massage
79548702|NCT05522582|Drug|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
79548703|NCT05522582|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
79548704|NCT05522582|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
79548705|NCT05491304|Drug|Dexamethasone|Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
79548706|NCT05491304|Drug|Etoposide|Used in severe group combined with etoposide.
79548707|NCT05491304|Drug|Ruxolitinib|Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
79712325|NCT01261611|Drug|Placebo|I.M. injection on day 1 of treatment cycle 1.
79712326|NCT04321629|Combination Product|autologous adipose tissue transfer|experimental group: liposuction, adipose tissue preparation and intra-articular injection
79393130|NCT03161184|Behavioral|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
79393131|NCT02675634|Device|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
79712327|NCT04321629|Combination Product|PRP injections|control group: blood collection, blood preparation and intra-articular PRP injection
79850278|NCT04674670|Drug|Bromocriptine Mesylate Capsules|Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
79850279|NCT04674670|Drug|Amisulpride 400 MG|Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
79850280|NCT04674670|Drug|Placebo|Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
79253520|NCT05353465|Procedure|Radiofrequency denervation of the cervical facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the cervical facet joint with a three-tined expandable needle.
79253521|NCT05347888|Other|Nutritional therapy|Either enteral or parenteral nutrition is used for the patient admitted in the ICU
79253522|NCT05345587|Other|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
79393132|NCT02675634|Device|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
79393133|NCT02675634|Device|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
79393134|NCT05373654|Other|F-SUS Questionnaire|"This F-SUS questionnaire uses a Likert scale including 5 possible responses ranging from  I do not agree at all to  I completely agree  (Celenza A 2011, Croasmun JT 2011). The F-SUS is a short questionnaire with 10 questions (Brooke J 2013). In its original version half of the questions express strong agreement and the other half disagreement. Thus, all the even-numbered items (2, 4, 6, 8, 10) allow the participant to express a very negative opinion (disagreement). On the other hand, the odd-numbered items allow the participant to express a very positive opinion (strong agreement)."
79548708|NCT05453643|Behavioral|sleep deprivation patterns|Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings
79548709|NCT05435417|Radiation|CBCT radiation|CBCT scanning
79712328|NCT04321863|Other|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
79712329|NCT04321863|Other|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
79712330|NCT04321863|Other|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
79712331|NCT04321707|Radiation|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
79253523|NCT05322473|Drug|Sonelokimab (M1095)|randomized treatment; parallel-group
79253524|NCT05322473|Drug|Adalimumab|randomized treatment; parallel-group
79253525|NCT05322473|Other|Placebo|randomized treatment; parallel-group
79712332|NCT04321083|Diagnostic Test|INVOS|INVOS monitoring brain o2 saturation
79253526|NCT05316220|Drug|Mesalamine|Oral Capsules
79253527|NCT05316220|Drug|Placebo|Oral Capsule
79253528|NCT05311878|Device|EEG-based perceptual training|Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
79277377|NCT02375451|Other|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
79277378|NCT02198339|Drug|BIBN 4096 BS|
79850281|NCT04666259|Drug|ABL001|Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
79875187|NCT03849300|Other|Land-based walking exercise group|12 week land-based walking exercise program
79850282|NCT04639674|Drug|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
79253529|NCT05311878|Device|Behavior based perceptual training|Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
79253530|NCT05311085|Drug|Cytisine|"Standard dosing of:~days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~days 13-16: one tablet every three hours (four tablets/day)~days 17-20: one tablet every 4-5 hours (three tablets/day)~days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
79253531|NCT05311085|Drug|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
79393135|NCT05373654|Other|Interview (only for dissatisfied patients)|"Patients that are dissatisfied with the recharge procedure (Score F-SUS < 70/100) will be invited to a so-called complementary information interview (an interview after the questionnaire has been completed).~The corpus (the study group that will be interviewed) will naturally be diverse men/women, patients who were improved or not by stimulation, implanted with a rechargeable stimulator directly/replacing a stimulator, different brands of stimulator… The patient must agree to the interview and the way it will be performed (signature of consent form). The interview may be face-to -face at the site or by remote videoconference depending on the wishes and availability of the patient. There is no payment for these interviews but travelling or videoconference expenses are reimbursed All interviews will be audio- taped for further qualitative analysis."
79277379|NCT02198339|Drug|Placebo|
79277380|NCT05724667|Other|Flippin' Pain Seminar Series|A chronic pain education campaign
79277381|NCT02198807|Drug|Fosmidomycin-Piperaquine|
79393136|NCT05231850|Drug|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
79393137|NCT03163212|Dietary Supplement|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
79393138|NCT05007678|Drug|leflunomide|leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
79393139|NCT03114384|Other|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
79393140|NCT03161106|Dietary Supplement|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
79393141|NCT03161106|Drug|Lactulose|Lactulose plus diet consumed by patient
79393142|NCT03161106|Dietary Supplement|Diet|Protein Powder 15 to 20 gm/meal/day
79548710|NCT05419570|Other|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
79548711|NCT05391555|Drug|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
79548712|NCT05391555|Device|Pupillometry measurement|The pupil will be examined with the pupillometer at regular intervals, before during and after the opioid infusion
79548713|NCT05387798|Drug|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
79548714|NCT05384457|Other|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
79548715|NCT05384457|Other|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
79548716|NCT05320471|Other|This is an observational study|This is an observational study
79548717|NCT05306275|Drug|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
79548718|NCT05230004|Device|iFIT prosthesis|An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.
79548719|NCT05197634|Other|Not Applicable (observation)|Questionnaire
79548720|NCT05190744|Drug|PB|500mg BID followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.
79548721|NCT05159765|Device|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
79548722|NCT05159765|Device|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
79548723|NCT05137080|Drug|Dexamethasone|24mg dexamethasone
79548724|NCT05137080|Drug|Isotonic saline|Isotonic saline
79712333|NCT04321161|Drug|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
79850283|NCT04629547|Drug|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
79850284|NCT04629547|Drug|Placebo|Placebo will be taken nightly for 24 months.
79850285|NCT04620174|Other|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
79850286|NCT04620174|Other|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
79850287|NCT04616144|Device|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
79253532|NCT05311085|Combination Product|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~days 13-16: one tablet every three hours (four tablets/day)~days 17-20: one tablet every 4-5 hours (three tablets/day)~days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
79712334|NCT04207125|Behavioral|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
79712335|NCT04320771|Drug|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
79253533|NCT05310435|Device|Single volume measurement with ESD|Single volume measurement with Edema Stocking device
79712336|NCT04320693|Drug|IMMU-132|IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
79850288|NCT04604314|Device|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
79850289|NCT04604301|Device|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
79850290|NCT04599907|Device|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
79850291|NCT04599907|Device|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
79850292|NCT04599907|Device|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
79850293|NCT04598074|Other|Opioid Package Prototype (OPP)|The Opioid Package Prototype (OPP) is a child-resistant/senior-friendly, calendar-blister packaging of limited pill counts with flat readable billboard space for medication labeling.
79850294|NCT04598074|Other|Usual Care (standard amber vial)|The standard amber vial (orange bottle) is the container that medication is normally dispensed in outside of the study.
79850295|NCT04596293|Drug|BBT-401-1S or Placebo|Administered by 200mg capsules of BBT-401-1S or placebo
79850296|NCT04594512|Other|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
79850297|NCT04593186|Procedure|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
79850298|NCT04592887|Radiation|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
79850299|NCT04585750|Drug|PC14586|First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.
79850300|NCT04585750|Drug|pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
79850301|NCT04580667|Other|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
79253534|NCT05310435|Device|Single volume measurement with WDV|Single volume measurement with water displacement volumetry method
79253535|NCT05310435|Device|Single circumference measurement with tape measure|Single circumference measurement with tape measure
79253536|NCT05310435|Device|Continuous volume measurement with ESD|Continuous volume measurement with Edema Stocking device
79253537|NCT05304390|Behavioral|Patient Navigation|Receive patient navigation intervention
79850302|NCT04580251|Procedure|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
79850303|NCT04574167|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
79850304|NCT04574167|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
79850305|NCT04570930|Behavioral|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity [step] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
79393143|NCT02671500|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
79253538|NCT05304390|Other|Questionnaire Administration|Ancillary studies
79393144|NCT03163056|Behavioral|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
79712337|NCT05555433|Other|NO INTERVENTION|no intervention
79253539|NCT05304390|Behavioral|Smoking Cessation Intervention|Receive an intervention for smoking cessation
79712338|NCT05554107|Other|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
79712339|NCT00624039|Other|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
79712340|NCT05523141|Drug|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
79253540|NCT05304390|Procedure|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
79712341|NCT05523141|Drug|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
79253541|NCT05303519|Drug|safusidenib|safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
79253542|NCT05300737|Other|intensive medical therapy|Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
79393145|NCT03163056|Behavioral|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
79404274|NCT01670305|Procedure|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
79404275|NCT05108142|Other|Dietary intervention|fresh, hot pasta and re-heated pasta
79548725|NCT05099835|Drug|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
79548726|NCT05099835|Drug|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
79548727|NCT05094245|Procedure|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
79548728|NCT05086094|Drug|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
79712342|NCT01304706|Drug|Fluocinolone Acetonide|0.2 μg/day
79712343|NCT05661240|Device|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
79712344|NCT05661240|Drug|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
79712345|NCT05661162|Device|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
79712346|NCT04324866|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
79712347|NCT00624117|Behavioral|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
79850306|NCT04570930|Behavioral|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
79850307|NCT04570371|Behavioral|Conversation Guide + Clinical Support|The intervention is a bundled intervention (conversation guide + clinician decision support tools) which promotes the solicitation and use of patient preferences for post-surgical, non-pharmacological pain management strategies.
79875188|NCT00412893|Drug|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
79253543|NCT05298384|Other|Compression stockings|Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
79253544|NCT05296421|Procedure|Biopsy|Undergo biopsy
79253545|NCT05296421|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79253546|NCT05296421|Other|Uniformly-labeled [13C]glucose|Given IV
79253547|NCT05294731|Drug|BGB-16673|BGB-16673 will be orally administered as per dosage needs
79253548|NCT05291676|Biological|Fluzone|Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
79850308|NCT04567264|Device|StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).|"Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each."
79712348|NCT05370651|Device|BTL Emsella Chair|Subjects will sit on the device. The RNC will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
79712349|NCT02889003|Drug|Pioglitazone + TKI|
79712350|NCT01303380|Drug|Canakinumab|
79712351|NCT01008553|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
79850309|NCT04564703|Drug|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
79393146|NCT03163056|Behavioral|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
79393147|NCT04177290|Drug|Sintilimab (M1b)|Intravenous infusion
79393148|NCT04177290|Drug|Sintilimab (approved)|Intravenous infusion
79393149|NCT02671266|Drug|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
79712352|NCT01008553|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
79850310|NCT04562805|Device|DynamX Bioadaptor|DynamX Bioadaptor Treatment
79253549|NCT05291676|Biological|Fluad|Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
79253550|NCT05289908|Drug|Pemetrexed (1)|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
79253551|NCT05289908|Drug|Pemetrexed (2)|The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
79393150|NCT02671266|Drug|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
79393151|NCT03160482|Diagnostic Test|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
79548729|NCT05046899|Device|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
79548730|NCT05046899|Device|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
79712353|NCT00623454|Behavioral|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
79712354|NCT05137041|Device|ITP FIRTECH|Infrared Therapy Patch
80017202|NCT04470362|Device|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
79850311|NCT04562805|Device|Resolute Onyx|Resolute Onyx Treatment
79850312|NCT04555226|Procedure|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
79875189|NCT00412893|Drug|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
79548731|NCT05043415|Procedure|Immediate endoscopic necrosectomy|In the immediate endoscopic necrosectomy group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent, immediately followed by endoscopic necrosectomy. Endoscopic necrosectomy involves removal of infected necrotic pancreatic tissue via the cystogastrostomy/cystoenterostomy tract using a variety of endoscopic accessories.
79875190|NCT00412737|Drug|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
79875191|NCT00412737|Drug|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
79875192|NCT00508742|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
79253552|NCT05289908|Drug|Folic Acid|Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
79253553|NCT05289908|Drug|Vitamin B12|A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
79253554|NCT05289908|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
79253555|NCT05285137|Combination Product|CD388 Injection|CD388 liquid for injection
79253556|NCT05285137|Drug|Saline placebo|Sterile normal saline for injection
79393152|NCT03160404|Drug|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
79875193|NCT00508742|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
79850313|NCT04555226|Radiation|Standard chemoradiation|"A point/HCR-CTV D90 ≥80Gy（+20%）~Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~Target doses for the image-positive nodes can range from 55 to 60Gy~Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~CCRT will be completed in 56 days~After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 < 96Gy) will be performed."
80017203|NCT04607356|Device|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
79712355|NCT05014503|Other|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
79850314|NCT04555226|Radiation|Chemoradiation|"A point/HCR-CTV D90 ≥80Gy（+20%）~Extended-field EBRT: Pathlogical positive para-aortic lymph node~Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~CCRT will be completed in 56 days~After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 < 96Gy) will be performed."
79850315|NCT04525183|Behavioral|Enhanced Usual Care (EOC)|Educational materials
79850316|NCT04525183|Behavioral|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
79850317|NCT04523168|Device|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
79253557|NCT05277207|Behavioral|Personalized Smoking Cessation Facilitation Meetings|Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.
79393153|NCT03160404|Behavioral|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
79393154|NCT05676996|Other|attachment-based support|attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
79393155|NCT03162822|Behavioral|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
79393156|NCT03162822|Other|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
79393157|NCT03162822|Other|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
79393158|NCT03162822|Other|Evaluative Conditioning|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
79253558|NCT05277207|Drug|Personalized Smoking Cessation Pharmacotherapy|Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.
79393159|NCT03162744|Behavioral|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
79393160|NCT03162666|Device|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
79548732|NCT05043415|Procedure|Step-up endoscopic interventions|In the step-up endoscopic interventions group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Endoscopic necrosectomy is not performed during the index drainage session, but is performed at a later time as needed.
79253559|NCT05277207|Behavioral|Personalized Text Messaging Support|If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.
79253560|NCT05277207|Behavioral|SmokefreeVET|Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.
79253561|NCT05277207|Behavioral|VA Quitline|Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.
79253562|NCT05277207|Other|Education about pharmacotherapy|Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
79253563|NCT05274074|Behavioral|Social LEAF|Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
79253564|NCT05269160|Drug|Dermaprazole 1%|Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
79253565|NCT05269160|Drug|Dermaprazole 2%|Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
79393161|NCT03162588|Drug|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
79850318|NCT04520451|Drug|rilzabrutinib|oral tablet
79548733|NCT05010018|Behavioral|Web-based application connecting small food store owners and suppliers of healthier foods and beverages|The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
80017204|NCT04607356|Other|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
79253566|NCT05267054|Drug|Ociperlimab|administered intravenously
79253567|NCT05267054|Drug|Tislelizumab|administered intravenously
79253568|NCT05267054|Drug|Rituximab|administered intravenously
79253569|NCT05265208|Drug|Capecitabine|Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
79712356|NCT05014503|Other|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
79253570|NCT05265208|Device|Selective Internal Radiotherapy (SIRT)|During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.
79850319|NCT04520451|Drug|Glucocorticoids|oral tablet or capsule
79850320|NCT04519541|Device|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
79253571|NCT05265208|Procedure|Surgery|Surgery will be performed according to local practice.
79253572|NCT05264025|Drug|Fexofenadine|tablet
79253573|NCT05264025|Drug|Placebo|tablet
79393162|NCT03320070|Drug|Acthar Gel|Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
79850321|NCT04507412|Drug|dexamethasone|perioperatively 9 mg i.v subministration
79850322|NCT04503096|Device|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
79253574|NCT05260567|Behavioral|Exercise and Lifestyle Change|"Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%."
79393163|NCT03320070|Drug|Placebo|Placebo gel for SC injection
79875194|NCT01041885|Device|INSTRUCT|INSTRUCT PolyActive scaffold implantation
80017205|NCT03530228|Drug|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
79393164|NCT05675358|Behavioral|Virtual Reality|Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
80017206|NCT03530228|Drug|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
79548734|NCT04999891|Other|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
79875195|NCT01041963|Drug|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
79548735|NCT04988815|Drug|Ropeginterferon alfa-2b|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
79548736|NCT04980378|Device|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
79393165|NCT02667912|Procedure|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
79393166|NCT02667912|Procedure|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
79253575|NCT05258058|Behavioral|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
79253576|NCT05248243|Procedure|Recruitment assessment|"Intervention Details:~Construction of the P/V curve with subsequent measurement of HR and Vmax."
79393167|NCT01373346|Procedure|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
79253577|NCT05243719|Biological|ADP101|Active dry powder formulation at various volumes.
79253578|NCT05241444|Biological|CD4^LVFOXP3|"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4^LVFOXP3 in the blood."
79253579|NCT05223127|Other|Aloe vera|The leaves of Aloe vera (Aloe barbadensis) will be identified and verified by Selçuk University Faculty of Agriculture. Aloe vera leaves will be washed with antiseptic solution and cut crosswise using gloves and sterile knife. The thick epidermis will be removed from the middle of the leaf. The gel will be obtained from the parenchyma of the thick juicy leaves of aloe vera.
79253580|NCT05219877|Drug|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
79253581|NCT05219877|Drug|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
79393168|NCT05634642|Device|Ultrasound|Using ultrasound to measure the diameter of distal radial artery
79393169|NCT04977336|Drug|VX-548|Tablets for oral administration.
79393170|NCT04977336|Drug|HB/APAP|Capsules for oral administration.
79548737|NCT04979572|Drug|TS-172|"Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~Multiple dose of TS-172 90 mg before breakfast and dinner"
79548738|NCT04979572|Drug|Placebo|"Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~Multiple dose of TS-172 placebo before breakfast and dinner"
79393171|NCT04977336|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
79393172|NCT04977336|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
79393173|NCT04915872|Procedure|Blood sampling (T0, inclusion)|Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
79548739|NCT04970147|Other|Gastrostomy care bundle|Gastrostomy care bundle
79548740|NCT04938180|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
79548741|NCT04927351|Behavioral|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
79548742|NCT04905615|Other|Data-driven and teacher led school based strategies.|The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
79548743|NCT04889300|Behavioral|Best Possible Self|Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
79548744|NCT04889300|Behavioral|Typical Day|Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
79548745|NCT04873323|Drug|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
79548746|NCT04873323|Drug|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
79548747|NCT04873323|Drug|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
79548748|NCT04834960|Other|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
79875196|NCT01041963|Drug|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
80017207|NCT03530228|Drug|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
79253582|NCT05217979|Device|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
79253583|NCT05217979|Device|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
79253584|NCT05217797|Behavioral|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
79253585|NCT05216978|Behavioral|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
79253586|NCT05199051|Combination Product|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|See Arms description paragraph
79548749|NCT04814771|Drug|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq [14C]TS-142 as an oral solution
79548750|NCT04792554|Other|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
79548751|NCT04777344|Behavioral|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
79548752|NCT04753580|Genetic|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
79548753|NCT04753268|Behavioral|Noom Healthy Weight Program|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."
79548754|NCT04748965|Diagnostic Test|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
79548755|NCT04746105|Drug|TS-142|Subjects received single-dose of 10 mg of TS-142 (oral tablet)
79548756|NCT04746105|Drug|Dose-matched Placebo to TS-142|Subjects received single-dose matched placebo to TS-142 (oral tablet)
79712357|NCT04971915|Other|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
79712358|NCT04901169|Drug|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of > 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
79850323|NCT04500795|Procedure|Middle meningeal artery embolization|"MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure."
79850324|NCT04497064|Other|survey|survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
79850325|NCT04494672|Procedure|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH & Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
79850326|NCT04494672|Procedure|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
79850327|NCT04488926|Dietary Supplement|micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
79850328|NCT04488926|Other|Placebo microgranules 1800mg|Placebo was prepared to be indistinguishable from color and flavor from the Product
79850329|NCT04488926|Drug|Standard Therapy|(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
79850330|NCT04488926|Drug|Rescue Drug|Use as needed allowed
79850331|NCT04485858|Device|CorNeat KPro|CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
80017208|NCT03530228|Drug|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
79253587|NCT05198024|Behavioral|Nutrition knowledge|Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
79253588|NCT05192642|Drug|Larotrectinib(Vitrakvi, BAY2757556)|Clinical trials
79253589|NCT05192642|Drug|Data on other treatments|Real word data
79253590|NCT05192122|Other|Discontinue maintenance therapy SOC|Continue maintenance therapy SOC
79253591|NCT05192109|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
79253592|NCT05192109|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
79253593|NCT05188053|Drug|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
79253594|NCT05188053|Drug|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
79548757|NCT04731675|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
79548758|NCT04715100|Other|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
79548759|NCT04713358|Drug|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
79548760|NCT04713358|Drug|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
79548761|NCT04705051|Drug|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
79548762|NCT04696952|Drug|TS-142|TS-142
79712359|NCT04901169|Drug|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of > 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
79712360|NCT04896333|Other|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
79712361|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
79850332|NCT04483739|Drug|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
79850333|NCT04483739|Drug|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
79850334|NCT04461535|Drug|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
79850335|NCT04441099|Drug|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
79850336|NCT04432012|Drug|Dexamethasone Sodium Phosphate 4 mg/ml intravenous|Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
79850337|NCT04432012|Drug|Dexamethasone Sodium Phosphate 4 mg/ml intra-articular|Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
79850338|NCT04431479|Procedure|Biospecimen Collection|Undergo collection of blood sample
79850339|NCT04431479|Other|Medical Chart Review|Review of medical chart
79850340|NCT04431479|Other|Quality-of-Life Assessment|Ancillary studies
79850341|NCT04431479|Other|Questionnaire Administration|Complete questionnaire
79850342|NCT04420598|Drug|Trastuzumab deruxtecan|"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor [ER] and/or progesterone receptor [PgR]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowe"
79850343|NCT04406103|Behavioral|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
79850344|NCT04406103|Behavioral|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
79850345|NCT04369937|Radiation|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
79850346|NCT04369937|Drug|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
79850347|NCT04369937|Drug|Cisplatin|Chemotherapy
79850348|NCT04369937|Biological|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
79850349|NCT04364152|Behavioral|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
79850350|NCT04313738|Other|Assigned Interventions|Home visit, health education
79850351|NCT04312360|Drug|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
79253595|NCT05177536|Drug|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
79253596|NCT05177302|Other|HAGOS-C|The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively
79253597|NCT05177302|Other|SF-36v2|The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
79277382|NCT02198417|Drug|Metformin ER|Treatment with metformin ER for 12 weeks
79548763|NCT04696952|Drug|Zopiclone|Zopiclone
79253598|NCT05177042|Drug|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
79548764|NCT04696952|Drug|Placebo|Placebo
79850352|NCT04290663|Drug|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
79850353|NCT04290663|Other|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~1.1 GBq after rhTSH if Tg/LT4>1 ng/mL or rhTSH-sTg>10 ng/mL and normal diagnostic RAI-scintigraphy.~3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
79253599|NCT05176392|Device|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
79253600|NCT05176392|Behavioral|Headache Management Therapy|Therapy will be provided on headache management.
79253601|NCT05176392|Device|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
79253602|NCT05176392|Behavioral|Headache Education Control|In the control, educational sessions on headaches will be provided.
79393174|NCT04915872|Procedure|other samplings (T1)|"- T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)"
79548765|NCT04631276|Drug|TS-091|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
79548766|NCT04627506|Device|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
79548767|NCT04617210|Other|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
79548768|NCT04586647|Behavioral|Noom Healthy Weight; mobile behavior change program for weight loss.|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
79548769|NCT04573725|Drug|TS-142|Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)
79548770|NCT04573725|Drug|Dose-matched Placebo to TS-142|Participants received single dose-matched placebo to TS-142 (oral capsule)
79548771|NCT04496999|Drug|HDM201|Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
79548772|NCT04496999|Drug|Midostaurin|Midostaurin 50mg bid d1-28 (morning, evening)
79548773|NCT04469023|Drug|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
79850354|NCT04289077|Other|Questionnaires|- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
79850355|NCT04272372|Drug|Ketoprofen|PO and local therapy
79253603|NCT05173870|Device|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
79393175|NCT05675124|Device|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
79393176|NCT05675124|Device|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
79850356|NCT04270760|Drug|Olpasiran|Dose 1 Dose 2 Dose 3 Dose 4
79393177|NCT03284424|Biological|Pembrolizumab|IV infusion
79393178|NCT05674890|Diagnostic Test|SmartSystem VR Headset perimeter|Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
79393179|NCT03273894|Diagnostic Test|Coagulation testing|"body temperature before the intervention~body temperature during the intervention including the way of measuring, each 15 minutes~body temperature at the end of surgery, signs of the patient's heat discomfort~body temperature during resting time in the postanesthesia care~standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
79393180|NCT02674854|Drug|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
79850357|NCT04270760|Drug|Placebo|Dose 5
79277383|NCT03527953|Other|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
79850358|NCT04256473|Drug|mutant pro-urokinase|Intravenous administration
79850359|NCT04256473|Drug|Alteplase|Intravenous administration
79850360|NCT04253002|Behavioral|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
79253604|NCT05173454|Behavioral|Breastfeeding Education and Support|The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
79393181|NCT02674854|Drug|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
79850361|NCT04253002|Behavioral|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
79850362|NCT04217746|Device|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
79393182|NCT02674854|Drug|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
79393183|NCT03231150|Procedure|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
79393184|NCT03231150|Procedure|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
79393185|NCT03231150|Procedure|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
79393186|NCT03133650|Drug|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
79548774|NCT04464421|Behavioral|Contingency Management (CM)|Participants will be able to draw a gift card from a fishbowl when their urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment). Gift cards in the bowl for drawing will be $25, $50, or $100.
79548775|NCT04464421|Behavioral|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants will have one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, and the importance of substance-free activities.
79548776|NCT04423939|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
79548777|NCT04416802|Combination Product|autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy|"The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS."
79548778|NCT04401813|Drug|IBI308 200mg|Received IBI310 combined with sintilizumab 200mg
79548779|NCT04330950|Other|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
79850363|NCT04198363|Drug|Vonoprazan|Vonoprazan Tablets
79850364|NCT04198363|Drug|Amoxicillin|Amoxicillin Capsules
79850365|NCT04198363|Drug|Clarithromycin|Clarithromycin Tablets
79850366|NCT04198363|Drug|Bismuth Potassium citrate|Bismuth Potassium citrate
79850367|NCT04198363|Drug|Esomeprazole|Esomeprazole Tablets
79850368|NCT04195828|Drug|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
79850369|NCT04195828|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
79850370|NCT04195828|Drug|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
79850371|NCT04195828|Drug|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
79850372|NCT04193371|Other|Active acupuncture|The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
80017209|NCT03530228|Drug|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
80017210|NCT03530228|Drug|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
79393187|NCT04036188|Drug|Triamcinolone|Triamcinolone 0.1% daily
79712362|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
79712363|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
79712364|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
79712365|NCT04724109|Drug|Equfina|Equfina oral tablets.
79712366|NCT04606407|Device|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
79712367|NCT02888847|Device|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
79712368|NCT02888847|Device|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
79712369|NCT04320537|Other|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
79712370|NCT04479267|Drug|Prednisone|Given PO
79712371|NCT04479267|Drug|Prednisolone|Given IV
79712372|NCT04479267|Drug|Methylprednisolone|Given IV
79712373|NCT04479267|Biological|Rituximab|Given IV
79712374|NCT04479267|Drug|Polatuzumab Vedotin|Given IV
79712375|NCT04479267|Drug|Cyclophosphamide|Given IV
79850373|NCT04193371|Other|Sham acupuncture|In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
79253605|NCT05173155|Procedure|surgical approach|Comparison of short-term outcomes (patient mobility, quality of life, function, pain, and safety parameters) for the direct anterior approach and Lateral approach for hemiarthroplasty for patients who have experienced a femoral-neck hip fracture.
79253606|NCT05169411|Diagnostic Test|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
79253607|NCT05169411|Diagnostic Test|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
79253608|NCT05167526|Drug|ASP8731|Oral
79253609|NCT05167526|Drug|ASP8731 Matching Placebo|Oral
79712376|NCT04479267|Drug|Doxorubicin Hydrochloride|Given IV
79253610|NCT05160766|Biological|Comirnaty(BTN162b2)|Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection
79850374|NCT04193371|Other|Lifestyle management|"All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week."
80017211|NCT03530228|Drug|Tegoprazan (C3)|Tegoprazan QD, oral administration
80017212|NCT03554928|Diagnostic Test|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
79393188|NCT04036188|Dietary Supplement|Vitamin D3|40,000 IU Vitamin D3 daily
79393189|NCT04036188|Drug|Placebo|Placebo daily
79712377|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
79712378|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
79712379|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
79712380|NCT04320459|Diagnostic Test|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
80017213|NCT01066923|Drug|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
80017214|NCT01066923|Other|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
79253611|NCT05160766|Biological|Spikevax (mRNA-1273)|Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
79253612|NCT05157568|Behavioral|Exercise Streaming (ES)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
79393190|NCT04003272|Device|Comprehensive Reverse Versa-Dial Titanium Glenosphere|Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
79393191|NCT02667288|Drug|A-101 Solution|
79393192|NCT02670330|Drug|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
79393193|NCT02694822|Drug|AGEN1884|anti-CTLA-4 antibody
79712381|NCT04320459|Diagnostic Test|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
79712382|NCT04320459|Diagnostic Test|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
79253613|NCT05157568|Behavioral|Exercise Streaming + Equipment (ES+E)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
79253614|NCT05157568|Behavioral|Control|Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
79253615|NCT05154591|Genetic|Adipose-derived stromal vascular fraction cells|Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
79850375|NCT04192747|Device|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
79850376|NCT04173247|Device|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
79253616|NCT05154084|Behavioral|Performance feedback and education|Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
79393194|NCT04479774|Other|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~Muscle re-education~Sit to stand exercise , 4 to 10 repetitions~Supported heel raise to 10 repetitions with 3 sets~Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~Gait training~Forward walk in parallel bars with number of 10 rounds.~Task oriented training balance training~A. Stepping exercise on 15 cm height step and number of repetitions 10.~B. Tandem standing for 10 seconds.~C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
79850377|NCT04173247|Other|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
79850378|NCT04167891|Diagnostic Test|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
79850379|NCT04149977|Behavioral|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
79850380|NCT04149977|Behavioral|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
79548780|NCT04314635|Behavioral|Brief family engagement intervention for CHR|The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.
79850381|NCT04144036|Biological|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
79850382|NCT04144036|Drug|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
79850383|NCT04144036|Drug|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
79548781|NCT04314635|Behavioral|Treatment as usual (TAU)|The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
79548782|NCT04298853|Drug|Morphine PRN|Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
79850384|NCT04144036|Drug|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
79850385|NCT04125355|Other|Reflexology|Foot reflexology massage for 3 consecutive days and 60 minutes per day.
79850386|NCT04125355|Other|Placebo|Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
79850387|NCT04112823|Drug|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
79850388|NCT04112823|Drug|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
79850389|NCT04093219|Drug|IV acetaminophen|use of IV tylenol for pain
79548783|NCT04298853|Drug|Morphine scheduled|Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
79548784|NCT04238793|Drug|KLS-2031|KLS-2031 administered by transforaminal epidural injection
79548785|NCT04238793|Other|Placebo|Saline solution administered by transforaminal epidural injection
79850390|NCT04093219|Other|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
79850391|NCT04089917|Device|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
79875197|NCT01041963|Drug|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
79253617|NCT05153499|Biological|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
79253618|NCT05153499|Other|Placebo|Placebo
79253619|NCT05152290|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79712383|NCT02888769|Behavioral|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
79712384|NCT05523531|Other|Self-administered questionnaires|"Neuropathic Eye Pain Questionnaire~5-item Dry Eye Evaluation Questionnaire (DEQ-5)~Visual Impact Assessment Questionnaire~Concise Ophthalmic Pain Questionnaire~Questionnaire to evaluate the effectiveness and tolerance of treatments~Chronic pain questionnaire"
79253620|NCT05147987|Device|Hands free wearable breast pump|Use of a supplementary breast pump which can be discreetly worn and is hands free
79393195|NCT04479774|Other|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~Muscle re-education~Sit to stand exercise , 4 to 10 repetitions~Supported heel raise to 10 repetitions with 3 sets~Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~Gait training~Forward walk in parallel bars with number of 10 rounds.~Task oriented training balance training~A. Stepping exercise on 15 cm height step and number of repetitions 10.~B. Tandem standing for 10 seconds.~C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
79393196|NCT02388438|Device|Bongener|
79393197|NCT02388516|Dietary Supplement|Vitamin D3|
79393198|NCT02388516|Dietary Supplement|Placebo|
79393199|NCT02388360|Drug|topical prostaglandin analogs|
79850392|NCT04087018|Drug|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
79548786|NCT04232683|Drug|Tamsulosin 0.4Mg Capsule|Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
79548787|NCT04232683|Drug|Placebo oral tablet|Placebo pill given preoperatively
79548788|NCT04216810|Other|muscle strengthening exercises|segmental stabilization exercises
79548789|NCT04216810|Other|muscle strengthening exercises and dry cupping|segmental stabilization exercises and dry cupping
79850393|NCT04050072|Other|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
79548790|NCT04201028|Behavioral|Video Conferencing Health Coaching with devices|Devices
79548791|NCT04201028|Behavioral|Video Conferencing Health Coaching with no devices|No Devices
79253621|NCT05147766|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79548792|NCT04200547|Other|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
79548793|NCT04200547|Other|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI > 220 together with an increase of 70 points) and biological relapse (CRP > 10mg/mL and fecal calprotectin > 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
79548794|NCT04184661|Other|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
79253622|NCT05147311|Behavioral|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
79253623|NCT05147168|Other|Questionnaire|Psychometric Validation of Chinese Version of the EORTC QLQ-PAN26 and EORTC QLQ-C30 in Taiwan
79253624|NCT05141357|Drug|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
79253625|NCT05141149|Drug|PBP1510 (400mg/16mL)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
79253626|NCT05141149|Drug|Gemcitabine (1000 mg/m^2)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
79393204|NCT02669862|Drug|A-101 Solution 40|
79393205|NCT02669862|Drug|A-101 Solution 45|
79393206|NCT02669862|Drug|Vehicle Solution|
79393207|NCT02168868|Diagnostic Test|Blood draw|A blood sample (5 mL) will be collected.
79393208|NCT02168868|Diagnostic Test|Stool Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
79850394|NCT04050072|Other|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
79253627|NCT05137184|Drug|Methoxyflurane|Inhalation of Methoxyflurane
79253628|NCT05137184|Drug|Fentanyl|Intranasal Fentanyl
79712385|NCT05523531|Procedure|Bilateral ophthalmologic examination|"Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~Lipiview® test~Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
79712386|NCT04320303|Biological|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
79712387|NCT04121169|Drug|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
79712388|NCT04066959|Behavioral|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
79548795|NCT04177576|Biological|2 additional tubes of blood|2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
79548796|NCT04112784|Device|INVSENSOR00039|Noninvasive pulse oximeter sensor
79548797|NCT04108351|Other|Road-tracking test|Driving with simulator program for SDLP measurement
79850395|NCT04050072|Other|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
79393209|NCT02168868|Diagnostic Test|Urine Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
79393210|NCT02388282|Device|diaphragm ecography|recording of diaphragm ecography
79393211|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
79548798|NCT04108351|Other|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
79548799|NCT04108351|Other|Harsh-braking test|Driving with simulator program for BRT measurement
79253629|NCT05137184|Drug|Morphine hydrochloride|Intravenous Morphine
79253630|NCT05136092|Dietary Supplement|Cohort 1: HFCS (fructose) fed|"Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~Blood sample of 5 ml~Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~Blood sample of 5 ml blood will be obtained from the IV line~Tissue samples~2 Tumor tissue samples 5mmx5mmx5mm,~2 Intestinal /colon tissue samples 5mmx5mmx5mm~2 tissue samples from mesentery tissue 5mmx5mmx5mm~Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~Urine Samples 5 ml"
79393212|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
79393213|NCT01531673|Drug|VX-661|
79548800|NCT04101227|Drug|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
79548801|NCT04101227|Drug|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
79548802|NCT04101227|Device|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
79712389|NCT04066959|Behavioral|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
79850396|NCT04046107|Biological|Cemiplimab|Administered as an intravenous (IV) infusion
79850397|NCT04039243|Behavioral|Being Brave|Up to 12 weekly sessions
79850398|NCT04039243|Other|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
79850399|NCT04037917|Device|CorNeat EverPatch|Covering Ophthalmic Implants
79850400|NCT03993509|Device|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
79850401|NCT03986736|Diagnostic Test|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
79393214|NCT01531673|Drug|Ivacaftor|
79393215|NCT01531673|Drug|Placebo matched to VX-661|
79393216|NCT01531673|Drug|Placebo matched to ivacaftor|
79393217|NCT01531205|Drug|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
79548803|NCT04101227|Behavioral|Brief Psychological Counseling|Brief Psychological Counseling
79712390|NCT04066959|Behavioral|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
79548804|NCT04096781|Behavioral|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
79548805|NCT04096781|Behavioral|Usual Care|The participants will receive usual care.
79850402|NCT03986736|Diagnostic Test|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
79712391|NCT04021017|Drug|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
79850403|NCT03981263|Device|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
79850404|NCT03981263|Device|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
79850405|NCT03966404|Diagnostic Test|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
79850406|NCT03951480|Other|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity < 2, manipulations will not be continued. The patient being considered as not very symptomatic.
79393218|NCT01531205|Drug|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
79393219|NCT01531205|Drug|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
79393220|NCT01531205|Drug|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
79850407|NCT03951480|Drug|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
79404276|NCT03581617|Diagnostic Test|NK cell analysis|"We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry"
79548806|NCT04049617|Drug|Evixapodlin|Tablets administered orally.
79850408|NCT03943446|Drug|TAK-018|TAK-018 immediate-release tablets.
79850409|NCT03943446|Drug|TAK-018 Placebo|TAK-018 placebo-matching tablets.
79253631|NCT05136092|Dietary Supplement|Cohort 2: D-Xylose (xylose-fed)|"Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~Blood sample of 5 ml~Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~Blood sample of 5 ml blood will be obtained from the IV line~Tissue samples~2 Tumor tissue samples 5mmx5mmx5mm,~2 Intestinal /colon tissue samples 5mmx5mmx5mm~2 tissue samples from mesentery tissue 5mmx5mmx5mm~Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~Urine Samples 5 ml"
79875198|NCT01044225|Drug|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
79712392|NCT04323111|Procedure|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
79712393|NCT03764553|Drug|Liposomal Irinotecan|Iv liposomal irinotecan
79712394|NCT03764553|Drug|Carboplatin|IV Carboplatin
79253632|NCT05129865|Drug|LYT-300|A prodrug of allopregnanolone, a small molecule drug
79712395|NCT03764553|Drug|Capecitabine|PO Capecitabine
79712396|NCT03764553|Drug|Oxaliplatin|IV Oxaliplatin
79712397|NCT03764553|Drug|5-fluorouracil|IV 5-fluorouracil
79253633|NCT05129865|Other|Placebo|Placebo for LYT-300
79712398|NCT03764553|Drug|Leucovorin|IV Leucovorin
79712399|NCT04319991|Dietary Supplement|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
79712400|NCT04320225|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
79712401|NCT04320147|Device|Artemia|Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
79712402|NCT02888925|Other|Mooney test|
79712403|NCT02888925|Other|Benton Face Recognition test|
79712404|NCT02888925|Other|Face inversion effect test|
79712405|NCT02888925|Other|Face composite effect test|
79875199|NCT01044225|Drug|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
79875200|NCT00848757|Behavioral|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
79253634|NCT05109091|Drug|ATH434 dose level 1|ATH434 taken BID
79253635|NCT05109091|Drug|ATH434 dose level 2|ATH434 taken BID
79253636|NCT05109091|Drug|Placebo|Placebo taken BID
79253637|NCT05108181|Other|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
79253638|NCT05108181|Other|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
79253639|NCT05100043|Biological|IL-4 and IFN-γ measurements|Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
79253640|NCT05096351|Other|Blood test|Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
79393221|NCT01531205|Drug|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
79393222|NCT02985671|Drug|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
79393223|NCT02985671|Drug|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
79393224|NCT02985671|Drug|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
79393225|NCT02985671|Drug|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
79393226|NCT04767269|Drug|Cuminum Cyminum|Cuminum Cyminum mouthwash in chronic gingivitis patients
79712406|NCT02888925|Other|Cambridge Face Memory Test|
79712407|NCT02888925|Other|Matching different view test|
79712408|NCT02888925|Other|Memorizing and recognition of new faces test|
79712409|NCT02888925|Other|Memorizing and recognition of new objects test|
79712410|NCT02888925|Other|Recognition of celebrities and access to semantic information test|
79712411|NCT02888925|Procedure|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
79712412|NCT03219177|Behavioral|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
79712413|NCT03219177|Other|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
79712414|NCT05608941|Other|Respiratory muscle training|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
79712415|NCT05608941|Other|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
79712416|NCT02866071|Drug|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
79712417|NCT02866071|Drug|Placebo-Comparator|50mg IN Placebo
79712418|NCT02888613|Procedure|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
79712419|NCT02888613|Procedure|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
79393227|NCT04767269|Drug|herbal Mouthwash|herbal mouthwash in chronic gingivitis patients
79712420|NCT02890524|Device|night guard|60 days before and after intervention with the night guard
79712421|NCT02890524|Device|placebo night guard|60 days before and after intervention with the placebo night guard
79548807|NCT04047004|Drug|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
79548808|NCT04047004|Drug|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
79712422|NCT02890602|Drug|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
79253641|NCT05092490|Procedure|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
79712423|NCT02890602|Drug|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
79850410|NCT03940482|Behavioral|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
79850411|NCT03896763|Other|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
79875201|NCT00508274|Drug|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
79253642|NCT05092490|Procedure|Standard local infiltration technique|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
79712424|NCT01259115|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
79712425|NCT01259115|Drug|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
79712426|NCT01259115|Drug|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
79712427|NCT01302366|Drug|TBL12|
79712428|NCT02888379|Drug|TOP1288|
79875202|NCT00508274|Drug|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
79253643|NCT05091437|Diagnostic Test|Observational study|Incidental lung nodules identification
79548809|NCT03944798|Other|Frequency: Every 3 Months|every 3 months
79712429|NCT02888379|Drug|Placebo (for TOP1288)|
79712430|NCT01302054|Drug|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
79712431|NCT01302054|Drug|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
79712432|NCT01301508|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
79712433|NCT01301508|Drug|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
79548810|NCT03944798|Other|Frequency: Every 6 Months|every 6 months
79548811|NCT03944798|Other|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
79548812|NCT03944798|Other|Imaging Modality: Chest CT|Chest computed tomography (CT)
79548813|NCT03911154|Device|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
79712434|NCT01301508|Drug|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
79712435|NCT01301508|Drug|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
79548814|NCT03911154|Device|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
79548815|NCT03911154|Device|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
79712436|NCT01301274|Drug|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
79712437|NCT01301274|Drug|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
79253644|NCT05086419|Other|Sub-symptom threshold aerobic exercise|For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
79712438|NCT02890446|Behavioral|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
79712439|NCT05643612|Diagnostic Test|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
79712440|NCT05643456|Procedure|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
79712441|NCT05367726|Other|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
79712442|NCT05643222|Device|red tint contact lenses|to compare the performance of these lenses.
79712443|NCT00623532|Behavioral|Mind-body exercises|
79712444|NCT00623532|Behavioral|Adapted Tai-chi|
79712445|NCT05367648|Dietary Supplement|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
79712446|NCT05367648|Other|Placebo|Placebo comparator
79712447|NCT05642910|Drug|Azvudine|Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
79850412|NCT03896737|Drug|Daratumumab plus Velcade Cyclophosphamide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
79875203|NCT01038999|Biological|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
79253645|NCT05085288|Device|Intermittent electrical stimulation system (IES) treatment and turning patient every two hours|The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
79253646|NCT05085288|Other|Turning population every two hours|The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
79253647|NCT05083364|Drug|ARO-C3|ARO-C3 for sc injection
79253648|NCT05083364|Drug|Placebo|sterile normal saline (0.9% NaCl) for sc injection
79253649|NCT05082038|Device|Mandibular partial rehabilitation with IF Tapared implants|2 IF Tapared Implants (Group IF) on one side of the mandible
79548816|NCT03893435|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
79712448|NCT05642910|Drug|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
79712449|NCT05642754|Other|Overall uncertainty language|We are testing different forms of information about overall study uncertainty and margin of error around main result
79712450|NCT05642364|Behavioral|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
79712451|NCT05642364|Other|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
79712452|NCT01300650|Drug|Anakinra|Anakinra 100 mg subcutaneous injection daily
79712453|NCT01300572|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
79712454|NCT01300572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
79712455|NCT01300572|Drug|Cyclosporine|Given PO or IV
79712456|NCT01300572|Drug|Fludarabine Phosphate|Given IV
79712457|NCT01300572|Biological|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
79712458|NCT01300572|Other|Laboratory Biomarker Analysis|Correlative studies
79712459|NCT01300572|Drug|Mycophenolate Mofetil|Given PO or IV
79712460|NCT01300572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
79548817|NCT03853837|Diagnostic Test|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
79253650|NCT05082038|Device|Mandibular partial rehabilitation with CF Tapared implants|2 CF Tapared Implants (Group CF) on the other side of the mandible
79850413|NCT03896737|Drug|Velcade Thalidomide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
79548818|NCT03818074|Device|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
79850414|NCT03896724|Biological|R21 adjuvanted with 25mcg Matrix-M|Vaccine
79850415|NCT03896724|Biological|Rabies Vaccine|Vaccine
79850416|NCT03896724|Biological|R21 adjuvanted with 50mcg Matrix-M|vaccine
79393228|NCT01529645|Biological|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
79253651|NCT05073133|Genetic|OAV101|Gene Therapy IV infusion
79253652|NCT05068830|Drug|ExPlas|"ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max >50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
79253653|NCT05068830|Drug|Octaplasma|"Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
79393229|NCT01529645|Biological|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
79393230|NCT01529645|Biological|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
79393231|NCT01529645|Biological|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
79712461|NCT01300572|Other|Pharmacological Study|Correlative studies
79393232|NCT01529645|Other|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
79393233|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the morning (AM) for 7 days
79393234|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD AM for 7 days
79712462|NCT01300572|Radiation|Total-Body Irradiation|Undergo TBI
79712463|NCT01300572|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
79712464|NCT05642286|Device|ALLVAS® robotic-assisted PCI|ALLVAS® robotic-assisted PCI
79712465|NCT01077154|Drug|Placebo|Administered subcutaneously for up to 5 years
79712466|NCT01077154|Drug|Denosumab|Administered subcutaneously for up to 5 years
79712467|NCT05642130|Other|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
79548819|NCT03813121|Drug|midazolam intravenous infusion|Participants will receive a single drug infusion
79850417|NCT03884049|Procedure|Embolization|transcatheter arterial embolization of neovessels around the knee
79850418|NCT03884049|Procedure|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
79850419|NCT03880838|Behavioral|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
79875204|NCT01042041|Drug|sorafenib tosylate|Given orally
79548820|NCT03813121|Drug|placebo intravenous infusion|Participants will receive a single placebo infusion
79548821|NCT03813121|Drug|ketamine intravenous infusion|Participants will receive a single drug infusion
79548822|NCT03784521|Device|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
79548823|NCT03784521|Device|Standard care|Patients are treated with standard intravenous solutions and vascular access management
79548824|NCT03781778|Other|Dietary Intervention (resistant starch)|Eat foods with resistant starch
79712468|NCT05642130|Other|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
79712469|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
79712470|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
79875205|NCT01042041|Drug|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
79875206|NCT01042041|Drug|cisplatin|Given via transarterial/hepatic chemoembolization
79875207|NCT01042041|Drug|mitomycin C|Given via transarterial/hepatic chemoembolization
79850420|NCT03880838|Behavioral|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
79253654|NCT05068830|Drug|Saline|"Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
79253655|NCT05062863|Device|T3 dental implant system|This clinical study will evaluate patients being treated with the T3 dental implant to confirm its safety and performance (effect of treatment of edentulism). The patients treated will experience a benefit from treatment of edentulism with the T3 dental implant system. The patients will be followed prospectively from the time of exposure (dental implant placement surgery) to outcome (implant survival at 2 years).
79712471|NCT01258101|Drug|ribavirin|800 mg orally daily
79712472|NCT01258101|Drug|ribavirin|400 mg orally daily
79712473|NCT04319835|Device|OnZurf Probe|
79712474|NCT05640804|Drug|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
79712475|NCT05640804|Drug|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
79712476|NCT05639478|Other|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
79712477|NCT00623610|Procedure|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
79712478|NCT00623688|Device|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
79712479|NCT00623688|Device|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
79712480|NCT01300338|Device|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
79712481|NCT01300338|Device|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
79850421|NCT03880838|Behavioral|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
79393235|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.04%|Administered to study eye, QD AM for 7 days
79393236|NCT01528787|Other|AR-13324 Ophthalmic Solution Vehicle|Administered to study eye, QD AM for 7 days
79393237|NCT01528709|Drug|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
79712482|NCT02890290|Dietary Supplement|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
79712483|NCT02890290|Dietary Supplement|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
79712484|NCT01300260|Biological|LY2189265|Administered subcutaneously
79712485|NCT01300260|Drug|Placebo|Administered subcutaneously
79875208|NCT01042041|Procedure|transarterial chemoembolization|
79875209|NCT01042041|Procedure|hepatic artery embolization|
79875210|NCT00499460|Dietary Supplement|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
79393238|NCT01528709|Drug|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
79393239|NCT01527383|Biological|V212|V212 viral antigen for HZ
79393240|NCT01527383|Biological|Placebo|Placebo comparator to V212 vaccine
79875211|NCT00499460|Drug|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
79393241|NCT01526057|Biological|PF-05280586|1000 mg, IV on days 1 and 15
79393242|NCT01526057|Biological|MabThera|1000 mg, IV on days 1 and 15
79393243|NCT01526057|Biological|Rituxan|1000 mg, IV on days 1 and 15
79548825|NCT03781778|Other|Dietary Intervention (regular starch)|Eat foods with regular corn starch
79548826|NCT03781778|Other|Questionnaire Administration|Ancillary studies
79548827|NCT03778177|Procedure|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
79548828|NCT03744117|Other|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
79548829|NCT03710590|Other|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
79712486|NCT01300260|Drug|Insulin|Administered intravenously
79712487|NCT01300260|Drug|Glucose|Administered intravenously
79712488|NCT01300260|Drug|Glucagon|Administered intravenously
79712489|NCT01256385|Biological|Cetuximab|Given IV
79712490|NCT01256385|Other|Laboratory Biomarker Analysis|Correlative studies
79712491|NCT01256385|Drug|Temsirolimus|Given IV
79712492|NCT05609760|Other|SIMAP|Pictographic depiction of medical indications alongside standard communication of these recommendations.
79253656|NCT05062161|Behavioral|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
79712493|NCT05609760|Other|Usual Care|Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
79712494|NCT00637182|Drug|Anastrozole|
79712495|NCT04324398|Other|Cryotherapy|cold application
79712496|NCT01298778|Drug|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
79712497|NCT01298778|Drug|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
79712498|NCT01298778|Drug|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
79712499|NCT01298700|Drug|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
79253657|NCT05062161|Behavioral|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
79712500|NCT01298700|Drug|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
79712501|NCT01297920|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
79393244|NCT01525901|Drug|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
79393245|NCT01525901|Drug|Normal saline|Saline solution will be administered for three months subcutaneously.
79548830|NCT03710590|Other|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
79393246|NCT00123123|Drug|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
79393247|NCT00123123|Drug|placebo|
79393248|NCT00262509|Device|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
79393249|NCT00242385|Biological|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
79548831|NCT03710590|Other|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
79548832|NCT03710590|Other|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
79548833|NCT03710590|Other|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
79712502|NCT01297920|Drug|Brinzolamide ophthalmic suspension, 1%|
79712503|NCT01297920|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
79393250|NCT00242385|Biological|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
79393251|NCT00242619|Drug|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
79393252|NCT01899027|Drug|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
79712504|NCT01255761|Biological|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
79712505|NCT04326972|Device|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
79712506|NCT01297062|Drug|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
79712507|NCT01297062|Drug|Moxifloxacin|Oral Moxifloxacin (400 mg)
79712508|NCT01297062|Drug|Placebo comparator|IV Placebo (matching volume of placebo)
79712509|NCT01254747|Device|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
79712510|NCT01254747|Device|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
79712511|NCT01254747|Device|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
79712512|NCT01254747|Device|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
79712513|NCT01296672|Drug|Finasteride|Finasteride 5mg every day by mouth for 3 months
79712514|NCT01296672|Drug|Placebo|Placebo every day by mouth for 3 months
79712515|NCT01254669|Behavioral|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
79712516|NCT04324476|Drug|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
79712517|NCT04321473|Procedure|PCI on left main|PCI on left main coronary stenosis
79712518|NCT04206969|Behavioral|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
79253658|NCT05052827|Dietary Supplement|Milk Protein Concentrate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27"
79712519|NCT04206657|Drug|1mg KHK7580|Single oral dose administration of 1mg KHK7580
79712520|NCT04206657|Drug|3mg KHK7580|Single oral dose administration of 3mg KHK7580
79712521|NCT04206657|Drug|6mg KHK7580|Single oral dose administration of 6mg KHK7580
79548834|NCT03710590|Other|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
79548835|NCT03676725|Drug|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
79712522|NCT04206657|Drug|12mg KHK7580|Single oral dose administration of 12mg KHK7580
79712523|NCT04206657|Drug|6mg KHK7580 for 8days|multiple oral dose administration of 6mg KHK7580 for 8days
79712524|NCT01295814|Drug|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
79253659|NCT05052827|Dietary Supplement|Rice Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11"
79712525|NCT01295814|Other|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
79712526|NCT01254045|Drug|placebo|intranasal placebo (48 international units)
79253660|NCT05052827|Dietary Supplement|Soy Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39"
79253661|NCT05050110|Other|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
79253662|NCT05047770|Biological|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
79253663|NCT05047770|Combination Product|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
79253664|NCT05047770|Biological|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
79253665|NCT05046886|Behavioral|Standardized|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on macronutrient distribution.
79253666|NCT05046886|Behavioral|Usual Care Control (UCC)|Participants are instructed to follow a Mediterranean-style diet,
79393253|NCT01899027|Drug|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
79548836|NCT03624816|Device|Restylane Defyne|hyaluronic acid dermal filler gel
79548837|NCT03607825|Device|Neurapheresis System|CSF filtration system and lumbar catheter
79548838|NCT03572985|Other|Road-tracking test|Driving with simulator program for SDLP measurement
79548839|NCT03572985|Other|Car-following test|Driving with simulator program for DCV measurement
79712527|NCT01254045|Drug|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
79712528|NCT01254045|Drug|oxytocin 48IU|intranasal oxytocin (48 international units)
79712529|NCT04324320|Diagnostic Test|medical assessment|"medical assessment includes the collection of~sociodemographic data~anthropometric data (weight, height, body mass index)~medical data~psycho-oncologic basis assessment (PO-BADO questionnaire)~pain assessment (VAS: visual analogue scale)~3 functional tests:~handgrip strength~6 Minute Walking Test~Timed Get up and Go Test"
79712530|NCT04324320|Diagnostic Test|psychological assessment|"psychological assessment includes several standardized screening and assessment questionnaires and tools:~quality of life: SF-36~anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~subjective stress perception: Perceived Stress Scale (PSS-10)~resilience: resilience scale (RS-13)~fatigue: Brief Fatigue Inventory (BFI)~disability related to pain: Pain Disability Index (PDI)~workability: Work Ability Index - short version (WAI-K)~psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))"
79712531|NCT01075282|Drug|Insulin Glargine|
79712532|NCT01075282|Drug|LY2189265|
79712533|NCT01075282|Drug|Metformin|
79712534|NCT01075282|Drug|Glimepiride|
79712535|NCT04324242|Other|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
79393254|NCT00264381|Drug|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
79393255|NCT00243243|Drug|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
79393256|NCT00243243|Drug|Placebo|intravenous infusion of placebo (sterile water)
79712536|NCT04324086|Device|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
79712537|NCT04324086|Device|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
79253667|NCT05046886|Behavioral|Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on their predicted PPGR to meals and snacks at the time they enter them into their smart phone. PPGR predictions will be generated from a gut microbiome-based machine learning algorithm.
79712538|NCT04324086|Device|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
79712539|NCT04326582|Other|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
79850422|NCT03880838|Behavioral|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
79253668|NCT05041218|Other|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
79253669|NCT05039424|Procedure|Endoscopic per-oral pyloromyotomy (POP)|Per-oral pyloromyotomy (POP), alternatively knows as gastric per-oral endoscopic myotomy (G-POEM), accomplishes longitudinal division of the pylorus using an endoscope. This procedure involves utilizing endoscopic electrosurgical knife to make an incision in the gastric mucosa and develop a submucosal tunnel to visualize the pyloric ring. The pyloric ring is divided longitudinally, and the mucosotomy incision is sealed with endoscopic clips.
79253670|NCT05039424|Procedure|Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption|While under general anesthesia, a standard gastroscope is introduced and a diagnostic upper endoscopy is performed. The operator talks through the procedure steps as if completing POP. The gastroscope is withdrawn and the patient is extubated.
79393257|NCT00265473|Biological|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
79393258|NCT00246441|Drug|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
79393259|NCT00246441|Drug|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
79393260|NCT00246519|Drug|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
79850423|NCT03828331|Other|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
79850424|NCT03815929|Drug|Estradiol 100 Micrograms Patch|Standard
79850425|NCT03815929|Drug|Estradiol Patch|Individualized
79850426|NCT03810170|Behavioral|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
79393261|NCT00246519|Drug|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
79393262|NCT00125619|Behavioral|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
79548840|NCT03572985|Other|Harsh-braking test|Driving with simulator program for BRT measurement
79548841|NCT03566615|Device|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
79548842|NCT03566615|Device|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
79548843|NCT03566615|Other|water|using water instead of traditional air insufflation to help insertion
79548844|NCT03548207|Biological|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
79548845|NCT03532490|Drug|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
79548846|NCT03532490|Drug|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
79548847|NCT03520517|Drug|BHV-0223|BHV-0223, 40 mg BID
79712540|NCT01253811|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
79712541|NCT01295580|Device|ARTZ|Hyaluronic acid (five 2.5 mL injections)
79712542|NCT01295580|Device|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
79712543|NCT01253577|Device|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
79712544|NCT01253577|Device|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
79253671|NCT05034627|Procedure|Biopsy|Undergo biopsy
79393263|NCT00248547|Drug|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
79712545|NCT02876692|Device|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
79393264|NCT00248547|Drug|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
79712546|NCT01295034|Dietary Supplement|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
79712547|NCT01295034|Drug|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
79712548|NCT01253421|Drug|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
79712549|NCT01253421|Drug|placebo|single-dose placebo capsule
79850427|NCT03810170|Other|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
79850428|NCT03809988|Drug|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
79253672|NCT05034627|Drug|Calaspargase Pegol-mknl|Given IV
79253673|NCT05034627|Drug|Cobimetinib|Given PO
79253674|NCT05033067|Behavioral|P3BC|The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
79253675|NCT05032196|Drug|WVE-003|WVE-003 is a stereopure antisense oligonucleotide (ASO)
79404277|NCT03581617|Diagnostic Test|Herpesvirus detection|Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
79548848|NCT03479606|Behavioral|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
79548849|NCT03468335|Drug|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
79850429|NCT03809988|Drug|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
79850430|NCT03808987|Behavioral|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
80017215|NCT01066923|Drug|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
79712550|NCT01077076|Drug|Zegerid|Zegerid taken once daily for 11 days.
79712551|NCT01077076|Drug|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
79712552|NCT01077076|Other|Placebo|Placebo taken once daily for 11 days.
79712553|NCT02876848|Other|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~Contact you over the phone or in person to provide medical advice on how to better take your pills,~Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
79850431|NCT03808987|Behavioral|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
79875212|NCT01010828|Procedure|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
79875213|NCT01010828|Procedure|Incision technique|Mini Mid-Vastus Approach
79875214|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 5 mg
80017216|NCT01066923|Other|Passive cooling|Removing protective garments for passive cooling following exercise
80017217|NCT01066923|Drug|Daily placebo|Placebo comparator for daily aspirin therapy
80017218|NCT01066923|Drug|Acute placebo|Placebo comparator for acute aspirin therapy
80017219|NCT03530150|Drug|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
79850432|NCT03782337|Behavioral|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
79393265|NCT00248547|Drug|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
79850433|NCT03773107|Drug|Carfilzomib|Irreversible proteasome inhibitor
79393266|NCT00248547|Drug|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
79850434|NCT03773107|Drug|Ruxolitinib|Oral JAK inhibitor
79850435|NCT03773107|Drug|Dexamethasone|glucocorticoid
79253676|NCT05031780|Drug|Mitapivat|Mitapivat tablets
79253677|NCT05031780|Other|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
79393267|NCT01525589|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
79393268|NCT01524887|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
79850436|NCT03755934|Biological|MEDI7352|MEDI7352
79850437|NCT03755934|Other|Placebo|Placebo
79253678|NCT05031780|Other|Mitapivat-matching placebo|Placebo to match selected Phase 3 dose tablets
79253679|NCT05018455|Other|Fall prevention program training based on Otago principles|balance and strength exercises
79253680|NCT05003960|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
80017220|NCT02098590|Biological|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
80017221|NCT02098590|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
80017222|NCT02098590|Biological|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
80017223|NCT02098590|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
79253681|NCT04999163|Device|Aortix System|Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
79253682|NCT04993066|Device|GentleMax Pro Plus|The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
79253683|NCT04977700|Behavioral|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
79253684|NCT04976920|Diagnostic Test|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
79393269|NCT01524887|Biological|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
79393270|NCT00266799|Drug|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
79393271|NCT00266799|Drug|Capecitabine|capecitabine (1250 mg/m^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
79548850|NCT03465722|Drug|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
79548851|NCT03465722|Drug|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
79548852|NCT03425591|Drug|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
79850438|NCT03743766|Drug|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
79850439|NCT03743766|Drug|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
80017224|NCT02098590|Drug|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
80017225|NCT04216264|Behavioral|Standard response|Parents pick from a menu of behavior changes
79548853|NCT03413592|Other|Road-tracking test|Driving with simulator program for SDLP measurement
79850440|NCT03743766|Drug|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
79850441|NCT03729817|Device|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
79850442|NCT03716817|Device|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
79850443|NCT03716544|Device|Amplification with hearing aid|Use of hearing aids
80017226|NCT04216264|Behavioral|Targeted response|Stepped up phone interaction with parents based on menu of behavior changes
79850444|NCT03716544|Device|Customized music|Customized music delivered via an iPod
79253685|NCT04976816|Procedure|peri-levator betamethasone injection|The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate &2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
79850445|NCT03716180|Drug|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
79850446|NCT03716180|Drug|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
79712554|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
79712555|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
79850447|NCT03716180|Drug|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
79850448|NCT03696199|Drug|Long-Acting Local Anesthesia|"The cocktail consists of:~0.5% Ropivicaine, 24.6 mL~Clonidine 100 mcg/mL, 0.4mL~Epinephrine 1mg/mL, 0.5mL~Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
79850449|NCT03696199|Drug|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
79253686|NCT04976816|Procedure|peri-levator triamcinolone injection|The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
79850450|NCT03684187|Behavioral|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
79850451|NCT03674229|Other|Informational Intervention|Receive information about weight management programs
79712556|NCT02876224|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
79712557|NCT02876224|Drug|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
79850452|NCT03674229|Other|Questionnaire Administration|Ancillary studies
79850453|NCT03674229|Behavioral|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
79850454|NCT03651349|Drug|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
79850455|NCT03651349|Drug|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
79850456|NCT03632993|Drug|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
79850457|NCT03626402|Behavioral|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
79393272|NCT00248781|Device|Telecommunications system|
79875215|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
79875216|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 10 mg
79393273|NCT00248781|Device|attention control|health education
79393274|NCT04101071|Other|Modular ketogenic feed|Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
79393275|NCT04101071|Other|Standard feed|Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
79393276|NCT00249249|Drug|Pitavastatin|
79393277|NCT00249249|Drug|Atorvastatin|
79393278|NCT01522235|Drug|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
79548854|NCT03413592|Other|Car-following test|Driving with simulator program for DCV measurement
79548855|NCT03413592|Other|Harsh-braking test|Driving with simulator program for BRT measurement
79712558|NCT02876224|Drug|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
79548856|NCT03312270|Behavioral|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
79712559|NCT01294800|Drug|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
79712560|NCT01294800|Drug|Placebo tablet to match Preladenant|tablets taken orally BID
79850458|NCT03620266|Dietary Supplement|Bilberry|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
79548857|NCT03280511|Drug|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
79850459|NCT03620266|Dietary Supplement|Placebo|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
79712561|NCT01294644|Drug|Deoxycholic acid injection|
79253687|NCT04976816|Procedure|peri-levator and retrobulbar betamethasone injection|In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
79712562|NCT01294644|Drug|Placebo|Phosphate buffered saline placebo for injection
79712563|NCT01293240|Device|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
79712564|NCT01253265|Drug|LY2439821|Administered subcutaneously
79712565|NCT01253265|Drug|Placebo|Administered subcutaneously
79712566|NCT01293084|Drug|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
79712567|NCT01293084|Drug|7% saline|5mL 7% saline inhaled once over 20 minutes
79712568|NCT01293006|Drug|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants <65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
79875217|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
79875218|NCT01014650|Drug|GLYX-13|single IV or SC dose
79875219|NCT01014650|Drug|IV normal saline|Single IV dose of normal saline
79875220|NCT00411645|Drug|maribavir|100 mg twice daily for up to 12 weeks
79875221|NCT00411645|Other|placebo|twice daily for up to 12 weeks
79253688|NCT04976816|Procedure|peri-levator and retrobulbar triamcinolone injection|In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
79253689|NCT04971356|Drug|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
79253690|NCT04971356|Drug|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
79393279|NCT01522235|Other|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
79393280|NCT01522235|Other|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
79393281|NCT00250497|Behavioral|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
79393282|NCT00125931|Drug|Talwin Nx|Talwin NX 50mg po twice
79393283|NCT00267111|Drug|Eucerin plus|1g, single application
79393284|NCT00267111|Drug|Amethocaine gel 4%|1 g, single application
79548858|NCT03267303|Drug|TS-091 5mg|Orally taken once daily for 3 weeks
79548859|NCT03267303|Drug|TS-091 10mg|Orally taken once daily for 3 weeks
79548860|NCT03267303|Drug|Placebo|Orally taken once daily for 3 weeks
79712569|NCT01293006|Drug|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
79712570|NCT02335749|Device|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
79548861|NCT03205423|Drug|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
79712571|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
79712572|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg / L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
79712573|NCT01253187|Drug|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
79712574|NCT01252563|Drug|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
79393285|NCT01521923|Biological|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
79393286|NCT01521923|Biological|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
79875222|NCT00490724|Drug|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
79393287|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
79393288|NCT00128193|Other|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
79393289|NCT00128193|Other|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
79548862|NCT03149302|Other|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
79548863|NCT03149302|Other|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
79548864|NCT03149302|Other|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
79548865|NCT03149302|Other|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
79548866|NCT03122821|Other|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS [2, 19-25]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
79253691|NCT04971356|Drug|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
79253692|NCT04971356|Drug|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
79393290|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
79712575|NCT01292226|Drug|mycophenolate mofetil|1 g PO BID for 24 weeks
79253693|NCT04971356|Drug|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
79253694|NCT04970888|Other|Cognitive training|"The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general."
79393291|NCT00128193|Other|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
79393292|NCT05240781|Device|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
79712576|NCT01292226|Drug|antibody induction|According to manufacturer recommendation
79712577|NCT01292226|Drug|Cyclosporine|According to manufacturer recommendation
79712578|NCT01292226|Drug|corticosteroid|According to manufacturer recommendation
79712579|NCT04207047|Device|Genius|"The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic."
79712580|NCT04207047|Device|eC02|The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
79712581|NCT04207047|Device|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
79712582|NCT04207047|Device|LaseMD|The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
79850460|NCT03620266|Dietary Supplement|Bioprocessed oat bran|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
79850461|NCT03620266|Dietary Supplement|Combination bilberry/oats|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
79850462|NCT03580616|Drug|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
79850463|NCT03566667|Drug|Metoprolol|Betablocker
79548867|NCT03122821|Other|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS [2, 19-25]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
79548868|NCT03073603|Drug|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
79548869|NCT03073603|Drug|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
79850464|NCT03566667|Drug|Standard care|Standard care
79850465|NCT03544489|Behavioral|E-ICD Intervention|Home walking 3 days/week x 12 weeks
79253695|NCT04970888|Other|Exercise training|Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
79393293|NCT05240781|Device|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
79548870|NCT03002155|Other|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
79393294|NCT01520987|Drug|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
79393295|NCT01520987|Drug|Placebo|once-daily
79393296|NCT00130923|Drug|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
79393297|NCT00130923|Drug|oral risperidone|0.50-6.00 mg oral risperidone daily
79393298|NCT04117581|Dietary Supplement|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
79393299|NCT04117581|Other|Placebo|Inert filler capsules daily over 12 weeks (84 days)
79393300|NCT02103153|Device|Picosure Laser System|
79393301|NCT01899573|Device|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
79548871|NCT02918006|Biological|VXA-A1.1|Enteric coated oral vaccine tablet
79548872|NCT02918006|Biological|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
79548873|NCT02918006|Other|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
79548874|NCT02918006|Other|Saline Solution for Placebo IM Injection|
79393302|NCT02103309|Device|Nelfilcon A contact lenses|
79393303|NCT02103309|Device|Etafilcon A contact lenses|
79253696|NCT04970888|Other|Usual care|All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
79850466|NCT03514589|Drug|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
79850467|NCT03514589|Drug|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
79253697|NCT04969081|Behavioral|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
79393304|NCT01897857|Device|duplex Doppler ultrasonography|
79393305|NCT00272337|Drug|Aspirin|Dosage
79548875|NCT02917772|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
79712583|NCT04207047|Device|LaseMD Flex|There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
79548876|NCT02909686|Dietary Supplement|Boswellia Serrata|
79850468|NCT03497546|Other|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
79548877|NCT02909686|Dietary Supplement|Curcumin|
79253698|NCT04969081|Other|treatment as usual|usual treatment
79253699|NCT04965701|Drug|Osimertinib 80 MG|Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
79253700|NCT04962646|Procedure|Carbon dioxide flooding|Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
79253701|NCT04961593|Drug|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
79253702|NCT04961580|Drug|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
79393306|NCT01562275|Drug|Ipatasertib|multiple doses
79548878|NCT02909686|Dietary Supplement|Epimedium|
79548879|NCT02909686|Dietary Supplement|Fisetin|
79548880|NCT02909686|Dietary Supplement|Luteolin|
79548881|NCT02909686|Dietary Supplement|Nettle|
79548882|NCT02909686|Dietary Supplement|Pycnogenol|
79548883|NCT02909686|Dietary Supplement|Reishi Mushroom|
79548884|NCT02909686|Dietary Supplement|Resveratrol|
79548885|NCT02909686|Dietary Supplement|Placebo|
79712584|NCT01290822|Device|BiVP|Biventricular pacing
79712585|NCT01290822|Device|AAI Pacing|Atrial pacing
79712586|NCT01075048|Drug|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
79393307|NCT01562275|Drug|Cobimetinib|multiple doses
79393308|NCT01535053|Biological|Dactinomycin|Given IV
79393309|NCT01535053|Drug|Leucovorin Calcium|Given PO
79393310|NCT01535053|Drug|Methotrexate|Given IV and IM
79393311|NCT01535053|Other|Quality-of-Life Assessment|Ancillary studies
79393312|NCT04410055|Behavioral|Sitting|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
79393313|NCT04410055|Behavioral|Static standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
79404278|NCT03581617|Diagnostic Test|sHLA-G analysis|sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
79548886|NCT02885324|Drug|Cabozantinib|Subjects will receive Cabozantinib
79850469|NCT03496805|Drug|MGE|The patients will take 4 capsules by mouth BID (twice daily).
79850470|NCT03496805|Other|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
79850471|NCT03496805|Other|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
79850472|NCT03495609|Drug|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
79850473|NCT03493282|Drug|Active Treatment- CT1812 100 mg|CT1812
79850474|NCT03493282|Drug|Active Treatment- CT1812 300 mg|CT1812
79850475|NCT03493282|Drug|Placebo|Matching Placebo
79393314|NCT04410055|Behavioral|Dynamic standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
79850476|NCT03475810|Device|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
79393315|NCT01534663|Drug|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
79393316|NCT01534663|Drug|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
79850477|NCT03475810|Drug|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
79393317|NCT01520909|Drug|Eltrombopag|Thrombopoietin receptor agonist
79393318|NCT01520909|Drug|Placebo|Placebo with no active pharmaceutical ingredient
79850478|NCT03445494|Procedure|Brace|A brace to be weared according to protocol
79850479|NCT03445494|Procedure|Normal sling|A normal sling to be weared according to protocol
79253703|NCT04961190|Behavioral|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
79850480|NCT03443856|Drug|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
79850481|NCT03443856|Other|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
79850482|NCT03418753|Diagnostic Test|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
79850483|NCT03389750|Drug|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
79850484|NCT03385330|Other|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
79850485|NCT03385330|Other|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
79850486|NCT03328884|Drug|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
79253704|NCT04961190|Drug|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
79253705|NCT04959890|Genetic|Strimvelis|This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
79253706|NCT04952597|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
79393319|NCT03027635|Device|PleurX, peritoneal tunnelated catheter|A permanent catheter
79393320|NCT03027635|Device|Large Volume Paracentesis|Short time drainage
79393321|NCT03027635|Drug|Ciprofloxacin 500Mg Tablet|SBP prophylaxis
79393322|NCT03027713|Procedure|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
79393323|NCT03027479|Other|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
79850487|NCT03326804|Device|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
79850488|NCT03303547|Diagnostic Test|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
79850489|NCT03301558|Drug|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
79850490|NCT03301558|Drug|High dose sodium bicarbonate|3000 mg sodium bicarbonate
79850491|NCT03301467|Drug|Avacopan|Orally administered
79393324|NCT01520363|Drug|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
79393325|NCT01520363|Drug|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
79850492|NCT03301467|Drug|Avacopan Matching Placebo|avacopan matching placebo
79253707|NCT04952597|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
79253708|NCT04952597|Drug|Concurrent Chemoradiotherapy|Cisplatin / Carboplatin and Etoposide, intravenous therapy Radiotherapy
79712587|NCT01075048|Drug|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
79850493|NCT03255954|Other|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
79850494|NCT03253978|Radiation|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
79850495|NCT03238755|Other|Cardiac MRI/MRS|whole blood, plasma, and serum
79850496|NCT03225222|Diagnostic Test|biopsy|prostate biopsy
79850497|NCT03161379|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
79850498|NCT03161379|Drug|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
79850499|NCT03161379|Drug|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
79850500|NCT03161379|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
79850501|NCT03156036|Drug|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
79850502|NCT03023215|Procedure|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
79850503|NCT03023215|Procedure|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
79850504|NCT03023215|Behavioral|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
79850505|NCT03023215|Procedure|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
79850506|NCT03005925|Device|Smartphone|Smartphone application coupled with a hand dynamometer
79850507|NCT03005925|Other|physical follow up|regular visits with the specialist
79850508|NCT03005327|Drug|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
79850509|NCT02998203|Dietary Supplement|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
79850510|NCT02972060|Drug|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
79850511|NCT02972060|Drug|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
79393326|NCT01578499|Drug|Brentuximab Vedotin|Brentuximab vedotin intravenous injection.
79393327|NCT01578499|Drug|Methotrexate|Methotrexate tablets.
79712588|NCT01075048|Drug|Cetuximab|Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
79712589|NCT01075048|Drug|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
79712590|NCT01290666|Device|Fistula Plug|Bioabsorbable fistula plug
79712591|NCT01252251|Drug|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
80017227|NCT03657381|Drug|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
80017228|NCT00005918|Drug|Efavirenz|
80017229|NCT00005918|Drug|Lamivudine|
80017230|NCT00005918|Drug|Stavudine|
79712592|NCT01289574|Drug|ASC-J9|Cream for twice daily topical application to the face
79712593|NCT02888301|Procedure|Computed Tomography|Undergo 18F-clofarabine PET/CT
80017231|NCT02250846|Drug|EGFR-TKI|egfr-TKI treatment
80017232|NCT02656797|Drug|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
80017233|NCT02101398|Device|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
79393328|NCT01578499|Drug|Bexarotene|Bexarotene tablets.
79393329|NCT01578187|Device|Hair2Go|Treatment with the device once under observation
79393330|NCT01561963|Drug|Apremilast|Tablets for oral administration
79393331|NCT01561963|Drug|Rifampin Oral Capsules|Capsules for oral administration
79393332|NCT01561963|Drug|Rifampin IV Solution|Intravenous (IV) solution
79393333|NCT04852003|Drug|SHR0410 Injection|SHR0410 Injection
79393334|NCT04852003|Drug|Placebo|Placebo for SHR0410 Injection
79393335|NCT04852003|Drug|Morphine|Morphine
79850512|NCT02968654|Procedure|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
79712594|NCT02888301|Radiation|Fluorine F 18 Clofarabine|Given IV
80017234|NCT02101398|Device|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
79548887|NCT02879812|Other|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
79393336|NCT01576783|Drug|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
79548888|NCT02879812|Other|Educational Video for Staff|Dialysis facility staff will watch a ~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
79393337|NCT01576783|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
79548889|NCT02879812|Other|Educational Video for Patients|Dialysis facilities will receive a ~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
79548890|NCT02879812|Other|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.
79548891|NCT02879812|Other|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
79393338|NCT01534351|Drug|Finasteride|Finasteride 5 mg oral tablet taken once daily.
79253709|NCT04952129|Drug|Selenomethionine|Seleno-amino acid
79712595|NCT02888301|Procedure|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
79712596|NCT00624273|Drug|Sildenafil therapy|oral use
79712597|NCT02874976|Device|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
79712598|NCT02874976|Device|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
79850513|NCT02968654|Procedure|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
80017235|NCT02101398|Device|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
80017236|NCT02101398|Device|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
79253710|NCT04952129|Drug|Methylselenocysteine|Seleno-amino acid
79253711|NCT04950816|Behavioral|tailored MBI (.b)|The session will include brief didactic presentations, videos, and mindfulness practice followed by inquiry. We anticipate that sessions will take place twice a week. Sessions will be held on site at the Covenant House Texas (CHT) shelter in a quiet, designated learning space to ease access to sessions for the participants and to assure access to shelter staff (e.g., social workers and case managers) and services (e.g., food and shelter). CHT has onsite, weekday clinical and mental health care and established protocols for accessing needed resources 24/7. Selection criteria for the interventionist include maintaining a personal mindfulness practice for at least two years, trained in .b, and prior experience working with high-risk youth. The interventionist will receive additional training in Trauma-Informed Care as well as study procedures.
79548892|NCT02879812|Other|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
79393339|NCT01534351|Drug|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
79393340|NCT01534351|Drug|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
79548893|NCT02829099|Drug|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
79548894|NCT02815254|Other|High intensity functional exercise|
79548895|NCT02815254|Other|Low intensity functional exercise|
79393341|NCT01534351|Drug|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
79393342|NCT01534273|Drug|LY2886721|Administered orally.
79393343|NCT01534273|Drug|Placebo|Administered orally.
79850514|NCT02873338|Drug|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
79253712|NCT04950816|Behavioral|attention control condition|Participants will receive no training in MBI or meditation. Topics covered may include physical activity, nutrition, managing weight, understanding adolescence, personal care, avoiding tobacco, alcohol, and drugs though this will be finalized in YR-1 with the HYWG and advisory panel. The HT program will be led by a positive adult instructor with training in health education or a related field and experience working with YEH.
79253713|NCT04948944|Device|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
79712599|NCT02874976|Device|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
79253714|NCT04946253|Behavioral|DOCC: Evidence-based treatment for disruptive behavior and ADHD|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
79253715|NCT04946253|Behavioral|TEAM: Implementation support strategies at the care team level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
79253716|NCT04946253|Behavioral|Implementation support strategies at the leadership level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
79712600|NCT02874976|Device|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
79712601|NCT04305964|Device|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
79712602|NCT04305964|Diagnostic Test|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
79850515|NCT02873338|Drug|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
79850516|NCT02873338|Drug|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
79253717|NCT04941703|Drug|Magnesium Citrate plus probiotic|296 ml magnesium citrate
79393344|NCT01534195|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
79548896|NCT02803853|Behavioral|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
79850517|NCT02864147|Drug|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
80017237|NCT02101398|Device|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
80017238|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 24Units|Experimental: Botulax® 24Units
79393345|NCT01534195|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
79393346|NCT04479384|Other|Manual therapy - osteopathic techniques|"HVLAT if any somatic dysfunction in T1-T5~Stretch intrathoracic fascia x 3~Recoil sternum x 3~Cranial base release, 4 phases"
79393347|NCT03825588|Behavioral|ASAP (As Safe As Possible)|ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
79393348|NCT03825588|Behavioral|BRITE smart phone app|BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
79548897|NCT02713373|Biological|Cetuximab|Given IV
79548898|NCT02713373|Other|Laboratory Biomarker Analysis|Correlative studies
79548899|NCT02713373|Biological|Pembrolizumab|Given IV
79393349|NCT03825588|Behavioral|TAU (treatment as usual)|TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
79393350|NCT01560949|Drug|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
79548900|NCT02686593|Drug|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
79548901|NCT02674438|Other|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
79712603|NCT01252095|Drug|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
79393351|NCT01560949|Drug|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
79712604|NCT04306042|Drug|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
79393352|NCT01560949|Drug|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
79393353|NCT01560949|Drug|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
79712605|NCT04305886|Other|Discussion Guide|Written list of prompts to facilitate discussion
79712606|NCT04305730|Behavioral|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
79712607|NCT04305730|Behavioral|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
79393354|NCT01560949|Radiation|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
79393355|NCT03113448|Drug|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
79393356|NCT03113448|Drug|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
79548902|NCT02583282|Other|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
79548903|NCT02583282|Other|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
79712608|NCT01074658|Device|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
79712609|NCT01074502|Drug|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
79712610|NCT01289028|Drug|Nilotinib|
79712611|NCT04305652|Other|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
79712612|NCT02875990|Biological|Blood sample|
79712613|NCT04777474|Diagnostic Test|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
79712614|NCT04777474|Diagnostic Test|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
79712615|NCT04777474|Diagnostic Test|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
79712616|NCT02890056|Behavioral|H2GO!|
79712617|NCT04303312|Other|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
79712618|NCT04303312|Combination Product|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
79712619|NCT05590026|Drug|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
79712620|NCT04303546|Device|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
79712621|NCT05579184|Drug|[177Lu]Ludotadipep|"Patients will receive 100 mCi of [177Lu]Ludotadipep every 8 [±1] weeks (up to 6 times)~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 4 to 6 x 3.7 GBq~Dosage form: solution for injection"
79712622|NCT04303624|Other|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
79712623|NCT04305574|Behavioral|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
79712624|NCT01250925|Drug|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
79393357|NCT01372878|Device|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
79393358|NCT01372878|Procedure|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
79393359|NCT01533493|Drug|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
79712625|NCT01250925|Drug|OPTI-FREE® RepleniSH®|Contact Lens care regimen
79393360|NCT01533493|Drug|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
79253718|NCT04933474|Behavioral|painTRAINER®|PainTRAINER is among the most widely-validated mHealth interventions for pain management.18-25 Originally developed by members of our team at Duke and Northwestern University under NIH funding, the app teaches evidence-based pain coping skills using a self-administered, home-based software program. The system delivers eight sessions via any web-connected platform, including Android or iOS smartphones, tablets, or personal computers. The digital curriculum covers progressive muscle relaxation, activity/rest cycling, pleasant activity scheduling, recognizing negative automatic thoughts, pleasant imagery/distraction, problem solving, and monitoring for maintenance. Patients complete one session per week in a pre-determined order. The program can be completed in a flexible manner to accommodate life and medical events.
79253719|NCT04933474|Device|PICO G2 4k|Patients allocated this arm will use a multi-modal, skills-based, selfmanagement VR program, called EaseVRx. Developed by AppliedVR (Los Angeles, CA) in partnership with Stanford pain psychologist Dr. Beth Darnall, the program teaches and trains users based on evidenced-based strategies and biofeedback exercises. EaseVRx combines psychoeducation, pain education, breathing training, relaxation exercises, and executive functioning games to provide a mind-body approach toward living better with pain. The standardized, reproducible, 56-day program delivers a combination of skills training and CBT-related treatments through scheduled daily virtual experiences. Each VR experience lasts between 2-16 minutes.
79393361|NCT01533493|Drug|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
79850518|NCT02864147|Drug|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
79712626|NCT01250925|Drug|Clear Care®|Contact lens care regimen
79712627|NCT01285908|Drug|Intravenous Norepinephrine Infusion|
79393362|NCT04743102|Procedure|multi-points and full-thickness Biopsy|Four points around the tumor site and center of the tumor site full-thickness Biopsy
79393363|NCT04743102|Diagnostic Test|traditional cCR|diginal examination, endoscopy test, rectal MRI, and serum CEA level
79548904|NCT02553941|Drug|Azacitidine|Given intravenous or subcutaneous
79548905|NCT02553941|Drug|Ibrutinib|Given by mouth once daily
79548906|NCT02546492|Drug|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
79548907|NCT02527564|Drug|Suvorexant|
79548908|NCT02527564|Drug|Placebo|
79712628|NCT05577234|Other|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
79712629|NCT05577234|Behavioral|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
79548909|NCT02282007|Behavioral|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
79712630|NCT01250769|Device|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
79712631|NCT01250769|Device|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
79712632|NCT05574270|Device|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
79712633|NCT01074268|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
79393364|NCT04439604|Other|regional ventilation monitoring|regional ventilation monitoring
79548910|NCT02179749|Drug|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
79712634|NCT01074268|Drug|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
79712635|NCT01074268|Drug|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
79712636|NCT04303234|Other|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
80017239|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 48Units|Experimental: Botulax® 48Units
80017240|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 72Units|Experimental: Botulax® 72Units
79548911|NCT02179749|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
79548912|NCT02179749|Drug|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
79548913|NCT02075593|Drug|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
79548914|NCT02065609|Drug|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
79548915|NCT02065609|Drug|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
80017241|NCT04443244|Drug|Botulinum Toxin Type A Injection (Botulax®) 96Units|Experimental: Botulax® 96Units
80017242|NCT04443244|Other|Normal Saline|Placebo Comparator: Normal Saline
79712637|NCT04303234|Other|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
79712638|NCT01074190|Drug|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
79712639|NCT01074190|Drug|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
79712640|NCT01074190|Drug|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
79548916|NCT01941108|Behavioral|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
79712641|NCT01073566|Device|Finesse|Finesse Insulin Delivery Patch
79712642|NCT01073566|Device|Pen/Syringe (Usual injection device)|Pen/Syringe
79712643|NCT01072396|Drug|Tiotropium|double blind randomized crossover
79712644|NCT01072396|Drug|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
79712645|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
79712646|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
79712647|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
79393365|NCT04479930|Other|Pulmonary Care Web-Based App (HappyAir App)|The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
79712648|NCT02876146|Drug|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
79712649|NCT02874586|Other|Plasma exchange combination of immunosuppressive regimens|
79712650|NCT02875756|Procedure|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
79712651|NCT02875756|Procedure|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
79253720|NCT04926597|Dietary Supplement|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
79253721|NCT04926597|Other|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
79253722|NCT04926597|Other|general nutritional information|general information about health food behavior upon hospital discharge
79393366|NCT02388048|Drug|Ibrutinib + ofatumumab|
79393367|NCT02388126|Device|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
79393368|NCT02388126|Device|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
79393369|NCT02387736|Behavioral|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
79548917|NCT01037816|Drug|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
79548918|NCT01037816|Other|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
79548919|NCT01009138|Behavioral|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~Problem Analysis and Definition~Problem Solving Intervention~Cognitive Restructuring~Activation of personal and social Resources~Goal Definition and Agreement"
79712652|NCT04305418|Other|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
79712653|NCT02875678|Drug|ABX-1431|Single-dose ABX-1431
79712654|NCT02875678|Drug|Placebo|Single-dose matching placebo
79712655|NCT02874820|Radiation|[11C]BU99008|Baseline and blocked scans
79712656|NCT02874820|Drug|Idazoxan|Idazoxan dose up to 80mg
79712657|NCT04305028|Drug|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
79712658|NCT04305028|Drug|Aspirin|Aspirin 75-100 mg once daily, tablet
79712659|NCT04304794|Procedure|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
79712660|NCT04304794|Drug|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
79393370|NCT02387736|Behavioral|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
79548920|NCT01009138|Behavioral|Standard Diabetes Education|"Standard Diabetes Education Lesson including~Health Care and specific Topics (e. g. Blood Pressure)~Social Aspects of Living with Diabetes~Diabetes Complications~Sports, Activities and Exercise~Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
79393371|NCT02387892|Dietary Supplement|Cheese & yogurt + Vitamin D|cheese & yogurt with added 420 IU cholecalciferol
79548921|NCT00641186|Drug|sodium oxybate|4.5 to 9.0 grams per night
79712661|NCT01285518|Drug|PF-05231023|0.5 mg QD IV x 1 day
79712662|NCT01285518|Drug|PF-05231023|1.5 mg QD IV x 1 day
79850519|NCT02863055|Drug|Nintedanib|Nintedanib 200 mg administered twice daily
79850520|NCT02863055|Drug|Placebo|Matching placebo administered twice daily
79393372|NCT02387892|Dietary Supplement|Cheese & yogurt|Cheese & yogurt without added vitamin D
79712663|NCT01285518|Drug|PF-05231023|5 mg QD IV x 1 day
79712664|NCT01285518|Drug|PF-05231023|15 mg QD IV x 1 day
79712665|NCT01285518|Drug|PF-05231023|50 mg QD IV x 1 day
79393373|NCT05581290|Device|AI-Flex|A flexible multi-modal bio-sensing device with integrated AI capability used to measure ECG (heart's electrical activity), body temperature, and PPG (blood volume in tissue); primarly mounted on the wrist and chest.
79548922|NCT01561482|Drug|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
79548923|NCT01561482|Drug|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
79712666|NCT01285518|Drug|PF-05231023|100 mg QD IV x 1 day
79712667|NCT01285518|Drug|PF-05231023|200 mg QD IV x 1 day
79712668|NCT01285518|Other|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
79712669|NCT01073020|Device|Allergan Adjustable Gastric Band Surgery|
79712670|NCT01073020|Other|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group
79712671|NCT01073020|Procedure|Roux-en-Y Gastric Bypass (RYGB) Surgery|
79850521|NCT02809690|Device|CAT|Undergo 18F-FMAU PET/CT
79850522|NCT02809690|Drug|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
79404279|NCT03581617|Diagnostic Test|HLA-G 14bp INS/DEL typing|Genomic DNA will be genotyped by RealTime PCR
79712672|NCT01073020|Other|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
79712673|NCT02875600|Other|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
79712674|NCT02874664|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
79850523|NCT02809690|Other|Laboratory Biomarker Analysis|Correlative studies
79850524|NCT02809690|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79404280|NCT03581617|Diagnostic Test|sHLA-E analysis|sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
79404281|NCT05102994|Diagnostic Test|mutation test|detect the tumor-related mutation in introcular fluid
79712675|NCT02889744|Device|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
79712676|NCT04754308|Diagnostic Test|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
79712677|NCT00623844|Behavioral|physical activity|activity program at kindergarten 5 * 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
79712678|NCT04207554|Device|Test Device-Strip Format|Sponsor's investigational device
79712679|NCT04207554|Device|Test Device-Cassette Format|Sponsor's investigational device
79712680|NCT04207554|Device|Predicate Device|Commercially available device
79712681|NCT02875522|Other|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
79712682|NCT02874196|Procedure|Standard arthrography|
79850525|NCT02809690|Device|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
79850526|NCT02809690|Device|Ultrasound|Undergo TRUS-guided biopsy
79850527|NCT02781935|Procedure|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
79850528|NCT02777385|Drug|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
79393374|NCT05298540|Behavioral|Home-based computerised cognitive training with BrainHQ|Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
79393375|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 intramuscularly (IM).
79393376|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 subcutaneously (SC).
79850529|NCT02777385|Drug|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
79393377|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
79253723|NCT04923633|Device|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
79253724|NCT04916535|Other|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
79712683|NCT02874196|Procedure|Dual energy arthrography|
79253725|NCT04914975|Other|Neuromuscular electrical stimulation|The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
79548924|NCT01561586|Drug|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
79253726|NCT04907383|Other|quality of life|QoL assessment
79393378|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
79393379|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^6 or 10^7 TCID50 intradermally (ID).
79712684|NCT02874196|Procedure|Arthro-tomosynthesis|
79712685|NCT02874196|Procedure|Arthro-tomography|
79712686|NCT02874196|Procedure|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
79850530|NCT02777385|Radiation|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
79850531|NCT02725567|Drug|IVA|Granules in sachet for oral administration.
79850532|NCT02674217|Procedure|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
79850533|NCT02639702|Drug|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
79850534|NCT02615275|Procedure|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
79253727|NCT04903002|Drug|24-IU oxytocin|Patients will self-administer a 2-week course of 24-IU intranasal oxytocin [4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland], twice per day (once in the morning and once in the evening).
79712687|NCT01284114|Drug|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
79712688|NCT02875444|Other|Angio-CT|
79712689|NCT01283334|Drug|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
79712690|NCT01283334|Drug|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
79712691|NCT01283334|Drug|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
79712692|NCT01282866|Device|LightSheer Duet|LightSheer Duet HS handpiece
79253728|NCT04903002|Drug|48-IU oxytocin|Patients will self-administer a 2-week course of 48-IU intranasal oxytocin [4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland], twice per day (once in the morning and once in the evening).
79850535|NCT02615275|Procedure|Computed Tomography|Undergo CT
79850536|NCT02615275|Procedure|Positron Emission Tomography|Undergo PET
79850537|NCT02615275|Other|Quality-of-Life Assessment|Ancillary studies
79850538|NCT02615275|Other|Questionnaire Administration|Ancillary studies
79850539|NCT02615275|Radiation|Radiation Therapy|Undergo RT
79850540|NCT02610673|Device|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
79850541|NCT02592356|Procedure|Computed Tomography|Correlative studies
79850542|NCT02592356|Procedure|Dual X-ray Absorptiometry|Correlative studies
79712693|NCT01071070|Drug|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
79712694|NCT04304716|Drug|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
79850543|NCT02592356|Procedure|Physical Examination|Correlative studies
79393380|NCT00133575|Biological|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
79712695|NCT01282476|Drug|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
79712696|NCT02889822|Drug|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
79712697|NCT04323618|Device|Breathe Well|
79850544|NCT02592356|Other|Quality-of-Life Assessment|Ancillary studies
79850545|NCT02592356|Other|Questionnaire Administration|Ancillary studies
79850546|NCT02592356|Drug|Cabozantinib|
80017243|NCT04383327|Behavioral|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers and PTAs (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training before the 1st school term. They will also receive 8 sessions (12 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
79712698|NCT04323696|Procedure|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
79850547|NCT02592356|Drug|Lenvatinib|
79850548|NCT02555579|Behavioral|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
79850549|NCT02517684|Drug|Infliximab|
79253729|NCT04903002|Drug|Placebo|Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
79850550|NCT02517684|Drug|Prednisolone|
79850551|NCT02517684|Other|Exclusive enteral nutrition|
79850552|NCT02517684|Drug|Azathioprine|
79850554|NCT02431130|Other|low-fidelity instructor driven simulation training|
79393381|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
79393382|NCT00133809|Drug|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
79393383|NCT00134043|Drug|vorinostat|Given orally
79393384|NCT01899495|Other|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
79850555|NCT02290951|Drug|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
79850556|NCT02290951|Drug|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
79850557|NCT02255773|Behavioral|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
79850558|NCT02255773|Behavioral|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
79850559|NCT02209545|Drug|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
79850560|NCT02209545|Drug|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
79850561|NCT02186509|Radiation|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
79393385|NCT05177367|Other|Sequential Variety|3 courses each consisting of a different food
79393386|NCT05177367|Other|Simultaneous Variety|3 courses each consisting of 3 foods
79393387|NCT05177367|Other|Single Food|3 courses each consisting of the same food
79393388|NCT05177367|Other|Small portion|Small meal portion size
79850562|NCT02186509|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
79850563|NCT02186509|Drug|Alisertib|Given PO
79393389|NCT05177367|Other|Large Portion|Large meal portion size
79850564|NCT02186509|Procedure|Quality-of-life assessment|Ancillary studies
79253730|NCT04898764|Drug|Mometasone Furoate|Mometasone furoate nasal spray suspension, 50µg/actuation
79253731|NCT04894890|Drug|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
79253732|NCT04878991|Diagnostic Test|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
79393390|NCT04389255|Other|Star Excursion Balance Test|The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.[
79712699|NCT01282164|Procedure|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
79393391|NCT04389255|Device|Balance Master device|The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
79712700|NCT01282164|Procedure|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
79712701|NCT01250379|Drug|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
79393392|NCT04751721|Biological|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
79393393|NCT03715998|Drug|Ramipril|1 or 2 capsules administered orally, twice daily
79393394|NCT03715998|Drug|Firibastat|1 or 2 capsules administered orally, twice daily
79850565|NCT02108964|Drug|EGF816|EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
79850566|NCT02086045|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
79393395|NCT01790451|Procedure|Irreversible Electroporation|
79393396|NCT01790529|Procedure|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
79393397|NCT01790529|Procedure|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
79712702|NCT01250379|Drug|Chemotherapy|Standard chemotherapy (doublets not allowed)
79712703|NCT01072630|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
79712704|NCT01072630|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
79712705|NCT04304638|Radiation|radiation or chemo-radiation|standard treatment for stage III lung cancer
79850567|NCT02086006|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
79850568|NCT01976065|Drug|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
79253733|NCT04872452|Procedure|Skin biopsy|Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
79253734|NCT04870853|Other|Electronic Health Record Review|Medical records reviewed
79712706|NCT04304638|Drug|EGFR-TKI Inhibitor|the standard treatment for stage IV lung cancer with EGFR mutation
79712707|NCT04302532|Drug|Coenzyme Q10|antioxidant used to decrease oxidative stress and improve fertility prospects
79712708|NCT04302532|Drug|clomiphene citrate|ovulation induction drug
79712709|NCT01281306|Drug|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
79712710|NCT01281306|Drug|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
79850569|NCT01976065|Other|Standard Treatment|Standard Treatment no use of study drug
79850570|NCT01970332|Procedure|Revascularization Surgery|
79850571|NCT01970332|Other|Supervised exercise therapy|
79850572|NCT01921335|Drug|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
79850573|NCT01921335|Drug|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
79850574|NCT01921335|Drug|Trastuzumab|6 mg/kg IV every 3 weeks
79850575|NCT01915810|Behavioral|Exercise Intervention|Complete SCwPA intervention
79850576|NCT01915810|Other|Laboratory Biomarker Analysis|Correlative studies
79850577|NCT01915810|Drug|Nicotine Patch|Receive nicotine patch
79850578|NCT01915810|Other|Questionnaire Administration|Ancillary studies
79850579|NCT01915810|Other|Tobacco Cessation Counseling|Receive smoking cessation counseling
79850580|NCT01909453|Drug|LGX818|LGX818- Orally 100 mg and 50 mg capsules
79850581|NCT01909453|Drug|MEK162|MEK162- Orally 15 mg tablets
79850582|NCT01909453|Drug|vemurafenib|Tablets in bottles or blisters 240 mg
79850583|NCT01882803|Drug|Duvelisib|Phosphoinositide-3-kinase (PI3K) inhibitor
79548925|NCT01561586|Drug|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
79712711|NCT01281306|Drug|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
79712712|NCT01281306|Drug|Placebo|Placebo was supplied as tablets in blister cards.
79712713|NCT04304560|Drug|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
79712714|NCT04304560|Drug|Placebo oral tablet|Similar Placebo oral tablet
79712715|NCT00626860|Biological|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
79712716|NCT04643470|Drug|Zanubrutinib|Administered as specified in the treatment arm
79712717|NCT04643470|Drug|Placebo|Placebo to match zanubrutinib
79712718|NCT01250145|Drug|LY333334|Transdermal patch
79712719|NCT01250145|Drug|Placebo|Transdermal patch
79712720|NCT04323384|Device|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
79712721|NCT01067326|Drug|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
79712722|NCT01067326|Drug|Placebo|1 pill per day by mouth for 4 months
79712723|NCT04319601|Drug|Rituximab|a new chemotherapy regimen
79393398|NCT04751643|Other|Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|"Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation"
79393399|NCT04751643|Other|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
79712724|NCT01279200|Other|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
79712725|NCT01279200|Other|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
79712726|NCT04640896|Drug|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
79712727|NCT04640896|Drug|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
79850584|NCT01855633|Device|Traditional Theta burst stimulation (TBS)|
79850585|NCT01855633|Device|Modified TBS rTMS|
79850586|NCT01855633|Device|Sham rTMS|
79850587|NCT01797523|Drug|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
79850588|NCT01797523|Drug|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
79712728|NCT04640896|Drug|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
79712729|NCT01273818|Drug|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
79850589|NCT01797523|Drug|Everolimus|10 mg by mouth once daily in a 28 day cycle.
79850590|NCT01787500|Biological|Cetuximab|Given IV
79850591|NCT01787500|Drug|Irinotecan Hydrochloride|Given IV
79850592|NCT01787500|Other|Laboratory Biomarker Analysis|Correlative studies
79850593|NCT01787500|Other|Pharmacological Study|Correlative studies
79850594|NCT01787500|Drug|Vemurafenib|Given PO
79850595|NCT01669824|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
79850596|NCT01472562|Drug|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
79712730|NCT01273818|Drug|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
79253735|NCT04868032|Behavioral|Positive Psychology-Motivational Interviewing|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
79253736|NCT04868032|Behavioral|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
79253737|NCT04861350|Other|motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will mentally simulate each exercise with video 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
79850597|NCT01472562|Biological|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
79850598|NCT01334021|Procedure|Biopsy|Undergo tumor biopsy
79850599|NCT01334021|Procedure|Conventional Surgery|Undergo surgery
79712731|NCT01273818|Drug|Gentamicin|80 mg gentamicin application intraoperatively
79850600|NCT01334021|Other|Genetic Testing|Undergo genetic testing
79850601|NCT01278225|Behavioral|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
79850602|NCT01278225|Behavioral|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
79850603|NCT01278225|Behavioral|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
79393400|NCT02387658|Procedure|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
79393401|NCT04717323|Device|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
79850604|NCT01266044|Procedure|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
79712732|NCT01245387|Drug|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
79850605|NCT01266044|Procedure|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
79850606|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
79548926|NCT01561859|Behavioral|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
79712733|NCT01037218|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
79712734|NCT01037218|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
79712735|NCT01038856|Drug|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
79712736|NCT04302688|Other||
79850607|NCT01266044|Other|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
79850608|NCT01202851|Other|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
79850609|NCT01202851|Behavioral|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
79850610|NCT01202851|Other|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
79393402|NCT04717323|Device|No Intervention|Gait with no pelvic assistance
79393403|NCT01790607|Drug|ONO-2745 /CNS 7056|
79393404|NCT03644472|Drug|nitrate rich beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
79393405|NCT03644472|Drug|nitrate depleted beetroot juice|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
79393406|NCT00278655|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
79850611|NCT01196390|Drug|Carboplatin|Given IV
79850612|NCT01196390|Other|Laboratory Biomarker Analysis|Correlative studies
79850613|NCT01196390|Drug|Paclitaxel|Given IV
79850614|NCT01196390|Other|Quality-of-Life Assessment|Ancillary studies
79850615|NCT01196390|Radiation|Radiation Therapy|Undergo radiation therapy
79850616|NCT01196390|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79253738|NCT04861350|Other|physical training|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will physically perform each exercise with supervision of investigator 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
79253739|NCT04861350|Other|combine physical training and motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, each exercises will be mentally simulated with video for a set and physically performed with supervision of investigator for 2 sets, 10 times for each set and 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
79253740|NCT04850222|Drug|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
79393407|NCT03113604|Other|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
79393408|NCT01533181|Other|Laboratory Biomarker Analysis|Correlative studies
79850617|NCT01196390|Biological|Trastuzumab|Given IV
79850618|NCT01164995|Drug|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
79850619|NCT01156129|Drug|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
79850620|NCT01156129|Device|Arm B: Acupressure bracelet|Bioband
79850621|NCT01156129|Dietary Supplement|sugar free gum|Orbit
79850622|NCT00956007|Biological|cetuximab|Given IV
79850623|NCT00956007|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy.
79393409|NCT01533181|Drug|Linsitinib|150 mg given orally (PO) twice a day (BID)
79393410|NCT01533181|Other|Pharmacological Study|Correlative studies
79393411|NCT01533181|Drug|Topotecan Hydrochloride|1.5 mg/m^2 intravenously (IV) or 2.3 mg/m^2 orally (PO)
79393412|NCT04641507|Drug|Tadalafil versus tamsulosin as MET|166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
79548927|NCT01561859|Behavioral|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
79712737|NCT01066546|Drug|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
79712738|NCT02874118|Behavioral|Fried scale for frailty assessement|
79712739|NCT02873572|Behavioral|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
79850624|NCT00905515|Drug|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
79850625|NCT00905515|Drug|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
79850626|NCT02455791|Procedure|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
79850627|NCT00898365|Other|Cytology Specimen Collection Procedure|Correlative studies
79850628|NCT00898365|Other|Laboratory Biomarker Analysis|Correlative studies
79850629|NCT00877500|Other|Best Practice|Receive standard of care
79850630|NCT00877500|Drug|Ixabepilone|Given IV
79850631|NCT00659126|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
79850632|NCT00659126|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
79850633|NCT00659126|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
79850634|NCT00659126|Drug|Ferumoxytol|Given IV
79850635|NCT00659126|Drug|Gadolinium|Given IV
79850636|NCT00659126|Procedure|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
79850637|NCT00659126|Procedure|Susceptibility Weighted Imaging|Undergo SWI
79850638|NCT00615082|Behavioral|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
79850639|NCT00615082|Behavioral|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
79393413|NCT04518969|Device|CytoSorb|"CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
79393414|NCT03113526|Procedure|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
79712740|NCT02873572|Behavioral|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~psychiatric assesment and~registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
79850640|NCT00581139|Behavioral|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
79850641|NCT00581139|Drug|Midazolam|0.5 mg/kg oral midazolam
79850642|NCT00581139|Behavioral|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
79850643|NCT00581139|Other|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
79850644|NCT00572013|Drug|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
79850645|NCT00572013|Drug|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
79712741|NCT01272804|Drug|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
79712742|NCT01272804|Drug|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
79712743|NCT01269918|Drug|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
79712744|NCT01269918|Drug|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
79850646|NCT00572013|Procedure|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
79850647|NCT00515372|Other|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
79850648|NCT00515372|Other|Usual Care|Lists of professional resources and referral recommendations will be provided.
79850649|NCT00498875|Behavioral|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
79850650|NCT00498875|Behavioral|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
79850651|NCT00496522|Procedure|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
79850652|NCT00493831|Drug|nicotine polacrilex, transdermal system or inhaler|on label use of Nicotine replacement therapy (NRT)
79850653|NCT00482690|Drug|nicotine polacrilex|
79393415|NCT04489173|Drug|trifluridine/tipiracil|"Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days."
79548928|NCT01562145|Procedure|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
79548929|NCT01562171|Other|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
79548930|NCT01562171|Other|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
79850654|NCT00482690|Drug|nicotine transdermal system|
79850655|NCT00482690|Drug|nicotine inhaler|
79850656|NCT00177645|Procedure|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
79850657|NCT00152503|Drug|Seletracetam (UCB44212)|"Pharmaceutical form: oral capsules~Concentration: 2, 10 and 50 mg~Route of administration: oral administration"
79850658|NCT00004197|Biological|keyhole limpet hemocyanin|
79850659|NCT00004197|Biological|sargramostim|
79548931|NCT01562184|Device|Sham tDCS device|Sham tDCS
79850660|NCT00004197|Biological|tumor cell-based vaccine therapy|
79850661|NCT00004197|Drug|cyclophosphamide|
79850662|NCT00004197|Drug|doxorubicin hydrochloride|
79548932|NCT01562184|Device|Soterix tDCS device|Active tDCS
79850663|NCT00004197|Drug|mitoxantrone hydrochloride|
79712745|NCT05658666|Behavioral|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
79850664|NCT00004197|Drug|prednisone|
79712746|NCT01036594|Drug|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
79850665|NCT00004197|Drug|vincristine sulfate|
79850666|NCT03865407|Drug|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
79850667|NCT00487942|Drug|armodafinil|50 mg/day armodafinil
79850668|NCT00487942|Drug|armodafinil|100 mg/day armodafinil
79850669|NCT00487942|Drug|armodafinil|200 mg/day armodafinil
79393416|NCT02669082|Drug|Ramelteon|Ramelteon tablets
79393417|NCT00138645|Behavioral|MicroDiet|MicroDiet
79850670|NCT00487942|Drug|placebo|placebo
79393418|NCT00138645|Behavioral|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
79548933|NCT01562392|Dietary Supplement|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
79850671|NCT00132301|Drug|Docetaxel|Chemotherapy agent
79548934|NCT01562392|Dietary Supplement|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
79850672|NCT00132301|Drug|Prednisone|steroid in combination with chemotherapy agent
79548935|NCT01562574|Drug|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
79850673|NCT00522873|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
79850674|NCT00522873|Drug|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
79850675|NCT03684057|Behavioral|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
79850676|NCT03864627|Drug|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
79850677|NCT03864627|Drug|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
80017244|NCT04383327|Behavioral|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including a half-day workshop for common stress management and a half-day for burnout management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group in each school, a total 15 hours of coaching).
79393419|NCT00512070|Drug|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
79393420|NCT00140205|Drug|r-metHuLeptin|r-metreleptin was given in 3 different dose in fed and fasting states
79548936|NCT01562574|Drug|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
79850678|NCT00519831|Biological|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
79850679|NCT00519831|Drug|vinflunine|Vinflunine 320 mg/m² every 21 days
79850680|NCT04303845|Drug|Erenumab|140 mg of erenumab via subcutaneous injection
79850681|NCT03964623|Diagnostic Test|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
79850682|NCT04269915|Biological|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
79850683|NCT04187703|Drug|5-azacytidine|5-azacytidine 50 mg/m^2 Day 1 every week ± G-CSF ~5 µg/kg (300µg vs 480µg)
80017245|NCT02101476|Drug|Percocet|10mg/650mg
80017246|NCT02101476|Drug|Xartemis|15mg/650mg
80017247|NCT00005606|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
79548937|NCT01562587|Drug|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
79548938|NCT01562587|Drug|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
79850684|NCT04187703|Drug|Decitabine|Decitabine 5 mg/m^2 Day 4 every week ± G-CSF ~5 µg/kg (300µg vs 480µg)
79850685|NCT00131911|Drug|sorafenib tosylate|400 mg given orally
80017248|NCT00005606|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
79712747|NCT01036594|Drug|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has <30% PSA decline, patient goes off study."
79393421|NCT05661552|Drug|Evolocumab 140 MG/ML|Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe
79548939|NCT01562704|Drug|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
79712748|NCT01036594|Drug|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
79850686|NCT01077037|Other|Decision Aid|Chest pain choice decision aid
79712749|NCT05657886|Other|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
79712750|NCT05657886|Other|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
79712751|NCT02874352|Device|high resolution impedance manometry with Automated Impedance Manometry analysis|
79712752|NCT04302610|Device|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
79712753|NCT04302610|Device|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
79712754|NCT04301908|Drug|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
79712755|NCT01036438|Device|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
79712756|NCT01036438|Device|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
79712757|NCT04304248|Drug|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
79712758|NCT01268046|Drug|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
79712759|NCT01268046|Drug|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
79850687|NCT03968887|Other|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
79850688|NCT01582633|Biological|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~influenza A/California/7/2009 (H1N1)~influenza A/Perth/16/2009 (H3N2)~influenza B/Brisbane/60/2008 Single dose."
79850689|NCT03968575|Device|laser treatment|sub-threshold micro-pulse laser treatment
79850690|NCT00184093|Drug|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
79850691|NCT01074619|Drug|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
79548940|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
79548941|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
79850692|NCT01074619|Drug|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
79850693|NCT00183625|Behavioral|Individual Placement and Support (Supported Employment)|
79850694|NCT00183625|Behavioral|Social Skills Training|
79850695|NCT00183625|Drug|Olanzapine|
79393422|NCT05661552|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg will be assigned to all participants
79393423|NCT05661552|Drug|Ezetimibe 10mg|Ezetimibe 10mg will be assigned to all participants
79393424|NCT00279591|Device|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
79393425|NCT00279591|Device|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
79548942|NCT01562821|Drug|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
79850696|NCT00183625|Drug|Risperidone|
79850697|NCT00511875|Drug|doxycycline monohydrate|50mg once daily for 24 months
79850698|NCT00511875|Drug|placebo|placebo taken once daily for 24 months
79850699|NCT02576327|Drug|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
79850700|NCT02576327|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
79850701|NCT02576327|Drug|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
79850702|NCT00183391|Drug|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
79850703|NCT00183391|Drug|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
79850704|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
79850705|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
79850706|NCT01021150|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
79850707|NCT01021150|Drug|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
79850708|NCT03997006|Drug|IV Aminophylline|IV Aminophylline (100 mg/8h)
79850709|NCT03997006|Drug|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
79393426|NCT03534102|Drug|Improved Opioid-Tapering Instructions|Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
79393427|NCT03534102|Behavioral|Clinical Patient Educator|Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
79548943|NCT01563133|Procedure|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
79548944|NCT01563133|Device|nCLE|needle-based Confocal Laser Endomicroscopy
79548945|NCT01563263|Biological|IC43|100 mcg
79253741|NCT04850222|Drug|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
79253742|NCT04849390|Drug|ESO-101|Daily administration in the evening at bedtime for 28 days
79253743|NCT04849390|Drug|Placebo|Daily administration in the evening at bedtime for 28 days
79253744|NCT04838457|Behavioral|Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM)|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
79253745|NCT04837378|Other|Abdominal Massage|The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.
79393428|NCT00141765|Procedure|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
79393429|NCT00141765|Procedure|Stem Cell Rescue|autologous stem cell transplantation
79393430|NCT02668692|Drug|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
79548946|NCT01563263|Drug|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
79548947|NCT01563445|Drug|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
79393431|NCT02668692|Drug|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
79393432|NCT01899807|Device|OssDsign AB|
79548948|NCT01563445|Drug|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
79548949|NCT01563458|Drug|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
79548950|NCT01563458|Drug|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
79712760|NCT01268046|Drug|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
79712761|NCT01268046|Drug|placebo oral capsule|placebo oral capsule administered daily for one month.
79712762|NCT04302298|Device|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
79712763|NCT00627484|Procedure|Gastric bypass|NOTE: the surgery is not paid for by the study
79712764|NCT00627484|Procedure|Gastric banding|NOTE: the surgery is not paid for by the study
79712765|NCT00627484|Procedure|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
79393433|NCT00281463|Device|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
79393434|NCT03106116|Device|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
79393435|NCT03106116|Drug|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
79393436|NCT03105882|Device|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
79393437|NCT00144963|Drug|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
79393438|NCT00144963|Drug|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
79393439|NCT02662764|Drug|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
79548951|NCT01563458|Drug|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
79548952|NCT01563471|Drug|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
79548953|NCT01563471|Drug|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
79712766|NCT00627484|Behavioral|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
79712767|NCT01267266|Drug|saracatinib|Given orally
79712768|NCT01267266|Other|hydrocortisone/placebo|Given orally
79712769|NCT01034176|Drug|levofloxacin|500 mg tablet, daily, 30 days
79712770|NCT01034176|Drug|placebo|no dose, tablet, daily, 30 days
79712771|NCT02889432|Drug|Oral Melatonin 10mg|
79712772|NCT02889432|Drug|Placebo|
79712773|NCT04323540|Procedure|Peri-implantitis reconstructive surgery|"For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap."
79253746|NCT04837378|Other|In-bed Exercise|In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
79548954|NCT01563497|Drug|PF-05089771|Oral dispersion TS formulation- fasted
79548955|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fasted
79548956|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fed
79548957|NCT01563510|Procedure|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
79548958|NCT01563510|Procedure|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
79712774|NCT01033942|Drug|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
79712775|NCT01033942|Drug|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
79712776|NCT01033942|Behavioral|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
79712777|NCT01062256|Drug|Placebo|One placebo tablet administered orally as a single dose
79712778|NCT01062256|Drug|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
79712779|NCT01062256|Other|Buckwheat Honey|10 mL administered orally as a single dose
79712780|NCT01029886|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly
79253747|NCT04818268|Behavioral|Adaptation|Sensorimotor adaptation in speech
79253748|NCT04818268|Other|cTBS|continuous theta-burst stimulation
79712781|NCT01029886|Drug|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
79850710|NCT02281955|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
79850711|NCT02281955|Drug|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
79850712|NCT02281955|Procedure|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
79712782|NCT02874274|Behavioral|Standard of Care|
79850713|NCT01015144|Drug|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
79850714|NCT00511797|Drug|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
79850715|NCT00511797|Drug|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
79712783|NCT02874274|Behavioral|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
79277384|NCT03527953|Other|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
79393440|NCT01519817|Biological|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
79393441|NCT01519661|Drug|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
79393442|NCT05549154|Drug|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D > 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
79393443|NCT05549154|Drug|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D > 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
79393444|NCT05549154|Drug|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
79393445|NCT05231538|Other|Neurodevelopmental therapy|NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
79393446|NCT05231538|Other|Routine physical therapy|stretching, passive range of motion, and active range of motion).
79393447|NCT01519427|Drug|Akt inhibitor MK2206|Given PO
79548959|NCT01563523|Drug|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
79548960|NCT01563523|Drug|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
79548961|NCT01563900|Device|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
79548962|NCT01563900|Device|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
79712784|NCT01244763|Drug|Roxadustat|Oral capsule
79712785|NCT01244061|Drug|Varenicline|Varenicline 1mg twice daily
79712786|NCT01244061|Drug|Placebo|Matched placebo twice daily
79393448|NCT01519427|Drug|selumetinib|Given PO
79712787|NCT01243671|Biological|Adalimumab|
79850716|NCT00511797|Drug|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
79850717|NCT00511797|Drug|Placebo|Placebo
79253749|NCT04818242|Device|Dexcom G6 CGM with GTS|CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to < 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) > 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.
79850718|NCT00487552|Device|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
79850719|NCT02272049|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
79850720|NCT03996538|Drug|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
79850721|NCT03996538|Biological|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
79850722|NCT02576015|Procedure|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
79253750|NCT04818242|Diagnostic Test|POC Blood Glucose Test + Blinded CGM|Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between <80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
79253751|NCT04818021|Behavioral|Adaptation|Sensorimotor adaptation in speech
79253752|NCT04818021|Behavioral|Facial Skin Stretch|Facial skin stretch
79253753|NCT04815876|Procedure|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
79393449|NCT01519427|Other|laboratory biomarker analysis|Correlative studies
79393450|NCT01518257|Biological|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
79393451|NCT01518257|Drug|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
79393452|NCT02668302|Combination Product|Steroid-eluting sinus implant|PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
79393453|NCT02668302|Other|Post-op standard of care|Post-op standard of care including debridement, irrigation, and/or topical steroids
79393454|NCT02387424|Behavioral|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
79393455|NCT02387424|Behavioral|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
79393456|NCT02387346|Device|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
79393457|NCT02387346|Device|Magstim Rapid 2 Sham Stimulation|
79393458|NCT02387190|Other|Telenursing monitoring|"The telenursing program protocol is based on:~Contact the patient by telephone, weekly;~Distribution and explanation of the educational booklet;~Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support."
79712788|NCT04319679|Device|Extracorporeal shockwave therapy|6 times during 2 weeks
79712789|NCT04319679|Device|Sham therapy|6 times during 2 weeks
79712790|NCT01240785|Drug|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
79712791|NCT01240785|Drug|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
79712792|NCT01240551|Drug|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
79712793|NCT01239381|Radiation|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
79712794|NCT01266876|Drug|Alirocumab|Alirocumab two SC injections in the abdomen only.
79712795|NCT01266876|Drug|Placebo|Placebo two SC injections in the abdomen only.
79850723|NCT02576015|Procedure|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
79253754|NCT04815876|Procedure|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
79253755|NCT04815876|Drug|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
79548963|NCT01564095|Drug|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
79850724|NCT02576015|Drug|lidocaine|
79548964|NCT01564095|Drug|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
79548965|NCT01564238|Other|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
79850725|NCT02576015|Device|ultrasound|
79548966|NCT01564238|Other|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
79548967|NCT01564524|Procedure|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
79548968|NCT01564576|Drug|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
79548969|NCT01564771|Other|Non Intervention|This Is A Non Interventional Study
79850726|NCT02576015|Device|insulated needle (Contiplex B Braun, Melsungen, Germany)|
79253756|NCT04815005|Other|Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.|Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
79253757|NCT04812925|Biological|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
79548970|NCT01564823|Drug|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
79548971|NCT01564823|Drug|Metronidazole|Metronidazole 250 mg/8h 3 months
79712796|NCT01033240|Drug|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
79850727|NCT02576015|Drug|ropivacaine|
79850728|NCT02576015|Drug|saline|
79850729|NCT03998475|Behavioral|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
79253758|NCT04811027|Drug|Eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
79253759|NCT04811027|Drug|Pembrolizumab|anti-PD-1 antibody
79253760|NCT04796597|Device|Subcutaneous implantation of Epios sub-scalp leads|The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
79253761|NCT04795934|Procedure|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
79253762|NCT04793737|Radiation|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
79548972|NCT01564823|Drug|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
79548973|NCT01564823|Drug|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
79712797|NCT01033240|Drug|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
79712798|NCT01033240|Drug|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
79712799|NCT01033240|Drug|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
79712800|NCT01033240|Drug|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
79850730|NCT02577965|Procedure|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
79850731|NCT02577965|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
79850732|NCT00182689|Drug|sorafenib tosylate|Given orally
79253763|NCT04767464|Other|Compass Course|The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer. Enrollment in this arm will involve participation in the Compass Course virtually.
79393459|NCT02387034|Behavioral|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
79712801|NCT01033240|Drug|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
79712802|NCT01266018|Drug|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m^2 (36.8 mg/m^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
79393460|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
79548974|NCT01565239|Device|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
79712803|NCT01032382|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
79712804|NCT01032382|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
79712805|NCT01029652|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
79712806|NCT01029652|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
79712807|NCT01029652|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
79712808|NCT01029652|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
79712809|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
79712810|NCT01029340|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
79850733|NCT01326247|Other|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
79850734|NCT03860259|Device|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
80017249|NCT02104128|Drug|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
80017250|NCT00004916|Drug|ifosfamide|
79253764|NCT04762888|Procedure|Computed Tomography|Undergo PET/CT
79253765|NCT04762888|Drug|Gallium Ga 68 Gozetotide|Given IV
79253766|NCT04762888|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79253767|NCT04762888|Procedure|Positron Emission Tomography|PET/MRI or PET/CT
79548975|NCT01565265|Drug|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
79548976|NCT01565265|Drug|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
79712811|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
79712812|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
79712813|NCT04301752|Diagnostic Test|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26. Maximum score is 30.
80017251|NCT00004916|Drug|paclitaxel|
80017252|NCT00004916|Drug|teniposide|
79253768|NCT04761419|Behavioral|Parents' longer presence beside their infant|They are not intervention. We will collect data about these items.
79253769|NCT04740307|Biological|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
79253770|NCT04740307|Drug|Lenvatinib|Lenvatinib 12 mg (body weight [BW] ≥60 kg) or 8 mg (BW <60 kg) administered orally every day (QD).
79393461|NCT02391636|Drug|Carbetocin|at delivery of anterior shoulder
79712814|NCT04304170|Dietary Supplement|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
79712815|NCT04304170|Other|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
79712816|NCT01265550|Device|Nissen fundoplication|laparoscopic antireflux surgery
79712817|NCT01265550|Drug|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
80017253|NCT00004916|Procedure|peripheral blood stem cell transplantation|
79712818|NCT01265550|Drug|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
79253771|NCT04740307|Biological|Pembrolizumab|Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
79253772|NCT04739969|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Soterix Neural Navigator neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
79253773|NCT04739969|Device|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79393462|NCT02391636|Drug|Oxytocin|at delivery of anterior shoulder
79393463|NCT01517867|Behavioral|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
79393464|NCT01517867|Behavioral|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
79393465|NCT02386878|Behavioral|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
79548977|NCT01565863|Behavioral|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
79548978|NCT01566292|Drug|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
79548979|NCT01566344|Other|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
79712819|NCT01265394|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
79712820|NCT02889354|Behavioral|Cognitive-behavioral therapy|
79712821|NCT01029262|Drug|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
79712822|NCT01029262|Other|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
79712823|NCT04301284|Drug|CAD-1883|150 mg filled capsules
79712824|NCT04301284|Drug|Placebos|capsules
79712825|NCT02875210|Procedure|Laximeter measurement|
79850735|NCT03860259|Device|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
79850736|NCT01078051|Procedure|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
79850737|NCT01078051|Drug|optimal medical therapy|optimal medical therapy
79253774|NCT04735549|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
79253775|NCT04735549|Drug|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
79253776|NCT04735549|Diagnostic Test|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
79253777|NCT04735549|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
79712826|NCT02873416|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
79850738|NCT03915977|Behavioral|Post ICU recovery program|Standardized follow up program
79253778|NCT04735549|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
79253779|NCT04735549|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
79253780|NCT04735549|Other|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
79393466|NCT02386878|Behavioral|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
79393467|NCT04098107|Device|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
79712827|NCT02873416|Biological|Precision Cells|Precision Cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
79712828|NCT01028560|Biological|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
79548980|NCT01566357|Other|Toothpaste|
79712829|NCT01028560|Other|Standard of care|standard of care asthma and allergy treatment
79712830|NCT01061710|Drug|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
79712831|NCT01028014|Drug|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
79712832|NCT01028014|Drug|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
79712833|NCT01028014|Drug|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
79712834|NCT01028014|Drug|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
79712835|NCT01028014|Drug|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
79712836|NCT01028014|Drug|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
79712837|NCT04300972|Diagnostic Test|Body/weight adaption|contrast media dose is adapted to weight and body type
79712838|NCT04300972|Diagnostic Test|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
79712839|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
79253781|NCT04735549|Other|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
79548981|NCT01566357|Dietary Supplement|Milk|
79548982|NCT01566357|Dietary Supplement|Fluoridated Milk|
79712840|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
79712841|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
79712842|NCT01264770|Drug|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
79712843|NCT01264770|Drug|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
79253782|NCT04735549|Other|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
79548983|NCT01566357|Drug|Tooth Mousse|
79548984|NCT01566357|Drug|MI Paste Plus|
79548985|NCT01566357|Drug|Elmex Erosion Protection|
79548986|NCT01566422|Drug|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
79548987|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
79548988|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
79548989|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
79712844|NCT02873650|Drug|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
79712845|NCT04301128|Other|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
79712846|NCT04301128|Other|control|Patients in the control group were informed same informations verbally and given an education book.
79712847|NCT04301050|Other|Yoga Intervention|Weekly 75-minute yoga classes.
79253783|NCT04735549|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
79253784|NCT04735549|Diagnostic Test|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
79253785|NCT04735549|Diagnostic Test|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
79253786|NCT04735549|Other|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
79393468|NCT01514357|Drug|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
79393469|NCT01514357|Drug|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
79712848|NCT01027702|Biological|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10^4, 4 x 10^4, 5 x 10^4, 6 X 10^4, 8 x 10^4, and 10 X10^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
79712849|NCT01302080|Drug|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
79712850|NCT01302080|Behavioral|psychotherapy|Non-interventional study- as above
79712851|NCT01238991|Biological|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
79712852|NCT01238991|Biological|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
79712853|NCT01238991|Biological|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
79712854|NCT05643716|Behavioral|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
79712855|NCT01238835|Device|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
79712856|NCT02888457|Other|Nasopharyngeal sampling with a swab|
79712857|NCT01032070|Drug|erlotinib|oral
79712858|NCT01032070|Drug|etoposide|oral
79712859|NCT01237899|Drug|LY2623091|Administered orally.
80017254|NCT02919267|Device|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
80017255|NCT02919267|Device|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
79712860|NCT01237899|Drug|Placebo|Administered orally.
79712861|NCT01237899|Drug|Eplerenone|Administered orally.
79712862|NCT01264380|Drug|RO5185426|Single oral dose, fasted
79712863|NCT01264380|Drug|RO5185426|Single oral dose, with high fat meal
79253787|NCT04728230|Drug|Carboplatin|Given IV
79253788|NCT04728230|Biological|Durvalumab|Given IV
79253789|NCT04728230|Drug|Etoposide|Given IV
79393470|NCT02383212|Drug|Cemiplimab|
79393471|NCT02383212|Radiation|Hypofractionated radiotherapy|
79393472|NCT02383212|Drug|Cyclophosphamide|
79548990|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
79548991|NCT01566760|Drug|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
79548992|NCT01566890|Drug|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
79548993|NCT01566890|Procedure|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
79548994|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
79548995|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
79548996|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
79548997|NCT01566929|Dietary Supplement|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
79712864|NCT01264380|Drug|RO5185426|Continuous administration, orally twice daily
79712865|NCT01263444|Drug|Brinzolamide 1% / timolol 0.5% Fixed Combination|
79712866|NCT01263444|Drug|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
79712867|NCT01263054|Device|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
79712868|NCT01263054|Other|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
79253790|NCT04728230|Drug|Olaparib|Given PO
79253791|NCT04728230|Radiation|Radiation Therapy|Undergo consolidative thoracic radiation therapy
79253792|NCT04727424|Drug|Fluvoxamine Maleate 100 MG [Luvox]|One tablet every 12 hours since randomization through day 09.
79253793|NCT04727424|Drug|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
79393473|NCT02383212|Drug|Docetaxel|
79393474|NCT02383212|Drug|Carboplatin|
79393475|NCT02383212|Drug|GM-CSF|
79393476|NCT02383212|Drug|Paclitaxel|
79393477|NCT02383212|Drug|Pemetrexed|
79253794|NCT04727424|Drug|Placebo (mild disease)|"Placebo SC normal saline syringe (single day schedule):~Matching syringes containing 0,5 ml normal saline administered by SC route after randomization Day 0 (single dose SC).~OR~Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS~Placebo Inhalation Therapy:~One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule)~OR~Placebo oral tablets (10-day schedule for patients with SPO2 < 94%):~One tablet after randomization (Day 0) followed by 01 tablet BID for the following 09 days (total of 10 days schedule)"
79548998|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
79548999|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
79549000|NCT01567072|Drug|Placebo|Only placebo treatment instead of NSAID painkillers
79712869|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
79712870|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
79712871|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
79712872|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
79549001|NCT01567098|Procedure|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
79712873|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
79712874|NCT01031836|Drug|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
79712875|NCT04301440|Device|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
79712876|NCT04301440|Device|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
79712877|NCT01237587|Drug|Duloxetine|Administered orally
79712878|NCT01237587|Drug|Placebo|Administered orally
79712879|NCT01031680|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
79850739|NCT04071509|Device|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
79850740|NCT00131365|Device|ExAblate 2000|
79253795|NCT04727424|Drug|Peginterferon Lambda-1a|One syringe of 180 mcg of Peginterferon Lambda SC right after randomization Day 0 (single dose SC administration).
79549002|NCT01567423|Drug|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
79549003|NCT01567423|Drug|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~tab/dose for children 5 to 14.9 kg (total 6 tabs)~tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
79549004|NCT01567631|Procedure|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
79549005|NCT01567631|Procedure|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
79549006|NCT01567787|Radiation|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
79712880|NCT01031680|Drug|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
79549007|NCT01567787|Radiation|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
79712881|NCT01031446|Drug|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
79712882|NCT01031446|Drug|everolimus|Taken daily by mouth.
79712883|NCT01031446|Drug|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
79712884|NCT01031446|Other|laboratory biomarker analysis|Blood collection
79712885|NCT02873728|Procedure|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
79712886|NCT02873728|Other|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
79850741|NCT02578121|Drug|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
79712887|NCT01030900|Biological|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
79712888|NCT01030900|Biological|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
79850742|NCT02578121|Drug|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
79850743|NCT02578121|Drug|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
79712889|NCT01030900|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
79712890|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
79712891|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
79850744|NCT00487240|Drug|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
79850745|NCT00487240|Drug|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
79253796|NCT04727424|Drug|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
79393478|NCT02387112|Device|Early VAD implantation|Implantation of a left ventricular assist device
79393479|NCT02386956|Other|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
79549008|NCT01568190|Biological|AVANZ MITE|Immunotherapy Dermatophagoides mix
79549009|NCT01568515|Procedure|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention & control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
79549010|NCT01568632|Drug|Imetelstat|
79253797|NCT04719390|Behavioral|TMI Component|The text messaging intervention will include 2 motivational interviewing components and 2 cognitive behavioral therapy components, targeting motivation and coping, and taking a harm reduction approach.
79253798|NCT04707417|Other|Home care|Advanced home care
79393480|NCT02386956|Other|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
79393481|NCT02386956|Other|Control|10 minutes with the patient lying on a machine off of magnetotherapy
79393482|NCT01532869|Drug|Placebo|Subcutaneously weekly, Weeks 0-48
79393483|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
79393484|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
79549011|NCT01568645|Drug|Carvedilol|
79549012|NCT01568645|Drug|Imatinib|
79549013|NCT01568684|Other|Citalopram|Treatment
79712892|NCT04288882|Device|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
79712893|NCT02873494|Device|PHYSIOFLOW - PF05 Lab1TM|
79712894|NCT04694872|Other|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
79712895|NCT04694872|Other|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
79850746|NCT01077115|Procedure|Laparoscopic cholecystectomy|
79850747|NCT01077115|Procedure|Open Surgery|
79850748|NCT02577809|Drug|Morphine100|100mcg added to the spinal anaesthetic
79850749|NCT02577809|Drug|Morphine50|50mcg added to the spinal anaesthetic
79850750|NCT02577809|Drug|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
79850751|NCT02577809|Drug|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
79850752|NCT02577809|Drug|Indomethacin|100mg Indomethacin suppository
79850753|NCT03998085|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
79850754|NCT00579579|Behavioral|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
79850755|NCT02224391|Behavioral|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
79850756|NCT02224391|Other|Laboratory Biomarker Analysis|Correlative studies
79850757|NCT02224391|Drug|Nicotine Patch|Given via transdermal patch
79253799|NCT04697602|Drug|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
79253800|NCT04697602|Drug|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
79253801|NCT04688151|Drug|Rituximab|Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
79253802|NCT04687072|Biological|Efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
79393485|NCT02383290|Other|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
79393486|NCT02391246|Other|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
79712896|NCT01026454|Drug|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
79253803|NCT04687072|Other|Placebo PH20 SC|Subcutaneous injection with placebo PH20 SC
79253804|NCT04683835|Device|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
79712897|NCT01026454|Drug|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
79393487|NCT02382978|Other|nurse-provided well child visit|
79549014|NCT01568970|Behavioral|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
79549015|NCT01568970|Behavioral|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
79549016|NCT01569347|Other|Interviews|Interviews
79549017|NCT01569347|Other|Blood sample|Blood sample
79712898|NCT01026220|Biological|bleomycin sulfate|Given IV or SC
79712899|NCT01026220|Drug|doxorubicin hydrochloride|Given IV
79712900|NCT01026220|Drug|liposomal vincristine sulfate|Given IV
79549018|NCT01569347|Other|Hair sample|Hair sample
79253805|NCT04677153|Other|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
79253806|NCT04677153|Other|Usual care|Participants are referred to another location for HCV treatment.
79393488|NCT02382900|Biological|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
79549019|NCT01569685|Drug|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
79549020|NCT01569685|Drug|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
79549021|NCT01569997|Other|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
79549022|NCT01570023|Behavioral|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
79549023|NCT01570049|Drug|Bendamustine|for injection
79712901|NCT01026220|Drug|vinorelbine tartrate|Given IV
79712902|NCT01026220|Drug|cyclophosphamide|Given IV
79712903|NCT01026220|Drug|etoposide phosphate|Given IV
79712904|NCT01026220|Drug|prednisone|Given IV
79850758|NCT02224391|Other|Questionnaire Administration|Ancillary studies
79850759|NCT02224391|Other|Sham Intervention|Undergo sham training
79850760|NCT00487162|Procedure|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
79850761|NCT00487162|Drug|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
79850762|NCT03998241|Other|No intervention was provided|No intervention given
79850763|NCT02219711|Drug|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
79850764|NCT01021384|Behavioral|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
79850765|NCT03871959|Drug|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
79712905|NCT01026220|Biological|filgrastim|Given IV or SC
79253807|NCT04669301|Behavioral|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
79393489|NCT02386644|Other|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
79850766|NCT03871959|Drug|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
79393490|NCT02386644|Device|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
79393491|NCT02386644|Device|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
79712906|NCT01026220|Drug|ifosfamide|Given IV
79850767|NCT00487084|Drug|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
79393492|NCT02386644|Other|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
79712907|NCT00627562|Device|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
79712908|NCT04301362|Diagnostic Test|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
79712909|NCT01026142|Drug|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
79712910|NCT01026142|Drug|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
79712911|NCT01026142|Drug|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
79712912|NCT01026142|Drug|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
79850768|NCT00487084|Drug|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
79850769|NCT00487084|Drug|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
79850770|NCT04770675|Diagnostic Test|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
79850771|NCT00466726|Biological|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
79850772|NCT00466726|Biological|sargramostim|
79850773|NCT03998787|Other|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
79850774|NCT01721291|Drug|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
79393493|NCT02386644|Other|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
79393494|NCT02386722|Device|Smartinhaler/POEMS with audio reminders and additional support calls|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
79549024|NCT01570062|Device|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
79549025|NCT01570062|Device|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
79549026|NCT01570075|Procedure|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
79712913|NCT06055582|Dietary Supplement|Bread|81g (3 slices) harvest gold white bread as standard food.
79712914|NCT06055582|Dietary Supplement|Mango|250g of mango pulp of each mango variety was given to the subjects.
79712915|NCT06055569|Other|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
79712916|NCT06055569|Other|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
79712917|NCT06055569|Other|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
79712918|NCT06055543|Dietary Supplement|Fortimel|2 bottles/day of the high energy ONS
79253808|NCT04669301|Behavioral|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
79393495|NCT01531387|Drug|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
79393496|NCT01531153|Drug|Galantamine|8mg or 16mg
79549027|NCT01570075|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
79393497|NCT01531153|Drug|Placebo|Placebo dose.
79549028|NCT01570088|Dietary Supplement|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
79549029|NCT01570088|Dietary Supplement|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
79549030|NCT01570088|Other|Placebo|Placebo contains no folic acids
79549031|NCT01570101|Device|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
79549032|NCT01570114|Device|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
79549033|NCT01570127|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
79549034|NCT01570127|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
79549035|NCT01570127|Procedure|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
79549036|NCT01570127|Other|Waiting|No interventions were applied to the patients in this group.
79549037|NCT01570140|Behavioral|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
79549038|NCT01570166|Procedure|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
79253809|NCT04668885|Drug|CPX-351|"Induction phase: CPX-351 15 mg/m^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m^2 on days 1 and 3 for two cycles alternating with 15 mg/m^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity."
79393498|NCT03027973|Drug|UPA|Experimental drug
79393499|NCT03027973|Drug|TEA|Active comparator
79393500|NCT03027973|Drug|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
79549039|NCT01570166|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
79549040|NCT01570179|Drug|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
79549041|NCT01570179|Drug|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
79549042|NCT01570179|Drug|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
79549043|NCT01570179|Drug|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
79549044|NCT01570205|Drug|XG-102|single intravenous infusion
79549045|NCT01570218|Behavioral|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
79393501|NCT03027973|Drug|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
79393502|NCT03027817|Procedure|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
79393503|NCT01529749|Drug|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --> oral, 600/200/245 mg, od Losartan --> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
79393504|NCT01529749|Drug|EFV/FTC/TDF|600/200/245 mg, od, oral
79393505|NCT01529749|Drug|FTC/TDF + MK-0518|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral
79393506|NCT01529749|Drug|FTC/TDF+MK-0518+Losartan|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral Losartan --> -> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
79393507|NCT01529515|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
79393508|NCT01529515|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
79393509|NCT01529515|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
79850775|NCT01021462|Procedure|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
79253810|NCT04667689|Behavioral|CAMPFIRE Online Cognitive Assessment for Cancer Patients|Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
79253811|NCT04656496|Behavioral|NOURISH-T+|NOURISH-T+ (Nourishing Our Understanding of Role Modeling to Improve Support and Healthy - Transitions) is a 6 session, psychoeducational program designed to teach parents of childhood cancer survivors with overweight/obesity knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
79253812|NCT04656496|Behavioral|Brief NOURISH-T+|Enhanced Usual Care (or Brief NOURISH-T+) is an abbreviated version of the full NOURISH-T+ intervention in which parents are engaged in a one-time information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
79253813|NCT04648462|Other|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
79253814|NCT04647240|Biological|Dermacyte® Liquid (human amniotic fluid)|Subcutaneous injection into and/or around wound bed weekly
79253815|NCT04638686|Drug|Dolutegravir 50 MG|The subjects started their antiretroviral treatment containing dolutegravir once a day.
79253816|NCT04638686|Drug|Lamivudine 300 MG|The subjects started their antiretroviral treatment containing lamivudine once a day
79549046|NCT01570231|Device|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
79712919|NCT06055517|Radiation|Pulsed low dose-rate radiotherapy (pLDRT)|Radiation treatment will be carried out with high-energy photons (6MV) using intensity modulated radiation therapy (IMRT) or volumetric arc radiation therapy (VMAT). The daily dose is 2 Gy, divided into 10 subfractions of 0.2 Gy spaced by 3 minutes. The cumulative dose will be individualized for each patient and can range from a minimum of 40 Gy to a maximum of 60 Gy.
79393510|NCT01529515|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
79850776|NCT01403350|Device|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
79850777|NCT01021540|Drug|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
79393511|NCT01529515|Drug|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
79850778|NCT04840511|Drug|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
79850779|NCT04840511|Drug|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
79393512|NCT01528969|Dietary Supplement|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
79850780|NCT04072133|Behavioral|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
79393513|NCT01528969|Dietary Supplement|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
79393514|NCT01514201|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
79393515|NCT01514201|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79393516|NCT01514201|Other|Laboratory Biomarker Analysis|Optional correlative studies
79393517|NCT01514201|Other|Pharmacological Study|Correlative studies
79850781|NCT00486226|Device|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
79850782|NCT02199665|Drug|selinexor|Given PO
79393518|NCT01514201|Drug|Temozolomide|Given PO
79393519|NCT01514201|Drug|Veliparib|Given PO
79393520|NCT02666664|Drug|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
79850783|NCT02199665|Drug|carfilzomib|Given IV
79850784|NCT02199665|Drug|dexamethasone|Given PO or IV
79850785|NCT01021696|Drug|Paracetamol|Paracetamol Max. dose: 3g/d
79850786|NCT01021696|Drug|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
79549047|NCT01570257|Procedure|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
79549048|NCT01570270|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
79549049|NCT01570374|Behavioral|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
79549050|NCT01570400|Behavioral|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
79549051|NCT01570400|Behavioral|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
79549052|NCT01570400|Behavioral|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
79549053|NCT01570413|Procedure|No Pelvic Exam|Will not receive pelvic examination.
79549054|NCT01570413|Procedure|Pelvic Examination|Pelvic examination will be performed.
79549055|NCT01570452|Procedure|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
79549056|NCT01570478|Drug|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
79549057|NCT01570478|Drug|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
79549058|NCT01570504|Drug|Ivermectin|oral formulation
79549059|NCT01570517|Device|IASD System|Implantation of the DC Devices Inc. IASD System
79549060|NCT01570530|Procedure|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
79549061|NCT01570530|Procedure|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
79549062|NCT01570556|Other|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
79549063|NCT01570569|Drug|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
79549064|NCT01570569|Drug|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
79549065|NCT01570569|Drug|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
79850787|NCT01021696|Drug|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
79850788|NCT01021696|Drug|Pregabalin|25mgx1/d; max 300mg/d
79850789|NCT01018498|Behavioral|Restricted FODMAPs diet|Restricted fermentable substrate diet
79850790|NCT02577575|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
79850791|NCT02577575|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
79253817|NCT04638478|Other|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
79277385|NCT03527953|Other|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
79549066|NCT01570569|Drug|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
79549067|NCT01570569|Drug|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
79549068|NCT01570569|Drug|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
79549069|NCT01570582|Drug|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
79549070|NCT01570595|Behavioral|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
79549071|NCT01570595|Behavioral|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
79549072|NCT01570608|Drug|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
79549073|NCT01570608|Drug|Verteporfin|Verteporfin photodynamic therapy standard fluence
79549074|NCT01570621|Procedure|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
79712922|NCT06055413|Combination Product|Remote patient monitoring (RPM) bundle|"Patient-families will be given a remote patient monitoring (RPM) bundle with tools to measure objective and subjective information about the child at home that are shared with the home ventilator provider team through an electronic dashboard. The tools include a device to measure carbon dioxide, a digital tablet, a digital weight scale, and a digital application that connects to the child's electronic health record. Each child will be assigned an individualized remote monitoring schedule (timing and data type) based on their indication for ventilation and ventilator regimen at enrollment."
79712923|NCT06055400|Device|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
79850792|NCT02577653|Other|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
79253818|NCT04635462|Other|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
79277386|NCT02201459|Drug|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
79393521|NCT02666664|Drug|Placebo|Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
79393522|NCT01528735|Drug|BI 207127 NA|one fix dose
79393523|NCT01528735|Drug|peginterferon|per package insert
79549075|NCT01570660|Drug|Pioglitazone|12 weeks of pioglitazone treatment
79549076|NCT01570673|Behavioral|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
79549077|NCT01570673|Behavioral|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
79549078|NCT01570699|Genetic|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
79393524|NCT01528735|Drug|Ribavirin|per weight BID
79393525|NCT01528735|Drug|Ribavirin|per weight BID
79393526|NCT01528735|Drug|BI 207127 NA|one fix dose
79393527|NCT01528735|Drug|BI 201335 NA|high dose
79393528|NCT01528735|Drug|BI 201335 NA|low dose
79393529|NCT01528735|Drug|peginterferon|per package insert
79393530|NCT02386332|Procedure|transplantation|
79393531|NCT02386410|Behavioral|Group parent training for anxious parents|
79393532|NCT02386410|Behavioral|Internet delivered parent training for anxious parents|
79393533|NCT02386488|Drug|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
79393534|NCT02386488|Drug|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
79712924|NCT06055387|Behavioral|Frailty intervention measures|"Providing specialized guidance:~Physical Function and Fall History:~Prioritizing home safety for those with physical impairments.~Arranging rehab consultations when necessary.~Nutrition:~Assessing diets and offering education.~Pre-treatment nutritionist assessments.~Monitoring weight, intervening if >5-10% loss, or >10% loss.~Social Support:~Evaluating the needs of those without family support.~Referring to social services and introducing care resources.~Cognition:~Detecting cognitive issues, addressing reversible causes.~Assessing decision-making and medication self-administration.~Refer to specialists when needed.~Polypharmacy and Comorbidity:~Collecting medication data, ensuring adherence.~Noting chronic illnesses.~Collaborating with specialists or pharmacists for complex cases.~Psychological:~Providing weekly support for psychological concerns.~Refer to specialists for assessments and treatment options."
79712925|NCT06055374|Drug|BxC-I17e|Pharmaceutical form : solution for injection
79712926|NCT06055374|Drug|Placebo|Pharmaceutical form : solution for injection
79712927|NCT06055361|Drug|BxC-I17e|Pharmaceutical form : solution for injection
79712928|NCT06055361|Drug|Placebo|Pharmaceutical form : solution for injection
79549079|NCT01570712|Other|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~Support in the development and the maintenance of the housing;~Support in the diverse steps (administrative, judicial, financiers, etc.);~Support around addictions / alcohol;~Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
79712929|NCT06055348|Drug|SC0191|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
79712930|NCT06055348|Drug|Gemcitabine|Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
79712931|NCT06055348|Drug|Paclitaxel|Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
79712932|NCT06055335|Other|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
79712933|NCT06055335|Other|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
79712934|NCT06055322|Behavioral|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
79712935|NCT06055283|Other|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
79712936|NCT06055270|Procedure|Stellate Ganglion Block|All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.
79549080|NCT01570712|Other|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\or the restoring, but this by means of the existing devices"
79850793|NCT04827407|Device|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
79850794|NCT02578979|Device|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
79850795|NCT02578979|Device|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
79850796|NCT00485758|Drug|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
79850797|NCT00485758|Drug|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
79850798|NCT04073459|Biological|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
79277387|NCT02201459|Drug|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
79277388|NCT02365389|Drug|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
79850799|NCT04073459|Biological|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
79549081|NCT01570725|Behavioral|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
79549082|NCT01570725|Behavioral|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
79549083|NCT01570764|Drug|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
79549084|NCT01570764|Drug|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
79549085|NCT01570777|Procedure|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
79549086|NCT01570777|Procedure|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
79549087|NCT01570790|Drug|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
79549088|NCT01570790|Drug|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
79549089|NCT01570790|Drug|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
79549090|NCT01570803|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
79549091|NCT01570803|Device|Complete SE Stent|same to SMART CONTROL Stent
79549092|NCT01570816|Device|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
79549093|NCT01570842|Other|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
79549094|NCT01570842|Procedure|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
79549095|NCT01570894|Drug|Quetiapine Fumarate|25 mg tablet
79549096|NCT01570907|Drug|Quetiapine Fumarate|25 mg tablet
79549097|NCT01570920|Behavioral|physical training|walking many times a week
79549098|NCT01570933|Device|NivNava|Non-invasive Nava ventilation mode on nasal cannula
79712937|NCT06055270|Other|Placebo|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
79850800|NCT01018576|Other|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
79712938|NCT06055257|Drug|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
79712939|NCT06055257|Drug|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
79712940|NCT06055244|Drug|Amantadine|Subjects will be give amantadine 100 mg twice daily.
79549099|NCT01570933|Device|Cpap|nasal Cpap on nasal cannula
79549100|NCT01570946|Behavioral|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
79549101|NCT01570959|Drug|Quetiapine Fumarate|300 mg tablet
79712941|NCT06055192|Other|Survey|Survey
79549102|NCT01570972|Behavioral|Group Cognitive Behavioral Therapy|weekly
79549103|NCT01570972|Behavioral|Multifamily Group Psychoeducation|twice monthly
79549104|NCT01570985|Drug|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
79549105|NCT01570985|Drug|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
79850801|NCT02577341|Drug|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
79850802|NCT02577341|Drug|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
79850803|NCT02577341|Radiation|daily RT to the chest|Patients received daily RT to the chest
79850804|NCT03998800|Dietary Supplement|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
79712942|NCT06055166|Drug|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
79712943|NCT06055153|Drug|RC48+PD-1+platinum-based|"Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If > 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs."
79549106|NCT01571011|Behavioral|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
79549107|NCT01571024|Drug|BKM120|BKM120 40 mg, orally, once daily.
79712944|NCT06055127|Procedure|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
79712945|NCT06055127|Procedure|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
79712946|NCT06055114|Diagnostic Test|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
79850805|NCT03998800|Behavioral|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
79850806|NCT02577497|Drug|beclomethasone|
79253819|NCT04635462|Other|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
79253820|NCT04633460|Dietary Supplement|Ketone ester|A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
79253821|NCT04633460|Dietary Supplement|placebo drink|KE free placebo drink
79253822|NCT04632056|Drug|Beovu|There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
79277389|NCT02365389|Drug|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
79393535|NCT02386488|Drug|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
79393536|NCT02386488|Drug|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
79393537|NCT02383446|Device|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
79393538|NCT02382822|Other|No intervention.|
79393539|NCT02661594|Drug|APD421 5 mg|Therapeutic dose of amisulpride
79393540|NCT02661594|Drug|APD421 40 mg|Supra-therapeutic dose of amisulpride
79393541|NCT02661594|Drug|Moxifloxacin|Positive control for assay sensitivity
79393542|NCT02661594|Drug|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
79393543|NCT02386566|Drug|natalizumab|As described in the treatment arm
79549108|NCT01571024|Drug|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
79549109|NCT01571050|Drug|Purified water|Ingestion of 30 mL of purified water
79253823|NCT04631302|Behavioral|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
79393544|NCT01528345|Drug|Dovitinib|Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
79549110|NCT01571050|Drug|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
79549111|NCT01571050|Drug|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
79549112|NCT01571050|Drug|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
79549113|NCT01571050|Drug|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
79549114|NCT01571063|Drug|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
79549115|NCT01571063|Drug|Placebo|Placebo Tbl. p.o.
79549116|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
79549117|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
79549118|NCT01571076|Other|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
79549119|NCT01571076|Other|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
79549120|NCT01571089|Behavioral|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
79549121|NCT01571115|Behavioral|Physical Exercise|
79549122|NCT01571141|Device|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
79850807|NCT02577497|Drug|fluticasone|
79393545|NCT01528345|Drug|Fulvestrant|Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
79549123|NCT01571167|Drug|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
79549124|NCT01571167|Drug|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
79549125|NCT01571167|Drug|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
79850808|NCT01021774|Procedure|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
79850809|NCT01602263|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
79549126|NCT01571206|Biological|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
79549127|NCT01571219|Biological|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
79549128|NCT01571258|Behavioral|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
79549129|NCT01571271|Procedure|Laser Lithotripsy|Laser Lithotripsy
79549130|NCT01571271|Procedure|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
79850810|NCT02577419|Other|Target Fortification|
79850811|NCT02577419|Other|Higher Initial Concentration|
79850812|NCT02577419|Other|Portagen Formula|
79875223|NCT00490724|Drug|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
79393546|NCT01528345|Drug|Dovitinib Placebo|Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
79393547|NCT01513967|Drug|RPh201, botanical drug product|SC administration at varying doses
79393548|NCT01513967|Drug|Placebo|SC administration at varying doses
79393549|NCT02099721|Device|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
79712947|NCT06055101|Drug|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
79253824|NCT04631302|Behavioral|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
79549131|NCT01571310|Other|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
79549132|NCT01571310|Other|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
79549133|NCT01571323|Drug|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
79549134|NCT01571323|Drug|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
79549135|NCT01571323|Drug|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
79549136|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
79712948|NCT06055101|Drug|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
79712949|NCT06055101|Drug|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
79712950|NCT06055036|Behavioral|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with >5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
79712951|NCT06055023|Drug|ZL-82 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712952|NCT06055023|Drug|ZL-82 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712953|NCT06055023|Drug|ZL-82 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712954|NCT06055023|Drug|ZL-82 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712955|NCT06055023|Drug|ZL-82 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712956|NCT06055023|Drug|ZL-82 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79850813|NCT02576171|Behavioral|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
79850814|NCT04071665|Procedure|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
79850815|NCT02575937|Behavioral|low glycemic diet|nutrition education-based low glycemic diet intervention
79850816|NCT02577263|Other|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
79549137|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
79549138|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
79850817|NCT02575859|Drug|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
79253825|NCT04627571|Drug|Cenegermin Ophthalmic Solution [Oxervate]|An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.
79253826|NCT04624672|Drug|Semaglutide (1 Mg Dose)|Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
79549139|NCT01571401|Behavioral|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
79549140|NCT01571414|Drug|PA-824|200-mg tablets once a day
79549141|NCT01571414|Drug|Efavirenz (EFV)|600-mg tablets once a day
79549142|NCT01571414|Drug|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
79253827|NCT04624672|Drug|Placebo|Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
79549143|NCT01571414|Drug|Rifampin (RIF)|300-mg capsules once a day
79253828|NCT04590404|Behavioral|Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.|Automated calls to assess smoking status, medication use, and additional support for quit attempt.
79549144|NCT01571440|Dietary Supplement|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
79549145|NCT01571440|Dietary Supplement|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
79549146|NCT01571466|Drug|Vaccination|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml~3 immunisations at week 0, 4 and 16"
79549147|NCT01571466|Drug|Placebo|3 immunisations at week 0, 4 and 16
79549148|NCT01571479|Procedure|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
79549149|NCT01571492|Procedure|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
79712957|NCT06055023|Drug|ZL-82 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712958|NCT06055023|Drug|ZL-82 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
79712959|NCT06055010|Other|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
80017256|NCT04809610|Behavioral|Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
79253829|NCT04590404|Drug|Nicotine Replacement Therapy|FDA-approved forms of nicotine replacement therapy for smoking cessation.
79549150|NCT01571492|Procedure|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
79549151|NCT01571505|Biological|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
79549152|NCT01571518|Drug|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
79712960|NCT06054932|Drug|LK101 injection|LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
79712961|NCT06054932|Drug|LK101 injection|LK101 administrated QW as the prime dose, and Q3W in the boost phase
79712962|NCT06054919|Drug|Cholecalciferol|vitamin D3
79712963|NCT06054906|Drug|sintilimab+metronomic PLOF|"Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles"
79549153|NCT01571518|Drug|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
79549154|NCT01571544|Device|Thermal suit|Thermal suit
79875224|NCT00490724|Drug|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
80017257|NCT03555318|Other|Ambulatory visit|All patients will have an ambulatory visit with the cardiologist.
79549155|NCT01571544|Other|Conventional clothing|Conventional clothing
79549156|NCT01571570|Drug|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
79549157|NCT01571570|Drug|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
79549158|NCT01571570|Drug|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
79549159|NCT01571570|Drug|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
79549160|NCT01571570|Drug|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
79549161|NCT01571583|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
79549162|NCT01571583|Drug|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
79549163|NCT01571583|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day [5 to 6 tablets] based on subject weight), twice daily regimen, for 48 weeks.
79549164|NCT01571609|Other|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:[9,10-3H]-palmitate 0,3 µCi/min. Duration 60 minutes."
79712964|NCT06054854|Biological|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
79712965|NCT06054841|Behavioral|Postpartum follow up card|The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.
79850818|NCT02575859|Procedure|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
79850819|NCT02576873|Other|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
79850820|NCT00469612|Device|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
79850821|NCT00469456|Drug|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
79850822|NCT00469456|Drug|placebo|Placebo oral administration twice daily for 12 weeks
79850823|NCT00581555|Drug|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
79850824|NCT00581555|Other|Placebo|Randomized to placebo during taper of ciclosporin
79850825|NCT00469144|Drug|Busulfan|"Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
79549165|NCT01571622|Dietary Supplement|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
79549166|NCT01571622|Dietary Supplement|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
79549167|NCT01571648|Drug|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
79712966|NCT06054841|Other|Control|No deviation from standard discharge education
79549168|NCT01571661|Drug|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
79712967|NCT06054828|Behavioral|mHELP@ICU|"The 14-day mHELP@ICU consists of the following three components:~Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~Feeding monitor daily: The exact feeding data will be abstracted from medical records."
79712969|NCT06054789|Drug|68Ga-PSMA-33|Subjects will receive one injection of 68Ga-PSMA-33/PSMA-617 (3-7mCi ), a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen. 68Ga-PSMA-33/PSMA-617 injection will be followed by a 10 ml saline flush.
79850826|NCT00469144|Drug|Fludarabine|40 mg/m^2 IV Daily Over 1 Hour x 4 Days
79850827|NCT01025050|Procedure|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
79850828|NCT02576093|Drug|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
79850829|NCT02576093|Drug|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
79850830|NCT02576093|Drug|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
79850831|NCT02576093|Drug|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
79712970|NCT06054737|Procedure|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
79712971|NCT06054711|Other|joint puncture|Patients reporting complications such as pain hindering mobility or affecting quality of life, or any other symptoms suspecting prosthesis failure or infection will undergo joint fluid aspiration.
79712972|NCT06054698|Drug|HRS9531 injection|HRS9531 injection , QW，36 weeks
79712973|NCT06054698|Drug|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
79712974|NCT06054672|Device|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
79712975|NCT06054633|Dietary Supplement|L-arginine tablet|L-arginine, 2 g, three times daily, for 12 weeks
79712976|NCT06054633|Dietary Supplement|Placebo tablet|Identical inert placebo, three times daily, for 12 weeks
79712977|NCT06054607|Dietary Supplement|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing ~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
79712978|NCT06054607|Other|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
79712979|NCT06054581|Behavioral|health seeking behavior|health seeking behavior in the form of wound management and receving anti rabies immunization
79712980|NCT06054542|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
79712981|NCT06054490|Behavioral|Self-management|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
79712982|NCT06054490|Other|Home exercises|It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
79712983|NCT06054412|Device|Neuroptimal (Zengar, Inc.) Neurofeedback|Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
79712984|NCT06054386|Other|Attentional Bias Modification Training (ABMT)|The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
79712985|NCT06054386|Other|General Attention Control Training|The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
79712986|NCT06054347|Other|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
79712987|NCT06054321|Drug|stepwise pharmacotherapy|In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
79712988|NCT06054321|Drug|antidepressant monotherapy group|In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
79712989|NCT06054243|Behavioral|CBT-I|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
79712990|NCT06054243|Behavioral|CBT-A|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
79712991|NCT06054178|Drug|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
79712992|NCT06054152|Drug|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
79712993|NCT06054139|Other|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
79712994|NCT06054100|Drug|Colchicine Tablets|Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
79850832|NCT03987022|Drug|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control post operatively
79850833|NCT03987022|Drug|Opioids|Use of narcotic for pain control post operatively
79850834|NCT03987022|Other|Ice Packs|Placement of Ice packs on surgical sites post operatively
79549169|NCT01571661|Other|Placebo|Placebo
79549170|NCT01571674|Procedure|Manipulation + Exercise Group|"First 2 sessions~High-velocity, low-amplitude manipulations to the thoracic spine.~Low-velocity mid to end-range mobilizations to the cervical spine.~Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
79549171|NCT01571674|Procedure|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
79253830|NCT04590404|Drug|Varenicline|FDA-approved smoking cessation medication.
79549172|NCT01571687|Dietary Supplement|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
79549173|NCT01571687|Dietary Supplement|Placebo|Intake of 6 identically appearing tablets daily containing placebo
79549174|NCT01571700|Procedure|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension >5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
79549175|NCT01571726|Drug|Fluciclatide|7mCi
79549176|NCT01571765|Other|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
79549177|NCT01571791|Drug|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
79549178|NCT01571791|Drug|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
79712995|NCT06054087|Procedure|Basal therapy+EA|"Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
79850835|NCT03987022|Drug|Tylenol|Use of pain medication post operatively
79850836|NCT03987022|Drug|Motrin|Use of non-steroidal anti-inflammatory drug for pain control post operatively
79850837|NCT03987022|Drug|dilaudid|Use of narcotic for pain control post operatively
79850838|NCT02575781|Drug|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
79850839|NCT03789838|Other|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
79850840|NCT01025128|Drug|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
79253831|NCT04590404|Other|Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)|Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
79253832|NCT04577755|Procedure|Biopsy|Undergo tissue biopsy
79253833|NCT04577755|Procedure|Biospecimen Collection|Undergo blood sample collection
79253834|NCT04577755|Procedure|Computed Tomography|Undergo CT
79253835|NCT04577755|Drug|Pomalidomide|Given PO
79253836|NCT04577755|Procedure|X-Ray Imaging|Undergo x-ray imaging
79253837|NCT04573660|Device|Coronary and peripheral stents|The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
79549179|NCT01571804|Drug|Placebo|to receive two identical placebo capsules 1 hr before surgery
79549180|NCT01571804|Drug|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
79549181|NCT01571804|Drug|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
79875225|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
79875226|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
79875227|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
79549182|NCT01571817|Biological|Isolated Human Pancreatic Islets|
79549183|NCT01571843|Other|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
79549184|NCT01571843|Other|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
79549185|NCT01571856|Drug|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
79549186|NCT01571856|Other|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
79549187|NCT01571869|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
79549188|NCT01571869|Other|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
79549189|NCT01571882|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
79875228|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
79875229|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
79712996|NCT06054087|Other|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
79712997|NCT06054074|Behavioral|Positive Appreciation of Body Functionality Induction|The positive induction takes place in a virtual environment of a dressing room and includes the following methods to induce positive appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a higher positive body image. 2) A green virtual costume, representing their body at that time in the past and the positive attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (green costume) to preserve the induction effect.
79253838|NCT04573660|Device|Pacing catheters|The participants in the Pacing catheters arm will receive Pacing catheters
79253839|NCT04573660|Device|Vascular plugs|The participants in the Vascular plugs arm will receive Vascular plugs
79393550|NCT01511939|Drug|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
79393551|NCT02391480|Drug|ABBV-075|ABBV-075 Oral tablets
79393552|NCT02391480|Drug|Venetoclax|Venetoclax tablets, film-coated
79393553|NCT01576705|Drug|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
79393554|NCT02666430|Drug|Mylan's insulin glargine|
79712998|NCT06054074|Behavioral|Negative Appreciation of Body Functionality Induction|The negative induction takes place in a virtual environment of a dressing room and includes the following methods to induce a lower appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a lower positive body image. 2) A red virtual costume, representing their body at that time in the past and the negative attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (red costume) to preserve the induction effect.
79393555|NCT02666430|Drug|Lantus®|
79253840|NCT04573660|Device|Measurement and imaging (FFR and OCT)|The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
79393556|NCT01576549|Drug|LY2127399|Administered subcutaneously
79393557|NCT02382666|Drug|Rolapitant|
79875230|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
79875231|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
79875232|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
79875233|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
79253841|NCT04573660|Device|Peripheral dilatation catheters|The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
79253842|NCT04573660|Device|Coronary dilatation catheters|The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
79393558|NCT00145041|Drug|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
79393559|NCT01576159|Other|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
79393560|NCT01576159|Other|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
79393561|NCT01576159|Other|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
79875234|NCT01039077|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
79253843|NCT04573660|Device|Coronary and peripheral guidewires|The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
79253844|NCT04573660|Device|Vessel closure/compression devices|The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
79393562|NCT02391012|Biological|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
79393563|NCT02099799|Behavioral|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
79393564|NCT04123561|Drug|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
79393565|NCT04123561|Drug|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
79875235|NCT01039155|Drug|Azacitidine|Given IV
79875236|NCT01039155|Other|Laboratory Biomarker Analysis|Correlative studies
79253845|NCT04573660|Device|Vascular access introducers|The participants in the Vascular access introducers arm will receive Vascular access introducers
79393566|NCT04123561|Other|Normal Saline|0.9% normal saline
79393567|NCT01510769|Drug|Lesinurad|Tablets, 400 mg once daily (QD)
79393568|NCT01510769|Drug|Lesinurad|Tablets, 200 mg QD
79393569|NCT01510769|Drug|Placebo|Tablets, Placebo QD
79393570|NCT01510769|Drug|Febuxostat|80 mg
79393571|NCT04479228|Device|Endosonography guided transmural drainage|The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris
79393572|NCT05133648|Procedure|Hip Fracture Surgery|Hip fracture surgery
79393573|NCT05133648|Other|COVID-19 infection|COVID-19 infection
79393574|NCT02391090|Device|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
79393575|NCT02391090|Device|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
79253846|NCT04571619|Behavioral|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
79549190|NCT01571882|Other|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
79549191|NCT01571882|Other|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
79549192|NCT01571921|Dietary Supplement|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
79712999|NCT06054048|Other|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
79713000|NCT06054035|Drug|Dapagliflozin (Forxiga®)|Dapagliflozin 10 mg once daily for 2 years. Route of administration: oral.
79549193|NCT01571947|Other|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
79549194|NCT01571960|Biological|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
79549195|NCT01571960|Biological|MVA/HIV62B (MVA62B) vaccine|1 x 10^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
79713001|NCT06054035|Drug|Placebo matching Dapaglifolzin|Placebo matching Dapaglifolzin once daily for 2 years. Route of administration: oral.
79713002|NCT06054035|Behavioral|Lifestyle Intervention|Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
79713003|NCT06054022|Device|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
79713004|NCT06054022|Device|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
79713005|NCT06053996|Radiation|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
79875237|NCT01039155|Drug|Oxaliplatin|Given IV
79875238|NCT01039155|Other|Pharmacological Study|Correlative studies
79875239|NCT03835221|Device|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
79875240|NCT03835221|Device|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
79393576|NCT02391090|Procedure|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
80017258|NCT03555318|Other|Combined ambulatory visit|Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
79393577|NCT02391090|Other|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
80017259|NCT03555318|Other|Geriatric intervention|After the geriatric assessment, measures to improve frailty will be started.
80017260|NCT04778566|Diagnostic Test|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
80017261|NCT02101632|Dietary Supplement|Bee Venom Ointment|2 weeks
79393578|NCT02391090|Procedure|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
79393579|NCT02391090|Procedure|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
79549196|NCT01571960|Biological|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
80017262|NCT02101632|Other|Vaseline Ointment|2 weeks
80017263|NCT00004910|Procedure|bowel obstruction management|
79549197|NCT01571960|Biological|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
79549198|NCT01571973|Procedure|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
79549199|NCT01571999|Drug|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
79549200|NCT01571999|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
79549201|NCT01572012|Drug|Ondansetron|Ondansetron solution 4 mg single administration
79549202|NCT01572012|Drug|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
79549203|NCT01572012|Drug|Zofran ODT|Zofran ODT (8 mg) single administration
79549204|NCT01572012|Drug|Ondansetron solution|Ondansetron solution (4 mg) single administration
79875241|NCT01039233|Drug|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
79875242|NCT00398073|Biological|mouse gp100 plasmid DNA vaccine|
79875243|NCT00398073|Device|The Dermal PowderMed® devices|
79875244|NCT00398073|Other|intramuscularly (IM injection)|
80017264|NCT00004910|Procedure|quality-of-life assessment|
80017265|NCT04434274|Drug|Micronized Purified Flavonoid Fraction|Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
79253847|NCT04571619|Drug|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
79713006|NCT06053970|Other|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~Eyes open with VR headset simulating a static environment~Eyes closed with VR helmet off~Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
79713007|NCT06053957|Procedure|early mobilization|early mobilization program
79713008|NCT06053931|Behavioral|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw&t=6478s)."
79713009|NCT06053931|Behavioral|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
79713010|NCT06053918|Other|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
79713011|NCT06053892|Diagnostic Test|Puncture|Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.
79253848|NCT04565327|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
80017266|NCT02101710|Drug|Elantan SR 60 mg|"Trade Name: Elantan~Active Substance: Isosorbide 5-mononitrate~Pharmaceutical form: Tablet~Concentration: 60 mg~Route of Administration: Oral administration"
79253849|NCT04565327|Procedure|Magnetic Resonance Imaging (MRI)|Undergo MRI
79253850|NCT04561986|Drug|Tocilizumab|Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor
79549205|NCT01572025|Drug|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
79549206|NCT01572025|Drug|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
79713012|NCT06053879|Other|Biofeedback electrical stimulation|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty
79713013|NCT06053814|Drug|NS-050/NCNP-03|NS-050/NCNP-03 solution for IV infusion.
79713014|NCT06053814|Drug|Placebo|NS-050/NCNP-03 placebo-matching solution for IV infusion.
79713015|NCT06053788|Diagnostic Test|PocDoc|Point of care digital lipid test
79713016|NCT06053762|Behavioral|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
79713017|NCT06053762|Behavioral|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
79713018|NCT06053671|Genetic|Blood and nasal swab sampling|Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
79875245|NCT00490646|Drug|ixabepilone|"Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
79549207|NCT01572051|Behavioral|Educational Course|2 Educational courses
79549208|NCT01572051|Behavioral|Phone Calls|Phone Calls
79713019|NCT06053229|Device|percussive massage|30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
79713020|NCT06053229|Combination Product|Leg Immobilization|All subjects will have their left leg immobilized using an immobilization brace for 10 days
79253851|NCT04561492|Drug|[68Ga]Ga-PentixaFor|Tomography by emission of positons (PET) with theradiopharmaceutic [68Ga]Ga-PentixaFor
79549209|NCT01572051|Behavioral|Printed Material|Printed Material
79549210|NCT01572064|Procedure|Blood sample|1 fasted blood sample taken for metabolomics
79549211|NCT01572064|Other|MRI Scan|1 single visit for MRI and MRS
79850841|NCT04073381|Combination Product|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
79850842|NCT00468910|Drug|acetylsalicylic acid|Given orally
79850843|NCT00468910|Drug|placebo|Given orally
79253852|NCT04561362|Drug|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive a 60-minute IV infusion of BT8009 on Days 1,8 and 15 of a 21-day cycle. Participants in Part B will receive BT8009 once weekly either on a 21-day or 28-day cycle. Participants in Cohort C will receive a 60-minute IV infusion of BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
79393580|NCT02391090|Procedure|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
79393581|NCT01575769|Drug|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
79549212|NCT01572077|Radiation|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
79549213|NCT01572090|Behavioral|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian."
79549214|NCT01572090|Other|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
79549215|NCT01572090|Procedure|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
79549216|NCT01572090|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
79549217|NCT01571908|Drug|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
79549218|NCT01571908|Drug|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
79549219|NCT01571908|Drug|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
79850844|NCT00468910|Other|laboratory biomarker analysis|Correlative study
79549220|NCT01571908|Drug|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
79850845|NCT01025206|Biological|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
79393582|NCT02382354|Drug|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
79549221|NCT01572103|Dietary Supplement|Coffee|Administration of 4 cups of coffee per day for 1 month
79549222|NCT01572103|Dietary Supplement|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
79549223|NCT01572116|Drug|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
79549224|NCT01572116|Drug|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
79850846|NCT01412333|Drug|Interferon beta-1a|
79850847|NCT01412333|Drug|Ocrelizumab-matching placebo|
79850848|NCT01412333|Drug|Ocrelizumab|
79850849|NCT01412333|Drug|Interferon beta-1a-matching placebo|
79850850|NCT02577185|Drug|Botulinum Toxin Type A|
79850851|NCT02577185|Drug|Sodium chloride 9 mg/ml|
79850852|NCT00519285|Drug|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
79850853|NCT00519285|Drug|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
79850854|NCT00519285|Drug|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
79253853|NCT04561362|Drug|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
79277390|NCT02201537|Device|renal echography|"Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
79277391|NCT04441411|Device|NEMOST system|Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
79393583|NCT02382354|Device|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
79393584|NCT02382354|Device|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
79393585|NCT02382354|Drug|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
79393586|NCT01510145|Drug|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
79393587|NCT03027167|Drug|Aspirin|
79549225|NCT01572129|Drug|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
79549226|NCT01572129|Drug|Placebo|Placebo in addition to the chronic daily dose of 75 mg
79393588|NCT03027167|Device|(Post- discharge) Mechanical Compression Device|
79393589|NCT02382198|Drug|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
79393590|NCT02382198|Drug|Placebo|
79393591|NCT01528033|Device|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
79393592|NCT01528033|Other|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
79393593|NCT02382432|Drug|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
79393594|NCT02382432|Drug|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
79393595|NCT00145587|Procedure|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
79393596|NCT00145587|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
79393597|NCT00145587|Drug|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
79393598|NCT02390934|Radiation|Radium 223|
79393599|NCT01560871|Behavioral|High-intensity IMT plus walking|"The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group."
79393600|NCT01560871|Behavioral|Low-intensity IMT plus walking|"The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
79393601|NCT04298463|Drug|Xydalba|Drugs were administered i.v.
79393602|NCT04298463|Drug|vancomycin, teicoplanin or daptomycin|Drugs were administered i.v.
79393603|NCT02386020|Drug|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
79393604|NCT02386020|Drug|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
79393605|NCT02381964|Dietary Supplement|Supradyn® (1RDA+CoQ10)|
79393606|NCT02381964|Dietary Supplement|Supradyn® (3RDA)|
79393607|NCT02381964|Dietary Supplement|Placebo|
79393608|NCT01509053|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014."
79549227|NCT01572155|Procedure|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
79850855|NCT00519285|Drug|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
79850856|NCT00464620|Drug|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
79393609|NCT01509053|Drug|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
79393610|NCT02100189|Other|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
79393611|NCT02100189|Procedure|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
79393612|NCT02100189|Other|Laboratory Biomarker Analysis|Correlative studies
79393613|NCT02390856|Device|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
79393614|NCT02390856|Device|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
79393615|NCT01560403|Drug|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
79393616|NCT02100579|Drug|Bupivacaine|10 ml of 0.25% bupivacaine
79393617|NCT02100579|Drug|Preservative free normal saline|10 ml of preservative free normal saline
79393618|NCT04096001|Device|Woebot-SUDs (W-SUDs)|Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
79393619|NCT04251351|Drug|Paracetamol|Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
79549228|NCT01572155|Procedure|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
79393620|NCT04251351|Procedure|Mechanical antipyresis|"Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature >38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed)."
79549229|NCT01572168|Other|Acupuncture|Eight session of weekly acupuncture
79549230|NCT01572181|Drug|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"IV fludarabine (30 mg/m²/day for 5 days)~IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
79549231|NCT01572194|Biological|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
79549232|NCT01572220|Other|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
79549233|NCT01572233|Behavioral|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
79549234|NCT01572246|Other|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
79549235|NCT01572259|Drug|Growth Hormone|
79549236|NCT01572259|Other|interruption of the traitment with growth hormone|
79549237|NCT01572285|Procedure|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
79549238|NCT01572285|Procedure|Sham|Sham procedure using a non-penetrating needle
79549239|NCT01572311|Behavioral|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
79549240|NCT01572311|Behavioral|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
79549241|NCT01572324|Drug|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
79549242|NCT01572350|Other|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
79549243|NCT01572350|Drug|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
79549244|NCT01572350|Drug|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
79549245|NCT01572363|Drug|Sildenafil|50 mg once
79549246|NCT01572376|Procedure|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
79549247|NCT01572402|Other|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
79850857|NCT05212857|Drug|Leuprolide acetate|Given subcutaneously or as an injection
79850858|NCT05212857|Drug|Goserelin acetate|Given subcutaneously or as an injection
79393621|NCT04748471|Biological|mRNA-1273|SARS-CoV-2 vaccine
79850859|NCT05212857|Drug|Triptorelin acetate|Given subcutaneously or as an injection
79850860|NCT05212857|Drug|Degarelix acetate|Given subcutaneously or as an injection
79393622|NCT05469282|Device|Blood circulation device|Blood circulation device of CGM MB-1701 (Ceragem Master V6)
79253854|NCT04547686|Behavioral|Smoke-Free Homes Intervention|The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.
79850861|NCT05212857|Drug|Abiraterone acetate|Given orally
79393623|NCT02382042|Behavioral|Intensive Referral Intervention|
79393624|NCT02390700|Biological|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
79850862|NCT05212857|Drug|Apalutamide|Given orally
79277392|NCT02201615|Other|Perineal massage in childbirth|
79850863|NCT05212857|Drug|Enzalutamide|Given orally
79713021|NCT06052033|Procedure|CO2|CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
79393625|NCT00284739|Drug|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
79549248|NCT01572402|Other|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
79549249|NCT01572402|Other|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
79549250|NCT01572454|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
79549251|NCT01572454|Drug|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
79549252|NCT01572467|Genetic|RNA analysis|
79549253|NCT01572467|Genetic|gene expression analysis|
79393626|NCT00284739|Other|saline|saline injection twice daily for three days
79393627|NCT01527487|Drug|Eribulin|1.4 mg/m2 IV (Days 1 & 8), given short (≤15 minute) IV infusion, per institutional standard
79549254|NCT01572467|Genetic|mutation analysis|
79549255|NCT01572467|Genetic|reverse transcriptase-polymerase chain reaction|
79549256|NCT01572467|Other|laboratory biomarker analysis|
79549257|NCT01572467|Other|medical chart review|
79549258|NCT01572519|Drug|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
79549259|NCT01572519|Drug|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
79549260|NCT01572519|Drug|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
79549261|NCT01572519|Drug|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
79549262|NCT01572519|Drug|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
79549263|NCT01572545|Drug|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
79549264|NCT01572545|Drug|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
79549265|NCT01572558|Procedure|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
79549266|NCT01572558|Drug|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
79549267|NCT01572597|Drug|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
79549268|NCT01572597|Drug|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
79549269|NCT01572610|Drug|RTA 402|once a day, oral administration
79549270|NCT01572623|Drug|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
79549271|NCT01572623|Drug|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
79549272|NCT01572636|Drug|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
79549273|NCT01572649|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
79549274|NCT01572649|Drug|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
79549275|NCT01572688|Drug|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
79549276|NCT01572701|Drug|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
79549277|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
79393628|NCT01527487|Drug|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
79393629|NCT01527487|Drug|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
79393630|NCT01506947|Drug|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~[Paricalcitol (µg) = iPTH (pg/mL) / 80]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
79393631|NCT01506947|Drug|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level < 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
79549278|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
79549279|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
79549280|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
79549281|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
79253855|NCT04547686|Behavioral|Control|The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
79549282|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
79713022|NCT06050824|Drug|Comparing Load and Concomitant therapy|Levofloxacin - Omeprazole - nitazoxanide - doxycycline
79253856|NCT04545957|Device|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
79713023|NCT06050499|Device|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
79713024|NCT06049459|Device|Optical Correction|Optical correction (if needed)
79713025|NCT06049459|Device|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
79253857|NCT04545957|Radiation|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
79253858|NCT04544683|Drug|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
79253859|NCT04529421|Behavioral|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
79393632|NCT00149643|Drug|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
79393633|NCT00149643|Other|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
79549283|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
79713026|NCT06040775|Device|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
79713027|NCT06040775|Device|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
79713028|NCT06040307|Procedure|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
79253860|NCT04529421|Behavioral|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
79393634|NCT02390622|Other|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
79393635|NCT04410289|Procedure|Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
79393636|NCT04410289|Procedure|Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
79549284|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
79549285|NCT01572766|Other|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
79549286|NCT01572779|Device|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
79713029|NCT06039982|Other|no intervention|no intervention
79713030|NCT06036251|Other|Questionnaires|Self-reported quality of life (QOL) measures completed online
79713031|NCT06033807|Diagnostic Test|QuantiFERON-TB Gold (QFT) test|Participants will be tested by QuantiFERON-TB Gold (QFT) test to see if they have ever infected by MTB. Those with positive results will proceed to sputum Xpert MTB/RIF, physical examination and chest CT scan, as well as sputum culture if necessary to distinguish latent TB infection (LTBI) from ATB. X-ray scan is conditional on age above 15 years with a positive QuantiFERON-TB Gold (QFT) test result.
79253861|NCT04521205|Drug|fecal microbiota capsule|a capsule full of fecal microbiota extracting from the health
79253862|NCT04519164|Drug|Eplerenone|mineralocorticoid receptor antagonist and potassium-sparing diuretic
79253863|NCT04519164|Drug|Chlorthalidone with potassium chloride|potassium-wasting diuretic with potassium chloride
79253864|NCT04509674|Drug|Empagliflozin|Empagliflozin
79253865|NCT04509674|Drug|Placebo|Placebo
79549287|NCT01572779|Device|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
79549288|NCT01572805|Drug|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
79253866|NCT04497428|Behavioral|Adaptation|Sensorimotor adaptation in speech
79549289|NCT01572805|Drug|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
79549290|NCT01572805|Drug|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
79549291|NCT01572818|Procedure|phlebotomy|7 ml/kg without exceeding 500 mL
79549292|NCT01572818|Behavioral|dietary and lifestyle counseling|dietary and lifestyle counseling
79549293|NCT01572831|Other|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (<12,000 and >4,000).
79253867|NCT04497428|Other|cTBS|continuous theta-burst stimulation
79253868|NCT04496115|Behavioral|Mindfulness|Mindfulness training
79253869|NCT04491955|Biological|CV301|CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
79549294|NCT01572857|Biological|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~Of the 24-hour urine~at 8 AM~at 12 AM~at 4 PM~On each of these urine samples, the following analysis will be performed:~Proteinuria~Albuminuria~Urinary FLC (Freelite ™)~Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
79713032|NCT06024096|Drug|Atorvastatin|"Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination."
79713033|NCT06024096|Biological|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
79253870|NCT04491955|Drug|MSB0011359C|"Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
79253871|NCT04491955|Drug|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
79253872|NCT04491955|Drug|NHS-IL12|NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
79253873|NCT04476108|Drug|LY3016859|Administered IV
79253874|NCT04476108|Drug|Placebo|Administered IV
79253875|NCT04456686|Drug|LY3016859|LY3016859 given IV.
79253876|NCT04456686|Drug|Placebo|Placebo given IV.
79253877|NCT04447352|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
79253878|NCT04447352|Drug|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
79253879|NCT04447352|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
79253880|NCT04447352|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
79253881|NCT04447352|Drug|Cisplatin|intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
79253882|NCT04435600|Drug|Risankizumab|Subcutaneous Injection
79253883|NCT04435600|Drug|Ustekinumab|Subcutaneous Injection
79253884|NCT04429607|Device|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
79253885|NCT04429607|Device|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
79253886|NCT04429607|Device|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
79253887|NCT04429607|Procedure|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
79253888|NCT04428398|Diagnostic Test|Analysis of urine samples with flow cytometry|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
79277393|NCT04441177|Device|PlayStation®VR training|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
79277394|NCT02201693|Dietary Supplement|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
79549295|NCT01572896|Behavioral|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
79549296|NCT01572896|Behavioral|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
79277395|NCT02201693|Dietary Supplement|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
79308617|NCT04842435|Drug|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
79393637|NCT02381730|Drug|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
79393638|NCT02390778|Behavioral|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
79393639|NCT02390778|Behavioral|leisure activity (film showing)|
79393640|NCT02665338|Device|Transcranial Magnetic Stimulation|
79713034|NCT06023485|Other|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
79393641|NCT01506479|Behavioral|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
79713035|NCT06013917|Device|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
79713036|NCT06011200|Biological|MCV4|1 dose of MCV4 on Day 0
79393642|NCT01506479|Behavioral|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
79713037|NCT06011200|Biological|MSPV4|1 dose of MSPV4 on Day 0
79713038|NCT06007924|Drug|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
79713039|NCT06007924|Drug|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
79393643|NCT01506479|Behavioral|No Intervention|No-exercise control (i.e., usual care);
79393644|NCT00149799|Drug|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
79393645|NCT00149799|Drug|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
79393646|NCT02385942|Device|Smart phone|"measure the Live assessed wound size and the transmitted Smart phone-based wound size~determine dressing materials using Smart phone-based tele-consultation"
79393647|NCT02390544|Drug|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
79549297|NCT01572961|Drug|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
79713040|NCT05993936|Device|mobile application|A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
79713041|NCT05983718|Device|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
79713042|NCT05983718|Procedure|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
79713043|NCT05983354|Drug|Oral metoclopramide and ibuprofen|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
79713044|NCT05983354|Drug|Intravenous metoclopramide and ketorolac|10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
79713045|NCT05971914|Procedure|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
79549298|NCT01572961|Drug|Placebo|
79549299|NCT01572987|Device|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
79549300|NCT01572987|Device|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
79549301|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
79713046|NCT05969548|Device|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
79253889|NCT04421014|Dietary Supplement|Ketone Ester drink|The main ingredient of the Ketone Ester drink [(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
79253890|NCT04421014|Dietary Supplement|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
79253891|NCT04420650|Device|transcranial direct current stimulation|anodal or cathodal transcranial direct current stimulation
79253892|NCT04420351|Drug|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
79393648|NCT01506323|Behavioral|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
79393649|NCT01506323|Behavioral|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
79393650|NCT04204863|Other|collection of patient data|Extract data from the digital medical records, the electroencephalographic and microbiologic database.
79393651|NCT02385630|Other|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
79393652|NCT04157673|Behavioral|Episodic Future Thinking introduced at 6 weeks|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week baseline period.
79393653|NCT04157673|Behavioral|Episodic Future Thinking introduced at 8 weeks|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 8-week baseline period.
79393654|NCT04157673|Behavioral|Episodic Future Thinking introduced at 10 weeks|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 10-week baseline period.
79393655|NCT02381340|Device|ACE stapling procedure|Endoscopic trans-oral gastroplication
79393656|NCT01790763|Device|Keramatrix|Dressing for second degree burn
79393657|NCT01790763|Device|Mepilex|Dressing for second degree wound
79393658|NCT02381262|Behavioral|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
79549302|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
79549303|NCT01573013|Dietary Supplement|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
79549304|NCT01573013|Dietary Supplement|iron fortified biscuits|control biscuit on a daily basis for 8 months
79549305|NCT01573065|Behavioral|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
79549306|NCT01573078|Behavioral|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
79549307|NCT01573091|Procedure|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
79549308|NCT01573104|Other|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
79549309|NCT01573104|Other|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
79549310|NCT01573104|Other|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
79713047|NCT05969548|Device|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
79850864|NCT05212857|Procedure|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
79850865|NCT05212857|Radiation|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
79713048|NCT05969548|Device|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
79253893|NCT04420351|Drug|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
79713049|NCT05969548|Device|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
79713050|NCT05969548|Device|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
79393659|NCT01790841|Device|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
79393660|NCT01505387|Dietary Supplement|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
79713051|NCT05969548|Device|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
79713052|NCT05960708|Drug|YH35324|Subcutaneous injection of YH35324
79713053|NCT05960708|Drug|Omalizumab|Subcutaneous injection of Omalizumab
79713054|NCT05960708|Drug|Placebo|Subcutaneous injection of None of active ingredient
79713055|NCT05959291|Other|Discontinuation of Anti-HER-2 Maintenance Treatment|Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
79713056|NCT05959044|Drug|Folic Acid Tablet|oral 5mg tablet two times daily for 8 weeks
79713057|NCT05959044|Other|Placebo|orally 5mg two times daily for 8weeks
79253894|NCT04414111|Diagnostic Test|Highly suppressive Treg measurement|Circulating highly suppressive Treg measurement
79253895|NCT04409418|Device|Extended dwell catheters|EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
79253896|NCT04409353|Device|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
79253897|NCT04406454|Device|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
79253898|NCT04405583|Device|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
79253899|NCT04400318|Drug|Dupilumab|solution for injection subcutaneous
79393661|NCT01505387|Dietary Supplement|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
79393662|NCT02390232|Biological|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
79393663|NCT02390232|Biological|collection of stools|collection of stools
79393664|NCT02390232|Biological|blood sample|collection of blood sample
79713058|NCT05955924|Drug|Nicotinamide|Oral nicotinamide (500 mg) twice daily
79713059|NCT05955924|Drug|Placebo|Matching placebo capsule twice daily
79713060|NCT05954962|Drug|Progesterone 200 MG|"The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation."
79713061|NCT05954962|Drug|Ganirelix Acetate|The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
79713062|NCT05943691|Drug|hetrombopag 5mg po qd|hetrombopag 5mg po qd for 8 weeks, combining with dexamethasone 40 mg qd for 4 days
79713063|NCT05943691|Drug|High-dose Dexamethasone|dexamethasone 40 mg qd for 4 days
79713064|NCT05935176|Biological|MCV4|2 dose of MCV4 on Day 0 and Month 1
79713065|NCT05935176|Biological|MCV4|2 dose of MCV4 on Day 0 and Month 3
79713066|NCT05931575|Drug|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
79713067|NCT05931575|Drug|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
79713068|NCT05927714|Other|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
79713069|NCT05927714|Other|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
79713070|NCT05919524|Radiation|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~Additional urethra and bladder trigone sparing constrains~Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
79713071|NCT05918744|Behavioral|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
79850866|NCT05212857|Radiation|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
79850867|NCT02099123|Drug|Atorvastatin|Atorvastatin 20 mg tablet
79850868|NCT02099123|Drug|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
79850869|NCT00464542|Drug|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
79549311|NCT01573117|Device|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
79549312|NCT01573117|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
79549313|NCT01573130|Behavioral|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
79549314|NCT01573143|Drug|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
79549315|NCT01573143|Drug|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
79713072|NCT05907525|Drug|Remimazolam|"To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
79713073|NCT05907525|Drug|1% propofol|"To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
79850870|NCT00468676|Behavioral|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
79850871|NCT00468676|Behavioral|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
79850872|NCT02578823|Device|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
79850873|NCT02578823|Device|Arcticgel™|
79850874|NCT02578823|Procedure|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
79253900|NCT04400318|Drug|Placebo|Solution for injection subcutaneous
79253901|NCT04396496|Drug|Daratumumab Injection|"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."
79253902|NCT04379050|Drug|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
79253903|NCT04375267|Drug|177Lu-DOTA-TATE + olaparib|177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
79253904|NCT04365660|Drug|18-F FTC 146|Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
79393665|NCT01899885|Procedure|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~GDT-LiDCO fluid management pre-, per- and postoperative~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
79393666|NCT02381496|Drug|ACT-453859 1 mg|Capsule
79393667|NCT02381496|Drug|ACT-453859 3 mg|Capsule
79393668|NCT02381496|Drug|ACT-453859 10 mg|Capsule
79393669|NCT02381496|Drug|ACT-453859 30mg|Capsule
79393670|NCT02381496|Drug|ACT-453859 100 mg|Capsule
79393671|NCT02381496|Drug|ACT-453859 300 mg|Capsule
79393672|NCT02381496|Drug|ACT-453859 800 mg|Capsule
79393673|NCT02381496|Other|Placebo|Matching ACT-453859 placebo capsule
79393674|NCT02381496|Drug|Setipiprant 500 mg|Capsule
79850875|NCT01969643|Drug|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
79393675|NCT02381496|Drug|Setipiprant 1000 mg|Capsule
79549316|NCT01573156|Drug|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 & 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
79253905|NCT04362670|Drug|OTX-CSI|OTX-CSI intracanalicular insert
79253906|NCT04362670|Other|Placebo Vehicle|Hydrogel Vehicle intracanalicular insert
79549317|NCT01573182|Biological|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
79549318|NCT01573234|Device|MySkin patch|Hydrogel and polyurethane film
79549319|NCT01573234|Device|Gauze and Patch|Traditional Dressing
79713074|NCT05901220|Behavioral|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
79713075|NCT05898750|Dietary Supplement|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
79393676|NCT01790919|Behavioral|Cognitive therapy for depression|"Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory."
79393677|NCT02385552|Behavioral|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
79713076|NCT05890586|Drug|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
79713077|NCT05890586|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
79713080|NCT05877300|Combination Product|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
79393678|NCT01790997|Drug|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
79393679|NCT01790997|Drug|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
79549320|NCT01573247|Drug|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
79549321|NCT01573286|Drug|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
79713081|NCT05875246|Behavioral|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
79713082|NCT05873946|Diagnostic Test|intraoperative ultrasound|Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
79713083|NCT05869656|Behavioral|Fluid restriction|Oral fluid restriction of 1000ml per day
79713084|NCT05869656|Behavioral|Free fluids|Continue care without any oral fluid restriction
79713085|NCT05867381|Device|HEPA filtration|HEPA filters with the capacity to reduce PM2.5 levels
79713086|NCT05867381|Device|Sham filtration|Sham filtration use the same appearance of air purifier but with HEPA filter removed.
79713087|NCT05866159|Other|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
79713088|NCT05866159|Other|Sham taping|sham taping with Rocktape®, with no tension.
79713089|NCT05866055|Drug|VX-973|Suspension for oral administration.
79713090|NCT05866055|Drug|Placebo|Suspension for oral administration.
79713091|NCT05866055|Drug|Midazolam|Syrup for oral administration.
79713092|NCT05864625|Drug|Remimazolam besylate|During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.
79713093|NCT05864625|Drug|Propofol/ Sevoflurane|During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
79253907|NCT04353258|Behavioral|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
79713094|NCT05855837|Other|Ready to Eat Cereal|Cereal products available in retail stores
79713095|NCT05854160|Procedure|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
79713096|NCT05853744|Drug|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
79253908|NCT04353258|Behavioral|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
79713097|NCT05853744|Drug|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
79713098|NCT05853744|Drug|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
79713099|NCT05852769|Drug|BMS-986196|Specified dose on specified days
79549322|NCT01573286|Drug|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
79713100|NCT05852769|Drug|Caffeine|Specified dose on specified days
79713101|NCT05852769|Drug|Montelukast|Specified dose on specified days
79713102|NCT05852769|Drug|Flurbiprofen|Specified dose on specified days
79713103|NCT05852769|Drug|Omeprazole|Specified dose on specified days
79713104|NCT05852769|Drug|Midazolam|Specified dose on specified days
79713105|NCT05852769|Drug|Digoxin|Specified dose on specified days
79253909|NCT04347161|Device|Conversational Agent/Chatbot|Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
79253910|NCT04347161|Other|Usual Care|Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
79713106|NCT05852769|Drug|Pravastatin|Specified dose on specified days
79713108|NCT05850364|Biological|Sabin Strain Inactivated Poliovirus Vaccine|Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old.
79713109|NCT05848518|Other|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
79713110|NCT05833685|Other|no intervention|no intervention
79713111|NCT05832736|Procedure|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
79713112|NCT05828277|Drug|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
79713113|NCT05827718|Behavioral|Method of Contact|Behavioral Intervention studied here is the method of contact (text vs. email vs. email+text).
79713114|NCT05827718|Behavioral|Source of Contact|Behavioral Intervention studied here is source of contact (personal physician vs. research team)
79850876|NCT01969643|Drug|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
79253911|NCT04345757|Behavioral|Structured exercise|The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
79253912|NCT04343053|Other|SARS-Cov-2 infection|blood sample withdrawal
79253913|NCT04332653|Drug|NT-I7|Administered by intramuscular (IM) injection
79549323|NCT01573299|Other|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
79549324|NCT01573312|Drug|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
79713115|NCT05827718|Behavioral|Framing Method (Appeal to Altruism)|"Behavioral Intervention studied here is the framing method appeal to altruism"
79713116|NCT05827718|Behavioral|Framing Method (Social Proof or Perceived Scarcity)|"Behavioral Interventions studied here are the framing methods social proof and perceived scarcity"
79713117|NCT05827718|Behavioral|Framing Method (Opt-Out)|"Behavioral Intervention studied here is the opt-out framing method"
79549325|NCT01573312|Biological|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
79549326|NCT01573338|Drug|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
79713118|NCT05827718|Behavioral|Incentive Structure|Behavioral Interventions studied here are gain-framed vs. loss-framed incentives as well as guarantees incentives vs. lottery incentives.
79713119|NCT05809700|Drug|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
79713120|NCT05808127|Behavioral|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
79713121|NCT05788848|Behavioral|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
79713122|NCT05786300|Device|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
79713123|NCT05786300|Procedure|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
79713124|NCT05773092|Drug|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
79713125|NCT05759962|Drug|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
79713126|NCT05759962|Other|Placebo|Matching Placebo
79713127|NCT05758935|Other|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
79850877|NCT00464308|Drug|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
79850878|NCT00464308|Drug|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
79850879|NCT00464308|Drug|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
79253914|NCT04332653|Drug|Pembrolizumab|Administered by intravenous (IV) injection
79549327|NCT01573338|Drug|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
79549328|NCT01573338|Drug|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
79253915|NCT04329806|Drug|Moxonidine 0.2 MG|Moxonidine 0.2 MG twice daily
79393680|NCT01790997|Drug|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
79393681|NCT02390388|Procedure|pudendal nerve block|nerve stimulator-guided Pudendal block
79549329|NCT01573338|Drug|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
79850880|NCT00194285|Procedure|FDG-PET Imaging|
79850881|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
79850882|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
79850883|NCT00463840|Drug|Oxaliplatin|
79850884|NCT00463840|Drug|5FU|
79549330|NCT01573377|Drug|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
79850885|NCT00463840|Radiation|Radiation|
79850886|NCT00463840|Procedure|Surgery|
79850887|NCT00463840|Drug|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
79850888|NCT00129389|Drug|Fluorouracil|Arm A: FAC Arm B: FAC-wP
79549331|NCT01573377|Drug|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
79253916|NCT04329806|Drug|Amlodipine 5 MG|Amlodipine 5 MG twice daily
79253917|NCT04325217|Drug|Nintedanib|Capsules
79253918|NCT04324840|Drug|CC-90010|Specified dose on specified days
79253919|NCT04324840|Drug|Temozolomide|Specified dose on specified days
79253920|NCT04324840|Radiation|Radiotherapy|Specified dose on specified days
79393682|NCT02390388|Procedure|caudal block|caudal block
79393683|NCT00324753|Behavioral|Communication|Communication sheet
79393684|NCT00324753|Behavioral|Standard of care|Standard of care brochures
79393685|NCT02385474|Drug|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
79393686|NCT02385474|Drug|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
79393687|NCT04439682|Other|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
79549332|NCT01573403|Drug|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
79549333|NCT01573403|Drug|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
79549334|NCT01573403|Drug|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
79549335|NCT01573416|Other|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
79549336|NCT01573416|Other|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
79549337|NCT01573468|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
79549338|NCT01573468|Drug|Placebo|Placebo orally once on Day 1 of each cycle
79549339|NCT01573468|Drug|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
79549340|NCT01573481|Other|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
79549341|NCT01573481|Other|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min).
79549342|NCT01573494|Other|Sampling of blood|7,5 ml of blood
79549343|NCT01573507|Other|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
79549344|NCT01573520|Other|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
79549345|NCT01573546|Behavioral|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
79549346|NCT01573546|Behavioral|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
79549347|NCT01573546|Other|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
79549348|NCT01573585|Behavioral|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
79549349|NCT01573585|Behavioral|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
79549350|NCT01573598|Drug|Placebo|Matching placebo given orally, once per day
79549351|NCT01573598|Drug|Vilazodone|Vilazodone, 20 mg per day, oral administration
79549352|NCT01573598|Drug|Vilazodone|Vilazodone, 40 mg once per day, oral administration
79549353|NCT01573611|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
79549354|NCT01573611|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
79549355|NCT01573637|Drug|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
79850889|NCT00129389|Drug|Doxorubicin|Arm A: FAC Arm B: FAC-wP
79850890|NCT00129389|Drug|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
79850891|NCT00129389|Drug|Paclitaxel|Arm B: FAC-wP
79850892|NCT01025362|Behavioral|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
79393688|NCT02390310|Device|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
79393689|NCT02390310|Drug|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
79393690|NCT02390310|Drug|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
79850893|NCT01025362|Behavioral|Standard care|Child Health Services offered standard care
79549356|NCT01573637|Drug|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
79549357|NCT01573663|Drug|Ambroxol and Levodropropizine|Ambroxol HCl 30mg & Levodropropizine 60mg, PO, Single dose
79549358|NCT01573663|Drug|Ambroxol|Ambroxol HCl 30mg, PO, single dose
79549359|NCT01573663|Drug|Levodropropizine|Levodropropizine 60mg, PO, single dose
79549360|NCT01573689|Behavioral|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
79549361|NCT01573715|Drug|NIMBEX|
79549362|NCT01573715|Drug|NIMBEX|
79253921|NCT04321759|Behavioral|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
79393691|NCT02381184|Drug|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
79393692|NCT02381184|Procedure|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
79393693|NCT02381028|Other|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
79393694|NCT02381028|Other|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
79549363|NCT01573715|Other|WITHOUT NIMBEX|
79549364|NCT01573728|Behavioral|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
79549365|NCT01573728|Behavioral|Public Health Exercise|At least 150 minutes at moderate intensity
79549366|NCT01573741|Drug|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
79549367|NCT01573793|Behavioral|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
79850894|NCT01025440|Device|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
79549368|NCT01573793|Behavioral|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
79549369|NCT01573806|Drug|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
79549370|NCT01573806|Drug|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
79549371|NCT01573819|Drug|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
79549372|NCT01573819|Drug|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
79549373|NCT01573832|Other|integrated client care group|receives integrated client care for wound treatment
79549374|NCT01573845|Behavioral|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~A 22-lesson classroom curriculum~Homework activities that involve the family~Monthly parent newsletters~A food shopping and packing guide for parents~Food demonstrations~A poster contest~School wide announcements"
79549375|NCT01573845|Behavioral|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~A 22-lesson classroom curriculum~Homework activities that involve the family~Monthly parent newsletters~A food shopping and packing guide for parents~Food demonstrations~A poster contest~School wide announcements"
79549376|NCT01573858|Other|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
79850895|NCT00468052|Drug|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
79850896|NCT00468052|Drug|fentanyl|1 microgram/kilogram as a bolus
79850897|NCT04712981|Other|Behavioral Intervention|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
79850898|NCT00453310|Drug|sunitinib malate|
79393695|NCT00326781|Drug|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
79393696|NCT00326781|Drug|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
79393697|NCT02385396|Dietary Supplement|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
79393698|NCT02390466|Biological|VAC-3S|Administered via intra-muscular injection in the arm
79393699|NCT00328263|Dietary Supplement|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
79850899|NCT04071743|Device|gammaCore Sapphire|non-invasive vagus nerve stimulator
79850900|NCT04071743|Device|sham gammaCore Sapphire|sham gammaCore Sapphire
80017267|NCT02101710|Drug|Imdur SR 60 mg|"Trade Name: Elantan~Active Substance: Isosorbide 5-mononitrate~Pharmaceutical form: Tablet~Concentration: 60 mg~Route of Administration: Oral administration"
79549377|NCT01573858|Other|Acupuncture treatment 2|Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
79549378|NCT01573858|Other|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
79549379|NCT01573858|Other|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
79549380|NCT01573871|Other|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
79549381|NCT01573923|Biological|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
79549382|NCT01573923|Biological|Conventional therapy|Conventional therapy without cell therapy
79549383|NCT01573936|Other|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
79549384|NCT01573975|Drug|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
79549385|NCT01573975|Drug|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
79393700|NCT00328263|Dietary Supplement|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
79549386|NCT01573975|Drug|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
79549387|NCT01573988|Other|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~breakfast in one intake at 8:00~breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
79253922|NCT04321759|Behavioral|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
79253923|NCT04320069|Device|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
79393701|NCT02390154|Drug|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of [14C] roniciclib solution
79393702|NCT02390154|Drug|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
79549388|NCT01574001|Behavioral|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
79549389|NCT01574001|Behavioral|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
79549390|NCT01574001|Behavioral|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
79549391|NCT01574014|Behavioral|CBGT|Cognitive-behavioral group therapy
79850901|NCT02578667|Device|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
79549392|NCT01574014|Drug|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
79549393|NCT01574014|Drug|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
79549394|NCT01574027|Drug|Vitamin D3 (cholecalciferol)|One capsule per day for six months
79549395|NCT01574027|Drug|Placebo|One capsule per day for six months
79393703|NCT01791075|Device|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
79393704|NCT01791075|Device|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
79253924|NCT04316637|Drug|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
79393705|NCT04710342|Device|CapBuster|Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.
79393706|NCT02979405|Drug|Phenylephrine|prophylactic infusion of phenylephrine 40 mcg/min
79393707|NCT01791231|Drug|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
79253925|NCT04314895|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
79549396|NCT01574040|Behavioral|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
79253926|NCT04310176|Drug|Bevacizumab|5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)
79549397|NCT01574040|Behavioral|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
79253927|NCT04310176|Drug|mFOLFOX6 regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
79253928|NCT04310176|Drug|mOXXEL regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
79253929|NCT04310176|Drug|Valproic acid|given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml
79253930|NCT04310176|Drug|Capecitabine|Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
79549398|NCT01574040|Behavioral|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
79549399|NCT01574040|Behavioral|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
79549400|NCT01574066|Procedure|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
79549401|NCT01574092|Drug|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
79549402|NCT01574131|Drug|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
79549403|NCT01574131|Drug|Sugar Pill|pill every day for 6 months
79549404|NCT01574196|Other|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
79549405|NCT01574222|Biological|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
79549406|NCT01574235|Biological|Nivestim®|
79549407|NCT01574261|Drug|Placebo|Placebo for four months
79549408|NCT01574261|Drug|Inositol|Inositol 4g/die for four months
79549409|NCT01574300|Other|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
79713128|NCT05745402|Behavioral|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
79850902|NCT00128843|Drug|Exemestane|25mg/day until progression disease
79850903|NCT00128843|Drug|Anastrozole|1mg/day until progression disease
79549410|NCT01574313|Procedure|stellate ganglion block|stellate ganglion block
79549411|NCT01574313|Drug|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
79549412|NCT01574313|Drug|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
79549413|NCT01574313|Drug|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
79713129|NCT05743842|Device|TriSalus™ TriNav™Infusion System|Given by Infusion
79850904|NCT02575703|Drug|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414
79850905|NCT04609553|Behavioral|Usual care including ROR|Usual care which includes ROR.
79850906|NCT04609553|Behavioral|Text messages|3 text messages per week and one interactive text per month.
79253931|NCT04310176|Drug|5-fluorouracil|Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
79253932|NCT04296175|Drug|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
79393708|NCT01791309|Drug|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
79253933|NCT04296175|Drug|CTX|600mg, d1 every 2 or 3 weeks
79253934|NCT04296175|Drug|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
79253935|NCT04296175|Drug|ddEpirubicin|90mg/m2, d1 every 2 weeks
79253936|NCT04296175|Drug|ddCTX|600mg, d1 every 2 weeks
79253937|NCT04296175|Drug|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
79253938|NCT04296175|Drug|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
79253939|NCT04295538|Drug|Elezanumab|Solution for infusion; Intravenous (IV)
79253940|NCT04295538|Drug|Placebo|Solution for infusion; Intravenous (IV)
79253941|NCT04291001|Device|ENG implant|This is an FDA-approved contraceptive device
79850907|NCT04609553|Behavioral|Connection to community resources|Referral to a non-profit that connects families with community resources and provides families with case management.
79393709|NCT03113682|Behavioral|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
79253942|NCT04291001|Drug|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
79253943|NCT04286282|Behavioral|Group Pyschotherapy|Group psychotherapy
79253944|NCT04286282|Other|Depression Standard of Care|Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
79253945|NCT04286282|Other|HIV Standard of Care|Standard clinical care for HIV
79253946|NCT04284540|Radiation|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
79253947|NCT04284540|Radiation|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
79253948|NCT04283539|Drug|systemic corticosteroid or biologic|Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
79393710|NCT02389920|Drug|Nilotinib|
79393711|NCT00329433|Drug|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
79393712|NCT00329433|Drug|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
79393713|NCT02384772|Other|Survey|
79850908|NCT04071431|Other|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
79850909|NCT04073927|Dietary Supplement|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
80017268|NCT02098668|Other|Fertility treatment|Fertility treatment
79253949|NCT04275232|Biological|Allogenic plasma aliquots, a source of plasminogen|Plasma eye drops, a source of plasminogen
79253950|NCT04269889|Drug|Eltrombopag|"Eltrombopag will be administered to participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth."
79253951|NCT04263597|Drug|2'-fucosyllactose|2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.
79393714|NCT03105960|Drug|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
79393715|NCT03105960|Drug|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
79393716|NCT03105804|Other|FT21039|An electronic cigarette
79393717|NCT03105804|Other|FT21041|An electronic cigarette
79393718|NCT03105804|Other|FT21044|An electronic cigarette
79393719|NCT03105804|Other|FT21042|An electronic cigarette
79393720|NCT02389842|Drug|Palbociclib + Taselisib / Pictilisib|
79393721|NCT02385006|Biological|Blood sample|
79393722|NCT00289341|Biological|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
79393723|NCT00289341|Biological|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
79393724|NCT02389686|Device|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
79549414|NCT01574339|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative."
79713130|NCT05743842|Diagnostic Test|Angiogram|X-ray photograph
79713131|NCT05743842|Procedure|Y90-radioembolization procedure|procedure
79253952|NCT04260854|Drug|Bupivacaine Hydrochloride|Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
79253953|NCT04260854|Drug|Saline|Normal saline injections.
79253954|NCT04253483|Radiation|High-Dose Rate Brachytherapy|Undergo HDR
79253955|NCT04253483|Other|Quality-of-Life Assessment|Ancillary studies
79253956|NCT04253483|Other|Questionnaire Administration|Ancillary studies
79253957|NCT04253483|Procedure|Stereotactic Ablative Radiotherapy|Undergo SABR
79393725|NCT04010175|Behavioral|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
79393726|NCT04010175|Behavioral|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
79713133|NCT05734443|Behavioral|non-treadmill trip training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
79713134|NCT05734443|Behavioral|treadmill trip training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
79713135|NCT05728073|Procedure|ERCP|Patients separated to two groups according to having a ERCP history before the operation
79713136|NCT05713279|Drug|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
79713137|NCT05707455|Other|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
79713138|NCT05699733|Device|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
79713139|NCT05690659|Other|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
79713140|NCT05676359|Other|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
80017269|NCT03529994|Other|Enrollment|All infants enrolled will have work of breathing assessed.
80017270|NCT03878368|Dietary Supplement|Sulforaphane|Intervention soup with dietary sulforaphane
80017271|NCT03878368|Dietary Supplement|Placebo|Control soup without dietary sulforaphane
79549415|NCT01574365|Drug|RTA 402|
79549416|NCT01574378|Device|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
79253958|NCT04243798|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
79253959|NCT04243798|Device|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
79253960|NCT04243226|Device|telehealth-based aerobic walking exercise|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
79549417|NCT01574378|Device|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
79549418|NCT01574391|Device|Epidrum|Epidrum is used
79549419|NCT01574404|Procedure|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
79850910|NCT00124657|Drug|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
79850911|NCT00581945|Drug|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
79549420|NCT01574417|Dietary Supplement|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
79850912|NCT00581945|Drug|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
79549421|NCT01574417|Dietary Supplement|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
79549422|NCT01574430|Procedure|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
79253961|NCT04240444|Device|drug-coated balloon Catheter|All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
79549423|NCT01574469|Other|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
79549424|NCT01574469|Other|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
79549425|NCT01574482|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
79549426|NCT01574482|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
79549427|NCT01574495|Other|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
79850913|NCT02578589|Procedure|Plica resection vs conservative treatment|Plica resection vs conservative treatment
79850914|NCT01079845|Behavioral|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
79850915|NCT02578277|Drug|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
79253962|NCT04233606|Other|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
79253963|NCT04233606|Other|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
79253964|NCT04230941|Behavioral|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
79393727|NCT04010175|Behavioral|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
79393728|NCT00289653|Drug|Nicoderm|
79549428|NCT01574508|Drug|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
79549429|NCT01574508|Drug|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
79549430|NCT01574534|Device|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
79549431|NCT01574534|Device|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
79549432|NCT01574560|Behavioral|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
79549433|NCT01574560|Behavioral|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
79549434|NCT01574573|Behavioral|Self support, group sessions|Self support,group sessions
79549435|NCT01574586|Device|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
79549436|NCT01574599|Other|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
79549437|NCT01574638|Drug|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
79549438|NCT01574664|Device|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
79549439|NCT01574690|Device|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
79549440|NCT01574690|Procedure|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
79549441|NCT01574690|Procedure|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
79253965|NCT04226508|Other|Physical exercise|"The patients can choose between three modality of EX:~Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants."
79549442|NCT01574729|Drug|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
79549443|NCT01574729|Procedure|Surgery|Surgery plus post-surgery chemotherapy
79393729|NCT02380950|Behavioral|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
79549444|NCT01574742|Drug|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
79549445|NCT01574768|Procedure|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
79549446|NCT01574781|Procedure|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
79549447|NCT01574781|Procedure|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
79393730|NCT02380872|Procedure|Connective tissue graft|gingival recession treated with connective tissue graft
79549448|NCT01574794|Other|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
79549449|NCT01574794|Other|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
79549450|NCT01574820|Drug|placebo tablet|placebo tablet for 6 months
79549451|NCT01574820|Drug|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
79549452|NCT01574833|Device|pulsed electromagnetic field|PEMF treatment
79549453|NCT01574833|Device|sham|sham treatment
79549454|NCT01574859|Other|levothyroxine|titration of T4 according to biochemical values
79549455|NCT01574872|Device|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
79713141|NCT05676359|Other|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
79713142|NCT05676359|Other|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
79253966|NCT04226248|Drug|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
79253967|NCT04226248|Other|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
79253968|NCT04219787|Procedure|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
79253969|NCT04219787|Procedure|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
79549456|NCT01574872|Device|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
79253970|NCT04208347|Drug|Apatinib 250mg|Apatinib 250mg
79393731|NCT02380872|Procedure|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
79549457|NCT01574885|Device|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
79549458|NCT01574885|Device|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
79549459|NCT01574898|Drug|V0474 - A mg|Single oral administration
79549460|NCT01574898|Drug|V0474 - B mg|Single oral administration
79549461|NCT01574898|Drug|V0474 - C mg|Single oral administration
79549462|NCT01574898|Drug|V0018 - B mg|Single oral administration
79549463|NCT01574898|Drug|Niquitin® Fresh Mint 4 mg|Single oral administration
79549464|NCT01574924|Other|No intervention.|There are no interventions in this observational study.
79549465|NCT01574937|Drug|Cabozantinib|28 day cycle
79393732|NCT00290199|Device|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
79549466|NCT01574937|Drug|Abiraterone|28 day cycle
79549467|NCT01574976|Behavioral|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
79549468|NCT01574989|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
79549469|NCT01574989|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35^2 electrodes.
79549470|NCT01575002|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
79549471|NCT01575015|Device|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
79549472|NCT01575015|Procedure|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
79549473|NCT01575041|Dietary Supplement|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
79253971|NCT04208347|Drug|Camrelizumab|Camrelizumab 200mg
79253972|NCT04208347|Drug|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
79253973|NCT04208347|Drug|Apatinib 500mg|Apatinib 500mg
79253974|NCT04198454|Other|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking
79253975|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound
79253976|NCT04198454|Device|Fractional ablative carbon dioxide laser|Participant will have laser applied to their wound bed.
79253977|NCT04186169|Procedure|Catheter ablation|Catheter ablation
79253978|NCT04179019|Drug|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
79393733|NCT02380794|Drug|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
79393734|NCT02380794|Drug|Placebo|
79393735|NCT00291135|Drug|letrozole|Letrozole 2.5 mg daily
79393736|NCT02389608|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
79393737|NCT02389608|Device|Functional electrical stimulation (FES)|
79393738|NCT02389608|Device|Sham stimulation|
79393739|NCT02103855|Drug|Belatacept|
79393740|NCT02380638|Device|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
79393741|NCT02380560|Device|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
79393742|NCT02104167|Device|ROIC interbody cage with VerteBRIDGE plating|
79393743|NCT02384694|Other|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
79393744|NCT02389530|Drug|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
79393745|NCT03706053|Drug|Midodrine Hydrochloride|Midodrine Hydrochloride, enteral, 10 or 20 mg
79393746|NCT03706053|Other|placebo|investigational pharmacy formulated placebo comparator
79393747|NCT02384616|Other|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
79393748|NCT02018835|Device|MRI|
79393749|NCT02018835|Device|cardiac echography transthoracic|
79393750|NCT02389296|Other|Questionnaire|Questionnaires will be distributed to nursing staff
79393751|NCT03117699|Device|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~A standing pass from sitting on a chair~A straight line movement~A succession of left and right turns~An upward and downward travel of less than 1%.~Standard doorway~Standing on the toilet~A sitting pass from the toilet~One way to a bed~A sitting pass on the bed~A passenger seat sitting upright from the bed~A return to the starting point~A sitting pass on the starting chair"
79393752|NCT01504841|Drug|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
79393753|NCT00330915|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
79393754|NCT02384304|Behavioral|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
79393755|NCT02384304|Behavioral|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
79393756|NCT02384304|Behavioral|Self help|A self help program consisting of 8 modules
79393757|NCT03026933|Drug|KI1107 4 Capsules, QD|KI1107 4 Capsules
79393758|NCT03026933|Drug|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
79393759|NCT02389140|Other|Trigger point release|Trigger point therapy
79393760|NCT02389140|Other|Ultrasound|sham ultrasound
79393761|NCT02380482|Other|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
79393762|NCT02380482|Other|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
79393763|NCT01502423|Biological|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
79393764|NCT02388984|Drug|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
79393765|NCT02388984|Drug|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
79393766|NCT01502033|Device|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
79393767|NCT02380326|Procedure|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
79549474|NCT01575041|Drug|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
79549475|NCT01575041|Drug|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
79393768|NCT04861584|Drug|Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin|4 cycle neoadjuvant therapy and radical cystectomy
79393769|NCT02389062|Other|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
79393770|NCT01500629|Device|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
79549476|NCT01575093|Other|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
79549477|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
79549478|NCT01575119|Behavioral|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
79549479|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
79549480|NCT01575119|Behavioral|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
79549481|NCT01575145|Behavioral|Quitline facilitation intervention|brief quitline facilitation intervention
79549482|NCT01575145|Behavioral|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
79253979|NCT04176731|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
79393771|NCT01500629|Device|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
79393772|NCT02384148|Other|Circadian rhythm measurement|
79393773|NCT02384148|Procedure|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
79253980|NCT04175301|Drug|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
79253981|NCT04175301|Drug|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
79393774|NCT02388750|Drug|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
79393775|NCT02388750|Radiation|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
79393776|NCT05231226|Procedure|Immediately CR|Immediately opening non-IRA after emergency opening IRA in STEMI patients with MVD
79393777|NCT05231226|Procedure|Staged (within 45 days) CR|Staged opening non-IRA after emergency opening IRA in STEMI patients with MVD
79393778|NCT02379936|Device|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
79549483|NCT01575158|Drug|Citalopram|
79549484|NCT01575158|Drug|Clomipramine|
79549485|NCT01575158|Drug|placebo|
79549486|NCT01575171|Behavioral|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
79549487|NCT01575184|Other|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
79549488|NCT01575184|Other|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
79549489|NCT01575210|Device|CPAP mask|A new vent CPAP mask system will be used in this trial.
79549490|NCT01575210|Device|CPAP mask|A new vent CPAP mask system will be used in this trial
79549491|NCT01575223|Device|NeilMed sinus rinse|High volume saline irrigation
79253982|NCT04166591|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
79253983|NCT04166591|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
79549492|NCT01575223|Device|Salinex|Low volume saline irrigation
79549493|NCT01575236|Device|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
79549494|NCT01575236|Device|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
79549495|NCT01575262|Behavioral|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
79850916|NCT02578277|Drug|BMS-955176|BMS-955176
79253984|NCT04162990|Behavioral|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
79549496|NCT01575262|Behavioral|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
79549497|NCT01575288|Drug|Placebo|100g maltose 1/day
79549498|NCT01575288|Drug|High-dose trehalose|100g 1/day
79549499|NCT01575301|Drug|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
79253985|NCT04162990|Behavioral|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
79549500|NCT01575314|Device|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
79549501|NCT01575327|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
79549502|NCT01575327|Device|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
79549503|NCT01575340|Dietary Supplement|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
79549504|NCT01575353|Device|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
79549505|NCT01575353|Device|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
79549506|NCT01575366|Behavioral|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
79253986|NCT04159311|Other|Osteopathy|testing osteopathy Vs Treating osteopathy
79253987|NCT04153136|Drug|Sacubitril-Valsartan 49-51Mg Oral Tablet|By mouth twice daily
79253988|NCT04153136|Drug|Placebo oral tablet|Placebo oral tablet By mouth twice daily
79253989|NCT04141605|Device|SherpaPak Cardiac Transport System|"The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached."
79253990|NCT04134104|Procedure|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
79393779|NCT02379936|Procedure|Traditional evaluation|Traditional way of evaluation
79393780|NCT02379936|Device|iPhone 4S|
79393781|NCT02388594|Drug|ZFN Modified CD4+ T Cells|
79549507|NCT01575405|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
79549508|NCT01575405|Drug|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy) propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
79253991|NCT04127409|Other|Control Chicken-meat|
79393782|NCT02388594|Drug|Cyclophosphamide|
79393783|NCT01500317|Drug|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
79393784|NCT01500317|Drug|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
79393785|NCT01500317|Drug|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
79549509|NCT01575405|Drug|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
79253992|NCT04127409|Other|Control Eggs|
79549510|NCT01575418|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
79549511|NCT01575418|Drug|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
79253993|NCT04127409|Other|Omega-3-PUFA Enriched Chicken-meat|
79549512|NCT01575418|Drug|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
79549513|NCT01575418|Radiation|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
79549514|NCT01575457|Behavioral|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
79549515|NCT01575483|Drug|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
79549516|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
79549517|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
79549518|NCT01575509|Other|Berry product|Sugar infused dried lingonberry
79549519|NCT01575509|Other|Bread product|Brown bread
79713143|NCT05676359|Other|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
79850917|NCT02578277|Drug|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
79253994|NCT04127409|Other|Omega-3PUFA Enriched Eggs|
79253995|NCT04103489|Drug|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
79713144|NCT05676359|Other|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
79713145|NCT05676359|Other|Rheumatic disease comorbidity index|It is rated from 0 to 9 and comprises 11 comorbid conditions including lung disease, cardio-vascular disease, hypertension, diabetes, fracture, depression, cancer, and gastrointestinal ulcer
79253996|NCT04099355|Drug|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
79253997|NCT04099355|Drug|Non-active comparator|1 QAM and 2 QHS PO 14 days
79253998|NCT04099251|Biological|Nivolumab|Specified dose on specified days
79253999|NCT04099251|Other|Placebo|Specified dose on specified days
79254000|NCT04097860|Behavioral|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
79549520|NCT01575509|Other|Bread product|Whole grain bread
79549521|NCT01575509|Other|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
79549522|NCT01575509|Other|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
79549523|NCT01575535|Genetic|gene expression analysis|
79549524|NCT01575535|Other|flow cytometry|
79549525|NCT01575535|Other|fluorescence activated cell sorting|
79549526|NCT01575535|Other|laboratory biomarker analysis|
79549527|NCT01575535|Other|medical chart review|
79850918|NCT04071197|Device|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
79850919|NCT04071197|Device|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
80017272|NCT03529916|Other|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
79549528|NCT01575574|Drug|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
79254001|NCT04088708|Other|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
79393786|NCT02379780|Procedure|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71*50 mm 22G*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
79549529|NCT01575587|Drug|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
79549530|NCT01575587|Drug|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
79549531|NCT01575587|Drug|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
79549532|NCT01575587|Drug|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
79549533|NCT01575600|Other|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
79549534|NCT01575613|Drug|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
79549535|NCT01575613|Biological|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
79713146|NCT05676359|Other|Living will questionnaire|A questionnaire with 17 items about knowledge of the living will.
79713147|NCT05676359|Other|Perceptions of Health Outcomes Questionnaire|A questionnaire with 7 items about the probability of quitting the job, getting an infectious disease, requiring emergency medical attention, hospitalization or intensive care, dependence and death.
79713148|NCT05674903|Device|Verum stimulation with Diadem prototype|Diadem prototype device delivers focused low-intensity ultrasound stimulation
79850920|NCT00555906|Drug|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
79850921|NCT00555906|Drug|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
79850922|NCT00555906|Drug|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
79850923|NCT03817879|Procedure|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
79393787|NCT02379780|Procedure|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71*50 mm 22 G* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
79393788|NCT02388672|Dietary Supplement|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
79393789|NCT02388672|Dietary Supplement|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
79549536|NCT01575613|Biological|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
79549537|NCT01575613|Biological|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
79549538|NCT01575626|Drug|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
79549539|NCT01575639|Drug|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
79713149|NCT05674903|Device|Sham stimulation with Diadem prototype|Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
79713150|NCT05664932|Biological|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
79850924|NCT03817879|Procedure|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
79850925|NCT04071353|Drug|Interferon|Interferon combined with ribavirin antiviral therapy
79850926|NCT04071353|Drug|ribavirin|Interferon combined with ribavirin antiviral therapy
79850927|NCT04071353|Drug|DAAs|DAAs antiviral treatment
79850928|NCT03968497|Other|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
79850929|NCT03968497|Other|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
79850930|NCT01078129|Behavioral|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
79850931|NCT01078129|Behavioral|non-CRT|waiting list
79393790|NCT02388672|Dietary Supplement|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
79713151|NCT05664932|Biological|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
79393791|NCT02388672|Dietary Supplement|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
79393792|NCT02379468|Drug|Pedyphar Ointment|
79393793|NCT02379468|Drug|Panthenol|Ointment
79393794|NCT02388828|Biological|lentiviral-based CART meso therapy|
79393795|NCT02379546|Drug|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
79393796|NCT02379546|Device|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
79393797|NCT00332163|Biological|Panitumumab|Administered by intravenous infusion
79549540|NCT01575652|Other|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
79549541|NCT01575652|Other|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
79549542|NCT01575665|Device|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
79549543|NCT01575678|Drug|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
79713152|NCT05663086|Biological|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
79850932|NCT04071899|Other|Scale vaidation|It's just filling a scale in order to validate it in French
79850933|NCT01078285|Behavioral|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
79850934|NCT01078285|Behavioral|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
79850935|NCT02576561|Biological|TVGV-1|Antigen + Adjuvant
79850936|NCT02576561|Biological|GPI-0100|Adjuvant Alone
79850937|NCT02576561|Biological|Placebo|Placebo
79850938|NCT04071275|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
79850939|NCT04071275|Other|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
79549544|NCT01575678|Drug|Lactose|blinded capsule 1/day, oral use, for 4 weeks
79549545|NCT01575704|Other|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
79549546|NCT01575704|Other|Mental Training|Memorial/ mental training and relaxation, 5 times per week
79549547|NCT01575717|Drug|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
79850940|NCT00709475|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79393798|NCT00332163|Drug|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
79393799|NCT00332163|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
79393800|NCT00332163|Drug|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
79393801|NCT00332163|Drug|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
79393802|NCT02377284|Other|Photograph|Add a photograph to a chef card.
79549548|NCT01575717|Drug|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
79713153|NCT05663086|Biological|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
79713154|NCT05663086|Biological|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
79713155|NCT05663086|Biological|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
79713156|NCT05659836|Device|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
79713157|NCT05637814|Diagnostic Test|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
79549549|NCT01575743|Behavioral|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
79713158|NCT05623423|Other|(Admira Fusion, Voco GmbH, Germany)|cavity margins will be extended to the proximal area, incisal edge, facial and lingual surfaces All enamel margins will be beveled at a 45° angle to the external cavosurface.(approximately 0.5-2.0 mm) An impression for the upper anterior teeth will be taken to produce a silicon palatal index The proximal margins of the restorations will be achieved using the Unica anterior matrix teeth will be etched using 37% phosphoric acid gel for 30 s then rinsed with air water for 20 s A single coat of universal bond cured using and LED light curing unit for 10 s Using the chosen enamel shade of the ORMOCER Resin Composite a thin layer (0.5-1 mm) Unica matrix will used to produce the proximal margins of the restorations Contouring, finishing and polishing of the restoration will be done Dental floss and finishing strips will be used Rubber dam will then be removed and occlusion will be checked using an articulating paper
79713159|NCT05623423|Other|Methacrylate Based Composite|The exact same steps as in the intervention will be done but using the chosen shades of Methacrylate Based Composite Resin. (Ceram.X Spectra ST, Dentsply Sirona, UK)
79713160|NCT05615051|Device|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
79393803|NCT02379702|Other|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
79713161|NCT05613842|Drug|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
79713162|NCT05603533|Other|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
79850941|NCT04071041|Drug|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
79850942|NCT02575625|Device|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
79850943|NCT02575625|Biological|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
79393804|NCT02379624|Drug|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
79549550|NCT01575782|Drug|Chloroquine|Daily intake of Chloroquine during radiotherapy
79850944|NCT02575625|Device|MRI|Liver MRI
79850945|NCT00555672|Drug|5-fluorouracil|5- fluorouracil is given as 4000 mg/m^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
79850946|NCT00555672|Drug|cisplatin|Cisplatin is given 80 mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
79850947|NCT00555672|Drug|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
80017273|NCT01368900|Device|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
79393805|NCT02379312|Dietary Supplement|Very low energy aerated beverage|
79393806|NCT02379312|Dietary Supplement|Normal energy aerated beverage 1|
79393807|NCT02379312|Dietary Supplement|Normal energy aerated beverage 2|
79393808|NCT02379312|Dietary Supplement|Normal energy aerated beverage 3|
79393809|NCT02379000|Drug|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
79393810|NCT02379000|Procedure|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
79393811|NCT04675398|Device|Summit RC+S|Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.
79393812|NCT04675398|Device|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.
79393813|NCT04675398|Device|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).
79393814|NCT04675398|Device|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
79393815|NCT00333177|Behavioral|Cognitive remediation training (CT)|Cognitive remediation training includes computerized cognitive training plus learning skills group.
79393816|NCT00333177|Behavioral|Healthy behavior training (HBT)|Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
79393817|NCT00333177|Drug|Risperidone, administered orally (Oral Ris)|Oral risperidone at dosage judged optimal by treating psychiatrist
79393818|NCT00333177|Drug|Risperidone, administered via injection (RLAI)|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
79393819|NCT02379234|Other|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
79393820|NCT02379156|Drug|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
79393821|NCT02379156|Other|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
79393822|NCT00333879|Device|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
79393823|NCT01792245|Device|Phototherapy|
79393824|NCT02383680|Biological|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
79393825|NCT02383524|Procedure|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
79393826|NCT01899261|Radiation|Stereotactic Radiosurgery|Undergo SBRT
79393827|NCT02383368|Drug|ASP4132|oral
79393828|NCT00335283|Drug|Lansoprazole Tablet|40 mg bid x 16 weeks
79393829|NCT00335283|Procedure|PH and impedence testing|24 hour ph monitoring
79393830|NCT00335283|Procedure|manometry|done prior to pH probe to measure length of esophagus
79393831|NCT00335283|Drug|lansoprazole|40mg bid
79393832|NCT00335283|Drug|placebo|one tablet bid
79393833|NCT02372214|Procedure|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
79393834|NCT02779803|Procedure|EC-IC bypass|To determine if cerebral revascularization via STA to MCA bypass to improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients.
79393835|NCT01500083|Drug|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
79393836|NCT01500083|Drug|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
79393837|NCT02779257|Drug|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
79393838|NCT02779257|Drug|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
79393839|NCT02371824|Other|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
79393840|NCT01890837|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
79393841|NCT01890837|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
79393842|NCT02378922|Biological|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
79393843|NCT02378922|Other|Laboratory Biomarker Analysis|Correlative studies
79393844|NCT02378922|Other|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
79393845|NCT02377128|Procedure|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
79393846|NCT02377128|Procedure|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
79393847|NCT02378688|Drug|MT-1303|
79393848|NCT02378688|Drug|Placebo|
79393849|NCT02487147|Other|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
79393850|NCT02487147|Other|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
79393851|NCT02378610|Other|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
79713163|NCT05600101|Behavioral|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
79713164|NCT05595720|Device|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
79850948|NCT02575547|Drug|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
79254002|NCT04088708|Other|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
79254003|NCT04085523|Drug|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
79254004|NCT04085523|Drug|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
79393852|NCT02371512|Device|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
79393853|NCT02371512|Procedure|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
79393854|NCT00295503|Drug|bevacizumab|15 mg/kg IV every 3 weeks
79393855|NCT00295503|Drug|cisplatin|75 mg/m2 IV every 3 weeks
79393856|NCT00295503|Drug|pemetrexed|500 mg/m2 every 3 weeks
79393857|NCT02371590|Drug|Lenalidomide|"Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject."
79393858|NCT02371590|Drug|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
79393859|NCT01791621|Other|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
79393860|NCT02371434|Biological|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10^6, 1 x 10^6, and 2.5-3 x 10^6 cells/kg body weight in cohorts of three patients each.
79393861|NCT03105648|Other|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
79393862|NCT00335517|Drug|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
79393863|NCT02376816|Biological|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
79393864|NCT00298155|Drug|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
79393865|NCT00298155|Drug|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
79393866|NCT00298155|Drug|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
79393867|NCT01499849|Drug|Rolapitant|(4 X 50 mg capsules) 200 mg PO
79393868|NCT01499849|Drug|Granisetron|10 mcg/kg IV
79393869|NCT01499849|Drug|dexamethasone|20 mg PO and 8 mg PO
79549551|NCT01575795|Drug|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
79549552|NCT01575795|Drug|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
79850949|NCT01037387|Drug|Control|Current treatment according to the ATS/ERS guidelines
79850950|NCT01037387|Device|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
79850951|NCT02574533|Biological|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
79393870|NCT01499849|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
79549553|NCT01575821|Dietary Supplement|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
79549554|NCT01575821|Dietary Supplement|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
79393871|NCT02371902|Device|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
79254005|NCT04070976|Radiation|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
79254006|NCT04070976|Radiation|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
79549555|NCT01575821|Dietary Supplement|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
79254007|NCT04070573|Drug|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
79393872|NCT02371902|Device|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
79549556|NCT01575821|Dietary Supplement|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
79549557|NCT01575938|Behavioral|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
79549558|NCT01575938|Behavioral|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
79549559|NCT01575951|Radiation|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
79549560|NCT01576029|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
79393873|NCT02377050|Other|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
79393874|NCT00298233|Drug|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
79393875|NCT02378376|Dietary Supplement|Arabinoxylan oligosaccharides|
79393876|NCT02378376|Dietary Supplement|Dietary fiber enriched bran|
79713165|NCT05592951|Dietary Supplement|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
79713166|NCT05592951|Dietary Supplement|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
79713167|NCT05592951|Dietary Supplement|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
79713168|NCT05592951|Dietary Supplement|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
79713169|NCT05589051|Dietary Supplement|Drink|Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
79393877|NCT01499303|Drug|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
79850952|NCT02574533|Drug|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
79850953|NCT00709553|Drug|midazolam|
79850954|NCT00709553|Drug|ZD4054|ZD4054 10 mg od
79850955|NCT02575391|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
79850956|NCT03958656|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
79393878|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
79850957|NCT03958656|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
79393879|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
79393880|NCT02376972|Drug|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
79254008|NCT04067882|Other|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
79393881|NCT02376972|Drug|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
79393882|NCT02378454|Device|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
79713170|NCT05583747|Device|iTBS|rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
79713171|NCT05579119|Drug|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
79713172|NCT05579119|Drug|Glargine|Glargine once daily.
79850958|NCT03958656|Drug|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
79850959|NCT03958656|Biological|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10^6- 12.0x10^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
79850960|NCT00950274|Drug|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
79850961|NCT00950274|Drug|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
79850962|NCT00561912|Drug|Decitabine|15 mg/m^2 IV Daily over one hour for 5 days
79850963|NCT00561912|Drug|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
79850964|NCT00561678|Drug|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
79850965|NCT00561678|Drug|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
79254009|NCT04066491|Drug|M7824|Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m^2) and 25 mg/m^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
79393883|NCT02378532|Drug|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
79393884|NCT02378532|Radiation|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
79393885|NCT02378532|Drug|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
79393886|NCT01498679|Drug|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
79393887|NCT01498679|Drug|Placebo|Placebo administered once daily in the evening via a NDPI
79393888|NCT02371122|Device|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
79393889|NCT02371122|Device|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
79393890|NCT02371122|Device|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
79393891|NCT02371122|Device|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
79713173|NCT05579119|Drug|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
79713174|NCT05575180|Drug|Acetazolamide 250Mg Tab|Oral acetazolamide
79713175|NCT05575180|Drug|Methazolamide Pill|Oral Methazolamide
79713176|NCT05575180|Drug|Placebo|Oral placebo
79850966|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
79850967|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
79850968|NCT00946608|Drug|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
79850969|NCT00463684|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
79850970|NCT00463684|Biological|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
79850971|NCT00463606|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
79850972|NCT00463606|Drug|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
79850973|NCT00463606|Drug|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
79393892|NCT02101437|Procedure|miRNA within 24hr|miRNA within 24hr
79549561|NCT01576029|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
79549562|NCT01576068|Other|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
79549563|NCT01576081|Device|HEPHAISTOS|HEPHAISTOS unloading orthotic
79549564|NCT01576094|Drug|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
79549565|NCT01576094|Drug|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
79549566|NCT01576107|Other|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
79713177|NCT05571033|Behavioral|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
79713178|NCT05549232|Device|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
79713179|NCT05537376|Behavioral|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
79713180|NCT05533918|Behavioral|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
79713181|NCT05533918|Behavioral|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
79713182|NCT05533359|Behavioral|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
79393893|NCT02101437|Procedure|miRNA after 1 week|miRNA after 1 week
79254010|NCT04066491|Drug|Placebo|Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
79254011|NCT04066491|Drug|Gemcitabine|Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
79254012|NCT04066491|Drug|Cisplatin|Cisplatin was received intravenously at a dose of 25 mg/m^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
79254013|NCT04066309|Device|Neodent GM Helix Implant|4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.
79254014|NCT04066309|Device|GM Customizable Healing Abutment|Customizable healing abutments will be placed at the time of implant placement.
79393894|NCT02101437|Procedure|miRNA after 1 month|miRNA after 1 month
79393895|NCT02371200|Device|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
79393896|NCT01000467|Drug|probucol|group 3: 250 mg 1 tablet in the morning and evening
79393897|NCT01000467|Drug|probucol|group 1: 250 mg
79254015|NCT04066309|Device|GM Pro PEEK Abutment|Placement of temporary single prostheses (early loading), over temporary abutments.
79254016|NCT04066309|Device|GM Exact Titanium Base|Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
79393898|NCT01000467|Drug|probucol|group 2: 250 mg 2 tablets at once in the morning
79393899|NCT02370966|Dietary Supplement|Berry powder|Berry and gingivitis trial
79393900|NCT00434499|Drug|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
79393901|NCT02371278|Dietary Supplement|Leucine|5 g leucine with sucrose and maltodextrin
79393902|NCT02371278|Dietary Supplement|Placebo|5 g glycine with sucrose and maltodextrin
79549567|NCT01576107|Other|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
79254017|NCT04066049|Behavioral|EMT en Español|EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser & Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
79549568|NCT01576133|Behavioral|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
79549569|NCT01576133|Behavioral|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
79549570|NCT01576185|Other|laboratory biomarker analysis|Correlative studies
79549571|NCT01576185|Drug|quizartinib|Via gavage
79549572|NCT01576185|Drug|sorafenib tosylate|Via gavage
79549573|NCT01576198|Genetic|DNA analysis|
79713183|NCT05533359|Behavioral|Conversational Agent (CA)|Patients in the CA condition will receive a link to an automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.
79713184|NCT05533359|Behavioral|Patient Navigation (PN)|"Participants in the PN condition will receive a call from a Community Health Worker to assist with the process of receiving a COVID test. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation. A person can be randomly assigned to either type, or no PN, or a combination of the two types."
79254018|NCT04064827|Drug|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
79254019|NCT04064008|Device|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
79713185|NCT05530954|Other|Mineral trioxide aggregate (MTA)|Materials for Vital Pulp Capping
79713186|NCT05530954|Other|Hard setting Calcium Hydroxide (Dycal)|Materials for Vital Pulp Capping
79713187|NCT05522205|Other|Regulated cannabis access in pharmacies|The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
79254020|NCT04062266|Drug|Azacitidine|Given SC or IV
79254021|NCT04062266|Drug|Venetoclax|Given PO
79254022|NCT04045665|Drug|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
79254023|NCT04045665|Drug|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
79254024|NCT04044443|Device|IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill|Peripheral vascular embolization
79393903|NCT01526785|Drug|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
79393904|NCT00198315|Combination Product|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
79393905|NCT00198315|Procedure|Tumor surgical excision|Patients have their tumor surgically removed.
79393906|NCT02370732|Other|Alcohol|A weight based dose of alcohol will be administered during each study day.
79393907|NCT02370654|Behavioral|Tai chi|
79393908|NCT02370654|Behavioral|Conventional exercise|
79393909|NCT01559389|Drug|Solifenacin|Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
79393910|NCT02378142|Drug|Pazopanib|
79549574|NCT01576198|Genetic|nucleic acid amplification|
79254025|NCT04034459|Drug|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1
79254026|NCT04034459|Drug|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
79254027|NCT04034459|Drug|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
79254028|NCT04034459|Drug|Oxaliplatin|Oxaliplatin 85mg/m² day 1
79254029|NCT04034459|Drug|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
79254030|NCT04034459|Drug|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
79254031|NCT04028401|Drug|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
79254032|NCT04023552|Drug|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
79254033|NCT04023552|Drug|Placebo|Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
79254034|NCT04023227|Drug|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
79393911|NCT02376582|Biological|DNA|DNA co-administered with protein at month 0, 1 and 6
79393912|NCT02376582|Biological|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
79393913|NCT02378064|Drug|6-month treatment|
79393914|NCT01526551|Other|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
79549575|NCT01576198|Other|diagnostic laboratory biomarker analysis|
79549576|NCT01576198|Other|medical chart review|
79549577|NCT01576211|Genetic|DNA methylation analysis|
79549578|NCT01576211|Genetic|RNA analysis|
79549579|NCT01576211|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
79549580|NCT01576211|Genetic|gene expression analysis|
79549581|NCT01576211|Genetic|nucleic acid sequencing|
79549582|NCT01576211|Genetic|polymorphism analysis|
79549583|NCT01576211|Other|laboratory biomarker analysis|
79549584|NCT01576224|Device|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
79549585|NCT01576237|Other|blood donation|blood donation with preparative hemapheresis
79549586|NCT01576250|Other|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
79549587|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
79549588|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
79549589|NCT01576289|Other|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
79713188|NCT05518929|Drug|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
79713189|NCT05518929|Drug|Propofol|The sedation of gastrointestinal endoscopy with Propofol
79393915|NCT01526551|Other|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
79393916|NCT00305565|Device|VNS Therapy|Received output current of 0.25 milliamps (mA)
79713190|NCT05518708|Drug|BI 3032950|BI 3032950
79713191|NCT05518708|Drug|Placebo|Placebo
79713192|NCT05511649|Device|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
79713193|NCT05510050|Dietary Supplement|Aloe Vera Extract 1|2 capsules taken daily for 30 days
79254035|NCT04023227|Drug|Enalapril|5 mg and 10 mg will be available for dose adjustments.
79254036|NCT04011800|Procedure|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
79393917|NCT00305565|Device|VNS Therapy|Received output current of 0.5-1.0 mA
79254037|NCT04011800|Combination Product|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
79254038|NCT04010825|Other|Hypnosis intervention focused on the emotional dimension of the dyspnea|Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
79393918|NCT00305565|Device|VNS Therapy|Received output current of 1.0-1.5 mA
79393919|NCT03113370|Dietary Supplement|Fish Oil|Fish Oil capsules
79393920|NCT03113370|Dietary Supplement|Placebo|Olive Oil
79393921|NCT02377908|Other|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
79393922|NCT02370576|Other|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
79393923|NCT00343083|Drug|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
79393924|NCT00343083|Radiation|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
79393925|NCT02370342|Procedure|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
79393926|NCT02370342|Procedure|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
79393927|NCT02370342|Procedure|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
79393928|NCT02370342|Device|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
79393929|NCT02376426|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.
79393930|NCT02376426|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.
79393931|NCT02376426|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
79393932|NCT00343785|Drug|cyclophosphamide|Given IV
79393933|NCT00343785|Biological|anti-thymocyte globulin|Given IV
79713194|NCT05510050|Dietary Supplement|Control|2 capsules taken daily for 30 days
79713195|NCT05510050|Dietary Supplement|Aloe Vera Extract 2|2 capsules taken daily for 30 days
79254039|NCT03999749|Drug|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
79254040|NCT03999749|Drug|Nivolumab|administered first at a dose of 3 mg/kg;
79254041|NCT03999749|Drug|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle.
79393934|NCT00343785|Drug|cyclosporine|Given IV or PO
79393935|NCT00343785|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
79393936|NCT00343785|Drug|methotrexate|Given IV
79393937|NCT00343785|Genetic|DNA analysis|Correlative studies
79393938|NCT00343785|Other|flow cytometry|Correlative studies
79393939|NCT00343785|Genetic|polymorphism analysis|Correlative studies
79393940|NCT00343785|Other|laboratory biomarker analysis|Correlative studies
79393941|NCT02370264|Procedure|Quality-of-Life Assessment|Ancillary studies
79713196|NCT05498961|Other|Gallstone characteristics|stone size, number, the thickness
79850974|NCT03996070|Procedure|Laser therapy|Erbium YAG laser
79850975|NCT03961308|Drug|Vedolizumab SC|Vedolizumab SC liquid.
79850976|NCT00956436|Drug|BIIB022|IV Q3W
79393942|NCT02370264|Other|Questionnaire Administration|Ancillary studies
79393943|NCT02370264|Other|Medical Chart Review|Ancillary studies
79713197|NCT05492136|Procedure|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
79393944|NCT02370108|Device|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
79393945|NCT00343863|Drug|palonosetron hydrochloride|Given IV
79713198|NCT05488340|Drug|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
79549590|NCT01576302|Behavioral|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
79393946|NCT00343863|Drug|cyclophosphamide|Given orally
79393947|NCT00343863|Drug|dexamethasone|Given orally or IV
79549591|NCT01576302|Behavioral|Muscle relaxation|Progressive passive muscle relaxation
79549592|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
79549593|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
79549594|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
79549595|NCT01576354|Drug|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
79549596|NCT01576354|Drug|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
79549597|NCT01576380|Drug|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
79549598|NCT01576393|Behavioral|Home-based Family Therapy|12 home-based family therapy sessions
79549599|NCT01576393|Behavioral|office-based family therapy|12 office-based family therapy sessions
79549600|NCT01576393|Behavioral|WHE|12 Women's Health Education Sessions
79549601|NCT01576419|Drug|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
79713199|NCT05488340|Drug|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
79713200|NCT05488340|Drug|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
79549602|NCT01576419|Drug|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
79549603|NCT01576432|Behavioral|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
79549604|NCT01576445|Procedure|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
79549605|NCT01576445|Procedure|medial parapatellar approach|medial parapatellar approach
79713201|NCT05488340|Drug|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
79713202|NCT05488340|Drug|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10^10 - 1x10^13 PFU) per dose.
79713203|NCT05488340|Drug|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
79850977|NCT00956436|Drug|Sorafenib|Standard dosing of Sorafenib
79850978|NCT00956514|Device|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
79393948|NCT00343863|Drug|doxorubicin hydrochloride|Given IV
79393949|NCT00343863|Procedure|quality-of-life assessment|Ancillary studies
79713204|NCT05484596|Procedure|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
79850979|NCT00950508|Procedure|High volume plasma exchange|3 high volume plasma exchanges over 3 days
79393950|NCT00343863|Procedure|nausea and vomiting therapy|Given IV
79393951|NCT00343863|Procedure|management of therapy complications|Given IV
79393952|NCT00343863|Drug|ondansetron hydrochloride|Given IV
79393953|NCT00343863|Other|survey administration|Ancillary studies
79713205|NCT05481216|Other|COVID-19|Diagnosed with COVID-19 infection
79713206|NCT05481216|Other|HIV-1 infection|Diagnosed with HIV-1 infection
79850980|NCT00950508|Procedure|Standard medical treatment|Standard medical treatment
79850981|NCT00950586|Drug|GSK1043702|Oral dose in liquid or tablet formulation
79850982|NCT00950586|Drug|Dextromethorphan|30mg Oral dose
79850983|NCT00950586|Drug|Placebo|To match GSK1034702
79850984|NCT00174187|Drug|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
79850985|NCT01011335|Biological|Monovalent rAT|10, 25, 50 or 100 μg
79850986|NCT01011335|Biological|Monovalent rLukS-PV|10, 25, 50 or 100 μg
79850987|NCT01011335|Biological|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
79549606|NCT01576458|Drug|ursodeoxycholic acid|450 mg/day for 14 days
79549607|NCT01576458|Drug|Placebo|placebo
79713207|NCT05479617|Other|Deep learning model|Use of deep learning model to predict individual patients disease course
79713208|NCT05477069|Device|Innovative medical device for sampling small intestine content|Ingestion of the medical device by the volunteer
79713209|NCT05477004|Drug|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
79713210|NCT05453058|Diagnostic Test|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
79713211|NCT05450029|Drug|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
79713214|NCT05439434|Other|Fear of Pain Questionnaire for Children Short Form|administering the questionnaire twice, one week apart.
79713215|NCT05428267|Other|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
79713216|NCT05428267|Other|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
79713217|NCT05422001|Drug|low dose ketamine|"Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml"
79713218|NCT05422001|Drug|Placebo (saline)|Isotonic Saline
79850988|NCT01011335|Biological|Placebo with adjuvant|Placebo with adjuvant
79850989|NCT01011335|Biological|Placebo|Placebo saline
79850990|NCT00467896|Drug|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
79850991|NCT00467896|Drug|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
79850992|NCT00946686|Drug|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
79850993|NCT00946686|Drug|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
79850994|NCT00579059|Device|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
79850995|NCT00579059|Device|Regular Maxim® Knee System|Used for total knee replacements
79713219|NCT05408676|Device|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
79713220|NCT05399082|Device|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
79713221|NCT05399082|Procedure|Forceps biopsy|Biopsy forceps used to collect tissue
79850996|NCT02531737|Drug|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
79850997|NCT02531737|Drug|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
79850998|NCT00467818|Drug|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
79850999|NCT00467818|Other|Placebo|Same dosage as that of omega 3 fatty acids
79851000|NCT01326559|Drug|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
79851001|NCT02575313|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
79851002|NCT00709709|Procedure|multislice coronary scan|multislice coronary scan
79549608|NCT01576497|Procedure|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
79739789|NCT04314440|Behavioral|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for ~5 minutes, followed by the same songs played on acoustic guitar for ~5 minutes and another ~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
79851003|NCT00709787|Other|Usual Care|Normal care for hypertensive patients with risk factors for CHD
79549609|NCT01576497|Device|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
79713222|NCT05398068|Other|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
79851004|NCT04069949|Drug|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
79851005|NCT00714467|Behavioral|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
79851006|NCT00714467|Behavioral|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
79851007|NCT02574767|Behavioral|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
79851008|NCT02574767|Dietary Supplement|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
79851009|NCT02574767|Behavioral|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
79851010|NCT02574767|Dietary Supplement|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
79851011|NCT02575235|Drug|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
79851012|NCT02575235|Drug|placebo|Control group takes the placebo for the same period.
79254042|NCT03988543|Behavioral|Patient Self-management|Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.
79393954|NCT02376504|Behavioral|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
79393955|NCT02370030|Dietary Supplement|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
79393956|NCT00344175|Drug|pitavastatin|
79549610|NCT01576497|Device|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
79739790|NCT02686996|Dietary Supplement|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
79739791|NCT02686996|Other|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
79739792|NCT02687074|Device|HFNC|patients treated with high flow nasal cannula
79851013|NCT00467740|Drug|BI 1744 CL|
79851014|NCT02575157|Other|No intervention|No intervention
79393957|NCT00344175|Drug|simvastatin|
79393958|NCT04406766|Device|Connected nutrition pump system|"For the patient, it consists of the installation of the connected pump at his home for a duration of one month.~Infusion data and events will be continuously collected and transmitted by the 4 different modes (LoRaAN, BLE , GSM and multimodality).Transmitted data won't be used to change the follow up of the patient.~At the end of the month, patients will be solicited by an ergonomic engineer to complete a specific questionnaire in order to evaluate the future acceptability of the proposed solution."
79393959|NCT02376660|Other|Oats|
79739793|NCT02687074|Device|NIV|patients treated with noninvasive ventilation
79851015|NCT04070963|Other|HbA1C|To take additional blood test of HbA1C once patient consented to the study
79851016|NCT00710099|Drug|sildenafil|systemic absorption of sildenafil
79851017|NCT00710099|Drug|nitroprussiate iontophoresis|nitroprussiate iontophoresis
79254043|NCT03987399|Other|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
79393960|NCT02101515|Other|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
79393961|NCT02376270|Dietary Supplement|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
79713223|NCT05398068|Other|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
79713224|NCT05388461|Other|electroconvulsive therapy|electroconvulsive therapy
79713225|NCT05386342|Device|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
79713226|NCT05386277|Device|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
79549611|NCT01576510|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
79549612|NCT01576614|Behavioral|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
79713227|NCT05377489|Drug|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
79713228|NCT05373992|Behavioral|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
79713229|NCT05373992|Behavioral|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
79393962|NCT02376270|Dietary Supplement|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
79713230|NCT05373992|Behavioral|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
79713231|NCT05373992|Behavioral|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
79713232|NCT05363631|Drug|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
79713233|NCT05363631|Drug|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
79713234|NCT05363631|Drug|Pembrolizumab|Pembrolizumab is a type of immunotherapy
79713235|NCT05362110|Drug|HCP1803-3|Take it once daily for 8 weeks orally.
79713236|NCT05362110|Drug|RLD2002|Take it once daily for 8 weeks orally.
79393963|NCT02376348|Behavioral|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
79713237|NCT05362110|Drug|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
79713238|NCT05362110|Drug|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
79549613|NCT01576627|Dietary Supplement|zinc citrate|10 mg of zinc as either zinc citrate
79549614|NCT01576627|Dietary Supplement|Zinc Gluconate|10 mg of zinc as either zinc gluconate
79549615|NCT01576627|Dietary Supplement|Zinc oxide|10 mg of zinc as either zinc oxide
79549616|NCT01576640|Drug|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
79549617|NCT01576640|Drug|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
79549618|NCT01576640|Other|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
79713239|NCT05361551|Procedure|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
79549619|NCT01576653|Other|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
79549620|NCT01576666|Drug|LDE225|
79549621|NCT01576666|Drug|BKM120|
79549622|NCT01576679|Drug|Cathflo (Alteplase)|
79549623|NCT01576679|Drug|Saline|
79713240|NCT05357833|Drug|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
79393964|NCT02376114|Drug|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
79713241|NCT05357833|Drug|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
79713242|NCT05357833|Diagnostic Test|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
79713243|NCT05351203|Procedure|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
79713244|NCT05351203|Procedure|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
79713245|NCT05316701|Biological|Orca-T|engineered donor allograft
79713246|NCT05316701|Biological|Standard-of-Care|unmanipulated donor allograft
79713247|NCT05316506|Other|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
79713248|NCT05316506|Other|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
79713249|NCT05295589|Procedure|Computed Tomography|Undergo CT scan
79713250|NCT05295589|Drug|Copanlisib Hydrochloride|Given IV
79713251|NCT05295589|Procedure|Magnetic Resonance Imaging|Undergo MRI
79851018|NCT02574689|Behavioral|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
79549624|NCT01576692|Biological|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m^2)/dose, over 4 hours daily~NK Cell dosage: minimum of 0.1 * 10^6 cells/kg; maximum of 400 * 10^6 CD45+ cells/kg, given once"
79549625|NCT01576692|Drug|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~cyclophosphamide: 400 mg/m^2 IV days 1-5~topotecan: 1.2 mg/m^2 IV days 1-5~temozolomide: 150 mg/m^2 PO at least 1 hour before irinotecan~irinotecan: 50 mg/m^2 IV over 1 hour daily for 5 days~carboplatin (AUC 8-dosing based on GFR), IV day 1 only~ifosfamide: 2 g/m2 IV days 1-3~etoposide: 100 mg/m2 days 1-3"
79713252|NCT05295589|Drug|Olaparib|Given PO
79713253|NCT05295589|Drug|Paclitaxel|Given IV
79713254|NCT05295589|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79713255|NCT05295589|Drug|Topotecan Hydrochloride|Given IV
79713256|NCT05294965|Drug|Fenoterol|Intravenous infusion
79713257|NCT05294965|Other|Mild cold exposure|Body surface cooling
79713258|NCT05289713|Procedure|appendectomy|Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
79739794|NCT01174550|Procedure|Coronary Angiography|Use of standard equipment for usual-care testing
79739795|NCT01174550|Procedure|Stress Echocardiogram|Use of standard equipment for usual-care testing
79851019|NCT02574689|Behavioral|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
79851020|NCT00714545|Radiation|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
79851021|NCT03944044|Other|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
79393965|NCT02376114|Drug|Placebo to Ginkgo biloba|
79739796|NCT01174550|Procedure|Nuclear Stress Test|Use of standard equipment for usual-care testing
79739797|NCT01174550|Procedure|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
79393966|NCT00345033|Drug|Aripiprazole|15-mg dose once a day for 8 weeks
79393967|NCT00345033|Drug|Placebo|1 tablet placebo dose once a day for 8 weeks
79393968|NCT02377518|Radiation|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
79713259|NCT05287867|Biological|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
79254044|NCT03985852|Other|Patient Directed Standard of Care|The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
79254045|NCT03981185|Device|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
79549626|NCT01576692|Other|Cytokines|"Cytokines may be given at the following dosages:~interleukin-2: 1 million units/m^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~GM-CSF: 250 mcg/m^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC >2,000/mm^3"
79393969|NCT00302055|Behavioral|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
79254046|NCT03978637|Drug|Itacitinib|Itacitinib administered orally at the specified dose.
79549627|NCT01576692|Biological|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy & Procedure Manual.
79549628|NCT01576692|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79254047|NCT03945513|Drug|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
79254048|NCT03941262|Biological|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
79254049|NCT03941262|Drug|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
79549629|NCT01576731|Drug|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
79549630|NCT01576731|Drug|Tenofovir, Emtricitabine, Raltegravir|Combination drug
79549631|NCT01576770|Device|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
79549632|NCT01576770|Drug|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
79713260|NCT05287867|Other|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
79713261|NCT05278520|Procedure|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
79713262|NCT05267899|Drug|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
79254050|NCT03941262|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
79254051|NCT03941080|Diagnostic Test|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
79254052|NCT03941080|Behavioral|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
79393970|NCT00302055|Behavioral|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
79393971|NCT01559311|Device|CRT-P OFF|CRT Pacemaker
79393972|NCT01559311|Device|CRT-P ON|CRT Pacemaker
79393973|NCT01559311|Device|DDDR|Dual-chamber, rate-modulated pacemaker
79393974|NCT00345969|Drug|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
79393975|NCT00345969|Behavioral|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
79549633|NCT01576796|Radiation|Radiotherapy|"No additional dose (patients negative F-miso)~Radiation therapy is conducted under standard conditions of conformal radiotherapy:~The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
79549634|NCT01576822|Other|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
79549635|NCT01576848|Dietary Supplement|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
79549636|NCT01576848|Dietary Supplement|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
79549637|NCT01576861|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
79393976|NCT01498445|Drug|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
79549638|NCT01576900|Behavioral|SyBeMeP (Systemized Behavioural Modification education Program)|"Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
79549639|NCT01576913|Other|Music listening|Listening to tempo music while cycling in an exercise test
79549640|NCT01576965|Drug|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
79549641|NCT01576978|Behavioral|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
79549642|NCT01577004|Dietary Supplement|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
79549643|NCT01577017|Drug|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
79549644|NCT01577030|Dietary Supplement|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
79549645|NCT01577030|Dietary Supplement|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
79549646|NCT01577043|Drug|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
79549647|NCT01577043|Other|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
79549648|NCT01577056|Dietary Supplement|Fish oil capsule|4g Omega capsule for 12 weeks
79549649|NCT01577056|Drug|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
79549650|NCT01577082|Drug|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
79549651|NCT01577082|Drug|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
79713263|NCT05255913|Drug|Nanosilver|preventive material for arresting caries
79254053|NCT03941080|Diagnostic Test|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
79254054|NCT03932643|Drug|ONC201|"ONC201 Capsules, 125 mg~Oral ONC 201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
79254055|NCT03926091|Drug|Docetaxel|Docetaxel chemotherapy (injection)
79254056|NCT03926091|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
79393977|NCT01498445|Drug|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
79393978|NCT01498445|Drug|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
79393979|NCT01558297|Behavioral|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
79393980|NCT01558297|Behavioral|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
79393981|NCT01558297|Behavioral|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
79393982|NCT01525849|Device|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
79549652|NCT01577121|Drug|indomethacin|50 mg / 6 hours during 5 days
79713264|NCT05255913|Drug|Silver diamine fluoride|preventive material for arresting caries
79393983|NCT01525849|Procedure|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
79393984|NCT00308061|Biological|FMP1/AS02A|FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
79254057|NCT03918421|Other|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
79713267|NCT05247320|Drug|Sotalol Injection|Standard of care IV sotalol infusion for atrial arrhythmias
79713268|NCT05238714|Drug|venglustat|Powder for Oral solution
79713269|NCT05228496|Drug|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
79713270|NCT05228496|Drug|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
79713271|NCT05223855|Other|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
79393985|NCT00308061|Biological|Imovax Rabies Vaccine|Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, <150g of neomycin sulfate, and >2.5 IU of rabies antigen.
79549653|NCT01577121|Drug|placebo|50 mg / 6 hours during 5 days
79713272|NCT05214599|Drug|Budesonide Gel|Twice daily regimen
79713273|NCT05192343|Device|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
79713274|NCT05192343|Other|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
79713275|NCT05189275|Dietary Supplement|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
79713276|NCT05187910|Behavioral|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
79713277|NCT05187910|Behavioral|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
79549654|NCT01577134|Behavioral|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
79254058|NCT03913559|Drug|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
79393986|NCT01525615|Device|Respimat inhaler|Respimat inhaler
79393987|NCT01525615|Drug|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
79549655|NCT01577134|Behavioral|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
79549656|NCT01577134|Behavioral|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
79549657|NCT01577095|Other|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
79549658|NCT01577095|Drug|TZD|Rosiglitazone 8 mg single dose
79549659|NCT01577147|Other|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
79549660|NCT01577199|Drug|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
79393988|NCT01525615|Drug|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
79713278|NCT05187910|Behavioral|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
79713279|NCT05183204|Drug|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
79713280|NCT05183204|Drug|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
79713281|NCT05183204|Other|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
79713282|NCT05181748|Biological|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
79713283|NCT05181644|Device|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
79713284|NCT05181644|Procedure|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
80017274|NCT04383808|Diagnostic Test|Injected radiotracer with PET Insert|"Informed consent will be obtained before beginning any study procedures.~Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
79393989|NCT01525615|Device|Respimat inhaler|Respimat inhaler
79393990|NCT01525615|Device|Respimat inhaler|Respimat inhaler
79549661|NCT01577199|Drug|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
79549662|NCT01577212|Radiation|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
79549663|NCT01577225|Device|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
79549664|NCT01577225|Device|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
80017275|NCT04383808|Diagnostic Test|Pre-injected group with PET insert|"Informed consent will be obtained before beginning any study procedures.~Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
79393991|NCT01525615|Drug|placebo to tiotropium+olodaterol|comparator
79393992|NCT00309465|Drug|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
79393993|NCT00309465|Other|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
79393994|NCT00309465|Drug|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
79393995|NCT01791699|Drug|Moxonidine|
79393996|NCT01791699|Drug|Placebo|
79549665|NCT01577290|Behavioral|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
79393997|NCT00302133|Drug|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
79393998|NCT00302133|Other|Placebo|Placebo arm
79393999|NCT01525225|Drug|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
79549666|NCT01577290|Behavioral|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
79713285|NCT05179603|Drug|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
79713286|NCT05179603|Drug|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
79713287|NCT05178173|Other|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
79713288|NCT05178173|Other|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
79713289|NCT05178173|Other|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
80017276|NCT02910063|Drug|Blinatumomab|Blinatumomab monotherapy
80017277|NCT03554694|Dietary Supplement|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
80017278|NCT03554694|Dietary Supplement|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
80017279|NCT04441762|Drug|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
79394000|NCT01525225|Drug|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
79394001|NCT01525225|Drug|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
79549667|NCT01577303|Behavioral|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
79254059|NCT03913559|Drug|Methotrexate|Intrathecal (IT) therapy
79254060|NCT03913559|Drug|Hydrocortisone|Intrathecal (IT) therapy
79394002|NCT01525225|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
79549668|NCT01577303|Behavioral|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
79549669|NCT01577303|Behavioral|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
79549670|NCT01577303|Behavioral|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
79254061|NCT03913559|Drug|Cytarabine|Intrathecal (IT) therapy
79549671|NCT01577303|Behavioral|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
79549672|NCT01577303|Behavioral|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
79713290|NCT05164341|Drug|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
79713291|NCT05164341|Drug|Placebo|Placebo
79713292|NCT05162820|Dietary Supplement|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
79713293|NCT05162820|Dietary Supplement|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
79713294|NCT05153343|Drug|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79713295|NCT05153343|Drug|flonoltinib 50mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79713296|NCT05153343|Drug|flonoltinib 100mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79713297|NCT05153343|Drug|flonoltinib 150mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79713298|NCT05153343|Drug|flonoltinib 225mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79254062|NCT03913559|Drug|Diphenhydramine|1 mg/kg (max 50 mg) IV
79254063|NCT03913559|Drug|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
79254064|NCT03913559|Drug|Methylprednisolone|1 mg/kg IV x 1
79254065|NCT03910218|Behavioral|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
79394003|NCT01525225|Drug|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
79394004|NCT00346905|Drug|Enteryx|
79394005|NCT00304161|Drug|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
79394006|NCT00304161|Drug|Placebo|40 to 80 mg orally once daily for 8 weeks
79394007|NCT04398420|Device|TVERP|Transurethral Vapor Enucleation Resection of the prostate
79394008|NCT04398420|Device|TURis|Transurethral Vapor Enucleation Resection of the prostate
79394009|NCT04398420|Device|HoLEP|Transurethral Vapor Enucleation Resection of the prostate
79394010|NCT01524991|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 & 8 (all cycles)
79394011|NCT01524991|Drug|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
79394012|NCT01524991|Drug|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
79713299|NCT05153343|Drug|flonoltinib 325mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
79254066|NCT03910218|Behavioral|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
79254067|NCT03909035|Other|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~Detailed feedback to the general practitioner.~An appointment with the patient to explain the modifications made by the general practitioner (GP)"
79254068|NCT03900897|Device|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
79549673|NCT01577316|Biological|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus."
79549674|NCT01577342|Drug|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
79549675|NCT01577355|Radiation|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
79549676|NCT01577368|Drug|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
79549677|NCT01577368|Drug|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
79549678|NCT01577394|Other|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
79549679|NCT01577407|Drug|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
79549680|NCT01577420|Other|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
79549681|NCT01577420|Other|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
79549682|NCT01577446|Procedure|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
79713300|NCT05151263|Drug|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
79739798|NCT00638326|Drug|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
79739799|NCT00638326|Drug|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
79739800|NCT04184830|Device|non-invasive brain stimulation|
79394013|NCT04039230|Drug|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
79394014|NCT04039230|Drug|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
79394015|NCT01524913|Drug|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
79394016|NCT01524913|Drug|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
79254069|NCT03900897|Other|Cochlear Implant|Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
80017280|NCT04441762|Drug|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
79254070|NCT03899376|Radiation|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
79254071|NCT03899376|Radiation|conventional radiotherapy|Radiotherapy focus on pelvis area
79394017|NCT01524913|Drug|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
79394018|NCT02376192|Device|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
79549683|NCT01577459|Drug|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
79549684|NCT01577459|Other|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
79549685|NCT01577472|Drug|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
79549686|NCT01577472|Drug|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
79549687|NCT01577472|Drug|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
79549688|NCT01577472|Drug|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
79549689|NCT01577485|Dietary Supplement|Probiotics in an pastille|Test group
79549690|NCT01577485|Dietary Supplement|Control pastille|Control group
79254072|NCT03892187|Behavioral|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
79254073|NCT03883828|Drug|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
79254074|NCT03883828|Drug|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
79394019|NCT02376192|Drug|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
79549691|NCT01577511|Biological|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
79549692|NCT01577524|Drug|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
79851022|NCT00714623|Device|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
79851023|NCT00553254|Drug|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
79549693|NCT01577524|Drug|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
79549694|NCT01577550|Drug|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
79549695|NCT01577550|Drug|Placebo, i.v.|Single i.v. administration of placebo
79549696|NCT01577550|Drug|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
79549697|NCT01577550|Drug|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
79549698|NCT01577550|Drug|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
79549699|NCT01577550|Drug|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
79549700|NCT01577550|Drug|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
79549701|NCT01577550|Drug|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
79851024|NCT01022476|Drug|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
79254075|NCT03860272|Drug|Botensilimab|An Fc-engineered anti-CTLA-4 monoclonal antibody
79254076|NCT03860272|Drug|Balstilimab|A fully human monoclonal anti-PD-1 antibody
79394020|NCT02376192|Device|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
79394021|NCT02376192|Drug|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
79394022|NCT02376192|Drug|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
79549702|NCT01577550|Drug|Placebo, s.c.|Single s.c. administration of placebo
79549703|NCT01577550|Drug|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
79549704|NCT01577589|Drug|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
79549705|NCT01577589|Drug|Placebo in 50 ml infusion volume|IV infusion
79394023|NCT03028285|Drug|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
79549706|NCT01577589|Drug|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
79549707|NCT01577589|Drug|Placebo in 250 ml infusion volume|IV infusion
79549708|NCT01577589|Drug|600 mg ceftaroline in 100 ml infusion volume|IV infusion
79549709|NCT01577589|Drug|Placebo in 100 ml infusion volume|IV infusion
79549710|NCT01577602|Other|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
79549711|NCT01577602|Other|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
79549712|NCT01577602|Other|Combined intervention|Combines the printed medication list with the open ended question
79549713|NCT01577615|Behavioral|Patterned Experience|"The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~Nonnutritive sucking will be offered to infants.~Blood work will be collected for inflammatory cytokines.~Saliva will be collected for genetic analysis~Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~Follow up visits will occur at 2,6and 24 months corrected age."
79851025|NCT05673239|Drug|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
79851026|NCT01025518|Other|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
79851027|NCT01025518|Dietary Supplement|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
79851028|NCT01025518|Dietary Supplement|Placebo|Maltodextrine
79254077|NCT03844269|Device|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
79254078|NCT03835819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
80017281|NCT02104284|Procedure|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
79254079|NCT03835819|Drug|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
79254080|NCT03833700|Drug|E7386|E7386, tablets, orally.
79254081|NCT03832361|Drug|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
79254082|NCT03828292|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
79394024|NCT03881137|Other|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
79394025|NCT02369640|Procedure|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
79394026|NCT02369718|Other|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
79394027|NCT02369718|Other|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR*2 coding strategies*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
79394028|NCT02375958|Drug|PCA062|
79394029|NCT02376036|Drug|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
79394030|NCT02376036|Drug|Placebo|Placebo comparator.
79394031|NCT02376036|Biological|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
79713301|NCT05151263|Diagnostic Test|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
79254083|NCT03828292|Drug|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
79254084|NCT03828292|Drug|Dexamethasone|Dexamethasone tablets will be administered orally.
79254085|NCT03828292|Drug|Pomalidomide|Pomalidomide capsules will be administered orally.
79254086|NCT03825250|Drug|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
79254087|NCT03805100|Biological|Ranibizumab|Intravitreal injection
79394032|NCT02375880|Drug|DKN-01|Administration by intravenous (IV) infusion.
79713302|NCT05130814|Device|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
79713303|NCT05130814|Procedure|cleansing|cleaning of the wound area with saline or ringer's lactate
79713304|NCT05130814|Combination Product|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
79739801|NCT04187560|Drug|LB-102|(N-Methyl amisulpride)
79549714|NCT01577667|Device|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
79549715|NCT01577680|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
79713305|NCT05130814|Drug|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
79713306|NCT05130814|Procedure|topical treatment|topical treatment indicated for that stage of the lesion
79713307|NCT05130814|Procedure|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
79713308|NCT05130294|Dietary Supplement|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
79713309|NCT05130294|Dietary Supplement|Placebo|MCT oil
79713310|NCT05124457|Drug|Insulin Detemir|Patients are to receive insulin detemir
79713311|NCT05124457|Drug|Insulin NPH|Patients are to receive insulin NPH
79713312|NCT05116865|Biological|HH-120 Dose 1|Dose level 1 of HH-120
79713313|NCT05116865|Biological|HH-120 Dose 2|Dose level 2 of HH-120
79713314|NCT05116865|Biological|HH-120 Dose 3|Dose level 3 of HH-120
79713315|NCT05116865|Drug|Placebo|Placebo to match
79713317|NCT05101239|Device|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
79713318|NCT05096195|Drug|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
79713319|NCT05096195|Other|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
79713320|NCT05096195|Diagnostic Test|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
79394033|NCT02375880|Drug|gemcitabine|Administered by IV infusion.
79394034|NCT02375880|Drug|cisplatin|Administered by IV infusion
79713321|NCT05093959|Drug|Metformin|An extended release formulation will be used which improves compliance and reduces GI side effects.
79713322|NCT05093959|Drug|Placebo|Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
79254088|NCT03804619|Device|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
79254089|NCT03803683|Device|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
79394035|NCT01524679|Drug|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
79394036|NCT02365194|Behavioral|Prehabilitation|information included in arm description
79549716|NCT01577680|Drug|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
79254090|NCT03803683|Behavioral|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
79254091|NCT03803683|Device|HIV Home Tests|Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
79394037|NCT02365194|Behavioral|Standard counseling|information included in arm description
79394038|NCT02365272|Drug|Amikacin|Amikacin administered in a single dose for critical care patients
79394039|NCT02369328|Device|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
79394040|NCT02369250|Drug|Rosuvastatin|Rosuvastatin, is a statin group of drug.
79394041|NCT02369250|Biological|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
79549717|NCT01577693|Drug|dutasteride|novel dutasteride
79549718|NCT01577693|Drug|dutasteride|dutasteride soft gel capsule
79549719|NCT01577719|Behavioral|Multimedia Lifestyle Improvement|"Online Goal setting to improve diet, physical activity or smoking behaviours~regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
79549720|NCT01577719|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
79549721|NCT01577771|Biological|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
79549722|NCT01577784|Drug|Pazopanib|800 mg / day of pazopanib in monotherapy.
79549723|NCT01577797|Behavioral|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
79549724|NCT01577810|Device|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
79549725|NCT01577823|Device|Foley Catheter|
79549726|NCT01577849|Drug|Vitamin D3|administration of Vitamin D3 24,000 IU
79549727|NCT01577849|Drug|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
79549728|NCT01577862|Drug|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
79549729|NCT01577862|Drug|Rifampicin|600 mg every 12 hours intravenously
79549730|NCT01577875|Device|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
79549731|NCT01577888|Device|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
79549732|NCT01577901|Other|Clearblue Advanced|Pregnancy test
79394042|NCT02369094|Other|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
79549733|NCT01577914|Drug|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
79549734|NCT01577914|Drug|Carvedilol|12.5mg tablet once a day
79549735|NCT01577927|Other|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
79549736|NCT01577927|Behavioral|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
79851029|NCT02575001|Behavioral|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~Child Attachment Interview (CAI)~General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~Parenting Stress Index with the 19-item Life Stress Scale (PSI)~Achenbach System of Empirically Based Assessment (CBCL, YSR)~Holmes and Rahe Social readjustment rating scale~Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
79394043|NCT01880541|Other|hypnosedation|hypnosedation
79549737|NCT01577940|Procedure|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
79549738|NCT01577940|Procedure|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
79713323|NCT05087303|Other|Types of Telemedicine Delivery Models|Each arm delivers standard sickle cell care using a different model based on patient location.
79394044|NCT01880541|Other|general anesthésia|general anesthesia
79394045|NCT02365428|Behavioral|Physical activity text messages|
79394046|NCT02365116|Behavioral|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
79394047|NCT02365116|Behavioral|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
79394048|NCT02368860|Drug|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
79549739|NCT01577953|Drug|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
79549740|NCT01577953|Drug|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
79549741|NCT01577979|Behavioral|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
79549742|NCT01577979|Behavioral|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
79713324|NCT05087290|Other|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
79739802|NCT04314674|Drug|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
79739803|NCT04314674|Drug|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
79254092|NCT03799562|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
79713325|NCT05087290|Other|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
79713326|NCT05074667|Device|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
79713327|NCT05074667|Other|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
79713328|NCT05066477|Dietary Supplement|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
79713329|NCT05066477|Other|Placebo|Pure maltodextrin
79713330|NCT05064722|Device|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
79713331|NCT05056246|Drug|AMG 133|Solution for injection
79713332|NCT05054556|Diagnostic Test|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
79713333|NCT05049824|Device|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
79713334|NCT05044468|Drug|Lidocaine|Given via injection
79394049|NCT02375646|Drug|Warfarin|
79394050|NCT02375646|Drug|LMW Heparin|
79549743|NCT01577992|Drug|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
79549744|NCT01577992|Procedure|determination of objective and subjective pain threshold|Test without levodopa intake
79549745|NCT01578018|Other|Measure DCAM levels in blood|Measure DCAM levels in blood
79549746|NCT01578018|Other|DCAM levels in blood|DCAM levels in blood
79713335|NCT05044468|Drug|Liposomal Bupivacaine|Given via injection
79851030|NCT02575001|Genetic|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
79851031|NCT02575001|Procedure|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
79254093|NCT03799562|Drug|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
79254094|NCT03794999|Drug|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
79394051|NCT02368704|Other|No intervention|
79394052|NCT01524289|Drug|Anacetrapib|One oral tablet, orally once daily for 52 weeks
79394053|NCT01524289|Drug|Placebo|One oral tablet once daily for 52 weeks
79394054|NCT02375490|Behavioral|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
79394055|NCT01498289|Drug|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, & leucovorin calcium.
79394056|NCT01498289|Drug|docetaxel|30 mg/m^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
79549747|NCT01578057|Drug|tasimelteon|20mg, once
79549748|NCT01578057|Drug|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
79549749|NCT01578057|Other|Placebo tasimelteon|once
79549750|NCT01578057|Drug|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
79713336|NCT05044468|Other|Questionnaire Administration|Ancillary studies
79713337|NCT05015452|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
79713338|NCT05013450|Drug|Dupilumab|three q3w cycles
79713339|NCT05013450|Drug|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
79713340|NCT04989283|Biological|Atezolizumab|Given IV
79713341|NCT04989283|Procedure|Biopsy|Undergo tumor biopsy
79713342|NCT04989283|Procedure|Biospecimen Collection|Undergo blood sample collection
79713343|NCT04989283|Drug|Carboplatin|Given IV
79713344|NCT04989283|Drug|Cisplatin|Given IV
79713345|NCT04989283|Procedure|Computed Tomography|Undergo PET/CT scan
79713346|NCT04989283|Drug|Etoposide|Given IV
79713347|NCT04989283|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
79713348|NCT04989283|Procedure|Magnetic Resonance Imaging|Undergo MRI
79713349|NCT04989283|Drug|Paclitaxel|Given IV
79713350|NCT04989283|Drug|Pemetrexed|Given IV
79254095|NCT03794999|Drug|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
79549751|NCT01578070|Biological|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
79549752|NCT01578070|Biological|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
79549753|NCT01578070|Biological|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
79549754|NCT01578070|Biological|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
79549755|NCT01578070|Biological|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
79549756|NCT01578096|Behavioral|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
79549757|NCT01578109|Procedure|Bone Marrow Transplantation|Undergo BMT
79549758|NCT01578109|Drug|Sorafenib|Given PO
79549759|NCT01578109|Drug|Sorafenib Tosylate|Given PO
79549760|NCT01578122|Device|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
79549761|NCT01578122|Device|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
79713351|NCT04989283|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79254096|NCT03777917|Device|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
79254097|NCT03755336|Other|Administered Slip Perturbations|Slips will be administered in early, middle or late phases of stance during overground walking.
79254098|NCT03750539|Radiation|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
79254099|NCT03750539|Radiation|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
79254100|NCT03750539|Procedure|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
79394057|NCT01498289|Drug|fluorouracil|400 mg/m^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
79394058|NCT01498289|Drug|irinotecan hydrochloride|65 mg/m^2, IV over 90 minutes on Days 1 & 8 of every 21 day cycle.
79394059|NCT01498289|Drug|leucovorin calcium|400 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
79394060|NCT01498289|Drug|oxaliplatin|85 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
79394061|NCT02364882|Drug|Sildenafil|
79549762|NCT01578148|Procedure|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
79549763|NCT01578148|Procedure|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~TENS stimulation (45 minutes):~• Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~Other modalities of PT per the therapist's choice:~Infrared treatment on the pain areas (about 15 minutes)~Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~Exercise and training:~Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~Hot/cold pack to the pain area for about 15 minutes"
79549764|NCT01578161|Drug|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
79549765|NCT01578161|Drug|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
79549766|NCT01578174|Drug|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
79549767|NCT01578174|Drug|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
79549768|NCT01578200|Drug|Lanthanum Carbonate|
79549769|NCT01578200|Drug|Calcium Carbonate|
79549770|NCT01578213|Drug|Imatinib mesylate|"Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~Total dosage per day: 800 mg~Oral use"
79549771|NCT01578252|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
79549772|NCT01578252|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
79713352|NCT04989283|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79713353|NCT04988841|Drug|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
79713354|NCT04988841|Drug|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
79713355|NCT04988841|Drug|Nivolumab|AntiPD1 ( immunothérapy)
79739804|NCT04314674|Drug|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
79713356|NCT04988841|Drug|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
79549773|NCT01578265|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
79549774|NCT01578265|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
79549775|NCT01578291|Behavioral|Parental information|An informational brochure indicating the study details
79851032|NCT02575001|Procedure|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
79549776|NCT01578291|Behavioral|Play therapy|Play therapy with a child life specialist
79549777|NCT01578304|Drug|Imidafenacin|Tablet, 12 weeks twice daily
79549778|NCT01578304|Drug|Fesoterodine|Tablet, 12 weeks once daily
79713357|NCT04988841|Drug|Normacol|hypertonic enema solution
79713358|NCT04988841|Drug|Placebo of Maat013|expérimental drug placebo of MaaT013
79713359|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
79713360|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
79713361|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
79713362|NCT04977778|Drug|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
79713363|NCT04977778|Drug|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
79713364|NCT04973254|Other|CAB-RPV LA|Monthly administration of injectable HIV medication
79851033|NCT01021930|Device|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
80017282|NCT00337532|Drug|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
79254101|NCT03750487|Behavioral|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
79254102|NCT03750487|Behavioral|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
79254103|NCT03745118|Device|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
79254104|NCT03745118|Device|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
79394062|NCT02364804|Drug|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
79394063|NCT02365038|Other|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
79394064|NCT02365038|Other|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
79581017|NCT01931618|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
79851034|NCT00946764|Drug|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
79851035|NCT00946764|Drug|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
79851036|NCT01022008|Device|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
79851037|NCT00950820|Drug|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
79851038|NCT00950820|Drug|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
80017283|NCT00337532|Drug|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
79254105|NCT03745118|Device|Empatica E4|wearable seizure detection wristband
79254106|NCT03745118|Device|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
79254107|NCT03745118|Device|GeneActiv|wearable seizure detection watch
79713365|NCT04973254|Other|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
79713366|NCT04964505|Drug|Azacitidine|Given IV or SC
80017284|NCT02106234|Other|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
79254108|NCT03735199|Device|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
79394065|NCT01524133|Drug|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
79394066|NCT01524133|Behavioral|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
79394067|NCT02368548|Other|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
79394068|NCT02368548|Other|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
79394069|NCT02368470|Drug|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
79394070|NCT02368470|Drug|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
79394071|NCT05800652|Behavioral|Peer Mentoring Program|Mentoring program created in academic, social, emotional and safety dimensions.In the academic dimension, there is information about the instructors, course selection, preparing a course study program,efficient study methods,information about the education and training program. Social dimension includes interpersonal relations, participation in social life, free time activities, making friends.The emotional dimension includes developing self-confidence,coping with stress,belonging and motivation.In the security dimension, there are student rights,scholarship opportunities, accommodation opportunities, library and internet facilities, use of the health center and clinical practice. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The mentoring program continued for 12 weeks.
79581018|NCT01931657|Drug|Mifepristone prior to Mirena|
79394073|NCT05800613|Other|Survey|Questionnaire
79254109|NCT03735199|Device|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
79713367|NCT04964505|Drug|Uproleselan|Given IV
79713368|NCT04964505|Drug|Venetoclax|Given PO
79713369|NCT04950153|Behavioral|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
79713370|NCT04950153|Behavioral|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
79713371|NCT04950153|Behavioral|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
79713372|NCT04950153|Behavioral|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
79254110|NCT03731585|Behavioral|Behavioral Intervention|Participate in psychological sessions
79394074|NCT05800587|Drug|Carboplatin|Standard of care chemotherapy regimen
79394075|NCT05800587|Drug|Pemetrexed|Standard of care chemotherapy regimen
79581019|NCT01931657|Drug|Placebo prior to Mirena insertion|
79713373|NCT04945707|Drug|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject <50 kg, 20 mg/kg
79713374|NCT04945707|Drug|Placebo|Normal saline
79739805|NCT00639262|Drug|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
79739806|NCT00639262|Drug|Temozolomide|For Cohort 2 - Gliomas only.
79254111|NCT03731585|Other|Educational Intervention|Participate in educational sessions
79254112|NCT03731585|Other|Questionnaire Administration|Ancillary studies
79394076|NCT05800587|Drug|Paclitaxel|Standard of care chemotherapy regimen
79394077|NCT05800587|Drug|Nab paclitaxel|Standard of care chemotherapy regimen
79394078|NCT05800587|Drug|Docetaxel|Standard of care chemotherapy regimen
79394079|NCT05800587|Drug|Gemcitabine|Standard of care chemotherapy regimen
79581020|NCT01931683|Drug|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
79581021|NCT01931683|Device|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
79581022|NCT01931696|Device|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
79739807|NCT00639262|Radiation|Radiotherapy|Radiation Therapy (XRT)
79549779|NCT01578343|Drug|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~Consolidation treatment for responders Patients not eligible for transplantation~Vorinostat maintenance up to 6 cycles~200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~Delay of the start of the next cycle by up to 7 days will be acceptable.~If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~High-dose chemotherapy followed by autologous stem cell transplantation"
79851039|NCT02574923|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
79713375|NCT04942106|Other|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings in a single day when they are receiving at least 30% and no more than 50% of feedings orally. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
79851040|NCT00950898|Other|decaff|2 mugs of decaffeinated coffee
79851041|NCT00950898|Other|caffcoff|2 mugs of caffeinated coffee
79394080|NCT05800587|Drug|Etoposide|Standard of care chemotherapy regimen
79549780|NCT01578369|Other|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
79739808|NCT02886104|Procedure|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
79851042|NCT00950898|Other|caffeine|2 mugs of hot water containing caffeine
79851043|NCT00950898|Other|placebo|2 mugs of hot water
79851044|NCT00168805|Drug|enoxaparin|40 mg once daily
79851045|NCT00168805|Drug|dabigatran etexilate|150 mg once daily
79851046|NCT00168805|Drug|dabigatran etexilate|220 mg once daily
79851047|NCT00950976|Other|citrulline|TID for 5 days
79851048|NCT00950976|Other|Lemonade|TID for 5 days
79851049|NCT00467584|Drug|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
79851050|NCT00467584|Drug|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
79851051|NCT00467584|Drug|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
79851052|NCT04521725|Device|Respiratory Function Monitor (RFM)|Use of respiratory function monitor to detect tidal volume and expired CO2 to guide mask ventilation during neonatal resuscitation.
79851053|NCT04521725|Device|Cerebral Near-Infrared Spectroscopy (NIRS)|Use of cerebral NIRS to determine cerebral oxygenation to guide oxygen titration during neonatal resuscitation.
79851054|NCT00956670|Other|Quality-of-Life Assessment|Ancillary studies
79394081|NCT05800587|Drug|Irinotecan|Standard of care chemotherapy regimen
79394082|NCT05800587|Drug|Topotecan|Standard of care chemotherapy regimen
79394083|NCT05800587|Drug|Lurbinectedin|Standard of care chemotherapy regimen
79394084|NCT05800561|Diagnostic Test|Hepatic venous-portal gradient (HVPG) measurement|preoperative evaluation of Hepatic venous-portal gradient (HVPG) and ICG-retention test
79394085|NCT05800548|Other|survey application|In data collection; Socio-demographic and obstetric characteristics of puerperant women, descriptive information form including questions about current birth, Postpartum Family Planning Attitude Scale The Health Literacy Scale was used.
79851055|NCT00956670|Other|Questionnaire Administration|Ancillary studies
79851056|NCT00956670|Procedure|Study of High Risk Factors|Undergo lymphedema assessment
79851057|NCT00956670|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79851058|NCT00956670|Procedure|Therapeutic Laparoscopic Surgery|Undergo surgery
79851059|NCT00956670|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
79851060|NCT02574611|Drug|Neostigmine|
79851061|NCT02574611|Drug|Glycopyrrolate|
79851062|NCT02574611|Other|Saline (Placebo)|
79851063|NCT02574611|Device|High Resolution Colonic Manometry|
79851064|NCT01025596|Drug|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
79851065|NCT00710255|Procedure|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
79851066|NCT01025674|Behavioral|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
79851067|NCT00714779|Drug|Fluoxetine|20-40 mg / day orally
79851068|NCT00714779|Behavioral|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
79851069|NCT03912467|Other|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
79851070|NCT03839212|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
79851071|NCT03839212|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
79851072|NCT03839212|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
79851073|NCT03839212|Behavioral|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
79549781|NCT01578395|Radiation|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
79254113|NCT03731585|Procedure|Support Group Therapy|Participate in group sessions
79254114|NCT03715504|Drug|TP-3654|oral PIM inhibitor
79254115|NCT03709784|Drug|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
79254116|NCT03709784|Other|One time survey|One time survey
79254117|NCT03706495|Behavioral|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
79739809|NCT02886104|Device|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
79739810|NCT02689102|Device|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
79739811|NCT02885558|Drug|Efonidipine|8 weeks treatment with either efonidipine
79851074|NCT00168103|Biological|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
79851075|NCT00168103|Biological|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
79851076|NCT04011228|Diagnostic Test|Blood sampling|After a fasting period over night blood samples will be taken.
79851077|NCT04011228|Diagnostic Test|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
79851078|NCT04011228|Diagnostic Test|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
79851079|NCT00463060|Drug|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
79254118|NCT03706495|Behavioral|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
79254119|NCT03698851|Device|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
79254120|NCT03698851|Device|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
79254121|NCT03697850|Drug|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
79394086|NCT05800535|Drug|Study of the adverse effects of long-term oncological treatments|Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
79394087|NCT05800535|Behavioral|Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients|Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
79394088|NCT05800522|Behavioral|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
79404282|NCT01670461|Behavioral|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
79549782|NCT01578395|Radiation|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
79549783|NCT01578395|Other|No radiation exposure|Subjects not undergoing any radiation exposure
79549784|NCT01578408|Procedure|Total Hip Arthroplasty|
79549785|NCT01578408|Device|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
79549786|NCT01578408|Device|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
79739812|NCT02885558|Drug|Nifedipine|8 weeks treatment with either nifedipine
79254122|NCT03696888|Behavioral|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
79549787|NCT01578421|Device|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
79851080|NCT00463060|Procedure|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
79394089|NCT05800522|Behavioral|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
79713376|NCT04942106|Other|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings in a single day when they are receiving at least 30% and no more than 50% of feedings orally. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
79713377|NCT04935879|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
79713378|NCT04935879|Drug|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
79713379|NCT04926896|Procedure|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
79713380|NCT04926896|Procedure|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
79713381|NCT04924491|Biological|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
79713382|NCT04923230|Behavioral|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
79739813|NCT04185688|Other|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
79739814|NCT01008150|Drug|Paclitaxel|
79851081|NCT00956748|Drug|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
79851082|NCT00956748|Drug|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
79851083|NCT00710333|Drug|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
79851084|NCT00710333|Drug|placebo|placebo
79851085|NCT01079923|Dietary Supplement|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
79851086|NCT01079923|Dietary Supplement|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
79254123|NCT03696888|Behavioral|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
79549788|NCT01578434|Drug|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
79549789|NCT01578434|Drug|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
79254124|NCT03696043|Other|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
79549790|NCT01578434|Drug|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
79549791|NCT01578447|Drug|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
79394090|NCT05800509|Behavioral|Clips Intervention|A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
79549792|NCT01578447|Drug|Intramuscular DMPA|Intramuscular DMPA
79549793|NCT01578460|Device|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
79851087|NCT00951054|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
79254125|NCT03696043|Other|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
79713383|NCT04923165|Device|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
79713384|NCT04923165|Diagnostic Test|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
79713385|NCT04923165|Device|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
79713386|NCT04923165|Diagnostic Test|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
79713387|NCT04917848|Other|Tele-Geriatric Oncology program|Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
79739815|NCT01008150|Drug|Trastuzumab|
79739816|NCT01008150|Drug|Neratinib|
79851088|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
79851089|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
79851090|NCT00462982|Drug|sunitinib malate|
79851091|NCT02573597|Drug|Bupivacaine|Continuous or bolus administration
79254126|NCT03693014|Radiation|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
79394091|NCT05800509|Device|Structured Questionnaire Only|A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
79394092|NCT05800496|Dietary Supplement|SesZen-Bio™|mode of usage: 1 capsule in the morning and 1 capsule at night. administration: Oral Administration
79394093|NCT05800496|Other|Placebo|Mode of Usage: 1 capsule in the morning and 1 capsule at night. Route of Administration: Oral Administration
79394094|NCT05800483|Behavioral|Healium|web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
79394095|NCT05800470|Other|fNIRS-based neurofeedback with motor imagery|A multichannel wearable fNIRS (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NY, USA) will be used to detect the cortical activity in SMA. The HbO concentration will be processed and displayed as a visual feedback during MI training.
79394096|NCT05800470|Other|Kinesthetic motor imagery|Participants will be asked to practice MI with kinesthetic strategy in the first-person perspective for balance and gait tasks in 10 mins. After the MI training, they will receive 20-min balance and gait training, the same as in experimental group.
79394097|NCT05800457|Procedure|Synovectomy|Patients in the intervention group will undergo synovectomy during total knee replacement surgery
79394098|NCT05800418|Drug|Ramucirumab Injection|Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
79549794|NCT01578460|Device|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
79549795|NCT01578473|Drug|Vitamin D2|oral softgel 2000 IU once daily 9 months
79549796|NCT01578473|Drug|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months"
79549797|NCT01578473|Drug|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
79549798|NCT01578512|Behavioral|Face-to-Face|Face-to-Face behavioral weight loss
79549799|NCT01578512|Behavioral|Web-based|Web-based behavioral weight loss
79549800|NCT01578512|Behavioral|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
79549801|NCT01578525|Other|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
79549802|NCT01578538|Procedure|inguinal hernia repair|strangulated hernias will be repaired surgically
79549803|NCT01578564|Drug|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
79851092|NCT02573597|Drug|Sufentanil|Continuous or bolus administration
79851093|NCT05300958|Drug|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
79851094|NCT00951210|Biological|PLX-PAD|IM injection
79851095|NCT04070729|Other|Placebo gel|Localized subgingival application
79549804|NCT01578590|Dietary Supplement|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
79394099|NCT05800418|Drug|Ramucirumab Injection [Cyramza]|Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
79394100|NCT05800340|Biological|Toripalimab|240mg Q3W
79549805|NCT01578603|Dietary Supplement|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
79549806|NCT01578603|Dietary Supplement|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
79549807|NCT01578629|Other|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
79549808|NCT01578629|Other|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
79549809|NCT01578642|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
79549810|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
79549811|NCT01578668|Drug|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
79549812|NCT01578668|Drug|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
79549813|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
79549814|NCT01578681|Procedure|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
79549815|NCT01578681|Procedure|Stretching|Patient will be instructed to do muscle stretching of the thorax
79549816|NCT01578694|Diagnostic Test|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
79549817|NCT01578720|Drug|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
79549818|NCT01578733|Dietary Supplement|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
79549819|NCT01578746|Procedure|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
79549820|NCT01578746|Procedure|Anterior approach|The use of anterior approach in total hip arthroplasty
79549821|NCT01578759|Procedure|Salpingectomy|Removal of the fallopian tubes
79394101|NCT05800340|Drug|Nab paclitaxel|135 mg/m2, d1, 8 Q3W
79549822|NCT01578811|Drug|Placebo|Dosage
79713388|NCT04917224|Radiation|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
79713389|NCT04917224|Radiation|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
79739817|NCT01008150|Drug|Doxorubicin|
79739818|NCT01008150|Drug|Cyclophosphamide|
79851096|NCT04070729|Drug|Hyaluronic acid gel|Localized subgingival application
79394102|NCT05800340|Drug|Pemetrexed|500mg/m2, d1 Q3W
79394103|NCT05800340|Drug|Carboplatin|AUC 5, d1 Q3W
79394104|NCT05800327|Drug|Levilimab|Subcutaneous or intravenous injection of levilimab with placebo.
79549823|NCT01578811|Drug|SK-MS10|Dosage
79549824|NCT01578811|Drug|SK-MS10|Dosage
79549825|NCT01578824|Other|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
79549826|NCT01578837|Dietary Supplement|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
79549827|NCT01578837|Dietary Supplement|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
79549828|NCT01578863|Other|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
79549829|NCT01578876|Device|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
79549830|NCT01578889|Biological|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
79549831|NCT01578889|Biological|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
79739819|NCT02687152|Other|N-hydroxy-nor-L-arginine|
79394105|NCT05800301|Biological|Wharton's jelly derived mesenchymal stemcells|The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.
79394106|NCT05800301|Device|Magnovision|Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.
79851097|NCT04070729|Biological|Platelet rich fibrin|Localized subgingival application
79549832|NCT01578889|Biological|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10^8 plaque-forming units (PFUs) administered as 5x10^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
79713390|NCT04901624|Behavioral|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
79713391|NCT04901624|Behavioral|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
79394107|NCT05800262|Behavioral|Dynamic stability exercises|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
79713392|NCT04901624|Behavioral|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
79713393|NCT04901624|Behavioral|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
79713394|NCT04873895|Drug|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
79394108|NCT05800236|Procedure|Gastrectomy|Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
79713395|NCT04873895|Drug|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
79713396|NCT04873895|Procedure|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
79851098|NCT00951288|Dietary Supplement|Saffron|Saffron 20 mg/day supplementation
79851099|NCT00951288|Dietary Supplement|Placebo|Placebo
79394109|NCT05800223|Drug|Almonertinib|The dosage is 110 mg/day (2 tablets/day) orally once a day
79394110|NCT05800223|Radiation|SBRT|SRT, 27Gy-40Gy/3-5f
79254127|NCT03693014|Biological|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
79254128|NCT03692897|Other|All approved therapies for the treatment of Chronic Hepatitis B (CHB)|All approved therapies for the treatment of Chronic Hepatitis B (CHB).
79394111|NCT05800132|Device|MammoScreen|Diagnostic reading aid for breast cancer screening
79394112|NCT05800106|Drug|Sunitinib malate capsules generic product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
79713397|NCT04869436|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
79851100|NCT00462904|Drug|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
79851101|NCT00956826|Device|Agit Vacuum|With an electrode and a regular vacuum device
79851102|NCT00709397|Other|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
79851103|NCT00467272|Drug|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
79254129|NCT03690661|Behavioral|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
79394113|NCT05800106|Drug|Sunitinib malate capsules reference product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
79549833|NCT01578889|Biological|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
79549834|NCT01578889|Device|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
79549835|NCT01578928|Drug|SOM230|
79549836|NCT01578941|Other|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
79713398|NCT04860492|Dietary Supplement|Renalof 325mg|RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
79254130|NCT03690661|Behavioral|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
79549837|NCT01579019|Drug|RO5024048|1500 mg po bid, 24 or 26 weeks
79549838|NCT01579019|Drug|RO5024048|1000 mg po bid, 24 or 26 weeks
79254131|NCT03643991|Other|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
79394114|NCT05800080|Drug|Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
79394115|NCT05800067|Drug|axi-cel|Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
79549839|NCT01579019|Drug|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
79549840|NCT01579019|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
79713399|NCT04860154|Drug|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
79851104|NCT00956904|Device|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
79254132|NCT03614793|Procedure|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
79254133|NCT03602235|Other|Ascorbate|Ascorbate is in the vitamin drug class
79254134|NCT03602235|Drug|Melphalan|Melphalan is an alkylating agent coupled to an amino acid
79254135|NCT03598530|Procedure|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
79254136|NCT03594123|Drug|Brexpiprazole|2 or 3 mg tablet
79549841|NCT01579019|Drug|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
79549842|NCT01579019|Drug|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
79549843|NCT01579058|Drug|bisoprolol|bisoprolol 5mg qd for 4 years
79549844|NCT01579058|Drug|placebo|placebo for 4 years
79549845|NCT01579071|Procedure|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
79549846|NCT01579097|Other|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
79549847|NCT01579097|Other|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
79549848|NCT01579110|Drug|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
79549849|NCT01579110|Drug|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
79549850|NCT01579123|Procedure|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
79713400|NCT04856085|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
79713401|NCT04856085|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
79713402|NCT04856085|Drug|PEG-IFNα|PEG-IFNα given by subcutaneous injection
79713403|NCT04844931|Procedure|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
79713404|NCT04844931|Procedure|Standard PCI|Standard PCI
79254137|NCT03594123|Drug|Brexpiprazole|0.5 to 3 mg tablet
79254138|NCT03583359|Device|Radiesse (+)|Radiesse (+) for jawlines.
79254139|NCT03575013|Drug|Avelumab|Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
79254140|NCT03575013|Drug|Docetaxel|Docetaxel is a antineoplastic agent belonging to the taxoid family
79254141|NCT03554356|Device|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
79254142|NCT03548428|Drug|Atezolizumab|1200mg IV every 3 weeks for 4 months
79254143|NCT03548428|Radiation|SBRT|3 to 5 fractions depending on tumor size
79851105|NCT00956982|Drug|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
79851106|NCT00714857|Drug|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
79851107|NCT00957060|Drug|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
79549851|NCT01579123|Procedure|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
79549852|NCT01579136|Behavioral|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
79549853|NCT01579149|Drug|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
79549854|NCT01579149|Drug|Placebo|Single subcutaneous (SC) dose of placebo
79549855|NCT01579175|Other|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
79713405|NCT04831606|Procedure|debridement|Cleaning of the wound area
79713406|NCT04831606|Device|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
79851108|NCT00957060|Drug|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
79713407|NCT04831606|Device|Advanced dressing|Protect the wound with Advanced dressing
79713408|NCT04831606|Device|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
79851109|NCT02573519|Radiation|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) [11C]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
79851110|NCT02573519|Device|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~A wireless electromagnetic capsule to be swallowed by the subject~A portable detector plate comprising four sensors worn in a belt around the waist~Specific software for visualizing and analyzing data"
79549856|NCT01579188|Drug|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
79549857|NCT01579188|Drug|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
79549858|NCT01579201|Drug|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
79549859|NCT01579227|Device|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
79549860|NCT01579227|Dietary Supplement|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
79549861|NCT01579227|Device|Tamoxifen Cream|Tamoxifen cream
79549862|NCT01579227|Device|Placebo cream|Placebo cream
79549863|NCT01579227|Dietary Supplement|placebo capsule|placebo capsule
79549864|NCT01579240|Other|Internet exercise program|12 voluntary weekly visits to website
79549865|NCT01579279|Drug|ABT-652 6 mg|6 mg capsules
79549866|NCT01579279|Drug|ABT-652 12 mg|12 mg capsules
79549867|NCT01579279|Drug|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
79549868|NCT01579279|Drug|Placebo|Placebo capsules
79549869|NCT01579279|Drug|Duloxetine|Duloxetine capsules
79549870|NCT01579292|Behavioral|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
79549871|NCT01579292|Behavioral|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
79713411|NCT04812730|Other|2D versus 3D analysis of EOS stereo radiographic analysis|The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
79713412|NCT04812730|Other|Static versus dynamic analysis|The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
79713413|NCT04812730|Other|Pre- versus postoperative analysis|The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
79549872|NCT01579331|Device|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
79713414|NCT04812730|Other|Reliability of the dynamic evaluation|Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
79713415|NCT04783506|Other|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
79713416|NCT04758637|Behavioral|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
79549873|NCT01579344|Drug|Radioiodine therapy|Radioiodine therapy with NaI131
79549874|NCT01579357|Other|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
79713417|NCT04725513|Device|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
79713418|NCT04725513|Device|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
79713419|NCT04725513|Other|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
79713420|NCT04717050|Behavioral|Progressive combine training (PCT)|8 month exercise program with 4 month follow up.
79713421|NCT04717050|Behavioral|Attention Control (AC)|12 month stretching program
79851111|NCT02573519|Drug|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
79851112|NCT02573519|Device|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
79851113|NCT00947232|Behavioral|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
79851114|NCT00947232|Behavioral|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
79851115|NCT02572661|Radiation|radiation in Squamous Head and Neck Cancer|
79851116|NCT02572583|Drug|Liugan Shuangjie Heji|
79851117|NCT02572583|Drug|Shufeng Jiedu Capsule|
79254144|NCT03537651|Drug|TEZ/IVA|Fixed-dose combination tablet for oral administration.
79254145|NCT03537651|Drug|IVA|Tablet for oral administration.
79851118|NCT02572583|Drug|Oseltamivir Phosphate Capsule|
79254146|NCT03506438|Behavioral|Needs-focused mobile app|A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.
79254147|NCT03506438|Other|Usual care|Usual ICU care as per the standards of the ICU attending
79254148|NCT03503786|Drug|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
79549875|NCT01579370|Other|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
79549876|NCT01579370|Other|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
79713422|NCT04699201|Procedure|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
79713423|NCT04699201|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
79713424|NCT04699201|Diagnostic Test|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
79713425|NCT04689009|Device|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
79254149|NCT03503786|Drug|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
79254150|NCT03503786|Drug|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
79254151|NCT03493542|Biological|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
79549877|NCT01579370|Other|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
79254152|NCT03484130|Dietary Supplement|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The diet will consist of >180 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.
79851119|NCT04011306|Device|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
80017285|NCT04433260|Other|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
79254153|NCT03484130|Dietary Supplement|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium restricted diet. The diet will consist of <40 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.
79549878|NCT01579370|Other|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
79549879|NCT01579383|Biological|ALD403|Single Dose IV infusion on Day 1
79549880|NCT01579383|Biological|ALD403|Single Dose subcutaneous injection on Day 1
79549881|NCT01579383|Biological|Sumatriptan|Single Dose subcutaneous injection on Day 1
79549882|NCT01579396|Device|septeX|12 h septeX CVVH treatment after cardiac surgery
79549883|NCT01579396|Other|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
79549884|NCT01579409|Other|PNNS guidelines|Application of PNNS guidelines
79549885|NCT01579422|Behavioral|social cognitive training|social cognitive training, 8-10 sessions
79549886|NCT01579435|Device|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
79549887|NCT01579448|Biological|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
79549888|NCT01579448|Biological|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
79549889|NCT01579448|Other|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
79549890|NCT01579461|Drug|mirabegron|oral
79549891|NCT01579487|Device|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
79549892|NCT01579500|Drug|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
79549893|NCT01579500|Drug|normal saline|Subcutaneous injection of normal saline
79549894|NCT01579526|Drug|FP01|comparison of different dosages
79549895|NCT01579539|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
79713426|NCT04689009|Procedure|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
79549896|NCT01579539|Drug|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
79549897|NCT01579591|Other|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
79549898|NCT01579591|Other|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
79851120|NCT00714935|Behavioral|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
79254154|NCT03473015|Device|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
79254155|NCT03472807|Other|Collection of blood sample or saliva|at Inclusion
79549899|NCT01579604|Procedure|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
79254156|NCT03472807|Other|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
79549900|NCT01579617|Behavioral|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
79254157|NCT03472807|Other|Collection of blood sample if tumor sample is not available|at Inclusion
79254158|NCT03459625|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
79404283|NCT01670461|Behavioral|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
79549901|NCT01579617|Behavioral|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
79549902|NCT01579630|Drug|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
79549903|NCT01579630|Drug|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
79549904|NCT01579643|Procedure|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~The host cornea bed will be prepared with an excimer laser.~Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
79549905|NCT01579643|Procedure|Penetrating Keratoplasty (KP)|"A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~The donor cornea is then sutured where the patient's cornea was."
79713427|NCT04685408|Behavioral|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
79713428|NCT04685408|Behavioral|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
79851121|NCT00714935|Behavioral|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
79851122|NCT00951444|Biological|dalotuzumab|Given IV
79713429|NCT04665180|Diagnostic Test|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
79713430|NCT04628871|Biological|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
79549906|NCT01579656|Dietary Supplement|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
79394116|NCT05800054|Dietary Supplement|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
79713431|NCT04628871|Biological|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
79851123|NCT00951444|Drug|carboplatin|Given IV
79713432|NCT04628871|Biological|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
79851124|NCT00951444|Drug|gemcitabine hydrochloride|Given IV
79851125|NCT00462826|Biological|ziv-aflibercept|
79851126|NCT00718601|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
79254159|NCT03459625|Behavioral|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
79254160|NCT03434262|Drug|Gemcitabine|Given intravenously (IV).
79549907|NCT01579656|Dietary Supplement|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
79713433|NCT04620889|Device|AV Access|Arteriovenous shunting for blood access.
79254161|NCT03434262|Drug|ribociclib|Given orally (PO).
79254162|NCT03434262|Drug|sonidegib|Given PO.
79254163|NCT03434262|Drug|trametinib|Given PO.
79713434|NCT04620889|Device|PVP|Bypass or reconstruction of diseased or occluded blood vessels
79713435|NCT04615403|Drug|Travoprost|Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
79713436|NCT04604899|Biological|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
79713437|NCT04586049|Device|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
79851127|NCT00951522|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
79851128|NCT00951522|Drug|Placebo|Inhaled placebo in sterile saline
79254164|NCT03434262|Biological|filgrastim|Given subcutaneously (SQ).
79254165|NCT03431064|Other|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
79254166|NCT03431064|Other|Fluid Administration|Administration of IV Fluid by Anesthesiologist
79254167|NCT03429218|Drug|TP-0184|Oral dose once weekly for 4 weeks
79394117|NCT05800054|Drug|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
79394118|NCT05800054|Drug|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
79713438|NCT04586049|Device|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
79713439|NCT04586049|Other|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
79713440|NCT04577014|Drug|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
79739820|NCT04186936|Drug|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
79851129|NCT00718679|Drug|IVN201|Intralymphativ injection of the study drug
79851130|NCT00718679|Drug|Placebo|
79851131|NCT00947388|Drug|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
79851132|NCT00947388|Biological|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
79851133|NCT00710645|Device|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
79851134|NCT00951600|Drug|oxcarbazepine 300 mg/5mL oral suspension|
79851135|NCT00710723|Procedure|vitrification|Vitrification using Hemi-straw carrier system.
79851136|NCT00951678|Other|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
79851137|NCT03910985|Drug|Duovent HFA|bronchodilation
79851138|NCT05300880|Other|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
79851139|NCT00957216|Drug|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
79713441|NCT04577014|Drug|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
79851140|NCT00957216|Drug|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
79713442|NCT04577014|Drug|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
79851141|NCT00718757|Drug|Dexamethasone|5 doses given on Days 6-10
79851142|NCT00718757|Drug|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
79851143|NCT00718757|Drug|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~* Patients < 1 year of age or < 10kg in weight: Vincristine 0.05 mg/kg"
79851144|NCT00947466|Drug|Buprenorphine|Transdermal patch
79851145|NCT00957606|Procedure|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
79851146|NCT04069013|Procedure|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
79851147|NCT00951756|Other|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
79851148|NCT00718835|Behavioral|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
79394119|NCT05800054|Radiation|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
79851149|NCT00946842|Drug|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
79394120|NCT05800041|Drug|WTX221|Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
79394121|NCT05799937|Procedure|Non Surgical Root Canal Treatment|After administration of LA and rubber dam isolation, access cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with rotary instruments . 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
79394122|NCT05799924|Device|Transcutaneous electrical acupoint stimulation|The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 ~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
79394123|NCT05799924|Drug|non steroidal anti inflammatory drugs|Hormonal contraception can suppress ovulation, NSAIDS can ease pain
79394124|NCT05799898|Other|No intervention for research purposes only|No intervention for research purposes only
79394125|NCT05799885|Other|Neuro-vestibular-ocular group|Neuro-vestibular-ocular exercise group (30 footballers)will do the exercises given in addition to their training
79394126|NCT05799885|Other|Myofascial Release group|Manual myofascial release will be applied by the physiotherapist.(30 football players)
79394127|NCT05799859|Device|Use of coronally advanced flap (CAF) and collagen matrix (CM)|
79394128|NCT05799859|Device|Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).|
79394129|NCT05799846|Behavioral|Standard Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention
79394130|NCT05799846|Behavioral|PREVENT Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity
79394131|NCT05799846|Behavioral|PROMOTE Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
79394132|NCT05799794|Behavioral|Supervisor-led Implementation Coaching|Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
79394133|NCT05799781|Device|MPC closed-loop system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled.
79549908|NCT01579656|Dietary Supplement|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
79713443|NCT04567784|Drug|Cannabidiol (CBD)|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
79549909|NCT01579656|Dietary Supplement|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
79549910|NCT01579656|Dietary Supplement|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
79851150|NCT00946842|Drug|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
79851151|NCT00946842|Drug|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
79851152|NCT00946842|Drug|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
79851153|NCT00946842|Drug|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
79851154|NCT00946842|Drug|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
79394134|NCT05799781|Device|t:slim X2 pump with Dexcom G6 CGM and Control IQ|The t:slim pump is a hybrid closed-loop system available to consumers for automated insulin delivery. Control IQ technology automatically adjusts insulin levels based on continuous glucose monitoring (CGM) readings from Dexcom G6.
79713444|NCT04567784|Drug|Placebo|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
79851155|NCT00951834|Drug|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
79713445|NCT04566107|Behavioral|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
79713446|NCT04566107|Behavioral|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
79851156|NCT00951834|Drug|Placebo|Placebo
79851157|NCT00715013|Drug|Patupilone|Patupilone
79851158|NCT00715091|Drug|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
79851159|NCT00715091|Drug|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
79851160|NCT00947622|Device|Transcranial direct current stimulation|Transcranial Direct current stimulation
79851161|NCT00957762|Other|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
79851162|NCT00718913|Drug|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
79851163|NCT00718913|Drug|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
79254168|NCT03426683|Other|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
79254169|NCT03425643|Biological|Pembrolizumab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
79254170|NCT03425643|Drug|Placebo|Normal saline by IV infusion Q3W, given on cycle day 1.
79254171|NCT03425643|Drug|Cisplatin|75 mg/m^2 by IV infusion Q3W, given on cycle day 1.
79254172|NCT03425643|Drug|Gemcitabine|1000 mg/m^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
79254173|NCT03425643|Drug|Pemetrexed|500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
79394135|NCT05799742|Procedure|Bilateral hernioplasty|
79394136|NCT05799716|Drug|IVIG|0.5g/Kg
79404284|NCT03155503|Drug|SUVN-911|Oral Tablet
79404285|NCT03155503|Drug|Placebo|Oral Tablet
79549911|NCT01579682|Behavioral|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
79549912|NCT01579682|Behavioral|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
79549913|NCT01579695|Drug|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
79394137|NCT05799690|Behavioral|Gait and balance training with dual-task + action observation and motor imagery (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~1 hour, 3 times a week for six weeks."
79394138|NCT05799690|Behavioral|Gait and balance training with dual-task (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~1 hour, 3 times a week for six weeks."
79394139|NCT05799690|Behavioral|Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
79851164|NCT00718913|Drug|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
79549914|NCT01579708|Behavioral|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
79549915|NCT01579721|Procedure|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
79713447|NCT04559620|Other|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
79713448|NCT04545177|Device|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
79851165|NCT00718913|Radiation|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
79851166|NCT00718913|Drug|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
79851167|NCT04011930|Drug|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
79851168|NCT04011930|Drug|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
79851169|NCT04068857|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
79851170|NCT00957840|Procedure|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
79851171|NCT00715169|Drug|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
79549916|NCT01579760|Drug|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
79549917|NCT01579760|Drug|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
79549918|NCT01579786|Procedure|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
79549919|NCT01579799|Drug|L-lysine|Dose finding study for L-lysine
79549920|NCT01579825|Other|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
79549921|NCT01579838|Drug|Eculizumab|PNH and or atypical TTP classical protocols
79713449|NCT04539574|Procedure|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
79713450|NCT04539574|Other|Questionnaire Administration|Ancillary studies
79713451|NCT04531046|Drug|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
79713452|NCT04517604|Device|Magventure MagProx100 with MagOption|iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B60 Butterfly coils). Only the active setting will be used.A MagVenture C-B60 coil will be used to deliver single pulse TMS to the non-dominant MC to identify the ab-ductor pollicis brevis (APB) muscle coordinates. The integrated Localite neuronavigation system will be used.
79549922|NCT01579864|Drug|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
79394140|NCT05799690|Behavioral|Gait and balance training with dual-task (twelve weeks: 6 +6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
79549923|NCT01579864|Drug|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
79549924|NCT01579877|Dietary Supplement|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
79549925|NCT01579877|Dietary Supplement|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
79851172|NCT00715169|Other|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
79549926|NCT01579890|Drug|Diclofenac|diclofenac topical lotion
80017286|NCT04433260|Other|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
79549927|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
79549928|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
79549929|NCT01579929|Drug|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
79549930|NCT01579955|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
79549931|NCT01579968|Drug|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
79549932|NCT01579981|Procedure|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
79549933|NCT01579994|Drug|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
79549934|NCT01580124|Procedure|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
79549935|NCT01580124|Procedure|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
79549936|NCT01580150|Other|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
79713453|NCT04511806|Other|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
79713454|NCT04494503|Drug|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
79713455|NCT04494503|Drug|Rituximab|Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
79713456|NCT04494503|Drug|Ibrutinib|Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
79713457|NCT04485611|Behavioral|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements]]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
79713458|NCT04483713|Behavioral|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
79739821|NCT04186936|Drug|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
79739822|NCT04186936|Drug|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
80017287|NCT04433260|Other|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
80017288|NCT04453683|Device|Air-Q. ILA insertion of proper size|Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
79851173|NCT00951990|Behavioral|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
79851174|NCT00951990|Behavioral|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
79851175|NCT00718991|Device|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
79851176|NCT00947700|Behavioral|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
79851177|NCT02574377|Drug|A: myDC vaccination|
79851178|NCT02574377|Drug|B: pDC vaccination|
79549937|NCT01580150|Other|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
79549938|NCT01580228|Drug|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m^2 on Day 1, 10 mg/m^2 on Day 8, and 14 mg/m^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
79549939|NCT01580228|Drug|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
79549940|NCT01580280|Other|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
79549941|NCT01580280|Other|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
79549942|NCT01580475|Other|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
79549943|NCT01580735|Drug|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
79549944|NCT01580787|Device|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
79549945|NCT01580787|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
79713459|NCT04483713|Behavioral|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
79713460|NCT04477304|Behavioral|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
79713461|NCT04477304|Behavioral|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
79851179|NCT02574377|Drug|C: combined myDC/pDC vaccination|
79851180|NCT00551616|Drug|CDB-2914|Single dose
79851181|NCT00551616|Drug|Levonorgestrel|Single dose
79851182|NCT00715325|Device|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
79851183|NCT02574221|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
80017289|NCT04453683|Device|ILMA insertion of proper size|Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
79549946|NCT01581034|Drug|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
79549947|NCT01581034|Drug|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
79549948|NCT01581333|Drug|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
79549949|NCT01581333|Drug|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
79549950|NCT01581359|Drug|Triptorelin acetate|"Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
79549951|NCT01581476|Drug|Statin|10mg daily for a minimum period of 2 years
79549952|NCT01581476|Drug|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
79549953|NCT01581476|Drug|Placebo|Participants receive statin placebo and ACEI placebo
79851184|NCT02574221|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
79851185|NCT00719147|Procedure|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
79851186|NCT00719147|Other|Functional Status and Symptom Questionnaire|Questionnaire
79851187|NCT02572349|Drug|IW-1701|
79851188|NCT02572349|Drug|Matching Placebo|
79851189|NCT00719303|Behavioral|Behavioral Dietary Intervention|Receive dietary intervention
79254174|NCT03416816|Drug|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
79394141|NCT05799664|Device|TLD|Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.
79394142|NCT05799664|Other|Sham TLD procedure|Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
79549954|NCT01581476|Drug|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
79549955|NCT01581502|Other|This is an observational study.|This is an observational, not intervention, study.
79549956|NCT01581749|Radiation|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
79549957|NCT01581762|Procedure|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
79549958|NCT01581892|Procedure|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
79549959|NCT01581905|Procedure|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
79549960|NCT01581905|Procedure|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
79549961|NCT01581957|Other|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
79549962|NCT01581957|Other|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
79713462|NCT04477304|Behavioral|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
79713463|NCT04451226|Drug|Fezolinetant|Oral
79713464|NCT04448873|Drug|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
79851190|NCT00719303|Behavioral|Compliance Monitoring|Complete daily fat gram and step diaries
79851191|NCT00719303|Other|Counseling|Undergo face-to-face and telephone counseling
79254175|NCT03400176|Drug|VAY736|Experimental
79394143|NCT05799664|Other|Standard of care|Patients will also receive standard of care that meet the recommendations of GOLD guideline.
79549963|NCT01582321|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
79549964|NCT01582321|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
79549965|NCT01582438|Drug|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
79549966|NCT01582711|Behavioral|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
79713465|NCT04442724|Procedure|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
79851192|NCT00719303|Other|Educational Intervention|Receive educational materials
79254176|NCT03400176|Drug|ibrutinib|Approved medication
79254177|NCT03365453|Other|frailty evaluation|frailty and comorbidity scores
79394144|NCT05799560|Other|THERAPEUTIC TOUCH|Therapeutic touch will be done. It will be applied twice a week for two weeks, each application for 20 minutes.
79394145|NCT05799560|Other|REİKİ|It will be applied twice a week for two weeks, each application for 20 minutes.
79394146|NCT05799547|Other|cold group|Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
79394147|NCT05799534|Other|Physical Therapy Rehabilitation|Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
79394148|NCT02365350|Procedure|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
79394149|NCT02365350|Procedure|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
79394150|NCT05799469|Drug|Envafolimab|SC
79394151|NCT05799469|Drug|Cisplatin|IV infusion
79394152|NCT05799469|Radiation|External Beam Radiotherapy (EBRT)|45-50.4Gy
79851193|NCT00719303|Behavioral|Exercise Intervention|Undergo physical activity intervention
79851194|NCT00719303|Other|Laboratory Biomarker Analysis|Correlative studies
79851195|NCT00719303|Other|Quality-of-Life Assessment|Ancillary studies
79851196|NCT00719303|Other|Questionnaire Administration|Ancillary studies
79851197|NCT00452530|Drug|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
79851198|NCT00452530|Drug|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
79851199|NCT00452530|Drug|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
79851200|NCT00452530|Drug|Apixaban-matching placebo|Oral tablet administered twice daily
79549967|NCT01582711|Behavioral|SMS reminders|Short Message Service (SMS) text reminders
79851201|NCT00549198|Drug|Abacavir/lamivudine and efavirenz|
79851202|NCT00549198|Drug|Tenofovir/Emtricitabine and efavirenz|
79851203|NCT00607724|Drug|GDC-0449|
79549968|NCT01582711|Drug|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
79549969|NCT01583062|Drug|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
79851204|NCT00506415|Drug|Rivastigmine 5 cm^2|5 cm^2 transdermal patch
79851205|NCT00506415|Drug|Rivastigmine 10 cm^2|10 cm^2 transdermal patch.
79549970|NCT01583062|Drug|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
79549971|NCT01583075|Procedure|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
79549972|NCT01583075|Procedure|single ring pulmonary vein ablation|single ring pulmonary vein ablation
79549973|NCT01583088|Device|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
79549974|NCT01583088|Device|sham phrenic nerve stimulation|sham phenic nerve stimulation
79549975|NCT01583309|Procedure|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
79713466|NCT04442724|Diagnostic Test|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 & T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
79713467|NCT04393376|Diagnostic Test|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
79713468|NCT04368429|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Pharmaceutical form: Liquid solution Route of administration: IM
79851206|NCT00506415|Drug|Rivastigmine 15 cm^2|15 cm^2 transdermal patch.
79851207|NCT00506415|Drug|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm^2.
79851208|NCT00506415|Drug|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm^2.
79851209|NCT04036526|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
79851210|NCT04036526|Other|Placebo|Placebo
79851211|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
79851212|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
79851213|NCT04036604|Other|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
79394153|NCT05799469|Radiation|Brachytherapy (BT)|Performed according to clinically required dose
79394154|NCT05799456|Diagnostic Test|Free glycosaminoglycan profiling|Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
79394155|NCT05799443|Drug|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
79394156|NCT05799443|Drug|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
79394157|NCT05799443|Drug|cetuximab|cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
79394158|NCT05799443|Radiation|SBRT|8-10Gy×5F，QOD
79394159|NCT05799417|Other|Acoustic stimuli|During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
79851214|NCT00947778|Other|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
79394160|NCT05799404|Diagnostic Test|ultra-high resolution CT|stapes footplate thickness measurement
79394161|NCT05799365|Other|GMFCS-FR Turkish Adaptation|GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
79549976|NCT01583309|Procedure|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
79549977|NCT01583335|Behavioral|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
79713469|NCT04368429|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration: IM
79713470|NCT04364750|Dietary Supplement|L-Histidine|1 capsule (0.6g) twice daily
79713471|NCT04364750|Dietary Supplement|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
79713472|NCT04364750|Dietary Supplement|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
79713473|NCT04364750|Dietary Supplement|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
79713474|NCT04364750|Other|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
79851215|NCT00947778|Other|1 training session|20 sessions of 30 minutes by week during 24 semaines
79851216|NCT02572115|Behavioral|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
79851217|NCT02572115|Behavioral|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
79713475|NCT04356326|Drug|Aspirin 150 mg|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
79549978|NCT01583400|Other|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
79549979|NCT01583400|Other|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
79549980|NCT01583426|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
79549981|NCT01583426|Drug|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
79549982|NCT01583517|Procedure|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
79549983|NCT01583517|Procedure|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
79549984|NCT01583517|Procedure|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
79549985|NCT01583712|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
79851218|NCT00893438|Behavioral|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
79254178|NCT03354390|Biological|cell infusion|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
79254179|NCT03350906|Drug|n3-PUFA|The DHA/EPA softgels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (~381 mg) and poloxamer 237, NF (~8.8 mg).
79549986|NCT01583712|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
79549987|NCT01583972|Dietary Supplement|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
79549988|NCT01583972|Dietary Supplement|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
79549989|NCT01584245|Other|Amino Acid formula|
79549990|NCT01584336|Procedure|LATG|"After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~After then, the operator performs the jejunojejunostomy."
79549991|NCT01584362|Drug|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
79549992|NCT01584362|Drug|placebo|single oral dose of placebo
79851219|NCT00893438|Other|Usual care|Usual care treatment for adolescents with CFS
79851220|NCT00952146|Procedure|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
79549993|NCT01584362|Drug|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
79549994|NCT01584362|Drug|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
79549995|NCT01584362|Drug|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
79549996|NCT01584362|Drug|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
79851221|NCT00452452|Biological|13-valent Pneumococcal Conjugate Vaccine|
79851222|NCT01009437|Drug|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
79851223|NCT01009437|Procedure|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
79549997|NCT01584362|Drug|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
79713476|NCT04356326|Drug|Placebo|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
79739823|NCT01007916|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
79739824|NCT01007916|Device|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
79739825|NCT02689180|Drug|Placebo|Replacement of furosemide by placebo
79739826|NCT02689180|Drug|Furosemide|Maintenance of furosemide on usual doses
80017290|NCT02101866|Drug|Vapendavir 300 mg tablet|tablet - single dose
79713477|NCT04349046|Device|Total hip arthoplasty (THA)|Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relieve pain and debilitating symptoms. THA was traditionally performed on patients over 60 years old, but now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications of THA include osteoarthritis, rheumatoid arthritis, avascular necrosis and hip fractures. The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.
79713478|NCT04300049|Drug|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
79713479|NCT04300049|Other|Saline|Study participants will receive saline infusion for 12 hours.
79713480|NCT04278729|Drug|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
79713481|NCT04259788|Other|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
79713482|NCT04234204|Drug|Fezolinetant|Oral
79713483|NCT04234204|Drug|Placebo|Oral
79713484|NCT04227574|Other|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
79713485|NCT04227574|Other|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
79713486|NCT04226716|Behavioral|Assessment of postural control, body perception and psychosocial factors|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
79713487|NCT04224181|Radiation|Cardiac PET|A scan examining blood flow to the heart
79713488|NCT04224181|Radiation|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
79713489|NCT04224181|Radiation|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
79713490|NCT04220970|Other|BIA-ALCL|Observational : no intervention
79713491|NCT04216017|Drug|kenalog|Cortisone injection into shoulder
79713492|NCT04216017|Drug|Lidocaine|Lidocaine injection into shoulder
79851224|NCT04322435|Other|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
79254180|NCT03350906|Drug|Placebo|Looks exactly like the study drug but contains soybean oil with no active ingredient.
79254181|NCT03350906|Procedure|Biopsy|Two muscle biopsies from the upper part of one leg. A small (~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
79394162|NCT05799352|Device|Endoscopic lung volume reduction|a prospective monocentric study on hyperinflated COPD patients without collateral ventilation. Patients were evaluated before and 3 months after unilateral ELVR by transdiaphragmatic pressure (Pdi) measured at the functional residual capacity (FRC) after magnetic phrenic stimulation and by high-resolution computed tomography at the FRC allowing 3D modelling of the diaphragm for measurements of fibers length, length of the zone of apposition and radius of curvature of the diaphragmatic domes.
79394163|NCT05799300|Procedure|Intrathecal anaesthesia|Low dose 0.5% hyperbaric bupivacaine (1.3mls, 0.65mg) intrathecal anaesthesia.
79394164|NCT05799248|Drug|rhPSMA-7.3 (18F)|Patients will receive a dose with an administered activity of 8 mCi (296 MBq) ± 20% of rhPSMA-7.3, delivered as an IV bolus injection with a 10 mL fast 0.9% sodium chloride flush, followed by PET imaging.
79713493|NCT04206813|Drug|Gardasil 9 2 dose regimen|a 2-dose regimen of Gardasil 9 at 0 and 6 months
79713494|NCT04206813|Drug|Gardasil 9 3 dose regimen|standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
79713495|NCT04206813|Drug|Gardasil 9 rescue dose|A rescue dose of Gardasil 9 will be given at 12 months
79713496|NCT04191421|Biological|Siltuximab|Given IV
79713497|NCT04191421|Biological|Spartalizumab|Given IV
79713498|NCT04179903|Other|Physical activity|Physical Activity program is performed in a group in a gym and at home
79713499|NCT04142125|Drug|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
79713500|NCT04142125|Drug|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
79713501|NCT04133194|Drug|Mesalazine|1600 mg Asacol [mesalazine]
79713502|NCT04133194|Drug|Mesalazine|800 mg Asacol [mesalazine]
79713503|NCT04123379|Drug|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
79713504|NCT04123379|Drug|BMS-813160|300mg oral twice a day for 28 days
79713505|NCT04123379|Drug|BMS-986253|2400mg once by injection
79713506|NCT04122183|Other|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
80017291|NCT02101866|Drug|Vapendavir 132 mg capsules|2 capsules - single dose
80017292|NCT02625441|Drug|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
80017293|NCT02625441|Drug|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
79254182|NCT03350906|Diagnostic Test|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
79254183|NCT03342079|Drug|Local Anesthetics,Topical|topical anesthetic
79254184|NCT03342079|Drug|Nitrous Oxide|inhaled nitrous oxide
79254185|NCT03342079|Drug|Placebos|placebo topical anesthetic
79739827|NCT01007838|Other|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
79739828|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
79549998|NCT01579851|Drug|Sugammadex|"sugammadex~4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~2 mg/kg : if there is at least two responses to Train of Four stimulations"
79549999|NCT01584453|Drug|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
79550000|NCT01584453|Drug|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
79550001|NCT01584713|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
79550002|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
79713508|NCT04104360|Dietary Supplement|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
79713509|NCT04104360|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
79851225|NCT04322435|Other|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~In the morning on an empty stomach, every first week of each month for 12 months.~In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
79851226|NCT00947934|Device|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
79394165|NCT05799235|Device|Telerehabilitation TAR program using a mobile application|Participants in this study arm will use a mobile application which allows participants to perform their home exercises with real-time feedback given, allowing for proper execution of exercises, on top of standard care.
79394166|NCT05799235|Other|Standard rehabilitation sessions|Participants in this control group will attend standard in person rehabilitation sessions with home exercise program given as per standard care.
79394167|NCT05799222|Dietary Supplement|Bariatrix Meal Replacement Products|Meal replacement products offered through the Massachusetts General Hospital Weight Center.
79394168|NCT05799196|Procedure|Microfracture|Microfracture was made in the non-weight bearing chondral to provide the release of MSC and growth factor.
79394169|NCT05799170|Other|regional trauma care|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
79550003|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
79550004|NCT01584921|Drug|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
79550005|NCT01585493|Other|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
79550006|NCT01585493|Behavioral|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
79713510|NCT04103567|Other|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
79713511|NCT04101630|Behavioral|Activity Monitoring|Monitoring with FitBit
79713512|NCT04101539|Device|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
79713513|NCT04101539|Device|Standard PVI|Standard PVI for AF.
79713514|NCT04095598|Diagnostic Test|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
79851227|NCT00719381|Drug|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
79851228|NCT00897416|Other|laboratory biomarker analysis|
80017294|NCT02104362|Radiation|exclusive single-fraction irradiation|
79550007|NCT01585493|Behavioral|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
79550008|NCT01585662|Procedure|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
79550009|NCT01586013|Drug|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
79851229|NCT01022086|Procedure|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
79851230|NCT01022086|Biological|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
79851231|NCT05673161|Other|iron|iron treatment
79851232|NCT00897494|Genetic|protein expression analysis|Venous blood collection
79851233|NCT00897494|Other|laboratory biomarker analysis|Venous blood collection
79394170|NCT05799131|Device|QBX (5F/6F) Peripheral Balloon Expandable Stent System|"The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths."
79550010|NCT01586221|Other|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
79394171|NCT05799053|Drug|Small intestinal release peppermint oil|Tempocol®, a gastric acid resistant (enteric-coated) capsule containing 182mg of Menthae Piperitae Aetheroleum (peppermint oil), is currently registered as an over the counter prescription drug on the Dutch market for treatment of abdominal pain, discomfort or flatulence.
79713515|NCT04095260|Other|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
79713516|NCT04091438|Drug|TAK-925|TAK-925 IV infusion.
79851234|NCT00897494|Other|mass spectrometry|Venous blood collection
79713517|NCT04091438|Drug|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
79851235|NCT00897494|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
79851236|NCT00952224|Other|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
79851237|NCT00510783|Drug|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
79394172|NCT05799053|Drug|Peppermint sweets|Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.
79394173|NCT05799053|Drug|Placebo|Capsule containing microcrystalline cellulose
79394174|NCT05799040|Device|Self-developed pulmonary lobar ventilation detector|The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
79394175|NCT05799040|Device|Chartis detection system|The participants would evaluated by the Chartis detection system.
79394176|NCT05799027|Diagnostic Test|Raman spectrum|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
79394177|NCT05799014|Procedure|CT-guided percutaneous lung biopsy|The participants would undergo CT-guided percutaneous lung biopsy.
79550011|NCT01586273|Device|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
79713518|NCT04084769|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
79713519|NCT04084769|Biological|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
79713520|NCT04084769|Biological|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
80017295|NCT04303468|Dietary Supplement|GABA|The dietary supplement GABA will be taken orally 3 times daily, before each main meal
79550012|NCT01586676|Behavioral|SAU|Supervision-as-usual
79550013|NCT01586676|Behavioral|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
79550014|NCT01586689|Behavioral|Oxford House|community-based recovery home for participants recovering from substance dependency
79550015|NCT01586689|Behavioral|Safe Haven|professionally-staffed treatment facility
79713521|NCT04068311|Other|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
79851238|NCT00510783|Drug|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
79394178|NCT05799014|Procedure|Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology|The participants would undergo percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.
79394179|NCT05798988|Behavioral|Neurophysiology-based exercise program|Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
79394180|NCT05798949|Behavioral|Chronic pain rehabilitation: exposure in vivo|Behavioral, chronic pain rehabilitation therapy
79394181|NCT05798949|Behavioral|Chronic pain rehabilitation: graded activity|Behavioral, chronic pain rehabilitation therapy
79394182|NCT05798949|Behavioral|Chronic pain rehabilitation: acceptance and commitment therapy|Behavioral, chronic pain rehabilitation therapy
79550016|NCT01586689|Behavioral|Usual aftercare|control group - participants may or may not seek treatment on their own
79713522|NCT04059224|Drug|Trametinib|Trametinib 2 mg once a day by mouth.
79713523|NCT04059224|Drug|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
79394183|NCT05798936|Drug|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
79394184|NCT05798936|Drug|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
79550017|NCT01586702|Behavioral|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~Measurement of risk factors~Assessment of medication intake~Monitoring of antithrombotic therapy~Joint agreement of an individual target plan~Target values for risk factors:~Blood pressure < 140/85 mmHg (<130/80 in diabetics), normal circadian profile~HbA1c <7.5%~Nicotine abstinence~LDL < 100mg/dl (< 70mg/dl in high risk patients)~Physical activity ≥ 30min >2 x / week~Targets for pharmaceutical treatment:~Platelet inhibitors for strokes / TIA of arterial etiology~Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~Cumarins (INR 2-3) or new oral anticoagulants in AF patients~Statin treatment in patients with LDL >100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
79550018|NCT01586715|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
79713524|NCT04045210|Other|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
79851239|NCT00510783|Drug|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
79851240|NCT02540252|Other|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
79394185|NCT05798910|Other|ALS VR (VR based serious gaming module for advanced life support training)|Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
79851241|NCT00952302|Drug|Iron sucrose|Single intravenous infusion of iron 200 mg
79394186|NCT05798910|Other|Lecture based training for advanced life support|Taking part in a classical lecture about advanced life support.
79394187|NCT05798897|Drug|MT-601|Multi-antigen specific CD4+ andCD8+ T cells
79404286|NCT04405687|Procedure|Severe head and face deformity reconstructive surgery|Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
79550019|NCT01586780|Dietary Supplement|Protein drink|Test drink providing 9g protein
79550020|NCT01586780|Dietary Supplement|Reference meal|Control meal
79550021|NCT01586793|Device|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
79550022|NCT01586793|Device|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
79550023|NCT01586845|Drug|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
79550024|NCT01586845|Drug|tacrolimus|tacrolimus as per labeled dose
79713525|NCT04013685|Biological|Orca-T (formerly TregGraft)|engineered donor allograft
79713526|NCT04002518|Device|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
79851242|NCT00952302|Drug|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
79851243|NCT00952302|Procedure|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
79851244|NCT00952302|Drug|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
79851245|NCT00952302|Drug|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
79254186|NCT03333356|Radiation|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
79254187|NCT03332017|Drug|Zanubrutinib|BGB-3111 will be administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
79550025|NCT01586884|Procedure|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
79851246|NCT00897650|Genetic|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
79851247|NCT00897650|Genetic|Protein expression analysis|Lung tumor tissue will be collected.
79851248|NCT00897650|Procedure|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
79851249|NCT00897650|Procedure|Blood sample|Patients will be asked for a venous blood sample
79254188|NCT03332017|Drug|Obinutuzumab|Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks. 1 cycle = 28 days.
79254189|NCT03327961|Device|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
79254190|NCT03319628|Drug|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
79713527|NCT03994861|Diagnostic Test|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
79713528|NCT03958903|Device|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
79254191|NCT03311074|Genetic|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
79254192|NCT03277170|Drug|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
79254193|NCT03253744|Drug|18F-DCFPyL|Participants will receive 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
79254194|NCT03253744|Radiation|Tumor Irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.
79254195|NCT03253744|Radiation|Prostate + tumor irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.
79254196|NCT03253744|Radiation|Tumor Irradiation|External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.
79394188|NCT05798884|Device|Acupuncture|Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
79550026|NCT01586949|Behavioral|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
79713529|NCT03958903|Behavioral|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
79851250|NCT05300646|Behavioral|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
79851251|NCT00897728|Other|laboratory biomarker analysis|
79851252|NCT00518973|Drug|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
79875246|NCT00490646|Drug|docetaxel|Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
79394189|NCT05798884|Device|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
79550027|NCT01586988|Behavioral|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
79254197|NCT03232203|Drug|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
79713530|NCT03940508|Behavioral|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
79713531|NCT03940508|Behavioral|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
79394190|NCT05798871|Procedure|Subgingival erythritol air polishing|"The intervention will start with supragingival debridement followed by subgingival erythritol air polishing by perioflow.~subgingival debridement"
79713532|NCT03918850|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
79713533|NCT03918850|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
79713534|NCT03916978|Biological|Autologous PRP intra ovarian infusion|Autologous PRP intra ovarian infusion
79394191|NCT05798871|Procedure|Conventional root planing|The intervention will start with supragingival debridement followed by root planing by curette.
79713535|NCT03916978|Biological|Autologous PFP intra ovarian infusion|Autologous PFP intra ovarian infusion
79851253|NCT00518973|Drug|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
79851254|NCT05300334|Diagnostic Test|adenosine deaminase test|adenosine deaminase deficiency test
79851255|NCT00897806|Genetic|Microarray analysis|
79550028|NCT01587248|Device|Harmonic|Dissection with harmonic scalpel
79394192|NCT05798858|Diagnostic Test|NIPT|universal nipt in group a, NIPT for intermediate risk in Group B
79713536|NCT03914170|Drug|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
79550029|NCT01587248|Procedure|electrocautery|Dissection in modified radical mastectomy
79851256|NCT00897806|Other|Laboratory biomarker analysis|
79394193|NCT05798845|Radiation|SBRT+LDRT|primary tumor SBRT, DT: 24Gy/3Fx, d1-3, d22-24; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles)
79550030|NCT01587339|Drug|retigabine/ezogabine|oral - all doses
79550031|NCT01587339|Drug|lacosamide|oral - all doses
79550032|NCT01587339|Drug|zonisamide|oral - all doses
79550033|NCT01587339|Drug|pregabalin|oral - all doses
79550034|NCT01587339|Drug|eslicarbazepine|oral - all doses
79713537|NCT03911739|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
79713538|NCT03911739|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
79713539|NCT03902080|Drug|Vibegron|oral administration
79713540|NCT03902080|Drug|Placebo|oral administration
79851257|NCT00958152|Drug|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
79713541|NCT03890367|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
79713542|NCT03890367|Biological|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
79713543|NCT03890367|Biological|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79739829|NCT01007838|Other|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
79851258|NCT00958152|Drug|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
79254198|NCT03214601|Device|penetrating atherosclerotic ulcer, aorta branch cardiovascular implant|The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
79254199|NCT03200834|Procedure|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
79394194|NCT05798845|Drug|Toripalimab|toripalimab 240mg ivgtt d5, d26 (2 cycles)
79394195|NCT05798845|Drug|Chemotherapy drug|Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
79394196|NCT05798845|Drug|Toripalimab|toripalimab 240mg ivgtt d1, d22 (2 cycles)
79394197|NCT05798832|Other|Virtually reality training group|BLS Training with VR
79550035|NCT01587378|Drug|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
79851259|NCT00958152|Drug|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
79851260|NCT00958152|Drug|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
79851261|NCT00897884|Drug|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
79550036|NCT01587378|Drug|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
79550037|NCT01587417|Drug|Placebo to BI 187004 CL|1 single dose per subject as oral solution
79550038|NCT01587417|Drug|BI 187004 CL|1 single dose per subject as oral solution
79739830|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
79851262|NCT00958230|Device|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
79851263|NCT01022164|Procedure|fibrin glue|
79851264|NCT01012401|Other|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
79851265|NCT00897962|Other|Healthy Controls|One blood draw (2 teaspoons)
79851266|NCT00897962|Other|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
79851267|NCT00897962|Other|Non-cancer medical illness|One blood draw (2 teaspoons)
79851268|NCT05300178|Procedure|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
79851269|NCT01012479|Drug|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
79851270|NCT04317287|Dietary Supplement|Cardio formulation|Tomato-based formulation with dietary supplement softgels
79851271|NCT04317287|Dietary Supplement|Placebo|Placebo softgels
79851272|NCT02541734|Drug|Gelofusine|Infusion of gelofusine
79851273|NCT02541734|Radiation|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
79851274|NCT02541734|Drug|Placebo|
79394198|NCT05798832|Other|Traditional training group|BLS Training with Traditional
79581023|NCT01931696|Device|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
79739831|NCT02686762|Drug|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
79739832|NCT02686762|Drug|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
79851275|NCT00952458|Device|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
79851276|NCT00898040|Genetic|polymorphism analysis|
79851277|NCT00462670|Drug|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
79851278|NCT01009593|Drug|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
79851279|NCT01009593|Drug|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
79851280|NCT00719459|Drug|Iron Sucrose|Venofer 20 mg/mL
79851281|NCT00719459|Drug|Iron Sucrose|Iron sucrose 20 mg/mL
79851282|NCT00898118|Genetic|polymerase chain reaction|
79851283|NCT00898118|Other|flow cytometry|
79394199|NCT05798819|Drug|GLS-010|IV infusion
79394200|NCT05798819|Drug|Placebo|IV infusion
79394201|NCT05798819|Drug|paclitaxel|IV infusion
79394202|NCT05798819|Drug|cisplatin|IV infusion
79394203|NCT05798819|Drug|carboplatin|IV infusion
79394204|NCT05798819|Drug|bevacizumab|IV infusion
79739833|NCT02686762|Drug|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
79851284|NCT00898118|Other|laboratory biomarker analysis|
79851285|NCT00898118|Procedure|allogeneic hematopoietic stem cell transplantation|
79851286|NCT00952536|Dietary Supplement|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule
79851287|NCT00952536|Dietary Supplement|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable & fruit & placebo capsule
79394205|NCT05798767|Behavioral|Neuropsychological tests|"Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium."
79739834|NCT02689336|Biological|Erlotinib|
79739835|NCT02689336|Drug|Temozolomide|
79713544|NCT03882268|Behavioral|MIYCN interventions|"Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A&T).~Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~Availability of standardized MIYCN-specific BCC materials and job aids.~Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A&T.~Dedicated community worker hired by A&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors."
79713545|NCT03877549|Drug|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
79713546|NCT03871673|Dietary Supplement|Sweet manioc starch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
79394206|NCT05798754|Procedure|Loss of resistance (LOR) technique|The thoracic epidural space will be identified by the loss of resistance (LOR) technique
79713547|NCT03871673|Dietary Supplement|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
79254200|NCT03200834|Procedure|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
79550039|NCT01587482|Procedure|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
79550040|NCT01587625|Drug|Oxytocin|
79713548|NCT03868124|Combination Product|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
79713549|NCT03868124|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
79713550|NCT03861923|Other|Dry needling|Trigger point dry needling to trigger points in the shoulder or parascapular muscles using monofilament needle (i.e., acupuncture needle). Clean needle approach using sterile needles.
79713551|NCT03861923|Other|Sham Dry Needling|Sham needle approach using a finishing nail in a tube sheath. The finishing nail will be placed over the trigger point so that the patient perceives a sharp sensation. The tube (not the nail) will be moved up and down to mimic the action of needling.
79713552|NCT03861923|Other|Therapeutic Exercise|Exercise including flexibility, range of motion, strengthening will be provided by the treating physical therapist based on the impairments identified.
79713553|NCT03833141|Other|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
79851288|NCT00952536|Dietary Supplement|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
79254201|NCT03199300|Drug|Anthracyclines|Chemotherapy regimen containing anthracyclines.
79254202|NCT03199300|Drug|Trastuzumab|Systemic treatment including trastuzumab.
79254203|NCT03199300|Drug|Cisplatin|Chemotherapy including cisplatin.
79550041|NCT01587820|Drug|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
79550042|NCT01587820|Drug|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
79550043|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
79851289|NCT01022320|Procedure|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
80017296|NCT04303468|Other|Placebo|Gelatin capsule containing powdered cellulose
79394207|NCT05798754|Device|CompuFlo® technology|The thoracic epidural space will be identified by the CompuFlo® technology
79394208|NCT05798728|Procedure|Outpatient transcervical foley balloon|These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.
79254204|NCT03199300|Drug|Bleomycin|Chemotherapy including bleomycin.
79394209|NCT05798728|Procedure|Inpatient Vaginal Misoprostol|These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
79394210|NCT05798715|Drug|Gleptomet 50/1000(Metformin HCl & Sitagliptin)|Test drug
79713554|NCT03824184|Procedure|manipulation of endometrium|Manipulation of endometrium with saline
79713555|NCT03803332|Behavioral|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
79254205|NCT03180086|Other|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
79254206|NCT03171844|Other|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
79550044|NCT01587846|Dietary Supplement|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
79550045|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
79550046|NCT01587846|Dietary Supplement|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
79713556|NCT03803332|Behavioral|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
79713557|NCT03752099|Drug|VERU-111|VERU-111
79713558|NCT03747458|Drug|OPN-375|OPN-375, BID
79713559|NCT03733249|Drug|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
80017297|NCT03555240|Other|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
79254207|NCT03134027|Procedure|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
79254208|NCT03134027|Procedure|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
79254209|NCT03121456|Other|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
79254210|NCT03121456|Other|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
79254211|NCT03104400|Drug|Adalimumab|Administered by subcutaneous injection
79254212|NCT03104400|Drug|Upadacitinib|Oral tablet
79254213|NCT03104400|Drug|Placebo to Upadacitinib|Oral tablet
79254214|NCT03104400|Drug|Placebo to Adalimumab|Administered by subcutaneous injection
79254215|NCT03092674|Drug|Azacitidine|Given SC or IV
79254216|NCT03092674|Drug|Cytarabine|Given IV
79713560|NCT03733249|Biological|rivogenlecleucel|donor T-cells modified with iCasp safety switch
79713561|NCT03720717|Drug|Baclofen 10mg|Baclofen administration pre-operatively
79713562|NCT03720717|Other|Placebo|Placebo administration
79713563|NCT03705078|Procedure|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
79254217|NCT03092674|Drug|Decitabine|Given IV
79254218|NCT03092674|Other|Laboratory Biomarker Analysis|Correlative studies
79254219|NCT03092674|Drug|Midostaurin|Given PO
79254220|NCT03092674|Biological|Nivolumab|Given IV
79254221|NCT03053453|Procedure|Spinal Surgery|TKA under standard of care spinal surgery.
79394211|NCT05798715|Drug|Janumet 50/1000(Metformin HCl & Sitagliptin)|Reference drug
79394212|NCT05796856|Device|repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)|crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.
79394213|NCT05796713|Other|Hydrocephalus|Interview
79394214|NCT05795608|Device|respiratory exercise with incentive spirometry|Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
79713564|NCT03705078|Procedure|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
79713565|NCT03704415|Procedure|Extended endoscopic sinus surgery|ESS of all sinuses
79713566|NCT03704415|Procedure|Limited endoscopic sinus surgery|Partial ethmoidectomy
79254222|NCT03053453|Device|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
79713567|NCT03701321|Drug|Bortezomib|Given SC
79713568|NCT03701321|Biological|Daratumumab|Given IV
79713569|NCT03701321|Drug|Dexamethasone|Given PO
79713570|NCT03701321|Drug|Venetoclax|Given PO
79713571|NCT03687710|Behavioral|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
79254223|NCT02999360|Behavioral|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
79254224|NCT02999360|Behavioral|Background Music|30 minutes background music only
79394215|NCT05795491|Device|Blue Light Emitting Diode Therapy|Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
79394216|NCT05795491|Drug|Azole Antifungal|Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
79394217|NCT05794490|Behavioral|Learning from excellence|Health care professionals´ experiences of learning from excellence in a hospital unit
79394218|NCT05794282|Procedure|the robot assisted total hip arthroplasty|the robot assisted total hip arthroplasty
79394219|NCT05794282|Procedure|the conventional total hip arthroplasty|the conventional total hip arthroplasty
79394220|NCT05791656|Device|Mectascrew-C|reconstruction of ACL or PCL rupture
79394221|NCT05788653|Procedure|Thiele Massage|Transvaginal Massage
79394222|NCT05788653|Procedure|Transverse Friction Massage|Transvaginal Massage
79394223|NCT05788627|Drug|Tap water|Oral lactulose in a dose of 30ml BD and tap water enema 1000ml BD
79394224|NCT05788627|Drug|Lactulose|Oral lactulose in a dose of 30ml BD and lactulose enema (300ml lactulose and 700ml water) in a dose of 1000ml BD.
79394225|NCT05787964|Procedure|Biological sample collection|Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
79394226|NCT05786833|Drug|Dexmedetomedine|Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.
79550047|NCT01587937|Other|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
79550048|NCT01588132|Drug|Anfibatide|"To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
79550049|NCT01588171|Drug|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
79550050|NCT01588171|Drug|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
79581024|NCT01931722|Dietary Supplement|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
79581025|NCT01931722|Behavioral|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
79581026|NCT01931748|Drug|MELSMON|
79581027|NCT01931748|Drug|UNCNT|
79581028|NCT01931761|Drug|[C14] selumetinib (oral)|Single oral administration [C14] 75mg
79581029|NCT01931787|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
79581030|NCT01931800|Biological|Sampling of blood|
79581031|NCT01931826|Procedure|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
79713572|NCT03678129|Drug|AZD7325_10|Single oral dose (10mg)
79713573|NCT03678129|Drug|AZD7325_20|Single oral dose (20mg)
79713574|NCT03678129|Drug|Placebo|Single oral dose placebo (capsule)
79713575|NCT03678129|Drug|Clobazam|Single dose (5mg)
79254225|NCT02999360|Behavioral|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
79581032|NCT01931826|Procedure|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
79581033|NCT01931917|Behavioral|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
79713576|NCT03661684|Drug|Prednisone|40 mg po q day of Prednisone for 3 days
79713577|NCT03620071|Other|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
79713578|NCT03620071|Other|Standard Care|Standard Clinical Care
79713579|NCT03585153|Other|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
79713580|NCT03561376|Drug|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
79713581|NCT03560037|Device|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
79713582|NCT03550443|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
79713583|NCT03550443|Drug|Placebo|Capsules containing an inert placebo
79254226|NCT02974998|Behavioral|Young Women's Health CoOp (YWHC)|Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
79254227|NCT02974998|Behavioral|Standard HTC|Participants received the standard HTC available in South Africa for this population.
79713584|NCT03536052|Device|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
79713585|NCT03520712|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
79713586|NCT03497637|Diagnostic Test|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
79713587|NCT03497637|Diagnostic Test|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
79713588|NCT03486938|Drug|Placebo Oral Tablet|Placebo oral tablet
79713589|NCT03486938|Drug|AGB101 220 mg tablet|220 mg AGB101 active compound
79713590|NCT03483844|Diagnostic Test|GE CT 750 HD|Low-dose dual-energy CT imaging
79713591|NCT03469271|Drug|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
79254228|NCT02974725|Drug|LXH254|LXH254 will be supplied as tablet for oral use.
79254229|NCT02974725|Drug|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
79254230|NCT02974725|Drug|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
79254231|NCT02974725|Drug|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
79254232|NCT02966756|Drug|Venetoclax|Tablet; Oral
79254233|NCT02938923|Drug|Testosterone|Topical testosterone gel 1%
79394227|NCT05786833|Drug|Ketofol|Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment. McFarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from half to 1 and 10 mg/kg/h from 1 to 2 hours.
79394228|NCT05786833|Drug|isotonic saline 0.9%|Patients will receive intravenous infusion of equivalent volume of isotonic saline 0.9%.
79394229|NCT05784883|Diagnostic Test|Echocardiography|A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.
79394230|NCT05783570|Biological|EU307 CAR-T Cell|"Dose to be administered: a single dose~IV administration~Dosing rate: To be administrated at a rate of approximately 2 mL/min"
79581034|NCT01931917|Behavioral|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
79581035|NCT01931930|Dietary Supplement|Perilla extract|
79713592|NCT03469271|Other|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
79254234|NCT02938923|Drug|Placebo gel|Inactive skin gel
79581036|NCT01931930|Dietary Supplement|Maltodextrin|
79581037|NCT01931943|Drug|selatinib ditosilate tablets|
79581038|NCT01931982|Drug|Victoza|
79581039|NCT01932021|Procedure|adipose tissue grafting|
79581040|NCT01932034|Device|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
79581041|NCT01932073|Device|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
79713593|NCT03469271|Drug|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
79713594|NCT03469271|Other|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
79254235|NCT02938923|Behavioral|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
79713595|NCT03469271|Device|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
79713596|NCT03458260|Drug|Pixantrone|6 cycles - dose = 80mg/m²
79254236|NCT02938923|Behavioral|Home exercise program|Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
79713597|NCT03458260|Other|Ifosfamide|6 cycles - 1500 mg/m2
79713598|NCT03458260|Other|Etoposide|6 cycles - 150 mg/m2
79713599|NCT03458260|Other|Rituximab|6 cycles - 375 mg/m2
79713600|NCT03458260|Procedure|Transplant|after 2 or 6 cycles
79713601|NCT03438188|Other|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
79713602|NCT03431467|Device|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
79713603|NCT03430921|Device|Enlighten™ Laser and a MLA Attachment|Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
79713604|NCT03425279|Biological|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
79713605|NCT03425279|Biological|PD-1 inhibitor|PD-1 inhibitor
79713606|NCT03381573|Drug|Roflumilast|Roflumilast
79713607|NCT03376672|Drug|Ixazomib|All patients will have similar induction and consolidation treatment with the same regimen.
79713608|NCT03376672|Drug|Lenalidomide|All patients will have similar induction and consolidation treatment with the same regimen.
79713609|NCT03376672|Drug|Dexamethasone|All patients will have similar induction and consolidation treatment with the same regimen.
79713610|NCT03357445|Other|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
79254237|NCT02938923|Behavioral|Health Education Modules|30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
79254238|NCT02938416|Device|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
79394231|NCT05780658|Behavioral|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
79394232|NCT05777135|Drug|Ringer Lactate prior to surgery and Propofol|Ringer Lactate prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
79713611|NCT03355209|Drug|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
79713612|NCT03355209|Drug|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
79713613|NCT03302234|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
79713614|NCT03302234|Biological|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
79713615|NCT03302234|Other|Placebo|Normal saline solution administered as an IV infusion Q6W
79394233|NCT05776849|Other|flipped classroom|Educational presentation, visuals and videos (her own video explaining episiotomy application and repair and other videos shared with the traditional group) prepared for the students on episiotomy were shared one week before the episiotomy application.
79394234|NCT05774392|Other|Observational|Observational
79394235|NCT05773742|Device|Low-volume irrigation|Qufora IrriSedo MiniGo
79713616|NCT03290937|Biological|Cetuximab|Given IV
79713617|NCT03290937|Drug|Irinotecan Hydrochloride|Given IV
79713618|NCT03290937|Other|Pharmacodynamic Study|Correlative studies
79713619|NCT03290937|Biological|Utomilumab|Given IV
79713620|NCT03272373|Device|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
79713621|NCT03272373|Device|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
79713622|NCT03247023|Device|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
79713623|NCT03245892|Drug|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
79713624|NCT03245892|Drug|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
79713625|NCT03245892|Procedure|Cytoreductive surgery|Cytoreductive surgery
79713626|NCT03245892|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
79713627|NCT03243591|Other|Livionex gel|Brushing area of mucositis with gel
79713628|NCT03243591|Other|Aquafresh gel|Aquafresh gel
79713629|NCT03228537|Drug|Atezolizumab|Given IV
79713630|NCT03228537|Drug|Cisplatin|Given IV
79550051|NCT01588210|Other|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
79550052|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
79550053|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
79713631|NCT03228537|Procedure|Extrapleural Pneumonectomy|Undergo EPP
79713632|NCT03228537|Drug|Pemetrexed Disodium|Given IV
79713633|NCT03228537|Procedure|Pleurectomy|Undergo PD
79713634|NCT03228537|Radiation|Radiation Therapy|Undergo RT
79713635|NCT03218137|Drug|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
79713636|NCT03217266|Drug|Navtemadlin|Given PO
79713637|NCT03217266|Radiation|Radiation Therapy|Undergo radiation therapy
79713639|NCT03202303|Drug|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
79713640|NCT03202303|Drug|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
79713641|NCT03161522|Drug|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
79713642|NCT03161522|Drug|Chemotherapy|Receive induction chemotherapy
79713643|NCT03161522|Procedure|Conventional Surgery|Undergo surgery
79713644|NCT03161522|Drug|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
79713645|NCT03161522|Radiation|Radiation Therapy|Undergo RT
79713646|NCT03160274|Genetic|Genetic screening|Germline and/or tumor samples will be screened for mutations
79713647|NCT03157102|Device|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher & Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
80017298|NCT04209868|Drug|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
80017299|NCT04209868|Drug|0.9% Sodium Chloride 20mL Injection|As per arm description
80017300|NCT03657225|Device|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
80017301|NCT03657225|Drug|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
80017302|NCT03554538|Behavioral|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
79713648|NCT03157102|Device|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
79713649|NCT03155100|Drug|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
79713650|NCT03155100|Drug|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
79713651|NCT03155100|Drug|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
79713652|NCT03126630|Biological|Anetumab Ravtansine|Given IV
79713653|NCT03126630|Other|Laboratory Biomarker Analysis|Correlative studies
79713654|NCT03126630|Biological|Pembrolizumab|Given IV
79713655|NCT03126630|Other|Pharmacological Study|Correlative studies
79713656|NCT03125720|Other|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
79713657|NCT03066908|Device|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
79713658|NCT03060473|Drug|Azithromycin|Azithromycin 1 gm PO once
80017303|NCT03554538|Behavioral|Exercise program|Exercise on an evidence based program for shoulder pain
79550054|NCT01588730|Device|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
79550055|NCT01588730|Procedure|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
79713659|NCT03060473|Drug|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
79550056|NCT01588873|Drug|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
79550057|NCT01589367|Drug|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
79713660|NCT03060473|Drug|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
79713661|NCT03060473|Drug|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
79713662|NCT03047213|Drug|Sapanisertib|Given PO
79713663|NCT03025386|Other|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
79713664|NCT03025386|Other|Electroencephalography|Mesure of the mismatch negativity wave
79713665|NCT02991625|Other|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
79713666|NCT02991625|Other|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
79713667|NCT02991625|Other|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
79713668|NCT02983578|Drug|Danvatirsen|Given IV
79713669|NCT02983578|Biological|Durvalumab|Given IV
79713670|NCT02949284|Drug|Abiraterone Acetate|Given PO
79713671|NCT02949284|Drug|Androgen Receptor Antagonist ARN-509|Given PO
79713672|NCT02949284|Biological|Gonadotropin-releasing Hormone Analog|Given SC
79713673|NCT02949284|Drug|Prednisone|Given PO
79713674|NCT02949284|Other|Quality-of-Life Assessment|Ancillary studies
79713675|NCT02949284|Other|Questionnaire Administration|Ancillary studies
79713676|NCT02949284|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
79713677|NCT02891954|Drug|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
79713678|NCT02860702|Other|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
79713679|NCT02860702|Other|Human/Bovine Milk|Bovine milk derived fortification
79713680|NCT02835313|Behavioral|FAST|Subjects participate in fast walking training 3x/week for 12 weeks.
79713681|NCT02835313|Behavioral|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
79713682|NCT02835313|Behavioral|SAM|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
79713683|NCT02766231|Device|Physica CR|Cruciate tretaining total knee replacement
79713684|NCT02766231|Device|Physica PS|Posterior Stabilized total knee replacement
79713685|NCT02754596|Drug|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
79713686|NCT02754596|Drug|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
79713687|NCT02754596|Drug|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
79713688|NCT02744898|Drug|Carboplatin AUC|
79713689|NCT02744898|Drug|Abraxane|100mg/m2
79713690|NCT02724540|Device|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
79713691|NCT02724540|Combination Product|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
79713692|NCT02724540|Combination Product|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
79713693|NCT02652195|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
79713694|NCT02652195|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
79713695|NCT02565225|Behavioral|RheumaLive App use|
79713696|NCT02425345|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
79713697|NCT02398773|Procedure|Computed Tomography|Undergo PET/CT
79713698|NCT02398773|Drug|F-18 16 Alpha-Fluoroestradiol|Given IV
79713699|NCT02398773|Other|Laboratory Biomarker Analysis|Correlative studies
79713700|NCT02398773|Procedure|Positron Emission Tomography|Undergo PET/CT
80017304|NCT04469738|Device|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
79550058|NCT01589367|Drug|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
79254239|NCT02938416|Device|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
79254240|NCT02938416|Behavioral|isometric strengthening exercise|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
79254241|NCT02932618|Biological|von Willebrand factor (Recombinant)|Lyophilized powder and solvent to prepare solution for injection.
79254242|NCT02932618|Biological|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
79550059|NCT01589432|Drug|ABT-639|two 50 mg oral capsules
79550060|NCT01589432|Drug|Placebo|2 placebo capsules
79550061|NCT01589432|Drug|Lidocaine|3mg/kg infusion over 30 minutes
79550062|NCT01589458|Drug|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
79550063|NCT01589614|Drug|PH-797804|Tablet, 6mg, single
79550064|NCT01589614|Drug|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
79550065|NCT01589718|Drug|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
79550066|NCT01589718|Drug|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
79550067|NCT01589757|Other|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
79550068|NCT01589757|Other|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
79713701|NCT02350764|Drug|nivolumab|
79713702|NCT02350764|Drug|pilimumab|
79550069|NCT01589796|Procedure|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
79550070|NCT01589861|Drug|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
79581042|NCT01932086|Dietary Supplement|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
79713703|NCT02095132|Drug|Adavosertib|Given PO
79713704|NCT02095132|Drug|Irinotecan Hydrochloride|Given PO
79713705|NCT01922388|Device|Bilateral deep brain stimulation of the subthalamic nucleus|
79713706|NCT01919086|Drug|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m^2, days 1, 8, 15 and 22
80017305|NCT04469738|Device|SCS is switched on|Spinal cord stimulator is functioning
80017306|NCT04281004|Biological|Amniotic Fluid (AFED)|One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days
79713707|NCT01919086|Drug|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
80017307|NCT04281004|Other|Saline Solution|One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
79713708|NCT01919086|Drug|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
79713709|NCT01908543|Drug|Ferrous sulphate 200mg oral tablet|Administration by mouth
79713710|NCT01867333|Biological|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
79713711|NCT01867333|Biological|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
79713712|NCT01867333|Biological|Enzalutamide|An androgen receptor inhibitor.
80017308|NCT03656991|Other|Bicycle intervention|
79254243|NCT02922764|Drug|RGX-104|
79254244|NCT02922764|Drug|Ipilimumab|
79254245|NCT02922764|Drug|Docetaxel|
79254246|NCT02922764|Drug|Pembrolizumab|
79254247|NCT02922764|Drug|Carboplatin|
79254248|NCT02922764|Drug|Pemetrexed|
79394236|NCT05771883|Drug|IMM0306|IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.
79394237|NCT05771883|Drug|Lenalidomide capsule|Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis
79394238|NCT05768256|Behavioral|Mindfulness-Based Cognitive-behavioral Therapy for Distress|Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.
79713713|NCT01833715|Drug|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
79851290|NCT00711503|Drug|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
79851291|NCT00711503|Drug|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
79713714|NCT01833715|Drug|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
79851292|NCT00948168|Drug|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
79851293|NCT00888212|Procedure|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
79851294|NCT00958386|Drug|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
79254249|NCT02919956|Other|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
79394239|NCT05767892|Drug|YK-209A tablet|YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
79394240|NCT05767892|Drug|Pemetrexed+carboplatin/Cisplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
79550071|NCT01589913|Behavioral|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~Introduction to participants and online system~Knowledge regarding ICDs~Strategies for behavior change~Psychological models for anxiety and depression~Strategies to cope with avoidance, anxiety and depression~Resume, evaluation, resolution of open questions, goal setting, good bye"
79550072|NCT01589965|Behavioral|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
79550073|NCT01589991|Drug|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
79550074|NCT01590030|Procedure|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
79550075|NCT01590043|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
79550076|NCT01590056|Other|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~listening to nonverbal affect bursts corresponding to emotions~applying a simple go-no-go auditory test"
79550077|NCT01590108|Drug|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
79550078|NCT01590108|Drug|Saline|Saline
79713715|NCT01833715|Drug|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
79713716|NCT01650701|Drug|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
79713717|NCT01650701|Drug|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
79713718|NCT01650701|Drug|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
79851295|NCT00711581|Device|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
79875247|NCT00490646|Drug|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
79875248|NCT01039311|Device|Optical Coherence Tomography|Obtain OCT images.
79254250|NCT02919956|Other|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
79254251|NCT02903290|Other|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|
79254252|NCT02903290|Other|walking track GAITRite,manual dynamometer, and treadmill|
79254253|NCT02878798|Drug|topiramate|Oral topiramate at a target dose of 50mg twice daily.
79394241|NCT05750355|Drug|TPN171H 10 mg Group|6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
79713719|NCT01650701|Drug|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
79394242|NCT05750355|Drug|TPN171H 30 mg Group|6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
79394243|NCT05750355|Drug|TPN171H 40 mg Group|6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
79713720|NCT01650701|Drug|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
79713721|NCT01534494|Drug|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
79394244|NCT05750355|Drug|TPN171H 50 mg Group|6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
79851296|NCT04035512|Other|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
79254254|NCT02878798|Other|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
79394245|NCT05741320|Other|questionnaire|27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
79394246|NCT05737433|Drug|[14C]-rencofilstat 225mg|radio-labelled 225mg oral dose of rencofilstat
79394247|NCT05730816|Drug|Magnesium sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
79394248|NCT05730816|Drug|Normal Saline|Intravenous infusion of normal saline.
79394249|NCT05728840|Other|Immersive virtual reality gamified cognitive activities|This intervention will include 20 sessions of training with the experimental rehabilitation program using immersive VR cognitive gamified activities, in addition to the standard of care.
79550079|NCT01590121|Other|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
79550080|NCT01590121|Other|Questionnaire|Flight by aeroplane (previous)
79550081|NCT01590134|Dietary Supplement|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
79550082|NCT01590134|Drug|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
79713722|NCT01428635|Drug|Eltrombopag Olamine|Given PO
79875249|NCT01039389|Drug|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
79875250|NCT01039389|Drug|Placebo|bid placebo
79254255|NCT02854436|Drug|Niraparib|Participants will receive 300 mg niraparib (3 capsules*100 mg) orally once daily.
79254256|NCT02845323|Drug|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
79254257|NCT02845323|Drug|Nivolumab monotherapy|Two cycles of Nivolumab alone
79254258|NCT02826434|Biological|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
79254259|NCT02826434|Biological|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
79254260|NCT02826434|Drug|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
79254261|NCT02824731|Radiation|Radiation with protons|
79550083|NCT01590147|Procedure|Yoga therapy|receive YST
79550084|NCT01590147|Other|questionnaire administration|Ancillary studies
79550085|NCT01590147|Procedure|quality-of-life assessment|Ancillary studies
79550086|NCT01590147|Other|laboratory biomarker analysis|Correlative studies
79254262|NCT02824731|Radiation|Radiation with photons|
79254263|NCT02819141|Drug|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
79254264|NCT02741193|Device|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
79550087|NCT01590147|Other|assessment of therapy complications|Ancillary studies
79550088|NCT01590147|Procedure|management of therapy complications|Receive YST or CE
79550089|NCT01590147|Other|educational intervention|Receive CE
79550090|NCT01590160|Drug|Ganetespib|IV, Using dose from Phase I
79550091|NCT01590173|Drug|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
79581043|NCT01932086|Dietary Supplement|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
79713723|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
79713724|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
79713725|NCT01208389|Biological|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
79550092|NCT01590173|Drug|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
79713726|NCT00968500|Behavioral|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
79713727|NCT00856037|Drug|Doxorubicin Hydrochloride|Given IV
79713728|NCT00856037|Other|Laboratory Biomarker Analysis|Correlative studies
79713729|NCT00856037|Other|Quality-of-Life Assessment|Ancillary studies
79713730|NCT00856037|Drug|Topotecan Hydrochloride|Given PO
79713731|NCT00788671|Other|Laboratory Biomarker Analysis|Correlative studies
79713732|NCT00788671|Device|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
79713733|NCT00788671|Other|Quality-of-Life Assessment|Ancillary studies
79254265|NCT02733003|Behavioral|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
79254266|NCT02729298|Drug|TP-0903|Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
79254267|NCT02726750|Procedure|Biospecimen Collection|Undergo collection of blood samples
79254268|NCT02726750|Other|Laboratory Biomarker Analysis|Correlative studies
79851297|NCT05352438|Other|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
79550093|NCT01590199|Drug|RAD001|
79713734|NCT00670852|Procedure|X-rays and CT scan|CT Scan x-rays
79875251|NCT04558827|Other|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
79550094|NCT01590199|Drug|SOM230|
79875252|NCT04558827|Other|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
79550095|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
79713735|NCT00602797|Drug|Paclitaxel|Given IV
79713736|NCT00602797|Other|Quality-of-Life Assessment|Ancillary studies
79713737|NCT00602797|Other|Questionnaire Administration|Ancillary studies
79254269|NCT02725177|Drug|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
79254270|NCT02725177|Drug|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
79254271|NCT02624596|Drug|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
79254272|NCT02624596|Drug|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
79254273|NCT02624128|Drug|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
79254274|NCT02624128|Drug|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
79254275|NCT02624128|Drug|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
79254276|NCT02621151|Biological|Pembrolizumab|
79254277|NCT02621151|Procedure|Transurethral Resection of Bladder Tumor|
79254278|NCT02621151|Drug|Gemcitabine|
79713738|NCT00602797|Drug|Vinorelbine Tartrate|Given IV
79713739|NCT00550615|Drug|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
79550096|NCT01590225|Drug|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 24 weeks.
79713740|NCT00550615|Drug|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
79713741|NCT00471848|Drug|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
79713742|NCT00006721|Biological|rituximab|Given IV
79713743|NCT00006721|Drug|cyclophosphamide|Given IV
79550097|NCT01590225|Drug|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 24 weeks.
79550098|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
79713744|NCT00006721|Drug|doxorubicin|Given IV
79713745|NCT00006721|Drug|prednisone|Given orally
79254279|NCT02621151|Radiation|External Beam Radiation Therapy|
79550099|NCT01590225|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 48 weeks.
79713746|NCT00006721|Drug|vincristine|Given IV
79713747|NCT00006721|Radiation|tositumomab|Given IV
79851298|NCT05352438|Other|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
79254280|NCT02579083|Drug|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
79394250|NCT05728840|Other|Double neuropsychological standard activities|This intervention will include 20 sessions of training using a standard neuropsychological rehabilitation program, in addition to the standard of care.
79394251|NCT05727345|Procedure|Interscalene brachial plexus block|Preoperative ultrasound-guided interscalene brachial plexus block application
79394252|NCT05727345|Procedure|Shoulder anterior capsular block|Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
79550100|NCT01590225|Drug|Ribavirin|"Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 48 weeks."
79550101|NCT01590251|Other|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
79713748|NCT04300582|Procedure|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
79713749|NCT04300582|Procedure|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
79713750|NCT05296876|Procedure|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
79713751|NCT02873260|Biological|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^4.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
79851299|NCT04069871|Device|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
79851300|NCT04069871|Device|Sham TENS|Patients in the control group will receive sham TENS.
79713752|NCT02873260|Biological|rDEN3Δ30|Administered at a dose of 10^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
79713753|NCT02873260|Biological|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
79713754|NCT01030666|Drug|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
79713755|NCT01030666|Drug|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
79851301|NCT04035746|Other|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
79713756|NCT01030666|Procedure|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
79254281|NCT02579083|Drug|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
79254282|NCT02578368|Drug|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
79254283|NCT02578368|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
79254284|NCT02578368|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
79254285|NCT02578368|Drug|Docetaxel|50mg/m², d1, i.v., every 2 weeks
79254286|NCT02578368|Drug|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
79550102|NCT01590251|Behavioral|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
79550103|NCT01590290|Other|financial compensation|financial monetary reimbursement
79713757|NCT01030666|Biological|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
79550104|NCT01590303|Drug|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
79550105|NCT01590303|Drug|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
79851302|NCT00948324|Drug|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
79394254|NCT05721677|Device|2-octyl cyanoacrylate based topical skin adhesive|Tissue adhesive on CVL exit-site
79550106|NCT01590316|Device|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
79550107|NCT01590329|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
79550108|NCT01590342|Drug|Diclofenac|Diclofenac 75 mg, two doses
79550109|NCT01590342|Drug|Placebo|Placebo, two doses
79550110|NCT01590368|Device|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
79550111|NCT01590368|Device|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
79550112|NCT01590407|Drug|ALS-002200|ALS-002200
79713758|NCT01030666|Drug|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
79851303|NCT01012635|Other|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
79851304|NCT01012635|Other|Meditation|"Meditation: focus on a single word (one) for the entire session."
79394255|NCT05707611|Other|Running|The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
79550113|NCT01590407|Drug|Placebo|Placebo
79713759|NCT01030666|Drug|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
79713760|NCT01030666|Drug|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
79713761|NCT01025752|Behavioral|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
79713762|NCT01025752|Behavioral|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
79713763|NCT01030198|Device|RevLite (Laser Treatment)|
79713764|NCT02873884|Behavioral|Case-management|
79394256|NCT05707611|Other|Cycling|The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
79394257|NCT05707611|Other|Swimming|The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
79394258|NCT05707403|Drug|BI 1015550|Treatment T
79394259|NCT05707403|Drug|BI 1015550 mixed with [C-14]-BI 1015550|Treatment R
79550114|NCT01590420|Device|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
79550115|NCT01590446|Drug|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
79550116|NCT01590446|Drug|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
79550117|NCT01590485|Other|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
79550118|NCT01590485|Other|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
79550119|NCT01590524|Behavioral|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
79550120|NCT01590537|Drug|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
79550121|NCT01590537|Device|Copper IUD|Copper device, inserted intrauterine
79550122|NCT01590615|Drug|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
79550123|NCT01590641|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
79713765|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
79713766|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
79550124|NCT01590641|Drug|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
79713767|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
79713768|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
79713769|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
79713770|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
79394260|NCT05705765|Other|Suspension training|Training with suspension devices. 12 sessions of 40-45 min in four weeks.
79550125|NCT01590654|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
79550126|NCT01590654|Drug|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
79713771|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
79713772|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
79713773|NCT01301456|Biological|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
79713774|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
79394261|NCT05705765|Other|Instability training|Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
79394262|NCT05702333|Drug|Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan|Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
79394263|NCT05691205|Other|PEEP|After a recruitment maneuver three levels of PEEP (14>10>6cmH2O) will be tested
79394264|NCT05690958|Other|Survey|Filling in a survey
79394265|NCT05682989|Procedure|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
79404287|NCT03581539|Procedure|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
79550127|NCT01590667|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
79550128|NCT01590667|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
79550129|NCT01590693|Drug|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
79550130|NCT01590732|Drug|Carboplatin|Given IV
79550131|NCT01590732|Drug|Etoposide|Given IV
79550132|NCT01590732|Drug|Ifosfamide|Given IV
79713775|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
79713776|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
79713777|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
79713778|NCT01023256|Drug|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
79550133|NCT01590732|Drug|Romidepsin|Given IV
79713779|NCT01023256|Drug|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
79713780|NCT01023256|Drug|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
79713781|NCT04303936|Device|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
79713782|NCT04286620|Device|LASIK|Correcting errors of refraction
79713783|NCT01023022|Other|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
79713784|NCT04324424|Drug|HMS5552|single dose of HMS5552 25mg
79713785|NCT00627718|Device|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
79713786|NCT02873182|Device|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
79713787|NCT04324736|Other|no interventional study|no interventional study
79713788|NCT05643326|Device|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
79713789|NCT05643326|Device|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
79713790|NCT05367674|Behavioral|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
79713791|NCT05367674|Behavioral|My Summer Plate (MSP)|My Summer Plate (MSP)
79713792|NCT01058668|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
79254287|NCT02578368|Drug|sodium folinate|can be used to replace leucovorin (calcium folinate)
79254288|NCT02578368|Procedure|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
79394266|NCT05682989|Procedure|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
79550134|NCT01590745|Device|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
79394267|NCT05682989|Procedure|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
79550135|NCT01590823|Drug|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
79550136|NCT01590836|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
79550137|NCT01590836|Drug|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
79550138|NCT01590849|Drug|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
79550139|NCT01590901|Drug|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
79550140|NCT01590914|Procedure|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
79550141|NCT01590914|Procedure|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
79550142|NCT01590940|Procedure|Open inguinal hernia repair with mesh|
79550143|NCT01590966|Drug|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
79550144|NCT01590966|Drug|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
79550145|NCT01590992|Behavioral|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
79550146|NCT01590992|Behavioral|Relaxation therapy|Progressive muscle relaxation (Jacobson)
79550147|NCT01591031|Drug|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
79550148|NCT01591031|Drug|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
79713793|NCT01058668|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
79254289|NCT02570542|Procedure|leukapheresis|
79254290|NCT02570542|Drug|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
79394268|NCT05671913|Drug|Ketamine|Treatment arm
79394269|NCT05671913|Drug|Placebo|Control arm
79550149|NCT01591057|Dietary Supplement|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
79713794|NCT00623558|Drug|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
79713795|NCT00623558|Drug|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
79713796|NCT00623558|Drug|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
79713797|NCT01301066|Drug|Pitavastatin|Pitavastatin 4 mg QD
79254291|NCT02570542|Drug|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
79254292|NCT02570542|Procedure|Autologous Stem Cell Transplantation|
79713798|NCT01301066|Drug|Pravastatin|Pravastatin 40 mg QD
79713799|NCT01022398|Drug|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
79713800|NCT05642624|Drug|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
79713801|NCT05642546|Drug|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
79394270|NCT05671198|Diagnostic Test|Ultrasound of the diaphragm|"Sonographic parameters of the diaphragm:~Thickening Fraction (TF); (Diaphragm thickness end-inspiration- Diaphragm thickness end-expiration) / Diaphragm thickness end-expiration. (continuous variable).~Diaphragm end-expiratory thickness: Diaphragm thickness at end-expiration (continuous variable)~Diaphragm excursion (DE): diaphragm inspiratory amplitude during deep breathing (continuous variable)."
79394271|NCT05668936|Drug|Cotadutide|Participants will receive a subcutaneous injection of cotadutide.
79550150|NCT01591057|Dietary Supplement|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
79550151|NCT01591057|Dietary Supplement|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
79550152|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
79713802|NCT05642546|Drug|Placebo|Saline Placebo
79713803|NCT05642390|Device|Breast implant|Patients operated for breast augmentation or reconstruction.
79713804|NCT04324346|Drug|FEC75 (or EC90) x 6|Type of Chemotherapy
79713805|NCT04324346|Drug|FEC100 + Taxotere (EC90 + Taxotere) 3+3|Type of Chemotherapy
79713806|NCT04324346|Drug|Paclitaxel|Type of Chemotherapy
79713807|NCT05642234|Procedure|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
79713808|NCT04300114|Drug|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
79713809|NCT04300114|Drug|Placebo|Placebo capsules po. twice daily
79713810|NCT02890238|Drug|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
79254293|NCT02560428|Behavioral|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
79254294|NCT02557464|Behavioral|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
79254295|NCT02557464|Behavioral|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
79254296|NCT02518243|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~aromatherapy~music therapy~cognitive training in multimedia application offering cognitive games"
79394272|NCT05668936|Drug|Cotadutide-placebo|Participants will receive a subcutaneous injection of cotadutide-placebo.
79394273|NCT05668936|Drug|Moxifloxacin|Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
79713811|NCT02890238|Drug|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
79394274|NCT05668936|Drug|Moxifloxacin-placebo|Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
79550153|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
79713812|NCT02890238|Drug|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
79550154|NCT01591083|Drug|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score >=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score <6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
79713813|NCT00627796|Drug|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
79713814|NCT05640206|Procedure|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
79713815|NCT05640206|Procedure|Arthrocentesis|Arthrocentesis performed with two-needle technique
79713816|NCT05639582|Other|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
79713817|NCT01262976|Biological|GSK's investigational vaccine 692342|Intramuscular, 2 doses
79713818|NCT01262976|Biological|Physiological saline|Intramuscular, 2 doses
79713819|NCT01300286|Drug|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
79713820|NCT05616728|Drug|EDP-235|capsule
79713821|NCT05616728|Drug|Placebo|capsule
79713822|NCT02890316|Other|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
79713823|NCT02890316|Radiation|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
79713824|NCT01300052|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
79713825|NCT01300052|Drug|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
79713826|NCT01299896|Other|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
79713827|NCT01299896|Other|Usual Care|Standard therapy to help participants with smoking cessation.
79713828|NCT01299584|Drug|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
79550155|NCT01591122|Drug|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
79713829|NCT00637208|Procedure|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
79713830|NCT01236573|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
79851305|NCT01012635|Other|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
79394275|NCT05657990|Drug|Tamsulosin|Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
79394276|NCT05655741|Other|Questionnaire|"Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round."
79851306|NCT01012635|Other|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
79851307|NCT04068701|Other|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
79851308|NCT05352360|Diagnostic Test|Pilates Exercises|Exercises with Kinesio Taping
79851309|NCT05352360|Diagnostic Test|Muscle Energy Technique|Exercises with Kinesio Taping
79851310|NCT02573285|Procedure|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
79394277|NCT05650203|Drug|JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006|"JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w)."
79394282|NCT05599568|Other|Exercise|Either concentric or excentric exercise
79550156|NCT01591122|Drug|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
79550157|NCT01591135|Drug|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
79550158|NCT01591135|Drug|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
79550159|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
79713831|NCT01236573|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
79851311|NCT02573285|Procedure|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
79550160|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
79713832|NCT01236573|Biological|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
79851312|NCT01009671|Drug|ART 44|
79851313|NCT01009671|Drug|ART 50|
79851314|NCT04199988|Diagnostic Test|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
80017309|NCT02106312|Radiation|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
80017310|NCT04469816|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
79550161|NCT01591148|Drug|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
79550162|NCT01591187|Other|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
79550163|NCT01591187|Other|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
79550164|NCT01591187|Other|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
79550165|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
79550166|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
79550167|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
79550168|NCT01591226|Dietary Supplement|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
80017311|NCT04469816|Other|Services as Usual|Services/Treatment as usual.
80017312|NCT03841864|Other|IV placement using ultrasound guidance vs traditional method|Ultrasound guided IV placement
79550169|NCT01591226|Dietary Supplement|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
80017313|NCT02361801|Drug|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
79254297|NCT02498665|Drug|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
79254298|NCT02488759|Drug|Nivolumab|
79550170|NCT01591226|Dietary Supplement|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
79254299|NCT02488759|Drug|Ipilimumab|
79550171|NCT01591226|Dietary Supplement|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
79550172|NCT01591265|Procedure|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
79550173|NCT01591265|Procedure|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
79254300|NCT02488759|Drug|Relatlimab|
79254301|NCT02488759|Drug|Daratumumab|
79254302|NCT02483247|Drug|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
79254303|NCT02483247|Drug|Capecitabine|Capecitabine 1000 mg/m^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
79254304|NCT02483247|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 body surface area is administered intravenously once every three weeks (21-days).
79254305|NCT02483247|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
79254306|NCT02483247|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
79394283|NCT05590676|Drug|Metformin Hydrochloride|"Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg."
79394284|NCT05590390|Diagnostic Test|DXA|bone densitometry at lumbar and femoral site+ morphometry (DXA),
79394285|NCT05590390|Diagnostic Test|serum sample|serum samples for bone biomarkers ( eg. P1NP, CTX, Dkk-1, etc)
79394286|NCT05590390|Diagnostic Test|PROs|questionnaires to investigate patients reported outcome on quality of life
79404288|NCT03581539|Procedure|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
79550174|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
79550175|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
79550176|NCT01591304|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
79550177|NCT01591343|Biological|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
79550178|NCT01591395|Procedure|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
79394287|NCT05587686|Other|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
79713833|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
79254307|NCT02483247|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
79254308|NCT02483247|Drug|Sunitinib|Sunitinib 37.5 mg is administered once daily.
79254309|NCT02467361|Drug|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
79394288|NCT05585983|Biological|Vaxigrip Tetra Sanofi Pasteur Europe|We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
79394289|NCT05583539|Diagnostic Test|Thromboelastography|Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
79394290|NCT05571150|Behavioral|Dyad-focused strategy training intervention|"The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
79394291|NCT05571150|Behavioral|Attention-control intervention|The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
79394292|NCT05565391|Drug|Elranatamab|BCMA-CD3 bispecific antibody
79394293|NCT05565391|Drug|Standard of care|Standard of care
79394294|NCT05563441|Procedure|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
79394295|NCT05559814|Drug|Intraluminal peppermint oil|Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
79394296|NCT05559814|Drug|Placebo|Intraluminal flushing of placebo solution through the scope during scope withdrawal
79394297|NCT05540938|Drug|Wangbi granules|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
79394298|NCT05540938|Drug|Wangbi granules simulant|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
79394299|NCT05522140|Behavioral|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
79394300|NCT05522140|Behavioral|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
79394301|NCT05520190|Behavioral|Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)|"The intervention will consist of 1 - 2 sessions. The first session is approximately 60 - 90 minutes and will be structured in 4 phases 1) subject's history of symptoms and current functioning, 2) their coping methods, 3) modification of treatment beliefs, 4) action planning. The interventionist will provide the subject with a list of resources for seeking treatment.~All subjects will be offered an optional second session with the interventionist. The second session will consist of a 60-minute appointment focused on providing practical assistance to identify available treatment options in the subject's area, scheduling treatment sessions, and problem-solving barriers to treatment."
79394302|NCT05492188|Behavioral|Operant Conditioning of Cutaneous Reflexes|This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
79550179|NCT01591434|Device|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
79550180|NCT01591434|Device|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
79254310|NCT02467361|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
79254311|NCT02467361|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
79254312|NCT02467361|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
79254313|NCT02466685|Drug|JNJ-18038683|JNJ-18038683 10-20 mg/day tablet for 8 weeks
79254314|NCT02466685|Drug|Placebo|placebo tablet daily
79254315|NCT02438085|Other|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
79550181|NCT01591525|Behavioral|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
79851315|NCT01009749|Behavioral|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
79550182|NCT01591525|Behavioral|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
79550183|NCT01591525|Behavioral|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
79550184|NCT01591551|Drug|Natalizumab (Tysabri)|300 mg IV every 4 weeks
79550185|NCT01591564|Behavioral|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
79550186|NCT01591590|Other|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
79550187|NCT01591590|Other|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
79550188|NCT01591590|Other|Blood samples (plasma preparation and CTC)|
79550189|NCT01591603|Procedure|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
79550190|NCT01591603|Procedure|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
79550191|NCT01591668|Drug|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
79550192|NCT01591668|Drug|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
79550193|NCT01591720|Behavioral|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
79550194|NCT01591759|Drug|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
79851316|NCT01009749|Behavioral|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
79254316|NCT02403843|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
79254317|NCT02369003|Procedure|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with PD undergoing deep brain stimulation (DBS) surgery.
79254318|NCT02368301|Drug|Elotuzumab in combination with Lenalidomide and Dexamethasone|Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
79550195|NCT01591759|Drug|Placebo|Placebo arm of single-blind study
79550196|NCT01591798|Procedure|Robotic surgery|Robotic assisted rectal resection
79550197|NCT01591798|Procedure|Laparoscopic surgery|Laparoscopic assisted rectal resection
79550198|NCT01591811|Radiation|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
79550199|NCT01591811|Radiation|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
79550200|NCT01591824|Other|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~general column.~lumbar muscles, and paraspinal muscles,~sacral decompression oscillatory~Opening by lateral vertebral lumbar rhythmic swing.~Balancing and pelvic decompression~Swing-lumbar vertebral rotation."
79550201|NCT01591824|Other|column exercise group|"paraspinal muscle stretching exercises~postural correction~mobilization exercises thoracic and lumbar~Motor control exercises"
79550202|NCT01591850|Drug|RO5093151|Single oral dose
79550203|NCT01591850|Drug|atazanavir|Multiple oral doses
79550204|NCT01591850|Drug|ketoconazole|Multiple oral doses
79550205|NCT01591850|Drug|rifampicin|Multiple oral doses
79550206|NCT01591850|Drug|ritonavir|Multiple oral doses
79550207|NCT01591876|Other|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
79550208|NCT01591876|Other|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
79550209|NCT01591889|Drug|Tinidazole|500 mg tablet
79851317|NCT00719693|Drug|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
79851318|NCT00719693|Drug|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
79851319|NCT00952770|Procedure|transradial coronary intervention|percutaneous coronary intervention with transradial approach
79851320|NCT01009827|Other|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
79851321|NCT00719771|Device|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
79550210|NCT01591889|Drug|Tinidazole|500 mg tablet
79550211|NCT01591902|Drug|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
79550212|NCT01591902|Drug|Placebo-Control|3.0 mL vials
79550213|NCT01591915|Other|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
79550214|NCT01591941|Other|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
79550215|NCT01591967|Device|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
79550216|NCT01591980|Drug|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
79550217|NCT01591980|Drug|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
79550218|NCT01591980|Drug|placebo|Identical placebo capsules will be administered in the same way.
79550219|NCT01591993|Procedure|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
79550220|NCT01591993|Procedure|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
79550221|NCT01592019|Drug|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
79550222|NCT01592019|Device|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
79550223|NCT01592019|Drug|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
79713834|NCT01236339|Procedure|LVP|Large Volume Paracentesis
79713835|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
79851322|NCT00948402|Drug|Metformin|metformin 1250 mg three times daily
79851323|NCT00948402|Drug|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
79851324|NCT04068467|Other|Smartphone App|The application consists of content areas focused on mental health.
79851325|NCT04068467|Other|Waitlist Control|Waitlist control
79851326|NCT05352126|Other|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
79550224|NCT01592019|Device|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
79550225|NCT01592032|Drug|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
79713836|NCT01262898|Drug|GSK962040 (5 mg tablet)|5 mg tablet
79713837|NCT01262898|Drug|GSK962040 (25 mg tablet)|25 mg tablet
79713838|NCT01262898|Drug|GSK962040 (125 mg tablet)|125 mg tablet
79713839|NCT01262898|Drug|Placebo|matching placebo tablet
79713840|NCT01262820|Drug|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
79713841|NCT04323072|Procedure|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
79713842|NCT04323072|Procedure|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
79713843|NCT04323228|Dietary Supplement|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
79851327|NCT00719927|Behavioral|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
79851328|NCT00948480|Biological|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
79851329|NCT00948480|Drug|GM-CSF|500 mcg
79851330|NCT05351970|Procedure|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
79851331|NCT05351814|Other|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
79851332|NCT00606086|Drug|GI-5005|40YU, subcutaneous
79851333|NCT00606086|Drug|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
79851334|NCT02573363|Drug|Cytarabine|Given per standard of care
79851335|NCT02573363|Drug|Mitoxantrone Hydrochloride|Given per standard of care
79550226|NCT01592032|Drug|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
79550227|NCT01592032|Drug|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
79550228|NCT01592032|Drug|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
79713844|NCT04323228|Dietary Supplement|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
79713845|NCT04322916|Device|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
79713846|NCT04322760|Drug|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
79851336|NCT02573363|Drug|Selinexor|Given PO
79851337|NCT03727113|Procedure|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
79851338|NCT03727113|Procedure|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
79394303|NCT05489432|Behavioral|Exercise|A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
79394304|NCT05487326|Procedure|Erector spinae plane block|fascial plane injection guided by ultrasound guidance
79851339|NCT00715637|Drug|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
79851340|NCT00715637|Drug|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
79851341|NCT01012791|Other|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
79851342|NCT00953004|Dietary Supplement|fiber drink and fiber bread|fiber drink or fiber bread three times daily
79851343|NCT00953316|Other|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
79851344|NCT00898274|Other|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
79851345|NCT00898274|Other|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
79394305|NCT05487326|Procedure|cervical epidural injection|cervical epidural injection by fluoroscopy
79851346|NCT02541656|Procedure|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
79851347|NCT00898352|Procedure|regional lymph node dissection|
79851348|NCT00898352|Radiation|radiation therapy|
79394306|NCT05469646|Drug|BI 1819479|BI 1819479
79394307|NCT05469646|Drug|Matching placebo|Matching placebo
79394308|NCT05439824|Biological|SYS6006 20 μg|SARS-CoV-2 mRNA Vaccine
79713847|NCT04322760|Drug|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
79713848|NCT04322838|Diagnostic Test|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
79713849|NCT04322838|Diagnostic Test|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
79550229|NCT01592032|Drug|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
79550230|NCT01592123|Procedure|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
79550231|NCT01592123|Behavioral|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score >5 is considered to be suggestive of significant sleep disturbance.
79550232|NCT01592123|Behavioral|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
79550233|NCT01592123|Behavioral|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
79394309|NCT05439824|Biological|SYS6006 30 μg|SARS-CoV-2 mRNA Vaccine
79550234|NCT01592136|Drug|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
79550235|NCT01592149|Other|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
79550236|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
79550237|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
79550238|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
79550239|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
79550240|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
79550241|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
79550242|NCT01592162|Drug|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
79550243|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
79550244|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
79550245|NCT01592188|Behavioral|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
79550246|NCT01592188|Behavioral|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
79550247|NCT01592201|Drug|Paliperdidone ER|Form = osmotic release oral system, route = oral
79550248|NCT01592201|Drug|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
79550249|NCT01592214|Other|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
79581044|NCT01932086|Dietary Supplement|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
79713850|NCT04322838|Diagnostic Test|Skin Prick Test|Diagnostic skin test for sensitization to allergens
79851349|NCT05300490|Drug|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
79394310|NCT05439824|Biological|Placebo|Placebo
79394311|NCT05438420|Drug|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
79394312|NCT05438420|Biological|Pembrolizumab|Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
79394313|NCT05432232|Device|HistoSonics System|HistoSonics System: non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
79394314|NCT05402371|Drug|Rencofilstat|Rencofilstat soft gel capsule
79394315|NCT05402371|Drug|Placebo|placebo soft gel capsule
79394316|NCT05384795|Other|Lung ultrasound|Lung atelectasis score
79394317|NCT05382481|Diagnostic Test|Peak value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
79550250|NCT01592214|Drug|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
79550251|NCT01592214|Drug|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
79550252|NCT01592227|Drug|Marketed paracetamol|Marketed paracetamol
79550253|NCT01592227|Drug|Experimental paracetamol formulation|Experimental paracetamol formulation
79550254|NCT01592253|Drug|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
79550255|NCT01592279|Drug|liraglutide|
79550256|NCT01592279|Drug|Insulin injections|
79550257|NCT01592305|Drug|atazanavir|multiple oral doses
79851350|NCT00720005|Device|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
79851351|NCT00898430|Genetic|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
79851352|NCT00898430|Genetic|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
79851353|NCT00898430|Genetic|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
79550258|NCT01592305|Drug|danoprevir|multiple oral doses
79550259|NCT01592305|Drug|ritonavir|multiple oral doses
79550260|NCT01592305|Drug|tenofovir disoproxil fumarate|single oral doses
79550261|NCT01592318|Drug|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
79550262|NCT01592318|Drug|danoprevir|Reference tablet, single oral dose
79550263|NCT01592318|Drug|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
79550264|NCT01592318|Drug|ritonavir|Reference tablet, single oral dose
79550265|NCT01592331|Drug|Placebo|Single oral dose
79550266|NCT01592331|Drug|RO5508887|Single oral dose
79550267|NCT01592357|Behavioral|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
79851354|NCT00893594|Drug|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
79851355|NCT00893594|Drug|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
79851356|NCT00715715|Drug|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
79851357|NCT00953394|Drug|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
79851358|NCT00720161|Drug|Metformin|daily 850 mg
79851359|NCT00720161|Drug|placebo|placebo
79851360|NCT00888368|Procedure|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
79851361|NCT00888368|Procedure|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
79851362|NCT04068077|Device|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
79875253|NCT00388947|Device|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
79875254|NCT03992937|Drug|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
79713851|NCT04322838|Diagnostic Test|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
79713852|NCT04322838|Diagnostic Test|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
79713853|NCT04322838|Diagnostic Test|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
79713854|NCT04322214|Drug|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
79713855|NCT04322214|Drug|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
79713856|NCT04322214|Drug|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
79851363|NCT04010916|Other|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
79851364|NCT04010916|Other|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
79851365|NCT04010916|Other|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
79851366|NCT00948714|Behavioral|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
79550268|NCT01592357|Behavioral|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
79394318|NCT05382481|Diagnostic Test|Trough value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
79550269|NCT01592422|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
79550270|NCT01592422|Other|Best Supportive Care|Best Supportive Care in the absence of disease progression
79550271|NCT01592448|Behavioral|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
79550272|NCT01592513|Device|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
79851367|NCT00948714|Behavioral|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
79851368|NCT00948714|Other|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
79254319|NCT02352558|Drug|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
79851369|NCT00898508|Genetic|gene expression analysis|
79254320|NCT02352558|Drug|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
79254321|NCT02352558|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
79394319|NCT05382481|Diagnostic Test|Control Group|This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
79851370|NCT00898508|Genetic|mutation analysis|
79394320|NCT05368987|Device|Transcranial magnetic stimulation (TMS)|Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
79394321|NCT05354089|Biological|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
79851371|NCT00898508|Genetic|proteomic profiling|
79851372|NCT00898508|Genetic|reverse transcriptase-polymerase chain reaction|
79851373|NCT00898508|Other|fluorescent antibody technique|
79851374|NCT00898508|Other|immunohistochemistry staining method|
79851375|NCT00898508|Other|laboratory biomarker analysis|
79851376|NCT00898508|Other|liquid chromatography|
79851377|NCT00898508|Other|mass spectrometry|
79851378|NCT00898508|Other|medical chart review|
79851379|NCT00898508|Procedure|quality-of-life assessment|
79550273|NCT01592526|Other|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
79550274|NCT01592526|Other|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
79394322|NCT05354089|Biological|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
79713857|NCT02889276|Other|Functional Resistance Training|Supervised group-based Functional Resistance Training
79550275|NCT01592565|Other|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
79550276|NCT01592578|Procedure|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
79550277|NCT01592578|Procedure|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
79550278|NCT01592604|Device|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
79713858|NCT02889276|Behavioral|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
79713859|NCT05656092|Drug|HIP0612|Test drug
79713860|NCT05656092|Drug|HPP2202|Placebo drug
79713861|NCT05656092|Drug|RLD2204|Reference drug
79713862|NCT05656092|Drug|HPP2201|Placebo drug
79713863|NCT01057810|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
79713864|NCT01057810|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
79394323|NCT05354089|Drug|Placebo|Placebo IM on day 0 and day 21.
79394324|NCT05354063|Biological|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
79713865|NCT01262352|Drug|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
79713866|NCT01262352|Drug|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
79851380|NCT00711893|Device|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
79713867|NCT01299272|Drug|LY2216684|
79713868|NCT01299272|Drug|Placebo|
79713869|NCT01299272|Drug|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
79713870|NCT02889198|Behavioral|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
79713871|NCT04322292|Drug|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10^6 CAR+T cells/kg),medium(3.0-6.0×10^6 CAR+T cells/kg) and high(6.0-9.0×10^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
79851381|NCT00720239|Other|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
79713872|NCT01299116|Drug|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
79713873|NCT01299116|Drug|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
79713874|NCT01299116|Drug|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
79875255|NCT03992937|Device|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
79394325|NCT05354063|Biological|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
79394326|NCT05354063|Drug|Placebo|Placebo IM on day 0 and day 21.
79394327|NCT05335369|Behavioral|UR-GOAL|UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
79713875|NCT01299116|Drug|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
79713876|NCT01299116|Drug|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
79739836|NCT02685592|Drug|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
79739837|NCT04417972|Drug|SHR7280|treatment
79739838|NCT04417972|Drug|Placebo oral tablet|blank control
79875256|NCT01039545|Drug|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
79875257|NCT01039545|Drug|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
79254322|NCT02352558|Drug|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
79394328|NCT05323786|Procedure|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
79713877|NCT04321590|Dietary Supplement|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
79550279|NCT01592604|Device|Below knee walking cast|Below knee walking cast for 4 weeks
79713878|NCT04321902|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
79739839|NCT01007448|Drug|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
79394329|NCT05323786|Procedure|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
79394330|NCT05311488|Diagnostic Test|neurofilament light chain|Blood test
79739840|NCT02686684|Drug|Dimethyl fumarate|
79851382|NCT00609986|Drug|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
79875258|NCT00490568|Drug|Rosiglitazone XR|Experimental drug
79394331|NCT05311488|Diagnostic Test|In-vivo Meissner Corpuscle imaging|Imaging
79394332|NCT05311488|Diagnostic Test|Nerve conduction study|Nerve conduction study
79394333|NCT05308316|Other|Sucrose cigarettes|Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
79394334|NCT05291065|Behavioral|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
79394335|NCT05291065|Behavioral|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
79394336|NCT05291065|Behavioral|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
79550280|NCT01592630|Drug|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
79550281|NCT01592630|Drug|Saline|On-Q pumps containing saline to be attached to TAP catheters
79550282|NCT01592656|Radiation|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
79550283|NCT01592656|Other|Lung compliance measurement|At baseline
79550284|NCT01592656|Device|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 > 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
79254323|NCT02352558|Drug|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
79254324|NCT02344485|Procedure|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
79394337|NCT05274516|Drug|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
79394338|NCT05274516|Drug|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
79550285|NCT01592669|Procedure|passive leg raising|bilateral PLR was achieved by raising the legs of patient
79550286|NCT01592682|Behavioral|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
79550287|NCT01592734|Drug|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
79550288|NCT01592734|Device|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children > 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
79550289|NCT01592812|Device|electrical muscle stimulation|Duration of the stimulation 20 minutes
79713879|NCT04207398|Procedure|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
79713880|NCT04207398|Other|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
79550290|NCT01592838|Other|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
79713881|NCT01299038|Drug|rosuvastatin|Taken orally once a day for 4 weeks
79851383|NCT00609986|Drug|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
79851384|NCT00715871|Drug|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
79851385|NCT00715871|Device|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
79550291|NCT01592890|Drug|RO4917523|[14C]-labeled RO4917523, single oral dose
79713882|NCT00623922|Behavioral|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
79713883|NCT04321434|Other|Hyperoxia|
79851386|NCT00898664|Genetic|cytogenetic analysis|
79851387|NCT00898664|Genetic|gene expression analysis|
79254325|NCT02312206|Drug|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
79254326|NCT02312206|Other|Placebo|Placebo
79254327|NCT02276430|Other|Vena punction|Once 90 ml
79550292|NCT01592890|Drug|RO4917523|[13C]-labeled RO4917523, single intravenous tracer dose
79550293|NCT01592903|Genetic|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~Sample digestion through controlled enzymes.~Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~Culture of these cells.~Morphological and genetic characterization.~Assessment of pluripotent potential from isolated cells.~Analysis of the degree of functionality."
79550294|NCT01592929|Radiation|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
79851388|NCT00898664|Genetic|mutation analysis|
79851389|NCT00898664|Genetic|polymerase chain reaction|
79550295|NCT01592929|Other|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
79550296|NCT01592929|Radiation|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
79713884|NCT04321434|Other|Normoxia|
79713885|NCT04321434|Device|laser Doppler|laser Doppler
79713886|NCT04321122|Procedure|ultrasound cyclo plasty|"The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast."
79739841|NCT04294056|Drug|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
79254328|NCT02264665|Drug|sunitinib|sunitinib 37.5mg/d orally
79254329|NCT02264665|Drug|everolimus|everolimus 10mg/d orally
79254330|NCT02264665|Drug|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
79254331|NCT02234557|Behavioral|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
79713887|NCT04321278|Drug|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
79713888|NCT04321278|Drug|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
79713889|NCT01261338|Drug|olestra|non-absorbable dietary fat
79713890|NCT01260948|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
79713891|NCT01260948|Drug|Aricept®|10 mg Orally Disintegrating Tablet
79713892|NCT01025284|Drug|LY2523355|Administered intravenously as a 1-hour infusion
79713893|NCT01025284|Drug|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
79713894|NCT01021852|Drug|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
79713895|NCT01021852|Drug|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
79713896|NCT04300660|Other|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
79713897|NCT02872636|Device|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
79713898|NCT02872870|Behavioral|auditory lexical decision task|
79713899|NCT02872870|Device|electroencephalogram|
79713900|NCT02875054|Behavioral|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
79713901|NCT02875054|Behavioral|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
79713902|NCT02873026|Drug|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
79713903|NCT00627640|Drug|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
79713904|NCT00627640|Drug|Matching Placebo|Matching Placebo
79254332|NCT02232646|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
79254333|NCT02232633|Drug|BBI503|
79254334|NCT02232620|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
79254335|NCT02221427|Other|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
79713905|NCT01056718|Drug|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
79713906|NCT01298570|Drug|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
79713907|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
79713908|NCT01298570|Drug|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
79713909|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
79713910|NCT01259856|Drug|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
79713911|NCT01259856|Drug|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
79713912|NCT01259856|Drug|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
79713913|NCT01020838|Drug|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
79713914|NCT00624000|Drug|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
79713915|NCT01259466|Drug|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
79713916|NCT01259388|Drug|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
79851390|NCT00898664|Other|immunohistochemistry staining method|
79254336|NCT02221427|Other|Static labour progression curve (F)|
79254337|NCT02207062|Drug|Ibrutinib|Given PO
79254338|NCT02207062|Other|Laboratory Biomarker Analysis|Correlative studies
79713917|NCT01298492|Drug|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
79713918|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
79713919|NCT05525910|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
79713920|NCT05525910|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
79713921|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
79713922|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
79713923|NCT04320654|Other|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
79550297|NCT01592929|Radiation|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
79550298|NCT01592929|Other|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
79550299|NCT01592942|Device|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
79550300|NCT01592942|Device|Progrip|self-gripping mesh
79550301|NCT01592942|Device|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
79254339|NCT02198690|Other|Mammography decision aid|
79254340|NCT02198690|Other|Home safety pamphlet|
79254341|NCT02155712|Device|Triathlon Tritanium Knee|Cementless
79254342|NCT02155712|Device|Triathlon Knee|Cemented
79550302|NCT01592955|Device|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
79550303|NCT01592981|Drug|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
79713924|NCT01297322|Other|Manual compression|Standard of Care
79254343|NCT02151032|Behavioral|Booklet|Participants read a booklet about colorectal cancer screening tests.
79254344|NCT02151032|Behavioral|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
79713925|NCT01297322|Device|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
79254345|NCT02151032|Behavioral|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
79254346|NCT02151032|Behavioral|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
79254347|NCT02151032|Behavioral|Questionnaires|Questionnaire completion before and after viewing the program.
79254348|NCT02052882|Biological|romiplostim|
79550304|NCT01592981|Drug|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
79550305|NCT01592981|Biological|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
79550306|NCT01592981|Drug|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
79550307|NCT01592994|Behavioral|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
79550308|NCT01592617|Drug|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
79550309|NCT01593007|Other|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
79713926|NCT02888886|Other|Questionnaires about food habits and tobacco|
79713927|NCT02888886|Other|Spirometry|
79713928|NCT02888886|Other|Carotid echography|
79713929|NCT02888886|Other|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
79254349|NCT02047474|Drug|oxaliplatin|Given IV
79254350|NCT02047474|Drug|leucovorin calcium|Given IV
79254351|NCT02047474|Drug|irinotecan hydrochloride|Given IV
79254352|NCT02047474|Drug|fluorouracil|Given IV
79254353|NCT02047474|Procedure|therapeutic conventional surgery|Undergo surgical resection
79254354|NCT02047474|Other|laboratory biomarker analysis|Correlative studies
79254355|NCT02039557|Genetic|NiCord®/CordIn™ (omidubicel)|
79254356|NCT02008045|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
79254357|NCT02008045|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
79254358|NCT01972217|Drug|Olaparib|Olaparib bid
79254359|NCT01972217|Drug|Placebo|Placebo bid
79254360|NCT01972217|Drug|Abiraterone|Abiraterone 1000 mg
79254361|NCT01972217|Drug|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
79254362|NCT01970735|Biological|Blood test|
79254363|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
79550310|NCT01593007|Other|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
79713930|NCT00624078|Drug|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
79713931|NCT00624156|Behavioral|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
79713932|NCT00624156|Behavioral|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
79713933|NCT05396586|Behavioral|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
79713934|NCT05396586|Behavioral|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
79739842|NCT04294056|Drug|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
79739843|NCT02870556|Device|cervical epidural analgesia|
79713935|NCT05396586|Behavioral|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
79713936|NCT01297244|Drug|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
79713937|NCT04320420|Other|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~3 supervised APA sessions/week on site:~two muscle strengthening sessions, stretching, flexibility in the gym~a cardio session (Nordic Walking: outdoors)~at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~the first 3 months:~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~1-hour cardio session/week independently~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
79713938|NCT05183022|Device|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
79713939|NCT02890394|Other|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
79713940|NCT04746378|Diagnostic Test|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
79713941|NCT04746378|Diagnostic Test|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
79713942|NCT04746378|Diagnostic Test|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
79713943|NCT04735692|Other|Full mouth or quadrant SRP|Full mouth or quadrant SRP
79713944|NCT04320576|Device|Bulk-fill|Bulk-fill resin composite (bulk technique)
79713945|NCT04320576|Device|Nano-fill|Nano-fill resin composite (layering technique)
79713946|NCT04554732|Drug|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
79851391|NCT00898664|Other|laboratory biomarker analysis|
79851392|NCT02572193|Procedure|POEM|To determine the feasibility of same-day discharge following a POEM procedure
79713947|NCT04499820|Dietary Supplement|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
79713948|NCT04499820|Dietary Supplement|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
79713949|NCT04481256|Radiation|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
79851393|NCT00888446|Biological|tgAAC09|
79254364|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
79713950|NCT04481256|Drug|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
79713951|NCT04481256|Drug|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
79713952|NCT04481256|Drug|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
79851394|NCT00888446|Biological|tgAAC09|
79254365|NCT01918007|Procedure|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
79254366|NCT01893554|Biological|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
79254367|NCT01893554|Biological|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
79254368|NCT01881334|Biological|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
79254369|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in left side|
79713953|NCT02888964|Drug|Add-on therapy|Pioglitazone therapy
79739844|NCT00628602|Device|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
79851395|NCT00888446|Biological|tgAAC09|
79851396|NCT00888446|Other|Formulation buffer|Sterile isotonic buffered salt solution
79851397|NCT02540174|Procedure|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
79875259|NCT00561353|Drug|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
79550311|NCT01593033|Dietary Supplement|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
79550312|NCT01593033|Dietary Supplement|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
79550313|NCT01593033|Drug|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
79550314|NCT01593046|Drug|GSK1265744 Oral|30mg tablet
79550315|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
79550316|NCT01593046|Drug|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
79550317|NCT01593046|Drug|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
79254370|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in right side|
79875260|NCT00561353|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
79875261|NCT00561353|Drug|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
79875262|NCT00561353|Drug|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
79875263|NCT03996746|Diagnostic Test|No intervention|No intervention
79254371|NCT01864109|Drug|Cyclophosphamide|
79254372|NCT01864109|Device|Doxorubicin|
79394339|NCT05267925|Dietary Supplement|CuraLin|"CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~Mormordica charantia (fruit) - 300mg~Gymnema sylvestre (leaf) - 80mg~Trigonella foenum-Graecum (seed) - 100mg~Curcuma longa (rhizome) - 100mg~Phyllanthus embilica officinalis (fruit) - 100mg~Swertia chiraytia (leaf) - 80mg~Syzgium Cumini (seed) - 100mg~Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~Cinnamoum verum/zeylanicum - 40 mg~Hydroxypropyl methylcellulose~Rice Flour"
79254373|NCT01864109|Drug|Vincristine|
79254374|NCT01864109|Drug|Ifosfamide|
79254375|NCT01864109|Drug|Etoposide|
79254376|NCT01864109|Procedure|Surgery|
79254377|NCT01864109|Radiation|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
79254378|NCT01864109|Drug|Temozolomide|
79394340|NCT05262387|Drug|Lyumjev|Administered SC.
79394341|NCT05262387|Drug|Humalog|Administered SC.
79394342|NCT05262231|Behavioral|Online Breastfeeding Education|Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
79394343|NCT05255705|Other|Observation only|Observation only
79394344|NCT05221554|Procedure|Computer-navigated THA surgery|Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
79394345|NCT05221554|Procedure|Standard of care THA surgery|Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
79394346|NCT05200104|Drug|PXL065|PXL065 22.5 mg QD
79394347|NCT05181098|Procedure|Robotic-guided spine surgery|The Mazor X Stealth Edition robotic platform will be used to guide posterior instrumentation during spine fusion surgery.
79394348|NCT05162937|Biological|IL-17A antibody|Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
79394349|NCT05154838|Procedure|Drainage and packing of pilonidal abscess|Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
79394350|NCT05119010|Dietary Supplement|Continuous ketogenic diet|ARM A : continuous ketogenic diet
79394351|NCT05119010|Dietary Supplement|Discontinuous ketogenic diet|ARM B : discontinuous ketogenic diet
79394352|NCT05119010|Dietary Supplement|beta-hydroxybutyrate (BHB) supplementation|ARM C : BHB supplementation
79254379|NCT01864109|Drug|Irinotecan|
79254380|NCT01864109|Drug|Mesna|Mesna 2,100 mg/m2 (or 70 mg/kg if < 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
79254381|NCT01864109|Drug|Dexrazoxane|Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
79394353|NCT05112302|Other|Virtual reality|Use of virtual reality goggles during procedure
79394354|NCT05100901|Dietary Supplement|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
79394355|NCT05046392|Behavioral|Face-to-Face ART Adherence Intervention|All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.
79550318|NCT01593046|Drug|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
79550319|NCT01593046|Drug|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
79550320|NCT01593046|Drug|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
79254382|NCT01864109|Drug|G-CSF|G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
79254383|NCT01863446|Device|Lighting1|Ocular light exposure to a red wavelength light
79713954|NCT04416516|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
79713955|NCT04387110|Drug|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
79713956|NCT04207008|Other|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
79713957|NCT04206930|Other|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
79713958|NCT02889042|Other|MRI and biological assessment|performing a MRI and a biological assessment
79254384|NCT01863446|Device|Lighting2|Ocular light exposure to a blue/green wavelength light
79394356|NCT05046392|Behavioral|Carium Mobile Health Platform|Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
79394357|NCT04998058|Procedure|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
79713959|NCT02888808|Other|Gastroscopy|Upper gastrointestinal endoscopy procedure
79851398|NCT02540174|Procedure|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
79550321|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
79851399|NCT02572271|Procedure|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
79851400|NCT02572271|Procedure|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
79851401|NCT04035824|Drug|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
79851402|NCT04035824|Drug|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
79254385|NCT01815788|Device|Use of a personal sound amplifying device = TeoFirst|
79254386|NCT01809691|Drug|TAK-700|300 mg, PO, twice daily
79254387|NCT01809691|Drug|Bicalutamide|50 mg, PO, q daily
79713960|NCT04320108|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
79254388|NCT01805349|Radiation|Hand X-rays|Hand X-rays to assess the digital arthrosis
79254389|NCT01786265|Drug|Abiraterone Acetate|Given PO
79254390|NCT01786265|Drug|Bicalutamide|Given PO
79254391|NCT01786265|Drug|Degarelix|Given via injection
79254392|NCT01786265|Drug|Flutamide|Given PO
79254393|NCT01786265|Drug|Goserelin Acetate|Given via injection
79550322|NCT01593072|Drug|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
79713961|NCT03582150|Device|Remote Monitoring with Ambulatory Detox|"Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
79713962|NCT03456726|Drug|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
79713963|NCT03377478|Drug|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
79713964|NCT03181932|Drug|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
79254394|NCT01786265|Drug|Leuprolide Acetate|Given via injection
79254395|NCT01786265|Drug|Nilutamide|Given PO
79254396|NCT01786265|Drug|Prednisone|
79254397|NCT01781455|Drug|BBI503|
79254398|NCT01775423|Drug|BBI608|
79550323|NCT01593072|Other|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
79713965|NCT03181932|Drug|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
79713966|NCT03181932|Drug|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
79550324|NCT01593085|Behavioral|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------"
79713967|NCT02864862|Device|Immediate implant|
79713968|NCT02864862|Biological|SCTG|
79713969|NCT02864862|Biological|ADM|
79713970|NCT02888730|Drug|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
79713971|NCT02888730|Drug|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
79713972|NCT02058264|Drug|BBI-4000|
79550325|NCT01593124|Drug|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
79713973|NCT01598298|Drug|duloxetine hydrochloride|Given PO
79851403|NCT00893750|Behavioral|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
79254399|NCT01775072|Genetic|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies."
79550326|NCT01593124|Other|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
79851404|NCT00893750|Behavioral|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
79851405|NCT00893750|Behavioral|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
79851406|NCT00712049|Drug|simvastatin|simvastatin 40 mg
79851407|NCT00712049|Drug|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
79550327|NCT01593124|Drug|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
79550328|NCT01593137|Drug|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin >1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
79550329|NCT01593137|Drug|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin >1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
79550330|NCT01593150|Drug|Pradaxa|Pradaxa for 3 weeks prior to DC
79550331|NCT01593150|Procedure|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
79713974|NCT01598298|Other|placebo|Given PO
79713975|NCT02888652|Drug|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
79713976|NCT01235949|Biological|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
79713977|NCT01235949|Biological|Infanrix hexa|Intramuscular injection, 3 doses
79713978|NCT01235949|Biological|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
79713979|NCT01235949|Drug|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
79713980|NCT01235949|Drug|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
79875264|NCT04383587|Other|Serologic testing|COVID19 IgG antibody testing to be performed
79550332|NCT01593150|Other|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
79550333|NCT01593163|Drug|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
79254400|NCT01775072|Genetic|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list).~Part D: Germline Profiling for Individuals at Elevated Cancer Risk"
79550334|NCT01593163|Drug|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
79550335|NCT01593176|Procedure|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
80017314|NCT02361801|Drug|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output < 2 mL/Kg/h despite adequate fluid replacement.
79254401|NCT01765777|Procedure|Osteopathic Manipulative Medicine|
80017315|NCT02104440|Biological|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
79254402|NCT01765777|Procedure|Phototherapy|
79550336|NCT01593189|Behavioral|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
79550337|NCT01593267|Procedure|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
79550338|NCT01593267|Procedure|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
79254403|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
79254404|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
79550339|NCT01593280|Device|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
79550340|NCT01593280|Drug|intrathecal morphine|0.3 mg
79550341|NCT01593293|Drug|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
79550342|NCT01593293|Drug|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
79550343|NCT01593306|Drug|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
79254405|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
79254406|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
79254407|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
79254408|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
79254409|NCT01619176|Procedure|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
79254410|NCT01532388|Behavioral|eScreen|Web based self-monitoring of problematic alcohol and drug use.
79254411|NCT01503086|Procedure|Cognitive Assessment|Ancillary studies
79254412|NCT01503086|Other|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
79254413|NCT01503086|Procedure|Psychosocial Assessment and Care|Ancillary studies
80017316|NCT04469972|Other|Breathing Exercises|Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
80017317|NCT03965728|Drug|BAY1830839|Tablet, oral.
79254414|NCT01503086|Other|Quality-of-Life Assessment|Ancillary studies
79254415|NCT01503086|Other|Questionnaire Administration|Ancillary studies
79254416|NCT01481974|Drug|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
79550344|NCT01593306|Drug|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
80017318|NCT03965728|Drug|Placebo|Tablet, oral.
79254417|NCT01413516|Behavioral|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
79254418|NCT01413516|Drug|Placebo|Sugar pill without any active medication
79254419|NCT01413516|Drug|Varenicline|Varenicline (an approved medication for smoking cessation)
79254420|NCT01374997|Other|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
79254421|NCT01371383|Dietary Supplement|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
79254422|NCT01371383|Dietary Supplement|placebo|Soybean oil
79254423|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,[1] thus helping to establish a periodontium that is free of disease.[2]
79254424|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
79550345|NCT01593319|Drug|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
79550346|NCT01593319|Drug|Natrium chloride|Placebo injection of Natrium chloride solution
79550347|NCT01593332|Drug|Rituximab|two 500 mg rituximab infusions 2 weeks apart
79550348|NCT01593332|Drug|Rituximab|500mg,two times with two weeks interval
79550349|NCT01593345|Other|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
79550350|NCT01593345|Other|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
79550351|NCT01593371|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
79550352|NCT01593371|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
79550353|NCT01593397|Drug|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
79550354|NCT01593410|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
79550355|NCT01593410|Drug|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
79550356|NCT01593436|Behavioral|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
79550357|NCT01593449|Behavioral|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
79254425|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
79254426|NCT01141023|Drug|DaTscan|
79550358|NCT01593462|Procedure|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
79550359|NCT01593462|Procedure|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
79254427|NCT01129544|Biological|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
79713981|NCT00691158|Drug|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
79713982|NCT00691158|Drug|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
79713983|NCT00691158|Drug|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
79713984|NCT00691158|Drug|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
79851408|NCT00712127|Other|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
80017319|NCT03965728|Drug|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
79254428|NCT01106534|Drug|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
79550360|NCT01593462|Behavioral|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
79550361|NCT01593475|Radiation|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
80017320|NCT03965728|Drug|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
79254429|NCT01106534|Drug|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
79550362|NCT01593501|Dietary Supplement|vitamin D3|pharmaceutical grade D3
79713985|NCT01235793|Drug|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
79254430|NCT01106534|Device|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
79713986|NCT01258998|Drug|Akt inhibitor MK2206|Given PO
79851409|NCT00712127|Other|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
79851410|NCT00898742|Genetic|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
79851411|NCT00898742|Genetic|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
79254431|NCT01098955|Behavioral|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
79254432|NCT01098955|Behavioral|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
79394358|NCT04992494|Behavioral|MBCT-Telephone|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
79394359|NCT04992494|Behavioral|MBCT-Video|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
79713987|NCT01258998|Other|laboratory biomarker analysis|Correlative studies
79713988|NCT05601648|Drug|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
79713989|NCT01235715|Drug|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
79851412|NCT00898742|Other|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
79851413|NCT00716027|Behavioral|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
80017321|NCT00337454|Drug|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
79254433|NCT01098955|Drug|Varenicline|2 mg daily for 12 weeks
79394360|NCT04985500|Procedure|ESP block|peripheral nerve block
79394361|NCT04985500|Procedure|PIF block|peripheral nerve block
79394362|NCT04985500|Procedure|Ultrasound|Ultrasound guidance
79713990|NCT01235403|Drug|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
79875265|NCT00944957|Drug|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
79875266|NCT00944957|Drug|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
79550363|NCT01593514|Biological|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
79550364|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
79550365|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
79550366|NCT01593514|Biological|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
79851414|NCT00716027|Behavioral|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
79254434|NCT01047735|Procedure|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
79851415|NCT00898820|Genetic|gene expression analysis|
79394363|NCT04985500|Drug|Bupivacain|10-20 mL of 0.25% bupivacaine
79550367|NCT01593514|Biological|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
79550368|NCT01593527|Drug|ACZ885|Canakinumab 150 mg s.c.
79550369|NCT01593527|Drug|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
79713991|NCT01024036|Drug|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
79713992|NCT01024036|Drug|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
79851416|NCT00898820|Genetic|polymorphism analysis|
79394365|NCT04973670|Drug|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
79394366|NCT04973670|Drug|Placebo|The same amount of NS containing only sivelestat sodium excipients
79394367|NCT04966858|Other|Individualized Caloric Refeeding (ICR)|Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
79394368|NCT04966858|Other|Higher Calorie Refeeding (HCR)|Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
79394369|NCT04929626|Drug|Magnesium Sulfate 500 mg/ml+ ventolin|3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
79394370|NCT04929626|Drug|Ventolin|it will be given to control group in nebulized form after every 20 min in 1st hour
79550370|NCT01593540|Device|metal-free interdental brush|one time per day
79713993|NCT01024036|Drug|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
79713994|NCT01234467|Drug|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
79713995|NCT01234467|Drug|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
79851417|NCT00898820|Genetic|protein expression analysis|
79851418|NCT00712205|Drug|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
79851419|NCT00712205|Drug|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
79851420|NCT02574299|Other|E-learning|Management of auditory processing disorders with serious game (E-learning)
79851421|NCT02574299|Device|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
79851422|NCT00720551|Other|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
79851423|NCT00451906|Drug|Platinum-based chemotherapy|As prescribed
79851424|NCT00451906|Drug|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
79851425|NCT04162691|Diagnostic Test|Tissue|Four 4-5 mm tissues of the thymoma
79875267|NCT00944957|Drug|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
79394371|NCT04908852|Other|Blood Sample Collection - Observational Study|Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.
79713996|NCT04300036|Dietary Supplement|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
79394372|NCT04908852|Other|Symptom questionnaires - Observational Study|Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
79394373|NCT04902196|Other|high intensity cardiorespiratory exercise protocol|During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
79851426|NCT00712283|Drug|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
79254435|NCT01047735|Procedure|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
79254436|NCT01047735|Behavioral|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
79254437|NCT01009788|Drug|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
79394374|NCT04902196|Other|moderate intensity cardiorespiratory exercise protocol|During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
79550371|NCT01593540|Device|metal-core interdental brush|one time per day
79550372|NCT01593553|Other|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
79550373|NCT01593566|Drug|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
79550374|NCT01593566|Drug|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
79550375|NCT01593579|Behavioral|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine & standing heart rate & blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
79550376|NCT01593579|Other|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
79550377|NCT01593605|Dietary Supplement|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
79713997|NCT04300036|Dietary Supplement|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
79713998|NCT02875912|Behavioral|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
79713999|NCT01233999|Drug|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
79714000|NCT01233687|Drug|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
79714001|NCT01023958|Drug|BI 6727, IV infusion|phase II
79714002|NCT01233609|Drug|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
79714003|NCT01233609|Drug|Placebo|Dosage per subject weight- same schedule as the active comparator
79714004|NCT01232283|Drug|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
79714005|NCT01232283|Drug|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
79851427|NCT04070495|Drug|KW-6356|A single oral dose will be administered at Day 1 and 15
79851428|NCT04070495|Drug|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
79714006|NCT01232283|Other|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
79254438|NCT01009788|Drug|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
79851429|NCT04070495|Drug|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
79851430|NCT00712361|Device|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
79851431|NCT00720707|Procedure|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
79394375|NCT04840004|Drug|PVT-1|Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
79394376|NCT04826198|Drug|AsiDNA|Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion
79550378|NCT01593605|Dietary Supplement|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
79550379|NCT01593605|Other|Placebo treatment|Placebo - one tablet taken twice a day by mouth
79714007|NCT01232127|Drug|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
79714008|NCT01232127|Drug|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
79851432|NCT00720707|Procedure|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
79851433|NCT00716105|Other|Standard infant formula|From 3 to 12 months of age. As per standard requirement
79851434|NCT00716105|Other|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
79714009|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
79254439|NCT00997009|Drug|paclitaxel|175 mg/m2 IV day 1, every 21 days
79714010|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
79714011|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
79714012|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
79714013|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
79254440|NCT00997009|Drug|carboplatin|AUC 5 IV day 1 every 21 days
79254441|NCT00997009|Drug|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
79254442|NCT00979238|Genetic|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
79254443|NCT00979238|Drug|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
79254444|NCT00961064|Drug|Eltrombopag|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
79254445|NCT00846209|Other|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
79254446|NCT00667030|Behavioral|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
79394377|NCT04826198|Drug|Niraparib|"Unit dose: Hard capsule containing 100mg of Niraparib Regimen: The last dose given during the 6 previous months of Niraparib 200 mg/day or 300 mg/day, (or 100 mg/day only if the patient has received this dose since at least 6 months) Daily, 1, 2 or 3 hard capsules at 100mg once daily at approximately the same time each day.~Mode/route: Per os"
79550380|NCT01593618|Behavioral|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
79714014|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
79851435|NCT02573129|Other|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
79851436|NCT02573129|Other|Red Meat Rich|Mediterranean diet rich in red meat
79851437|NCT00712439|Drug|Gabapentin Extended Release tablets|
79254447|NCT00657878|Drug|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
79254448|NCT00657878|Drug|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
79254449|NCT00657878|Drug|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
79254450|NCT00657878|Drug|Topotecan|dosing and schedule according to Institutional guidelines
79254451|NCT00657878|Drug|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
79550381|NCT01593618|Other|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
79550382|NCT01593631|Dietary Supplement|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
79714015|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
79714016|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
79851438|NCT00712439|Drug|Placebo|
79851439|NCT00451282|Behavioral|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
79851440|NCT00716183|Biological|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
79851441|NCT00716183|Biological|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
79851442|NCT00716183|Biological|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
79875268|NCT00944957|Drug|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
79851443|NCT00716183|Drug|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
79714017|NCT01258608|Drug|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
79714018|NCT01258608|Drug|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
79394378|NCT04826198|Drug|Olaparib|Product name: Olaparib Pharmaceutical form: Tablets containing 100 or 150mg of Olaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Olaparib 600 mg/day or 500 mg/day, (or 400 mg/day only if the patient has received this dose since at least 6 months) Two times daily (300mg or 250 mg or 200mg) at approximately the same time each day.
79394379|NCT04826198|Drug|Rucaparib|Product name: Rucaparib Pharmaceutical form: Tablets containing 200 or 250 or 300mg of Rucaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Rucaparib 1200 mg/day or 1000 mg/day, or 800mg/day (or 600 mg/day only if the patient has received this dose since at least 6 months) Two times daily (600mg or 500mg or 400mg or 300mg) at approximately the same time each day.
79394380|NCT04808934|Drug|Apixaban|Adults receiving apixaban
79714019|NCT01258608|Drug|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
79714020|NCT01015612|Device|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
79851444|NCT03995446|Device|low-level laser|low level laser emission on specific acupuncture points
79714021|NCT04319874|Drug|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
79851445|NCT03995446|Device|Sham laser|Sham laser
79254452|NCT00611585|Device|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
79254453|NCT00513526|Biological|Gardasil|week 0, 8, 24, 128
79254454|NCT00443274|Other|NBIR - US National Breast Implant Registry|NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..
79394381|NCT04808934|Drug|dabigatran|Adults receiving dabigatran
79394382|NCT04808934|Drug|rivaroxaban|Adults receiving rivaroxaban
79394383|NCT04808934|Drug|VKAs|Adults receiving VKA
79714022|NCT04319874|Drug|Chemotherapy|Subjects are treated with conventional chemotherapy
79714023|NCT04319874|Drug|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
79714024|NCT01231659|Drug|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
79851446|NCT04069559|Other|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
79254455|NCT00443274|Device|410 Arm|Anatomically shaped silicone gel-filled breast implants.
79254456|NCT00443274|Device|BIFs - Breast Implant Follow-Up Study|Round silicone gel-filled breast implants and saline-filled breast implants
79254457|NCT00412594|Drug|Cladribine|Given IV
79394384|NCT04772183|Device|SpO2 and SaO2 comparison|"Several pulse oximeter will be place on patient find few minutes before arterial blood gases.~During an arterial blood sample, all SpO2 will be recorded"
79394385|NCT04754230|Drug|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
79394386|NCT04727086|Drug|BP1.3656|BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
79714025|NCT01231659|Drug|Letrozole|Letrozole 2.5 mg once daily
79851447|NCT04070417|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
79851448|NCT03996226|Drug|E7386|E7386 oral tablets.
79851449|NCT00712517|Drug|propofol|propofol anesthesia 3-5mg/kg
79851450|NCT00712517|Drug|sevoflurane|sevoflurane anesthesia
79851451|NCT04070339|Other|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
79254458|NCT00412594|Other|Laboratory Biomarker Analysis|Correlative studies
79254459|NCT00412594|Biological|Rituximab|Given IV
79254460|NCT00394641|Behavioral|listening to music / stories via stereophonic headphones|
79254461|NCT00323921|Device|dermatological infrared laser|
79254462|NCT00321555|Drug|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
79254463|NCT00184119|Procedure|Psychiatric Intensive Care Unit|
79254464|NCT00184119|Procedure|Care in whole acute unit|psychiatric acute care as usual
79254465|NCT00143923|Behavioral|Nutrition, Exercise, Stress Management Counseling|Individualized advice
79254466|NCT00143923|Other|usual care|usual care
79254467|NCT00131885|Dietary Supplement|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
79254468|NCT00131885|Dietary Supplement|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
79254469|NCT00131885|Drug|Levonorgestrel|Levonorgestrel in a single oral dose
79254470|NCT00047060|Other|A matched peripheral donor stem cells|A matched peripheral donor stem cells
79254471|NCT00047060|Drug|cyclosporine|cyclosporine
79254472|NCT00047060|Drug|fludarabine|fludarabine
79254473|NCT00047060|Drug|Campath|Campath
79254474|NCT02084329|Device|Weighted Compression Vest|
79254475|NCT02087917|Drug|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
79550383|NCT01593631|Dietary Supplement|Acid lactase|capsules containing 9000 FCC of acid lactase
79550384|NCT01593631|Dietary Supplement|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
79714026|NCT02875288|Drug|liposomal bupivicaine|"The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~Route of drug administration; Surgical site infiltration"
79254476|NCT02087917|Drug|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
79714027|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
79714028|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
79714029|NCT01052428|Drug|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
79714030|NCT01052428|Drug|Placebo|Placebo 100 mg once a day for 2 years
79714031|NCT01052272|Drug|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
79714032|NCT01052272|Drug|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
79254477|NCT02082223|Behavioral|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
79394387|NCT04727086|Drug|Placebo|Administered once daily in tablet form.
79714033|NCT01052272|Drug|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
79851452|NCT03838198|Behavioral|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
79875269|NCT00945113|Behavioral|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
79875270|NCT00945347|Drug|Miglustat|Nasal instillation of miglustat
79394388|NCT04711759|Device|High flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher & Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
79394389|NCT04711759|Device|Standard oxygen therapy|Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
79394390|NCT04659928|Device|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
79550385|NCT01593631|Dietary Supplement|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
79550386|NCT01593631|Dietary Supplement|Placebo|Capsules containing di-calcium-phosphate
79550387|NCT01593644|Drug|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
79550388|NCT01593657|Other|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
79550389|NCT01593657|Other|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
79550390|NCT01593657|Procedure|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
79550391|NCT01593657|Procedure|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
79550392|NCT01593683|Behavioral|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
79254478|NCT02084407|Other|Clinical examination, skin biopsy, blood and urine sampling|
79254479|NCT02084485|Drug|PH-797804|30 MG Single dose
79254480|NCT02084485|Drug|Placebo|matching placebo
79254481|NCT03559231|Procedure|dFTRD|Duodenal Full-Thickness Resection
79254482|NCT03559231|Procedure|EMR|Endoscopic Mucosal Resection
79254483|NCT02084563|Drug|Induction Chemotherapy|"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~Cytarabine 200 mg/m2 IV continuous infusion days 1-7~Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"
79714034|NCT01257204|Drug|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
79254484|NCT02084563|Drug|Consolidation Chemotherapy|"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"
79550393|NCT01593735|Drug|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
79550394|NCT01593735|Drug|Placebo|Placebo tablets, orally, once daily for 7 days
79254485|NCT02084563|Drug|Autologous Stem Cell Transplantation|"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"
79254486|NCT02084563|Drug|Allogeneic Stem Cell Transplantation|"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"
79550395|NCT01593774|Drug|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
79254487|NCT02084563|Drug|Low Dose Cytarabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
79550396|NCT01593774|Drug|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
79550397|NCT01593800|Dietary Supplement|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
79550398|NCT01593826|Drug|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
79550399|NCT01593826|Drug|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
79254488|NCT02084563|Drug|Decitabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
79394391|NCT04659928|Device|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
79254489|NCT03559153|Other|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
79254490|NCT03559153|Other|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
79394392|NCT04659928|Device|External evacuation device (EED)|Extraoral suction unit will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
79550400|NCT01593826|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
79550401|NCT01593826|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
79550402|NCT01593865|Procedure|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
79714035|NCT01257204|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
79851453|NCT03838198|Behavioral|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
79851454|NCT03838198|Behavioral|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
79851455|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
79550403|NCT01593865|Procedure|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
79851456|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
79550404|NCT01593878|Other|TV|test taken with TV on
79550405|NCT01593930|Other|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
79550406|NCT01593930|Other|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
79550407|NCT01593930|Other|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
79550408|NCT01593930|Other|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
79714036|NCT01257204|Drug|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
79714037|NCT01257204|Drug|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
79714038|NCT01231581|Drug|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
79550409|NCT01593943|Behavioral|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
79550410|NCT01593956|Behavioral|tDCS|
79550411|NCT01593969|Dietary Supplement|RUTF/Flax Oil|Ready to Use Therapeutic Food
79550412|NCT01593969|Dietary Supplement|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
79550413|NCT01593969|Dietary Supplement|Standard RUTF|Standard formulation RUTF given according to National Guidelines
79851457|NCT00115765|Drug|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
79851458|NCT00115765|Drug|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
79851459|NCT00115765|Drug|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
79550414|NCT01593982|Other|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
79254491|NCT02084641|Other|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
79254492|NCT02084719|Device|Oraquick HCV Rapid Antibody Test|
79254493|NCT02084719|Device|Standard algorithm|
79550415|NCT01593995|Drug|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
79394393|NCT04659928|Drug|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
79550416|NCT01594008|Other|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
79550417|NCT01594008|Other|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
79714039|NCT01231581|Drug|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
79714040|NCT01231581|Drug|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
79714041|NCT01050634|Drug|Aromasin (exemestane)|25mg oral tablet, daily, for >1yr
79714042|NCT01020526|Drug|pregabalin|Oral capsule 75-450 mg/day
79851460|NCT00115765|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
79875271|NCT00945347|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
79875272|NCT00945425|Drug|AZD7325|oral capsule, once or twice daily, 7 days
79875273|NCT00945425|Drug|Placebo|oral capsule, once or twice daily, 7 days
79875274|NCT00560885|Device|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
79875275|NCT00945503|Drug|GSK1018921|GSK1018921 is a GT1 recepor antagonist
79394394|NCT04653337|Combination Product|Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).
79394395|NCT04653337|Combination Product|Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
79394396|NCT04653337|Combination Product|Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
79254494|NCT02088307|Dietary Supplement|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
79550418|NCT01594008|Other|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
79550419|NCT01594021|Drug|Gelatin 500 mL|intravenous administration
79550420|NCT01594021|Drug|Gelatin 50 mL|intravenous administration
79714043|NCT01020448|Drug|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
79714044|NCT02872324|Other|Procurement questionnaires|
79714045|NCT02872168|Other|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
79875276|NCT00945581|Other|Experimental Nutritional Powder Formula|Powder twice a day
80017322|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
80017323|NCT00337454|Drug|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
79550421|NCT01594034|Procedure|expired air|collection of expired air from ventilator
79550422|NCT01594060|Drug|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
79550423|NCT01594060|Drug|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
79714046|NCT04286230|Behavioral|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
79550424|NCT01594086|Dietary Supplement|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
79851461|NCT00606008|Drug|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
79254495|NCT02082379|Behavioral|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
79254496|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
79254497|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
79394397|NCT04642417|Other|dietary fiber literacy|education
79394398|NCT04642417|Other|routine care|routine care
79404289|NCT03581539|Procedure|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
79404290|NCT03155113|Other|blood drawing|Before starting therapy a blood sample will be collected from any subject.
79550425|NCT01594099|Radiation|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
79550426|NCT01594099|Drug|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
79550427|NCT01594099|Drug|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
79714047|NCT04286230|Behavioral|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
79714048|NCT01256658|Drug|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
79714049|NCT01256502|Device|SERI® Surgical Scaffold|Breast reconstruction surgery
79851462|NCT00721019|Other|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
79851463|NCT00721019|Other|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
79851464|NCT03837184|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
79851465|NCT00716261|Device|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
79851466|NCT00898898|Other|diagnostic laboratory biomarker analysis|Correlative studies
80017324|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
80017325|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
79254498|NCT02689453|Biological|IL-15 plus|Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.
79404291|NCT03076164|Drug|Trametinib|Trametinib 1.5mg once daily by mouth
79714050|NCT04319952|Device|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
79851467|NCT04068233|Other|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
79851468|NCT04035122|Other|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
79875277|NCT00945581|Other|Placebo comparator|Powder twice a day
80017326|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
79714051|NCT01256190|Biological|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
79851469|NCT04035122|Other|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
79851470|NCT00461812|Drug|Mometasone|
79394399|NCT04641897|Procedure|Respiratory rate modification|"During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate)."
79404292|NCT03076164|Drug|Erlotinib|Erlotinib 75mg once daily by mouth
79851471|NCT00461812|Drug|Advair|
79404293|NCT03157609|Device|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
80017327|NCT02909907|Drug|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
79851472|NCT00721097|Other|spirometry, and blood taken|each month during one year
80017328|NCT02909907|Other|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
79404294|NCT03155893|Drug|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 [mg] ODV [1*25 mg tablet]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
79404295|NCT03155893|Drug|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2 in Treatment E.
79851473|NCT02539862|Other|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
79851474|NCT02539862|Other|psychoeducation|the psychoeducation is delivered by a doctor
79851475|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
79851476|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
79550428|NCT01594138|Other|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
79550429|NCT01594151|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
79714052|NCT01256190|Device|Gelatin sponge|absorbable gelatin sponge for topical use
79714053|NCT01255722|Drug|iobitridol|single IV injection
79714054|NCT01255722|Drug|iopromide|Single IV injection
79714055|NCT01255722|Drug|iomeprol|Single IV injection
79851477|NCT00721331|Drug|nortriptyline HCl|Topical
79851478|NCT00721331|Drug|mometasone furoate|Topical
79851479|NCT00721331|Drug|Active ingredient free vehicle cream of CRx-197|Topical
79851480|NCT01025908|Behavioral|Psychotherapy|Cognitive Behavioral Therapy
79851481|NCT01025908|Behavioral|Supportative psychotherapy|Supportative psychotherapy
79851482|NCT02540096|Other|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
79550430|NCT01594164|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
79550431|NCT01594164|Radiation|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
79714056|NCT02888574|Drug|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
79714057|NCT02888574|Drug|Placebo|Placebo nasal spray
79714058|NCT01231503|Biological|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
79714059|NCT01231503|Biological|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=< 7 days of age)
79714060|NCT01231503|Biological|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
79851483|NCT02540096|Other|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
79550432|NCT01594177|Drug|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
79714061|NCT01231503|Biological|BCG|1 dose, intradermal route, in shoulder at birth (=< 7 days of age)
79714062|NCT01231503|Biological|OPV|4 doses, orally, at birth (=< 7 days of age) and at 6, 10 and 14 weeks of age
79851484|NCT00123955|Drug|Spironolactone|25mg tablet daily for 9 months
79851485|NCT00123955|Drug|Placebo|Placebo tablet daily for 9 months
79851486|NCT04372121|Drug|75 mg linzagolix tablet|For oral administration once daily
79851487|NCT04372121|Drug|200 mg linzagolix tablet|For oral administration once daily
79851488|NCT04372121|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
79851489|NCT04372121|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
79550433|NCT01594177|Drug|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
79550434|NCT01594177|Drug|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
79851490|NCT04372121|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
79851491|NCT04372121|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
79714063|NCT01231503|Biological|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
79550435|NCT01594177|Drug|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
80017329|NCT03962842|Other|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
80017330|NCT02104596|Device|Xylitol|
79254499|NCT02689453|Biological|alemtuzumab|Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
79254500|NCT02082457|Drug|YKP10811 5mg|
79851492|NCT03837028|Other|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
79851493|NCT02539784|Device|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
79851494|NCT04069481|Other|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
79851495|NCT04069481|Other|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
79851496|NCT00898976|Other|immunohistochemistry staining method|
80017331|NCT00004898|Biological|filgrastim|
80017332|NCT00004898|Drug|cyclophosphamide|
79254501|NCT02082457|Drug|YKP10811 20mg|
79254502|NCT02082457|Drug|YKP10811 placebo|
79254503|NCT02084953|Drug|BMS-791325|
79254504|NCT02084953|Drug|Moxifloxacin|
79254505|NCT02084953|Drug|Placebo matching BMS-791325|
79254506|NCT02082613|Procedure|Lord´s procedure|
79254507|NCT02082613|Procedure|Sclerotherapy|
79851497|NCT00898976|Other|laboratory biomarker analysis|
79851498|NCT01027546|Drug|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
80017333|NCT00004898|Drug|etoposide|
80017334|NCT00004898|Procedure|peripheral blood stem cell transplantation|
80017335|NCT00004898|Radiation|radiation therapy|
79254508|NCT02085031|Procedure|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
79254509|NCT02085031|Procedure|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
79254510|NCT02085109|Dietary Supplement|Fat milkshake|
79254511|NCT02085109|Dietary Supplement|Theobromine|
79254512|NCT02088463|Procedure|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
79254513|NCT02088463|Procedure|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
79254514|NCT02088463|Device|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
79254515|NCT02082691|Drug|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
79550436|NCT01594177|Drug|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
79550437|NCT01594190|Behavioral|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
79550438|NCT01594190|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
79550439|NCT01594203|Other|F18-FGD PET/CT|
79550440|NCT01594229|Drug|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
79550441|NCT01594229|Drug|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
79550442|NCT01594229|Drug|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
79550443|NCT01594242|Drug|Bortezomib|
79550444|NCT01594255|Drug|sotrastaurin|
79550445|NCT01594255|Drug|sotrastaurin|
79550446|NCT01594255|Drug|placebo to sotrastaurin|
79550447|NCT01594255|Drug|Avelox|
79550448|NCT01594268|Drug|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
79714064|NCT01230489|Biological|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
79714065|NCT01229397|Biological|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
79714066|NCT01229397|Biological|Inflexal V|Inflexal V 0.5 mL administrated once only
79714067|NCT05492097|Behavioral|Exercise Therapy|Traditional exercise therapy and NMES
79714068|NCT05492097|Behavioral|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
79254516|NCT02085187|Other|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
79254517|NCT02547727|Biological|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
79254518|NCT02310919|Drug|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
79851499|NCT00901082|Behavioral|Relaxation and information session|Relaxation and information session before the medial branch block
80017336|NCT02106468|Drug|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
79254519|NCT02310919|Drug|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
79254520|NCT02082925|Other|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
79254521|NCT03557983|Drug|Fenofibrate|Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
79254522|NCT03557983|Drug|Saline|Saline is topically spread three times per day at the irradiated areas for one week.
79851500|NCT05667545|Drug|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
79851501|NCT00115063|Behavioral|group sessions|group sessions lead by a trained primary care clinic employee
79254523|NCT02085343|Behavioral|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
79254524|NCT02085343|Behavioral|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
79254525|NCT02085343|Behavioral|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
79254526|NCT03558919|Drug|Mirabegron 25mg|
79254527|NCT03558919|Drug|Solifenacin Succinate 5 MG|
79254528|NCT02083003|Dietary Supplement|Polyamine low-diet|
79254529|NCT02083003|Dietary Supplement|Liberal alimentation|
79254530|NCT02085577|Drug|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
79254531|NCT02085577|Drug|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
79254532|NCT02085577|Drug|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
79254533|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
79394400|NCT04606303|Drug|Toripalimab combination with platinum-containing dual-drug chemotherapy.|"cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician."
79550449|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
79851502|NCT00115063|Drug|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
79851503|NCT00115063|Behavioral|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
79851504|NCT00115063|Other|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
80017337|NCT02106468|Drug|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
79550450|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
79851505|NCT00115063|Other|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
79550451|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
79254534|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
79394401|NCT04563039|Device|Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer|Applaud's Acoustic Enhancer is provided in a lyophilized form. After reconstitution, it is a liquid, containing micron-scale particles that are made of a perfluoroalkane gas core with a lipid shell. The device is intended to be used with cleared/approved pulsed laser systems in fragmenting urinary stones (calculi) in the upper (superior) pole, lower (inferior) pole, and interpolar region of the kidney, pelvis of the kidney, and proximal ureter.
80017338|NCT03956446|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
80017339|NCT03956446|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
79550452|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
79550453|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
80017340|NCT03956446|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
79550454|NCT01594320|Biological|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 & Day 21
80017341|NCT03529682|Other|exercise|10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
79254535|NCT02085577|Drug|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
79550455|NCT01594346|Drug|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
79254536|NCT02085577|Drug|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
79550456|NCT01594346|Drug|Sugar Pill|
79550457|NCT01594359|Other|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
79714069|NCT01228071|Drug|testosterone gel 2%|40 mg testosterone gel 2%
79851506|NCT01026064|Other|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
79851507|NCT01026064|Drug|Azithromycin|Zithromax (250 mg oral capsule).
79254537|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
79254538|NCT02085577|Drug|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
79254539|NCT03557827|Drug|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
79254540|NCT03557827|Procedure|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
79254541|NCT02088619|Behavioral|Quality of Life Therapy (QOLT)|
79254542|NCT02088619|Behavioral|Heart Healthy Education (HHE)|
79394402|NCT04563039|Device|Standard Ureteroscopic Laser Lithotripsy|Standard of care Ureteroscopic Laser Lithotripsy
79394403|NCT04541849|Other|Critical Care|Critical care in the intensive care units
79550458|NCT01594359|Other|BEAN|Placebo
79550459|NCT01594437|Biological|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
79550460|NCT01594437|Biological|Placebo|One or two doses administered by intravenous infusion.
79550461|NCT01594450|Biological|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
79581045|NCT01932086|Dietary Supplement|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
79581046|NCT01932086|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
79851508|NCT01026064|Drug|Placebo|Matching placebo
80017342|NCT03529682|Other|control group|60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
80017343|NCT02106624|Other|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
80017344|NCT02250768|Biological|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
80017345|NCT00325364|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
80017346|NCT00325364|Drug|Injectable insulin|patient specific dose, injectable, before meals, 24 months
79714070|NCT04319289|Other|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
79851509|NCT00899054|Drug|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
79851510|NCT00899054|Radiation|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
79851511|NCT05659745|Other|VM-02|VM-02 is a personal care product for vaginal health.
79851512|NCT05659745|Dietary Supplement|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
79851513|NCT05659745|Other|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
79851514|NCT00899132|Genetic|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
79714071|NCT04319289|Drug|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
80017347|NCT02102178|Other|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
79851515|NCT00899132|Genetic|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
79851516|NCT00899132|Other|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
79254543|NCT03558841|Other|Gait training with the THERA-Trainer Lyra|Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
79254544|NCT03558841|Other|Physical therapy|Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
79254545|NCT02088853|Dietary Supplement|high fat diet (hfd)|Sixty % of the energy content is based on fat.
79254546|NCT02088853|Dietary Supplement|high carb diet|Sixty % of the energy content is based on carbohydrates.
80017348|NCT02102178|Other|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
79851517|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
79851518|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
79851519|NCT00461500|Drug|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
79851520|NCT00461500|Drug|Fluticasone propionate|FP 100
79394404|NCT04539626|Drug|Estrogen Therapy|EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
79394405|NCT04531709|Other|Comprehensive Score for financial toxicity (COST)|Measure indirect and direct health care cost that burden patients and their loved ones.
79394406|NCT04531709|Other|Functional Assessment of Cancer Therapy: General (FACT-G)|General quality of life instrument
79394407|NCT04531709|Other|EORTC QLQ C-30|Assess quality of life in cancer patients
79394408|NCT04531709|Other|EORTC QLQ-TC26.|To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
79851521|NCT00893906|Biological|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
79851522|NCT00893906|Biological|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
79851523|NCT00721487|Drug|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
79851524|NCT00167245|Drug|Topiramate|300mg/day for 13 weeks
79851525|NCT00167245|Drug|placebo|placebo pills
79851526|NCT00901160|Procedure|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
79851527|NCT00716339|Behavioral|motivation|
79851528|NCT00894062|Device|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
79851529|NCT00894062|Device|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
79550462|NCT01594450|Procedure|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
79550463|NCT01594463|Other|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
79550464|NCT01594463|Other|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
79254547|NCT02085655|Drug|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79254548|NCT02085655|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79550465|NCT01594489|Drug|Aminophylline|"200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
79550466|NCT01594489|Drug|Hydration plus N-acetylcisteine|"Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
79550467|NCT01594502|Drug|Dutasteride|0.5 mg daily
79714072|NCT04319289|Other|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~Frequency: 3 days/week. The whole training lasting for 12 weeks"
79714073|NCT04319133|Behavioral|Fasting|Doing fasting 2 days a week within 8 weeks
79714074|NCT01008475|Drug|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
79851530|NCT00721565|Behavioral|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
80017349|NCT02102178|Other|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
79254549|NCT02085655|Drug|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
79254550|NCT02085655|Drug|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79254551|NCT02085655|Drug|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79254552|NCT02085655|Drug|Thalidomide|100-200mg, PO, after chemotherapy
79254553|NCT02085811|Other|radiography standard|
79394409|NCT04516252|Behavioral|BodyWorks Intervention|BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)
79394410|NCT04516252|Behavioral|Canine Curriculum|Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.
79254554|NCT02090881|Other|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
79394411|NCT04516252|Behavioral|Ecological Momentary Assessment|Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).
79550468|NCT01594502|Drug|Placebo|Placebo Comparator
79550469|NCT01594567|Other|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
79550470|NCT01594593|Behavioral|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
79550471|NCT01594606|Behavioral|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
79550472|NCT01594619|Drug|Naloxegol|Oral 25mg tablet
79550473|NCT01594619|Drug|Diltiazem XR|Oral 240mg tablet
79550474|NCT01594632|Drug|Jadelle|LNG containing subdermal contraceptive implant
79550475|NCT01594632|Drug|Sino-implant (II)|LNG containing subdermal contraceptive implant
79550476|NCT01594645|Procedure|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
79851531|NCT00894140|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
79851532|NCT00443560|Other|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
79851533|NCT04098341|Diagnostic Test|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
79851534|NCT00922454|Procedure|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
79851535|NCT00922454|Device|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
79851536|NCT00922454|Device|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
79851537|NCT00721643|Dietary Supplement|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
79394412|NCT04516252|Behavioral|Physical Activity Trackers|Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
79851538|NCT00721643|Dietary Supplement|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
79394413|NCT04512534|Drug|PD-1 antibody+ HDAC inhibitor|"Patients receive anti-PD-1 antibody Sintilimab+ HDAC inhibitor Chidamide three weeks for a cycle, detailed as follows:~Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip (without pretreatment), infusion time: 30 minutes (no less than 20 mins, no more than 60 mins), the maximum treatment period is 2 years (up to 35 doses), complete remission（CR）patients confirmed by imaging assessment can be considered off anti-PD-1 treatment after 12 treatment cycles.~Chidamide: Chidamide is administered orally at a dose of 30mg (initial dose). It is recommended to be administered within 0.5h after a meal with a fixed time. Chidamide will be given until disease progression or intolerant toxicity. The maximum treatment is 2 years. If chidamide therapy requires to be continued over 2 years due to clinical benefit, the prescription/decision should be made after discussion with the principal investigator."
79394414|NCT04504630|Device|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
79254555|NCT02085889|Other|no intervention: observational study|observational
79254556|NCT02085967|Drug|rifampin 600 mg|
79254557|NCT02085967|Drug|itraconazole 200 mg|
79394415|NCT04504630|Device|Sham HD-tDCS|Sham HD-tDCS
79550477|NCT01594658|Procedure|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
79254558|NCT02085967|Drug|midazolam 2 mg with bupropion 75 mg|
79550478|NCT01594658|Procedure|conservative|This arm only has medical standard handling (healings performed by the nurse group)
79550479|NCT01594671|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
79550480|NCT01594671|Drug|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
79550481|NCT01594671|Other|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
79851539|NCT00899210|Other|laboratory biomarker analysis|
79851540|NCT00899210|Procedure|cryosurgery|
79851541|NCT00899210|Procedure|radiofrequency ablation|
79851542|NCT00899210|Procedure|therapeutic conventional surgery|
79851543|NCT00721721|Behavioral|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
79254559|NCT02085967|Drug|E2006|
79254560|NCT02089009|Other|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
79254561|NCT02089009|Other|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
79254562|NCT02089009|Other|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
79254563|NCT02089087|Biological|CFZ533|Single dose at varying dosage levels depending on treatment assignment
79254564|NCT02089087|Drug|Placebo|
79254565|NCT02091115|Dietary Supplement|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
79254566|NCT02091115|Dietary Supplement|Dairy drink|
79254567|NCT02091193|Dietary Supplement|Krill Oil (Supplement A)|
79254568|NCT02091193|Dietary Supplement|Placebo (Supplement B)|
79254569|NCT02091349|Other|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
79254570|NCT02091349|Other|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
79851544|NCT00721721|Behavioral|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
79851545|NCT00721721|Dietary Supplement|Potassium Supplementation|60 mmol potassium supplement
79851546|NCT01022632|Dietary Supplement|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
79394416|NCT04442581|Drug|Cabozantinib S-malate|Given PO
79550482|NCT01594684|Device|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
79394417|NCT04442581|Biological|Pembrolizumab|Given IV
79394418|NCT04436731|Other|Hypoxia Exposure|Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
79550483|NCT01594684|Device|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
79550484|NCT01594684|Device|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
79550485|NCT01594684|Device|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
79550486|NCT01594697|Drug|Metformin|
79550487|NCT01594736|Drug|ORSIRO|due randomization ORSIRO will be implanted
79550488|NCT01594736|Device|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
79550489|NCT01594775|Drug|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
79550490|NCT01594775|Drug|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
79714075|NCT01008475|Drug|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
79714076|NCT01008475|Drug|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
79714077|NCT01008475|Drug|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
79739845|NCT03538756|Device|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
79851547|NCT01022632|Drug|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
79394419|NCT04436731|Drug|Phenylephrine|Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
79254571|NCT02086123|Procedure|Epidural Analgesia|Bupivacaine + Fentanyl
79394420|NCT04436731|Drug|Dexmedetomidine|Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
79550491|NCT01594801|Device|InsuPad|Use of the InsuPad for at least 3 times a day.
79550492|NCT01594814|Procedure|RFA|radiofrequency ablation of slow pathway or accesory pathway
79550493|NCT01594840|Device|Changing chat|Diapers with tips
79550494|NCT01594866|Drug|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
79550495|NCT01594866|Drug|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
79851548|NCT01022632|Dietary Supplement|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
79851549|NCT00899288|Procedure|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
79254572|NCT02086123|Procedure|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
79254573|NCT02091505|Drug|Ranibizumab|
79254574|NCT02086201|Behavioral|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
79254575|NCT02086201|Behavioral|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
79254576|NCT02089165|Dietary Supplement|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
79254577|NCT02089165|Dietary Supplement|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
79550496|NCT01594879|Device|MIrena(LNG-IUS), oral MPA|"General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
79550497|NCT01594892|Radiation|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
79550498|NCT01594905|Drug|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
79550499|NCT01594918|Drug|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
79550500|NCT01594918|Drug|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
79550501|NCT01594918|Drug|Prednisone|5 mg PO BID
79550502|NCT01594918|Drug|Pegfilgrastim|6 mg, SC, once every 21 days
79550503|NCT01594957|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
79550504|NCT01595009|Drug|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
79851550|NCT03716999|Other|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
79851551|NCT00899366|Genetic|microarray analysis|
79851552|NCT00899366|Genetic|mutation analysis|
79851553|NCT00899366|Other|immunologic technique|
79394421|NCT04436731|Drug|Phentolamine|Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
79550505|NCT01595022|Drug|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
80017350|NCT02102178|Other|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
80017351|NCT02651194|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
80017352|NCT02104674|Drug|lebrikizumab|Given SC on Days 1, 29, and 57
80017353|NCT02104674|Drug|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
79550506|NCT01595022|Drug|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
80017354|NCT02104674|Other|placebo|SC injection given on Days 1, 29, and 57
80017355|NCT03529604|Other|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
80017356|NCT03529604|Diagnostic Test|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
79851554|NCT01026298|Other|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
79254578|NCT02089165|Dietary Supplement|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
79254579|NCT02091661|Procedure|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
79254580|NCT02091661|Radiation|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
79254581|NCT02079259|Procedure|Ultrafiltration|
79394422|NCT04436731|Drug|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
79394423|NCT04423068|Behavioral|SexHealth II|SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
79394424|NCT04423068|Drug|Contraceptive|"The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet"
79404296|NCT03155893|Drug|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) orally once daily on Days 3 to 7 in Treatment E.
80017357|NCT03529604|Diagnostic Test|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
80017358|NCT01917604|Procedure|open exposure|the open surgical methods of exposing the canine is compared with control
80017359|NCT01917604|Procedure|closed exposure|closed exposure is compared with control
80017360|NCT01903330|Drug|ERC1671|Given intradermally
80017361|NCT01903330|Drug|GM-CSF|Given intradermally
80017362|NCT01903330|Drug|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
79550507|NCT01595022|Drug|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
79550508|NCT01595035|Behavioral|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
79851555|NCT03683381|Behavioral|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
79851556|NCT03683381|Other|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
79851557|NCT00899522|Other|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
80017363|NCT01903330|Drug|Oral Control (Sucrose pill)|Given PO
80017364|NCT01903330|Drug|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
79550509|NCT01595074|Other|medical chart review|Correlative studies
79550510|NCT01595074|Other|laboratory biomarker analysis|Correlative studies
79254582|NCT02089243|Procedure|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
79254583|NCT02089243|Procedure|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
79550511|NCT01595087|Drug|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
79550512|NCT01595152|Drug|solifenacin succinate|8 mg once daily for 60 days
80017365|NCT01903330|Drug|Bevacizumab/Bevacizumab Biosimilar|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
80017366|NCT03529526|Drug|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
79550513|NCT01595152|Drug|fesoterodine|8 mg, once daily for 60 dyas
79550514|NCT01595165|Procedure|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
79550515|NCT01595165|Procedure|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
79550516|NCT01595178|Behavioral|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
80017367|NCT02102256|Device|Auditory Brainstem Implant|
80017368|NCT03529370|Radiation|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
80017369|NCT02106702|Behavioral|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
79254584|NCT02091817|Drug|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
79254585|NCT02091817|Drug|Placebo|Placebo will be given to control group and experimental group as well.
79254586|NCT03557671|Dietary Supplement|rice formula|new rice based thickened formula
79254587|NCT03557671|Dietary Supplement|placebo|formula previously tolerated by the subject - only for the 1st part of the study
79404297|NCT03155893|Drug|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV [2*50 mg tablets] orally once daily on Days 8 to 14 in Treatment E.
79404298|NCT03155893|Drug|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV [2*75 mg capsules]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
79404299|NCT03155893|Drug|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 [3*400 mg tablets]) administered orally on Day 15 in Treatment A and B.
79404300|NCT03155893|Drug|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
79404301|NCT03155893|Drug|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
79550517|NCT01595191|Other|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
79851558|NCT00899522|Procedure|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
79404302|NCT03155893|Drug|ODV 200 mg|Participants will receive ODV 200 mg (4*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
79404303|NCT03155893|Drug|ODV 125 mg|Participants will receive ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
79550518|NCT01595191|Other|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
79550519|NCT01595204|Procedure|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
79550520|NCT01595217|Device|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
79550521|NCT01595230|Procedure|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
79851559|NCT01026376|Drug|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
79851560|NCT01026376|Drug|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
79851561|NCT00712829|Drug|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
79550522|NCT01595243|Behavioral|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
79254588|NCT02086279|Drug|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
79851562|NCT00712829|Drug|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
79851563|NCT00899756|Genetic|molecular diagnostic method|
79851564|NCT00899756|Genetic|mutation analysis|
79254589|NCT02086357|Procedure|SWUE|
79254590|NCT02086435|Procedure|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
79254591|NCT02086435|Procedure|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
79254592|NCT02091895|Procedure|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
79550523|NCT01595256|Behavioral|muscular strength|12-week moderate intensity walking program
79550524|NCT01595269|Other|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
79550525|NCT01595295|Other|non interventional|
79550526|NCT01595308|Dietary Supplement|Pomegranate juice|Pomegranate juice
79550527|NCT01595334|Drug|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (>4.5 mIU/ml) in the study arm
79550528|NCT01595334|Drug|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
79550529|NCT01595347|Drug|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
79550530|NCT01595347|Other|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
79550531|NCT01595360|Drug|Placebo|It is applied directly to the bleeding site after tooth extraction
79550532|NCT01595360|Drug|TT-173|It is applied directly to the bleeding site after tooth extraction
79550533|NCT01595373|Drug|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
79550534|NCT01595373|Drug|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
79550535|NCT01595399|Drug|atropine|Atropine 0.02 mg/kg IV
79550536|NCT01595399|Drug|Placebo|an equivalent volume of normal saline to atropine IV
79550537|NCT01595412|Procedure|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
79550538|NCT01595412|Procedure|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
79550539|NCT01595425|Drug|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
79550540|NCT01595425|Drug|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
79550541|NCT01595451|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
79714078|NCT01008475|Drug|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
79851565|NCT00712907|Dietary Supplement|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
79550542|NCT01595464|Behavioral|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
79550543|NCT01595477|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
79550544|NCT01595490|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
79550545|NCT01595542|Behavioral|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~Cover letter~Vaccine promotional flyer~Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~Improved consent form~Note advertising a lottery for free movie tickets for returning the consent form~Self-addressed stamped envelope"
79550546|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
79254593|NCT02081911|Procedure|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
79550547|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
79550548|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
79851566|NCT00712907|Dietary Supplement|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
79550549|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
79851567|NCT00712907|Other|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
79254594|NCT02081911|Procedure|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
79394425|NCT04413214|Drug|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
79550550|NCT01595594|Drug|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
79550551|NCT01595594|Drug|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
79550552|NCT01595607|Other|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
79550553|NCT01595633|Drug|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
79714079|NCT01008475|Drug|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
79714080|NCT04294303|Other|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
79851568|NCT00901238|Procedure|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
79394426|NCT04379570|Other|Educational Intervention|Receive online educational information about ET medication
79394427|NCT04379570|Other|Text Message-based Navigation Intervention|Receive text messages
79851569|NCT03734224|Procedure|Adhesix mesh|Adhesix mesh
79851570|NCT03734224|Procedure|Progrip mesh|Progrip mesh
79851571|NCT05003141|Drug|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
79851572|NCT00716495|Biological|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
79394428|NCT04379570|Behavioral|Motivational Interviewing|Receive motivational interviewing counseling sessions
79394429|NCT04379570|Other|Best Practice|Attend usual care clinic visits
79550554|NCT01595659|Behavioral|Passenger|Driving with risk accepting or risk averse passenger
79851573|NCT00899912|Genetic|microarray analysis|
79851574|NCT00899912|Other|diagnostic laboratory biomarker analysis|
79394430|NCT04379570|Other|Questionnaire Administration|Ancillary studies
79550555|NCT01595672|Device|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
79851575|NCT00716573|Drug|everolimus|0,75 mg bid, 24 months
79851576|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
79851577|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
79851578|NCT00900068|Other|immunoenzyme technique|
79851579|NCT00900068|Other|laboratory biomarker analysis|
79851580|NCT00900068|Other|medical chart review|
79254595|NCT02081911|Procedure|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
79550556|NCT01595672|Other|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
79550557|NCT01595685|Drug|Telbivudine|Telbivudine 600 mg Daily Oral
79550558|NCT01595685|Drug|Entecavir|Entecavir 0.5 mg Daily Oral
79851581|NCT00451204|Drug|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
79550559|NCT01595698|Other|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
79714081|NCT04294303|Other|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
79714082|NCT02870725|Behavioral|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
79714083|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
79714084|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
79714085|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
79714086|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
79714087|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
79851582|NCT00451204|Drug|Placebo|Placebo capsule, once a day, treatment duration is 2 years
79394431|NCT04379570|Other|Quality-of-Life Assessment|Ancillary studies
79714088|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
79714089|NCT02870647|Other|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
79714090|NCT01226511|Drug|Duloxetine|Administered orally
79714091|NCT01226511|Drug|Placebo|Administered orally
79714092|NCT02691351|Other|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~Regimen~Response Evaluation~SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
79714093|NCT01226121|Biological|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
79714094|NCT01226043|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79714095|NCT04206579|Drug|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
79714096|NCT04206579|Drug|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
79714097|NCT01001377|Drug|Cetuximab|Administered by intravenous infusion
79714098|NCT01001377|Drug|Panitumumab|Administered by intravenous infusion
79394432|NCT04376476|Biological|Blood sample|blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
79394433|NCT04376476|Biological|Low or upper respiratory tract sample|"Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0"
79714099|NCT01225887|Drug|Nintedanib|Given PO
79394434|NCT04376476|Biological|Stool collection or fecal swab|"The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0"
79394435|NCT04376476|Other|phone call|phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
79404304|NCT03155893|Drug|ODV 100 mg|Participants will receive ODV 100 mg (2*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
79714100|NCT04326829|Drug|QL1604|QL1604, IV infusion
79714101|NCT01001299|Drug|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
79714102|NCT01001299|Drug|RO5185426|960 mg orally twice daily
79714103|NCT01296932|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
79714104|NCT01296698|Drug|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
79714105|NCT01296698|Drug|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
79714106|NCT01001221|Drug|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1"
79851583|NCT00451204|Drug|Copaxone|Injection, once a day, all subjects
79851584|NCT04067999|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
79550560|NCT01595698|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
79714107|NCT01001221|Drug|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1."
79714108|NCT01296152|Drug|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
79714109|NCT04326608|Other|physiotherapy|manual therapy and sef-care exercises
79714110|NCT02870257|Other|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
79714111|NCT02870257|Other|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
79851585|NCT00900302|Genetic|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
79851586|NCT00900302|Other|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
79851587|NCT00900302|Other|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
79875278|NCT00941135|Other|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
80017370|NCT02106702|Behavioral|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
79550561|NCT01595711|Device|Pain Monitor|Measurement of cutaneous conductance
79550562|NCT01595724|Drug|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
79550563|NCT01595737|Drug|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
79394436|NCT04308382|Behavioral|Health Risk Assessment|"Heath Risk Assessment consists of:~Survey to include questions about physical activity, stress, hope, household hunger and demographics.~Lipid panel and HbA1c~Height and Weight, blood pressure and resting pulse"
79714112|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
79714113|NCT01002547|Drug|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
79394437|NCT04304534|Drug|BAY2433334|Tablet, taken orally once a day.
79394438|NCT04304534|Other|BAY2433334 matching placebo|Tablet, taken orally once a day.
79394439|NCT04268706|Drug|CD30.CAR-T|Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
79394440|NCT04268706|Drug|Fludarabine|Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
79714114|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
79875279|NCT00397215|Biological|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
79875280|NCT00397215|Biological|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
80017371|NCT03869632|Drug|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
79254596|NCT02091973|Drug|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
79254597|NCT02091973|Drug|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
79254598|NCT02092051|Device|Continuous glucose monitoring with DexCom G4 platina|
79254599|NCT02086513|Drug|LDE225|Treatment with LDE225
79254600|NCT03558295|Drug|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
79254601|NCT02086669|Procedure|Pneumatic dilatation|
79254602|NCT02086669|Procedure|Laparoscopic myotomy|
79254603|NCT02089399|Drug|Sevikar(amlodipne/olmesartan)|Treatment AB
79394441|NCT04268706|Drug|Bendamustine|Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
79550564|NCT01595737|Drug|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
79550565|NCT01595750|Drug|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
79550566|NCT01595750|Drug|Placebo|Placebo 500 mcg , 12 weeks of treatment
79550567|NCT01595763|Other|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
79550568|NCT01595776|Other|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
79550569|NCT01595789|Drug|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
79550570|NCT01595789|Drug|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
79550571|NCT01595815|Other|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
79550572|NCT01595815|Other|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
79550573|NCT01595828|Drug|Pitavastatin|
79550574|NCT01595867|Drug|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
80017372|NCT02104908|Procedure|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
79550575|NCT01595867|Drug|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
79550576|NCT01595867|Drug|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
79550577|NCT01595880|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
79254604|NCT02089399|Drug|crestor(Rosuvastatin)|Treatment AB/Treatment C
79394442|NCT04250259|Drug|Placebo|2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
79394443|NCT04250259|Drug|SAMe 400 mg tablet|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
79394444|NCT04223609|Drug|Oxycodone|5 mg tablet
79550578|NCT01595880|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
79550579|NCT01595893|Drug|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
79550580|NCT01595893|Drug|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
79714115|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
79714116|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
79714117|NCT01002547|Drug|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
79714118|NCT04295161|Drug|Abiraterone Acetate|Abiraterone acetate immediate release formulations
79254605|NCT03557593|Other|Educational|Multi component educational intervention in long-term care
79254606|NCT02089477|Other|Support group|"The participants in the intervention group receives the intervention and support consisting of:~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
79394445|NCT04223609|Drug|Placebo|Oxycodone-matched placebo tablet
79394446|NCT04223609|Device|EyeLink 1000 Plus|Non-invasive video-based eye tracking system
79254607|NCT02089555|Procedure|Lumbar puncture|Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
79254608|NCT02089555|Procedure|Blood draw|One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
79254609|NCT02089555|Procedure|Magnetic Resonance Imaging (MRI)|Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
79394447|NCT04223609|Diagnostic Test|Oculo-Cognitive Addition test (OCAT)|Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
79254610|NCT03557515|Behavioral|Stress Management and CBT|"Stress Management will focus on:~Mind-Body Connection~Coping Skills~Communication~Social Support~Cognitive Behavioral Therapy will focus on:~Intro to CBT-Tracking Automatic Thoughts~Identifying Distorted Thoughts~Challenging Distorted Thoughts~Core Beliefs/Relapse Prevention"
79254611|NCT03557515|Behavioral|Stress Management and Metta-Meditation|"Stress Management will focus on:~Mind-Body Connection~Coping Skills~Communication~Social Support~Metta-Meditation will focus on:~Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~Intro to Brief Loving-Kindness Meditation and Self-Care~Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~Review/Plan for Future"
79394448|NCT04223609|Device|VT3mini - Eye Tracking Technology for OEMs|Non-invasive eye-tracking device
79394449|NCT04194385|Procedure|Upper trunk block|Block will be applied to supraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine .
79394450|NCT04194385|Procedure|Costoclavicular block|Block will be applied to infraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
79394451|NCT04194385|Procedure|Diaphragmatic function assessment|Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.
79394452|NCT04194385|Procedure|Cervical plexus blockade|Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.
79550581|NCT01595906|Procedure|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
79394453|NCT04178304|Drug|Prolotherapy with 25% Dextrose|Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
80017373|NCT02104908|Procedure|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
79550582|NCT01595919|Other|Nutritional Intervention|Ad libitum amounts of beverage at a meal
79550583|NCT01595932|Dietary Supplement|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children < 20kg: 4 drops;~children > 20kg and < 40kg: 8 drops;~children > 40kg: 1 tablet."
79550584|NCT01595932|Dietary Supplement|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children < 20kg: 4 drops;~children > 20kg and < 40kg: 8 drops;~children > 40kg: 1 tablet."
79254612|NCT03557437|Drug|Esomeprazole|Proton pump inhibitor
79254613|NCT03557437|Drug|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
79254614|NCT03557437|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
79394454|NCT04176458|Device|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
79394455|NCT04137939|Device|smart exercise system|The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
79394456|NCT04118920|Drug|Topical insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
79550585|NCT01595945|Procedure|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
80017374|NCT04366648|Drug|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
80017375|NCT02106780|Drug|14C-labeled ASP1707|oral
80017376|NCT02907177|Drug|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
79851588|NCT00900302|Procedure|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
79550586|NCT01595945|Behavioral|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
79550587|NCT01595958|Drug|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
79550588|NCT01595958|Procedure|cardio-pulmonary resuscitation|usual care of cardiac arrest
79851589|NCT00721877|Drug|resveratrol|Given orally
79851590|NCT00721877|Other|pharmacological study|Correlative studies
79851591|NCT00721877|Other|laboratory biomarker analysis|Correlative studies
80017377|NCT02907177|Other|Placebo|One tablet of matching placebo administered orally once daily in the morning
80017378|NCT00004172|Biological|filgrastim|
80017379|NCT00004172|Drug|carboplatin|
80017380|NCT00004172|Drug|cyclophosphamide|
80017381|NCT00004172|Drug|ifosfamide|
80017382|NCT00004172|Drug|thiotepa|
79851592|NCT03742570|Behavioral|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
79851593|NCT00716651|Drug|mepolizumab|750 mg mepolizumab iv q4wk until week 32
79851594|NCT00900380|Other|flow cytometry|
79851595|NCT00900380|Other|immunological diagnostic method|
79851596|NCT00900380|Other|laboratory biomarker analysis|
80017383|NCT00004172|Procedure|peripheral blood stem cell transplantation|
80017384|NCT00004172|Radiation|radiation therapy|
80017385|NCT04353310|Drug|Curcumin|Curcumin 1500mg PO BID
80017386|NCT04353310|Other|Placebo|identical in appearance to curcumin
80017387|NCT00004166|Drug|amifostine trihydrate|
79254615|NCT02089633|Biological|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
79254616|NCT02086747|Drug|Acetaminophen|100 ml iv, 4 times a day for 72 hours
79254617|NCT02086747|Drug|Isotonic|100 ml iv, 4 times a day for 72 hours
79550589|NCT01595971|Behavioral|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
79254618|NCT02086825|Drug|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
79851597|NCT01026532|Biological|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
79851598|NCT01022788|Behavioral|Home-based counselling|
79254619|NCT02086825|Drug|Lactulose|20g dose titrated
79254620|NCT02086903|Drug|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
79254621|NCT02086903|Drug|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
79254622|NCT05502055|Other|Individual interviews|One on One interviews by Zoom video conferencing, < 2 hours in duration
79254623|NCT05502055|Other|Focus Groups|Focus Groups discussions by Zoom video conferencing, < 2 hours in duration
79254624|NCT05502055|Other|National Survey|Survey conducted online and distributed nationally
79254625|NCT02087137|Behavioral|Memory and Aging Program|
79254626|NCT02087215|Drug|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
79394457|NCT04118920|Drug|Topical insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
79394458|NCT04118920|Drug|Artificial tears|N=3, 40 microliters per drop
79254627|NCT02087215|Drug|Placebo|
79254628|NCT02087293|Behavioral|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
79394459|NCT04089449|Drug|PRT811|PRT811 will be administered orally
79394460|NCT04083144|Device|Deep Repetitive Transcranial Magnetic Stimulation (Active)|Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
79394461|NCT04083144|Device|Deep Repetitive Transcranial Magnetic Stimulation (Sham)|Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
79851599|NCT00900458|Behavioral|Aerobic Exercise training|aerobic exercise training (cycling)
79851600|NCT02571803|Behavioral|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
79851601|NCT02571803|Other|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
80017388|NCT00004166|Procedure|quality-of-life assessment|
79254629|NCT02087527|Drug|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
79254630|NCT02087527|Drug|Normal Saline|IV normal saline every 6 hours for 48 hours
79254631|NCT02249611|Device|Mobile physical activity promotion tool|"Mobile activity sensor~Smartphone with APP~Interactional webpage of internet~Evidence based health information~Individualized reminding messages according to the data from activity recording system~Personal counseling from professional personnel"
79254632|NCT02249611|Other|Standard care|Counseling on lifestyles with health education material
79394462|NCT04083144|Drug|Varenicline|12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
79254633|NCT02092207|Drug|KL7016 900mg|oral administration, 150mg 3tab, bid
79254634|NCT02092207|Drug|KL7016 600mg|oral administration, 150mg 3tab, bid
79254635|NCT02092207|Drug|Placebo|oral administration, 150mg 3tab, bid
79254636|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
79254637|NCT02087683|Other|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
79404305|NCT03155893|Drug|SMV 150 mg|Participants will receive SMV 150 mg (2*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
79550590|NCT01595971|Other|usual care|Received the usual care provided
79550591|NCT01595984|Drug|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
79550592|NCT01595984|Drug|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
79550593|NCT01595997|Drug|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
79550594|NCT01596010|Drug|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
79550595|NCT01596023|Device|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
79550596|NCT01596036|Behavioral|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
79714119|NCT04367623|Other|Brain computer interface based therapy|Participants who decide to take part will be assigned to a treatment or a control group. Both groups will have the same assessments and the same number of therapy sessions. Therapy group will have a training that consists of Brain Computer Interface controlled Functional Electrical Stimulation followed by a physical practice of the dominant upper limb, while the control group will have a physical practice only. One experimental session will last about 60 min for both groups (including setup and therapy) and participants in each group will receive 20 sessions, about 3 times per week. The expected time needed for completion of 20 sessions is 7 weeks
79714120|NCT05240911|Drug|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
79254638|NCT02092363|Drug|OMP-54F28, Paclitaxel and Carboplatin|
79394463|NCT04067180|Other|allogeneic stem cell transplantation with a haplo-identical family donor graft|"The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil."
79550597|NCT01596036|Other|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
79714121|NCT02870491|Behavioral|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
79714122|NCT02870491|Behavioral|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
79714123|NCT04452253|Dietary Supplement|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
79714124|NCT04452253|Dietary Supplement|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
79714125|NCT04452253|Dietary Supplement|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
79851602|NCT03537586|Drug|Bivalirudin|After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
79851603|NCT03537586|Drug|Adenosine|An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
79394464|NCT04067180|Other|allogeneic stem cell transplantation with a matched unrelated donor graft|"Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied."
80017389|NCT00004106|Drug|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
79254639|NCT03558139|Drug|Magrolimab|Administered intravenously
79254640|NCT03558139|Drug|Avelumab|Administered intravenously
79254641|NCT02089867|Other|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
79714126|NCT04452253|Other|Placebo|The placebo capsule contains microcrystalline cellulose.
80017390|NCT02105064|Device|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
79254642|NCT02089867|Drug|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
79254643|NCT02089867|Dietary Supplement|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
79254644|NCT02092519|Device|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
79254645|NCT02092519|Device|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
79550598|NCT01596049|Device|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
79550599|NCT01596075|Drug|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
79550600|NCT01596114|Other|Stopping treatment with TKI|stopping until loss of MMR
79550601|NCT01596140|Drug|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
79550602|NCT01596140|Drug|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
79550603|NCT01596140|Drug|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
79550604|NCT01596153|Dietary Supplement|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
79550605|NCT01596166|Drug|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
79550606|NCT01596166|Drug|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
79714127|NCT01225731|Biological|tildrakizumab|SC administration of tildrakizumab at assigned dose
79714128|NCT01225731|Drug|Placebo|SC administration of Placebo
79851604|NCT03537586|Drug|Heparin|Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
79851605|NCT03537586|Device|Pressure-Temperature Sensor Guidewire|Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
80017391|NCT02105064|Device|SHAM rTMS|Sham rTMS, without brain stimulation
80017392|NCT00002246|Drug|Stavudine|
79851606|NCT03537586|Device|Guiding Catheter|Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
79851607|NCT00894218|Procedure|Arthroplasty|Hip or knee arthroplasty
79851608|NCT00722033|Drug|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
79851609|NCT00894374|Drug|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
79254646|NCT03777397|Other|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
79851610|NCT00894374|Drug|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
80017393|NCT02652442|Behavioral|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
79254647|NCT02092597|Drug|Exenatide|
79254648|NCT02092597|Drug|Linagliptin|
80017394|NCT02652442|Behavioral|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
79394465|NCT04061967|Other|Sending of screening summon.|A Cobas PCR Female swab sample packet will be sent. Response rates will be measured.
79254649|NCT02092597|Drug|Gliclazide|
79851611|NCT04920149|Drug|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
79254650|NCT02092753|Other|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
79550607|NCT01596179|Behavioral|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
79550608|NCT01596179|Behavioral|Internet access|a netbook computer with internet access is provided to participants on the control arm.
79851612|NCT04920149|Drug|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
79851613|NCT01026610|Drug|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
79254651|NCT02092753|Other|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
79394466|NCT04055818|Drug|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
79851614|NCT01026610|Drug|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
80017395|NCT02652442|Behavioral|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
79851615|NCT01026610|Drug|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
79394467|NCT04047953|Drug|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40~60mg，bid, d1-14( BSA<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\PR\SD and decided by the investigator to continue the treatment for two cycles or directly.
80017396|NCT03554460|Device|dual-limb NIV|dual-limb NIV was served with servo i ventilator
80017397|NCT00002240|Drug|Atazanavir|
80017398|NCT00002240|Drug|Nelfinavir mesylate|
80017399|NCT00002240|Drug|Stavudine|
79851616|NCT00900536|Genetic|mutation analysis|
79851617|NCT00900536|Genetic|polymorphism analysis|
79851618|NCT00900536|Genetic|protein expression analysis|
79851619|NCT00900536|Other|immunohistochemistry staining method|
79851620|NCT00900536|Other|laboratory biomarker analysis|
79851621|NCT00713063|Behavioral|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
79851622|NCT00713063|Behavioral|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
79394468|NCT04039620|Other|Observational study, no interventions expected|No interventions are planned
79394469|NCT03981900|Drug|Tofacitinib|5 mg BID, oral administrtaion
79394470|NCT03981900|Drug|Tofacitinib|tablet form 11mg once daily oral
79851623|NCT03530254|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
79851624|NCT03530254|Diagnostic Test|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
79851625|NCT00901550|Drug|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
79851626|NCT00901550|Drug|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
79851627|NCT02573051|Drug|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
79851628|NCT02573051|Drug|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
79851629|NCT02573051|Other|placebo|
79851630|NCT02539940|Device|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
79851631|NCT01028092|Drug|Anti R-IL2 + Cyclosporine|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
79714129|NCT04319211|Other|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
79714130|NCT01007149|Drug|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
80017400|NCT00002240|Drug|Didanosine|
79254652|NCT02092753|Other|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
79714131|NCT01007149|Drug|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
79714132|NCT04295083|Behavioral|clay based group study|"Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods."
79851632|NCT01028092|Drug|Thymoglobulin + Everolimus|"Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
80017401|NCT02105142|Behavioral|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
79714133|NCT00998335|Drug|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
79714134|NCT00998335|Drug|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
79714135|NCT04204681|Diagnostic Test|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
79851633|NCT01028092|Drug|Anti R-IL2 + Cyclosporine then Everolimus|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
79851634|NCT00900614|Drug|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
79851635|NCT00900692|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
80017402|NCT02105142|Behavioral|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
79254653|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 1
79254654|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 2
79254655|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 3
79254656|NCT02092831|Drug|GDC-0941|Single dose Phase 2 tablet formulation
79254657|NCT02250391|Drug|NPB-06|5 days continuous-infusion
79550609|NCT01596192|Other|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
79714136|NCT02871505|Drug|Benzathine Penicillin G|
79254658|NCT02250391|Drug|Placebo|5 days continuous-infusion
79254659|NCT02093143|Drug|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
79404306|NCT03155893|Drug|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3*400 mg tablets) administered on Day 15 in Treatment C.
79404307|NCT01670773|Drug|CAT-1004|
79404308|NCT01670773|Drug|Salsalate + DHA|
79404309|NCT01670773|Drug|Placebo|
79404310|NCT05228418|Drug|Naltrexone Pill|Naltrexone oral bridge to IM naltrexone maintenance therapy
79404311|NCT01676233|Drug|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
79404312|NCT01676233|Drug|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
79550610|NCT01596205|Behavioral|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
79550611|NCT01596205|Behavioral|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
79254660|NCT02095795|Device|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
79550612|NCT01596218|Drug|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
79394471|NCT03981107|Other|Chest Compression Only CPR (CO-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions only~The instructions from the dispatcher in interventional arm include:~An ambulance is dispatched and is on it´s way to you~Do CPR with chest compressions only~Push hard on the chest with a pace of 100/minute without interruptions for rescue breathing."
79394472|NCT03981107|Other|Standard CPR (S-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a ration of 30:2~The Instructions from the dispatcher in the control arm include:~An ambulance is dispatched and is on it´s way to you~Do CPR with chest compressions and rescue breathing~Push hard on the chest 30 times and give 2 rescue breaths. The pace of the compressions should be 100/minute."
79851636|NCT02571647|Other|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
79851637|NCT00901706|Other|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
79851638|NCT00901706|Other|APS usual care|APS usual care consists of social, medical, and legal assistance.
79851639|NCT00605306|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
79851640|NCT00605306|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
79254661|NCT02095795|Other|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
79851641|NCT00905918|Dietary Supplement|vitamin E|Given orally
79714137|NCT01294670|Drug|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
79714138|NCT01006603|Drug|Saxagliptin|5 mg, oral tablet, once daily
79714139|NCT01006603|Drug|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
79714140|NCT02870335|Other|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
79714141|NCT02870335|Other|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
79714142|NCT02870569|Drug|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
79851642|NCT00905918|Other|laboratory biomarker analysis|All patients undergo biomarker analyses
79851643|NCT00894608|Drug|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
79851644|NCT00894608|Drug|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
79851645|NCT00901784|Drug|Topiramate|25mg Tablets
79254662|NCT00701103|Drug|Dalotuzumab|IV infusion
79254663|NCT02093299|Drug|Clopidogrel|a blood sample is drawn on all patients to determine responder status
79394475|NCT03947034|Drug|Drugs inducing hyperammonemia|Drugs susceptible to induce metabolic toxicities such as hyperammonemia
79851646|NCT00607022|Device|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
79394476|NCT03941548|Drug|CTP-543|Administered as 12 mg tablets.
79394477|NCT03941548|Drug|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
79394478|NCT03928431|Other|Maternal microbiota|See arm descriptions
79394479|NCT03925727|Drug|Tavilermide ophthalmic solution|BID topical dosing
79394480|NCT03925727|Other|Placebo|BID topical dosing
79254664|NCT00454753|Drug|Dasatinib|
79550613|NCT01596244|Behavioral|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
79851647|NCT00722345|Behavioral|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
79394481|NCT03899922|Drug|Drugs inducing uveitis|Drugs susceptible to induce uveitis
79714143|NCT02870569|Drug|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
79851648|NCT00722345|Behavioral|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current & past activities; 2) reviewing the pros & cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
79851649|NCT00905996|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
79851650|NCT00905996|Drug|Beta-blocker (propranolol)|
79851651|NCT02574065|Drug|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
79851652|NCT02574065|Other|The placebo consists of an identical formulation without L. reuteri DSM 17938|
79851653|NCT02539628|Drug|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
79851654|NCT00713297|Behavioral|satisfaction questionnaire|Satisfaction questionnaire
79851655|NCT00901862|Device|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
79851656|NCT00901862|Device|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
79851657|NCT02573987|Drug|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
79851658|NCT02573987|Drug|Lidocaine|standard strategy by local injection anesthesia of lidocaine
79254665|NCT02093377|Device|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
79550614|NCT01596270|Drug|SAR245409|Pharmaceutical form: tablet Route of administration: oral
79714144|NCT00997321|Drug|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
79714145|NCT00997321|Drug|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
79714146|NCT01294592|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
79714147|NCT01294592|Drug|tamsulosin|Take 1 capsule daily when escalation criteria met
79851659|NCT00901940|Biological|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
79851660|NCT00901940|Biological|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
79851661|NCT00906308|Drug|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
79254666|NCT04106427|Device|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
79254667|NCT04106427|Device|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
79394482|NCT03858686|Drug|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
79394483|NCT03858686|Drug|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
79394484|NCT03856671|Drug|Neomycin,metronidazole|Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
79394485|NCT03855982|Drug|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
79394486|NCT03840343|Biological|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
79550615|NCT01596296|Device|Transcervical foley catheter|16 French foley catheter insertion
79550616|NCT01596296|Drug|Dinoprostone 10mg|Dinoprostone vaginal insertion
79550617|NCT01596309|Dietary Supplement|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
79714148|NCT00997243|Biological|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
79714149|NCT00997243|Drug|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
79714150|NCT02869321|Drug|Fentanyl|
79714151|NCT02869321|Drug|Morphine Sulfate|
79714152|NCT02869321|Drug|Fentanyl placebo|
79851662|NCT00906308|Drug|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
79404313|NCT01670851|Device|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
79714153|NCT02869321|Drug|Morphine Sulfate placebo|
80017403|NCT02105142|Behavioral|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
79714154|NCT02869321|Procedure|Gastrostomy|
79714155|NCT01294436|Drug|Dapagliflozin|Oral Dose 5 or 10 mg
79714156|NCT04293913|Behavioral|illustrated communication material|Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
79714157|NCT04293211|Other|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
79714158|NCT02870413|Behavioral|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
79851663|NCT00906308|Drug|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
79851664|NCT00906386|Drug|Varenicline|oral, 1 mg twice daily, 12 weeks
79714159|NCT04296487|Other|autologous chondrocytes|autologous chondrocytes implantation (ACI)
79714160|NCT02870179|Device|Pulse Oximeter|Measurement of physiological parameters
79714161|NCT02869477|Other|Data collection|
79714162|NCT00995371|Device|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
79851665|NCT00906386|Drug|placebo|oral, 1 mg twice daily, 12 weeks
79851666|NCT00722501|Drug|ERB-257|
79851667|NCT00722501|Other|placebo|
80017404|NCT03803566|Other|Pegboard practice|Practice of the grooved pegboard test
80017405|NCT03803566|Other|Force control practice|Practice performing steady muscle contractions
79394487|NCT03840343|Biological|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
79394488|NCT03833297|Drug|Drugs inducing hepatological toxicity|Drugs susceptible to induce hepatological toxicities
79851668|NCT00722579|Device|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
79851669|NCT04067687|Other|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
79851670|NCT04035902|Drug|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
79851671|NCT04035902|Drug|control|Ferric carboxymaltose is not administered
79851672|NCT00894842|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
79851673|NCT00894842|Drug|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
80017406|NCT02250924|Dietary Supplement|Caffeine|caffeinated gum
80017407|NCT02250924|Other|Gum|Chewing gum
80017408|NCT02250924|Behavioral|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
80017409|NCT03645148|Biological|iNeo-Vac-P01|Neoantigen peptides
80017410|NCT03645148|Other|GM-CSF|immune adjuvant
80017411|NCT04142164|Other|MacInfo presentation|Presentation about intravitreal drug injection
80017412|NCT04142164|Other|Placebo presentation|Placebo presentation
80031474|NCT04905472|Device|Vestibular prosthesis/implant|The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
79404314|NCT04078776|Other|No intervention|There is no intervention in this study
79404315|NCT01670929|Drug|Progesterone|
79714163|NCT00995371|Drug|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
79714164|NCT02869555|Other|Data collection|
79714165|NCT02870023|Other|Balance training|
79714166|NCT02870023|Other|Strength training|
79714167|NCT01294358|Drug|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
79714168|NCT00994279|Behavioral|Yoga|Yoga sessions
79714169|NCT00994279|Behavioral|Education|Educational Wellness Group
79851674|NCT02571569|Drug|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
79851675|NCT02571569|Drug|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
79714170|NCT01294046|Device|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
79714171|NCT02869711|Other|Health care quality management|
79714172|NCT01224639|Biological|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU
79714173|NCT01224639|Biological|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.
79714174|NCT01224639|Biological|Placebo|Phosphate Buffered Saline (PBS)
79714175|NCT01293968|Drug|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
79851676|NCT00906620|Other|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
79851677|NCT02539472|Other|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
79851678|NCT00902252|Device|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
79851679|NCT00902252|Device|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
79851680|NCT00902252|Device|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
79254668|NCT04106427|Behavioral|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
79254669|NCT04106427|Behavioral|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
79714176|NCT01293968|Drug|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
79714177|NCT04324190|Behavioral|Guided online support program|"Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)"
79714178|NCT04324190|Behavioral|WHO recommendations (waiting condition)|"During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided"
79714179|NCT02869867|Other|refrigerated cushion|refrigerated cushion
79714180|NCT04292665|Behavioral|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
79851681|NCT00902408|Dietary Supplement|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
79851682|NCT00713687|Drug|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"Photodynamic therapy (PDT) after successful drainage:~Photosan® 2 mg/kg i.v. 48 hrs before laser activation~9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~iteration every 14 days~afterwards 4 weeks intermission~Iteration of 1. and 2. in case of good compatibility"
79851683|NCT02539550|Drug|Placebo|Placebo
79851684|NCT02539550|Drug|PF-06266047|PF-06266047
79851685|NCT00717431|Procedure|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
79851686|NCT02540876|Drug|Ilorasertib|Given PO
79851687|NCT02540876|Other|Laboratory Biomarker Analysis|Correlative studies
79851688|NCT04353791|Drug|OST-122|Active dose
79851689|NCT04353791|Drug|Placebo|Placebo
79254670|NCT02093533|Drug|Eculizumab|
79254671|NCT02461251|Device|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
79254672|NCT02090257|Behavioral|TRANSIT|Educational Modules, staff follow up.
79254673|NCT03297957|Device|Hands-free goggle system|-Manufactured at Washington University
79404316|NCT01670929|Other|Placebo|
79404317|NCT02673996|Drug|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
79714181|NCT04292665|Behavioral|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
80017413|NCT05725538|Device|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
79254674|NCT03773341|Other|research questionnaire|Patient personal data History taking clinical knee examination
79254675|NCT02093611|Dietary Supplement|Placebo|
79254676|NCT02093611|Dietary Supplement|ATP|400 mg of ATP
79254677|NCT03297879|Drug|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
79254678|NCT02090335|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
79254679|NCT02090335|Behavioral|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
79550618|NCT01596387|Drug|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
79550619|NCT01596400|Drug|granisetron transdermal system|patch
79254680|NCT03297801|Dietary Supplement|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
79254681|NCT03297723|Other|Therapeutic education Programm|"Intervention will include:~an identification of educational needs and expectations,~a bilateral agreement between patient and medical staff on the priority skills acquirement,~a structured educational activities tailored to the patient's need.~the making of an educational record."
79714182|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
79714183|NCT01293032|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
79851690|NCT00894920|Dietary Supplement|biotin|capsule approximately 30 mcg daily 21 days
79851691|NCT00894920|Dietary Supplement|biotin|capsule 300 mcg daily 21 days
79714184|NCT01293032|Procedure|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
79714185|NCT01293032|Other|Laboratory Biomarker Analysis|Correlative studies
79714186|NCT01293032|Genetic|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
79714187|NCT01293032|Drug|Systemic Chemotherapy|Undergo chemotherapy
79714188|NCT01293032|Drug|Tamoxifen Citrate|Undergo hormonal therapy
79714189|NCT01293032|Drug|Aromatase Inhibition Therapy|Undergo hormonal therapy
79714190|NCT01292876|Device|Extracellular Matrix|Extracellular Matrix
79714191|NCT01224171|Drug|vedolizumab|Vedolizumab for intravenous infusion
79254682|NCT02096185|Radiation|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
79254683|NCT02096185|Radiation|2 dimensional digital imaging|
79254684|NCT02093767|Dietary Supplement|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
79254685|NCT05011461|Other|Almond Oil|Almond Oil Pressed Cold
79254686|NCT02093845|Device|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
79254687|NCT02093845|Device|SYNERGY stent|Percutaneous coronary intervention involving use of stent
79550620|NCT01596400|Drug|Granisetron IV|IV
79550621|NCT01596413|Drug|Sancuso|granisetron transdermal system
79714192|NCT01224171|Other|Placebo|Placebo intravenous infusion
79851692|NCT00722735|Drug|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
79851693|NCT00722735|Drug|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
79851694|NCT00902642|Behavioral|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
79550622|NCT01596413|Drug|IV granisetron|IV
79714193|NCT01292486|Device|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
79714194|NCT01223937|Drug|Desmopressin|
79714195|NCT01223937|Drug|Placebo|
79714196|NCT01290224|Other|scrambler therapy|Undergo MC5-A therapy
79714197|NCT01290224|Procedure|sham intervention|Undergo sham procedure
79714198|NCT01290224|Other|questionnaire administration|Ancillary studies
79714199|NCT01223235|Biological|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
79714200|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
79714201|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
79714202|NCT01290068|Device|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
79714203|NCT00998881|Drug|Teneligliptin 20 mg|
79714204|NCT00998881|Drug|Placebo|
79714205|NCT01222767|Drug|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
79714206|NCT00993967|Drug|idebenone|Idebenone 1350 mg/d, patients < or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
79254688|NCT04489797|Drug|Acalabrutinib|Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
79254689|NCT04489797|Drug|Rabeprazole|Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
79254690|NCT02094001|Radiation|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
79851695|NCT00722813|Other|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
79851696|NCT04067531|Drug|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
79851697|NCT00606632|Drug|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
79851698|NCT00606632|Procedure|CT|contrast enhanced CT scan
79851699|NCT00713765|Drug|AZD3480|18 total doses of 40 mg, on days 1-18
79404318|NCT02673996|Drug|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
79550623|NCT01596426|Drug|Sancuso|granisetron transdermal system
79550624|NCT01596426|Drug|IV granisetron|IV granisetron
79714207|NCT04278079|Procedure|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
79714208|NCT04259359|Drug|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
79714209|NCT04204603|Drug|CKD-506|Tablets for oral administration
79714210|NCT04204603|Drug|Placebo|Tablets for oral administration
79714211|NCT01222533|Drug|Tiotropium medium|Tiotropium inhalation solution medium dose
79714212|NCT01222533|Drug|Tiotropium low|Tiotropium inhalation solution low dose
79714213|NCT01222533|Drug|Tiotropium high|Tiotropium inhalation solution high dose
79714214|NCT01222533|Drug|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
79714215|NCT01222533|Drug|Tiotropium placebo|Placebo inhalation solution
79714216|NCT01221753|Drug|docetaxel|
79714217|NCT01221753|Drug|cisplatin|Given intravenously on day 1 of each cycle
79714218|NCT01221753|Drug|5-FU|
79714219|NCT01221753|Radiation|IMRT|
79714220|NCT01221753|Drug|cetuximab|
79714221|NCT01221753|Drug|carboplatin|
79714222|NCT01221597|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
79851700|NCT00713765|Drug|Donepezil|One single dose of mg on day 5
79851701|NCT00717587|Drug|motexafin gadolinium|
79851702|NCT00717587|Drug|sunitinib malate|
79851703|NCT00717587|Genetic|comparative genomic hybridization|
79851704|NCT00717587|Genetic|gene expression analysis|
79851705|NCT00717587|Genetic|mutation analysis|
79851706|NCT00717587|Genetic|polymorphism analysis|
79851707|NCT00717587|Other|immunohistochemistry staining method|
79851708|NCT00717587|Other|iodine I-124 girentuximab|
79851709|NCT00717587|Other|laboratory biomarker analysis|
79851710|NCT00717587|Other|pharmacological study|
79851711|NCT00717587|Procedure|adjuvant therapy|
79851712|NCT00717587|Procedure|neoadjuvant therapy|
79851713|NCT00717587|Procedure|therapeutic conventional surgery|
79851714|NCT00713843|Other|Manual Therapy Utrecht|Manual Therapy (6 weeks).
79851715|NCT00713843|Other|Physical Therapy|Physical Therapy (six weeks).
79851716|NCT00894998|Biological|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
79851717|NCT00894998|Biological|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
79394493|NCT03792061|Behavioral|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
79394494|NCT03786354|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
79714223|NCT01221597|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
79714224|NCT01221363|Behavioral|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
79851718|NCT02572895|Dietary Supplement|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
79394495|NCT03786354|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79851719|NCT00717665|Device|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
79851720|NCT00717665|Other|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
79851721|NCT00713921|Drug|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
79851722|NCT04067453|Other|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
79851723|NCT02571335|Behavioral|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
80017414|NCT05725538|Other|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
79404319|NCT03925272|Procedure|Collection of samples (blood, stool, etc.)|
79714225|NCT01221285|Biological|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
79714226|NCT02888223|Biological|SCT800|
79714227|NCT02888223|Biological|Xyntha|
79404320|NCT03925272|Genetic|Genetic determinants analysis|
79404321|NCT03925272|Procedure|Sample obtained after surgery performed in the context of care|
79404322|NCT04746937|Drug|Nitazoxanide|nitazoxanide adjuvant to standard therapy
79714228|NCT01014988|Drug|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
79714229|NCT04299724|Biological|Pathogen-specific aAPC|The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.
79714230|NCT01014910|Other|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
79851724|NCT02571335|Behavioral|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
79851725|NCT04067375|Other|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
80017415|NCT04082728|Drug|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
79550625|NCT01596465|Other|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
79254691|NCT02090569|Device|Functional micro-Doppler Sonography (fmDS)|"Craniotomy according to MRI images~Dura opening~Sulcal Localization using neuronavigation~Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~Exeresis of the dysplasic tissue~Control using fmDS before wound closure"
79254692|NCT02250079|Device|polyethylene plastic bag|Inborn neonates with both a gestational age >29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
79394496|NCT03743532|Behavioral|E-cigarette|Participants will receive an e-cigarette device and pods. Each participant in this group will be yoked to a participant in the financial incentives group, thus receiving equal payments. Yoking will reduce or eliminate differential attendance rates between groups because participants have the opportunity to earn the same amount of money regardless of group assignment. Participants will be followed for the first 4 weeks following a scheduled quit attempt.
79394497|NCT03743532|Behavioral|Financial incentives + E-cigarette|Participants will receive an e-cigarette device and pods and the opportunity to earn financial incentives for biochemically-verified cigarette smoking abstinence, credited to a gift card with biochemical evidence of smoking abstinence during the first 4 weeks following a scheduled quit attempt.
79394498|NCT03728361|Biological|Nivolumab|Given IV
79550626|NCT01596465|Other|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
79550627|NCT01596478|Behavioral|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
79550628|NCT01596478|Behavioral|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
79550629|NCT01596478|Behavioral|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
79550630|NCT01596491|Procedure|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
79550631|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight <75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
79550632|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
79550633|NCT01596530|Drug|Drug-AZD8931|Active drug for biological activity
79550634|NCT01596530|Drug|Drug-Placebo|Placebo comparator for biological activity comparison
79550635|NCT01596543|Other|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
79550636|NCT01596556|Drug|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
79550637|NCT01596556|Other|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
79550638|NCT01596569|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
79714231|NCT01014910|Device|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
79851726|NCT02571413|Other|score before teaching|score the check-point of correct INCS usage before teaching
79851727|NCT02571413|Other|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
79851728|NCT02571413|Other|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
80017416|NCT04082728|Drug|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
80017417|NCT02906709|Drug|Omarigliptin|Omarigliptin, 25 mg orally once weekly
80017418|NCT02906709|Drug|Placebo|Placebo to omarigliptin orally once weekly
79714232|NCT04298866|Other|Experimental Arm|"3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~Neuropsychological battery including chronometric measures obtained through a computer interface"
79714233|NCT02872480|Other|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
79714234|NCT04297930|Device|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
79714235|NCT01019980|Drug|Diclofenac potassium|Diclofenac potassium
79550639|NCT01596569|Behavioral|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
79714236|NCT01019980|Drug|Acetaminophen|Acetaminophen
79851729|NCT00713999|Drug|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
79714237|NCT00993499|Drug|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
80017419|NCT02906709|Biological|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
79254693|NCT02250079|Device|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
79254694|NCT02094079|Other|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
79254695|NCT02090647|Behavioral|aesthetic outcome|
79581047|NCT01932138|Other|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
79714238|NCT00993499|Drug|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
79714239|NCT04293367|Other|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
79714240|NCT01014442|Drug|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
79714241|NCT00628264|Drug|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
79714242|NCT00628264|Drug|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
79714243|NCT04298398|Behavioral|Mindfulness Based-Cognitive Therapy (MBCT)|MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
79714244|NCT04298398|Behavioral|Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice & Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott & Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
79851730|NCT04072601|Drug|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
79851731|NCT04072601|Drug|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
80017420|NCT00321308|Drug|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
79254696|NCT02096341|Drug|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"
79394499|NCT03728361|Drug|Temozolomide|Given PO
79394500|NCT03714503|Device|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
79550640|NCT01596608|Device|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
79550641|NCT01596634|Other|questionnaire administration|Ancillary studies
79550642|NCT01596634|Procedure|quality-of-life assessment|Ancillary studies
79550643|NCT01596634|Other|laboratory biomarker analysis|Correlative studies
80017421|NCT00321308|Drug|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
79550644|NCT01596634|Dietary Supplement|bovine lactoferrin|Given PO
79550645|NCT01596647|Drug|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
79550646|NCT01596647|Drug|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
79550647|NCT01596647|Drug|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
80017422|NCT02110056|Device|tDCS|transcranial direct current stimulation (tDCS)
80017423|NCT02110056|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
79308618|NCT04842435|Drug|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
79550648|NCT01596647|Drug|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
79714245|NCT04298398|Other|Treatment as usual (no intervention)|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
79550649|NCT01596647|Drug|TKI258|dovitinib, 5 days on / 2 days off dose schedule
79550650|NCT01596660|Drug|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
79550651|NCT01596660|Drug|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
79550652|NCT01596673|Drug|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
79550653|NCT01596673|Drug|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
79550654|NCT01596686|Drug|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
79550655|NCT01596712|Drug|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
79550656|NCT01596712|Drug|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
79550657|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
79714246|NCT04297774|Behavioral|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
79714247|NCT04297774|Behavioral|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
80017424|NCT03943732|Diagnostic Test|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
80017425|NCT02110134|Device|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
80017426|NCT02110134|Other|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
80017427|NCT03532646|Procedure|upper endoscopy|endoscopy of the gastrointestinal tract
80017428|NCT04108546|Device|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% & low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
79714248|NCT04297774|Behavioral|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
80017429|NCT04108546|Drug|Epidural analgesia|Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
79714249|NCT00996307|Biological|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
79714250|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
79714251|NCT00996307|Biological|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
79851732|NCT00717821|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
79714252|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
79851733|NCT00717821|Drug|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
79254697|NCT02096419|Drug|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
79254698|NCT03775603|Device|TOFscan|comparison of TOFscan over TOF-Watch SX
79714253|NCT04293835|Diagnostic Test|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
79714254|NCT04293991|Device|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
79254699|NCT02094157|Drug|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
79254700|NCT02094157|Drug|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
79254701|NCT03059329|Drug|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
79550658|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
79550659|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
79550660|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
79550661|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
79550662|NCT01596725|Biological|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
79714255|NCT04293991|Device|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
79851734|NCT00717821|Drug|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
79550663|NCT01596738|Drug|Tranexamic Acid|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
79550664|NCT01596738|Drug|Saline|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
79254702|NCT01369225|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
79550665|NCT01596764|Drug|Loperamide placebo|200 ml apple juice
80017430|NCT03529214|Behavioral|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
79254703|NCT01369225|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
79254704|NCT01369225|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
79254705|NCT01369225|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
79254706|NCT01369225|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
79254707|NCT03556813|Other|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
79851735|NCT00722891|Device|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
79394502|NCT03696524|Device|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
79550666|NCT01596764|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
79550667|NCT01596764|Device|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
79550668|NCT01596764|Drug|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
79550669|NCT01596764|Drug|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
80017431|NCT02105220|Other|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
79550670|NCT01596764|Drug|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
79714256|NCT04263337|Drug|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
79851736|NCT00722891|Device|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
79254708|NCT03556267|Device|spinal needle|It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
79254709|NCT03556735|Device|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
79254710|NCT02094235|Drug|E6005 0.05%|
79254711|NCT02094235|Drug|Placebo|0.5 g placebo ointment
79254712|NCT02094235|Drug|E6005 0.2%|
79394503|NCT03662685|Other|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
79404323|NCT04746937|Drug|Norfloxacin|Standard therapy
79550671|NCT01596764|Drug|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
79550672|NCT01596777|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
79851737|NCT00717899|Device|Spirometry (Pony spirometer)|Spirometry at rest
79254713|NCT02094313|Drug|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
79254714|NCT02098759|Device|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
79254715|NCT02250235|Other|Health risk information|
79550673|NCT01596777|Drug|Loperamide placebo|200 ml apple juice
79550674|NCT01596777|Drug|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
79550675|NCT01596777|Drug|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
79550676|NCT01596777|Drug|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
79550677|NCT01596777|Drug|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
79550678|NCT01596777|Device|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
79550679|NCT01596777|Drug|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
79550680|NCT01596790|Other|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
79714257|NCT04263337|Drug|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
79714258|NCT04263337|Drug|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
79714259|NCT02869165|Drug|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
79851738|NCT02571257|Drug|Gemcabene|1-300 mg tablet, QD, 56 days
79714260|NCT02869165|Drug|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
79714261|NCT04292041|Other|Fasting mimicking diet|"3 cycles of programmed nutrition using a fasting mimicking diet (Chemolieve (R)), each cycle consisting of 4 days. Pre and post nutritional cycles, clinical and metabolic assessments are taken, as per protocol. Allowing for a 3 month washout time, the 'post' assessment is planned approximately 6 months from the initial (pre) assessment."
79714262|NCT00629161|Drug|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
79851739|NCT02571257|Drug|Gemcabene|3-300 mg tablets, QD, 56 days
79851740|NCT02571257|Drug|Placebo|
79851741|NCT00714155|Other|Questionnaires, Physical Examination|Questionnaires, Physical Examination
79851742|NCT02572973|Other|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
79851743|NCT00722969|Drug|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
79394504|NCT03662685|Drug|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
79394505|NCT03662685|Device|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
79851744|NCT04069325|Drug|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
79394506|NCT03651765|Drug|Setmelanotide|Once daily subcutaneous injection
79714263|NCT00629161|Drug|placebo|12 months period of placebo plus 1 month period without placebo
79714264|NCT01219959|Drug|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
79714265|NCT01219959|Drug|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
79714266|NCT00993421|Drug|LY377604|Given daily, orally for 24 weeks
79714267|NCT00993421|Drug|Sibutramine|given daily, orally for 24 weeks
79851745|NCT04069325|Drug|placebo|pills, 6g twice daily (BID), oral, 12 weeks
79851746|NCT04069325|Drug|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
79851747|NCT00723047|Procedure|Fibrin glue injection in fistula|
79851748|NCT03444779|Device|Tibial Tuberoplasty|Kyphoplasty ballon
79404324|NCT04588350|Device|i-SEP autotransfusion system|Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
79714268|NCT00993421|Drug|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
79714269|NCT00993421|Drug|Placebo sibutramine|given daily, orally for 24 weeks
79851749|NCT03444779|Device|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
79851750|NCT00726791|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
79851751|NCT05374031|Other|descriptive study|descriptive study
79851752|NCT04069403|Other|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
79851753|NCT05373797|Behavioral|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
79714270|NCT00993421|Drug|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
79714271|NCT00993421|Drug|Placebo LY377604|given daily, orally for 24 weeks
79714272|NCT04292509|Device|SAP with stop before low|cross-over comparison from stop on low to stop before low
79714273|NCT04292509|Device|SAP with stop on low|cross-over comparison from stop before low to stop on low
79714274|NCT02868853|Behavioral|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
79714275|NCT02868853|Behavioral|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
79714276|NCT02868853|Behavioral|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
79714277|NCT01014208|Drug|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
79714278|NCT01014208|Drug|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
79714279|NCT04205578|Drug|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
79714280|NCT04205578|Drug|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
80017432|NCT03877822|Behavioral|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
79254716|NCT02094391|Drug|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
79714281|NCT04297540|Device|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
79875281|NCT01042353|Procedure|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
80017433|NCT03877822|Behavioral|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
79254717|NCT03556189|Device|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
79254718|NCT02094469|Drug|Cilostazol|Oral, Bid, 24 weeks
79254719|NCT02094547|Dietary Supplement|New infant formula|New infant formula
79254720|NCT02094547|Dietary Supplement|Standard infant formula|Standard infant formula
79254721|NCT02094547|Dietary Supplement|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
79254722|NCT02094703|Drug|Levofloxacin|
79254723|NCT02094703|Drug|Solifenacin succinate|
79254724|NCT02094703|Drug|Placebo (for Solifenacin succinate)|
79254725|NCT03556111|Procedure|Sticky bone augmentation|"Autogenous sticky bone augmentation for the first group~Autogenous sticky bone preparation with xenograft usage~After 5-month of bone grafting; esthetic implant placement"
79254726|NCT02098837|Drug|Dolutegravir|Dolutegravir 50mg once daily
79550681|NCT01596803|Procedure|Taking of blood|Taking venous blood samples to analyse oxidant stress
79550682|NCT01596803|Dietary Supplement|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
79550683|NCT01596803|Dietary Supplement|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
79550684|NCT01596803|Dietary Supplement|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
79550685|NCT01596816|Radiation|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
79550686|NCT01596816|Procedure|Fiducials placement|Placement of intra-prostatic markers for the tracking
79714282|NCT04297540|Device|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
79714283|NCT00628420|Drug|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
79714284|NCT00628420|Drug|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
79714285|NCT00628420|Drug|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
79254727|NCT02094781|Dietary Supplement|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
79550687|NCT01596816|Radiation|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
79254728|NCT02094781|Dietary Supplement|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
79550688|NCT01596829|Dietary Supplement|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
79550689|NCT01596829|Dietary Supplement|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
79550690|NCT01596855|Drug|FG-4592|TIW dosing, capsule
79875282|NCT01042353|Procedure|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
79875283|NCT01039623|Biological|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
79875284|NCT01042431|Other|No Intervention|No intervention
79875285|NCT01042587|Other|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
79254729|NCT02094781|Dietary Supplement|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
79254730|NCT02098915|Drug|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
79550691|NCT01596855|Drug|Epoetin Alfa|TIW
79394507|NCT03545906|Other|TEAM-UP Intervention Group|Children randomly assigned to TEAM-UP will have a telemedicine assisted specialist visit scheduled after 4 weeks of initiating DOT at school, as well as 2 subsequent follow-up visits. The visits will be performed by a specialist in pediatric asthma, to implement guideline-based care. Prescriptions for asthma medications will be prescribed to be delivered as directly observed therapy in school.
79404325|NCT05220319|Drug|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
79550692|NCT01596868|Drug|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
79550693|NCT01596868|Drug|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
79550694|NCT01596894|Drug|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
79550695|NCT01596894|Drug|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
79550696|NCT01596907|Drug|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
79550697|NCT01596907|Drug|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
79550698|NCT01596920|Other|Tissue|Allograft Tissue Cellular Repair Matrix
79550699|NCT01596920|Other|Control|Non-adherent Dressing
79550700|NCT01596933|Dietary Supplement|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
79714286|NCT00991939|Drug|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients < 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
79851754|NCT05373251|Diagnostic Test|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
79851755|NCT04066985|Behavioral|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
79851756|NCT04066985|Behavioral|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
80017434|NCT02110446|Drug|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
79714287|NCT00991939|Drug|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients < 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
79714288|NCT04293445|Diagnostic Test|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
79714289|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
80017435|NCT02110446|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
80017436|NCT03847168|Drug|KN026|Patient will be intravenously administrated with one dose of KN026 every week or every other week.
80017437|NCT00318656|Drug|rosiglitazone-metformin fixed dose combination|
80017438|NCT00318656|Drug|metformin + glimepiride|
79851757|NCT04066985|Behavioral|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
79851758|NCT00723359|Drug|BT062|biologic
80017439|NCT02110524|Device|Percutaneous Transluminal Angioplasty|
79254731|NCT02098915|Other|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
79254732|NCT03556033|Drug|Dapagliflozin|8 weeks treatment with dapagliflozin on top of insulin treatment
79254733|NCT03556033|Drug|Placebo oral capsule|8 weeks treatment with placebo capsules on top of insulin treatment
79254734|NCT02096653|Procedure|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
79851759|NCT00450814|Drug|Cyclophosphamide|Given IV
79851760|NCT00450814|Other|Laboratory Biomarker Analysis|Correlative studies
79394508|NCT03545906|Other|Enhanced Care Comparison|Similar to the TEAM-UP group, children in the Enhanced Care group will receive a symptom assessment and asthma education materials at baseline, and we will contact the PCP by facsimile or email and will recommend DOT of preventive asthma medication through school as well as a referral to specialist. However specialist visits will not be facilitated via telemedicine.
79394509|NCT03497780|Procedure|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
79851761|NCT00450814|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
79851762|NCT00450814|Other|Pharmacological Study|Correlative studies
80017440|NCT02908347|Drug|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
80017441|NCT02908347|Drug|Placebo|hard gelatine capsules without active ingredient
80017442|NCT02110602|Other|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
79394510|NCT03461835|Diagnostic Test|Risk classification of PUL by M4|High or low risk of being an ectopic pregnancy
79851763|NCT02571491|Drug|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
79851764|NCT02571491|Other|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
79851765|NCT02571491|Drug|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
79550701|NCT01596933|Dietary Supplement|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
79550702|NCT01596946|Behavioral|Contact tracing mode test at clinic|
79714290|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
79714291|NCT02869087|Device|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
79714292|NCT04291807|Behavioral|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
79714293|NCT02868697|Drug|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
79714294|NCT02868697|Drug|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis[tetrahydro-1,1,1',1'-tetraoxide], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
79851766|NCT02571491|Drug|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
79851767|NCT00723437|Drug|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
79714295|NCT02868385|Drug|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
79714296|NCT02868385|Drug|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
79851768|NCT01026688|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
79254735|NCT02096653|Procedure|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
80017443|NCT02110602|Other|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
79254736|NCT03556657|Other|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
79254737|NCT02099071|Drug|ACT-389949 1 mg|
79851769|NCT01026688|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
79851770|NCT02571023|Procedure|microscope surgery|
79851771|NCT02571023|Procedure|neuroendoscope surgery|
79851772|NCT00723515|Drug|sodium fluoride|sodium fluoride 5%
79851773|NCT00723515|Drug|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
80017444|NCT00317486|Drug|bosentan|
80017445|NCT02107170|Drug|Sevoflurane|sevoflurane-based general anesthesia
80017446|NCT02107170|Drug|Propofol|total intravenous anesthesia
80017447|NCT02107170|Drug|Remifentanil|
80017448|NCT03622281|Other|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
80017449|NCT00313196|Drug|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
80017450|NCT02107248|Behavioral|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
79254738|NCT02099071|Drug|ACT-389949 5 mg|
79254739|NCT02099071|Drug|ACT-389949 20 mg|
79254740|NCT02099071|Drug|ACT-389949 50 mg|
79254741|NCT02099071|Drug|ACT-389949 100 mg|
79254742|NCT02099071|Drug|ACT-389949 200 mg|
79254743|NCT02099071|Drug|ACT-389949 500 mg|
79254744|NCT02099071|Drug|ACT-389949 1000 mg|
79254745|NCT02099071|Drug|Placebo|
79254746|NCT02639546|Drug|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
79254747|NCT02095093|Device|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
79254748|NCT02095093|Device|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
79550703|NCT01596946|Behavioral|Self-sampling at home - Sent Test Kit|
79550704|NCT01596959|Procedure|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
79550705|NCT01596959|Procedure|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
79550706|NCT01596985|Procedure|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
79714297|NCT02868307|Behavioral|Answering questionnaire|
79714298|NCT00993265|Drug|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
79714299|NCT00993265|Drug|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
79714300|NCT04211389|Drug|ARQ-151 0.3% cream|ARQ-151 0.3% cream
79851774|NCT01022944|Procedure|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
79550707|NCT01596985|Procedure|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
79714301|NCT04211389|Drug|ARQ-151 vehicle cream|ARQ-151 vehicle cream
79714302|NCT00993031|Drug|Lopinavir/ritonavir|LPV 200mg/r 50mg
79714303|NCT00993031|Drug|Efavirenz|600mg
80017451|NCT02107248|Behavioral|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
80017452|NCT02983305|Device|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
79714304|NCT00993031|Drug|Zidovudine|Zidovudine 300 mg
80017453|NCT02110680|Device|Sports TENS 2|transcutaneous electric stimulation
79254749|NCT02096809|Procedure|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
79394511|NCT03461835|Diagnostic Test|Risk classification of PUL by NICE|High or low risk of being an ectopic pregnancy
79714305|NCT00993031|Drug|Lamivudine|Lamivudine 150 mg
79714306|NCT01010776|Drug|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
79714307|NCT04291729|Drug|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
79714308|NCT02868775|Procedure|cystoscopy, bladder hydrodistention and bladder biopsy|
79714309|NCT00637702|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
79714310|NCT04291963|Procedure|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
79394512|NCT03461666|Behavioral|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
79394513|NCT03461666|Behavioral|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
79394514|NCT03461666|Behavioral|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
80017454|NCT03532568|Other|skin biopsy|4mm punch skin biopsy
80017455|NCT03532568|Radiation|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
80017456|NCT03656679|Procedure|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
80017457|NCT03656679|Procedure|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
80017458|NCT02110836|Dietary Supplement|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
79254750|NCT02096809|Device|Cochlear Baha BI300/BA400 Implant System|
79254751|NCT02096887|Behavioral|Patient Education|"Patient Education using the following two instruments:~Framingham Risk Score calculator:~Know your numbers patient booklet"
79254752|NCT02095171|Drug|PRX002|
79254753|NCT02095171|Other|Placebo|
79254754|NCT05046860|Drug|Dalbavancin|"The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin.~In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment.~Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg."
79394515|NCT03461666|Behavioral|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
79404326|NCT05220319|Drug|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
79714311|NCT04291963|Procedure|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
79714312|NCT04170985|Other|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
79714313|NCT02868619|Other|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
79714314|NCT02868619|Other|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
79714315|NCT02868619|Other|R-CMAS scale|Evaluate the anxiety
79714316|NCT00637741|Device|Everflex 200|
79714317|NCT02868931|Behavioral|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
79714318|NCT01018810|Drug|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
80017459|NCT02110836|Dietary Supplement|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
79254755|NCT05069480|Device|Virtual reality-based training equipment.|It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
79550708|NCT01596998|Drug|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
79394516|NCT03391934|Drug|Cetuximab + FOLFIRI|Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
79394517|NCT03387150|Biological|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
79550709|NCT01596998|Drug|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
79550710|NCT01596998|Other|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
79550711|NCT01596998|Other|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
79550712|NCT01597011|Procedure|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
79550713|NCT01597011|Procedure|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
79550714|NCT01597024|Other|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
79550715|NCT01597024|Other|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
79550716|NCT01597037|Behavioral|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
79550717|NCT01597063|Device|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
79714319|NCT01018810|Drug|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
79714320|NCT01018810|Drug|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
79714321|NCT01018810|Drug|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
79714322|NCT02867917|Drug|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
79254756|NCT05069480|Other|Traditional physical therapy program|The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
79254757|NCT05046626|Other|Nutritional counseling|Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
79254758|NCT02099305|Other|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
79394518|NCT03387150|Biological|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
79394519|NCT03325322|Dietary Supplement|Fisetin|Flavonoid family
79254759|NCT02095405|Drug|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
79394520|NCT03325322|Drug|Placebo oral capsule|Placebo
79394521|NCT03289234|Drug|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
79714323|NCT02867917|Drug|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
79714324|NCT02867917|Drug|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
79714325|NCT01018732|Biological|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
79714326|NCT01218867|Biological|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
79714327|NCT01218867|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
79714328|NCT01218867|Biological|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
79714329|NCT01218867|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
79714330|NCT01018264|Drug|solifenacin succinate (VESIcare)|up to 10mg every day orally
79714331|NCT01018264|Drug|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
79851775|NCT01022944|Procedure|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
79851776|NCT01028170|Drug|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
79254760|NCT02095405|Other|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
79254761|NCT03099980|Biological|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
79254762|NCT02099383|Other|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
79254763|NCT05057156|Behavioral|cognitive rehabilitation|patients have to use an app with cognitive games
79254764|NCT02096965|Drug|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
79254765|NCT02096965|Drug|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
79254766|NCT03099902|Diagnostic Test|Lung function|Spirometry test
79254767|NCT03099902|Diagnostic Test|White blood cell DNA extraction|GSTP1 and TNFa polymorphisms with PCR
79394522|NCT03289208|Drug|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
79394523|NCT03281343|Behavioral|Motivational Interviewing & Patient Navigator|The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.
79550718|NCT01597076|Dietary Supplement|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas & Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
79550719|NCT01597102|Other|No interventions|No intervention is planned in this study
79254768|NCT03099902|Diagnostic Test|Urinary testing|Urinary nicotine and cotinine detection
79254769|NCT02097043|Drug|DA-7218|
79254770|NCT02097043|Drug|Placebo|
79254771|NCT05069246|Other|Nigella Sativa oil|5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.
79254772|NCT05069246|Drug|Chlorhexidine mouthwash|10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
79254773|NCT02095717|Drug|Curcumin|
79254774|NCT02095717|Drug|Placebo|
79254775|NCT02095717|Drug|Taxotere|
79394524|NCT03281343|Behavioral|Standard of Care (SOC)|SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
79550720|NCT01597115|Procedure|Duplex ultrasonography|
79550721|NCT01597154|Behavioral|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
79550722|NCT01597167|Dietary Supplement|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
79550723|NCT01597206|Device|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
79550724|NCT01597206|Other|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
79550725|NCT01597219|Procedure|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
79550726|NCT01597219|Procedure|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
79851777|NCT01028170|Drug|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
79851778|NCT00723671|Procedure|MRI|
79851779|NCT00518115|Drug|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
79851780|NCT04067219|Procedure|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
79851781|NCT00723983|Drug|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
79714332|NCT04318899|Behavioral|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus & Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
79550727|NCT01597232|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
79714333|NCT04318899|Behavioral|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
79254776|NCT05044988|Drug|HS-10342|HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
79394525|NCT03276351|Device|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
79550728|NCT01597232|Other|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
79550729|NCT01597232|Other|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
79550730|NCT01597297|Drug|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
79550731|NCT01597297|Other|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
79714334|NCT01018186|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
79714335|NCT01018186|Drug|Fluticasone propionate|Inhaled corticosteroid
79714336|NCT00987337|Drug|Filibuvir|300 mg BID
79714337|NCT00987337|Drug|Filibuvir|600 mg BID
79714338|NCT00987337|Drug|Placebo|BID
79851782|NCT00723983|Drug|NP101 Study Patch|NP101 study patch 4 hour application
79254777|NCT02102425|Procedure|Patients with or without bandage over exit site|
79254778|NCT02097199|Other|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
79394526|NCT03276351|Device|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
79394527|NCT03244059|Biological|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
79394528|NCT03244059|Drug|Placebo|An identically appearing placebo infusion.
79394529|NCT03155854|Procedure|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
79394530|NCT03155854|Procedure|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
79394531|NCT03036566|Device|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
79394532|NCT03010228|Biological|VLA15 with Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
79394533|NCT03010228|Biological|VLA15 without Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
79394534|NCT02937389|Diagnostic Test|Patients after esophagectomy|Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
79550732|NCT01597310|Drug|Warfarin|single doses at specified time periods
79550733|NCT01597310|Drug|Dexpramipexole|multiple doses
79550734|NCT01597336|Procedure|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
79550735|NCT01597336|Procedure|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
79550736|NCT01597362|Procedure|laparoscopy|Trocar access in laparoscopy
79581048|NCT01932138|Other|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
79714339|NCT00992407|Drug|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
79714340|NCT00992407|Drug|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
79714341|NCT00986479|Drug|AZD6765|Single IV infusion of 150 mg AZD6765.
79714342|NCT00986479|Drug|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
79851783|NCT00450658|Drug|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
79394535|NCT02927249|Other|Placebo|Given PO
79851784|NCT00450658|Drug|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
79851785|NCT02572505|Drug|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
79851786|NCT03720574|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
79851787|NCT03720574|Drug|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
79714343|NCT00986245|Drug|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
79714344|NCT00989833|Drug|budesonide|400 yg x 1
79394536|NCT02927249|Drug|Aspirin|Given PO
79714345|NCT00989833|Drug|terbutaline|0.4 mg as-needed
80017460|NCT02110914|Behavioral|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
80017461|NCT03532334|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
79714346|NCT00989833|Drug|budesonide/formoterol|160/4.5 yg as-needed
79714347|NCT04292119|Drug|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
79714348|NCT04292119|Drug|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
79714349|NCT04292119|Drug|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
79714350|NCT04292119|Drug|TNO155|TNO155 will be taken orally once daily for 14 days.
79550737|NCT01597362|Procedure|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
79714351|NCT01218477|Drug|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
79714352|NCT01218477|Drug|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
80017462|NCT02107326|Device|Webdia Software|
80017463|NCT03663166|Radiation|Thoracic Radiotherapy|2 Gy in 30 fractions directed at all sites of suspected disease
79714353|NCT04318509|Dietary Supplement|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
80017464|NCT03663166|Drug|Platinum Based Chemotherapy|Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).
79714354|NCT01218243|Device|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
79714355|NCT00989287|Biological|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
79714356|NCT00989287|Biological|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
79714357|NCT01218087|Device|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
79714358|NCT01218087|Device|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
79851788|NCT00724139|Device|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
80017465|NCT03663166|Drug|ipilimumab|ipilimumab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy
80017466|NCT03663166|Drug|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
79394537|NCT02890368|Drug|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
79550738|NCT01597362|Procedure|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
79851789|NCT00718133|Device|Spirometry (Pony spirometer)|Spirometry at rest
79851790|NCT03720418|Drug|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
79851791|NCT03720418|Other|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
79875286|NCT01042587|Other|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
79875287|NCT01039701|Drug|AZD1446|capsules, oral, 3 times daily
79875288|NCT01039701|Drug|Placebo|capsules, oral, 3 times daily, 4 weeks
79875289|NCT03742401|Procedure|Surgery|Traditional open excisional surgery
79875290|NCT03742401|Device|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
79550739|NCT01597362|Procedure|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
79550740|NCT01597401|Drug|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
79550741|NCT01597401|Drug|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
79550742|NCT01597401|Drug|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
79550743|NCT01597401|Drug|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
80017467|NCT02107404|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
79550744|NCT01597401|Drug|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
79550745|NCT01597427|Drug|Clonidine|Administration of 2 μg/kg of intravenous clonidine
79254779|NCT05055674|Behavioral|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
79394538|NCT02890368|Drug|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
79550746|NCT01597427|Drug|Placebo|Injection of placebo solution.
79550747|NCT01597453|Behavioral|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
79550748|NCT01597466|Device|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
79550749|NCT01597466|Procedure|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
79550750|NCT01597518|Drug|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
79550751|NCT01597518|Drug|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
79714359|NCT04291339|Procedure|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
80017468|NCT03524404|Behavioral|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
79851792|NCT00517881|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
79394539|NCT02890368|Drug|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
79394540|NCT02890368|Other|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
79550752|NCT01597531|Drug|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
79714360|NCT04291339|Procedure|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
79714361|NCT01218009|Drug|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
80017469|NCT03529136|Biological|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
79851793|NCT02572739|Device|PICCO|measurements based on thermodilution
79851794|NCT02572739|Device|NICCOMO|measurements based on impedance
79851795|NCT01009905|Drug|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
79851796|NCT05372081|Other|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
79851797|NCT01565577|Biological|MenbVac|Blood test
79851798|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
79851799|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
79851800|NCT01010139|Drug|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
79254780|NCT05055674|Behavioral|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
79254781|NCT02097355|Other|TriVox for clinical care|Use TriVox disease modules to manage patients
79550753|NCT01597531|Drug|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
79254782|NCT03099824|Drug|GC4711 Oral Capsule G-101|82 mg (1 capsule)
79550754|NCT01597531|Drug|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
79550755|NCT01597544|Procedure|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
79550756|NCT01597570|Device|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
79550757|NCT01597609|Drug|sibutramine|10 mg, taken orally once per day for 12 weeks
79550758|NCT01597609|Other|sibutramine placebo|taken orally once per day for 12 weeks
79550759|NCT01597648|Drug|Maraviroc|300 mg
79550760|NCT01597648|Drug|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
79550761|NCT01597648|Drug|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
79550762|NCT01597661|Drug|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
79550763|NCT01597661|Drug|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
79851801|NCT00724295|Drug|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
79851802|NCT00724295|Drug|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
79851803|NCT00718289|Other|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
79851804|NCT00718289|Other|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
79851805|NCT02571101|Drug|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
79851806|NCT02571101|Drug|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
79851807|NCT02571101|Drug|Condencia|Contains chlomipramine HCl 15mg.
79851808|NCT02571101|Drug|CDFR0812-Placebo|Placebo tablet of CDFR0812.
79254783|NCT03099824|Drug|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
79254784|NCT03099824|Drug|GC4711 Oral Capsule G-101|164 mg (2 capsules)
79254785|NCT03099824|Drug|GC4711 Oral Capsule G-101|246 mg (3 capsules)
79254786|NCT03099824|Drug|GC4711 Oral Capsule G-111|175 mg (1 capsule)
79851809|NCT02571101|Drug|Condencia-Placebo|Placebo tablet of Condencia
79851810|NCT03525886|Drug|NBI-74788|Capsule, administered daily.
79254787|NCT03099824|Drug|GC4711 Oral Capsule G-112|145 mg (1 capsule)
79254788|NCT03099824|Drug|GC4711 Oral Capsule G-119|233 mg (1 capsule)
79254789|NCT03099824|Drug|GC4711 Oral Capsule G-125|233 mg (1 capsule)
80017470|NCT03554304|Drug|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
79550764|NCT01597661|Other|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
79550765|NCT01597674|Drug|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
79851811|NCT00517413|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
79851812|NCT00724529|Biological|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
79254790|NCT03099824|Drug|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
79254791|NCT02639390|Device|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
79254792|NCT02639390|Other|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
79254793|NCT05055518|Drug|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
79394541|NCT02890368|Other|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
79550766|NCT01597700|Drug|10mg Ezetimibe|1 tablet taken by mouth
79550767|NCT01597700|Drug|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
79394542|NCT02804828|Dietary Supplement|Individualized mitochondrial cocktail|Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
79714362|NCT01218009|Drug|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
80017471|NCT03554304|Drug|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
80017472|NCT03554304|Drug|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
80017473|NCT02107716|Procedure|Lidocaine injection with bicarbonate|bicarbonate added to change pH
80017474|NCT02107716|Procedure|lidocaine injection|Lidocaine injection with pH unchanged
80017475|NCT02110992|Drug|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
80017476|NCT02110992|Radiation|Stereotactic Radiation|SBRT will be given over 5 fractions separated by > 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
80017477|NCT03306394|Drug|Trifluridine/Tipiracil hydrochloride (S95005)|
79254794|NCT05068154|Diagnostic Test|Myovista® WavECG™|The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities
79254795|NCT05067608|Biological|Control arm receiving normal (never before frozen) platelets as per current clinical practice|Liquid platelets arm (control) and may receive multiple platelet transfusions per thrombocytopenic cycle.
79394543|NCT02804828|Dietary Supplement|Placebo|6 months for the double-blind phase
79394544|NCT02754141|Biological|BMS-986179|Specified dose on specified days
79394545|NCT02754141|Biological|Nivolumab|Specified dose on specified days
79394546|NCT02754141|Biological|rHuPH20|Specified dose on specified days
79394547|NCT02659059|Biological|Nivolumab|Specified Dose on Specified Days
79394548|NCT02659059|Biological|Ipilimumab|Specified Dose on Specified Days
79394549|NCT02659059|Drug|Platinum Doublet Chemotherapy|
79394550|NCT02572427|Other|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
79394551|NCT02572427|Other|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
79714363|NCT04291183|Behavioral|horticultural therapy|Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
80017478|NCT02287844|Other|XOS|5 g of XOS everyday for 4 weeks.
80017479|NCT02287844|Other|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
80017480|NCT02287844|Other|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
80017481|NCT02105376|Device|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
80017482|NCT02111070|Biological|IL-YANG FLU Vaccine|0.5mL
80017483|NCT02983227|Drug|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
80017484|NCT02107794|Other|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
79714364|NCT04291417|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
79714365|NCT00992017|Biological|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
79714366|NCT01217463|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
79714367|NCT02868151|Drug|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
80017485|NCT00311090|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
80017486|NCT00311090|Drug|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
79714368|NCT02868151|Drug|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
79714369|NCT01217307|Drug|Metformin|Metformin 500mg twice daily during 4 months
79714370|NCT01217307|Drug|Placebo|Placebo twice daily during 4 months
79714371|NCT02868073|Biological|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
79714372|NCT02868073|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
79714373|NCT02868073|Biological|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
79714374|NCT01217229|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
79714375|NCT04318743|Drug|Glepaglutide|GLP-2
79714376|NCT01013740|Drug|Vinorelbine|Vinorelbine
80017487|NCT00311090|Drug|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
80017488|NCT00311090|Drug|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
80017489|NCT02105532|Other|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
79550768|NCT01597713|Drug|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
79550769|NCT01597713|Drug|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
79550770|NCT01597713|Drug|placebo|Subjects will receive a single dose of oral placebo within each dose group
79550771|NCT01597713|Drug|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
79714377|NCT01013740|Drug|Lapatinib|Lapatinib
79714378|NCT01013740|Drug|Capecitabine|Capecitabine
80017490|NCT02105532|Other|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
79394552|NCT02285530|Drug|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle.
79394553|NCT02285530|Procedure|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
79394554|NCT02285530|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
79394555|NCT02208388|Device|computed tomography perfusion guided treatment|
79394556|NCT02208388|Device|Fractional flow reserve guided treatment|
79550772|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
79550773|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
79714379|NCT02872246|Drug|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79714380|NCT02872246|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79714381|NCT00627874|Device|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
79851813|NCT03714178|Device|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
79851814|NCT01012869|Device|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
79851815|NCT03690999|Dietary Supplement|Placebo|Placebo product
79851816|NCT03690999|Dietary Supplement|Prebiotic supplement|Prebiotic supplement
80017491|NCT05622188|Other|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
80017492|NCT05622188|Other|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
80017493|NCT05622188|Other|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
79254796|NCT05067608|Biological|Treatment arm receiving cryopreserved platelets|Cryopreserved platelets arm (treatment) and may receive multiple platelet transfusions per thrombocytopenic cycle.
79550774|NCT01597726|Drug|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&E, repeated once 3 hours after the first dose if needed
79394557|NCT02186470|Radiation|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
79550775|NCT01597726|Device|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D&E
79550776|NCT01597739|Drug|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
79550777|NCT01597739|Drug|Placebo|Form=capsule; route=oral use; twice daily.
79550778|NCT01597752|Biological|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
79550779|NCT01597765|Drug|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
79550780|NCT01597765|Drug|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
79550781|NCT01597804|Procedure|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
79714382|NCT04299256|Behavioral|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
79714383|NCT01018030|Drug|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
79714384|NCT01018030|Drug|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
79851817|NCT05361785|Biological|FMT|FMT from healthy donor or placebo
79254797|NCT05055284|Other|Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.|Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
79254798|NCT05044754|Procedure|Local treatment of the prostate (SCAP or HIFU)|Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)
79254799|NCT03097640|Other|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
79254800|NCT02718417|Drug|carboplatin|Given Q3W during chemotherapy phase
79254801|NCT02718417|Drug|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
79550782|NCT01597817|Other|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
79714385|NCT01018030|Drug|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
79714386|NCT01217073|Drug|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
79851818|NCT03709342|Drug|CM4620-IE|single IV infusion on Day 1 over 4 hours
79851819|NCT01010295|Drug|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
79851820|NCT03632291|Biological|UB-221|UB-221 (75 mg/ml)
79851821|NCT01010373|Drug|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
79254802|NCT02718417|Drug|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
79394558|NCT02186470|Radiation|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
79394559|NCT02186470|Radiation|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
79394560|NCT02186470|Procedure|therapeutic conventional surgery|Lumpectomy
79550783|NCT01597817|Other|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
79550784|NCT01597830|Other|Mobility shoe|flat, specialized shoe
79550785|NCT01597830|Other|control shoe|control shoe
79550786|NCT01597869|Device|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
79550787|NCT01597895|Drug|Maraviroc|Maraviroc 150 mg BID x 5 days with food
79550788|NCT01597895|Drug|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
79550789|NCT01597895|Drug|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
79550790|NCT01597934|Drug|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
79550791|NCT01597934|Drug|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
79851822|NCT02570945|Procedure|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
79851823|NCT01010451|Procedure|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
79851824|NCT01010451|Procedure|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
79851825|NCT02570789|Drug|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
79851826|NCT00604214|Drug|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
79851827|NCT00604214|Drug|Placebo|0.9% sodium chloride, intravenous, 96 hours
79550792|NCT01597947|Drug|ACHN-975|Intravenous single dose
80017494|NCT03554070|Procedure|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
80017495|NCT03554070|Device|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
79394561|NCT01907412|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
79550793|NCT01597947|Drug|placebo|Intravenous single dose
79550794|NCT01597960|Other|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
79550795|NCT01597986|Drug|isavuconazole|oral
79714387|NCT01217073|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
79714388|NCT01217073|Drug|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
79851828|NCT01010529|Other|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
80017496|NCT03553992|Behavioral|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
80017497|NCT03553992|Behavioral|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
79550796|NCT01597986|Drug|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
79550797|NCT01597999|Radiation|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
79550798|NCT01598012|Drug|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
79550799|NCT01598012|Drug|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
79550800|NCT01598038|Other|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
79550801|NCT01598051|Drug|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
79550802|NCT01598077|Drug|LJM716|
79550803|NCT01598142|Procedure|Team 1|experienced endoscopist with a experienced assistant
79550804|NCT01598142|Procedure|Team 2|same experienced endoscopist with a new trained assistant
79714389|NCT01217073|Drug|Metformin|Metformin 500 mg oral tablet administered once or twice daily
79714390|NCT01217073|Drug|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
79714391|NCT00985621|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
79714392|NCT00985621|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
79714393|NCT00985621|Drug|oxycodone|oxycodone CR, 10-40 mg q12h
79714394|NCT00985621|Other|placebo|placebo
79714395|NCT01215981|Biological|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
79714396|NCT01215981|Biological|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
79851829|NCT04066439|Other|specimen|Immunohistochemistry analysis
79851830|NCT05325203|Biological|Ongericimab|Administered by subcutaneous injection
79851831|NCT05325203|Drug|Placebo|Administered by subcutaneous injection
79851832|NCT00450580|Drug|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
79851833|NCT00724685|Drug|Naropeine (Ropivacaine)|
80017498|NCT03815734|Procedure|motor imagery|motor imagery during the postoperative immobilization period
80017499|NCT02105610|Drug|desflurane, isoflurane, sevoflurane|
80017500|NCT02105610|Drug|total intravenous anesthetics|
80017501|NCT00301262|Drug|Viagra (Sildenafil citrate)|
80017502|NCT02254941|Drug|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
80017503|NCT02254941|Biological|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
79550805|NCT01598155|Procedure|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~Scaling, planning and polishing coronary surface;~Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
80017504|NCT03713476|Other|Motor task training|motor task specific training
80017505|NCT02107872|Drug|REGN1500|
79550806|NCT01598155|Procedure|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~Scaling, planning and polishing of coronary surface;~Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
80017506|NCT02107872|Drug|placebo|
80017507|NCT02111148|Procedure|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
80017508|NCT02111148|Procedure|Nitrazine|Nitrazine detection in vaginal wash
80017509|NCT02111148|Drug|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
79394562|NCT01788657|Behavioral|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
79394563|NCT01788657|Behavioral|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
79851834|NCT00724685|Drug|Placebo|saline
79550807|NCT01598168|Drug|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
79714397|NCT02887833|Other|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
79714398|NCT01215513|Drug|Degarelix|
79714399|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
79714400|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
79714401|NCT01215357|Drug|Ecopipam|50mg tablets
79714402|NCT05433441|Procedure|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
79714403|NCT00984295|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
79714404|NCT00984295|Biological|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
79254803|NCT02718417|Drug|Avelumab|Given as single agent in maintenance portion Q2W
79254804|NCT05067530|Drug|Palbociclib|CDK4/6 inhibitor
79851835|NCT00123487|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
79550808|NCT01598181|Device|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
79254805|NCT05067530|Drug|Paclitaxel|Chemotherapy
79254806|NCT05067530|Drug|Carboplatin|Chemotherapy
79254807|NCT05067218|Device|buzzy device|bee shaped with wings could be frozen.
79550809|NCT01598181|Device|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
79714405|NCT00984295|Biological|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
79714406|NCT00984295|Biological|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
79254808|NCT05067218|Other|Conventinal anasthesia|normal technique of injection
79254809|NCT03097562|Procedure|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
79254810|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
79714407|NCT00984295|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
79714408|NCT04291027|Other|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
79714409|NCT04291027|Other|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
79851836|NCT00123487|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
79851837|NCT00509925|Drug|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
79851838|NCT00509925|Drug|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
79851839|NCT00509925|Drug|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
80017510|NCT02111226|Other|SMS text messaging|short message service
80017511|NCT02905149|Procedure|Serrato|Serratus plane block.
80017512|NCT02905149|Procedure|Control|Standard anesthesia
80017513|NCT03553680|Behavioral|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
80017514|NCT03656913|Diagnostic Test|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
80017515|NCT02790606|Device|Covera(TM) Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
80017516|NCT03656523|Other|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
80017517|NCT02105922|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
79254811|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
79254812|NCT05054972|Procedure|Exclusion of the aortic aneurysm.|Surgical procedure in which an aortic aneurysm is excluded.
79851840|NCT00724763|Device|acupuncture|to Liv 3 and PE 9.
79851841|NCT00724763|Device|sham needle treatment|needle not in meridian area
79254813|NCT05067296|Other|By TVS|Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
79254814|NCT03297567|Behavioral|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
79851842|NCT05277974|Drug|inj bupivicain|In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
79851843|NCT00504777|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
79851844|NCT00504777|Drug|Methotrexate|10-25mg/week po or parenteral
79851845|NCT00902798|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
79254815|NCT03097406|Procedure|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
79254816|NCT03097406|Procedure|Global Advantage|A total shoulder prosthesis used for osteoarthritis
79254817|NCT03097406|Procedure|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
79714410|NCT00628186|Device|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
79851846|NCT00902798|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
79851847|NCT03968263|Device|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
79254818|NCT03097406|Procedure|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
79254819|NCT02461095|Other|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
79254820|NCT02461095|Other|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
79254821|NCT03099590|Dietary Supplement|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
79714411|NCT00628186|Device|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
79714412|NCT01017952|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
79851848|NCT03968263|Device|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
79851849|NCT03968263|Device|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
79851850|NCT03968263|Device|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
79851851|NCT00895076|Drug|dexamethasone|iontophoretic patch and injection
79851852|NCT01078519|Drug|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
79851853|NCT02539316|Drug|Smoflipid|
79254822|NCT03099590|Dietary Supplement|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
79851854|NCT02539316|Drug|Médialipides|
79851855|NCT00724997|Biological|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
79851856|NCT03968185|Other|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
79851857|NCT03968185|Other|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
79550810|NCT01598220|Behavioral|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
79254823|NCT04005963|Diagnostic Test|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
79550811|NCT01598220|Other|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
79550812|NCT01598233|Device|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
79254824|NCT05067062|Dietary Supplement|New Zealand blackcurrant extract|Capsules taken daily or intermittent
79550813|NCT01598259|Drug|Melatonin|po 1 hour before bedtime
79550814|NCT01598259|Other|placebo|po, 1 hour before bed
79714413|NCT01017952|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
79714414|NCT01214655|Drug|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
79714415|NCT01017874|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
79714416|NCT01017874|Drug|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
79714417|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
80017518|NCT02105922|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
79254825|NCT03297489|Procedure|Diagnostic Microscopy|Undergo observation via intravital microscopy
79254826|NCT03297489|Drug|Fluorescein Sodium Injection|Given IV
79254827|NCT03297489|Other|Laboratory Biomarker Analysis|Correlative studies
79254828|NCT03297411|Procedure|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
79254829|NCT03297411|Procedure|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
79254830|NCT03297411|Procedure|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
79254831|NCT03297411|Procedure|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
79254832|NCT03098498|Procedure|Subgingival Debridement|Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
79254833|NCT02461017|Other|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
79851858|NCT00509769|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
79851859|NCT02531503|Other|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
79851860|NCT00902876|Device|Mucograft|Collagen Matrix for soft tissue regeneration
79851861|NCT00902876|Procedure|Coronally advanced flap (CAF)|
79550815|NCT01598272|Dietary Supplement|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
79550816|NCT01598272|Dietary Supplement|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
79550817|NCT01598337|Drug|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
79550818|NCT01598337|Drug|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
79550819|NCT01598337|Drug|Clopidogrel|75 mg orally started 6-8hours before surgery
79550820|NCT01598337|Drug|Prasugrel|10 mg daily as per instructions of investigators
79550821|NCT01598376|Procedure|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
79851862|NCT02977715|Biological|IMVAMUNE (Liquid Formulation)|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
79851863|NCT02977715|Biological|IMVAMUNE (Lyophilized Formulation)|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
79851864|NCT01074697|Drug|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
79851865|NCT01074697|Drug|Placebo|Saline water
79851866|NCT02539082|Device|Regenseal|Regenseal, collagen, injection in the defect area
80017519|NCT02105922|Procedure|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
79714418|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
79714419|NCT04299568|Device|Anti gravity treadmill training|Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes
79714420|NCT04299568|Procedure|Physical Therapy|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
79254834|NCT02461017|Other|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
79851867|NCT02539082|Drug|normal saline|placebo, normal saline, injection in the defect area
79851868|NCT03997695|Other|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
79714421|NCT00627952|Drug|amlodipine 10 mg|amlodipine 10 mg once daily
79714422|NCT00627952|Drug|manidipine 20 mg|manidipine 20 mg once daily
79714423|NCT00627952|Drug|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
79714424|NCT00627952|Drug|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
79714425|NCT04299334|Procedure|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
79714426|NCT01015768|Device|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
79714427|NCT01015768|Device|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
79851869|NCT03997695|Other|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
79851870|NCT01074775|Biological|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
79254835|NCT05054270|Other|Chest examination with Ultrasound device|Chest examination with Ultrasound device
79714428|NCT04426630|Other|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
79714429|NCT01010230|Device|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
79714430|NCT01010230|Device|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
79714431|NCT01009840|Drug|IV busulfan|PK-directed dosing of IV busulfan for 4 days
79851871|NCT01080079|Drug|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
79714432|NCT01009840|Drug|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m^2.
79714433|NCT01009840|Procedure|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
79714434|NCT04297696|Other|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
79254836|NCT03297333|Other|Resistance training|The resistance training group
79394578|NCT01422421|Other|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
79394579|NCT01422421|Other|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
79394580|NCT01171573|Procedure|Venepuncture|Venepuncture - Taking blood
79394581|NCT01164891|Drug|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
79394582|NCT00178932|Procedure|genetic analysis|genetic assay of blood sample drawn with patient's consent
79714435|NCT04205500|Other|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
79851872|NCT01080079|Other|Purified Water|Purified Water
79851873|NCT02538536|Drug|PBI4050|
79851874|NCT00725231|Biological|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
79851875|NCT00725231|Drug|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
79851876|NCT02539238|Other|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
79851877|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
79851878|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
79714436|NCT04420936|Behavioral|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
79714437|NCT04420936|Behavioral|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
79714438|NCT04295980|Procedure|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
79714439|NCT02872090|Drug|Indacaterol|inhalation
79714440|NCT02872090|Drug|Glycopyrronium|inhalation
79714441|NCT02872090|Drug|Tiotropium|inhalation
79714442|NCT02872090|Drug|Placebo|
79851879|NCT03381521|Device|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
79254837|NCT03297333|Other|Aerobic interval training|The aerobic interval training group
79254838|NCT05066906|Device|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
79714443|NCT02872090|Procedure|photoplethysmography|inhalation
79714444|NCT04514458|Other|Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
79714445|NCT04282486|Other|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
79254839|NCT05066906|Other|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
79550822|NCT01598376|Procedure|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
79714446|NCT04296058|Other|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
79851880|NCT03381521|Drug|Normal saline|The normal saline was used for injection solution
79714447|NCT04295746|Other|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
79851881|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day
80017520|NCT03077620|Drug|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
79254840|NCT04477460|Dietary Supplement|Thickened feeds|Thickened feeds directed by medical team
79254841|NCT04477460|Dietary Supplement|Non-thickened feeds|Non-thickened feeds directed by medical team
79394583|NCT00178932|Procedure|genetic assay|genetic assay of blood sample drawn with patient's consent
79550823|NCT01598389|Other|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
79550824|NCT01598402|Drug|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
79550825|NCT01598415|Drug|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
79550826|NCT01598415|Drug|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
79714448|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
79714449|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
79851882|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
79851883|NCT00114127|Drug|Placebo|60mg placebo 1x per day
79851884|NCT05158179|Device|Sensation testing|Sensation testing tactile aesthesiometer.
79851885|NCT00902954|Drug|anastrozole|anastrozole 1 mg qd
79851886|NCT00902954|Drug|letrozole|letrozole 2.5 mg qd
79851887|NCT00902954|Drug|exemestane|exemestane 25 mg qd
79851888|NCT02570009|Behavioral|TEAMS (Talking about Eating, Activity, Mutual Support)|
79851889|NCT02570009|Behavioral|Need Support Training|
79851890|NCT04034966|Device|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
79851891|NCT05077553|Dietary Supplement|TCI999 probiotic sachet|Testing product
79851892|NCT05077553|Dietary Supplement|Placebo sachet|Blank
80017521|NCT03077620|Drug|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
79851893|NCT00572624|Behavioral|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
79851894|NCT00572624|Procedure|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
79851895|NCT02540720|Drug|Dexamethasone|
79851896|NCT02540720|Drug|Gamma globulin|
79851897|NCT02540720|Procedure|Hemoperfusion|
79851898|NCT02540642|Dietary Supplement|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
79851899|NCT00122317|Drug|eculizumab|
79851900|NCT00895388|Behavioral|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
79851901|NCT00895466|Biological|PEP-223/CoVaccine HT|
79851902|NCT03964675|Device|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
79851903|NCT03870555|Drug|TAK-954|TAK-954 infusion administered intravenously.
79851904|NCT03870555|Drug|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
79851905|NCT02569931|Other|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
79254842|NCT05044442|Behavioral|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
79254843|NCT05044442|Behavioral|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
79394584|NCT02375412|Procedure|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
79851906|NCT02569931|Other|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
79851907|NCT02569931|Procedure|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
80017522|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
80017523|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
79254844|NCT05054426|Drug|Methotrexate|intravenous versus intrathecal methotrexate
79394585|NCT02375568|Other|103024-F|mesenchymal stem cell isolation
79851908|NCT00908336|Drug|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
79851909|NCT00908336|Drug|Erlotinib|150 mg/day po daily
79851910|NCT03964519|Other|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
79851911|NCT03964519|Other|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
79851912|NCT03964519|Other|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
79254845|NCT04475900|Diagnostic Test|Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)|To measure corneal biomechanics with Scheimpflug based tonometry
79254846|NCT04475900|Diagnostic Test|Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)|To measure corneal topography and tomography with Scheimpflug tomograph
79254847|NCT04475900|Diagnostic Test|Optic nerve head measurement|To measure optic nerve excavation
79254848|NCT00701727|Drug|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
79254849|NCT00701727|Drug|Placebo|1 tablet, once a day, for 7 weeks
79394586|NCT02368392|Other|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
79851913|NCT00908414|Drug|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
79851914|NCT00908414|Drug|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
79851915|NCT00908414|Drug|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
79851916|NCT00908414|Drug|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
79851917|NCT00908414|Drug|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
79851918|NCT00908414|Drug|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
79851919|NCT00908414|Drug|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
79851920|NCT00908414|Drug|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
79851921|NCT00908414|Drug|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
79851922|NCT00908414|Drug|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
79714450|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
79714451|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
79714452|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
79714453|NCT00982657|Drug|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
79714454|NCT02867683|Other|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
79714455|NCT02867839|Drug|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
79714456|NCT02867839|Drug|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
79714457|NCT04119973|Other|standard treatment|standard medical treatment
79714458|NCT02867293|Procedure|ultrasound guided ascitic fluid drainage|
79714459|NCT02867293|Procedure|operative drainage of ascites through small skin incision after induction of anesthesia|
79714460|NCT02867293|Device|ultrasound|
79714461|NCT02867137|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
79714462|NCT02867371|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
80017524|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
79714463|NCT02867215|Other|Barley bread|120g barley bread per day for 3 weeks.
79714464|NCT02867215|Other|Wheat bread|120g wheat bread per day for 3 weeks.
79714465|NCT01005316|Drug|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
79714466|NCT01005316|Drug|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
79851923|NCT00908414|Drug|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
79851924|NCT00908414|Drug|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
79851925|NCT00908414|Drug|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
79851926|NCT00908414|Drug|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
80017525|NCT02111304|Drug|iOWH032|
80017526|NCT01903486|Drug|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
79254850|NCT05054660|Other|caring chatbot|The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
79394587|NCT02368626|Device|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
79714467|NCT01005316|Drug|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
79714468|NCT01005316|Procedure|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
79714469|NCT01005316|Procedure|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
79714470|NCT01005316|Drug|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
79714471|NCT01005316|Drug|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
79714472|NCT01004848|Behavioral|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
79714473|NCT01009294|Drug|Ataluren|Oral powder
79851927|NCT00908414|Drug|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
79851928|NCT00908414|Drug|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
79851929|NCT00908414|Drug|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
79851930|NCT01074853|Drug|propranolol|10mg twice daily escalated to 80mg once daily
79394588|NCT02375256|Biological|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
79550827|NCT01598441|Drug|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
79550828|NCT01598441|Drug|distilled water|1-2 ml aerosolized distilled water inhalation per session
79550829|NCT01598454|Drug|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
79550830|NCT01598467|Procedure|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
79851931|NCT01074853|Drug|placebo|Matched placebo
80017527|NCT03656289|Drug|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
79394589|NCT02375256|Biological|Placebo|Identical buffer solution in which AERAS-402 is formulated.
79394590|NCT02375256|Biological|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
79394591|NCT02375334|Other|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
79550831|NCT01598480|Drug|Flamazine|Silver sulfadiazine cream
79851932|NCT03870477|Device|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
79550832|NCT01598480|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
79550833|NCT01598493|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
79851933|NCT02570633|Other|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
79550834|NCT01598493|Drug|Flamazine|Silver sulfadiazine cream
80017528|NCT02106000|Device|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
79714474|NCT01009294|Drug|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
80017529|NCT02106078|Behavioral|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
79714475|NCT04205422|Procedure|BIPAP|Biphasic Intermittent Positive Airway Pressure
79714476|NCT04205422|Procedure|APRV|Airway Pressure Release Ventilation
79714477|NCT04205188|Other|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
79714478|NCT01009060|Drug|GSK239512|Histamine H3 Antagonist
79714479|NCT01009060|Drug|Placebo|Placebo to match GSK239512
79714480|NCT00988429|Drug|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
79714481|NCT00988429|Drug|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
79714482|NCT00988429|Drug|Placebo|Placebo tablet given QD
79714483|NCT01008904|Drug|magnesium oxide|Given PO
79714484|NCT01008904|Other|questionnaire administration|Ancillary studies
80017530|NCT02106078|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~What is bipolar disorder? - Content about symptoms and diagnosis~Stress and triggers of illness~Medication and the biological basis of bipolar disorder~Depression - Symptoms, early detection and helpful strategies~Mania and hypomania - Symptoms, early detection and helpful strategies"
79714485|NCT01008904|Procedure|quality-of-life assessment|Ancillary studies
79714486|NCT04295590|Behavioral|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
79714487|NCT04295590|Behavioral|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
79714488|NCT04291495|Diagnostic Test|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
79714489|NCT04290559|Procedure|Reveal LINQ ILR implant before AF ablation|Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.
79714490|NCT04290793|Drug|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
79714491|NCT04290793|Drug|Epirubicin|90mg/m^2 d1 iv Q2W for 4 cycles
79714492|NCT04290793|Drug|Cyclophosphamide|600 mg/m^2 d1 iv Q2W for 4 cycles
79714493|NCT04290793|Drug|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
79714494|NCT04290793|Biological|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
79714495|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
79851934|NCT02570633|Other|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
79851935|NCT00908492|Behavioral|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
79714496|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
79714497|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
79714498|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
79714499|NCT02871700|Behavioral|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
79714500|NCT02871700|Behavioral|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
79254851|NCT03099512|Other|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
79714501|NCT02871700|Behavioral|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
79714502|NCT02871076|Device|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
79714503|NCT04297462|Drug|Oseltamivir 3 days|Non-inferiority study of 3 versus 7-days duration of PEP
79714504|NCT04297462|Drug|Oseltamivir 7 days|Active comparator
79714505|NCT00981409|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
79714506|NCT00981409|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
79714507|NCT04297228|Behavioral|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
79714508|NCT04298710|Behavioral|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
79714509|NCT04298710|Behavioral|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
79714510|NCT04298710|Behavioral|Sitting|Remain seated for 20 minutes.
79714511|NCT02865655|Procedure|Hysteroscopic|
79714512|NCT04297072|Drug|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
79714513|NCT04297072|Drug|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
79714514|NCT02871310|Dietary Supplement|IQP-AS-118|1 tablet in the morning
79714515|NCT02871310|Dietary Supplement|Placebo|1 tablet in the morning
79714516|NCT01008748|Drug|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
79714517|NCT01008748|Behavioral|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
79714518|NCT01008748|Behavioral|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
79714519|NCT01008748|Behavioral|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
79714520|NCT02865265|Procedure|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
79714521|NCT04295512|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. UOT will be adapted for use in mental health service settings. Mental health therapists will be trained in UOT and deliver to youth and caregivers.
79714522|NCT04289545|Dietary Supplement|Functional bread|Postprandial effects of bread containing galactomannan
79714523|NCT00628732|Drug|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
79714524|NCT04289701|Other|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~Healthcare provider training and patient education.~Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~Outcome and performance evaluation quarterly.~Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
79714525|NCT02867449|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
79254852|NCT03099512|Other|Exercise|Exercises which improves muscle strength, ROM...
79254853|NCT02463513|Dietary Supplement|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
79254854|NCT02463513|Dietary Supplement|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
79714526|NCT02867449|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
79714527|NCT02866825|Biological|IFX-1|
79714528|NCT02866825|Biological|Placebo|
79714529|NCT04290715|Other|no intervention|no intervention
79714530|NCT02870998|Other|Active learning|1-day continuing education activity consisting of a lecture on patient education.
79714531|NCT02870998|Other|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
79254855|NCT02463513|Dietary Supplement|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
79254856|NCT04155008|Drug|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
79254857|NCT04155008|Drug|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
79550835|NCT01598519|Behavioral|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
79550836|NCT01598558|Drug|Cu-64 Rituximab|Up to 14 mCi, iv
79550837|NCT01598571|Drug|Fostamatinib|Fostamatinib 50 mg tablet
79550838|NCT01598571|Drug|Fostamatinib|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose
79550839|NCT01598584|Drug|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
79550840|NCT01598584|Drug|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
79550841|NCT01598623|Drug|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
79550842|NCT01598623|Behavioral|Social Skills Training|three times a week for three weeks.
79550843|NCT01598623|Behavioral|Placebo + Non Specific Counselling|
79714532|NCT05212441|Device|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
79714533|NCT05212441|Behavioral|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
79254858|NCT04155008|Drug|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
79254859|NCT04155008|Behavioral|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
79394592|NCT04439448|Radiation|dual-energy X-ray absorptiometry (DEXA) scan|Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass
79394593|NCT04439448|Other|Carotid and branchial artery ultrasound|Ultrasound to assess carotid plaque and brachial artery flow mediated dilation
79394594|NCT04439448|Diagnostic Test|2-hour oral glucose tolerace test|Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min
79394595|NCT04439448|Diagnostic Test|Blood collection|Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells
79394596|NCT02368080|Device|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
79394597|NCT02375178|Drug|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
79394598|NCT02375178|Drug|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
79394599|NCT02375178|Drug|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
79394600|NCT02368236|Behavioral|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
79394601|NCT02364648|Dietary Supplement|MitoQ|Mitochondria targeted antioxidant
79394602|NCT02364648|Dietary Supplement|Placebo|Placebo
79394603|NCT02375100|Procedure|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
79714534|NCT05212441|Procedure|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
80017531|NCT02106078|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
80017532|NCT01883817|Drug|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
79714535|NCT05212441|Other|Therapeutic Exercises|"Passive ROM (PROM).~Active ROM (AROM) & Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~Stretching exercises: A low-load (low-intensity), long-duration stretch~Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
79714536|NCT04298788|Other|Blue dishware|blue dishware is used for plates and bowls
79714537|NCT02865421|Drug|stem cells|adipose tissue derived stromal vascular fraction
79714538|NCT02865421|Drug|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
79714539|NCT04205344|Drug|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
79714540|NCT04205344|Drug|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
79714541|NCT01004146|Procedure|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
79714542|NCT01012414|Drug|paricalcitol|2 mcg oral paricalcitol daily
79714543|NCT01012414|Drug|placebo|placebo
79714544|NCT00975715|Drug|TRI476|TRI476 oral suspension doses, based on body weight twice daily
80017533|NCT01883817|Drug|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
80017534|NCT00599170|Drug|Rituximab|375 mg/m2 IV
80017535|NCT05128240|Dietary Supplement|Placebo|1g corn oil capsules
80017536|NCT05128240|Dietary Supplement|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
80017537|NCT03656211|Other|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
79394604|NCT02375100|Procedure|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
79394605|NCT02375100|Procedure|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
79394606|NCT02375100|Drug|Bupivacaine %0.5 (hyperbaric)|
79394607|NCT02375100|Drug|Bupivacaine %0.25 (isobaric)|
79550844|NCT01598649|Dietary Supplement|Fabricated foods with lupin protein|- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
79550845|NCT01598649|Dietary Supplement|Mannitol|- Placebo capsules containing mannitol (four capsules per day)
79550846|NCT01598649|Dietary Supplement|Arginine|- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
79550847|NCT01598649|Dietary Supplement|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
79714545|NCT00975715|Drug|Placebo to TRI476|Placebo oral suspension, taken twice daily
79714546|NCT00975715|Drug|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
79714547|NCT04295668|Behavioral|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
80017538|NCT04256434|Drug|Dinalbuphine sebacate|150 mg Dinalbuphine sebacate
80017539|NCT04256434|Drug|Nalbuphine HCl|20 mg Nalbuphine
80017540|NCT03553602|Radiation|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen[until end of radiotherapy])"
80017541|NCT04234126|Procedure|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
80017542|NCT03655977|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before external beam radiation therapy (EBRT).
79550848|NCT01598675|Other|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
79851936|NCT00908492|Behavioral|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
79851937|NCT04880291|Drug|GFB-024|Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
79851938|NCT04880291|Drug|Placebo|Matched placebo
79851939|NCT00908570|Drug|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
79851940|NCT00908570|Drug|Placebo|Placebo cream
79851941|NCT01010607|Device|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
79254860|NCT05044364|Drug|This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.|Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
79851942|NCT01010607|Device|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
79851943|NCT01010607|Device|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
79254861|NCT03096860|Other|Active alcohol consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
79254862|NCT03096860|Other|Placebo consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
79254863|NCT02461173|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
79254864|NCT02461173|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
79851944|NCT00725777|Drug|artemether-lumefantrine|Standard artemether-lumefantrine treatment
79851945|NCT00165841|Drug|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
79851946|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
79254865|NCT02461173|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
79254866|NCT02461173|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
80017543|NCT03655977|Device|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
80017544|NCT03655977|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before brachytherapy (BT).
80017545|NCT03655977|Device|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
79254867|NCT02461173|Device|shepherd catheter|
79550849|NCT01598675|Other|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
79851947|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
79851948|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
79851949|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
79851950|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
79851951|NCT00725855|Drug|MEM 3454|1 mg dose
79851952|NCT00725855|Drug|MEM 3454|5 mg dose
79851953|NCT00725855|Drug|MEM 3454|15 mg dose
79851954|NCT00725855|Drug|MEM 3454|50 mg dose
79851955|NCT00725855|Drug|Placebo for MEM 3454|Placebo dose
79394608|NCT02375100|Device|25G Quincke needle|
79394609|NCT02375100|Device|Echogenic Needle with 30° bevel|
79394610|NCT02375100|Drug|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
79394611|NCT02375100|Drug|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
79394612|NCT02364414|Device|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
79394613|NCT02364258|Drug|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
79714548|NCT04295668|Behavioral|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
79714549|NCT02866981|Other|Observation|
79851956|NCT01326637|Other|Patient Overview Document|"The Intervention has two components:~Pre-visit care coordination:~5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
79851957|NCT02538458|Drug|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
80017546|NCT03769584|Other|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
80017547|NCT03769584|Other|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
79394614|NCT02364258|Drug|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
79714550|NCT00629317|Other|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
79714551|NCT00629317|Drug|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
79714552|NCT04298476|Procedure|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
79714553|NCT02866591|Other|mammography according to an auto-compression procedure|
79714554|NCT02866591|Other|mammography according to a standard procedure|
79394615|NCT02368158|Other|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
79714555|NCT02866591|Other|questionary|
79714556|NCT02871154|Other|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
79714557|NCT03962491|Behavioral|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
79714558|NCT03962491|Behavioral|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
79714559|NCT02866513|Other|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
79714560|NCT04290637|Other|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
79714561|NCT04290637|Other|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
79714562|NCT00978757|Drug|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
79714563|NCT00978757|Other|Placebo|saline solution
79714564|NCT01214421|Drug|Tolvaptan|Tablets of 15 or 30 mg
79714565|NCT04102111|Drug|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
79851958|NCT02538458|Drug|3 % hypertonic saline up to 24H|"Treatment by inhalation of 3 % hypertonic saline, up to 24H.~followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
80017548|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
80017549|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
80017550|NCT02113722|Procedure|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
80017551|NCT02113722|Procedure|Standard of Care|Medical therapy
80017552|NCT03655509|Procedure|Dynamic test ACTH stimulation|
80017553|NCT02111460|Radiation|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
80017554|NCT02111538|Other|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
80017555|NCT02982213|Other|Companion Present|A companion will be present during the epidural catheter placement.
80017556|NCT05403424|Other|Evaluation of pain|The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
80017557|NCT05403424|Diagnostic Test|Application of pelvic girdle diagnostic tests|Pelvic girdle pain diagnostic tests will be applied.
80017558|NCT05403424|Other|Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia|The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
79714566|NCT04102111|Drug|Placebo|Participants will receive oral tablets of matching placebo twice daily.
79714567|NCT01214187|Drug|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
79714568|NCT01214187|Other|Oxygen|Room air oxygen concentrations will be administered as placebo
79714569|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
79714570|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
79714571|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
79714572|NCT02865031|Drug|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
79714573|NCT02864875|Drug|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
79254868|NCT04434716|Device|Feasibility of wearing a Readiband to monitor Sleep and Fatigue|On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
79714574|NCT01003990|Drug|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
79254869|NCT04489329|Device|Ingestible Capsule|Participants will swallow capsule and undergo X-rays to establish transit
79254870|NCT04489329|Dietary Supplement|Probiotic|Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
79254871|NCT02463279|Device|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
79714575|NCT01003990|Drug|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
79714576|NCT01003990|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
79714577|NCT01003990|Drug|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
79714578|NCT01003210|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
79714579|NCT01002820|Drug|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
80017559|NCT05403424|Other|Evaluation of activity limitation|Pelvic Girdle Questionnaire will be filled
79254872|NCT03096938|Diagnostic Test|methylation markers screening|Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
79254873|NCT02463435|Behavioral|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
79394616|NCT02375022|Drug|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
79394617|NCT04439058|Other|ultrasound guided left stellate ganglion block|"Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
79394618|NCT02374710|Procedure|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
79394619|NCT02374710|Procedure|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
79714580|NCT01012258|Biological|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
79714581|NCT00628810|Biological|bevacizumab|
79714582|NCT00628810|Drug|fluorouracil|
79714583|NCT00628810|Drug|irinotecan hydrochloride|
79714584|NCT00628810|Drug|leucovorin calcium|
79714585|NCT04298320|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
79714586|NCT04298320|Drug|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
79714587|NCT04298164|Behavioral|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
79714588|NCT04298164|Behavioral|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
79851959|NCT00509223|Device|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
79550850|NCT01598688|Other|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
79254874|NCT02463435|Other|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
79550851|NCT01598688|Other|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
79254875|NCT02463435|Dietary Supplement|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
79254876|NCT04152668|Procedure|Titanium curette.|Implant debridement.
79851960|NCT00509223|Behavioral|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
79254877|NCT04152668|Procedure|Ultrasonic|Implant debridement.
79550852|NCT01598714|Device|Darco shoe|Darco shoe
79550853|NCT01598714|Device|Podalux shoe|Podalux shoe
79550854|NCT01598714|Device|Standard dressing shoe|Standard dressing shoe
79714589|NCT01011946|Device|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
79851961|NCT01582867|Device|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
79714590|NCT04296682|Procedure|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
79851962|NCT02538380|Procedure|EUS-B-FNA followed by EUS-FNA for LAG analysis|
79851963|NCT05277662|Diagnostic Test|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
79851964|NCT04067063|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
79254878|NCT04152668|Procedure|Air-polishing|Implant debridement and polishing.
79254879|NCT03297177|Procedure|Microcannula Harvest Adipose|Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
79714591|NCT04296760|Diagnostic Test|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
79714592|NCT04296760|Diagnostic Test|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
79550855|NCT01598727|Device|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
79550856|NCT01598766|Device|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
79550857|NCT01598792|Biological|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
79550858|NCT01598805|Behavioral|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
79714593|NCT00975481|Drug|dimebon|Oral tablet; 20 mg dimebon, single dose
79851965|NCT00460798|Other|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
79851966|NCT03965455|Device|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
79851967|NCT03965455|Procedure|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
80017560|NCT02111616|Behavioral|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
79550859|NCT01598844|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
79714594|NCT00975481|Drug|dimebon|Oral tablet; 40 mg dimebon, single dose
79394620|NCT02367612|Dietary Supplement|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
79550860|NCT01598857|Drug|Blisibimod|
79550861|NCT01598857|Drug|Placebo|
79550862|NCT01598870|Other|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
79714595|NCT00975481|Drug|dimebon|Oral tablet; 60 mg dimebon, single dose
79714596|NCT00975481|Drug|placebo|Oral tablet or capsule; placebo, single dose
79714597|NCT00975481|Drug|alprazolam|Oral capsule; 1 mg alprazolam, single dose
79550863|NCT01598883|Drug|Heparin|150 U/kg
79714598|NCT00975481|Drug|alprazolam|Oral capsule; 3 mg alprazolam, single dose
79714599|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
79714600|NCT01011868|Drug|BI 10773 low dose|BI 10773 low dose
79714601|NCT01011868|Drug|BI 10773 high dose|BI 10773 high dose
79714602|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
79714603|NCT04290013|Drug|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
79714604|NCT04290013|Drug|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
79254880|NCT03297177|Device|Centricyte 1000|Closed System, Digestive Isolation & Concentration of AD-cSVF
79714605|NCT04288999|Drug|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
79714606|NCT04288999|Radiation|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
79714607|NCT04288999|Other|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
79714608|NCT01213251|Device|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
79714609|NCT01213251|Device|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
79254881|NCT03297177|Procedure|Sterile Normal Saline Infusion|Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
79254882|NCT03099668|Other|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
79254883|NCT03297099|Procedure|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
79254884|NCT03297099|Procedure|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
79254885|NCT05066828|Other|two pieces obturator|patient received two pieces obturator connecting by magnet attachment
79254886|NCT05054114|Drug|Interferon gamma human recombinant (IFN-G)|nasal form
79254887|NCT02463045|Drug|TOP1288|
79394621|NCT02367612|Dietary Supplement|Placebo|Maltodextrin
79550864|NCT01598883|Drug|ATryn|1000 IU
79550865|NCT01598909|Drug|Arnica|Application of Arnica ointment periorbitally
79550866|NCT01598909|Drug|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
79550867|NCT01598948|Drug|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
79550868|NCT01598961|Other|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
79550869|NCT01598961|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
79550870|NCT01598961|Other|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
79550871|NCT01598974|Procedure|Traditional Acupuncture|
79550872|NCT01598974|Procedure|Laser Acupuncture|
79550873|NCT01599000|Drug|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
79714610|NCT02865109|Drug|Nusinersen|Administered by intrathecal injection
79714611|NCT03934177|Dietary Supplement|Blueberry powder|Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
79714612|NCT03934177|Dietary Supplement|Placebo powder|A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
79714613|NCT02864017|Procedure|Enteral nutrition|
79714614|NCT02864017|Dietary Supplement|L-Citrulline|
79714615|NCT02864017|Dietary Supplement|Placebo|
80017561|NCT02111616|Behavioral|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
79714616|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
79714617|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
79714618|NCT02864173|Genetic|Whole genome small nucleotide polymorphism genotyping|
79254888|NCT05053802|Combination Product|Microwave ablation plus Camrelizumab|Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab
79550874|NCT01599013|Drug|Vinflunine, Gemcitabine|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
79550875|NCT01599013|Drug|Vinflunine, Carboplatin|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
79714619|NCT04318431|Diagnostic Test|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
79714620|NCT02866435|Drug|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
79714621|NCT02866435|Drug|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
79851968|NCT04034342|Other|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
79550876|NCT01599065|Other|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
79714622|NCT02866435|Drug|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
79714623|NCT04287751|Device|CheckMeO2 Oximeter|Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
79714624|NCT01212159|Device|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
79714625|NCT00973765|Drug|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
79714626|NCT00973765|Drug|placebo|placebo 2 pills po BID x 7 days
79851969|NCT02570399|Radiation|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
79851970|NCT01075165|Other|silicone spray|application of silicone spray to predefined area qd 12 weeks
79851971|NCT01075165|Other|saline spray|application of saline spray to predefined area qd 12 weeks
79254889|NCT05053802|Device|Microwave ablation|Tumor received treatment of microwave ablation
79254890|NCT04665531|Procedure|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
79254891|NCT04665531|Procedure|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
79550877|NCT01599078|Drug|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
79550878|NCT01599078|Drug|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
79550879|NCT01599091|Other|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
79550880|NCT01599117|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
79714627|NCT04287595|Other|Inhalation aromatherapy with orange essential oil|
79851972|NCT00725933|Drug|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
79550881|NCT01599117|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
79714628|NCT01211769|Drug|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
79714629|NCT01211769|Drug|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
79714630|NCT01211769|Drug|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
79714631|NCT01211769|Drug|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
79714632|NCT04287673|Other|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
79714633|NCT04288609|Other|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
79714634|NCT04288609|Other|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
79714635|NCT04288765|Drug|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
79714636|NCT01211613|Procedure|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
79254892|NCT04665531|Drug|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
79394622|NCT02367534|Procedure|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
79394623|NCT01497899|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
79394624|NCT01497899|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
79394625|NCT01497899|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
79550882|NCT01599130|Drug|Entecavir|entecavir 0.5mg per day
79550883|NCT01599130|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
79714637|NCT01211613|Device|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
79714638|NCT01211613|Other|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
79714639|NCT02864797|Other|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
79714640|NCT01211535|Device|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
79714641|NCT01211535|Device|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
79714642|NCT01211535|Device|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
79714643|NCT04287439|Behavioral|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
79714644|NCT04287439|Behavioral|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
79714645|NCT04287439|Other|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
79714646|NCT02863861|Drug|Dexmedetomidine-ketamine|
79714647|NCT02863861|Drug|propofol-ketamine|
79714648|NCT05406765|Drug|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
79254893|NCT05053568|Device|CARTBox|CARTBox performs analysis of cardiac MRI scans. The result is a treatment file that displays optimal targets for left ventricular lead implantation in CRT. This file will be used as an overlay with live fluoroscopy during the implantation procedure in the intervention group.
79394626|NCT01497899|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
79394627|NCT02374866|Other|closer monitoring|
79550884|NCT01599143|Behavioral|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
79851973|NCT00726869|Drug|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8.
79851974|NCT01028248|Drug|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
79851975|NCT00726011|Biological|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
79394628|NCT02363712|Device|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
79714649|NCT01011556|Drug|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
79714650|NCT01011556|Drug|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
79714651|NCT01211145|Drug|Placebo|Placebo nasal spray
79254894|NCT04943289|Biological|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
79714652|NCT01211145|Drug|Zolmitriptan|0.5 mg nasal spray
79714653|NCT01211145|Drug|Zolmitriptan|2.5 mg nasal spray
79714654|NCT01211145|Drug|Zolmitriptan|5.0 mg nasal spray
79714655|NCT02871622|Device|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
79714656|NCT00977665|Drug|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
79714657|NCT00977665|Drug|placebo|placebo tablet for 48 weeks
79714658|NCT04298008|Drug|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
79714659|NCT04298008|Drug|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
79714660|NCT02871544|Other|BNP and NGAL|
79714661|NCT04295278|Diagnostic Test|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
79254895|NCT05053724|Other|Star to move Protocol|"Progressive physical therapy according to the Gosslink protocol called Start to move."
79254896|NCT01369069|Drug|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
79394629|NCT02363712|Device|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
79394630|NCT02374788|Behavioral|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
79394631|NCT02374788|Behavioral|Group meetings|Participants receive 12 group meetings over two years' time.
79714662|NCT00628342|Drug|Esomeprazole|20mg Oral tablet once daily
79714663|NCT00628342|Drug|Esomeprazole|40mg Oral tablet once daily
79714664|NCT00628342|Drug|Placebo|Oral once daily
79714665|NCT04290325|Drug|HMPL-453|HMPL-453 tablet
79714666|NCT01210443|Drug|Sitaxentan|sitaxentan sodium 100 mg
79714667|NCT02870764|Drug|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
79714668|NCT02870764|Drug|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
79714669|NCT02870764|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
79714670|NCT04287361|Other|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
79714671|NCT00624429|Drug|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
79714672|NCT02864719|Other|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
79714673|NCT01007812|Device|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
79714674|NCT01007812|Device|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
79851976|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
79851977|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
79851978|NCT01028326|Biological|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
79851979|NCT00603980|Drug|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
79851980|NCT00603980|Drug|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
79851981|NCT00603980|Drug|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
79851982|NCT00603980|Drug|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
79851983|NCT00603980|Drug|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
79550885|NCT01599156|Procedure|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
79550886|NCT01599169|Dietary Supplement|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
79714675|NCT04204525|Diagnostic Test|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
79714676|NCT01208961|Drug|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
79714677|NCT01208961|Drug|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
79851984|NCT00603980|Drug|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
79851985|NCT00603980|Drug|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
79851986|NCT00603980|Drug|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
79851987|NCT00603980|Drug|Oral placebo qualifying session|Qualifying control session (oral placebo)
79851988|NCT04880603|Device|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
79851989|NCT04880603|Procedure|Standard of Care Skin Graft|Standard of Care Skin Graft
79851990|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
79851991|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
80017562|NCT03655431|Other|Telerehabilitation|Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
79394632|NCT02374788|Behavioral|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
79254897|NCT01369069|Drug|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
79254898|NCT04489563|Device|i-ACT|Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
79254899|NCT05053178|Behavioral|Mindfulness-based mandala activity|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented
79254900|NCT04489641|Behavioral|Psychological treatment|Psychological treatment
79550887|NCT01599169|Dietary Supplement|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
79254901|NCT04489641|Drug|Medication|Pharmacological intervention
79394633|NCT01497275|Drug|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
79394634|NCT02363790|Procedure|LVHR PFC|Information included in arm description
79550888|NCT01599195|Device|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
79851992|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
79254902|NCT02441218|Drug|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
79714678|NCT01001572|Drug|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
79714679|NCT01001572|Drug|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
79714680|NCT01001572|Drug|Placebo|1 capsule or tablet taken orally once daily
79851993|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
79714681|NCT02866357|Other|No intervention|Just collection of nasopharyngeal aspirate for assessment
79550889|NCT01599208|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
79714682|NCT01208415|Device|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
79714683|NCT02871232|Other|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
79550890|NCT01599221|Device|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
79550891|NCT01599260|Other|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
79550892|NCT01599273|Drug|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
79714684|NCT04287205|Drug|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
79714685|NCT00628576|Drug|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
79714686|NCT00628576|Drug|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
79851994|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
79851995|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
79851996|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Acute DVT
79254903|NCT02441218|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
79254904|NCT03098264|Procedure|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
79254905|NCT03098264|Procedure|staged surgery|staged surgery in complicated hepatolithiasis
79714687|NCT01208337|Drug|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
79714688|NCT04295122|Device|Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser|"A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded."
79851997|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Chronic DVT
79851998|NCT00450190|Device|Saizen® E-Device|Saizen® (recombinant human growth hormone [r-hGH]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
79254906|NCT03296943|Combination Product|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
79394635|NCT02363790|Procedure|Bridging LVHR|Information included in arm description
79394636|NCT01557517|Drug|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
79394637|NCT01557517|Drug|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
79394638|NCT02363556|Procedure|Misoprostol administered vaginally|
79394639|NCT02363556|Procedure|Misoprostol administered buccally|
79394640|NCT02363556|Procedure|Misoprostol administered vaginally with Dilapan|
79394641|NCT02363556|Procedure|Misoprostol administered buccally with Dilapan|
79394642|NCT01497197|Drug|GONAL-f®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen.
79394643|NCT01497197|Drug|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
79394644|NCT01497197|Biological|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
79714689|NCT04370548|Drug|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
79550893|NCT01599312|Device|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
79714690|NCT01208181|Drug|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
79714691|NCT01208181|Drug|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
79714692|NCT01208181|Drug|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
79714693|NCT01208181|Drug|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
79714694|NCT02870842|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
79714695|NCT02870842|Other|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
79714696|NCT01208103|Biological|Bevacizumab|Given IV
79714697|NCT01208103|Drug|Capecitabine|Given PO
79714698|NCT01208103|Drug|Oxaliplatin|Given CVC
79714699|NCT01206777|Drug|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
79714700|NCT01001494|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
79394645|NCT03483246|Drug|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
79394646|NCT03483246|Drug|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
79394647|NCT01496885|Other|Observational study|This was an observational study and no study drug was administered.
79394648|NCT01557283|Other|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
79550894|NCT01599338|Drug|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
79550895|NCT01599351|Radiation|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
79550896|NCT01599364|Drug|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
79550897|NCT01599377|Drug|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
79714701|NCT01001494|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
79714702|NCT01001494|Drug|Placebo|Placebo twice-daily by inhalation for 24 weeks
79714703|NCT01205685|Drug|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~Dose level 2 = 150 mg twice a day~Dose level 1 = 100 mg twice a day~Dose level -1 = 100 mg twice a day~Dose level -2 = 100 mg twice a day"
79714704|NCT01205685|Drug|Erlotinib|"During the safety run phase of the study:~Dose Level 2 = 100 mg/d~Dose Level 1 = 100 mg/d~Dose Level -1= 75 mg/d~Dose Level -2 = 50 mg/d"
79714705|NCT01205685|Drug|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
79714706|NCT01205685|Drug|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
79714707|NCT04362514|Behavioral|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
79714708|NCT04362514|Other|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
79714709|NCT01205529|Drug|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
79714710|NCT02870374|Behavioral|Answering specific quality of life questionnaire in kidneys transplantation population|
79714711|NCT04295200|Other|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
79714712|NCT01205451|Drug|Botulinum toxin type A|Botulinum toxin type A
79394649|NCT00349713|Biological|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
79714713|NCT04294732|Drug|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
79714714|NCT04294732|Drug|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
79714715|NCT04294888|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
79714716|NCT02887677|Drug|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
79714717|NCT02887677|Drug|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
79714718|NCT02871466|Drug|stem cells infusion|
79714719|NCT01001104|Drug|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
79714720|NCT01001104|Drug|Placebo|Administered by SC injection, QW for 12 weeks.
79714721|NCT04296526|Behavioral|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
79714722|NCT04296526|Behavioral|Exercise Education|To organize sessions for how to proper exercise.
79714723|NCT04296526|Behavioral|Social Support|Supports such as peer influence or reminder phone messages
79714724|NCT00628888|Behavioral|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
79851999|NCT01028482|Drug|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
80017563|NCT03655431|Other|Standard treatment|Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
79254907|NCT03296943|Combination Product|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
79254908|NCT03296943|Behavioral|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
79394650|NCT00349713|Biological|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
79394651|NCT02374632|Other|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
79394652|NCT02374632|Other|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
79394653|NCT02374632|Other|Sham feeding|
79550898|NCT01599377|Drug|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
79550899|NCT01599390|Other|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
79550900|NCT01599403|Procedure|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
79550901|NCT01599403|Procedure|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
79550902|NCT01599403|Procedure|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
79852000|NCT01028482|Drug|placebo|placebo
79852001|NCT01028482|Other|psychotherapy|psychotherapy
79852002|NCT00726167|Device|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
80017564|NCT02111694|Behavioral|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
79254909|NCT05052788|Device|Optical coherence tomography angiography|"OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2* weighted images, using a machine 1.5 tesla General Electric machine ."
79254910|NCT02097433|Drug|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
79394654|NCT03372564|Procedure|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
79852003|NCT00907322|Drug|Dimebon|Oral tablet; 20 mg Dimebon, single dose
79254911|NCT03296865|Device|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
79550903|NCT01599416|Dietary Supplement|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
79550904|NCT05691153|Drug|ThisCART19A with Dose Level 1|ThisCART19A，2×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
79852004|NCT00907322|Drug|Dimebon|Oral tablet; 40 mg Dimebon, single dose
79852005|NCT00907322|Drug|Dimebon|Oral tablet; 60 mg Dimebon, single dose
79852006|NCT00907322|Drug|Dimebon|Oral tablet; placebo, single dose
79852007|NCT00903188|Drug|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
79852008|NCT00903188|Drug|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
79394655|NCT01523743|Device|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
79852009|NCT00726245|Biological|PRGF|3-6mg IM (to area of muscle tear)
79852010|NCT00726245|Biological|Placebo|3cc IM of physiological saline
79852011|NCT00450112|Device|Gel-200|Single Intra-articular Injection
79852012|NCT00727181|Device|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
79254912|NCT05043818|Other||This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
79550905|NCT05691153|Drug|ThisCART19A with Dose Level 2|ThisCART19A，3×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
79254913|NCT02097511|Drug|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
79550906|NCT05691088|Device|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
79550907|NCT05691049|Device|Profhilo® Structura|"Dosage form: Profhilo® Structura (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of 4.5% hyaluronic acid for intradermal use (45 mg H-HA + 45 mg L-HA) dissolved in 1.5 ml of saline buffered sodium chloride.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation."
79852013|NCT00908726|Drug|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
79852014|NCT02948309|Drug|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
79254914|NCT02097511|Drug|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
79254915|NCT02097511|Drug|Metoprolol|Metoprolol Tartrate 100 mg once a day
79254916|NCT03957681|Drug|KHK4827|210 mg Q2W, SC
79254917|NCT03957681|Drug|Placebo|Q2W, SC
79394656|NCT01523743|Device|Standard care|The coated intermittent catheter normally used by subject
79852015|NCT02948309|Drug|Placebo|1ml subcutaneous injection 3 times/week
79852016|NCT00726401|Drug|COLD-fX|200mg BID for 4 weeks
79852017|NCT00726401|Drug|Placebo|200mg BID for 4 weeks
79852018|NCT00903266|Behavioral|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
79852019|NCT00903266|Behavioral|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
79852020|NCT02569775|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
79852021|NCT00449956|Drug|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
79852022|NCT00449956|Drug|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
79714725|NCT02870686|Procedure|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
79714726|NCT02870686|Procedure|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
79714727|NCT04204954|Other|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
79714728|NCT04204954|Drug|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
79714729|NCT04204954|Other|Baby shampoo|Twice a day eyelid margin cleansing for three days.
79714730|NCT04204954|Other|Blephaclean|Twice a day eyelid margin cleansing for three days.
79714731|NCT02870608|Other|lung and liver elastography measurement of fetus|
79714732|NCT04344886|Procedure|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
79714733|NCT04344886|Procedure|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
79714734|NCT04344886|Procedure|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
79714735|NCT04344886|Procedure|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
79714736|NCT00998764|Drug|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
79714737|NCT01204671|Biological|Influenza vaccine GSK2321138A|One intramuscular injection
79714738|NCT01204671|Biological|FluarixTM|One intramuscular injection
79714739|NCT01204671|Biological|Influenza vaccine GSK2604409A|One intramuscular injection
79714740|NCT02887755|Device|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
79714741|NCT01202955|Drug|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
79714742|NCT01202955|Drug|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
79714743|NCT01202877|Drug|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
79714744|NCT01202877|Drug|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
79714745|NCT01202409|Drug|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
79714746|NCT01202175|Drug|Nebivolol|Oral nebivolol 2.5-5mg once daily
79714747|NCT01201785|Drug|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
79852023|NCT00449956|Drug|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
79852024|NCT00908804|Procedure|open appendectomy|
79852025|NCT00908804|Procedure|laparoscopic appendectomy|
79852026|NCT00726479|Drug|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
79550908|NCT05691023|Device|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
79550909|NCT05690945|Drug|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
79550910|NCT05690945|Drug|Tilesizumab|Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
79550911|NCT05690867|Other|Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes|group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
79714748|NCT01201317|Drug|AZD2423|20 mg tablet
79714749|NCT01201317|Drug|AZD2423|150 mg tablet
79852027|NCT00903422|Drug|eltrombopag olamine|thrombopoietin receptor agonist
79714750|NCT01201317|Drug|Placebo|Placebo
79714751|NCT04318353|Other|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
79714752|NCT04317885|Biological|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
79714753|NCT01200069|Drug|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
79714754|NCT01200069|Drug|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
79714755|NCT01199601|Behavioral|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
79714756|NCT01199289|Drug|AMG 827|SC injection.
79714757|NCT01199289|Drug|Placebo|SC injection.
79714758|NCT01199055|Drug|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)
79852028|NCT00903422|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
79852029|NCT01323088|Other|Control|Standard care control (no exercise)
79852030|NCT01323088|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
80017565|NCT03655353|Diagnostic Test|ABY-PET|Diagnostic PET for HER2 expression
80017566|NCT02649634|Behavioral|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
79254918|NCT05043740|Drug|Repatha or Praluent|Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
79254919|NCT02099539|Biological|ALT-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
79254920|NCT03928275|Biological|Interleukin-2|IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
79550912|NCT05690867|Other|Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes|group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
79550913|NCT05690802|Drug|Palonosetron hydrochloride capsules|"This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage."
79550914|NCT05690711|Drug|HRS8179|HRS8179 injection
79550915|NCT05690711|Drug|Placebo|physiological saline
79550916|NCT05690620|Behavioral|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
79550917|NCT05690620|Other|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
79714759|NCT01199055|Drug|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
79852031|NCT01323088|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
79852032|NCT03906461|Device|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
79852033|NCT00907400|Drug|PN400|oral tablet
79852034|NCT00907400|Drug|Naproxen|oral tablet
79852035|NCT00726635|Behavioral|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
79852036|NCT00726635|Other|Control group|A one hour conversation with a nurse
79852037|NCT00726635|Other|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
79550918|NCT05690607|Other|Doctors Laboratory TINIES small volume blood testing kit|Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.
79550919|NCT05690568|Other|multimodal chiropractic care|functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
79550920|NCT05690542|Other|blood tests|evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
79550921|NCT05690529|Procedure|Ablation|Radiofrequency AF ablatoon
79550922|NCT05690490|Procedure|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
79550923|NCT05690490|Procedure|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
79550924|NCT05690399|Radiation|Radiotherapy|Effect of radiotherapy on patients
79550925|NCT05690347|Behavioral|Back At work After Surgery (BAAS)|see protocol
79714760|NCT01199055|Drug|Paclitaxel|Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
79714761|NCT01198977|Behavioral|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
79714762|NCT01198977|Other|Education counseling|Mailed informational video of exercise programs
79852038|NCT03995602|Dietary Supplement|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
79852039|NCT03995602|Dietary Supplement|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
79714763|NCT01198587|Drug|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
79852040|NCT05277506|Device|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
79550926|NCT05690321|Drug|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
79550927|NCT05690321|Drug|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
79254921|NCT03928275|Biological|Combination therapy Interleukin-2 and Bacillus Calmette Guerin|"BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions)."
79254922|NCT05043896|Procedure|Li-ESWT|Li-ESWT twice weekly for 4 weeks
79394657|NCT04091633|Behavioral|WHO School Mental Health Program|World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
79550928|NCT05690191|Drug|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
79550929|NCT05690191|Drug|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
79550930|NCT05690191|Drug|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
79550931|NCT05690152|Device|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
79550932|NCT05690139|Procedure|Pre-operative LSG patients|Baseline
79714764|NCT01198587|Drug|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
79852041|NCT05277506|Device|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
79852042|NCT00727493|Drug|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
79852043|NCT00727493|Drug|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
79852044|NCT03878914|Drug|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
79852045|NCT00727727|Drug|Piribedil|
79852046|NCT00907712|Other|cardiac echo examination|cardiac echo examination - before and after the surgery
79852047|NCT04720079|Procedure|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
79254923|NCT05043896|Drug|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
79254924|NCT02410252|Device|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
79254925|NCT03097016|Drug|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
79254926|NCT03096704|Diagnostic Test|vitamine d dosage|dosage of vitamine D in slow transit time constipation
79550933|NCT05690139|Procedure|Post-operative patients 1st month|1 month after surgery
79550934|NCT05690139|Procedure|Post-operative patients 3rd month|3 months after surgery
79550935|NCT05690139|Procedure|Post-operative patients 6th month|6 months after surgery
79550936|NCT05690022|Procedure|sleeve gastrectomy|Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
79714765|NCT01198509|Drug|doxycycline|doxycycline - 100 mg twice per day, for 2 months
79714766|NCT01198509|Drug|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
79254927|NCT04933929|Behavioral|Post-hospitalization nutritional monitoring|Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs & Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
79254928|NCT02099695|Drug|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
79714767|NCT01198275|Drug|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
79714768|NCT01198275|Drug|Placebo|1.0 g of olive oil,one capsule twice a day
79714769|NCT01198275|Drug|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
79852048|NCT04720079|Procedure|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
79852049|NCT00909116|Procedure|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
79254929|NCT02099695|Drug|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
79254930|NCT02440594|Behavioral|Enhanced BHL Program Services|Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
79550937|NCT05689996|Drug|Ozone-Based Agent|Ozone-based eye drops as adjuvant therapy in microbial keratitis
79550938|NCT05689983|Drug|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
79550939|NCT05689970|Diagnostic Test|AI platform to detect ST elevation in ECG|A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
79550940|NCT05689957|Drug|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
79550941|NCT05689931|Biological|Mepolizumab|"Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)"
79550942|NCT05689931|Drug|Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)|Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
79550943|NCT05689918|Other|No intervention|No intervention
79550944|NCT05689905|Diagnostic Test|HLA typing of the children|The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
79714770|NCT01198275|Drug|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
79714771|NCT01197417|Drug|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
79714772|NCT01197417|Drug|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
79714773|NCT04206267|Device|Acceledent|Device for accelerating tooth movement
79714774|NCT00977431|Drug|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
79852050|NCT00729989|Procedure|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
79550945|NCT05689801|Other|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
79550946|NCT05689801|Other|SF-12 questionnaire|Questionnaire about quality of life of the patient
79714775|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
79714776|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
79852051|NCT00903656|Drug|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
79852052|NCT00730067|Drug|sildenafil|Sildenafil 50 mg three times daily
79852053|NCT00730067|Drug|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
79852054|NCT00909194|Behavioral|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
79852055|NCT00509145|Drug|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
79254931|NCT02440594|Behavioral|Standard BHL Program Services|Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
79254932|NCT05043662|Diagnostic Test|UroCAD assay, CTU examination and urine cytology|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
79254933|NCT02099851|Device|Carotid body ablation (Cibiem)|
79254934|NCT02102503|Behavioral|Standard Treatment|
79254935|NCT02102503|Behavioral|MI and Medication review|
79254936|NCT04935580|Biological|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
79550947|NCT05689801|Other|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
79550948|NCT05689801|Other|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
79714777|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
79714778|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
79550949|NCT05689801|Procedure|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
79550950|NCT05689801|Procedure|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
79550951|NCT05689775|Procedure|Reconstruction with robot-assisted rectus abdominis muscle flap|Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
79550952|NCT05689723|Procedure|Lumbar manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
79852056|NCT00509145|Other|Placebo|oral, once daily, capsule
79852057|NCT00907790|Behavioral|Usual Care (Control Group)|
79852058|NCT00907790|Behavioral|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
79714779|NCT04290169|Drug|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
79714780|NCT04290169|Device|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
79714781|NCT02864095|Drug|Tranexamic acid (TXA)|IV and topical administration
79254938|NCT05066516|Drug|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
79550953|NCT05689723|Procedure|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
79550954|NCT05689697|Dietary Supplement|PanTrek|administration of exogenouse keton body
79714782|NCT02864095|Drug|Epinephrine|
79714783|NCT02864641|Behavioral|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
79714784|NCT04286893|Diagnostic Test|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
79714785|NCT04286893|Diagnostic Test|High resolution ECG|Measurement HRV using high resolution ECG
79550955|NCT05689632|Dietary Supplement|Vitamin D3 + K2-MK7|Combined supplementation
79714786|NCT04286893|Diagnostic Test|Blood withdrawal|Measurement of endothelial inflammation markers
79714787|NCT04290247|Diagnostic Test|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
79714788|NCT02863939|Device|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
79714789|NCT02863939|Other|exercise|
79714790|NCT00977197|Drug|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
79714791|NCT00977197|Drug|Placebo|A matching placebo will be administered twice a day
79714792|NCT04065139|Drug|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
79714793|NCT04065139|Drug|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
79714794|NCT04288297|Procedure|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
79852059|NCT02538224|Drug|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
79394658|NCT04091633|Behavioral|Enhanced School Mental Health Program (eSMHP)|Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
79394659|NCT02367300|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
79550956|NCT05689632|Dietary Supplement|Placebo|MCT
79550957|NCT05689632|Dietary Supplement|Vitamin D3|Vitamin D3 - 7000 IU
79254939|NCT02097589|Drug|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
79254940|NCT02097589|Drug|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
79254941|NCT02097589|Other|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
79550958|NCT05689606|Behavioral|Exercise|Exercise includes acute high-intensity interval training.
79550959|NCT05689580|Dietary Supplement|Ketogenic diet|The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake
79550960|NCT05689580|Dietary Supplement|Balanced diet|Balanced diet
79852060|NCT02538224|Drug|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
79852061|NCT04018781|Other|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
79714795|NCT04288219|Device|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
79550961|NCT05689554|Behavioral|STOP Falls Educational Intervention|This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial. The unit of randomization is the clinic, to avoid the risk of contamination if healthcare providers within a clinic were randomized (i.e., reducing the potential for intervention providers to communicate with control providers about the intervention and share materials). Eighteen clinics were identified for the trial, of which 9 were randomized to the intervention and 9 to usual care.
79254942|NCT05066594|Device|Transoral incisionless fundoplication|The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
79714796|NCT04288219|Drug|Nifedipine|Nifedipine 30mg, Pharmacotherapy
79852062|NCT02538302|Drug|Minirin|Minirin 5 to 10 mg daily for 6 months
79852063|NCT02538302|Drug|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
79254943|NCT02102581|Procedure|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
79254944|NCT05066438|Behavioral|Antenatal hand expression|Standardized counselling and provision of information/resources on the practice of antenatal hand expression to encourage milk let down and colostrum production/collection.
79550962|NCT05689515|Behavioral|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
79714797|NCT04288219|Other|supplemental oxygen|supplemental oxygen
79852064|NCT00903734|Drug|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
79852065|NCT04603079|Behavioral|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
79852066|NCT00903812|Other|No intervention|No intervention as observational study
79875291|NCT00556439|Drug|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~Participants weighing less than 60kg will receive 500mg of abatacept.~Participants weighing 60 to 100kg will receive 750mg of abatacept.~Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
79254945|NCT02099929|Other|Coffee with Sugar|300mL of Coffee with 30g of Sugar
79254946|NCT02099929|Other|Coffee without Sugar|300mL of Coffee without Sugar
79254947|NCT02099929|Other|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
79254948|NCT02099929|Other|Water with Sugar|300mL of Water with 30g of Sugar
79394660|NCT02363634|Dietary Supplement|magnesium threonate|nutritional product
79394661|NCT02374554|Device|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
79394662|NCT02374554|Device|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
79394663|NCT02363400|Drug|MEP|Adjuvant Chemotherapy
79394664|NCT02367222|Other|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
79714798|NCT00974311|Drug|Enzalutamide|MDV3100, 160 mg orally per day
79714799|NCT00974311|Drug|Placebo|Placebo comparator
79714800|NCT00974233|Drug|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
79714801|NCT00974233|Drug|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
79254949|NCT02099929|Other|Water without Sugar|300mL of Water without Sugar
79254950|NCT05052164|Behavioral|Gluten-free nutrition plan + exercise group|Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric
79394665|NCT02367222|Other|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
79714802|NCT00974233|Drug|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
79714803|NCT02866123|Other|ultrasonography|
79714804|NCT02866123|Radiation|pulmonary radiography|
79714805|NCT00629395|Behavioral|Captain's Log Computer Program|12 Computer Program
79714806|NCT04270357|Procedure|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
79394666|NCT00350025|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
79714807|NCT02863627|Other|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
79714808|NCT00972595|Drug|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
79550963|NCT05689489|Other|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
79550964|NCT05689489|Other|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
79550965|NCT05689437|Other|Application of ILD prediction machine learning model to planning imaging|The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.
79714809|NCT00972595|Drug|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
79550966|NCT05689437|Other|Routine, automatic presentation of ILD risk level for evaluation by the clinician.|Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
79714810|NCT01196091|Drug|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
79714811|NCT01196091|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
79714812|NCT01196091|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
79714813|NCT01196091|Drug|Standard of Care|
79714814|NCT01195623|Procedure|preoperative duplex examination|
79714815|NCT01195623|Procedure|Preoperative duplex|
79714816|NCT01195545|Device|Veritas® Collagen Matrix|biological mesh in hernia repair
79714817|NCT01194999|Device|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
79714818|NCT01194531|Device|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
79852067|NCT00907946|Procedure|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
79852068|NCT02569619|Behavioral|Activity Intervention|
79852069|NCT02569619|Behavioral|Healthy Diet Intervention|
79254951|NCT05052164|Behavioral|Gluten-free nutrition plan group|Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program
79394667|NCT00350025|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
79394668|NCT01496807|Drug|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
79714819|NCT00972517|Biological|GSK investigational vaccine GSK2340272A|Three intramuscular injections
79714820|NCT04286737|Other|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
79714821|NCT02863549|Device|MitraClip in tricuspid valve|MitraClip in tricuspid valve
79714822|NCT00972283|Drug|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
79714823|NCT00972283|Drug|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
79714824|NCT00972283|Drug|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
79714825|NCT05366049|Other|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
79714826|NCT02887599|Procedure|Blood collection|1ml of blood specimen collection
79394669|NCT01496807|Drug|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
79394670|NCT02374320|Drug|liposomal bupivacaine|injected as an axillary block
79394671|NCT02374086|Behavioral|Exercise training|
79394672|NCT01496183|Drug|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
79394673|NCT01496183|Drug|Placebo|Placebo capsule administered orally at bedtime for 14 days
79394674|NCT01495793|Drug|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
79394675|NCT02363166|Other|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
79550967|NCT05689437|Other|Application of SGR machine learning model to diagnostic and planning imaging|The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
79550968|NCT05689437|Other|Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.|Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
79550969|NCT05689437|Other|Application of CBCT machine learning model to on-treatment imaging|The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
79550970|NCT05689437|Other|Routine monitoring of lung density changes during the course of treatment presented to clinician.|Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
79550971|NCT05689320|Other|Behavioral: EMA-based intervention|This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
79550972|NCT05689242|Drug|Dexmedetomidine Injection [Precedex]|intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
79550973|NCT05689229|Drug|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
79550974|NCT05689216|Behavioral|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
79550975|NCT05689203|Drug|QLS1128|dose 1
79550976|NCT05689203|Drug|QLS1128|dose 2
79550977|NCT05689203|Drug|Placebo|Placebo
79852070|NCT00909272|Procedure|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
79852071|NCT00909272|Procedure|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
79394676|NCT02362776|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
79394677|NCT02374008|Drug|Ropivacaine|
79394678|NCT04505280|Drug|Lidocaine 1% Injectable Solution|Greater occipital nerve and cervical region injections once a week for 4 weeks
79394679|NCT02366988|Device|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
79394680|NCT02366988|Procedure|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
79394681|NCT02366832|Procedure|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
79394682|NCT02366832|Device|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
79394683|NCT02366754|Device|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
79394684|NCT02366754|Device|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
79394685|NCT02373930|Drug|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
79254952|NCT05052164|Behavioral|Active Comparator: Celiac controls group|Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
79714827|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
79714828|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
79852072|NCT00509067|Drug|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
79254953|NCT02102659|Genetic|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
79254954|NCT02102659|Genetic|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
79852073|NCT00509067|Drug|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
79852074|NCT00509067|Drug|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
79254955|NCT03836001|Drug|Serlopitant Tablet|Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.
79254956|NCT03836001|Drug|Placebo Oral Tablet|The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
79254957|NCT05052242|Diagnostic Test|primary angle closure disease|2 swept source OCT biometers, IOL Master700 and Anterion
79254958|NCT02100085|Biological|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
79254959|NCT02465866|Drug|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
79254960|NCT02465866|Drug|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
79254961|NCT02465866|Drug|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
79254962|NCT02465866|Drug|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
79254963|NCT05052008|Drug|Erenumab|Erenumab is monoclonal antibody used for management of migraine
79714829|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
79714830|NCT00969709|Drug|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
79852075|NCT00509067|Drug|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
79254964|NCT02100163|Behavioral|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
79254965|NCT02100163|Behavioral|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
79254966|NCT02100163|Other|Standard treatment|
79254967|NCT05052320|Device|Audiological assessment|TO assess audiological profile in recovered covid19 subjects
79254968|NCT03555955|Drug|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
79254969|NCT03555955|Drug|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
79254970|NCT05066360|Diagnostic Test|serum antimullerian hormone|serum antimullerian hormone will be analyzed for all participants
79254971|NCT03296631|Other|collection of diapers with fresh stools|collection of diapers with fresh stools
79254972|NCT02439970|Drug|Brincidofovir|
79254973|NCT02439970|Drug|Valganciclovir|
79254974|NCT02097901|Procedure|Microfracture|Rotator Cuff Repair AND Microfracture
79254975|NCT02097901|Procedure|NO microfracture|Rotator Cuff Repair without microfracture
79254976|NCT05065814|Other|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
79714831|NCT01193517|Drug|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
79714832|NCT01193517|Drug|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
79714833|NCT01193517|Drug|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
79714834|NCT01193517|Drug|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
79852076|NCT04504487|Other|Drain Removal|Abdominal drain placed during surgery removal
79852077|NCT02538146|Dietary Supplement|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
79852078|NCT00504309|Drug|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
79852079|NCT00504309|Drug|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
79852080|NCT00504309|Drug|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
79254977|NCT05065814|Other|Systemic sclerosis group|Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
79254978|NCT05065814|Other|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
79254979|NCT03290859|Procedure|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
79254980|NCT03555799|Diagnostic Test|Inferior vena cava ultrasound|Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
79254981|NCT02437864|Device|Supplemental oxygen via nasal cannula|
79714835|NCT02866045|Procedure|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
79714836|NCT02866045|Procedure|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
79714837|NCT02863705|Drug|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
79394686|NCT02373930|Drug|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
79394687|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
79394688|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
79714838|NCT02863705|Drug|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
79714839|NCT01193283|Drug|Cyclophosphamide|30 my/kg for 4 days
79714840|NCT01193283|Drug|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
79714841|NCT00971425|Biological|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
79714842|NCT00971425|Biological|Fluarix™|1 dose intramuscular injection
79852081|NCT04034654|Other|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
79852082|NCT00730145|Drug|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
79394689|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
79394690|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
79550978|NCT05688046|Drug|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
79550979|NCT05688046|Drug|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
79550980|NCT05687812|Dietary Supplement|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
79550981|NCT05686252|Other|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
79550982|NCT05684471|Procedure|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
79714843|NCT00971425|Biological|Placebo|1 dose intramuscular injection
79714844|NCT02863471|Drug|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
79714845|NCT01193127|Drug|OMS302 Solution|
79714846|NCT01193127|Drug|OMS302 Mydriatic Solution|
79714847|NCT01193127|Drug|OMS302 Anti-inflammatory Solution|
79852083|NCT00908024|Drug|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
79852084|NCT00908024|Drug|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
79852085|NCT00730223|Drug|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
79254982|NCT03098186|Behavioral|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
79254983|NCT03098186|Behavioral|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
79394691|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
79394692|NCT03105414|Device|Mechanical ventilation|Mechanical ventilation
79550983|NCT05684471|Procedure|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
79550984|NCT05680246|Device|DHOPE-PRO|Prolonged DHOPE preservation >4 hours
79550985|NCT05678140|Device|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
79550986|NCT05678140|Other|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
79550987|NCT05673473|Radiation|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
79714848|NCT01193127|Drug|Balanced Salt Solution (BSS) Solution|
79714849|NCT01192815|Drug|erlotinib hydrochloride|Given orally or via gastronomy tube
79714850|NCT01192815|Radiation|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
79714851|NCT01192815|Other|pharmacogenomic studies|Optional correlative studies
79714852|NCT01192815|Other|gene expression analysis|Correlative studies
79852086|NCT00508755|Device|Gait Robot|gait training with the use of a gait robot
79852087|NCT00508755|Device|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
79875292|NCT00556439|Drug|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
79875293|NCT04012229|Genetic|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score > or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
79394693|NCT03112746|Behavioral|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
79394694|NCT02366676|Drug|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd~5th month:once a month)
79394695|NCT03003780|Behavioral|Mindful Steps|Integrated website, activity tracker, and mind-body training
79394696|NCT02366442|Other|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
79394697|NCT03112668|Behavioral|Cognitive Behavior Therapy|Undergo ACT
79394698|NCT03112668|Other|Quality-of-Life Assessment|Ancillary studies
79394699|NCT03112668|Other|Questionnaire Administration|Ancillary studies
79394700|NCT03112668|Other|Survey Administration|Ancillary studies
79550988|NCT05641519|Behavioral|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
79550989|NCT05641519|Behavioral|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
79550990|NCT05634109|Biological|Transfusion of blood products|The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
79875294|NCT00945737|Dietary Supplement|Soy protein; 25 grams/day|Soy protein
79875295|NCT00945737|Dietary Supplement|Control protein|Milk protein
79875296|NCT04012307|Drug|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
79875297|NCT04012307|Drug|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
79875298|NCT00939263|Other|assessment of disease activity using the EEsAI|disease activity index
79875299|NCT00941213|Device|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
79254984|NCT03296475|Procedure|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
79550991|NCT05632237|Behavioral|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
79550992|NCT05618132|Diagnostic Test|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
79550993|NCT05595291|Other|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
79550994|NCT05567848|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
79550995|NCT05553808|Drug|Docetaxel|Docetaxel was administered as IV infusion.
79550996|NCT05553808|Drug|Feladilimab|Feladilimab was administered as IV infusion.
79852088|NCT04065815|Other|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week"
79852089|NCT04065815|Other|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
79852090|NCT04065815|Other|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~2 training sessions per week"
79852091|NCT04065815|Other|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~1 training session per week~Resistance Training:~five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~1 training session per week"
79875300|NCT00941213|Device|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
79875301|NCT00387465|Drug|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
79254985|NCT02102737|Drug|6-DIG|injection of 6-DIG
79254986|NCT02102737|Procedure|clamp|hyperinsulinemic euglycemic clamp
79254987|NCT05065658|Drug|Posaconazole|Intravenous posaconazole prophylaxis
79254988|NCT03296397|Biological|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
79394701|NCT02373384|Drug|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~Potassium citrate 20 mEq three times daily~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
79394702|NCT02373384|Behavioral|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
79394703|NCT02373384|Dietary Supplement|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
79394704|NCT01494467|Drug|CD5024|CD5024 1% Cream, once daily
79550997|NCT05549388|Other|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
79550998|NCT05544890|Procedure|Exercise|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Therapeutic exercise"
79550999|NCT05544890|Procedure|Manual Therapy|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Manipulation"
79551000|NCT05544890|Procedure|Kinesiotape|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Kinesiotaping"
79551001|NCT05540184|Drug|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
79551002|NCT05540184|Drug|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
79551003|NCT05540184|Drug|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
79551004|NCT05533268|Other|Mental training|Mental training (guided mindfulness meditation by Jon Kabat-Zinn for 20 minutes, 3 times per week.
79551005|NCT05533268|Other|Physical training|Physical training (continuous moderate-intensity training at 40-60% of participants' heart rate reserve for 20 minutes excluding warm-up/cool-down, 3 times per week.
79714853|NCT01192815|Radiation|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
79714854|NCT01192815|Other|biopsy|Optional correlative studies
79714855|NCT01192815|Other|pharmacological study|Optional correlative studies
79714856|NCT01192815|Other|laboratory biomarker analysis|Optional correlative studies
79714857|NCT01192815|Other|questionnaire administration|Optional ancillary studies
79714858|NCT01192815|Other|enzyme-linked immunosorbent assay|Optional correlative studies
79714859|NCT01192815|Other|polymorphism analysis|Optional correlative studies
79714860|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
79394705|NCT01494467|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
79714861|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
79714862|NCT04317729|Device|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
79714863|NCT01307267|Drug|PF-05082566|Intravenous, Dose escalation, once per month
79714864|NCT01307267|Drug|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
79714865|NCT01307267|Drug|PF-05082566|IV, Dose escalation, once per month
79714866|NCT01307111|Drug|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
79714867|NCT01307111|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
79714868|NCT01306877|Device|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
79714869|NCT01306877|Device|Endosurgery Proximate PPH03 Stapling Set|Surgical device
79254989|NCT03296397|Biological|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
79394706|NCT02362698|Other|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
79714870|NCT01191801|Drug|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
79714871|NCT01191801|Drug|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
79714872|NCT01306643|Drug|Idelalisib|Tablet(s) administered orally twice daily
79852092|NCT00908102|Other|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
79551006|NCT05533268|Other|Mental & physical training|Mental and physical training (combination of mindfulness mediation for 20-minutes, 3 times per week and continuous moderate-intensity training for 20 minutes, 3 times per week.
79551007|NCT05533268|Other|DASH diet|DASH diet ( (more vegetables, fruits and low-fat dairy foods and moderate amounts of whole grains, fish, poultry and nuts; and less than 3 grams of sodium daily) for 6-weeks.
79852093|NCT00908102|Other|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
79254990|NCT02102815|Drug|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
79551008|NCT05523271|Diagnostic Test|CAD EYE (Computer Aided Diagnosis ----?|CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
79551009|NCT05522777|Other|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10^9 CFU Lacticaseibacillus paracasei strain Shirota
79714873|NCT04317495|Other|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
79714874|NCT04317339|Drug|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
79714875|NCT04317339|Drug|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
79394707|NCT02362698|Other|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
79394708|NCT02363088|Other|Neutral text message reminder|"Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
79394709|NCT02363088|Other|Messenger text message reminder|"<GP NAME>: Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
79394710|NCT02363088|Other|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
79551010|NCT05512884|Behavioral|Speeded anomia therapy|The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
79551011|NCT05506852|Behavioral|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
79551012|NCT05506852|Behavioral|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
79551013|NCT05488769|Device|Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
79714876|NCT05656833|Device|Fractional 1927nm Low-Powered Diode Laser|Clear & Brilliant Permea® Laser used on the side of the face randomized to receive laser
79714877|NCT05656833|Other|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
79714878|NCT05656755|Other|Strengthening|The strengthening exercises were executed with the body weight without any additional weight and were composed of exercises like the squats, the lunges, the plank, and the mountain climbers
79714879|NCT05656755|Other|Running|running for two supervised training sessions of one hour, and one free session of 30 minutes per week during 24 weeks
79714880|NCT05656677|Behavioral|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
79852094|NCT00908102|Other|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
79254991|NCT02102815|Drug|Normal saline|NSS 50 mL IV slowly push over 5 minutes
79254992|NCT04935112|Drug|Sitravatinib|100 mg sitravatinib on Day 1
79254993|NCT04935112|Drug|Pantoprazole|40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
79254994|NCT04935112|Drug|Famotidine|40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2
79254995|NCT05065112|Procedure|Pulmonary veins isolation + Cartofinder-guided ablation|The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
79254996|NCT05065112|Procedure|Pulmonary veins isolation|Wide area circumferential pulmonary veins isolation
79254997|NCT03296319|Device|Echocardiography|Echocardiography guided fluid administration
79254998|NCT02102971|Procedure|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
79254999|NCT03296241|Device|laser|
79255000|NCT03296241|Device|sham control|
79714881|NCT05656677|Radiation|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
79714882|NCT01306331|Drug|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
79714883|NCT01306331|Drug|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
79852095|NCT00908102|Other|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
79852096|NCT00730301|Procedure|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
79394711|NCT02363088|Other|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
79394712|NCT02363088|Other|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
79551014|NCT05473195|Drug|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
79255001|NCT04909996|Device|Sentinox--Group A|"GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
79551015|NCT05473195|Drug|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
79852097|NCT00908180|Biological|alemtuzumab|
80017567|NCT02649634|Behavioral|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
80017568|NCT02107950|Biological|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
79255002|NCT04909996|Device|Sentinox--Group B|"GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
79255003|NCT04908033|Device|pacemaker implantation|pacemaker implantation
79394713|NCT02363088|Other|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
79551016|NCT05473195|Drug|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
79551017|NCT05473195|Drug|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
79551018|NCT05463406|Other|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
79551019|NCT05463406|Other|Usual care|Management as usual
79551020|NCT05458817|Other|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
79852098|NCT00908180|Biological|donor lymphocytes|
79852099|NCT00908180|Drug|carmustine|
79852100|NCT00908180|Drug|cyclosporine|
79852101|NCT00908180|Drug|cytarabine|
79852102|NCT00908180|Drug|etoposide|
79255004|NCT03555487|Drug|18F-choline PET|5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
79255005|NCT05043194|Drug|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
79394714|NCT02366364|Drug|Placebo|Single oral administration of placebo consumption on Day 1
79394715|NCT02366364|Drug|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
79394716|NCT02366364|Drug|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
79394717|NCT02366364|Drug|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
79852103|NCT00908180|Drug|melphalan|
79852104|NCT00908180|Procedure|allogeneic hematopoietic stem cell transplantation|
79852105|NCT02538068|Behavioral|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
79852106|NCT02538068|Behavioral|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
79852107|NCT00904124|Dietary Supplement|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
79852108|NCT00504231|Biological|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
79852109|NCT00909506|Drug|Placebo|"Control: Receive placebo pill once every evening on 1~2 weeks.~Receive placebo pill in every morning and evening on 3~24 weeks (twice a day)."
79852110|NCT00909506|Drug|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks."
79852111|NCT00909506|Drug|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day)."
79714884|NCT05656287|Other|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if >90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if >90% medication adherence.
79714885|NCT05656287|Other|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
79714886|NCT05656287|Other|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
79714887|NCT00624663|Drug|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
79714888|NCT05656209|Dietary Supplement|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2*10^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
79714889|NCT04317573|Device|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
79714890|NCT01306253|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
79714891|NCT05655975|Procedure|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
79255006|NCT04909606|Other|nurse-led prevention program|"Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~A video explaining corticosteroids related adverse events and adequate preventive measures~An individual interview with the trained nurse~A consultation with a dietetician~An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures"
79551021|NCT05450952|Dietary Supplement|Theanine Formulation|Theanine Formulation Tablet
79551022|NCT05450952|Dietary Supplement|Placebo|Placebo Tablet
79551023|NCT05433103|Other|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
79714892|NCT02890823|Drug|Cholecalciferol|
79714893|NCT05655897|Device|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
79714894|NCT05655663|Other|Vascular investigation|Measure of of carotid stiffness
79714895|NCT02887443|Drug|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
79852112|NCT03997539|Drug|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
79255007|NCT04909606|Other|Current care|Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
79852113|NCT03997539|Drug|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
79852114|NCT03997539|Drug|vinorelbine|vinorelbine
79852115|NCT04422899|Drug|AIV007|intravitreal
79255008|NCT02103049|Drug|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
79255009|NCT03099278|Drug|Ezetimibe|Ezetimibe 20 mg oral daily
79394718|NCT02373540|Device|Algovita Spinal Cord Stimulation system|
79394719|NCT02881086|Drug|Rituximab|
79394720|NCT02881086|Drug|Nelarabine|
79394721|NCT02881086|Drug|PEG-Asparaginase|
79394722|NCT02881086|Procedure|Cranial irradiation|
79394723|NCT02881086|Drug|Imatinib|
79394724|NCT02881086|Drug|Idarubicin|
79394725|NCT02881086|Drug|Dexamethasone|
79394726|NCT02881086|Drug|Cyclophosphamide|
79394727|NCT02881086|Drug|Fludarabine|
79394728|NCT02881086|Drug|Vincristine|
79394729|NCT02881086|Drug|Mercaptopurine|
79551024|NCT05433103|Other|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
79255010|NCT04909528|Device|Low-level tragus stimulation|Frequency: 20Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulation spot: ear tragus; Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
79255011|NCT04909528|Device|Sham stimulation|Frequency: 20 Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulate spot: ear lobe. Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
79551025|NCT05422053|Device|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
79551026|NCT05418127|Dietary Supplement|Active|Traditionally-fermented coconut milk kefir
79551027|NCT05418127|Other|Placebo|Solution of Calcium Carbonate and coconut extract
79551028|NCT05360056|Device|DexCom G6|Wearable continuous glucose monitor
79551029|NCT05349760|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
79551030|NCT05349760|Drug|Placebo|Saline/D5W
79255012|NCT02097979|Behavioral|Glaucoma Educational Intervention|
79255013|NCT05043272|Biological|SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
79255014|NCT02103205|Dietary Supplement|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
79255015|NCT02103205|Dietary Supplement|Formula with low iron concentration (2mg/L) without lactoferrin|
79551031|NCT05344911|Drug|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
79551032|NCT05344911|Drug|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
79551033|NCT05338021|Procedure|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
79551034|NCT05338008|Procedure|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
79714896|NCT02887443|Drug|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
79714897|NCT04317261|Diagnostic Test|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
79255016|NCT02103205|Dietary Supplement|Formula with normal iron concentration (8 mg/L) without lactoferrin|
79255017|NCT03290703|Drug|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
79255018|NCT03290703|Drug|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
79255019|NCT02098057|Dietary Supplement|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
79255020|NCT02098057|Drug|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
79255021|NCT02408068|Drug|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
79255022|NCT02408068|Drug|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
79255023|NCT02408068|Drug|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
79255024|NCT02408068|Drug|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
79255025|NCT02465853|Drug|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
79255026|NCT02465853|Drug|Physiological saline solution|Injection 0.9% Physiological saline solution<1.0 ml
79255027|NCT02465853|Other|physical therapy and occupational therapy|rehabilitation
79394730|NCT02881086|Drug|VP16|
79394731|NCT02881086|Drug|Daunorubicin (DNR)|
79394732|NCT02881086|Drug|Methotrexate|
79394733|NCT02881086|Procedure|Stem cell transplantation|
79394734|NCT02881086|Drug|Cytarabine|
79394735|NCT02881086|Drug|Vindesine|
79394736|NCT02881086|Drug|Adriamycin|
79394737|NCT02881086|Drug|Prednisolone|
79394738|NCT02362854|Procedure|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
79394739|NCT02362854|Device|DL application in peri-implantitis|Diode laser application in the diseased implants.
79394740|NCT02362932|Other|Sanitation|Shared sanitation
79852116|NCT04034108|Procedure|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
79875302|NCT00387465|Drug|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
80017569|NCT02107950|Drug|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
79255028|NCT03098108|Radiation|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
79255029|NCT02103283|Drug|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
79255030|NCT05050838|Other|Transcranial Doppler (TCD)|"TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow).~Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s)."
79255031|NCT02100241|Procedure|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
80017570|NCT03655275|Biological|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
79255032|NCT02465385|Drug|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
79255033|NCT05050604|Drug|Choline Alfoscerate 400mg|Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
79551035|NCT05334680|Device|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
79255034|NCT05050604|Drug|Placebo of Choline Alfoscerate 400mg|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
79255035|NCT03290625|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
79255036|NCT03290625|Drug|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
79255037|NCT02250781|Drug|Oral ONC201|Given PO
79255038|NCT03099122|Biological|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
79255039|NCT03099122|Drug|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
79255040|NCT03099122|Drug|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
79255041|NCT03099122|Drug|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
79551036|NCT05325112|Diagnostic Test|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
79551037|NCT05323097|Other|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
79255042|NCT03099122|Drug|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
79714898|NCT05359263|Drug|Dapagliflozin 10 mg|The intervention arm consists of dapagliflozin 10 mg orally once daily
79714899|NCT05359263|Drug|Placebo|The comparator arm consists of placebo orally once daily
79714900|NCT01305941|Drug|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
79714901|NCT01305941|Drug|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
79875303|NCT00387465|Drug|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
79875304|NCT00945971|Other|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
79875305|NCT01042665|Drug|latanoprost 0.005%|Active comparator
79255043|NCT03099122|Drug|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
79255044|NCT03099044|Other|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
79255045|NCT03099044|Other|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
79255046|NCT03099044|Other|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
79255047|NCT04335201|Drug|Defibrotide Injection|Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
79255048|NCT02098135|Device|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
79714902|NCT01305941|Drug|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
79714903|NCT05658549|Drug|N-acetyl cysteine|N-acetyl cysteine dosage 600 mg and 1200 mg
79714904|NCT02887365|Drug|tegafur-uracil|
79875306|NCT01042665|Drug|Placebo|Placebo comparator
79875307|NCT00949949|Drug|everolimus|Given PO
79875308|NCT00949949|Drug|gemcitabine hydrochloride|Given IV
79875309|NCT00949949|Drug|cisplatin|Given IV
79852117|NCT00728117|Other|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
79852118|NCT00728117|Other|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
79852119|NCT00909584|Drug|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
79852120|NCT00927134|Genetic|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
79551038|NCT05322590|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
79852121|NCT02570243|Drug|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
79394741|NCT02362386|Device|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
79551039|NCT05322590|Other|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
79551040|NCT05314023|Biological|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
79551041|NCT05308797|Procedure|ESP block|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
79551042|NCT05308797|Procedure|CASP block|Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
79714905|NCT05658315|Other|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
79714906|NCT05658159|Diagnostic Test|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
79714907|NCT05658159|Diagnostic Test|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
79714908|NCT05658159|Other|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
79714909|NCT01305239|Drug|Aromasin|Aromasin 25 mg daily.
79714910|NCT04317027|Device|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
79714911|NCT05380557|Diagnostic Test|Germline genetic testing|Germline genetic testing will be provided to each patient
79714912|NCT05658081|Procedure|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
79714913|NCT05658081|Procedure|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
79852122|NCT02570243|Drug|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
79852123|NCT00927212|Drug|AS101 ointment|Twice daily topical application
79852124|NCT00730379|Drug|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
79852125|NCT00730457|Biological|VAX125|Single intramuscular dose
79852126|NCT00927290|Drug|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
79852127|NCT00927290|Drug|Placebo|Placebo 45 mg QD (30 mg QD the first month)
79394742|NCT02362542|Device|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
79394743|NCT01493687|Drug|CD5024|CD5024 1% Cream, once daily
79394744|NCT01493687|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
79394745|NCT02362308|Other|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
79394746|NCT02362308|Drug|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
79714914|NCT05657847|Device|Photon-counting detector-CT|CT scan
79714915|NCT04317183|Drug|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
79714916|NCT04317183|Drug|Miconazole Topical Gel|topical anti fungal agent
79852128|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
79852129|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
79852130|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
79852131|NCT00728195|Drug|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
79852132|NCT00728195|Drug|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
80017571|NCT03655275|Biological|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
80017572|NCT02108106|Drug|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
80017573|NCT02108106|Drug|Placebo|
79551043|NCT05305638|Other|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
79852133|NCT00927446|Procedure|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
79551044|NCT05303545|Other|standard of care for patients with poliomyelitis sequelae|clinical examination, radiological, biological and physiological examinations.
79551045|NCT05282992|Dietary Supplement|Native type II collagen|1 capsule/day
79852134|NCT00927524|Drug|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
79255049|NCT05050370|Behavioral|Brief messaging and personalized support|Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.
79551046|NCT05282992|Dietary Supplement|Placebo|1 capsule/day
79551047|NCT05251376|Drug|Levomethadone HCl|One dose given orally on Day 8 of the study.
79551048|NCT05251376|Drug|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
79714917|NCT04317183|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
79714918|NCT04317183|Drug|Oracure gel|Topical analgesic gel
79714919|NCT01194219|Drug|Apremilast|
79852135|NCT00927524|Drug|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
79852136|NCT00728273|Dietary Supplement|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
79394747|NCT02373618|Other|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
79394748|NCT02373618|Other|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
79551049|NCT05251376|Drug|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
79852137|NCT00927602|Drug|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
79852138|NCT04286867|Other|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
79394749|NCT02366208|Drug|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
79551050|NCT05251376|Diagnostic Test|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
79551051|NCT05251376|Diagnostic Test|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
79551052|NCT05248555|Diagnostic Test|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
79551053|NCT05219097|Diagnostic Test|CBA Assay|Comparsion of specificity, sensitivity and clinical correlation of CBA, ELISA and RIPA assay in autoantibodies detection of myasthenia gravis
79714920|NCT01194219|Drug|Placebo|Identical matching placebo
79714921|NCT01194219|Drug|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
79714922|NCT01304693|Biological|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
80017574|NCT03655041|Dietary Supplement|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
80017575|NCT03655041|Dietary Supplement|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
79255050|NCT03555175|Other|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
79255051|NCT03555175|Other|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
79255052|NCT03555175|Other|Control group|Any exercise
79255053|NCT03099200|Other|No Intervention|
79255054|NCT03295851|Drug|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
79394750|NCT02366208|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
79394751|NCT02366208|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
79714923|NCT01304693|Biological|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
79852139|NCT04286867|Behavioral|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
79852140|NCT00909662|Procedure|assessment of therapy complications|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
79852141|NCT00909662|Procedure|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
79852142|NCT00909662|Procedure|fatigue assessment and management|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
79852143|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
79852144|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
79551054|NCT05196906|Procedure|Modified Broström operation and anatomic reconstruction operation|Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
79551055|NCT05164354|Other|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
79852145|NCT00730535|Drug|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
80017576|NCT02108184|Drug|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
80017577|NCT02108184|Drug|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
79551056|NCT05164354|Other|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
80017578|NCT02108184|Drug|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
79255055|NCT03295851|Drug|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
80017579|NCT02108184|Drug|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
79551057|NCT05163613|Other|magnetostimulation|Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
79551058|NCT05163613|Other|standard therapy|Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
79714924|NCT04316793|Other|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
79714925|NCT04316793|Other|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
79714926|NCT05657067|Behavioral|Emotionally Focused Family Therapy (EFFT)|The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
79714927|NCT05656989|Other|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
79714928|NCT01304147|Drug|Ketamine|A single dose of intranasal ketamine up to 50 mg
79852146|NCT00909818|Radiation|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
79852147|NCT00909818|Radiation|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
79852148|NCT03743558|Behavioral|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
79852149|NCT00728429|Behavioral|exercise intervention|24 week program of exercise
79852150|NCT04066595|Drug|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
80017580|NCT03654963|Procedure|Medication reconciliation|Medication reconciliation is the systematic process described above.
79255056|NCT02098213|Other|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
79714929|NCT01304147|Drug|placebo|Single dose of saline intranasal
79714930|NCT05661227|Drug|Dexmedetomidine|Whether apply DEX or not
79714931|NCT05661227|Drug|0.9% Sodium chloride|Whether apply DEX or not
79714932|NCT05661227|Device|Tourniquet(Early)|Timing of tourniquet application
79551059|NCT05147246|Behavioral|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
79551060|NCT05145036|Behavioral|Tai-Chi|Tai Chi exercise could improve muscle performance, balance and have the benefit for fall down prevention in the elders and patients with frailty.
79852151|NCT00927836|Biological|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
79852152|NCT00927836|Drug|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
79551061|NCT05145036|Behavioral|Comprehensive training|There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down.
79551062|NCT05127954|Drug|Ubrogepant|Oral Tablet
79551063|NCT05111964|Device|High Intensity Focused Ultrasound Ablation|"The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours."
79551064|NCT05111964|Diagnostic Test|Tumour Biopsy and Venous Blood Tests|"Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic."
79551065|NCT05082831|Biological|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
79551066|NCT05071820|Other|Health U mobile application|Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application
79551067|NCT05071820|Other|National Diabetes Prevention Program|CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
79551068|NCT05062265|Device|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
79551069|NCT05062265|Device|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
79551070|NCT05012904|Behavioral|parent involvement application|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
79551071|NCT05011565|Other|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
79551072|NCT04997395|Drug|MediCabilis Cannabis sativa 50|Already described
79852153|NCT02570321|Procedure|Bacterial ulcer cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
79852154|NCT02570321|Procedure|Bacterial ulcer control|For those bacterial ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for bacterial ulcers. This group will have their eyes irrigated with a balanced salt solution.
79551073|NCT04997161|Drug|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
79551074|NCT04997161|Other|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
79714933|NCT05661227|Device|Tourniquet(Late)|Timing of tourniquet application
79714934|NCT04325087|Device|iTBS|Administration of an iTBS protocol over the dlPFC
79714935|NCT04325087|Device|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
79875310|NCT00941369|Drug|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
79875311|NCT01042743|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
79551075|NCT04997161|Other|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
80017581|NCT02113800|Drug|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
80017582|NCT03622203|Device|Biofreedom|Use of Biofreedom in real life patients
79551076|NCT04969250|Biological|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
79551077|NCT04969250|Biological|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
79551078|NCT04956016|Device|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
79852155|NCT02570321|Procedure|Fungal ulcer cross-linking|"Prior to receiving cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis."
79852156|NCT02570321|Procedure|Fungal ulcer control|"Prior to receiving sham cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those fungal ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for fungal ulcers. This group will have their eyes irrigated with a balanced salt solution."
79852157|NCT00904280|Drug|Oxymorphone ER|Open label
79852158|NCT04015310|Device|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
79852159|NCT00924092|Biological|GI-6207 [Recombinant Saccharomyces Cerevisia|
79852160|NCT00924092|Drug|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
79852161|NCT00904358|Diagnostic Test|cross sectional area|
79852162|NCT00730613|Biological|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
79852163|NCT00730613|Genetic|gene expression analysis|At the time of excess pathology samples documenting response/relapse
80017583|NCT02108340|Procedure|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
80017584|NCT05405062|Device|Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision|Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
80017585|NCT01066143|Drug|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
80017586|NCT02108418|Drug|TG-2349 as the original formulation|single oral dose under fed condition
79255057|NCT02098213|Other|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
79255058|NCT03096470|Procedure|anesthesia|no anesthesia
79255059|NCT04484649|Behavioral|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
79255060|NCT04484649|Behavioral|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
79551079|NCT04956016|Device|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
79551080|NCT04938609|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
79551081|NCT04938609|Radiation|Stereotactic Body Radiation Therapy (5 days)|8Gy x 3 (Mon-Fri) GTV+3mm
79551082|NCT04938609|Procedure|Surgical Resection|Surgical Resection of Tumor
79852164|NCT00730613|Other|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
79852165|NCT00928148|Drug|SPD465|50 or 75 mg once daily for 7 days
79852166|NCT00928148|Drug|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
79551083|NCT04935411|Other|nAMD|patients diagnosed with Neovascular Age-Related Macular Degeneration
79551084|NCT04934007|Device|rTMS Treatment|1 Hz rTMS
79551085|NCT04917419|Other|Luminotherapy and /or Psychoeducation Program|TO complete
79852167|NCT00928148|Drug|Placebo|Once daily for 7 days
79852168|NCT02430077|Drug|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
80017587|NCT02108418|Drug|TG-2349 as a new capsule formulation|single oral dose under fed condition
79551086|NCT04898062|Device|CRP-apheresis|The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
79551087|NCT04891354|Drug|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
79551088|NCT04891354|Drug|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
80017588|NCT05404984|Other|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
79255061|NCT02103517|Dietary Supplement|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
79255062|NCT02103517|Dietary Supplement|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
79551089|NCT04885491|Drug|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
79551090|NCT04885491|Drug|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
79551091|NCT04873557|Other|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
79551092|NCT04866511|Other|Narrative Exposure Therapy|"NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic."
79551093|NCT04830995|Dietary Supplement|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
79551094|NCT04812457|Drug|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
79551095|NCT04812457|Drug|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
79714936|NCT05643989|Procedure|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
79852169|NCT02430077|Drug|Placebo|Identical to Obeticholic Acid - placebo drug
80017589|NCT05404984|Other|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
79255063|NCT04489875|Behavioral|Chewing Gum|The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
79255064|NCT02098291|Drug|G17DT|
79255065|NCT05042570|Other|Instrument Assisted Soft Tissue Mobilization|"This technique will be performed using instruments of different sizes, shapes and treatment styles.~During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~The instrument will be sterilized before treatment.~IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument."
79394752|NCT00350337|Biological|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
79394753|NCT00350337|Biological|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
79394754|NCT00350337|Biological|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
79714937|NCT05643989|Procedure|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
79551096|NCT04789616|Drug|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
79714938|NCT01303445|Drug|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
79714939|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
79714940|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
79714941|NCT01303445|Drug|Omeprazole alone|omeprazole 80 once daily for 7 days
79551097|NCT04789616|Behavioral|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for PT & OT) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
79394755|NCT00350337|Other|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
79551098|NCT04789616|Other|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
79714942|NCT01188681|Drug|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
79714943|NCT01188681|Drug|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
79714944|NCT01188681|Drug|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
79714945|NCT01188681|Drug|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
79714946|NCT02887131|Other|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
79714947|NCT01302899|Drug|Aliskiren|Aliskiren 150 mg (Tablet)
79714948|NCT01302899|Drug|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
79714949|NCT01302899|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
79852170|NCT00904436|Drug|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
79852171|NCT00728585|Drug|Palifermin|Given IV
79852172|NCT00728585|Other|Placebo|Given IV
79852173|NCT02422433|Device|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
79852174|NCT00730769|Drug|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
79255066|NCT05042570|Other|Stretching Exercises|"The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~3 different functional stretching exercises will be applied;~With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist."
79394756|NCT02366052|Behavioral|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
79394757|NCT02366052|Dietary Supplement|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
79394758|NCT02366052|Other|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
79394759|NCT02365896|Procedure|TLDG or LADG|
79714950|NCT01302899|Drug|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
79714951|NCT01302899|Drug|Ramipril|Ramipril 10mg (Tablet)
79714952|NCT04324775|Other|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
79714953|NCT04324775|Other|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
79714954|NCT05643833|Other|no intervention|no intervention
79714955|NCT01187901|Drug|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
79714956|NCT01187901|Drug|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
79852175|NCT04200287|Behavioral|Online decision aid tool|The decision aid intervention will be presented via a website
79875312|NCT01042743|Procedure|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
79551099|NCT04789616|Device|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
79714957|NCT01187901|Drug|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
79714958|NCT01187901|Drug|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
79714959|NCT01302119|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
79714960|NCT01302119|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
79714961|NCT05931900|Device|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
79714962|NCT05927922|Drug|Oral Ibuprofen (Abbott, Egypt)|ibuprofen is analegisic drug used to relieve pain
79714963|NCT05927883|Behavioral|Indigenously Adapted Cognitive Behavioral Therapy|IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
79852176|NCT00728663|Biological|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
79852177|NCT00728663|Drug|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
79714964|NCT05927857|Drug|nal-IRI /Experimental|infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
79714965|NCT05927857|Drug|Ramucirumab /Experimental|infusional 8mg/kg over 60 minutes day 1, every 14 days.
79714966|NCT05927857|Drug|Trifluridine/Tipiracil /Experimental|oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
79714967|NCT05927844|Drug|XH-30002 capsule|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
79714968|NCT05927844|Drug|Afatiinb tablet|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
79852178|NCT00728897|Drug|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
79852179|NCT00728897|Drug|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
80017590|NCT03654339|Procedure|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
80017591|NCT02251470|Other|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
80017592|NCT02251470|Other|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
79394760|NCT02373462|Drug|Olmesartan|
79551100|NCT04789616|Behavioral|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 24 hours of the initial assessment (initial test and 24-hour retention test).
79852180|NCT04124705|Drug|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
79394761|NCT02373462|Drug|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
79394762|NCT01523587|Drug|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
79394763|NCT01523587|Drug|erlotinib|erlotinib taken once daily
79394764|NCT00310401|Drug|Albuterol|5 mg nebulized q4h
79394765|NCT00310401|Drug|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
79394766|NCT02373228|Other|Audio signal processing (applied offline before playback)|
79551101|NCT04785300|Drug|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
79551102|NCT04785300|Drug|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
79551103|NCT04765280|Diagnostic Test|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
79714969|NCT05927831|Drug|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
79714970|NCT05927831|Device|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
79714971|NCT05927818|Diagnostic Test|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
79852181|NCT04124705|Drug|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
79852182|NCT00731003|Drug|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
80017593|NCT05404828|Other|Polysomnography|Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
80017594|NCT05404828|Other|Questionnaires|STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
79714972|NCT05927805|Other|E-bibliotherapy|Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.
79714973|NCT05927805|Other|Control|The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
79714974|NCT05927779|Drug|TFX06 tablet|TFX06 tablet taken orally
79714975|NCT05927766|Device|esophagogastroduodenoscopy|patients with upper gastrointestinal symptoms will gone to upper endoscopy and biopsy when indicated
79714976|NCT05927740|Diagnostic Test|Optic coherence tomography|Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
79714977|NCT05927727|Diagnostic Test|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
79714978|NCT05927675|Behavioral|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
79714979|NCT05927662|Procedure|lumbar discectomy|mini-open discectomy
79255067|NCT05042570|Other|Control Group / NDT program|"Efforts to eliminate tone disorders,~Sensory-perception-motor integrity development studies,~Activities aimed at facilitating movements in daily life,~Stretching and strengthening exercises due to muscle shortness and weakness,~Studies to increase lower and upper extremity functionality,~It will include the training of activities such as standing up, walking and balance."
79852183|NCT00731003|Other|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
79255068|NCT02098447|Device|PrimeStim|
79551104|NCT04765280|Other|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
79551105|NCT04765280|Other|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability in patients with low back pain. The score of the scale is between 0-90. It is accepted that the higher the score, the higher the disability.
79255069|NCT02103595|Device|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
79255070|NCT02103595|Device|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
79551106|NCT04765280|Other|Disabilities of the Arm, Shoulder and Hand (DASH)|Standardized questionnaire to investigate the disability in patients with upper extremity musculoskeletal disorders. The score of the scale is between 0-100 It is accepted that the higher the score, the higher the disability.
79551107|NCT04765280|Other|Neck Pain and Disability scale|Standardized questionnaire to investigate the disability in patients with neck pain. The score of the scale is between 0-100. It is accepted that the higher the score, the higher the disability.
79551108|NCT04765280|Other|Knee Injury and Osteoarthritis Outcome Score|Standardized questionnaire to investigate the disability in patients with knee pain. The score of the scale is between 0-100It is accepted that the higher the score, the higher the disability.
79551109|NCT04765280|Other|Western Ontario and McMaster Universities Arthritis Index|Standardized questionnaire to investigate the disability in patients with hip osteoarthritis. The score of the scale is between 0-240. It is accepted that the higher the score, the higher the disability.
79255071|NCT05064566|Device|caries assessment|clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
79255072|NCT05392465|Other|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
79394767|NCT02365974|Device|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
79394768|NCT02365974|Device|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
79394769|NCT00310791|Drug|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
79394770|NCT00310791|Other|Placebo (Sugar Pill)|Placebo (sugar pill)
79551110|NCT04765280|Other|Visual analogue scale|global pain score on a 0 to 10
79551111|NCT04753216|Biological|Bevacizumab|Given IV
79394771|NCT00310791|Drug|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
79551112|NCT04753216|Drug|Irinotecan Sucrosofate|Given IV
79852184|NCT00731003|Other|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
80017595|NCT05404828|Other|Blood and urine sample|Na, K, Creat, Osm, Urea
80017596|NCT03654495|Other|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (~1 min) for game change."
79714980|NCT05927623|Behavioral|Multifaceted Virtual Fracture Prevention Program|"Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Physiotec app (physiotec.com) and monthly virtual exercise consultations.~Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
79714981|NCT05927623|Behavioral|Attention Control|"Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
80017597|NCT03654495|Other|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
80017598|NCT02108574|Device|Placebo Filter|
79394772|NCT02362152|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
79551113|NCT04714619|Drug|CB-103|"Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first."
79714982|NCT05927597|Drug|INS1007|Oral tablets.
79714983|NCT05927597|Drug|Placebo|Oral tablets.
79714984|NCT05927545|Procedure|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
79394773|NCT02362152|Drug|5-fluorouracil|Topical field treatment as prescribed by dermatologist
79394774|NCT02362152|Drug|Imiquimod|Topical field treatment as prescribed by dermatologist
79551114|NCT04689945|Drug|Morphine|"PREOPERATIVE ANALGESIA: None~INTRAOPERATİVE ANALGESIA:~Paracetamol 1000 mg IV~Morphine 0,1 mg/kg IV~POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol"
79394775|NCT02362152|Drug|Diclofenac|Topical field treatment as prescribed by dermatologist
79714985|NCT05927545|Procedure|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
79714986|NCT05927545|Procedure|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
79714987|NCT05927506|Behavioral|Other|Observational study of behavior cognitive and motor control
79714988|NCT05927480|Behavioral|Audio distraction|Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
79714989|NCT05927428|Drug|BRM424 Ophthalmic Solution|A topical drop of BRM424 ophthalmic solution.
79394776|NCT01493531|Drug|Lesinurad|Tablets, 200 mg QD
79394777|NCT01493531|Drug|Lesinurad|Tablets, 400 mg QD
79394778|NCT01493531|Drug|Placebo|Tablets, Placebo QD
79394779|NCT01493531|Drug|Allopurinol|Tablets
79394780|NCT02105415|Drug|Ketamine / Propofol Admixture|
79394781|NCT02105415|Drug|Etomidate|
79714990|NCT05927428|Drug|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
79852185|NCT00731003|Drug|Placebo capsule|Placebo for 5-HTP
79852186|NCT00729131|Drug|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
79852187|NCT02569385|Other|Spontaneous breathing trial|
79852188|NCT00731159|Biological|sperm capacitation|sperm capacitation measured at Bar Ilan University
79394782|NCT01523275|Drug|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
79852189|NCT00731159|Other|biologic|sperm synthesis of G-actine to F-actine
79852190|NCT00731159|Other|sperm capacitation|sperm synthesis of G-actine to F-actine
80017599|NCT02108574|Device|Rhinix Nasal Filter|
80017600|NCT03654183|Diagnostic Test|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
79714991|NCT05927389|Other|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
79714992|NCT05927350|Other|Survey|Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
79714993|NCT05927337|Behavioral|Cognitive Behavioral Therapy (CBT) for managing Obesity|Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
79714994|NCT05927298|Other|Non-interventional|Standard of care intervention
79714995|NCT05927259|Drug|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
79714996|NCT05927259|Drug|standard treatment|stabilization and antidotes
79714997|NCT05927246|Diagnostic Test|ECG|12 lead ecg for each participant
79714998|NCT05927220|Diagnostic Test|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
79714999|NCT05927194|Behavioral|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
79715000|NCT05927181|Procedure|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
79715001|NCT05927168|Device|TENS|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
79852191|NCT04095611|Procedure|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
79852192|NCT04095611|Procedure|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
79852193|NCT00729209|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
79551115|NCT04689945|Procedure|Erector Spinae Block|"PREOPERATIVE ANALGESIA:~Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection~INTRAOPERATİVE ANALGESIA:~Paracetamol 1000 mg IV~dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
79551116|NCT04689945|Drug|Control|"PREOPERATIVE ANALGESIA: none~INTRAOPERATİVE ANALGESIA:~Paracetamol 1000 mg IV~Dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
79852194|NCT00729209|Drug|Placebo; oral|matching placebo
80017601|NCT02111928|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
80017602|NCT02112006|Procedure|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
79551117|NCT04643366|Drug|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
79551118|NCT04643366|Radiation|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
79715002|NCT05927155|Drug|LABA|Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
79715003|NCT05927155|Drug|LAMA|Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
79715004|NCT05927129|Drug|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
79715005|NCT05927129|Other|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
79715006|NCT05927129|Other|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
79715007|NCT05927077|Procedure|planned surgery for weight reduction|planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
79852195|NCT04026347|Device|Vesair Balloon|Indwelling, intravesical balloon
79852196|NCT04026347|Other|Sham balloon placement|Sham balloon placement procedure
79852197|NCT00731315|Other|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
79852198|NCT00731315|Other|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
79852199|NCT00729287|Dietary Supplement|selenium|Given orally
79852200|NCT00729287|Other|placebo|Given orally
79551119|NCT04642625|Other|Visual Analog Score|"The VAS is a widely used tool in research and clinical practice, and its reliability and validity in pain assessment has been clearly demonstrated. It consists of a 100 mm line. 0 cm no pain, 10 cm is associated with 'worst possible pain'. The patient is asked to mark the line to 'score' the pain. VAS values of 1cm - 3cm weak, 4cm - 6cm moderate, and >7cm are the indicators of severe pain."
79551120|NCT04642625|Other|patient satisfaction|The patient's satisfaction with postoperative pain treatment will be recorded. 4 options; excellent, good, medium and bad.
79551121|NCT04600154|Drug|MS-20|Specific fraction from fermented soy milk
79551122|NCT04600154|Other|Placebo|Fermented soy milk without active component
79551123|NCT04584827|Other|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
79551124|NCT04584827|Other|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
79715008|NCT05927051|Other|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
79715009|NCT05927051|Other|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
79715010|NCT05927051|Other|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks
79852201|NCT02570087|Procedure|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
79852202|NCT02569697|Other|HEC Placebo gel|
79852203|NCT02569697|Other|Placebo Intravaginal Ring|
79852204|NCT02569697|Other|Placebo Vaginal Film|
79852205|NCT02569697|Other|Placebo Vaginal Insert|
79852206|NCT03095417|Behavioral|Physical Exercise Intervention|In home exercise intervention.
79852207|NCT03095417|Behavioral|Cognitive Training Intervention|Online cognitive training modules.
79852208|NCT03095417|Behavioral|Stretching Control|In home stretching.
79852209|NCT03095417|Behavioral|Cognitive Control|Online control puzzles and games.
79852210|NCT00731393|Biological|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
79852211|NCT00731393|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
79715011|NCT05927038|Other|Caffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
79715012|NCT05927038|Other|Decaffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
79852212|NCT00731471|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
79852213|NCT04390217|Drug|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
79852214|NCT04390217|Drug|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
79715013|NCT05927025|Procedure|Hand K-files|It is used for cleaning and shaping root canals.
79715014|NCT05926986|Other|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
79715015|NCT05926986|Other|control|No additional treatment will be practiced to the control group.
79715016|NCT05926973|Other|Enhanced cardiac arrest bundle|"Delivering shocks with the LUCAS mechanical CPR device running~After 5 shocks have been delivered placing new pads in the Anterior Posterior (AP) position~Delivering shocks using the TVAA Tempus Pro defibrillator rather than the Ambulance Service defibrillator."
79715017|NCT05926934|Device|Experimental: Single strand β-Ti fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
79852215|NCT02569463|Drug|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
79852216|NCT00729443|Drug|AZD3241|single oral dose
79852217|NCT00729443|Drug|Placebo|
79852218|NCT00731627|Drug|placebo|one tablet a day for up to 21 days
79852219|NCT00731627|Drug|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
79852220|NCT00731705|Procedure|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
79852221|NCT03050489|Procedure|On-Pump CABG.|Standard On-Pump CABG.
79852222|NCT03050489|Procedure|Off-Pump CABG.|Standard Off-Pump CABG.
79852223|NCT03050489|Procedure|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
79875313|NCT00941447|Behavioral|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
79875314|NCT00941447|Behavioral|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
79852224|NCT00568178|Drug|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed <50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
79551125|NCT04582045|Device|silver impregnated dressing|comparison of Mepilex versus our standard techniques
79551126|NCT04563494|Drug|dexamethasone|Prevention of post op nausea and vomiting
79715018|NCT05926934|Device|Experimental: SS fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
79715019|NCT05926934|Device|Experimental: Twisted fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
79715020|NCT05926908|Behavioral|A Mobilisation Initiative|The Mobilisation Initiative consists of physiotherapists assisting nursing staff in mobilising patients to sit in a chair for breakfast and lunch. This intervention follows the interventions of focus group interviews, formal education, observations of patients and the environment, and awareness of mobilisation survey
79852225|NCT00568178|Other|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
79852226|NCT00568178|Drug|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
79852227|NCT00568178|Other|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
79852228|NCT00568178|Other|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
79852229|NCT00568178|Drug|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
79852230|NCT00924248|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
80017603|NCT02112006|Procedure|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
79255073|NCT05392465|Other|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
79255074|NCT05049668|Drug|ATGAM plus CsA with or without Eltrombopag|Standard treatment with or without Eltrombopag
79255075|NCT04445103|Diagnostic Test|Assessment of cardiac function|Echocardiographic examination and assessment of cardiac biomakers
79255076|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
79255077|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
79394783|NCT01523275|Other|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
79394784|NCT00304707|Drug|Bupropion|300 mg QD
79255078|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
79255079|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
79394785|NCT00304707|Drug|placebo|placebo
79394786|NCT02038686|Device|PFN-A|
79394787|NCT04409483|Drug|Lopinavir-Ritonavir Drug Combination|400mg/100mg taken orally twice daily for 14 days.
79394788|NCT04409483|Combination Product|Standard Care|Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
79394789|NCT02362230|Drug|Icotinib|Icotinib 125 mg BID
79394790|NCT02365740|Other|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
79394791|NCT02365740|Other|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
79394792|NCT02365740|Other|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
79394793|NCT02365740|Drug|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
79394794|NCT02365740|Drug|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
79551127|NCT04542343|Behavioral|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
80017604|NCT02521324|Device|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
79852231|NCT00904514|Genetic|gene expression analysis|
79551131|NCT04539795|Drug|Alvelestat|oral tablet
79551132|NCT04539795|Drug|Placebo|oral tablet
79551133|NCT04530747|Drug|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
79551134|NCT04530747|Drug|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
79852232|NCT00904514|Genetic|microarray analysis|
79852233|NCT00904514|Genetic|mutation analysis|
79852234|NCT00904514|Genetic|polymerase chain reaction|
79852235|NCT00904514|Other|flow cytometry|
79852236|NCT00904514|Other|immunoenzyme technique|
79852237|NCT00904514|Other|laboratory biomarker analysis|
79852238|NCT00928460|Procedure|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
79852239|NCT00577889|Drug|gemcitabine hydrochloride|750 mg/m2 Given IV
79852240|NCT00577889|Drug|tanespimycin|154 mg/m2 Given IV
79852241|NCT00928538|Other|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
79852242|NCT00928616|Dietary Supplement|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
79255080|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
79255081|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
79394795|NCT01492439|Behavioral|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
79715021|NCT05926908|Behavioral|Focus Group Interviews|Focus group interviews using a semi-structured interview guide are conducted with health care professionals at the wards to explore the acceptability and demand for the contents of the Mobilisation Initiative, including the identification of facilitators and barriers to mobilisation
79715022|NCT05926908|Behavioral|Formal Education|Formal education for all nursing staff employed at the two wards includes information on the consequences of immobilisation, with the purpose of enhancing confidence, competencies, and awareness of mobilisation
79715023|NCT05926908|Behavioral|Self-reported Level of Mobilisation|Patient's self-reported mealtime mobilisation level reported through interview-based surveys, including structured follow-up questions
79715024|NCT05926908|Behavioral|Observations of Patients and the Environment|During breakfast and lunch, the mobilisation status of all patients in the wards is observed using an observation checklist
79852243|NCT00928616|Dietary Supplement|margarine (placebo)|non-sterol ester supplemented margarine
79852244|NCT00460564|Drug|GSK1358820|botulinum toxin type A
79852245|NCT00460564|Drug|Placebo|Placebo
79852246|NCT00729599|Drug|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
79852247|NCT04015076|Drug|Inzomelid|Active Drug
79852248|NCT04015076|Drug|Placebo|Placebo to Match
79852249|NCT03743480|Other|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
79852250|NCT02538926|Drug|Asparaginase|Given IM or IV
79852251|NCT02538926|Drug|Cyclophosphamide|Given IV
79852252|NCT02538926|Drug|Doxorubicin Hydrochloride|Given IV
79852253|NCT02538926|Drug|Etoposide|Given IV
79852254|NCT02538926|Drug|Imatinib Mesylate|Given PO
79852255|NCT02538926|Other|Laboratory Biomarker Analysis|Correlative studies
79852256|NCT02538926|Drug|Prednisone|Given PO
79852257|NCT02538926|Biological|Rituximab|Given IV
79852258|NCT02538926|Drug|Vincristine Sulfate|Given IV
79852259|NCT01323400|Drug|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
79852260|NCT01323400|Other|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
79852261|NCT00904592|Drug|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
79852262|NCT00904592|Drug|Placebo Comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
79875315|NCT00941447|Behavioral|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
79875316|NCT00946049|Device|Vicryl Plus|
79875317|NCT00946049|Device|Vicryl|
79255082|NCT03290469|Other|clinical whole genome sequencing (cWGS)|Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
79255083|NCT04444245|Procedure|lipoaspiration harvest tSVF|Use of disposable, sterile microcannula lipoharvest to acquire tSVF
79551135|NCT04483440|Biological|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
79394796|NCT01492439|Behavioral|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
79551136|NCT04456296|Drug|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
79551137|NCT04456296|Drug|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
79715025|NCT05926908|Behavioral|Awareness of Mobilisation Survey|To assess the nursing staff's awareness of and confidence in the mobilisation of the patients, a short survey on mobilisation awareness is distributed to the nursing staff at both wards
79715026|NCT05926895|Drug|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
79715027|NCT05926882|Drug|Apremilast 30mg|Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
79715028|NCT05926869|Drug|Clindamycin and Dapsone gel for 03 months|Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
79852263|NCT00928850|Procedure|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
79852264|NCT00928850|Procedure|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
79852265|NCT00928850|Procedure|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
79852266|NCT00928850|Procedure|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
79551138|NCT04456296|Drug|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
79852267|NCT03745313|Device|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
79852268|NCT00904904|Drug|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
79852269|NCT00904904|Drug|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
79852270|NCT00731861|Drug|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
79852271|NCT00928928|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
79551139|NCT04429165|Other|collection of Patient Reported Outcome (PRO) data|collection of Patient Reported Outcome (PRO) data by questionnaires
79551140|NCT04429165|Other|collection of anthropometric and clinical functional data|collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
79551141|NCT04429165|Other|gait analysis|gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
79551142|NCT04412837|Drug|Topical CBD Patch|35 mg CBD patch
79551143|NCT04412837|Other|Placebo Patch|Identical patch without active ingredient.
79551144|NCT04403321|Drug|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
79551145|NCT04403321|Drug|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
79551146|NCT04300400|Other|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
79551147|NCT04265755|Drug|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
79852272|NCT00928928|Procedure|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
79551148|NCT04260984|Procedure|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
79852273|NCT00729755|Dietary Supplement|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
79852274|NCT00729755|Dietary Supplement|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
80017605|NCT02980107|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
80017606|NCT02980107|Other|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
80017607|NCT02108730|Procedure|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
80017608|NCT02114112|Other|NCPAP cycling|
80017609|NCT02114112|Other|NCPAP continuous|
80017610|NCT02251158|Drug|Tipranavir oral solution|
80017611|NCT02251158|Drug|Tipranavir capsules|
79255084|NCT04444245|Procedure|Platelet Rich Plasma|Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)
79255085|NCT04444245|Procedure|Endovaginal Ultrasound|Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally
79551149|NCT04260984|Procedure|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
79715029|NCT05926843|Procedure|Spinal cord stimulation surgery (device) and motor rehabilitation|The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
79852275|NCT03903263|Diagnostic Test|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
79852276|NCT00567476|Drug|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
79852277|NCT00567476|Drug|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
79852278|NCT00567476|Drug|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
79852279|NCT00567476|Drug|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
79852280|NCT04065737|Drug|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
79852281|NCT00516321|Drug|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
79852282|NCT00516321|Drug|placebo|matched placebo taken once daily orally
79852283|NCT00729911|Procedure|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
79852284|NCT00729911|Drug|Amiodarone|Taken orally on a daily basis.
79852285|NCT04018703|Drug|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
79852286|NCT04018703|Drug|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
79852287|NCT04629872|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
79852288|NCT04065581|Drug|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
79852289|NCT04065581|Drug|Glucobay|Single dose: 50 mg tablet, oral
79852290|NCT04065581|Drug|Glucophage|Single dose: 500 mg tablet, oral
79852291|NCT00929084|Other|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
80017612|NCT02251158|Drug|Ritonavir oral solution|
80017613|NCT02251158|Drug|Ritonavir soft gel capsules|
79255086|NCT04444245|Device|Cellular Isolation cSVF|Digestion of tSVF with Liberase, isolation & concentration of cSVF in Centricyte 1000
80017614|NCT02251158|Other|High fat breakfast|
80017615|NCT02652130|Biological|Remestemcel-L|No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
80017616|NCT03553914|Drug|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
79715030|NCT05926791|Other|Cosmetic product|The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2
79715031|NCT05926778|Other|Liver allograft fibrosis|Observational studies without intervention
79715032|NCT05926752|Device|SoLá therapy|SoLá therapy is a photobiomodulation device that works by stimulating mitochondria, soothing tense muscles, and promotes healing.
79715033|NCT05926752|Other|Pelvic floor physical therapy|Physical therapy is manual myofascial release, muscles stretches, and exercises designed to help myofascial pelvic pain
79715034|NCT05926739|Device|Electrical stimulation and biofeedback group|12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.
79551150|NCT04246320|Other|Goal directed therapy (GDT)|Goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
79715035|NCT05926726|Biological|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
79715036|NCT05926713|Dietary Supplement|Sarcojoint®|All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.
79715037|NCT05926713|Behavioral|supervised exercise|All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
79715038|NCT05926700|Drug|Candonilimab|The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
79852292|NCT05585645|Biological|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
79852293|NCT04572854|Drug|Pegcetacoplan|Complement (C3) Inhibitor
79852294|NCT00732017|Device|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
79852295|NCT00732017|Device|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
80017617|NCT02114190|Behavioral|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
79255087|NCT04444245|Drug|Normal Saline (NS) .9% 10 mL Injection|10 cc Sterile Normal Saline for Injection
79255088|NCT04444245|Device|emulsification tSVF|Harvested tSVF emulsification with sterile, disposable Nanofat screen device
79255089|NCT01361126|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
79255090|NCT02100709|Device|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
79394797|NCT02365662|Drug|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
79394798|NCT02365818|Biological|CG0070|
79551151|NCT04231981|Drug|INCMGA0012|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
79394799|NCT03113214|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
79551152|NCT04230512|Other|Pump prototype|Effects of pump function on gait
79551153|NCT04229771|Drug|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
79551154|NCT04229771|Drug|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
79551155|NCT04192409|Behavioral|Smartphone Application|Patients will use a smartphone application contain the following functions: providing health education information about DM and CAD, reminding patients to take medicine on time by alarm, recording patients' recent fast plasma glucose value.
79852296|NCT00732017|Other|standard physical therapy treatment|"Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
79852297|NCT00924794|Procedure|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
79394800|NCT03113214|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
79551156|NCT04169295|Other|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
79715039|NCT05926596|Device|Wearable Robotic Exoskeleton|"Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~Treadmilll and Overground Walking (60-90 minutes including rest periods)~Cool down (5-10 minutes)"
79551157|NCT04169295|Other|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
79852298|NCT00733889|Drug|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
79551158|NCT04167540|Biological|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
79551159|NCT04146441|Combination Product|SonoVue|1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
79394801|NCT03113214|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
79394802|NCT03113214|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
79551160|NCT04146441|Drug|Chemotherapy|FOLFIRINOX Regime according to Norwegian national guidelines
79551161|NCT04142788|Drug|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
79551162|NCT04124380|Behavioral|Imaginal Exposure|Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
79551163|NCT04124380|Behavioral|Alcohol Skills Training|Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
79551164|NCT04124380|Behavioral|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
79551165|NCT04123444|Drug|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
79551166|NCT04123444|Drug|Isotonic saline|Continuously infusion for 72 hours.
79551167|NCT04120025|Behavioral|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
79551168|NCT04072926|Drug|BioRoot|Influence of biomaterial BioRoot on periapical healing
79715040|NCT05926531|Device|CBTI online programe|20 MIN VR RELAX PROGRAME
79715041|NCT05926518|Procedure|blood sampling|Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
79255091|NCT03555097|Procedure|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
79255092|NCT04434872|Procedure|Colonoscopy|Fecal microbiota transplantation through colonoscopy
79255093|NCT04434872|Procedure|Gastroscopy|Fecal microbiota transplantation through gastroscopy
79715042|NCT05926492|Drug|Surufatinib plus chemotherapy|"Sururfatinib: (1) for patients aged > 21 years old and ≤70 years old, sorafenib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
79255094|NCT04434872|Drug|Fecal Microbiota|
79255095|NCT04434872|Procedure|Enema|Fecal microbiota transplantation through enema
79394803|NCT03113214|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
79394804|NCT03113214|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
79715043|NCT05926492|Drug|Chemotherapy|"1) High-dose Dethotrexate: 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
79852299|NCT03903731|Device|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
79551169|NCT04041375|Behavioral|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
79715044|NCT05926414|Drug|Enavogliflozin|treated with Envlo tab. 0.3mg
79715045|NCT05926375|Dietary Supplement|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100~200 kcal food at breakfast per day, for 8 weeks.
79852300|NCT01010685|Procedure|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
79852301|NCT05153655|Procedure|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
79715046|NCT05926271|Drug|Clopidogrel|See arm description earlier.
79715047|NCT05926245|Dietary Supplement|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
79715048|NCT05926245|Dietary Supplement|Placebo Solution|Empty nanoparticles
79715049|NCT05926206|Drug|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
79715050|NCT05926206|Drug|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
79715051|NCT05926154|Procedure|Surgical tourniquet pressure selection|Limb occlusion pressure is calculated using the formulation by Graham: LOP = [(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
79852302|NCT00929318|Procedure|blood sampling|
79852303|NCT00929318|Procedure|blood sampling|
79852304|NCT00733967|Drug|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
79852305|NCT00733967|Drug|Placebo|Matching oral placebo capsules as control.
79852306|NCT01010841|Dietary Supplement|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
79852307|NCT01010841|Other|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
79852308|NCT00732095|Behavioral|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
79852309|NCT00732173|Behavioral|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
79852310|NCT00732173|Behavioral|exercise intervention|Undergo SUCCEED lifestyle intervention
79852311|NCT00732173|Other|counseling intervention|Undergo SUCCEED lifestyle intervention
79715052|NCT05926141|Behavioral|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes). On any day during the week, the students will make a dish using groceries they received (1 hour).
79715053|NCT05926128|Drug|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
79715054|NCT05926115|Diagnostic Test|Diagnostic Ultrasound|During the initial visit, a transvaginal or transabdominal pelvic ultrasonography will be performed in all participants, based on the sexual history and consent form by trained gynecologists who are part of study investigators. A transvaginal ultrasound is the accepted and validated method to assess the ovarian morphology in the study of patients with PCOS.
79852312|NCT00732173|Other|educational intervention|Receive information
79255096|NCT03290313|Drug|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
79551170|NCT04041375|Other|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
79852313|NCT00732173|Other|survey administration|Undergo SUCCEED lifestyle intervention
79852314|NCT04650243|Drug|ursodeoxycholic acid|The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.
79852315|NCT00738569|Drug|Raltegravir|Raltegravir 400 mg PO BID for 12 months
79852316|NCT04646811|Procedure|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
79852317|NCT04646811|Other|Best medical treatment|Best medical therapy alone
79551171|NCT04040751|Behavioral|CARE-CITE|The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
79715055|NCT05926115|Diagnostic Test|Venous puncture|After an overnight fast of at least 6 hours (ideally), a 18 ml sample of venous blood will be collected from each study participant (i.e., the basal fasting sample). About 12 ml of the venous blood will be collected in plain tubes for serum cryopreservation and subsequent analysis, and the remainder in plain tubes for immediate glucose estimation in serum.
79715056|NCT05926076|Other|Treatment plan|Patients with different diagnoses will get different treatment options
79715057|NCT05926050|Dietary Supplement|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
79551172|NCT04040751|Behavioral|Standard of care|The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
79394805|NCT03113058|Combination Product|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
79715058|NCT05926050|Other|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
79255097|NCT03290313|Drug|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
79394806|NCT00313209|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
79852318|NCT00732329|Behavioral|Occupational Therapy|"optimized home Based Occupational Therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
79852319|NCT04644627|Drug|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
79394807|NCT00313209|Drug|Placebo|once daily
79394808|NCT02372994|Other|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
79852320|NCT02568761|Procedure|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
79852321|NCT02568761|Other|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
79852322|NCT00460408|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
79852323|NCT02569151|Device|HBP & CBP measurement using systo 130 mmHg|
79715059|NCT05925998|Other|Observational study: no interventions|Not applicable as observational study with no intervention
79852324|NCT00732407|Drug|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
79852325|NCT00732407|Drug|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
79852326|NCT00507819|Drug|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
79852327|NCT00507819|Drug|Placebo|One placebo capsule will be taken by mouth three times-a-day.
79852328|NCT00738647|Procedure|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
79852329|NCT01566058|Device|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
79852330|NCT01566058|Other|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
79255098|NCT03290313|Other|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
79255099|NCT02100787|Other|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
79255100|NCT03295695|Diagnostic Test|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
79394809|NCT02361606|Behavioral|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
79394810|NCT02373150|Drug|Imeglimin|
79394811|NCT02373150|Drug|Placebo|
79394812|NCT00313443|Procedure|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
79852331|NCT02569307|Drug|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
79852332|NCT02569307|Drug|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
79852333|NCT02569307|Drug|Placebo|Placebo added to TAU
79715060|NCT05925296|Device|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
79715061|NCT05925244|Other|Control Condition|Control (no alteration to body mass).
79852334|NCT02569307|Drug|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
79852335|NCT01013103|Drug|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
79852336|NCT01013103|Drug|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
79852337|NCT00732485|Drug|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
79852338|NCT00732485|Drug|placebo|Placebo, sugar pill, from admission to 6 months post burn
79852339|NCT01010919|Dietary Supplement|Chicory root extract|
79715062|NCT05925244|Other|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
79852340|NCT01566136|Behavioral|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
79255101|NCT03295695|Biological|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-[18F]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
79255102|NCT03295695|Diagnostic Test|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
79715063|NCT05925244|Other|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
79715064|NCT05924568|Other|Educational session with Keep Your Move in the Tube and PrimusRS|
79715065|NCT05924152|Drug|Adagrasib|Adagrasib
79715066|NCT05924152|Drug|Eltrombopag + adagrasib|Eltrombopag + adagrasib
79715067|NCT05922644|Device|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
79715068|NCT05922644|Other|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
79852341|NCT02569073|Drug|Dronabinol|Dronabinol 5 mg, every other night, orally
79852342|NCT02569073|Drug|Placebo|Placebo--no drug
79852343|NCT03490084|Other|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
79852344|NCT03490084|Other|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
79852345|NCT00732563|Drug|chemotherapy|Given IV and Orally
79852346|NCT00732563|Procedure|lymphadenectomy|Removal of lymph nodes
79852347|NCT00732563|Procedure|neoadjuvant therapy|Tumor reduction
79852348|NCT00732563|Procedure|quality-of-life assessment|Correlative Study
79852349|NCT00732563|Procedure|therapeutic conventional surgery|Treatment for cancer
79852350|NCT00732563|Procedure|thoracic surgical procedure|removal of tissue
79852351|NCT00732563|Radiation|fludeoxyglucose F 18|given IV
79255103|NCT02100865|Device|Solar powered oxygen|
79255104|NCT02100865|Device|Oxygen from cylinders|
79255105|NCT04718805|Drug|Darunavir|Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
79255106|NCT04718805|Drug|Cobicistat|Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
79255107|NCT04718805|Drug|Darunavir/Cobicistat FDC|Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
79255108|NCT02098603|Behavioral|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
79255109|NCT03290235|Drug|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
79255110|NCT05063708|Device|Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|In the present study, VitalStim equipment will be used (VitalStim Therapy; Chattanooga Group, Chattanooga, TN, USA). Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation.
79852352|NCT00732563|Radiation|radiation therapy|undergoing radiotherapy
79255111|NCT05063708|Device|Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation. The training was given according to the manual of the manufacturer, the VitalStim certification course (http://www.vitalstim.com).
79852353|NCT03449667|Device|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
79852354|NCT03449667|Device|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
79715069|NCT05922176|Other|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~American house dust mite-specific immunogloblin G4 (sIgG4)~American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
79715070|NCT05922176|Other|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
79852355|NCT00734123|Drug|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
79852356|NCT00734123|Drug|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
79255112|NCT03555019|Dietary Supplement|Formulaid|Supplementation with ARA and DHA
79255113|NCT03555019|Dietary Supplement|MCT-oil|Supplementation with medium chain fatty acids
79255114|NCT04857255|Behavioral|Technology assisted language intervention|speech language therapy that has integrated technology delivered through specific software on an iPad
79394813|NCT02361684|Behavioral|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
79551175|NCT03998748|Other|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
79551176|NCT03997916|Device|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
79551177|NCT03997916|Diagnostic Test|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
79551178|NCT03987503|Drug|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
79715071|NCT05920590|Other|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~Application of the hold - relax technique to increase the range of motion of knee flexion.~Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~Application of stabilizing reversals from a sitting and standing position.~Application of dynamic reversals from a standing position.~Rhythmic stabilization.~Combination of isotonics.~Gait retraining."
79852357|NCT00734123|Drug|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
79852358|NCT00734123|Drug|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
79852359|NCT00734201|Drug|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
79255115|NCT04857255|Behavioral|Treatment as usual|No change will occur to the current ongoing speech-language therapy being delivered.
79255116|NCT05042336|Drug|camrelizumab/lenvatinib combined with TACE|"Lenvatinib 4mg qd body weight≤60,8mg；body weight>60,12mg~Camrelizumab 200mg q2w/q3w"
79255117|NCT02103673|Drug|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
79255118|NCT02103673|Drug|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
79255119|NCT03295617|Procedure|Thoracoscopy|Thoracoscopy surgery
79255120|NCT03096392|Drug|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
79551179|NCT03987503|Drug|Standard of care|Standard of HCV care provided by medical care provider
79551180|NCT03987503|Device|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
79715072|NCT05920590|Other|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
79255121|NCT03096392|Drug|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
79551181|NCT03977181|Behavioral|Group-based Community Health Club|GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
79255122|NCT04428645|Device|DailyDose Decision Support|DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
79255123|NCT05049434|Device|Medicurtain®|Medicurtain® 5ml prefilled syringe
79255124|NCT05049434|Device|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
79255125|NCT02103829|Behavioral|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
79715073|NCT05920590|Other|Conventional Home-based Physiotherapy Program|"Participants in this group will follow a conventional six-week home physical therapy program that will include:~Range exercises of the knee joint and the ankle joint of the operated limb.~Stretching of the muscles of the lower limbs.~Walking inside and outside the house.~Exercises to strengthen the muscles of the lower limbs."
79715074|NCT05914831|Radiation|Ultra-fractionated WBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
79715075|NCT05914831|Radiation|Ultra-fractionated PBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
79394814|NCT02361684|Other|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
79394815|NCT04271397|Other|Multiple blood samples|Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.
79715076|NCT05910671|Behavioral|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
79715077|NCT05907343|Device|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
79852360|NCT00734279|Drug|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
79255126|NCT02103829|Behavioral|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
79255127|NCT02103829|Behavioral|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
79255128|NCT03290157|Device|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
79255129|NCT02103907|Other|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
79255130|NCT05042024|Procedure|Scaling and root planing|Conventional periodontal therapy, non-surgical periodontal therapy
79394816|NCT04271397|Other|Single blood sample|Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
79394817|NCT05267847|Other|Cryotherapy|local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs
79394818|NCT05267847|Other|Traditional local anesthesia|local anesthetic injection with articaine 4% 1:100,000 epinephrine
79255131|NCT05042024|Drug|Oral L-arginine aspartate administration|The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
79715078|NCT05907343|Device|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
79715079|NCT05907343|Device|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
79852361|NCT00734279|Drug|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
79852362|NCT00734279|Drug|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
79255132|NCT05042024|Drug|Oral L-ornithine aspartate administration|The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
79394819|NCT02372838|Procedure|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
79394820|NCT05267457|Other|Plasma vanadium concentration|Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700 Series, United States)
79394821|NCT02373306|Procedure|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
79852363|NCT00734279|Drug|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
79852364|NCT00442936|Drug|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
79852365|NCT00442936|Drug|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
79852366|NCT00442936|Drug|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
80017618|NCT02114190|Behavioral|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
80017619|NCT05404750|Behavioral|Harm Reduction|Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
79255133|NCT02460393|Drug|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
79255134|NCT02460393|Other|placebo|Subcutaneous injection of different doses for healthy people
79255135|NCT03554941|Device|noise stimulation|noise stimulation
79255136|NCT02106169|Behavioral|Therapeutic education group|
79255137|NCT02464995|Device|Bronchial thermoplasty with the Alair System|
79255138|NCT05063630|Procedure|Medical treatment plus intracranial stenting|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
79394822|NCT00351039|Drug|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
79394823|NCT00351039|Drug|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
79715080|NCT05907239|Device|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
79715081|NCT05907239|Device|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
79255139|NCT05063630|Drug|Medical treatment alone|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
79394824|NCT00351039|Drug|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
79394825|NCT02361918|Procedure|Colon surgery|
79394826|NCT02372916|Drug|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
79852367|NCT00442936|Drug|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
79852368|NCT00442936|Drug|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
79852369|NCT00442936|Drug|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
79551182|NCT03977181|Behavioral|Individual-based Adherence Support|IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
79255140|NCT02103985|Drug|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
79255141|NCT03289845|Device|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
79715082|NCT05896306|Other|No intervention|No intervention
79715083|NCT05892653|Drug|ABM-1310|"Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed."
79551183|NCT03967197|Drug|Saline spray|Physiologic saline spray
79255142|NCT05063864|Other|Nursing Support Program|"Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature."
79255143|NCT03295539|Device|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
79394827|NCT00351741|Device|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
79394828|NCT00351741|Device|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
79394829|NCT02361528|Drug|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
79394830|NCT02361528|Drug|Placebo|placebo subcutaneously, for 5 days
79394831|NCT01572727|Drug|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
79394832|NCT01572727|Drug|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
79551184|NCT03967197|Drug|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
79715084|NCT05882370|Drug|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
79715085|NCT05882370|Procedure|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
79715086|NCT05876182|Drug|Oral Vancomycin|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
79715087|NCT05876182|Other|Placebo|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
79875318|NCT00946127|Procedure|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
79875319|NCT00946127|Procedure|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
79255144|NCT02250859|Drug|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
79255145|NCT02465229|Procedure|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
79394833|NCT01572727|Drug|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
79551185|NCT03935646|Drug|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
79551186|NCT03935646|Drug|Placebo|Placebo
79715088|NCT05874596|Behavioral|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
79715089|NCT05873140|Behavioral|application LINE|Online lifestyle modification education for weight loss
79715090|NCT05864196|Radiation|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
79715091|NCT05848427|Other|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
79715092|NCT05848050|Procedure|biological samples (blood test and lumbar puncture)|"On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses."
79715093|NCT05836168|Dietary Supplement|Omnibiotic Stress Repair|multispecies probiotic
79715094|NCT05836168|Dietary Supplement|Placebo|Placebo
79715095|NCT05833321|Diagnostic Test|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
79852370|NCT00442936|Drug|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
79852371|NCT00734357|Procedure|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
79852372|NCT04065503|Biological|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
79852373|NCT00732719|Device|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
79852374|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
79852375|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
79255146|NCT02101099|Device|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
79255147|NCT03295461|Procedure|SRP+ 10% Emblica officinalis irrigation|
79255148|NCT03295461|Procedure|SRP + 0.2% Chlorhexidine irrigation)|
79255149|NCT03295461|Procedure|SRP + 0.9% Saline irrigation|
79255150|NCT03295461|Procedure|SRP +10% E. officinalis gel application.|
79255151|NCT03295461|Procedure|SRP+ placebo gel application.|
79255152|NCT05063474|Diagnostic Test|No Intervention-Clinical Assessments only|No Intervention. Clinical Assessments include: vital signs, near infrared spectrometry, general leg strength, and 6-minute walking test.
79255153|NCT03289767|Other|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
79255154|NCT02104063|Procedure|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
79255155|NCT05048420|Procedure|surgery|ACL reconstruction and RAMP lesion repair
79551187|NCT03831009|Procedure|Open reduction internal fixation (ORIF)|Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
79551188|NCT03831009|Other|Conservative treatment|Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
79551189|NCT03788616|Drug|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
79551190|NCT03788616|Drug|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
79551191|NCT03769493|Behavioral|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
79852376|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
79852377|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
79852378|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
79852379|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
79852380|NCT01010997|Device|Foresee Home|using the Foresee home device
79875320|NCT00946205|Procedure|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
79394834|NCT01791777|Behavioral|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
79715096|NCT05830461|Behavioral|Online psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
79255156|NCT03295383|Drug|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
79715097|NCT05830461|Behavioral|Psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
79852381|NCT01011231|Procedure|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
79852382|NCT00738803|Procedure|Total hip replacement|Total hip replacement typically preformed for hip arthritis
79255157|NCT03295383|Drug|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~patients younger than 75 years: 1.5 mg/kg/day, orally.~patients older than 75 years: 1 mg/kg/day, orally."
79852383|NCT01013259|Drug|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
79255158|NCT03295383|Drug|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
79255159|NCT03295383|Drug|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
79715098|NCT05826834|Device|ball-rolling (Myostorm ball)|the intervention group
79715099|NCT05815810|Other|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
79255160|NCT03096236|Device|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
79255161|NCT02101255|Device|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
79255162|NCT02101255|Device|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
79255163|NCT05063318|Drug|Lurbinectedin alone|The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
79255164|NCT05063318|Drug|Lurbinectedin+Itraconazole co-administration|The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
79394835|NCT02359266|Dietary Supplement|Vitamin D|Given to patients with existing vitamin D deficiency
79715100|NCT05815810|Other|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
79852384|NCT01013259|Drug|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
79852385|NCT00732953|Device|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
79852386|NCT00732953|Device|Genous stent implantation|Genous stent implantation
79852387|NCT00577655|Drug|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
79852388|NCT00577655|Drug|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
79255165|NCT02106247|Drug|BI 1181181 high dose|two tablet
79255166|NCT02106247|Drug|BI 1181181 low dose|one tablet
79255167|NCT02106247|Drug|Placebo|tablet
79255168|NCT02465151|Other|Protein-based beverage|protein-based beverage
79394836|NCT02359500|Drug|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
79394837|NCT02372526|Other|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
79255169|NCT03096002|Behavioral|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
79255170|NCT03289689|Device|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
79715101|NCT05791071|Device|Floreo VR Building Social Connections|Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.
79715102|NCT05791071|Device|Sham|This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.
79852389|NCT00577655|Drug|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
79852390|NCT01013337|Procedure|acupuncture therapy|
79852391|NCT01013337|Procedure|sham intervention|Placebo acupuncture
79852392|NCT04514679|Behavioral|Healthy Lifestyles Program|Regular group visits with a health coach in addition to routine dietician and clinician visits, reviewing successes and challenges from the previous session as well as data collected through self-monitoring
79852393|NCT04514679|Behavioral|Obesity Medicine Program|A tailored approach to obesity care for patients including individual dietician and health coach visits as appropriate.
80017620|NCT02112084|Behavioral|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
79852394|NCT00733031|Drug|AZD6918|liquid suspension, daily, oral dose
79852395|NCT00733031|Drug|gemcitabine|intravenous, doses are on an intermittent schedule
79852396|NCT00733031|Drug|pemetrexed|intravenous, dose administered every 21-days
80017621|NCT05404516|Drug|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
80017622|NCT05404516|Drug|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
79255171|NCT02104297|Drug|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
79255172|NCT02104297|Drug|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
79255173|NCT02104297|Drug|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
79394838|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
79394839|NCT02372526|Other|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
79715103|NCT05789238|Behavioral|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
79715104|NCT05789238|Behavioral|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
79852397|NCT00734669|Drug|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
79852398|NCT00738959|Drug|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
79852399|NCT00113269|Drug|basiliximab|IV
79852400|NCT00113269|Drug|rabbit anti-thymocyte globulin|IV
79852401|NCT00113269|Drug|tacrolimus|oral
79852402|NCT00113269|Drug|alemtuzumab|Intravenous (IV)
79852403|NCT00113269|Drug|mycophenolate mofetil|oral
79852404|NCT00113269|Drug|steroids|IV and/or oral
79852405|NCT04065269|Drug|AZD6738|ATR inhibitor
79852406|NCT04065269|Drug|Olaparib|PARP inhibitor
79852407|NCT00515619|Drug|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
79852408|NCT00733109|Procedure|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
79852409|NCT00733109|Other|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
79852410|NCT00733187|Drug|ABT-869|0.25 mg/kg
79852411|NCT00449644|Drug|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
79852412|NCT00449644|Drug|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
79852413|NCT00449644|Drug|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
80017623|NCT05404516|Drug|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
80017624|NCT02114346|Drug|Atorvastatin|
80017625|NCT02114346|Drug|Placebo|
79852414|NCT00515541|Drug|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
79255174|NCT03096158|Other|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
79394840|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
79852415|NCT00733265|Drug|AZD6140|single oral dose
79551194|NCT03732768|Drug|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
79715105|NCT05778526|Behavioral|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
79852416|NCT03462628|Procedure|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
79852417|NCT03462628|Procedure|CPVI alone|circumferential pulmonary vein isolation
79852418|NCT00112489|Drug|carboplatin|
79852419|NCT00112489|Drug|paclitaxel|
79255175|NCT03096158|Other|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
79394841|NCT00315627|Drug|Islet transplantation|Islet transplantation
79394842|NCT02985697|Drug|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
79394843|NCT02985697|Drug|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
79394844|NCT02985697|Drug|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
79394845|NCT02359188|Device|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
79394846|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring & Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
79394847|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring & Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
79394848|NCT02361450|Device|Retrograde Colonic Irrigation|
79394849|NCT02361450|Other|Usual Care|
79551195|NCT03713619|Drug|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
79551196|NCT03713619|Drug|Placebo|Placebo 300mg every 2 or every 4 weeks
79551197|NCT03670693|Diagnostic Test|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
79551198|NCT03670693|Diagnostic Test|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
79715106|NCT05778526|Behavioral|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
79715107|NCT05773001|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
79852420|NCT03666598|Device|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
79852421|NCT01023100|Drug|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
79852422|NCT00711971|Drug|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
79852423|NCT00711971|Drug|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
79852424|NCT00711971|Drug|placebo|control arm
79394850|NCT02982759|Behavioral|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
79394851|NCT02982759|Behavioral|Genetic Newsletters|The comparison will receive generic newsletters
79255176|NCT03096158|Other|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
79715108|NCT05765045|Diagnostic Test|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
79715109|NCT05752760|Other|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
79715110|NCT05752760|Other|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
79852425|NCT01078831|Other|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
79852426|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
79852427|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
79852428|NCT00739037|Drug|Placebo|
79255177|NCT03295305|Behavioral|Action-Based Cognitive Remediation|
79255178|NCT03295305|Behavioral|Unstructured support group|
79255179|NCT02106481|Drug|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
79255180|NCT02106481|Drug|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
79255181|NCT05048186|Behavioral|Attention Deficit Hyperactivity Disorder Treatment Decision Aid|The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
79255182|NCT03289611|Biological|sFlt-1 / PlGF ratio|"Ambulatory management if sFlt-1 / PlGF ratio is below 38~usual management if sFlt-1/PlGF is between 38 and 85.~If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued"
79255183|NCT02106559|Drug|porfimer sodium|Given IV
79255184|NCT02106559|Procedure|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
79255185|NCT02106559|Drug|photodynamic therapy|Undergo PDT
79255186|NCT05047796|Other|Intervention Protocol|The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.
79255187|NCT05047796|Other|Sham Protocol|The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
79255188|NCT03289377|Behavioral|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
79255189|NCT05047874|Behavioral|systemic methylprednisolone|short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
79255190|NCT02101333|Drug|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
79394852|NCT02372760|Device|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
79394853|NCT02372760|Other|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
79394854|NCT02372760|Drug|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
79394855|NCT02361294|Other|Blood samples|
79394856|NCT02361372|Other|Placebo|Placebo daily for 6 months
79394857|NCT02361372|Other|CaCO3|CaCO3 daily for 6 months
79394858|NCT02361372|Other|Kefir|Kefir daily for 6 months
79394859|NCT00352911|Drug|VGX-410 (Mifepristone)|
79394860|NCT00352911|Drug|Placebo for VGX-410 (Mifepristone)|
79394861|NCT02359032|Drug|ASP6858|Oral tablets
79394862|NCT02359032|Drug|Placebo|Oral tablets
79394863|NCT05267145|Combination Product|blood preservation solution III|Blood bag added blood preservation solution III
79394864|NCT02358954|Procedure|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
79852429|NCT00739037|Drug|PAZ-417|
79852430|NCT01080157|Device|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
79394865|NCT02358954|Procedure|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
79394866|NCT02358954|Procedure|3D Turntable|
79394867|NCT02358954|Procedure|Vection stimulation|
79394868|NCT02358798|Other|3 years-assessment of respiratory function|
79394869|NCT00353301|Drug|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
79394870|NCT00353301|Drug|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
79852431|NCT03902483|Device|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
79255191|NCT04434794|Biological|mesenchymal stem cells|autologous mesenchymal stem cells
79852432|NCT01080235|Other|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
80017626|NCT02114346|Drug|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
79551199|NCT03670693|Diagnostic Test|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
79551200|NCT03670693|Diagnostic Test|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
79715111|NCT05741853|Behavioral|Video-Implemented Script Training for Aphasia (VISTA)|Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
80017627|NCT02112162|Radiation|fludeoxyglucose F 18|Undergo FDG PET/MRI
79715112|NCT05741853|Behavioral|Lexical Retrieval Training (LRT)|Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
79852433|NCT01080235|Other|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
80017628|NCT02112162|Device|positron emission tomography|Undergo FDG PET/MRI
80017629|NCT02112162|Device|magnetic resonance imaging|Undergo FDG PET/MRI
80017630|NCT02112162|Other|laboratory biomarker analysis|Correlative studies
80017631|NCT02108808|Drug|Ticagrelor|
80017632|NCT02108808|Drug|Prasugrel or Clopidogrel|
80017633|NCT02108886|Drug|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
80017634|NCT02108886|Drug|Placebo|empty capsule filled with sugar
80017635|NCT02108886|Other|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
79255192|NCT04434794|Other|standard treatment|standard treatment according to clinical protocols
79255193|NCT01368835|Device|Ulthera treatment|treatment of cheeks and upper neck area of face
79255194|NCT04488705|Drug|ETD002 - single dose|Single ascending doses of ETD002
79255195|NCT04488705|Drug|Placebo - single dose|Single doses of placebo
79255196|NCT04488705|Drug|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
79255197|NCT04488705|Drug|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
79255198|NCT04488705|Drug|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
79255199|NCT04488705|Drug|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
79394871|NCT02372604|Drug|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~the evening : 10 mg of levocetirizine (capsule))"
79394872|NCT02372604|Drug|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~the evening : placebo tablet"
79715113|NCT05724654|Dietary Supplement|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
79852434|NCT00734825|Other|Omnipaque|oral contrast for CT scan
79852435|NCT01080313|Other|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
79852436|NCT00739115|Other|Heliox gas|Heliox gas used in conjunction with nasal CPAP
79394873|NCT02372448|Other|ALK analysis on CTCs detected by ISET|
79852437|NCT01082731|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
79852438|NCT01082731|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
79852439|NCT00739193|Drug|amiodarone|
79852440|NCT01011543|Procedure|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
79255200|NCT04488705|Drug|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 & 7)
79255201|NCT03295071|Other|Patient-reported outcomes (PROs)|Patient-reported outcomes (PROs)
79255202|NCT02104375|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
79852441|NCT00733577|Drug|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
79852442|NCT03997461|Device|BPro|BPro and Oscar 2 comparison for 24 hours
79852443|NCT00739271|Other|Early feeding|
79852444|NCT00739271|Other|late feeding after bowel sounds return|Traditional method
79852445|NCT04513977|Other|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
79852446|NCT00735059|Device|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, > 3 hours
79852447|NCT00735059|Device|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, > 3 hours
79852448|NCT00735137|Device|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
79852449|NCT04064255|Other|Practical Body Image (session 1 - 7)|Practical body image therapy
79852450|NCT04064255|Other|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
79852451|NCT00733733|Drug|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
79852452|NCT00733811|Drug|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
79852453|NCT00733811|Drug|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
79852454|NCT00739505|Biological|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
79852455|NCT00739505|Biological|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
79715114|NCT05723861|Device|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
79715115|NCT05690984|Drug|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
79715116|NCT05690984|Drug|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
79715117|NCT05690984|Drug|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
79852456|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 16 weeks
79852457|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 8 weeks
79852458|NCT00920777|Behavioral|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
79852459|NCT00507507|Drug|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
79852460|NCT00507507|Drug|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
79852461|NCT00507507|Drug|Placebo|Placebo to match FTC taken once daily
79852462|NCT00540761|Device|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
79255203|NCT03289221|Diagnostic Test|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
79394874|NCT01792323|Drug|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
79394875|NCT02358642|Drug|Angiotensin converting enzyme inhibitor (Lisinopril)|
79394876|NCT02358642|Drug|Placebo|
79394877|NCT00318357|Device|Continuation of CRT|Implantation of CRT device and medical treatment according normal hospital routine.
79394878|NCT00318357|Device|Upgrade to CRT|Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
79852463|NCT00459706|Device|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
79852464|NCT00459706|Device|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
79852465|NCT00735293|Device|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
79852466|NCT02568527|Device|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
79852467|NCT00735527|Drug|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
79852468|NCT00735527|Drug|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
79551201|NCT03670693|Diagnostic Test|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
79715118|NCT05688332|Drug|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
79715119|NCT05688332|Drug|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
79715120|NCT05685147|Genetic|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
79715121|NCT05680688|Other|Manual Therapy|"Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
79715122|NCT05647304|Device|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
79715123|NCT05647304|Device|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
79715124|NCT05642962|Drug|Pertzye|Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
79715125|NCT05619445|Other|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
79715126|NCT05619445|Other|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
79715127|NCT05597735|Drug|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
79715128|NCT05597735|Drug|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
79852469|NCT00735605|Other|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
79255204|NCT02106637|Drug|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
79551202|NCT03666416|Behavioral|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
79715129|NCT05578781|Behavioral|Music Therapy|Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
79852470|NCT00735605|Procedure|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
79255205|NCT02106637|Drug|placebo|placebo
79394879|NCT01791933|Drug|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
79394880|NCT01791933|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
79394881|NCT01791933|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10~20 acupoints 1-2times a week for more than 2 months
79715130|NCT05578781|Behavioral|Music Medicine|Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
79715131|NCT05578781|Behavioral|Control group|Control group will listen to an audio recording of text being spoken by the board certified music therapist
79715132|NCT05556954|Procedure|Wound debridement|"Participant that are having usual care visits for management of diabetic foot ulcers will be enrolled into this study. The procedure is done as part of standard of care. Tissue from the samples will be analyzed for this study.~Aliquoting and Deoxyribonucleic acid (DNA) extraction will be done on the specimens. Bacterial DNA from biospecimens will be isolated, quantified, amplified, and sequenced."
79852471|NCT00735605|Other|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
79551203|NCT03615937|Behavioral|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
79551204|NCT03615937|Behavioral|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
79581049|NCT01932151|Drug|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
79715133|NCT05549960|Device|The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).|"EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present."
79715134|NCT05541978|Other|Multiple myeloma|We will explore the multiple myeloma associated thrombosis risk.
79852472|NCT05741255|Behavioral|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
79852473|NCT05741177|Diagnostic Test|lung ultrasound|lung ultrasound score
79852474|NCT05741099|Biological|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
79852475|NCT05741099|Other|Comparator|Patients in comparator group will receive placebo treatment
79852476|NCT04063475|Drug|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
79852477|NCT00735683|Drug|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
79852478|NCT00735683|Drug|Placebo|includes diet, physical activity, and lifestyle modification
79852479|NCT03663322|Procedure|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
79852480|NCT03663322|Procedure|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
79852481|NCT00735761|Drug|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
79255206|NCT02104453|Procedure|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
79255207|NCT05047328|Biological|inolimomab|"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."
79255208|NCT03288909|Other|MRI|
79255209|NCT05047484|Drug|ALXN2050|Powder-in-capsule (PIC).
79255210|NCT05047484|Drug|Placebo|PIC.
79852482|NCT00735761|Drug|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
79255211|NCT02460861|Procedure|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
79255212|NCT02460861|Procedure|RPVE|Open Radical prostatovesiculectomy in Magdeburg
79255213|NCT02460861|Procedure|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
79551205|NCT03615937|Behavioral|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
79551206|NCT03615937|Other|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
79394882|NCT01791933|Procedure|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
79551207|NCT03615937|Other|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
79551208|NCT03596177|Drug|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
79551209|NCT03596177|Drug|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
79551210|NCT03585517|Drug|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
79551211|NCT03579459|Biological|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
79551212|NCT03579459|Biological|placebo|Normal saline solution
79715135|NCT05535348|Behavioral|Relaxation Response Resiliency Program for Father of CYSHCN|Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
79715136|NCT05492032|Device|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
79715137|NCT05492032|Device|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
79852483|NCT03454438|Procedure|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
79852484|NCT00740285|Drug|Lidocaine 2% without vessel constrictor|"first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
79852485|NCT00740285|Other|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
79852486|NCT00507429|Drug|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
79852487|NCT00507429|Drug|paclitaxel|200mg/m squared on Day 1
79852488|NCT00507429|Drug|carboplatin|6 AUC on Day 1 following paclitaxel
79852489|NCT01011621|Drug|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
79394883|NCT03160248|Drug|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
79394884|NCT03160248|Drug|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
79394885|NCT02372370|Procedure|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
79394886|NCT02372370|Procedure|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
79551213|NCT03547999|Drug|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
79852490|NCT01011621|Drug|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
79255214|NCT02460861|Procedure|CE|Open cystectomy in Magdeburg/Gronau
79255215|NCT02460861|Procedure|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
79255216|NCT02104609|Drug|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
79255217|NCT05047562|Other|Pilates Group|16 Pilates exercise sessions twice a week for 2 months.
79715138|NCT05492032|Behavioral|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
79715139|NCT05488431|Drug|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in >4300 individuals and is currently being studied in >14,000 individuals in CLEAR Outcomes (NCT02993406).
79255218|NCT05047562|Other|Segmental Stabilization group|16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
80017636|NCT05392816|Other|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
79715140|NCT05488431|Other|Placebo|Placebo
79715141|NCT05467228|Device|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
79715142|NCT05436925|Device|Dexcom G6 sensor Continuous Glucose Monitor (CGM)|The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
79715143|NCT05405283|Biological|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
79394887|NCT02372370|Procedure|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
79715144|NCT05405283|Biological|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
79852491|NCT00449176|Drug|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
79715145|NCT05392179|Drug|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
79715146|NCT05392179|Drug|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
79852492|NCT00449176|Drug|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
79852493|NCT00449176|Drug|placebo|matching placebo twice daily for 15 weeks
79852494|NCT00515073|Drug|Paclitaxel|50 mg/m^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
80017637|NCT02114424|Device|Positional vibrator belt|Belt with vibarator to avoid sleep supine
79394888|NCT02372370|Procedure|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
79394889|NCT02372370|Procedure|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
79394890|NCT02372370|Drug|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
79394891|NCT02372370|Other|Untreated Control|Untreated control. No interventions.
79394892|NCT01522651|Drug|Ranolazine|Tablets administered orally twice daily.
80017638|NCT02114502|Drug|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
80017639|NCT02114502|Drug|SAHA|1,000 mg by mouth on Days -8 to -3.
80017640|NCT02114502|Drug|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
80017641|NCT02114502|Drug|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
80017642|NCT02114502|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
80017643|NCT02114502|Procedure|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
79394893|NCT01522651|Drug|Dronedarone|Capsule administered orally twice daily
79394894|NCT01522651|Drug|Ranolazine placebo|Tablets administered orally twice daily.
79255219|NCT03294915|Dietary Supplement|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
79255220|NCT03294915|Dietary Supplement|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
79394895|NCT01522651|Drug|Dronedarone placebo|Capsules administered orally twice daily
80017644|NCT02114502|Drug|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
80017645|NCT02114502|Drug|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
79715147|NCT05904223|Diagnostic Test|Respiratory Panel PCR Sputum|Multiplex PCR Respiratory Panel from Biomerieux used on Patients Sputum
79551214|NCT03547999|Biological|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
79715148|NCT05378841|Procedure|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
79715149|NCT05377359|Device|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
79715150|NCT05377359|Device|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
79715151|NCT05377359|Device|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
79715152|NCT05377359|Device|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
79715153|NCT05377320|Other|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
79715154|NCT05377320|Other|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
79715155|NCT05365269|Behavioral|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
79852495|NCT00515073|Radiation|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
80017646|NCT02114502|Drug|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
79551215|NCT03547999|Biological|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
79715157|NCT05354453|Drug|BI 1839100|BI 1839100
79551216|NCT03547999|Drug|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
79852496|NCT00515073|Drug|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
80017647|NCT02114502|Drug|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
80017648|NCT02114502|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
79255221|NCT02106715|Other|Training|Two exercises for training of core stability and mobility.
79255222|NCT02104687|Procedure|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
79255223|NCT02104687|Procedure|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
79394896|NCT00318591|Device|SpeediCath|hydrophilic coated urinary intermittent catheter
79394897|NCT00318591|Device|Conveen Uncoated|Uncoated urinary intermittent catheter
79551217|NCT03536728|Drug|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
79551218|NCT03536728|Drug|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
79715158|NCT05354453|Drug|Placebo|Placebo
79715159|NCT05354453|Drug|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
79715160|NCT05344378|Behavioral|ATTAIN NAV Technology-Enhanced Family Navigation Model|The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
79715161|NCT05333341|Behavioral|TCM|TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.
79852497|NCT00515073|Drug|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
79852498|NCT00515073|Drug|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
79852499|NCT00710021|Drug|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
79852500|NCT00710021|Drug|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
79852501|NCT00504153|Drug|dasatinib|
79852502|NCT00504153|Other|laboratory biomarker analysis|Correlative studies
79852503|NCT05740787|Other|No intervention|Observation only
79852504|NCT00739895|Procedure|Cardiac magnetic Resonance study|follow-up studies
80017649|NCT02979639|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
79715162|NCT05333341|Behavioral|TCM plus COPES|Pharmacist will assist participants engagement with the COPES program that will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
79852505|NCT00739895|Procedure|Blood testing|Blood sample tested for myocardial biomarkers
79715163|NCT05303116|Diagnostic Test|Brainscope modified EEG and cognitive testing|Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
79551219|NCT03517423|Drug|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
79551220|NCT03477305|Behavioral|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
79551221|NCT03477019|Drug|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
79852506|NCT00735995|Behavioral|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
79852507|NCT00735995|Behavioral|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
79852508|NCT04064177|Device|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
79852509|NCT05740631|Drug|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
79551222|NCT03477019|Procedure|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
79551223|NCT03462251|Combination Product|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
79715164|NCT05286151|Behavioral|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
79715165|NCT05282095|Other|Follow up|Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
79852510|NCT05740631|Drug|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
79852511|NCT00740363|Drug|sitagliptin|Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
79852512|NCT00740363|Drug|placebo|No active sitagliptin treatment for 4 weeks
79852513|NCT04065035|Other|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
79852514|NCT04065035|Other|Body Cleanser|Body cleanser to be used by study participants
79852515|NCT04065035|Other|Sunscreen|Sunscreen to be applied after application of moisturizer
79852516|NCT04065035|Other|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
79852517|NCT00442702|Drug|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
79852518|NCT00442702|Drug|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
79852519|NCT04065191|Other|High-intensity interval training|Heart rate based high-intensity interval training
79852520|NCT03444844|Drug|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
79852521|NCT00740441|Drug|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
79852522|NCT00740519|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
79852523|NCT00740675|Other|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
79394898|NCT02358408|Device|Blood glucose monitoring systems for self-testing|
79394899|NCT02372292|Drug|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
79394900|NCT01792011|Device|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
79394901|NCT02358486|Device|Acupuncture|"Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 ~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
79394902|NCT02358486|Device|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
79551224|NCT03462251|Combination Product|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
79551225|NCT03434132|Procedure|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
79551226|NCT03430479|Drug|Cohort A|Radiation + Nivolumab + hormone therapy
79551227|NCT03404089|Device|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
79551228|NCT03404089|Device|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
79852524|NCT03385486|Biological|TBX-3400|Autologous transfusion
79551230|NCT03327857|Biological|Neihulizumab (ALTB-168)|"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."
79551231|NCT03272685|Drug|Very Low Nicotine Content Cigarettes|0.4 mg/g nicotine; 9 mg tar
79715166|NCT05223218|Other|Schirmer strip, a Class I Medical Device typically used to test for dry eye.|Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
79715167|NCT05203900|Dietary Supplement|Infant formula with Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
79852525|NCT00736151|Drug|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
80017650|NCT02109120|Procedure|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
79551232|NCT03272685|Drug|Normal Nicotine Content Cigarettes|15.8 mg/g nicotine; 9 mg tar
79551233|NCT03272334|Drug|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
79551234|NCT03258281|Drug|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
79852526|NCT00514917|Drug|Docetaxel|75 mg/m^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
79852527|NCT00514917|Drug|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
79852528|NCT00514917|Drug|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
80017651|NCT02114580|Other|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
80017652|NCT01674634|Biological|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent [0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride])
79394903|NCT05267067|Other|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
79852529|NCT00711425|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
79852530|NCT05740397|Other|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
79852531|NCT01011699|Drug|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
79394904|NCT02358564|Procedure|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
79394905|NCT02358564|Procedure|Upper Endoscopy|
79394906|NCT02358564|Procedure|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
79551235|NCT03258281|Drug|Placebo|Patients will receive placebo administered subcutaneously
79581050|NCT01932177|Drug|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
79255224|NCT04488627|Diagnostic Test|Conventional transthoracic echocardiographic examination at the intensive care unit.|Conventional transthoracic echocardiographic examination at the intensive care unit targeted to inferior caval vein examination from different views.
79551236|NCT03231787|Diagnostic Test|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
79715168|NCT05203900|Dietary Supplement|Infant formula without Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
79852532|NCT01011699|Drug|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
79255225|NCT02106793|Drug|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
79255226|NCT02106793|Drug|Identical placebo solution|Identical placebo solution
79551237|NCT03230981|Device|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
79551238|NCT05705466|Drug|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
79715169|NCT05198700|Dietary Supplement|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
79715170|NCT05198700|Dietary Supplement|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
79852533|NCT01011699|Drug|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
79852534|NCT00740909|Behavioral|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
79255227|NCT05041556|Other|Case-control study of clinical outcomes|A case-control questionnaire will be administered at the home of cases and controls
79255228|NCT05041556|Other|Case-control study of mortality outcome|A case-control questionnaire will be administered at the home of cases and controls
79255229|NCT02104843|Drug|Daclatasvir, Asunaprevir and BMS-791325 FDC|
79255230|NCT02104843|Drug|BMS-791325|
79255231|NCT02104843|Drug|Rosuvastatin|
79255232|NCT03283293|Radiation|Target Volume Delineation after NACT|The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
79255233|NCT05041634|Behavioral|IHOPE|Integrating Healthy Habits Optimized by Community Participation and Engagled Learning
79255234|NCT02460315|Procedure|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
79852535|NCT05740319|Other|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
80017653|NCT02109198|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
79255235|NCT02460315|Procedure|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
79255236|NCT02104999|Device|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
79255237|NCT05041790|Drug|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
79551239|NCT05705466|Drug|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
79551240|NCT05705466|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
79581051|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
79581052|NCT01932177|Drug|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
79551241|NCT05705388|Device|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
79581053|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
80017654|NCT02109198|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
79394907|NCT04389021|Device|Virtual Reality|"The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol."
79394908|NCT02358330|Other|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
79394909|NCT01792089|Other|fat+protein meal|cream+ whey protein
79394910|NCT01792089|Other|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
79394911|NCT01792089|Other|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
79394912|NCT01792089|Other|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
79394913|NCT01792089|Other|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
79394914|NCT01554241|Dietary Supplement|D3 2000 IU/day|2000 IU/day D3
79394915|NCT01554241|Dietary Supplement|D3 4000 IU/day|vitamin D3 4000 IU/day
79394916|NCT01554241|Dietary Supplement|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
79394917|NCT01554241|Dietary Supplement|vitamin D3 800 IU/day|vitamin D3 800 IU/day
79394918|NCT05266833|Behavioral|Slow diaphragmatic breathing|"The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session."
79394919|NCT01792167|Behavioral|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
79394920|NCT03027739|Biological|CART-19|CART-19 cells treated
79394921|NCT02361138|Drug|SHR3824|
79394922|NCT02361138|Drug|Placebo|
79394923|NCT03840369|Device|Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
79394924|NCT03840369|Device|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
79394925|NCT03840369|Device|Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
79394926|NCT02353026|Drug|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
79394927|NCT01792401|Drug|Probiotics|
79394928|NCT01792401|Drug|Placebo|
79394929|NCT02358096|Drug|ASP8232|oral capsule
79394930|NCT02358096|Drug|Placebo|oral capsule
79394931|NCT02982681|Drug|Platelet rich fibrin|In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
79394932|NCT02982681|Drug|Bioactive Glass|The control site were packed with the bioactive glass graft alone
79394933|NCT01521559|Procedure|Macular Laser Photocoagulation|
79394934|NCT01521559|Drug|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
79394935|NCT02352870|Behavioral|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
79394936|NCT02352870|Behavioral|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
79394937|NCT04438980|Drug|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
79394938|NCT04438980|Other|Placebo|-An infusion bag of 100 mL of 0.9% saline
79394939|NCT05266755|Other|Fracture Territorial Liaison Service afert a Hip fracture|Give a diferent than the current one way of follow up to the patients with hip fracture
79551242|NCT05705388|Drug|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
79551243|NCT05705362|Procedure|Simple Crossover|Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
79551244|NCT05705362|Procedure|Side branch opening|According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
79551245|NCT05705336|Drug|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
79551246|NCT05705336|Drug|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
79551247|NCT05705310|Behavioral|Self Management Strategies|During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
79255238|NCT05041790|Drug|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
79551248|NCT05705284|Other|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
79551249|NCT05705245|Other|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
79551250|NCT05705180|Biological|recombinant adjuvanted zoster vaccine|vaccination with recombinant adjuvantes zoster vaccine
79551251|NCT05705076|Drug|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
79551252|NCT05705063|Other|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
79551253|NCT05705037|Other|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
79581054|NCT01932190|Procedure|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
79715171|NCT05159076|Behavioral|Behavioral Intervention to Increase Physical Activity|"The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active.~The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time."
79715172|NCT05135546|Drug|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
80017655|NCT03654027|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
80017656|NCT03654027|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
79715173|NCT05135546|Drug|Placebo|6 ml of 0.9% solution of NaCl for inhalation
80017657|NCT03005964|Drug|AM001 Cream, 7.5%|Active Cream
80017658|NCT03005964|Drug|Vehicle Cream|Placebo
80017659|NCT02112240|Other|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
80017660|NCT02112240|Drug|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
79255239|NCT02101489|Other|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
79255240|NCT03283215|Diagnostic Test|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
79255241|NCT02105077|Drug|Anesthesia with inhalative application of xenon gas|
79255242|NCT03288831|Dietary Supplement|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
79255243|NCT03288831|Dietary Supplement|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
79255244|NCT03095924|Other|News items with spin|Interpretation of news items with spin
79255245|NCT03095924|Other|News items without spin|Interpretation of news items without spin
79551254|NCT05705037|Other|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
79551255|NCT05705037|Other|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
79551256|NCT05704998|Other|Physiotherapy|Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage
79551257|NCT05704972|Other|the operating room environment risk|in determining the risks they face in the operating room environment.
79551258|NCT05704959|Diagnostic Test|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
79551259|NCT05704894|Biological|Erythropoietin|Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between <12g/dL
79715174|NCT05117099|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
79715175|NCT05112640|Device|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
79715176|NCT05112640|Device|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
79715177|NCT05085834|Drug|Zinc Gluconate|Two 45 mg capsules once daily
79255246|NCT02101567|Drug|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
79715178|NCT05085834|Drug|Placebo|Two placebo capsules once daily
79715179|NCT05081596|Behavioral|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
79255247|NCT02101567|Drug|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
79715180|NCT05066113|Device|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
79715181|NCT05046873|Drug|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
80017661|NCT02112240|Other|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
79255248|NCT05061914|Procedure|pericardial effusion drainage|tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
79394940|NCT03827499|Dietary Supplement|HMB dietary supplementation|Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
79394941|NCT03827499|Other|Multicomponent physical exercise program|Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
79394942|NCT02358720|Radiation|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
79394943|NCT02358720|Radiation|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
79394944|NCT03824847|Drug|Clarithromycin 250 MG|Clarithromycin 1 tablet (250mg) twice daily for three days
79394945|NCT03824847|Drug|Placebos|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
79394946|NCT01554163|Drug|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
79255249|NCT02101645|Procedure|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
79255250|NCT02101645|Procedure|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
79394947|NCT01554163|Drug|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
79394948|NCT02360826|Drug|Pravastatin|
79551260|NCT05704881|Diagnostic Test|End-Tidal CO2 measurement during COPD exacerbation|The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.
79551261|NCT05704842|Behavioral|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
79551262|NCT05704816|Other|Spinal anesthesia application|The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
79551263|NCT05704790|Other|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
79551264|NCT05704777|Behavioral|Exercise|A 24-weeks concurrent exercise training program
79551265|NCT05704777|Other|Control|Usual care
79715182|NCT05046873|Drug|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
79715183|NCT05046873|Drug|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
79852536|NCT01011777|Drug|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
79852537|NCT00740987|Device|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
79255251|NCT03108105|Device|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
79394949|NCT02360826|Drug|Simvastatin|
79394950|NCT02361060|Drug|Neostigmine|40mcg/kg
79551266|NCT05704699|Behavioral|eTRE|eating between 0800h and 1600h daily
79255252|NCT05036954|Device|EyeBrid Excel hybrid lenses|new lenses
79551267|NCT05704699|Behavioral|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
79551268|NCT05704686|Device|Isopure 1.2.3 intraocular EDOF lens implantation|Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.
79551269|NCT05704660|Behavioral|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
79715184|NCT05046873|Drug|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
79715185|NCT05038982|Drug|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
79715186|NCT04992650|Procedure|Fat grafting|Fat grafting
79255253|NCT03294603|Drug|CC-220|1mg [14C]-CC-220 will be administered as a single dose
79255254|NCT03294603|Radiation|[14C]|Single dose of [14C]-CC-220 will contain approximately 1.4 μCi of radioactivity
79394951|NCT02361060|Drug|Sugammadex|4mg/kg
79394952|NCT02361060|Drug|Atropine|10 mcg/kg
79394953|NCT04099927|Drug|SHR0410|SHR0410 monotherapy,given intravenously
79394954|NCT02360904|Other|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
79394955|NCT01792479|Drug|BIND-014|
79394956|NCT02352792|Radiation|radiochemotherapy with 70 Gy|
79394957|NCT02352792|Radiation|radiochemotherapy with 77 Gy|
79394958|NCT02360982|Behavioral|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
79715187|NCT04983966|Drug|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
79715188|NCT04983966|Drug|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
79715189|NCT04983797|Device|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
79715190|NCT04980872|Drug|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
79715191|NCT04972942|Drug|Daratumumab|"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~Induction: DARA IV weekly x 8 doses (Weeks 1-8)~Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~Maintenance: DARA every 4 weeks (Stop at Day +270)"
79715192|NCT04953897|Drug|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
79715193|NCT04935775|Other|Untrained Touch|Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
79715194|NCT04917406|Drug|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
79715195|NCT04917406|Device|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
80017662|NCT02112240|Procedure|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
80017663|NCT02112240|Radiation|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
80017664|NCT03455842|Biological|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
79255255|NCT02101723|Dietary Supplement|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
79394959|NCT02360982|Behavioral|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
80017665|NCT03455842|Biological|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
80017666|NCT03455842|Drug|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
80017667|NCT02979249|Drug|Oral Iron|for one year
79394960|NCT03153774|Diagnostic Test|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
79255256|NCT02101723|Dietary Supplement|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
79255257|NCT02101723|Dietary Supplement|Placebo|Placebo powder without micronutrients
79255258|NCT05061836|Drug|Ringer acetate|Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
79551270|NCT05704660|Behavioral|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
79551271|NCT05704608|Other|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
79255259|NCT05061836|Drug|1.25%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
79255260|NCT05061836|Drug|2.5%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
79255261|NCT05061836|Drug|Dextrose 5|5%dextrose in normal saline (5%DNSS) infused with maintenance rate
79255262|NCT02106871|Drug|Sildenafil|50mg of Sildenafil daily for 4 weeks
79255263|NCT04488783|Dietary Supplement|zinc and ascorbate|oral zinc and ascorbate
79394961|NCT02360748|Dietary Supplement|Plant based high protein food items|Patients will add high protein plant based food items to their diet
79551272|NCT05704348|Procedure|Sleeve gastrectomy with gastropexy|Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
79394962|NCT01553851|Drug|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
79394963|NCT02360670|Other|control imaging|
79394964|NCT02360670|Other|additional multimodal imaging|
79551273|NCT05704348|Procedure|Sleeve gastrectomy without gastropexy|Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
79551274|NCT05704270|Behavioral|Multi-domain adaptive cognitive training|The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.
79551275|NCT05704270|Behavioral|Basic cognitive training with no difficulty change|The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
79551276|NCT05704231|Behavioral|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
79715196|NCT04916639|Device|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~Nasal wash four times every day~These washes are to be carried out in each nostril~By continuously pressing the spray for 3 seconds in each nostril~Subjects are recommended to distribute the 4 nasal washes as follows:~1st : morning~2nd : midday~3rd : afternoon~4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
79551277|NCT05704218|Biological|blood sample|the patient will have a blood sample in order to perform serology tests
79715197|NCT04916249|Drug|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
79715198|NCT04916249|Other|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
79715199|NCT04908215|Drug|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
79715200|NCT04908215|Drug|Vehicle Cream|topical cream base for dermal application containing no active agent
79852538|NCT04064645|Device|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
79852539|NCT00736307|Procedure|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
79852540|NCT00504075|Biological|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
79852541|NCT00741065|Procedure|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
80017668|NCT05404438|Other|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
80017669|NCT02112396|Behavioral|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
79255264|NCT05036564|Procedure|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
79394965|NCT00355797|Device|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
79551281|NCT05704140|Other|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
79551282|NCT05704127|Other|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
79581055|NCT01932190|Procedure|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
80017670|NCT02114658|Drug|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
80017671|NCT05126602|Dietary Supplement|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
80017672|NCT05126602|Dietary Supplement|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
80017673|NCT02114736|Procedure|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
80017674|NCT02114736|Drug|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
80017675|NCT02109276|Device|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
80017676|NCT02109276|Device|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
79255265|NCT02251015|Procedure|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
79394966|NCT00355797|Device|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
79715201|NCT04867785|Drug|LY3437943|Administered SC
79255266|NCT02251015|Procedure|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
79255267|NCT04371471|Diagnostic Test|STC-19 score|Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
79394967|NCT00355797|Device|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
79581056|NCT01932203|Drug|aspirin|100mg once a day
79581057|NCT01932203|Drug|cilostazol|200mg once a day
79715202|NCT04867785|Drug|Dulaglutide|Administered SC
79581058|NCT01932216|Procedure|Cholecystectomy|Gallbladder removal
79581059|NCT01932229|Drug|Afatinib treatment|
79581060|NCT01932255|Procedure|prophylactic spinal tap|
79581061|NCT01932255|Procedure|no prophylactic spinal tap|
79581062|NCT01932268|Drug|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
79581063|NCT01932281|Dietary Supplement|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
79715203|NCT04867785|Drug|Placebo|Administered SC
79715204|NCT04867317|Drug|Somatropin|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
80017677|NCT04689373|Diagnostic Test|VAS Score|"The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain.~The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills."
80017678|NCT02114970|Other|Randomized- paper consent|
80017679|NCT02114970|Other|Randomized- Tablet-delivered consent|
80017680|NCT02114970|Other|Focus Group- paper and tablet consent|
80017681|NCT05126368|Other|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
80017682|NCT02251392|Other|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
80017683|NCT02251392|Other|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
80017684|NCT02251392|Drug|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
80017685|NCT05126212|Other|User experience|User experience is assessed by validated scale
80017686|NCT02112474|Device|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
80017687|NCT02112474|Device|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
80017688|NCT02112474|Device|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
80017689|NCT02112552|Drug|Paclitaxel|Given IV
80017690|NCT02112552|Drug|Carboplatin|Given IP
80017691|NCT02112552|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
80017692|NCT02112552|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
80017693|NCT02112552|Other|Quality-of-Life Assessment|Ancillary studies
80017694|NCT02112552|Other|Laboratory Biomarker Analysis|Correlative studies
80017695|NCT02976519|Drug|BI 443651|twice daily
80017696|NCT02976519|Drug|Placebo|twice daily
79551283|NCT05704127|Other|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
80017697|NCT05124028|Drug|Orelabrutinib|50mg po qd 6 weeks
79551284|NCT05704114|Drug|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
79551285|NCT05704088|Drug|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
79551286|NCT05704088|Drug|placebo|randomized control trial, control group will receive placebo tablets
79551287|NCT05704075|Procedure|Transverse Tibial Transport (TTT)|Transverse tibial transport is a novel adaptation of concepts used in distraction histogenesis. The most common use of this surgical principle is in bone lengthening surgery, which is a well-established surgical procedure by applying an external fixator to the bone, creating a corticotomy, and gradually lengthening the bone at the optimal rate of 0.5mm/12hrs. The biological mechanisms of distraction histogenesis involve activating signalling pathways such as cytokines Interleukin 1 and Interleukin 6, pro-inflammatory markers TNF alpha, pro-osteogenic TGF-beta, BMPs and pro-angiogenic factors VEGF and angiopoietin . TTT utilises the concept of distraction histiogenesis, but distraction is performed in the transverse plane instead of a longitudinal distraction. In addition, the period of distraction is coupled with a corresponding compression period and ultimately results in no net change in limb length.
79551288|NCT05704075|Procedure|Conventional|Dressing + Negative Pressure Wound Therapy
79551289|NCT05704023|Behavioral|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
79551290|NCT05703997|Dietary Supplement|Cyclic, 5-day calorie restriction|Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
79715205|NCT04867317|Other|Placebo|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
79852542|NCT00503997|Drug|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
80017698|NCT02109354|Biological|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of >1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
79394968|NCT02358174|Procedure|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
79394969|NCT02358174|Other|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
79394970|NCT02358174|Other|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
79394971|NCT02358018|Drug|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately ~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
79551291|NCT05703997|Drug|Atezolizumab|Atezolizumab 1200 mg administered intravenously.
79551292|NCT05703984|Drug|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
79551293|NCT05703984|Drug|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
79551294|NCT05703984|Drug|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
79551295|NCT05703984|Drug|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
79581064|NCT01932281|Dietary Supplement|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
80017699|NCT02109354|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
80017700|NCT02109354|Biological|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
80017701|NCT02109354|Biological|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
80017702|NCT02109354|Biological|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
80017703|NCT02109354|Biological|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
80017704|NCT02109354|Biological|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
80017705|NCT02109354|Biological|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
79551296|NCT05703932|Other|home-based exercises|Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
79715206|NCT04853550|Device|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
80017706|NCT04412746|Drug|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
79255268|NCT05041244|Device|Negative pressure wound therapy delivered through VAC|Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)
79255269|NCT05041244|Device|Standard of care|"Participants in the control arm will have their dressings changed as per the current standard of care.~Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated."
79255270|NCT02251093|Drug|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
79255271|NCT02251093|Drug|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
79255272|NCT03288597|Radiation|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
79255273|NCT03288597|Radiation|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
79394972|NCT02359344|Drug|CNV1014802|
79255274|NCT05040854|Genetic|HLA-DQA1*05 and DRB1|All patients will be asked to give blood samples to search for HLA-DQA1*05 and DRB1
79394973|NCT02359344|Drug|Placebo|
79394974|NCT03842163|Diagnostic Test|Diagnosis of TTR amyloidosis cardiomyopathy|Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
79394975|NCT02357862|Procedure|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
79394976|NCT02357628|Device|Wound treatment with RO-NPT|
79394977|NCT02357628|Device|Wound Irrigation|
79394978|NCT01552915|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
79394979|NCT01552915|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
79394980|NCT01552915|Drug|Placebo|Daily oral dosing in the AM for 8 weeks
79394981|NCT03112512|Device|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
79551297|NCT05703906|Behavioral|Telerehabilitation - VRRS Khymeia|Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
79551298|NCT05703893|Diagnostic Test|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
79551299|NCT05703802|Diagnostic Test|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
79551300|NCT05703789|Procedure|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
79551301|NCT05703789|Other|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
79715207|NCT04850573|Other|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
79715208|NCT04829110|Other|ETOH|Participants will consume Vodka
79715209|NCT04829110|Other|Sucrose|Participants will consume sucrose in solution with water
79715210|NCT04812912|Diagnostic Test|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
79715211|NCT04812912|Behavioral|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
80017707|NCT04565353|Behavioral|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
79715212|NCT04806958|Other|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
79255275|NCT02407990|Biological|BGB-A317|In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
79852543|NCT00503997|Drug|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
79852544|NCT00741143|Other|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
79551302|NCT05703776|Behavioral|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
79852545|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
79852546|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
79715213|NCT04774224|Drug|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
79715214|NCT04774224|Drug|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
79852547|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
79852548|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
79852549|NCT01011855|Device|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
79852550|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
79852551|NCT04063319|Other|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
79852552|NCT00736463|Drug|Simvastatin|One arm of randomized crossover
79255276|NCT02407990|Biological|BGB-A317|Participants were assigned to different groups based on their tumor types
79852553|NCT00736463|Drug|Atorvastatin 80 mg|Second arm of randomized crossover
79852554|NCT00736541|Drug|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
79255277|NCT02105155|Drug|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
79255278|NCT02105155|Drug|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
79255279|NCT03294525|Drug|Escitalopram Pill|escitalopram 10~20mg/day
79255280|NCT03294525|Drug|Duloxetine|duloxetine 30~120mg/day
79255281|NCT03294525|Drug|Mirtazapine Pill|Mirtazapine 15~45mg/day
79255282|NCT03294525|Drug|Other Antidepressants|
79255283|NCT05040620|Drug|Olive Oil Topical Oil|the effect of olive oil local application in decreasing orthodontic alighment phase
79255284|NCT02106949|Device|SMS contact with patient after discharge in intervention group|
79394982|NCT03112512|Device|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
79394983|NCT03112122|Biological|autologous bone marrow concentrate|injection of autologous bone marrow concentrate
79581065|NCT01932307|Procedure|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
79715215|NCT04761302|Other|Use of non-steroid anti-inflammatory drugs (NSAIDS) as an alternative for post-operative pain management after a femur and tibia fracture|This is a randomized controlled, single blind, parallel groups, opioid control trial of all patients (total of 150 patients) who suffered tibial and femoral shaft fractures and were treated with intramedullary nailing. Patients will be aleatory assigned to two study groups: Group-1 will receive non-opioid medications, and Group-2 will receive opioid medications. During the inpatient postoperative period, patients will undergo subjective evaluation of pain utilizing a previously validated questionnaire, the Visual Analogue Score (VAS). The first questionnaire will be completed twelve hours after surgery and during subsequent twelve-hour intervals until discharge. Secondary outcomes will include efficiency such as time to gastrointestinal motility, time to weight bearing of affected limb, resumption of ambulation, and length of hospital stay. The evaluation will take approximately 15 minutes to complete each time, we the entire participation time to be 60 minutes.
79715216|NCT04717557|Drug|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
79394984|NCT03112122|Biological|bone substitute i-FactorTM|subchondral injections of i-FactorTM
79394985|NCT03112122|Procedure|core decompression|subchondral anterograde drilling
79715217|NCT04702373|Other|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
79715218|NCT04695717|Biological|IVACFLU-S|"The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019)."
79715219|NCT04691375|Drug|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
79394986|NCT02360514|Drug|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
79394987|NCT03027505|Drug|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC <125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~MUAC <115 mm: 175 kcal /kg/day~115 <MUAC <120mm: 125kcal/kg/day~120 <MUAC <125mm: 75kcal/kg/day"
79394988|NCT02352714|Drug|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
79715220|NCT04691375|Drug|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
79394989|NCT02352714|Drug|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
79715221|NCT04687033|Device|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
79715222|NCT04630158|Other|SAF312 Placebo|Topical ocular, suspension eye drops,
79715223|NCT04630158|Drug|SAF312|Topical ocular, suspension eye drops
79715224|NCT04618185|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
79715225|NCT04549025|Drug|JTX-4014|Specified dose on specified days
79715226|NCT04549025|Drug|Vopratelimab|Specified dose on specified days
79715227|NCT04541004|Biological|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
79715228|NCT04513041|Procedure|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
79715229|NCT04478240|Behavioral|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
79715230|NCT04466917|Drug|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
79715231|NCT04466917|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
79715232|NCT04466917|Drug|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
79715233|NCT04466917|Drug|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
79715237|NCT04444076|Device|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
79715238|NCT04432493|Device|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
79715239|NCT04432493|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
79852555|NCT00096265|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
79715240|NCT04422730|Behavioral|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
79715241|NCT04370483|Drug|Leflunomide|Gievn PO
79715242|NCT04370483|Other|Quality-of-Life Assessment|Ancillary studies
79715243|NCT04283656|Drug|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
79394990|NCT03027583|Dietary Supplement|Probiotic|6 weeks daily oral intake of a probiotic strain.
79551303|NCT05703698|Behavioral|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
79715244|NCT04283656|Drug|Spironolactone 100mg|200mg orally for two doses, twice-daily
79852556|NCT00096265|Drug|Erlotinib Hydrochloride|Given orally
79852557|NCT00096265|Radiation|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
79852558|NCT00096265|Drug|Temozolomide|Given orally
79394991|NCT03027583|Dietary Supplement|Placebo|6 weeks daily oral intake of placebo.
79551304|NCT05703620|Device|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
79551305|NCT05703594|Diagnostic Test|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
79551306|NCT05703581|Procedure|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
79715245|NCT04283656|Drug|Estradiol 2mg|4mg orally for two doses, twice-daily
79715246|NCT04283656|Other|Placebo|Placebo for one dose, daily
79852559|NCT01082809|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
79852560|NCT01078987|Procedure|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
79852561|NCT01080469|Drug|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
79852562|NCT01079065|Drug|Famotidine|Tablets
79852563|NCT01079221|Behavioral|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at < 90 % of peak power, 3 days/week for 6 weeks
79852564|NCT00711191|Biological|monoclonal antibody|CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
79852565|NCT00711191|Drug|chemotherapy|gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
79852566|NCT00741221|Drug|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
79394992|NCT03911557|Drug|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
79394993|NCT02357550|Drug|ketone|3-OHB is infused intravenously.
79394994|NCT02357550|Drug|placebo|Saline infusion.
79394995|NCT00356031|Drug|Bevacizumab|Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
79715247|NCT04274374|Dietary Supplement|Gluten-Free Diet|Dietary supplement without gluten
79715248|NCT04274374|Dietary Supplement|Gluten Diet|Dietary supplement with gluten
79715249|NCT04270630|Behavioral|Shared Decision Aid|The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
79715250|NCT04238624|Drug|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
79715251|NCT04238624|Drug|Trametinib|Participants will receive trametinib 2 mg orally once a day
79852567|NCT00741221|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
79551308|NCT05703529|Behavioral|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
79551309|NCT05703529|Other|Usual Care|Usual Care means treating as usual, including a regular home visit.
79551310|NCT05703451|Other|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
79852568|NCT00736619|Other|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
79852569|NCT04557761|Device|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
80017708|NCT02975973|Device|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
79551311|NCT05703321|Behavioral|preoperative fasting|Fasting for 6 hours is required for the patients regarding the preparation of the operation and preparation for anesthesia
80017709|NCT02109510|Drug|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
79551312|NCT05703308|Biological|Autologous Menstrual Blood Stem Cells|The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
79551313|NCT05703295|Procedure|Biopsy|Sentinel lymph node biopsy
79551314|NCT05702320|Other|the heating procedure|The patients will undergo a heating procedure.
79551315|NCT05702190|Drug|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
79551316|NCT05702190|Drug|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
79551317|NCT05701124|Drug|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
79551318|NCT05700071|Diagnostic Test|MRI|MRI without contrast agent
79715252|NCT04233385|Other|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
80017710|NCT02109510|Drug|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
80017711|NCT02109510|Procedure|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
79394996|NCT00356031|Radiation|Radiation Therapy|External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
79394997|NCT00356031|Procedure|Surgery|Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
79394998|NCT03028441|Other|Placebo|Placebo
79394999|NCT03028441|Biological|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
79395000|NCT02352636|Other|magnetotherapy|The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
79255285|NCT03294447|Behavioral|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
79255286|NCT05036174|Drug|Diphenhydramine 5%|Diphenhydramine 5% ointment
79255287|NCT05036174|Drug|Placebo|Placebo matched to diphenhydramine 5% ointment
79395001|NCT02352636|Device|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
79395002|NCT02352636|Other|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
79395003|NCT02038842|Biological|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
79395004|NCT02038842|Biological|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
79395005|NCT02038842|Biological|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
79395006|NCT01790139|Drug|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
79395007|NCT05266599|Other|MTA Fillapex root canal sealer|Root canal treatments were performed with MTA Fillapex
79395008|NCT05266599|Other|AH Plus root canal sealer|Root canal treatments were performed with AH plus
79395009|NCT02360592|Drug|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
79395010|NCT02360592|Drug|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
79395011|NCT02360592|Drug|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
79395012|NCT02360592|Drug|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
79395013|NCT00321321|Drug|Sulfonylurea|
79395014|NCT02360202|Procedure|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
79395015|NCT02360202|Drug|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
79395016|NCT00322101|Radiation|total-body irradiation|Radiation
79395017|NCT00322101|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
79551319|NCT05699889|Other|Data collection|acute kidney injury and tubular dysfunction
79551320|NCT05696015|Behavioral|Standard education|Without telehealth education, this group has only postdischarge education.
79551321|NCT05696015|Behavioral|Ampiled Education|With telehealth education, in addition of discharge education.
79715253|NCT04233385|Other|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
79715254|NCT04219709|Other|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
79715255|NCT04219709|Other|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
79715256|NCT04200391|Other|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
79551322|NCT05692037|Combination Product|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres|Yttrium-90 carbon microspheres SIRT
79852570|NCT04557761|Device|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
79852571|NCT00741377|Drug|BHQ880|
79852572|NCT00741377|Drug|Zoledronic acid|
79852573|NCT02567903|Device|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
79852574|NCT02567903|Procedure|Knee arthroscopy|Knee arthroscopy
79715257|NCT04114422|Other|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
79715258|NCT04106414|Drug|Nivolumab|Nivolumab 480 mg every 4 weeks.
80017712|NCT02109588|Behavioral|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
79255288|NCT02107027|Device|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
79255289|NCT02107027|Device|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
79715259|NCT04106414|Drug|BMS- 986205|BMS-986205 100 mg every 4 weeks.
79715260|NCT04091646|Drug|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
80017713|NCT05404126|Other|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
79255290|NCT05235087|Device|Bovine atelocollagen intradermal injection|Intradermal skin test injection
79255291|NCT04469426|Other|Interactive online informational and peer support app|The app contains LARS information, bowel function diaries, and online platform with trained peer support mentor
79255292|NCT02101801|Other|vegetables from fresh or recycled water|
79715261|NCT04091646|Drug|Vehicle foam|Vehicle foam for topical application.
79715262|NCT04090957|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
79715263|NCT04090957|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
79715264|NCT04086550|Device|LIQOSEAL|Adjunctive bioresorbable patch
79715265|NCT04086550|Device|DuraSeal, Adherus|synthetic absorbable sealants
79715266|NCT04081298|Behavioral|Health Education|Attend nutrition and PA classes, and cooking sessions
79715267|NCT04081298|Other|Physical Activity|Participate in physical activities
79255293|NCT02101801|Other|receives vegetables from fresh water or recycled waste water farms|
79255294|NCT03283059|Drug|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
79255295|NCT03283059|Drug|Aricept|Aricept 5mg/day, P.O.
79255296|NCT03283059|Drug|Placebos|Placebo Tablet: P.O. tid
79255297|NCT05060900|Procedure|Ligament Reconstruction with Allograft Ligament|Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
79715268|NCT04081298|Other|Health Promotion and Education: Text Messages|Receive motivational text messages
79715269|NCT04081298|Other|Health Promotion and Education: Web Site|Given access to nutrition website
79715270|NCT04081298|Other|Quality-of-Life Assessment|Ancillary studies
79715271|NCT04081298|Other|Questionnaire Administration|Ancillary studies
79715272|NCT04063267|Device|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
79715273|NCT04063267|Other|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
79715274|NCT04063241|Other|Health Literacy-Informed Discharge Instructions|Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
79715275|NCT04063241|Other|Provider Training|20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
79852575|NCT00706511|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
79852576|NCT00448864|Drug|Ecallantide|
79852577|NCT00448864|Drug|Placebo|
79852578|NCT00567398|Drug|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
79852579|NCT00567398|Drug|Physioneal|Physioneal 40 or Physioneal 35
79852580|NCT00567398|Drug|Extraneal|Extraneal - 7.5% Icodextrin
79852581|NCT00567398|Drug|Nutrineal|Nutrineal - 1.1% Amino Acids
79852582|NCT02538848|Drug|HTD4010|injectable solution
79255298|NCT02105233|Biological|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
79551323|NCT05673291|Other|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p<0.05.
79551324|NCT05627453|Other|Arm-in-arm gait training|An older adult walk side-by-side, arm-in-arm with a younger adult while synchronizing steps.
79551325|NCT05627453|Other|Normal gait training|An older adult walk side-by-side, without contact, with a younger adult without step synchronization.
79715276|NCT04053335|Behavioral|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
79715277|NCT04051541|Other|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
79715278|NCT04047914|Device|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
79715279|NCT04047914|Drug|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
79255299|NCT03288441|Drug|Hold|Hold antithrombotic therapy
79255300|NCT03288441|Drug|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
79255301|NCT03288441|Drug|Change antithrombotic Drug|Change in type of antithrombotic therapy
79715280|NCT04042753|Drug|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
79715281|NCT04042753|Drug|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
79255302|NCT03288441|Biological|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
79255303|NCT03288441|Drug|Full dose antithrombotics|Continue full dose antithrombotic therapy
79255304|NCT03288441|Device|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
79255305|NCT03288441|Drug|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
79715282|NCT04042753|Drug|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
79395018|NCT00322101|Drug|cyclophosphamide|Given IV
79395019|NCT00322101|Drug|mycophenolate mofetil|Given orally
79395020|NCT00322101|Drug|busulfan|Given IV or orally
79395021|NCT00322101|Drug|cyclosporine|Given IV or orally
79395022|NCT00322101|Drug|fludarabine phosphate|Given IV
79395023|NCT00322101|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
79395024|NCT00322101|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
79395025|NCT00322101|Other|laboratory biomarker analysis|Correlative studies
79715283|NCT04040933|Device|Marketed Adhesive Bandage #1|On the randomized wound site, a marketed adhesive bandage will be applied.
79715284|NCT04040933|Device|Marketed Bandage #2|On the randomized wound site, a marketed adhesive bandage will be applied.
79715285|NCT04040933|Device|Non-Marketed Bandage #1|On the randomized wound site, a non-marketed adhesive bandage will be applied.
79715286|NCT04040933|Device|Non-Marketed Bandage #2|On the randomized wound site, a non-marketed adhesive bandage will be applied.
79715287|NCT04040933|Device|Non-Marketed Adhesive Bandage #3|On the randomized wound site, a non-marketed adhesive bandage will be applied.
79715288|NCT04040933|Device|Non-Marketed Adhesive Bandage #4|On the randomized wound site, a non-marketed adhesive bandage will be applied.
79715289|NCT04040933|Device|Non-Marketed Adhesive Bandage #5|On the randomized wound site, a non-marketed adhesive bandage will be applied.
79715290|NCT04030338|Drug|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
79715291|NCT04030338|Drug|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
79852583|NCT00448708|Device|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm^2 paclitaxel
79852584|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
79852585|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
79852586|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
79395026|NCT00322101|Genetic|cytogenetic analysis|Correlative studies
79395027|NCT00322101|Other|flow cytometry|Correlative studies
79395028|NCT00322101|Genetic|fluorescence in situ hybridization|Correlative studies
79395029|NCT00322101|Other|pharmacological study|Correlative studies
79395030|NCT00322101|Genetic|polymorphism analysis|Correlative studies
79551326|NCT05612529|Device|US , Echocardiography|"Carotid ultrasonography: Parameters will be measured by single blinded independent examiner using an ultrasound device. Baseline carotid FTc, ΔVpeak, will be measured.~Echocardiography: Stroke Volume will be measured by transthoracic echocardiography.~Renal and splenic Doppler resistivity index.~Inferior vena cava collapsibility and distensibility indices.~Central venous pressure estimation by central venous catheter, and central - Lung ultrasound for detection of lung congestion~Lung ultrasound for detection of lung congestion."
79551327|NCT05610254|Drug|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
79551328|NCT05593107|Drug|[68Ga]N188|68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
79551329|NCT05584709|Biological|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
79551330|NCT05576441|Procedure|volume stable collagen matrix|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
79551331|NCT05576441|Procedure|subepithelial connective tissue graft|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
79715292|NCT04030338|Diagnostic Test|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
79715293|NCT04026490|Behavioral|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
79715294|NCT04026490|Behavioral|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
79715295|NCT04026477|Behavioral|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
79852587|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
79852588|NCT00929552|Dietary Supplement|Dietary oils (fish, vegetable oil)|6g pr day.
79852589|NCT00924872|Other|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
79852590|NCT00925028|Drug|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
79852591|NCT00925028|Drug|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
79852592|NCT00905138|Drug|GLPG0259|single ascending doses, oral solution
79852593|NCT00905138|Drug|placebo|single dose, oral solution
79852594|NCT00905138|Drug|GLPG0259|multiple dose, oral solution, 5 days
79852595|NCT00905138|Drug|placebo|oral solution, 5 days
79852596|NCT00905216|Drug|heparin sodium - Bergamo|5.000 UI/mL
79852597|NCT00905216|Drug|heparin sodium - APP|5.000 USP
79852598|NCT00929630|Procedure|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
79852599|NCT00929630|Procedure|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
79852600|NCT00929630|Procedure|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
79395031|NCT00322101|Drug|tacrolimus|Given IV or orally
79395032|NCT00322101|Drug|methotrexate|Given IV
79395033|NCT02360046|Drug|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
79395034|NCT02360046|Drug|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
79395035|NCT02352480|Device|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
79395036|NCT01552681|Biological|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
79852601|NCT00929630|Procedure|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
80017714|NCT04470895|Diagnostic Test|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
79255306|NCT05060588|Drug|Sacubitril/Valsartan 49/51mg/Tab|patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
79852602|NCT00905294|Other|Blood draws|Observational: blood draws only
80017715|NCT03553368|Diagnostic Test|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
80017716|NCT03553368|Diagnostic Test|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
79255307|NCT05060588|Drug|Valsartan 80mg/Tab|Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
79395037|NCT01552681|Other|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
79551332|NCT05568030|Behavioral|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
79551333|NCT05568030|Behavioral|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
79715296|NCT04026477|Behavioral|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
79852603|NCT00925106|Drug|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
80017717|NCT03553368|Diagnostic Test|MR|MRI data will be acquired without the use of any device as a reference.
80017718|NCT03553368|Diagnostic Test|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
80017719|NCT03553368|Diagnostic Test|CPAP-MR|MRI data will be acquired with the use of CPAP.
80017720|NCT02818972|Device|RelayPro|Endovascular treatment with investigational device.
79551334|NCT05506098|Other|no intervention|no intervention
79551335|NCT05504486|Drug|Brexpiprazole|Oral tablet; take once daily; target daily dose of 2 mg
79551336|NCT05502835|Device|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
79551337|NCT05502835|Other|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
79852604|NCT00925106|Drug|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
80017721|NCT04466995|Device|manometer|cuff pressure to be measured with manometer
80017722|NCT02115126|Biological|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be > 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be > 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
79255308|NCT03554863|Device|Nasal High Flow Oxygen|Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
79255309|NCT03554863|Device|Facial Mask|Preoxygenation with facial mask
79255310|NCT02101957|Drug|RP103|
79255311|NCT02101957|Drug|Placebo|
79255312|NCT02107183|Device|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
79255313|NCT02107183|Device|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
79395038|NCT02360358|Drug|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
79395039|NCT02360358|Other|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
79715297|NCT04024956|Device|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
79395040|NCT05266443|Dietary Supplement|Lactobacillus containing cultured milk drink|Each bottle of 125ml cultured milk drink contains a billion colony forming unit (CFU) Lactobacillus acidophillus (LA-5) and Lactobacillus paracasei (L. CASEI-01). Each patient will be given 2 bottles to consume daily for a period of 12 weeks.
79395041|NCT05266443|Dietary Supplement|Placebo cultured milk drink|The placebo prepared was identical to the probiotic-containing product in terms of color, taste and packaging. However, there is no trace of live microorganism in this product.
79395042|NCT02352402|Drug|Ticagrelor|
79715298|NCT03995355|Device|9618X investigational lipid eye drops|Test Eye Drops
79715299|NCT03995355|Device|Blink® Tears|Control Eye Drops
79715300|NCT03995212|Drug|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
79852605|NCT00925106|Drug|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
79852606|NCT00925106|Drug|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
79852607|NCT02538692|Drug|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
79852608|NCT02538692|Drug|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
79852609|NCT00706355|Drug|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
79852610|NCT00905528|Drug|Telmisartan 80 mg/d|
79852611|NCT00905528|Drug|Ramipril 10 mg/d|
79715301|NCT03995212|Drug|Placebo|Oral Placebo administered twice daily
79715302|NCT03946618|Device|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
79715303|NCT03942211|Drug|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
79715304|NCT03942211|Drug|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
79852612|NCT00925262|Behavioral|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
79852613|NCT00925262|Behavioral|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
79255314|NCT03294369|Other|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
79551338|NCT05479630|Other|Transition With a Heart (TWAH)|TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
79852614|NCT00925262|Behavioral|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
79852615|NCT04063553|Other|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
79852616|NCT04063553|Other|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
79852617|NCT00925340|Behavioral|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
79852618|NCT00925340|Behavioral|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
79852619|NCT00736697|Drug|moxidectin|
79852620|NCT00929942|Device|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
79255315|NCT02105311|Device|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
79255316|NCT02105311|Drug|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
79255317|NCT05062850|Other|observation|Our study does not involve an intervention. Chronic diseases and geriatric syndromes of the participants will be studied.
79395043|NCT02352402|Drug|Placebo|
79395044|NCT02357472|Drug|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
79395045|NCT00322335|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
79551339|NCT05476939|Drug|Everolimus|Tablets of 2.5 mg or 10mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10mg once daily.
79551340|NCT05476939|Drug|ONC201|Capsules of 125mg. 375mg/m2 per dose, day 1 and day 2 of each week. Dose will be capped at 625mg per dose.
79715305|NCT03933397|Other|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
79715306|NCT03933397|Other|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
79715307|NCT03933397|Drug|Morphine|4 mg for participants weighing <50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
79715308|NCT03933397|Drug|Hydromorphone|1 mg for participants weighing <60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
79715309|NCT03925090|Drug|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
79852621|NCT00711113|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
79852622|NCT02568995|Drug|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
79255318|NCT05035550|Behavioral|Non-Deceptive Placebo|"The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening."
79255319|NCT03294291|Procedure|Quadratus lumborum block|Postoperative pain procedure
79395046|NCT00322335|Biological|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
79852623|NCT03784898|Other|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
79852624|NCT00930020|Drug|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
79395047|NCT00322335|Biological|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
79852625|NCT00930020|Drug|Matched placebo|matched placebo (cornstarch) once a day for 5 days
79852626|NCT00710879|Device|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
79852627|NCT00930098|Drug|clofarabine|
80017723|NCT02115126|Biological|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
79852628|NCT00905684|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
79852629|NCT00905684|Drug|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
79852630|NCT00736775|Drug|anti-Abeta|Intravenous single and multiple doses
79852631|NCT00736775|Drug|placebo|Intravenous single and multiple doses
79852632|NCT00925418|Procedure|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
79852633|NCT05742191|Other|Daylight Savings time transitions|Daylight Savings time transitions.
79852634|NCT03979274|Drug|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
79852635|NCT03979274|Drug|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
80017724|NCT03627793|Other|resistance training|Moving muscles against loads with the purpose of increasing strength.
80017725|NCT02109666|Drug|Abatacept|
80017726|NCT03208855|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
79852636|NCT00930254|Procedure|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
79852637|NCT00905762|Drug|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
79852638|NCT00905762|Drug|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
79852639|NCT00905762|Drug|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
79852640|NCT02568137|Behavioral|Smart-phone based technology|
79852641|NCT02568059|Drug|Sahastara remedy alcoholic extract|comparison of different dose of drug
79715310|NCT03925090|Drug|Cisplatin+placebo|chemotherapy
80017727|NCT03167281|Combination Product|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
79395048|NCT00322335|Biological|Engerix-B|Intramuscular injection into the thigh as a birth dose
79395049|NCT00322335|Biological|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
79395050|NCT00322335|Biological|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
79255320|NCT03294291|Procedure|Caudal block|Postoperative pain procedure
79395051|NCT00322335|Biological|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
79715311|NCT03919266|Procedure|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
79852642|NCT00459316|Biological|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
79852643|NCT00925574|Drug|CNTO 1959; Placebo|
79852644|NCT02568839|Drug|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
79852645|NCT02568839|Drug|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
80017728|NCT02760004|Behavioral|PRogram In Support of Moms (PRISM)|"PRogram In Support of Moms Toolkit with Stepped Care Algorithms~Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~Customization of depression screening for each practice~Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~Employ psychoeducation and Motivational Interviewing to engage patients with depression~medical assistant champion and psychiatrist contact bi-weekly to review cases~Stepped care treatment to depression screening/assessment"
80017729|NCT02760004|Behavioral|Enhanced Usual Care group (Access to MCPAP for Moms)|"30-60 minute presentation on perinatal depression~Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~Access to assessment and treatment protocols in Provider Toolkit~Resource provision/referrals"
79395052|NCT02352324|Other|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
79581066|NCT01932320|Drug|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
79715312|NCT03919266|Procedure|Control: usual antibiotic treatment|usual antibiotic treatment
79715313|NCT03913273|Procedure|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
79715314|NCT03913273|Procedure|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
79715315|NCT03899753|Device|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
79715316|NCT03899753|Device|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
79715317|NCT03896672|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
79715318|NCT03829436|Drug|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
79852646|NCT00930410|Procedure|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
79852647|NCT02538770|Other|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
80017730|NCT02109900|Other|Serum Progesterone Levels|
80017731|NCT04408417|Device|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
80017732|NCT04408417|Device|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
79255321|NCT05040074|Device|SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System|Transesophageal echocardiography-guided, implantable mitral valve clip repair system
80017733|NCT02112630|Drug|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
80017734|NCT02112630|Drug|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
79255322|NCT05039762|Procedure|Extracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
79395053|NCT05265897|Other|CAQ|Informational document
79395054|NCT03153852|Drug|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
79715319|NCT03829436|Drug|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
79715320|NCT03829436|Drug|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
79715321|NCT03829436|Drug|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
79852648|NCT02538770|Other|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
79852649|NCT05742035|Procedure|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
80017735|NCT02112630|Drug|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
79715322|NCT03827187|Other|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
79551341|NCT05476939|Radiation|Radiotherapy|"All patients will be treated with 30 conventional single daily fraction of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start ideally within three weeks (MAXIMUM four weeks) after the biopsy or last surgery. Radiotherapy should be planned as soon as the biopsy date is known (between 10 and 21/28 days after the planned date of biopsy).~Treatments will start on the first day of irradiation (+3 days max). Reirradiation is permitted according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within three weeks (4 weeks maximum) after the biopsy while targeted treatment will start at the end of the irradiation."
79581067|NCT01932320|Drug|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
79715323|NCT03825965|Drug|MPL-001 (CBD: THC 25:1)|25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
79715324|NCT03825965|Drug|Placebo oil for oral use|Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
79715325|NCT03790488|Drug|JTX-4014|Specified dose on specified days
79715326|NCT03788434|Drug|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.
79715327|NCT03788434|Drug|Placebo|Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
79715328|NCT03767257|Drug|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
79715329|NCT03758261|Drug|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
79852650|NCT06140875|Device|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
79852651|NCT06140862|Other|calf muscle strengthening and streching|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
80017736|NCT02112630|Drug|Boceprevir|800 mg PO three times daily starting at week 4
79395055|NCT03153852|Drug|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
79395056|NCT03153852|Drug|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
79395057|NCT04751253|Device|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
79395058|NCT04751097|Other|CUSH Health Digital platform|Remote mobility monitoring and physiotherapy video app
79395059|NCT04320030|Drug|[18F]-DPA-714 PET/CT scan|Pretherapeutic [18F]-DPA-714 PET/CT scan
79395060|NCT04750863|Other|diagnosis criteria performance|
79395061|NCT02359734|Other|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
79395062|NCT04751019|Device|Amber Glasses|It is hoped that the use of amber glasses to complement the natural sleep-wake by inducing a perceived 'physiological darkness' to aid the secretion of melatonin should help sleep and reduce the use of hypnotic medication
79395063|NCT02359656|Procedure|surgical treatment|C1-C1 arthrodesis
79395064|NCT02359656|Other|non operative treatment for odontoid non unions|specific non operative treatment protocol
79395065|NCT01792557|Drug|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
79395066|NCT01792557|Procedure|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
79395067|NCT01792557|Procedure|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
79852652|NCT06140849|Diagnostic Test|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
79852653|NCT06140797|Combination Product|Pre-operative risk assessment combined with targeted intervention|Preoperative risk assessment and targeted intervention provided by multidisciplinary team
79852654|NCT06140784|Drug|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79255323|NCT05039762|Procedure|Intracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
79852655|NCT06140784|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79852656|NCT06140784|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79551342|NCT05465057|Behavioral|High intensity interval training (HIIT) + lifestyle intervention (TCOCT)|"The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks."
79715330|NCT03758261|Drug|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
79852657|NCT06140784|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79852658|NCT06140771|Drug|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79852659|NCT06140771|Drug|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79255324|NCT02102035|Procedure|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
79255325|NCT03294057|Behavioral|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
79255326|NCT03294057|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
79255327|NCT03294057|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
79255328|NCT02105389|Behavioral|Individualized Yoga Intervention|
79255329|NCT02459925|Behavioral|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
79395068|NCT01792557|Procedure|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
79852660|NCT06140771|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79852661|NCT06140771|Drug|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
79255330|NCT02459925|Behavioral|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
79255331|NCT03095534|Behavioral|3-Step Workout for Life|a 10-week moderate exercise program
79255332|NCT03554395|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
79395069|NCT02352246|Procedure|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
79395070|NCT02352246|Procedure|Physical activity programs high intensity intermittent exercise (HIIE)|
79395071|NCT01792713|Drug|Sertaconazole 2% cream|
79395072|NCT01792713|Drug|Placebo|
79395073|NCT03666507|Procedure|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
79551343|NCT05465057|Behavioral|Lifestyle intervention (TCOCT)|The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
79852662|NCT06140758|Drug|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
79852663|NCT06140758|Drug|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
79852664|NCT06140758|Drug|Toms of Maine 0 ppm Fluoride Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
79852665|NCT06140758|Drug|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
79852666|NCT06140758|Drug|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
79852667|NCT06140758|Drug|1100 ppm (0.454% Stannous fluoride) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
79852668|NCT06140745|Drug|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
79715331|NCT03713268|Device|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
79715332|NCT03710928|Other|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
79852669|NCT06140745|Drug|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
79395074|NCT02352168|Drug|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
79551344|NCT05458232|Drug|Tadalafil 5mg|Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
79715333|NCT03710928|Other|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
79551345|NCT05447598|Other|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
79852670|NCT06140745|Drug|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
79395075|NCT02352168|Drug|Placebo|1 putt/nostril,b.i.d
79715334|NCT03689634|Device|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
79715335|NCT03672019|Behavioral|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
79395076|NCT01792791|Procedure|Tissue sample collection at the time of surgery|"Spanning surgery~A blood sample (32.5 ml)~joint aspirate (removal of synovial fluid) from both knees~urine sample~ORIF surgery~Joint aspirate (removal of synovial fluid) from both knees~A blood sample (32.5 ml)~Urine Sample~If patients only require one surgery, sample will be collected only once."
79395077|NCT03154008|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
79852671|NCT06140745|Drug|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
79852672|NCT06140745|Drug|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
79852673|NCT06140732|Drug|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
79852674|NCT06140706|Behavioral|transcutaneous Spinal Cord Stimulation (tSCS)|Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
79852675|NCT06140680|Behavioral|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University & Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
79255333|NCT03554395|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
79852676|NCT06140680|Behavioral|Physical education|The control group received 12-week traditional physical education lesson as usual.
80017737|NCT02654470|Device|Watchman FLX|Patients who are receiving the Watchman FLX device
80017738|NCT04873375|Drug|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
79255334|NCT03282825|Drug|Decitabine|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
79255335|NCT03282825|Drug|Paclitaxel|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
79255336|NCT02105623|Behavioral|Standard Therapy|Risk factor control Diet Exercise for 24months
79255337|NCT02105623|Drug|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
79255338|NCT03293979|Diagnostic Test|Test A i Flu A&B implemented in emergency service|Test A i Flu A&B implemented in emergency service
79551346|NCT05447598|Other|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
79715336|NCT03668977|Dietary Supplement|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
79715337|NCT03642327|Behavioral|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
79715338|NCT03642327|Other|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
79715339|NCT03624881|Device|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
79715340|NCT03594487|Drug|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
79715341|NCT03594487|Procedure|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
79852677|NCT06140654|Diagnostic Test|Clinical oral examination|Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
80017739|NCT02112708|Other|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
80017740|NCT02112708|Other|Control Group usual care|In the control group the depression is treated as usual with the conventional treatment.
80017741|NCT05125666|Other|Dual Task Training (Motor + Cognitive)|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.
79551347|NCT05412693|Device|Functional orthosis|See arm descriptions
79255339|NCT05026190|Diagnostic Test|transrectal ultrasound|we perform trus to identify the cause of azospermia and its type either obstructive or not
79255340|NCT02107417|Device|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
79395078|NCT02359578|Drug|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
79395079|NCT00323193|Behavioral|MOVE!|group based psychoeducation, motivation and support
79551348|NCT05412693|Device|Cast immobilization|See arm descriptions
79551349|NCT05404594|Behavioral|Maternal vocal contact|"Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture."
79395080|NCT02359422|Behavioral|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
79395081|NCT02357160|Behavioral|Artwork|Prints by local artists that are hung on the walls of patient rooms.
79395082|NCT02357004|Drug|Carvedilol|CR 40 mg daily in addition to normal BP medications
79395083|NCT02357004|Drug|Chlorthalidone|12.5 mg daily in addition to normal BP medications
79551350|NCT05389124|Behavioral|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
79551351|NCT05383274|Combination Product|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
79551352|NCT05382702|Other|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
79551353|NCT05364840|Drug|STI-1558|Orally available protease inhibitor capsule
79551354|NCT05364840|Drug|Placebo|Placebo product capsule
79715342|NCT03594487|Other|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
79715343|NCT03588975|Biological|MACI|autologous cultured chondrocytes on porcine collagen membrane
79715344|NCT03588975|Procedure|microfracture|Arthroscopic microfracture treatment
79715345|NCT03576690|Biological|REGN3470-3471-3479|
79715346|NCT03573947|Drug|Nivolumab|360 mg intravenously every 3 weeks
79715347|NCT03573947|Drug|Ipilimumab|1 mg/kg intravenously over 30 minutes
79715348|NCT03573947|Drug|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
79715349|NCT03569449|Behavioral|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
79715350|NCT03569449|Behavioral|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
79715351|NCT03569449|Behavioral|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
79852678|NCT06140654|Diagnostic Test|Food behavior|"Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons."
79852679|NCT06140641|Dietary Supplement|Probiotics|Bifidobacterium Longum BL21 or placebo for 8 weeks.
79852680|NCT06140589|Drug|Cadonilimab|The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
79852681|NCT06140576|Drug|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
79852682|NCT06140576|Drug|Nab-paclitaxel|Nab-paclitaxel，125mg/m^2, d1,8, every three weeks
79852683|NCT06140576|Drug|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
79852684|NCT06140550|Device|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
80017742|NCT05125666|Other|Traditional Regular Exercise|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
79255341|NCT02107417|Device|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
79551355|NCT05341622|Behavioral|Differentiated Box|Patients will receive mailed FIT kits in a box with differentiated packaging
80017743|NCT02112786|Device|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
80017744|NCT05125588|Drug|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
80017745|NCT05125588|Drug|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
79255342|NCT05039918|Behavioral|Affective touch|Gentle stroking at CT-optimal speed
79852685|NCT06140550|Device|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
79852686|NCT06140524|Drug|Linvoseltamab|Administration by intravenous (IV) infusion
79852687|NCT06140498|Behavioral|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
79852688|NCT06140498|Behavioral|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
80017746|NCT02115204|Drug|Epirubicin|
79551356|NCT05341622|Behavioral|Standard Mail|Patients will receive mailed FIT in a standard mailing envelope
79551357|NCT05341622|Behavioral|Text|Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
79852689|NCT06140472|Behavioral|Phoenix|Specific individualized nurse follow-up using the PHOENIX application.
79255343|NCT05039606|Drug|Nedaplatin|Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
79551358|NCT05341622|Behavioral|No Text|Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
79551359|NCT05341622|Behavioral|Reminder|Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
79852690|NCT06140472|Behavioral|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
80017747|NCT02115204|Drug|Cyclophosphamide|
79551360|NCT05341622|Behavioral|No Reminder|Patients will not receive any mailed letter reminder to complete their FIT kit.
79551361|NCT05324709|Behavioral|Yoga Based Stress Management Program|Yoga-based stress management program is applied to the intervention group.
79715352|NCT03569449|Behavioral|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
79715353|NCT03569449|Behavioral|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
79715354|NCT03569449|Behavioral|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
80017748|NCT02115204|Drug|Docetaxel|
79551362|NCT05319964|Behavioral|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes 30% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
79551363|NCT05319964|Behavioral|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
80017749|NCT02115204|Drug|Methotrexate|
80017750|NCT02115204|Drug|5-fluorouracil|
79551364|NCT05319964|Behavioral|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
79551365|NCT05288413|Device|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
79551366|NCT05273879|Procedure|decompression|laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.
79551367|NCT05273879|Procedure|fusion|First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
79551368|NCT05271799|Drug|Gepotidacin|Gepotidacin will be administered
79551369|NCT05261841|Other|Standard care for T2D patients, Smartwatch|No intervention, observational study
79551370|NCT05253417|Drug|50 mg Cannabidiol (CBD)|For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
79551371|NCT05253417|Drug|Placebo|Participants take four (4) placebo capsules.
79551372|NCT05253417|Drug|100 mg Cannabidiol (CBD)|For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
79551373|NCT05250570|Behavioral|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
79551374|NCT05250570|Behavioral|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
79551375|NCT05204030|Other|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
79551376|NCT05204030|Other|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
79551377|NCT05200416|Device|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
79715355|NCT03569449|Behavioral|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
79852691|NCT06140433|Device|VSC-MEDlib|VSC-MEDlib will be used for post-processing
80017751|NCT02115360|Drug|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
79255344|NCT05039606|Drug|Cisplatin|Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
79255345|NCT03288129|Drug|Perampanel|film-coated tablets
79255346|NCT05039372|Behavioral|TRAINING AND CONSULTANCY|TRAINING AND CONSULTANCY
79255347|NCT02107495|Device|Samsung LABGEO IVD-A20 CHF Test|
79395084|NCT02352012|Other|Autologous blood|Autologous blood was perfused to the target pulmonary segment
79395085|NCT02352012|Device|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
79255348|NCT05039294|Behavioral|School-Based Physical Activity Educational Program|The structure of the educational sessions includes physical education lectures, group discussions, videos, training sessions, physical activities diaries, short quizzes, and feedback after each session. The educational programs were conducted among students with intervention groups at two-level individually and in school. The individual-level includes classroom lectures that mainly emphasized the health benefits of physical activity and provided necessary information about physical activity fitness for 60 minutes and were given weekly for four weeks. In coordination with the school sports teacher, training sessions included moderate to vigorous physical activities for 45 minutes twice weekly for four weeks
79715356|NCT03569449|Behavioral|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
79715357|NCT03557697|Behavioral|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
79715358|NCT03557697|Behavioral|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
79551378|NCT05200416|Device|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
79255349|NCT03555253|Behavioral|Resilience-Based Program for Support Partners of PwMS|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
79715359|NCT03532880|Drug|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
79715360|NCT03532880|Drug|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
79715361|NCT03532880|Drug|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
79395086|NCT03152838|Genetic|DNA methylation and Real-time Polymerase Chain Reaction Analysis|"Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes."
79852692|NCT06140381|Procedure|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
79852693|NCT06140381|Procedure|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
79852694|NCT06140368|Behavioral|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
79852695|NCT06138093|Device|Sealing device|Intratracheal tracheostomy sealing
79551380|NCT05184582|Behavioral|Physical training|Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
79551381|NCT05085470|Biological|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
79551382|NCT05085470|Biological|Placebo mock infection|Placebo mock infection with water
79581068|NCT01932320|Drug|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
79852696|NCT06138093|Device|No device|Open tracheostomy wound
79852697|NCT06138080|Diagnostic Test|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
80017752|NCT02115360|Drug|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
79255350|NCT03288051|Other|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
79255351|NCT03288051|Drug|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
79255352|NCT03288051|Drug|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
79395087|NCT03152838|Diagnostic Test|Gilliam Autism Rating Scale Arabic version|"An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt."
79395088|NCT02356848|Behavioral|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
79395089|NCT02356848|Behavioral|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
79551383|NCT05071846|Other|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
79551384|NCT05060133|Procedure|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
79551385|NCT05037188|Biological|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
79715362|NCT03532880|Drug|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
79852698|NCT06138041|Drug|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
79852699|NCT06138041|Drug|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
79852700|NCT06138028|Drug|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
79852701|NCT06138015|Behavioral|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
79852702|NCT06138015|Behavioral|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
79852703|NCT06137989|Procedure|Fill-Up Class ӀӀ restoration|Bulk-fill technique
79852704|NCT06137989|Procedure|QuiXfil Class ӀӀ restoration|Bulk-fill technique
80017753|NCT01362322|Biological|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
80017754|NCT01362322|Biological|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
80017755|NCT02112942|Drug|IDX21459|
80017756|NCT02112942|Drug|Matching Placebo|
79395090|NCT02356536|Device|Agilitas|WCD trial
79395091|NCT02356770|Device|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
79551386|NCT05037188|Biological|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
79551387|NCT05037188|Biological|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
79551388|NCT05037188|Other|Placebo injection|Placebo injection
79581069|NCT01932320|Drug|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
80017757|NCT02113020|Drug|TAK-233|Oral administration of TAK-233
80017758|NCT02113020|Drug|Placebo|Oral admininstration of Placebo
80017759|NCT03553290|Device|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
80017760|NCT03553290|Procedure|Control|Mechanical debridement alone
80017761|NCT02432404|Drug|NuvaRing|
79551389|NCT05032365|Device|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
79551390|NCT05032365|Device|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
79551391|NCT05030506|Drug|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
79551392|NCT05030506|Biological|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
80017762|NCT02115516|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
79255353|NCT05035472|Drug|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to < 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
79551393|NCT05030506|Drug|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
79715363|NCT03532880|Drug|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
79715364|NCT03532880|Drug|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
79852705|NCT06137989|Procedure|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
80017763|NCT02115516|Biological|0.9% Sodium Chloride (Placebo)|
79255354|NCT05035472|Drug|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
79551394|NCT05008328|Other|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
79551395|NCT05008328|Procedure|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
79551396|NCT04989517|Drug|AT193|Topical
79715365|NCT03532880|Radiation|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
79715366|NCT03531957|Drug|ASN002|Daily dose of ASN002 for 12 weeks
79715367|NCT03531957|Drug|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
79715368|NCT03531255|Drug|Pegcetacoplan|Complement (C3) Inhibitor
79852706|NCT06137950|Drug|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
79852707|NCT06137950|Drug|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
79852708|NCT06137937|Behavioral|Aerobic Exercise|Intradialytic aerobic exercise for eight weeks
79852709|NCT06137924|Drug|Local anesthetic injection Bupivacaine plus dexamethasone|The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.
79852710|NCT06137924|Drug|Local anesthetic injection bupivacainde plus dexamethasone plus a colloid|bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.
79852711|NCT06137924|Drug|Local anesthetic injection bupivacaine plus clonidine|bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
79852712|NCT06137898|Biological|biological check-up|Blood sampling
80017764|NCT02192788|Radiation|Stereotactic Body Radiation Therapy for Oligometastases|
80017765|NCT02113098|Other|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
80017766|NCT02113098|Other|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
80017767|NCT02113176|Drug|Minocycline|
79715369|NCT03473795|Behavioral|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
79715370|NCT03473795|Other|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
79715371|NCT03450824|Other|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
79852713|NCT06137885|Behavioral|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
79255355|NCT02105779|Other|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
79852714|NCT06137885|Other|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
79255356|NCT02105779|Other|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
79852715|NCT06137885|Other|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
79852716|NCT06137885|Other|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
79255357|NCT02460471|Radiation|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
79255358|NCT05035238|Biological|Triple dose vaccination by inactivated Covid19 vaccine|triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
79255359|NCT03282747|Behavioral|no intervention|no intervention
79715372|NCT03446079|Other|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
79551397|NCT04955379|Device|EQ103|Ophthalmic Refractometer with a measurement and background channel
79715373|NCT03435042|Behavioral|Self care + Hypnosis group|Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
79551398|NCT04911621|Biological|Dendritic cell vaccination + temozolomide-based chemoradiation|"Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
79715374|NCT03428997|Device|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
79551399|NCT04911621|Biological|Dendritic cell vaccination +- conventional next-line treatment|"Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~(Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
79715375|NCT03428997|Other|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
79715376|NCT03313999|Device|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
79715377|NCT03252431|Drug|F-627|single dose pre-filled syringe
79852717|NCT06137859|Behavioral|Weekly-based functional fitness training|Participants will receive a 12-week duration of functional fitness training in daycare centers, which will be implemented twice a week. The 60-minute per session training series will be delivered and guided by qualified elderly health and fitness instructors, who will be provided with a workshop before this intervention. The workshop will be designed and delivered by the research team. The first session will focus on the physical literacy of older adults and the second session will focus on how to lead functional fitness training under the FITT principle for older adults. The main goal of functional training is to improve the range of joint motion, increase muscle strength and flexibility, and boost blood circulation safely. Therefore, symmetry training together with cardiovascular training is the core of the training program. Examples of the main training activities include cardio-full-body exercises, upper-body exercises, lower-body exercises and sensory integrative training.
79852718|NCT06137859|Behavioral|Mastering Physical Literacy Class|"A 30-minute MPLC program will be conducted by experienced elderly health and fitness instructors after WBFFT. This MPLC program aims to enhance the knowledge and understanding of physical literacy. Referring to the newly developed consensus statement, the MPLC includes the following five domains related to the relationship with movement and physical activity throughout life:~i) Why physical literacy matters - improves health, well-being and quality of life.~ii) Understanding physical literacy - value, enjoy and engage in physical activity for life.~iii) Everyone's physical literacy is different - their individual needs and experiences of movement and physical activity.~iv) Building physical literacy - think, feel, move and connect with others. v) How experience affects physical literacy - people, places and spaces around us."
79852719|NCT06137859|Behavioral|Daily based reflective writing|At the end of the baseline stage of this study, each participant of the intervention group will receive a template notebook for daily-based reflective writing. The required columns consist of the daily diet, physical activity, mood and sleep quality. Participants will be required to write down their behavior in this notebook daily. In each week's functional training course, there will be a life-sharing session, where the participants will be reminded to bring their notebooks and share their daily activities with others. They will receive feedback, advice and encouragement from the instructor and each other. The notebook will be collected during the last week of the intervention.
79852720|NCT06137859|Behavioral|Buddy Peers Support Group|Peer-support groups with buddy members will be arranged in each daycare center. Three pairs of buddies and hence about 6 participants will be formed per group. A total of 6 buddy pairs and 2 groups will be formed per daycare center. Buddy peers will encourage each other to do functional exercises regularly or to perform functional exercises together. The time and place for the practice will be decided among buddy members. A member in each group will be nominated as the leader to assist in the liaison and coordination of group activities. The group will perform weekly group-based functional exercises, and the time and place for the practice will be decided among group members. The group will be encouraged to hold monthly gatherings with their fitness instructor in order to strengthen social support.
79852721|NCT06137833|Dietary Supplement|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
79852722|NCT06137833|Other|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
79852723|NCT06137820|Device|Cetilar® (topical cream)|Topical cream twice daily for 30 days. An average amount of 5 g per day.
79852724|NCT06137820|Device|Cetilar Placebo|Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
79852725|NCT06137807|Device|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve implantation system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
80017768|NCT01831570|Other|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
79715378|NCT03252431|Drug|Neulasta|single dose pre-filled syringe
79715379|NCT03234595|Drug|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
79255360|NCT02105857|Other|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
79715380|NCT03216486|Drug|BPS804|IV administration of BPS804 in 5% Dextrose solution
80017769|NCT02113254|Other|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
79255361|NCT03287973|Behavioral|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
79395092|NCT02356770|Procedure|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
79551400|NCT04900428|Biological|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
79551401|NCT04900428|Drug|Placebo|Diluent solution
79551402|NCT04873492|Other|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
79551403|NCT04852172|Drug|L-citrulline|L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
79551404|NCT04852172|Other|D5 1/2NS|Saline
79551405|NCT04818580|Procedure|Progressive Tension Sutures|In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
79551406|NCT04804215|Procedure|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
79551407|NCT04804215|Procedure|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
79551408|NCT04802707|Combination Product|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 730. Doses was chosen according to the safety and efficacy doses used in the literature.
79551409|NCT04781127|Device|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
79551410|NCT04764643|Drug|N-acetylcysteine solution|use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
79551411|NCT04764643|Drug|sodium thiosulfate solution|use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
79551412|NCT04657705|Procedure|High power ablation|High power ablation parameters (50-55 W)
79551413|NCT04657705|Procedure|Standard ablation power|Standard ablation power parameters (40-45 W)
80017770|NCT01755208|Procedure|light-scattering spectroscopy|Undergo light-scattering spectroscopy
79255362|NCT03287973|Device|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
79255363|NCT05026892|Other|no intervention|no intervention, only collection of data
79395093|NCT01570387|Drug|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
79395094|NCT01570387|Drug|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
79551414|NCT04610047|Drug|Norketotifen|Oral capsule
79551415|NCT04610047|Drug|Placebo|Oral capsule
79715381|NCT03207945|Drug|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
79715382|NCT03207945|Other|Placebo|Placebo
79551416|NCT04563234|Behavioral|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
79852726|NCT06137807|Procedure|Medical Therapy Arm|"Subjects will be randomized and managed on standard of care therapy, per physician discretion.~*Ability to cross-over after 18-Month Follow-Up completed"
80017771|NCT02118870|Drug|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
79551417|NCT04563234|Behavioral|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
79551418|NCT04558892|Drug|Enoxaparin|
79551419|NCT04558476|Biological|Convalescent Plasma|2 units of convalescent plasma
79551420|NCT04558476|Other|Standard of Care|Gold Standards
79551421|NCT04506359|Other|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
79551422|NCT04449276|Biological|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
79551423|NCT04449276|Drug|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
80017772|NCT02118870|Drug|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
79715383|NCT03149757|Behavioral|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
79255364|NCT04488939|Device|Restylane® Skinboosters™ Vital (SBV)|Hyaluronic acid
79715384|NCT03149757|Behavioral|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
79715385|NCT03134703|Drug|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
79715386|NCT03134703|Drug|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
79551424|NCT04391894|Drug|ECF843|Topical ocular eye drop
79852727|NCT06137794|Other|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
79852728|NCT06137781|Behavioral|Six weeks of digital prehabilitation|All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
79852729|NCT06137768|Drug|HRS-5965|HRS-5965
79852730|NCT06137768|Drug|Placebo|Placebo.
79852731|NCT06137729|Drug|PF-07899895|Participants will receive oral ascending doses.
79852732|NCT06137729|Drug|Placebo|Participants will receive matching placebo.
79551425|NCT04391894|Other|ECF843 vehicle|Topical ocular eye drop
79551426|NCT04288830|Behavioral|Tai Chi Moving Mindfulness Meditation and Resilience Training|Low-impact mind-body exercise adapted from traditional tai chi.
79551427|NCT04288830|Behavioral|Aerobic Exercise|Low-impact aerobic exercise, led by instructor
79551428|NCT04288271|Behavioral|Adherence Intervention|"Intervention:~Adherence Support Team (patient, parent or a significant other, Coach)~Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
79715387|NCT03126851|Other|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
79715388|NCT03118674|Drug|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
79715389|NCT03085056|Drug|Trametinib|trametinib orally 2mg daily during each 4 week cycle
79715390|NCT03085056|Drug|Paclitaxel|paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks
79715391|NCT03069352|Drug|Placebo|tablet
79715392|NCT03069352|Drug|Venetoclax|tablet
79715393|NCT03069352|Drug|Cytarabine|Subcutaneous injection
79715394|NCT03037437|Drug|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
79715395|NCT03037437|Drug|Hydroxychloroquine (HCQ)|400mg by mouth daily
79852733|NCT06137716|Device|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
79255365|NCT05034380|Behavioral|Acute exercise|All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
79255366|NCT02102191|Device|e-cigarette|smoking cigarette without tobacco
79395095|NCT03147846|Procedure|delayed cord clamping|delay of cord clamping for 60 seconds
79395096|NCT03147846|Procedure|cord milking|active cord milking 5 times
79255367|NCT02102191|Device|cigarette|smoking cigarette with tobacco
79395097|NCT03147456|Dietary Supplement|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
79395098|NCT03147456|Dietary Supplement|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
79395099|NCT02348424|Drug|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
79852734|NCT06137703|Drug|Zavegepant 100mg non-enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
79255368|NCT03287895|Behavioral|Decision Support|A two-part intervention to help patients make better decisions about CPR
79255369|NCT03287739|Behavioral|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
79395100|NCT01570309|Drug|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
79852735|NCT06137703|Drug|Zavegepant 100mg immediate release tablet|Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
79852736|NCT06137703|Drug|Zavegepant 2 x 100mg immediate release tablets|2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
79255370|NCT05033834|Other|covid-19 vaccines registered in Egypt|Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine
79551429|NCT04288271|Other|Healthy living education intervention|"Intervention:~Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
79551430|NCT04260282|Diagnostic Test|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
79715396|NCT03036488|Biological|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
79551431|NCT04260282|Diagnostic Test|Induced sputum microbiome|Microbiome in induced sputum
79551432|NCT04233788|Device|MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)|The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
79551433|NCT04225533|Drug|SP16|All patients will receive a single dose of SP16
79551434|NCT04202705|Drug|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
79551435|NCT04077515|Drug|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
79551436|NCT04077515|Drug|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
79551437|NCT04026711|Drug|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
79551438|NCT04026711|Drug|Placebo oral tablet|Placebo daily for 12 weeks
79852737|NCT06137703|Drug|Zavegepant 4 x 25mg enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
79852738|NCT06137677|Other|Sweet Snack|A sweet food will be served for the snack
79395101|NCT01570309|Other|Sugar pill|Oral capsule, once a week, 12 weeks
79551439|NCT04022616|Other|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
79551440|NCT04021589|Drug|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
79551441|NCT04021589|Drug|Chemotherapy|chemotherapy
79715397|NCT03036488|Drug|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
79852739|NCT06137677|Other|Savory Snack|A savory food will be served for the snack
79395102|NCT03147300|Behavioral|Current routine practice|Current routine practice for the primary care management of LBP
79395103|NCT03147300|Behavioral|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:~Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
79715398|NCT03036488|Drug|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
79715399|NCT03036488|Drug|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
79715400|NCT03036488|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
79715401|NCT03036488|Drug|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
79715402|NCT03036488|Drug|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
79852740|NCT06137664|Biological|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10^6.0, or high-dose (HD) 10^6.5 CCID₅₀/dose
79852741|NCT06137664|Biological|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10^5.3 and HD 10^5.6 CCID₅₀/dose.
79852742|NCT06137664|Biological|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10^6.0, or HD 10^6.5 CCID₅₀/dose.
79852743|NCT06137664|Biological|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10^6.0 infective units of type 1 and 10^5.8 of type 3.
79852744|NCT06137651|Procedure|Biospecimen Collection|Undergo collection of blood samples
79852745|NCT06137651|Procedure|Computed Tomography|Undergo CT scan
79852746|NCT06137651|Procedure|Magnetic Resonance Imaging|Undergo MRI
79852747|NCT06137651|Radiation|Radiation Therapy|Undergo radiation therapy
79852748|NCT06137651|Procedure|Resection|Undergo surgery
79852749|NCT06137651|Drug|Trotabresib|Given PO
79255371|NCT03554239|Genetic|genotyping|Blood sample
79255372|NCT03095690|Other|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
79255373|NCT02460627|Drug|Lidocaine adhesive tape|700 mg for 12 hours
79255374|NCT02460627|Other|Adhesive tape|For 12 hours
79255375|NCT02107729|Procedure|Large needle gauge lidocaine injection|21 G
79255376|NCT02107729|Procedure|Normal needle gauge lidocaine injection|23 G
79715403|NCT03036488|Biological|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
79715404|NCT03033927|Diagnostic Test|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
79852750|NCT06137651|Drug|Vinorelbine|Given IV
79715405|NCT03006315|Device|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
79852751|NCT06137625|Behavioral|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
79715406|NCT03006315|Behavioral|Mobile Health quality of life assessements|
79852752|NCT06137625|Behavioral|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
79852753|NCT06137612|Diagnostic Test|MRI|axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
79852754|NCT06137599|Other|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
79852755|NCT06137573|Drug|[14C]TNP-2198|600mg suspension containing 150μCi of [14C] TNP-2198
79852756|NCT06137547|Device|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
79852757|NCT06137521|Procedure|Coronary angiography|
79852758|NCT06137456|Device|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
79852759|NCT06137456|Other|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
79852760|NCT06137443|Device|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
79852761|NCT06137430|Drug|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
79255377|NCT02107729|Procedure|Small needle gauge lidocaine injection|27 G
79255378|NCT05038748|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
79395104|NCT03147534|Device|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
79395105|NCT03147534|Device|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
79852762|NCT06137417|Device|PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
79852763|NCT06137404|Other|Splint|Comparison of splints for trigger finger
79255379|NCT05038748|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
79395106|NCT03147534|Device|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
79395107|NCT03147534|Device|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
79395108|NCT02356224|Drug|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
79395109|NCT02356224|Drug|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
79395110|NCT02356146|Drug|Tacrolimus C12|
79395111|NCT01519921|Drug|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
79551443|NCT03959982|Device|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
79551444|NCT03959982|Diagnostic Test|Spirometry|Pre and post spirometry using albuterol.
79551445|NCT03959982|Diagnostic Test|6-minute walk|6-minute walk
79551446|NCT03959982|Diagnostic Test|CT scan|CT scan
79551447|NCT03959982|Other|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
79551448|NCT03959982|Other|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
79551449|NCT03959982|Other|COPD Assessment Test (CAT)|CAT questionnaire
79715407|NCT02993523|Drug|Azacitidine|Solution for subcutaneous or intravenous administration.
79715408|NCT02993523|Drug|Venetoclax|Tablet
79715409|NCT02993523|Drug|Placebo|Matching placebo tablet
79715410|NCT02989584|Drug|Atezolizumab|
79715411|NCT02989584|Drug|Gemcitabine|
79715412|NCT02989584|Drug|Cisplatin|
79551450|NCT03959982|Other|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
79715413|NCT02957058|Procedure|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
79715414|NCT02905617|Device|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
79715415|NCT02884219|Drug|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
79715416|NCT02884219|Other|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
79715417|NCT02884219|Drug|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
79715418|NCT02795429|Drug|Spartalizumab|Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
79715419|NCT02795429|Drug|Capmatinib|Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
79715420|NCT02792114|Drug|Cyclophosphamide|
79715421|NCT02792114|Biological|Mesothelin-targeted T cells|
79715422|NCT02792114|Drug|AP1903|
79551451|NCT03959982|Other|CASA-Q|CASA-Q questionnaire
79551452|NCT03959982|Other|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
79551453|NCT03958461|Procedure|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
79715423|NCT02783625|Drug|Romidepsin|
79715424|NCT02783625|Drug|Bortezomib|
79715425|NCT02783625|Drug|duvelisib|
79715427|NCT02632344|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
79852764|NCT06137352|Other|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
79255380|NCT03287661|Behavioral|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
79255381|NCT05038670|Device|Total Knee Replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
79255382|NCT03293823|Behavioral|VSOP training|a computerized cognitive training of attention and processing speed
79715429|NCT02605486|Drug|Palbociclib|
79551454|NCT03928808|Biological|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
79551455|NCT03926637|Other|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
79551456|NCT03922217|Device|Mindful My Way|Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
79551457|NCT03851705|Drug|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
79551458|NCT03851705|Drug|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
79715430|NCT02605486|Drug|Bicalutamide|
79715431|NCT02552186|Other|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
79715432|NCT02538198|Drug|Lenalidomide|
79715433|NCT02507141|Device|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
79715434|NCT02484287|Device|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
79715435|NCT02484287|Device|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
79715436|NCT02484287|Device|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
79715437|NCT02375841|Behavioral|psychometric tests, questionnaires and neurocognitive assessments|
79715438|NCT02341144|Procedure|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
79395112|NCT02039154|Behavioral|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
79551459|NCT03851705|Drug|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
79715439|NCT02341144|Procedure|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
79715440|NCT02341144|Drug|Ropivacaine|
79715441|NCT02213328|Drug|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
79715442|NCT02204241|Drug|Carfilzomib|
79715443|NCT02204241|Drug|Cyclophosphamide|
79715444|NCT02204241|Drug|Dexamethasone|
79715445|NCT02198729|Procedure|Endoscopic Submucosal Dissection|
79715446|NCT02198729|Procedure|Endoscopic Mucosal Resection|
80017773|NCT05125432|Device|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
80017774|NCT05123638|Device|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
79715447|NCT02185820|Drug|Carfilzomib|
79715448|NCT02185820|Drug|Pomalidomide|
79715449|NCT02185820|Drug|Dexamethasone|
79852765|NCT06137339|Other|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
80017775|NCT05123638|Behavioral|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
79255383|NCT03293823|Behavioral|MLA control|a computerized cognitive intervention of multiple mental leisure activities
79255384|NCT02102347|Other|exercise|
79255385|NCT02102347|Other|Phototherapy|
79551460|NCT03841110|Drug|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
79551461|NCT03841110|Drug|Nivolumab|Immune Checkpoint Inhibitor
79551462|NCT03841110|Drug|Pembrolizumab|Immune Checkpoint Inhibitor
79551463|NCT03841110|Drug|Atezolizumab|Immune Checkpoint Inhibitor
79551464|NCT03841110|Drug|Cyclophosphamide|Lympho-conditioning agent
79551465|NCT03841110|Drug|Fludarabine|Lympho-conditioning agent
79551466|NCT03841110|Drug|IL-2|Biologic response modifier
79551467|NCT03824366|Device|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
79551468|NCT03824366|Radiation|Radiation therapy|-Standard of care
79551469|NCT03810313|Drug|Brolucizumab 6 mg|Solution for injection (intravitreal use)
79715450|NCT02150967|Drug|BGJ398 (infigratinib)|Capsule for oral use
79715451|NCT02137603|Other|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
79715452|NCT02127398|Biological|fecal microbiota|fecal microbiota in capsule form
79715453|NCT02085408|Drug|Daunorubicin|Given IV
79715454|NCT02085408|Drug|Cytarabine|Given IV
79715455|NCT02085408|Drug|Clofarabine|Given IV
79715456|NCT02085408|Drug|Decitabine|Given IV
79715457|NCT02085408|Other|Observation|Undergo clinical observation
79715458|NCT02085408|Procedure|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
79715459|NCT02004782|Drug|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
79715460|NCT02004782|Drug|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
79715461|NCT01969786|Other|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
79715462|NCT01908777|Other|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
79715463|NCT01892397|Device|Optune (NovoTTF-100A)|
79715464|NCT01873326|Drug|Paclitaxel|
79715465|NCT01873326|Drug|Ifosfamide|
79715466|NCT01873326|Drug|Cisplatin|
79715467|NCT01873326|Drug|Mesna|
79715468|NCT01873326|Drug|Bleomycin|
79715469|NCT01873326|Drug|Etoposide|
79715470|NCT01862315|Drug|Floxuridine (FUDR)|
79715471|NCT01862315|Drug|dexamethasone|
79715472|NCT01862315|Drug|Gemcitabine|
79715473|NCT01862315|Drug|Oxaliplatin|
79715474|NCT01862315|Other|MRI|
79715475|NCT01862315|Other|Research blood draws|These are optional
80017776|NCT02118948|Behavioral|Abuse-focused intervention|
80017777|NCT02118948|Behavioral|Sexual behavior-focused intervention|
79551470|NCT03810313|Drug|Aflibercept 2 mg|Solution for injection (Intravitreal use)
79715476|NCT01854151|Other|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
79715477|NCT01806558|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
79715478|NCT01745588|Drug|Pomalidomide|
79715479|NCT01745588|Procedure|stem cell|
79715480|NCT01745588|Drug|Dexamethasone|
79715481|NCT01745588|Drug|Clarithromycin|
79715482|NCT01737567|Other|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
79715483|NCT01737567|Other|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
79715484|NCT01475786|Biological|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
79715485|NCT01475786|Biological|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
79255386|NCT05039060|Dietary Supplement|Modified MAC diet (3-weeks)|"Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis"
79551471|NCT03810313|Other|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
79551472|NCT03808389|Other|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
79581070|NCT01932333|Drug|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
79715486|NCT01475786|Other|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
79715487|NCT01372696|Other|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
79715488|NCT01369316|Procedure|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
79715489|NCT01369316|Procedure|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
79715490|NCT01368289|Procedure|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
79715491|NCT01290692|Biological|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
79715492|NCT00996866|Drug|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
79715493|NCT00996866|Drug|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
79715494|NCT00876993|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
79715495|NCT00876993|Drug|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
79715496|NCT00876993|Drug|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
79852766|NCT06137326|Device|Pulsed Electromagnetic Field Therapy|Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.
79255387|NCT03282513|Drug|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
79255388|NCT02106091|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
79255389|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
79255390|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
79255391|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
79255392|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
79255393|NCT01673282|Drug|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
79255394|NCT03554161|Biological|Tocilizumab (TCZ)|Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
79715497|NCT00700882|Drug|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
79255395|NCT05025254|Other|Neurocognitive testing|"We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided."
79255396|NCT02113735|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
79255397|NCT02113735|Drug|Placebo|
79255398|NCT02113813|Drug|naquotinib|oral
79255399|NCT02113813|Drug|midazolam|oral
79551473|NCT03808389|Other|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
79551474|NCT03802630|Drug|Brolucizumab 6 mg|Solution for injection (intravitreal use)
79715498|NCT00673309|Procedure|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
79255400|NCT03095144|Device|Spinal anesthesia|Pyloromyotomy under spinal anesthesia
79255401|NCT03095144|Device|General anesthesia|Pyloromyotomy under general anesthesia
79255402|NCT02109991|Device|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
79255403|NCT03095222|Drug|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
79255404|NCT03095222|Drug|Opioids|Standard of care for pain management.
79255405|NCT02113891|Drug|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
79255406|NCT03095378|Procedure|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
79255407|NCT03095378|Procedure|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
79255408|NCT03095378|Procedure|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
79255409|NCT02107885|Drug|DS-1971|6 subjects in each group will receive DS-1971.
79255410|NCT02107885|Drug|placebo|2 subjects in each group will receive placebo.
79255411|NCT05025566|Diagnostic Test|Cognitive (behavioural and neurophysiological) screening|"Cognitive disorders are attested at the behavioral level by the psychologist specialized in neuropsychology who makes the patient take a standardized battery of specific psychometric tests. This assessment thus makes it possible to obtain behavioral data such as reaction time, error rates and modeling parameters.~The electroencephalogram (EEG) consists of collecting the signal of the brain's bioelectrical activity by means of electrodes placed on the scalp. The EEG is used to determine the cerebral functioning underlying cognitive functions by performing it simultaneously with the behavioral tasks of the neuropsychological assessment, thus obtaining a neurophysiological phenotyping of cognitive disorders."
79255412|NCT02113969|Device|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
79395113|NCT02039154|Behavioral|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
79551475|NCT03802630|Drug|Aflibercept 2 mg|Solution for injection (Intravitreal use)
79551476|NCT03802630|Other|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
79551477|NCT03785691|Drug|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
79715499|NCT00673309|Drug|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
79715500|NCT00673309|Drug|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
79715501|NCT00673309|Drug|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
79715502|NCT00673309|Drug|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
79551478|NCT03785691|Drug|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
79551479|NCT03785691|Drug|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
79852767|NCT06137326|Device|Laser Acupuncture|Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
79255413|NCT03003247|Drug|IDP-120 Gel|IDP-120 Gel is a combination product
79255414|NCT03003247|Drug|IDP 120 Component A Gel|Monad of Component A
79255415|NCT03003247|Drug|IDP 120 Component B Gel|Monad of Component B
79395114|NCT02356380|Other|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
79395115|NCT01519765|Drug|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
79395116|NCT01519765|Drug|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
79395117|NCT03147066|Drug|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
79395118|NCT03147066|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
79395119|NCT02351622|Drug|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
79551480|NCT03775213|Behavioral|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
79551481|NCT03775213|Behavioral|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
79395120|NCT02351622|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
79551482|NCT03739450|Behavioral|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
79395121|NCT02351622|Drug|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
79581071|NCT01932333|Drug|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
79715503|NCT00673309|Drug|Insulin Low Dose|Insulin administered IV until 95% wound healing
79715504|NCT00673309|Drug|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
79715505|NCT00673309|Drug|Itraconazole|Itraconazole administered until 95% wound healing
79715506|NCT00673309|Drug|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
79715507|NCT00673309|Drug|Oxandrolone and Propranolol|Oxandrolone and Propranolol
79715508|NCT00673309|Drug|Placebo or Control|Administration of Placebo or Control until 95% wound healing
79715509|NCT00666835|Drug|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
79255416|NCT03003247|Drug|IDP 120 Vehicle Gel|Vehicle
79255417|NCT05038046|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
79255418|NCT05025098|Drug|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
79395122|NCT01552603|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
79395123|NCT02351466|Other|Observational|
79395124|NCT04824703|Drug|Oxygen|"Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1"
79255419|NCT05025098|Drug|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
79551483|NCT03739450|Behavioral|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
79551484|NCT03710564|Biological|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
79551485|NCT03710564|Biological|Aflibercept|2 mg/0.05mL solution for intravitreal injection
79551486|NCT03624127|Drug|BMS-986165|Specified dose on specified days
79551487|NCT03624127|Other|Placebo|Specified dose on specified days
79551488|NCT03624127|Drug|Apremilast|Specified dose on specified days
79551489|NCT03616912|Drug|Baricitinib|Administered orally.
79551490|NCT03616912|Drug|Placebo|Administered orally.
79551491|NCT03594253|Behavioral|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
79551492|NCT03499899|Drug|LAG525|LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
79551493|NCT03499899|Drug|PDR001|Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
79551494|NCT03499899|Drug|Carboplatin|Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
79551495|NCT03481634|Drug|Brolucizumab|Intravitreal injection
79551496|NCT03481634|Drug|Aflibercept|Intravitreal injection
79551497|NCT03430700|Drug|Pembrolizumab|Intravenous infusion
79255420|NCT02114125|Behavioral|Physical Activity|group-based physical activity
79551498|NCT03373461|Drug|LNP023|LNP023 5, 25, 100 mg capsles
79395125|NCT02348190|Other|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
79551499|NCT03373461|Other|Placebo|Matching placebo to LNP023
79551500|NCT03364751|Other|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
79551501|NCT03364751|Other|Cigarette|Patients will continue to smoke cigarettes ad libitum.
79551502|NCT03364127|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
79255421|NCT02114125|Behavioral|Cognitive Training|individual-based, multi-domains cognitive training
79395126|NCT02347956|Procedure|Reduced port robotic distal gastrectomy|
79551503|NCT03364127|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
79551504|NCT03251508|Drug|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
79551505|NCT03106454|Drug|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
79551506|NCT03106454|Drug|Norethindrone|Norethindrone 1.05mg
79551507|NCT03074617|Other|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
79551508|NCT03074617|Other|sham field|no electromagnetic field
79551509|NCT03045913|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
79551510|NCT02990806|Drug|NI-071|IV infusion.
79551511|NCT02990806|Drug|Remicade|IV infusion.
79551512|NCT02947048|Drug|L1-79|
79551513|NCT02947048|Drug|Placebo|
79581072|NCT01932333|Drug|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
79581073|NCT01932359|Other|rapidly absorbable suture (Vicryl Rapide)|
79715510|NCT00666835|Drug|ERYPO®, Janssen-Cilag|Solution for i.v. injection
79255422|NCT05024786|Other|continuous quality improvements|We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
79255423|NCT02114281|Other|Care|
79255424|NCT02114281|Other|Not care|
79255425|NCT05038202|Drug|Bencycloquidium Bromide Nasal Spray|"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."
79581074|NCT01932359|Other|non-absorbable suture (Ethilon)|
79581075|NCT01932372|Drug|Tofacitinib (Xeljanz)|5 mg Tablet BID
79581076|NCT01932372|Drug|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
79715511|NCT00588068|Other|Tumor and Marrow Markers|Tumor and Marrow Markers
79715512|NCT00551759|Drug|5-Fluorouracil|given IV
79715513|NCT00551759|Drug|Oxaliplatin|given IV
79715514|NCT00551759|Drug|Cetuximab|given IV
79852770|NCT06137274|Radiation|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
79852771|NCT06137274|Other|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
79852772|NCT06137235|Other|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
79852773|NCT06137235|Other|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
79551514|NCT02866721|Biological|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10^6, 3 x 10^6 or 5 x 10^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
79551515|NCT02814227|Device|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
79551516|NCT02557438|Procedure|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
79551517|NCT02557438|Procedure|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
79551518|NCT02503254|Other|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
79551519|NCT02503254|Other|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
79551520|NCT02489539|Device|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
79551521|NCT02438436|Dietary Supplement|simo decoction|
79551522|NCT02438436|Other|gum chewing|
79551523|NCT02420821|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
79581077|NCT01932385|Drug|Sorafenib|
79581078|NCT01932385|Other|Best Supportive Care|
79715515|NCT00551759|Drug|Docetaxel|given IV
79715516|NCT00551759|Procedure|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
79715517|NCT00551759|Radiation|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
79715518|NCT00335140|Biological|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
79715519|NCT00335140|Drug|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
79715520|NCT00335140|Drug|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
79715521|NCT00335140|Drug|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
79852774|NCT06137222|Device|Tenex TXB MicroTip Ultrasound system plus SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
79852775|NCT06137222|Other|Standard of Care for diabetic foot ulcer|Use of standard of care for the treatment of a diabetic foot ulcer
79852776|NCT06137209|Other|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)
79852777|NCT06137209|Other|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
79852778|NCT06137157|Drug|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
79852779|NCT06137144|Drug|AZD3470|AZD3470 is a novel, potent and selective, secondgeneration, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
79852780|NCT06137092|Drug|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
79852781|NCT06137040|Drug|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~>40 kg: 2000 mg"
79715522|NCT00335140|Drug|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
79852782|NCT06137040|Other|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
79852783|NCT06137027|Drug|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
79852784|NCT06137027|Drug|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
79852785|NCT06137014|Drug|Fortified Oral Rehydration Therapy|Oral rehydration solution with reduced glucose and added amino acids.
79852786|NCT06137014|Dietary Supplement|Standard of Care Oral Rehydration Therapy|Glucose-based oral rehydration therapy according to World Health Organization guidelines.
79852787|NCT06136988|Drug|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m^2, Intravenous infusion, Q3W
79852788|NCT06136988|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
80017778|NCT05125120|Other|COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH|Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
80017779|NCT03552666|Dietary Supplement|vitamin D3|
80017780|NCT05123404|Diagnostic Test|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
79551524|NCT02420821|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
79551525|NCT02420821|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
79551526|NCT02811263|Drug|Normal saline placebo|Equal volume of normal saline to be used as placebo
80017781|NCT05123404|Procedure|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
80017782|NCT02115594|Drug|Fulvestrant|
80017783|NCT02115594|Drug|Entinostat|
80017784|NCT02115594|Drug|Placebo|
80017785|NCT05125042|Procedure|Amiodarone hydrochloride tablet + acupoint catgut embedding|Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
80017786|NCT05125042|Drug|Amiodarone hydrochloride tablet|Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
80017787|NCT02115672|Drug|BL-8040|BL-8040 will be added to imatinib to improve CML response.
79551527|NCT02811263|Drug|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
79551528|NCT02188121|Drug|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
79551529|NCT02188121|Drug|Losartan|Angiotensin II receptor antagonist
79551530|NCT02177162|Other|Education to physiotherapists|
79551531|NCT02085486|Device|Ultrasound-assisted puncture|Portable ultrasound device
79551532|NCT02085486|Other|Standard|Standard inspection, palpation.
79551533|NCT02039063|Drug|E6011 2 mg/kg|
79551534|NCT02039063|Drug|E6011 5 mg/kg|
79551535|NCT02039063|Drug|E6011 10 mg/kg|
79551536|NCT02039063|Drug|E6011 15 mg/kg|
79551537|NCT01970410|Drug|teriflunomide|14 mg oral teriflunomide daily
79551538|NCT01746173|Drug|Cyclophosphamide|
79551539|NCT01746173|Drug|Doxorubicin|
79551540|NCT01746173|Drug|Vincristine|
79551541|NCT01746173|Drug|Etoposide|
79551542|NCT01746173|Drug|Prednisone|
79551543|NCT01746173|Drug|Filgrastim|
79715523|NCT00335140|Drug|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
79715524|NCT00335140|Drug|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
79852789|NCT06136988|Drug|Cisplatin for injection|Cisplatin for injection, 25 mg/m^2, Intravenous infusion, D1-D3, Q3W
79852790|NCT06136988|Drug|Paclitaxel|Paclitaxel 135 mg/m^2, Intravenous infusion, Q3W
79852791|NCT06136988|Radiation|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
79852792|NCT06136975|Device|Low-level laser therapy|The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
79852793|NCT06136910|Drug|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
79715525|NCT00304239|Combination Product|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
79715526|NCT00304239|Combination Product|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
79715527|NCT00101283|Drug|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
79715528|NCT00101283|Drug|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
79715529|NCT00101283|Drug|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
79715530|NCT01302041|Drug|Enzalutamide|Oral
79715531|NCT04327895|Behavioral|evaluation of the need for training|analyse of results of survey
79551544|NCT01746173|Drug|Plerixafor|
79852794|NCT06136858|Device|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
80017788|NCT05124964|Other|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
79255426|NCT05038202|Drug|Mometasone Furoate Aqueous Nasal Spray|"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."
79551545|NCT01746173|Procedure|Stem Cell Collection|
79551546|NCT01746173|Drug|Palifermin|
79852795|NCT06136806|Diagnostic Test|Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography|When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.
79255427|NCT02114359|Drug|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
79255428|NCT02114359|Drug|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
79255429|NCT02114359|Drug|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
79255430|NCT02114359|Drug|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
79255431|NCT02114359|Drug|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 1000mg/m2 po bid)
79255432|NCT02114359|Drug|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 30mg/m2 po bid)
79551547|NCT01746173|Drug|Gemcitabine|
79551548|NCT01746173|Drug|Busulfan|
79551549|NCT01746173|Drug|Melphalan|
79551550|NCT01746173|Procedure|Stem Cell Transplant|
79551551|NCT01694004|Drug|Benzocaine Infusion into Duodenum|
79551552|NCT01679275|Other|measuring cerebral oxygenation|
79551553|NCT01545843|Behavioral|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
79551554|NCT01545843|Drug|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
79551555|NCT00843791|Drug|placebo|treatment with placebo for 3 months
79715532|NCT01301729|Drug|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
79715533|NCT01301729|Drug|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
79255433|NCT02114359|Drug|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
79551556|NCT00843791|Drug|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
79551557|NCT03187769|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
79551558|NCT03187769|Drug|Olanzapine|Daily oral dosing
79551559|NCT03158402|Other|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
79551560|NCT03136731|Diagnostic Test|Celiac disease antibody screening|Observational parameters
79551561|NCT03092245|Drug|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
79715534|NCT01301729|Drug|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
79715535|NCT05643677|Drug|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
79715536|NCT05643677|Drug|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
79715537|NCT01187043|Drug|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
79715538|NCT02890589|Device|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
79715539|NCT02890589|Device|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
79852796|NCT06136806|Diagnostic Test|Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.|When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
79852797|NCT06136780|Other|Free reading glasses immediately following surgery|Free reading glasses will be given immediately after cataract surgery in the intervention arm and four months after cataract surgery in the control arm.
79715540|NCT05357001|Other|Connective tissue manipulation|to remove muscle spasticity
79715541|NCT05357001|Other|stretching exercises|to remove muscle spasticity
79715542|NCT05643521|Other|Dietary composition of macronutrients and calories|Carbohydrate restriction
79715543|NCT05643443|Other|Gradual increase of force|steady force
79715544|NCT01186809|Biological|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
79715545|NCT05367713|Other|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
79715546|NCT05643053|Other|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
79715547|NCT05643053|Other|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
79852798|NCT06136702|Behavioral|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
79852799|NCT06136702|Behavioral|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
79852800|NCT06136702|Behavioral|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
79852801|NCT06136676|Behavioral|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
79551562|NCT03092245|Drug|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
79551563|NCT03008642|Other|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
79551564|NCT02995733|Drug|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
79551565|NCT02994043|Behavioral|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
79551566|NCT02994043|Behavioral|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
79715548|NCT05643053|Other|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
79715549|NCT05643053|Other|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
79715550|NCT01186419|Drug|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
79715551|NCT01301027|Drug|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
79715552|NCT01301027|Drug|Placebo|1 pill a day for 26 weeks
79715553|NCT01185639|Radiation|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
79715554|NCT04207385|Diagnostic Test|pharmacogenomics|pharmacogenomics
79715555|NCT04207385|Diagnostic Test|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics & therapeutic drug monitoring
79715556|NCT04207385|Drug|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
79852802|NCT06136676|Behavioral|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
79852803|NCT06136676|Behavioral|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
79852804|NCT06136611|Device|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
79875321|NCT00946205|Procedure|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
80017789|NCT05124964|Other|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
80017790|NCT05124964|Other|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests [Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)] and five performance tests [Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
80017791|NCT02119182|Behavioral|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
79551567|NCT02956382|Drug|Ibrutinib|Ibrutinib is dispensed as a capsule.
79255434|NCT05024942|Procedure|Transfemoral TAVR (Transcatheter aortic valve replacement)|Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.
79255435|NCT02110303|Drug|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
79255436|NCT02110303|Drug|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
79255437|NCT03095846|Procedure|Cooling|Individualized cooling protocol
79255438|NCT05037890|Dietary Supplement|Margarine|Intake of margarine
79551568|NCT02956382|Drug|Venetoclax|Venetoclax is dispensed as a tablet.
79551569|NCT02855229|Drug|Methylphenidate|cross-over, single-dose intervention
79551570|NCT02833883|Drug|Enzalutamide|
79551571|NCT02833883|Drug|CC-115|
79255439|NCT02108119|Dietary Supplement|Probiotics|
79255440|NCT02108119|Dietary Supplement|Control placebo|
79255441|NCT02108197|Device|Continuous positive airway pressure (S9, ResMed)|
79395127|NCT01552369|Drug|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
79255442|NCT05024630|Procedure|Renal artery cryoablation|Renal denervation were achieved by cryoablation of renal artery with cryoballoon.
79395128|NCT02356068|Other|ROTEM analysis|3 blood samples for ROTEM analysis
79395129|NCT02355912|Device|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
79551572|NCT02829931|Radiation|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
79551573|NCT02829931|Drug|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
79551574|NCT02829931|Drug|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
79551575|NCT02829931|Drug|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
79551576|NCT02815566|Drug|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
79551577|NCT02815566|Drug|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
79551578|NCT02702492|Drug|KPT-9274|
79551579|NCT02702492|Drug|Niacin ER|
79551580|NCT02702492|Drug|Nivolumab|
79551581|NCT02652455|Drug|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
79715557|NCT01185561|Behavioral|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
79852805|NCT06136533|Other|Assessment-OHS|Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.
79875322|NCT00950027|Drug|povidone iodine|oropharyngeal decontamination every 4 hours
79875323|NCT00950027|Drug|Placebo|oropharyngeal decontamination every 4 hours
79875324|NCT00941525|Drug|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
79875325|NCT00456261|Drug|Pemetrexed|pemetrexed 500 mg/m2
79875326|NCT00456261|Drug|Gemcitabine|gemcitabine 1500 mg/m2
79875327|NCT00456261|Drug|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
80017792|NCT02119182|Behavioral|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
79395130|NCT03149952|Other|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
79875328|NCT00456261|Drug|Carboplatin|carboplatin AUC=5
80017793|NCT02119182|Procedure|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
79255443|NCT05024630|Procedure|Pulmonary vein cryoablation|Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
80017794|NCT02119182|Procedure|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
79255444|NCT05024630|Procedure|Renal arteriography|Renal artery was examined by renal arteriography
79255445|NCT02114437|Device|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
79255446|NCT02114437|Device|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
79255447|NCT02114593|Behavioral|Parent support program|Parent support program
79551582|NCT02652455|Procedure|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
79551583|NCT02652455|Drug|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
79255448|NCT03093740|Drug|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
79255449|NCT03093740|Drug|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
79255450|NCT02108353|Drug|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
79255451|NCT02108353|Drug|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
79395131|NCT02348034|Device|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
79395132|NCT02351232|Drug|Liraglutide|
79395133|NCT02351232|Drug|Placebo|
79551584|NCT02652455|Drug|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
79551585|NCT02652455|Drug|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
79715558|NCT02887209|Behavioral|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger & Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
79715559|NCT05367557|Procedure|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
79715560|NCT01185249|Procedure|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
80017795|NCT01341574|Procedure|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
80017796|NCT01341574|Procedure|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
80017797|NCT03622125|Diagnostic Test|Vital signs|Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
80017798|NCT02113332|Drug|Liraglutide|
80017799|NCT02113332|Drug|Placebo|
79852806|NCT06136533|Other|Assessment-Sarcopenic Obesity With OHS|The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
79875329|NCT01042821|Procedure|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
79255452|NCT04157751|Drug|Empagliflozin|Film-coated tablet
79395134|NCT02355834|Other|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
79551586|NCT02652455|Biological|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
79551587|NCT02652455|Drug|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
79551588|NCT02590289|Drug|BBI-5000|BBI-5000 low dose, middle dose, or high doses
79551589|NCT02572284|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
79875330|NCT01042821|Procedure|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
80017800|NCT03653949|Other|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
80017801|NCT03653949|Other|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
79551590|NCT02572284|Procedure|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
79551591|NCT02572284|Other|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
79551592|NCT02525783|Device|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty
79551593|NCT02491983|Drug|Palbociclib|
79551594|NCT02491983|Drug|Fulvestrant|
79551595|NCT02491983|Drug|Letrozole|
79255453|NCT04157751|Drug|Placebo to Empagliflozin|Film-coated tablet
79255454|NCT05033444|Drug|PRV-002|Eligible participants will be randomised to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomised to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.161 to 0.645 mg/kg will be investigated.
79255455|NCT05033444|Drug|Placebo|Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
79255456|NCT02114671|Drug|Faldaprevir high dose|capsules, oral
79255457|NCT02114671|Drug|Placebo|capsule, oral
79255458|NCT02114671|Drug|Ciprofloxacin|tablets, oral
79255459|NCT02114671|Drug|Faldaprevir low dose|capsules, oral
79255460|NCT03093506|Drug|Low-dose rhEpo|60IU/kg/week
79255461|NCT03093506|Drug|Micro-dose rhEpo|20IU/kg/week
79255462|NCT03093506|Other|Placebo Control|Saline
79255463|NCT02110459|Drug|POL7080|Intravenous infusion
79255464|NCT03094988|Behavioral|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
79395135|NCT02355756|Drug|Maxadilan|
79395136|NCT02355756|Drug|Placebo|
79551596|NCT02467478|Drug|Linagliptin|5 mg tablet once daily for 12 weeks
79551597|NCT02467478|Drug|Placebo|1 tablet daily for 12 weeks
79551598|NCT02466243|Drug|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
79551599|NCT02466243|Drug|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
79551600|NCT02321098|Drug|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
79551601|NCT02321098|Drug|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
79551602|NCT02321098|Drug|Loceryl NL 15 months|Loceryl once/week for additional 15 months
79551603|NCT02250339|Other|LAKU family program|Multi-systemic and multicomponent family-based intervention program
79551604|NCT02250339|Other|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
79551605|NCT02250339|Other|Family therapy|Treatment as usual (TAU)
79551606|NCT02211794|Other|data collection|
79551607|NCT02185417|Drug|Hydrochlorothiazide (HCTZ)|Thiazide-type diuretic. Daily dose of 50 or 25 mg for duration of the study.
79581079|NCT01932424|Device|Pelorus 1500|a bedside blood propofol measurement device
79715561|NCT05641883|Combination Product|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
79715562|NCT02886897|Biological|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
79715563|NCT04324697|Procedure|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
79551608|NCT02185417|Drug|Chlorthalidone|Thiazide-type diuretic. Daily dose of 25 or 12.5 mg for duration of the study.
79715564|NCT05619497|Other|Clinic-wide Trainings|The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
79852807|NCT06136520|Behavioral|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
79852808|NCT06136429|Procedure|Transcatheter aortic valve replacement|Device: Transcatheter Heart Valve System (Silara SR)
79395137|NCT03150030|Other|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
79852809|NCT06136416|Other|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
79852810|NCT06136377|Radiation|177Lu-PSMA-617 PET scan|Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
79395138|NCT03150030|Device|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
79852811|NCT06136364|Biological|CAR-T|CAR-T immunotherapy targeting CD7+
79852812|NCT06136338|Behavioral|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
79852813|NCT06136325|Procedure|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
79255465|NCT03094988|Other|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
79551609|NCT02158234|Drug|Cisplatin|Cisplatin 15 mg/m^2 prior to each fraction
79551610|NCT02158234|Radiation|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
79551611|NCT01953926|Drug|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
79551612|NCT01953926|Drug|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
79852814|NCT06136312|Device|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
79255466|NCT02114749|Device|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
79255467|NCT02108431|Device|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
79255468|NCT02108431|Device|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
79551613|NCT01953926|Drug|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
79551614|NCT01859026|Drug|MEK162|Treatment as outlined in study arms.
79551615|NCT01859026|Drug|Erlotinib|Treatment as outlined in study arms.
79551616|NCT01753089|Biological|WDVAX|
79551617|NCT01705067|Device|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
79551618|NCT01657591|Drug|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
79581080|NCT01932424|Drug|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
79852815|NCT06136299|Other|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
79852816|NCT06136286|Device|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
79852817|NCT06136273|Behavioral|Treatment measures and intervention strategies|To conduct observational process improvement and hypothesis-deriving studies related to penetrating traumatic injuries using data from the Methodist trauma registry and open source data repositories.
79715565|NCT05619497|Other|Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)|"The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.~The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk."
79715566|NCT05619497|Other|Standard Care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma informed care. These participants will view the decision support tool. These participants were recruited in Aim 1 of this study.
79715567|NCT01184859|Drug|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
79852818|NCT06136260|Other|CommunityRx-Bereavement|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For CRx-B, a Grief Navigator from Missing Pieces will call the parent; share information about grief and support resources; learn what resources the parent needs for themselves and their family; send the parent a personalized list of grief and social support community resources called a HealtheRx via text, email, or mail; and plan future text message communications with bidirectional functionality and, if requested, calls from the Grief Navigator to occur at least 3, 6, and 12 months after the child's death."
79551619|NCT01657591|Drug|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
79551620|NCT01558544|Procedure|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
79715568|NCT01184859|Drug|Placebo|Placebo melt tablet for sublingual administration
79715569|NCT00623675|Dietary Supplement|Mineralox C|Mineralox C 2 capsules three times a day.
79715570|NCT02890511|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
79715571|NCT05609981|Other|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
79715572|NCT02887287|Drug|EEN|
79852819|NCT06136260|Other|General Bereavement Support Information|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For GBSI, Missing Pieces sends parents a unidirectional text message providing a general list of grief resources (e.g., support groups) and information about grief and bereavement within two weeks of the child's death and again 3, 6, and 12 months after the child's death."
79852820|NCT06136208|Drug|s.c 25 mg estradiol pellet|Subcutaneous insertion of 25 mg estradiol pellet.
79852821|NCT06136195|Drug|Mavoglurant|Participants randomized to the Mavoglurant arm will take 100mg of Mavoglurant each day during the first medication period for 6-8 days. During the second medication period, participants will take 200mg of Mavoglurant each day for 6-8 days.
79395139|NCT03150030|Device|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
79852822|NCT06136195|Other|Placebo|Participants randomized to the placebo arm will take matching placebo tablets during both the first and second medication period.
79255469|NCT03094754|Procedure|nevi excision|After general anesthesia, nevi excision in children is performed.
79395140|NCT02355678|Drug|dexamethasone|IV 0.5 mg/kg
79551621|NCT01028144|Behavioral|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
79551622|NCT01028144|Behavioral|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
79551623|NCT01025726|Behavioral|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
79255470|NCT03287505|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
79255471|NCT03553381|Other|hypocaloric balanced diet|
79255472|NCT02459691|Behavioral|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
79255473|NCT02459691|Other|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
79395141|NCT02355678|Drug|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
79551624|NCT01025726|Behavioral|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
79551625|NCT01025726|Behavioral|General Health Education|Host community events for chronic disease education
79255474|NCT05032586|Device|wearing virtual reality headsets|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
79852823|NCT06136182|Procedure|Pericardial Closure Using Gentrix Following Cardiac Surgery|To determine feasibility and effectiveness of Gentrix for cardiac use, and if this product is patient population specific.
79852824|NCT06136169|Behavioral|Reminder-cue scanning training|Auditory reminders to scan when scanning to the side of the field loss is inadequate
79852825|NCT06136143|Procedure|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
79852826|NCT06136143|Procedure|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
79852827|NCT06136143|Procedure|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
79852828|NCT06136143|Procedure|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
79551626|NCT01599468|Drug|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
79852829|NCT06136130|Device|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
79852830|NCT06136104|Dietary Supplement|Mixhers HERTIME|A daily self-administered powder supplement packet mixed into water.
79255475|NCT03090698|Drug|Hylan G-F 20|intra-articular administration
79255476|NCT03090698|Drug|Triamcinolone|Intra-articular administration
79551627|NCT01599468|Drug|saline serum|The Placebo group received normal saline with the same volumes
79551628|NCT01599481|Behavioral|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
79551629|NCT01599481|Behavioral|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
79551630|NCT01599507|Drug|FG-4592|TIW dosing, capsule
79715573|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
79715574|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
79715575|NCT04316403|Procedure|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
79715576|NCT05340699|Device|Defocus Distributed Multi-point lens|Wear DDM lens
79715577|NCT05340699|Device|Single vision lens|Wear single vision lens
79715578|NCT04316325|Drug|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
79852831|NCT06136104|Dietary Supplement|Placebo|A daily self-administered powder placebo supplement packet mixed into water.
79852832|NCT06136078|Other|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
79852833|NCT06136065|Diagnostic Test|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
79852834|NCT06136052|Other|Forms|All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18.
79852835|NCT06136039|Procedure|Arm I (Sarcopenia)|Same as standard treatment
79852836|NCT06136039|Procedure|Arm II(Normal)|Same as standard treatment
79852837|NCT06136013|Behavioral|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
79852838|NCT06135987|Device|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
79852839|NCT06135974|Drug|LC106|Tablet containing at least 2 x 10^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
79852840|NCT06135974|Drug|LC115|Tablet containing at least 2 x 10^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
79715579|NCT01190865|Biological|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
79551631|NCT01599507|Drug|Placebo|TIW dosing, capsule
79551632|NCT01599533|Other|blood samples|
79715580|NCT01190475|Drug|Active treatment with a high dose of BGS649|
79715581|NCT01190475|Drug|Active treatment with a low dose of BGS649|
79551633|NCT01599572|Other|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
79715582|NCT01190475|Drug|Placebo treatment to blind study|
79255477|NCT02460549|Behavioral|therapeutic education program|
79395142|NCT02355678|Drug|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
79395143|NCT02355678|Procedure|Tonsillectomy|Mono-polar electrocautery or cold dissection
79715583|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715584|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79255478|NCT02114827|Behavioral|Video|23-minute video
79255479|NCT02114827|Behavioral|FAQ Sheet|
79395144|NCT02355678|Procedure|gastric content suction|By orogastric tube
79395145|NCT02355678|Drug|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
79395146|NCT02355678|Drug|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
79395147|NCT02355678|Drug|Paracetamol Suppository|If Visual Analogue Scale was less than 4
79395148|NCT03147144|Other|Ultrasonographic imaging|Ultrasound pelvic scan
79395149|NCT03146988|Drug|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
79395150|NCT03149796|Other|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
79395151|NCT02351310|Drug|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
79395152|NCT02351310|Genetic|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
79395153|NCT02347878|Drug|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
79395154|NCT02355600|Other|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
79715585|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715586|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
79852841|NCT06135974|Drug|Placebo|Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
79395155|NCT02355522|Drug|Intrauterine lidocaine|
79255480|NCT05018468|Device|Ventilation|Patients in group 1 undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Patients in group 2 undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
79255481|NCT03287115|Other|Broccoli consumption|All subjects will eat broccoli on day 11
79255482|NCT02108587|Device|optical coherence tomography|Undergo optical coherence tomography
79255483|NCT03090542|Dietary Supplement|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
79255484|NCT03293589|Procedure|open revascularization|surgical revascularization (i.e. Bypass surgery)
79255485|NCT03293589|Procedure|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
79255486|NCT02108665|Radiation|Radiographic hysterosalpingography|
79255487|NCT02108665|Radiation|Magnetic resonance imaging hysterosalpingography|
79255488|NCT04954274|Drug|Cyclic peptide Fertiline|"Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide."
79395156|NCT02355522|Drug|Lidocaine gel|
79395157|NCT02355522|Drug|KY jelly|
79395158|NCT02355522|Drug|Intrauterine normal saline|
79395159|NCT02351388|Device|Transcranial Direct Current Stimulation|
79395160|NCT02351388|Other|Sham Stimulation|
79395161|NCT02355444|Dietary Supplement|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
79551634|NCT01599598|Behavioral|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
79551635|NCT01599598|Behavioral|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
79715587|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715588|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715589|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715590|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715591|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715592|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715593|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715594|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715595|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
79715596|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715597|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715598|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715599|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79852842|NCT06135974|Drug|Metronidazole Oral|Metronidazole tablet orally twice daily for 7 days
79852843|NCT06135935|Other|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
79852844|NCT06135935|Other|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
79852845|NCT06135922|Biological|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10^6/kg to 1×10^8/kg EBV-TCR-T cells per dose.
79852846|NCT06135896|Drug|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
79852847|NCT06135857|Device|Protocol ECOEMS|Use electo estimulation therapy. The 4-channel stimulator will be used. The 6 electrodes will be located on the biceps, triceps and deltoids. Two daily sessions will be distributed, five days a week, lasting 20 minutes, the vascular program designed by the electro stimulation team itself will be applied.
79852848|NCT06135844|Drug|Purell Hand Sanitizer|Active ingredient. Ethyl alcohol 70%
79852849|NCT06135844|Drug|Medical Grade Mineral Oil|Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
79852850|NCT06135818|Diagnostic Test|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
79551636|NCT01599611|Procedure|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
79255489|NCT03293511|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
79255490|NCT03293511|Drug|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
79395162|NCT02355444|Dietary Supplement|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
79395163|NCT02355366|Behavioral|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
79581081|NCT01932450|Procedure|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
79581082|NCT01932450|Drug|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
79581083|NCT01932463|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
79581084|NCT01932476|Dietary Supplement|Gluten Challenge|Three-day gluten containing dietary challenge.
79715600|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715601|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715602|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715603|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
79715604|NCT01289990|Drug|Sitagliptin 100mg|Sitagliptin once daily
79715605|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
79715606|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79255491|NCT02251171|Drug|Tipranavir|
79852851|NCT06135805|Drug|Fluocinonide 0,05% oral gel|Application of Fluocinonide oral gel on oral syntomatic lesions
79852852|NCT06135805|Drug|Placebo|Application of placebo oral gel on oral lesions
79852853|NCT06135792|Other|Arginine|See arm description
79852854|NCT06135792|Other|Placebo|See arm description
79852855|NCT06135753|Other|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
79852856|NCT06135753|Behavioral|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
79255492|NCT02251171|Drug|Ritonavir|
79255493|NCT02251171|Drug|Rifabutin|
79255494|NCT03093194|Other|vaginal preparation before CS with Septal soap and septol.|vaginal preparation before CS with Septal soap and septol.
79255495|NCT03093194|Other|No vaginal preparation before CS with Septal soap and septol.|No vaginal preparation before CS with Septal soap and septol.
79255496|NCT03553927|Dietary Supplement|Low Energy Diet|Caloric restriction to achieve weight loss
79255497|NCT03553927|Other|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
79715607|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715608|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715609|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715610|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
79715611|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
80017802|NCT05130112|Device|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher & Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher & Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
79715612|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
79715613|NCT04206345|Other|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
79715614|NCT04206345|Other|exercise|Elbow bending exercises
79715615|NCT02886975|Behavioral|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
79715616|NCT01190007|Drug|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
79715617|NCT01189461|Drug|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
79715618|NCT01189227|Procedure|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
79715619|NCT01189227|Procedure|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
79255498|NCT03293433|Other|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
79715620|NCT01300247|Drug|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
79715621|NCT01300247|Drug|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
79715622|NCT01300247|Drug|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
79852857|NCT06135753|Other|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
79852858|NCT06135727|Device|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
79255499|NCT03293355|Behavioral|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
79395164|NCT02355366|Behavioral|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
79395165|NCT02347644|Behavioral|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~No perception of any alcohol consumption problem~Realization of alcohol consumption problem with no corresponding action"
79395166|NCT03146832|Behavioral|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
79715623|NCT01300247|Drug|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
79715624|NCT02890277|Device|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
79715625|NCT02890277|Drug|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
79715626|NCT01289678|Drug|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
79715627|NCT02886741|Other|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
79715628|NCT02886819|Other|vibration|Whole body vibration
79715629|NCT01289210|Drug|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
79715630|NCT01183221|Drug|Syntocinon|One dose of 24 IU (3 sprays/nostril)
79715631|NCT01183221|Drug|Placebo|Intranasal Placebo
79715632|NCT01183143|Drug|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
79852859|NCT06135675|Drug|TNP-2092 placebo capsules|TNP-2092 placebo capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
79852860|NCT06135675|Drug|TNP-2092 capsules|TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
79852861|NCT06135649|Procedure|Systematic lymphadenectomy|The nodal dissection protocol included the ISGPS lymphadenectomy stations (5, 6, 8a, 12b-c, 13, 14a-b, and 17) extended to stations contiguous to the regional basin (8p, 12a-p, and jejunal mesentery nodes). Stations embedded in the PD specimen (13, 14a-b, 17 and jejunal mesentery LN) were defined as first nodal echelon, while stations sampled as distinct specimens (5, 6, 8a-p, 12a-b-p-c) were defined as second nodal echelon.
79715633|NCT01183065|Drug|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
79852862|NCT06135636|Behavioral|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
80017803|NCT02115906|Other|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
79581085|NCT01932476|Dietary Supplement|Sham Challenge|Three-day sham (gluten free) dietary challenge
80017804|NCT02115906|Other|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
80017805|NCT02115906|Other|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
79395167|NCT03146832|Behavioral|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
79395168|NCT02351154|Other|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
79395169|NCT03146598|Other|No intervention as it is a observational study|No intervention as it is a observational study
79395170|NCT03146520|Device|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
79715634|NCT01182441|Device|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
80017806|NCT05129956|Device|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
80017807|NCT02119338|Drug|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
79715635|NCT01182441|Drug|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
79715636|NCT02886507|Dietary Supplement|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
80017808|NCT02918877|Drug|Sevoflurane|Volatile Anesthetic
79395171|NCT02355288|Procedure|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
79395172|NCT02355288|Procedure|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
79395173|NCT02350842|Device|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
79395174|NCT02350842|Device|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
79715637|NCT02886507|Dietary Supplement|Placebo|The placebo capsules contain microcrystalline cellulose.
79395175|NCT02355132|Other|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
79715638|NCT01182285|Drug|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
79715639|NCT01182285|Drug|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
79715640|NCT04315935|Drug|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
79852863|NCT06135636|Biological|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
80017809|NCT02918877|Drug|Propofol|Intravenous Anesthetic
79581086|NCT01932489|Procedure|Biopsy of a metastatic lesion.|
79852864|NCT06135610|Diagnostic Test|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
79852865|NCT06135597|Other|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
79715641|NCT04315935|Drug|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
79715642|NCT04316091|Drug|neoadjuvant chemotherapy+SPIONs/SMF|Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
79715643|NCT04316091|Drug|neoadjuvant chemotherapy|Conventional neoadjuvant chemotherapy only
79715644|NCT04188015|Biological|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
79715645|NCT04188015|Biological|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
79715646|NCT04188015|Other|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
79715647|NCT01182207|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
79715648|NCT01182207|Drug|YAZ®|3 mg/0.02 mg Tablets
79715649|NCT01181895|Drug|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
79715650|NCT01181895|Drug|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
79715651|NCT01181895|Drug|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
80017810|NCT02116062|Device|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
80017811|NCT02116062|Device|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
79395176|NCT02355054|Drug|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
79395177|NCT02354742|Other|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
79551637|NCT01599624|Behavioral|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
79715652|NCT01181895|Drug|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
80017812|NCT02116062|Device|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
79395178|NCT02354742|Other|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
79395179|NCT02347566|Behavioral|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
79395180|NCT02347566|Other|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
79395181|NCT04478448|Drug|Flupirava|1 tablet contains 200 mg Favipiravir
79395182|NCT04478448|Drug|Avigan|1 tablet contains 200 mg Favipiravir
79715653|NCT04187781|Device|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
79715654|NCT01181271|Drug|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
79715655|NCT01181271|Drug|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
79715656|NCT01181271|Drug|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
80017813|NCT03653871|Behavioral|Performing Arts Instruction|Professionally delivered performing arts curriculum
79715657|NCT01181271|Drug|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
79715658|NCT01181271|Other|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
79715659|NCT01181271|Drug|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
79715660|NCT01181271|Drug|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
79715661|NCT01181271|Drug|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
79715662|NCT01181271|Other|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight
79255500|NCT02110537|Procedure|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
79255501|NCT02110537|Procedure|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
79395183|NCT04478526|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
79551638|NCT01599624|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad & Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
79715663|NCT01181271|Drug|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
79715664|NCT01181271|Drug|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
79715665|NCT01181271|Drug|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
79852866|NCT06135584|Drug|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
79852867|NCT06135584|Drug|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
79852868|NCT06135584|Other|Drug-free|Drug-free
79852869|NCT06135571|Procedure|Laparoscopic colorectal surgery|Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
79852870|NCT06135558|Diagnostic Test|MAI detection|to detect the presence of marginal acute inflammation
79852871|NCT06135532|Procedure|Non-Surgical Periodontal Treatment|Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
79715666|NCT00624741|Drug|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
79715667|NCT01180647|Drug|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
79852872|NCT06135480|Other|subcision ,PRP or saline and microneedling|minimally invasive procedures
79852873|NCT06135415|Drug|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
79852874|NCT06135415|Other|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
79852875|NCT06135402|Device|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
79852876|NCT06135402|Drug|Treatment with Clobetasol|Application of Clobetasol twice per week
79852877|NCT06135376|Behavioral|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
79852878|NCT06135363|Drug|SC1011|SC1011 tablet
79852879|NCT06135363|Drug|Placebo tablet|SC1011-matching placebo tablet
80017814|NCT05129800|Other|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
79551639|NCT01599663|Other|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
79395184|NCT04478526|Behavioral|Electronic Cognitive Behavioural Therapy|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
79715668|NCT01180647|Behavioral|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
79715669|NCT02886663|Other|stimulation of the blind visual field|
79715670|NCT00969553|Drug|BI 6727|Dose level 1
79255502|NCT02110537|Drug|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
79715671|NCT04285957|Other|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
79715672|NCT04285957|Other|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
79551640|NCT01599676|Dietary Supplement|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
79551641|NCT01599676|Dietary Supplement|Non essential amino acid|Non essential amino acid supplementation
79551642|NCT01599689|Other|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
79551643|NCT01599702|Drug|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
79551644|NCT01599715|Behavioral|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
79551645|NCT01599715|Behavioral|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
79852880|NCT06135350|Drug|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~2400 mg/day (4 tablets twice a day) for the first 2 days and;~1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
79852881|NCT06135350|Other|Placebo|"Placebo arm patients will receive placebo:~4 tablets twice a day for the first 2 days and;~3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
79852882|NCT06135285|Device|Control subjects|The subject will be repositioned from the prone to recovery position
79255503|NCT03293277|Drug|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
79715673|NCT01179477|Device|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
79715674|NCT02863159|Device|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
79715675|NCT01179399|Drug|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
79255504|NCT03293277|Drug|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
79255505|NCT03293277|Drug|Intranasal Placebo|Intranasal Placebo
79255506|NCT03293277|Drug|Intravenous Placebo|Intravenous Placebo
79255507|NCT02110615|Other|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
79255508|NCT03093584|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
79715676|NCT01178853|Drug|Warfarin|Warfarin 5 mg once daily
79715677|NCT01178853|Drug|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
79715678|NCT01178853|Drug|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
79852883|NCT06135272|Drug|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
79852884|NCT06135272|Drug|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
79255509|NCT03093584|Behavioral|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
79852885|NCT06135272|Drug|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
79852886|NCT06135246|Device|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
79852887|NCT06135246|Other|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
79852888|NCT06135233|Other|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
79852889|NCT06135194|Drug|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
79852890|NCT06135181|Drug|Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
79852891|NCT06135181|Drug|Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
79852892|NCT06135181|Drug|Matching placebo|0.9% sodium chloride by intravenous injection (at 2 mL/s)
79852893|NCT06135168|Drug|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
79852894|NCT06135168|Drug|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
79852895|NCT06135155|Drug|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
79852896|NCT06135155|Drug|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
79255510|NCT02114905|Behavioral|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
79255511|NCT03293199|Procedure|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
79852897|NCT06135129|Device|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
79852898|NCT06135090|Behavioral|Trauma Recovery Program (official title TBD)|See arm description
79852899|NCT06135077|Other|T-PRF alone|T-PRF is the material to be tested in this study as an alternative to classical bone graft
79852900|NCT06135077|Other|T-PRF/Xenograft|One part of T-PRF will be divided into minute pieces to be mixed with xenograft
79852901|NCT06135064|Device|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
79852902|NCT06135051|Device|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
79852903|NCT06135038|Other|Suprascapular nerve block with physical therapy|"Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
79852904|NCT06135038|Other|Group 2 Physical therapy|"A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
79852905|NCT06135025|Other|Telemonitoring|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
79852906|NCT06135012|Device|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
80017815|NCT05129800|Other|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
79551646|NCT01599728|Drug|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min [15, 50 and 150 ng/min] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) [to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
79852907|NCT06135012|Other|Scalpel|Transection of pancreatic tissue with scalpel.
79852908|NCT06134999|Device|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
79852909|NCT06134999|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
79852910|NCT06134960|Biological|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
80017816|NCT03653793|Other|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
80017817|NCT05129488|Device|Biotrue ONEday lenses with an alternate packaging solution (EPG03)|Biotrue ONEday lenses with an alternate packaging solution (EPG03)
79551647|NCT01599767|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
79551648|NCT01599819|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
79551649|NCT01599819|Biological|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
79551650|NCT01599858|Drug|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
79715679|NCT02863393|Other|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
79715680|NCT01178385|Behavioral|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
79852911|NCT06134947|Other|Echocardiographic examination|"Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE <-2 Z Score is considered abnormal .~Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler <-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś)."
80017818|NCT05129488|Device|Biotrue ONEday lenses|Commercially available Biotrue ONEday lenses
80017819|NCT03652857|Drug|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
79255512|NCT03293199|Procedure|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
79255513|NCT02114983|Other|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
79551651|NCT01599858|Drug|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
79551652|NCT01599871|Drug|theophylline|theophylline 100 mg, twice at day
79551653|NCT01599871|Other|placebo|Placebo
79551654|NCT01599884|Drug|N-acetylcysteine|1800 mg twice daily for 8 weeks
79852912|NCT06134908|Behavioral|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
79852913|NCT06134895|Drug|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
79852914|NCT06134895|Drug|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
80017820|NCT05129410|Drug|Mycophenolate Mofetil|"Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~MMF1.5g-2.0g/d"
80017821|NCT02113566|Drug|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
80017822|NCT03652779|Drug|Tecarfarin 10mg|Tecarfarin 10mg tablets
80017823|NCT03652779|Drug|Tecarfarin 20mg|two tecarfarin 10mg tablets
79551655|NCT01599884|Drug|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
79395185|NCT02350920|Behavioral|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
79551656|NCT01599897|Biological|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
79715681|NCT01178385|Behavioral|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
79715682|NCT02863315|Device|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
79852915|NCT06134882|Behavioral|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
79852916|NCT06134882|Behavioral|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
79852917|NCT06134882|Behavioral|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
79852918|NCT06134882|Behavioral|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
79395186|NCT02350608|Device|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
79395187|NCT01552057|Drug|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
79395188|NCT01552057|Drug|Placebo|Placebo taken orally once every day for 15 weeks
79395189|NCT03160014|Drug|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
79395190|NCT02350686|Drug|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
79395191|NCT02350686|Drug|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
79395192|NCT03160092|Other|Intervention|"The intervention aims to:~Support the participant to explore their unusual experiences~Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~Helping them to recognise how common these unusual experience~Supporting them to make sense of their unusual experiences~Supporting them to understand why they may be experiencing these symptoms~Challenging any unhelpful beliefs they hold about their symptoms~Help the participant to recognise the triggers to their unusual experiences~Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
79395193|NCT03159078|Drug|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
79551657|NCT01599897|Biological|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
79551658|NCT01599910|Other|Scribes|Scribe
80017824|NCT03652779|Drug|Tecarfarin 30mg|three tecarfarin 10mg tablets
80017825|NCT03652779|Drug|Tecarfarin 40mg|four tecarfarin 10mg tablets
80017826|NCT02113644|Other|Lifestyle intervention|
80017827|NCT05124730|Drug|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
80017828|NCT05124730|Drug|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
79551659|NCT01599923|Biological|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
79551660|NCT01599936|Biological|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
79551661|NCT01599949|Drug|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
79551662|NCT01599962|Drug|Cinacalcet|single administration, 90mg
79551663|NCT01599962|Drug|Placebo|single administration
79551664|NCT01599975|Drug|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
79715683|NCT04286035|Drug|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
79852919|NCT06134882|Behavioral|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
79852920|NCT06134882|Behavioral|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
79852921|NCT06134869|Procedure|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
79852922|NCT06134856|Procedure|Ankle mobilization|Ankle joint mobilization as described in treatment arm description
79852923|NCT06134856|Procedure|Sham treatment|Light passive movement of the foot and ankle, avoiding the end-ranges which may actually elicit a mechanical change
79551665|NCT01599975|Drug|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
79551666|NCT01599975|Drug|Matched placebo|2 tablets of matched placebo daily by mouth
79551667|NCT01599988|Dietary Supplement|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
79551668|NCT01599988|Dietary Supplement|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
79551669|NCT01600157|Procedure|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
79551670|NCT01600391|Behavioral|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
79551671|NCT01600391|Behavioral|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
79715684|NCT04286035|Drug|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
79715685|NCT02865889|Procedure|Laparoscopy in Gynecologic Oncologic Indications|
79715686|NCT02865889|Procedure|Conventional surgery (abdominal radical surgery)|
79852924|NCT06134843|Combination Product|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
79852925|NCT06134817|Device|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
79852926|NCT06134791|Other|No intervention|No intervention
79852927|NCT06134778|Other|Inspiratory Muscle Training|Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
79852928|NCT06134765|Drug|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
79852929|NCT06134739|Other|No intervention.|Observational study, no intervention.
79852930|NCT06134713|Drug|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
79852931|NCT06134713|Drug|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
79852932|NCT06134700|Procedure|Laparoscopic Surgery|"Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~Port Placement~Reflection of colon~Isolation of ureterogonadal packet~Upper pole dissection~Hilar dissection~Vessel clipping and division~Dissection of kidney~Delivery through either Pfannenstiel or iliac fossa incision"
79852933|NCT06134661|Device|cTBS (continuous Theta Burst Stimulation)|"Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 500 pulses per session (total 1500 pulses per day)."
79852934|NCT06134635|Drug|Statins|Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
79852935|NCT06134635|Drug|Evolocumab|Evolocumab 140mg twice a month, subcutaneous injection
79852936|NCT06134622|Drug|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
79852937|NCT06134622|Drug|Intravenous thrombolysis plus placebo|placebo (saline)
79715687|NCT04286815|Device|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
79715688|NCT02865967|Other|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
79715689|NCT02865967|Other|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
79551672|NCT01600391|Behavioral|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
79551673|NCT01600430|Dietary Supplement|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
79715690|NCT04289857|Other|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
79715691|NCT01288976|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
79715692|NCT01288976|Drug|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
79715693|NCT01288976|Procedure|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
79715694|NCT05187169|Drug|VS-6766|Dual RAF/MEK inhibitor
79715695|NCT02863081|Other|Survey|Administered to healthcare providers
79715696|NCT02863081|Other|interview|Administered to patients and LAR (i.e., interviews)
79715697|NCT02862925|Procedure|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
79551674|NCT01600430|Dietary Supplement|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
79715698|NCT00629473|Drug|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
79715699|NCT00629473|Drug|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
79715700|NCT00629473|Drug|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
79715701|NCT04286503|Drug|Carrimycin|Carrimycin
79715702|NCT04286503|Drug|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
79715703|NCT04286503|Drug|basic treatment|basic treatment
80017829|NCT02251626|Dietary Supplement|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
79715704|NCT00970489|Drug|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
80017830|NCT02251626|Dietary Supplement|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
80017831|NCT02116218|Procedure|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
80017832|NCT02116218|Procedure|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
79551675|NCT01600430|Dietary Supplement|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
80017833|NCT02119572|Behavioral|peer support|
80017834|NCT02119572|Other|usual education lectures|
79715705|NCT00970489|Drug|Placebo|Olive Oil capsules
79715706|NCT00968617|Drug|MK2578|MK2578 1.0 mcg/kg/month
79715707|NCT00968617|Drug|MK2578|MK2578 2.0 mcg/kg/month
79715708|NCT00968617|Drug|MK2578|MK2578 3.6 mcg/kg/month
79715709|NCT00968617|Drug|Comparator: darbepoetin alfa|darbepoetin alfa
79715710|NCT00968539|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
79715711|NCT00968539|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
79715712|NCT00976573|Biological|bevacizumab|Given IV
79715713|NCT00976573|Drug|carboplatin|Given IV
79715714|NCT00976573|Drug|everolimus|Given orally
79715715|NCT00976573|Drug|paclitaxel|Given IV
79715716|NCT00629863|Drug|cisplatin|
79715717|NCT00629863|Drug|fluorouracil|
79715718|NCT00629863|Other|questionnaire administration|
79715719|NCT00629863|Procedure|diagnostic endoscopic procedure|
79852938|NCT06134583|Procedure|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
79852939|NCT06134583|Procedure|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
79255514|NCT03293121|Behavioral|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength & coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
79255515|NCT03293121|Behavioral|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
79255516|NCT05031728|Behavioral|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
79255517|NCT02108743|Drug|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
79395194|NCT01551745|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
79715720|NCT00629863|Procedure|neoadjuvant therapy|
79715721|NCT00629863|Procedure|quality-of-life assessment|
79395195|NCT01551745|Drug|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
79852940|NCT06134531|Drug|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
79852941|NCT06134518|Other|The education program|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC. The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
79852942|NCT06134518|Other|the initial orientation from the PHCs|the initial orientation from the PHCs
79852943|NCT06134479|Drug|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
79395196|NCT02350452|Procedure|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
79395197|NCT02350452|Procedure|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
79395198|NCT02350530|Drug|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
79551676|NCT01600508|Other|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
79551677|NCT01600599|Drug|Tranexamic Acid|intravenous 1g and topical 1g
79551678|NCT01600599|Drug|saline|100mls of topical saline
79551679|NCT01600937|Behavioral|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
79551680|NCT01600976|Drug|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
79715722|NCT00629863|Procedure|therapeutic conventional surgery|
79715723|NCT00629863|Procedure|therapeutic endoscopic surgery|
79715724|NCT00629863|Procedure|ultrasound imaging|
79395199|NCT02350530|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
79551681|NCT01601028|Drug|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
79551682|NCT01601028|Drug|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
79715725|NCT00629863|Radiation|radiation therapy|
79715726|NCT00629863|Radiation|radioisotope therapy|
79715727|NCT02865733|Drug|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
79715728|NCT02865733|Drug|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
79551683|NCT01601301|Device|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
79715729|NCT00976495|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
79551684|NCT01601457|Drug|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
79715730|NCT00976495|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
79715731|NCT00976495|Drug|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
79715732|NCT00630019|Drug|1.5% levofloxacin ophthalmic solution|Topical application
79715733|NCT00630019|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
79255518|NCT02108743|Drug|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
79551685|NCT01601457|Drug|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
79715734|NCT01288430|Drug|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
79715735|NCT02889848|Other|Saline|Saline injection
79715736|NCT02889848|Drug|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
79715737|NCT01287416|Behavioral|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
79715738|NCT01287416|Behavioral|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
79715739|NCT05660252|Other|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
79715740|NCT00998296|Drug|BIBW 2992|EGFR inhibitor
79715741|NCT00998296|Drug|BIBF 1120|VEGF inhibitor
79715742|NCT01178073|Drug|ambrisentan|ambrisentan (target dose: 10mg)
79255519|NCT03293043|Device|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
79255520|NCT01673126|Device|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
79715743|NCT01178073|Drug|tadalafil|tadalafil (target dose: 40mg)
79715744|NCT00997984|Drug|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
79715745|NCT00997984|Drug|placebo|dosed in the AM or PM
79715746|NCT00997984|Drug|extended-release guanfacine hydrochloride|Dosed in the PM
79255521|NCT01673126|Device|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
79715747|NCT04206111|Procedure|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
79715748|NCT01177293|Drug|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
79715749|NCT01177293|Drug|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
79715750|NCT01177137|Device|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
79715751|NCT01177137|Device|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
79255522|NCT02115061|Device|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
79715752|NCT01177137|Behavioral|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
79715753|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
79551686|NCT01601587|Other|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~What is mental health?~Treatment options: orientation about individual and group based treatment modalities.~Former patients experience with their own treatment, self-help and participation.~How to influence and participate actively in the treatment and patient rights.~What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
79715754|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
79715755|NCT02886429|Drug|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
79715756|NCT02886429|Drug|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
79715757|NCT01177059|Genetic|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
79715758|NCT04315779|Procedure|Salpingectomy|Patients will undergo removal of the affected tube
79715759|NCT01176513|Drug|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
79715760|NCT01299389|Drug|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
79715761|NCT01299389|Drug|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
80017835|NCT02122926|Other|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~Inpatient protocol for adjusting the discharge diabetes regimen;~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~Visiting nurse intervention after discharge;~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~Follow-up with PCP or endocrinologist within 1 week of discharge."
80017836|NCT02123004|Drug|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
79255523|NCT02115061|Device|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
79255524|NCT03292965|Drug|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
79551687|NCT01601639|Device|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
79255525|NCT03292965|Drug|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
79255526|NCT02109055|Other|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
79715762|NCT02886351|Drug|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
79715763|NCT02890667|Other|Incident cancer|The number of incident cancer cases
79715764|NCT01298999|Drug|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
79715765|NCT01298999|Drug|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
79715766|NCT04324541|Diagnostic Test|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
79715767|NCT01007032|Biological|Cixutumumab|Cixutumumab intravenously
79715768|NCT00976027|Biological|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
79715769|NCT00976027|Biological|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
79715770|NCT01298765|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
79715771|NCT04296214|Drug|5-azacitidine|Cycles of 28 days
79715772|NCT04296370|Drug|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
79715773|NCT04296370|Drug|Fluzoparib|Fluzoparib Orally twice daily
79715774|NCT04296370|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
79715775|NCT02870296|Behavioral|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
80017837|NCT02123004|Drug|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
80017838|NCT02116296|Behavioral|ToyBox-intervention|
80017839|NCT02123082|Device|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
79255527|NCT02109055|Other|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
79255528|NCT03094910|Diagnostic Test|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
79715776|NCT04204720|Device|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
79715777|NCT04204720|Device|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
79255529|NCT03094910|Diagnostic Test|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
79551688|NCT01601639|Device|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
79715778|NCT00997438|Dietary Supplement|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
79255530|NCT03094910|Diagnostic Test|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
79551689|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
79715779|NCT00997126|Drug|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
79715780|NCT00997126|Drug|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
79715781|NCT01000636|Procedure|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
79715782|NCT00965419|Drug|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
79715783|NCT04433494|Drug|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
79715784|NCT01000480|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
79551690|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
79551691|NCT01602029|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
80017840|NCT02123082|Device|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
79551692|NCT01602029|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
79551693|NCT01602029|Drug|Placebo|Placebo added to TAU
79551694|NCT01602029|Drug|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
79551695|NCT01602705|Other|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
79551696|NCT01602705|Other|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
79551697|NCT01602705|Other|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
79551698|NCT01602718|Other|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
79551699|NCT01602796|Behavioral|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
79715785|NCT01000480|Drug|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
79715786|NCT01000480|Radiation|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
79255531|NCT03094910|Diagnostic Test|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
79255532|NCT03094910|Diagnostic Test|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
79715787|NCT02862691|Drug|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
79715788|NCT02862691|Drug|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
79715789|NCT02871388|Behavioral|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
79715790|NCT00965341|Drug|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
79715791|NCT00965341|Drug|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
79715792|NCT01175811|Drug|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
79715793|NCT01175811|Drug|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
80017841|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
79715794|NCT01175811|Drug|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
79852944|NCT06134479|Drug|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
79852945|NCT06134427|Other|basic combat training (investigator did not design the intervention)|12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
79852946|NCT06134401|Device|saline|nebulised
79852947|NCT06134388|Drug|Sulfasalazine|Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
79255533|NCT03094910|Diagnostic Test|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
79255534|NCT02460705|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
79255535|NCT03282435|Biological|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
79395200|NCT01551355|Behavioral|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
79551700|NCT01602848|Other|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
79551701|NCT01602874|Drug|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
79551702|NCT01602874|Drug|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
79715795|NCT04293952|Other|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
79715796|NCT04293952|Other|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
79715797|NCT00965263|Biological|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
79715798|NCT02869594|Other|Data collection|
80017842|NCT01674712|Drug|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
79255536|NCT03282435|Other|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
79255537|NCT03282435|Biological|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
79395201|NCT02354664|Other|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
79395202|NCT02354664|Other|Spirometry|Upright forced vital capacity (FVC)
79395203|NCT02354664|Other|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
79395204|NCT02354664|Other|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
79715799|NCT03642691|Biological|Ryplazim|Plasminogen IV replacement therapy
79852948|NCT06134349|Device|lithium MRSI|lithium magnetic resonance spectroscopy imaging
79852949|NCT06134310|Procedure|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
80017843|NCT01674712|Drug|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
80017844|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
80017845|NCT01674712|Drug|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
80017846|NCT02119728|Drug|HPPH|Undergo photodynamic therapy with HPPH
80017847|NCT02119728|Device|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
80017848|NCT02119728|Procedure|therapeutic conventional surgery|Undergo standard of care surgery
79395205|NCT02354664|Other|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
79715800|NCT04206189|Dietary Supplement|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
79715801|NCT04283695|Drug|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
79715802|NCT02886195|Drug|pemetrexed|500mg/m2 ivgtt d1, per three weeks
79551703|NCT01602874|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
79715803|NCT02886195|Drug|cisplatin|80mg/m2 ivgtt d1, per three weeks
79715804|NCT02886195|Drug|Erlotinib|150mg po. every day
79715805|NCT04267783|Diagnostic Test|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
79715806|NCT05331963|Other|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
79715807|NCT02862769|Drug|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
79715808|NCT02862769|Drug|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
79715809|NCT00965185|Drug|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
79715810|NCT00965185|Drug|Placebo|Placebo
79715811|NCT01174563|Drug|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
79715812|NCT02861599|Other|proprioceptive therapy|
79715813|NCT02861599|Other|speech therapy|
79852950|NCT06134310|Procedure|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
79852951|NCT06134310|Procedure|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
79852952|NCT06134310|Behavioral|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
80017849|NCT01368432|Drug|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
80017850|NCT01368432|Drug|Placebo|Sugar pill placebo
79255538|NCT03092882|Behavioral|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
79255539|NCT02109211|Device|Intubation with Magill forceps|
79255540|NCT02109211|Device|Intubation with altered Magill forceps|
79395206|NCT02354664|Other|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
79395207|NCT01569841|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
79395208|NCT01569841|Drug|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
79395209|NCT03112356|Drug|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
79395210|NCT02350374|Other|carbohydrate counting|"patients must fill their logbook with the following data:~cho amount at breakfast, lunch, snack and dinner~insulin amount at breakfast, lunch, snack and dinner"
79395211|NCT01569763|Device|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
79395212|NCT01569763|Device|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
79551704|NCT01602874|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
79551705|NCT01602887|Drug|PD-0332991|isethionate hard capsule, 125 mg, single dose
79551706|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
79715814|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
79551707|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
79715815|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
79715816|NCT01298531|Drug|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
79715817|NCT02862145|Drug|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
79715818|NCT02862145|Drug|Dexamethasone|Premedication during the week of treatment
79852953|NCT06134297|Device|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
79852954|NCT06134297|Device|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
80017851|NCT05122858|Procedure|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
79715819|NCT04284709|Other|cognitive-physical training|combined physical and cognitive training
79715820|NCT01174173|Drug|Ranolazine|ranolazine 1000 mg PO BID for 3 months
79715821|NCT02862379|Behavioral|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
79715822|NCT04315623|Procedure|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
80017852|NCT05122858|Procedure|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
79551708|NCT01602887|Drug|PD-0332991|oral solution, 50 mg, single dose
79715823|NCT04315623|Procedure|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
79715824|NCT05281653|Behavioral|Neuromuscular exercise Training|Progressive neuromuscular exercise training
79715825|NCT05281653|Behavioral|Routine training sessions|Routine training sessions
79715826|NCT05661071|Other|Modified Mini Mental Test:|To assess the cognitive function of children
79715827|NCT05661071|Other|The Controlled Oral Word Association Test|To assess the cognitive function of children
79715828|NCT05661071|Other|The Central Nervous System Vital Signs|To assess the cognitive function of children
79715829|NCT05661071|Other|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
79715830|NCT05661071|Other|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
79551709|NCT01602926|Procedure|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
79715831|NCT05661071|Other|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
79715832|NCT05661071|Other|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
79715833|NCT05661071|Other|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
79715834|NCT05661071|Other|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
79715835|NCT05661071|Other|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
79715836|NCT05661071|Other|Timed Performance Test|10 meters Walk& Run Test, Gower's(from a supine to a standing position), Right& Left Leg Standing, Ascent/Descent of 4 Steps
79715837|NCT00964795|Drug|Intravitreal Aflibercept Injection 2mg|
79715838|NCT01173471|Drug|AZD4017|tablet, oral, one tablet once daily, 28 days
79715839|NCT01173471|Drug|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
79715840|NCT01173471|Drug|AZD4017|tablet, oral 2 tablets twice daily, 28 days
79715841|NCT01173471|Drug|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
79715842|NCT01172847|Drug|oseltamivir [Tamiflu]|multiple oral doses
79715843|NCT01172847|Drug|rimantadine|multiple oral doses
79715844|NCT04285645|Other|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
79715845|NCT00966355|Drug|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
79715846|NCT00966355|Drug|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
79715847|NCT00966355|Drug|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
79715848|NCT02861209|Other|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
79715849|NCT02862301|Biological|blood sample|
79715850|NCT04283305|Other|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
79852955|NCT06134297|Device|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
79852956|NCT06134271|Drug|Rezvilutamide|Rezvilutamide 240mg qd
79852957|NCT06134271|Drug|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
79852958|NCT06134271|Drug|Continue previous treatment|Continue using the previous treatment regimen for treatment.
79852959|NCT06134245|Device|Entia Liberty|Home monitoring
79852960|NCT06134232|Drug|Sipuleucel-T Injection|Single Infusion
79852961|NCT06134206|Diagnostic Test|Trans-burr hole ultrasound|All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
79551710|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
79852962|NCT06134193|Drug|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
79852963|NCT06134193|Drug|Surufatinib|250mg PO d1, Q3W
79551711|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
79551712|NCT01603147|Biological|normal saline|saline 225 ml
79715851|NCT04283305|Other|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
79852964|NCT06134193|Drug|Tislelizumab|200mg IV d1, Q3W
79852965|NCT06134128|Behavioral|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
79852966|NCT06134115|Dietary Supplement|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
79852967|NCT06134115|Dietary Supplement|Lipocet Placebo|Lipocet Placebo matching to Lipocet
79852968|NCT06134076|Other|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
79852969|NCT06134076|Other|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
79852970|NCT06134063|Drug|Xuanfei Baidu granule|Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
79852971|NCT06134063|Drug|Xuanfei Baidu granule Placebo|Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
79852972|NCT06134050|Procedure|Procedure: HTO using PSI aiming at 55% correction|HTO using PSI designed to achieve correction to 55% tibial width.
79852973|NCT06134050|Procedure|Procedure: HTO using PSI aiming at 62% correction|HTO using PSI designed to achieve correction to 62% tibial width.
79852974|NCT06134024|Procedure|Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections|During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.
79852975|NCT06134024|Procedure|Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only|During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
79852976|NCT06134011|Other|Without any intervention|There were no special interventions for the two groups.
79852977|NCT06133998|Device|incentive spirometer with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~In sitting position, for the relaxation of body, patient will take a deep breath.~In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~We will check the dyspnea of the patient by the borage scale~We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~We will check the quality of life by the questionnaire."
80017853|NCT05122780|Procedure|Coronary angiography|coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
80017854|NCT05122780|Diagnostic Test|OCT imaging|"OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment."
80017855|NCT05122780|Procedure|Percutaneous coronary intervention (PCI):|PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
79255541|NCT02110771|Behavioral|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
79255542|NCT02110771|Behavioral|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
79255543|NCT03282279|Procedure|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
79255544|NCT03282201|Other|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
79255545|NCT05031884|Device|MGIR3-US|MGIR3-US is an remote scanning robot which can do ultrasonic examinations.
79255546|NCT02110849|Radiation|Proton|Proton Therapy for Prostate Cancer
79255547|NCT03282045|Drug|Lysobact Complete Sprey|Inhaling spray
79551713|NCT01603147|Biological|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
79551714|NCT01603264|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
79551715|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
79551716|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
79551717|NCT01603485|Drug|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
79551718|NCT01603485|Drug|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
79255548|NCT03282045|Drug|Tantum Verde® Spray|Inhaling spray
79551719|NCT01603485|Drug|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
79551720|NCT01603485|Drug|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
79551721|NCT01603485|Drug|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
79715852|NCT01172535|Drug|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
79715853|NCT05160493|Drug|S-ketamine and pregabalin|"S-ketamine and pregabalin~Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
79715854|NCT05160493|Drug|Normal saline and placebo capsule|Normal saline and placebo capsule
79715855|NCT00966277|Drug|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
79715856|NCT03625063|Other|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
79715857|NCT03625063|Other|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
79715858|NCT02862223|Dietary Supplement|Neoprinol|
79715859|NCT01298141|Biological|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
79715860|NCT01171989|Biological|GSK2202083A vaccine|Intramuscular, one dose.
79715861|NCT01171989|Biological|Infanrix hexa™|Intramuscular, one dose.
79715862|NCT01171989|Biological|Menjugate™|Intramuscular, one dose.
79255549|NCT03282045|Drug|Pharyngal® Oromucosal Spray|Inhaling spray
79551722|NCT01603524|Other|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
79395213|NCT02354430|Behavioral|Water-exercise|"An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~Unsupervised water-exercises (The six AquaMama exercises)~Motivating weekly emails during the 12 week training period.~Brush up sessions is held once every month for guidance in performing the exercises."
79395214|NCT02039076|Drug|avatrombopag|
79395215|NCT02350296|Drug|KSL 40 mg|Ketoprofen lysine salt oral immediate release tablets 40 mg
79715863|NCT01171989|Biological|NeisVac-C™|Intramuscular, one dose.
79715864|NCT01171989|Biological|Synflorix™|Intramuscular, one dose.
79255550|NCT03282045|Drug|Placebo|Inhaling spray
79255551|NCT02407054|Drug|LY3023414|Administered orally
79255552|NCT02407054|Drug|Enzalutamide|Administered orally
79395216|NCT02350296|Drug|OKi® 80 mg|Ketoprofen lysine salt granules for oral solution 40 mg (half of a bipartite sachet)
79395217|NCT03149718|Behavioral|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
79395218|NCT03149718|Behavioral|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
79395219|NCT02354196|Procedure|CCTA|CT of heart to assess coronary disease
79715865|NCT01297517|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
79715866|NCT01297517|Drug|Brinzolamide ophthalmic suspension, 1%|
79715867|NCT01297517|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
79255553|NCT02407054|Drug|Placebo|Administered orally
79255554|NCT03090464|Other|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
79715868|NCT01171677|Behavioral|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
79715869|NCT01171521|Device|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
79715870|NCT01296347|Drug|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
79715871|NCT01296035|Biological|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
79715872|NCT01294787|Drug|indacaterol and glycopyrronium bromide (QVA149)|
79255555|NCT02115217|Device|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
79395220|NCT01550965|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79395221|NCT02354040|Behavioral|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
79255556|NCT02115217|Device|Sham kinesiotape|KT put with no effects
79551723|NCT01603524|Behavioral|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
79715873|NCT01294787|Drug|placebo|
79715874|NCT01294787|Drug|tiotropium|
79715875|NCT04207463|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
79255557|NCT03281967|Device|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
79255558|NCT02110927|Device|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
79255559|NCT02110927|Device|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
79715876|NCT04207463|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
79255560|NCT03287037|Device|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
79395222|NCT02268474|Device|532nm KTP Laser vs 595nm Pulse Dye Laser|Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
79715877|NCT01294553|Drug|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
79715878|NCT04326023|Drug|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
79715879|NCT01294397|Drug|Etanercept|Administered by subcutaneous injection once a week
79715880|NCT01294397|Drug|Denosumab|Administered by subcutaneous injection
79715881|NCT01293695|Behavioral|Hypnosis|Hypnosis relaxation in five weekly sessions
79715882|NCT01293695|Other|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
79715883|NCT01293539|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
79715884|NCT01292837|Drug|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
79715885|NCT00965731|Drug|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
79715886|NCT00965731|Drug|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
79715887|NCT00965731|Drug|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
79715888|NCT03252847|Genetic|AAV2/5-RPGR|Single, subretinal administration of AAV2/5-RPGR
79715889|NCT02862067|Other|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
79715890|NCT02861989|Other|qualitative study|
79715891|NCT00630175|Drug|zolpidem-MR (modified release)|
79715892|NCT00630175|Drug|zolpidem (SL800750)|
79715893|NCT00630175|Drug|placebo|
79715894|NCT02861911|Other|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
79255561|NCT05024084|Procedure|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane|Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
79255562|NCT05024084|Procedure|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane|Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
79255563|NCT02109289|Drug|etanercept|Etanercept is a tumor necrosis factor antagonist
79255564|NCT04908670|Behavioral|Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI|Watching pain neuroscience education video
79255565|NCT04908670|Procedure|PA manipulation|Low grade PA manipulation on the cervical, thoracic and lumbar spine
79395223|NCT02353962|Other|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
79395224|NCT03158766|Other|Microdiscectomy|It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
79715895|NCT02861911|Device|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
79715896|NCT00965575|Drug|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
79715897|NCT00965575|Drug|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
79715898|NCT04282837|Diagnostic Test|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
79715899|NCT04285177|Procedure|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
79715900|NCT02862847|Other|stool samples|
79715901|NCT04285099|Device|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
79255566|NCT03090386|Other|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
79255567|NCT03553303|Drug|Sacubitril / Valsartan Oral Tablet|Increasing doses of Sacubitril/Valsartan
79255568|NCT03090308|Other|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for > 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
79395225|NCT03658629|Biological|NanoFlu (Quad-NIV)|2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine
79715902|NCT04285099|Device|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
79715903|NCT02862613|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
79715904|NCT02862613|Biological|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
79715905|NCT00965497|Drug|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
79715906|NCT02859805|Other|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
79715907|NCT00963937|Drug|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
79255569|NCT03286959|Procedure|PCR with calcium hydroxide|
79255570|NCT03286959|Procedure|PCR with RMGIC|
79395226|NCT03658629|Other|Matrix-M Adjuvant|Adjuvant
79395227|NCT03658629|Other|Placebo|Placebo
79715908|NCT00963937|Drug|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
79715909|NCT00963937|Drug|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
79715910|NCT03375697|Drug|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
79715911|NCT03375697|Drug|Placebo|Subjects will receive matching placebo intravenously.
79715912|NCT04284241|Behavioral|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
79715913|NCT01170663|Biological|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
79715914|NCT01170663|Drug|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
79715915|NCT01170663|Drug|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
79715916|NCT04315155|Drug|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
79715917|NCT04315155|Drug|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
79715918|NCT04315155|Drug|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
79715919|NCT04315155|Drug|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
79715920|NCT04315155|Drug|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
79715921|NCT01170273|Dietary Supplement|vitamin D|cholecalciferol
79852978|NCT06133998|Device|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~In aerobic exercise following treatment protocol will be involve~In sitting position, for the relaxation of body, patient will take a deep breath.~In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~We will check the dyspnea of the patient by the borage scale~We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~We will check the quality of life by the questionnaire.~We will check the chest expansion by measuring tap."
79852979|NCT06133985|Other|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
79852980|NCT06133985|Other|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
79715922|NCT01170273|Dietary Supplement|placebo|placebo tablet
79715923|NCT04315077|Dietary Supplement|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
79852981|NCT06133972|Drug|Placebo|Placebo s.c. monthly
79852982|NCT06133972|Drug|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
79852983|NCT06133946|Genetic|Genetic screening test (Deafness gene variant detection array kit)|Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
79852984|NCT06133933|Device|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
79715924|NCT04315077|Other|Resistance Training|5 days of supervised and programmed whole-body resistance training.
79715925|NCT01170039|Drug|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
79715926|NCT01170039|Drug|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
79715927|NCT01169649|Drug|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
79715928|NCT01169493|Device|VVI-40|Pacing mode set to VVI-40, RV only pacing
79715929|NCT01169493|Device|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
79715930|NCT01169493|Device|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
79715931|NCT01287104|Biological|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
79715932|NCT01287104|Biological|Stem Cell Infusion|Transplant Day 0: >4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) >5000/microliters x2
79715933|NCT05593562|Drug|SPH3127|Oral 100 mg [14 c] SPH3127 mixed suspension
79715934|NCT01286558|Drug|40 mg telmisartan|once daily
79715935|NCT01286558|Drug|5 mg amlodipine|once daily
79715936|NCT01286558|Drug|5 mg amlodipine|once daily
79715937|NCT01286558|Drug|80 mg telmisartan|once daily
79852985|NCT06133920|Other|Early Range of Motion|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
79255571|NCT03286959|Procedure|PCR with direct composite|
79852986|NCT06133920|Other|Immobilization|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
79255572|NCT03090074|Behavioral|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
79255573|NCT03090074|Behavioral|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
79255574|NCT03292575|Drug|Anticoagulants|
79255575|NCT05023928|Biological|Tumor antigen-sensitized DC vaccine|subcutaneous administration
79255576|NCT03286881|Other|Brief individual psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
79255577|NCT03286881|Other|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
79255578|NCT03286881|Other|Combined intervention|Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
79255579|NCT03286881|Other|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
79255580|NCT03286881|Other|Usual treatment|Medication provided by a general practitioner.
79255581|NCT02115529|Drug|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
79255582|NCT02115529|Drug|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
79255583|NCT03092804|Procedure|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
79255584|NCT01652716|Drug|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
79255585|NCT01652716|Drug|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
79395228|NCT03658629|Biological|Fluzone HD|2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
79395229|NCT03658629|Biological|Flublok Quadrivalent|2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
79395230|NCT03658629|Biological|Influenza Vaccine|2018-19 Licensed Seasonal Influenza Vaccine
79395231|NCT02353650|Dietary Supplement|Q10|
79395232|NCT02353650|Dietary Supplement|placebo|
79395233|NCT03146364|Device|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
79551724|NCT01603589|Procedure|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
79551725|NCT01603589|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
79715938|NCT01169103|Drug|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
79715939|NCT01169103|Drug|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
79852987|NCT06133907|Genetic|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
79715940|NCT01286480|Behavioral|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
79255586|NCT03292341|Other|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
79715941|NCT01286168|Device|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
79715942|NCT01286168|Device|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
79715943|NCT01286168|Procedure|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
79255587|NCT03292341|Other|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
79255588|NCT03292341|Other|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
79715944|NCT01286168|Device|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
79715945|NCT01286012|Drug|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
79255589|NCT03292341|Other|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
79395234|NCT02347020|Behavioral|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
79395235|NCT02347020|Behavioral|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
79715946|NCT01286012|Drug|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
79715947|NCT01286012|Drug|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
79715948|NCT01286012|Drug|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
79715949|NCT02889692|Drug|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
79875331|NCT01042899|Behavioral|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
79255590|NCT02109601|Other|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
79255591|NCT02109601|Other|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
79255592|NCT05024240|Diagnostic Test|Stabilometry|Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
79255593|NCT05024240|Diagnostic Test|Stroop test|There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
79255594|NCT05024240|Diagnostic Test|Backward counting test|In this counting test probands are given number from interval <180-200> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
79852988|NCT06133894|Behavioral|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
79255595|NCT02459613|Drug|99mTc-Annexin V-128 SPECT|
79255596|NCT02251249|Drug|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
79255597|NCT05023538|Other|Cycling|Exercise on bicycle ergometer
79551726|NCT01603680|Procedure|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
79715950|NCT02889692|Drug|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
79715951|NCT02889692|Drug|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
79715952|NCT02889692|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
79715953|NCT02889692|Drug|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
79715954|NCT02889692|Drug|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
79715955|NCT02889692|Drug|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
79715956|NCT05569382|Drug|Verapamil|"1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
79715957|NCT05569382|Drug|Bisoprolol|"1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
79715958|NCT05569382|Drug|Placebo|"1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
79255598|NCT02115685|Other|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
79395236|NCT02347020|Behavioral|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
79551727|NCT01603680|Procedure|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
79715959|NCT02889770|Other|PEEP titration|Exposure to different PEEP levels
79255599|NCT03281889|Radiation|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
79715960|NCT00623792|Behavioral|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
79551728|NCT01603706|Procedure|Echo guided implantation group|Lead placement according echo strain imaging result
79715961|NCT00963547|Drug|MK-2206|[Part 1]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. [Part 2] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
79852991|NCT06133868|Drug|Lavender and Chamomile Essential Oils|essential oils
79852992|NCT06133842|Diagnostic Test|Intra-op EEG and CO data collection|Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
79852993|NCT06133803|Drug|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
79852994|NCT06133803|Drug|Aspirin|Aspirin 81mg daily tablet.
79255601|NCT03292263|Drug|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
79255602|NCT03292263|Drug|Nivolumab|iv infusion 100 mg on day -3, +17
79551729|NCT01603914|Device|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
79551730|NCT01603927|Device|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
79551731|NCT01604213|Drug|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
79551732|NCT01604213|Drug|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
79551733|NCT01604798|Other|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
79551734|NCT01605240|Drug|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
79715962|NCT00963547|Biological|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
79715963|NCT00963547|Drug|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
79715964|NCT01285310|Drug|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
79715965|NCT01285310|Drug|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
79715966|NCT01285310|Drug|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
79852995|NCT06133803|Procedure|Embryo transfer|Embryo transfer
79852996|NCT06133712|Drug|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
79852997|NCT06133712|Drug|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.
79852998|NCT06133712|Drug|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL [8 mg] dexamethasone) via the same technique.
79852999|NCT06133504|Procedure|Early Multimodal Therapy|Early multimodal therapy is defined as the collection of therapeutic maneuvers performed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy team at the time of study inclusion.
79853000|NCT06133504|Procedure|Late Multimodal Therapy|Late multimodal therapy is characterized by the same set of maneuvers carried out by the same disciplinary team, but it is initiated once indicated by the attending physician.
79853001|NCT06133465|Procedure|Surgical wide local excision|Surgical excision of breast carcinoma
79853002|NCT06133465|Procedure|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
79853003|NCT06133465|Procedure|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
79255603|NCT03292263|Procedure|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
79255604|NCT05017844|Drug|KSR-001-04|One drop to both eyes four times a day for 12 weeks
79255605|NCT05017844|Drug|KSR-001-02|One drop to both eyes four times a day for 12 weeks
79255606|NCT05017844|Drug|KSR-001-03|One drop to both eyes four times a day for 12 weeks
79255607|NCT02115763|Drug|Caffeine|
79255608|NCT02115763|Drug|Placebo|
79255609|NCT03286803|Biological|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
79255610|NCT03553693|Other|RAPID-VL study intervention|"Viral load (VL) ordering flowsheet with periodic health facility performance feedback~Rapid near-point-of-care VL testing and telephone delivery of results~Structured VL counseling package"
79255611|NCT03292185|Drug|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
79255612|NCT03292185|Drug|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
79255613|NCT03292185|Drug|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
79715967|NCT01254630|Biological|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
79715968|NCT01254630|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
79715969|NCT01284140|Behavioral|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
79715970|NCT01284140|Behavioral|Usual care|Usual care.
79715971|NCT01254318|Other|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
79715972|NCT04319796|Other|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~Name of specialist center~Pseudonym:~Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~Sex~Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~Age of onset~Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=DE~Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~Agreement to be contacted for research purposes: Yes/No~Biological samples (Yes / No)~Link to a biobank (Link / No)~Classification of disability (Disease group specific score)"
79551735|NCT01605240|Drug|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
79715973|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
79853004|NCT06133465|Radiation|Adjuvant Radiotherapy|Adjuvant radiotherapy
79853005|NCT06133465|Biological|Adjuvant Hormone Therapy|Adjuvant hormone therapy
79853006|NCT06133309|Behavioral|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
79255614|NCT05031260|Device|applying COMORAL®|The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
79255615|NCT02115841|Device|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
79551736|NCT01605279|Drug|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
79551737|NCT01605279|Drug|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
79551738|NCT01605565|Procedure|A nasal brushing|A nasal brushing in every nostril
79853007|NCT06132828|Drug|DR30206|Subjects receive DR30206 intravenously
79853008|NCT06132737|Drug|[90Y]Y-PentixaTher|[90Y]Y-PTT i.v. injection
79853009|NCT06132178|Drug|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
79853010|NCT06132178|Device|Accelerated intermittent theta burst (aiTBS) rTMS treatment|A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
79853011|NCT06132178|Drug|Low-dose psilocybin|A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
79255616|NCT05031104|Other|Physical Exercise|The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
79255617|NCT05031104|Other|Physical Exercise plus Low-energy Laser Therapy|The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
79551739|NCT01606072|Drug|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
79551740|NCT01606657|Procedure|Irrigation|The patient will receive irrigation as a part of their wound care
79551741|NCT01606657|Other|No Irrigation|The patient will not receive irrigation as part of their wound care
79551742|NCT01606722|Drug|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
79551743|NCT01606904|Behavioral|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
79551744|NCT01607060|Drug|Lactulone|Patients will receive lactulone to daily laxation
79551745|NCT01607242|Other|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
79551746|NCT01607242|Other|Voice Handicap Index|Subjective Evaluation of Voice disorders
79551747|NCT01607242|Other|Swallowing Assesment|Swallowing function questionnaire
79715974|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
79715975|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
79715976|NCT01284062|Other|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
80017856|NCT05122780|Diagnostic Test|Acetylcholine provocative test|ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
79715977|NCT01253304|Drug|LY2189265|Subcutaneous (SC) injection
79551748|NCT01607489|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
79715978|NCT04319484|Drug|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight < 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight < 60 kg) or 12 mg orally once a day.
79715979|NCT04319484|Drug|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight < 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight < 60 kg) or 12 mg orally once a day.
80017857|NCT05122780|Diagnostic Test|TT-Echocardiography|TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
79551749|NCT01607749|Behavioral|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
79551750|NCT01607749|Other|Usual Asthma Information for teachers|Common asthma information for teachers
79551751|NCT01607983|Drug|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
79551752|NCT01608217|Drug|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
79551753|NCT01608217|Drug|Placebo|placebo (tablet) three times daily for a period of three weeks.
79715980|NCT01253226|Drug|LY2127399 (Tabalumab)|Administered subcutaneously
80017858|NCT05122780|Diagnostic Test|TE/contrast echocardiography|In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
79551754|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
79551755|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
79551756|NCT01608425|Procedure|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
79715981|NCT01253226|Drug|Placebo|Administered subcutaneously
79715982|NCT01252290|Drug|Lovaza™|4 capsules daily for 6 months
79715983|NCT02888418|Biological|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
79715984|NCT02888418|Biological|placebo|
79715985|NCT02888340|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
79715986|NCT01252134|Device|Biotrue multipurpose solution|Contact lens care solution
79715987|NCT01252134|Device|Sauflon Synergi multipurpose solution|Contact lens care solution
79715988|NCT01252134|Device|OTE Elements multipurpose solution|Contact lens care solution
79715989|NCT01252134|Device|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
79715990|NCT01251744|Procedure|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
79715991|NCT01251744|Procedure|Cord blood sample|Cord blood sample taken at the time of delivery.
79715992|NCT01251744|Procedure|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
79715993|NCT01251744|Procedure|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
79715994|NCT01251744|Procedure|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
79715995|NCT00624312|Drug|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
79715996|NCT00624312|Drug|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
79715997|NCT01251354|Drug|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
79715998|NCT01251276|Biological|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
79853012|NCT06132178|Device|Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment|The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
79853013|NCT06131944|Behavioral|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
79853014|NCT06131892|Other|Defibrillation|Defibrillation
80017859|NCT05122780|Diagnostic Test|Cardiac magnetic resonance|CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
80017860|NCT05122780|Diagnostic Test|Circulating biomarkers|Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
80017861|NCT05122780|Drug|Antiplatelet Drug|acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
79551757|NCT01608594|Drug|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
79715999|NCT01251120|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
79716000|NCT01251120|Drug|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
79716001|NCT01250418|Drug|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
79853015|NCT06131723|Behavioral|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
79853016|NCT06131619|Other|assesment of cognitive parameters with DLOTCA-G|All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.
79853017|NCT06131528|Other|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
79853018|NCT06131528|Other|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
79853019|NCT06131502|Device|ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy|The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
80017862|NCT05122780|Drug|Statin|i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
80017863|NCT05122780|Drug|Beta blocker|i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
80017864|NCT05122780|Drug|ACEi/ARB|i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
80017865|NCT05122780|Drug|CCB|i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
80017866|NCT05122780|Drug|Nitrates|i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
80017867|NCT05122780|Drug|Anticoagulant|i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
79716002|NCT04319562|Procedure|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
80017868|NCT01063881|Drug|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
80017869|NCT02116374|Other|Physiopathology study|
80017870|NCT02116452|Dietary Supplement|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
79716003|NCT04319562|Device|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
79716004|NCT05490810|Other|Trunk stabilization|"Trunk stabilization exercises with~Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
79716005|NCT05490810|Other|Activation exercises|"Activation exercises with~Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
79716006|NCT01292603|Drug|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
79716007|NCT01292603|Drug|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
79255618|NCT02115919|Drug|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
79716008|NCT01292603|Drug|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
79716009|NCT01292603|Drug|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
79716010|NCT01292603|Drug|rituximab [MabThera]|6 cycles of intravenous MabThera
79716011|NCT01292057|Drug|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
79716012|NCT01292057|Drug|Placebo|Placebo to match active drug Aripiprazole for 8 days
79716013|NCT01291277|Device|Endoscopic Variceal Ligation|Ligation of esophageal varices
79716014|NCT01290887|Drug|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
79255619|NCT02115919|Drug|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
79255620|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
79716015|NCT01290731|Drug|TMC435|100-mg capsule once daily for 12 weeks
79716016|NCT01290731|Drug|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
79853020|NCT06131463|Device|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
79255621|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
79853021|NCT06131242|Other|It is an observational study|It is an observational study
79853022|NCT06131164|Other|Diaphragmatic Breathing Exercise Group|The subjects in this group will perform Diaphragmatic Breathing Exercise Group
79853023|NCT06131164|Other|Thoracic Extension Exercise Group|The subjects in this group will perform Thoracic Extension Exercise Group
80017871|NCT02119806|Drug|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
79255622|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
79255623|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
79716017|NCT01290731|Drug|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
79716018|NCT01290341|Drug|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
79716019|NCT01290341|Drug|Placebo|Topical; applied once daily for two weeks.
79716020|NCT01290263|Drug|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
79255624|NCT05030636|Procedure|Acute moderate to vigorous exercise performed at a specific moment of the day|Treadmill (30 minutes) at 70% of maximal aerobic capacity
79255625|NCT03553849|Dietary Supplement|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
79255626|NCT02460237|Procedure|Disease Screening|Complete HPV self-test
79255627|NCT02460237|Other|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
79255628|NCT02460237|Other|Informational Intervention|Receive standard instructions and information sheet
79853024|NCT06131112|Diagnostic Test|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
79853025|NCT06130813|Other|increased perioperative communication program|Thanks to this communication program, informative content (8 times) will be shared with patients.
79853026|NCT06130579|Drug|IFN-Α|Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
79551758|NCT01608594|Drug|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
80017872|NCT02119806|Drug|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
80017873|NCT02119806|Drug|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
79551759|NCT01608607|Other|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
79551760|NCT01608854|Other|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
79551761|NCT01608880|Drug|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
79551762|NCT01608880|Drug|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
80017874|NCT05124496|Device|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
80017875|NCT04054245|Drug|LOXL2 Inhibitor PAT-1251|Given PO
80017876|NCT04054245|Other|Quality-of-Life Assessment|Ancillary studies
80017877|NCT04054245|Other|Questionnaire Administration|Ancillary studies
80017878|NCT02119884|Drug|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
80017879|NCT02119884|Drug|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
80017880|NCT03653559|Behavioral|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
79255629|NCT02460237|Other|Laboratory Biomarker Analysis|Correlative studies
79255630|NCT02460237|Other|Survey Administration|Ancillary studies
79255631|NCT02109757|Other|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
79255632|NCT02109757|Other|Education only|
79551763|NCT01608958|Drug|Oxytocin|10 IU oxytocin in 500 ml infusion
79551764|NCT01608958|Drug|Oxytocin|10 IU oxytocin IM injection
79551765|NCT01609140|Drug|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
79551766|NCT01609140|Drug|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
79551767|NCT01609140|Drug|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
79551768|NCT01609140|Drug|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
79551769|NCT01609140|Drug|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
79551770|NCT01609140|Drug|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
79551771|NCT01609153|Drug|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
79551772|NCT01609153|Drug|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
79551773|NCT01609153|Drug|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
79716021|NCT01290263|Drug|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
79716022|NCT01290029|Drug|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
79716023|NCT02890199|Drug|Bupivacaine liposomal|
79716024|NCT02890199|Drug|Lidocaine|
79716025|NCT04324073|Drug|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
79716026|NCT01289639|Drug|fenofibrate|micronized fenofibrate 200 mg 1 po qd
79716027|NCT01289639|Drug|pioglitazone|pioglitazone 30 mg po qd
79716028|NCT01289639|Drug|placebo|placebo 1 capsule po qd
80017881|NCT03653559|Behavioral|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
80017882|NCT05109910|Procedure|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
79716029|NCT01289015|Drug|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
79716030|NCT01289015|Drug|Placebo|Topical; applied once daily for two weeks
79716031|NCT01288937|Drug|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
79716032|NCT01288937|Drug|Placebo|Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
79255633|NCT05023694|Other|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
79551774|NCT01609309|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
79551775|NCT01609309|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience."
79716033|NCT01288469|Drug|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
79716034|NCT01288469|Drug|Placebo (for alirocumab)|One SC injection in the abdomen only.
80017883|NCT02123160|Behavioral|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
80017884|NCT02123160|Behavioral|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
79716035|NCT01288469|Drug|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
79716036|NCT01288469|Drug|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
80017885|NCT05104918|Drug|Vortioxetine|10 mg tablets
80017886|NCT05104918|Drug|Venlafaxine|75 mg tablets
80017887|NCT02123238|Other|bed positioning|
80017888|NCT03653403|Drug|IDP-126 Gel|Component A
79255634|NCT05023694|Other|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
79255635|NCT02116075|Procedure|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
80017889|NCT03653403|Drug|Control Gel|gel
80017890|NCT05089942|Drug|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
80017891|NCT05089942|Drug|Placebo|health subjects receive placebo patch
79716037|NCT02890043|Procedure|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
79716038|NCT02890043|Procedure|free-hand surgery|traditional free-hand surgery
79716039|NCT02890043|Device|TiRobot system|a robot-assisted spine surgery system
79716040|NCT01288079|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
79716041|NCT01288079|Drug|Duloxetine|Capsule, oral, once daily
79716042|NCT01288079|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
79716043|NCT00623753|Biological|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
79716044|NCT01287221|Drug|Rifampicin|300 mg, 2 times daily
79716045|NCT01287221|Drug|placebo|placebo
79716046|NCT01168401|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
79716047|NCT01168401|Biological|Saline|Two doses 28 days apart
79716048|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
79716049|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
79716050|NCT01287065|Drug|Placebo AM|Inhalation powder
79255636|NCT02116075|Procedure|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
79551776|NCT01609530|Procedure|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
79551777|NCT01609530|Procedure|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
79551778|NCT01609608|Procedure|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
79551779|NCT01609725|Device|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
79551780|NCT01609725|Device|Oral prophylaxis|One session of supraginigval calculus removal
79716051|NCT01287065|Drug|Placebo PM|Inhalation powder
79716052|NCT04314999|Diagnostic Test|Examination of stool samples|Tests for diagnosis of parasitic diseases
79716053|NCT01167153|Drug|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
79716054|NCT01167153|Drug|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
79716055|NCT02886273|Other|Group 1|Observation
79551781|NCT01609751|Dietary Supplement|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
79716056|NCT02886273|Other|Group 2|Observation
79716057|NCT02886273|Other|Group 3|Observation
79716058|NCT02886273|Other|Group 4|Observation
79716059|NCT01166763|Drug|vitamin D3|oral capsules, 10,000 IU per week for 6 months
79716060|NCT02886039|Other|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
79551782|NCT01609894|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
79853029|NCT06130358|Other|Experimental: Well-being intervention followed by classic intervention|2 x 6 weeks of weekly museum visits
79551783|NCT01609894|Dietary Supplement|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
79551784|NCT01610024|Dietary Supplement|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
79853030|NCT06130358|Other|Experimental: Classic intervention followed by well-being intervention|2 x 6 weeks of weekly museum visits
79551785|NCT01610050|Drug|LFA102|
79716061|NCT02885961|Drug|Dabigatran|Anti-coagulant
79716062|NCT02885961|Radiation|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
79716063|NCT02885727|Drug|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
79716064|NCT02885727|Radiation|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
79716065|NCT01166373|Behavioral|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
79716066|NCT01166373|Procedure|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
79716067|NCT01166373|Procedure|ULS|uterosacral ligament suspension to suspend the vaginal apex
79716068|NCT01166373|Behavioral|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
79716069|NCT01166373|Other|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
79716070|NCT04314765|Procedure|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
79716071|NCT00963235|Biological|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
79716072|NCT00963235|Procedure|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
79853031|NCT06130280|Radiation|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
79853032|NCT06128616|Device|ESWT|Extracorporeal Shock Wave Therapy
79853033|NCT06128616|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
79853034|NCT06128616|Other|Serial Casting|Serial Casting
79395237|NCT02347020|Behavioral|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
79716073|NCT02861833|Other|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
79716074|NCT04284163|Behavioral|Gamification|Teaching through gamification
79716075|NCT04284163|Behavioral|Traditional teaching|Teaching through master lesson methodology
79716076|NCT00630097|Drug|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
79716077|NCT04284085|Other|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
79716078|NCT01165281|Drug|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
79716079|NCT01165281|Drug|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
79716080|NCT04283929|Other|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
79395238|NCT02346786|Dietary Supplement|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
79716081|NCT04283929|Other|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
79716082|NCT04283929|Other|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows > 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
79716083|NCT02861053|Other|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
79716084|NCT02861053|Other|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
79716085|NCT02860897|Drug|Premarin|Vaginal estrogen cream
79716086|NCT02860897|Drug|Vagifem|Vaginal estrogen tablet
79853035|NCT06128616|Behavioral|Physical Therapy|Physical Therapy
79853036|NCT06128616|Behavioral|Occupational Therapy|Occupational Therapy
79853037|NCT06127771|Other|Programming DBS using Percept PC neurostimulator's full potential|This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
79395239|NCT02346786|Dietary Supplement|tap water|
79716087|NCT04314609|Device|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
79716088|NCT02860819|Drug|Veliparib|Veliparib 250mg BID, continuously
79716089|NCT02860819|Drug|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
79716090|NCT02860819|Drug|Carboplatin|Carboplatin AUC = 4, day 1
79716091|NCT05367453|Dietary Supplement|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
79716092|NCT05367453|Other|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
79716093|NCT05367453|Other|lactase tablet|lactase tablet
79853038|NCT06127069|Device|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
79853039|NCT06127069|Device|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
79853040|NCT06126770|Behavioral|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
79716094|NCT05367453|Other|placebo tablet (cornstarch)|placebo tablet (cornstarch)
80017892|NCT04055181|Device|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
80017893|NCT04055181|Device|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
79551786|NCT01610089|Other|stable isotope infusion|"Control subjects: [15N2-ureido] arginine (0.69 mg/kg); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of [15N2-ureido] arginine (0.69 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,[15N2-ureido] arginine (4.14 mg/kg); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of [15N2-ureido] arginine (4.14 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr)."
80017894|NCT04055181|Device|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
79551787|NCT01610141|Other|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
79551788|NCT01610141|Other|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
79551789|NCT01610180|Drug|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~If platelet count <60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~If platelet count >60000/µL and ≤200000/µL same dose for the next 14 days.~If platelet count >200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~If platelet count >400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is <150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
79551790|NCT01610193|Procedure|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
79716095|NCT04284007|Drug|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
79551791|NCT01610219|Behavioral|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
79716096|NCT04284007|Drug|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
79716097|NCT04284007|Drug|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
79853041|NCT06126614|Drug|Chlorhexidine Gluconate|0.05% chlorhexidine gluconate solution for irrigation
79853042|NCT06126614|Drug|Vancomycin Hydrochloride|2 grams of topical vancomycin hydrochloride added to the wound
79853043|NCT06126614|Other|Povidone-Iodine|0.35% povidone-iodine solution for irrigation
79853044|NCT06126614|Other|Saline|saline for irrigation
79853045|NCT06125548|Other|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
79853046|NCT06125132|Procedure|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
79853047|NCT06124794|Biological|PROTOXIN|Clostridium botulinum toxin type A
79853048|NCT06124534|Device|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
80017895|NCT04055181|Device|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
79716098|NCT02861677|Other|pharmaceutical care|
79716099|NCT02861287|Other|Economic evaluation|
79716100|NCT01165203|Biological|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
79716101|NCT01165203|Biological|Placebo|intramuscular injection
79716102|NCT00960661|Drug|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
79716103|NCT00960661|Drug|insulin lispro|titrated based on pre-meal glucose level; three times a day
79551792|NCT01610219|Other|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
79551793|NCT01610232|Device|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
79716104|NCT00960661|Drug|Metformin|
79551794|NCT01610232|Other|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
79551795|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
79716105|NCT00960661|Drug|Insulin/ Glargine|
79716106|NCT04119193|Device|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
79716107|NCT04282993|Device|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
79716108|NCT04282993|Other|Standard of care monitoring|Periodical medical examinations
79716109|NCT00960193|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
79716110|NCT00960193|Other|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
79716111|NCT00960115|Biological|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram [mcg]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
79716112|NCT00960115|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg/m^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
79716113|NCT00960115|Biological|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
79716114|NCT00960115|Other|Saline|A single dose of saline (sodium chloride, 9 grams per liter [g/L]) will be administered intravenously, 3 days prior to the start of placebo.
79716115|NCT02859883|Device|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
79716116|NCT04281355|Procedure|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
79716117|NCT04281355|Radiation|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
79551796|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
79551797|NCT01610323|Other|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
79551798|NCT01610323|Other|Standard Care|
79716118|NCT04281277|Device|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
79716119|NCT04281277|Device|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
79551799|NCT01610362|Biological|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
79716120|NCT04281121|Dietary Supplement|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
79716121|NCT00959647|Drug|Vismodegib|Vismodegib was supplied in capsules.
79716122|NCT00959647|Drug|FOLFOX|FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
79716123|NCT00959647|Drug|FOLFIRI|FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
79716124|NCT00959647|Drug|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
79716125|NCT02859493|Device|Saccharomyces cerevisiae|
79716126|NCT02859493|Device|Placebo|
79716127|NCT02859649|Behavioral|neuropsychological test|neuropsychological test
79716128|NCT02861443|Behavioral|practice of colonic irrigation|
79853051|NCT06123208|Other|Whole cooked pinto bean|Meal comprised of whole cooked pinto beans
79853052|NCT06123208|Other|Pinto bean flour|Meal comprised of pinto bean flour
79853053|NCT06123208|Other|Control|Control meal
79716129|NCT02808403|Other|No intervention|No intervention; observation of routine medical care
79716130|NCT00957931|Procedure|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
79255637|NCT05023304|Drug|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
79551800|NCT01610375|Other|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
79551801|NCT01610388|Drug|500mg IV GSK1322322/placebo|500mg IV
79716131|NCT00957931|Biological|Mesenchymal Stromal Cells|
79551802|NCT01610388|Drug|1000mg oral GSK1322322/placebo|1000mg oral
79551803|NCT01610388|Drug|1000mg IV GSK1322322/placebo|1000mg IV
79716132|NCT00957853|Drug|Cetuximab|First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
79716133|NCT00957853|Drug|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
79716134|NCT00957853|Procedure|Surgical tumor resection|Surgical tumor resection on Day 10.
79716135|NCT02858167|Device|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
79716136|NCT02858245|Other|No intervention - registry|
79551804|NCT01610388|Drug|1500mg oral GSK1322322/placebo dose|1500mg oral
79853054|NCT06121479|Drug|Branched-chain amino acid|Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
79255638|NCT05023304|Drug|Topical Prednisolone|Standard of care topical drop treatment
79255639|NCT05017376|Procedure|small incision lenticular extraction|In patients with the same degree of myopia, different optical zones were designed for operation
79395240|NCT00323271|Behavioral|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
79551805|NCT01610388|Drug|1500mg IV GSK1322322/placebo|1500mg IV
79551806|NCT01610388|Drug|2000mg IV GSK1322322J/placebo|2000mg IV
79551807|NCT01610388|Drug|3000mg IV GSK1322322J/placebo|3000mg IV
79551808|NCT01610388|Drug|1000mg IV GSK1322322J/placebo|1000mg IV
79551809|NCT01610401|Drug|Metformin|metformin 500 mg three times a day, for 3 days
79551810|NCT01610401|Drug|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
79716137|NCT00957229|Drug|GDC-0449|capsule, 150 mg, one pill daily, 18 months
79716138|NCT02604511|Drug|Ibrutinib|
79716139|NCT02858011|Other|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
79716140|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
79716141|NCT02858011|Dietary Supplement|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
79716142|NCT02858011|Other|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
79716143|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
79716144|NCT02859571|Drug|Oxytocin|
79716145|NCT04282369|Device|HHHFNC|noninvasive ventilation modality
79716146|NCT04282369|Device|NCPAP|noninvasive ventilation modality
79716147|NCT04282369|Device|NIPPV|noninvasive ventilation modality
79716148|NCT04282369|Device|NHFO|noninvasive ventilation modality
79853055|NCT06121440|Other|Listening to audiobook|Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.
79255640|NCT03281655|Drug|Visnadine, prenylflavonoids and bovine colostrum|15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
79716149|NCT04280809|Device|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
79551811|NCT01610401|Drug|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
79716150|NCT02857933|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
79716151|NCT00956839|Drug|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
79716152|NCT00956293|Drug|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
79716153|NCT00956293|Drug|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
79716154|NCT00956293|Drug|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
79716155|NCT00956293|Drug|Cyclosporin A (CsA)|Dosage was based according to blood level
79716156|NCT00956293|Drug|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
79551812|NCT01610440|Biological|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
79551813|NCT01610466|Procedure|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
79853056|NCT06121440|Other|Playing musical-moving toy|Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
79853057|NCT06121089|Procedure|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
79853058|NCT06121089|Procedure|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
79853059|NCT06120998|Procedure|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
80017896|NCT04055259|Behavioral|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
79255641|NCT05030168|Drug|Ketosteril|ketoanalogues of essential amino acid
79551814|NCT01610479|Drug|TAS-114 + S-1|
79551815|NCT01610518|Dietary Supplement|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
79551816|NCT01610518|Dietary Supplement|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
79551817|NCT01610531|Other|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
79255642|NCT03286647|Procedure|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
79255643|NCT03092648|Biological|Bronchial basal cell|autologous bronchial basal cell transplantation
79255644|NCT02109913|Drug|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
79255645|NCT05030246|Drug|Surufatinib/Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
79853060|NCT06120205|Device|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
79853061|NCT06118385|Drug|BEN8744|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
79853062|NCT06118385|Drug|Matching Placebo|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
80017897|NCT04055259|Behavioral|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
79551818|NCT01610544|Drug|3'-deoxy-3'-18F fluorothymidine (FLT)|
79551819|NCT01610544|Other|PET/CT scan|
79853063|NCT06116266|Other|Education and support for primary care providers (PCPS)|All PCPs in the EUC and Co-Care arms receive brief education on SUD treatment, including medications for OUD and AUD and contingency management for StUD, and recognizing and counteracting stigma while caring for patients with SUD.
79853064|NCT06116266|Other|Nurse Care Manager (NCM) visits|A full-time clinic-embedded nurse care manager who works with patients and their PCPs to facilitate and support patient engagement in evidence-based treatment for polysubstance use and management of associated health conditions
79853065|NCT06116266|Other|Addiction specialist consultant|An addiction specialist consultant who supports the nurse care manager and PCP in formulating and adjusting treatment plans
79853066|NCT06116266|Other|Health coaching sessions|Health coaches who use motivational interviewing and cognitive behavioral therapy to motivate and support patients in behavior change to reduce polysubstance use-related harms. Patients may receive up to 12 health coaching sessions in total. The sessions will occur via phone and/or HIPAA compliant video chat software.
79853067|NCT06116266|Other|Patient educational materials|Patient participants receive an educational pamphlet addressing overdose prevention, information about accessing naloxone, and local SUD treatment options.
79853068|NCT06113263|Procedure|Anterior cervical decompression surgery|The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
79853069|NCT06113263|Procedure|Posterior cervical foraminotomy with or without laminectomy|The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
80017898|NCT04941508|Behavioral|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
79551820|NCT01610609|Behavioral|Population Health Management Intervention|"This intervention includes:~Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
79551821|NCT01610622|Device|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
79551822|NCT01610635|Other|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
79551823|NCT01610661|Other|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
79551824|NCT01610674|Other|Tailored improvement strategy|"A step-wise implementation model is applied:~1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
79551825|NCT01610726|Procedure|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
79551826|NCT01610739|Drug|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
79551827|NCT01610765|Drug|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
79551828|NCT01610765|Drug|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
79551829|NCT01610778|Dietary Supplement|Placebo|
79551830|NCT01610778|Dietary Supplement|5-aminolevulinic acid phosphate|
79716157|NCT04204369|Other|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
79716158|NCT04282291|Procedure|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
79716159|NCT04282291|Drug|Morphine|The continuous (basal) dose
79853070|NCT06111794|Other|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
80017899|NCT04941508|Drug|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
80017900|NCT04941508|Other|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
79255646|NCT03291873|Procedure|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
79255647|NCT02116231|Drug|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
79255648|NCT02116231|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
79255649|NCT03291795|Other|Exercise Intervention|Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
79551831|NCT01610817|Other|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
79551832|NCT01610856|Drug|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
79551833|NCT01610856|Drug|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
79551834|NCT01610869|Drug|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
79551835|NCT01610882|Device|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
79551836|NCT01610882|Device|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
79551837|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
79551838|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
79551839|NCT01610921|Other|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
79255650|NCT05030480|Diagnostic Test|renal functions|urea, creatinine, GFR
79255651|NCT02111161|Drug|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
79255652|NCT02111161|Drug|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
79255653|NCT03291717|Behavioral|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
79551840|NCT01610934|Drug|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
79716160|NCT04282291|Device|PCA CADD Smith Medical pumps|perfusion
79551841|NCT01610934|Drug|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
79716161|NCT00955825|Drug|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
79716162|NCT00955825|Drug|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
79853071|NCT06110572|Drug|Carboplatin|Given by IV
79853072|NCT06110572|Biological|Atezolizumab|Given by IV
79853073|NCT06110572|Drug|Etoposide|Given by IV
79853074|NCT06110572|Radiation|Total Body Irradiation|Undergo Total Body Irradiation
79853075|NCT06110572|Radiation|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
79853076|NCT06110572|Procedure|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
79255654|NCT05017220|Other|Nature-based sensory stimuli|A program based on stimulation using nature-based sensory stimuli will be implemented
79551842|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
79551843|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
80017901|NCT03552510|Procedure|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
79255655|NCT05017220|Other|Control group intervention|An activity based on a placebo intervention will be implemented
79551844|NCT01610960|Device|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
79551845|NCT01610960|Device|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
79551846|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
80017902|NCT04934254|Other|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
79255656|NCT03286569|Device|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
79255657|NCT02111239|Device|CTA|pelvic/abdominal CTA scan
79255658|NCT02111239|Device|MRA|pelvic/abdominal MRA scan
79255659|NCT02116387|Other|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
79255660|NCT02116387|Device|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
79255661|NCT05016830|Device|Bilateral transcranial direct current stimulation|A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
79255662|NCT03092570|Device|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
79551847|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
79551848|NCT01610986|Dietary Supplement|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
79551849|NCT01610986|Dietary Supplement|Water|Only water intake during training
79551850|NCT01610999|Drug|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
79551851|NCT01611038|Dietary Supplement|Methylselenocysteine|Methylselenocysteine capsule given daily
79551852|NCT01611038|Dietary Supplement|Placebo|Placebo capsule given daily
79551853|NCT01611051|Drug|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
79551854|NCT01611051|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
79551855|NCT01611051|Drug|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
79551856|NCT01611064|Drug|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
79551857|NCT01611064|Drug|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
79551858|NCT01611077|Drug|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
79551859|NCT01611077|Drug|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
79551860|NCT01611077|Drug|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
79551861|NCT01611103|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
79716163|NCT02859181|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
79716164|NCT02859103|Drug|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
79716165|NCT04282135|Diagnostic Test|MCC IMS|Diagnosis by MCC IMS
79716166|NCT02859025|Biological|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
79716167|NCT02859025|Biological|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
79716168|NCT02859025|Biological|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
79716169|NCT02869009|Drug|clopidogrel|
79551862|NCT01611129|Behavioral|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI & CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
79551863|NCT01611142|Biological|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
79716170|NCT02869009|Drug|Aspirin|
79716171|NCT01164579|Drug|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
79875332|NCT01042899|Behavioral|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
80017903|NCT01062555|Drug|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
80017904|NCT01062555|Drug|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
79395241|NCT00323271|Other|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
79395242|NCT02346864|Behavioral|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
79551864|NCT01611181|Drug|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
79551865|NCT01611181|Drug|Kräuterblut|40 mg iron, 20 ml twice daily.
79551866|NCT01611181|Drug|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
79551867|NCT01611207|Device|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
79255663|NCT03092570|Device|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
79255664|NCT02790073|Drug|SNF472|SNF472 for calciphylaxis
79551868|NCT01611207|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
79551869|NCT01611220|Behavioral|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
79551870|NCT01611246|Device|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
79551871|NCT01611311|Drug|BI 409306 BS|Medium dose film-coated tablet
79551872|NCT01611311|Drug|BI 409306 BS|High dose film-coated tablet
79551873|NCT01611311|Drug|Placebo|Film-coated tablet
79551874|NCT01611324|Drug|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
79551875|NCT01611324|Drug|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
79551876|NCT01611337|Other|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
79551877|NCT01611350|Other|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
79255665|NCT05016986|Other|Standard clinical management|outcomes in GSW cardiac injuries
79255666|NCT02116465|Drug|Levodopa Carbidopa immediate release tablets|oral administration
79255667|NCT03552679|Diagnostic Test|Echocardiography|Echocardiography
79716172|NCT01164579|Drug|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
79853077|NCT06110156|Behavioral|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
79853078|NCT06109480|Device|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
79853079|NCT06109480|Device|Sham High definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
79853080|NCT06109480|Device|electroconvulsive therapy device|ECT induces brief generalized epileptic seizures by electric current to stimulate the forehead under general anesthesia
79395243|NCT02346864|Behavioral|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
79551878|NCT01611350|Other|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
79551879|NCT01611350|Other|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
79551880|NCT01611363|Drug|ASP1941|Oral
79853081|NCT06108037|Behavioral|Generative AI for electronic communication and disclosure|We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
79875333|NCT01042899|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
79255668|NCT03094676|Other|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
79255669|NCT03094676|Other|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
79255670|NCT02118883|Other|Essentia Water|
79255671|NCT02118883|Other|Bottled water|
79255672|NCT03094598|Other|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
79395244|NCT05265819|Device|X-BOX kinetic360|1) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
79395245|NCT05265819|Dietary Supplement|mediterranean diet|Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
79395246|NCT05265819|Drug|thyroid hormone replacement therapy|thyroid hormone replacement therapy
79395247|NCT02346552|Device|AutoLap|
79395248|NCT00323427|Behavioral|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
79395249|NCT00323427|Device|hearing aid services|Standard VA audiological hearing aid dispensing services
79395250|NCT03146286|Dietary Supplement|Saturated fat|Palm stearin
79395251|NCT03146286|Dietary Supplement|Placebo|Water
79395252|NCT03146286|Dietary Supplement|Fish Oil|Fish Oil, Omega 3 PUFA
79551881|NCT01611363|Drug|Placebo|Oral
79716173|NCT01164579|Drug|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
79716174|NCT02859259|Drug|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
79716175|NCT02859259|Drug|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
79716176|NCT04280731|Dietary Supplement|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
79716177|NCT02858947|Procedure|Aelite Flo|Microhybrid flowable composite
79255673|NCT03094598|Other|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
79716178|NCT02858947|Procedure|x-tra base|Bulk-fill flowable composite
79853082|NCT06107907|Device|Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)|Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
79551882|NCT01611376|Device|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
79551883|NCT01611389|Device|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
79255674|NCT03094598|Other|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
79551884|NCT01611389|Device|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
79551885|NCT01611415|Drug|Ipragliflozin|Oral
79551886|NCT01611415|Drug|Furosemide|Oral
79551887|NCT01611428|Drug|Ipragliflozin|Oral and Intravenous (i.v.)
79551888|NCT01611467|Drug|CC-223|20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
79551889|NCT01611467|Drug|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
79551890|NCT01611480|Drug|Imiquimod (topical use)|
79551891|NCT01611493|Device|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
79551892|NCT01611493|Device|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
79551893|NCT01611506|Biological|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
79551894|NCT01611506|Drug|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
79551895|NCT01611506|Drug|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
79551896|NCT01611545|Genetic|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
79551897|NCT01611584|Drug|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
79551898|NCT01611597|Other|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
79551899|NCT01611610|Other|Functional tests|"The ambulant patients will perform~MFM (20 items)~Hammersmith modified module - MHMFS~Timed tests (time to rise from the floor,...)~6 minute walk test~PedsQL - neuromuscular module"
79551900|NCT01611610|Other|Functional tests|"The non-ambulant patients will perform:~MFM (20 items)~Hammersmith modified module - MHMFS~Upper Limb Functional Items~Egen Klassifikation 2 questionnaire - EK2~PedsQL questionnaire - neuromuscular module"
79551901|NCT01611623|Drug|SNX-5422|Tablets dose every other day; dose escalation based on safety
79551902|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils|4 months consumption
79551903|NCT01611649|Dietary Supplement|Formula containing plant oils|4 months consumption
79716179|NCT00958789|Device|Triathlon TS Knee System|Total knee replacement for revision cases
79853083|NCT06107725|Drug|Minocycline|Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
79551904|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
79551905|NCT01611675|Drug|Vemurafenib|take orally, twice daily
79551906|NCT01611675|Drug|Leflunomide|take orally, once daily
79551907|NCT01611688|Drug|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
79255675|NCT02116543|Drug|TD-6450|
79255676|NCT02116543|Drug|Placebo|
79551908|NCT01611688|Drug|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
79551909|NCT01611688|Drug|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
79551910|NCT01611701|Procedure|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
79716180|NCT02857777|Drug|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
79716181|NCT02858635|Other|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
79716182|NCT05367375|Procedure|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
79716183|NCT00630643|Biological|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
79255677|NCT03553225|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
79716184|NCT00630643|Drug|Placebo|Placebo
79551911|NCT01611701|Procedure|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
79853084|NCT06107218|Other|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
80017905|NCT01062555|Drug|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
80017906|NCT01062555|Drug|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
79551912|NCT01611714|Other|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
79551913|NCT01611714|Other|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
79551914|NCT01611727|Drug|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
79551915|NCT01611740|Procedure|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~the variability of the cardiac cycle duration ;~the variability of respiratory cycle amplitude and duration ;~and their relationships."
79551916|NCT01611753|Other|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
79551917|NCT01611766|Procedure|Secondary Cytoreductive Surgery|Complete Cytoreduction
79551918|NCT01611766|Drug|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
79551919|NCT01611805|Drug|GSK1605786|Opaque Swedish orange body and cap.
79551920|NCT01611805|Drug|GSK1605786 Placebo|Opaque Swedish orange body and cap.
79551921|NCT01611818|Other|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
79551922|NCT01611818|Other|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
79551923|NCT01611818|Other|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
79551924|NCT01611831|Behavioral|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
79551925|NCT01611831|Behavioral|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
79551926|NCT01611844|Device|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~1 intradermal injection of Tuberculin (5UI)~1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
79716185|NCT03202849|Dietary Supplement|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
79716186|NCT03202849|Dietary Supplement|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
79716187|NCT04277533|Diagnostic Test|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
79716188|NCT04277221|Biological|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
79716189|NCT02445391|Drug|Capecitabine|Given PO
79716190|NCT02445391|Drug|Carboplatin|Given IV
79716191|NCT02445391|Drug|Cisplatin|Given IV
79716192|NCT01246986|Drug|LY2157299|Administered orally
79853085|NCT06107218|Other|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
79853086|NCT06107075|Dietary Supplement|Active|40g bio-active whey protein concentrate powder containing phospholipids
79853087|NCT06107075|Dietary Supplement|Placebo|around 40g pea protein powder not containing phospholipids
79853088|NCT06104930|Other|Explorative biomarker study|Analysis of blood biomarker
80017907|NCT02119962|Behavioral|Working memory training|
80017908|NCT02119962|Behavioral|Placebo training|
80017909|NCT05128864|Procedure|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
80017910|NCT03652701|Other|Hair Up|Herbal topical
79255678|NCT03553225|Dietary Supplement|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
80017911|NCT03652701|Other|Placebo|Placebo
80017912|NCT05128708|Procedure|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
80017913|NCT03622047|Drug|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
80017914|NCT03622047|Drug|No analgesia labor|No analgesia labor control group
79255679|NCT03553225|Dietary Supplement|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
79716193|NCT01246986|Drug|Sorafenib|Administered orally
79716194|NCT01246986|Drug|Ramucirumab|Administered IV
79716195|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
79716196|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
79255680|NCT02119039|Device|RGTA OTR 4120 (CACICOL20)|
79551927|NCT01611844|Device|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~1 intradermal injection of Tuberculin (5UI)~1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
79551928|NCT01611896|Dietary Supplement|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
79551929|NCT01611896|Other|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
79716197|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
79716198|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
79716199|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
79716200|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
79716201|NCT05322291|Behavioral|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
79716202|NCT04276831|Device|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
79716203|NCT04276831|Device|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
79716204|NCT04282057|Device|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
79716205|NCT04282057|Device|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
79551930|NCT01611909|Drug|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
79716206|NCT04282057|Device|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
79716207|NCT04319640|Behavioral|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
79716208|NCT04319640|Behavioral|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
79716209|NCT04275271|Behavioral|Educational intervention|Skill centered Protocol Training based on IMB model
79716210|NCT00958711|Device|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
79716211|NCT00958711|Other|Saline and Gauze|gauze moistened with sterile saline
79716212|NCT01163721|Drug|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
79716213|NCT01163721|Drug|Placebo|Placebo to match ranolazine administered orally twice daily
79716214|NCT03178981|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
79716215|NCT02885493|Behavioral|tests|
79716216|NCT04314453|Other|percutaneous endoscopic lumbar discectomy|Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
79716217|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
79716218|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
79716219|NCT00958243|Biological|Placebo|Placebo
79716220|NCT01241760|Drug|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
79255681|NCT02119039|Device|Genteal HA eye drops|
79255682|NCT03092258|Other|Questionnaire|Questionnaire to be completed by staff
79255683|NCT02119117|Dietary Supplement|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
79255684|NCT02119117|Dietary Supplement|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
79304749|NCT02458001|Behavioral|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
80017915|NCT05128552|Device|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
80017916|NCT05128552|Other|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
79853089|NCT06096922|Other|No intervention|No intervention
79551931|NCT01611922|Other|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
79551932|NCT01611922|Device|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
79551933|NCT01611961|Drug|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
79551934|NCT01611961|Drug|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
79551935|NCT01611987|Other|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
79551936|NCT01611987|Other|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
79551937|NCT01612013|Drug|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
79551938|NCT01612013|Drug|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
79551939|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
79551940|NCT01612013|Drug|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
79551941|NCT01612013|Drug|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
79716221|NCT01241760|Drug|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
79716222|NCT01241760|Drug|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
79716223|NCT01241760|Drug|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
79716224|NCT04280263|Drug|Caffeine|caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
79716225|NCT04280263|Drug|Placebo oral tablet|oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
79853090|NCT06095492|Drug|Empagliflozin 25 MG|Patient will get Empagliflozin 25
79853091|NCT06095492|Drug|Linagliptin|linagliptin 5 mg once a day
79853092|NCT06092749|Other|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
79853093|NCT06092749|Other|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
80017917|NCT05073562|Dietary Supplement|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
80017918|NCT05073562|Behavioral|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
80017919|NCT05073562|Drug|Mebendazole Pill|One-time deworming treatment with mebendazole.
80017920|NCT05073562|Other|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
80017921|NCT01064817|Drug|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
80017922|NCT01064817|Drug|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
80017923|NCT01368276|Biological|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
79551942|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
79716226|NCT02858557|Behavioral|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
79716227|NCT02858557|Behavioral|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
79853094|NCT06091995|Behavioral|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
79255685|NCT05029700|Other|Combined exercise training|Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
79395253|NCT02353494|Drug|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
79395254|NCT03149406|Other|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
79395255|NCT02353260|Device|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
79395256|NCT02353260|Drug|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
79395257|NCT03148938|Other|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~walking test~coordination test~attention test~vision test"
79395258|NCT03158610|Drug|Capecitabine|Oral fluorouracil
79395259|NCT02350140|Other|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
79551943|NCT01612026|Procedure|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
79551944|NCT01612052|Drug|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
79551945|NCT01612065|Drug|Misoprostol|200 ug
79551946|NCT01612065|Drug|Misoprostol|Misoprostol vaginally, 400 ug
79853095|NCT06091124|Drug|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
79853096|NCT06091124|Drug|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
79853097|NCT06091124|Drug|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
79853098|NCT06091124|Procedure|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
79551947|NCT01612078|Drug|Droxidopa|200mg/tab 2tablets, po, three times a week
79551948|NCT01612078|Drug|Placebo|200mg/tab, po, three times a week.
79551949|NCT01612091|Device|Monitoring Messenger|Monitoring Messenger prototype device
79551950|NCT01612091|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
79853099|NCT06089915|Behavioral|Standard occupational therapy|Standard occupational therapy as part of inpatient rehabilitation
79395260|NCT02350140|Other|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
79853100|NCT06089915|Device|Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton|Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
79716228|NCT00958165|Device|CardioFocus EAS-AC|PVI for PAF
79395261|NCT00323739|Drug|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
79395262|NCT00323739|Drug|RAD001|RAD001 10 mg by mouth daily
79395263|NCT02350218|Drug|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
79551951|NCT01612104|Behavioral|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
79551952|NCT01612130|Drug|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
79716229|NCT04280185|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
79716230|NCT02858479|Other|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
79716231|NCT02858479|Other|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
79716232|NCT02858479|Radiation|MRI scan|"2 sessions for 10 minutes :~11 controls stimulations for 6 s each spaced 20 s without stimulation.~11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
79551953|NCT01612130|Drug|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
79716233|NCT00958009|Device|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
79716234|NCT02857075|Other|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
79716235|NCT00953407|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
79716236|NCT00953407|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
79716237|NCT00953407|Device|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
79716238|NCT00953407|Device|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
79716239|NCT00953407|Device|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
79716240|NCT00953329|Drug|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
79716241|NCT02857153|Drug|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
79853101|NCT06088641|Diagnostic Test|preoperative BNP value|preoperative BNP value
79853102|NCT06088329|Behavioral|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
79853103|NCT06087432|Other|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
79853104|NCT06087432|Other|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
79853105|NCT06086184|Behavioral|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
79395264|NCT03157518|Dietary Supplement|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
79551954|NCT01612143|Drug|setrobuvir|200 mg capsule formulation, single oral dose
79551955|NCT01612143|Drug|setrobuvir|200 mg tablet formulation, single oral dose
79395265|NCT05242341|Behavioral|application(APP) teaching|Teaching the use of the APP
79551956|NCT01612169|Behavioral|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
79716242|NCT02857153|Drug|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
79716243|NCT02857153|Procedure|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
79716244|NCT02857153|Procedure|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
79716245|NCT02856997|Drug|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
79716246|NCT00953017|Drug|Miralax (PEG 3350)|Miralax 255gm bottle
79716247|NCT00953017|Drug|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
79716248|NCT00953017|Drug|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
79716249|NCT00953017|Drug|Golytely (polyethylene glycol)|Golytely 1 gallon
79716250|NCT00952705|Biological|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
79716251|NCT00952705|Biological|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
79853106|NCT06085755|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
79551957|NCT01612169|Behavioral|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
80017924|NCT01368276|Drug|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
80017925|NCT05009524|Device|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
79395266|NCT03157284|Dietary Supplement|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
79551958|NCT01612182|Other|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
79716252|NCT00952705|Biological|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
79716253|NCT00955357|Drug|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
79716254|NCT00955279|Drug|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
79853107|NCT06085755|Drug|Afatinib|Afatinib will be administered orally 20mg ~40mg once a day or three times a week(Monday, Wednesday, Friday [MWF]) or twice weekly (Monday, Thursday [MT]) for 3weeks as one cycle.
79853108|NCT06085209|Device|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
79853109|NCT06085209|Device|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
79853110|NCT06085209|Device|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
79853111|NCT06085092|Behavioral|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
79853112|NCT06085092|Behavioral|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
79853113|NCT06084793|Other|Music|In the pre-transfer room, the personalized playlist will be played through earphones or speakers, according to the patient´s preference. In the transfer room, the personalized playlist will be played through speakers at a volume that is loud enough for the participant to hear but soft enough to ensure clear communication between the patient and doctor, without causing any disturbance to the doctor.
80017926|NCT05009524|Device|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
80017927|NCT01064739|Dietary Supplement|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
80017928|NCT01064739|Other|Fixed Sodium Diet|Fixed sodium low monoamine diet
79304750|NCT03268187|Device|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
79304751|NCT03268187|Behavioral|Self-Alert Training|Self-Alert Training
79304752|NCT03268187|Behavioral|Relaxation Training|Relaxation Training
79304753|NCT03272711|Drug|Vortioxetine 10 mg|
79304754|NCT03272711|Behavioral|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
79395267|NCT03157284|Dietary Supplement|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
79395268|NCT03156192|Behavioral|Survey|Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
79395269|NCT02346318|Drug|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
79395270|NCT04121442|Biological|Isunakinra|Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling
80017929|NCT02116686|Device|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
80017930|NCT02116842|Drug|0.1% bupivacaine|Epidural block in early labour.
80017931|NCT02116842|Drug|0.075% bupivacaine|Epidural block in early labour.
80017932|NCT02116842|Drug|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
79304755|NCT03267719|Device|laser therapy|Transvaginal erbium-laser treatment
79853114|NCT06081920|Biological|IBI363|RP2D of IBI363
79853115|NCT06080451|Other|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~Training health workers on diabetes and hypertension treatment protocols~Team-based care and task sharing~Strengthening access to medications and diagnostics~Electronic medical record system and registry~Systems monitoring and feedback of key indicators"
79853116|NCT06080451|Other|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~Training health workers on diabetes and hypertension treatment protocols~Team-based care and task sharing~Strengthening access to medications and diagnostics~Electronic medical record system and registry~Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
79853117|NCT06079697|Other|Electronic Health Record Review|Ancillary studies
79853118|NCT06079697|Other|Exercise Intervention|Receive prehabilitation exercise intervention
80017933|NCT03652623|Drug|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
80017934|NCT02120118|Radiation|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
80017935|NCT02120118|Other|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
80017936|NCT02120118|Drug|Cisplatin|30mg/m2
80017937|NCT02120118|Drug|Taxotere|20mg/m2
80017938|NCT04054089|Drug|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
80017939|NCT04054089|Drug|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
79395271|NCT04121442|Biological|PD-(L)1 Inhibitor|Monoclonal antibody targeting PD-1 or PD-L1
79395272|NCT00390429|Drug|docetaxel|Given IV
79395273|NCT00390429|Drug|erlotinib hydrochloride|Given orally
79395274|NCT02349750|Procedure|endometrial scratch injury|ESI using No.8 neonatal feeding tube
79395275|NCT02349828|Drug|Acyclovir|
79395276|NCT02353416|Behavioral|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
79853119|NCT06079697|Other|Medical Device Usage and Evaluation|Wear Fitbits
79853120|NCT06079697|Other|Survey Administration|Ancillary studies
79853121|NCT06079229|Other|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
79853122|NCT06078241|Drug|Intravenous lidocaine infusion|Intravenous lidocaine infusion
79853123|NCT06078241|Other|Erector spinae plane block (ESPB)|Unilateral erector spinae plane block
79853124|NCT06078241|Other|Intravenous infusion of normal saline|Intravenous infusion of normal saline
79853125|NCT06078241|Other|ESPB with normal saline|Unilateral ESPB with normal saline
79853126|NCT06077656|Biological|IVT PCV-25 Formulation A|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
79853127|NCT06077656|Biological|IVT PCV-25 Formulation B|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
79395277|NCT02353416|Other|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
79395278|NCT02353182|Drug|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
79395279|NCT02353182|Drug|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
79853128|NCT06077656|Biological|IVT PCV-25 Formulation C|25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
80017940|NCT02120196|Drug|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
80017941|NCT02120196|Drug|Norfloxacin|FDA approved:400mg once daily
80017942|NCT05001802|Procedure|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
80017943|NCT05001802|Procedure|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
80017944|NCT04242771|Behavioral|Mindfulness|Subjects practice mindfulness before bedtime
80017945|NCT02120274|Drug|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
80017946|NCT02120274|Drug|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
80017947|NCT02402842|Drug|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
80017948|NCT02123316|Biological|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
80017949|NCT02123316|Biological|Placebo|Placebo for subcutaneous injection
80017950|NCT03652935|Behavioral|Mindfulness Based Stress Reduction|
80017951|NCT03652935|Other|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
79551959|NCT01612195|Procedure|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
79551960|NCT01612208|Device|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
79551961|NCT01612208|Device|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
79551962|NCT01612234|Dietary Supplement|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
79551963|NCT01612247|Drug|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
79551964|NCT01612260|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
79551965|NCT01612260|Drug|placebo Capsule|4 granules t.i.d. po for 12 weeks
79716255|NCT00955279|Drug|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
79716256|NCT00955279|Drug|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
79716257|NCT00954733|Other|Arterial blood draw|One arterial blood draw
79716258|NCT00630721|Other|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
79255686|NCT05029700|Other|Aerobic training|Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
79395280|NCT02353182|Drug|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
79395281|NCT02353182|Drug|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
80017952|NCT02123394|Other|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
80017953|NCT02123394|Other|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
80017954|NCT04054479|Drug|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
80017955|NCT04054479|Drug|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
79395282|NCT02353104|Dietary Supplement|Onion-Pumpkin Extract|
79395283|NCT03145974|Device|mechanical ventilation|ventilatory support
79395284|NCT03146130|Biological|Variation of behaviors of Parkinson's disease|Variation of hyper dopaminergic behaviors of Parkinson's disease
79395285|NCT02349672|Procedure|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
79716259|NCT00954421|Device|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
80017956|NCT03553134|Diagnostic Test|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
80017957|NCT03553134|Diagnostic Test|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
79255687|NCT02119195|Procedure|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
79255688|NCT05016128|Drug|S-ketamine|S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
79255689|NCT05016128|Drug|saline|saline is used for control
79395286|NCT02349516|Drug|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
79255690|NCT02111317|Drug|ASP015K|oral
79255691|NCT02111317|Drug|verapamil|oral
79551966|NCT01612273|Drug|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
79716260|NCT02857309|Device|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
79716261|NCT02857309|Drug|Optimal medical therapy|OMT using standard heart failure (HF) drugs
79853129|NCT06077656|Biological|PCV 20|20 valent pneumococcal conjugate vaccine
79853130|NCT06074614|Diagnostic Test|Hypercapnic ventilatory response|Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.
79853131|NCT06074614|Diagnostic Test|Respiratory related evoked potential|The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.
79853132|NCT06074614|Diagnostic Test|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
79853133|NCT06069934|Drug|Pridopidine|Pridopidine 45 mg once daily p.o. (or via feeding tube) over a 2-week up-titration period; followed by pridopidine 45 mg twice daily p.o. (or via feeding tube) for the remainder of the treatment period (through Week 104)
79853134|NCT06069180|Drug|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
80017958|NCT01061775|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
79551967|NCT01612273|Drug|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
79853135|NCT06069180|Drug|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
80017959|NCT02123628|Drug|duration of the antibiotic therapy|
80017960|NCT02651116|Drug|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
79255692|NCT03092414|Procedure|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
79255693|NCT03092414|Procedure|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
79255694|NCT03553615|Drug|Ivermectin Pill|oral anti-parasitic agent taken as a weekly dose for four weeks
79255695|NCT05016206|Drug|Danicopan|Danicopan tablets administered as a single oral dose.
79551968|NCT01612286|Drug|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle *4cycles
79853136|NCT06067711|Device|resistance band|The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
79853137|NCT06067217|Drug|Tranexamic acid 250 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
79875334|NCT03993405|Other|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
79255696|NCT05016206|Drug|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo was administered as a single oral dose.
79875335|NCT00387153|Drug|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
79255697|NCT05016206|Drug|Danicopan-matching placebo|Danicopan-matching placebo was administered as a single oral dose.
79255698|NCT05016206|Drug|Moxifloxacin|Moxifloxacin 400 mg was administered as a single tablet oral dose.
79255699|NCT02116855|Other|according to the efficacy of AJBRs|
79255700|NCT02111473|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
79255701|NCT02111551|Drug|DMXB-A 150 mg|
79255702|NCT02111551|Other|placebo|
79255703|NCT02111551|Drug|DMXB-A 75 mg|
79255704|NCT05029544|Other|Dynamic taping|The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.
79255705|NCT05029544|Other|Kinesio taping|The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.
79255706|NCT05029544|Other|Physiotherapy and Rehabilitation|exercise, manuel therapy, mobilization, massage, sensorimotor control
79255707|NCT02119273|Drug|Prednisone|See arm description
79255708|NCT02119273|Drug|Placebo|See arm description
79255709|NCT02119351|Device|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
79716262|NCT04261231|Procedure|Surgery and anesthesia|Elective surgery in adults
79716263|NCT02857465|Drug|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
79716264|NCT02857465|Drug|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
79716265|NCT02857465|Drug|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
79716266|NCT02857465|Drug|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
79716267|NCT02857387|Biological|blood sample withdrawn|
79716268|NCT04273009|Device|Renew VS PTNS|These will be prescribed and applied as described above.
79875336|NCT00386607|Drug|Aliskiren|Aliskiren 300 mg
79875337|NCT00386607|Drug|Valsartan|Valsartan 320 mg
79875338|NCT00386607|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
79875339|NCT00410163|Drug|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
79551969|NCT01612299|Drug|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml."
79551970|NCT01612312|Procedure|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
79551971|NCT01612312|Procedure|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
79551972|NCT01612325|Device|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
80017961|NCT02651116|Drug|Placebo|10 mL Placebo
80017962|NCT02651116|Device|Cough recording device|FDA approved device validated for use in adults and children
79255710|NCT02119351|Device|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
79255711|NCT05029778|Dietary Supplement|L-arginine 3g + L-Citruline 2 g|receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.
79255712|NCT05029778|Drug|Placebo|receive placebo 3g PO, for 24 h, until birth.
79551973|NCT01612338|Behavioral|Targeted|Targeted letter and booklet
79551974|NCT01612338|Behavioral|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
79551975|NCT01612364|Procedure|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
79551976|NCT01612377|Drug|Prednisolone-Dipyridamole|Oral, QD
79395287|NCT03155256|Procedure|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
79551977|NCT01612377|Drug|Prednisone|Oral QD Prednisone 5mg
79255713|NCT02119429|Dietary Supplement|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
79395288|NCT03155256|Procedure|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
79395289|NCT02349594|Drug|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
79551978|NCT01612377|Drug|prednisone|Oral, QD prednisone 7.5mg
79551979|NCT01612403|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
79551980|NCT01612416|Device|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
79255714|NCT02119429|Dietary Supplement|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
79716269|NCT04260139|Procedure|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~Proximal colon,~Ileum in cases with right hemicolectomy only,~Proximal border,~Tumor,~Distal border,~Total specimen,~Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
79716270|NCT01241448|Drug|LY2409021|Administered Orally
79716271|NCT01241448|Drug|Placebo|Administered Orally
79255715|NCT05029076|Drug|Liraglutide injection|Human glucagon-like peptides-1 analogue
79255716|NCT05029076|Drug|Victoza|Human glucagon-like peptides-1 analogue
79255717|NCT02119507|Device|Curodont Repair|Single application on Day 0
79853138|NCT06067217|Drug|Progynova 1 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
79875340|NCT00410163|Drug|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
80017963|NCT03552042|Behavioral|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
80017964|NCT03552042|Behavioral|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
79716272|NCT04319406|Procedure|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
79716273|NCT04319406|Procedure|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
79551981|NCT01612429|Dietary Supplement|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
79716274|NCT01240356|Device|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
79716275|NCT01240356|Device|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
79551982|NCT01612442|Behavioral|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
79551983|NCT01612442|Behavioral|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
79716276|NCT04206618|Drug|Teriparatide|1 subcutaneous injection daily for 12 months
79551984|NCT01612455|Behavioral|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
79853139|NCT06067009|Behavioral|ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease|ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.
79551985|NCT01612468|Drug|Liraglutide|1.8 mg/day subcutaneous
79551986|NCT01612468|Drug|Placebo|1.8 mg/day subcutaneous
79551987|NCT01612481|Procedure|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
79551988|NCT01612481|Procedure|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
79551989|NCT01612507|Drug|600 mg Ceftaroline fosamil|1 h infusion
79853140|NCT06066723|Combination Product|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
79551990|NCT01612507|Drug|Placebo|1 h infusion
79853141|NCT06062108|Other|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
79853142|NCT06061523|Drug|Sotorasib|Oral Tablet
79551991|NCT01612507|Drug|600 mg Ceftaroline fosamil|2 h infusion
79551992|NCT01612507|Drug|Placebo|2 h infusion
79716277|NCT04206618|Drug|Denosumab|1 subcutaneous injection every 6 months for 12 months
79716278|NCT01239732|Drug|Paclitaxel|175 mg/m^2 on Day 1 every 3 weeks or at a dose of 80 mg/m^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
79255718|NCT02119507|Other|No treatment - control|
79716279|NCT01239732|Drug|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
79716280|NCT01239732|Drug|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
79716281|NCT02227147|Drug|rhNGF 20µg/ml|
79716282|NCT02227147|Other|Placebo|Formulation containing antioxidant
79716283|NCT02856919|Drug|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
79716284|NCT02854735|Other|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
79716285|NCT00948025|Device|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
79716286|NCT00948025|Other|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
79716287|NCT02854579|Biological|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
79716288|NCT02854579|Biological|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
79716289|NCT02854579|Biological|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
79551993|NCT01612520|Behavioral|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
79551994|NCT01612598|Other|counseling intervention|Undergo PCI
79551995|NCT01612598|Procedure|quality-of-life assessment|Ancillary studies
79551996|NCT01612598|Other|questionnaire administration|Ancillary studies
79551997|NCT01612598|Other|educational intervention|Undergo PCI
79551998|NCT01612637|Behavioral|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
79551999|NCT01612637|Behavioral|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
79552000|NCT01612650|Device|tomosynthesis|2 incidences 3D numeric mammography
79552001|NCT01612650|Device|2D mammography|2 incidences 2D analogic mammography
79552002|NCT01612689|Device|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
79552003|NCT01612715|Other|Segmental Allergen Challenge|segmental allergen challenge
79552004|NCT01612728|Other|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine & Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
79552005|NCT01612728|Drug|Women with Arthralgia|
79552006|NCT01612741|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
79552007|NCT01612754|Behavioral|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
79552008|NCT01612754|Behavioral|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
79552009|NCT01612806|Device|PriMatrix|fetal bovine dermal scaffold
79552010|NCT01612806|Device|PriMatrix Ag|fetal bovine dermal scaffold with Ag
79552011|NCT01612806|Procedure|moist wound therapy|standard of care moist wound therapy
79716290|NCT02854423|Device|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
79716291|NCT00947011|Drug|Placebo|1 tablet 100 mg once a day
79716292|NCT00947011|Drug|Januvia|1 tablet 100 mg once a day
79716293|NCT02856685|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
79853143|NCT06060392|Drug|Semaglutide Pill|Patient will receive oral semaglutide
79853144|NCT06059872|Other|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
79716294|NCT02860663|Dietary Supplement|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
79716295|NCT02860663|Dietary Supplement|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
79716296|NCT02860663|Dietary Supplement|25OHD|10 ug/d of vitamin D3 for 6 weeks
79716297|NCT04270513|Other|Endovascular treatment by Flying Intervention Team|After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
79853145|NCT06057597|Procedure|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
79875341|NCT00410163|Drug|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
79552012|NCT01612832|Drug|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
79853146|NCT06057597|Procedure|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
79552013|NCT01612832|Other|Control|pain treatment as customary in the department
79552014|NCT01612845|Procedure|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
79552015|NCT01612845|Biological|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
79552016|NCT01612871|Drug|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
79552017|NCT01612897|Other|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
79552018|NCT01612910|Drug|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
79552019|NCT01612910|Other|laboratory biomarker analysis|Correlative studies
79552020|NCT01612923|Other|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
79552021|NCT01612936|Biological|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
79552022|NCT01612936|Procedure|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
79552023|NCT01612975|Drug|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
79552024|NCT01612975|Drug|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
79716298|NCT02854189|Device|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
79716299|NCT02854345|Device|Tomoscintigraphic parathyroid imaging on a CZT camera|
79716300|NCT04281823|Diagnostic Test|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
79716301|NCT02853877|Behavioral|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
79853147|NCT06056804|Drug|capecitabine|825-1000mg/m2,po,bid
79853148|NCT06056804|Drug|tislelizumab|200mg,iv.gtt,q3w
79853149|NCT06056804|Drug|thymalfasin|4.8mg,sc,biw
79853150|NCT06056804|Radiation|long-term radiotherapy|50 Gy/25 f, 2 Gy/day
79875342|NCT00410163|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
79255719|NCT05016440|Drug|Lisinopril|10mg Lisinopril daily for 6-8 weeks postpartum
79255720|NCT02116933|Procedure|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
79255721|NCT02116933|Procedure|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
79255722|NCT05016362|Procedure|medial fat preservation upper blepharoplasty|medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold
79255723|NCT02251639|Behavioral|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
79255724|NCT02251639|Device|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
79716302|NCT02854111|Other|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
79716303|NCT02854111|Other|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
79552025|NCT01612988|Drug|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
79716304|NCT01239342|Drug|Akt Inhibitor MK2206|Given PO
79853151|NCT06050889|Other|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
79853152|NCT06050889|Other|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
79255725|NCT02251639|Procedure|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
79255726|NCT05029388|Other|Aerobic Exercise|The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.
79304756|NCT03267797|Other|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
79716305|NCT01239342|Drug|Everolimus|Given PO
79716306|NCT01239342|Other|Laboratory Biomarker Analysis|Optional correlative studies
79716307|NCT04319250|Other|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
79716308|NCT04319250|Other|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
79853153|NCT06050265|Device|DEXCOM Continuous Glucose Monitor (CGM)|Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
79304757|NCT03267797|Other|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
79395290|NCT02349594|Drug|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
79395291|NCT02346084|Drug|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
79395292|NCT03149250|Diagnostic Test|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
79552026|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 1
79552027|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 11
79552028|NCT01613040|Drug|RO4917838|Multiple daily low doses of RO4917838 for 10 days
79552029|NCT01613040|Drug|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
79552030|NCT01613040|Drug|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
79552031|NCT01613053|Drug|Glivec|800 mg per day
79716309|NCT04319250|Other|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
79716310|NCT00946309|Drug|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
79716311|NCT00946309|Drug|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
79716312|NCT04269499|Device|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
79853154|NCT06049732|Device|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
80017965|NCT02120430|Other|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
79255727|NCT05029388|Other|High Intensity Interval Training|The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
79255728|NCT03553147|Other|SARC-F score, handgrip test and impedancemetry|Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
79552032|NCT01613066|Procedure|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
79552033|NCT01613079|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
79552034|NCT01613079|Drug|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
79552035|NCT01613092|Drug|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
79552036|NCT01613092|Drug|Cefazolin|Preoperative antibiotic
79552037|NCT01613105|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
79552038|NCT01613170|Drug|Toviaz|Toviaz 4mg daily
79716313|NCT02853799|Other|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"Placement of feeding tube stomach (oral- or naso-gastric tube)~Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~There will be five blood glucose checks in each data collection period.~If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
79716314|NCT02853799|Dietary Supplement|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
79716315|NCT02888496|Drug|tocilizumab|3 monthly IV infusions in PMR patients
79716316|NCT01236534|Drug|Lubiprostone|24 mcg twice daily for 21 days.
79716317|NCT01236534|Drug|Placebo|matching placebo twice daily for 21 days.
79716318|NCT01235598|Other|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
79853155|NCT06049238|Other|Maitland Mobilization|"Hot Pack for 10 mints~Active and active-assisted exercises (10 reps x 3 sets) for the~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation"
80017966|NCT01061385|Device|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
80017967|NCT01061385|Other|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
80017968|NCT03652467|Drug|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
79552039|NCT01613170|Drug|Premarin|Premarin cream 1 g per vagina twice weekly
79552040|NCT01613170|Drug|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
79552041|NCT01613183|Drug|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
79552042|NCT01613183|Other|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
79716319|NCT01235598|Biological|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
79853156|NCT06049238|Other|Post facilitation stretch|"Hot Pack for 10 mints~Active and active-assisted exercises (10 reps x 3 sets) for the~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation"
79853157|NCT06047756|Other|Hippotherapy|Patient will perform different movement of the trunk while sitting on a horse.
79853158|NCT06047756|Other|Swiss Ball therapy|Patient will perform movements of trunk on swiss ball
79853159|NCT06047223|Diagnostic Test|Magnetic resonanace imaging|Magnetic resonance imaging for measurement of diffustion tensor imaging
79853160|NCT06046053|Drug|Placebo Vaginal Film with Square Corners|"2 x 2 placebo vaginal film with square corners"
80017969|NCT03652467|Drug|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
80017970|NCT00292292|Device|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
79552043|NCT01613196|Other|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~*except if already done in the last 15 days."
79716320|NCT01235598|Biological|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
79552044|NCT01613209|Drug|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
79716321|NCT01235442|Drug|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
79716322|NCT01235442|Drug|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
79716323|NCT01163253|Drug|CP-690,550|5 mg oral BID
79716324|NCT01163253|Drug|CP-690,550|10 mg oral BID
79853161|NCT06046053|Drug|Placebo Vaginal Film with Rounded Corners|"2 x 2 placebo vaginal film with rounded corners"
79853162|NCT06045273|Behavioral|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
79853163|NCT06042647|Drug|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
80017971|NCT00292292|Device|Charite Artificial Disc|Insertion of the Charite
80017972|NCT02120508|Device|rTMS|To test the efficacy of this specific setting.
79255729|NCT05022836|Diagnostic Test|four-limb blood pressure measurements|Four-limb blood pressures were measured by certificated nurses at admission.
79255730|NCT03094364|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
79255731|NCT05022992|Other|Resistance Training|Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
79255732|NCT05029232|Diagnostic Test|MLPA for duchenne|MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up
79255733|NCT05015582|Device|Pre op upper body forced air warming (32˚C)|Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes
79255734|NCT05015582|Device|Pre op lower body forced air warming (32˚C)|lower body forced air warming at ambient (32˚C) for at least 30 minutes
79255735|NCT05015582|Device|Pre op fluids (45˚C)|fluids from warmed cabinet set at 45˚C
79255736|NCT05015582|Device|Intra op upper body forced air warming (32˚C)|Use of upper body forced air warming intra-operative at ambient (32˚C)
79395293|NCT02345928|Drug|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
79395294|NCT02345928|Drug|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
79395295|NCT02345928|Drug|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
79395296|NCT02345928|Drug|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
79395297|NCT02353338|Procedure|Surgical intervention|Surgical management of radial fracture
79395298|NCT02353338|Procedure|Conservative management|Immobilized/cast for 6 weeks
79395299|NCT02353338|Device|cast|
79552045|NCT01613209|Drug|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
79395300|NCT03149094|Behavioral|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
79395301|NCT03149094|Behavioral|CBSM-SMI control|this group will receive the LifeSum app.
79716325|NCT01162863|Drug|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
79716326|NCT01162863|Drug|Placebo|taken orally for 28 days
79716327|NCT01162863|Other|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
79716328|NCT02885805|Drug|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
79716329|NCT02885805|Drug|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
79716330|NCT01162473|Dietary Supplement|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
79853164|NCT06042647|Drug|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
79853165|NCT06042647|Drug|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
80017973|NCT05403814|Other|observational screening procedure (no intervention)|observational screening procedure (no intervention)
79255737|NCT05015582|Device|Intra op fluids at room temperature|IV fluids at room temperature
79395302|NCT05255718|Dietary Supplement|Aronia juice|Once daily dose of 100 mL of aronia juice
79395303|NCT05255718|Other|Placebo|Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
79716331|NCT01162473|Drug|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
79716332|NCT01162473|Other|Food Challenge|
79716333|NCT04314921|Other|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
79716334|NCT02885649|Drug|Enzalutamide|Given PO
79716335|NCT02885649|Other|Laboratory Biomarker Analysis|Correlative studies
79716336|NCT02885649|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
79716337|NCT02885883|Device|MRI 3T|
79716338|NCT01162239|Drug|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
79853166|NCT06042062|Device|Novel spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
79853167|NCT06042062|Device|Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
79853168|NCT06042049|Drug|Nirsevimab|Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is <5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is <5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
79853169|NCT06042036|Other|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
79853170|NCT06041009|Diagnostic Test|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
79853171|NCT06037889|Drug|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
79853172|NCT06037889|Drug|Aspirin tablet|Aspirin. Oral administration.
79255738|NCT05015582|Device|Intra op upper body forced air warming at (32˚C)|upper body forced air warming intra-operative at ambient (32˚C)
79255739|NCT05015582|Device|Intra op upper body forced air warming at (42˚C)|upper body forced air warming intra-operative at ambient (42˚C)
79395304|NCT03149016|Procedure|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
79395305|NCT02346006|Behavioral|More physical activity.|Subjects receiving more physical activity in school.
79255740|NCT05015582|Device|Intra op lower body forced air warming at (32˚C)|Lower body forced air warming intra-operative at ambient (32˚C)
79395306|NCT03148782|Behavioral|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
79395307|NCT00391443|Drug|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight > 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight < 40 kg)
79395308|NCT00391443|Drug|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
79255741|NCT05015582|Device|Intra op lower body forced air warming at (42˚C)|Lower body forced air warming intra-operative at ambient (42˚C)
79552046|NCT01613235|Other|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
79255742|NCT05015582|Device|Intra op fluid (42˚C)|IV fluids with hotline fluid warmer set at 42˚C
79255743|NCT05015738|Other|Traditional education|Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
79552047|NCT01613261|Drug|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
79552048|NCT01613274|Other|gum chewing|gum chewing three times a day for up to 20 minutes
79552049|NCT01613274|Other|no gum chewing|no gum chewing
79552050|NCT01613287|Device|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
79716339|NCT01162239|Behavioral|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
79716340|NCT01162239|Behavioral|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
79716341|NCT01162239|Behavioral|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
79716342|NCT01162239|Behavioral|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
79716343|NCT01161537|Drug|VX-770|Tablet.
79716344|NCT01161537|Drug|Placebo|Tablet.
79716345|NCT04314297|Drug|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
79255744|NCT05015738|Device|Diabetes Education supported by digital tools|Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
79716346|NCT02885571|Device|SomnoDent Flex with DentiTrac|
79853173|NCT06037889|Drug|Clopidogrel tablet|Clopidogrel. Oral administration.
79255745|NCT03094520|Device|tDCS|Transcranial direct current stimulation (tDCS)
79552051|NCT01613300|Drug|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
79853174|NCT06034340|Device|LET Gel after STAR Particle Application (Right Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles will vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 grams of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the mid-forearm at two locations (right antecubital fossa and wrist). Immediately after application of the STAR particles, the topical lidocaine (LET gel) will be applied. Immediately after the topical lidocaine (LET gel) is applied, the pain will be assessed every minute using the Pin-Prick Pain test. The time that the subject reports no pain (complete local anesthesia) will be recorded as the time to achieve anesthesia for the topical lidocaine after STAR particle application (TSP) at both sites.
79853175|NCT06034340|Other|LET Gel Application without STAR Particle Application (Left Arm)|Topical lidocaine (0.5 grams of Lidocaine in LET gel) will be applied immediately after applying aloe gel (CONTROL) to the volar surface of the mid-forearm at two locations (right antecubital fossa and right wrist). Immediately after application of the aloe gel, the topical lidocaine (LET gel) will be applied. Immediately after the topical lidocaine (LET gel) is applied, the pain will be assessed by the investigator every minute using the Pin-Prick Pain test. The time that the subject reports no pain (complete local anesthesia) will be recorded as the time to achieve anesthesia for the topical lidocaine without STAR particle application (TLET) at both sites.
79853176|NCT06033781|Behavioral|Cognitive Behavioral Therapy for Nightmares in Children|The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
79853177|NCT06023368|Drug|Num Vapocoolant Spray|Spray applied around port prior to access
79853178|NCT06023368|Drug|EMLA Cream|cream applied around the port prior to access
79552052|NCT01613352|Other|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
79552053|NCT01613365|Drug|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
79552054|NCT01613365|Drug|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
79853180|NCT06019546|Other|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
79853181|NCT06018974|Device|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
79853182|NCT06010953|Drug|SS109|on-demand treatment with SS109 at the time of a new hemorrhage event
79853183|NCT06008028|Drug|BR1015|One tablet administered alone
79552055|NCT01613404|Other|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
79853184|NCT06008028|Drug|BR1015-1|One tablet administered alone
79853185|NCT06008028|Drug|BR1015-2|One tablet administered alone
79255746|NCT03094520|Device|sham-tDCS|sham stimulation
79255747|NCT05028686|Other|No intervention|Observational cohort
79255748|NCT05028842|Other|No intervention|None.This is an observational study
79255749|NCT03094208|Other|dual task balance training|balance exercises with cognitive and motor dual tasks
79255750|NCT03094208|Other|traditional balance training|balance exercises
79255751|NCT03089060|Device|Silicone Finger cap|Treatment with silicone finger cap
79255752|NCT03089060|Device|Film Dressing|Treatment with conventional film dressing
79255753|NCT02111629|Drug|Fluconazole and Secnidazole|
79255754|NCT05015348|Other|fish oil with omega-3 PUFA|3.6g per day fish oil with omega-3 PUFA (EPA+DHA)
79255755|NCT05015348|Other|placebo|palm oil as placebo
79255756|NCT05028218|Drug|TQB3824 tablets|TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
79395309|NCT02343432|Drug|Triamcinolone|Triamcinolone
79395310|NCT02343432|Drug|Epidural Volume|Epidural Volume
79395311|NCT02343432|Drug|Bupivacaine|Bupivacaine
79395312|NCT02343510|Other|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
79395313|NCT02349282|Dietary Supplement|Calcifediol 10ug/day|
79395314|NCT02349282|Dietary Supplement|Vitamin D3 20ug/day|
79395315|NCT02349282|Dietary Supplement|Placebo|
79395316|NCT02345694|Device|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
79255757|NCT02117011|Other|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
80017974|NCT02120586|Other|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
79853186|NCT06004570|Dietary Supplement|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
79853187|NCT06004570|Dietary Supplement|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
79853188|NCT06004570|Other|Placebo|Single oral dose - 2 capsules
79853189|NCT06003790|Device|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
79853190|NCT06002178|Diagnostic Test|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
79853191|NCT05994976|Procedure|Blood samples collection|biomarkers and optional genetic analysis
79853192|NCT05994976|Procedure|Oral samples collection|biomarkers analysis
79853193|NCT05994976|Procedure|Hair samples collection|biomarkers analysis
79853194|NCT05994976|Procedure|Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)|biomarkers analysis
80017975|NCT02120586|Other|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
79255760|NCT02111707|Drug|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
79255761|NCT05015036|Procedure|ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
79552056|NCT01613430|Behavioral|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
79716347|NCT04314063|Other|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
79716348|NCT04124133|Device|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
79716349|NCT01233258|Biological|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
79716350|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
79716351|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
79853195|NCT05994976|Procedure|Skin surface material samples|biomarkers analysis
79853196|NCT05994976|Procedure|Drainage fluid samples collection|biomarkers analysis
79853197|NCT05994976|Procedure|Stool samples collection|biomarkers analysis
79875343|NCT03617523|Biological|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79875344|NCT03617523|Biological|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
80017976|NCT05725148|Device|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
80017977|NCT02117154|Device|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
80017978|NCT03528824|Other|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
79255762|NCT05015036|Procedure|Minimally invasive surgery|Classic Minimally invasive surgery of the lumbar spine
79255763|NCT05015192|Drug|NH102|tablets, orally
79255764|NCT05015192|Drug|Placebo|tablets, orally
79255765|NCT02119897|Device|Low Level Light Therapy|
79875345|NCT03617523|Biological|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79875346|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Other Week dosing
79716352|NCT01232868|Biological|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
79552057|NCT01613430|Behavioral|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
79716353|NCT01232790|Dietary Supplement|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
79716354|NCT01232790|Drug|Placebo|Placebo
79716355|NCT01232556|Drug|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
79716356|NCT01232556|Drug|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
79853198|NCT05993845|Other|Recording of total hip arthroplasty|"We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video & audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data & other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- & postoperative Standard axial hip x-rays pre- & postoperative Western Ontario & McMaster Universities Osteoarthritis Index & Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM."
79716357|NCT01232556|Drug|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
79853199|NCT05991570|Procedure|Video Assisted Thoracoscopic Surgery (VATS)|VATS is minimally invasive procedure for exploration to diagnose and treat thoracic injuries alternative to exploratory thoracotomy.
79552058|NCT01613456|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
79716358|NCT01232556|Drug|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
79716359|NCT00946153|Drug|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
79716360|NCT04258891|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
79853200|NCT05990764|Dietary Supplement|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
79853201|NCT05990764|Dietary Supplement|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
79853202|NCT05990764|Other|Placebo|"placebo~Once a day"
79853203|NCT05989919|Other|CT scan for nose and paranasal sinuses|CT scan for nose and paranasal sinuses
79853204|NCT05989555|Other|Blood drawing|Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
79853205|NCT05989204|Biological|TMhuCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
79853206|NCT05985044|Other|Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention|The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
79853207|NCT05984459|Dietary Supplement|VLCKD|The analysis will focus on the observation of the evolution of anthropometric and clinical parameters,such as the improvement or normalization of HbA1c, as well as on the evolution of the hypoglycemic medication between patients who accept VLCKD method
79853208|NCT05984056|Behavioral|Multidisciplinary lifestyle interventions|Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
79853209|NCT05981547|Device|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
80017979|NCT03528824|Drug|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
80017980|NCT03553056|Other|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
79716361|NCT01914367|Biological|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
79395317|NCT02345694|Device|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
79552059|NCT01613456|Dietary Supplement|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
79552060|NCT01613469|Drug|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
79552061|NCT01613482|Radiation|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
79552062|NCT01613482|Drug|Trastuzumab|Weekly, 2mg/kg of corporal weight
79552063|NCT01613482|Drug|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
79552064|NCT01613508|Procedure|Direct Anterior Approach|
79552065|NCT01613508|Procedure|Mini-Posterior Approach|
79853210|NCT05981209|Procedure|Biospecimen Collection|Undergo blood sample collection
79395318|NCT05075421|Procedure|Gastrectomy|Any type of gastrectomy for gastric cancer
79552066|NCT01613521|Other|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
79552067|NCT01613534|Drug|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
79552068|NCT01613534|Drug|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
79552069|NCT01613547|Drug|Amoxicillin|80 mg/kg/day for 7 days
79552070|NCT01613547|Drug|Placebo|7 days
79552071|NCT01613573|Drug|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
79552072|NCT01613573|Drug|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
79552073|NCT01613586|Drug|ASP3652|Oral
79552074|NCT01613586|Drug|Placebo|Oral
79552075|NCT01613612|Procedure|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
79552076|NCT01613612|Procedure|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
79552077|NCT01613625|Procedure|Elastography|
79853211|NCT05981209|Procedure|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
79853212|NCT05981209|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
79552078|NCT01613651|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
79552079|NCT01613651|Other|questionnaire administration|Ancillary studies
79552080|NCT01613651|Other|intraoperative complication management/prevention|Undergo placement of pelvic drain
79552081|NCT01613664|Drug|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
79552082|NCT01613664|Other|no tisseel|the surgeon does not applied tissucol during the surgery
79552083|NCT01613677|Drug|BKM120|
79552084|NCT01613690|Drug|NVA237|NVA237 is administered via a BREEZHALER device
79552085|NCT01613703|Drug|ONO-2952|1 mg to 200 mg QD at a single descending dose
79552086|NCT01613755|Drug|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
79552087|NCT01613755|Drug|Metformin|Metformin 500 mg twice daily for four days
79552088|NCT01613781|Other|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
79552089|NCT01613781|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
79853213|NCT05981209|Procedure|Computed Tomography|Undergo CT
79853214|NCT05981209|Drug|Dexamethasone|Given IV or PO
79853215|NCT05981209|Procedure|Echocardiography|Undergo ECHO
79853216|NCT05981209|Biological|Elotuzumab|Given IV
79853217|NCT05981209|Procedure|Magnetic Resonance Imaging|Undergo MRI
79853218|NCT05981209|Biological|Mezigdomide|Given PO
80017981|NCT03553056|Other|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
79395319|NCT02349204|Behavioral|Music - Mozart's sonata for 2 pianos in D-440|
79395320|NCT00391599|Procedure|enema|
79395321|NCT02345616|Drug|Nitric oxide|
79395322|NCT02343354|Behavioral|Nutrition/physical activity intervention|Please see arm description
79395323|NCT00391989|Drug|Dasatinib|
79395324|NCT03148704|Drug|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
79395325|NCT02348970|Device|ONIRIS®|sleeping test
79395326|NCT02348970|Device|TALI|sleeping test
79395327|NCT01795287|Procedure|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
79395328|NCT01795287|Procedure|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
79552090|NCT01613794|Drug|Rosuvastatin|20 mg od
79552091|NCT01613807|Drug|Insulin LISPRO|Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
79552092|NCT01613807|Drug|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
79552093|NCT01613820|Drug|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
79552094|NCT01613820|Drug|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
79552095|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
79552096|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
79552097|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
79853219|NCT05981209|Procedure|X-Ray Imaging|Undergo x-ray imaging
80017982|NCT00289640|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
80017983|NCT00289640|Drug|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
79552098|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
79853220|NCT05978414|Other|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
79716362|NCT01914367|Biological|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
79716363|NCT02856529|Other|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
79853221|NCT05978414|Other|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
79552099|NCT01613846|Drug|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
79716364|NCT02856529|Other|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
79716365|NCT02856373|Procedure|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
79853222|NCT05977348|Behavioral|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
79552100|NCT01613846|Drug|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
79255766|NCT03552601|Other|traditional speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
79255767|NCT03552601|Other|faster speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
79552101|NCT01613872|Other|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
79716366|NCT02856607|Other|determine the prognosis of threated patients according to the clinical care pathway.|
79716367|NCT01160289|Drug|LY2452473|Administered orally, once daily for 12 weeks
79716368|NCT01160289|Drug|tadalafil|Administered orally, once daily for 12 weeks
79716369|NCT01160289|Drug|placebo (tadalafil)|Administered orally, once daily for 12 weeks
79853223|NCT05977348|Behavioral|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
80017984|NCT00289640|Drug|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
79716370|NCT01160289|Drug|placebo (LY2452473)|Administered orally, once daily for 12 weeks
80017985|NCT03552432|Drug|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
80017986|NCT05006170|Drug|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
80017987|NCT05006170|Drug|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
79255768|NCT05021588|Procedure|steroid and anticoagulants according to different protocols.|As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
79552102|NCT01613885|Other|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
79552103|NCT01613898|Biological|Blood tests|Blood tests
79552104|NCT01613924|Device|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
79716371|NCT02885415|Procedure|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
79716372|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
79716373|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
79716374|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
79716375|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
79716376|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
79716377|NCT01159431|Device|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
79716378|NCT04314141|Procedure|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~Sexual quality of life before and after the surgery~Satisfaction after surgery~Data collection in medical file :~Surgery outcomes~Functional outcomes"
79716379|NCT02885259|Drug|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
79716380|NCT01158261|Biological|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
79716381|NCT02885103|Device|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
79716382|NCT02885103|Device|Nebulizer|Inhalation will be done will Nebulizer and via mouth
79716383|NCT04313829|Behavioral|Pharmacist Counseling Intervention|We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
79716384|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
79716385|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
79716386|NCT04313907|Combination Product|low level laser therapy plus topical clonazepam|combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)
79716387|NCT04313907|Drug|Sham laser plus topical clonazepam|Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)
79716388|NCT04313907|Radiation|Active laser plus placebo of topical clonazepam|low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
79552105|NCT01613924|Device|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
79716389|NCT01231620|Drug|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
79716390|NCT01231620|Drug|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
79716391|NCT01231620|Drug|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
79716392|NCT01231620|Drug|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
79716393|NCT05511558|Drug|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
79853224|NCT05977348|Behavioral|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
79853225|NCT05977348|Behavioral|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
79853226|NCT05974969|Drug|BCD-264|a single intravenous infusion of BCD-264
79853227|NCT05974969|Drug|Darzalex|a single intravenous infusion of Darzalex
79853228|NCT05974293|Drug|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
79853229|NCT05974293|Drug|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
79552106|NCT01613937|Behavioral|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
79552107|NCT01613950|Drug|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
79552108|NCT01613950|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
79716394|NCT01231464|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
79716395|NCT01231464|Drug|placebo|placebo
79716396|NCT01156311|Drug|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
79716397|NCT02888028|Procedure|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
79716398|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
79716399|NCT01230060|Device|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
79716400|NCT02853955|Device|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
79716401|NCT04281745|Biological|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
79716402|NCT02853721|Other|iPTH|iPTH assay six hours after surgery
79716403|NCT02853721|Other|no dosage of iPTH|Ca and P on postoperative day 1 and 2
79716404|NCT02860429|Drug|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
79716405|NCT02860429|Drug|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
79716406|NCT01155531|Drug|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
79716407|NCT02856061|Behavioral|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
79716408|NCT01138579|Drug|FBTA05|
79552109|NCT01613963|Drug|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
79853230|NCT05972109|Other|Workplace SSB sales ban|Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.
79552110|NCT01613976|Drug|Panobinostat|
79552111|NCT01614015|Behavioral|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
79552112|NCT01614015|Behavioral|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
79716409|NCT04313595|Device|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
79716410|NCT02860195|Other|oral dose of alcohol|
79716411|NCT02860195|Device|alcotest|
79716412|NCT02860195|Biological|blood samples|
79716413|NCT02860195|Device|Transdermal monitor|
79716414|NCT01155219|Drug|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
79716415|NCT01155219|Drug|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
79716416|NCT01229436|Drug|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
79716417|NCT01155141|Drug|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
79716418|NCT00631033|Drug|Placebo|
79716419|NCT00631033|Drug|Diazoxide|
79716420|NCT00631033|Drug|Metformin + Diazoxide|
79552113|NCT01614028|Procedure|Total Hip Arthoplasty|
79255769|NCT03087890|Drug|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
79552114|NCT01614041|Drug|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
79552115|NCT01614041|Drug|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
79552116|NCT01614054|Other|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
79716421|NCT04262323|Device|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the mobile phone application and the non-invasive reference method (upper arm cuff).
79716422|NCT01155063|Other|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
79853231|NCT05972109|Behavioral|Brief Intervention|Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.
79853232|NCT05968261|Procedure|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
79853233|NCT05967962|Behavioral|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
79552117|NCT01614119|Other|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
79552118|NCT01614132|Drug|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
79853234|NCT05967962|Behavioral|non-traumatic (neutral) film|non-traumatic (neutral) film
79552119|NCT01614132|Radiation|Radiotherapy|Radiotherapy of the partial brain
79853235|NCT05966155|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
79552120|NCT01614158|Device|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) [Schiefer 2008] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
79853236|NCT05966155|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
79255770|NCT03087890|Drug|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
79255771|NCT02112019|Procedure|Sialoendoscopy|
79552121|NCT01614158|Other|D-BCVA|D-BCVA using EDTRS chart
79552122|NCT01614158|Other|RAPD|RAPD using swinging flashlight test
79552123|NCT01614158|Device|IOP|IOP using applanation tonometer
79552124|NCT01614158|Device|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
79552125|NCT01614158|Other|Fundus photography|Optic disk morphology will be documented by fundus photography
79552126|NCT01614184|Drug|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
79552127|NCT01614223|Procedure|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
79552128|NCT01614223|Drug|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
79552129|NCT01614236|Drug|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
79552130|NCT01614236|Drug|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
79552131|NCT01614262|Other|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
79255772|NCT02112019|Drug|saline|
79716423|NCT04313517|Other|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
79716424|NCT04313673|Diagnostic Test|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
79552132|NCT01614275|Behavioral|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
79255773|NCT02112019|Drug|hydrocortisone|
79305024|NCT03060681|Drug|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
79716425|NCT01154673|Drug|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
79716426|NCT01154673|Drug|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
79716427|NCT01154673|Drug|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
79716428|NCT01154673|Drug|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
79716429|NCT02884869|Device|Intubating Laryngeal Mask|Direct laryngoscopy
79716430|NCT01154283|Device|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
79255774|NCT04434638|Other|Transitions of Care Coordinator|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
79255775|NCT04434638|Other|Usual Care|Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
79395329|NCT02342964|Other|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE."
79552133|NCT01614275|Behavioral|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
79552134|NCT01614275|Behavioral|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
79552135|NCT01614275|Behavioral|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
79552136|NCT01614288|Procedure|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
79552137|NCT01614288|Other|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
79552138|NCT01614301|Drug|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
79552139|NCT01614314|Other|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
79395330|NCT05013411|Other|Qualitative study|Individual interviews and focus groups will be conducted to explore current strengthens and barriers in obtaining patient observations. Views on use of technology in assisting with patient observations will also be discussed and documented.
79552140|NCT01614314|Other|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
79716431|NCT00944125|Device|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
79853237|NCT05966142|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
79853238|NCT05966142|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
79395331|NCT02343198|Device|Custom-built research muscle stimulator|Muscle stimulator
79395332|NCT04976283|Drug|Pioglitazone|Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
79395333|NCT04976283|Drug|Empagliflozin|Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
79395334|NCT04976283|Drug|Pioglitazone + Empagliflozin|Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
79716432|NCT00944125|Device|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
79395335|NCT02345382|Drug|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
79716433|NCT02884713|Drug|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
79716434|NCT02884713|Drug|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
79716435|NCT02884713|Drug|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
79255776|NCT02117401|Drug|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
79853239|NCT05966129|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
79853240|NCT05966129|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
79853241|NCT05961527|Drug|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
79853242|NCT05961527|Behavioral|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
79853243|NCT05960955|Drug|Cadonilimab|IV infusion,Specified dose on specified days
79255777|NCT02117401|Drug|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
79255778|NCT02117401|Drug|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
79255779|NCT02117401|Drug|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
79255780|NCT02117401|Drug|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
79255781|NCT04434404|Drug|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
79552141|NCT01614340|Behavioral|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
79552142|NCT01614353|Other|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
79853244|NCT05960955|Drug|AK117|IV infusion,Specified dose on specified days
79853245|NCT05960955|Drug|Oxaliplatin|IV infusion,Specified dose on specified days
79853246|NCT05960955|Drug|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
79853247|NCT05960955|Drug|Docetaxel|IV infusion,Specified dose on specified days
79853248|NCT05960955|Drug|5-Fluorouracil|IV infusion,Specified dose on specified days
79853249|NCT05960682|Other|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
79255782|NCT03092336|Other|Electrical Stimulation|electrical stimulation training
79255783|NCT03092336|Other|Strength training|strength training group
79552143|NCT01614353|Other|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
79552144|NCT01614366|Drug|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
79853250|NCT05960630|Procedure|MIRRORS Protocol|Diagnostic laparoscopic assessment proceeding to either robotic (if considered appropriate following laparoscopic assessment) or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
79853251|NCT05960630|Procedure|Standard Open Cytoreductive Surgery|Extended midline incision. Open surgical approach to interval cytoreductive surgery with the aim of removing all visible disease.
79552145|NCT01614366|Drug|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
79552146|NCT01614366|Drug|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
79552147|NCT01614366|Drug|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
79853252|NCT05959499|Drug|BR6002A|One tablet administered alone
79853253|NCT05959499|Drug|BR6002B|One tablet administered alone
79853254|NCT05959499|Drug|BR6002|One capsule administered alone
79716436|NCT00912223|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~Rituxan 375 mg/m^2 on Day -13~Rituxan 1000 mg/m^2 on Days -6, +1, and +8~Fludarabine 30 mg/m^2 on Days -5 to -3~Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
79716437|NCT04313439|Other|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
79716438|NCT01154127|Drug|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
79716439|NCT01154127|Drug|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
79716440|NCT01228734|Drug|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
79716441|NCT01228734|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
79716442|NCT01228734|Drug|Folinic Acid|FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
79255784|NCT02117557|Procedure|Single incision laparoscopic surgery|
79255785|NCT02117557|Procedure|Conventional laparoscopic surgery|
79255786|NCT02119975|Behavioral|Working memory training|
79552148|NCT01614405|Drug|Truvada and Kaletra|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
79552149|NCT01614418|Device|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
79552150|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
79716443|NCT01228734|Drug|5Fluorouracil|5-FU as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
79716444|NCT01227954|Radiation|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
79716445|NCT01153971|Drug|rituximab|1
79716446|NCT01153893|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
79716447|NCT01153893|Biological|InfanrixTM|Intramuscular injection, 1dose
79875347|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
79255787|NCT02119975|Behavioral|Placebo training|
79255788|NCT02120053|Device|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
79395336|NCT02108223|Drug|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
79395337|NCT02108223|Drug|r-LH supplementation|recombinant luteinizing hormone
79552151|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
79255789|NCT02120053|Device|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
79255790|NCT03552445|Biological|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
79255791|NCT03552445|Biological|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
79255792|NCT03552445|Biological|Td alone|437 Td recipients: one vaccine injection administered on Day 0
79255793|NCT02117635|Biological|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
79255794|NCT02251483|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|
79395338|NCT02108223|Drug|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
79395339|NCT03148548|Genetic|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
79395340|NCT02345304|Drug|Omeprazole|
79395341|NCT02345304|Drug|Warfarin|
79395342|NCT02345304|Drug|BI 1181181|
79395343|NCT02345304|Drug|Midazolam|
79395344|NCT02345304|Drug|Omeprazole|
79395345|NCT02345304|Drug|BI 1181181|
79395346|NCT02345304|Drug|Midazolam|
79395347|NCT02345304|Drug|Midazolam|
79395348|NCT02345304|Drug|Warfarin|
79395349|NCT02345304|Drug|BI 1181181|
79395350|NCT02345304|Drug|Digoxin|
79395351|NCT02345304|Drug|Digoxin|
79395352|NCT01569295|Drug|Idelalisib|Idelalisib 150 mg administered orally twice daily
79395353|NCT01569295|Drug|Rituximab|Rituximab 375 mg/m^2 on Day 1, then 500 mg/m^2 every 28 days administered intravenously for a maximum of 6 infusions
79395354|NCT01569295|Drug|Bendamustine|Bendamustine 70 mg/mg^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
79395355|NCT01569295|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
79552152|NCT01614444|Other|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
79716448|NCT00951379|Drug|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
79716449|NCT00951379|Other|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
79716450|NCT00951379|Other|laboratory biomarker analysis|Correlative studies
79716451|NCT02855749|Procedure|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
79716452|NCT01153815|Drug|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
79716453|NCT01153815|Drug|placebo|placebo
79716454|NCT02855983|Procedure|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
79853255|NCT05956223|Device|Virtual Reality measurement of essential tremor and dystonia|"The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
79853256|NCT05953038|Drug|Lysergic Acid Diethylamide Tartrate|D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
79853257|NCT05952089|Drug|Danicamtiv|Specified dose on specified days
79853258|NCT05952089|Drug|Midazolam|Specified dose on specified days
79255795|NCT02251483|Other|Placebo|
79255796|NCT02117869|Other|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
79552153|NCT01614444|Other|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
79552154|NCT01614496|Other|Algorithm for insulin administration|
79552155|NCT01614522|Drug|ASLAN001|ASLAN001 500mg BID
79552156|NCT01614535|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
79552157|NCT01614639|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
79552158|NCT01614652|Device|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
79552159|NCT01614678|Device|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
79552160|NCT01614678|Device|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
79552161|NCT01614691|Drug|SPARC1203|Active
79552162|NCT01614691|Drug|Placebo|Placebo
79716455|NCT01153425|Other|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
79716456|NCT01153425|Drug|Teriparatide|Participants are clinically indicated for treatment.
79853259|NCT05949983|Other|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
79875348|NCT00300274|Drug|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
79716457|NCT01153425|Drug|Zoledronic Acid|Participants are clinically indicated for treatment.
79716458|NCT01153347|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
79716459|NCT01153347|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
79716460|NCT02884557|Other|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
79716461|NCT01153269|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
79716462|NCT02884635|Drug|ASP1707|Oral
79716463|NCT02884635|Drug|Placebo|Oral
79716464|NCT02884635|Drug|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
79255797|NCT02117869|Other|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
79255798|NCT02117869|Other|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
79255799|NCT02120599|Dietary Supplement|ready-to-use supplementary food|
79255800|NCT02120599|Dietary Supplement|corn-soy blend|
79255801|NCT02120599|Dietary Supplement|iron|
79255802|NCT02120599|Dietary Supplement|folic acid|
79255803|NCT02120599|Dietary Supplement|UNIMMAP|
79305025|NCT02456753|Device|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
79552163|NCT01614717|Device|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
79552164|NCT01614730|Device|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
79552165|NCT01614730|Device|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
79552166|NCT01614756|Biological|BMS-981164|
79552167|NCT01614756|Biological|Placebo matching with BMS-981164|
79552168|NCT01614782|Drug|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
79552169|NCT01614782|Other|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
79552170|NCT01614808|Other|laboratory biomarker analysis|Correlative studies
79552171|NCT01614873|Device|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
79552172|NCT01614938|Drug|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
79552173|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
79552174|NCT01614938|Drug|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
79552175|NCT01614938|Radiation|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
79552176|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
79552177|NCT01614951|Procedure|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
79552178|NCT01614951|Drug|HTK Custodiol|Pulmoplegia before ECC.
79552179|NCT01614951|Other|Standard ECC|ECC after standard procedure
79552180|NCT01614964|Drug|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
79552181|NCT01614964|Drug|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
79552182|NCT01613729|Drug|Rosuvastatin 5 mg|Rosuvastatin 5 mg
79552183|NCT01613729|Drug|Rosuvastatin 10 mg|
79552184|NCT01614977|Drug|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
79552185|NCT01615003|Drug|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
79552186|NCT01615003|Drug|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
79552187|NCT01615016|Other|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
79552188|NCT01615042|Drug|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
79552189|NCT01615055|Drug|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
79552190|NCT01615055|Other|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
79552191|NCT01615081|Other|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
79552192|NCT01615107|Device|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
79875349|NCT00300274|Drug|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
79255804|NCT02112097|Drug|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
79305026|NCT04974411|Other|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
79716465|NCT02884479|Drug|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
79255805|NCT02112097|Drug|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
79552193|NCT01615107|Drug|PITOCIN|: Oxytocin infusion alone (Standard Protocol
79552194|NCT01615107|Other|double balloonand oxytocin|balloonand oxytocin
79552195|NCT01615107|Other|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
79552196|NCT01615107|Procedure|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
79395356|NCT03112278|Procedure|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
79853260|NCT05949983|Other|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
79716466|NCT02884479|Drug|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
79853261|NCT05949281|Drug|Colchicine 0.5 MG Oral Tablet|Colchicine 0.5 mg once-daily
79853262|NCT05949281|Drug|Placebo|Placebo tablet once-daily
79255806|NCT02112097|Drug|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
79552197|NCT01615146|Other|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is < 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
79853263|NCT05949021|Drug|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
79552198|NCT01615172|Procedure|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
79552199|NCT01615185|Drug|full-dose amisulpride|amisulpride 800mg/d
79853264|NCT05948566|Biological|TS23|Monoclonal antibody
79255807|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
79305027|NCT04974411|Other|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
79305028|NCT03261479|Diagnostic Test|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
79552200|NCT01615211|Drug|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
79305029|NCT04831203|Dietary Supplement|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
79395357|NCT03112278|Procedure|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
79395358|NCT02108457|Radiation|[18F]Fluorothymidine (FLT) PET/CT Imaging|
79395359|NCT03148626|Other|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
79395360|NCT03148626|Other|Control|Usual Education
79552201|NCT01615211|Drug|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
79552202|NCT01615224|Drug|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
79716467|NCT01152021|Drug|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
79875350|NCT00300274|Drug|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
79875351|NCT00300274|Drug|corticosteroids|Corticosteroids standard dose.
79395361|NCT02345148|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
79395362|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
79395363|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
79395364|NCT00394329|Drug|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
79395365|NCT02342808|Behavioral|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
79853265|NCT05947656|Device|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
79853266|NCT05946655|Drug|Ofloxacin + Metronidazole|Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
79853267|NCT05941013|Device|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
79255808|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
79552203|NCT01615237|Behavioral|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
79552204|NCT01615237|Behavioral|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
79853268|NCT05939726|Other|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
79853269|NCT05939726|Other|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
79853270|NCT05939726|Other|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
79853271|NCT05939713|Device|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
79853272|NCT05939193|Procedure|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
79853273|NCT05939193|Procedure|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
79853274|NCT05939193|Drug|Forced administration of furosemide|Forced administration of furosemide
79552205|NCT01615237|Behavioral|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
79552206|NCT01615250|Biological|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
79552207|NCT01615276|Device|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
79552208|NCT01615276|Device|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
79552209|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
79552210|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
79552211|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
79552212|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
79552213|NCT01615302|Procedure|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
79853275|NCT05939193|Drug|Routine administration of furosemide|Routine administration of furosemide
79853276|NCT05938933|Behavioral|PHP|personalized health planning (PHP)
79853277|NCT05938933|Behavioral|SMA|shared medical appointments (SMAs)
79305030|NCT04831203|Dietary Supplement|Placebo|As described in the Control arm
79716468|NCT01152021|Drug|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
79716469|NCT00637221|Drug|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
79716470|NCT00624975|Biological|Peru-15 Vaccine|up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
79552214|NCT01615302|Other|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
79716471|NCT00624975|Biological|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
79716472|NCT01151085|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
79552215|NCT01615354|Drug|Aleglitazar|Multiple oral doses
79255809|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
79716473|NCT01149681|Drug|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
79716474|NCT04313127|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
79716475|NCT02883933|Other|Data collection|
79716476|NCT01149369|Drug|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
79305031|NCT03260777|Device|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
79716477|NCT01149369|Drug|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
79716478|NCT02853487|Device|Actigraphy|An actigraph from Philips
79716479|NCT02853487|Other|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
79716480|NCT00879931|Drug|Methylprednisolone|Methylprednisolone
79305032|NCT03060837|Diagnostic Test|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
79305033|NCT03060837|Other|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
79552216|NCT01615354|Drug|Microgynon®|Multiple oral doses
79552217|NCT01615354|Drug|Placebo|Multiple oral doses
79552218|NCT01615380|Behavioral|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
79716481|NCT00879931|Drug|Placebo|Placebo (NaCl 0.9%)
79716482|NCT01149057|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
79853278|NCT05938439|Device|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~Placement through the endoscope of a soft guidewire through the upper GI tract;~Insertion of the MAGUS system on the guidewire;~Advancement of the MAGUS system until proximal magnet reach the top of the septum;~Release and placement of the proximal magnet at the bottom of the septum, pouch side;~Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~Release of the distal magnet and activate the retractable wire;~Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
79853279|NCT05929729|Drug|Ferric derisomaltose|Refer to arm/group descriptions
79853280|NCT05929729|Drug|NovaFerrum|Refer to arm/group descriptions
79552219|NCT01615380|Behavioral|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
79552220|NCT01615393|Drug|ribavirin [Copegus]|Single oral dose of 400 mg tablets
79552221|NCT01615393|Drug|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
79716483|NCT04281589|Other|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
79716484|NCT01227564|Biological|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
79552222|NCT01615406|Drug|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
79552223|NCT01615432|Device|V-PAP III ventilator|
79552224|NCT01615432|Device|Stellar 150 ventilator|
79552225|NCT01615432|Device|BiPAP vision ventilator|
79552226|NCT01615432|Device|V60 ventilator|
79552227|NCT01615445|Drug|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
79552228|NCT01615445|Drug|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
79552229|NCT01615458|Behavioral|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
79552230|NCT01615471|Behavioral|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
79552231|NCT01615497|Behavioral|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
79552232|NCT01615497|Behavioral|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
79552233|NCT01615497|Behavioral|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
79552234|NCT01615523|Other|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
79853281|NCT05926466|Drug|BTZ-043|BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
79552235|NCT01615536|Procedure|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
79552236|NCT01615536|Procedure|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
79552237|NCT01615549|Procedure|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
79552238|NCT01615575|Procedure|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
79552239|NCT01615575|Procedure|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
79255810|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
79552240|NCT01615588|Dietary Supplement|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
79552241|NCT01615601|Drug|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
79552242|NCT01615601|Drug|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
79552243|NCT01615601|Drug|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
79552244|NCT01615601|Drug|Other antiretroviral medications|Given as per Canadian Product Monograph
79552245|NCT01615614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
79552246|NCT01615614|Drug|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
79552247|NCT01615627|Drug|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
79552248|NCT01615627|Drug|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
79552249|NCT01615653|Procedure|EUS|EUS Guided Therapy
79552250|NCT01615718|Procedure|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
79716485|NCT01227564|Biological|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
79716486|NCT01227564|Other|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
79853282|NCT05926466|Drug|Bedaquiline|Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
79853283|NCT05926466|Drug|Delamanid|Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
79853284|NCT05926466|Drug|Moxifloxacin|Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
79853285|NCT05925127|Biological|NVX-CoV2373 (5μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
80017988|NCT02117232|Device|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
79255811|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
79305034|NCT03060837|Other|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
79305035|NCT03060837|Other|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
79552251|NCT01615718|Procedure|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
79552252|NCT01615744|Procedure|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
79552253|NCT01615744|Procedure|Non-surgical management|Early active exercises and elevation to decrease swelling
79552254|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
79716487|NCT00739141|Drug|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
79853286|NCT05925127|Biological|NVX-CoV2601 (5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
79853287|NCT05925127|Biological|NVX-CoV2601(5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
79853288|NCT05925127|Biological|NVX-CoV2601 (35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
79853289|NCT05925127|Biological|NVX-CoV2601(35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
79853290|NCT05925127|Biological|NVX-CoV2601(50μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
80017989|NCT02117232|Device|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
80017990|NCT03765632|Genetic|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
79552255|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
79552256|NCT01615770|Behavioral|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
79552257|NCT01615783|Other|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
79716488|NCT01148979|Drug|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
80017991|NCT03765632|Drug|Busulfan|Busulfan is used for non-myeloablative conditioning
80017992|NCT03765632|Drug|Peg-Ada|Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
79853291|NCT05925127|Biological|Bivalent BA.4/5|The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
80017993|NCT02973477|Drug|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
80017994|NCT02973477|Drug|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
79552258|NCT01615783|Other|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
79552259|NCT01615796|Drug|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
79552260|NCT01615796|Drug|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
79552261|NCT01615835|Other|EnSite NavX System|EnSite NavX system is a 3D Mapping system
79552262|NCT01615848|Other|mediterranean diet restricted calorie|1500 k/cal 30% fat
79853292|NCT05919888|Drug|Povidone-Iodine|Applied to skin incision.
79853293|NCT05919888|Device|SURGX Wound Gel|Applied to skin incision.
80017995|NCT04558450|Diagnostic Test|carotid-femoral pulse-wave velocity|early vascular aging tests
80017996|NCT02117388|Behavioral|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
80017997|NCT02117388|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
79305036|NCT03060837|Procedure|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
80017998|NCT02117388|Behavioral|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
80017999|NCT03528746|Other|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
80018000|NCT03528746|Other|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
79552263|NCT01615848|Other|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
79716489|NCT01148979|Drug|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
79716490|NCT04281433|Other|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
79853294|NCT05915533|Other|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
79853295|NCT05914779|Other|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
79853296|NCT05914779|Other|with antibiotics treatment|with antibiotics treatment
79853297|NCT05908630|Other|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature <35C"
79552264|NCT01615848|Other|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
79552265|NCT01615861|Procedure|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
79552266|NCT01615861|Device|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
79716491|NCT01735825|Device|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
79716492|NCT01735825|Device|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
79716493|NCT01735825|Device|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
79716494|NCT02855905|Other|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
79716495|NCT01148511|Drug|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
79853298|NCT05907720|Behavioral|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
79853299|NCT05906875|Other|Lateral Stepping Exercise 1|1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
80018001|NCT03552354|Drug|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
79552267|NCT01615900|Other|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
79716496|NCT02860117|Device|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
79716497|NCT02860117|Drug|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
80018002|NCT03531944|Other|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
79255812|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
79255813|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
79716498|NCT02853253|Dietary Supplement|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
80018003|NCT03531944|Other|Usual care|Usual care with physician and as needed visit to the nurse
80018004|NCT04847362|Behavioral|Experimental|education group
79255814|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
79255815|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
79255816|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
79255817|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
80018005|NCT02288000|Drug|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
80018006|NCT02288000|Drug|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
80018007|NCT02788656|Device|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
80018008|NCT02788656|Drug|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
80018009|NCT02788656|Drug|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
80018010|NCT02788656|Drug|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
79552268|NCT01615913|Drug|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
79552269|NCT01615913|Drug|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
79853300|NCT05906875|Other|Active Control Group Exercise 1|1. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
79552270|NCT01615913|Drug|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
79853301|NCT05906875|Other|Active Control Group Exercise 2|2. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
80018011|NCT03531866|Behavioral|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
79552271|NCT01615965|Other|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
79552272|NCT01615978|Drug|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
79552273|NCT01615978|Drug|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
79552274|NCT01615978|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
79552275|NCT01615991|Drug|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
79552276|NCT01616004|Drug|N2O|
79552277|NCT01616004|Drug|Air|sham comparator
79552278|NCT01616030|Other|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
79552279|NCT01616043|Procedure|Glyaderm|acellular dermis
79716499|NCT02853253|Dietary Supplement|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
79716500|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
79716501|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
79716502|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
79552280|NCT01616043|Procedure|STSG|autologous split skin only
79552281|NCT01616069|Drug|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
79716503|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
79716504|NCT04269187|Drug|Theophylline|Theophylline oral 200 mg daily for 12 days
79853302|NCT05906875|Other|Active Control Group Exercise 3|3. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
79853303|NCT05906875|Other|Active Control Group Exercise 4|4. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
79255818|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
79552282|NCT01616108|Drug|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
79552283|NCT01616121|Other|Usual treatment of patients with developing acute heart failure|
79552284|NCT01616121|Device|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
79552285|NCT01616134|Other|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
79552286|NCT01616134|Other|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
79716505|NCT02853565|Drug|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
79716506|NCT02856217|Procedure|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
79853304|NCT05906875|Other|Lateral Stepping Exercise 2|2. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
79853305|NCT05906875|Other|Lateral Stepping Exercise 3|3. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
79853306|NCT05906875|Other|Lateral Stepping Exercise 4|4. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
79853307|NCT05906875|Other|Lateral Stepping Exercise 5|5. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
80018012|NCT03652311|Device|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
80018013|NCT00284804|Drug|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
80018014|NCT05258110|Drug|midazolam|midazolam
79552287|NCT01616147|Behavioral|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
79552288|NCT01616147|Behavioral|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
79853308|NCT05905276|Other|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
80018015|NCT05258110|Drug|BI 425809|BI 425809
80018016|NCT03652233|Drug|Nivolumab|Given by vein every 14 days for up to 12 months
80018017|NCT03652233|Drug|Afatinib|Taken by mouth daily for up to 12 months
79552289|NCT01616186|Drug|Everolimus and sorafenib|"Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
79716507|NCT02856217|Procedure|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
79716508|NCT04269109|Other|Multi-modal Opioid Sparing Pain Management Protocol|Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
79716509|NCT04268953|Drug|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
79853309|NCT05905276|Other|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
80018018|NCT03652155|Procedure|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
80018019|NCT03621969|Other|Physical exam and medical history|This will be completed by a medical doctor on the research team
79305037|NCT03060837|Procedure|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
79305038|NCT03260933|Other|No intervention given. This is a qualitative interview study|This is a qualitative interview study
79305039|NCT04967547|Other|Self-care PD ability assessment form|Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
79716510|NCT01227252|Drug|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
79716511|NCT01227252|Drug|Placebo|Administered orally as capsules, daily for 14 days
80018020|NCT03621969|Diagnostic Test|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
79716512|NCT02855671|Device|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
79552290|NCT01616186|Drug|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
80018021|NCT03621969|Device|Patient Instruction and use of Device (RePlay)|"providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~improving assessment and evaluation of patients involved in future interventional studies,~producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
79552291|NCT01616212|Other|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
80018022|NCT02117466|Drug|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
79552292|NCT01616212|Other|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
79552293|NCT01616212|Other|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
79552294|NCT01616212|Other|Drug Education for adolescents|Drug Education for adolescents
79552295|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
79552296|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
79552297|NCT01616225|Drug|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
79552298|NCT01616238|Drug|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
79552299|NCT01616251|Other|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
79552300|NCT01616290|Drug|PRT-201|0.03, 1, or 3 mg single adventitial administration
79716513|NCT01227018|Drug|STA-9090|Given IV
79853310|NCT05904717|Drug|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
79853311|NCT05904717|Drug|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
79552301|NCT01616316|Procedure|subfascial flap|subfacial dissection to thyroid
79716514|NCT01227018|Radiation|Radiologic imaging|radiologic modalities used to evaluate response to treatment
79552302|NCT01616316|Procedure|subplatysmal flap|subplatysmal approach to thyroid
79716515|NCT01227018|Procedure|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
79853312|NCT05898100|Device|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
79853313|NCT05898100|Behavioral|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
80018023|NCT02117466|Drug|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
80018024|NCT04766320|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-3x10^11 autologous TILs to patients i.v. in 30-120 minutes.
80018025|NCT02123940|Device|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
80018026|NCT02117622|Drug|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
80018027|NCT04529902|Drug|Tumor Necrosis Factor Inhibitors|TNFi claim is used as the reference group.
79552303|NCT01616342|Device|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
79716516|NCT01659541|Device|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
79552304|NCT01616355|Other|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
79552305|NCT01616368|Behavioral|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
79716517|NCT01659541|Procedure|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
79255819|NCT02112097|Drug|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
79716518|NCT01226472|Biological|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
79552306|NCT01616381|Drug|Sildenafil|PDE-5 Inhibitor
79716519|NCT04268563|Drug|placebo|Oral rehydration solution
79716520|NCT04268563|Drug|metformin|metformin tablet
79716521|NCT04268563|Drug|Sitagliptin|Sitagliptin tablet
79552307|NCT01616381|Drug|Placebo|Placebo for sildenafil 40mg x 3 daily
79552308|NCT01616407|Drug|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
79552309|NCT01616407|Drug|Methylphenidate|40 mg per os, single dose
79716522|NCT04268563|Drug|Sitagliptin/metformin|Sitagliptin/metformin tablet
79552310|NCT01616407|Drug|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
79716523|NCT04319016|Other|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
79305040|NCT04967547|Other|Education|Education on renal replacement therapy and dialysis
79305041|NCT03522701|Behavioral|CBTI|Refer to the arm description
79552311|NCT01616420|Other|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
79552312|NCT01616433|Behavioral|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
79552313|NCT01616433|Behavioral|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
79552314|NCT01616472|Drug|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
79552315|NCT01616485|Drug|TA-1790|2 TA-1790 100 mg capsules
79552316|NCT01616485|Drug|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
79552317|NCT01616485|Drug|Placebo|2 placebo capsules for TA-1790 100 mg capsules
79552318|NCT01616485|Drug|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
79552319|NCT01616537|Other|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
79552320|NCT01616550|Other|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
79552321|NCT01616550|Other|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
79552322|NCT01616550|Other|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
79716524|NCT04206462|Other|Questionnaire of eating habits|frequency and type of aliments
79716525|NCT01225146|Drug|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
79716526|NCT01223196|Drug|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
79716527|NCT01223196|Drug|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
79716528|NCT01222416|Radiation|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
79716529|NCT01222416|Radiation|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
79716530|NCT01221948|Device|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
79716531|NCT01221090|Behavioral|PDA|Technological assistance
79716532|NCT01221090|Behavioral|CDSMP|6-week classes
79716533|NCT01221090|Behavioral|PDA/CDSMP|Combined technology and education
79716534|NCT00950911|Drug|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
79716535|NCT02855515|Procedure|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
79716536|NCT01220856|Drug|Reparixin|Reparixin + immunosuppression
79552323|NCT01616550|Other|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
80018028|NCT04529902|Drug|Abatacept|Abatacept claim is used as the exposure group.
79552324|NCT01616602|Other|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
79552325|NCT01616602|Other|Standard Position|The traditional left-lateral decubitus position
79552326|NCT01616615|Drug|Aspirin|150 mg/day oral use
79552327|NCT01616615|Drug|placebo|1 capsule / day oral use
79552328|NCT01616277|Biological|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
79552329|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
79552330|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
79552331|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
79552332|NCT01616277|Biological|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
79552333|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
79716537|NCT04206228|Drug|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
79716538|NCT04206228|Drug|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
79716539|NCT01218594|Drug|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
80018029|NCT02117778|Procedure|Continuous Nerve Block|
80018030|NCT04696900|Procedure|Exercise training|exercise training in an approved rehabilitation program
80018031|NCT02120742|Behavioral|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
80018032|NCT03528668|Device|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
79552334|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
79395366|NCT02342808|Behavioral|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
80018033|NCT02120820|Behavioral|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
80018034|NCT02120820|Behavioral|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
79552335|NCT01616277|Drug|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
79552336|NCT01616277|Biological|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
79552337|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
79552338|NCT01616277|Biological|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
79552339|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
79395367|NCT02342730|Behavioral|Weight Loss Specialist|Referred to a weight loss specialist
79395368|NCT02342730|Other|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
79552340|NCT01616277|Biological|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
79552341|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
79552342|NCT01616628|Behavioral|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
79552343|NCT01616667|Procedure|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
79552344|NCT01616680|Drug|brentuximab vedotin|Given IV
79552345|NCT01616680|Other|laboratory biomarker analysis|Correlative studies
79552346|NCT01616680|Other|pharmacological study|Correlative studies
79552347|NCT01616719|Device|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
79552348|NCT01616732|Drug|Testosterone|TU im
79552349|NCT01616732|Drug|placebo|placebo im
79552350|NCT01616758|Drug|GTx-024 9mg|
79552351|NCT01616784|Other|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
79552352|NCT01616784|Other|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
79552353|NCT01616797|Behavioral|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
79716540|NCT01610557|Drug|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
80018035|NCT02120820|Other|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
80018036|NCT02120820|Behavioral|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
80018037|NCT02288078|Other|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
79255820|NCT02112097|Drug|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
79716541|NCT01610557|Drug|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
79716542|NCT00943735|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
79255821|NCT02112097|Drug|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
80018038|NCT02288078|Other|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
80018039|NCT02288078|Other|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
80018040|NCT02288078|Other|Clinical findings|"Blood and lymphatic system disorders: febrile neutropenia~Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~General disorders and administration site conditions: fatigue and malaise~Immune system disorders: allergic reaction~Metabolism and nutrition disorders: anorexia~Nervous system disorders: dysgeusia and peripheral sensory neuropathy~Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~Vascular disorders: hypertension~Symptomatic pancreatitis"
80018041|NCT02288078|Other|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
80018042|NCT02288078|Other|Coagulation and fibrinolysis system|international normalized ratio (INR)
80018043|NCT02288078|Other|Urinalysis|Proteinuria (qualitative)
80018044|NCT02288078|Other|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
80018045|NCT02288078|Other|Adverse event|CTCAE ver.4.0
80018046|NCT02288078|Other|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
80018047|NCT02288078|Other|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
80018048|NCT02288078|Other|Brain MRI|If any symptom of brain metastasis is suspected
79255822|NCT02112097|Drug|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
79255823|NCT02112097|Drug|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
79255824|NCT02112175|Drug|Lenalidomide|
79305042|NCT04964037|Other|No intervention|No intervention
79305043|NCT03255551|Drug|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
79552354|NCT01616836|Other|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
79552355|NCT01616836|Other|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
79552356|NCT01616836|Other|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
79552357|NCT01616849|Drug|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
79716543|NCT00943735|Behavioral|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
79716544|NCT02853097|Other|Cytology Specimen Collection Procedure|Undergo blood collection
79716545|NCT02853097|Other|Laboratory Biomarker Analysis|Correlative studies
79716546|NCT00943579|Drug|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
80018049|NCT02288078|Drug|Dexamethasone|Capsule filled with dexamethasone and lactose
80018050|NCT02288078|Drug|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
80018051|NCT02288078|Drug|Placebo|Capsule filled with lactose
80018052|NCT02288078|Drug|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
80018053|NCT02117856|Procedure|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
80018054|NCT02117856|Procedure|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
80018055|NCT02117856|Procedure|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
80018056|NCT02117856|Device|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
80018057|NCT02117856|Device|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
79716547|NCT04204213|Behavioral|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
80018058|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
80018059|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
79255825|NCT05027984|Device|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
79552358|NCT01616875|Drug|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
79716548|NCT02852707|Behavioral|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
79255826|NCT05027984|Device|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
79552359|NCT01616888|Device|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
79552360|NCT01616901|Procedure|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~7 cm H2O continuous positive airway pressure~T piece~7 cmH2O of pressure support~0 cmH20 of pressure support~7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
79716549|NCT02852707|Behavioral|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
79716550|NCT02852707|Behavioral|Not exposed|People not engaged in regular sports competition/exercise training.
79716551|NCT02852551|Drug|PAT-1251|
79716552|NCT02852551|Drug|Placebo|
79716553|NCT01147809|Drug|Eltrombopag olamine|thrombopoietin receptor agonist
79716554|NCT01147809|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
79716555|NCT00943111|Drug|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (<) 5 nanogram per milliliter [ng/mL] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
79716556|NCT00943111|Drug|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was <5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was >=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
79716557|NCT04268719|Diagnostic Test|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
79716558|NCT01147497|Drug|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
79716559|NCT01147497|Drug|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
79716560|NCT01147341|Drug|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
79716561|NCT01147341|Drug|Placebo|prefilled saline syringe
79716562|NCT00950755|Biological|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
79716563|NCT01147107|Drug|Raltegravir|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
79716564|NCT01147107|Drug|Efavirenz|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
79716565|NCT02852473|Other|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
79853314|NCT05897775|Device|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
80018060|NCT03531554|Dietary Supplement|ketone ester drink|395 mg of ketone ester/kg
79716566|NCT02852863|Other|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
79716567|NCT00942409|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
79716568|NCT01146951|Drug|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
79853315|NCT05893381|Drug|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
79716569|NCT01146951|Drug|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
79716570|NCT01146873|Drug|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
79716571|NCT01146873|Drug|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
79716572|NCT01146873|Drug|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
79716573|NCT01146873|Drug|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
79716574|NCT01146795|Drug|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
79716575|NCT01146795|Drug|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
79853316|NCT05893381|Radiation|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
79853317|NCT05893277|Behavioral|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
79853318|NCT05888597|Drug|L-menthol|(Sigma-Aldrich, St. Louis, US)
79255827|NCT03553537|Drug|Decitabine|10mg/m² iv on day 1-5
79552361|NCT01616927|Drug|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
79552362|NCT01616940|Behavioral|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~Introduction and Assessment~HIV Transmission & Viral Life Cycle~Effective Communication and Self-Advocacy~Understanding Lab Values~HIV Medications~Drug Resistance & Adherence, and Understanding & Managing Side Effects~Disclosure and Stigma~Harm & Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~Are any services needed?~Have referrals or appointments been made?~Does patient need accompaniment to a visit?~Connect patient with services as needed.~Appointment reminders.~Overall well-being?~Schedule next peer contact."
79853319|NCT05888597|Other|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
79255828|NCT03553537|Drug|Cyclophosphamide|750mg/m² iv on day 6
79716576|NCT01146795|Drug|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
79853320|NCT05885542|Drug|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
79853321|NCT05885542|Drug|Placebo|Double-blind placebo oral solution administered once
79875352|NCT01043211|Drug|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
79255829|NCT03553537|Drug|Doxorubicin|DOX
79255830|NCT03553537|Drug|Vincristine|1.4mg/m² iv on day 6
79255831|NCT03553537|Drug|Prednisone|100mg/m² po on day6-10
79255832|NCT02117947|Behavioral|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
79552363|NCT01616966|Drug|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
79552364|NCT01616966|Drug|propofol|Maintenance of anesthesia with propofol
79552365|NCT01616979|Procedure|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
79716577|NCT00625053|Procedure|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
79716578|NCT00625053|Procedure|Open midline incisional hernia repair|"Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
79716579|NCT01146561|Biological|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
79716580|NCT01146561|Other|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
79853322|NCT05884424|Behavioral|PARO Therapy Robot|"Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~Welcome and presentation.~Main activity with PARO.~PARO cleaning.~End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2)."
79853323|NCT05882721|Device|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
79853324|NCT05881850|Other|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
79853325|NCT05880992|Behavioral|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
80018061|NCT03531554|Behavioral|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
80018062|NCT03531554|Procedure|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
80018063|NCT03531554|Diagnostic Test|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
79853326|NCT05880992|Dietary Supplement|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
79853327|NCT05880992|Behavioral|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
79552366|NCT01616992|Drug|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
79552367|NCT01617044|Dietary Supplement|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
79552368|NCT01617044|Dietary Supplement|Placebo|Placebo
79552369|NCT01617057|Drug|tiludronic acid|400 mg / day for 3 months
79552370|NCT01617057|Drug|Placebo|400 mg / day for 3 month
79552371|NCT01617109|Dietary Supplement|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
79552372|NCT01617109|Other|Placebo|administered as 5 pills daily or as 2 snack bars
79716581|NCT00942175|Drug|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
79716582|NCT00942175|Drug|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
79853328|NCT05876689|Device|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
79853329|NCT05876312|Drug|ADX-038|siRNA duplex oligonucleotide
80018064|NCT02120976|Drug|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
80018065|NCT02120976|Drug|JTT-252|Subjects will receive JTT-252
80018066|NCT04346524|Other|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
80018067|NCT02288234|Drug|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
80018068|NCT03531398|Other|Metabolic test meal challenge|Metabolic test meal challenge
80018069|NCT04654312|Drug|Hydrochlorothiazide|Please see arm descriptions
80018070|NCT04654312|Drug|Placebo|Please see arm descriptions
80018071|NCT02973087|Biological|von Willebrand factor (Recombinant)|OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
79716583|NCT00942175|Drug|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
79552373|NCT01617122|Biological|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
79255833|NCT02117947|Behavioral|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
79716584|NCT00942175|Drug|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
79552374|NCT01617135|Drug|CVT-301|
79853330|NCT05876312|Drug|Placebo|Saline
79552375|NCT01617135|Drug|Placebo|
79552376|NCT01617135|Drug|Sinemet (carbidopa/levodopa)|
79552377|NCT01617135|Drug|CVT-301|
79716585|NCT00942175|Drug|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
79853331|NCT05872945|Diagnostic Test|Electrocardiogram|Study by Artificial Intelligence the biosignal or biodata from profesional football players
79853332|NCT05872256|Drug|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
79853333|NCT05871905|Drug|TY-9591|C14 TY-9591
79853334|NCT05871541|Biological|JCXH-105|As IM injection
79853335|NCT05871541|Biological|Active Control (Shingrix)|As IM injection
79853336|NCT05870995|Drug|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
79853337|NCT05869708|Device|Active RS-EFP|15 (+/- 3) active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
79552378|NCT01617174|Behavioral|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
79305044|NCT03255239|Procedure|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
79395369|NCT02342730|Other|Medical Chart Review|Chart reviews are performed
79395370|NCT02108691|Dietary Supplement|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
79395371|NCT02108691|Dietary Supplement|Placebo|Placebo (2.5g/day)
79716586|NCT01145625|Drug|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
79716587|NCT01145625|Drug|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
79716588|NCT02852941|Device|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
79716589|NCT02852941|Device|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
79716590|NCT02852083|Drug|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
79716591|NCT02852083|Drug|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
79716592|NCT02852083|Drug|Treosulfan|Treosulfan 250 mg twice daily, p.o.
79716593|NCT02852083|Drug|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
79716594|NCT02852395|Drug|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
79395372|NCT03146052|Drug|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
79395373|NCT02109159|Other|A short online video with emotional content|
79395374|NCT02109159|Other|A short online video with less emotional content|
79716595|NCT02852395|Drug|Placebo|Oral dose; appearance matched to JNJ-48816274
79716596|NCT02852629|Other|observational study|
79716597|NCT00602407|Drug|Cilostazol|
79716598|NCT01144377|Drug|LY2541546|Administered subcutaneously
79716599|NCT01144377|Drug|Placebo|Administered subcutaneously
79716600|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
79716601|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
79716602|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
79716603|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
79716604|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
79716605|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
79716606|NCT00950599|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
79716607|NCT01144299|Biological|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
79716608|NCT04313205|Drug|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
79716609|NCT02883621|Procedure|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
79716610|NCT02883621|Procedure|standard upper endoscopy|standard examination without using a cap
79853338|NCT05869708|Device|Sham RS-EFP|15 (+/- 3) sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
79552379|NCT01617200|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
79716611|NCT02883699|Behavioral|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
79716612|NCT02883699|Behavioral|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
79716613|NCT02883699|Behavioral|Standard resistance training|Machine based hypertrophy training 2 x per week
79853339|NCT05869643|Drug|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
79853340|NCT05869643|Drug|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
79853341|NCT05869643|Drug|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
79853342|NCT05869643|Drug|Placebo|Matching placebo capsule, taken orally once daily after breakfast
79853343|NCT05868226|Drug|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
79853344|NCT05868226|Drug|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
79552380|NCT01617200|Drug|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
79552381|NCT01617200|Drug|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
79716614|NCT02883699|Behavioral|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
79716615|NCT04313049|Device|JACO2|Performing tasks using joystick control
79716616|NCT04313049|Device|VOCAL CONTROL|Performing tasks using vocal control
79853345|NCT05868226|Drug|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
79853346|NCT05868226|Drug|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
79853347|NCT05867615|Drug|[177Lu]Lu-PSMA I&T|177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
79853348|NCT05864456|Device|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
79853349|NCT05859555|Other|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
79853350|NCT05858801|Device|PRIMUS|Peripheral Nerve Stimulator System
79853351|NCT05855083|Drug|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
79853352|NCT05853406|Diagnostic Test|Functional Reach test|"The determination by statistical research is carried out during a usual physiotherapy assessment of the volunteers. Data patient demographics and standard tests (FRT, Tinetti test, Timed Up and Go test, unipodal station) will be noted.~A satisfaction questionnaire inspired by Patient rating of change will be sent to participants for the determination of the MCID by ANCHOR method.~Concerning the Delphi method, a questionnaire will be sent to physiotherapists with proven geriatric activity."
79853353|NCT05851976|Drug|Naproxen|Naproxen 500mg twice daily for 16 days
79853354|NCT05851976|Drug|Duloxetine|Duloxetine 60mg daily for 14 days
79875353|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
80018072|NCT02973087|Biological|Antihemophilic Factor (Recombinant)|During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
80018073|NCT05284656|Drug|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
80018074|NCT05284656|Drug|folic acid|drugs used to delay progression of chronic kidney disease
79395375|NCT03148158|Device|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
79395376|NCT01549951|Drug|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
79395377|NCT03145740|Other|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
79395378|NCT03145740|Other|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
79395379|NCT02342652|Drug|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
79552382|NCT01617200|Drug|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
79552383|NCT01617213|Drug|Melphalan|200 mg/m2/IV
79552384|NCT01617213|Drug|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
79552385|NCT01617226|Drug|Azacitidine|Azacitidine both arms; 75mg/m^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
79552386|NCT01617226|Drug|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
80018075|NCT05284656|Drug|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
79305045|NCT03255161|Behavioral|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
79305046|NCT03261011|Biological|AK-104|Subjects will receive AK104 by intravenous administration.
79552387|NCT01617239|Biological|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
79552388|NCT01617252|Device|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
79552389|NCT01617265|Procedure|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
79552390|NCT01617265|Procedure|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
79552391|NCT01617278|Device|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
79552392|NCT01617278|Device|HD Colon|High definition white light
79552393|NCT01617278|Device|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
79552394|NCT01617304|Other|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
79395380|NCT02342652|Drug|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
79395381|NCT02342496|Dietary Supplement|Placebo|Powder
79552395|NCT01617317|Drug|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
79305047|NCT04954521|Drug|Anlotinib|This is an observational study
79305048|NCT03254849|Drug|Empagliflozin|1 tablet
79305049|NCT03254849|Drug|Hydrochlorothiazide 25 mg|1 tablet
79305050|NCT04954209|Other|Physical activities in hospital|3 month in a resumption program of physical activity in hospital
79395382|NCT02342496|Dietary Supplement|Active, only probiotics|Powder
79305051|NCT04954209|Other|Physical activity outside hospital|3 month in a resumption program of physical activity outside hospital with discovery sessions
79305052|NCT02455895|Device|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
79395383|NCT02342496|Dietary Supplement|Active, blend of berries and probiotics|Powder
79395384|NCT03148314|Drug|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
79395385|NCT03148314|Drug|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
79552396|NCT01617317|Drug|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
79552397|NCT01617330|Procedure|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
79552398|NCT01617343|Behavioral|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
79552399|NCT01617356|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
79552400|NCT01617356|Other|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
79552401|NCT01617473|Procedure|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
80018076|NCT04287088|Diagnostic Test|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
80018077|NCT02288390|Procedure|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
80018078|NCT02124174|Drug|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
79853355|NCT05848674|Other|CArdiac Brief INtervention (CABIN)|CABIN is designed as a brief intervention with a facilitated discussion between a patient and a nurse, with the provision of a short leaflet that summarises information and acts as an aide memoir. The discussion takes place in a quiet area and is intended to last 15-20 minutes. CABIN involves a nurse listening to the patient and recognising any concerns he / she may have and / or identifying erroneous beliefs. It also provides the patient with personalised education on coronary artery disease and cardiac rehabilitation (i.e., information about stenting, stent placement, medication, and purpose / potential benefits of cardiac rehabilitation), along with facilitating psychological and emotional support discussions with a nurse (i.e., explaining causes of a STEMI, discussing support / treatment options, and exploring methods of improving health).
79853356|NCT05848674|Other|Refined version of CABIN|Participants of the control group will receive a refined version of CABIN, which excludes psychological and emotional support discussions with a nurse and details some standard discharge information (information about coronary artery disease and stenting / stent placement).
79552402|NCT01617486|Behavioral|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
79552403|NCT01617499|Behavioral|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
79552404|NCT01617512|Device|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
79552405|NCT01617525|Other|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
79552406|NCT01617538|Drug|atorvastatin|40mg per day,duration for 24 weeks
79552407|NCT01617551|Drug|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
79552408|NCT01617564|Drug|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
79552409|NCT01617564|Other|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
79552410|NCT01617590|Drug|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
79552411|NCT01617590|Drug|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
79552412|NCT01617694|Drug|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
79853357|NCT05848232|Device|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
79853358|NCT05848232|Device|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
79853359|NCT05848232|Device|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
79853360|NCT05846893|Device|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
80018079|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
80018080|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
79395386|NCT01517893|Drug|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
79395387|NCT01517893|Drug|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
79395388|NCT02342340|Other|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
79395389|NCT02342340|Other|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
79395390|NCT02342340|Other|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
79395391|NCT02342340|Other|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
79395392|NCT02342340|Other|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
79395393|NCT02342340|Other|White Rice|One time consumption of 3/4 cup of cooked white rice.
79395394|NCT02344992|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
79395395|NCT02344992|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
79395396|NCT01489891|Drug|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
79395397|NCT01489891|Drug|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
79552413|NCT01617694|Drug|Normal Saline|
79552414|NCT01617707|Drug|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
79552415|NCT01617707|Drug|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
79552416|NCT01617733|Drug|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
79552417|NCT01617746|Drug|Ambrisentan|5mg od two weeks
79552418|NCT01617746|Drug|Bosentan|62.5mg bd two weeks
79552419|NCT01617746|Drug|Placebo|bd for two weeks
79552420|NCT01617772|Drug|Atorvastatin|Atorvastatin 20 mg
79552421|NCT01617772|Drug|L-Carnitine|1000mg L-carnitine
79552422|NCT01617772|Drug|Placebo|Identically looking placebo
79853361|NCT05846893|Device|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
79853362|NCT05846815|Device|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
80018081|NCT00277238|Drug|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
79395398|NCT02342574|Drug|F901318|Administration of active compound
79395399|NCT02342574|Drug|Placebo|Administration of placebo
79395400|NCT00360009|Procedure|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
79552423|NCT01617798|Drug|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
79552424|NCT01617798|Drug|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
79552425|NCT01617811|Procedure|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
79552426|NCT01617824|Drug|Linagliptin|Linagliptin 5 mg tablets for 4 days
79552427|NCT01617824|Drug|Placebo|Placebo tablets for 4 days
79552428|NCT01617837|Device|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
79552429|NCT01617837|Other|Placebo band|Comparison between groups 0-48 hours postoperatively
79552430|NCT01617850|Other|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
79552431|NCT01617850|Other|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
79552432|NCT01617889|Other|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
79552433|NCT01617889|Other|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
79395401|NCT00360009|Procedure|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
79395402|NCT03148002|Drug|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
79395403|NCT03148002|Drug|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
79395404|NCT02342262|Dietary Supplement|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
79853363|NCT05846815|Other|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
79853364|NCT05839574|Drug|MTX monotherapy|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
79853365|NCT05839574|Drug|MTX + letrozole add-on|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
80018082|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
80018083|NCT02124252|Behavioral|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
80018084|NCT02124252|Behavioral|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
80018085|NCT03956368|Drug|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
80018086|NCT03956368|Drug|Placebos|20mg (every evening orally) for 8 weeks.
79552434|NCT01617928|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
80018087|NCT02124330|Dietary Supplement|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
80018088|NCT02124330|Dietary Supplement|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
79552435|NCT01617928|Drug|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
79552436|NCT01617928|Drug|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
79552437|NCT01617941|Drug|BGG492|
79853366|NCT05839561|Drug|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
80018089|NCT02124330|Dietary Supplement|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
80018090|NCT02118090|Drug|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
80018091|NCT02118090|Drug|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
79395405|NCT02342262|Other|Placebo|similar appearance as the probiotic product, but without bacteria
79395406|NCT02342184|Drug|GB-0998|
79395407|NCT00360243|Drug|flibanserin|Experimental: flibanserin 25 mg b.i.d
79395408|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg qhs
79395409|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg b.i.d.
79395410|NCT00360243|Drug|placebo|placebo
79395411|NCT02039232|Device|Pedicle screw system|
79395412|NCT02344914|Device|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
79395413|NCT02348892|Other|Coordinator|Patients in complex situation taken care by coordinator
79395414|NCT02348892|Other|Classic plan|Patients in complex situation taken care by classic plan
79395415|NCT03147924|Other|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
79552438|NCT01617941|Drug|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
79552439|NCT01617954|Device|MammaPrint|All subjects
79552440|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
79552441|NCT01618006|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
79552442|NCT01618006|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
79552443|NCT01618006|Drug|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
79552444|NCT01618032|Other|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
79552445|NCT01618032|Other|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
79552446|NCT01618032|Other|placebo|Manual contact during a period of time similar of teh other interventions
79552447|NCT01618045|Dietary Supplement|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
79552448|NCT01618058|Drug|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
79716619|NCT01143207|Drug|Medroxyprogesterone acetate|Injectable hormonal contraceptive
79716620|NCT04312893|Other|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
79716621|NCT04312893|Other|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
79716622|NCT01143051|Drug|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
79716623|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
79716624|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
79716625|NCT02883543|Drug|icotinib|Icotinib is orally administered three times per day.
79716626|NCT02883543|Drug|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
79716627|NCT02883543|Radiation|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
79716628|NCT05199597|Drug|0.01% atropine|0.01%, room temp, Lab A
79716629|NCT05199597|Drug|0.05% atropine|0.05%, room temp, Lab A
79716630|NCT05199597|Drug|0.05% atropine|0.05%, refrigerated, Lab A
79716631|NCT05199597|Drug|0.05% atropine|0.05%, room temperature, Lab B
79552449|NCT01618071|Dietary Supplement|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
79552450|NCT01618084|Device|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
79552451|NCT01618097|Behavioral|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
79552452|NCT01618097|Behavioral|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
79552453|NCT01618110|Device|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
79552454|NCT01618110|Other|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
79552455|NCT01618149|Radiation|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
79552456|NCT01618175|Device|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
79716632|NCT01142661|Drug|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
79716633|NCT01142193|Drug|USL255|
79853367|NCT05839561|Drug|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
79853368|NCT05834959|Other|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
79716634|NCT01142193|Drug|Placebo|
79716635|NCT01142115|Device|Intermittent catheter CP063CC|intermittent catheterisation
79716636|NCT01142115|Device|SpeediCath|intermittent catheterisation
79716637|NCT01140477|Device|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
79716638|NCT01140477|Device|Accommodating Lens|Accommodating lens implanted after cataract extraction
79716639|NCT01139775|Drug|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
79716640|NCT01139775|Drug|Cisplatin|Administered intravenously as a continuous 1-hour infusion
79716641|NCT01139775|Drug|LY2603618|Administered intravenously as a continuous 1-hour infusion
79716642|NCT05224557|Other|No intervention|No intervention
79716643|NCT02883777|Behavioral|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
79552457|NCT01618253|Drug|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
79552458|NCT01618253|Radiation|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or >10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If >1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions >10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
79552459|NCT01618292|Procedure|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
79255834|NCT05027672|Drug|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
79255835|NCT02118025|Procedure|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
79255836|NCT02118025|Procedure|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
79552460|NCT01618331|Behavioral|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
79552461|NCT01618331|Dietary Supplement|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
79716644|NCT02883777|Behavioral|Conventional Diet|Conventional diet over 1 year after transplantation.
79716645|NCT02883465|Procedure|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
79716646|NCT04312425|Procedure|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
79716647|NCT04312425|Procedure|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
79716648|NCT01283516|Drug|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
79716649|NCT04205721|Behavioral|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
79716650|NCT01137435|Biological|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
79716651|NCT02883309|Other|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
79853369|NCT05833204|Procedure|Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
79853370|NCT05833204|Procedure|Laparoscopic colporrhaphy with standard 0-caliber absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
79255837|NCT02118103|Procedure|Spinal Manipulation|Lumbar spinal manipulation
79552462|NCT01618370|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
79716652|NCT02883231|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
79716653|NCT01283282|Drug|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
79853371|NCT05829317|Drug|Magnesium sulfate|Intravenous Magnesium sulfate
79853372|NCT05829317|Drug|Placebo|0.9% NaCl
79255838|NCT03086174|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
79853373|NCT05826886|Behavioral|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
79853374|NCT05825391|Drug|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
79255839|NCT02112253|Device|Deep brain stimulator ventral electrode up to 2 mA|
79552463|NCT01618383|Other|colonoscopy or rectosigmoidoscopy|Usual procedure
79552464|NCT01618396|Drug|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
79552465|NCT01618409|Behavioral|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
79552466|NCT01618188|Drug|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
79552467|NCT01618188|Drug|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
79552468|NCT01618435|Biological|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
79716654|NCT01283282|Drug|Placebo|Placebo PO qday for 6 weeks
79552469|NCT01618448|Drug|Tolvaptan|Tolvaptan 15mg once daily
79552470|NCT01618448|Drug|Placebo|Placebo
79552471|NCT01618461|Behavioral|Drug indication icons|Icons illustrate the purpose of each medication
79716655|NCT01282814|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
79716656|NCT01282814|Drug|Effexor® XR|150 mg Extended-Release Capsule
79716657|NCT00941863|Drug|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
79875354|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
79716658|NCT00941863|Drug|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
79716659|NCT00941863|Drug|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
79875355|NCT01043289|Other|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
79255840|NCT02112253|Device|Deep brain stimulator ventral electrode up to 3 mA|
79716660|NCT00941863|Drug|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
80018092|NCT04539184|Other|Motion Style Acupuncture Treatment (MSAT)|MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.
79255841|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 2 mA|
79716661|NCT00941863|Drug|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
80018093|NCT04539184|Other|Acupuncture|General acupuncture
79255842|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 3 mA|
79255843|NCT02112253|Device|Deep brain stimulator empirical programming|
79255844|NCT04131764|Diagnostic Test|Reflex (Brightlamp Inc., Purdue University)|The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
79552472|NCT01618461|Behavioral|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
79552473|NCT01618474|Drug|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
79552474|NCT01618474|Drug|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
79552475|NCT01618487|Procedure|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
79552476|NCT01618487|Procedure|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
79552477|NCT01618487|Procedure|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
79552478|NCT01618513|Drug|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
79552479|NCT01618526|Dietary Supplement|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
79552480|NCT01618526|Dietary Supplement|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
79716662|NCT00602485|Other|Action Control Education|30 minute educational intervnetion
79716663|NCT00602173|Drug|Cilostazol|
79716664|NCT02854969|Behavioral|Device: Anapphylaxis|
79716665|NCT02852239|Drug|dabrafenib|Single dose dabrafenib 100 mg
79716666|NCT01282424|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
79255845|NCT03085784|Drug|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
79255846|NCT02788747|Drug|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
79552481|NCT01618539|Drug|propofol|varying intravenous dosages
79552482|NCT01618552|Behavioral|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
79552483|NCT01618552|Other|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
79552484|NCT01618578|Procedure|rubber hand illusion|"There were three consecutive trials of the RHI:~one control trial: asynchronous condition (3 Min.)~two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
79552485|NCT01618591|Drug|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
79552486|NCT01618591|Drug|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
79552487|NCT01618591|Drug|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
79552488|NCT01618591|Drug|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
79255847|NCT02788747|Drug|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
79552489|NCT01618591|Drug|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
79875356|NCT01043367|Dietary Supplement|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
79255848|NCT02788747|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
79255849|NCT05021276|Drug|Ruxolitinib|Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
79552490|NCT01618604|Procedure|Quantitative Sensory Testing|following the standardized protocol of DFNS
79552491|NCT01618604|Procedure|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
79552492|NCT01618604|Procedure|Repetition of four QST parameters|"warm detection threshold (WDT)~cold detection threshold (CDT)~mechanical detection threshold (MDT)~mechanical pain threshold (MPT)"
79552493|NCT01618617|Dietary Supplement|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
79552494|NCT01618617|Dietary Supplement|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
79552495|NCT01618630|Dietary Supplement|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
79552496|NCT01618630|Dietary Supplement|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
79552497|NCT01618643|Procedure|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
79552498|NCT01618760|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
79552499|NCT01618760|Drug|Risperidone|1 mg tablet once a day
79552500|NCT01618773|Drug|0.1% adapalene / 2.5% benzoyl peroxide|topical application
79552501|NCT01618799|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
79552502|NCT01618799|Drug|Lamotrigine|2 x 25 mg tablet once a day
79552503|NCT01618812|Procedure|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
79716667|NCT02852785|Behavioral|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
79716668|NCT02852785|Behavioral|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
79716669|NCT02852785|Behavioral|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
79716670|NCT02852785|Behavioral|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
79716671|NCT00602251|Drug|Terbinafine|
79716672|NCT01281956|Drug|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
79716673|NCT01281956|Drug|Placebo|Placebo
79552504|NCT01618825|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
79552505|NCT01618825|Drug|Lamotrigine|2 x 25 mg tablet once a day
79875357|NCT01043367|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
79875358|NCT01043445|Dietary Supplement|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
79875359|NCT01043445|Dietary Supplement|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
79255850|NCT01796054|Behavioral|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
79255851|NCT01796054|Behavioral|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
79875360|NCT01043445|Dietary Supplement|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
79552506|NCT01618877|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
79552507|NCT01618877|Other|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
79552508|NCT01618890|Procedure|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement< 12 mmHg or >20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
79552509|NCT01618903|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
79552510|NCT01618903|Drug|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
79552511|NCT01618929|Drug|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
79552512|NCT01618981|Procedure|pace make active/inactive cross over|
79552513|NCT01618994|Procedure|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
79552514|NCT01619007|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
79552515|NCT01619007|Drug|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
79552516|NCT01619020|Dietary Supplement|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
79716674|NCT02889536|Other|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
79716675|NCT02889614|Other|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
79875361|NCT00299728|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
79255852|NCT03552367|Other|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
79255853|NCT03552367|Other|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
79255854|NCT05014490|Drug|Exib 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
79255855|NCT05014490|Drug|Arcoxia® 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
79255856|NCT03552991|Drug|Agiocur Pregranules|6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
79255857|NCT05020964|Drug|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
79255858|NCT03552913|Procedure|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
79552517|NCT01619033|Drug|BF2.649|single dose 20 mg
79552518|NCT01619046|Biological|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate < 10 mL/min
79552519|NCT01619046|Biological|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
79716676|NCT00623870|Drug|RO5045337|Multiple ascending doses
79716677|NCT04323410|Procedure|Cast immobilization|Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
79716678|NCT04323410|Procedure|Percutaneus pinning|Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
79716679|NCT05561270|Device|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
79716680|NCT05561270|Device|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
79716681|NCT00949975|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
79875362|NCT03741946|Procedure|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
79875363|NCT00396591|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
79552520|NCT01619046|Biological|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
79716682|NCT00949975|Drug|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
79255859|NCT03552913|Procedure|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
79716683|NCT00949975|Drug|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
79716684|NCT00949975|Drug|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
79395416|NCT00396201|Drug|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
79716685|NCT00939055|Device|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
79716686|NCT00939055|Procedure|Sham procedure|False procedure
79255860|NCT03552913|Procedure|No specific program toward improving practices|No specific program toward improving practices
79255861|NCT05020886|Behavioral|turning task|Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
79716687|NCT00602563|Behavioral|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
79395417|NCT03145662|Device|high pressure balloon|high pressure balloon will be used to treat stenosis
79716688|NCT00602563|Behavioral|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
79716689|NCT00602563|Behavioral|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
79716690|NCT00602563|Behavioral|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
79255862|NCT02118181|Dietary Supplement|HMB|
79255863|NCT02112409|Procedure|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
79255864|NCT02112409|Procedure|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
79395418|NCT03145662|Device|cutting balloon|cutting balloon will be used to treat stenosis
79395419|NCT03145896|Dietary Supplement|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
79395420|NCT02341872|Other|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
79552521|NCT01619046|Biological|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
79552522|NCT01619072|Other|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
79552523|NCT01619072|Other|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
79552524|NCT01617291|Other|Induced therapeutic hypothermia|induced therapeutic hypothermia
79875364|NCT00316264|Biological|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
79875365|NCT00316264|Biological|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
79875366|NCT00316264|Biological|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
79395421|NCT02341872|Other|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
79395422|NCT02342028|Biological|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
79552525|NCT01619098|Other|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
79552526|NCT01619098|Other|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
79395423|NCT05255094|Biological|AK102|Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
79395424|NCT05255094|Biological|AK102|Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
79552527|NCT01619137|Drug|water and soap|water and soap for 6-8 hours per day.
79552528|NCT01619137|Drug|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
79552529|NCT01619150|Drug|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
79552530|NCT01619150|Drug|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
79552531|NCT01619163|Drug|Placebo|
79552532|NCT01619163|Drug|Prednisolone|low dose, 7.5 mg/day
79552533|NCT01619189|Biological|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
79552534|NCT01619189|Procedure|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
79552535|NCT01619202|Behavioral|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
79552536|NCT01619241|Other|PET/CT|F-18 FLT PET/CT
79395425|NCT05255094|Drug|Placebo|Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
79552537|NCT01619254|Behavioral|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
79552538|NCT01619280|Drug|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
79716691|NCT04268017|Device|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
79875367|NCT02532946|Behavioral|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
79395426|NCT05255094|Drug|Placebo|Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
79552539|NCT01619345|Drug|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
79552540|NCT01619371|Device|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
79552541|NCT01619384|Behavioral|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
79552542|NCT01619397|Device|Test condom with new Xanthan gum condom coating|
79552543|NCT01619436|Drug|Clonidine|bolus, clonidine 2 mg/kg IV
79552544|NCT01619436|Drug|Ringer lactato|1 ML ringer lactato IV, as placebo
79552545|NCT01619449|Procedure|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
79552546|NCT01619462|Biological|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
79552547|NCT01619527|Drug|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
79552548|NCT01619527|Drug|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
79552549|NCT01619540|Other|Valsalva maneuver|
79552550|NCT01619566|Drug|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
79716692|NCT00604357|Drug|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
79716693|NCT05381701|Procedure|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
79552551|NCT01619592|Device|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
79255865|NCT02118259|Other|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time."
79255866|NCT05014100|Drug|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
79255867|NCT05014100|Drug|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
79552552|NCT01619605|Procedure|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
79255868|NCT02251327|Device|Investigational Xpert DST test|One investigational test performed directly on the same sputum specimen.
79395427|NCT02348580|Behavioral|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
79552553|NCT01619618|Genetic|mutation analysis|
79552554|NCT01619618|Genetic|polymerase chain reaction|
79716694|NCT04269733|Device|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
79716695|NCT02854891|Other|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
79716696|NCT00602719|Drug|Zolpidem|
79255869|NCT03083912|Dietary Supplement|Fortimel Complete|The residents included receive 2 bottle por day.
79255870|NCT03552835|Procedure|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
79395428|NCT02348736|Device|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
79395429|NCT00360399|Drug|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
79395430|NCT00360399|Drug|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
79395431|NCT00360399|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
79395432|NCT02341794|Drug|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
79395433|NCT02341950|Behavioral|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
79395434|NCT02344836|Behavioral|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
79552555|NCT01619618|Genetic|polymorphism analysis|
79552556|NCT01619618|Other|laboratory biomarker analysis|
79552557|NCT01619631|Behavioral|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
79395435|NCT02344836|Behavioral|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
79395436|NCT00360555|Drug|flibanserin|flibanserin 25 mg b.i.d
79395437|NCT00360555|Drug|flibanserin 50mg|flibanserin 50mg qhs/b.i.d.
79395438|NCT00360555|Drug|flibanserin 100mg|flibanserin 50 mg b.i.d/100mg qhs
79395439|NCT00360555|Drug|placebo|placebo comparator
79552558|NCT01619631|Behavioral|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
79716697|NCT02854657|Behavioral|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
79716698|NCT00604435|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
80018094|NCT03551808|Drug|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
79853375|NCT05824819|Diagnostic Test|Next Generation Sequencing (NGS)|Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
79853376|NCT05824507|Diagnostic Test|Endometrial aspiration biopsies for CE diagnosis|1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
79853377|NCT05823311|Drug|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
79853378|NCT05823311|Drug|Gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
79853379|NCT05821205|Behavioral|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
79853380|NCT05821205|Behavioral|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
79552559|NCT01619644|Drug|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
79552560|NCT01619644|Drug|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
79552561|NCT01619657|Drug|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
79853381|NCT05821205|Behavioral|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
79853382|NCT05821205|Behavioral|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
79853383|NCT05819099|Diagnostic Test|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
79853384|NCT05816122|Device|MSCopilot® Detect mobile application|MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
79853385|NCT05814055|Drug|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 37.5 mg of kavalactones) orally three times daily for 4 weeks.
79853386|NCT05814055|Drug|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
79853387|NCT05814055|Drug|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
79853388|NCT05813535|Drug|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
79255871|NCT03552835|Procedure|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
79255872|NCT03552835|Procedure|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
79395440|NCT03145506|Device|Multimodal Spectroscopy|optical measurement of excised tissue
79395441|NCT02344602|Drug|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
79395442|NCT02348268|Other|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
79395443|NCT02348268|Other|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
79552562|NCT01619657|Drug|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
79255873|NCT05014022|Diagnostic Test|Multiparametric renal MRI|10 patients in the cohort will undergo MRI scanning at day 30 and 90
79255874|NCT02251405|Behavioral|One bag, stainless container|
79255875|NCT05027126|Drug|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
79255876|NCT05027126|Drug|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
79552563|NCT01619670|Device|Apligraf|non adhesive layer
79552564|NCT01619683|Drug|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
79552565|NCT01619683|Drug|Placebo|1 placebo capsule per day, oral
79552566|NCT01619696|Procedure|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
79552567|NCT01619709|Other|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
79552568|NCT01619761|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
79552569|NCT01619761|Drug|Cyclophosphamide|Given IV
79552570|NCT01619761|Drug|Fludarabine Phosphate|Given IV
79255877|NCT02120677|Drug|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
79552571|NCT01619761|Other|Laboratory Biomarker Analysis|Correlative studies
79552572|NCT01619761|Drug|Lenalidomide|Given PO
79552573|NCT01619761|Drug|Melphalan|Given IV
79552574|NCT01619761|Drug|Mycophenolate Mofetil|Given IV or PO
79552575|NCT01619761|Biological|Natural Killer Cell Therapy|Given IV
79552576|NCT01619761|Biological|Rituximab|Given IV
79716699|NCT00604435|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
79552577|NCT01619761|Drug|Tacrolimus|Given IV or PO
79552578|NCT01619761|Radiation|Total-Body Irradiation|Undergo TBI
79552579|NCT01619761|Procedure|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
79552580|NCT01619891|Dietary Supplement|Vitamin D|100mcg per day
79552581|NCT01619904|Procedure|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
79716700|NCT01136967|Drug|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
79716701|NCT01218516|Biological|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
79716702|NCT01218516|Other|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
79716703|NCT01218516|Drug|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL^min [AUC5-6].
79716704|NCT01218516|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 will be administered intravenously.
79853389|NCT05812287|Other|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
79853390|NCT05810116|Drug|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
79853391|NCT05810116|Drug|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
79255878|NCT03091946|Other|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
79255879|NCT03091946|Other|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
79552582|NCT01619904|Procedure|Standard Therapy|Following standard protocol during peri-operative period
79552583|NCT01619930|Behavioral|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
79552584|NCT01619930|Behavioral|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
79853392|NCT05807932|Drug|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
79853393|NCT05807932|Drug|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
79853394|NCT05807932|Drug|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
79552585|NCT01619930|Behavioral|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
79552586|NCT01619930|Behavioral|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
79552587|NCT01619943|Other|no intervention|clinical follow up
79552588|NCT01619943|Other|no intervention|no intervention
79552589|NCT01619956|Device|SLA dental implants|Dental implant with surface modification.
79552590|NCT01619956|Procedure|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
79552591|NCT01619956|Procedure|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
79552592|NCT01619969|Drug|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
79552593|NCT01619969|Drug|placebo|Capsules of identical appearance containing starch
79552594|NCT01620008|Procedure|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
79552595|NCT01620034|Radiation|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
79552596|NCT01620073|Other|HIV counseling and testing|Male partner HIV counseling and testing
79552597|NCT01620099|Drug|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
79552598|NCT01620112|Drug|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
79552599|NCT01620112|Drug|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
79552600|NCT01620112|Drug|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
79552601|NCT01620112|Drug|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
79552602|NCT01620125|Dietary Supplement|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
79552603|NCT01620151|Procedure|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
79552604|NCT01620164|Other|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
79552605|NCT01620229|Drug|brentuximab vedotin|Given IV
79552606|NCT01620229|Other|laboratory biomarker analysis|Correlative studies
79853395|NCT05807932|Drug|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
79853396|NCT05807932|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
79853397|NCT05806944|Device|TMS followed by Sham TMS|double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
79255880|NCT02118415|Other|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
79552607|NCT01620229|Other|pharmacological study|Correlative studies
79552608|NCT01620242|Drug|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
79552609|NCT01620268|Drug|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
79552610|NCT01620281|Device|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
79552611|NCT01620294|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
79552612|NCT01620294|Procedure|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
79552613|NCT01620307|Drug|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
79552614|NCT01620320|Other|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
79552615|NCT01620333|Drug|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
79552616|NCT01620333|Drug|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
79552617|NCT01620346|Procedure|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
79552618|NCT01620346|Procedure|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
79552619|NCT01620359|Device|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
79853398|NCT05806944|Device|Sham TMS followed by TMS|double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
79853399|NCT05803941|Drug|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent clinical interventional Novartis sponsored clinical trials.
80018095|NCT04053543|Drug|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
79716705|NCT01218516|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously.
79716706|NCT01218516|Drug|Cisplatin|Cisplatin 75 mg/m^2 will be administered intravenously.
79552620|NCT01620385|Device|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
79853400|NCT05798078|Behavioral|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
79853401|NCT05798078|Behavioral|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
79853402|NCT05797376|Drug|Rivaroxaban 2.5mg|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
79853403|NCT05797116|Other|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
79552621|NCT01620398|Behavioral|BALANCE|
79552622|NCT01620398|Behavioral|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
79552623|NCT01620411|Other|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
79716707|NCT00938431|Drug|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
79716708|NCT02851927|Procedure|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
79716709|NCT02851927|Procedure|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
79716710|NCT05381545|Behavioral|laser puncture, energy expenditure programming, and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34&28, ST25&36&40, SP6, and CV4&9&12.
79716711|NCT05381545|Behavioral|energy expenditure programming and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
79853404|NCT05794321|Drug|Intravenous TXA|Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
79853405|NCT05789407|Diagnostic Test|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
79853406|NCT05789056|Drug|QRX003, 4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
79552624|NCT01620411|Procedure|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
79552625|NCT01620424|Drug|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
79552626|NCT01620424|Drug|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
79552627|NCT01620437|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
79552628|NCT01620450|Drug|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
79552629|NCT01620463|Drug|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
79552630|NCT01620463|Drug|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
79552631|NCT01620476|Drug|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
79552632|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
79552633|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
79716712|NCT04312815|Drug|SM03|SM03: 600 mg intravenous (IV)
79716713|NCT04312815|Drug|Placebo|Placebo: 600 mg intravenous (IV)
79716714|NCT04312815|Drug|MTX|Methotrexate: 7.5-20 mg/wk oral
79716715|NCT05381389|Drug|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
79853407|NCT05782582|Diagnostic Test|Package investigation|Investigations performed on a single visit, according to arm description
79853408|NCT05782582|Device|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
79853409|NCT05782582|Diagnostic Test|Standard investigation|Sequential investigations according to arm description
79716716|NCT05381389|Drug|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
79716717|NCT01136811|Device|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
79716718|NCT00949117|Dietary Supplement|Ensure|Given orally
79716719|NCT00949117|Dietary Supplement|PediaSure|Given orally
79716720|NCT00949117|Drug|cyproheptadine hydrochloride|Given orally
79716721|NCT04312347|Drug|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
79716722|NCT00631267|Procedure|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
79716723|NCT00631267|Procedure|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
79716724|NCT00938041|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
80018096|NCT04229914|Other|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
79552634|NCT01620476|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
79552635|NCT01620502|Dietary Supplement|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
79552636|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
79552637|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
79552638|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
79552639|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
79716725|NCT00604513|Other|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun & Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
79716726|NCT00604513|Other|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
79716727|NCT05381233|Other|Gross motor function classification System (GMFCS)|assessment
79716728|NCT05381233|Other|Arabic Version of Zarit burden Inventory measure|assessment
79716729|NCT05381233|Other|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
79853412|NCT05776758|Drug|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
79552640|NCT01620554|Drug|Placebo|1 capsule per week during 2 weeks
79552641|NCT01620580|Behavioral|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
79716730|NCT04266691|Other|nonIntervention|nonIntervention
79716731|NCT02851693|Device|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
79716732|NCT02851693|Device|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
79716733|NCT05379283|Drug|Lidocaine|effect of lidocaine on sweat production during exercise in the heat
79716734|NCT05379283|Other|control|one arm will be pretreated with topical lidocaine, the other arm will not
79716735|NCT02851849|Drug|LGD-6972-5 mg|5 mg LGD-6972 QD
79716736|NCT02851849|Drug|LGD-6972-10 mg|10 mg LGD-6972 QD
79853413|NCT05776758|Procedure|Radical cystectomy alone|RC alone
80018097|NCT05724758|Procedure|Breast-conserving surgery|"Following oncoplastic surgeries are performed at the Brust-Zentrum in Zurich:~Oncoplastic reconstruction with round-block technique~Oncoplastic reconstruction using J-Plastic~Oncoplastic reconstruction using V-Plastic~Oncoplastic reconstruction using Grisotti~Oncoplastic reconstruction using Batwing~Oncoplastic reconstruction using Mammareductionplasty (Wise Pattern, Vertical)~Oncoplastic perforator flap surgery"
79255881|NCT05026970|Combination Product|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
79716737|NCT02851849|Drug|LGD-6972-15 mg|15 mg LGD-6972 QD
79716738|NCT02851849|Other|Placebo|Placebo QD
79716739|NCT01218438|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
79716740|NCT01218438|Drug|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
79716741|NCT05381077|Other|MRI|Whole body MRI (ZTE sequence)
79716742|NCT00604591|Drug|Tolcapone|200 mg by mouth three times a day
79716743|NCT00604591|Drug|Placebo|200 mg by mouth three times a day
79853414|NCT05763160|Drug|RZL-012|Ready to use drug product for injection into the subcutaneous fat
79853415|NCT05760365|Other|3D printed educational model|3D printed cardiac catheterization model
79853416|NCT05760365|Other|Slide-based presention|Slide-based presention
79853417|NCT05757310|Biological|Anti-Thymocyte Globulin|Given IV
79853418|NCT05757310|Procedure|Biospecimen Collection|Undergo blood sample collection
79853419|NCT05757310|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
80018098|NCT02124408|Behavioral|Personalized Behavioral Intervention|
79716744|NCT05380999|Diagnostic Test|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
79853420|NCT05757310|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79853421|NCT05757310|Drug|Cyclophosphamide|Given PO and IV
79255882|NCT05026970|Device|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
79255883|NCT05026970|Combination Product|Biofeedback+Kegel|Biofeedback+Kegel exercises
79255884|NCT02120755|Biological|AmnioClear™ Human Allograft Amniotic Membrane|
79255885|NCT03092102|Drug|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
79552642|NCT01620580|Behavioral|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills & adherence to renal diet and fluid restriction without discussing any intervention with the group.
79552643|NCT01620606|Behavioral|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy & Social Learning
79255886|NCT02120911|Drug|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
79255887|NCT02120989|Behavioral|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
79552644|NCT01620606|Behavioral|Education and Support|Education about the GI system, nutrition and food safety
79552645|NCT01620619|Other|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
79552646|NCT01620619|Procedure|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
79255888|NCT05013866|Procedure|Repair resin composite proximal|Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
79255889|NCT02121145|Biological|Vivotif|3 oral doses
79395444|NCT02348268|Device|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
79395445|NCT02348346|Other|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
79552647|NCT01620632|Procedure|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
79716745|NCT00606073|Other|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
79716746|NCT02691156|Diagnostic Test|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
79255890|NCT02121145|Biological|Typherix|one intramuscular dose
79716747|NCT02691156|Diagnostic Test|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
79716748|NCT02691156|Diagnostic Test|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
79716749|NCT00603031|Other|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
79716750|NCT00603031|Other|NaCl|infusion with NaCl for 120 minutes as placebo-arm
79716751|NCT00603031|Other|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
79853422|NCT05757310|Procedure|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
79853423|NCT05757310|Drug|Pentostatin|Given IV
79853424|NCT05757310|Other|Questionnaire Administration|Ancillary studies
79853425|NCT05754034|Device|High flow oxygen|humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%
79853426|NCT05754034|Other|Standard flow oxygen|oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%
79853427|NCT05752539|Device|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
79853428|NCT05748626|Device|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
79853429|NCT05748626|Procedure|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
79255891|NCT05020262|Other|CT Image reconstruction|Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.
79255892|NCT02112487|Drug|Macitentan|10 mg once daily
79552648|NCT01620645|Radiation|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
79552649|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
79552650|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
79552651|NCT01620684|Drug|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
79552652|NCT01620684|Drug|placebo|placebo capsules
79716752|NCT04268329|Other|Educational website|A website is used to educate patients and family members about head and neck cancer.
79853430|NCT05745727|Drug|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 7
79853431|NCT05745727|Drug|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 7
79853432|NCT05745064|Drug|TL-925|TL-925 is an eye drop.
79853433|NCT05745064|Drug|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
79853434|NCT05741489|Device|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
79853435|NCT05739331|Device|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
79255893|NCT03094442|Drug|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
79395446|NCT02337348|Other|Optical coherence tomography|Preintervention imaging
79395447|NCT02337348|Radiation|Coronary angiography|Conventional coronary intervention
79552653|NCT01620697|Procedure|Colorectal surgery|Colorectal surgery
79552654|NCT01620710|Radiation|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
79552655|NCT01620710|Radiation|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
79552656|NCT01620723|Other|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
79552657|NCT01620723|Other|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
79552658|NCT01620736|Drug|Raltegravir|Raltegravir 400 mg po bid
79552659|NCT01620749|Radiation|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
79552660|NCT01620775|Other|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
79552661|NCT01620775|Other|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
79552662|NCT01620801|Biological|AAV8-hFIX19|One-time IV vector administration.
79552663|NCT01620814|Drug|Dinoprostone|
79552664|NCT01620814|Drug|misoprostol|
79552665|NCT01620814|Drug|control|
79716753|NCT00935701|Device|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
79716754|NCT02851537|Other|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
79853436|NCT05733611|Biological|RP2|Genetically modified herpes simplex type 1 virus
79853437|NCT05733611|Biological|RP3|Genetically modified herpes simplex type 1 virus
79255894|NCT03094442|Drug|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
79255895|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
79255896|NCT02406742|Drug|Ibrutinib|
79395448|NCT00361257|Drug|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
79395449|NCT00361257|Drug|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
79395450|NCT02344758|Device|Non-invasive lateral flow test for monitoring gluten intake|
79395451|NCT02344758|Behavioral|gluten-free diet (GFD)|
79395452|NCT02344758|Behavioral|gluten-containing diet|
79395453|NCT02344524|Device|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
79395454|NCT04062240|Device|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
79395455|NCT02344446|Other|Skilled Therapy|Active physical therapy treatment
79552666|NCT01619319|Other|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
79552667|NCT01619319|Other|computer games|computer games that that consist of word puzzles
79552668|NCT01619826|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
79552669|NCT01619826|Behavioral|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
79552670|NCT01620827|Other|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
79255897|NCT02406742|Drug|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
79552671|NCT01620827|Other|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
79552672|NCT01620840|Drug|Lacosamide 10mg/ml|intravenous administration up to 10 days
79552673|NCT01620866|Other|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
79552674|NCT01620905|Procedure|Manipulation|Single level cervical spine joint manipulation
79552675|NCT01620931|Drug|RO5469754|Single ascending doses, iv or sc
79552676|NCT01620931|Drug|Placebo|Single doses, iv or sc
79552677|NCT01620970|Drug|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
79552678|NCT01621022|Drug|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
79255898|NCT05020340|Procedure|External cephalic version|In the intervention group, ECV will be performed by two operators with one of them having experience of ≥ 5 successful ECV. The procedure will be performed by the first operator under real time continuous ultrasonographic guidance. The fetal head and buttock will be grasped by both hands and attempt to rotate the fetus to a longitudinal lie either in a clockwise or anti-clockwise fashion. The second operator will perform the ECV if the first operator fails the procedure.
79255899|NCT02112643|Drug|Sodium selenate|A 100 microgram pill will be orally administered twice a day for 6 months.
79255900|NCT02112643|Dietary Supplement|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
79552679|NCT01621022|Drug|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
79552680|NCT01621022|Drug|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
79552681|NCT01621074|Dietary Supplement|Sodium bicarbonate|Ergogenic effect
79552682|NCT01621074|Dietary Supplement|Placebo|Placebo effect
79552683|NCT01621087|Other|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
79716755|NCT05379049|Biological|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
79716756|NCT04266613|Diagnostic Test|TruGraf® Testing|5 mL collection PAXgene blood sample
79716757|NCT00604747|Other|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
79716758|NCT04268095|Other|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
79255901|NCT03094130|Other|News items with spin|Interpretation of news items with spin
79255902|NCT03094130|Other|News items without spin|Interpretation of news items without spin
79552684|NCT01621100|Drug|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
79552685|NCT01621113|Drug|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
79552686|NCT01621113|Drug|Placebo|Placebo tablet, twice daily, for 10 weeks.
79552687|NCT01621139|Procedure|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
79552688|NCT01621165|Drug|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
79552689|NCT01621165|Drug|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
79552690|NCT01621204|Drug|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
79716759|NCT02851459|Behavioral|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
79716760|NCT02851459|Behavioral|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
79716761|NCT02851459|Behavioral|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
79716762|NCT02851459|Behavioral|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
79716763|NCT02851459|Behavioral|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
79552691|NCT01621204|Drug|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
79853438|NCT05733611|Biological|atezolizumab|anti-PD-L1 monoclonal antibody
79853439|NCT05733611|Biological|bevacizumab|anti-VEGF therapy
79716764|NCT02851459|Behavioral|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
79552692|NCT01621217|Drug|Cetuximab|Will be given weekly intravenously during study treatment.
79552693|NCT01621217|Drug|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
79716765|NCT05378815|Procedure|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
79716766|NCT05378815|Procedure|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
79716767|NCT00603343|Drug|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
79716768|NCT00603343|Drug|placebo|placebo corresponding to body weight
79716769|NCT04266535|Device|Target controlled infusion|Target controlled infusion vs manually controlled infusion
79716770|NCT00606385|Procedure|Liver resection|Laparoscopic or Open hepatectomy
79716771|NCT05378659|Behavioral|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
79716772|NCT05378659|Behavioral|Stroop Test|Evaluates Processing Speed and Executive Control
79716773|NCT05378659|Diagnostic Test|4AT Delirium|Screening tool to test for delirium post surgery
79853440|NCT05733598|Biological|RP3|Genetically modified herpes simplex type 1 virus
79853441|NCT05733598|Biological|atezolizumab|anti-PD-L1 monoclonal antibody
79853442|NCT05733598|Biological|bevacizumab|anti-VEGF therapy
79552694|NCT01621217|Drug|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
79716774|NCT05378659|Behavioral|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
79716775|NCT05378659|Behavioral|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
79716776|NCT05378659|Diagnostic Test|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
79716777|NCT05378659|Diagnostic Test|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
79853443|NCT05730309|Behavioral|Customized discharge and expedited referral instructions|The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
79255903|NCT02118493|Device|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
79255904|NCT02121223|Device|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (>=16atm) for at least 15 seconds.
79552695|NCT01621217|Radiation|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
79552696|NCT01621256|Drug|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
79552697|NCT01621256|Drug|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
79552698|NCT01621269|Drug|Fingolimod|
79552699|NCT01621282|Other|Education|A 6-month interactive course on critical appraisal
79552700|NCT01621282|Other|Conventional|Conventional method/no intervention
79716778|NCT05378659|Diagnostic Test|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
79716779|NCT01277510|Drug|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
79853446|NCT05723445|Behavioral|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
79552701|NCT01621308|Other|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
79255905|NCT02121223|Device|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
79255906|NCT02714595|Drug|Cefiderocol|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance >120 mL/min.
79255907|NCT02714595|Drug|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
79255908|NCT02112721|Dietary Supplement|Vitamin D|
79552702|NCT01621321|Drug|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
79716780|NCT01277510|Drug|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
79716781|NCT01277510|Drug|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
79716782|NCT04323332|Drug|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
79716783|NCT00937495|Drug|vorinostat|400 mg given PO
79716784|NCT00937495|Drug|bortezomib|1.3 mg/m^2 given IV
79716785|NCT04323488|Behavioral|Lindamood-Bell Seeing Stars|Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
79716786|NCT00603421|Other|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
79716787|NCT00603421|Other|treatment as usual|Treatment as usual
79716788|NCT05378581|Device|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
79716789|NCT05378581|Other|control arm|usual process
79395456|NCT03145428|Diagnostic Test|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
79395457|NCT01793571|Procedure|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
79716790|NCT02851381|Drug|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~Dose: 35 mg/kg~Route: IV over one hour following completion of gemcitabine infusion~Schedule:~Days 1, 8, and 15~Please note that Day 8 infusion will on be completed during the first treatment cycle"
79716791|NCT01268306|Device|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch & Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
79716792|NCT04265833|Other|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
79716793|NCT04265833|Other|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
79255909|NCT02112721|Dietary Supplement|Placebo|
79255910|NCT02112799|Drug|NVR 3-778|
79255911|NCT02112799|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
79255912|NCT02112799|Drug|Pegasys|
79255913|NCT03093896|Dietary Supplement|snack mix|commercial cereal mix with bits of beef jerky and coconut
79255914|NCT03093896|Dietary Supplement|almonds, 1.5 oz|almonds, 1.5 oz/day
79255915|NCT03093896|Dietary Supplement|almonds, 3 oz|almonds, 3.0 oz/day
79255916|NCT02122939|Drug|Escitalopram|
79255917|NCT04434014|Dietary Supplement|proper diet|diet containing all essential vitamins
79255918|NCT02121379|Behavioral|pulmonary rehabilitation|
79255919|NCT04434248|Drug|Favipiravir|200 mg coated tablets
79395458|NCT02341404|Drug|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
79395459|NCT04477980|Other|Disease outcome (mortality)|Mortality rate between the two groups
79395460|NCT02341638|Drug|BMS-986141|
79395461|NCT02341638|Drug|Placebo|
79552703|NCT01621321|Drug|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
79552704|NCT01621334|Behavioral|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
79552705|NCT01621334|Behavioral|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
79552706|NCT01621360|Procedure|Arthroscopic hip surgery|Hip arthroscopy
79552707|NCT01621360|Other|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
79853447|NCT05719714|Drug|Dapagliflozin 10 MG [Farxiga]|10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
79552708|NCT01621373|Drug|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
79552709|NCT01621386|Drug|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
79552710|NCT01621386|Drug|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
79552711|NCT01621399|Drug|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
79552712|NCT01621399|Drug|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
79552713|NCT01621425|Other|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
79552714|NCT01621425|Other|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
79552715|NCT01621425|Other|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
79552716|NCT01621451|Drug|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
79552717|NCT01621451|Drug|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
79716794|NCT04265833|Other|Calcium hydroxide|Calcium hydroxide (Ca[OH]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
79716795|NCT05380297|Device|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
79716796|NCT00604903|Device|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
79716797|NCT00606541|Drug|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
79716798|NCT00606541|Drug|Placebo|Placebo
79716799|NCT04266067|Other|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
79716800|NCT04266067|Other|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
79716801|NCT02851225|Other|telemedicine transmission of biological results|telemedicine transmission of biological informations
79853448|NCT05719077|Behavioral|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
79853449|NCT05714566|Diagnostic Test|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
79853450|NCT05714501|Device|Millipede System|Mechanical thrombectomy
79255920|NCT04434248|Drug|Standard of Care|Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
79395462|NCT02341638|Drug|Aspirin|
79552718|NCT01621464|Device|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
79395463|NCT02341638|Drug|Itraconazole|
79395464|NCT02337192|Drug|Curcumin|
79395465|NCT02337192|Device|LED|
79395466|NCT02337192|Drug|Surfactant|
79395467|NCT02337192|Drug|DMSO + water|
79395468|NCT02337192|Drug|Chlorhexidine gluconate|
79395469|NCT02344368|Other|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
79395470|NCT02344368|Other|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
79395471|NCT02349126|Drug|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
79395472|NCT02344212|Behavioral|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
79395473|NCT02341092|Behavioral|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
79395474|NCT03111966|Other|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
79395475|NCT02341170|Radiation|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
79716802|NCT00604981|Behavioral|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
79255921|NCT04433936|Diagnostic Test|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
79255922|NCT02121457|Dietary Supplement|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
79552719|NCT01621503|Device|NT-530P|intraocular pressure and central corneal thickness measurement
79552720|NCT01621620|Drug|Yohimbine|
79552721|NCT01621646|Other|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
79552722|NCT01621685|Biological|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
79552723|NCT01621698|Procedure|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
79552724|NCT01621698|Procedure|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
79552725|NCT01621724|Genetic|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
79552726|NCT01621750|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
79552727|NCT01621763|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
79716803|NCT00604981|Behavioral|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
79716804|NCT00605059|Drug|[123I]AV94|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
79716805|NCT00936715|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
79255923|NCT02121457|Dietary Supplement|selenium|
79255924|NCT03281421|Other|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
79255925|NCT03286491|Diagnostic Test|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
79255926|NCT03091790|Device|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
79255927|NCT03091790|Device|Biologic Mesh|Biologic mesh used during open ventral hernia repair
79255928|NCT02251795|Drug|Tipranavir|
79255929|NCT02251795|Drug|Ritonavir|
79255930|NCT02251795|Drug|Darunavir|
79255931|NCT02251795|Drug|Aspirin|single dose on day 2
79552728|NCT01621789|Other|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
79552729|NCT01621815|Behavioral|Video Game|Playing various video games: RPG, Race, FPS, Strategy
79552730|NCT01621854|Drug|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
79552731|NCT01621867|Drug|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
79552732|NCT01621867|Drug|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
79552733|NCT01621893|Procedure|Subchondroplasty|
79552734|NCT01621932|Procedure|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
79552735|NCT01621932|Procedure|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
79552736|NCT01621945|Biological|MenBvac|Blood test
79552737|NCT01621958|Behavioral|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
79552738|NCT01621958|Behavioral|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
79552739|NCT01621971|Drug|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
79552740|NCT01621971|Drug|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
79716806|NCT00606619|Other|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
79716807|NCT00606619|Other|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
79716808|NCT05378191|Drug|COMIRNATY|One dose of COMIRNATY
79716809|NCT00605137|Drug|insulin detemir|
79255932|NCT05026658|Device|Visibly Digital Acuity Product|"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~V1, E, V2~E, V1, V2~V2, E, V1~E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."
79255933|NCT03286413|Procedure|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
79255934|NCT02112955|Behavioral|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
79255935|NCT02112955|Behavioral|Usual care|Usual care such as hospital-based or community-based health education or services.
79255936|NCT05013398|Behavioral|The Together Webinar Programme|"The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT)."
79552741|NCT01621984|Other|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
79716810|NCT00605137|Drug|insulin NPH|
79716811|NCT00603499|Dietary Supplement|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
79716812|NCT00603499|Other|Placebo|Subjects in the control group received inert placebo once per day during 4 months
79716813|NCT04267627|Behavioral|Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)|Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
79716814|NCT00606775|Drug|Carvedilol|2.5-5mg/day
79716815|NCT04265989|Device|Single BMS|Single bare metal stent covered the coronary artery aneurysm
79716816|NCT04265989|Device|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
79716817|NCT04265989|Device|Single or Double BMS|Treated with single or double layer bare metal stents
79716818|NCT04265989|Device|BMS+DES|Treated with bare metal stent combined with drug eluting stent
79255937|NCT02113033|Device|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
79255938|NCT05013164|Drug|Folinic Acid|Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks
79255939|NCT03291561|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
79255940|NCT03291561|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
79255941|NCT02251951|Drug|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
79716819|NCT04267471|Behavioral|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
79255942|NCT03091868|Drug|Placebo oral capsule|Matching placebo capsules. Oral administration.
79255943|NCT03091868|Drug|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
79552742|NCT01621997|Behavioral|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
79552743|NCT01622023|Procedure|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
79716820|NCT04267471|Behavioral|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
79716821|NCT00605371|Drug|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
79716822|NCT00605371|Drug|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
79716823|NCT04265677|Other|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
79716824|NCT04265677|Other|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
79716825|NCT01267994|Drug|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
79395476|NCT02341248|Other|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
79395477|NCT02340702|Other|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of <0.7.
79255944|NCT03091868|Drug|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
79255945|NCT03091868|Drug|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
79255946|NCT03091868|Drug|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
79255947|NCT03291483|Other|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
79716826|NCT00606853|Behavioral|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
79716827|NCT02850757|Device|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
79716828|NCT02850757|Device|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
79255948|NCT03291483|Other|plyometric training|Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
79255949|NCT02121613|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
79255950|NCT02121613|Drug|Tamsulosine LP|Oral administration - 0.4 mg daily.
79255951|NCT02121613|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
79255952|NCT02121613|Drug|Placebo matching Tamsulosine LP|Oral administration - daily.
79255953|NCT05026268|Procedure|intracorporeal anastomosis|"intracorporeal stapled side-to-side isoperistaltic anastomosis"
79255954|NCT02460081|Drug|PDA-002|
79716829|NCT05379751|Procedure|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
79716830|NCT02850913|Drug|Doxycycline|"115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
79716831|NCT02850913|Other|Placebo|- Placebo (matching capsules containing no active ingredients)
79716832|NCT00603655|Other|Low glycemic load diet|Low glycemic load diet
79716833|NCT00603655|Other|High glycemic load diet|High glycemic load diet
79716834|NCT05371561|Device|reusable respirators|Dentist wearing reusable respirator will examin the patient
79716835|NCT02850835|Other|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
79716836|NCT00934843|Drug|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
79716837|NCT00934843|Drug|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
79716838|NCT04268251|Diagnostic Test|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
79716839|NCT00607009|Behavioral|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
79716840|NCT04265521|Device|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
79255955|NCT02460081|Drug|Placebo|
79255956|NCT03091712|Device|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
79395478|NCT05254938|Behavioral|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
79395479|NCT05254860|Procedure|LPS Ventral Rectopexy|Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
79716841|NCT00605605|Drug|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
79716842|NCT04256395|Other|mobile internet survey on self-test|1. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
79716843|NCT04267237|Drug|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
79716844|NCT04267237|Drug|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
79716845|NCT05379517|Device|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
79716846|NCT05379517|Other|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
79716847|NCT00605995|Drug|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
79716848|NCT05383105|Procedure|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
79716849|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
79716850|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
79716851|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
79716852|NCT05379361|Behavioral|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
79716853|NCT05379361|Behavioral|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
79552744|NCT01622049|Device|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
79716854|NCT01266902|Drug|Rilpivirine|25 mg once daily
79255957|NCT02121691|Behavioral|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
79552745|NCT01622075|Device|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
79552746|NCT01622075|Device|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
79716855|NCT04266847|Device|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
79716856|NCT00605761|Drug|SB656933|50 mg treatment
79716857|NCT00605761|Drug|SB656933|150 mg treatment
79255958|NCT02123407|Drug|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
79552747|NCT01622101|Dietary Supplement|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
79552748|NCT01622114|Other|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
79716858|NCT05365867|Behavioral|iCAN Group|See description in iCAN study arm.
79716859|NCT05363995|Behavioral|i-Sleep & BioClock Intervention|"The 'i-Sleep & BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~psychoeducation on insomnia, sleep hygiene and the biological clock,~stimulus control and sleep restriction therapy,~worrying and relaxation exercises,~cognitive therapy to change dysfunctional thoughts about sleep, and~summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep & light exposure diary daily."
79716860|NCT01266824|Drug|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
79716861|NCT05383027|Behavioral|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
79716862|NCT05383027|Behavioral|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
79552749|NCT01622153|Procedure|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
79552750|NCT01622153|Procedure|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
79716863|NCT04266769|Device|LightForce Orthodontic System|The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
79716864|NCT04253119|Drug|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
79716865|NCT01266590|Drug|LY2216684|Administered orally
79716866|NCT01266590|Drug|Digoxin|Administered orally
79716867|NCT01266122|Behavioral|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
79716868|NCT00607555|Device|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
79716869|NCT04252027|Other|Sample collection|Plasma and urine sample collection
79716870|NCT04264975|Procedure|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
79716871|NCT00603811|Biological|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
79716872|NCT00603811|Biological|Placebo|Placebo
79716873|NCT05089435|Device|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
79716874|NCT01265498|Drug|obeticholic acid|25 mg daily for 72 weeks
79716875|NCT01265498|Drug|placebo|placebo capsule, 25 mg daily for 72 weeks
79716876|NCT00603967|Procedure|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
79716877|NCT00603967|Procedure|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
79853451|NCT05707858|Other|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
79255959|NCT02123407|Procedure|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
79255960|NCT03081650|Device|Airvo Humidifier|
79552751|NCT01622166|Behavioral|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
79552752|NCT01622179|Procedure|sewed indirectly|The epitenon was repaired and sewed indirectly.
79716878|NCT00603967|Behavioral|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
79716879|NCT00607711|Drug|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
79716880|NCT01265420|Biological|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
79716881|NCT04324658|Device|Lactiplus|capsules containing L. gasseri LA806
79716883|NCT04323644|Procedure|Surgery|Emergency or elective surgery
79716884|NCT01264718|Behavioral|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
79716885|NCT01264016|Device|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
79255961|NCT03291327|Dietary Supplement|Probiotics|Lozenges for Home use
79255962|NCT02121769|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
79552753|NCT01622179|Procedure|sewed directly|The epitenon was unrepaired and sewed directly.
79716886|NCT01263782|Drug|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
79716887|NCT01263782|Drug|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
79716888|NCT01263782|Drug|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
79716889|NCT01263782|Drug|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
79716890|NCT01263704|Drug|Cyclophosphamide|150 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
79716891|NCT01263704|Drug|Fludarabine|12.5 mg/m^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
79716892|NCT01263704|Drug|Rituximab|375 mg/m^2 IV Day 0 of Cycle 1, 500 mg/m^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
79716893|NCT01263470|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
79716894|NCT01263470|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
79716895|NCT01263470|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
79716896|NCT01263470|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
79853452|NCT05706402|Drug|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
79716897|NCT01263470|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
79716898|NCT01263470|Drug|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
79716899|NCT04322942|Diagnostic Test|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
79552754|NCT01622205|Other|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
79716900|NCT04322630|Other|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
79552755|NCT01622205|Other|Ordinary rehabilitation|Ordinary rehabilitation
79716901|NCT04322786|Drug|ACE inhibitor|Any prescription of ACE inhibitor
79716902|NCT04322240|Drug|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
79716903|NCT01262456|Drug|Desmopressin|
79853453|NCT05706402|Drug|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
79552756|NCT01622218|Behavioral|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
79716904|NCT01262456|Drug|Placebo|
79552757|NCT01622244|Other|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
79552758|NCT01622244|Other|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
79552759|NCT01622244|Behavioral|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
79552760|NCT01622270|Other|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
79552761|NCT01622283|Drug|Levocetirizine|Levocetirizine
79716905|NCT02889380|Drug|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
79716906|NCT02889302|Drug|KPS-0373|24 weeks
79716907|NCT02889302|Drug|Placebo|24 weeks
79716908|NCT04321694|Drug|KHK2455|
79716909|NCT04321850|Drug|Zinc Sulfate 50 Mg Tab|The tablets were manufactured specifically for this study.
79716910|NCT04321850|Drug|Placebo oral tablet|The tablets were manufactured specifically for this study.
79716911|NCT04321616|Drug|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
79716912|NCT04321616|Drug|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
79716913|NCT04321616|Other|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
79716914|NCT04321772|Other|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
79716915|NCT04321772|Other|Traditional Resistance Training|Subjects trained the other leg with HIIRT
79716916|NCT04207658|Behavioral|Valsalva's Style Pushing|The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
79716917|NCT00623948|Device|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
79716918|NCT04321304|Device|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
79716919|NCT04321304|Device|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
79716920|NCT04321304|Device|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
79716921|NCT00932893|Drug|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
79716922|NCT00932893|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
79716923|NCT00932893|Drug|Docetaxel|Docetaxel, 75 mg/m^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
79716924|NCT04321070|Drug|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
79716925|NCT04321070|Drug|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
79716926|NCT04321070|Drug|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
79716927|NCT04321226|Device|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
79552762|NCT01622283|Drug|Cetirizine|Cetirizine
79552763|NCT01622309|Dietary Supplement|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
80018099|NCT04202458|Drug|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
79552764|NCT01622309|Other|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
79552765|NCT01622361|Drug|Adriamycin+Cyclophosphamide>Docetaxel|"Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~Route: by slow intravenous bolus~Schedule: every 3weeks for 4 cycle~Docetaxel 75mg/m2~Route: intravenous as per local practice~Schedule: every 3weeks for 4 cycle"
79552766|NCT01622361|Drug|GnRHa with Tamoxifen|"Goserelin(GnRHa) 3.6mg~Route: subcutaneously under the abdominal skin~Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~Tamoxifen 20mg/day~Route: Oral~Schedule: everyday"
79552767|NCT01622374|Behavioral|Music|Ten minutes of music or silence were applied prior to dental procedures
79552768|NCT01622387|Procedure|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
79716928|NCT02889224|Other|Obese|
79716929|NCT02889224|Procedure|Hypercortisolism|
79716930|NCT02889224|Other|Hydrocortisone|
79716931|NCT02889224|Other|Control|
79716932|NCT02889146|Other|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
79716933|NCT02889146|Other|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
79716934|NCT02889146|Other|Respiratory therapy|Respiratory therapy according to the service routine.
79552769|NCT01622387|Procedure|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
79552770|NCT01622400|Other|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
79716935|NCT01260896|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
79716936|NCT01260896|Drug|Effexor® XR|150 mg Extended-Release Capsule
79552771|NCT01622413|Procedure|joimax TESSYS|Transforaminal Endoscopic Surgery System
79552772|NCT01622413|Procedure|Microdiscectomy|Standard procedure for disc surgery
79716937|NCT00932737|Drug|Placebo|1-5 tablets per episode
79716938|NCT00932737|Drug|HBB 20 mg|Active drug, one to five tablets per episode
79716939|NCT00607399|Drug|SGX523 Capsules|This is a dose escalation study
79716940|NCT00939523|Drug|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
79716941|NCT04264741|Device|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
79853454|NCT05704725|Drug|ABP 938|IVT injection
79853455|NCT05704725|Drug|Aflibercept|IVT injection
79853456|NCT05700903|Drug|Gonadotropin-Releasing Hormone Agonist|8 weeks of GnRH agonist
79853457|NCT05700903|Drug|Androgen receptor inhibitor|2 weeks of AR Inhibitor
79552773|NCT01622426|Dietary Supplement|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
79853458|NCT05700903|Drug|Placebo|Placebo tablet and injection
79853459|NCT05698901|Drug|Agalsidase beta|The treatment is following local reimbursement criteria and judge by physician
80018100|NCT00273650|Drug|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
79552774|NCT01622426|Dietary Supplement|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
79552775|NCT01622439|Drug|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
79716942|NCT04264741|Device|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
79853460|NCT05697029|Drug|Tetrandrine|tetrandrine TID for 28 days
79552776|NCT01622439|Drug|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
79552777|NCT01622439|Drug|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
79552778|NCT01622439|Drug|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
79552779|NCT01622439|Drug|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
79552780|NCT01622439|Drug|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
79552781|NCT01622465|Behavioral|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
79552782|NCT01622465|Behavioral|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
79552783|NCT01622478|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
79552784|NCT01622478|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
79552785|NCT01622478|Procedure|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
79552786|NCT01622478|Procedure|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
79853461|NCT05696197|Behavioral|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
79853462|NCT05695105|Device|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
79255963|NCT02460003|Behavioral|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
79255964|NCT02460003|Other|Home exercise program|Home exercise program
79255965|NCT03552211|Drug|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
79552787|NCT01622504|Drug|MVP005|2 mg single dose administered intranasally
79552788|NCT01622504|Drug|MVP005|4 mg single dose administered intranasally
79552789|NCT01622504|Drug|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
79552790|NCT01622556|Drug|Fludarabine|35 mg/m2 IV/day x 5 days
79552791|NCT01622556|Drug|Busulfan|.8 mg/kg IV Q6h x 8 doses
79552792|NCT01622556|Drug|Thymoglobulin|1.5 mg/kg/day x 3 days
79552793|NCT01622556|Radiation|Total Body Irradiation|150 cGy for 2 days
79552794|NCT01622556|Biological|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
79552795|NCT01622608|Behavioral|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
79552796|NCT01622621|Procedure|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
79255966|NCT03552211|Other|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
79716943|NCT05382247|Device|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
79255967|NCT03281265|Other|standard treatment|
79853463|NCT05695105|Device|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
79853464|NCT05693805|Behavioral|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
79552797|NCT01622621|Radiation|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
79853465|NCT05693805|Behavioral|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
79853466|NCT05689710|Dietary Supplement|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
79716944|NCT04264429|Device|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
79716945|NCT04264429|Other|Elastic band|Orthotic device which is positioned over the patellar tendon
79853467|NCT05687084|Device|Uterine manipulator use|The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
79853468|NCT05684549|Other|No intervention|Observational study, no intervention
79255968|NCT03091634|Drug|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
79255969|NCT03091634|Drug|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
79255970|NCT03286335|Radiation|Proton Radiation|Radiation treatment
79255971|NCT02113111|Behavioral|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
79255972|NCT05009810|Dietary Supplement|astaxanthin 4 mg|They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
79255973|NCT05009810|Dietary Supplement|astaxanthin 6 mg|They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
79255974|NCT05009810|Dietary Supplement|Placebo|They will take placebo 1 capsule once daily for 2 months.
79255975|NCT02113267|Drug|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
79255976|NCT02113267|Drug|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
79552798|NCT01622634|Behavioral|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
79552799|NCT01622634|Other|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
79552800|NCT01622634|Other|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
79552801|NCT01622647|Other|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
79552802|NCT01622686|Behavioral|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
79255977|NCT05009576|Other|silver alginate|silver alginate hydrofiber dressing
79255978|NCT05009576|Other|VAC dressing without silver alginate|vaccum assisted dressing
79255979|NCT03281187|Drug|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
79853469|NCT05683990|Drug|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
79255980|NCT03281187|Drug|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
79255981|NCT03281187|Other|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
79716946|NCT01260584|Drug|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
79255982|NCT03281187|Other|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
79552803|NCT01622764|Radiation|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
79552804|NCT01622777|Drug|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
79552805|NCT01622777|Drug|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
79552806|NCT01622790|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
79552807|NCT01622790|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
79716947|NCT01260584|Drug|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
79716948|NCT05176327|Device|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
79716949|NCT05331313|Genetic|DNA sequencing|The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
79716950|NCT00609349|Device|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
79716951|NCT04262635|Drug|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
79716952|NCT04262635|Drug|Cetuximab|Maintenance treatment ( ArmB )
79716953|NCT00608101|Drug|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
79716954|NCT00608101|Drug|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
79716955|NCT04264039|Biological|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
79716956|NCT04264039|Drug|Fludarabine|30mg/m^2 per day for 6 days
79716957|NCT04264039|Drug|Cytoxan|300mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
79716958|NCT04264039|Drug|Melphalan|50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
79716959|NCT00608179|Drug|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
79716960|NCT00608179|Drug|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
79716961|NCT00608179|Other|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
79255983|NCT02113345|Behavioral|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
79255984|NCT03291249|Drug|Foralumab|Anti CD3 mAb
79716962|NCT00608179|Other|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
79716963|NCT00608335|Drug|Micafungin|IV
79716964|NCT00927589|Drug|carboplatin|Intravenous repeating dose
79716965|NCT00927589|Drug|docetaxel|Intravenous repeating dose
79716966|NCT00927589|Drug|trastuzumab|Intravenous repeating dose
79716967|NCT04264117|Procedure|FlexAbility (Mesh-like irrigated tip catheter) group|"AF catheter ablation (PV isolation and linear ablations)~30 sec ablation in each point~35W in anterior LA, 30 W in posterior LA~Irrigation flow rate 13mL/min~Measuring procedure time, Ablation time~Rhythm follow-up based on guidelines"
79716968|NCT04264117|Procedure|TactiCath (Contract force monitoring catheter) group|"AF catheter ablation (PV isolation and linear ablations)~contact force >10g, target force-time integral 400 in each point~35W in anterior LA, 30 W in posterior LA~Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~Measuring procedure time, Ablation time~Rhythm follow-up based on guidelines"
79716969|NCT05145517|Device|Open repair|Open repair of the aorta and peripheral arteries
79716970|NCT04262557|Diagnostic Test|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
79716971|NCT04262557|Diagnostic Test|Polysomnography|Gold standard method to diagnose SAS used as comparator
79716972|NCT04262245|Procedure|Traditional Irrigation|irrigation with syringe
79716973|NCT04262245|Device|Xp-endo Finisher (XPF)|irrigation activation file
79716974|NCT04262245|Device|Passive Ultrasonic Irrigation|irrigation activation method
79716975|NCT04262245|Device|EndoActivator|irrigation activation method
79255985|NCT03291249|Other|placebo|Placebo oral solution
79255986|NCT03291249|Drug|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
79255987|NCT05013320|Drug|Glycopyrrolate + dexmedetomidine|Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.
79255988|NCT05013320|Drug|Dexmedetomidine|Dexmedetomidine administration during the surgery.
79716976|NCT00932425|Device|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
79853470|NCT05682859|Drug|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
79853471|NCT05682859|Drug|Placebo|Placebo tablets
79716977|NCT04260061|Device|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
79716978|NCT05938816|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
79716979|NCT05938816|Behavioral|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
79716980|NCT05938764|Behavioral|MICRA|see earlier description
79716981|NCT05938764|Behavioral|TAU|see earlier description
80018101|NCT00273650|Other|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
80018102|NCT04053777|Device|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
79716982|NCT05938751|Behavioral|TEAm_YOUNG ADULTS program|The TEAm_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
79716983|NCT05938738|Device|PEP-buddy|PEP-buddy
79716984|NCT05938686|Other|Home_Based Digital Mindful Dance Program|Home_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
79716985|NCT05938673|Other|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
79853472|NCT05680272|Behavioral|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
80018103|NCT02121288|Drug|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
79552808|NCT01622790|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
79552809|NCT01622803|Procedure|parallel stent|bilateral parallel stent insertion (right and left side)
79552810|NCT01622803|Device|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
79552811|NCT01622829|Procedure|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
79552812|NCT01622829|Other|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
79552813|NCT01622829|Other|usual physiotherapy|physiotherapy, treatment as usual
80018104|NCT02121288|Drug|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
79552814|NCT01622855|Behavioral|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
79716986|NCT05938673|Other|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
79552815|NCT01622881|Drug|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
79716987|NCT05938660|Other|acupressure at Sanyinjiao point|When pressing Sanyinjiao point, the subject should be in a comfortable sitting position. Press the acupoints with the thumb until the subject feels soreness, then press and knead in a circle according to the strength acceptable to the subject. Press and knead once a second, and rest for 1 second every 5 seconds are one cycle, the speed is 10 cycles/minute, and it lasts for five minutes.
79853473|NCT05679245|Diagnostic Test|Assessment for exposure to psychological trauma and related symptoms|To be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma-related symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
79853474|NCT05669365|Behavioral|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
79716988|NCT05938569|Device|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
79255989|NCT02437162|Drug|Placebo|Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
79255990|NCT02437162|Drug|Ustekinumab 45 mg|Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
79255991|NCT02437162|Drug|Ustekinumab 90 mg|Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
79716989|NCT05938504|Other|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS_320275) orally daily at any time of day.
79395480|NCT05254704|Other|TEX-Q-F before scheduled surgery|"The TEX-Q-F questionnaire (French version of the breif version of the TEX-Q) contains 15 questions to assess the patient's overall expectations concerning the surgery.~The first 11 questions concern the patient's expectations regarding the postoperative period: pain and functional recovery. The last 4 questions focus on the patient's hopes for the outcome of the surgery. Each item is scored from 0 to 10, according to the intensity of the level of expectation."
79716990|NCT05938504|Other|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS_211567) orally daily at any time of day.
79716991|NCT05938491|Diagnostic Test|OCT and OCT-A|OCT and OCT angiography for the macula
79395481|NCT05254470|Device|Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
79716992|NCT05938478|Drug|Tralokinumab|This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
79716993|NCT05938400|Device|Polyvinylsiloxane impression with different techniques|One step impression technique will be compared with the standard two step technique
79716994|NCT05938374|Drug|Fluzoparib|One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).
79716995|NCT05938374|Radiation|Preoperative moderately fractionated radiotherapay|Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
79716996|NCT05938361|Other|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
79395482|NCT02344134|Biological|NBP607|0.5 mL, intramuscular, a single dose
79552816|NCT01622881|Drug|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
79552817|NCT01622920|Other|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
79552818|NCT01622933|Biological|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
79255992|NCT02437162|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
79255993|NCT02113423|Radiation|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID*2F
79716997|NCT05938361|Other|Quality of life evaluation|DLQI questionnaire at each visit
80018105|NCT03552900|Behavioral|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
79716998|NCT05938361|Other|Satisfaction assessment|Visual analogic scale at W16, W28, W52
79853475|NCT05663541|Diagnostic Test|Lower extremity position test|Assessing proprioception of the lower extremity of individuals multiple sclerosis
79853476|NCT05659563|Drug|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
79255994|NCT03286179|Other|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
79552819|NCT01622933|Biological|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
79552820|NCT01622946|Drug|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
79552821|NCT01622946|Drug|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
79853477|NCT05659563|Drug|Tamoxifen|Tamoxifen is a selective estrogen receptor (ER) modulator
79853478|NCT05654103|Device|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
79853479|NCT05654103|Procedure|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
79853480|NCT05652062|Device|Prizvalve® system|Transcatheter valve-in-valve replacement
79255995|NCT03553459|Diagnostic Test|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
79255996|NCT03291093|Drug|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
79395483|NCT02344134|Biological|Agrippal S1|0.5 mL, intramuscular, a single dose
79716999|NCT05938361|Other|Pruritus evaluation|Visual analogic scale at each visit
79395484|NCT02343978|Drug|KWA-0711|
79717000|NCT05938348|Behavioral|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
79717001|NCT05938335|Genetic|sequencing of a panel of 14 genes in leptin melanocortin pathway|sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
79853481|NCT05647512|Drug|LM-305|Administered intravenously
79853482|NCT05647512|Drug|Dexamethasone|Administered orally
79853483|NCT05645042|Behavioral|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
79395485|NCT02344056|Other|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
79395486|NCT02344056|Other|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
79395487|NCT02343822|Other|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
79395488|NCT02343822|Other|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
79717002|NCT05938322|Other|Ketogenic Diet|"In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates < 30g/day, 1.2g-1.5g protein/kg/day and lipids > 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)"
79717003|NCT05938322|Other|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
79717004|NCT05938257|Procedure|TMJ discopexy|Arthroscopic versus open TMJ discopexy
79853484|NCT05645042|Behavioral|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
79853485|NCT05644561|Drug|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
79875368|NCT00385827|Drug|Mitoxantrone|Mitoxantrone 12 mg/m^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2)
80018106|NCT03552900|Behavioral|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
80018107|NCT04501042|Procedure|Bariatric surgery|Bariatric surgery
80018108|NCT05724680|Other|cognitive behavior therapy|Psycho-therapeutic intervention
79717005|NCT05938231|Device|Gastric Bypass Stent System|Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
79717006|NCT05938231|Behavioral|Dietary Intervention|The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
79717007|NCT05938218|Device|Intervention|Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
79717008|NCT05938205|Dietary Supplement|AA-1|low dose aminoacids
79853486|NCT05644002|Behavioral|Puff Topography Biofeedback Training|"Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
79853487|NCT05644002|Behavioral|Control|"Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
79853488|NCT05640245|Drug|Sonelokimab|randomized treatment; parallel group
79552822|NCT01622959|Procedure|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
79853489|NCT05640245|Drug|Placebo|randomized treatment; parallel-group
79853490|NCT05640245|Drug|Adalimumab|randomized treatment; parallel-group
79552823|NCT01622972|Drug|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
79395489|NCT02343744|Drug|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
79395490|NCT02343588|Behavioral|The Health Lifestyles Interventions|"Creating supportive school and family environment, whole intervention periods;~Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~Instruct and promote school physical education, whole intervention periods;~The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
79717009|NCT05938205|Dietary Supplement|AA-2|high dose aminoacids
79717010|NCT05938205|Behavioral|Placebo|Nutritional Placebo
79717011|NCT05938205|Behavioral|Exe-H|high intensity physical exercise
79717012|NCT05938192|Procedure|LASER surgery|Patients will have laser surgery for managing HPV-related lesions
79853491|NCT05638568|Diagnostic Test|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 > 0.30)
79853492|NCT05638412|Behavioral|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
79875369|NCT00385827|Drug|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
79255997|NCT03079466|Other|CPAP|This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
79395491|NCT02343666|Biological|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
79395492|NCT02343666|Drug|Carmustine|Given IV
79395493|NCT02343666|Biological|Filgrastim|Given SC
79395494|NCT02343666|Other|Laboratory Biomarker Analysis|Correlative studies
79552824|NCT01623011|Procedure|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
79853493|NCT05638412|Behavioral|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
79853494|NCT05633550|Diagnostic Test|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
79853495|NCT05633108|Other|No Intervention|No intervention will be administered.
79853496|NCT05631093|Drug|ART|Standard of care ART, per approved product list, taken orally
79552825|NCT01623011|Procedure|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
79552826|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
79552827|NCT01623024|Drug|Vitamin D|20.000 UI/week for 96 weeks
79717013|NCT05938153|Other|observational physical tests|"Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu."
79717014|NCT05938140|Drug|Nirmatrelvir/ritonavir|Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
79717015|NCT05937997|Procedure|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
79717016|NCT05937997|Procedure|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
79717017|NCT05937997|Procedure|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
79853497|NCT05631093|Drug|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
79853499|NCT05629910|Device|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
79853500|NCT05629026|Procedure|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
79853501|NCT05628116|Drug|XC243 50 mg single|The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
79853502|NCT05628116|Drug|XC243 100 mg single|The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
79552828|NCT01623024|Behavioral|Lifestyle counseling|Lifestyle counseling for 96 weeks
79552829|NCT01623063|Procedure|Hysteroscopy|hysteroscopy with guided biopsies
79853503|NCT05628116|Drug|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 tablets once)
79853504|NCT05628116|Drug|XC243 200 mg single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
79853505|NCT05628116|Drug|Placebo single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
79853506|NCT05628116|Drug|XC243 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
79853507|NCT05628116|Drug|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
79875370|NCT00385827|Drug|Prednisone|Prednisone 5 mg orally twice daily
79875371|NCT00498602|Biological|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
79875372|NCT00498602|Biological|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
79875373|NCT00498602|Other|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
79875374|NCT00498602|Biological|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
79552830|NCT01623102|Drug|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
79395495|NCT02343666|Drug|O6-Benzylguanine|Given IV
79853508|NCT05619354|Other|Survey study|Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
80018109|NCT01525329|Drug|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting ~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
79552831|NCT01623102|Drug|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
79552832|NCT01623128|Behavioral|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
79552833|NCT01623141|Procedure|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
79552834|NCT01623180|Device|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
79552835|NCT01623180|Device|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
79552836|NCT01623206|Drug|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
79552837|NCT01623219|Behavioral|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
79552838|NCT01623232|Biological|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
79717018|NCT05937984|Device|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
79717019|NCT05937984|Device|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
79717020|NCT05937919|Drug|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
79717021|NCT05937880|Drug|Leflunomide|When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
79717022|NCT05937867|Drug|HS-10353 Capsules 30 mg, Oral, QN for 14 days|HS-10353 Capsules 30 mg
79853509|NCT05619211|Behavioral|Sprint-Intensity Interval Training with Telecoaching|Maximal intensity exercises that use the arms.
79853510|NCT05615974|Drug|LM101|Administered intravenously
79853511|NCT05615974|Drug|Toripalimab|Administered intravenously
79853512|NCT05615974|Drug|Rituximab|Administered intravenously
79395496|NCT02343666|Drug|Plerixafor|Given SC
79395497|NCT04823676|Dietary Supplement|Probiotic composition|Mixture of two Lactoplantibacillus plantarum strains (formerly Lactobacillus plantarum) and one Levilactobacillus brevis strain (formerly Lactobacillus brevis), in a maltodextrin carrier (E1400)
79395498|NCT04823676|Other|Placebo|Maltodextrin (E1400, qs)
79395499|NCT02332278|Procedure|Early feeding|Fluid diet four hours after cesarean section
79395500|NCT02332278|Procedure|Late feeding|Fluid diet 12 hours after cesarean section
79552839|NCT01623232|Biological|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
79552840|NCT01623284|Drug|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
79717023|NCT05937867|Drug|HS-10353 Capsules 50 mg, Oral, QN for 14 days|HS-10353 Capsules 50 mg
79717024|NCT05937867|Drug|HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.|Placebo
79717025|NCT05937867|Drug|HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days|Placebo
79717026|NCT05937841|Drug|Compound 21|"AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response"
79717027|NCT05937828|Other|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
79255998|NCT02123563|Other|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
79255999|NCT02123563|Other|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
79256000|NCT03091322|Device|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
79552841|NCT01623284|Drug|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of [18-F]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
79552842|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
79853513|NCT05615974|Drug|Envafolimab|Administered intravenously
79552843|NCT01623336|Drug|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
79552844|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
79256001|NCT03291015|Device|radiographic|using plain x ray to determind the treatment plan
79853514|NCT05615818|Drug|Futibatinib|Dose 20 mg once a day (QD)
79853515|NCT05615818|Drug|Ivosidenib|Dose 500 mg QD
79853516|NCT05615818|Drug|Zanidatamab|Dose: Patients < 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
79552845|NCT01623349|Drug|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
79552846|NCT01623349|Drug|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
79717028|NCT05937815|Procedure|Sample collection|collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
79853517|NCT05615818|Drug|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
79853518|NCT05615818|Drug|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
79853519|NCT05615818|Drug|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
79853520|NCT05615818|Drug|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
79853521|NCT05615818|Drug|Niraparib|Dose: 200 mg QD or 300 mg QD
79853522|NCT05615818|Drug|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
79853523|NCT05615818|Drug|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
79256002|NCT03291015|Device|arthroscopy|using wrist arthroscopy to determind the treatment plan
79717029|NCT05937802|Dietary Supplement|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
79717030|NCT05937789|Dietary Supplement|Vitamin D|1ampoule (72000IU) Q3H on ICU day 3 Number of Cycles: until progression or subject develops severe diarrhea (greater than 1000 grams) associated with vitamin D supplementation for two consecutive days.
79853524|NCT05612880|Drug|androgen receptor signaling inhibitors|Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
79853525|NCT05609682|Drug|Gabapentin|Scheduled gabapentin given for two weeks after surgery
79853526|NCT05609682|Drug|Placebo|Placebo given for two weeks after surgery
79853527|NCT05600322|Drug|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
79853528|NCT05600322|Device|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
79717031|NCT05937789|Dietary Supplement|Medium Chain Triglycerides|1ampoule Q3H on ICU day 3 Number of Cycles: until progression or subject develops severe diarrhea (greater than 1000 grams) associated with vitamin D supplementation for two consecutive days.
79717032|NCT05937763|Other|Staffing model|Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
79717033|NCT05937711|Other|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
79256003|NCT02122003|Drug|Sorafenib|Sorafenib 400 mg bid
79256004|NCT03079388|Dietary Supplement|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
79717034|NCT05937711|Drug|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
79717035|NCT05937633|Other|Transformational Education Programme|"An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills."
79717036|NCT05937607|Behavioral|Hand massage|It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
79717037|NCT05937594|Genetic|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
79853529|NCT05600062|Drug|Racecadotril 100 milligram (MG) Oral Capsule|Licensed NEP inhibitor
79853530|NCT05600062|Drug|Placebo|Placebo capsule
79853531|NCT05599932|Drug|Siremadlin|HDM201 capsule
79853532|NCT05597657|Other|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
79853533|NCT05597475|Diagnostic Test|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
79853534|NCT05596630|Radiation|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
79875375|NCT00507728|Drug|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
79256005|NCT03079388|Dietary Supplement|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
79395501|NCT04766268|Other|Prostate artery embolization|Prostate artery embolization (PAE) is a safe and effective minimally invasive interventional radiology procedure in which intraprostatic vessels are embolized to shrink the size of the prostate gland. LUTS is mainly categorized into irritative, obstructive, and mixed types. This has a variable impact on patients' quality of life by interfering with sleep, activities of daily living, anxiety, mobility, leisure, and effect on sexual activities. This trial aims to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
79395502|NCT02340936|Drug|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
79395503|NCT02340936|Drug|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
79552847|NCT01623362|Other|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
79552848|NCT01623362|Other|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
79552849|NCT01623362|Other|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
79552850|NCT01623375|Drug|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
79552851|NCT01623375|Drug|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
79552852|NCT01623388|Procedure|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
79552853|NCT01623401|Drug|TR-701 FA|TR-701 FA 200 mg once daily
79552854|NCT01623427|Procedure|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
79552855|NCT01623427|Procedure|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
79552856|NCT01623440|Combination Product|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
79552857|NCT01623440|Combination Product|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
79552858|NCT01623453|Biological|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
79552859|NCT01623453|Biological|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
79875376|NCT00507728|Drug|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
79875377|NCT00507728|Drug|Placebo|Placebo by mouth for 12 weeks.
79875378|NCT00507728|Behavioral|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
79552860|NCT01623492|Other|Subjects with diagnosis of Eisenmenger Syndrome|"Antibiotic recommendation for SBE prophylaxis and influenza vaccine~Contraception counseling, and recommendations regarding avoidance of pregnancy~Documentation and prescription of the specific medications:~Oxygen~Diuretic~ASA, Anticoagulant~CCB, BB, ACEI, ARB~Iron Supplementation~Allopurinol~PAH specific therapy"
79552861|NCT01623505|Drug|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
79717038|NCT05937568|Drug|Imetelstat|Participants will receive imetelstat, intravenously (IV) by infusion every 4 weeks.
79717039|NCT05937529|Other|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
79717040|NCT05937529|Other|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
79717041|NCT05937516|Device|Nasotracheal intubation with conventionally|Nasotracheal intubation will be applied conventionally to patients in this group.
79717042|NCT05937516|Device|Nasotracheal intubation with angled ETT using guidewire|a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
79853535|NCT05596318|Device|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
79853536|NCT05596318|Device|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
79853537|NCT05594069|Other|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
79256006|NCT03079388|Drug|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
79256007|NCT03079388|Drug|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
79256008|NCT03079388|Other|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
79256009|NCT03079388|Drug|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
79256010|NCT03079388|Drug|Albendazole|Single dose albendazole 400mg given in the second trimester.
79256011|NCT03079388|Combination Product|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
79256012|NCT03552055|Other|Non-interventional Study|no interventions in this study, just specimen collection
79717043|NCT05937490|Drug|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
79875379|NCT00498368|Drug|Intravenous Rituximab|"Rituximab Therapy [27 Patients]~Rituximab 1 gm IV on Treatment Day 1~Rituximab 1 gm IV on Treatment Day 15~Rituximab 1 gm IV on Treatment Day 168~Rituximab 1 gm IV on Treatment Day 182"
79717044|NCT05937490|Drug|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
79717045|NCT05937490|Drug|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
79717046|NCT05937490|Drug|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
79256013|NCT03281109|Diagnostic Test|diagnosis|diagnosis with ELISA
79256014|NCT03079544|Combination Product|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
79256015|NCT03286101|Drug|0.5% Ivermectin lotion|The intervention is composed of a single application of the 0.5% ivermectin lotion.
79256016|NCT03286101|Drug|Vehicle|The intervention is composed of a single application of the vehicle control.
79552862|NCT01623505|Drug|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~*Off-label dosage approved by Health Canada via No Objection letter."
79717047|NCT05937464|Other|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
79853538|NCT05594069|Other|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
79256017|NCT01368211|Biological|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:~Platelet yield between 2.4x10e11 and 4.5x10e11~Plasma carryover of >32%~Cell count > 800x103/µL"
79256018|NCT01368211|Biological|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:~Platelet yield between 2.4x10e11 and 4.5x10e11~Plasma carryover of >32%~Cell count > 800x103/µL"
79256019|NCT02437084|Drug|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
79853539|NCT05593055|Drug|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
79256020|NCT03286023|Radiation|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
79853540|NCT05593055|Drug|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
79853541|NCT05593055|Drug|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
79853542|NCT05592054|Procedure|Balloon guide catheters (BGCs)|MT procedure with Balloon guide catheters (BGCs)
79853543|NCT05592054|Procedure|Standard guide catheter|MT procedure with standard guide catheter
79853544|NCT05589688|Drug|Acyclovir|Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
79552863|NCT01623505|Drug|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
79256021|NCT05009498|Dietary Supplement|Vitamin D3 supplementation|Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year
79256022|NCT05009498|Other|Placebo|Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
79256023|NCT03280953|Diagnostic Test|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
79256024|NCT02123641|Other|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
79256025|NCT02123641|Other|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
79256026|NCT02123641|Other|Control|No training
79552864|NCT01623518|Biological|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10^8 vp, 5 x10^9 vp, 2.5 x10^10 vp, 5 x10^10 vp"
79552865|NCT01623557|Biological|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
79552866|NCT01623557|Biological|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
79552867|NCT01623557|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
79853545|NCT05584735|Biological|Influenza vaccine|Observe effects of flu vaccine on microbiome
79853546|NCT05584735|Biological|COVID-19 vaccine|Observe effects of COVID-19 vaccine on microbiome
79552868|NCT01623570|Drug|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
79552869|NCT01623570|Drug|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
79256027|NCT03079622|Procedure|Electric Vacuum Aspiration|
79256028|NCT03079622|Procedure|Manual Vacuum Aspiration|
79256029|NCT03285945|Drug|PET3|Prednisolone 60 mg daily for 3 days
79853547|NCT05584514|Other|Sentence Stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
80018110|NCT02121366|Procedure|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
80018111|NCT03914014|Other|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
79256030|NCT03285945|Drug|PET10|Prednisolone 60 mg daily for 10 days
79552870|NCT01623583|Other|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
79717048|NCT05937464|Other|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
79717049|NCT05937438|Drug|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
79717050|NCT05937412|Other|Alcohol sterilization|Sterilizing skin using alcohol
79717051|NCT05937412|Other|Honey sterilization|Sterilizing skin using honey
79717052|NCT05937360|Other|cross-sectional community based study|Participants (women between the ages of 18 and 45 years) are selected randomly throughout various regions of Trinidad. Every 10th house from the selected regions would be assessed.
79717053|NCT05937347|Behavioral|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
79717054|NCT05937347|Behavioral|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
79717055|NCT05937347|Behavioral|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
79717056|NCT05937347|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
79717057|NCT05937334|Diagnostic Test|Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma|lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
79717058|NCT05937243|Behavioral|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
79853548|NCT05584514|Other|Auditory Noise|The sentences will be presented either A) in quiet, or B) with speech- shaped stationary background noise presented 3dB below the speech.
79853549|NCT05582512|Other|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
79853550|NCT05578326|Drug|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
79853551|NCT05578326|Drug|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
79256031|NCT02123719|Other|Surgery|
80018112|NCT03914014|Other|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
79256032|NCT05009654|Dietary Supplement|L-carnitine|
79256033|NCT05009654|Dietary Supplement|L-leucine|
79256034|NCT02122159|Biological|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
79256035|NCT02406586|Drug|Salsalate|Salsalate 750 mg
79552871|NCT01623583|Other|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~Basic training on relaxation breathing~Brief video of a patient overcoming needle phobia~Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
79717059|NCT05937243|Behavioral|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
79717060|NCT05937243|Behavioral|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
79717061|NCT05937191|Drug|Leflunomide|Leflunomide+Glucocorticoids treatment Group
79717062|NCT05937191|Drug|Steroid Drug|Steroid Treatment
79717063|NCT05937178|Drug|ETV/TAF/TDF/TMF/IFN|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
79717064|NCT05937178|Drug|ETV/TAF/TDF/TMF|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
79717065|NCT05937139|Other|Breastfeeding education|Breastfeeding education will be given to fathers.
79717066|NCT05937126|Diagnostic Test|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
79853552|NCT05574868|Device|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
79853553|NCT05566366|Other|Qualitative research interview|Qualitative research interview Administration of quantitative scales
79552872|NCT01623609|Drug|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
79717067|NCT05937126|Diagnostic Test|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
79853554|NCT05565729|Drug|LY3471851|Administered SC.
79853555|NCT05565729|Drug|Placebo|Administered SC.
79853556|NCT05565729|Drug|Levocetirizine|Administered orally.
79853557|NCT05564416|Biological|Atezolizumab|Given IV
79395504|NCT02340936|Drug|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
79395505|NCT02340936|Drug|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
79853558|NCT05564416|Procedure|Biospecimen Collection|Undergo collection of blood
79853559|NCT05564416|Procedure|Biospecimen Collection|Correlative studies
79853560|NCT05564416|Procedure|Computed Tomography|Undergo CT
79853561|NCT05564416|Procedure|Cystoscopy|Undergo cystoscopy
79853562|NCT05564416|Drug|Erdafitinib|Given PO
79853563|NCT05564416|Procedure|Magnetic Resonance Imaging|Undergo MRI
79853564|NCT05562960|Procedure|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
79853565|NCT05561257|Drug|Vitamin C|Vitamin C
79853566|NCT05558995|Other|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
79853567|NCT05558280|Drug|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
79853568|NCT05557955|Other|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
79853569|NCT05551377|Other|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
79853570|NCT05542355|Drug|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
79395506|NCT02337114|Behavioral|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
79395507|NCT02337114|Behavioral|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
79552873|NCT01623609|Drug|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
79552874|NCT01623622|Drug|HC-58|once or more / week
79552875|NCT01623622|Drug|Placebo|once or more / week
79717068|NCT05937100|Drug|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
79717069|NCT05937100|Drug|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
79717070|NCT05937100|Drug|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
79717071|NCT05937061|Biological|Blood sample analysis|Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
79717072|NCT05937061|Other|Anthropometrics measurement - at inclusion to the study (all groups).|Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
79717073|NCT05937061|Radiation|Bone mineral density measurement (DXA)|Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
79717074|NCT05937061|Other|Influence of food allergy on growth (intervention groups)|Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
79717075|NCT05937048|Biological|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
79717076|NCT05937048|Other|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
79717077|NCT05937035|Procedure|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
79717078|NCT05936918|Other|Transcutaneous electrical acupoint stimulatios|Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
79853571|NCT05542355|Drug|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
79717079|NCT05936918|Other|Bilateral transverse abdominal plane block|Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
79717080|NCT05936905|Other|Acupuncture|Acupuncture 1 time per month
79717081|NCT05936905|Other|Chiropractic|Chiropractic 1 time per month
79717082|NCT05936892|Other|upper extremity aerobic training|upper extremity aerobic training & baseline treatment will be given. Overall session time will be 40-45 minutes
79717083|NCT05936892|Other|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
79853572|NCT05542355|Other|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
79853573|NCT05542355|Other|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
79717084|NCT05936879|Other|Inspiratory muscle training|Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
79717085|NCT05936879|Other|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
79717086|NCT05936853|Other|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
79853574|NCT05540314|Procedure|robotic bariatric surgery|robotic bariatric surgery
79853575|NCT05539560|Other|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
79256036|NCT02406586|Drug|Carvedilol|Carvedilol 3.125 mg
79717087|NCT05936853|Other|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
79717088|NCT05936840|Device|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
79717089|NCT05936827|Diagnostic Test|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams & Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
79717090|NCT05936827|Diagnostic Test|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
79853576|NCT05539560|Other|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
79853577|NCT05539014|Other|Data collection|Prospectif data collection
79853578|NCT05537259|Other|Observation Group|No intervention; this is an observational study.
79853579|NCT05536414|Drug|Centanafadine|capsule
79853580|NCT05536414|Drug|Escitalopram|capsule
79853581|NCT05536414|Drug|Placebo|capsule
79853582|NCT05536349|Drug|Pirtobrutinib|Given by PO
79853583|NCT05536349|Drug|Obinutuzumab|Given by (IV) vein
79853584|NCT05536349|Drug|Venetoclax|Given by PO
79853585|NCT05536349|Drug|Valacyclovir|Given by PO
80018113|NCT04382313|Procedure|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%<SVV<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
80018114|NCT03133754|Procedure|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
79256037|NCT02406586|Drug|Placebo|One tablet
79256038|NCT02406586|Drug|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
79256039|NCT03285867|Procedure|TACE|transcatheter arterial chemoembolization
79256040|NCT05012852|Device|VagiVitalAC|In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
79395508|NCT02340858|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
79853586|NCT05536349|Drug|Allopurinol|Given by PO
79256041|NCT05330689|Biological|PRP injection dose (<5 billion platelets)|PRP injection with a dose of platelets that is less than 5 billion platelets
79853587|NCT05535309|Drug|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
79853588|NCT05533944|Other|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
79853589|NCT05533619|Drug|Proton pump inhibitor|Inpatients using proton pump inhibitor
79853590|NCT05533606|Drug|Beta-Lactam Drugs|During hospitalization，patients used Beta-Lactam drugs.
79853591|NCT05533593|Drug|Aminoglycoside|Inpatients using aminoglycoside
79853592|NCT05532059|Drug|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
79256042|NCT05330689|Biological|PRP injection dose (between 5 and <10 billion platelets)|PRP injection with a dose of platelets that is between 5 and <10 billion platelets
79853593|NCT05532059|Drug|gemcitabine and cisplatin|gemcitabine and cisplatin
79853594|NCT05531149|Drug|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
79853595|NCT05531149|Drug|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
79853596|NCT05530460|Device|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
80018115|NCT03133754|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
80018116|NCT02121444|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|
80018117|NCT02121444|Device|BETACONNECT auto-injector.|
80018118|NCT04413526|Procedure|radiofrequency|radiofrequency combined with liver resection
80018119|NCT04413526|Procedure|TACE|only TACE treatment
80018120|NCT04413526|Procedure|TACE+radiofrequency|TACE followed by radiofrequency
79395509|NCT02332122|Procedure|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is >= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
79552876|NCT01623635|Drug|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~each subdiaphragmatic area 3.5 ml + 3.5ml~surgical dissection site 3 ml~diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
79552877|NCT01623635|Drug|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~each subdiaphragmatic area 3.5 ml + 3.5ml~surgical dissection site 3 ml~diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
79552878|NCT01623648|Other|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
79552879|NCT01623648|Other|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
79552880|NCT01623648|Other|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
79552881|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
79552882|NCT01623687|Device|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
79552883|NCT01623687|Device|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
79552884|NCT01623687|Device|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
79552885|NCT01623687|Device|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson & Johnsson, USA).
79552886|NCT01623713|Drug|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
79552887|NCT01623713|Drug|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
79552888|NCT01623726|Procedure|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
79552889|NCT01623778|Drug|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
79552890|NCT01623804|Device|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
79552891|NCT01623804|Device|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
79552892|NCT01623817|Drug|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
79552893|NCT01623843|Procedure|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
79552894|NCT01623843|Procedure|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
79552895|NCT01623856|Other|laboratory biomarker analysis|Correlative studies
80018121|NCT00271544|Device|Pacing Lead|implant and follow-up of study device
79717091|NCT05936801|Other|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
79717092|NCT05936801|Other|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
79717093|NCT05936788|Other|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
79853597|NCT05530460|Device|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
79552896|NCT01623908|Drug|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
79552897|NCT01623921|Drug|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
79853598|NCT05529927|Drug|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
79853599|NCT05529927|Drug|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
79853600|NCT05527444|Drug|Secukinumab 150 mg/ml|Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24
79552898|NCT01623921|Drug|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
79552899|NCT01623921|Drug|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
79552900|NCT01623921|Drug|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
79552901|NCT01623947|Dietary Supplement|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
79717094|NCT05936788|Other|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
79717095|NCT05936775|Other|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
79717096|NCT05936775|Other|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
79717097|NCT05936762|Device|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
79717098|NCT05936749|Genetic|Pre-implantation genetic testing|
79717099|NCT05936723|Behavioral|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
79853601|NCT05527444|Drug|Adalimumab Ab|adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24
79853602|NCT05527444|Drug|NSAID|stable dose
79552902|NCT01623947|Dietary Supplement|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
79552903|NCT01623947|Dietary Supplement|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
79552904|NCT01623973|Other|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
79552905|NCT01623986|Device|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
79552906|NCT01623986|Device|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
79552907|NCT01624012|Device|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
79552908|NCT01624012|Device|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
79552909|NCT01624025|Other|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
79395510|NCT02332122|Procedure|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of >= 3mm is a positive result.
79552910|NCT01624038|Drug|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
79717100|NCT05936723|Behavioral|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
79717101|NCT05936697|Device|fNIRS|For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
79717102|NCT05936697|Device|EEG|For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
79717103|NCT05936697|Other|Baseline Training|In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
79717104|NCT05936658|Drug|[F-18]Florastamin|A single dose of [F-18]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then [F-18]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
79717105|NCT05935059|Drug|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
79717106|NCT05935059|Drug|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
79717107|NCT05933746|Behavioral|Sleep Hygiene Intervention|This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
79717108|NCT05933746|Behavioral|Non-behavioral Sleep Education|1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
79853603|NCT05527444|Drug|Thalidomide Pill|If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
79853604|NCT05527054|Other|Diuretics|Inpatients using diuretics
79853605|NCT05525468|Drug|TDM-180935|TDM-180935 topical ointment
79853606|NCT05525468|Drug|Placebo|Placebo for TDM-180935 topical ointment
79853607|NCT05524870|Other|Mobilization|Movement with mobilization plus exercise
79395511|NCT02332122|Other|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
79395512|NCT02332044|Drug|Erdos|capsule, 300mg
79395513|NCT02332044|Drug|Talion|tablet, 10mg
79395514|NCT02332044|Drug|Erdos, Talion|capsule 300mg and tablet 10mg
79395515|NCT02337036|Other|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
79552911|NCT01624038|Drug|hydroxyurea, blood transfusion|Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
79552912|NCT01624051|Other|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
79717109|NCT05933707|Behavioral|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by ~25% to achieve ~10% weight loss in about 4 to 5 months.
79853608|NCT05524415|Device|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
79853609|NCT05521438|Drug|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
79853610|NCT05521438|Drug|QRX003-4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
79853611|NCT05521438|Drug|Vehicle|Vehicle Lotion
79853612|NCT05521191|Drug|RGLS8429|Solution for subcutaneous injection
79853613|NCT05521191|Drug|Placebo|Solution for subcutaneous injection
79853614|NCT05520775|Drug|Semaglutide|Semaglutide (subcutaneous)
79853615|NCT05520775|Drug|Sham/placebo|Sham subcutaneous injection
79717110|NCT05932719|Other|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~Diagnostic date~Diagnostic stage~Date of surgery~Date of surgery appointment~First antineoplastic treatment date~Last antineoplastic treatment date~Number of treatment cycles recommanded by MDTM"
79717111|NCT05931523|Behavioral|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
79717112|NCT05929534|Device|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
79717113|NCT05929534|Device|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
79717114|NCT05929391|Procedure|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
79717115|NCT05928962|Drug|Recombinant Human Adenovirus Type 5 Injection|"Recombinant Human Type 5 Adenovirus Injection:~This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles."
79717116|NCT05927285|Diagnostic Test|Vexus|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
79853616|NCT05520619|Drug|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
79853617|NCT05520619|Drug|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
79853618|NCT05520619|Radiation|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
79853619|NCT05520008|Other|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
79395516|NCT02337036|Other|Pharmacogenetic|Pharmacogenetic study
79395517|NCT02337036|Drug|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
79395518|NCT02336880|Behavioral|Internet-delivered cognitive behavioural therapy|
79395519|NCT02336802|Behavioral|Avoidance experiment|Participants complete an avoidance task
79552913|NCT01624051|Other|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
79552914|NCT01624064|Drug|Enalapril|2.5-20 mg/day
79552915|NCT01624064|Drug|Calcium Supplement|Calcium 2.5-20 mg/day
79552916|NCT01624077|Biological|Regulatory T cells|Tregs will inject after liver transplantation
79853620|NCT05514990|Drug|Bortezomib|Given SC or IV
79853621|NCT05514990|Drug|Dexamethasone|Given PO, IV, or IM
79853622|NCT05514990|Biological|Pelareorep|Given IV
79853623|NCT05514990|Biological|Pembrolizumab|Given IV
79853624|NCT05512793|Diagnostic Test|Standard technique First colonoscopy without PolyDeep|Standard technique First colonoscopy without PolyDeep
79853625|NCT05512793|Diagnostic Test|Combination technique First colonoscopy with PolyDeep|Combination technique First colonoscopy with PolyDeep
79853626|NCT05512520|Combination Product|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
79853627|NCT05505474|Device|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
79853628|NCT05505396|Other|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
79552917|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
79552918|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
79853629|NCT05505279|Device|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
79395520|NCT02340390|Device|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
79552919|NCT01624116|Drug|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
79256043|NCT05330689|Biological|PRP injection dose (between 10 and <20 billion platelets)|PRP injection with a dose of platelets that is between 10 and <20 billion platelets
79552920|NCT01624116|Other|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
79552921|NCT01624116|Drug|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
79552922|NCT01624116|Drug|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
79552923|NCT01624116|Drug|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
79552924|NCT01624129|Drug|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
79552925|NCT01624155|Behavioral|Education|EMR referral to teratogen and contraception counseling
79552926|NCT01624207|Drug|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
79552927|NCT01624207|Drug|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
79552928|NCT01624246|Drug|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil [600 mg] plus avibactam [600 mg]) infused over 60 (± 5) minutes.
79552929|NCT01624272|Device|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
79552930|NCT01624272|Other|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
79717117|NCT05927285|Other|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested
79717118|NCT05920746|Other|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
79853630|NCT05494502|Procedure|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
79256044|NCT05330689|Biological|PRP injection dose (20 billion or greater platelets)|PRP injection with a dose of platelets that is 20 billion platelets or greater
79256045|NCT05330689|Other|Saline injection control|Saline control
79256046|NCT04262115|Behavioral|AM-EX|AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
79552931|NCT01624298|Behavioral|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
79552932|NCT01624311|Other|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
79552933|NCT01624311|Other|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
79552934|NCT01624337|Drug|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
79552935|NCT01624337|Drug|placebo|
79552936|NCT01624376|Drug|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
79552937|NCT01624376|Drug|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
79552938|NCT01624389|Drug|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
79717119|NCT05919914|Other|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
79717120|NCT05919914|Other|Exercise without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric)
79717121|NCT05917327|Device|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
79256047|NCT04262115|Behavioral|PM-EX|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
79717122|NCT05912894|Procedure|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
79853631|NCT05494502|Procedure|Control group|General anesthesia alone.
79853632|NCT05492370|Dietary Supplement|EpiCor|2 gummies daily
79853633|NCT05492370|Dietary Supplement|Placebo|2 gummies daily
79256048|NCT05012774|Behavioral|Speech Recognition Training|Training for each training arm takes place over 10 sessions carried out at home. on the participant's own computer without experimenter direct supervision. Pre- and post-training tests are carried out under experimenter supervision.
79717123|NCT05910190|Drug|Use of buprenorphine with FAO > 30 OME|Patients will receive buprenorphine with concurrent FAO >30 OME and be assessed for withdrawal, pain, and other symptoms.
79717124|NCT05910190|Behavioral|CPM Rx application use|The CPM Rx application is used on smart phones to allow patients to input time-stamped data about medication type, dosage, and pain score. This will allow analysis of trends in self-reported pain and optimal dosing patterns. Usage over three months will be assessed.
79256049|NCT04282551|Other|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
79256050|NCT05012696|Device|Non-invasive ventilation (NIV)|Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
79552939|NCT01624402|Behavioral|Education on Stroke and Depression (ESD)|"Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
79717125|NCT05908435|Behavioral|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
79717126|NCT05905861|Procedure|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
79552940|NCT01624402|Behavioral|Ecosystem Focused Therapy (EFT)|"EFT offers an action-oriented, new perspective about the subject's recovery;~It provides an adherence enhancement structure;~It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
79552941|NCT01624428|Drug|Varenicline|1 mg bid varenicline titrated over a 2 week period
79552942|NCT01624428|Drug|Placebo|1 mg bid placebo titrated over a 2 week period
79552943|NCT01624441|Drug|Dinaciclib|Given IV
79717127|NCT05905861|Procedure|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
79717128|NCT05902910|Device|LUNA-EMG Robot|During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
79552944|NCT01624441|Drug|Epirubicin Hydrochloride|Given IV
79552945|NCT01624441|Other|Laboratory Biomarker Analysis|Correlative studies
79552946|NCT01624454|Other|Laxabon|4 l PEG solution split dose cleansing
79552947|NCT01624454|Other|CitraFleet|Small volume osmotic bowelcleansing
79552948|NCT01624493|Drug|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
79552949|NCT01624493|Drug|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
79717129|NCT05898919|Other|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
79717130|NCT05898919|Other|Sham acupuncture|Participants will receive sham acupuncture at sham points.
79717131|NCT05898919|Drug|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
79717132|NCT05881291|Drug|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
79717133|NCT05881291|Drug|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
79717134|NCT05871125|Behavioral|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
79717135|NCT05870280|Behavioral|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
79717136|NCT05867563|Drug|TQB2103 for injection|TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
79717137|NCT05867342|Drug|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
79717138|NCT05867342|Drug|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
79717139|NCT05867342|Drug|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
79717140|NCT05866952|Diagnostic Test|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
79717141|NCT05855733|Device|radiofrequency treatment|patient undergoing radiofrequency using the Fistura procedure for treatment of a infected pilonidal sinus
79717142|NCT05854368|Procedure|Additional blood collection as part of routine care|Collection of an additional blood volume (10mL) as part of a blood sampling performed during routine care
79717143|NCT05854368|Procedure|Blood collection|Blood sample collection (10 mL)
79717144|NCT05853757|Drug|Zzowin Nutra Tablet|1 Tablet daily half an hour before going to bed
79256051|NCT05012696|Device|High-flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher & Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
79395521|NCT02340390|Device|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
79395522|NCT02336568|Drug|Oxytoine|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
79552950|NCT01624493|Drug|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
79395523|NCT02336568|Drug|PLACEBO|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
79552951|NCT01624493|Drug|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
79256052|NCT04918342|Other|Multidimensional Exercise Program|The multidirectional exercise program will include cardiovascular training, strengthening, balance training, and flexibility training. This will be delivered 2 times per week for 8 weeks using telehealth and will be delivered by a physical therapist. The exercises will be modified to meet the participants needs. Intensity of exercise interventions will be monitored through patient self report and use of continuous heart rate monitoring.
79552952|NCT01624493|Drug|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
79717145|NCT05843448|Biological|PD-L1/IDO Peptide Vaccine|Given SC
79717146|NCT05843448|Biological|Pembrolizumab|Given IV
79717147|NCT05836051|Other|Flavor|E-liquid flavor chemicals
79717148|NCT05829759|Behavioral|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
79717149|NCT05829759|Behavioral|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
79717150|NCT05828602|Other|Conventional treatment|Conventional treatment
79717151|NCT05828602|Other|TeleRehabilitation|TeleRehabilitation
79717152|NCT05821322|Other|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
79717153|NCT05820022|Other|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
79717154|NCT05818319|Other|12 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting 12 hours.
79717155|NCT05818319|Other|36 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
79717156|NCT05818319|Other|60 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
79717157|NCT05812651|Other|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
79717158|NCT05810480|Diagnostic Test|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
79717159|NCT05802836|Other|no interventions|no intervention, only 3 different patients groups
79717160|NCT05798533|Biological|Neo-T|Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
79717161|NCT05798533|Combination Product|Toripalimab|"3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma."
79717162|NCT05798533|Combination Product|Tislelizumab|"200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types."
79256053|NCT03280875|Other|pedalling exercises|pedalling exercises on a bicycle ergometer
79256054|NCT02122237|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
79717163|NCT05793632|Drug|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
79256055|NCT04420858|Behavioral|Enhanced (experimental) education|See arm description.
79256056|NCT04420858|Behavioral|Standard (control) education.|See arm description.
79256057|NCT03285633|Behavioral|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
79256058|NCT02122315|Other|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
79256059|NCT02122315|Other|Physical therapy|Best-evidence physical therapy intervention
79256060|NCT03091166|Drug|Dexmedetomidine|
79395524|NCT05253768|Biological|Fecal microbiota transplant (FMT)|"Patients will randomized to a fecal microbiota transplantation by using a nasointestinal tube for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of FMT is 200-300ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
79395525|NCT05253768|Other|normal saline and glycerin/food coloring|"Patients will receive an equivalent volume of normal saline and glycerin/food coloring via a nasointestinal tube (sham transplantation) for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of placebo FMT is 200-300ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
79395526|NCT02331732|Behavioral|Virtually Observed Treatment|
79395527|NCT02331732|Other|Directly Observed Treatment|
79717164|NCT05791643|Behavioral|Personalized internal and external coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
79395528|NCT02336646|Drug|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
79395529|NCT02336646|Drug|Normal saline|
79552953|NCT01624519|Procedure|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
79552954|NCT01624545|Other|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
79552955|NCT01624558|Device|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
79552956|NCT01624571|Drug|LD02GIFRO|comparison of different dosages of drug
79552957|NCT01624584|Behavioral|Experimental treatment|six sessions of child anxiety treatment
79552958|NCT01624584|Behavioral|Traditional Treatment|six sessions of treatment consistent with current practice
79552959|NCT01624597|Behavioral|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
79717165|NCT05791643|Behavioral|Personalized internal coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.
79717166|NCT05791643|Behavioral|Personalized external coping strategies|A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
79717167|NCT05791643|Behavioral|General internal and external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.
79717168|NCT05791643|Behavioral|General internal coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.
79717169|NCT05791643|Behavioral|General external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.
79717170|NCT05791643|Behavioral|General internal coping strategies, relaxation|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.
79717171|NCT05791643|Behavioral|General internal coping strategies, distraction|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.
79717172|NCT05791643|Behavioral|General internal coping strategies, physical activity|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
79256061|NCT02460562|Device|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
79256062|NCT02460562|Device|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
79256063|NCT02122393|Drug|Sertraline|
79256064|NCT02122393|Behavioral|Cognitive Behavioural Therapy|
79552960|NCT01624597|Behavioral|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
79256065|NCT03080870|Other|Art|Multicomponent art intervention
79395530|NCT05253612|Diagnostic Test|Analog testing conducted by a trained test leader using, ISPOCD test battery|Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
79552961|NCT01624610|Other|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
79552962|NCT01624649|Drug|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
79395531|NCT05253612|Diagnostic Test|self-administered Mindmore digital cognitive screening battery|Cognitive function will be measured by using the Mindmores digital test battery
79552963|NCT01624649|Drug|Atomoxetine|Form = tablet, route = oral;
79717173|NCT05789277|Other|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~Vertical jumps~Multiple forward jumps~Running exercises~Sprints alternating with slow jogging"
79717174|NCT05789277|Other|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
79717175|NCT05789251|Diagnostic Test|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
79256066|NCT03821883|Drug|Aspirin Tablet|Aspirin 100mg qd
79717176|NCT05787782|Device|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
79717177|NCT05768191|Drug|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
79717178|NCT05768191|Drug|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
79717179|NCT05762666|Device|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
79717180|NCT05759481|Drug|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
79717181|NCT05759481|Other|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
79256067|NCT03821883|Drug|Placebo|Placebo qd
79256068|NCT03080636|Other|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
79256069|NCT03080636|Other|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
79256070|NCT03080636|Other|Control session|30 minutes seated resting
79256071|NCT03285243|Device|Monochromatic blue light|Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
79256072|NCT03080480|Drug|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
79256073|NCT02126761|Biological|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
79256074|NCT02126761|Biological|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
79395532|NCT02039466|Procedure|volume controlled ventilation|
79395533|NCT02039466|Procedure|pressure controlled ventilation|
79395534|NCT02340312|Procedure|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
79717182|NCT05758987|Behavioral|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
79256075|NCT02126761|Biological|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
79256076|NCT02126761|Biological|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
79552964|NCT01624675|Drug|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
79552965|NCT01624675|Drug|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
79552966|NCT01624688|Procedure|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
79552967|NCT01624701|Other|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
79552968|NCT01624714|Drug|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
79552969|NCT01624714|Drug|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
79552970|NCT01624727|Dietary Supplement|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
79552971|NCT01624753|Device|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
79552972|NCT01624766|Biological|Anakinra|Given SC
79552973|NCT01624766|Biological|Denosumab|Given SC
79552974|NCT01624766|Drug|Everolimus|Given PO
79552975|NCT01624779|Drug|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1&2
79552976|NCT01624792|Dietary Supplement|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
79552977|NCT01624792|Dietary Supplement|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
79552978|NCT01624792|Dietary Supplement|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
79552979|NCT01624818|Behavioral|Cardiac habilitation program|physical activity three weeks
79552980|NCT01624844|Other|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
79552981|NCT01624857|Drug|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
79853634|NCT05489341|Diagnostic Test|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
79853635|NCT05489341|Diagnostic Test|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
79853636|NCT05484544|Diagnostic Test|High sensitivity troponin T|Collection of hs-cTnT samples
80031475|NCT04905472|Device|Vestibular Implant Stimulation|VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction & integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes & postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
79256077|NCT03605277|Drug|Asciminib|40 mg single dose
79717183|NCT05758987|Behavioral|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
79853637|NCT05484115|Device|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
79853638|NCT05484115|Device|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
79256078|NCT05008952|Other|High-fat shake|All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
79552982|NCT01624857|Drug|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
79875380|NCT00498368|Drug|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
79717184|NCT05751083|Other|brisk walk+ low intensity aerobic exercises|"Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~Extending leg up then down~Raising up then down on toes later heels~Marching in place~Bringing leg to sideway then back towards middle~Bringing leg towards chair then forward~Bend arms up towards shoulders then back down again.~Pushing arms away from chest then back~Pushing arm up from shoulders then back down~Raising shoulders towards ears then back down~Rolling shoulders forward and backward~Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~Bringing elbows inwards and outwards from chest Standing Balance Exercises"
79552983|NCT01624935|Behavioral|interpersonal psychotherapy|interpersonal psychotherapy
79552984|NCT01624961|Biological|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
79552985|NCT01624987|Behavioral|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
79552986|NCT01624987|Other|Control group|The control group receives no intervention.
79552987|NCT01625026|Drug|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
79552988|NCT01625026|Drug|Placebo|Placebo to obeticholic acid
79552989|NCT01625039|Behavioral|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
79552990|NCT01625039|Behavioral|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
79552991|NCT01625052|Device|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
79552992|NCT01625078|Device|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
79552993|NCT01625117|Behavioral|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
79552994|NCT01625130|Dietary Supplement|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
79552995|NCT01625130|Dietary Supplement|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
79552996|NCT01625143|Other|laboratory biomarker analysis|Correlative studies
79552997|NCT01625195|Dietary Supplement|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
79717185|NCT05751083|Other|Brisk walk|"Brisk Walking Protocol~The brisk walking protocol will consist of :~10 min: warming up of the knees, hips and back by flexibility exercises~30 min of walking~5 min of cool down."
79717186|NCT05738733|Device|MsChief Classic Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
79717187|NCT05738733|Device|MsChief Ylang Ylang Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
79552998|NCT01625195|Dietary Supplement|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
79717188|NCT05738733|Device|MsChief Vanilla & Citrus Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
79717189|NCT05738733|Device|MsChief Tea & Peach Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
79256079|NCT02788357|Drug|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
79552999|NCT01625208|Procedure|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
79717190|NCT05735808|Behavioral|Physician based education|Regular education provided by physician
79717191|NCT05735808|Behavioral|VR based education|VR based education
79717192|NCT05731284|Procedure|Platelet rich plasma (PRP) Injection|Randomly picked (like the flip of a coin) by a computer to receive either platelet-rich plasma (PRP) or normal saline. This is a double-blind study. During vaginal prolapse surgery, the surgeon will inject PRP into the vaginal tissue at the surgical site.
79717193|NCT05731284|Procedure|Placebo|Normal saline Injection
79717194|NCT05719610|Other|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
79717195|NCT05719610|Other|Swiss Ball Exercises|Swiss Ball Exercises
79717196|NCT05706961|Other|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
79256080|NCT02788357|Drug|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
79256081|NCT05009186|Other|PSA value|We measure PSA value during and after covid-19 infection
79256082|NCT02458599|Dietary Supplement|Test product|Whey protein hydrolysate (20 g)
79553000|NCT01625208|Procedure|Supraclavicular block|Standard supraclavicular brachial plexus block
79553001|NCT01625247|Procedure|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
79553002|NCT01625260|Biological|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
79553003|NCT01625260|Drug|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
79553004|NCT01625273|Other|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10^8 CFU per day from 28 days to 6 months of infant age
79553005|NCT01625299|Dietary Supplement|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
79553006|NCT01625299|Dietary Supplement|Placebo|Rice flour 1.0 g/kg/day
79553007|NCT01625351|Drug|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
79553008|NCT01625351|Drug|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
79553009|NCT01625351|Drug|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
79553010|NCT01625351|Drug|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
79553011|NCT01625351|Drug|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
79553012|NCT01625351|Biological|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
79553013|NCT01625351|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79553014|NCT01625364|Behavioral|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
79553015|NCT01625364|Behavioral|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
79553016|NCT01625403|Drug|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
79553017|NCT01625403|Drug|standard of care|standard of care for heart failure
79553018|NCT01625429|Drug|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
79553019|NCT01625442|Drug|Saffron tablet|Saffron tablets 100 mg
79553020|NCT01625442|Drug|Barberry tablet|Barberry tablets 200 mg
79256083|NCT02458599|Dietary Supplement|Reference product 1|Iso-energetic carbohydrate (20 g)
79256084|NCT02458599|Dietary Supplement|Reference product 2|Negligible energy placebo (20 g)
79256085|NCT03552133|Device|Smart CO2|A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
79256086|NCT03091088|Other|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
79553021|NCT01625442|Drug|Placebo|Placebo tablets received daily for 45 days
79553022|NCT01625468|Behavioral|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
79553023|NCT01625481|Device|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
79553024|NCT01625494|Drug|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
79553025|NCT01625494|Drug|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
79553026|NCT01625494|Drug|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
79553027|NCT01625494|Drug|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
79553028|NCT01625520|Drug|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
79553029|NCT01625533|Procedure|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
79553030|NCT01625533|Procedure|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
79717197|NCT05706961|Other|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
79256087|NCT03091088|Other|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
79256088|NCT03280641|Drug|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
79256089|NCT03280641|Drug|Warfarin Sodium|Target INR:1.6-3.0
79256090|NCT02123875|Other|Physiotherapy|
79256091|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
79717198|NCT05706948|Other|High Intensity Interval Training (With Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with Face mask
79717199|NCT05706948|Other|High Intensity Interval Training (Without Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
79553031|NCT01625546|Device|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
79717200|NCT05696327|Other|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
79717201|NCT05696327|Other|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
79256092|NCT05008640|Device|TrueLoo™|TrueLoo™ is an Internet-connected, smart toilet seat that uses computer vision technology to log and capture daily bowel movements and urinations. This data is then categorized by physical excreta characteristics to train and develop machine learning algorithms that are intended to eventually identify significant changes in stool and urine in real-time.
79256093|NCT03285165|Drug|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
79717202|NCT05665855|Dietary Supplement|Ketone monoester|A commercial liquid ketone monoester supplement.
79717203|NCT05665855|Other|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
79717204|NCT05665426|Other|acupuncture|Patients allocated to the acupuncture group will be punctured at the pre-specified acupoints. According to the theory of traditional Chinese medicine and clinical experience, we will use the Bilateral Weizhong point (BL 40). Because of the similar anatomy, the Chize point (LU 5) was chosen as a control. Sterile disposable stainless steel acupuncture needles (length: 40 mm, diameter: 0.25 mm; Hwato, Suzhou, China) will be used.
79717205|NCT05665426|Other|moxibustion|Moxibustion Participants in the moxibustion group will receive moxibustion treatment via portable Moxibustion (Aikeshu, Bozhou, China); the moxibustion is composed of The inner tube (containing the moxa pillar) and the outer tube. To use, pull out the inner tube and light the moxa pillar, then insert the outer tube and fix the moxibustion on the acupuncture points. Two Moxibustion devices will be sequentially applied at two acupoints Weizhong (BL 40) and Chize (LU 5), for 30 minutes.
79717206|NCT05635110|Drug|VX-548|Tablets for oral administration.
79717207|NCT05635110|Drug|Omeprazole|Tablets for oral administration.
79256094|NCT03285165|Drug|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
79256095|NCT02123953|Drug|TAK-438|TAK-438 tablets
79717208|NCT05635110|Drug|Rifampin|Capsules for oral administration.
79717209|NCT05630807|Drug|Bepirovirsen|Bepirovirsen will be administered.
79717210|NCT05630807|Other|Placebo|Matching placebo will be administered.
79717211|NCT05619367|Drug|Odronextamab|
79256096|NCT02123953|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
79553032|NCT01625572|Procedure|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
79256097|NCT03285087|Drug|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
79256098|NCT05008406|Other|Satisfaction|Students Satisfaction
79256099|NCT02122627|Drug|Vitamin D|Colecalciferol 16.800 IU per week
79256100|NCT02122627|Drug|Placebo|
79853639|NCT05478512|Drug|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~if uMRD = Venetoclax 400 mg/d orally until cycle 13.~if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~if uMRD = stop treatment~if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
79256101|NCT03516591|Drug|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
79256102|NCT02458443|Other|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
79256103|NCT02122705|Device|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
79256104|NCT03285009|Other|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
79853640|NCT05478031|Drug|REM0046127 High Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days"
79853641|NCT05478031|Drug|REM0046127 Low Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days"
79853642|NCT05478031|Drug|Placebo|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase"
79256105|NCT03280485|Other|no intervention|no intervention validation of guidelines via database
79256106|NCT05019248|Biological|Most recent vaccine to seasonal influenza|Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
79256107|NCT05011916|Drug|KDR2-2 suspension eye drops|All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
79256108|NCT03466203|Biological|LLF580|LLF580 300mg
79717212|NCT05616702|Other|Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy|"Pressure Biofeedback Therapy~prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~Duration: 15 mins~Frequency: 3 sessions/ week~Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~Tense => five seconds and,~release => ten seconds (Each group of muscle)~2 circuits daily~Exercising dosage:~Duration: 15 mins~Frequency: weekly 3 sessions; for 6 weeks~Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
79717213|NCT05616702|Other|Progressive Muscles Relaxation + thermotherapy|"Progressive Muscles Relaxation Technique~Tense => five seconds and,~release => ten seconds (Each group of muscle)~2 circuits daily~Exercising dosage:~Duration: 15 mins~Frequency: weekly 3 sessions; for 6 weeks~Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
79717214|NCT05615025|Drug|Sevoflurane|Anesthesia will be maintained by sevoflurane.
79256109|NCT03466203|Drug|Placebo|Placebo to LLF580
79853643|NCT05472337|Drug|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
79256110|NCT05011604|Device|Full-Digital Workflow in Single-Tooth Implant Rehabilitation|"For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented."
79717215|NCT05615025|Drug|Propofol|Anesthesia will be maintained by propofol.
79717216|NCT05608018|Other|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
79256111|NCT03411837|Biological|Dupilumab|Biologic (monoclonal antibody)
79256112|NCT03079310|Device|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
79256113|NCT03384225|Drug|Cladribine|
79256114|NCT03384225|Drug|Fludarabine|
79853644|NCT05467046|Device|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
79256115|NCT03384225|Drug|Busulfan|
79853645|NCT05463133|Drug|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
79853646|NCT05463133|Drug|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
79853647|NCT05463133|Drug|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
79853648|NCT05463133|Drug|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
79256116|NCT03384225|Drug|Cytarabine|
79853649|NCT05463133|Biological|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
79853650|NCT05463133|Drug|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
79256117|NCT03079700|Biological|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
79256118|NCT03091010|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
79256119|NCT03091010|Drug|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
79256120|NCT03284697|Procedure|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
79256121|NCT03284697|Procedure|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
79256122|NCT03080012|Other|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
79256123|NCT03080012|Other|Plasma/serum sampling|Simultaneously with saliva sampling.
79256124|NCT03272607|Other|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
79717217|NCT05608018|Other|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
79717218|NCT05608018|Other|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
79853651|NCT05463133|Drug|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
79256125|NCT05008094|Diagnostic Test|Whole-exome sequencing|Whole-exome sequencing with the focus on Parkinson's disease loci.
79875381|NCT00498368|Dietary Supplement|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
80018122|NCT04383028|Procedure|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
80018123|NCT02124486|Procedure|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
79553033|NCT01625572|Procedure|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
79395535|NCT02340312|Other|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
79553034|NCT01625598|Procedure|Photography of the retina|Every subject will undergo photography of the retina in both eyes
79553035|NCT01625598|Procedure|Retinal photography|"Device~Subjects will have photography of both eyes"
79553036|NCT01625624|Other|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
79553037|NCT01625624|Other|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
79553038|NCT01625637|Behavioral|AAT-experiment|This AAT condition trains kids to avoid cigarettes
79553039|NCT01625637|Behavioral|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
80018124|NCT02124486|Behavioral|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
80018125|NCT03665506|Drug|Trifluridin/Tipiracil|QoL assessment
80018126|NCT02118168|Other|No intervention|No intervention is foreseen in this Observational Study
79256126|NCT05008094|Diagnostic Test|Microbiota sequencing|Next generation sequencing of microbiota from stool and saliva samples.
79256127|NCT05008094|Diagnostic Test|Magnetic resonance imaging|Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.
79553040|NCT01625676|Other|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
79553041|NCT01625676|Other|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
79553042|NCT01625702|Device|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
79553043|NCT01625715|Drug|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
79553044|NCT01625741|Drug|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
79553045|NCT01625754|Behavioral|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
79553046|NCT01625767|Behavioral|AAT experiment|Smokers and nonsmokers complete AAT experiment
79553047|NCT01625780|Procedure|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
79553048|NCT01625780|Procedure|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
79717219|NCT05608018|Other|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
79717220|NCT05602181|Behavioral|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
79853652|NCT05463133|Drug|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
79853653|NCT05462496|Procedure|Biopsy|Pre-treatment tumor biopsy
80018127|NCT03868540|Drug|BI 1291583|tablet
79256128|NCT05008094|Diagnostic Test|Transcranial ultrasound and Electroencephalography|Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.
79256129|NCT05008094|Diagnostic Test|ELISA (Enzyme-Linked Immunosorbent Assay)|ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples
79256130|NCT05008094|Diagnostic Test|Fluorescent correlation spectroscopy (FCS)|Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.
79256131|NCT02459535|Other|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
79256132|NCT02459535|Other|oral stimulation saccharin|
79256133|NCT02459535|Other|oral stimulation aspartame|
79395536|NCT02340546|Device|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
79717221|NCT05602181|Behavioral|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
79553049|NCT01625793|Drug|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
79553050|NCT01625806|Drug|RO4602522|Single oral dose
79717222|NCT05583461|Procedure|Positive end-expiratory pressure titration|Positive end-expiratory pressure level
79553051|NCT01625806|Drug|ketoconazole|Multiple oral doses
79717223|NCT05578963|Other|Schaeffer's Test for palmaris tendon|After demographics, Schaeffer's Test will be used to check the presence or absence of palmaris longus muscle. In this test, students will maintain the forearm at 90 degrees first followed by moving the thumb in opposition towards the little finger with the wrist partially flexed. If the tendon bulges out, it will reflect presence of palmaris longus and vice versa. This finding will be recorded. After that, students will perform Phalen's test. In this test, researcher will ask them to press the backs of their hands and fingers together with their wrists flexed and fingers pointed down. they'll stay that way for a minute or two. If fingers tingle or get numb, it will indicate carpal tunnel syndrome. The reading will be recorded.
79717224|NCT05549414|Device|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
79256134|NCT02459535|Other|oral stimulation sucralose|
79256135|NCT05019326|Drug|Andrographis Paniculata|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
79256136|NCT05019326|Drug|Boesenbergia|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
79256137|NCT05019326|Other|Standard supportive treatment|as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
79717225|NCT05541627|Genetic|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
79717226|NCT05521256|Drug|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
79717227|NCT05521256|Drug|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
79853654|NCT05462496|Drug|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows*:~Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~Leucovorin**: 400 mg/m2 IV over 2 hours on Day 1, followed by,~5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
79853655|NCT05462496|Drug|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
79875382|NCT04460066|Drug|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
79305053|NCT04963647|Diagnostic Test|Adult subjects diagnosed with IS or TIA|From the moment the person decides to participate, the patient will undergo the first 24-hour cycle of monitoring with a high-resolution 12-lead Holter. The following day, the Holter report generated will be analyzed by an expert electrocardiographic. After the removal of the first Holter, the study subject will undergo a second monitoring with a 3-lead Holter device for a duration of 6 days, followed by decontamination of the device and archiving of data The electronic data relating to the monitoring periods with Holter will be analyzed with various high-sensitivity AF detection algorithms in order to identify the outcome of the study.
79553052|NCT01625819|Behavioral|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
79553053|NCT01625819|Behavioral|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
79553054|NCT01625819|Behavioral|Health Education|32 1-hour bi-weekly group sessions of health education
79553055|NCT01625832|Procedure|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
79553056|NCT01625871|Drug|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
79553057|NCT01625936|Drug|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
79553058|NCT01625936|Drug|Bevacizumab|
79553059|NCT01625949|Procedure|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
79553060|NCT01625949|Procedure|coronary dilatation and stenting|coronary dilatation and stenting
79553061|NCT01626001|Procedure|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
79553062|NCT01626014|Behavioral|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
79717228|NCT05519644|Other|Sleep Deprivation|The sleeping protocol will be monitored by investigators and personnel with experience in sleep medicine. Participants will be required to reduce sleep by 50% of normal, for 4 consecutive nights, to observe potential deficits in physical and cognitive performance
79717229|NCT05519644|Other|Heart Rate|HR will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets. Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
79717230|NCT05519644|Other|Sleep Monitoring|Sleep will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets.Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
79717231|NCT05519644|Other|Diet|Diet will be included and the same meals will be available for all subjects while controlling for caffeine. Participants will be given food during each intervention week.
79717232|NCT05519644|Other|Exercise Performance|Since weight training is now a crucial part of any warfighter's physical preparation, we will have subjects perform weight training workouts emphasizing all major muscle groups on Days 2, 3 and 4
79717233|NCT05519644|Behavioral|Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index|These will be administered on Days 1 and 5 of each intervention trial to assess different behavioral outcomes.
79553063|NCT01626014|Behavioral|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
79717234|NCT05519644|Other|Cognitive performance|Automated Neuropsychological Assessment Metrics (ANAM), Cambridge Neuropsychological Test Automated Battery. (CANTAB),Gradual-onset Continuous Performance Task (GRAD-CPT),Face-Name Task will be used to assess cognitive function and performance.
79717235|NCT05519644|Other|Marksmanship Performance|The Virtual Training Simulator (VirTra V-100) system (VirTra Corporate HQ, Tempe, AZ) is used by both military and law enforcement agencies to provide training. The V-100 and associated compatible weapons are equipped with recoil kits for unsurpassed live-fire simulation, at distances up to 2,000-m, authoring capabilities for the creation of customized scenarios on 4 individual firing lanes. Multiple metrics of marksmanship (total number of shots fired/silhouette target presentation, percentage of targets successfully hit/min, the radial distance of a shot from the center on target, shot group tightness, and time from target presentation to trigger pull) will be collected during each visit.
79717236|NCT05519644|Other|Quick Board|Upper body and lower body reaction tests will be assess using Quick Board Analysis on days 1 and 5 of the sleep restriction intervention.
79553064|NCT01626040|Drug|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
79717237|NCT05519644|Other|Advanced Medical Technologies Inc, Jump Test|Whole body power will be assessed with a repetitive jump test. Power (peak, average, curve functions) will be assessed using an AMTI force plate with Accupower 2.0 software (Advanced Mechanical Technology Inc, Watertown, MA).
79717238|NCT05519644|Other|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day.
79717239|NCT05519644|Biological|Blood Draw|Blood samples will be collected according to the schedule in Figure 1.
79717240|NCT05519644|Dietary Supplement|Ketone Supplement|Participants will take a diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) during one of the trial interventions
79717241|NCT05501002|Device|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
79256138|NCT05008250|Drug|Tongmai Yangxin Pill (TMYXP)|"TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction."
79553065|NCT01626053|Behavioral|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
79553066|NCT01626053|Other|Control Group|no intervention
79553067|NCT01626066|Drug|LUM015|LUM015 assigned dose given once by IV push
79717242|NCT05485441|Other|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
79717243|NCT05456815|Other|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
79853656|NCT05462496|Drug|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
79875383|NCT04460066|Drug|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
79717244|NCT05453071|Other|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
79717245|NCT05429372|Genetic|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
79717246|NCT05427292|Other|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
79256139|NCT05008250|Drug|metoprolol tartrate|metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
79256140|NCT05008250|Drug|placebo|simulated pills
79717247|NCT05423925|Procedure|Bipolar hysteroscopic myomectomy|Bipolar hysteroscopic myomectomy.
79717248|NCT05423925|Procedure|Monopolar hysteroscopic myomectomy|Monopolar hysteroscopic myomectomy
79853657|NCT05462496|Drug|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
79853658|NCT05462496|Procedure|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
79853659|NCT05460741|Other|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
79853660|NCT05460741|Other|educational program|educational program related to menstrual cycle will be given to females.
80018128|NCT03868540|Drug|Placebo|tablet
79256141|NCT02459301|Drug|IPH2201|
79256142|NCT05018936|Drug|Hetrombopag|Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
79256143|NCT02459379|Radiation|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
79395537|NCT02340624|Behavioral|Referral to SmokeFreeMoms, Quitline or Brief intervention|"SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
79256144|NCT03079076|Drug|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
79256145|NCT03079076|Drug|Saline|2 ml saline subcutaneously bilaterally
79305054|NCT00701051|Behavioral|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
79305055|NCT00701051|Behavioral|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
79553068|NCT01626131|Behavioral|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
79553069|NCT01626131|Behavioral|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
79553070|NCT01625156|Other|Laboratory Biomarker Analysis|Correlative studies
79553071|NCT01625156|Other|Pharmacological Study|Correlative studies
79553072|NCT01625156|Drug|Temsirolimus|Given IV
79553073|NCT01625156|Drug|Tivantinib|Given PO
79553074|NCT01626170|Other|laboratory biomarker analysis|Correlative studies
79553075|NCT01626183|Genetic|RNA analysis|
79553076|NCT01626183|Genetic|proteomic profiling|
79553077|NCT01626183|Other|laboratory biomarker analysis|
79553078|NCT01626196|Other|No intervention|This was an observational study
79553079|NCT01626209|Drug|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
79553080|NCT01626222|Drug|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
79256146|NCT03272061|Other|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
79717249|NCT05413603|Procedure|ultrasonic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
79717250|NCT05413603|Procedure|fluoroscopic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
79717251|NCT05410938|Drug|Chemotherapy|Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
79853661|NCT05460676|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
79256147|NCT03079934|Device|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
79553081|NCT01626222|Drug|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
79553082|NCT01626261|Device|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
79256148|NCT03271827|Device|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
79256149|NCT03079856|Behavioral|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a ~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
79553083|NCT01626274|Device|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
79256150|NCT03271749|Other|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
79305056|NCT04963881|Diagnostic Test|Antibody testing|Blood samples were taken and analyzed for APS antibodies
79395538|NCT02331888|Device|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
79717252|NCT05395520|Other|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
79717253|NCT05393193|Diagnostic Test|Point-of-Care Cepheid Xpert HIV-1|Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
79717254|NCT05393193|Drug|DTG/ABC/3TC|Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
79717255|NCT05385718|Other|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
79717256|NCT05381753|Drug|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
79853662|NCT05460676|Other|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
79395539|NCT02331810|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79395540|NCT02331810|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
80018129|NCT03318874|Device|Blephasteam|Steam delivery goggles, once daily
79553084|NCT01626287|Other|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
79553085|NCT01626287|Other|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
79256151|NCT03079778|Procedure|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
79553086|NCT01626326|Behavioral|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
79256152|NCT03079778|Radiation|TACE plus RT|radiobiologically guided radiation
79256153|NCT03079154|Other|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
79256154|NCT03079154|Other|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
79256155|NCT03284619|Device|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
79256156|NCT05019092|Diagnostic Test|Ultrasound examination of lower limb veins|Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
79553087|NCT01626339|Drug|Intravitreal Ranibizumab|
79256157|NCT02458677|Drug|PRX003|
79256158|NCT02458677|Other|Placebo|
79256159|NCT03078998|Device|Leap Motion Based Exercises|Game based exercise
79553088|NCT01626339|Drug|Intravitreal bevacizumab|
79553089|NCT01626365|Procedure|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
79553090|NCT01626365|Procedure|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
79553091|NCT01626417|Device|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
79553092|NCT01626430|Dietary Supplement|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
79553093|NCT01626430|Dietary Supplement|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
79553094|NCT01626443|Dietary Supplement|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
79553095|NCT01626443|Dietary Supplement|Folic acid|Folic acid (200 mcg); 2 x die
79853663|NCT05460676|Other|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
79256160|NCT03079232|Device|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
79256161|NCT03079232|Device|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
79853664|NCT05459818|Device|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
79853665|NCT05458284|Procedure|Real Acupuncture|Real Acupuncture weekly till taxane completion
79256162|NCT03078920|Device|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
79256163|NCT03280407|Drug|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
79256164|NCT03280407|Drug|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
79256165|NCT03280407|Drug|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
79256166|NCT05011136|Other|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
79256167|NCT02457910|Other|Biomarker Analysis|Correlative studies
79256168|NCT02457910|Drug|Enzalutamide|Given PO
79256169|NCT02457910|Other|Pharmacological Study|Correlative studies
79553096|NCT01626469|Drug|Captopril|25mg Captopril
79553097|NCT01626469|Drug|placebo|placebo
79553098|NCT01626482|Other|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
79553099|NCT01626482|Other|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
79553100|NCT01626521|Other|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
79553101|NCT01626534|Drug|Clopidogrel|600mg loading dose then 75mg/day
79553102|NCT01626534|Drug|trigagrelor|180 mg loading dose then 90 mg Twice a day
79553103|NCT01626560|Drug|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
79553104|NCT01626560|Drug|Vancomycin|Vancomycin 1g q12h 10 - 14 days
79853666|NCT05458284|Other|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
80018130|NCT03318874|Device|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
80018131|NCT03318874|Drug|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
80018132|NCT03551652|Drug|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged > 80 years with patients aged 18 to 50 years
80018133|NCT05724524|Other|Stool sample collection|50mg stool sample taken for protein extraction
79553105|NCT01626586|Behavioral|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
79553106|NCT01626612|Procedure|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
79853667|NCT05457010|Biological|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
79553107|NCT01626612|Procedure|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
79553108|NCT01626625|Drug|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
79553109|NCT01626625|Other|autograft taken from iliac crest|patient will be transplanted with autograft
79717257|NCT05381753|Drug|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
79717258|NCT05350813|Procedure|Measurement of the PCT plasma levels|antibiotic treatment duration will be based on PCT plasma levels
79717259|NCT05350813|Procedure|Usual practice based on guidelines|antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
79853668|NCT05457010|Biological|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
79853669|NCT05455138|Procedure|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
80018134|NCT05724524|Other|Blood sample collection|Venous blood sample taken for analysis of serum and plasma
80018135|NCT03615976|Procedure|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~Scoring of patellofemoral disorders( Kujala) score~Knee Injury and Osteoarthritis Outcome Score (KOOS)"
80018136|NCT02118246|Device|Dry Needling|Dry needling was performed for one week, three times a week.
80018137|NCT02118246|Device|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
80018138|NCT00263042|Drug|Rimonabant|Tablet, oral administration
80018139|NCT00263042|Drug|Placebo (for Rimonabant)|Tablet, oral administration
80018140|NCT05055934|Drug|SHR-1314 injection|SHR-1314 injection
80018141|NCT05055934|Drug|placebo|placebo
80018142|NCT02251782|Device|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
79256170|NCT02457910|Drug|Taselisib|Given PO
80018143|NCT02251782|Device|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
79395541|NCT04630938|Drug|Morphine Sulfate|intrathecal morphine will be added to anaesthetics
79395542|NCT04630938|Drug|morphine+lidocaine|local anesthetic will be infused intravenously
79395543|NCT04630938|Drug|Saline|intravenous saline infusion
79395544|NCT04604262|Device|Waterpik|Waterpik dental water jet
79395545|NCT03111888|Device|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
79395546|NCT02336724|Drug|Famitinib|
79395547|NCT02331342|Device|NICOM cardiac output measurement|
79395548|NCT02331342|Device|Innocor cardiac output measurement|
79395549|NCT02340234|Drug|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
79553110|NCT01626638|Procedure|Confocal Micro Endoscopy|
79717260|NCT05350267|Behavioral|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
79717261|NCT05350267|Behavioral|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
79553111|NCT01626651|Drug|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
79553112|NCT01626651|Drug|Ketoconazole|Ketoconazole (400 mg [2 x 200 mg] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
79553113|NCT01626677|Biological|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
79553114|NCT01626677|Procedure|Microfracture|Active control
79553115|NCT01626703|Other|Reminding call|
79553116|NCT01626716|Other|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
79553117|NCT01626729|Behavioral|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
79553118|NCT01626729|Behavioral|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
79553119|NCT01626729|Behavioral|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
79553120|NCT01626729|Behavioral|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
79553121|NCT01626729|Behavioral|No label control group|No label control group
79717262|NCT05349123|Behavioral|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
79717263|NCT05349123|Behavioral|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
79717264|NCT05333107|Drug|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
79717265|NCT05333107|Drug|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
79717266|NCT05333107|Drug|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
80018144|NCT03218410|Procedure|surgical pulmonary embolectomy|
80018145|NCT03218410|Combination Product|catheter-directed thrombolysis|
80018146|NCT03528590|Device|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
80018147|NCT03528590|Device|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
80031476|NCT04905550|Drug|Almonertinib|Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
79553122|NCT01626742|Other|Ready to Drink Flavored Beverage|2 servings a day
79553123|NCT01626742|Other|Ready to drink flavored beverage w/ AN 777|2 servings a day
79553124|NCT01626755|Procedure|Sciatic name block|Ultrasound-guided sciatic nerve block.
79553125|NCT01626781|Device|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
79553126|NCT01626781|Other|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
79553127|NCT01626794|Biological|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
79553128|NCT01626794|Biological|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
79553129|NCT01626794|Biological|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
79553130|NCT01626807|Behavioral|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
79553131|NCT01626833|Drug|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
79553132|NCT01626833|Biological|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
80018148|NCT03552744|Other|Mailed training intervention|"PCPs from the intervention group will be mailed an intervention package that includes:~2-page structured evidence summary on CRC screening and information about Colonoscopy & FIT (Decision box)~patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~sample FIT for PCPs who may not be familiar with its contents and use"
80018149|NCT05002192|Drug|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
79395550|NCT02340234|Drug|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
79553133|NCT01626898|Behavioral|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
79553134|NCT01626898|Behavioral|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
79553135|NCT01626911|Procedure|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
79553136|NCT01626911|Other|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
79717267|NCT05318352|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that modulates cortical activity. tDCS has been conducted to improve wide range of neurological impairments including sleep.
79717268|NCT05305963|Radiation|Mammogram|mammogram
79256171|NCT02458521|Device|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
79717269|NCT05295420|Procedure|platelet rich plasma|Injection of Platelet Rich Plasma in the female conditions that suffer from SUI
79717270|NCT05295004|Behavioral|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
79256172|NCT02458521|Device|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
79395551|NCT02340234|Drug|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
79395552|NCT02331420|Procedure|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
79395553|NCT02331420|Behavioral|Medical therapy|"Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);~Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;~Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;~Programs for diet and lifestyle modification, including reduced overall energy and fat intake (<30% total fat, <10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);~low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids)."
79395554|NCT02336490|Other|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
79717271|NCT05278312|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
79853670|NCT05453630|Behavioral|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
79553137|NCT01626924|Drug|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
79553138|NCT01626937|Other|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
79553139|NCT01626937|Other|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
79553140|NCT01626963|Procedure|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
79553141|NCT01626963|Procedure|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
79717272|NCT05278013|Other|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D & C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
79717273|NCT05276206|Drug|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
79717274|NCT05274178|Device|"Audeo P hearing aid labeled as Prescriptive"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant."
79717275|NCT05274178|Device|"Audeo P hearing aid labeled as OTC"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant."
79717276|NCT05265689|Behavioral|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
79717277|NCT05265689|Behavioral|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
79717278|NCT05262062|Other|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4. Once the position of ease was identified, it was held for 20 to 30 seconds."
79256173|NCT03078842|Dietary Supplement|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
79256174|NCT03078842|Dietary Supplement|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
79256175|NCT03078842|Dietary Supplement|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
79256176|NCT03284151|Radiation|Cyberknife|
79256177|NCT03090854|Diagnostic Test|ADASCog|Neuropsychological test
79256178|NCT05007860|Biological|PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.|Vaccines administered per standard of care
79395555|NCT02336412|Other|SMS reminder|Daily SMS medication reminder
79395556|NCT02331654|Other|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
79395557|NCT02331654|Other|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
79395558|NCT02336334|Device|Positioning measurement|Logging of posturing informations
79395559|NCT02336334|Device|Patient feedback|Evaluation of patients questionary
79395560|NCT02336334|Procedure|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
79395561|NCT02336334|Device|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
79395562|NCT04594746|Drug|Amiodarone Hydrochloride|Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food
79395563|NCT04594746|Drug|Placebo|Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
79395564|NCT02790138|Drug|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
79395565|NCT02790138|Drug|Ciprofloxacin|Ciprofloxacin tablets
79553142|NCT01626976|Drug|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
79553143|NCT01626976|Drug|Placebo|Solution, single dose
79553144|NCT01626976|Drug|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
79553145|NCT01626976|Drug|Placebo|suspension, single dose
79553146|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
79553147|NCT01626976|Drug|Placebo|suspension, single dose
79553148|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
79553149|NCT01626976|Drug|Placebo|suspension, single dose
79553150|NCT01626976|Drug|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
79553151|NCT01626976|Drug|Placebo|suspension, single dose
79553152|NCT01627015|Other|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
79553153|NCT01627015|Other|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
79553154|NCT01627028|Procedure|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
79553155|NCT01627041|Drug|Cytarabine|Given IV
79553156|NCT01627041|Drug|Daunorubicin Hydrochloride|Given IV
79553157|NCT01627041|Drug|Decitabine|Given IV
79553158|NCT01627041|Other|Laboratory Biomarker Analysis|Correlative studies
79553159|NCT01627041|Other|Pharmacological Study|Correlative studies
79717279|NCT05262062|Other|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
79553160|NCT01627080|Other|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
79553161|NCT01627106|Drug|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
79553162|NCT01627106|Drug|Amiodarone|Administered IV as per product label
79553163|NCT01627132|Drug|Dasatinib|100mg QD
79553164|NCT01627145|Drug|Solifenacin|Solifenacin 5 mg qd,
79553165|NCT01627158|Drug|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
79553166|NCT01627158|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler
79553167|NCT01627158|Drug|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
79395566|NCT02790138|Drug|Vedolizumab|Vedolizumab IV infusion
79395567|NCT02339844|Drug|Aripiprazole|6 weeks of individual doses of aripiprazole
79553168|NCT01627158|Drug|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
79553169|NCT01627171|Drug|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
79553170|NCT01627171|Drug|Polyethelene Glycol|280g reconstituted in 4 liters of water
79395568|NCT04492800|Device|Paxman Scalp Cooling Device|Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
79395569|NCT02339610|Device|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
79553171|NCT01627171|Drug|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
79553172|NCT01627184|Device|Dexcom G4 CGM System|
79553173|NCT01627197|Procedure|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
79553174|NCT01627223|Drug|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
79553175|NCT01627223|Drug|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
79553176|NCT01627236|Drug|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
79553177|NCT01627262|Drug|Mesalamine|3x1000mg mesalamine granules per day
79553178|NCT01627262|Drug|Placebo|3x1000mg placebo granules per day
79553179|NCT01627275|Biological|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
79553180|NCT01627353|Procedure|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
79853671|NCT05453630|Behavioral|Usual Care Control|Educational brochure about colonoscopy
79853672|NCT05447910|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79853673|NCT05447910|Drug|Letrozole|Given PO
79875384|NCT04460066|Drug|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
79553181|NCT01627353|Procedure|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
80018150|NCT05002192|Drug|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
80018151|NCT05002192|Drug|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
79553182|NCT01627366|Other|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
79553183|NCT01627379|Drug|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
79553184|NCT01627379|Drug|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
79553185|NCT01627392|Behavioral|Smoking abstinence|6 hour smoking abstinence
79553186|NCT01627418|Behavioral|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
79553187|NCT01627418|Behavioral|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
79553188|NCT01627431|Drug|Acetylsalicylic acid|100 mg once per day
79553189|NCT01627431|Drug|Clopidogrel|75 mg once per day
79553190|NCT01627444|Procedure|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
79553191|NCT01627457|Device|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
79553192|NCT01627470|Device|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
79553193|NCT01627483|Other|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
79553194|NCT01627522|Procedure|TURP|Transurthral resection of prostate
79553195|NCT01627535|Other|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
79553196|NCT01627561|Biological|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
79717280|NCT05262062|Other|Integrated Neuromuscular Inhibition Technique|"Group c will receive Combination of exercise (strain counter strain , muscle energy & ischemic compression. In ischemic compression patient will receive compression,~After MTrPs identification,~Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
79717281|NCT05250505|Device|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
79717282|NCT05249829|Biological|mRNA-1273.529|Sterile liquid for injection
80018152|NCT03528434|Dietary Supplement|Zinc|10mg dispersible zinc sulfate tablet
79553197|NCT01627561|Biological|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
79553198|NCT01627561|Biological|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
79553199|NCT01627587|Drug|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
79553200|NCT01627587|Drug|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
79553201|NCT01627587|Drug|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
79553202|NCT01627587|Drug|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
79553203|NCT01627587|Drug|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
79553204|NCT01627613|Drug|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
79553205|NCT01627613|Drug|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
79553206|NCT01627626|Drug|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
79553207|NCT01627626|Drug|saline|0.9% saline solution
79553208|NCT01627639|Drug|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
79553209|NCT01627639|Drug|Placebo|Placebo
79553210|NCT01627652|Other|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
79553211|NCT01627665|Drug|D->R->C+R|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
79553212|NCT01627665|Drug|D->R->C+D|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
79553213|NCT01627665|Drug|R->D->C+D|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
79553214|NCT01627665|Drug|R->D->C+R|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
79553215|NCT01627678|Drug|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
79553216|NCT01627678|Drug|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
79553217|NCT01627704|Drug|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
79553218|NCT01627717|Drug|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
79553219|NCT01627717|Drug|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
79553220|NCT01627730|Other|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
80018153|NCT03528434|Other|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
80018154|NCT02121600|Other|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
79256179|NCT02405962|Behavioral|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
79395570|NCT00396981|Device|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
79395571|NCT00396981|Device|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
79395572|NCT02336100|Device|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
79395573|NCT02339688|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
79395574|NCT00397839|Drug|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
79395575|NCT00397839|Drug|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
79395576|NCT02336022|Device|Respiratory Motion Inc|
79395577|NCT03105024|Other|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
79395578|NCT03105024|Other|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
79395579|NCT03104946|Diagnostic Test|Mental Development Index;Auditory Brainstem Response;okineticnystagmus|mental development index(MDI）<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
79395580|NCT02336256|Procedure|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
79395581|NCT01793649|Drug|GS-5737|A single dose of GS-5737 in 2.8% saline
79395582|NCT02331576|Drug|rocaine|
79395583|NCT02331576|Drug|Fentanyl|
79395584|NCT01793727|Device|Glidescope videolaryngoscope|
79553221|NCT01627756|Other|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
79553222|NCT01627756|Other|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
79553223|NCT01627795|Drug|Oshadi D and Oshadi R|anti cancer agents
79553224|NCT01627834|Drug|Ropinirole|
79553225|NCT01627847|Drug|Ropinirole|
79553226|NCT01627873|Drug|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
79553227|NCT01627873|Drug|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
79553228|NCT01627886|Drug|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
79553229|NCT01627912|Other|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink [white wine or red wine or 12.5% ethanol or water]/kg of individual, parallel with a standardized meal.
79553230|NCT01627925|Device|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
80018155|NCT02121600|Radiation|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
80018156|NCT02121600|Radiation|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
79853674|NCT05445830|Procedure|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
79256180|NCT02405962|Behavioral|Control|One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
79256181|NCT03270033|Drug|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
79256182|NCT03270033|Drug|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
79256183|NCT05007626|Other|axial length and refractive error|Comparing the correlation between heterophoria and refraction, even after age adjustment.
79256184|NCT03280329|Other|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
79256185|NCT03280329|Other|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
79256186|NCT04959110|Diagnostic Test|Pharmacokinetic study|"Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter"
79256187|NCT03280173|Drug|tafamidis|bioavailability study
79256188|NCT02436304|Drug|EXE844 Sterile Otic Suspension, 0.3%|
79553231|NCT01627938|Drug|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
79553232|NCT01627938|Drug|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
79553233|NCT01627951|Other|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
79553234|NCT01627951|Other|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
79553235|NCT01627951|Other|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
79553236|NCT01627977|Other|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
79395585|NCT02339454|Device|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
79717283|NCT05249829|Biological|mRNA-1273|Sterile liquid for injection
80018157|NCT02288468|Device|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
80018158|NCT04988698|Other|none intervention|none intervention
79395586|NCT02339454|Device|Placebo group|Placebo Applicator
79395587|NCT02339376|Device|Low-frequency repetitive transcranial magnetic stimulation|
79395588|NCT02339376|Device|High-frequency repetitive transcranial magnetic stimulation|
79395589|NCT02339376|Device|Sham repetitive transcranial magnetic stimulation|
79553237|NCT01628003|Device|Brain MRI|Brain MRI
79553238|NCT01628003|Device|MRI|Physical examination Neuropsychological testing Questionnaires
79553239|NCT01628055|Biological|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (~3-4 hours depending on weight).
79717284|NCT05249829|Biological|mRNA-1273.214|Sterile liquid for injection
79717285|NCT05246111|Drug|[14C]M6620|Participants will receive single intravenous infusion of [14C]M6620 on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
79717286|NCT05246111|Drug|M6620|Participants will receive intravenous infusion of M6620 on Day 2 and Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
79717287|NCT05246111|Drug|Topotecan|Participants will receive intravenous infusion of topotecan on Day 1 through Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
79853675|NCT05445830|Procedure|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
79553240|NCT01628055|Other|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
79553241|NCT01628068|Device|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
79553242|NCT01628081|Dietary Supplement|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
79853676|NCT05445830|Procedure|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
79717288|NCT05243303|Device|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
79717289|NCT05243303|Device|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
79717290|NCT05228015|Drug|IK-930|tablets for oral administration
79853677|NCT05445830|Procedure|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
79853678|NCT05445830|Procedure|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
79553243|NCT01628081|Dietary Supplement|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
79553244|NCT01628133|Procedure|ultrasound|sonographic evaluation of intestinal blood flow
79553245|NCT01628146|Device|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
79717291|NCT05211466|Other|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
79717292|NCT05207436|Drug|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
79256189|NCT02436304|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
79256190|NCT03076736|Behavioral|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
79256191|NCT03076736|Behavioral|Resource pack|Resource pack with information on living with aphasia and local community activities.
79256192|NCT03284073|Procedure|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
79717293|NCT05207436|Behavioral|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
79853679|NCT05445557|Drug|RZL-012|small synthetic molecule for submental fat reduction
80018159|NCT02121678|Other|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~Week 0-4: 70-80 % of 1-RM~Week 5-8: 75-86 % of 1-RM~Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
80018160|NCT02121678|Other|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
79853680|NCT05445557|Drug|Placebo|Placebo
79853681|NCT05439161|Device|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
79853682|NCT05429645|Procedure|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
80018161|NCT04973020|Drug|SHR6390、efavirenz|SHR6390 tablet single dose；Efavirenz single dose.
79553246|NCT01628172|Device|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
79853683|NCT05428982|Procedure|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
79553247|NCT01628185|Procedure|Repositioning|pain assessment at baseline then following routine care repositioning in bed
80018162|NCT02118324|Behavioral|Exergaming Program|Participants will exercise through exergaming play.
79853684|NCT05428956|Procedure|Single Inhalation technique|Single maximal inhalation with breath hold technique
79853685|NCT05428956|Procedure|Tidal inhalation technique|5 tidal breaths technique
80018163|NCT05724446|Drug|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
79256193|NCT03280095|Drug|co-codamol 15mg/500mg capsule|
79853686|NCT05428384|Device|MRI/ CardioMEMS comparison|Each subject will have CardioMEMS readings paired with MRI scans
79853687|NCT05422690|Drug|Induction Chemotherapy Triplet Therapy|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2, Nab-paclitaxel 125 mg/m2 given on days 1 and 8 of a 21-day cycle for two cycles.
79853688|NCT05422690|Radiation|Concurrent Y-90 treatment|One or two cycles (depending on whether or not one or two sessions of yttrium-90 are indicated as per the treating interventional radiologist) of gemcitabine 300 mg/m2 and cisplatin, 25 mg/m2 given on day 1 and 8 of a 21-day cycle. Y-90 will be administered on day 3-7 or day 10-21 of the cycle.
79853689|NCT05422690|Drug|Consolidation Doublet Therapy:|Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle for 4-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
79853690|NCT05415709|Drug|Carboplatin|Given IV
79853691|NCT05415709|Drug|Cisplatin|Given IV
79853692|NCT05415709|Procedure|Cytoreductive Surgery|Undergo CRS
79853693|NCT05415709|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
79853694|NCT05415709|Drug|Paclitaxel|Given IV
79853695|NCT05415709|Other|Quality-of-Life Assessment|Ancillary studies
79853696|NCT05415709|Other|Questionnaire Administration|Ancillary studies
79853698|NCT05409872|Dietary Supplement|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
79853699|NCT05409872|Other|Placebo|The subject takes the placebo twice a day for three months.
79256194|NCT03280095|Drug|co-codamol 30mg/500mg tablet|
79553248|NCT01628237|Device|comparison of spinal cord stimulation|
79553249|NCT01628263|Other|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
79553250|NCT01628276|Behavioral|Cog Rehab|Cognitive rehab for MS patients
79553251|NCT01628289|Other|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
79553252|NCT01628289|Other|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
79553253|NCT01628302|Behavioral|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
79553254|NCT01628315|Device|MRI|Annual MRIs as part of participation in the ASA study.
79553255|NCT01628341|Drug|insulin|Patients will be asked to complete 2 self-assessment questionnaires
79717294|NCT05206331|Device|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
79717295|NCT05206331|Drug|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
79717296|NCT05206123|Other|Interview|Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence
79717297|NCT05165927|Device|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
79853700|NCT05404425|Procedure|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
79853701|NCT05404425|Procedure|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
79853702|NCT05404100|Procedure|Aortic valve replacement|SAVR or TAVR
79875385|NCT04460066|Drug|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
79875386|NCT04460066|Procedure|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
79875387|NCT00385671|Drug|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
79875388|NCT00385671|Drug|pregabalin|Pregabalin (PGB) orally (PO)
80018164|NCT05724446|Drug|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
80018165|NCT03177772|Behavioral|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
79853703|NCT05401903|Other|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
79853704|NCT05390775|Behavioral|Written Exposure Therapy (WISE)|WISE consists of five weekly sessions. At session one, the therapist will provide psychoeducation about PTSD, rationale for the proposed intervention, and then instructions for writing about their traumatic experience during each session. Psychoeducation and treatment rationale are scripted to ensure consistency. The participant will be instructed to write about the same trauma memory (their recent MVC) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report SUDs levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
80018166|NCT02124642|Dietary Supplement|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
79553256|NCT01628354|Drug|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of >5 letters or increase in retinal thickness of >100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
79553257|NCT01628380|Procedure|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
80018167|NCT02124642|Dietary Supplement|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
79553258|NCT01628380|Procedure|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
79875389|NCT00385671|Drug|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
79875390|NCT00497198|Drug|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
79875391|NCT00497198|Drug|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
80018168|NCT00262106|Drug|PRO 2000/5|Gel
79553259|NCT01628419|Behavioral|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
79553260|NCT01628432|Procedure|conservative hysterectomy I|conservative hysterectomy for benign disease
79553261|NCT01628432|Procedure|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
80018169|NCT00262106|Drug|Placebo|Placebo
79875392|NCT00496964|Drug|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
79256195|NCT04463030|Dietary Supplement|Liposomal vitamin C, 1 gram|after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
79553262|NCT01628445|Drug|liraglutide|liraglutide titrated to 1.8 mg sc daily
79553263|NCT01628445|Drug|placebo injection|placebo injected sc daily volume equal to active comparator
79553264|NCT01628458|Procedure|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
80018170|NCT03094234|Device|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
80018171|NCT03094234|Procedure|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
80018172|NCT03094234|Drug|Propranolol|Appropriate dose of propranolol was administered to the patients.
80018173|NCT02118402|Dietary Supplement|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
80018174|NCT00260156|Drug|vildagliptin|
80018175|NCT00260156|Drug|placebo|
80018176|NCT04367103|Drug|Norepinephrine|prophylaxis for hypotension
80018177|NCT04367103|Drug|Phenylephrine|standerd prophylaxis for hypotension
80018178|NCT01950130|Procedure|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
79717298|NCT05163301|Behavioral|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
79717299|NCT05145738|Behavioral|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
79853705|NCT05390775|Behavioral|Non-emotional Writing|Following randomization, the first session for the control writing condition will be conducted as follows, which is detailed in a structured manual for therapists. The therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did yesterday from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. As discussed, the participant will self-report Subjective Unites of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
79853706|NCT05387655|Biological|BCG|BCG vaccination
79853707|NCT05387655|Biological|Placebo vaccine|Placebo vaccination
79853708|NCT05385653|Behavioral|"experimentation of the virtual reality RevBED"|"ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed."
79256196|NCT04463030|Dietary Supplement|Liposomal vitamin C, 2 grams|after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
79553265|NCT01628471|Drug|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
79553266|NCT01628484|Other|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
79553267|NCT01628484|Other|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
79553268|NCT01628484|Other|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
80018179|NCT02118480|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
79717300|NCT05145738|Behavioral|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
79853709|NCT05383456|Diagnostic Test|Diagnostic Test|Standard diagnostic tests.
79853710|NCT05383456|Drug|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
79853711|NCT05378893|Drug|DR10624 for injection|administered via subcutaneous injection
79256197|NCT04463030|Dietary Supplement|Liposomal vitamin C, 5 grams|after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
79553269|NCT01628562|Drug|Esmolol|Esmolol 50 mcg/kg/min
79553270|NCT01628562|Drug|Remifentanil|Remifentanil 0.5 mcg/kg/min
79717301|NCT05139498|Procedure|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
79717302|NCT05139498|Procedure|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
79717303|NCT05129969|Other|Physician's choice according to patient's needs.|Routine care as per site standard.
79717304|NCT05103618|Drug|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, [F-18] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
79717305|NCT05103618|Behavioral|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
79553271|NCT01628575|Procedure|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
79553272|NCT01628627|Device|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly ~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
79553273|NCT01628627|Device|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
79717306|NCT05082181|Behavioral|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
79717307|NCT05082181|Behavioral|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
79717308|NCT05057221|Drug|Uproleselan|Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
79717309|NCT05054842|Drug|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
79717310|NCT05054842|Drug|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
79717311|NCT05040477|Other|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I & II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
79717312|NCT05039528|Behavioral|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
79853712|NCT05378893|Drug|Placebo|administered via subcutaneous injection
79853713|NCT05374590|Biological|Efgartigimod IV or Efgartigimod PH20 SC|Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
79853714|NCT05367024|Other|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
79553274|NCT01628653|Device|U-SMART|4-weeks' training
79553275|NCT01628666|Drug|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
79717313|NCT05039528|Other|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
79717314|NCT05024916|Dietary Supplement|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
79853715|NCT05367024|Other|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
79853716|NCT05365490|Procedure|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
79853717|NCT05364580|Biological|PROTOXIN|Botulinum toxin Type A
79853718|NCT05364580|Biological|Botox®|Botulinum toxin Type A
79853719|NCT05361343|Other|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"Nutrition: intermittent fasting;~Physical activity: medium-intensity or high-intensity physical activity;~Hypoxic training (at least three per visit to the center);~correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~Individual motivational counseling."
79853720|NCT05359081|Drug|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
79853721|NCT05358860|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
79853722|NCT05358847|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
79256198|NCT04463030|Dietary Supplement|Placebo|after a blood draw placebo will be consumed followed by 3 additional blood draws
79553276|NCT01628666|Drug|Conventional|Cefazolin preoperative
79553277|NCT01628679|Behavioral|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
79553278|NCT01628705|Other|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat <7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
79853723|NCT05358327|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
79717315|NCT05024916|Dietary Supplement|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
80018180|NCT02118480|Other|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
80018181|NCT00260078|Drug|Atazanavir|200 mg to 400 mg orally daily
79256199|NCT03279627|Other|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
79256200|NCT04462640|Other|Management of Infant Digestive Disorders and Quality of Life|The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.
79553279|NCT01628705|Dietary Supplement|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
79553280|NCT01628731|Drug|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
79853724|NCT05358145|Behavioral|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
79553281|NCT01628731|Drug|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
79717316|NCT05022485|Device|ZNN Bactiguard tibia|Tibia fracture fixation
79717317|NCT05015478|Device|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
79717318|NCT05015478|Device|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered with a random interval determined by a Poisson process with an average interval of 40 hertz (Hz). The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
79853725|NCT05358145|Behavioral|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
79853726|NCT05358145|Behavioral|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
80018182|NCT00260078|Drug|Darunavir|300 mg or 600 mg orally twice daily
80018183|NCT00260078|Drug|Efavirenz|Dosage dependent on participant
80018184|NCT00260078|Drug|Nevirapine|Dosage dependent on participant
80018185|NCT00260078|Drug|Ritonavir|50 mg or 100 mg orally twice daily
79395590|NCT00400803|Drug|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
79256201|NCT03269721|Behavioral|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
79717319|NCT04957745|Behavioral|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
79717320|NCT04957745|Behavioral|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
80018186|NCT00260078|Drug|Tenofovir disoproxil fumarate|300 mg orally daily
80018187|NCT00260078|Procedure|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
80018188|NCT03034564|Drug|Northera|
79395591|NCT02335866|Procedure|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
79395592|NCT02335866|Procedure|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
79395593|NCT04681443|Drug|Crystallized phenol application|Crystallized phenol application into the sinus tract
79395594|NCT02339298|Other|music application|music is applied during anaesthesia using headphones
79395595|NCT02339298|Other|only headphones|music is not applied, only headphones are placed
79395596|NCT02339298|Drug|a caudal block|
79717321|NCT04957745|Behavioral|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
79717322|NCT04950166|Drug|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
79717323|NCT04945655|Other|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
79717324|NCT04945655|Other|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
79717325|NCT04945655|Other|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
79553282|NCT01628770|Drug|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
79553283|NCT01628770|Drug|Ferrous sulphate|200mg twice daily
79717326|NCT04945642|Radiation|High-Dose Rate Brachytherapy|Undergo HDR-BT
79717327|NCT04945642|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79717328|NCT04915508|Drug|Hormone Therapy|Receive hormonal therapy
79717329|NCT04915508|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79717330|NCT04867525|Other|Physician's choice according to patient's needs.|Routine care as per site standard.
79717331|NCT04866004|Behavioral|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
79717332|NCT04864028|Other|physical activity|15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
79717333|NCT04820998|Other|Families|Families's interviews about their precarious situation of living and the consequences on their autistic child care
79717334|NCT04820998|Other|professionals|Interviews so as to know how the specifics of precarious situations are identified and taken into account by the professionals
79717335|NCT04818008|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
79853727|NCT05353569|Diagnostic Test|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
79853728|NCT05352698|Diagnostic Test|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
79853729|NCT05351229|Drug|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
79853730|NCT05351229|Other|Placebo|Sterile saline
79853731|NCT05351164|Drug|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
79853732|NCT05349851|Other|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
80018189|NCT03034564|Drug|Placebo Oral Tablet|
80018190|NCT03651921|Behavioral|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
79553284|NCT01628783|Drug|escitalopram 10 mg|orally once daily
79553285|NCT01628783|Drug|Placebo|once daily
79553286|NCT01628796|Other|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
80018191|NCT05342532|Drug|Amoxicillin|1 g
80018192|NCT05342532|Drug|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
80018193|NCT05342532|Drug|Clarithromycin|500 mg twice daily
79717336|NCT04793867|Diagnostic Test|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time <10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
79717337|NCT04790526|Other|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
79717338|NCT04758611|Device|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
79717339|NCT04752462|Behavioral|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
79717340|NCT04749433|Drug|[11C]CPPC Injection|A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
79256202|NCT03269721|Procedure|Spirometry|Pre and post bronchodilator spirometry will be administered according to the American Thoracic Society (ATS) guidelines.
79717341|NCT04700800|Other|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
79853733|NCT05346484|Biological|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
79853734|NCT05346484|Biological|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
79853735|NCT05346081|Device|Electrical impedance tomography|Electrical impedance tomography (EIT) is a potential alternative non-invasive diagnostic screening measure to spirometry.
79717342|NCT04700800|Other|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
79717343|NCT04698018|Drug|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
79853736|NCT05344508|Drug|Brensocatib|Brensocatib tablets
79853737|NCT05343793|Other|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
79853738|NCT05343793|Other|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
79853739|NCT05343793|Other|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
79717344|NCT04698018|Drug|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
79717346|NCT04657367|Other|Observational study - registry|Observational study - registry
79256203|NCT03269721|Procedure|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
79256204|NCT03269721|Procedure|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
79256205|NCT03269721|Diagnostic Test|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
79256206|NCT03269721|Procedure|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
79256207|NCT03269721|Biological|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
79717347|NCT04634591|Procedure|Bariatric surgery|Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
79717348|NCT04577729|Procedure|Allogenic Fecal Microbiota Transplantation|Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
79717349|NCT04577729|Procedure|Autologous Fecal Microbiota Transplantation|Patients receiving their own stool in terms of sham FMT.
79717350|NCT04566159|Behavioral|CBI-CHW|2 sessions of computer delivered counseling + nicotine replacement therapy and CHW follow up post hospitalization up to twice weekly for up to 8 weeks
79717351|NCT04566159|Other|Standard Care|Standard tobacco treatment care offered by the inpatient care
79875393|NCT00496964|Drug|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
79256208|NCT03269721|Behavioral|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
80018194|NCT03651843|Other|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
80018195|NCT04469114|Drug|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
79717352|NCT04561453|Diagnostic Test|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
80018196|NCT04469114|Drug|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
79553287|NCT01628809|Behavioral|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
79256209|NCT03269721|Procedure|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
79256210|NCT05010356|Drug|Insulin|Hyperinsulinemic euglycemic clamp
79553288|NCT01628822|Behavioral|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
79256211|NCT03269955|Drug|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
79553289|NCT01628822|Behavioral|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
79553290|NCT01628835|Behavioral|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
79717353|NCT04526860|Other|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
79717354|NCT04520490|Behavioral|Family Based Behavioral Treatment|Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
79717355|NCT04520490|Drug|Exenatide 2 mg [Bydureon]|Weekly injections of active drug.
79256212|NCT05010278|Procedure|Latarjet|Patients followed up 6 months after a Latarjet procedure
79256213|NCT03269643|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
79256214|NCT03269643|Device|Reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
79256215|NCT03076424|Other|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
79256216|NCT03283995|Other|Cardiac Volume Monitoring VolumeView|hemodynamic measure
79717356|NCT04520490|Drug|Placebo|Weekly placebo injections
79717357|NCT04483778|Biological|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
80018197|NCT02118558|Device|Negative Pressure Wound Therapy (NPWT)|
80018198|NCT02118558|Drug|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
80018199|NCT02400567|Drug|Fluorouracile|
80018200|NCT02400567|Drug|Epirubicin|
79553291|NCT01628835|Behavioral|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
79553292|NCT01628861|Device|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
80018201|NCT02400567|Drug|Cyclophosphamide|
80018202|NCT02400567|Drug|Letrozole|
80018203|NCT02400567|Drug|Palbociclib|
80018204|NCT02124720|Behavioral|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
80018205|NCT05724368|Diagnostic Test|Fecal Calprotectin ELISA kit|"Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
80018206|NCT02868112|Other|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
80018207|NCT02868112|Other|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
79717358|NCT04483778|Biological|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
79256217|NCT03283995|Device|echocardiography|hemodynamic measure
79717359|NCT04483778|Drug|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
79717360|NCT04480554|Drug|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
79717361|NCT04480554|Drug|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
79717362|NCT04480554|Drug|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
79717363|NCT04477889|Other|Treatment for COVID-19|Patients treated for COVID-19
79717364|NCT04472000|Drug|Vitamin C|Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
79717365|NCT04472000|Drug|Placebo|The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
79717366|NCT04463446|Behavioral|Use of the CHD app|Use of the CHD app
79717367|NCT04463446|Behavioral|Nurse-led intervention|Teaching session with clinic nurse
79717368|NCT04433117|Biological|Shefabone|Silica-calcium phosphate composite.
79717369|NCT04433117|Biological|Bio-Oss|Xenograft Bone substitute. Bone from animals.
79256218|NCT03269799|Drug|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
79256219|NCT03269799|Other|placebo|non surgical periodontal treatment+placebo for 2 months
79553293|NCT01628861|Behavioral|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
79717370|NCT04427930|Biological|JOINTSTEM|Autologous Adipose Tissue derived MSCs
79717371|NCT04398394|Device|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
79717372|NCT04378452|Behavioral|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
79717373|NCT04371861|Device|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
79717374|NCT04340362|Drug|VX-147|Tablets for oral administration.
79717375|NCT04308759|Other|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
79717376|NCT04308759|Other|Control Smoking Cessation Program|Participate in Quitbot control cessation program
79717377|NCT04290806|Other|Routine care as per site standard|Physician's choice according to patient's needs. Routine care as per site standard.
79717378|NCT04272216|Device|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
79717379|NCT04269031|Drug|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
79717380|NCT04269031|Drug|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
79853740|NCT05343793|Other|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
80018208|NCT03531242|Biological|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
79395597|NCT04648449|Other|Artificial intelligence on emergency calls|AI listens to all calls to Bergen EMCC, detecting calls regarding possible stroke.
80018209|NCT04937920|Biological|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
80018210|NCT04937920|Biological|Aqueous gel|Topical application on skin affected with tinea versicolor
80018211|NCT04936360|Other|questionnaires for clinical assessments|questionnaires for clinical assessments
79553294|NCT01628887|Other|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
79553295|NCT01628900|Other|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
79553296|NCT01628900|Other|Care management|Hospital vs home
79553297|NCT01628939|Other|MRI of the lumbar spine|standard protocol, approximately 30 minutes
79553298|NCT01628939|Other|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
79553299|NCT01628952|Drug|Transversus Abdominis Plane|PIA coelioscopic
79717381|NCT04268498|Drug|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
79553300|NCT01628952|Drug|Curare|IAP coelioscopic
79256220|NCT05006846|Other|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
79553301|NCT01628978|Other|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
79553302|NCT01628978|Other|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
79256221|NCT03283839|Diagnostic Test|Posturography|Evaluation of postural control and of orientation function
79395598|NCT02339142|Radiation|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
79395599|NCT02339142|Drug|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
79553303|NCT01628991|Behavioral|behavioural program|interventional behavioural program
79553304|NCT01628991|Device|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
79553305|NCT01629004|Other|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
79553306|NCT01629004|Other|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
79553307|NCT01629056|Procedure|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
79553308|NCT01629056|Procedure|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
79717382|NCT04268498|Drug|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
79717383|NCT04268498|Drug|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
79717384|NCT04268498|Drug|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
79717385|NCT04268498|Drug|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
80018212|NCT04468646|Drug|NK-1R antagonist|NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
80018213|NCT00962884|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
80018214|NCT00962884|Device|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
80018215|NCT02802124|Radiation|carbon-ion radiotherapy for tumor away from GI|
79256222|NCT05010044|Behavioral|mindfulness-based cognitive therapy (MBCT)|Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.
79395600|NCT04615299|Device|Auricular acupuncture|Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
79395601|NCT02338908|Other|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
79395602|NCT02338908|Other|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
79395603|NCT02331264|Other|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
79395604|NCT00362817|Drug|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
79395605|NCT00362817|Drug|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
79395606|NCT02335554|Behavioral|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
79395607|NCT02335554|Behavioral|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
79553309|NCT01629069|Behavioral|Mindfulness based Resilience Training|6 weekly group sessions
79553310|NCT01629082|Drug|Clofarabine|
79553311|NCT01629082|Drug|Lenalidomide|
79553312|NCT01629121|Behavioral|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
79553313|NCT01629147|Dietary Supplement|Biogaia|5 drops containing Lactobacillus reuteri Protectis
79553314|NCT01629147|Other|Placebo|5 drops
79717386|NCT04268498|Drug|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
80018216|NCT02802124|Radiation|carbon-ion radiotherapy for tumor adjacent to GI|
80018217|NCT00228176|Drug|Rimonabant|Tablet, oral administration
80018218|NCT00228176|Drug|Placebo (for Rimonabant)|Tablet, oral administration
80018219|NCT02984943|Device|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
79256223|NCT05010044|Other|Antipsoriatic treatment|The routine drug therapy for psoriasis.
79553315|NCT01629173|Procedure|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
79553316|NCT01629173|Procedure|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
79553317|NCT01629173|Procedure|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
79553318|NCT01629173|Procedure|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
79553319|NCT01629186|Other|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) <5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) <80 beats/min or oxygen saturation (SpO2) <85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
79553320|NCT01629199|Drug|rhEGF(recombinant human Epidermal Growth Factor)|
79553321|NCT01629199|Drug|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
79553322|NCT01629212|Drug|Tiropramide HCl 100mg|
79553323|NCT01629212|Drug|Octylonium bromide 20mg|
79553324|NCT01629225|Drug|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
79256224|NCT03269565|Biological|BCD-100|Anti-PD-1 monoclonal antibody
79553325|NCT01629251|Device|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
79553326|NCT01629264|Device|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
79553327|NCT01629264|Device|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
79553328|NCT01629264|Other|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
79553329|NCT01629277|Device|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
79553330|NCT01629277|Device|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
79553331|NCT01629303|Procedure|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
79256225|NCT05000918|Dietary Supplement|Okara protein hydrolysate (OPH)|Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
79553332|NCT01629316|Behavioral|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
79553333|NCT01629316|Behavioral|Standard of care - control arm|The control arm is standard of care for each subject.
79553334|NCT01629342|Behavioral|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~treadmill walking (5 minutes, 1 and 2km/h)~staircase walking (1 floor, normal pace)~cycling with fixed load (5 minutes)~standing up from sitting position and sitting down again (x5)~standing up from supine position~turning from left to right and back while lying in bed~raising outstretched arm 90° (x5, standing position)~eating (5 minutes, sitting position)~drinking a glass of water~sleeping (6 hours)"
79256226|NCT02402218|Other|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
79256227|NCT02402218|Other|Usual care plus incentives|Participants are given incentives after completing treatment goals.
79256228|NCT02402218|Other|Usual Care|Participants receive standard of care in the clinic from their health care team.
79256229|NCT05006768|Drug|Barcimiant|1 tablet contains 4 mg Barcitinib
79256230|NCT05006768|Drug|Olumiant (first dose)|1 tablet contains 4 mg Barcitinib
79256231|NCT05006768|Drug|Olumiant (second dose)|1 tablet contains 4 mg Barcitinib
79553335|NCT01629368|Drug|Carbamazepine|Multiple doses of carbamazepine
79553336|NCT01629368|Drug|RO4917523|Single dose of RO4917523
80018220|NCT02091232|Biological|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
79717387|NCT04268498|Drug|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
79717388|NCT04268498|Drug|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
79717389|NCT04268498|Biological|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
79717390|NCT04264819|Drug|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
79553337|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
79553338|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
79717391|NCT04220931|Drug|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
79717392|NCT04198688|Behavioral|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
79717393|NCT04194775|Drug|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
79853741|NCT05343585|Device|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
79853742|NCT05339711|Other|Robotic Pet Therapy/Robot Cat Group|"İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher."
79853743|NCT05339711|Other|Pet Therapy/Betta Fish Group|İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
79853744|NCT05331443|Diagnostic Test|Reactive hyperemia-peripheral arterial tonometry Index (RHI )|RHI was assessed by RH-PAT using the EndoPAT2000 system .
79853745|NCT05324098|Other|STAND-T platform|Internet-based intervention comprised of evidence-based, patient materials and resources
79853746|NCT05324098|Other|Survey Administration|Satisfaction and follow-up surveys will be administered to participants
79853747|NCT05324098|Other|Text Messages|Participants will receive periodic text messages
79256232|NCT03278457|Diagnostic Test|Positron Emission Tomography|Positron Emission Tomography
79256233|NCT03269331|Behavioral|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
79256234|NCT04993508|Diagnostic Test|PSA test|testing for blood levels of PSA
79256235|NCT04993508|Device|multiparametric prostate Magnetic Resonance Imaging (mpMRI)|mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD > 0.15 will considered suspicious for csPCa.
79395608|NCT00363675|Behavioral|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
79395609|NCT01792947|Procedure|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
79553339|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
79553340|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
79553341|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)]
79395610|NCT01792947|Behavioral|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
79395611|NCT00400881|Other|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
79395612|NCT01795365|Other|Active surveillance|
79395613|NCT02040792|Drug|TD-4208|
79395614|NCT02040792|Drug|Placebo|
79553342|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
79717394|NCT04194775|Drug|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
79717395|NCT04146545|Behavioral|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
79717396|NCT04104217|Behavioral|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
79717397|NCT04104217|Behavioral|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
79853748|NCT05319587|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
79853749|NCT05319587|Drug|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
79553343|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
79853750|NCT05318755|Drug|GAHT for transgender men|Testosterone undecanoate
79853751|NCT05318755|Drug|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
79553344|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
79853752|NCT05317429|Other|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
79853753|NCT05315258|Drug|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
79853754|NCT05308472|Drug|DISC-1459|Oral dose level 1, once a day for 120 days
79853755|NCT05308472|Drug|DISC-1459|Oral dose level 2, once a day for 120 days
79853756|NCT05308472|Drug|Placebo|Oral dose, once a day for 120 days
79853757|NCT05308472|Drug|DISC-1459|Oral dose level 1, once a day for up to 8 months
79853758|NCT05308186|Behavioral|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
79717398|NCT04098432|Drug|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
79717399|NCT04098432|Radiation|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
79717400|NCT04083534|Drug|REGN5459|Administered by intravenous (IV) infusion
79717401|NCT04073628|Device|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
79717402|NCT04069702|Behavioral|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
79717403|NCT04048356|Drug|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
79717404|NCT03996850|Procedure|Computed Tomography|Undergo SPECT/CT
79717405|NCT03996850|Other|Questionnaire Administration|Ancillary studies
79853759|NCT05308186|Behavioral|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
79853760|NCT05306561|Procedure|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
79853761|NCT05305053|Other|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
79853762|NCT05301933|Behavioral|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
79853763|NCT05298995|Biological|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
79853764|NCT05297045|Drug|RGT001-075|Oral GLP1 Receptor Agonist
79853765|NCT05297045|Other|Placebo|Placebo comparator
80018221|NCT03528356|Behavioral|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
80018222|NCT05131984|Drug|Ocrelizumab|At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
79553345|NCT01629407|Other|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
79553346|NCT01629420|Drug|KLH-2109|
79553347|NCT01629420|Drug|KLH-2109|
80018223|NCT05724290|Genetic|EGR2|We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
79256236|NCT04993508|Procedure|targeted MRI/US fusion-guided biopsy|Targeted MRI/US fusion-guided biopsy (TB) are performed using transrectal ultrasound (max. 6 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
79256237|NCT04993508|Procedure|combined prostate biopsy (systematic biopsy plus targeted MRI/US fusion-guided biopsy)|The combined biopsy comprises systematic biopsy (SB) and targeted MRI/US fusion-guided biopsy (TB). They are performed using transrectal ultrasound (number of cores: SB 12 cores, TB max. 6 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
79553348|NCT01629446|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
79256238|NCT04993508|Procedure|MRI inbore biopsy|MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
79256239|NCT02457520|Drug|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
79256240|NCT04993820|Behavioral|Physical activity|The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
79256241|NCT04993820|Behavioral|Education control|Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
79553349|NCT01629459|Behavioral|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
79553350|NCT01629472|Behavioral|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
79553351|NCT01629485|Behavioral|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
79717406|NCT03996850|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
79717407|NCT03996850|Radiation|Technetium Tc-99m Sestamibi|Given IV
79717408|NCT03985761|Behavioral|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
79717409|NCT03980808|Behavioral|American Sign Language-Accessible Diabetes Education|Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
79717410|NCT03980808|Behavioral|Control Intervention|Non-health related video approximately the same length as ASL-ADE.
79717411|NCT03976219|Other|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
79717412|NCT03972215|Drug|Berberine Chloride|Traditional Chinese Medicine
79717413|NCT03972215|Drug|Placebo|Placebo Control
79717414|NCT03956238|Behavioral|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
79717415|NCT03956238|Behavioral|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
79553352|NCT01629485|Behavioral|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
79717416|NCT03955055|Device|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
79717417|NCT03953157|Dietary Supplement|Dietary Intervention|Receive dietary intervention
79717418|NCT03953157|Behavioral|Exercise Intervention|Receive exercise intervention
79717419|NCT03953157|Other|Questionnaire Administration|Ancillary studies
79553353|NCT01629485|Behavioral|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
79256242|NCT05000684|Drug|JS004 in combination with toripalimab|Usage and dosage: Inject 200mg once every 3 weeks
79553354|NCT01629511|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
79553355|NCT01629511|Biological|Anti-Thymocyte Globulin|Given IV
79553356|NCT01629511|Drug|Busulfan|Given IV
79553357|NCT01629511|Drug|Clofarabine|Given IV
79553358|NCT01629511|Biological|Filgrastim|Given SC
79553359|NCT01629511|Drug|Gemcitabine|Given IV
79553360|NCT01629511|Drug|Methotrexate|Given IV
79553361|NCT01629511|Drug|Tacrolimus|Given PO
79553362|NCT01629537|Procedure|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
79553363|NCT01629537|Procedure|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
79553364|NCT01629550|Procedure|skin disinfection prior catheter insertion|
79553365|NCT01629576|Other|economic incentive|economic incentive for weight loss
79553366|NCT01629576|Other|economic incentive|economic incentive for weight loss
79553367|NCT01629602|Procedure|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
79553368|NCT01629628|Drug|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
79256243|NCT04993274|Diagnostic Test|PASS-MS|protocol using short motor tasks performed by the subject and recorded by a depth camera, motion analysis by visuo-perceptive computing
79717420|NCT03943953|Behavioral|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~Facial palsy: Coping with the early stages.~Facial palsy: Coping with comments, questions and staring.~Facial palsy: Communicating with confidence.~Facial palsy: Managing anxiety.~Facial palsy: Managing your mood.~Facial palsy: Building your self-esteem.~Facial palsy: Advice for friends, family and partners."
79256244|NCT04993118|Other|Integrated Neuromuscular Inhibition technique|Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
79395615|NCT02338830|Drug|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
79395616|NCT00364377|Drug|Sitagliptin|100 mg once daily
79395617|NCT00364377|Other|Placebo|once daily for duration of the study
80018224|NCT04874662|Dietary Supplement|NAM/B6|Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
80018225|NCT03133442|Device|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
79553369|NCT01629628|Drug|6 Mercaptopurine|"6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------"
79553370|NCT01629654|Behavioral|Health promotion program|"A 13 weeks organized program:~One group session about poststroke fatigue involving both patient and relatives~Two personal meetings, involving both patient and relatives~Three telephone meetings, involving only patient"
79553371|NCT01629680|Drug|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
79553372|NCT01629680|Drug|Placebo|coated tablets identical in number and appearance as the study drug
79553373|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
79553374|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
79553375|NCT01629732|Drug|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
79553376|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
79553377|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
79553378|NCT01629732|Drug|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
79553379|NCT01629732|Drug|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
79717421|NCT03927573|Drug|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
79717422|NCT03906136|Biological|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
79256245|NCT04993118|Other|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
79853766|NCT05291403|Other|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
79853767|NCT05291403|Other|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
79853768|NCT05291403|Other|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
79853769|NCT05288088|Diagnostic Test|No intervention|This is an observational study
79853770|NCT05283239|Other|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
80018226|NCT01308190|Drug|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
79256246|NCT03269175|Other|Brain MRI|Brain MRI will be performed
79256247|NCT03269175|Other|Blood sampling|Blood samples will be taken
79256248|NCT05006690|Other|Spinal stabilization exercise|Spinal stabilization exercises aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
79256249|NCT05006222|Drug|Enzyme Replacement Agent|Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
79717423|NCT03906136|Other|Standard-of-care|Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
79717424|NCT03902600|Radiation|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
79717425|NCT03896529|Behavioral|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
79717426|NCT03876301|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
79853771|NCT05283135|Drug|risankizumab|Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
79853772|NCT05282745|Other|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
79853773|NCT05282641|Dietary Supplement|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
79853774|NCT05282641|Dietary Supplement|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
79256250|NCT03268707|Device|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
79256251|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
79256252|NCT03078530|Drug|Placebo|This is a pill with inactive ingredients
79553380|NCT01629745|Genetic|gene expression analysis|
79553381|NCT01629745|Other|flow cytometry|
79553382|NCT01629745|Other|laboratory biomarker analysis|
80018227|NCT01308190|Radiation|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
80018228|NCT01308190|Procedure|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
79553383|NCT01629758|Biological|Denenicokin|
79553384|NCT01629758|Biological|Nivolumab|
79553385|NCT01629810|Device|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
79553386|NCT01629849|Drug|Placebo to BI 1021958 qd|tablet
79553387|NCT01629849|Drug|BI 1021958 bid|tablets
79553388|NCT01629849|Drug|Placebo to BI 1021958 bid|tablets
79553389|NCT01629849|Drug|BI 1021958 qd|tablet
79717427|NCT03875820|Drug|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
79717428|NCT03875820|Drug|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
79717429|NCT03860935|Drug|acoramidis|TTR stabilizer administered orally twice daily (BID)
79717430|NCT03860935|Drug|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
79717431|NCT03818243|Behavioral|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
79717432|NCT03800524|Drug|Tauroursodeoxycholic Acid|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
79256253|NCT03078530|Drug|Visbiome|This is a probiotic mixture available to randomized study participants, starting with subject 29
79256254|NCT03078530|Drug|VSL#3|This is a probiotic mixture available to the first 28 subjects randomized to the study
79256255|NCT02457585|Drug|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
79256256|NCT03078764|Other|Mobile health system|Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.
79256257|NCT03078764|Other|E-mail reports and technical support for mHealth system|Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
79717433|NCT03800524|Drug|Placebo|"Placebo 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
79717434|NCT03742076|Dietary Supplement|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
79717435|NCT03742076|Dietary Supplement|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
79717436|NCT03742076|Dietary Supplement|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
79717437|NCT03733028|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
79717438|NCT03733028|Behavioral|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
79717439|NCT03695744|Drug|Daratumumab|Daratumumab
79717440|NCT03695744|Drug|Bortezomib|Bortezomib
79717441|NCT03695744|Drug|Dexamethasone|Dexamethasone
79717442|NCT03690869|Drug|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
79717443|NCT03690869|Drug|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
79717444|NCT03690869|Radiation|Conventional or hypofractionated|Combined with cemiplimab IV administration
79717445|NCT03690869|Radiation|Re-irradiation|Combined with cemiplimab IV administration
79717446|NCT03670628|Device|Shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
79717447|NCT03670628|Other|Sham shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
79717448|NCT03637764|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
80018229|NCT01308190|Procedure|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
80018230|NCT02787408|Device|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
79256258|NCT02457507|Dietary Supplement|Vitamin B12|2 tablets
79256259|NCT02457507|Dietary Supplement|Placebo|2 tablets
79256260|NCT03265197|Drug|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
79717449|NCT03637764|Drug|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79717450|NCT03636022|Other|VR System|Use of virtual reality to deliver exposure therapy
79717451|NCT03636022|Other|Control|Use of conventional delivery of exposure therapy
80018231|NCT00226772|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
79256261|NCT03265197|Other|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
79256262|NCT03078374|Drug|Warfarin|Reduced dosage to obtain lower INR range
79256263|NCT03269019|Diagnostic Test|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
79256264|NCT05005598|Other|catheter dysfunction|prevalence of catheter dysfunction
79256265|NCT02459223|Dietary Supplement|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
79256266|NCT02459223|Dietary Supplement|Khichadi|Khichadi.
79256267|NCT03078686|Procedure|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
79553390|NCT01629875|Drug|Generic equivalent of Clostridium Botulinum A Toxin|
79553391|NCT01629875|Drug|Botox (Clostridium Botulinum A Toxin)|
79553392|NCT01629888|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
79553393|NCT01629888|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
79553394|NCT01629901|Device|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
79553395|NCT01629914|Behavioral|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
79553396|NCT01629979|Procedure|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
79553397|NCT01629979|Radiation|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
79553398|NCT01629992|Other|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
79717452|NCT03594266|Device|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
79717453|NCT03594266|Device|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
79717454|NCT03591965|Drug|ATG-008|Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
79717455|NCT03589794|Other|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
79717456|NCT03589794|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
79256268|NCT03078686|Procedure|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
79256269|NCT03078686|Procedure|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
79256270|NCT03078686|Procedure|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
79256271|NCT03078686|Procedure|cSVF in Normal Saline IV|cSVF + NS for IV Placement
79553399|NCT01630005|Behavioral|talk therapy|Psychotherapy
79256272|NCT03264729|Other|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
79553400|NCT01630018|Drug|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
79553401|NCT01630018|Drug|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
79553402|NCT01630044|Device|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
79553403|NCT01630057|Drug|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
79553404|NCT01630057|Drug|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
79553405|NCT01630070|Device|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
79553406|NCT01630083|Drug|epirubicin|Epirubicin will be administered at a dose of 50 mg/m^2 as a 15-minute intravenous infusion on day 1 of each cycle.
79717457|NCT03589794|Biological|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
79717458|NCT06268938|Procedure|Canal wall down tympanomastoidectomy|Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
79717459|NCT06268925|Other|Exercises|number of exercises will be guided to do through zoom
79717460|NCT06268912|Procedure|Cold Mepivacaine|change the temperature, 3% at 5ºC
79717461|NCT06268912|Procedure|Mepivacaine at room temperature|no change the temperature of anesthesia
80018232|NCT00226772|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
80018233|NCT01210768|Drug|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
79553407|NCT01630083|Drug|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m^2 as a 2-hour intravenous infusion on day 1 of each cycle.
79256273|NCT03264729|Other|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
79256274|NCT03264729|Other|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
79553408|NCT01630083|Drug|capecitabine|The daily dose of capecitabine will be 1250 mg/m^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
79256275|NCT03276819|Procedure|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
79553409|NCT01630083|Drug|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
79256276|NCT03276819|Behavioral|Psychological and Sociological evaluation|Cohort B ....
79553410|NCT01630096|Drug|Nu-Lytely|Bowl prep solution.
79553411|NCT01630148|Drug|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
79553412|NCT01630161|Behavioral|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
79256277|NCT03276819|Behavioral|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
79553413|NCT01630161|Behavioral|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
79553414|NCT01630187|Drug|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
79553415|NCT01630187|Drug|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
79553416|NCT01630226|Drug|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
79717462|NCT06268899|Other|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed >60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
79717463|NCT06268886|Drug|BMS-986446|Specified dose on specified days
79256278|NCT03276819|Behavioral|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
79717464|NCT06268886|Other|Placebo|Specified dose on specified days
79717465|NCT06268873|Drug|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
80018234|NCT01210768|Drug|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
79256279|NCT03276663|Other|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
79553417|NCT01630239|Procedure|Laser ablation|Laser ablation of hepatic tumors
79553418|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
79553419|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
79553420|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
79553421|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
79553422|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
79553423|NCT01630265|Other|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
79553424|NCT01630265|Other|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
79553425|NCT01630278|Drug|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
79553426|NCT01630278|Drug|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
79553427|NCT01630291|Device|Electrode device|Lacrimal gland stimulation
79553428|NCT01630304|Behavioral|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
79553429|NCT01630317|Procedure|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
79553430|NCT01630317|Procedure|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
79553431|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
79553432|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
79553433|NCT01630343|Drug|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
79553434|NCT01630343|Drug|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
79717466|NCT06268873|Drug|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
79717467|NCT06268860|Drug|Rocatinlimab vial injection|Vial solution for SC injection administered on Day 1
79717468|NCT06268860|Combination Product|Rocatinlimab prefilled syringe|Prefilled syringe solution for SC injection administered on Day 1
79717469|NCT06268847|Dietary Supplement|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo."
79717470|NCT06268847|Dietary Supplement|ACT01|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
79256280|NCT02788279|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
79553435|NCT01630356|Behavioral|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
79717471|NCT06268847|Dietary Supplement|ACT02|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
79717472|NCT06268834|Diagnostic Test|Blood for zonulin level was drawn from the group.|Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.
80018235|NCT02971605|Drug|Psilocybin|25 mg/70 kg Psilocybin
80018236|NCT02288624|Dietary Supplement|Processed orange juice|3 different formulation of edible orange drinks
79553436|NCT01630356|Device|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
79553437|NCT01630356|Behavioral|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
79553438|NCT01630356|Behavioral|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
79553439|NCT01630369|Drug|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79553440|NCT01630395|Procedure|protective ventilation|low tidal volume and PEEP
79553441|NCT01630395|Procedure|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
79256281|NCT02788279|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
79553442|NCT01630408|Drug|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
79553443|NCT01630473|Procedure|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
79553444|NCT01630473|Procedure|Conventional orthodontics|Conventional orthodontic treatment
80018237|NCT04410874|Biological|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10^7, 1x10^8, or 4x10^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
79256282|NCT02788279|Drug|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
80018238|NCT03651999|Other|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
79256283|NCT03268785|Diagnostic Test|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
79256284|NCT03268863|Device|Virtual Reality|Google Cardboard virtual reality headset
79256285|NCT03268863|Other|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
79256286|NCT03078608|Behavioral|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
79553445|NCT01630499|Behavioral|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
79553446|NCT01630499|Behavioral|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
79553447|NCT01630512|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
79553448|NCT01630512|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
79553449|NCT01630525|Other|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
79553450|NCT01630525|Other|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
79553451|NCT01630525|Other|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
79553452|NCT01630538|Drug|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
79553453|NCT01630551|Dietary Supplement|Fishoil supplement|1 capsule per day
79553454|NCT01630551|Dietary Supplement|Olive Oil|1 capsule per day
79553455|NCT01630564|Biological|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
80018239|NCT03054337|Drug|Vadadustat|
79256287|NCT03078608|Behavioral|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
79256288|NCT03264651|Drug|enobosarm|Oral combination therapy of enobosarm and anastrozole
79553456|NCT01630564|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
79553457|NCT01630564|Biological|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
80018240|NCT03054337|Drug|Placebo|
80018241|NCT05134324|Other|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
79256289|NCT03073226|Device|Olympus Elite|New generation Olympus endoscope
79256290|NCT03073226|Device|Olympus Spectrum|Current generation Olympus endoscope
79256291|NCT03275727|Behavioral|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
79256292|NCT05000606|Other|A home visit program|A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
79553458|NCT01630577|Other|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
79553459|NCT01630642|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
79553460|NCT01630655|Drug|Torrent's Felodipine Extended-Release Tablets|
79553461|NCT01630668|Dietary Supplement|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
79553462|NCT01630668|Dietary Supplement|One-a-Day placebo capsule|Once per day, 12 weeks
79553463|NCT01630681|Behavioral|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
79395618|NCT02338596|Procedure|Total hip replacement|"Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
79395619|NCT04271241|Other|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
79717473|NCT06268821|Device|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
79717474|NCT06268808|Device|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
79395620|NCT02338674|Drug|Tenofovir and telbivudine|tenofovir and telbivudine administered at least 48 weeks
79717475|NCT06268769|Drug|Tacrolimus Pill|Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
79853775|NCT05281939|Diagnostic Test|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
79395621|NCT02338674|Drug|Tenofovir|tenofovir administered at least 48 weeks
79853776|NCT05280756|Device|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
79553464|NCT01630720|Dietary Supplement|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
79717476|NCT06268769|Drug|Tacrolimus capsule|Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
79717477|NCT06268756|Other|Data collection|Data collection
79717478|NCT06268743|Other|High intensity|High intensity exercise
79717479|NCT06268743|Other|Moderate intensity|Moderate intensity exercise
79717480|NCT06268730|Other|SinuSonic|The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
79717481|NCT06268717|Other|Ground pork containing alpha-gal|150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
79717482|NCT06268717|Other|Pork meat not containing alpha-gal|150 grams of cooked, ground pork meat not containing alpha-gal sugar
79853777|NCT05280756|Device|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
79853778|NCT05280379|Other|no intervention will take place|no intervention will take place
79853779|NCT05276024|Device|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
79395622|NCT02338752|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
79395623|NCT02338752|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
79553465|NCT01630733|Drug|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
79553466|NCT01630733|Drug|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
79553467|NCT01630746|Drug|TAK-438|
79553468|NCT01630746|Drug|TAK-438|
79853780|NCT05275088|Device|Prizvalve® system|Transcatheter atrioventricular valve replacement
79553469|NCT01630759|Device|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
79395624|NCT01826838|Drug|Dasatinib|"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
79553470|NCT01630759|Other|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
79553471|NCT01630772|Other|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
79553472|NCT01630772|Other|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
79553473|NCT01630798|Drug|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
79553474|NCT01630824|Other|Structured education program|structured education program after kidney transplantation
79553475|NCT01630837|Other|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
79553476|NCT01630863|Procedure|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
79553477|NCT01630876|Procedure|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
79553478|NCT01630876|Procedure|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
79553479|NCT01630902|Drug|Torrent's Felodipine Extended-Release Tablets|
79553480|NCT01630915|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
79553481|NCT01630928|Procedure|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
79717483|NCT06268704|Drug|Dexamethasone|This is a non-particulate steroid commonly used to treat SI joint pain.
79717484|NCT06268704|Drug|Methylprednisolone|This is a particulate steroid commonly used to treat SI joint pain.
79717485|NCT06268704|Drug|2% Lidocaine HCl Injection|Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
79717486|NCT06268691|Other|Insecticide Coating INESFLY|The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.07%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
79717487|NCT06268678|Other|Phase of the menstrual cycle|Follicular or luteal phase
79717488|NCT06268665|Drug|Tart Cherry Juice|Given PO
79853781|NCT05273749|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
79395625|NCT00365391|Biological|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
79395626|NCT00365391|Drug|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
79395627|NCT03105180|Other|A mixture of 2.7% sorbitol-0.54% mannitol solution|Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
79395628|NCT02331030|Procedure|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
79395629|NCT02331030|Procedure|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
79395630|NCT02331030|Procedure|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
79395631|NCT02331030|Drug|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
79395632|NCT02331030|Drug|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
79395633|NCT02331186|Procedure|bariatric surgery|bariatric surgery for obese women
79395634|NCT02639676|Other|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
79395635|NCT04270929|Drug|FOLFIRI|During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
79553482|NCT01630941|Drug|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
79853782|NCT05273749|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
80018242|NCT05134324|Other|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
79853783|NCT05272579|Other|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
80018243|NCT05134324|Other|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
79553483|NCT01630954|Procedure|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
79553484|NCT01630954|Procedure|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
79553485|NCT01630967|Drug|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
79553486|NCT01630980|Other|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
79553487|NCT01630993|Other|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
79553488|NCT01631006|Device|CPAP|A low or high CPAP pressure is delivered for 20 minutes
79853784|NCT05272579|Other|Placebo|Saline solution
79553489|NCT01631019|Behavioral|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
79717489|NCT06268652|Other|Organoid-guided personalized treatment|After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.
79717490|NCT06268652|Drug|Gemcitabine|1000mg/m2，IV, days 1, 8, q3w
79717491|NCT06268652|Drug|Capecitabine|1000mg/m² , PO, bid, days1-14, q3w
79717492|NCT06268652|Drug|Vinorelbine|25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w
79717493|NCT06268652|Drug|Eribulin|1.4mg/m², IV, days 1 and 8, q3w
79853785|NCT05269459|Drug|Cannabidiol (CBD) as Nantheia ATL5|Gel caps containing 100mg of Nantheia ATL5. Subjects will take 4 capsules twice daily.
79853786|NCT05269459|Drug|Placebo|Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
79853787|NCT05268250|Behavioral|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
79853788|NCT05267184|Procedure|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
79853789|NCT05267184|Procedure|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
79256293|NCT03264885|Other|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
79853790|NCT05261672|Drug|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
79853791|NCT05261672|Drug|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
79853792|NCT05259527|Drug|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
79853793|NCT05259527|Dietary Supplement|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
79853794|NCT05257187|Device|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
79853795|NCT05255588|Device|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
79853796|NCT05251207|Dietary Supplement|L-carnitine|L-carnitine-L-tartrate
79853797|NCT05251207|Dietary Supplement|L-leucine|L-leucine
79553490|NCT01631019|Behavioral|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
79553491|NCT01631032|Drug|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
79553492|NCT01631058|Drug|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
79553493|NCT01631097|Drug|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
79553494|NCT01631123|Other|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
79553495|NCT01631123|Other|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
79553496|NCT01631136|Drug|Cisplatin|75 mg/m²
79553497|NCT01631136|Drug|Pemetrexed|500 mg/m²
79553498|NCT01631136|Drug|Cisplatin|80 mg/m²
79553499|NCT01631136|Drug|Gemcitabine|1250 mg/m²
79553500|NCT01631162|Other|Breath sample in all patients|Breath sample will be collected by a special nylon bag
79553501|NCT01631175|Behavioral|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
79553502|NCT01631201|Drug|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
79395636|NCT04270929|Drug|FOLFIRINOX|During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
79717494|NCT06268639|Procedure|Osseodensification|The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.
79717495|NCT06268613|Drug|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
79717496|NCT06268613|Drug|EU sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
79717497|NCT06268613|Drug|US sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
79853798|NCT05251207|Behavioral|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
79875394|NCT05076578|Device|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
79553503|NCT01631201|Drug|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
79553504|NCT01631253|Procedure|Laparoscopic ovarian cyst enucleation|
79553505|NCT01631266|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
79553506|NCT01631266|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
79395637|NCT04270929|Device|TriSalus Infusion System|The TriSalus Infusion System administers therapeutics using PEDD technology.
79395638|NCT02338440|Drug|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
79395639|NCT01793961|Other|electroretinogram|
79395640|NCT01793961|Other|contrast sensitivity tests|
79395641|NCT00401817|Drug|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
79553507|NCT01631279|Drug|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
79553508|NCT01631305|Drug|Levothyroxine|3 mcg/kg/day
79553509|NCT01631305|Other|Calcium magnesia|Placebo.
79553510|NCT01631344|Other|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
79553511|NCT01631357|Biological|CIK cell|CIK cell injection
79553512|NCT01631357|Drug|Gemcitabine Injection|Gemcitabine injection
79553513|NCT01631357|Drug|Cisplatin injection|Cisplatin injection
79717498|NCT06268587|Combination Product|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
79717499|NCT06268574|Drug|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
79717500|NCT06268561|Other|Visual acuity analysis|Collection of information on visual acuity from the medical file concerning the surgery
79717501|NCT06268561|Other|Intraocular pressure analysis|Collection of information on intraocular pressure from the medical file concerning the surgery
79717502|NCT06268561|Other|Analysis of optical coherence tomography (OCT) images|Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery
80018244|NCT05134324|Other|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
79717503|NCT06268561|Other|Analysis of retinograms|Collection and analysis of retinography images of the medical file concerning the surgery
79717504|NCT06268548|Other|Manual diaphragmatic activation|Manual diaphragm release on diaphragm
79717505|NCT06268535|Drug|Cancer therapy with FDA and/or EMA approval on the 31st March 2022|Disproportionality analysis studying the association between cancer therapy with FDA and/or EMA approval on the 31st March 2022 and heart failure or cardiac dysfunction in the World Health Organization pharmacovigilance database.
79717506|NCT06268522|Behavioral|Mindfulness-Oriented Recovery Enhancement: (MORE) group|Mindfulness-Oriented Recovery Enhancement (MORE) is a novel social work intervention and mental training program that unites complementary aspects of mindfulness training.
79717507|NCT06268522|Behavioral|Psychoeducation|Education on the neurobiology of pain, healthy eating, diet, sleep and stress
79853799|NCT05240716|Other|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
79853800|NCT05240547|Other|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
79717508|NCT06268509|Diagnostic Test|Nutritional panel laboratory examination|As stated in group description
79717509|NCT06268509|Dietary Supplement|Pregnancy supplements (other than provided by Ministry of Health)|As stated in group description
79717510|NCT06268509|Diagnostic Test|Fetomaternal ultrasound|As stated in group description
79717511|NCT06268496|Other|serum formula 2039125 03|application twice a day of the tested product (in the morning and evening) to the face for 3 months
79717512|NCT06268483|Dietary Supplement|HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
79717513|NCT06268483|Dietary Supplement|cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
79717514|NCT06268457|Procedure|Chemoembolization with Doxorubicin|"Identification of the main vessels afferent to the metastasis to be treated.~Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~Injection of embolizing material (hydrogel microspheres with doxorubicin)~Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature)."
79717515|NCT06268444|Device|7-day actimetry sleep recording|7-day actimetry sleep recording
79717516|NCT06268444|Other|Determination of environmental pollutants in breast milk|Determination of environmental pollutants in breast milk
79717517|NCT06268444|Other|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
79717518|NCT06268444|Other|Continuous recording of the child&#39;s temperature for 7 days|Continuous recording of the child&#39;s temperature for 7 days
79553514|NCT01631370|Procedure|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
79553515|NCT01631383|Drug|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
79717519|NCT06268444|Other|Use of a sleep diary for 7 days|Use of a sleep diary for 7 days
79717520|NCT06268444|Other|Parental questionnaire of environmental exposure|Parental questionnaire of environmental exposure
79717521|NCT06268431|Other|Oxytocin rest|60-minute oxytocin rest
79853801|NCT05240547|Other|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
79853802|NCT05238896|Drug|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
79853803|NCT05238896|Drug|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
79875395|NCT01011062|Procedure|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
79875396|NCT01011062|Drug|Losartan|Acute administration of losartan 200mg total prior to clamp
80018245|NCT02124954|Drug|TA-8995|
80018246|NCT02124954|Drug|Midazolam|
80018247|NCT02124954|Drug|Digoxin|
79256294|NCT03264963|Other|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
79395642|NCT00401817|Drug|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"
79395643|NCT00401817|Drug|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
79553516|NCT01631383|Drug|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
79553517|NCT01631396|Drug|Sugammadex vs. Neostigmine|"Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
79553518|NCT01631409|Other|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
79553519|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
79553520|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
79553521|NCT01631409|Procedure|PCA|Percutaneous coronary angioplasty
79553522|NCT01631409|Procedure|CABG|Coronary artery bypass grafting
79553523|NCT01631409|Device|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
79553524|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
79553525|NCT01631422|Drug|RO4602522|Single radiolabeled dose
79553526|NCT01631448|Biological|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
79553527|NCT01631487|Drug|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
79553528|NCT01631487|Drug|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
79553529|NCT01631487|Drug|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
79553530|NCT01631487|Drug|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
79553531|NCT01631500|Behavioral|Conventional treatment|Conventional treatment
79553532|NCT01631500|Other|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
79553533|NCT01631500|Other|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
79717522|NCT06268405|Genetic|Liquid Biopsy|Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing (cfMeDIP) and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
79553534|NCT01631513|Drug|Nucynta ER|100 to 250 mg every 12 hours
79553535|NCT01631526|Dietary Supplement|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
79717523|NCT06268405|Device|Positron Emission Mammography (PEM)|PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
79717524|NCT06268379|Procedure|Surgery|Not an interventional study, it is an observational, longitudinal study.
79717525|NCT06268366|Other|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
79717526|NCT06268340|Procedure|ECochG monitored CI surgery incl. corrective action guide|Interventional surgery with surgeon having access to intra-operative ECochG monitoring feedback to deploy ECochG based corrective action guide
79717527|NCT06268340|Procedure|Routine CI surgery without ECochG monitoring|Routine CI surgery with access to ECochG monitoring by surgeon
79875397|NCT01011062|Drug|Saline|Infusion of Saline as a volume control intervention
79395644|NCT02338284|Other|ultrasound of globe|"A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~A value > 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
79395645|NCT04417179|Procedure|transversus abdominis block|transversus abdominis block
79553536|NCT01631539|Device|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
79553537|NCT01631539|Drug|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
79553538|NCT01631539|Drug|5 FU|every 2 weeks IV
79553539|NCT01631539|Drug|Irinotecan|every 4 weeks chemoembolization
79256295|NCT03264963|Other|Control|Recording of sleep environment 2 nights per week for 12 weeks
79256296|NCT03078062|Drug|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
79256297|NCT03078062|Drug|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
79256298|NCT03264807|Procedure|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
79717528|NCT06268327|Drug|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
79717529|NCT06268327|Drug|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
79717530|NCT06268301|Drug|Budesonide|Budesonide oral suspension
79717531|NCT06268288|Device|GammaCore intervention|Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day
79717532|NCT06268288|Other|STEPS management protocol|STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
79717533|NCT06268275|Procedure|Scalp block|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
79717534|NCT06268275|Drug|Esmolol|Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
79553540|NCT01631565|Behavioral|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
79553541|NCT01631565|Behavioral|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
79717535|NCT06268249|Drug|Ulinastatin|Ulinastatin was pumped continuously during the operation
79717536|NCT06268236|Other|Electroacupuncture|Electro-acupuncture at Shuigou and Yintang.
79717537|NCT06268236|Other|Sham electroacupuncture|Sham-EA at sham-Shuigou and sham-Yintang.
79717538|NCT06268223|Other|Chewing Exercise Training|All groups will implement the Functional Chewing Exercise, consisting of 5 sets per day, 5 days a week, for 12 weeks. Additionally, the study group will participate in an Action Observation Training program, conducted via telerehabilitation, involving 1 set per day, 3 days a week, for 12 weeks, with the guidance of a physiotherapist.
79717539|NCT06268210|Drug|Lazertinib+Pemetrexed+Carboplatin|Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)
79717540|NCT06268210|Drug|Lazertinib|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
79256299|NCT03264807|Procedure|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
79256300|NCT02435992|Drug|RPC1063|
79395646|NCT04417179|Procedure|Erector spinae block|Erector spinae block
79395647|NCT04417179|Drug|Bupivacaine 0.25% Injectable Solution|Local Anesthetic used in both blocks
79395648|NCT04417179|Device|Siemens Acuson x300 3-5MHz Ultrasound|Ultrasound used to aid in the blocks
79256301|NCT02435992|Drug|Placebo|
79256302|NCT05000060|Other|Timing/1 week|Time of restart of antiplatelet therapy is one week after injury
79256303|NCT05000060|Other|Timing/3 weeks|Time of restart of antiplatelet therapy is left to treating clinician discretion
79395649|NCT02330718|Other|No intervention|
79395650|NCT02330796|Drug|Bucillamine|Bucillamine Tablets
79395651|NCT02330796|Drug|Colchicine|
79395652|NCT04410627|Other|HoPE Website|Educational website focused on hospice care
79395653|NCT04270851|Diagnostic Test|LiMAx test|The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
79395654|NCT04270851|Diagnostic Test|HepaT1ca magnetic resonance scan|The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
79395655|NCT02330640|Drug|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
79395656|NCT02330640|Drug|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
79553542|NCT01631565|Behavioral|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
79553543|NCT01631578|Procedure|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
79553544|NCT01631604|Device|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
79553545|NCT01631604|Drug|Muscle/nerve injection|Injection to muscle or nerve
79853804|NCT05234879|Other|Frame Running|Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
79717541|NCT06268197|Behavioral|Yoga Intervention|The yoga intervention will consist of twice weekly, in-person, gentle Hatha yoga classes delivered by a certified yoga instructor. Each class will last 60-75 minutes and will include an introduction to the day's topic, an opening breathing/meditation practice, yoga postures, a closing breathing/meditation practice, and end with a savasana pose and intention setting for a home practice.
79717542|NCT06268184|Dietary Supplement|D3 LAB SYRUP|omega 3 suplementation
79717543|NCT06268184|Dietary Supplement|placebo capsule|placebo capsule contain only the standard ingredients of soft gelatin capsules
79717544|NCT06268171|Other|ultrasound measurement of the cross-sectional area of the rectus femoris|ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
79553546|NCT01631604|Procedure|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
79553547|NCT01631604|Other|Physical therapy treatment|
79553548|NCT01631643|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
79553549|NCT01631669|Drug|Celecoxib|200 mg Q 12 hours orally
79395657|NCT02330640|Drug|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
79395658|NCT01795443|Other|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
79395659|NCT01795443|Other|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.~Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
79717545|NCT06268158|Behavioral|Eye patch|The experimental group will fill out the patient introduction form, Richmond Agitation-Sedation Scale, Nursing Delirium Screening Scale and Richard-Campbell Sleep Scale on the first day. On the 4th day of the study, the Nursing Delirium Screening Scale and the Richard-Campbell Sleep Scale will be completed.
79717546|NCT06268145|Drug|ECC5004|A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
79717547|NCT06268119|Other|training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium.|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
79717548|NCT06268106|Behavioral|Graphic novel visualization|Patients in interventional group do receive and visualize graphic novel, which is more informative than standard informed consent.
79717549|NCT06268093|Drug|Thalidomide|Thalidomide 50 - 200 mg once at nightime
79717550|NCT06268080|Behavioral|Depth of anesthesia titration using pEEG|Processed EEG targeting will be achieved using titration of intravenous propofol (maintenance anesthetic agent).
79717551|NCT06268067|Device|PET/CT|F-18 FDG PET/CT studies
79717552|NCT06268041|Behavioral|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
80018248|NCT04440800|Device|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
79256304|NCT03264573|Biological|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
79256305|NCT03264573|Device|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
79717553|NCT06268041|Behavioral|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
79717556|NCT06267976|Device|ProSomnus RPMO2|The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
79717557|NCT06267963|Drug|Oral [14C]PF-07220060|A single oral dose of [14C]PF-07220060, will be administered as a liquid formulation in Cohort 1.
79717558|NCT06267963|Drug|Oral PF-07220060|A single oral dose of PF-07081532, will be administered as a liquid formulation in Cohort 2.
79717559|NCT06267963|Drug|IV [14C] PF-07220060|A single IV infusion of [14C]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
80018249|NCT04928794|Procedure|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
80018250|NCT04928794|Procedure|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
79256306|NCT03078140|Dietary Supplement|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
79395660|NCT01795443|Other|Measures - no vibration|"The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
79717560|NCT06267950|Behavioral|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
79853805|NCT05232851|Biological|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
80018251|NCT04441112|Drug|Ketorolac Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
80018252|NCT04441112|Drug|Triamcinolone Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
79256307|NCT03078140|Dietary Supplement|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
79256308|NCT03274557|Procedure|RFM|
79256309|NCT03077984|Combination Product|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
79256310|NCT02457351|Drug|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 & Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
79256311|NCT02457351|Drug|Itraconazole (Sporanox)|Part 1 & Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
79395661|NCT01795443|Other|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
79553550|NCT01631708|Procedure|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to ~100 ug/L in accordance with current guidelines."
79553551|NCT01631708|Procedure|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
79553552|NCT01631760|Genetic|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
79553553|NCT01631773|Genetic|microRNA|Biological samples will be taken from subjects w/ Nasal polyps & AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
79853806|NCT05232851|Biological|Pembrolizumab|Given IV
79853807|NCT05232851|Procedure|Computed Tomography|Undergo CT, FDG-PET/CT
80018253|NCT05131906|Device|gait task and activity of daily living task|use of lasers on shoes to potentially minimize freezing of gait
80018254|NCT02125032|Device|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
80018255|NCT02125032|Device|Placebo Transcranial low voltage electromagnetic fields|
79256312|NCT03077906|Other|Medical Files data extraction|Medical Files data extraction
79256313|NCT02788513|Drug|BI 425809 dose 1|
79256314|NCT02788513|Drug|BI 425809 dose 2|
79256315|NCT02788513|Drug|BI 425809 dose 3|
79256316|NCT02788513|Drug|BI 425809 dose 4|
79853808|NCT05232851|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
79853809|NCT05232851|Procedure|Biospecimen Collection|Undergo blood sample collection
79853810|NCT05232851|Procedure|Biopsy|Undergo biopsy
79875398|NCT01016366|Drug|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
79875399|NCT01016366|Drug|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
79875400|NCT03996980|Device|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
79875401|NCT00490490|Drug|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
79256317|NCT02788513|Drug|Placebo|
79395662|NCT01795443|Other|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
79553554|NCT01631799|Device|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
79553555|NCT01631799|Device|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
79553556|NCT01631838|Dietary Supplement|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
79553557|NCT01631838|Dietary Supplement|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
79553558|NCT01631877|Drug|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
79717561|NCT06267950|Device|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
79717562|NCT06267950|Device|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
79717563|NCT06267937|Procedure|Access to surgery|access to surgery after hip fracture
79717564|NCT06267937|Other|type of intitution|public or private health care facility
79717565|NCT06267924|Device|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
79717566|NCT06267924|Device|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
79717567|NCT06267885|Procedure|Cannulated screws vs wagner's technique|Fixation of fracture neck of femur by cannulated screws or wagner's technique
79717568|NCT06267872|Biological|CD4BS CH505M5 Pr-NP1|A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
79717569|NCT06267872|Biological|CH505TF chTrimer|A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
79717570|NCT06267872|Biological|3M-052-AF (labeled as AP 60-702)|An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
79717571|NCT06267872|Biological|Aluminum Hydroxide Suspension (Alum)|Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
79717572|NCT06267872|Biological|ACU-026-001-1 (labeled as empty LNP)|An AF consisting of 4 lipid components.
79717574|NCT06267846|Drug|NBI-1070770|Suspension for oral administration
79717575|NCT06267846|Drug|Placebo|Suspension for oral administration
79717576|NCT06267833|Behavioral|exercise|In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
79717577|NCT06267820|Drug|Bupivacain|analgesia
79717578|NCT06267820|Drug|Ketorolac|analgesia
80018256|NCT04440878|Behavioral|Static stretching|Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
79256318|NCT03268395|Diagnostic Test|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
79256319|NCT03077750|Drug|VBP-245 Topical Gel|Topical application BID
79256320|NCT03077750|Drug|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
79395663|NCT02335632|Drug|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
79395664|NCT02335632|Drug|Placebo|For probiotics
79717579|NCT06267807|Diagnostic Test|Dynamic contrast-enhanced lymphangiography|The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
80018257|NCT04440878|Behavioral|Mulligan TSLR technique|Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
80018258|NCT05134168|Procedure|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
79717580|NCT06267794|Drug|Pirfenidone 1200 mg|1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
79256321|NCT03268629|Behavioral|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
79256322|NCT03268629|Behavioral|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
79395665|NCT02330328|Other|No Telemetry Monitoring|
79395666|NCT02330328|Device|Telemetry Monitoring|
79395667|NCT02335398|Drug|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
79717581|NCT06267794|Drug|Pirfenidone 1800 mg|1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
79717582|NCT06267794|Drug|Placebo|0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
79717583|NCT06267768|Diagnostic Test|Various intensities of inspiratory muscle training|Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
79853811|NCT05231070|Other|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
79853812|NCT05230745|Device|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
79853813|NCT05227326|Drug|PCNA Inhibitor AOH1996|Given PO
79853814|NCT05226871|Drug|Palbociclib|oral
80018259|NCT05134168|Procedure|LIFT|The fistula tract is ligated in the intersphincteric space
80018260|NCT04440956|Drug|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
79395668|NCT02338206|Drug|Growth hormone|
79395669|NCT02338050|Biological|Moxetumomab Pasudotox|
79395670|NCT02337816|Procedure|laparoscopic surgery, obtainment of biological samples|
79395671|NCT02330484|Behavioral|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
79553559|NCT01631877|Other|placebo|injection placebo will be given for 5 days along with placebo tablets
79553560|NCT01631890|Procedure|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
79553561|NCT01631890|Procedure|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
79553562|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
79553563|NCT01631903|Drug|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
79553564|NCT01631903|Drug|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
79553565|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
79553566|NCT01631903|Drug|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
79717584|NCT06267755|Other|Extracorporeal Shockwave therapy|the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius
79717585|NCT06267755|Other|Traditional physical therapy|the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
79853815|NCT05226871|Drug|Cetuximab|Intravenous (IV) infusion
79853816|NCT05226871|Drug|Fulvestrant|Intramuscular (IM)
79853817|NCT05226871|Drug|Letrozole|oral
79853818|NCT05225428|Behavioral|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
79853819|NCT05225428|Behavioral|Genetic Counseling|Standard genetic counseling
79853820|NCT05222451|Other|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~A variety of vegetables and fruits~Grains, at least half of which are whole grains~Fat-free or low-fat dairy~A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
79853821|NCT05222451|Other|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
79395672|NCT02330484|Behavioral|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
79256323|NCT03268239|Device|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:~3D T1 GRE after injection (Gradient-Recalled Echo)~3D T1 TSE before injection (Turbo Spin Echo)~3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
79553567|NCT01631916|Drug|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
79853822|NCT05222451|Other|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
79853823|NCT05218980|Dietary Supplement|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
79553568|NCT01631942|Drug|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
79553569|NCT01631955|Drug|Ciprobay|Ciprobay (250mg, bid, oral)
79853824|NCT05217849|Behavioral|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
79853825|NCT05217849|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
79853826|NCT05217849|Behavioral|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
80031477|NCT04905550|Radiation|Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)|Image guided, 24-15 Gy*1F was recommended if use SRS. 9-12 Gy*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
79256324|NCT04999670|Procedure|Fascial closure method during caesarean section via pfannenstiel incision.|Comparison of three different methods of fascial closure.
79553570|NCT01631968|Procedure|Cement without antibiotic.|
79256325|NCT03268161|Diagnostic Test|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
79553571|NCT01631968|Procedure|Cement with erytromycin and colistin.|
79717587|NCT06267729|Biological|AZD0754|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
79256326|NCT03077828|Drug|Carboplatin|Given IV
79553572|NCT01631981|Drug|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
79553573|NCT01631981|Drug|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
79553574|NCT01631994|Drug|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
79553575|NCT01632046|Drug|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
79553576|NCT01632072|Dietary Supplement|Nutritional support|Nutritional support and counseling
79717590|NCT06267690|Procedure|surgery|Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
79853827|NCT05215132|Radiation|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
79395673|NCT02330406|Drug|Anagliptin|Suiny 100 mg
79395674|NCT02330406|Drug|Sitagliptin|Januvia 50 mg Glactiv 50 mg
79853828|NCT05215132|Drug|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
79853829|NCT05206617|Other|No intervention - pure observational study|No intervention
80031478|NCT04667000|Other|Forced Air Warming|We will use Forced Air Warming for cesarean patient
79256327|NCT03077828|Drug|Etoposide|Given IV
79853830|NCT05205486|Drug|Cefazolin 3gm for Injection USP and Dextrose Injection USP|Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing >/= 120 kg
79853831|NCT05203159|Other|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
79395675|NCT02330250|Other|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
79717591|NCT06267677|Dietary Supplement|High protein liquid formula|liquid and high amount of protein
79717592|NCT06267638|Drug|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
79395676|NCT02330250|Other|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
79553577|NCT01632085|Device|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
79553578|NCT01632111|Other|Lung function measurement|Spirometry
79553579|NCT01632124|Other|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
79553580|NCT01632163|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
79553581|NCT01632163|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
79717593|NCT06267638|Drug|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
79717594|NCT06267625|Other|Physical Evaluations of individuals|Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
79853832|NCT05203159|Other|Routine|No sound will be played before, during and after the ROP examination.
79853833|NCT05200403|Drug|Crisaborole 2%|The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
79553582|NCT01632176|Behavioral|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
79553583|NCT01632189|Drug|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
79553584|NCT01632293|Behavioral|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
79553585|NCT01632319|Behavioral|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
79853834|NCT05200403|Drug|Vehicle treatment|The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
79256328|NCT03077828|Drug|Ifosfamide|Given IV
79256329|NCT03077828|Other|Laboratory Biomarker Analysis|Correlative studies
79256330|NCT03077828|Biological|Pembrolizumab|Given IV
79256331|NCT03264495|Other|Weight the food served minus the left-overs|
79256332|NCT02122861|Biological|ID-LV305|pembrolizumab
79717595|NCT06267612|Device|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
79717596|NCT06267599|Procedure|ACAR-Style Bladder Suture|In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
79717597|NCT06267586|Dietary Supplement|PeptiSleep|Plant protein hydrolysate
79256333|NCT04931290|Procedure|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
79553586|NCT01632319|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
79853835|NCT05200403|Device|Accelerometry device for children|Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to <2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
79853836|NCT05200403|Device|Accelerometry device for adult caregivers|Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
79853837|NCT05200117|Device|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
79853838|NCT05195138|Behavioral|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education described in study arm.
79853839|NCT05195138|Behavioral|Standard Diabetes Self-Management Education (DSME)|Standard DSME described in study arm.
79717598|NCT06267586|Dietary Supplement|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
79853840|NCT05193500|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
79853841|NCT05193500|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
79853842|NCT05193149|Behavioral|Inspiratory muscle training|Training of respiratory muscles
79717599|NCT06267573|Device|Fenestrated and branched endovascular devices for TAAA|Devices for TAAA
79717600|NCT06267560|Drug|TQJ230|TQJ230 80mg QM s.c.
79717601|NCT06267560|Drug|Placebo|matching placebo
79853843|NCT05193149|Behavioral|Exercise training|Supervised aerobic exercise intervention
79853844|NCT05192603|Dietary Supplement|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
79553587|NCT01632332|Biological|HER-2/neu peptide vaccine|Given ID
79553588|NCT01632332|Other|laboratory biomarker analysis|Correlative studies
80018261|NCT03528278|Behavioral|Motivational interviewing and environmental interventions|"Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~Training equipment~Motivational Interviewing (MI) techniques applied by staff~Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
79256334|NCT03264183|Diagnostic Test|Transesophageal Echocardiography|TEE measures of right ventricular function
80018262|NCT02121990|Drug|Paclitaxel,|
80018263|NCT02121990|Drug|Bevacizumab|
80018264|NCT02121990|Drug|Cisplatin|
80018265|NCT02121990|Drug|Olaparib|
79256335|NCT03264183|Diagnostic Test|Transthoracic Echocardiography|TTE measures of right ventricular function
79853845|NCT05188807|Diagnostic Test|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
79853846|NCT05185115|Drug|Oxygen|administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
79853847|NCT05185115|Other|no oxygen therapy|No oxygen therapy during hospitalization
79853848|NCT05184621|Other|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
80018266|NCT05724056|Device|Idroflog®|"The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
79256336|NCT02251873|Drug|TPV + RTV (low dose)|
79256337|NCT02251873|Drug|TPV + RTV (high dose)|
79256338|NCT02251873|Drug|ddl|
79256339|NCT02126995|Drug|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
79395677|NCT02337972|Drug|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
79395678|NCT02337894|Dietary Supplement|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
79395679|NCT02337894|Dietary Supplement|Placebo|Flavored drink without essential amino acids plus arginine.
79395680|NCT02337660|Procedure|Liver biopsy|One ultrasound guided liver biopsy
79553589|NCT01632358|Drug|TAP311 capsules|
79553590|NCT01632358|Drug|Placebo|
79553591|NCT01632371|Device|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
79553592|NCT01632371|Device|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
79553593|NCT01632384|Behavioral|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
79853849|NCT05183776|Device|Fractional administration device|The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.
79853850|NCT05178862|Drug|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
79853851|NCT05178862|Drug|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
79717602|NCT06267547|Other|HAIL Online Platform|The HAIL online platform was developed based on feedback from our focus groups with older adults affiliated with BMA churches (conducted per IRB Protocol 2020P003100). Specifically, the HAIL online platform has a landing page where participants can access the links to the F&S! exercise sessions, complete the exercise log, obtain tips from an exercise instructor, as well as view study announcements. The landing page has a navigation bar on the left to access 1) the study assessments; 2) the F&S! exercise program participant manual; and 3) information on how to contact study staff. The goal of this adjunctive HAIL online platform is to support the continuation of exercise in the follow-up period once the 8-week F&S! exercise program is over. We conducted an open trial (per IRB protocol 2022P001782) to assess the feasibility and acceptability of the HAIL online platform adjunct to the F&S! program, which yielded positive results.
79717603|NCT06267547|Behavioral|Fit and Strong! Program|The Fit and Strong! Program (F&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F&S! exercise program assists older adults to improve strength and functioning.
79717604|NCT06267534|Device|mindfulness-based mobile applications program|Every two days is the same practice sound file, which must be practiced in order, so each sound file will be locked, for example: 9/9, 9/10 listen to the first sound file practice, 9/11, 9/12 listen to the second Practice with two sound files... and so on. After two days, the sound files will be automatically unlocked, and the subjects can continue to practice. The first ten days need to be practiced in order. From the eleventh day, each sound file will be unlocked. You can choose an audio file to practice, and the page will record the time and items of the practice, and you can also use text to record your experience after the practice
79553594|NCT01632397|Behavioral|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
79853852|NCT05178862|Drug|Echinocandin|Intravenous echinocandin
79256340|NCT02457429|Device|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
79256341|NCT02457429|Other|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
79256342|NCT02457429|Other|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
79256343|NCT02401672|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
79256344|NCT05257291|Drug|Melatonin|Supplementation with 1 mg/day of melatonin for 1 year
79256345|NCT03267927|Device|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
79256346|NCT03267927|Device|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
79256347|NCT03267927|Device|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
79256348|NCT04930900|Drug|ARS-1 with URTI|ARS-1
79256349|NCT04930900|Drug|ARS-1 without URTI|ARS-1 without URTI
79256350|NCT03264339|Behavioral|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
79256351|NCT02458209|Biological|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
79256352|NCT02458209|Biological|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
79256353|NCT02458209|Biological|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
79256354|NCT02127151|Drug|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
79256355|NCT03077516|Device|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
79395681|NCT02337660|Other|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
79395682|NCT02335164|Biological|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
79395683|NCT02335164|Biological|Advax1|Delta inulin adjuvant formulation 1
79395684|NCT02335164|Biological|Advax2|Delta inulin adjuvant formulation 2
79395685|NCT00365859|Drug|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
79395686|NCT02337504|Other|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
79395687|NCT02337426|Drug|Dimethyl Fumarate|Given PO
79553595|NCT01632397|Behavioral|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
79553596|NCT01632449|Drug|Test product|Dimethyl Fumarate (BG00012)
79553597|NCT01632449|Drug|Reference product|Dimethyl Fumarate (BG00012)
79395688|NCT02337426|Drug|Temozolomide|Given PO
79717605|NCT06267521|Other|Healthy Minds Program|Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.
79717606|NCT06267521|Other|Sham Meditation Didactic Material|Participants will listen to lessons from the Healthy Minds Program at home for four weeks, which will not include any actual meditation exercises.
79717607|NCT06267521|Device|Sham Stimulation in Lab|On two nights each week during the four weeks of the intervention, participants will sleep in the lab and undergo sham TES-TI stimulation for approximately 10 hours per night
79717608|NCT06267521|Device|Stimulation in Lab|Participants will sleep in the lab and undergo active TES-TI stimulation for approximately 10 hours per night.
79717609|NCT06267521|Device|MRI Scanner|Imaging protocol will include: structural T1-weighted and T2-weighted images, resting-state functional MRI, task-based functional MRI, and multi-shell diffusion weighted MRI, total scan time will be approximately 2 hours
79853853|NCT05171153|Other|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
79717610|NCT06267508|Procedure|Maternal HIV viral load testing at delivery for VHT risk assessment|Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
79717611|NCT06267495|Procedure|Epithelium-on corneal cross-linking (epi-on CXL)|In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
79717612|NCT06267482|Procedure|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
79853854|NCT05171153|Other|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
79853855|NCT05171153|Other|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
79853856|NCT05165888|Behavioral|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
79853857|NCT05165888|Behavioral|Communication skills training|Training to improve communication skills between physicians and caregivers.
79853858|NCT05163353|Device|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
79853859|NCT05162664|Other|Pressure pain thresholds|PPT will be performed firstly at the anterior tibial muscle halfway between the most superior attachment to the tibia and its tendon in the upper one third of the muscle belly (13) and secondly at the middle of the temporalis muscle (12), using a digital algometer (Wagner FPX 50) with a 1 cm2 rubber tip. The pressure algometer will apply a perpendicular increasing pressure (1kg/s) at the different test locations until the participant reports the first feeling of pain. The PPT of 4 series of ascending stimulus intensities, with an inter-stimulus interval (ISI) of 20sec between the different stimuli and an ISI of 60sec between the 2 locations, will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated.
79256356|NCT03075800|Behavioral|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
79717613|NCT06267482|Procedure|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
79717614|NCT06267469|Device|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
79256357|NCT02435914|Drug|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
79256358|NCT02435914|Drug|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
79395689|NCT02337426|Radiation|Radiation Therapy|Undergo radiation therapy
79395690|NCT02337582|Other|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
79395691|NCT02337582|Other|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
79395692|NCT01795521|Radiation|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
79395693|NCT01794195|Behavioral|Diffusion tensor imaging and fibres tracking|
79717615|NCT06267443|Procedure|Comparison of erector spina plane block, parasternal block plus local infiltration to the tube sides for postoperative analgesia|"Group 1: erector spina plane block: With USG guidance at the thoracal level of 4-5, with 20ml 2.5% bupivacaine ESPB will be performed. after surgery in the ICU pain score and atelectasia will be evaluated.~Group 2: With USG guidance parasternal block will be performed after intubation bilaterally with 10 ml 0.25% bupivacaine each side. at the end of the surgery infiltration of chest tube sides will be performed with 10 ml 2.5% bupivacain."
79553598|NCT01632462|Drug|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
79717616|NCT06267430|Behavioral|Kleuter Extra training program|The intervention was described in the included arm/group explanation.
79717617|NCT06267417|Device|Laser therapy|- Laser will be applied with the specified wave length using Diode laser (Sirrolaser Blue ™, USA) device over 5 consecutive days from start of chemotherapy cycle beside the standard preventive protocol applied in the hospital
79717618|NCT06267417|Device|Mock treatment|The exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital
79717619|NCT06267391|Device|ReCET Treatment|Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
79717620|NCT06267391|Device|Sham Procedure|The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
79717621|NCT06267378|Other|Frailty measure|"All participants will be asked to complete baseline assessments and a blood test.~30 participants out of the 100 will be selected to wear a digital motion device before their surgery for seven days. (15 participants will be non-frail and 15 patients will be frail).~Where possible, all baseline assessments will be scheduled to coincide with a routine clinic/hospital visit. The first assessment will complete functional, frailty, nutritional, and quality of life questionnaires. A blood test will be taken for baseline tests and metabolomic assessment. Participants who opt into having a digital motion device will also be shown how to use the device and will wear this for seven days. Written instructions to fit the device will also be given."
79717622|NCT06267339|Device|transcranial random noise stimulation|This intervention will give children tRNS during reaching or grasping repetitive movements.
79717623|NCT06267339|Device|Sham stimulation|This intervention will give children sham stimulation during reaching or grasping repetitive movements.
79717624|NCT06267326|Procedure|debridment|resection of dead bone
79717625|NCT06267287|Diagnostic Test|Microbiological examination of the patient's biological material and determination of antibiotic resistance|Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
79717626|NCT06267274|Drug|Bimatoprost Ophthalmic Solution, 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
79717627|NCT06267274|Drug|LUMIGAN® (bimatoprost ophthalmic solution) 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
79717628|NCT06267261|Device|KOLMI® surgical face mask (OP-Air)|12 subjects are exposed to birch pollen allergen in ALYATEC EEC while wearing a KOLMI® surgical face mask (OP-Air)
79717629|NCT06267248|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
79853860|NCT05162664|Other|Thermal detection and pain thresholds|The thermal tests will be performed unilateral at tibial anterior, thenar and the forehead, using a TSA-2 (Neuro Sensory Analyzer, MEDOC). At first cold and heat detection thresholds will be measured. The patient will be asked to indicate when they feel a change in temperature. Afterwards the patient will be asked to indicate when the stimulus becomes painful to determine the cold and heat pain thresholds. The thresholds of 4 series of stimuli will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated for every location. The subject will push a button when the thresholds are reached. The baseline temperature will be 32°C and the stimuli will increase with 1°C/s (14).
79875402|NCT00490490|Procedure|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
80031479|NCT04890418|Drug|Ketalar, 5 mg/mL Injectable Solution|The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
79717630|NCT06267235|Other|Dietary protein restriction|The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
79717631|NCT06267222|Device|TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises|Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
79853861|NCT05162664|Other|Temporal summation|The temporal summation will be assessed at the thenar eminence (19,20) using a ramp and hold protocol with the TSA-2 (Neuro Sensory Analyzer, MEDOC). Heat stimuli will be applied for a duration of 15sec. The stimulus temperature will increase from a baseline temperature of 35°C for 9sec at a sensitivity-adjusted rate of about 1,5°C/s until the HTP 5/10 of the thenar is reached. Afterwards the temperature will remain steady for the next 6 seconds. The maximal pain rating should be 50 ± 10 NRS. Subjects rate the pain intensity at the end of the ramp (9sec) and at the end of the hold procedure (15sec) using the NRS. Afterwards the ramp and hold aftersensations are measured. The subjects have to rate the pain intensity every 5sec for 30sec after the termination of the heat stimulus.
79553599|NCT01632475|Biological|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10^7 cells/kg, High Dose Group (6 patients): 2 x 10^7 cells/kg~* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
79553600|NCT01632501|Device|Coronary stent - Tsunami|A coronary angioplasty was done
79875403|NCT00490490|Drug|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~Lugol's solution 20 drops orally 3-times-a-day, OR~KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
79395694|NCT02334930|Other|Biopsy|
79717632|NCT06267209|Other|Observational group|"After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
79717633|NCT06267196|Other|The use of a stress ball|The effect of the stress ball used during spinal anesthesia on pain and anxiety
79717634|NCT06267183|Drug|SV001|SV001 ： single-dose
79717635|NCT06267183|Drug|Placebo|Placebo ： single-dose
79256359|NCT03273699|Device|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
79256360|NCT02124343|Other|Interval Exercise|
79256361|NCT03077282|Drug|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
79717636|NCT06267170|Drug|Adebrelimab|Treatment with adbelizumab
79256362|NCT02457273|Drug|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
79256363|NCT03551275|Biological|BCD-132|Dose Escalation Study
79256364|NCT03077126|Other|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
79395695|NCT04271319|Device|BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device|"Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
79553601|NCT01632514|Drug|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
79553602|NCT01632527|Drug|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
79553603|NCT01632540|Drug|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
79256365|NCT03077126|Device|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
79256366|NCT03077126|Diagnostic Test|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
79256367|NCT03077126|Procedure|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
79395696|NCT04271319|Device|Sham PRO-SPORT Ultra® Device|"Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications."
79395697|NCT02330016|Device|Voluma XC|Voluma XC
79553604|NCT01632592|Drug|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
79553605|NCT01632592|Drug|Placebo|placebo given by injection 2mg subcutaneously daily
79553606|NCT01632605|Drug|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
79553607|NCT01632618|Behavioral|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
79717637|NCT06267157|Device|virtual reality training|Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.
79717638|NCT06267157|Other|theoretical breastfeeding training|Classic 2-hour theoretical breastfeeding training with ppt
79553608|NCT01632618|Behavioral|Passive control intervention|Passive physical therapy approach to low back pain
79853862|NCT05162664|Other|Conditioned pain modulation|CPM will be assessed by comparing heat pain thresholds and pressure pain thresholds before and after giving a conditioning stimulus at a pain free distant zone by using a second thermode of the TSA-2 (17). The conditioning stimulus (HPT 4/10 (18) at the TA) will be applied for 120 seconds. The first test stimulus will be applied at the forehead 30 seconds after the start of the conditioning stimulus (17). The HPT will be measured twice with an ISI of 20 seconds. Immediately after the end of the application of the conditioning stimulus (120 seconds), the HPT at the forehead will be measured again twice, with an ISI of 20 seconds. Afterwards, there will be 10 minutes of rest to avoid bias.
79853863|NCT05162508|Other|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
79256368|NCT03264105|Other|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
79256369|NCT03264105|Other|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
79553609|NCT01632670|Other|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
79256370|NCT02127229|Procedure|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
79256371|NCT04993040|Drug|Oraxol|"HM30181 methanesulfonate monohydrate~Oral paclitaxel capsules"
79553610|NCT01632696|Drug|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
79553611|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
79553612|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
79553613|NCT01632748|Device|Neurotech Vital Device|5 minute treatment
79553614|NCT01632748|Device|Modified Neurotech Vital Device|5 minute stimulation
79553615|NCT01632761|Dietary Supplement|Vitamin D3 .|
79553616|NCT01632761|Drug|omega-3 fatty acids (fish oil)|
79553617|NCT01632761|Dietary Supplement|Vitamin D3 placebo|
79553618|NCT01632761|Dietary Supplement|Fish oil placebo|
79553619|NCT01632787|Other|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
79553620|NCT01632826|Drug|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
80031480|NCT04890418|Other|Placebo|The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
79256372|NCT03072992|Drug|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
79256373|NCT03072992|Drug|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
79256374|NCT03072992|Drug|Placebo|Placebo i.v. solution, once weekly for 12 weeks
79256375|NCT04992806|Procedure|hip arthroscopy|Use epidural anesthesia or general anesthesia. The patient lies on the orthopedic traction bed to protect the perineum and perform traction of the lower limbs on the surgical side. Under arthroscopy, check the labrum, acetabular articular surface and femoral head cartilage, and round ligament in turn. The acetabular labrum with tear degeneration was treated with labrum suture or labrum revision surgery according to the injury. Perform femoral head and neck plastic or acetabular plastic surgery, osteoid osteoma debridement, etc.
79553621|NCT01632852|Biological|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
79553622|NCT01632865|Device|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
79553623|NCT01632917|Drug|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
79553624|NCT01632917|Drug|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
79875404|NCT04431830|Behavioral|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
79875405|NCT04420364|Other|Maintenance or reduction of immunosuppression|Maintenance versus reduction of immunosuppression
80031481|NCT04890184|Dietary Supplement|grape juice|grape juice
80031482|NCT04890184|Other|control|no intervention
79256376|NCT03267771|Drug|Progesterone Suppositories Vaginal|progesterone vaginal suppository
79256377|NCT03267771|Drug|Dydrogesterone Oral Tablet|oral progesterone drug
79256378|NCT03267771|Device|doppler ultrasound|pulsed doppler ultrasound
79256379|NCT04992962|Drug|CBD/CBN|A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
79256380|NCT04992962|Drug|CBD/THC|A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
79256381|NCT04992962|Drug|Placebo|An inactive compound.
79256382|NCT03267693|Diagnostic Test|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
79717639|NCT06267144|Drug|Sintilimab plus chemotherapy|"Sintilimab: 200 mg via intravenous infusion on Day 1 of each 21-day cycle for 2-3 cycles in the neoadjuvant therapy and the maintenance therapy.~Chemotherapy drugs: carboplatin/cisplatin+Pemetrexed/gemcitabine/albuminpaclitaxel.~Carboplatin: AUC 5 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Pemetrexed: 500mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Gemcitabine:1.0g/m2 via intravenous infusion in day1 and day8, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly. Albuminpaclitaxel: 260 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly."
79717640|NCT06267131|Device|Brain Pulse Oximeter|Sensor is placed on the right and/or left forehead and maintained with an elasticized headband. The duration of monitoring will last for approximately 60 minutes per monitoring session to obtain sufficient data. Serial monitoring will occur on three consecutive days.
79717641|NCT06267118|Drug|Hypertonic Saline Solution, 1 Ml|Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
79717642|NCT06267118|Drug|Adrenaline|dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
79553625|NCT01632943|Device|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
79717643|NCT06267105|Procedure|Longitudinal incision|Incision performed longitudinally
79717644|NCT06267105|Procedure|Transverse incision|Incision performed transversally
79853864|NCT05157438|Behavioral|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
79853865|NCT05157438|Behavioral|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
79853866|NCT05155449|Dietary Supplement|Probiotics|Capsule
79553626|NCT01632969|Behavioral|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
79553627|NCT01632982|Behavioral|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
79553628|NCT01632982|Behavioral|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
79553629|NCT01632982|Behavioral|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
79717648|NCT06267079|Other|core stability exercise|Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
79853867|NCT05155449|Dietary Supplement|Placebo|Capsule
79853868|NCT05152147|Drug|Zanidatamab|Administered IV
79853869|NCT05152147|Drug|Tislelizumab|Administered IV
79853870|NCT05152147|Drug|Trastuzumab|Administered intravenously (IV)
79853871|NCT05152147|Drug|Capecitabine|Administered orally (PO bid)
79853872|NCT05152147|Drug|Oxaliplatin|Administered IV
79717649|NCT06267066|Drug|Betamethasone Valerate 0.1% Cream|Moderate potency
79853873|NCT05152147|Drug|Cisplatin|Administered IV
79853874|NCT05152147|Drug|5-Fluorouracil|Administered IV
79853875|NCT05143567|Other|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
79853876|NCT05143567|Other|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
79853877|NCT05143567|Other|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
79853878|NCT05139563|Other|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
79256383|NCT02131207|Device|magnetic resonance imaging|Undergo pelvic MRI
79395698|NCT02329938|Procedure|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
79717650|NCT06267066|Device|SmartXide® fractional carbon dioxide laser|Ablative
79717651|NCT06267066|Drug|Vaseline Topical Product|Emollient
79717652|NCT06267053|Diagnostic Test|Direct digital radiography|All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis
79717653|NCT06267053|Diagnostic Test|25-OH Vitamin D|All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis
79553630|NCT01633008|Behavioral|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
79717654|NCT06267053|Diagnostic Test|Vitamin B12|All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis
79717655|NCT06267053|Diagnostic Test|Folic acid|All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
79717656|NCT06267027|Behavioral|Exercise|The aim of exercise therapy is to stretch and strengthen the wrist extensor and flexor muscles. All study groups were given a home exercise program including stretching and eccentric strengthening exercises. The patient was instructed to start with stretching, and the patient was informed to stretch for 30s by flexing the wrist with the other hand while the shoulder was flexed 90 degrees, the elbow was in extension and the forearm was pronated. When stretching exercises could be performed painlessly, the patient was instructed to move on to strengthening exercises. Eccentric strengthening exercises for wrist extensors and flexors were explained with a support under the forearm and each patient was given a written program supported with visuals. It was emphasized that the exercises should be performed within the pain limit and patients were told to stop if they had severe pain. The exercise program was told to be performed 2 times a day, in 3 sets, 10 repetitions.
79853879|NCT05139563|Other|Placebo implant|placebo subdermal implant rod
79853880|NCT05138549|Drug|Astaxanthin|12 mg oral astaxanthin supplement
79853881|NCT05138549|Other|Placebo|Oral placebo identical to astaxanthin supplement
80031483|NCT03051802|Device|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
80031484|NCT04905238|Device|Continuous positive airway pressure|Continuous positive airway pressure
79256384|NCT02131207|Procedure|prostate biopsy|Undergo prostate biopsy
79256385|NCT03267537|Behavioral|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
79256386|NCT03267537|Behavioral|Conventional office-based CBT-I|Conventional office-based CBT-I
79256387|NCT03072836|Other|analysing microbiota|16SRNA gene sequencing of feces
79256388|NCT03550651|Other|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
79395699|NCT02329938|Procedure|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
79395700|NCT00406107|Drug|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
79395701|NCT02335008|Dietary Supplement|Sucralose|2 packets per 12 fl oz
79395702|NCT02335008|Dietary Supplement|Sucrose|equisweet to sucralose
79553631|NCT01633047|Other|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
79553632|NCT01633047|Other|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
79553633|NCT01633073|Device|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
79553634|NCT01633073|Device|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
79553635|NCT01633086|Drug|nitric oxide gel|"st gel: sodium nitrites,BID local use X 28 days~nd gel: maleic/ascorbic acids ,BID local use X 28 days"
79553636|NCT01633086|Drug|placebo gel|placebo gel,BID local use X 28 days
79553637|NCT01633099|Drug|Decitabine|"Number of Cycles: 4 cycles.~Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle)."
79553638|NCT01633125|Other|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
79553639|NCT01633138|Behavioral|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
79553640|NCT01633138|Behavioral|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
79553641|NCT01633164|Behavioral|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
79256389|NCT03550651|Other|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
79256390|NCT03550651|Other|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
79717657|NCT06267027|Device|Kinesiotaping|Area where the tape would be applied was clean and dry. If there is excessive hair in the application area, patients were asked to shave this area. It was explained that cream and similar substances should not be used. Muscle inhibition technique and fascia correction technique were used as the application technique. An X strip of approximately 25 cm and a Y strip of 10 cm in length are prepared as long as the distance between the lateral epicondyle and the wrist. The short arms of the X strip are adhered to the dorsal side of the hand without stretching and the crossed part of the strip is placed on the wrist with maximal stretching. The long arms of the X strip are adhered along the extensor carpi ulnaris and extensor carpi radialis to the lateral epicondyle without stretching. The Y strip was applied using the fascia correction method. The tails of the Y band were applied using an oscillating motion. The taping procedure was applied 2 times a week for 3 weeks for a total of 6 times.
79553642|NCT01633164|Other|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
79717658|NCT06267027|Device|High intensity laser therapy|The elbow area was marked and then the epicondylitis protocol was selected. The epicondylitis protocol consists of 3 phases. Phase 1 and 2 consist of analgesic treatment and phase 3 consists of anti-inflammatory treatment. In phase 1 and phase 2 treatment protocol, 8 W was applied to a circular area with a radius of 1.0 cm for 3 min. In Phase 3 protocol, a dose of 80 J/cm2 at 8 W power was applied and the patient's treatment was completed.
79717659|NCT06267014|Behavioral|Virtual Reality sessions|One session during 10-15 minutes per week for 6 weeks.
79717660|NCT06267001|Drug|Atezolizumab|Atezolizumab will be administered IV.
79717661|NCT06267001|Drug|Tiragolumab|Tiragolumab will be administered IV.
79717662|NCT06267001|Drug|Placebo|Placebo will be administered IV.
79717663|NCT06266988|Drug|Sacubitril and Valsartan Tablets 97mg/103mg|Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan
79853882|NCT05137743|Behavioral|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
79256391|NCT03550651|Other|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
79256392|NCT03550651|Other|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
79256393|NCT02456961|Procedure|iontophoresis of riboflavin|
79256394|NCT02456961|Procedure|epithelium-off|
79256395|NCT02456961|Procedure|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
79395703|NCT02329782|Behavioral|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
79395704|NCT04290351|Procedure|band ligation|"Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
79395705|NCT04290351|Drug|oral 450 mg diosmin+50 mg hesperidin|"450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
79395706|NCT02334774|Procedure|Swallowing and Oral Care Program|An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
79395707|NCT02327520|Other|Colitis with CDI treatment|All patients will be treated with standard treatment
79395708|NCT00407355|Drug|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
79395709|NCT00407355|Drug|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
79395710|NCT02327208|Dietary Supplement|Control|
79395711|NCT02327208|Dietary Supplement|Protein|
79395712|NCT02327208|Dietary Supplement|Carbohydrate|
79395713|NCT02334540|Dietary Supplement|purses|food intake
79256396|NCT02456961|Device|galvanizator, Potok-1|Device for providing iontophoresis procedure
79553643|NCT01633203|Drug|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
79553644|NCT01633216|Biological|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
79553645|NCT01633216|Biological|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
79553646|NCT01633216|Biological|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
79553647|NCT01633216|Biological|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
79553648|NCT01633216|Biological|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
79553649|NCT01633229|Procedure|Bone Marrow Stromal Cell Infusion|
79553650|NCT01633255|Drug|18F-Fluciclatide|
79553651|NCT01633281|Procedure|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
79553652|NCT01633294|Drug|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
79553653|NCT01633307|Other|Education|Teaching program
79717664|NCT06266988|Drug|Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)|Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
79256397|NCT02456961|Drug|Dextralink|Riboflavin 0,1% + Dextran T-500
79256398|NCT02456961|Drug|Riboflavin 0,1%|
79256399|NCT02456961|Device|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
79256400|NCT03075956|Drug|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
79256401|NCT03075956|Drug|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
79256402|NCT03075956|Drug|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
79256403|NCT03075956|Drug|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
79256404|NCT03551197|Drug|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
79395714|NCT02334540|Dietary Supplement|a calorie/protein matched smoothie|
79395715|NCT02334462|Biological|Pfs230D1M-EPA/Alhydrogel|
79553654|NCT01633333|Other|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
79553655|NCT01633333|Other|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
79553656|NCT01633359|Drug|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
79553657|NCT01633359|Drug|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
79553658|NCT01633437|Drug|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
79395716|NCT02334462|Biological|Pfs25M-EPA/Alhydrogel|
79395717|NCT02334462|Drug|TWINRIX|
79395718|NCT02334462|Drug|Menactra|
79395719|NCT02110485|Other|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
79553659|NCT01633437|Other|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
79553660|NCT01633450|Other|Zinc biofortified rice|1.12 mg zinc per meal
79553661|NCT01633450|Other|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
79553662|NCT01633476|Drug|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
79717665|NCT06266975|Device|Biobsy from kidney|using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
79717666|NCT06266962|Drug|1% Atropine drops|Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.
79717667|NCT06266962|Drug|Epinephrine|Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
79717668|NCT06266949|Diagnostic Test|SONDA|Perimetry based visualfield analysis
79717669|NCT06266936|Other|No intervention|The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
79717670|NCT06266923|Drug|SPH6516 tablets|SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
79256405|NCT03072914|Procedure|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
79717671|NCT06266910|Other|Visual training video|"The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment."
79717672|NCT06266884|Other|Kangaroo care|Kangaroo care is a safe and effective method in which the baby is placed in an upright position on the parent's bare chest, wearing only a diaper and a hat, and the baby's needs for nutrition, warmth, love and trust are met and provides positive interaction between the parent and the baby.
79256406|NCT02456883|Drug|gilteritinib|oral
79717673|NCT06266871|Drug|SOX+Tislelizumab+LDRT|"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
79717674|NCT06266858|Other|rehydration|The fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
79256407|NCT02456883|Drug|14C-labeled gilteritinib|oral
79256408|NCT02786953|Behavioral|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
79717675|NCT06266858|Diagnostic Test|UCG|UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
79717676|NCT06266858|Diagnostic Test|CMR|CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
79717677|NCT06266858|Other|fasting|At the beginning of the study, the patients need to fast when receive UCG.
79717678|NCT06266845|Behavioral|In-person Escape Room|The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.
79717679|NCT06266845|Behavioral|Virtual Escape-Room|The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
79717680|NCT06266832|Drug|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
79717681|NCT06266832|Drug|Oxaliplatin|130mg/m2, ivgtt, d1, Q3W
79717682|NCT06266832|Drug|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W
79717683|NCT06266832|Radiation|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
79717684|NCT06266832|Procedure|Biopsy|local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
79717685|NCT06266819|Other|chewing gum|In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
79853883|NCT05137743|Behavioral|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
79853884|NCT05135377|Other|Observational|Not applicable - observational study
79853885|NCT05130593|Dietary Supplement|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
80031485|NCT04349150|Device|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
79256409|NCT02435836|Drug|Aripiprazole|
79256410|NCT02457117|Radiation|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
79256411|NCT05004818|Procedure|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
79256412|NCT05004818|Procedure|Sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
79256413|NCT03075488|Device|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
79256414|NCT03075488|Procedure|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
79553663|NCT01633515|Procedure|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
79553664|NCT01633528|Drug|Asprin|100 mg
79553665|NCT01633528|Drug|placebo|100mg
79553666|NCT01633567|Behavioral|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
79553667|NCT01633567|Behavioral|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
79553668|NCT01633580|Drug|corifollitropin alfa|long acting FSH
79553669|NCT01633593|Drug|Donepezil|5 mg PO a day, during 2 weeks
79553670|NCT01633632|Behavioral|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
79553671|NCT01633632|Behavioral|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
79553672|NCT01633645|Drug|Bortezomib|Velcade
79553673|NCT01633645|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
79553674|NCT01633645|Drug|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
79553675|NCT01633658|Dietary Supplement|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
79553676|NCT01633658|Dietary Supplement|25(OH)D|a single dose of 625 micrograms of 25(OH)D
79717686|NCT06266780|Behavioral|PROMPTS Enhanced Family Planning Counselling|Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
79717687|NCT06266767|Drug|Levobupivacaine and Fentanyl|Programmed Intermittent Epidural Bolus
79717688|NCT06266754|Biological|Oral polio vaccine|Standard oral polio vaccine
79717689|NCT06266754|Other|Placebo|Saline 0.9%
79717690|NCT06266741|Diagnostic Test|Lubricin|Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
79717691|NCT06266650|Other|Osteopathic Treatment Technique- Muscle Energy Treatment|Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
79717692|NCT06266598|Drug|Metformin|Only obese children with insulin resistance were treated with metformin.
79717693|NCT06265896|Other|Kinesio taping|Tape will be applied on rectus abdominis muscles using muscles facilitation technique from origin to insertion of muscle with a tension between 15-35%. Band will start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xiphoid process. Tape will be applied on the right and left external oblique muscles; the procedure will start without tension from bottom and of 6-12 ribs, then the hip will be placed in flexion and rotation to opposite direction and the tape will be attached to pubic bone with tension between 15-35%. Finally, the tape will be performed on the right and left internal oblique muscles; the procedure will start without tension from anterior superior iliac spine and then the hip will be placed in extension position and the tape will be attached to lower 4 ribs and linea alba with tension between 15-35%.
79875406|NCT01014884|Other|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
79875407|NCT01014884|Other|Multidisciplinary team bimonthly visits either in person or via telephone.|
79256415|NCT02127463|Drug|MC-1101|Topically, two times a day, morning and bedtime
79256416|NCT02127463|Drug|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
79256417|NCT03075722|Device|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
79553677|NCT01633697|Behavioral|Pranayama|Specific yoga-related breathing method.
79553678|NCT01633697|Behavioral|Education alone|No special attention to breathing
79553679|NCT01633723|Drug|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
79553680|NCT01633723|Drug|Placebo of DA-6886|DA-6886 placebo
79875408|NCT01014884|Other|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
80018267|NCT05724056|Device|Sodium Hyaluronate 0.18% (Vismed®)|"The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
80018268|NCT05131360|Behavioral|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
80018269|NCT05131360|Behavioral|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
79553681|NCT01633736|Other|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
79553682|NCT01633749|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
79553683|NCT01633762|Drug|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
79553684|NCT01633775|Procedure|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
79717694|NCT06265896|Other|Pelvic floor exercise training|The intervention will be applied by a trained physical therapist. First of all, each participant will be instructed to relax thighs, bottom and abdomen musculature, then squeeze pelvic floor muscles 'focus on tightening without flexing abdomen, thighs or buttocks- avoid holding breath' 10 repetitions, 3 to 5 times a day (morning, afternoon, and night). Rest for 4 seconds and then repeat each contraction. Build up pelvic floor musculatures strength until each participant be able to do 10 slow contractions each time, holding them for 10 seconds each with rests of 4 seconds in between. Then do not hold your breath or tighten your stomach, bottom or thigh muscles at the same time. Will instruct participants to try holding each squeeze for a few seconds.
79717695|NCT06265870|Drug|Albendazole|Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days
79717696|NCT06265870|Drug|Ivermectin or albendazole|Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
79256418|NCT05075265|Drug|Methadone|Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
79256419|NCT02127541|Other|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
79717697|NCT06265376|Behavioral|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
79717698|NCT06265129|Diagnostic Test|Complete blood picture (done in the morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)|morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)
79717699|NCT06264557|Device|SB-100|"Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.~It consists of cognitive training and educational videos."
79717700|NCT06264557|Other|Educational book|Book of education on daily rules for preventing dementia
79717701|NCT06264414|Drug|DTT106|oral route
79875409|NCT01011140|Behavioral|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
79875410|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
79875411|NCT01014962|Drug|Placebo|Placebo oral once daily for 5 days
79875412|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
79875413|NCT01014962|Drug|Placebo|Placebo oral every 12 hours for 5 days
79875414|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
79875415|NCT01014962|Drug|Placebo|Placebo oral every 8 hours for 5 days
79875416|NCT05058248|Procedure|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
79875417|NCT05049980|Drug|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
79875418|NCT05049980|Procedure|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
79875419|NCT01039779|Behavioral|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
79875420|NCT01016522|Dietary Supplement|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
79875421|NCT00385593|Drug|Symbicort (budesonide/formoterol) Turbuhaler|
79875422|NCT00385593|Drug|Conventional treatment|
79875423|NCT01015040|Drug|solifenacin succinate suspension|Oral
79875424|NCT01015040|Drug|solifenacin succinate tablet|Oral
79875425|NCT04388618|Other|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
80018270|NCT05131360|Behavioral|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
79717702|NCT06264414|Drug|Dutasteride-Tamsulosin|oral route
79853886|NCT05127603|Behavioral|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
79395720|NCT03144882|Drug|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
79395721|NCT03144882|Drug|Placebo|placebo
79553685|NCT01633801|Device|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
79717703|NCT06264310|Drug|Placebo|Matching placebo SC injection
79717704|NCT06264310|Drug|R2R01|Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
79553686|NCT01633801|Device|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
79553687|NCT01633840|Other|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
79553688|NCT01633840|Other|Elemental E028|Elemental E028 with no added food allergens
79553689|NCT01633879|Behavioral|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
79717705|NCT06264271|Behavioral|structured nutrition intervention|Structured nutrition education on carbohydrate counting and flexible insulin dosing by qualified nutritionist.
79717707|NCT06263816|Drug|Experimental group: Patients will be treated with carvedilol.|Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
79717708|NCT06263816|Other|Control group: Patients will receive a placebo.|Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
79717709|NCT06263751|Other|Product prescription program- NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F&V shopping. The Rewards credit can be used either through the Schnucks App or in store.
79853887|NCT05122078|Device|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
79853888|NCT05122078|Other|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
79875426|NCT01039857|Behavioral|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
79395722|NCT01793259|Drug|methotrexate prefilled pen|
79717710|NCT06263751|Other|Product prescription program- NutriConnect Delivery|Patient receives produce (F&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
79717711|NCT06263088|Other|EQUITY GI|"Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."
80018271|NCT05131360|Behavioral|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
80018272|NCT05131360|Behavioral|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
79717712|NCT06262984|Other|Therapeutic Play|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
79717713|NCT06262919|Drug|Tafinlar/Mekinist|There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
79717714|NCT06262867|Dietary Supplement|Ready. Set. Food! Stage 1 Mix ins|These supplements contain cow's milk, eggs, and peanuts.
79717715|NCT06262165|Other|Patients with Anorexia Nervosa|Patients with Anorexia Nervosa hospitalized for malnutrition
79395723|NCT01793259|Drug|methotrexate prefilled syringe|
79395724|NCT02329548|Other|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
79395725|NCT04210245|Biological|aldafermin|aldafermin
79553690|NCT01633879|Behavioral|health and success parent and school|Parenting education and school intervention
79553691|NCT01633918|Behavioral|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
79717716|NCT06261632|Other|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will include performing squats and knee extension for 5-10 and 10 minutes respectively. In both exercises, 4 series will be performed (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
79717717|NCT06261593|Other|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
79717718|NCT06261411|Diagnostic Test|Lung Ultrasound|Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
79717719|NCT06260852|Diagnostic Test|Diagnostic Test: Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity & Reading Test (DDART).
79717720|NCT06257238|Device|Fully immersive Head-Mounted Display Virtual Reality|patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
79717721|NCT06257238|Behavioral|Traditional Physical Therapy Program|patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
79853889|NCT05106595|Device|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
79395726|NCT04210245|Other|Placebo|Placebo for aldafermin
79553692|NCT01633918|Behavioral|Usual health education|Usual health education lessons
79553693|NCT01633957|Other|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
79553694|NCT01633957|Other|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
79553695|NCT01633970|Drug|5-FU|Participants will receive 5-FU 400 mg/m^2 IV q2w.
79717722|NCT06257212|Drug|BCG vaccine (Danish strain 1331)|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
79717723|NCT06257212|Drug|MMR Vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
79717724|NCT06257212|Drug|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
79717725|NCT06255756|Behavioral|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
79853890|NCT05106387|Other|Noninterventional|No investigational treatment will be given in this noninterventional extension study
79853891|NCT05091190|Other|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
79853892|NCT05084378|Drug|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
79853893|NCT05084378|Drug|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
79853894|NCT05084378|Drug|Topical Antibiotic|2 grams Vancomycin powder
79853895|NCT05084378|Drug|Saline Lavage Solution|1 litre of sterile isotonic saline
79853896|NCT05077072|Other|Best Practice|Receive SOC
79853897|NCT05077072|Other|Counseling|Participate in CHAT counseling intervention
79853898|NCT05077072|Procedure|Electroencephalography|Undergo EEG
79853899|NCT05077072|Behavioral|Neurofeedback|Undergo NFB intervention
79853900|NCT05077072|Other|Questionnaire Administration|Ancillary studies
79853901|NCT05076630|Other|Air pollutants|Particulate matter and gaseous pollutants
79853902|NCT05074498|Drug|TB006|intravenous infusion
79853903|NCT05074498|Drug|Placebo|intravenous infusion
79395727|NCT02329626|Device|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
79395728|NCT02334228|Behavioral|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
79395729|NCT02334228|Behavioral|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
79553696|NCT01633970|Drug|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
79553697|NCT01633970|Drug|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
79553698|NCT01633970|Drug|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
79553699|NCT01633970|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV q2w.
79553700|NCT01633970|Drug|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m^2 IV qw.
79553701|NCT01633970|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV q2w.
79553702|NCT01633970|Drug|Paclitaxel|Participants will receive paclitaxel 200 mg/m^2 IV q3w.
79553703|NCT01633970|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV q3w.
79553704|NCT01633983|Drug|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
79553705|NCT01633983|Drug|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
79553706|NCT01633996|Procedure|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
79553707|NCT01634009|Dietary Supplement|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
79553708|NCT01634022|Procedure|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
79553709|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
79553710|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
79853904|NCT05073926|Other|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
79875427|NCT01039857|Behavioral|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
79553711|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
79553712|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
79553713|NCT01634126|Behavioral|1 FIT kit|Patient receives 1 FIT
79553714|NCT01634126|Behavioral|2 FIT kit|Patient receives 2 FIT kits
79553715|NCT01634204|Other|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
79553716|NCT01634204|Other|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
79553717|NCT01634217|Biological|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
79553718|NCT01634230|Drug|OCR-002|daily dose: 10 g infused over 24 hours
79553719|NCT01634282|Drug|OPC-262|Orally administered once daily
79553720|NCT01634295|Drug|CKD-828 2.5/40mg|"Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~With the others investigation product placebo 4 tabs QD 2 weeks."
79553721|NCT01634295|Drug|CKD-828 5/40mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~With the others investigation product placebo 4 tabs QD 2 weeks."
79553722|NCT01634295|Drug|CKD-828 5/80mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~With the others investigation product placebo 4 tabs QD 6 weeks."
79553723|NCT01634295|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 4 weeks~With the others investigation product placebo 4 tabs QD 4 weeks."
79553724|NCT01634295|Drug|S-amlodipine 5mg|"S-amlodipine 2.5mg QD 6weeks~With the others investigation product placebo 4 tabs QD 6 weeks."
79553725|NCT01634308|Drug|Novosis(bongros/BMP-2)|
79553726|NCT01634308|Drug|Bio-oss|
79553727|NCT01634321|Drug|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
79553728|NCT01634334|Behavioral|Real-Time Intervention|Lights and Sound Brief Coaching
79553729|NCT01634334|Behavioral|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
79553730|NCT01634347|Drug|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
79553731|NCT01634347|Drug|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
79553732|NCT01634373|Drug|Torrent's Quetiapine Fumarate Tablets|
79553733|NCT01634386|Drug|Torrent's Quetiapine Fumarate Tablets|
79553734|NCT01634399|Drug|Torrent's Quetiapine Fumarate Tablets|
79553735|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
79553736|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
79553737|NCT01634412|Drug|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
79553738|NCT01634412|Drug|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
79553739|NCT01634425|Device|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
79553740|NCT01634438|Drug|unfractionated heparin|unfractionated heparin
80018273|NCT05131360|Behavioral|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
79717726|NCT06255756|Behavioral|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
79553741|NCT01634451|Other|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
79717727|NCT06255756|Procedure|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
79717728|NCT06254534|Diagnostic Test|optic nerve ultrasonography|The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.
79717729|NCT06254014|Drug|Exendin-4 Fc fusion protein injection|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
79717730|NCT06254014|Drug|Exendin-4 Fc fusion protein injection|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
79717731|NCT06254014|Drug|Placebo|0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
79717732|NCT06253091|Procedure|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist laparoscopic radical cystectomy was performed extraperitoneal
79717733|NCT06251492|Radiation|Stereotactic body radiotherapy|8 Gray x 3 for 2 cycles
79717734|NCT06251492|Drug|Adebrelimab|Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
79717735|NCT06249711|Device|Active stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused low-intensity ultrasound stimulation
79717736|NCT06249711|Device|Sham stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused zero-intensity ultrasound stimulation
79717737|NCT06249087|Behavioral|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
79717738|NCT06249087|Device|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
79875428|NCT00495794|Behavioral|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
79875429|NCT01011296|Drug|PF-04427429|Single 0.2mg dose of intravenous infusion
79553742|NCT01634451|Other|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
79875430|NCT01011296|Drug|PF-04427429|Single 1mg dose of intravenous infusion
79875431|NCT01011296|Drug|PF-04427429|Single 3 mg dose of intravenous infusion
79875432|NCT00495170|Drug|Carboplatin|2 area under curve (AUC) by vein Weekly
79553743|NCT01634451|Device|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
79553744|NCT01634503|Genetic|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
79553745|NCT01634516|Behavioral|Dietary support|Face to face intervention plus subsequent telephone support
79553746|NCT01634516|Behavioral|No dietary support|No face to face intervention or subsequent telephone support
79553747|NCT01634529|Drug|V158866|Single ascending oral doses of V158866 and Placebo
79553748|NCT01634529|Drug|V158866|Multiple ascending oral doses of V158866 and Placebo
79553749|NCT01632956|Behavioral|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
79717739|NCT06249087|Device|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
79717740|NCT06247800|Device|Virtual Reality Device|A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
79553750|NCT01632956|Behavioral|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
79553751|NCT01634568|Drug|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
79717741|NCT06247800|Other|Without virtual reality|Patients undergoing intercostal chest drain without the use VR device
79717742|NCT06246721|Behavioral|Self-management of vaginal pessary|Self-management of vaginal pessary
79717743|NCT06244550|Drug|Ganwei|Capsules
79717744|NCT06244550|Drug|Metformin|Tablets
79553752|NCT01634594|Drug|Group R|
79553753|NCT01634594|Drug|Group N|
79717745|NCT06244550|Drug|Placebo|Matching capsules
79717746|NCT06242288|Drug|ISOtretinoin 20 MG|Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne
79717747|NCT06241352|Drug|statin addition to chemotherapy|Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels rose more than 20% above baseline.
79717748|NCT06238245|Drug|Cyclophosphamid|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
79717749|NCT06234189|Device|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|30 minutes without DIMS and 30 minutes with DIMS
79717750|NCT06234150|Other|Aerobic dance|Patients assigned to the aerobic dance group will participate in a one-on-one training session before their first chemotherapy session, including aerobic dance instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
79853905|NCT05072821|Drug|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
79853906|NCT05072821|Drug|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
79853907|NCT05067582|Drug|L1-79|tyrosine hydroxylase inhibitor
79553754|NCT01634594|Drug|Group D|
79553755|NCT01634646|Dietary Supplement|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
79553756|NCT01634685|Radiation|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
79553757|NCT01634685|Drug|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
79553758|NCT01634685|Drug|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
79853908|NCT05067166|Drug|Ansuvimab|single infusion 50 mg/kg IV
79853909|NCT05059535|Drug|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
79853910|NCT05053867|Drug|tranexamic acid|Inhaled
79853911|NCT05053867|Other|Usual Care|Standard of Care
79853912|NCT05052268|Drug|XTX202|XTX202 Monotherapy
79853913|NCT05051852|Other|Follow up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
79853914|NCT05048407|Device|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
79853915|NCT05045963|Other|Electronic Health Record Review|Medical record reviewed
79853916|NCT05035420|Device|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
79553759|NCT01634698|Dietary Supplement|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
79853917|NCT05035420|Device|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
79853918|NCT05035420|Device|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
79853919|NCT05035420|Device|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
79853920|NCT05035420|Device|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
79853921|NCT05035420|Device|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
79853922|NCT05031130|Other|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
79553760|NCT01634724|Drug|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
79853923|NCT05029193|Behavioral|Langerian mindfulness|A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
79853924|NCT05026723|Behavioral|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
79853925|NCT05026723|Behavioral|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
79853926|NCT05022511|Behavioral|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
80018274|NCT05131360|Behavioral|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
79853927|NCT05021614|Device|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
79853928|NCT05020574|Drug|Cephalexin|Given orally (PO)
79395730|NCT02329704|Procedure|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
79395731|NCT02329704|Procedure|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
79395732|NCT02329704|Procedure|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
80018275|NCT05131360|Behavioral|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
79395733|NCT02329704|Procedure|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
79553761|NCT01634750|Drug|ManNAc|Single dose
79553762|NCT01634763|Drug|LDK378|
79553763|NCT01634776|Dietary Supplement|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
79553764|NCT01634776|Dietary Supplement|corn oil|
79553765|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
79875433|NCT00495170|Radiation|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
79875434|NCT00495170|Drug|Paclitaxel|50 mg/m^2 by vein Weekly
79875435|NCT03853148|Behavioral|Otago|Exercise program for strength and balance
79875436|NCT03853148|Behavioral|Gentle yogic breathing|yogic breathing
79875437|NCT03853148|Behavioral|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
80018276|NCT02126904|Drug|IVA group|
79553766|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
79553767|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
79553768|NCT01634789|Drug|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
79717751|NCT06234150|Other|Fast-walking|Patients assigned to the fast-walking group will participate in a one-on-one training session before their first chemotherapy session, including fast-walking instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
79717752|NCT06233864|Drug|Disitamab Vedotin|Disitamab Vedotin
80018277|NCT02609737|Device|PET/CT Imaging|
80018278|NCT02609737|Radiation|68Ga-DOTA-JR11|
79553769|NCT01634802|Other|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
79553770|NCT01634802|Other|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
79553771|NCT01634815|Procedure|The Edge|measuring blood lactate
79553772|NCT01634841|Dietary Supplement|Walnuts|30 to 60g (1 to 2 oz) per day of walnuts
79553773|NCT01634841|Other|habitual diet|Dietary information will be provided
79553774|NCT01634880|Drug|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
79553775|NCT01634893|Drug|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
79853929|NCT05018169|Behavioral|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
79853930|NCT05017974|Behavioral|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
80018279|NCT02609737|Radiation|177Lu-DOTA-JR11|
79395734|NCT02329704|Procedure|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
79553776|NCT01634906|Drug|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
79553777|NCT01634919|Device|chronic hepatitis C|acoustic radiation force impulse ultrasonography
79553778|NCT01634932|Other|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
79553779|NCT01634932|Other|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
79395735|NCT02329704|Procedure|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
79717753|NCT06233864|Drug|Gemcitabine|Gemcitabine
79395736|NCT02329704|Biological|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
79853931|NCT05017974|Other|Treatment as Usual|TAU
79853932|NCT05013710|Other|Complete Clinical Interaction|The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)
79853933|NCT05013632|Drug|Antiviral Agents|Antiviral medications indicated for the treatment of mild to severe COVID-19
80018280|NCT05723978|Procedure|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
80018281|NCT01060059|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
80018282|NCT01060059|Drug|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
80018283|NCT02122068|Behavioral|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
80018284|NCT02122068|Behavioral|Relaxation cd|
80018285|NCT04329481|Dietary Supplement|Mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder"
80031486|NCT03051724|Other|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
79717754|NCT06233513|Behavioral|Exp 3 Speaking Task|Participant will sit in front of a computer screen in a quiet room and to produce speech based on what is on the screen. Participant may see real words or nonsense words to read. Investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. This task takes about one hour to complete.
79717755|NCT06230822|Drug|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
79717756|NCT06230575|Procedure|erector spinae block|Erector spinae plane block
79717757|NCT06230575|Procedure|retrolaminar block|Retrolaminar block
79717758|NCT06230575|Procedure|serratus anterior block|Serratus anterior plane block
79717759|NCT06230575|Procedure|pectoral nerve block|Pectoral nerve block
79717760|NCT06230289|Procedure|Transabdominal plane block|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (RedCAP, Ver 6.6.2 Vanderbilt University, Tennessee, USA) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block, while no interventional procedures will be performed on patients in Group C.
79717761|NCT06228924|Genetic|TN-401|TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
79717762|NCT06223841|Drug|IAP0971|IAP0971 should be subcutaneous injected，q3w
79717763|NCT06221735|Diagnostic Test|Cy-TB test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
79717764|NCT06221735|Diagnostic Test|STANDARD F TB-Feron FIA test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
79853934|NCT05013632|Drug|Monoclonal antibody|Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
79553780|NCT01634932|Other|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
79717765|NCT06220370|Other|Observational|There is no clinical intervention as part of this study. Participants will receive treatment as per their clinical treating team.
79717766|NCT06220201|Drug|CC-97540|Specified dose on specified days
79717767|NCT06220201|Drug|Fludarabine|Specified dose on specified days
79717768|NCT06220201|Drug|Cyclophosphamide|Specified dose on specified days
79717769|NCT06210334|Drug|Tislelizumab|Tislelizumab 200mg, iv, d3, q3w
79853935|NCT05009823|Dietary Supplement|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
79717770|NCT06210334|Drug|Lenvatinib|Lenvatinib 8mg (<60kg) or 12mg (≥60kg), po, qd
79717771|NCT06206746|Device|May Health System|The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
79853936|NCT05009823|Dietary Supplement|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
79853937|NCT05009823|Dietary Supplement|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
79853938|NCT05009823|Dietary Supplement|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
80018286|NCT02252094|Device|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
79553781|NCT01634945|Drug|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
79553782|NCT01634945|Dietary Supplement|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
79553783|NCT01634945|Drug|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
79553784|NCT01634945|Dietary Supplement|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
79553785|NCT01634945|Other|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
79553786|NCT01634958|Biological|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
79853939|NCT05009823|Dietary Supplement|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
79853940|NCT05009823|Dietary Supplement|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
79717772|NCT06203587|Radiation|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq [0.05-0.1 mCi]/kg, and was administered as an intravenous push, with a single dose given once.
79553787|NCT01634971|Procedure|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
79553788|NCT01635010|Procedure|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
79553789|NCT01635023|Drug|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
79553790|NCT01635023|Drug|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
79717773|NCT06202612|Drug|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
79717774|NCT06202612|Drug|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
79717775|NCT06202495|Device|Laser and Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
79717776|NCT06202495|Other|Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
79717777|NCT06201728|Other|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
79717778|NCT06195943|Behavioral|Exercise Intervention with use of El-Fit App|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
79717779|NCT06192082|Procedure|The conscious sedation group|The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
79717780|NCT06192082|Procedure|Intravenous general anesthesia group|Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
79717781|NCT06191692|Drug|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
79853941|NCT05009823|Dietary Supplement|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
79717782|NCT06191692|Drug|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
80018287|NCT02252094|Other|Ultra-protective ventilation|Ventilation with </= 3ml/kg predicted body weight
79717783|NCT06191692|Drug|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
79717784|NCT06190561|Drug|PF-07940367|Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
79717785|NCT06190561|Drug|PF-07940367|Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
79853942|NCT05008718|Other|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
79853943|NCT05008718|Other|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
79853944|NCT05005845|Drug|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
79853945|NCT05005845|Drug|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
79853946|NCT05004181|Biological|BNT162b2|Intramuscular (IM)
79853947|NCT05004181|Biological|BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
79853948|NCT05004181|Biological|BNT162b2 (B.1.1.7)|Intramuscular (IM)
79853949|NCT05004181|Biological|BNT162b2 (B.1.617.2)|Intramuscular (IM)
80018288|NCT02252094|Other|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
79853950|NCT05004181|Biological|BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
80031487|NCT04456010|Other|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
79553791|NCT01635023|Drug|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
79553792|NCT01635023|Drug|AZD6244 Dosing Period 4|Treatment B
79553793|NCT01635036|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
79553794|NCT01635075|Behavioral|Exercise|1-mile treadmill walk
79553795|NCT01635075|Behavioral|passive control|20 min inactivity
79553796|NCT01635088|Drug|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
79553797|NCT01635088|Device|KoKo Spirometry|
79717786|NCT06187428|Other|PainSMART-strategy|"Be PainSMART:er is a seven minute long film developed by the research group based on modern pain science and previous qualitative studies.~The film is divided into three sections:~Section 1- Educates that MSKP is a complex protective system that does not reflect the anatomical state of the body and provides reassurance that MSKP is rarely caused by serious pathology.~Section 2- Provides advice on active MSKP coping, such as encouraging work despite some pain, in an attempt to reconceptualise the belief that a painful body part needs to be rested.~Section 3- Aims to prepare patients for a biopsychosocial physiotherapy consultation by encouraging them to reflect on the film's messages.~In addition to the film, the questions posed to the participant at the initial consultation aim to facilitate the discussion around the film and MSKP reflections. Management subsequent to the initial consultation will follow usual management."
79717787|NCT06187428|Other|Usual physiotherapy management|Patients randomised to the control group follow usual MSKP physiotherapy management. Specifically, patients first contact their physiotherapy department online or via telephone and are triaged by a certified physiotherapist and are booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients in the control group receive online data collection questionnaires identical to those of the intervention group at baseline and prior to the consultation, excluding the film and the questions linked to the film. The initial consultation will take place as usual according to the preferences of the physiotherapist. The physiotherapist will pose one question at start of the consultation to acknowledge the completion of control group questionnaires. Management subsequent to the initial consultation will follow usual management.
79717788|NCT06185881|Procedure|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
79717789|NCT06185296|Device|Intelligent telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
79717790|NCT06185296|Device|Telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data
79717791|NCT06185218|Other|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
79717792|NCT06182566|Procedure|Convergent ablation|Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
79553798|NCT01635088|Drug|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
79717793|NCT06182566|Procedure|Catheter ablation|Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
79717794|NCT06176365|Drug|BI 456906|once weekly subcutaneous injection
79717795|NCT06176365|Drug|Placebo matching BI 456906|once weekly subcutaneous injection
79717796|NCT06174961|Drug|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
79717797|NCT06174961|Behavioral|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
79553799|NCT01635088|Device|Oscillometry|
79553800|NCT01635114|Dietary Supplement|resveratrol|150 mg resVida per day for 12 weeks
80018289|NCT04846816|Combination Product|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
80018290|NCT05134090|Device|Ovaian tissue explant|Ovarian tissue explant for cryopreservation of ovarian tissue
79717798|NCT06174961|Behavioral|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
79717799|NCT06174961|Behavioral|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
79553801|NCT01635114|Dietary Supplement|Placebo|Placebo for 12 weeks
79717800|NCT06174961|Behavioral|No exercise|No exercise
79717801|NCT06174467|Behavioral|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
80018291|NCT04318015|Drug|Hydroxychloroquine|All treatment will be administered orally.
79553802|NCT01635127|Drug|Canakinumab|150mg s.c.
79553803|NCT01635127|Drug|Placebo|Constituent of canakinumab
80018292|NCT04318015|Drug|Placebo oral tablet|All placebo will be administered orally
79553804|NCT01635140|Radiation|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
79553805|NCT01635140|Radiation|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
79553806|NCT01635166|Device|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
79553807|NCT01635179|Procedure|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
79553808|NCT01635192|Biological|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
79553809|NCT01635192|Biological|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
79553810|NCT01635205|Procedure|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
79853951|NCT05004181|Other|Observational|No vaccination within 3 months after Visit 1.
79853952|NCT05004077|Drug|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
79256420|NCT05075343|Device|Custom foot orthoses|"3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could."
79553811|NCT01635205|Procedure|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
79553812|NCT01635231|Other|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
79553813|NCT01635257|Other|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
79853953|NCT05003505|Other|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
79553814|NCT01635270|Radiation|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
79553815|NCT01635270|Radiation|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
79553816|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
79553817|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
79717802|NCT06174467|Behavioral|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
79717803|NCT06172894|Drug|APN401|APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
79717804|NCT06170125|Other|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
79717805|NCT06169969|Device|magnetic therapy|Kegel exercises
79717806|NCT06162429|Procedure|Flexible Bronchoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
80018293|NCT02127060|Drug|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
79717807|NCT06162429|Procedure|Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
79717808|NCT06161948|Other|Time-restricted enteral nutrition therapy group|Control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 ~ 08:00, end time: 16:00 ~ 18:00. Enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the ICU, or enteral nutrition is used until 28 days, whichever event occurs first.
79717809|NCT06161948|Other|Continuous enteral nutrition control group|The control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the ICU, or enteral nutrition was used until 28 days, whichever event occurred first.
79256421|NCT03076892|Device|Aktilite® Galderma|preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
79256422|NCT03076892|Device|PHOS ISTOS PDT|preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
79256423|NCT02131285|Other|Sensory training|
79256424|NCT03263871|Dietary Supplement|PTM202|PTM202 given twice daily for 30 days.
79553818|NCT01635296|Drug|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
79553819|NCT01635296|Drug|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
79553820|NCT01635309|Other|Coronary CT Angiogram|pre-operative coronary CTA
79553821|NCT01635322|Device|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
79553822|NCT01635335|Behavioral|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
79717810|NCT06161506|Device|Elidah Device|The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
79717813|NCT06155981|Other|Coke Zero|Coca-Cola Zero Sugar drink will be given.
79717814|NCT06155981|Other|Coke|Coca-Cola drink will be given.
79853954|NCT05003453|Drug|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
79853955|NCT05003453|Drug|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
79853956|NCT05001854|Drug|Fludrocortisone|100 μg every 6 hours of fludrocortisone per os
79853957|NCT05001854|Drug|Placebo|100 μg every 6 hours of placebo per os
79853958|NCT04998487|Drug|LY3471851|Administered SC.
79853959|NCT04997486|Behavioral|Time restricted eating|Participants will be asked consume all meals/snacks during a ~9-h daily eating period (~15-h fasting).
79853960|NCT04991493|Drug|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
79553823|NCT01635348|Behavioral|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
79853961|NCT04991493|Other|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
79256425|NCT03263871|Dietary Supplement|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
79553824|NCT01635348|Behavioral|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
79553825|NCT01635361|Other|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
79553826|NCT01635374|Procedure|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
79553827|NCT01635387|Drug|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
79553828|NCT01635400|Drug|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
79553829|NCT01635413|Behavioral|Exercise Intervention|Undergo strength training classes
79553830|NCT01635413|Behavioral|Exercise Intervention|Undergo tai chi classes
79553831|NCT01635413|Behavioral|Exercise Intervention|Undergo stretching and relaxation classes
79553832|NCT01635413|Other|Questionnaire Administration|Ancillary studies
79717815|NCT06152731|Genetic|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
79553833|NCT01635530|Drug|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
79553834|NCT01635530|Drug|Ceftriaxone|2 g intravenous once a day, three weeks
79553835|NCT01635556|Behavioral|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
79553836|NCT01635582|Other|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
79717816|NCT06149624|Behavioral|upfront advice to walk|Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.
79853962|NCT04989712|Other|Exposure|Participants randomised to one of the three exposures
79853963|NCT04988516|Device|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
79853964|NCT04988516|Other|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
79853965|NCT04986852|Drug|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
79853966|NCT04982406|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
79875438|NCT03853148|Behavioral|Caregiver Gentle yogic breathing|yogic breathing
79875439|NCT01011374|Drug|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
79256426|NCT02131363|Device|Ingrowing Toenail Treatment Kit|detailed in arm description
79256427|NCT03077048|Drug|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
79256428|NCT02131441|Procedure|laparoscopic hepatectomy|
79553837|NCT01635582|Other|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
79553838|NCT01635595|Procedure|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
79875440|NCT00385203|Drug|AZD2171|45 mg oral tablet once daily dose
79717817|NCT06149624|Behavioral|Supervised exercise|The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
79717818|NCT06148935|Drug|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
79717819|NCT06142877|Behavioral|Social Media Use Reduction|Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
79553839|NCT01635595|Procedure|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
79717820|NCT06142825|Other|Community-Facility Transfusion Committee (CFTC)|Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
79717821|NCT06139328|Drug|BI 765845|BI 765845
79717822|NCT06139328|Drug|Placebo matching BI 765845|Placebo matching BI 765845
79717823|NCT06137469|Drug|Acetaminophen/SHR20004|SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
79553840|NCT01635608|Drug|Acetaminophen|administration of 500 mg paracetamol
79717824|NCT06137469|Drug|Acetaminophen/Placebo|Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
79553841|NCT01635608|Drug|Talinolol|administration of 50 mg talinolol
79553842|NCT01635608|Drug|Amoxicillin|administration of 500 mg amoxicillin
79717825|NCT06137287|Drug|BOTOX|Intramuscular Injection
79717826|NCT06137287|Drug|Placebo for BOTOX|Intramuscular Injection
79717827|NCT06136585|Drug|2 mg/kg sugammadex|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
79717828|NCT06136585|Drug|0.07 mg/kg neostigmine|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
79717829|NCT06135337|Device|Thioderm Elate|Test Device
79717830|NCT06135337|Device|Juvéderm Ultra 3|Active Comparator Device
79256429|NCT02131441|Procedure|open liver resection|
79553843|NCT01635608|Other|non-caloric water|administration of 240 ml water
79553844|NCT01635608|Other|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
79717831|NCT06133140|Device|Unblinded postoperative vital sign monitoring|Unblinded postoperative GE Portrait monitoring
79717832|NCT06133140|Device|Blinded postoperative vital sign monitoring|Blinded postoperative GE Portrait monitoring
79717833|NCT06132022|Other|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
79717834|NCT06132022|Other|Routine care|The clinic's routine information will be given to the caregivers of the control group.
79717835|NCT06128109|Device|Thioderm Strong|Test Device
79256430|NCT05075499|Biological|COVID-19 vaccination|Blood sample obtained before, 1 , 3 and 6 months after the intervention
79553845|NCT01635621|Drug|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~OKZ 120 mg every 2 weeks~OKZ 240 mg every 2 weeks~OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
79553846|NCT01635621|Drug|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
79553847|NCT01635634|Other|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
79553848|NCT01635647|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 1 x 10^8 pfu heterologous prime-boost immunisation
79553849|NCT01635647|Biological|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
79553850|NCT01635660|Device|Intubation|Tracheal Intubation with the assigned video laryngoscope
79553851|NCT01635673|Other|Exercise intervention|Whole body vibration exercise 3 times per week
79553852|NCT01635686|Drug|DWP422 25mg|
79553853|NCT01635686|Drug|ENBREL 25MG PFS INJ.|
79553854|NCT01635712|Drug|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
79553855|NCT01635738|Biological|LP GMNL-133 capsule|One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
79553856|NCT01635738|Biological|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
79553857|NCT01635738|Biological|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
79553858|NCT01635738|Biological|Placebo|Placebo
79717836|NCT06128109|Device|Juvéderm VOLUMA Lidocaine|Comparator Device
79717837|NCT06122311|Drug|N Acetylcysteine|N-acetylcysteine sachets 600 mg twice daily
79553859|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
79717838|NCT06118099|Drug|Amlitelimab|Injection solution SC injection
79717839|NCT06118099|Drug|Placebo|Injection solution SC injection
79717840|NCT06117735|Device|Transjugular Intrahepatic Portosystemic shunt|The experimental device is a class III implanted shunt device, which will be used to create a shunt between intrahepatic and portosystemic to reduce portal hypertension.
79853967|NCT04980612|Behavioral|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
79875441|NCT01043601|Drug|Inhaled PT005|inhaled, twice daily for 1 week duration
79256431|NCT03072758|Behavioral|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
79256432|NCT02131519|Procedure|internal jugular vein catheter placement|
79256433|NCT04992182|Biological|Placebo|0.3 mL IM saline solution
79553860|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
79553861|NCT01635751|Drug|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
79256434|NCT04992182|Biological|Inactivated vaccine booster|0.5 mL IM
79553862|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 12 weeks
79553863|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 8 weeks
79256435|NCT04992182|Biological|mRNA vaccine booster|0.3 mL IM
79256436|NCT04992182|Drug|Viral vector vaccine booster|0.5 mL IM
79256437|NCT05074797|Diagnostic Test|laboratory|laboratory data
79256438|NCT02131675|Dietary Supplement|Boost shake|Blood draw after mixed-meal consumption
79256439|NCT03072524|Diagnostic Test|FAST PLUS test|FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
79256440|NCT03267069|Other|survey|surveys will be administered at inclusion and follow-ups
79553864|NCT01635790|Drug|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
79553865|NCT01635790|Drug|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
79553866|NCT01635803|Drug|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
79717841|NCT06117722|Other|Eplerenone torasemide in chronic heart failure|Heart Failure patients treated with eplerenone and torasemide
79717842|NCT06113068|Device|Fistura® procedure|The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
79717843|NCT06112626|Behavioral|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
79717844|NCT06112353|Drug|Neostigmine Injectable Solution|Examine GI-2 recovery
79717845|NCT06112353|Drug|Sugammadex injection|Examine GI-2 recovery
79717846|NCT06111508|Device|Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs|A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
79717847|NCT06110936|Device|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
79717848|NCT06109272|Drug|Livmoniplimab|Intravenous (IV) Solution
79717849|NCT06109272|Drug|Budigalimab|Intravenous (IV) Solution
79717850|NCT06109272|Drug|Durvalumab|Intravenous (IV) Solution
79717851|NCT06109272|Drug|Atezolizumab|Intravenous (IV) Solution
79717852|NCT06109272|Drug|Bevacizumab|Intravenous (IV) Solution
79717853|NCT06109272|Drug|Tremelimumab|Intravenous (IV) Solution
79717854|NCT06107062|Drug|Cannabidiol - fsCBD|Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
79553867|NCT01635803|Drug|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
79553868|NCT01635816|Biological|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
79553869|NCT01635816|Biological|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
79553870|NCT01635816|Biological|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
79553871|NCT01635816|Biological|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
79553872|NCT01635829|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
79717855|NCT06107062|Drug|Placebo|Placebo arm
79553873|NCT01635829|Drug|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
79717856|NCT06107062|Drug|Cannabidiol - bsCBD|Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
79717857|NCT06107036|Drug|BI 1015550|BI 1015550
79717858|NCT06107036|Drug|Moxifloxacin|Moxifloxacin
79717859|NCT06107036|Drug|Placebo|Placebo-matching BI 101550
79717860|NCT06105528|Drug|PMN310|60-minute intravenous infusion
79717861|NCT06105528|Drug|Placebo|60-minute intravenous infusion
79717862|NCT06094686|Diagnostic Test|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
79717863|NCT06094673|Other|No intervention|No intervention
79717864|NCT06094556|Drug|SHR-1826|dose is calculated based on the subjects' baseline weight.
79717865|NCT06089837|Drug|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
79853968|NCT04980612|Behavioral|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
79853969|NCT04978779|Drug|VIP152|Weekly IV infusion for 28 day cycles.
79853970|NCT04978779|Drug|BTKi|Taken per local prescribing information
79853971|NCT04976140|Biological|PN-101|"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."
79553874|NCT01635829|Drug|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
79853972|NCT04971993|Device|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
79875442|NCT01043601|Drug|Inhaled Placebo|inhaled, twice daily for 1 week duration
79553875|NCT01635894|Behavioral|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
79553876|NCT01635946|Drug|Isavuconazole|oral
79553877|NCT01635946|Drug|atorvastatin|oral
79553878|NCT01635972|Drug|Isavuconazole|oral
79553879|NCT01635972|Drug|bupropion hydrochloride|oral
79553880|NCT01635985|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
79553881|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
79553882|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
79553883|NCT01635985|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
79553884|NCT01635985|Drug|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
79875443|NCT01043601|Drug|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
79553885|NCT01635985|Drug|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
79553886|NCT01636011|Other|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
79553887|NCT01636011|Other|Light Touch sham|Light Touch sham
79553888|NCT01636024|Drug|AZD7594|Suspension inhaled via Spira nebuliser
79553889|NCT01636024|Drug|Placebo to match|Matching placebo inhaled via Spira nebuliser
79553890|NCT01636037|Drug|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
79553891|NCT01636050|Other|squat exercise training|Intervention may include squat exercise for 8 weeks
79553892|NCT01636089|Drug|bicarbonates|sodium bicarbonates 1,4%
79553893|NCT01636089|Drug|saline|sodium chloride 0,9%
79553894|NCT01636128|Drug|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
79717866|NCT06089837|Drug|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
79717867|NCT06089317|Combination Product|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
79717868|NCT06089317|Combination Product|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
79717869|NCT06089317|Combination Product|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
79717870|NCT06089317|Combination Product|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
79717871|NCT06089317|Drug|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
79717872|NCT06087640|Biological|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). The strain composition is that recommended by the World Health Organization (WHO) for quadrivalent influenza vaccines contemporaneous to the timing of the study.
79717873|NCT06087640|Biological|QIV|Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). The strain composition is that recommended by the WHO for quadrivalent influenza vaccines contemporaneous to the timing of the study.
79717874|NCT06084481|Drug|ABBV-400|Intravenous (IV) Infusion
79717875|NCT06082843|Drug|Placebo|Placebo matching Avenciguat (BI 685509)
79717876|NCT06082843|Drug|Avenciguat (BI 685509)|Avenciguat (BI 685509)
79717877|NCT06081725|Behavioral|Playful interactions in an online format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
79717878|NCT06081725|Behavioral|An active control condition in a face-to-face format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
79256441|NCT03266913|Drug|Probiotic|Probiotics drop
79853973|NCT04970485|Behavioral|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
79853974|NCT04969094|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
79853975|NCT04969094|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
79853976|NCT04964076|Other|No intervention|No intervention
79553895|NCT01636128|Drug|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
79853977|NCT04957329|Drug|Xalatan|Eye drop
79256442|NCT02124655|Drug|Essential oils|
79553896|NCT01636141|Drug|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
79553897|NCT01636141|Drug|Placebo gel|
79553898|NCT01636154|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
79853978|NCT04957329|Drug|Monoprost|Eye drop
79853979|NCT04953949|Device|NU-MAX®|Topical Hemostat
79853980|NCT04946279|Other|Best Practice|Receive usual/standard of care
79853981|NCT04946279|Other|Informational Intervention|Receive conversation tool
79853982|NCT04946279|Other|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
79853983|NCT04938596|Combination Product|Respiratory bundle|"Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~Promotion of strategies to improve house ventilation during 2 weeks~Provision of a TB leaflet and nurse education about TB transmission."
79853984|NCT04934826|Dietary Supplement|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
79853985|NCT04934826|Dietary Supplement|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
79853986|NCT04932096|Drug|melatonin|melatonin supplementation
79256443|NCT02124655|Drug|0.2% chlorhexidine|
79256444|NCT02124655|Drug|Sterile water|
79256445|NCT04911140|Radiation|Photobiomodulation twice a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.
79553899|NCT01636154|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
79553900|NCT01636154|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
79553901|NCT01636167|Device|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
79553902|NCT01636180|Drug|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
79553903|NCT01636180|Drug|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
79553904|NCT01636193|Biological|Oral Rotarix®|2 doses administered orally.
79553905|NCT01636193|Other|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
79553906|NCT01636245|Biological|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
79553907|NCT01636245|Biological|placebo|placebo, two doses, 28 days interval
79717879|NCT06081725|Behavioral|An active control condition in an online format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
79717880|NCT06081725|Behavioral|Playful interactions in a face to face format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
79717881|NCT06079385|Other|Acupuncture treatment|Acupuncture treatment with needles
79553908|NCT01636271|Drug|darapladib|darapladib enteric coated tablets 160 mg
79553909|NCT01636271|Drug|placebo|placebo
79553910|NCT01636310|Other|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
79553911|NCT01636323|Other|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
79717884|NCT06079164|Drug|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
79853987|NCT04932096|Other|placebo|microcrystalline cellulose filled capsule
79395737|NCT04138173|Behavioral|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
79395738|NCT02034396|Procedure|Blood Draw|One blood draw at enrollment
79553912|NCT01636336|Other|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
79553913|NCT01636336|Other|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
79553914|NCT01636349|Other|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
79553915|NCT01636388|Biological|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
79553916|NCT01636401|Drug|aclidinium bromide 400 μg|
79553917|NCT01636401|Drug|aclidinium bromide placebo|
79717885|NCT06079164|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
79717886|NCT06079164|Drug|Fludarabine|Lymphodepleting chemotherapy administered intravenously
79717887|NCT06077864|Drug|survodutide|once weekly subcutaneous injection
79717888|NCT06077864|Drug|Placebo|once weekly subcutaneous injection
79717889|NCT06066528|Drug|Survodutide|once weekly subcutaneous injection
79853988|NCT04931082|Dietary Supplement|Probiotics|Capsule
79853989|NCT04931082|Dietary Supplement|Placebo|Capsule
79853990|NCT04928586|Drug|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
79717890|NCT06066528|Drug|Placebo|once weekly subcutaneous injection
79717891|NCT06066515|Drug|survodutide|once weekly subcutaneous injection
79717892|NCT06066515|Drug|Placebo|once weekly subcutaneous injection
79717893|NCT06065826|Other|Assessment|All subjects will be assessed for FHP by taking a lateral view picture to calculate the CVA using the Kinovea software. Each subject with FHP will be examined for myofascial trigger points done by the therapist finger to palpate bilaterally on tender nodules in masticatory and neck muscles. Then using a pressure algometer, the PPT value will be scored for each trigger in each muscle bilaterally. Masticatory muscle endurance will be measured by asking the subject to bite on load sensor for as long as the subject can until exhaustion. Using a stopwatch, the time will be recorded in seconds. Using the craniocervical extension endurance test, the subject will lie prone with their head unsupported and with a bubble inclinometer attached to their head. Using a stopwatch, time in seconds will be recorded to test how long the subject can sustain the neck in neutral position. Finally, a smartphone addiction scale will be answered by the subject to identify how much they are addicted to its use.
79853991|NCT04928586|Drug|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
79853992|NCT04928066|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79395739|NCT02111187|Drug|LDE225|Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
79395740|NCT02039544|Drug|Xuebi formula|
79395741|NCT02039544|Drug|placebo|
79395742|NCT02326740|Drug|gevokizumab|
79717894|NCT06065670|Drug|Clemastine Fumarate|12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
79717895|NCT06065670|Drug|Placebo|Matched sugar tablet
79717896|NCT06060821|Other|No intervention|No intervention
79717897|NCT06056024|Drug|BI 3706674|BI 3706674
79717898|NCT06053749|Drug|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
79717899|NCT06053749|Drug|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
79553918|NCT01636440|Device|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
79553919|NCT01636440|Device|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
79717900|NCT06053749|Drug|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
79717901|NCT06053749|Drug|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
79717902|NCT06053749|Drug|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
79717903|NCT06053749|Drug|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
79717904|NCT06053710|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
79256446|NCT04911140|Radiation|Photobiomodulation three times a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.
79553920|NCT01636479|Drug|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
79553921|NCT01636492|Drug|bitopertin|Single oral dose
79717905|NCT06048120|Drug|BAY2701250 IV|Single does, intravenous infusion
79717906|NCT06048120|Drug|Placebo IV|Matching placebo for BAY2701250 IV
79717907|NCT06048120|Drug|BAY2701250 SC|Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
79717908|NCT06048120|Drug|Placebo SC|Matching placebo for BAY2701250 SC
79717909|NCT06041789|Drug|Donepezil|10 mg tablet
80018294|NCT02127060|Drug|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
80018295|NCT05133934|Other|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
79256447|NCT04911140|Other|Simulated Photobiomodulation|Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
79256448|NCT03263793|Behavioral|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
79395743|NCT02326740|Drug|Placebo|
79256449|NCT03075332|Other|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
79256450|NCT03263715|Drug|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
79395744|NCT02326740|Drug|gevokizumab open-label|
79395745|NCT03111810|Drug|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
79395746|NCT03111810|Drug|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
79395747|NCT02334150|Drug|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
79553922|NCT01636492|Drug|placebo|Single oral dose
79553923|NCT01636505|Drug|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
79553924|NCT01636505|Drug|gnrh agonist (suprefact)|suprefact 5.5 ml
79553925|NCT01636518|Procedure|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
79553926|NCT01636531|Drug|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
79717910|NCT06041789|Drug|Placebo|Donepezil placebo tablet
79717911|NCT06039137|Drug|Cetirizine|Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
79717912|NCT06039098|Device|DCS|DCS monitoring of brain
79853993|NCT04928066|Drug|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
80018296|NCT04307797|Drug|0.9% Sodium-chloride|Part A - 0.9% saline infusion during cardiac PET-MRI scan
79256451|NCT03263715|Drug|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
79553927|NCT01636531|Drug|gantenerumab|Lyophilized formulation (LyoF), single dose sc
79717913|NCT06033001|Drug|[Lu-177]-PNT2002|[Lu-177]-PNT2002, is a radiopharmaceutical investigational drug. [Lu-177]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. [Lu-177]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. [Lu-177]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
79717914|NCT06032637|Procedure|Pfannenstiel incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
79853994|NCT04928066|Drug|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
79853995|NCT04926376|Device|Eye90 Microspheres|Y90 glass microspheres
79853996|NCT04925700|Dietary Supplement|ProDentis Lozenge|1-2 ProDentis Lozenges per day
79853997|NCT04925700|Other|Placebo Lozenge|1-2 Placebo Lozenges per day
79256452|NCT03263715|Drug|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
79256453|NCT03075566|Biological|Healthy subjects|- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
79256454|NCT03075566|Biological|Patients|- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
79256455|NCT02457039|Procedure|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
79256456|NCT02457039|Procedure|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
79256457|NCT02457039|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
79853998|NCT04918524|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
79553928|NCT01636557|Drug|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
79553929|NCT01636557|Drug|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
79853999|NCT04918524|Drug|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
79553930|NCT01636557|Drug|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
79553931|NCT01636557|Drug|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
79553932|NCT01636557|Drug|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
79553933|NCT01636557|Drug|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
79854000|NCT04918524|Drug|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
79854001|NCT04918524|Drug|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
79854002|NCT04912115|Drug|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
79854003|NCT04912115|Drug|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
79854004|NCT04908631|Device|Transcranial Direct Stimulation|Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
79854005|NCT04908631|Other|Auditory Training Program|Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
79854006|NCT04906044|Drug|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
79875444|NCT01043679|Drug|Utapine|Efficacy and Safety of Utapine
79875445|NCT01043679|Drug|Seroquel|Efficacy and Safety of Seroquel
79717915|NCT06032637|Procedure|Supra-umbilical transverse incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
79717916|NCT06032546|Drug|Budigalimab|IV
79717917|NCT06032546|Drug|Placebo for Budigalimab|IV
79717918|NCT06032546|Drug|ABBV-382|IV
79717919|NCT06032546|Drug|Placebo for ABBV-382|IV
79553934|NCT01636570|Drug|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
79553935|NCT01636570|Drug|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
80018297|NCT04307797|Drug|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part A - exenatide and glucagon infusion during cardiac PET-MRI scan
80018298|NCT04307797|Drug|Glucagon 12.5ng/kg/min and 0.9% saline|Part A - Glucagon and 0.9% saline infusion during PET-MRI scan
79717920|NCT06031259|Drug|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
79854007|NCT04896645|Device|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
79717921|NCT06031259|Drug|Elaprase|Elaprase IV infusion.
79256458|NCT02457039|Drug|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) [Adriamycin + Cytoxan], TC (x4) [Taxotere + Cytoxan], AC-P (4+4) [Adriamycin + Cytoxan + Paclitaxel], TAC (x6) [Taxotere + Adriamycin + Cytoxan], or AC-PH (4+4) [Adriamycin + Cytoxan + Paclitaxel + Herceptin]."
79395748|NCT02326428|Device|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
79854008|NCT04894266|Drug|Apabetalone|Apabetalone 100mg BID
79395749|NCT02326428|Drug|Intravenous thrombolysis by alteplase (Actilyse) (optional)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
79717922|NCT06028503|Behavioral|Acceptance and Commitment Therapy|"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~What is ACT?~Coping and Stress Management~Acceptance and Action"
79717923|NCT06028503|Device|Abbott FreeStyle® Libre® 3|The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
79717924|NCT06028503|Other|Generic Education|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
79717925|NCT06026397|Drug|SK10|Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
79717926|NCT06026397|Drug|Placebo|Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
79854009|NCT04894266|Other|Standard of care|Standard of Care
79854010|NCT04877236|Device|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
79854011|NCT04873752|Biological|UDI-001|2.5 x 10^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
79854012|NCT04871113|Biological|GSK3810109A|GSK3810109A will be available as sterile aqueous solution.
80018299|NCT04307797|Drug|0.9% Sodium-chloride|Part B - 0.9% saline infusion during 7T 31P MRS scan
79395750|NCT02329158|Drug|6% hydroxyethyl starch|
79395751|NCT02333916|Other|overfeeding + exercise pre-training|
79395752|NCT02333916|Behavioral|fitness training|
79553936|NCT01636583|Device|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
79553937|NCT01636583|Device|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
79553938|NCT01636583|Other|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
79395753|NCT02333916|Other|overfeeding + exercise post-training|
79553939|NCT01636596|Drug|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
79717927|NCT06021639|Dietary Supplement|The last 24 hours will consume low fiber food.|White bread, white rice, plain pasta or noodles, cereals not containing more than 1 gram of fiber per serving., canned or cooked skinless and seedless fruit, skinless and seedless raw fruit, pulp-free or low-fiber fruit or vegetable broth, seedless, seedless, skinless, such as canned or well-cooked carrots, string beans or peppers vegetables, tender red meat, poultry and fish, eggs, no more than two tablespoons per day, soft (creamy) peanut butter, milk, yogurt or plain cheese, salad dressings without oils or nuts, desserts without nuts.
79717928|NCT06019507|Biological|TCD601|Investigational Product
79717929|NCT06019507|Biological|Cyclophosphamide|Conditioning Regimen
79717930|NCT06019507|Drug|TAC|Immunosuppression Therapy
79256459|NCT04998890|Other|adventure-based cognitive behavioral intervention|"The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues."
79553940|NCT01636609|Drug|Azacitidine|Given IV or SC
79717931|NCT06019507|Drug|MMF|Immunosuppression Therapy
79717932|NCT06019507|Drug|Corticosteroids|Immunosuppression Therapy
79717933|NCT06014580|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
79717934|NCT06013384|Device|Low-Intensity Focused Ultrasound Pulsation|Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.
79717935|NCT06013384|Device|Sham Low-Intensity Focused Ultrasound Pulsation|Sham low-intensity focused ultrasound pulsation will be given.
79854013|NCT04871074|Drug|UCB-J|PET imaging with UCB-J
79256460|NCT02459145|Behavioral|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
79256461|NCT04991636|Procedure|Angioscan|"La procédure d'étude prévoit de prendre des images pendant une inspiration profonde ainsi que pendant une expiration profonde. Cette deuxième mesure ne nécessite pas l'administration d'une quantité supplémentaire de produit de contraste. Cependant, le temps d'exposition aux rayonnements ionisants est doublé. L'examen utilise une acquisition hélicoïdale en mode rapide. La durée de l'hélice est de l'ordre de 2 secondes en phase d'inspiration, puis il y a un délai de 5 secondes de machine ( demi-tour ) et à nouveau 2 secondes d'exposition en phase d'expiration, soit 4 secondes d'exposition effective aux rayonnements ionisants, le temps de la prise d'image et 9 secondes le temps total de l'examen. l'image et 9 secondes la durée totale de l'examen."
79553941|NCT01636609|Drug|Cytarabine|Given SC
79553942|NCT01636609|Drug|Tosedostat|Given PO
79553943|NCT01636622|Drug|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
79854014|NCT04870580|Diagnostic Test|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
79854015|NCT04856163|Behavioral|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
79854016|NCT04854395|Drug|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
79854017|NCT04852016|Behavioral|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
79875446|NCT00408993|Drug|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
79717936|NCT06012435|Drug|sigvotatug vedotin|Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle
79717937|NCT06012435|Drug|docetaxel|75 mg/m^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
79553944|NCT01636622|Drug|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
79717938|NCT06010914|Other|No Intervention|"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."
79717939|NCT06009068|Other|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
79717940|NCT06003777|Drug|PF-06954522|PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
79717941|NCT06003777|Drug|Placebo|Placebo will be administered as oral suspensions as escalating single doses to be determined.
79553945|NCT01636622|Drug|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
79553946|NCT01636635|Other|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
79553947|NCT01636648|Device|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
79717942|NCT06003192|Other|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
79717943|NCT05991518|Combination Product|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
79717944|NCT05991518|Combination Product|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
79717945|NCT05988827|Device|NGenuity|Cataract surgery performed under microscope using NGenuity
79717946|NCT05987410|Other|Nordic Walking (NW)|The experimental group will carry out NW sessions three times a week for 12 weeks, supervised by a NW instructor and under the control of a cardiologist. The duration of each NW session will initially be 90 minutes: 10 minutes of warm-up, 60 of NW, and 15 minutes of cool-down. The intensity of the course will be gradually increased each week, starting at 70 to 85% of the heart rate (HR) reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
79717947|NCT05987410|Other|Standard Rehabilitation (SR)|The second group will follow a standard rehabilitation program with an initial cardiological prescription and supervised by physiotherapists, carried out 5 days a week with sessions lasting 40 minutes, including 5 minutes of warm-up up), 30 min of aerobic physical activity on a conveyor belt or cycle ergometer and 5 minutes of cooling down (cool down). The intensity of your aerobic activity will gradually increase each week, starting at 70 to 85% of HR reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
79717948|NCT05987410|Other|Cardiological Counselling (CC)|The third group of participants will receive cardiological counselling with indications of unsupervised aerobic physical activity. The group will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
79854018|NCT04852016|Behavioral|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
79854019|NCT04844294|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
79854020|NCT04844294|Behavioral|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
79854021|NCT04841811|Drug|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
79854022|NCT04839991|Drug|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
79854023|NCT04839900|Other|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
79854024|NCT04827537|Drug|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
79553948|NCT01636674|Other|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
79717949|NCT05984277|Drug|Volrustomig|Volrustomig
79717950|NCT05984277|Drug|Pembrolizumab|Pembrolizumab
79717951|NCT05984277|Drug|Carboplatin|Carboplatin
79717952|NCT05984277|Drug|Paclitaxel|Paclitaxel
79717953|NCT05984277|Drug|Pemetrexed|Pemetrexed
79854025|NCT04827537|Drug|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
79256462|NCT04433624|Other|Group (B)|Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
79553949|NCT01636700|Drug|Tramadol 2mg/kg|2mg/kg
79553950|NCT01636700|Drug|Saline solution|saline solution- 1 dose
79553951|NCT01636726|Drug|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
79553952|NCT01636739|Biological|Oral Rotarix®|2 doses administered orally.
79553953|NCT01636739|Other|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
79553954|NCT01636752|Behavioral|Deprexis|Online self-help with and without e-mail-support
79395754|NCT02329002|Device|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
79553955|NCT01635426|Drug|Aspirin|Aspirin 75 mg daily for 2 months after meals
79854026|NCT04827537|Drug|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
79854027|NCT04825288|Biological|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
79854028|NCT04822740|Device|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
79854029|NCT04820179|Drug|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
79854030|NCT04820036|Diagnostic Test|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
79854031|NCT04820036|Behavioral|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
79854032|NCT04820036|Diagnostic Test|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
79277396|NCT02375529|Procedure|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
79553956|NCT01635426|Drug|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
79553957|NCT01636791|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
79717954|NCT05983458|Procedure|Transaortic valve replacement|"TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view."
79717955|NCT05983133|Drug|SGN-EGFRd2|Given into the vein (IV; intravenously)
79717956|NCT05979935|Diagnostic Test|tongue diagnosis|The tongue image of participants will be collected via camera and professional tongue diagnosis report will be provided to pariticipants.
79717957|NCT05979337|Behavioral|Empowered Relief|"This is a single-session (2-hour) behavioral intervention utilizing pain psychology principles (cognitive-behavioral therapy for pain, pain neuroscience education).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
79717958|NCT05979337|Behavioral|Health Education (HE)|"This is a single-session (2-hour) health education class reviewing principles of medically indicated self-management of migraine headaches (e.g., consistent dietary and hydration habits, exercise, understanding of and adherence to medical treatment regimens).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
79717959|NCT05979337|Behavioral|Treatment as Usual|"Participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life. In addition, participants will complete daily diaries for 28 days.~If participants are interested in attending classes that were not part of this group assignment, participants will be invited to do so after completing the 6-month follow-up questionnaire."
79717960|NCT05977686|Device|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
79717961|NCT05977686|Device|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
79553958|NCT01636791|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
79553959|NCT01636804|Device|Quicksite|St. Jude Medical produced lead called Quicksite
79553960|NCT01636804|Device|Quickflex|St. Jude Medical produced lead called Quickflex
79553961|NCT01636830|Device|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
79553962|NCT01636856|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
79553963|NCT01636856|Behavioral|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
79553964|NCT01636869|Drug|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
79553965|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
79553966|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
79553967|NCT01636908|Drug|Sunitinib|50 mg once daily, oral use, 14 days
79553968|NCT01636908|Drug|Sorafenib|400 mg, twice daily, oral use, 14 days
79553969|NCT01636908|Drug|Erlotinib|150 mg once daily, oral use, 14 days
79854033|NCT04820036|Diagnostic Test|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
79854034|NCT04820036|Diagnostic Test|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
79854035|NCT04817865|Diagnostic Test|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
79854036|NCT04817865|Diagnostic Test|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
79553970|NCT01636908|Drug|Everolimus|10 mg once daily, oral use, 14 days
79553971|NCT01636908|Drug|Lapatinib|1250 mg once daily, oral use, 14 days
79553972|NCT01636908|Drug|Dasatinib|100 mg once daily, oral use, 14 days
79553973|NCT01636908|Drug|Pazopanib|800 mg once daily, oral use, 14 days
79553974|NCT01636908|Drug|Vemurafenib|960 mg twice daily, oral use, 15-21 days
79553975|NCT01636908|Procedure|tumor biopsy|
79553976|NCT01636908|Procedure|skin biopsy (optional)|
79553977|NCT01636973|Procedure|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
79553978|NCT01636999|Drug|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
79553979|NCT01637012|Procedure|Implantation|index angioplasty with ALEX stent implatation
79553980|NCT01637025|Device|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
79553981|NCT01637025|Device|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
79553982|NCT01637038|Other|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
79553983|NCT01637064|Drug|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
79553984|NCT01637103|Behavioral|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
79553985|NCT01637103|Behavioral|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
79553986|NCT01637129|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
79854037|NCT04817124|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).
79875447|NCT00408993|Drug|Placebo|Placebo every day (QD), by mouth (PO)
79553987|NCT01637129|Device|Sham Magnetic Stimulation|Sham Magnetic Stimulation
79553988|NCT01637155|Drug|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
79553989|NCT01637168|Drug|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
79553990|NCT01637168|Drug|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
79553991|NCT01637181|Procedure|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
79553992|NCT01637194|Drug|everolimus|Given PO
79553993|NCT01637194|Biological|cetuximab|Given IV
79553994|NCT01637194|Other|pharmacological study|Correlative studies
79553995|NCT01637194|Other|laboratory biomarker analysis|Correlative studies
79854038|NCT04817124|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
79854039|NCT04817124|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
79553996|NCT01637220|Biological|Blood volume collected specifically for this study|"case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~Control patients: 20 ml following neuromuscular blocking drug injection"
79553997|NCT01637233|Drug|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
79854040|NCT04816773|Device|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
79854041|NCT04815564|Device|Invisalign|Invisalign clear aligner system
79553998|NCT01637233|Drug|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
79553999|NCT01637233|Drug|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
79554000|NCT01637259|Drug|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
79554001|NCT01637259|Drug|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
79554002|NCT01637259|Drug|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
79554003|NCT01637285|Biological|PF-04856883|Dose A
79256463|NCT02788201|Drug|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
79854042|NCT04808986|Diagnostic Test|Serological test for the detection of IgG anti-SARS-CoV-2|Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
79256464|NCT02788201|Other|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
79256465|NCT05004194|Procedure|Vestibular Caloric Stimulation|Irrigation of the right external ear canal
79256466|NCT04998656|Device|Werewolf FLOW 50|Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
79256467|NCT04998656|Other|Control|Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
79395755|NCT02333994|Device|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
79554004|NCT01637285|Biological|PF-04856883|Dose B
79554005|NCT01637285|Biological|PF-04856883|Dose C
79554006|NCT01637285|Biological|PF-04856883|Dose D
79554007|NCT01637311|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
79554008|NCT01637337|Procedure|laparoscopic pyelolithotomy|laparoscopy
79554009|NCT01637337|Procedure|percutaneous nephrolithotomy|percutaneous nephrolithotomy
79854043|NCT04805918|Behavioral|VIPP-SD|Parenting program
79554010|NCT01637350|Procedure|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
79554011|NCT01637363|Behavioral|Psychoeducation|6 x 2 hours of psychoeducation
79554012|NCT01637376|Drug|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
79554013|NCT01637389|Other|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
79854044|NCT04800692|Drug|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
79854045|NCT04800692|Drug|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
79854046|NCT04800692|Drug|L-Ascorbate|3300 mg of l-ascorbate once daily
79854047|NCT04800692|Drug|L-Arginine|3400mg of l-arginine once daily
79256468|NCT03266679|Other|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
79554014|NCT01637389|Other|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
79554015|NCT01637428|Device|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
79554016|NCT01637441|Procedure|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
79554017|NCT01637441|Procedure|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
79554018|NCT01637454|Drug|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
79554019|NCT01637454|Drug|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
79554020|NCT01637467|Other|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
79554021|NCT01637467|Other|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
79554022|NCT01637480|Other|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
79554023|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
79554024|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
79554025|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
79554026|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
79256469|NCT02127619|Device|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
79554027|NCT01637532|Drug|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
79554028|NCT01637532|Drug|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
79554029|NCT01637545|Drug|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want"
79717962|NCT05977582|Behavioral|Spanish version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
79554030|NCT01637558|Drug|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
79554031|NCT01637558|Drug|Nevirapine|
79554032|NCT01637558|Drug|Lopinavir/Ritonavir|
79554033|NCT01637571|Drug|Dexilant|60mg of Dexilant QD for 12 weeks
79554034|NCT01637571|Drug|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
79554035|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 12
79554036|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 6
80018300|NCT04307797|Drug|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part B - exenatide and glucagon infusion during 7T 31P MRS scan
79554037|NCT01637636|Drug|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
79554038|NCT01637636|Drug|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
80018301|NCT04307797|Drug|Glucagon 12.5ng/kg/min|Part B - Glucagon infusion during 7T 31P MRS scan
79554039|NCT01637662|Drug|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
79554040|NCT01637675|Drug|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
79554041|NCT01637675|Drug|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
79554042|NCT01637701|Procedure|PkEP|Plasmakinetic enucleation of the prostate
79554043|NCT01637701|Procedure|B-TURP|Bipolar transurethral resection of the prostate
79554044|NCT01637714|Drug|Multi-strain probiotics|"B. longum BORI: 1 x 109~B. bifidum BGN4: 1 x 109~B. lactis AD011: 1 x 109~B. infantis IBS007: 1 x 109~Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
79554045|NCT01637714|Drug|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
79554046|NCT01637753|Drug|Carmustine(BCNU)|Carmustine Sustained Release Implant
79554047|NCT01637753|Procedure|Surgery|Routine tumor resection surgery
79554048|NCT01637766|Drug|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
79554049|NCT01637779|Behavioral|Fact sheet|fact sheet about pain management during immunization
79554050|NCT01637792|Other|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
79554051|NCT01637792|Other|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
79554052|NCT01637805|Biological|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
79554053|NCT01637818|Procedure|Lichtenstein's operation|
79554054|NCT01637818|Procedure|Mesh Plug Repair|
79554055|NCT01637818|Drug|Opiate|Postoperative pain therapy
79554056|NCT01637818|Drug|Paracetamol|Postoperative pain therapy
79554057|NCT01637818|Drug|non-steroidal anti-inflammatory drug|Postoperative pain therapy
79554058|NCT01637831|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
79554059|NCT01637844|Drug|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
79554060|NCT01637857|Dietary Supplement|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
79554061|NCT01637857|Dietary Supplement|oligoantigenic diet|oligoantigenic diet associated to life style counseling
79554062|NCT01637883|Drug|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
79554063|NCT01637896|Device|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
79554064|NCT01637896|Device|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
79554065|NCT01637909|Drug|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
79717963|NCT05977582|Behavioral|Psychoeducationa Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
79717964|NCT05976763|Drug|Zanubrutinib|Given PO
79717965|NCT05976763|Biological|Rituximab|Given IV
79256470|NCT02456740|Drug|Erenumab|Administered by subcutaneous injection once a month
79256471|NCT02456740|Drug|Placebo|Administered by subcutaneous injection once a month
79395756|NCT02333994|Other|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
79395757|NCT03144336|Behavioral|Information provision|All study participants will receive weekly messages with HIV prevention information.
79395758|NCT03144336|Behavioral|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
79395759|NCT03144336|Behavioral|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
79395760|NCT03144414|Procedure|Laparoscopic hysterectomy|Laparoscopic hysterectomy
79554066|NCT01637909|Dietary Supplement|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
79717966|NCT05976763|Other|Patient Observation|Undergo observation
79854048|NCT04800055|Other|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
79854049|NCT04791709|Behavioral|Happy Older Latinos are Active (HOLA)|HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
79854050|NCT04791306|Other|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
80018302|NCT02288858|Dietary Supplement|Viviscal Oral Supplement Tablets|Tablet (512 mg)
79395761|NCT04477590|Drug|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
79395762|NCT02326506|Device|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
79717967|NCT05976763|Procedure|Bone Marrow Biopsy|undergo bone marrow biopsy
79395763|NCT02328690|Other|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz [Hz]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
79717968|NCT05976763|Other|Fludeoxyglucose F-18|Given IV
79717969|NCT05976763|Procedure|Positron Emission Tomography|Undergo PET
79395764|NCT02326662|Biological|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
79395765|NCT02334072|Device|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
79717970|NCT05976763|Procedure|Computed Tomography|Undergo CT
79717971|NCT05976763|Procedure|Magnetic Resonance Imaging|Undergo MRI
79717972|NCT05976763|Procedure|Esophagogastroduodenoscopy|Undergo EGD
79717973|NCT05976763|Procedure|Colonoscopy|Undergo colonoscopy
79854051|NCT04791306|Other|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
79717974|NCT05976763|Procedure|Biospecimen Collection|Undergo blood sample collection
79717975|NCT05976763|Other|Questionnaire Administration|Ancillary studies
79717976|NCT05976581|Behavioral|Electronic alert|An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.
79717977|NCT05976581|Behavioral|Structured communication of test results|A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
79854052|NCT04786600|Device|Signatera ctDNA assay|Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
79854053|NCT04786600|Drug|pre-specified sequence of FDA-approved drugs and drug combinations|Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
79854054|NCT04783454|Other|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
79854055|NCT04783415|Drug|Acalabrutinib|Given PO
79854056|NCT04783415|Biological|Ublituximab|Given IV
79854057|NCT04783415|Drug|Umbralisib|Given PO
79854058|NCT04781140|Drug|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
79854059|NCT04781140|Drug|Placebo|Placebo will be administered once daily
79717978|NCT05968144|Behavioral|Dietary recommendations|One-on-one meeting with a nutritionist to discuss and personalize dietary recommendations for patients with prostate cancer undergoing ADT.
80018303|NCT00790803|Drug|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
80018304|NCT02125188|Drug|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
80018305|NCT02125188|Drug|saline|saline 100ml ivdrip before surgery
80018306|NCT05131126|Procedure|Latarjet method|This operation consists of fixing a bone graft
80031488|NCT04905004|Procedure|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
80031489|NCT04455932|Diagnostic Test|Abbreviated non-contrast MRI of the liver|every 6 months
79717979|NCT05968144|Behavioral|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
80018307|NCT05131126|Other|Different arms exercices|"Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~Perform 5 circumduction movements with the right and left arms~Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation."
79717980|NCT05961241|Other|runnin training program|gradual training program
80018308|NCT02288936|Drug|Enzalutamide|Enzalutamide 160 mg/day
79395766|NCT02334072|Device|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
79395767|NCT02334072|Device|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
79554067|NCT01637909|Other|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
79717981|NCT05956587|Drug|BL-B01D1|Administration by intravenous infusion
79717982|NCT05956587|Drug|SI-B003|Administration by intravenous infusion
79717983|NCT05955729|Behavioral|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
79717984|NCT05955729|Behavioral|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
79717985|NCT05955729|Device|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
79717986|NCT05955729|Device|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
79717987|NCT05955729|Device|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
79717988|NCT05955729|Device|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
79717989|NCT05955729|Biological|Fasting blood sample|15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
79717990|NCT05955729|Other|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
79717991|NCT05955729|Other|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
79395768|NCT02334072|Device|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
79395769|NCT02334072|Device|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
79395770|NCT02328612|Other|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
79395771|NCT02328924|Other|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
79395772|NCT02333838|Drug|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
79554068|NCT01637948|Drug|Listerine mouthrinse|For six months
79717992|NCT05955729|Other|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
79717993|NCT05955729|Other|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score > 5 indicates poor sleep quality
79717994|NCT05955729|Other|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
79717995|NCT05955729|Other|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
79717996|NCT05955729|Device|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
80018309|NCT05131048|Other|conventional group|this group will perform conventional therapy
80018310|NCT05131048|Other|experimental group|this group will perform home based exercises
80018311|NCT02125344|Drug|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
80018312|NCT02125344|Drug|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
80018313|NCT02125344|Drug|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
80018314|NCT02125344|Drug|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
80018315|NCT02125344|Drug|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
80018316|NCT02125344|Drug|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
80031490|NCT04455932|Diagnostic Test|Ultrasound surveillance|every 6 months
79554069|NCT01637948|Drug|Chinese Medicine mouthrinse|six months
79554070|NCT01637974|Drug|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
79554071|NCT01638026|Drug|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
79554072|NCT01638039|Other|Laboratory Tests|Stool, blood, urine and saliva samples
79554073|NCT01638078|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
79554074|NCT01638078|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
79554075|NCT01638091|Behavioral|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
79554076|NCT01638091|Behavioral|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
79554077|NCT01638104|Drug|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
79554078|NCT01638104|Drug|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
79554079|NCT01638117|Other|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
79554080|NCT01638117|Drug|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
79554081|NCT01638117|Drug|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
79554082|NCT01638117|Drug|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
79554083|NCT01638117|Other|Saline|Saline, Daily for up to 21 days
79554084|NCT01638117|Other|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
79554085|NCT01638143|Dietary Supplement|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
79554086|NCT01638143|Dietary Supplement|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
79554087|NCT01638143|Dietary Supplement|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
79554088|NCT01638169|Device|adding a heel|walking with and without heels on the gaitrite system
79554089|NCT01638182|Dietary Supplement|Placebo|27 participants received for three months 1 placebo capsule per day
79554090|NCT01638182|Dietary Supplement|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
79554091|NCT01638182|Dietary Supplement|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
79554092|NCT01638195|Device|Focused Ultrasound|Focused Ultrasound
79717997|NCT05952687|Drug|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMATRIX trial using single agent idasanutlin.
79717998|NCT05952687|Drug|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.
79554093|NCT01638208|Drug|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
79554094|NCT01638234|Dietary Supplement|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
79554095|NCT01638234|Dietary Supplement|Placebo|starch pill
79717999|NCT05952687|Drug|Selinexor|Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.
80031491|NCT04455932|Diagnostic Test|Multiphase contrast-enhanced liver MRI|screening
79395773|NCT02333838|Drug|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
79395774|NCT02333838|Drug|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
79395775|NCT02333838|Drug|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
79395776|NCT02326584|Drug|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
79554096|NCT01638247|Drug|Tamoxifen|25 mg daily.
79554097|NCT01638247|Drug|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~Goserelin (10.8 mg s.c. after randomisation and after three months) or~Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
79554098|NCT01638247|Drug|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~Goserelin (10.8 mg s.c. after randomisation and after three months) or~Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
79554099|NCT01638260|Drug|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
79395777|NCT02326584|Drug|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
79395778|NCT02326584|Drug|Daunorubicin|60 mg/m2/day Days 1-3
79395779|NCT02326584|Drug|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
79554100|NCT01638260|Behavioral|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
79554101|NCT01638273|Drug|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
79554102|NCT01638273|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
79554103|NCT01638299|Device|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
79554104|NCT01638325|Drug|Insulin Lispro|Administered SC
79554105|NCT01638325|Drug|BC106 insulin lispro|Administered SC
79718000|NCT05952401|Behavioral|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
79718001|NCT05952401|Behavioral|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
79718002|NCT05950997|Drug|Acalabrutinib|100 mg capsules administered by mouth once daily (28-day cycles)
79554106|NCT01638338|Behavioral|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
79554107|NCT01638338|Behavioral|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
79554108|NCT01638351|Behavioral|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
79554109|NCT01638351|Behavioral|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
79554110|NCT01638364|Drug|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
80018317|NCT02125344|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
79554111|NCT01638364|Drug|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
79718003|NCT05950997|Drug|Obinutuzumab|100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
79718004|NCT05950256|Device|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
79718005|NCT05949099|Drug|Nirogacestat|Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
79256472|NCT03263403|Biological|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
79256473|NCT03263403|Biological|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo [Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
79395780|NCT02333760|Genetic|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
79718006|NCT05949099|Procedure|Cryoablation|Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
79718007|NCT05944016|Drug|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily)
79718008|NCT05944016|Drug|Placebo|Placebo (standard dose p.o. once daily)
79718009|NCT05934942|Drug|Yasmin®|Ethinylestradiol (EE) and Drospirenone (DRSP)
79854060|NCT04779736|Behavioral|A set of implementation strategies to reduce sexual stigma|The intervention will be finalized based on formative interviews and consultation with an advisory board. It is likely to include an educational mHealth component followed by an in-person workshop for skills development, then supportive coaching components (i.e., coaching calls and an optional email listserve) to encourage and respond to the implementation of recommended practices.
80018318|NCT02125344|Drug|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is <70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is <50 kg, both dosages will be reduced to 500 mg each.
79256474|NCT03768115|Drug|Autologous Plasma Eye Drop|Autologous plasma crimped segments
79395781|NCT03111654|Diagnostic Test|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
79395782|NCT03111342|Drug|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
79395783|NCT03111342|Procedure|Dry-needling|A placement of thin needle into the cervix without substance injection
79395784|NCT03111420|Drug|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
79395785|NCT03111420|Device|Platelet function test|Blood is drawn for testing of platelet aggregation activity
79395786|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
79395787|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
80018319|NCT03651609|Procedure|Simple decompression of the ulnar nerve|Surgical HUA release 2-3 cm distal to medial epicondyle with minimal-incision technique .
80018320|NCT03651609|Behavioral|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
79554112|NCT01638377|Drug|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
79554113|NCT01638377|Drug|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
79554114|NCT01638403|Drug|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
79554115|NCT01638403|Drug|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
79554116|NCT01638403|Drug|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
79554117|NCT01638455|Device|Noninvasive device|Noninvasive device
79554118|NCT01638520|Drug|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
79554119|NCT01638520|Drug|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
79554120|NCT01638585|Drug|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
79554121|NCT01638598|Drug|matching placebo|matching placebo in each dose level
79554122|NCT01638598|Drug|Test drug|BI 1021958
79554123|NCT01638598|Drug|matching placebo|matching placebo in each dose level
79554124|NCT01638598|Drug|Test drug|BI 1021958
79554125|NCT01638598|Drug|Test drug|BI 1021958
79554126|NCT01638598|Drug|Test drug|BI 1021958
79554127|NCT01638598|Drug|Test drug|BI 1021958
79554128|NCT01638598|Drug|matching placebo|matching placebo in each dose level
79554129|NCT01638598|Drug|matching placebo|matching placebo in each dose level
79554130|NCT01638598|Drug|matching placebo|matching placebo in each dose level
79554131|NCT01638611|Drug|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
79554132|NCT01638611|Drug|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
79554133|NCT01638624|Drug|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
79554134|NCT01638624|Drug|Placebo|
79554135|NCT01638637|Device|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
79554136|NCT01638650|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
79554137|NCT01638650|Drug|ritonavir|100 mg bid orally, Days 1-14
79554138|NCT01638650|Drug|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
79554139|NCT01638663|Drug|Tolvaptan|15 mg pr day for 1 day
79256475|NCT03075098|Device|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
79718010|NCT05934942|Drug|BI 1358894|BI 1358894
79718011|NCT05933382|Other|Corticosteroid Group|Conventional exercise and corticosteroid injection
79718012|NCT05933382|Other|Mulligan Group|Conventional exercise and mulligan mobilization
79718013|NCT05932914|Procedure|Liver Biopsy|Standard transjugular liver biopsy under moderate sedation
79256476|NCT03266835|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
79395788|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
79395789|NCT02333682|Dietary Supplement|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
79395790|NCT02328534|Behavioral|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
79395791|NCT02328534|Procedure|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
79554140|NCT01638663|Drug|Placebo|1 tablet Unikalk 1 pr day for 1 day
79554141|NCT01638676|Drug|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
79554142|NCT01638676|Drug|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
79554143|NCT01638689|Drug|Escitalopram|20 mg p.o.
79554144|NCT01638702|Other|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
79554145|NCT01638715|Drug|Remicade|- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
79718014|NCT05931406|Behavioral|Control|A normal working day from of 12h
79718015|NCT05931406|Behavioral|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
79718016|NCT05931406|Behavioral|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
80018321|NCT05468840|Drug|Ketamine Hydrochloride|see study arm description
80018322|NCT05468840|Drug|Normal saline|see study arm description
79554146|NCT01638715|Drug|Orencia|- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
79554147|NCT01638715|Drug|Ro-Actemra|- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
79554148|NCT01638715|Drug|Mabthera|"- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
79554149|NCT01638741|Behavioral|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
79554150|NCT01638754|Procedure|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
79554151|NCT01638754|Procedure|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
79554152|NCT01638767|Drug|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
79554153|NCT01638767|Drug|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
79554154|NCT01638780|Dietary Supplement|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
79554155|NCT01638780|Dietary Supplement|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
79554156|NCT01638793|Device|Microcap (Oridion, Needham, MA, USA)|
79554157|NCT01638793|Device|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
79554158|NCT01638806|Procedure|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
79554159|NCT01638832|Device|Transient Elastography (FibroScan), Echosens, Paris, France|
79554160|NCT01638832|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
79554161|NCT01638845|Procedure|continuous perineural catheter|continuous perineural catheter
79554162|NCT01638858|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
79554163|NCT01638871|Behavioral|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
79554164|NCT01638884|Behavioral|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
79256477|NCT03550495|Behavioral|psychiatry involvement|See arm description.
79554165|NCT01638884|Other|Structural MRI|to compare differences between each populations
79554166|NCT01638884|Other|Functional MRI|to compare differences between each populations
79554167|NCT01638884|Other|Virtual reality / Memory assessment|to compare differences between each populations
79554168|NCT01638910|Drug|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
79554169|NCT01638923|Drug|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
79554170|NCT01638923|Drug|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
79554171|NCT01638936|Drug|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
79554172|NCT01638962|Drug|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
79718017|NCT05928416|Diagnostic Test|Saliva sample|"During the inclusion visit :~a neurological examination is taken~a saliva sample is taken"
79256478|NCT05003492|Combination Product|Combination therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
79718018|NCT05928416|Diagnostic Test|Saliva sample|"During the inclusion visit :~a saliva sample is taken"
79718019|NCT05924789|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
79554173|NCT01638962|Other|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
79554174|NCT01638975|Behavioral|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
79554175|NCT01638988|Drug|Metformin|"cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
79554176|NCT01638988|Drug|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
79554177|NCT01639014|Drug|F2695|75 mg OD in 2 capsules
79554178|NCT01639014|Drug|placebo|2 capsules
79554179|NCT01639027|Drug|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
79554180|NCT01639027|Drug|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
79554181|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
79554182|NCT01639066|Drug|Entecavir|Entecavir 1 mg daily Oral
79554183|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
79554184|NCT01639079|Behavioral|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
79554185|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
79554186|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
79554187|NCT01639092|Drug|Entecavir|Entecavir 1 mg daily Oral
79554188|NCT01639170|Radiation|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
79554189|NCT01639183|Device|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
79554190|NCT01639183|Other|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
79554191|NCT01639209|Procedure|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
79554192|NCT01639209|Procedure|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
79554193|NCT01639248|Drug|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
79554194|NCT01639261|Drug|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever >38,5 dose increase: 50µg/m² BSA three times/week
79554195|NCT01639274|Other|COPD prevalence|Determine prevalence of COPD
79554196|NCT01639300|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
79554197|NCT01639300|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
79554198|NCT01639326|Drug|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
79554199|NCT01639326|Drug|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
79554200|NCT01639378|Procedure|Renal Denervation|Symplicity Catheter System
79718020|NCT05924776|Biological|Plasmodium immunotherapy|Inoculation 1-5 × 10^6 Plasmodium vivax once
79256479|NCT05003492|Radiation|Photodynamic therapy|After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose will be performed.
79554201|NCT01639391|Procedure|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
79554202|NCT01639404|Procedure|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
79718021|NCT05922722|Other|Decision-making tool|The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
79718022|NCT05922722|Other|Questionnaire|Questionnaire to assess participant's understanding of the decision-making tool
79718023|NCT05914259|Other|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
79718024|NCT05911776|Drug|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 mg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
79256480|NCT05003492|Drug|Standard therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
79256481|NCT03266601|Drug|Recombinant Human Interferon α-2b Spray|Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
79256482|NCT03266601|Drug|Ribavirin|Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
79256483|NCT03266523|Other|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
79854061|NCT04779437|Behavioral|Imagery Cognitive Bias Modification|"The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell & Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. The training aims to train a bias to automatically imagine positive resolutions for ambiguous situations encountered in daily life.~Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website."
80018323|NCT03651375|Drug|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
79554203|NCT01639404|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
79554204|NCT01639430|Other|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
79256484|NCT03266211|Other|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
79554205|NCT01639456|Biological|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
79718025|NCT05911776|Drug|Intravenous Dexmedetomidine|patients will receive 0.5 mg/kg bolus over 10 min then 0.1- 0.4 mg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
79718026|NCT05910619|Device|Neurolith Transcranial Pulse Stimulation Active|5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume ~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume ~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume ~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
79718027|NCT05910619|Device|Neurolith Transcranial Pulse Stimulation Sham|The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
79718028|NCT05909332|Drug|Antivascular therapy|BP102 (anti VEGFR)
79718029|NCT05909332|Drug|Chemotherapy|ddEC-P
79854062|NCT04779437|Behavioral|Cognitive Control Training|The cognitive control training is an adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015; Blackwell et al., 2018). Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website.
79854063|NCT04761770|Other|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
80018324|NCT03651375|Radiation|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
80018325|NCT02122224|Other|High fiber breakfast|Breakfast will contain 10-11g fiber.
80018326|NCT02122224|Other|High Protein Breakfast|Breakfast will contain 19-20g of protein.
80018327|NCT02122224|Other|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
80031492|NCT04899154|Other|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
79256485|NCT03266211|Other|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
79256486|NCT02458755|Drug|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
79256487|NCT03551587|Device|Vibringe|The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
79256488|NCT04462406|Biological|Ipilimumab|Given IV
79256489|NCT04462406|Biological|Nivolumab|Given IV
79256490|NCT04462406|Other|Patient Observation|Undergo active surveillance
79554206|NCT01639456|Biological|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
79554207|NCT01639456|Device|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
80018328|NCT05723900|Drug|Castor oil|"Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil"
79256491|NCT04462406|Biological|Pembrolizumab|Given IV
80018329|NCT05723900|Drug|Formocresol|Group II treated with formocresol
79554208|NCT01639456|Device|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
79554209|NCT01639456|Drug|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
79554210|NCT01639456|Drug|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
79554211|NCT01639456|Drug|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
79554212|NCT01639521|Drug|cisplatin|Given IV
79554213|NCT01639521|Drug|gemcitabine hydrochloride|Given IV
79554214|NCT01639521|Drug|methotrexate|Given IV
79554215|NCT01639521|Drug|vinblastine|Given IV
79718030|NCT05906771|Dietary Supplement|Metabolaid(R)|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~The nutraceutical has been elaborated by Monteloeder, S.L. It is a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves. The dose that the participants of the experimental group will receive will be 300mg plus 20mg of microcrystalline cellulose. The product is presented in an unflavored capsule, it is a reddish-brown powder with a characteristic odor and a slightly bitter taste. The manufacturing date of the product was 01/12/2022 and the expiration date was 30/11/2024."
79256492|NCT02400580|Drug|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
79256493|NCT02400580|Drug|placebo|The patients in the placebo arm will receive normal saline.
79256494|NCT02132065|Drug|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
79256495|NCT03262857|Drug|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
79256496|NCT02132143|Radiation|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
79256497|NCT02132143|Radiation|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
79256498|NCT02260609|Other|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
79256499|NCT05074329|Device|Moventis PNS|Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
79256500|NCT02127697|Drug|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
79256501|NCT02127697|Drug|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
79554216|NCT01639521|Drug|doxorubicin hydrochloride|Given IV
79854064|NCT04761770|Drug|conditioning regimen|"Based on the Geriatric assessment.~HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -> Myeloablative (MA) regimen~HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
80018330|NCT03970291|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
80018331|NCT03651297|Other|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
80031493|NCT04899154|Other|stool sampling|Participants will provide one stool sample at inclusion
79256502|NCT02127697|Drug|salbutamol/ albuterol|Taken as rescue medication
79554217|NCT01639521|Biological|pegfilgrastim|Given SC
79554218|NCT01639521|Other|laboratory biomarker analysis|Correlative studies
79554219|NCT01639547|Drug|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
79554220|NCT01639612|Biological|ALD-451|ALD-451 iv
79554221|NCT01639625|Drug|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
79554222|NCT01639638|Drug|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
79256503|NCT05074095|Other|retrospective analysis|
79256504|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 1)|
79256505|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 2)|
79256506|NCT03266133|Behavioral|Sleep Education for Pregnancy|Sleep education specific to pregnancy
79256507|NCT02124967|Other|Exercise|A one hour exercise class including both aerobic activity and resistance training
79256508|NCT02252341|Dietary Supplement|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
79256509|NCT03266367|Diagnostic Test|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
79256510|NCT02127853|Drug|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
79256511|NCT02127853|Drug|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
79256512|NCT03266445|Drug|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
79256513|NCT03550339|Procedure|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
79256514|NCT03550339|Behavioral|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
79256515|NCT03550339|Behavioral|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
79256516|NCT02458833|Behavioral|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
79256517|NCT02125045|Dietary Supplement|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
79256518|NCT02125045|Dietary Supplement|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
79256519|NCT02456805|Other|Infant Formula 1|Feed ab libitum
79554223|NCT01639651|Other|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
79554224|NCT01639651|Other|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
79554225|NCT01639677|Procedure|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
79554226|NCT01639677|Procedure|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
79554227|NCT01638494|Dietary Supplement|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
79554228|NCT01639768|Drug|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
79256520|NCT02456805|Other|Infant Formula 2|Feed ab libitum
79256521|NCT03265977|Biological|H56:IC31|The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
79554229|NCT01639781|Dietary Supplement|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
79554230|NCT01639781|Dietary Supplement|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
79554231|NCT01639794|Drug|Vesitirim™ (Solifenacin)|Oral
79554232|NCT01639807|Drug|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
79554233|NCT01639807|Procedure|SLT|Selective Laser Trabeculoplasty
79256522|NCT03265977|Other|Placebo|Normal saline
79256523|NCT03550105|Device|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
79256524|NCT03263169|Behavioral|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
79256525|NCT03550027|Device|PleurX|Positioning of drainage PleurX
79256526|NCT03550027|Device|Pleurocath|Positioning of drainage Pleurocath
79256527|NCT03265743|Other|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
79256528|NCT01367119|Drug|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
79256529|NCT01367119|Drug|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
79554234|NCT01639820|Procedure|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
79554235|NCT01639820|Procedure|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
79554236|NCT01639846|Drug|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
79554237|NCT01639846|Drug|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
79554238|NCT01639859|Other|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
79554239|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
79554240|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
79256530|NCT05068011|Device|Spinal Cord Stimulation|differential target multiplexed stimulation
79256531|NCT05066685|Other|All participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
79554241|NCT01639885|Biological|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
79256532|NCT02252107|Drug|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
79395792|NCT02328534|Procedure|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
79718031|NCT05906771|Dietary Supplement|Nutraceutical placebo|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~Nutraceutical placebo contains microcystalline cellulose (185mg) and maltodextrin (185mg)."
79718032|NCT05899166|Other|Ketogenic diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
79854065|NCT04761770|Procedure|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
79854066|NCT04758338|Other|VUMC telehealth services|Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
79554242|NCT01639898|Drug|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
79554243|NCT01639898|Drug|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
79854067|NCT04758338|Other|Interview|25-30 participants will be interviewed
80018332|NCT03651297|Other|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
80031494|NCT04905160|Other|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
79256533|NCT03262545|Drug|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
79256534|NCT03262545|Drug|Placebos|Physical properties of placebos are consistent with apatinib
79554244|NCT01639911|Drug|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
79554245|NCT01639911|Drug|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
79256535|NCT02128009|Other|osteoporosis|
79256536|NCT02125123|Other|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
79554246|NCT01640119|Dietary Supplement|Bicarbonate|bicarbonate administration
79554247|NCT01640158|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
79554248|NCT01640158|Other|Commercially available computerized training|Commercially available computerized training, up to 65 hours
79554249|NCT01640431|Other|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
79554250|NCT01640457|Drug|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
79554251|NCT01640457|Device|NOVOCART® Disc basic|ADCT (Media with no active cell component)
79554252|NCT01640561|Behavioral|MISC|The Mediational Interventions for Sensitizing Caregivers
79554253|NCT01640561|Behavioral|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
79554254|NCT01640743|Drug|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
79718033|NCT05899166|Other|Standard diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
79854068|NCT04758338|Other|Educational materials|Participants will be provided educational materials
79854069|NCT04752618|Behavioral|P-STAIR|PCIT+ STAIR
79256537|NCT02125123|Other|Counseling|Dietary counseling
79395793|NCT02328456|Other|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
79395794|NCT02326350|Drug|Aspirin 75mg|Active treatment
79395795|NCT02326350|Drug|Lactose powder|Placebo
79554255|NCT01640743|Drug|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
79554256|NCT01641016|Drug|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
79554257|NCT01641354|Procedure|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
79554258|NCT01641614|Procedure|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
79554259|NCT01641614|Procedure|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
79554260|NCT01641757|Procedure|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
79554261|NCT01642394|Behavioral|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
79554262|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
79554263|NCT01642511|Procedure|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
79554264|NCT01642511|Drug|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
79554265|NCT01642511|Device|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
79554266|NCT01642511|Procedure|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
79554267|NCT01642511|Procedure|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
79554268|NCT01642771|Drug|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
79554269|NCT01642771|Drug|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
79554270|NCT01642979|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
79554271|NCT01642979|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
79554272|NCT01642979|Drug|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
79854070|NCT04752618|Behavioral|Supportive Counseling|Non-trauma focused psychotherapy
79256538|NCT03262077|Drug|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
79854071|NCT04751773|Behavioral|Exercise training|Perioperative exercise training
79854072|NCT04751279|Other|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
80018333|NCT02122302|Device|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
80018334|NCT02127138|Device|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
79256539|NCT03262077|Drug|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
79256540|NCT03551119|Behavioral|Exercise|See previous description
79256541|NCT03551119|Other|Enhanced usual care|See previous description
79256542|NCT03265899|Drug|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
79256543|NCT03265899|Drug|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
79256544|NCT04460846|Dietary Supplement|Alkaline water|1.5 liters per day
79256545|NCT04460846|Dietary Supplement|Reverse osmosis water|1.5 liters per day
79256546|NCT02132221|Behavioral|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
79256547|NCT03265587|Other|No intervention|No intervention
79854073|NCT04749043|Device|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
79256548|NCT04459988|Drug|Ocrelizumab|Description Needed
79256549|NCT02132299|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
79256550|NCT02132299|Biological|Normal Saline (Placebo)|
79554273|NCT01643031|Drug|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
79554274|NCT01643031|Drug|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
79554275|NCT01643291|Procedure|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
79554276|NCT01640067|Biological|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
79554277|NCT01643434|Drug|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
79554278|NCT01643434|Drug|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
79554279|NCT01643694|Behavioral|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
79554280|NCT01643941|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
79554281|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79554282|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
79554283|NCT01643941|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
79554284|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79554285|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
79554286|NCT01643941|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
79718034|NCT05895136|Drug|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
79718035|NCT05895136|Drug|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
79554287|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79395796|NCT02326194|Biological|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
79395797|NCT02326194|Biological|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
79718036|NCT05895136|Drug|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
79718037|NCT05894564|Drug|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
79718038|NCT05894564|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
79256551|NCT02132299|Biological|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
79256552|NCT03072680|Behavioral|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
79854074|NCT04749043|Drug|Nitrous oxide|30 min exposure for labor analgesia
79854075|NCT04747626|Device|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
79256553|NCT03072680|Behavioral|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
79395798|NCT02326194|Biological|placebo (one dose)|placebo, one doses
79395799|NCT02326194|Biological|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
79395800|NCT02326038|Drug|Methylphenidate|single oral administration of 20 mg tablet
79395801|NCT02328378|Procedure|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
79718039|NCT05889975|Device|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
79718040|NCT05889975|Device|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
79718041|NCT05889975|Device|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
79718042|NCT05888116|Device|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
79718043|NCT05888116|Device|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
79718044|NCT05886062|Other|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
79718045|NCT05886062|Other|Control Group|They will only continue their routine basketball technical-tactical training.
79718046|NCT05885685|Drug|Nabilone Oral Capsule|Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
79854076|NCT04745403|Drug|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
79854077|NCT04728334|Drug|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
79854078|NCT04726566|Procedure|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
79854079|NCT04726566|Procedure|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
79854080|NCT04719663|Behavioral|Biological illness and treatment rationale|Depression is described as a brain disorder and the role of monoamine, brain structures, and brain functions are reported as central mechanisms of relevance for its etiology and treatment. Biological processes are illustrated using typical charts and visualizations. Psychological influences are mentioned, but only as a byproduct of the disorder.
79854081|NCT04719663|Behavioral|Psychological illness and treatment rationale|Depression is described as a psychological disorder resulting from emotion regulation deficits. The suppression of emotions receives a special role in explaining depression. The psychological processes are illustrated using charts and visualizations. Biological aspects are mentioned, but only as a byproduct of the disorder.
79854082|NCT04719663|Drug|Active pharmacological placebo|"The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments."
79854083|NCT04719663|Behavioral|Active psychological placebo|"Emotional writing consists of writing about emotional experiences (4 sessions, one per week, 30 minutes each). The study instructor will be present displaying standard psychotherapeutic attitudes but will not read the participant's notes. The rationale for this treatment is briefly explained as improving the dealing with emotions to achieve a psychological balance in humans with depression."
79854084|NCT04716933|Biological|Pembrolizumab|IV infusion Q3W
79854085|NCT04716933|Drug|Carboplatin|IV infusion Q3W
79718047|NCT05881733|Device|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
79718048|NCT05876377|Biological|Pfizer-BioNTech COVID-19 bivalent mRNA vaccine|Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
79718049|NCT05873504|Device|High Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
79718050|NCT05873504|Device|Low Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
79718051|NCT05870917|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10^6 anti-BCMA CAR+T cells/kg respectively
79718052|NCT05870540|Drug|BPL-003|A single dose administered intranasally
79718053|NCT05870228|Behavioral|Strathclyde Sleep Intervention|Manual-based CBT-I
79718054|NCT05866094|Behavioral|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
79718055|NCT05865405|Behavioral|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
79718056|NCT05864144|Drug|SNS-101 (anti-VISTA)|SNS-101 IV every 21 days.
79718057|NCT05864144|Drug|Cemiplimab|Cemiplimab IV every 21 days.
79718058|NCT05856526|Drug|Spesolimab - solution for infusion|Solution for infusion
79854086|NCT04716933|Drug|Cisplatin|IV infusion Q3W
79854087|NCT04716933|Drug|Pemetrexed|IV infusion Q3W
79854088|NCT04716933|Drug|Lenvatinib|Oral capsule once daily
79854089|NCT04716933|Drug|Placebo matching lenvatinib|Oral capsule once daily
79854090|NCT04715230|Biological|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
79854091|NCT04715230|Drug|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
79395802|NCT00970866|Dietary Supplement|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
79395803|NCT00970866|Dietary Supplement|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
79554288|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
79554289|NCT01643941|Biological|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
79554290|NCT01643941|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
79554291|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
79854092|NCT04715230|Drug|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
79404327|NCT05615077|Other|Combined exercise-education intervention|"Combined exercise and education intervention by fall risk state for 12 months during intervention period.~Exercise intervention includes balance exercise and strength exercise according to protocol.~Education intervention includes medication review, nutrition intervention, and home hazard modification.~The key to medication review is paying special attention to medications known to increase the risk of falls. Reduction of these medications is recommended, and redundant psychotropic medications are withdrawn. Nutrition intervention includes investigating dietary habits and calculate insufficient protein intake to provide customized diet and high protein drink. If vitamin D necessary, supplements are prescribed. Home hazard modification includes providing instructions to reduce and modify the home hazards that increase the risk of falls."
79554292|NCT01643941|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
79554293|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
79554294|NCT01643941|Procedure|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
79554295|NCT01643980|Drug|Vaginal micronized progesterone|200 mg vaginal route per day
79554296|NCT01643980|Device|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
79554297|NCT01644214|Other|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
79554298|NCT01644708|Behavioral|Self empowerment|"1. Group meeting, introducing the method and the assessment tools~Self-empowerment,~Handing over the journal,~Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
79554299|NCT01644721|Biological|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
79718059|NCT05856526|Drug|Placebo matching to spesolimab - solution for infusion|Solution for infusion
79718060|NCT05856526|Drug|Spesolimab - solution for injection|Solution for injection
79718061|NCT05856526|Drug|Placebo matching to spesolimab - solution for injection|Solution for injection
79718062|NCT05851768|Drug|Bupivacaine|Bupivacaine 0.25%
79718063|NCT05851768|Drug|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
79718064|NCT05851768|Drug|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
79718065|NCT05849922|Drug|SAR442970|1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
79718066|NCT05849922|Drug|Placebo|1 mL extractable volume of placebo filled in 2 mL glass vial
79718068|NCT05848297|Device|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
79718069|NCT05846230|Drug|BI 1291583|Tablet
79718070|NCT05846230|Drug|Placebo matching BI 1291583|Tablet
79718071|NCT05839925|Diagnostic Test|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
79854093|NCT04710368|Drug|Evolocumab Injections|Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.
79854094|NCT04709939|Other|OPAT|Observation of patients who are discharged from the hospital on OPAT.
79854095|NCT04709939|Other|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
79854096|NCT04708834|Drug|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
79554300|NCT01644916|Procedure|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
79718072|NCT05837494|Drug|Intra-articular Ozone and corticosteroids|"patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection."
79718073|NCT05837494|Drug|intra-articular PRGF Method|"Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors [PRGF] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration."
79854097|NCT04708730|Device|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
79256554|NCT03072680|Behavioral|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
79854098|NCT04705116|Biological|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
79718074|NCT05836896|Genetic|MDC-CAR-BCMA001 (BCMA directed CAR T-cells)|Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
79718075|NCT05824598|Behavioral|Multifunctional rehabilitation treatment|multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
79854099|NCT04704375|Device|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
79395804|NCT00970866|Dietary Supplement|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
79718076|NCT05820035|Device|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
79718077|NCT05819398|Drug|Spesolimab Formulation 1|Spesolimab Formulation 1
79854100|NCT04704375|Procedure|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
79718078|NCT05819398|Drug|Spesolimab Formulation 2|Spesolimab Formulation 2
79854101|NCT04704375|Procedure|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
79854102|NCT04695340|Dietary Supplement|Psyllium|Psyllium is given to patients
79854103|NCT04692324|Procedure|Biospecimen Collection|Undergo collection of CSF samples
79854104|NCT04692324|Other|Electronic Health Record Review|Review of medical records
79854105|NCT04692324|Other|Survey Administration|Ancillary studies
79256555|NCT02125201|Drug|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
79256556|NCT03072368|Other|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
79256557|NCT02125357|Drug|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
79854106|NCT04684641|Drug|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
79256558|NCT02125357|Drug|Enzalutamide|160mg PO OD as per standard of care.
79256559|NCT03265509|Dietary Supplement|glutamine supplementation|30 g/day glutamine supplementation for three months
79256560|NCT03265509|Dietary Supplement|fantomalt supplementation|30 g/day fantomalt supplementation for three months
79256561|NCT03074942|Drug|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
79256562|NCT02125435|Drug|ASP2408|intravenous
79854107|NCT04684641|Other|Placebo|Participants will be randomized to receive the placebo.
79854108|NCT04676529|Drug|PXS-5505|PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
79256563|NCT02125435|Drug|Placebo|intravenous
79554301|NCT01644916|Procedure|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
79256564|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|7 days of the prescribed diet
79554302|NCT01644929|Procedure|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
79554303|NCT01644929|Procedure|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
79554304|NCT01644929|Procedure|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
79554305|NCT01645137|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
79554306|NCT01645137|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
79554307|NCT01645228|Radiation|coronary calcium score measurement|
79554308|NCT01645228|Biological|high sensitivity C reactive protein measurement|
79554309|NCT01645228|Procedure|ankle brachial index measurement|
79718079|NCT05819398|Drug|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
79718080|NCT05819398|Drug|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
79854109|NCT04676490|Other|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
79854110|NCT04676490|Other|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
79854111|NCT04672005|Drug|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
79256565|NCT03265353|Other|Moderate Potassium/High Sodium Diet|7 days of the prescribed diet
79395805|NCT03145350|Other|High-fat, low-carbohydrate|Dietary intervention: 4 week
79395806|NCT03145350|Other|Low-fat, high-carbohydrate|Dietary intervention: 4 week
79395807|NCT03145584|Drug|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
79395808|NCT03145584|Other|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
79395809|NCT03145194|Drug|Ticagrelor|2 x 90mg Ticagrelor tablets
79395810|NCT03145194|Other|Placebo|2 x matching placebo tablets
79395811|NCT05076864|Other|No intervention|No intervention
79395812|NCT03145116|Device|CT ASPHINA 509|Intraocular lens
79395813|NCT03812250|Procedure|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
79395814|NCT03812250|Procedure|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
79718081|NCT05812807|Biological|Pembrolizumab|Given IV
79718082|NCT05812807|Other|Patient Observation|Undergo observation
79718083|NCT05812807|Procedure|Biopsy|Undergo biopsy
79718084|NCT05812807|Procedure|Biospecimen Collection|Undergo collection of blood
79395815|NCT03810378|Behavioral|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
79395816|NCT03810378|Behavioral|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
79395817|NCT02328300|Drug|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
79404328|NCT04555902|Behavioral|Postcard|The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
79854112|NCT04668651|Other|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
79854113|NCT04658537|Radiation|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
80018335|NCT03651531|Drug|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
79554310|NCT01645566|Behavioral|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
79718085|NCT05812807|Other|Questionnaire Administration|Ancillary studies
79718086|NCT05812807|Other|Quality-of-Life Assessment|Ancillary studies
79854114|NCT04652375|Other|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
79256566|NCT03265353|Other|High Potassium/High Sodium Diet|7 days of the prescribed diet
79256567|NCT03072446|Device|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
79718087|NCT05809687|Drug|DKP21102_C|Placebo
79718088|NCT05809687|Drug|DKP21102_B|Treatment
79718089|NCT05809687|Drug|DKP21102_A|Active Control
79718090|NCT05800210|Device|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
79718091|NCT05793450|Drug|IBI362|2.0mg, SC, single dose
79718092|NCT05791305|Behavioral|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
79554311|NCT01645722|Procedure|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
79718093|NCT05784012|Drug|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
79554312|NCT01645839|Drug|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
79718094|NCT05784012|Drug|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
79718095|NCT05784012|Drug|cisplatin plus radiotherapy|In the concurrent phase
79718096|NCT05784012|Drug|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
79718097|NCT05775861|Drug|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
79854115|NCT04652375|Other|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
79718098|NCT05775861|Drug|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
79718099|NCT05772637|Procedure|Repeated cystometries with bladder sensations assessment|A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
79718100|NCT05766514|Drug|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
79718101|NCT05766514|Drug|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
79718102|NCT05766514|Drug|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
79718103|NCT05766514|Drug|azacitadine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitadine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
79718104|NCT05766514|Drug|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
79718105|NCT05760313|Drug|Linaclotide|Capsule; oral
79718106|NCT05760313|Drug|Placebo|Capsule; oral
79718107|NCT05759949|Drug|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
79718108|NCT05759949|Drug|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
79718109|NCT05759949|Drug|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
79854116|NCT04649125|Radiation|dose escalation|single fraction dose escalation to the tumour
79854117|NCT04643379|Drug|Olaparib|Supplied by Merck & Co.
79854118|NCT04643379|Drug|Pembrolizumab|Supplied by Merck & Co.
79395818|NCT03144492|Biological|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
79395819|NCT03144024|Device|band implantation|
79395820|NCT03144024|Device|rigid ring implantation|
79395821|NCT03144102|Behavioral|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
79395822|NCT03144102|Device|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
79554313|NCT01645995|Dietary Supplement|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
79554314|NCT01645995|Dietary Supplement|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
79554315|NCT01646190|Dietary Supplement|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
79554316|NCT01646190|Procedure|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
79554317|NCT01646190|Behavioral|Fasting state after midnight|No preoperative glucose load
79554318|NCT01646190|Behavioral|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
79554319|NCT01646190|Behavioral|urinary catheter removal|at POD 1
79554320|NCT01646190|Behavioral|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
79554321|NCT01646190|Behavioral|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
79554322|NCT01646190|Behavioral|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), >4h out of bed on POD1, >6h on POD2, complete at POD3
79554323|NCT01646190|Other|Preanesthetic medication|Preanesthetic oral medication before surgery
79554324|NCT01646437|Drug|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
79554325|NCT01646437|Drug|Aspirin|75 mg daily
79554326|NCT01646437|Drug|Vitamin D|60,000 IU monthly
79554327|NCT01646437|Drug|Matching Placebo|Matching Placebo
79554328|NCT01646619|Drug|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
79554329|NCT01646619|Drug|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
79554330|NCT01646749|Dietary Supplement|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
79718110|NCT05759949|Drug|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
79718111|NCT05759949|Drug|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
79718112|NCT05757492|Drug|CHS-006 (anti-TIGIT)|Arm A participants will receive CHS-006 administered via IV Q3W.
79718113|NCT05757492|Drug|toripalimab (anti-PD-1)|Arm B participants will receive toripalimab administered via IV Q3W.
79718114|NCT05756348|Device|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
79718115|NCT05751993|Behavioral|ADAPT|The intervention is testing the feasibility of a reinforcement learning tool to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (early morning, morning, midday, and evening on a daily basis), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability).
79554331|NCT01646840|Drug|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
79718116|NCT05751668|Drug|Paclitaxel|Given IV
79718117|NCT05751668|Drug|Monosialotetrahexosylganglioside|Given IV
79854119|NCT04643379|Drug|Carboplatin|Commercially available
79395823|NCT03144102|Behavioral|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
79395824|NCT03144102|Device|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
79554332|NCT01646840|Drug|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
79554333|NCT01647490|Procedure|Permanent Cardiac Pacemaker Implantation|
79554334|NCT01647750|Drug|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
79554335|NCT01647750|Drug|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
79718118|NCT05751668|Other|Questionnaire Administration|Ancillary Studies
79718119|NCT05751668|Other|Quality-of-life assessment|Ancillary Studies
79718120|NCT05751668|Drug|Placebo Administration|Given IV
79395825|NCT03143946|Dietary Supplement|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
79718121|NCT05744063|Drug|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
79854120|NCT04643379|Procedure|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
79395826|NCT03143946|Other|Diet advice|
79395827|NCT02039700|Drug|Lesinurad 400 mg|
79395828|NCT02039700|Drug|[14C]lesinurad (100 μg per 10 mL)|
79404329|NCT04555902|Behavioral|Small Gift|Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
79554336|NCT01647880|Drug|Verum arm receiving Gilenya®|
79554337|NCT01647880|Drug|Active Comparator receiving Extavia®|
79395829|NCT02333214|Other|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
79404330|NCT04555902|Behavioral|Loss Frame and Fear Appeals|The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
79554338|NCT01647997|Other|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
79554339|NCT01648218|Drug|Neutral protamine hagedorn (NPH) insulin|
79554340|NCT01648218|Drug|Regular human insulin or Insulin Aspart|
79554341|NCT01648218|Drug|Insulin glargine|
79554342|NCT01648465|Drug|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
79554343|NCT01648621|Behavioral|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
79554344|NCT01648621|Behavioral|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
79554345|NCT01648621|Behavioral|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
79554346|NCT01648621|Behavioral|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
79718122|NCT05743179|Drug|Zoledronate|Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
79718123|NCT05740839|Behavioral|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
79718124|NCT05740839|Behavioral|Control Group|Usual Activities
79718125|NCT05739279|Diagnostic Test|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
79256568|NCT02128087|Behavioral|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
79554347|NCT01648621|Behavioral|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness [MRC] Class 4 & 5 or modified MRC [mMRC] 3 & 4) f. frequent ED visits (> 2) in last 12 months~5. 12 weeks of clinical stability with no ED visits."
79554348|NCT01648621|Behavioral|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
79554349|NCT01648621|Behavioral|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
79554350|NCT01648621|Behavioral|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
79718126|NCT05739279|Diagnostic Test|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
79718127|NCT05739279|Diagnostic Test|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
79718128|NCT05739279|Diagnostic Test|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
79256569|NCT02128087|Behavioral|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
79404331|NCT01676389|Other|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
79554351|NCT01648621|Behavioral|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~have had a recent exacerbation, but are now clinically stable;~symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~have sufficient motivation to participate."
79554352|NCT01648621|Behavioral|Smoking cessation|Referral to a smoking cessation program (as applicable)
79554353|NCT01648621|Behavioral|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
79554354|NCT01648621|Behavioral|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
79554355|NCT01648777|Device|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
79554356|NCT01648777|Drug|placebo|"Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
79718129|NCT05737212|Radiation|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
79718130|NCT05737212|Radiation|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
79718131|NCT05737212|Radiation|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
79718132|NCT05736835|Biological|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
79718133|NCT05730036|Drug|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
79718134|NCT05730036|Drug|Elotuzumab|Elotuzumab will be administered by IV infusion
79854121|NCT04642066|Other|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
79854122|NCT04642066|Other|No cold water immersion|People without cold water immersion
79854123|NCT04638751|Drug|Immunotherapy|Checkpoint inhibitor
79854124|NCT04638751|Drug|Chemotherapy|Any form of chemotherapy
79854125|NCT04638751|Procedure|CRC surgical resection|Surgical resection to remove colorectal cancer
79854126|NCT04638751|Procedure|Colonoscopy|Standard-of-care colonoscopy for CRC screening
79854127|NCT04634916|Device|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
79854128|NCT04628507|Other|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
79718135|NCT05730036|Drug|Pomalidomide|Pomalidomide capsules will administered by mouth (PO)
79718136|NCT05730036|Drug|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
79718137|NCT05724199|Drug|Rocatinlimab|Subcutaneous (SC) injection
79718138|NCT05724199|Other|Placebo|SC injection
79718139|NCT05720637|Drug|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
79854129|NCT04616209|Biological|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
79854130|NCT04614870|Diagnostic Test|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
79854131|NCT04614519|Procedure|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
79854132|NCT04614519|Procedure|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
79854133|NCT04614038|Diagnostic Test|DETEC® pH|DETEC® pH is a disposable diagnostic device that is used to indicate the alkalinity of the wound by testing wound exudate adsorbed onto wound dressing.
80018336|NCT03651531|Drug|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
79854134|NCT04608305|Biological|IIBR-100, low dose (prime)|Single administration of IIBR-100 1*10E5 pfu/ml
79854135|NCT04608305|Biological|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1*10E6 pfu/ml
79854136|NCT04608305|Biological|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1*10E7 pfu/ml
79854137|NCT04608305|Biological|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1*10E5 pfu/ml, 28 days apart
80018337|NCT02648932|Biological|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
80018338|NCT02648932|Procedure|Matched Unrelated Donor Transplant|
79256570|NCT02458911|Device|Paclitaxel-eluting balloon|
79256571|NCT03075020|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
79554357|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
79554358|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
79256572|NCT03075020|Other|AIR|Room air will be administered as placebo
79395830|NCT02333214|Other|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
79554359|NCT01648998|Drug|Fludrocortisone|single dose 500 mg, capsule
79554360|NCT01648998|Drug|Placebo|
79554361|NCT01649024|Drug|Tremelimumab|Given IV
79554362|NCT01649843|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
79554363|NCT01649934|Behavioral|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
79554364|NCT01649934|Behavioral|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
79554365|NCT01649960|Drug|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
79554366|NCT01650012|Drug|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
79395831|NCT05076474|Drug|Orlistat 60mg Cap|Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
79395832|NCT05076318|Other|Aminoacid, alanine-infusion|During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
79395833|NCT05076240|Procedure|FilmArray® analysis|FilmArray® multiplex PCR analysis to diagnose ventilator associated pneumonia in COVID-19 ARDS
79395834|NCT05076162|Diagnostic Test|PAED|Delirium positive or negative
79554367|NCT01650012|Drug|Placebo|Placebo
79554368|NCT01650025|Dietary Supplement|VSL#3 active probiotic|
79554369|NCT01650025|Other|VSL#3 placebo|
79718140|NCT05720637|Device|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
79854138|NCT04608305|Other|Saline Placebo (single)|Single administration of saline placebo
79854139|NCT04608305|Other|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
80018339|NCT03627637|Dietary Supplement|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
79854140|NCT04608305|Biological|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1*10E6 pfu/ml, 28 days apart
79854141|NCT04608305|Biological|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1*10E7 pfu/ml, 28 days apart
79854142|NCT04608305|Biological|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1*10E8 pfu/ml, 28 days apart
79256573|NCT03262311|Other|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
79256574|NCT02128165|Device|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
79256575|NCT02128165|Device|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
79256576|NCT02125591|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
79256577|NCT02125591|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
79256578|NCT05002634|Dietary Supplement|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
79554370|NCT01650038|Other|treatment with faecal transplantation (donor faeces)|faecal transplantation
79554371|NCT01650038|Other|treatment with faecal transplantation (own faeces)|faecal transplantation
79554372|NCT01650090|Drug|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
79554373|NCT01650129|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
79554374|NCT01650129|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
79554375|NCT01650142|Other|No intervention|No intervention
79554376|NCT01650155|Drug|BI 1005273 s.c.|injection
79554377|NCT01650155|Drug|BI 105273 i.v. Placebo|infusion
80018340|NCT02127216|Behavioral|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
79256579|NCT04831437|Radiation|Hypofractionated EBRT|EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
79395835|NCT05075616|Procedure|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
79554378|NCT01650155|Drug|BI 1005273 s.c. Placebo|injection
79554379|NCT01650155|Drug|BI 1005273 i.v.|infusion
79554380|NCT01650181|Drug|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
79554381|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
79554382|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
79718141|NCT05720637|Device|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
79718142|NCT05718934|Drug|Neostigmine and glycopyrrolate|See arm descriptions
79718143|NCT05718934|Drug|Sugammadex|See arm descriptions
79718144|NCT05718427|Behavioral|Ayres Sensory Integration Therapy|Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
79395836|NCT02328066|Device|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
79395837|NCT02328144|Drug|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
79395838|NCT02328144|Drug|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
79554383|NCT01650181|Drug|Metformin|Patients with fatty liver treated with diet, exercise and metformin
79554384|NCT01650207|Procedure|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
79554385|NCT01650207|Procedure|TENS|
79554386|NCT01650207|Procedure|sham acupuncture|
79554387|NCT01650233|Behavioral|Mindfulness-based stress reduction|
79554388|NCT01650272|Drug|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
79554389|NCT01650272|Drug|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
79554390|NCT01650337|Other|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
79256580|NCT04831437|Radiation|Standard EBRT|EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
79256581|NCT02128243|Drug|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
79256582|NCT02128243|Drug|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
79256583|NCT03072212|Other|Observational study|No intervention
79395839|NCT02327988|Other|Cryotherapy|
79395840|NCT02327988|Device|Laser therapy|
79395841|NCT02327676|Drug|Emtricitabine|emtricitabine were given to each patients for 48 weeks
79395842|NCT02327832|Procedure|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
79395843|NCT02327832|Drug|bone marrow-derived mesenchymal stem cells|
79395844|NCT02035566|Other|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
79554391|NCT01650363|Other|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
79554392|NCT01650363|Drug|Homeopathic placebo medication|2-3 mm small spheric suger pils
79554393|NCT01650376|Drug|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
79554394|NCT01650376|Drug|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
80018341|NCT03133520|Device|High flow oxygen therapy|High-flow nasal oxygen [HFNO] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
79404332|NCT01676389|Other|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
79554395|NCT01650376|Drug|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
79554396|NCT01650389|Biological|MVA85A|
79554397|NCT01650389|Biological|Candin|
79554398|NCT01650389|Biological|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
79554399|NCT01650415|Drug|Erythropoietin|twice a week for 1 month
79554400|NCT01650415|Drug|Placebo erythropoietin|twice a week for 1 month
79554401|NCT01650428|Biological|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
79554402|NCT01650428|Drug|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
79554403|NCT01650428|Drug|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
79554404|NCT01650428|Drug|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
79554405|NCT01650441|Drug|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
79256584|NCT02132455|Procedure|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
79404333|NCT05227872|Device|ultrasound|POCUS
79718147|NCT05716425|Drug|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
79554406|NCT01650441|Radiation|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
79554407|NCT01650454|Other|2 night polysomnography|Polysomnography
80018342|NCT05130736|Device|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
80018343|NCT02122458|Device|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
79256585|NCT04769427|Device|PDO max threads|To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
79554408|NCT01650454|Other|battery of neuropsychological tests|
79554409|NCT01650454|Other|virtual reality test|
79718148|NCT05716425|Drug|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
79718149|NCT05712200|Biological|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
79854143|NCT04606446|Drug|PF-07248144|KAT6 Inhibitor
79256586|NCT02125669|Procedure|Laser treatment|Pulsed dye laser 595nm
79256587|NCT02125669|Device|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
79256588|NCT03072056|Drug|MIN-101|
79256589|NCT02125747|Other|No Respiratory Therapy|Patients received conventional treatment.
79404334|NCT04499352|Drug|BI 754091|BI 754091
79404335|NCT04499352|Drug|BI 836880|BI 836880
79404336|NCT03155035|Drug|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
79554410|NCT01650454|Other|subjective evaluation of sleep and somnolence|
79404337|NCT03155035|Dietary Supplement|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
79404338|NCT01671163|Procedure|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
79718150|NCT05712200|Drug|Placebo|"Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab"
79554411|NCT01650480|Other|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
79554412|NCT01650493|Device|Clinpro 5000|Dentrifice containing 950ppm fluoride
79554413|NCT01650493|Device|MI Paste Plus|Dentrifice containing 950ppm fluoride
79554414|NCT01650493|Device|Tom's of Maine|Dentrifice that is fluoride free
79554415|NCT01650506|Drug|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
80031495|NCT04890548|Drug|AZD3427|Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
80031496|NCT04904848|Other|Survey evaluation|examine the convergent validity and reliability of a Turkish version
79554416|NCT01650506|Drug|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
79554417|NCT01650532|Behavioral|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
79395845|NCT02333058|Drug|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
79395846|NCT03144960|Procedure|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
79718151|NCT05711030|Procedure|Thoracic paravertebral block multiple (3) injections|already described in arm description
79718152|NCT05711030|Procedure|Thoracic paravertebral block single injection|already described in arm description
79554418|NCT01650532|Behavioral|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
79554419|NCT01650597|Drug|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
79718153|NCT05710406|Drug|Encorafenib|Given PO
79718154|NCT05710406|Biological|Cetuximab|Given IV
79554420|NCT01650597|Drug|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
79554421|NCT01650597|Drug|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
79554422|NCT01650610|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
79718155|NCT05710406|Procedure|Biospecimen Collection|Undergo collection of blood samples
79718156|NCT05710406|Procedure|Computed Tomography|Undergo CT
79718157|NCT05710406|Procedure|Magnetic Resonance Imaging|Undergo MRI
79718158|NCT05710406|Other|Patient Observation|Undergo observation per usual care
79718159|NCT05707468|Drug|ADT combined with abiraterone|The patients will receive long-term ADT combined with abiraterone.
79718160|NCT05707468|Radiation|neoadjuvant hormone and RT|The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
79718161|NCT05706532|Diagnostic Test|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
79854144|NCT04606446|Drug|Fulvestrant|Endocrine Therapy
79256590|NCT02125747|Other|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
79256591|NCT03265041|Diagnostic Test|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
79256592|NCT03072290|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
79256593|NCT03072290|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
79554423|NCT01650623|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
79554424|NCT01650623|Behavioral|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
79554425|NCT01650649|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
79554426|NCT01650649|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
79554427|NCT01650662|Drug|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
79554428|NCT01650675|Behavioral|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
79554429|NCT01650675|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
79395847|NCT03144570|Other|None, non-interventional study|Not applicable, non-interventional study
79256594|NCT05002712|Other|Heavy resistance training|Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.
79554430|NCT01650714|Other|Full thickness gastric biopsy|
79554431|NCT01650714|Procedure|Full thickness gastric biopsy|
79554432|NCT01650727|Drug|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m^2 up to a maximum dose of 14 mg/m^2.
79554433|NCT01650727|Biological|Rituximab|Rituximab 375 mg/m^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
79554434|NCT01650740|Drug|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
79554435|NCT01650740|Drug|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
79554436|NCT01650740|Other|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
79554437|NCT01650753|Dietary Supplement|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10^10 cells/sachet)
79718162|NCT05701306|Drug|APG-115|Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
79395848|NCT03144726|Device|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
79395849|NCT03144726|Other|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
79395850|NCT03143634|Behavioral|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
79395851|NCT03143634|Behavioral|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
79554438|NCT01650753|Dietary Supplement|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
79718163|NCT05701306|Drug|APG-2575|Orally once a day (QD) for 21 days, 21 days as a cycle.
79718164|NCT05696717|Drug|Ampreloxetine|Oral tablet, QD
79718165|NCT05696717|Drug|Placebo|Oral tablet, QD
79718166|NCT05694871|Drug|Palbociclib|Given PO
79718167|NCT05694871|Biological|Cemiplimab|Given IV
79718168|NCT05694871|Procedure|Magnetic Resonance Imaging|undergo MRI
79718169|NCT05694871|Procedure|Computed Tomography|Undergo a CT Scan
79718170|NCT05694871|Procedure|Biospecimen collection|Undergo blood sample collection
79395852|NCT03111186|Drug|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
79395853|NCT03111186|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
79395854|NCT03111186|Drug|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
79718171|NCT05694871|Other|Questionnaire Administration|Ancillary Studies
79854145|NCT04606446|Drug|Letrozole|Endocrine Therapy
79854146|NCT04606446|Drug|Palbociclib|CDK4/6 Inhibitor
79395855|NCT03144648|Other|lifestyle|Observational study
79395856|NCT02332512|Drug|Apatinib|
79395857|NCT02332512|Drug|Placebo|
79854147|NCT04606446|Drug|PF-07220060|CDK4 inhibitor
79875448|NCT00395967|Drug|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
79718172|NCT05689645|Drug|F573 for injection|The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL,intramuscular injection (IM),once a day for 7 daysand. the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dose of the second stage was determined according to the results of the efficacy and safety trials in the first stage. The dose volume was 2 mL, and was administered intramuscular injection (IM) once a day for 14 days. The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days. The dosage of the above three stages of administration was calculated according to the weight of the most recent visit
79718173|NCT05689645|Drug|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
79718174|NCT05688241|Drug|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
79718175|NCT05686694|Other|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
79718176|NCT05686642|Drug|LT3001 Drug:high dose|Administered by intravenous infusion.
79718177|NCT05686642|Drug|Placebo|Administered by intravenous infusion.
79256595|NCT05002712|Other|Contrast strength training|Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.
79256596|NCT05002712|Other|Elastic resistance training|During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
79554439|NCT01650818|Other|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
79554440|NCT01650818|Other|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
79718178|NCT05686642|Drug|LT3001 Drug:low dose|Administered by intravenous infusion.
79718179|NCT05683977|Drug|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
79718180|NCT05682053|Diagnostic Test|Multiparametic MRI|patients will have a Multiparametric MRI
79718181|NCT05681130|Other|questionaire|two questionaires for each group
79554441|NCT01650870|Drug|Crystalline Lactulose|
79554442|NCT01650883|Dietary Supplement|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
79718182|NCT05674318|Dietary Supplement|Alpha-lactalbumin|Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
79718183|NCT05673512|Combination Product|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
79718184|NCT05673512|Combination Product|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
79718185|NCT05669352|Drug|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
79718186|NCT05669352|Drug|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
79854148|NCT04602117|Drug|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 ([vic-]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
79854149|NCT04599764|Other|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.The respective excitability alterations-enhancement by anodal and reduction by cathodal tDCS-can last for over an hour after the end of stimulation.
79718187|NCT05667454|Drug|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
79718188|NCT05667454|Drug|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
79854150|NCT04599764|Other|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.
79854151|NCT04596865|Procedure|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
79854152|NCT04592289|Procedure|Full bowel preparation|MBP+OA
79854153|NCT04592289|Procedure|Mechanical bowel preparation only|MBP
79854154|NCT04590963|Drug|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
80018344|NCT04468724|Behavioral|MAKASI|"The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~Listening and building trust~Active referral to structures that answers sanitary and social needs~Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons."
79554443|NCT01650883|Dietary Supplement|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
79554444|NCT01650896|Other|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
79854155|NCT04590963|Drug|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
79854156|NCT04590963|Other|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
79854157|NCT04583488|Drug|Intraperitoneal docetaxel|Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
79854158|NCT04581382|Biological|Nivolumab|Given IV
79854159|NCT04581382|Biological|Pembrolizumab|Given IV
80018345|NCT02903511|Drug|Metformin|Monitoring of safety and tolerability
80018346|NCT02903511|Drug|Placebo|Monitoring of safety and tolerability
80018347|NCT05133778|Dietary Supplement|Sweet orange and pomegranate extract|From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
80018348|NCT05133778|Other|Maltodextrin control|Supplementation with 760 mg maltodextrin
80018349|NCT05325528|Drug|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
79554445|NCT01650922|Procedure|phlebotomy|
80018350|NCT00147290|Device|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
79256597|NCT02132689|Drug|Actilyse (Thrombolytic therapy)|
79554446|NCT01650922|Procedure|biopsy|
79554447|NCT01650935|Behavioral|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
79554448|NCT01650948|Device|RetnaGene AMD LDT|
79554449|NCT01650961|Drug|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
79554450|NCT01650961|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
79554451|NCT01650974|Device|HFNOT|high flow nasal oxygen therapy
79554452|NCT01651091|Other|Meditation Awareness Training|Psychotherapy Intervention
79554453|NCT01651091|Other|Treatment as usual|
79554454|NCT01651130|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
79554455|NCT01651156|Drug|Tolvaptan|oral taken
79554456|NCT01651156|Drug|Placebo|
79854160|NCT04581382|Radiation|Radiation Therapy|Undergo radiation therapy
79854161|NCT04581382|Biological|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
79854162|NCT04580160|Device|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
79854163|NCT04579107|Combination Product|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
79854164|NCT04575051|Other|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
79854165|NCT04575051|Other|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
79854166|NCT04573985|Behavioral|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
79854167|NCT04573712|Other|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
79854168|NCT04565665|Other|Best Practice|Receive standard of care
79854169|NCT04565665|Biological|Mesenchymal Stem Cell|Given IV
80018351|NCT05441696|Device|ezCVP measurement|"Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
80018352|NCT02125422|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
80018353|NCT05130580|Other|Enhanced Consultation|Attend an enhanced consultation with decision aid
80018354|NCT05130580|Other|Standard of Care Consultation|Attend standard of care consultation
80018355|NCT05130580|Procedure|Conventional Imaging|Undergo 2D and 3D torso imaging
80018356|NCT05130580|Other|Educational Intervention|Receive educational materials
80018357|NCT05130580|Other|Questionnaire Administration|Ancillary studies
80018358|NCT02125500|Drug|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
80018359|NCT05130502|Other|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
79718189|NCT05667441|Combination Product|Standard lifestyle recommendations + dietary supplementation|refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
79718190|NCT05667441|Combination Product|Risk profiling|Personalized risk profiling for lifestyle and genetics.
79554457|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
79554458|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
79718191|NCT05667441|Behavioral|Coaching|Coaching
79718192|NCT05667012|Other|Educational videos|There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
79854170|NCT04563598|Behavioral|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
79854171|NCT04563598|Behavioral|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
79554459|NCT01651182|Drug|No tranexamic acid|Control
79854172|NCT04562935|Other|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
79554460|NCT01651182|Drug|Tranexamic Acid|
79854173|NCT04561778|Device|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
79854174|NCT04561778|Device|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
79854175|NCT04559646|Procedure|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
79854176|NCT04559646|Drug|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
79554461|NCT01651221|Other|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
79718193|NCT05666401|Procedure|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
79854177|NCT04559646|Drug|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
79854178|NCT04559646|Diagnostic Test|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
79854179|NCT04559646|Diagnostic Test|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
79718194|NCT05665595|Biological|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
79718195|NCT05665595|Biological|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
79718196|NCT05665062|Drug|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
79718197|NCT05665062|Drug|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
79854180|NCT04559646|Diagnostic Test|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
79854181|NCT04558528|Diagnostic Test|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
80018360|NCT05130502|Other|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
80018361|NCT02125578|Drug|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
79718198|NCT05665062|Drug|Cyclophosphamide|lymphodepletion
79718199|NCT05665062|Drug|Fludarabine|lymphodepletion
79718200|NCT05662501|Device|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
79854182|NCT04558515|Diagnostic Test|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
79854183|NCT04556656|Drug|Pridopidine|Pridopidine hard gelatin capsule
79854184|NCT04556656|Drug|Placebo|Pridopidine-matching placebo hard gelatin capsule
80018362|NCT02125578|Drug|Placebo|Each participant will receive placebo every other week or every 4 weeks.
79554462|NCT01651234|Drug|GCC-4401|"Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~single dose~dosage~Cohort 1: 2.5-mg GCC-4401C~Cohort 2: 5.0-mg GCC-4401C~Cohort 3: 10-mg GCC-4401C~Cohort 4: 20-mg GCC-4401C~Cohort 5: 40-mg GCC-4401C~Cohort 6: 80-mg GCC-4401C"
79718201|NCT05661019|Other|Obtain Myotrace measurements|Myotrace measurement equipment, consisting of an application (i.e. non-medical software) running on a Philips laptop, Porti7 data acquisition system and software (Twente Medical Systems International (TMSi), Netherlands) (CE-approved), ECG cables, and three standard ECG (for EMG) electrodes. Also an on the shelf accelerometry sensor and respiration belt (TMSi) are used for the NRD measurement (CE-approved).
79718202|NCT05647265|Biological|Nivolumab|Given IV
79554463|NCT01651234|Drug|GCC-4401C|"Capsule, identical in appearance to GCC-4401C, for oral use~single dose~dosage~Cohort 1: 2.5-mg matching placebo~Cohort 2: 5.0-mg matching placebo~Cohort 3: 10-mg matching placebo~Cohort 4: 20-mg matching placebo~Cohort 5: 40-mg matching placebo~Cohort 6: 80-mg matching placebo"
79718203|NCT05647265|Biological|Ipilimumab|Given IV
79554464|NCT01651247|Procedure|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
79554465|NCT01651273|Drug|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
79554466|NCT01651273|Drug|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
79554467|NCT01651273|Drug|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
79554468|NCT01651273|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
79554469|NCT01651286|Procedure|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
79554470|NCT01651286|Procedure|full face mask|using a standard full face mask during the induction of general anesthesia.
79554471|NCT01651312|Drug|14C-labeled YM178|oral solution (1.85 MBq)
79554472|NCT01651325|Drug|Isavuconazole|oral
79554473|NCT01651325|Drug|dextromethorphan|oral
79404339|NCT03154879|Device|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
79554474|NCT01651338|Procedure|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
79554475|NCT01651364|Drug|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
79554476|NCT01651364|Drug|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
79718204|NCT05647265|Procedure|Surgical Procedure|Undergo surgery
79718205|NCT05647265|Procedure|Computed Tomography|undergo CT
79718206|NCT05647265|Procedure|Magnetic Resonance Imaging|Undergo MRI
79718207|NCT05647265|Procedure|Positron Emission Tomography|Undergo PET
79554477|NCT01651377|Drug|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
79554478|NCT01651377|Drug|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
79404340|NCT01463696|Drug|MK-8242|10 mg, 100 mg and 150 mg capsules
79554479|NCT01651390|Device|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
79718208|NCT05643859|Dietary Supplement|Dietary Fiber|Given PO
79718209|NCT05643859|Procedure|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
79718210|NCT05643859|Procedure|Colonoscopy|Undergo Colonoscopy
79718211|NCT05643859|Other|Questionnaire Administration|Ancillary studies
79256598|NCT02132689|Drug|Heparine (Standard anticoagulation therapy)|
79256599|NCT02458053|Behavioral|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
79256600|NCT02458053|Behavioral|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
79256601|NCT02458053|Behavioral|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
79256602|NCT02458053|Behavioral|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
79256603|NCT02458053|Other|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
79256604|NCT02458053|Behavioral|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
79256605|NCT02128321|Drug|Isavuconazole|oral
79256606|NCT02128321|Drug|Repaglinide|oral
79404341|NCT03154723|Drug|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
79404342|NCT01671397|Behavioral|Diet and exercise counseling|Not needed
79404343|NCT01671397|Behavioral|Diet, exercise, sleep hygiene counseling|None needed
79404344|NCT04080908|Drug|Ferumoxytol injection|Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
79404345|NCT04409678|Behavioral|activity|physical activity
79404346|NCT01671553|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
79404347|NCT02653482|Drug|Dapagliflozin|
79404348|NCT02653482|Drug|Dapagliflozin matching placebo|
79404349|NCT03154567|Drug|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
79404350|NCT02707939|Other|Observation|Patients will be observed before and after they receive anesthesia
79718212|NCT05641194|Device|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
79718213|NCT05641194|Device|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
79718214|NCT05639946|Drug|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
79718215|NCT05639946|Drug|Placebo|Participants will receive placebo drug
79718216|NCT05639348|Other|Data collection on POD for calculation of the PIPRA score|"Data collection for presence of POD as diagnosed by the 4 A Tests (4AT) or the Intensive Care Delirium Screening Checklist (ICDSC). The collected data will be used to validate the existing PIPRA algorithm and to improve the algorithm and evaluate it in a cross-validation setting. For the model validation the area under the receiver operating characteristics (ROC) curve (AUC) will be computed."
79718217|NCT05638880|Drug|Valsartan 80 mg|Valsartan is an angiotensin receptor blocker.
79554480|NCT01651390|Device|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
79554481|NCT01651416|Drug|Artemether-lumefantrine combination|
79554482|NCT01651416|Drug|Dihydroartemisinin Piperaquine combination|
79718218|NCT05638880|Drug|Empagliflozin 10 MG|Empagliflozin is an oral hypoglycemic drug.
79718219|NCT05638880|Drug|Levocetirizine|Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
79718220|NCT05637086|Drug|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
79554483|NCT01651416|Drug|Amodiaquine plus sulphadoxine-pyrimethamine combination|
79718221|NCT05637086|Drug|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
79718222|NCT05631847|Procedure|Endovascular treatment|It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
79395858|NCT03143868|Behavioral|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
79718223|NCT05631847|Drug|Intravenous thrombolysis (Alteplase)|Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
79718224|NCT05630235|Drug|CBD|Participants will be administered a one time dose of 250mg of CBD orally.
79718225|NCT05630235|Other|Placebo|The placebo equivalent of the CBD oil administered orally.
79718226|NCT05628103|Drug|SEP-363856|SEP-363856 flexibly dosed
79718227|NCT05623397|Other|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10 sec ECGs collected at approximatively 2-minute intervals, 3 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and 10 seconds triplicate acquisition with QT-medical ® device collected at approximatively 2-minute intervals ).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
79718228|NCT05622747|Other|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature ~38.5°C and <39°C)
79718229|NCT05618197|Other|Passive heating|~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature ~38.5°C and <39°C) sessions over a period of 6 weeks.
79718230|NCT05615220|Drug|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
79395859|NCT03143478|Device|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
79718231|NCT05612581|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
79718232|NCT05612581|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
79718233|NCT05612581|Drug|TDF|TDF given orally
79718234|NCT05612581|Drug|PEG-IFNα|PEG-IFNα given by subcutaneous injection
79718235|NCT05610163|Drug|Capecitabine|Given PO
79718236|NCT05610163|Drug|5-fluorouracil|Given IV
79395860|NCT03143712|Drug|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
79395861|NCT03111264|Behavioral|CHAMP|"The CHAMP only group intervention is based on Food Friends & Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
79718237|NCT05610163|Drug|Leucovorin calcium|Given IV
79718238|NCT05610163|Drug|Irinotecan|Given IV
79718239|NCT05610163|Drug|Oxaliplatin|Given IV
79554484|NCT01651429|Behavioral|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
79554485|NCT01651468|Dietary Supplement|HEMOFIX|unique complex herbal mixture
79718240|NCT05610163|Radiation|Long Course Chemoradiotherapy|Receive LCRT
79718241|NCT05610163|Procedure|Computed Tomography|undergo CT
79718242|NCT05610163|Procedure|Magnetic Resonance Imaging|undergo MRI
79554486|NCT01651481|Drug|HCP1102|
79554487|NCT01651481|Drug|Singulair and Xyzal|
79554488|NCT01651494|Drug|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
79554489|NCT01651494|Other|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
79554490|NCT01651520|Drug|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
79256607|NCT02128321|Drug|Caffeine|oral
79395862|NCT03111264|Behavioral|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
79554491|NCT01651546|Behavioral|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
79554492|NCT01651572|Drug|Cisatracurium|"Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
79718243|NCT05610163|Procedure|Sigmoidoscopy|undergo sigmoidoscopy
79718244|NCT05610163|Procedure|biopsy|undergo biopsy
79256608|NCT02458131|Behavioral|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
79395863|NCT03143790|Procedure|Extracorporeal Shockwave Terapy|Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
79395864|NCT03111498|Other|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
79395865|NCT03111498|Other|theory-based training programme|theory-based training programme for conducting VAD
79554493|NCT01651572|Drug|Rocuronium|"Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
79554494|NCT01651585|Drug|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
79554495|NCT01651598|Drug|Placebo to BI 144807|multiple dose (bid)
79554496|NCT01651598|Drug|BI 144807|multiple dose (bid, low to high dose)
79554497|NCT01651611|Behavioral|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
79554498|NCT01651611|Behavioral|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
79554499|NCT01651611|Behavioral|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
79554500|NCT01651611|Behavioral|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
79554501|NCT01651624|Other|Invitation to screening|
79554502|NCT01651637|Drug|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
79718245|NCT05608655|Device|DKutting LL balloon|After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
79718246|NCT05608655|Device|Chocolate balloon|After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
79718247|NCT05602454|Other|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
79718248|NCT05597020|Drug|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
79718249|NCT05597020|Drug|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
79718250|NCT05596734|Biological|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
79718251|NCT05596734|Biological|qIRV (22/23)|Intramuscular injection
79718252|NCT05596734|Biological|QIV|Intramuscular injection
79718253|NCT05596734|Biological|bIRV|Intramuscular injection
79718254|NCT05596734|Biological|tIRV|Intramuscular injection
79718255|NCT05591534|Radiation|Endorectal brachytherapy|Endorectal brachytherapy : 30 Gy in 3 sessions of 10 Gy delivered weekly
79718256|NCT05590169|Other|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
79718257|NCT05579886|Device|Control Lens|Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
79718258|NCT05579886|Device|Test Lens|Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
79875449|NCT03993093|Other|CD4 cell count|CD4 cell count from treatment naive HIV patients
79875450|NCT00395733|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
79718259|NCT05577910|Device|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
79718260|NCT05577910|Device|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
79718261|NCT05577910|Behavioral|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
79718262|NCT05577910|Drug|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
79854185|NCT04550143|Other|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
79854186|NCT04550143|Other|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
80031497|NCT03050944|Other|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
79554503|NCT01651650|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
79395866|NCT02327754|Drug|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
79395867|NCT02327754|Drug|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
79395868|NCT02327910|Other|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
79554504|NCT01651663|Drug|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
79554505|NCT01651663|Other|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
79554506|NCT01651663|Drug|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
79554507|NCT01651663|Other|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
79554508|NCT01651676|Other|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
79554509|NCT01651702|Device|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
79554510|NCT01651702|Device|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
79395869|NCT02327910|Other|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
79395870|NCT04869930|Other|specimen collection|participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits
79395871|NCT02332434|Other|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
79395872|NCT02327442|Radiation|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
79395873|NCT06103539|Device|Cardiac catheterization and evoked response to cardiac stimulation|Cardiac catheterization with a combined elecrtophysiology and pressure sensing catheter to perform multisite stimulation and measure the evoked pressure response in a connected software.
79718263|NCT05577390|Other|Intraneural Facilitation® Therapy Treatment|Intraneural Facilitation® Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
79854187|NCT04550143|Other|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
79718264|NCT05577390|Other|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
79718265|NCT05575505|Drug|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
79718266|NCT05574387|Drug|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
79395874|NCT06103526|Dietary Supplement|Immunonutrition|enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
79554511|NCT01651715|Drug|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
79554512|NCT01651728|Drug|Simvastatin|Tablet 20 mg once daily for 30 days
79554513|NCT01651728|Drug|Placebo|daily for 30 days
79554514|NCT01651741|Dietary Supplement|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~Form: brown granule~Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~Duration: 4 weeks of treatment period~Duolac7S:~The probiotics, Duolac7S, consist of 7 bacteria.~Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (30 min after morning and evening meal)~Duration: 4 weeks of treatment period"
79718267|NCT05572931|Device|Fu's Subcutaneous Needling(FSN)|"Insertion points are both sides of 1) inferior edge of the scapula; 2)the midpoint of inferior edge of the posterior superior iliac spine and the ischial tuberosity.~FSN (Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.) ) is a solid needle with plastic cannula tube on the outside. Add on swaying movement (SM) and reperfusion approach (RA) after the needle inserting into the subcutaneous layer. The SM is a horizontal fan sway movement with the base of the needle for the fulcrum, The SM speed is 200 times in 2 minutes. Apply RA when performing SM. RA movement is hip extension in prone position with resistance by physician's hand for 10 seconds. And then rest for 10 seconds. Repeat 3 cycles. The same RA is performed over the other three insertion point."
79718268|NCT05572931|Device|fine acupuncture needle|(36G, 0.5 inch, Wujiang city cloud & dragon medical device Co.,Ltd.) Only inserted to skin, not into the subcutaneous layer. No SM and RA.
79718269|NCT05570760|Device|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
79718270|NCT05570760|Procedure|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
79718271|NCT05570760|Device|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
79854188|NCT04550143|Other|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score <48 indicating the presence of weakness."
80031498|NCT05053958|Other|superimposition of DICOM file from CBCT and STL file of Intraoral scanner|These files will be imported in implant planning software,and virtual implant planning will be performed.
79395875|NCT06103500|Other|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|A clinical decision support algorithm for empiric antibiotic selection in suspected infection.
79395876|NCT06103487|Genetic|No Intervention|Observational study
79395877|NCT06103461|Procedure|Autologous fat grafting|Autologous fat grafted at contour defects with pigmentary changes
79395878|NCT06103448|Device|Ankle-brachial index - system 100|Measurement of ankle brachial index on all four limbs, drawing three blood drops for point of care (POC) cholesterol meter and one drop of blood for POC glucometer
79554515|NCT01651741|Dietary Supplement|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~Form: brown granule~Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
79554516|NCT01651754|Biological|Seasonal influenza vaccination|single dose of influenza vaccination
79554517|NCT01651767|Drug|Placebo|Form=suspension, route=oral.
79554518|NCT01651767|Drug|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
79554519|NCT01651819|Procedure|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
79554520|NCT01651832|Behavioral|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
79554521|NCT01651858|Drug|Nurigra Chewable tablet|1 tablet of 100mg, once a day
79554522|NCT01651884|Device|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
79554523|NCT01651884|Device|Transcranial Direct Current Stimulation (Neuroconn)|
79554524|NCT01651923|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
79554525|NCT01651962|Drug|Terbutaline|
79554526|NCT01651962|Drug|Fentanyl|
79554527|NCT01651962|Drug|0.9% NaCl|
79554528|NCT01651975|Dietary Supplement|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
79554529|NCT01651975|Dietary Supplement|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
79554530|NCT01651988|Drug|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures < 10 minutes~Ketamine-Propofol Combination KETOFOL 1:1~Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Ketamine-Propofol Combination KETOFOL 1:2~Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures > 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
79554531|NCT01652014|Drug|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
79554532|NCT01652014|Drug|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
79554533|NCT01652014|Drug|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
79554534|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
79554535|NCT01652014|Procedure|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
79554536|NCT01652014|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
79554537|NCT01652014|Radiation|total-body irradiation|Undergo TBI
79554538|NCT01652014|Drug|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
79554539|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
79554540|NCT01652014|Procedure|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
79395879|NCT06103435|Procedure|Extent od surgical resection|
79395880|NCT06103422|Diagnostic Test|Whole mouth taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering whole mouth taste tests. In the whole mouth taste test, one ml of the specific solution was drawn into the syringe and sprayed into the mouth of the patient circularly. After each administration, patients spat out the solutions and reported whether they perceived any taste and, if so, which taste it was.
79395881|NCT06103422|Diagnostic Test|Localized taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.
79718272|NCT05570045|Dietary Supplement|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
79554541|NCT01652027|Drug|FVIII concentrate|usual treatment as directed by treating physician
79554542|NCT01652053|Device|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
79554543|NCT01652066|Dietary Supplement|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
79554544|NCT01652066|Dietary Supplement|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
79554545|NCT01652079|Drug|CRLX101|q 14 days
79554546|NCT01652105|Dietary Supplement|Standard diet versus standard VLCD (Prodimed)|
79554547|NCT01652118|Drug|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
79554548|NCT01652118|Drug|Saline|
79554549|NCT01652131|Other|Tetrastarch (130/0.4)|
79554550|NCT01652157|Biological|ULTRESA|pancreatic enzyme replacement therapy
79554551|NCT01652157|Biological|PANCREAZE|pancreatic enzyme replacement therapy
79554552|NCT01652157|Biological|CREON|pancreatic enzyme replacement therapy
79554553|NCT01652157|Biological|ZENPEP|pancreatic enzyme replacement therapy
79554554|NCT01652157|Biological|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
79554555|NCT01652157|Biological|PERTZYE|pancreatic enzyme replacement therapy
79554556|NCT01652157|Other|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
79554557|NCT01652183|Drug|intravenous paracetamol|
79554558|NCT01652183|Drug|Placebo|
79718273|NCT05567328|Device|Research FibroScan (FS)|"Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 & 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 & 191 to 230 Exams1&2 Two consecutive Exploratory exams with the Research FS Exams3&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS"
79718274|NCT05566171|Dietary Supplement|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
79554559|NCT01652196|Biological|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
79554560|NCT01652196|Drug|oxaliplatin|85 mg/m2 IV infused over 2 hours
79554561|NCT01652196|Drug|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
79554562|NCT01652196|Drug|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
79554563|NCT01652196|Other|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
79554564|NCT01652196|Procedure|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
79554565|NCT01652196|Radiation|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
79554566|NCT01652196|Procedure|PET (positron emission tomography)|Correlative studies
79554567|NCT01652209|Biological|Hearticellgram-AMI|
79554568|NCT01652222|Other|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
79554569|NCT01652222|Other|Socio-educational training only|4 socio-educative training sessions during 8 weeks
79554570|NCT01652248|Procedure|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
79554571|NCT01652261|Drug|ABVD + FDG-PET/CT Scan treatment adaptation|
79554572|NCT01652261|Drug|BEACOPPesc|
79554573|NCT01652300|Behavioral|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
79554574|NCT01652300|Behavioral|no education|women in the control group received no education
79554575|NCT01652313|Drug|Rasagiline|1 mg/day, tablets for 7 days, orally
79554576|NCT01652326|Drug|Diazepam|
79554577|NCT01652339|Drug|Exforge tab. 10/160mg|
79554578|NCT01652339|Drug|Lodivixx tab. 5/160mg|
79554579|NCT01652365|Behavioral|RDT Training and Subsidy Offered|
79554580|NCT01652365|Behavioral|Information/Education Campaign|
79718275|NCT05564403|Drug|Binimetinib|Given PO
79718276|NCT05564403|Procedure|Biopsy|Undergo biopsy
79718277|NCT05564403|Procedure|Biospecimen Collection|Undergo collection of blood
79718278|NCT05564403|Procedure|Bone Scan|Undergo bone scan
79718279|NCT05564403|Procedure|Computed Tomography|Undergo CT
79718280|NCT05564403|Procedure|Echocardiography|Undergo ECHO
79718281|NCT05564403|Drug|Fluorouracil|Given IV
79718282|NCT05564403|Drug|Leucovorin Calcium|Given IV
79718283|NCT05564403|Procedure|Magnetic Resonance Imaging|Undergo MRI
79854189|NCT04545151|Drug|Verapamil SR 120 mg|"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~from Day 0 to Week 4: 120 mg once daily~from Week 4 to Week 8: 240 mg once daily~from Week 8 to Month 12: 360 mg once daily"
79718284|NCT05564403|Procedure|Multigated Acquisition Scan|Undergo MUGA
79718285|NCT05564403|Drug|Oxaliplatin|Given IV
79718286|NCT05560867|Device|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
79718287|NCT05558657|Other|Home-based, acupressure combined with nursing education|"The intervention group will focus on 11 acupoints on the abdomen (RN12, RN4, ST25), back (BL20, BL21, BL22, BL23, BL24, BL25), and limbs (LI4, ST36). The participants or their caregivers can perform acupressure 30 minutes after meals and twice a day. Participants can choose between two sets of acupressure: (1) Acupressure of the abdominal and back acupoints in a seated position, or (2) Acupressure of the abdominal and limb acupoints in a supine position. Each session lasts approximately 15 minutes.~Besides, the intervention group will also receive nursing education on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation habits, (3) understand appropriate defecation environments and postures, and (4) Moderate exercise to increase gastrointestinal motility."
79718288|NCT05558657|Other|Home-based, manual light touch of the abdomen combined with nursing education|Control group or their caregivers will apply the manual light touch to the abdomen in any direction or body position at home. In keeping consistent with the intervention group, abdomen touching will also be administered twice daily for approximately 15 minutes each for 10 days. Participants will also receive nursing education.
79718289|NCT05556837|Other|Control Cereal|A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured
79718290|NCT05556837|Other|OBG Cereal|A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
79718291|NCT05556837|Other|BBG Cereal|A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
79854190|NCT04545151|Drug|Placebo|"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~from Day 0 to Week 4: 120 mg once daily~from Week 4 to Week 8: 240 mg once daily~from Week 8 to Month 12: 360 mg once daily"
79854191|NCT04544592|Drug|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
80031499|NCT04898998|Device|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
79395882|NCT06103409|Biological|Implantation of allogeneic MSCs on burn wounds|Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.
79395883|NCT06103383|Drug|Controlled ovarian stimuation|3 days stimullation protocol using hMG-HP
79395884|NCT06103383|Procedure|Oocyte pick up|Surgical oocyte pick up without triggering
79718292|NCT05555940|Device|Transcranial magnetic stimulation|The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
79718293|NCT05555628|Other|Mandibular Exercise|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
79718294|NCT05555628|Other|Mandibular Exercise and Postural Exercise Group|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
79718295|NCT05555628|Other|Occlusal Splint Group|Patients will use occlusal splints for 6 weeks. The occlusal splints will be used only sleep time.
79718296|NCT05554380|Procedure|Biopsy|Undergo tumor biopsy
79718297|NCT05554380|Procedure|Biospecimen Collection|Undergo blood collection
79718298|NCT05554380|Procedure|Computed Tomography|Undergo CT scan
79718299|NCT05554380|Drug|Ipatasertib|Given PO
79718300|NCT05554380|Procedure|Magnetic Resonance Imaging|Undergo MRI
79718301|NCT05554380|Drug|Paclitaxel|Given IV
79718302|NCT05550402|Drug|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
80031500|NCT04898998|Other|routine care|routine care
79854192|NCT04540822|Other|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
79718303|NCT05550402|Drug|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
79718304|NCT05550402|Drug|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
79718305|NCT05550402|Other|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
79854193|NCT04540822|Other|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
79854194|NCT04538573|Device|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
79875451|NCT00395733|Drug|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
79875452|NCT00441987|Drug|GSI-953|
79554581|NCT01652378|Drug|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
79875453|NCT00395343|Drug|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
80031501|NCT03051022|Drug|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
79554582|NCT01652391|Device|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
79554583|NCT01652404|Behavioral|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
79718306|NCT05537467|Other|Music|Patients randomized to the music group will listen to upbeat music using headphones.
79875454|NCT00395343|Drug|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
79875455|NCT00560573|Drug|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
79875456|NCT00560573|Drug|Cisplatin|"Cisplatin 75* mg/m2 or 80* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
79875457|NCT00560573|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
79875458|NCT00560573|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
79875459|NCT00950105|Drug|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
79395885|NCT06103383|Procedure|Oocyte in vitro maturation|In vitro maturation procedure
79395886|NCT06103383|Procedure|Oocyte in vitro activation|In vitro oocyte activation procedure
79554584|NCT01652404|Behavioral|Conventional treatment|The antibiotics duration will be determined by treating physician.
79554585|NCT01652417|Drug|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
79554586|NCT01652456|Other|Addiction support|one consultation with an addiction specialist
79554587|NCT01652508|Other|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
79554588|NCT01652508|Behavioral|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
79554589|NCT01652534|Drug|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
79554590|NCT01652534|Drug|Placebo|Sugar Pill
79718307|NCT05530590|Other|Training to Serve (TTS) in person training|Participants receive in person training.
79718308|NCT05530590|Other|Training to Serve online training (eTTS)|Participants receive online training.
79718309|NCT05521672|Drug|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
79256609|NCT05002556|Diagnostic Test|Urinary Biomarkers|Prior to each examination, participating patients will produce a urine sample of approximately 20 to 40 ml in total dedicated to the determination of the marker proposed by your urologist, done by medical analysis laboratory. At each follow-up endoscopic examination scheduled in the patient's personalized care plan, the investigating urologist will record its date and endoscopic findings (white light bladder fibroscopy). The name and result of the urine test will also be recorded by the investigating urologist. The performance of the test will be evaluated from these data by calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and by means of an analysis of variance (ANOVA) to explore possible differences within the test by tumor grade and stage, and according to previous endovesical treatments received
79256610|NCT02457975|Device|670nm PBM|Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
79256611|NCT02457975|Drug|intravitreous VEGF-inhibitors|Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
79256612|NCT03074864|Drug|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
79256613|NCT04997720|Other|Training|"Each course will consist of:~Initial evaluation~Theoretical tutorial~Training with exercises of increasing complexity.~Final evaluation."
79256614|NCT02456571|Device|CTC biomarker expression prevalence|
79256615|NCT03550963|Other|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
79256616|NCT03550963|Other|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
79256617|NCT03071978|Device|CRT with LV-only pacing / bi-ventricular pacing|LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
79256618|NCT04733703|Other|questionnaire|assessment of postoperative quality of recovery with the QoR-15
79554591|NCT01652547|Drug|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
79718310|NCT05512377|Drug|brigimadlin|brigimadlin
79718311|NCT05507827|Drug|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
79718312|NCT05507827|Drug|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
79718313|NCT05491616|Drug|Nivolumab|In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
79875460|NCT00946283|Dietary Supplement|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
80031502|NCT03051022|Drug|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
80031503|NCT03052504|Other|Registration of complications|Prospective registration
80031504|NCT04648826|Device|AeroEclipse II Breath Actuated Nebulizer|Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
79875461|NCT00946361|Other|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
79875462|NCT00946439|Device|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
79875463|NCT00941837|Dietary Supplement|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
79256619|NCT02132845|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
79256620|NCT02132845|Drug|targeted therapy|Receive target-directed therapy
79256621|NCT02132845|Procedure|therapeutic procedure|Receive standard of care therapy
79256622|NCT02132845|Other|laboratory biomarker analysis|Correlative studies
79256623|NCT04901468|Other|No Intervention|This is an observational study
79256624|NCT03261687|Other|water based exercise|
79256625|NCT03261687|Other|land based exercise|
79256626|NCT03261687|Behavioral|advice|general advice given to all subjects
79875464|NCT00946517|Other|Questionnaires|Parenting and behavioral questionnaires
79875465|NCT00950261|Radiation|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
79256627|NCT03551431|Diagnostic Test|Video EEG with verbal suggestion|Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
79854195|NCT04538573|Drug|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
79854196|NCT04538092|Other|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
79554592|NCT01652547|Drug|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
79854197|NCT04518670|Device|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
80018363|NCT05723744|Device|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
80018364|NCT05723666|Other|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
79256628|NCT04729257|Device|Philips IntelliSpace Cognition (ISC).|Philips ISC is a Class-II Medical Device in the US that aids in assessing cognition and helps inform the HealthCare Professional (HCP) to make a diagnosis and treatment plan. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
80018365|NCT05130424|Drug|Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
79256629|NCT04729257|Diagnostic Test|Paper-Pencil Tests.|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
79554593|NCT01652560|Drug|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
79718314|NCT05478200|Behavioral|physical exercise|Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
79395887|NCT06103370|Behavioral|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
79718315|NCT05478200|Other|Manual therapy|Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
79395888|NCT06103318|Behavioral|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores <54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
79554594|NCT01652586|Drug|dexmedetomidine-remifentanil|
80018366|NCT02122536|Drug|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
79554595|NCT01652586|Drug|midazolam-remifentanil|
79554596|NCT01652599|Drug|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
79554597|NCT01652612|Other|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
79554598|NCT01652625|Drug|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
79854198|NCT04516135|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
79395889|NCT06103292|Diagnostic Test|ionized calcium levels|measuring calcium level in trauma patients
79395890|NCT06103279|Drug|Empagliflozin 10 MG|1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
79854199|NCT04516135|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79854200|NCT04516135|Other|Quality-of-Life Assessment|Ancillary studies
79554599|NCT01652625|Drug|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
79554600|NCT01652638|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
79718316|NCT05471973|Other|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
79718317|NCT05471973|Other|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
79718318|NCT05471973|Other|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
79554601|NCT01652651|Behavioral|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
79554602|NCT01652677|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
79554603|NCT01652742|Drug|BI 135585 XX|one single dose
79554604|NCT01652768|Other|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin & Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
79554605|NCT01652768|Other|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~Introduce the palliative care team concept.~Provide contact information for the palliative care team given~Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~Offer community resources to patient and caregiver (Appendix B)~Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~Provide supportive care"
79718319|NCT05471973|Other|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
79854201|NCT04516135|Other|Questionnaire Administration|Ancillary studies
79854202|NCT04516135|Radiation|Volume Modulated Arc Therapy|Undergo VMAT
79395891|NCT06103266|Drug|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
79395892|NCT06103253|Dietary Supplement|a Bla80 group|the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
79395893|NCT06103240|Other|Lacticaseibacillus rhamnosus LRa05|Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
79718320|NCT05464251|Other|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
79718321|NCT05459571|Biological|Axicabtagene Ciloleucel|Administered intravenously
79718322|NCT05459571|Drug|Cyclophosphamide|Administered intravenously
79718323|NCT05459571|Drug|Fludarabine|Administered intravenously
79718324|NCT05459571|Drug|Dexamethasone|Administered orally or intravenously
79718325|NCT05459402|Drug|Methadone (100% dose)|Methadone for the treatment of opioid use disorder
79854203|NCT04502849|Procedure|Bypass surgery|Creating a bypass with graft or vein.
79256630|NCT02132923|Biological|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
79395894|NCT06103214|Other|acute normovolemic hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a medical procedure that involves removing a certain volume of blood from a patient before surgery and replacing it with a volume expander or blood substitute. The goal of ANH is to reduce the need for blood transfusions during or after surgery. During the ANH procedure, a patient's blood is typically withdrawn and replaced with a crystalloid or colloid solution. This dilutes the patient's blood, reducing the concentration of red blood cells. The withdrawn blood is then stored and can be reinfused back into the patient after the surgical procedure is completed.
79854204|NCT04502849|Procedure|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
79854205|NCT04502849|Procedure|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
79854206|NCT04502849|Drug|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
79854207|NCT04502849|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
79854208|NCT04502849|Diagnostic Test|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
79854209|NCT04502849|Diagnostic Test|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
79256631|NCT04900688|Device|LithoVue Elite|LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
79256632|NCT04798911|Other|Phase 1 Observational Interviews|Qualitative interviews with patients with SS
79256633|NCT02456649|Device|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to < 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as < 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
79256634|NCT02125903|Drug|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
79554606|NCT01652768|Other|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~Provide supportive care."
79554607|NCT01652768|Other|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~Provide resources/referrals for any needs identified during the social work follow-up assessment~Provide supportive care"
79554608|NCT01652768|Other|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Administer Symptom Assessment Tool~Provide pain and/or symptom management intervention~Provide supportive care"
79554609|NCT01652768|Other|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Re-assess pain and/or symptom management issues and /or intervention~Provide resources/referrals for any needs identified during the social work follow-up assessment~Provide supportive care."
79554610|NCT01652781|Drug|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
79554611|NCT01652794|Radiation|stereotactic body radiation therapy|Undergo SBRT
79554612|NCT01652794|Drug|carboplatin|Given IV
79554613|NCT01652794|Drug|gemcitabine hydrochloride|Given IV
79554614|NCT01652794|Other|laboratory biomarker analysis|Optional correlative studies
79554615|NCT01652794|Other|pharmacogenomic studies|Optional correlative studies
79718326|NCT05459402|Drug|Methadone (50% dose)|Methadone for the treatment of opioid use disorder
79718327|NCT05457283|Drug|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
80018367|NCT02122536|Drug|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
80018368|NCT03835039|Device|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
80018369|NCT00144014|Drug|V10153|Single acute intravenous bolus dose up to 10 mg/kg
79256635|NCT05002166|Other|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
79256636|NCT02126059|Behavioral|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
79395895|NCT06103214|Other|acute hypervolemic hemodilution (AHH)|The purpose of diluting the blood with fluids and removing some of the red blood cells is to decrease the viscosity of the blood. This can improve blood flow and oxygen delivery to tissues, especially in cases of decreased blood flow or oxygenation.
79718328|NCT05454410|Drug|MIJ821 Subcutaneous Injection - low dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
79718329|NCT05454410|Drug|MIJ821 Subcutaneous Injection - medium dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
79718330|NCT05454410|Drug|MIJ821 Subcutaneous Injection - high dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
79718331|NCT05454410|Drug|Placebo Subcutaneous Injection|0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
79718333|NCT05450718|Drug|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
79718334|NCT05450718|Drug|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
80018370|NCT04573114|Procedure|Verticalization|Progressive levels of verticalization
80018371|NCT03551184|Biological|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
80018372|NCT03551184|Biological|Placebo|Saline administered intravenously
79395896|NCT06103162|Device|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
79854210|NCT04502602|Drug|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
79256637|NCT02126059|Behavioral|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
79554616|NCT01652807|Behavioral|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
79554617|NCT01652820|Drug|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
79554618|NCT01652820|Drug|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
79554619|NCT01652859|Drug|Liposomal Amphotericin B|
79554620|NCT01652859|Drug|AmBisome|
79554621|NCT01652898|Drug|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
79554622|NCT01652898|Drug|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
79554623|NCT01652898|Drug|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
79554624|NCT01652924|Device|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
79554625|NCT01652924|Device|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
79554626|NCT01652937|Drug|BIIB057|Oral
79554627|NCT01652937|Drug|Placebo|Oral
79554628|NCT01652950|Behavioral|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: <150 fitness points per month - equivalent to < 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month."
79554629|NCT01652963|Other|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
79554630|NCT01652989|Behavioral|Weight loss maintenance intervention face-to-face|
79554631|NCT01652989|Behavioral|Weight loss maintenance intervention delivered via DVD|
79554632|NCT01653002|Other|No intervention|
79554633|NCT01653015|Biological|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
79854211|NCT04502602|Drug|Neratinib 200 mg|Determined RP2D dose
79854212|NCT04502602|Drug|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
79554634|NCT01653015|Biological|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
79256638|NCT02126059|Behavioral|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
79256639|NCT04713501|Behavioral|PARTS Program|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
79256640|NCT02133079|Biological|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
79554635|NCT01653041|Drug|Everolimus|
79554636|NCT01653054|Procedure|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
79554637|NCT01653067|Drug|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
79554638|NCT01653106|Procedure|cryotherapy|Receive shaved ice
79554639|NCT01653106|Other|questionnaire administration|Participate in PROMS
79854213|NCT04502602|Drug|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
79854214|NCT04502602|Drug|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
79854215|NCT04502602|Drug|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
79854216|NCT04502602|Drug|Niraparib at RP2D|Phase 1b: Determined dose
79854217|NCT04502602|Drug|Neratinib at RP2D|Phase 1b: Determined dose
79854218|NCT04499612|Procedure|Cardiac implantable electronic device implantation.|Patients who have indications will receive cardiac implantable electronic device implantation.
79854219|NCT04499612|Procedure|Cardiac implantable electronic device replace.|Patients who have indications will receive cardiac implantable electronic device replace.
79854220|NCT04499612|Diagnostic Test|Duplex ultrasound.|Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
79718335|NCT05425823|Other|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
79718336|NCT05424003|Drug|Semaglutide Pen Injector|Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
79718337|NCT05424003|Drug|Placebo|Placebo solution injected weekly for 72 weeks
79554640|NCT01653106|Other|pharmacological study|Correlative studies
79718338|NCT05423717|Drug|Daridorexant 10 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
79718339|NCT05423717|Drug|Daridorexant 25 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
79718340|NCT05423717|Drug|Daridorexant 50 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
80031505|NCT04648826|Drug|Bintrafusp alfa|Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W [once every 3 weeks]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
79554641|NCT01653119|Drug|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
79554642|NCT01653145|Other|Diet A|Dietary
79554643|NCT01653145|Other|Diet B|Dietary
79554644|NCT01653145|Other|Diet C|Dietary
79554645|NCT01653171|Drug|Water (Placebo)|Water 100 mL
79554646|NCT01653171|Drug|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
79256641|NCT04997876|Other|Biomarker analysis|Biomarkers from presurgical OCTs are assessed
79256642|NCT02133157|Drug|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
79554647|NCT01653171|Drug|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
79554648|NCT01653171|Drug|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
79554649|NCT01653184|Dietary Supplement|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
79554650|NCT01653197|Behavioral|Control|No scratch off element
79554651|NCT01653197|Behavioral|Curiosity|The recipient will be prompted to scratch off for answer to question.
79554652|NCT01653197|Behavioral|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
79554653|NCT01653236|Drug|Boceprevir|
79554654|NCT01653236|Drug|Peginterferon alfa-2b|
79554655|NCT01653236|Drug|ribavirin|
79554656|NCT01653249|Biological|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
79554657|NCT01653275|Other|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
79554658|NCT01653301|Drug|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
79718341|NCT05423717|Drug|Placebo|Placebo will be taken orally, once daily in the evening during the treatment period.
79718342|NCT05422638|Behavioral|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
79718343|NCT05422638|Behavioral|PCT|8-week health promotion group focused on providing support and facilitating problem solving
79718344|NCT05419661|Other|Operational Pre-Planning|Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
79718345|NCT05411172|Behavioral|Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses|"The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice."
79718346|NCT05402202|Other|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
79718347|NCT05402202|Other|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
79718348|NCT05398263|Biological|Tezepelumab|Tezepelumab subcutaneous injection
79554659|NCT01653301|Drug|XELOX RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
79718349|NCT05398263|Other|Placebo|Placebo subcutaneous injection
79718350|NCT05397964|Device|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
79718351|NCT05393804|Biological|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
79718352|NCT05392114|Drug|Donidalorsen|Donidalorsen will be administered by SC injection.
79718353|NCT05387057|Behavioral|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
79718354|NCT05387057|Behavioral|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
79305094|NCT04965987|Drug|Oxaloacetate|Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue
79554660|NCT01653314|Drug|Megavec|
79554661|NCT01653314|Drug|Glivec|
79554662|NCT01653340|Device|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
79554663|NCT01653353|Behavioral|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
79554664|NCT01653366|Behavioral|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
79554665|NCT01653392|Biological|Observational Intervention|This is an observational study, therefore no interventions are specified.
79554666|NCT01653431|Device|Transcranial direct current stimulation|
79554667|NCT01653444|Drug|GC1119|biweekly, IV infusion
79554668|NCT01653457|Drug|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~1st week: 5 mg daily~2nd week: 10 mg daily~3rd week: 15 mg daily~From 4th week up to 24th week: 20 mg daily"
79554669|NCT01653457|Drug|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
79554670|NCT01653470|Drug|Paclitaxel|
79554671|NCT01653470|Drug|5-Fluorouracil (5FU)|
79554672|NCT01653470|Drug|Carboplatin|
79554673|NCT01653470|Drug|Leucovorin|
79554674|NCT01653470|Drug|Irinotecan|
79554675|NCT01653470|Drug|Paclitaxel|
79554676|NCT01653470|Drug|BMS-906024|
79554677|NCT01653483|Drug|GSK573719|Novel Dry-Powder Inhaler
79554678|NCT01653483|Drug|GSK573719matched-placebo|Novel Dry-Powder Inhaler
79554679|NCT01653496|Procedure|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
79554680|NCT01653522|Drug|Triptan|
79554681|NCT01653522|Drug|Doxycycline|
79554682|NCT01653548|Behavioral|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
79554683|NCT01653548|Behavioral|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
79554684|NCT01653548|Behavioral|Habituation|Participants will habituate to personally-relevant stressor.
79554685|NCT01653561|Drug|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
79718355|NCT05384392|Other|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
79718356|NCT05384392|Other|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
79854221|NCT04499612|Diagnostic Test|Echocardiography.|Patients will undergo an ultrasound examination of the heart.
79395897|NCT06103149|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
79554686|NCT01653574|Drug|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
79554687|NCT01653600|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
79554688|NCT01653600|Device|LifeStent|same to SMART STENT
79554689|NCT01653613|Genetic|DNA analysis|
79554690|NCT01653613|Genetic|fluorescence in situ hybridization|
79554691|NCT01653613|Genetic|gene expression analysis|
79554692|NCT01653613|Genetic|microarray analysis|
79554693|NCT01653613|Genetic|mutation analysis|
79554694|NCT01653613|Genetic|polymorphism analysis|
79554695|NCT01653613|Genetic|reverse transcriptase-polymerase chain reaction|
79554696|NCT01653613|Other|laboratory biomarker analysis|
79554697|NCT01653626|Other|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
79554698|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
79554699|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
79554700|NCT01653652|Dietary Supplement|Probiotic|
79554701|NCT01653652|Dietary Supplement|Maltodextrin|
79554702|NCT01653665|Drug|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
79554703|NCT01653665|Drug|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
79554704|NCT01653691|Procedure|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
79554705|NCT01653691|Procedure|Sham|No treatment to one side of subject's scar.
79554706|NCT01653717|Procedure|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
79854222|NCT04499612|Diagnostic Test|Blood sampling.|Patients will be taken venous blood to determine the studied markers of hemostasis system.
79305095|NCT04965987|Drug|Placebo|Placebo
79554707|NCT01653717|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
79554708|NCT01653717|Drug|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
79554709|NCT01653717|Procedure|T-cell Infusion|Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
79554710|NCT01653730|Device|Eclipse 3 portable oxygen concentrator|
79554711|NCT01653730|Device|EverGo portable oxygen concentrator|
79554712|NCT01653730|Device|iGo portable oxygen concentrator|
79554713|NCT01653756|Drug|IPI-145, a PI3K Inhibitor|Active drug
79554714|NCT01653756|Drug|Placebo to match IPI-145|Comparator
79554715|NCT01653795|Device|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
79554716|NCT01653795|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
79554717|NCT01653808|Device|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
79554718|NCT01653808|Procedure|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
79554719|NCT01653808|Procedure|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
79554720|NCT01653821|Procedure|Carotid body excision|
79554721|NCT01653834|Procedure|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
79554722|NCT01653860|Behavioral|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
79854223|NCT04494386|Biological|Umbilical Cord Lining Stem Cells (ULSC)|IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
79854224|NCT04494386|Other|Placebo (carrier control)|IV infusion of carrier control consisting of sterile saline for injection
79854225|NCT04493216|Drug|GSK3640254|GSK3640254 will be available as a 25 mg and 100 mg tablets to be administered via oral route.
79554723|NCT01653860|Behavioral|Ordinary group treatment|group treatment 8 weeks (16 hours)
79554724|NCT01653886|Other|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
79554725|NCT01653886|Other|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
79554726|NCT01653886|Other|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
79554727|NCT01653938|Behavioral|video decision aid|
79554728|NCT01653951|Other|nurse-led care management or peer-led self management|
79554729|NCT01653977|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
79554730|NCT01653977|Other|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
79554731|NCT01653990|Drug|moxifloxacin|oral dose of 400mg moxifloxacin
79554732|NCT01653990|Drug|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
79554733|NCT01654003|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
79554734|NCT01654003|Other|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
79554735|NCT01654016|Drug|Detralex|Detralex 500 mg twice daily for three month prior to surgery
79718357|NCT05384392|Biological|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
79718358|NCT05384392|Other|MRI scans of the brain|The MRI scans of the brain will be performed. This exam is performed in routine care in the context of this pathology
79718359|NCT05384015|Drug|Lenvatinib|"Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance)."
79718360|NCT05384015|Drug|Pembrolizumab|"Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion"
79718361|NCT05384015|Drug|Etoposide|"Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles"
79718362|NCT05384015|Drug|Carboplatin|"Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles"
79554736|NCT01654029|Behavioral|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
79554737|NCT01654042|Other|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
79554738|NCT01654081|Drug|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
79854226|NCT04493216|Drug|ABC/3TC|ABC/3TC will be available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
79554739|NCT01654094|Device|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
79854227|NCT04493216|Drug|FTC/TAF|FTC/TAF will be available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
79854228|NCT04493216|Drug|Dolutegravir|Dolutegravir will be available as a 50 mg tablet to be administered via oral route.
79854229|NCT04493216|Drug|Placebo|Placebo matching GSK3640254 will be administered in the form of tablets via oral route.
79854230|NCT04488523|Behavioral|Family-based Telehealth Intervention|"The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis."
79854231|NCT04486261|Other|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
79554740|NCT01654094|Other|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
79554741|NCT01654120|Drug|Liraglutide|SC, 1.8mg,QD, six months to one year
79554742|NCT01654120|Drug|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
80018373|NCT03528200|Other|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
80018374|NCT02125656|Other|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
80018375|NCT03830359|Other|T2769|At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
80018376|NCT04551820|Procedure|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
80018377|NCT04551820|Procedure|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
79554743|NCT01654146|Drug|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
79554744|NCT01654146|Drug|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
79554745|NCT01654146|Drug|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
79554746|NCT01654146|Drug|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
79554747|NCT01654172|Dietary Supplement|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is ~900mg
79554748|NCT01654172|Dietary Supplement|Low Flavanol Cocoa|
79554749|NCT01654185|Drug|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
79554750|NCT01654185|Drug|Aromatase Inhibitor|1 tablet per day
79554751|NCT01654198|Radiation|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
79554752|NCT01654211|Drug|danoprevir|single iv infusion
79554753|NCT01654211|Drug|danoprevir|single oral dose
79554754|NCT01654211|Drug|placebo|single iv infusion
79554755|NCT01654211|Drug|ritonavir|oral doses
79554756|NCT01654237|Other|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
79554757|NCT01654328|Drug|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
79554758|NCT01654328|Drug|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
79554759|NCT01654341|Behavioral|Exercise, dietary and educational program|
79554760|NCT01654354|Drug|NEOVIST 370 INJ.(Iopromide 768.86mg)|
79554761|NCT01654354|Drug|Ultravist 370 INJ.(Iopromide 768.86mg)|
79554762|NCT01654367|Drug|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
79554763|NCT01654393|Other|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
79554764|NCT01654406|Device|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
79554765|NCT01654406|Device|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
79718363|NCT05377229|Device|MarginProbe2.0|The MarginProbe System is an adjunctive diagnostic tool for identification of cancerous tissue at the margins of the ex-vivo lumpectomy specimen following primary excision and is indicated for intraoperative use, in conjunction with standard methods (such as intraoperative imaging and palpation) in patients undergoing breast lumpectomy surgery for previously diagnosed breast cancer.
79718364|NCT05375019|Behavioral|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
79554766|NCT01654419|Device|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
79554767|NCT01654419|Device|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
79718365|NCT05375019|Behavioral|active control group|free interaction group consisting of topics determined by the families.
79554768|NCT01654432|Other|Paravertebral Blocks (PVB)|
79554769|NCT01654458|Behavioral|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
79554770|NCT01654484|Drug|DE-117|Ophthalmic Solution, QD, 28 Days
79554771|NCT01654484|Drug|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
79395898|NCT06103136|Device|Laparoscopic surgery using the Maestro Platform|"Patients scheduled for laparoscopic surgery will be operated on as per standard of care, using standard port, surgical table and instrument placements (following local applicable guidelines), and off-the-shelf surgical equipment. Standard of care surgical technique following local applicable guidelines will be used.~The Maestro Platform may be used to position and hold the scope as well as the retractor in the locations determined by the surgeon during the procedure, with the ability to revert at any time to standard of care (manual minimally invasive surgery) without the usage of the Maestro Platform, or to convert to open surgery."
79554772|NCT01654484|Drug|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
79554773|NCT01654484|Drug|Placebo|Ophthalmic Solution, QD, 28 days
79718366|NCT05374512|Drug|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
79718367|NCT05374512|Drug|Paclitaxel|IV Infusion. Active comparator
79718368|NCT05374512|Drug|Nab-paclitaxel|IV infusion. Active comparator
79718369|NCT05374512|Drug|Carboplatin|IV infusion. Active comparator
79718370|NCT05374512|Drug|Capecitabine|Tablet. Oral route of administration. Active comparator
79718371|NCT05374512|Drug|Eribulin mesylate|IV infusion. Active comparator
79718372|NCT05372653|Drug|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
79718373|NCT05371717|Other|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
79718374|NCT05371717|Other|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
79718375|NCT05362877|Device|Earplug|Using earplugs to reduce the symptoms of temporomandibular disorder
79718376|NCT05362877|Device|occlusal splint|Using occlusal splints to reduce the symptoms of temporomandibular disorder
79718377|NCT05362877|Other|exercise|Applying exercise to reduce the symptoms of temporomandibular disorder
79718378|NCT05361941|Device|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a two-stage revision of an infected total joint.
79718379|NCT05361941|Device|empty voids|Voids are left empty
79718380|NCT05351281|Device|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
79875466|NCT00946595|Drug|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
79875467|NCT00946595|Drug|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
79395899|NCT06103123|Diagnostic Test|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
79554774|NCT01654497|Drug|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
79554775|NCT01654510|Behavioral|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
79554776|NCT01654510|Other|Vocational Services as Usual|
79554777|NCT01654562|Drug|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
79554778|NCT01654575|Drug|Methotrexate|Methotrexate 25mg/week for 16 weeks
79554779|NCT01654575|Drug|Placebo|Placebo tablets once a week for 16 weeks
79718381|NCT05348733|Drug|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
79718382|NCT05337202|Device|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
79718383|NCT05334069|Other|Questionnaire Administration|Complete questionnaire
79718384|NCT05334069|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
79718385|NCT05329987|Other|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
79718386|NCT05326412|Drug|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
79554780|NCT01654627|Device|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
79554781|NCT01654627|Device|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
79554782|NCT01654640|Drug|Metformin|metformin 500mg p.o. bid for 24 weeks
79554783|NCT01654640|Drug|Placebo (for metformin)|placebo 1T bid
79554784|NCT01654653|Drug|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
79554785|NCT01654653|Drug|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
79554786|NCT01654679|Device|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
79554787|NCT01654679|Other|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
79554788|NCT01654692|Drug|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
79554789|NCT01654705|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
79554790|NCT01654705|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
79554791|NCT01654718|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
79554792|NCT01654718|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
79554793|NCT01654770|Device|video capsule endoscopy|
79554794|NCT01654770|Device|double balloon enteroscopy|
79554795|NCT01654809|Biological|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
79554796|NCT01654809|Biological|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
79554797|NCT01654809|Biological|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
79554798|NCT01654822|Drug|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
79554799|NCT01654822|Drug|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
79554800|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
79554801|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
79554802|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
79554803|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
79554804|NCT01654835|Other|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
79875468|NCT00942071|Biological|MVA-NP+M1|1. Intradermal injection at 5 x 10^7 pfu at day 0
79395900|NCT06103123|Other|Baseline Quality of Life questionnaire|Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
79554805|NCT01654835|Other|standard of care|A Low Blood Pressure condition as specified (SAP <80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
79554806|NCT01654874|Drug|99mTc-MIP-1404|
79554807|NCT01654900|Other|No intervention in this study|
79554808|NCT01654913|Device|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
79554809|NCT01654926|Procedure|blood ultrafiltration|
79554810|NCT01654939|Drug|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
79554811|NCT01654965|Other|Laboratory Biomarker Analysis|Correlative studies
79875469|NCT00942071|Biological|MVA-NP+M1|2.Intramuscular injection at 5 x 10^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10^8 pfu/ml at day 0
79875470|NCT00942071|Biological|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
79395901|NCT06103110|Device|Photobiomodulation|Laser therapy using low level laser
79395902|NCT06103097|Other|No interventions done (obervational)|Observational study
79395903|NCT06103084|Dietary Supplement|Bahgina|Bahgina, a locally produced cereal based food, will be provided at 200g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
79395904|NCT06103084|Dietary Supplement|SQLNS|Small quantity lipid based nutrient supplement (SQ-LNS) will be provided at 20g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
79554812|NCT01654965|Biological|Pegfilgrastim|Given SC
79554813|NCT01654965|Other|Pharmacological Study|Correlative studies
79554814|NCT01654965|Drug|Tivantinib|Given PO
79554815|NCT01654965|Drug|Topotecan Hydrochloride|Given IV
79554816|NCT01654991|Behavioral|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
79554817|NCT01654991|Behavioral|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
79554818|NCT01655004|Drug|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
79554819|NCT01655017|Procedure|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
79554820|NCT01655056|Drug|YM150|oral
79554821|NCT01655056|Drug|Placebo|oral
79875471|NCT03961529|Drug|0.3% OPA-15406 ointment|Twice daily
79875472|NCT03961529|Drug|1% OPA-15406 ointment|Twice daily
79554822|NCT01655082|Drug|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
79554823|NCT01655082|Drug|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
79554824|NCT01655095|Drug|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
79554825|NCT01655095|Drug|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
79554826|NCT01655095|Drug|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
79554827|NCT01655095|Drug|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
79554828|NCT01655095|Procedure|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
79554829|NCT01655095|Procedure|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
79554830|NCT01655108|Drug|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
79554831|NCT01655108|Drug|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
79554832|NCT01655121|Dietary Supplement|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
79554833|NCT01655134|Other|Blood simples|
79554834|NCT01655134|Other|Capillary punction|
79554835|NCT01655134|Other|Urine simples|
79554836|NCT01655147|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
79554837|NCT01655147|Drug|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
79554838|NCT01655160|Behavioral|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
79554839|NCT01655160|Behavioral|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
79554840|NCT01655160|Behavioral|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
79395905|NCT06103071|Procedure|Sweeping of membranes|After informed consent all the patients in interventional group will have sweeping of membranes from 37 weeks of pregnancy . It will be repeated weekly till 40 weeks.
79395906|NCT06103058|Other|Cross sectional|Cross sectional
79395907|NCT06103045|Other|unilateral and bilateral mirror therapy|The mirror box is placed on a table in the sagittal plane of the participant. The affected upper extremity of the participant is hidden in the morror box and the unaffected upper extremity is placed symmetrically. During the unilateral or bilateral mirror therapy, the participant is requested to execute a serial of movements and tasks and pay attention on observing the reflection of the unaffected side in the mirror simultaneously. In the bilateral mirror therapy, the participant also has to move the affected upper extremity simultaneously; while in the unilateral mirror therapy, the participant only keeps the affected side relaxed.
79395908|NCT06103032|Procedure|Breast Conserving Surgery|Patients undergoing breast conserving surgery
79395909|NCT06103032|Procedure|Mastectomy|Patients undergoing mastectomy
79395910|NCT06102993|Other|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
79395911|NCT06102967|Behavioral|delirium|Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
79395912|NCT06102954|Other|Falls prevention intervention including exercise and educational components|This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
79395913|NCT06102928|Drug|Combined therapy of anlotinib and aumolertinib|Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
79554841|NCT01655160|Behavioral|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
79554842|NCT01655173|Behavioral|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
79554843|NCT01655173|Behavioral|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
79718389|NCT05303792|Drug|Cyclophosphamide|Given IV
79718390|NCT05303792|Drug|Vincristine|Given IV
79718391|NCT05303792|Drug|Dexamethasone|Given IV or PO
79854232|NCT04481399|Behavioral|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
80018378|NCT04551820|Device|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
80018379|NCT00141284|Drug|nelfinavir 1,250 mg twice daily|
80018380|NCT00141284|Drug|Zidovudine 300 mg twice daily|
79256643|NCT03265275|Other|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
79395914|NCT06102863|Drug|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
79395915|NCT06102850|Behavioral|Critical Time Intervention for Young Adults with Mental Health conditions|SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
79395916|NCT06102837|Biological|tumor vaccine|tumor vaccine produced by our team
79395917|NCT06102837|Radiation|Radiotherapy|conventional treatment in clincial
79554844|NCT01655199|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
79554845|NCT01655212|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
79554846|NCT01655238|Other|BMI|Screening guideline to assess body mass index.
79718392|NCT05303792|Biological|Inotuzumab Ozogamicin|Given IV
79718393|NCT05303792|Drug|Methotrexate|Given IV or PO
79875473|NCT00494780|Drug|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
79875474|NCT00494780|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
80018381|NCT00141284|Drug|Lamivudine 150 mg twice daily|
79395918|NCT06102837|Drug|Chemotherapy|conventional treatment in clinical
79395919|NCT06102837|Procedure|Surgery|conventional treatment in clinical
79554847|NCT01655251|Behavioral|Intervention|
79554848|NCT01655264|Behavioral|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
79718394|NCT05303792|Drug|Cytarabine|Given IV
79718395|NCT05303792|Drug|Methylprednisolone|Given IV
79718396|NCT05303792|Biological|Rituximab|Given IV
79718397|NCT05303792|Drug|Prednisone|Given PO
79718398|NCT05303792|Drug|Mercaptopurine|Given PO
79718399|NCT05303792|Drug|Doxorubicin|Given IV
79718400|NCT05297552|Drug|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
79718401|NCT05297552|Drug|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
79718402|NCT05277168|Drug|SHR-A1904|Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
79718403|NCT05270213|Drug|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
79875475|NCT00494780|Drug|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
79875476|NCT00494780|Drug|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
79875477|NCT00494780|Drug|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
80018382|NCT02127294|Device|transcatheter patent foreman ovale closure|
80018383|NCT04328506|Drug|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
79718404|NCT05267093|Procedure|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
79718405|NCT05267093|Procedure|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
79718406|NCT05263622|Other|Split-mouth administration for group B|"Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
79718407|NCT05263622|Other|Split-mouth administration for group A|"Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
79718408|NCT05253651|Drug|tucatinib|300mg given by mouth (orally) twice daily
79718409|NCT05253651|Drug|trastuzumab|8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
79718410|NCT05253651|Drug|bevacizumab|5mg/kg given by IV every 2 weeks
79256644|NCT04997564|Drug|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
79395920|NCT06102785|Drug|Fruquintinib, TAS102|Fruquintinib combined with TAS102
79718411|NCT05253651|Drug|cetuximab|400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
79718412|NCT05253651|Drug|oxaliplatin|85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
79718413|NCT05253651|Drug|leucovorin|400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
79718414|NCT05253651|Drug|levoleucovorin|200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
79718415|NCT05253651|Drug|fluorouracil|400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
79718416|NCT05251909|Biological|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
79256645|NCT04997564|Drug|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
79256646|NCT03842943|Drug|Pembrolizumab|Preoperative infusions
79256647|NCT03842943|Drug|Talimogene Laherparepvec|Preoperative intralesional injection
79256648|NCT02126137|Drug|Ezetimibe|
79256649|NCT04647591|Other|Questionnaires|Use of a questionnaire focused on diver experience and medical history upon inclusion and another questionnaire in case of ENT Barautrauma over a period of two years to standardize Barotrauma assessment.
79395921|NCT06102772|Drug|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
79718417|NCT05251909|Biological|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
79718418|NCT05247905|Drug|Lutetium Lu 177 Dotatate|Given IV
79718419|NCT05247905|Drug|Capecitabine|Given PO
79718420|NCT05247905|Drug|Temozolomide|Given PO
79718421|NCT05247905|Other|Quality-of-Life Assessment|Ancillary studies
79875478|NCT01011452|Drug|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
79256650|NCT02126215|Procedure|MRI CO2 and O2 stress testing|Pre and post operatively
79256651|NCT03261843|Biological|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
79395922|NCT06102759|Drug|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
79395923|NCT06102746|Drug|Sintilimab，Surufatinib|Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.
79395924|NCT06102733|Behavioral|Rehabilitation therapy|Chronic pain rehabilitation therapy
79718422|NCT05247905|Other|Questionnaire Administration|Ancillary studies
79718423|NCT05241860|Other|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
79875479|NCT01011452|Drug|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
79875480|NCT00490022|Drug|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
79256652|NCT03261843|Procedure|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
79395925|NCT06102707|Drug|Fluzopril Combined With Apatinib|Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd
79395926|NCT06102655|Drug|Jiajian Guishen Formulation|Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
79718424|NCT05241860|Other|Follow-Up|Undergo follow-up
79718425|NCT05241860|Other|Questionnaire Administration|Ancillary studies
79718426|NCT05241860|Other|Quality-of-Life Assessment|Ancillary studies
79854233|NCT04481399|Other|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
79854234|NCT04476901|Biological|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
79854235|NCT04476901|Other|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
79854236|NCT04472338|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
79854237|NCT04472338|Other|Laboratory Biomarker Analysis|Correlative studies
79854238|NCT04472338|Other|Quality-of-Life Assessment|Ancillary studies
79854239|NCT04472338|Other|Questionnaire Administration|Ancillary studies
79854240|NCT04469790|Behavioral|SIT+WALK|Participants will interrupt their sitting for one week
79854241|NCT04469790|Behavioral|EX|Participants will perform a single bout of exercise and then sit for the remaining time for one week
79854242|NCT04462328|Drug|Durvalumab|Durvalumab will be administered over 60 minutes
79854243|NCT04462328|Drug|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
80018384|NCT04328506|Drug|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
79854244|NCT04458961|Procedure|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
80018385|NCT03530930|Drug|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
79718427|NCT05241457|Device|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
79854245|NCT04458961|Procedure|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
79854246|NCT04458506|Procedure|Maxillary expansion|Correction of the unilateral posterior cross bite in children
79854247|NCT04449432|Behavioral|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
79854248|NCT04449432|Behavioral|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
79854249|NCT04445844|Biological|Pelareorep|Given IV
79854250|NCT04445844|Other|Quality-of-Life Assessment|Ancillary studies
79854251|NCT04445844|Other|Questionnaire Administration|Ancillary studies
79854252|NCT04445844|Biological|Retifanlimab|Given IV
79854253|NCT04445792|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
79854254|NCT04445792|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
80018386|NCT02125812|Other|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
80018387|NCT02125812|Other|scaling and root planing|scaling and root planing
80018388|NCT01473199|Device|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
80018389|NCT02125890|Drug|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
80018390|NCT03530774|Dietary Supplement|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
80018391|NCT03530774|Dietary Supplement|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
79718428|NCT05241457|Procedure|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
79718429|NCT05238675|Drug|BI 1291583|BI 1291583
79718430|NCT05238675|Drug|Placebo|Placebo
79854255|NCT04433585|Drug|LY3471851|Administered SC
79854256|NCT04433585|Drug|Placebo|Administered SC
80018392|NCT05132764|Procedure|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
80018393|NCT03551418|Behavioral|Watching a video|Watching a video of an adult with DS washing his hands
80018394|NCT05287984|Drug|Zanubrutinib, Fludarabine, cyclophosphamide and rituximab|Patients aged 65 years or younger who can tolerate FCR.
80018395|NCT05287984|Drug|Zanubrutinib, bendamustine, rituximab|For patients older than 65 years or who cannot tolerate FCR regimens.
79554849|NCT01655264|Behavioral|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
79554850|NCT01655277|Procedure|Ultrasound Guided Adductor Canal Block|
79554851|NCT01655277|Procedure|Ultrasound Guided Femoral Nerve Block|
79395927|NCT06102642|Biological|Combining free gingival graft with frenotomy procedure|The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
79554852|NCT01655290|Other|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
79554853|NCT01655303|Drug|Propranolol|
79554854|NCT01655303|Drug|Metoprolol|
79554855|NCT01655303|Drug|Verapamil|
79554856|NCT01655303|Drug|Diltiazem|
79554857|NCT01655316|Drug|Verapamil|
79554858|NCT01655368|Behavioral|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
79554859|NCT01655368|Behavioral|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
79554860|NCT01655407|Drug|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
79554861|NCT01655407|Drug|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
79554862|NCT01655420|Procedure|LASIK|Laser eye surgery
79554863|NCT01655433|Device|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
79554864|NCT01655433|Other|No Hypothermia Treatment|
79718431|NCT05231824|Behavioral|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
79718432|NCT05231824|Behavioral|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
79554865|NCT01655446|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
79854257|NCT04433338|Other|14-day Low Calorie Diet|"Participants will be asked to:~Use 4 (women) or 5 (men) Modifast meal replacements per day.~Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~Daily consume 100 grams of lean meat/fish/meat analogues.~Daily consume two spoons of liquid oil~Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
79395928|NCT06102629|Procedure|laparoscopy / laparotomy|"We will take both blood and ovarian tissue samples used to diagnosis.~We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
79554866|NCT01655446|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
79554867|NCT01655446|Behavioral|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
79554868|NCT01655446|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
79718433|NCT05225675|Biological|ARGX-117|Intravenous administration of ARGX-117
79718434|NCT05225675|Other|Placebo|Intravenous administration of placebo
79854258|NCT04423783|Behavioral|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
79256653|NCT02457663|Procedure|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
79256654|NCT02126293|Drug|Zinc Supplement|
79256655|NCT02126293|Procedure|Repeat blood and urine tests|
79718435|NCT05220410|Drug|Psilocybin|Open-Label
79875481|NCT00490022|Drug|Placebo gel|Placebo gel for one month
79256656|NCT03261765|Other|Assessment of adhesions|Modified Nair scoring system
79256657|NCT02126371|Drug|LEO32731|
79256658|NCT02133391|Other|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
79256659|NCT02133391|Other|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
79554869|NCT01655446|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
79256660|NCT03261921|Drug|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
79256661|NCT03261921|Drug|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
79256662|NCT03261921|Drug|Bupivacaine|local anesthetic agent
79256663|NCT02635724|Drug|Peramivir|
79256664|NCT02133469|Biological|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
79395929|NCT06102629|Other|NO INTERVENTION|".We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
80018396|NCT05132608|Other|Social media-based Health education program|The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
79256665|NCT02133469|Biological|Hib Vaccine|Single Dose
79256666|NCT03760653|Other|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of ~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
79554870|NCT01655459|Procedure|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
79554871|NCT01655472|Device|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
79554872|NCT01655472|Device|imaging follow up: Ultrasonographic examination|
79554873|NCT01655485|Other|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
79256667|NCT03760653|Dietary Supplement|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
79256668|NCT03760653|Dietary Supplement|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
79256669|NCT02635646|Other|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~nutritional counseling,~physical activity counseling,~psychological counseling,~metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
79256670|NCT02635646|Other|individual approach|"individual approach that includes:~nutritional and physical activity counseling in individual appointments,~metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
79256671|NCT02128555|Procedure|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
79256672|NCT02128555|Procedure|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
79256673|NCT02456259|Procedure|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
79395932|NCT06102564|Behavioral|Group schematherapy|Brief group schematherapy for mothers with young children (age 0-5) focused on attachment relations between mother and child
79554874|NCT01655511|Drug|Tafamidis|240 mg, solution, single dose
79554875|NCT01655511|Drug|Tafamidis|480 mg, solution, single dose
80018397|NCT00134264|Drug|torcetrapib/atorvastatin|
79395933|NCT06102551|Behavioral|Recurrence after surgery|Recurrence after repair was the main outcome
79395934|NCT06102538|Behavioral|# The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support|# Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
80018398|NCT00134264|Drug|atorvastatin|
79256674|NCT02126449|Other|Fasting mimicking diet|
79256675|NCT03259659|Other|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
79256676|NCT03724305|Behavioral|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
79256677|NCT05001542|Other|Educational moral injury video|Educational video that addresses the identification of moral injury and distress in frontline healthcare workers during COVID-19; offers available interventions at the levels of individual, team and organization
79554876|NCT01655511|Drug|Tafamidis|TBD dose will be a single dose if < 720 mg or a loading dose followed by additional dose if > 720 mg.
79395935|NCT06102525|Drug|RZ-001|Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
79395936|NCT06102525|Combination Product|VGCV|VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
79554877|NCT01655524|Drug|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
79554878|NCT01655550|Other|Withhold oral contrast|The intervention is to withhold oral contrast
79554879|NCT01655576|Procedure|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
79554880|NCT01655602|Procedure|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
79554881|NCT01655602|Procedure|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
79554882|NCT01655602|Procedure|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
79554883|NCT01655615|Behavioral|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
79554884|NCT01655628|Drug|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
79718436|NCT05217615|Behavioral|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
79256678|NCT02126527|Drug|auranofin|Given PO
79256679|NCT02126527|Drug|sirolimus|Given PO
79256680|NCT02126527|Other|laboratory biomarker analysis|Correlative studies
79256681|NCT02126527|Other|pharmacological study|Correlative studies
79256682|NCT04997330|Device|Active rTMS|Bilateral high frequency (20Hz) rTMS will be delivered (over dorsolateral prefrontal cortex), at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive days on working day, 1500 pulses/session, 110% of motor threshold determined, 30 trains, 50 pulses per train and 15s inter train. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
79395937|NCT06102512|Drug|[¹⁴C]-LOXO-783|Administered orally
79395938|NCT06102512|Drug|LOXO-783|Administered orally
79395939|NCT06102512|Drug|[¹⁴C]-LOXO-783|Administered IV
79395940|NCT06102499|Device|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
79395941|NCT06102473|Other|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
79395942|NCT06102460|Dietary Supplement|Casein protein|40 grams of casein protein powder mixed with 8-10 fl. oz. of water.
79554885|NCT01655628|Drug|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
79554886|NCT01655641|Drug|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
79554887|NCT01655641|Other|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
79554888|NCT01655654|Behavioral|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
79554889|NCT01655654|Behavioral|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
79554890|NCT01655654|Other|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
79554891|NCT01655706|Drug|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
79554892|NCT01655706|Drug|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
79554893|NCT01655732|Procedure|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
79554894|NCT01655745|Procedure|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
79554895|NCT01655758|Drug|0.5% timolol|
79854259|NCT04423783|Behavioral|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
79256683|NCT04997330|Device|Sham rTMS|Sham rTMS will be delivered (over dorsolateral prefrontal cortex) , at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive working days. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
79256684|NCT02133625|Drug|carboplatin|
79256685|NCT02133625|Drug|pioglitazone|
79256686|NCT04997252|Drug|Apalutamide|apalutamide as neoadjuvant therapy
79256687|NCT02455635|Procedure|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath & 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
79256688|NCT02260687|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
79256689|NCT05001464|Device|reflectance pulse oximeter|Wearing reflectance pulse oximeter at the same time on the night of PSG examination
79395943|NCT06102460|Dietary Supplement|a-lactalbumin protein|40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.
79395944|NCT06102460|Dietary Supplement|Carbohydrate|40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
79554896|NCT01655758|Drug|timolol-dorzolamide fixed combination|
79554897|NCT01655758|Drug|Latanoprost|
79554898|NCT01655758|Drug|Travoprost|
79554899|NCT01655758|Drug|Bimatoprost|
79554900|NCT01655771|Drug|TD-1211 Dose 1|
79554901|NCT01655771|Drug|TD-1211 Dose 2|
79554902|NCT01655797|Behavioral|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
79554903|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
79395945|NCT06102460|Dietary Supplement|Placebo|Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
79395946|NCT06102447|Drug|Netopitam Palonosetron capsules and dexamethasone|On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
79554904|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
79554905|NCT01655810|Dietary Supplement|Calcium carbonate|500 mg orally twice daily
79554906|NCT01655849|Drug|z160|
79554907|NCT01655849|Drug|Placebo|
79554908|NCT01655862|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
79554909|NCT01655875|Drug|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
79554910|NCT01655888|Drug|Tremelimumab|Tremelimumab is administered as endovenous infusion
79554911|NCT01655914|Drug|Flumazenil|
79718437|NCT05217615|Behavioral|Coaching calls|The purpose of the brief (~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
79718438|NCT05217615|Behavioral|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
79718439|NCT05215119|Procedure|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (>20 IU/L) and a corresponding rise in progesterone (>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached >16 mm (and LH was <20 IU/L).
79854260|NCT04413994|Dietary Supplement|Humavant|"Premature infants are randomized to either:~An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
79854261|NCT04409873|Drug|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
79256690|NCT03252639|Procedure|EVT for RAS & PBV acquisition protocol for target kidneys|
79554912|NCT01655927|Drug|Tranexamic Acid|
79854262|NCT04409873|Drug|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
79854263|NCT04409873|Drug|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
79554913|NCT01655927|Drug|Placebo: Saline|
79854264|NCT04409873|Drug|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
79554914|NCT01655940|Device|Somanetics cerebral oximeter|Somanetics cerebral oximeter
79554915|NCT01655940|Device|CASMED cerebral oximeter|CASMED cerebral oximeter
79854265|NCT04409873|Drug|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
79875482|NCT01011530|Drug|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
79875483|NCT00493454|Drug|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
79875484|NCT00493454|Drug|Rituximab|250 mg/m^2 IV Over 6 to 8 Hours
79256691|NCT02260765|Device|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
79256692|NCT03071900|Diagnostic Test|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
79256693|NCT03252483|Other|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
79256694|NCT03252483|Other|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
79256695|NCT03071510|Device|Atlas Genetics io® system|Specimen Collection
79256696|NCT02260843|Other|Generic Fitness|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
79256697|NCT02260843|Other|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
79256698|NCT03071588|Device|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
79256699|NCT03071588|Device|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
79395947|NCT06102434|Drug|Psilocybin|Five oral capsules containing 5 mg of psilocybin each
79395948|NCT06102421|Device|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
79395949|NCT06102356|Other|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
79554916|NCT01655953|Dietary Supplement|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
79554917|NCT01655953|Other|Control: high NaCl|7.7 mmol Na/kgBW/d
79554918|NCT01655966|Drug|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
79718440|NCT05214729|Diagnostic Test|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
79256700|NCT03259347|Behavioral|Group-based Therapy|Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
79554919|NCT01655966|Drug|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
79854266|NCT04409821|Behavioral|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
79718441|NCT05214729|Diagnostic Test|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
79854267|NCT04392297|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
79854268|NCT04392297|Diagnostic Test|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
79854269|NCT04392297|Diagnostic Test|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
79854270|NCT04391348|Radiation|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
79854271|NCT04387734|Drug|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
79854272|NCT04387734|Drug|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
79854273|NCT04380324|Drug|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
79256701|NCT03071822|Drug|cisplatin|PIGLETs
79256702|NCT03071822|Drug|ifosfamide|PIGLETs
79256703|NCT03071822|Drug|gemcitabine|PIGLETs
79256704|NCT03071822|Drug|L-asparaginase|PIGLETs
79554920|NCT01655979|Dietary Supplement|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
79554921|NCT01655979|Other|Control|Bed rest without dietary supplement
79256705|NCT03071822|Drug|etoposide|PIGLETs
79256706|NCT03071822|Drug|dexamethasone|PIGLETs
79256707|NCT03551353|Other|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
79256708|NCT03551353|Other|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
79256709|NCT04930172|Device|Steerable introducers|endografts via total transfemoral approach for visceral vessels cannulation
79395950|NCT06102343|Device|Alma Harmony|Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.
79554922|NCT01655992|Drug|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
79554923|NCT01655992|Drug|S1 generic|40mg／m2 bid four weeks on two weeks off
79554924|NCT01656005|Drug|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
79554925|NCT01656005|Drug|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
79554926|NCT01656005|Drug|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
79554927|NCT01656005|Drug|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
79554928|NCT01656005|Drug|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
79718442|NCT05205850|Drug|RC118-ADC|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
79718443|NCT05205174|Device|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
79718444|NCT05205109|Drug|ATG-037|"Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1."
79718445|NCT05205109|Drug|Keytruda(Pembrolizumab, MK-3475)|"Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda(Pembrolizumab, MK-3475) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda(Pembrolizumab, MK-3475) will be administered from C1."
79718446|NCT05202353|Drug|BI 456906|BI 456906
79256710|NCT02456415|Device|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
79256711|NCT04991012|Device|PDT Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
79554929|NCT01656018|Drug|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
79554930|NCT01656044|Procedure|wound care management|Receive SSD
79256712|NCT04991012|Drug|Triamcinolone (Substance) therapy side|th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
79395951|NCT06102317|Other|nursing consultancy with smartphone support|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
79256713|NCT03261219|Device|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
79256714|NCT03261219|Device|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
79256715|NCT02252731|Drug|Warfarin|Oral
79554931|NCT01656044|Procedure|wound care management|Receive NPT
79554932|NCT01656057|Drug|Acetaminophen|Acetaminophen dissolved in 50 ml of water
79554933|NCT01656057|Drug|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
79554934|NCT01656057|Drug|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
79554935|NCT01656057|Other|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
79554936|NCT01656057|Other|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
79554937|NCT01656070|Drug|oral cholecalciferol 1000000 UI (vitamin D3)|
79554938|NCT01656070|Drug|Placebo|
79554939|NCT01656096|Device|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
79554940|NCT01656096|Other|Sham procedure|
79554941|NCT01656109|Drug|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
79554942|NCT01656122|Drug|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
79554943|NCT01656122|Drug|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
79718447|NCT05202353|Drug|Semaglutide|Semaglutide
79718448|NCT05200000|Biological|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
79854274|NCT04380324|Drug|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
79854275|NCT04380077|Procedure|vitrectomy with sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
79256716|NCT02252731|Drug|FG-4592|Oral
79256717|NCT03259113|Device|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
79256718|NCT02128633|Drug|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
79256719|NCT02128633|Drug|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
79256720|NCT02128633|Drug|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
79256721|NCT04990856|Procedure|Exercise|Tumor blood flow after acute exercise
79256722|NCT03259191|Procedure|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
79554944|NCT01656135|Other|Blood drawing for immune monitoring and questionnaires|
79718449|NCT05188183|Device|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
79256723|NCT02126683|Drug|Hydroxychloroquine|
79854276|NCT04380077|Procedure|vitrectomy with balanced salt solution|vitreous substitution with balances salt solution during vitrectomy
79256724|NCT03258957|Other|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
79554945|NCT01656148|Drug|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
79554946|NCT01656174|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
79554947|NCT01656213|Device|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
79554948|NCT01656226|Device|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
79554949|NCT01656226|Other|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
79718450|NCT05188183|Behavioral|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
79854277|NCT04380064|Procedure|ILM Peeling|ILM peeling performed during primary PPV for PDR
79854278|NCT04380064|Procedure|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
79854279|NCT04371510|Other|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
79854280|NCT04355533|Biological|serology test|volume according to child weight
79854281|NCT04355533|Biological|nasopharyngeal swab|nasopharyngeal swab for PCR
79854282|NCT04355533|Biological|rectal swab|rectal swab for PCR
79854283|NCT04355533|Biological|saliva sample|for biocollection
79854284|NCT04345341|Drug|TAP block with liposomal bupivacaine and bupivacaine|injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
79256725|NCT02252185|Device|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson & Johnson Medical Suzhou Ltd.
79256726|NCT02252185|Device|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
79256727|NCT03252561|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
79256728|NCT03252561|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
79256729|NCT02455323|Other|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
79554950|NCT01656265|Drug|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
79554951|NCT01656278|Procedure|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28>3.2 AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)"
79554952|NCT01656278|Other|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28>3.2"
79854285|NCT04332705|Diagnostic Test|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
79854286|NCT04329949|Drug|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
79854287|NCT04329949|Drug|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
79854288|NCT04329065|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
79854289|NCT04329065|Drug|Paclitaxel|Given via infusion
79854290|NCT04329065|Biological|Trastuzumab|Given IV
79854291|NCT04329065|Biological|Pertuzumab|Given IV
79875485|NCT00493454|Drug|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
79256730|NCT02455323|Other|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
79718451|NCT05188183|Other|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
79554953|NCT01656317|Other|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
79718452|NCT05179343|Device|Active AffeX-CT device|(Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.
79256731|NCT02455323|Other|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
79554954|NCT01656330|Drug|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
79554955|NCT01656330|Drug|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
79554956|NCT01656330|Drug|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
79554957|NCT01656330|Drug|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
79554958|NCT01656330|Other|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
79554959|NCT01656356|Biological|Avian Flu Vaccine|
79554960|NCT01656356|Biological|Placebo|
79554961|NCT01656369|Procedure|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
79256732|NCT02455323|Other|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
79256733|NCT02252263|Drug|Elotuzumab|
79256734|NCT02252263|Drug|Lirilumab|
79256735|NCT02252263|Drug|Urelumab|
79554962|NCT01656369|Procedure|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
79554963|NCT01656382|Drug|ABLC|
79718453|NCT05179343|Device|Sham AffeX-CT device|Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
79718454|NCT05174507|Drug|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
79718455|NCT05174507|Drug|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
79718456|NCT05174507|Other|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
79256736|NCT04996550|Drug|Carvedilol|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
79554964|NCT01656473|Other|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
79554965|NCT01656473|Other|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
79554966|NCT01656499|Dietary Supplement|Arabinoxylanoligosaccharides|
79554967|NCT01656499|Dietary Supplement|Maltodextrine|
79554968|NCT01656512|Drug|zolendronic acid|"patients will receive calcium & vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~Initial dose: (0.025) mg /kg~Subsequent doses ( 0.05) mg /kg.~Maximum dose of 4 mg."
79854292|NCT04310891|Radiation|Markerless Tumour Tracking|Intrafraction Kolovoltage X-ray Imaging using Fiducials
79718457|NCT05174507|Other|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
79395952|NCT06102291|Other|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
79395953|NCT06102291|Other|Acupuncture|The main acupoints are Ashi points, Shenshu (BL23), Guanyuanshu (BL26). There are three sessions per week with each session lasting for 20 min. There will be 4 weeks of treatment for each participant in total.
79395954|NCT06102278|Other|Peritoneal Metastasis|Patients experiencing postoperative peritoneal metastasis
79554969|NCT01656512|Drug|calcium & vitamin D|patients will receive calcium & vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
79718458|NCT05168865|Drug|Letrozole 2.5mg|Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
79718459|NCT05166395|Device|Er:YAG laser|2940 nm Er:YAG laser treatment spread over 3 sessions within 4 weeks on participant's scar on either the head/neck, trunk or extremities.
79718460|NCT05161013|Diagnostic Test|LINFU™|A method to detect pancreatic cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. LINFU™ involves analysis of pancreatic fluid collected.
79718461|NCT05155332|Drug|BI 1831169|BI 1831169; Intratumoral (i.t.) and/or Intravenous (i.v.)
79718462|NCT05155332|Drug|ezabenlimab|ezabenlimab; Intravenous (i.v.)
79256737|NCT04996550|Drug|Metoprolol Succinate|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
79256738|NCT03252171|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
79256739|NCT04996784|Other|Capillary blood sampling|The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S&S (Whatman).
79256740|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
79395955|NCT06102265|Procedure|sterilization|the use of sterilization methods and the reuse of gowns
79395956|NCT06102252|Drug|Paclitaxel/epirubcin/carboplatin|adjuvant treatment in endometrial carcinoma
79395957|NCT06102252|Drug|Paclitaxel/carboplatin|Dose dense paclitaxel/carboplatin
79395958|NCT06102239|Diagnostic Test|Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium &c-reactive protein as indicator of complicated appendicitis
79395959|NCT06102226|Diagnostic Test|coronary artery imaging (coronary CTA or coronary angiography)|In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
79395960|NCT06102213|Drug|B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)|PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
79554970|NCT01656525|Drug|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
79554971|NCT01656525|Drug|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
79554972|NCT01656525|Drug|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
79554973|NCT01656525|Drug|Placebo|subcutaneous doses every 4 weeks for 24 weeks
79554974|NCT01656577|Drug|Pexacerfont|
79554975|NCT01656590|Other|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age & gender~500 cc Formula - Nutren Replete with Fiber overnight [8 hours] via gastrostomy tube~Conditioning Exercise once daily"
79554976|NCT01656616|Drug|Cyanide antidote administration|
79554977|NCT01656642|Drug|Atezolizumab|Atezolizumab will be administered q3w or q2w.
79718463|NCT05147792|Device|CLAAS|CLAAS
79718464|NCT05147792|Device|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
79718465|NCT05146336|Device|CytoSorb|Sorbent hemoperfusion system
79854293|NCT04300504|Other|observational study|observational study
79256741|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a lyophilized formulation
79256742|NCT03252405|Device|mask ventilation|before intravenous induction, mask application is made. then intravenous cannulation and induction
79256743|NCT03252405|Device|intravenous cannulation|induction is applied by using intravenous cannulation
79256744|NCT02135965|Drug|2mg of Albuterol|2mg of Albuterol on metabolic rate
79256745|NCT02135965|Drug|4mg of Albuterol|4mg of Albuterol on metabolic rate
79554978|NCT01656642|Drug|Cobimetinib|Oral repeating dose
79554979|NCT01656642|Drug|Vemurafenib|Oral repeating dose, depending on arm/cohort
79554980|NCT01656668|Drug|BC1036|
79554981|NCT01656681|Dietary Supplement|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
79554982|NCT01656681|Dietary Supplement|Placebo|Placebo tablet
79554983|NCT01656694|Device|DePuy Sigma HP Partial Knee|
79554984|NCT01656707|Behavioral|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
79554985|NCT01656707|Behavioral|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
79554986|NCT01656720|Drug|1R, 2S-methoxamine hydrochloride|
79554987|NCT01656720|Drug|Placebo|
79554988|NCT01656746|Procedure|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
79718466|NCT05145283|Drug|Conestat alfa (Ruconest®)|In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
79718467|NCT05145283|Drug|NaCl 0.9%)|Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
79554989|NCT01656785|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
79256746|NCT02135965|Drug|100mg of Caffeine|100mg of caffeine on metabolic rate
79395961|NCT06102200|Behavioral|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
79554990|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
79718468|NCT05127733|Behavioral|Online Cognitive Behavioural Therapy|Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).
79718469|NCT05127733|Behavioral|Individual Peer Support|Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.
79554991|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
79554992|NCT01656811|Drug|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
79554993|NCT01656811|Drug|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
79554994|NCT01656811|Drug|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
79718470|NCT05127733|Behavioral|Group Peer Support|Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
79554995|NCT01656811|Drug|Placebo|Placebo 2 actuations QID
79854294|NCT04296617|Other|Medical Chart Review|Review of medical chart
79854295|NCT04290624|Other|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
79854296|NCT04290624|Device|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
79256747|NCT02135965|Drug|200mg of Caffeine|200mg of Caffeine on metabolic rate
79554996|NCT01656837|Behavioral|Comprehensive Community Treatment|
79554997|NCT01656837|Behavioral|MST-BSF|
79554998|NCT01656863|Other|Questionnaire|
79554999|NCT01656876|Behavioral|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
79555000|NCT01656876|Other|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
79555001|NCT01656876|Behavioral|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
79555002|NCT01656928|Behavioral|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
79256748|NCT02135965|Drug|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
79256749|NCT02135965|Drug|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
79256750|NCT02135965|Drug|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
79256751|NCT02135965|Drug|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
79555003|NCT01656954|Procedure|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
79555004|NCT01656980|Drug|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
79555005|NCT01656980|Procedure|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
79555006|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
79395962|NCT06102200|Behavioral|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
79395963|NCT06102200|Behavioral|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
79395964|NCT06102161|Procedure|Wedge resection|Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
79555007|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
79555008|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
79555009|NCT01657058|Dietary Supplement|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
79555010|NCT01657058|Dietary Supplement|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
79555011|NCT01657058|Dietary Supplement|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
79555012|NCT01657058|Dietary Supplement|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
79555013|NCT01657058|Dietary Supplement|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
79555014|NCT01657071|Drug|YH14659|YH14659 capsule by oral
79555015|NCT01657071|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
79718471|NCT05119556|Behavioral|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
79854297|NCT04290624|Other|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
79256752|NCT03261141|Combination Product|(PV-RQOL),(APA) ,Acoustic analysis|"severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
79256753|NCT04987424|Diagnostic Test|Development and validation of Lymphedema levels diagnostic|A single intervention was carried out in which the patients were summoned for an interview and anthropometric measurements of the upper limbs, thus calculating the arm volume for a lymphedema primary diagnosis .
79256754|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
79256755|NCT02455401|Drug|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
79555016|NCT01657084|Device|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
79555017|NCT01657084|Device|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
79555018|NCT01657097|Drug|INCS|
79256756|NCT02455401|Drug|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
79256757|NCT02455401|Drug|No remifentanil|Intervention: no remifentanil will be administrated
79256758|NCT02128789|Other|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
79256759|NCT02136043|Device|PBASE system 1.1 (active treatment)|
79256760|NCT04987268|Genetic|clonal hematopoiesis of indeterminate potential|Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
79555019|NCT01657097|Drug|Placebo|
79555020|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
79555021|NCT01657123|Other|ergometry|ergometry measurements
79555022|NCT01657123|Other|ergometry|Ergometry measurements
79555023|NCT01657136|Drug|Ivabradine|comparison of different drugs
79854298|NCT04288115|Drug|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
79256761|NCT02136121|Device|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
79256762|NCT03070262|Drug|CA|caffeic acid, 300mg, tid, po
79256763|NCT03070262|Drug|placebo group|placebo tablet, 3 tablets, tid, po
79256764|NCT03260829|Drug|vitamin C|25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
79256765|NCT03258879|Procedure|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
79256766|NCT03258879|Procedure|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
79256767|NCT04987190|Procedure|alveolar bone graft|alveolar bone graft with Scarpa fascia done when patients were at 9 year of age
79256768|NCT03260985|Other|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
79256769|NCT04990700|Procedure|Partial rib resection|1 cm partial rib resection during thoracotomy opening
80018399|NCT02122614|Behavioral|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
79256770|NCT03260907|Procedure|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6~13.9mA).
79256771|NCT03260907|Procedure|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
79256772|NCT02134093|Drug|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)
79256773|NCT02134093|Drug|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
79256774|NCT02134093|Drug|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
79256775|NCT02134093|Drug|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3~6 mg/kg/h）, remifentanil （0.05~0.3 μg/kg/min）is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05~0.1mg/kg） as needed to maintain muscle relaxation.
79256776|NCT03071354|Dietary Supplement|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
79256777|NCT03071354|Dietary Supplement|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
79256778|NCT03252327|Other|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
79256779|NCT03261063|Device|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
79256780|NCT03074786|Drug|Dapivirine|Silicone elastomer vaginal matrix ring
79256781|NCT03074786|Drug|Truvada|Tablets to be taken orally daily
79256782|NCT04990076|Procedure|Hysterectomy|Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
79395965|NCT06102148|Other|PNF Group|Exercise training and PNF training
79395966|NCT06102148|Other|Control Group|Exercise training
79395967|NCT06102135|Dietary Supplement|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
79395968|NCT06102109|Procedure|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
79395969|NCT06102109|Procedure|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
79555024|NCT01657136|Drug|Beta blocker|comparison of different drugs
79555025|NCT01657149|Procedure|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
79555026|NCT01657149|Procedure|individual physiotherapy only|individual physiotherapy only
79854299|NCT04288115|Other|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
79854300|NCT04287868|Biological|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
80018400|NCT02122614|Behavioral|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
80031506|NCT04648826|Drug|Azacytidine|Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
79555027|NCT01657175|Other|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~Discharge information about surgery and life after surgery together with their relatives.~Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
79555028|NCT01657188|Device|Cheyne-Stokes respiration by adaptive servoventilation|
79555029|NCT01657201|Drug|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
79555030|NCT01657201|Drug|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
79256783|NCT03260751|Dietary Supplement|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
79256784|NCT03260751|Dietary Supplement|Placebo|Placebo for 12 weeks
79256785|NCT03074552|Dietary Supplement|LactoLevure|The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).
79555031|NCT01657214|Drug|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
79555032|NCT01657227|Behavioral|Intervention to patients|"Multifaceted intervention consisting of:~Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
79555033|NCT01657227|Behavioral|Intervention to professionals|"Multifaceted intervention consisting of:~Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
79555034|NCT01657227|Other|Usual care|Usual care for T2DM received in primary health care
79555035|NCT01657240|Drug|PRO-118|instill one drop in each eye once a day for 21 days
79555036|NCT01657240|Drug|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
79555037|NCT01657279|Other|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome [i.e. from low (<10%) to high (>50%) expected risk death at 30 days].
79555038|NCT01657318|Other|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
79555039|NCT01657331|Drug|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
79555040|NCT01657331|Drug|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
79555041|NCT01657331|Drug|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
79256786|NCT03074552|Other|Placebo|Placebo will consist of identical capsules of powdered glucose polymer
79555042|NCT01657357|Other|Routine followup|questionnaires
79555043|NCT01657409|Drug|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
79555044|NCT01657409|Drug|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
79555045|NCT01657409|Drug|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
79555046|NCT01657422|Behavioral|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
79555047|NCT01657435|Device|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
79555048|NCT01657448|Drug|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
79555049|NCT01657448|Drug|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
79555050|NCT01657474|Other|Weekly application of EpiFix plus standard of care|
79555051|NCT01657474|Other|Biweekly application of EpiFix plus standard of care|
79555052|NCT01657487|Drug|Fluticasone/Salmeterol high dose|
79555053|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
79256787|NCT04986878|Procedure|single-shot adductor canal block|An ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe was used to perform the adductor canal block immediately postoperatively.
79256788|NCT03258333|Procedure|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
79256789|NCT03260673|Other|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
79256790|NCT03070028|Procedure|crystallised phenol|crystallised phenol will be applied to sinus cavity
79256791|NCT03070028|Procedure|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
79555054|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
79555055|NCT01657526|Biological|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
79555056|NCT01657539|Dietary Supplement|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
79718472|NCT05108363|Behavioral|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
79718473|NCT05104255|Procedure|Spinal anesthesia|Twins delivered under under spinal anesthesia
79718474|NCT05104255|Procedure|General anesthesia|Twins delivered under general anesthesia
79718475|NCT05101096|Drug|Sacituzumab Govitecan-hziy|Administered intravenously (IV)
79718476|NCT05100264|Other|Vaginal washing with 5% acetic acid|Induction of labor (vaginal tablet dinoprostone and vaginal washing with 5% acetic acid)
79256792|NCT03260439|Drug|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
79555057|NCT01657539|Dietary Supplement|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
79718477|NCT05100264|Other|Vaginal washing with 0.9% NS|Induction of labor (vaginal tablet dinoprostone and vaginal washing 0.9% NS)
79854301|NCT04287868|Biological|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
79854302|NCT04287868|Biological|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
79854303|NCT04287738|Behavioral|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
79718478|NCT05098938|Drug|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
79718479|NCT05098938|Drug|Placebo|Oral (upper gum area), 1 table.
79718480|NCT05095727|Drug|mRNA-3745|Sterile frozen liquid dispersion for injection
79718481|NCT05094388|Other|Admitted to intensive care units|Admitted to intensive care units
79718482|NCT05089734|Biological|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
79256793|NCT03260439|Drug|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
79256794|NCT03258411|Device|Rapid Expansion of palatal suture|
79555058|NCT01657552|Drug|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
79854304|NCT04279028|Behavioral|Adapted CBT|"ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments."
79256795|NCT03251703|Procedure|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
79256796|NCT03260517|Device|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
79256797|NCT02634788|Drug|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
79555059|NCT01657552|Drug|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
79555060|NCT01657552|Drug|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
79555061|NCT01657578|Drug|Omeprazole|administration of Omeprazole
79718483|NCT05089734|Drug|Docetaxel|Administered intravenously
79718484|NCT05082233|Drug|SHR7280 tablets|Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
79718485|NCT05060003|Drug|Atezolizumab|Atezolizumab is provided by Genentech.
79718486|NCT05060003|Drug|Tiragolumab|Tiragolumab is provided by Genentech.
79718487|NCT05060003|Device|Signatera Assay|"To detect residual disease or to determine cancer recurrence with ctDNA~Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
79875486|NCT00493220|Drug|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
80031507|NCT03052270|Drug|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
79555062|NCT01657630|Device|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
79555063|NCT01657643|Dietary Supplement|Probiotics|
79718488|NCT05058495|Other|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
79718489|NCT05058495|Other|standart lymphedema education|The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
79555064|NCT01657643|Dietary Supplement|placebo|
79718490|NCT05041595|Diagnostic Test|Lyme diagnostic assay|Serological and immunoresponse assay
79555065|NCT01657656|Dietary Supplement|Vitamin D|
79718491|NCT05039086|Drug|PDE5 inhibitor|PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
79718492|NCT05039086|Drug|Endothelin Receptor Antagonists|Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
79854305|NCT04279028|Behavioral|Standard CBT|CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
79854306|NCT04276935|Other|Interview|Participate in cognitive interview
79256798|NCT02634788|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
79256799|NCT03258255|Procedure|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
79395970|NCT06102109|Procedure|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
79555066|NCT01657669|Drug|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
79718493|NCT05036278|Biological|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~40 IU/kg/dose two times per week~50 IU/kg/dose every 5 days~60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
79718494|NCT05020158|Other|Family Talk Intervention|A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
79718495|NCT05008848|Behavioral|Smoking Cessation Intervention|Participate in schedule gradual reduction program
79718496|NCT05008848|Other|Health Promotion and Education|Receive cessation support messages
79395971|NCT06102109|Procedure|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
79555067|NCT01657708|Other|Shared Decision Making|
79555068|NCT01657721|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
79718497|NCT05008848|Other|Informational Intervention|Receive NCI's Clearing the Air booklet
79718498|NCT05008848|Other|Questionnaire Administration|Ancillary studies
79718499|NCT05004610|Drug|Sodium Lactate Solution|continuous intravenous infusion of half-molar sodium lactate
79718500|NCT05002777|Drug|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
79718501|NCT04998903|Procedure|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
79718502|NCT04998682|Procedure|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
79718503|NCT04996511|Device|PulseOn|Postoperative HRV measurement
79718504|NCT04994769|Device|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling.
79718505|NCT04993677|Drug|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
79718506|NCT04993677|Drug|pembrolizumab|Given by IV; schedule is cohort-specific.
79854307|NCT04276935|Other|Quality-of-Life Assessment|Ancillary studies
79854308|NCT04276935|Other|Questionnaire Administration|Ancillary studies
79256800|NCT03071432|Diagnostic Test|Paced breathing at 6, 10 and 15 breaths per minute|
79256801|NCT03260283|Drug|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
79555069|NCT01657734|Other|MR imaging|MR imaging
79718507|NCT04993677|Drug|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
79395972|NCT06102070|Other|Blood samples drawing|10 ml of periferal blood
79555070|NCT01657747|Other|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
79718508|NCT04993677|Drug|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
79718509|NCT04989595|Device|MyIUS app|Data will be self-reported by participants through the MyIUS app.
79718510|NCT04989504|Other|Best Practice|Receive standard of care
79718511|NCT04989504|Device|Wound Dressing Material|Apply Mepitel Film
79718512|NCT04989504|Other|Quality-of-Life Assessment|Ancillary studies
79718513|NCT04989504|Other|Questionnaire Administration|Ancillary studies
79718514|NCT04984577|Drug|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
79718515|NCT04984577|Drug|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
79718516|NCT04984577|Drug|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
79718517|NCT04984577|Drug|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
79718518|NCT04980638|Biological|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
79718519|NCT04978493|Drug|BI 706321|BI 706321
79718520|NCT04978493|Drug|ustekinumab|ustekinumab
79718521|NCT04978493|Drug|Placebo|Placebo
79718522|NCT04971642|Device|Intraoral ultrasound|Intraoral ultrasound scanning of the periodontium complex
79718523|NCT04966624|Procedure|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
79718524|NCT04966624|Procedure|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
79854309|NCT04271813|Drug|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
79395973|NCT06102070|Other|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
79395974|NCT06102044|Dietary Supplement|Zinc Supplements|Dispersible zinc sulfate tablets
79395975|NCT06102044|Dietary Supplement|Placebo Supplements|Dispersible placebo tablets
79395976|NCT06102031|Device|ReDS-Guided|"ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading <36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading <20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization."
79555071|NCT01657773|Other|Ultrasound examination and Colonoscopy examination|
79718525|NCT04951583|Combination Product|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
79718526|NCT04945278|Other|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
79718527|NCT04945278|Other|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
79718528|NCT04944316|Behavioral|Dietary intervention|Low-fat, plant-based diet
79718529|NCT04944316|Behavioral|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
79718530|NCT04939090|Drug|Olanzapine|Given PO
79718531|NCT04939090|Drug|Megestrol Acetate|Given PO
79718532|NCT04939090|Other|Questionnaire Administration|Ancillary studies
79718533|NCT04934514|Biological|IAH0968|IAH0968 is an investigational product.
79718534|NCT04934514|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenous infusion
79718535|NCT04934514|Drug|Cisplatin|Cisplatin 75 mg/m^2 intravenous infusion
79718536|NCT04934137|Behavioral|Sensoria|The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
79875487|NCT00493220|Drug|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
79718537|NCT04934137|Behavioral|AW-Shift|The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
79718538|NCT04926818|Drug|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
79718539|NCT04926818|Drug|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
79718540|NCT04926818|Drug|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
79718541|NCT04926818|Other|Fingolimod placebo|Fingolimod matching placebo capsule
79256802|NCT03260283|Drug|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
79256803|NCT03260283|Drug|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
79256804|NCT03071198|Procedure|TME|"Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
79256805|NCT03071198|Radiation|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
79256806|NCT03071198|Drug|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
79555072|NCT01657786|Dietary Supplement|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
79555073|NCT01657812|Drug|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
79555074|NCT01657825|Drug|Isavuconazole|oral
79555075|NCT01657825|Drug|Warfarin|oral
79555076|NCT01657838|Drug|Isavuconazole|oral
79555077|NCT01657838|Drug|Ketoconazole|oral
79555078|NCT01657851|Drug|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
79718542|NCT04926818|Other|Siponimod placebo|Siponimod matching placebo tablet
79718543|NCT04926818|Other|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
79718544|NCT04925024|Biological|Lomecel-B medicinal signaling cells|A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
79718545|NCT04914676|Drug|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
79718546|NCT04914676|Drug|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
79256807|NCT03071198|Drug|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
79395977|NCT06102031|Other|Usual care|ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
79395978|NCT06102018|Diagnostic Test|Collect blood and urine，pathological specimens if necessary|Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
79555079|NCT01657851|Drug|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
79718547|NCT04908995|Drug|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
79718548|NCT04908995|Other|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
79718549|NCT04906616|Behavioral|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
79718550|NCT04903119|Drug|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
79718551|NCT04903119|Drug|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
79718552|NCT04903119|Drug|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
79718553|NCT04903119|Drug|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
79555080|NCT01657851|Drug|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
79854310|NCT04269577|Behavioral|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
79555081|NCT01657864|Drug|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
79718554|NCT04903119|Drug|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
79854311|NCT04263714|Behavioral|Exercise|Aerobic exercise and resistance exercise
79854312|NCT04262193|Drug|Suvorexant|In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
79854313|NCT04262193|Drug|Suvorexant Placebo|Suvorexant Placebo
79854314|NCT04261478|Device|Carotid artery stenting|The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.
79854315|NCT04261478|Drug|Antiplatelet Agents|The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
79854316|NCT04251026|Drug|tividenofusp alfa|Intravenous repeating dose
79854317|NCT04248452|Drug|Capecitabine|Given PO
79854318|NCT04248452|Drug|Fluorouracil|Given IV
80018401|NCT05285800|Drug|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
79256808|NCT03258489|Device|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
79256809|NCT03258489|Device|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
79256810|NCT03258489|Device|TENS and IES Placebo|Same protocol without electrical output.
79555082|NCT01657890|Drug|isavuconazole|oral
79555083|NCT01657929|Biological|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
80018402|NCT02122692|Drug|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
79555084|NCT01657929|Biological|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
79555085|NCT01657929|Biological|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
79555086|NCT01657929|Biological|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
79555087|NCT01657942|Device|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
79555088|NCT01657955|Drug|Bendamustine Hydrochloride Injection|
79555089|NCT01657955|Drug|Chlorambucil|
79718555|NCT04903119|Drug|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
79718556|NCT04899661|Drug|Molidustat (Musredo, BAY85-3934)|Tablets, administered orally at the discretion of investigators
79718557|NCT04899544|Behavioral|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
79718558|NCT04899544|Behavioral|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
79718559|NCT04886804|Drug|BI 1810631|BI 1810631
79718560|NCT04886453|Drug|Balanced general anesthesia without morphine|Balanced general anesthesia without morphine
79718561|NCT04886453|Drug|Standard general anesthesia balanced with morphine|Standard general anesthesia balanced with morphine
79718562|NCT04886453|Other|Data collection|Data collection
79718563|NCT04886453|Other|Assessment of pain|visual analog scale
79718564|NCT04886453|Other|Recovery quality score|QoR15 questionnaire
79718565|NCT04886180|Device|Oxiris membrane|Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
79555090|NCT01657513|Drug|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~infliximab or~adalimumab or~etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
80018403|NCT02122692|Drug|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
79718566|NCT04886180|Device|Prismaflex membrane|Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
79718567|NCT04886180|Biological|Blood tests|Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
79718568|NCT04880733|Procedure|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
79718569|NCT04880733|Other|Usual care for pain management|Patient will receive usual care for pain management.
79718570|NCT04875260|Other|Critical Care|Critical care in the intensive care units
79718571|NCT04873401|Behavioral|Chain-referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing. The peer recruiters are paid for each suvcessful and eligible recruit who enrolls to be tested. Those individuals are then themselves trained to recruit peers from their social networks to receive COVID-19 testing. This is repeated over a period of 4-6 months."
79854319|NCT04248452|Drug|Leucovorin|Given IV
80018404|NCT02122692|Drug|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
80031508|NCT04898842|Other|Dietary intervention|To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
79256811|NCT03074396|Device|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
79256812|NCT03074396|Device|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
79256813|NCT03251469|Drug|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
79256814|NCT03251469|Drug|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
79718572|NCT04873401|Behavioral|Credible Messenger|In the credible messenger intervention, peers noted to be popular and socially influential individuals with lived experience will be trained to engage within community settings and areas to encourage community members to receive COVID-19 testing at the community partnering agencies. Peers will recruit community members over a period of 4-6 months.
79718573|NCT04862143|Drug|Alpelisib|Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
79718574|NCT04862143|Drug|Fulvestrant|Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
79718575|NCT04862143|Drug|Goserelin|Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
79718576|NCT04860830|Drug|iclepertin|iclepertin
79718577|NCT04860830|Drug|Placebo|Placebo
79718578|NCT04858126|Device|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
79854320|NCT04248452|Drug|Leucovorin Calcium|Given IV
79854321|NCT04248452|Drug|Oxaliplatin|Given IV
80031509|NCT05390762|Other|Common phase|A common face to face day hospital combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.
79256815|NCT04986644|Device|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
79256816|NCT03251625|Drug|Probiotic Formula Capsule|
79256817|NCT04920266|Device|Smart Cap, running and fitness exercisers only|Bottle cap
79256818|NCT04920266|Device|Sweat Patch, all subjects- running, fitness, cycling|Regional contralateral forearm patch
79256819|NCT04920266|Device|Reference sweat patch, all subjects - running, fitness, cycling|Regional contralateral forearm patch
79256820|NCT04920266|Other|Bottle Scale, all subjects - running, fitness, cycling|Bottle weight
79555091|NCT01657981|Drug|YM150|14C-labeled YM150, oral solution
79555092|NCT01657994|Other|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
79854322|NCT04248452|Radiation|Radiation Therapy|Undergo radiation therapy
79854323|NCT04244942|Device|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
79854324|NCT04238637|Drug|Durvalumab|Durvalumab IV (intravenous Infusion)
79854325|NCT04238637|Drug|Tremelimumab|Tremelimumab IV (intravenous Infusion)
79256821|NCT03251547|Drug|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
79555093|NCT01658007|Drug|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
79555094|NCT01658033|Drug|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
79555095|NCT01658046|Other|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
79555096|NCT01658046|Other|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
79555097|NCT01658046|Other|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
79555098|NCT01658085|Device|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
79555099|NCT01658085|Device|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
79555100|NCT01658098|Behavioral|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
79555101|NCT01658124|Drug|Tranexamic Acid|
79555102|NCT01658124|Drug|Placebo|
79555103|NCT01658137|Other|Prudent Diet|This intervention lasts 2 weeks (14 days).
79555104|NCT01658137|Other|Typical Western Diet|This intervention lasts 2 weeks (14 days).
79555105|NCT01658176|Drug|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
79555106|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
79555107|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
79555108|NCT01658202|Drug|V0116 transdermal patch (Test treatment )|
79718579|NCT04857242|Diagnostic Test|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
79718580|NCT04853394|Behavioral|MASLIHAT|peer educator intervention
79718581|NCT04853394|Behavioral|TANSIHAT|health education intervention
79718582|NCT04846881|Drug|Iclepertin|Iclepertin
79718583|NCT04846881|Drug|Placebo|Placebo
79256822|NCT03069872|Diagnostic Test|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
79256823|NCT03259893|Other|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
79555109|NCT01658202|Drug|Nicotine transdermal patch (Reference Treatment )|
79555110|NCT01658215|Drug|V0116 transdermal patch (Test treatment )|
79555111|NCT01658215|Drug|Nicotine transdermal patch (Reference treatment )|
79555112|NCT01658254|Other|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
79555113|NCT01658267|Other|nutritional supplement|2 servings per day
79555114|NCT01658280|Device|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
79555115|NCT01658306|Procedure|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
79555116|NCT01658306|Procedure|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
79555117|NCT01657396|Procedure|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
79718584|NCT04828668|Dietary Supplement|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
79718585|NCT04799288|Drug|Teriflunomide|Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
79718586|NCT04793633|Combination Product|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
79718587|NCT04791540|Diagnostic Test|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
79718588|NCT04791540|Diagnostic Test|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
79718589|NCT04791540|Diagnostic Test|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
79854326|NCT04232670|Procedure|EUS + SHAM|Endoscopic Ultrasound
79256824|NCT03259893|Behavioral|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
79256825|NCT03259893|Other|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
79256826|NCT03069794|Diagnostic Test|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
79854327|NCT04232670|Procedure|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
79854328|NCT04230278|Behavioral|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
79718590|NCT04791540|Diagnostic Test|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
79555118|NCT01657396|Procedure|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
79718591|NCT04791540|Biological|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
79718592|NCT04791540|Biological|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
79718593|NCT04791540|Other|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
79854329|NCT04230278|Behavioral|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
79854330|NCT04225182|Device|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
79854331|NCT04225182|Device|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
79256827|NCT02238587|Other|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
79256828|NCT02238587|Dietary Supplement|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
79256829|NCT03251391|Other|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
79256830|NCT03251391|Other|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
79256831|NCT02785939|Drug|Docetaxel|Given IV (arm II closed to accrual 12/18/2015)
79854332|NCT04221893|Radiation|Radiation Therapy (RT)|Undergo radiation therapy
79854333|NCT04217551|Device|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
79256832|NCT02785939|Other|Laboratory Biomarker Analysis|Correlative studies
79256833|NCT02785939|Drug|Palbociclib|Given PO
79256834|NCT04990154|Behavioral|a 12-week intradialytic exercise|a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
79256835|NCT03583229|Drug|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
79256836|NCT03583229|Other|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
79256837|NCT02456181|Behavioral|JumpMath|
79256838|NCT04989920|Behavioral|Experimental group: CIMT group (Constraint-Induced Movement Therapy)|2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
79256839|NCT02456337|Device|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
79256840|NCT02456337|Device|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
79256841|NCT02456337|Procedure|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
79718594|NCT04757376|Biological|CT-P41|60 mg/mL single dose, Solution for injection in PFS
79718595|NCT04757376|Biological|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
79718596|NCT04744844|Procedure|blastocoel fluid biopsy|In the present study, blastocoel fluid biopsy (BF-biopsy) and collapse will be performed using a microinjection pipette similar to that used to perform ICSI. The pipette will be pushed gently through the zona pellucida and TE, and up to 90% of the BF will be aspirated.
79718597|NCT04740294|Drug|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
79718598|NCT04736628|Drug|BI 685509|BI 685509
79718599|NCT04736628|Drug|Placebo|Placebo
79854334|NCT04204473|Drug|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
79854335|NCT04198623|Drug|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
79854336|NCT04191096|Biological|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
79854337|NCT04191096|Drug|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
79718600|NCT04736199|Drug|Darolutamide (Nubeqa, BAY1841788)|Coated tablet, oral administration
79718601|NCT04736199|Drug|Placebo|Coated tablet matching Darolutamide in appearance, oral administration
79718602|NCT04736199|Other|Androgen deprivation therapy (ADT)|Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
79256842|NCT04915742|Behavioral|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
79555119|NCT01657396|Procedure|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
79718603|NCT04734535|Device|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
79718604|NCT04734535|Device|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
79718605|NCT04731142|Device|Huma|Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.
79718606|NCT04731142|Behavioral|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals."
79555120|NCT01658319|Drug|fludarabine phosphate|Given IV
79718607|NCT04731142|Behavioral|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
79854338|NCT04191096|Drug|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
79718608|NCT04731142|Other|Standard of care|Normal primary care service provided to matched control group.
79718609|NCT04715958|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
79718610|NCT04715958|Drug|Perflutren Lipid Microspheres|Given IV
79718611|NCT04710420|Device|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
79718612|NCT04709380|Other|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
79718613|NCT04709380|Drug|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
79718614|NCT04708067|Drug|Bintrafusp Alfa|Given IV
79718615|NCT04708067|Procedure|Biopsy|Undergo biopsy
79718616|NCT04708067|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79718617|NCT04703244|Procedure|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
79854339|NCT04191096|Other|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
79256843|NCT04915742|Behavioral|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
79555121|NCT01658319|Drug|methoxyamine|Given IV
79854340|NCT04188652|Other|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
79854341|NCT04187833|Drug|Nivolumab|480mg intravenously every 4 weeks (28 days)
79854342|NCT04187833|Drug|Talazoparib|1mg orally daily
79875488|NCT00493220|Drug|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
80031510|NCT05390762|Other|Telecare rehabilitation|A Second phase of 5 weeks of telecare rehabilitation of the reconditioning type of 15 sessions.
79256844|NCT02259803|Drug|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
79256845|NCT02259803|Drug|Telmisartan|
79256846|NCT02259803|Drug|Amlodipine|
79555122|NCT01658319|Other|laboratory biomarker analysis|Correlative studies
79555123|NCT01658319|Other|pharmacological study|Correlative studies
79555124|NCT01658319|Genetic|western blotting|Correlative studies
79555125|NCT01658319|Other|mass spectrometry|Correlative studies
79718618|NCT04697771|Other|Fine Motor Skills Training|The fine motor skills training program was planned for the areas of difficulty that children with ADHD experience in the fine motor area as stated in the literature (Lavasani & Stagnitti, 2011). The fine motor goals were organized for 8 weeks, each week including a different fine motor area and practicing handwriting. For each fine motor goal, 3 different activities were identified that did not require materials or could be practiced with materials that could be easily found in each child's home. For example, for the fine motor strengthening goal, three different activities were planned for the same purpose with tools such as play dough, nails, and staples (Case-Smith & O'Brien, 2013). The activities determined each week were repeated three days a week in the same way and applied to all children. Within the 40-minute session, each activity was performed for 10 minutes under the guidance of an expert occupational therapist.
80018405|NCT03627247|Behavioral|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar & Kofman, 2012).
80018406|NCT05285722|Behavioral|Cognitive Behavioral Therapy form for dental anxiety|Message to Dentist form
79718619|NCT04697628|Drug|tisotumab vedotin|2.0 mg/kg every 3 weeks (Q3W)
79718620|NCT04697628|Drug|topotecan|1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
79718621|NCT04697628|Drug|vinorelbine|30 mg/m2 IV on Days 1 and 8, every 21 days
79718622|NCT04697628|Drug|gemcitabine|1000 mg/m2 IV on Days 1 and 8, every 21 days
79854343|NCT04183426|Diagnostic Test|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
79854344|NCT04183426|Diagnostic Test|Arterial Stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~Peripheral pressure parameters~Central and abdominal aneurysm pressure parameters (derived using a transfer function)~Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED))~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
80018407|NCT02122848|Device|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
80018408|NCT05707039|Other|Open kinetic chain exercises|In open chain exercises extremities are free to move and there is no weight bearing.
79395979|NCT06101966|Radiation|external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)|Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
79555126|NCT01658319|Genetic|DNA analysis|Correlative studies
79718623|NCT04697628|Drug|irinotecan|100 or 125 mg/m2 IV weekly for 28 days, every 42 days
79718624|NCT04697628|Drug|pemetrexed|500 mg/m2 IV on Day 1, every 21 days
80018409|NCT05707039|Other|Closed kinetic chain exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done.
79718625|NCT04692675|Diagnostic Test|mpMRI|3T endorectal coil MR imaging of the prostate gland
79395980|NCT06101953|Behavioral|Stress management|It spanned 12 weeks, with three hours per week (comprising two hours of theoretical content and one hour of practical application) and employed diverse teaching methods, including lectures, interactive learning, research, fieldwork, hands-on practice, and question-answer sessions. The primary objective of this course was to enhance students' awareness of stress by helping them identify its sources, symptoms, and effects. Also interception and resilience. Furthermore, it aimed to teach students how to assess stress and apply stress-management techniques effectively in their daily lives.
79555127|NCT01658332|Other|blood samples|3 tubes (15 ml)
79555128|NCT01658358|Drug|Lapatinib|"dose level I, II 1000mg po daily~dose level III, IV 1250mg po daily"
79256847|NCT03260049|Procedure|pars plana vitrectomy|pars plana vitrectomy
79256848|NCT03069950|Drug|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
79256849|NCT03069950|Drug|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
79256850|NCT03069950|Drug|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
79256851|NCT03069950|Drug|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
79256852|NCT03069950|Drug|DEXAMETHASONE|flat dose of 25 mg on Day 1
79395981|NCT06101940|Diagnostic Test|Brain MRI scan|Normal brain MRI scan to evaluate the integrity of the nervous system
79395982|NCT06101888|Device|TaurusTrio™ Heart Valve System|The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.
79555129|NCT01658358|Drug|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
79555130|NCT01658397|Behavioral|Fasting|Ten day fast
79555131|NCT01658410|Drug|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
79555132|NCT01658410|Drug|NaCl|NaCl, Route: intracoronary
79718626|NCT04680481|Device|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
79718627|NCT04671966|Drug|Estradiol patch|Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
79718628|NCT04671966|Drug|Cetrotide|Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
79718629|NCT04671966|Other|Fasting|Subjects will abstain from food for 48 hours. Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
79555133|NCT01658449|Other|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
79718630|NCT04671966|Other|Lower Body Negative Pressure|This test simulates Earth's gravity. The subject will rest on his/her back, with their lower body sealed in an air-tight chamber from the waist down. The chamber is connected to a vacuum that sucks air from the chamber and creates negative pressure inside and around the subject's lower body. As a result, the subject's blood pool shifts towards their legs, away from their chest and arms.
79718631|NCT04660682|Other|Modified static cross-body posterior shoulder stretching|For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
79854345|NCT04178915|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
79854346|NCT04178915|Diagnostic Test|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
79854347|NCT04174963|Behavioral|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
79854348|NCT04167748|Procedure|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
79854349|NCT04162418|Device|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
80018410|NCT04270786|Procedure|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
80018411|NCT04270786|Procedure|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
80018412|NCT05132530|Behavioral|yoga|yoga practice will be done two days a week for 10 weeks.
80018413|NCT02126046|Genetic|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
80018414|NCT05132452|Diagnostic Test|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
80018415|NCT02127606|Device|Vibration with tilt-table standing|
79555134|NCT01658449|Other|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
79555135|NCT01658462|Drug|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
79555136|NCT01658462|Drug|Nintedanib|"200 mg x 2 per os daily from D2*~*No Nintedanib on days when docetaxel is administered"
80018416|NCT05284630|Other|Exercise follow up with mobile application|Exercises will be followed by mobile application. Electrotherapy will be performed.
80018417|NCT05284630|Other|Home-Based Exercise Program followed by paper booklet|Exercise will be followed by paper booklet. Electrotherapy will be performed.
80018418|NCT05284630|Procedure|Electrotherapy|Electrotherapy will be performed.
80018419|NCT00131924|Biological|esterified estrogens|
79555137|NCT01658462|Drug|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
79555138|NCT01658488|Other|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
79555139|NCT01658488|Other|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
79555140|NCT01658527|Drug|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
79718632|NCT04660682|Other|Traditional static cross-body posterior shoulder stretching|For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
79555141|NCT01658527|Drug|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
79718633|NCT04660682|Other|Control Group|In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
79718634|NCT04660240|Device|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
79555142|NCT01658553|Drug|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
79718635|NCT04660240|Device|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
79718636|NCT04655976|Biological|Cobolimab|Cobolimab will be administered
79718637|NCT04655976|Biological|Dostarlimab|Dostarlimab will be administered
79718638|NCT04655976|Drug|Docetaxel|Docetaxel will be administered
79718639|NCT04641442|Biological|MAS825|Experimental drug
79718640|NCT04641442|Biological|Placebo|matching placebo
80018420|NCT02126124|Device|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
79718641|NCT04622150|Behavioral|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
79555143|NCT01658592|Other|Deep brain stimulation|Stimulator setting is ON
79555144|NCT01658592|Other|Placebo|Stimulator setting is OFF
79555145|NCT01658605|Drug|GSK1605786|500 mg twice daily administered orally
79854350|NCT04160013|Behavioral|Discipline education|Discipline education using the Play Nicely program.
79854351|NCT04160013|Behavioral|Cavity Prevention|Cavity prevention using a 2 page handout.
79854352|NCT04157335|Biological|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
79854353|NCT04157335|Biological|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
79854354|NCT04157127|Biological|Autologous DC vaccine|Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.
79854355|NCT04146493|Diagnostic Test|Blood samples for Heparin-binding protein measurement|Blood samples before and after given heparin
79854356|NCT04145531|Drug|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 & 2
79854357|NCT04145531|Drug|IV JZP-458|IV JZP-458 will be administered in Part B
80018421|NCT02126124|Device|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
79555146|NCT01658605|Other|Placebo|500 mg twice daily administered orally
79555147|NCT01658618|Biological|HP802-247|
79555148|NCT01658631|Device|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
79555149|NCT01658644|Other|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
79555150|NCT01658696|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu heterologous prime-boost immunisation
79555151|NCT01658696|Biological|Rabies vaccine|2 x 2.5IU Verorab
79555152|NCT01658722|Drug|Bapineuzumab|
79555153|NCT01658748|Device|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
80018422|NCT05284474|Diagnostic Test|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
79256853|NCT03069950|Drug|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
79555154|NCT01658748|Device|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
79555155|NCT01658761|Procedure|vitrectomy|Surgery
79555156|NCT01658774|Drug|Albendazole|Single 400mg dose
79555157|NCT01658774|Dietary Supplement|Vitamin C|500 mg Vitamin C
79555158|NCT01658800|Biological|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
79555159|NCT01658852|Drug|metronidazole|
79555160|NCT01658852|Drug|Placebo|
79555161|NCT01658891|Drug|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
79555162|NCT01658891|Drug|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
79555163|NCT01658956|Drug|GCSF administration on days 8 and 12 after chemotherapy|
79555164|NCT01658982|Other|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
79555165|NCT01659008|Drug|Estradiol|
79555166|NCT01659008|Drug|Lysteda|
79555167|NCT01659034|Drug|Thienopyridine for 3 months|
79555168|NCT01659047|Drug|GS-1101|150 mg taken twice daily by mouth
79555169|NCT01659060|Other|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
79718642|NCT04622150|Behavioral|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
79718643|NCT04617314|Drug|RC108|RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
79718644|NCT04609566|Drug|brentuximab vedotin|1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
79718645|NCT04609566|Drug|pembrolizumab|200 mg given intravenously every 3 weeks
79854358|NCT04143295|Drug|Diiodothyropropionic acid|Drug Administration
79854359|NCT04133116|Drug|LY3471851|Administered SC
79256854|NCT03433287|Diagnostic Test|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
79395983|NCT06101875|Other|Health Coach (Health coaching)|Patients will be assigned a health coach and be eligible to 8 times, 1 hour sessions over a 12 week period. The health coach will use techniques to increase their ability to self-manage, motivation levels and commitment to change their behaviour.
79395984|NCT06101875|Other|Digital Toolkit (Control)|This is an online website, unsupervised, 12-week self-management programme.
79395985|NCT06101849|Behavioral|I-Can-Manage-Pain after cancer (Pain Management Program)|6-week online interprofessional cancer pain management program (I-Can-Manage-Pain after cancer) for survivors of breast cancer. The program will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain
79395986|NCT06101836|Other|Training intervention|Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
79854360|NCT04133116|Drug|Placebo|Administered SC
79854361|NCT04124692|Device|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
79854362|NCT04123795|Drug|Certolizumab pegol|"Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~Cimzia~CDP870~CZP"
79256855|NCT03582839|Behavioral|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
79555170|NCT01659060|Other|Placebo Chocolate|Placebo intervention
79555171|NCT01659073|Procedure|Caloric Vestibular Stimulation|
79555172|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
79555173|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
79555174|NCT01659086|Biological|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
79555175|NCT01659099|Drug|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
79555176|NCT01659099|Drug|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
79256856|NCT04913870|Drug|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers treatment for 2 years.
79555177|NCT01659099|Drug|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
79555178|NCT01659099|Drug|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
79555179|NCT01659099|Drug|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
79555180|NCT01659099|Drug|Bleomycin|in ACBVP 10 mg from D1 to D5
79555181|NCT01659099|Drug|Vindesin|in ACBVP 2 mg/m² from D1 to D5
79555182|NCT01659099|Drug|Vincristine|in CHOP 1,4 mg/m² on D1
79555183|NCT01659112|Other|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
79555184|NCT01659112|Other|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
79555185|NCT01659164|Behavioral|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
79555186|NCT01659177|Drug|LY2140023|Administered orally
79555187|NCT01659190|Other|Oiled-limestone liniment|
79555188|NCT01659203|Radiation|IG-IMPT|Daily, Monday-Friday for about 6 weeks
80018423|NCT05223361|Drug|Six percent hydroxy ethyl starch 130/0.4|6% HES 130/0.4 additive to ringer lactate as prime solution
79256857|NCT04913870|Other|Placebo|Placebo administration for 2 years.
79256858|NCT03251001|Procedure|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
79256859|NCT03251001|Device|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
79555189|NCT01659203|Radiation|IG IMRT|Daily, Monday-Friday for about 6 weeks
79555190|NCT01659242|Drug|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
79555191|NCT01659242|Drug|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
79555192|NCT01659281|Drug|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
79555193|NCT01659281|Drug|Artesunate|4 mg/kg/day for 3 days
79555194|NCT01659281|Drug|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
79555195|NCT01659281|Drug|Mefloquine|8 mg/kg daily for 3 days
79555196|NCT01659294|Behavioral|Nurse Case Management|
79555197|NCT01659294|Behavioral|standard diabetologist care|routine care by diabetologist & team
79555198|NCT01659346|Procedure|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
79555199|NCT01659346|Drug|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
79555200|NCT01659359|Device|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
79555201|NCT01659359|Drug|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
79555202|NCT01659372|Radiation|low level laser therapy|
79555203|NCT01659372|Drug|Naproxen|
79555204|NCT01659398|Device|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
79555205|NCT01659411|Other|Observational|Yearly clinical visits
79718646|NCT04600336|Drug|Oxybutynin Chloride|Given PO
79718647|NCT04600336|Drug|Placebo Administration|Given PO
79718648|NCT04600336|Other|Quality-of-Life Assessment|Ancillary studies
79854363|NCT04123795|Drug|Placebo|"Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~-PBO"
80018424|NCT05223361|Drug|Ringer lactate|Ringer lactate as prime solution
80018425|NCT05223283|Other||
80018426|NCT05132218|Drug|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
80018427|NCT05405816|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy for obesity
79718649|NCT04600336|Other|Questionnaire Administration|Ancillary studies
79718650|NCT04596423|Diagnostic Test|Fetal echocardiography|fetal heart examination by medical ultrasound
79718651|NCT04594993|Device|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
79718652|NCT04587154|Other|low-fat vegan diet with 1/2 cup soybeans daily|Weekly instructions will be given to the participants in the intervention group about following vegan diet with 1/2 cup of soybeans daily.
79718653|NCT04582812|Other|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
79718654|NCT04582812|Other|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
79718655|NCT04576091|Procedure|Biospecimen Collection|Undergo blood sample collection
79718656|NCT04576091|Procedure|Computed Tomography|Undergo CT and/or PET-CT scan
79718657|NCT04576091|Drug|Elimusertib|Given PO
79718658|NCT04576091|Biological|Pembrolizumab|Given IV
79854364|NCT04119986|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds.
79256860|NCT03577691|Other|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
79718659|NCT04576091|Procedure|Positron Emission Tomography|Undergo PET-CT scan
79718660|NCT04576091|Other|Quality-of-Life Assessment|Ancillary studies
79256861|NCT03577691|Other|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
79854365|NCT04119986|Device|drug eluted stent|with regular techniques
79256862|NCT03577691|Other|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
79395989|NCT06101771|Diagnostic Test|echoCARDIOGRAPHY|Assessment of epicardial fat thickness in children with familial dyslipidemia
79256863|NCT03577691|Other|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
79256864|NCT04989608|Other|Neuroimaging|realization of a neuroimaging 1 and 3 years after the transient ischemic accident
79256865|NCT03251235|Behavioral|Cognitive Behaviour Therapy|
79395990|NCT06101758|Diagnostic Test|Handgrip strength test|A handgrip strength test using a hydraulic hand dynamometer will be performed
79718661|NCT04576091|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79718662|NCT04575025|Drug|Tabrecta tablets|There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
79718663|NCT04570150|Drug|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
79718664|NCT04570150|Drug|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
79718665|NCT04569032|Drug|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
79718666|NCT04569032|Drug|cyclophosphamide|750 mg/m^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
79718667|NCT04569032|Drug|doxorubicin|50 mg/m^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
79718668|NCT04569032|Drug|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
79718669|NCT04561648|Drug|Unfractionated Heparin|Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
79718670|NCT04558866|Drug|Testosterone Cypionate|One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
79718671|NCT04558866|Drug|Darolutamide|During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
79718672|NCT04553744|Other|Survey Administration|Complete survey
79718673|NCT04547673|Diagnostic Test|rigid nasal endoscopes|The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
79718674|NCT04536077|Drug|CDX-301|The drug will be supplied free of charge by Celldex
79718675|NCT04536077|Drug|CDX-1140|The drug will be supplied free of charge by Celldex
79718676|NCT04536077|Procedure|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
79718677|NCT04535999|Drug|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
79854366|NCT04106128|Diagnostic Test|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
79854367|NCT04104854|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds
79875489|NCT00950339|Drug|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
79555206|NCT01659424|Radiation|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
79555207|NCT01659437|Drug|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
79854368|NCT04103970|Behavioral|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
79854369|NCT04096664|Device|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
79854370|NCT04092894|Drug|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
79854371|NCT04092894|Drug|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
79854372|NCT04088292|Drug|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
79854373|NCT04088292|Device|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
79854374|NCT04083495|Biological|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10^8 CAR-T/m^2 with a maximum dose of 5 × 10^8 CAR-T cells
80018428|NCT05609695|Drug|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
79256866|NCT03577613|Procedure|Open radical hysterectomy|
79555208|NCT01659437|Drug|Streptomycin intramuscular injection|daily intramuscular drug injection
79555209|NCT01659450|Other|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
79256867|NCT03577613|Procedure|laparoscopic radical hysterectomy|
79256868|NCT03577613|Procedure|Robotically assisted radical hysterectomy|
79555210|NCT01659450|Other|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
79555211|NCT01659450|Other|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
79555212|NCT01659463|Other|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
79555213|NCT01659463|Behavioral|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
79256869|NCT03258099|Genetic|detection of genotype|detection of genotype by next generation sequencing
79256870|NCT03259971|Dietary Supplement|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
79555214|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
79555215|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
79555216|NCT01659502|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
79555217|NCT01659515|Drug|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
79555218|NCT01659580|Drug|T89 high dose|225mg bid
79555219|NCT01659580|Drug|T89 Low dose|150mg bid
79718678|NCT04521478|Drug|BI 1358894|BI 1358894
79718679|NCT04521478|Drug|Placebo|Placebo
79718680|NCT04521478|Drug|Quetiapine|quetiapine
79555220|NCT01659580|Drug|Sanqi+Bingpian|225 mg bid
79555221|NCT01659580|Drug|Placebo|225mg bid
79555222|NCT01659593|Other|procog|3 to 5 people group program
79555223|NCT01659593|Other|Placebo|
79718681|NCT04520672|Other|Blood samples|Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
79718682|NCT04520672|Other|Samples from tumor draining vessels|In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
79718683|NCT04519619|Drug|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
79854375|NCT04083495|Drug|Bendamustine|70 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
79854376|NCT04083495|Drug|Fludarabine|30 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
80018429|NCT05624515|Device|dry needling|Active trigger point puncture of the angularis scapulae muscle
80018430|NCT05624515|Other|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
80018431|NCT04246060|Drug|Cysteamine Bitartrate|ERT
80018432|NCT05599633|Dietary Supplement|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
80018433|NCT05599633|Dietary Supplement|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
80018434|NCT05132062|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
79256871|NCT03259971|Dietary Supplement|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
79555224|NCT01659619|Drug|Erythromycin|125mg in normal saline single use infusion for 5 min.
79555225|NCT01659645|Drug|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
79555226|NCT01659671|Procedure|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
79555227|NCT01659684|Biological|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
79555228|NCT01659697|Behavioral|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
79718684|NCT04510727|Device|Optical Coherence Tomography (OCT)|VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
79718685|NCT04510727|Procedure|Curettage & Desiccation (C&D) Procedure|Standard of care C&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
79718686|NCT04497779|Procedure|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
79718687|NCT04497779|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79718688|NCT04497779|Other|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
79718689|NCT04497779|Other|Questionnaire Administration|Ancillary studies
79718690|NCT04468984|Drug|Navitoclax|Tablet; Oral
79718691|NCT04468984|Drug|Ruxolitinib|Tablet; Oral
79718692|NCT04468984|Drug|Best Available Therapy (BAT)|Tablet/Capsule; Oral or Solution for Subcutaneous Injection
79718693|NCT04467489|Other|observational|There is no intervention for any group in this observational study.
79718694|NCT04466488|Behavioral|Choice Architecture|"Providers will receive general training on TPT benefits, indications, and contra-indications.~Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
79718695|NCT04464226|Drug|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
79718696|NCT04457596|Biological|Trastuzumab Emtansine|Given IV
79718697|NCT04457596|Drug|Placebo Administration|Given PO
79718698|NCT04457596|Drug|Tucatinib|Given PO
79718699|NCT04457596|Other|Questionnaire Administration|Ancillary studies
79718700|NCT04457596|Other|Quality-of-Life Assessment|Ancillary studies
79718701|NCT04455698|Behavioral|Remote Telegenetic Counseling by Phone|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
80018435|NCT04141852|Device|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
80031511|NCT05390762|Other|Care in Face to Face|A Second phase of 5 weeks of care in face to face day hospital of the reconditioning type of 15 sessions.
80031512|NCT03052348|Other|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
79256872|NCT03577535|Dietary Supplement|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
79395991|NCT06101758|Diagnostic Test|total body Dual Energy X-Ray Absorptiometry (DXA)|A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed
79395992|NCT06101758|Diagnostic Test|Muscle ultrasound|A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed
79395993|NCT06101745|Drug|Nizaracianine Triflutate|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.
79395994|NCT06101745|Drug|Placebo Comparator|In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
79395995|NCT06101719|Diagnostic Test|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
79395996|NCT06101706|Behavioral|Fatigue assessment|FACIT-F questionnaire and Visual Analog Scale for fatigue
79395997|NCT06101706|Behavioral|Quality of life assessment|PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire
79395998|NCT06101706|Other|Assess severity of psoriatic arthritis|DAPSA score
79395999|NCT06101706|Other|Assess severity of cutaneous psoriasis|PASI score
79396000|NCT06101654|Device|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
79555229|NCT01659723|Drug|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
79854377|NCT04083495|Drug|Cyclophosphamide|300 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
79854378|NCT04080063|Other|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
79854379|NCT04074642|Procedure|Neurosurgery|adenoma removal
80031513|NCT03052348|Other|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
79555230|NCT01659762|Biological|autologous mesenchymal stromal cell|
79555231|NCT01659788|Dietary Supplement|Coenzyme Q10 concomitant treatment|
79555232|NCT01659788|Dietary Supplement|Placebo|
79555233|NCT01659801|Device|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
79555234|NCT01659827|Other|Marcaine|Injection of 2cc of Marcaine
79555235|NCT01659827|Other|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
79555236|NCT01659827|Other|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
79555237|NCT01659827|Other|Saline|Injection of 1.25cc of Saline
79555238|NCT01659840|Radiation|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
79555239|NCT01659840|Radiation|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
79718702|NCT04455698|Behavioral|Remote Telegenetic Counseling by Videoconferencing|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
79718703|NCT04455698|Behavioral|Usual Care Arm|Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
79854380|NCT04066946|Device|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
79854381|NCT04066946|Other|Standard of care|"Standard of Care consists of:~During the first two weeks:~Histoacryl glue to close the surgical incisions.~Suture strips to keep the wound closed.~Isobetadine Dermicum as anti-septic treatment~Dry wound dressings during the first 2 weeks.~Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
79256873|NCT03258021|Device|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
79555240|NCT01659892|Drug|Montelukast|5 mg Chewable Tablet
79555241|NCT01659892|Drug|Singulair|5 mg Chewable Tablet
79555242|NCT01659905|Drug|Montelukast|Chewable Tablet
80031514|NCT04172480|Other|Blood sampling|Peripheral blood sampling on EDTA
79555243|NCT01659905|Drug|Singulair|5 mg Chewable Tablet
79555244|NCT01659918|Drug|Montelukast|
79718704|NCT04453722|Device|Oxalert Monitor Mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.
79256874|NCT04989530|Device|Extracorporeal Shock Wave Therapy|different energy levels of ESWT
79256875|NCT03577457|Drug|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
79256876|NCT03577457|Drug|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
79555245|NCT01659918|Drug|Singulair|
79555246|NCT01659931|Drug|Montelukast|10 mg Tablet
79555247|NCT01659931|Drug|Singulair|10 mg Tablet
79555248|NCT01659944|Drug|Eliglustat|Capsules for oral administration
79555249|NCT01659944|Drug|Metoprolol|Tablets for oral administration
79555250|NCT01659957|Behavioral|Group Couples Counseling|
79555251|NCT01659957|Behavioral|One-on-One Couples Counseling|
79555252|NCT01659983|Procedure|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
79555253|NCT01660009|Other|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
79256877|NCT03577457|Drug|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
79256878|NCT03577457|Drug|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
79256879|NCT02455245|Drug|Carboplatin|
79256880|NCT02455245|Drug|Vincristine|
79256881|NCT04989296|Diagnostic Test|Peripheral blood samples were obtained following the standard procedures.|Taking 4 ml of peripheral blood from patients on an empty stomach.
79555254|NCT01660048|Procedure|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
79256882|NCT03577223|Other|Whole Eggs|3 whole eggs per day for 4 weeks
79256883|NCT03577223|Other|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
79718705|NCT04453722|Device|Oxalert Normal mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
79718706|NCT04450966|Behavioral|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
79718707|NCT04428307|Other|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
79256884|NCT03537599|Biological|Daratumumab|Given IV
79256885|NCT03537599|Procedure|Donor Lymphocyte Infusion|Given via infusion
79555255|NCT01660048|Procedure|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
79555256|NCT01660074|Other|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
79555257|NCT01660087|Device|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
79555258|NCT01659775|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
79555259|NCT01659775|Drug|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
79718708|NCT04428307|Other|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
79718709|NCT04424225|Drug|Psilocybin|25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
79718710|NCT04424225|Drug|Niacin|100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
79718711|NCT04409301|Other|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
79718712|NCT04409301|Behavioral|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
79718713|NCT04405102|Drug|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
79718714|NCT04405102|Other|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
79718715|NCT04404283|Drug|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
79256886|NCT03537599|Other|Laboratory Biomarker Analysis|Correlative studies
79256887|NCT03251157|Other|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
79256888|NCT04986410|Diagnostic Test|CCTA, CT-MPI, CT-FFR, SPECT-MPI|Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI
79256889|NCT02239133|Device|ProVATE vaginal pessary|
79256890|NCT04986254|Other|Blood sampling|During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
79256891|NCT04986254|Other|Epithelial lining fluid sampling|Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
79256892|NCT04986254|Other|Urine sampling|The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
79256893|NCT04986254|Drug|Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam|Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
79718716|NCT04404283|Drug|Rituximab|375 mg/m^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
79718717|NCT04404283|Drug|Lenalidomide|20 mg given by mouth (orally) daily
79718718|NCT04404283|Other|Placebo|Administered via intravenous infusion every 3 weeks
79718719|NCT04389632|Drug|sigvotatug vedotin|Administered into the vein (IV; intravenously)
79718720|NCT04389632|Drug|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
79718721|NCT04389632|Drug|cisplatin|75 mg/m2 every 3 weeks, given by IV
79718722|NCT04389632|Drug|carboplatin|AUC 5 mg/mL per min every 3 weeks, given by IV
79718723|NCT04374877|Drug|CHS-388|CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
79555260|NCT01660100|Procedure|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
79854382|NCT04066777|Procedure|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
79256894|NCT03257943|Drug|Ivermectin Lotion, 0.5%|Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
79256895|NCT03257943|Drug|SKLICE (ivermectin) Lotion, 0.5%|SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
79555261|NCT01660100|Procedure|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
79555262|NCT01660126|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
79555263|NCT01660126|Drug|Placebo|
79854383|NCT04059393|Other|Internet-Based Intervention|Complete web-based legacy intervention
79854384|NCT04059393|Other|Best Practice|Receive standard of care
79854385|NCT04059393|Other|Quality-of-Life Assessment|Ancillary studies
79256896|NCT03257943|Drug|Vehicle of the Test product|Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
79256897|NCT02239211|Drug|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
79256898|NCT03577145|Dietary Supplement|Tomato, onion & lovage soup with inulin|Source of polyphenols and non digestible carbohydrate
79256899|NCT03577145|Dietary Supplement|Tomato, onion & lovage soup|Source of polyphenols
79256900|NCT03577145|Dietary Supplement|Inulin|Source of non digestible carbohydrate
79256901|NCT03246165|Procedure|Cardiac surgery|Coronary bypass, heart valve replacement
79256902|NCT03577067|Procedure|Liver resection for primary and secondary disease|Liver resection in parenchyma-sparing setting for primary and secondary disease
79718724|NCT04374877|Drug|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
79718725|NCT04374877|Drug|Toripalimab|Toripalimab by IV infusion
79718726|NCT04353492|Biological|Ofatumumab|Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
79718727|NCT04342390|Other|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
79718728|NCT04340141|Drug|Oxaliplatin|Given IV
79718729|NCT04340141|Drug|Irinotecan Hydrochloride|Given IV
79718730|NCT04340141|Drug|Leucovorin Calcium|Given IV
79718731|NCT04340141|Drug|Fluorouracil|Given IV
79718732|NCT04340141|Procedure|Resection|Undergo surgical resection
79718733|NCT04340141|Other|Questionnaire Administration|Ancillary studies
79718734|NCT04337619|Behavioral|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
79718735|NCT04337619|Behavioral|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
79854386|NCT04059393|Other|Questionnaire Administration|Ancillary studies
79854387|NCT04040530|Procedure|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
79854388|NCT04040530|Procedure|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
79854389|NCT04039750|Drug|antibiotic rinse with suction|antibiotic rinse with suction
79854390|NCT04039750|Procedure|suction only|no irrigation, suction only
79854391|NCT04038840|Drug|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
79718736|NCT04337619|Behavioral|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
79854392|NCT04038840|Device|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
79854393|NCT04029883|Behavioral|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
79854394|NCT04029883|Behavioral|Behavior Economic Incentive|In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
79555264|NCT01660152|Other|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
79854395|NCT04029883|Behavioral|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
79854396|NCT04028596|Drug|Paracetamol|once, 1000mg, 2 h before ECT session
79854397|NCT04028596|Drug|Nimotop|once, 60mg, 2 h before ECT session
79854398|NCT04018066|Dietary Supplement|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
79555265|NCT01660152|Procedure|management of therapy complications|Receive VED
79555266|NCT01660152|Procedure|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
79555267|NCT01660204|Other|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
79555268|NCT01660217|Other|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
79555269|NCT01660295|Drug|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
79854399|NCT04012645|Procedure|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
79854400|NCT04012645|Procedure|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
79555270|NCT01660295|Drug|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
79854401|NCT04009330|Diagnostic Test|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
79854402|NCT04008485|Device|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
79854403|NCT04006483|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
79555271|NCT01660295|Drug|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
79555272|NCT01660295|Drug|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
79555273|NCT01660347|Biological|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
79854404|NCT04006483|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
79854405|NCT04006483|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
79854406|NCT04003649|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
79854407|NCT04003649|Biological|Ipilimumab|Given IV
79854408|NCT04003649|Biological|Nivolumab|Given IV
79854409|NCT04003649|Other|Quality-of-Life Assessment|Ancillary studies
79854410|NCT04003649|Other|Questionnaire Administration|Ancillary studies
79555274|NCT01660347|Biological|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
79555275|NCT01660347|Procedure|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
79555276|NCT01660360|Biological|Tanibirumab|
79555277|NCT01660373|Drug|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
79555278|NCT01660373|Drug|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
79555279|NCT01660386|Drug|Sitagliptin|100mg po once
79555280|NCT01660386|Drug|Saxagliptin|5mg po once
79555281|NCT01660386|Drug|Glimepiride|2mg po once
79718737|NCT04337619|Behavioral|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
79718738|NCT04336878|Behavioral|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
79854411|NCT04002141|Drug|Placebo oral tablet|1 tablet oral daily
79854412|NCT04002141|Drug|Letrozole|5mg oral daily
79854413|NCT03999710|Radiation|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
79718739|NCT04285658|Procedure|Ureteroscopy|An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
79718740|NCT04285658|Procedure|Percutaneous Nephrolithotomy|A minimally invasive surgery in which a ~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
79854414|NCT03999710|Drug|Durvalumab|A dose of 1500mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
79854415|NCT03991416|Behavioral|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
79854416|NCT03991416|Behavioral|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
79555282|NCT01660386|Drug|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
79256903|NCT03257709|Procedure|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
79256904|NCT03257709|Procedure|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
79396001|NCT06101615|Other|IASTM (FAT)|Group-A participants would receive Facial Abrasion Technique (FAT) with an Instrument, FAT-Tool. Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm), to avoid possible confounding circadian effects. The FAT group will receive 2 min application on the quadriceps and hamstring muscles with a FAT-tool Pro Large model, which consists of a handle and 20cm treatment surface. The muscles will be treated in a pre-stretched position, meaning a knee flexion in a supine position for the quadriceps muscle and a hip flexion and knee extension in a side-lying position for the hamstring muscles.
79555283|NCT01660399|Drug|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
79555284|NCT01660399|Drug|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
79555285|NCT01660425|Behavioral|Enhancement with psychosocial intervention|
79555286|NCT01660464|Behavioral|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
79555287|NCT01660477|Drug|Isavuconazole|oral
79555288|NCT01660477|Drug|Lopinavir/ritonavir|oral
79555289|NCT01660490|Procedure|ORIF|Open reduction internal fixation of the proximal femur
79718741|NCT04285658|Procedure|Shock Wave Lithotripsy|A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
79718742|NCT04271280|Other|Non-interventional|This is a non-interventional study.
79718743|NCT04253275|Genetic|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
79718744|NCT04253275|Diagnostic Test|MRI without injection|MRI at inclusion for controls
79854417|NCT03975660|Device|Pain Measurement Device|When participants request labor analgesia, the sensors of the pain measurement device (ROPA System [CereVu Medical, Inc. San Francisco, CA] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
79718745|NCT04248140|Other|radio frequency electromagnetic field|Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
79854418|NCT03970096|Radiation|Total-Body Irradiation|Undergo TBI
79854419|NCT03970096|Drug|Thiotepa|Given IV
79854420|NCT03970096|Drug|Fludarabine|Given IV
79256905|NCT03250533|Device|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
79555290|NCT01660503|Dietary Supplement|0 grams SCF|Given in snack foods (muffins and flavored beverage)
79555291|NCT01660503|Dietary Supplement|10 grams SCF|Given in snack foods (muffins and flavored beverage)
79555292|NCT01660503|Dietary Supplement|20 grams SCF|Given in snack foods (muffins and flavored beverage)
79555293|NCT01660529|Biological|hTERT|
79555294|NCT01660542|Drug|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
80018436|NCT05656261|Genetic|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
79718746|NCT04242095|Procedure|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
79718747|NCT04242095|Other|Medical Chart Review|Review of medical records
79718748|NCT04226599|Device|Dissolve AVF|Subjects in the test group will be treated with peripheral scoring drug balloon.
79854421|NCT03970096|Drug|Tacrolimus|Given IV
79256906|NCT03250533|Device|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
79256907|NCT04986020|Diagnostic Test|MRI|Identification of novel biomarkers from MRI
79256908|NCT02239367|Behavioral|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
79256909|NCT04986098|Device|TurboHawk|Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
79854422|NCT03970096|Biological|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
79854423|NCT03970096|Drug|Methotrexate|Given IV
79854424|NCT03970096|Drug|Cyclophosphamide|Given IV
79854425|NCT03970096|Biological|Peripheral Blood Stem Cell|Given IV
79854426|NCT03970096|Drug|Cyclosporine|Given IV
79854427|NCT03970096|Drug|Sirolimus|Given IV
79854428|NCT03970096|Drug|Busulfan|Given IV
79854429|NCT03970096|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
79854430|NCT03970096|Procedure|Echocardiography|Undergo ECHO
79854431|NCT03970096|Procedure|Multigated Acquisition Scan|Undergo MUGA
79256910|NCT04986098|Drug|Paclitaxel|Paclitaxel
79256911|NCT03246321|Combination Product|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area [BSA]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
79718749|NCT04226599|Device|Armada 35|Subjects in the test group will be treated with plain balloon catheter.
79718750|NCT04224545|Drug|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
79718751|NCT04224545|Drug|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
79718752|NCT04199299|Device|Heart rate and respiration rate sensors|The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
79854432|NCT03970096|Procedure|Biospecimen Collection|Undergo blood sample collection
79854433|NCT03964454|Behavioral|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
79854434|NCT03964454|Behavioral|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
79854435|NCT03957161|Other|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
79854436|NCT03944954|Drug|Marinol|Individuals will receive 0, 10, 30mg of Marinol.
79854437|NCT03944954|Device|Transcranial Magnetic Stimulation|Individuals will receive excitatory or inhibitory TMS
79854438|NCT03940313|Procedure|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
79875490|NCT00950339|Drug|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
79875491|NCT00950339|Drug|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
79718753|NCT04198701|Device|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
79718754|NCT04195906|Drug|Experimental: SNF472|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
79718755|NCT04195906|Drug|Placebo Comparator: Placebo|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
79256912|NCT02239445|Drug|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
79718756|NCT04195906|Drug|Experimatenl SNF472 (Open-label)|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
79718757|NCT04194203|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
79718758|NCT04194203|Drug|Placebo|Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
79718759|NCT04194203|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
79718760|NCT04194203|Drug|Paclitaxel|Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
79718761|NCT04194203|Drug|Pemetrexed|Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
79718762|NCT04194203|Drug|Carboplatin|Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
79718763|NCT04192981|Drug|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
79718764|NCT04192981|Radiation|whole brain radiation therapy radiation|30Gy in 10 fractions
79718765|NCT04180462|Other|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
79718766|NCT04180462|Other|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
79718767|NCT04180462|Other|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
80018437|NCT05283460|Behavioral|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
80018438|NCT05129176|Drug|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
80018439|NCT05129176|Drug|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
79256913|NCT02239445|Drug|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
79256914|NCT02239445|Drug|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
80018440|NCT02127684|Drug|ranibizumab|ranibizumab 0.3mg intravitreally monthly
79256915|NCT04985786|Behavioral|Cognitive Behavioral Therapy for reducing risk behaviors|Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD & SZ it is alcohol use.
79256916|NCT04985786|Behavioral|Cognitive Behavioral Therapy for increasing non-risk behaviors|Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.
79256917|NCT02238665|Device|Endomicroscopy|
79555295|NCT01660581|Biological|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
79555296|NCT01660581|Biological|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
79555297|NCT01660594|Other|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
79555298|NCT01660620|Drug|Betaxolol|
79555299|NCT01660620|Drug|topical betaxolol|given topically
79718768|NCT04180462|Other|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
79718769|NCT04175847|Drug|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
79718770|NCT04174014|Procedure|Recruitment manoeuvre|PEEP increment and decrement
79718771|NCT04169321|Drug|Single Arm|[68Ga]-NOTA-hGZP is a PET imaging agent.
79718772|NCT04166461|Other|Not application, observational study|Not application, observational study
79718773|NCT04165590|Other|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites.
79718774|NCT04147234|Drug|BI 1387446|intratumoral injection
79718775|NCT04147234|Drug|BI 754091|intravenous infusion
80018441|NCT02127684|Drug|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
80018442|NCT05091658|Device|LH Urine Test|Test for qualitative detection of LH in urine
79396002|NCT06101615|Other|Foam Rolling|Group-B participants would receive Foam Rolling (FR). Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm) to avoid possible confounding circadian effects. The Foam Roller group will receive 2x1 min of FR on the quadriceps and the hamstrings on the dominant leg with the opposite leg crossed over the dominant one. During each minute the muscle will be rolled out 4-5 times, with a break of 30s in between sets. They will be instructed to utilize short, kneading like movements in one direction and a quick motion in the other direction. A grid foam roller will be utilized with a length of 33cm, diameter of 14 cm and with a hard hollow core, wrapped in ethylene vinyl acetate foam.
79718776|NCT04141293|Procedure|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
79718777|NCT04134325|Biological|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
79256918|NCT02454465|Other|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
79396003|NCT06101602|Other|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
79718778|NCT04134325|Biological|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
79718779|NCT04122976|Drug|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
79718780|NCT04119999|Device|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
79718781|NCT04119999|Device|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
79718782|NCT04119557|Drug|Placebo|Administered SC
79256919|NCT03071042|Drug|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
79256920|NCT03071042|Drug|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
79256921|NCT03582605|Drug|Amoxicillin|see previous descriptions
79256922|NCT03582605|Drug|Placebo oral capsule|see previous descriptions
79396004|NCT06101602|Other|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
79396005|NCT06101576|Procedure|TUIP|Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.
79256923|NCT03257553|Diagnostic Test|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
79396006|NCT06101576|Procedure|TURP|Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.
79396007|NCT06101576|Procedure|Prostate Vaporization|Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).
79718783|NCT04119557|Drug|LY3471851|Administered SC
79718784|NCT04118088|Biological|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
79718785|NCT04102358|Procedure|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
79256924|NCT04433546|Drug|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
79256925|NCT04433546|Drug|Low Dose (10 mg) Control|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
79256926|NCT03251781|Other|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
79256927|NCT03574883|Device|tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
79396008|NCT06101576|Procedure|AEEP|Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
79396009|NCT06101563|Procedure|Early ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 7 days after normalization of inflammatory indices.
79718786|NCT04102358|Procedure|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
79555300|NCT01660646|Behavioral|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
79555301|NCT01660659|Device|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
79718787|NCT04098874|Drug|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
79256928|NCT03574883|Device|tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
79256929|NCT03257787|Other|new adhesive strip|This is a strip made of a newly developed adhesive
79256930|NCT03246243|Device|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
79396010|NCT06101563|Procedure|Delayed Ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 2-4 weeks after normalization of inflammatory indices.
79396011|NCT06101550|Procedure|partial pulpotomy|Partial removal of pulp tissue in young permanent teeth
79396012|NCT06101550|Procedure|Complete pulpotomy|Complete removal of pulp tissue in young permanent teeth
79396013|NCT06101524|Procedure|Free gingival unit, free gingival greft|The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
79396014|NCT06101485|Device|Telerehabilitation|Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
79396015|NCT06101446|Other|Lavander Aromatherapy|Aromatherapy is one of the potential non-pharmacological methods. Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system
79396016|NCT06101433|Dietary Supplement|Soy isoflavone|the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
79396017|NCT06101433|Other|Placebo|the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
79396018|NCT06101420|Drug|Vonoprazan|Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
79396019|NCT06101381|Biological|CART-19|The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
79555302|NCT01660685|Behavioral|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
79555303|NCT01660685|Behavioral|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
79555304|NCT01660685|Behavioral|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
79555305|NCT01660685|Behavioral|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
79555306|NCT01660750|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
79555307|NCT01660750|Drug|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
79555308|NCT01660750|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
79555309|NCT01660789|Behavioral|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
79555310|NCT01660828|Other|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
79555311|NCT01660841|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
79555312|NCT01660854|Biological|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
79718788|NCT04098874|Drug|Placebo oral tablet|12 weeks postpartum of blinded placebo
79718789|NCT04097145|Device|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
79718790|NCT04097145|Drug|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
79718791|NCT04097145|Device|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
79875492|NCT00942227|Other|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
79875493|NCT00942227|Other|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
79875494|NCT01011608|Other|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
79875495|NCT01011608|Other|standard hospital food|standard hospital diet ad. lib.
79875496|NCT00950417|Drug|Nimotuzumab|
79854439|NCT03932656|Behavioral|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
79854440|NCT03932656|Drug|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
79555313|NCT01660854|Drug|Malarone treatment|Three days: 4 tablets 250/100mg per day
79555314|NCT01660867|Drug|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
79555315|NCT01660867|Drug|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
79555316|NCT01660919|Drug|placebo|
79555317|NCT01660919|Drug|rosuvastatin|
79555318|NCT01660932|Drug|placebo|
79555319|NCT01660932|Drug|omega|
79555320|NCT01660945|Drug|placebo|
79555321|NCT01660945|Drug|vytorin|
79555322|NCT01660958|Dietary Supplement|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
79555323|NCT01660958|Behavioral|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
79555324|NCT01660997|Drug|MLN9708|
79718792|NCT04062214|Behavioral|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
79875497|NCT03996902|Behavioral|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
79875498|NCT03996902|Behavioral|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
79555325|NCT01660997|Drug|Dexamethasone|
79875499|NCT00946673|Drug|Vorinostat|Orally up to 400 mg
79256931|NCT03471377|Other|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
79875500|NCT00946673|Procedure|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
79875501|NCT00394953|Drug|Darbepoetin alfa|As prescribed, iv.
79256932|NCT03471377|Other|assigned a planned case duration value from predictive model|"Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model."
79256933|NCT04989140|Drug|Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone|Treatment was continued until disease progression, unacceptable toxicity
79555326|NCT01661101|Drug|Dabigatran|Dabigatran 110 mg taken twice daily
79555327|NCT01661101|Drug|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
79555328|NCT01661101|Drug|Omeprazole|Omeprazole 20 mg capsule taken once daily
79555329|NCT01661101|Drug|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
79555330|NCT01661192|Drug|AAT( Alpha 1 Antitrypsin)|
79555331|NCT01661231|Device|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
79555332|NCT01661244|Drug|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
79555333|NCT01661244|Drug|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
79555334|NCT01661244|Drug|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
79555335|NCT01661244|Drug|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
79555336|NCT01661257|Drug|Infliximab|
79555337|NCT01661296|Other|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
79555338|NCT01661296|Drug|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
79555339|NCT01661309|Dietary Supplement|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
79555340|NCT01661309|Dietary Supplement|Methylcobalamin|Aimed at reducing plasma tHcy.
79718793|NCT04061798|Drug|ACT guided heparinization|"If the ACT is <180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is >200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is >200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If >250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
79718794|NCT04061798|Drug|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
79718795|NCT04032301|Drug|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
79718796|NCT04032301|Other|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
79875502|NCT00394953|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
79875503|NCT00946751|Drug|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
79555341|NCT01661322|Drug|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
79718797|NCT04024774|Biological|Biological samples|blood samples, urine samples, tissue samples
79718798|NCT04024774|Genetic|Genetic test|anamnesis and NGS sequencing
79718799|NCT03994796|Drug|Abemaciclib|Given PO
79718800|NCT03994796|Drug|PI3K Inhibitor paxalisib|Given PO
79718801|NCT03994796|Drug|Entrectinib|Given PO
79718802|NCT03994796|Drug|Adagrasib|Given PO
79718803|NCT03991962|Drug|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
79718804|NCT03991962|Radiation|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
79718805|NCT03975647|Drug|tucatinib|300mg given twice per day by mouth (orally)
79256934|NCT02134171|Other|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
79256935|NCT03246009|Drug|rHSA/GCSF|single injection-1.8mg
79718806|NCT03975647|Drug|placebo|Given twice per day orally
79718807|NCT03975647|Drug|T-DM1|3.6 mg/kg given into the vein (IV; intravenously) every 21 days
79875504|NCT00946751|Drug|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
79875505|NCT00485732|Biological|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
79718808|NCT03973983|Procedure|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
79718809|NCT03973983|Procedure|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
79718810|NCT03971500|Drug|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
79718811|NCT03971500|Procedure|Percutaneous coronary intervention|PCI with DES implantation
79718812|NCT03948490|Device|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
79718813|NCT03948490|Device|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
79256936|NCT03246009|Drug|rHSA/GCSF|single injection-2.1mg
79256937|NCT03246009|Drug|rHSA/GCSF|single injection-2.4mg
79256938|NCT03246009|Drug|rHSA/GCSF|multiple injection-1.8mg
79256939|NCT03246009|Drug|rHSA/GCSF|multiple injection-2.1mg
79256940|NCT03246009|Drug|rHSA/GCSF|multiple injection-2.4mg
79256941|NCT04995770|Behavioral|Praise Text Messages|Texting messages with praise content, to positive reinforce medication adherence
79256942|NCT04995302|Procedure|Microoneedling and Amnion Bilayer|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.
79256943|NCT04995302|Procedure|Microoneedling|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.
79256944|NCT02136199|Other|Active Implementation of ShareEBM Toolkit|
79256945|NCT02136199|Other|Passive Dissemination of Share EBM|
79256946|NCT03246399|Drug|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
79256947|NCT03574805|Drug|PRS-060|Study drug
79256948|NCT03574805|Drug|Placebo|Inhalant designed to mimic PRS-060
79256949|NCT02134249|Drug|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
79256950|NCT02134249|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
79256951|NCT03245853|Drug|Riboflavin 5'-Phosphate|Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg [0.12%] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
79256952|NCT04989062|Diagnostic Test|Fibroscan|Controlled attenuation parameter and liver stiffness measurement are measured.
79555342|NCT01661335|Drug|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
79256953|NCT04989062|Diagnostic Test|Bioelectrical impedance analysis|Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
79555343|NCT01661335|Drug|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
79718814|NCT03948490|Behavioral|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
79256954|NCT04989062|Diagnostic Test|Urine unclear magnetic resonance metabolomics|Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.
79718815|NCT03948490|Behavioral|Telehealth cognitive rehabilitation|The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
79718816|NCT03947307|Device|lymphtaping using Easytape®|lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
79718817|NCT03947307|Procedure|compression treatment|manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
79718818|NCT03947307|Device|sham taping|sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
79256955|NCT04989062|Diagnostic Test|Hand grip strength|Hand grip strength in both hands is measured by hand-held dynamometer.
79256956|NCT03574649|Drug|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79256957|NCT03574649|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79256958|NCT03574649|Drug|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79256959|NCT03574649|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79256960|NCT03574649|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
79718819|NCT03936270|Drug|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
79718820|NCT03936270|Drug|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
79718821|NCT03932682|Biological|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
79718822|NCT03932682|Biological|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (MenC vaccine, Neisvac-C)
79875506|NCT00485732|Biological|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
79875507|NCT00946829|Drug|telmisartan|
79875508|NCT00489554|Biological|Synflorix|Intramuscular injection, 3 doses.
79256961|NCT03574649|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79256962|NCT03574649|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
79256963|NCT03574649|Biological|GI-4000|RAS yeast vaccine
79256964|NCT03574649|Biological|GI-6301|Brachyury yeast vaccine
79256965|NCT03574649|Drug|Aldoxorubicin|INNO-206
79555344|NCT01661361|Procedure|blood levels|
79555345|NCT01661439|Drug|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
79555346|NCT01661452|Other|Referral to counseling services if desired|
79555347|NCT01661478|Other|Training on motivational interviewing|
79256966|NCT03574649|Drug|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79396020|NCT06101368|Behavioral|Phsical Activity|Combined Aerobic and Resistance Training
79396021|NCT06101368|Drug|Medication|The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
80018443|NCT05706571|Other|control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)|In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
79718823|NCT03932240|Drug|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
79718824|NCT03932240|Drug|Cryoprecipitate|The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
79718825|NCT03926338|Drug|Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
79718826|NCT03926338|Drug|Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
79875509|NCT00489554|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
79875510|NCT00489554|Biological|Rotarix|Oral, 2 doses.
80018444|NCT02126202|Procedure|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
80018445|NCT04066816|Other|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
80018446|NCT02126280|Other|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
80018447|NCT02127762|Behavioral|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
80018448|NCT02126358|Drug|Gemigliptin and/or Rosuvastatin|
79555348|NCT01661504|Behavioral|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
79718827|NCT03926338|Drug|Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.
79718828|NCT03926338|Drug|Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
79718829|NCT03924167|Behavioral|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
79718830|NCT03909282|Procedure|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
79875511|NCT00408681|Drug|lithium carbonate|Given orally
79875512|NCT00408681|Other|laboratory biomarker analysis|Correlative studies
80018449|NCT05088382|Device|LH Urine Test|Test for the qualitative measurement of LH in urine
80018450|NCT02127840|Drug|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
80018451|NCT05066074|Procedure|Distal Radial Vascular Access|Distal Radial Vascular Access
79555349|NCT01661517|Behavioral|Motivational interviewing and referral to treatment|
79256967|NCT03574649|Drug|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]
79256968|NCT03574649|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
79555350|NCT01661530|Dietary Supplement|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
79555351|NCT01661530|Dietary Supplement|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
79875513|NCT01040013|Procedure|Laparoscopy|Laparoscopic Left-Colectomy
79875514|NCT01040013|Procedure|left colectomy by laparotomy|PatientS will be operated by laparotomy
79875515|NCT00560417|Drug|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
79875516|NCT00560417|Drug|Insulin Glargine|Administered subcutaneously once a day at bedtime
79875517|NCT01044927|Other|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
79875518|NCT01044927|Other|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
79875519|NCT01040091|Drug|Emtricitabine (FTC)|200 mg once a day
79875520|NCT01040091|Drug|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
79875521|NCT01040091|Drug|Efavirenz (EFV)|600 mg once a day
79256969|NCT03574649|Drug|Docetaxel|Docetaxel
79718831|NCT03909282|Radiation|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
79718832|NCT03900429|Drug|MGL-3196|Tablet
79718833|NCT03900429|Drug|Placebo|Matching Tablets
79718834|NCT03900429|Procedure|Liver Biopsy|A procedure in which a needle is inserted into the liver to collect a tissue sample
79718835|NCT03887780|Drug|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
79718836|NCT03886948|Drug|LY3074828|Administered subcutaneously (SC)
79718837|NCT03886948|Device|Pre-filled syringe (PFS)|PFS used to administer LY3074828
79718838|NCT03886948|Device|Autoinjector (AI)|AI used to administer LY3074828
79718839|NCT03885089|Drug|Infliximab [infliximab biosimilar 3]|<Psoriasis> The usual dose is 5 mg as Infliximab (Genetical Recombination) [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
79718840|NCT03884075|Drug|Semaglutide|Semaglutide injection once weekly
79718841|NCT03875339|Behavioral|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
79718842|NCT03863613|Device|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix.
79718843|NCT03863613|Procedure|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
79854441|NCT03930199|Other|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
79854442|NCT03924219|Other|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
79875522|NCT01040091|Drug|Truvada|200 mg emtricitabine + 300 mg TDF once a day
79256970|NCT03574649|Drug|carboplatin|carboplatin
79256971|NCT02128945|Other|[18F] - Fludarabine PET/CT|[18F] - Fludarabine PET/CT before treatment
79256972|NCT03250611|Procedure|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
79555352|NCT01661543|Dietary Supplement|Beans|90g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
79555353|NCT01661543|Dietary Supplement|Control (rice)|90g of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group.
79555354|NCT01661543|Dietary Supplement|Peas|90 grams of peas will be consumed 5 out of 7 days per week
79555355|NCT01661556|Drug|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
79718844|NCT03863613|Drug|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
79718845|NCT03861234|Drug|BI 836880|Solution for Intravitreal (IVT) injection
79256973|NCT02136277|Drug|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
79256974|NCT03245775|Behavioral|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
79256975|NCT03245775|Behavioral|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
79256976|NCT04985474|Other|questionnaires|
79256977|NCT03578939|Procedure|Biopsy EUS guided|NGS Sequencing on Biopsy samples
79718846|NCT03860480|Procedure|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
79718847|NCT03860480|Procedure|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
79718848|NCT03812653|Device|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
79718849|NCT03801369|Procedure|Biopsy|Undergo biopsy
79718850|NCT03801369|Drug|Capivasertib|Given PO (orally)
79718851|NCT03801369|Drug|Ceralasertib|Given PO (orally)
79718852|NCT03801369|Biological|Durvalumab|Given IV (infusion)
79718853|NCT03801369|Drug|Olaparib|Given PO (orally)
79718854|NCT03801369|Other|Quality-of-Life Assessment|Ancillary studies
79718855|NCT03801369|Drug|Selumetinib|Given PO (orally)
79718856|NCT03793426|Biological|Fibryga|Human plasma-derived fibrinogen concentrate
80018452|NCT02126436|Other|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
79854443|NCT03899805|Drug|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
79854444|NCT03899805|Drug|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
79718864|NCT03777306|Other|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~1 video/picture/worksheet per week covering the topic to be covered.~1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
80018453|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
79256978|NCT02129023|Device|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
79256979|NCT03250455|Diagnostic Test|CTA CTP|CT Angiography myocardial CT Perfusion
79256980|NCT03250455|Diagnostic Test|CTA|CT Angiography
79256981|NCT03073928|Procedure|Interscalene Block|Regional Anesthesia procedure in the neck
79256982|NCT03073928|Procedure|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
79854445|NCT03897491|Drug|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
79396022|NCT06101355|Other|Telerehabilitation|"Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp."
79256983|NCT03073928|Drug|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
79256984|NCT03578861|Other|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
79256985|NCT03257397|Device|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
79396023|NCT06101355|Other|Standard Home Based Exercise Group|Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
79396024|NCT06101316|Drug|CB06-036|CB06-036 Capsule
79396025|NCT06101199|Other|Acute Intermittent Hypercapnic Hypoxia|15 x [1 min 9% O2, 4% CO2, and balance N2, followed by 1.5 min normoxia];
79396026|NCT06101199|Other|Transcutaneous spinal cord stimulation|Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of ~25-35 mA and a pulse width of 400 µsec, using a biphasic symmetric waveform. Paired with Respiratory Resistance Training and Hand Grip Strength Training.
79396027|NCT06101199|Other|SHAM Acute Intermittent Hypercapnic Hypoxia|Normoxia for the amount of time AIHH is delivered.
79396028|NCT06101199|Other|SHAM Transcutaneous spinal cord stimulation|"Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of 0mA and a pulse width of 400 µsec,using a biphasic symmetric waveform.~Paired with Respiratory Resistance Training and Hand Grip Strength Training."
79555356|NCT01661556|Drug|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
79555357|NCT01661569|Other|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
79555358|NCT01661582|Other|CT/PET Myocardial Perfusion Imaging using O-15 water|
79555359|NCT01661582|Other|Coronary blood flow measured by doppler echocardiography|
79555360|NCT01661608|Device|Using the EOS for gastric restriction|
79555361|NCT01661673|Drug|EVP-0962|Arms: 1,2,3,4
79555362|NCT01661673|Drug|Placebo|Arm 5
79396029|NCT06101186|Other|NPECP based on NSM|A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
79555363|NCT01661725|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
79555364|NCT01661738|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2~6 years of age), early youth (7~15 years of age) and adult (16~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
79718865|NCT03777306|Other|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
79718866|NCT03745235|Other|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
79256986|NCT03257397|Device|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
79396030|NCT06101121|Device|Lubri-Cream|Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional
79396031|NCT06100419|Procedure|serratus posterior superior intercostal plane block|With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
79396032|NCT06100341|Other|Virtual reality|A role-playing game set in a spaceship in outer space where a user will need to accomplish three activities to complete the game. These activities were designed based on typical therapy goals for children with cerebral palsy of improving balance, gross motor performance, walking speed, and functional mobility.
79396033|NCT06099821|Drug|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
79396034|NCT06099821|Drug|Regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
79396035|NCT06099821|Drug|Apatinib|Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
79396036|NCT06099613|Biological|EG-COVII|EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
79396037|NCT06098586|Behavioral|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
79396038|NCT06098586|Procedure|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
79396039|NCT06098274|Behavioral|Motivational interviewing program based on transtheoretical model|It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
79396040|NCT06097455|Genetic|ARI0003|Treatment with ARI0003 cells
79396041|NCT06097351|Other|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
79396042|NCT06096766|Diagnostic Test|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
79555365|NCT01661751|Biological|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
79718867|NCT03745235|Biological|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
79718868|NCT03745235|Other|psychometric questionnaires|"Cohen PSS' perceived stress scale~Beck's anxiety and depression questionnaires~Watson's affectivity questionnaire, positive affect and negative affect schedule~optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~IN-OUT DASQ dispositional affective style questionnaire"
79718869|NCT03743649|Drug|Haloperidol|Given IV
79718870|NCT03743649|Drug|Lorazepam|Given IV
79256987|NCT02134405|Drug|Rebamipide|Rebamipide 100mg tid
79256988|NCT02134405|Drug|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
79256989|NCT02134405|Drug|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
79256990|NCT03574415|Drug|DWP14012|DWP14012 tablets
79256991|NCT03574415|Drug|Placebo|DWP14012 placebo-matching tablets
79256992|NCT03074006|Drug|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
79256993|NCT02456025|Drug|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
79396043|NCT06096571|Drug|Aterixen|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
79396044|NCT06095258|Drug|Traditional Chinese medicine treatment|About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
79396045|NCT06095258|Drug|Western medicine treatment|Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
79555366|NCT01661751|Biological|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
79555367|NCT01661777|Drug|Nasal steroid|
79555368|NCT01661777|Procedure|Myringotomy tube placement|
79718871|NCT03743649|Other|Placebo|Given IV
79718872|NCT03743649|Other|Quality-of-Life Assessment|Ancillary studies
79718873|NCT03743649|Other|Questionnaire Administration|Ancillary studies
79718874|NCT03728179|Combination Product|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
79718875|NCT03724747|Drug|BAY2315497 Injection|BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
79718876|NCT03724747|Drug|Darolutamide(BAY1841788)|600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
79718877|NCT03698955|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
79718878|NCT03698955|Other|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
79718879|NCT03668223|Behavioral|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
79854446|NCT03897127|Drug|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~Patients age 18-60 years~o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~Patients age >60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
79854447|NCT03897127|Drug|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
80018454|NCT02131116|Behavioral|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
79256994|NCT02136433|Device|Tablet - self exercise|
79256995|NCT02136433|Other|GRASP self exercise|
79256996|NCT04985552|Procedure|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice: 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
79256997|NCT04985552|Device|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system [V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)] applied by the operating surgeon in a sterile fashion. The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
79555369|NCT01661777|Drug|Diuretic|
79555370|NCT01661777|Drug|Antihistamine|
79555371|NCT01661777|Behavioral|Low salt diet|
79555372|NCT01661816|Behavioral|interview|psychological, emotional, family and social parameters
79555373|NCT01661842|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
79555374|NCT01661842|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
79555375|NCT01661855|Drug|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
79555376|NCT01661855|Drug|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
79555377|NCT01661868|Drug|Olaparib|Tablet formulation will be used.
79718880|NCT03661970|Other|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
79718881|NCT03650933|Biological|G-CHOP|6 cycles(each cycle is 3 weeks)
79256998|NCT04985552|Other|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
79718882|NCT03650933|Biological|R-CHOP|6 cycles(each cycle is 3 weeks)
79718883|NCT03642665|Drug|Natural cycle|no medication
79256999|NCT02035631|Behavioral|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
79257000|NCT02035631|Behavioral|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
79555378|NCT01661894|Device|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
79555379|NCT01661907|Procedure|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
79555380|NCT01661907|Procedure|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
79555381|NCT01661920|Other|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
79718884|NCT03642665|Drug|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
79718885|NCT03642665|Drug|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
79257001|NCT02035631|Behavioral|Minimal diet intervention|Some basic diet recommendations
79257002|NCT02035631|Behavioral|Minimal physical activity intervention|Some basic recommendations on physical activity
79257003|NCT03246087|Device|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
79555382|NCT01661920|Other|Control group|Those antibiotic duration treatments which are not modified by their doctors.
79555383|NCT01662011|Device|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
79555384|NCT01662011|Device|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
79555385|NCT01662037|Drug|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
79718886|NCT03612271|Behavioral|mGlide|BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
79718887|NCT03609216|Drug|Gemcitabine Hydrochloride|Given IV
79718888|NCT03609216|Drug|Cisplatin|Given IV
79718889|NCT03609216|Biological|Pegfilgrastim|Given SC
79257004|NCT03246087|Other|Standard of care|standard of care home exercise program
79718890|NCT03609216|Procedure|Conventional Surgery|Undergo bladder sparing
79718891|NCT03609216|Procedure|Radical Cystectomy|Undergo radical cystectomy
79718892|NCT03609216|Other|Chemoradiotherapy|Undergo chemoradiotherapy
79854448|NCT03897127|Drug|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3"
79875523|NCT00950495|Device|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
80018455|NCT02131116|Behavioral|Treatment as Usual|Treatment as Usual
79257005|NCT02134483|Biological|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
79257006|NCT04985240|Dietary Supplement|Lettuce with no biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
80018456|NCT05031442|Device|RH1 (low waist)|Investigational product variant 1 low waist
79257007|NCT04985240|Dietary Supplement|Intervention Molibdenum group|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
79555386|NCT01662076|Other|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
79555387|NCT01660724|Procedure|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
79555388|NCT01660724|Procedure|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
79555389|NCT01662089|Drug|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
79555390|NCT01662089|Drug|Placebo drug supplement|Placebo drug instead of Zinc supplement
79257008|NCT02136511|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
79555391|NCT01662128|Drug|Xeloda|Xeloda as Adjuvant Therapy
79555392|NCT01662154|Device|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
79555393|NCT01662154|Device|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
79555394|NCT01662167|Drug|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
79555395|NCT01662167|Drug|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
79718893|NCT03561103|Behavioral|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
79718894|NCT03530969|Behavioral|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
79718895|NCT03530969|Behavioral|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
79718896|NCT03530969|Behavioral|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
79854449|NCT03896425|Device|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
79854450|NCT03895203|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
79854451|NCT03895203|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
79854452|NCT03895203|Other|Placebo|Subjects will receive placebo at pre-specified time-points.
79257009|NCT02136511|Drug|Rituximab|Rituximab administered intravenously starting at 375 mg/m^2 at Week 0 and continuing with a dose of 500 mg/m^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
79555396|NCT01662180|Drug|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
80018457|NCT05031442|Device|Reference variant 1 (low waist)|Reference product variant 1
80018458|NCT05031442|Device|RC2 (high waist)|Investigational product variant 2 high waist
80018459|NCT05031442|Device|Reference variant 2 (high waist)|Reference product variant 2
80018460|NCT03527888|Drug|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
79257010|NCT02454387|Drug|ONO-4474 Part A1|Healthy volunteers
79257011|NCT02454387|Drug|Placebo Part A1|Healthy volunteers
79257012|NCT02454387|Drug|ONO-4474 Part A2|Healthy volunteers
79257013|NCT02454387|Drug|Placebo Part A2|Healthy volunteers
79257014|NCT02454387|Drug|ONO-4474 Part B|Healthy volunteers
79257015|NCT02454387|Drug|Placebo Part B|Healthy volunteers
79257016|NCT02454387|Drug|ONO-4474 Part C|Healthy volunteers
80018461|NCT02131194|Dietary Supplement|Lenstatin|Dietary Supplement Lenstatin
80018462|NCT02131194|Drug|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
79257017|NCT02454387|Drug|Placebo Part C|Healthy volunteers
79257018|NCT02454387|Drug|ONO-4474 Part D|Healthy volunteers
79396046|NCT06090591|Other|SGLT-2 inh therapy, CIED implantation, thromboaspiration,|long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
79555397|NCT01662193|Dietary Supplement|vitamin D3 supplement|
79555398|NCT01662193|Dietary Supplement|calcium supplement|
79555399|NCT01662193|Dietary Supplement|vitamin D3 and calcium supplement|
79555400|NCT01662193|Dietary Supplement|placebo|
79555401|NCT01662206|Dietary Supplement|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
79555402|NCT01662206|Dietary Supplement|Placebo|2 capsules daily containing 348.25 mg of potato starch
79555403|NCT01662219|Other|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
79555404|NCT01662232|Dietary Supplement|Green tea beverage|
79555405|NCT01662232|Dietary Supplement|Green tea extract|
79555406|NCT01662232|Dietary Supplement|EGCG|
79555407|NCT01662232|Other|Placebo|
79555408|NCT01662258|Device|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
79555409|NCT01662284|Drug|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
79555410|NCT01662323|Behavioral|GP's treating HF according the dutch guidelines|
79555411|NCT01662349|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
79555412|NCT01662375|Other|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
79854453|NCT03892915|Combination Product|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
79854454|NCT03892200|Behavioral|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.
80018463|NCT04820920|Behavioral|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
80018464|NCT04820920|Behavioral|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
80018465|NCT04820920|Behavioral|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
79555413|NCT01662388|Device|Separation ring|Separation ring placed along with automatrix band
80018466|NCT02127918|Drug|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
79257019|NCT02454387|Drug|Placebo Part D|Healthy volunteers
79257020|NCT04433702|Device|Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle|"The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
79396047|NCT06089278|Drug|300mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
79396048|NCT06089278|Drug|600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
79396049|NCT06089278|Drug|TQH2722 injection matching placebo|Placebo without active substance.
79396050|NCT06089083|Other|Physical function assessment|Physical assessments of frailty will be conducted in person.
79555414|NCT01662388|Device|automatrix band|band placed with a tightening device
79555415|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
79555416|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
79555417|NCT01662414|Dietary Supplement|Whey protein|1 sachect (10 g) 2times/ day
79555418|NCT01662414|Dietary Supplement|Soy protein|1 sachect (10g) 2times/day
79555419|NCT01662427|Other|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
79555420|NCT01662466|Drug|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
79555421|NCT01662466|Dietary Supplement|DHEA|DHEA 25mg tid
79555422|NCT01662466|Drug|Placebo|Carrier cream without added testosterone in the identical type of pump
79555423|NCT01662518|Device|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
79555424|NCT01662544|Procedure|Oxygen delivery|
79555425|NCT01662557|Behavioral|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
79718897|NCT03530969|Behavioral|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
79718898|NCT03530969|Behavioral|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
79718899|NCT03530969|Behavioral|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
79718900|NCT03509909|Behavioral|Hatha yoga|Manualized hatha yoga
79718901|NCT03509909|Behavioral|Supportive physical activity|Manualized stretching and strengthening
79718902|NCT03503097|Procedure|Biospecimen Collection|Provide saliva samples
79555426|NCT01662557|Other|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
79718903|NCT03503097|Other|Genetic Counseling|Undergo counseling
79257021|NCT04433702|Device|Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle|"The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
79257022|NCT03578705|Device|"Electrical Impedance Myography unit or EIM"|
79257023|NCT02134561|Behavioral|psychological interview|
79257024|NCT02134561|Radiation|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
79257025|NCT02134561|Other|cognitive tests|
79257026|NCT02134561|Other|neurological tests|
79257027|NCT04985006|Behavioral|running at moderate intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 50-59% Heart rate reserve (HRR) for 30 minutes from the time the target intensity is reached.
79257028|NCT04985006|Behavioral|running at high intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 70-75% HRR for 30 minutes from the time the target intensity is reached.
79555427|NCT01662570|Behavioral|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
79555428|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
79718904|NCT03503097|Other|Genetic Testing|Undergo genetic testing
79257029|NCT03576833|Device|Elipse Balloon system|intragastic balloon
79718905|NCT03503097|Other|Laboratory Biomarker Analysis|Correlative studies
79718906|NCT03503097|Behavioral|Questionnaire|Complete questionnaire
79718907|NCT03500380|Drug|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
79718908|NCT03500380|Drug|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
79718909|NCT03500380|Drug|Capecitabine|Capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle.
79718910|NCT03485677|Drug|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
79718911|NCT03485677|Drug|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
79718912|NCT03474822|Biological|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
79718913|NCT03463824|Behavioral|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
79257030|NCT02136589|Drug|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
79718914|NCT03463824|Behavioral|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
79718915|NCT03406091|Drug|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) [3]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
79718916|NCT03401788|Drug|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
79718917|NCT03396341|Other|Salvia sample|salvia sample
79854455|NCT03888404|Other|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
80018467|NCT00127634|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
79257031|NCT03245931|Other|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
79718918|NCT03396341|Behavioral|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
79718919|NCT03390322|Device|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
79555429|NCT01662622|Drug|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
79555430|NCT01662661|Drug|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
79718920|NCT03379857|Other|Drug urinal test|Non Applicable
79718921|NCT03376646|Device|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
79718922|NCT03376646|Device|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
79718923|NCT03376646|Device|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
79718924|NCT03375983|Biological|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
79555431|NCT01662661|Drug|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
79555432|NCT01662674|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
79555433|NCT01662674|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
79257032|NCT04995614|Drug|Radium-223|Prospective observational cohort study investigating patient-reported outcomes
79555434|NCT01662687|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
79555435|NCT01662687|Drug|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~Kytril tab. 1mg: administered twice a day by orally at Day 2~4."
79555436|NCT01662700|Drug|Artesunate|
79555437|NCT01662700|Drug|Chloroquine|
79555438|NCT01662726|Drug|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
79555439|NCT01662739|Behavioral|Questionnaire|
79718925|NCT03373695|Device|Dissolve™|Dissolve™ are to be used in the trial
79718926|NCT03373695|Device|SeQuent®Please|SeQuent®Please are to be used in the trial
79718927|NCT03367741|Drug|Cabozantinib S-malate|Given PO
79718928|NCT03367741|Biological|Nivolumab|Given IV
79718929|NCT03366155|Device|Codman 3000 constant flow pump catheter|implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
80018468|NCT00127634|Drug|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
79257033|NCT02134639|Procedure|68Ga-DOTATOC PET-CT Imaging|
79257034|NCT03257475|Radiation|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
79257035|NCT04985162|Other|Intervention group|Differential learning based physiotherapy to improve torso control, balance and gait
79718930|NCT03366155|Drug|Panitumumab|6 mg/kg, IV
79718931|NCT03366155|Drug|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
79718932|NCT03366155|Drug|Oxaliplatin|85 mg/m2, IV
79718933|NCT03366155|Drug|5FU|2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
79718934|NCT03366155|Drug|Irinotecan|150 mg/m2, IV
79718935|NCT03366155|Procedure|HAIP installation|HAI pump installation
79718936|NCT03366155|Drug|cetuximab|500 mg/m2, IV
79718937|NCT03366155|Device|Medtronic SynchroMed II Pump|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
79718938|NCT03355482|Drug|Methylprednisolone|160mg IM at baseline
79718939|NCT03355482|Drug|Placebos|IM saline injection at baseline
79718940|NCT03345784|Drug|Adavosertib|Given PO
79718941|NCT03345784|Drug|Cisplatin|Given IV
79257036|NCT04985162|Other|Control group|Ordinary physiotherapy program
79257037|NCT02129101|Drug|Azacitidine|Given SC or IV
79718942|NCT03345784|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
79257038|NCT02129101|Drug|Decitabine|Given IV
79718943|NCT03345576|Device|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
79718944|NCT03345576|Drug|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
79718945|NCT03327805|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
79718946|NCT03327805|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
79718947|NCT03326947|Drug|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy"
79718948|NCT03313180|Drug|Nintedanib|Administered twice daily
79718949|NCT03307824|Device|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
79718950|NCT03307824|Procedure|Glue-Free Suture Technique|Suture Technique
79854456|NCT03888404|Other|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
79854457|NCT03888404|Other|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
79854458|NCT03888404|Other|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
79854459|NCT03878628|Drug|Adipose tissue-derived mesenchymal stem cells|CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
79854460|NCT03871309|Device|Tigertriever|Mechanical Thrombectomy
79555440|NCT01662804|Drug|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
79555441|NCT01662817|Behavioral|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
79854461|NCT03868514|Device|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
79854462|NCT03860142|Behavioral|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
79854463|NCT03855007|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79854464|NCT03855007|Drug|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
80018469|NCT00127634|Drug|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
80018470|NCT03550638|Device|Coil system(Ton-bridgeMT)|1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
79257039|NCT02129101|Other|Laboratory Biomarker Analysis|Correlative studies
79257040|NCT02129101|Other|Quality-of-Life Assessment|Ancillary studies
79555442|NCT01662817|Behavioral|Control|PCP manages depression in the usual way for six months
79555443|NCT01662869|Drug|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m^2) IV bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
79718951|NCT03275285|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79718952|NCT03275285|Drug|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79718953|NCT03275285|Drug|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
79854465|NCT03855007|Drug|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
79854466|NCT03855007|Drug|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
79854467|NCT03854474|Procedure|Biospecimen Collection|Undergo collection of blood samples
79854468|NCT03854474|Procedure|Computed Tomography|Undergo CT
79854469|NCT03854474|Procedure|Magnetic Resonance Imaging|Undergo MRI
79257041|NCT02129101|Drug|Sonidegib|Given PO
79257042|NCT03250221|Device|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
79257043|NCT03250221|Device|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
79854470|NCT03854474|Biological|Pembrolizumab|Given IV
79854471|NCT03854474|Drug|Tazemetostat|Given PO
79854472|NCT03847636|Device|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
80018471|NCT03550638|Device|Axium Detachable Coil(Medtronic)|2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
80018472|NCT04730050|Drug|TT-01025-CL|Oral tablet
80018473|NCT03550560|Procedure|EUS-Guided drainage|Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
80018474|NCT03528122|Procedure|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
79396051|NCT06089083|Other|Self-reported Assessments and Questionnaires|Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
79555444|NCT01662869|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
79555445|NCT01662869|Drug|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
79555446|NCT01662869|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
79718954|NCT03260530|Other|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
79718955|NCT03260530|Other|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
79718956|NCT03256344|Biological|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
79718957|NCT03256344|Biological|Atezolizumab|A monoclonal antibody given by intravenous injection.
79718958|NCT03192007|Device|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
79718959|NCT03150732|Drug|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
79718960|NCT03150732|Drug|Local nalbuphine|Patients will receive local nalbuphine 10 mg
79718961|NCT03150693|Drug|Allopurinol|Given PO
79718962|NCT03150693|Drug|Cytarabine|Given IT, IV, SC
79718963|NCT03150693|Drug|Daunorubicin Hydrochloride|Given IV
79718964|NCT03150693|Drug|Vincristine Sulfate|Given IV
79718965|NCT03150693|Drug|Dexamethasone|Given PO or IV
79718966|NCT03150693|Drug|Pegylated L-Asparaginase|Given IV
79718967|NCT03150693|Drug|Methotrexate|Given IT, IV, PO
79718968|NCT03150693|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
79718969|NCT03150693|Drug|Cyclophosphamide|Given IV
79555447|NCT01662869|Drug|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
79718970|NCT03150693|Drug|Mercaptopurine|Given PO
79854473|NCT03828019|Biological|Adalimumab (ADA)|Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
79555448|NCT01662921|Drug|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
79555449|NCT01662921|Drug|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
79555450|NCT01662921|Drug|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
79555451|NCT01662934|Device|I RUNE|
79555452|NCT01662934|Device|sham|
79555453|NCT01662947|Device|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
79555454|NCT01662947|Device|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
79718971|NCT03150693|Biological|Rituximab|Given IV
79718972|NCT03150693|Drug|Doxorubicin|Given IV
79854474|NCT03828019|Drug|Conventional immunosuppression (CON)|The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
79854475|NCT03825458|Other|Blood sampling|Blood sampling at each clinical follow-up visit.
79396052|NCT06089083|Procedure|Surgery (Standard of Care, Non-Interventional)|Surgical data will be reviewed via medical record
79396053|NCT06085157|Other|electronic diary|a smartphone application for self-documentation of drinking pattern
79396054|NCT06072430|Drug|VBI-S|VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
79718973|NCT03150693|Drug|Thioguanine|Given PO
79718974|NCT03150693|Biological|Inotuzumab Ozogamicin|Given IV
79718975|NCT03150693|Other|Laboratory Biomarker Analysis|Correlative studies
79718976|NCT03052608|Drug|Lorlatinib|ALK-positive NSCL treatment
79718977|NCT03052608|Drug|Crizotinib|ALK-positive NSCL treatment
79718978|NCT03047603|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
79718985|NCT03023540|Drug|PXT3003|Liquid oral solution, twice 5 mL (Dose 1) bid
79718986|NCT03008369|Other|Laboratory Biomarker Analysis|Correlative studies
79718987|NCT03008369|Drug|Lenvatinib|Given PO
79718988|NCT03008369|Other|Quality-of-Life Assessment|Ancillary studies
79718989|NCT03004183|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
79718990|NCT03004183|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
79718991|NCT03004183|Radiation|SBRT|Low-dose SBRT
79718992|NCT03004183|Drug|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
79854476|NCT03819322|Drug|sofosbuvir/velpatasvir|12 week, oral, fixed dose
80018475|NCT02126514|Drug|AZD3293|7 subjects will receive AZD3293
79257044|NCT04894916|Other|My Diabetes Care Mobile (MDC-m)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
80018476|NCT04720222|Device|TENA-PROTO1|Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
79718993|NCT03003117|Behavioral|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
79257045|NCT03250065|Device|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
80018477|NCT05060926|Procedure|Awake prone positioning|Awake prone position as long as possible according to the patients' tolerance
80018478|NCT02127996|Drug|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
80018479|NCT02127996|Drug|placebo|Normal saline
79257046|NCT02134717|Drug|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
79257047|NCT02134717|Procedure|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
79257048|NCT02134717|Procedure|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
79257049|NCT02134717|Procedure|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
79555455|NCT01662973|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks.
79718994|NCT03003117|Behavioral|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
79718995|NCT03000439|Drug|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
79854477|NCT03817970|Drug|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
79854478|NCT03817970|Drug|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
79854479|NCT03817970|Drug|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
79257050|NCT03245385|Drug|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
79555456|NCT01662973|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
80018480|NCT03551106|Other|Web based learning module|Web based learning module available on a especially designed website
79555457|NCT01663025|Behavioral|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
79555458|NCT01663038|Drug|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
79555459|NCT01663038|Drug|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
79555460|NCT01663038|Drug|Aspirin|
79555461|NCT01663051|Device|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
79555462|NCT01663064|Device|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
79555463|NCT01663077|Drug|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
79555464|NCT01663090|Drug|Ferumoxytol|
80018481|NCT00126776|Behavioral|case management|case/self management for COPD vs usual care
80018482|NCT00126776|Behavioral|usual care|usual care for COPD
80018483|NCT02131350|Procedure|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
80018484|NCT02131350|Drug|Ranibizumab|
80018485|NCT02128308|Drug|Levofloxacin and Streptomycin added|
80018486|NCT02128308|Drug|Moxifloxacin and Kanamycin added|
80018487|NCT02131506|Drug|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die
80018488|NCT01674010|Drug|ELND005|
80018489|NCT01674010|Drug|Lamotrigine|
80018490|NCT01674010|Drug|Valproic acid|
80018491|NCT01674010|Drug|Placebo|
79854480|NCT03815812|Drug|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
80018492|NCT02131740|Other|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest & eye rubbing for a further 1 minute.
80018493|NCT02131740|Other|No eye rubbing|This eye will not be rubbed
80018494|NCT03551340|Diagnostic Test|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
79396055|NCT06069427|Behavioral|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
79555465|NCT01663116|Genetic|Stem cells|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
79396056|NCT06069427|Behavioral|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
79396057|NCT06069427|Behavioral|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
79396058|NCT06068192|Other|no intervention|no intervention
79555466|NCT01663116|Genetic|Placebo|"first cohort: 20 ml administered at days 1, 8 and 15~second cohort: 40 ml administered at days 1, 8 and 15~third cohort: 80 ml administered at days 1, 8 and 15"
79555467|NCT01663155|Device|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
79555468|NCT01663168|Drug|Rifabutin|
79718996|NCT03000439|Drug|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
79718997|NCT02957240|Behavioral|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
79854481|NCT03815812|Drug|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
79854482|NCT03815058|Biological|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
79854483|NCT03815058|Drug|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
79854484|NCT03814395|Other|No intervention|This is an observational study without any intervention
79854485|NCT03811249|Device|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
79854486|NCT03810742|Drug|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
80018495|NCT02252328|Drug|Simvastatin|Simvastatin 80mg once daily
80018496|NCT02252328|Drug|Placebo|Placebo tablets once daily
80018497|NCT05392400|Device|Steri3X|This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the Steri3X wound dressing will have the liquid polymer applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s).
80018498|NCT05392400|Other|Control|"Device: Steri3X~This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the control wound dressing will have the current standard of care dressing applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s)."
80018499|NCT05388968|Biological|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
80018500|NCT05388968|Diagnostic Test|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
79396059|NCT06064721|Other|Buerger-Allen Exercise|Buerger-Allen exercise will be taught by researcher and perform by patient at home twice a day
79396060|NCT06063161|Behavioral|Music therapy intervention|Music therapy intervention administered for 30 minutes 3x/week by certified music therapist.
79396061|NCT06063161|Other|Non-guided music listening|Participants will listen to generic music playlists.
79396062|NCT06063161|Other|Standard of care|placebo arm, routine standard of care
79396063|NCT06058429|Other|no intervention|This is an observation study after vaccination, no intervention will be used
79396064|NCT06056154|Device|LIO ASQELIO TM monofocal QLIO130C|Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
79854487|NCT03807531|Device|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
80018501|NCT02135952|Procedure|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
79854488|NCT03790670|Drug|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
79854489|NCT03786536|Device|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
79854490|NCT03783494|Drug|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
79854491|NCT03774472|Drug|Hydroxychloroquine|Given PO
79854492|NCT03774472|Drug|Letrozole|Given PO
79854493|NCT03774472|Drug|Palbociclib|Given PO
79854494|NCT03764592|Other|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
79854495|NCT03762291|Biological|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
79555469|NCT01663194|Procedure|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
79718998|NCT02957240|Behavioral|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
79718999|NCT02949128|Biological|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to < 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to < 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
79854496|NCT03753659|Drug|Pembrolizumab|IV infusion
79257051|NCT02136745|Behavioral|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
79257052|NCT03249987|Other|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
79719000|NCT02901899|Drug|Guadecitabine|Given SC
79719001|NCT02901899|Other|Laboratory Biomarker Analysis|Correlative studies
79719002|NCT02901899|Biological|Pembrolizumab|Given IV
79719003|NCT02832505|Other|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
79719004|NCT02826083|Dietary Supplement|XXS|
79719005|NCT02826083|Dietary Supplement|non-XXS|
79854497|NCT03753659|Procedure|Radio Frequency Ablation (RFA)|Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
79854498|NCT03753659|Procedure|Microwave Ablation (MWA)|Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
79854499|NCT03753659|Radiation|Brachytherapy|Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
79854500|NCT03753659|Drug|Transarterial Chemoembolisation (TACE)|According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
80018502|NCT02135952|Other|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
79719006|NCT02821572|Biological|blood sample|
79719007|NCT02821572|Procedure|spleen sample|
79719008|NCT02804074|Other|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
79719009|NCT02804074|Other|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
80018503|NCT02135952|Drug|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
79719010|NCT02756845|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
80031515|NCT04890340|Diagnostic Test|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
79257053|NCT04894838|Procedure|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
79555470|NCT01663246|Procedure|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
79555471|NCT01663298|Procedure|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
79719011|NCT02746081|Drug|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
79719012|NCT02722252|Device|Embryoscope|
79719013|NCT02722252|Device|Embryo culture system without incorporated camera|
79719014|NCT02719574|Drug|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
79719015|NCT02719574|Drug|Azacitidine|azacitidine will be administered per site's standard of care
79719016|NCT02719574|Drug|Cytarabine|low-dose cytarabine will be administered per site's standard of care
79719017|NCT02675452|Drug|AMG 176|Study Drug
79719018|NCT02675452|Drug|Azacitidine|Non-investigational product
79719019|NCT02675452|Drug|Itraconazole|Non-investigational product
79719020|NCT02637687|Drug|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
79719021|NCT02576431|Drug|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
79719022|NCT02523014|Drug|Vismodegib|Given PO
79719023|NCT02523014|Drug|FAK Inhibitor GSK2256098|Given PO
79719024|NCT02523014|Drug|Capivasertib|Given PO
79719025|NCT02523014|Drug|Abemaciclib|Given PO
79719026|NCT02474160|Other|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
79719027|NCT02452697|Biological|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
79719028|NCT02452697|Biological|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
79719029|NCT02363335|Other|Placebo|mixed meal
79854501|NCT03706417|Diagnostic Test|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
79854502|NCT03705416|Procedure|Endoscopy|endoscopic suturing of stomach
79854503|NCT03705416|Procedure|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
79875524|NCT00950495|Device|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
79257054|NCT02136823|Drug|sugar pill|
79257055|NCT02136823|Drug|Riluzole|
79257056|NCT02136823|Drug|Isradipine|
79257057|NCT02136823|Drug|Memantine|
79257058|NCT02136823|Procedure|Therapeutic muscle stretching|
79257059|NCT03250143|Drug|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
79257060|NCT03073850|Drug|Antiplatelet|ASA or clopidogrel
79555472|NCT01663311|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
79719030|NCT02363335|Other|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin together
79854504|NCT03700034|Other|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
79257061|NCT03073850|Drug|Low dose oral anticoagulant|Edoxaban of 30mg
79555473|NCT01663311|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
79719031|NCT02363335|Other|Sitagliptin|This is already known to increase GLP-1 &amp; GIP secretion.
79719032|NCT02363335|Other|Roflumilast|This is already known to increase GLP-1 &amp; GIP secretion
79719033|NCT02354911|Biological|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (~10 million cells/injection).
79555474|NCT01663324|Device|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
79555475|NCT01663324|Device|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
79719034|NCT02354911|Other|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
79719035|NCT02333448|Biological|Blood sample taken on the day the treatment is initiated|
79719036|NCT02333448|Biological|Blood sample taken on day 3 after initiation of treatment|
79719037|NCT02333448|Biological|Blood sample taken on day 5 after initiation of|
79719038|NCT02333448|Biological|Blood sample taken on day 7 after initiation of treatment|
79719039|NCT02333448|Biological|Blood sample taken on day 10 after initiation of treatment|
79719040|NCT02325557|Drug|ADXS31-142|ADXS31-142 IV infusion
79719041|NCT02325557|Drug|Pembrolizumab|Pembrolizumab IV infusion
79719042|NCT02312960|Other|Data Collection|No study treatment will be provided in this long term follow up study.
79854505|NCT03679676|Drug|Omalizumab|Omalizumab is injected every 2 to 4 weeks
79854506|NCT03679676|Drug|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
79854507|NCT03679676|Other|Placebo|Placebo is injected every 2 to 4 weeks
79854508|NCT03678688|Drug|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
79854509|NCT03678688|Drug|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
79854510|NCT03678688|Drug|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
79854511|NCT03678688|Drug|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
79875525|NCT00950495|Device|placebo|as a placebo, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
79875526|NCT00942461|Procedure|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
79875527|NCT00942461|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
79257062|NCT03073850|Drug|Standard dose oral anticoagulant|Edoxaban of 60mg
79257063|NCT03549793|Behavioral|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
79257064|NCT03549793|Behavioral|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
79257065|NCT03257319|Drug|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
79257066|NCT03257319|Drug|IV placebo|Patient in arm A will receive 1 to 6 injection
79257067|NCT03257319|Device|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
79257068|NCT03257319|Drug|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
79396065|NCT06055881|Other|Non-Interventional Study|Non-interventional study
79396066|NCT06045299|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine+Brimonidine combination ophthalmic solution
79396067|NCT06045299|Drug|Aceclidine ophthalmic solution|Aceclidine ophthalmic solution
79396068|NCT06045299|Drug|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution
79396069|NCT06044493|Drug|Myreptic-N Tablet|Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
79396070|NCT06044493|Drug|Mycophenolate mofetil Tablet/Capsule|Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
79854512|NCT03678688|Drug|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~Participants weighing 30 to 37 kg received 2 tablets per day~Participants weighing 38 to 54 kg received 3 tablets per day~Participants weighing 55 to 70 kg received 4 tablets per day~Participants weighing > 70 kg received 5 tablets per day"
79854513|NCT03678688|Drug|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
79854514|NCT03678688|Drug|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
79854515|NCT03678688|Drug|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
79854516|NCT03667196|Procedure|antegrade and retrograde approach|This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
79257069|NCT03070574|Drug|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
79719043|NCT02284737|Procedure|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
79257070|NCT03070574|Drug|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
79257071|NCT03070574|Other|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
80018504|NCT05387096|Other|Definitive multi-faceted intervention consisting of several components|The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.
79555476|NCT01663337|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
79555477|NCT01663337|Behavioral|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
79555478|NCT01663376|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells
79555479|NCT01663389|Drug|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
79719044|NCT02284737|Procedure|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
79719045|NCT02284737|Drug|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
79719046|NCT02254746|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
79854517|NCT03666780|Device|LAmbre occluder|All patients are implanted with a LAmbre occluder device
79854518|NCT03666000|Genetic|PBCAR0191|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
79555480|NCT01663389|Drug|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
79555481|NCT01663415|Drug|Enzalutamide|oral
79555482|NCT01663428|Other|Sup-ER Splint|
79854519|NCT03666000|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
79854520|NCT03666000|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
79854521|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
80018505|NCT05387096|Other|Sham Intervention|Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
79257072|NCT02134795|Device|TNM (trade name), a form of brainstem Stimulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
79396071|NCT06038721|Behavioral|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
79719047|NCT02226276|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
79555483|NCT01663428|Other|Currently accepted treatment|
79719048|NCT02226276|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
79719049|NCT02226276|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
79719050|NCT02226276|Biological|trastuzumab|Given IV
79555484|NCT01663441|Drug|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
79719051|NCT02226276|Radiation|copper Cu 64-DOTA-trastuzumab|Given IV
79719052|NCT02226276|Procedure|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
79719053|NCT02226276|Biological|ado-trastuzumab emtansine|Given IV
79719054|NCT02226276|Other|laboratory biomarker analysis|Correlative studies
79719055|NCT02213458|Behavioral|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
79719056|NCT02160015|Procedure|Biospecimen Collection|Undergo blood sample collection
79719057|NCT02160015|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79719058|NCT02160015|Procedure|Computed Tomography|Undergo CT
79719059|NCT02160015|Procedure|Electrocardiogram|Undergo ECG
79719060|NCT02160015|Drug|Ibrutinib|Given PO
79719061|NCT02160015|Drug|Lenalidomide|Given PO
79719062|NCT02160015|Procedure|Magnetic Resonance Imaging|Undergo MRI
79719063|NCT02160015|Biological|Rituximab|Given IV
79719064|NCT02152995|Procedure|Computed Tomography|Undergo iodine I-124 PET/CT
79719065|NCT02152995|Other|Iodine I 124|Undergo iodine I-124 PET/CT
79719066|NCT02152995|Radiation|Iodine I-131|Given PO
79719067|NCT02152995|Other|Laboratory Biomarker Analysis|Correlative studies
79719068|NCT02152995|Other|Pharmacodynamic Study|Correlative studies
79719069|NCT02152995|Procedure|Positron Emission Tomography|Undergo iodine I-124 PET/CT
79719070|NCT02152995|Drug|Trametinib|Given PO
79719071|NCT02141438|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
79719072|NCT02056756|Drug|Carfilzomib|
79719073|NCT02003924|Drug|Enzalutamide|160 mg by mouth once daily
79719074|NCT02003924|Drug|Placebo|Sugar pill to mimic enzalutamide
79396072|NCT06038721|Behavioral|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
79555485|NCT01663441|Drug|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
79555486|NCT01663441|Drug|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
79555487|NCT01663441|Drug|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
79719075|NCT01973452|Drug|Dexmedetomidine|
79719076|NCT01973452|Drug|Placebo|
79719077|NCT01937117|Procedure|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
79719078|NCT01937117|Drug|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
79719079|NCT01937117|Drug|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
79719080|NCT01910402|Drug|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
79719081|NCT01910402|Drug|Atazanavir|Atazanavir capsule 300 mg
79719082|NCT01910402|Drug|Ritonavir|Ritonavir tablet 100 mg
79719083|NCT01910402|Drug|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
79719084|NCT01860365|Other|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
79719085|NCT01860365|Other|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
79719086|NCT01857115|Drug|Carfilzomib|
79719087|NCT01857115|Drug|Cyclophosphamide|
79719088|NCT01857115|Drug|Dexamethasone|
79719089|NCT01754402|Drug|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
79719090|NCT01754402|Drug|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
79719091|NCT01754402|Drug|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
79875528|NCT00946907|Drug|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
80018506|NCT04656964|Drug|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
79719092|NCT01740297|Drug|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
79719093|NCT01740297|Drug|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
79719094|NCT01644591|Other|Quality-of-Life Assessment|Ancillary studies
80018507|NCT04656964|Drug|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
80018508|NCT02136030|Drug|Liposomal amphotericin B|4mg/kg/day, IV infusion
80018509|NCT02136030|Drug|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
79257073|NCT02134873|Other|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
79257074|NCT04984694|Behavioral|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai[SSD] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
79257075|NCT04984694|Behavioral|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
79555488|NCT01663454|Behavioral|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
79555489|NCT01661985|Drug|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
79555490|NCT01661985|Drug|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
79719095|NCT01644591|Other|Questionnaire Administration|Ancillary studies
79719096|NCT01644591|Radiation|Stereotactic Radiosurgery|Undergo SRS
79719097|NCT01588015|Biological|tetanus-CMV fusion peptide vaccine|Given SC
79719098|NCT01588015|Other|laboratory biomarker analysis|Correlative studies
79719099|NCT01572506|Drug|Biotin RBC survival|
79719100|NCT01539720|Drug|Ulipristal acetate|30 mg tablet
79555491|NCT01661985|Drug|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
79719101|NCT01539720|Device|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
79854522|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
79854523|NCT03665493|Behavioral|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
79719102|NCT01517100|Other|Nabilone|CB agonist
80018510|NCT04468178|Device|Total joint arthroplasty of the glenohumeral joint|The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.
80018511|NCT02136108|Other|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
79555492|NCT01663467|Drug|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
79555493|NCT01663467|Behavioral|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
79555494|NCT01663493|Procedure|FNB|
79555495|NCT01663519|Other|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
79555496|NCT01663519|Other|Prefabricated insoles|Prefabricated insoles
79719103|NCT01517100|Drug|CP-945,598|Cannabinoid Receptor 1 antagonist
79719104|NCT01517100|Other|hyperglycemic clamp|assesses beta cell response
79719105|NCT01517100|Other|euglycemic-hyperinsulinemic clamp|measures insulin sensitivity
79719106|NCT01517100|Other|Nabilone|cannabinoid receptor agonist
79719107|NCT01236560|Biological|Bevacizumab|Given IV
79719108|NCT01236560|Drug|Temozolomide|Given PO
79719109|NCT01236560|Drug|Vorinostat|Given PO
79719110|NCT01163942|Drug|G-CSF|Yes/no addition of G-CSF
79719111|NCT01163942|Drug|Early retreatment with ATG|Yes/no early retreatment with ATG
79719112|NCT00887146|Drug|concomitant temozolomide (TMZ)|75 mg/m^2, orally daily
79719113|NCT00887146|Radiation|radiotherapy|
79719114|NCT00887146|Drug|procarbazine|Days 8-21: 60 mg/m^2 orally
79719115|NCT00887146|Drug|adjuvant temozolomide (TMZ)|150 or 200 mg/m^2 orally
80018512|NCT02136108|Other|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
80018513|NCT02131818|Drug|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
80018514|NCT02131818|Drug|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
79257076|NCT03257241|Drug|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is > 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
79257077|NCT03257241|Drug|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is > 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
79257078|NCT03257241|Drug|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
79719116|NCT00887146|Drug|CCNU|Day 1: 110 mg/m^2 orally
79719117|NCT00887146|Drug|vincristine|Days 8 and 29: 1.4 mg/m^2 IV
79719118|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
79555497|NCT01663519|Other|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
79555498|NCT01663558|Drug|imiquimod|
79719119|NCT00775476|Drug|Placebo|placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
79555499|NCT01663558|Procedure|ablative|
79257079|NCT03257241|Drug|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
79257080|NCT02129179|Drug|Glucagon-Like Peptide 1|
79719120|NCT00725049|Device|Dental Implant (Nanotite)|Root form titanium dental implant
79719121|NCT00694850|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
79719122|NCT00663611|Drug|Norditropin|Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
79719123|NCT00663611|Drug|Placebo|0.9% normal saline
79719124|NCT00333801|Behavioral|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
79719125|NCT00333801|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
79719126|NCT03498495|Behavioral|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
79396073|NCT06028893|Diagnostic Test|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
79396074|NCT06028893|Diagnostic Test|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
79396075|NCT06027307|Drug|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
79396076|NCT06027307|Drug|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
79719127|NCT03483116|Biological|RV3-BB|Oral administration
79719128|NCT03483116|Biological|Placebo|Oral administration
79719129|NCT03481569|Other|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
79875529|NCT00946907|Drug|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
79555500|NCT01663584|Procedure|Blood draw|
79555501|NCT01663610|Behavioral|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
79555502|NCT01663649|Behavioral|Deprexis|web-based treatment program for depression
79555503|NCT01663649|Behavioral|Wait-list|the wait-list group receives Deprexis after 6 month
79555504|NCT01663662|Drug|Tolvaptan|
79555505|NCT01663662|Drug|placebo|
79555506|NCT01663675|Genetic|karyotype|
79555507|NCT01663701|Other|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
79555508|NCT01663701|Other|Usual care|Patients are managed according to admitting doctors' orders
79555509|NCT01663753|Device|18F-FDG-PET|
79555510|NCT01663766|Drug|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
79555511|NCT01663792|Other|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
79555512|NCT01663792|Other|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
79555513|NCT01663792|Other|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
79854524|NCT03665493|Drug|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
79854525|NCT03665493|Drug|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
79257081|NCT04984460|Diagnostic Test|Fluorescence morphological detection of liquid-based thin-layer film-making fungi|"Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.~Samples are human vaginal secretions. Each sample should be the amount on one swab.~The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days."
79555514|NCT01663805|Drug|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
79555515|NCT01663818|Device|Tack-It Endovascular Stapler|
79555516|NCT01663831|Other|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
79719130|NCT03443791|Diagnostic Test|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
79854526|NCT03660280|Dietary Supplement|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
79719131|NCT03443791|Diagnostic Test|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
79719132|NCT03393546|Behavioral|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
79854527|NCT03660280|Other|Placebo|Placebo
79854528|NCT03648385|Drug|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
79257082|NCT02129257|Drug|AFLIBERCEPT|
79555517|NCT01663870|Behavioral|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
79555518|NCT01663870|Behavioral|Focus Group Session|Focus group session taking 60-90 minutes.
79719133|NCT03320577|Behavioral|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
79719134|NCT03320577|Behavioral|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
79719135|NCT03320577|Behavioral|Control|Log dinner times
79719136|NCT03286387|Other|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
79719137|NCT03222076|Biological|Ipilimumab|Given IV
79719138|NCT03222076|Biological|Nivolumab|Given IV
79854529|NCT03648385|Other|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
79854530|NCT03641209|Drug|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
79257083|NCT02129257|Drug|Irinotecan|
79257084|NCT02129257|Drug|5-Fluorouracil|
79257085|NCT02129257|Drug|Folinic Acid|
79555519|NCT01663870|Other|Website Session|10-15 minute session with the HealthATM website.
79719139|NCT02970747|Drug|Carfilzomib|In accordance with SmPC.
79719140|NCT02936843|Drug|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
79854531|NCT03641209|Other|Placebo|Half physiological saline solution as the non-active placebo solution
79854532|NCT03637062|Drug|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
79854533|NCT03637062|Device|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
79854534|NCT03624036|Biological|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
79854535|NCT03624036|Drug|Fludarabine|Administered intravenously
79854536|NCT03624036|Drug|Cyclophosphamide|Administered intravenously
79854537|NCT03621306|Device|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
79719141|NCT02936843|Drug|PLACEBO|Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
79396077|NCT06023199|Drug|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
79396078|NCT06020690|Device|bioabsorbable steroid-releasing stent|The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).
79396079|NCT06020677|Other|L-WebTIPS|This mobile health application includes cultural adaption and grounding of a previously developed and tested tailored mHealth intervention, WebTIPS. LWebTIPS is a culturally adapted mHealth intervention that is aimed at the child and parent and strives to improve clinical outcomes and patient experience of Latinx children. Tailoring variables include: Simpatia, Religiosity and Familism.
79396080|NCT06008964|Other|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
79555520|NCT01663870|Behavioral|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
79555521|NCT01663883|Other|Isometric exercise|use of a handgrip for 3x2 minutes
79555522|NCT01663909|Behavioral|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
79555523|NCT01663961|Drug|YM178 OCAS|oral
79555524|NCT01663961|Drug|Digoxin|oral
79719142|NCT02828202|Other|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
79719143|NCT02828202|Other|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
79719144|NCT02828202|Other|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
79854538|NCT03618134|Biological|Durvalumab|Given IV
80018515|NCT05171920|Drug|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
79257086|NCT03256929|Behavioral|Personalized Diet-driven microbiota|Based on the results of the individual microbiota profile, the investigators will formulate a specific diet aiming to enrich the distinct microbiota with organisms correlated to better mental health. The dietitian will visit each participant twice a month.
79257087|NCT03256929|Behavioral|General information on nutrition and health|General information on nutrition and health. The dietitian will visit each participant twice a month.
79257088|NCT04995146|Other|Clinical stroke extended management pathway|"Extracranial imaging~ECG in 2-7 days~DVT prophylaxis~Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~Fasting lipid profile, HbA1c~Holter monitor~Specialized workup for young stroke~PFO Study, MES Study~Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~Follow-up plan and 90 day mRS"
79396081|NCT06008964|Other|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
79396082|NCT06003855|Behavioral|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
79396083|NCT06002971|Device|Blood pressure measurement|Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
79555525|NCT01664000|Drug|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
79555526|NCT01664013|Drug|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
79555527|NCT01664026|Behavioral|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
79555528|NCT01664026|Behavioral|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
79555529|NCT01664065|Drug|200 mg Ceftaroline fosamil|1 h infusion
79555530|NCT01664065|Drug|600 mg Ceftaroline fosamil|1 h infusion
79555531|NCT01664143|Drug|Placebo|Multiple doses of placebo
79555532|NCT01664143|Drug|RO5508887|Multiple doses of RO5508887
79719145|NCT02816879|Procedure|Cytology Specimen Collection Procedure|Undergo anal cytology collection
79719146|NCT02816879|Other|Laboratory Biomarker Analysis|Correlative studies
79719147|NCT02811861|Drug|Lenvatinib|
79719148|NCT02811861|Drug|Everolimus|
79719149|NCT02811861|Drug|Pembrolizumab|
79719150|NCT02811861|Drug|Sunitinib|
79719151|NCT02700451|Drug|Ketorolac|"Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed."
79719152|NCT02700451|Drug|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
79719153|NCT02700451|Drug|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
79719154|NCT02697344|Drug|Dexamethasone|Given PO
79719155|NCT02697344|Other|Laboratory Biomarker Analysis|Correlative studies
79719156|NCT02697344|Drug|Lenalidomide|Given PO
79719157|NCT02697344|Other|Pharmacological Study|Correlative studies
79719158|NCT02697344|Drug|R-(-)-Gossypol Acetic Acid|Given PO
79719159|NCT02696343|Device|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
79719160|NCT02696343|Device|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
79719161|NCT02667418|Drug|Fidaxomicin|200 mg PO twice daily for 10 days
79854539|NCT03618134|Procedure|Modified Radical Neck Dissection|Undergo modified radical neck dissection
80018516|NCT05171920|Drug|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
80018517|NCT04467398|Procedure|trigeminal nerve block|Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
80018518|NCT02131896|Other|Interventional arm-Mediterranean diet|
80018519|NCT02131896|Other|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
79257089|NCT03249441|Behavioral|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~__________________________________________________________________________"
79555533|NCT01664156|Drug|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
79555534|NCT01664156|Drug|Placebo|
79555535|NCT01664169|Other|laboratory biomarker analysis|
79555536|NCT01664195|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
79719162|NCT02667418|Drug|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
79854540|NCT03618134|Other|Quality-of-Life Assessment|Ancillary studies
79854541|NCT03618134|Other|Questionnaire Administration|Ancillary studies
79854542|NCT03618134|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79854543|NCT03618134|Procedure|Transoral Robotic Surgery|Undergo TORS
79854544|NCT03618134|Biological|Tremelimumab|Given IV
79854545|NCT03609944|Procedure|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
79257090|NCT03550729|Behavioral|Endurance training|Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
79257091|NCT03070652|Behavioral|NBO, Newborn behavioral observation|
79719163|NCT02667418|Drug|Vancomycin|125 mg PO for times daily for 10 days
79257092|NCT03070652|Behavioral|Practice as usual|
79719164|NCT02623426|Drug|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
79719165|NCT02623426|Drug|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
79719166|NCT02623426|Drug|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
79854546|NCT03609944|Procedure|EUS|Endoscopic ultrasound
79257093|NCT03245307|Drug|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
79257094|NCT03245307|Drug|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
79257095|NCT03245307|Drug|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
79257096|NCT02136979|Drug|Propofol|group of patients with propofol-based anesthesia
79555537|NCT01664221|Drug|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
79555538|NCT01664260|Drug|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
79555539|NCT01664260|Drug|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
79555540|NCT01664273|Drug|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
79719167|NCT02580058|Biological|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
79719168|NCT02580058|Drug|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
79719169|NCT02539394|Drug|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
79719170|NCT02539394|Other|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
79719171|NCT02530437|Drug|Carboplatin|Given IV
79854547|NCT03607032|Device|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
79854548|NCT03607032|Other|usual treatment|medical aerosol session followed by aspiration or not, as required
79854549|NCT03602612|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
79854550|NCT03602612|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
79854551|NCT03602612|Biological|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10^6 - 12.0X10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
79854552|NCT03585010|Behavioral|Supportive Parenting for Anxious Childhood Emotions|12 sessions with parents
79854553|NCT03585010|Behavioral|Parent Educational Support|12 sessions with parents
79854554|NCT03585010|Behavioral|Cognitive-Behavioral Therapy|12 sessions with child
79854555|NCT03584113|Other|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
79854556|NCT03584113|Other|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase [5mg] and alteplase [10mg] Q12hours).
79875530|NCT00942539|Drug|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
79257097|NCT02136979|Drug|Sevoflurane|group of patients with sevoflurane-based anesthesia
79257098|NCT03249363|Procedure|Group A - Pulsed PVP-I Irrigation|
79719172|NCT02530437|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
79257099|NCT04983758|Other|Oral Rehabilitation with dental implants|Patients have been treated with oral dental implants supporting fixed dental prostheses
79719173|NCT02530437|Other|Laboratory Biomarker Analysis|Correlative studies
79719174|NCT02530437|Drug|Paclitaxel|Given IV
79719175|NCT02530437|Drug|Taladegib|Given PO
79719176|NCT02412670|Drug|Methotrexate|Given IV
79719177|NCT02412670|Drug|Vinblastine|Given IV
79719178|NCT02412670|Drug|Doxorubicin|Given IV
79555541|NCT01664520|Drug|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
79555542|NCT01664546|Procedure|Trophectoderm biopsy|
79555543|NCT01664585|Behavioral|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
79555544|NCT01664585|Behavioral|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
79719179|NCT02412670|Drug|Cisplatin|Given IV
79719180|NCT02412670|Drug|Gemcitabine|Given IV
79719181|NCT02412670|Drug|Carboplatin|Given IV
79719182|NCT02412670|Drug|Pegfilgrastim|Administered subcutaneously
79719183|NCT02412670|Procedure|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
79719184|NCT02405208|Device|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
79719185|NCT02206360|Procedure|Endoscopic Ultrasound|
79719186|NCT02206360|Procedure|Magnetic Resonance Imaging (MRI)|
79719187|NCT01973153|Behavioral|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
79719188|NCT01973153|Behavioral|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
79719189|NCT01973153|Behavioral|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
79719190|NCT01889199|Drug|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
79719191|NCT01889199|Other|Placebo|Placebo orally each 28 day cycle for 6 cycles
79719192|NCT01816152|Other|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
79719193|NCT01816152|Other|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
79719194|NCT01737502|Drug|Auranofin|Given PO
79719195|NCT01737502|Drug|Sirolimus|Given PO
79719196|NCT01737502|Other|Laboratory Biomarker Analysis|Correlative studies
79719197|NCT01737502|Other|Pharmacological Study|Correlative studies
79719198|NCT01666080|Drug|Busulfan|0.4 mg/kg (0.5 mg/kg if <4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
79719199|NCT01666080|Drug|Fludarabine|40 mg/m^2 intravenously (IV) over 1 hour on days -6 through -2.
79719200|NCT01666080|Radiation|Total body irradiation|200 cGy on Day -1
79719201|NCT01666080|Biological|Stem cell transplant|stem cell infusion on day 0
79719202|NCT01666080|Drug|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
79719203|NCT01494103|Biological|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
79719204|NCT01494103|Drug|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
79719205|NCT01263379|Biological|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
79719206|NCT00992238|Drug|Flavoxate Hydrochloride Tablets, 100mg|
79719207|NCT00992238|Drug|Urispas® Tablets, 100mg|
79719208|NCT00858897|Other|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-[3,3-2H2]cysteine
79719209|NCT00858897|Drug|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
79555545|NCT01664611|Procedure|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
79719210|NCT05940922|Other|No intervention. Retrospective observation only.|No intervention. Retrospective observation only.
79719211|NCT05940909|Drug|Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet|"Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine."
79719212|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
79719213|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
79719214|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
79257100|NCT03257007|Behavioral|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
79854557|NCT03583190|Other|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
79555546|NCT01664611|Procedure|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
79555547|NCT01664637|Drug|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
79555548|NCT01664637|Drug|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
79555549|NCT01664650|Dietary Supplement|Genistein|
79719215|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
79257101|NCT04983992|Procedure|extracapsular release of lateral retinaculum|A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
79719216|NCT05940883|Drug|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
79854558|NCT03583190|Other|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
79257102|NCT03245073|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
79719217|NCT05940883|Drug|Placebo|Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
79719218|NCT05940844|Drug|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
79719219|NCT05940831|Behavioral|Support-Moms|Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).
79854559|NCT03583190|Other|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
79719220|NCT05940831|Behavioral|Control|Routine care/ information giving
79854560|NCT03583190|Other|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
79854561|NCT03583190|Other|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
79875531|NCT00947063|Drug|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
79257103|NCT03245073|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
79257104|NCT03257085|Other|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
79555550|NCT01664650|Dietary Supplement|Placebo|
79555551|NCT01664663|Radiation|Standard radiochemotherapy to 68 Gy|
79555552|NCT01664663|Radiation|Dose escalated radiochemotherapy up to 84 Gy|
79555553|NCT01664676|Drug|Liraglutide|
79555554|NCT01664676|Drug|Placebo-liraglutide|
79555555|NCT01664689|Procedure|Microcoaxial Phacoemulsification|
79555556|NCT01664702|Dietary Supplement|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
79555557|NCT01664702|Dietary Supplement|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
79555558|NCT01664728|Drug|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
79555559|NCT01664728|Drug|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
79555560|NCT01664754|Drug|exemestane|Given PO
79555561|NCT01664754|Drug|pemetrexed disodium|Given IV
79555562|NCT01664754|Drug|carboplatin|Given IV
79555563|NCT01664754|Other|laboratory biomarker analysis|Correlative studies
79555564|NCT01664754|Other|pharmacological study|Correlative studies
79555565|NCT01664754|Other|questionnaire administration|Ancillary studies
79555566|NCT01664754|Procedure|quality-of-life assessment|Ancillary studies
79555567|NCT01664767|Other|Sulfur Thermal water|
79719221|NCT05940818|Behavioral|the intensive oral care|the intensive oral care
79257105|NCT03257085|Other|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
79555568|NCT01664767|Other|Placebo|
79555569|NCT01664780|Device|ARFI imaging|
79257106|NCT04988594|Dietary Supplement|Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205|Cultures containing 3.7 × 10 ^ 9 CFU/mg
79555570|NCT01664819|Dietary Supplement|Antioxidant|
79555571|NCT01664819|Dietary Supplement|Placebo|
79719222|NCT05940805|Procedure|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
79719223|NCT05940805|Procedure|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
79719224|NCT05940792|Other|Nonelastic taping|Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
79719225|NCT05940792|Other|Conservative physiotherapy|The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
79719226|NCT05940779|Other|Therapeutic exercise program|The intervention is a therapeutic program composed of self-resisted strength exercises, balance training and exercises to improve posture.
79719227|NCT05940766|Other|Automated fever alerts|Fever alerts are automated sent to participants if fever is detected
79719228|NCT05940753|Other|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
79257107|NCT04988594|Dietary Supplement|Lactobacillus bulgaricus and Streptococcus thermophillus|Cultures containing 3.7 × 10 ^ 6 CFU/mg
79257108|NCT04988594|Dietary Supplement|No culture|No probiotic cultures
79555572|NCT01664832|Device|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
79257109|NCT04988828|Device|Whole body vibration|vertical vibration platform with the frequency of 30Hz, amplitude of 4mm. The intervention will last for 5 weeks, twice /week.
79555573|NCT01664845|Drug|metformin|metformin 500mg tid
79555574|NCT01664845|Drug|pegylated-IFN|pegasys 180 mcg qw
79555575|NCT01664845|Drug|ribavirin|ribavirin 800-1200 mg qd according to BW
79555576|NCT01664871|Device|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
79555577|NCT01664936|Radiation|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
79555578|NCT01665001|Other|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients <55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD <0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients >55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
79257110|NCT03249597|Diagnostic Test|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
79257111|NCT04994678|Other|Virtual Reality Training|The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
79555579|NCT01665014|Radiation|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
79719229|NCT05940740|Other|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
79719230|NCT05940727|Other|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
79555580|NCT01665027|Procedure|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
79257112|NCT04994678|Other|Moderate Aerobic Exercise Training|Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up &amp; 7-10 min cool-down.
79257113|NCT03244839|Procedure|bariatric surgery|bariatric surgery
79257114|NCT02455011|Biological|REMD-477|
79257115|NCT03249285|Drug|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
79719231|NCT05940727|Other|No macroalgae consumption|The participants exclude any macroalgae products from their diet
79719232|NCT05940714|Behavioral|Video participants|Showing a video of oral hygiene intructions
79719233|NCT05940701|Combination Product|Curasept Biosmalto Mousse and toothpaste|at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
79719234|NCT05940701|Other|Colgate toothpaste|The control group will receive a fluoridated toothpaste (Colgate toothpaste)
79719235|NCT05940662|Procedure|Immediate Implant Placement|"The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
79719236|NCT05940662|Procedure|Early Implant Placement|"The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
79257116|NCT03249285|Drug|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
79555581|NCT01665027|Procedure|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
79719237|NCT05940662|Procedure|Late Implant Placement|"The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
79719238|NCT05940597|Device|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
79257117|NCT03070496|Biological|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
79257118|NCT03070496|Procedure|ECG|ECG will be performed at 6 months after myocardial infarction
79257119|NCT03070496|Device|MRI|MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
79257120|NCT03070496|Other|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
79257121|NCT03244683|Dietary Supplement|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
79257122|NCT03244683|Other|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
79257123|NCT03244683|Other|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
79257124|NCT04988204|Behavioral|Diabetes Prevention Program|The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
79257125|NCT03249519|Radiation|Radiation|50.4 Gy
79257126|NCT03249519|Radiation|brachytherapy|35-40 Gy
79257127|NCT03249519|Drug|Cisplatin|weekly 40 mg/m^2 (6cycles)
79257128|NCT03249519|Other|Hyperthermia|10 times
79257129|NCT04983524|Dietary Supplement|propolis|resinous product of honeybees
79257130|NCT04983524|Drug|Calcium Hydroxide|Gold standard control intracanal medicament
79257131|NCT03073772|Behavioral|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
79257132|NCT03073772|Behavioral|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
79257133|NCT03576911|Dietary Supplement|Coenzyme Q10|
79257134|NCT03576911|Other|Placebo|
79719239|NCT05940597|Device|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
80018520|NCT04636138|Other|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
79555582|NCT01665066|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
79719240|NCT05940571|Drug|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
79719241|NCT05940558|Drug|MBF-018 oral capsules|MBF-018 oral capsules PPAR gamma receptor partial agonist
79719242|NCT05940532|Drug|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
79719243|NCT05940480|Behavioral|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
79719244|NCT05940480|Behavioral|Health education|Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
79719245|NCT05940454|Procedure|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
79719246|NCT05940441|Drug|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
79257135|NCT04983212|Other|periodontal control|patient were called and visited in the dentistry department and gingival sulcus were gentle probed to assess gingiva and peri-implant tissues status
79257136|NCT02454777|Behavioral|Exercise Intervention|Undergo HIT
79257137|NCT02454777|Other|Laboratory Biomarker Analysis|Correlative studies
79257138|NCT02454777|Other|Quality-of-Life Assessment|Ancillary studies
79257139|NCT02454777|Other|Questionnaire Administration|Ancillary studies
79257140|NCT04983290|Dietary Supplement|weancare-domus|Participants belonging to the experimental group will receive at home a set of foods that allows to receive the right amount of proteins and energy in a modified texture form to be prepared by themselves or by their caregivers
79396084|NCT05998824|Behavioral|SCD-specific COVID-19 vaccination information (SCVI) video|SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
79396085|NCT05995366|Drug|ABBV-903|Solution; Oral
79555583|NCT01665066|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
79555584|NCT01665066|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
79555585|NCT01665066|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
79555586|NCT01665066|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
79719247|NCT05940389|Device|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique [8] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
79719248|NCT05940389|Device|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
79719249|NCT05940376|Drug|rapid acting insulin|Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
79854562|NCT03582514|Radiation|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
79854563|NCT03576859|Other|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
79854564|NCT03557619|Drug|Venetoclax|tablet; oral
80018521|NCT03525626|Behavioral|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
80018522|NCT04605796|Combination Product|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
80018523|NCT02252640|Biological|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
79396086|NCT05987293|Device|Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.|A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
79555587|NCT01665079|Drug|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 > 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
79719250|NCT05940363|Combination Product|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
79257141|NCT02455089|Other|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
79257142|NCT02634320|Drug|Aripiprazole Lauroxil|Monthly IM injection
80018524|NCT02252640|Biological|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
79257143|NCT03244761|Procedure|The modified HFT|The HFT was modified by increasing the expiratory resistance.
79257144|NCT03256617|Other|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
79257145|NCT04982978|Behavioral|PMT Threat Appraisal|"The first half of the PMT present video will include narration by Science Insider producer, Benji Jones, including dialogue regarding the risks associated with vaping by Chief Pediatric Pulmonology at the NYU Winthrop Hospital, Dr. Melodi Pirzada, and information on nicotine by the Director of Pediatric Pulmonology at NYU's Langone Hassenfeld Children's Hospital, Dr. Mikhail Kazachkov. The second half of the PMT present video will include personal experiences and narratives by students at the University of Utah with information regarding our current knowledge of vaping health effects through research by Dr. Sean Maddock and Dr. Sean Callahan from the University of Utah to highlight the susceptibility of vaping for a population of young adults in university."
79257146|NCT04982978|Behavioral|General Nutrition and Lifestyle|The first half of the PMT absent video will be presented by the Alliance for Aging Research, including an immersive video design, explaining the impact that nutrition may have as the participants age, reviewed by Dr. Steven Austad and Senior Nutritionist Johanna Dwyer. The second half of the PMT absent video will be presented by TED-Ed with narration by Addison Anderson, including a similar immersive video design, explaining how the food the participants eat may affect our brain and overall health. The nutrition and lifestyle information design will be administered as a control because it provides informative lifestyle choices regarding nutrition that can help promote the participants overall health without having an underlying link to vaping behaviour and its subsequent effect on the status of health.
79396087|NCT05985109|Drug|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
79396088|NCT05985109|Drug|regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
79396089|NCT05978128|Behavioral|Health Education|Access electronic patient portal with educational material
79396090|NCT05978128|Other|Health Promotion and Education|Receive materials on breast/lung cancer screening
79396091|NCT05978128|Behavioral|Patient Navigation|Interact with a patient navigator
79555588|NCT01665105|Device|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
79555589|NCT01665131|Device|Cameron Health S-ICD SQ-RX|
79555590|NCT01665183|Drug|ADI-PEG 20|
79555591|NCT01665196|Drug|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
79555592|NCT01665209|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
79719251|NCT05940298|Drug|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of [99mTc]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
79719252|NCT05940272|Behavioral|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
79396092|NCT05978128|Other|Survey Administration|Ancillary studies
79719253|NCT05940272|Behavioral|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
79719254|NCT05940259|Drug|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
79854565|NCT03557619|Drug|ethinyl estradiol/levonorgestrel|tablet; oral
79854566|NCT03556007|Drug|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
79854567|NCT03556007|Drug|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
79854568|NCT03550911|Other|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
80018525|NCT02252640|Biological|ChAd63 ME-TRAP (5 x 10^10 vp)|
80018526|NCT02252640|Biological|MVA ME-TRAP (2 x 10^8 pfu)|
79854569|NCT03539705|Other|There is no intervention|There is no intervention
80018527|NCT04534660|Device|SMI-01|SMI-01 is a device consisting of silk particles in a hydrogel carrier.
80018528|NCT01345669|Drug|Placebo|Once daily
79257147|NCT03244605|Other|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
79257148|NCT03244605|Other|Rehabilitation Education|General health education
79257149|NCT03244605|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
79555593|NCT01665222|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
79555594|NCT01665235|Drug|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
79555595|NCT01665235|Drug|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
79555596|NCT01665235|Drug|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
79555597|NCT01665235|Drug|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
79555598|NCT01665248|Other|18-F Sodium Fluoride Uptake in Positron emission tomography|
79555599|NCT01665339|Other|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
79719255|NCT05940246|Behavioral|Motivational Interviewing|"MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it."
79854570|NCT03524573|Procedure|Appendectomy|Appendectomy is the surgical removal of the appendix.
79854571|NCT03518099|Biological|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
79854572|NCT03505229|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
79854573|NCT03503110|Other|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
79257150|NCT03244605|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
79257151|NCT03244371|Other|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
79257152|NCT03256461|Behavioral|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
79257153|NCT03256461|Behavioral|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
79257154|NCT03256461|Behavioral|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
79257155|NCT02435680|Drug|MCS110|taken by I.V
79257156|NCT02435680|Drug|carboplatin|taken by I.V
79257157|NCT02435680|Drug|gemcitabine|taken by I.V
79257158|NCT03249051|Other|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
79257159|NCT04988126|Other|Interventions|Observational study, not applicable
79396093|NCT05975333|Behavioral|Writing|Participants will be asked to write about their experiences with cancer, guided by several specific open-ended writing prompts to spark ideas.
79396094|NCT05975333|Behavioral|Interview|Following completion of the writing exercise, participants will reflect on their experiences with the writing intervention in a semi-structured private interview with a member of the research team.
79396095|NCT05972291|Dietary Supplement|Oral Glutamine|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 26 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
79854574|NCT03503110|Other|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
80018529|NCT01345669|Drug|Afatinib|Once daily
80018530|NCT05334212|Device|Surgical Theater|The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
80018531|NCT02136186|Device|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
80018532|NCT05144464|Biological|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
79719256|NCT05940233|Drug|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
79257160|NCT04988048|Biological|COVID-19 vaccines|"Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular T° less than -18 ° C~BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular T° 2 to 8 ° C~ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular T°: 2 to 8 ° C~mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. T°-15 ° to -50 °"
79719257|NCT05940207|Device|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
79719258|NCT05940181|Biological|XH001+ sintilimab|During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).
79555600|NCT01665339|Other|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
79555601|NCT01665365|Procedure|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
79555602|NCT01665378|Dietary Supplement|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
79555603|NCT01665378|Dietary Supplement|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
79555604|NCT01665378|Dietary Supplement|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
79719259|NCT05940168|Behavioral|I-Navigator ACT|The intervention is an internet-delivered ten module Acceptance and Commitment Therapy treatment program for stressed and distressed parents of children with disabilities. The contents of the program is mostly text based, but also includes videos, mindfulness exercises and written exercises, as well as homework between modules.
79719260|NCT05940168|Behavioral|Navigator ACT group|The intervention is a five session Acceptance and Commitment Therapy group treatment for stressed and distressed parents of children with disabilities. All five sessions have different themes and are held by two group leaders. Sessions are around two and a half hours long. Homework is given between sessions.
79719261|NCT05940155|Diagnostic Test|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
79719262|NCT05940064|Drug|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m^2 ivgtt D1
79719263|NCT05940051|Drug|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
79719264|NCT05939986|Behavioral|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
79555605|NCT01665404|Drug|Fluvoxamine|Multiple doses of fluvoxamine
79555606|NCT01665404|Drug|RO4917523|Single dose of RO4917523
79555607|NCT01665417|Drug|Experimental|Icotinib: 125mg, oral administration, three times per day.
79719265|NCT05939986|Behavioral|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
79719266|NCT05939986|Behavioral|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
79719267|NCT05939973|Device|g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
79719268|NCT05939960|Diagnostic Test|CGT test|GCT、PRP-CT、PPP-CT monitor
79719269|NCT05939934|Device|Mandibular advancement device treatment|a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.
79719270|NCT05939908|Other|Using Jamar Dynamometer for Grip Strength.|Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.
79719271|NCT05939882|Drug|low concentration atropine (0.01%)|low concentration atropine (0.01%)
79719272|NCT05939882|Drug|low concentration atropine (0.02%)|low concentration atropine (0.02%)
79719273|NCT05939882|Drug|low concentration atropine (0.04%)|low concentration atropine (0.04%)
79719274|NCT05939882|Drug|Placebo|Placebo eye drop
79719275|NCT05939817|Biological|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
79719276|NCT05939817|Biological|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
80018533|NCT02128464|Procedure|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
79719277|NCT05939817|Drug|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
79257161|NCT03248895|Device|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
79257162|NCT03073616|Device|Lung ultrasound|Lung ultrasound and chest RX
79719278|NCT05939778|Biological|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2. 7 subjects were included in the second step."
79719279|NCT05939661|Radiation|Radiation|Neoadjuvant radiation therapy : 5Gyx5
79719280|NCT05939661|Drug|Chemotherapy|CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
79719281|NCT05939661|Procedure|Surgery|Operation: Total methorectum excision wiht radical lymph node dissection
79719282|NCT05939583|Other|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
79719283|NCT05939583|Other|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
79719284|NCT05939557|Procedure|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
79719285|NCT05939557|Device|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
79719286|NCT05939466|Drug|Bedrocan®-type cannabis (22% THC, <1% CBD)|Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, <1% CBD)
79719287|NCT05939440|Other|Proactive Cost of Care (P-COC) intervention|As in Arm description
79257163|NCT03244527|Dietary Supplement|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
79257164|NCT03244527|Other|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
79257165|NCT04987736|Diagnostic Test|RT-PCR|COVID 19 diagonostic test
79257166|NCT03256383|Device|Lead testing|Fingerstick
79719288|NCT05939440|Other|Usual Care|As in Arm description
79257167|NCT03244215|Diagnostic Test|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
79854575|NCT03498521|Drug|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
79854576|NCT03498521|Drug|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
79854577|NCT03498521|Drug|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
79875532|NCT00947063|Drug|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
80018534|NCT02128464|Procedure|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
79719289|NCT05939375|Behavioral|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
79719290|NCT05939284|Drug|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
79719291|NCT05939284|Drug|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
80018535|NCT04313608|Drug|Glofitamab|Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.
79719292|NCT05939271|Procedure|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
79719293|NCT05939206|Procedure|rTARUP|robotic assisted transabdominal retromuscular umbilical prosthetic repair
79719294|NCT05939180|Drug|Venetoclax Oral Tablet|VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
79719295|NCT05939180|Drug|Daunorubicin|DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
79257168|NCT03244215|Diagnostic Test|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
79257169|NCT03244215|Other|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
79257170|NCT03073460|Other|Ultrasound examination|This exam is performed at 40 weeks gestation
79257171|NCT03244137|Other|Pulmonary rehabilitation|See group description.
79396096|NCT05972291|Other|Control Arm|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 26 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
79396097|NCT05951582|Other|Plyometric Exercises|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~Horizontal jumps over hurdle.~Standing long jump~Front cone hops~Forward-backward run~Double leg horizontal jump~Lateral jump over hurdle~Side to side sprint~Jumps over low hurdles~Split squat jump~Cone hops with change of sprint direction~Lateral jump over hurdle~Side to side slide and hops.~Lateral and horizontal jump~Cone hops with 180o turn~Vertical, Lateral, and horizontal jump~Lateral cone jump~Single leg lateral jump~Diagonal Jumps.~Standing long jump with diagonal sprint.~Single leg vertical jump~Cone hop with 1800 turn~Skipping over cone"
79396098|NCT05951582|Other|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~Single Leg Squat/ Lunges~Modified Box Step Ups~Press Ups~Box Jumps~Shoulder Press~Standing Band Row~Band Butterfly Pills"
79719296|NCT05939141|Device|Genio System|"All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy."
79719297|NCT05939115|Device|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
79719298|NCT05939102|Combination Product|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
79719299|NCT05939102|Combination Product|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
79396099|NCT05950919|Other|TASKPEN|"The package of integrated HIV/NCD services:~Integrated non-communicable/HIV care (one stop shop for services)~WHO PEN protocols, algorithm, & training materials adapted for Zambia~Access to cardio-metabolic condition screening & laboratory monitoring~Non-communicable disease-focused electronic medical record module~Strengthened NCD medication supply chain"
79719300|NCT05939089|Diagnostic Test|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
79719301|NCT05939076|Device|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
79719302|NCT05939076|Drug|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
79719303|NCT05939050|Device|Powered toothbrush|Oral-B Powered toothbrush
79719304|NCT05939037|Drug|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
79719305|NCT05938998|Behavioral|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
79719306|NCT05938985|Diagnostic Test|Questionnaires and dry eye tests|Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
79719307|NCT05938972|Biological|Mepolizumab|Monoclonal antibodies
79719308|NCT05938881|Procedure|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
79719309|NCT05938881|Procedure|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
79257172|NCT04982900|Drug|furmonertinib|AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist. It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs. Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.
79719310|NCT05938868|Device|Low intensity pulsed ultrasound (LIPUS)|LIPUS will be delivered intra-orally using a probe applied on the buccal aspect of the implant site. The probe is in contact with the buccal attached gingiva with a thin film of intra oral gel intervening between them, acting as a transmitting medium. It will be applied twice a week for 20 minutes each session that commenced after surgery on the second day and continued for 10 weeks. The intensity of ultrasound therapy used was 30 mW/cm2 with a frequency of 1.5 MHz and temporal average power of 20 Mw
79719311|NCT05938868|Device|low level diode laser therapy|The patients will be irradiated with low level diode laser therapy (GaAs) (Chattanooga, model 27841, USA) .Patient will be irradiated with low level diode laser therapy with parameters: wavelength 850 nm and power of 200 mw in continuous mode will be applied in six points in non-contact method 10 mm away from the peri-implant soft tissue after suturing. The laser irradiations will be administered at six sites that included mesiobuccally, distobuccal, midbuccal, midlingual, mesial, and distal areas around implant for a duration of 10 seconds for each site. The total energy delivered was 6 J per session. And is based on a previous study by Gulati et al., 2020
79719312|NCT05938868|Other|Standard Care|Patients in all three groups will receive the standard care which includes: (1) Extra-oral ice packs during the first 2 days every two hour; (2) maintain daily routine oral hygiene after surgery; (3) Patients will be instructed to eat a soft diet for one weeks; (4) Broad spectrum oral antibiotics in a dose of one capsule every twelve hours for a week; (5) Non-steroidal anti-inflammatory drugs at a dose of one tablet every 8 hours for four days; (6) Warm chlorhexidine gluconate solution as a mouthwash for a period of 2 weeks to enhance plaque control.
79719313|NCT05938855|Device|Electrical stimulation and biofeedback group|10 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.
79719314|NCT05938842|Behavioral|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
80018536|NCT04313608|Drug|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
80018537|NCT04313608|Drug|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
79257173|NCT04982900|Drug|Placebo|The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
79257174|NCT03256071|Drug|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
79257175|NCT03256071|Drug|Modified BUCY|"Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
79719315|NCT05938842|Behavioral|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz & Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz & Oz, 2020; Dowd et al., 2015).
79854578|NCT03498521|Drug|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
80018538|NCT04313608|Drug|Mosunetuzumab|Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.
80018539|NCT04313608|Drug|Obinutuzumab|Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.
80018540|NCT04313608|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
79257176|NCT03248817|Drug|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
80018541|NCT02136264|Other|PCFA interventional dietary counselling|
80018542|NCT02136264|Other|conventional DASH diet counselling|
79854579|NCT03498521|Drug|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
79854580|NCT03498521|Drug|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
79555608|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
79555609|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
79555610|NCT01665469|Dietary Supplement|Tomato extracted lycopene|
79555611|NCT01665469|Dietary Supplement|Placebo|
79719316|NCT05938829|Other|Ultrasound following the SMFM guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery. This information will be captured in our ultrasound reporting software, Viewpoint.
79719317|NCT05938829|Other|Ultrasound following the ISUOG guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery, middle cerebral artery, and ductus venosus. This information will be captured in our ultrasound reporting software, Viewpoint.
79854581|NCT03498521|Drug|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
79719318|NCT05938179|Drug|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
79719319|NCT05938179|Drug|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
79719320|NCT05938179|Drug|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
79719321|NCT05938179|Drug|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
79719322|NCT05938166|Device|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
79854582|NCT03498521|Drug|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
79854583|NCT03498521|Drug|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
79854584|NCT03498521|Drug|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
79257177|NCT03248817|Drug|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
79257178|NCT03248817|Drug|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
79257179|NCT03248817|Drug|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
79396100|NCT05950269|Device|Walking aid|A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).
79396101|NCT05950269|Other|Telemonitoring|Telemonitoring will occur every two weeks for three months after the emergency department discharge, through video call (about 15 minutes). On these opportunities, the importance of using mobile devices and the guidance on safe gait will be reinforced.
79396102|NCT05950269|Other|Guidance on safe walking and risk of falling|Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.
79396103|NCT05941520|Drug|Acolbifene Hydrochloride|Given PO
79396104|NCT05941520|Procedure|Biospecimen Collection|Undergo collection of blood
79396105|NCT05941520|Procedure|Mammography|Undergo 3D mammography
79396106|NCT05941520|Procedure|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
79396107|NCT05941520|Drug|Tamoxifen|Given PO
79555612|NCT01665482|Other|A 2000 kcal test meal|
79555613|NCT01665482|Other|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
79555614|NCT01664988|Behavioral|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
79555615|NCT01664988|Behavioral|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
79555616|NCT01664988|Other|control (routine care)|received routine care of clinic or health center and use drugs if necessary
79555617|NCT01665495|Procedure|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return<30 ml.
79555618|NCT01665534|Behavioral|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
79555619|NCT01664507|Drug|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
79555620|NCT01664507|Drug|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
79555621|NCT01665547|Drug|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
79555622|NCT01665586|Drug|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
79555623|NCT01665612|Device|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
79854585|NCT03498521|Drug|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
79854586|NCT03498521|Drug|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
79555624|NCT01665625|Procedure|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
79257180|NCT05635994|Diagnostic Test|AID strategy|AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
79257181|NCT03248583|Other|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
79257182|NCT03248583|Other|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
79396108|NCT05934773|Device|KineAssist robotic treadmill|"A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4)."
79555625|NCT01665638|Drug|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
79555626|NCT01665638|Drug|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
79555627|NCT01665638|Drug|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
79555628|NCT01665638|Drug|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
79719323|NCT05938049|Device|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as ([PV max- PV min]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
79719324|NCT05937737|Behavioral|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
79719325|NCT05937282|Drug|Dexmedetomidine|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
79719326|NCT05937282|Drug|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.
79719327|NCT05937282|Drug|Lidocain|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
79396109|NCT05933395|Drug|Fulvestrant|Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
79719328|NCT05937282|Drug|normal saline|Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
79719329|NCT05936814|Procedure|total knee arthroplasty|cemented bicondylar PCL substituting total knee replacement
79396110|NCT05933395|Drug|Neratinib|Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
79396111|NCT05933395|Drug|Alpelisib|Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
79396112|NCT05933395|Drug|Everolimus|Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
79854587|NCT03498521|Drug|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
79396113|NCT05933395|Drug|Abemaciclib|Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
79719330|NCT05936268|Drug|Genakumab for injection|150 mg/1ml/bottle
79396114|NCT05928572|Other|CGM initiation approach|Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
79555629|NCT01665651|Drug|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
79555630|NCT01665651|Drug|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
79555631|NCT01665651|Drug|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
79555632|NCT01665651|Drug|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
79555633|NCT01665664|Other|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
79555634|NCT01665690|Other|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
79555635|NCT01665690|Behavioral|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
79555636|NCT01665703|Procedure|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
79719331|NCT05936268|Drug|Colchicine|0.5mg/table
79719332|NCT05935787|Drug|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days
79854588|NCT03498521|Drug|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
79854589|NCT03498521|Drug|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
79854590|NCT03498521|Drug|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
79854591|NCT03498521|Drug|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
79854592|NCT03498521|Drug|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
79854593|NCT03489291|Genetic|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
79854594|NCT03483038|Drug|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
79854595|NCT03483038|Drug|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
79396115|NCT05919849|Behavioral|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
79396116|NCT05919849|Other|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
79719333|NCT05935787|Drug|Placebo|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
79719334|NCT05933642|Drug|Aminophylline|aminophylline 150mg
79719335|NCT05933642|Drug|Frusemide|frusemide 120mg
79719336|NCT05933226|Behavioral|Khanya|"Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2."
79719337|NCT05933109|Behavioral|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
79396117|NCT05916261|Biological|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
79396118|NCT05909800|Drug|Phenofibrate|Administred orally, once daily, for 12 months.
79396119|NCT05909800|Drug|Placebo|Administred orally, once daily, for 12 months.
79396120|NCT05905055|Drug|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
79719338|NCT05933109|Behavioral|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
79555637|NCT01665742|Dietary Supplement|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
79555638|NCT01665742|Dietary Supplement|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
79555639|NCT01665755|Device|Upstroke Compression Defibrillation|
79555640|NCT01665755|Device|Precompression Defibrillation|
79555641|NCT01665781|Drug|Erythropoietin|
79719339|NCT05932251|Drug|Metformin|All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice
79555642|NCT01665820|Device|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
79555643|NCT01665846|Drug|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
79555644|NCT01665885|Device|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
79719340|NCT05932173|Biological|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
79719341|NCT05932108|Behavioral|Education in TERMA|"Education of staff in TERMA. The primary aim of TERMA is to prevent aggression and violence through a system of low-effective treatment that is divided into escalating levels based on the patient's aggression level, risk of violence, and acts of violence . The TERMA model focuses on treatment, communication, and management of compassionate healthcare in forensic psychiatric settings . The levels of the TERMA model are in a cascading order, whereby if the treatment and management of one level are ineffective, the next level is initiated, and so on. The primary level involves the daily behavior and health status of the patient. The secondary level involves risk assessment and violence management, with a focus on creating an understanding of the situation for both the patient and healthcare workers. The tertiary level is utilized when violence cannot be avoided . Each level corresponds to a specific response according to the demands of the situation and environment."
79854596|NCT03479515|Device|Ultrasound|Ultrasound, ADP, bioimpedance measurements
79854597|NCT03472742|Drug|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
79257183|NCT03248583|Other|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
79555645|NCT01665885|Device|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
79555646|NCT01665898|Procedure|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
79555647|NCT01665898|Procedure|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
79555648|NCT01665924|Drug|GLPG0634 100mg capsule once a day for 10 days|
79555649|NCT01665937|Drug|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
79555650|NCT01665963|Device|TopClosure(c) System|
79555651|NCT01665963|Device|Pressure Bandage|
79555652|NCT01665976|Drug|RO4917838|film coated tablet, single dose
79555653|NCT01665976|Drug|RO4917838|oral suspension, single dose
79555654|NCT01665976|Drug|RO4927838|hard gelatin capsule, single dose
79719342|NCT05932108|Other|Changed work routines based on TERMA|NO planned intervention but staff work routines and behavior may change after their education in TERMA. Patients are exposed to these changes.
79719343|NCT05928520|Drug|Tramadol 5%|Topical tramadol 5%
79719344|NCT05928520|Drug|Lidocaine 2%|Topical Lidocaine 2%
79719345|NCT05927441|Device|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
79719346|NCT05927324|Behavioral|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
79719347|NCT05924048|Other|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
79719348|NCT05923411|Drug|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
79854598|NCT03457948|Procedure|Arterial Embolization|Undergo TAE
79854599|NCT03457948|Biological|Pembrolizumab|Given IV
79854600|NCT03457948|Biological|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
79555655|NCT01665989|Behavioral|Group Lifestyle Program|
79555656|NCT01665989|Behavioral|Usual Care|Visits with a dietitian at nutrition services at MGH
79555657|NCT01666015|Other|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
79555658|NCT01666015|Other|Standard Care|This group will be under standard care without any EX intervention.
79719349|NCT05923411|Drug|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
79854601|NCT03457948|Device|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
79854602|NCT03444324|Biological|BT524|BT524 is administered intravenously, patient specific dosage calculated based on body weight and fibrinogen level.
79257184|NCT03647774|Drug|Extended release naltrexone|380mg injectable extended release naltrexone every four weeks
79257185|NCT03248973|Drug|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
79854603|NCT03444324|Biological|FFP/Cryo|FFP/Cryo is administered intravenously; dosage according to local standards in mL per kg body weight.
79854604|NCT03442569|Drug|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
79854605|NCT03442569|Drug|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
79257186|NCT02832531|Drug|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~Left atrial enlargement ≥ 5.5 cm, OR~Left atrial spontaneous echo contrast OR~Left atrial thrombus OR~Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG."
79719350|NCT05923411|Drug|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
79854606|NCT03442569|Drug|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
79854607|NCT03422848|Dietary Supplement|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
79854608|NCT03422848|Behavioral|general life style advice|oral and written advice on diet and physical activity
79854609|NCT03420963|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
79257187|NCT02832531|Drug|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~Left atrial enlargement ≥ 5.5 cm, OR~Left atrial spontaneous echo contrast OR~Left atrial thrombus OR~Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG."
79257188|NCT05635760|Behavioral|Group-based Parent-implemented Social Communication Training|The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
79396121|NCT05905055|Drug|co-administration of aztreonam and nacubactam|2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
79719351|NCT05923411|Drug|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
79719352|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
79719353|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|Single dose of PF-07220060 tablets under fasting conditions and under Proton Pump Inhibitor (PPI) administration (following a 7 day oral rabeprazole tablets daily administration).
79719354|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|Single dose of PF-07220060 tablets given with high-fat, high-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
79854610|NCT03420963|Drug|Cyclophosphamide|Given IV
79854611|NCT03420963|Drug|Etoposide|Given IV
79854612|NCT03412227|Behavioral|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
79257189|NCT05635760|Behavioral|Self-learning-based Parent-implemented Social Communication Training|Self-learning families will learn the same materials without the guidance of a therapist.
79257190|NCT03248505|Device|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
79875533|NCT00942617|Drug|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
79875534|NCT00345345|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
79257191|NCT03248505|Device|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
79257192|NCT03248505|Other|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
79257193|NCT03248505|Device|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
79396122|NCT05905055|Drug|BAT|Dosage of BAT will be based per site's standard of care
79396123|NCT05901532|Drug|Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol|The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.
79396124|NCT05901532|Drug|edible caramel|The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
79396125|NCT05834062|Drug|Qsymia and lifestyle management therapy|Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.
79396126|NCT05834062|Behavioral|Placebo and lifestyle management therapy|Placebo will be used in lieu of Qsymia to maintain the blind. Participants will be offered lifestyle management therapy.
79257194|NCT03248505|Device|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
79257195|NCT03248505|Other|Placebo TENS|TENS device turned on, but with zero amplitude.
79257196|NCT05635682|Other|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
79719355|NCT05923190|Drug|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
79719356|NCT05923190|Drug|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
79257197|NCT03248661|Behavioral|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
79257198|NCT03248427|Drug|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
79555659|NCT01666028|Device|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
79257199|NCT03248427|Drug|Letrozole 2.5mg|Daily continuous
79257200|NCT03248427|Drug|Doxorubicin|60 mg/m2 as a continuous IV perfusion
79257201|NCT03248427|Drug|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
79555660|NCT01666028|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
79555661|NCT01666041|Drug|placebo|
79555662|NCT01666041|Drug|fenofibrate/omega|
79555663|NCT01666041|Drug|fenofibrate|
79555664|NCT01666054|Other|PSV|Pressure Support Ventilation will be used until patient is extubated
79555665|NCT01666054|Other|PAV|Proportional Assist Ventilation will be used until patient is extubated.
79555666|NCT01666067|Drug|placebo|
79555667|NCT01666067|Drug|vytorin|
79854613|NCT03412227|Behavioral|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, & Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, & LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b).
79854614|NCT03412227|Behavioral|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall & Hedtke, 2006; Kendall, Choudhury, Hudson, & Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
79875535|NCT03968159|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
79875536|NCT03968159|Drug|Placebo|Placebo (2×placebo tablets [size- and color-matched to pimavanserin]) administered orally as a single dose once daily
79257202|NCT03248427|Drug|Paclitaxel|80 mg/m2, in one hour IV infusion
79555668|NCT01666067|Drug|simvastatin|
79555669|NCT01666093|Procedure|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
79719357|NCT05922657|Device|Cerene|Real world use of Cerene.
79555670|NCT01666132|Other|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
79555671|NCT01666132|Other|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
79555672|NCT01666132|Other|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
79555673|NCT01666158|Behavioral|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
79555674|NCT01666171|Drug|metformin hydrochloride|
79719358|NCT05919173|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)
79719359|NCT05919173|Drug|Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight|Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
79719360|NCT05910580|Behavioral|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|See SBIRT arm description.
79719361|NCT05908747|Drug|surufatinib + gemcitabine + nab-paclitaxel|surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
79719362|NCT05908240|Other|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
79555675|NCT01666171|Other|clinical observation|
79555676|NCT01666171|Other|diagnostic laboratory biomarker analysis|
79555677|NCT01666171|Other|imaging biomarker analysis|
79719363|NCT05904808|Drug|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
79719364|NCT05904808|Drug|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
79719365|NCT05904808|Drug|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
79257203|NCT03248349|Drug|Pharmacokinetics|"Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~Whole blood is stored for DNA analysis~Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
79396127|NCT05831332|Device|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
79719366|NCT05899426|Other|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 3 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
79719367|NCT05899426|Other|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
79719368|NCT05897931|Other|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
79719369|NCT05897931|Other|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
79555678|NCT01666171|Other|medical chart review|
79555679|NCT01666171|Procedure|digital mammography|
79555680|NCT01666223|Drug|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
79555681|NCT01666223|Drug|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
79719370|NCT05897502|Behavioral|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
79854615|NCT03412227|Other|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
79396128|NCT05827302|Device|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
79555682|NCT01666223|Other|saline|100 ml saline
79555683|NCT01666223|Drug|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
79555684|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
79719371|NCT05896280|Procedure|EST|Stones are taken by cutting the papillary sphincter
79875537|NCT01045005|Other|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
79396129|NCT05793138|Behavioral|Geriatric Care Model|First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
79555685|NCT01666249|Biological|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
79555686|NCT01666262|Biological|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
79555687|NCT01666262|Other|Placebo:Stabilizer|5% sucrose
79555688|NCT01666301|Drug|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
79555689|NCT01666327|Drug|MT-1303|
79719372|NCT05896280|Procedure|ECPP|During ERCP, a generous biliary sphincterotomy (>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
79719373|NCT05895721|Other|Virtual Reality|Virtual Reality as adjunct treatment
79257204|NCT03248193|Device|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
79719374|NCT05891782|Behavioral|HAPA-based multicomponent fall intervention|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 phases: pre-intention phase → intention phase → action phase.~The pre-intention phase: Group lectures will be used, and the intervention is conducted from week 1 to week 3, with a frequency of 2 times per week and a duration of 30-45 minutes per intervention.~The intention phase: Individualized plans will be used, and the intervention is week 4, with an intervention length of 20-30 minutes. By designing action goals and plans in exercise, daily habits, and external improvements, the intention of the study subjects to manage fall risk is clarified.~The action phase: face-to-face interviews will be used, and the intervention keep from week 5 to week 16. It is supplemented with the text tool Tumbler: A Falls Risk Management Manual for Older Adults in Nursing Homes to assist participants in removing barriers to action and increasing their subjective motivation to change health behaviors."
79257205|NCT03248193|Device|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
79257206|NCT03248115|Dietary Supplement|Green tea and green coffee extract tablets|"Tablets: participants were required to take 6 green tea and 3 green coffee extract tablets daily for a period of 8 weeks. No tablets were taken during the last 4 weeks of the study. Randomly chosen tablets were analysed to quantify their polyphenol content.~Urine collections: Several urine collections were required during the supplementation period in order have sufficient time points to estimate the plateau of the concentration of green tea and coffee polyphenols excreted in the urine to then be able to determine their bioavailability. There was a total of five 24-hour urine collections (at week 0 -before supplementation-, 2, 4, 8, and 12 -4 weeks after finishing the supplementation period).~Completion of study documents: Participants were provided with urine collection sheets, polyphenol questionnaires, checklists to record polyphenol tablet intake, and detailed instructions."
79719375|NCT05891782|Behavioral|Regular health education lectures|Conduct regular health education lectures and distribute relevant materials in paper or electronic form. At the same time, follow-up visits is conducted once a month by phone, WeChat or face-to-face, with each visit lasting at least 25-30 minutes. We will understand the questions and needs of the study participants in multiple ways, and provide answers and support. Weekly bulletin board with information about falls.
79875538|NCT01045005|Other|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
79257207|NCT03256305|Device|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
79257208|NCT03256305|Device|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
79257209|NCT03255837|Device|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
79396130|NCT05793138|Behavioral|Usual Care|Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
79396131|NCT05793112|Drug|INF108F probiotic|Oral suspension
79396132|NCT05793112|Drug|Placebo|Oral suspension
79396133|NCT05782127|Drug|Onureg + Venetoclax|Combination of Onureg and Venetoclax
79555690|NCT01666353|Radiation|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
79555691|NCT01666366|Procedure|Coronary artery bypass grafting|
79555692|NCT01666379|Drug|Fentanyl|
79555693|NCT01666392|Dietary Supplement|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
79555694|NCT01666392|Dietary Supplement|Placebo|Placebo
79555695|NCT01666405|Device|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
79555696|NCT01666418|Drug|Pazopanib/Paclitaxel|
79555697|NCT01666431|Drug|Lapatinib|
79555698|NCT01666457|Other|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
80018543|NCT04466774|Diagnostic Test|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
79257210|NCT03255681|Procedure|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
79555699|NCT01666470|Other|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
79555700|NCT01664715|Behavioral|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
79719376|NCT05891184|Device|color doppler ultrasound, transient elastography, upper endoscopy|"Abdominal US: for detecting the portal hypertension, splenomegaly and portosystemic abdominal collaterals .~Doppler US: detecting the diameter and mean blood flow velocity, blood flow volume, perfusion pressure gradient, congestion index, resistive index, pulsatility index of hepatic artery and platelet count-to-spleen diameter ratio will be performed using logic 10 with a 3.5-MHz duplex convex transducer, in supine position after overnight fasting, with holding their breath in maximal expiration in order to minimize the effect of respiration, body position and postprandial changes on the portal flow Endoscopy : Using Sarin classification ( The presence of esophageal varices, their number, exact location, shape, size and cherry-red spots ) Fibroscan: using the standard-probe, and on a fasting (4 h) patient lying flat on his/her back, with the right arm tucked behind the head to facilitate access to the right upper quadrant."
79719377|NCT05888350|Drug|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
79555701|NCT01664715|Behavioral|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
79555702|NCT01664715|Behavioral|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
79555703|NCT01666483|Procedure|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
79555704|NCT01666483|Procedure|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
79555705|NCT01666496|Behavioral|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
79555706|NCT01666496|Behavioral|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
79555707|NCT01666509|Device|Rossoseq™|
79555708|NCT01666509|Device|Placebo|
79555709|NCT01666522|Drug|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
79555710|NCT01666522|Other|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
79555711|NCT01666535|Biological|Influenza vaccination|
79719378|NCT05888350|Drug|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
79719379|NCT05881083|Behavioral|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
79555712|NCT01666561|Other|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
79719380|NCT05881083|Behavioral|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
79555713|NCT01666561|Other|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
80018544|NCT04466774|Device|Urine analysis predicate device for professional user|Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
80018545|NCT03767166|Device|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
80018546|NCT04552418|Drug|Potato starch|Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
79854616|NCT03410498|Other|Incremental shuttle walk test|"In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself."
80018547|NCT02136342|Drug|chlorogenic acid|
79257211|NCT03255759|Diagnostic Test|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
79257212|NCT03371732|Behavioral|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
79257213|NCT03371732|Behavioral|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
79257214|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
79257215|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
79257216|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
79257217|NCT03255603|Other|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
79555714|NCT01666561|Other|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
79555715|NCT01666574|Other|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
79854617|NCT03409458|Drug|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
80018548|NCT04502264|Device|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
79555716|NCT01666574|Other|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
79555717|NCT01666587|Dietary Supplement|Antioxidant|
79555718|NCT01666587|Drug|Prostaglandin inhibitor (Ibuprophen)|
79719381|NCT05874271|Combination Product|Revised case management package|"Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~Prescription of short course primaquine (7 mg/kg total) (Day 0):~PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~Participant counselling at the health facility (Day 0):~Supervision of first dose of primaquine~Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
79854618|NCT03409458|Biological|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
80018549|NCT04502264|Drug|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
80018550|NCT05222503|Device|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
80018551|NCT05222503|Device|Knee Brace|Knee Brace without OPUM Digital Knee
80018552|NCT05222347|Dietary Supplement|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently [22, 23]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects [24, 25]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
79555719|NCT01666600|Drug|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
79854619|NCT03406897|Drug|Cholecalciferol|Oral Administration
79854620|NCT03406897|Drug|Omega 3 fatty acid|Oral Administration
80018553|NCT02128620|Behavioral|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
80018554|NCT05530603|Behavioral|Educational mobile app|7 day educational course to educate American Indian women to receive regular mammogram.
79257218|NCT03255525|Other|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
79555720|NCT01666600|Radiation|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
79555721|NCT01666613|Drug|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
79555722|NCT01666613|Drug|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
79555723|NCT01666613|Drug|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
79257219|NCT03255525|Other|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
79257220|NCT03255525|Other|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
79555724|NCT01666613|Drug|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
79555725|NCT01666626|Procedure|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
79257221|NCT03244449|Other|No apply|
79257222|NCT02454309|Dietary Supplement|Cranberry concentrate|
79555726|NCT01666639|Behavioral|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
79555727|NCT01666639|Behavioral|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
79555728|NCT01666665|Drug|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
79854621|NCT03404895|Device|Conventional Therapy|Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
79257223|NCT02454309|Dietary Supplement|Placebo|
79257224|NCT03255369|Other|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
79257225|NCT03069560|Device|SMS|SMS contact from the caregiver with patient after discharge in intervention group
79257226|NCT03255447|Device|Immunoadsorption|Fresenius Globaffin
79257227|NCT03247959|Behavioral|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
79257228|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
79257229|NCT03247881|Other|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
79257230|NCT03243903|Device|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
79555729|NCT01666665|Drug|Sugar pill|Sugar pill up to 3 times per day for 12 months
79555730|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
79555731|NCT01666678|Drug|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
79555732|NCT01666678|Drug|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
79555733|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
79555734|NCT01666691|Drug|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
79555735|NCT01666691|Drug|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
79555736|NCT01666704|Drug|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
79555737|NCT01666704|Drug|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
79555738|NCT01666704|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
79555739|NCT01666743|Drug|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
79555740|NCT01666756|Dietary Supplement|Chinese herbal formulation PHY906|Given PO
79555741|NCT01666756|Drug|sorafenib tosylate|Given PO
79555742|NCT01666756|Other|laboratory biomarker analysis|Correlative studies
79257231|NCT03243903|Device|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
79257232|NCT03247647|Behavioral|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
79257233|NCT03247647|Behavioral|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
79719382|NCT05872100|Behavioral|MINDFULNESS BASED APPLICATION|"The effectiveness of mindfulness practices in the field of health~Breathing exercise~Discussing and sharing about exercise~Introduction of informal and formal mindfulness practices~Communication exercise with conscious awareness~Sounds and thoughts meditation~The concept of compassion~Biological foundations of compassion~Self-compassion~Barriers to compassion~Coping with compelling emotions~Coping with the intensity of compassion~Compassionate mindfulness attitudes~Admission stages and improving acceptance~Compassion Meditation~Courtesy Meditation~My partner activity~Body Scan~Mindfulness Sitting Meditation~Receiving feedback on the development of mindfulness skills and the content of the training program~Integration of conscious awareness exercises in daily life for the future"
79719383|NCT05871983|Device|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~Nitinol stent frame~Bovine pericardium~Polyester skirt~Anchoring system allows anchoring the frame to the annulus~Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~Transfemoral / transseptal access~Self-expanding~Dry pericardium (can be pre-loaded)~No anchors~27 Fr delivery catheter (~Sizes: 40/48/55mm~Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
79854622|NCT03404895|Device|Venous Stent(s)|After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
79854623|NCT03403894|Behavioral|Asking caregivers in their practice|A questionary is given to caregivers
79854624|NCT03403361|Device|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
79875539|NCT00947141|Drug|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR >200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
80018555|NCT05521867|Device|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
80031516|NCT05018234|Device|Noval Oral Appliance|A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
80031517|NCT05015114|Other|Sarcopenia Assessment|Sarcopenia Assessment
80031518|NCT05390684|Other|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
79555743|NCT01666756|Other|pharmacological study|Correlative studies
79719384|NCT05870683|Drug|Tegoprazan|Included in dual eradication medication.
79719385|NCT05870683|Drug|Amoxicillin|Included in dual eradication medication.
79719386|NCT05870683|Drug|Esomeprazole|Included in dual eradication medication.
79719387|NCT05870293|Behavioral|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
79257234|NCT03247491|Behavioral|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
79257235|NCT02745119|Drug|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
79875540|NCT00947141|Other|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
79555744|NCT01666769|Drug|Micafungin|4 mg/kg/day
79555745|NCT01666769|Drug|Micafungin|8 mg/kg/day
79555746|NCT01666769|Drug|Micafungin|Standard of care Dosing
79555747|NCT01666821|Other|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
79555748|NCT01666847|Procedure|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
79555749|NCT01666860|Procedure|Anterior Lumbar Interbody Fusion procedure|
79555750|NCT01666886|Device|Mandibular Advancement Device (MAD)|
79555751|NCT01666899|Procedure|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
79555752|NCT01666925|Biological|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu
79555753|NCT01666925|Biological|Rabies vaccine|2 x 2.5IU Verorab
79555754|NCT01666938|Other|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
80031519|NCT04889482|Other|No intervention|No intervention
79555755|NCT01666938|Other|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
79555756|NCT01666964|Other|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
79555757|NCT01666990|Drug|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
79257236|NCT03247725|Other|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
79555758|NCT01666990|Drug|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
79555759|NCT01667068|Other|Comprehensive non invasive cardiovascular examination|"Anamnesis with the participian~File recherche,Physical examination~Documentation of the carciovascular and antiretroviral medical therapy~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~Measuring of the arterial media thickness~Exercise Montreal Cognitive Assesment test~Exercise the Grooved Pegboard test~Blood collection~Questionnaire to quality of life and health economics"
79555760|NCT01667094|Drug|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
79555761|NCT01667094|Drug|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
79257237|NCT03247725|Other|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
79257238|NCT03247803|Device|air-Q® SP|air-Q SP placement for airway maintenance,
79555762|NCT01667094|Drug|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
79555763|NCT01667094|Drug|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
79555764|NCT01667094|Drug|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
79555765|NCT01667094|Drug|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
79555766|NCT01667094|Drug|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
79555767|NCT01667094|Drug|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
79555768|NCT01667094|Drug|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
79555769|NCT01667094|Drug|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
79555770|NCT01667146|Other|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH > 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
79555771|NCT01667146|Other|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
79555772|NCT01667159|Behavioral|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
79555773|NCT01667159|Behavioral|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
79555774|NCT01667172|Device|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
79555775|NCT01667198|Procedure|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
79555776|NCT01667198|Behavioral|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
79555777|NCT01667211|Drug|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
79719388|NCT05862675|Diagnostic Test|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
79719389|NCT05860400|Behavioral|Healthy life style|Healthy diet, regular exercise, and quitting smoking
79719390|NCT05860400|Drug|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
80031520|NCT03963518|Drug|Immune checkpoint inhibitor|Immune checkpoint inhibitor
80031521|NCT04885114|Genetic|Intraparenchymal rAAV1 - (mi)RNA HTT|Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
79719391|NCT05860400|Drug|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
79719392|NCT05860400|Procedure|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
79719393|NCT05860400|Drug|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
79719394|NCT05856747|Drug|TBP-PI-HBr|TBP-PI-HBr tablets.
79854625|NCT03403361|Device|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
79257239|NCT03247803|Device|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
79719395|NCT05850052|Other|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
79719396|NCT05850052|Device|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
79719397|NCT05847452|Drug|Benralizumab|30mcg ever month for 3 months
79719398|NCT05842499|Procedure|Line Set Strategy|Substrate-guided ablation procedure of atypical atrial flutter
79719399|NCT05842499|Procedure|Conventional strategy|Electrical activation-guided ablation
79719400|NCT05837507|Other|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
79719401|NCT05837507|Other|Usual management including NIV.|Usual management including NIV.
79719402|NCT05834387|Procedure|EICU Transfer Routine Care|EICU Transfer Routine Care
79257240|NCT03243825|Radiation|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
79719403|NCT05834387|Procedure|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
79854626|NCT03386045|Radiation|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
79257241|NCT03243825|Drug|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
79555778|NCT01667237|Behavioral|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
79854627|NCT03386045|Radiation|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach|) and one third will get the standard treatment (60 Gy in 20 treatments)"
79854628|NCT03383458|Biological|Nivolumab|Specified dose on specified days
79854629|NCT03383458|Other|Placebo|specified dose on specified days
79854630|NCT03361852|Drug|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
79257242|NCT03247179|Other|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
79396134|NCT05778227|Drug|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
79396135|NCT05778227|Drug|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
79396136|NCT05778227|Drug|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
79396137|NCT05778227|Drug|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
79396138|NCT05755191|Drug|NEU-411|Oral Doses
79396139|NCT05755191|Drug|Placebo|Oral Doses
79555779|NCT01667263|Drug|All-trans retinoic acid|
79854631|NCT03361852|Biological|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
79396140|NCT05753150|Drug|Tafenoquine|Tafenoquine 300 mg (2x150 mg tablets)
79396141|NCT05753150|Drug|Primaquine|Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
79396142|NCT05753150|Drug|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
79396143|NCT05752552|Drug|DO-2|Deuterated MET kinase inhibitor
79396144|NCT05738551|Other|stress ball|Applicable to group 1
79396145|NCT05738551|Other|chewing gum|Applicable to group 2
79854632|NCT03361852|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
79555780|NCT01667263|Drug|Danazol|
79555781|NCT01667289|Radiation|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
79555782|NCT01667289|Drug|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
79555783|NCT01667302|Drug|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
79854633|NCT03320122|Other|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
79555784|NCT01667315|Drug|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
79555785|NCT01667328|Procedure|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
79555786|NCT01667328|Procedure|Standard of care|Control group will receive standard of care with no massage therapy
79555787|NCT01667354|Behavioral|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
79555788|NCT01667367|Drug|RG1662|Single oral dose
79555789|NCT01667367|Drug|placebo|Single oral dose
79555790|NCT01667393|Device|IDEV SUPERA Stent|
79555791|NCT01667393|Device|Percutaneous Transluminal Angioplasty|
79555792|NCT01667445|Drug|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
79555793|NCT01667445|Drug|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
79555794|NCT01667484|Drug|Adderall XR 5mg|
79555795|NCT01667484|Drug|Adderall XR 10 mg|
79555796|NCT01667484|Drug|Placebo|
79555797|NCT01667497|Drug|Fampridine SR|
79555798|NCT01667497|Drug|Placebo|
79555799|NCT01667510|Dietary Supplement|Cardio Mato|Soft gel capsule for oral use
79555800|NCT01667510|Dietary Supplement|Placebo|Soft gel capsule without test material
79555801|NCT01667523|Dietary Supplement|Capsaicin|1.5 mg capsaicin administered intraduodenally
79555802|NCT01667523|Dietary Supplement|Cinnamaldehyde|70 mg per intervention administered intraduodenally
79555803|NCT01667523|Dietary Supplement|Placebo|Physiological saline
79719404|NCT05833776|Procedure|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
79719405|NCT05832957|Behavioral|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
79555804|NCT01667575|Drug|Esomeprazole|antisecretary drug of the quadruple therapy
79555805|NCT01667575|Drug|Amoxicillin|antibiotic of the quadruple therapy
79555806|NCT01667575|Drug|Clarithromycin|antibiotic of the quadruple therapy
79555807|NCT01667575|Drug|Bismuth Potassium Citrate|one of a component of a quadruple therapy
79555808|NCT01667575|Other|long duration (14 day)|
79555809|NCT01667601|Other|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
79555810|NCT01667601|Behavioral|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
79555811|NCT01667601|Behavioral|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
79555812|NCT01667614|Drug|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
79555813|NCT01667627|Dietary Supplement|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
79555814|NCT01667627|Other|Placebo|Identical placebo
79854634|NCT03320122|Other|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
79854635|NCT03320122|Other|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
79854636|NCT03319745|Biological|Pembrolizumab|Given IV
79854637|NCT03309150|Drug|M6620|Participant will either receive M6620 intravenously as a monotherapy on Day 1, 8 and 15 OR as a combination therapy on Day 2 and 9 of the study.
79854638|NCT03309150|Drug|Carboplatin|Participant will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
79854639|NCT03309150|Drug|Paclitaxel|Participant will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
79555815|NCT01667640|Radiation|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
79854640|NCT03302663|Diagnostic Test|MRI scan|Addition of advanced imaging sequences for fetal MRI
79257243|NCT03578627|Behavioral|BioBehavioral Intervention|Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
79719406|NCT05832957|Behavioral|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
79719407|NCT05832957|Other|No intervention|one-time short guidance on safe driving at the end of the study.
79257244|NCT03576677|Drug|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
79257245|NCT03576677|Drug|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
79257246|NCT03247257|Procedure|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
79257247|NCT03247257|Procedure|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
79257248|NCT03578471|Device|Hearing Aid without NR and BF|Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
79555816|NCT01667640|Radiation|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
79555817|NCT01667653|Dietary Supplement|Probiotic|Probiotic capsule once daily
79555818|NCT01667653|Dietary Supplement|Placebo|Placebo capsule once daily
79719408|NCT05830981|Other|Educational intervention|3 months of educational intervention (Lectures, information bulletin, handbook and hardcopy presentation slides) among professionals and patients.
79719409|NCT05822869|Procedure|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
79719410|NCT05822869|Procedure|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
79719411|NCT05821244|Behavioral|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
79854641|NCT03297060|Other|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
79257249|NCT03578471|Device|Hearing Aid with NR|Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
79257250|NCT03578471|Device|Hearing Aid with BF|Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
79854642|NCT03296709|Device|PPC z|Installation of a preformed pediatric zircona crown
79257251|NCT02454699|Drug|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
79257252|NCT02454699|Other|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
79396146|NCT05737420|Diagnostic Test|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
79396147|NCT05730582|Behavioral|Parkland Diabetes Detection Program (PDDP) Screening Invitation|"The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days."
79854643|NCT03296709|Device|PPC m|Installation of a preformed pediatric metal crown
79555819|NCT01667666|Drug|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
79555820|NCT01667692|Drug|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.[1] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
79257253|NCT03243123|Device|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
79555821|NCT01667692|Drug|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
79257254|NCT03576599|Drug|Zoledronic Acid Injectable Product|One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
79555822|NCT01667718|Drug|Bismuth|Bismuth 220mg b.i.d for 2 weeks
79555823|NCT01667718|Drug|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
79555824|NCT01667718|Drug|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
79555825|NCT01667718|Drug|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
79555826|NCT01667770|Procedure|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
79555827|NCT01667783|Procedure|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
79555828|NCT01667783|Behavioral|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
79555829|NCT01667783|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
79555830|NCT01667809|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
79555831|NCT01667809|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
79555832|NCT01667822|Behavioral|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
79555833|NCT01667822|Behavioral|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
79719412|NCT05816616|Diagnostic Test|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
79854644|NCT03282292|Procedure|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
79854645|NCT03243058|Biological|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
79257255|NCT03576599|Drug|Placebo|Placebo
79257256|NCT03247101|Drug|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
79257257|NCT03247101|Drug|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
79257258|NCT03247101|Drug|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
79257259|NCT02239757|Procedure|Left radial approach|Primary PCI performed through left radial approach.
79257260|NCT02239757|Procedure|Right radial approach|Primary PCI performed through right radial approach.
79719413|NCT05809349|Device|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
79854646|NCT03243058|Other|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
79854647|NCT03243058|Other|Placebo Arm|Participants in this group will receive a placebo injection for two years.
79854648|NCT03235544|Drug|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
79854649|NCT03228940|Drug|RVX000222|oral, BID
79854650|NCT03217305|Device|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
79854651|NCT03196011|Other|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
79854652|NCT03196011|Other|TKR with alternative alignment method|TKR implanted using alternative alignment methods
79257261|NCT03255213|Other|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
80018556|NCT05521867|Device|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
79257262|NCT02239835|Drug|Tipranavir (TPV) low dose|
79555834|NCT01667835|Behavioral|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
79555835|NCT01667874|Drug|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
79555836|NCT01667913|Other|6 minutes walking test|
79854653|NCT03191760|Behavioral|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
79555837|NCT01667939|Behavioral|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
79555838|NCT01667965|Behavioral|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
79555839|NCT01668043|Drug|Antibody UB-421|UB-421 is administered by intravenous infusion
79555840|NCT01668056|Drug|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
79555841|NCT01668056|Procedure|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
79555842|NCT01668056|Other|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
79555843|NCT01668069|Drug|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
79555844|NCT01668095|Other|Laboratory Biomarker Analysis|Correlative studies
79555845|NCT01668121|Drug|Symbicort Turbohaler|
79555846|NCT01668121|Drug|Budesonide/formoterol Easyhaler|
79555847|NCT01668134|Radiation|Stereotactic radiation|
79555848|NCT01668160|Procedure|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
79555849|NCT01668199|Drug|TZP-101|
79555850|NCT01668212|Procedure|Doppler ultrasound|Doppler Ultrasound
79555851|NCT01668264|Procedure|Echocardiograph|
79555852|NCT01668264|Procedure|Magnetic Resonance Imaging (MRI)|
79555853|NCT01668277|Drug|7.2% NaCl|
79555854|NCT01668277|Drug|0.9% NaCl|
79555855|NCT01668303|Behavioral|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
79719414|NCT05805475|Other|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
79719415|NCT05805475|Other|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
79257263|NCT02239835|Drug|Tipranavir (TPV) high dose|
79257264|NCT02239835|Drug|Ritonavir low dose|
79257265|NCT02239835|Drug|Ritonavir high dose|
79257266|NCT02239835|Drug|Saquinavir|
79257267|NCT02239913|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
79257268|NCT02239913|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
79257269|NCT02239913|Drug|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
79257270|NCT02239913|Drug|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
79719416|NCT05804825|Behavioral|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
79719417|NCT05804825|Behavioral|Simple forewarning message|Participants will be presented with a simple forewarning message.
79719418|NCT05798572|Drug|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
79854654|NCT03187353|Drug|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
79854655|NCT03187353|Drug|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
79854656|NCT03187080|Procedure|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
79555856|NCT01668303|Behavioral|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
80018557|NCT03550482|Dietary Supplement|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI <20 and serum albumin levels <30 g/l received nutritional support.
80018558|NCT03527732|Drug|Albendazole|Monotherapy of albendazole (400 mg)
79555857|NCT01668316|Behavioral|Weight loss|"Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
79396148|NCT05722652|Behavioral|CONFIDENCE|"This clinic-based, multicomponent intervention consists of 3 parts:~Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~Parent-facing educational materials about COVID-19 vaccination~Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination"
79555858|NCT01668342|Behavioral|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
79555859|NCT01668368|Other|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
79719419|NCT05798572|Procedure|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
79719420|NCT05795140|Drug|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
79719421|NCT05792189|Other|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
80018559|NCT03527732|Drug|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
80018560|NCT03550326|Procedure|airway management|patients will be intubated or will be placed an airway device
80018561|NCT01673854|Drug|Ipilimumab|
80018562|NCT01673854|Biological|Vemurafenib|
80018563|NCT05514301|Diagnostic Test|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
79396149|NCT05715203|Device|Pulsotonometry|Evaluation of arterial stiffness
79257271|NCT03243201|Drug|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
79396150|NCT05705817|Behavioral|Assistive Soft Skills and Employment Training (ASSET)|The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
79854657|NCT03187080|Other|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to our current standard of care, we will utilize the following perioperative strategies [Arsalani]:~Standardized written information given preoperatively.~Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~Use paravertebral block to augment postoperative pain control.~Standardized multimodal analgesic regimen~Antiemetics~Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~PVB is less commonly used in elective surgery.~Patients do not eat or drink after midnight.~There is no standardized preoperative information packet.~Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
79875541|NCT00947141|Drug|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
80018564|NCT03550248|Behavioral|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
80018565|NCT02136654|Behavioral|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
80018566|NCT03525470|Biological|Water|150 mil of water was drunk on two occasions
80018567|NCT03525470|Other|No drink|Although body weight lost no drink consumed
80018568|NCT02804152|Behavioral|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
80018569|NCT03549702|Drug|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
79555860|NCT01668381|Procedure|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
79555861|NCT01668394|Behavioral|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
79555862|NCT01668394|Other|Control arm|Usual care. Teaching style: deductive.
79719422|NCT05792189|Other|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
79719423|NCT05792189|Other|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
79875542|NCT00947141|Other|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
79257272|NCT03243201|Other|Purified Water|Purified water will be given as placebo
79257273|NCT03243435|Procedure|Native 1,5 Tesla breast MRI|
79396151|NCT05681806|Dietary Supplement|Carnipure AAS|A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate
79396152|NCT05681806|Dietary Supplement|Creatine Monohydrate|5g creatine monohydrate
79396153|NCT05666726|Other|Pain|Thermal pain
79396154|NCT05666726|Other|Stress|Stress state induction
79396155|NCT05666726|Behavioral|Craving|Snack craving induction
79396156|NCT05666726|Behavioral|Frustration|Real effort task
79555863|NCT01668420|Other|thermal stimulation|hot and cold/warm and cool pads applying.
79555864|NCT01668433|Drug|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
79555865|NCT01668446|Drug|Sildenafil|sildenafil tablets(50 mg) daily
79555866|NCT01668446|Drug|estradiol valerat|
79396157|NCT05666726|Behavioral|Negative valence emotion|Passive video watching with emotional valence
79555867|NCT01668459|Drug|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
79555868|NCT01668459|Other|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
79719424|NCT05792189|Other|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
79719425|NCT05781906|Drug|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
79719426|NCT05781906|Drug|150 µCi [14C]HMPL-523|D8: [14C] HMPL-523 Suspension 300 mg/150 μCi Single dose
79719427|NCT05777005|Behavioral|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
79719428|NCT05777005|Other|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
79719429|NCT05777005|Other|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
79719430|NCT05777005|Behavioral|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
79719431|NCT05777005|Behavioral|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
79719432|NCT05771389|Diagnostic Test|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
79719433|NCT05760261|Drug|Midazolam|Midazolam will be administered.
79719434|NCT05760261|Drug|GSK3882347|GSK3882347 will be administered.
80018570|NCT02136732|Other|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
80018571|NCT02136732|Other|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
79257274|NCT03070418|Procedure|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
79719435|NCT05759832|Device|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher & Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
79719436|NCT05759832|Device|Face mask|In the face mask group, oxygen was delivered via a face mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen > 90%.
79719437|NCT05756192|Other|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
79719438|NCT05751915|Device|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
79875543|NCT03966911|Device|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
79875544|NCT03966365|Drug|PRO-122|"PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: topical ophthalmic."
79875545|NCT03966365|Drug|Krytantek Ofteno®|"- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~- Route of administration: topical ophthalmic."
79875546|NCT02007239|Drug|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
79257275|NCT03243357|Procedure|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
79875547|NCT00375219|Drug|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
79854658|NCT03187080|Procedure|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
79854659|NCT03187080|Drug|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is *NOT* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
79854660|NCT03179384|Drug|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
79257276|NCT03243357|Procedure|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
79555869|NCT01668485|Procedure|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
79854661|NCT03176693|Drug|Phenoxybenzamine|Non-selective alpha blocker
79854662|NCT03176693|Drug|Doxazosin|Selective alpha blocker
79555870|NCT01668498|Drug|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
79555871|NCT01668498|Drug|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
79555872|NCT01668511|Biological|ABT-981|Injection
79555873|NCT01668511|Biological|Placebo|Placebo Injection
79555874|NCT01668524|Drug|ATS907|Single dose of each of three increasing concentrations
79555875|NCT01668550|Drug|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
79555876|NCT01668615|Drug|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
79555877|NCT01668641|Drug|GLPG0634|
79555878|NCT01668641|Drug|Placebo|
79854663|NCT03175874|Procedure|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
80018572|NCT03550950|Drug|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
79854664|NCT03143075|Dietary Supplement|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
80018573|NCT03550950|Drug|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
80018574|NCT03550950|Drug|Placebo|Matching placebo will be administered as IV infusion or SC injection.
79257277|NCT03576521|Combination Product|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment* and up to three weeks after the end of the treatment.~*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
79555879|NCT01668680|Drug|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
79854665|NCT03142919|Biological|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
79555880|NCT01668693|Other|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
79555881|NCT01668693|Other|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
79555882|NCT01668693|Other|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
79555883|NCT01668745|Biological|Early measles vaccine|
79555884|NCT01668823|Drug|HPPH|Given IV
79555885|NCT01668823|Drug|photodynamic therapy|Undergo photodynamic therapy with HPPH
79555886|NCT01668823|Procedure|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
79555887|NCT01668862|Biological|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
79555888|NCT01668862|Drug|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
79854666|NCT03142919|Biological|Placebo|Saline solution
79854667|NCT03141034|Drug|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
79854668|NCT03141034|Drug|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
79854669|NCT03141034|Genetic|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
79854670|NCT03141034|Genetic|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
79257278|NCT03576521|Combination Product|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment* and up to three weeks after the end of the treatment.~*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
79854671|NCT03094052|Drug|Neratinib|Given orally (PO)
80018575|NCT01343407|Drug|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
80018576|NCT01343407|Drug|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
79257279|NCT03255135|Device|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
79257280|NCT03578315|Device|HGM|To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
79257281|NCT02455713|Device|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
79257282|NCT03576287|Drug|Apremilast Oral Product|Apremilast
79396158|NCT05650788|Diagnostic Test|NMR spectrometry|"The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~Realization of a morphological sequence for the identification of the zone of interest.~Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left)."
79396159|NCT05650229|Drug|KL1333|Twice daily
79396160|NCT05650229|Drug|Placebo|Twice daily
79396161|NCT05636904|Drug|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
79854672|NCT03094052|Biological|Trastuzumab|Given Intravenously (IV)
79555889|NCT01668875|Other|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
79555890|NCT01668875|Other|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
80018577|NCT01343407|Drug|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
80018578|NCT01343407|Drug|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
80018579|NCT02529904|Biological|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
79257283|NCT02455869|Drug|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
79257284|NCT02455869|Drug|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
79257285|NCT02455869|Drug|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
79396162|NCT05636904|Drug|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
80018580|NCT01367886|Drug|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
80018581|NCT04442594|Procedure|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
80018582|NCT05706415|Diagnostic Test|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
80018583|NCT02128698|Dietary Supplement|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
79257286|NCT03574025|Other|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
79396163|NCT05636904|Drug|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
79396164|NCT05636904|Drug|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
79396165|NCT05633745|Drug|NEU-723|Oral Doses
79396166|NCT05633745|Drug|Placebo|Oral Doses
79396167|NCT05630794|Procedure|Biopsy|Undergo biopsy
79396168|NCT05630794|Procedure|Biospecimen Collection|Undergo collection of blood
79396169|NCT05630794|Procedure|Colonoscopy|Undergo colonoscopy
79396170|NCT05630794|Drug|Dordaviprone|Given PO
79396171|NCT05630794|Other|Questionnaire Administration|Complete questionnaire
79396172|NCT05630794|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
79555891|NCT01668901|Drug|warfarin|anticoagulation
79555892|NCT01668901|Drug|Aspirin|antiplatelet
79555893|NCT01668914|Procedure|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
79555894|NCT01668914|Radiation|99mTc-SC|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
79555895|NCT01668914|Device|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
79555896|NCT01668914|Device|LSG|lymphoscintigraphy was performed 0.5~1.0 hour before surgery
79854673|NCT03094052|Drug|Loperamide|Given PO
79854674|NCT03094052|Drug|Diphenoxylate Hydrochloride/Atropine Sulfate|Given PO
79854675|NCT03092323|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
79854676|NCT03083821|Drug|Baraclude|Specified dose on specified day
79854677|NCT03073278|Radiation|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
79854678|NCT03071393|Device|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
79257287|NCT03246867|Other|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
79854679|NCT03071393|Device|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
79854680|NCT03056001|Drug|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
79854681|NCT03056001|Drug|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
79854682|NCT03043599|Radiation|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
79854683|NCT03043599|Drug|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
79854684|NCT03043599|Drug|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
79555897|NCT01668914|Drug|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
79555898|NCT01668927|Drug|Proton Pump Inhibitor|
79555899|NCT01668927|Drug|Bismuth|
79555900|NCT01668927|Drug|Metronidazole|
79555901|NCT01668927|Drug|Tetracycline|
79555902|NCT01668927|Drug|Furazolidone|
79555903|NCT01668927|Drug|Amoxicillin|
80018584|NCT02128698|Dietary Supplement|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
80018585|NCT02128698|Behavioral|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
80018586|NCT02128698|Behavioral|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
79555904|NCT01668979|Device|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
79555905|NCT01668992|Behavioral|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
79555906|NCT01669018|Procedure|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
79555907|NCT01669018|Procedure|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
79555908|NCT01669031|Other|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
79555909|NCT01669044|Drug|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
79555910|NCT01669044|Drug|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
79719439|NCT05748730|Behavioral|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
79854685|NCT03041987|Other|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
80018587|NCT04060420|Other|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
80018588|NCT05706337|Drug|Propofol|Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
79257288|NCT03246867|Other|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
79257289|NCT03246867|Other|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
79257290|NCT03578159|Other|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
79257291|NCT03246945|Behavioral|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
79555911|NCT01669070|Drug|FF, 50 mcg|Novel dry powder inhaler
79719440|NCT05748730|Behavioral|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
79719441|NCT05746377|Drug|Metoclopramide 10mg|IV Metoclopramide
79719442|NCT05746377|Drug|Saline|Placebo
79719443|NCT05744180|Other|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
79854686|NCT03039309|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
79854687|NCT03023449|Drug|Nitric Oxide|Inhaled Nitric Oxide gas
79719444|NCT05725798|Drug|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
79854688|NCT03016130|Other|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
79854689|NCT03009331|Procedure|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
79854690|NCT03009331|Procedure|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
79257292|NCT03573869|Procedure|Cryoballoon ablation|Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
79396173|NCT05617326|Other|AAA screening by a GP|The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..
79396174|NCT05617326|Other|AAA screening by a radiologist|General practitioners in the control group will refer their patients to the radiologist for AAA screening.
79719445|NCT05725525|Behavioral|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
79396175|NCT05609032|Behavioral|Sense2Quit App|Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
79719446|NCT05721157|Other|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
79396176|NCT05599594|Other|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
79396177|NCT05598372|Behavioral|shotblocker|infant pain during vaccination and mother anxiety
79555912|NCT01669070|Drug|FF, 100 mcg|Novel dry powder inhaler
79719447|NCT05704296|Procedure|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
79719448|NCT05704296|Procedure|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
79854691|NCT02998918|Dietary Supplement|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
79854692|NCT02998918|Dietary Supplement|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
79854693|NCT02990338|Drug|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
79854694|NCT02990338|Drug|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
79854695|NCT02990338|Drug|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
79854696|NCT02964182|Drug|Cigarette|Smoke usual brand of cigarettes
79257293|NCT03243045|Procedure|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
79257294|NCT03576209|Behavioral|healthy lifestyle program|Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
79854697|NCT02964182|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
79854698|NCT02964182|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
79854699|NCT02964182|Other|Questionnaire Administration|Ancillary studies
79396178|NCT05598372|Behavioral|lullaby|infant pain during vaccination and mother anxiety
79396179|NCT05594836|Behavioral|Infant Calming Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
79396180|NCT05590637|Drug|Pimavanserin|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
79396181|NCT05590637|Drug|Quetiapine|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
79555913|NCT01669070|Drug|FF, 200 mcg|Novel dry powder inhaler
79555914|NCT01669070|Drug|FF, 250 mcg|Intravenous
79555915|NCT01669083|Drug|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
79555916|NCT01669083|Drug|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
79555917|NCT01669083|Drug|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
79719449|NCT05699252|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
79719450|NCT05699252|Behavioral|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
79854700|NCT02964182|Other|Survey Administration|Ancillary studies
79555918|NCT01669083|Drug|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
79555919|NCT01669109|Behavioral|Hatha yoga|
80018589|NCT05706337|Drug|Ciprofol|Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
79396182|NCT05583721|Drug|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
79555920|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|
79555921|NCT01669161|Device|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
79854701|NCT02964182|Drug|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
79854702|NCT02964182|Device|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
79854703|NCT02964182|Device|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
79396183|NCT05583721|Drug|Lexiscan|Given IV prior to PET stress test
79396184|NCT05583721|Diagnostic Test|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
79396185|NCT05579782|Device|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.~Other Name: PTeye Device"
79854704|NCT02950766|Drug|NeoVax|combination of Neoantigen peptides and poly-ICLC
79854705|NCT02950766|Drug|Ipilimumab|local administration of ipilimumab
79854706|NCT02933918|Other|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
79854707|NCT02907983|Drug|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
80018590|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
79396186|NCT05565417|Drug|IMT-009|Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
79396187|NCT05564624|Other|Fasting mimicking diet (FMD)|The ProLon(TM) Fasting Mimicking Diet regimen is a meal replacement plan that mimics water only fasting. It consists of 100% natural ingredients, which are generally regarded as safe (GRAS). It is comprised of bars, soups, and beverages aiming to achieve consistent and effective short-term calorie restriction, while providing adequate micronutrients. The very low protein and very low sugar content are essential characteristics of the diet. Complex carbohydrates and polyunsaturated fatty acids are its main components.
79555922|NCT01669161|Other|Rehab Only|Rehabilitation without device implant and VNS
79555923|NCT01669213|Drug|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
79555924|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
79555925|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
79555926|NCT01669213|Drug|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
79555927|NCT01669226|Drug|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
79555928|NCT01669226|Drug|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
79555929|NCT01669239|Drug|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
79555930|NCT01669252|Drug|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
79555931|NCT01669278|Device|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
79555932|NCT01669291|Drug|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
79719451|NCT05699252|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
79257295|NCT03242811|Diagnostic Test|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
79555933|NCT01669291|Drug|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
79854708|NCT02907983|Drug|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
79555934|NCT01669291|Drug|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
79719452|NCT05688683|Other|use of a theremin-type musical instrument|The patient will perform the task of reproducing sounds by manipulating an object. The settings of the object will be changed and the patient will have to reproduce the sounds a second time by manipulating the object.
79719453|NCT05683964|Drug|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
79719454|NCT05683964|Diagnostic Test|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
79555935|NCT01669304|Drug|Verapamil|
79719455|NCT05678998|Drug|WTX-330|Investigation Product
79257296|NCT03578003|Other|Morning Bright Light Therapy|60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
79555936|NCT01669304|Drug|Sertraline|
79719456|NCT05638802|Drug|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
79257297|NCT03246555|Drug|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
79555937|NCT01669317|Other|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
79555938|NCT01669317|Other|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
79555939|NCT01669330|Procedure|Nissen fundoplication|Laparoscopic Nissen fundoplication
79555940|NCT01669330|Procedure|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
79555941|NCT01669356|Other|Parenteral supplement with enteral nutrition for patients after esophagectomy|
79555942|NCT01669356|Other|Enteral Nutrition alone for patients after esophagectomy|
79555943|NCT01669369|Drug|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
79555944|NCT01669369|Drug|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
79555945|NCT01669382|Device|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
79854709|NCT02892487|Other|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
79854710|NCT02886533|Other|Antithrombotic|Collection of clinical, biological data
79854711|NCT02877303|Biological|Blinatumomab|Given IV
79854712|NCT02877303|Drug|Cyclophosphamide|Given IV
79854713|NCT02877303|Drug|Cytarabine|Given IT and IV
79854714|NCT02877303|Drug|Dexamethasone|Given PO
79719457|NCT05638802|Drug|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
79719458|NCT05637762|Other|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
79719459|NCT05633888|Device|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
79854715|NCT02877303|Drug|Doxorubicin Hydrochloride|Given IV
79854716|NCT02877303|Biological|Inotuzumab Ozogamicin|Given IV
79854717|NCT02877303|Other|Laboratory Biomarker Analysis|Correlative studies
79854718|NCT02877303|Drug|Mercaptopurine|Given PO
79854719|NCT02877303|Drug|Methotrexate|Given IT, IV, and PO
79854720|NCT02877303|Biological|Ofatumumab|Given IV
79854721|NCT02877303|Drug|Prednisone|Given PO
79854722|NCT02877303|Biological|Rituximab|Given IV
79854723|NCT02877303|Drug|Vincristine Sulfate|Given IV
79854724|NCT02875561|Device|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
79719460|NCT05627869|Procedure|Transversus thoracic plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
79719461|NCT05627869|Procedure|Pecto intercostal fascial block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
79719462|NCT05625594|Procedure|Aspiration|Undergo CSF aspiration
79854725|NCT02875561|Device|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
79854726|NCT02850146|Drug|18F-AV-1451|
79555946|NCT01669395|Other|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
79854727|NCT02846571|Biological|Human Pancreatic Islet Transplantation|Human Pancreatic Islet Transplantation in the Eye Anterior Chamber of legally blind Type 1 Diabetic Patients with or without a Stable Prior Kidney Transplant
79257298|NCT03246555|Drug|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
79854728|NCT02837939|Drug|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~3 x TF in first week: day 1,3,5~2 x TF in week 2: day 8 , 11~1 xTF in week 3 and 4 : day 15, 22~1 x TF once a month up to 6 month"
79257299|NCT03576053|Drug|Lidocaine|Lidocaine intradermal injection
79257300|NCT03576053|Other|Histamine|Skin Prick Test with Histamine
79257301|NCT03576053|Other|Cowhage|Manually skin insertion of cowhage spicules
79555947|NCT01669395|Other|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
79555948|NCT01669408|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
79257302|NCT03576053|Other|Heat stimulation|Short heat stimulation
79555949|NCT01669447|Biological|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
79555950|NCT01669460|Other|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
79719463|NCT05625594|Procedure|Biospecimen Collection|Undergo blood sample collection
79257303|NCT03576053|Other|Pre-heating|Mild skin pre-heating
79257304|NCT03576053|Other|Serotonin|Serotonin electrophoresis
79257305|NCT03246711|Behavioral|Fasting|Totally or partially fasting the holy month of ramadan for muslims
79257306|NCT02239991|Procedure|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
79257307|NCT03246633|Other|Perceptual Training|Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
79257308|NCT03242967|Drug|Vadadustat|Oral tablet
79257309|NCT03242967|Drug|Darbepoetin alfa|subcutaneous or intravenous
79719464|NCT05625594|Procedure|Catheterization|Undergo catheterization
79719465|NCT05625594|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given ICV
79719466|NCT05625594|Procedure|Computed Tomography|Undergo CT
79719467|NCT05625594|Drug|Cyclophosphamide|Given IV
79719468|NCT05625594|Drug|Fludarabine|Given IV
79719469|NCT05625594|Procedure|Leukapheresis|Undergo leukapheresis
79719470|NCT05625594|Procedure|Lumbar Puncture|Undergo lumbar puncture
79719471|NCT05625594|Procedure|Magnetic Resonance Imaging|Undergo MRI
79719472|NCT05625594|Procedure|Positron Emission Tomography|Undergo PET
79854729|NCT02837939|Drug|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~3 doses in first week: day 1,3,5~2 doses in week 2: day 8 , 11~1 dose in week 3 and 4 : day 15, 22~1 dose once a month up to 6 month"
79854730|NCT02822378|Dietary Supplement|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
79854731|NCT02822378|Dietary Supplement|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
79854732|NCT02822378|Dietary Supplement|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
79875548|NCT03965351|Drug|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
79854733|NCT02813655|Drug|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
79257310|NCT03573713|Other|Care Groups|The Care Groups model has strong evidence of improvement of maternal and child health and maternal hygiene/nutrition behaviors.Through Care Groups, women will learn about proper water, sanitation, and hygiene behaviors; Infant and Young Child Feeding practices; management of childhood illnesses; home management, referral and care seeking for sick children; family planning; and use of preventive services available at health facilities (e.g., growth monitoring, deworming, vitamin A supplementation). All children under five years of age will also be screened for acute malnutrition by the Care Group Volunteers, and receive deworming medication and vitamin A supplementation twice a year through the Ministry of Health and Community Health Workers as part of national campaigns.
79719473|NCT05622565|Diagnostic Test|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
79719474|NCT05618158|Behavioral|4 Corners Rural Health Cancer Prevention|Participants, aged 18-26, will join a private Facebook group to participate in the intervention. The group is not viewable to the public, including other Facebook users. Content that focuses on cancer prevention behaviors will be posted twice per day for up to 12 months. Each group will be hosted by a moderator who is responsible for managing the intervention goals and participants' engagement.
79719475|NCT05596695|Other|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
79719476|NCT05590975|Behavioral|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
79875549|NCT03965351|Other|Placebo|placebo
79555951|NCT01669473|Other|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~Medication Review: a consolidated list of the medications a patient is currently taking.~Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
79555952|NCT01669486|Other|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
79555953|NCT01669499|Drug|Dexamethasone acetate|
79555954|NCT01669499|Drug|Placebo|
79875550|NCT00947375|Drug|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
79257311|NCT03573713|Behavioral|IPT-G|"IPT-G is an effective, low-cost, short-duration community-based method for decreasing depression has been established that was first rigorously tested in Uganda. Several Private Voluntary Organizations in Africa have used this low-cost, short-duration, community-based group psychosocial approach and found it to be a culturally-sensitive, acceptable, and feasible approach to address depression.~IPT-G treatment spans 12 weeks of treatment, consisting of 3 phases (early, middle, and termination). Within this treatment, participants are also assessed for symptoms of depression every week."
79257312|NCT01367665|Drug|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
79257313|NCT02576847|Drug|Omiganan|Topical gel
79257314|NCT02454621|Behavioral|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
79257315|NCT03107949|Device|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
79257316|NCT03242733|Other|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
79257317|NCT03239379|Drug|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
79257318|NCT03239379|Drug|Placebo|Normal Saline
79396188|NCT05559346|Other|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
79555955|NCT01669512|Biological|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
79555956|NCT01669512|Biological|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
79555957|NCT01669512|Biological|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
79719477|NCT05576636|Behavioral|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
79719478|NCT05576636|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
79719479|NCT05549778|Drug|Polaprezinc group|Abiraterone plus Polaprezinc for 6 months
79854734|NCT02813655|Drug|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
79854735|NCT02742246|Behavioral|Individual clinician-provided CBT|Individual clinician-provided CBT
79257319|NCT03239457|Biological|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
79555958|NCT01669564|Other|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
79257320|NCT04487535|Other|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
79555959|NCT01669564|Other|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
79257321|NCT00075803|Drug|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients > 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients < 12 years, intravenous doses will be prepared.
79257322|NCT00075803|Drug|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients > 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients > 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age < 12 years.
79257323|NCT03242499|Drug|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
79396189|NCT05559346|Other|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
79396190|NCT05544552|Drug|TYRA-300|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
79257324|NCT03242499|Drug|Placebo|placebo for 48 weeks
79555960|NCT01669668|Procedure|radiofrequency ablation|Undergo RFA
79555961|NCT01669668|Procedure|laparoscopy|Undergo laparoscopic ultrasound
79555962|NCT01669694|Other|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
79555963|NCT01669707|Drug|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
79719480|NCT05549778|Drug|Control group|Abiraterone, radio- or chemotherapy
79396191|NCT05534737|Other|MAICP + usual care of social services|The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
79396192|NCT05534737|Other|Control|usual care of social services
79396193|NCT05527990|Device|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
79396194|NCT05520346|Device|Electronic Device for Toilet|Device will be installed on toilet of patients will in hospital to measure all waste output.
79719481|NCT05541796|Device|Intraocular lens|"Tecnis Symfony Optiblue (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles."
79719482|NCT05535933|Drug|HMPL-523(300mg PO QD)|No more than two doses will be explored
79719483|NCT05535933|Drug|Placebo|Placebo
79854736|NCT02742246|Behavioral|CBT4CBT|CBT computer program assisted therapy
79854737|NCT02733042|Drug|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
79854738|NCT02733042|Drug|Lenalidomide|Administered orally
79854739|NCT02733042|Drug|Rituximab|Administered by intravenous infusion
79854740|NCT02733042|Drug|Ibrutinib|Administered orally
79854741|NCT02733042|Drug|Bendamustine|Administered as a 30-minute intravenous infusion
79854742|NCT02725619|Behavioral|CBT|
79854743|NCT02725619|Behavioral|PST|
79854744|NCT02723721|Drug|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
79854745|NCT02709278|Biological|BCG|BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
79854746|NCT02709278|Other|Saline placebo|Saline placebo
79555964|NCT01669707|Drug|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
79555965|NCT01669733|Other|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
79854747|NCT02709278|Biological|BCG|BCG Bulgaria (InterVax)
79854748|NCT02704416|Procedure|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
79555966|NCT01669733|Other|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
79854749|NCT02690402|Behavioral|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
79854750|NCT02689427|Procedure|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
79854751|NCT02689427|Drug|Enzalutamide|Given PO
79257325|NCT03254979|Behavioral|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
79257326|NCT02523911|Drug|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
79555967|NCT01669746|Biological|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
79555968|NCT01669772|Drug|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
79555969|NCT01669772|Drug|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
79719484|NCT05513924|Drug|Latanoprost 0.005% Ophthalmic Solution|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months."
79854752|NCT02689427|Other|Laboratory Biomarker Analysis|Correlative studies
79854753|NCT02689427|Procedure|Lymph Node Biopsy|Undergo lymph node biopsy
79854754|NCT02689427|Drug|Paclitaxel|Given IV
79854755|NCT02689427|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
79854756|NCT02686528|Other|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
79854757|NCT02686528|Other|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
79854758|NCT02673931|Drug|Byetta (Lilly, Exenatide)|See description of arms
79854759|NCT02673931|Drug|Conoxia (AGA, oxygen)|See description arms
79854760|NCT02673931|Drug|20% Human Albumin|
79854761|NCT02663297|Drug|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2 (maximum dose 5x10^7 cells)~Group Two, 1x10^8 cells/m^2 (maximum dose 2.5x10^8 cells)~Group Three, 2x10^8 cells/m^2 (maximum dose 5x10^8 cells)"
79854762|NCT02654561|Drug|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
79854763|NCT02654561|Drug|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
79555970|NCT01669837|Device|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
79854764|NCT02614066|Biological|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
79257327|NCT02523911|Drug|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
79257328|NCT02523911|Drug|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
79555971|NCT01669850|Device|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
79854765|NCT02614066|Drug|Cyclophosphamide|Administered intravenously.
79854766|NCT02614066|Drug|Fludarabine|Administered intravenously.
79854767|NCT02600949|Drug|Imiquimod|Applied topically
79257329|NCT03239223|Drug|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
79257330|NCT03573635|Device|Supratube|Aspiration of orotracheal secretions with supratube device
79257331|NCT03573635|Other|Reference|Usual aspiration with any other device
79257332|NCT03573479|Other|PICU Liber8 Bundle|Bundle of elements for quality improvement
79257333|NCT03575741|Diagnostic Test|Balance Tests|"Following balance exercises will be performed by the participants:~Bipedal, hip wide stand, eyes open and hands on hips, 60sec~Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~One-leg-stand, eyes open, hands on hips, 30sec (other leg)~Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
79555972|NCT01669850|Procedure|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
79396195|NCT05497050|Behavioral|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
79257334|NCT03575663|Diagnostic Test|Indirect bronchial challenge|Mannitol dry powder inhalation
79257335|NCT03575663|Other|Sham bronchial challenge|Mock dry powder inhalation
79854768|NCT02600949|Biological|Pembrolizumab|Given IV
79854769|NCT02600949|Biological|Sotigalimab|Given IV
79257336|NCT03572231|Drug|mirabegron|oral
79257337|NCT03572231|Device|solifenacin|oral
79257338|NCT03572231|Drug|darifenacin|oral
79257339|NCT03572231|Drug|imidafenacin|oral
79396196|NCT05495828|Drug|Orelabrutinib|Orelabrutinib, 150mg, po, qd
79555973|NCT01669876|Dietary Supplement|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
79555974|NCT01669876|Dietary Supplement|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
79555975|NCT01669941|Drug|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
79555976|NCT01669941|Drug|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
79555977|NCT01669941|Drug|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
79555978|NCT01669967|Drug|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
79854770|NCT02600949|Biological|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
79854771|NCT02600949|Procedure|Computed Tomography|Undergo CT
79854772|NCT02600949|Procedure|Magnetic Resonance Imaging|Undergo MRI
79854773|NCT02599324|Drug|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
79854774|NCT02599324|Drug|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
79854775|NCT02599324|Drug|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m^2, once weekly, in continual 3 weekly cycles.
79854776|NCT02599324|Drug|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m^2 (according to local institutional standard of care), given continually in 21-day cycles.
79257340|NCT03572231|Drug|tolterodine|oral
79257341|NCT03572231|Drug|oxybutynin|oral
79555979|NCT01669967|Drug|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
80018591|NCT01613560|Drug|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
79555980|NCT01670149|Drug|Rifaximin|Tablets
79555981|NCT01670149|Drug|Placebo|Tablets
79555982|NCT01670370|Drug|R-GemOx|Rituximab Gemcitabine Oxaliplatin
79555983|NCT01670552|Drug|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
79555984|NCT01670552|Drug|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
79555985|NCT01670578|Biological|PRP|
79555986|NCT01670578|Device|Hyaluronic acid|
79555987|NCT01670604|Drug|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
79555988|NCT01670604|Drug|Tetraspan, B. Braun, Melsungen, Germany|
79555989|NCT01670617|Other|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
79555990|NCT01670812|Drug|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
79555991|NCT01670916|Dietary Supplement|probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
79555992|NCT01671241|Device|Polyethylene wrap|
79555993|NCT01671241|Device|Polyethylene wrap|
79555994|NCT01671267|Behavioral|Strength training|
79555995|NCT01671267|Behavioral|Ergonomic|
79257342|NCT03572231|Drug|trospium|oral
79257343|NCT03572231|Drug|fesoterodine|oral
79257344|NCT03572231|Device|propiverine|oral
79257345|NCT02135029|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
79555996|NCT01671371|Other|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
79555997|NCT01671449|Drug|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
79257346|NCT02135029|Drug|Atorvastatin|Atorvastatin PO QD
79257347|NCT02135029|Other|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
79555998|NCT01671449|Drug|Cisplatin|60 mg/m2/day Day 1
79555999|NCT01671449|Drug|Oxaliplatin|130 mg/m2/day Day 1
79556000|NCT01671462|Device|BD HPV assay on Viper LT|
79556001|NCT01671475|Device|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
79556002|NCT01671501|Behavioral|Motivational Interviewing|
79556003|NCT01671501|Behavioral|Email Feedback|
79257348|NCT02135029|Other|Placebo for atorvastatin|PO QD
79257349|NCT03575585|Behavioral|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
79556004|NCT01671501|Other|Usual Care|
79556005|NCT01669187|Other|Education brochure|
79556006|NCT01669187|Other|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
79556007|NCT01671800|Drug|Botulinum Type B|
80018592|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
79396197|NCT05491044|Drug|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
79396198|NCT05483088|Diagnostic Test|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
79556008|NCT01671800|Drug|Placebo|
79556009|NCT01671917|Other|Educational and exercise program|"4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~4 (twice a week) sessions of an exercise programme lasting 1 hour"
79556010|NCT01671917|Other|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
79556011|NCT01671995|Procedure|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
79556012|NCT01671995|Procedure|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
79556013|NCT01672359|Dietary Supplement|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
79556014|NCT01672359|Dietary Supplement|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
79556015|NCT01672359|Dietary Supplement|Placebo|
80018593|NCT05222113|Drug|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
79719485|NCT05513924|Drug|5Fluorouracil|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months."
79556016|NCT01672437|Other|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
79719486|NCT05502562|Drug|Oral semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
79719487|NCT05496062|Device|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
79719488|NCT05470205|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
79719489|NCT05470205|Drug|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
79719490|NCT05463835|Dietary Supplement|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
79719491|NCT05463835|Dietary Supplement|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
79719492|NCT05463835|Dietary Supplement|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
79556017|NCT01672541|Behavioral|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
79257350|NCT03575585|Behavioral|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
79257351|NCT03575585|Behavioral|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
79556018|NCT01672541|Behavioral|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
79556019|NCT01672645|Biological|NIC7-001|Intramuscular, multiple dose
79719493|NCT05451979|Device|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
79719494|NCT05447416|Device|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
79719495|NCT05447416|Device|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
79719496|NCT05444777|Drug|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
79719497|NCT05433961|Drug|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
79719498|NCT05429411|Other|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach >21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
79257352|NCT03575585|Behavioral|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
79556020|NCT01672645|Biological|NIC7-003|Intramuscular, multiple dose
79556021|NCT01672645|Biological|Saline|Saline (0.9% sodium chloride)
79719499|NCT05423613|Procedure|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
79257353|NCT03575507|Device|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
79257354|NCT03573245|Drug|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
79257355|NCT02241161|Other|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
79257356|NCT02241161|Other|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
79257357|NCT02241161|Other|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
79556022|NCT01673035|Behavioral|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
79556023|NCT01673035|Behavioral|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
79556024|NCT01673165|Other|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
79719500|NCT05421130|Device|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
79719501|NCT05410821|Drug|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
79719502|NCT05410821|Drug|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
79719503|NCT05410821|Drug|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
79719504|NCT05410743|Drug|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
79719505|NCT05410743|Drug|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
79719506|NCT05410743|Drug|177Lu-LNC1010 3|The patients were intravenously injected with single dose 5.18GBq (140 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
79719507|NCT05408546|Drug|TS23|Monoclonal antibody to a2-antiplasmin
79719508|NCT05408546|Drug|Placebo|Placebo
80018594|NCT03854578|Drug|BI 1358894|Film-coated tablet
79257358|NCT02135185|Other|custom work endurance|Experimental: Rehabilitation effort
79257359|NCT02135185|Behavioral|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
79257360|NCT03573167|Behavioral|In-Person Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.
79257361|NCT03573167|Behavioral|Mobile Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
79257362|NCT02240147|Behavioral|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
79257363|NCT02135263|Drug|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
79257364|NCT02135263|Drug|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
79257365|NCT03572075|Diagnostic Test|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
79257366|NCT03572075|Procedure|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
79257367|NCT03572075|Procedure|standard care protocol|the treatment is the same as usual in our center
79556025|NCT01673165|Other|Specialized Formula|Infants will receive our standard of care - specialized formula
79556026|NCT01673308|Drug|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
79556027|NCT01673503|Device|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
79556028|NCT01673516|Procedure|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
79556029|NCT01673516|Device|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
79556030|NCT01673737|Drug|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
79719509|NCT05402579|Genetic|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
79719510|NCT05388526|Other|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
79719511|NCT05384431|Dietary Supplement|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
79556031|NCT01673737|Drug|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
79854777|NCT02599324|Drug|cetuximab|Cetuximab 400 mg/m^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m^2 infused over 60 minutes.
79257368|NCT03572075|Diagnostic Test|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
79257369|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
79257370|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
79257371|NCT03573011|Diagnostic Test|[18F]PSMA-11|18F-PET imaging
79257372|NCT03572855|Combination Product|Scoliosis Brace|Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
79257373|NCT03549637|Diagnostic Test|Psychiatric population|Genetic and biological analysis of patients
79257374|NCT02137135|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
79719512|NCT05384431|Other|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
79719513|NCT05355168|Procedure|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
79719514|NCT05352542|Biological|LCAR-H93T Cells|before treatment with LCAR-H93T cells, subjects will receive a conditioning regimen
79854778|NCT02599324|Drug|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
79854779|NCT02586831|Drug|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
79854780|NCT02586831|Drug|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
79257375|NCT02137135|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
79257376|NCT02137135|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
79556032|NCT01673815|Other|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
79257377|NCT03575273|Behavioral|Sniffin' Sticks Odor Identification and Hedonic Scale|This task measures odor identification accuracy and perceived pleasantness of odors.
79257378|NCT03575273|Behavioral|Sucrose Taste Preference Assessment|This task measures participant ratings of sucrose preference.
79257379|NCT03575273|Behavioral|Food Preferences Task|Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
79257380|NCT03575273|Behavioral|Progressive Ratio (PR) Task|In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
79257381|NCT03575273|Procedure|Clinical Electrophysiology|To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
79257382|NCT03575273|Dietary Supplement|Standardized Meal and Hunger and Satiety Ratings|Participants will receive a standardized meal and complete hunger and satiety ratings.
79257383|NCT02129335|Other|stress|stress level and survival
79556033|NCT01674114|Procedure|TAP block|
79556034|NCT01674114|Procedure|control|
79556035|NCT01674153|Procedure|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
79719515|NCT05342337|Other|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
79719516|NCT05342337|Other|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
79719517|NCT05340868|Drug|Semaglutide Pill|Oral semaglutide treatment
79854781|NCT02586831|Drug|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
79854782|NCT02586831|Drug|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
79854783|NCT02586831|Other|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
79854784|NCT02586831|Other|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
79854785|NCT02586831|Other|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
79854786|NCT02586831|Other|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
79854787|NCT02504866|Other|Vigorous exercise|Exercise training of vigorous intensity
79854788|NCT02504866|Other|Light to moderate exercise|Exercise training of light to moderate intensity
79854789|NCT02502162|Drug|LDN|
79257384|NCT02239523|Procedure|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
79556036|NCT01674335|Behavioral|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
79556037|NCT01674335|Behavioral|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
79556038|NCT01674426|Behavioral|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
79556039|NCT01674439|Procedure|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
79556040|NCT01674439|Procedure|Without supplementation of ADRC|Standard fat graft preparation
79556041|NCT01674556|Drug|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
79556042|NCT01674595|Biological|AVANZ olea|Immunotherapy Olea europaea
79556043|NCT01675115|Drug|BNG-1|BNG-1 3 grams TID for 4 weeks
79556044|NCT01675115|Drug|Aspirin|Aspirin 100 mg QD for 4 weeks
79556045|NCT01675271|Other|individual exercise|individual exercise and dietary prescription
79257385|NCT02239523|Procedure|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
79257386|NCT02253043|Device|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
79556046|NCT01675271|Other|general exercise|general exercise counselling
79556047|NCT01675310|Drug|medical nutrition therapy + metformin|
79556048|NCT01675310|Behavioral|Medical nutrition therapy|medical nutrition therapy
79556049|NCT01675401|Other|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
79556050|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
79556051|NCT01675674|Other|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
79257387|NCT03575117|Behavioral|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
79257388|NCT03575117|Behavioral|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
79556052|NCT01675713|Behavioral|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
79556053|NCT01676103|Dietary Supplement|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
79556054|NCT01676103|Other|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
79556055|NCT01676649|Biological|Ipilimumab|3 mg/kg
79556056|NCT01676649|Drug|Carboplatin|AUC = 6
79719518|NCT05330130|Drug|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
79854790|NCT02502162|Drug|Placebo|Sugar pill
79875551|NCT00947375|Drug|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
79556057|NCT01676649|Drug|Paclitaxel|175 mg/m2
79556058|NCT01676883|Device|Bioelectric impedance|removal of calluses and corns by pedicure
79556059|NCT01676883|Device|Air displacement plethysmography|
79556060|NCT01676987|Drug|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
79556061|NCT01676987|Drug|Budesonide|Delivered dry powder inhaler for 12 weeks.
79556062|NCT01677039|Drug|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
79556063|NCT01677039|Drug|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
79556064|NCT01677039|Drug|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
79556065|NCT01677065|Drug|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
79556066|NCT01677065|Drug|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
80018595|NCT03854578|Drug|Placebo matching BI 1358894|Film-coated tablet
79556067|NCT01677247|Drug|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
79556068|NCT01677247|Drug|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
79556069|NCT01677260|Drug|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
79556070|NCT01677260|Drug|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
79556071|NCT01677572|Drug|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
79556072|NCT01677572|Drug|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
79556073|NCT01677650|Drug|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
79556074|NCT01678053|Drug|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
80018596|NCT03854578|Drug|Citalopram|Film-coated tablet
80018597|NCT03550014|Procedure|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
80018598|NCT03550014|Procedure|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
79556075|NCT01678053|Drug|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
79556076|NCT01678326|Procedure|EUS-Rendezvous or direct intervention|
80018599|NCT03627325|Other|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
79257389|NCT03575117|Behavioral|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
79257390|NCT02129413|Device|Delta system|
79556077|NCT01678326|Procedure|Advanced ERCP Biliary Access Techniques|
79257391|NCT03575039|Device|VitaFlow II Transcatheter Aortic Valve System|VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
79556078|NCT01678391|Procedure|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
79719519|NCT05330130|Drug|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
80018600|NCT03038594|Drug|Somatropin|
80018601|NCT03038594|Drug|0.09% Saline Solution|
80018602|NCT05138302|Other|Observation|This study is an observe research
80018603|NCT05222035|Drug|Camrelizumab|PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
80018604|NCT05222035|Drug|G-CSF|G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
80018605|NCT02136888|Drug|Ponesimod Placebo|
80018606|NCT02136888|Drug|Moxifloxacin Placebo|
80018607|NCT02136888|Drug|Ponesimod 10 mg|
80018608|NCT02136888|Drug|Ponesimod 20 mg|
80018609|NCT02136888|Drug|Ponesimod 40 mg|
80018610|NCT02136888|Drug|Ponesimod 60 mg|
80018611|NCT02136888|Drug|Ponesimod 80 mg|
80018612|NCT02136888|Drug|Ponesimod 100 mg|
80018613|NCT02136888|Drug|Moxifloxacin 400 mg|
80018614|NCT04465994|Procedure|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
79257392|NCT02137213|Drug|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
79257393|NCT02137213|Drug|Placebo|Normal saline will be added to oral methadone preparations as placebo.
79556079|NCT01678937|Procedure|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
79556080|NCT01678937|Procedure|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
79556081|NCT01678937|Procedure|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
79556082|NCT01678937|Procedure|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
79556083|NCT01678937|Procedure|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
79556084|NCT01678937|Procedure|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
79556085|NCT01679041|Drug|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
79556086|NCT01679041|Drug|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
79556087|NCT01679041|Drug|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
79556088|NCT01679093|Drug|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
79556089|NCT01679093|Drug|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
79556090|NCT01679093|Drug|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
79556091|NCT01679210|Behavioral|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
80018615|NCT05488951|Other|Otago Exercise Program|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
80018616|NCT02128776|Other|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
80018617|NCT02128776|Other|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
80018618|NCT02132286|Drug|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
79257394|NCT03574961|Behavioral|e-Support group|Online (remote), web-based support group via private video link.
79257395|NCT03574961|Behavioral|e-Journaling placebo|Online journaling activity.
79257396|NCT03571919|Drug|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
79257397|NCT03571919|Drug|Saline infusion|Intravenous bolus of saline and then infusion
79257398|NCT02135575|Behavioral|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
79556092|NCT01679418|Device|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
79556093|NCT01679418|Other|No-drain after surgery|After surgery, no drain was put
79556094|NCT01679431|Diagnostic Test|Doppler-echocardiography|
79556095|NCT01679431|Radiation|Computed tomography|
79556096|NCT01679431|Other|Magnetic resonance imaging|
79556097|NCT01679431|Biological|Fasting blood sample|
79556098|NCT01679496|Other|Food items|Food items with different fatty acid composition
79556099|NCT01679587|Drug|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
79556100|NCT01679587|Drug|Placebo|Single oral dose of matching placebo will be given in each treatment arm
79556101|NCT01679743|Drug|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
79875552|NCT00942695|Other|1.5PD|average American diet plus 1.5 oz per day pistachios
79875553|NCT00942695|Other|3.0PD|average American diet plus 3.0 oz per day pistachios
79875554|NCT00942695|Other|control|average American diet without pistachios
79875555|NCT00947453|Drug|montelukast|montelukast 10 mg once daily for 8 weeks
79257399|NCT03570671|Diagnostic Test|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~Diffuse small diameter (< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
79257400|NCT03570671|Diagnostic Test|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
79396199|NCT05478213|Device|Monophasic Action Potential (MAP) Catheter|The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
79396200|NCT05466487|Device|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
80018619|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
80018620|NCT03627169|Device|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
79257401|NCT02252809|Drug|adalimumab|
79257402|NCT02252809|Drug|methylprednisolone|
79556102|NCT01679743|Drug|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
79719520|NCT05326711|Behavioral|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
79719521|NCT05323981|Drug|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
79719522|NCT05323981|Drug|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
79719523|NCT05323981|Drug|Perjeta|Intravenous drip of 420mg PERJETA
79719524|NCT05319860|Drug|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
79257403|NCT03571685|Behavioral|Sustainable Early Episode Clinic Model of Care|The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
79257404|NCT03570593|Procedure|REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY|Removal of urinary catheter on the first day after radical surgery
79257405|NCT02137525|Drug|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
79396201|NCT05466487|Behavioral|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, & Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
79396202|NCT05457959|Biological|Dendritic Cell Tumor Peptide Vaccine|Given ID
79396203|NCT05457959|Biological|Ipilimumab|Given IV
79396204|NCT05457959|Procedure|Leukapheresis|Undergo leukapheresis
79556103|NCT01679977|Device|Vibrational-proprioceptive Resistance Exercise Training|
79556104|NCT01679977|Device|Neuromuscular Electrical Stimulation Training|
79556105|NCT01680094|Drug|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
79556106|NCT01680120|Procedure|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
79556107|NCT01680198|Drug|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
79556108|NCT01680198|Drug|placebo|
80018621|NCT01673698|Device|ReShape Duo balloon|
80018622|NCT01673698|Other|Diet counseling|
80018623|NCT01673698|Other|Exercise counseling|
80018624|NCT05706103|Behavioral|Specific skilled motor training|Participants allocated to the skilled motor training group will receive sensorimotor training of the intrinsic muscles of the lumbopelvic region, namely the multifidus, transversus abdominis, and pelvic floor muscles.
80018625|NCT05706103|Behavioral|General extension training|Participants allocated to the general extension training group will receive general training exercises using the David Back equipment from the Back Unit at Ghent University Hospital
80031522|NCT04889170|Other|Intervention|"Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software"
79854791|NCT02497677|Behavioral|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
79257406|NCT02137525|Drug|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
79556109|NCT01680224|Behavioral|Healthy Weight|
79556110|NCT01680224|Behavioral|Project Health|
79556111|NCT01680224|Behavioral|Placebo Control|Participants will view a video on overweight and obesity
79556112|NCT01680289|Procedure|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
79556113|NCT01680289|Procedure|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
79556114|NCT01680315|Behavioral|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
79556115|NCT01680315|Behavioral|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
79556116|NCT05597215|Radiation|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
79257407|NCT02137525|Drug|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
79257408|NCT02137525|Drug|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
79556117|NCT05597111|Diagnostic Test|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
79556118|NCT05597072|Behavioral|Intervention|Less people within the OR but longer waiting time.
79556119|NCT05597072|Behavioral|Control|More people in the OR but shorter waiting time
79556120|NCT05596981|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
79556121|NCT05596968|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
79719525|NCT05319860|Drug|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
79719526|NCT05311475|Drug|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
79719527|NCT05311475|Drug|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
79719528|NCT05311475|Drug|Placebo|Placebo nasal spray
79257409|NCT02137525|Drug|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
79257410|NCT02137525|Drug|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
79257411|NCT02842151|Procedure|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
79257412|NCT02842151|Device|ACRYSOF® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
79257413|NCT02842151|Device|Topcon® KR-1W Wave-Front Analyzer|Wavefront and topography system used to obtain autorefraction data
79257414|NCT02135731|Other|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
79719529|NCT05311176|Biological|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
79719530|NCT05311176|Drug|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
79719531|NCT05311176|Biological|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
79854792|NCT02497677|Behavioral|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
79854793|NCT02494115|Procedure|subcutaneous drainage|
79257415|NCT02244593|Other|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
79396205|NCT05457959|Biological|Nivolumab|Given IV
79396206|NCT05457959|Drug|Placebo Administration|Given ID
79396207|NCT05457959|Drug|Placebo Administration|Given IV
79396208|NCT05457959|Drug|Poly ICLC|Given IM
79396209|NCT05457959|Procedure|Resection|Undergo standard of care surgical resection
79396210|NCT05456529|Drug|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
79396211|NCT05453396|Biological|Loncastuximab Tesirine|Given IV
79396212|NCT05451654|Drug|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
79719532|NCT05309226|Other|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
79854794|NCT02459769|Behavioral|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
79854795|NCT02434744|Drug|KD026|Dosed in combination
79854796|NCT02434744|Drug|Placebo|Dosed in combination
79854797|NCT02434744|Drug|Metformin|Drug prescribed by each subject's prescribing physician
79854798|NCT02432417|Drug|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
79257416|NCT02135809|Device|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
79854799|NCT02390895|Procedure|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
79257417|NCT02137681|Drug|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
79257418|NCT02842073|Drug|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
79257419|NCT02842073|Drug|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
79257420|NCT02135887|Drug|MB-6|6# TID with meal
79257421|NCT02135887|Drug|Placebo|6# TID with meal
79257422|NCT03572777|Drug|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
79257423|NCT03572777|Drug|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
79257424|NCT03572777|Drug|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
79854807|NCT02369016|Drug|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
79257425|NCT03572777|Drug|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
79719533|NCT05294549|Other|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
79854808|NCT02363959|Drug|Hyperbaric Oxygen Therapy|2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
79257426|NCT03572777|Drug|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
79257427|NCT03572777|Drug|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
79257428|NCT03572777|Drug|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
79257429|NCT03572777|Drug|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
79257430|NCT02253277|Drug|Nilotinib|Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
79719534|NCT05292781|Other|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
79854809|NCT02363959|Procedure|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
79854810|NCT02317887|Biological|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
79854811|NCT02316886|Device|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
79854812|NCT02316886|Drug|Optimal Medical treatment|
79854813|NCT02316314|Procedure|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
79854814|NCT02316314|Procedure|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
79854815|NCT02316314|Procedure|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
80031523|NCT04526912|Drug|VIB7734|Single subcutaneous dose
80031524|NCT04526912|Drug|Placebo|Intravenous single dose matched to VIB7734.
79719535|NCT05292781|Other|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
79854816|NCT02316314|Procedure|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
79854817|NCT02288221|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~aromatherapy~music therapy~cognitive training in multimedia application offering cognitive games"
79854818|NCT02288221|Other|Patient's answer without non pharmacological therapeutic|No installation at patient's home
79854819|NCT02276573|Biological|buccal cavity sample|
79854820|NCT02252237|Biological|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
79854821|NCT02250352|Other|cytology specimen collection procedure|Correlative studies
79854822|NCT02239783|Device|total hip arthroplasty implant|
79854823|NCT02238301|Other|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
79854824|NCT02238301|Other|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
79396213|NCT05451654|Drug|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
79396214|NCT05442866|Device|Virtual reality experience for 10 minutes|Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
79556122|NCT05596942|Dietary Supplement|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
79854825|NCT02231723|Drug|BBI608|Administered continuously twice daily with doses separated by 12 hours
79854826|NCT02231723|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
79854827|NCT02231723|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
79257431|NCT02253277|Drug|Ruxolitinib|Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
79257432|NCT03572699|Other|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
79257433|NCT02129569|Other|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
79257434|NCT02129569|Behavioral|behavioral intervention|Receive individualized walking prescription and wear pedometer
79257435|NCT02129569|Other|counseling intervention|Receive supplemental counseling support over the phone
79257436|NCT02129569|Other|educational intervention|Receive NCI educational booklets and a link to the ACS website
79556123|NCT05596890|Drug|Paclitaxel-albumin|260mg/m2, ivdrip, d1
79556124|NCT05596890|Drug|Cisplatin|60mg/m2, ivdrip, d1
79556125|NCT05596890|Drug|Carboplatin|AUC=4-6, ivdrip, d1
79556126|NCT05596890|Drug|Tislelizumab|200mg, ivdrip, d1
79556127|NCT05596890|Radiation|VMAT or IMRT|15Gy/5F (d43-d50, d57-d64), 5 times a week
79556128|NCT05596890|Procedure|Esophagectomy|Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
79556129|NCT05596864|Diagnostic Test|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
79556130|NCT05596812|Other|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
79854828|NCT02231723|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
79854829|NCT02231723|Drug|Leucovorin|Arm C, D: Leucovorin 400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
79257437|NCT02129569|Other|telephone-based intervention|Receive calls that are primarily social in nature
79257438|NCT02129569|Other|questionnaire administration|Ancillary studies
79257439|NCT02129569|Other|quality-of-life assessment|Ancillary studies
79556131|NCT05596669|Drug|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
79556132|NCT05596643|Diagnostic Test|Composite Autonomic Symptom Score-31|Standardized questionnaire to determine the level of autonomic dysfunction
79556133|NCT05596643|Diagnostic Test|r-r interval variability with normal breathing|electrophysiological test to detect parasympathetic dysfunction
79556134|NCT05596643|Diagnostic Test|r-r interval variability with deep breathing|electrophysiological test to detect parasympathetic dysfunction
79556135|NCT05596643|Diagnostic Test|Valsalva ratio|electrophysiological test to detect parasympathetic dysfunction
79556136|NCT05596643|Diagnostic Test|30:15 ratio|electrophysiological test to detect parasympathetic dysfunction
79556137|NCT05596643|Diagnostic Test|sympathetic skin response|electrophysiological test to detect sympathetic dysfunction
79556138|NCT05596643|Diagnostic Test|blood pressure response to standing|clinical test to detect sympathetic dysfunction
79556139|NCT05596643|Diagnostic Test|blood pressure response to sustained handgrip test|clinical test to detect sympathetic dysfunction
79257440|NCT02524067|Behavioral|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
79556140|NCT05596643|Other|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
79556141|NCT05596643|Diagnostic Test|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
79854830|NCT02231723|Drug|Irinotecan|Arm B: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
79854831|NCT02231723|Drug|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m^2 I.V. bolus followed by 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
79854832|NCT02231723|Drug|MM-398|MM-398 70 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
79257441|NCT02137915|Biological|Human Central Nervous System Stem Cells|
79556142|NCT05596643|Other|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
79854833|NCT02199145|Procedure|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
79854834|NCT02198404|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
80031525|NCT04884646|Other|VR with Routine physical therapy and Virtual reality|VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
79257442|NCT03571529|Device|EMG-driven exoskeleton hand robot|"Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~Action Research Arm Test~Motor Activity Log~Data from force and EMG measurement records of HOH robot~Grip strength (with hand dynamometer)~Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~Manuel muscle testing for wrist and finger muscles.~Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record."
79257443|NCT03571529|Other|Conventional physiotherapy|"Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~Action Research Arm Test~Motor Activity Log~Data from force and EMG measurement records of HOH robot~Grip strength (with hand dynamometer)~Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~Manuel muscle testing for wrist and finger muscles.~Modify Asworth sclale"
79257444|NCT05579353|Other|nothing|nothing
79257445|NCT02137993|Drug|A-prexa|A-prexa 5-20 mg for 6 weeks
79257446|NCT02137993|Drug|Zyprexa|Zyprexa 5-20 mg for 6 weeks
79257447|NCT03571373|Other|No intervention|No intervention due to the observational set-up of this study.
79556143|NCT05596643|Other|Jenkins Sleep Evaluation Scale|Standardized questionnaire to investigate the sleep quality and disturbance
79556144|NCT05596643|Other|The Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue severity
79556145|NCT05596617|Drug|Oral bedtime melatonin|Different doses of oral bedtime melatonin
79556146|NCT05596604|Other|survey- no intervention|survey- no intervention
79556147|NCT05596565|Other|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
79556148|NCT05596552|Drug|hyperbaric bupivacaine and dexmedetomidine|In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
79854835|NCT02150889|Behavioral|Running Program|16 week supervised running program
79257448|NCT02253355|Device|Deep Brain Stimulation|
79257449|NCT03571295|Device|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
79257450|NCT03571295|Device|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
79257451|NCT03262259|Behavioral|GSDG multi-component intervention|Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
79719536|NCT05292599|Other|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
79719537|NCT05292599|Other|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
79556149|NCT05596552|Drug|Bupivacaine-Fentanyl group|In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
79556150|NCT05596539|Other|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
79556151|NCT05596526|Biological|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
79854836|NCT02150889|Behavioral|Yoga Program|once weekly supervised yoga
79396215|NCT05442606|Other|Ultrasound Therapy|Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses
79556152|NCT05596500|Dietary Supplement|Blueberry-protein gel|Sport gel with blueberry extract and plant protein.
79556153|NCT05596500|Dietary Supplement|Blueberry gel|Sport gel with blueberry extract only.
79556154|NCT05596500|Dietary Supplement|Placebo|Sport gel without the blueberry extract polyphenols and without protein.
79556155|NCT05596487|Other|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
79556156|NCT05596448|Procedure|Coccygeal nerve radiofrequency ablation|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
79719538|NCT05289492|Drug|EOS884448|EOS884448 will be administered in arm A,B and C
79719539|NCT05289492|Drug|Iberdomide|Iberdomide will be administered in arm B and C
79556157|NCT05596435|Other|No intervention|No intervention
79854837|NCT02131597|Drug|Guadecitabine|Given SC
79556158|NCT05596396|Behavioral|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
79854838|NCT02108054|Device|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
79556159|NCT05596396|Behavioral|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
79556160|NCT05596305|Behavioral|educational psychiatry intervention|educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
79854839|NCT02104349|Behavioral|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
79556161|NCT05596279|Diagnostic Test|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
79556162|NCT05596279|Diagnostic Test|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
79556163|NCT05596266|Biological|CD5 CAR-T|CD5 CAR-T will be administered by I.V. infusion.
79556164|NCT05596227|Drug|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
79556165|NCT05596227|Drug|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
79719540|NCT05289492|Drug|Dexamethasone|Dexamethasone will be administered in arm C
79719541|NCT05255666|Drug|Pembrolizumab|400 mg intravenously
79719542|NCT05255666|Drug|Liposomal Irinotecan|Starting at 50 mg/m^2. The dose may be increased to 70 mg/m^2 if tolerated or dose reduced to 35 mg/m^ if treatment-emergent severe adverse event (TESAE) occurs.
79854840|NCT01969968|Other|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
79854841|NCT01965184|Behavioral|Cognitive-Behavioral Therapy for Anger and Aggression|
79854842|NCT01965184|Behavioral|Supportive Psychotherapy (SPT)|
79854843|NCT01931709|Radiation|fludeoxyglucose F 18|Undergo FDG PET
79854844|NCT01931709|Device|positron emission tomography|Undergo FDG PET
79556166|NCT05596227|Drug|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
79854845|NCT01931709|Device|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
79854846|NCT01931709|Other|laboratory biomarker analysis|Correlative studies
79854847|NCT01834755|Other|Evaluation of psychological phenotype|
79854848|NCT01806129|Other|Standard practice related to reproductive heath|Patients undergo usual standard practice related to reproductive health.
79854849|NCT01806129|Other|Training modules, algorithm, referral development|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
79854850|NCT01774240|Other|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
79854851|NCT01765218|Drug|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
79396216|NCT05442606|Other|Manual Drainage Techniques|Manual Drainage Techniques for the frontal and maxillary sinuses
79854852|NCT01765218|Drug|Placebo|A placebo identical in appearance to the active agent (topiramate)
79854853|NCT01756040|Drug|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
79854854|NCT01701284|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
79854855|NCT01698892|Drug|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
79854856|NCT01698892|Drug|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
79854857|NCT01685541|Other|Maximum After Visit Summary Content|
79854858|NCT01685541|Other|Intermediate After Visit Summary Content|
79854859|NCT01685541|Other|Minimum After Visit Summary Content|
79854860|NCT01685541|Other|Usual AVS|
79854861|NCT01631851|Behavioral|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
79854862|NCT01550861|Procedure|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
79396217|NCT05442606|Other|Self Sinus Massage Technique|Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
79396218|NCT05431855|Behavioral|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
79556167|NCT05596227|Drug|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
79556168|NCT05596227|Other|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
79556169|NCT05596227|Other|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
79556170|NCT05596149|Other|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
79556171|NCT05596149|Other|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
79556172|NCT05596149|Other|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
80031526|NCT04884646|Other|Motor Imagery with Routine physical therapy|MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
79719543|NCT05255146|Device|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
79719544|NCT05247541|Drug|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
79556173|NCT05596149|Other|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
79556174|NCT05596136|Diagnostic Test|Artery Alert|A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment
79719545|NCT05199259|Diagnostic Test|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
79719546|NCT05198609|Procedure|FOLFOX-HAIC|Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
79719547|NCT05198609|Drug|Camrelizumab|Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
79719548|NCT05198609|Drug|Apatinib|Apatinib was administered orally 250mg once per day
79719549|NCT05191004|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
79719550|NCT05191004|Drug|Fulvestrant|Fulvestrant
79719551|NCT05190926|Behavioral|Smart-Treatment for Anorexia Nervosa Recovery (STAR)|"Adolescents will use their smartphone to access short 5-10 minute modules that teach them about the function of emotions, ways to regulate challenging emotions, and strategies to improve negative thinking, mood, and reduce eating-disorder symptoms. Module content will include text, images, videos, and interactive questions and quizzes."
79719552|NCT05190926|Behavioral|Present-focused Anorexia Nervosa Coping Treatment (PACT)|Adolescents will use their smartphone to access two brief psychoeducational modules that teach about the common symptoms of AN, common reactions and problems associated with AN, and goals for treatment. Starting in Week 3, adolescents will complete a Daily Diary that will ask them to record life stressors, challenges, and problems, which will serve as a launching point for discussion with their outpatient therapist.
79719553|NCT05181826|Diagnostic Test|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
80031527|NCT04884646|Other|Routine physical therapy|Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
79719554|NCT05144347|Drug|XL114|Tablets of XL114
79719555|NCT05132881|Other|Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)|The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.
79719556|NCT05132881|Other|Waitlist Control|Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.
79719557|NCT05132881|Other|Healthy Controls: Substudy Group III|fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
79719558|NCT05132881|Other|Distressed Workers: Subgroup II|Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
79719559|NCT05128461|Other|Exercise|M-CIMT-based telerehabilitation will be implemented.
79719560|NCT05128461|Other|Home program|Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
79719561|NCT05111145|Drug|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
79719562|NCT05111145|Drug|IVA|Tablets for oral administration.
79719563|NCT05101824|Radiation|SABR|Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
79854863|NCT01550861|Procedure|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
79854864|NCT01500473|Drug|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
80031528|NCT04406896|Drug|Selatogrel|A single subcutaneous injection of 16 mg.
79556175|NCT05596097|Drug|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
80031529|NCT04454996|Drug|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
79257452|NCT02245841|Drug|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
79257453|NCT03571139|Device|Phacoemulsification|Cataract surgery and in the bag posterior chamber lens implantation
79556176|NCT05596071|Drug|Sufentanil Citrate|Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
79556177|NCT05596071|Drug|Ropivacaine 0.75% Injectable Solution|Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
79257454|NCT02129881|Biological|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
79556178|NCT05596071|Procedure|Epidural catheter|Intraoperative and postoperative analgesia
79556179|NCT05595928|Other|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
79556180|NCT05595824|Drug|Molnupiravir (Esperavir)|Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
79556181|NCT05595824|Drug|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
79556182|NCT05595759|Other|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
79556183|NCT05595759|Other|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
79556184|NCT05595733|Device|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
79556185|NCT05595590|Drug|Tislelizumab|Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
79556186|NCT05595590|Radiation|Pulse radiation|66-70Gy/33-35Fx, 2Gy/Fx.
79556187|NCT05595564|Device|Photobiomodulation therapy|A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
79556188|NCT05595538|Biological|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; ~300-600 mL with the presence of IgG anti-SARS-CoV-2.
79556189|NCT05595525|Device|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
79556190|NCT05595525|Device|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
79556191|NCT05595512|Behavioral|Naser Al-Husban|depressive symptoms within 6 months of delivery
79556192|NCT05595473|Drug|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
79556193|NCT05595473|Drug|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
79854865|NCT01459510|Behavioral|Play Nicely Program|Multi media educational intervention
79556194|NCT05595473|Drug|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
79556195|NCT05595473|Drug|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
79556196|NCT05595408|Drug|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
79556197|NCT05595408|Drug|adjuvant immunotherapy|immunotherapy for one year
79556198|NCT05593822|Procedure|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
79854866|NCT01326182|Behavioral|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
79396219|NCT05417204|Behavioral|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
79396220|NCT05415215|Drug|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
79556199|NCT05577455|Drug|Medical prescription before ovulation|Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
79556200|NCT05577455|Drug|Medical prescription after ovulation|Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
79854867|NCT01326182|Behavioral|MAAS|Group-based intervention including asthma education and education regarding general child health
79854868|NCT01306357|Drug|Somatropin|4 mg or 10 mg delivered by needle-free device
79854869|NCT01219075|Dietary Supplement|soy isoflavones|Given orally
79854870|NCT01219075|Other|placebo|Given orally
79854871|NCT01219075|Other|questionnaire administration|Ancillary studies
79556201|NCT05571683|Other|oxygen support|40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
80018626|NCT02136966|Other|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
80031530|NCT04454996|Drug|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
79257455|NCT05709041|Other|Individualized lung-protective ventilation|"Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released."
79396221|NCT05415215|Drug|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
79396222|NCT05415215|Drug|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
79396223|NCT05415215|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
79556202|NCT05567822|Drug|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
79556203|NCT05567822|Drug|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
79556204|NCT05557253|Drug|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
79854872|NCT01219075|Procedure|magnetic resonance imaging|Correlative studies
80031531|NCT04454996|Drug|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
80031532|NCT04454996|Drug|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
79396224|NCT05415215|Drug|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
79396225|NCT05415215|Procedure|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
79396226|NCT05415215|Radiation|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
79556205|NCT05557253|Drug|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
79556206|NCT05546372|Device|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
79854873|NCT01219075|Procedure|biopsy|Correlative studies
79556207|NCT05546372|Device|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
79556208|NCT05539924|Drug|Pregabalin 150mg gabapentin 400mg|oral administration
79556209|NCT05536050|Other|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
79556210|NCT05530096|Diagnostic Test|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
79556211|NCT05528250|Other|Survey|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.
79854874|NCT01219075|Other|immunohistochemistry staining method|Correlative studies
79854875|NCT01219075|Other|laboratory biomarker analysis|Correlative studies
79854876|NCT01219075|Procedure|mammography|Correlative studies
79854877|NCT00929214|Drug|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
80031533|NCT04297124|Drug|CC-90009|0.6 mg [ 14C]-CC-90009 administered IV as a single dose
79257456|NCT05709041|Other|Standard lung-protective ventilation|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
79257457|NCT02138305|Device|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
79719564|NCT05095272|Biological|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
79719565|NCT05064826|Other|Observation|"Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)"
80031534|NCT04297124|Radiation|[14C]|A single dose of [ 14C]-CC-90009 will contain approximately 2 µCi of radioactivity.
79556212|NCT05528250|Device|Treadmill|Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
79257458|NCT02138305|Procedure|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
79257459|NCT03254225|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
79257460|NCT02242565|Device|ShangRing|ShangRing device for male circumcision
79396227|NCT05407844|Other|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
79556214|NCT05514782|Other|Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
79556215|NCT05514782|Other|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
79556216|NCT05514782|Other|Sunscreen SPF 40+|"Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter"
79556217|NCT05512065|Device|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
79556218|NCT05501925|Device|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
79556219|NCT05501925|Device|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
79719566|NCT05050864|Procedure|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
79719567|NCT05050864|Procedure|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
80031535|NCT04888780|Other|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
79854878|NCT00929214|Procedure|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
79854879|NCT00871936|Drug|SLx-4090|SLx-4090
79854880|NCT00871936|Other|Placebo|matching tablets
80031536|NCT04101890|Drug|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
79257461|NCT03570281|Drug|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
79257462|NCT03570281|Drug|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
79257463|NCT03570203|Diagnostic Test|Serum Sodium|Measurement of serum sodium.
80031537|NCT04898218|Other|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
79396228|NCT05402423|Device|Computerized cognitive training plus aerobic exercise with the JDome System|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~30 minutes of aerobic training with the JDOME system,"
79396229|NCT05402423|Device|Computerized cognitive training plus aerobic exercise with standard exercise bike|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~30 minutes of aerobic training with standard exercise bike"
79719568|NCT05032755|Other|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
79719569|NCT05032755|Other|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
79719570|NCT05023980|Drug|Pirtobrutinib|Oral
79257464|NCT02242799|Drug|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
79257465|NCT02242799|Drug|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
79257466|NCT02242799|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
79257467|NCT03548857|Other|Lung transplantation|Single or double lung transplantation in patients with COPD
79257468|NCT02243423|Procedure|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
79257469|NCT02243423|Procedure|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
79257470|NCT02138383|Drug|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
79257471|NCT02138383|Drug|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
79257472|NCT02138383|Drug|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
79556222|NCT05479370|Biological|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79556223|NCT05479370|Biological|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79257473|NCT02243735|Drug|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
79396230|NCT05401396|Other|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
79257474|NCT02243735|Drug|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
79556224|NCT05479370|Biological|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79556225|NCT05479136|Drug|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
79556226|NCT05478369|Behavioral|storybook|anxiety and fear during operative
79719571|NCT05023980|Drug|Bendamustine|IV
79719572|NCT05023980|Drug|Rituximab|IV
79719573|NCT05019521|Drug|Danicopan|Oral tablet.
79719574|NCT05019521|Drug|Placebo|Oral tablet.
79719575|NCT05009004|Behavioral|text messages to support medication adherence|text messages to support medication adherence
79719576|NCT05007522|Drug|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
79719577|NCT05007522|Drug|Placebo|Matching placebo tablet
79719578|NCT05004012|Device|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
79854881|NCT00871936|Drug|Metformin|
79854882|NCT00810979|Drug|SLx-4090|tablet
79854883|NCT00810979|Drug|SLx-4090|tablet
79854884|NCT00810979|Other|Placebo|matching tablet
80031538|NCT04456712|Drug|Ciprofloxacin 400 MG/200 ML Intravenous Solution|antibiotic
80031539|NCT04456712|Drug|Levofloxacin 750 MG|antibiotic
80031540|NCT04889014|Genetic|Personal genomic educational testing (PGET)|PGET consisted of a panel of pharmacogenomic variants
80031541|NCT04889014|Genetic|No personal genomic educational testing (NPGET)|Lack of pharmacogenomic testing
80031542|NCT04456868|Behavioral|Electroencephalogram|Electroencephalogram will be done for P300 wave assessment
79719579|NCT05003349|Other|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
79719580|NCT05003349|Other|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
79719581|NCT05003349|Other|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
79719582|NCT05003349|Other|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
79719583|NCT05003349|Other|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
79719584|NCT05003349|Other|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
79719585|NCT04971278|Behavioral|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
79854885|NCT00810979|Drug|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
79854886|NCT00741910|Drug|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
79854887|NCT00567684|Device|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
79854888|NCT00567684|Other|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
79257475|NCT02138539|Other|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
79556227|NCT05475821|Drug|ABBV-990|Oral Tablet
79556228|NCT05475821|Drug|Placebo for ABBV-990|Oral Tablet
79556229|NCT05454098|Drug|Clifutinib with fed state|40 mg Clifutinib with food
79854889|NCT00562614|Drug|SLx-2101|
79257476|NCT02138539|Drug|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
79257477|NCT03571061|Procedure|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
79257478|NCT02244047|Drug|Bifidobacterium breve|
79257479|NCT02244047|Drug|Placebo (for Bifidobacterium breve)|
79854890|NCT00562575|Drug|SLx-4090|
79854891|NCT00562575|Drug|Placebo|
79854892|NCT00528242|Drug|SLx-2101|
79854893|NCT00528242|Drug|Placebo|
79854894|NCT00483249|Device|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
79854896|NCT00931424|Procedure|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
79854897|NCT05701319|Procedure|PCI|percutaneous coronary intervention
79257480|NCT03570125|Dietary Supplement|Prolon|The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
79854898|NCT00930488|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
79556230|NCT05454098|Drug|Clifutinib with fasted state|40 mg Clifutinib without food
79854899|NCT04063943|Device|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
79854900|NCT00736931|Drug|Brivaracetam|Brivaracetam 10 mg tablets
79854901|NCT00736931|Drug|levetiracetam|500mg tablets
79854902|NCT00736931|Drug|lorazepam|lorazepam 2 mg over encapsulated tablets
79854903|NCT00736931|Other|placebo|placebo capsules
79257481|NCT05578729|Behavioral|Single surgical mask group, Double surgical mask group, N95 mask group|Masks were given to the resting pregnant women 30 minutes before the NST, and they were provided to wear masks. After 30 minutes, the vital signs of the pregnant women were measured just before and after the NST, and the images of the NST traces were taken.
79257482|NCT03569969|Procedure|device: Tympanoplasty with Membrane Amniotic|amniotic membrane Tympanoplasty
79257483|NCT03569969|Procedure|Tympanoplasty With Autologous Fascia|Autologous Temporalis fascia Tympanoplasty
79257484|NCT02130037|Behavioral|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
79719586|NCT04957537|Behavioral|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
79719587|NCT04952779|Drug|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
79854904|NCT00737087|Device|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
79719588|NCT04941573|Combination Product|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
79719589|NCT04936776|Behavioral|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
79719590|NCT04934995|Other|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
79719591|NCT04900623|Device|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
79719592|NCT04900623|Radiation|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
79854905|NCT04064099|Device|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
79854906|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
79854907|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
79854908|NCT00567164|Drug|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
79257485|NCT02130037|Other|psychotherapy|standard psychotherapy for eating disorders
79854909|NCT00920933|Biological|AIN457|
79257486|NCT02244359|Behavioral|Training|
79257487|NCT02244359|Behavioral|Usual care|
79257488|NCT02252419|Drug|Dexamethasone|Dexamethasone will be administered.
79257489|NCT02252419|Drug|Paracetamol|Paracetamol will be administered.
79396231|NCT05385588|Other|cognitive functional assessment|"Self-administered questionnaire~Cognitive and functional tests~Medical questionnaire~Sampling for biobank (28-32 ml will be collected)"
79396232|NCT05385224|Diagnostic Test|PillSense|The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
79396233|NCT05382221|Other|Comprehensive Chronic Care|Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.
79396234|NCT05382221|Other|Standard Care|one offer of cessation treatment annually
79854910|NCT00920933|Other|Placebo|
79257490|NCT03570905|Other|Sugar Tong Splint|A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
79396235|NCT05381090|Diagnostic Test|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
79396236|NCT05365789|Device|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
79719593|NCT04900623|Drug|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
79854911|NCT00920933|Drug|prednisolone|
79257491|NCT03570905|Other|Clam Shell Splint|A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
79556231|NCT05451901|Procedure|Immediate necrosectomy|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement."
79556232|NCT05451901|Procedure|Step-up approach|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN)."
79556233|NCT05451602|Drug|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
79556234|NCT05433402|Drug|ChlorproMAZINE 50 MG|The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
79556235|NCT05433402|Drug|Control|The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
79556236|NCT05418153|Device|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
79556237|NCT05406596|Device|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
79719594|NCT04899180|Drug|99mTc-PYP|Radioisotope used by SPECT/CT imaging
79719595|NCT04899050|Drug|Cannabidiol (Epidiolex)|Use of Epidiolex to control absence seizures.
79719596|NCT04874441|Diagnostic Test|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
79854912|NCT00930566|Drug|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
80031543|NCT04456868|Behavioral|walking test|8-Meter walking test will be done for gait parameter assessment
80031544|NCT04456868|Behavioral|Quality of life questionnaire|Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn & Yahr
79396237|NCT05365789|Other|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
79257492|NCT02252497|Drug|Active comparator : Tranexamic Acid (Exacyl)|"1g Exacyl Intra Venous, just before surgery~Then infusion of 1g of Exacyl over eight hours ."
79257493|NCT02252497|Drug|Placebo comparator : physiologic serum|"1g Intra Venous just before surgery~Then infusion of 1g of physiologic serum over eight hours"
79257494|NCT02252575|Device|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
79396238|NCT05364684|Drug|LUM-201|LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
79396239|NCT05363709|Drug|Balstilimab|Given by Vein (IV)
79396240|NCT05363319|Drug|Cemiplimab|solution for injection via intravenous (IV) infusion
79396241|NCT05362370|Device|Stryker's PEEK Customized Implant|The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).
79396242|NCT05360966|Drug|AR-15512 Ophthalmic Solution|Topical ocular administration of one drop in both eyes BID for 90 days.
79396243|NCT05360966|Drug|Vehicle|Topical ocular administration of one drop in both eyes BID for 90 days.
79396244|NCT05339022|Other|Best Practice|Receive standard of care
79396245|NCT05339022|Other|Exercise Intervention|Undergo exercise intervention
79396246|NCT05339022|Procedure|Physical Therapy|Undergo physical therapy
79396247|NCT05339022|Other|Quality-of-Life Assessment|Ancillary studies
79396248|NCT05339022|Other|Questionnaire Administration|Ancillary studies
79396249|NCT05339022|Procedure|Relaxation Therapy|Undergo progressive muscles relaxation exercises
79854913|NCT00930566|Procedure|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
79854914|NCT00737165|Behavioral|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~Building support networks for suicide prevention and mental health promotion in public health system~Primary prevention of suicide and suicide related behaviors~Secondary prevention of suicide and suicide related behaviors~Tertiary prevention; after care for suicide survivors~Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~Suicide prevention targeting for people with work-related problems"
79854915|NCT00737165|Behavioral|Suicide prevention program as usual|Usual suicide prevention program
79257495|NCT03548701|Diagnostic Test|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
79556238|NCT05406076|Behavioral|oral motor therapy|Rigorous Chinese language oral motor therapy, including treatment of oral perceptual disorders and treatment of oral motor disorders. The treatment follows three basic principles: a combination of basic training and specific treatment; a combination of self-help and assisted treatment; and a combination of exercises, cues, and stimulation techniques. 30-40 min/session, 1 session/day, 5 sessions/week.
79257496|NCT02138773|Drug|Tamsulosin formulation-A|oral
79556239|NCT05406076|Behavioral|ABA|The mainstream ASD intervention approach with evidence-based support is currently recognized worldwide. Treatment follows the operational core principles of ABA, which are to establish learning goals based on the child's ability level, design teaching situations and select reinforcers for them, change the child's behavior problems with operational constraints, and to eliminate or improve problem behaviors through appropriate interventions to shape new adaptive behaviors. The training time is at least 20 hours per week.
79556240|NCT05405621|Drug|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30~120 minutes.
79556241|NCT05400395|Drug|GNX80|GNX80 oral intake(BID) for 24 weeks
79556242|NCT05400395|Drug|Placebo|Placebo oral intake(BID) for 24 weeks
79556243|NCT05374941|Device|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
79556244|NCT05351333|Other|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
79556245|NCT05339828|Procedure|unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.
79556246|NCT05339672|Other|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
79556247|NCT05322200|Radiation|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
79556248|NCT05322200|Procedure|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
79719597|NCT04870099|Behavioral|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
79854916|NCT00925730|Drug|Pimecrolimus|
79257497|NCT02138773|Drug|Tamsulosin formulation-B|oral
79257498|NCT05578573|Device|KARAHOC device|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by KARAHOC device.
79719598|NCT04868994|Diagnostic Test|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
79854917|NCT00925808|Behavioral|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
79854918|NCT00925886|Procedure|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
79854919|NCT00713219|Radiation|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
80031545|NCT04456868|Procedure|Position emission tomography|Position emission tomography will be done for
80031546|NCT04884490|Drug|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
80031547|NCT04884490|Drug|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
79257499|NCT05578573|Device|Angiocatheter|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by angiocatheter
79257500|NCT02138851|Dietary Supplement|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
79257501|NCT02138851|Dietary Supplement|Placebo (300g/day)|Placebo (300g/day), parallel design
79854920|NCT03699644|Device|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
79854921|NCT03699644|Device|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
79257502|NCT05578495|Other|Accelerometer data|Patients will wear an accelerometer 3 times a year for 5 days (3 weekdays and 2 weekend days), the data will be collected
79396250|NCT05329545|Drug|Upifitimab rilsodotin|Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
79396251|NCT05329545|Other|Placebo|Placebo controlled arm.
79396252|NCT05317858|Device|Blood Brain Barrier Disruption - Oncology|BBB opening via Exablate Type 2 system with microbubble resonators on the day of pembrolizumab infusion to treat brain metastases
79396253|NCT05317858|Drug|Pembrolizumab|Pembrolizumab infusion
79396254|NCT05312762|Device|MaxioCel|Microfiber wound dressing
79396255|NCT05312762|Device|AquaCel Extra|Hydrofiber dressing
79556249|NCT05322200|Other|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
79719599|NCT04859335|Radiation|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
79854922|NCT03699644|Device|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
79396256|NCT05312567|Drug|FP-101|daily oral tablet administration (b.i.d.)
79396257|NCT05281484|Drug|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
79396258|NCT05275205|Drug|UBX1325 injection 50 μL|Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
79257503|NCT02130115|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
80031548|NCT04898530|Other|NO INTERVENTION|There is no intervention for this study.
79257504|NCT01367275|Drug|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
79257505|NCT01367275|Drug|Irinotecan|180 mg/m^2 by vein on Day 1 of a 14 day cycle.
79257506|NCT02138929|Drug|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
79257507|NCT02138929|Drug|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
79257508|NCT05578339|Device|Biometry|Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).
79396259|NCT05275205|Drug|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
79396260|NCT05265416|Procedure|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
79396261|NCT05265416|Other|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) will be applied around the upper canine in 10 sites from buccal and palatal.
79396262|NCT05265416|Device|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
79396263|NCT05253495|Drug|DOC Group B|Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
79396264|NCT05253495|Drug|Pv-COMRAD 1 and 2 Group B|polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1
79396265|NCT05253495|Drug|Pv-R-CYM 1 and 2 Group B|polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
79396266|NCT05253495|Drug|DOC Group C|cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
79396267|NCT05253495|Drug|MAD CPR 1 and 2|methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2
79396268|NCT05253495|Drug|Pv-R CYVE 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;
79396269|NCT05253495|Drug|Pv-R CYVE-MTX 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
79719600|NCT04829071|Behavioral|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
79719601|NCT04829071|Behavioral|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
79719602|NCT04828551|Device|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
80018627|NCT05225090|Other|Smartphone App|"Medisafe is a Med_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app."
79396270|NCT05253495|Drug|MAD CP|dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
79396271|NCT05253495|Drug|Pv-Cytarabine/etoposide|polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
79556250|NCT05303974|Other|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
79556251|NCT05299346|Other|Follow up|Comprehensive follow up in dedicated follow up unit
79257509|NCT02253199|Drug|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
79257510|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
79396272|NCT05253495|Drug|AD CP|polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
79396273|NCT05253495|Drug|Bv-AVD-R 1 and 2: COHORT IIa|brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
79396274|NCT05253495|Drug|Bv-NVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
79396275|NCT05253495|Drug|Bv-NVD-R, Cycle 1-4 SER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
79396276|NCT05253495|Drug|Bv-AVD-R|Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
79556252|NCT05261477|Behavioral|Bilingual Brain Injury Education and outpatient Navigation for Hispanic families|1st BIEN was informed by Hispanic parents and clinical providers working with them. It considers their specific needs including lack of familiarity with shared decision models and of knowledge about patient rights and eligibility for community and school services. Based on principles of Social Cognitive Theory, 1st BIEN provides TBI education, teaches problem-solving skills to promote self-efficacy and advocacy; and provides outpatient navigation that allows for observational and experiential learning while supporting access to services in a timely manner. Central to the development of our intervention is the recognition of heterogeneity in individuals' level of readiness to adopt a health behavior according to their level of self-efficacy, expectations, and environment. The 1stBIEN intervention flexibly reduces barriers to access care, and simultaneously improves parental knowledge, health literacy, and self-efficacy to optimize outcomes.
79556253|NCT05256355|Other|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
79556254|NCT05226923|Drug|KSP-1007|Single and multiple doses, intravenous administration
79854923|NCT03699644|Diagnostic Test|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
79396277|NCT05253495|Drug|Bv-NVD-R, Cycle 1-4 RER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
79556255|NCT05226923|Other|Placebo:0.9% sodium chloride|Single and multiple doses, intravenous administration
79556256|NCT05226923|Drug|Meropenem|Multiple doses, intravenous administration
79719603|NCT04828551|Diagnostic Test|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
80018628|NCT02128854|Behavioral|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
79257511|NCT02842853|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
79854924|NCT03699644|Device|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
79854925|NCT00931580|Dietary Supplement|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
79854926|NCT00930800|Other|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
79854927|NCT00930878|Device|Cardiac Stenting|Drug Eluting stent
79854928|NCT00931736|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
79854929|NCT00931736|Drug|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
79257512|NCT02130271|Drug|Radioactive dye|The radioactive dye [11C]PBR28 will be administered through an intravenous line (IV).
79719604|NCT04828551|Other|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
79719605|NCT04828551|Other|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
79719606|NCT04825717|Other|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
79854930|NCT00930956|Dietary Supplement|Resistant Starch|30 g of carbohydrate per Arm
79257513|NCT02130271|Radiation|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
79719607|NCT04823754|Other|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
79719608|NCT04823130|Drug|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79854931|NCT00931034|Behavioral|South Beach Diet with South Beach Diet Products|
79257514|NCT02130271|Other|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
79257515|NCT02139085|Device|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
79396278|NCT05253495|Drug|Bv-NAVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
79854932|NCT00931034|Behavioral|American Diabetes Association Diabetes Meal Plan|
79854933|NCT02567981|Dietary Supplement|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
79854934|NCT02567981|Dietary Supplement|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
80018629|NCT03522818|Behavioral|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
80018630|NCT03522818|Behavioral|Normal|Will use the alarm as provided by the manufacture.
79396279|NCT05253495|Radiation|Involved Site Radiation Therapy|21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.
79396280|NCT05224050|Behavioral|Cognitive-Behavioral Smoking Cessation|Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
79396281|NCT05224050|Biological|Heart Rate Variability Biofeedback|Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.
79396282|NCT05224050|Drug|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
80018631|NCT05706025|Device|EnteroTracker|The EnteroTracker® is a capsule device that includes an absorbent string.
80031549|NCT03962036|Device|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
80018632|NCT03525236|Other|Tasting of flavours|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
79556257|NCT05209464|Device|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via an application installed on a tablet. The intervention emphasizes essential TC movements that are easily comprehensible and can be performed repetitively in a flowing manner. The protocol includes up to six core TC movements based on the traditional Cheng Man-Ch'ing's Yang-style short form. Additionally, a set of traditional TC warm-up exercises that focus on loosening the physical body, incorporating mindfulness and imagery into movement, promoting overall relaxation, and coordinating breathing awareness are included. Chairs are used in the protocol for a subset of seated warm-up exercises, as well as for stability and rest as needed. Participants will be asked to practice the protocol (45-60 min) at home for at least 3 days a week for 12 weeks. The TC program will also include 2 or more live instructional sessions via Zoom with a TC instructor.
79556258|NCT05209165|Drug|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
79556259|NCT05209165|Drug|Placebo|Matching placebo and intake visit for VA MOVE
80018633|NCT02137044|Behavioral|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
80018634|NCT05032846|Procedure|Ultrasound guided laparoscopic ovarian cystectomy|Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
79257516|NCT02139085|Device|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
79556260|NCT05202769|Other|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
79719609|NCT04822129|Behavioral|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
79719610|NCT04822129|Behavioral|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
79719611|NCT04820595|Diagnostic Test|RASS|Richmond Agitation-Sedation Scale
79257517|NCT02130505|Dietary Supplement|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
79257518|NCT03548545|Device|tDCS|subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
79257519|NCT02246543|Dietary Supplement|Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
79719612|NCT04820595|Diagnostic Test|CAM-ICU|Confusion Assessment Method for the ICU
79719613|NCT04808622|Drug|Trans-Sodium Crocetinate|TSC given as a one-time IV bolus injection
79719614|NCT04808622|Drug|Placebo|Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
79854935|NCT02567981|Dietary Supplement|Ferrous sulphate|"Ferrous sulfate drops children <12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
79854936|NCT02567981|Dietary Supplement|Vitamin A|Vitamin A Capsules: children <12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
79854937|NCT00931814|Other|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
79854938|NCT05741567|Procedure|correction of anterior prolapse|percentage of failed prolapse correction
79854939|NCT00931112|Other|individualized exercise training|Lower extremities resistance exercise and bicycle training
79854940|NCT00926120|Dietary Supplement|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
79854941|NCT00737555|Drug|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
79854942|NCT00932048|Drug|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
79854943|NCT04015778|Biological|Nivolumab|240mg Q2W or 360mg Q3W
79854944|NCT04015778|Drug|carboplatin|AUC 5, d1 every three weeks
79854945|NCT04015778|Drug|nab-paclitaxel|135 mg/m2, d1, 8
79854946|NCT02568293|Other|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
79854947|NCT02568293|Other|Saline|Saline is used as a control.
79854948|NCT00926276|Procedure|Fundoplication|Fundoplication
79854949|NCT05540873|Drug|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
79556261|NCT05172297|Behavioral|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
79257520|NCT02246543|Dietary Supplement|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
79556262|NCT05169983|Diagnostic Test|iPad-Based Visual Field Test|In this study, the investigators aim to teach the participants to use the the visualFields easy App . The investigators will be using the app in the clinic with the patients watching, demonstrating its use and discussing and explaining its functions. Having observed how to use the application, the participant will then complete the visual field assessment.
79556263|NCT05158933|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556264|NCT05158114|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556265|NCT05158101|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556266|NCT05152368|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556267|NCT05147701|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556268|NCT05137275|Biological|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10^9 cells and then escalate to 6.0× 10^9 and 9.0× 10^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
79556269|NCT05126316|Drug|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
79257521|NCT02246543|Dietary Supplement|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
79257522|NCT02246543|Dietary Supplement|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
79556270|NCT05126316|Drug|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
79556271|NCT05094713|Other|Flossing experimental group|Flossing of the tight muscles with medium wrapping pressure, which is individualized in based on the tight circumference of the participant.
79556272|NCT05094713|Other|Low wrapping pressure|Control group where flossing wrapping pressure is between 20 and 30 mmHg
79556273|NCT05071729|Drug|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
79556274|NCT05059886|Other|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
79556275|NCT05057949|Drug|Larotinib|Larotinib Capsules
79556276|NCT05057949|Drug|Rifampin|Rifampin Capsules
79556277|NCT05057949|Drug|Itraconazole|Itraconazole Capsules
79556278|NCT05048368|Drug|Larotinib|Capsules, Oral, 350 mg, single dose, one day
79556279|NCT05047159|Device|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
79556280|NCT05047159|Device|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
79257523|NCT02246543|Dietary Supplement|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
79556281|NCT05047159|Device|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
79556282|NCT05047159|Device|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
79556283|NCT05047159|Drug|drug therapy|There is no restriction on the choice of therapeutic drugs.
79556284|NCT05033431|Drug|Brazikumab|Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
79556285|NCT05023616|Other|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
79556286|NCT05023616|Other|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
79556287|NCT05018858|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556288|NCT05018845|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556289|NCT05018819|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79854950|NCT00926354|Drug|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
79257524|NCT02139163|Other|Cohort Study|
79257525|NCT03569267|Drug|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
79257526|NCT03569267|Drug|Placebo|Placebo
79257527|NCT02139241|Drug|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
79257528|NCT02139241|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
79257529|NCT02433340|Drug|ABT-122|
79257530|NCT05578105|Other|no intervention|No intervention, only observation
79257531|NCT03569579|Drug|Memantine Tab. 10mg|Memantine Tab. 10mg* 2T/day, QD, PO
79556290|NCT05016817|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556291|NCT05016804|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556292|NCT05009277|Device|Device|LINDA thermal device
79556293|NCT05003947|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79719615|NCT04802603|Radiation|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
79719616|NCT04783675|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
79719617|NCT04782856|Drug|Levothyroxine|levothyroxine sodium tablet for oral use
79719618|NCT04782856|Drug|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
79719619|NCT04782856|Drug|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
79854951|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
79854952|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
79854953|NCT00712985|Drug|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
79854954|NCT00926510|Behavioral|Language toolkit|Simple toolkit of interactive things to stimulate language.
79854955|NCT00926510|Behavioral|Safety counseling|Smoke detector and general safety counseling
79854956|NCT00737789|Drug|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
79854957|NCT00737789|Drug|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
79854958|NCT05612789|Behavioral|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
79854959|NCT05612789|Behavioral|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
79854960|NCT00700115|Drug|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
79854961|NCT00700115|Drug|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
79854962|NCT04062929|Behavioral|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
79854963|NCT04062773|Behavioral|TRF|time restricted feeding group
79854964|NCT04062773|Behavioral|Normal timing of food intake|no time restricted feeding
79854965|NCT02568917|Procedure|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
79854966|NCT02568917|Procedure|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
79854967|NCT00566852|Drug|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
80018635|NCT05032846|Other|Laparoscopic Ovarian Cystectomy|Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
80018636|NCT03548246|Drug|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
79257532|NCT03569579|Drug|Memantine Tab. 10mg + Donepezil Tab. 10mg|Memantine Tab. 10mg* 2T/day + Donepezil Tab. 10mg * 1T/day, QD, PO
79396283|NCT05220241|Biological|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
79396284|NCT05219149|Behavioral|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
79556294|NCT05003934|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
79556295|NCT05001581|Procedure|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
79854968|NCT00566852|Other|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
79854969|NCT00566852|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
79854970|NCT00931346|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
79257533|NCT03548389|Other|Skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
79854971|NCT00931346|Drug|Placebo|Placebo
79556296|NCT05001581|Procedure|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
79257534|NCT03569501|Dietary Supplement|DHA|500 mg DHA tablets
79854972|NCT00936650|Drug|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
79854973|NCT00936650|Drug|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
79257535|NCT03569501|Dietary Supplement|oat grains|90 mg oat, containing 4.05 mg β-glucan
79556297|NCT04980365|Behavioral|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
79257536|NCT02130661|Drug|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
79257537|NCT02130661|Drug|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
79257538|NCT02130661|Drug|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
79556298|NCT04980365|Behavioral|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
79556299|NCT04980365|Behavioral|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
79719620|NCT04781374|Drug|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
79257539|NCT02139475|Procedure|Colonoscopy|
79257540|NCT03569189|Other|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
79257541|NCT02139553|Procedure|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
79257542|NCT03569423|Procedure|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
79396285|NCT05196152|Behavioral|MomMoodBooster|MomMoodBooster is an empirically validated online intervention for perinatal women.
79396286|NCT05196152|Behavioral|Phone Coaching|Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
79257543|NCT03569423|Procedure|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
79719621|NCT04767009|Drug|PD-1 Blockade|Patients will receive PD-1 blockade for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1 blockade will be administrated as an intravenous(IV) infusion.
79719622|NCT04767009|Radiation|SBRT|Patients with oligo-residual or oligoprogressive NSCLC after treatment with PD-1 inhibitors will be treated with curative-intent SBRT of progressing lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1 blockade will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
79854974|NCT00442546|Drug|pregabalin|150 milligram (mg)/ day (double blind)
79854975|NCT00442546|Drug|pregabalin|300 mg/day (double blind)
79854976|NCT00442546|Drug|Placebo|Placebo
80018637|NCT03548246|Drug|Placebo|Daily placebo for 2 years.
80018638|NCT03548246|Drug|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
79257544|NCT02130739|Procedure|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
79396287|NCT05195632|Drug|Encorafenib|Hard capsule
79396288|NCT05195632|Drug|Binimetinib|Film-coated tablet
79396289|NCT05183646|Drug|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
79396290|NCT05183646|Drug|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
79396291|NCT05182658|Drug|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
79719623|NCT04746170|Other|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
79854977|NCT03545594|Other|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
79854978|NCT03545594|Other|Control|Usual follow-up in the municipality
79854979|NCT00936962|Biological|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
79854980|NCT00514683|Drug|low dose BIBF1120 once daily|low dose BIBF1120 once daily
79854981|NCT00514683|Drug|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
79257545|NCT02130739|Procedure|mastectomy|mastectomy with/without breast reconstruction
79257546|NCT02130739|Drug|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
79556301|NCT04959162|Device|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
79556302|NCT04959162|Device|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
79719624|NCT04736316|Behavioral|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
79257547|NCT02130739|Drug|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
79257548|NCT02130739|Drug|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
79854982|NCT00514683|Drug|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
79854983|NCT00514683|Drug|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
79257549|NCT02248493|Drug|Paracetamol|
79257550|NCT02248493|Drug|Placebo (for paracetamol)|
79257551|NCT02248493|Drug|Ketoprofen|
79257552|NCT02248493|Drug|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
79257553|NCT02248493|Drug|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
79556303|NCT04936620|Procedure|Duroplasty|Expansion Duroplasty
79257554|NCT05577949|Other|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
79257555|NCT03569345|Drug|AFXl-assisted ingenol mebutate delivery|"Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30."
79257556|NCT05577871|Drug|Dexmedetomidine|infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
79556304|NCT04936620|Procedure|Spinal surgery|Spinal surgery including laminectomy
79556305|NCT04904432|Genetic|PLIN1 gene sequencing|One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
79581087|NCT01932502|Drug|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
79854984|NCT00514683|Drug|placebo|placebo
79854985|NCT00566696|Device|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
79854986|NCT00566696|Procedure|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
79854987|NCT00566696|Drug|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79854988|NCT00566696|Drug|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79854989|NCT00566696|Drug|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79854990|NCT00566696|Drug|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79854991|NCT00566696|Drug|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79854992|NCT00566696|Drug|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
79257557|NCT05577871|Drug|normal saline|infusion of normal saline during the off pump coronary artery bypass grafting surgery
79257558|NCT03166319|Diagnostic Test|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
79257559|NCT05577793|Other|Mother's Voice|The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.
79854993|NCT00566696|Drug|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79257560|NCT05577793|Other|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
79257561|NCT05577793|Other|Mother's Voice +Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
79556306|NCT04901312|Behavioral|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
79556307|NCT04901312|Behavioral|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
79556308|NCT04901312|Behavioral|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
79556309|NCT04901312|Behavioral|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
79556310|NCT04901312|Other|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
79556311|NCT04886297|Drug|Mega Resveratrol® capsules|Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
79556312|NCT04886297|Drug|Mega Resveratrol® Placebo capsules|Mega Resveratrol® Placebo capsules
79556313|NCT04810793|Drug|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
79719625|NCT04720456|Drug|SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
79719626|NCT04720456|Drug|SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
79719627|NCT04709653|Other|Occupation-based nursing program|"First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille."
79719628|NCT04709653|Other|Control Group|Routine nursing care
79719629|NCT04695080|Drug|Cladribine (MAVENCLAD®)|"Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
79719630|NCT04695080|Drug|Placebo|"Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
80018639|NCT03548246|Drug|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
79719631|NCT04648124|Device|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
79719632|NCT04624932|Behavioral|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
79556314|NCT04810793|Drug|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
79556315|NCT04810793|Drug|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
79556316|NCT04810793|Drug|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
79556317|NCT04810793|Drug|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
79257562|NCT05577793|Other|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
79556318|NCT04810793|Drug|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
79396292|NCT05182658|Drug|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
79556319|NCT04797832|Drug|IV Sodium Ferric Gluconate Complex|125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
79556320|NCT04742647|Procedure|Double cerclage|Two cervical cerlages will be placed
79556321|NCT04742647|Procedure|Single cerclage|One cerclage will be placed
79257563|NCT02247791|Procedure|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
79556322|NCT04709575|Drug|REGN5713|Administered subcutaneously
79257564|NCT02247791|Procedure|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
79257565|NCT02139631|Other|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
79556323|NCT04709575|Drug|REGN5714|Administered subcutaneously
79556324|NCT04709575|Drug|REGN5715|Administered subcutaneously
79556325|NCT04709575|Drug|Placebo|Placebo that replaces REGN5713-5714-5715
79556326|NCT04684511|Drug|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
79556327|NCT04684511|Drug|Placebo|Matching Placebo
79719633|NCT04624932|Behavioral|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
79719634|NCT04609319|Drug|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
79719635|NCT04605484|Biological|Posoleucel (formerly known as ALVR105) cells|Infusion
80018640|NCT05705869|Diagnostic Test|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
79257566|NCT02130817|Drug|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
79257567|NCT02130817|Drug|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
79257568|NCT02130817|Procedure|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
79396293|NCT05162781|Behavioral|Speed of Processing Training|"This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors."
79396294|NCT05162781|Behavioral|Instrumental Activities of Daily Living In-lab Training|The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
79719636|NCT04605484|Biological|Placebo (visually identical to Posoleucel)|Infusion
79257569|NCT02130817|Drug|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
79556328|NCT04679311|Biological|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L
79556329|NCT04679311|Other|Normal Saline|Subjects will be treated with normal saline 500 cc
79556330|NCT04673149|Biological|GLS-5310|GLS-5310 DNA plasmid vaccine
79719637|NCT04594473|Behavioral|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|[see arm/group descriptions]
80018641|NCT02132442|Dietary Supplement|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
79556331|NCT04673149|Biological|Placebo|Placebo
79556332|NCT04669652|Device|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
79719638|NCT04592588|Behavioral|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
80018642|NCT03522662|Drug|GSK1070806|Single 10mg/kg infusion on Day 0
80018643|NCT05010148|Drug|Lidocaine IV|Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery
80018644|NCT05010148|Drug|Placebo|D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
79854994|NCT00566696|Drug|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79854995|NCT00566696|Drug|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
79719639|NCT04592588|Behavioral|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
79719640|NCT04591353|Drug|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
79396295|NCT05162781|Behavioral|Cognitive Transfer Packagke|This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
79396296|NCT05162781|Behavioral|Family Caregiver Coaching|One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
79556333|NCT04644978|Other|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
79556334|NCT04637438|Other|Fecal Microbiota Transplantation|FMT via colonoscopy
79556335|NCT04637438|Other|Placebo|Water infusion via colonoscopy
79854996|NCT00566696|Drug|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
80018645|NCT03550872|Behavioral|Physical Training|Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
80018646|NCT03525158|Behavioral|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
80018647|NCT05007028|Drug|EMONO|Exposure to 1 hour of EMONO via facial mask
79396297|NCT05162781|Behavioral|Follow-up Phone Calls|After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
79556336|NCT04912648|Other|Longitudinal follow up|Repeat follow up at 3,5 and 10 years
79556337|NCT04636164|Diagnostic Test|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
79556338|NCT04565171|Drug|Yimitasvir Phosphate Capsule|DAG181 100 mg (100 mg Capsule) administered orally
79556339|NCT04528238|Other|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
79556340|NCT04505449|Diagnostic Test|Left heart catheterization|Patients who underwent left heart catheterization
79556341|NCT04463719|Behavioral|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
79556342|NCT04463719|Behavioral|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
79556343|NCT04450407|Drug|LY3209590|Administered SC
79556344|NCT04450407|Drug|Insulin Degludec|Administered SC
79556345|NCT04396886|Drug|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
79719641|NCT04591353|Drug|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
79719642|NCT04580914|Device|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
79719643|NCT04556123|Other|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
79719644|NCT04556123|Other|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
79854997|NCT00937196|Drug|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
79854998|NCT00937196|Drug|Histaminum hydrochloricum globuli|
79854999|NCT00937274|Other|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
79556346|NCT04388826|Drug|Veru-111|Respiratory Distress Syndrome, Adult
79556347|NCT04336202|Radiation|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
79556348|NCT04334681|Procedure|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
79556349|NCT04334681|Procedure|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
79855000|NCT00937274|Other|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
79855001|NCT00937274|Other|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
79855002|NCT00926666|Drug|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
80018648|NCT05007028|Drug|Medical Air|Exposure to 1 hour of Medical Air via facial mask
79556350|NCT04317911|Other|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
79556351|NCT04309292|Dietary Supplement|Prebiotic food supplement|Darmocare Pre = trade name Gut microbiome modulator
79556352|NCT04309292|Dietary Supplement|Protein supplement|commercially available protein supplementation with high leucine content
79556353|NCT04309292|Dietary Supplement|Maltrodextrin (placebo)|Starchy substance
79556354|NCT04306601|Device|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
79556355|NCT04301544|Behavioral|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
79556356|NCT04301544|Behavioral|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
79556357|NCT04301544|Behavioral|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
79556358|NCT04284319|Procedure|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
79556359|NCT04231838|Other|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
79556360|NCT04231838|Other|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with their allocated products to select the C-F NDS of their preference. They will be trained and counselled on the chosen C-F NDS; participants will also have the option to try and choose among a selection of either 3 e-liquids or 3 tobacco sticks (depending on the C-F NDS they have chosen). Participants wishing to use a heated tobacco device (HTD) will receive one kit and a full 1 week supply of tobacco sticks of their choice (they will receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 1 week supply of e-liquids of their choice (they will receive 4 x 10 ml refill containers).
79556361|NCT04218266|Drug|BAY2433334|Tablet, taken orally once a day.
79556362|NCT04218266|Drug|Apixaban|Capsule, taken orally twice a day.
79556363|NCT04218266|Other|BAY2433334 matching placebo|Tablet, taken orally once a day.
79855003|NCT00926744|Behavioral|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
80018649|NCT03549936|Other|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
79257570|NCT02130817|Drug|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
79257571|NCT02130817|Drug|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
79257572|NCT04420390|Radiation|Radiotherapy|Low-dose radiotherapy
79257573|NCT02139865|Behavioral|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
79257574|NCT02139865|Behavioral|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
79396298|NCT05162781|Behavioral|Healthy Lifestyle In-lab Training|This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
80018650|NCT05381935|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79257575|NCT02400346|Drug|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
79257576|NCT02400346|Drug|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
79396299|NCT05162781|Behavioral|Healthy Lifestyle Transfer Package|This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
79396300|NCT05158075|Behavioral|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
79719645|NCT04502758|Device|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
79719646|NCT04502758|Device|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
79257577|NCT02130895|Other|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with >=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
79257578|NCT05354843|Drug|ET0038|ET0038 for oral administration
79855004|NCT00932204|Device|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
79855005|NCT04014686|Other|No exercise intervention group|no exercise intervention
79855006|NCT04014686|Behavioral|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
79855007|NCT00926900|Drug|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
79855008|NCT00926900|Drug|Placebo|Placebo
79257579|NCT02140099|Behavioral|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
79257580|NCT02140099|Behavioral|Control Condition (Classroom Activities)|
79257581|NCT03568955|Diagnostic Test|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
79396301|NCT05158075|Behavioral|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
79556364|NCT04218266|Other|Apixaban matching placebo|Capsule, taken orally twice a day.
79855009|NCT00937430|Other|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
79556365|NCT04172363|Drug|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
79855010|NCT00503841|Drug|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
79257582|NCT03567317|Device|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
79257583|NCT02130973|Drug|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
79257584|NCT02130973|Drug|Experimental Cyclic Regimen|Experimental Cyclic Regimen
79556366|NCT04087304|Behavioral|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
79556367|NCT04074603|Device|The needle-free jet injector|Continuous insulin therapy for 2 weeks
79556368|NCT04074603|Device|Conventional insulin pen|Continuous insulin therapy for 2 weeks
79855011|NCT00503841|Other|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
79855012|NCT00503841|Other|laboratory biomarker analysis|Correlative studies
79855013|NCT00503841|Procedure|biopsy|14 days prior to surgery
79855014|NCT00503841|Procedure|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
79855015|NCT00503841|Procedure|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
79257585|NCT03567239|Device|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
79855016|NCT00937508|Behavioral|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
80018651|NCT05381935|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79257586|NCT02456662|Drug|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
79719647|NCT04499950|Drug|Contrave|Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
79719648|NCT04499950|Behavioral|Behavioral Weight Loss|6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
79719649|NCT04488055|Behavioral|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
79719650|NCT04488055|Behavioral|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
79855017|NCT00937508|Drug|varenicline|varenicline (an approved medication for smoking cessation)
79257587|NCT02456662|Drug|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
79257588|NCT03567161|Procedure|Cavitron ultrasonic surgical aspirator|"Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects ."
79257589|NCT03567083|Behavioral|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, & van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
79257590|NCT03548311|Drug|methylcobalamin|Patients receive methylcobalamin 50mg intramuscular injection twice a week.
79257591|NCT03548311|Drug|saline solution|Patients receive saline solution intramuscular injection twice a week.
79257592|NCT01653262|Drug|Brivaracetam|
79257593|NCT03568877|Dietary Supplement|Metabolaid®|500 mg per day, in fasting conditions.
79257594|NCT03568877|Dietary Supplement|Placebo|500 mg per day, in fasting conditions.
79855018|NCT00937508|Drug|placebo|sugar pill without any active medication
79855019|NCT00937664|Drug|AZD7762|solution, intravenous, weekly
79855020|NCT00937664|Drug|gemcitabine|intravenous, weekly
79257595|NCT05577325|Behavioral|control group will be followed without health education|After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.
79556369|NCT04068246|Drug|Metformin|1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
79855021|NCT03743324|Procedure|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
79855022|NCT03743324|Procedure|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
79257596|NCT03566927|Combination Product|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
79257597|NCT03568799|Radiation|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
79257598|NCT02455336|Drug|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
79556370|NCT04068246|Drug|Placebo|Placebo tablet plus plus Methotrexate 7.5 mg weekly
79556371|NCT04063033|Drug|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
79556372|NCT04061915|Behavioral|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
79556373|NCT04061915|Behavioral|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
79556374|NCT04012333|Drug|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
79556375|NCT04002258|Drug|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
79257599|NCT02455336|Other|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
79257600|NCT05577169|Behavioral|Mind-body skills|The purpose of mind-body medicine is to use conscious thoughts and actions to positively impact autonomic responses from the brain as well as coping mechanisms for life's stresses. Examples of mind-body skills include deep breathing exercises, meditation, drawing, guided imagery, journaling, affirmations, and biofeedback.
79257601|NCT05577169|Behavioral|Diabetes education|When children and adolescents are diagnosed with diabetes, education is typically focused on the parents; as our older adolescents prepare to transition to adult care with full responsibility of their health, the goal of short education sessions is to review the basics of T1D along with addressing each individual's needs and questions as they make this transition.
79396302|NCT05158075|Behavioral|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if… then…. This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
79556376|NCT03993184|Behavioral|Hot Yoga|Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
79556377|NCT03926819|Drug|HBI-002|Oral liquid carbon monoxide drug product.
79556378|NCT03910959|Other|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
79556379|NCT03910959|Other|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
79556380|NCT03909204|Procedure|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
79556381|NCT03907800|Drug|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
79556382|NCT03907800|Drug|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
79556383|NCT03907800|Drug|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
79556384|NCT03900117|Radiation|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
79556385|NCT03900117|Drug|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
79556386|NCT03894904|Drug|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
79556387|NCT03894904|Drug|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
79556388|NCT03894904|Drug|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
79556389|NCT03811158|Device|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
79257602|NCT02253121|Drug|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
79556390|NCT03811158|Device|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
79556391|NCT03797833|Procedure|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
79556392|NCT03789630|Device|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
79257603|NCT02253121|Drug|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
79257604|NCT03548233|Biological|bcg vaccine|live attenuated vaccine
79257605|NCT03568721|Drug|Ibuprofen|prescription of ibuprofen 400 mg
79257606|NCT03568721|Drug|Acetaminophen|prescription of acetaminophen 500 mg
79257607|NCT03568721|Other|Chewing gum|prescription of one tablet of chewing gum
79855023|NCT03743324|Radiation|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
79257608|NCT03549325|Biological|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
79257609|NCT03568565|Behavioral|ePREP Program|see arm descriptions
79257610|NCT03568565|Behavioral|OurRelationship Program|see arm descriptions
79257611|NCT03764917|Other|Time|Different detecting time
79556393|NCT03771014|Other|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
79556394|NCT03749174|Procedure|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
79719651|NCT04461626|Device|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
79556395|NCT03722927|Drug|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
79581088|NCT01932502|Drug|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
79719652|NCT04448613|Other|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
79855024|NCT00937820|Drug|YM150|oral
79855025|NCT00932516|Behavioral|South Beach Diet™ with South Beach Diet™ Products|
79855026|NCT00932516|Behavioral|South Beach Diet™|
79396303|NCT05158075|Behavioral|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
79719653|NCT04427254|Drug|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
79719654|NCT04411303|Behavioral|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
79719655|NCT04411303|Behavioral|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
79719656|NCT04411303|Behavioral|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
79855027|NCT00932516|Behavioral|Calorie restricted diet with South Beach Diet™ Products|
79855028|NCT00932516|Behavioral|Calorie Restricted Diet|
79855029|NCT00442468|Other|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
79855030|NCT00937976|Procedure|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
79855031|NCT00926978|Radiation|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
79855032|NCT00506883|Drug|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
79855033|NCT00506883|Drug|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
79257612|NCT04905940|Drug|Turmeric mouthwash|Turmeric mouthwash evaluation in controlling halitosis
79855034|NCT00506883|Other|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
79855035|NCT00932594|Procedure|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
79855036|NCT00932594|Other|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
79855037|NCT01028638|Other|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
79257613|NCT03566849|Other|KC group|"1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
79257614|NCT03566849|Other|CT group|"1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
79257615|NCT03568487|Other|Intensive scapula-focused approach|scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks
79257616|NCT03568487|Other|Control Therapy|not have any physical training but is encouraged to stay active as usual.
79257617|NCT05576935|Behavioral|Stroop task|The task is partitioned in 4 blocks of 360 stimuli and each word will be presented on screen in 34 point font for 1000 ms with an inter-stimulus interval based on their performance on the Stroop max test. This max test will be performed during the familiarization trial, and is divided in blocks of 96 stimuli. After each block, the accuracy (ACC) will be calculated. When ACC > 85%, the difficulty of the Stroop task will be increased by decreasing the stimulus presentation time (SPT). If ACC < 85%, this block will be considered as an 'error' and the subject must redo the block without changing the SPT. The first block will have a SPT of 1500 ms. When the required ACC is achieved, the SPT will decrease in the following order: 1100, 900, 800,… to determine the individualized cognitive load. When the subject makes 3 errors in a row, or 5 errors during the whole trial, the trial will end. The SPT of the last block will be considered as the maximum capacity of that individual.
79396304|NCT05158075|Behavioral|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
79396305|NCT05158075|Behavioral|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
79581089|NCT01932502|Drug|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
79855038|NCT00938132|Drug|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
79855039|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
79855040|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
79581090|NCT01932502|Drug|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
79581091|NCT01932502|Drug|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
79581092|NCT01932515|Behavioral|A revised screening instrument for use in Deaf children|
79581093|NCT01932528|Drug|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as [14C]-LX1606.
79855041|NCT04015388|Device|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
79855042|NCT00932672|Behavioral|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
79855043|NCT00927056|Procedure|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
79855044|NCT00938210|Procedure|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
79855045|NCT00932750|Dietary Supplement|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
79855046|NCT00932750|Dietary Supplement|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
79257618|NCT05576935|Behavioral|Documentary|In order to avoid under- and over-arousal, participants will have the opportunity to choose between several documentaries. The participants will also receive a list of the available documentaries (based on selections from Netflix and Disney+) after the familiarization trial so that the trial can go as smoothly as possible.
79257619|NCT05576779|Other|Ofatunumab|All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
79257620|NCT03566771|Behavioral|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
79257621|NCT03566771|Behavioral|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
79556396|NCT03722927|Drug|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
79257622|NCT01562899|Drug|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
79719657|NCT04411303|Behavioral|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
79719658|NCT04402385|Drug|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
79257623|NCT01562899|Drug|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
79257624|NCT05354375|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
79257625|NCT03549247|Behavioral|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
79396306|NCT05158075|Behavioral|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
79396307|NCT05158075|Behavioral|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
79257626|NCT03566693|Device|Dexcom G6 CGM System|continuous glucose monitor
79257627|NCT03566693|Device|Blood glucose meter|Blue-tooth enabled blood glucose meter
79257628|NCT03568331|Drug|Tradipitant|Oral Capsule
79257629|NCT03568331|Drug|Placebo|Oral Capsule
79556397|NCT03698084|Procedure|venepuncture|sample collection for analysis
79556398|NCT03698084|Procedure|nasopharyngeal swab|sample collection for analysis
79257630|NCT03548077|Behavioral|POWERPLAY|"All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
79257631|NCT05468827|Procedure|lymphatic mapping with indocyanine green|subserosal injection of indocyanine green near the primary tumour with subsequent assessment of the dye spread along lymphatics
79257632|NCT03566537|Procedure|Thyroidectomy|Thyroidectomy
79257633|NCT03566459|Other|CBOC offering Tele-MOUD to Veterans|CBOC offering medications for opioid use disorder (MOUD) using telemedicine
79257634|NCT03566459|Other|CBOC not offering Tele-MOUD to Veterans|CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
79257635|NCT03566303|Drug|Rivaroxaban 15 mg|Rivaroxaban 15 mg BID
79257636|NCT03566303|Drug|Warfarin|Warfarin
79556399|NCT03696485|Biological|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
79719659|NCT04402385|Drug|Placebo|Participants randomized to placebo daily
79719660|NCT04399031|Drug|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
79719661|NCT04396730|Drug|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
79719662|NCT04396730|Drug|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
79257637|NCT02140333|Drug|Erlotinib|100mg vs. 150mg
79257638|NCT05936541|Dietary Supplement|Probiotic Bifidobacterium Bifidum PRL2010|Probiotic supplement
79257639|NCT05936541|Other|Control group|No probiotic supplementation
79257640|NCT05936528|Drug|Lactoferrin|antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect
79257641|NCT05936515|Other|Training of nurses and nursing assistants|Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
79257642|NCT05936450|Biological|delivery of placentrex gel after open flap debridement|placentrex gel is placed after open flap debridement only in the test group
79257643|NCT05936450|Procedure|Open Flap Debridement|Open Flap Debridement done in both test and control groups
79257644|NCT05936424|Other|Unilateral Resistance Exercise Leg|One will perform unilateral resistance exercise
79257645|NCT05936424|Other|Non-Exercise Control Leg|One leg will serve as a non-exercise control
79855047|NCT00938288|Drug|KW-3357|50IU/mL, IV single dose
79257646|NCT05936411|Device|Siemens Quadra PET/CT and [18F]FDG|The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer [18F]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq [18F]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.
80018652|NCT04467632|Other|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
79396308|NCT05158075|Behavioral|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
79556400|NCT03578198|Drug|Rituximab + MG4101|"Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~MG4101 3x107 cells/kg IV Weekly (X4)~Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~MG4101 3x107 cells/kg IV q 4 weeks (X4)"
79556401|NCT03554200|Drug|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
79556402|NCT03554200|Drug|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
79556403|NCT03517176|Drug|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
79556404|NCT03517176|Drug|Nab-paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
79556405|NCT03517176|Drug|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
79556406|NCT03512964|Drug|Dolutegravir 50 MG|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
79556407|NCT03512964|Drug|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
79556408|NCT03478384|Behavioral|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
79556409|NCT03476109|Drug|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
79556410|NCT03476109|Drug|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
79396309|NCT05158075|Behavioral|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
79556411|NCT03463499|Drug|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
79556412|NCT03366974|Drug|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
79855048|NCT00932906|Other|Different self-training methods|Self training with MiniAnne Training Kit
79855049|NCT00932906|Other|Standard training|Instructor-based training meeting ERC directions
79855050|NCT00938522|Drug|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
79855051|NCT00938522|Drug|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
79855052|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
79257647|NCT05936411|Device|Apple i-Watch|The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
79719663|NCT04396730|Drug|Combined oral contraceptive pill|All participants will receive oral contraceptives
79855053|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
79855054|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
79396310|NCT05158075|Behavioral|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
79396311|NCT05154669|Other|Financial counseling|The goals of the financial counseling will be to: (1) screen and refer participants to financial benefits and empowerment programs; (2) help participants create and maintain a household budget to meet short- and long-term goals; and (3) help participants link smoking cessation to their budgeting goals.
79556413|NCT03366974|Drug|Clarithromycin|Clarithromycin 500 mg bid
79556414|NCT03366974|Dietary Supplement|Grapefruit juice|Grapefruit juice 500 mL
79556415|NCT03294083|Biological|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
79556416|NCT03294083|Biological|Cemiplimab|Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
79556417|NCT03136835|Drug|Maternal Hyperoxygenation|Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
79855055|NCT00932984|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
79855056|NCT00938678|Drug|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
79257648|NCT05936398|Behavioral|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
79556418|NCT03128398|Drug|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
79556419|NCT03128138|Drug|SPH3127|"Drug: SPH3127 Tablet~Drug: Placebo Tablet"
79556420|NCT03119038|Drug|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
79556421|NCT03119038|Drug|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
79556422|NCT03119038|Drug|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
79556423|NCT03119038|Drug|Ketorolac|Intraoperative periarticular injection of 30 mg
79556424|NCT03119038|Drug|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
79581094|NCT01932541|Drug|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
79719664|NCT04378868|Drug|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
79719665|NCT04378868|Drug|No antibiotics|No antibiotics are given while waiting surgery.
79719666|NCT04378868|Other|urgent schedule|Patients can wait up to 8 hours for surgery.
79719667|NCT04378868|Other|less urgent schedule|Patients can wait up to 24 hours for surgery.
79719668|NCT04347135|Drug|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
79855057|NCT00938678|Drug|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
79855058|NCT03743168|Other|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
79855059|NCT03743168|Other|Continuous stretch|2 minutes continuous stretch
79855060|NCT00933062|Drug|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
79855061|NCT00933062|Drug|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
79855062|NCT00938756|Other|diagnostic laboratory biomarker analysis|
79855063|NCT00938756|Other|immunoenzyme technique|
79855064|NCT00938756|Procedure|magnetic resonance imaging|
79855065|NCT00503685|Biological|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
79719669|NCT04305769|Drug|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
79719670|NCT04301206|Behavioral|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
79855066|NCT00503685|Biological|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
79556425|NCT03099265|Drug|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
79556426|NCT03099265|Drug|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
79257649|NCT05936398|Behavioral|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
79257650|NCT05936333|Procedure|Biological collection|up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
79257651|NCT05936320|Behavioral|Information leaflets with illustrations about hearing aid functions|The information leaflet contains written information with simple illustrations about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
79257652|NCT05936320|Behavioral|Information leaflets with only text about hearing aid functions|The information leaflet contains written information about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
79556427|NCT03033459|Behavioral|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
79556428|NCT03033459|Behavioral|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
79855067|NCT00712673|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
79855068|NCT00712673|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
79855069|NCT00712673|Device|Pen auto-injector|
79855070|NCT00712673|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
79855071|NCT01562990|Drug|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
79855072|NCT00939380|Behavioral|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
79855073|NCT00939380|Other|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
79396312|NCT05154669|Drug|Nicotine Replacement Therapy Agent - Patches|24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.
79581095|NCT01932554|Drug|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
79581096|NCT01932554|Drug|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
79719671|NCT04285125|Other|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
79719672|NCT04254185|Procedure|Simple decompression|Surgical technique
79719673|NCT04254185|Procedure|Subcutaneous anterior transposition|Surgical technique
79855074|NCT00939380|Other|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
79855075|NCT00939380|Other|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
79556429|NCT02975362|Other|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
79719674|NCT04253379|Diagnostic Test|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
79719675|NCT04221269|Behavioral|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
79719676|NCT04221269|Behavioral|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
79719677|NCT04218357|Drug|Probenecid|safety
79719678|NCT04218357|Drug|Matching placebo|Placebo
79855076|NCT00933218|Dietary Supplement|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
79855077|NCT00933218|Dietary Supplement|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
79855078|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
79556430|NCT02975362|Other|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
79556431|NCT02975037|Drug|Sildenafil|sildenafil 25 mg PO
79556432|NCT02975037|Drug|Clarithromycin|clarithromycin 250 mg PO
79556433|NCT02975037|Drug|Itraconazole|itraconazole 100 mg PO
79556434|NCT02970591|Other|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
79556435|NCT02970591|Other|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
79719679|NCT04204330|Device|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~Download the CardioQVARK mobile application; create a profile.~Fill out the questionnaire:~age;~date of birth;~sex;~weight;~height;~blood type;~eye color;~hair color;~occupation;~town;~alcohol consumption;~tobacco use;~overeating;~insufficient sleep;~hypertension;~type 2 diabetes;~pacemaker;~the 10th revision of the International Classification of Diseases (ICD-10) code;~medicines.~Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~abnormal rhythms;~heart rate variability;~additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
79719680|NCT04203550|Procedure|Intraoperative irrigation|Operation with irrigation
79556436|NCT02970591|Other|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
79556437|NCT02931890|Drug|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
79556438|NCT02931890|Drug|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
79556439|NCT02931890|Drug|Capecitabine|oral capecitabine in arm 1 and 2
79719681|NCT04203550|Procedure|No irrigation|Operation without irrigation
80018653|NCT04467632|Other|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
79556440|NCT02931890|Procedure|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
79719682|NCT04166877|Drug|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
79719683|NCT04166877|Drug|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
79719684|NCT04164979|Drug|Cabozantinib|Given PO
79719685|NCT04164979|Drug|Pembrolizumab|Given IV
79719686|NCT04153643|Procedure|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
79719687|NCT04135846|Drug|Doxazosin|16 mg or maximum tolerated dose (MTD)
79855079|NCT00737867|Drug|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
79855080|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
79855081|NCT00737867|Drug|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
79556441|NCT02931890|Radiation|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
80031550|NCT04883866|Behavioral|Telephone Breastfeeding Support Program|On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.
79257653|NCT05936307|Procedure|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 2 mA for a duration of 25min. The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task.
79556442|NCT02931890|Drug|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
79556443|NCT02931890|Drug|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
79556444|NCT02893670|Procedure|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
79556445|NCT02812862|Drug|Spiolto® Respimat® (Tiotropium / Olodaterol)|"LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent."
79556446|NCT02734979|Device|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
79855082|NCT03976466|Device|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
79855083|NCT03976466|Procedure|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
79556447|NCT02658656|Device|ReWalk 6.0|Exoskeletal Assisted Walking Device
79556448|NCT02588846|Device|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
79556449|NCT02587312|Other|Very low nicotine content cigarettes|
79556450|NCT02587312|Other|Standard nicotine content cigarettes|
79556451|NCT02549677|Drug|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
79556452|NCT02549677|Drug|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
79556453|NCT02549677|Drug|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
79556454|NCT02549599|Behavioral|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
79556455|NCT02549599|Behavioral|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
79556456|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
79719688|NCT04135846|Drug|Placebo|Matching placebo
79719689|NCT04117893|Drug|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
79719690|NCT04117893|Drug|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
79719691|NCT04113395|Other|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
79719692|NCT04103190|Device|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
79719693|NCT04098003|Drug|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
79719694|NCT04098003|Drug|Placebo|Matched placebo control
79855084|NCT02536755|Drug|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
79855085|NCT02567279|Drug|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
79855086|NCT02567279|Drug|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
79855087|NCT00938834|Other|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
79875556|NCT00554801|Procedure|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
79719695|NCT04054414|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
79719696|NCT04054414|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
79556457|NCT02540655|Biological|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
79556458|NCT02540655|Procedure|Excipients|Patients will receive excipients through intravenous infusion
79556459|NCT02512250|Other|Registry|
79257654|NCT05936307|Procedure|High-definition transcranial direct current (HD-tDCS), placebo condition|"Participants will receive a session of placebo HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 2mA during the 30 first seconds at the beginning of the 25-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task"
79257655|NCT05936294|Diagnostic Test|Optimization of CRT Device|Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
79257656|NCT05936281|Drug|Genakumab for injection|150 mg/1ml/bottle
79257657|NCT05936281|Drug|Etoricorxib|60mg/table
79719697|NCT04049851|Drug|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
79257658|NCT05936216|Biological|TVI-Brain 1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
79719698|NCT04049851|Drug|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
79719699|NCT04049851|Drug|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
79719700|NCT03970954|Drug|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
79719701|NCT03963375|Drug|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
79257659|NCT05936125|Other|Annuloplasty Using Flexible Band|Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
79719702|NCT03936361|Drug|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
79719703|NCT03907644|Device|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
79719704|NCT03886909|Behavioral|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
79719705|NCT03886909|Behavioral|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
79719706|NCT03880162|Other|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
79855088|NCT05460689|Other|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
79855089|NCT05460689|Other|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
79257660|NCT05936112|Other|Fecal calprotectin dosage|Dosing calprotectin in infants' feces + questionnaire/interview with parents
79875557|NCT00942773|Drug|Voriconazole|
79257661|NCT05936112|Other|Questionnaire and interview with parents|Dosing calprotectin in infants' feces + questionnaire/interview with parents
79556460|NCT02450253|Drug|Tadalafil|single dose, 20 mg capsule p.o.
79257662|NCT05936060|Biological|INMUNOCEM|Mesenchymal Stromal Cell suspension intraarticularly injected
79257663|NCT05936060|Drug|PLACEBO COMPARATOR|Administration of plasmalyte as a vehicle for MSC
79556461|NCT02450253|Drug|Placebo|single dose, matching capsule p.o.
79556462|NCT02450253|Behavioral|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
79556463|NCT02450253|Behavioral|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan & then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
79855090|NCT04013594|Dietary Supplement|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
79855091|NCT00933374|Drug|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
79257666|NCT05935969|Procedure|ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage)|For transpapillary gallbladder drainage, biliary cannulation was performed with a duodenoscope (JF-260V or TJF-260V; Olympus Optical). After successful deep cannulation of the CBD, we checked the cholangiogram, performed endoscopic sphincterotomy, and removed the CBD stone using a memory basket and/or retrieval balloon. Cholangiography was then performed again to locate the cystic duct orifice, and a guide wire (Jagwire; Boston Scientific, Marlborough, Massachusetts, USA or Visiglide; Olympus, Tokyo, Japan) was inserted into the gallbladder with different types of catheters (standard catheter, pull-sphincterotome, or rotating sphincterotome) under fluoroscopic guidance. After placement of the guide wire into the gallbladder, contrast dye was injected to confirm good entry into the gallbladder. Once the gallbladder was selected and the guidewire was coiled in the GB, a 7Fr 12-15cm double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Winston-Salem, NC) was inserted into the GB.
79257667|NCT05935956|Device|Magnetic Peripheral Nerve Stimulation|Magnetic Peripheral Nerve Stimulation
79257668|NCT05935904|Other|Exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
79257669|NCT05935904|Other|Non exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
79396313|NCT05154669|Drug|Nicotine Replacement Therapy Agent - Lozenges|"General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated"
79556464|NCT02450253|Other|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
79556465|NCT02411812|Device|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
79556466|NCT02411812|Device|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
79556467|NCT02411812|Device|Twin-Block appliance|Group treated with Twin-Block appliance
79556468|NCT02263807|Procedure|MPFL Group|MPFL reconstruction or standard treatment followed by physiotherapy
79556469|NCT02263807|Procedure|Control|Arthroscopy followed by active rehabilitation
79556470|NCT02257970|Drug|Ketoprofen|
79556471|NCT02257970|Drug|Placebo|Placebo to match ketoprofen.
79855092|NCT00933374|Drug|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
79855093|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
79556472|NCT02246413|Behavioral|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
79556473|NCT05838690|Other|Personalized Intubation Safety (PINS) Bundle|The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
79855094|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
79556474|NCT05838651|Device|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
79556475|NCT05838651|Device|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
79556476|NCT05838612|Other|Heat acclimation|Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (~40°C) for 1 hour over 7 consecutive days.
79556477|NCT05838599|Drug|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
79556478|NCT05838599|Radiation|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
79556479|NCT05838547|Drug|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 18 months.
79855095|NCT00933452|Drug|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
79855096|NCT00933452|Drug|duloxetine|15mg, oral administer
79855097|NCT00933452|Drug|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
79855098|NCT03263325|Other|Discarded urine sample|Collection of discarded urine during surgery and following surgery
79855099|NCT00933530|Drug|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
79875558|NCT00947687|Drug|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
79875559|NCT00947687|Drug|Placebo|
79875560|NCT00943007|Device|Stealth Station|Neuronavigation based on preoperative MRI
79257670|NCT05935891|Drug|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
79257671|NCT05935891|Drug|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
79257672|NCT05935852|Device|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
79257673|NCT05935839|Device|Multispectral optoacoustic tomography|Molecular Imaging of tissue changes using MSOT in macroangiopathy in diabetes. Dual imaging before and after physical stress.
79257674|NCT05935839|Diagnostic Test|Ankle Brachial Index|Dual measurement of ABI index before and after physical exercise.
79257675|NCT05935839|Diagnostic Test|Neuropathy Disability Score|Single measurement of the NSS
79257676|NCT05935813|Other|Study characteristics of adolescents affected by dental caries|Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
79556480|NCT05838547|Drug|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
79556481|NCT05838508|Behavioral|Exercise intervention|Research participants will be assigned to two exercise conditions.
79257677|NCT05935761|Drug|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
79719707|NCT03880162|Other|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
79719708|NCT03860805|Procedure|Laparoscopic tubal ligation|Laparoscopic tubal ligation
79855100|NCT00933530|Drug|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
79257678|NCT05935761|Drug|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
79257679|NCT05935761|Drug|Placebo|Same as active comparator arms, except placebo dispensed
79257680|NCT05935722|Behavioral|Parenting Young Children|PYC is a home-based intervention programme involving weekly, one-hour sessions over a period of at least six months. The programme has two core modules (1) Parent-Child Interaction and (2) Child Care Skills and Safety. The Parent-Child Interaction module focuses on the parent-child relationship and interaction skills such as parents' responsiveness to the child's signals, giving the child attention and encouragement, and supporting prosocial behaviour. The Child Care Skills and Safety module targets safety at home and the parent's caring skills (e.g. food, health, and hygiene). Checklists are adapted to each parent in order to support the PYC practitioner and the parent. The programme is compiled in a manual that includes work tasks, instructions for how to perform the tasks, and teaching materials.
79257681|NCT05935722|Behavioral|Treatment as Usual|TAU consists of a variety of interventions from the social services. The support will be logged and classified in accordance with the Swedish National Board of Health and Welfare's guidelines for classifications of its activities. TAU will be divided into the following five categories: 1) conversation counselling or emotional support, 2) practical support, 3) skills training, 4) compensatory strategies, and 5) other support. Support will also be classified based on whether it is home-based or given outside the home and whether it is individualised or in a group setting.
79556482|NCT05838469|Other|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
79581097|NCT01932554|Other|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
79719709|NCT03860805|Procedure|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
79581098|NCT01932554|Drug|Ibuprofen|Scheduled ibuprofen,~10 mg/kg every 6-8 hours
79581099|NCT01932554|Drug|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
79719710|NCT03837847|Behavioral|Health Coaching Calls|12 weekly health coaching calls
79719711|NCT03837847|Behavioral|Wait list control|after being 12 week in the usual care arm , patient will compassionately be offered the health coaching intervention
79257682|NCT05935670|Device|Ischemic Conditioning|The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
79257683|NCT05935592|Behavioral|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
79257684|NCT05935592|Behavioral|Didactic health information|Web-based newsletters (for child and parent) by email and/or text
79257685|NCT05935566|Other|health questionnaire|Telephone interview with patient to verify medical history, including tonsillectomy and adenoidectomy.
79257686|NCT05935501|Device|Formaderm Young|Dermal filler injection to facial areas.
79257687|NCT05935501|Device|Restylane|Dermal filler injection to facial areas.
79257688|NCT05935449|Device|Formaderm Lidocaine|Dermal filler injection to facial areas
79257689|NCT05935449|Device|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
79556483|NCT05838443|Other|Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation|Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.
79556484|NCT05838443|Other|Provider-directed mindfulness|"Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions."
79556485|NCT05838443|Other|Conventional Care|Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
79556486|NCT05838365|Device|Zirconia implant|(Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)
79556487|NCT05838326|Device|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio < 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
79855101|NCT00447694|Drug|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
79855102|NCT00564278|Drug|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
79855103|NCT00564278|Behavioral|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
79855104|NCT04013906|Diagnostic Test|Rotational atherectomy|Rotational atherectomy
79855105|NCT00933842|Drug|LACTIC ACID(ND)|Treatment duration: 5 weeks
79257690|NCT05935423|Biological|Umbilical Cord Mesenchymal Stem Cell transplantation|50 million UC MSC will be transplanted 10-15 days after primary PCI
79855106|NCT00565604|Device|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
79257691|NCT05935397|Device|percutaneous coronary intervention|patients with CAD undergoing PCI with second generation DES
79396314|NCT05154669|Drug|Nicotine Replacement Therapy Agent - Gum|Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
79855107|NCT00933920|Drug|Aliskiren|
79855108|NCT00933920|Drug|Aliskiren|
79855109|NCT00938990|Drug|Etomidate|
79855110|NCT00938990|Drug|Midazolam|
79257692|NCT05935345|Behavioral|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
79257693|NCT05935345|Other|Control condition|Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
79257694|NCT05935319|Other|Vivifrail|Assess the physical activity status of the elderly, use the Vivifrail grade, provide exercise intervention, and improve physical activity function.
79257695|NCT05935293|Drug|Dexmedetomidine|iv administration dexmedetomidine
79257696|NCT05935280|Other|Room temperature|Room temperature injection
79396315|NCT05150106|Other|Clinical assessments of laryngeal function|Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
79719712|NCT03827031|Other|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
79556488|NCT05838326|Device|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio < 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
79556489|NCT05838300|Device|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
79719713|NCT03827031|Other|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
79719714|NCT03810105|Drug|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
79719715|NCT03810105|Drug|Durvalumab|Durvalumab 1500mg IV monthly
79719716|NCT03785210|Drug|nivolumab|480 mg intravenous (IV) every 4 weeks
79719717|NCT03785210|Drug|tadalafil|10 mg by mouth (PO) daily
79719718|NCT03785210|Drug|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
79719721|NCT03750968|Drug|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
79719722|NCT03750968|Dietary Supplement|Control Group|Placebo ingredients: Safflower oil
79556490|NCT05838300|Device|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
79556491|NCT05838261|Procedure|Pharyngeal flap|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
79556492|NCT05838248|Other|antibiotic duration|Duration of antibiotic treatment post appendectomy
79556493|NCT05838235|Other|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
79556494|NCT05838157|Biological|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
79556495|NCT05838118|Drug|Fecal Microbiota Transplantation|Biologically active human fecal fluid (donor stool) is provided in fluid form.
79719723|NCT03742817|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
79719724|NCT03741335|Other|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
79719725|NCT03741335|Other|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
79719726|NCT03741335|Other|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
79257697|NCT05935280|Other|Cold temperature|Cold temperature injection
79257698|NCT05935280|Drug|Lidocain|Unspecific sodium channel blocker
79257699|NCT05935280|Drug|PF-05105679|Specific antagonist of the TRPM8 ion channel
79257700|NCT05935280|Drug|A967079|Specific antagonist of the TRPA1 ion channel
79257701|NCT05935280|Drug|PF-05089771|Specific antagonist of the Nav1.7 sodium channel
79257702|NCT05935280|Drug|PF-06305591|Specific antagonist of the Nav1.8 sodium channel
79556496|NCT05838118|Other|Standard of Care for Chronic Kidney Disease|Patients accepted oral drug or dialytic therapy like they used to be to treat CKD.
79719727|NCT03722498|Drug|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
79719728|NCT03722498|Drug|Sorafenib|administration of Sorafenib
79719729|NCT03710824|Drug|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
79719730|NCT03699826|Device|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
79875561|NCT00943007|Device|PoleStar N20|Intraoperative MRI guided surgery
79719731|NCT03690388|Drug|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
79719732|NCT03690388|Drug|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
79719733|NCT03665922|Dietary Supplement|BroccoMax®|Nutraceutical neoadjuvant
79719734|NCT03665922|Other|Placebo|control
79719735|NCT03648892|Drug|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both [18F]fallypride and [11C]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from [18F]fallypride and [11C]raclopride.
79719736|NCT03648892|Drug|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both [18F]fallypride and [11C]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from [18F]fallypride and [11C]raclopride.
79855111|NCT00933998|Other|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
80018654|NCT04467632|Other|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~Day #1: baseline assessment of outcome measures;~Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~Phase B (11 days): similar as in phase A:~Day #1: similar as in phase A;~Days #2 to #6: reverted conditions compared to phase A.~Days #7 to #11: reverted conditions compared to phase A."
80018655|NCT05138146|Drug|609A|"609A 200mg,IV, Day 1of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first.~Every 3 weeks a treatment cycle."
79556497|NCT05838105|Drug|GnRH agonist|125 mcg once at the day mentioned
79556498|NCT05838105|Drug|hCG|dose as mentioned
79556499|NCT05838105|Drug|Progesterone 100Mg Vag Tab|dose as mentioned
79556500|NCT05838079|Other|Clinical examination|Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
79556501|NCT05838066|Drug|KN026|IV infusion
79719737|NCT03626831|Drug|Evolocumab Prefilled Syringe|Injection of study drug
79719738|NCT03626831|Drug|Placebos|Injection of placebo
79719739|NCT03619213|Drug|Dapagliflozin|10 mg tablets given once daily, per oral use.
79719740|NCT03619213|Drug|Placebo|Placebo matching dapagliflozin 10 mg
79719741|NCT03570515|Behavioral|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
79719742|NCT03570515|Behavioral|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
79719743|NCT03527992|Device|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
79855112|NCT00447226|Drug|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
80018656|NCT05138146|Drug|doxorubicin hydrochloride|60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
80018657|NCT02252952|Other|Beverage Consumption|
79396316|NCT05148234|Drug|decitabine and cedazuridine|FDA-approved DNMTi PO decitabine and cedazuridine according to guidelines Abbreviated Title: BMS-986253 in MDS 34 Version Date: 9/08/2021 outlined in FDA product label. SOC DNMTi will
79396317|NCT05148234|Drug|BMS-986253|IV infusion, 200 mg/Vial (20 mg/mL) or 1000 mg/vial (100mg/mL)
79396318|NCT05131607|Procedure|Supine MRI|After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
79556502|NCT05838066|Drug|HB1801|IV infusion
79556503|NCT05838066|Drug|Pertuzumab|840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
79556504|NCT05838066|Drug|Trastuzumab|8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
79556505|NCT05838066|Drug|Docetaxel|75 mg/m^2, D1 Q3W, IV infusion
79556506|NCT05838014|Other|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
79556507|NCT05838014|Other|Normal sleep|Participants will undertake ~8 hours of normal sleep prior to completing exercise
79556508|NCT05838001|Procedure|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the breast lesion
79556509|NCT05838001|Procedure|marker clip localization|Positioning marker clip in the center of the breast lesion
79581100|NCT01932554|Other|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
79581101|NCT01932554|Other|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
79581102|NCT01932567|Other|Physiotherapy|
79581103|NCT01932567|Procedure|Electrical impedance tomography|
79581104|NCT01932580|Drug|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
79257703|NCT05935267|Procedure|thoracic irrigation|We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.
79257704|NCT05935254|Device|Plaque removal efficacy of children's electric toothbrush (Oral-B D100 Vitality; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with an electric toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
79257705|NCT05935254|Device|Plaque removal efficacy of children's soft manual toothbrush (Oral-B Stages 6-12 years; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with a manual toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
79257706|NCT05935215|Drug|Iptacopan|Open Label
79556510|NCT05837962|Behavioral|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|"The nursing professional will perform 1 session weekly, for 4 weeks, lasting 90 minutes each. The contents that make up each of the sessions are:~Session 1. Knowledge about the risk factors, signs and symptoms, maternal and fetal complications of HDP.~Session 2. Control over behaviour, positive attitude and family and social support: essential components for conducting self-care behaviour.~Session 3. Nutritional recommendations: eating healthy helps prevent or reduce the risk of developing HDP.~Recommendations to improve sleep, rest and physical exercise: key routines in my health to prevent or reduce the risk of developing HDP.~Session 4. Mental health promotion: managing my stress, anxiety and depression levels help prevent or decrease the risk of HDP"
79556511|NCT05837949|Behavioral|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
79556512|NCT05837936|Other|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
79556513|NCT05837936|Other|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
79556514|NCT05837793|Behavioral|Modified frailty index|The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
79556515|NCT05837780|Other|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
79556516|NCT05837689|Drug|Blinatumomab|IV
79556517|NCT05837572|Other|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
79556518|NCT05837559|Other|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
79556519|NCT05837520|Device|i-BiSSkApp (tablet application) with swallowing therapy|"The device, International Biofeedback Strength and Skill App (i-BiSSkApp) is an at-home swallowing biofeedback tool (hardware and software) to target rehabilitation of both skill and strength of swallowing function. The program utilizes submental surface electromyography coupled with a user-friendly interface to display visual feedback of swallowing strength and timing."
79556520|NCT05837520|Behavioral|Traditional behavioral swallowing therapy|Participants will receive standard behavioral swallowing exercises based on the results of a swallowing evaluation. Participants will complete daily at-home exercises with written and verbal instructions and return weekly to clinic for 12 weeks of therapy.
79556521|NCT05837468|Behavioral|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
79556522|NCT05837442|Other|Osteopathic Manual Therapy|Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
79556523|NCT05837429|Behavioral|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
80018658|NCT05221957|Drug|Iron(III)isomaltoside|Individual weight and hemoglobin dependent dosage
79719744|NCT03527992|Device|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
79719745|NCT03481049|Behavioral|Usual CM|Behavioral reinforcement for alcohol abstinence
79719746|NCT03481049|Behavioral|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
79719747|NCT03481049|Behavioral|Shaping CM|Behavioral reinforcement for alcohol abstinence
79719748|NCT03445949|Drug|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
79719749|NCT03445949|Drug|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
79257707|NCT05935163|Procedure|Conventional therapy for hamstring tightness|Conventional Physical therapy will include TENS , hot pack , Hamstring self stretch , Calf self stretching , bridging exercise , piriformis stretch , prone on hands and prone on elbows.
79257708|NCT05935163|Procedure|Bowen Technique|"Bowen Technique:~The patient will assume a full prone-lying position on the plinth.~Sequence of short gentle moves will be applied over hamstrings. Firstly, the thumbs will be placed on top of the hamstrings muscle and the tightness is assessed.~Then, the muscle will be hooked by the thumbs from its lateral edge. Then, gentle pressure will be applied to the point of resistance to challenge the muscle in medial direction, as the thumbs will be flattened in medial direction, the muscle will pluck under the thumbs.~First with the thumbs, then will be followed by the fingers. Often, the hands are placed with a distance of inch of space between the thumbs and fingers so that the hands performed the technique on the muscle easily.~The whole procedure will be repeated again. The treatment time for each session will be 20 minutes for each side."
79556524|NCT05837429|Behavioral|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
79556525|NCT05837416|Drug|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
79556526|NCT05837416|Drug|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
79556527|NCT05837416|Drug|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
79719750|NCT03445949|Drug|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
79855113|NCT00446992|Drug|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
79855114|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
79855115|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
79556528|NCT05837364|Other|Development of an algorithm|Development of an algorithm to predict the risk of new onset Atrial Fibrillation
79556529|NCT05837299|Drug|IMC008|allowing 10% dose error
79556530|NCT05837286|Device|Oval-8 ® Orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
79719751|NCT03445949|Drug|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
79855116|NCT00503139|Drug|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
79855117|NCT00577031|Drug|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
79855118|NCT00577031|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
79719752|NCT03421977|Biological|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
79719753|NCT03342690|Drug|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
79719754|NCT03331601|Drug|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
79719755|NCT03313817|Device|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
79855119|NCT00577031|Drug|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
79855120|NCT00565448|Drug|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
79855121|NCT00565448|Drug|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
79556531|NCT05837286|Other|Cortisone injection only|The control group will receive a cortisone injection and be instructed to move their fingers normally
79257709|NCT05935163|Procedure|Dynamic Soft Tissue Mobilization (DSTM):|"To access the hamstring muscle group, the subject will be asked to attain prone position and deep longitudinal strokes will be applied to the entire muscle group. Once the specific area of hamstring muscle tightness will be located, the remaining treatment will be limited to this target area.~To execute the dynamic intervention, the subject will be requested to move in the supine position with the hip and knee flexed to 90 degree.~Deep longitudinal strokes will be applied in a distal to proximal direction to the area of hamstring tightness and the leg will be passively moved to knee extension. Five strokes will be applied and 20 seconds of shaking is performed at the completion of this technique.~This treatment will be given for 20 minutes on each side."
79556532|NCT05837273|Device|Fully-immersive VR|For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.
79556533|NCT05837273|Behavioral|Cognitive training|For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
79556534|NCT05837260|Other|Sample collection only|Sample collection only
79556535|NCT05837195|Device|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
79556536|NCT05837130|Other|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
79556537|NCT05837130|Other|Blood sample collection|No study drug will be administered to study participants.
79556538|NCT05837078|Procedure|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
79556539|NCT05837065|Other|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
79556540|NCT05837026|Behavioral|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
79556541|NCT05837026|Other|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
79556542|NCT05836961|Other|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
79556543|NCT05836857|Behavioral|Cannabis (Marijuana)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
79556544|NCT05836857|Behavioral|Cannabidiol (CBD)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
79556545|NCT05836831|Drug|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
79556546|NCT05836805|Drug|[14C]XZP-3621|Extemporaneously compounded oral suspension solution of [14C]XZP-3621 (400 mg/200 µCi)
79556547|NCT05836649|Behavioral|Oculus Go headset without active intervention|VR software with non-interactive content.
79556548|NCT05836649|Behavioral|Oculus Go headset with active intervention|Participant will engage with the game display on the VR headset. Engagement time depends on the HPT limits test.
79719756|NCT03267459|Device|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
79855122|NCT00565448|Drug|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
79257710|NCT05935150|Procedure|Omit SLNB|Omit SLNB in cN0 EBC patients. All patients enrolled have to receive two or more of the following radiographic examinations including ultrasound, breast MRI, breast PET-CT, breast PET-MRI, and breast PET.
79257711|NCT05935137|Diagnostic Test|Coagulation test on device ClotPro|The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
79257712|NCT05935124|Diagnostic Test|WLE first, then B-NBI|
79556551|NCT05836558|Procedure|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
79556552|NCT05836545|Drug|Remimazolam|The patient with remimazolam
79556553|NCT05836545|Drug|Midazolam|The patient with midazolam
79719757|NCT03262662|Drug|Varenicline|oral varenicline tablets
79719758|NCT03262662|Behavioral|Brief smoking cessation counseling|~10-minute individual counseling at each of 6 clinic visits
79556554|NCT05836532|Procedure|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
79556555|NCT05836519|Other|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
79556556|NCT05836493|Procedure|Ring annuloplasty|A prosthetic ring is implanted to treat tricuspid regurgitation
79556557|NCT05836493|Procedure|Suture procedure|Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
79556558|NCT05836480|Procedure|mitral valve repair|conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
79556559|NCT05836467|Procedure|Valvular interventions|Any kind of intervention on heart valves
79556560|NCT05836441|Radiation|Exposure to white patches|Exposure to white patches
79556561|NCT05836441|Radiation|Exposure to edge of white patches and normal skin around white patches|Exposure to edge of white patches and normal skin around white patches
79556562|NCT05836428|Other|no intervention|no intervention
79556563|NCT05836415|Procedure|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
79556564|NCT05836389|Procedure|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
79556565|NCT05836376|Procedure|Mitral valve annuloplasty|implantation of a prosthetic ring to treat mitral valve regurgitation
79556566|NCT05836363|Procedure|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
79556567|NCT05836350|Drug|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, ~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
79556568|NCT05836350|Drug|4.8 g/m^2/day placebo|12-week oral administration of 4.8 g/m^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, ~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
79556569|NCT05836337|Device|Tattoo- Black Eye|Device name: Black eye Manufacturer: The Standard Co., Ltd
79556570|NCT05836337|Device|clip- HydroMARK|Device name: HydroMARK Manufacturer: Biopsy Sciences, LLC
79556571|NCT05836233|Drug|Pulmonary Vasodilators|"Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose."
79556572|NCT05836207|Behavioral|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
79556573|NCT05836207|Behavioral|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
79556574|NCT05836181|Behavioral|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
79257713|NCT05935046|Behavioral|Walk test and meal test|"The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption."
79556575|NCT05836116|Other|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
79556576|NCT05836077|Other|Education with pecha kucha method|Education with pecha kucha method
79719759|NCT03257267|Drug|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
79556577|NCT05835726|Drug|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
79855123|NCT01012011|Drug|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
79257714|NCT05934968|Other|Mad Dog cooking class series|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
79257715|NCT05934929|Other|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
79556578|NCT05835037|Drug|Zinc Acetate 25 MG|Participants will take one tablet per day (25mg Zinc acetate [Galzin]) for 1 year
79556579|NCT05835037|Drug|Placebo|Participants will take one placebo tablet per day for 1 year
79556580|NCT05834660|Behavioral|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
79556581|NCT05833217|Procedure|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
79556582|NCT05833217|Diagnostic Test|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
79556583|NCT05832021|Procedure|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
79556584|NCT05832021|Procedure|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
79556585|NCT05830682|Device|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
79719760|NCT03257267|Drug|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~Antifolate: Pemetrexed~Topoisomerase 1 inhibitor: Topotecan or Irinotecan~Nucleoside analogue: Gemcitabine~Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
79719761|NCT03245645|Other|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
79719762|NCT03190668|Drug|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
79257716|NCT05934916|Device|CPAP ( Continuous positive airway pressure)|The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.
79257717|NCT05934916|Device|oxygen therapy|both groups will receive oxygen
79719763|NCT03190668|Drug|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
79855124|NCT00934076|Drug|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
79855125|NCT04495803|Other|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
79855126|NCT00934154|Drug|Thalidomide|100 mg/day continuously for 12 months
79855127|NCT00934154|Drug|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
79855128|NCT00446446|Drug|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
79257718|NCT05934864|Genetic|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
79556586|NCT05823857|Other|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
79556587|NCT05823857|Other|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
79556588|NCT05814744|Drug|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
79556589|NCT05814744|Drug|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
79257719|NCT05934825|Biological|Injectable suspension of allogeneic adult mesenchymal stem cells|Cell therapy treatment will be administered in a single dose at the beginning of the study. The treatment consists of the administration of a single dose of allogeneic adult mesenchymal stem cells from adipose tissue. The dose is 120 million cells (drug volume: 20 ml, concentrated at 6 million cels/ml).
79396319|NCT05130632|Behavioral|The community working group|"The intervention consists of educational working group (WG) sessions over a 12-week period. Eight core modules-the essential ingredients-and 4 periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize 1 task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as: -starting an organic compost pile free of plastic waste -training on community recycling, focusing on plastics recycling -making organic soaps, to use for personal grooming or washing clothes, eliminate plastic packaging -creating materials out of plastic, like bottle planters, crocheted plastic bags, purses."
79556590|NCT05814744|Procedure|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
79556591|NCT05814744|Procedure|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
79396320|NCT05124808|Other|Intensive glycemic targets|Fasting blood glucose <90 mg/dL, 1 hour post-prandial blood glucose <120 mg/dL
79556592|NCT05798221|Behavioral|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
79556593|NCT05798221|Other|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
79556594|NCT05797558|Procedure|Unilateral adrenalectomy|Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
79556595|NCT05797558|Drug|Medical treatment (eplerenone)|The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e > ~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
79556596|NCT05789095|Other|Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)|"Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation."
79556597|NCT05786820|Dietary Supplement|Pycnogenol|daily consumption of a pycnogenol-containing capsule
79556598|NCT05786820|Dietary Supplement|Placebo|Daily consumption of a placebo capsule
79719764|NCT03190668|Device|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
79719765|NCT03190668|Device|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
79719766|NCT03162653|Drug|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
79719767|NCT03162653|Drug|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
79556599|NCT05781308|Drug|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
79556600|NCT05781308|Drug|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
79855129|NCT05078255|Drug|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
79556601|NCT05781308|Drug|Atezolizumab|1200 mg every 3 weeks
79257720|NCT05934825|Other|Placebo|The placebo consists of the administration of the excipient of the suspension without cells. The excipient is a mixture of 50% hyaluronic acid, 49% DMEM without phenol red and 1% L-Alanine-L Glutamine.
79556602|NCT05772156|Drug|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
79719768|NCT03144206|Drug|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
79719769|NCT03098004|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
79257721|NCT05934812|Drug|Oxytocin nasal spray|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
79556603|NCT05772156|Drug|Placebo|Matching saline placebo
79556604|NCT05769868|Drug|Esmolol Injection [Brevibloc]|"Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min)."
79556605|NCT05756894|Device|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
79556606|NCT05756894|Other|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
79556607|NCT05727579|Other|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
79556608|NCT05715879|Diagnostic Test|covid infection|patients with covid infection which was proved with positive test
79556609|NCT05715879|Biological|admission to hispital|patients with sever covid disease, who was admitted in hospital
79556610|NCT05685186|Diagnostic Test|Spirometry|To assess lung function
79556611|NCT05685186|Diagnostic Test|Multiple Breath Washout (MBW)|To measure Lung Clearance Index (LCI)
79556612|NCT05685186|Diagnostic Test|Mucociliary Clearance (MCC)|To measure lung clearance after the inhalation of radiolabeled particles
79719770|NCT03025789|Drug|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (1 tablet) for 6 days (with food)
79719771|NCT02999932|Other|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
79719772|NCT02991456|Drug|Rolapitant|single 180 mg dose by mouth
79719773|NCT02991456|Drug|Ondansetron|8 mg by mouth daily
79719774|NCT02876640|Procedure|Biospecimen Collection|Undergo blood and urine sample collection
79556613|NCT05685186|Diagnostic Test|CT of the chest|Low radiation to assess structural lung disease
79556614|NCT05685186|Diagnostic Test|MRI of the chest|To assess lung function and structural lung disease
79257722|NCT05934812|Drug|Placebo|Placebo liquid nasal spray administered twice-daily
79257723|NCT05934799|Drug|Clopidogrel film-coated tablet 75 mg|Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
79396321|NCT05124808|Other|Standard glycemic targets|Fasting blood glucose <95 mg/dL, 1 hour post-prandial blood glucose <140 mg/dL
79396322|NCT05118503|Behavioral|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
79396323|NCT05118503|Behavioral|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
79556615|NCT05668117|Device|Depuy Synthes Advanced Retrograde femoral nail|The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.
79581105|NCT01932593|Procedure|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
79719775|NCT02876640|Drug|Retinoid 9cUAB30|Given PO
79719776|NCT02876640|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection surgery
79719777|NCT02848586|Other|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
79855130|NCT05078255|Drug|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
79257724|NCT05934799|Drug|Plavix® film-coated tablet 75 mg|Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
79396324|NCT05109312|Drug|Bupivacaine Hydrochloride|100 mg
79396325|NCT05109312|Drug|Bupivacaine Hydrochloride|125 mg
79855131|NCT05078255|Other|Semaglutide 1.34 mg/ml placebo|Saline
79855132|NCT05078255|Other|GIP placebo|Saline
79855133|NCT00939458|Drug|Lamotrigine|
79875562|NCT00943085|Behavioral|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
79396326|NCT05109312|Drug|HTX-011|400 mg
79396327|NCT05109312|Device|Luer lock applicator|Applicator for instillation
79396328|NCT05109312|Drug|Ibuprofen|400 mg
79556616|NCT05666778|Device|Menstrual Cup|Menstrual cups are inserted vaginally to collect menstrual flow, with some designed especially for use during intercourse, which will be used in this study. Medical devices registered with the U.S. FDA, a reusable silicon cup can last up to 10 years, is cost-effective, and has reduced environmental impact.
79556617|NCT05652764|Other|Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients|In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
79556618|NCT05650827|Behavioral|Resistance training|10 weeks of resistance training 3 times pr. week.
79556619|NCT05650827|Dietary Supplement|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
79556620|NCT05639296|Other|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
79556621|NCT05603364|Combination Product|100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose|Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
79257725|NCT05934786|Behavioral|Cognitive rehabilitation|Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
79396329|NCT05109312|Drug|Acetaminophen|1 g
79556622|NCT05603364|Other|Routine feeding|Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
79556623|NCT05597254|Dietary Supplement|Probiotic with niacin and berry extract|1 capsule daily of probiotic with niacin supplementation for 8 weeks
79556624|NCT05597254|Dietary Supplement|Probiotic without niacin and berry extract|1 capsule daily of probiotic without niacin supplementation for 8 weeks
79556625|NCT05597254|Dietary Supplement|Placebo|1 capsule daily of placebo supplementation for 8 weeks
79556626|NCT05583994|Other|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
79556627|NCT05579340|Other|Exercise|6 months of combined aerobic and resistance exercise
79396330|NCT05103566|Device|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
79396331|NCT05082519|Behavioral|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
79396332|NCT05076448|Procedure|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
79556628|NCT05576415|Drug|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
79556629|NCT05557188|Other|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
79556630|NCT05557188|Other|Sham grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
79556631|NCT05549596|Device|Ceragem Master V6 Traction|Ceragem Master V6 Traction for L2~L3
79556632|NCT05549596|Device|Physical therapy with standard traction device|Physical therapy with standard traction device
79556633|NCT05511064|Device|Blood circulation device|Blood circulation device of CGM MB-1701
79556634|NCT05507151|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
79556635|NCT05506436|Device|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
79257726|NCT05934760|Other|High intensity interval training (HIIT)|"Each HIIT session last 15 minutes. Participants will be asked to measure their own heart rate during their rest periods and provided with an estimated max heart rate which they should be aiming to achieve within the final 2 exercises. Participants will be provided with a logbook to record the heart rate achieved in each exercise. The regimen will include:~2 min warm-up: jogging on the spot~Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~Star jumps~Standing squats~On-the-spot sprints~Standing squats~Star jumps~2 min cool-down: jogging on the spot"
79875563|NCT00943085|Behavioral|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
80018659|NCT05221879|Other|Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a|We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
80018660|NCT03450772|Drug|Creon® 25000|Experimental drug
80018661|NCT03450772|Drug|Creon® 10000|Active comparator
80018662|NCT04083196|Biological|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
80018663|NCT04083196|Biological|Placebo|Placebo
79556636|NCT05506436|Other|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
79556637|NCT05490069|Other|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
79257727|NCT05934760|Other|Resistance based training (RET)|"Each RET session lasts an estimated 20minutes. Participants will be provided with a set of resistance bands to provide resistance to their workout, and a logbook to record the number of repetitions and band used.~Each session will include:~2 min warm-up jogging on the spot~2 sets of 12-15 repetitions of:~Squats~Hip flexion~Hip extension~Hip abduction~Seated row~Bench press~Lateral raises~2 min jogging on the spot cooldown.~Each exercise will be separated by 1-minute rest, with participants encouraged to workout to mild fatigue on their final repetition in each set. If able to perform more than the allocated maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the resistance by using a tougher resistance band."
79257728|NCT05934734|Other|No intervention|This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
79719778|NCT02848586|Behavioral|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
79719779|NCT02848586|Other|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
79556638|NCT05482672|Drug|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
79719780|NCT02842827|Drug|bomedemstat|oral administration
79719781|NCT02842827|Drug|tretinoin|oral administration
79875564|NCT04279769|Drug|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
79875565|NCT04279769|Drug|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
79875566|NCT00374907|Drug|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
79875567|NCT00374907|Drug|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
80018664|NCT02129088|Drug|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
80018665|NCT02129088|Drug|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
80018666|NCT05280080|Other|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
80018667|NCT05221801|Behavioral|angle of inclination|The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
80018668|NCT05221801|Other|food type|the swallowing was tested with 3 food types
80018669|NCT05137756|Other|no intervention|no intervention
80018670|NCT02137200|Procedure|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
80018671|NCT02137200|Procedure|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
80018672|NCT03404362|Procedure|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
80018673|NCT05274932|Other|BFR resistance exercise|4 sets (30, 15, 15, 15 reps).
80018674|NCT02786004|Device|Full Field Digital Mammography|
80018675|NCT02786004|Device|Digital Breast Tomosynthesis|
79257729|NCT05934721|Other|Questionnaire and physical assessments|Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
79257730|NCT05934565|Behavioral|Mindful Steps|Integrated website, activity tracker, and mind-body training
79556639|NCT05482672|Behavioral|GetHealthy-OA mind-body program|The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms
79556640|NCT05482672|Drug|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
79556641|NCT05482672|Behavioral|Health education booklet|The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
79556642|NCT05472532|Procedure|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~Blood (40 ml)~Pleural Fluid (40 ml)~Peritoneal liquid (40 ml)~Solid tumors"
79556643|NCT05469295|Device|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
79556644|NCT05469295|Device|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
79556645|NCT05468476|Other|No intervention|No intervention
79556646|NCT05465044|Other|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
79556647|NCT05465044|Other|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
79556648|NCT05463003|Dietary Supplement|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
79556649|NCT05458778|Device|Daily test with urine by the product|Women perform the hCG test and share the test results
79556650|NCT05456516|Behavioral|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
79556651|NCT05434286|Diagnostic Test|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
79556652|NCT05410327|Other|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
79556653|NCT05409443|Procedure|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
79257731|NCT05934552|Drug|Lactulose|lactulose and lactobacillus acidophilus on ckd patients
79556654|NCT05409443|Procedure|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
79556655|NCT05401409|Dietary Supplement|Beetroot juice|70mls beetroot juice (400mg nitrate) given daily for 4 weeks
79257732|NCT05934539|Drug|ALG.APV-527|ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
79556656|NCT05401409|Dietary Supplement|Nitrate-depleted beetroot juice|70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
79581106|NCT01932632|Other|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
79719782|NCT02778750|Procedure|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
79719783|NCT02666378|Other|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
79257733|NCT05934513|Drug|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
79257734|NCT05934422|Other|Intervention (Study Nutritional Drink)|Study nutritional drink containing a mix of enriched micronutrients, probiotics and myo-inositol.
79257735|NCT05934422|Other|Control (Standard Nutritional Drink)|Control nutritional drink containing a standard mix of micronutrients
79257736|NCT05934396|Behavioral|Safety Planning|Prior to discharge and following the conclusion of all Virtual Reality (VR) sessions, the participant will develop a safety planning intervention for school settings in collaboration with relevant individuals (e.g., the researcher, a school professional).
79396333|NCT05076448|Procedure|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
79719784|NCT02666378|Other|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
79719785|NCT02503774|Drug|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
79719786|NCT02503774|Drug|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
79719787|NCT02476734|Other|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
79719788|NCT02432274|Drug|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
79556657|NCT05401175|Other|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
79396334|NCT05076448|Procedure|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
79396335|NCT05075200|Drug|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
79719789|NCT02432274|Drug|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
79719790|NCT02432274|Drug|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
79719791|NCT02432274|Drug|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
79719792|NCT02432274|Drug|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
79719793|NCT02432274|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
79719794|NCT02432274|Drug|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
79396336|NCT05063539|Drug|LY3372689|given orally
79396337|NCT05063539|Drug|LY3372689|given orally
79396338|NCT05063539|Drug|Placebo|given orally
79396339|NCT05053854|Drug|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
79396340|NCT05030194|Other|Electronic Cigarette|Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.
79396341|NCT05030194|Other|Oral Nicotine Pouch|Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
79556658|NCT05393622|Device|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
79556659|NCT05388422|Device|Application of 3D scanner to measure physical size in patients with severe cerebral palsy|Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
79556660|NCT05337995|Other|Quantified analysis of walking during a task of passage through a horizontal opening|Functional test that reproduce a task of daily living, similar to a doorway
79581107|NCT01932658|Biological|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
79719795|NCT02432274|Drug|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
79719796|NCT02432274|Drug|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
79719797|NCT02424955|Drug|perflutren lipid microspheres|
79719798|NCT02424955|Diagnostic Test|3D ultrasound|
79257737|NCT05934396|Behavioral|VR Enhanced Affect Regulation|Participants will receive an overview of affect regulation in VR and then have the opportunity to practice using affect regulation in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
79719799|NCT02369393|Behavioral|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
79556661|NCT05324761|Drug|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
79257738|NCT05934396|Behavioral|VR Enhanced Cognitive Restructuring|Participants will receive an overview of cognitive restructuring in VR and then have the opportunity to practice using cognitive restructuring in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
79257739|NCT05934396|Behavioral|VR Enhanced Problem Solving|Participants will receive an overview of problem solving in VR and then have the opportunity to practice using problem solving in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
79556662|NCT05324761|Drug|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
79556663|NCT05318807|Other|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~Patient Activation Measure - to measure patient activation~Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~Patient Generated Subjective Global Assessment - to identify malnutrition risk~Emotions thermometer - to detect emotional disorders and identify risk"
79396342|NCT05023005|Other|Strain-Counterstrain treatment of piriformis muscle|Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
79556664|NCT05318807|Other|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~Review the initial questionnaires to inform the personalised plan and goal setting~Complete a further four questionnaires related to quality of life, diet and exercise~Measure handgrip strength~Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
79719800|NCT02369393|Behavioral|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
79719801|NCT02096588|Drug|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
79719802|NCT02096588|Drug|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
79719803|NCT02095288|Procedure|Blood draw|This is a single blood donation, no drugs or devices administered
79719804|NCT01827098|Procedure|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
79396343|NCT05022550|Device|DEEP VR|DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
79257740|NCT05934396|Behavioral|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
79257741|NCT05934383|Device|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
79257742|NCT05933538|Drug|Cariprazine|The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.
79257743|NCT05933538|Combination Product|Treatment as usual|Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.
79257744|NCT05933408|Diagnostic Test|TREM-1|The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
79257745|NCT05933278|Biological|SARS-CoV-2 Subunit Recombinant Protein Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
79257746|NCT05932160|Other|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
79855134|NCT05077943|Behavioral|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
79257747|NCT05932160|Other|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
79396344|NCT05022316|Other|CDS Tool Access|Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
79556665|NCT05318807|Other|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
79556666|NCT05317403|Drug|Venetoclax|"Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)"
79719805|NCT01622335|Drug|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
79719806|NCT01622335|Other|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
79257748|NCT05931497|Device|whole body hyperthermia|heat will be applied to the participant through a sauna to increase core body temperature
79257749|NCT05930509|Device|Non-invasive transcranial direct current stimulation (tDCS)|Electrical stimulation
79257750|NCT05928221|Device|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
79257751|NCT05925452|Drug|GenaKumab|GenaKumab 0.5mg/kg dose group : GenaKumab 0.5 mg/kg, Subcutaneous injection, Q4w, Dose adjustable, The maximum is 4.0 mg/kg; GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg fixed dose, Subcutaneous injection, Q4w
79257752|NCT05918653|Other|Home Healthcare|No intervention in this study
79257753|NCT05916053|Dietary Supplement|Vitamin D supplementation|50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
79257754|NCT05915078|Combination Product|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
79257755|NCT05914376|Biological|Recombinant human IL-21 oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
79719807|NCT01359592|Biological|rituximab|
79719808|NCT01359592|Drug|cyclophosphamide|
79257756|NCT05912556|Device|Digital Program 1|2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
79257757|NCT05912556|Device|Digital Program 2|1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
79257758|NCT05901558|Behavioral|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
79257759|NCT05901558|Behavioral|Community intervention|Regular community intervention
79257760|NCT05899881|Behavioral|Yoga intervention|10 weeks of Hatha yoga, once per week, 60 minutes per class
79257761|NCT05898165|Other|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
79257762|NCT05894902|Drug|SM-001|The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
79257763|NCT05892393|Drug|Zirconium Zr 89-DFO-YS5|Given IV
79556667|NCT05317403|Drug|Azacitadine|75 mg/m2/dose IV once daily over 15 minutes
79855135|NCT05077943|Behavioral|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
79875568|NCT00374907|Drug|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
79257764|NCT05892393|Procedure|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
79396345|NCT05007717|Behavioral|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
79556668|NCT05317403|Drug|Vorinostat|"1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)"
79556669|NCT05317403|Drug|Cytarabine|"2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~- 1.99 years old: 30 mg~- 2.99 years old: 50 mg~3 years old: 70 mg"
79719809|NCT01359592|Drug|doxorubicin hydrochloride|
79719810|NCT01359592|Drug|prednisone|
79719811|NCT01359592|Drug|vincristine sulfate|
79719812|NCT01359592|Other|R-CHOP regimen|
79719813|NCT01359592|Other|laboratory biomarker analysis|
79719814|NCT01359592|Radiation|fludeoxyglucose F 18|
79719815|NCT01359592|Radiation|selective external radiation therapy|
79719816|NCT01359592|Radiation|yttrium Y 90 ibritumomab tiuxetan|
79719817|NCT01331018|Procedure|Bone Marrow Aspiration|Undergo bone marrow harvest
79257765|NCT05892393|Procedure|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
79556670|NCT05317403|Drug|Fludarabine|30 mg/m2/dose IV once daily over 30 minutes
79396346|NCT04957355|Device|Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)|"Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)"
79396347|NCT04937413|Drug|Evolocumab|Evolocumab subcutaneous injection
79257766|NCT05892393|Other|Fludeoxyglucose F-18|Given IV
79257767|NCT05889702|Behavioral|KATR Linkage Strategy|"The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.~The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a last resort approach for linking to RSSs."
79556671|NCT05317403|Drug|Filgrastim|5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
79257768|NCT05879419|Biological|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A [MPL] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
79556672|NCT05312242|Dietary Supplement|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
79556673|NCT05312242|Dietary Supplement|Iron Folic Acid Supplement|Standard of Care Intervention
79556674|NCT05298813|Biological|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
79396348|NCT04934969|Dietary Supplement|Adjunctive use of lavender and peppermint essential oils|passive inhalation aromatherapy following joint surgery
79396349|NCT04930159|Behavioral|Facilitated group support|Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.
79396350|NCT04930159|Behavioral|1:1 Peer Support|1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.
79396351|NCT04927338|Dietary Supplement|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
79556675|NCT05298813|Other|Placebo|Matching Placebo
79556676|NCT05292352|Behavioral|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
79556677|NCT05290675|Diagnostic Test|Quantra QPlus System|Whole blood coagulation testing system
79556678|NCT05288829|Drug|ALXN1210 SC|All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
79556679|NCT05288829|Drug|ALXN1210 IV|All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
79556680|NCT05288829|Drug|Placebo|All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
79396352|NCT04927338|Drug|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
79581108|NCT01932684|Other|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
79719818|NCT01331018|Biological|Filgrastim|Given SC
79875569|NCT00374907|Drug|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
79396353|NCT04921917|Other|neoadjuvant exercise therapy|brief exercise regimen completed immediately prior to neoadjuvant radiation therapy. Rubber bands will be used for the exercise training of patients with lower extremity tumors while an electronic hand-held dynamometer will be used for the exercise training for patients with upper extremity tumors.
79396354|NCT04901325|Drug|Baricitinib|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
79396355|NCT04896606|Other|Standard of Care|Patients will receive standard of care for COVID-19.
79257769|NCT05879419|Other|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
79257770|NCT05879419|Other|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for one week after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
79396356|NCT04896606|Biological|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
79396357|NCT04880655|Device|WSD|Post debridement and within 24 hours of injury, wound care and WSD applied daily
79396358|NCT04880655|Device|Dressed with bacitracin and petrolatum gauze|Post debridement and within 24 hours of injury, wound care and dressing applied daily
79396359|NCT04861987|Drug|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
79396360|NCT04827056|Drug|Placebo|Placebo will be administered orally, as individual films in the SL space.
79396361|NCT04827056|Drug|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
79396362|NCT04827056|Drug|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
79556681|NCT05282368|Behavioral|PHM™ Pathway|"The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell | Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell | Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items."
79556683|NCT05250726|Biological|MENISC-T|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
79556684|NCT05236049|Biological|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
79719819|NCT01331018|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
79855136|NCT04014608|Other|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
79396363|NCT04827056|Procedure|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
79396364|NCT04827056|Behavioral|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
79556685|NCT05233566|Drug|Ketamine|NMDA antagonist
79556686|NCT05233566|Drug|Normal saline|IV fluid acting as a placebo
79556687|NCT05229601|Drug|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
79556688|NCT05216848|Other|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
79556689|NCT05216848|Other|Clinical data collection|Collection of the standard clinical data during hospitalization
79556690|NCT05210517|Drug|Empagliflozin 25 MG|25 once daily one week treatment
79556691|NCT05210517|Drug|Benzbromaron|100 mg once daily 1 one week treatment
79396365|NCT04827056|Behavioral|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
79556692|NCT05210517|Drug|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
79719820|NCT01331018|Other|Laboratory Biomarker Analysis|Correlative studies
79719821|NCT01331018|Procedure|Leukapheresis|Undergo leukapheresis
79719822|NCT01331018|Drug|Methylprednisolone|Given IV
79719823|NCT01331018|Drug|Plerixafor|Given SC
79719824|NCT01331018|Drug|Prednisone|Given PO
79719825|NCT01091857|Behavioral|STRIDE|
79855137|NCT02566967|Drug|tofacitinib|oral tofacitinib will be taken 2 times daily
79257771|NCT05879419|Other|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
79257772|NCT05879419|Other|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
79396366|NCT04817488|Other|Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound with tele-supervision in patients with acute dyspnoea
79396367|NCT04817488|Other|Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound without tele-supervision in patients with acute dyspnoea
79257773|NCT05879419|Other|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
79257774|NCT05875467|Other|SE3 Game|A prototype online game designed to increase environmental health literacy
79396368|NCT04817475|Other|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
79396369|NCT04813601|Device|ATLAS 2030|The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
79257775|NCT05845697|Other|Trigger point dry needling|Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle
79257776|NCT05845697|Other|Sham dry needling|A validated sham dry needle that is blunted on the end and does not pierce the skin
79556693|NCT05199155|Biological|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
79556694|NCT05191745|Drug|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
79257777|NCT05845658|Device|Active VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
79396370|NCT04807296|Procedure|TFLEP|"Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.~Fifty (50) patients will undergo TFLEP."
79396371|NCT04807296|Procedure|m-HoLEP|"The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.~Fifty (50) patients will undergo m-HoLEP"
79257778|NCT05845658|Device|Sham VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
79396372|NCT04777422|Drug|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
79257779|NCT05843669|Drug|Guafenesin tablets|During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
79396373|NCT04749329|Device|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
79556695|NCT05191745|Drug|Standard of care|All standard management of postoperative pain, as per local protocols
79556696|NCT05191628|Biological|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
79556697|NCT05180994|Drug|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
79556698|NCT05180994|Other|No topical infliximab|No treatment with infliximab.
79556699|NCT05148299|Drug|Pegcetacoplan|20-cc glass vials-1080 mg
79719826|NCT00930111|Other|2-week rotation|Attending physician is assigned to a 2-week rotation.
79719827|NCT00930111|Other|4-week rotation|Attending physician is assigned to a 4-week rotation.
79257780|NCT05842356|Behavioral|Communication Technique 2|A new communication technique.
79257781|NCT05841979|Behavioral|Moodlifters|Mood Lifters, a novel mental wellness program, was developed as a more accessible means to provide psychotherapy (Votta & Deldin, 2022). Meetings covered biopsychosocial areas and skills that were drawn from multiple therapeutic interventions consistent with a biopsychosocial framework. Areas included physical health, negative thoughts, problem-solving, emotional awareness and regulation, building relationships, behavioral activation, and using a strengths-based approach. ML is delivered by peer leaders who are individuals that have completed the program as well as a training program.
79257782|NCT05841979|Behavioral|Physical Activity|Participants randomized to the exercise arm received 14 weeks of a structured weekly strength and conditioning training program to enhance muscle mass, strength, cardiorespiratory fitness, and overall well-being. The program is based on previous research showing that cardiorespiratory fitness and muscle strength/size can both contribute to decreased mortality/increased longevity and enhanced mental health (Burke et al., 2017; McLeod et al., 2016; Srikanthan & Karlamangla, 2014; Strasser & Burtscher, 2018). The training program consists of three training sessions per week, with one being an in-person group session guided by a certified strength and conditioning specialist. The other two training sessions are self-guided via the mobile app Trainheroic. This weekly training schedule aligns with previous research showing benefits to structuring an exercise program using a variety of social contexts (group setting, own, etc.; Burke et al., 2017).
79556700|NCT05141175|Device|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
79556701|NCT05141175|Device|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
79556702|NCT05141123|Procedure|Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for|Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
79257783|NCT05841979|Behavioral|Nature Experiences|Participants randomized to the Nature Experiences participated in 14 weeks of group and self-directed activities to connect with the natural environment. Weekly group activities will be led by Nature Guides, who are undergraduate and graduate students with extensive outdoor education training. Group activities will last one hour a week and include hiking in forests, walking in parks, bird-watching, mindfulness exercises, and snow activities. Participants will be given a list of self-directed activity suggestions each week. The goal of self-directed activities is to spend an additional two hours in a natural environment each week.
79556703|NCT05119959|Other|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
79556704|NCT05119959|Other|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
79556705|NCT05118685|Drug|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
79556706|NCT05118685|Combination Product|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
79556707|NCT05112185|Behavioral|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
79556708|NCT05109650|Drug|BAT6026|IV infusions
79556709|NCT05109650|Drug|BAT1308|Ⅳ infusions
79556710|NCT05108259|Drug|PBP1502|40 mg/0.4 mL single SC injection via PFS
79556711|NCT05108259|Drug|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
79556712|NCT05108259|Drug|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
79556713|NCT05107271|Diagnostic Test|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
79257784|NCT05836636|Other|Torque teno virus DNA measurement|Torque teno virus DNA level will be obtained from all study subjects upon recruitment, when subjects are admitted and when subjects undergo kidney allograft biopsies.
79257785|NCT05828875|Other|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
79257786|NCT05820594|Biological|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
79396374|NCT04725305|Device|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
79396375|NCT04725305|Procedure|Standard of care|This method would involve removal of tonsils using electrocautery technique
79396376|NCT04724382|Behavioral|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
79396377|NCT04724382|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
79556714|NCT05087823|Dietary Supplement|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
79556715|NCT05087823|Dietary Supplement|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
79556716|NCT05087823|Dietary Supplement|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
79556717|NCT05084833|Behavioral|Control|Electronic educational materials
79556718|NCT05084833|Behavioral|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
79556719|NCT05084833|Behavioral|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
79556720|NCT05059795|Drug|Albumin|Type of resuscitation fluid, dose and use of inotrope
79556721|NCT05055817|Other|bloody stool group|bloody stool appear in the hospitalized neonate
79257787|NCT05819879|Procedure|peri capsular nerve group block|The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
79257788|NCT05819879|Procedure|scaitico femoral block|. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
79556722|NCT05055817|Other|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
79556723|NCT05053269|Other|good body weight growth|body weight growth after birth is consistent with the growth curve
79556724|NCT05053269|Other|poor body weight growth|body weight growth after birth is inconsistent with the growth curve
79556725|NCT05050383|Other|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
79556726|NCT05050383|Other|Submental Ultrasound|Ultrasound of airway soft tissues
79556727|NCT05032118|Drug|Ketamine Hydrochloride|Titratable ketamine infusion + low fixed-dose propofol.
79556728|NCT05032118|Drug|Propofol|Standard of care titratable propofol infusion.
79855138|NCT00939068|Drug|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
79396378|NCT04710979|Behavioral|Yoga Intervention|This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
79556729|NCT05021679|Other|AMP Implementation|Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
79556730|NCT05000970|Device|blood pressure cuff PLUS tablet|all arms
79556731|NCT05000970|Other|Telehealth Consult|Telehealth consult with an RN
79855139|NCT00939068|Biological|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
79855140|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
79396379|NCT04707313|Drug|Placebo (Cohorts 1 and 2)|4 matching placebo tablets taken twice daily
79556732|NCT04921696|Other|RBC transfusion|RBC was transfused to the infants.
79556733|NCT04921696|Other|no-RBC transfusion|RBC was not transfused to the infants.
79556734|NCT04913493|Procedure|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
79556735|NCT04880681|Device|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
79556736|NCT04880681|Device|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
79556737|NCT04874597|Drug|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
79581109|NCT01932684|Other|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
79581110|NCT01932684|Device|5000 Voldyne ® Sherwood Medical, USA|
79556738|NCT04869345|Behavioral|LARKSPUR|This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
79556739|NCT04867850|Other|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
79257789|NCT05804812|Behavioral|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
79556740|NCT04867850|Other|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
79257790|NCT05802680|Device|Transcranial photobiomodulation|Administration of Sham or 1064 (+/- 50) nanometers tPBM
79257791|NCT05802680|Device|Sham transcranial photobiomodulation|Sham treatment
79556741|NCT04867850|Other|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
79257792|NCT05790499|Drug|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
79396380|NCT04707313|Drug|PF-06882961 (Cohorts 1 and 2)|Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
79556742|NCT04862234|Drug|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
79719828|NCT00840853|Genetic|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
79719829|NCT00840853|Drug|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
79396381|NCT04707313|Drug|Placebo (Cohort 3)|2 matching placebo tablets taken twice daily
79396382|NCT04707313|Drug|PF-06882961 (Cohort 3)|Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
79396383|NCT04705441|Behavioral|SMART 2|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
79556743|NCT04862234|Drug|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
79556744|NCT04862234|Device|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
79556745|NCT04846738|Device|Transcranial Doppler|This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
79556746|NCT04846738|Device|Pupillometry.|This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
79556747|NCT04842643|Biological|IGSC 20% infusion|IGSC 20% infusion, The dose of IGSC will be established in previous study (TAK-664-3001)
79581111|NCT01932684|Device|Silicone face mask|
79719830|NCT00710892|Biological|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
79719831|NCT00699816|Biological|Immuncell-LC|Activated T lymphocyte
79719832|NCT00697073|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
79719833|NCT00656331|Drug|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
79719834|NCT00653432|Device|Monovisc®|Intra-articular injection
79719835|NCT00653432|Other|Saline|0.9% Sterile Saline
79719836|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
79719837|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
80018676|NCT05137522|Drug|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
80018677|NCT05271890|Procedure|Immediate non-surgical periodontal treatment and oral hygiene instructions|
79257793|NCT05787327|Drug|Chinese Herb|Yinqiaosan-Maxingganshitang granules
79257794|NCT05787327|Diagnostic Test|Placebo|Placebo
79257795|NCT05781503|Behavioral|Identity Capital Intervention (Coach + Co-designed Leadership Guide)|Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
79556748|NCT04821336|Other|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
79257796|NCT05781503|Other|Monthly Rent Subsidies|All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
79257797|NCT05776472|Drug|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
79257798|NCT05771974|Device|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
79556749|NCT04777747|Other|viral infection|a child is infected by virus only
79257799|NCT05768919|Drug|Concurrent CRT Period|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks"
79257800|NCT05768919|Drug|Post-CRT Period|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
79257801|NCT05768919|Drug|Adjuvant Period|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over 3 hours Schedule: Weekly: Adjuvant Cycles 1-6: Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks"
79257802|NCT05768399|Diagnostic Test|The level of biomarkers in Peripheral blood|All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
79556750|NCT04777747|Other|viral and bacterial infection|a child is infected by virus and progress to bacterial infection
79556751|NCT04775368|Other|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
79719838|NCT00537680|Drug|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
79719839|NCT00446043|Drug|Adapalene/Benzoyl Peroxide|Adapalene 0.1 percent (%) [weight by weight (W/W)] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
79719840|NCT00400725|Drug|Clobex® Shampoo|Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
79719841|NCT00400725|Drug|Clobex® Vehicle Shampoo|Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
79719842|NCT00400725|Drug|Clobex® Shampoo|Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
79855141|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
79257803|NCT05766917|Behavioral|peer education group|Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
79396384|NCT04691986|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.
79396385|NCT04691986|Other|Placebo|Placebo pills contain micro cellulose powder.
79396386|NCT04684485|Drug|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
79396387|NCT04684485|Drug|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
79396388|NCT04684485|Drug|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
79396389|NCT04684485|Drug|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
79396390|NCT04682639|Drug|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
79396391|NCT04682639|Drug|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
79396392|NCT04682639|Drug|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
79396393|NCT04681144|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
79719843|NCT00316342|Device|Back supports|
80018678|NCT02129166|Drug|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
79556752|NCT04747353|Device|Catheter ablation procedure with heart 3D model|Device: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
79257804|NCT05757180|Behavioral|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
79257805|NCT05757180|Behavioral|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
79257806|NCT05723211|Behavioral|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
79257807|NCT05723211|Other|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
79257808|NCT05701800|Biological|mRNA-1468|Sterile liquid dispersion for injection
79257809|NCT05701800|Biological|Placebo|Sterile liquid for injection
79396396|NCT04641338|Drug|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
79396397|NCT04641338|Drug|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
79396398|NCT04641338|Drug|Codeine|30 mg codeine every 6 hours if necessary.
79556753|NCT04745234|Drug|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
79556754|NCT04733469|Behavioral|Multimedia Psychoeducational Intervention|"The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following:~A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy~Take-home and online copies of the video for repeat viewing~A video summary~A question prompt list patients can use to ask clinicians more questions about palliative care~Contact information and brochures for local palliative care programs"
79556755|NCT04733469|Behavioral|Enhanced Usual Care|"Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following:~Usual care~A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)"
79556756|NCT04688567|Behavioral|Patient-driven iCBT|1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
79556757|NCT04688567|Behavioral|Standardized iCBT (TAU)|2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
79855142|NCT00934232|Drug|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
79855143|NCT01013571|Drug|insulin glargine|pre-filled disposable pen, in package of 5.
79855144|NCT01013571|Drug|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
79257810|NCT05701800|Biological|Shingrix|Sterile suspension for injection
79257811|NCT05700786|Behavioral|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
79257812|NCT05643170|Drug|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
79556758|NCT04641637|Procedure|TACE|Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
79257813|NCT05641441|Radiation|Stereotactic radiosurgery|Stereotactic radiosurgery
79556759|NCT04635917|Other|Personalized diet|Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
79719844|NCT04264195|Other|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
79257814|NCT05635916|Drug|Liposomal bupivacaine|Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
79257815|NCT05635916|Drug|Bupivacaine|Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
79719845|NCT04264195|Other|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
79855145|NCT04061837|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
79855146|NCT03128385|Other|Intensive CIT Model Program|"Day Camp Model:~The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
79855147|NCT03128385|Other|Distributed CIT Model Program|"Home-Based Model:~The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
79257816|NCT05633771|Other|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
79855148|NCT04062071|Other|no intervention|no intervention
79257817|NCT05613062|Drug|Modified Huang-Lian-Jie-Du Decoction (MHLJDD)|Chinese medicine granules for 12 weeks twice daily
79257818|NCT05613062|Drug|Placebo|Placebo granules for 12 weeks twice daily
79257819|NCT05610267|Device|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
79257820|NCT05604417|Drug|TAZEMETOSTAT|Dosage and treatment timings per protocol
79396399|NCT04587791|Drug|400mg Cannabidiol|Participants will receive 400mg
79396400|NCT04587791|Drug|800mg Cannabidiol|Participants will receive 800mg
79396401|NCT04587791|Drug|1200mg Cannabidiol|Participants will receive 1200mg
79855149|NCT00514449|Drug|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
79257821|NCT05604417|Drug|Zandelisib|Dosage and treatment timings per protocol
79257822|NCT05551975|Other|Experimental Product|Fed ad libitum from Study Day 1
79257823|NCT05551975|Other|Control Product|Fed ad libitum from Study Day 1
79396402|NCT04587791|Drug|Saline|Participants will receive saline
79396403|NCT04575727|Drug|[11C]MPC6827|Subjects will receive a microdose ( 10 µg) of [11C]MPC6827 (dose of 20 mCi)
79396404|NCT04569942|Drug|Vasopressor|Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
79396405|NCT04569942|Other|Fluids|An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
80018679|NCT02129166|Drug|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
80018680|NCT02858830|Other|High fat mixed meal|
80018681|NCT02137278|Drug|Vasoactive drug therapies|Continue current vasoactive therapy
80018682|NCT02137278|Other|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
80018683|NCT05137444|Biological|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.
79257824|NCT05538481|Other|Semi-structured interview|A collection of individual cultural values and palliative care preferences within the focus group meetings
79257825|NCT05538481|Other|Developed survey completion|A collection of individual responses to a survey created after focus group completion and analysis
79257826|NCT05538481|Other|Systems of Belief Inventory (SBI-15R)|A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
79257827|NCT05537675|Other|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
79556760|NCT04635917|Other|Conventional dietary advice|Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
79556761|NCT04612972|Biological|Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo|This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
79556762|NCT04586868|Behavioral|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
79556763|NCT04586868|Behavioral|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
79556764|NCT04586868|Behavioral|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
79257828|NCT05536336|Device|Condom|Contraception
79581112|NCT01932710|Procedure|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
79855150|NCT00514449|Drug|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
80018684|NCT05137444|Biological|Placebo|Aluminum hydroxide
79257829|NCT05535296|Behavioral|Risk profile|Compiliation of risk profile based on fitness, strength, mobility, balance, posture, physical activity level, weight and pain. Advice based on the above and support in goal-setting.
79257830|NCT05529823|Behavioral|warm shower|A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
79257831|NCT05528562|Other|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
79257832|NCT05528562|Other|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
80018685|NCT05705635|Drug|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
80018686|NCT05705635|Drug|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
80018687|NCT03527030|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
80018688|NCT03527030|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
79257833|NCT05528562|Other|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
80018689|NCT04467320|Behavioral|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
80018690|NCT04467320|Behavioral|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
79257836|NCT05509829|Device|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
80018691|NCT00085774|Drug|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
80018692|NCT00085774|Drug|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
80018693|NCT00085774|Drug|placebo aerosol by HFA|placebo HFA
80018694|NCT05193968|Other|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
79396406|NCT04554225|Drug|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
80018695|NCT05193968|Drug|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
80018696|NCT05193968|Drug|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
80018697|NCT05193968|Drug|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
79396407|NCT04551807|Procedure|Modified natural cycle|This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
79257837|NCT05509712|Behavioral|Focus Groups to Refine MobileMen App Content|Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
80018698|NCT05193968|Drug|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
80018699|NCT02137356|Radiation|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
79396408|NCT04551807|Procedure|Programmed cycle|This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
79556767|NCT04536766|Behavioral|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
79396409|NCT04549116|Drug|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
79556768|NCT04536766|Behavioral|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
79556769|NCT04534075|Biological|Capsules containing either dietary fiber or placebo|The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
80018700|NCT02137356|Drug|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
79556770|NCT04505878|Drug|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
79556771|NCT04505189|Drug|Psilocybin|Psilocybin assisted psychotherapy
80018701|NCT02137356|Drug|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
79257838|NCT05509712|Behavioral|Beta testing of MobileMen App Prototype|Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
79257839|NCT05451407|Drug|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
79257840|NCT05451407|Drug|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
79257841|NCT05428696|Drug|ALXN2080|Powder-in-capsule
79257842|NCT05428696|Drug|Placebo|Powder-in-capsule
79396410|NCT04549116|Drug|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
79556772|NCT04503135|Diagnostic Test|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
79556773|NCT04496830|Device|SOMAscan|Analysis of previously donated cerebrospinal fluid using a SOMAscan assay
79556774|NCT04404881|Drug|Bevacizumab|"Induction Period (first 3 months of bevacizumab treatment):~-- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~Maintenance Period (second 3 months of bevacizumab treatment):~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
79396411|NCT04549116|Drug|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
79556775|NCT04342325|Biological|infusion of ADR-001 (Mesenchymal stem cell)|Once or twice with two week interval at a dose of 100 x 10 ^ 6 cells.
79556776|NCT04335058|Drug|Lactoferrin + Iron Supplement|Lactoferrin 100 mg twice daily +oral iron
79556777|NCT04335058|Drug|Iron Supplement|Oral iron supplement alone
80031551|NCT04883866|Behavioral|Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure|In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.
80031552|NCT03681392|Dietary Supplement|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
79556778|NCT04325594|Procedure|Cardiac catheterization|Catheterization of the right and left heart cavities
79556779|NCT04325594|Biological|Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells|After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute
79556780|NCT04319224|Drug|Vopratelimab|Specified dose on specified days
80018702|NCT05137288|Drug|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
79855151|NCT04061759|Other|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
79257843|NCT05427487|Biological|IVX037|Bioselected oncolytic RNA virus
79556781|NCT04319224|Drug|Ipilimumab|Specified dose on specified days
79556782|NCT04319224|Drug|Nivolumab|Specified dose on specified days
79719846|NCT04263883|Device|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
79719847|NCT00932113|Drug|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
79855152|NCT00565136|Device|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
80018703|NCT04467476|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
80018704|NCT03767868|Other|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
79396412|NCT04549116|Drug|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
79396413|NCT04541082|Drug|ONC206|ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
80018705|NCT05135182|Drug|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
79556783|NCT04318626|Drug|PMPBB3|F-18 PMPBB3 PET Imaging
79556784|NCT04318626|Drug|THK5351|F-18 THK5351 PET Imaging
79556785|NCT04309253|Drug|PMPBB3|F-18 PMPBB3 PET Imaging
79556786|NCT04309253|Drug|AV45|F-18 AV45 PET Imaging
79719848|NCT00932113|Drug|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
79719849|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
79719850|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
79855153|NCT00738179|Device|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
79855154|NCT00738179|Other|Standard care|Standard care of cardiovascular risk factors
80018706|NCT05135182|Drug|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
79396414|NCT04537013|Procedure|Microfracture|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.
79396415|NCT04537013|Device|Microfracture plus placement of Chondro-Gide® ACC|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
79396416|NCT04533009|Procedure|spine surgery|Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
79396417|NCT04504903|Behavioral|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
79556787|NCT04307589|Other|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
79855155|NCT00492921|Drug|Cyclophosphamide|
79556788|NCT04257448|Drug|Romidepsin|Powder and solvent for solution for infusion; Intravenous use
79556789|NCT04257448|Drug|Azacitidine|Powder for suspension for injection; Subcutaneous use
79257844|NCT05426616|Device|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
79855156|NCT00738257|Drug|Pamidronate|
79855157|NCT00738335|Drug|erlotinib hydrochloride|
79855158|NCT00738335|Other|immunoenzyme technique|
79855159|NCT00738335|Other|laboratory biomarker analysis|
80018707|NCT02137434|Other|Dietary calcium|Dietary calcium from skimmed milk
79396418|NCT04504903|Behavioral|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
79396419|NCT04491370|Drug|Polatuzumab vedotin|All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
79396420|NCT04478474|Drug|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
79396421|NCT04475692|Behavioral|Repetitive, task-specific upper limb practice|A self-directed upper limb intervention (implementing a self-selected dose). This intervention uses an adapted upper limb rehabilitation system to support repetitive upper limb training for stroke survivors.
79556790|NCT04257448|Drug|nab-Paclitaxel|Powder for suspension for injection; Intravenous use
79556791|NCT04257448|Drug|Gemcitabine|Powder for solution for infusion; Intravenous use
79556792|NCT04257448|Drug|Durvalumab|Concentrate for solution for infusion; Intravenous use
79556793|NCT04257448|Drug|Lenalidomide capsule|Hard capsule for oral use
80018708|NCT02137434|Dietary Supplement|Supplementary calcium|Supplementary calcium from calcium carbonate
80018709|NCT02137590|Dietary Supplement|Spanish Black Radish product|
80018710|NCT03051607|Drug|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
80018711|NCT02137668|Drug|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
79556794|NCT04221789|Other|TB treatment assistant|Cell phone app to support self administered treatment and monitor adherence
79556795|NCT04196387|Diagnostic Test|urine culture|urine culture and antibiotic susceptibility test
79556796|NCT04178954|Diagnostic Test|semen fluid analysis|semen fluid analysis
79556797|NCT04105751|Device|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
79556798|NCT04097756|Drug|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
79556799|NCT04093388|Diagnostic Test|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
79556800|NCT04093388|Diagnostic Test|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
79556801|NCT04082234|Behavioral|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.
79855160|NCT00738335|Other|liquid chromatography|
79855161|NCT00738335|Other|mass spectrometry|
79855162|NCT00738335|Other|pharmacological study|
79855163|NCT00738335|Radiation|stereotactic radiosurgery|
79855164|NCT00502671|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
79855165|NCT00738413|Drug|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
79855166|NCT00738413|Drug|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
79855167|NCT00697463|Drug|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
79855168|NCT04409795|Drug|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
79855169|NCT04409795|Drug|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
80018712|NCT02137746|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
80018713|NCT04962568|Diagnostic Test|DTEE|endexpiratory diaphragm thickness in mm
80018714|NCT04962568|Diagnostic Test|DTEI|endinspiratory diaphragm thickness in mm
80018715|NCT04962568|Diagnostic Test|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
80018716|NCT05291767|Other|Diet|participants will consume a high fat (intervention) or high carbohydrate (control) meal.
79257845|NCT05426616|Device|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
79257846|NCT05424679|Behavioral|Safety Planning Intervention|The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
79396422|NCT04475692|Other|Conventional care|Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
79396423|NCT04470817|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil
79556802|NCT04082234|Other|Treatment as Usual (TAU)|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
79257847|NCT05424679|Behavioral|Caring Contacts|Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
79257848|NCT05405218|Device|CTR-US|Carpal Tunnel Release with Ultrasound Guidance
79257849|NCT05405218|Procedure|mOCTR|Mini Open Carpal Tunnel Release
79556803|NCT04081454|Behavioral|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
79719851|NCT00931801|Drug|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
79257850|NCT05402475|Behavioral|CBT + Mindfulness|Eight weeks of online CBT intervention combined with mindfulness
79257851|NCT05381857|Other|Human Biological Samples|Blood, urine, nasal swab, fecal samples
79257852|NCT05373017|Other|EGS Delirium Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
79719852|NCT04263805|Other|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
79719853|NCT00931723|Drug|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
79719854|NCT00931723|Drug|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
79257853|NCT05373017|Other|Questionnaires|Physical, cognitive, and psychological assessments
79257854|NCT05369299|Device|Implant Straumann® Pure Ceramic Two Piece Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
79257855|NCT05369299|Device|two-piece titanium implant Neoss® ProActive Tapered Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
79719855|NCT00931723|Drug|Placebo|Oral treatment twice daily.
79257856|NCT05362734|Behavioral|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
79257857|NCT05350215|Drug|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
79257858|NCT05350215|Drug|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
79396424|NCT04470050|Drug|Dexmedetomidine|Sublingual Film of Dexmedetomidine
79396425|NCT04470050|Drug|Placebo|Sublingual Placebo film
79396426|NCT04457258|Procedure|Computed Tomography|Undergo PET/CT
79396427|NCT04457258|Drug|Gallium Ga 68 FAPi-46|Given IV
79396428|NCT04457258|Procedure|Positron Emission Tomography|Undergo PET/CT
79396429|NCT04457258|Radiation|18F-FDG|Given IV
79396430|NCT04456842|Other|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
79396431|NCT04456660|Diagnostic Test|Markers of ultrasound|CRL, HR, and other ultrasound measurements.
79257859|NCT05349643|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
80018717|NCT05291767|Behavioral|Exercise|participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
79257860|NCT05340686|Behavioral|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
80018718|NCT04956406|Behavioral|Motivational Interviewing for Adult Kidney Transplant Recipients|Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews
79556804|NCT04081454|Behavioral|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
79855170|NCT00492531|Drug|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
79855171|NCT00492531|Drug|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
79855172|NCT04334603|Other|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
79855173|NCT04334655|Other|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
79257861|NCT05340686|Behavioral|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
80018719|NCT04956406|Other|Routine care|The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
79257862|NCT05340686|Behavioral|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
79257863|NCT05324488|Other|No intervention|In this registry no intervention is carried out
79257864|NCT05301881|Procedure|Surgery|resection of the oligometastatic lesion(s)
79257865|NCT05301881|Radiation|Radiotherapy|radiation of the oligometastatic lesion(s)
79257866|NCT05301881|Other|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
79257867|NCT05299515|Behavioral|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life."
79257868|NCT05295979|Drug|Inflammatory skin disease formula|ISDF granules (10.85g twice daily) for 12 weeks
79257869|NCT05295979|Drug|Placebo|Placebo granules (10.85g twice daily) for 12 weeks
79396432|NCT04456660|Diagnostic Test|Immunologic factors|Measurement of NK cells subpopulations types in the maternal serum
79396433|NCT04456660|Diagnostic Test|Serum factors|Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.
79556805|NCT04059406|Drug|sapablursen|sapablursen administered subcutaneously
79556806|NCT04055467|Drug|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
79556807|NCT04055467|Behavioral|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
79855174|NCT00111475|Drug|Romiplostim|Administered by subcutaneous injection
79855175|NCT00111475|Drug|Placebo|Administered by subcutaneous injection
79855176|NCT02566655|Biological|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
79855177|NCT01015209|Device|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
79855178|NCT04948463|Drug|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
79257870|NCT05288634|Other|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
79257871|NCT05266976|Behavioral|10 Weeks of Supervised Resistance Exercise Training|Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
79257872|NCT05266976|Behavioral|10 Weeks of Supervised Endurance Exercise Training|Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
79257873|NCT05264714|Drug|Rimegepant|150 mg oral disintegrating tablet every other day for one week
79396434|NCT04452721|Other|dynamic compression system|It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
80018720|NCT03522428|Dietary Supplement|vitamin b12|Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
80018721|NCT05575999|Drug|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg [3 mg/mL], Ketorolac Tromethamine 24 mg [1.2mg/mL], Ketamine HCl 24 mg [1.2 mg/mL]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg [5mg/ml]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
80018722|NCT02132988|Biological|OPT-822/OPT-821|
80018723|NCT04449484|Drug|MEDI1341|Intravenous infusion over 60 minutes
80018724|NCT04449484|Other|Placebo|Intravenous infusion over 60 minutes
80018725|NCT01062399|Drug|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
79556808|NCT04033718|Diagnostic Test|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
79556809|NCT04033718|Behavioral|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
79556810|NCT04006561|Radiation|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
80018726|NCT01062399|Drug|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
80018727|NCT01062399|Radiation|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
80018728|NCT01062399|Drug|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
80018729|NCT01062399|Drug|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
79257874|NCT05258747|Drug|Olaparib tablets, 150 mg|Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
79556811|NCT04004169|Device|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
79556812|NCT04004169|Device|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
79556813|NCT04004169|Device|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
79556814|NCT03999658|Biological|STI-3031|anti-PD-L1 antibody
79556815|NCT03959566|Drug|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
79855179|NCT04948463|Drug|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
79855180|NCT04948463|Drug|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
79719856|NCT05026021|Biological|Blood sample|For each patient blood (17 ml of whole blood) will be collected during a peripheral venous blood sample carried out in the the standard care at inclusion visit, M3 visit (3 months after inclusion) and M6 visit ( (6 months after inclusion)
80018730|NCT01062399|Drug|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
79257875|NCT05258747|Drug|Lynparza® (olaparib) tablets 150 mg|Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, DE
79719857|NCT05025397|Drug|Danavorexton|Danavorexton intravenous infusion.
79719858|NCT05025397|Drug|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
79719859|NCT05025397|Drug|Propofol|Propofol intravenous bolus.
79719860|NCT05025397|Drug|Sevoflurane|Sevoflurane inhalation.
79719861|NCT05025397|Drug|Propofol|Propofol intravenous infusion.
79719862|NCT00608803|Drug|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
79719863|NCT05234359|Diagnostic Test|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
79719864|NCT05234359|Diagnostic Test|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
80018731|NCT01062399|Drug|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
80018732|NCT02133144|Behavioral|overeating fat|
80018733|NCT02133144|Behavioral|overeating carbohydrate|
80018734|NCT05136508|Drug|Propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
79855181|NCT04948463|Drug|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
79855182|NCT04948463|Drug|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
79396435|NCT04451590|Other|VR-based simulation|Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
79556816|NCT03959566|Drug|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
79719865|NCT00931411|Other|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
79719866|NCT00931411|Other|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
79719867|NCT04250935|Diagnostic Test|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
79719868|NCT00931255|Drug|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
79855183|NCT04948463|Drug|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
79855184|NCT04948463|Drug|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
79719869|NCT00931255|Drug|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
80018735|NCT05136508|Drug|Sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
80018736|NCT02133222|Procedure|blood sample|
80018737|NCT05221567|Behavioral|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
79257876|NCT05254067|Device|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
79257877|NCT05240534|Behavioral|ET-Text (Laptop)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop."
79719870|NCT05204485|Procedure|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
79855185|NCT04948463|Drug|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
80018738|NCT05132140|Device|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
80018739|NCT02129322|Drug|Sorafenib|
80018740|NCT02129322|Drug|S-1|
80018741|NCT02129322|Drug|Oxaliplatin|
80018742|NCT05221489|Other|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
80018743|NCT03767712|Diagnostic Test|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
80018744|NCT05136274|Drug|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
80018745|NCT05221411|Drug|Mycophenolate Mofetil|Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.
80018746|NCT05221411|Drug|Tacrolimus|Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
79396436|NCT04451590|Other|Mannequin-based simulation|Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
79556817|NCT03959566|Drug|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
79556818|NCT03948295|Dietary Supplement|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
79257878|NCT05240534|Behavioral|ET-Voice (Smart System)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience."
79556819|NCT03946163|Dietary Supplement|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
79556820|NCT03946163|Drug|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
79257879|NCT05238779|Other|Standard of care including palliative care|Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
79396437|NCT04448600|Other|MRI|"The patients included in the study will all have a cerebral MRI as part of the cholesteatoma follow-up or for the assessment of cerebral or inner ear pathology.~- ENT evaluation"
79396438|NCT04430894|Drug|Carfilzomib|"Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
79719871|NCT05204485|Procedure|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
79257880|NCT05230641|Other|No intervention|This is a prospective observational study
79719872|NCT04263103|Other|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
79719873|NCT00609193|Drug|lithium|standard clinical care
79719874|NCT00609193|Drug|quetiapine|standard clinical care
79719875|NCT00930553|Biological|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
79855186|NCT04948463|Drug|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
79396439|NCT04430894|Drug|Isatuximab|"Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~-- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
79396440|NCT04430894|Drug|Lenalidomide|- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
79257881|NCT05229549|Other|GOLIKE PLUS 3-16|PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
79257882|NCT05229549|Other|Free AAs|It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
79257883|NCT05225220|Device|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
79396441|NCT04430894|Drug|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
79396442|NCT04428476|Biological|CAP-1002|Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months
79556821|NCT03909529|Drug|Digoxin 250 MCG Oral Tablet|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
79556822|NCT03909529|Drug|Spironolactone 25 mg/ 5 mL S/F Suspension|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
79556823|NCT03884517|Drug|BAT8003|Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
79556824|NCT03875755|Dietary Supplement|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
79719876|NCT00609427|Behavioral|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
79719877|NCT00609427|Behavioral|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
79719878|NCT00609505|Other|Telemedicine|Telemedicine genetic counseling
79719879|NCT00609505|Other|Face-to-Face|Face-to-face genetic counseling
79719880|NCT04262011|Procedure|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
79855187|NCT04948463|Drug|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
79855188|NCT04948463|Drug|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
80018747|NCT02133300|Other|electrical stimulation|
79855189|NCT04948463|Drug|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
79855190|NCT04945421|Drug|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
79855191|NCT04945421|Drug|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
79855192|NCT01080547|Procedure|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
79257884|NCT05219474|Diagnostic Test|Cochlear implant Computer Model Implementation|"The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes)."
79257885|NCT05181449|Behavioral|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
79855193|NCT01080547|Drug|XELOX Chemotherapy|XELOX chemotherapy
79855194|NCT01080547|Drug|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
79855195|NCT01080547|Other|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
80018748|NCT05306002|Combination Product|Antioxidant therapy|Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
80018749|NCT03650517|Procedure|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
79257886|NCT05127395|Other|To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.|The study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
79257887|NCT05127200|Device|Starstim (Neuroelectrics)|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
79396443|NCT04390750|Behavioral|Care Partner-Assisted Intervention|Tailored teaching and coaching
79396444|NCT04386993|Radiation|Intensity modulated radiation therapy|Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
79556825|NCT03875755|Other|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
79257888|NCT05122975|Drug|S48168 (ARM210)|Ryanodine Receptor modulator
79257889|NCT05122975|Drug|Matching Placebo|Placebo of same size and consistency as S48168 (ARM210)
79556826|NCT03819686|Behavioral|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching ~20-minutes of videos from the website)
79396445|NCT04375384|Drug|Cetuximab|"A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment."
79556827|NCT03819686|Behavioral|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two ~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
79396446|NCT04375384|Other|Questionnaire administration|Ancillary studies
79556828|NCT03794323|Drug|BI 764122|Tablet
79556829|NCT03794323|Drug|Placebo|Tablet
79855196|NCT01080547|Other|Conventional Perioperative Treatment|Conventional treatment during perioperation period
79855197|NCT01080547|Procedure|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
80018750|NCT03650517|Procedure|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
80018751|NCT03650517|Procedure|Robotic Surgery|Procedure is performed using robotic instruments
80018752|NCT03650517|Procedure|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
80018753|NCT05705557|Device|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
79855198|NCT02566811|Procedure|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
79855199|NCT02566811|Procedure|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
79855200|NCT00111241|Drug|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
79556830|NCT03763942|Behavioral|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
79855201|NCT02567747|Other|Data collection|Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014. *Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. **Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. ***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
79855202|NCT00492297|Drug|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
79396447|NCT04375384|Other|Quality of life assessment|Ancillary studies
79396448|NCT04369664|Drug|Statin|Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
79396449|NCT04369664|Drug|PCSK9 inhibitor|Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
79556831|NCT03763942|Behavioral|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
79556832|NCT03736707|Device|Selective HFOV|Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
79855203|NCT02567513|Behavioral|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
79556833|NCT03736707|Device|CMV|CMV was delivered by time-cycled, pressure-limited ventilators
79556834|NCT03727906|Other|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
79556835|NCT03727906|Other|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
79556836|NCT03727906|Other|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
79556837|NCT03704805|Behavioral|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
79855204|NCT02567513|Behavioral|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
79855205|NCT04608435|Other|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
79855206|NCT03997227|Procedure|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
79875570|NCT00374127|Drug|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
79875571|NCT00374127|Drug|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
79875572|NCT01040247|Other|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
79875573|NCT01045083|Drug|RO4917523|Oral single dose
79396450|NCT04369664|Drug|Ezetimibe 10mg|Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
79257890|NCT05118204|Drug|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
79396451|NCT04349852|Behavioral|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
79556838|NCT03704805|Other|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
79556839|NCT03667079|Other|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
79556840|NCT03667079|Other|Mass deworming only|Delivery of mass deworming to people only
79556841|NCT03667079|Other|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
79556842|NCT03630003|Device|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
79556843|NCT03630003|Other|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
79855207|NCT00565058|Biological|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
79855208|NCT04061681|Behavioral|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
79855209|NCT00934388|Procedure|Pre peritoneal mesh placement|
79855210|NCT00934388|Procedure|Laparoscopy|
79855211|NCT00939224|Device|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
79257891|NCT05118204|Drug|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
79257892|NCT05118204|Behavioral|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
79556844|NCT03617939|Procedure|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
79556845|NCT03617939|Other|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
79556846|NCT03617939|Other|Medical Chart Reviews|Data taken directly from the patients' medical charts.
79855212|NCT00564902|Drug|3R 3'R Zeaxanthin|8 mg per day during 12 months
79855213|NCT00564902|Dietary Supplement|Lutein|9 mg of Lutein during 12 months
79855214|NCT00564902|Dietary Supplement|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
79855215|NCT04013516|Behavioral|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
79855216|NCT04013516|Behavioral|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
79855217|NCT04014452|Procedure|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
79855218|NCT04014452|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
79855219|NCT04013750|Other|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
79855220|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
79257893|NCT05093400|Other|no intervention|saliva collection
79855221|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
80018754|NCT02137902|Behavioral|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
79257894|NCT05082935|Behavioral|Phase II Promotores de Salud|Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
79257895|NCT05082935|Behavioral|Phase I Promotores de Salud Outreach|Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
79257896|NCT05082870|Behavioral|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
79257897|NCT05077722|Device|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
79257898|NCT05064930|Dietary Supplement|Probiotic Bifidobacterium lactis|The probiotic will be administered orally over a period of 12 weeks.
79855222|NCT00446134|Drug|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
80018755|NCT02137902|Behavioral|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
80018756|NCT05135962|Device|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
79396452|NCT04349852|Behavioral|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
79396453|NCT04344899|Other|Observational|Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
79396454|NCT04341194|Behavioral|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
79556849|NCT03603145|Procedure|Immediate insertion|Immediate insertion of intrauterine contraception within 48 hours of medical abortion
79556850|NCT03591796|Device|HFOV|Ventilated infants were randomized to HFOV
79556851|NCT03591796|Device|CMV|Ventilated infants were randomized to CMV.
79556852|NCT03537183|Other|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
79556853|NCT03534050|Radiation|postoperative adjuvant RT|
79556854|NCT03380546|Drug|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
79556855|NCT03380546|Drug|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
79556856|NCT03378063|Drug|transplantation of mesenchymal stem cell|allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
79556857|NCT03378063|Drug|no transplantation of mesenchymal stem cell|MSC transplantation will be not given to preterm infants
79556858|NCT03329157|Other|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
79556859|NCT03321929|Combination Product|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
79556860|NCT03318094|Drug|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
79556861|NCT03318094|Other|Saline|Intrabrachial saline will be given this day
79556862|NCT03318094|Drug|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
79257899|NCT05064930|Dietary Supplement|Probiotic Bacillus coagulans|The probiotic will be administered orally over a period of 12 weeks.
79257900|NCT05064930|Dietary Supplement|Placebo|Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
79396455|NCT04341194|Behavioral|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
79556863|NCT03268499|Drug|Cisplatin|The procedure of TACE is the same irrespective of which regimen is used.
79556864|NCT03250624|Drug|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm^2) once daily for 6 weeks.
79556865|NCT03250624|Drug|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm^2 once daily for 6 weeks.
79855223|NCT00446134|Drug|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
79855224|NCT00934466|Drug|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
79556866|NCT03223675|Radiation|hippocampal-sparing WBRT|
79556867|NCT03204955|Drug|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
79556868|NCT03204955|Drug|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
79556869|NCT03204955|Drug|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
79855225|NCT00934466|Drug|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
79556870|NCT03189485|Drug|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
79719881|NCT04262011|Procedure|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
79855226|NCT00934466|Drug|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
79855227|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
79855228|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
79855229|NCT00921245|Drug|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
79257901|NCT05036369|Device|Vibrant capsule|Vibrant capsule - Administered twice a week (Monday and Thursday).
79257902|NCT05036369|Device|Placebo capsule|Placebo Capsule administered twice a week (Monday and Thursday)
79257903|NCT05031663|Dietary Supplement|Almond group|Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
79719882|NCT04261933|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
79855230|NCT00563186|Other|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
79855231|NCT00699413|Drug|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
79855232|NCT00699413|Drug|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
79257904|NCT05031663|Dietary Supplement|Control Group|Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
79719883|NCT00609817|Drug|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
79257905|NCT05027685|Device|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
79719884|NCT00609817|Drug|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
79855233|NCT01028872|Device|Intraocular lens|
79855234|NCT01028872|Device|Intraocular lens|
79257906|NCT05022342|Other|alpelisib plus fulvestrant|Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
79556871|NCT03159481|Behavioral|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
79855235|NCT01028872|Device|Intraocular lens|
79556872|NCT03069326|Drug|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
79556873|NCT03069326|Drug|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
79556874|NCT03059043|Device|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
79556875|NCT03059043|Device|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
79556876|NCT03015740|Other|Laboratory Biomarker Analysis|Correlative studies
79719885|NCT00929695|Drug|prednisone|immunosuppressive drug
79719886|NCT00929695|Drug|methylprednisolone|immunosuppressive drug
79719887|NCT00929695|Other|questionnaire administration|Ancillary studies
79719888|NCT00609895|Drug|INSULIN GLARGINE|
79719889|NCT04261465|Drug|Olaparib|PARP INHIBITOR
79719890|NCT04261465|Drug|Paclitaxel|Chemotherapy
79855236|NCT04061525|Procedure|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
79855237|NCT04808609|Device|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
79257908|NCT05008549|Dietary Supplement|Cranberry Juice Product|"The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum."
79556877|NCT03015740|Biological|Nivolumab|Given IV
79556878|NCT03015740|Other|Quality-of-Life Assessment|Ancillary studies
79556879|NCT03015740|Other|Questionnaire Administration|Ancillary studies
79556880|NCT03015740|Drug|Sitravatinib|Given PO
79556881|NCT03011294|Device|Continuous positive airway pressure (CPAP)|
79556882|NCT03011294|Device|Nasal strip|
79556883|NCT02946242|Device|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
79556884|NCT02881242|Other|Laboratory Biomarker Analysis|Correlative studies
79855238|NCT04808609|Behavioral|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
79855239|NCT00940160|Drug|QAX576|
79855240|NCT00940160|Drug|QAX576|
79556885|NCT02881242|Other|Quality-of-Life Assessment|Ancillary studies
79719891|NCT04261465|Drug|Carboplatin|Chemotherapy
79719892|NCT05115643|Behavioral|Immobilization|Immobilization of left arm using a brace and sling.
79719893|NCT05095519|Drug|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
79719894|NCT04260919|Procedure|Chest physiotherapy|
79719895|NCT04260997|Dietary Supplement|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
79719896|NCT04260997|Other|Placebo capsule|Once per day (QD), 12 weeks
79855241|NCT00940160|Drug|QAX576|
79855242|NCT00940160|Drug|Placebo|
79855243|NCT00940238|Drug|Citalopram Hydrobromide|
79855244|NCT02565875|Behavioral|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
79855245|NCT02565875|Behavioral|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
79855246|NCT02565875|Other|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
79875574|NCT01045083|Drug|escitalopram|Oral single dose
79875575|NCT01045083|Drug|methylphenidate|Oral single dose
79875576|NCT01045083|Drug|placebo|Oral single dose
79875577|NCT01040325|Biological|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
79875578|NCT01040325|Biological|TD Vaccine System|TD Vaccine System Containing Placebo Product
79875579|NCT01045239|Device|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
79875580|NCT01045239|Device|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
79855247|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
79855248|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
79855249|NCT02565719|Drug|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
80018757|NCT05135962|Device|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
80018758|NCT05135962|Device|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
80018759|NCT05221333|Device|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
80018760|NCT05565703|Other|PARO Robotic Seal Intervention|PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
80018761|NCT05565703|Other|Attention Control|The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
79257909|NCT04981106|Other|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
79556886|NCT02881242|Drug|Trametinib|Given PO
79556887|NCT02841462|Device|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
79556888|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 6 weeks.|
79556889|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 5 weeks.|
79556890|NCT02717234|Other|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
79556891|NCT02655744|Radiation|Standard treatment protocol with combined chemoradiation|
79719897|NCT04260763|Behavioral|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
79556892|NCT02638519|Other|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
79257910|NCT04968574|Drug|taladegib|hedgehog pathway inhibitor dosed once daily
79556893|NCT02638519|Other|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
79556894|NCT02638519|Drug|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
79556895|NCT02638519|Device|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
79556896|NCT02608762|Radiation|standard adjuvant local radiation therapy or cranial radiation therapy|
79257911|NCT04968574|Drug|placebo|identical tablets to the experimental arm with no active ingredient
79257912|NCT04958694|Behavioral|CEDARS|This intervention is intended to help adolescents cope with stress.
79257913|NCT04950270|Biological|Blood copeptin monitoring|Blood copeptin monitoring during the first 6 days of ICU stay with PRES
79257914|NCT04950270|Other|phone interview|Structured phone interview at 3 months to collect vital status and modified Rankin Scale score
79257915|NCT04893447|Behavioral|SPI+|Suicide prevention hotline follow-up specialists will call participants to (1) conduct a brief suicide risk assessment; (2) review and discuss the participant's connection and support plan or safety plan; and (3) provide referrals to social services or other support with treatment engagement, if indicated. Participants will receive at least one and optional additional phone calls, generally delivered according to the following schedule: days 3, 7, 14, 30, 60, 90. Modifications may be made to the schedule due to weekends, holidays, or participant availability, and additional calls may be scheduled as desired by the participant. The follow-up will stop once the participant is successfully engaged in outpatient treatment or does not desire further follow-up support.
79257916|NCT04893447|Behavioral|SP+CC (Caring Contacts)|SP+CC follow-up includes one phone conversation with a suicide prevention hotline follow-up specialist and a series of personalized caring messages sent over the course of 12 months via text or email (based on participant preference). Caring contacts will generally be sent according to the following schedule: 3 in the first week, 6 weekly, 6 bi-weekly, 4 monthly; 2 bi-monthly, and one each for the participant's birthday, Thanksgiving, Christmas, and New Year's (total of 25 over 12 months). Slight variation in the schedule is allowed. There is no expectation that participants respond to the text messages; if they do, follow-up specialists reply to any incoming texts. Replies are individually-tailored and caring.
79556897|NCT02507297|Device|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
79556898|NCT02504788|Radiation|hippocampal-sparing WBRT|
79556899|NCT02448992|Radiation|hippocampal-sparing WBRT|
79556900|NCT02376699|Drug|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
79556901|NCT02376699|Drug|Pembrolizumab|Given intravenously; schedule is cohort-specific.
79556902|NCT02376699|Drug|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
79556903|NCT02376699|Drug|Gemcitabine|1000 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
79556904|NCT02376699|Drug|Nab-paclitaxel|125 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
79556905|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
79556906|NCT02174315|Behavioral|Contingency Management|
79556907|NCT02141542|Drug|Tremelimumab|
79556908|NCT02141542|Drug|MEDI3617|
79556909|NCT01984710|Device|Medtronic Activa PC+S System|
79556910|NCT01930955|Drug|Amoxicillin|β-lactam antibiotics
79855250|NCT02565719|Drug|Pegasys|immunotherapy
79855251|NCT02565719|Drug|Viread|HBV RT polymerase inhibitor
79855252|NCT02565719|Drug|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
79855253|NCT00934778|Procedure|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
79855254|NCT00111007|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
79257917|NCT04878731|Biological|PF-06741086|single dose SC injection of 300 mg PF-06741086
79257918|NCT04864834|Biological|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
79556911|NCT01333514|Drug|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
79556912|NCT01333514|Drug|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
79556913|NCT00587561|Behavioral|Social Cognition Interaction Training|manualized group therapy
79556914|NCT00587561|Behavioral|WLC|wait-list control for 6 months, followed by the experimental group therapy
79556915|NCT02098512|Drug|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
79556916|NCT02098512|Procedure|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
79556917|NCT02098512|Drug|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
79556918|NCT02066636|Drug|Nivolumab|
79556919|NCT02036086|Drug|Vemurafenib|Drug
79556920|NCT02036086|Drug|Cobimetinib|Drug
79556921|NCT01878435|Other|SMS reminder|
79556922|NCT01878435|Other|Travel subsidy|
79855255|NCT00111007|Drug|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
79855256|NCT00111007|Drug|Placebo|Placebo, 2 tablets bid Study Days 2-19
79556923|NCT01878435|Other|Travel subsidy 2|
79556924|NCT01719146|Other|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
79556925|NCT01486264|Biological|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
79556926|NCT01323270|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
79257919|NCT04864834|Biological|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
79257920|NCT04855253|Drug|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
79556927|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
79257921|NCT04854850|Device|Apollo|The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle & Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
79556928|NCT01323270|Biological|Saline|0.5 mL dose, given at 0, 2 and 6 months.
79719898|NCT04260763|Device|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
79257922|NCT04829279|Other|CONNECT AI system group|"A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival."
79257923|NCT04826809|Device|N95 mask|Standard 1870 N95 one time use mask
79257924|NCT04826809|Device|Nordell single E-100 layer mask|Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
79257925|NCT04826809|Device|Nordell double E-100 layer mask|Nordell mask design using two layers of E-100 fabric
79257926|NCT04809064|Procedure|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
79556929|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
79556930|NCT01300728|Drug|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
79556931|NCT01300728|Other|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
79556932|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
79556933|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
79556934|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
79556935|NCT01299480|Biological|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
79556936|NCT01299480|Biological|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
79556937|NCT01680419|Behavioral|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
79719899|NCT05080465|Biological|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
79581113|NCT01932723|Behavioral|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
79581114|NCT01932736|Other|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
79875581|NCT01045317|Drug|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
79875582|NCT01045863|Drug|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
79875583|NCT01045863|Drug|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
79257927|NCT04809064|Procedure|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
79257928|NCT04809064|Procedure|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
79257929|NCT04809064|Other|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
79257930|NCT04802876|Drug|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
79855257|NCT03975920|Device|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
79257931|NCT04802876|Drug|Tislelizumab|Tislelizumab 300mg will be given intravenously every 28 days
79257932|NCT04802291|Behavioral|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
79257933|NCT04793464|Behavioral|Promotores de Salud|The Promotores de Salud intervention is delivered by a paid Promotor(a) who is a trusted member of the community where the testing site is located. The intervention includes: (1) psychoeducation to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores are on-site at testing events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
79396456|NCT04337580|Drug|Omeprazole 80 mg twice daily|Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
79396457|NCT04321005|Procedure|arthroscopic rotator cuff reconstruction|arthroscopic rotator cuff reconstruction and assessment with evaluation and prediction of core outcomes
79396458|NCT04308330|Drug|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
79396459|NCT04284553|Other|Order Entry|An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
79396460|NCT04284553|Other|Open Encounter|An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
79556938|NCT01680419|Behavioral|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
79556939|NCT01680705|Other|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
79556940|NCT01681017|Behavioral|HBB/ENC Training and Equipment|See the detailed description section
79719900|NCT00610285|Other|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
79719901|NCT04260841|Device|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
79719902|NCT00610519|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
79396461|NCT04284553|Other|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
79556941|NCT01681017|Other|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
79556942|NCT01681225|Other|Esophageal-pressure guided mechanical ventilation|
79719903|NCT00610519|Dietary Supplement|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
79719904|NCT05063617|Device|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
79855258|NCT00699335|Drug|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
79257934|NCT04793464|Behavioral|Services as usual|Services as usual, our control condition, includes strategies that are typically conducted by county and community-based organizations that serve under-represented groups to notify people of testing opportunities related to COVID-19. These include Facebook advertisements, email announcements, circulation to other community-based organizations and state agencies (e.g., Oregon Health Authority, county public health), and other flyer distribution means. This condition also includes a pamphlet about health behaviors and community resources handed out by testing facilitators at testing events.
79257935|NCT04789928|Drug|Gentamicins-EDTA|Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
79257936|NCT04774536|Drug|CRISPR_SCD001|CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
79257937|NCT04772963|Genetic|blood sample|During the arteriography a peripheral venous sampling
79396462|NCT04284553|Other|Cold State outreach|An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
79396463|NCT04284553|Other|Simplified|The alert language itself will be simplified.
79396464|NCT04284553|Other|Sign-off alert|An alert will display in the electronic health record when the medication is sent to sign-off for providers.
79257938|NCT04763083|Drug|NVG-111|Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
79257939|NCT04762992|Drug|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
79556943|NCT01681225|Other|High PEEP mechanical ventilation|
79719905|NCT05062213|Other|Moisturizer Body Lotion|Moisturizer Body Lotion
79556944|NCT01681238|Procedure|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR <100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
79396465|NCT04284553|Other|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
79556945|NCT01681238|Procedure|Protocol group 1|The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP <8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
79719906|NCT04875325|Other|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
79719907|NCT00927355|Drug|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
79396466|NCT04284553|Other|Different Risks|Risks of the high-risk medications will be framed differently.
79396467|NCT04284553|Other|Standard Epic Basic Alert|This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
79396468|NCT04284553|Other|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory [BPA]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
79581115|NCT01932749|Device|Transcranial Magnetic stimulation|
79581116|NCT01932775|Device|GlucoTab System|
79719908|NCT00927355|Drug|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
79719909|NCT00923845|Drug|Pentostatin|Pentostatin: 2- 4mg/m^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
79719910|NCT00923845|Drug|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
79257940|NCT04762992|Other|standard of care|Obsteric standard of care.
79257941|NCT04745325|Behavioral|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
79719911|NCT00923845|Drug|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
79719912|NCT00923845|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
79719913|NCT00923845|Procedure|Th2 rapa cells|Th2 rapa cell Transplantation
79719914|NCT00923845|Procedure|Donor Lymphocyte Harvest|Apheresis
79719915|NCT00923845|Procedure|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
79719916|NCT00923845|Procedure|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
79719917|NCT00923845|Procedure|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
79719918|NCT05329597|Genetic|Genotyping|Genotyping is performed using the subjects' blood cells
79875584|NCT01045863|Drug|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
79875585|NCT01045863|Drug|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
79855259|NCT01082887|Other|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
79396469|NCT04278690|Other|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of <1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take ~5-10 minutes.
79855260|NCT00939614|Drug|Lamotrigine|
79257942|NCT04738123|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
79257943|NCT04738123|Drug|Placebo|Placebo Capsules
79396470|NCT04278690|Other|HELPix+Tech|After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
79556946|NCT01681251|Other|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
79396471|NCT04257578|Drug|Acalabrutinib|Given PO
79396472|NCT04257578|Biological|Axicabtagene Ciloleucel|Given IV
79396473|NCT04254250|Diagnostic Test|Preoperative risk estimation of disc herniation recurrence|Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
79581117|NCT01932827|Behavioral|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
79719919|NCT05329519|Behavioral|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
79719920|NCT04256239|Behavioral|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
79855261|NCT03963037|Other|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
79257944|NCT04711369|Device|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
79855262|NCT00935168|Drug|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
79855263|NCT00935168|Drug|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
79855264|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
79855265|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
79855266|NCT03962881|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
79855267|NCT00940394|Behavioral|mutual support group|bi-weekly, 12-session, family-led mutual support group
79855268|NCT00940394|Behavioral|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
79855269|NCT00940394|Other|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
79719921|NCT04260451|Other|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
79719922|NCT04260373|Drug|[14C]SHR4640|Patients will receive single dose of orally [14C]SHR4640 on Day 1.
79719923|NCT05052541|Drug|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
79257945|NCT04711369|Device|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
79556947|NCT01681251|Other|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
79719924|NCT05052541|Drug|THC|Oral solution containing 5mg THC per 1 ml
79719925|NCT05052541|Drug|Placebo|Oral solution containing no active drug
79719926|NCT04260685|Drug|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
79719927|NCT04260685|Drug|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
79257946|NCT04704453|Drug|Capsaïcin patch (Qutenza®)|Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).
79855270|NCT00935246|Drug|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
79855271|NCT04013360|Other|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
79257947|NCT04704453|Drug|Amitriptyline (Laroxyl®)|Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.
79257948|NCT04697563|Device|Laser|real laser beam administered
79257949|NCT04697563|Device|Placebolaser|no laser beam admitted
79257950|NCT04695847|Drug|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
79257951|NCT04695847|Drug|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
79855272|NCT04013360|Other|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
79855273|NCT02793284|Radiation|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
79719928|NCT04259593|Other|exercise training|
79719929|NCT05052151|Other|Low dialysate temperature|35°C
79719930|NCT05052151|Other|High dialysate temperature|37°C
79719931|NCT05052151|Other|Low dialysate bicarbonate concentration|30 mmol/L
79719932|NCT05052151|Other|High dialysate bicarbonate concentration|38 mmol/L
79719933|NCT05013853|Procedure|Restoration teeth|Remove caries and restore with resin composite
79855274|NCT00935402|Behavioral|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
79855275|NCT02667002|Procedure|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
79556948|NCT01681446|Drug|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
79556949|NCT01681602|Other|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
79556950|NCT01681615|Drug|Acetylsalicylate|1-2 drops
79556951|NCT01681615|Drug|Isotonic NaCl|1 drop
79719934|NCT00610831|Device|DIRECTVIEW CR Mammography|4 views screening mammogram
79257954|NCT04676360|Drug|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
79257955|NCT04665050|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
79257956|NCT04665050|Biological|PNEUMOVAX™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
79257957|NCT04663399|Other|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
79257958|NCT04644159|Other|Human biological samples|Blood , saliva, nasopharyngeal mucosa
79719935|NCT05013463|Drug|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
79719936|NCT05013463|Drug|Indapamide Pill|Oral Indapamide, 2.5 mg OD
79719937|NCT05011591|Other|Swimming economy|Detailed in arm's section
79556952|NCT01681797|Device|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
79257959|NCT04640753|Procedure|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
79257960|NCT04637009|Drug|TAS1553|Form: tablet; Route of Administration: oral
79257961|NCT04628468|Device|moveUp|Mobile application for use in the rehabilitation of primary knee and hip arthroplasty
79556953|NCT01681875|Other|very low nicotine content cigarettes|
79556954|NCT01681953|Drug|Lamazym|ERT, i.v. infusions weekly
79257962|NCT04628468|Other|Predefined number of traditional physiotherapy sessions|exercises with a physiotherapist being physically present
79257963|NCT04601038|Drug|CORT108297|120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
79556955|NCT01681953|Drug|Placebo|Infusions weekly
79257964|NCT04601038|Drug|Placebo|Placebo taken as 2 tablets daily for 2 weeks
79719938|NCT00922987|Drug|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
79719939|NCT00610909|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
79257965|NCT04581395|Other|non-pretreated Succinylcholine|no pretreatment
79257966|NCT04581395|Drug|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
79257967|NCT04581395|Drug|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
79257968|NCT04580368|Drug|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
79257969|NCT04572100|Other|Transoral Robotic Surgery (TORS) or Radiotherapy|Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.
79257970|NCT04572100|Other|Chemotherapy and Low-Dose Radiotherapy|Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.
79396474|NCT04246346|Other|An interactive chatbot for patient decision aid|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
79396475|NCT04246346|Other|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
79396476|NCT04245722|Drug|FT596|Experimental Interventional Therapy
79396477|NCT04245722|Drug|Cyclophosphamide|Lympho-conditioning agent
79396478|NCT04245722|Drug|Fludarabine|Lympho-conditioning agent
79396479|NCT04245722|Drug|Rituximab|Monoclonal Antibody
79396480|NCT04245722|Drug|Obinutuzumab|Monoclonal Antibody
79396481|NCT04245722|Drug|Bendamustine|Conditioning agent
79396482|NCT04204772|Biological|Activated charcoal and Tap Water|12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water
79396483|NCT04204772|Biological|Activated Charcoal and Apple Juice|12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
79396484|NCT04197700|Other|Target MAP Management|Target MAP Management
79396485|NCT04197596|Biological|BK CTL|"Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
79396486|NCT04188873|Drug|Preparation Varenicline and Standard Duration Varenicline|16 weeks of varenicline starting 4 weeks pre-quit
79396487|NCT04188873|Drug|Preparation Varenicline and Extended Duration Varenicline|28 weeks of varenicline starting 4 weeks pre-quit
79396488|NCT04188873|Drug|Standard Duration Varenicline|12 weeks of varenicline
79396489|NCT04188873|Drug|Extended Duration Varenicline|24 weeks of varenicline
79556956|NCT01682239|Other|RVAP|In this arm pacemaker leads will be placed in the RV apex.
79556957|NCT01682239|Other|RVSP|In this arm pacemaker leads will be placed in the RV septum.
79556958|NCT06225388|Other|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
79556959|NCT06225388|Other|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
80018762|NCT04346914|Biological|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
79257971|NCT04572100|Other|Chemotherapy and High-Dose Radiotherapy|Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.
79257972|NCT04572100|Drug|Paclitaxel|This drug will be combined with carboplatin during induction therapy for 9 weeks.
79257973|NCT04572100|Drug|Carboplatin|This drug will be combined with paclitaxel during induction therapy for 9 weeks.
79257974|NCT04564625|Other|Vitamin D Assessment|index admission vitamin D assessment
79556960|NCT06225375|Device|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
79719940|NCT00610909|Drug|Placebo|Placebo
79719941|NCT05331079|Other|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
79719942|NCT05046691|Behavioral|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
79719943|NCT00928135|Drug|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
79257975|NCT04564625|Other|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
79257976|NCT04560322|Drug|Venetoclax|Tablet, taken by mouth
79719944|NCT00928135|Drug|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
79719945|NCT04259827|Other|Neuronation|Online cognitive training app, with exercises created for patients with mild cognitive impairment
79257977|NCT04560322|Drug|Obinutuzumab|Intravenous infusion
79556961|NCT06225310|Drug|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
79719946|NCT04259827|Other|Aspecific online games|Online gaming without cognitive training
79719947|NCT00928057|Device|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
80018763|NCT02129400|Drug|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
80018764|NCT02129400|Drug|Aer medicinalis Linde 100%|
79257978|NCT04560322|Drug|Acalabrutinib|Capsule, taken by mouth
79257979|NCT04538755|Drug|Placebo oral capsule|Placebo before sleep
79257980|NCT04538755|Drug|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
79257981|NCT04528303|Genetic|Whole genome sequencing|Genomic sequencing and molecular diagnostic results
79257982|NCT04528303|Genetic|Whole exome sequencing|Genomic sequencing and molecular diagnostic results
79257983|NCT04525703|Behavioral|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
79257984|NCT04509076|Behavioral|PrEP iT! (plus usual PrEP care)|"The PrEP iT! intervention is a mobile-optimized website, with the following components:~PrEP Adherence, PrEP Appointment, and Sexual Activity Self-Monitoring~Tailored feedback on PrEP adherence/non-adherence~PrEP and sexual health information tailored for YMSM~Text message reminders for PrEP adherence and healthcare appointments~An ask the expert feature"
79257985|NCT04509076|Behavioral|Usual PrEP care|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
79257986|NCT04504734|Drug|Bucillamine|100mg tablets
79257987|NCT04504734|Drug|Placebo|100mg tablets
79257988|NCT04504734|Drug|Bucillamine|200mg tablets
79257989|NCT04499079|Other|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
79257990|NCT04445532|Other|Gene expression analysis|Gene expression analysis
79257991|NCT04445532|Other|Genomic analysis|Genomic analysis
79257992|NCT04445532|Other|Protein expression analysis|Protein expression analysis
79257993|NCT04445532|Other|Proteomic profiling|Proteomic profiling
79396490|NCT04188873|Drug|Preparation Combination NRT and Standard Duration Combination NRT|16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
79396491|NCT04188873|Drug|Preparation Combination NRT and Extended Duration Combination NRT|28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
79257994|NCT04445532|Other|Polymerase chain reaction|Polymerase chain reaction
79257995|NCT04445532|Other|Mass spectrometry|Mass spectrometry
79257996|NCT04445532|Other|Immunohistochemistry|Immunohistochemistry
79257997|NCT04445532|Other|Metabolomics profiling|Metabolomics profiling
79396492|NCT04188873|Drug|Standard Duration Combination NRT|12 weeks of nicotine patch + nicotine mini-lozenge
79396493|NCT04188873|Drug|Extended Duration Combination NRT|24 weeks of nicotine patch + nicotine mini-lozenge
79556962|NCT06225310|Drug|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
79556963|NCT06225310|Drug|Methylprednisolone|Glucocorticoid, steroid
79556964|NCT06225297|Combination Product|Intervention package|Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
79581118|NCT01932840|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
79581119|NCT01932866|Other|diabetic risk score|
79257998|NCT04445532|Other|Methylation and epigenetic analysis|Methylation and epigenetic analysis
79257999|NCT04445532|Other|Liquid biopsy analysis|Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
79258000|NCT04445532|Other|Laboratory biomarker analysis|Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
79719948|NCT00928057|Device|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
79719949|NCT00928057|Device|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
79719950|NCT05331547|Device|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
79855276|NCT02667002|Procedure|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
79855277|NCT02667002|Other|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
79719951|NCT00927901|Drug|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
79258001|NCT04388774|Drug|Ketamine|A single 40-minute intravenous infusion
79258002|NCT04380454|Device|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
79258003|NCT04380454|Other|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
79258004|NCT04377932|Genetic|AGAR T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10^7/m2 DL2: 1x10^8/m2 DL3: 3x10^8/m2 DL4: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
79258005|NCT04376736|Other|Home visit|Home visit by medical provider
79258006|NCT04362072|Drug|Lorlatinib|25 milligram (mg) tablet
79258007|NCT04343209|Diagnostic Test|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
79258008|NCT04343209|Drug|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
79258009|NCT04332172|Other|General information|General information related to pregnancy is provided electronically.
79719952|NCT00927901|Drug|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
79719953|NCT00927901|Drug|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
79719954|NCT00927901|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
79719955|NCT04255771|Drug|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
79719956|NCT04255771|Drug|Placebos|Use a placebo as a comparison
79719957|NCT05329363|Diagnostic Test|PEPITS Programme|"The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery."
79719958|NCT05329363|Other|Usual care|Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
79719959|NCT01218204|Drug|10mg atorvastatin|10mg
79719960|NCT01218204|Drug|80mg atorvastatin|80mg
79719961|NCT01218204|Drug|GSK1292263 Placebo|Placebo
79719962|NCT01218204|Drug|100mg GSK1292263|100mg
79719963|NCT01218204|Drug|300mg GSK1292263|300mg
79855278|NCT00935480|Drug|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
79855279|NCT00935480|Drug|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
79855280|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
79855281|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
79855282|NCT00939848|Drug|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
79855283|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
79396494|NCT04188873|Behavioral|Intensive Counseling|4 phone or video counseling sessions
79719964|NCT01218204|Drug|800mg GSK1292263|800mg
79855284|NCT00939848|Drug|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
79258010|NCT04332172|Behavioral|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
79258011|NCT04332172|Behavioral|Remote online booster sessions|Two < 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
79396495|NCT04188873|Behavioral|Minimal Counseling|2 brief phone or video counseling sessions
79396496|NCT04179409|Drug|Amondys 45|This drug is used to target skipping of exon 45 of the dystrophin gene.
79556965|NCT06225271|Behavioral|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
79556966|NCT06225258|Dietary Supplement|Xanthohumol|Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day *every 8 hours) at the dose of 2 mg.\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
79719965|NCT01218204|Drug|10mg ezetimibe|10mg
79719966|NCT01218204|Other|Washout|No interventions - washout period
79855285|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
79855286|NCT04013048|Drug|[14C]-Fluzoparib|Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.
79396497|NCT04179409|Drug|Exondys 51|This drug is used to target skipping of exon 51 of the dystrophin gene.
79396498|NCT04179409|Drug|Vyondys 53|This drug is used to target skipping of exon 53 of the dystrophin gene.
79855287|NCT04014218|Drug|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
79396499|NCT04169906|Drug|Placebo|Participants will receive placebo once daily for 7 consective days
79396500|NCT04169906|Drug|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
79396501|NCT04169906|Drug|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
79396502|NCT04169906|Drug|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
79396503|NCT04169893|Drug|Placebo (fasting)|Participants will receive placebo once in fasting condition
79396504|NCT04169893|Drug|Placebo (feeding)|Participants will receive placebo once after meal condition
79719967|NCT00926575|Drug|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
79719968|NCT00926575|Drug|Placebo|Two tablets QID for 50 days
79719969|NCT01218126|Drug|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
79719970|NCT01218126|Drug|placebo|placebo comparison with active
79719971|NCT05456412|Other|JAK inhibitor treatment|Standard care
79719972|NCT01217892|Drug|dapagliflozin|2.5 mg tablet, taken orally, twice daily
79719973|NCT01217892|Drug|dapagliflozin|5 mg tablet taken orally, twice daily
79719974|NCT01217892|Drug|dapagliflozin|10 mg tablet taken orally, once daily
79719975|NCT01217892|Drug|metformin|>/= 1500 mg total daily dose, tablets taken orally, twice daily
79719976|NCT01217892|Drug|placebo|placebo
79855288|NCT04014218|Drug|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
79855289|NCT00935558|Biological|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
79855290|NCT00935558|Drug|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
79855291|NCT05280236|Drug|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
79855292|NCT05280236|Drug|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
79855293|NCT00940472|Drug|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
79855294|NCT00940472|Drug|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
79875586|NCT01045863|Drug|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
80018765|NCT05135884|Behavioral|Standard inpatient stroke rehabilitation|According to Swiss national guidelines and local protocols
80018766|NCT05704465|Behavioral|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
80018767|NCT05704465|Behavioral|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
79258012|NCT04332172|Behavioral|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
79258013|NCT04325646|Other|Human Biological samples|Blood samples for serological tests
79719977|NCT01217814|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79719978|NCT01217814|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79719979|NCT01217814|Drug|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79258014|NCT04325646|Other|Human Biological samples|Blood samples, saliva, nasopharyngeal swab for serological tests
79719980|NCT01217814|Drug|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
79396505|NCT04169893|Drug|1 mg of TS-142|Participants will receive 1 mg of TS-142 once in fasting condition
79396506|NCT04169893|Drug|3 mg of TS-142|Participants will receive 3 mg of TS-142 once in fasting condition
79855295|NCT04013204|Other|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
79396507|NCT04169893|Drug|10 mg of TS-142 (fasting)|Participants will receive 10 mg of TS-142 once in fasting condition
79855296|NCT00939926|Drug|Risperidone|
79855297|NCT00940550|Drug|Prolonged-release melatonin|2 mg tablet, once.
79855298|NCT00940550|Drug|Temazepam|20 mg capsule, once
79396508|NCT04169893|Drug|10 mg of TS-142 (feeding)|Participants will receive 10 mg of TS-142 once after meal condition
79396509|NCT04169893|Drug|30 mg of TS-142|Participants will receive 30 mg of TS-142 once in fasting condition
79396510|NCT04126603|Drug|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
79396511|NCT04126603|Drug|Placebos|Placebo injection
79396512|NCT04099966|Drug|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
79855299|NCT00940550|Drug|Zolpidem|10 mg capsule, once
79855300|NCT00940550|Drug|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
79855301|NCT00935714|Other|Exercise|
79855302|NCT00935714|Other|Exercise|
79396513|NCT04087707|Drug|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
79396514|NCT04087707|Drug|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
79396515|NCT04087707|Drug|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
79855303|NCT00935870|Device|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
79855304|NCT00935948|Drug|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
79855305|NCT00935948|Drug|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
79719981|NCT01217814|Drug|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
79719982|NCT01217190|Drug|Ondansetron (ODFS)|Test Article
79719983|NCT01217190|Drug|Zofran (ODT)|Comparator
79719984|NCT01136733|Drug|Lenvatinib|taken orally, once a day
80018768|NCT05305768|Drug|IncobotulinumtoxinA|Injection of glabellar rhytids
80018769|NCT05245981|Device|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
80018770|NCT02133378|Device|Hemopatch|Baxter Hemopatch
80018771|NCT02133378|Behavioral|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
79258015|NCT04306939|Other|venipuncture|Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.
79719985|NCT01136733|Drug|Everolimus|taken orally, once a day
79396516|NCT04053855|Biological|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
79719986|NCT05178693|Drug|ASTX727|Cedazuridine 100mg + 35mg decitabine
79719987|NCT05178693|Radiation|Lutathera|Peptide receptor radionuclide therapy (PRRT)
79855306|NCT00936026|Drug|Neramexane|Drug-Drug Interaction Study
79855307|NCT00940628|Behavioral|Diet and Exercise|mildly hypocaloric diet and physical exercise
79855308|NCT00940628|Drug|orlistat [Xenical]|120mg po tid
79855309|NCT00921323|Behavioral|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
79258016|NCT04306939|Behavioral|Questionnaires|PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
79258017|NCT04306939|Other|Additional Sample Collections|We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
79396517|NCT04043286|Device|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
79396518|NCT04023071|Drug|FT516|Experimental Interventional Therapy
79396519|NCT04023071|Drug|Rituximab|Monoclonal Antibody
79396520|NCT04023071|Drug|Obinutuzumab|Monoclonal Antibody
79719988|NCT01136655|Drug|80/2.25 μg Symbicort pMDI|inhalation
79719989|NCT01136655|Drug|80/4.5 μg Symbicort pMDI|inhalation
79719990|NCT01136655|Drug|Foradil Aerolizer 12 μg|inhalation
79719991|NCT01136655|Drug|40 μg budesonide HFA pMDI|inhalation
79719992|NCT01136655|Drug|placebo HFA pMDI|inhalation
79719993|NCT04312581|Device|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
79719994|NCT04312581|Other|Conventional rehabilitation|physical & occupational therapy
79719995|NCT01135017|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
79719996|NCT01135017|Drug|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
79719997|NCT02883153|Drug|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
79855310|NCT00921323|Behavioral|Control|The control group will be advised to continue to be physically active and record daily steps
79855311|NCT00940004|Biological|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
79855312|NCT02565797|Device|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
79855313|NCT00936182|Drug|Fluconazole|Fluconazole daily for 30 days
79855314|NCT00936260|Drug|alendronate|several duration of treatment
79855315|NCT00445978|Drug|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
79855316|NCT02566733|Drug|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
79855317|NCT02566733|Drug|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
79855318|NCT00936338|Behavioral|splint and joint mobilization self exercise|
79855319|NCT05281991|Device|Doppler ultrasonography|color flow Doppler ultrasonography
79855320|NCT05281991|Device|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
79855321|NCT00936416|Procedure|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
79855322|NCT02566421|Other|Laboratory Biomarker Analysis|Correlative studies
79855323|NCT02566421|Other|Quality-of-Life Assessment|Ancillary studies
79855324|NCT02566421|Other|Targeted Therapy|Receive treatment based on genomic sequencing
79875587|NCT03081585|Behavioral|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
79875588|NCT00553787|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
79875589|NCT00553787|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
79875590|NCT00553787|Drug|VI-0521|placebo
79556967|NCT06225245|Device|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) [31-33]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
79258018|NCT04305340|Device|Myant SKIIN Device|"Supine position: Participant lays on a bed on their back for 5 minutes~Sitting position: Participant sits on a chair for 5 minutes~Standing position: Participant stands for 5 minutes.~Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~Cool-down: Participants cool-down for 5 minutes"
79258019|NCT04267614|Drug|Etanercept|Patients who received etanercept for RA
79556968|NCT06225232|Drug|Psilocybin combined with Psychotherapy|The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
79556969|NCT06225219|Behavioral|Counseling|To introduce a model of holistic care to the patient populations served by the GCAC through chaplain interventions that focus on spiritual and emotional health.
80018772|NCT05135416|Procedure|chewing gum Group|control of consciousness chewing gum listening to bowel sounds assessment of pain
79556970|NCT06225206|Behavioral|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant <1 year PTX and >1 year PTX
79719998|NCT01134783|Behavioral|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
79719999|NCT01134705|Drug|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
79720000|NCT01134705|Drug|Placebo Nasal Aerosol|HFA Vehicle Aerosol
79720001|NCT00927823|Drug|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
79855325|NCT00940706|Device|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
79855326|NCT00940706|Other|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
79855327|NCT00940706|Behavioral|Monitoring physical activity|Activity monitoring with accelerometers
80018773|NCT05135416|Procedure|Control group|control of consciousness listening to bowel sounds assessment of pain
79258020|NCT04264442|Drug|Losmapimod|Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
79258021|NCT04225663|Behavioral|Guided Meditation|Participants will meditate in response to the guidance provided by a trained meditation coach in person.
79277397|NCT02375529|Procedure|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
79720002|NCT01134627|Drug|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
79720003|NCT01134627|Drug|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
79720004|NCT04992715|Diagnostic Test|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
79720005|NCT01134393|Drug|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
79720006|NCT05331469|Drug|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
79855328|NCT01023412|Dietary Supplement|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
79875591|NCT00947843|Drug|aspirin + pregrel (Clopidogrel resinate)|
79875592|NCT00947843|Drug|aspirin + placebo|
79875593|NCT00947843|Drug|aspirin + plavix (Clopidogrel bisulfate)|
79875594|NCT00943475|Procedure|circumcision|circumcision by plastbell
79875595|NCT00947921|Procedure|Plasty|Restrictive Annuloplasty
79875596|NCT00947921|Procedure|Prosthesis|Valve replacement
79720007|NCT00610753|Behavioral|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
79258022|NCT04171999|Other|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
79855329|NCT02566499|Device|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
80018774|NCT03550716|Procedure|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
79258023|NCT04170309|Drug|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
80018775|NCT03550716|Procedure|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
79396521|NCT04023071|Drug|Cyclophosphamide|Conditioning agent
79556971|NCT06225167|Behavioral|To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.|"To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol."
79720008|NCT00610753|Behavioral|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
79258024|NCT04164212|Drug|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
79396522|NCT04023071|Drug|Fludarabine|Conditioning agent
79396523|NCT04023071|Drug|IL-2|Biologic response modifier
79556972|NCT06225141|Other|Clinical Data reuse|Clinical Data reuse
79258025|NCT04112199|Drug|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
79396524|NCT04023071|Drug|Bendamustine|Conditioning agent
79396525|NCT03991481|Biological|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
79396526|NCT03991481|Biological|Liquid-stored platelets|Liquid-stored platelets as per standard practice
79396527|NCT03965390|Behavioral|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
79720009|NCT04246957|Behavioral|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
79720010|NCT04246957|Behavioral|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
79396528|NCT03917173|Procedure|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
79720011|NCT00922441|Drug|Fimasartan 60 mg group|Fimasartan 60 mg
79720012|NCT00922441|Drug|Fimasartan 120 mg group|Fimasartan 120 mg
79855330|NCT00936494|Procedure|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
79855331|NCT01028950|Drug|YM150|oral
79855332|NCT00940784|Drug|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
80018776|NCT05305690|Other|No intervention|This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
80018777|NCT03525080|Diagnostic Test|PET imagery|Every patients will have a PET imagery in addition to standard MRI
80018778|NCT05305378|Device|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
79258026|NCT04089904|Drug|Pembrolizumab Injection|Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
79396529|NCT03917173|Procedure|Standard surgery|Standard surgery without HIPEC CO2
79556973|NCT06225128|Other|Biobanking blood|Additional volume of 30mL (EDTA) At Screening, pre-Cycle 1 Day 1,Day 1 H8, Day 2, and Day of post-cycle 1 evaluation.
79720013|NCT00922441|Drug|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
79720014|NCT01217112|Drug|GWP42003|100 mg capsules, PO, BD, 91 days
80018779|NCT04171622|Drug|Lenvatinib|Given PO
80018780|NCT04171622|Biological|Pembrolizumab|Given IV
80018781|NCT05234580|Drug|PA9159 nasal spray solution, 10 μg once daily for 14 days|PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
80018782|NCT05234580|Drug|PA9159 nasal spray solution, 20 μg once daily for 14 days|PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
80018783|NCT05234580|Drug|PA9159 nasal spray solution, 40 μg once daily for 14 days|PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
79258027|NCT04076735|Procedure|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
79258028|NCT04076735|Procedure|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
79258029|NCT04055428|Drug|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
79396530|NCT03910751|Device|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
79396531|NCT03910738|Drug|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
79396532|NCT03910738|Drug|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
79720015|NCT01217112|Drug|GWP42003|5 mg capsules, PO, BD, 91 days
79720016|NCT01217112|Drug|GWP42004|5 mg capsules, PO, BD, 91 days
79258030|NCT04055428|Drug|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
79258031|NCT04055428|Other|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
79258032|NCT04055428|Dietary Supplement|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
79396533|NCT03910738|Procedure|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
79720017|NCT01217112|Drug|Placebo|0 mg capsules, QDS, PO, 91 days
79277398|NCT02198495|Drug|Supplementation of ferric carboxymaltose|
79396534|NCT03910738|Behavioral|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
79556974|NCT06225128|Other|Bone marrow specimens|"Additional volume of 2mL (EDTA)~at screening for correlative studies and at Day 7 for smears and for correlative studies.~Day 1 and day 6 post-cycle evaluations for correlative studies.~Trephine biopsy at screening and at post-cycle 1 and 6 evaluations (performed at the same time as aspiration)"
79581120|NCT01932905|Device|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
79720018|NCT01216332|Drug|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
79720019|NCT01216332|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
79720020|NCT00922207|Drug|Adefovir|From week -4 to week 2
79720021|NCT00922207|Drug|Entecavir|From week -4 to week 2
79720022|NCT00922207|Drug|Placebo|From week -4 to week 2
79720023|NCT00922207|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
79720024|NCT05316103|Device|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
79720025|NCT04255459|Other|Moist Snuff|Moist Snuff product
79720026|NCT04255459|Other|Camel Snus|Camel Snus product
79720027|NCT04255459|Other|Cigarettes|Cigarette product
79720028|NCT04255459|Other|No tobacco usage|No tobacco usage
79720029|NCT01134315|Drug|Paricalcitol|
79720030|NCT01134315|Drug|Calcitriol|
79720031|NCT04253431|Device|Droplet lancing device (HTL-Strefa S.A.)|
80018784|NCT05234580|Drug|Placebo nasal spray solution without PA9159, once daily for 14 days|Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
80018785|NCT05305222|Drug|Risankizumab|Intravenous (IV) Infusion
80018786|NCT05305222|Drug|Placebo|Intravenous (IV) Infusion
80018787|NCT03522272|Device|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
79258033|NCT04055428|Other|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
79258034|NCT04049383|Biological|CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level -1: 5 x 10^5 CAR-20/19-T cells/kg"
79720032|NCT04253431|Device|Microlet 2 lancing device (Bayer)|
79258035|NCT04049383|Biological|CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10^6 CAR-20/19-T cells/kg (starting dose level)"
79556975|NCT06225102|Behavioral|Kegel Exercise|"Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening."
79720033|NCT04253431|Device|OneTouch Delicia lancing device (LifeScan)|
79720034|NCT04253431|Device|ReliOn lancing device (ReliOn)|
79396535|NCT03910738|Behavioral|Assessment of disability|EDSS (Baseline, week 30 and 66)
79556976|NCT06225063|Other|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
79581121|NCT01932918|Drug|Patient controlled analgesia|"PCA with morphine in liver transplant:~Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~PCA with morphine and ketorolac:~Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
79855333|NCT00940784|Drug|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
79581122|NCT01932931|Dietary Supplement|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
79720035|NCT04253431|Device|Accu-Chek Softclix lancing device (Roche)|
79277399|NCT02198495|Drug|Supplementation of iron sucrose|
79277400|NCT02368509|Other|Perform sensory tests|
79277401|NCT02201849|Drug|Study Drug|
79277402|NCT02201849|Drug|Active Control|
79277403|NCT02201849|Drug|Placebo|
79277404|NCT02375217|Drug|Sugammadex|half dose
79396538|NCT03887052|Device|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
79396539|NCT03869996|Procedure|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
79396540|NCT03869996|Procedure|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
79396541|NCT03851601|Other|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
79720036|NCT04253431|Device|BGStar lancing device (Sanofi Aventis)|
79720037|NCT04253431|Device|Ultra-Fine 33G lancets (BD)|
79720038|NCT04253431|Device|Droplet 33G lancets (HTL-Strefa S.A.)|
79396542|NCT03841084|Drug|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
79720039|NCT04253431|Device|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
79720040|NCT04253431|Device|HaemoFine 33G lancets (HTL-Strefa S.A.)|
79720041|NCT04253431|Device|Softclix 28 G lancets (Roche)|
79720042|NCT04253431|Device|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
79720043|NCT04253431|Device|GlucoJect Dual S lancing device (Menarini)|
79720044|NCT04253431|Device|Microlet 28G lancets (Bayer)|
79720045|NCT04253431|Device|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
79720046|NCT01216176|Drug|Anastrozole|
79720047|NCT01216176|Drug|AZD0530 (saracatinib)|
79855334|NCT00940784|Drug|Aspirin|81-100 mg qd
79855335|NCT01023490|Drug|Vitamin D|34,5000 IU vitamin D per week
79855336|NCT01023490|Drug|Placebo|Placebo
79855337|NCT00566228|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
79855338|NCT00566228|Procedure|leukapheresis|Stem cells collected
79855339|NCT00698009|Drug|Fludarabine|25 mg/m^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
79855340|NCT00698009|Drug|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
80018788|NCT03522272|Device|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
79396543|NCT03785223|Drug|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
79396544|NCT03785223|Drug|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
79396545|NCT03779126|Device|Electrical stimulation|1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
80018789|NCT03522272|Other|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
80018790|NCT02138058|Drug|Topiramate|
79556977|NCT06225063|Other|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
79720048|NCT01216176|Drug|Placebo|
80018791|NCT02138058|Behavioral|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
79396546|NCT03779087|Drug|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
79258036|NCT04049383|Biological|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10^6 CAR-20/19-T cells/kg (goal cell dose)"
79258037|NCT04049383|Biological|CAR-20/19-T cells|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~The dose expansion dose level is still to be determined and this section will be updated."
79258038|NCT04049019|Diagnostic Test|Urine collection through a collecting device (Uridome®) for maximum 1 week|"The child will collect:~Urine at bedtime before a wet and a dry night.~Urine during a wet night through a collecting device.~First morning voided volume following both a wet and a dry night."
79396547|NCT03779087|Drug|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
79396548|NCT03779074|Drug|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
79720049|NCT05330845|Biological|IL6 assessment|Blood IL6 will be assessed during trial
79720050|NCT05330845|Biological|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
79720051|NCT01133847|Drug|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
79720052|NCT01133847|Behavioral|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
79855341|NCT00698009|Biological|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
79855342|NCT00698009|Drug|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
79855343|NCT00698009|Drug|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
79258039|NCT04049019|Diagnostic Test|Urine collection|"The child will collect:~Urine at bedtime.~First morning voided volume"
79258040|NCT04035590|Procedure|No drain|Mastectomy with flap fixation without low vacuum drainage
79855344|NCT01027156|Behavioral|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
79258041|NCT04035590|Procedure|With drain|Mastectomy with flap fixation with low vacuum drainage
79258042|NCT04026425|Other|Two-day cardiopulmonary exercise test|A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
79277405|NCT02375217|Drug|Sugammadex|full dose
79720053|NCT01133847|Behavioral|Parent Training|Nine sessions on parenting a child with ADHD
79556978|NCT06225050|Device|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
79556979|NCT06225037|Device|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
79258043|NCT04021355|Other|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
80018792|NCT05187403|Drug|Laquinimod|Eye-drops
79258044|NCT04004000|Drug|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
79258045|NCT03998488|Drug|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
79258046|NCT03998488|Dietary Supplement|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
79855345|NCT01029106|Procedure|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
79396549|NCT03779074|Drug|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
79396550|NCT03779074|Drug|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
79556980|NCT06225037|Device|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
79556981|NCT06225011|Drug|Fluoxetine|Receive PO
79396551|NCT03758066|Device|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
79396552|NCT03754257|Procedure|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
79581123|NCT01932944|Device|No treatment|
79720054|NCT01133847|Drug|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
79720055|NCT01133847|Drug|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
79720056|NCT01133847|Drug|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
79720057|NCT05000125|Diagnostic Test|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
79396553|NCT03754257|Procedure|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
79396554|NCT03754257|Other|Conventional Physiotherapy|Active and passive exercises, and walking.
79396555|NCT03750786|Drug|Arfolitixorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
79581124|NCT01932957|Procedure|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
79581125|NCT01932957|Procedure|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
79720058|NCT02887950|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
79720059|NCT02887950|Dietary Supplement|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
79855346|NCT05264831|Procedure|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
79855347|NCT05264831|Procedure|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
79855348|NCT00936572|Procedure|Probiotics (La1, BB536)|
79855349|NCT00936572|Biological|probiotics (La1, BB536)|
79855350|NCT00936572|Biological|placebo|Maltodoxtrin
79855351|NCT04012658|Other|No intervention|No intervention
79855352|NCT03894605|Device|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
79855353|NCT00944606|Dietary Supplement|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
80018793|NCT05187403|Drug|Placebo|Eye-drops
80018794|NCT02129634|Device|CB-PTA|
80018795|NCT02129634|Device|DEB-PTA|
80018796|NCT05174455|Drug|Niraparib Tosylate Monohydrate|Given PO
79855354|NCT00944606|Other|Placebo candy|candy gum drops
79556982|NCT06224998|Behavioral|Exercise|Exercise is the most appropriate treatment for low and moderate AIS cases due to its low cost and low risk of complications. Exercises prevent the development of many problems by controlling the severity of curvature and preventing the progression of curvature. It is thought that scoliosis exercises can delay or even prevent surgery and reduce the duration or degree of brace, especially in patients with low-to-moderate curvature during growth. One of these exercise approaches, the Schroth technique, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The core component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions.
79556983|NCT06224972|Device|Vlab|The study is observational, there is no intervention.
79556984|NCT06224946|Diagnostic Test|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
79556985|NCT06224933|Device|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
79556986|NCT06224920|Diagnostic Test|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
80018797|NCT04142606|Other|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
80018798|NCT04335604|Drug|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
80018799|NCT05063084|Procedure|Optiflow - HFNO|Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2
80018800|NCT05063084|Procedure|Classic|Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
80018801|NCT02138292|Drug|Trametinib (2mg)/Digoxin (.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.~Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
80018802|NCT04468100|Biological|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
80018803|NCT04468100|Biological|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
80018804|NCT01317277|Behavioral|individualized Texting for Adherence Building (iTAB)|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group."
80018805|NCT01317277|Behavioral|Psychoeducation|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence."
79277406|NCT02375217|Drug|Neostigmine|IV = 50mcg/kg
79556987|NCT06224920|Other|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
79556988|NCT06224920|Diagnostic Test|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
79855355|NCT00941018|Drug|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
80018806|NCT04467788|Other|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
80018807|NCT04467788|Other|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
80018808|NCT03526952|Other|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
79277407|NCT02375217|Drug|glycopyrrolate|
79277408|NCT05724433|Other|Virtual HF Care|Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
79277409|NCT05724433|Other|Routine HF Care|Care as determined by the treating physician
79277410|NCT02368587|Biological|WJMSCs Vs. placebo|WJMSCs Vs. placebo
79277411|NCT02368587|Biological|Placebo|WJMSCs Vs. placebo
80018809|NCT03526952|Other|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
80018810|NCT03626935|Device|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
80018811|NCT05134870|Behavioral|Mimic- game and groove- Telerehabilitation|Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
79556989|NCT06224920|Diagnostic Test|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand [18F]-GE-180, [18F]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand [18F]-PI-2620. In brief, [18F]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. [18F]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic [18F]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
79855356|NCT04060901|Behavioral|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
79258049|NCT03959904|Procedure|Small stitch|Wound closure will be using small stiches or larger spaced stitches
79258050|NCT03959904|Other|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
79556990|NCT06224920|Diagnostic Test|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
79556991|NCT06224907|Biological|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
79556992|NCT06224894|Other|Music Therapy|Music Therapy
79556993|NCT06224894|Other|antiemetic treatment|antiemetic treatment
79556994|NCT06224881|Drug|Ascorbic acid|2 gm every 8hrs for 4 days
79556995|NCT06224868|Other|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
79556996|NCT06224868|Other|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
79556997|NCT06224842|Drug|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
79556998|NCT06224842|Drug|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
79556999|NCT06224842|Drug|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
79557000|NCT06224829|Procedure|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
79557001|NCT06224829|Procedure|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
79557002|NCT06224829|Procedure|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
79557003|NCT06224816|Device|Custom 3D mask (3DM) application in neonate|Premature infants with a birth weight less than 1500 g r first received 3D mask during 4 hour, then crossed over to traditional mask.
80018812|NCT02133612|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
80018813|NCT03522194|Drug|Sevoflurane|Anesthesia maintenance with Sevoflurane
79258051|NCT03959904|Other|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
79258052|NCT03959904|Other|Pain Score|A pain score will be recorded following the surgical procedure.
79258053|NCT03959904|Other|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
79258054|NCT03953417|Device|Accelerated intermittent theta-burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator."
79855357|NCT00944684|Drug|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
80018814|NCT03522194|Drug|Propofol|Anesthesia maintenance with Propofol
79720060|NCT02887950|Dietary Supplement|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
80018815|NCT05304988|Other|Testing of the EFT|A research committee which composes of a paediatric oncologist, a ward manager, an assistant professor and a research assistant will be set up. The committee will develop specific questions in EFT and design and implement the clinical Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The oncologist will rate the subject with the most appropriate level of physical activity on a 4-point scale.
80018816|NCT02260752|Procedure|hysterectomy|surgical removal of the uterus
79396556|NCT03750786|Drug|Leucovorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
80018817|NCT02260752|Procedure|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
80018818|NCT02260752|Procedure|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
80018819|NCT02260752|Drug|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
79557004|NCT06224816|Device|Traditional mask (TM) application in neonate|Premature infants with a birth weight less than 1500 g r first received traditional mask during 4 hours, then crossed over to 3D mask.
80018820|NCT02260752|Procedure|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
79557005|NCT06224803|Dietary Supplement|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
80018821|NCT02260752|Procedure|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
80018822|NCT02260752|Procedure|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
80018823|NCT04820686|Drug|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
80018824|NCT04820686|Drug|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
79396557|NCT03742414|Combination Product|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
80018825|NCT04820686|Drug|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
80018826|NCT02260830|Drug|Lu AF11167|
80018827|NCT02260908|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
79396558|NCT03742414|Combination Product|Fluticasone propionate Cream 0.05%|Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
79396559|NCT03742414|Combination Product|Moisturizer|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a moisturizer and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
79396560|NCT03742414|Other|Standard of Care|Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
79557006|NCT06224803|Dietary Supplement|Indigestible dextrin|Indigestible dextrin as placebo intervention
79557007|NCT06224790|Drug|Pirfenidone|Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
79557008|NCT06224790|Other|Placebo|2 Capsules 3 times a day for 3 months
79720061|NCT02883075|Other|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
79855358|NCT00944684|Drug|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
80018828|NCT02260908|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
80018829|NCT02969655|Drug|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
80018830|NCT02969655|Drug|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
80018831|NCT02969655|Drug|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
80018832|NCT02969655|Drug|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
80018833|NCT02969655|Drug|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
80018834|NCT02969655|Drug|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
80018835|NCT02129712|Behavioral|Cognitive training|
80018836|NCT04489420|Biological|CYNK001-IV|Planned Starting dose dor IV 1.2x10^9 cells/dose
80018837|NCT04489420|Biological|CYNK001-IT|Planned starting dose for IT 200 x10^6 +/- 50 x10^6 cells dose
79258055|NCT03946228|Behavioral|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
79258056|NCT03912246|Biological|biological samples|collection of blood, urine, saliva, stool, skin and mouth swabs, tears
79396561|NCT03736395|Behavioral|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
79258057|NCT03912246|Procedure|lumbar puncture|collection of cerebrospinal fluid
79396562|NCT03736395|Behavioral|Control|Schools in this condition will receive a four-day training session about SWPBIS.
79396563|NCT03728933|Drug|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm^2) patch size).
79396564|NCT03728933|Drug|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm^2) patch size).
79557009|NCT06224777|Biological|5% Albumin (human) Solution|Albumin is a biological product derived from human blood donors.
79258058|NCT03896776|Behavioral|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling ~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
79720062|NCT02883075|Other|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
79720063|NCT02883075|Other|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
79258059|NCT03892798|Other|No interventions are planned|No interventions are planned
79258060|NCT03874455|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
79557010|NCT06224777|Drug|Paeds solution|Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
79557012|NCT06224751|Diagnostic Test|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
79855359|NCT04061057|Drug|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
79855360|NCT04061057|Drug|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
79855361|NCT00921167|Drug|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks
79855362|NCT04061447|Drug|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
80018838|NCT02138526|Drug|pazopanib|pazopanib 800mg OD without food
79557013|NCT06224751|Diagnostic Test|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
79557014|NCT06224751|Diagnostic Test|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
79557015|NCT06224751|Diagnostic Test|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
79557016|NCT06224751|Diagnostic Test|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
79557017|NCT06224751|Diagnostic Test|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
79557018|NCT06224751|Diagnostic Test|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
79720064|NCT04984525|Drug|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
79720065|NCT04984525|Drug|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
80018839|NCT02138526|Other|continental breakfast|pazopanib 600mg OD with food
80018840|NCT03526796|Procedure|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
79396565|NCT03728933|Drug|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
79396566|NCT03719105|Drug|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
79258061|NCT03809351|Drug|[F-18]AV-1451-PET|All study participants will undergo brain imaging with [F-18]AV-1451-PET/MRI. [F-18]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
79258062|NCT03735680|Drug|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
79258063|NCT03726658|Drug|AGN-241751|AGN-241751 is supplied in tablet form
79396567|NCT03719105|Drug|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396568|NCT03719105|Drug|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396569|NCT03719105|Drug|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79557019|NCT06224738|Biological|human HER2-targeted CAR-M cells|The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
79557020|NCT06224699|Drug|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
79557021|NCT06224686|Other|conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
79557022|NCT06224686|Other|motor imagery based on action observation treatment|First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
79557023|NCT06224673|Drug|ARX788|Given IV
79855363|NCT04061447|Drug|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
79855364|NCT03968978|Biological|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
79258064|NCT03726658|Drug|Placebo|Placebo is supplied in tablet form
79396570|NCT03719105|Drug|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396571|NCT03719105|Drug|calaspargase pegol|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396572|NCT03719105|Drug|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396573|NCT03719105|Drug|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396574|NCT03719105|Drug|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79557024|NCT06224673|Procedure|Computed Tomography (CT)|Undergo CT or Positron Emission Tomography(PET)/CT
79258065|NCT03719885|Device|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
79258066|NCT03718091|Drug|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
79277412|NCT03527875|Procedure|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
79277413|NCT03527875|Procedure|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
79396575|NCT03719105|Drug|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
79396576|NCT03705819|Drug|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of [11C]-NOP46.
79396577|NCT03705819|Radiation|PET/CT scan|After subjects receive a microdose of [11C]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
79557025|NCT06224673|Procedure|Biospecimen Collection|Undergo collection of blood samples
79720066|NCT01133379|Device|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
79720067|NCT01133379|Device|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
79720068|NCT01133379|Device|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
79720069|NCT04259437|Other|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
79396578|NCT03694561|Other|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
79855365|NCT03968978|Biological|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
80018841|NCT04488874|Drug|Sodium Lactate|"Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose"
79396579|NCT03678935|Other|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
79258067|NCT03662607|Behavioral|Virtual reality experience|"Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~Seated comfortably and free of direct obstruction~Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~Begin the VR experience. Study personnel stay in the room & provide guidance and answer questions regarding the technology~When VR experience concluded, wellness self-assessment will be administered again."
79396580|NCT03663790|Other|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
79396581|NCT03663790|Other|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
79396582|NCT03649841|Drug|Antiandrogen Therapy|Undergo ADT
79396583|NCT03649841|Drug|Abiraterone Acetate|Undergo Abiraterone Acetate Treatment SOC
79557026|NCT06224660|Genetic|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
79258068|NCT03654664|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
79557027|NCT06224621|Procedure|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
79396584|NCT03649841|Drug|Prednisone|Undergo Prednisone Treatment SOC
79557028|NCT06224608|Biological|Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)|"1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration."
79855366|NCT02567591|Other|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
79855367|NCT02565953|Device|Paclitaxel-releasing PTA balloon catheter|
79855368|NCT02565953|Device|PTA balloon catheter|
79396585|NCT03649841|Radiation|Radiation Therapy|Undergo neutron radiation therapy
79557029|NCT06224582|Drug|Yinxingmihuan oral solution|Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
79557030|NCT06224582|Drug|Placebo|The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
79855369|NCT00562718|Drug|capecitabine|
79855370|NCT00562718|Procedure|adjuvant therapy|
79855371|NCT00562718|Radiation|radiation therapy|
80018842|NCT04488874|Drug|Mannitol 20% Infusion|Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
80018843|NCT02129790|Behavioral|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
79258069|NCT03654664|Biological|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
79258070|NCT03653338|Biological|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
79258071|NCT03653338|Biological|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
79396586|NCT03627026|Other|Blood samples will be collected at different time points:|"Baseline~Week 6 Day 1~Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."
79396587|NCT03599713|Drug|Retifanlimab|INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
79396588|NCT03557372|Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule|"Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
79396589|NCT03557281|Drug|GSK3036656|GSK3036656 will be administered
79396590|NCT03557281|Drug|Rifafour e-275|Rifafour e-275 will be administered
79396591|NCT03538041|Drug|Parsaclisib|Parsaclisib administered orally.
79396592|NCT03537196|Drug|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
79855372|NCT05222165|Drug|Infigratinib|Hard gelatin capsules for oral use
79855373|NCT02567357|Behavioral|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
80018844|NCT05304754|Biological|NK cells stimulated ex vivo with IL-15|When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
79258072|NCT03653338|Drug|Hydroxyurea|Sickle Cell Disease Conditioning
79258073|NCT03653338|Drug|Rituximab|Sickle Cell Disease Conditioning
79258074|NCT03653338|Drug|Alemtuzumab|Sickle Cell Disease Conditioning
79258075|NCT03653338|Drug|Fludarabine|Sickle Cell Disease Conditioning
79258076|NCT03653338|Drug|Thiotepa|Sickle Cell Disease Conditioning
79396593|NCT03537196|Drug|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
79396594|NCT03537196|Drug|Ribavirin|"In case of cirrhosis:~Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight < 75 kg) will receive 500 mg x 2/day.~In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
79855374|NCT02567357|Behavioral|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
79855375|NCT04555811|Drug|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
80018845|NCT05304754|Biological|Alloreactive NK cells|When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
80018846|NCT01317199|Drug|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
80018847|NCT01317199|Drug|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
79396595|NCT03537196|Drug|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
79258077|NCT03628703|Device|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
79557031|NCT06224556|Combination Product|Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program|"Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed."
79557032|NCT06224530|Drug|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
79557033|NCT06224530|Drug|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
79557034|NCT06224504|Behavioral|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
79258078|NCT03610724|Biological|Tisagenlecleucel|Single intravenous infusion
79258079|NCT03610724|Drug|lymphodepleting chemotherapy|Prior to tisagenlecleucel infusion, each subject should undergo lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
79258080|NCT03610724|Drug|Bridging Therapy|Pre-study treatment phase may also include bridging therapy of investigator's choice
79258081|NCT03600324|Behavioral|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
79396599|NCT03525223|Procedure|Change of dialysate [Na+]|Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
79396600|NCT03515304|Drug|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
79396601|NCT03515304|Drug|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
79396602|NCT03502746|Drug|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
79396603|NCT03502746|Drug|Ramucirumab|8mg/kg, IV over 60 minutes.
79396604|NCT03482310|Device|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
79396605|NCT03437993|Other|Recollect, the game|"Recollect is a working memory training game"
79396606|NCT03437993|Other|Tetris|App-based video game where shapes are rotated and placed to fit a grid
79396607|NCT03427866|Drug|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
80018848|NCT01317199|Drug|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
80018849|NCT01317199|Drug|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
79396608|NCT03384134|Other|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
80018850|NCT03650439|Diagnostic Test|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
79396609|NCT03345797|Drug|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
79720070|NCT04259515|Drug|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
79720071|NCT04259515|Drug|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
79720072|NCT04259671|Device|My Autism Passport (MAP) Application|Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
79855376|NCT04555811|Drug|Rituximab|Rituximab 375 mg/m^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
80018851|NCT02138682|Drug|l-123 Ioflupane|5 millicuries of Ioflupane
80018852|NCT03651219|Drug|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
80018853|NCT03651219|Drug|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
80018854|NCT02648698|Drug|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
80018855|NCT05032417|Other|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
80018856|NCT02133690|Biological|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
80018857|NCT02133690|Other|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
79396610|NCT03292458|Drug|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
79396611|NCT03287817|Biological|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).
79396612|NCT03265873|Other|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
79396613|NCT03260894|Drug|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
79396614|NCT03260894|Drug|Epacadostat|Epacadostat 100 mg administered orally twice daily.
79396615|NCT03260894|Drug|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
79396616|NCT03260894|Drug|Pazopanib|Pazopanib 800 mg administered orally once daily.
79396617|NCT03197935|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
79396618|NCT03197935|Drug|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
79396619|NCT03197935|Drug|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
79396620|NCT03197935|Drug|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
79396621|NCT03197935|Drug|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
79396622|NCT03197935|Drug|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
79396623|NCT03197935|Drug|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
79396624|NCT03136965|Biological|PRP|Injection of autologous platelet rich plasma (PRP)
80018858|NCT03627559|Procedure|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
79557035|NCT06224504|Behavioral|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
79557036|NCT06224504|Behavioral|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
79557037|NCT06224504|Behavioral|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
79557038|NCT06224491|Other|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
79557039|NCT06224478|Other|Measurement of palatal mucosa thickness on CBCT scans|Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
79557040|NCT06224465|Other|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
80018859|NCT02129868|Device|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
79557041|NCT06224452|Drug|ibrutinib exposure|We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
79557042|NCT06224439|Procedure|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
79557043|NCT06224439|Procedure|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
79557044|NCT06224413|Other|No Intervention|This is non-interventional study.
79557045|NCT06224400|Drug|ENC1018 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
79557046|NCT06224400|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
79557047|NCT06224400|Drug|ENC1018 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
79720073|NCT01132755|Procedure|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
79720074|NCT04312035|Procedure|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
79258082|NCT03576755|Drug|Spironolactone 100mg|Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
79258083|NCT03576755|Drug|Placebo oral capsule|Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
79258084|NCT03572049|Drug|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
79258085|NCT03572049|Drug|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
79258086|NCT03556332|Drug|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
79557048|NCT06224400|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
79557049|NCT06224387|Drug|CTS2190 capsules|"Dose Escalation:~Cohort 1: QD,4 dose groups are pre-specified. Cohort 2:QD, 2-weeks-on and 1-week-off, 4 dose groups are pre-specified. Cohort 3:QD,5-days-on and 2-days-off,4 dose groups are pre-specified.~Dose Expansion:~Cohort 4: Pancreatic cancer with specified doses. Cohort 5: Non-small cell lung cancer (NSCLC) with specified doses. Cohort 6: Triple-negative breast cancer (TNBC) with specified doses. Cohort 7: Other types of solid tumor with specified doses."
79557050|NCT06224348|Drug|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
79557051|NCT06224348|Drug|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
79557052|NCT06224348|Drug|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
79557053|NCT06224348|Drug|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
79258087|NCT03556332|Drug|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
79557054|NCT06224296|Device|DFPP|One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
79557055|NCT06224296|Device|DFPP|One session of blood purification using DFPP to remove lipids in peripheral blood.
79557056|NCT06224296|Device|DFPP|One session of blood purification using DFPP to remove toxic metal ions.
79557057|NCT06224270|Biological|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
79557058|NCT06224257|Drug|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
79720075|NCT04312035|Procedure|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
79258088|NCT03556332|Drug|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
80018860|NCT03524846|Drug|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
79396625|NCT03136965|Procedure|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
79396626|NCT03136965|Procedure|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
79258089|NCT03556332|Drug|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
79720076|NCT04312035|Procedure|Control|hands-on cutaneous technique
79720077|NCT04311957|Drug|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
79720078|NCT04311957|Drug|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
79720079|NCT02882997|Behavioral|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
79258090|NCT03556332|Procedure|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine >2mg/dL, they will receive 140 mg/m2.
79396627|NCT03115151|Drug|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
79258091|NCT03555877|Drug|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
79258092|NCT03555877|Drug|Anastrozole|1mg once daily as indicated in the SmPC
79258093|NCT03555877|Drug|Letrozole|2,5mg once daily as indicated in the SmPC
79258094|NCT03555877|Drug|Exemestane|25mg once daily as indicated in the SmPC
79258095|NCT03555877|Drug|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
79258096|NCT03481972|Drug|Doxycycline and tauroursodeoxycholic acid|doxycicline and tauroursodeoxycholic acid
79258097|NCT03481972|Drug|Standard of care|Standard of care
79258098|NCT03476876|Combination Product|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
79277414|NCT03527875|Procedure|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
79396628|NCT03115151|Drug|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
79277415|NCT02206295|Drug|selexipag|
79396629|NCT03115151|Drug|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
80018861|NCT03524846|Drug|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
80018862|NCT03524846|Drug|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
80018863|NCT02138760|Procedure|MRI UroNav fusion biopsy|
79396633|NCT03042962|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
79396634|NCT03042962|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
79720080|NCT02882997|Behavioral|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
79720081|NCT00637455|Drug|fexofenadine HCl|
79720082|NCT00919711|Drug|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
79720083|NCT00919711|Drug|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
80018864|NCT05134558|Radiation|Xenon-enhanced Ventilation CT-guided Radiotherapy|Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
79855377|NCT04546217|Combination Product|Treadmill training + transfer package (TT+TP)|Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
79258099|NCT03476876|Combination Product|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
79258100|NCT03472560|Drug|Avelumab (MSB0010718C)|IV treatment: Avelumab administered at 800 mg IV every two weeks
79258101|NCT03472560|Drug|Axitinib (AG-013736)|Oral treatment: Axitinib given 5 mg PO BID
79258102|NCT03421184|Other|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
79258103|NCT03421184|Other|urine sample|10 ml
79258104|NCT03421184|Other|food questionnaire|dietary habit enquiry and a 48h dietary
79258105|NCT03421184|Other|hair|lock of hair
79258106|NCT03408379|Other|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~A Tissue sample will be taken during the surgery~Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
79396635|NCT03019757|Radiation|DaTscan|A functional imaging of the dopamine transporter using the radioligand [123I]FP-CIT
79557059|NCT06224244|Radiation|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
79258107|NCT03401489|Device|PACESETTER|Patients will be given a Viaca electronic pill tray & blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational & reinforcement messages guided by self-determination theory constructs of competence & autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
79557060|NCT06224244|Radiation|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
79720084|NCT01131585|Procedure|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
79396636|NCT03019757|Radiation|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
79396637|NCT03019757|Radiation|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
79396638|NCT03019757|Genetic|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
79396639|NCT03019757|Procedure|Polysomnogram|Overnight sleep study
79396640|NCT03019757|Behavioral|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
79720085|NCT01131585|Drug|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
79720086|NCT01131585|Drug|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
79720087|NCT01131507|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
79720088|NCT01131351|Drug|Delamanid|OPC-67683 film-coated tablets
79720089|NCT01131351|Drug|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
79396641|NCT03001713|Behavioral|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
79396642|NCT02908685|Drug|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
79557061|NCT06224218|Procedure|Single Port Robotic Surgery|Single port Robotic surgery will remove the whole prostate
79557062|NCT06224218|Procedure|Laser Surgery|Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
79855378|NCT04546217|Device|Treadmill training (TT)|Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
80018865|NCT05220553|Device|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
80018866|NCT02129946|Other|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
79258108|NCT03397004|Drug|Doxycycline Hyclate|Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
80018867|NCT04916236|Drug|RMC-4630|"SHP2-inhibitor~Powder in capsule~Administered on day 1 and day 2 of every week"
79396643|NCT02908685|Drug|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
79396644|NCT02845596|Drug|cyclosporine|cyclosporine
79396645|NCT02845596|Procedure|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
79396646|NCT02845596|Drug|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
79855379|NCT00697619|Drug|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
79396647|NCT02845596|Drug|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
80018868|NCT04916236|Drug|LY3214996|"ERK inhibitor~Powder in capsule~Administered every day"
80018869|NCT02970669|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
79720090|NCT04311879|Device|Soft tissue Diode laser application|post-operative soft tissue diode laser application
79258109|NCT03397004|Drug|Placebo|Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
79258110|NCT03371602|Procedure|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
79720091|NCT04311879|Other|Placebo|mock diode laser application
79258111|NCT03371602|Procedure|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
79720092|NCT00919633|Drug|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
79258112|NCT03336216|Biological|Cabiralizumab|specified dose on specified days
79396648|NCT02845596|Drug|methotrexate|methotrexate
79720093|NCT00919633|Drug|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
79720094|NCT00919633|Drug|ribavirin, USP|All patients will receive oral ribavirin
79720095|NCT00919633|Device|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
79720096|NCT04311801|Diagnostic Test|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
79720097|NCT05143905|Drug|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
79720098|NCT05143905|Drug|Placebo|Randomised participants will receive placebo by SC injection
79396649|NCT02845596|Drug|fludarabine|fludarabine
79396650|NCT02845596|Drug|cyclophosphamide|cyclophosphamide
79396651|NCT02845596|Radiation|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
79396652|NCT02845596|Procedure|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
79396653|NCT02778685|Drug|Fulvestrant|
79396654|NCT02778685|Other|Laboratory Biomarker Analysis|Correlative studies
79396655|NCT02778685|Drug|Letrozole|Given PO
79396656|NCT02778685|Drug|Palbociclib|Given PO
79396657|NCT02778685|Biological|Pembrolizumab|Given IV
79720099|NCT04859647|Other|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
79720100|NCT04255225|Behavioral|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
79855380|NCT02566187|Drug|Fimasartan/Atorvastatin Combination Tablet|
79855381|NCT02566187|Drug|Fimasartan|
79396658|NCT02772276|Drug|MB-102-- single dose of 4 µmol/kg|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
79396659|NCT02772276|Drug|MB-102-- single dose of 130 mg|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
79396660|NCT02772276|Drug|MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
79720101|NCT04255225|Behavioral|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
79720102|NCT04255225|Behavioral|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
79720103|NCT00926029|Drug|Fluoride|Brush twice daily
79720104|NCT00926029|Drug|Triclosan, fluoride|Brush twice daily
79855382|NCT02566187|Drug|Atorvastatin|
79855383|NCT05324891|Drug|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
80018870|NCT02970669|Drug|enalapril|Enalapril tablet taken orally.
80018871|NCT02970669|Drug|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
80018872|NCT02970669|Drug|matching placebo enalapril|matching placebo enalapril tablet taken orally
80018873|NCT05220085|Drug|Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution|Intravitreal injection
80018874|NCT02133846|Drug|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
79557063|NCT06224205|Other|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
79855384|NCT05324891|Drug|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
79557064|NCT06224153|Other|3-day dietary record|This is the conventional ingesta assessment. It will be performed twice during the study.
80018875|NCT02133846|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
80018876|NCT02133846|Drug|Placebo|500mL 0.9% sodium chloride
80018877|NCT02133846|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
79258113|NCT03336216|Drug|Nab-paclitaxel|specified does on specified days
79258114|NCT03336216|Drug|Onivyde|specified dose on specified days
79258115|NCT03336216|Biological|Nivolumab|specified dose on specified days
79258116|NCT03336216|Drug|Fluorouracil|specified dose on specified days
79258117|NCT03336216|Drug|Gemcitabine|specified dose on specified days
79557065|NCT06224153|Other|Food Frequency Questionnaire (FFQ)|This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
79557066|NCT06224127|Device|active heat|Users receive an active Soovu heating pod(s).
79557067|NCT06224127|Drug|Active c tactile fiber stimulation|Hair brushes that activate c tactile fibers
79557068|NCT06224127|Device|sham heat|A Soovu heating pod(s) in the subtherapeutic temperature range
79557069|NCT06224127|Device|Sham c tactile fiber stimulation|Hair brushes that do not activate c tactile fibers
79557070|NCT06224114|Device|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
79557071|NCT06224114|Device|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
79557072|NCT06224088|Other|VV ECMO|treatment with VV ECMO in the ICU
79557073|NCT06224075|Behavioral|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
79720105|NCT00926029|Other|Metal salt|Brush twice daily
79258118|NCT03336216|Drug|Oxaliplatin|specified dose on specified day
79258119|NCT03336216|Drug|Leucovorin|Specified dose on specified days
79258120|NCT03336216|Drug|Irinotecan Hydrochloride|Specified dose on specified days
79258121|NCT03298815|Biological|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
79258122|NCT03298815|Other|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
79258123|NCT03269994|Drug|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
79258124|NCT03269994|Drug|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
79557074|NCT06224075|Other|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
79557075|NCT06224062|Biological|SARS-CoV-2|Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
79258125|NCT03220646|Drug|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
79258126|NCT03220646|Drug|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
79720106|NCT04254835|Drug|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
79720107|NCT04254835|Drug|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
79855385|NCT00445432|Biological|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
79855386|NCT00445432|Other|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
79855387|NCT00696137|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
79855388|NCT02565641|Drug|Capecitabine|Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).
80031553|NCT04888546|Drug|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
79855389|NCT02565641|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
79557076|NCT06224062|Biological|Adenovirus (AdV)|Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
79720108|NCT04254991|Diagnostic Test|ImmunoXpert™|The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
79258127|NCT03219827|Other|Human biological samples|Blood samples collection
79258128|NCT03217006|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
79396661|NCT02772276|Drug|MB-102-- two doses of 130 mg 24 hours apart|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
79557077|NCT06224062|Biological|Rhinovirus|RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
79557078|NCT06224062|Biological|No Intervention|no infection
79258129|NCT03217006|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
79557079|NCT06224049|Biological|hNeo-T|After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T injection. hNeo-T injection is expected to be ready for clinical study 35-39 days after blood collection. In this study, bridging therapy is allowed before chemotherapeutic treatment, and it is up to the investigators to decide whether to use it and the time and program of bridging therapy. Lymphocyte clearance pretreatment was performed before hNeo-T injection transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is <0.8×10^9/L and meets the criteria for cell reinfusion, no pretreatment is required and subsequent cell reinfusion can be performed directly.
79720109|NCT04980547|Device|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
79557080|NCT06224049|Drug|Cyclophosphamide|Lymphocyte clearance pretreatment was performed before hNeo-T injection transfusion
79720110|NCT04254757|Procedure|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
79720111|NCT01130493|Drug|IPX066|experimental product
79258130|NCT03062358|Biological|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
79258131|NCT03062358|Drug|placebo|Normal saline solution administered as an IV infusion Q3W
79258132|NCT03062358|Other|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
79258133|NCT02936700|Behavioral|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
79258134|NCT02936700|Behavioral|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~decreasing the tendency to try to escape unpleasant mental experiences~increasing psychological flexibility~developing acceptance of psychological events and engagement in valued actions"
79720112|NCT01130493|Drug|CLE|active comparator
79277416|NCT02375139|Drug|DA-1229_01|complex single administration
79720113|NCT04255069|Drug|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
79720114|NCT04255069|Drug|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
79720115|NCT04255069|Drug|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
79396662|NCT02772276|Drug|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
79396663|NCT02772276|Device|QuantumLeap|Optical Renal Function Monitor (ORFM)
79396664|NCT02772276|Device|Radiance|Optical Renal Function Monitor (ORFM)
79396665|NCT02772276|Device|Brilliance (1 or 2 sensors)|Optical Renal Function Monitor (ORFM)
79396666|NCT02772276|Device|Brilliance (2-part sensor)|Optical Renal Function Monitor (ORFM)
79557081|NCT06224049|Drug|Fludarabine|Lymphocyte clearance pretreatment was performed before hNeo-T injection transfusion
79720116|NCT04252651|Other|Blood Draw|This study will involve blood draws to test for specific cytokines
79855390|NCT04036721|Drug|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
79855391|NCT04036721|Drug|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
79855392|NCT00441142|Drug|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
79720117|NCT01130337|Drug|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
79855393|NCT00441142|Drug|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
79557082|NCT06224036|Drug|JDB0131|"JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
79557083|NCT06224036|Drug|Delamanid|Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
79855394|NCT00441142|Radiation|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
79557084|NCT06224036|Drug|Ethylpyrazine rifampicide (II)|Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
79557085|NCT06224010|Other|Respiratory drive and effort assessment|The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
79258135|NCT02903537|Drug|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
79258136|NCT02903537|Drug|Interferon-beta|Subcutaneous administration interferon-beta
79557086|NCT06223984|Drug|pulse steroid and nanogam|patients received pulse steroid and ivig treatments in addition to standard treatment.
79720118|NCT01130337|Drug|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
79855395|NCT05208281|Drug|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
79855396|NCT05208281|Drug|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
79855397|NCT05208281|Drug|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
79855398|NCT00921401|Behavioral|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
79855399|NCT01029184|Other|commercialized complete cereals|complete cereals suitable for the weaning period
79855400|NCT01029184|Other|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
79557087|NCT06223945|Diagnostic Test|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
79557088|NCT06223932|Drug|Molnupiravir|COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
79581126|NCT01932983|Device|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
79581127|NCT01933022|Drug|Eligard|Subcutaneous Injection
79720119|NCT01130337|Drug|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
79720120|NCT04901689|Drug|Leronlimab|Leronlimab 700 mg
79720121|NCT04901689|Drug|Placebo|Placebo
79720122|NCT04252963|Drug|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
79720123|NCT04252963|Drug|Placebo|Placebo of MUCOLASE tablet
79720124|NCT04258657|Drug|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
79720125|NCT04252729|Procedure|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
79720126|NCT01130103|Drug|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
79720127|NCT01130103|Behavioral|Prolonged Exposure Therapy|Weekly for 10 weeks
79855401|NCT03896555|Device|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
79258137|NCT02878915|Device|Ultrasound guided femoral puncture|
79258138|NCT02849002|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
79258139|NCT02845401|Other|Stop NA therapy|Cases will stop antiviral therapy
79258140|NCT02792322|Device|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
79855402|NCT04025021|Dietary Supplement|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
79855403|NCT04025021|Device|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
79258141|NCT02706873|Drug|Placebo to Upadacitinib|Tablet; Oral
79396667|NCT02733848|Drug|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
79396668|NCT02733848|Other|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
79720128|NCT04254523|Device|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
79720129|NCT04254523|Device|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
79720130|NCT04254523|Device|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
79855404|NCT03848416|Biological|Ixekizumab|Administered SC
79855405|NCT01029418|Drug|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
79855406|NCT04060979|Drug|Nitric Oxide|Nitric Oxide given intermittently via inhalation
79396669|NCT02733848|Other|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
79855407|NCT04060979|Other|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
79855408|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
79855409|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
80018878|NCT05220007|Diagnostic Test|Humphrey visual field testing|Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
79581128|NCT01933035|Other|Immune Thrombocytopenics|Full blood count with extended platelet parameters
79581129|NCT01933035|Other|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
79581130|NCT01933035|Other|Control Population|Full blood count with extended platelet parameters
79581131|NCT01933061|Drug|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
79581132|NCT01933061|Drug|Abraxane|Abraxane 150 mg/m^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
79855410|NCT03851146|Biological|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
79855411|NCT01023646|Other|Carbohydrate + Protein|Light Tuna Packed in water.
79855412|NCT01023646|Other|Carbohydrate + Fat|Butter
79258142|NCT02706873|Drug|Methotrexate|Capsule or Tablet; Oral
79258143|NCT02706873|Drug|Placebo to Methotrexate|Capsule or Tablet; Oral
79258144|NCT02706873|Drug|Upadacitinib|Tablet; Oral
79258145|NCT02677038|Drug|Olaparib|Given PO
79258146|NCT02591134|Other|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
79258147|NCT02591134|Other|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
79855413|NCT01023646|Other|Fiber|Unrefined Carbohydrate
79855414|NCT01023646|Other|Carbohydrate load|Carbohydrate
79855415|NCT00444106|Drug|Artesunate-mefloquine|
79855416|NCT00444106|Drug|Atovaquone-proguanil|
79855417|NCT00444106|Drug|Artemether-lumefantrine|
79855418|NCT00561470|Drug|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
79855419|NCT00561470|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
79557089|NCT06223893|Device|CirrhoCare management system|"This is a UKCA-marked, digital-therapeutic system consisting of:~clinical-grade, cirrhosis monitoring sensors and a smartphone app,~a clinical team-facing, decision-facilitating dashboard, and~CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: ~Wellue BP monitor, ~Wellue weighing scale ~Bluetooth thermometer.~The CirrhoCare management system also includes:~The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring."
79557090|NCT06223880|Drug|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
79720131|NCT02882919|Behavioral|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
80018879|NCT02252484|Other|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
79720132|NCT04258501|Other|Mulberry fruit|
79855420|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
79557091|NCT06223880|Drug|Bupropion|Up to 26 weeks in double-blind period
80018880|NCT02252484|Other|Standard of Care|Standard of Care for this patient population.
79720133|NCT04258501|Other|Mulberry leaf|
79557092|NCT06223867|Device|Jaspr App + JAH|With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
79557093|NCT06223867|Behavioral|ETAU|Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
79720134|NCT04258501|Other|White bean|
79557094|NCT06223802|Behavioral|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
79855421|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
79855422|NCT00443872|Drug|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
80018881|NCT05113108|Device|CUS|All neonates undergoing CUS at nursery unit at assiut university hospital. Cranial ultrasound is performed with basic grayscale imaging. For optimal resolution and good overview, a multifrequency (5-10 MHz) linear or convex sector transducer is used. Imaging is obtained through the anterior fontanel in the coronal and sagittal planes.{12,13} Typically, six to eight coronal images are obtained beginning at the frontal lobes just anterior to the frontal horns and extending to the occipital lobes posterior to the lateral ventricle trigones.{14} The transducer is then rotated 90°, and approximately five images are obtained, including a midline sagittal view of the corpus callosum and cerebellar vermis in addition to bilateral parasagittal images beginning in the midline and progressing laterally through the peripheral cortex.Doppler ultrasound may be added to assess ischemic areas.{13-15}
79396670|NCT02728661|Behavioral|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
79396671|NCT02728661|Behavioral|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
79396672|NCT02676739|Drug|Adderall XR|
79396673|NCT02675959|Drug|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
79557095|NCT06223776|Procedure|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
79557096|NCT06223763|Procedure|Cytoreductive surgery|Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
79720135|NCT04258501|Other|Apple|
79720136|NCT04258501|Other|Elderberry|
79720137|NCT04258501|Other|Turmeric|
79720138|NCT04258501|Other|Rice porridge|
79720139|NCT00625209|Drug|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
79720140|NCT00625209|Drug|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
79258148|NCT02584634|Drug|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
79258149|NCT02584634|Drug|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
79396674|NCT02668562|Procedure|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
80018882|NCT03651453|Behavioral|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
79720141|NCT00625209|Drug|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
79720142|NCT00625209|Drug|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
80018883|NCT03651453|Behavioral|Standard care|Standard harm reduction information
80018884|NCT05219773|Device|NuvoAir Air Next spirometer|"The collection of medical history and demographic data~Spirometry testing in both the clinic and home setting.~The measurement of height and weight.~The evaluation of the perception of home spirometry via a survey."
79396675|NCT02668562|Procedure|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
79720143|NCT04254445|Other|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
79720144|NCT02882841|Other|Biopsies, stool and blood collection|
79720145|NCT04254601|Device|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
79720146|NCT04254601|Drug|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
79855423|NCT01323166|Procedure|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
79855424|NCT01323244|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
79396676|NCT02646839|Device|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
79396677|NCT02644460|Drug|Abemaciclib|
79855425|NCT01027234|Drug|AZD8418|Single oral dose
79396678|NCT02601313|Biological|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
79396679|NCT02601313|Drug|Cyclophosphamide|Administered intravenously
79396680|NCT02601313|Drug|Fludarabine|Administered intravenously
79855426|NCT01027234|Drug|Placebo|single oral dose
79396681|NCT02601313|Drug|Axicabtagene Ciloleucel|A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
79396682|NCT02550652|Drug|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
79396683|NCT02550652|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
79396684|NCT02550652|Other|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
79396685|NCT02550652|Drug|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
79258150|NCT02584634|Drug|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
79258151|NCT02584049|Other|Osteopathy|3 sessions of osteopathy during 60 minutes each
79258152|NCT02584049|Other|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
79258153|NCT02573753|Behavioral|Sleep restriction|
79258154|NCT02573753|Dietary Supplement|Weight gain|
79258155|NCT02409316|Drug|[18F]FES|[18F]FES PET/CT scan
79258156|NCT02391909|Biological|Vivotif|
79258157|NCT02365441|Drug|Regorafenib|
79258158|NCT02365441|Drug|imatinib|
79258159|NCT02124941|Drug|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
79258160|NCT02124941|Diagnostic Test|[18F]FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
79258161|NCT02124941|Diagnostic Test|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
79277417|NCT02375139|Drug|E+M|co-administration of 2 drugs
79396686|NCT02550652|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
79396687|NCT02547025|Drug|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
79396688|NCT02547025|Drug|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
79396689|NCT02547025|Drug|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
79396690|NCT02491099|Drug|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
79396691|NCT02484443|Biological|Dinutuximab|Given IV
79396692|NCT02484443|Other|Laboratory Biomarker Analysis|Correlative studies
79396693|NCT02484443|Other|Pharmacological Study|Correlative studies
79396694|NCT02484443|Biological|Sargramostim|Given SC
79396695|NCT02480374|Biological|IMNN-001|
80018885|NCT02134002|Drug|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
80018886|NCT02134002|Drug|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
80018887|NCT03650361|Drug|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
80018888|NCT03650361|Drug|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
80018889|NCT03650361|Drug|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
80018890|NCT02138994|Device|Next Science Wound Gel|
80018891|NCT02138994|Drug|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~Subject may continue the application of Neosporin until wound closure or~Subject may cross over to the treatment group for 3 months"
80018892|NCT05219461|Drug|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
80018893|NCT05219461|Drug|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
79258162|NCT02124941|Diagnostic Test|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
79557097|NCT06223763|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
79258163|NCT01967849|Diagnostic Test|Oral Glucose tolerance test|
79258164|NCT01892566|Other|mHealth Intervention|See arm description
79396696|NCT02475707|Biological|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
79396697|NCT02454907|Other|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
79396698|NCT02422381|Drug|MK-3475|Investigational drug.
79557098|NCT06223763|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
80018894|NCT05219461|Drug|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
80018895|NCT05219461|Drug|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
80018896|NCT05219461|Drug|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
80018897|NCT05219461|Drug|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
80018898|NCT04771234|Behavioral|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
80018899|NCT03549546|Biological|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~before lung cancer surgery,~the next day lung cancer surgery,~3 days after lung cancer surgery. They will be treated in flow cytometry."
80018900|NCT04761796|Other|Sleeping condition self-questionnaire|Professional flight members will answer a self questionnaire related to their sleeping conditions
80018901|NCT02130102|Device|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
79258165|NCT01868451|Drug|Brentuximab vedotin (SGN-35)|
79258166|NCT01868451|Drug|Doxorubicin HCL|
79258167|NCT01868451|Drug|Vinblastine Sulfate|
79258168|NCT01868451|Drug|Dacarbazine|
79258169|NCT01868451|Radiation|Involved-Site Radiation Therapy (ISRT)|
79258170|NCT01868451|Procedure|Interim PET|
79258171|NCT01868451|Radiation|consolidation volume RT (CVRT)|
79258172|NCT01835964|Procedure|Glucose Variability Observation|On the morning of ~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
79258173|NCT01678547|Device|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
79557099|NCT06223750|Other|population-based screening for chronic kidney disease|Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
79855427|NCT01029496|Procedure|different time of umbilical cord clamping|"for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
79855428|NCT01027390|Behavioral|physical training exercise|physical exercise training at the work site during work time
79258174|NCT01678547|Device|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
79258175|NCT01678547|Other|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
79258176|NCT01668407|Device|Robot-Assisted Gait Training (RAGT)|Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
79396699|NCT02422381|Drug|Gemcitabine|Standard care drug.
79557100|NCT06223737|Diagnostic Test|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
79557101|NCT06223737|Diagnostic Test|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
79557102|NCT06223711|Radiation|Thoracic Radiochemotherapy|Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
79557103|NCT06223711|Drug|durvalumab|Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
79557104|NCT06223711|Radiation|Stereotactic radiotherapy of further tumor locations|Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
79557105|NCT06223711|Drug|Chemotherapy|Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
79557106|NCT06223698|Drug|Letrozole|Letrozole 2.5 mg daily
79557107|NCT06223698|Drug|Anastrozole|Anastrozole 1 mg daily
79557108|NCT06223698|Drug|Exemestane|Exemestane 25 mg daily
79855429|NCT03034642|Procedure|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
79855430|NCT04839562|Drug|Solriamfetol 75 MG|Daily oral consumption
79855431|NCT04839562|Drug|Solriamfetol 150 MG|Daily oral consumption
79855432|NCT04839562|Other|Placebo|Placebo
80018902|NCT02253186|Device|Auto-Adjustable MOBIDERM Armsleeve|
79258177|NCT01668407|Procedure|Treadmill Gait Training (TT)|"Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
79258178|NCT01536522|Dietary Supplement|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
79258179|NCT01536522|Dietary Supplement|Low Caloric Shake|participants will be provided a low caloric dietary shake
79396700|NCT02371941|Drug|oral cromolyn sodium|Oral cromolyn sodium
79396701|NCT02371941|Drug|Placebo|Saline
79396702|NCT02221310|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m^2/dose given IV over 2 hours once during conditioning
79396703|NCT02140788|Drug|Metformin|
79557109|NCT06223698|Drug|Tamoxifen|Tamoxifen 20 mg daily
79557110|NCT06223685|Drug|Rifaximin 200 MG|Dosage 3x2 tablets per day 14 days
79557111|NCT06223685|Dietary Supplement|Probiotic|2x1 capsules per day. 12 weeks.
79557112|NCT06223659|Drug|Eutectic Mixture of Local Anesthetics|Apply topically to skin
79557113|NCT06223659|Drug|Placebo Administration|Apply topically to skin
79557114|NCT06223659|Other|Questionnaire Administration|Ancillary studies
80018903|NCT05303818|Drug|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
80018904|NCT05024149|Other|infrared thermography (IRT)|The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
80018905|NCT02134080|Drug|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
80018906|NCT02134080|Drug|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
79396704|NCT02140788|Drug|Fish Oil|
79396705|NCT02117297|Drug|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
79396706|NCT02088554|Device|Model 400 aortic valve bioprosthesis|
80018907|NCT05303740|Drug|Anlotinib|This is an observational study.
80018908|NCT02139072|Device|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
80018909|NCT02139072|Procedure|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
80018910|NCT02139150|Radiation|[18F] FLT|
80018911|NCT02139150|Device|PET/CT scans|
80018912|NCT02130336|Behavioral|Aerobic interval training|
79258180|NCT01536522|Biological|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
79557115|NCT06223646|Biological|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
79855433|NCT04888624|Device|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
80018913|NCT02130336|Behavioral|Continuous moderate-intensity exercise|
80018914|NCT02902965|Drug|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
80018915|NCT02902965|Drug|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
79396707|NCT01894802|Device|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
79557116|NCT06223633|Device|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
80018916|NCT02902965|Drug|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects >75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
79258181|NCT01275729|Drug|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
79258182|NCT01107626|Drug|Paclitaxel|Given IV
79258183|NCT01107626|Drug|Carboplatin|Given IV
79396708|NCT01863745|Drug|nilotinib|Nilotinib can be provided as 200 mg and 150 mg hard gelatin capsules. The starting dose of nilotinib should be the same as the last dose that was given in the parent nilotinib study. After this, the dose of nilotinib is based on the investigator's judgment.
79396709|NCT01711554|Biological|Dinutuximab|Given IV
79396710|NCT01711554|Drug|Isotretinoin|Given PO
79557117|NCT06223620|Other|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
79557118|NCT06223594|Other|Intravenous Fluid Therapy|Evaluate the safety and efficacy of the Dallas acute pancreatitis protocol(DAPP) order set on Acute pancreatitis(AP) patients receiving aggressive, goal-directed Intravenous fluid(IVF )therapy.
79557119|NCT06223581|Other|ECHO in sever asthma patient|Evaluation of cardiac burden in patients with sever bronchial asthma
80018917|NCT02134158|Device|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
80018918|NCT02130414|Drug|Sandimmun® IV|2 mg/kg IV
80018919|NCT02130414|Drug|CyCol® capsules|37.5 mg CyCol® capsules
79258184|NCT01107626|Biological|Bevacizumab|Given IV
79557120|NCT06223542|Procedure|Biopsy|Undergo biopsy
79557121|NCT06223542|Procedure|Biospecimen Collection|Undergo collection of blood
79557122|NCT06223542|Procedure|Computed Tomography|Undergo CT
79557123|NCT06223542|Procedure|Magnetic Resonance Imaging|Undergo MRI
79557124|NCT06223542|Drug|UAE Inhibitor TAK-243|Given IV
79557125|NCT06223529|Behavioral|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
79258185|NCT01107626|Drug|Pemetrexed Disodium Heptahydrate|Given IV
79258186|NCT01082224|Drug|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
79258187|NCT01082224|Drug|motexafin gadolinium|motexafin gadolinium
79396711|NCT01711554|Other|Laboratory Biomarker Analysis|Correlative studies
79396712|NCT01711554|Drug|Lenalidomide|Given PO
79396713|NCT01711554|Other|Pharmacological Study|Correlative studies
79396714|NCT01703949|Drug|Brentuximab Vedotin|Given IV
79396715|NCT01703949|Other|Laboratory Biomarker Analysis|Correlative studies
79396716|NCT01703949|Biological|Nivolumab|Given IV
79557126|NCT06223516|Drug|Subcutaneous (SC) ABBV-383|SC Injection
79855434|NCT04888624|Device|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
80031554|NCT05390294|Procedure|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
80018920|NCT03651141|Other|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
79557127|NCT06223516|Drug|Intravenous (IV) ABBV-383|IV Infusion
79557128|NCT06223503|Behavioral|Transitional Pain Service|The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
79557129|NCT06223490|Procedure|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
79258188|NCT01082224|Other|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
79258189|NCT00828009|Biological|bevacizumab|IV
79258190|NCT00828009|Biological|Tecemotide|
79258191|NCT00828009|Drug|carboplatin|IV
79258192|NCT00828009|Drug|cyclophosphamide|IV
79557130|NCT06223477|Other|Platelet-rich Fibrin|PRF will be injected distal to the canine on the experimental side.
79557131|NCT06223477|Other|Vitamin D3|Vitamin Dꝫ will be injected distal to the canine on the experimental side
79720147|NCT01129557|Drug|Aliskiren|
79720148|NCT01129557|Drug|Valsartan|
79720149|NCT04976413|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
79720150|NCT04976413|Behavioral|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
79720151|NCT04831567|Radiation|MIBG-I131|Radiopharmaceutical
79720152|NCT04884295|Drug|XVR011|Single dose of XVR011 via intravenous (IV) infusion
79258193|NCT00828009|Drug|paclitaxel|IV
79720153|NCT04254679|Drug|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
79720154|NCT04254679|Drug|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
79258194|NCT00828009|Radiation|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
79720155|NCT05330533|Radiation|scrotal duplex|Scrotal colour doppler ultrasonography
80031555|NCT04888234|Drug|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
79258195|NCT00578721|Drug|Aspirin|325 mg taken daily with an arginine-restricted diet
79258196|NCT00357890|Device|Insulin pump therapy|CSII initiated within 1 month of diagnosis
79258197|NCT00357890|Drug|Multiple daily injections using insulin glargine + rapid acting analog|MDI as control
79258198|NCT00068393|Drug|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
79258199|NCT00068393|Drug|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
79258200|NCT00068393|Drug|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
79258201|NCT00068393|Drug|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
79396717|NCT01695941|Drug|Alisertib|Given PO
79396718|NCT01695941|Drug|Bortezomib|Given SC
79396719|NCT01695941|Other|Laboratory Biomarker Analysis|Correlative studies
79396720|NCT01695941|Biological|Rituximab|Given IV
79396721|NCT01617161|Radiation|Proton Beam Therapy|5 days per week up to 9 weeks
79396722|NCT01617161|Radiation|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
79396723|NCT01461837|Drug|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
79396724|NCT01375829|Drug|Ixabepilone|Given IV
79396725|NCT01375829|Other|Pharmacological Study|Correlative studies
79396726|NCT01375829|Drug|Temsirolimus|Given IV
79396727|NCT01364051|Drug|Cediranib|Given PO
79396728|NCT01364051|Drug|Cediranib Maleate|Given PO
79396729|NCT01364051|Other|Laboratory Biomarker Analysis|Correlative studies
79396730|NCT01364051|Other|Pharmacological Study|Correlative studies
79396731|NCT01364051|Drug|Selumetinib|Given PO
79396732|NCT01364051|Drug|Selumetinib Sulfate|Given PO
79396733|NCT01328977|Behavioral|education|teaching
79396734|NCT01307956|Drug|Fluorouracil|Given IV
79396735|NCT01307956|Other|Laboratory Biomarker Analysis|Correlative studies
79557132|NCT06223451|Device|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
79557133|NCT06223451|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
79557134|NCT06223425|Behavioral|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
79557135|NCT06223412|Behavioral|virtual based climate change program|The Interactive digital-based educational program Sessions:
79557136|NCT06223399|Other|Imaging-based programming|Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.
79557137|NCT06223399|Other|Threshold assessment-based programming|The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.
79557138|NCT06223386|Behavioral|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
79557139|NCT06223386|Behavioral|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
79557140|NCT06223386|Behavioral|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
79557141|NCT06223386|Behavioral|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
79557142|NCT06223347|Diagnostic Test|Chromoendoscopy|"Chromoendoscopy: is a dye based staining of colonic mucosa. NBI: is an optical image enhancing technology that allows a detailed inspection of vascular and mucosal patterns, providing the ability to predict histology during real-time endoscopy.~TXI: is a digital technique that enhance texture and color of the tissues to be more visible."
79557144|NCT06223321|Diagnostic Test|Computed Tomography in congenital heart diseases|"● CT examination will be done by~160 MDCT Toshiba Machine or 128 MDCT GE machine or 160 MDCT Philips Machine:~We used the following parameters during cardiac CT scanning:~Pitch of 1.3, helical thickness of 0.5 mm and coverage of 32 cm.~The radiation dose set to 80-100 kvp.~Tube current from 10 to 40 mA/kg.~The gantry rotation speed at 0.35-.4 sec.~ECG gated Retrospective With MA modulation.~Wide FOV.~A scout will be taken and dual-phase injection conducted using non ionized contrast material. The total contrast volume is 1.5-3 ml/kg.~Scanning begins when contrast filled the LV by bolus tracking.~All images were transferred to workstation multiplanar reformation (MPR), maximum (MIP) and minimum (MinIP) intensity projections and volume rendering images will be performed for reporting."
79720156|NCT01129011|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
79720157|NCT01129011|Drug|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
79720158|NCT04254211|Other|NLR|neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
79855435|NCT01030978|Behavioral|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
80031556|NCT04454762|Drug|Cabozantinib|oral administration (40 mg daily, reduced dose 20 mg daily)
80031557|NCT03050788|Device|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
80031558|NCT04897984|Biological|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
79855436|NCT01030978|Behavioral|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
79855437|NCT01029574|Other|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
79855438|NCT03316222|Drug|GNS561|Escalating doses to be administered 3 times a week.
79258202|NCT00062010|Biological|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
79258203|NCT00062010|Drug|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
79258204|NCT00062010|Drug|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
79258205|NCT00061568|Procedure|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
79258206|NCT00061568|Drug|Alemtuzumab|Alemtuzumab
79557145|NCT06223308|Drug|HB0028|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
79557146|NCT06223282|Other|short inter-set rest resistance exercise|Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.
79557147|NCT06223282|Other|medium inter-set rest|Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.
79557148|NCT06223282|Other|long inter-set rest|Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.
79557149|NCT06223282|Other|medium inter-set rest with failure|Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
79557150|NCT06223269|Drug|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
79557151|NCT06223269|Procedure|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
80018921|NCT03651141|Other|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
79258207|NCT00061568|Procedure|Peripheral blood hematopoietic progenitor cell Apherisis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
79557152|NCT06223256|Drug|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
79258208|NCT00061568|Drug|Sirolimus|Sirolimus
79557153|NCT06223243|Other|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
79557154|NCT06223243|Other|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
79855439|NCT01031056|Procedure|Blood Draw|
79855440|NCT01031056|Procedure|Frozen Tumor Specimens|
79855441|NCT03742492|Dietary Supplement|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
79855442|NCT03742492|Dietary Supplement|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
79855443|NCT04773652|Diagnostic Test|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
79855444|NCT00441064|Drug|Aliskiren|
79855445|NCT03962738|Drug|Lasmiditan|Administered orally
79855446|NCT03962738|Drug|Placebo|Administered orally
79855447|NCT05280002|Biological|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
79258209|NCT00047008|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22
79258210|NCT00047008|Radiation|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
79396736|NCT01307956|Drug|Leucovorin Calcium|Given IV
79396737|NCT01307956|Drug|Oxaliplatin|Given IV
79396738|NCT01307956|Biological|Panitumumab|Given IV
79396739|NCT01307956|Other|Pharmacological Study|Correlative studies
79396740|NCT01307956|Radiation|Radiation Therapy|Undergo radiation therapy
79396741|NCT01307956|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79396742|NCT01280669|Drug|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
79396743|NCT01280669|Drug|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
79396744|NCT01225913|Drug|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
79557155|NCT06223243|Other|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
80018922|NCT03651141|Other|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
80018923|NCT03650283|Other|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of >0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
80018924|NCT02130648|Other|A sampling of blood|A sampling of blood de 14 ml
79557156|NCT06223217|Other|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
79557157|NCT06223204|Other|Controlled euglycemia, hypoglycemia and hyperglycemia|EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
79557158|NCT06223191|Other|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
80018925|NCT02139462|Other|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
80018926|NCT02139462|Other|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
80018927|NCT02902809|Biological|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
80018928|NCT01362244|Drug|Mepolizumab|750 mg of mepolizumab by IV infusion
80018929|NCT01362244|Drug|Placebo|Placebo by IV infusion
80018930|NCT01362244|Drug|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
80018931|NCT02134470|Drug|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
80018932|NCT05285631|Device|Speckle tracking echocardiography (STE)|"Two-dimensional (2D) and 3D STE are based on the quantitative analysis of spatial dislocation (tracking) of acoustic markers (speckles) generated by the interaction between the ultrasound beam and myocardial fibers during the cardiac cycle."
80018933|NCT02130726|Procedure|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
79720159|NCT04253041|Behavioral|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
79855448|NCT00561392|Drug|Rivastigmine 5 and 10 cm^2 patch|
79855449|NCT00694109|Drug|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
79855450|NCT03137693|Other|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
80018934|NCT02130726|Procedure|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
80031559|NCT04456088|Combination Product|150 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
79258211|NCT00047008|Radiation|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
79396745|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
79396746|NCT01089101|Procedure|Biospecimen Collection|Undergo blood sample collection
79396747|NCT01089101|Drug|Selumetinib|Given PO
79396748|NCT01041027|Drug|Paclitaxel|Given IV
79396749|NCT01041027|Drug|Carboplatin|Given IV
79396750|NCT01041027|Radiation|Internal Radiation Therapy|Undergo HDR brachytherapy
79396751|NCT01041027|Radiation|External Beam Radiation Therapy|Undergo EBRT
79396752|NCT01041027|Other|Laboratory Biomarker Analysis|Correlative studies
80031560|NCT04456088|Combination Product|80 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
79720160|NCT02882607|Behavioral|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
79720161|NCT04203589|Behavioral|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
79258212|NCT00047008|Procedure|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
79258213|NCT03547921|Device|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
79258214|NCT03568253|Other|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
79258215|NCT03568253|Other|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
79258216|NCT05575921|Diagnostic Test|Polysomnography|Children underwent at-home polysomnography in routine clinical practice. The exam is interpreted in 2 ways by the physician with sleep stages (PSG) and without sleep stages (PG). The data are retrospectively collected from the patient's recording
79258217|NCT03567941|Drug|Placebo|Tablet orally administered under fasting
79720162|NCT04203589|Other|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
79258218|NCT03567941|Drug|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
79720163|NCT02882763|Other|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
79720164|NCT02882373|Dietary Supplement|Arginine|Given PO
79720165|NCT02882373|Drug|Placebo|Given PO
79720166|NCT04824781|Other|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
79720167|NCT04258735|Diagnostic Test|Genomic analysis|WES, RNASeq, ctDNA, Exosome
79720168|NCT04873765|Biological|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
79720169|NCT04873765|Biological|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
79720170|NCT04254055|Other|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
79720171|NCT04245241|Other|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
79720172|NCT04252885|Drug|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
79720173|NCT04252885|Drug|Arbidol|As indicated in arm/group descriptions
79720174|NCT04258345|Other|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
79720175|NCT04252417|Drug|MD1003|Single oral dose administration of MD1003 at Day 1
79720176|NCT02887872|Other|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
79258219|NCT03567941|Drug|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
79720177|NCT04939207|Diagnostic Test|CT-FFR|CT-images will be processed by an algorithm to calculate FFR-values of the full coronary tree
79720178|NCT04939207|Diagnostic Test|Angiography-derived FFR|FFR-values are calculated during coronary angiography based on the acquired images of the coronary arteries
79720179|NCT04939207|Diagnostic Test|Angiography with invasive FFR-measurements|during coronary angiography, a specialized pressure wire is passed through the coronary stenosis to calculate FFR based on the difference between the actual pressure and the expected pressure in the hypothetical healthy coronary artery.
79258220|NCT03567941|Drug|Reference|Tablet orally administered under fasted conditions
79258221|NCT02140489|Drug|amosartan|
79258222|NCT02140489|Drug|rosuvastatin|
80031561|NCT04897828|Device|Covered Stent placement|Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
79258223|NCT02140489|Drug|amosartan and rosuvastatin|
79258224|NCT03566225|Drug|Pioglitazone|Insulin sensitizing agents
79258225|NCT03566225|Drug|Metformin|Insulin sensitizing agent
79258226|NCT03566225|Drug|Clomiphene Citrate|Induction drug
79720180|NCT04253743|Other|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
79720181|NCT04258189|Drug|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
79720182|NCT04962841|Other|Nutraceuticals|To observe the effect on cognitive and physical impairment.
79720183|NCT04253197|Device|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
79258227|NCT05462353|Drug|2mg of ASC41|ASC41 tablet administered orally once daily.
79720184|NCT00919867|Drug|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
79258228|NCT05462353|Drug|4mg of ASC41 (2 tablets of 2 mg ASC41)|ASC41 tablets administered orally once daily.
79720185|NCT00919867|Drug|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
79258229|NCT05462353|Drug|Placebo|Placebo tablets administered orally once daily.
79557159|NCT06223191|Other|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
79557160|NCT06223165|Behavioral|Floreciendo (Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
79557161|NCT06223165|Behavioral|Floreciendo (Foundations, Condoms & Contraception, and Family Strengthening)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
79557162|NCT06223165|Behavioral|Floreciendo (Foundations, Condoms & Contraception, Gender & Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
79557163|NCT06223165|Behavioral|Floreciendo (Foundations, Family Strengthening, and Gender & Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
79557164|NCT06223165|Behavioral|Floreciendo (Foundations and Condoms & Contraception)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them."
79557165|NCT06223165|Behavioral|Floreciendo (Foundations and Family Strengthening)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
79855451|NCT03137693|Procedure|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
80031562|NCT04883710|Other|Gene therapy|This is a prospective patient registry.
80031563|NCT04454840|Biological|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
79258230|NCT03566147|Biological|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
79258231|NCT02397694|Drug|BIC|75 mg tablet administered orally once daily
79258232|NCT02397694|Drug|F/TAF|200/25 mg FDC tablet administered orally once daily
79258233|NCT02397694|Drug|DTG|50 mg tablet administered orally once daily
79258234|NCT02397694|Drug|BIC Placebo|Tablet administered orally once daily
79258235|NCT02397694|Drug|DTG Placebo|Tablet administered orally once daily
79258236|NCT02397694|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
79258237|NCT05452369|Drug|Rhomboid intercostal plane block|- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
79258238|NCT03567863|Device|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
79258239|NCT03567863|Device|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
79258240|NCT03549169|Behavioral|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
79258241|NCT03549169|Behavioral|Regular attention|Regular attention focused on education for therapeutic adherence
79258242|NCT03566069|Drug|Intranasal Oxytocin|32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
79258243|NCT03566069|Other|Intranasal Placebo|32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol.
79258244|NCT05353907|Radiation|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
79720186|NCT00919867|Drug|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
79720187|NCT04252261|Drug|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
79720188|NCT04252261|Drug|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
79258245|NCT03565757|Behavioral|SMART intervention|All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
79258246|NCT03565601|Other|Follow-up|Clinical data, radiological data and laboratory tests follow-up
79720189|NCT01215942|Drug|LY2127399|Administered Subcutaneously
79720190|NCT04251871|Drug|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
79258247|NCT03567629|Drug|Irinotecan|Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
79258248|NCT03567629|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
79720191|NCT04251871|Drug|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
79720192|NCT04253353|Drug|tafamidis|61 mg capsule
79720193|NCT04253353|Drug|rosuvastatin|10 mg tablet
79720194|NCT04924543|Other|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
79720195|NCT04924543|Other|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
79720196|NCT01128621|Drug|GSK1292263|Tablet
79720197|NCT01128621|Drug|GSK1292263 matching placebo|Tablet
79720198|NCT01128621|Drug|Sitagliptin|Tablet
79720199|NCT00918463|Drug|dasatinib|100 mg daily dosing
80031564|NCT04454840|Drug|Riluzole|The basic treatment is Riluzole 25~50mg twice daily
79258249|NCT02783599|Drug|Olaratumab|Administered IV
79258250|NCT02783599|Drug|Doxorubicin|Administered IV
79258251|NCT02783599|Radiation|External Beam Radiotherapy|
79258252|NCT03565523|Other|Beetroot|Containing 385 mg nitrate
79258253|NCT03565523|Other|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
79258254|NCT03567395|Dietary Supplement|Melatonin|Melatonin (5 mg sublingual tablet) administered for 3 days
79258255|NCT03567395|Dietary Supplement|Honey|Raw Honey (1.5 tablespoons) administered for 3 days
79258256|NCT03565289|Diagnostic Test|Blood sample collection|During a routine blood draw an additional tube of blood will be taken for the study.
79258257|NCT03565133|Dietary Supplement|Quinine sham feeding quinine|Oral sham feeding with quinine
79258258|NCT03565133|Dietary Supplement|Gastric quinine|A gastric capsule containing quinine
79258259|NCT03565133|Dietary Supplement|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
79720200|NCT04251793|Other|Observation|Soft tissue implant measurements and radiographs
79720201|NCT04811989|Behavioral|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
79720202|NCT04811989|Behavioral|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
79720203|NCT04811989|Behavioral|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
79720204|NCT04811989|Behavioral|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
79720205|NCT04251637|Other|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
79720206|NCT04251559|Other|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
79720207|NCT05048641|Other|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
79720208|NCT05330065|Drug|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
79720209|NCT01128543|Drug|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
80018935|NCT04076319|Behavioral|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
80018936|NCT05202067|Behavioral|pharmaceutical education|The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
79258260|NCT03565133|Dietary Supplement|Gastric placebo|A gastric capsule containing placebo (cellulose)
79557166|NCT06223165|Behavioral|Floreciendo (Foundations and Gender & Partner Relationships)|"Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
79557167|NCT06223165|Behavioral|Floreciendo (Foundations)|• Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.
79557168|NCT06223152|Other|parental support|parental support
79720210|NCT01128387|Drug|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
79720211|NCT01214850|Biological|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
79720212|NCT01214850|Biological|MenACWY-CRM conjugate vaccine|
79720213|NCT01214850|Biological|Japanese Encephalitis vaccine|
79720214|NCT01128153|Drug|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
80018937|NCT03649737|Behavioral|Exercise Intervention|Attend supervised and unsupervised exercise sessions
80018938|NCT03649737|Other|Survey Administration|Ancillary studies
79258261|NCT05353673|Drug|Sitagliptin|Oral Sitagliptin (100mg/m2 daily) for 12 weeks. DPP4 inhibitors have anti-inflammatory, immunomodulatory, and hematopoietic effects in addition to their glycemic regulatory effects. In vivo experiments found that endogenous DPP-4 inhibits megakaryopoiesis, and knockout or inhibition of DPP4 in vivo can enhance the recovery of hematopoietic function after stress. The loss of DPP-4 activity in DPP-4-/-mice mice resulted in an expansion of the megakaryocyte progenitor population in vivo, the recovery time of platelets was shorter than in normal mice after platelet depletion with anti-mouse CD41 antibody. Compared with ordinary mice, the number of platelets increased, which provides a theoretical basis for the use of DPP-4 inhibitors in patients with ITP, and has potential clinical significance.
79258262|NCT05353673|Drug|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
79258263|NCT03565055|Behavioral|IPCST|"Integrative Psychosocial & Community Skills Training (IPCST) programme~The IPCST programme includes:~psychoeducation, internalized stigma reduction, & strength and coping enhancement~motivational interviewing skills~Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~augmented supported employment with social skills training (Tsang, Fung, Li, Leung & Cheung, 2010) and~family and patient involvement in care"
79258264|NCT03565055|Behavioral|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~Extensive public education~Early referral and assessment~Ongoing treatment services"
79258265|NCT05708495|Other|posterior ilium mobilization|the therapist will mobilize the innominate on the affected side posteriorly
79557169|NCT06223139|Diagnostic Test|Handgrip strength|Handgrip strength will be measured by 3 efforts.
79557170|NCT06223126|Other|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
79557171|NCT06223126|Other|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
79557172|NCT06223100|Drug|Eravacycline|There is no other intervention.
79557173|NCT06223087|Other|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
79557174|NCT06223074|Other|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
79720215|NCT01128153|Drug|Placebo|tablet once daily for 24 weeks to be taken orally
79720216|NCT04318782|Device|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
79720217|NCT00925015|Biological|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
79720218|NCT00925015|Biological|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m^2, followed by subsequent once weekly intravenous infusions of 250 mg/m^2
79720219|NCT00925015|Drug|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m^2, once every other week for 42 days
79720220|NCT00925015|Biological|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
79720221|NCT01127763|Drug|RAD001|
79720222|NCT01127763|Drug|Carboplatin|
79720223|NCT04251403|Diagnostic Test|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
80018939|NCT03649737|Other|Quality-of-Life Assessment|Ancillary studies
80018940|NCT02134626|Drug|Simvastatin|40mg / pill, one pill orally once a day for three months
80018941|NCT02134626|Drug|Placebo pill|
80018942|NCT05199883|Other|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
80018943|NCT02134704|Other|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
80018944|NCT02969187|Drug|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
80018945|NCT02969187|Drug|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
80018946|NCT02969187|Drug|Saline|
80018947|NCT05220475|Device|fully covered self-expandable metal stent with an anchoring external plastic stent|Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent
80018948|NCT05220475|Device|uncovered self-expandable metal stent|Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
80018949|NCT02134860|Other|Bed rest|8 days of full bed rest
79557175|NCT06223074|Drug|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
80018950|NCT02134860|Other|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
80018951|NCT02134860|Other|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
79258266|NCT05708495|Other|strengthening and stretching exercises|the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
79557176|NCT06223035|Other|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
79557177|NCT06223009|Drug|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
79720224|NCT04251325|Other|Basic Life Support Courses|4 hours basic life support courses for laypersons
79720225|NCT04257409|Other|Physical intervention by exercise|12 week lasting exercise intervention
79720226|NCT04250779|Device|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
79720227|NCT04250779|Behavioral|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
79720228|NCT05252299|Other|Rolling Fresher Group|The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
79720229|NCT01127607|Drug|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
79720230|NCT00924781|Drug|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
79258267|NCT03564899|Behavioral|Lighter intensity physical activity intervention|Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
79557178|NCT06223009|Other|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
79557179|NCT06222996|Behavioral|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
79720231|NCT00924781|Drug|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
79720232|NCT00924781|Drug|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
80018952|NCT02134860|Other|Cognitive testing|Daily testing of memory and concentration using standardized tests
80018953|NCT02134860|Other|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
80018954|NCT02134860|Other|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
80018955|NCT02134860|Other|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
80018956|NCT03650985|Procedure|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
80018957|NCT02139618|Drug|Methyl Aminolevulinate (MAL)|
80018958|NCT02139618|Drug|Placebo|
80018959|NCT04850287|Behavioral|Digital Sensors for Population Awareness about Health Issues using Social Media|A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
80018960|NCT05285085|Drug|Statin|Statin use
80018961|NCT02139696|Radiation|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
80018962|NCT05057416|Behavioral|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
80018963|NCT04850209|Other|oral and written education|oral and written education
79258268|NCT03564899|Behavioral|Higher intensity physical activity intervention|Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
79258269|NCT05353205|Drug|Flumatinib mesylate tablets (400mg)|Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.
79258270|NCT05353205|Drug|Flumatinib mesylate tablets (600mg)|Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
79258271|NCT03564665|Dietary Supplement|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
79557180|NCT06222983|Procedure|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
79557181|NCT06222944|Drug|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
79557182|NCT06222944|Drug|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
79557183|NCT06222944|Drug|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
79720233|NCT05252065|Other|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
79720234|NCT05251987|Biological|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
79720235|NCT01127451|Drug|Denileukin diftitox|Denileukin diftitox intravenous infusion over 30-60 minutes.
79720236|NCT04759651|Other|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
79258272|NCT03564665|Other|Placebo|Placebo BID for 8 weeks.
79258273|NCT05353049|Behavioral|Bathing technique based on Basale Stimulation|"The relaxing somatic modelling technique will be applied, framed within the concept of Basal Stimulation®. To do this, the user remains seated and the parts of the body that are not being washed at that moment are covered with a towel, favouring the preservation of the user's privacy. The user is lathered up with soft mittens previously moistened with lukewarm water and lathered up. This process shall be carried out starting from the shoulder in a proximal to distal direction on the upper limbs, lower limbs and trunk (taking into account the sagittal anatomical plane) and in a cephalic to caudal direction (taking into account the transverse anatomical plane).~Subsequently, rinsing is carried out following the same guidelines as described above, using moistened soft mittens. Finally, intimate hygiene is performed with a disposable soapy sponge and the soap is rinsed off again with moistened soft terrycloth mittens. Throughout the whole process, the activity is explained to the user."
79258274|NCT02838017|Device|Tissue Adhesive|
79258275|NCT02838017|Device|Sterile strips|
79258276|NCT03564431|Device|Magnetic resonance|magnetic resonance spectrum of brain
79258277|NCT02870465|Procedure|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
79258278|NCT03188666|Drug|REGN2477|Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
79258279|NCT03188666|Drug|Matching placebo|Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
79258280|NCT03564977|Biological|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
79258281|NCT02770703|Device|DynaMesh visible mesh|Implantation of a MRI visible mesh
79557184|NCT06222931|Device|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
79557185|NCT06222931|Device|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
79557186|NCT06222931|Other|Sham vibration|Simulated vibration
79557187|NCT06222918|Procedure|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
79557188|NCT06222905|Other|non interventional|non interventional
79557189|NCT06222892|Drug|Camlipixant|Camlipixant will be administered.
79557190|NCT06222879|Drug|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
79557191|NCT06222879|Drug|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
79557192|NCT06222879|Drug|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
79557193|NCT06222866|Diagnostic Test|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
79557194|NCT06222853|Biological|anti-CD19-CAR-T cells|Three dose groups (1×105/kg, 3×105/kg, 5×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
79557195|NCT06222840|Other|Electro-clinical analysis of epileptic seizures|Electro-clinical analysis of epileptic seizures
79557196|NCT06222840|Other|Electro-encephalographic cases|Electro-encephalographic connectivity analysis compared to controls
79557197|NCT06222840|Other|Clinical datas analysis|Clinical datas analysis
79557198|NCT06222840|Other|Electro-encephalographic control|Electro-encephalographic connectivity analysis compared to cases
79557199|NCT06222814|Procedure|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
79557200|NCT06222814|Procedure|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
79720237|NCT04759651|Other|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
79720238|NCT04759651|Other|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
79720239|NCT04759651|Other|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
79720240|NCT04759651|Other|Insomnia Questionnaire|Subjective evaluation of insomnia.
79720241|NCT04759651|Other|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
79720242|NCT04759651|Other|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
80018964|NCT04850209|Other|Wechat group|Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
80018965|NCT02139774|Behavioral|Walk with Ease|A six week walking program by the Arthritis Foundation
80018966|NCT03650205|Drug|Ivabradine|Ivabradine capsule
80018967|NCT03650205|Drug|Placebo|Placebo oral capsule.
80018968|NCT05698459|Biological|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
79557201|NCT06222801|Drug|Tumor necrosis factor alpha|Antitumor agent. Immunomodulatory agent.
79557202|NCT06222801|Drug|Interferon gamma|Immunostimulating agent.
79557203|NCT06222762|Other|Experimental arm|Personalized follow-up in adapted physical activities
79557206|NCT06222736|Other|Rocabado Exercises|Patients trained by Rocabado Exercises
79557207|NCT06222736|Other|Servical Core Exercises|Servical Core Exercises
80018969|NCT02139930|Behavioral|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
79557208|NCT06222723|Drug|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
80018970|NCT02139930|Behavioral|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
80018971|NCT02139930|Behavioral|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
80018972|NCT05285163|Behavioral|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
80018973|NCT04494490|Behavioral|Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback|The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.
80018974|NCT02140008|Device|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
80018975|NCT02140008|Device|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
80018976|NCT04590118|Drug|it-hMSC|Single intravenous infusion of it-hMSC for ischemic stroke patients
80018977|NCT04590118|Drug|Placebo|Single intravenous infusion of 1 ml/kg placebo
80018978|NCT04810351|Other|observational study|There is no intervention. It is an observational study
79557209|NCT06222723|Drug|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
79557210|NCT06222710|Procedure|Pharmacoacupuncture with ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
79277418|NCT04468945|Other|mirror box therapy|"Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~The patient is seated close to a table a mirror (33*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously."
79557211|NCT06222710|Procedure|Pharmacoacupuncture without ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
79557213|NCT06222671|Drug|608|608 subcutaneous (SC) injection.
79557214|NCT06222671|Drug|608|608 subcutaneous (SC) injection.
79557215|NCT06222671|Drug|Placebo|Placebo subcutaneous (SC) injection.
79557216|NCT06222658|Device|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
79720243|NCT04759651|Other|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
80018979|NCT03549390|Behavioral|Physical activity|Light-moderate intensity physical activities
80018980|NCT05303506|Diagnostic Test|serum ferritin and AST|observiational study
80018981|NCT03650907|Behavioral|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
80018982|NCT03650907|Behavioral|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
80018983|NCT02130804|Drug|Salsalate (4 g/day)|Given orally twice daily
80018984|NCT02130804|Drug|Placebo (4 g/day)|Given orally twice daily
80018985|NCT03650751|Other|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
80018986|NCT05303272|Drug|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
79258282|NCT02836769|Behavioral|Rehabilitation Consult (RC)|The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
79258283|NCT03069092|Behavioral|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
79396758|NCT00734513|Behavioral|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
79396759|NCT00734513|Behavioral|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
79396760|NCT00669734|Biological|Falimarev|Given intratumorally or SC
79396761|NCT00669734|Biological|Inalimarev|Given SC
79396762|NCT00669734|Other|Laboratory Biomarker Analysis|Correlative studies
79396763|NCT00669734|Biological|Sargramostim|Given SC
79557217|NCT06222632|Other|Mind diet intervention|These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.
79557218|NCT06222632|Other|Mind plus FB intervention|The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 &amp; 12 of the intervention.
79720244|NCT01127373|Radiation|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
79396764|NCT00576069|Drug|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
79396765|NCT00576069|Drug|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
79396766|NCT00576069|Drug|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
79396767|NCT00576069|Drug|Prednisone|0-15 mg daily as needed
79396768|NCT00501150|Drug|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
79557219|NCT06222632|Other|Usual care|Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
79557220|NCT06222619|Procedure|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
79720245|NCT01127373|Behavioral|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
79720246|NCT01214616|Drug|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
79720247|NCT01214616|Drug|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
79396769|NCT00389610|Biological|GVAX pancreas vaccine|Given intradermally
79396770|NCT00280943|Behavioral|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
79396771|NCT05081778|Behavioral|Obese patient following a medical course|Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
79396772|NCT03142620|Drug|Esomeprazole|40mg twice daily
79396773|NCT03142620|Drug|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
79396774|NCT03142620|Drug|Clarithromycin|500mg twice daily
79396775|NCT03142620|Drug|Vitamin D3|5000IU
79396776|NCT05077878|Biological|DSPP level in GCF|quantification of DSPP
79258284|NCT03069092|Behavioral|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
79396777|NCT05077644|Device|Stella (TM) Mobile Application|Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
79557221|NCT06222606|Procedure|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
79557222|NCT06221930|Behavioral|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
79720248|NCT01214616|Drug|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
79720249|NCT01213836|Drug|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
79720250|NCT01213836|Drug|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
79720251|NCT01213836|Drug|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
79720252|NCT01213836|Drug|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
79720253|NCT01127061|Behavioral|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
79720254|NCT00924703|Drug|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
79720255|NCT01213524|Behavioral|sensorimotor replacement|denicotinized cigarettes
79557223|NCT06221683|Drug|Homoharringtonine|3mg/m2/day for weighing >10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
79557224|NCT06221683|Drug|Cytarabine|100mg/m2/q12h for weighing >10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing >10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
79557225|NCT06221683|Drug|Etoposide|100mg/m2/d for weighing >10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
79557226|NCT06221683|Drug|Venetoclax|100mg/m2/d for weighing >10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
79557227|NCT06221683|Drug|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing >10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
79557228|NCT06221683|Drug|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
79720256|NCT01213524|Drug|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
79720257|NCT01213524|Drug|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
79720258|NCT01213524|Other|usual brand smoking|participant smokes usual brand of cigarette
79258285|NCT03069092|Behavioral|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
79396778|NCT03140904|Other|Standard weekly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
79396779|NCT03140904|Other|Monthly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
79396780|NCT03110952|Biological|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
79396781|NCT03110952|Biological|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
79557229|NCT06221683|Drug|Idarubicin Hydrochloride|3mg/m2/day for weighing >10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
79557230|NCT06221683|Drug|Sorafenib|100mg/m2/day for weighing >10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
79557231|NCT06221683|Drug|Gilteritinib|20mg/m2/day for weighing >10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
79557232|NCT06221683|Drug|Avapritinib|50mg/m2/day for weighing bodyweight >10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
79557233|NCT06221644|Diagnostic Test|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent [18F]SynVesT-1 PET/CT for synaptic density assessment
79557234|NCT06221462|Drug|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
79557235|NCT06221462|Drug|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
79557236|NCT06221332|Other|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
79557237|NCT06221332|Other|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
79557238|NCT06221319|Other|sacral erectör spinae plane group|sacral erectör spinae plane will be applied to patients in Group S
79396782|NCT03110952|Other|Placebo|0.5 mL vial
79396783|NCT03143400|Drug|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
79557239|NCT06220903|Other|Complex Decongestive Therapy|"Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity."
79557240|NCT06220682|Diagnostic Test|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
79557241|NCT06220344|Biological|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
80018987|NCT05303272|Drug|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
80018988|NCT02131038|Other|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
80018989|NCT02140086|Behavioral|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
79396784|NCT03143244|Drug|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
80018990|NCT03549312|Drug|Genvoya|"Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA < 50 copies/mL at weeks 4, 12, 24, 36 and 48."
79557242|NCT06220344|Drug|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
79557243|NCT06220318|Drug|C019199|The C019199 will be taken orally, once a day
79557244|NCT06220318|Drug|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
79557245|NCT06220071|Other|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
80018991|NCT03549312|Drug|Epclusa|"HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96."
80018992|NCT03549312|Drug|Biktarvy|"Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA < 50 copies/mL at weeks 52, 60, 72, 84 and 96."
79557246|NCT06219759|Other|Observational study|Observational study.
79720259|NCT01212744|Drug|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
80018993|NCT04573036|Drug|HRS4800 tablets|single oral administration
80018994|NCT04573036|Drug|Placebo tablets|single oral administration
80018995|NCT03524768|Diagnostic Test|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
79396785|NCT03143244|Drug|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
79396786|NCT03143244|Drug|Control group (Normal Saline) (C)|Patients received normal saline in two sets
79396787|NCT02328222|Drug|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
79396788|NCT04024410|Other|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
79396789|NCT03838692|Drug|Ponatinib|A daily oral dose at 30 mg.
79396790|NCT03505944|Drug|Venetoclax|venetoclax + lenalidomide + rituximab
79557247|NCT06218758|Other|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
79557248|NCT06218745|Other|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
79557249|NCT06218537|Diagnostic Test|Test group|Contains protease from KREON capsules, activated by adding sodium bicarbonate.
79557250|NCT06218537|Diagnostic Test|Control group|Contains only sodium bicarbonate.
79557251|NCT06217198|Behavioral|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
79557252|NCT06217120|Drug|Colchicine|Colchicine 0.5 mg daily
79557253|NCT06217120|Drug|Placebo|Placebo once daily
79720260|NCT01212588|Drug|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
79720261|NCT01212588|Drug|Placebo|3 tablets once daily for seven days
79720262|NCT00918385|Drug|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
79720263|NCT00918385|Drug|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
79855452|NCT03078491|Other|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
79396791|NCT05071950|Other|Control period|"first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~participants did not allow to have added sugar/ sweetness drinks before the iftar meal~flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~food diary was used to record the iftar meal"
79258286|NCT04451642|Procedure|Peripheral nerve block|Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
79557254|NCT06215755|Drug|VRG50635|Specified dose on specified days
79557255|NCT06215352|Other|Chrono-nutrition factors|Dietary records would be used to assess the chrono-nutrition factors such as night eating, breakfast skipping, meal frequency, and daily fasting.
79720264|NCT05253235|Behavioral|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
79720265|NCT05253235|Other|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
79720266|NCT05253157|Other|Virtual Reality Augmented remote rehabilitation|XRHealth offers remote skilled therapy treatments such as education, exercise, and VR-augmented activities. The platform consists of the VRHealth portal with multiple immersive applications for measurement, motor-cognitive training, and mindfulness/cognitive behavioral applications for symptom relief, the external control application, and the XR Health data portal with real-time analytics for evaluating performance. Contraindications for VR use are assessed. Treatment sessions are 60 min long. Duration and frequency are based on clinical judgement. VR interventions used are; VR motor-cognitive: ReAct, Color Match, Memorize, Rotate, and Balloon Blast; VR Reliever: Relax 8, Luna, and Mindset. An external VR portal and mirroring software allows the clinician to view patient activities in real time. Additionally, the clinician can remotely monitor patient performance via the external portal and adjust parameters accordingly.
79720267|NCT04727281|Other|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
79720268|NCT05251831|Drug|Intradermal injection|Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
79720269|NCT04761679|Behavioral|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
79396792|NCT05071950|Dietary Supplement|D-allulose period|"[started after 7 days of control period],~participants continued with D-allulose period for 7 days continuously~participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~participants did not allow to have added sugar/ sweetness drinks before the iftar meal~flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~food diary was used to record the iftar meal~a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose"
79396793|NCT01489189|Other|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
80018996|NCT03649269|Dietary Supplement|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
80018997|NCT03649269|Drug|Bezafibrate|Patients were prescribed 200 mg/day at night.
80031565|NCT03050710|Device|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
79396794|NCT01489189|Drug|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
79396795|NCT01489189|Other|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
79396796|NCT01549873|Drug|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
79258287|NCT02836613|Biological|Galcanezumab|Administered SC
79396797|NCT01549873|Drug|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
79396798|NCT01489111|Drug|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
79557257|NCT06212388|Biological|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
79557258|NCT06212388|Drug|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
79557259|NCT06212388|Drug|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
79258288|NCT03068234|Drug|Pirfenidone|A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
79258289|NCT03068234|Drug|Placebo oral capsule|Placebo for pirfenidone capsule
79557260|NCT06212284|Drug|Citalopram 20mg|Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
79557261|NCT06212284|Drug|Placebo|Doses were gelatine capsules filled with microcrystalline cellulose
79557262|NCT06212232|Procedure|Piezoelectric surgery|Application of a new piezoelectric technique in third molar surgery
79557263|NCT06211257|Other|Dematerialized Personalized Care Plan (ePCP)|Post-treatment support with standard support combined with dematerialized support
79557264|NCT06209476|Diagnostic Test|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
79557265|NCT06207734|Drug|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
79557266|NCT06207734|Drug|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
79557267|NCT06207734|Drug|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
79557268|NCT06207734|Drug|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
79557269|NCT06207734|Drug|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
79557270|NCT06207734|Drug|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
79557271|NCT06206707|Procedure|Faecal Microbiota Transplantation (FMT)|Capsule FMT
79557272|NCT06206707|Procedure|Placebo|Placebo capsules
79557273|NCT06206603|Diagnostic Test|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
79258290|NCT03068234|Drug|Steroids|Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
79258291|NCT02397460|Drug|Gefapixant|Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
79258292|NCT02397460|Drug|Placebo|
79258293|NCT05344079|Device|18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
79396799|NCT04106401|Other|carbon-monoxide rebreathing|Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
79396800|NCT04106401|Other|venous blood sampling|venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
79557274|NCT06206603|Diagnostic Test|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
79557275|NCT06204848|Device|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
79557276|NCT06204276|Device|Experimental: Asymmetrical high-flow nasal cannula|Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) >/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
79557277|NCT06204276|Device|Active comparator: Conventional high-flow nasal cannula|Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 >/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
79557278|NCT06202274|Device|Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE|Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
79557279|NCT06201741|Radiation|[131I]/[18F]/[68Ga]ZT-111|[131I]/[18F]/[68Ga]ZT-111, single dose
79557280|NCT06199232|Drug|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
79557281|NCT06196905|Drug|MT-2990|i.v. infusion
79557282|NCT06193889|Biological|KYV-101|Anti-CD19 CAR-T cell therapy
79557283|NCT06193889|Drug|Standard lymphodepletion regimen|Standard lymphodepletion regimen
79277419|NCT04468945|Other|Repetitive Facilitation Exercise|"The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)"
79557284|NCT06192160|Drug|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
79557285|NCT06192160|Drug|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
79557286|NCT06192160|Drug|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
79557287|NCT06192160|Drug|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
79557288|NCT06192160|Drug|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
79720270|NCT04899037|Other|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
79557289|NCT06192160|Drug|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
79557290|NCT06192160|Drug|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
79557291|NCT06192160|Drug|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
79557292|NCT06192160|Drug|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
79557293|NCT06192160|Drug|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
79557294|NCT06192160|Drug|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
79557295|NCT06188741|Drug|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
79720271|NCT04257643|Other|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
79720272|NCT04257643|Other|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles [14]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
79720273|NCT04703725|Behavioral|Psychosocial Care|"First Follow-Up: One of the implementation of the module~Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
79277420|NCT02199119|Behavioral|Exercise|30 min of moderate exercise on a treadmill
79277421|NCT02199119|Behavioral|TV viewing|watching TV (animated children's programming) for 30 min
79557296|NCT06187168|Procedure|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
79557301|NCT06179212|Diagnostic Test|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
79557302|NCT06171633|Behavioral|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
79557303|NCT06171633|Behavioral|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
79557304|NCT06170905|Dietary Supplement|Whey protein-preload OGTT|Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
79557305|NCT06168318|Drug|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
79557306|NCT06168318|Drug|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
79557307|NCT06168318|Drug|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
79557308|NCT06168318|Drug|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
79855453|NCT00562484|Biological|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
79258294|NCT05344079|Device|20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump|spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
79557309|NCT06168318|Drug|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
79720274|NCT00637819|Drug|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
79258295|NCT05347862|Other|Control group|At baseline, this group will receive only the usual standard advice to practice physical activity as an important measure to promote health benefits. During the intervention period, they will receive only telephone calls monthly to assess the physical activity practice, changes in medication, and adverse events. When appropriate, evaluations of 12 and 24 weeks will be scheduled.
79557310|NCT06165341|Drug|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
79557311|NCT06165341|Drug|Placebo|Fazirsiran matching placebo.
79557312|NCT06153797|Behavioral|PATH-C|PATH-C, a phone-delivered positive psychology intervention for caregivers of patients undergoing HSCT, consists of the following nine sessions: 1) Enhancing gratitude and increasing awareness for physical activity; 2) Expressing gratitude and goal setting for physical activity; 3) Integrating gratitude and goals for physical activity; 4) Personal strengths and environmental scan to enhance physical activity; 5) Enhancing strengths via reflection on past successes; 6) Integrating strengths to enhance well-being and physical activity; 7) Engaging in enjoyable and meaningful activities; 8) Promoting optimism and integrating long-term activity habits; 9) Integrating meaning for sustainable physical activity goals. Each session takes about 30 minutes, and a trained interventionist will guide participants to complete the sessions.
79557313|NCT06152744|Other|Monitoring membrane lung function at different altitudes|The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
79277422|NCT02199119|Behavioral|Sitting quietly|Sitting quietly for 30 min
79720275|NCT05253079|Other|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
79855454|NCT00562484|Biological|Placebo|Placebo
79855455|NCT00944762|Behavioral|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
79855456|NCT00944762|Behavioral|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
79855457|NCT04012892|Combination Product|CD19 CART|CD19 CART
79855458|NCT00940862|Biological|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
79855459|NCT00940862|Device|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
79855460|NCT00940862|Other|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
79855461|NCT03068741|Drug|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
79855462|NCT03068741|Drug|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
79277423|NCT02375061|Behavioral|e-BPS|
79277424|NCT02375061|Behavioral|Daily Activities|
79396801|NCT04106401|Other|physical activity monitoring|recording of physical activity by actimetry
79396802|NCT04106401|Other|apnea-hypopnea index and nocturnal oxygenation|recorded by ambulatory sleep recording device
79396803|NCT04106401|Other|24-hour blood pressure|recorded by ambulatory device
79396804|NCT03871075|Device|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
79855463|NCT03068741|Drug|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
79855464|NCT03068741|Drug|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is <90mmHg and continued until systolic blood pressure is >=100mmHg.
79855465|NCT04012580|Behavioral|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
79855466|NCT03937661|Biological|PRP|Autologous PRP intra ovarian infusion
80018998|NCT04758520|Device|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
80018999|NCT02134938|Dietary Supplement|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
79277425|NCT04468867|Diagnostic Test|Automated whole breast ultrasound|This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
79277426|NCT04468867|Diagnostic Test|Breast MRI|This will be performed by band 6 or 7 radiographer with MRI training
79557314|NCT06148597|Procedure|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
79557315|NCT06144944|Drug|Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
79720276|NCT05253079|Other|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
79855467|NCT03937661|Biological|Placebo|Autologous PFP intra ovarian infusion
79855468|NCT04012502|Other|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
80019000|NCT04750408|Device|Standard oxygen|COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).
79720277|NCT04758715|Other|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
80019001|NCT04750408|Device|Nasal high-flow|F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.
79557316|NCT06144944|Drug|Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Placebo orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
79720278|NCT04256863|Behavioral|Breakfast / Lunch|Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
79720279|NCT04256863|Behavioral|Dinner (DIN)|Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume >50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
79720280|NCT00631501|Drug|Placebo|
79720281|NCT00631501|Drug|Doxycycline|
80019002|NCT03649893|Device|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
79277427|NCT02201927|Device|galvanic vestibular stimulation|
79277428|NCT02202005|Drug|Nevirapine|Nevirapine 400mg PR tablet
79277429|NCT02202005|Drug|Viramune®|Viramune® 400 mg Retardtabletten
79258296|NCT05347862|Other|Physical activity promotion|"The intervention will be based on a remote approach, for 24 weeks. The intervention will consist of telephone calls and sent messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants, plus short text messages promoting health behaviors related to self-care, nutrition, physical activity, and sedentary behavior.~Initially, this group will be followed weekly during the first 4 weeks. After this period this group can up to two weekly calls, according to their preference. The text messages will be weekly. During the telephone calls, the research team will verify the volume of PA achieved and help the participants to identify and overcome barriers to PA practice, and motivate and register any adverse events related or not to the study."
79557317|NCT06142955|Device|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
79258297|NCT03069170|Biological|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
79557318|NCT06139523|Device|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
79258298|NCT05339399|Other|oxytocin augmentation|Only observation of the outcome
79258299|NCT05634980|Other|FEES|Fiberoptic Endoscopic Evaluation of Swallowing (FEES) exam
79557319|NCT06139523|Device|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
79720282|NCT04782037|Drug|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
79720283|NCT04257019|Other|Lavender oil|Inhalation of Lavender oil
79720284|NCT04257019|Other|Almond oil|Inhalation of Almond oil
79720285|NCT04257019|Other|Water|Inhalation of water
79720286|NCT01211262|Drug|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
79720287|NCT01211184|Dietary Supplement|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
79720288|NCT01211184|Dietary Supplement|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
79396805|NCT03871075|Behavioral|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
79396806|NCT03871075|Device|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
80019003|NCT05185609|Other|Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
80019004|NCT05185609|Other|Exposure 2: Changes in anorectal motor function or compliance.|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
80019005|NCT02135172|Behavioral|Sitting|
80019006|NCT02135172|Behavioral|Standing|
80019007|NCT02135172|Behavioral|Walking|
80019008|NCT04549558|Diagnostic Test|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
79396807|NCT03871075|Behavioral|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
79258300|NCT05634902|Behavioral|CME Educational Intervention|The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
79258301|NCT05634902|Behavioral|Study Developed Educational Materials for Patients|Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
79720289|NCT01211184|Behavioral|Fasting.|The patient is fasting from midnight before the surgery.
79258302|NCT02834819|Drug|3% Nebulized Hypertonic Saline|
79557320|NCT06132763|Behavioral|Hydration Intervention|"Teacher & student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, & update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
79557321|NCT06132763|Other|Control - Assessments Only|Assessments only
79557322|NCT06132503|Drug|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
79557323|NCT06131801|Other|1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.|Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
79720290|NCT00924469|Drug|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
79557324|NCT06128421|Dietary Supplement|Individual nutritional support|Nutritional products and route（oral, parenteral）is possible to reach goals
79720291|NCT00924469|Drug|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
79720292|NCT00924469|Drug|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
79720293|NCT00631579|Drug|Rasburicase (SR29142)|
79720294|NCT04256551|Other|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
79855469|NCT04012502|Other|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
79557325|NCT06118905|Drug|Denosumab 60 MG/ML|Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
79557326|NCT06118905|Drug|Zoledronic Acid 5Mg/Bag 100Ml Infusion|Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
79855470|NCT04062149|Other|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
79855471|NCT04062149|Other|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
79855472|NCT02565563|Other|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
79557327|NCT06101394|Drug|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
79258303|NCT05634824|Drug|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
79258304|NCT05634824|Drug|intravenous immunoglobulin|intravenous immunoglobulin
79258305|NCT02454478|Drug|Lenvatinib|
79258306|NCT02454478|Drug|Everolimus|
79258307|NCT01341587|Device|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
80019009|NCT03649191|Other|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
80019010|NCT03649191|Other|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
80019011|NCT02135250|Drug|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
79258308|NCT02361515|Radiation|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
79258309|NCT02361515|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
79258310|NCT05730452|Behavioral|Risk-stratified discharge and post-discharge care|"Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)"
79258311|NCT02359097|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
79396808|NCT01488487|Drug|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
79396809|NCT01488487|Drug|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
79720295|NCT04256551|Other|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
79855473|NCT02565563|Device|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
79855474|NCT00561080|Biological|Zostavax|
79855475|NCT01307306|Drug|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
80019012|NCT02135250|Other|placebo|the placebo is not drug.
80019013|NCT05182723|Procedure|renal replacement therapy|Extracorporeal Methods for Removing Mediators of Systemic Inflammation
80019014|NCT05373446|Drug|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
80019015|NCT05373446|Drug|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
80019016|NCT05373446|Drug|SSD8432Placebo|SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
79396810|NCT01488097|Drug|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
80019017|NCT03649113|Procedure|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
80019018|NCT03649035|Device|HTP treatment|Elegible patients will undergo HTP treatment, followed by standard of care Chemo therapy and SBRT protocol.
80019019|NCT04734028|Drug|Clopidogrel Tablets|DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
79258312|NCT02359097|Drug|Ferumoxytol|Given IV
79258313|NCT02359097|Drug|Gadoteridol|Given IV
79258314|NCT02359097|Procedure|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
79396811|NCT03027115|Drug|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
79396812|NCT03026881|Drug|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
79396813|NCT03026881|Drug|Apatinib|Oral
79396814|NCT03026881|Drug|Paclitaxel|Intravenous injection
79396815|NCT01516879|Biological|Evolocumab|Administered by subcutaneous injection once a month
80019020|NCT02135328|Behavioral|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
79396816|NCT01516879|Biological|Placebo|Administered by subcutaneous injection once a month
79396817|NCT01516879|Drug|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
79396818|NCT01516879|Drug|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
79396819|NCT01516879|Other|Diet Only|Diet only, no lipid lowering background drug given
79396820|NCT01515865|Drug|Midodrine HCl|dose at subject's current dose level
79258315|NCT05634668|Other|Interviewing sheet|". Interviewing sheet: It was designed by the researchers and used to obtain subjects' sociodemographic data; their age, menopausal age, gravidity, parity, BMI, residency, occupation, education level, hot flashes, sweating, and daily habits.~. Menopause specific quality of life questionnaire (MENQOL): MENQOL was designed by Hilditch and used to assess the presence of menopausal symptoms, its severity, and the degree to which they adversely affect women's life. It consisted of 29 items categorized into four domains~. Pittsburgh Sleep Quality Index (PSQI): The PSQI was a self-report scale consisting of 7 components and 19 questions. PSQI studies quality of sleep in the recent month."
79258316|NCT05634590|Drug|Fruquintinib|4mg, orally, once daily, 3 weeks on/ 1 week off
79258317|NCT05634590|Drug|FOLFIRI|Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
79557330|NCT06098456|Drug|EGCG, FA, HA, B12|Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
79557331|NCT06084884|Biological|AZD5851|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion."
79557332|NCT06084338|Radiation|stereotactic ablative radiotherapy|Metastasis directed
79557333|NCT06084338|Drug|Pluvicto|PSMA targeted radiopharmaceutical therapy
79557334|NCT06084338|Drug|topical testosterone|Topical testosterone 1.62% gel
79557335|NCT06081465|Drug|VG290131|The study drug and matching placebo will be administered orally.
79855476|NCT01307306|Drug|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
79855477|NCT00941096|Drug|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
79855478|NCT04012424|Drug|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
79720296|NCT04256551|Other|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
79720297|NCT00924313|Drug|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
79720298|NCT01209780|Biological|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
79855479|NCT04012424|Dietary Supplement|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
79855480|NCT00562094|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
79258318|NCT05634590|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
79258319|NCT05708339|Other|virtually fabricated ear prosthesis|virtually designed ear prosthesis
79258320|NCT05708339|Other|conventionally fabricated ear prosthesis|conventionally fabricated ear prosthesis
79258321|NCT01358825|Procedure|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
79258322|NCT03563963|Drug|Ropivacaine 0.5% Injectable Solution|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
79557339|NCT06071767|Biological|ChAdOx1.tHIVconsv1|Administered as 0.4 mL intramuscularly (IM) at Week 0
79557340|NCT06071767|Biological|ChAdOx1.HIVconsv62|Administered as 0.3 mL IM at Week 0
79557341|NCT06071767|Biological|MVA.tHIVconsv3|Administered as 0.3 mL IM at Week 4
79557342|NCT06071767|Biological|MVA.tHIVconsv4|Administered as 0.5 mL IM at week 4
79557343|NCT06071767|Drug|Vesatolimod (VES)|VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
79557344|NCT06071767|Drug|GS-5423|Administered via intravenous (IV) infusion at week 7
79557345|NCT06071767|Drug|GS-2872|Administered via IV infusion at week 7
79557346|NCT06071767|Biological|MVA.tHIVconsv4|Administered 0.5 mL IM at week 60
79557347|NCT06071767|Biological|Placebo|Placebos for vaccines, VES, and bnAbs
79557348|NCT06067555|Device|MicronJet|MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
79557349|NCT06067555|Biological|Fluzone® Quadrivalent|Intradermal injections of 0.3mL
79557350|NCT06067555|Biological|Fluzone® Quadrivalent|Intramuscular injection of 0.3mL
79557351|NCT06067555|Other|Bacteriostatic Saline|Intradermal injection of 0.3mL (control)
79720299|NCT01209780|Biological|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
79557352|NCT06066021|Other|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
79720300|NCT01209780|Biological|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children <4 years.
79720301|NCT00916357|Drug|Humalog|
79855481|NCT03817853|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
79855482|NCT03817853|Drug|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
79855483|NCT03817853|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
79720302|NCT00916357|Drug|Humulin-R|
79855484|NCT03817853|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
79855485|NCT03817853|Drug|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
80019021|NCT02135328|Behavioral|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
80019022|NCT05285397|Drug|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
79258323|NCT03563963|Drug|Lidocaine 2% Preservative-Free Injectable Solution|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
79258324|NCT03563963|Other|Air|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
79258325|NCT03066518|Drug|Melatonin 5 mg|
79258326|NCT03066518|Other|Placebo|
79258327|NCT05252156|Device|eXciteOSA|eXciteOSA
79396821|NCT01515865|Drug|Placebo|single dose of matching placebo
79396822|NCT01547299|Drug|Enzalutamide|
79396823|NCT01547299|Drug|Leuprolide|
79396824|NCT01547299|Drug|Dutasteride|
79720303|NCT00916357|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
79720304|NCT00916279|Device|Lutonix Paclitaxel-Coated Balloon|PTCA
79720305|NCT05329753|Device|Mobile health application|Health intervention through a smartphone application that favors the process of learning
79720306|NCT04849897|Device|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
79396825|NCT01515475|Procedure|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
79396826|NCT00408603|Drug|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
79396827|NCT04072107|Drug|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
79720307|NCT04849897|Other|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
79720308|NCT00631345|Behavioral|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
79855486|NCT03817853|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
79855487|NCT02565251|Device|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
79855488|NCT02565251|Device|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
79855489|NCT02565251|Device|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
80019023|NCT05302960|Device|Fitbit|The use of Fitbit sensors to see if activity levels can be improved to track recovery from COVID
80019024|NCT05302882|Behavioral|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
79720309|NCT00631345|Other|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
79855490|NCT02565095|Procedure|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
80019025|NCT05302882|Behavioral|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
79720310|NCT00631345|Behavioral|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
79855491|NCT02567045|Procedure|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
79258328|NCT03069014|Drug|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning & evening) for 26 weeks
79557354|NCT06061796|Procedure|prone position|"patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~ratio P/F > 150 mm Hg~FiO2 < 60%~PEEP ≤ 10 cm d'H2O"
79557355|NCT06061211|Other|TREADMILL(PRECOR 964i treadmill) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: PRECOR 964i treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
79557356|NCT06056596|Drug|Lamivudine 300 MG|Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
79557357|NCT06056596|Drug|Placebo|Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
79557358|NCT06053216|Other|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
79557359|NCT06053216|Other|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
79557360|NCT06051617|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for up to 36 months.
79557361|NCT06051617|Drug|Placebo|One capsule daily for up to 36 months.
79855492|NCT02567045|Procedure|colonoscopy with sedation|One-time Colonoscopy with sedation.
79855493|NCT00944840|Drug|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
79855494|NCT00944840|Drug|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
79258329|NCT03069014|Drug|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning & evening) for 26 weeks
79258330|NCT03069014|Drug|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning & evening) for 26 weeks
79258331|NCT03069248|Drug|Rituximab|
79258332|NCT03069248|Drug|Alpha Interferon|
79855495|NCT00439270|Drug|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
79258333|NCT05730296|Device|TMS|10 rTMS sessions combined with cognitive training
79258334|NCT05730296|Device|TMS|10 rTMS sessions
79258335|NCT05730296|Device|TMS|10 sham coils sessions without cognitive training
79557362|NCT06050083|Behavioral|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
79557363|NCT06033586|Drug|Open-label rusfertide|subcutaneous rusfertide
79258336|NCT05730140|Other|this study did not involve interventions; it only observational study|this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
79258337|NCT05730062|Drug|Oxycodone Hydrochloride|Oxycodone 10 mg IR
79258338|NCT05730062|Drug|Placebo|placebo comparator
79258339|NCT02453386|Drug|tozadenant|
79258340|NCT02453386|Drug|placebo|
80019026|NCT03526640|Device|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
79258341|NCT03068936|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
79557364|NCT06025656|Diagnostic Test|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
79557365|NCT06024408|Drug|ALN-PNP|Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
79258342|NCT03068936|Drug|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
79258343|NCT05017610|Drug|Liothyronine|Given PO
79258344|NCT05017610|Drug|Lomustine|Given PO
79258345|NCT05017610|Drug|Methimazole|Given PO
79258346|NCT03068078|Dietary Supplement|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
79557366|NCT06024408|Drug|Placebo|Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
79258347|NCT02431468|Drug|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
79258348|NCT02431468|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
79258349|NCT02452762|Drug|Vitamin D3|
79720311|NCT00631345|Behavioral|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
79720312|NCT05252455|Behavioral|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
79720313|NCT04698421|Biological|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
79258350|NCT02452762|Drug|Placebo|
79258351|NCT03068858|Diagnostic Test|real-time feedback of SYNTAX score category|
79720314|NCT05217823|Device|Er:YAG laser|
79720315|NCT05217823|Other|hand instruments|
79720316|NCT01209078|Drug|GSK1322322|GSK1322322 1500mg BID
79720317|NCT01209078|Drug|Linezolid|Linezolid 600mg
79258352|NCT04957472|Device|fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function|24 hours of automated control of FiO2
79720318|NCT01209078|Drug|GSK1322322 placebo|Placebo
80019027|NCT03050359|Drug|TAK-438|TAK-438 tablets
79258353|NCT04957472|Other|Manual Control|24 hours of manual control of FiO2
79258354|NCT05729750|Diagnostic Test|Trans abdominal ultrasound for assess biophysical profile|The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
79258355|NCT04915118|Other|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
79720319|NCT01209078|Drug|Linezolid placebo|placebo
79720320|NCT04708561|Behavioral|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
79720321|NCT04849585|Other|semi-directed entretien|semi-directed entretien
80019028|NCT03050359|Drug|Lansoprazole|Lansoprazole capsules
79258356|NCT03068702|Device|Optical Coherence Tomography Angiography|
79258357|NCT04886414|Other|Phone-based monitoring|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.
79855496|NCT00439270|Drug|Docetaxel|Infusion, 60 or 75 mg/m^2, administered every 3 weeks.
79720322|NCT04672135|Drug|REM0046127|Oral solution: 100 mg/mL REM0046127
79720323|NCT04672135|Drug|Placebo|Oral solution with 0 mg/mL REM0046127
79720324|NCT04584385|Diagnostic Test|EEG|EEG monitoring
79720325|NCT05212909|Behavioral|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
79720326|NCT04318470|Diagnostic Test|mNGS|Metagenomic next generation sequencing for microbial DNA
79720327|NCT04318158|Drug|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
79720328|NCT04318158|Drug|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
80019029|NCT03050359|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets.
79557367|NCT06023641|Drug|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
79557368|NCT06023641|Drug|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
80019030|NCT03050359|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
79720329|NCT04318158|Drug|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
79720330|NCT05418426|Device|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
80019031|NCT03050359|Drug|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
79258358|NCT04886414|Other|Oxygen saturation monitoring|Oxygen saturation will be monitored and recorded at regular intervals.
79258359|NCT04886414|Other|Alcohol-based hand sanitizer|Alcohol-based hand sanitizer will be distributed to subjects.
79258360|NCT04411004|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasonographic scan to diagnosis the recurrence of rectal endometriosis
79720331|NCT05418426|Device|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
79720332|NCT05418426|Drug|Oral Reference|estradiol 1mg/progesterone 100 mg
79855497|NCT00944918|Drug|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
79855498|NCT00944918|Drug|anastrozole|Tablet, oral, once daily until disease progression.
79855499|NCT00944918|Drug|exemestane|Tablet, oral, once daily until disease progression.
79855500|NCT04012268|Device|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
79720333|NCT05416710|Diagnostic Test|Invitae's 84 gene multi-cancer panel.|Invitae's Multi-Cancer panel analyzes 84 genes associated with hereditary cancers across major organ systems.
79855501|NCT04012268|Drug|Aspirin|patients will accept medication guided by neurologists
80019032|NCT03648957|Behavioral|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
80019033|NCT03648957|Behavioral|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
80019034|NCT03648957|Device|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
80019035|NCT05302726|Drug|Estrogen|Transdermal and oral estrogen both as substitution therapy
80019036|NCT05012072|Behavioral|The Mastery Lifestyle Intervention|Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST
80019037|NCT04721236|Other|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
79258361|NCT04411004|Behavioral|5-point Likert scale|Subjective scale to evaluate satisfaction to previous surgical treatment for rectal endometriosis
79720334|NCT01207596|Drug|Hydromorphone|Oral hydromorphone extended release, once daily
79720335|NCT00915343|Drug|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
79720336|NCT00915343|Drug|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
79720337|NCT04667533|Drug|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~Cohort I: Single-dose 100 mg~Cohort II: Single-dose 150 mg~Cohort III: Single-dose 200 mg"
79720338|NCT04578301|Other|No Intervention|No Intervention
79720339|NCT04651621|Device|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
79855502|NCT03995134|Combination Product|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
79855503|NCT00553280|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
80019038|NCT02135406|Biological|CART-19 T cells|
80019039|NCT03648411|Genetic|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
80019040|NCT04549402|Other|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
79855504|NCT01024192|Drug|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
79855505|NCT01024270|Drug|Misoprostol|
79855506|NCT00944996|Drug|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
79258362|NCT05729672|Behavioral|Received the Nightingale in Gen-sEx course|The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
79855507|NCT03266536|Behavioral|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with < 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
79855508|NCT00950066|Drug|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
80019041|NCT04549402|Other|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
80019042|NCT02253264|Drug|Rituximab|
80019043|NCT03648333|Drug|Exforge tab. 10/160mg|
80019044|NCT03648333|Drug|Lodivixx tab. 5/160mg|
80019045|NCT03626779|Other|Prf|Take 10cc blood from patient and gain prf blug
80019046|NCT02252796|Radiation|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
79720340|NCT04651621|Device|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
79258363|NCT05633420|Drug|Pyramax|"Participant body weight~≥65 kg (Pyramax 4 tablets)~≥45 kg and <65 kg (Pyramax 3 tablets)"
79277430|NCT02364921|Device|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
79557369|NCT06023641|Drug|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
79557370|NCT06023641|Procedure|Surgical Resection|Low, Intermediate and High-risk
79557371|NCT06023641|Procedure|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
79557372|NCT06023641|Drug|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
79720341|NCT00632047|Other|active surveillance|
79720342|NCT00632047|Other|educational intervention|
79720343|NCT00632047|Procedure|examination|
79720344|NCT00632047|Procedure|long-term screening|
79720345|NCT04203043|Drug|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
79720346|NCT04203043|Other|Placebo|Placebo
79855509|NCT00950066|Drug|Amlodipine|Oral administration of Amlodipine 5mg once a day
79855510|NCT00950066|Drug|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
79855511|NCT00950066|Drug|Placebo|Oral administration of a placebo once a day
79855512|NCT01031212|Drug|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
79855513|NCT01031212|Drug|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
79855514|NCT01031212|Drug|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
79855515|NCT01031212|Drug|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
79855516|NCT00950144|Other|medical chart review|
79855517|NCT00950144|Other|questionnaire administration|
79855518|NCT00950144|Other|study of socioeconomic and demographic variables|
79855519|NCT00950144|Procedure|quality-of-life assessment|
79855520|NCT01024348|Drug|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
79855521|NCT01024348|Drug|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
80019047|NCT02252796|Drug|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
80019048|NCT02252796|Drug|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
80019049|NCT02252796|Radiation|Image-guided IMRT|Given during chemo-radiation phase
80019050|NCT05285007|Other|Mobilization with Movement|Participants will be lunging on a box with posterior ankle glide of 10 seconds times 5 sets. They will have 30 seconds rest between trials. Participant will have their ankle taped and then walk on a treadmill at a self-selected pace for 5 minutes.
80019051|NCT05285007|Other|No mobilization with movement and education|Participants ankle will not be taped and they will walk on the treadmill for 5 minutes and receive education.
80019052|NCT03524690|Dietary Supplement|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
80019053|NCT03524690|Dietary Supplement|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
80019054|NCT04721197|Other|Egg vouchers|30-day egg vouchers will be provided monthly, in addition to standard of care.
80019055|NCT04721197|Other|Standard of Care|Participants will continue to receive the standard of care. No egg vouchers.
79258364|NCT05633030|Procedure|using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy|under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser [20 W; Lumenis (UK) Ltd., Elstree, UK] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
79557373|NCT06023641|Drug|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
79557374|NCT06023641|Drug|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
79258365|NCT05632094|Dietary Supplement|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
79720347|NCT04435015|Drug|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
79720348|NCT04435015|Drug|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
79720349|NCT04235725|Other|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
80019056|NCT03648177|Behavioral|IPGT|Behavioral Intervention for Patients with Chronic Pain
79258366|NCT04768322|Device|HeartMate 3 TM Left Ventricular Assist System|The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
79720350|NCT04170361|Other|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
79720351|NCT04170361|Other|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
79258367|NCT04768322|Other|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
79258368|NCT05729438|Dietary Supplement|BCAA|status of nutrition evaluation after 3 months of BCAA
79258369|NCT03068156|Radiation|308-nm excimer laser|monochromator UVB laser (308nm)
79557375|NCT06023641|Drug|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose [for patients < 45 kg] or 6 mg/dose [for patients ≥ 45 kg] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
79720352|NCT04817293|Other|Questionnaire|Questionnaire SSD-12 and EQ5D5L
80019057|NCT03648177|Behavioral|Treatment as Usual|Standard Care
79258370|NCT05575466|Diagnostic Test|Blood samples|Hemostatic biomarkers
79258371|NCT05575466|Diagnostic Test|Questionnaires|Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
79258372|NCT05729360|Drug|GamCoviMab|A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
79720353|NCT04817293|Other|medical consultation|Medical consultation during the visit with data collection
79720354|NCT04408651|Behavioral|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
79720355|NCT04408651|Behavioral|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
79855522|NCT00945074|Other|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
79855523|NCT00945074|Other|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
80019058|NCT02785770|Drug|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
80019059|NCT02785770|Drug|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
79855524|NCT00945074|Other|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
79258373|NCT03067922|Other|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
79258374|NCT04699058|Diagnostic Test|COVID-antibody test|Questionnaire and COVID-antibody test for all participants
79258375|NCT05729126|Other|Questionnare|A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
79557376|NCT06014567|Procedure|Magnetic Resonance Imaging|"A single (≤45 minutes) brain MRI will include T1w and T2w imaging to assess the morphology and structure of the brain, as well as inflammatory processes. Diffusion-weighted imaging will be used to gain information about internal brain connectivity related to brain functions. MRI, MR angiography (MRA) and fMRI pulse sequences will also be acquired to detect vascular pathologies and brain lesions. T2w morphological images of the whole spine will also be obtained.~A single (≤45 minutes) MR imaging investigation to include cardiovascular, abdominal, and musculoskeletal regions. MRI will be performed to assess the structure and function of these body regions and organs, including functional imaging of the heart. These investigations will include T1w and T2w imaging to assess morphology and structure, mapping studies of T1, T2 and T2*, perfusion imaging and cine imaging to assess the heart dynamically."
79557377|NCT06012136|Drug|VH4004280|VH4004280 will be administered.
79557378|NCT06012136|Drug|Placebo|Placebo will be administered.
79258376|NCT05518760|Other|no intervention|no intervention
79557379|NCT06012136|Drug|VH4011499|VH4011499 will be administered.
79258377|NCT05487092|Drug|Letrozole|Letrozole 2.5mg daily for 6 months
79720356|NCT04576429|Procedure|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~each 3 months up to 12 months.~for patients of cohort B2:~before the radiotherapy;~within the 6 weeks after the end of radiotherapy;~at the 2 following evaluations (every 3 months)."
79720357|NCT04576429|Procedure|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
79720358|NCT04203277|Other|IVY|a combination of practice education and quality improvement interventions
79720359|NCT00631813|Drug|Prucalopride|0.5 mg bid
79720360|NCT00631813|Drug|Prucalopride|1 mg bid
79720361|NCT00631813|Drug|Prucalopride|2 mg bid
79720362|NCT00631813|Drug|Placebo|bid
79557380|NCT06009055|Drug|Remimazolam|0.3mg/kg，injection completed in 30 seconds
79557381|NCT06009055|Drug|Propofol|2mg/kg，injection completed in 30 seconds
79557382|NCT06008574|Other|AmDTx-PCSP|Step-by-step program modules including meditation training and other activities relevant for people living with cancer
79720363|NCT04404049|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
79720364|NCT04404049|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
79258378|NCT05487092|Other|Placebo|Placebo
79258379|NCT04568954|Diagnostic Test|Truenat TB platform/TB assays|"Truenat TB platform/TB assays, a molecular diagnostic test developed by Molbio diagnostics, for the diagnosis of Mycobacterium tuberculosis complex (MTBC) and Truenat MTB-RIF Dx for detection of RIF resistance was endorsed in 2020 by the WHO for TB diagnosis.~The system has been designed to be operated as a point-of-care- diagnostic solution in peripheral laboratories with minimal infrastructure.~It takes about 25 minutes to do the DNA extraction and another 35 minutes to diagnose TB.~It is portable and battery operated, have no need for a computer or laptop, and operate from 2-40 C ambient temperature. The system uses room temperature stable reagents with long shelf life."
80019060|NCT02785770|Drug|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
79258380|NCT04554056|Drug|MW05|Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
79258381|NCT04554056|Drug|PEG-rhG-CSF|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
79258382|NCT03067766|Procedure|Art Therapy|Participate in a comic art creation workshop
79557383|NCT06008574|Other|AmDTx-2048|"Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value."
79720365|NCT00911989|Device|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
79258383|NCT03067766|Other|Interview|Undergo qualitative interviews
79258384|NCT03067766|Procedure|Quality-of-Life Assessment|Ancillary studies
79258385|NCT03067766|Other|Questionnaire Administration|Ancillary studies
79258386|NCT03067688|Drug|Temisartan+Amlodipine+Rosuvastatin (Combination drug)|PO, Once daily(QD), 8weeks
79258387|NCT03067688|Drug|Temisartan+Amlodipine|PO, Once daily(QD), 8weeks
79258388|NCT03067688|Drug|Temisartan+Rosuvastatin|PO, Once daily(QD), 8weeks
79258389|NCT03067532|Procedure|existed simulation system user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
79258390|NCT03067532|Procedure|home made simulator user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
79396828|NCT04072107|Drug|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
79396829|NCT04013061|Other|Pluridisciplinary consultation|Pharmacist-anesthesiologist team will be present during the anesthetic consultation
79720366|NCT04635163|Other|None intervention|None intervention
79855525|NCT03994744|Drug|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
80019061|NCT03650595|Device|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS|Thermal Therapy"
79258391|NCT03067454|Procedure|Early mobilisation|"Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
79258392|NCT03067454|Procedure|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
79855526|NCT03994744|Drug|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
79855527|NCT00950222|Drug|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
79855528|NCT01031290|Device|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
79855529|NCT05301530|Drug|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
79855530|NCT05301530|Drug|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
79258393|NCT03067064|Other|no intervention|Clinical examination
79258394|NCT03067142|Other|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
79557384|NCT06008574|Other|Questionnaires|Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
79557385|NCT06007508|Drug|Insulin Glargine|Long-acting insulin
79557386|NCT06004622|Other|Calgary Family Intervention Model|under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
79557387|NCT06000059|Behavioral|Radio Drama|An hour long radio drama adapted from from a previous community-led theater intervention
79720367|NCT04911517|Combination Product|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
79720368|NCT04617379|Behavioral|Stretching|One-year stretching program for 15 minutes every day
79720369|NCT04503655|Other|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
79720370|NCT04853563|Other|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
79720371|NCT03880279|Biological|TAC01-CD19|Dose-escalating cohorts plus expansion groups
79720372|NCT00637897|Drug|docetaxel|
79720373|NCT00637897|Drug|ixabepilone|
79720374|NCT00637897|Drug|paclitaxel|
79720375|NCT00637897|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
79720376|NCT00637897|Drug|paricalcitol|
79720377|NCT03992443|Drug|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
79720378|NCT04334707|Procedure|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
79720379|NCT03926689|Behavioral|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
79720380|NCT03926689|Behavioral|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
79258395|NCT03067220|Other|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
79258396|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
79258397|NCT03065972|Procedure|Surgical fistula creation from patient's anatomy|Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.
79277431|NCT02364921|Device|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
79720381|NCT03915535|Dietary Supplement|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
79720382|NCT03915535|Dietary Supplement|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
79720383|NCT04816513|Drug|Ustekinumab|Ustekinumab will be administered as SC injection.
79720384|NCT03858283|Behavioral|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
79720385|NCT04203511|Drug|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
79720386|NCT04203511|Drug|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
79855531|NCT05301530|Drug|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
80019062|NCT05302648|Drug|Human Derived anti-BCMA CAR-T Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
80019063|NCT03648099|Behavioral|Labor dance|The dance group which involved pregnant women who performed the labor dance
79855532|NCT03228160|Other|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
79855533|NCT00941174|Drug|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
79855534|NCT00950456|Biological|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
80019064|NCT03648099|Behavioral|Music|The music group involving pregnant women who were exposed to music.
79557388|NCT05998629|Device|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
80019065|NCT05302258|Diagnostic Test|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
80019066|NCT04522492|Behavioral|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
79557389|NCT05998629|Other|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
79557390|NCT05995535|Drug|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
80019067|NCT04522492|Other|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
80019068|NCT05284929|Genetic|A single blood sample for HLA typing|Extracting of DNA from the blood sample using PCR-reaction
80019069|NCT04660123|Drug|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
80019070|NCT03526406|Dietary Supplement|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
80019071|NCT03526406|Dietary Supplement|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
80019072|NCT02965833|Device|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
80019073|NCT02965833|Device|Habitual Multi-Purpose Contact Lens Solution|
80019074|NCT02965833|Device|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
79557391|NCT05995535|Drug|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
79557392|NCT05994287|Drug|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
79557393|NCT05994287|Drug|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
80019075|NCT04647019|Dietary Supplement|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
79557394|NCT05994287|Drug|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
79557395|NCT05992428|Drug|DA-8010 5mg|[Part 1] DA-8010 5mg + Paroxetine 20mg [Part 2] DA-8010 5mg + Mirabegron 50mg
79557396|NCT05992428|Drug|Paroxetine 20mg|[Part 1] DA-8010 5mg + Paroxetine 20mg
79557397|NCT05992428|Drug|Mirabegron 50mg|[Part 2] DA-8010 5mg + Mirabegron 50mg
79557398|NCT05991401|Drug|DA-8010 5mg|[Period 1] DA-8010 5mg [Period 2] DA-8010 5mg, Clarithromycin 500mg [Period 3] DA-8010 5mg, Rifampicin 600mg
79277432|NCT02741245|Drug|Ezetimibe 10 mg|
79557399|NCT05991401|Drug|Clarithromycin 500mg|[Period 2] DA-8010 5mg, Clarithromycin 500mg
79557400|NCT05991401|Drug|Rifampicin 600mg|[Period 3] DA-8010 5mg, Rifampicin 600mg
79557401|NCT05988762|Other|Supramaximal Walkout|Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
79557402|NCT05988762|Other|Submaximal Walkout|Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
79557403|NCT05984654|Procedure|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
79855535|NCT00440518|Drug|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
79258398|NCT03065972|Device|Surgical Graft implant|Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
79258399|NCT03065894|Other|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
79258400|NCT03065894|Other|Current Care in Family Medicine|Patient education, medication management
79258401|NCT05555030|Device|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
79258402|NCT05555030|Diagnostic Test|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
79258403|NCT03066128|Diagnostic Test|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
79258404|NCT03066128|Other|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
79258405|NCT02633306|Device|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
79557404|NCT05953077|Behavioral|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
79557405|NCT05939531|Behavioral|BOUNCE Program|Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
79557406|NCT05939531|Behavioral|Standard Care|Standard post-stroke care
79557407|NCT05937581|Drug|CSL040|IV Administration
79557408|NCT05937581|Drug|Placebo|0.9% w/v NaCI, IV Administration
79557409|NCT05935358|Drug|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
79557410|NCT05933265|Drug|LP-184|LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
79557411|NCT05932862|Drug|XL309 (ISM3091)|XL309 will be administered orally once daily.
79557412|NCT05930431|Behavioral|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
79557413|NCT05930431|Behavioral|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
79557414|NCT05915039|Other|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
79557415|NCT05913388|Drug|GB1211|Administered orally twice daily at 400mg.
79277433|NCT02741245|Drug|Rosuvastatin 2.5 mg|
79557416|NCT05913388|Drug|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
79557417|NCT05913388|Drug|Placebo|Administered orally twice daily at 400mg.
79557418|NCT05902338|Other|Music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music)."
79557419|NCT05900154|Biological|RSVpreF 120 µg|RSVpreF standard dose level
79855536|NCT00440518|Other|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
79855537|NCT00440518|Drug|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
79855538|NCT00945230|Procedure|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
79855539|NCT00950534|Drug|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
79855540|NCT00950534|Drug|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
79258406|NCT02396758|Device|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
79258407|NCT02396758|Biological|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
79557420|NCT05900154|Biological|RSVpreF 60 µg|RSVpreF low dose level
79258408|NCT05728424|Drug|Vonoprazan, Amoxicillin, Levofloxacin|No additional information
79557421|NCT05900154|Other|placebo|Placebo
79557422|NCT05899127|Drug|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
79557423|NCT05899127|Drug|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
79396830|NCT05288049|Behavioral|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
79396831|NCT05288049|Behavioral|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
79396832|NCT00409539|Drug|Placebo|Placebo, 2 week duration.
79396833|NCT00409539|Drug|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
79258409|NCT03065738|Other|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
79258410|NCT05538182|Device|Spectacles|Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
79396834|NCT00409539|Drug|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
79557424|NCT05897593|Device|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
79557425|NCT05894681|Other|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
79557426|NCT05890313|Diagnostic Test|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
79557427|NCT05890313|Diagnostic Test|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
79557428|NCT05890313|Device|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
79557429|NCT05870800|Drug|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
79557430|NCT05870800|Drug|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
79720387|NCT04203511|Drug|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
79720388|NCT04203511|Drug|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
79855541|NCT01029964|Behavioral|Individually and in groups|During three year in a clinical setting.
79258411|NCT03067376|Drug|[14C]-CORT125134|
79258412|NCT04407260|Device|Oxygen Hood|High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
79258413|NCT05728268|Drug|dose-dense nab-paclitaxel followed by EC|dose-dense nab-paclitaxel followed by EC
79277434|NCT02741245|Drug|Placebo for Ezetimibe|
79258414|NCT02632838|Device|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
79557431|NCT05870800|Drug|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
79557432|NCT05870787|Diagnostic Test|Swede score colposcopy|New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
79557433|NCT05855603|Procedure|Cardioneuroablation|"Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase >20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase <10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response."
79557434|NCT05855603|Device|Permanent pacemaker therapy|All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
79557435|NCT05854784|Drug|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
80019076|NCT04647019|Dietary Supplement|Placebo powder|22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
79557438|NCT05837767|Radiation|Stereotactic body radiotherapy|The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).
79557439|NCT05837767|Radiation|Lattice Radiation Therapy|A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
79557440|NCT05832281|Drug|Purysis CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
79557441|NCT05832281|Drug|Placebo|Placebo for Purysis
79557442|NCT05828511|Drug|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
79557443|NCT05826353|Drug|Ripasudil|K-321 ophthalmic solution
79557444|NCT05826353|Drug|Placebo|Placebo ophthalmic solution
79557445|NCT05824013|Diagnostic Test|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
79557446|NCT05823974|Biological|Flu mRNA|Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.
79557447|NCT05823974|Combination Product|Control 1|Control 1 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control group from Phase 1, at Day 1 and to participants in Control YA group from Phase 2, at Day 1.
79557448|NCT05823974|Combination Product|Control 2|Control 2 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control OA group from Phase 2, at Day 1.
79258415|NCT05728190|Other|steril/salin water|Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose. Green food coloring was added (one drop of food coloring to 5 ml of sterile/saline water) to make sterile/saline water similar to lavender oil.
79258416|NCT05728190|Other|Lavender essential oil|Five days seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
79720389|NCT04203511|Drug|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
79720390|NCT04203511|Drug|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
79258417|NCT02396212|Biological|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
79277435|NCT02741245|Drug|Placebo for Rosuvastatin|
79557449|NCT05819424|Dietary Supplement|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
79557450|NCT05818930|Diagnostic Test|REMI|Diagnostic monitoring
79557451|NCT05817890|Drug|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
80019077|NCT05302024|Drug|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
80019078|NCT04252339|Drug|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
80019079|NCT04467944|Other|Pre-existing degenerative factors at adjacent segment|Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
80019080|NCT03647631|Procedure|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
79855542|NCT00941252|Drug|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
79258418|NCT04449458|Behavioral|Positively Me|12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
79396835|NCT00411411|Drug|Januvia|200 mg t.i.d
79557452|NCT05814666|Drug|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
79557453|NCT05814666|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
79720391|NCT04203511|Drug|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
79557454|NCT05804838|Other|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
79557455|NCT05804383|Drug|BMS-984923|Capsules
79720392|NCT04203511|Radiation|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
79855543|NCT01031368|Drug|cytarabine|Given IV
79258419|NCT04449458|Behavioral|Positively Living|12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
79258420|NCT04883762|Biological|Fecal Microbiota Transplantation (FMT)|Undergo FMT via colonoscopy.
79258421|NCT04882358|Device|ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
79855544|NCT01031368|Drug|clofarabine|Given IV
79258422|NCT04882358|Drug|SGLT2 inhibitor|treatment with a standard dose of SGLT-2 inhibitor
79855545|NCT01031368|Drug|filgrastim|Given SC
79855546|NCT01031368|Biological|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
79258423|NCT02395822|Biological|IL-15|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if < 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
79396836|NCT00411411|Drug|Placebo|Placebo
79396837|NCT05287815|Behavioral|training/observation|In the study, elderly individuals who met the sampling criteria and accepted to participate in the study were 30 in the experimental group and 30 in the control group, using the stratified randomization method to control and balance the effects of age (65-75 years, 76 and over) and gender (female and male) variables. It will be planned to be an elderly individual. Computer-assisted randomization, which is one of the simple randomization methods, was assigned to the groups according to the determined.
79396838|NCT05287659|Dietary Supplement|meal replacements or supplementation with leucine|meal replacements or animal protein or supplementation with leucine
79396839|NCT02107599|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
79557456|NCT05804383|Drug|Placebo|Capsules
79557457|NCT05803603|Behavioral|Stipend and Social Work Supports|Same as arm description
79557458|NCT05781295|Device|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
79720393|NCT04203121|Radiation|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
80019081|NCT03900442|Drug|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
79855547|NCT01031368|Other|laboratory biomarker analysis|Correlative studies
80019082|NCT04225351|Procedure|MCAF+CM|CAF procedure + collagen matrix
80019083|NCT04225351|Procedure|MCAT+CM|Tunnel procedure + collagen matrix
79720394|NCT04299685|Other|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
80019084|NCT05579418|Drug|Evolocumab|Evolocumab is an injection for management of dyslipidemia
79720395|NCT04297891|Other|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
80019085|NCT05301868|Behavioral|Multidomain intervention|For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.
79258424|NCT05726942|Other|Healthi|Healthi refers to the Healthi app, which is a mobile application for weight loss
79720396|NCT04297891|Other|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
79855548|NCT00945308|Drug|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
80019086|NCT02968173|Drug|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
80019087|NCT02785458|Behavioral|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
80019088|NCT05301790|Device|MRI|use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
80019089|NCT04053231|Other|liver resection|all type of liver surgical procedures
80019090|NCT02140320|Drug|RV1729 single dose|Safety and tolerability of single dose
79258425|NCT04926844|Drug|Levetiracetam|Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
79258426|NCT04926844|Drug|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
79258427|NCT04926844|Drug|Placebo|Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
79258428|NCT05482256|Diagnostic Test|Esophageal String Test (EST)|Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.
79258429|NCT05482256|Other|Colgate|2 grams of toothpaste (pea sized amount) for 2 minutes
79258430|NCT05482256|Diagnostic Test|High Resolution Esophageal Manometry (HREM)|Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
79396840|NCT01794273|Drug|ephedrine and phenylephrine|
79258431|NCT01651936|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
79258432|NCT01651936|Drug|Methotrexate|MTX dosed at the stable dose received upon study entry
79258433|NCT01651936|Drug|Dose-match placebo|Dose-matched placebo dosed orally BID
79277436|NCT02202083|Other|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
79277437|NCT02368353|Other|Cognitive behavioral therapy|
79277438|NCT02368353|Other|Supportive therapy|
79396841|NCT02109939|Genetic|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
79396842|NCT01795599|Drug|Mifegyne ®|
79396843|NCT01795599|Drug|Gymiso®|
79396844|NCT01794351|Dietary Supplement|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
79720397|NCT04297891|Other|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
79855549|NCT00945308|Drug|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
79855550|NCT00950768|Procedure|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
79855551|NCT03172936|Drug|MIW815|MIW 815 (ADU-S100) is a STING agonist
79855552|NCT03172936|Biological|PDR001|PDR001 is an anti-PD-1 antibody
80019091|NCT02140320|Drug|RV1729 matching placebo single dose|Safety and tolerability of single dose
80019092|NCT02140320|Drug|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
80019093|NCT02140320|Drug|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
80019094|NCT02140320|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
80019095|NCT02140320|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
80019096|NCT04867694|Behavioral|BCC|Behavior change communication on Nutrition, Health & Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
79258434|NCT04217174|Behavioral|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
79258435|NCT04217174|Behavioral|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
79557459|NCT05781295|Device|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
79258436|NCT04199078|Device|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
79855553|NCT00950924|Device|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
79396845|NCT01794351|Other|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
79396846|NCT01515319|Drug|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
79557461|NCT05777486|Behavioral|TikTok Ads - With Food|TikTok posts from influencers promoting food.
79557462|NCT05777486|Behavioral|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
79557463|NCT05763563|Behavioral|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
79557464|NCT05763563|Behavioral|Aerobic Exercise|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
79557465|NCT05753956|Drug|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
79557466|NCT05753956|Drug|Placebo|GH002 placebo administered via i.v. bolus injection
79557467|NCT05753501|Drug|ABBV-101|Oral:Tablet
79855554|NCT00950924|Device|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
79557468|NCT05748197|Biological|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells.
79855555|NCT01024426|Procedure|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
80019097|NCT04867694|Dietary Supplement|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to [6-11] months old children diagnosed as non-wasted (green MUAC); or children [12-59] months old for 6 months after discharge from a CMAM treatment or consolidation program.
80019098|NCT04867694|Dietary Supplement|MNP|Delivery of micronutrient powders to [12-23] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
79396847|NCT01515319|Drug|0.9% saline|Identical volume to that of Y242
79396848|NCT02110095|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
79396849|NCT04409431|Procedure|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
79396850|NCT01794507|Drug|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
79396851|NCT01794507|Drug|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
79557469|NCT05748197|Drug|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
79557470|NCT05747027|Procedure|Laparoscopic abdominal ventral rectopexy|Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.
79557471|NCT05747027|Procedure|Transvaginal sacrospinous rectopexy|Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
80019099|NCT04867694|Other|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with [6-11] months old children, or children [12-59] months old enrolled in a CMAM treatment program and for 6 months after discharge.
79557472|NCT05745480|Other|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
80019100|NCT04867694|Behavioral|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with [6-59] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
79258437|NCT05634512|Drug|Laronidase therapy and a stem cell transplant|To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
79557473|NCT05745376|Behavioral|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
79557474|NCT05743881|Biological|mRNA-1345|Sterile liquid for injection
79557475|NCT05743881|Biological|mRNA-1365|Sterile liquid for injection
79720398|NCT04297891|Diagnostic Test|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
79557476|NCT05743881|Biological|Placebo|0.9% sodium chloride (normal saline) solution for injection
79557477|NCT05743881|Drug|Nimenrix|Solution for injection
79855556|NCT01024426|Other|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
79855557|NCT00951002|Procedure|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
79855558|NCT01030042|Drug|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
79258438|NCT04042844|Biological|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
79258439|NCT04042844|Drug|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
79258440|NCT03065504|Dietary Supplement|Turmeric|
79258441|NCT03065504|Dietary Supplement|Turmeric-containing combination tablet|
79258442|NCT03065504|Dietary Supplement|Placebo tablets|
79557478|NCT05738902|Other|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
79557479|NCT05734586|Other|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
79557480|NCT05734586|Procedure|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
79557481|NCT05734040|Biological|OVX836 480µg|One single administration intramuscularly at Day 1
79557482|NCT05734040|Biological|Fluarix Tetra|One single administration intramuscularly at Day 1
79557483|NCT05734040|Biological|Afluria Quad|One single administration intramuscularly at Day 1
79557484|NCT05734040|Biological|Placebo|One single administration intramuscularly at Day 1
79557485|NCT05732961|Drug|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
79557486|NCT05721261|Device|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
79557487|NCT05721261|Device|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
79720399|NCT03690037|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
79720400|NCT03690037|Drug|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
79720401|NCT00910273|Drug|etanercept|etanercept 50 mg/week
79720402|NCT04202653|Drug|ETV|entecavir 0.5 mg qd
79720403|NCT04202653|Drug|TQ-A3334|TQ-A3334 po qw
79720404|NCT04202653|Drug|TQ-B2450|TQ-B2450 q3w iv
79557488|NCT05714826|Other|Preop Intervention and Monitored Recovery|Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care
79855559|NCT01030042|Drug|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
80019101|NCT04867694|Behavioral|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of [6-59] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
79557489|NCT05714826|Other|Usual Care|ERAS, Usual referral and recovery care, and Standard follow-up protocol
79557490|NCT05706870|Drug|GN-037|GN-037
79557491|NCT05706870|Drug|Clobetasol 17-propionate|Clobetasol 17-propionate
79557492|NCT05706870|Drug|Placebo|Placebo
79855560|NCT00941408|Procedure|Diagnostic tumor core biopsy|
79855561|NCT01024504|Drug|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
79258443|NCT02395042|Drug|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
79855562|NCT01024504|Drug|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
79557493|NCT05704933|Drug|Nivolumab|Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.
79557494|NCT05704933|Drug|Ipilimumab|Ipilimumab is a recombinant, human antibody to CTLA-4.[18-20] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
79557495|NCT05704933|Drug|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.[6] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.
79557496|NCT05704933|Procedure|Standard of Care Craniotomy|Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
79855563|NCT01024504|Drug|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
79855564|NCT00945464|Other|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
79855565|NCT01030120|Drug|etanercept|etanercept 50mg BIW S.Q.
79855566|NCT01030120|Drug|placebo|placebo
79855567|NCT04012112|Device|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
79855568|NCT01024582|Procedure|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
79258444|NCT02395042|Drug|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
79557497|NCT05700201|Behavioral|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
79557498|NCT05700201|Other|standard care|Standard care (psychotherapy)
79557499|NCT05695209|Behavioral|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
79557500|NCT05694364|Drug|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
79557501|NCT05694364|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
79557502|NCT05694364|Biological|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
79855569|NCT01024582|Procedure|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
79258445|NCT02394808|Device|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
79258446|NCT02394808|Device|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
79258447|NCT02630966|Drug|Vedolizumab|Vedolizumab 300 mg IV infusion
79258448|NCT02630966|Drug|Placebo|0.9% sodium chloride IV infusion
79855570|NCT01024582|Radiation|accelerated partial breast irradiation|
80019102|NCT04867694|Behavioral|CMAM compliance|"Weekly follow-up of [6-59] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
79855571|NCT01024582|Radiation|image-guided radiation therapy|
79855572|NCT00941564|Other|Infant Formula milk based|Consume ad lib
80019103|NCT04329598|Other|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
79557506|NCT05677360|Behavioral|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
79720405|NCT00910039|Drug|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
79720406|NCT00910039|Other|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
79855573|NCT00941564|Other|Infant formula milk based|consume ad lib
79557507|NCT05677360|Behavioral|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
79557508|NCT05677360|Behavioral|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
79557509|NCT05673109|Drug|AC176|AC176 will be given orally (PO) on a 28-day cycle.
79855574|NCT00951158|Dietary Supplement|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
80019104|NCT04329598|Other|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
80019105|NCT02135562|Dietary Supplement|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
80019106|NCT02135562|Other|Informational Material|Receive carbohydrate reintroduction handout
79557510|NCT05662306|Drug|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
79720407|NCT00632437|Procedure|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
79720408|NCT00909181|Drug|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
79855575|NCT00951158|Drug|Conjugated Linoleic Acid|Phase I Dose Escalation Study
80019107|NCT02135562|Other|Dietary Education|Receive education on nutrition label reading for carbohydrates
79720409|NCT00909181|Drug|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
79720410|NCT02691169|Drug|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
79720411|NCT03944161|Dietary Supplement|Oral nutrition supplement|Hypercaloric and high protein supplement
79720412|NCT03944161|Other|Nutritional advice|Advice given by the clinician
79720413|NCT04268797|Device|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
79720414|NCT04268797|Device|sham|SHAM HF rTMS coil once daily x 20 days
79258449|NCT05453942|Drug|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
79258450|NCT05453942|Drug|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
79720415|NCT01286987|Drug|Talazoparib|Oral capsule with multiple dosage forms given once daily
79258451|NCT05446220|Behavioral|Lifestyle intervention|Dietary advise and/or advise on physical activity monitored by pedometer
79396852|NCT01794507|Drug|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
79720417|NCT01286753|Drug|Vemurafenib|Vemurafenib 960 mg orally twice daily.
79720418|NCT01286129|Procedure|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
79396853|NCT00412425|Drug|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
79258452|NCT05724992|Genetic|Saliva swab testing|41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
79396854|NCT01492361|Drug|AMR101|Parallel Assignment
79258453|NCT05724212|Diagnostic Test|Interferon gamma release assay (IGRA)|in vitro test
79258454|NCT01651780|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
79258455|NCT01651780|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
79258456|NCT05723354|Procedure|axillary block guided by ultrasound|axillary block using local anesthetics
79258457|NCT02394730|Drug|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
79396855|NCT01492361|Drug|Placebo|Parallel Assignment
79258458|NCT02394730|Drug|Placebo|Sugar pill taken orally once daily for 12 weeks
79258459|NCT04926610|Other|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
79557511|NCT05662306|Behavioral|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
79557512|NCT05660746|Device|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
79557513|NCT05660746|Drug|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
79557514|NCT05655689|Drug|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79720419|NCT05590013|Drug|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
79258460|NCT02430532|Drug|dimethyl fumarate|capsule
79258461|NCT02430532|Other|Placebo|matched placebo capsule
79258463|NCT02394340|Drug|Omeprazole 40 mg|Oral capsule to be taken as per the instructions regarding proper dosing technique.
79258464|NCT02394340|Drug|Luliconazole Cream 1%|Topical cream to be applied as per the instructions regarding proper study drug application technique.
79258465|NCT01672736|Drug|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
79258466|NCT05337410|Behavioral|YES-ERACE|YES-ERACE is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES-ERACE curriculum empowers youth from diverse backgrounds to address racism and racial discrimination as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting inclusion, diversity, equity, appreciation, and solidarity in their community.
79258467|NCT05686850|Procedure|High-Flow Oxygen|Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
79396856|NCT01492361|Drug|Statin therapy|Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C >40 mg/dL and ≤100 mg/dL)
79396857|NCT00415857|Biological|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
79396858|NCT00415857|Drug|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
79396859|NCT00415857|Drug|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
79396860|NCT00415857|Drug|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
79396861|NCT03586635|Other|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
79720420|NCT05566925|Other|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
79720421|NCT01285349|Behavioral|Couple HIV/STI prevention intervention|
79720422|NCT01285349|Behavioral|Couple-based HIV/STI prevention|
80019108|NCT02135562|Dietary Supplement|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
79258468|NCT05686850|Procedure|Non invasive ventilation|NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
79258469|NCT03065660|Drug|Mifepristone, Oral, 200 Mg|The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
79258470|NCT03065660|Drug|Placebo Oral Tablet|The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
79557515|NCT05655689|Drug|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79720423|NCT01285349|Behavioral|Individual HIV/STI prevention|
79720424|NCT01285349|Behavioral|Couple Wellness Promotion|
79258471|NCT03065348|Dietary Supplement|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
79258472|NCT03065348|Dietary Supplement|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
79720425|NCT01284959|Drug|risperidone|risperidone 3mg, PO, 3 times
79720426|NCT01284959|Drug|paliperidone ER|paliperidone ER 6mg, PO,3 times
79720427|NCT01284959|Drug|placebo|lactose PO, 3times
79720428|NCT01284491|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
79258473|NCT03065348|Dietary Supplement|Carbohydrate Drink|"Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, < 10mg sodium, 190kcal"
79258474|NCT03065348|Other|Preoperative hydration|If urine specific gravity is >1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
79258475|NCT03065348|Other|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
79258476|NCT03065270|Other|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
79720429|NCT01284491|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
79720430|NCT01283009|Drug|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
79258477|NCT03065270|Other|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
79720431|NCT01283009|Drug|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
79720432|NCT05659277|Other|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
79720433|NCT01282463|Drug|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
79557516|NCT05655689|Drug|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79720434|NCT01282463|Biological|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
79720435|NCT01282463|Biological|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
79720436|NCT01282229|Device|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
79720437|NCT01281917|Drug|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
79557517|NCT05655689|Drug|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79720438|NCT01281917|Drug|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
79720439|NCT01281839|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
79720440|NCT01281839|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
79720441|NCT01281839|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
79720442|NCT01281839|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
79258480|NCT03893630|Drug|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
79396862|NCT03529071|Behavioral|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
79720443|NCT01281137|Genetic|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
79396863|NCT03491631|Drug|SHR9146+SHR-1210|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
79396864|NCT03491631|Drug|SHR9146+SHR-1210+Apatinib|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
79396865|NCT01794585|Behavioral|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
79396866|NCT01794585|Behavioral|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
79396867|NCT03464175|Device|Aerogen Solo®|Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
79396868|NCT03464175|Device|Heated-humidified circuit|It will be left on during the transfer and the nebulization in group 1
79720444|NCT01281137|Other|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
80019109|NCT02135562|Other|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
80019110|NCT04854746|Biological|VXA-GI.1.NN|GI.1 oral vaccine tablet
80019111|NCT04854746|Biological|Placebo Tablet|Tablets matching in number and appearance to active vaccine tablets
79258481|NCT03893630|Drug|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
79258482|NCT03893630|Other|Control|Standard of Care
79258483|NCT04879238|Behavioral|BEING|60 minute yoga session that blends mindfulness techniques
79396869|NCT03464175|Device|Heated-humidified circuit|It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).
79396870|NCT03464175|Device|Dry ventilator circuit specific for aerosol therapy|Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece
79396871|NCT03464175|Device|Conventional dry ventilator circuit with HME filter|The nebulizer is placed between the filter and the endotracheal tube.
79396872|NCT03442335|Diagnostic Test|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
79720445|NCT01281137|Procedure|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
79720446|NCT01280981|Drug|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
79855576|NCT00951236|Drug|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
79855577|NCT00951236|Drug|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
80019112|NCT03647865|Procedure|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
79258484|NCT03066986|Drug|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
79258485|NCT03066986|Biological|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely <20mcg. Therefore minimum effective maintenance dose not yet defined."
79258486|NCT03065816|Drug|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
79258487|NCT03065816|Drug|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
79258488|NCT05619848|Drug|Rocuronium Bromide|0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
79258489|NCT03066674|Other|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
79396873|NCT03442335|Diagnostic Test|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
79396874|NCT00416793|Drug|bortezomib|Given IV
79396875|NCT00416793|Drug|carboplatin|Given IV
79396876|NCT00416793|Other|laboratory biomarker analysis|Correlative studies
80019113|NCT05118841|Drug|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
80019114|NCT04255342|Device|Atlantis Abutment|A gold-hue titanium Atlantis abutment will be connected and secured to the implant fixture, and a provisional screwmentable PMMA crown seated to verify marginal adaptation, proximal contact intensity, and occlusion. Upon any necessary modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
80019115|NCT04255342|Procedure|Intra-oral photographs|Intra-oral photographs of the sites of interest will be obtained
80019116|NCT04255342|Device|provisional crown (te + 12 weeks)|modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
80019117|NCT04255342|Other|medical history|medical history updated to medical record
79557518|NCT05655689|Drug|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79557519|NCT05655689|Drug|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79557520|NCT05655689|Drug|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79720447|NCT01280903|Behavioral|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
79855578|NCT00945542|Other|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
80019118|NCT04255342|Other|dental history|dental history updated to medical record
80019119|NCT04255342|Procedure|suture removal|sutures will be removed
79557521|NCT05655689|Drug|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
79855579|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
79855580|NCT00438256|Procedure|Proton Beam Radiation|Given over different schedules and duration
79855581|NCT00438256|Drug|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
79855582|NCT00951392|Drug|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
80019120|NCT04255342|Procedure|intra-oral digital scan|An intra-oral digital scan of the arch will be obtained using an intra-oral scanner
79258490|NCT03066674|Other|Control group|TENS,Exercises,Postural education ,Home exercises program.
79258491|NCT03066362|Other|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
79258492|NCT01560637|Drug|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
79557522|NCT05652205|Drug|Linaclotide|Capsule; oral
79855583|NCT00951392|Procedure|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~Global transcriptome analysis by DNA Chip"
79855584|NCT00951392|Device|indirect calorimetry|energy expenditure measurement
80019121|NCT04255342|Diagnostic Test|wound healing index|Visual assessment of the healing status will be made using a wound healing index (WHI)
80019122|NCT04255342|Other|pain|Participants will be asked to report pain in terms of function, comfort and esthetics (PROMs).
80019123|NCT04255342|Other|level of satisfaction|Participants will be asked to report level of satisfaction in terms of function, comfort and esthetics (PROMs).
80019124|NCT04255342|Procedure|debridement|wound will be debrided
79258493|NCT05268380|Diagnostic Test|Covid-19, TB and HIV diagnosis|GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
79557523|NCT05652205|Drug|Placebo for Linaclotide|Capsule; oral
79557524|NCT05639153|Drug|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
79581133|NCT01933087|Behavioral|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
80019125|NCT04255342|Other|oral hygiene|oral hygiene instructions will be given
80019126|NCT04255342|Other|Shade selection|definitive shade selection will occur at this appointment, and a final monolithic screwmentable all-ceramic zirconium-oxide crown will be fabricated from the original Atlantis CoreFile
80019127|NCT04255342|Other|photographs|Intra-oral photographs will be obtained using a dSLR camera
79557525|NCT05637203|Behavioral|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
79720448|NCT01280903|Behavioral|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
80019128|NCT04255342|Procedure|plaque removal|removal of plaque on crown and surrounding teeth
79258494|NCT05416567|Procedure|Endovascular embolization|Therapeutic endovascular embolization in general anesthesia
79720449|NCT04323605|Other|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
79258495|NCT05408455|Other|EMST150 (Expiratory muscle training)|Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
79258496|NCT05408455|Other|Sham EMST150 (Expiratory muscle training)|The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
79855585|NCT00941642|Drug|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
79855586|NCT00941642|Drug|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
80019129|NCT04255342|Other|probing depth|probing depths will be measured
80019130|NCT04255342|Other|Bleeding on probing|bleeding on probing will be recorded
80019131|NCT04255342|Other|recession|recession respective to the incisal/occlusal plane
80019132|NCT04255342|Other|keratinized mucosa height|keratinized mucosa height
79258497|NCT04157036|Drug|Ibuprofen|Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
79258498|NCT04157036|Drug|Methylprednisolone|Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
79258499|NCT03547375|Drug|Apatinib|Apatinib 500mg/d po,28 days as one cycle
79258500|NCT01353911|Drug|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
79720450|NCT01280591|Drug|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
79720451|NCT01280591|Drug|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
79258501|NCT01353911|Drug|Boceprevir|Four 200 mg capsules orally three times daily.
79258502|NCT01353911|Drug|Placebo for Grazoprevir|Orally once daily in AM.
79258503|NCT01353911|Drug|Placebo for Boceprevir|Four capsules orally three times daily.
79396877|NCT00417417|Drug|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
79396878|NCT00417417|Drug|Placebo|Normal saline subcutaneously at each treatment visit.
79396879|NCT05286723|Other|Multicomponent Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
79855587|NCT01031524|Biological|PfCS102|Antigen of the sporozoite protein
79855588|NCT01031524|Biological|Montanide ISA 720|adjuvant alone
80019133|NCT04255342|Other|plaque index|plaque index
80019134|NCT04255342|Other|gingival index|gingival index
80019135|NCT04255342|Device|provisional crown (te + 24 weeks)|modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
80019136|NCT04255342|Device|provisional crown (te + 36 weeks)|modifications and adjustments to the provisional crown, the abutment and crown will be cemented extraorally, disinfected ultrasonically in 0.12% chlorohexidine gluconate, and torqued to 25N/cm2, and screw-access channel obturated with polytetrafluorethylene (PTFE) tape and resin composite.
79258504|NCT01353911|Drug|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
79258505|NCT01353911|Drug|Ribavirin|300 mg to 700 mg orally twice daily.
79557526|NCT05637203|Behavioral|Discharge / Safety Planning|"A written safety plan completed with the person~Mental health appointment scheduled within seven days~One phone follow-up call within 30 days"
79557527|NCT05630872|Drug|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
79720452|NCT01280591|Drug|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
79720453|NCT01280591|Drug|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
79720454|NCT04323683|Genetic|Microarray|High throughput technique for determining global gene expression of the condition of interest
79258506|NCT05575375|Behavioral|Values Affirmation + Usual Care|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. The participant's study medication monitoring devices will be labeled with the participants' most important core value(s). Participants will also continue with their usual care.
79258507|NCT05575375|Other|Usual Care|Participants will be asked to continue with their usual care (e.g., cardiac rehabilitation, ongoing medical management)
79258508|NCT05575297|Drug|Methotrexate Sodium|Methotrexate oral administration alone
79258509|NCT05575297|Drug|Rifampicin Sodium|Co-administration of methotrexate and rifampicin
79258510|NCT05575297|Drug|Febuxostat Tablets|Co-administration of methotrexate and febuxostat
79258511|NCT05575141|Procedure|Component separation (transversus abdominis release)|Component separation by transversus abdominis release, to allow for adequate medialization of the fascial borders and a complete closure of the defect in case of large incisional hernias.
79258512|NCT01671488|Biological|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
79258513|NCT01671488|Drug|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
79258514|NCT01671488|Drug|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
79258515|NCT01671488|Radiation|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
79258516|NCT05574829|Device|Esophageal manometry and monitoring of electrical activity of the diaphragm|Esophageal manometry and monitoring of electrical activity of the diaphragm
79258517|NCT02783911|Device|MTA|Mineral Trioxide Aggregate grey paste
79258518|NCT02783911|Drug|Ferric Sulfate|Ferric Sulfate paste
79258519|NCT05400889|Drug|tofacitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
79258520|NCT01561807|Drug|VX-787|
79258521|NCT01561807|Drug|Placebo|
79258522|NCT04870177|Drug|AK112|AK112 infusion biweekly
79258523|NCT05325229|Drug|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m^2 or 100 mg/m^2 once every 3 weeks.
79258524|NCT05325229|Drug|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
79258525|NCT03547609|Other|No arm intervention|No arm intervention
79557528|NCT05630872|Drug|DTG 50 mg orally QD plus TDF/3TC|DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
79557529|NCT05630872|Drug|2HPZM|Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
79557530|NCT05630872|Drug|2HPM|Daily rifapentine-moxifloxacin plus isoniazid regimen
79557531|NCT05626257|Other|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
79557532|NCT05618808|Drug|REGN9933|Participants will receive a single dose of REGN9933 by IV infusion
79557533|NCT05618808|Drug|Enoxaparin|Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
79557534|NCT05618808|Drug|Apixiban|Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
79557535|NCT05608265|Device|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
79720455|NCT01280357|Device|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
79720456|NCT01280357|Device|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
79720457|NCT04323917|Diagnostic Test|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
79720458|NCT04323761|Drug|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
79720459|NCT05566223|Drug|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
79720460|NCT05566223|Drug|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
79720461|NCT05566223|Biological|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
79720462|NCT05566223|Drug|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
79720463|NCT05566223|Drug|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
79720464|NCT01274351|Drug|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
79720465|NCT01271933|Drug|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
79720466|NCT01271933|Drug|placebo|matching placebo tablet; given once daily
79720467|NCT01269125|Drug|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
79258526|NCT05573581|Drug|Botox|Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
79258527|NCT01358357|Drug|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
79258528|NCT01358357|Drug|Placebo|20-80 mg flexible dose
79396880|NCT00418977|Behavioral|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
79557536|NCT05598294|Procedure|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
79557537|NCT05590247|Behavioral|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
79557538|NCT05581407|Biological|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
79557539|NCT05579639|Other|Xylitol|Xylitol wipes
79557540|NCT05579639|Other|Placebo|Placebo wipes
79557541|NCT05573022|Other|Pre-consultation electronic patient decision aid|This group is invited to access an electronic version before the consultation. The group of colorectal cancer patients is also introduced to a paper-based version by the clinician in the consultation.
79557542|NCT05573022|Other|In-consultation paper-based patient decision aid|This group is introduced to a paper-based version by the clinician in the consultation
79557543|NCT05570123|Dietary Supplement|Flexofytol Forte|standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
79557544|NCT05570123|Dietary Supplement|Placebo|2 tablets a day, one in the morning, one in the evening
79557545|NCT05566847|Other|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
79557546|NCT05566847|Other|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
79258529|NCT05573425|Drug|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
79258530|NCT05573425|Device|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
79258531|NCT02253901|Drug|BILR 355 BS|
79557548|NCT05565950|Biological|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
79557549|NCT05565950|Biological|Vehicle|Vehicle Formulation
79557550|NCT05539053|Drug|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
79258532|NCT02253901|Drug|Ritonavir|
79557551|NCT05539053|Drug|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
79258533|NCT02253901|Drug|TRUVADA|
79557552|NCT05536804|Drug|Tirzepatide|Administered SC
79557553|NCT05536804|Drug|Placebo|Administered SC
79557554|NCT05536011|Drug|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
79557555|NCT05536011|Drug|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
79557556|NCT05533697|Biological|mRNA-4359|Intramuscular Injection
79557557|NCT05533697|Biological|Pembrolizumab|Intravenous infusion
79720468|NCT01269125|Procedure|IVF|Assisted Reproduction Technique.
79720469|NCT01268891|Drug|Placebo|Once daily; tablet; orally; 18 weeks
79720470|NCT01268891|Drug|Azilect®|1 mg daily; tablet; orally; 18 weeks
79720471|NCT01268501|Device|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
79720472|NCT04323527|Drug|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
79855589|NCT00945620|Drug|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
79855590|NCT00945620|Drug|placebo|Placebo
79258534|NCT03563885|Procedure|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
79258535|NCT03546283|Drug|Placebos|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
79258536|NCT03546283|Drug|Cattle Encephalon Glycoside and Ignotin|The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
79258537|NCT03065114|Other|PGS|chromosome abnormality test from PGS and relationship between embryo development
79258538|NCT03761719|Other|No intervention|No intervention
79258539|NCT02831387|Drug|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
80019137|NCT03646929|Diagnostic Test|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
79557558|NCT05529251|Radiation|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~20 Gy if no more disease is visible (node < 1 cm in large diameter)~24 Gy for nodes <= 2 cm~30 Gy for nodes > 2 cm"
79557559|NCT05529251|Drug|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
79557560|NCT05529251|Drug|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
79720473|NCT01268267|Device|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
79557561|NCT05528133|Radiation|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
79557562|NCT05528133|Radiation|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
79557563|NCT05527977|Behavioral|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
79557564|NCT05516134|Behavioral|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
79557565|NCT05508984|Device|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
79720474|NCT01267253|Drug|Brivanib Alaninate|Given PO
79720475|NCT01267253|Other|Laboratory Biomarker Analysis|Correlative studies
79720476|NCT04378777|Procedure|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study [GWAS]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
79855591|NCT01030276|Other|Bright light therapy|Bright light therapy
79855592|NCT01030276|Other|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
79855593|NCT03814252|Device|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
79855594|NCT02037620|Device|5-6-5 Specify electrode|
79855595|NCT02037620|Device|Restore Advance Pulse Generator|
79258540|NCT02831387|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
79258541|NCT02253511|Drug|Cidan capsule|
79258542|NCT04948736|Combination Product|Combined exercise and nutrition intervention|"Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink."
79855596|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
80019138|NCT03646929|Diagnostic Test|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
79855597|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
79258543|NCT04948736|Other|Conventional medial care|"Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
79258544|NCT02253589|Behavioral|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
79557568|NCT05493709|Drug|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
79557569|NCT05493280|Device|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
79557570|NCT05489679|Drug|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
79557571|NCT05486208|Drug|LY3844583|Administered SC and/or IV.
79557572|NCT05486208|Drug|Placebo|Administered SC and/or IV.
79557573|NCT05474014|Procedure|superior trunk block|Local anesthetic injection will be applied to the superior trunk of the brachial plexus accompanied by ultrasonography.
79557574|NCT05474014|Drug|intravenous patient-controlled analgesia|Analgesics will be given using a patient-controlled analgesia device.
79557575|NCT05473520|Drug|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
79557576|NCT05473520|Drug|Placebo|Placebo + standard anti-tuberculous treatment
79720477|NCT04378777|Procedure|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
79720478|NCT02889419|Device|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
79720479|NCT02889497|Biological|the first batch vaccine|
79720480|NCT02889497|Biological|the second batch vaccine|
79258545|NCT03563573|Drug|Potassium Gluconate Oral Capsule|Each subject will receive a dose of ~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.
79258546|NCT03563573|Drug|Placebo oral capsule|Each subject will receive a dose of ~8 mg/kg of a placebo capsule
79258547|NCT05555719|Device|Mandibular Protraction Appliance|Mandibular Protraction Appliance was installed on fixed orthodontic appliance
79258548|NCT05555719|Device|PowerScope Appliance|PowerScope Appliance was installed on fixed orthodontic appliance
79258549|NCT02259881|Drug|Low dose of BIBT 986 CL, per i.v. infusion|
79258550|NCT02259881|Drug|Medium dose of BIBT 986 CL, per i.v. infusion|
79258551|NCT02259881|Drug|High dose of BIBT 986 CL, per i.v. infusion|
79258552|NCT02259881|Drug|Placebo|
79258553|NCT02259881|Drug|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
79557577|NCT05466279|Drug|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
79557578|NCT05466279|Drug|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
79557579|NCT05466279|Drug|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
79557580|NCT05462639|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
79557581|NCT05459636|Device|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
79720481|NCT02889497|Biological|the third batch vaccine|
79720482|NCT01266317|Drug|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
79720483|NCT01266161|Drug|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
79720484|NCT01266161|Drug|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
79720485|NCT01265849|Biological|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
79855598|NCT00951470|Other|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
79258554|NCT05543239|Device|Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) works by stimulating the auricular branches of the vagus nerve (mainly distributed in the concha cavity and conchae) through electrical impulses.Electrodes were placed on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. Stimulation pulses (frequency 30 Hz, pulse width 300 us) were generated by TaVNS device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then descend within 15 seconds to the maximum tolerable amount without pain. Inform the subject that target stimulus has been reached, then stimulate for 30 minutes."
79258555|NCT05543239|Device|Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)|"Place electrodes on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. The same stimulation pulses (30 Hz frequency, 300 us pulse width) were generated by the same device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then ramps down to zero stimulus over 15 seconds. The subjects were told that the target stimulus has been reached. Patients receive sham stimulation for 30minutes."
79396881|NCT00418977|Behavioral|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
79396882|NCT05286645|Device|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
79557582|NCT05459636|Device|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
79396883|NCT05286645|Device|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
79720486|NCT01265849|Drug|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
79557583|NCT05458128|Drug|Pitolisant|"Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets"
79557584|NCT05457257|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
79720487|NCT01265849|Drug|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
79557585|NCT05457257|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
79720488|NCT01265849|Dietary Supplement|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
79720489|NCT01265849|Procedure|Surgery|Excise tumor and nodes
79720490|NCT01265849|Drug|Cisplatin|Cisplatin was administered 100mg/m^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
79720491|NCT01265849|Radiation|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
79720492|NCT01265615|Drug|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
79720493|NCT01265615|Drug|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
79855599|NCT00951470|Other|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
79557586|NCT05457257|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
79557587|NCT05457257|Drug|Prednisone|5mg(5mg x 1 tablet) twice daily
79557588|NCT05456581|Behavioral|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
79557589|NCT05456581|Behavioral|Control Training|The task will be performed in the control group without the visible scotoma.
79557590|NCT05456256|Drug|LP-300|LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
79557591|NCT05456256|Drug|Pemetrexed|Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
79258556|NCT05708261|Behavioral|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
79258557|NCT05708261|Other|Be Well Attention Match|Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
79258558|NCT04132778|Device|AsthmaTuner|Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
79855600|NCT00951470|Other|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
79855601|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
79855602|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
79720494|NCT01265615|Drug|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
79557592|NCT05456256|Drug|Carboplatin|Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
79557593|NCT05438602|Drug|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
79557594|NCT05438602|Drug|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
79557595|NCT05438602|Drug|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
79557596|NCT05438602|Drug|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
79557597|NCT05436093|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
79720495|NCT01265615|Dietary Supplement|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
79258559|NCT03563807|Other|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
79720496|NCT05545865|Other|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
79720497|NCT05545865|Other|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
79258560|NCT03563807|Other|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
79258561|NCT03547219|Drug|Escitalopram|
79258562|NCT05269069|Other|Assessment of body composition, bone mineral density and bone marrow adiposity.|DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
79258563|NCT05265091|Drug|KL590586 Capsule|Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
79557598|NCT05432817|Behavioral|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
79720498|NCT05545865|Other|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
79720499|NCT05545865|Other|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
79258564|NCT03064880|Other|SV maximization|Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change < 10% and maintained for 20 minutes
79258565|NCT05521945|Behavioral|Intermittent Fasting|16 hours fasting and 8 hours eating window
79720500|NCT05545865|Other|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
79720501|NCT01264835|Device|Slotted Anoscope|SA411
79720502|NCT00623909|Device|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
79720503|NCT01264679|Drug|Ferumoxytol|IV Ferumoxytol
79720504|NCT02889341|Dietary Supplement|DHA|
79720505|NCT02889341|Other|Placebo|
79855603|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
79855604|NCT00951548|Dietary Supplement|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
79855605|NCT00951548|Dietary Supplement|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
79855606|NCT01031602|Behavioral|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
79258566|NCT05521945|Behavioral|Calorie Restricted Diet|The customized diet plan will be given to the participants according to their calorie intake requirements
79557599|NCT05432817|Behavioral|Therapist-facilitated Support group|Therapist-facilitated Support: group therapy oriented toward providing general support networks and communities of individuals with similar experiences. Sessions will also focus on establishing trust, open communication, and developing therapeutic alliance with group members and the therapist facilitator. Occurs over 12 sessions.
79720506|NCT05542043|Other|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
79720507|NCT01263665|Device|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
79855607|NCT00951626|Behavioral|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
79855608|NCT00951626|Behavioral|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
79855609|NCT00951626|Dietary Supplement|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
79855610|NCT00951626|Other|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
79855611|NCT00951626|Other|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
79258567|NCT05521945|Behavioral|Normal dietary intake|normal diet without any customization
79855612|NCT00951626|Procedure|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
79855613|NCT00951626|Procedure|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
79855614|NCT00951626|Procedure|assessment of therapy complications|Collected throughout the 12 month study period
79855615|NCT00951626|Procedure|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
79855616|NCT00951626|Procedure|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
79855617|NCT00951626|Procedure|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
79855618|NCT00951626|Procedure|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
79855619|NCT03994666|Biological|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
79855620|NCT03994666|Biological|Placebo (NaCl)|Placebo injection
79855621|NCT00951782|Device|High frequency TMS|deep TMS HADD coil
79855622|NCT00951782|Device|Sham TMS|sham deep TMS HADD coil
79258568|NCT05518201|Biological|Placebo among 18-45 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
79855623|NCT00951782|Device|Low frequency TMS|Deep TMS - HADD coil
79855624|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
79258569|NCT05518201|Biological|Placebo among 9-17 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
79258570|NCT03064802|Device|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
79557600|NCT05428826|Drug|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
79557601|NCT05422222|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
79557602|NCT05421741|Drug|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
79557603|NCT05421741|Other|Standard Intramedullary Nail|Standard Intramedullary Nail
79557604|NCT05414474|Other|Reference|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
79557605|NCT05414474|Other|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
79557606|NCT05414474|Other|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
79557607|NCT05414474|Other|Coffee|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
79557608|NCT05414474|Other|Breakfast|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
79855625|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
79855626|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
79258571|NCT02253667|Device|HFONC|
79258572|NCT02253667|Device|Conventional oxygen therapy|
79557609|NCT05414474|Other|Afternoon|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
79720508|NCT04323371|Diagnostic Test|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
79720509|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
79720510|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
79855627|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
79855628|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
79855629|NCT00945698|Dietary Supplement|Maize-soy flour|"No food supplement during the primary trial period (6 to 18 months of age)~1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
79855630|NCT01565824|Other|web-based support|
79855631|NCT01030510|Drug|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
79855632|NCT00941876|Behavioral|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
79855633|NCT04813822|Drug|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
79855634|NCT04813822|Drug|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
79855635|NCT04813822|Drug|Miconazole Nitrate 2%|Active Comparator
79855636|NCT00951860|Other|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
79855637|NCT00945776|Behavioral|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
79258573|NCT03065036|Drug|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
79258574|NCT04625413|Behavioral|Behavioral: UR-GOAL communication tool|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
79258575|NCT04069819|Drug|Cilostazol 50 MG Oral Tablet|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
79557614|NCT05399381|Device|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
79557615|NCT05369208|Drug|Avatrombopag Oral Tablet|Avatrombopag 20 mg given once daily (initial dose). Dose adjustments will be determined by the physician and in accordance with the overseas Doptelet prescribing information.
79557616|NCT05363111|Biological|Actinium Ac 225-DOTA-Daratumumab|Given IV
79557617|NCT05363111|Biological|Daratumumab|Given IV
79557618|NCT05363111|Biological|Indium In 111-DOTA-Daratumumab|Given IV
79557619|NCT06235424|Drug|Del Nido Cardioplegia Solution|The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4*C.
79557620|NCT06235424|Drug|HTK solution|The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4*C
79557621|NCT06235411|Drug|Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 25 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
79581134|NCT01933100|Other|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
79581135|NCT01933126|Drug|HCG injection|
79720511|NCT01263197|Drug|LY2216684|administered orally
79720512|NCT01263197|Drug|albuterol|administered orally
79720513|NCT01263197|Drug|propranolol|administered orally
79855638|NCT00945776|Behavioral|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
79855639|NCT00945776|Behavioral|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
79720514|NCT01263197|Drug|placebo for LY2216684|administered orally
79720515|NCT01263197|Drug|placebo for albuterol|administered orally
79720516|NCT01263197|Drug|placebo for propranolol|administered orally
79720517|NCT01263119|Drug|Warfarin|10-mg warfarin oral dose
79720518|NCT01263119|Drug|LY2216684|18-mg LY2216684 oral dose
79720519|NCT05537597|Procedure|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
79720520|NCT05537597|Procedure|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
79720521|NCT01262651|Drug|Nabiximols|
79720522|NCT01262651|Drug|Placebo (GA-0034)|
79720523|NCT01262573|Procedure|Closure of vaginal cuff|Closure of the vaginal cuff
79720524|NCT04323059|Dietary Supplement|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
79720525|NCT04323215|Device|Support system|A support system named Provement will be used to provide behavioral treatment.
79720526|NCT04322903|Behavioral|Passport to Freedom (P2F)|During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
79720527|NCT04322045|Diagnostic Test|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
79720528|NCT04322201|Device|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
79258576|NCT04069819|Drug|Escitalopram|Escitalopram 20 mg tablet once daily for 6 week
79258577|NCT04069819|Drug|Placebo|placebo
79720529|NCT04322201|Procedure|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
79720530|NCT02889185|Device|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
79855640|NCT02917564|Drug|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
79855641|NCT02917564|Other|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
79855642|NCT00941954|Behavioral|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
79396884|NCT04271631|Other|Mobile Application-Based Diabetes Education|Additional education was given using application, subjects were asked to open the application at least once a day
79557622|NCT06235411|Drug|Inactive Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 1 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
79855643|NCT00941954|Behavioral|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
79258578|NCT03064646|Other|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
79720531|NCT01262027|Drug|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
79720532|NCT01261793|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
79258579|NCT03545815|Biological|anti-mesothelin CAR-T cells|Cells will be infused on day 0.
79258580|NCT03064724|Behavioral|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
79258581|NCT04102514|Behavioral|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
79258582|NCT04102514|Behavioral|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
79396885|NCT04271631|Other|Health Coaching|Health coaching was given as face to face with a coach
79557623|NCT06235411|Other|Electroencephalogram|"Rest EEG prior to first treatment administration~EEG during first treatment administration~Rest EEG during integration session after second treatment administration"
79557624|NCT06235398|Biological|Hematopoietic stem-cell transplantation|Upfront related donor transplantation
79258583|NCT04084496|Drug|Folfirinox|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
79396886|NCT02539563|Other|peanut shaped birthing ball|peanut ball will be utilized
79396887|NCT00419445|Drug|GTS21/Placebo|
79396888|NCT00420147|Device|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
79396889|NCT00420147|Device|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
79557625|NCT06235385|Other|Intervention not provided|This study is purely observational
79557626|NCT06235359|Device|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
79557627|NCT06235333|Behavioral|Gambling Disorder Screening Day screener|See descriptions
79557628|NCT06235333|Behavioral|Gambling Disorder Screening Day information sheet|See descriptions
79581136|NCT01933126|Drug|Placebo|
79581137|NCT01933139|Other|Audio-visual presentation|
79720533|NCT01261793|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
79720534|NCT01261793|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
79720535|NCT04321967|Drug|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
79720536|NCT04321967|Drug|Dermabond|Topical skin adhesive
79557629|NCT06235307|Other|motivational interviewing|Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
79557630|NCT06235294|Dietary Supplement|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
79557631|NCT06235294|Dietary Supplement|Folic acid|Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
79855644|NCT03079414|Procedure|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
79258584|NCT02831855|Drug|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
79258585|NCT02831855|Drug|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
79258586|NCT02831855|Drug|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
79557632|NCT06235281|Drug|Mogamulizumab-Kpkc|Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.
79720537|NCT04321655|Other|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
79258587|NCT05167448|Drug|ES104|ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79557633|NCT06235281|Device|Phototherapy|Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
79557634|NCT06235268|Other|Active systemic or non-systemic treatment (palliative or observation procedure)|The study includes medical visits and clinical-radiological re-evaluations according to clinical practice. The clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen.
79557635|NCT06235255|Behavioral|Guided Imagery|The participant will complete the Guided Imagery Intervention for 21 consecutive days.
79557636|NCT06235255|Behavioral|Cognitive Power Intervention|The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
79557637|NCT06235255|Behavioral|Combined Guided Imagery and Cognitive Power Intervention|This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
79557638|NCT06235216|Drug|Sacituzumab govitecan|Dose of 10 mg/kg intravenously
79557639|NCT06235203|Procedure|endoscopic surgery|The tumor was resected by endoscopic nasopharyngectomy.
79557640|NCT06235203|Drug|Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy|Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
79258588|NCT05167448|Drug|ES104|ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79258589|NCT05167448|Drug|ES104|ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
79557641|NCT06235203|Drug|Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy|Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
79855645|NCT00945932|Drug|GW870086X|Investigational product
79855646|NCT00945932|Drug|Placebo|Placebo control
79557642|NCT06235203|Drug|Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy|Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
79557643|NCT06235190|Device|Felix NeuroAI Wristband|The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
79557644|NCT06235190|Device|Sham Device|The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).
79581138|NCT01933152|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
79581139|NCT01933165|Device|LipiView|
79581140|NCT01933178|Device|Cirrus AS-OCT|
79720538|NCT04321655|Other|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
79720539|NCT04321655|Other|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
80019139|NCT04052919|Other|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
80019140|NCT02135640|Drug|denosumab 60mg|solution
79557645|NCT06235177|Combination Product|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
80019141|NCT02135640|Drug|denosumab 120 mg|solution
80019142|NCT02135640|Drug|placebo|solution
79258590|NCT03064412|Biological|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
79258591|NCT03064412|Biological|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
79258592|NCT02628938|Other|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
79258593|NCT02628938|Other|Miswak stick|Miswak stick twice a day for 7 days
79557646|NCT06235177|Dietary Supplement|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
79557647|NCT06235177|Other|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
79557648|NCT06235177|Diagnostic Test|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
79720540|NCT04321655|Other|Conventional Physiotherapy (CPT)|"Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~Heel raise ( 3sets X10 Reps X 3 min rest in between)~One leg balance ( 3sets X10 Reps X 3 min rest in between)~Step ups ( 3sets X10 Reps X 3 min rest in between)~Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
80019143|NCT03647787|Other|observational study|This study is a longitudinal observational study
80019144|NCT02784834|Drug|dimethyl fumarate|
79258594|NCT02628938|Other|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
80019145|NCT03862274|Other|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
79258595|NCT04904510|Diagnostic Test|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
79258596|NCT01356407|Drug|PICOPREP|
79258597|NCT01356407|Drug|PEG-ELS|
79277439|NCT03529279|Drug|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA > 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
79557649|NCT06235177|Dietary Supplement|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
80019146|NCT04564495|Behavioral|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
80019147|NCT02140398|Procedure|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
80019148|NCT04467710|Procedure|Laparoscopic common bile duct exploration.|"Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time."
80019149|NCT05284695|Procedure|Bariatric surgery|Patients undergoing elective bariatric surgery
79258598|NCT04433312|Other|Questionnaire|The questionnaire is developed based on a literature review and clinical experience. Initial testing of the questionnaire will be performed with 20 patients to assess the reliability and inter-rater variations. After initial testing, the final questionnaire will be formulated. The first sector of the questionnaire includes patient demographics and baseline characteristics; the second sector is regarding patient clinical condition, diagnosis, and scheduled surgery. The following sector examines the process of delivering the cancellation to the patient and requirements for re-scheduling. Patients will be classified into satisfied or dissatisfied according to the responses in this sector. The following sector addresses the course of care after cancellation and whether the patient conducted the surgery elsewhere or not. The last sector explores the impact of cancellation on patient health, career, and financial aspects.
80019150|NCT04468022|Procedure|Toric Trifocal IOL|Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
80019151|NCT02140476|Device|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
80019152|NCT02140476|Procedure|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
79258599|NCT05708027|Procedure|Thoracoscopic surgical ablation|Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
79258600|NCT05228717|Diagnostic Test|Point of Care Ultrasound|q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
79258601|NCT03563495|Other|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
79258602|NCT03563495|Procedure|autogenous bone graft group|
79258603|NCT00109837|Biological|filgrastim|As needed per physician discretion
79557650|NCT06235177|Behavioral|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
79720541|NCT04207541|Behavioral|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
79720542|NCT05532605|Other|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
79855647|NCT01031758|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
79855648|NCT05300828|Drug|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
79855649|NCT05300750|Other|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
79258604|NCT00109837|Drug|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
79258605|NCT00109837|Drug|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
79258606|NCT00109837|Drug|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
79258607|NCT00109837|Drug|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
79258608|NCT00109837|Drug|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
79720543|NCT05532605|Other|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
79720544|NCT04321499|Genetic|lung cancer|PCR for SHOX2 and PTGER4
79720545|NCT04321577|Procedure|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
79258609|NCT00109837|Drug|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC < 3,000
79855650|NCT05300750|Other|Chewing gum|Chewed free sugar gum for 15 minutes
79855651|NCT00952016|Drug|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
79855652|NCT00952094|Drug|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
79855653|NCT00942110|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
79855654|NCT00942344|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
79855655|NCT00942344|Drug|Amlodipine|amlodipine 5mg, 10mg
79855656|NCT00942344|Drug|Losartan|Losartan 50mg, 100mg
79258610|NCT00109837|Drug|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
79720546|NCT04321889|Device|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
79720547|NCT04321889|Other|Placebo|nanotechnological system loaded with placebo cream
79720548|NCT04321421|Other|hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
79855657|NCT00952172|Behavioral|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
79720549|NCT02889107|Other|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
79855658|NCT00952250|Behavioral|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
79855659|NCT00952250|Behavioral|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
80019153|NCT03133364|Other|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
79258611|NCT00109837|Drug|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
79258612|NCT00109837|Drug|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
79258613|NCT00109837|Drug|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
79855660|NCT00952328|Dietary Supplement|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
79855661|NCT00952406|Other|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
79855662|NCT00946010|Biological|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
79855663|NCT00436852|Drug|ABT-751|Given orally
79258614|NCT00109837|Drug|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
79258615|NCT00109837|Drug|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
79258616|NCT00109837|Drug|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
79855664|NCT00436852|Procedure|quality-of-life assessment|Ancillary studies
79720550|NCT04320875|Other|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
80019154|NCT02966223|Radiation|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
80019155|NCT04157179|Other|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
80019156|NCT02253342|Drug|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
79258617|NCT00109837|Radiation|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
79258618|NCT00109837|Drug|allopurinol|300 mg/d PO Days 1-7
79557651|NCT06235177|Behavioral|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
79720551|NCT04320875|Other|Conventional Physiotherapy|"Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~Heel raise ( 3sets X10 Reps X 3 min rest in between)~One leg balance ( 3sets X10 Reps X 3 min rest in between)~Step ups ( 3sets X10 Reps X 3 min rest in between)~Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
79720552|NCT01261325|Drug|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
79855665|NCT00946166|Drug|simvastatin|40 mg daily in the evening for a maximum of 14 days
79855666|NCT00946166|Drug|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
79855667|NCT00952562|Dietary Supplement|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
79855668|NCT00952562|Dietary Supplement|placebo|Empty capsules, 3 capsules per day for 16 weeks
79855669|NCT00952640|Dietary Supplement|vitamin A|high dose vitamin A, 200.000 IU
80019157|NCT03844022|Diagnostic Test|MRI|magnetic resonance imaging
80019158|NCT02252874|Behavioral|Slow-paced action video game|20 hours slow-paced action video games
80019159|NCT02252874|Behavioral|Fast-paced action video game|20 hours fast-paced action video games
80019160|NCT02252874|Behavioral|Control|20 hours leisure activities
80019161|NCT05284461|Device|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
79258619|NCT00109837|Drug|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
79258620|NCT03547141|Drug|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
79258621|NCT03547141|Drug|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
79720553|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
79720554|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
79720555|NCT01261325|Drug|Antiepileptic drugs with market authorization available per country|
79720556|NCT01260701|Drug|Akt Inhibitor MK2206|Given PO
79720557|NCT01260467|Drug|memantine|10 milligrams orally twice a day
79720558|NCT01260311|Drug|Fesoterodine|Any dose of Fesoterodine
79720559|NCT00623987|Drug|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
79720560|NCT01259375|Drug|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
79720561|NCT05487053|Procedure|Single-shot adductor canal block|Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.
79720562|NCT05487053|Procedure|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
79720563|NCT05468021|Other|Educational intervention|Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
79720564|NCT02888873|Other|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
79720565|NCT02888873|Other|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
79258622|NCT02253979|Device|Standard double lumen tube|Endotracheal left side double lumen tube
79258623|NCT02253979|Device|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
79258624|NCT05229445|Device|continuous glucose monitor based insulin bolus calculator|Participants will use the bolus calculator with meals to calculate their insulin bolus doses
79258625|NCT02828111|Drug|Patidegib|
79258626|NCT02828111|Drug|Vehicle gel|
79557652|NCT06235177|Behavioral|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
79581141|NCT01933191|Behavioral|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
79581142|NCT01933191|Behavioral|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
79720566|NCT00624143|Drug|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
79720567|NCT05284799|Biological|OVX836 480µg|One single administration intramuscularly at Day 1
79720568|NCT05284799|Biological|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)|One single administration intramuscularly at Day 1
79720569|NCT05284799|Biological|Placebo|One single administration intramuscularly at Day 1
79720570|NCT05245253|Radiation|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
79720571|NCT05154695|Device|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
79720572|NCT05154695|Device|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
79720573|NCT05154695|Drug|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
79720574|NCT02889029|Device|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
79720575|NCT04913129|Other|Exercise Training|8 week home-based exercise therapy 4-5 times/week
79720576|NCT04323995|Other|Sprint Interval Training|Sprint interval training of 2 weeks and more.
79720577|NCT04320641|Other|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
79720578|NCT02888795|Drug|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
79720579|NCT04320095|Device|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
80019162|NCT04802096|Other|inspiratory muscle training|Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.
79855670|NCT00942500|Procedure|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade <2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
80019163|NCT04802096|Other|pulmonary rehabilitation|Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
79720580|NCT04232735|Other|Tool and training|"The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills."
79720581|NCT04005287|Drug|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
80019164|NCT00495508|Drug|Quinine|
80019165|NCT00495508|Drug|artemether / lumefantrine|
79258627|NCT04013945|Dietary Supplement|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
79720582|NCT04005287|Drug|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
79720583|NCT04005287|Drug|Placebo Low Dose|Topical Solution
79720584|NCT04005287|Drug|Placebo High Dose|Topical Solution
79720585|NCT03763799|Procedure|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
79720586|NCT03763799|Procedure|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
80019166|NCT02135718|Device|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
79258628|NCT04013945|Dietary Supplement|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
79258629|NCT01671332|Drug|Docetaxel|IV over 60 minutes, 75 mg/m2
79720587|NCT04319861|Procedure|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
79720588|NCT02888717|Procedure|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~Slices A and C are sent OSNA analysis~Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~Free (-): <250 copies~Micrometastatic (+): 250 ≤ - <5,000 copies,~Macrometastatic (++): ≥ 5000 copies."
79720589|NCT03741569|Device|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
79855671|NCT00952796|Drug|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
79720590|NCT03616379|Behavioral|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
79855672|NCT00952796|Drug|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
80019167|NCT02135718|Device|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
80019168|NCT03646851|Diagnostic Test|Questionnaries|patients will have to do a sputum and to complete some questionnaries
80019169|NCT04793828|Behavioral|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
79258630|NCT01671332|Drug|Suramin|IV over 30 minutes
79258631|NCT01671332|Drug|Docetaxel|IV over 60 minutes. 56 mg/m2
79258632|NCT04433000|Diagnostic Test|Butterfly|Standardized lung ultrasound scan with two different instruments
79258633|NCT04432766|Drug|BAT2020|After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
79720591|NCT03616379|Behavioral|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
79720592|NCT03616379|Behavioral|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
80019170|NCT03549156|Dietary Supplement|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
80019171|NCT03549156|Dietary Supplement|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
80019172|NCT04052451|Biological|MET-2|Subjects will take study medication once daily for the duration of the study
79557653|NCT06235164|Drug|immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab|"Drug: Sintilimab, Nivolumab, and Camrelizumab，One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2.~Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2.~Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2.~Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time"
79557654|NCT06235151|Drug|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
79258634|NCT04856930|Biological|Imsidolimab|Humanized Monoclonal Antibody
79557655|NCT06235125|Drug|Cytalux|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
79720593|NCT04320173|Drug|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
79396890|NCT05286489|Combination Product|Qigong exercise|The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
79396891|NCT00420459|Drug|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
79720594|NCT04320173|Drug|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
79720595|NCT04320173|Drug|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
79720596|NCT04321733|Drug|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
79720597|NCT03002519|Biological|PLX-R18|Intramuscular (IM) administration of PLX-R18
79720598|NCT02915549|Other|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
79855673|NCT00952952|Drug|Mesalamine|
79258635|NCT04856930|Biological|Placebo Solution|Placebo
79258636|NCT03966872|Behavioral|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
79258637|NCT03966872|Behavioral|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
79855674|NCT00953030|Behavioral|COACH|
79258638|NCT05093270|Drug|BGB-23339|Administered orally as a tablet
79258639|NCT05093270|Drug|Placebo|Administered orally as a tablet
79258640|NCT03063242|Drug|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
79258641|NCT03063242|Biological|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
79258642|NCT03062852|Device|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
79258643|NCT03063008|Device|PEEK|"Procedure/Surgery:~TLIF fusion with common PEEK cages."
79258644|NCT03063008|Device|TiPEEK|"Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages."
79258645|NCT03897062|Drug|Suvorexant 20 mg|Placebo controlled double blind suvorexant vs placebo
79396892|NCT01514461|Drug|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
79396893|NCT01514461|Drug|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
79396894|NCT00420771|Drug|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
79396895|NCT00420771|Drug|Placebo|placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
79855675|NCT00953030|Behavioral|RealAge|
79855676|NCT00953108|Drug|quetiapine|300 mg per day
79258646|NCT03897062|Other|placebo|Placebo controlled double blind suvorexant vs placebo
79557656|NCT06235112|Device|Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment|The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).
79258647|NCT01355627|Procedure|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
80019173|NCT03526328|Other|EMR and RFA effect on stem cell marker expression in BE/EAC|Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
79258648|NCT01355627|Procedure|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
79258649|NCT04740710|Behavioral|Breathing and Attention Training|A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.
79258650|NCT03563105|Device|The Ox-Imager Mini (Desaturation)|Vascular Occlusion Test
79258651|NCT05102435|Other|Tool Translation & Validation study|In this English version of POMA scale will be translated into Urdu.
79258652|NCT05085041|Behavioral|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
79258653|NCT03831659|Other|self-questionnaires|After collecting their non-opposition, a self-questionnaire will be given to them. This questionnaire is validated in the literature concerning the diagnosis of migraine. It includes questions about medical history and possible headaches
79258654|NCT05006183|Procedure|PCI|Percutaneous coronary intervention with Drug-Eluting Stents
79258655|NCT03836768|Drug|DTRMWXHS-12|DTRMWXHS-12 capsules: 150 mg, 300 mg
79396896|NCT00426153|Drug|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
79396897|NCT00426153|Drug|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
79396898|NCT01793415|Drug|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
79557657|NCT06235099|Drug|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
79557658|NCT06235086|Drug|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
79720599|NCT02915549|Other|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
79396899|NCT01793415|Other|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
80019174|NCT03549078|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
79396900|NCT04750317|Drug|Tofacitinib|Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
79396901|NCT01996449|Drug|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
79720600|NCT02914301|Device|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
79720601|NCT02914301|Device|Placebo|No Mobile App, Usual care
79720602|NCT02693093|Drug|NI-03|
79720603|NCT02693093|Drug|Placebo|
79396902|NCT01996449|Drug|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
79557659|NCT06235086|Drug|Dulaglutide|Dulaglutide, SC, once a week
79557660|NCT06235060|Other|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
79720604|NCT01613495|Drug|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
79855677|NCT00953108|Drug|escitalopram|escitalopram 10 mg per day
79855678|NCT00953186|Device|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
79557661|NCT06235060|Other|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
79258656|NCT04954547|Behavioral|Subsidy Treatment|Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
79720605|NCT01613495|Drug|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
79258657|NCT04954547|Behavioral|Cash Treatment|Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
79720606|NCT01429493|Radiation|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
79557662|NCT06235034|Other|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
79855679|NCT00953186|Device|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
79855680|NCT00953264|Behavioral|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
79855681|NCT00953342|Behavioral|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
79855682|NCT00953342|Behavioral|Usual care|Standard medical care
79258658|NCT03829397|Diagnostic Test|Questionnaire|Questionnaire
79258659|NCT02673749|Drug|RP-G28|Study drug taken orally
79258660|NCT02673749|Other|Placebo|Placebo taken orally
79258661|NCT00100802|Other|Laboratory Biomarker Analysis|Correlative studies
79855683|NCT00953498|Drug|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
79855684|NCT00953498|Drug|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
79258662|NCT00100802|Drug|Lomustine|Given PO
79258663|NCT00100802|Radiation|Radiation Therapy|Undergo radiation therapy
79258664|NCT00100802|Drug|Temozolomide|Given PO
79557663|NCT06235021|Other|Saffron|"Saffron powder (purchased from Moayeri Copmany2 in Oman, prepared from the stigma of Crocus sativus L.).~Total of 10 mg of saffron powder will be added to 100 ml of distilled water. Then, it will be incubated on a shaker for 24 h. The material will be passed through several layers of muslin cloth. The extracts will then be poured into a round bottom balloon and placed in the freezer at a temperature of -80°C. After freezing, the extracts were placed in a freeze-dryer.~In vacuum, the solvent will be removed and saffron powder will be obtained. After preparing the initial concentration, serial dilution with ratios of one-half and one-third will be performed in sterile vials and one-half of the final concentration will be discarded.~After the preparation of extract, the 0.2% saffron mouthwash will be prepared by mixing the following ingredients: 1. propylene glycol (5 g) 2. saffron extract (0.2 g) 3. polysorbate 80 (1.8 g) 4. sodium benzoate (0.2 g) 5. water (91 g)."
80019175|NCT05284851|Biological|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
79258665|NCT01355159|Drug|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
79258666|NCT01355159|Drug|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
79258667|NCT03064334|Procedure|Total Knee Arthroplasty|surgical knee joints Arthroplasty
79557664|NCT06235021|Other|chlorhexidine mouthwash|commercial product of 0.2% chlorhexidine mouthwash.
79258668|NCT03747380|Other|inspiratory muscle program|pre-operative inspiratory muscular training program
79258669|NCT04763837|Device|Intraureteral stent|This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
79258670|NCT04763837|Device|Conventional Double-J stent|This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
79258671|NCT04661852|Drug|Cabozantinib|PO (dose and schedule based upon dose level and nomogram)
79855685|NCT00942656|Other|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
79855686|NCT00942656|Other|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
79855687|NCT00942656|Other|VA|base diet plus 3.0% energy added from vaccenic acid
79855688|NCT00942656|Other|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
79855689|NCT00942812|Other|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
79855690|NCT00942812|Other|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
79258672|NCT04661852|Drug|Topotecan|IV, over 30 minutes (schedule based upon dose level)
79258673|NCT04661852|Drug|Cyclophosphamide|IV, over 30 minutes (schedule based upon dose level)
79258674|NCT04661852|Drug|Myeloid growth factor|subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
79258675|NCT03562949|Drug|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
79258676|NCT03562949|Drug|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
79557665|NCT06234995|Drug|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
79855691|NCT00943046|Device|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
79855692|NCT04012034|Device|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
79557666|NCT06234995|Device|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
79557667|NCT06234995|Device|Sham DBS|Deep brain stimulation performed with sham stimulation.
79557668|NCT06234995|Device|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
79557669|NCT06234995|Device|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
79855693|NCT04012034|Device|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
79557671|NCT06234943|Other|Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results|Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
79557672|NCT06234930|Device|Audiovisual stimulation VR system|Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
79557673|NCT06234917|Other|EEG-based neurofeedback for brain activity modulation|NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
79557674|NCT06234904|Biological|IBR733 Cell Injection|The minimum initial dose is 5.0×10^9 cells and then escalate to 7.5×10^9 cells and 10.0×10^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
79557675|NCT06234852|Behavioral|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
79557676|NCT06234852|Behavioral|Glucocorticoid maintenance group|Daily 5-mg prednisolone over 24 weeks
79557677|NCT06234839|Dietary Supplement|L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets|Each subject of the experimental group was instructed to dissolve inside the mouth two tablets per day (in the morning and before going to bed at night), during the experimental period of 30 days. The tablets were provided by BioGaia ProDentis® (Stockholm, Sweden). The tablets contained two strains of L. reuteri (DSM-17938 and ATCC PTA 5289), at a dose of 2 x 108 CFU/tablet.
79720607|NCT01429493|Radiation|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
79855694|NCT00946400|Other|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
79855695|NCT00946400|Other|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
79258677|NCT03562949|Drug|Placebo|Placebo Product
79258678|NCT02630186|Drug|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
79855696|NCT05301296|Diagnostic Test|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
79855697|NCT00943358|Biological|MF59 H1N1 vaccine|3.75-7.5ug dose
79855698|NCT00943358|Biological|Plain H1N1 vaccine|7.5-15ug
79258679|NCT02630186|Drug|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
79258680|NCT01669928|Drug|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
79258681|NCT00510848|Procedure|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
79557678|NCT06234813|Other|Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen|"TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~500 µL of whole blood for each point;~7 points for each condition;~Around 4 mL of whole blood will be needed for each patient or healthy subject;~Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported."
79720608|NCT01429493|Radiation|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
79720609|NCT00694733|Drug|Placebo injection|Normal saline injection IM monthly for 4 months
79720610|NCT00694733|Drug|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
79855699|NCT00120289|Drug|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
79855700|NCT00120289|Drug|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
79855701|NCT00946556|Drug|Valacyclovir|1g po od for 2 months
79855702|NCT00946556|Drug|Placebo|Placebo po od for 2 months
79855703|NCT00946634|Drug|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
79855704|NCT00946634|Drug|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
80019176|NCT05284851|Biological|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
79855705|NCT00946634|Drug|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
80019177|NCT05284851|Biological|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
79855706|NCT00953732|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
80019178|NCT03764904|Radiation|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
80019179|NCT03783884|Device|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
79720611|NCT00694733|Drug|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
79720612|NCT00694733|Drug|placebo|Placebo Cream 1ml applied twice daily for four months
80019180|NCT03049735|Drug|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
80019181|NCT03049735|Drug|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
80019182|NCT03049735|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
80019183|NCT03049735|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
80019184|NCT05579028|Dietary Supplement|Nutridrink ONS 200 ml|Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
80019185|NCT03957447|Other|thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
80019186|NCT02135796|Other|Echocardiography|
80019187|NCT03646695|Procedure|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
80019188|NCT03646695|Procedure|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
80019189|NCT03522116|Other|No intervention|No intervention
80019190|NCT03548844|Procedure|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
80019191|NCT03548844|Procedure|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
80019192|NCT04785638|Combination Product|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
79258682|NCT00510848|Procedure|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
79258683|NCT01355081|Drug|Vortioxetine|Vortioxetine tablets
79720613|NCT00694733|Drug|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
79720614|NCT04320953|Device|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
79720615|NCT00242021|Behavioral|Fatty acid composition of a margarine (spread)|
79258684|NCT01355081|Drug|Placebo|Vortioxetine placebo
79258685|NCT04606823|Procedure|Minimally invasive surgery|The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.
79720616|NCT01259297|Drug|Aliskiren|Aliskiren 150/300 mg once daily
79720617|NCT01259297|Drug|Amlodipine|Amlodipine 5 mg
79855707|NCT04011488|Other|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
80019193|NCT05578794|Other|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
80019194|NCT04762472|Drug|Montelukast Oral Tablet|i) Montelukast 10mg daily (tablet) orally x 26 weeks
80019195|NCT04762472|Drug|Montelukast Placebo Oral Tablet|i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
79720618|NCT01259297|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
79855708|NCT01083277|Device|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
79855709|NCT01083277|Other|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
79258686|NCT04606823|Other|Glasgow Benefit Inventory (GBI)|A quality of life-questionnaire is to be completed by the subjects at one occasion.
79258687|NCT04606823|Other|Additional follow-up visits after surgery|There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
79258688|NCT02259959|Drug|Single rising doses of BI 1744 CL, solution for oral inhalation|
79557679|NCT06234813|Other|: PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM|"ROTEM (single measurements)~ROTEM cups will be added~20 µL calcium reagent (STARTEM)~20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported."
79396903|NCT01996449|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
79396904|NCT01996449|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
79557680|NCT06234813|Other|Thrombin Generation Assay (TGA) in PRP using TF trigger|"TGA (single measurements)~The following will be added to well:~20 uL of PRP-Reagent~80 uL of spiked PRP (600 µL/patient at 100 G/L)~20 uL FluCa~Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported."
79720619|NCT01259297|Drug|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
79557681|NCT06234813|Other|Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis|Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min
79720620|NCT01259297|Drug|Placebo for Amlodipine|Placebo for Amlodipine
79720621|NCT01259297|Drug|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
79855710|NCT00943748|Drug|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
79258689|NCT02259959|Drug|Tiotropium, fixed dose, solution for oral inhalation|
79720622|NCT01126437|Drug|tiotropium 18 mcg|HandiHaler
79720623|NCT01126437|Drug|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
79720624|NCT01126437|Drug|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
79720625|NCT01258595|Biological|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
79258690|NCT02259959|Drug|Placebo|
79258691|NCT04983056|Procedure|Necrotesectomy associated with cleanleness stoma|Excision of all necrotised tissues after stool diversion and wound dressing using
79258692|NCT01354223|Device|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
79258693|NCT01354223|Device|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
79258694|NCT03062462|Drug|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
79258695|NCT03062462|Drug|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
79258696|NCT04433078|Drug|Doxycycline|100 MG Tablet
79720626|NCT01258595|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
79720627|NCT05596799|Behavioral|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
79258697|NCT04433078|Drug|Placebo|Placebo Tablet
79258698|NCT04591730|Other|First time father questionnaire self-administration|The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
79258699|NCT03062930|Behavioral|Track 1|Training of non-paretic arm followed by sham condition
79258700|NCT03062930|Behavioral|Track 2|Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
79258701|NCT04458311|Drug|Abiraterone Acetate|Supplied as 125 mg tablets
79258702|NCT04458311|Drug|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
79258703|NCT04982432|Drug|Orismilast|Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
79258704|NCT04382183|Behavioral|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
79720628|NCT01257737|Drug|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine [PAGN] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
80019196|NCT03647397|Device|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
79258705|NCT04382183|Behavioral|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
79557682|NCT06234813|Other|Concizumab|Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
79258706|NCT03062774|Biological|PB-119 injection|
79258707|NCT03064100|Other|Observational Study|Exclusion from the study
79258708|NCT04368533|Other|Livionex Dental Gel|The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
79557683|NCT06234800|Procedure|Removal of failed dental implants|Removal (with various techniques) of failed dental implants.
80019197|NCT01295944|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
79720629|NCT01126359|Drug|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
80019198|NCT01295944|Drug|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
80019199|NCT03647319|Device|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
80019200|NCT03647319|Device|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
80019201|NCT03647319|Device|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
80019202|NCT04742348|Drug|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
79258709|NCT04368533|Other|A standard children's toothpaste containing 1500 ppm fluoride|The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
79258710|NCT03062696|Behavioral|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
79557684|NCT06234748|Radiation|Radiation|"Patients will undergo 2 phases of RT replanning:~Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume_2 wks+ MTV3_2 weeks)+ 3mm margin.~Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV_2 wks + MTV3_4wks)+ 3mm margin~Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose)."
79557685|NCT06234748|Drug|Platinum based chemotherapy|Standard of care therapy, weekly, with either Cisplatin or Carboplatin
79557686|NCT06234722|Drug|Very Low Nicotine Cigarette|Participants will be assigned to one of two investigational cigarette nicotine levels for the duration of the experiment: 0.4mg/g or 15.8mg/g
79557687|NCT06234722|Behavioral|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and only the participants' assigned investigational cigarette will be the only available combustible cigarette.
79258711|NCT04043455|Drug|Olorinab|Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
79258712|NCT04043455|Drug|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
79258713|NCT04043455|Drug|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
79258714|NCT04043455|Drug|Placebo|Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
79258715|NCT04043455|Drug|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
79258716|NCT04043455|Drug|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
79258717|NCT04365959|Procedure|Prone position|The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
79258718|NCT03064256|Behavioral|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
79557688|NCT06234722|Behavioral|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored combustible nicotine products will be the only combustible nicotine products available.
79258719|NCT03064256|Behavioral|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
79855711|NCT00943748|Drug|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
79396905|NCT01996449|Procedure|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
79396906|NCT01996449|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
79396907|NCT01996449|Procedure|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
79396908|NCT01996449|Procedure|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
79396909|NCT00426855|Drug|Bendamustine|starting with 60 mg/m^ 2, IV, dose escalation, weekly d1,8,15 q5w
79557689|NCT06234722|Behavioral|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
79557690|NCT06234696|Other|entrepreneurial intervention|The experimental group will be given psychoeducation for 4 weeks.
79396910|NCT00426855|Drug|Bortezomib|weekly 1.5mg/m^2, IV, d1,8,15,22 q5w
79720630|NCT01126359|Drug|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
79720631|NCT00637533|Procedure|Lumbar sympathetic block with Botulinum Toxin type A|
79396911|NCT01491737|Drug|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
79720632|NCT01125813|Biological|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
79396912|NCT01491737|Drug|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
79720633|NCT00996892|Drug|Cobimetinib|Repeated oral dosing.
79720634|NCT00996892|Drug|Pictilisib|Repeated oral dosing.
79720635|NCT04311645|Drug|Activated charcoal|Activated charcoal
79720636|NCT04311645|Dietary Supplement|Dry seeds|Dry seeds
79258720|NCT03064022|Other|Growth|Some preterm infants grow at higher rates than others
79258721|NCT02627144|Drug|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
79258722|NCT02627144|Drug|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
79258723|NCT04586335|Drug|CYH33|Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
79258724|NCT03062384|Dietary Supplement|AT-001|
79258725|NCT03062384|Dietary Supplement|Placebo|
79396913|NCT01491737|Drug|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
79557691|NCT06234683|Other|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
79557692|NCT06234683|Other|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
79557693|NCT06234670|Other|No intervertion|This study is a retrospective observational study without intervention.
79557694|NCT06234657|Behavioral|Telerehabilitation for stroke patient|The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke PT management from the US Department of Veterans Affairs (2010) 5 and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
79720637|NCT01257581|Drug|creatine|creatine monohydrate powder
79720638|NCT01257581|Drug|tamoxifen|Tamoxifen citrate capsules
79720639|NCT01257503|Drug|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
79720640|NCT01257503|Drug|placebo|liquid made to look like the active homeopathic remedy
79720641|NCT04205032|Device|Test of the different devices integrated in cardiospace II|"The different devices included in CARDIOSPACE II will be tested~Electrocardiogram~Vascular Doppler~LaserDoppler and iontophoresis~Brachial blood pressure~Continuous blood pressure recorded at the finger level~Ultrasound~Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)"
79855712|NCT01326793|Other|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
79855713|NCT00953810|Other|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
79855714|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
79855715|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
79855716|NCT00953888|Drug|AZD5069|Single dose of oral solution.
79855717|NCT00953888|Drug|Placebo|Single dose of oral solution.
79855718|NCT00953966|Other|Genetically modified potatoes|Starch from genetically modified potatoes
80019203|NCT04742348|Drug|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
80019204|NCT03548766|Biological|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
80019205|NCT03548766|Biological|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
79557695|NCT06234644|Other|Standardized Walking Obstacle Course (SWOC)|The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.
79557696|NCT06234644|Other|Conventional Gait Training|Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
80031566|NCT03051568|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
79557697|NCT06234631|Drug|Epidiolex oral solution|"Participants assigned to CBD will take the medication one hour before or two hours after eating a meal.~If participants can't tolerate the full-strength dose, the participant can decrease the dosing to 0.75 milliliter twice a day. If this is still not well tolerated, dosing can further be decreased to 0.75 milliliter once per day in the evening."
79557698|NCT06234631|Other|Placebo|Participants will be instructed to take one hour before or two hours after eating a meal.
79557699|NCT06234618|Other|visual deprivation|A group of patients walking with eyes open and walking with visual deprivation.
79557700|NCT06234605|Drug|HC-7366|HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
79720642|NCT02870452|Behavioral|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
79557701|NCT06234605|Drug|Belzutifan|Belzutifan is a potent and selective HIF-2α inhibitor
79720643|NCT02870452|Behavioral|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
79720644|NCT00995566|Drug|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
79720645|NCT01257425|Drug|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
79720646|NCT00995488|Drug|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
79720647|NCT04293172|Drug|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to <24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight >9 to ≤12 kg) or 15 mg twice a day (body weight >12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
79557702|NCT06234592|Drug|Angiotensin II|Angiotensin II infusion
79557703|NCT06234592|Drug|Vasopressin|Vasopressin infusion
79258726|NCT04981886|Drug|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
79258727|NCT04981886|Drug|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
79258728|NCT03873727|Biological|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
79258729|NCT03873727|Biological|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
79557704|NCT06234592|Drug|Norepinephrine|Standard care vasopressor therapy, norepinephrine infusion
79855719|NCT00954044|Behavioral|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
79855720|NCT00954044|Behavioral|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
79855721|NCT00954200|Drug|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
79855722|NCT00954200|Drug|ibuprofen|10mg/kg syrup - single dose
79855723|NCT00954278|Drug|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
79855724|NCT00550446|Drug|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
79855725|NCT00550446|Drug|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
79855726|NCT00550446|Drug|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
79258730|NCT03873727|Biological|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
79557705|NCT06234579|Diagnostic Test|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
79557706|NCT06234566|Procedure|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
79855727|NCT00550446|Drug|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
79557707|NCT06234566|Procedure|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
79557708|NCT06234540|Procedure|PRP|a-PRP intrauterine instillation before frozen-thawed embryo transfer cycle
79557709|NCT06234540|Other|Standard treatment|Standard treatment
79557710|NCT06234527|Other|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
79557711|NCT06234514|Drug|Jueling Mingmu decoction|Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
79557712|NCT06234514|Drug|intravitreal injections of 0.5mg ranibizumab|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
79557713|NCT06234501|Dietary Supplement|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
79557714|NCT06234501|Other|Placebo|Placebo tablet once daily
79258731|NCT04982276|Biological|AK104 and AK109|Subjects will receive AK104 and AK109 by intravenous administration.
79855728|NCT00550446|Drug|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
79855729|NCT00550446|Drug|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
79258732|NCT04982276|Drug|PTX|Subjects will receive AK104 and AK109 in combination with PTX.
79855730|NCT00550446|Drug|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
79855731|NCT00953472|Drug|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
79258733|NCT03870295|Diagnostic Test|Sympathetic skin response (SSR) measure|Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
79258734|NCT02254057|Drug|BIBT 986 BS - single rising dose|
79557715|NCT06234462|Drug|Amantadine|Participants that have been randomized to the study group will be instructed to begin taking amantadine on the day after this study visit. They will self-administer amantadine 100 mg twice daily (morning and noon) for four weeks
79557716|NCT06234462|Other|Physical, Occupational, Speech Therapy|Physical Therapy (PT) and Occupational Therapy (OT) train patients on breathing exercises and gradual reconditioning. Patients are referred to speech therapy (SLP) for cognitive remediation and metacognitive strategies.
79557717|NCT06234462|Other|Provider Counseling|Clinic providers will provide counseling/education on Long-COVID.
79557718|NCT06234462|Other|Medications for symptoms management|Clinic providers may recommend targeted pharmacologic management for symptoms the patient is experience. As an example, if a patient reports a headache the provider may recommend over-the-counter or prescription medications to target this particular symptom.
79720648|NCT04293172|Drug|Placebo|"Patients in the open-label Run-in period (patients aged 6 to <24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight >9 to ≤12 kg) or 15 mg twice a day (body weight >12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
79258735|NCT02254057|Drug|Placebo|
79258736|NCT04548440|Drug|Sintilimab|Route of administration: Intravenous
79258737|NCT04548440|Drug|Nab paclitaxel|Route of administration: Intravenously over 30min
79258738|NCT04548440|Drug|Cisplatin|Route of administration: Intravenous
79258739|NCT04982120|Device|Repris Needle|Injection of Botox
79258740|NCT04981652|Dietary Supplement|Whole Milk|Participants will consume twice daily whole milk beverages in addition to a standardized diet.
79258741|NCT04981652|Dietary Supplement|Skim Milk|Participants will consume twice daily skim milk beverages in addition to a standardized diet.
79258742|NCT04981652|Dietary Supplement|Almond Beverage|Participants will consume twice daily almond beverages in addition to a standardized diet.
79720649|NCT01256879|Drug|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
79720650|NCT04293250|Procedure|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
79720651|NCT04292938|Dietary Supplement|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
79855732|NCT00953472|Other|no-added salt diet|instruction to reduce salt for one week prior to study
80019206|NCT05284773|Other|Caretaker MUAC screening - training by health workers|Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
79557719|NCT06234449|Procedure|Vaginal pessary before surgery for pelvic organ prolapse|use of vaginal pessary for patients waiting for gynecological surgery for stage III and IV pelvic organ prolapse
80019207|NCT05284773|Other|Caretaker MUAC screening - training by caregivers|Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
80019208|NCT03522038|Procedure|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with <30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
79557720|NCT06234436|Biological|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
79720652|NCT04293718|Other|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
79720653|NCT02869672|Biological|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
79720654|NCT02869672|Biological|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
79720655|NCT01125189|Drug|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
79720656|NCT01125189|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
79720657|NCT01125189|Drug|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
80019209|NCT05495178|Procedure|laparoscopic restorative proctocolectomy|laparoscopic restorative proctocolectomy
80019210|NCT04731584|Biological|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
79557721|NCT06234410|Radiation|Computed tomography coronary angiography (CTCA)|Single CTCA scan prior to kidney transplantation
79557722|NCT06234384|Other|Sarcoidosis diagnosis|Participants have been diagnosed with sarcoidosis.
79720658|NCT01125189|Drug|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
79720659|NCT01125189|Drug|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
79720660|NCT01256567|Biological|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
79720661|NCT01256567|Drug|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
79557723|NCT06234371|Behavioral|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
79557724|NCT06234358|Device|osteosynthesis|calcaneus osteosynthesis is a surgical fixation of a displaced fracture of the calcaneous bone. The surgery is performed under general or regional anesthesia. A scar is made on the lateral side of the ankle below the lateral malleolus. The bone fragments are repositioned as anatomically as possible. They are fixed by a percutaneous nailing fastener.
79557725|NCT06234345|Drug|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
79557726|NCT06234345|Drug|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
79557727|NCT06234332|Other|No Interventions|No intervention This is an observational study without any intervention
79557728|NCT06234319|Diagnostic Test|CXCR4|Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
79720662|NCT00996736|Drug|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
79720663|NCT00996736|Drug|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
79720664|NCT00996658|Drug|Placebo|Placebo matching linagliptin tablets once daily
79720665|NCT00996658|Drug|Linagliptin|Linagliptin tablets once daily
79720666|NCT01124643|Biological|Replagal|0.2 mg/kg administered intravenously [IV] every other week
79720667|NCT04310631|Drug|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
79720668|NCT04309851|Diagnostic Test|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
79720669|NCT05108025|Drug|Topical Powder|Topical Powder mixed with diluent
79720670|NCT05108025|Drug|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
79855733|NCT05279820|Procedure|Partial pulpotomy|Partial pulp tissue amputation
79720671|NCT01256411|Drug|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
79557729|NCT06234280|Device|Implantation of Eluvia stent|Implantation of Eluvia stent
79720672|NCT01256411|Drug|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
79557730|NCT06234254|Behavioral|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
79557731|NCT06234241|Other|Echocardiography|Echocardiography was performed in all enrolled populations.
79720673|NCT01256411|Drug|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
79720674|NCT00996580|Drug|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
79855734|NCT05279820|Procedure|Full Pulpotomy|Full Pulpotomy
79720675|NCT01124175|Drug|Losartan|100 mg Tablets
79557732|NCT06234215|Device|functional electrical stimulation|electrical stimulation during function
79557733|NCT06234215|Other|functional task training|functional exercise
79581143|NCT01933204|Other|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
79720676|NCT01124175|Drug|Cozaar®|100 mg Tablets
79720677|NCT04259554|Device|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
79720678|NCT00625521|Drug|ASF 1096 0.5 % cream applied twice daily|
79720679|NCT00625521|Drug|Cream vehicle for ASF 1096 cream applied twice daily|
79855735|NCT00953550|Drug|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
79855736|NCT00953550|Drug|Succinylcholine|1 mg/kg
79855737|NCT00948870|Drug|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
79855738|NCT05351034|Device|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
79855739|NCT05350956|Drug|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
80019211|NCT02140632|Procedure|Local methylprednisolone acetate and lidnocaine injection|
80019212|NCT02140632|Device|wrist splinting|
80019213|NCT05536375|Other|Exhaled breath condensate collection and blood draw|"Venepuncture- 10mls of blood to be collected~and~Exhaled breath condensate (EBC) collection method- this involved breathing in and out through a disposable device (akin to breathing onto cold glass to produce condensate) with an external cooler device. The R Tube starter kit is a complete disposable EBC collection kit and It has been used in many research clinical investigations."
80019214|NCT02965599|Drug|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
80019215|NCT02965599|Drug|Placebo|Placebo is a white, opaque, gelatin capsule.
79581144|NCT01933204|Drug|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
79581145|NCT01933256|Drug|HIP2B|
79581146|NCT01933256|Drug|Placebo|
79396914|NCT01491737|Drug|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
79396915|NCT00427557|Drug|Fludarabine|30 mg/m^2 by vein for 4 Days (Day -10 through Day -7).
79396916|NCT00427557|Drug|Melphalan|140 mg/m^2 by vein for 1 Day (Day -7).
79396917|NCT00427557|Procedure|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
79396918|NCT00427557|Drug|Rituximab|375 mg/m^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
79396919|NCT00427557|Other|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
79396920|NCT01487863|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
79396921|NCT01487863|Drug|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
79396922|NCT04088305|Drug|Individualized therapy|Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
79581147|NCT01933269|Drug|FACBC|
79720680|NCT01256177|Drug|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
79720681|NCT01256177|Drug|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
79720682|NCT02882451|Dietary Supplement|pinaverium bromide|
79720683|NCT02882451|Dietary Supplement|Vitamin C|
79720684|NCT00999544|Drug|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
79720685|NCT00999544|Drug|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
79720686|NCT00999544|Drug|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
79720687|NCT00999544|Drug|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
79396923|NCT04088227|Drug|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
79396924|NCT04088227|Other|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
79396925|NCT04750629|Device|POC CoviDx™ Rapid Antigen Test|All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
79396926|NCT00427791|Drug|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
79396927|NCT00427791|Radiation|Total Body Irradiation|3 Gy Daily for 4 Days
79258743|NCT04982042|Other|Pulmonary Rehabilitation|The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
79557734|NCT06234176|Behavioral|Personalised psychomotor therapy|"The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment.~The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation.~Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions.~The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted.~During each session, the participant will be required to complete the Duke health profile."
79258744|NCT04981340|Behavioral|Diaphragmatic breathing|Same as previously described
79258745|NCT04981340|Behavioral|Standard urotherapy|Same as previously described
79557735|NCT06234176|Other|Usual treatment|Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
79581148|NCT01933282|Drug|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
79581149|NCT01933282|Drug|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
79720688|NCT00999544|Drug|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
79720689|NCT00999544|Drug|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
79720690|NCT00999544|Drug|Oxycodone 0mg, IN|Oxycodone 0mg, IN
79720691|NCT00999544|Drug|Oxycodone 15mg, IN|Oxycodone 15mg, IN
79720692|NCT00999544|Drug|Oxycodone 30mg, IN|Oxycodone 30mg, IN
79720693|NCT02869984|Drug|Ramosetron|
79258746|NCT03688867|Behavioral|Prehabilitation regimen|"The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log."
79258747|NCT02626520|Drug|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
79258748|NCT02626520|Drug|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
79258749|NCT02626520|Radiation|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
79396928|NCT00427791|Drug|Rituximab|375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
79396929|NCT01487161|Drug|FX006|Single 3 mL intra-articular injection
79396930|NCT01487161|Drug|TCA IR|Single 1 mL intra-articular injection
79396931|NCT00429507|Drug|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
79720694|NCT01124097|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
79720695|NCT01124097|Drug|Placebo|Tablets will be used.
79720696|NCT02882529|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
79720697|NCT01123941|Biological|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
79720698|NCT01123941|Biological|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
79258750|NCT02626520|Procedure|Definitive resection|Definitive surgical resection of primary tumor
79258751|NCT03545659|Other|Mode of relapse/SMN detection|Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.
79258752|NCT04498754|Behavioral|Cognitive Behavior Therapy for Insomnia|8 sessions of treatment for insomnia.
79396932|NCT00429507|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
79396933|NCT00429507|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
79396934|NCT01794897|Drug|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
79396935|NCT01794897|Drug|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
79396936|NCT00098709|Device|Fetal pulse oximeter|
79720699|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
79720700|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
79720701|NCT01255787|Drug|Vortioxetine|Vortioxetine tablets
79720702|NCT01255787|Drug|Placebo|Vortioxetine placebo-matching tablets
79720703|NCT01123161|Device|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
79720704|NCT01123161|Drug|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
79720705|NCT01255631|Device|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
79720706|NCT01255631|Device|Sham PEMF Device|Inactive PEMF device, delivers no PMF
79720707|NCT04540835|Drug|Calcium phosphate desensitizer|Calcium phosphate containing desensitizing agent that creates hydroxyappatite
79720708|NCT00999466|Drug|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
79720709|NCT00999466|Drug|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
79720710|NCT01255163|Drug|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
79720711|NCT01255163|Drug|Placebo SC|Placebo SC twice daily
79720712|NCT01123083|Biological|Otelixizumab|infusion
79720713|NCT01123083|Biological|Placebo|Infusion
79855740|NCT05350956|Drug|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
79258753|NCT04498754|Behavioral|Weekly phone contacts|Weekly calls to monitor insomnia symptoms.
79258754|NCT03063710|Drug|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
79258755|NCT03546985|Device|episil®|Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
79258756|NCT03546985|Device|Kang Su|Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
79396937|NCT01795755|Behavioral|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
79396938|NCT01795755|Behavioral|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
79396939|NCT00371631|Biological|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
79396940|NCT00372957|Drug|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
79396941|NCT00372957|Drug|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
79720714|NCT02870062|Other|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
79720715|NCT02870062|Other|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
79720716|NCT02869516|Other|Clinical data collection|
79720717|NCT02870140|Device|SUPRAFLEX|Percutaneous Coronary Intervention
79720718|NCT02870140|Device|XIENCE|Percutaneous Coronary Intervention
79720719|NCT01254305|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
79720720|NCT01254305|Drug|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
79720721|NCT01254305|Drug|Placebo|Matching placebo capsules, oral administration, once daily dosing
79720722|NCT01122927|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
79720723|NCT02869906|Other|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
79720724|NCT02869828|Device|Monitoring by arterial catheter and Spot-on|
79720725|NCT02869828|Device|Monitoring by oesophagal probe and Spot-on|
79720726|NCT01254227|Drug|Deferasirox and Deferoxamine|
79720727|NCT04311333|Diagnostic Test|Endostomal three-dimensional ultrasonography|Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
79720728|NCT04311333|Diagnostic Test|Computerized tomography of the abdomen|"Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study."
80019216|NCT03524456|Other|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
80019217|NCT05517577|Behavioral|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
80019218|NCT04631848|Device|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
79557736|NCT06234163|Behavioral|Assigned intervention|"Enteral and parenteral nutrition training will be given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature (Weimann et al., 2021; Atabek Aştı and Karadağ; 2020; Koçhan and Akn., 2018; Şenoğlu, 2016; Gök and Özdemir; 2015) will be sent to ten experts in the field. and content validity will be done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition."
79720729|NCT04311333|Diagnostic Test|Clinical examination|Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
79720730|NCT04311333|Diagnostic Test|Evaluation at laparotomy/laparoscopy|During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
79720731|NCT00995410|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
79720732|NCT04311255|Procedure|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
80019219|NCT05578404|Drug|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
79557737|NCT06234137|Drug|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
79720733|NCT02691299|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
79720734|NCT02691299|Drug|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
79720735|NCT00995020|Procedure|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
79855741|NCT00948948|Device|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~Gel-filled device which is available in smooth surface and textured surface (Siltex®)~Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
80019220|NCT05578404|Drug|Placebo|matching placebo to Vit D
80019221|NCT03646539|Behavioral|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
79557738|NCT06234137|Drug|Carboplatin|AUC=6 min/mL iv 3-weekly
79557739|NCT06234137|Drug|Inetetamab|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
79557740|NCT06234137|Drug|Pyrotinib|400mg orally daily
79557741|NCT06234111|Combination Product|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
79557742|NCT06234098|Drug|AT-1965 Liposome Injection|AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
79720736|NCT00995020|Procedure|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
79855742|NCT00953628|Drug|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
79855743|NCT00953628|Drug|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
79557743|NCT06234085|Other|VCA feedback report available|Access to feedback report described in the intervention
79720737|NCT01122381|Drug|ethosuximide|ethosuximide (ESX)
79720738|NCT01122381|Other|placebo comparator|placebo
79720739|NCT00996034|Biological|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
80019222|NCT03646539|Other|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
80019223|NCT03521960|Drug|Buspirone oral capsule|15 milligrams, three times daily
80019224|NCT03521960|Drug|Placebo oral capsule|0 milligrams (placebo), three times daily
80019225|NCT03548922|Other|Tanner stage|a scale of pubertal development in children, adolescents
80019226|NCT03548922|Other|Risser stage|a measure showing the growth left in the spine
80019227|NCT03548922|Other|Pressure of correction|an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
80019228|NCT03548922|Other|Pectus carinatum protrusion|distance from the point of maximum protrusion to the estimated normal level of chest wall
80019229|NCT04616170|Other|Hip extension|Hips extended at the time of vaginal delivery
80019230|NCT04616170|Other|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
79557744|NCT06234059|Device|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
79720740|NCT00996034|Radiation|[123I]5-IA-85380|up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days
80019231|NCT03524300|Procedure|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
79277440|NCT03529279|Drug|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
79396942|NCT00372957|Drug|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
80019232|NCT03524300|Procedure|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
80019233|NCT02898597|Behavioral|Cognitive Behavioral Therapy|Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
79396943|NCT01794975|Drug|Ketamine|
79557745|NCT06234059|Behavioral|Speaking Tasks|Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
79720741|NCT00996034|Drug|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
79396944|NCT01794975|Drug|Atomoxetine|
79557746|NCT06234046|Drug|Rifaximin 550Mg Tab|group (1) received Rifaximin as 550 mg twice daily dosage for six months.
79396945|NCT01794975|Other|Cold pressor test|
79557747|NCT06234046|Drug|Ciprofloxacin 750 MG|group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.
79557748|NCT06234046|Diagnostic Test|ascitic fluid sample|aspiration of ascitic fluid sample and analysis for differential cell count
79557749|NCT06234033|Behavioral|Discrimination Acuity test|Estimating the just-noticeable difference of auditory loudness and vibrotactile displacement to fit a psychometric function for each modality with parameters: threshold, slope, sensitivity, and response criterion.
79557750|NCT06234033|Diagnostic Test|Transiently Evoked Otoacoustic Emission|Examination of integrity of outer hair cells in the inner ear; with and without contralateral suppression.
79557751|NCT06234033|Other|Questionnaires|Caregiver questionnaires send to parents online to acquire demographic information Autism Quotient (AQ), Child Behavior Checklist (CBCL6-16), Sensory Profile 2 (SP-2).
79557752|NCT06234033|Behavioral|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|Estimates intelligence quotient
79557753|NCT06234033|Diagnostic Test|Clinical tests of ASD|Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2)
79557754|NCT06234033|Other|Electroencephalography (EEG) with auditory or vibrotactile stimuli|Two paradigms will be used: an auditory frequency tagging paradigm with interspersed pitch oddballs and a classical sensory gating paradigm with either vibrotactile stimuli or auditory clicks.
80019234|NCT05479578|Drug|Cyclophosphamide|Given PO
79396946|NCT01794975|Drug|Placebo|
79396947|NCT05286099|Other|Imaging examination and/or blood test|Imaging examination and/or blood test will be performed at a certain time
79396948|NCT01795989|Device|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
79557755|NCT06234033|Diagnostic Test|Clinical tests of ADHD|ADHD-Rating Scale (ADHD-RS)
79720742|NCT04311021|Other|No intervention|No intervention
79720743|NCT04278196|Other|AI-Box|AI-box is a system fixed adjacent to magnet controlled capsule endoscopy. Patients who accept the check of magnet controlled capsule endoscopywill be enrolled .
79396949|NCT05285787|Drug|EPN-701 (Oral)|MK-7
79396950|NCT01491035|Drug|Vortioxetine|5 mg tablets for 14 days; orally; once daily
79720744|NCT01253447|Drug|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
79720745|NCT01253447|Other|laboratory biomarker analysis|Correlative studies
79720746|NCT04230382|Diagnostic Test|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
79720747|NCT01121991|Drug|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
79720748|NCT04277728|Diagnostic Test|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
79720749|NCT00994240|Procedure|Electrodessication & Curettage|Electrodessication & Curettage 1 or 3 cycles
80019235|NCT05479578|Drug|Dexamethasone|Given PO
79396951|NCT01491035|Drug|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
79396952|NCT01491035|Drug|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
79396953|NCT01491035|Drug|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
80019236|NCT04482088|Behavioral|Occupational Therapy in an Equine Environment|10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
79720750|NCT01253369|Drug|Pazopanib|
79258757|NCT03546127|Genetic|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~Data from each cancer and normal genome will be analysed for the presence of somatic variants.~DNA and RNA sequencing results will be integrated.~Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
79720751|NCT04292548|Diagnostic Test|taking saliva samples to determine TAS, TOS and LL-37|
79720752|NCT04292236|Dietary Supplement|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
79258758|NCT05084521|Drug|Famotidine 400 mg/50 mL|Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
79258759|NCT03610789|Device|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
79258760|NCT03574987|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
79396954|NCT00375999|Drug|Docetaxel and epirubicin|
79396955|NCT04748315|Other|SEMT(1:1)|Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set
79720753|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
79720754|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
80019237|NCT04482088|Behavioral|Occupational Therapy in a Clinic (OTC)|10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
79258761|NCT05063851|Drug|Memantine Hydrochloride Tablets|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
79396956|NCT04748315|Other|SEMT (1:3)|Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
79396957|NCT04409327|Drug|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
79396958|NCT04409327|Drug|Placebo|Oral matching placebo once daily for 4 weeks
79396959|NCT01488071|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
79557756|NCT06234007|Drug|Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine|"Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was >1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;"
79557757|NCT06233994|Biological|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
79557758|NCT06233994|Drug|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
79557759|NCT06233994|Biological|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
79557760|NCT06233981|Radiation|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
79557761|NCT06233981|Drug|Tislelizumab|One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
79557762|NCT06233955|Device|Low Level laser therapy|is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation
79557763|NCT06233955|Other|Maitland mobilization technique|is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
79557764|NCT06233890|Device|Motion watch|Actigraphy watch to be worn for 14 days
79720755|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
79855744|NCT00949026|Drug|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
79855745|NCT00953784|Procedure|standard operating management|As previously described
79855746|NCT00949104|Drug|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
79855747|NCT00949104|Drug|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
79855748|NCT00953940|Drug|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
79855749|NCT00436618|Drug|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
79855750|NCT03995836|Device|CPAP|Decision of CPAP treatment is according to clinical guidelines
79258762|NCT05063851|Drug|Placebo|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
80019238|NCT02899377|Radiation|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
80019239|NCT02899377|Radiation|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
80019240|NCT02899377|Procedure|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
80019241|NCT02899377|Procedure|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
80019242|NCT05578248|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
79258763|NCT04522141|Behavioral|Self-control intervention|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
79258764|NCT04522141|Behavioral|Control condition|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
79258765|NCT03545581|Other|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
79396960|NCT01488071|Drug|Agomelatine|encapsulated tablets, daily, orally
80019243|NCT05578248|Procedure|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
80019244|NCT04052217|Device|Penile Ring|Penile Ring at base of penis
79396961|NCT01487525|Device|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
79557766|NCT06233838|Device|KHA80 hemoperfusion treatment|On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
79557767|NCT06233812|Procedure|Simple interrupted suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
79855751|NCT03995836|Procedure|Bariatric Surgery|All patients.
80019245|NCT04467164|Device|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
80019246|NCT04467164|Device|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
79855752|NCT01024660|Drug|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
80019247|NCT04853628|Behavioral|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
79396962|NCT01487525|Other|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
79396963|NCT01486199|Other|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
79855753|NCT01024660|Drug|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
79855754|NCT01024660|Drug|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
79855755|NCT01751126|Drug|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
79855756|NCT01751126|Drug|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
79855757|NCT00943982|Drug|Interferon Gamma 1-b|
79258766|NCT03545581|Other|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
79720756|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
80019248|NCT04853628|Behavioral|Alerta Alcohol 2.0|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
79258767|NCT03481543|Procedure|In-line nebulization through NIV mask|In-line nebulization will be given through NIV circuit.
79720757|NCT00994162|Device|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
79720758|NCT04292158|Device|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
79258768|NCT03481543|Procedure|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
79258769|NCT03433339|Device|Active transcutaneous spinal direct current stimulation|Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
80019249|NCT04052763|Diagnostic Test|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
80019250|NCT04052763|Diagnostic Test|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
79258770|NCT03433339|Device|Sham transcutaneous spinal direct current stimulation|Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
80019251|NCT03521726|Drug|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
79258771|NCT03359161|Combination Product|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
79258772|NCT05031871|Drug|HR17031 injection ；INS068 injection；SHR20004 injection|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
79258773|NCT05031871|Drug|HR17031 injection ；INS068 injection；SHR20004 injection|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
79258774|NCT05031871|Drug|HR17031 injection ；INS068 injection；SHR20004 injection|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
79258775|NCT05031871|Drug|HR17031 injection ；INS068 injection；SHR20004 injection|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
79720759|NCT04292158|Device|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
79720760|NCT04293640|Diagnostic Test|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
79720761|NCT02868814|Drug|Pregabalin Release Tablets|
79720762|NCT02868814|Drug|Pregabalin Release Tablets|
79720763|NCT02868814|Drug|Placebo|
79720764|NCT04292314|Drug|Omega 3|Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months
79720765|NCT04292314|Drug|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
79720766|NCT04292314|Drug|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
79258776|NCT05016583|Other|Paula Method|12 weeks of Paula Method of Exercises
79258777|NCT05015725|Diagnostic Test|Quality of life assessment, biochemical measures|"Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables.~Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels."
79720767|NCT04292314|Drug|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
79258778|NCT02253823|Drug|EFV|
79258779|NCT02253823|Drug|TPV/RTV - low dose|
79258780|NCT02253823|Drug|TPV/RTV - high dose|
79557768|NCT06233812|Procedure|Running suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
79557769|NCT06233799|Drug|extended-release naltrexone (XR-NTX)|Once per three weeks injections of extended-release naltrexone
79557770|NCT06233799|Drug|extended release bupropion (BUP-XL) tablets (BUP-XL)|Daily oral extended release bupropion tablets
79557771|NCT06233799|Drug|iPLB|Once per three weeks injections of placebo
79258781|NCT04308967|Other|balance exercises|Three-stage progressive balance exercises will be applied.
79258782|NCT03277339|Drug|Paroxetine|Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
79557772|NCT06233799|Drug|oPLB|Daily oral placebo tablets
79720768|NCT04292314|Drug|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
79720769|NCT04292314|Procedure|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
79557773|NCT06233786|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
79557774|NCT06233760|Other|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
79720770|NCT00993928|Behavioral|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
80019252|NCT03521726|Drug|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
80019253|NCT03647241|Device|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
79258783|NCT03277339|Other|Thermal cure|Thermal cure is realized for 3 weeks
79258784|NCT03232801|Behavioral|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
79258785|NCT03232801|Behavioral|general health education group|A general health and aging education group
79258786|NCT03145675|Drug|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5+0.25 mg/kg administered intravenously.
79258787|NCT03145675|Drug|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg administered intravenously.
79258788|NCT03145675|Drug|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg administered intravenously.
79258789|NCT03145675|Drug|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg administered intravenously.
79396964|NCT01485887|Drug|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
79720771|NCT01253291|Drug|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
79720772|NCT04292002|Behavioral|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
79720773|NCT01121757|Drug|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
79720774|NCT01121757|Drug|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
79720775|NCT04319471|Drug|Capecitabine/S-1|Drug: Capecitabine/S-1
79720776|NCT04319471|Drug|Chemotherapy|Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
79720777|NCT04319471|Radiation|Head and neck radiotherapy|IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
79855758|NCT01570010|Other|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
79258790|NCT01329029|Drug|Roflumilast|500 µg, once daily
79396965|NCT01546519|Drug|Vismodegib|oral repeating dose of 150 mg once daily
79396966|NCT01484951|Drug|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
79396967|NCT01484873|Drug|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
79396968|NCT01486927|Biological|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
79396969|NCT01486927|Biological|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
79720778|NCT04319471|Other|Local Consolidative Therapy|radiotherapy，surgery or interventional therapy for all metastatic sites.
80019254|NCT03647241|Device|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
80019255|NCT03647241|Procedure|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
79258791|NCT01329029|Drug|Placebo|once daily
79396970|NCT00376935|Drug|Palifermin|Keratinocyte growth factor administered via injection
79396971|NCT00376935|Drug|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
79396972|NCT04656925|Behavioral|Contingency management|Reinforcement, or incentives, in exchange for evidence of not drinking alcohol.
79396973|NCT04767451|Diagnostic Test|ultrasound assessment|Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements
79396974|NCT00379197|Drug|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
79557775|NCT06233760|Other|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
79720779|NCT02882217|Drug|XC8 (histamine glutarimide)|
79720780|NCT02882217|Drug|Placebo|
80019256|NCT03524222|Other|Home Hospitalization|See above
79557776|NCT06233760|Other|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
79720781|NCT01253135|Biological|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
79720782|NCT01253135|Other|White Petrolatum|Topical application
79720783|NCT02882061|Procedure|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
79720784|NCT02881905|Device|ball attachment|it is attachment part that connects the overdenture to the implant
79720785|NCT02881905|Device|cm loc attachment|It is a new attachment made of peek material
79720786|NCT00993616|Drug|belinostat|Given IV
79720787|NCT00993616|Drug|carboplatin|Given IV
79720788|NCT01120899|Drug|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
79720789|NCT01120275|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
79720790|NCT01120275|Other|laboratory biomarker analysis|Correlative studies
79258792|NCT03111277|Device|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
79258793|NCT02254135|Drug|BEA 2180 BR - rising dose|
79258794|NCT02254135|Drug|Placebo|
79720791|NCT00991510|Drug|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
79258795|NCT04300673|Procedure|Radio guided surgery (RGS) using Indium-labelled PSMA|Approximately 24hours prior to surgery (PLND) patients receive a radiolabelled PSMA-tracer. During surgery, urologists will use a gamma-probe to detect PSMA-postitive tumour depostitions in pelvic lymph nodes.
79720792|NCT00991510|Drug|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
79720793|NCT01119963|Drug|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
79720794|NCT01119963|Drug|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
80019257|NCT03548610|Other|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (>1.5cm) involving the lower limbs
79396975|NCT00379197|Procedure|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
79258796|NCT03545425|Procedure|Biofluid samplings|Blood and Urine
79258797|NCT01372085|Drug|LY2584702 Reference Formulation|Administered orally
79258798|NCT01372085|Drug|LY2584702 Test Formulation|Administered orally
79258799|NCT01372085|Drug|Placebo|Administered orally
79258800|NCT04042727|Drug|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
79720795|NCT02868736|Device|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
80019258|NCT03621579|Procedure|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
80019259|NCT04781946|Procedure|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
80019260|NCT04781946|Procedure|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
79258801|NCT04042727|Other|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
79557777|NCT06233760|Other|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
79557778|NCT06233760|Other|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
79720796|NCT01252667|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
80019261|NCT04781946|Procedure|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
79720797|NCT01252667|Drug|Clofarabine|Given IV
79720798|NCT01252667|Drug|Cyclosporine|Given PO
79720799|NCT01252667|Other|Laboratory Biomarker Analysis|Correlative studies
79720800|NCT01252667|Drug|Mycophenolate Mofetil|Given PO
79720801|NCT01252667|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
79720802|NCT01252667|Other|Pharmacological Study|Optional correlative studies
79720803|NCT01252667|Radiation|Total-Body Irradiation|Undergo TBI
79720804|NCT04292626|Diagnostic Test|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
79720805|NCT02881827|Radiation|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
79720806|NCT02881827|Other|Placebo|Simulation of treatment with the device switched off
79720807|NCT02881827|Other|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
79720808|NCT02868580|Drug|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
79720809|NCT02868658|Biological|Blood sampling|
79720810|NCT02868658|Other|Nasal swab|
79720811|NCT02881749|Radiation|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
79720812|NCT02881749|Drug|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
79720813|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
79720814|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
79396976|NCT01796067|Behavioral|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
79396977|NCT01796067|Behavioral|Basic Health Education|This group will receive the comprehensive basic health education intervention.
79396978|NCT01796067|Behavioral|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
79396979|NCT01796067|Behavioral|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
79396980|NCT01513759|Drug|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
79720815|NCT00629044|Biological|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
79720816|NCT01119105|Drug|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
79720817|NCT01119105|Drug|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
79720818|NCT01119105|Drug|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
79720819|NCT01118949|Drug|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
79720820|NCT04310865|Drug|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
79855759|NCT00944060|Other|lifestyle intervention|
80019262|NCT04302064|Drug|Eplontersen|Eplontersen administered SC
79557779|NCT06233760|Other|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
79557780|NCT06233760|Other|Big Five Inventory|The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
80019263|NCT04302064|Drug|Placebo|Eplontersen-matching placebo administered SC
79720821|NCT04310865|Drug|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
79720822|NCT04310865|Other|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
79720823|NCT01252355|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
80019264|NCT03645993|Genetic|Genetic Testing|A one time blood sample will be taken.
80019265|NCT03524144|Other|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
80019266|NCT03548376|Other|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
80019267|NCT04291690|Other|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
79258802|NCT04012853|Device|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
79258803|NCT02035943|Dietary Supplement|Insulin separated|separate continuos infusion of insulin
79258804|NCT02035943|Dietary Supplement|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
79258805|NCT05707637|Other|Ablation|Unipolar and bipolar ablation
79396981|NCT01513759|Device|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
79396982|NCT01484561|Drug|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
79396983|NCT01484561|Drug|Placebo|Placebo BID orally, approximately 72 days
79396984|NCT01546207|Procedure|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
79557781|NCT06233760|Other|Family APGAR Questionnaire|Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
79557782|NCT06233747|Behavioral|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by licensed nursing assistants or other non-specialist clinicians who provide one-on-one safety supervision during boarding. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy. Given that one-on-one safety supervision is the current standard of care during boarding, I-CARE requires minimal additional resources beyond those already available in acute care hospitals and builds on well established research demonstrating the effectiveness of task-sharing, the redistribution of tasks within the workforce, to address the shortage of mental health professionals.
79720824|NCT01252355|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
79258806|NCT03820583|Procedure|Whipple Procedure|Patients underwent Whipple procedure for pancreatic tumors. The procedure commenced with rooftop incision. then layers of abdomen dissected to reach the peritoneum. Then Duodenum dissected out along with pancreas and common bile duct. After rescetion of these structures the anatomy of the tract restored with three anastomosis namely pancreaticojejunostomy, gastrojejunostomy and choledochojejunostomy/hepaticojejunostomy.
79258807|NCT02941549|Other|Placebo capsules|
79258808|NCT02941549|Drug|Epeleuton|
79258809|NCT03819413|Diagnostic Test|serum aquaporin 4 antibody (AQP-4-Ab)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)
79258810|NCT03819413|Diagnostic Test|serum MOG antibody (anti-MOG)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)
79396985|NCT01513291|Drug|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
79396986|NCT01513291|Drug|Placebo|Placebo, 2 tablets, orally, once daily
79720825|NCT01252355|Drug|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
79720826|NCT01118325|Drug|ticagrelor|Drug oral treatment
79720827|NCT01118325|Drug|clopidogrel|Drug oral treatment
79720828|NCT01117857|Drug|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
79720829|NCT02888405|Other|High-carbohydrate diet|
79258811|NCT03819413|Diagnostic Test|MRI brain, spine and orbit|All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium
79258812|NCT02394028|Drug|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
79720830|NCT02888405|Other|Low-carbohydrate diet|
79720831|NCT01251887|Dietary Supplement|Linoleic Acid|
79396987|NCT01483937|Device|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
79557783|NCT06233721|Other|Online education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as oral anticoagulant (OAC) medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
79720832|NCT01251887|Dietary Supplement|Docosahexaenoic Acid|
79720833|NCT01251887|Dietary Supplement|Eicosapentaenoic Acid|
79720834|NCT00991276|Drug|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
79557784|NCT06233721|Other|Face-to-face education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as OAC medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
79720835|NCT00991276|Drug|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
79720836|NCT00991276|Drug|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
79258813|NCT02394028|Drug|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
79258814|NCT03546751|Device|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
79258815|NCT03546751|Other|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
79396988|NCT01483937|Other|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
79720837|NCT02869282|Other|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
79720838|NCT02869282|Other|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
79720839|NCT02869204|Other|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
79720840|NCT02869204|Dietary Supplement|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
79720841|NCT02869204|Dietary Supplement|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
80031567|NCT04981964|Procedure|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
79258816|NCT04005677|Diagnostic Test|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
79396989|NCT01483625|Drug|tiotropium|18mcg
79396990|NCT01483625|Drug|Placebo|placebo
79396991|NCT01485991|Drug|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
79396992|NCT01485991|Drug|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
79396993|NCT00379821|Drug|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
79396994|NCT00379821|Drug|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
79396995|NCT00379821|Drug|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
79720842|NCT02869204|Dietary Supplement|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
79720843|NCT04291846|Drug|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
79720844|NCT04291846|Drug|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
79720845|NCT04291924|Diagnostic Test|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
79557785|NCT06233708|Drug|Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use|Non-selective blocker including Propranolol, Carvedilol PO was prescribed
79720846|NCT02869126|Procedure|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~Stress conventional acquisition with D.SPECT camera 20 min after injection~60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~double isotope acquisition 5 min after thallium-201 injection~injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~rest conventional acquisition 20 min later"
79720847|NCT02869126|Drug|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
79720848|NCT02869126|Drug|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
79720849|NCT00990652|Drug|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
79720850|NCT00990652|Drug|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
79720851|NCT02867878|Drug|Adenosine|
79720852|NCT02867878|Drug|Saline solution|
79720853|NCT00990340|Device|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
79720854|NCT00990340|Procedure|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
79720855|NCT01207440|Drug|Ponatinib|Ponatinib tablets.
79720856|NCT00990184|Drug|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
79720857|NCT00990184|Other|placebo|tablet (s) orally given with evening meal
79720858|NCT00986830|Device|FinESS Sinus Treatment|
79720859|NCT00990106|Drug|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
80019268|NCT04291690|Other|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
79258817|NCT04073069|Drug|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
79258818|NCT04073069|Drug|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
79258819|NCT01371539|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
79258820|NCT01371539|Device|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
79258821|NCT02819297|Drug|BLI400 Laxative|21 gm BLI400 powder
79258822|NCT02819297|Drug|BLI400 Placebo|Equivalent amount of placebo powder
79258823|NCT03546673|Behavioral|Self-Regulation Condition|
79258824|NCT03546673|Behavioral|Emotional Disclosure Condition|
79396996|NCT00379821|Drug|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
79396997|NCT01482767|Drug|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
79396998|NCT01482767|Drug|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
79557787|NCT06233682|Other|Enriched environment|In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
79557788|NCT06233643|Drug|Phloroglucinol|The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.
79720860|NCT00990106|Drug|placebo|placebo
79720861|NCT02867566|Drug|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
79720862|NCT02867566|Drug|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
79396999|NCT01482767|Drug|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
79720863|NCT02868502|Device|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
79557789|NCT06233643|Combination Product|Acupuncture Combined Intradermal Sterile Water|Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
79258825|NCT04980950|Dietary Supplement|Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science|Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
79557790|NCT06233630|Drug|Control Test - spinal anesthesia|No peripheral nerve block Only spinal anesthesia
79557791|NCT06233630|Drug|Ropivacaine 0.2% Injectable Solution ESPB|ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
79557792|NCT06233630|Drug|Ropivacaine 0.2% Injectable Solution iPACK+ACB|ultrasound guided iPACK block + Adductor Canal Block
80031568|NCT04888390|Behavioral|Muti-model exercise intervention|The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
79720864|NCT02868502|Device|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
79557793|NCT06233617|Drug|0.9% Sodium Chloride Injection|biliteral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
79557794|NCT06233617|Drug|Dexamethasone 4 Mg/mL Injectable Solution|biliteral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
79557795|NCT06233617|Drug|Dexmedetomidine injection|biliteral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
79557796|NCT06233604|Drug|0.9%sodium chloride|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
79557797|NCT06233604|Drug|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
79557798|NCT06233604|Drug|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
79258826|NCT03546595|Other|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
79397000|NCT00435591|Drug|Conivaptan|ampoule or premix bag
79397001|NCT00435591|Drug|placebo|ampoule or premix bag
79397002|NCT05258331|Genetic|CT303|"Cohort 1 : Single-dose administration, intravenous injection~Dose 1(Starting dose) : 1.0*10^6 cells/kg~Dose 2 : 2.0*10^6 cells/kg~Dose 3 : 3.0*10^6 cells/kg~Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~Dose 1(Starting dose) : 1.0*10^6 cells/kg~Dose 2 : 2.0*10^6 cells/kg~Dose 3 : 3.0*10^6 cells/kg"
79397003|NCT05244681|Other|Semi-structured interview|Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
79557799|NCT06233591|Drug|LP-10 (Liposomal Tacrolimus)|Liposomal oral rinse formulation of Tacrolimus
79557800|NCT06233565|Drug|0.9%sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
79557801|NCT06233565|Drug|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
79557802|NCT06233565|Drug|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
79557803|NCT06233552|Procedure|conventional denture conversion|conventional workflow usually done to do immediate loading for full arch implant cases
79557804|NCT06233552|Procedure|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
79557805|NCT06233539|Other|Observational research without intervention|Observational research without intervention
79557806|NCT06233526|Other|Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test|"Leukemia cells from newly diagnosed and relapsed children with AML were tested for high throughput in vitro drug sensitivity and resistance.~Combined with multi-omics sequencing technology such as whole exome and transcriptome, the data of drug sensitivity, drug resistance and genomic characteristics of children AML patients were integrated, and the internal rules between drug sensitivity or drug resistance and molecular characteristics such as gene fusion, gene mutation and abnormal gene expression of children AML patients were deeply analyzed, and the molecular characteristics of drug sensitivity in children AML were mapped"
79557807|NCT06233500|Procedure|pars plana vitrectomy|"All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~23 G trocar system will be used~Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~Shaving of the vitreous base, and then fluid air exchange~SF 6 gas tamponade will be used"
79557808|NCT06233487|Diagnostic Test|Repeat hip ultrasound measurements|See earlier
79557809|NCT06233448|Device|Indirect cardiometry|Measurements of thorathic fluid content
79720865|NCT02868502|Device|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
79720866|NCT02868502|Device|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
79720867|NCT02868424|Drug|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
79720868|NCT02867722|Drug|aminolevulinic acid HCl|Drug will be administered to consented patients
79720869|NCT04291222|Device|Iron biocorrodable coronary scaffold system|Implantation of Iron biocorrodable coronary scaffold system
79720870|NCT02867800|Drug|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
79720871|NCT02867800|Drug|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
79720872|NCT02867800|Drug|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
79720873|NCT02867800|Drug|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
79258827|NCT03546595|Other|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
79258828|NCT04981028|Other|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
79720874|NCT02867800|Drug|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
79258829|NCT02429830|Device|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
79258830|NCT03063788|Drug|3BNC117-Copper-64|3 mg/kg 3BNC117 combined with radio-isotope Copper-64
79258831|NCT02821715|Drug|Active comparator: Modafinil + placebo|
79258832|NCT02821715|Drug|THN102 300/3|
79258833|NCT02821715|Drug|THN102 300/27|
79258834|NCT02877823|Behavioral|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
79258835|NCT02877823|Behavioral|Control|Healthy Lifestyle Education
79557810|NCT06233435|Behavioral|PADSS|Observe PADSS after total knee arthroplasty at 6 and 24 hours
79557811|NCT06233422|Other|No intervention involved|No intervention involved
79258836|NCT02036177|Device|SCu300A IUB intrauterine device|Spherical copper IUD
79557812|NCT06233396|Other|Extra 4DCT scan|Extra 4DCT scan after routine simulation
79557813|NCT06233370|Behavioral|Moderate intensity walking exercise|For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)
79557814|NCT06233344|Drug|Psilocybin plus mindfulness training|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists. The psilocybin dosing session will take place approximately halfway through an 8-week mindfulness training course. The mindfulness training course will consist of weekly 2-hour classes with experienced mindfulness teachers; participants will be encouraged to practice mindfulness for 45 minutes per day between classes.
79557815|NCT06233344|Drug|Psilocybin|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists.
79557816|NCT06233331|Drug|Dose Level 1 ACU-D1 ointment|"ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks."
79720875|NCT02867800|Drug|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
79720876|NCT02867800|Drug|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
79720877|NCT02867800|Drug|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
79720878|NCT02867800|Drug|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
79720879|NCT02867800|Drug|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
79258837|NCT02036177|Device|T380A IUD|T-shaped copper IUD
79258838|NCT02036099|Other|Driving in Mild Dementia Decision Tool|
79258839|NCT04855838|Device|Oral neuromuscular training|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
79258840|NCT04436276|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
79258841|NCT04436276|Biological|Placebo|Participants will receive Placebo.
79258842|NCT03546517|Other|Dry Needling|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
80019269|NCT04291690|Other|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
79720880|NCT02867800|Drug|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
80019270|NCT04291690|Other|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin <130g/L in men or <120g/L in women with (ii) a Ferritin <100μg/L or a Ferritin <300μg/L with a Saturation <20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
80019271|NCT04466696|Behavioral|ERAS protocol|items of ERAS protocol applied
80019272|NCT03546426|Drug|Pembrolizumab|200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
79258843|NCT03546517|Other|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
79557817|NCT06233331|Drug|Dose Level 2 ACU-D1 ointment|Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
79720881|NCT02867800|Drug|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
79720882|NCT02867800|Drug|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
79258844|NCT02813681|Procedure|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
80019273|NCT03546426|Biological|Autologous dendritic cells|Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
79258845|NCT02813681|Procedure|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
79258846|NCT02813681|Procedure|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
79720883|NCT02867800|Procedure|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
79720884|NCT02867800|Drug|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
79720885|NCT02867800|Drug|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
79855760|NCT00548808|Drug|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
79855761|NCT00548808|Drug|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
80019274|NCT03546426|Drug|Interleukin-2|3 MU s.c. from day +2 to day +6 after each DC administration
79258847|NCT04900363|Drug|AK112|Subjects receive AK112 intravenously.
79258848|NCT03817151|Procedure|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
79557818|NCT06233331|Drug|Dose Level 3 ACU-D1 ointment|Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
79557819|NCT06233331|Procedure|Vulvar/ Perianal Biopsy|3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
79557820|NCT06233318|Procedure|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
79258849|NCT03545347|Drug|Nandrolone Decanoate|Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone < 11 nmol/l will receive a dose of 200 mg.
80019275|NCT03525938|Procedure|TAP block|Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
79720886|NCT00983476|Behavioral|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
79855762|NCT00548808|Drug|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
79855763|NCT00944138|Behavioral|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
80019276|NCT01316887|Drug|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
79557821|NCT06233318|Procedure|Pecto-intercostal Fascial Block with normal saline|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
79720887|NCT00983476|Behavioral|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
80019277|NCT01316887|Drug|125mcg once-daily GSK573719|GSK573719
79720888|NCT00629200|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
79720889|NCT00629200|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
79720890|NCT02867488|Other|Soybean oil in salad dressing|
79855764|NCT00954434|Dietary Supplement|red wine|intake of red wine on a daily basis
80019278|NCT01316887|Drug|Placebo once-daily|inactive
80019279|NCT02897349|Drug|placebo|
79258850|NCT03545347|Dietary Supplement|Protein-rich nutritional supplement|The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
79258851|NCT03545347|Other|Physical therapy|The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
79258852|NCT03545347|Drug|Sodium Chloride 9mg/ml Injection|Placebo injection of 1 ml Sodium Chloride
80019280|NCT02897349|Drug|linagliptin|
79258853|NCT02393950|Drug|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
79855765|NCT04011878|Procedure|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
79855766|NCT00954096|Drug|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
79855767|NCT00949338|Procedure|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
79855768|NCT00954252|Drug|CHF 5074|1x, oral capsule, single dose
79855769|NCT00954252|Drug|placebo|placebo, oral capsule, single dose
79855770|NCT00954252|Drug|CHF 5074|2x, oral capsule, single dose
79855771|NCT00954252|Drug|CHF 5074|4x, oral capsule, single dose
79855772|NCT00954252|Drug|CHF 5074|8x, oral capsule, single dose
80019281|NCT02897349|Drug|background therapy|insulin with or without metformin
80031569|NCT04888390|Behavioral|Disease and exercise suggestion|The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
80031570|NCT03993314|Drug|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
80031571|NCT03993314|Drug|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
80031572|NCT04888078|Procedure|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
79557822|NCT06233292|Biological|ZG005 Powder for Injection|The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
79557823|NCT06233292|Biological|ZG005 Powder for Injection|Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
79557824|NCT06233279|Device|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
79855773|NCT00954252|Drug|CHF 5074|16x, oral capsule, single dose
79855774|NCT00954252|Drug|CHF 5074|24x, oral capsule, single dose
79855775|NCT01563042|Drug|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
80019282|NCT03749044|Other|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
79258854|NCT02393950|Drug|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
79720891|NCT02867176|Drug|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
79258855|NCT02815397|Drug|Metformin|given in addition to standard of care treatment
79258856|NCT03562403|Device|Deep Brain Stimulation|stimulation of different basal ganglionic nuclei by a inserting a device
79258857|NCT02427958|Drug|Leuprorelin|Suspension for injection.
79258858|NCT03715127|Drug|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
79258859|NCT03715127|Drug|Placebo oral capsule|single dose of placebo (100% mannitol)
80019283|NCT03525782|Biological|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
80019284|NCT03525782|Combination Product|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
80031573|NCT04887532|Drug|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
79557825|NCT06233279|Device|Sham Stimulation|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
79258860|NCT03562325|Behavioral|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
79258861|NCT02260037|Drug|Epinastine nasal|
79258862|NCT02260037|Drug|Placebo|
79258863|NCT02036489|Drug|Vincristine|
79258864|NCT02036489|Drug|Daunorubicin|
79557826|NCT06233266|Drug|Ticagrelor-Test product|Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
79557827|NCT06233266|Drug|Ticagrelor-Reference product|Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
79557828|NCT06233253|Other|Best Practice|Receive usual care
79557829|NCT06233253|Other|Medical Chart Review|Ancillary studies
79720892|NCT02867176|Drug|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
79720893|NCT02868034|Behavioral|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
79855776|NCT01563042|Drug|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
79855777|NCT00110617|Drug|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
79258865|NCT02036489|Drug|Prednisone|
79258866|NCT02036489|Drug|L-asparaginase|
79258867|NCT02036489|Drug|Ciclophosphamide|
79258868|NCT02036489|Drug|Metotrexate|
79258869|NCT02036489|Drug|ARA-C|
79258870|NCT02036489|Drug|Hidrocortisone|
79258871|NCT02036489|Drug|Mercaptopurine|
79258872|NCT02036489|Drug|VP-16|
79258873|NCT02036489|Drug|Dexametasone|
79258874|NCT02392624|Drug|Omalizumab|Omalizumab 300 mg administered SC Q4W.
79258875|NCT02392624|Drug|Placebo|Placebo matched to omalizumab administered SC Q4W.
79258876|NCT02047565|Drug|60mg edoxaban|
79258877|NCT02047565|Drug|180mg edoxaban|
79258878|NCT02047565|Drug|50 IU/kg Beriplex P/N|
79258879|NCT02047565|Drug|25 IU/kg Beriplex P/N|
79258880|NCT02047565|Drug|10 IU/kg Beriplex P/N|
79258881|NCT03156686|Procedure|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
79258882|NCT03063866|Drug|Propofol|Propofol 1 mg/kg i.v
79258883|NCT03063866|Drug|Midazolam|Midazolam 3 mg i.v
79258884|NCT03063866|Drug|Fentanyl|fentanyl 0.5 ug/kg
79258885|NCT02037191|Drug|Methotrexate|"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
79855778|NCT00110617|Drug|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
79258886|NCT02037191|Drug|Placebo|"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
79258887|NCT04980170|Drug|Clindamycin 300 mg|patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
79258888|NCT04980170|Drug|Amoxicillin with Clavulanic Acid 635mg|patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
79258889|NCT02047721|Behavioral|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
79258890|NCT02047721|Behavioral|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by ~2000 kcal/week.
79258891|NCT02387164|Drug|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
79557830|NCT06233253|Behavioral|Online Mindfulness Meditation|Receive an online mindfulness intervention
79557831|NCT06233253|Other|Survey Administration|Ancillary studies
79557832|NCT06233240|Drug|Sitagliptin and Metformin Hydrochloride Tablets Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India
79557833|NCT06233240|Drug|Sitagliptin and Metformin Hydrochloride Tablets Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
79720894|NCT02868034|Behavioral|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
79720895|NCT02868034|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
79720896|NCT02868034|Behavioral|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
79258892|NCT02387164|Drug|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
79557834|NCT06233227|Drug|Dutasteride-Test product|Dutasteride soft capsule 0.5 mg Test product Manufactured by: Phil Inter Pharma Co., Ltd., Vietnam
79557835|NCT06233227|Drug|Dutasteride-Reference product|Dutasteride soft capsule 0.5 mg Reference product Manufactured by: DELPHARM POZNAN S.A., Poland
79557836|NCT06233214|Device|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
79557837|NCT06233201|Drug|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
79720897|NCT00982228|Drug|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
79720898|NCT00982228|Drug|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
79720899|NCT00982228|Drug|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
79720900|NCT02867956|Drug|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
79720901|NCT02867956|Drug|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
79557838|NCT06233201|Drug|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
79557839|NCT06233188|Procedure|orthogantic surgery|surgery that correcting the maxilla and mandible related with each other
79557840|NCT06233175|Other|combined kinetic chain exercises|combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,
79855779|NCT00954330|Procedure|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
79855780|NCT00954330|Device|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
79855781|NCT00949494|Device|Synvisc|intra-articular, 3 weekly injections
80019285|NCT03525782|Biological|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
79258893|NCT02047799|Dietary Supplement|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
79258894|NCT02047799|Dietary Supplement|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
79855782|NCT04011462|Device|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
79258895|NCT02048033|Device|Regular endoscopy + endogastric suturing|Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
79557841|NCT06233175|Other|conventional|stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
79258896|NCT02048033|Diagnostic Test|Regular endoscopy|Patients will get the usual endoscopy used for diagnosis.
79258897|NCT02048111|Biological|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
79557842|NCT06233162|Drug|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
79557843|NCT06233162|Drug|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
79557844|NCT06233149|Drug|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
79557845|NCT06233149|Drug|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
79557846|NCT06233136|Device|Leg pedalling exercise|Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher
79557847|NCT06233136|Other|The designed physical therapy program|"It applied for all participated children in both groups. It includes;~Flexibility exercises~Static and dynamic balance~Functional training exercises"
79557848|NCT06233123|Behavioral|the Medisafe android application (https://www.medisafe.com).|software for Android mobile phones that can remind the patient of his treatment on time
79557849|NCT06233110|Drug|Fostamatinib|Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
79557850|NCT06233110|Drug|Ruxolitinib|Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
79557851|NCT06233097|Drug|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
79557852|NCT06233097|Drug|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
79720902|NCT04290832|Behavioral|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
79855783|NCT04011462|Device|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
79855784|NCT00954486|Drug|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
79855785|NCT03956862|Drug|GB001|film-coated oral tablet
80019286|NCT03525782|Drug|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
80019287|NCT03525782|Other|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
80019288|NCT03103048|Diagnostic Test|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
80019289|NCT03103048|Diagnostic Test|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
80019290|NCT03103048|Diagnostic Test|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
80031574|NCT03889340|Device|IQool|Subjects will undergo hypothermia therapy with the IQool system
79557853|NCT06233084|Drug|Desogestrel-Test product|Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
79557854|NCT06233084|Drug|Desogestrel-Reference product|Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
79557855|NCT06233071|Drug|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
79557856|NCT06233071|Drug|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
79557857|NCT06233058|Drug|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
79557858|NCT06233058|Drug|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
79855786|NCT03956862|Drug|Placebo|film-coated oral tablet
79855787|NCT00550238|Drug|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
79855788|NCT00946946|Drug|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
79855789|NCT00946946|Drug|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
79855790|NCT00946946|Drug|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
79855791|NCT00946946|Drug|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
79855792|NCT03956550|Drug|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
79855793|NCT03956550|Drug|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
79557859|NCT06233045|Drug|Dapagliflozin-Test product|Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
79720903|NCT04291066|Drug|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
79557860|NCT06233045|Drug|Dapagliflozin-Reference product|Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
79720904|NCT04290910|Behavioral|Weight Loss Program|There are three components of the intervention, this includes: psychology, nutrition, and physical activity. For the psychological portion, a therapist will assess the participant at baseline to determine if there are barriers associated with making lifestyle changes. For nutrition, the dietitian will assess the participant and create a meal plan based on their nutritional needs and guide the participant to reaching their nutritional goals. The psychological and nutrition portion may be interchangeable depending on the participants needs. For physical activity, the personal trainer will assess the participant and create an exercise plan that consists of resistance training and weight bearing exercises suitable for the participant while also guiding the participant to reach their exercise goals.
79258898|NCT02048267|Procedure|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
79258899|NCT02392234|Drug|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
79258900|NCT02392234|Drug|Ivacaftor|Tablet, oral use
79258901|NCT02392234|Drug|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
79720905|NCT01260350|Drug|SOF|Sofosbuvir (SOF) tablets administered orally once daily
79258902|NCT02392234|Drug|Placebo matched to Ivacaftor|Tablet, oral use
79720906|NCT01260350|Drug|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
79720907|NCT01260350|Drug|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
79720908|NCT01260350|Drug|LDV|Ledipasvir (LDV) tablets administered orally once daily
79720909|NCT01260350|Drug|GS-9669|GS-9669 tablets administered orally once daily
79720910|NCT01260350|Drug|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
79720911|NCT04150120|Device|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
79720912|NCT04291378|Radiation|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
79258903|NCT02036723|Drug|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
79258904|NCT02036723|Drug|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
79258905|NCT02036801|Other|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
79258906|NCT02036879|Drug|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
79258907|NCT02036957|Procedure|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
79557861|NCT06233032|Drug|Ephedrine|Patient Will receive 6mg IV
79557862|NCT06233032|Drug|Dexmedetomidine|Patient Will receive 30mcg IV
79557863|NCT06233019|Other|Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart|Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
79557864|NCT06233006|Other|Assessment|upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
79557865|NCT06232993|Other|Kinesio taping|Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.
79557866|NCT06232993|Other|Occlusal Splinting|Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.
79557867|NCT06232993|Other|Exercises|For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
79258908|NCT02036957|Procedure|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
79557868|NCT06232967|Procedure|Primary tumor resection or not|For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
79720913|NCT04273828|Procedure|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
79720914|NCT01260194|Drug|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
79720915|NCT00629278|Biological|trastuzumab|
79258909|NCT02049983|Device|Use of Levita Magnetics Grasper|
79855794|NCT00954668|Procedure|immediate angiography and revascularization|immediate angiography < 2 hours after randomization
79258910|NCT02050061|Other|compression stocking|study the impact of compression stocking
79855795|NCT00954668|Procedure|early invasive angiography|early invasive angiography 12-72 h after randomization
79855796|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
79855797|NCT00947024|Drug|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
79855798|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
79855799|NCT01033708|Behavioral|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
79258911|NCT02050139|Dietary Supplement|L-cysteine|
79258912|NCT02050139|Other|Placebo|
79258913|NCT02050217|Procedure|Neurally Adjusted Ventilatory Assist|
79258914|NCT02048345|Drug|Suspension Fasted State|
79557869|NCT06232954|Device|Mossie-Go containing treated transfluthrin disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
79557870|NCT06232954|Device|Mossie-Go containing untreated blank disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
79720916|NCT00629278|Drug|aromatase inhibition therapy|
79720917|NCT00629278|Drug|cyclophosphamide|
79720918|NCT00629278|Drug|docetaxel|
79720919|NCT00629278|Drug|doxorubicin hydrochloride|
79720920|NCT00629278|Drug|epirubicin hydrochloride|
79720921|NCT00629278|Drug|fluorouracil|
79855800|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
79258915|NCT02048345|Drug|Suspension Fed State|
79258916|NCT02048345|Drug|Solution Fasted State|
79258917|NCT02048345|Drug|Solution Fed State|
79258918|NCT02963090|Drug|Topotecan|"Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities."
79258919|NCT02963090|Drug|Pembrolizumab|200 mg IV every 21-days until progression of disease or unacceptable toxicities.
79258920|NCT02048423|Drug|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
79258921|NCT02037035|Drug|Ketamine|
79258922|NCT02048501|Other|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
79258923|NCT02048501|Other|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
79720922|NCT00629278|Drug|paclitaxel|
79720923|NCT00629278|Drug|releasing hormone agonist therapy|
79720924|NCT00629278|Drug|tamoxifen citrate|
79720925|NCT00629278|Procedure|adjuvant therapy|
79720926|NCT00629278|Radiation|radiation therapy|
79720927|NCT04320758|Other|conventional preparation design|chamfer finish line
79720928|NCT04320758|Other|biologically oriented preparation technique|shoulder less preparation design
79855801|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
79855802|NCT01031992|Drug|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
79855803|NCT01031992|Drug|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
79855804|NCT00954564|Other|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
79855805|NCT00954564|Other|medical chart review|Observational only
79720929|NCT04207112|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
79557871|NCT06232941|Procedure|Full pulpotomy procedure|vital pulp therapy for molars with irreversible pulpitis instead of doing root canal treatment
79258924|NCT02048501|Other|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
79557872|NCT06232928|Device|Early Class II elastics|Participants were treated by a fixed orthodontic appliance with intermaxillary class II elastics to correct the class II malocclusion. patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
79557873|NCT06232928|Device|Conventional Class II elastics|patients were treated by a fixed orthodontic appliance with intermaxillary Class II elastics. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours after reaching to rigid stainless steel arch wires.
79557874|NCT06232915|Procedure|Mechanical ventilation|Mechanical ventilation during surgery
79258925|NCT02048501|Other|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
79258926|NCT04979936|Procedure|laparoscopic cholecystectomy|
79720930|NCT04207112|Drug|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
79720931|NCT04207112|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
79720932|NCT04207112|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
79720933|NCT04207112|Drug|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
79720934|NCT04207112|Drug|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
79855806|NCT00954564|Other|questionnaire administration|Observational only
79258927|NCT04979936|Procedure|percutaneous cholecystostomy|
79258928|NCT04979468|Drug|DOVATO|Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
79557875|NCT06232902|Drug|QL1101|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
79557876|NCT06232902|Drug|Avastin®|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
79557877|NCT06232889|Diagnostic Test|Deuterium Glucose Metabolic Imaging with MRI spectroscopy|MRI spectroscopy of the liver, following ingestion of 20 mg deuterium glucose p.o., prior to and after radioembolization treatment for mCRC
79557878|NCT06232876|Device|Blinded continuous vital sign monitoring|Continuous blinded vital sign monitoring.
79557879|NCT06232876|Device|Unblinded continuous vital sign monitoring|Continuous unblinded vital sign monitoring.
79557880|NCT06232837|Device|Direct laryngoscopy using Macintosh blade|Patients in operative room requiring direct laryngoscopy for endotracheal intubation
79557881|NCT06232824|Behavioral|Tele-rehabilitation|The whole program is constituted of preoperative education and postoperative rehabilitation (in hospital and out of hospital). All the participants received the same preoperative education through the mobile phone application and oral communication. Participants in the intervention group get the multicomponent supervised tele-rehabilitation, while participants in the control group get the home-based self-rehabilitation. All the postoperative rehabilitation programs are presented and executed through the mobile phone application.
79557882|NCT06232811|Behavioral|Assessment|Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
79557883|NCT06232785|Drug|Ibuprofen|0.8g intravenous injection 30min before the end of the operation
79557884|NCT06232785|Drug|sufentanil|0.2ug/kg intravenous injection 30min before the end of the operation
79557885|NCT06232746|Device|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
79557886|NCT06232720|Device|Q300 QART Medical|The Q300TM Imaging system includes a Quantitative Phase Microscope. Q300TM uses a low intensity coherent light source, in a uniquely configured interferometer, which measures light delay as it passes different locations across the sperm cell. The amount
79557887|NCT06232694|Drug|Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;|Induction Phase Regimen
79557888|NCT06232694|Drug|Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;|Consolidation therapy after remission
79557889|NCT06232694|Other|utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).|Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
79855807|NCT00954564|Procedure|assessment of therapy complications|Observational only
79258929|NCT02048579|Behavioral|Behavior Therapy + Motivational Interviewing|
79258930|NCT03562169|Drug|Ixazomib, thalidomide, & dexamethasone (ITD) re-induction|"4 - 6 ITD 28-day cycles as follows:~Ixazomib 4mg capsule on days 1, 8 and 15~Thalidomide 100mg capsule on days 1-28~Dexamethasone 40mg tablets on days 1, 8, 15 and 22"
79397004|NCT05241795|Other|Knee then Ankle rehabilitation protocol|"Patients will start with knee exercise program that includes~Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction.~Then, Patients will start ankle exercises program that includes:~Standing calf raises~Foot lift~Ankle eversion exercises~Ankle Plantarflexion exercises"
79397005|NCT05241795|Other|Ankle then Knee rehabilitation protocol|"Patients will start ankle exercises program that includes:~Standing calf raises~Foot lift~Ankle eversion exercises~Ankle Plantarflexion exercises~Then, Patients will start with knee exercise program that includes~Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction."
79557890|NCT06232668|Procedure|Chorionic biopsy and peripheral blood collection in cases group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
79557891|NCT06232668|Procedure|Chorionic biopsy and peripheral blood collection in control group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
79397006|NCT01482221|Drug|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
79397007|NCT01482221|Drug|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
79397008|NCT01482221|Drug|Placebo|0.9 sodium chloride [normal saline] solution for injection by iv infusion
79397009|NCT01482065|Device|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
79397010|NCT04649879|Biological|SARS-CoV-2 convalescent plasma|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay >9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.
79720935|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
79720936|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
79720937|NCT01259726|Other|Placebo|10 mL placebo once daily for 14 days
79258931|NCT03562169|Drug|Conventional autologous stem cell transplant (ASCT-con)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
79397011|NCT04649879|Other|Standard of care|Standard of care as determined by hospital practices for COVID-19 patients.
79397012|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
79397013|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
79397014|NCT00439335|Drug|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
79397015|NCT00439335|Drug|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
79557892|NCT06232642|Dietary Supplement|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
79720938|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 14 days
79720939|NCT05527730|Device|Comparison of PRO-FIT or SELF-FIT fitting|add
79720940|NCT01259492|Drug|Placebo|Placebo Comparator: Placebo
79720941|NCT01259492|Drug|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
79720942|NCT01259492|Drug|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
79720943|NCT04320446|Behavioral|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
79720944|NCT04320446|Behavioral|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
79720945|NCT00624026|Drug|Memantine-HCl|20 mg per day (once daily)
79855808|NCT04012346|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
79855809|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
79258932|NCT03562169|Drug|Augmented autologous stem cell transplant (ASCT-aug)|Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
79397016|NCT01545817|Drug|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
79397017|NCT04408781|Procedure|Ridge expansion by osseodensifcation/Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
79557893|NCT06232642|Dietary Supplement|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
79258933|NCT03562169|Drug|ITD consolidation and ixazomib maintenance vs. No further therapy|"Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression."
79258934|NCT03063554|Procedure|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
79258935|NCT03063554|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
79557894|NCT06232642|Dietary Supplement|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
79258936|NCT02427802|Drug|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
79557895|NCT06232616|Procedure|vitrectomy combined with intravitreal dexamethasone implant|The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
79557896|NCT06232590|Device|Control Lens (comfilcon A)|Multifocal monthly replacement contact lens for 1 month
79557897|NCT06232590|Device|Test Lens (lehfilcon A)|Multifocal monthly replacement contact lens for 1 month
79557898|NCT06232577|Drug|Hydrocodone|Given by PO
79258937|NCT02427802|Other|Placebo|Matching collagen sponge
79258938|NCT03562091|Other|Data collection|The study is an observational evaluation that does not affect physician practices, the physician-patient relationship, or the care of subjects. The prescriptions will be decided prior to inclusion of the subject into the study. The information will be recorded using the data available in the medical file or collected during the visit (as part of the routine subject management).
79258939|NCT02050295|Procedure|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
79258940|NCT02050295|Procedure|Sham washout|Infusion of saline to maintain catheter patency.
79397018|NCT00382785|Behavioral|moderated support|one 12-week online support group led by a professional healthcare provider
79397019|NCT00382785|Behavioral|peer-led|12-week online support in a peer-led format
79557899|NCT06232577|Drug|Tramadol|Given by PO
79557900|NCT06232577|Drug|Oxycodone|Given by PO
79557901|NCT06232096|Drug|MBS314 Injection|"Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg ~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ."
79557902|NCT06231550|Drug|FC084CSA tablets|"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."
79557903|NCT06231381|Drug|HB0034|Anti-IL-36R antibody
79557904|NCT06231381|Other|Placebo|non-biologically active drug
79557906|NCT06231030|Other|Validity, Reliability and Adaptation|Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
79557907|NCT06230757|Drug|Psilocybin 25mg|25mg psilocybin capsule
79557908|NCT06230757|Drug|Placebo (active placebo)|1mg psilocybin capsule
79720946|NCT05512910|Drug|Minocycline|200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
79258941|NCT02050295|Drug|Saline|
79720947|NCT02888990|Drug|Dasatinib|
79720948|NCT05476016|Device|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
79720949|NCT05463302|Device|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
79258942|NCT02050451|Dietary Supplement|Ensure Plus®|
79397020|NCT01512979|Drug|metformin|1000 mg to 2000 mg per day
79397021|NCT01512979|Drug|linagliptin|5 mg daily
79397022|NCT01512979|Drug|metformin placebo|0 to 2 tablets daily
79397023|NCT01512979|Drug|metformin placebo|4 tablets daily
79397024|NCT00383565|Drug|romidepsin|Given IV
79397025|NCT01512745|Drug|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
79397026|NCT01512745|Drug|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
79557909|NCT06230744|Behavioral|Lifestyle|All participants will receive diet and exercise goals and coaching.
79557910|NCT06230744|Behavioral|Lifestyle II|All participants will receive diet and exercise goals and coaching.
79557911|NCT06230718|Other|Motor Imagery (MI)|mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.
79258943|NCT02050451|Dietary Supplement|Multivitamin|
79557912|NCT06230718|Other|Action Observation (AO)|rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.
79557913|NCT06230718|Other|Control condition- placebo|Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
79557914|NCT06230627|Other|Home-Based Rehabilitation rogram|The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
79720950|NCT05463302|Device|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
79258944|NCT02050529|Drug|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
79258945|NCT02050529|Drug|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
79258946|NCT02050607|Other|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
79258947|NCT02427646|Drug|BoNT-A|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
79720951|NCT00624104|Dietary Supplement|Food (fat free meal)|Fat free meal (40% of REE)
79258948|NCT02048657|Device|Foley Airway Stylet Tool|
79258949|NCT02048657|Device|introducer-tool|
79720952|NCT02889068|Other|Blood sample|
79720953|NCT05273450|Behavioral|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
79720954|NCT05252078|Drug|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
79720955|NCT05252078|Drug|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
79720956|NCT05118386|Drug|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 ≥ 300 mg - ≤ 600 mg IM"
79258950|NCT02392000|Device|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
79258951|NCT02392000|Behavioral|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
79258952|NCT02051465|Device|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
79258953|NCT02051465|Device|Removal without overtube|Endoscopic removal of polyp without overtube
79258954|NCT02048969|Drug|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
79397027|NCT01478321|Drug|Temozolomide|Given PO
79397028|NCT01478321|Radiation|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
79397029|NCT01478321|Biological|bevacizumab|Given IV
79720957|NCT05118386|Other|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
79720958|NCT05101928|Drug|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
79720959|NCT05101928|Drug|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
79720960|NCT05069714|Drug|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
79258955|NCT02048969|Drug|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
79258956|NCT02050685|Other|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
79258957|NCT03561935|Drug|Propafenone|prescribing propafenone for the management of premature ventricular complex
79258958|NCT03561935|Drug|Indenol|prescribing indenol for the management of premature ventricular complex
79258959|NCT02385526|Device|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
79258960|NCT02808143|Biological|BCG Solution|Given intravesically
79397030|NCT01478321|Other|questionnaire administration|Ancillary studies
79397031|NCT01544491|Drug|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
79557915|NCT06230107|Behavioral|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
79557916|NCT06229912|Drug|Revumenib|Given by PO
79557917|NCT06229886|Other|Application of positive-end-expiratory pressure|Application of PEEP on mechanically ventilated pediatric patients. Point-of-care-ultrasound performed after each PEEP application.
79557918|NCT06229821|Device|Intrapulmonary Percussive Ventilation|IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
79557919|NCT06229418|Other|DFR AED Pilot Program|Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
79397032|NCT01544491|Drug|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
79397033|NCT00383643|Drug|zolpidem tartrate|
79397034|NCT00383643|Drug|sodium oxybate|
79397035|NCT00383643|Drug|Matching Placebos|
79557920|NCT06229327|Behavioral|THERAPEUTICGAMES|THERAPEUTICGAMES
80019291|NCT03103048|Diagnostic Test|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
79258961|NCT02808143|Other|Laboratory Biomarker Analysis|Correlative studies
79258962|NCT02808143|Biological|Pembrolizumab|Given intravesically
79258963|NCT02808143|Other|Pharmacological Study|Correlative studies
79557921|NCT06228638|Other|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
79557922|NCT06227494|Behavioral|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
79720961|NCT05048966|Behavioral|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
79720962|NCT05048966|Behavioral|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
79258964|NCT02427100|Behavioral|Diet/Physical Activity|Diet/Physical Activity Intervention
79258965|NCT02659202|Device|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
79258966|NCT02050763|Behavioral|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau & Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska & DiClemente, 1983; Prochaska & Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
79258967|NCT02629796|Other|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
79397036|NCT01478087|Device|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
79258968|NCT04979390|Drug|SHR-1316|SHR-1316 administrated intravenously (IV) at protocol defined dose levels
79397037|NCT00439413|Drug|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
79397038|NCT00439413|Drug|Placebo|Matching placebo via transdermal system
79397039|NCT00439413|Behavioral|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
79557923|NCT06227494|Behavioral|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
79557924|NCT06227234|Other|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
79557925|NCT06227234|Other|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
79855810|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
79855811|NCT00949728|Procedure|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
79855812|NCT00947102|Other|Observation|
79397040|NCT01477853|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally daily
79397041|NCT01477853|Drug|Atorvastatin|Atorvastatin 80 mg tablet orally daily
79855813|NCT00954902|Dietary Supplement|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
79397042|NCT01477853|Other|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
80019292|NCT01003262|Other|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
80019293|NCT01003262|Other|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
80019294|NCT04282408|Device|Scoliosis back brace|The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
80031575|NCT03050632|Behavioral|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
79258969|NCT02806973|Drug|Nasal Glucagon|Administered intranasally.
79258970|NCT03561857|Device|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~Ex vivo study~Prostate specimens will be stained using Fluorescein~Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~In vivo study~Intravenous injection of contrast agent~pCLE imaging every 5mm of the NVB dissection zone."
80019295|NCT04465604|Other|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
79397043|NCT01477853|Other|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
79258971|NCT02049203|Drug|Ataciguat|
79397044|NCT01477853|Drug|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
79397045|NCT01477853|Drug|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
79557926|NCT06227234|Other|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
79855814|NCT00954902|Behavioral|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
79855815|NCT00954902|Other|Placebo antioxidant concentrate|Placebo capsules
79855816|NCT01034020|Drug|Nicotine|
79557927|NCT06227143|Procedure|Anesthesia depth monitoring|Anesthesia depth monitoring during opioid-free anesthesia
79855817|NCT00944372|Drug|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
79855818|NCT01032148|Drug|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
79855819|NCT00949806|Drug|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
79855820|NCT00947180|Behavioral|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
79720963|NCT04207034|Procedure|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
79855821|NCT00947180|Other|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
79855822|NCT00947180|Behavioral|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
79855823|NCT01032304|Drug|Erdosteine|One 300 mg capsule twice a day
79258972|NCT02049203|Drug|Placebo|
80019296|NCT03645915|Other|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
79855824|NCT01032304|Drug|Placebo|One capsule twice a day
79258973|NCT02037737|Drug|Abatacept|
79258974|NCT02051543|Behavioral|Brief Behavioral Treatment of Insomnia -Military Version|
79258975|NCT02049281|Drug|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
79258976|NCT02037503|Drug|Ketamine|
79258977|NCT02037503|Drug|Saline|
79258978|NCT02049671|Drug|Growth Hormone Therapy|
79258979|NCT03561779|Drug|YYD302 2ml|YYD302 2ml
79258980|NCT03561779|Drug|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
79258981|NCT02037815|Drug|20% mannitol solution, 125 ml, IV infusion in 15 min|
79258982|NCT02037815|Drug|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
79397046|NCT01477853|Drug|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
79397047|NCT01477853|Drug|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
79397048|NCT00384813|Behavioral|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
79397049|NCT00384813|Behavioral|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
79557929|NCT06225856|Drug|YY201|Oral administration under fasting state.
79557930|NCT06220266|Drug|Phytoestrogen|consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
79557931|NCT06220266|Drug|Placebo|consume 1 starch capsule twice a day for 2 months
79557932|NCT06212609|Other|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
79557933|NCT06212323|Other|Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.|"Patients with high-risk smoldering myeloma will be prospectively followed and chart review will be performed to determine if progression events happen, and how they happen.~All patients will undergo the following standard of care interventions:~Imaging every 6 months with diffusion weighted whole body magnetic resonance imaging~Bone marrow biopsy every year~Labs every month for first year, and every two months for second year."
79557934|NCT06211231|Behavioral|Digitally delivered mindfulness- and acceptance-based psychological intervention|MY-ENDO is developed specifically for endometriosis and includes ten themes; one for each session: 1) endometriosis, 2) chronic pain and pain mechanisms, 3) stress, 4) thoughts and feelings, 5) grief, 6) identity and meaning, 7) everyday life and relations, 8) health, diet and exercise, 9) value-based action and 10) a good life with endometriosis.
79557935|NCT06211140|Device|tACS|tACS in 4 weeks, once per weekday for 40 minutes each, 20 sessions. The treatment group will receive transcranial alternating current stimulation at a gamma frequency (77.5Hz) with a peak amplitude of 15mA.
79557936|NCT06211140|Other|Control|Without the tACS stimulation in this group.
79557937|NCT06207851|Device|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
79557938|NCT06206876|Procedure|Biopsy|Undergo biopsy
79557939|NCT06206876|Procedure|Biospecimen Collection|Undergo collection of blood samples
79557940|NCT06206876|Procedure|Computed Tomography|Undergo CT
79720964|NCT04207034|Procedure|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
79720965|NCT02888912|Other|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
79720966|NCT02888912|Other|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
79720967|NCT04320524|Device|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
79855825|NCT05190510|Other|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
79855826|NCT05190510|Procedure|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
80019297|NCT03362710|Diagnostic Test|simplified tools|"Skin temperature on the back of the foot with infra-red thermometry~Toe saturometry~ABI with an automatic sphygmomanometry~Skin Recoloration time at the foot"
79258983|NCT02037581|Behavioral|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
79557941|NCT06206876|Drug|DDX5 Degrader FL118|Given PO
80019298|NCT03645291|Diagnostic Test|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
79557942|NCT06206876|Procedure|Magnetic Resonance Imaging|Undergo MRI
79258984|NCT02037581|Behavioral|Standard Care|Standard care as being offered by private psychiatrists
79557943|NCT06202339|Device|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
79557944|NCT06198816|Other|ultrasound accelerated thrombolysis and venoplasty|IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
79557945|NCT06195540|Drug|Rivaroxaban 10 MG|"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
79258985|NCT02051621|Drug|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
79258986|NCT02051621|Procedure|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
79258987|NCT02051621|Procedure|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
79258988|NCT02051699|Procedure|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
79258989|NCT02806505|Drug|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
79258990|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 1|Containing macro and micronutrients
79258991|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 2|Containing macro and micronutrients
79258992|NCT02051777|Dietary Supplement|Dietary Advice|
79258993|NCT02053337|Device|Self adhesive foam dressing|Self adhesive foam dressing
79557946|NCT06195540|Drug|Low Heparin Molecular Weight|"Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
79557947|NCT06193512|Device|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.
79557948|NCT06193512|Procedure|Oral care treatment as usual|Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
79557949|NCT06192758|Device|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
79557950|NCT06192420|Drug|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
79557951|NCT06192420|Drug|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
79557952|NCT06192420|Drug|Placebo|3g of gel three times daily for 7days (+1 day visit window)
79557953|NCT06192355|Device|Endoscopic hemostasis using a Esophagogastroduodenoscopy|performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
79557954|NCT06185257|Device|EEG|"Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~Patients in remission~Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured"
79720968|NCT04795700|Behavioral|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
79720969|NCT04685720|Device|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
79720970|NCT04678544|Device|Scalp cooling system 2|The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.
79720971|NCT04654052|Drug|Clopidogrel|Clopidogrel during 11 months
79720972|NCT04654052|Drug|Previous treatment|non-intervention
79720973|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79720974|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79258994|NCT02037971|Procedure|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
80019299|NCT03761082|Other|NA(observation study)|NA(observation study)
79557955|NCT06183502|Behavioral|Quantitative survey|Quantitative surveys will be conducted through Alchemer, a HIPPA-compliant online survey system previously used by our group in collaborative research with CDC and supported by the Emory University Center for AIDS Research (CFAR). Surveys will be optimized for participants to take them through a personal computer, mobile phone, tablet, or the SMART study app. For participants who do not have any of these devices or prefer to not take the survey from their device, each city will have a research space where participants can schedule a convenient time to take the survey on a computer or tablet that the study will provide for that purpose.
79557956|NCT06183502|Diagnostic Test|HIV & STI testing|The research team has developed and validated procedures for self-collection of specimens for testing for STIs (syphilis, urethral, rectal, and pharyngeal gonorrhea/chlamydia) and HIV self-testing. All participants will be mailed self-collection kits to provide samples for STIs (urine, rectal swab, and pharyngeal swab for gonorrhea/chlamydia; dried blood spot (DBS) for syphilis testing) and HIV (HIV 4th generation testing on DBS specimens in a CLIA-certified laboratory). Participants will be asked to collect specimens for their STI and HIV testing (every 6 months) and return them to Molecular Testing Labs. For participants who prefer in-person procedures, they will meet study staff who will provide them with the STI and HIV self-collection kit and instructions and provide a room for participants to collect their specimens.
79855827|NCT05190510|Other|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
80019300|NCT03134378|Drug|Rabeprazole Sodium 20mg|Twice daily
80019301|NCT03134378|Drug|Clarithromycin 500mg|Twice daily
80019302|NCT03134378|Drug|Amoxicillin 500 Mg|Twice daily
80019303|NCT03645837|Other|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
80019304|NCT05434104|Other|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
80019305|NCT05434104|Drug|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
80019306|NCT03699748|Behavioral|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
79855828|NCT00954642|Drug|bevacizumab|Intravenous repeating dose
79258995|NCT02037971|Other|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
79258996|NCT02053415|Dietary Supplement|Krill oil low dose|3 capsules krill oil per day
79258997|NCT02053415|Dietary Supplement|Krill oil high dose|9 capsules krill oil per day
79258998|NCT02053571|Procedure|TIPS with 3D Overlay|
79855829|NCT00954642|Drug|MNRP1685A|Escalating intravenous dose
79855830|NCT00954642|Drug|paclitaxel|Intravenous repeating dose
79855831|NCT00955058|Drug|OCP|Daily For 3 months
79875597|NCT00948077|Drug|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)"
79875598|NCT00407745|Drug|placebo|Placebo
80019307|NCT03699748|Other|Usual Care|Usual care as provided by Unite Here Health and local oncologists
80019308|NCT03524066|Drug|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
80019309|NCT03524066|Drug|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
80019310|NCT03524066|Other|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
80019311|NCT03903861|Other|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
80019312|NCT03903861|Other|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
80019313|NCT03903861|Other|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
80031576|NCT03050632|Behavioral|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
79258999|NCT02053649|Behavioral|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
79259000|NCT02053649|Other|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
79259001|NCT02053727|Drug|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
79259002|NCT02053727|Drug|Placebo|
79259003|NCT02053805|Other|PSA|PSA. Serum & plasma will be stored for future investigations
79259004|NCT02053805|Other|IPSS questionnaire|the validated International Prostate Symptom Score
79259005|NCT02053805|Other|DRE (Digital Rectal Examination )|physical examination for the prostate gland
79875599|NCT00407745|Drug|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
80031577|NCT04920890|Device|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
80031578|NCT04920890|Device|Placebo without radiofrequency.|The device will be used without turning on the patient, thus administering a placebo treatment.
79557957|NCT06183502|Behavioral|Qualitative Assessment|Focus group discussions (n=up to 48 men for 3 qualitative assessments; total n=up to 144 men) as a part of the study consisting of 9 to 12 focus group discussions (FGD) with an average of 8 (range 3-10) participants in each (3 per city). These focus groups will be conducted once during the first year of the study. FGD will be conducted by a trained moderator using a semi-structured interview guide developed in collaboration with CDC scientists. For the FGD, in each city, there will be one FGD with men who have never used PrEP, one with men who are using PrEP and report no adherence issues, and one with men who are currently using PrEP or used PrEP previously and report sub-optimal adherence. In-Depth Interviews (IDIs) A series of 90 in-depth interviews (same n=up to 45 men for each of 3 qualitative assessments) will be conducted over 18 months: up to 45 IDIs each 6 months apart, with up to 15 IDIs per city each wave.
79557958|NCT06182124|Biological|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
79557959|NCT06182124|Biological|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
79557960|NCT06182124|Biological|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
79557961|NCT06181136|Drug|DNL126|intravenous repeating dose
79557962|NCT06180694|Other|Reminiscence therapy|In the research, reminiscence therapies will be carried out once a week for 8 weeks, in sessions of approximately 45 minutes.
79557963|NCT06179459|Procedure|Endoscopic management of pancreatic fluid collections|Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
80031579|NCT04920890|Other|Manual therapy.|Common manual therapy administered for said pathology by traditional physiotherapy.
79259006|NCT02053805|Other|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
79397050|NCT03026855|Biological|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
79557964|NCT06179355|Procedure|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
79557965|NCT06179355|Procedure|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
79557967|NCT06177184|Other|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
79557968|NCT06175390|Radiation|68Ga-FAPI-46 PET/CT|Tumor assessments by 18F-FDG PET/CT (per PERCIST v1.0) and 68Ga-FAPI-46 PET/CT will be performed at: baseline and after the first 2 treatment cycles (between C2D15 and C3D1).
79259007|NCT02053805|Procedure|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
79397051|NCT03026699|Behavioral|eSNAP|Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
79557969|NCT06175390|Biological|Tumor samples analysis|"Patients will undergo a mandatory biopsy of the primary tumor at baseline, after the first 2 treatment cycles and during the surgery. A lymph node biopsy will be performed at baseline if feasible in cohort A, and and in case of disease progression for cohort B (if clinically feasible).~In addition to the usual morphological and immunohistochemical (ER, PR, HER2+, CPS score, PD-L1 status with SP142 …) analyses in the cohort A and cohort B , exploratory analyses will be performed."
79720975|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79875600|NCT00948233|Behavioral|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
79875601|NCT00948233|Behavioral|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
79259008|NCT02053805|Procedure|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
79259009|NCT02051075|Biological|PXN sperm treatment|immotile sperm activation with PXN
79259010|NCT02051075|Biological|Sperm activation with PXN and oocyte activation|
79259011|NCT02051153|Drug|Modafinil|Modafinil (2-[(Diphenylmethyl) sulfinyl]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg & Carter, 2008).
79259012|NCT02051153|Drug|Placebo|
79259013|NCT02807363|Drug|Leuprolide Oral Tablet 4-mg QD|4-mg Leuprolide oral tablet once daily for 28 consecutive days.
79259014|NCT02807363|Drug|Leuprolide Oral Tablet 4-mg BID|4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
79397052|NCT03026699|Behavioral|Questionnaires|Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
79397053|NCT00440505|Drug|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
79397054|NCT00440505|Drug|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
79397055|NCT00440505|Drug|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
79557970|NCT06175390|Biological|Blood samples analysis: Circulating Tumor DNA|Blood samples will be collected at baseline. In addition for cohort A at cycles 2 and 3, within 21 days before surgery, 10 to 21 days after surgery and at cycle 8 after surgery. In addition for cohort B after the first 2 treatment cycles and in case of disease progression (if clinically feasible).
80019314|NCT05063305|Dietary Supplement|Probiotic|The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
79397056|NCT01511419|Biological|LAIV H7N3|2 doses of vaccine
79557971|NCT06172413|Device|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
79557972|NCT06172413|Device|Sham tACS|Sham tACS
79259015|NCT02807363|Drug|Leuprolide Depot|3.75 mg intramuscular depot injection
79397057|NCT01511419|Biological|placebo|2 doses of placebo
79397058|NCT00441285|Drug|Praziquantel|- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
79397059|NCT00441285|Drug|Albendazole|"Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
79397060|NCT00441285|Drug|ABZ Placebo|- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
79397061|NCT00441285|Drug|PZQ Placebo|- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
79397062|NCT01796613|Device|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
79397063|NCT01796613|Device|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
79397064|NCT04388631|Other|Coronavirus Disease 2019|male patients who have developed COVID-19
79397065|NCT00442611|Drug|Abatacept|
79397066|NCT00442611|Drug|Placebo|
79855832|NCT01024816|Behavioral|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
79259016|NCT02807363|Drug|Leuprolide Oral Tablet 10-mg BID|10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
79259017|NCT02052089|Procedure|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
79259018|NCT02052089|Procedure|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (<0.2 mJ/mm2) or high energy (>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
79855833|NCT01024816|Behavioral|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
79259019|NCT02052089|Procedure|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
79557973|NCT06171711|Behavioral|Exposure Therapy|The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
79557974|NCT06171659|Drug|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
79557975|NCT06171659|Device|PET/MRI|positron emission tomography and magnetic resonance imaging
79855834|NCT00954720|Other|No Intervention|There is no intervention on this trial
79259020|NCT02052089|Procedure|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
79259021|NCT02051231|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
79557976|NCT06171659|Device|PET/CT imaging|positron emission tomography and computed tomography imaging
79557977|NCT06171477|Device|Ventilation 20-40-60|The respiratory rate during mechanical ventilation will be altered from 20 to 40 and finally to 60 breaths per minute.
79557978|NCT06171477|Device|Ventilation 60-40-20|The respiratory rate during mechanical ventilation will be altered from 60 to 40 and finally to 20 breaths per minute.
79557979|NCT06171477|Device|Ventilation 40-60-20|The respiratory rate during mechanical ventilation will be altered from 40 to 60 and finally to 20 breaths per minute.
79557980|NCT06166758|Behavioral|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
79557981|NCT06165367|Drug|EmbryoGlue Medium|Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
79855835|NCT01024894|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
79855836|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
79855837|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
79557982|NCT06164613|Drug|Cinnamomum Verum oil extract|one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
79557983|NCT06164613|Drug|Placebo|400 mg PO Canola oil soft gel capsule
79259022|NCT03561623|Other|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
79259023|NCT03561623|Other|quantitative muscle force assessment|quantitative assessment of muscle force
79557984|NCT06163326|Drug|Ritlecitinib|Ritlecitinib 50 mg capsule once daily
79557985|NCT06163326|Drug|Ritlecitinib 100 mg|Ritlecitinib 100 mg capsule once daily
79557986|NCT06163326|Drug|Placebo|Matching capsule once daily
79557987|NCT06161012|Device|Senofilcon A contact lenses (TEST)|Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
79557988|NCT06161012|Device|Delefilcon A contact lenses (CONTROL)|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
79855838|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
79259024|NCT02051387|Drug|Cannabidiol CR|
79259025|NCT02051387|Drug|Cannabidiol|
79259026|NCT02051387|Drug|Amisulpride|
79259027|NCT02051387|Drug|Olanzapine|
79259028|NCT02051387|Drug|Quetiapine|
79259029|NCT02051387|Drug|Risperidone|
79259030|NCT02051387|Drug|Placebo|
79855839|NCT00110305|Drug|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
79855840|NCT00110305|Drug|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
79259031|NCT03808883|Behavioral|TGNC Directed Advocacy Meetings|Series of community meetings with TGNC individuals to include meeting with health professionals to articulate barriers to access and to enter into dialogue with medical providers and staff
79259032|NCT02053883|Drug|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
79557989|NCT06155968|Procedure|QL block|"The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles.."
79557990|NCT06155968|Drug|PCA|the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
79557991|NCT06155032|Procedure|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
79557992|NCT06155032|Drug|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
79557993|NCT06152302|Other|Mobility study in dry conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves outside of the water.
79557994|NCT06152302|Other|Mobility study in water conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves inside the water.
79557995|NCT06152250|Other|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
79259033|NCT02053883|Drug|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
79259034|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
79557996|NCT06151938|Drug|Standardised allergen extract from house dust mites|Drug: Allergen immunotherapy [ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
79720976|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79397067|NCT04388397|Procedure|Arteriovenous Grafts|Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
79855841|NCT00110305|Drug|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
79557998|NCT06149715|Device|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
79720977|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79557999|NCT06149715|Device|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
79259035|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
79259036|NCT02052167|Device|methotrexate prefilled pen|
79558000|NCT06149715|Device|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
79558001|NCT06148246|Behavioral|Family Fit Condition|Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
79855842|NCT00110305|Drug|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
79875602|NCT00948233|Behavioral|Surveys|Computer surveys taken at 4 points throughout the study.
79259037|NCT02054039|Device|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
79259038|NCT02054039|Device|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
79259039|NCT03561545|Other|weightlessness (parabolic flight)|weightlessness (parabolic flight)
79259040|NCT02054117|Other|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
79259041|NCT02054195|Behavioral|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
79397068|NCT01511107|Drug|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
79397069|NCT01511107|Drug|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
79397070|NCT00387621|Drug|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
79558002|NCT06148246|Behavioral|Fitbit Only Condition|Dyads in the Fitbit only condition will use a Fitbit and the Fitbit app for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
79558003|NCT06145906|Procedure|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
79558004|NCT06145906|Procedure|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
79720978|NCT01117623|Drug|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79720979|NCT01117623|Drug|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79720980|NCT01117623|Drug|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
79259042|NCT02054195|Behavioral|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
79397071|NCT00387621|Drug|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
79397072|NCT00387621|Drug|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
79720981|NCT05625308|Dietary Supplement|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
79720982|NCT02888834|Other|Adverse drug reaction|
79720983|NCT04291664|Drug|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
79259043|NCT03524417|Biological|Equine rabies immunoglobulin injection on day 7|The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
79259044|NCT03806543|Drug|Vancomycin|adult patients treated with intravenous vancomycin in intensive care unit
79397073|NCT00442689|Drug|flutamide|250 mg twice daily
79720984|NCT04291664|Drug|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
79720985|NCT04291664|Drug|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
79259045|NCT02052323|Drug|Artesunate/mefloquine (AS/MQ)|"artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
79259046|NCT02056067|Behavioral|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
79397074|NCT00442689|Drug|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
79397075|NCT00442689|Other|placebo|
79397076|NCT01484977|Drug|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."
79397077|NCT00442767|Drug|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
79397078|NCT00442767|Drug|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
79397079|NCT00443547|Device|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
79397080|NCT00445263|Drug|TIROFIBAN|intravenous infusion
79397081|NCT00445263|Procedure|CORONAROGRAPHY|standard procedure of coronarography
79397082|NCT00389493|Drug|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
79397083|NCT00389493|Behavioral|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
79397084|NCT00389493|Drug|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
79397085|NCT01795053|Behavioral|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
79558005|NCT06144632|Device|THERMOCOOL STSF Bi- Directional Navigation Catheter|THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
79558006|NCT06144632|Device|TRUPULSE Generator|TRUPULSE Generator will be used to deliver PF/RF ablation.
79855843|NCT00110305|Drug|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
79855844|NCT00954954|Device|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
79259047|NCT02056067|Behavioral|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
79855845|NCT00954954|Device|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
79259048|NCT02056145|Procedure|LFCNB|LFCNB - Normal Saline solution 10 cc
79259049|NCT02056145|Procedure|FNB|FNB - Normal saline solution 10 cc
79259050|NCT02056145|Procedure|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
79855846|NCT00428116|Drug|HAART|Combination first line antiretrovirals as previously described.
79259051|NCT02056145|Procedure|FNB|FNB - Chirocaine 0.25%, 20 cc
79558007|NCT06142994|Dietary Supplement|Atusin CAP|This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.
79558008|NCT06142994|Dietary Supplement|Placebo|The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
79558009|NCT06142799|Procedure|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
79558010|NCT06137170|Drug|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
79558011|NCT06136390|Other|Oxytocin|Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).
79558012|NCT06136390|Other|Placebo|Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
79855847|NCT00560066|Biological|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
79855848|NCT00560066|Biological|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
79855849|NCT00549900|Biological|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
79855850|NCT00435994|Drug|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
79855851|NCT00435994|Other|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
79259052|NCT02056223|Drug|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
79259053|NCT02056223|Drug|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
79259054|NCT02056379|Drug|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
79259055|NCT02056379|Drug|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
79397086|NCT01795053|Behavioral|Placebo open play session|
79397087|NCT04388709|Drug|Peginterferon Lambda-1A|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
79397088|NCT00389805|Drug|bortezomib|
79397089|NCT00389805|Drug|pemetrexed disodium|
79558013|NCT06134934|Other|Telemonitoring 1|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
79558014|NCT06134934|Other|Telemonitoring 2|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
79855852|NCT00947258|Other|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
79855853|NCT01563120|Drug|metformin|metformin up to 2550mg per day.
79855854|NCT01563120|Drug|glybenclamide|glybenclamide up to 20mg per day.
79855855|NCT00435370|Drug|Tropisetron|10 mg/day
79855856|NCT00435370|Drug|Placebo|placebo
79855857|NCT00435370|Drug|Risperidone|6mg/day
79558015|NCT06134362|Drug|CAB LA|Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
80019315|NCT05063305|Dietary Supplement|Placebo|A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
80019316|NCT04052529|Other|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
80019317|NCT03446794|Other|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
79558016|NCT06134180|Behavioral|CONFIDENCE-AI|Multicomponent psychoeducational intervention focused on financial wellbeing
80019318|NCT04515121|Device|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
80019319|NCT04515121|Device|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
79397090|NCT00389805|Genetic|gene expression analysis|
79397091|NCT00389805|Genetic|mutation analysis|
80019320|NCT04515121|Other|Lower limb rehabilitation|Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
79558017|NCT06133010|Biological|mRNA-1647|Sterile liquid for injection
79558018|NCT06133010|Biological|Placebo|Sterile liquid for injection
79558019|NCT06132477|Drug|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
79720986|NCT04310553|Procedure|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
80019321|NCT03523910|Device|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
79397092|NCT00389805|Genetic|protein expression analysis|
79397093|NCT00389805|Genetic|reverse transcriptase-polymerase chain reaction|
79558020|NCT06131450|Drug|BL-M07D1|Administration by intravenous infusion
79558021|NCT06129487|Behavioral|Narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and narrative imagery (e.g., photos of cancer patients) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
79558022|NCT06129487|Behavioral|Non-narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and non-narrative imagery (e.g., images of diseased organs) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
79855858|NCT05098548|Procedure|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
79855859|NCT00096031|Biological|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
79855860|NCT04010526|Combination Product|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
79855861|NCT04010526|Other|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
79855862|NCT05043324|Drug|AntiCov-220 (1)|The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
79855863|NCT05043324|Drug|AntiCov-220 (2)|The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
79855864|NCT04303728|Diagnostic Test|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
79558023|NCT06129240|Combination Product|LIQ861|trepostinil inhalation powder
79855865|NCT00118417|Drug|Clonazepam|Participants will receive clonazepam.
79397094|NCT00389805|Other|flow cytometry|
79397095|NCT00389805|Other|immunoenzyme technique|
79397096|NCT00389805|Other|immunohistochemistry staining method|
79397097|NCT00456807|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
79397098|NCT00456807|Biological|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
79397099|NCT00456885|Drug|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
79397100|NCT00456885|Drug|Placebo|Twice daily injection of placebo
79397101|NCT01475825|Drug|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
79855866|NCT00118417|Drug|Sertraline|Participants will receive sertraline.
80019322|NCT03525704|Device|Saline Solution Enriched|Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution
79259056|NCT02056457|Behavioral|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
79558024|NCT06129019|Behavioral|Reiki|Reiki application will be done
79720987|NCT04187469|Drug|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day > 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
79720988|NCT04187469|Drug|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, >50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, >50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
79259057|NCT02056457|Behavioral|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
79259058|NCT02056535|Behavioral|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
79259059|NCT02056691|Procedure|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
79558027|NCT06126666|Drug|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
79558028|NCT06125743|Behavioral|Usual Care|Participants will conduct self-care activities prescribed by their treating lymphedema therapists.
79720989|NCT04320212|Procedure|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
79259060|NCT02056691|Procedure|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
79259061|NCT02054507|Behavioral|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
79558029|NCT06125743|Behavioral|In-Person LEF-SMP|Participants will receive the in-person LEF-SMP intervention.
79558030|NCT06125743|Behavioral|Telehealth LEF-SMP|Participants will receive the telehealth LEF-SMP intervention.
79558031|NCT06124638|Diagnostic Test|Panbio™ COVID-19/Flu A&B Panel|The Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
79558032|NCT06123754|Drug|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
79720990|NCT04320212|Procedure|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
79720991|NCT01116687|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
79720992|NCT01116687|Other|laboratory biomarker analysis|Correlative studies
79720993|NCT04139486|Procedure|combined EMBOTRAP II or III and Contact Aspiration|refer to title
79720994|NCT04139486|Procedure|Contact Aspiration alone|refer to title
79720995|NCT00625599|Other|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
79720996|NCT02867020|Drug|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
79720997|NCT02867020|Drug|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
79720998|NCT02867020|Drug|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
79720999|NCT02867020|Drug|Prednisone|Subjects will receive prednisone 10mg/day.
79721000|NCT05067855|Other|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
79721001|NCT04320056|Other|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
79721002|NCT04320056|Device|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
79397102|NCT01475825|Drug|Placebo|Placebo vehicle for subcutaneous injection.
79397103|NCT01475825|Drug|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
79259062|NCT03805685|Procedure|Non-Cardiac Surgery|Non-cardiac surgery
79397104|NCT00457197|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
80019323|NCT03525704|Device|Saline Rinse Solution|sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
79397105|NCT00457197|Drug|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
79397106|NCT04408859|Drug|Neoadjuvant Chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
79558033|NCT06123754|Drug|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
79558034|NCT06119854|Behavioral|Attitudinal inoculation|A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two text messages (1 and 3 days after the inoculation intervention). These text messages will include reminders to get vaccinated.
79558035|NCT06119854|Behavioral|Cognitive-behavioral therapy-informed intervention|A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two text messages (1 and 3 days after the inoculation intervention). These text messages will include reminders to get vaccinated.
80019324|NCT03047551|Procedure|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
79259063|NCT02383966|Drug|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m^2) on Day 1 and a subsequent dose of 250 mg/m^2 on Day 8 and Day 15 of each 21-day treatment cycle.
79259064|NCT02383966|Drug|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
79259065|NCT02383966|Drug|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
79259066|NCT02054585|Other|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
79259067|NCT02054585|Other|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
79397107|NCT01484431|Drug|Tadalafil- Tablet or Oral suspension|Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
79397108|NCT00445887|Other|Laboratory Biomarker Analysis|Correlative studies
79397109|NCT00445887|Drug|Levonorgestrel|Given orally
79397110|NCT00445887|Other|Placebo|Given orally
79397111|NCT02114307|Device|REVITIVE IX|neuromuscular electrical stimulation device
79397112|NCT01473953|Drug|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
79397113|NCT01473953|Drug|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
79259068|NCT02054663|Drug|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
79558036|NCT06119854|Behavioral|Conventional public health messaging|A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two text messages (1 and 3 days after the inoculation intervention). These text messages will include reminders to get vaccinated.
79558037|NCT06118333|Drug|BL-B01D1|Administration by intravenous infusion
79558038|NCT06118333|Drug|capecitabine|Oral administration
79558039|NCT06118333|Drug|gemcitabine|Administration by intravenous infusion
79558040|NCT06118333|Drug|docetaxel|Administration by intravenous infusion
79558041|NCT06116955|Drug|Midazolam and sufentanil|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
79558042|NCT06116955|Drug|Midazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
79397114|NCT04408703|Diagnostic Test|Red Density|Image analysis of endoscopic images in patients with ulcerative colitis
79397115|NCT01510717|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
79397116|NCT01510717|Device|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
79397117|NCT00457977|Biological|Pneumovax (PPSV23)|Injection
79397118|NCT00457977|Biological|Prevnar (PCV7)|Injection
79397119|NCT01473563|Drug|Pemetrexed|Administered intravenously
79397120|NCT01795209|Drug|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
79397121|NCT01795209|Device|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
79259069|NCT02054819|Other|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
79558043|NCT06116955|Drug|Remazolam and sufentanil.|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
79558044|NCT06116955|Drug|Remazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
79558045|NCT06114511|Drug|BL-M07D1|Administration by intravenous infusion
79558046|NCT06113276|Radiation|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
80019325|NCT03047551|Procedure|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
79855867|NCT00118417|Behavioral|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
79855868|NCT04293744|Device|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
79855869|NCT04293744|Device|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
79259070|NCT02054819|Other|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
79259071|NCT02383576|Other|No Intervention|No intervention administered in this study.
79855870|NCT00955188|Other|computer-assisted intervention|
79855871|NCT00955188|Other|educational intervention|
79855872|NCT00955188|Other|medical chart review|
79855873|NCT01080703|Other|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
79259072|NCT02748317|Drug|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
79259073|NCT02054975|Drug|Vitamin D2 + vitamin D3|higher dose vitamin D
79558047|NCT06112392|Diagnostic Test|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
79558048|NCT06112392|Diagnostic Test|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
79721003|NCT03834272|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.
79259074|NCT02054975|Drug|Vitamin D3|lower dose vitamin D
79721004|NCT03817502|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily.
79721005|NCT03817502|Drug|Placebo|Matching placebo capsules, oral administration, once daily.
79721006|NCT04319978|Drug|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
79855874|NCT01079455|Drug|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
79855875|NCT00549848|Drug|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
79259075|NCT02052401|Other|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
79259076|NCT02055131|Drug|aspirin|
79259077|NCT02056847|Drug|Pitavastatin calcium 4mg|taking once a day
79259078|NCT02056847|Drug|Pitavastatin calcium 2mg|Taking once a day
79855876|NCT00549848|Drug|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
79259079|NCT02052479|Other|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
79259080|NCT02056925|Other|Echocardiography|
79259081|NCT02055287|Drug|LY03004|
79855877|NCT01083589|Drug|Imatinib Mesylate|Oral 400 mg daily
79855878|NCT01083589|Drug|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
79855879|NCT01080859|Device|OCT|Optical coherence tomography
79855880|NCT01080859|Device|OCT|Optical coherence tomography
79855881|NCT01079533|Behavioral|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
79855882|NCT01079533|Behavioral|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
80019326|NCT02964741|Device|Active Comparator|non-invasive brain stimulation (active protocol)
79259082|NCT02052713|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
79558049|NCT06110897|Behavioral|High Dose Resistance Exercise Training|Progressive resistance exercise training
79558050|NCT06110897|Behavioral|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
79558051|NCT06110247|Device|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
79721007|NCT01114737|Drug|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
79721008|NCT01114737|Drug|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
79721009|NCT00624182|Biological|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
79721010|NCT00624182|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
79721011|NCT04322474|Device|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
79721012|NCT02881983|Other|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
79259083|NCT02052713|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
79259084|NCT02055443|Other|12-lead holter monitor application|"-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
79259085|NCT02052791|Drug|nusinersen|Administered by intrathecal (IT) injection
79558052|NCT06110247|Other|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
79558053|NCT06105853|Behavioral|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors, representing the judging panel, and a faked exam situation (15 minutes duration).
79558054|NCT06105853|Behavioral|Barlab Cue-Exposure|Participants are exposed to a bar situation with their individual favorite alcohol presented. They handle their favorite alcoholic drink and water (9 minutes duration).
79558055|NCT06105853|Behavioral|Functional magnetic resonance imaging|Participants undergo a fMRI screening including three different behavioral tasks assessing alcohol cue reactivity, response inhibition, and emotion processing
79721013|NCT05131269|Drug|Dextrose 15 % in Water|A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
79721014|NCT05131269|Drug|Normal Saline 20 mL Injection|A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
79721015|NCT03292874|Diagnostic Test|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
79721016|NCT00625677|Biological|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
79721017|NCT00625677|Biological|Menjugate (Meningococcal C conjugate vaccine)|Dosage
79721018|NCT03258008|Drug|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
79721019|NCT03258008|Biological|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
79721020|NCT05116605|Other|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
79721021|NCT01113879|Behavioral|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
79721022|NCT01113879|Behavioral|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
79721023|NCT00979576|Drug|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m^2
79721024|NCT00979576|Drug|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m^2
79721025|NCT00979576|Drug|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m^2
79721026|NCT00979576|Drug|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m^2
79721027|NCT00979576|Drug|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m^2
79721028|NCT02867332|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
79721029|NCT02867332|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
79721030|NCT02867332|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
79721031|NCT02867410|Other|No intervention|
79721032|NCT02867098|Drug|XmAb5871|
79721033|NCT02702180|Drug|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
79855883|NCT05299788|Other|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
79855884|NCT05299788|Other|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
79558056|NCT06102941|Device|Cognitive Control Training (CT)|4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
79855885|NCT00949182|Drug|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
79259086|NCT02055521|Procedure|Blood sample, biopsy|
79558057|NCT06101472|Device|ASQELIO Toric Biaspheric Monofocal Lens|Intraocular lens implantation in cataract surgery
79855886|NCT00949182|Other|laboratory biomarker analysis|
80019327|NCT02964741|Device|Sham Comparator|non-invasive brain stimulation (sham protocol)
79259087|NCT02057003|Drug|DAA against HCV|
79259088|NCT02426086|Drug|Imetelstat 4.7 mg/kg|Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
79558058|NCT06100614|Diagnostic Test|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
79558059|NCT06100614|Diagnostic Test|Standard Care|Standard care according to the Dutch EOS guideline
80019328|NCT05577780|Procedure|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
80019329|NCT03523832|Drug|Celecoxib and Pregabaline|Single dose versus repetition dose
79558060|NCT06098469|Device|Neurofeedback sessions|10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
79558061|NCT06092801|Other|No intervention|No intervention
79558062|NCT06092580|Biological|AWT020|Participants receiving AWT020 once every two weeks at designated dose levels
79558063|NCT06089850|Other|Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.|"Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant"
79558064|NCT06089460|Other|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
79558065|NCT06089460|Other|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
79558066|NCT06089460|Other|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
79558067|NCT06089161|Other|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
79721034|NCT02702180|Drug|Placebo|Placebo nebulizer solution for inhalation
79721035|NCT02702180|Device|PARI eFlow nebulizer system|PARI eFlow nebulizer system
79721036|NCT00980980|Drug|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
80019330|NCT03523832|Other|Placebo|Placebo
80019331|NCT05577624|Drug|AMG 510|Oral tablet
79721037|NCT02888522|Biological|immunomodulation|Immunomodulation depending on chimerism
79721038|NCT02866864|Other|Animal allergy +|Allergic symptom occurs when subject contact animal
79721039|NCT02866864|Other|Animal allergy -|Allergic symptom does not occur when subject contact animal
79721040|NCT00980200|Drug|Dose 4 QD|QD once daily
79721041|NCT00980200|Drug|Dose 3 QD|QD once daily
79721042|NCT00980200|Drug|placebo|placebo
79721043|NCT00980200|Drug|Dose 2 QD|QD once daily
79721044|NCT00980200|Drug|Dose 1 BD|BD twice daily
79721045|NCT04116502|Drug|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
79721046|NCT04116502|Drug|Hydroxycarbamide|Via standard hospital mechanisms
79721047|NCT04116502|Drug|Interferon-Alpha|Any formulation, via standard hospital mechanisms
80019332|NCT05577624|Drug|Rifampin|Oral capsule
80019333|NCT03294694|Drug|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
80019334|NCT03294694|Drug|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
79259089|NCT02426086|Drug|Imetelstat 9.4 mg/kg|Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
79259090|NCT02057159|Biological|NeuroVax|TCR peptides in IFA
79259091|NCT02057159|Biological|IFA Placebo|IFA Placebo
79259092|NCT03561467|Other|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
79558068|NCT06089161|Behavioral|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
79259093|NCT02052869|Procedure|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
79259094|NCT02052947|Radiation|SPECT-DaTscan|"Measurement of fixation of DaTscan® in the caudate and lenticular nucleus~LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted)."
79721048|NCT04290442|Procedure|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
79558076|NCT06080399|Other|Continuous subcutaneous apomorphine infusion (CSAI)|the CSAI proposed in the usual healthcare pathway of each PD patients included
79721049|NCT04290442|Procedure|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
79259095|NCT03805217|Device|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
79259096|NCT02055833|Dietary Supplement|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
79558077|NCT06077461|Behavioral|mandala painting|Patients in this group will be subjected to mandala painting.
79558078|NCT06074666|Behavioral|CareMeds Intervention|3 parenting sessions will be offered during weeks 2 through 4 of the study period.
79558079|NCT06074666|Behavioral|Usual Care Group|3 parenting sessions will be offered during weeks 13 through 15 of the study period.
79721050|NCT04290442|Drug|Ropivacaine|ropivacaine 0.5% will be use in the block
79721051|NCT02866708|Device|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
79721052|NCT02866786|Drug|Metformin|
79721053|NCT02866786|Drug|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
79259097|NCT02055833|Other|Nutritional counseling|Nutritional counseling
79259098|NCT02055911|Drug|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
79721054|NCT00979654|Drug|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
79721055|NCT02866552|Drug|Stromal Vascular fraction|
79558080|NCT06074458|Other|Glucosano|Glucosano is a remote patient monitoring diabetes dashboard with a patient facing Smartphone application
79721056|NCT02866552|Drug|Ringer lactate|
79721057|NCT00978562|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
79721058|NCT00978562|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
79558081|NCT06074458|Behavioral|Community Health Worker diabetes technology coach|Community Health Workers will work with participants as a diabetes technology coach during scheduled and as needed visits
79558082|NCT06072183|Drug|Ritlecitinib|100mg Capsule
79558083|NCT06072183|Drug|Ritlecitinib|50mg Capsule
79558084|NCT06072183|Drug|Placebo|Matching capsule
79558085|NCT06071494|Other|Tropical fruits|papaya, mango, banana, orange
79558086|NCT06071416|Procedure|Lateral sinus floor augmentation|maxillary sinus floor augmentation by lateral approach
79558087|NCT06071416|Drug|Biphasic Calcium Phosphate|appliaction of BCP bone substitute
79558088|NCT06071416|Procedure|Injectable platlets rich fibrin|centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
79721059|NCT00978562|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
79721060|NCT00978562|Drug|Gadolinium|Given IV
79721061|NCT04289974|Drug|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
79721062|NCT02866630|Biological|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
79721063|NCT02866162|Genetic|High-throughput exome sequencing|
79855887|NCT00955344|Behavioral|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
80019335|NCT03294694|Drug|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
79721064|NCT02865616|Drug|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
79558089|NCT06066203|Drug|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
79558090|NCT06064526|Other|No intervention|Non-interventional study based on secondary use of hospital medical records
79721065|NCT02865616|Drug|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
79259099|NCT02422264|Biological|Infanrix hexa|• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
79259100|NCT02422264|Drug|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. *In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
79721066|NCT02865460|Drug|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
79855888|NCT00955344|Behavioral|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
79855889|NCT01083823|Other|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
79855890|NCT00549770|Drug|LCZ696|
79855891|NCT00549770|Drug|Valsartan|
79855892|NCT00549770|Drug|AHU377|
79855893|NCT00549770|Drug|Placebo|
79855894|NCT00548184|Drug|Lapatinib|Monoclonal Antibody
79855895|NCT00548184|Drug|Trastuzumab|Monoclonal Antibody
79855896|NCT00548184|Drug|Endocrine|Hormonal Therapy
79397122|NCT01795209|Procedure|Rescue laser|"In the Lucentis group: performed if BCVA < 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA < 20/40 or CFT ≥ 350um from Month 3"
79855897|NCT00955500|Dietary Supplement|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
79855898|NCT00955500|Dietary Supplement|Maltodextrin|30 grams of oral maltodextrin daily
79855899|NCT00955578|Procedure|Punch Biopsy|5-6 punch biopsies of affected areas
79855900|NCT00955734|Other|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
79259101|NCT02390362|Drug|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
79721067|NCT02865460|Drug|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
80019336|NCT03523754|Drug|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening & induction of labor in study group
80019337|NCT04727034|Drug|Remimazolam tosylate|Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
79259102|NCT02390362|Drug|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
79259103|NCT02389894|Device|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
79721068|NCT01206816|Drug|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
79721069|NCT01206582|Biological|Hemin|10 iv infusions for 8 weeks
79721070|NCT01206582|Biological|Albumin|10 iv infusions for 8 weeks
79721071|NCT05409456|Other|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
79721072|NCT05409456|Other|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
79721073|NCT01259102|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
79855901|NCT00955734|Other|Immobilization|This set of patients will be casted for 6 weeks after surgery.
79855902|NCT00955812|Drug|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
79855903|NCT04010994|Procedure|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
79855904|NCT05299710|Procedure|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
79855905|NCT00454636|Drug|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
79855906|NCT00454636|Drug|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
80019338|NCT04727034|Drug|Propofol|Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
80019339|NCT05283759|Other|No intervention because it is a patient registry|
79558091|NCT06061003|Other|Clinical Anatomical Education with Fractured Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.
79721074|NCT00978250|Drug|5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
79855907|NCT00454636|Drug|Epirubicin|50 mg/m2/day, IV, every 3 weeks
80019340|NCT03523676|Diagnostic Test|Red Cell Distribution Width|
80019341|NCT03644511|Drug|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
80019342|NCT03644511|Drug|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
79721075|NCT01259024|Device|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
79721076|NCT04319900|Drug|favipiravir tablets+chloroquine phosphatetablets tablets|"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug."
79721077|NCT04319900|Drug|Favipiravir tablets|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
79855908|NCT00454636|Drug|Cisplatin|60 mg/m2/day, IV, every 3 weeks
79855909|NCT00454636|Drug|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
79855910|NCT00454636|Drug|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
79259104|NCT02389894|Device|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
79855911|NCT00454636|Drug|Docetaxel|60 mg/m2/day, IV, every 3 weeks
79855912|NCT00454636|Drug|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
79259105|NCT02389816|Drug|Placebo|Placebo tablets
79259106|NCT02389816|Drug|Vortioxetine|Vortioxetine tablets
79259107|NCT02388724|Drug|Vonoprazan|Vonoprazan tablets
80019343|NCT03290560|Drug|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
80019344|NCT03290560|Other|Placebo|Placebo Comparator: Phosphate buffered saline
80019345|NCT03523598|Other|Placebo gel + Normal Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
80019346|NCT03523598|Other|Placebo Gel + Potassium Nitrate Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
79259108|NCT02388724|Drug|Lansoprazole|Lansoprazole capsules
79259109|NCT02388724|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
79259110|NCT02388724|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
79855913|NCT04850196|Device|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
79397123|NCT02115633|Device|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
79397124|NCT02115633|Device|Walkasins OFF|Subjects will be wearing a device that is turned off.
79397125|NCT01484275|Drug|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
79397126|NCT01484275|Drug|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
79397127|NCT01544335|Other|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
79397128|NCT01484197|Drug|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
79721078|NCT04319900|Drug|Placebo|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
79558092|NCT06061003|Other|Clinical Anatomical Education with Standard Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.
80019347|NCT03523598|Other|Potassium Nitrate Gel + Normal Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
79558093|NCT06060548|Other|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
79558094|NCT06056258|Dietary Supplement|VL-NL-02|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
79721079|NCT01257698|Drug|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
79721080|NCT01257542|Drug|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
79721081|NCT01257542|Drug|Placebo|A single 10 mL dose of matching placebo syrup
79721082|NCT01257230|Drug|tiotropium Respimat low dose|IMP
80019348|NCT01316419|Drug|Telmisartan|Telmisartan 40mg or 80mg
79259111|NCT02382796|Drug|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
79259112|NCT04901260|Device|AMAZE™ Disease Management Platform|The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
79259113|NCT02382640|Drug|Febuxostat XR|Febuxostat extended-release (XR) capsules
79259114|NCT02382640|Drug|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
79259115|NCT02801669|Drug|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
79558095|NCT06056258|Dietary Supplement|Placebo|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
79721083|NCT01257230|Drug|placebo Respimat|placebo representing comparator
79721084|NCT01257230|Drug|tiotropium Respimat high dose|IMP
79721085|NCT01113801|Drug|LY2382770|Subcutaneous injection given monthly for 12 months
79855914|NCT04850196|Other|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
79855915|NCT00427960|Behavioral|Dietary advice|
79259116|NCT02801669|Drug|placebo|Placebo orally administered once daily.
79259117|NCT02057471|Drug|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
79558096|NCT06055231|Behavioral|Vape device|Consume THC via vape defice
79558097|NCT06055231|Behavioral|Joint|Consume THC via joint
79558098|NCT06055231|Drug|Marijuana via vape device|Given via vape device
79558099|NCT06055231|Drug|Marijuana via joint|Given via joint
79558100|NCT06049693|Drug|Ferrous Gluconate 300 MG|Ferrous Gluconate 300 MG twice a day
79558101|NCT06047457|Biological|Botulinum toxin type A|"Dose A U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
79721086|NCT01113801|Drug|Placebo|Subcutaneous injection given monthly for 12 months
79721087|NCT01256684|Drug|Placebo|Placebo vaginal suppository
79721088|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
79721089|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
79721090|NCT01204710|Biological|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
79721091|NCT01204710|Drug|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
79721092|NCT01204710|Drug|Prednisone|5 mg orally (PO) twice daily (BID) on each day
79721093|NCT02881359|Device|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
79721094|NCT00625755|Biological|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
79721095|NCT01256450|Drug|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
79855916|NCT00427960|Drug|rosuvastatin|rosuvastatin 5 mg
79855917|NCT00427960|Drug|atorvastatin|atorvastatin 10 mg
79855918|NCT00548340|Drug|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
79259118|NCT02057627|Behavioral|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
79558102|NCT06047457|Biological|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
79558103|NCT06047457|Other|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
79558104|NCT06047457|Biological|Botulinum toxin type A|"Dose A U/I, IM on Week 24 and Week 36 with a total of 2 injections."
79558105|NCT06047457|Biological|Botulinum toxin type A|"Dose B U/I, IM on Week 24 and Week 36 with a total of 2 injections."
79558106|NCT06047444|Biological|Botulinum toxin type A|"Dose A Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
79558107|NCT06047444|Biological|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
79558108|NCT06047444|Other|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
79721096|NCT01256450|Drug|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
79855919|NCT00548340|Drug|Placebo|Placebo capsules, PO daily for five weeks
79855920|NCT00548340|Drug|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
80019349|NCT01316419|Drug|amlodipine|amlodipine 5mg or 10mg
79259119|NCT02057627|Behavioral|Placebo Comparator|Standard care plus depression monitoring by phone
79558109|NCT06047444|Biological|Botulinum toxin type A|"Dose A U/I, IM at Week 24 and Week 36 with a total of 2 injections."
79558110|NCT06047444|Biological|Botulinum toxin type A|"Dose B U/I, IM at Week 24 and Week 36 with a total of 2 injections."
79721097|NCT01204398|Drug|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
79259120|NCT02804399|Drug|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
79259121|NCT02804399|Drug|rifampin|600 mg QD from day 1 to day 12 in period 2.
79721098|NCT04306575|Other|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
80019350|NCT03262324|Other|VAS-FA Turkish version|Self-reported outcome questionnaires
79259122|NCT02053025|Dietary Supplement|mycoprotein|
80019351|NCT03547362|Dietary Supplement|Casein|See arm description
80019352|NCT03547362|Dietary Supplement|Dairy protein blend 1|See arm description
79259123|NCT02053025|Dietary Supplement|control protein|
79259124|NCT02038439|Behavioral|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
79259125|NCT02038439|Behavioral|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
79259126|NCT02038439|Behavioral|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
79259127|NCT02055989|Radiation|Dose-escalated radiotherapy level 1|
79558117|NCT06044818|Device|Accexible|Speech Analysis
79558118|NCT06043817|Drug|STX-721 (Escalated)|STX-721 dose will be escalated per Safety Evaluation Team (SET) decision and BLRM-design.
79558119|NCT06043817|Drug|STX-721 (2 doses)|Participants will receive 2 doses of STX-721.
79558120|NCT06043817|Drug|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
79558121|NCT06042179|Behavioral|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
79558122|NCT06042179|Behavioral|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
79721099|NCT04318236|Behavioral|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
79721100|NCT01111851|Drug|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
80019353|NCT03547362|Dietary Supplement|Whey protein|See arm description
80019354|NCT03547362|Dietary Supplement|Dairy protein blend 2|See arm description
79259128|NCT02055989|Radiation|Sequential dose-escalated radiotherapy level 2|
79259129|NCT02053181|Drug|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
79259130|NCT05614037|Drug|Felodipine sustained release tablets (trade name: plendil®)|Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
79259131|NCT05614037|Drug|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
79558123|NCT06041334|Biological|Collection of a urine sample|Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
79558124|NCT06041334|Diagnostic Test|Magnetic Resonance Imaging of the bladder|Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
79558125|NCT06039605|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.
79259132|NCT02058797|Behavioral|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
79259133|NCT02058797|Behavioral|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
79558126|NCT06039189|Drug|Guselkumab|Guselkumab will be administered as subcutaneous injection.
79558127|NCT06039189|Drug|Placebo|Placebo will be administered as subcutaneous injection.
79558128|NCT06038175|Device|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, & LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of >150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is <0.8 in the presence of refixation saccades .
79558129|NCT06038175|Other|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
79558130|NCT06035549|Behavioral|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
79558131|NCT06031584|Drug|BL-M07D1|BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
79558132|NCT06030076|Drug|Tildrakizumab|As provided in real-world clinical practice.
79558133|NCT06029257|Drug|Tildrakizumab|As provided in real-world clinical practice.
80019355|NCT03547362|Dietary Supplement|Dairy protein blend 3|See arm description
79558134|NCT06028997|Behavioral|Behavioral and Sleep Hygiene Education with Mindfulness Intervention|Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
79721101|NCT01111851|Drug|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
80019356|NCT03547362|Dietary Supplement|Dairy protein blend 4|See arm description
79259134|NCT02058875|Drug|Myfortic®|
79259135|NCT02058875|Drug|Neoral®|
79558138|NCT06028165|Procedure|Coronary artery bypass grafting based on conventional coronary angiography|Revascularized coronary arteries are decided based on conventional coronary angiography.
79558139|NCT06028165|Procedure|Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.|Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
79721102|NCT01111851|Drug|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
79721103|NCT01111851|Drug|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
79721104|NCT01111851|Drug|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
79721105|NCT01111851|Drug|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
79721106|NCT01111851|Drug|MK0999|I.V. infusion of MK0999 containing ~100 MBq (~3 mCi) containing ≤ 5 ug of MK0999)
79721107|NCT01256294|Drug|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
79721108|NCT01256294|Drug|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
79259136|NCT02058875|Drug|Cellcept®|
79259137|NCT02058875|Drug|Prednisone|
79259138|NCT02058953|Procedure|Craniotomy scheduled|Resection of affected brain tissue
79259139|NCT02058953|Procedure|Collection for non-craniotomy|CSF, Blood, biopsy
79259140|NCT03561155|Device|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
79558140|NCT06027008|Device|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~severe ventilator instability (requiring > 12 cm H2O PEEP and dependency of > 60% FiO2);~severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~extra corporal membrane oxygenation (ECMO); and~deeply sedated patient (RASS score ≤ -4)."
79558141|NCT06024642|Drug|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
79558142|NCT06024642|Drug|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
79721109|NCT04310241|Behavioral|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
79721110|NCT01256060|Drug|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
79721111|NCT02880501|Device|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
79721112|NCT01255904|Drug|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
79721113|NCT01255904|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
79397129|NCT01484197|Drug|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
79397130|NCT01484197|Drug|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
79721114|NCT01255904|Other|Oral placebo|Oral saline administered
79721115|NCT01255904|Other|Intranasal placebo|Intranasal saline administered
79721116|NCT01255670|Drug|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
79721117|NCT01255592|Drug|AZD5069|Oral dose bid
79721118|NCT01255592|Drug|Placebo|Oral dose bid
79397131|NCT01484197|Drug|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
79397132|NCT01484197|Drug|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
79397133|NCT01473407|Biological|Epoetin Hospira|Variable dose
79397134|NCT01473407|Biological|Epogen (Amgen)|Variable dose
79397135|NCT01472939|Drug|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
79721119|NCT01255436|Other|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
79721120|NCT01255436|Other|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
79721121|NCT01203930|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
79721122|NCT01203930|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
79721123|NCT01254890|Drug|Azacitidine|75 mg/m^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
79721124|NCT01254890|Drug|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
79721125|NCT01203852|Drug|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
79259141|NCT03561155|Other|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
79259142|NCT02038595|Radiation|PET imaging|
79259143|NCT02059031|Drug|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
79721126|NCT01203852|Drug|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
79721127|NCT01105533|Drug|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
79721128|NCT01105533|Drug|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
79721129|NCT01105533|Drug|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
79721130|NCT01105533|Drug|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
79721131|NCT01105533|Drug|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
79721132|NCT01105533|Drug|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
79721133|NCT01105533|Drug|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
79721134|NCT01105533|Drug|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
79721135|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
79721136|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
79259144|NCT02059031|Drug|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
79558143|NCT06018662|Other|A medication management mobile application|A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
79558144|NCT06018064|Device|Prone Positioner|An innovative device to allow for infants to be supported while in the prone position
79558145|NCT06017908|Device|Optokinetic stimulation through Virtual Reality|The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
79558146|NCT06016842|Drug|Elafibranor|Duration: up to an estimated 84-month (7-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
79558147|NCT06016842|Other|Matched 80 mg placebo|Duration: up to an estimated 84-month (7-year) double-blind treatment period during which matching placebo tablet will be administered once daily
79721137|NCT01203072|Drug|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
79721138|NCT01203072|Drug|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
79721139|NCT01203072|Drug|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
79721140|NCT01203072|Drug|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
79721141|NCT01203072|Drug|Placebo|Matching placebo oral tablets, once daily for 2 weeks
79721142|NCT01105377|Drug|entinostat|Given orally
79721143|NCT01105377|Drug|azacitidine|Given SC
79721144|NCT01105377|Other|laboratory biomarker analysis|Correlative studies
79721145|NCT04309071|Other|Dietary intervention|Salivary insulin responses to a standardized mixed meal
79721146|NCT01105065|Drug|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
79721147|NCT01111539|Drug|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
79721148|NCT01111539|Drug|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
79721149|NCT01111539|Drug|Blinded capsule|Blinded capsule administered orally, once daily.
79721150|NCT02880345|Drug|PEMBROLIZUMAB|
79721151|NCT02880345|Radiation|hypofractionated radiation|
80019357|NCT04465682|Device|Experimental: Dip Home-Based Dipstick Analyzer|Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
80031580|NCT04883164|Other|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
79259145|NCT02059031|Drug|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
79259146|NCT02059109|Procedure|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
79721152|NCT02880267|Device|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
79721153|NCT02879955|Other|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
79721154|NCT02879955|Other|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
79721155|NCT02879955|Other|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
79721156|NCT02879955|Other|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
79721157|NCT02880033|Drug|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
79721158|NCT02880033|Drug|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
79721159|NCT04308993|Procedure|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
79721160|NCT05052645|Procedure|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
79721161|NCT00625911|Drug|morphine|intravenous patient controlled analgesia, standard protocol
79721162|NCT00625911|Drug|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
79721163|NCT04110496|Drug|RTX-134|RTX-134 is a cellular therapy containing AvPAL
79721164|NCT01111149|Other|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
79721165|NCT01111149|Drug|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
79721166|NCT01111149|Drug|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
79721167|NCT01254656|Drug|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
79721168|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
79721169|NCT01254656|Drug|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
79721170|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
79721171|NCT01254656|Drug|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
79721172|NCT01254656|Drug|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
79397136|NCT01472939|Drug|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
79397137|NCT01472939|Drug|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
79397138|NCT01472939|Drug|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
79397139|NCT04082897|Drug|Obinutuzumab 25 MG/ML [Gazyva]|Obinutuzumab will be administered from C1 to C8
79397140|NCT04082897|Drug|Atezolizumab 60 MG/ML [Tecentriq]|Atezolizumab will be administered iv from C1 to C18
79397141|NCT04082897|Drug|Venetoclax Oral Tablet|Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35
79558148|NCT06016179|Drug|Tocilizumab|Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
79558149|NCT06015841|Biological|Placebo|The placebo is a solution matching the study vaccine formulation.
79558150|NCT06015841|Biological|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
79721173|NCT01110915|Device|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
79721174|NCT01110915|Device|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
79721175|NCT01254344|Drug|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
79259147|NCT03561077|Other|Mindfulness-based interventions (MBI's)|Mindfulness Based Intervention with eight sessions (one session per week) of two hours dedicated to adolescents will be provided. The intervention will focus on skill building and will incorporate mindfulness meditation, exercises and activities specially adapted to teenagers with chronic pain. Topics will include mind body connection, the effect of stress on pain, living in the present moment, focused awareness, responding versus reacting to pain and/ or difficult situations, non judgement, gratitude, kindness and compassion towards self and others.
79558151|NCT06015841|Biological|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
79558152|NCT06015841|Biological|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
79721176|NCT01254344|Drug|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
79721177|NCT01254344|Drug|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
79721178|NCT01254344|Drug|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
79721179|NCT02879877|Drug|UCB7858|
79721180|NCT02879877|Drug|Placebo|
79259148|NCT02059421|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~Sleep restriction therapy~Stimulus control instructions~Sleep hygiene education"
79259149|NCT02059421|Other|Johrei therapy|"Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~Therapy will be administered without physical contact.~During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
79397142|NCT01544179|Drug|Gefitinib|Investigational Drug
79397143|NCT01544179|Drug|Placebo|Matching placebo as comparator
79397144|NCT01544179|Drug|Pemetrexed|Chemotherapy (concomitant therapy)
79397145|NCT01544179|Drug|Cisplatin|Chemotherapy (concomitant therapy)
79397146|NCT01483651|Drug|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
79581150|NCT01933308|Other|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
79721181|NCT05051007|Drug|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
79721182|NCT05051007|Drug|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
79721183|NCT02881671|Genetic|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
80019358|NCT02290262|Other|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
80019359|NCT03763968|Other|treatment and outcome|
80019360|NCT04258150|Drug|Nivolumab|6 mg/kg IV q4w
80019361|NCT04258150|Drug|Ipilimumab|1 mg/kg IV twice q6w
80019362|NCT04258150|Drug|Tocilizumab|8 mg/kg IV q4w
80019363|NCT04258150|Radiation|SBRT|"A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~PTV should be covered by 95% isodose (PTV D99% > 95%)."
79558153|NCT06014125|Other|psychoeducative program|"The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent."
79721184|NCT02879565|Other|Semi structured interviews + EEG exams|
79721185|NCT04310319|Dietary Supplement|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
79721186|NCT04310319|Dietary Supplement|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
80019364|NCT03546348|Other|no intervention|only measurement of the carrying angle
80019365|NCT02964039|Behavioral|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
79259150|NCT01333943|Procedure|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
80019366|NCT02964039|Behavioral|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
79259151|NCT01333943|Procedure|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
79259152|NCT01333865|Drug|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
79259153|NCT01333475|Drug|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
79259154|NCT04978922|Device|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
79397147|NCT01483651|Drug|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
80019367|NCT02964039|Behavioral|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
79397148|NCT03027349|Other|No intervention are provided|
79397149|NCT01464307|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
79397150|NCT01464307|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
79558154|NCT06012708|Drug|KN510 60mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
79558155|NCT06012708|Drug|KN510 120mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
79721187|NCT04310319|Dietary Supplement|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
79721188|NCT04310319|Dietary Supplement|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
80019368|NCT03217708|Device|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
79397151|NCT03027193|Biological|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
79558156|NCT06012708|Drug|KN510 120mg/day + KN713 90mg/day|Once daily with 28 days (4 weeks) as one cycle.
79558157|NCT06012708|Drug|KN510 120mg/day + KN713 120mg/day|Once daily with 28 days (4 weeks) as one cycle.
79558158|NCT06010329|Drug|Sutetinib Maleate Capsule|Oral administration
79721189|NCT01102803|Behavioral|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
79721190|NCT01102803|Drug|D-Cycloserine|D-Cycloserine
79721191|NCT01102803|Drug|Placebo|Sugar Pill
79721192|NCT01254188|Drug|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
79721193|NCT01109979|Drug|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
79721194|NCT01109979|Drug|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
79259155|NCT04978688|Drug|Relugolix|Administered as an oral tablet once daily.
79855921|NCT04839588|Other|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
80019369|NCT02290418|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
80019370|NCT02290418|Procedure|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
80019371|NCT04227730|Diagnostic Test|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
80019372|NCT02290496|Behavioral|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
79259156|NCT04978688|Drug|E2/NETA|Administered as an oral tablet once daily.
79259157|NCT03062072|Drug|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
79277441|NCT03529279|Radiation|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
79397152|NCT03027193|Biological|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
79397153|NCT01483183|Drug|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
79721195|NCT01102491|Drug|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
79721196|NCT01102257|Drug|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
79397154|NCT01483183|Drug|Placebo|Placebo dose, 10-minute constant rate IV infusion
79397155|NCT01483027|Device|TheraSphere|yttrium 90 microspheres
79397156|NCT01463683|Biological|2XP HEPTAVAX™-II SC|
79397157|NCT01463683|Biological|1XP HEPTAVAX™-II SC|
79397158|NCT01463683|Biological|2XP HEPTAVAX™-II IM|
79855922|NCT03994198|Dietary Supplement|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
79721197|NCT01102257|Drug|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
79721198|NCT01253564|Drug|RO5185426|960 mg b.i.d. orally
79721199|NCT04309149|Dietary Supplement|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
79721200|NCT01108809|Drug|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
80019373|NCT02290496|Behavioral|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
79721201|NCT01253408|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
79558167|NCT06003556|Diagnostic Test|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
79558168|NCT06003543|Behavioral|Virtual Reality|Virtual Reality
79721202|NCT01253408|Drug|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
79721203|NCT02879799|Other|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
79558169|NCT06003049|Drug|OnabotulinumtoxinA|BOTOX injection series
79558170|NCT06003049|Other|Placebo|Placebo injection series
79558171|NCT05998655|Other|tele nursing|"In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets."
79558172|NCT05997420|Behavioral|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
79558173|NCT05997420|Behavioral|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
79558174|NCT05995925|Other|Clinical Observation|Clinical Observation
79721204|NCT02879643|Drug|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
79721205|NCT02879487|Device|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
79721206|NCT02879721|Drug|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
79721207|NCT02879721|Drug|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
79721208|NCT01253174|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
79721209|NCT01253174|Drug|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
79721210|NCT01253174|Drug|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
79558175|NCT05994612|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions
79558176|NCT05994612|Behavioral|Services as Usual|Participants will receive services that they would normally receive in the community.
79721211|NCT01108731|Drug|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
79721212|NCT01108731|Drug|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
79721213|NCT04308447|Device|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
79721214|NCT01253018|Behavioral|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
79259158|NCT04876820|Other|Pharmacist intervention|"In the intervention arm, the patient meets with the pharmacist. Pharmaceutical intervention (H1) about anti-epileptic drugs prescribed will be done: information on when to take the medication, what to do if you forget to take it or vomit, and an explanation of adverse events. The aim is to improve medication adherence and patient knowledge. A report will be sent to the community pharmacist.~An assessment of medication adherence to antiepileptic drug by MPR at H1 3 months and 6 months (phone call to community pharmacist) will be done. The health insurance score will also be done.~An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at H1 in pre- post interview -, 3 and 6 months (phone call to patient) will be done.~An assessment of pharmacists' satisfaction about community hospital network by a satisfaction questionnaire will be done."
79259159|NCT04876820|Other|Standard of care|An assessment of medication adherence to antiepileptic drug by MPR at the inclusion then 3 months and 6 months later will be done by a phone call to the community pharmacist. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at the inclusion then 3 and 6 months later will be done by a phone call to the patient. The health insurance score will be also done during this call.
79259160|NCT04434326|Drug|[14]CM082 suspension|Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
79259161|NCT01333397|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
79259162|NCT01333397|Biological|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
79259163|NCT01333397|Drug|Placebo|I.M. on day 1 (single treatment cycle)
79259164|NCT04974320|Biological|blood biomarkers|All patients were obtained blood biomarkers: troponin, ST2, copeptin
79259165|NCT02172872|Drug|standard combination chemotherapy|"Cycle 1~daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~Cycle 2~daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~Cycle 3 (mini-ICE)~idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~etoposide (100 mg/m²) infusion (1 hr) for 3 days~Cycle 4 (mini-ICE) (optional)~idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~etoposide (100 mg/m²) infusion (1 hr) for 3 days"
79558177|NCT05994157|Drug|CD38-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
79558178|NCT05991544|Behavioral|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
79558179|NCT05990803|Drug|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
79558180|NCT05990803|Drug|SI-B003|SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
79558181|NCT05989802|Diagnostic Test|Oral swab molecular testing|Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.
79558182|NCT05989802|Diagnostic Test|Automated Cough Sound Analysis|Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.
79721215|NCT01253018|Behavioral|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
79721216|NCT04308915|Behavioral|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
79721217|NCT04308525|Behavioral|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
79855923|NCT03994198|Dietary Supplement|Collagen peptides|Collagen peptides from bovine sources
79855924|NCT04142814|Procedure|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
79259166|NCT02172872|Drug|decitabine|"Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~Cycle 2~if bone marrow (BM) blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~Cycle 3~if BM blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
79259167|NCT02059577|Dietary Supplement|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
79259168|NCT04974242|Other|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
79259169|NCT02059655|Drug|Bimatoprost|
79259170|NCT02059655|Drug|Eye drop solution|Artificial tear drops
79259171|NCT03061448|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
79558183|NCT05989802|Diagnostic Test|Automated Lung Sound Analysis|Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.
79558184|NCT05989802|Other|Chest X Ray Computer Aided Detection|Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
79558185|NCT05989412|Other|Patient health questionnaire-9 via the Your Research application|Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
79558186|NCT05988515|Behavioral|Speech-Language Pathologist-led Speech Motor Chaining|Sessions begin with Pre-practice to elicit the /r/ sound. During Structured Practice, the same utterance is practiced several times in a row (with systematic increases in difficulty based on performance). Our web-based software manipulates the principles of motor learning, including feedback prompts for the clinician, the complexity of the utterance, and the variability in the practice trial; the software will analyze the clinician's rating to increase the difficulty of practice when the child is more accurate. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order. A trained speech-language pathologist is involved in all practice trials to provide feedback throughout the session.
79259172|NCT02059733|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
79259173|NCT03062618|Drug|PRCL-02|Oral tablet(s) administered with water
79259174|NCT03062618|Drug|Placebo Oral Tablet|Administered with water
79259175|NCT02057783|Other|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
79259176|NCT02260115|Device|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
79259177|NCT02260115|Procedure|Surgical Control|Surgery only
79397159|NCT01482169|Drug|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
79397160|NCT01481779|Drug|Glargine|Administered by SC injection via a pen device.
79855925|NCT04142814|Procedure|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
79397161|NCT01481779|Drug|LY2605541|Administered by SC injection with a pen device.
79259178|NCT03561311|Device|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
79397162|NCT01481779|Drug|Insulin Lispro|Administered by SC injection with a pen device.
79397163|NCT04409587|Drug|Aspart|"A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion."
79259179|NCT03561311|Device|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
79558187|NCT05988515|Behavioral|Artificial Intelligence-led Speech Motor Chaining (CHAINING-AI)|Sessions include Structured Practice and Randomized Practice using our web-based software with an Artificial Intelligence clinician to address the /r/ sound. Within a practice session, participants speak into a microphone, and the audio file is sent to a server to be analyzed by a classifier, which returns a binary accurate/inaccurate rating of productions in a fashion similar to SLP judgment. Our web-based software manipulates the principles of motor learning, including feedback prompts, the complexity of the utterance, and the variability in the practice trial. The software will analyze the child's accuracy as determined by the classifier to increase the difficulty of practice when the child is more accurate.
79259180|NCT02058017|Drug|OPB-51602|
79855926|NCT04010760|Diagnostic Test|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
79558188|NCT05986591|Combination Product|Test Product - Tiotropium Bromide Inhalation Powder 18 mcg|Test Product
79558189|NCT05986591|Combination Product|Spiriva Handihaler (Tiotropium Bromide) 18 mcg|RLD
79721218|NCT04308525|Behavioral|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
79721219|NCT04308525|Other|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
79721220|NCT04308525|Procedure|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
79721221|NCT04308525|Procedure|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
79855927|NCT00955890|Drug|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
79855928|NCT00955890|Drug|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
79558190|NCT05986591|Combination Product|Placebo|Placebo Product
79558191|NCT05984147|Drug|AUR108|3 Days dosing, and 4 days no dose in a week
79259181|NCT05636501|Other|Treat-to-target Prednisolone Taper|Systematic prednisolone taper
79259182|NCT05636501|Other|Usual care|Prednisolone taper performed by discretion of the patient's general practitioner.
79259183|NCT02058173|Drug|150 mg/daily chloroquine compare to placebo for 12 week|
79259184|NCT02058173|Drug|Chloroquine|
79259185|NCT02058173|Drug|placebo|
79259186|NCT02058329|Other|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
79259187|NCT02060201|Drug|Saxagliptin|
79259188|NCT02060201|Drug|Dapagliflozin|
79259189|NCT02060201|Drug|Saxagliptin/Dapagliflozin FDC|
79259190|NCT03561233|Drug|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
79259191|NCT02058407|Drug|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
79259192|NCT02058407|Drug|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
79259193|NCT02058407|Drug|Placebo solution|Matching placebo to GSK2793660 solution
79259194|NCT02058407|Drug|Placebo capsule|Matching placebo to GSK2793660 capsule
79259195|NCT02058485|Drug|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
79259196|NCT02058485|Drug|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
79397164|NCT04096261|Diagnostic Test|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
79397165|NCT01463527|Device|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
79259197|NCT02060279|Other|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
79259198|NCT02060279|Other|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
79721222|NCT04308525|Other|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
79558192|NCT05978102|Drug|STI-7349|Administered by intravenous infusion (IV)
79558193|NCT05978102|Drug|Pembrolizumab|Administered by intravenous infusion (IV)
79558194|NCT05978102|Drug|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
79558195|NCT05977439|Device|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
79721223|NCT04308525|Other|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
79721224|NCT02881437|Drug|IgHy10|Sub Cutaneous IgHy10 administration
79721225|NCT01108341|Drug|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
79259199|NCT02058641|Drug|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
79558196|NCT05972889|Device|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
79558197|NCT05972889|Device|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
79558198|NCT05972174|Biological|mRNA-1018 for H5N8|Sterile liquid for injection
79259200|NCT03560921|Diagnostic Test|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
79259201|NCT03560843|Behavioral|MBSR|Mindfulness Based Stress Reduction
79259202|NCT02060357|Device|Optical coherence tomography|
79259203|NCT02060435|Other|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
79259204|NCT02059811|Other|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
79558199|NCT05972174|Biological|mRNA-1018 for H7N9|Sterile liquid for injection
79558200|NCT05972174|Biological|mRNA-1018 for H5 Only|Sterile liquid for injection
79558201|NCT05972174|Biological|mRNA-1018 for H7 Only|Sterile liquid for injection
79721226|NCT01108341|Drug|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
79721227|NCT01108263|Drug|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
79721228|NCT01252940|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
79558202|NCT05972174|Biological|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
79721229|NCT01252940|Drug|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
79721230|NCT01252940|Drug|RTV|Ritonavir (RTV) was administered according to prescribing information.
79721231|NCT01252940|Drug|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
79721232|NCT02879331|Procedure|10 coils in upper lobes|
79721233|NCT02879331|Procedure|15 coils in upper and lower lobes|
79721234|NCT02879331|Procedure|cycloergometry|
79721235|NCT04319744|Other|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
79397166|NCT01509547|Drug|Varenicline|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
79855929|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
79397167|NCT01509547|Drug|placebo|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
79855930|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
80019374|NCT03548298|Procedure|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
79397168|NCT01509079|Drug|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
79721236|NCT04206878|Diagnostic Test|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
79721237|NCT01252238|Drug|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
79855931|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
79259205|NCT02059811|Other|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
79855932|NCT00454246|Drug|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
79259206|NCT02060981|Behavioral|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
79397169|NCT01509079|Drug|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
79259207|NCT02060981|Behavioral|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
79259208|NCT02060981|Behavioral|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
79721238|NCT01252238|Drug|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
79721239|NCT01252238|Drug|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
79721240|NCT01101477|Procedure|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~Patients become irritant and interfere procedures.~Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~Systolic blood pressure is less than 90mmHg;~Mean arterial blood pressure is less than 65mmHg;~Oxyhemoglobin saturation is less than 90 %~with any duration."
79721241|NCT00624260|Other|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
79259209|NCT03799367|Device|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
79397170|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
79397171|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
79721242|NCT00624260|Other|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
79721243|NCT04308213|Device|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
79855933|NCT00454246|Drug|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
80019375|NCT03644433|Procedure|Single layer closure|Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
79397172|NCT01463293|Dietary Supplement|Placebo|Capsule containing no probiotic once a day
79397173|NCT04650217|Drug|Carbidopa/levodopa|"L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose."
79397174|NCT04650217|Drug|Placebo|Carbidopa/levodopa matched placebo
80019376|NCT03644433|Procedure|Double layer closure after resection uterine scar|Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
80019377|NCT02289014|Other|online stress Management program|Active treatment group
79721244|NCT01251770|Drug|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 body surface.
79855934|NCT00454246|Drug|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
80019378|NCT05577078|Procedure|Transcatheter edge-to-edge repair (TEER)|Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
80019379|NCT02289170|Device|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
80019380|NCT02289170|Device|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
79259210|NCT03560687|Drug|Sucrosomial Iron|CardioSideral 2 caps per day
79259211|NCT02061059|Other|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
79397175|NCT04650217|Behavioral|Exercise training|Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
80019381|NCT02854696|Procedure|Islet graft|Patients will be transplanted with pancreatic islet cells
79558204|NCT05971537|Drug|antibiotic lock|"In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL"
79558205|NCT05971537|Drug|conventional IP antibiotics|In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
80019382|NCT02854696|Drug|best medical care|Patients will continue their insulin treatment
80019383|NCT02289248|Drug|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
80019384|NCT02289248|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
79558206|NCT05970120|Device|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
79721245|NCT01251770|Drug|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 surface.
79721246|NCT01101321|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
80019385|NCT05348304|Dietary Supplement|EUDIAMET|A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
80019386|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 & Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
79558207|NCT05969145|Procedure|application of thermophor|The experimental group will be given hot and cold application to the bladder
79721247|NCT01101321|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
79259212|NCT02061059|Other|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
79259213|NCT02061059|Other|standard|patient wears shoes produced with standard method
79259214|NCT02061059|Other|with measurements|patient wears shoes produced with plantar pressure measurements
79259215|NCT02059889|Device|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
79259216|NCT02059889|Device|4-dimensional computed tomography|Undergo 4D CT
79259217|NCT02059889|Radiation|fludeoxyglucose F 18|Undergo FDG-PET
79259218|NCT02059889|Device|FDG-PET|Undergo FDG-PET
79259219|NCT02798861|Device|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
79259220|NCT02059967|Drug|Paclitaxel|Given IV
79855935|NCT04717284|Other|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
79259221|NCT02059967|Radiation|image-guided adaptive radiation therapy|Undergo IGART
79721248|NCT04309929|Drug|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
79721249|NCT01101165|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
79721250|NCT01101165|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
79721251|NCT01100853|Drug|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
79721252|NCT02881281|Other|educational program for Development of problem-solving skills|
79721253|NCT02881281|Other|no education program|no education program
79855936|NCT04717284|Other|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
79855937|NCT00434590|Drug|Enteric coated mycophenolate sodium (Myfortic®)|
79855938|NCT04711512|Behavioral|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
79855939|NCT04711512|Behavioral|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
79855940|NCT04010838|Procedure|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
79855941|NCT04012164|Biological|blood sampling|5ml blood sampling
79855942|NCT04012164|Biological|stool collection|self stool collection (2g)
79855943|NCT04012164|Other|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
79855944|NCT04012164|Other|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
79855945|NCT04674618|Device|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
80019387|NCT02253420|Drug|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
79259222|NCT02059967|Drug|carboplatin|Given IV
79259223|NCT02061137|Drug|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
79259224|NCT02061215|Other|CMV viral load|
79397176|NCT04650217|Behavioral|Control|Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
79855946|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
79855947|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
79855948|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
80019388|NCT02253420|Drug|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
80019389|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
79259225|NCT02061371|Other|virtual therapy|
79259226|NCT02061371|Other|conventional physiotherapy|
79259227|NCT02061449|Drug|Romidepsin|
79259228|NCT02061449|Drug|Poly ICLC|
79259229|NCT02061449|Radiation|Focal lesional radiation|
79259230|NCT02060591|Drug|Exparel|
79259231|NCT02060591|Drug|Marcaine|
79259232|NCT02060045|Other|Bundle implementation|
79259233|NCT03800615|Procedure|Cut the sling|Cut the mid-urethral sling for stress urinary incontinence
79397177|NCT01479985|Other|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
79397178|NCT02074345|Biological|TAK-816|TAK-816 intramuscular injection
79397179|NCT01462435|Drug|Diclofenac Test (lower dose)|Capsules
79397180|NCT01462435|Drug|Diclofenac Test (upper dose)|Capsules
79721254|NCT00626067|Device|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
79721255|NCT00626067|Device|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
79721256|NCT00626067|Device|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
79721257|NCT01100307|Drug|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
79721258|NCT01100307|Other|sham injection|sham injection every 6 weeks
79855949|NCT02891837|Drug|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
79259234|NCT02060669|Drug|Xeloda|Xeloda
79558208|NCT05965414|Drug|CS6253 Solution for Injection|Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)
79558209|NCT05965414|Drug|Placebo|Physiological saline solution for intra-venous injection
79558211|NCT05956002|Drug|Estraimod Immediate Release (IR)|an immediate release tablet
79558212|NCT05956002|Drug|Etrasimod Mini Tab in water|very small tablet mixed in water
79558213|NCT05956002|Drug|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
79558214|NCT05956002|Drug|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
79721259|NCT01099917|Drug|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
79558215|NCT05956002|Drug|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
79558216|NCT05948826|Drug|TORL-3-600|antibody drug conjugate
79855950|NCT02891837|Other|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
79259235|NCT02060123|Behavioral|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
79259236|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
79259237|NCT05654441|Biological|Influenza vaccine|0.5 mL single-dose injection
79259238|NCT05654441|Biological|Placebo|0.5 mL single-dose injection with no therapeutic effect
79558221|NCT05946252|Other|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~To imagine walking activity in different environments (seaside, beach, walking path).~The rest activity will be imagined by sitting on a bench.~Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~The rest activity will be imagined by sitting on a bench.~Imagination will end with homecoming and domestic activities."
79558222|NCT05946252|Other|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
79558223|NCT05940415|Behavioral|active surveillance|active surveillance without prostate biopsy
79259239|NCT04428008|Drug|Thymalfasin|Synthetic 28 amino acid peptide
79259240|NCT02061527|Procedure|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
79259241|NCT02061527|Procedure|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
79558224|NCT05928546|Drug|Quercetin|"Intra-pocket application of quercetin nanoemulgel :~After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket ."
79558225|NCT05928546|Device|scaling and root planing|- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
79558226|NCT05926830|Device|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
79397181|NCT01462435|Drug|Celecoxib|200 mg Capsules
79397182|NCT01462435|Drug|Placebo|Capsules
79397183|NCT01472081|Biological|Nivolumab|
79397184|NCT01472081|Biological|Pazopanib|
79558227|NCT05924217|Other|Survey questionnaire|This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.
79558228|NCT05922319|Other|Computerized cognitive training with different training doses|The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.
79721260|NCT02879097|Biological|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
79721261|NCT02879097|Biological|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
79721262|NCT02879097|Drug|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
79721263|NCT02879097|Drug|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
79855951|NCT03682458|Genetic|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
79259242|NCT02061527|Procedure|Reconstruction with implant|Immediate breast reconstruction with implant
79259243|NCT02061527|Procedure|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
79259244|NCT02061527|Procedure|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
79259245|NCT02046590|Drug|Propofol|
79397185|NCT01472081|Drug|Sunitinib|
79397186|NCT01472081|Biological|Ipilimumab|
79397187|NCT01471691|Drug|ranibizumab 0.5mg|Standard dose
79558229|NCT05921370|Drug|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 3 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
79721264|NCT04307901|Device|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
79855952|NCT04009590|Other|Educational Intervention|Read educational booklet
79855953|NCT04009590|Other|Questionnaire Administration|Ancillary studies
79855954|NCT04009590|Behavioral|Smoking Cessation Intervention|Utilize Quit4Health
79558230|NCT05921370|Drug|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 3 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 3 days before their scheduled retrograde intrarenal surgery."
79558231|NCT05919069|Drug|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
79855955|NCT00961974|Behavioral|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
79259246|NCT02046590|Other|General anesthesia|
79259247|NCT02060747|Behavioral|Coordinator-based post fracture program|
79397188|NCT01471691|Drug|ranibizumab 1.0mg|High dose
79397189|NCT01471379|Drug|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
79397190|NCT01471379|Drug|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
79397191|NCT01471379|Drug|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
79259248|NCT02062073|Drug|Abametapir Lotion 0.74% w/w|
79259249|NCT02062073|Other|0.1% sodium lauryl sulfate|
79259250|NCT02062073|Other|saline 0.9%|
79259251|NCT02062073|Other|Vehicle Lotion|
79259252|NCT02060825|Device|Regional saturation monitor|
79259253|NCT02063243|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
79259254|NCT02796755|Drug|Riluzole|Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
79259255|NCT02796755|Drug|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
79397192|NCT01471379|Drug|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
79397193|NCT01470989|Drug|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
79397194|NCT01470989|Drug|Triamcinolone acetonide 40 mg|Participants received 40 mg intramuscular (IM)
79397195|NCT01470599|Drug|CP-690,550|ORAL TABLET, TWICE DAILY
79259256|NCT02062541|Other|Funct. assessment+fast rehabilitation|
80019390|NCT03523364|Device|dental restorations|partial or complete ceramic restorations bonded to dental tissues after WAB and total etching or after total etching
79721265|NCT04307823|Other|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
79721266|NCT04307823|Other|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
80019391|NCT04483180|Other|Comparison of sweetener blends in liquid form (cross-over study)|The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
80019392|NCT01566396|Device|A3F|A3F fractional RF treatments for facial wrinkles
80019393|NCT02289404|Drug|NVP-1203|Oral
80019394|NCT02289404|Drug|NVP-1203|Oral
79259257|NCT02062541|Other|Funct. assessment+usual rehabilitation|
79721267|NCT02880969|Behavioral|answering questionnaires|
79721268|NCT01099215|Biological|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
79855956|NCT00961974|Behavioral|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
79259258|NCT02062541|Other|usual assessment+fast rehabilitation|
79259259|NCT02062619|Behavioral|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
80019395|NCT05576766|Procedure|Routine care|"Routine information provided before surgery.~No nutritional therapy.~No aerobic exercise.~No pelvic floor muscle training.~No psychiatrist intervention.~Bowel preparation with oral cathartic agent.~Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~Hypothermia prevention not emphasized.~General anesthesia; regional block not emphasized.~Routine blood pressure management.~Mobilization from postoperative day 1.~Start oral feeding from postoperative day 1.~Patient-controlled analgesia with opioids.~Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~Routine pelvic drainage tube removal (usually at postoperative day 4).~Routine urinary catheterization removal (usually at postoperative day 14)."
79855957|NCT00962130|Device|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
79855958|NCT00695903|Drug|daptomycin|daptomycin 10 mg/kg IV every 24 hours
79855959|NCT00695903|Drug|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
79259260|NCT02062619|Other|Real tDCS|Real tDCS 20 minutes per session, three times per week
79259261|NCT02062619|Other|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
79855960|NCT02793167|Device|AKI alert|
79259262|NCT02062697|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
79259263|NCT02062697|Procedure|Liquid-PAP smear|
79259264|NCT02061839|Other|Sunscream with visible light protection|
79259265|NCT02061839|Other|Sunscream|
79259266|NCT02061917|Other|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
79259267|NCT02061917|Other|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
79259268|NCT02061917|Other|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
79259269|NCT03793049|Device|CADence testing will be performed|CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software
79259270|NCT02061995|Drug|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
79259271|NCT02062775|Procedure|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
79397196|NCT01470599|Drug|CP-690,550|ORAL TABLETS, TWICE DAILY
79397197|NCT04409171|Diagnostic Test|oral glucose tolerance test|
79397198|NCT01469819|Drug|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
79397199|NCT04618523|Drug|Artesunate-amodiaquine|Artemisinin-based combination treatment
79397200|NCT04618523|Drug|Artemether-lumefantrine|Artemisinin-based combination treatment
79397201|NCT01507831|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
79855961|NCT00548262|Drug|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
79855962|NCT00548262|Drug|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if <40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if <40 kg body weight).
79855963|NCT00742547|Other|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
79855964|NCT02757989|Other|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
79855965|NCT02565173|Drug|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
79558232|NCT05916937|Drug|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
79558233|NCT05916937|Drug|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
79397202|NCT01507831|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
79397203|NCT01507831|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
79397204|NCT01479595|Drug|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
79397205|NCT01479595|Drug|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
79259272|NCT02062775|Procedure|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
79721269|NCT02878941|Procedure|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
79721270|NCT02879019|Other|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
79721271|NCT02879019|Other|Walking training group|Patients will perform two walking session per week, each consisting of 15*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
79721272|NCT05087745|Biological|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
79721273|NCT02878863|Drug|Paeoniflorin + phosphatidylcholine or silymarin|
79259273|NCT02062775|Procedure|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures >2cm
79397206|NCT01462357|Biological|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
79397207|NCT01462357|Biological|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
79721274|NCT02878863|Drug|Phosphatidylcholine or silymarin|
79721275|NCT02881125|Drug|Nortriptyline Hydrochloride|Given PO
79721276|NCT02881125|Drug|Paclitaxel|Given IV
79855966|NCT02565173|Drug|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
79397208|NCT01462357|Drug|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
79397209|NCT03026569|Other|Orange juice (500 mL/d)|The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
79397210|NCT01479439|Drug|Losartan|Form: suspension, tablet. Dosage & frequency: age 6-16 = 0.7mg/kg once daily; age >16 = 50mg once daily. Duration: 6 months
79558236|NCT05902169|Device|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
79558237|NCT05902169|Drug|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x [glomerular filtration rate (GFR) mL/minute + 25]."
79558238|NCT05902169|Drug|Lomustine|Dosed and administered per labelling.
79558239|NCT05902169|Drug|Temozolomide|Dosed and administered per labelling.
79721277|NCT02880657|Dietary Supplement|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
79721278|NCT02880657|Dietary Supplement|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
79721279|NCT02880735|Device|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
79721280|NCT02880813|Other|Infusion|infusion of nutrients
79855967|NCT02565173|Drug|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
79721281|NCT05354193|Other|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure < 65 mmHg, cardiac index < 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
79855968|NCT02565173|Drug|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
79721282|NCT01107405|Drug|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
79259274|NCT05654285|Other|Cola beverage with aspartame and acesulfame K|"Before starting the study: Subjects were asked to avoid non-nutritive sweetener consumption for 48 hours prior to the study sessions. A standardized menu of 346 Kcal was prescribed for dinner and fasting for at least 8 hours prior to each study session. A 7-day washout period was left between each study session.~Session 1: Weight, height, and waist circumference were measured, the BMI was calculated, and sociodemographic data of the participants and information on the habitual consumption of soft drinks were collected.~In each session: The beverages were offered at approximately 4°C, in standardized disposable cups, and the participants were asked to drink them in a maximum time of 10 minutes. Heart rate, respiratory rate, and blood pressure were measured before the intervention and every 30 minutes during the observation period. The subjects who manifested adverse sensations were referred to receive medical attention and withdrawn from the session."
80019396|NCT05576766|Procedure|ERAS management pathway|"Patient consultation and education before surgery.~Nutritional intervention for patients whose BMI<18.5 or BMI>24 kg/m2.~Aerobic exercise for 2 weeks before surgery.~Pelvic floor muscle training for 2 weeks before surgery.~Psychiatrist intervention for patients with severe depression and anxiety.~No bowel preparation before surgery.~Provide oral carbohydrate solution 2 hours before surgery.~Hypothermia prevention.~General anesthesia combined with regional block.~Goal-directed fluid infusion and targeted blood pressure management.~Early mobilization.~Early oral feeding.~Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
79259275|NCT05654285|Other|Cola beverage with sucrose and stevia|
79855969|NCT02565173|Drug|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
79855970|NCT04619082|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
80019397|NCT04171804|Device|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
79259276|NCT03560375|Behavioral|Circuit resistance training (CRT)|"Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27"
80019398|NCT03521648|Procedure|PAE|Prostatic artery embolization
80019399|NCT03521648|Procedure|TURP|Transurethral resection of the prostate
79855971|NCT02724683|Device|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
79397211|NCT01478971|Drug|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous [IV] or subcutaneous [SC]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of <11 g/dL.
79397212|NCT01478971|Drug|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at <11 g/dL.
79397213|NCT01507051|Drug|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
79855972|NCT02724683|Behavioral|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
79855973|NCT02724683|Behavioral|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
79855974|NCT02724683|Device|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
79855975|NCT02724683|Other|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
79855976|NCT04593342|Device|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
79855977|NCT04593342|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
80019400|NCT03521648|Procedure|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
79259277|NCT03560375|Behavioral|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
79259278|NCT03560375|Drug|Empagliflozin 10 MG|Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
79259279|NCT02063477|Dietary Supplement|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
79259280|NCT02063477|Dietary Supplement|Oligopin®|"Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~- TOTAL POLYPHENOL CONTENT > 96~MONOMERS + PHENOLIC ACIDS 30~DIMERS >15~OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) > 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule"
79855978|NCT02717897|Other|No intervention|This study is not interventional
79259281|NCT02382016|Drug|Macitentan|Macitentan film-coated tablet 10 mg once daily.
79558242|NCT05892432|Drug|Semaglutide 3 MG [Rybelsus]|Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
79558243|NCT05892432|Drug|Semaglutide 7 MG [Rybelsus]|Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
79721283|NCT01107405|Drug|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
80019401|NCT02253732|Behavioral|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength & aerobic exercises
80019402|NCT02028364|Drug|Everolimus|10mg orally daily
80019403|NCT02028364|Drug|Exemestane|25mg orally daily
79397214|NCT01507051|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
79397215|NCT01507051|Drug|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
79397216|NCT01507051|Drug|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
79721284|NCT01107405|Drug|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
79397217|NCT04079257|Other|Blood collection for measurement of eculizumab peak concentrations|collection of blood
79397218|NCT04408339|Other|No Intervention|No Intervention
79397219|NCT01478347|Biological|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
79397220|NCT01478113|Drug|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
79558244|NCT05892432|Drug|Placebo|A medically inert placebo medication will be taken for 8 weeks.
79558245|NCT05890001|Drug|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
79721285|NCT01107405|Drug|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
79721286|NCT01107405|Drug|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
79721287|NCT01097577|Drug|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
79721288|NCT01097577|Drug|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
79721289|NCT01097421|Drug|Pramipexole Extended Release|
79721290|NCT02878629|Device|Mandibular Advancement Devices|
79721291|NCT02878395|Procedure|Ileocolic resection|
79721292|NCT04205877|Device|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
79721293|NCT01251614|Biological|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
79721294|NCT01251614|Drug|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
79721295|NCT01251614|Biological|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
80019404|NCT03547284|Drug|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
80031581|NCT02809833|Drug|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
80031582|NCT03788642|Procedure|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
79558246|NCT05888571|Procedure|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
79558247|NCT05888571|Procedure|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
79558248|NCT05888311|Device|Liquid bandage|Two areas measuring 3.0 cm x 3.0 cm will be randomly demarcated on one of your forearms, with activated carbon applied to both areas. An area to be treated with the experimental product will be determined by randomization.
79558249|NCT05888311|Other|Activated carbon|Two areas measuring 3.0 cm x 3.0 cm will be randomly demarcated on one of your forearms, with activated carbon applied to both areas. An untreated area (control area) will be determined by randomization.
79558250|NCT05886777|Biological|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
79721296|NCT01251614|Drug|Placebo to Methotrexate|Orally once a week
79721297|NCT01106625|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
79721298|NCT01106625|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
79855979|NCT04060667|Combination Product|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
79259282|NCT02382016|Other|Placebo|Matching placebo tablet once daily.
79855980|NCT03717623|Drug|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
79259283|NCT04899700|Device|Linked Color Imaging|Inspection of the postpolypectomy scar will be made with Linked Color Imaging
79259284|NCT04899700|Other|White light endoscopy|Inspection of the postpolypectomy scar will be made with White light Endoscopy
80019405|NCT02290652|Other|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
79259285|NCT02422186|Drug|Esketamine|All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
79259286|NCT02422186|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
79721299|NCT01106625|Drug|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
79721300|NCT01106625|Drug|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
80031583|NCT03788642|Procedure|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
80031584|NCT04897126|Drug|MUSK Pill|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
79259287|NCT02422186|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
79259288|NCT02422186|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
79397221|NCT01478113|Drug|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
79259289|NCT02422186|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
79397222|NCT01478113|Behavioral|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
79397223|NCT01506271|Drug|Relebactam 250 mg|Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
79397224|NCT01506271|Drug|Relebactam 125 mg|Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
79397225|NCT01506271|Drug|Imipenem/cilastatin|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
79397226|NCT01506271|Drug|Matching placebo to relebactam|Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
79397227|NCT01506193|Biological|PriorixTetra™|One dose administered subcutaneously
79397228|NCT01506193|Biological|Meningitec|One dose administered intramuscularly
79558251|NCT05886777|Biological|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
79558252|NCT05886777|Biological|RSVpreF|RSVpreF given as an intramuscular injection
79558253|NCT05886777|Biological|QIV|Licensed QIV given as an intramuscular injection
79721301|NCT01251380|Biological|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
79721302|NCT04307979|Dietary Supplement|High-fat coffee|A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
79721303|NCT04307979|Dietary Supplement|Black coffee|A regular black coffee with no added caloric content.
79855981|NCT00742703|Other|Mineralized water|
79558254|NCT05886777|Biological|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
79558255|NCT05886504|Other|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
79855982|NCT00742703|Other|Low mineralized water|
79721304|NCT04309539|Procedure|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
79558258|NCT05883644|Drug|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
79397229|NCT01505881|Drug|dabigatran etexilate low dose|active treatment (low)
79721305|NCT04309539|Procedure|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
79721306|NCT01251146|Drug|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
79721307|NCT01251146|Drug|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
79721308|NCT04309695|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
79721309|NCT04307745|Other|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
79855983|NCT00095173|Drug|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
79558259|NCT05883644|Drug|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
79855984|NCT00095173|Drug|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
79558260|NCT05878691|Drug|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
79558261|NCT05878691|Drug|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
79855985|NCT00095173|Drug|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly
79855986|NCT03704753|Drug|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
79855987|NCT03704753|Drug|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
79855988|NCT02565017|Behavioral|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
79855989|NCT01079689|Other|needle stimulation|stimulation with acupuncture needles
79855990|NCT00690443|Drug|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
79855991|NCT00690443|Drug|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
79855992|NCT03954834|Drug|Tirzepatide|Administered SC
79855993|NCT03954834|Drug|Placebo|Administered SC
79397230|NCT01505881|Drug|warfarin 5mg|comparator warfarin
79397231|NCT01505881|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
79397232|NCT01505881|Drug|warfarin 1mg|comparator warfarin
79397233|NCT01505881|Drug|dabigatran etexilate high dose|active treatment (high)
80031585|NCT04897126|Drug|Placebo|Placebo
79397234|NCT01505881|Drug|warfarin 3mg|comparator warfarin
79397235|NCT01462045|Behavioral|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
79397236|NCT01505647|Biological|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
79558262|NCT05878691|Drug|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
79259290|NCT02422186|Drug|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
79397237|NCT01505647|Biological|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
79397238|NCT01461811|Device|Nelfilcon A toric contact lenses (with comfort additives)|
79558263|NCT05878548|Procedure|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
79558264|NCT05876546|Device|Liquid bandage|The liquid bandage will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The liquid bandage will be applied again to the participants' back, in a naive area and removed after 48 hours.
79558265|NCT05876546|Device|Saline Solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back, in a naive area and removed after 48 hours.
79558266|NCT05876091|Other|Vaping|Undergo vape puffing regimen
79558267|NCT05876091|Procedure|Biospecimen Collection|Undergo collection of saliva samples and oral cell samples
79558268|NCT05876091|Other|Questionnaire Administration|Administer Quesitonnaire
79558269|NCT05869669|Drug|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
79558270|NCT05869669|Drug|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
79558271|NCT05868850|Behavioral|auricular point sticking|"Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
79721310|NCT02888678|Behavioral|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
79721311|NCT02888678|Behavioral|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
79721312|NCT00626145|Procedure|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
79855994|NCT00693017|Drug|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
79259291|NCT02796677|Drug|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
79397239|NCT01461811|Device|Nelfilcon A toric contact lenses|
79558272|NCT05865002|Drug|AUR107|Once daily
79558273|NCT05861947|Drug|AUR106|Once or twice daily
79558274|NCT05861934|Behavioral|Distant reiki group|ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
79259292|NCT02796677|Drug|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
79558275|NCT05852756|Behavioral|pecha kucha|pecha kucha training
79721313|NCT00626145|Procedure|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
79721314|NCT02878707|Drug|Dexmedetomidine|Intraoperative dexmedetomidine infusion
79721315|NCT02878551|Other|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
79259293|NCT02796677|Drug|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
79259294|NCT02796677|Other|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
79259295|NCT02796677|Drug|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
79259296|NCT02796677|Other|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
79397240|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
79397241|NCT01505491|Drug|BI695501|BI 695501 single s.c injection
79397242|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
79397243|NCT04077775|Diagnostic Test|assesment|assesment
79397244|NCT01504867|Drug|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
79721316|NCT01096017|Drug|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
79721317|NCT01096017|Drug|Salbutamol pMDI|200 μg, inhalation, single dose
79397245|NCT01504867|Drug|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
79397246|NCT01476475|Drug|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
79397247|NCT01476475|Drug|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
79259297|NCT05585099|Other|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
79558276|NCT05850520|Drug|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
79558277|NCT05850520|Drug|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
79721318|NCT01096017|Other|pMDI placebo pMDI|Placebo pMDI 2 inhalations
80019406|NCT02290652|Other|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
80019407|NCT02897115|Biological|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
80019408|NCT02897115|Other|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
79259298|NCT02062853|Other|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
79259299|NCT02062853|Other|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
79259300|NCT02063555|Biological|DAR-901|
79259301|NCT02063555|Biological|BCG|
79259302|NCT02063555|Biological|Sterile saline|
79259303|NCT04978532|Other|Guided Imagery|The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.
79259304|NCT04978532|Other|Control Group|No intervention was made in the children.
79259305|NCT01947842|Device|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
79259306|NCT04973462|Drug|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
79259307|NCT02421172|Biological|CJM112|CJM112 Fully human IgG1 monoclonal antibody
79259308|NCT02421172|Drug|Placebo|
79259309|NCT02379052|Drug|Dupilumab|
79397248|NCT01476475|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
79397249|NCT01475851|Drug|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
79397250|NCT01460719|Biological|V212|V212 viral antigen for HZ
79558278|NCT05850520|Drug|Sham|Sham procedure will be given on visits when an active injection is not planned.
79558279|NCT05850520|Diagnostic Test|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
79558280|NCT05849311|Drug|Envafolimab with new manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
79558281|NCT05849311|Drug|Envafolimab with old manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
79721319|NCT01096017|Other|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
79721320|NCT00626223|Drug|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
79721321|NCT00626223|Drug|folic acid|5 mg per day of oral folic acid
79259310|NCT02379052|Drug|Placebo|
79259311|NCT02378662|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
79259312|NCT02378506|Biological|etanercept|50mg subcutaneous, once weekly, 24 weeks
79259313|NCT02347774|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
79259314|NCT02347774|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
79259315|NCT02347774|Drug|Placebo eFlow (CS) nebulizer|Placebo BID eFlow (R) Closed System (CS) nebulizer
79259316|NCT02794883|Biological|Durvalumab|Given IV
79259317|NCT02794883|Other|Laboratory Biomarker Analysis|Correlative Studies
79259318|NCT02794883|Procedure|Surgical Procedure|Undergo surgical tumor resection
79259319|NCT02794883|Biological|Tremelimumab|Given IV
79397251|NCT00527943|Drug|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
79397252|NCT00527943|Drug|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
79259320|NCT02062931|Biological|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
79259321|NCT02063711|Behavioral|Yoga intervention|
79259322|NCT02063789|Drug|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
79259323|NCT03795857|Behavioral|Semi-structured interviews|The purpose of this study is to describe the experience of pregnancy by parents who have chosen to carry to term despite a lethal fetal diagnosis. Therefore, semi-structured interviews will be conducted to explore the links between context, feeling, involvement, decision and actions during pregnancy, whether within the couple or in its environment.
79397253|NCT00448227|Drug|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
79397254|NCT00529191|Drug|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
79397255|NCT00529191|Other|Placebo|One out of three subjects will receive a placebo.
79397256|NCT00459303|Device|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
79855995|NCT00693017|Drug|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
79855996|NCT03965065|Device|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
79855997|NCT03965065|Device|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
79397257|NCT00459303|Device|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
79397258|NCT00459381|Drug|pazopanib hydrochloride|Given orally
79558282|NCT05847231|Behavioral|Perceived Stress, Mandala application|Mandala
79558283|NCT05846984|Behavioral|Learning Skills Together Intervention|Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises.
79855998|NCT00692237|Drug|Sildenafil|100 mg daily (3 capsules/day)
79855999|NCT00692237|Drug|Placebo|Placebo 100 mg (3 capsules/day)
80031586|NCT03161054|Drug|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
79259324|NCT02063945|Drug|Methylphenidate|As stated in arm/group
79558284|NCT05846984|Behavioral|Caregiver Healthy Living Intervention|Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.
79558285|NCT05843747|Other|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
79856000|NCT00110149|Biological|rituximab|
79259325|NCT02063945|Drug|Risperidone|As stated in arm/group
79259326|NCT02064647|Other|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
79397259|NCT00459381|Other|laboratory biomarker analysis|Correlative studies
79397260|NCT00449007|Drug|fluoxetine|6 months
79397261|NCT00449007|Drug|bupropion|6 months
79397262|NCT00460551|Biological|Zalutumumab|8 mg/kg
79856001|NCT00110149|Radiation|yttrium Y 90 ibritumomab tiuxetan|
79397263|NCT00460551|Drug|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
79397264|NCT00460551|Radiation|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
79397265|NCT01468181|Drug|LY2189265|
79397266|NCT01468181|Drug|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
79397267|NCT01468181|Drug|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
79856002|NCT03890081|Other|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
79856003|NCT03964285|Other|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
79856004|NCT03964285|Other|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
79856005|NCT02530957|Device|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
79856006|NCT02530957|Device|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
79259327|NCT02064647|Other|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
79558287|NCT05840952|Drug|ALG-097558|single or multiple doses of ALG-097558
79558288|NCT05840952|Drug|Placebo|single or multiple doses of placebo
79558289|NCT05840952|Drug|Midazolam|Multiple doses of Midazolam
79558290|NCT05840952|Drug|Itraconazole|Multiple doses of Itraconazole
79558291|NCT05840952|Drug|Carbamazepine|Multiple doses of Carbamazepine
79856007|NCT01084057|Drug|vorinostat|Given orally
79558292|NCT05840952|Drug|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
79558293|NCT05840952|Drug|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
79558294|NCT05838378|Other|Package image sorting with pictorial warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories [fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
79856008|NCT01084057|Drug|ixabepilone|Given IV
79856009|NCT01084057|Other|laboratory biomarker analysis|Correlative studies
79856010|NCT01084057|Other|pharmacological study|Correlative studies
79856011|NCT03954444|Drug|Oxymetazoline Hydrochloride|Test Comparator
79856012|NCT03954444|Drug|Rhofade Cream, 1%|Reference Comparator
79856013|NCT03954444|Drug|Placebo|Placebo Comparator
79856014|NCT03953820|Drug|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
79856015|NCT03953820|Drug|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
79856016|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
79856017|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
79856018|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
79856019|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
79856020|NCT03678636|Device|Silver antimicrobial dressing|Silver dressing suitable for exudate level
79856021|NCT03678636|Device|Standard care|Usual care for wound type and condition
79856022|NCT04517994|Behavioral|Active Treatment|See arm description.
79259328|NCT02064023|Device|insulin pump|subjects in the experimental arm will administer insulin using a pump
79259329|NCT02064023|Other|multiple daily insulin injection|Subjects will continue with usual insulin injections
79259330|NCT05573477|Drug|ATB-1011|Oral tablet
79259331|NCT05573477|Drug|ATB-1012|Oral tablet
79259332|NCT05573477|Drug|ATB-1013|Oral tablet
79856023|NCT04517994|Behavioral|Supportive Treatment|See arm description.
79856024|NCT04492956|Drug|Ecopipam|Oral tablet
79856025|NCT04492956|Drug|Placebo|Oral tablet
79856026|NCT04478136|Diagnostic Test|Blood test of factor levels|Blood draw from central line to check coagulation factors
79856027|NCT00117793|Device|Total Surface Bearing Suction Socket|Current clinical practice
79397268|NCT01468181|Drug|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
79397269|NCT01468181|Drug|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
79856028|NCT00117793|Device|Vacuum assisted socket system|Novel socket system
79856029|NCT01084213|Drug|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
79856030|NCT01084213|Drug|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
79259333|NCT05573477|Drug|ATB-1011 placebo|Placebo matched to ATB-1011
79259334|NCT05573477|Drug|ATB-1012 placebo|Placebo matched to ATB-1012
79259335|NCT05573477|Drug|ATB-1013 placebo|Placebo matched to ATB-1013
79397270|NCT01468181|Drug|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
79397271|NCT01693562|Drug|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
79397272|NCT00461097|Drug|Egg oral immunotherapy|Egg white solid powder
79397273|NCT00461097|Drug|Control Group|Placebo for egg white solid
79856031|NCT00695669|Biological|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
79259336|NCT02064101|Procedure|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
79558295|NCT05838378|Other|Package image sorting with Surgeon General text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories [fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
79259337|NCT02064725|Drug|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
80031587|NCT03161054|Drug|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
79558296|NCT05838378|Other|Package image sorting with FDA text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories [fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
79558297|NCT05835375|Other|EQ-778|"capsule daily after breakfast (in case of no URTI episode);~capsules after breakfast (in case of URTI episode)"
79259338|NCT01370603|Drug|Atorvastatin|40 mg tablet administered orally once daily
79558298|NCT05835375|Other|Placebo|"capsule daily after breakfast (in case of no URTI episode);~capsules after breakfast (in case of URTI episode)"
79558299|NCT05831982|Other|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
79558300|NCT05831982|Other|Standard training|Training as usual when discharged with a rehabilitation plan.
79558301|NCT05827653|Drug|NX210c|3 times a week, for 28 days
79558302|NCT05827653|Drug|Placebo|3 times a week, for 28 days
79558303|NCT05821777|Drug|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
79558304|NCT05819697|Other|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
79558305|NCT05815199|Other|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
79558306|NCT05815199|Other|Nicotine Replacement Therapy (NRT)|Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
79558307|NCT05815199|Behavioral|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15~20 minutes each.
79856032|NCT03671369|Other|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
80031588|NCT03161054|Drug|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
79259339|NCT01370603|Drug|Ezetimibe|10 mg tablet administered orally once daily
79397274|NCT01467713|Drug|Ramelteon SL|Ramelteon sublingual (SL) tablets
79397275|NCT01467713|Drug|Placebo|Ramelteon sublingual (SL) placebo-matching tablets
79259340|NCT01370603|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
79397276|NCT00531453|Drug|bortezomib, dexamethasone, and thalidomide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime)."
79397277|NCT00531453|Drug|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles."
79397278|NCT00531843|Drug|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
79259341|NCT01370603|Drug|Placebo to atorvastatin|Administered orally once daily
79259342|NCT01370603|Drug|Placebo to ezetimibe|Administered orally once daily
79259343|NCT01370603|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
79558308|NCT05815199|Behavioral|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
79558309|NCT05814133|Device|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones < 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
79259344|NCT03560219|Diagnostic Test|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~Clinical~Age~Gender~BMI~Diabetes Mellitus~Hypertension~Heart Failure~Ischemic Stroke / TIA~Thromboembolism~Coronary Artery Disease~Peripheral Arterial Disease~Glomerular Filtration Rate~Contrast-enhanced MRI~o Presence and extent of atrial fibrosis~Biomarkers~IL-6~CRP~D-dimer~Fibrinogen~Transthoracic Echocardiography~LA Volume Index (LAVI)~LA Strain, Global~LA Strain rate, Positive peak, Global~LA Strain rate, early negative peak, Global~LA Strain rate, late negative peak, Global~LA Emptying Fraction (LAEF)~LVH~LVEF~Endothelial function o FMD"
79558310|NCT05812859|Device|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
79558316|NCT05804227|Drug|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
79558317|NCT05804045|Drug|Pimicotinib(ABSK021)|capsule
79558318|NCT05804045|Drug|Placebo|capsule
79558319|NCT05803018|Drug|BL-B01D1|Administration by intravenous infusion
79558320|NCT05797181|Other|medical nutrition therapy in kidney diseases|Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates
79558321|NCT05794139|Drug|NMD670|Tablets
79558322|NCT05794139|Drug|Placebo|Tablets
79558323|NCT05791513|Other|Using the MAP-Knee Tool|Using the MAP-Knee Tool
79558324|NCT05791513|Other|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
79558325|NCT05790551|Device|Addinex|Medication dispensing system for Suboxone
79558326|NCT05789537|Drug|SerpinPC|Administered as SC injection.
79558327|NCT05785039|Drug|BL-B01D1|Administration by intravenous infusion
79558328|NCT05782894|Drug|Remimazolam besylate|0~2.0mg/kg/h
79558329|NCT05782894|Drug|Propofol|0.3~4.0mg/kg/h
79558330|NCT05782894|Drug|Remifentanil|1.5~12μg/kg/h
79259345|NCT02659397|Drug|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
79397279|NCT00531843|Device|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
79397280|NCT01693250|Behavioral|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
79558331|NCT05782244|Drug|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
79558332|NCT05782244|Drug|Placebo|Placebo, oral, TID
79558333|NCT05782244|Drug|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
79259346|NCT02659397|Drug|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
79259347|NCT02659397|Drug|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
79558334|NCT05782244|Drug|Sildenafil high dose|Sildenafil 80 mg, oral, TID
79558335|NCT05773664|Drug|Azeliragon|Given PO
79558336|NCT05773664|Procedure|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
79558337|NCT05773664|Procedure|Computed Tomography|Undergo CT scan
79558338|NCT05773664|Drug|Dexamethasone|Given PO or IV
79558339|NCT05773664|Procedure|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
79558340|NCT05773053|Drug|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton [kD], free of complexing proteins) powder for solution for injection.
79558341|NCT05773053|Drug|NT 201 Placebo|NT 201 Matching-placebo.
79558342|NCT05772663|Other|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20*20). At D119, the person returns the accelerometric writbands."
79558343|NCT05772663|Other|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20*20). At D119, the person returns the accelerometric writbands."
79259348|NCT02064257|Behavioral|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
79259349|NCT04973618|Biological|APVO436|"APVO436~Dosage: APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.~Dosage Form: IV Solutions for Intravenous Administration~Frequency: Weekly"
79397281|NCT01693250|Behavioral|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
79721322|NCT04908111|Biological|ChAdOx1-MAGEA3-NYESO|"Patients will commence their standard of care chemotherapy in combination with an immune checkpoint inhibitor in three weekly cycles. Patients will be screened during the first two cycles of standard of care treatment to confirm whether they are eligible to take part in the trial.~Patients who are to receive the trial vaccines (in the safety run in stage and in Arm A of the NSCLC randomisation cohort) will continue to receive their standard of care treatment plus:~First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of standard of care treatment.~First boost MVA-MAGEA3 vaccine 21 days later.~Only for patients who have not progressed: Second prime ChAdOx1-MAGEA3-NYESO vaccine 15 week following the first prime vaccine.~Second boost MVA-MAGEA3 vaccine 21 days following the second prime vaccine.~Patients in Arm B will continue to receive their standard of care treatment only throughout the trial (i.e. no trial vaccines)."
79856033|NCT04060745|Other|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
79397282|NCT02073461|Drug|CD1579 2.5%|
79397283|NCT02073461|Drug|CD1579 5%|
79558344|NCT05760586|Drug|Tovorafenib|Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
79558345|NCT05760482|Diagnostic Test|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
79558346|NCT05760482|Behavioral|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
79558347|NCT05759390|Diagnostic Test|Ultrasound elastography|Using an ultrasound scanner for chest ultrasound examinations. If patients has multiple sub pleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
79397284|NCT02073461|Drug|Vehicle|
79397285|NCT04408547|Device|embryo transfer catheter|undergoing embryo transfer
79558348|NCT05757869|Drug|Milvexian|Milvexian will be administered orally.
79558349|NCT05757869|Drug|Apixaban|Apixaban will be administered orally.
79558350|NCT05757869|Drug|Placebo|Milvexian matching milvexian placebo will be administered orally.
80019409|NCT05576688|Other|Balance|Balance was evaluated with Berg Balance Scale (BBS), Functional Reach Test (FRT), One Leg Stance Test (OLST) and Five-Repeat Sit-and-Stand Test (5STS). BBS consists of 14 functional tasks of increasing difficulty, each scored on a scale ranging from 0 to 4. The maximum possible score is 56, indicating no identifiable balance difficulties. FRT measures the maximum distance that participants can reach forward with their dominant arm raised to 90 degrees without moving their feet, which were positioned 10 cm apart. OLST measures the time one is able to stand on one lower limb without support. The test was repeated for both sides. 5STS assesses the time it takes to get up and sit from the chair five times. Measurements were repeated 3 times and the average duration was calculated as a patient score.
79856034|NCT04060745|Other|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
80019410|NCT05576688|Other|Trunk control|Trunk control was evaluated with Trunk Impairment Scale (TIS).TIS evaluates static sitting balance, dynamic sitting balance, and trunk coordination on a scale from 0 to 23 points, a higher score indicating a better performance.
79397286|NCT01590758|Drug|Topical pexiganan cream 0.8%|14 days of treatment
79397287|NCT01590758|Drug|Topical placebo cream|14 days of treatment
79397288|NCT01590758|Other|Standard wound care|14 days of treatment
79558351|NCT05757869|Drug|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
79558352|NCT05754957|Drug|Milvexian|Milvexian will be administered orally.
79558353|NCT05754957|Other|Placebo|Placebo will be administered orally.
79558354|NCT05752396|Other|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
79397289|NCT01590212|Other|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
79397290|NCT01590212|Other|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
79397291|NCT00534417|Drug|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight < 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
79856035|NCT00742937|Dietary Supplement|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
79558355|NCT05752396|Other|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
79558356|NCT05752396|Other|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
79397292|NCT00534417|Drug|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
79558357|NCT05752396|Other|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
79856036|NCT00742937|Dietary Supplement|Placebo|second capsule with vitamin E, eight days after delivery.
80031589|NCT03161054|Drug|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
79397293|NCT01692782|Drug|SEP-225289|SEP-225289 4mg once daily
79397294|NCT01692782|Drug|SEP-225289|SEP-225289 8mg once daily
79558358|NCT05748405|Drug|Placebo|Matching Tablets
79558359|NCT05748405|Drug|AEF0217|Tablets of 100 mcg AEF0217
79397295|NCT01692782|Drug|Placebo|Placebo once daily
79721323|NCT04908111|Biological|MVA-MAGEA3|"Patients will commence their standard of care chemotherapy in combination with an immune checkpoint inhibitor in three weekly cycles. Patients will be screened during the first two cycles of standard of care treatment to confirm whether they are eligible to take part in the trial.~Patients who are to receive the trial vaccines (in the safety run in stage and in Arm A of the NSCLC randomisation cohort) will continue to receive their standard of care treatment plus:~First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of standard of care treatment.~First boost MVA-MAGEA3 vaccine 21 days later.~Only for patients who have not progressed: Second prime ChAdOx1-MAGEA3-NYESO vaccine 15 week following the first prime vaccine.~Second boost MVA-MAGEA3 vaccine 21 days following the second prime vaccine.~Patients in Arm B will continue to receive their standard of care treatment only throughout the trial (i.e. no trial vaccines)."
79397296|NCT04472013|Other|Data collection from lumbar puncture|Cerebro spinal fluid (CSF) will be acquired by lumbar puncture and sent for routine analysis including CSF chemistry, cytology and microbiology. Targeted CSF proteomics using OLINK Proximity Extension Assay (PEA) technology to assess a potential CNS-contribution of the disease will be performed.
79721324|NCT04908111|Combination Product|Standard of care treatment|Patients will continue to receive standard of care treatment (chemotherapy and checkpoint inhibitor).
79856037|NCT00692003|Drug|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
79856038|NCT00692003|Drug|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
79856039|NCT02564315|Drug|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
79558360|NCT05748171|Drug|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
79558361|NCT05748171|Drug|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and asparaginase) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
79397297|NCT04472013|Other|Data collection from blood draw|Plasma samples will be acquired for plasma cytokine proteomics using CyTOF (mass cytometry analysis) technology.
79397298|NCT04472013|Other|CNS magnetic resonance imaging (MRI) imaging|3Tesla magnetic resonance imaging (MRI) will be performed to document early/manifest encephalitic changes in COVID-19 patients.
79397299|NCT04472013|Other|Microscopy of defined brain regions on autopsy specimens|High dimensional, microglia-centric CODEX fluorescent microscopy of defined brain regions on autopsy specimens will be acquired from medulla oblongata, cortex, cerebellum, and olfactory bulb. A brain-specific CODEX panel for the assessment of the immune microenvironment was implemented, with inclusion of a wide array of myeloid/microglia markers, T-cell markers, and a few neuronal markers. All the antibodies have been validated and tested in formalin-fixed tissues of different zones of glioblastoma tumors including invading tumor periphery. The Panel will be modified to include the viral entry receptors, CD147, ACE2 and TMPRSS2. Presence of SARS-CoV-2 virus particles will be assessed by qPCR, andMultiplexed Ion Beam Imaging (MIBI) technology will be used to visualize tropism of virus to specific cellular brain compartments.
79856040|NCT02564315|Behavioral|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
79856041|NCT02564315|Behavioral|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
79856042|NCT02564315|Behavioral|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
79397300|NCT01692626|Drug|Pimecrolimus|Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
79259350|NCT02065427|Behavioral|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
79397301|NCT01692626|Drug|Placebo|Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
79558362|NCT05747495|Other|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link [https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/]."
79558363|NCT05746832|Procedure|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large [≥ 20 mm] or multiple [≥ 3 sized ≥ 15 mm] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
79397302|NCT00535587|Behavioral|Exercise|
79397303|NCT00535587|Drug|pyridostigmine|
79259351|NCT02064335|Behavioral|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
79558364|NCT05746039|Drug|Semaglutide Pen Injector|Once weekly subcutaneous injection
79558365|NCT05745103|Behavioral|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
79558366|NCT05745103|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
79558367|NCT05744921|Drug|Pozelimab|Administered subcutaneously (SC) every 4 weeks (Q4W)
79721325|NCT02880423|Procedure|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
79721326|NCT02880423|Procedure|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
79721327|NCT04123275|Other|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
79397304|NCT00535587|Drug|Placibo|
79397305|NCT00535587|Behavioral|Attention Control|
79397306|NCT01797237|Device|PFNA|
79397307|NCT01797237|Device|InterTAN|
79259352|NCT04977596|Other|No intervention|Retrospective study without intervention
79259353|NCT02347072|Drug|GFF MDI (PT003)|
79259354|NCT02347072|Drug|Placebo MDI|
79259355|NCT02347072|Drug|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
79259356|NCT02064413|Device|ESS310 (BAY1454032)|
79259357|NCT02064491|Drug|Erlotinib|
79259358|NCT02064491|Drug|Chemotherapy|
79259359|NCT02064569|Genetic|GS010|
79259360|NCT02065505|Other|Mat Pilates|
79259361|NCT02065505|Other|Water Pilates|
79397308|NCT01475461|Drug|Placebo|double-dummy placebo tablets administered once-daily for 84-days
79397309|NCT01475461|Drug|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
79721328|NCT04307199|Procedure|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
79721329|NCT01106157|Drug|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
79259362|NCT02064881|Drug|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
79397310|NCT01475461|Drug|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
79397311|NCT01475461|Drug|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
79856043|NCT02564315|Behavioral|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
80019411|NCT05576688|Other|Gait|Gait was evaluated with Dynamic Gait Index (DGI). DGI has 8 items: walking, walking while changing speed, walking while turning the head horizontally and vertically, walking with pivot turn, walking over and around obstacles, and stair climbing. The scoring of the DGI is based on a 4-point scale ranging from 0 to 3, with 0 indicating severe impairment and 3 indicating normal ability. The best performance total score is 24. A low composite DGI score indicates greater impairment in gait.
79259363|NCT02064881|Drug|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
79259364|NCT02067845|Behavioral|Adapted Many Men, Many Voices (3MV) group level intervention|"The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning."
79558368|NCT05744921|Drug|Cemdisiran|Administered SC Q4W
79558369|NCT05743062|Behavioral|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
79558370|NCT05743062|Other|Control|For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
79558371|NCT05741229|Drug|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
79721330|NCT01106157|Drug|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
79259365|NCT02067845|Behavioral|A group-based HIV/STI prevention intervention for women who have sex with women|
79259366|NCT02794103|Device|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
79397312|NCT01475461|Drug|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
79397313|NCT01475461|Drug|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
79397314|NCT01589822|Biological|EVICEL Fibrin Sealant|Intraoperative
79397315|NCT01565642|Behavioral|Goals of care decision support|Decision aid and care plan meeting
79397316|NCT01475071|Drug|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
79397317|NCT01475071|Drug|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
79558372|NCT05741229|Drug|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
79721331|NCT01106157|Drug|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
79856044|NCT02564315|Behavioral|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
79558373|NCT05732116|Other|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
80019412|NCT05576688|Other|Functional mobility|Functional mobility was evaluated with Timed Up and Go Test (TUG). TUG is a test of the time required for an individual to stand up from a chair with armrests, walk 3 m, turn, walk back to the chair, and sit down. The stopwatch timing started when the participant's bottom left the chair and ended when the bottom made contact with the chair after the walk.
79259367|NCT02065037|Device|room temperature air insufflation|control arm
79558375|NCT05728944|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
79558376|NCT05728944|Drug|Aceclidine|Aceclidine ophthalmic solution
79856045|NCT02564315|Behavioral|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
80019413|NCT05576688|Other|Fear of falling|Fear of falling was evaluated with the Falls Efficacy Scale-International (FES-I). FES-I was used to assess the level of concern about falls during 16 activities of daily living, ranging from basic to more demanding activities including social activities that may contribute to quality of life. It was administered as a self-report questionnaire.
79259368|NCT02065037|Device|warmed carbon dioxide insufflation|comparator arm
79397318|NCT01474993|Drug|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing ~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to ~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~Subjects with body weight less than 101 lbs will receive ~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~Subjects with body weight 101 lbs to 199 lbs will receive ~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~Subjects with bidy weight > 199 lbs will receive ~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
79558377|NCT05728944|Drug|Vehicle|Proprietary vehicle ophthalmic solution
79558379|NCT05725512|Drug|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
79558380|NCT05725512|Drug|Placebo|Placebo identical to prednisolone tablets
79721332|NCT01094301|Device|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
79721333|NCT04835571|Other|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~blood pressure <140/90 mmHg~Tot cholesterol <5 mmol/l~LDL <1,8 mmol/l~Waist circumference: men <94 cm, women <80 cm~BMI <25 kg/m2~HbA1c without diabetes mellitus <42 mmol/mol, HbA1c with diabetes mellitus <52 mmol/mol~Antithrombotic treatment (or anticoagulants, if indicated)~Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~Smoking cessation~Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
79721334|NCT04828005|Drug|Nalmefene hydrochloride|3mg Nasal spray
79721335|NCT04828005|Drug|Naloxone hydrochloride|4mg Nasal Spray
79721336|NCT04306887|Drug|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
80019414|NCT02290730|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
80019415|NCT03062878|Other|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
79259369|NCT02346370|Drug|PEGylated recombinant human hyaluronidase PH20|
79259370|NCT02346370|Drug|Docetaxel|
79259371|NCT02065739|Drug|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
79259372|NCT02065739|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
79259373|NCT02068001|Procedure|Roux-en-Y Gastric Bypass|
79259374|NCT02068079|Drug|Vemurafenib and Trientine|
79259375|NCT02346136|Behavioral|Tai Chi training|
79259376|NCT02346136|Behavioral|Educational Control|
79721337|NCT02877459|Device|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
79721338|NCT04306497|Drug|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
79558381|NCT05722561|Behavioral|Telehealth Motivational Counseling|At baseline, after randomization, participants will receive their first telehealth session (20~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15~20 minutes each.
79721339|NCT02878161|Drug|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
79721340|NCT02878161|Biological|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
79721341|NCT02878161|Biological|etanercept|Etanercept :hypodermic injection,25mg/twice a week
79721342|NCT02878161|Biological|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
80019416|NCT03062878|Other|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
80019417|NCT03062878|Other|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
80019418|NCT03062878|Other|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
80019419|NCT03548142|Behavioral|provision of relevant information|caregivers are provided with brochure that informs about end-of-life issues for persons with advanced dementia
80019420|NCT02290808|Behavioral|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
80019421|NCT03818373|Procedure|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
80019422|NCT01452802|Device|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
79259377|NCT02793947|Drug|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
79259378|NCT02793947|Drug|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
79259379|NCT02793947|Drug|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
79259380|NCT02793947|Drug|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
79259381|NCT03787121|Procedure|care management pathways|different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up
79259382|NCT02065817|Other|stable isotope of cholesterol|
79259383|NCT02065115|Other|Cryotherapy (ice pack)|
79259384|NCT02345512|Device|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
79259385|NCT03560063|Procedure|Corin Optimised Positioning System|"Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient."
79397319|NCT01474993|Drug|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
79397320|NCT01691768|Drug|1% tenofovir gel|"Participants will be randomized to receive 1% tenofovir gel through either:~Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."
79397321|NCT01503229|Drug|Abiraterone Acetate|Given by mouth
79397322|NCT01503229|Other|Laboratory Biomarker Analysis|Correlative studies
79558382|NCT05722561|Drug|Nicotine Replacement Product|Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
79558383|NCT05722561|Device|National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).|Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
79558384|NCT05721638|Diagnostic Test|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
79558385|NCT05717114|Procedure|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
79558389|NCT05713630|Drug|GD-Tranexamic Acid 500 MG Oral Tablet|Tranexamic acid film-coated oral tablet.
79558390|NCT05713630|Drug|Sandoz-Tranexamic Acid 100 MG/ML|Sandoz-Tranexamic acid 100 milligram/millilitre (mg/mL) via nasogastric tube.
79558391|NCT05713630|Drug|Sandoz-Tranexamic Acid 100 Mg/mL Solution for Injection|Sandoz-Tranexamic acid 100 mg/mL solution for injection via intravenous (IV).
79558392|NCT05713630|Drug|Placebo|The placebo 500 mg will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 MG/ML via nasogastric tube and placebo 100 Mg/mL solution for injection via intravenous (IV). The solution form of the placebo will consist of 0.9% sodium chloride (saline).
79558393|NCT05713370|Dietary Supplement|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
79259386|NCT03560063|Procedure|Standard templating|Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
79259387|NCT02345434|Other|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
79721343|NCT02878161|Drug|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
80019423|NCT01452802|Drug|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
79721344|NCT02878161|Drug|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
80019424|NCT02289482|Drug|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
80019425|NCT02289482|Drug|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
80019426|NCT02289482|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
80019427|NCT02289482|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
79721345|NCT02878161|Drug|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
79721346|NCT02877069|Device|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
80019428|NCT03645213|Device|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
79721347|NCT02877225|Drug|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
79721348|NCT02877225|Drug|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
79721349|NCT01093755|Drug|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
80019429|NCT03645213|Device|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
80019430|NCT03594422|Drug|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
79259388|NCT02065973|Biological|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
79259389|NCT02065193|Behavioral|ADOS/ADI-R/Clinical assessment|
79259390|NCT02068235|Drug|Ponesimod 5mg i.v.|
79558394|NCT05712161|Device|DurAVRTM THV System|The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
79721350|NCT01093755|Drug|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
80019431|NCT03645135|Other|Goal elicitation|Patients will be asked to list 2 goals for their visit
80019432|NCT02921230|Device|Peripheral stenting|stent implantation during the index procedure
80019433|NCT04600128|Other|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
80019434|NCT04600128|Other|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
80019435|NCT04600128|Other|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
80019436|NCT04600128|Other|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
79259391|NCT02068235|Drug|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
79259392|NCT02068235|Drug|Ponesimod 10 mg tablet|
79259393|NCT01370213|Drug|Preparative Regimen|"Preparative Regimen:~1) fludarabine 40 mg/m^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
79259394|NCT01370213|Biological|NK Cells|CD3^- CD19^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
79259395|NCT01370213|Drug|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
79259396|NCT01370213|Biological|CD34 Graft/Anti-thymocyte globulin|Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
79721351|NCT01093599|Behavioral|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
79721352|NCT01093599|Behavioral|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
80019437|NCT02289638|Device|Intubrite|Video-Laryngoscopy
80019438|NCT02289638|Device|MIL|Direct-Laryngoscopy
79558395|NCT05706363|Procedure|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
79259397|NCT01370213|Biological|Donor TCR α/β-depleted Graft/ATG|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
79259398|NCT02068313|Radiation|Toxicity and outcome measures of IMRT|
79558397|NCT05704634|Drug|Cemiplimab|Given by Injection under the skin every 2 weeks
79558398|NCT05704634|Drug|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
79721353|NCT01092663|Drug|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
79721354|NCT01092663|Drug|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
79721355|NCT02877147|Other|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
79721356|NCT01078623|Drug|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
79721357|NCT01078623|Drug|Placebo|Placebo control twice daily
79721358|NCT01078623|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
79721359|NCT01078623|Drug|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
80019439|NCT05575986|Drug|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
80019440|NCT02896569|Other|Topical combination therapy|
79259399|NCT02066207|Drug|Fenofibrate|
79259400|NCT02066207|Drug|Atorvastatin|
79259401|NCT02065271|Dietary Supplement|herbal supplement|
79259402|NCT02065271|Other|placebo supplement|
79259403|NCT02068391|Behavioral|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
79721360|NCT01078623|Drug|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
79721361|NCT04879251|Other|No intervention|No intervention
79721362|NCT01092507|Biological|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
79721363|NCT01092507|Biological|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
79397323|NCT01503229|Other|Pharmacological Study|Correlative studies
79397324|NCT01503229|Drug|Prednisone|Given PO
79397325|NCT01691612|Biological|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
79397326|NCT01565564|Behavioral|Shared glycaemic control care within the local three-tier's antenatal care network|"Individualized dietary and physical activity consultation plus group diabetes education~Self blood glucose monitoring~Insulin therapy if indicated~Self blood glucose monitoring~Insulin therapy institutions if indicated;"
79397327|NCT01460407|Drug|LY2216684|Administered orally
79397328|NCT01460407|Drug|Clarithromycin|Administered orally
79558409|NCT05701930|Behavioral|symptom management|pecha kucha training
79558410|NCT05698381|Dietary Supplement|Liquid vinegar|2 tablespoons consumed twice daily with meals
79558411|NCT05698381|Dietary Supplement|Vinegar pill|2 pills consumed upon waking
80019441|NCT02290964|Procedure|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
80019442|NCT04599036|Device|MARK|EMG controlled arm orthosis
80019443|NCT04066270|Diagnostic Test|video nystagmography|routine test battery applied to all cochlear implant candidates
80019444|NCT04030195|Genetic|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
80019445|NCT04030195|Drug|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m^2/day, Days -5 to -3).
80019446|NCT04030195|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m^2/day, Days -5 to -3).
80019447|NCT02253966|Drug|Methylprednisoloneacetate|
80019448|NCT02253966|Drug|Lidocaine|
80019449|NCT02253966|Other|sodium chloride|
80019450|NCT03644979|Other|Skydiving|Tandem skydiving (with an experienced instructor)
79259404|NCT02068391|Behavioral|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
79721364|NCT05051397|Biological|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
79721365|NCT05051397|Biological|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
79721366|NCT02877381|Procedure|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
79721367|NCT02877381|Procedure|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
79721368|NCT02878239|Other|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
79721369|NCT02878239|Other|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
79721370|NCT01078545|Drug|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
79856046|NCT02564315|Drug|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke <=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
80019451|NCT02291042|Drug|B+O Suppository|
80019452|NCT01673620|Drug|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
79721371|NCT01202760|Drug|LY2127399|
79721372|NCT01202760|Drug|Placebo|
79721373|NCT01091259|Drug|Irinotecan|
79721374|NCT01091259|Drug|Bevacizumab|
80019453|NCT01673620|Drug|Placebo|Matching placebo tablet administered once daily
80019454|NCT03547206|Drug|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
80019455|NCT03547206|Other|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene [BHT]).
80019456|NCT03547206|Drug|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
80019457|NCT03547206|Other|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene [BHT]).
79259405|NCT01370525|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
79721375|NCT05381844|Other|Blood sampling|30 ml blood sampling for virological research
79721376|NCT01091103|Drug|Enzalutamide|
79721377|NCT01078389|Drug|Febuxostat|Febuxostat capsules
79721378|NCT01078389|Drug|Placebo for Febuxostat|Febuxostat placebo-matching capsules
79856047|NCT00743015|Drug|BI 44370 TA tablet|
79259406|NCT02065349|Drug|ASP8477|oral
79259407|NCT02065349|Drug|Placebo|oral
79259408|NCT02068625|Drug|Rasagiline|Rasagiline 1mg daily orally for 7 days
79259409|NCT02068625|Drug|Placebo|Oral treatment with placebo for 7 days
79259410|NCT02068703|Behavioral|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
80019458|NCT02291120|Procedure|Pulpotomy|
80019459|NCT05284149|Dietary Supplement|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
79397329|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
80019460|NCT05284149|Dietary Supplement|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
80019461|NCT04037956|Procedure|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
79397330|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
79856048|NCT02564237|Biological|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
79259411|NCT02068703|Behavioral|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
79397331|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
79558412|NCT05697757|Other|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
79259412|NCT02068781|Dietary Supplement|Low-sodium diet|50 mmol NaCl per 24h
79558413|NCT05697757|Other|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
79558414|NCT05695274|Behavioral|Progressive muscle relaxation exercise|Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
79558415|NCT05688345|Drug|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
79721379|NCT01090323|Drug|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
79721380|NCT00626301|Drug|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
79721381|NCT02878005|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
79721382|NCT02878005|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
79558416|NCT05688345|Drug|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
79259413|NCT02068781|Dietary Supplement|High-sodium diet|250 mmol NaCl per 24h
79259414|NCT02068859|Drug|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
79558417|NCT05688345|Drug|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
79558418|NCT05684445|Other|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
79558419|NCT05682781|Dietary Supplement|Oral Nutritional Supplement|Oral Nutritional Supplement
79558420|NCT05682781|Other|Dietary Counseling|Dietary Counseling
79397332|NCT01502371|Drug|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
79397333|NCT01502371|Drug|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
79721383|NCT00626457|Behavioral|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
79856049|NCT02564237|Biological|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
79259415|NCT02068859|Drug|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
79259416|NCT02068937|Drug|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
79259417|NCT02068937|Drug|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
79259418|NCT02066363|Dietary Supplement|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
79259419|NCT02066363|Dietary Supplement|Parenteral nutrition|Supportive parenteral nutrition.
79259420|NCT02066441|Dietary Supplement|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
79259421|NCT02066441|Other|Placebo|
79259422|NCT02066519|Behavioral|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
79397334|NCT01502371|Drug|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
79397335|NCT01588496|Biological|Evolocumab|Administered by subcutaneous injection
79397336|NCT01588496|Drug|Placebo|Administered by subcutaneous injection
79397337|NCT01502293|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
79558421|NCT05678712|Device|Access to CGM data (Dexcom G6)|Acces to CGM data (not blinded CGM)
79856050|NCT02564237|Biological|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
79558422|NCT05677152|Drug|Intravenous Infusion of Aclasta®|Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
79558423|NCT05666362|Drug|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
79397338|NCT01502293|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
79397339|NCT03026647|Procedure|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
79397340|NCT01474681|Biological|HSC835|
79397341|NCT01459783|Behavioral|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
79397342|NCT01588184|Drug|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
79397343|NCT01564862|Drug|vortioxetine (Lu AA21004)|Lu AA21004 capsules
79397344|NCT01564862|Drug|Duloxetine|Duloxetine capsules
79259423|NCT02792777|Other|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
79397345|NCT01564862|Drug|Placebo|Placebo matching capsules
79558424|NCT05666362|Drug|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
79558425|NCT05665530|Drug|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
79558426|NCT05665530|Drug|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once daily.
79721384|NCT02876991|Procedure|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
79856051|NCT02564237|Biological|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
79259424|NCT02792777|Other|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
79721385|NCT01201356|Drug|Fingolimod|0.5 mg/day
79721386|NCT04872153|Behavioral|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
79558432|NCT05662280|Device|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
79558433|NCT05662280|Device|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
79856052|NCT00434512|Biological|HIV vaccine 732461|
79856053|NCT02564939|Drug|ramelteon|double-blind RCT
79558434|NCT05662202|Combination Product|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
79856054|NCT02564939|Drug|Placebo|double-blind RCT
79856055|NCT02564783|Other|No intervention|No intervention
80019462|NCT04037956|Procedure|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
79558435|NCT05662202|Combination Product|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
79558436|NCT05658835|Other|Thrombi and blood analyses|Thrombi and blood will be collected during thrombectomy
79558437|NCT05658575|Drug|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
79721387|NCT00637611|Drug|Fexofenadine HCl|
79721388|NCT00626535|Drug|Esomeprazole|20mg Oral Once Daily
79259425|NCT02066597|Device|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
79721389|NCT00626535|Drug|Matching placebo|Oral Once Daily
79721390|NCT05400642|Device|THRIVE|Apneic ventilation
79721391|NCT05400642|Device|mechanical ventilation|mechanical ventilation in Positive Pressure
79856056|NCT03605771|Other|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
79856057|NCT02470468|Biological|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
79856058|NCT02470468|Biological|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
79856059|NCT02470468|Other|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
80019463|NCT04671355|Drug|Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg|Pressurized metered dose inhaler
80019464|NCT04671355|Drug|Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg|Dry powder inhaler
80019465|NCT03644901|Procedure|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
80019466|NCT04034212|Other|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
80019467|NCT03521492|Diagnostic Test|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
79856060|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
79856061|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
80019468|NCT03765879|Other|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of themselves receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
80019469|NCT03765879|Other|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of themselves receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
79259426|NCT05540171|Other|Oral health education and instructions/training for self-oral care|Education intervention
80019470|NCT04644991|Other|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
79259427|NCT03786107|Diagnostic Test|Almac HER-Seq Assay|whole blood sample analysis
79397346|NCT01691378|Other|Window to Hope|Psychotherapy - Group
79397347|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
79721392|NCT01200810|Other|placebo|Given orally
79721393|NCT01200810|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
79721394|NCT01200810|Drug|bicalutamide|Given orally
79721395|NCT04317378|Device|Braun thermoscan /, IRT 6520|The temperature will be measured in both ears with an ear thermometer. Practically, we will measure the temperature twice when generel anaesthsia is established, and immidiately before and after the MRI scan.
79721396|NCT01200342|Drug|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
79397348|NCT01467479|Drug|Telaprevir|Tablet
79397349|NCT01467479|Drug|Ribavirin|Tablet
79397350|NCT01467479|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
79397351|NCT01467479|Drug|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
79397352|NCT01466387|Biological|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
79397353|NCT01466387|Biological|Yellow Fever Vaccine|One dose of yellow fever vaccine.
79397354|NCT01466387|Biological|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
79397355|NCT01466387|Biological|Rabies Vaccine|Three doses of Rabies vaccine.
79397356|NCT01466387|Biological|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
79558438|NCT05658575|Other|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
79558439|NCT05658237|Procedure|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
79558440|NCT05656027|Drug|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
79558441|NCT05656027|Drug|Aceclidine|LNZ100 Aceclidine ophthalmic solution
79558442|NCT05656027|Drug|Brimonidine|Brimonidine ophthalmic solution
79721397|NCT01200342|Drug|Paclitaxel|175 mg/m^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
79558443|NCT05655351|Biological|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
79721398|NCT01200342|Drug|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
79721399|NCT01199016|Procedure|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
79856062|NCT00427648|Drug|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
79856063|NCT00427648|Drug|placebo|normal saline
79856064|NCT02153177|Procedure|Rotator cuff repair|Arthroscopic procedure
79856065|NCT02153177|Drug|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
79856066|NCT02153177|Drug|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
79856067|NCT00743327|Drug|Pioglitazone|45mg capsule, once daily for 1 year
79856068|NCT01032460|Device|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
79856069|NCT01032460|Device|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
79856070|NCT01032460|Device|intubate with the Airtraq device|intubate with the Airtraq device
79856071|NCT03888599|Behavioral|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
79856072|NCT02564861|Drug|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
79856073|NCT02564861|Drug|Placebo|Placebo matching DS-1971a suspension
79856074|NCT00416884|Drug|Campath|30 mg on day -8 over 5-6 hours
79856075|NCT00416884|Drug|Fludarabine|Fludarabine 30 mg/m^2 on day -4 through day -2
79856076|NCT00416884|Radiation|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
79856077|NCT00416884|Other|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
80019471|NCT04644991|Other|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
80019472|NCT04644991|Other|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
80019473|NCT03521414|Device|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
79856078|NCT02564627|Procedure|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
79856079|NCT02564627|Procedure|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
79856080|NCT02564627|Dietary Supplement|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
79856081|NCT00743405|Drug|GSK1034702|Oral or liquid
79856082|NCT00743405|Drug|Placebo|To match GSK1034702
80019474|NCT03521414|Drug|Sevoflurane|we used sevoflurane drug at inoperative
80019475|NCT00432094|Drug|carboplatin|Days -6, -5, -4: 500mg/m2^/day intravenously (IV) over 60 minutes
80019476|NCT00432094|Drug|etoposide|600mg/m^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
80019477|NCT00432094|Drug|ifosfamide|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
80019478|NCT00432094|Drug|paclitaxel|225 mg/m^2 intravenous over 3 hours on Day -7.
80019479|NCT00432094|Drug|thiotepa|150mg/m^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
80019480|NCT00432094|Procedure|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (< 4 x 10^6 CD34+ cells/kg)
80019481|NCT00432094|Drug|Mesna|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
80019482|NCT00432094|Biological|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
80019483|NCT04562779|Drug|Naltrexone 380 MG|XR naltrexone to be given once prior to hospital discharge
80019484|NCT04562779|Drug|Ketamine Hydrochloride|IV ketamine infusion to be given once prior to hospital discharge
80019485|NCT04562779|Behavioral|Enhanced linkage|Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
79721400|NCT01199016|Procedure|Nose/throat swab|To be performed at every study visit
79721401|NCT01199016|Biological|Observational|Observational Study Only
79721402|NCT01198548|Drug|leucovorin calcium|Given IV
79721403|NCT01198548|Biological|bevacizumab|Given IV
79721404|NCT01198548|Dietary Supplement|cholecalciferol|Given PO
79721405|NCT01198548|Drug|fluorouracil|Given IV
79721406|NCT01198548|Drug|oxaliplatin|Given IV
79721407|NCT01198548|Other|pharmacological study|Correlative studies
79721408|NCT01198470|Device|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
79721409|NCT00977938|Drug|Placebo & Aspirin|
79721410|NCT00977938|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|
79856083|NCT01032616|Other|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
80019486|NCT02291198|Device|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
79721411|NCT02716675|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
79721412|NCT02716675|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
80019487|NCT05218200|Other|deep breathing and coughing exercises with triflo|patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
80019488|NCT03751761|Drug|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
79558444|NCT05655325|Behavioral|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
80019489|NCT03523130|Diagnostic Test|Imaging|Macrophage-specific inflammation
80019490|NCT03044197|Device|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
80019491|NCT03044197|Device|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
79558445|NCT05655325|Other|Attention control|Health education and stretching
79721413|NCT04227925|Biological|Trichuris trichiura|Infective eggs from human whipworm, Trichuris trichiura
79721414|NCT00632515|Behavioral|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
79721415|NCT04259203|Behavioral|Erickson hypnosis|Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
79721416|NCT00977548|Drug|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
79721417|NCT04290208|Drug|Acetaminophen|IV Acetaminophen
79721418|NCT04290208|Drug|Acetaminophen|Acetaminophen liquid syrup
80019492|NCT05202990|Drug|Fecal Microbiota Transplantation by Stool capsules|"After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces)."
80019493|NCT05202990|Drug|Fecal Microbiota Transplantation by Intra-rectal enemas|"After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas."
80019494|NCT02291354|Drug|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
80019495|NCT02291354|Other|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
80019496|NCT02291354|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
80019497|NCT03644823|Drug|Atezolizumab|PDL1- inhibitor
80019498|NCT03644823|Radiation|Radiotherapy|6 Gy x 3
80031590|NCT03161054|Drug|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
79397357|NCT00535743|Drug|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
79397358|NCT00535743|Drug|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
79397359|NCT00535743|Drug|Esmeron®|Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
79721419|NCT04290208|Drug|Placebos|Flavored, non-medicated (placebo) liquid syrup
79721420|NCT04290208|Drug|Placebos|IV salt solution (non-medicated)
79721421|NCT03223597|Drug|Radium-223 dichloride|Registry of patients who receive Radium-223.
79721422|NCT02865382|Procedure|white light was used for colonoscopy withdrawal|
80031591|NCT03050554|Drug|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
79397360|NCT00535821|Device|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
79558447|NCT05651516|Drug|18F-PI-2620 PET/CT|PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer [18F]PI-2620. Each subject will have one [18F]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
79558448|NCT05650866|Device|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
79721423|NCT02865382|Procedure|OE mode was used for colonoscopy withdrawal|
79721424|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
79721425|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
79259428|NCT02069249|Behavioral|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
79558449|NCT05649943|Drug|APA + ADT|"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
79558450|NCT05649943|Procedure|Local Treatmetn RT or RP|"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
79558451|NCT05644054|Drug|THC|Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)
79558452|NCT05644054|Drug|Placebo|Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
79721426|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
79558455|NCT05640778|Drug|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
80019499|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
79558456|NCT05639634|Dietary Supplement|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
79558457|NCT05639634|Other|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (~ 5 min), a main physical conditioning phase (~ 40 min), and a cool-down phase (~ 5 min).
79558458|NCT05639634|Dietary Supplement|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
79721427|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
79721428|NCT03206905|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
79721429|NCT03206905|Behavioral|Diet and Exercise|nutritional/exercise counseling
79397361|NCT00535821|Device|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
80031592|NCT03050554|Radiation|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
80031593|NCT04909112|Other|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
80031594|NCT04909112|Other|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
79397362|NCT01564784|Drug|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
79397363|NCT01564784|Drug|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m^2/day IV days 1-6 fludarabine30 mg/m^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
79558459|NCT05637944|Procedure|oro tracheal intubation|chest trauma requiring oro tracheal intubation
79856084|NCT01032616|Other|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
79856085|NCT02564081|Other|Static Stretching lower limb|
79856086|NCT02564081|Other|Static stretching Cervical|
79856087|NCT01032772|Behavioral|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
79397364|NCT01564784|Drug|HIDAC (high dose cytarabine)|cytarabine 3 g/m^2 IV every 12 hours for up to 12 times
79397365|NCT01564784|Drug|cytarabine and mitoxantrone|mitoxantrone 12 mg/m^2 IV days 1-3 cytarabine 200 mg/m^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
79397366|NCT00536601|Drug|etoposide|Given IV
79397367|NCT00536601|Drug|cyclophosphamide|Given IV
79856088|NCT01032772|Behavioral|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
79856089|NCT00434122|Drug|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
79856090|NCT00434122|Drug|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
79259429|NCT02069249|Behavioral|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
79558460|NCT05631964|Drug|BL-M07D1|Administration by intravenous infusion
79856091|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
79558461|NCT05631548|Device|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
80019500|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
79558462|NCT05631548|Device|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
79558463|NCT05627856|Drug|GNC-038|Administration by intravenous infusion
80019501|NCT03644745|Behavioral|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
80019502|NCT03546114|Other|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
79259430|NCT03559907|Behavioral|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
79397368|NCT00536601|Drug|carmustine|Given IV
79558468|NCT05623982|Drug|GNC-038|Administration by intravenous infusion
79558469|NCT05619575|Device|CP1170 sound processor|The CP 1170 sound processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
79558470|NCT05619575|Device|CP1150 Sound processor|Active comparator off the ear sound processor.
79558471|NCT05617781|Behavioral|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
79856092|NCT00555620|Drug|oxaliplatin|Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
79856093|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
79856094|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
80019503|NCT02289794|Biological|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
80019504|NCT02289794|Biological|Placebo|Single dose, intramuscular injection (0.5 mL)
79397369|NCT00536601|Drug|melphalan|Given IV
79397370|NCT00536601|Drug|busulfan|Given IV
79397371|NCT00536601|Drug|carboplatin|Given IV
79397372|NCT00536601|Drug|thiotepa|Given IV
79397373|NCT00536601|Radiation|total-body irradiation|Undergo TBI
79397374|NCT00536601|Procedure|autologous hematopoietic stem cell transplantation|Undergo ASCT
79397375|NCT00536601|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
79397376|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25ug + spacer|
79397377|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25 ug|
79397378|NCT00462423|Drug|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
79397379|NCT00462423|Drug|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
79558472|NCT05616546|Biological|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
79259431|NCT03559907|Behavioral|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
79721430|NCT04257331|Behavioral|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
79721431|NCT04300803|Biological|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
79397380|NCT00461331|Drug|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
79558473|NCT05609630|Drug|Upadacitinib|Oral tablet or Oral solution
79558474|NCT05609630|Drug|Tocilizumab|Subcutaneous injection or Intravenous infusion
79558475|NCT05609409|Behavioral|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
79558476|NCT05607199|Drug|AUR103|Twice Daily
79721432|NCT04242355|Behavioral|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
80019505|NCT03644355|Behavioral|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
79558477|NCT05605119|Drug|AUR105|Once daily
80019506|NCT03521336|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
79259432|NCT02069405|Other|Relaxation Music|
79259433|NCT02066675|Drug|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
79259434|NCT02069483|Behavioral|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
79558478|NCT05603832|Drug|F14|625 mg intra-articular sustained-release celecoxib
79558479|NCT05603832|Drug|0.25 % Bupivacaine HCl|Local anesthetic
79558480|NCT05603832|Drug|Acetaminophen|Analgesic
80019507|NCT03521336|Drug|Placebo|Saline，Sham operation
79259435|NCT02069483|Behavioral|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
79259436|NCT02066753|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
79259437|NCT02066831|Behavioral|Telemedical coaching|
79558481|NCT05603832|Drug|Methocarbamol|Muscle relaxant
79558482|NCT05602038|Procedure|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
79558483|NCT05602038|Drug|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
79397381|NCT00461331|Drug|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
79558484|NCT05602038|Drug|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
79558485|NCT05601154|Drug|Crest Cavity Protection toothpaste|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
79558486|NCT05601154|Drug|Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
79259438|NCT02066831|Other|Telemedicine|
79259439|NCT02069561|Dietary Supplement|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
79558487|NCT05601154|Drug|Colgate PreviDent 5000+ toothpaste|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
79558488|NCT05601154|Drug|Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
79259440|NCT02066909|Drug|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
79259441|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
79259442|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
79259443|NCT02066909|Drug|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
79259444|NCT02066909|Drug|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
79558489|NCT05599100|Behavioral|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
79721433|NCT02877615|Drug|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
79721434|NCT02877615|Drug|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
79721435|NCT02877615|Drug|Placebo|Two sachets of placebo twice a day
79721436|NCT02437279|Procedure|Surgery of the tumor|
79721437|NCT02437279|Drug|Infusion with ipilimumab 3 mg/kg q3wks|
79721438|NCT02437279|Drug|Infusion with nivolumab 1 mg/kg q3wks|
79721439|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
79721440|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
79721441|NCT01251653|Drug|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
79721442|NCT01251653|Drug|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
79721443|NCT00910663|Drug|Mycophenolate Mofetil|250 mg Capsule
79721444|NCT00910663|Drug|CellCept®|250 mg Capsule
79721445|NCT04306185|Procedure|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
79721446|NCT01077375|Drug|Placebo|"Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
79721447|NCT01077375|Drug|Milnacipran|"Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
79721448|NCT00624299|Drug|Botox|Botox injection (100 ius) per muscle
80019508|NCT03104920|Procedure|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
80019509|NCT03104920|Procedure|Traditional treatment|A traditional perioperative management for HCC.
79259445|NCT02066909|Drug|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
79259446|NCT02066909|Drug|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
79397382|NCT01564394|Behavioral|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
79721449|NCT00624299|Other|Saline|Saline injection
79721450|NCT02877849|Device|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
79721451|NCT02877771|Device|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
79721452|NCT04306653|Drug|ACTH|patients with acute gout will receive 100 IU ACTH IM
79259447|NCT02066909|Drug|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
79259448|NCT02066909|Drug|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
79721453|NCT04306653|Drug|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
79721454|NCT04306731|Dietary Supplement|Nanotechnology Structured water Magnalife|Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
80019510|NCT03645447|Diagnostic Test|Taste test|A device is used to present a pseudo-randomised series of taste solutions to the participant for identification, in order to establish taste thresholds.
80019511|NCT02289872|Device|Macintosh Laryngoscope|Direct-Laryngoscopy
80019512|NCT02289872|Device|TruView PCD Video laryngoscope|Video-Laryngoscopy
80031595|NCT04909112|Other|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
80031596|NCT03050164|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
79558490|NCT05597787|Behavioral|HIV Connect|online education and clinical skills
79259449|NCT02066987|Behavioral|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
79397383|NCT01564394|Behavioral|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
79558491|NCT05597787|Behavioral|Project ECHO for HIV Prevention|education and clinical skills
80019513|NCT03104998|Drug|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
79397384|NCT00462735|Drug|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
79558492|NCT05597787|Behavioral|Project ECHO for HIV Prevention and Stigma Reduction|education, clinical skills and contact
79721455|NCT04306731|Drug|Trimethoprim|Antibiotic
79558493|NCT05595369|Drug|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
79558494|NCT05595369|Drug|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
79721456|NCT04306731|Dietary Supplement|Ordinary bottled drinking water|Placebo
79721457|NCT02877537|Drug|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
79397385|NCT00462735|Drug|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
79397386|NCT00462735|Drug|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
80019514|NCT04572984|Procedure|EBUS-TBMCB|endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
80019515|NCT04545138|Other|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
80019516|NCT04545138|Other|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10~12 points (slight).
80031597|NCT03050164|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
79397387|NCT00462735|Procedure|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
79397388|NCT01690988|Drug|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
79558495|NCT05595369|Drug|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
79558496|NCT05593614|Drug|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
79558497|NCT05593614|Drug|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
79558498|NCT05593614|Drug|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
79397389|NCT01690988|Drug|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
79558499|NCT05593523|Drug|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
79558500|NCT05593523|Device|OnLume|The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.
79558501|NCT05592015|Drug|Ruxolitinib|Given PO
79721458|NCT02877537|Procedure|Forced oscillation technique|before and after bronchodilation
79721459|NCT02877537|Procedure|Plethysmography|
79721460|NCT01250873|Drug|LY2216684|po administration
79721461|NCT01250873|Drug|Sertraline|po administration
79721462|NCT01250171|Biological|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
79721463|NCT01250171|Biological|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
79721464|NCT01250171|Biological|Placebo|The placebo solution for infusion contained 5% glucose.
79721465|NCT02888327|Drug|AL-794|
79721466|NCT02888327|Drug|Oseltamivir|
79721467|NCT02888327|Drug|Digoxin|
79721468|NCT02888327|Drug|Midazolam|
79721469|NCT02888327|Drug|Pitavastatin|
79721470|NCT02888327|Drug|JNJ-63623872|
79721471|NCT01077063|Procedure|paracentesis|surgical drainage of malignant ascites
79721472|NCT01077063|Device|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
79721473|NCT01248065|Drug|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
80019517|NCT04543032|Other|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
79721474|NCT01248065|Drug|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
79721475|NCT01250756|Biological|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
79558502|NCT05590793|Drug|Triptorelin pamoate (embonate) salt|Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
79558503|NCT05587322|Drug|BLI5100|Orally via tablet
79558504|NCT05587322|Drug|Placebo|Orally via tablet
79558505|NCT05587309|Drug|BLI5100|Orally via tablet
79558506|NCT05587309|Drug|PPI Control|Orally via tablet
79558507|NCT05585749|Other|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
79558508|NCT05582304|Device|Test Lens|ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
79558509|NCT05582304|Device|Control Lens|ACUVUE OASYS 1-Day with HydraLuxe Technology
79558510|NCT05579249|Drug|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
79721476|NCT01250756|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
79721477|NCT01250756|Biological|DTaP|0.5 mL per dose, 4 doses
79721478|NCT01250054|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
79721479|NCT01250054|Device|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
80019518|NCT03990766|Drug|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
80019519|NCT03990766|Drug|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
80019520|NCT02294162|Drug|Ketamine i.v|
79259450|NCT02066987|Behavioral|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
79259451|NCT02066987|Behavioral|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
79558511|NCT05579249|Drug|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
79558512|NCT05579249|Drug|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
79856095|NCT00555620|Drug|cisplatin|Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
80019521|NCT05176158|Drug|Dexketoprofen 25 MG|Pill at morning
80019522|NCT05176158|Drug|Dexketoprofen 25 MG|Pill at night
80019523|NCT03522896|Other|control|balancing sugars and organic acids
79558513|NCT05579249|Drug|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
79558514|NCT05579249|Drug|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
79558515|NCT05577221|Device|High Flow Nasal Air|Administration of air at high flow by using a high flow nasal oxygenation (FiO2 21%) device
79558516|NCT05575609|Other|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
79558517|NCT05573373|Drug|Parimparib|The dosage and protocol of the drug were carried out according to the description.
79721480|NCT00977470|Drug|Erlotinib|150 mg taken orally once daily
79721481|NCT00977470|Drug|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
79721482|NCT04319666|Device|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
79856096|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
79856097|NCT00433966|Drug|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
79856098|NCT00433966|Drug|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
79856099|NCT00433966|Device|Bare metal stent|Uncoated bare metal stent
79856100|NCT00433966|Device|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
80019524|NCT03522896|Other|test meal 1|orange juice plus hesperidin low dose
80019525|NCT03522896|Other|test meal 2|orange juice plus hesperidin higher dose
80019526|NCT03522896|Other|test meal 3|diluted orange juice plus hesperidin low dose
80019527|NCT03104764|Device|Scalpel|Labial frenulum removed by scalpel
80019528|NCT03104764|Device|Er:YAG laser|Labial frenulum removed by Er:YAG laser
79721483|NCT04289896|Other|Plyometric exercise|"The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions."
79721484|NCT01245374|Device|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
80019529|NCT05575050|Procedure|Oral Procedure|Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
80019530|NCT04323163|Behavioral|Physical Activity|3 sessions per week, 60 minutes per session for 6 months
80019531|NCT02294240|Dietary Supplement|Energy dense biscuits|Energy dense biscuits will be provided
79856101|NCT00743561|Device|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
79856102|NCT00743561|Device|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
79259452|NCT02071979|Device|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
79259453|NCT02071979|Device|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
79558518|NCT05573373|Drug|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
79558519|NCT05573373|Drug|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
79558520|NCT05572788|Procedure|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
79721485|NCT02865304|Drug|endostar|
80019532|NCT02294240|Other|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
80019533|NCT04481724|Dietary Supplement|gamma-linolenic acid|3 capsules per day of GLA for 24 months
79397390|NCT01690988|Drug|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
80019534|NCT04481724|Dietary Supplement|placebo|3 capsules per day of placebo for 24 months
80019535|NCT02298218|Drug|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
80019536|NCT03547830|Drug|Plerixafor|Plerixafor for Conditioning before HSCT.
80019537|NCT03547830|Drug|Gcsf|GCSF for Conditioning before HSCT.
80019538|NCT02920216|Drug|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
80019539|NCT03132662|Dietary Supplement|Omega-3|3 gr/day of Omega-3
80019540|NCT03132662|Dietary Supplement|Very Low Calorie Diet|4 servings/day Optifast
80019541|NCT05431933|Biological|Eupolio|Inactivated Polio vaccine (Sabin strains)
79397391|NCT00463437|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
79397392|NCT00463437|Biological|Prevenar|Intramuscular injection, 1 dose.
79397393|NCT00463437|Biological|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
79397394|NCT00463437|Biological|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
80019542|NCT03132818|Other|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
80031598|NCT02037087|Behavioral|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
79397395|NCT00463437|Biological|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
79558526|NCT05564949|Other|CKD|Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
79259454|NCT02071979|Device|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
79259455|NCT02071979|Procedure|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
79721486|NCT04289272|Behavioral|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
79721487|NCT04075474|Device|silver diamine fluoride|38% SDF on primary upper anterior teeth
79558527|NCT05564117|Drug|Semaglutide|Semaglutide tablets orally once daily for 64 weeks.
79721488|NCT04075474|Device|sodium fluoride|5% NaF on primary upper anterior teeth
79721489|NCT00977314|Device|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
79721490|NCT00977314|Device|SoundBite|
79856103|NCT00743639|Procedure|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
79856104|NCT00947336|Drug|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
79259456|NCT02072057|Drug|Ruxolitinib|
79259457|NCT03292523|Other|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
79259458|NCT02069639|Other|no treatment|
79259459|NCT02072135|Drug|Exparel|
79259460|NCT02067065|Drug|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
79721491|NCT00977314|Device|SoundBite Hearing System|
79259461|NCT02067065|Drug|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
79259462|NCT02067065|Procedure|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
79558528|NCT05564117|Drug|Placebo semaglutide|Semaglutide placebo-matching tablets orally once daily for 64 weeks.
79558529|NCT05561140|Drug|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
79558530|NCT05561140|Other|Placebo|Placebo
79558531|NCT05560412|Dietary Supplement|Zein nanocapsules|1 g of Zein nanoencapsulated daily
79558532|NCT05560412|Dietary Supplement|control|1 g of Zein non-encapsulated daily
79558533|NCT05557396|Other|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
79558534|NCT05556187|Other|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
79721492|NCT02866396|Drug|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
79856105|NCT00947336|Drug|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
79856106|NCT00956384|Procedure|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
80019543|NCT05692765|Behavioral|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
80019544|NCT03547752|Other|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
80019545|NCT04390945|Drug|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
80019546|NCT02291588|Drug|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
80019547|NCT02291588|Drug|Placebo|contains no active drug
80019548|NCT03521258|Device|Dehydrated Human Amnion/Chorion Membrane|
80019549|NCT03521258|Procedure|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
80019550|NCT03102814|Behavioral|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
80019551|NCT03102814|Behavioral|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
80019552|NCT04465890|Drug|ASC22|200mg/1ml/1bottle
79721493|NCT02866396|Other|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
79721494|NCT01087203|Biological|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
79721495|NCT01087203|Biological|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
79721496|NCT04289350|Diagnostic Test|fetal heart rate variability|An observational study. No intervention
79721497|NCT02865226|Other|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
79721498|NCT02865226|Other|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
79721499|NCT01246583|Drug|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
79721500|NCT01246583|Drug|Vehicle 1|Vehicle 1 twice daily for 4 weeks
79721501|NCT01246583|Drug|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
79721502|NCT01246583|Drug|Vehicle 2|Vehicle 2 twice daily for 4 weeks
79721503|NCT01084239|Radiation|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
79721504|NCT01244906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
79721505|NCT00626613|Drug|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
79721506|NCT01080807|Drug|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
79721507|NCT01080807|Drug|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
79856107|NCT00956384|Procedure|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
79856108|NCT00955214|Device|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
80019553|NCT04465890|Drug|sodium chloride|90mg/10ml/1 bottle
80019554|NCT03625843|Behavioral|Mindfulness exercises|
80019555|NCT03102502|Device|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
80019556|NCT03102502|Drug|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
80019557|NCT02291666|Drug|CRCHUM-MT cocktail|
80019558|NCT03102658|Drug|Micafungin|Administration of study drug
80019559|NCT03546036|Device|Weighted metal chain blanket|Use of a weighted metal chain blanket of 8 kg
80019560|NCT03546036|Device|Control plastic chain blanket|A blanket with light plastic chains
79259463|NCT02067143|Drug|Prephase PDN + CY|
80019561|NCT02291744|Procedure|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
79259464|NCT02067143|Drug|Cycle 1 Induction|
79259465|NCT02067143|Drug|Cycle 2 Induction / Early consolidation|
79259466|NCT02067143|Drug|Cycle 3 Early consolidation|
79259467|NCT02067143|Drug|Cycle 4 Consolidation|
79259468|NCT02067143|Drug|Cycle 5 Consolidation|
79259469|NCT02067143|Drug|Cycle 6 Consolidation|
79259470|NCT02067143|Drug|Cycle 7 Consolidation|
79259471|NCT02067143|Drug|Cycle 8 Reinduction|
79856109|NCT00947414|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
79721508|NCT01079949|Drug|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
79259472|NCT02067143|Drug|Maintenance|If MRD negative MRD u/k SR
79721509|NCT01079949|Drug|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
79856110|NCT00947414|Device|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
79856111|NCT00955292|Drug|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
79856112|NCT00956462|Drug|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
80019562|NCT02291744|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
79259473|NCT02067143|Procedure|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
80019563|NCT02646748|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
79259474|NCT02072213|Drug|GL2702 GLARS-NF1|0.4mg once a day
79259475|NCT02072213|Drug|Omix Ocas|0.4mg once a day
79259476|NCT03330743|Behavioral|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
79259477|NCT03330743|Behavioral|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
79259478|NCT02072291|Drug|Nifedipine|PO Nifedipine 5mg single dose
79259479|NCT02069717|Other|Not applicable-observational study|
79259480|NCT02072369|Other|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
79259481|NCT02072369|Other|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
79259482|NCT02067221|Device|RIRS|"RIRS arm~Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
79397396|NCT00463437|Biological|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
79558542|NCT05547633|Other|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
79558543|NCT05542446|Drug|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
79558544|NCT05541640|Drug|normal saline group|normal saline infusion at the start of surgery
79558545|NCT05541640|Drug|lidocaine group|lidocaine infusion at the start of surgery
79558546|NCT05538806|Device|TTFields|all patients will receive routine clinical care and TTFields
79558547|NCT05533294|Drug|ARO-RAGE Injection|ARO-RAGE injection for sc administration
79558548|NCT05533294|Drug|Placebo|normal saline (0.9% NaCl) by sc injection
79721510|NCT01079949|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
79721511|NCT01079949|Drug|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
79856113|NCT00947492|Biological|Venous blood sample|Venous blood sample twice a year during 3 years
79856114|NCT05300360|Diagnostic Test|adenosine deaminase test|adenosine deaminase enzyme deficiency test
79856115|NCT00956696|Drug|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
79856116|NCT00955448|Device|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
79856117|NCT00955448|Procedure|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
80019564|NCT02646748|Drug|itacitinib|Itacitinib tablets administered orally once daily.
80019565|NCT02646748|Drug|INCB050465|INCB050465 tablets administered orally once daily.
80019566|NCT03547674|Other|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
80019567|NCT03547674|Other|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
80031599|NCT02037087|Behavioral|Care seeking|"Danger-sign recognition~Reminders for government projects"
79259483|NCT02067221|Device|MPCNL|"MPCNL arm~A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
79259484|NCT04977440|Dietary Supplement|Whey protein|"Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2~-Full calculated caloric amount in DAY 3~This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:~The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given"
79259485|NCT02069795|Other|Voice recording|
79259486|NCT04154462|Other|Scribes|Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
79259487|NCT02069873|Behavioral|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
79259488|NCT04977518|Other|no intervention|no intervention
79397397|NCT00463437|Biological|Meningitec|Intramuscular injection, 1 dose.
79397398|NCT00463437|Biological|NeisVac-C|Intramuscular injection, 1 dose.
79721512|NCT04306263|Dietary Supplement|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
79721513|NCT04306263|Dietary Supplement|Standard formula|Infants receiving a standard infant formula.
79721514|NCT04306263|Dietary Supplement|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
79259489|NCT02067299|Drug|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
79259490|NCT02067299|Other|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
79259491|NCT04977284|Device|DS7R, Digitimer, UK|Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
79259492|NCT02072447|Drug|YH4808 PO and [14C]-YH4808 IV|
79259493|NCT03060122|Device|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
79259494|NCT03060122|Device|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
79259495|NCT03060122|Device|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
79558549|NCT05532813|Drug|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
79259496|NCT03784937|Diagnostic Test|Doppler ultrasound|Each patient received Doppler ultrasound for research of DVT, no matter the risk stratification.
79259497|NCT02072525|Biological|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
79259498|NCT02072525|Biological|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
79259499|NCT02072525|Biological|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
79397399|NCT00463437|Biological|Menitorix|Intramuscular injection, 1 dose.
79397400|NCT01466153|Drug|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m^2 on Day 2 of Cycle 1 and then at 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycles
79397401|NCT01466153|Drug|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
79397402|NCT01466153|Drug|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
79397403|NCT00464685|Drug|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
79558555|NCT05526157|Drug|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
79558556|NCT05526157|Drug|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
79558557|NCT05526157|Drug|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
79558558|NCT05526157|Drug|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
79721515|NCT00909727|Drug|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
79721516|NCT00909727|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
79721517|NCT00977080|Drug|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
79721518|NCT00977080|Drug|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
79259500|NCT02072525|Biological|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
79558559|NCT05526157|Drug|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
79856118|NCT03952650|Drug|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
79856119|NCT03952650|Biological|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
79721519|NCT04098055|Device|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
79259501|NCT04977128|Drug|89Zr-KN035|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
79259502|NCT03059888|Drug|Abatacept Injection|Subcutaneous administration of abatacept
79397404|NCT00464685|Drug|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
79397405|NCT00464685|Procedure|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
79397406|NCT01474291|Biological|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
79397407|NCT01465997|Drug|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
79397408|NCT01465997|Drug|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
79397409|NCT00538863|Drug|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
79397410|NCT00539253|Drug|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
79721520|NCT04098055|Device|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
79721521|NCT05581381|Behavioral|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
79259503|NCT02069951|Other|Practice a procedural module on a simulator|
79259504|NCT03061292|Procedure|Pectoral Nerve Block|
79259505|NCT03061292|Procedure|Without Pectoral Nerve Block|
79397411|NCT01465763|Drug|tofacitinib|10 mg oral BID
79397412|NCT01465763|Drug|Placebo|Plabebo oral BID
79397413|NCT00540579|Drug|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
79558561|NCT05504070|Device|Venclose System (digiRF generator w EVSRF catheter)|The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
79558562|NCT05504070|Device|Venclose MAVEN System (digiRF generator w MAVEN catheter)|The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
79259506|NCT02070029|Procedure|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
79259507|NCT03059966|Procedure|Microsurgery technique for root coverage|Microsurgery technique for root coverage adapted for macrosurgery
79259508|NCT03059966|Biological|Microsurgery technique for root coverage associated to EMD|Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
79397414|NCT00540579|Drug|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
79397415|NCT00466323|Behavioral|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
79397416|NCT00466323|Behavioral|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
79397417|NCT04081727|Device|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
80031600|NCT02037087|Behavioral|Full bank of SMS|"Danger-sign recognition~Reminders for government projects~Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
79397418|NCT01690520|Drug|Cyclophosphamide|Given IV
79259509|NCT02260349|Drug|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
79721522|NCT03873649|Other|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
79721523|NCT00975676|Other|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
79721524|NCT03770221|Behavioral|CATCH|Brief, intensive case management service.
79259510|NCT02072603|Other|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
79259511|NCT02072603|Other|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
79259512|NCT04964648|Device|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
79397419|NCT01690520|Drug|Cyclosporine|Given IV or PO
79397420|NCT01690520|Biological|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
79397421|NCT01690520|Drug|Fludarabine Phosphate|Given IV
79558569|NCT05492344|Other|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~PEEP ≥ 15 cm H2O~Tidal volume: 4 to 6 mL/kg PBW~Daily recruitment maneuver"
79721525|NCT03770221|Other|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
79721526|NCT03766087|Procedure|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
79721527|NCT02866240|Device|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
79558570|NCT05492344|Other|Standard care|"Patient who are randomized in the control group will receive standard care~Tidal volume: 6 mL/kg PBW~PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is < 150 mmHg"
79721528|NCT02866318|Device|Echocardiography|
79721529|NCT00629356|Genetic|dengue fever|
79721530|NCT02865148|Behavioral|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
79259513|NCT03061838|Drug|MabThera®|1000 mg intravenously
79259514|NCT03061838|Drug|Ritumax®|1000 mg intravenously
79259515|NCT03061370|Procedure|Esophagectomy or Gastrectomy|Surgical resection
79259516|NCT02070107|Other|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
79259517|NCT04972994|Procedure|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
79259518|NCT04964180|Drug|Indomethacin suppository|two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
79259519|NCT04964180|Drug|Lidocaine 2% Injectable Solution|200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
79259520|NCT02067377|Dietary Supplement|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
79397422|NCT01690520|Drug|Mycophenolate Mofetil|Given IV or PO
79397423|NCT01690520|Drug|Thiotepa|Given IV
79397424|NCT01690520|Radiation|Total-Body Irradiation|Undergo high dose or middle intensity TBI
79397425|NCT01690520|Procedure|Umbilical Cord Blood Transplantation|Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
79397426|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
79397427|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
79259521|NCT02067377|Dietary Supplement|Placebo (for serum bovine immunoglobulin)|
79856120|NCT03952650|Drug|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
80019568|NCT03547674|Other|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
79397428|NCT00541593|Procedure|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
79558571|NCT05488938|Other|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
79721531|NCT00629434|Other|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
79721532|NCT00629434|Other|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
79856121|NCT03952650|Drug|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
79259522|NCT02070185|Behavioral|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
79259523|NCT02070185|Behavioral|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
79397429|NCT04081103|Drug|Nexagon® (lufepirsen) High Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
79397430|NCT04081103|Drug|Nexagon® (lufepirsen) Low Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
79721536|NCT03935854|Other|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
79856122|NCT03952650|Drug|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
79856123|NCT00955526|Drug|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
79397431|NCT04081103|Drug|Vehicle|Vehicle is administered topically in the affected eye three (3) times over 28 days.
79397432|NCT04081103|Drug|Open-label Nexagon® (lufepirsen)|Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
79397433|NCT00541671|Drug|Saline|10 c of saline
79397434|NCT00541671|Drug|Phenergan|Physician ordered dose
79397435|NCT01563536|Drug|ABT-267|Tablet
79397436|NCT01563536|Drug|ABT-450|Tablet
79397437|NCT01563536|Drug|ABT-333|Tablet
79397438|NCT01563536|Drug|Ritonavir|Capsule
79397439|NCT01563536|Drug|Ribavirin|Tablet
79397440|NCT03158337|Behavioral|Aerobic exercise|
79397441|NCT03156465|Device|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
79397442|NCT04163835|Drug|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
79397443|NCT04163835|Drug|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
79397444|NCT04163835|Drug|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
79397445|NCT04163835|Drug|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
79259524|NCT04976504|Device|Oxygen reserve index|This is an observational study of the routine clinical practice with no specific additional interventions required. The investigators enrolled the ASA physical status I to III patients scheduled for elective surgery with planned arterial catheter placement before induction. ORi and standard monitors were placed. The patients were preoxygenated and received anesthesia induction as routine clinical practice. Intubation was done by video-laryngoscope. The endotracheal tube was not connected to the breathing circuit to avoid apneic oxygenation. Ventilation was resumed when SpO2 fell to 90%. ORi and SpO2 were recorded every ten seconds.
79259525|NCT04964102|Behavioral|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
79259526|NCT02072759|Dietary Supplement|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~1 carnitine supplement at breakfast (500mg)~1 carnitine supplement at lunch (500mg)~2 carnitine supplements at diner (2x 500mg=1000mg)"
79259527|NCT02072759|Dietary Supplement|Placebo|
79558574|NCT05485753|Drug|GNC-038|Administration by intravenous infusion
79259528|NCT02067455|Other|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
79558575|NCT05478993|Drug|SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone|"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."
79558576|NCT05471349|Behavioral|Flyer and video|Participants will view a flyer and video
79558577|NCT05470348|Drug|BL-B01D1|Administration by intravenous infusion
79558578|NCT05464407|Dietary Supplement|Cubitan|2 bottles of Cubitan daily, for 12 weeks.
79558579|NCT05461768|Drug|BL-M07D1|Administration by intravenous infusion
79558580|NCT05455112|Biological|RUTI® Vaccine|One subcutaneous injection of RUTI 25µg FCMtb
79558581|NCT05455112|Biological|Placebo|One subcutaneous injection of saline
79721537|NCT04289584|Other|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
79721538|NCT03857191|Dietary Supplement|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
79721539|NCT04289818|Other|Health Coaching|Health Coaching as face to face with a coach
79721540|NCT03812809|Drug|BPI-7711|BPI-7711: 180mg, QD, oral
79721541|NCT04083157|Biological|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
79721542|NCT04083157|Biological|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
79721543|NCT05522101|Device|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
79721544|NCT05522101|Device|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340*340, working time is not less than 8 hours.
79259529|NCT02072915|Procedure|Suction|
79721545|NCT00975286|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
79721546|NCT00975286|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
79721547|NCT00975286|Drug|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
79721548|NCT00975286|Device|Pen auto-injector|Lantus® SoloStar® OptiClik®
79721549|NCT00975286|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
79721550|NCT00975286|Drug|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
79721551|NCT00907777|Biological|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
79259530|NCT02070341|Drug|Polyethylene Glycol|
79259531|NCT02070341|Drug|Picosalax|
79259532|NCT02072993|Drug|AZD1979|Single dose, oral solution administration
79259533|NCT02072993|Drug|Placebo to match|Single dose, oral solution administration
79259534|NCT02070419|Procedure|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
79558587|NCT05453474|Genetic|Whole genome amplification|DNA is amplified by whole genome amplification
79558588|NCT05451017|Drug|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
79558589|NCT05451017|Drug|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
79721552|NCT00907777|Biological|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
79856124|NCT00955526|Drug|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
79259535|NCT02070419|Radiation|stereotactic radiosurgery|Undergo SBRT
79259536|NCT02073071|Other|Preterm infant formula per standard of care|Commercially available preterm infant formula
79259537|NCT02073149|Dietary Supplement|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
79856125|NCT00955526|Drug|Placebo|Two placebo tablets once daily for 12 weeks
79856126|NCT00955604|Drug|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
79856127|NCT00955604|Drug|Group R Rasagiline|At least 2 months of rasagiline
79856128|NCT00955604|Drug|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
79856129|NCT00947570|Behavioral|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
79856130|NCT03623646|Drug|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
79259538|NCT02073149|Dietary Supplement|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
79856131|NCT03623646|Drug|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
79856132|NCT00947648|Other|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
80019569|NCT03547674|Other|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
80019570|NCT03624985|Drug|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
79259539|NCT02073149|Dietary Supplement|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
79397446|NCT01690130|Device|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
79721553|NCT03741517|Radiation|18F-FDG-PET|Fludeoxyglucose F18
79721554|NCT03741517|Radiation|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
79721555|NCT03741517|Radiation|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
79721556|NCT03741517|Other|Core needle biopsy|Core needle biopsy of metastatic lesions
79721557|NCT03741517|Other|Phlebotomy|Phlebotomy from peripheral vein
79721558|NCT04270396|Behavioral|Presence or absence of implant|We procedure to observed clinically the sample size, to be able to determine if the dental implant was present or no. If the implant was absent we recorded if it was early( prior to restoration) or late ( after prosthesis was delivered).
79856133|NCT00947648|Other|Cooked Foods|Diet containing only cooked foods.
79397447|NCT01690130|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
79856134|NCT00962286|Drug|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
79856135|NCT00691301|Drug|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
79259540|NCT02625974|Drug|Nifurtimox (Lampit, BAYA2502)|"For pediatric subjects with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days of nifurtimox treatment"
79259541|NCT02625974|Drug|Placebo|Matching placebo
79259542|NCT02067689|Device|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
79259543|NCT02070497|Other|case management|case management group will accept the case manager's service; the control group will just accept the routine care
79259544|NCT02067767|Drug|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
79259545|NCT02073227|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
79259546|NCT02073227|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
79397448|NCT04750161|Other|No intervention|No intervention will be given to participants. It is purely observational.
79856136|NCT00691301|Drug|pemetrexed disodium|
79856137|NCT00955760|Drug|Neramexane|Drug-Drug Interaction Study
79856138|NCT04010448|Biological|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
79856139|NCT04010448|Biological|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
79856140|NCT00955838|Other|Rehabilitation technique|12 therapy session
80019571|NCT03624985|Drug|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
79856141|NCT03554382|Other|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
79856142|NCT00947726|Drug|CeraVe|Using OTC cream on foot twice daily for two weeks.
80019572|NCT03521024|Other|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
79259547|NCT02073227|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
79856143|NCT03887819|Diagnostic Test|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
79856144|NCT00955994|Drug|asimadoline|
79558592|NCT05441605|Other|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
79259548|NCT02073227|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
79259549|NCT04976582|Device|dry needle|modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
79397449|NCT01690052|Drug|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
79397450|NCT01690052|Drug|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
79397451|NCT02117193|Other|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
79397452|NCT02117193|Other|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
79259550|NCT02073305|Other|No Sleep Apnea|No intervention
79397453|NCT01689974|Drug|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
79856145|NCT05277480|Drug|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
79259551|NCT02073305|Other|Sleep Apnea - untreated|No intervention
79259552|NCT02073305|Device|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
79259553|NCT04972838|Behavioral|Remaking Recess (RR)|Remaking Recess is a flexible, school-based social engagement intervention for students with autism and their peers. The research team will work with school personnel to deliver RR during recess. RR is tailored based on the needs of schools, students, and staff.
79259554|NCT02073383|Procedure|Axillary brachial plexus block|
79259555|NCT03060044|Drug|Salmeterol/fluticasone Easyhaler|
79856146|NCT05277480|Drug|IE|ifosfamide ivgtt ; etoposide ivgtt .
79259556|NCT03060044|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
79259557|NCT03060044|Drug|Seretide Diskus|
79259558|NCT03060044|Drug|Seretide Diskus with charcoal|
79259559|NCT02073539|Device|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
79259560|NCT02073539|Device|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
79397454|NCT01689974|Radiation|Radiation Therapy|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
80019573|NCT03521024|Other|lithium disilicate|well documented in the literatures as successful restoration modality.
79397455|NCT04750083|Drug|HX008|HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
79397456|NCT04750083|Drug|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
79397457|NCT04750083|Drug|pemetrexed|pemetrexed 500 mg/m^2 IV on Day 1 of Q3W for up to 35 cycles
79397458|NCT04750083|Drug|cisplatin/carboplatin|cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
80031601|NCT02797262|Device|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
79397459|NCT04071405|Other|Non-intervention|Non-intervention observational study
79397460|NCT03092271|Behavioral|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
79397461|NCT03092271|Behavioral|Zero Suicide Quality Improvement|ZSQI
79721559|NCT02866084|Device|Device|"The following parameters will be set for active treatments using the CVS Device:~A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
79259561|NCT04972370|Other|Patients with Unilateral Cleft Lip with or without Cleft Palate|2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
79397462|NCT02954991|Drug|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
80019574|NCT05178108|Other|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~3 sequences with no food~3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
80019575|NCT05431465|Other|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
80019576|NCT05431465|Other|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
79259562|NCT02070653|Drug|Ticagrelor|
79259563|NCT02070653|Drug|Placebo|
79259564|NCT02073617|Radiation|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
80019577|NCT02294552|Drug|Cyclophosphamide|
79721560|NCT00908011|Drug|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
80019578|NCT02294552|Drug|Busulfan|
79397463|NCT02954991|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
79397464|NCT02954991|Drug|Mocetinostat|Mocetinostat is an HDAC inhibitor.
79259565|NCT03059732|Other|Treatment|Observe the treatments of gastric cancer in each group
79397465|NCT02954991|Drug|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
79397466|NCT02945787|Behavioral|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
79721561|NCT00908011|Drug|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
79397467|NCT02945787|Behavioral|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
79397468|NCT02982837|Drug|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
80019579|NCT02294552|Drug|Fludarabine monophosphate|
79558598|NCT05432635|Biological|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
79558599|NCT05432635|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
79558600|NCT05432635|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
80019580|NCT02294552|Drug|Tacrolimus|
80019581|NCT02294552|Drug|Mycophenolate mofetil|
80019582|NCT02294552|Procedure|Allogeneic hematopoietic stem cell transplantation|
80019583|NCT03514706|Diagnostic Test|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
79259566|NCT04976114|Procedure|Story book with information about surgery techniques|Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.
79259567|NCT04976114|Procedure|Video with information about surgery techniques|Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.
79259568|NCT04976114|Procedure|Story book and Video with information about surgery techniques|Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
79259569|NCT02076269|Other|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
79397469|NCT02982837|Drug|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
79558601|NCT05432635|Procedure|Myeloablative Conditioning|Given standard conditioning regimen
79558602|NCT05426174|Biological|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79558603|NCT05426174|Biological|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
79558604|NCT05415358|Other|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of pembrolizumab discontinuation.
79721562|NCT02864836|Procedure|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
79259570|NCT04831892|Other|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
79259571|NCT04831892|Other|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
79558605|NCT05413005|Combination Product|ECP regular-intensity arm|"Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
79721563|NCT00976456|Drug|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
79558606|NCT05413005|Combination Product|ECP accelerated-intensity arm|"Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~Weeks 9-16: Cryo-ECP bags infused once-a-week~Weeks 17-24: Cryo-ECP bags infused every two weeks"
79721564|NCT00976456|Drug|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
79721565|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79721566|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79721567|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79259572|NCT02070731|Device|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
79259573|NCT04831112|Drug|Honey|Dressing of necrotizing fascitis wounds with honey.
79259574|NCT04831112|Combination Product|EUSOL|Dressing of necrotizing fascitis wounds with EUSOL.
79558607|NCT05413005|Biological|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
79558608|NCT05411588|Drug|PF-07275315|Active drug
79721568|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79721569|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79721570|NCT00629512|Drug|Esomeprazole|20mg oral daily
79721571|NCT00629512|Drug|Esomeprazole|40mg oral daily
79721572|NCT00629512|Drug|Placebo|
79856147|NCT03429335|Behavioral|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
79856148|NCT03429335|Behavioral|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
79856149|NCT03429335|Behavioral|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
79856150|NCT00956072|Drug|imatinib mesylate|Patients receive imatinib mesylate
79259575|NCT02073695|Procedure|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
79259576|NCT02073695|Device|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
79721573|NCT01711021|Drug|d-Amphetamine Transdermal Patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
79259577|NCT02073695|Other|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
79259578|NCT02073695|Other|Functional outcome forms filled in|
79259579|NCT02073695|Other|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
79721574|NCT01711021|Drug|Placebo patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
79259580|NCT02073695|Other|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
79397470|NCT00469911|Procedure|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
79397471|NCT00469911|Procedure|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
79397472|NCT03934359|Drug|DN1508052-01|DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
79397473|NCT00470301|Drug|tipifarnib|Given orally
79397474|NCT00470301|Drug|paclitaxel|Given IV
79397475|NCT00470301|Drug|doxorubicin|Given IV
79397476|NCT00470301|Drug|cyclophosphamide|Given IV
79721575|NCT02864680|Other|Electroretinography|
79721576|NCT02864680|Other|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
79856151|NCT00956072|Procedure|therapeutic conventional surgery|Patients undergo surgery
79856152|NCT03518190|Device|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
80031602|NCT03049930|Drug|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
79721577|NCT02864680|Other|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
80019584|NCT03514706|Diagnostic Test|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
80019585|NCT03940924|Other|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
79558609|NCT05411588|Drug|Placebo|Placebo
80019586|NCT05692531|Behavioral|A Story Within A Story|"The intervention is the screening via Zoom of A Story Within A Story, two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use."
80019587|NCT03517982|Drug|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
80019588|NCT02298374|Other|Homecare reablement|
80019589|NCT02298374|Other|usual care|
80019590|NCT03869944|Drug|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
79397477|NCT00543777|Diagnostic Test|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
79558610|NCT05407779|Biological|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
79558611|NCT05407779|Biological|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
79558612|NCT05407779|Biological|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
79721578|NCT02864680|Other|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
79856153|NCT02565407|Behavioral|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
79856154|NCT02565407|Behavioral|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
79397478|NCT00543777|Diagnostic Test|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
79397479|NCT00544713|Drug|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
79397480|NCT00544713|Drug|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
79558613|NCT05407779|Biological|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
79558614|NCT05407779|Biological|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
79558615|NCT05407779|Biological|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
79558616|NCT05407779|Biological|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
79558617|NCT05405166|Drug|Isatuximab IV|Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
79721579|NCT02864680|Other|CAST (cannabis abuse screening test)|
79721580|NCT02864680|Other|PANSS (Positive And Negative Symptoms Scale) test|
79721581|NCT02864680|Other|Delayed Matching to Sample (DMS) test|
79721582|NCT02864680|Other|Spatial Working Memory (SWM) test|
79721583|NCT02864680|Other|Rapid Visual Information Processing (RVP) test|
79721584|NCT02864680|Other|Test for attentional performance (TAP) / Divided Attention|
79721585|NCT02864680|Other|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
79721586|NCT02864602|Drug|IV dexamethasone|An infusion of IV dexamethasone
79856155|NCT00962364|Biological|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
79856156|NCT02564003|Drug|Oxycodone|oxycodone 0,1 mg/kg iv
79856157|NCT00956150|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
79259581|NCT02073773|Drug|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
79558618|NCT05405166|Drug|Isatuximab SC|Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
80019591|NCT02291822|Drug|Gadobenate Dimeglumine|gadolinium contrast agent
79558619|NCT05405166|Drug|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
79558620|NCT05405166|Drug|Pomalyst or equivalent|Pharmaceutical form: hard capsules; Route of administration: Oral
79558621|NCT05403658|Behavioral|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
79721587|NCT03788083|Drug|Trimix|Intratumoral TriMix injection
79721588|NCT03788083|Drug|Placebo|Intratumoral placebo injection
79721589|NCT04289506|Diagnostic Test|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
79721590|NCT00993148|Drug|maraviroc|150 mg tab by mouth once daily for 96 weeks
79856158|NCT00956150|Drug|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
79856159|NCT00956150|Drug|Placebo|Placebo TID PO x 10 days
79259582|NCT02073773|Other|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
79259583|NCT04830800|Biological|COVIVAC|COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
79721591|NCT00993148|Drug|darunavir|800 mg tab by mouth once daily for 96 weeks
79721592|NCT00993148|Drug|ritonavir|100 mg capsule by mouth once daily for 96 weeks
79721593|NCT03775369|Other|endurance training|physical activity and exercising (PAE)
79721594|NCT03775369|Other|social support and counseling|social support and counseling
79721595|NCT03775369|Other|resistance training|physical activity and exercising (PAE)
79721596|NCT03661177|Other|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
79721597|NCT05505955|Drug|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
79721598|NCT05505955|Drug|Placebo|Subjects took Placebo in Part 1 and Part 2.
79721599|NCT04223947|Procedure|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
79856160|NCT00967824|Other|informational intervention|
79856161|NCT00967824|Other|questionnaire administration|
79856162|NCT00967824|Other|survey administration|
79856163|NCT00947960|Drug|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
79856164|NCT00947960|Other|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
79856165|NCT00923663|Drug|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
79856166|NCT00956228|Radiation|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
79856167|NCT00743873|Biological|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
79856168|NCT00743873|Drug|placebo|injection of 6 cc of saline into injured area
80019592|NCT05105178|Other|Giving orientation with headphones|During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
80019593|NCT05105178|Other|Emergence as usual with headphones|During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
80019594|NCT02291900|Procedure|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
80019595|NCT05429905|Biological|Phase I|"Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D."
80019596|NCT05429905|Biological|Phase II|RP2D will be determined in Phase I
80019597|NCT05692219|Behavioral|Lifestyle medicine|6 weeks booklet-delivered multicomponent lifestyle medicine intervention
79259584|NCT04830800|Biological|Phosphate-buffered saline|Phosphate buffer solution (pH 7.2), manufactured by IVAC
79259585|NCT04964336|Other|Analysis of B cells|B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
79558622|NCT05403658|Behavioral|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
79558623|NCT05400317|Drug|AD-218|PO, Once daily(QD), 12weeks
79721600|NCT00907621|Procedure|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
79721601|NCT04230811|Diagnostic Test|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
79721602|NCT03601117|Device|Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
79721603|NCT03601117|Device|Anterior Cingulate Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
79721604|NCT03587233|Behavioral|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
79721605|NCT03587233|Device|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
79259586|NCT02073851|Device|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
79259587|NCT04963868|Procedure|Stent removed by the novel strategy|The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved；
79259588|NCT04963868|Procedure|Stent removed by the conventional strategy|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.
79259589|NCT02076347|Behavioral|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
79259590|NCT02076347|Behavioral|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
79558624|NCT05400317|Drug|AD-218A|PO, Once daily(QD), 12weeks
79558625|NCT05398185|Behavioral|WiseApp|The Intervention group will receive the WiseApp that delivers medication adherence reminders
79558626|NCT05396638|Behavioral|Contingency Management|Participants will be paid for abstinence at each study visit.
79558627|NCT05396014|Behavioral|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
80019598|NCT05692219|Behavioral|Cognitive behavioral therapy|6 weeks booklet-delivered self-help cognitive behavioral therapy
80019599|NCT03547596|Other|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
80019600|NCT03514628|Other|Standard Care|The Valsalva strain will be produced using Standard Care techniques
79397481|NCT02126319|Behavioral|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
80019601|NCT03514628|Device|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
79259591|NCT03061760|Procedure|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
79259592|NCT03061760|Diagnostic Test|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
79259593|NCT03061760|Diagnostic Test|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
79259594|NCT03062150|Drug|Placebo|Placebo
79259595|NCT03062150|Drug|Fludrocortisone|Fludrocortisone
79259596|NCT03062150|Drug|D-Cycloserine|D-Cycloserine
79259597|NCT02076503|Procedure|PET-MR 18f-FACBC|
79856169|NCT04011098|Drug|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
79856170|NCT04011098|Drug|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
79721606|NCT03587233|Behavioral|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
79856171|NCT00927563|Drug|Tolcapone|pill, 100-300mg/day for 8 weeks
79856172|NCT00967902|Device|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
79856173|NCT00956306|Drug|Udenafil|100mg Single Oral Dose of Udenafil
79856174|NCT00957164|Behavioral|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
79856175|NCT00957164|Behavioral|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
79856176|NCT00957164|Behavioral|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
79856177|NCT05228340|Procedure|Flexor tenotomy|Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
79856178|NCT00775229|Drug|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
79259598|NCT02076503|Procedure|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
79259599|NCT03061916|Dietary Supplement|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
79259600|NCT03061916|Dietary Supplement|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
79259601|NCT03061916|Drug|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
79721607|NCT03581695|Other|Blood test|Blood test
79721608|NCT03517111|Behavioral|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
80019602|NCT04435522|Drug|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
79259602|NCT02076659|Drug|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
79856179|NCT00775229|Drug|Placebo|pill, by mouth, daily
79856180|NCT00962442|Drug|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
79856181|NCT00962442|Drug|placebo|Glucosé 5% perfusion for 14 days, intravenously
79856182|NCT00948038|Dietary Supplement|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
79259603|NCT02076659|Drug|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
79259604|NCT04963556|Dietary Supplement|Red Bull|Drinking of Red Bull before exercise
79259605|NCT04963244|Other||
79721609|NCT03517111|Behavioral|Substance use prevention only|Parenting program focusing only on substance use prevention
79721610|NCT03517111|Behavioral|Academic success program|Program focusing on academic success and college acceptance
79721611|NCT04225429|Drug|Tazemetostat|800mg/dose taken orally twice every day.
79856183|NCT00948038|Dietary Supplement|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
80019603|NCT03843970|Drug|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
80019604|NCT03843970|Drug|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
80019605|NCT02298452|Device|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
79259606|NCT02076815|Drug|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
79259607|NCT02076815|Drug|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
79259608|NCT04971434|Device|laser stimulation for acupoints|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
79397482|NCT02126319|Behavioral|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
79397483|NCT00545025|Biological|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
79856184|NCT00967980|Procedure|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
79397484|NCT00545025|Biological|Fluarix™|Single dose, Intramuscular injection
79397485|NCT00545181|Drug|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
79397486|NCT00545181|Drug|Metronidazole control|oral metronidazole therapy alone
79397487|NCT01797315|Drug|Sirolimus|
79397488|NCT00471705|Drug|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
80019606|NCT03645369|Device|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
79397489|NCT00471705|Device|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
79259609|NCT04971434|Other|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
79397490|NCT00471705|Drug|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
79397491|NCT01797861|Procedure|Half-dose photodynamic therapy (PDT)|"At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds."
79397492|NCT01797861|Procedure|Micropulse laser (ML) treatment|"The following ML treatment settings will be used: a power of 1800 mW*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area."
79397493|NCT00472797|Drug|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
79397494|NCT00472797|Drug|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
79397495|NCT01458535|Drug|ABT-450|tablets
80019607|NCT03645369|Device|Ice pack|Ice pack containing gel
79259610|NCT02071043|Drug|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3
79259611|NCT02071043|Drug|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
79259612|NCT02076893|Drug|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
79397496|NCT01458535|Drug|ABT-267|tablets
79558628|NCT05396014|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
80019608|NCT02294708|Behavioral|postoperative postures|two postoperative postures: supine and temporal-lateral
79397497|NCT01458535|Drug|ribavirin|tablets
79397498|NCT01458535|Drug|ritonavir|capsules
79397499|NCT01464827|Drug|ABT-450|ABT-450 tablets
79397500|NCT01464827|Drug|ABT-333|ABT-333 tablets
79397501|NCT01464827|Drug|ABT-267|ABT-267 tablets
79397502|NCT01464827|Drug|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
79397503|NCT01464827|Drug|Ritonavir|Ritonavir capsules
79856185|NCT00743951|Behavioral|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
79856186|NCT00743951|Behavioral|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
79259613|NCT02076893|Drug|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
79259614|NCT02076893|Drug|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
79397504|NCT01463111|Drug|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
79397505|NCT01463111|Drug|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
79721612|NCT00907153|Dietary Supplement|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
79397506|NCT01463111|Drug|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
79259615|NCT02076893|Drug|Placebo|Simple syrup suspension
79856187|NCT00957320|Drug|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
79856188|NCT00957320|Drug|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
79856189|NCT00968058|Procedure|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
79856190|NCT00957476|Dietary Supplement|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
79856191|NCT04316078|Other|patient engagement platform|"Allows patients to receive the action plan as educational videos on demand.~Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
79856192|NCT05277324|Other|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
79856193|NCT00653159|Device|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
79856194|NCT00653159|Device|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
79856195|NCT03047070|Drug|Lidocaine|IV Lidocaine infusion
79856196|NCT03047070|Drug|Normal saline|IV normal saline infusion
79259616|NCT04963322|Other|extracorporeal membrane oxygenation therapy|Extracorporeal membrane oxygenation for the management of severe refractory heart and lung dysfunction
79259617|NCT04963478|Other|exercise|exercise testing
79397507|NCT01463033|Drug|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
79259618|NCT02074163|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
79721613|NCT00907153|Drug|Placebo|Placebo by mouth once daily for 12 weeks
79721614|NCT03984799|Procedure|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
79856197|NCT00948272|Biological|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
79721615|NCT00904033|Drug|Calcitriol|Calcitriol tablet taken once per week.
79721616|NCT00904033|Behavioral|Exercise|Exercise consisting of progressive walking and resistance band training
79856198|NCT00948272|Biological|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
79856199|NCT00968214|Genetic|polymorphism analysis|
79856200|NCT00968214|Other|laboratory biomarker analysis|
79856201|NCT00957554|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
79259619|NCT02074163|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
79259620|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79259621|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79397508|NCT03026543|Procedure|Pulmonary Recruitment Maneuver|
79397509|NCT03026543|Procedure|Laparoscopic cholecystectomy|
79397510|NCT03026543|Device|Ventilator|
79397511|NCT01461707|Behavioral|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
79397512|NCT01461707|Behavioral|Activity monitor|Participants will receive an activity monitor
79397513|NCT01461551|Drug|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
79397514|NCT01461551|Drug|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
79721617|NCT00904033|Dietary Supplement|Multivitamin|
79721618|NCT05175625|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
79721619|NCT05175625|Biological|Saline placebo|0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
79721620|NCT02647177|Other|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
79856202|NCT00957554|Drug|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
79856203|NCT00921713|Other|Oncology Nurse Care Management|
79558629|NCT05396014|Behavioral|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
79558630|NCT05396014|Drug|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
79558631|NCT05393427|Drug|BL-B01D1|Administration by intravenous infusion
79721621|NCT00903877|Drug|T3|Patients receive T3 in a dose of 25mcg and 50mcg
79721622|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
79856204|NCT00921713|Other|Patient-centered materials|
79856205|NCT00744029|Behavioral|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
79856206|NCT03024684|Drug|Atorvastatin|Atorvastatin 10mg daily
79856207|NCT03024684|Drug|Placebo Oral Tablet|Placebo one tablet daily
79856208|NCT00746057|Biological|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
79856209|NCT00948350|Procedure|awake intubation|two anesthesia techniques
79856210|NCT00968292|Device|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
80019609|NCT04367298|Behavioral|Chronoprevention|Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
79259622|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79558632|NCT05391308|Other|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
79558633|NCT05391308|Other|Polysomnography measure|Apnea-Hypopnea Index
79558634|NCT05391308|Other|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
79558635|NCT05390710|Combination Product|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
79721623|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
79856211|NCT00957710|Behavioral|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
79856212|NCT00744107|Device|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
80019610|NCT02291978|Device|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
80019611|NCT02807350|Device|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
80019612|NCT02807350|Device|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
79558636|NCT05388669|Drug|Lazertinib|Lazertinib tablets will be administered orally.
79259623|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79259624|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79558637|NCT05388669|Drug|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection
79721624|NCT03353389|Other|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
79721625|NCT03353389|Other|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
79558638|NCT05388669|Drug|Amivantamab Intravenous|Amivantamab will be administered by IV infusion
79558639|NCT05386108|Drug|Elacestrant|300 mg, 400 mg
79558640|NCT05386108|Drug|Abemaciclib|100 mg, 150 mg
79558641|NCT05385692|Drug|BL-M02D1|Administration by intravenous infusion
79721626|NCT03353389|Other|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
79721627|NCT05332249|Procedure|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
79856213|NCT00117637|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
79856214|NCT00117637|Drug|Interferon|Interferon
79558642|NCT05384691|Drug|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
79558643|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
79558644|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)
79721628|NCT01241591|Drug|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
79856215|NCT00746135|Device|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
79856216|NCT00744185|Drug|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
79259625|NCT02074163|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79721629|NCT01241591|Drug|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
79856217|NCT00744185|Drug|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
79856218|NCT02897778|Drug|Entinostat|Single, supratherapeutic dose of entinostat given orally.
79259626|NCT02074163|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79259627|NCT02074163|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79259628|NCT02074163|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79259629|NCT02074163|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
79259630|NCT02074163|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
79259631|NCT02074163|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
79259632|NCT04963088|Drug|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason
79259633|NCT04963088|Drug|Anlotinib|oral administration daily d1-d14, q3w;
79558645|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
79558646|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
79558647|NCT05383352|Drug|Folinic Acid|LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle
79558648|NCT05383352|Drug|5-Fluorouracil|5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle
79856219|NCT02897778|Drug|Placebo|Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
79856220|NCT00746291|Other|6 min walk test, Step climbing|walking for 6 minute and climbing steps
79856221|NCT01084291|Biological|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
79856222|NCT01084291|Other|Placebo injection|Subcutaneous injection of placebo
79721630|NCT01241591|Biological|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
79721631|NCT01241591|Other|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
79721632|NCT05463679|Drug|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
79721633|NCT05463679|Drug|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
79856223|NCT00741689|Drug|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
79721634|NCT02513251|Other|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
79721635|NCT05332171|Behavioral|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
79721636|NCT03315247|Behavioral|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
79721637|NCT04319705|Drug|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
79721638|NCT04319705|Drug|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
79856224|NCT00963066|Device|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
79856225|NCT00963066|Device|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
79856226|NCT00963066|Device|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
79721639|NCT04319393|Behavioral|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
79721640|NCT04319315|Other|survey|online survey
79721641|NCT00906373|Biological|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
79856227|NCT01081093|Procedure|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
79856228|NCT00744341|Drug|SLV320|1.25mg i.v. bid
79856229|NCT00744341|Drug|SLV320|3.75mg i.v. bid
79856230|NCT00744341|Drug|SLV320|7.5mg i.v. bid
79856231|NCT00744341|Drug|SLV320|15.0mg i.v. bid
80019613|NCT03043651|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
79259634|NCT04963088|Drug|Oxaliplatin|30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle
79558657|NCT05378503|Drug|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
79558658|NCT05378503|Drug|Qsymia 7.5Mg-46Mg Extended Release Capsule|"From W2 to W14, once a daily.~At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
79856232|NCT00744341|Drug|Placebo|
79856233|NCT00968370|Other|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
79856234|NCT00968370|Other|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
79856235|NCT02685384|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
80019614|NCT04353024|Drug|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
80019615|NCT04353024|Drug|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
80019616|NCT04465292|Drug|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
79558659|NCT05378503|Drug|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
79558660|NCT05378503|Drug|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
79558661|NCT05378503|Drug|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
79558662|NCT05375292|Other|PREHABILITATION|"Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~Cardio-respiratory endurance exercises."
79721642|NCT00906373|Biological|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
79397515|NCT01461551|Drug|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
79721643|NCT00906373|Drug|Sorafenib|400 milligrams (mg) twice per day orally
79721644|NCT02850445|Drug|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
79721645|NCT02850445|Other|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
79721646|NCT02850445|Other|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
79721647|NCT02850445|Other|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
79721648|NCT04220203|Drug|Tucatinib|300 mg orally two times per day
79721649|NCT04220203|Drug|Capecitabine|1000 mg/m^2 orally two times per day on Days 1-14 of each 21-day cycle
79721650|NCT04220203|Drug|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
79721651|NCT02850211|Drug|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
79856236|NCT00968448|Behavioral|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
79856237|NCT00968448|Behavioral|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
79856238|NCT00741767|Drug|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
79856239|NCT00741845|Drug|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
79856240|NCT02564549|Procedure|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
79856241|NCT02564549|Procedure|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
79856242|NCT00741923|Other|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
80031603|NCT03049930|Drug|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
79558663|NCT05367492|Drug|Double Blind Varenicline|"For participants 16-17 years old, ≤ 55 kg:~0.5 mg once daily for 7 days, then~0.5 mg twice daily for 11 weeks~For participants 16-17 years old, >55 kg:~0.5 mg once daily or 3 days,~0.5 mg twice daily for 4 days~1.0 mg twice daily for 11 weeks~For participants 18+ years old:~0.5 mg once daily or 3 days,~0.5 mg twice daily for 4 days~1.0 mg twice daily for 11 weeks"
79558664|NCT05367492|Drug|Double Blind Placebo|"For participants 16-17 years old, ≤ 55 kg:~0.5 mg once daily for 7 days, then~0.5 mg twice daily for 11 weeks~For participants 16-17 years old, >55 kg:~0.5 mg once daily or 3 days,~0.5 mg twice daily for 4 days~1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~0.5 mg once daily or 3 days,~0.5 mg twice daily for 4 days~1.0 mg twice daily for 11 weeks"
79397516|NCT04077359|Diagnostic Test|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
79558665|NCT05367492|Behavioral|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
79721652|NCT02850211|Drug|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
79721653|NCT02850211|Drug|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
79397517|NCT01461005|Device|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
79856243|NCT00746369|Behavioral|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
79721654|NCT02850289|Drug|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
79397518|NCT04599257|Device|BTL-899|The device applicator combines high-intensity focused electromagnetic procedure and radiofrequency energy to induce visible muscle contractions along with heating of the subcutaneous fat.
79397519|NCT01460381|Drug|LY2216684|
79397520|NCT01460381|Drug|Quinidine|
79397521|NCT02985359|Dietary Supplement|Nutributter|Daily 20g Nutributter provided to children 6 to 24 month of age
79397522|NCT02985359|Behavioral|Social Behavioral Change Communication (SBCC)|Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
79397523|NCT00546897|Drug|Lenalidomide|
79721655|NCT02850289|Drug|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
79721656|NCT02393521|Device|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
79856244|NCT00746447|Drug|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
79856245|NCT00746447|Drug|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
79856246|NCT00746447|Drug|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
80031604|NCT02036463|Drug|Prednisone|
80031605|NCT02036463|Drug|Placebo|
80019617|NCT03638817|Drug|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is < 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
80019618|NCT02298530|Other|Combination of caffeine and theanine|Beverage containing caffeine and theanine
80019619|NCT02298530|Other|Caffeine|Beverage containing caffeine
80019620|NCT04218877|Other||There will be no intervention, only observation
80019621|NCT03634215|Diagnostic Test|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
79259635|NCT04963088|Drug|Capecitabine|1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
79259636|NCT04970732|Procedure|Gum chewing|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
79259637|NCT02074241|Other|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
79259638|NCT02074319|Drug|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
79558666|NCT05367492|Behavioral|This Is Quitting|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
79259639|NCT04975022|Drug|N11005|oral insulin N11005, 300IU, p.o.
79721657|NCT05176171|Procedure|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
79721658|NCT04984057|Drug|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
79721659|NCT04984057|Drug|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
79856247|NCT00744419|Drug|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose [0.4 mg/kg (< 44 wks PMA) or 0.8 mg/kg (44 wks to < 1 yr)] and the last 6 subjects in each age group will receive high dose [0.8 mg/kg(< 44 wks PMA) or 1.6 mg/kg(44 wks to < 1 yr)]
79397524|NCT00474123|Drug|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
79856248|NCT00549302|Drug|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
79856249|NCT00549302|Drug|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
79856250|NCT00957788|Drug|NST-001|Comparison of different dosages of drug.
79856251|NCT05299424|Drug|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
80019622|NCT02294864|Device|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
80019623|NCT02294864|Procedure|Physical Therapy|
80019624|NCT04084522|Dietary Supplement|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
80019625|NCT04084522|Dietary Supplement|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
80019626|NCT03644589|Biological|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
80019627|NCT03644589|Drug|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
79558669|NCT05346549|Behavioral|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
80019628|NCT02298608|Device|Nano Knife|Percutaneous, CT guided, ablation of renal mass
79397525|NCT00474123|Drug|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
79397526|NCT00474201|Drug|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
79397527|NCT00474201|Drug|Gemfibrozil|Control arm (no intervention used in this arm)
79397528|NCT03720327|Behavioral|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
79259640|NCT04975022|Drug|Novolin R|reference preparation Novolin R, 0.1 IU/Kg, i.h.
79259641|NCT04975412|Diagnostic Test|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
79259642|NCT02071121|Drug|BIIB061|BIIB061 capsules for oral administration
79558670|NCT05346549|Behavioral|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
79721660|NCT05331781|Procedure|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
79721661|NCT05331781|Drug|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
79721662|NCT04202887|Drug|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
79721663|NCT04202887|Drug|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
79856252|NCT05299424|Drug|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856253|NCT05299424|Drug|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856254|NCT05299424|Drug|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856255|NCT05299424|Drug|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856256|NCT05299424|Drug|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856257|NCT05299424|Drug|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856258|NCT05299424|Drug|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856259|NCT05299424|Drug|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856260|NCT05299424|Drug|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79259643|NCT02071121|Drug|Placebo|BIIB061 matching placebo capsules
79558671|NCT05339685|Drug|BL-M02D1|Administration by intravenous infusion
79721664|NCT04202887|Device|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
79721665|NCT05331703|Other|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
79721666|NCT05331703|Other|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
79721667|NCT02850367|Dietary Supplement|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
79259644|NCT02071121|Drug|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
79558675|NCT05338749|Behavioral|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
79558676|NCT05338151|Behavioral|Brief Negotiated Interview (BNI)|Brief Negotiated Interview (with referral and telephone booster) alone
79558677|NCT05338151|Behavioral|BNI+facilitated provision of MAUD|Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
79558678|NCT05338151|Behavioral|Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT|Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
80019629|NCT03621423|Procedure|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
79721668|NCT02850367|Dietary Supplement|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
79721669|NCT02850367|Dietary Supplement|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
79558679|NCT05335434|Device|THOR LX2.3 with LED Lollipop|The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
79558682|NCT05327595|Drug|LY3549492|Administered orally.
79721670|NCT02850367|Dietary Supplement|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
79721671|NCT02850367|Biological|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
79721672|NCT02850367|Biological|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
79721673|NCT02850523|Other|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
79721674|NCT05117203|Device|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
79721675|NCT05117203|Device|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
79856261|NCT05299424|Drug|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856262|NCT05299424|Drug|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856263|NCT05299424|Drug|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856264|NCT05299424|Drug|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
79856265|NCT05299424|Drug|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
79856266|NCT03969914|Procedure|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
80019630|NCT03536143|Biological|Topical beremagene geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
79259645|NCT03061604|Device|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
79259646|NCT03061604|Drug|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
79558683|NCT05327595|Drug|Placebo|Administered orally.
79558684|NCT05327595|Drug|Atorvastatin|Administered orally.
79856267|NCT03961724|Device|magnetic resonance image (MRI)|serum metabolomics
80019631|NCT03536143|Biological|Placebo gel|Placebo gel
80019632|NCT03514550|Drug|Propofol|Propofol will be used for anesthesia during surgery
80019633|NCT03514550|Drug|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
80019634|NCT03514550|Procedure|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
79259647|NCT03061604|Biological|Blood transfusion|Blood transfusion will be administered to all patients if needed
79558685|NCT05327595|Drug|Midazolam|Administered orally.
79558686|NCT05322941|Drug|AEF0117|AEF0117 (1.0, 0.3, and 0.1 mg) capsules
79558687|NCT05322941|Drug|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
79558688|NCT05321121|Drug|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
79721676|NCT05117203|Device|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
79721677|NCT05324215|Procedure|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
79558689|NCT05321121|Other|Placebo|The control arm will receive an infusion of normal saline
79558690|NCT05319067|Other|Stool sampling|Stool sample taken at home 24 hours before hospital visit
79558691|NCT05318092|Device|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
79558692|NCT05316688|Procedure|Near Infrared Imaging|Undergo NIR imaging
79558693|NCT05316688|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79856268|NCT00957866|Drug|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
79856269|NCT00117325|Drug|GW685698X|Aqueous Nasal Spray 100mcg
79856270|NCT00958022|Drug|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin & mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
79558694|NCT05316688|Drug|Tozuleristide|Given IV
79558695|NCT05300620|Device|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
79558696|NCT05300620|Device|Original Liner|these are original shoe liners
79856271|NCT00958100|Drug|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
79856272|NCT00958100|Drug|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
79856273|NCT00958100|Drug|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
79259648|NCT03061604|Drug|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
79558697|NCT05300620|Device|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
79558698|NCT05300620|Device|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
79558699|NCT05298501|Other|No intervention/exposure|No interventions/exposures will be administered or evaluated
79558700|NCT05297539|Other|Point light display|Visualization of point-light human actions
79558701|NCT05292521|Other|Best Practice|Receive usual care
79558702|NCT05292521|Other|Informational Intervention|Receive QOL fact sheet
79558703|NCT05292521|Other|Questionnaire Administration|Ancillary studies
79558704|NCT05292105|Device|NC Xperience|Coronary dilatation balloon catheter (non compliant)
79558705|NCT05292092|Drug|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
79558706|NCT05287945|Drug|Orellanine|single intravenous administration of orellanine over 30 (±5 minutes) following hemodialysis
79558707|NCT05287126|Drug|Etrasimod|Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
79721678|NCT05324215|Device|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
79558708|NCT05278858|Combination Product|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
79721679|NCT05070559|Other|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone & wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~Hot pack for 15 minutes~TENS for 15 minutes~Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
79721680|NCT05070559|Other|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~Hot pack for 15 minutes~TENS for 15 minutes~Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
79721681|NCT02850133|Other|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
79721682|NCT04202419|Device|FRAX 1940 nm laser|A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
79721683|NCT02849821|Other|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
79721684|NCT02849821|Other|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H&E).
79721685|NCT04202575|Procedure|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
79259649|NCT02077049|Device|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
79721686|NCT00905437|Drug|Placebo|Placebo as an adjunct to standard of care
79721687|NCT00905437|Drug|Pregabalin|75 mg BD for 14 days
79721688|NCT05081947|Behavioral|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
79721689|NCT04219111|Genetic|Clariom|Clariom S Assay
79721690|NCT05007691|Device|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
79721691|NCT01238861|Biological|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
79721692|NCT01238861|Biological|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
79721693|NCT01238861|Biological|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
79856274|NCT00948584|Other|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
79856275|NCT00958178|Drug|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
80019635|NCT04173988|Genetic|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10^6 CAR+ cells/kg~For children with body weight > 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10^8 CAR+ cells."
79259650|NCT02077049|Other|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
79259651|NCT04974944|Drug|Camrelizumab|IV injection
79721694|NCT01238861|Other|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
79721695|NCT02888561|Drug|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
79721696|NCT02888561|Drug|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
79721697|NCT04319549|Other|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
79721698|NCT04319549|Other|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
79856276|NCT00948662|Drug|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
79856277|NCT00948662|Drug|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
79856278|NCT00948662|Drug|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
80019636|NCT04173988|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
80019637|NCT04173988|Drug|Fludarabine|Chemotherapy for lymphodepletion
80019638|NCT02294942|Drug|RANCAD|Extended-Release RANCAD
79856279|NCT03748472|Procedure|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
79856280|NCT03748472|Procedure|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
79856281|NCT04010084|Radiation|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
79856282|NCT04010084|Procedure|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
79856283|NCT03571022|Behavioral|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
79721699|NCT00903409|Drug|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) [formerly known as Omacor]
79856284|NCT00948740|Drug|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
79856285|NCT00108433|Drug|Cefazolin IV|
79259652|NCT04974944|Drug|Apatinib|Oral
79259653|NCT04974944|Drug|Paclitaxel|IV injection
80019639|NCT01344759|Drug|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
79259654|NCT04974944|Drug|Cisplatin|IV infusion
79259655|NCT04974944|Drug|Carboplatin|IV infusion
79259656|NCT04974944|Drug|Bevacizumab|IV infusion
79259657|NCT02071199|Drug|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
79259658|NCT02071199|Drug|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
79259659|NCT02071199|Drug|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
79558716|NCT05268172|Drug|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
79558717|NCT05265455|Dietary Supplement|Plant sterols 2.5 g/day|Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks
79721700|NCT02850055|Other|Conventional Physiotherapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home."
79721701|NCT02850055|Other|Specific Manual Therapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home.~Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
79721702|NCT02849665|Other|Kangaroo Position|
79259660|NCT04974632|Procedure|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
79259661|NCT02071277|Other|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
79259662|NCT04970498|Diagnostic Test|MRI|MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
79259663|NCT04970498|Diagnostic Test|blood routine test|The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
79259664|NCT02077205|Behavioral|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
79259665|NCT02074397|Procedure|Distant extrafascial injection|
79259666|NCT02074397|Procedure|Subfascial injection|
79558718|NCT05265455|Dietary Supplement|Placebo|Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
79558719|NCT05265039|Behavioral|Cognitive Processing Therapy|An evidence-based treatment for posttraumatic stress disorder (PTSD)
79721703|NCT01237223|Drug|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
79721704|NCT01237223|Drug|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
79721705|NCT01237223|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
79721706|NCT01237223|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
79721707|NCT01237223|Drug|Placebo of Aliskiren|Aliskiren placebo tablet
79721708|NCT01237223|Drug|Placebo of Amlodipine|Amlodipine placebo capsule
79721709|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
79721710|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
79721711|NCT01236755|Device|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
79721712|NCT01236755|Device|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
79558720|NCT05265039|Behavioral|Relaxation Training|Guided relaxation
79721713|NCT01236365|Drug|Atorvastatin|10 or 20 mg daily
80019640|NCT01344759|Drug|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
79558721|NCT05264961|Behavioral|voice therapy|sessions of voice therapy
80019641|NCT05692141|Device|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
79721714|NCT01236365|Drug|Atorvastatin Placebo|10 or 20 mg daily
80019642|NCT03520868|Diagnostic Test|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
80019643|NCT05885386|Drug|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
80019644|NCT05885360|Drug|Istradefylline Pill|"Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time."
79721715|NCT01235975|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
79856286|NCT00108433|Drug|Linezolid IV|
80019645|NCT05885308|Behavioral|Otago|Group training is compared with training performed at participants' homes, using an online film
79558722|NCT05262491|Drug|BL-B01D1|Administration by intravenous infusion
79558723|NCT05261139|Drug|nirmatrelvir|PF-07321332
79558724|NCT05261139|Drug|ritonavir|ritonavir
79721716|NCT01235975|Biological|MencevaxACWY TM|Subcutaneous injection
79721717|NCT00903331|Drug|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
79721718|NCT00903331|Drug|Placebo|matching placebo, once daily
79721719|NCT02849431|Behavioral|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
79721720|NCT01235741|Drug|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
79721721|NCT01235741|Drug|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
79721722|NCT02849353|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
79721723|NCT02849353|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
79721724|NCT04206527|Behavioral|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
79721725|NCT04206527|Behavioral|Enhanced FP training|Participation in an enhanced FP training including PCC
79721726|NCT04571827|Other|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell & Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
79721727|NCT01235507|Drug|methotrexate|stable dose as prescribed
79721728|NCT01235507|Drug|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
79721729|NCT04708015|Other|No Intervention|A retrospective chart review of medical records
79721730|NCT01933477|Other|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
79856287|NCT00108433|Drug|Vancomycin (IV)|
79856288|NCT00949052|Genetic|DNA analysis|
79856289|NCT00949052|Genetic|polymorphism analysis|
79856290|NCT00949052|Other|laboratory biomarker analysis|
80019646|NCT05885295|Diagnostic Test|MRI brain, Blood tests, cognitive assessments|observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
80019647|NCT05885269|Drug|Group A applied topical Clobetasol Propionate|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
80019648|NCT05885269|Drug|Group B applied topical Tacrolimus|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
79558725|NCT05258786|Behavioral|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~Finally, the provider will turn the screen again from the patient and repeat the first stage."
79558726|NCT05255393|Other|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
79721731|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
79721732|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
79721733|NCT01234883|Drug|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
79721734|NCT01234883|Drug|saline|IV solutions dosed as clinically indicated for rehydration
79721735|NCT01234649|Drug|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
79721736|NCT01234649|Drug|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
79721737|NCT02876679|Drug|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
79721738|NCT02876679|Drug|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
79721739|NCT02876679|Drug|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
79721740|NCT01075815|Drug|Recombinant human luteinizing hormone (rhLH)|
79721741|NCT01075815|Drug|Recombinant follicle-stimulating hormone (rFSH)|
79721742|NCT04306107|Device|Prone position during non-invasive respiratory support|HFNC and NIV application with patient on prone position
79721743|NCT00626691|Behavioral|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
79721744|NCT00905359|Procedure|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
79721745|NCT00905359|Procedure|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
79721746|NCT01072149|Drug|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
79721747|NCT01072149|Device|placebo|placebo
79721748|NCT04413253|Drug|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
79721749|NCT04413253|Drug|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
79558727|NCT05252533|Drug|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
79721750|NCT01071915|Drug|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
79721751|NCT02876445|Other|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
79721752|NCT02849275|Other|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
79721753|NCT02849275|Other|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
79721754|NCT02876133|Device|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
79721755|NCT02876133|Device|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
79721756|NCT01679119|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
79721757|NCT01679119|Drug|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
79721758|NCT01679119|Drug|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
79721759|NCT01679119|Drug|Rituximab|Rituximab 375mg/m2 IV given day 1
79721760|NCT01679119|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
79721761|NCT01679119|Drug|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
79856291|NCT00949052|Other|medical chart review|
79856292|NCT00949052|Other|questionnaire administration|
79856293|NCT00949052|Procedure|assessment of therapy complications|
79856294|NCT00949052|Procedure|evaluation of cancer risk factors|
79259667|NCT04970420|Other|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).|In this study, individual training, training via mobile application and telephone counseling will be given to the experimental group. During the meetings, attention will be paid to the pandemic rules.
79259668|NCT04970420|Other|Control group|Individual training, mobile application and telephone counseling will be given to the control group after the study data is collected.
79259669|NCT02074475|Other|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
79259670|NCT04962386|Drug|Hormone replacement therapy|HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
79259671|NCT02071355|Drug|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
79856295|NCT01084369|Drug|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
79259672|NCT02071355|Drug|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
79856296|NCT05352308|Behavioral|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
79856297|NCT03416738|Behavioral|Semantically focused treatment|"Tasks are as follows:~Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
80031606|NCT04887844|Drug|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
79259673|NCT03061682|Device|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
79259674|NCT04962464|Dietary Supplement|Peak Human Labs calorie mimetic supplement|Supplement
79259675|NCT04962464|Behavioral|Fasting Mimicking Diet|Diet
79259676|NCT02071433|Procedure|Saphenous nerve blockade|
79259677|NCT02071433|Procedure|Femoral nerve blockade|
79259678|NCT04962308|Biological|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
79259679|NCT04962308|Biological|The SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
79259680|NCT02071589|Drug|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
79558732|NCT05247242|Behavioral|Lakeshore Online Fitness (Online)|Online physical activity program delivered to residents of Tarrant, AL via teleconferencing technology to a local community center. Instructors from Lakeshore will lead the physical activity program. This intervention will last six weeks.
79558733|NCT05247242|Behavioral|Get Active with Virtual Reality (VR)|Participants will utilize the Oculus Quest 2 virtual reality headset, which is a head-mounted display system where users can interact with a virtual environment in a gaming setting. The Oculus Quest 2 incorporates social features where participants can interact with other users. This VR intervention will include periods of gameplay where participants can play games in either competitive or cooperative settings. This intervention will last six weeks.
79558734|NCT05247034|Dietary Supplement|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
79558735|NCT05247034|Other|Placebo|Each capsule contains 500 mg of methylcellulose
79259681|NCT02071589|Drug|Nifedipine oral solution|6 mL of Nife Par solution
79259682|NCT04962620|Drug|Bovhyaluronidase azoximer|Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
79259683|NCT02077439|Device|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
79259684|NCT02077439|Device|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
79259685|NCT02077439|Other|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
79259686|NCT03059654|Procedure|tracheostomy|
79259687|NCT02077517|Procedure|Roux en Y Gastric Bypass|
79259688|NCT02077595|Device|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
79558736|NCT05243212|Biological|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
79259689|NCT02076737|Device|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
79259690|NCT04970030|Procedure|ML lithotripsy|we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
79721762|NCT04778787|Drug|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
79721763|NCT02876289|Drug|Perampanel|
79721764|NCT04304391|Procedure|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
79721765|NCT04304157|Drug|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
79721766|NCT04305717|Device|ReDS-guided strategy|A discharge scheme based on specific target value given by the device
79558745|NCT05239221|Drug|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
79721767|NCT02875587|Drug|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
79721768|NCT02875587|Drug|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
79721769|NCT00904969|Device|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
79558746|NCT05239221|Drug|Placebo|Saline solution visually matching active medication
79558747|NCT05238519|Behavioral|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
79558748|NCT05231122|Biological|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
79558749|NCT05231122|Biological|Bevacizumab|Given IV
79721770|NCT00904969|Device|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
79721771|NCT01070979|Drug|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
79721772|NCT01070979|Drug|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
79721773|NCT01070979|Drug|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
79721774|NCT01234337|Drug|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
79721775|NCT01234337|Drug|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
79721776|NCT01234337|Drug|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
79721777|NCT02848963|Drug|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
79721778|NCT01070043|Drug|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
79721779|NCT01070043|Drug|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
79259691|NCT04970030|Procedure|EHL lithotripsy|after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
79259692|NCT02077751|Drug|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
79856298|NCT03416738|Behavioral|Phonologically focused treatment|"Tasks are as follows:~Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
79856299|NCT04010006|Procedure|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
79856300|NCT04010006|Procedure|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
79856301|NCT04010162|Other|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
79856302|NCT03084224|Genetic|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
79856303|NCT02994446|Device|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
79856304|NCT00116779|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
79856305|NCT00949130|Drug|NXL103|BID for 7-14 days
79856306|NCT00949130|Drug|Linezolid|BID for 7-14 days
79856307|NCT03943290|Drug|ACE-083|Recombinant fusion protein
79856308|NCT04010318|Procedure|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
79259693|NCT04847960|Dietary Supplement|BioGaia Probiotic Lozenges|BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
79259694|NCT02077829|Behavioral|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
79856309|NCT00108355|Drug|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
79856310|NCT00108355|Drug|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
79259695|NCT02071667|Other|Blood draw|
79558750|NCT05231122|Biological|Pembrolizumab|Given IV
79856311|NCT00108355|Drug|Midodrine|Midodrine oral tablet at 10 mg three times a day.
79856312|NCT00108355|Drug|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
79558751|NCT05231122|Other|Quality-of-Life Assessment|Ancillary studies
79558752|NCT05231122|Other|Questionnaire Administration|Ancillary studies
79721780|NCT02849119|Procedure|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
79721781|NCT04772391|Other|Exercise Sessions|Participant will complete up to 8 exercise sessions
79721782|NCT04718545|Procedure|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
79721783|NCT02849197|Procedure|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
79721784|NCT01074255|Drug|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
79721785|NCT02848807|Dietary Supplement|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
79558753|NCT05225545|Drug|Sucrosomial Iron|Experimental Arm
79558754|NCT05225545|Drug|Oral Iron|Active Comparator
79558755|NCT05222802|Drug|ERAS-801|Administered orally
79558756|NCT05216926|Other|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
79856313|NCT00108355|Drug|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
79856314|NCT00108355|Drug|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
79558757|NCT05216926|Other|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
79558758|NCT05214612|Combination Product|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
79856315|NCT00108355|Procedure|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
79397529|NCT03720327|Behavioral|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
79397530|NCT00548691|Drug|Ferric Carboxymaltose|
79397531|NCT00548691|Drug|Standard Medical Care (SMC)|
79397532|NCT03431259|Other|Patient Gateway|Patients will be enrolled in the Patient Gateway app.
79397533|NCT00549393|Drug|2% Chlorhexidine gluconate cloth|Daily bathing
79397534|NCT00549783|Biological|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
79856316|NCT05351996|Device|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
80031607|NCT04887844|Drug|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
79397535|NCT00549783|Biological|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
79397536|NCT00475215|Drug|Sugammadex|Sugammadex solution for injection.
79397537|NCT00475215|Drug|Rocuronium|Rocuronium bromide solution for injection.
79397538|NCT00477087|Drug|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
79397539|NCT00477087|Drug|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
79397540|NCT04409912|Device|Sirolimus coated balloon|"Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety."
79558759|NCT05209477|Other|lung ultrasound assessment|"In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio < 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~baseline, in supine position under protective ventilation~after two minute of recruitment maneuver in pressure controlled ventilation~at 1 hour following prone positioning application"
79397541|NCT04409912|Device|Plain balloon|Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
79397542|NCT01473589|Drug|Teriparatide|Administered by SC injection
79397543|NCT01473589|Drug|Placebo|Administered by SC injection
79397544|NCT01473589|Dietary Supplement|Calcium supplementation|Administered orally
79397545|NCT01473589|Dietary Supplement|Vitamin D supplementation|Administered orally
79397546|NCT00478335|Drug|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
79397547|NCT00478335|Drug|calcitonin|one nasal spray daily for 4 days
79397548|NCT00478335|Drug|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
79558760|NCT05208697|Behavioral|Tele-Harm Reduction|THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.
79856317|NCT05351996|Device|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
79397549|NCT00478335|Drug|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
79397550|NCT00478335|Drug|Placebo for sildenafil|one tablet daily for 4 days
79397551|NCT00478335|Drug|placebo for calcitonin|one nasal spray daily
79856318|NCT05351996|Other|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
79856319|NCT02755220|Device|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
79856320|NCT00963222|Drug|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
79856321|NCT00963222|Drug|placebo|1 cap placebo/day for 3 month
79397552|NCT04085263|Procedure|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
79397553|NCT04085263|Procedure|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
79397554|NCT01500187|Device|Vanish Varnish|5% sodium fluoride varnish with tricalcium phosphate
79397555|NCT01500187|Device|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
79397556|NCT00478569|Drug|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
79397557|NCT01500031|Device|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
79721786|NCT01073943|Drug|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
79721787|NCT01073943|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
79721788|NCT01073943|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
79721789|NCT05273125|Behavioral|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
79721790|NCT05254483|Behavioral|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
79721791|NCT05254483|Behavioral|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
79721792|NCT05254483|Device|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
79397558|NCT03026491|Other|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
79397559|NCT04085185|Drug|IBI110|Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
79308619|NCT04842279|Other|FACE-Q scale|"FACE-Q is a recently developed and validated patient reported outcome measure (PROM) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face.The PROM is used to assess the perspective and impact of skin cancer as well as its treatment on the patient's quality of life (QoL). Patients with skin cancer may have increased anxiety, social isolation, and cosmetic concerns after surgery. The FACE-Q utilizes five scales to measure the psychometric, QoL, patient experience, and cosmetic outcomes. Raw scores are transformed to a 0-100 scale with a higher score indicating a better outcome.~Any studies using FACE-Q for facial surgery reconstruction at our center may be eligible for inclusion in the database"
79397560|NCT04085185|Drug|IBI110|IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
79397561|NCT04085185|Drug|IBI110+ Sintilimab|"IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
79558761|NCT05208697|Other|off-site linkage|standard of care linkage to a Ryan White clinic
79558762|NCT05207943|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
79721793|NCT01073865|Drug|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
79721794|NCT01073865|Drug|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
79721795|NCT02900053|Device|tDCS|tDCS for transcranial Direct-Current Stimulation
79721796|NCT02900053|Device|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
79721797|NCT04862065|Device|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
79558763|NCT05207943|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
79721798|NCT04714645|Device|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
79856322|NCT00963300|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
79856323|NCT00963300|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79721799|NCT04714645|Device|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
79721800|NCT01064635|Drug|Letrozole|letrozole for 2-3 years after Tam
79721801|NCT01064635|Drug|Letrozole|Letrozole for 5 years after Tam
79721802|NCT00930007|Other|Blood sampling|Blood sampling for later hormone measurements
79721803|NCT04697485|Drug|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~Loop diuretic (bumetanide 0.5 mg)~Mineralocorticoid receptor antagonist (eplerenone 25 mg)~Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
79721804|NCT02768935|Procedure|blood sample|blodd sample at 12 months
79721805|NCT01073631|Drug|voriconazole tablet|200 mg PO bid (orally, twice a day)
79721806|NCT00626769|Dietary Supplement|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
79721807|NCT00626769|Dietary Supplement|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
79721808|NCT04305171|Procedure|non-surgical periodontal treatment|scaling and root planing, home care instruction
79721809|NCT04294797|Diagnostic Test|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
79721810|NCT02875743|Drug|Posaconazole|
79856324|NCT00963300|Procedure|magnetic resonance spectroscopic imaging|
79856325|NCT00963300|Procedure|tissue-oxygen-level-dependent functional magnetic resonance imaging|
79856326|NCT05297474|Other|MRI|No intervention was performed in this study.
79856327|NCT00968604|Genetic|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
79856328|NCT02703584|Drug|Buseralin|
79308620|NCT04854681|Drug|TQB2928 Injection|4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
79308621|NCT02607735|Drug|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
79721811|NCT01073163|Drug|Bendamustine|Bendamustine at 90 mg/m^2 IV on Days 1 and 2 of a 28-day cycle.
79721812|NCT01073163|Drug|Rituximab|Rituximab at 375 mg/m^2 IV on Day 1 of a 28-day cycle.
79721813|NCT04305483|Procedure|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
79721814|NCT04305483|Procedure|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
79308622|NCT02607735|Drug|Placebo|Tablet administered orally once daily with food
79856329|NCT02703584|Other|Placebo|
79856330|NCT02703584|Drug|pregnyl|
79721815|NCT04304859|Diagnostic Test|BASIC|Validation
79856331|NCT00968682|Biological|trastuzumab|
79856332|NCT00968682|Other|laboratory biomarker analysis|
79856333|NCT00968682|Procedure|assessment of therapy complications|
79856334|NCT04010292|Behavioral|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
79856335|NCT02575976|Behavioral|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
79856336|NCT02575976|Other|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
79856337|NCT02575976|Other|wait list control|No cardiac rehabilitation.
79856338|NCT04009980|Other|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
79856339|NCT04009980|Other|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
79856340|NCT02465138|Drug|Ketorolac|Intravenous ketorolac
79856341|NCT02465138|Drug|Placebo|Intravenous saline
79856342|NCT00968916|Drug|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
79721816|NCT02875665|Device|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
79721817|NCT02875821|Drug|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
79259696|NCT03059576|Other|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
79259697|NCT02077907|Dietary Supplement|Super Cereal Plus (SC+)|
79259698|NCT02077907|Dietary Supplement|Super Cereal (SC), fortified oil, sugar|
79721818|NCT02875821|Drug|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
79721819|NCT04721535|Drug|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
79721820|NCT04721535|Drug|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
79721821|NCT02875119|Drug|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
79721822|NCT02875119|Drug|Placebo Gel|Placebo Gel
79721823|NCT04757415|Other|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
79721824|NCT04757415|Other|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
79721825|NCT04304313|Drug|Sildenafil citrate tablets|0.1g/day for 14 days
79721826|NCT01072929|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
79721827|NCT01072929|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
79721828|NCT02875197|Other|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
79721829|NCT04305015|Device|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
79721830|NCT04305015|Other|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
79397562|NCT04085185|Drug|IBI110+ Sintilimab|"IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
79721831|NCT04304937|Other|patient reported outcome measure|2 questionnaires are tested against each other
79721832|NCT01231607|Drug|1mg Finasteride active|1mg finasteride active, by mouth once daily
79397563|NCT00479037|Drug|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
79259699|NCT02077907|Dietary Supplement|Plumpy Sup|
79259700|NCT02077907|Dietary Supplement|Corn Soy Blend 14 (CSB14) and fortified oil|
79259701|NCT04954508|Diagnostic Test|The hug-up test|It is a new physical test used to detect supraspinatus tear
79721833|NCT01231607|Drug|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
79721834|NCT01231607|Drug|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
79721835|NCT01231607|Drug|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
79721836|NCT01231607|Drug|Finasteride placebo|finasteride placebo, by mouth once daily
79721837|NCT01231607|Drug|Dutasteride placebo|dutasteride placebo, by mouth once daily
79721838|NCT04304547|Drug|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~Each tablet of CKD-828 and D097 and D337 be taken at once~CKD-348 T1 1 tablet~CKD-348 T2 1 tabet"
79856343|NCT05351528|Other|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
79558774|NCT05196451|Behavioral|Rehabilitation based on CBT principles|Cf. arm description
79558775|NCT05195775|Drug|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
79259702|NCT04954508|Diagnostic Test|EC test|It is a traditional physical test used to detect supraspinatus tear
79259703|NCT04954508|Diagnostic Test|FC test|It is a traditional physical test used to detect supraspinatus tear
79259704|NCT04954508|Diagnostic Test|Neer impingement sign|It is a traditional physical test used to detect supraspinatus tear
79558776|NCT05195775|Drug|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
79558777|NCT05194748|Other|No intervention, observational only|No intervention, observational only
79397564|NCT00479037|Drug|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
79397565|NCT02985229|Drug|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
80019649|NCT05885256|Diagnostic Test|Amending current standard trauma order set|Blood draw happens as part of routine clinical care for all trauma activations. As part of the study, we will use existing blood that is drawn as part of routine clinical care, or when necessary, draw additional blood to obtain samples at 0, 3, 6, 12, 18, and 24 hours assessing ionized calcium, serum calcium, and magnesium. We will strive to have draws occur within +/- 1 hour of the goal times. However, given that the blood draws will be performed by way of the clinical team and the unpredictable nature of trauma care, missed draws or draws out of the goal time frame will not be considered protocol violations
79856344|NCT00968994|Device|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
79259705|NCT04954508|Diagnostic Test|Hawkins-Kennedy impingement sign|It is a traditional physical test used to detect supraspinatus tear
79397566|NCT02985229|Drug|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
79856345|NCT00968994|Device|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
79856346|NCT00969072|Drug|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
79856347|NCT00969072|Drug|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
79856348|NCT00969072|Drug|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
79856349|NCT00094861|Drug|Palifermin|
79856350|NCT00094861|Drug|Placebo|
79856351|NCT00094861|Radiation|Radiotherapy|
79558778|NCT05194111|Drug|Sacubitril-valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
79558779|NCT05194111|Drug|Valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
79558780|NCT05189379|Other|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
79856352|NCT00094861|Drug|Paclitaxel|
79856353|NCT00094861|Drug|Carboplatin|
79856354|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
79856355|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
79856356|NCT00963612|Procedure|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
79856357|NCT00963690|Device|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
79856358|NCT00963690|Procedure|Standard compression|Use standard compression to achieve hemostasis
79856359|NCT01079767|Drug|temsirolimus|
79856360|NCT01151124|Biological|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
79856361|NCT01084447|Device|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
80019650|NCT05885243|Device|ESWT|will be given once a week, total 5 sessions ofESWT+ home exercises program
80019651|NCT05885243|Device|customized insoles|Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
80019652|NCT05885243|Combination Product|combined ESWT and custtomized insoles|Will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
79259706|NCT04954508|Diagnostic Test|diagnostic arthroscopy|The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
80019653|NCT05885204|Procedure|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
80019654|NCT05885204|Procedure|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
79259707|NCT02074865|Biological|biological samples|
79259708|NCT02074787|Device|Thermography|Standard thermographic images
79259709|NCT02074787|Device|Laser Doppler|standard laser doppler analysis
79259710|NCT02074787|Device|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
79259711|NCT04961684|Device|Solver Pen|One application per day for 3 months
79397567|NCT01473355|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
79397568|NCT00479115|Drug|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
79397569|NCT00479115|Device|AmCell CliniMACs|CD34+ cell selection from peripheral collection
79397570|NCT01472965|Drug|ethanol|70% ethanol catheter lock therapy
79397571|NCT01472965|Drug|heparin-saline placebo|heparin-saline placebo catheter lock therapy
79856362|NCT01084447|Device|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
79856363|NCT00969306|Drug|Chloroquine, A-CQ 100|"Administration:~Orally~Timing: Once daily~Tablets of 100 mg~During or after meals~In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~Patients should always note date and time of intake on the chloroquine monitoring form."
79856364|NCT05260710|Behavioral|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases."
79259712|NCT04961684|Drug|Loceryl 5%|One application per week for 3 months
79259713|NCT02074943|Biological|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
79259714|NCT03061058|Drug|Docetaxel|intraperitoneal and/or intravenous
79259715|NCT03061058|Drug|Oxaliplatin|intravenous
79558781|NCT05189379|Other|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
79558782|NCT05189379|Other|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
79558783|NCT05189379|Other|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
79558784|NCT05188027|Other|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
79558785|NCT05188027|Other|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
79558786|NCT05188027|Other|No exercise|Participants will rest in a supine position for 30 minutes.
79558788|NCT05184816|Drug|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
79721839|NCT04304547|Drug|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~CKD-348 T1 1 tablet~CKD-348 T2 1 tablet~Each tablet of CKD-828 and D097 and D337 be taken at once"
79721840|NCT04304547|Drug|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~CKD-348 T2 1 tablet~Each tablet of CKD-828 and D097 and D337 be taken at once~CKD-348 T1 1 tablet"
79721841|NCT01231373|Drug|polidocanol injectable foam, 0.125%|active placebo for blinding
79721842|NCT01231373|Drug|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
79721843|NCT01231373|Drug|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
79397572|NCT00480987|Drug|Oxaliplatin|30 mg/m^2 IV days 1-4
79397573|NCT00480987|Drug|Fludarabine|30 mg/m^2 IV days 2-6
79721844|NCT01231373|Drug|Vehicle|injection of vehicle comparator
79721845|NCT00975130|Biological|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
79721846|NCT00975130|Biological|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
79721847|NCT01230827|Drug|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
79721848|NCT01230827|Drug|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
79259716|NCT03061058|Drug|Cisplatin|intraperitoneal
79259717|NCT03061058|Drug|Irinotecan|intraperitoneal and/or intravenous
79259718|NCT03061058|Drug|Pemetrexed|intraperitoneal and/or intravenous
79259719|NCT03061058|Drug|S1|oral
79259720|NCT04954118|Procedure|Internal jugular vein cannulation|The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.
79308623|NCT04772313|Biological|Pegloticase|Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
79308624|NCT04772313|Drug|Methotrexate (MTX)|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
79721849|NCT01230827|Drug|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
79721850|NCT01230749|Drug|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
79721851|NCT01230749|Drug|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
79397574|NCT00480987|Drug|Cytarabine|500 mg/m^2 by IV continuous infusion days 2-6
79721852|NCT01230749|Drug|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
79721853|NCT02865694|Other|Cascade|
79721854|NCT04292392|Other|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
79558789|NCT05182307|Device|DurAVR™ THV System|Transcatheter Aortic Valve Implantation (TAVI) Procedure
79558790|NCT05182255|Device|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
79558794|NCT05178901|Biological|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
79558795|NCT05178901|Other|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
79558796|NCT05176457|Other|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
79558803|NCT05164783|Combination Product|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
79558804|NCT05161702|Other|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
79558805|NCT05161702|Other|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
79558807|NCT05160545|Drug|GNC-035|Administration by intravenous infusion
79558809|NCT05149313|Biological|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
79558810|NCT05149313|Drug|Lebrikizumab-matching Placebo|Matching Placebo solution for injection administered subcutaneously.
79558811|NCT05147662|Biological|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
79558812|NCT05145907|Biological|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
79558813|NCT05144009|Drug|Loncastuximab Tesirine|Intravenous (IV) Infusion
79558814|NCT05144009|Drug|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
79558815|NCT05142787|Device|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro & localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
79558816|NCT05142410|Diagnostic Test|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company [Bouvier and Fortier et al. 2021]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
79558817|NCT05139251|Other|Recovering from Intimate partner violence through Strengths and Empowerment (RISE)|RISE intervention will be implemented for a period of 4 weeks at the beginning of the program. Four components/modules of the RISE intervention which includes a) education on health effects of violence, b) improving coping and self-care, c) enhancing social support, and d) addressing sexual violence will be used. Toward the beginning of each session the participant will complete a brief survey including a 10-item general self-efficacy scale to be graphed and discussed together to provide more immediate feedback to women about their progress, and at times, inform module selection. At the conclusion of each RISE session, women are asked to set a goal related to the topic in consultation with the clinician
79721855|NCT04292392|Other|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
79721856|NCT04292392|Other|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
79721857|NCT00903175|Drug|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
79721858|NCT00903175|Drug|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
79721859|NCT01229735|Drug|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
79721860|NCT01229735|Drug|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
79721861|NCT03866200|Drug|resveratrol|125 mg/day or 5 ml once per day for 90 days
79721862|NCT03866200|Drug|Placebo|5 ml once per day for 90 days
79721863|NCT02742493|Other|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
79721864|NCT02742493|Other|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
79721865|NCT02742493|Other|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
79856365|NCT00958464|Procedure|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- [Gd-DTPA2-] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
79856366|NCT00963768|Drug|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
79856367|NCT00963768|Drug|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
79856368|NCT00969384|Behavioral|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
79856369|NCT00958542|Procedure|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
79856370|NCT00969462|Drug|Doxorubicin|measurements of serum Doxorubicin levels
79856371|NCT00963846|Drug|placebo|matching pill placebo
79856372|NCT00963846|Drug|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
79856373|NCT00963846|Drug|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
79308625|NCT04770285|Device|MIRAI Depression Study Digital Therapetic|Two different versions of the MIRAI Depression Study digital therapeutics will be compared.
79308626|NCT04836663|Drug|TQ-B3525 tablet|TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
79308627|NCT04836741|Device|Micro Hand S robot|The surgeries are performed with the Micro Hand S robot
79721866|NCT02848495|Genetic|Non-Interventional|
79721867|NCT02848183|Drug|Cytarabine|
79308628|NCT04836741|Device|Laparoscope|The surgeries are performed with the laparoscope
79308629|NCT03040791|Drug|Nivolumab|Nivolumab
79308630|NCT04429113|Device|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
79721868|NCT02848183|Drug|Idarubicin|
79721869|NCT02848183|Drug|Mitoxantrone|
79721870|NCT02848183|Drug|Etoposide|
79721871|NCT02848183|Procedure|Hematopoietic stem cell transplantation|
79721872|NCT00974974|Drug|IPX066|extended-release carbidopa-levodopa capsules
79308631|NCT04854525|Radiation|Pre reconstruction Radiotherapy|Previous PMRT
79308632|NCT03039855|Device|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
79721873|NCT00974974|Drug|IR CD-LD|immediate-release carbidopa-levodopa tablets
79856374|NCT00963846|Drug|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
79856375|NCT00958620|Procedure|Shock Wave Therapy|Extracorporal shock-wave therapy
79856376|NCT00958698|Other|Communication Intervention|Ancillary studies
79856377|NCT00958698|Other|Educational Intervention|Ancillary studies
79856378|NCT00958698|Other|Internet-Based Intervention|Ancillary studies
79856379|NCT00958698|Procedure|Psychosocial Assessment and Care|Ancillary studies
79856380|NCT00958698|Other|Quality-of-Life Assessment|Ancillary studies
79856381|NCT00958698|Other|Questionnaire Administration|Ancillary studies
79856382|NCT00969696|Drug|Placebo|8Mg a day of a sugar pill
79856383|NCT00969696|Drug|Galantamine|8mg of Galantamine
79856384|NCT00958854|Drug|cyclophosphamide|
79856385|NCT00958854|Drug|fludarabine phosphate|
79558818|NCT05139251|Other|ePALS|"Participants and their children will then receive 6 weekly sessions of ePALS. The ePALS sessions include rapport building, recognizing and understanding children's signals, contingently responding to signals, labeling objects and actions, learning book reading strategies, maintaining children's focus of attention, helping children with self-regulation, and language scaffolding techniques. Each parent will have a personal parenting coach who remotely supports their progress through the program.~After a parent views a PALS coaching session, they will videotape themselves trying the strategy for that week with their child. Then their coach sets up a zoom call and together they talk about the PALS strategy and view the video. The coach facilitates parental appraisal of their behavior and discuss what they thought worked with their child and what they want to do differently."
79721874|NCT02715583|Drug|11C-Acetate|
79856386|NCT00958854|Drug|thalidomide|
79856387|NCT00958854|Other|laboratory biomarker analysis|
79721875|NCT02848417|Drug|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
79721876|NCT02848417|Drug|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
79721877|NCT02848417|Other|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
79721878|NCT04221841|Other|descriptive|correlation
79721879|NCT04204642|Other|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
79721880|NCT02847403|Drug|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
79259721|NCT04954430|Diagnostic Test|pupillometer|The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
79259722|NCT04962074|Device|Microfluidic sperm sorting chip|Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
79259723|NCT04962074|Device|Density gradient|Density gradient centrifugation
79259724|NCT04969484|Other|Telehealth visit|ImPACTT Telehealth visit with the PC provider
79259725|NCT04961918|Procedure|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
79259726|NCT04961294|Device|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
79259727|NCT04969172|Drug|Exosomes overexpressing CD24|The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
79558819|NCT05137158|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
79721881|NCT02847403|Other|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
79721882|NCT04801537|Other|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
79721883|NCT04801537|Other|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
79721884|NCT02863900|Other|cohort of BC of each subtypes|
79721885|NCT02848339|Drug|aspirin|aspirin desensitization
79721886|NCT04288492|Behavioral|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
79856388|NCT04009278|Other|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
79856389|NCT00964080|Drug|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
79397575|NCT01457053|Drug|Loop diuretics (furosemide, torsemide, bumetanide)|"Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety."
79397576|NCT01457053|Other|Ultrafiltration|"Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety."
79259728|NCT04954040|Drug|Hydroxychloroquine Pill + Azithromycin Pill|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0"
79558820|NCT05137158|Device|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
79558821|NCT05134714|Device|CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
79259729|NCT04954040|Drug|SOC|Acetaminophen or Metamizole. Antitussives if needed.
79721887|NCT04288180|Other|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
79856390|NCT00958932|Behavioral|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
79259730|NCT04968704|Other|3D photography and computer modelling|3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
79259731|NCT04424654|Drug|Testosterone cypionate|Testosterone cypionate 400 mg IM
79856391|NCT00958932|Behavioral|Speech recognition|Automated, speech recognition telephone calls
79259732|NCT04968860|Other|This study is observational|"Clinical evaluation of the oral health condition~Microbiota evaluation by analyzing the collected saliva~Application of questionnaires of quality of life"
79397577|NCT00481845|Drug|Vandetanib|300 mg daily
79397578|NCT00481845|Drug|Anastrozole|1 mg daily
79397579|NCT01472185|Drug|Ranolazine|Ranolazine tablets administered orally twice daily.
79397580|NCT01472185|Drug|Placebo|Placebo to match ranolazine administered orally twice daily.
79558822|NCT05134714|Device|Conventional metal band and loop space maintainer|Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
79721888|NCT02847481|Procedure|fecal microbiota transplantation|fecal microbiota transplantation
79259733|NCT04968626|Radiation|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
79721889|NCT02847481|Drug|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
79721890|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
79721891|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
79721892|NCT04287634|Other|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
79721893|NCT04287634|Other|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
79721894|NCT04795453|Other|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
79721895|NCT04795453|Other|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
79856392|NCT00969852|Drug|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
79856393|NCT00959010|Dietary Supplement|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
79259734|NCT04969016|Procedure|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
79259735|NCT04969016|Procedure|stapler|surgical wound closure with stapler
79259736|NCT04953572|Genetic|autologous peripheral blood mesenchymal stem cell|Transplantation of autologous peripheral blood mesenchymal stem cell
79259737|NCT04953572|Procedure|Microfracture|Microfracture
79259738|NCT04953572|Combination Product|Microfracture + collagen membrane|Microfracture plus collagen membrane transplantation
79856394|NCT00959010|Dietary Supplement|Placebo|capsules containing middle chain triglycerides
79397581|NCT01472185|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
80019655|NCT05885178|Procedure|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
80019656|NCT05885165|Behavioral|Supervised team-based exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.
79558823|NCT05134012|Drug|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|[15-O]-H2O injection is a novel PET imaging agent labeled with the radioisotope [15-O] administered as an intravenous (IV) injection. Participants will receive [15-O]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of [15-O]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
79397582|NCT01472185|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
79721896|NCT04287712|Diagnostic Test|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
79721897|NCT04288102|Biological|UC-MSCs|3 does of UC-MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
79721898|NCT04288102|Biological|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo（intravenously at Day 0, Day 3, Day 6）
79721899|NCT02848261|Behavioral|Developmental Demands|Education and training related to use of CGM in this age group
80019657|NCT05885165|Behavioral|Unsupervised exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
80019658|NCT05885126|Other|MANDALA TECHNIQUE|The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
80019659|NCT05885100|Drug|Eleveld Model|Target plasma propofol
79397583|NCT00482547|Device|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
79397584|NCT00482547|Device|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
79397585|NCT00482625|Drug|erlotinib hydrochloride|Given PO
79397586|NCT00482625|Procedure|conventional surgery|Undergo pancreatectomy
79397587|NCT00482625|Other|immunohistochemistry staining method|Correlative studies
79397588|NCT00482625|Genetic|protein expression analysis|Correlative studies
79397589|NCT00482625|Procedure|biopsy|Correlative studies
79397590|NCT00482625|Other|pharmacological study|Correlative studies
79397591|NCT00482625|Other|laboratory biomarker analysis|Correlative studies
79397592|NCT01456897|Drug|OPC-34712|orally administered once daily
79558826|NCT05128734|Drug|Temozolomide|Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
79558827|NCT05128734|Drug|Olaparib|Olaparib will be administered orally twice daily in treatment arm 2.
79558828|NCT05126758|Biological|CAP-1002|Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
79558829|NCT05126758|Biological|Placebo|Placebo
79397593|NCT00553839|Drug|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
79397594|NCT01797393|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
79558835|NCT05121103|Drug|EZM0414|Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
79721900|NCT02848261|Behavioral|Distress Reduction|Education and training on reducing distress
79721901|NCT02848261|Behavioral|Remote Monitoring|Education and training on the use of remote monitoring
79721902|NCT02848261|Behavioral|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
79721903|NCT02848261|Behavioral|No intervention|No intervention - serves as the control group
79721904|NCT04287244|Device|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
79721905|NCT02848105|Drug|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
79721906|NCT02864524|Other|Manipulative and Massage Therapy|
79721907|NCT02864524|Other|Exercise Program|
79856395|NCT04009434|Device|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
79856396|NCT04009434|Device|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
79721908|NCT02847871|Behavioral|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~Perform a nutritional assessment by a dietician followed by appropriate care management.~Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
79856397|NCT00426556|Drug|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
79721909|NCT04288024|Behavioral|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
79558836|NCT05120349|Drug|Osimertinib|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
79558837|NCT05120349|Drug|Placebo|Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
79721910|NCT02847793|Behavioral|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
79856398|NCT00426556|Drug|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel & Trastuzumab
79856399|NCT00426556|Drug|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
79259739|NCT04953572|Procedure|Autologous osteochondral transplantation|Autologous osteochondral transplantation
79259740|NCT04953416|Device|1565nm non ablative fractional laser|The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
79259741|NCT04953494|Diagnostic Test|Patient information collection, exon sequencing and follow-up.|Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
79856400|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
79259742|NCT04424186|Other|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
79856401|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
79856402|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
79856403|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
79259743|NCT04424186|Other|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
79558838|NCT05117086|Behavioral|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
80019660|NCT05885087|Device|Foley or balloon catheter|Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
80019661|NCT05885048|Diagnostic Test|Blood samples for analysis|Test hormone levels in blood
80019662|NCT05885048|Diagnostic Test|Sperm samples for analysis|Spermiogram
79259744|NCT04961606|Other|interview|semi-structured individual interview
79259745|NCT04953260|Other|APRF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film
79558839|NCT05112991|Drug|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
79558840|NCT05112991|Drug|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
79558841|NCT05107856|Drug|PRT1419|PRT1419 will be administered by intravenous infusion
79558842|NCT05107856|Drug|Azacitidine|Azacitidine will be administered by intravenous or subcutaneous
79558843|NCT05107856|Drug|Venetoclax|Venetoclax will be administered orally
79721911|NCT02847793|Behavioral|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
79721912|NCT02847325|Drug|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
79721913|NCT02847325|Drug|Placebo capsules|Placebo capsules
80019663|NCT05885048|Other|Satisfaction evaluation|Participant satisfaction assessment
80019664|NCT05885048|Other|Quality of Life questionnaire|Short-Form 12-items health survey (SF-12)
79721914|NCT04216303|Diagnostic Test|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
79397595|NCT01797393|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
79259746|NCT04953260|Other|CGF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
79397596|NCT01797393|Other|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
79397597|NCT01456195|Drug|Placebo|Fasiglifam placebo-matching tablets
79397598|NCT01456195|Drug|Fasiglifam|Fasiglifam tablets
79259747|NCT04968392|Drug|Dexmedetomidine Hydrochloride|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
79259748|NCT04968392|Drug|Levobupivacaine|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
79259749|NCT04953026|Diagnostic Test|Diagnositic test|The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.
79259750|NCT02792699|Drug|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
79558844|NCT05101148|Drug|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
79558845|NCT05101109|Drug|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
79721915|NCT02847013|Drug|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
79721916|NCT02847013|Procedure|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
79397599|NCT00554463|Drug|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
79397600|NCT00554463|Drug|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
79856404|NCT03994354|Procedure|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
79259751|NCT02792699|Drug|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
79259752|NCT02792699|Drug|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
79259753|NCT04968002|Drug|pablizumab combined with apatinib and neoadjuvant chemotherapy|The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
79856405|NCT03950856|Drug|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
79856406|NCT03950856|Drug|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
79856407|NCT00970008|Other|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
79856408|NCT00970008|Other|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
79259754|NCT04961216|Behavioral|OPTIMISE|Self-regulation intervention
79259755|NCT04961138|Procedure|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
79259756|NCT04961138|Procedure|Surgery|Removing tumor by surgery.
79259757|NCT03061136|Drug|Clonazepam|
79259758|NCT03061136|Drug|Placebo|
79259759|NCT04953182|Other|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
79397601|NCT00554463|Drug|Etoposide|Concurrent: 120 mg/m^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m^2, IV on days 43-45 and days 65-66.
79397602|NCT00554463|Drug|Cisplatin|Concurrent: 60 mg/m^2, IV on days 1 and 22. Adjuvant: 60 mg/m^2, IV on days 43 and 64.
79397603|NCT00554463|Radiation|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
79397604|NCT04748263|Other|No intervention. Only survey and normal use of eye-tracking|"The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE."
79397605|NCT00554853|Drug|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
79558846|NCT05099536|Drug|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
79558847|NCT05097287|Drug|Dupilumab|solution for injection subcutaneous
79259760|NCT04952948|Other|PILATES Training|During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
79259761|NCT04960982|Diagnostic Test|blood test|blood sample is taken in first, second and third trimester of pregnancy
80019665|NCT05885035|Drug|Calcium Hydroxyapatite|Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
80019666|NCT05885009|Genetic|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
80019667|NCT05885009|Genetic|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
80019668|NCT05884983|Procedure|participants will undergo dual-energy CT and endoscopy|Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
79558848|NCT05097287|Drug|Placebo|solution for injection subcutaneous
79558850|NCT05089955|Behavioral|Ambient Experience|MRI examination with Ambient Experience
79558851|NCT05083611|Other|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
79721917|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
79856409|NCT00970008|Other|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
80019669|NCT05884970|Drug|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
79397606|NCT00554853|Drug|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
80019670|NCT05884970|Drug|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
80019671|NCT05884970|Drug|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
80019672|NCT05884970|Drug|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
80019673|NCT05884944|Procedure|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
79259762|NCT02079857|Other|Standard protocol|Subjects will receive a standard treatment
79397607|NCT00556491|Drug|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
79397608|NCT00556491|Drug|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
79397609|NCT05622357|Radiation|short course radiation therapy followed by 6 cycles of CAPOX then surgery|Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
79558862|NCT05070208|Other|NOT PROVIDED|NOT PROVIDED
79856410|NCT00970008|Other|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
79856411|NCT05281146|Dietary Supplement|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
79856412|NCT05281146|Other|Cognitive stimulation for the mothers|"I. Sessions for mothers~Informing mothers about the most common causes of poor school achievement~Clarification of mother's and family roles in improving student's cognitive abilities~Defining cognitive functions needed for learning and school achievement~o Attention, perceptive reasoning, memory, problem solving, proper use of language~Identifying sensory functions necessary for the growth of cognitive functions~Explaining factors that assist in academic excellence"
79856413|NCT05281146|Other|Cognitive stimulation for students|"Activities to improve focus and visual attention~Activities to improve visual memory~Activities to improve vigilance and auditory attention~Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~Training on skills of problem-solving"
79856414|NCT00433654|Device|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
79856415|NCT00433654|Other|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
79856416|NCT00970086|Drug|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
79856417|NCT00689351|Biological|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
79856418|NCT00689351|Biological|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
79856419|NCT05448287|Behavioral|Health and family planning|Promotion of health and family planning behaviors
79856420|NCT05448287|Behavioral|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
79259763|NCT02079857|Other|Individualized protocol|Subjects will receive an individualized treatment
79558863|NCT05067634|Drug|Xcopri|Age groups 12 to <18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to <12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to <6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to <4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
79259764|NCT02079857|Other|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
79558864|NCT05067426|Other|Exercise|high-intensity interval training sessions
79558865|NCT05065268|Device|Immersive Virtual-Reality Stimulation|IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
79721918|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
79721919|NCT01233869|Drug|Bosutinib|Once daily oral dose of 200 mg of bosutinib
79721920|NCT01233869|Drug|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
79721921|NCT01233869|Drug|Placebo|Once daily oral dose of placebo
79856421|NCT05448287|Behavioral|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
79558866|NCT05054439|Drug|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
79721922|NCT02847091|Drug|Ipragliflozin|Oral administration, 50mg once daily
79558867|NCT05054439|Drug|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
79558868|NCT05052736|Device|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
79856422|NCT05448287|Behavioral|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
79721923|NCT02847091|Drug|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
79721924|NCT02846935|Drug|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested ~60 minutes after THU capsules.
79856423|NCT02563301|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
79856424|NCT03950622|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
79856425|NCT03950622|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
79259765|NCT03058874|Device|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
79856426|NCT00746525|Other|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
79856427|NCT00746525|Other|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
79259766|NCT03058874|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
79856428|NCT00746525|Other|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
79259767|NCT02075099|Other|tensing exercises|Donors will do tensing exercises during blood donation
79259768|NCT02075099|Other|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
79259769|NCT03058718|Other|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
79259770|NCT03058718|Other|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
79259771|NCT04967924|Other|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
79721925|NCT02846935|Drug|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
79721926|NCT02844751|Biological|[StroMed + platelet rich plasma (PRP)]|[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
79721927|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
79721928|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
79721929|NCT02844829|Other|Prostate MRI|MRI of the prostate prior to prostate biobsy
79721930|NCT02844673|Drug|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
79721931|NCT02844673|Device|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
79259772|NCT04967924|Other|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
79259773|NCT04968080|Device|Infrared Cameras Inc. (ICI) FMX 400 Infrared (IR) Camera System|Infrared thermal camera
79259774|NCT04968080|Device|Welch Allyn SureTemp Plus 690|Oral thermometer
79259775|NCT04968080|Device|Welch Allyn ThermoScan PRO 6000|Ear thermometer
79558876|NCT05049382|Procedure|Extraction of impacted mandibular third molar|surgical extraction of impacted mandibular third molar tooth
79558877|NCT05044897|Drug|SI-B001|administration weekly by intravenous infusion（QW）.
79558878|NCT05039892|Drug|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
79721932|NCT02847247|Drug|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
79856429|NCT02563847|Dietary Supplement|0.52 g L-Tryptophan|
79856430|NCT02563847|Dietary Supplement|1.56 g L-Tryptophan|
79856431|NCT02563847|Dietary Supplement|1.56 g L-Leucine|
79856432|NCT02563847|Dietary Supplement|50 g Xylitol|
79856433|NCT02563847|Dietary Supplement|75 g Erythritol|
79856434|NCT02563847|Dietary Supplement|75 g Glucose|
79856435|NCT02563847|Dietary Supplement|300 mL tap water|
79856436|NCT02563847|Other|50 mg 13C-sodium acetate|
79856437|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
79856438|NCT00746681|Drug|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
79856439|NCT00746681|Drug|Placebo|Placebo, Oral, twice daily for 4 weeks
79558882|NCT05036915|Procedure|Pacifier randomly|"Common Action Steps:~Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~Inclusion and exclusion criteria are evaluated.~Study group is determined in line with the randomization order of the newborn to be included in the study.~First part of the patient information and follow-up form is completed.~Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~Common procedure steps are applied.~Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~Second part of the patient information and follow-up form is completed daily."
79721933|NCT00992992|Biological|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
79721934|NCT04201951|Drug|Tranexamic acid injection|Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
79259776|NCT04968080|Device|Infrared Cameras Inc. (ICI) HotSpot Infrared (IR) NonContact Infrared Thermometer|Forehead temperature gun
79856440|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
79259778|NCT03010319|Device|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
80019674|NCT05884944|Procedure|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
79721935|NCT04201951|Other|Glucose water 5%|Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
79259779|NCT03010319|Device|Secondary Dressings|Dressings to ensure moist wound environment
79721936|NCT02847715|Device|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
79721937|NCT00992836|Biological|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
79721938|NCT04753723|Combination Product|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
79721939|NCT04751851|Behavioral|Medium duration withdrawal programme with ACT|"10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
79856441|NCT00746681|Drug|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
79856442|NCT00746759|Device|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
79856443|NCT00746837|Drug|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
79856444|NCT00746837|Drug|AZD5672|50 mg od, 12 days
79259780|NCT03010319|Device|Offloading device|Offloading device to decrease pressure to wound area
79856445|NCT00746837|Drug|AZD5672|150mg od, 12 days
79259781|NCT03058640|Other|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
79259782|NCT02079935|Behavioral|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
79259783|NCT02079935|Behavioral|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
79259784|NCT02080013|Other|radiofrequency|ClosureFAST
79259785|NCT02075333|Dietary Supplement|Ingestion of solution|Participants will ingest the solution
79259786|NCT02075333|Dietary Supplement|Rinising of solution|Participants rinse the solution in the oral cavity
79259787|NCT02075489|Other|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for ~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for ~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
79721940|NCT04751851|Behavioral|Long duration withdrawal programme with ACT|"10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
79558883|NCT05036915|Procedure|Pacifier other|"Procedure Steps of the Experimental Group:~Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~Common procedure steps are applied.~Pacifier is given for 5 min before each feeding.~Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~Second part of the patient information and follow-up form is completed daily."
80019675|NCT05884905|Procedure|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
80019676|NCT05884905|Procedure|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
79721941|NCT04751851|Behavioral|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
79721942|NCT04751851|Behavioral|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
79721943|NCT02844517|Device|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
79721944|NCT03901729|Drug|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
79721945|NCT03901729|Other|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
79721946|NCT03901729|Drug|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
79856446|NCT00964236|Drug|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
79856447|NCT00749099|Drug|pancrelipase|"The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
79856448|NCT00749099|Drug|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
79558886|NCT05031026|Drug|Dexmedetomidine|dexmedetomidine infusion rule in prevention of IRI
79558887|NCT05031026|Drug|Normal Saline|normal saline infusion as a placebo
79558888|NCT05027802|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
79558889|NCT05024214|Drug|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
79558890|NCT05024214|Drug|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
79856449|NCT00959322|Device|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
80019677|NCT05884879|Behavioral|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
80019678|NCT05884749|Behavioral|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
80019679|NCT05884749|Behavioral|Care as Usual (UC)|Participants in this group will receive care available typically in the community
79558891|NCT05023785|Behavioral|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
79259788|NCT02075489|Other|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
79558892|NCT05022654|Drug|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
79558893|NCT05022654|Drug|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
79721947|NCT03901729|Other|Placebo Furosemide|Tablet; Once daily in the morning; Oral
79721948|NCT03834844|Behavioral|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
79721949|NCT03834844|Other|AF Education|6 weekly education modules on topics related to AF
79721950|NCT03834844|Other|Phone Calls|Weekly phone call to discuss patient concerns or questions
80019680|NCT05884723|Dietary Supplement|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
80019681|NCT05884697|Other|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
79856450|NCT00749177|Other|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
79856451|NCT00964314|Other|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
79856452|NCT04059419|Behavioral|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
79856453|NCT04059419|Behavioral|Geriatric Care|Remain under geriatric care as usual
79856454|NCT00959400|Drug|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
79856455|NCT00970398|Other|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
79856456|NCT00970398|Other|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
80019682|NCT05884697|Other|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
80019683|NCT05884697|Other|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
80019684|NCT05884697|Other|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
79259789|NCT03060824|Other|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
79558894|NCT05020457|Drug|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
79558895|NCT05020457|Drug|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
79721951|NCT02846857|Other|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
79259790|NCT02075567|Procedure|Experimental|
79259791|NCT04960436|Procedure|Meniscus Allograft Transplantation|patients received surgery of Meniscus Allograft Transplantation
79259792|NCT04960436|Procedure|Meniscectomy|patients received surgery of Meniscectomy
79259793|NCT02075645|Other|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
79259794|NCT04967768|Other|Questionnaire about impact of the COVID-19 pandemic on orthopaedic resident training|Answers were collected for the effects of the COVID-19 pandemic on the real-life experiences of orthopaedic residents
79856457|NCT00959478|Behavioral|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
79856458|NCT03937908|Drug|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
79856459|NCT03937908|Drug|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
79856460|NCT00964470|Device|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
79856461|NCT00689273|Drug|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
79856462|NCT00689273|Drug|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
79856463|NCT00959556|Other|laboratory biomarker analysis|
79856464|NCT00959634|Drug|ABT-126|Dose administered twice daily on Study Days 1-10
79856465|NCT00959634|Drug|Placebo|Dose administered twice daily on Study Days 1-10
79856466|NCT00970554|Other|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
79856467|NCT00970554|Other|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
79856468|NCT00959790|Dietary Supplement|Vegetables|200 or 50 grams of vegetables daily for four weeks
79259795|NCT02075723|Dietary Supplement|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
79856469|NCT00959790|Dietary Supplement|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
79721952|NCT02846857|Other|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
79856470|NCT04059575|Other|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
79259796|NCT02075723|Behavioral|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
79259797|NCT04967456|Diagnostic Test|Measurement of pulpal blood flow of traumatised tooth|"Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)"
79558896|NCT05020457|Drug|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
79558897|NCT05017987|Drug|ATB-101, ATB-1011, ATB-1012|"Test drug~- Code name: ATB-101~Control drug1~Code name: ATB-1011~Active ingredient: Olmesartan~Control drug2~Code name: ATB-1012~Active ingredient: Dapagliflozin"
79558898|NCT05013476|Combination Product|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
79558899|NCT05001711|Device|Aria CV Acute PH System|The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
79558900|NCT04993742|Behavioral|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
79721953|NCT02846857|Other|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
79721954|NCT02846857|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
79721955|NCT02846857|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
79721956|NCT02846857|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
79721957|NCT02846857|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
79721958|NCT04287322|Behavioral|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
79721959|NCT04287322|Behavioral|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
79721960|NCT03833128|Drug|Low Dose REN001|Oral
79721961|NCT03833128|Drug|High Dose REN001|Oral
79856471|NCT04059575|Other|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
79856472|NCT00964626|Drug|cisplatin|
79856473|NCT00964626|Drug|paclitaxel|
79856474|NCT02562209|Dietary Supplement|PACER Diet|Pacer diet to be followed for 8 weeks
79856475|NCT02562209|Other|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
79856476|NCT00749333|Drug|AZD8566|solution. Specific dose will be selected by the safety review committee
79856477|NCT00749333|Drug|Placebo|Single 10ml oral solution.
79856478|NCT02562287|Drug|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
79856479|NCT02562287|Drug|Risperidone|Risperidone, in a flexible dosage
79856480|NCT02562287|Drug|Olanzapine|Olanzapine, flexible dosage
79856481|NCT02562287|Drug|Quetiapine|Quetiapine, flexible dosage
79856482|NCT02562053|Drug|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
80019685|NCT05884645|Procedure|Video-directed endotracheal intubation|There will be no intervention in this prospective observational cohort study. Endotracheal intubation is already used to secure the airway by placing an endotracheal tube into the trachea via the oral or nasal route. Indications include the need for airway control during general anaesthesia, mechanical ventilation, resuscitation, and various forms of acute respiratory distress.
80019686|NCT05884632|Radiation|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
79259798|NCT02075801|Other|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
79259799|NCT02075801|Other|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
79259800|NCT04967300|Procedure|Dental treatment|bilateral restorative treatment on the mandibular primary first molars
79259801|NCT02077985|Behavioral|Sensory Adapted Dental Environment|See study arm description.
79397610|NCT02613819|Radiation|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
79397611|NCT00485433|Drug|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
79397612|NCT00485433|Drug|SKY0402|SKY0402 given during hernia repair
79397613|NCT02850081|Drug|Statin|"Standard of care treatment (one of four):~Simvastatin (to 40mg without amlodipine)~Simvastatin (to 20 mg if currently on amlodipine)~Atorvastatin (to 80mg)~Rosuvastatin (to 20mg)"
79397614|NCT02850081|Drug|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
79397615|NCT02850081|Other|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
79397616|NCT01456039|Drug|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
79397617|NCT01455415|Drug|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
79397618|NCT01455415|Drug|placebo|matching placebo 3 time a day
79558901|NCT04990804|Drug|Opioid Analgesic|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
79721962|NCT02844205|Other|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
79721963|NCT04672525|Drug|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
79721964|NCT04672525|Drug|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
79721965|NCT00992446|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79721966|NCT00992446|Drug|Bortezomib|Given IV
79721967|NCT00992446|Drug|Carmustine|Given IV
79721968|NCT00992446|Drug|Cytarabine|Given IV
79721969|NCT00992446|Drug|Etoposide|Given IV
79856483|NCT02562053|Drug|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
79856484|NCT02562053|Drug|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
80019687|NCT05884606|Device|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
79259802|NCT02080169|Drug|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
79259803|NCT02080169|Drug|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
79397619|NCT01471171|Drug|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
79721970|NCT00992446|Drug|Melphalan|Given IV
79721971|NCT00992446|Drug|Rituximab|Given IV
79721972|NCT00992446|Drug|Vorinostat|Given PO
79721973|NCT04452565|Drug|Drug: NA-831|NA-831 is a neuroprotective drug, available at 30 mg capsule
79856485|NCT02562053|Drug|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
79856486|NCT00746915|Device|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
79856487|NCT02563223|Other|Parabolic flight|
79856488|NCT02563223|Device|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
79259804|NCT02080169|Drug|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS <3.
79397620|NCT01471171|Drug|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
79397621|NCT01471093|Drug|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
79397622|NCT01471093|Drug|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
79558902|NCT04990804|Drug|Opioid-Free Postoperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
79397623|NCT01471015|Drug|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
79558903|NCT04990687|Device|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
79558904|NCT04989803|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
79558905|NCT04989803|Drug|Fludarabine|Lymphodepleting chemotherapy administered intravenously
79558906|NCT04989803|Biological|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
79558907|NCT04989803|Biological|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
79721974|NCT04452565|Combination Product|NA-831 and Atazanavir|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet"
79721975|NCT04452565|Combination Product|NA-831and Dexamethasone|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg"
79259805|NCT04960670|Other|Evaluation of microbiome and maternal/infant lifestyle|Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
79721976|NCT04452565|Combination Product|Atazanavir and Dexamethasone|Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
79721977|NCT04615195|Other|cries 13 questionnaire|"Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria."
79721978|NCT04285840|Other|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
79259806|NCT02078063|Drug|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
79259807|NCT02078063|Drug|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
79259808|NCT04960358|Procedure|Surface Electromyography|will be applied Surface Electromyography to assess Flexion Relaxation Response
79259809|NCT02075879|Behavioral|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
79397624|NCT01471015|Drug|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
79397625|NCT01471015|Drug|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
79397626|NCT01497067|Device|ACRYSOF CACHET Phakic Lens (L-series)|Intraocular lens for the treatment of moderate to high myopia
79558912|NCT04987775|Drug|N-Acetyl Cysteine|900mg 2x daily
79558913|NCT04987775|Drug|Placebo|Matching placebo bid
79558914|NCT04985916|Biological|Vehicle|topical liniment without investigational product
79558915|NCT04985916|Biological|botulinum toxin, Type A|ET-01 topical liniment
79558916|NCT04981808|Device|Telemonitoring|Telemonitoring of CGM and insulin pen data
79558917|NCT04977349|Other|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
79558918|NCT04977349|Other|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
79558919|NCT04976530|Device|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
79558920|NCT04976530|Device|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
79856489|NCT00746993|Other|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
79856490|NCT04060433|Behavioral|Family Therapy|Swedish version of the evidence based manualized Family Therapy
79856491|NCT04060043|Drug|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
79558921|NCT04976452|Other|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
79558922|NCT04973124|Drug|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
79721979|NCT04440319|Behavioral|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
79259810|NCT02075879|Other|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
79259811|NCT04952168|Drug|Almonertinib|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
79721980|NCT00629668|Genetic|TNF-alpha and HBV genotype|
79721981|NCT00629668|Other|TNF-alpha and HBV genotypes|
79721982|NCT02863120|Drug|liposomal bupivacaine|
79721983|NCT02863120|Drug|bupivacaine HCl|
79721984|NCT02863120|Drug|Ropivacaine|
79856492|NCT00553358|Drug|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
79856493|NCT00553358|Biological|Trastuzumab|Therapeutic Monoclonal Antibody
79856494|NCT00553358|Drug|Paclitaxel|antimicrotubule agent
79856495|NCT00744809|Drug|TMC278; Moxifloxacin; Efavirenz|
79558923|NCT04973124|Drug|Placebo|These participants will not receive intraoperative dexmedetomidine.
79558924|NCT04962217|Other|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
79856496|NCT00688259|Behavioral|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
79721985|NCT02863120|Drug|Saline|
79721986|NCT04201795|Other|Laser|laser with no emision will applied
79259812|NCT04951856|Drug|Evolocumab 140 MG/ML|Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
79259813|NCT04951856|Drug|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
79259814|NCT02260427|Device|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
79259815|NCT02260427|Device|Insertion of the air-Q sp|
79721987|NCT04201795|Other|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
79721988|NCT02846701|Drug|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
79856497|NCT00688259|Behavioral|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
79856498|NCT00749489|Procedure|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
79259816|NCT04952012|Drug|LT4|LT4 is used to improve the thyroid function of pregnant women.
79856499|NCT00744887|Drug|Darunavir|
79856500|NCT04059029|Procedure|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
79259817|NCT04966832|Drug|XW10508|XW10508 capsules or tablets
79856501|NCT02286830|Drug|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
79856502|NCT00688181|Device|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
79856503|NCT02563535|Device|DEB|angioplasty with Litos drug eluting balloon
79259818|NCT04966832|Other|Placebo|Placebo capsules or tablets
79721989|NCT04344301|Other|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
79721990|NCT00970294|Behavioral|Health Promotion Program|10 week health promotion program 3-4 times per week
80019688|NCT05884567|Other|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
80019689|NCT05884567|Other|Mobilization|These exercises are used to increase ROM and used for pain reduction
80019690|NCT05884502|Drug|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
80019691|NCT05884502|Drug|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
79259819|NCT04966286|Other|multimedia education|The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes
79259820|NCT04966442|Behavioral|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
79259821|NCT04966208|Procedure|xenogeneic collagen matrix|xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
79259822|NCT03058484|Behavioral|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
79259823|NCT03058406|Drug|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
79856504|NCT02563535|Device|PTA|angioplasty with conventional balloon
79558927|NCT04954898|Device|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
79721991|NCT04285918|Procedure|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
79721992|NCT02844283|Drug|Ad-HGF|
79721993|NCT02844283|Other|0.9% NaCl|
79721994|NCT02844361|Other|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
79856505|NCT00749567|Drug|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
79856506|NCT00749567|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
79856507|NCT04010942|Drug|Vit D|Injection
79856508|NCT04010942|Drug|Metformin|tablets
79259824|NCT04951232|Drug|Cinepazide Maleate|The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
79259825|NCT04951232|Other|Placebo|Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
79397627|NCT02334787|Drug|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
79856509|NCT04010942|Drug|Clomiphene|Tablet
79397628|NCT02334787|Drug|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
79397629|NCT02334787|Drug|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
79856510|NCT00749645|Drug|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
79856511|NCT00749645|Drug|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
80019692|NCT05884489|Behavioral|A gamified smartphone app-based eating behaviour intervention|All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
79721995|NCT02844361|Other|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
80019693|NCT05884463|Drug|18F-FAPI|Intravenous injection of one dosage of 18F-FAPI.
80019694|NCT05884463|Drug|18F-FDG|Intravenous injection of one dosage of 18F-FDG.
80019695|NCT05884450|Other|Acupressure|Acupressure is an integrated method of applying physical pressure to acupuncture points on the body surface with hands, elbows or various tools. With good counseling, patients can apply this method, which is non-invasive, easy to apply and safe, on their own.
80019696|NCT05884411|Device|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
80019697|NCT05884411|Diagnostic Test|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
80019698|NCT05884385|Other|Simulated exercises|as detailed in arm description
80019699|NCT05884385|Other|Mental Visualisation|as detailed in arm description
80019700|NCT05884281|Drug|Roflumilast|0.5 mg once daily for treatment period
80019701|NCT05884281|Drug|Placebo|Placebo for treatment period
80019702|NCT05884268|Drug|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
79259826|NCT04959578|Drug|Recombinant human erythropoietin|Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
79259827|NCT04959578|Drug|Darbepoetin Alfa|Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo <2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
79558930|NCT04941326|Other|Diaphragmatic stimulation treatment with PNF techniques|Thumbs and palms are placed along the cartilage edges of the lower ribs. At the end of the expiration, pressure and stretching are given as far into the chest and upwards as possible and a deep inspiration is requested immediately after the pressure. Both sides can be stimulated by repeated contraction technique. Hand holding positions may differ according to the patient's preference. If the patient's physical condition is not suitable, the application can be done with the thumbs, the thumb of the left hand for the right rib, and the thumb of the right hand for the left rib in the same lying position. The patient will be asked to do the application 2 times in a day with 10 repetitions for 4 weeks.
79558931|NCT04941326|Other|Costal mobilization|In the supine position, the individual will place both hands around the 10-12th ribs and alternately apply an oblique push from the right and left sides to the opposite side. The exercise will be taught to the patient as training, and he will be asked to apply it 2 times a day with 20 repetitions for 4 weeks.
79721996|NCT04286698|Other|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes [25]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
79259828|NCT04950140|Procedure|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
79721997|NCT04286698|Other|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point [3]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
80019703|NCT05884268|Drug|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
80019704|NCT05884255|Drug|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
79721998|NCT05337865|Other|Aerobic exercise test.|Aerobic exercise test at a treadmill.
79721999|NCT02864056|Other|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
79722000|NCT05242861|Radiation|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
79722001|NCT02863822|Behavioral|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
80019705|NCT05884255|Drug|long-acting Octreotide.|High-dose long-acting Octreotide.
80019706|NCT05884229|Other|Intra-operative analgesia guided by SPI|In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
79259829|NCT04950140|Procedure|Laparoscopic Surgery for the Treatment of Parastomal Hernia|Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
79397630|NCT02334787|Drug|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
79397631|NCT01470469|Drug|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
79397632|NCT01470469|Drug|Placebo|Once-daily oral dosing in the evening for 12 weeks.
79558932|NCT04941326|Other|Breathing exercises|It is done to increase the diaphragm activity of the individual and to suppress chest breathing. While lying in the supine position, the legs are placed in a hooked position, with one hand on the abdomen and the other on the chest, and the deep breath that is taken from the nose in 2 seconds is asked to exhale through the mouth in 4 seconds, while revealing as little movement in the chest as possible, the main movement is requested to be around the abdomen. The application will be given to the patient as a home program and he will be asked to do it 2 times a day with 5 repetitions for 4 weeks.
79558933|NCT04941326|Other|Spinal mobilization|T12 vertebrae will be found by following the 12th rib in the prone position of the individual and spinous of L1 and L2 vertebrae will be determined with this reference. Then, small amplitude rotational movements in the vertebrae will be revealed by pushing in the anterior direction over the transverse processes. This application will be applied once a week for an average of 10 minutes for 4 weeks.
79397633|NCT04644367|Other|Tai Chi intervention|TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
79558934|NCT04941326|Other|Sham mobilization|Sham pressures will be applied to the lumbar region of the patient, away from the vertebrae. This application will be applied once a week for an average of 10 minutes for 4 weeks.
79558935|NCT04940039|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
79558936|NCT04940039|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
79558937|NCT04940039|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
79558938|NCT04940039|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
79558939|NCT04940039|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
79558940|NCT04940039|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
79558941|NCT04940039|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
79558942|NCT04940039|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
79558943|NCT04940039|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
79558946|NCT04935710|Behavioral|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
79722002|NCT02863822|Behavioral|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
79722003|NCT05337787|Other|flipped classroom approach|All students in the experimental group were trained only according to the flipped classroom approach.
79722004|NCT04292704|Radiation|the fractional CO2 laser|The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 ~ 1000 μ m
79722005|NCT04292704|Drug|Clotrimazole|Clotrimazole vaginal tablets
79722006|NCT05242783|Drug|Terlipressin|intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
79558947|NCT04935710|Genetic|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
79722007|NCT04181944|Other|Exercise Treatment Group|be specific
79722008|NCT05336305|Dietary Supplement|Polydextrose|Administration of 3g polydextrose per day, for 2 months
79722009|NCT04214743|Device|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
79558954|NCT04927091|Other|Integration of HIV and PWID services|Co-location of clinical services for HIV and PWID patients
79558961|NCT04921215|Behavioral|Morning bright light|All participants will receive phase advancing morning bright light.
79558962|NCT04915092|Device|CoSIE app|"The app is a mobile phone application compatible with both iOS and Android operating system. Parents are able to register their children and to keep track of their weight status and activities. The app include five themes: child development, physical activity, healthy food, critical situations, BMI.~Push notification on healthy behaviours, on important event taking place in the province of Reggio Emilia, on food advices based on seasonality and on party tips are constantly delivered by the app."
79558963|NCT04906772|Drug|Dexmedetomidine|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
79722010|NCT04214743|Device|Fundus camera from Optomed|It allows to monitor retinal microvasculature
79722011|NCT02846467|Other|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
79722012|NCT02846467|Other|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
79722013|NCT03987685|Drug|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
79722014|NCT00969436|Biological|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
79722015|NCT00969436|Biological|Priorix™|Subcutaneous injection
80019707|NCT05884164|Procedure|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
79259830|NCT03059186|Behavioral|Gratitude diary|"The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week."
79558964|NCT04906772|Drug|Propofol|participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
79722016|NCT00969436|Biological|Varilrix™|Subcutaneous injection
79722017|NCT00900757|Drug|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
79259831|NCT04959500|Drug|Anlotinib Hydrochloride|Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
79856512|NCT00949364|Drug|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
80019708|NCT05884164|Procedure|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
80019709|NCT05884151|Drug|Tranexamic acid|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
80019710|NCT05884151|Drug|Platelets rich plasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
79397634|NCT04644367|Other|Regular Physical Activity (control) group|Regular Physical Activity group who will not be receiving the TC intervention
79397635|NCT01470001|Drug|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
79397636|NCT01469377|Drug|Placebo|Placebo was supplied in capsules
79722018|NCT05242393|Other|No intervention is planned|No intervention is planned
79722019|NCT02846311|Device|Flu Test|
79722020|NCT00969280|Device|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
79397637|NCT01469377|Drug|Cariprazine|Cariprazine was supplied in capsules.
79397638|NCT01469221|Drug|Apaziquone|6 weekly multi-instillation of Apaziquone 4 mg in 40 mL
79397639|NCT01469221|Drug|Placebo|6 weekly multi-instillation of matching placebo in 40mL
79397640|NCT01453855|Drug|Travoprost ophthalmic solution, 0.003%|
79397641|NCT01453855|Drug|Travoprost ophthalmic solution, 0.004%|
79558968|NCT04896073|Drug|Minnelide|Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.
79558969|NCT04893798|Combination Product|Sayana Press|Sayana Press is a drug-device combination and is considered a medical product in the EU.
79558970|NCT04885218|Drug|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
79558971|NCT04885218|Drug|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
79397642|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
80019711|NCT05884112|Device|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
79558972|NCT04885218|Drug|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
79558973|NCT04883281|Radiation|Intensity modulated radiation therapy (IMRT) with or without chemotherapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
79558974|NCT04883281|Drug|cisplatin, cetuximab, or carboplatin-paclitaxel|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
79722021|NCT00969280|Device|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
79856513|NCT01634048|Dietary Supplement|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
79856514|NCT00689117|Drug|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
79856515|NCT00689117|Drug|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
79856516|NCT00689117|Drug|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
79856517|NCT00689117|Drug|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
79856518|NCT00949442|Drug|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
79856519|NCT00949442|Drug|Glimepiride|tablets of 1 and 2 mg
79856520|NCT00949442|Drug|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
80019712|NCT05884112|Device|sham control|sham control
80019713|NCT05884086|Other||no intervention is necessary. Clinical observation and clinical examination only.
80019714|NCT05884073|Behavioral|Circuit-based Resistance Training|Participants will engage in a 12-week, twice weekly circuit-based resistance training program. Each supervised session will last about 25 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.
80019715|NCT05884073|Behavioral|Circuit-based Resistance Training + Home-based Walking|"Participants will engage in a 12-week, twice weekly circuit-based resistance training program. Each supervised session will last about 25 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.~Participants will also be asked to engage in 25 minutes of brisk power walking or light jogging at home (unsupervised) 3 days/week for 25 minutes on days when they have not engaged in resistance training."
79397643|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
79397644|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
79397645|NCT01469065|Drug|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
79397646|NCT01469065|Drug|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
79558980|NCT04874207|Drug|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
79558981|NCT04870203|Drug|baricitinib treatment|4 mg daily during 12 months
79558982|NCT04870203|Drug|adalimumab|40 mg every 2 weeks during 6 monts
79558983|NCT04870203|Drug|Placebo|40 mg every 2 weeks during 6 months
79558984|NCT04862767|Drug|TASO-001((TGF-β2 targeting anti-sense oligonucleotide)|96 hour continuous infusion
79558985|NCT04862767|Combination Product|Aldesleukin|SC, Bid
79856521|NCT00749723|Drug|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
79856522|NCT00749723|Drug|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
79856523|NCT00749723|Drug|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
79856524|NCT00749723|Drug|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
79856525|NCT00749723|Drug|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
79856526|NCT00749723|Procedure|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
79856527|NCT00749723|Drug|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to <3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
79558986|NCT04860713|Drug|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
80019716|NCT05884073|Behavioral|Home-based Walking|Participants will be asked to engage in 25 minutes of self-paced walking at home (unsupervised) 3 days/week.
79856528|NCT00749723|Drug|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
80019717|NCT05884047|Device|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel & Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel & Relax is a Paris-Notre Dame museum tour video."
80019718|NCT05884034|Other|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
80019719|NCT05884034|Other|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
80019720|NCT05884021|Other|Postoperative analgesia|In patients who used intravenous PCA after surgery
80019721|NCT05883995|Other|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
79558987|NCT04860713|Drug|Nurtec (Rimegepant)|Drug: 75 mg of ODT
79722022|NCT04136743|Device|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
79856529|NCT00958490|Other|Walking program|4 week physical activity walking program
79856530|NCT00949520|Other|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
79397647|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79722023|NCT04136743|Drug|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
79856531|NCT00949520|Other|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
80019722|NCT05883982|Procedure|I-PRF injection|Intra-articular I-PRF injection to temporomandibular joint cavity
79856532|NCT00749801|Drug|Nattokinase|2 capsules in the morning and before bed-time daily
79856533|NCT00958646|Other|Osteopathic Manipulation|Standardized rib raising protocol
79259832|NCT04959500|Drug|Placebo|Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
79259833|NCT04959500|Radiation|Radiation Therapy|Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.
79397648|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79558988|NCT04860635|Drug|F14 (sustained release celecoxib)|Celecoxib in BEPO® drug delivery system
79558989|NCT04848064|Drug|Cyclophosphamide|Given IV
79558990|NCT04848064|Drug|Fludarabine|Given IV
79558991|NCT04848064|Biological|Mogamulizumab|Given IV
79558992|NCT04848064|Biological|Natural Killer Cell Therapy|Given via infusion
79558993|NCT04848064|Other|Quality-of-Life Assessment|Ancillary studies
79558994|NCT04848064|Other|Questionnaire Administration|Ancillary studies
79722024|NCT03931057|Drug|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
79856534|NCT00958646|Other|Placebo|Light touch control procedure
79856535|NCT02561975|Other|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~Alveolar volume (VA)~Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
79856536|NCT00958802|Other|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
79856537|NCT00958802|Other|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
79856538|NCT00547248|Biological|Synflorix|Intramuscular injection, 1 dose
79558995|NCT04840147|Device|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
79558996|NCT04840147|Procedure|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
79558997|NCT04836559|Drug|JNJ-40411813|JNJ-40411813 will be administered orally.
79558998|NCT04836559|Drug|Placebo|Placebo will be administered orally.
79558999|NCT04836247|Behavioral|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
79559000|NCT04836247|Behavioral|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
79559003|NCT04823377|Other|Usual care|Patients receiving systemic anticancer treatment in their last days of life
79856539|NCT00547248|Biological|Tritanrix-HepB|Intramuscular injection, 1 dose
79856540|NCT00547248|Biological|Hiberix|Reconstituted with Tritanrix-Hep B before injection
79856541|NCT00547248|Biological|Polio Sabin|Oral, 1 dose
79259834|NCT04959500|Drug|Temozolomide|Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
79259835|NCT04414670|Procedure|C/S|laparoscopic or robotic metroplasty
79259836|NCT04950452|Behavioral|Exercise Training|Supervised exercise training
79259837|NCT04958564|Device|DCP|"Dynamic compression plating to compress the fracture~Intramedullary device to share the load."
80031608|NCT04887844|Other|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
79259838|NCT01369511|Drug|LY2495655|Administered subcutaneously
79856542|NCT00547248|Biological|Poliorix|Intramuscular injection, 1 dose
79856543|NCT00547248|Biological|Prevenar (Wyeth)|Intramuscular injection, 1 dose
79559004|NCT04823377|Other|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
79559005|NCT04822350|Drug|Avelumab|As provided in real world practice
79559006|NCT04820985|Other|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
79856544|NCT02562833|Device|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
79856545|NCT02562833|Device|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
79856546|NCT05351060|Other|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
79856547|NCT05350982|Device|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
79856548|NCT00688103|Drug|ETN Alone|etanercept (25 mg, twice/week, s.c.)
79856549|NCT00688103|Drug|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
79856550|NCT00949598|Drug|letrozole|Given orally
79856551|NCT00949598|Drug|tamoxifen citrate|Given orally
79259839|NCT01369511|Drug|Placebo|Administered subcutaneously
79259840|NCT04949984|Device|Bright light therapy|BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
79259841|NCT04950374|Other|Moisturizer Body Lotion|The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.
79259842|NCT04950374|Other|Lip Moisturizer|The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
79856552|NCT02562911|Procedure|Data collection|"Clinical examination~Complete pelvic ultrasound abdominal ultrasound~Bone age: X-ray~biological examination~Lung function assessed by the Maximum Volume Expired~Brasfield radiological score (if available)"
79856553|NCT00964704|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
79856554|NCT00964704|Drug|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
79559007|NCT04820985|Other|Blood test|Blood sample to measure plasma dose of progesterone
79559008|NCT04819191|Behavioral|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
79259843|NCT02076191|Drug|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
79559009|NCT04819009|Other|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~Creating a therapeutic alliance (communication skills and reassurance)~Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~Postcard with reminder messages on how to self manage the back."
79559010|NCT04802174|Drug|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
79559011|NCT04802174|Drug|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
79559012|NCT04794972|Drug|GNC-039|Administration by intravenous infusion.
79559013|NCT04782375|Drug|Stop group|discontinue antiviral treatment
79559014|NCT04777994|Drug|ABBV-CLS-484|Oral Capsule
79559015|NCT04777994|Drug|Programmed Cell Death-1 (PD-1) Inhibitor|Intravenous (IV) infusion
79722025|NCT03931057|Drug|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
79722026|NCT00969124|Device|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
79856555|NCT00964704|Drug|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
79856556|NCT00964704|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
79856557|NCT00747071|Drug|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
79559016|NCT04777994|Drug|Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)|Oral Tablet
79559017|NCT04762498|Biological|Pegloticase and Methotrexate (MTX)|16 mg IV dose of pegloticase q4 weeks co-administered with 15 mg oral dose methotrexate weekly
79559018|NCT04762498|Biological|Pegloticase and Methotrexate (MTX)|Potential higher IV dose of pegloticase (between 24-32 mg) q4 weeks co-administered with 15 mg oral dose methotrexate weekly and/or potential reduction of infusion duration
79722027|NCT02846155|Other|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
79722028|NCT02846155|Drug|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
79722029|NCT02846155|Drug|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
79722030|NCT02846077|Other|No intervention. Observation only|No intervention. Observation only
79722031|NCT03825523|Other|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
79722032|NCT03825523|Other|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
79722033|NCT03744403|Drug|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
79722034|NCT02845921|Other|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
79722035|NCT02845921|Other|leg wrapping|Esmarch bandage is used to wrap each lower limb
79856558|NCT05350670|Behavioral|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
79856559|NCT00970710|Behavioral|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
79856560|NCT00958958|Other|multifaceted strategy|"There are multifaceted Interventions Including~Distribution of educational materials: distribution of published or printed recommendations for clinical care.~Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~Reminders~Practical training"
79722036|NCT02845921|Other|control|no intervention has been done
79722037|NCT05336149|Procedure|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
79856561|NCT00959868|Drug|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
79856562|NCT00686855|Drug|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
79559022|NCT04751656|Behavioral|Steady Intervention|"Participants will be asked to weigh themselves daily via a smart scale that transmits weight data directly to the study team via the cellular network for 12 months. Every-other week, participants will be sent text messages providing brief feedback encouraging continued self-weighing. Moreover, if a small weight gain is observed, participants will be sent text messages aiming to engage them in commercial or community-based evidence-based weight management resources."
79559023|NCT04745065|Behavioral|Connect2BWell|Please see the description provided for arm 1.
79559024|NCT04734626|Diagnostic Test|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
79856563|NCT00686855|Drug|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
79856564|NCT00949754|Drug|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
79856565|NCT00960024|Behavioral|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
79856566|NCT00960024|Behavioral|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
79856567|NCT00745043|Drug|bronchodilator response|
79559029|NCT04723810|Drug|Indocyanine Green|The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
79559030|NCT04722991|Drug|Runcaciguat (BAY1101042)|Oral dose of runcaciguat
79722038|NCT05336149|Procedure|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
79722039|NCT02845843|Drug|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
79856568|NCT00949832|Dietary Supplement|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
79259844|NCT02076191|Drug|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
79722040|NCT02845843|Drug|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
79722041|NCT02845999|Biological|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10^6 ; 8.10^6 and 12.10^6 cells/kg of recipient body weight
79722042|NCT02845999|Biological|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
79722043|NCT02845999|Drug|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
79856569|NCT00949832|Dietary Supplement|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
79722044|NCT02845999|Drug|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
79856570|NCT00949832|Dietary Supplement|Vitamin D2|50,000 IU given orally once
79856571|NCT00949832|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU given orally once
79856572|NCT00970788|Behavioral|Video intervention|Video of goals of care
79856573|NCT00745199|Drug|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
79856574|NCT00745199|Drug|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
79856575|NCT00961844|Biological|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
79856576|NCT00961844|Drug|Temozolomide|
79856577|NCT00959426|Drug|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
79259845|NCT04949906|Drug|Raise serum brain granules|Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
79397649|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79559031|NCT04722991|Other|Placebo|Oral dose of matching placebo
79559038|NCT04713449|Other|Empowered Survivor Online|Informational online intervention for head and neck cancer survivors
79559039|NCT04713449|Other|Springboard Beyond Cancer|Informational online intervention for all cancer survivors
79722045|NCT02845999|Drug|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
79856578|NCT00959426|Drug|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
79856579|NCT05328050|Other|Registry|observational, data collection
79259846|NCT04949906|Drug|No nourishing serum brain granules are used|No nourishing serum brain granules are used
79259847|NCT02080247|Drug|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
79259848|NCT02080247|Drug|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
80031609|NCT05390138|Behavioral|Smart Sleep Apnea Self-management Support Programme (4S)|The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
79397650|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79559040|NCT04713449|Other|Survey Administration|Survey measures administered at BL, two and 6 months post-baseline
79559041|NCT04704154|Drug|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
79559042|NCT04704154|Drug|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
79559043|NCT04701203|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
79559044|NCT04701203|Combination Product|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
79559045|NCT04696159|Procedure|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
79559046|NCT04688710|Behavioral|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed …) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
79559047|NCT04688710|Behavioral|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
79259849|NCT04950062|Other|High Intensity Interval Training|"Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit."
79259850|NCT04950062|Other|Intermittent Fasting 16/8 Protocol|Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
79259851|NCT02078375|Dietary Supplement|Protein|whey protein plus casein protein
79259852|NCT02078375|Dietary Supplement|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
79259853|NCT02078375|Other|Resistance Exercise Program|All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
79259854|NCT02080325|Other|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
79559048|NCT04682847|Drug|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
79559049|NCT04682366|Drug|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
79559050|NCT04682366|Drug|Placebo|Oral drug: 10 days of identical-appearing placebo
79559051|NCT04679818|Drug|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
79559052|NCT04679818|Device|PMD-200 Nol-guided opioid administration|PMD-200 NOL values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
79559053|NCT04677738|Dietary Supplement|B. breve|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
79559054|NCT04677738|Dietary Supplement|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
80019723|NCT05883969|Behavioral|GO-PLAY|The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
80019724|NCT05883969|Behavioral|Usual care|Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
79259855|NCT02080325|Other|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
79259856|NCT04965974|Device|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
79559065|NCT04658381|Genetic|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
79856580|NCT05297162|Diagnostic Test|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
79259857|NCT02080559|Biological|4CMenB|0.5ml IM
79259858|NCT04966052|Other|No intervention|No intervention
79259859|NCT02078453|Procedure|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
79856581|NCT00686777|Biological|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
79259860|NCT04965896|Other|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
79259861|NCT04965896|Other|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
79259862|NCT03558659|Device|Positional therapy belt|The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
79856582|NCT00686777|Drug|Ribavirin|Ribavirin 400 mg/day orally
79856583|NCT04009772|Drug|Cefepime|Antibiotic prophylaxis
79856584|NCT04009772|Drug|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
79259863|NCT04422236|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
79259864|NCT03558581|Other|Educational|
79259865|NCT02080715|Drug|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
79259866|NCT02080715|Drug|Placebo|
79259867|NCT04965662|Drug|Maraviroc|Maraviroc 300 mg, TWO tablets once daily.
79259868|NCT04965662|Drug|Truvada|Truvada one tablet once daily
79259869|NCT02083445|Other|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
79259870|NCT02083445|Other|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
79397651|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79559066|NCT04658381|Procedure|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
79856585|NCT00961922|Other|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
79856586|NCT00961922|Other|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
79856587|NCT00959582|Procedure|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
79856588|NCT00962156|Drug|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
79856589|NCT00962156|Drug|Ringers acetate|Infusion for volume expansion in the ICU
79856590|NCT00959738|Procedure|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
79856591|NCT00959738|Procedure|diverting loop ileostomy without rod|diverting loop ileostomy without rod
79856592|NCT00686699|Drug|Preladenant|capsules
79259871|NCT02083445|Device|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
79856593|NCT00686699|Drug|Placebo|capsules
79259872|NCT02083445|Other|Intermittent hypobaric hypoxia|
79259873|NCT02083523|Behavioral|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
79259874|NCT02083523|Behavioral|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
79259875|NCT04949126|Behavioral|questionnaire|questionnaires of precarity, dental anxiety, self medication, pain
79259876|NCT02083601|Behavioral|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
80019725|NCT05883943|Device|Cook® Venous Valve System|The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
80019726|NCT05883917|Procedure|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
79259877|NCT02083601|Behavioral|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
79259878|NCT02078609|Drug|LGH447|LGH447 in patients with AML or MDS
79397652|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79559067|NCT04656873|Procedure|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
79559068|NCT04656873|Other|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
79559069|NCT04656873|Other|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
79559070|NCT04655963|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
79559071|NCT04644497|Procedure|ACL-reconstruction|Surgery technique in skeletally immature patients
79559072|NCT04640623|Drug|TAR-200|TAR-200 will be administered transuretherally.
79722046|NCT00900601|Procedure|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
79856594|NCT00959816|Drug|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
79856595|NCT01563068|Drug|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
79856596|NCT00747305|Drug|sunitinib malate|
79856597|NCT00747305|Genetic|gene expression analysis|
80019727|NCT05883891|Diagnostic Test|prothrombin time|Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
80019728|NCT05883878|Genetic|PRS|genetic test for the evaluation of PRS cardiovascular risk
80019729|NCT05883878|Device|Digital app and wearable device|a wearable device connected with its app
80019730|NCT05883865|Drug|Fenofibrate|Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
80019731|NCT05883839|Other|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
80031610|NCT05390138|Behavioral|General Hygiene Information (GH)|The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
79259879|NCT02078609|Drug|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
79259880|NCT04958330|Procedure|lateral prostate capsule sparing|When resect the bladder and prostate, the lateral prostate capsule will be preserved.
79259881|NCT02078687|Dietary Supplement|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
79559073|NCT04640623|Biological|Cetrelimab|Cetrelimab will be administered.
79259882|NCT02078687|Dietary Supplement|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
79559077|NCT04631926|Behavioral|Hip Muscle Exercise|Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
79856598|NCT00747305|Genetic|reverse transcriptase-polymerase chain reaction|
79856599|NCT00747305|Genetic|western blotting|
79856600|NCT00747305|Other|immunohistochemistry staining method|
79856601|NCT00747305|Other|laboratory biomarker analysis|
79856602|NCT00747305|Procedure|adjuvant therapy|
79856603|NCT00747305|Procedure|neoadjuvant therapy|
79856604|NCT00747305|Procedure|therapeutic conventional surgery|
79856605|NCT05254106|Device|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
79856606|NCT00747383|Drug|Glimepiride|3mg oral tablet.
79856607|NCT00747383|Drug|Sitagliptin|100mg oral tablet.
79856608|NCT00106639|Drug|CP-690,550|15 mg twice daily
79856609|NCT00106639|Drug|CP-690,550|30 mg twice daily
79856610|NCT00106639|Drug|tacrolimus|dose adjusted according to level
79856611|NCT00747539|Drug|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
79856612|NCT00962234|Other|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
79856613|NCT00962234|Biological|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
79856614|NCT00962234|Procedure|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
79856615|NCT00747695|Drug|Rabeprazole sodium|
79856616|NCT00959972|Drug|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
79856617|NCT00959972|Drug|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
79856618|NCT00747773|Device|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
79856619|NCT04059653|Device|Electrical stimulation|Electrical stimulation device
79856620|NCT04059653|Other|Treatment as usual|GP treatment as usual
79856621|NCT04009616|Drug|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
79856622|NCT04009616|Drug|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
79856623|NCT04009616|Drug|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
79856624|NCT00750035|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
79856625|NCT00750035|Procedure|Subtotal abdominal hysterectomy|
79259883|NCT02078687|Dietary Supplement|Mothers own milk|Group 1 received mothers own milk without fortification
79856626|NCT00106249|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
79856627|NCT00106249|Device|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
79856628|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
79856629|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
79856630|NCT01086943|Device|LT2420|
79856631|NCT00960284|Drug|capecitabine|Given orally
80019732|NCT05883813|Procedure|sustained natural apophyseal glides (SNAGS)|SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction & maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.
79259884|NCT03060356|Biological|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
79856632|NCT00960284|Drug|cisplatin|Given IV
80031611|NCT04897204|Procedure|Catheter ablation and left atrial appendage occlusion|The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.
79259885|NCT04957940|Drug|SMOFlipid|Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
79259886|NCT04957940|Other|0.9% saline|Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
79397653|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 2) followed by vandetanib steady state dose of 300 mg OD (Days 3 to 14) followed by vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79397654|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
79397655|NCT01586156|Drug|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
79856633|NCT00960284|Drug|epirubicin hydrochloride|Given IV
79856634|NCT00960284|Drug|fluorouracil|Given IV
79856635|NCT00960284|Drug|gemcitabine hydrochloride|Given IV
79559085|NCT04628663|Drug|Dexmedetomidine|Administration
79559086|NCT04628663|Other|Normal Saline|Administration
79559087|NCT04622969|Behavioral|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
79722047|NCT03671239|Behavioral|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
79722048|NCT03671239|Behavioral|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
79722049|NCT03671239|Behavioral|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
79722050|NCT02845609|Drug|Sialic Acid-Extended Release|Oral drug of Sialic acid
79856636|NCT00105469|Drug|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
79856637|NCT00105469|Drug|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
79397656|NCT01586156|Drug|placebo|Placebo will be taken twice daily for 6 months
79397657|NCT01459913|Drug|Telaprevir|Tablet
79397658|NCT01459913|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
79397659|NCT01459913|Drug|Ribavirin|Tablet
79397660|NCT04408391|Other|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
79397661|NCT01458587|Drug|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
79397662|NCT01458587|Drug|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
79397663|NCT01458275|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
79559088|NCT04621500|Drug|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
79559089|NCT04621500|Procedure|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
79559090|NCT04621500|Procedure|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
79559091|NCT04621500|Diagnostic Test|Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation|Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.
79397664|NCT01458275|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
79397665|NCT01458275|Drug|Placebo|Placebo - one actuation per nostril
79397666|NCT01458119|Drug|migalastat hydrochloride|Oral capsule QOD
79722051|NCT05177185|Radiation|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
79856638|NCT05192408|Behavioral|Multi-component intervention|"Individual intervention will comprise:~Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
79559101|NCT04616560|Biological|Trastuzumab Deruxtecan|Given IV
79559102|NCT04615104|Procedure|Operative|surgical treatment
79722052|NCT05177185|Radiation|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
79722053|NCT05337085|Drug|Dexmedetomidine|Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
79722054|NCT05337085|Drug|Midazolam|Midazolam
79722055|NCT02845765|Device|Dynamic Vessel Analyzer (DVA)|
79722056|NCT02845765|Drug|Phosphodiesterase type 5 Inhibitor (PDE5I)|
79722057|NCT05097937|Other|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
79722058|NCT05097937|Other|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
79722059|NCT05097937|Other|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
79722060|NCT01723579|Drug|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
79722061|NCT01723579|Drug|Estradiol (E2)|Daily release of 1.5 mg
79722062|NCT03648931|Behavioral|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
79856639|NCT05192408|Other|Usual Care|Patient Education Materials
79856640|NCT04009694|Other|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
79856641|NCT00960362|Drug|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
79559103|NCT04615104|Procedure|Nonoperative|nonsurgical treatment
79559104|NCT04612478|Behavioral|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
79559105|NCT04612478|Behavioral|Clinic-Based Physical|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
79559109|NCT04606472|Drug|SI-B003|Administration by intravenous infusion.
79559110|NCT04606381|Drug|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
79559111|NCT04606381|Drug|Ami-LC|Participants will receive amivantamab SC infusion.
79856642|NCT00960362|Drug|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
79559112|NCT04606381|Drug|Ami-HC|Participants will receive amivantamab SC infusion.
79559113|NCT04606381|Drug|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
79559114|NCT04606381|Drug|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
79559115|NCT04603287|Drug|SI-B001|Administration by intravenous infusion.
79559116|NCT04600713|Other|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
79559117|NCT04599855|Drug|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
79559118|NCT04599855|Drug|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
79559119|NCT04599855|Drug|Placebo|Matching placebo will be self administered as nasal spray.
79559120|NCT04596319|Biological|AP-PA02|Bacteriophage administered via inhalation
79559121|NCT04596319|Other|Placebo|Inactive Placebo administered via inhalation
79559125|NCT04584047|Procedure|Cell-based non-invasive prenatal testing|Blood sampling.
79722063|NCT03648931|Behavioral|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
79722064|NCT01481935|Other|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
79722065|NCT01481935|Other|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
79722066|NCT00901927|Drug|Bendamustine|Starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
79722067|NCT00901927|Drug|Mitoxantrone|10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle.
80019733|NCT05883813|Procedure|suboccipital muscle release|Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
79722068|NCT00901927|Drug|Rituximab|375 mg/m^2 by vein over several hours on Day 1 of each cycle.
79397667|NCT02334527|Drug|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
79259887|NCT03060200|Other|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
79259888|NCT03060200|Other|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
79259889|NCT02080793|Other|Questionnaire|
79259890|NCT03060278|Behavioral|Self-help materials|Self-help smoking cessation materials.
79259891|NCT03060278|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke < 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
79259892|NCT03060278|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
79259893|NCT03060278|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
79397668|NCT01688726|Other|SYSTANE® BALANCE eyedrops|
79559129|NCT04564417|Biological|W0180|Participants will receive W0180 in a 21-day cycle.
79559130|NCT04564417|Drug|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
79397669|NCT01688726|Other|Minims® Saline 0.9% eyedrops|
79397670|NCT01585766|Drug|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
79397671|NCT01585766|Drug|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
79397672|NCT01585766|Drug|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
79397673|NCT01585766|Drug|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
79397674|NCT01585766|Drug|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
79559131|NCT04562870|Drug|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
79559132|NCT04562870|Other|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
79559133|NCT04562389|Drug|Selinexor|Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
79559134|NCT04562389|Drug|Selinexor|Participants will receive a dose of 60 mg selinexor oral tablets QW.
80019734|NCT05883813|Procedure|Supplemental therapy|General warm-up exercises, TENS, hot pack, trapezius stretching
79259894|NCT02080949|Radiation|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
79559135|NCT04562389|Other|Placebo|Participants will receive a matching placebo of selinexor oral tablets QW
79559136|NCT04562389|Drug|Ruxolitinib|Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
79856643|NCT00962312|Drug|capecitabine|
79856644|NCT00962312|Drug|lapatinib ditosylate|
79856645|NCT00962468|Other|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
79722069|NCT01400269|Behavioral|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
79722070|NCT02845141|Procedure|Actifuse|bone tunnel filled with Actifuse
79722071|NCT02845141|Procedure|bone graft|bone graft to fill bone tunnel
79722072|NCT04602871|Diagnostic Test|Breath Biopsy|Breath Biopsy sampling using the ReCIVA® Breath Sampler
79856646|NCT00960518|Drug|adefovir|adefovir at 10 mg daily for 48 weeks
79856647|NCT00960518|Procedure|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
79856648|NCT00960596|Behavioral|Health promotion and health education for smoking habits|We provide the education to intervention group.
79856649|NCT00960674|Procedure|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
79856650|NCT00960674|Behavioral|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
79259895|NCT02308449|Drug|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
79856651|NCT04010864|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
79856652|NCT01563146|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
79856653|NCT05069948|Other|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
79856654|NCT00960830|Drug|mirtazapine|mirtazapine 15 mg daily tablets
79856655|NCT00960830|Drug|mirtazapine|15 mg daily
79856656|NCT00960908|Device|Endeavor Resolute stents|2nd generation ZES
79856657|NCT00960908|Device|Endeavor Sprint stent|1st generation ZES
80019735|NCT05883787|Other|Exploration of a database|extraction of data
80019736|NCT05883722|Procedure|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
80019737|NCT05883709|Drug|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
79259896|NCT02308449|Drug|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
79559141|NCT04551417|Procedure|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
79559142|NCT04545593|Behavioral|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
79722073|NCT05335837|Procedure|Regional Anesthesia and Sedation|Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
79722074|NCT05336929|Other|Roy adaptation model-based nursing education|
79722075|NCT00903721|Drug|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
79722076|NCT02844985|Other|No Intervention|
79856658|NCT00962624|Drug|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
79856659|NCT00962702|Device|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
79856660|NCT00105235|Drug|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
79856661|NCT00105235|Drug|Cyclosporine|Oral immunosuppressant
79559143|NCT04545593|Behavioral|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
79856662|NCT00105235|Drug|Mycophenolate mofetil|Oral immunosuppressant
79856663|NCT00105235|Drug|Tacrolimus|Oral immunosuppressant
80019738|NCT05883696|Other|Swedish Palliative Care Guide (S-PCG)|"S-PCG is a care guide that aim to inform best practice and to meet palliative care needs of patients and their families throughout all the time with palliative care needs. The S-PCG support palliative care for adult patients regardless of diagnosis, place of care and if it is early och late palliative care.~The S-PCG includes three parts~Assements of palliative care needs~Initiating palliative care 2D. End of life care.~After death. In this study only the first part of the S-PCG will be used."
80019739|NCT05883683|Other|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
79722077|NCT04900987|Device|Steri-strips|Pneumatic TR band compression with use of steri-strips
79722078|NCT02845219|Drug|semaglutide|Oral administration once daily alone or together with oral contraceptive.
79722079|NCT02845219|Drug|SNAC|Oral administration once daily together with oral contraceptive.
79722080|NCT02845219|Drug|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
79722081|NCT00968968|Drug|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
79722082|NCT00968968|Biological|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
79722083|NCT02842801|Other|Hip manipulation|High-amplitude and low-velocity thrust mobilization
79722084|NCT02862886|Other|myometrium biopsy|
79856664|NCT00105235|Procedure|Liver transplant|Occurs at study entry
79856665|NCT00105235|Procedure|Immunosuppression withdrawal|Beginning no earlier than Year 1
79856666|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
79856667|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
79856668|NCT03962803|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
80019740|NCT05883670|Drug|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
79722085|NCT00973102|Drug|Premarin IV|One time dose of Premarin IV
79722086|NCT00973102|Drug|Placebo|One time dose of placebo.
79856669|NCT00547118|Drug|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
79856670|NCT00547118|Drug|Placebo|One placebo tablet given 1 time per day for 112 days.
79856671|NCT01087021|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
79856672|NCT01084525|Drug|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
79856673|NCT01084525|Drug|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
79856674|NCT01084525|Drug|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
79856675|NCT00962936|Drug|CT-011|CT-011
79722087|NCT04689061|Device|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
79722088|NCT04622605|Device|Trabecular bypass and Schlemm's canal stent|ab interno Microstent placement after cataract surgery
79722089|NCT05205070|Biological|Rosnilimab|humanized monoclonal antibody
79722090|NCT05205070|Biological|Placebo|Placebo solution
79722091|NCT02863588|Biological|seropositive for Toxoplasma gondii|blood sample
79722092|NCT03691090|Drug|SHR-1210|SHR-1210 200mg
79722093|NCT03691090|Drug|Placebo|Placebo
79722094|NCT03691090|Drug|paclitaxel|paclitaxel 175mg/m2
79722095|NCT03691090|Drug|cisplatin|cisplatin 75mg/m2
79722096|NCT00783211|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
79722097|NCT00783211|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
79722098|NCT00783211|Drug|placebo|placebo, once daily for 15 days
79722099|NCT00779545|Drug|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
79722100|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
79722101|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
79856676|NCT00502593|Biological|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
79856677|NCT00502593|Biological|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
79259897|NCT02083913|Behavioral|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
80019741|NCT05883657|Device|Condition 1 : Prototypes (816-v1) every weeks|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79397675|NCT01585766|Drug|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
79397676|NCT01562444|Other|Blood draw|Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
79559149|NCT04538144|Other|Simulated heat wave|Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.
79722102|NCT00779545|Drug|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
79722103|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
79722104|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
79722105|NCT00901459|Device|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
79722106|NCT00901459|Device|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
79856678|NCT01087099|Drug|Albendazole|Treatment with albendazole
79856679|NCT00686543|Drug|Posaconazole|Posaconazole will be used for prophylaxis
79856680|NCT04009538|Other|Rehabilitation program|exercise program twice a week
79856681|NCT02561741|Drug|COV155|COV155 tablets
79856682|NCT00750113|Drug|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
79259898|NCT03242655|Behavioral|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
79259899|NCT02083991|Drug|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
79259900|NCT04948190|Behavioral|Testing with medical detection dogs|Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
79259901|NCT03254901|Other|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
79259902|NCT02081027|Drug|Riluzole|
79259903|NCT02081027|Other|placebo|
79397677|NCT01457339|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
79397678|NCT01457339|Drug|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
79559157|NCT04511702|Biological|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
79559158|NCT04504812|Drug|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
79722107|NCT00901459|Device|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
79856683|NCT00750113|Drug|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
79856684|NCT00750113|Drug|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
79856685|NCT04971590|Other|Participant completed survey|Participants will be required to complete the participant survey.
79559159|NCT04504812|Combination Product|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.
79559160|NCT04504812|Procedure|Nerve Procedure with long acting blocks|People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
79559161|NCT04504812|Procedure|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
79722108|NCT02842567|Drug|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
79559162|NCT04504812|Behavioral|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. They will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
79722109|NCT02842567|Drug|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
79722110|NCT02842489|Procedure|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
79722111|NCT02842489|Procedure|left lateral horizontal position|patients will be horizontally positioned on their left side
79722112|NCT02133703|Behavioral|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
79722113|NCT02133703|Behavioral|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
79722114|NCT02133703|Behavioral|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
79722115|NCT02133703|Behavioral|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
79722116|NCT02133703|Behavioral|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
79722117|NCT00896233|Procedure|MRE|"Part 1: Participants will have a screening visit, followed ~1 month later by two imaging visits over ~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed ~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
79722118|NCT00705211|Drug|Ezetimibe|Ezetimibe, 10-mg tablets,
79722119|NCT00705211|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
79856686|NCT04971590|Other|Medical chart review|Data will be collected from medical charts of participants.
79856687|NCT00963092|Genetic|DNA analysis|
79856688|NCT00963092|Genetic|RNA analysis|
79559163|NCT04504812|Other|Best Practices|Best Practice includes treatments that experts recommend for knee arthritis pain. Best Practice can include topical or oral pain relievers, a structured exercise program, and weight management if BMI is over 30. Other non-invasive treatments such as acupuncture and yoga are also included.
79559164|NCT04502095|Drug|Clindamycin|Given PO
79559165|NCT04502095|Other|Diary|Complete drug diary
79722120|NCT02839993|Device|tDCS|
79722121|NCT02839993|Behavioral|training|
79722122|NCT02842255|Device|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
79856689|NCT00963092|Genetic|microarray analysis|
79856690|NCT00963092|Genetic|protein analysis|
79856691|NCT00963092|Other|cytology specimen collection procedure|
79856692|NCT00963092|Other|laboratory biomarker analysis|
79856693|NCT00963092|Other|questionnaire administration|
79856694|NCT00745511|Drug|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
79856695|NCT00745511|Drug|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
79856696|NCT00961376|Biological|PBMC re-infusion|Autologous PBMC re-infusion
79856697|NCT00961376|Biological|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
79856698|NCT00961454|Device|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
79856699|NCT00545688|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
79856700|NCT00545688|Drug|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
79856701|NCT00545688|Drug|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
80031612|NCT04897204|Procedure|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion|These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
79856702|NCT01563380|Biological|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
79856703|NCT00961610|Behavioral|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
79856704|NCT00961766|Drug|BG00010 (Neublastin)|Single dose, weight-based IV administration
79559166|NCT04502095|Drug|Ertapenem|Given PO
79856705|NCT00961766|Drug|Placebo|Single dose IV matched placebo
79856706|NCT00502203|Drug|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
79559167|NCT04502095|Drug|Levofloxacin|Given PO
79559168|NCT04502095|Drug|Nitrofurantoin|Given PO
79856707|NCT00502203|Drug|Paclitaxel|175 mg/m^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
79259904|NCT04957784|Other|questionnaire survey|Understand the current situation of hypertension management in a poor county in Shanxi Province through questionnaire surveys, and explore the factors that affect patients' blood pressure control based on local conditions
79559169|NCT04502095|Drug|Trimethoprim-Sulfamethoxazole|Given PO
79856708|NCT03049371|Other|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
79856709|NCT00546078|Biological|Cervarix™|Intramuscular injection, one or three doses
79856710|NCT04819256|Other|PACE-It mobile application|Care co-ordination platform
79856711|NCT03035565|Behavioral|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
79856712|NCT03035565|Behavioral|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
79722123|NCT02840071|Other|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
79856713|NCT00963326|Other|laboratory biomarker analysis|
79856714|NCT00967772|Drug|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
79722124|NCT02839837|Behavioral|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
79259905|NCT02455947|Other|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
79259906|NCT03058172|Other|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
79397679|NCT01456949|Device|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
79397680|NCT01456169|Drug|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
79397681|NCT01456169|Drug|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
79397682|NCT01454531|Drug|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
79559170|NCT04501276|Drug|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
79559171|NCT04501276|Drug|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
79559172|NCT04501276|Drug|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
79559173|NCT04495946|Behavioral|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
79559174|NCT04495946|Behavioral|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
79722125|NCT02839837|Device|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
79722126|NCT02839759|Other|TELLYHealth|Educational videos and questions.
79722127|NCT02839525|Dietary Supplement|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
79722128|NCT02839525|Dietary Supplement|Isolate whey protein|23g of protein of whey protein
79722129|NCT02839525|Dietary Supplement|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
79722130|NCT02839525|Other|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
79722131|NCT02839213|Drug|Hyoscine Butyl bromide|
79722132|NCT02839213|Drug|Saline|
79722133|NCT02839447|Other|no intervention|
79722134|NCT05334043|Drug|CuminUP30|7 capsules, 500 mg / capsule
79722135|NCT05334043|Drug|Curcumin capsules|5 capsules, 450 mg / capsule
79722136|NCT02839369|Other|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
79722137|NCT02839369|Other|walking under varies conditions|walking on electronic walkway under different conditions
79259907|NCT03058172|Other|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
79259908|NCT03239535|Biological|Mesenchymal stem cells|Intramuscular injection
79259909|NCT03239535|Biological|Normal saline|Intramuscular injection
79259910|NCT04965194|Procedure|erector spinae plane block|Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
79259911|NCT04965194|Procedure|Quadratus lumborum plane block|"A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1."
79259912|NCT04965194|Other|placebo|patients received no regional block
79722138|NCT04250623|Other|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
79856715|NCT00967850|Drug|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
79856716|NCT00967850|Drug|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
79722139|NCT04250701|Other|Body Posture Assessment|Application of three evaluations above at a one time.
79722140|NCT02838823|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
79722141|NCT05333887|Behavioral|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
79722142|NCT03362749|Other|RFA, MWA, cryo and IRE|local tumor ablation
79722143|NCT03340207|Device|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
79856717|NCT00964938|Device|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
79856718|NCT00965016|Procedure|hypothermia|Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
79856719|NCT00967928|Drug|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
80019742|NCT05883657|Device|Condition 2 : Prototypes (816-v1) every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
79259913|NCT04964882|Diagnostic Test|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
79259914|NCT04957706|Diagnostic Test|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
79259915|NCT04957706|Diagnostic Test|Lachman test|Lachman test
79722144|NCT04201717|Procedure|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
79259916|NCT04957706|Diagnostic Test|anterior drawer test|anterior drawer test
79259917|NCT04957706|Diagnostic Test|pivot-shift test|pivot-shift test
79259918|NCT03238833|Other|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
79397683|NCT01454063|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
79559179|NCT04485793|Dietary Supplement|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
79559180|NCT04485793|Other|Placebo|Oral administration: 1 tablet/day at evening meal
79856720|NCT00967928|Drug|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
79856721|NCT00967928|Radiation|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
79856722|NCT00546000|Drug|Fluticasone propionate 0.05% lotion|Daily applications
79259919|NCT03238833|Other|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
79259920|NCT04947878|Other|Prompt list|The patients in the intervention group will review a prompt list before their visit.
79259921|NCT03238989|Other|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
79259922|NCT04948034|Radiation|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
79259923|NCT04948034|Drug|Fruquintinib|Starts within two weeks upon SABR completion: 5mg, d1-14, qd; Continued until disease progression, unacceptable toxicity or patient withdrawal.
79397684|NCT01454063|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
79259924|NCT04948034|Drug|Tislelizumab|Starts within one week upon SABR completion: 200mg, d1, q3w; the dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
79397685|NCT01453595|Drug|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
79559181|NCT04481451|Procedure|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
79559182|NCT04481451|Procedure|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
79559183|NCT04481451|Drug|Ropivacaine|ropivacaine 0.2% nerve block injection
79856723|NCT00963404|Radiation|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
79856724|NCT00968006|Drug|Sitagliptin|100 mg once daily for 4 weeks
80019743|NCT05883618|Other|Exposure|Human Development Index of Country
79722145|NCT04201717|Procedure|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
79559184|NCT04476862|Drug|Cerliponase Alfa|Commercially available product provided to patient by participating clinic site.
79559185|NCT04476862|Device|Administration Kit|Commercially available administration kit provided to the patient by participating clinic site.
79559186|NCT04466475|Biological|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
79559187|NCT04466475|Drug|Melphalan|Given via infusion
79559188|NCT04466475|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
79559189|NCT04458545|Drug|Placebo|Intranasal placebo 0mg
79559190|NCT04458545|Drug|Oxy 25 mg|Intranasal oxycodone 25mg
79722146|NCT00156091|Drug|Olanzapine|5- 20 mg QD
79722147|NCT00156091|Drug|Asenapine|5 or 10 mg BID
79722148|NCT00156091|Other|Placebo|
79722149|NCT00140959|Drug|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
79259925|NCT02453763|Device|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
79722150|NCT00140959|Drug|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
80019744|NCT05883605|Device|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
79722151|NCT00095017|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
79722152|NCT00092755|Drug|MK0663, etoricoxib|
79722153|NCT00092755|Drug|Comparators: ibuprofen and placebo|
79722154|NCT00899431|Drug|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
79722155|NCT00899431|Drug|Fludarabine|30 mg/m^2 intravenously daily on days -5, -4, -3.
80019745|NCT05883592|Device|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
80019746|NCT05883579|Procedure|percutaneous coronary intervention|doing percutaneous revascularization of chronic coronary total occlusion.
79397686|NCT01453439|Behavioral|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
79259926|NCT02453763|Procedure|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
79259927|NCT04947956|Drug|Camrelizumab|The camrelizumab-based treatment will be determined by the investigator.
79259928|NCT03254511|Drug|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
79397687|NCT01453439|Behavioral|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
79397688|NCT01453361|Biological|Vigil™ Vaccine|
79397689|NCT04530773|Behavioral|Watch VR movies/ Play VR games|The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
79559191|NCT04458545|Drug|OXY 50 mg|Intranasal oxycodone 50mg
79559192|NCT04458545|Drug|OXY 100 mg|Intranasal oxycodone 100mg
79559193|NCT04458545|Drug|Heroin|Intranasal heroin 100mg
79559194|NCT04455789|Procedure|routine lung protective, conventional mechanical ventilation|routine lung protective, conventional mechanical ventilation with stabil PEEP
79559195|NCT04454671|Other|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
79559196|NCT04454671|Other|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
79559197|NCT04443660|Other|Blood test|Blood samples taken to test levels of autophagy and apoptosis
79559198|NCT04440839|Other|Telemedicine specialty consultation|Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
79722156|NCT00899431|Drug|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8.
79722157|NCT00899431|Drug|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
79722158|NCT00899431|Procedure|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
79722159|NCT00899431|Drug|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
79722160|NCT00899431|Drug|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
79722161|NCT05335213|Diagnostic Test|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
79722162|NCT02843971|Device|Intraocular pressure measurement with the Sensimed triggerfish Device|
79722163|NCT00899353|Dietary Supplement|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
79722164|NCT02844127|Procedure|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
79722165|NCT02843893|Device|Measure the minimum intensity of a painful stimulation|With Neurolight device.
79722166|NCT00898807|Drug|citalopram|target dose 30mg daily for 9 weeks
79722167|NCT00898807|Drug|placebo|daily for 9 weeks
79397690|NCT01585298|Drug|FTY720|
80019747|NCT05883553|Device|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
80019748|NCT05883527|Other|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
80019749|NCT05883527|Other|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
80019750|NCT05883514|Behavioral|Motivational interviewing|According to the Miller and Rollnick principles, the framework of the motivational interviewing group's sessions was taken from the workbook of the intervention's six sessions of motivational interviewing. A researcher recruited participants in groups of 7 patients for six sessions of 60-90 minutes each (two sessions per week). The training sessions covered topics like stress alleviation, appropriate drug usage, quitting smoking, regular physical activity, healthy eating habits, and regular physical activity. Patients in the control group got standard treatment for PPM, including education on proper medication usage, nutrition, and exercise, as well as regular checking.
80019751|NCT05883501|Behavioral|Self-affirmation versus back massage|"Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation"
79259929|NCT03254511|Radiation|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
79259930|NCT03254511|Drug|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]).
79259931|NCT04957004|Device|CPAP|CPAP ventilator was worn at nigh
79722168|NCT05335135|Other|TriageGO-MDW Clinical Decision Support|TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record
79722169|NCT05335135|Other|Usual Care|Clinical care without decision support provided by TriageGo-MDW
79722170|NCT02842177|Procedure|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
79722171|NCT02842177|Procedure|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
79722172|NCT02842177|Radiation|Transvaginal ultrasound|
79722173|NCT02842177|Device|Cu-IUD|
79722174|NCT01229267|Biological|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
79856725|NCT00971022|Behavioral|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
79856726|NCT00971022|Behavioral|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
79259932|NCT04947566|Drug|Comparison of Efficacy of Naproxen versus Ibuprofen|Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
79559204|NCT04438369|Procedure|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
79856727|NCT00963716|Device|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
79856728|NCT00963716|Device|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
79397691|NCT04124198|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Accelerated or hyper-fractionated radiotherapy
79397692|NCT04124198|Drug|Cisplatin|Concurrent weekly cisplatin 40 mg/sqm to fit patients
79397693|NCT04124198|Drug|Nimorazole.|Concurrent nimorazole
79397694|NCT04124198|Procedure|Transoral Robotic Surgery (TORS) with neck dissection|Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
79559205|NCT04420702|Device|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
80019752|NCT05883475|Other|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
79397695|NCT01453205|Drug|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
79722175|NCT01229267|Biological|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
79397696|NCT01453205|Drug|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
79722176|NCT02690779|Other|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
79722177|NCT02690779|Other|Routine Care Instructions|patients will follow routine care and instructions
79722178|NCT00897715|Drug|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
79722179|NCT00897715|Drug|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
79259933|NCT03242265|Diagnostic Test|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
79259934|NCT04948346|Other|diagnosed with ALS|diagnosed with ALS
79856729|NCT00971100|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
79856730|NCT00968162|Drug|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
79259935|NCT03254745|Other|Pharmacist led pharmaceutical care|The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
79259936|NCT04964804|Procedure|real-time ultrasound-CT fusion imaging|selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging
79397697|NCT01453205|Drug|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min [800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
79559206|NCT04411420|Behavioral|Pain modulation with physical pain treatment|Examples of pain modulation with physical pain treatment include spinal manipulation, massage, or transcutaneous electrical nerve stimulation
79559207|NCT04411420|Behavioral|Telephone delivered self-management counseling for increasing physical activity|Centrally located physical therapy assistants will provide six weeks of telehealth consults to increase physical activity for the patient
79559208|NCT04411420|Behavioral|Telephone delivered behavioral treatment for participants with high risk for continued disability|Patients with a higher risk of developing chronic or persistent back pain will be identified using the nine question risk stratification start back screening tool (SBST) and will receive six additional weeks of physical activity instructions and additional pain modulation treatments as needed.
79559209|NCT04411420|Behavioral|Patient preference treatment protocol|the pain navigator will work through a shared decision making process with the patient to determine the preferred treatment protocol
79722180|NCT00633295|Drug|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
79722181|NCT04205773|Device|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
79722182|NCT02842099|Drug|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
79722183|NCT02842099|Drug|X|Capecitabine
79259937|NCT04964804|Procedure|ultrasound alone|selective lumbar nerve root block puncture under the guidance of ultrasound alone
79259938|NCT03242031|Procedure|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
79259939|NCT03242031|Procedure|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
79259940|NCT04431986|Other|No intervention: secondary use of a database|Statistical analyses
79259941|NCT03241875|Drug|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
79259942|NCT03241875|Drug|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
79722184|NCT02842021|Drug|S2G6T-1|Twice a day topical cream
79722185|NCT02842021|Drug|S2G6T-2|Twice a day topical cream
80019753|NCT05883475|Other|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
79722186|NCT02842021|Drug|S2G6T-3|Twice a day topical cream
79722187|NCT02842021|Drug|S2G6T-4|Twice a day topical cream
79722188|NCT02839057|Procedure|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
79259943|NCT03241875|Drug|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
79259944|NCT03057938|Drug|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
79259945|NCT03238521|Procedure|Spinal osteosynthesis with classical pedicle finder|Posterior thoracic and lumbar osteosynthesis with classical pedicle finder
79259946|NCT03238521|Procedure|Spinal osteosynthesis with pedicle finder with impedancemetry|Posterior thoracic and lumbar osteosynthesis with pedicle finder with impedancemetry
79722189|NCT02839057|Procedure|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
79722190|NCT01229111|Drug|cediranib maleate|Given PO
80019754|NCT05883475|Other|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
79559210|NCT04411420|Behavioral|Nonpharmacological guideline adherent treatment protocol|the pain navigator will select only nonpharmacological guideline adherent treatment options for the patient
79722191|NCT01229111|Drug|oxaliplatin|Given IV
79722192|NCT01229111|Drug|leucovorin calcium|Given IV
79722193|NCT01229111|Drug|fluorouracil|Given IV
79722194|NCT00894361|Procedure|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
79259947|NCT04956614|Device|immobilisation duration|immobilisation duration of 2,4,6 week after suture of Achilles tendon
79259948|NCT03241953|Procedure|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
79259949|NCT03058094|Drug|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
79259950|NCT03058094|Drug|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
79259951|NCT03058094|Drug|AC0010|300mg, orally, BID
79559211|NCT04411420|Behavioral|Facilitated referrals to existing VA or non-VA pain management resources|the pain navigator will work with the referring physician to select only existing VA or non-VA pain management resources for the patient.
79722195|NCT00894361|Procedure|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
79856731|NCT00968240|Drug|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
79722196|NCT02843815|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
79722197|NCT02843815|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
79722198|NCT01228175|Drug|Placebo|25mg look alike riboflavin tablets to match active study medication.
79722199|NCT01228175|Drug|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
79856732|NCT00501969|Drug|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
79856733|NCT03942042|Drug|Ixekizumab|Administered SC
79856734|NCT00968318|Procedure|Excision of strip of deep fascia|operative technique to excise deep fascia.
79856735|NCT00968396|Procedure|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
79856736|NCT00968396|Procedure|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
79856737|NCT00968396|Drug|Melphalan|100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
80019755|NCT05883475|Other|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
80019756|NCT05883475|Other|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
80019757|NCT05883436|Device|DEXA-C Cervical Interbody System|The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
79722200|NCT02843737|Other|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
79722201|NCT01228019|Drug|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
79722202|NCT02987959|Drug|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
79722203|NCT05335057|Behavioral|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
79856738|NCT04008732|Drug|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
79856739|NCT04008732|Drug|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
79856740|NCT04008732|Drug|Nitro Pohl|to be dosed intravenously in Part 2 of the study
79856741|NCT01013727|Radiation|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
79856742|NCT00960180|Drug|MR1817|
79856743|NCT00960180|Drug|Placebo|
79856744|NCT00963794|Other|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
80019758|NCT05883423|Other|FPCMP-Old Age|"Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
79856745|NCT04593290|Device|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
79856746|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
79259952|NCT03242187|Procedure|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
79722204|NCT05335057|Behavioral|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
79722205|NCT05335057|Behavioral|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
79722206|NCT05335057|Behavioral|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
79722207|NCT02841631|Genetic|HPV status and typing of tissue|HPV status and typing of tissue
79722208|NCT01227707|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
79722209|NCT01227707|Drug|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
79856747|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
79856748|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
79856749|NCT01015365|Procedure|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
79259953|NCT03242187|Procedure|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
79722210|NCT01227707|Radiation|Radiation therapy|Total dose of 45 Gy over 38 days
79259954|NCT04431596|Device|Forearm cooling|forearm immersion will be performed for active cooling assessment.
79722211|NCT01227707|Procedure|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
79722212|NCT01227707|Drug|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
79722213|NCT01227707|Drug|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
79722214|NCT01227707|Drug|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
79856750|NCT01013805|Radiation|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
80019759|NCT05883397|Other|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
80019760|NCT05883397|Other|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
79856751|NCT01013805|Drug|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
80019761|NCT05881720|Drug|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
80019762|NCT05881720|Drug|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
80019763|NCT05881564|Other|blood use for priming cardiopulmonary bypass circuit|one arm will have the cardiopulmonary bypass circuit primed with blood
80019764|NCT05881564|Other|clear prime for cardiopulmonary bypass|this arm will not have bypass circuit primed with blood
79259955|NCT04431596|Other|Mist-fan cooling|A mist-fan will be placed in front of the participant for active cooling.
79259956|NCT04486443|Behavioral|music therapy|patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
79559212|NCT04404387|Drug|Administration of vitamin C|"The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid."
79722215|NCT00633373|Drug|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
79722216|NCT05334745|Other|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
79722217|NCT04586179|Other|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. [3.2 mph] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90*[{208-(.7*age)}-resting HR]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
79259957|NCT04956380|Other|Self-administered Triage|Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
79397698|NCT01453205|Drug|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
79397699|NCT01453205|Procedure|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
79397700|NCT01453205|Drug|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
79559213|NCT04404387|Drug|Administration of placebo|Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
79559214|NCT04403282|Drug|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
79722218|NCT04586179|Other|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90*[{208-(.7*age)}-resting HR]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
79722219|NCT02821273|Other|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
79722220|NCT02821273|Other|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
80019765|NCT05881174|Procedure|acupuncture|acupuncture
80019766|NCT05881096|Other|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
80019767|NCT05881096|Other|Sham Control|Practice of movement task without START
80019768|NCT05879016|Other|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
80019769|NCT05879016|Other|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
80019770|NCT05879016|Other|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
80019771|NCT05879016|Other|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
79559215|NCT04403282|Drug|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
79559216|NCT04396873|Drug|11C-MC1|Injected IV followed by PET scanning
79856752|NCT01013805|Drug|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
80019772|NCT05876884|Device|Celsi Warmer Mattress|The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time
80019773|NCT05873725|Drug|Follitropin delta|Evaluation of the IVF cycle using the prescribed medication
80019774|NCT05873166|Other|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
79259958|NCT03241797|Procedure|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
79559217|NCT04396873|Drug|11C-PS13|Injected IV followed by PET scanning
79559218|NCT04396873|Drug|18f-florbetaben|Injected IV followed by PET scanning
79559219|NCT04393558|Device|ADAM Sensor|ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
79722221|NCT02838589|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
80019775|NCT05873166|Other|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
80019776|NCT05872061|Other|Acceptability of food-to-food fortified (FtFF) instant porridge flours|This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.
80019777|NCT05871398|Drug|Tegoprazan|Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea
80019778|NCT05871398|Drug|Placebo|Placebo
79259959|NCT04944524|Drug|Tofacitinib|"Tofacitinib 5mg twice a day for 12months;~Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
79559220|NCT04390243|Drug|Binimetinib|Given PO
79559221|NCT04390243|Drug|Encorafenib|Given PO
79559222|NCT04386811|Drug|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
79559223|NCT04386811|Other|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
79559224|NCT04378270|Device|PopSole™ Offloading Device|Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
79559225|NCT04354649|Drug|Hydroxychloroquine|Hydroxychloroquine 5mg/kg PO daily
79559226|NCT04354649|Other|Placebo|Hydroxychloroquine-matching placebo
79722222|NCT02838589|Drug|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
79722223|NCT02841475|Other|Charlson comorbidity index|Charlson comorbidity index
79722224|NCT02838511|Other|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
79722225|NCT02838511|Other|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
79722226|NCT02839135|Drug|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
79722227|NCT02839135|Drug|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
79722228|NCT00895843|Drug|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
80019779|NCT05864469|Other|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
79722229|NCT00895843|Drug|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
79856753|NCT01013805|Drug|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
80019780|NCT05860530|Drug|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
80019781|NCT05860530|Drug|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
79559227|NCT04336722|Drug|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
79259960|NCT04944524|Drug|Methotrexate|"Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
79259961|NCT04412876|Drug|Duloxetine|Duloxetine 30 mg qd
79722230|NCT00895843|Drug|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
79722231|NCT02838433|Other|biological samples|blood and tissue samples
79559228|NCT04336722|Drug|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
79559229|NCT04335422|Device|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
79722232|NCT05333809|Drug|Pembrolizumab|an anti-PD-1 monoclonal antibody
79722233|NCT05333809|Drug|Disitamab vedotin|HER2-ADC
79722234|NCT02838667|Procedure|Standard of Care plus Nephrology Care|
79722235|NCT05333731|Drug|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
79722236|NCT02838355|Device|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
79559230|NCT04335422|Behavioral|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
79559231|NCT04325204|Behavioral|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
79559232|NCT04322357|Drug|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
79559233|NCT04322357|Behavioral|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
79559234|NCT04322357|Drug|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
79559235|NCT04312841|Drug|Letermovir|Given PO
79722237|NCT02838355|Other|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
79722238|NCT02843581|Device|Cryosurgery|Argon-helium cryosurgical system
79722239|NCT02843581|Biological|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
79722240|NCT02843503|Device|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
79722241|NCT02843503|Device|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
79722242|NCT02843503|Device|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
79722243|NCT02815813|Behavioral|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
79559236|NCT04309630|Procedure|intercostal block|pain control by intercostal block
79559237|NCT04309630|Procedure|erector spina plane block|pain control by erector spina plane block
79559238|NCT04286373|Device|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
80019782|NCT05859451|Device|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
79856754|NCT01013805|Procedure|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
79559239|NCT04286373|Device|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
79856755|NCT04491045|Other|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
79856756|NCT04491045|Other|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
79856757|NCT04491045|Other|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
79722244|NCT02815813|Behavioral|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
79856758|NCT00104299|Drug|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m^2 infusions once weekly for 4 week
80019783|NCT05859451|Other|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
80019784|NCT05858450|Biological|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
80019785|NCT05858450|Biological|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
79856759|NCT00104299|Drug|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
79856760|NCT00104299|Drug|Azathioprine|2 mg/kg/day orally for months 4-6
80019786|NCT05849272|Drug|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
79397701|NCT01453049|Drug|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
79559240|NCT04277598|Biological|APO-2|APO-2: dose adjusted gel for topical administration.
79559241|NCT04277598|Other|Placebo|Placebo gel for topical administration.
80019787|NCT05839340|Device|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
80019788|NCT05839340|Device|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
79259962|NCT04412876|Drug|Imipramine|Imipramine 25mg qd
79259963|NCT02454231|Biological|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
79259964|NCT02454231|Biological|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
79722245|NCT02690857|Drug|Docosahexaenoic acid|
79722246|NCT02690857|Drug|Sunflower Oil|
79856761|NCT00104299|Drug|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
79259965|NCT04955912|Other|music medicine|To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
79397702|NCT01453049|Drug|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
79397703|NCT01452347|Drug|warfarin 1mg|comparator warfarin
79397704|NCT01452347|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
79397705|NCT01452347|Drug|dabigatran etexilate low dose|active treatment (low)
79397706|NCT01452347|Drug|warfarin 5mg|comparator warfarin
79397707|NCT01452347|Drug|dabigatran etexilate high dose|active treatment (high)
79397708|NCT01452347|Drug|warfarin 3mg|comparator warfarin
79856762|NCT00104299|Drug|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
79856763|NCT03939312|Drug|Atogepant|Atogepant Tablets
79856764|NCT00968552|Procedure|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
79856765|NCT00968630|Other|Laboratory Biomarker Analysis|Correlative studies
79856766|NCT00968630|Procedure|Leukapheresis|Undergo leukapheresis
79722247|NCT02843269|Behavioral|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
80019789|NCT05836675|Other|Intradialytic exercise|The exercise program will be carried out during dialysis time. Participants will be asked to carry out cycling for 15-20 minutes, resistance exercises, and Kegel exercises during the first 2 hours of their regular routine hemodialysis session. Exercise can be done with rest periods as necessary.
80019790|NCT05835687|Drug|B7-H3-CAR T cells|Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Six (6) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
80019791|NCT05831241|Dietary Supplement|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
79259966|NCT04946786|Diagnostic Test|Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis|"Complete history taking.~Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height m, weight Kg, waist circumference (WC) Cm, hip circumference (HC) Cm.~3. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.~5. Body composition analysis: to detect water, muscle and fat percentage in the body.~6. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).~• Fasting insulin levels will be measured using ELISA kits"
79722248|NCT02843347|Procedure|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
79259967|NCT03241563|Drug|Sodium Deoxycholate|
79259968|NCT03241563|Drug|Triamcinolone|Triamcinolone 40mg/ml
79259969|NCT04955522|Diagnostic Test|radiomics|Differential diagnosis of spinal myeloma and metastases by radiomics
79559246|NCT04254627|Drug|Etanercept|Etanercept 50 mg weekly injection
79559247|NCT04254627|Drug|Mifepristone|Mifepristone 300 mg pill
79856767|NCT00963950|Procedure|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
79856768|NCT00963950|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
79856769|NCT01563432|Drug|Feburic®|80 mg*1 tablet
79856770|NCT01563432|Drug|TMX-67|40 mg*2 tablets
79856771|NCT00968786|Device|Home monitoring|automated measuring devices for patients using at home
79856772|NCT00960258|Drug|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
79856773|NCT04566926|Drug|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
79856774|NCT04566926|Drug|Placebo|Participant will receive matching placebo.
79856775|NCT00082381|Drug|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
80019792|NCT05831241|Other|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
80019793|NCT05830799|Drug|Drug Drug Interaction|The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
80019794|NCT05827523|Drug|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
80019795|NCT05826470|Device|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
79259970|NCT04946474|Drug|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
79259971|NCT03241641|Drug|Tenofovir Alafenamide|25mg, Daily Oral
79559251|NCT04250805|Drug|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
79559252|NCT04250805|Drug|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
79559253|NCT04248335|Drug|Pantoprazole|single-dose administration
79559254|NCT04248335|Drug|Midazolam injection|single-dose administration
79722249|NCT02843113|Behavioral|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
79856776|NCT00082381|Drug|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
79856777|NCT00964106|Drug|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
79856778|NCT00964106|Drug|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
79856779|NCT00964106|Drug|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
79856780|NCT00964106|Drug|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
79856781|NCT00964106|Drug|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
80019796|NCT05803928|Drug|Ronvatinib + sindillimab|A RFA treatment group B RFA+ Ronvatinib + sindillimab treatment group
80019797|NCT05803928|Procedure|radiofrequency ablation|radiofrequency ablation
80019798|NCT05799911|Dietary Supplement|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
79722250|NCT02841319|Other|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
79559255|NCT04245085|Drug|Atezolizumab|"Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit."
79559256|NCT04245085|Drug|Bevacizumab|Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
79559257|NCT04245085|Drug|Carboplatin|Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
79559258|NCT04245085|Drug|Paclitaxel|Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
79722251|NCT02841007|Device|geko neuromuscular electrostimulation device|
79259972|NCT03241641|Drug|Tenofovir Disoproxil Fumarate|300mg, Daily Oral
79259973|NCT03058562|Drug|ABX-1431|ABX-1431, capsules, 40 mg in the fasting state
79259974|NCT03058562|Drug|Placebo Comparator|Matching Placebo
79397709|NCT01451723|Drug|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
79559259|NCT04245085|Drug|Pemetrexed|Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
79722252|NCT02842957|Behavioral|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
79722253|NCT02615353|Behavioral|Intensive Lifestyle Intervention|6-months of lifestyle education
79722254|NCT02615353|Other|Usual Care Control|Medical visit and dietary counseling
79722255|NCT02842879|Other|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
79722256|NCT05334667|Other|Routine management|Routine management
79722257|NCT05334667|Device|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
79722258|NCT05334667|Device|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
79722259|NCT00895453|Drug|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
79722260|NCT00895453|Drug|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
79722261|NCT00895453|Drug|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
79722262|NCT00893971|Drug|PT001|Inhaled PT001, single dose
79722263|NCT00893971|Drug|PT005|Inhaled PT005, single dose
79722264|NCT00893971|Drug|PT003|Inhaled PT003, single dose
79722265|NCT00893971|Drug|PT001 + PT005|Inhaled PT001 + PT005, single dose
79722266|NCT00893737|Drug|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
79259975|NCT03058562|Drug|ABX-1431|ABX-1431, capsules, 20 mg with a high fat meal
79259976|NCT03058016|Other|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
79259977|NCT04486521|Drug|Interleukin 6 (IL6) Antagonist|anti-IL6 alone
79397710|NCT01451723|Other|Placebo|Matching placebo capsules
79397711|NCT01451645|Drug|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
79397712|NCT01451645|Drug|placebo|daily placebo dosing for 16 weeks
79397713|NCT01451645|Drug|allopurinol|background therapy
79559260|NCT04241835|Drug|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
79559261|NCT04234724|Other|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
79559262|NCT04231019|Other|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
79722267|NCT00893113|Drug|Placebo|Alfuzosin-matched One tablet once daily
79722268|NCT00893113|Drug|Alfuzosin|10 mg once daily
80019799|NCT05799911|Dietary Supplement|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
79856782|NCT00964106|Drug|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
79856783|NCT00964106|Drug|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
79856784|NCT00964106|Drug|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
79856785|NCT00964106|Drug|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
79856786|NCT00964106|Drug|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
79856787|NCT00964106|Drug|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
79856788|NCT00960336|Drug|pegylated liposomal doxorubicin hydrochloride|
79559263|NCT04221204|Drug|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily [QD], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
79856789|NCT00971646|Other|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
79559264|NCT04216329|Drug|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
79856790|NCT00971646|Other|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
79559265|NCT04216329|Drug|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-RT, the adjuvant temozolomide will be given per standard of care.
79559266|NCT04216329|Radiation|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
79722269|NCT05333653|Other|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
79722270|NCT05333653|Other|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
79722271|NCT02838199|Device|SAPIEN 3|
79722272|NCT02838199|Procedure|SAVR|
79856791|NCT00971646|Other|EuroQol-5D|This questionnaire grades the health condition of the subject.
79856792|NCT00971646|Other|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
79856793|NCT00965172|Other|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
79856794|NCT00965172|Other|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
79856795|NCT01084681|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
79259978|NCT04486521|Drug|Interleukin 6 (IL6) Antagonist and corticosteroids|anti-IL6 + corticosteroid combination
79722273|NCT02840929|Procedure|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
79722274|NCT02840929|Drug|Esomeprazole|
79722275|NCT04201483|Other|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
79722276|NCT04201483|Other|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
79722277|NCT02837887|Behavioral|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
79856796|NCT01084681|Device|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
79856797|NCT04505852|Device|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
79856798|NCT00969020|Procedure|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
79856799|NCT01084837|Drug|velcade|"INDUCTIoN (Cycles 1-4)~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
79856800|NCT03962413|Procedure|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
79856801|NCT00545844|Drug|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
79856802|NCT01084993|Drug|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
79856803|NCT01084993|Drug|Heparin|70 U/kg
79397714|NCT03026621|Dietary Supplement|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
79559267|NCT04209569|Behavioral|Nutrition Impact and Positive Practice Circle (NIPP)|GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
79559274|NCT04200651|Drug|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
79559275|NCT04200651|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
79559276|NCT04190628|Drug|ABM-1310|"Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
79559277|NCT04190628|Drug|Cobimetinib|"Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules."
79722278|NCT02840617|Drug|Indocyanine Green (ICG)|
79722279|NCT02838121|Drug|Aclasta|Aclasta once annually for 2 years
79397715|NCT03026621|Other|Herbal tea|This is an herbal tea that will look like the control
79397716|NCT01450943|Device|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
79722280|NCT02838121|Drug|Placebo|No IV aclasta
79397717|NCT01450943|Procedure|debridement, irrigation|debridement, irrigation
79397718|NCT01450943|Device|Dermagraft|Dermagraft per company protocol
79397719|NCT01450943|Device|Oasis|Oasis per company protocol
79559283|NCT04179864|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
79559284|NCT04179864|Drug|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
79559285|NCT04179864|Drug|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
79559288|NCT04173273|Drug|Etrasimod|Dose A taken by mouth, once daily.
79559289|NCT04173273|Drug|Etrasimod|Dose B taken by mouth, once daily.
79856804|NCT00492063|Biological|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
79856805|NCT00492063|Biological|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
79856806|NCT04008654|Behavioral|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
79856807|NCT04008654|Behavioral|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
79259979|NCT04486521|Drug|corticosteroid alone|"dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent"
79856808|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
79856809|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
79856810|NCT00960492|Drug|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
79856811|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
79856812|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
79856813|NCT00960492|Radiation|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
79856814|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
79856815|NCT00971724|Drug|Placebo|Oral administration, once daily, for 15 days
79559290|NCT04173273|Drug|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
79259980|NCT04411472|Biological|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
79856816|NCT00971724|Drug|Prednisolone|Oral administration
79259981|NCT04411472|Other|Placebo|Placebo
79259982|NCT04486365|Procedure|Bifocal bone transport.|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
79259983|NCT04486365|Procedure|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments.
79259984|NCT04486287|Drug|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
79259985|NCT03254199|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
79259986|NCT03254199|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
79259987|NCT04955834|Drug|Insulin degludec injection|long-acting insulin
79722281|NCT04250389|Other|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~Mean, systolic, diastolic arterial, heart rate (HR)~Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~Cutaneous and gingival refill time~Tissue oxygen saturation combined with vascular occlusion test (VOT)~Video microscopy measurements of the sublingual microcirculation~Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
79722282|NCT02838043|Dietary Supplement|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
79722283|NCT00892957|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
79722284|NCT00892957|Other|Surgical gauze pads|Manual compression with surgical gauze pads
79259988|NCT04955834|Drug|Tresiba®|long-acting insulin
79259989|NCT03254277|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
79259990|NCT03254277|Drug|Placebo|Placebo
79259991|NCT04943978|Other||just observational blood and liver sampling
79259992|NCT03241719|Drug|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
79259993|NCT03241407|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
79856817|NCT04331301|Procedure|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
79559294|NCT04163042|Behavioral|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
79856818|NCT04331301|Procedure|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
79559295|NCT04159688|Drug|Alcohol|Alcohol Challenge
79559296|NCT04159155|Radiation|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
79856819|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
80019800|NCT05798091|Behavioral|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
80019801|NCT05798091|Other|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
79559297|NCT04159155|Drug|Niraparib|Oral drug
79559298|NCT04159155|Radiation|Vaginal high-dose rate brachytherapy|Internal radiation to the vagina
79559299|NCT04159155|Other|Observation - no drugs|Observation
79559300|NCT04152421|Other|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
79559301|NCT04147923|Dietary Supplement|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of >1 x 10^9 CFU. Participants will also consume a multivitamin.
79559302|NCT04147923|Dietary Supplement|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
79559303|NCT04142437|Drug|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
79722285|NCT02834611|Drug|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
79722286|NCT02834689|Behavioral|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
79722287|NCT02834689|Behavioral|Seated Control|Sitting for 50 minutes
79722288|NCT05322733|Drug|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
79722289|NCT05322733|Drug|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
79722290|NCT05322733|Drug|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
79559311|NCT04111172|Biological|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
79559312|NCT04109079|Procedure|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
79559313|NCT04109079|Radiation|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
79559314|NCT04109079|Radiation|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
79559319|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
79559320|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
79559321|NCT04094753|Diagnostic Test|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
79722291|NCT05322733|Drug|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
79856820|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
79856821|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
79259994|NCT03241407|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
80019802|NCT05787054|Other|Third trimester ultrasound|Third Trimester U/S on indication (TT-Indication) vs Late Third Trimester Protocol (Late-TT)(Trial n°2).
79259995|NCT04944056|Other|conventional physiotherapy|"Ultrasound therapy 3-4 minutes.~Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~Patellar glides 1 set x 5 reps x 3 sets.~Quads isometrics 1 set x 10 reps.~Hams self stretching 1 sets x 10 reps.~Home plan:~Quads isometrics 1 set x 10 reps.~Hams self stretching 1 sets x 10 reps.~Active range of motion."
79259996|NCT04944056|Other|compression mobilization|"Ultrasound therapy 3-4 minutes.~Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~Patellar glides 1 set x 5 reps x 3 sets.~Quads isometrics 1 set x 10 reps.~Hams self stretching 1 sets x 10 reps.~Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~Quads isometrics 1 set x 10 reps.~Hams self stretching 1 sets x 10 reps.~Active range of motion."
79259997|NCT03241095|Procedure|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
79259998|NCT03241095|Procedure|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
79259999|NCT03238287|Device|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
79260000|NCT03238287|Other|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
79559322|NCT04094753|Diagnostic Test|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
79559323|NCT04094753|Diagnostic Test|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
79722292|NCT00968812|Drug|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
79722293|NCT00968812|Drug|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
79722294|NCT00968812|Drug|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
79260001|NCT03238131|Drug|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
79559324|NCT04094753|Diagnostic Test|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
79559325|NCT04094753|Diagnostic Test|Questionaires|"Patients have to fulfill the following questionaires~ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~TILBURG FRAILTY INDICATOR~SF-36 Quality of Life score~N- QOL"
79722295|NCT02834767|Device|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
79722296|NCT02834767|Device|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
79722297|NCT02834845|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
79722298|NCT02834845|Drug|Desflurane|Desflurane %6-8 for general anesthesia maintenance
79856822|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
79856823|NCT05181813|Procedure|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
79856824|NCT05181813|Procedure|Metapex|Fill the infected root canal of of primary teeth with Metapex
79856825|NCT00971880|Other|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
79856826|NCT02976909|Drug|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
79856827|NCT00960648|Device|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
79856828|NCT00960648|Device|Cypher|Retrospective historical controls that received sirolimus-eluting stent
79856829|NCT02878083|Drug|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
79260002|NCT03238131|Drug|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
79722299|NCT02840851|Device|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
79260003|NCT01369433|Drug|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
79260004|NCT01369433|Drug|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
79260005|NCT01369433|Drug|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
79559326|NCT04094753|Diagnostic Test|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
79260006|NCT01369433|Drug|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
79260007|NCT01369433|Drug|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
79260008|NCT01369433|Drug|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
79559327|NCT04094753|Diagnostic Test|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
79722300|NCT02840851|Device|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
79559328|NCT04094311|Biological|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
79559330|NCT04083235|Drug|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
79559331|NCT04083235|Drug|Oxaliplatin|Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
79722301|NCT02834533|Device|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
79722302|NCT02834143|Other|No intervention|The is no intervention. This study is a descriptive one
79722303|NCT02834299|Behavioral|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
79722304|NCT02834299|Behavioral|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
79722305|NCT02834299|Behavioral|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
79722306|NCT05333575|Behavioral|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
79722307|NCT05333575|Behavioral|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
79722308|NCT02837809|Radiation|Low dose CT|annual CT vs biennial CT
79722309|NCT00992056|Drug|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
79722310|NCT00992056|Drug|Metoprolol|Metoprolol 50 mg titrated to 100 mg
79722311|NCT02837653|Behavioral|Physical Activity Counselling|
79722312|NCT02837653|Other|Therapeutic Exercise for LBP|
79722313|NCT02837653|Other|Superficial Thermotherapy|
79722314|NCT04249999|Behavioral|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
79260009|NCT04151108|Other|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
80019803|NCT05776368|Other|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
80019804|NCT05776368|Other|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
80019805|NCT05776368|Other|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
79559332|NCT04083235|Drug|5Fluorouracil|Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
79559333|NCT04083235|Drug|Leucovorin|Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
79722315|NCT04286074|Other|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
79722316|NCT04286074|Other|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
79260010|NCT04151108|Other|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
80019806|NCT05776368|Other|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
80019807|NCT05776368|Other|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
79722317|NCT02834221|Device|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
79397720|NCT01450631|Device|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
79559334|NCT04083235|Drug|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
79722318|NCT02834221|Other|Anatomical landmark guided puncture|Anatomical landmark puncture
79722319|NCT00972322|Drug|MK-8245|MK-8245 50 mg twice daily for 28 days
79722320|NCT00972322|Drug|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
79722321|NCT02840773|Other|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
79722322|NCT02840773|Other|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
79722323|NCT02840773|Other|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
80019808|NCT05776368|Other|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
79559335|NCT04083235|Drug|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
79559336|NCT04079166|Biological|SCIB1 DNA vaccine|"The plan for this research study is for SCIB1 to be given for up to 85 weeks, in combination with either nivolumab with ipilimumab or pembrolizumab according to the current label.~After receiving the first dose of SCIB1, the patient will receive SCIB1 at 4, 7, 13 and 25 weeks, then every 12 weeks up to Week 85. Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 and given as per standard treatment."
79722324|NCT02840773|Other|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
79722325|NCT02840773|Other|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
79856830|NCT02878083|Drug|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
79856831|NCT00971958|Procedure|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
79260011|NCT03238209|Diagnostic Test|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
79260012|NCT04946162|Drug|Tadalafil Pill|Each patient will be given tadalafil 40 mg one time
79260013|NCT04485819|Other|Cleavage stage transfer|transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
79260014|NCT04485819|Other|Blast stage transfer|transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
79260015|NCT04955288|Procedure|Aortic balloon assisted resuscitation|On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
80019809|NCT05776368|Other|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
80019810|NCT05776368|Other|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
79260016|NCT04955288|Procedure|Traditional cardiopulmonary resuscitation|"Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds."
79559341|NCT04075916|Drug|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
79559342|NCT04051242|Device|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
79856832|NCT00971958|Device|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
79856833|NCT00971958|Device|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
79856834|NCT00971958|Device|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
79856835|NCT00093145|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
79856836|NCT00093145|Drug|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
79856837|NCT00093145|Drug|Herceptin®|Administered by IV infusion
79856838|NCT02808195|Other|Constraint-induced therapy|
79856839|NCT02808195|Other|kinect-based constraint-induced therapy|
79722326|NCT02863744|Procedure|coronally advanced flap with subepithelial connective tissue graft|"Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
79856840|NCT00965328|Procedure|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
79260017|NCT04955288|Procedure|Esophageal cooling|The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
79856841|NCT00965328|Procedure|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
79856842|NCT01014039|Procedure|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
79856843|NCT00965406|Drug|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
79856844|NCT00960726|Drug|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
79856845|NCT00972036|Device|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
79260018|NCT04955288|Procedure|traditional cooling|The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
79260019|NCT02084225|Procedure|ultrasound guided regional nerve block|participants were the physicians performing the procedure
79559350|NCT04032418|Biological|Pembrolizumab|Given IV
79856846|NCT00513357|Drug|Melatonin|20 mg by mouth daily for 4 Weeks
79856847|NCT00513357|Drug|Placebo|Capsule by mouth daily for 4 Weeks
79856848|NCT00960882|Drug|DMMET-01|1050.6 mg daily for 30 days
79856849|NCT05163678|Other|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
79856850|NCT00972114|Procedure|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
79722327|NCT02834377|Other|Treatment algorithm targeting individual cardiac output|
79856851|NCT00972114|Procedure|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
79856852|NCT00972114|Procedure|CABG alone|Coronary artery bypass graft surgery alone
79856853|NCT01014117|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
79856854|NCT01014117|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
79856855|NCT00960960|Drug|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
79856856|NCT00960960|Drug|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
79856857|NCT00960960|Drug|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
79856858|NCT00960960|Drug|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
79856859|NCT00960960|Drug|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
79856860|NCT00972192|Behavioral|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
79856861|NCT00972192|Behavioral|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
79722328|NCT02834455|Device|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
79856862|NCT04315857|Other|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
79856863|NCT01014195|Other|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
79559351|NCT04029337|Device|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
79559352|NCT04027036|Biological|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
79559353|NCT04013971|Other|AGRF Biofeedback Game|During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
79559354|NCT04013971|Other|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
79559355|NCT04013971|Other|Control Condition|Participants will complete a control walk with out feedback.
79559356|NCT04013971|Other|Optional Game with VR|During the optional AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
79722329|NCT02834455|Device|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
79722330|NCT02837575|Biological|VCL-HB01|Investigational Product
79722331|NCT02837575|Other|Phosphate-buffered saline|Placebo
79722332|NCT04209361|Other|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
79856864|NCT00972270|Device|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
79856865|NCT00972270|Device|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
79856866|NCT01015521|Drug|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
79856867|NCT00965640|Drug|Botulinum Toxin - A injections|
80019811|NCT05769062|Procedure|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
80019812|NCT05762692|Device|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
80019813|NCT05748873|Drug|SPVN06|AAV-RdCVF-RdCVFL
79559357|NCT04002479|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
79559358|NCT03977467|Drug|Atezolizumab|atezolizumab at a flat dose of 1200 mg IV every 3 weeks
80019814|NCT05731843|Drug|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
80019815|NCT05731843|Drug|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
79559359|NCT03977467|Other|Chemotherapy (Arm A Only)|Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.
79856870|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
79856871|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
79856872|NCT00961038|Drug|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
79856873|NCT00972348|Other|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
79559360|NCT03977467|Drug|Tiragolumab|tiragolumab at a flat dose of 600 mg IV every 3 weeks
79559361|NCT03973333|Drug|IMC-C103C|Weekly IV infusions
79559362|NCT03973333|Drug|Atezolizumab|IV infusions every 3 weeks
79260020|NCT03237975|Behavioral|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
79559363|NCT03973333|Drug|IMC-C103C|Weekly subcutaneous Injection
79559364|NCT03967002|Procedure|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~the second premolars and first premolars,~the first lower premolars and canines,~the canines and lateral incisors,~the lateral incisors and central incisors, and,~the two lower central incisors."
79559365|NCT03964571|Diagnostic Test|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
79856874|NCT00972348|Other|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
79559366|NCT03954067|Biological|ASP9801|Administered by intratumoral injection
79559367|NCT03954067|Combination Product|Pembrolizumab|Administered by Intravenous Infusion
79260021|NCT03237975|Other|Routine health education|The control group will receive routine health education.
79722333|NCT04249765|Other|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
79722334|NCT05334355|Other|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
79856875|NCT00961194|Drug|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~0.35 mg/kg~0.7 mg/kg~1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
79856876|NCT02665923|Other|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
79856877|NCT03933462|Device|InnoSpire Go|Participants will use for 30 days.
79856878|NCT03933462|Device|Jet Nebulizer|Participants will use for 30 days.
80019816|NCT05730387|Other|Observational only|This is a non-interventional study
79260022|NCT02078843|Drug|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
79260023|NCT02078843|Drug|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
79260024|NCT04946240|Other|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
79260025|NCT04946240|Other|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
79260026|NCT02078921|Drug|Sodium Nitrate|
79559368|NCT03952091|Drug|TJ202, Lenalidomide and Dexamethasone|One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
79559369|NCT03952091|Drug|Lenalidomide and Dexamethasone|Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
79559370|NCT03950232|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
79559371|NCT03944837|Other|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
79722335|NCT02840695|Drug|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
79856879|NCT03929562|Behavioral|Brief advice|One 10-minute brief advice session
79856880|NCT03929562|Behavioral|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
79856881|NCT05279586|Drug|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
79722336|NCT02837497|Other|ICU-RESUS CPR Improvement Bundle|"Point-of-care CPR training~Post-cardiac arrest educational debriefings"
79722337|NCT00967798|Drug|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
79559372|NCT03939624|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
79559373|NCT03939624|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
79559374|NCT03938792|Drug|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
79722338|NCT02837419|Behavioral|Health related Quality of life EQ-5D|Quality of Care
79559375|NCT03919292|Drug|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
79722339|NCT04248361|Diagnostic Test|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
79722340|NCT04248361|Other|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
79722341|NCT04248439|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
79722342|NCT02863510|Device|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
79722343|NCT04286464|Other|No intervention|No intervention
79722344|NCT04248205|Drug|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
79722345|NCT02833831|Drug|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
79722346|NCT02833831|Drug|Placebo|Matching Placebo will be administered.
79722347|NCT02833831|Drug|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
79722348|NCT02833987|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
79722349|NCT02833987|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
79260027|NCT02078921|Drug|Placebo|
79722350|NCT02833987|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
79722351|NCT02833987|Drug|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
79260028|NCT03254043|Behavioral|Take-home Dosing Procedures|Within-subject evaluation across 2 phases with a final choice condition
79260029|NCT04954976|Other|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
79397721|NCT01450631|Device|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
79397722|NCT01450007|Drug|Ropivacaine|25 ml ropivacaine 0.5%
79397723|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (perineural)
79397724|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
79397725|NCT01450007|Drug|Normal saline|5 ml normal saline (intravenous)
79397726|NCT01450007|Drug|Normal saline|0.8 ml normal saline (perineural)
79397727|NCT01496365|Drug|DS-5565 tablet|5mg and 10mg tablets
79397728|NCT01496365|Drug|pregabalin capsule|75mg and 150mg over-encapsulated
79722352|NCT02833909|Other|surgery|
79722353|NCT02833519|Behavioral|group exercise|"Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~A weekly supportive email."
79260030|NCT02081261|Procedure|Coronary artery bypass surgery|coronary artery bypass surgery
79260031|NCT03253965|Other|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
79260032|NCT03253965|Other|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
79260033|NCT03253965|Other|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
79397729|NCT01496365|Drug|Placebo tablet|
79722354|NCT02833441|Behavioral|Peer Support|
79856882|NCT05279586|Drug|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
80019817|NCT05720949|Drug|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
80031613|NCT03686228|Procedure|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
79722355|NCT04248049|Other|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
80031614|NCT03686228|Drug|No-PB-MNC therapy|Patients will receive ASA 81 mg once daily and wound care and pain killer drug
79559376|NCT03919292|Drug|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
79856883|NCT00965796|Drug|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
79260034|NCT03253965|Other|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
79397730|NCT01496365|Drug|placebo capsule|
79397731|NCT01496287|Device|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
79722356|NCT04247893|Device|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
79722357|NCT04247893|Device|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
79722358|NCT04247893|Device|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
79722359|NCT02837341|Device|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
79722360|NCT02837185|Procedure|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
79722361|NCT02837185|Other|Physiological measures|These include TMS and EMG measurements
79722362|NCT00965458|Biological|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
79856884|NCT00415636|Drug|IC83/LY2603618|40 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m^2.
79856885|NCT00415636|Drug|IC83/LY2603618|70 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
79856886|NCT00415636|Drug|IC83/LY2603618|105 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
79397732|NCT01495975|Other|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
79397733|NCT01468987|Drug|LY2605541|
79397734|NCT01468987|Drug|Insulin Glargine|
79260035|NCT03253965|Other|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
79260036|NCT03253965|Other|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
79260037|NCT03253965|Other|No Auditory cueing|Steps are not timed with any auditory cue.
79397735|NCT01468987|Drug|Insulin Lispro|
79397736|NCT01687712|Drug|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
79397737|NCT01687712|Drug|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
79397738|NCT01603628|Biological|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
79397739|NCT01603628|Drug|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
79397740|NCT04546412|Device|Vitrification and thawing|Vitrification using the Cryotop® - Open System followed by thawing
79559379|NCT03899649|Drug|SOC|Standard of Care treatment
79856887|NCT00415636|Drug|IC83/LY2603618|150 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
79856888|NCT00415636|Drug|IC83/LY2603618|195 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
79856889|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
79856890|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
79856891|NCT00965874|Drug|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
79260038|NCT04945694|Other|Ultrasound-guided bilateral pecto-intercostal fascial block|- PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
79260039|NCT04945694|Drug|Intravenous fentanyl|In this group, patients will receive only incremental doses of intravenous fentanyl
79260040|NCT04945694|Drug|Propofol|Propofol anesthesia
79260041|NCT04945694|Drug|Sevoflurane|Sevoflurane anesthesia
79722363|NCT00965458|Drug|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
79722364|NCT02837107|Dietary Supplement|Mind Master|80ml Mind Master / day for 8 weeks
79722365|NCT02837107|Dietary Supplement|Placebo|80ml a look-alike Placebo / day for 8 weeks
80019818|NCT05699915|Procedure|Cardiology consultation|"Electrocardiogram (ECG).~Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio > 15 and left atrial (LA) area > 30 cm2."
79260042|NCT04945694|Drug|Atracurium|Intravenous atracurium
80019819|NCT05699915|Diagnostic Test|Chest Computed Tomography (CT) without contrast|Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
79722366|NCT04249531|Drug|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
79856892|NCT00965874|Drug|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
80019820|NCT05699915|Procedure|Non-invasive endothelial function tests|"FMD~PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues."
79260043|NCT04945694|Device|ultrasound|ultrasound-guided block
79559380|NCT03899649|Device|NanoKnife System|Irreversible Electroporation
79722367|NCT04249531|Drug|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
79722368|NCT02836951|Other|Withdrawal of blood|Withdrawal of blood
79722369|NCT02836639|Drug|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
79722370|NCT02836639|Drug|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
79722371|NCT02836639|Drug|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
79722372|NCT00972244|Drug|Dapagliflozin|once daily, 12 weeks
79722373|NCT00972244|Drug|Placebo|once daily, 12 weeks
79722374|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
79722375|NCT00892723|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
79260044|NCT04943276|Device|Embr Device|The Embr thermal device will be worn at all times from study start to the study endpoint.
79260045|NCT02084303|Other|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
79260046|NCT03253653|Device|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
79722376|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
79856893|NCT00965874|Drug|Placebos|serum salin
79856894|NCT00972426|Drug|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
79856895|NCT00972582|Dietary Supplement|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
79856896|NCT00972660|Biological|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
79260047|NCT02084381|Device|MCO-Ci 400|hemodialysis
79260048|NCT02084381|Device|Revaclear 400|hemodialysis
79260049|NCT03241251|Other|questionnaire|Questionnaire of psychosocial risk factors
80019821|NCT05699915|Procedure|Electrocardiogram|An ECG will be taken prior to each ICI cycle during the first three months of treatment.
79722377|NCT04286854|Diagnostic Test|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
80019822|NCT05699915|Diagnostic Test|Extra serum sample (7.5 mL)|An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
80019823|NCT05683405|Procedure|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
80019824|NCT05683405|Procedure|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
80019825|NCT05676411|Drug|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
79722378|NCT03811912|Drug|CTP-543|CTP-543 administered as 8 mg tablet.
79722379|NCT03811912|Drug|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
80019826|NCT05676411|Procedure|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
80019827|NCT05647369|Dietary Supplement|Mastic mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
80031615|NCT03049696|Behavioral|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
79260050|NCT03253887|Drug|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
79260051|NCT03237663|Biological|The oral O1 / O139 cholera vaccine (enteric capsules)|
79722380|NCT02836561|Other|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
79722381|NCT05333419|Drug|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
79856897|NCT00972660|Drug|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
79722382|NCT04285996|Procedure|PET Scan|
79722383|NCT02836795|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
79722384|NCT04285762|Other|LVEEA|lymphaticovenous end-to-end
79722385|NCT04285762|Other|LVESA|lymphaticovenous end-to-side
79722386|NCT04285762|Other|LVSEA|lymphaticovenous side-to-end
79722387|NCT02836483|Drug|LCB01-0371 800mg, QD|Oral administration
79856898|NCT00961506|Procedure|LESS cholecystectomy|LESS cholecystectomy
79856899|NCT00961506|Procedure|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
79856900|NCT04008966|Drug|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
79397741|NCT01453153|Drug|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
79397742|NCT01453153|Drug|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
79397743|NCT01453153|Drug|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
79397744|NCT04767932|Behavioral|vibration machine|Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
79397745|NCT04113200|Dietary Supplement|MerMed One|A 1 kcal per ml enteral feed containing an alginate.
79722388|NCT02836483|Drug|LCB01-0371 400mg, BID|Oral administration
79722389|NCT02836483|Drug|LCB01-0371 800mg, BID|Oral administration
79722390|NCT02836483|Drug|Tubes 3~5Tablet, QD|Oral administration
79722391|NCT02836483|Drug|Zyvox 600mg, BID|Oral administration
79722392|NCT02836483|Drug|LCB01-0371 1200mg, QD|Oral administration
79856901|NCT04008966|Drug|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
79856902|NCT04008966|Drug|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
79856903|NCT04008966|Drug|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
79856904|NCT04008966|Drug|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
80019828|NCT05647369|Dietary Supplement|Placebo mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
80019829|NCT05633563|Drug|Trimetazidine|Oral intake of capsules
80019830|NCT05633563|Drug|Placebo|Oral intake of capsules
80019831|NCT05627271|Other|ocrelizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
80019832|NCT05627271|Other|natalizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
79559381|NCT03886259|Other|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
79722393|NCT02836171|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
79722394|NCT02836171|Drug|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
79856905|NCT04008966|Drug|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
79856906|NCT04008966|Procedure|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
79856907|NCT04008966|Procedure|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
80019833|NCT05627271|Other|ofatumumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
80019834|NCT05614960|Other|Dried purple laver (Nori)|Dried purple laver (Nori) that has been test to have bioactivity vitamin B12 will be given for intervention groups.
80019835|NCT05611866|Procedure|Fecal Microbiota Transplantation|FMT at Week 0
80019836|NCT05584176|Device|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
80019837|NCT05584176|Device|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
80019838|NCT05576337|Other|16 weeks of strength training protocol|16 weeks of strength training protocol
79260052|NCT02453607|Drug|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
79260053|NCT02453607|Drug|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
79722395|NCT00971932|Drug|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
79722396|NCT00971932|Drug|Cisplatin/Carboplatin|Subjects will receive 100 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 [AUC5]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
79722397|NCT00971932|Drug|5-Fluorouracil|Subjects will receive 1000 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
79722398|NCT02840305|Other|Evaluation of visual function|
79722399|NCT02840305|Other|Magnetic Resonance Imaging|
79260054|NCT02453529|Drug|WCK 4873|Oral tablets
79260055|NCT03241017|Drug|Durvalumab|Immunotherapy with Durvalumab after ASCT
79260056|NCT03240705|Behavioral|Gratitude journaling|Gratitude journaling 3 times a week during surgical rotation
79856908|NCT04008966|Drug|natural Progesterone|400 mg twice daily per vagina
79856909|NCT00425854|Drug|BIBW 2992|high dose once daily
79856910|NCT00961740|Behavioral|Cognitive Behavioural Therapy|See summary
79856911|NCT00961740|Other|Waitlist condition|See Summary
79856912|NCT02771938|Other|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
79856913|NCT00972972|Dietary Supplement|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
79559382|NCT03886259|Other|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
79559383|NCT03881488|Drug|CTX-471|IV infusion every 2 weeks
79559384|NCT03881488|Drug|Pembrolizumab (KEYTRUDA®)|IV infusion every 6 weeks
79559385|NCT03877796|Device|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
79559386|NCT03873207|Device|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
79559387|NCT03873207|Device|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
79559388|NCT03865706|Drug|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
79559389|NCT03865706|Drug|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
79559390|NCT03865706|Drug|Broad-spectrum antibiotics|Standard of care treatment for infections
79722400|NCT00629746|Device|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
79722401|NCT04400929|Drug|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
79856914|NCT00972972|Dietary Supplement|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
79856915|NCT00425698|Drug|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
80019839|NCT05571514|Dietary Supplement|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
80019840|NCT05571514|Dietary Supplement|Calcium Carbonate|Calcium carbonate is a source of calcium.
80019841|NCT05559372|Dietary Supplement|Acute energy drink or placebo consumption|Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
79559391|NCT03860038|Drug|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
79559392|NCT03856216|Procedure|Allogeneic Bone Marrow Transplantation|Given IV
79559393|NCT03856216|Drug|Bendamustine|Given IV
79559394|NCT03856216|Biological|Filgrastim-sndz|Given IV
79559395|NCT03856216|Drug|Fludarabine|Given IV
79559396|NCT03856216|Biological|Inotuzumab Ozogamicin|Given IV
79559397|NCT03856216|Drug|Melphalan|Given IV
79559398|NCT03856216|Procedure|Peripheral Blood Stem Cell Transplantation|Given IV
79856916|NCT00425698|Drug|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
79559399|NCT03856216|Biological|Rituximab|Given IV
79559400|NCT03856216|Drug|Tacrolimus|Given IV and PO
79559401|NCT03848689|Other|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
79559402|NCT03848689|Other|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
79856917|NCT00966030|Drug|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
79856918|NCT00966030|Drug|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
79856919|NCT01037530|Drug|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
79856920|NCT00973050|Drug|Bicalutamide|50 mg Tablet
79856921|NCT00973050|Drug|Casodex®|50 mg Tabelt
79856922|NCT00973128|Drug|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
79856923|NCT00973128|Drug|Meglumine antimoniate|20mg/daily for 20 days
79856924|NCT00966108|Device|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
79856925|NCT00973908|Drug|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
79856926|NCT00973908|Drug|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
79856927|NCT00966342|Drug|Fluviral 2009/10|single dose given IM .05 mL
79856928|NCT00966420|Device|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
79856929|NCT00966498|Procedure|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
79856930|NCT00973986|Drug|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
80019842|NCT05556720|Biological|Pfizer Bivalent COVID-19 Vaccine|One or Two doses three months apart, per manufacturer's recommendations.
80019843|NCT05556720|Biological|Moderna Bivalent mRNA vaccine|One or Two doses three months apart, per manufacturer's recommendations.
79260057|NCT03237741|Drug|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
79260058|NCT03237741|Drug|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
79397746|NCT04113200|Dietary Supplement|Nutricomp Soy Fibre|A 1kcal per ml enteral feed not containing alginate.
79559403|NCT03843957|Other|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients eligible for CRC screening use in primary care clinics to help them receive CRC screening.
79559404|NCT03843957|Other|mPATH-Checkin|The mPATH-CheckIn program includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
79722402|NCT04400929|Other|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
79722403|NCT05170672|Biological|Abatacept|
79722404|NCT02836405|Device|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
79722405|NCT04285138|Other|phantom limb exercise|phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
79722406|NCT04285138|Other|conventional treatment|"Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror [Figure 1]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity"
79856931|NCT00979524|Behavioral|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
79856932|NCT00966576|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
79856933|NCT00425308|Drug|Everolimus + Cyclosporine|
79856934|NCT00425308|Drug|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
79856935|NCT00425308|Drug|Steroids|
79856936|NCT04008888|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
79856937|NCT04008888|Procedure|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
79260059|NCT03237741|Drug|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
79260060|NCT03237585|Behavioral|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
79260061|NCT03253575|Diagnostic Test|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
79260062|NCT03240939|Drug|Dutasteride 0.5 mg|single dose
79397747|NCT01584440|Drug|AVP-923-20|AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
79260063|NCT03240939|Drug|Tadalafil 5 mg|single dose
79260064|NCT03240939|Drug|YY-201|single dose
79397748|NCT01584440|Drug|Placebo|Placebo capsule
79397749|NCT01584440|Drug|AVP-923-30|AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
79397750|NCT01687478|Drug|Olanzapine|Administered Orally
79397751|NCT01687478|Drug|Fluoxetine|Administered Orally
79397752|NCT01687478|Drug|Placebo|Administered Orally
79397753|NCT01468909|Other|Laboratory Biomarker Analysis|Correlative studies
79397754|NCT01468909|Drug|Paclitaxel|Given IV
79397755|NCT01468909|Drug|Pazopanib Hydrochloride|Given PO
79856938|NCT04008888|Drug|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes
79856939|NCT04008888|Drug|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
79856940|NCT04008888|Drug|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
79856941|NCT04008888|Drug|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11&12 of each 21-day.
79856942|NCT01563588|Behavioral|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
80019844|NCT05555485|Device|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
80019845|NCT05555485|Device|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
79260065|NCT03237429|Diagnostic Test|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
79397756|NCT01468909|Other|Placebo|Given PO
79397757|NCT01687166|Device|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
79397758|NCT01687166|Device|FDA Approved Open-Irrigated Ablation Catheter|
79722407|NCT02862652|Other|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
79722408|NCT04284982|Behavioral|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
79260066|NCT02624492|Drug|BI 836826|
79722409|NCT00970684|Biological|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
80019846|NCT05552378|Device|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
79722410|NCT00970684|Drug|docetaxel|75 mg/m2 on day 1
79722411|NCT00970684|Drug|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
79722412|NCT00967330|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
79722413|NCT00967330|Drug|irinotecan|125mg/m2 iv every 2 weeks
80019847|NCT05509309|Behavioral|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
79260067|NCT02624492|Drug|GemOx|
79260068|NCT02624492|Drug|Rituximab|
79260069|NCT02624492|Drug|GemOx|
79397759|NCT01561976|Drug|Metformin hydrochloride prolonged release|1000mg in fasting state
79397760|NCT01561976|Drug|metformin hydrochloride prolonged release|1000mg in fed state
79397761|NCT01561976|Drug|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
79397762|NCT01686932|Drug|Vildagliptin|vildagliptin 50mg BID for 8 weeks
79397763|NCT01686932|Drug|Sitagliptin|sitagliptin 100mg QD for 8 weeks
79397764|NCT01468207|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
79397765|NCT01468207|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
79397766|NCT04530175|Other|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
79397767|NCT03026725|Other|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate & Fluoride
79397768|NCT03026725|Other|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
79397769|NCT01494649|Drug|Test Toothpaste|0.454% stannous fluoride toothpaste
79397770|NCT01494649|Drug|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
79397771|NCT01686152|Drug|Imiquimod Cream, 3.75%|
79397772|NCT01686152|Drug|Zyclara®|
79397773|NCT01686152|Other|Vehicle of Test Product|
79397774|NCT01452919|Drug|LY2140023|Administered orally
79722414|NCT00967330|Drug|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
79722415|NCT02863276|Procedure|Intensified insulin therapy|
79722416|NCT00967018|Drug|Degarelix|
79722417|NCT00965146|Device|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
79722418|NCT02863042|Procedure|Repair Deltoid Tendon|
79722419|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
79722420|NCT04286152|Drug|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
79260070|NCT03240783|Drug|Betamethasone OR Dexamethasone Injectable|Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).
79397775|NCT01452919|Drug|Placebo|Administered orally
79397776|NCT01582178|Procedure|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
79397777|NCT01582178|Procedure|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
80019848|NCT05498389|Drug|EMB-01|EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).
79559405|NCT03843957|Other|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~Clinic champion identified.~Study team meeting with clinic champion~Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~Phone/email technical support, as needed.~Access to web-based QA dashboard~Monthly program usage report sent to clinic champions~Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~Implementation adaptations as needed for clinic flow~Goal-triggered follow-up on-site trainings~Additional on-site trainings as requested.~Months 7 - 12~Phone/email technical support, as needed~Access to web-based QA dashboard"
79722421|NCT04286152|Drug|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
79722422|NCT00966940|Drug|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
79722423|NCT00966940|Drug|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
79722424|NCT00965848|Drug|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
79722425|NCT04284748|Other|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
79722426|NCT04284748|Other|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
79722427|NCT04284748|Other|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
79856943|NCT00966732|Behavioral|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
79856944|NCT01033006|Procedure|Active Comparator: Arm 1: catheter injection|
79856945|NCT01033006|Procedure|Active Comparator: Arm 2: transarterial injection|
79856946|NCT01033006|Procedure|Active Comparator: Arm 3: catheter and transarterial injection|
79856947|NCT00974298|Procedure|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
79856948|NCT01033084|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
79856949|NCT01033084|Drug|Sertraline|Patient will receive sertraline 50mg/day.
79856950|NCT01033084|Other|double placebo|double placebo arm (sham stimulation/placebo pill)
79856951|NCT00979758|Drug|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
80019849|NCT05498389|Drug|Osimertinib|Osimertinib is an approved, third-generation EGFR tyrosine kinase inhibitor
80019850|NCT05467085|Device|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
79260071|NCT03240783|Drug|Normal Saline Flush, 0.9% Injectable Solution|Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
79260072|NCT03240783|Drug|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.
79397778|NCT01561898|Drug|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
79397779|NCT01685840|Other|Usual Care|Usual Care
79397780|NCT01685840|Device|Biomarker-guided care NT-proBNP|Device: NT-proBNP
79856952|NCT01672060|Behavioral|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
79559406|NCT03843957|Other|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~Phone/email technical support, as needed.~Access to web-based QA dashboard~Months 7 - 12~Phone/email technical support, as needed~Access to web-based QA dashboard"
80019851|NCT05462782|Device|Transcranial Magnetic Stimulation (TMS) Cone Coil|The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
80019852|NCT05462782|Device|Transcranial Magnetic Stimulation (TMS) Sham Coil|The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
79260073|NCT03240783|Other|Sham Injection and/or oral placebo|The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
79397781|NCT01452529|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
79397782|NCT01452529|Drug|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
79397783|NCT01685606|Biological|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
79559407|NCT03838107|Behavioral|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
79559408|NCT03837483|Genetic|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
79559409|NCT03833154|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met.
79559410|NCT03833154|Other|Placebo|Matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met.
79559411|NCT03833154|Drug|Osimertinib (single-arm, open-label)|Osimertinib 80 mg every day [qd] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
79559412|NCT03823144|Device|Diagnostic Microscopy|Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
79559413|NCT03823144|Drug|Fluorescein Sodium Injection|Given IV as part of IVM procedure
79559414|NCT03815045|Procedure|Landmark-based lumbar puncture|Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.
79559415|NCT03815045|Procedure|Ultrasound-guided lumbar puncture|Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
79559416|NCT03813147|Drug|Azacitidine|Given IV
79559417|NCT03813147|Drug|Cytarabine|Given intrathecally and IV
79559418|NCT03813147|Drug|Fludarabine Phosphate|Given IV
79559419|NCT03813147|Drug|Methotrexate|Given intrathecally
79559420|NCT03813147|Drug|Pevonedistat|Given IV
79559421|NCT03813147|Drug|Therapeutic Hydrocortisone|Given intrathecally
79559422|NCT03798782|Procedure|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
79559423|NCT03798782|Procedure|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
79260074|NCT03240393|Drug|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and < 6 cMET mutations
79260075|NCT04955054|Diagnostic Test|diagnose|Patients from UAP and AMI meet the criteria of UAP or STEMI.
79260076|NCT04942808|Radiation|Periapical radiographs|Periapical radiographs on reevaluation
79260077|NCT03237507|Drug|S-1|40-60mg/m^2 bid, days 1-14, oral，every 3 weeks.
79260078|NCT03237507|Drug|oxaliplatin|100mg/m^2 days 1，intravenous infusion, every 3 weeks.
79397784|NCT01685372|Biological|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
79397785|NCT01685372|Biological|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
79856953|NCT01672060|Behavioral|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
80019853|NCT05459363|Other|I-THINC|Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
80019854|NCT05458531|Other|Questionnaire|A single questionnaire
80019855|NCT05458531|Other|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
80019856|NCT05438771|Combination Product|Ankaferd Blood Stopper|mouth wash
80019857|NCT05438771|Other|Bicarbonate|mouth wash
79260079|NCT03237507|Device|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
80019858|NCT05437458|Other|Delirium (exposure)|No interventions.
80019859|NCT05434871|Other|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
80019860|NCT05434871|Other|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
80019861|NCT05417568|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
80019862|NCT05417568|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
79260080|NCT03237507|Drug|Paclitaxel|intraperitoneal perfusion
79559427|NCT03772977|Behavioral|Brain Health Champion|A health coach embedded within an existing clinical care team
79559428|NCT03771534|Drug|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
79559429|NCT03768440|Procedure|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
79559430|NCT03768440|Procedure|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
79559431|NCT03768440|Drug|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
79559432|NCT03767582|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
79559433|NCT03767582|Drug|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
79559434|NCT03767582|Drug|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
79559435|NCT03767582|Drug|GVAX|Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
79559439|NCT03739931|Biological|mRNA-2752|Solution for intratumoral injection
79856954|NCT00545064|Drug|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
79260081|NCT04945226|Drug|Finasteride 1mg Tablet|Propecia Tablet 1mg
79260082|NCT04945226|Drug|IVL3001|Finasteride long acting injection
79260083|NCT03253419|Other|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
79260084|NCT01975831|Drug|Durvalumab|Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
79559440|NCT03739931|Biological|Durvalumab|Solution for infusion after dilution
79559441|NCT03739775|Procedure|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
79559442|NCT03698461|Drug|Atezolizumab|"1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
79559443|NCT03698461|Drug|Bevacizumab|5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
79856955|NCT01034332|Procedure|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
79260085|NCT01975831|Drug|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
79559444|NCT03698461|Drug|Oxaliplatin|85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
79559445|NCT03698461|Drug|Levoleucovorin|200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
79559446|NCT03698461|Drug|5-FU|"5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
79559447|NCT03691207|Drug|AL101|"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously"
79559448|NCT03688139|Behavioral|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
79559449|NCT03688139|Behavioral|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
79559450|NCT03677739|Other|Informational Intervention|Receive information focusing on skin cancer
79722428|NCT03447574|Other|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
79722429|NCT04284826|Procedure|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
79722430|NCT04284670|Other|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
79856956|NCT00979836|Drug|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
79856957|NCT01588912|Drug|Telbivudine|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
79856958|NCT01588912|Drug|Tenofovir|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
79856959|NCT01588912|Drug|Entecavir|Maintain the entecavir through the study period
79260086|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
79260087|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
79260088|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
79260089|NCT04945070|Drug|IGlarLixi|Switching T2DM subjects from MDI to iGlarLixi
79260090|NCT04945070|Drug|MDI - Multiple dose insulin injection|Continuing with established MDI regimen
79260091|NCT04944914|Drug|camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy
79397786|NCT01685216|Biological|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
79397787|NCT01685138|Drug|LDK378|LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
79559451|NCT03677739|Other|Informational Intervention|Receive information on healthy lifestyle
79559452|NCT03677739|Other|Survey Administration|Ancillary studies
79559453|NCT03667170|Biological|KN035|subcutaneous injection
79559458|NCT03630224|Drug|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
79559459|NCT03630224|Drug|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
79856960|NCT00966810|Procedure|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
79856961|NCT00966888|Procedure|standard follow-up care|No intervention
79856962|NCT00966888|Radiation|radiation therapy|Chest wall radiotherapy
79856963|NCT00974454|Drug|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
79856964|NCT00974454|Drug|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
79559460|NCT03621137|Other|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
79722431|NCT03442192|Other|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
79722432|NCT04284904|Diagnostic Test|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
79722433|NCT04284592|Procedure|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
79722434|NCT04204564|Device|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
79722435|NCT04285528|Drug|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
79856965|NCT00432562|Drug|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
79559461|NCT03599765|Other|Best Practice|Receive routine therapy
79856966|NCT00966966|Drug|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
79856967|NCT00979914|Other|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
79856968|NCT00974532|Dietary Supplement|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
79856969|NCT00974532|Dietary Supplement|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
79856970|NCT00980070|Device|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
79856971|NCT00980070|Device|Lumbar Puncture Device|Lumbar Puncture positioner
79856972|NCT00980070|Other|Standard of Care|Lumbar Puncture positioner
79856973|NCT00432172|Drug|Epirubicin|
79856974|NCT00432172|Drug|Cyclophosphamide|
79260092|NCT04944914|Radiation|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.
79260093|NCT03240471|Procedure|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
79856975|NCT00432172|Drug|Docetaxel|
79856976|NCT00432172|Drug|Exemestane|
79856977|NCT00432172|Drug|Goserelin|
79856978|NCT00432172|Drug|Carboplatin|
79856979|NCT01034410|Drug|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
79856980|NCT01034410|Drug|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
79260094|NCT03240471|Procedure|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
79559462|NCT03599765|Procedure|Local Consolidation Therapy|Receive LCT
79559463|NCT03599752|Drug|Chemotherapy|Receive chemotherapy
79559464|NCT03599752|Procedure|Metastasectomy|Undergo pulmonary metastasectomy
79559465|NCT03599219|Biological|sample|confirmation of platelet dysfunction
79856981|NCT01034488|Biological|Suine|5000UI /mL
79856982|NCT01034488|Biological|Suine|5000UI/mL
79260095|NCT04942652|Drug|Itraconazole 200 mg|Itraconazole 100 mg capsule x 2
79260096|NCT04942652|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg tablet x 1
79559466|NCT03598244|Procedure|Biospecimen Collection|Undergo blood sample collection
79559467|NCT03598244|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79559468|NCT03598244|Drug|Savolitinib|Given PO
79559469|NCT03598244|Procedure|X-Ray Imaging|Undergo X-ray imaging
79856983|NCT00415168|Drug|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
79260097|NCT03253497|Drug|Chlorobenzene Liquid|before induction will be used for oropharynx
79260098|NCT04942418|Other|Multicolor hybrid ceramic laminate veneers.|Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
79397788|NCT01685060|Drug|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
79397789|NCT01582100|Device|Reletex|Neuromodulation device worn on the wrist
79722436|NCT04285528|Combination Product|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
79722437|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
79856984|NCT00415168|Drug|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
79856985|NCT01034566|Radiation|Proton Beam Radiation Therapy|
79856986|NCT00424762|Drug|rosiglitazone|6 months of treatment of blinded study drug
79856987|NCT00424762|Drug|placebo|blinded treatment with matching placebo
79856988|NCT00967122|Procedure|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
79856989|NCT00967200|Other|laboratory biomarker analysis|laboratory biomarker analysis
79397790|NCT01579916|Biological|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
79559472|NCT03583866|Drug|Candesartan|7 days of Candesartan (16mg/day)
79559473|NCT03583866|Drug|Placebo|7 days of Placebo
79559474|NCT03560752|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given via injection
79856990|NCT00967200|Other|pharmacogenomic studies|pharmacogenomic studies
79856991|NCT00974688|Behavioral|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
79856992|NCT00974688|Behavioral|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
79856993|NCT00967356|Drug|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
79856994|NCT00967356|Drug|Placebo|Oral suspension
79856995|NCT00980304|Drug|Rituximab|
79856996|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
79856997|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
79856998|NCT00980382|Drug|S-1, Docetaxel|"Phase I study~S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~Phase II study~S-1 (80mg/m2/day) q 12 hours po Days 1-14~Docetaxel (35 mg/m2) iv : Days 1, 8"
79856999|NCT00967434|Drug|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
79260099|NCT04942418|Other|Multicolor fieldspathic ceramic laminate veneers.|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
79260100|NCT03240549|Drug|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
79260101|NCT04933292|Drug|Methylprednisolone and Mycophenolate mofetil|Methylprednisolone combination of mycophenolate mofetil
79260102|NCT04933292|Drug|Methylprednisolone and azathioprine|Methylprednisolone combination of azathioprine
79260103|NCT04942496|Drug|Chlorhexidine Gluconate|Antimicrobial Skin Wash
79397791|NCT01579916|Other|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
79260104|NCT04942496|Device|Hibi Universal Bathing System|Cloths used for patient bathing
79260105|NCT04942496|Other|0.1% SLS|Positive control
79260106|NCT04942496|Other|Distilled Water|Negative Control
79559475|NCT03555331|Behavioral|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
80019863|NCT05401461|Other|Evening mobilisation|Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
79559476|NCT03555331|Behavioral|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
79260107|NCT03237039|Radiation|X-ray examination|Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.
79857000|NCT00967434|Drug|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
79722438|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
79857001|NCT00967434|Drug|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
79857002|NCT00967512|Drug|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
79857003|NCT00967512|Drug|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
79857004|NCT00967512|Drug|idarubicin, cytarabine|idarubicin, cytarabine
79260108|NCT03237039|Other|fall-risk assessment|This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.
79559477|NCT03511664|Drug|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
79559478|NCT03511664|Other|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
79559479|NCT03508232|Drug|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
79857005|NCT00414544|Device|CosmetaLife|Dermal filler
79397792|NCT04410458|Behavioral|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
79397793|NCT01684202|Drug|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
79397794|NCT01684046|Device|Opti-Free® PureMoist® MPDS|
79722439|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
79857006|NCT00414544|Device|Restylane|Dermal filler
79857007|NCT04082910|Drug|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
79397795|NCT01684046|Device|RevitaLens MPDS|
79397796|NCT01684046|Device|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
79397797|NCT01559090|Drug|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
79722440|NCT04285216|Other|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
79722441|NCT04285216|Other|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
79722442|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
79857008|NCT04082910|Drug|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
80019864|NCT05400291|Diagnostic Test|Chondroitin Sulfate Staining|Staining of histopathological slides
79857009|NCT01618786|Other|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
80019865|NCT05384379|Drug|Inhaled BZ371B|Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.
80019866|NCT05382962|Behavioral|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
80019867|NCT05380284|Other|Senior Driving Simulation Training|The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .
80019868|NCT05380284|Other|Waiting list control|The control group is waiting list control. They will also receive the (Senior Driving Simulation Training) after all research is done.
80019869|NCT05375604|Drug|CDK-004|ASO-STAT6 exosome administered Intravenously
80019870|NCT05375201|Other|VR skateboarding training|The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
79260109|NCT03237039|Other|gait cycle analysis|This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
79559480|NCT03508232|Drug|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
79722443|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
79722444|NCT00961636|Drug|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
79722445|NCT00961636|Drug|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
79722446|NCT04285060|Device|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
79857010|NCT01618786|Other|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
79857011|NCT00967590|Drug|RO5036505|380mg iv infusion once weekly for 8 weeks
79857012|NCT00967590|Drug|placebo|iv infusion once weekly for 8 weeks
80019871|NCT05368038|Diagnostic Test|Confirmatory Testing|All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
79260110|NCT04932668|Other|Feasibility and Impact of Home-based Electrical Stimulation Program|"Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion."
79559481|NCT03503630|Drug|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
79559482|NCT03503630|Radiation|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
79559483|NCT03503630|Drug|mFOLFOX|Given every 2 weeks for 6 cycles
79559484|NCT03503630|Procedure|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
79559485|NCT03489707|Behavioral|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
79559486|NCT03489707|Behavioral|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
79722447|NCT02862262|Device|ARIES Bordetella Assay|
79722448|NCT02862340|Genetic|Genetic test|
79722449|NCT04283422|Diagnostic Test|Biofire filmarray|"Identification of microorganisms including:~Isolation of microorganisms:~The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~Identification of the organism by Vitek2~Antibiotic sensitivity test of the organism by Vitek2~Identification of the organism by Biofire filmarray"
79559487|NCT03489252|Device|Monitoring Device|Wear Fitbit Charge 3
79559488|NCT03479671|Drug|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
79559489|NCT03478488|Drug|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
79559490|NCT03478488|Drug|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
79857013|NCT00975078|Procedure|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
79857014|NCT00975078|Drug|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
79857015|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
79857016|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
79857017|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
79260111|NCT03240159|Drug|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
79260112|NCT04942262|Drug|denture adhesive (Polident®, GlaxoSmithKline, Ireland)|cream-type denture adhesive available as an over-the-counter product in Thailand
79260113|NCT03253185|Drug|SC-007|intravenous
79260114|NCT03237117|Biological|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
79260115|NCT04944758|Device|Light therapy|Light therapy
79260116|NCT03239691|Drug|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
79722450|NCT00964678|Drug|Carvedilol|twice daily oral treatment in escalating dose
79722451|NCT00964366|Drug|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
79857018|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
79260117|NCT03239691|Drug|Placebo|Matching placebo available as matching capsules for oral administration
79260118|NCT04944446|Other|Treatment|Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
79722452|NCT00964366|Drug|Dapsone gel|Twice-daily applications of dapsone gel
79722453|NCT02861326|Device|Gracey Curettes|
79722454|NCT02861404|Genetic|skin flakes collection|viral status assessment of skin flakes
79722455|NCT03523702|Drug|PembroRT|Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.
79260119|NCT03237195|Other|additional soft tissue in neck dissections|Evaluation of submission of additional soft tissue in neck dissections for head and neck squamous cell carcinomas
79260120|NCT04945382|Device|Scotchbond Universal 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
79260121|NCT04945382|Device|Single Bond 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
79722456|NCT03523702|Drug|ChemoRT|Patients whose tumors are found to have low (< 50%) PD-L1 expression will automatically be placed in the ChemoRT group. These patients will receive radiotherapy over a course of four to seven weeks. During radiotherapy, patients will also receive two standard chemotherapy agents (carboplatin and paclitaxel) once each week. Following completion of chemotherapy and radiotherapy, patients may receive additional treatments with chemotherapy or immunotherapy as part of routine care. These treatments are optional and are not required by this clinical trial.
79722457|NCT04284514|Drug|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
79722458|NCT04284514|Drug|Placebo Ophthalmic Solution|Matched vehicle-control
79857019|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
79857020|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
79857021|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
79260122|NCT04944602|Biological|SYN008|injection of 300 mg
79260123|NCT04944602|Biological|Omalizumab for injection|injection of 300 mg
79559499|NCT03460769|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
79722459|NCT02861248|Procedure|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
79722460|NCT04283344|Other|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
79722461|NCT02860078|Device|Ultrasound|Location and function of sacral epidural space with ultrasound
79857022|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
79857023|NCT04007016|Procedure|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
79857024|NCT00980616|Drug|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
79857025|NCT00980694|Dietary Supplement|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
79857026|NCT00980850|Biological|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
79857027|NCT00980850|Biological|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
80019872|NCT05357742|Behavioral|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
80019873|NCT05357742|Behavioral|Enhanced usual care|During each session participants will receive DKD education only.
79397798|NCT01559090|Drug|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
79260124|NCT03237273|Other|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
79397799|NCT01559090|Drug|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
79397800|NCT01683266|Drug|HOE901-U300 (Insulin glargine new formulation)|
80019874|NCT05357118|Behavioral|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
79260125|NCT03237351|Device|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
79260126|NCT03253029|Dietary Supplement|Pure Encapsulations Branched Chain Amino Acid powder|
79260127|NCT03253029|Dietary Supplement|control group (no BCAAs provided)|
79308686|NCT04834323|Procedure|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum & mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum & mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
79397801|NCT01683266|Drug|Lantus (Insulin glargine)|
79559500|NCT03457194|Biological|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
79559501|NCT03457194|Biological|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
79857028|NCT00414466|Drug|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
79857029|NCT00975234|Procedure|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
80019875|NCT05338463|Drug|Fespixon Cream|"Name : Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 20 weeks"
80019876|NCT05334056|Drug|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
80019877|NCT05328414|Drug|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
79722462|NCT02860078|Device|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
79260128|NCT04921748|Procedure|Neurorehabilitation|All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
80019878|NCT05316181|Procedure|HIPEC|HIPEC perfusion, doxorubicin 35mg/m2 & mitomycin 15 mg/m2, 41.5'C, 90 min.
79260129|NCT03253107|Drug|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
80019879|NCT05298085|Drug|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
79559502|NCT03433456|Behavioral|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
79559503|NCT03433456|Behavioral|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
79559504|NCT03419260|Other|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
80019880|NCT05298085|Drug|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
79722463|NCT02859922|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
79722464|NCT02859922|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
79722465|NCT02860936|Drug|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
80019881|NCT05295693|Device|Correlation of the Quantra with the TEG|"The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB.~The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device."
79260130|NCT03239847|Other|EndoPhys Sheath and Radial Arterial Line|
79260131|NCT03239847|Other|EndoPhys Sheath|
79260132|NCT03252717|Biological|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~Three 6 ml EDTA samples for proteomic and genomic work package~One 6 ml dry sample for auto-antibodies analysis in the immunology work package~Two 4 ml EDTA samples for DNA extraction in the immunology work package~Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
79397802|NCT01467661|Drug|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
79397803|NCT01577186|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
79397804|NCT01559012|Drug|Clonidine|transdermal clonidine patch 5 mg q. 5 days
79397805|NCT01451827|Drug|Tolvaptan MR|50/80 mg capsules
79397806|NCT01451827|Drug|Tolvaptan IR|60/30 mg capsules
79397807|NCT01451827|Drug|Placebo|tablet
79397808|NCT01557920|Drug|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
79857030|NCT00975234|Procedure|Revascularisation|Revascularisation surgery
79857031|NCT00984750|Drug|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
79857032|NCT00984750|Drug|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
80019882|NCT05291598|Drug|Institution specific joint replacement pain protocol|"Participants will be treated with a standard orthopaedic joint replacement protocol which includes:~Dexamethasone~Tylenol~Lyrica~Celebrex~Meloxicam~Oxycodone"
80019883|NCT05291598|Drug|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
80019884|NCT05291598|Drug|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
80019885|NCT05277779|Diagnostic Test|cardiac magnetic resonance(CMR)|CMR was performed to assess myocardial tissue characteristics in the study population
79397809|NCT01557920|Drug|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
80019886|NCT05272709|Drug|TT-702|TT-702 will be administered orally, once daily, for up to 12 months.
79722466|NCT04283266|Dietary Supplement|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
79397810|NCT04408261|Drug|Buqitongluo Granule|Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
79260133|NCT03239925|Radiation|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
79260134|NCT03239925|Radiation|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
79397811|NCT04408261|Drug|Buqitongluo Granule Placebo|Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
79397812|NCT04408261|Other|Standard care|Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
79397813|NCT01688882|Drug|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
79397814|NCT01688882|Drug|Placebo|Placebo will be used to control for normal variability in disease severity.
79397815|NCT01467583|Drug|Fondaparinux|2.5 mg every 48 hours
79397816|NCT01576718|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
79559505|NCT03412812|Radiation|Dose Escalated Five Fraction Stereotactic Radiosurgery|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
79722467|NCT04283266|Dietary Supplement|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
79722468|NCT04281550|Other|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
80019887|NCT05267678|Other|No intervention|This is an observational study without any intervention
79397817|NCT01576718|Other|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
79397818|NCT01576718|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
79559506|NCT03399981|Biological|Tysabri|Administered as specified in the treatment arm.
79260135|NCT04941014|Behavioral|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
79260136|NCT04941014|Behavioral|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
79260137|NCT04941014|Behavioral|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
79260138|NCT03239769|Procedure|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
79260139|NCT03236883|Drug|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
79260140|NCT03236883|Other|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)*10^8/kg,once a month,repeated every 4weeks,three times in all.
79397819|NCT01576718|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
79397820|NCT03028610|Device|radiofrequency generator|
79397821|NCT01493557|Drug|pantoprazole|40 mg q.a.m, p.o.
79397822|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
79260141|NCT03236961|Drug|Ertapenem|I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
79260142|NCT03236961|Drug|Moxifloxacin|P.o. moxifloxacin 400 mg x1 for 7 days
79260143|NCT04921826|Other|online survey|online survey
79260144|NCT03235323|Device|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
79260145|NCT04921592|Other|upper extremity stimulation|transcutaneous stimulation of the upper extremities
79260146|NCT03239301|Procedure|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
79559513|NCT03382561|Drug|Carboplatin|Given IV
79559514|NCT03382561|Drug|Cisplatin|Given IV
79559515|NCT03382561|Drug|Etoposide|Given IV
79559516|NCT03382561|Biological|Nivolumab|Given IV
79559517|NCT03376438|Other|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
79559518|NCT03372057|Drug|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
79559519|NCT03372057|Drug|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
79559520|NCT03372057|Drug|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
79397823|NCT01493557|Drug|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
79397824|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
79397825|NCT01451749|Drug|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
79559521|NCT03367754|Other|Placebo|Placebo
79559522|NCT03367754|Drug|Pembrolizumab|Pembrolizumab, 200 mg, or placebo via intravenous (IV) infusion, single dose.
79559523|NCT03339349|Drug|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
79722469|NCT00630214|Dietary Supplement|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
79260147|NCT03239301|Procedure|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
79308687|NCT04851951|Procedure|one-shot PRP injection|A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
79397826|NCT01451749|Drug|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
79559524|NCT03334006|Drug|Pentaglobin®/Standard of Care|Standard of Care treatment + Pentaglobin®
79559525|NCT03325855|Other|None - Observational|None - Observational
79559527|NCT03300648|Other|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
79559528|NCT03300648|Drug|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
79559529|NCT03289962|Drug|Autogene cevumeran|Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
79559530|NCT03289962|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
79559531|NCT03278548|Drug|Volulyte 6%|Solution for infusion
79559532|NCT03278548|Drug|Ionolyte|Solution for infusion
79559533|NCT03246984|Device|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
79559534|NCT03245489|Drug|Pembrolizumab|200mg intravenous (IV) over 30 minutes
79722470|NCT00630214|Dietary Supplement|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
79722471|NCT04204486|Behavioral|Exercise|Functional strength training, 1 hour, 3 times a week.
80019888|NCT05253261|Diagnostic Test|Preoperative Cone Beam Computed Tomography (CBCT) scan|CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).
79559535|NCT03245489|Drug|Clopidogrel|75mg/day oral
79559536|NCT03245489|Drug|acetylsalicylic acid|81mg/day oral
79260148|NCT04932044|Behavioral|Early Sleep Facilitation Program|It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
79260149|NCT04932044|Other|Routine care|Receives routine care and provide general discharge care and nursing guidance.
79722472|NCT04284358|Other|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
79722473|NCT02859766|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
79875603|NCT00948467|Drug|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
79875604|NCT03958955|Drug|Delgocitinib cream|Cream for topical application.
79875605|NCT03958955|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
79397827|NCT01576484|Drug|Alirocumab|Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
79397828|NCT01576484|Drug|Placebo Matched to Alirocumab|Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
79397829|NCT01467505|Drug|Telaprevir|Tablet
79722474|NCT04282798|Other|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
79722475|NCT02862028|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
79397830|NCT01467505|Drug|Ribavirin|Tablet
79397831|NCT01467505|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
79559545|NCT03197922|Behavioral|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement."
79559546|NCT03197922|Drug|Glycerin Suppository|If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
79559547|NCT03197922|Combination Product|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
79559548|NCT03177460|Biological|Daratumumab|Given IV
79559549|NCT03177460|Drug|FMS Inhibitor JNJ-40346527|Given PO
79559550|NCT03177460|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
79559551|NCT03152409|Drug|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
79559552|NCT03152409|Drug|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
79559553|NCT03110770|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
79559554|NCT03110770|Other|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
79559555|NCT03110354|Drug|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
79559556|NCT03109080|Drug|Olaparib|five levels of dose, per os administration, twice daily each day
79559557|NCT03109080|Radiation|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
79559558|NCT03073811|Dietary Supplement|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
79559559|NCT03073811|Other|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
79722476|NCT02860858|Biological|Intravitreous aflibercept injection|
79722477|NCT00960154|Device|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
79722478|NCT00960154|Procedure|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
79722479|NCT02861170|Behavioral|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
79722480|NCT00960076|Drug|Saxagliptin|5mg oral tablet once daily
79722481|NCT00960076|Drug|Metformin XR|500mg oral tablet once daily
79722482|NCT00960076|Drug|Metformin XR|750mg, 2 tablets once daily
79277442|NCT03529279|Radiation|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
79397832|NCT01467505|Drug|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
79397833|NCT01449929|Drug|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
79559560|NCT03040115|Other|Non-Interventional Study|
79559561|NCT03026998|Procedure|MRI|MRI will be performed each year during 10 years.
79722483|NCT02859688|Genetic|pyrosequencing|
79277443|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
79397834|NCT01449929|Drug|darunavir 800mg OAD|2 x 400mg tablets OAD
79397835|NCT01449929|Drug|ritonavir 100mg OAD|1 x 100mg tablet OAD
79397836|NCT01449539|Drug|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
79559562|NCT03016819|Drug|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
79722484|NCT02859688|Genetic|Methylome|
79722485|NCT04281082|Drug|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
79397837|NCT01451515|Drug|Prednisone|Given orally (PO).
79397838|NCT01451515|Drug|Vincristine|Given intravenously (IV).
79722486|NCT04284202|Drug|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
79722487|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79722488|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79722489|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79260150|NCT05234619|Drug|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
79875606|NCT00951119|Device|Resperate|device-guided breathing exercises
80019889|NCT05253261|Procedure|tooth removal and cystostomy|Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.
80019890|NCT05253261|Procedure|Decompression|The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.
79260151|NCT05234619|Drug|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
79260152|NCT05234619|Drug|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
79559563|NCT03016819|Drug|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
79559564|NCT03016819|Drug|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
79559565|NCT03016377|Biological|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10^5), dose level 1 (5 x 10^5), and dose level 2 ( 1x 10^6)
79559566|NCT03016377|Drug|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
79559567|NCT03016377|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
79722490|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79722491|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79722492|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79722493|NCT01227629|Drug|warfarin|comparator
80019891|NCT05253261|Diagnostic Test|Postoperative Cone Beam Computed Tomography (CBCT) scan|Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.
80019892|NCT05253261|Procedure|Cyst Enucleation|Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
80019893|NCT05239026|Behavioral|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
80019894|NCT05239026|Behavioral|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
79722494|NCT01227629|Drug|dabigatran without ASA|dose comparison
79722495|NCT01227629|Drug|dabigatran without ASA|dose comparison
79722496|NCT01227629|Drug|dabigatran without ASA|dose comparison
79875607|NCT00951119|Device|Resperate|breathing device without slowing of breathing frequency
79875608|NCT00464334|Biological|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
80019895|NCT05225480|Behavioral|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
80019896|NCT05225480|Behavioral|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
80019897|NCT05202379|Drug|CC-42344|CC-42344 capsules
80019898|NCT05202379|Drug|Placebo|Placebo capsules
80019899|NCT05202340|Other|No intervention|No intervention
79260153|NCT05234619|Drug|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
79559568|NCT03016377|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
79559569|NCT03012230|Other|Laboratory Biomarker Analysis|Correlative studies
79722497|NCT00963820|Drug|Ixazomib citrate|Ixazomib citrate capsules
79722498|NCT03241186|Drug|Ipilimumab|1mg/kg
79722499|NCT03241186|Drug|Nivolumab|3mg/kg
79722500|NCT03241186|Drug|Nivolumab|480mg
79722501|NCT01227395|Drug|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
79722502|NCT02859532|Radiation|elastography SWIRE|
79875609|NCT00464334|Biological|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
79875610|NCT00464334|Biological|Placebo to V950|
79875611|NCT00951197|Other|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
79875612|NCT00951431|Drug|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
79875613|NCT00951431|Drug|Placebo|Placebo in the form of study drug
79722503|NCT04319003|Behavioral|Sugar-reduction intervention|The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
79559570|NCT03012230|Biological|Pembrolizumab|Given IV
79260154|NCT04921904|Drug|Abemaciclib|150mg dose administered orally twice daily every day
79559571|NCT03012230|Drug|Ruxolitinib Phosphate|Given PO
79260155|NCT04921904|Drug|Ramucirumab|8mg/kg iv every 2 weeks until evidence of disease
79559572|NCT02996227|Procedure|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
79559573|NCT02996227|Procedure|Epidural analgesia|Epidural catheters will be inserted preoperatively.
79559574|NCT02996227|Drug|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
79722504|NCT04281238|Other|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
79857033|NCT01033162|Behavioral|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~Reduce patients' negative affect and increase their emotional well being~Improve patients' sense of social support~Improve patients' health self-efficacy~Improve patients' ratings of experience with cancer specialty care services~Improve patients' health related quality of life (HRQL)~Improve clinicians' ratings of quality of patient contacts~Reduce healthcare utilization and costs (obtained via the EMR)"
79260156|NCT03234933|Other|Mobility Tracker|Tracking Patient's movements and calories
79260157|NCT02622386|Drug|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
79260158|NCT02622386|Other|Placebo|Matching placebo capsule taken daily for 12 weeks.
79260159|NCT02453451|Other|2D-/3D-TTE|recording of 3 cardiac cycles
79260160|NCT02453451|Other|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
79260161|NCT02453451|Other|Walking Test|for 6 minutes
79260162|NCT02453451|Procedure|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
79260163|NCT03120195|Device|The EndoRotor®|The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
79260164|NCT04430114|Device|branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms|"Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts."
79559575|NCT02996227|Drug|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
79559576|NCT02966548|Drug|Relatlimab|Specified dose on specified days
79722505|NCT04281238|Other|Control group|Home exercises 5 days a week for 8 weeks
79722506|NCT02859376|Dietary Supplement|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
79722507|NCT04283032|Procedure|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
79722508|NCT01226459|Drug|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
79722509|NCT01226459|Drug|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
79857034|NCT00975312|Drug|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
79857035|NCT00975312|Drug|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
79857036|NCT00984906|Other|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
79559577|NCT02966548|Drug|Nivolumab|Specified dose on specified days
79559578|NCT02948400|Behavioral|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
79559579|NCT02875652|Biological|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
79559580|NCT02875548|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
79559581|NCT02866136|Drug|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
79260165|NCT04427618|Drug|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
79260166|NCT04427618|Drug|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
79260167|NCT03236727|Drug|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
79260168|NCT03229161|Behavioral|IWT-group|
79559582|NCT02866136|Drug|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
80019900|NCT05198375|Diagnostic Test|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
79559583|NCT02866136|Drug|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
79559584|NCT02866136|Drug|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
79559585|NCT02866136|Device|Laser (local treatment)|
79857037|NCT00424528|Drug|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
80019901|NCT05190432|Dietary Supplement|Taxifolin|A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
79559586|NCT02866136|Device|cryoapplication (local treatment)|
79559587|NCT02866136|Radiation|I125 radioactive plaques (local treatment)|
79559588|NCT02866136|Drug|intravitreal Melphalan (local treatment)|
79260169|NCT04921202|Other|Metabolic syndrome and meniscus injuries|Metabolic syndrome
79260170|NCT03236493|Drug|PF-06700841|PF-06700841 will be administered as tablet
79260171|NCT03236493|Drug|Placebo|Matching placebo will be administered as tablet
79559589|NCT02853500|Device|TriNav|TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
79559590|NCT02853500|Device|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
79559591|NCT02853500|Drug|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
79559592|NCT02851940|Procedure|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
79559593|NCT02851940|Procedure|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
79722510|NCT01225991|Drug|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
79722511|NCT00959374|Device|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
79722512|NCT00959374|Device|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
79857038|NCT00424528|Drug|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
79857039|NCT00424528|Drug|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
79857040|NCT00424528|Drug|Placebo|Placebo inhalation solution and placebo inhalation powder
79857041|NCT04974996|Drug|Loncastuximab tesirine|Intravenous (IV) infusion
79857042|NCT04974996|Drug|Prednisone|Orally via tablet or capsule
79857043|NCT04974996|Drug|Rituximab|Intravenous (IV) infusion
79857044|NCT04974996|Drug|Cyclophosphamide|Intravenous (IV) infusion
79857045|NCT04974996|Drug|Doxorubicin|Intravenous (IV) infusion
79260172|NCT04921280|Behavioral|Internet based Cognitive Behavioural Therapy|"The treatment program consists of 12 chapters or modules spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures."
79260173|NCT03234855|Device|LMD|Physician uses LMD to measure defect during procedure.
79260174|NCT04931966|Procedure|block|Adductor canal block
79260175|NCT04931966|Procedure|adductor canal block|adductor canal block bupivacain
79260176|NCT04931966|Procedure|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using bupivacaine
79559594|NCT02849145|Biological|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
79559595|NCT02842723|Radiation|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
79559596|NCT02841371|Radiation|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
79559597|NCT02840409|Drug|Vinblastine|
79559598|NCT02840409|Drug|Bevacizumab|
79559599|NCT02839473|Device|Castalie water spray|
79559600|NCT02839473|Device|Hydrogel Hydrosorb®|
79559601|NCT02834494|Procedure|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
79559602|NCT02834494|Biological|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
79559603|NCT02831634|Procedure|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
79857046|NCT04974996|Drug|Vincristine|Intravenous (IV) infusion
80019902|NCT05190432|Dietary Supplement|Ergothioneine|An amino acid found in mushrooms, oats and some bean varieties.
80019903|NCT05190432|Dietary Supplement|Control|Microcrystalline cellulose.
80019904|NCT05167318|Other|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
79559604|NCT02772562|Biological|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
79559605|NCT02768337|Drug|Afatinib|
79722513|NCT02859298|Device|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
79857047|NCT00981006|Procedure|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
79857048|NCT00975390|Dietary Supplement|Carbohydrate|1.2 g/kg/h
79857049|NCT00975390|Dietary Supplement|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
79559606|NCT02768337|Radiation|2 Gy targeted radiotherapy|
79722514|NCT04283110|Drug|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
79857050|NCT00975390|Dietary Supplement|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
79260177|NCT04931966|Procedure|adductor Canal Block plus PAI Block|Adductor Canal Block plus PAI Block using bupivacaine
79260178|NCT03229005|Procedure|implant insertion|during surgery soft tissues will be measured
79559607|NCT02768337|Radiation|4 Gy targeted radiotherapy|
79559608|NCT02747589|Procedure|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
79559609|NCT02695628|Drug|18F-Fluoromisonidazole|Undergo [18F] FMISO PET/CT
79722515|NCT02859610|Other|research on interactions between portal hypertension and microparticles|
79559610|NCT02695628|Procedure|Arterial Embolization|Undergo transcatheter arterial embolization
79559611|NCT02695628|Diagnostic Test|Computed Tomography|Undergo [18F] FMISO PET/CT
79722516|NCT02860780|Drug|prexasertib|Administered IV
79857051|NCT00981240|Drug|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
79857052|NCT00981318|Drug|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
79857053|NCT00975468|Other|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
79857054|NCT00984984|Drug|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
79857055|NCT00984984|Drug|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
79559612|NCT02695628|Diagnostic Test|Positron Emission Tomography|Undergo [18F] FMISO PET/CT
79722517|NCT02860780|Drug|ralimetinib|Administered orally
79722518|NCT01225835|Drug|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
79722519|NCT01225835|Drug|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
79722520|NCT01225835|Drug|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
79722521|NCT01225835|Drug|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
79722522|NCT01225835|Drug|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
79857056|NCT00975546|Other|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
79857057|NCT00975546|Procedure|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
79875614|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
79875615|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
79397839|NCT01451515|Drug|Daunorubicin|Given IV.
79397840|NCT01451515|Drug|PEG-asparaginase|Given intramuscularly (IM) or IV.
79397841|NCT01451515|Drug|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
79397842|NCT01451515|Drug|Doxorubicin|Given IV.
79397843|NCT01451515|Drug|Cyclophosphamide|Given IV.
79397844|NCT01451515|Drug|Cytarabine|Given IV or IT.
79397845|NCT01451515|Drug|Thioguanine|Given PO.
79397846|NCT01451515|Drug|Clofarabine|Given IV.
79397847|NCT01451515|Drug|Methotrexate|Given IV, IM or IT.
79397848|NCT01451515|Drug|Mercaptopurine|Given PO.
79397849|NCT01451515|Drug|Dexamethasone|Given PO or IV.
79397850|NCT01451515|Drug|Hydrocortisone|Given IT.
79857058|NCT00985062|Procedure|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
79857059|NCT00985062|Procedure|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
79857060|NCT00981552|Radiation|IMRT planning|
79857061|NCT00981552|Radiation|4-Field Radiation Planning|
80019905|NCT05161377|Procedure|Surgical management|Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
80019906|NCT05161377|Procedure|Endovascular management|Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
79260179|NCT03229005|Procedure|operculectomy|during second surgery soft tissues will be measured again
79260180|NCT03229005|Procedure|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
79260181|NCT04931186|Other|retrospective analyis|retrospective analysis of data
79260182|NCT03234777|Behavioral|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
79260183|NCT03234777|Behavioral|Regular video|Developed by CDC
79857062|NCT00975702|Procedure|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
79559613|NCT02690064|Dietary Supplement|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
79857063|NCT00985218|Device|SMART System|microfluidic embryo culture system
79857064|NCT00985218|Device|Culture dish|Standard IVF culture dish
79857065|NCT00545532|Drug|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
79857066|NCT00545532|Other|placebo|Placebo matched to oseltamivir po twice daily for 10 days
79857067|NCT00544440|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
79857068|NCT00544440|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
79857069|NCT04006860|Drug|SHC014748M Capsules|SHC014748M Capsules: 200mg
79857070|NCT00981708|Drug|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
79857071|NCT04007718|Behavioral|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
80019907|NCT05149326|Drug|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
80019908|NCT05149326|Drug|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
79559614|NCT02690064|Dietary Supplement|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
80019909|NCT05141760|Diagnostic Test|PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)|Additional staging PET and MRI scan prior to prostatectomy and lymph node dissection
79559615|NCT02690064|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
79559616|NCT02683889|Drug|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
79559617|NCT02671435|Drug|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
79559618|NCT02671435|Drug|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
80019910|NCT05123131|Drug|Isatuximab|Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.
80019911|NCT05123131|Drug|Bortezomib|Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32.
79260184|NCT04921124|Drug|Teriparatide|PTH(1-34) cartridge and pen device
79397851|NCT01451515|Drug|Etoposide|Given IV.
79397852|NCT01466881|Drug|Alisertib|Given PO
79397853|NCT01466881|Other|Laboratory Biomarker Analysis|Correlative studies
79397854|NCT01466881|Other|Pharmacological Study|Correlative studies
79397855|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
79397856|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
79397857|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
79397858|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
79397859|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
79397860|NCT01576172|Drug|Abiraterone Acetate|Given PO
79857072|NCT03920670|Device|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
80019912|NCT05123131|Drug|Lenalidomide|Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance [CrCl] ≥30 to <60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.
79260185|NCT04921046|Drug|lignocaine|After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
79260186|NCT04921046|Drug|Midazolam 1 milligram Prefilled Syringe|after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
79260187|NCT03229239|Procedure|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
79857073|NCT03920670|Device|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
79857074|NCT00430300|Drug|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
79559619|NCT02671435|Drug|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
79559620|NCT02671435|Drug|mFOLFOX6|Participants will receive IV infusion of mFOLFOX as stated in arm description.
79559621|NCT02671435|Drug|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
79559622|NCT02649166|Device|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
79857075|NCT00430300|Drug|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
79260188|NCT03234543|Procedure|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
79857076|NCT00981786|Drug|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
79559623|NCT02649166|Device|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
79260189|NCT03234543|Procedure|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
79260190|NCT04940702|Other|Focal Vibration|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group."
79260191|NCT04940702|Other|Blood Flow Restriction|Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
79559624|NCT02624765|Drug|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
79559625|NCT02624765|Drug|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
79559626|NCT02624765|Drug|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
79559627|NCT02624765|Drug|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
79559628|NCT02624765|Drug|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
79559629|NCT02624765|Drug|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
79722523|NCT00962650|Device|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
79722524|NCT04282252|Drug|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
79875616|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
79260192|NCT04940702|Other|Traditional Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
79722525|NCT04282096|Other|native and non native casein|selected participant will test the 3 treatments in a random order
79722526|NCT04284046|Other|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
80019913|NCT05123131|Drug|Dexamethasone (IV)|Dexamethasone (IV on the days of Isatuximab and PO on other days): 20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33. If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32.
79260193|NCT02792231|Drug|Ofatumumab subcutaneous injection|Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
79260194|NCT02792231|Drug|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
79260195|NCT02792231|Drug|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
79722527|NCT00630136|Behavioral|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
79857077|NCT00981786|Drug|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
79260196|NCT02792231|Drug|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
79260197|NCT03234621|Other|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
79857078|NCT00975858|Procedure|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
79559630|NCT02619838|Device|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
79722528|NCT04280614|Behavioral|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
79857079|NCT04007562|Drug|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
79857080|NCT04007484|Device|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
79857081|NCT00981864|Radiation|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
79857082|NCT00985374|Drug|RAD001|5mg or 10mg po daily
79857083|NCT00985374|Drug|RG1507|16mg/kg iv every 3 weeks
80031616|NCT04430608|Device|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
79397861|NCT01576172|Other|Laboratory Biomarker Analysis|Correlative studies
79260198|NCT04930952|Drug|Ethanol-amine Oleate Sclerotherapy Injection|Intralesional Sclerotherapy Injection
79397862|NCT01576172|Drug|Prednisone|Given PO
79559631|NCT02608346|Procedure|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
79559632|NCT02604277|Behavioral|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
79857084|NCT00975936|Drug|[14C]-GSK706769|50µg [14C]-GSK706769 containing 250 nCi
79857085|NCT00975936|Drug|Ketoconazole|200 mg Ketoconazole (Q12)
79857086|NCT00976092|Drug|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
79857087|NCT00976092|Drug|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
79857088|NCT00976092|Drug|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
79260199|NCT03236571|Device|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
79260200|NCT04920968|Drug|Obinutuzumab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
79260201|NCT04920968|Drug|Rituximab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
79397863|NCT01576172|Drug|Veliparib|Given PO
79397864|NCT01542788|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
79397865|NCT01542788|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
79397866|NCT01542788|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
79397867|NCT01542788|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
79559633|NCT02604277|Behavioral|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
79722529|NCT04280770|Procedure|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
79857089|NCT00976092|Drug|Heparin|i.v. bolus of 70-100 IU/kg body weight
79857090|NCT00985452|Other|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
80031617|NCT02595320|Drug|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
79260202|NCT00700401|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
79260203|NCT00700401|Drug|ribavirin [Copegus]|800mg po daily for 24 weeks
79260204|NCT04931108|Drug|Nitrendipine/Atenolol|Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
79260205|NCT04931108|Drug|Nitrendipine|Nitrendipine 5mg, oral tablet, one pill daily.
79260206|NCT04931108|Drug|Atenolol|Atenolol 25mg, oral tablet, one pill daily.
79260207|NCT03229317|Other|Plethysmography|Lung plethysmography
79260208|NCT03228927|Other|comparison of twin A to twin B|Comparison of Twin A to Twin B
79260209|NCT02084459|Behavioral|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
79260210|NCT02453217|Behavioral|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
79260211|NCT02453217|Other|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
79260212|NCT02084537|Procedure|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
79260213|NCT02084537|Procedure|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
79260214|NCT04920500|Drug|Daunorubicin Cytarabine liposome for injection|Induction 1: [100 U/m²] i.v. d1,3,5 Induction 2: [100 U/m²] i.v. d1,3
79260215|NCT04920500|Drug|Vyxeos、Daunorubicin Cytarabine liposome for injection|Induction 1: [100 U/m²] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: [100 U/m²] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
79397868|NCT01542632|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
79397869|NCT01542632|Biological|TDV New Formulation|TDV New Formulation subcutaneous injection
79397870|NCT01542632|Drug|Placebo|Placebo subcutaneous injection
79397871|NCT01542632|Drug|New Formulation Placebo|New Formulation placebo subcutaneous injection
79397872|NCT01557842|Drug|Drug Treatment|Class I and III antiarrhythmic drug treatment.
79397873|NCT01557842|Device|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
79397874|NCT01541930|Drug|GK567|Once or twice daily, for 14 days, up to 30 g per day
79397875|NCT01576016|Device|Accent MRI system (lead safety)|Patients implanted with an Accent MRI system
79397876|NCT01576016|Device|Accent MRI system (with MRI scan)|Patients implanted with an Accent MRI system will receive an MRI scan
79397877|NCT03028298|Drug|Low dose sildenafil citrate|
79397878|NCT03028298|Drug|High dose sildenafil citrate|
79722530|NCT02899000|Drug|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
79722531|NCT02899000|Drug|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets [50 mg], twice daily)
79722532|NCT02858986|Procedure|3D laparoscopy|
79722533|NCT02858986|Procedure|4K laparoscopy|
79722534|NCT02859220|Other|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
79857091|NCT00985452|Other|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
79857092|NCT00985530|Drug|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
79857093|NCT00985530|Drug|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
79857094|NCT04006782|Device|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
79857095|NCT04006470|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
79857096|NCT04006470|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
80031618|NCT04887376|Device|Mirror frame|Combined Mirror and NMES therapy
80031619|NCT04887376|Device|Control|Only NMES therapy
80031620|NCT04666766|Device|Microwave scanning of the head|A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
79559634|NCT02604277|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
79559635|NCT02604277|Behavioral|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education & Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education & Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
80019914|NCT05108090|Procedure|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
80019915|NCT05101187|Drug|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
80019916|NCT05101187|Drug|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
80019917|NCT05073978|Other|No intervention|This is an observational study without any intervention
79559636|NCT02601950|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
79559637|NCT02546453|Biological|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
79722535|NCT02859220|Other|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
79722536|NCT04281862|Drug|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
79722537|NCT04281862|Drug|Topical Prednisolone|Standard of care topical drop treatment
79722538|NCT00958828|Device|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
79722539|NCT00958828|Device|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
79722540|NCT03122002|Drug|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
79722541|NCT03122002|Diagnostic Test|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
79722542|NCT03122002|Other|Intravascular therapy|Intravascular therapy including thrombectomy
79722543|NCT03122002|Other|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
79722544|NCT03122002|Other|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
80019918|NCT05065502|Behavioral|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better.[practice]."
80031621|NCT02809053|Biological|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
79260216|NCT02453295|Behavioral|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
79260217|NCT02084615|Drug|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
79260218|NCT02453139|Behavioral|Exercise|6 month supervised and home based aerobic exercise intervention
79277444|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
79559638|NCT02546453|Biological|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
79722545|NCT02858596|Dietary Supplement|Semi-solid feed (Terumo PG soft)|
79722546|NCT02858596|Dietary Supplement|Liquid feed (Meibalance)|
79722547|NCT02861482|Device|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
80031622|NCT02809053|Biological|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
80031623|NCT04396756|Drug|PLN-74809|PLN-74809
80031624|NCT04396756|Drug|Placebo|Placebo
80031625|NCT05390060|Device|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
79722548|NCT02861482|Drug|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
79722549|NCT02861482|Drug|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
79260219|NCT04939688|Radiation|Conventional dose AND ultra low-dose CT scanning in the search for cranial lesions|As well as undergoing the usual, conventional radiation dose CT scan, these patients will also undergo ultra low-dose CT scanning in the search for cranial lesions.
79722550|NCT02861482|Drug|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
79857097|NCT04006470|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
79857098|NCT01323712|Dietary Supplement|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
79857099|NCT04911036|Other|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
79857100|NCT00981942|Drug|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
79260220|NCT02084693|Device|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
79260221|NCT03236337|Behavioral|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
79260222|NCT04931030|Other|Dietary advice|Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
79260223|NCT02084771|Drug|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
79397879|NCT02985944|Procedure|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
79397880|NCT04410536|Drug|Symptomatic drugs|indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
79722551|NCT02861482|Procedure|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
79722552|NCT02861482|Procedure|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
79857101|NCT03927846|Behavioral|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
80031626|NCT04887142|Other|Standard of health care|The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
79260224|NCT02084771|Biological|Oral Salt and Water|Oral salt capsules and water, based on patient weight
79397881|NCT04410536|Drug|Bridge therapy|prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
79397882|NCT04410536|Behavioral|Mindfulness program|home based withdrawal program
79397883|NCT04410614|Procedure|Free epithelial (gingival) graft|1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
79397884|NCT01540838|Drug|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
79397885|NCT01540838|Drug|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
79722553|NCT02861482|Procedure|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
79722554|NCT02861482|Procedure|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
79722555|NCT02861482|Procedure|Hysterectomy|Hysterectomy with all the above measures not working
79722556|NCT02861482|Drug|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
79857102|NCT00982098|Procedure|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
79857103|NCT00976170|Drug|GC33(RO5137382)|IV administration at 6 escalating dose levels.
79857104|NCT00976170|Drug|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
79857105|NCT00982176|Other|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
79857106|NCT00982254|Drug|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
79857107|NCT00982254|Drug|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
79875617|NCT00299494|Drug|Rituximab|rituximab 375 mg/m^2 via IV infusion on Day 1
80019919|NCT05065502|Behavioral|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
79260225|NCT03236415|Device|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
79260226|NCT03236415|Device|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
79559639|NCT02543255|Drug|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
79722557|NCT02861716|Drug|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
79722558|NCT02861716|Drug|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
79857108|NCT00985608|Drug|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
79260227|NCT03559751|Other|VLN cigarettes (A)|0.4mg nicotine / g tobacco king size filter cigarette
79857109|NCT00985608|Drug|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
79857110|NCT00985764|Procedure|cesarean delivery|
79260228|NCT03559751|Other|Usual Brand Cigarettes (B)|Usual brand king size non-menthol cigarettes
79260229|NCT03559751|Drug|Nicotine gum (C)|4 mg nicotine gum
79857111|NCT00976326|Drug|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
79857112|NCT00985842|Device|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
80031627|NCT04666688|Drug|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
79260230|NCT04485975|Device|Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood
79559640|NCT02543255|Drug|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
79559641|NCT02543255|Drug|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
80031628|NCT04666688|Drug|Tislelizumab|anti-PD-1 monoclonal antibody
80031629|NCT04666688|Drug|Gemcitabine/nab-paclitaxel|chemotherapy
79875618|NCT00951587|Device|PillCam™ (Capsule Endoscopy)|Medical Device
79875619|NCT00943553|Drug|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
79875620|NCT00943553|Drug|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
79260231|NCT03234699|Drug|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
79875621|NCT04011917|Behavioral|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
79260232|NCT03234699|Drug|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
79260233|NCT03234699|Drug|Warfarin Pill|5 mg (Days 7 and 105)
79260234|NCT03234699|Drug|Omeprazole Pill|20 mg (Days 7 and 105)
79260235|NCT03234699|Drug|Bupropion Pill|150 mg (Days 1 and 99)
79260236|NCT02621606|Drug|[11C]MK-6884|IV bolus dose of ~370 MBq [11C]MK-6884
79260237|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
79260238|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo R-LESS RP
79260239|NCT02079155|Other|laboratory biomarker analysis|Correlative studies
79260240|NCT02079155|Other|quality-of-life assessment|Ancillary studies
79260241|NCT02079155|Other|questionnaire administration|Ancillary studies
79260242|NCT03228771|Drug|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
79260243|NCT03228771|Drug|ATV gel|Atorvastatin loaded in methyl cellulose gel
79260244|NCT02079233|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
79260245|NCT03234231|Behavioral|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
79857113|NCT00985842|Device|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
79857114|NCT00985842|Device|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
79857115|NCT00985842|Device|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
79857116|NCT00985842|Device|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
79857117|NCT00982332|Drug|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
79857118|NCT00982332|Drug|isotonic sodium chloride solution (placebo)|4 ml intramuscular
79857119|NCT00976638|Other|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
79857120|NCT00976638|Other|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
79857121|NCT04007328|Drug|Methylprednisolone Sodium Succinate|methylprednisolone vial
79857122|NCT04007328|Drug|Placebo|Normal saline manufactured to mimic methylprednisolone vial
79857123|NCT04007250|Device|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~FENIX™ System Implant~FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
79260246|NCT03234231|Behavioral|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
79260247|NCT02079389|Device|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
80019920|NCT05051501|Dietary Supplement|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
80019921|NCT05027451|Drug|IXT-m200|Anti-methamphetamine chimeric monoclonal antibody (mAb)
80019922|NCT05027451|Other|Placebo|Normal saline
80019923|NCT05024045|Drug|LOXO-338|Oral
80019924|NCT05024045|Drug|Pirtobrutinib|Oral
80019925|NCT05019339|Behavioral|Healthy HomeStyles|Comparison of 2 educational interventions
80019926|NCT05019339|Behavioral|Eat Healthy Be Active|Comparison of 2 educational interventions
80019927|NCT05001958|Behavioral|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm & hand.
80019928|NCT05000047|Device|3D ear scanner|A commercially-available ear scanning device used according to standard of care. A hand-held device is used and is considered less invasive than conventional earmold impressions.
80019929|NCT05000047|Other|Conventional silicon ear impressions|A two part silicon impression material that is used to fill the ear and produce a physical cast of the ear canal. The procedure is standard of care.
80019930|NCT04996420|Device|Clearsight non invasive hemodynamic monitoring|Goal directed fluid therapy fuided by Clearsight monitoring
79260248|NCT03228615|Other|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
79397886|NCT04109144|Biological|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin during the 2nd of 3 total paracentesis being monitored
79397887|NCT04109144|Biological|Albumin|Albumin will be used during the 1st and 3rd paracentesis
80019931|NCT04974047|Drug|Tislelizumab|Administered intravenously as specified in the treatment arm.
80019932|NCT04920942|Drug|Ivermectin 0.4mg/kg/day for 5 days|Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
80019933|NCT04911530|Other|no intervention|no intervention
80019934|NCT04875169|Drug|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
80019935|NCT04875169|Drug|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
80019936|NCT04875169|Drug|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
80019937|NCT04875169|Drug|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
80019938|NCT04875169|Drug|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
80019939|NCT04873505|Dietary Supplement|troches|Take one troche after each meal.
80019940|NCT04866342|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
79857124|NCT04007172|Procedure|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
79857125|NCT04007172|Device|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
79857126|NCT00985920|Drug|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
79857127|NCT00985920|Drug|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
80019941|NCT04844034|Dietary Supplement|High-EPA multinutrient supplement.|"Three capsules with the largest meal of the day providing:~1,125 mg EPA~441 mg DHA~330 mg Magnesium~7.5 mg a-tocopherol"
80019942|NCT04844034|Other|Placebo|"Three capsules with the largest meal of the day providing:~3,060 mg sunflower seed oil~60 mg lecithin~300 mg glyceryl monostearate~465 mg EPA/DHA (18%/12% respectively for blinding)"
79260249|NCT02452593|Other|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
79260250|NCT02079467|Procedure|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
79260251|NCT02079467|Procedure|Standard rehabilitation|Standard care range of motion restrictions will remain in place
79260252|NCT04431362|Behavioral|Self-selected music|Participants will be given iPods and headphones to listen to their music
79722559|NCT02861716|Drug|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
79722560|NCT04265092|Drug|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
79722561|NCT00960934|Drug|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
79722562|NCT00960934|Drug|Placebo|Dose-matched oral placebo to MK-5442
79260253|NCT03228147|Dietary Supplement|Nutritional Supplementation|Given PO
79260254|NCT03228147|Other|Questionnaire Administration|Ancillary studies
79260255|NCT02081339|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|
79260256|NCT04939766|Device|Activation of a closed loop device in an insulin pump device with GCM|After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.
79722563|NCT00960934|Dietary Supplement|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
79722564|NCT00960934|Dietary Supplement|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
79260257|NCT03228849|Procedure|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
79722565|NCT00892177|Biological|bevacizumab|Given intravenously
79722566|NCT00892177|Drug|dasatinib|Given orally
79722567|NCT00892177|Other|placebo|Given orally
79260258|NCT03228849|Procedure|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
79260259|NCT02079545|Drug|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
79722568|NCT00962104|Drug|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
79260260|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
79397888|NCT04109144|Procedure|Large Volume Paracentesis (LVP)|All participants who have this procedure, meet eligibility criteria and who consent
79260261|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
79260262|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
79260263|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
79722569|NCT00962104|Drug|Placebo|Taken by mouth, once daily for 10 weeks.
79722570|NCT02821000|Biological|Pembrolizumab|Intravenous infusion
79722571|NCT02836327|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging
80019943|NCT04840134|Behavioral|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in two consecutive phases:~Intensive Intervention Phase (week 1-9), including 9 weekly peer-led group sessions (90min) and four one-on-one coaching sessions (60min); and~Follow-up Intervention Phase (weeks 10-24),consisting of 3 monthly group sessions (90min) and bi-weekly phone check-ins to provide ongoing support (15-20min).~Key intervention components:~Peer-led group sessions include personal stories of financial empowerment; practical information about available financial supports; basic financial coaching and mutual support/ accountability (e.g., goal/action check-ins);~One-on-one peer coaching sessions (throughout 24 weeks) to help participants identify their personal financial stressors and facilitate a personalized Financial Wellness Action Plan.~Support to navigate and access financial supports in the community (e.g., financial counseling, free tax prep, housing eviction prevention, debt relief)."
80019944|NCT04821687|Drug|Ongentys 50mg|Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
79722572|NCT02860624|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
80019945|NCT04821687|Drug|Madopar Tab. 125 or Perkin Tab. 25-100mg|Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
80019946|NCT04810247|Behavioral|Body Project|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
79397889|NCT01451437|Drug|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
79397890|NCT01451203|Drug|Placebo|Subcutaneous (SC)
79559648|NCT02465333|Procedure|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
79559649|NCT02438202|Device|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
79722573|NCT02860624|Drug|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
79722574|NCT02831647|Dietary Supplement|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
79722575|NCT02860468|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
79722576|NCT02860468|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
79722577|NCT02858518|Other|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
79722578|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given weekly
79722579|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given monthly
79722580|NCT00892099|Other|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
79722581|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
79722582|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
79722583|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
79559650|NCT02430129|Procedure|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
79559651|NCT02430129|Procedure|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
79260264|NCT04939376|Procedure|IVF|In vitro fertilization
79260265|NCT03559673|Drug|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
79397891|NCT01451203|Drug|CZP|SC
79397892|NCT01451203|Drug|methotrexate (MTX)|oral
79397893|NCT01556438|Biological|Tabalumab|Administered IV
79397894|NCT01556438|Drug|Bortezomib IV|Administered IV
79397895|NCT01556438|Drug|Bortezomib SC|Administered SC
79397896|NCT01556438|Drug|Dexamethasone|Administered orally
79397897|NCT02073487|Drug|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
79397898|NCT02073487|Drug|Trastuzumab|anti-Her2 monoclonal antibody
79397899|NCT02073487|Drug|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
79722584|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
79722585|NCT04248907|Other|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
79722586|NCT04248907|Other|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
79857128|NCT00976794|Drug|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
79857129|NCT00976794|Drug|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
79857130|NCT00985998|Drug|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12~18 weeks)."
79857131|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
79559652|NCT02430129|Device|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
79857132|NCT00982566|Drug|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
80019947|NCT04809402|Other|remote monitoring after cataract surgery|remote monitoring after cataract surgery
80019948|NCT04764344|Drug|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
79260266|NCT02084927|Biological|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
79260267|NCT03234387|Other|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
80019949|NCT04764344|Drug|Ondansetron|Ondansetron
79260268|NCT03235947|Drug|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
79559653|NCT02430129|Device|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
80019950|NCT04738981|Drug|UC-MSC|UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks.
80019951|NCT04738981|Drug|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
80019952|NCT04709185|Drug|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
79260269|NCT03235947|Drug|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
79559654|NCT02379377|Biological|Fluorine F 18 L-glutamate Derivative 18F-FSPG|Undergo 18F-FSPG PET scan
79559655|NCT02379377|Biological|Carbon C 11 Acetate|Undergo 11C-acetate PET scan
79559656|NCT02379377|Procedure|Positron Emission Tomography|Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET
79559657|NCT02379377|Other|Laboratory Biomarker Analysis|Correlative studies
79559658|NCT02379377|Biological|Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose|Undergo 18F-FDG PET scan
79559659|NCT02345265|Procedure|Biopsy|Undergo biopsy of tumor
79559660|NCT02345265|Procedure|Biospecimen Collection|Undergo blood sample collection
79722587|NCT04248907|Other|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
79722588|NCT02835937|Other|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
79722589|NCT02835781|Other|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
79722590|NCT00958438|Drug|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
79722591|NCT00958438|Drug|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
79722592|NCT00958438|Drug|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
80019953|NCT04709185|Drug|Placebo|oral placebo at 23:00-24:00 the night before AVS
80031630|NCT04548986|Device|Aktiia.product|The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
80031631|NCT05701839|Procedure|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
80031632|NCT05701839|Procedure|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
79260270|NCT03235947|Drug|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
79277445|NCT02368119|Biological|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
79277446|NCT02368119|Other|Placebo|IM injection injection of Phosphate Buffered Saline
79559661|NCT02345265|Drug|Cediranib Maleate|Given PO
79559662|NCT02345265|Procedure|Computed Tomography|Undergo CT scan
79559663|NCT02345265|Procedure|Echocardiography|Undergo echocardiogram
79559664|NCT02345265|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
79559665|NCT02345265|Procedure|Multigated Acquisition Scan|Undergo MUGA
79559666|NCT02345265|Drug|Olaparib|Given PO
79559667|NCT02345265|Other|Questionnaire Administration|Ancillary studies
79559668|NCT02340676|Procedure|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
79559669|NCT02340676|Drug|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
79559670|NCT02262117|Other|standard care|No specific medical care
79397900|NCT02073487|Drug|Abraxane|albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
79397901|NCT02073487|Drug|Paclitaxel|chemotherapy - microtubule inhibitor
79397902|NCT02073487|Drug|Pertuzumab|anti-HER2 monoclonal antibody
79397903|NCT01554176|Drug|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
79260271|NCT03055910|Diagnostic Test|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
79559671|NCT02262117|Drug|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
79559672|NCT02213003|Biological|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
79559673|NCT02206230|Radiation|Hypofractionated radiation therapy|
79559674|NCT02206230|Radiation|Standard radiation therapy|
79559675|NCT02188381|Other|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
79559676|NCT02185560|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
79559677|NCT02150902|Procedure|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
79260272|NCT04930640|Dietary Supplement|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
79260273|NCT04930640|Dietary Supplement|Placebo|Placebo for 8 week
79559678|NCT02150902|Procedure|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
79559679|NCT02128152|Device|Ekso exoskeleton|
79559680|NCT02116335|Drug|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
79559681|NCT02116335|Drug|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
79559682|NCT01999361|Drug|Myfortic|treatment with myfortic
79559683|NCT01956552|Other|biopsy or cytopuncture|
79559684|NCT01937468|Other|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
79722593|NCT02835859|Other|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
79722594|NCT02835859|Other|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
79722595|NCT02835703|Procedure|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
79722596|NCT02835469|Drug|Menotrophin|
79722597|NCT02858674|Other|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
79722598|NCT02858674|Other|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
79857133|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
79260274|NCT03236259|Dietary Supplement|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
79260275|NCT03236259|Dietary Supplement|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
79260276|NCT03236259|Dietary Supplement|Placebo|Maltodextrin. Daily ingestion of capsule
79260277|NCT03057470|Drug|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
79260278|NCT03057470|Drug|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
79260279|NCT03057470|Drug|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
79397904|NCT01554176|Drug|Placebo|Placebo, one tablet, orally, once daily at bedtime
79397905|NCT01466491|Drug|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
79397906|NCT01466179|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
79397907|NCT01493089|Drug|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
79397908|NCT01493089|Drug|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
79397909|NCT01450813|Drug|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
79397910|NCT01450813|Drug|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
79397911|NCT01450813|Drug|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
79260280|NCT03057470|Other|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
79260281|NCT03228225|Behavioral|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
79260282|NCT04919876|Dietary Supplement|fruit/vegetable supplement (FVS)|The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
79260283|NCT04919876|Dietary Supplement|Placebo|The product does not contain nutrients present in the FVS.
79722599|NCT02860390|Other|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
79857134|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
79559685|NCT01937468|Drug|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
79559686|NCT01932125|Drug|Bevacizumab|Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
79559687|NCT01922076|Drug|Adavosertib|Given PO
79559688|NCT01922076|Other|Laboratory Biomarker Analysis|Correlative studies
79559689|NCT01922076|Other|Pharmacological Study|Correlative studies
79559690|NCT01922076|Radiation|Radiation Therapy|Undergo radiation therapy
79559691|NCT01913275|Procedure|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
79559692|NCT01913275|Procedure|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
79559693|NCT01868269|Drug|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
79559694|NCT01868269|Drug|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
79559695|NCT01868269|Drug|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
79260284|NCT04930718|Other|Thumb active Exercises|Active específico exercises; Reeducation program
79260285|NCT02871401|Drug|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
79260286|NCT02871401|Drug|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
79260287|NCT03236181|Other|SFA|High saturated fatty acid/SFA oil source
79260288|NCT03236181|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
79559697|NCT01742299|Drug|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
79559698|NCT01687608|Biological|AskBio009|Single dose IV injection
79722600|NCT02860390|Other|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
79722601|NCT02832973|Drug|Spironolactone|Spironolactone 25 mg
79260289|NCT03236181|Other|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
79260290|NCT03236181|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
79277447|NCT02202239|Drug|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
79559699|NCT01684397|Biological|Bevacizumab|Given IV
79559700|NCT01684397|Other|Laboratory Biomarker Analysis|Correlative studies
79559701|NCT01684397|Drug|Pazopanib Hydrochloride|Given PO
79559702|NCT01684397|Other|Pharmacological Study|Correlative studies
79559703|NCT01680549|Drug|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
79559704|NCT01661400|Drug|Metronomic Cyclophosphamide|
79559705|NCT01661400|Drug|Thalidomide|
79559706|NCT01515462|Genetic|OTL-103|OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
79722602|NCT02832973|Drug|Furosemide,|Furosemide 20-40 mg
79722603|NCT02832973|Drug|Amiloride|Amiloride 5 mg
79559707|NCT01366092|Drug|Interleukin-2|Daily subcutaneous IL-2 (1 x 10^6 IU/m^2/day) for self-administration for 12 weeks followed by 4-week hiatus
79559708|NCT01351870|Radiation|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
79722604|NCT02832973|Drug|Ramipril|Ramipril 5-10 mg
79722605|NCT02832973|Drug|Bisoprolol|Bisoprolol 5-10 mg
79722606|NCT02832739|Device|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==> www.senaca.ch
79857135|NCT00976872|Drug|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
79857136|NCT00976872|Drug|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
79857137|NCT00977028|Drug|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
79857138|NCT00977028|Procedure|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
80019954|NCT04693156|Procedure|unilateral ultrasound-guided oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. The rectus abdominis and underlying transversus abdominis muscles will be identified. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
79260291|NCT04919720|Behavioral|FRAM Model and Human Factors/Quality Improvement Intervention|The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
79559709|NCT01351870|Radiation|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
79559710|NCT01350908|Other|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
79260292|NCT03228303|Drug|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
79722607|NCT00958360|Other|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
79722608|NCT00958360|Other|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
79722609|NCT02832895|Other|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
79722610|NCT02832817|Device|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
79722611|NCT02860312|Behavioral|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
79722612|NCT02860312|Behavioral|Non-exercising group|Patients are having their usual physical activity
79722613|NCT02831491|Drug|Ramucirumab|Administered IV
79722614|NCT02831491|Drug|Docetaxel|Administered IV
79857139|NCT04006938|Behavioral|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
80019955|NCT04693156|Procedure|unilateral ultrasound-guided oblique subcostal TAP block with %0.9 NaCl 30ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. %0.9 NaCl 30ml will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
80031633|NCT05701839|Device|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
79260293|NCT03228303|Drug|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
79260294|NCT02085005|Drug|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
79397912|NCT01450813|Drug|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
79559711|NCT01334008|Biological|Blood sampling|30ml of patient peripherical blood will be collected
79559712|NCT01316250|Drug|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
79559713|NCT01192555|Biological|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
79559714|NCT01192555|Drug|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
79722615|NCT02860234|Drug|Oxaliplatin|
79722616|NCT02860234|Drug|Capecitabine|
79722617|NCT02860234|Radiation|intensity modulated radiotherapy|
79722618|NCT02860234|Procedure|DRE-Endoscopy-MRI-CEA|
79722619|NCT02860234|Procedure|Nonoperative Management|
79722620|NCT02860234|Procedure|Local Excision|
79722621|NCT02860234|Procedure|Total Mesorectal Excision|
79722622|NCT02860234|Behavioral|Quality of Life Questionnaires|
79722623|NCT02858752|Other|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
79857140|NCT04006938|Behavioral|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
79857141|NCT00982722|Drug|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
79857142|NCT00982722|Drug|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
79857143|NCT00982800|Drug|Gabapentin|200mg 3x/day for 3 days (9 doses total)
79857144|NCT00982800|Drug|Placebo Sugar Pill|
79857145|NCT00986076|Drug|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
79857146|NCT00986076|Drug|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
79559715|NCT01167270|Behavioral|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
79857147|NCT00977262|Other|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
79857148|NCT00977262|Other|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
79857149|NCT00977262|Other|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
79722624|NCT02858752|Other|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
79857150|NCT00984828|Drug|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
79260295|NCT02085005|Drug|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
79260296|NCT02085005|Drug|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
79559716|NCT01167270|Behavioral|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
79722625|NCT02858752|Other|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
79722626|NCT02858752|Other|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
79857151|NCT00983034|Drug|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
79857152|NCT00977340|Behavioral|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
79857153|NCT00977340|Behavioral|confrontation|Confrontation
79260297|NCT04431440|Other|silver nanoparticles|effect silver nanoparticles will be examined on multidrug resistant bacteria
79857154|NCT00977340|Behavioral|imagination|Imagination
79857155|NCT00977418|Behavioral|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
79559717|NCT01112813|Drug|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
79559718|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
79559719|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
79559720|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
79559721|NCT01065454|Drug|Placebo|Placebo three times a day
79559722|NCT01049347|Drug|amitriptyline|150 mg oral, daily, single evening dose, 35 days
79559723|NCT01049347|Drug|paroxetine|40 mg oral, single dose, morning, 35 days
79857156|NCT00977418|Other|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
79857157|NCT00983112|Drug|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
79857158|NCT00983112|Drug|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
79857159|NCT04006704|Drug|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
80031634|NCT05701839|Device|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
79857160|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
79857161|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
79857162|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
79260298|NCT03228381|Device|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
79277448|NCT02202239|Drug|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
79277449|NCT02202239|Drug|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
79857163|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
79857164|NCT00977496|Procedure|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
79277450|NCT02202239|Drug|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
79277451|NCT02202239|Drug|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
79559726|NCT00703222|Biological|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10^7 cells/m2~SKNLP at 1 x 10^6 cells/m2"
79559727|NCT00703222|Biological|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10^7 cells/m2~SKNLP at 1 x 10^7 cells/m2"
79559728|NCT00569127|Biological|Bevacizumab|Given IV
79559729|NCT00569127|Other|Laboratory Biomarker Analysis|Correlative studies
79722627|NCT02858752|Other|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
79857165|NCT00983190|Device|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
79857166|NCT00545298|Drug|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
79857167|NCT00545298|Drug|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
79857168|NCT00977652|Procedure|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
79857169|NCT00977652|Procedure|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
79857170|NCT00977730|Dietary Supplement|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
79857171|NCT00977730|Dietary Supplement|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
79857172|NCT00983268|Drug|capecitabine|1000 mg taken by mouth on the days of radiation only.
79722628|NCT02832583|Device|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
79722629|NCT04280380|Diagnostic Test|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with >500 copies/mL of plasma will be considered positive.
80031635|NCT04882618|Drug|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
79277452|NCT02202239|Drug|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
79277453|NCT02202239|Drug|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
79559730|NCT00569127|Drug|Octreotide Acetate|Given IM
79559731|NCT00569127|Biological|Recombinant Interferon Alfa-2b|Given SC
79559732|NCT00401167|Drug|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
79559733|NCT00390026|Drug|Bevacizumab (Avastin)|
79559734|NCT00390026|Drug|Verteporfin photodynamic therapy (PDT)|
79559735|NCT00306098|Drug|islets|Islet transplantation
79857173|NCT00983268|Drug|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~Vorinostat,at 100 mg~Vorinostat,at 200 mg~Vorinostat, at 300 mg~Vorinostat, at 400 mg"
79559736|NCT00099086|Drug|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
79559737|NCT00099086|Drug|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
79857174|NCT00983268|Radiation|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
79857175|NCT00983268|Procedure|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
79857176|NCT03811236|Other|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
79857177|NCT00977886|Drug|Placebo|Oral, 10 days
79857178|NCT00977886|Drug|ELB353|Oral, 10 days
80031636|NCT03462290|Drug|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
80031637|NCT03462290|Drug|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
79559738|NCT00099086|Drug|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
79559739|NCT00099086|Radiation|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
79559740|NCT00005398|Other|There is no intervention|No applicable
79559741|NCT05357482|Radiation|TBI|300 cGy total body irradiation (TBI, day -2)
79559742|NCT05357482|Drug|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
79559743|NCT05357482|Biological|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
79559744|NCT05357482|Drug|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
79722630|NCT04280146|Behavioral|daily energy intake|Investigate daily energy intake according to eating rate and food processing
80031638|NCT04879394|Other|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
79277454|NCT02202239|Drug|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
79722631|NCT05263141|Procedure|retro-auricular single-site endoscopic thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
79722632|NCT05263141|Procedure|traditional open surgery thyroidectomy|The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
79722633|NCT00630370|Drug|Placebo|2 Placebo tablets, TID, orally, 58 days
79559745|NCT05357482|Drug|Sirolimus|For immune suppression (day -1)
79277455|NCT05370001|Other|Entotracheal tube size|Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
79559746|NCT05357482|Biological|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
79277456|NCT02368197|Drug|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
79722634|NCT00630370|Drug|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
79722635|NCT00630370|Drug|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
79722636|NCT00630370|Drug|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
79722637|NCT02832349|Other|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
79722638|NCT04280068|Behavioral|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
79722639|NCT04280068|Behavioral|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
79277457|NCT02368197|Device|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
79722640|NCT02835547|Other|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
79722641|NCT02835391|Device|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
79722642|NCT02835391|Device|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
79722643|NCT02835391|Procedure|Electrocautery/Diatermy|Procedure for the control of bleeding
79722644|NCT02997826|Other|Infantil formula|
79722645|NCT02835001|Procedure|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
79722646|NCT02835001|Device|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
79722647|NCT02835235|Drug|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
79722648|NCT02835235|Drug|placebo|Administered daily subcutaneously (s.c., under the skin)
79722649|NCT02831101|Drug|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
79722650|NCT02831101|Drug|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
79722651|NCT02834923|Behavioral|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
79722652|NCT02834923|Behavioral|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
79722653|NCT04247659|Drug|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
79857179|NCT00977964|Other|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
79559747|NCT05357482|Drug|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
79559748|NCT05356741|Drug|AMX-818|Administered as IV infusion
79857180|NCT00977964|Other|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
79857181|NCT00977964|Other|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
79857182|NCT00977964|Other|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
79857183|NCT00977964|Other|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
79260299|NCT02085083|Behavioral|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
79260300|NCT02085083|Behavioral|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
79397913|NCT03026335|Behavioral|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
79722654|NCT02831413|Behavioral|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
79722655|NCT02831413|Behavioral|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
79722656|NCT04201327|Behavioral|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
79722657|NCT04245787|Drug|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
79857184|NCT00977964|Other|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
79857185|NCT00983424|Drug|Cyclosporins|dose escalation, administered orally twice a day
79397914|NCT03026335|Behavioral|Control|Business as usual with students in non-itervened schools
79397915|NCT01539512|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
79559749|NCT05356741|Drug|pembrolizumab|Administered as IV infusion
79559750|NCT05337943|Behavioral|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
79559751|NCT05337943|Device|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
79722658|NCT04201171|Device|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
79722659|NCT02831803|Dietary Supplement|Walnuts|28 gm/day in single-serve package
79722660|NCT02831803|Dietary Supplement|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
79857186|NCT00983424|Drug|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
79857187|NCT00978198|Drug|ASP1517|oral
79857188|NCT00978198|Drug|Placebo|oral
79559752|NCT05333822|Dietary Supplement|Bashan|a vegetable plant based compound drink add after three meals for 14 days
79559753|NCT05333822|Other|water|water as placebo
79559754|NCT05332535|Behavioral|serious game based web application education|serious game based web application education for nursing students
79559755|NCT05325671|Procedure|transarticular multimodal drug infiltration|as described previously
79559756|NCT05321316|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
79559757|NCT05316129|Drug|Follicle Stimulating Hormone Receptor T Cells|Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.
79722661|NCT00633451|Other|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
79722662|NCT00633451|Other|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
79722663|NCT02828605|Device|Virtual Interactive Platform (VIP) Transplant|
79722664|NCT02831179|Drug|Capecitabine|Given PO
79722665|NCT02831179|Drug|Temozolomide|Given PI
79722666|NCT02831179|Drug|Veliparib|given PO
79722667|NCT02831179|Other|Pharmacological Study|Correlative studies
79722668|NCT02831179|Other|Laboratory Biomarker Analysis|Correlative studies
79857189|NCT00983658|Drug|huMAb OX40L|Intravenous repeating dose
79857190|NCT00983658|Drug|placebo|Intravenous repeating dose
79857191|NCT00983736|Drug|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
79857192|NCT00983736|Drug|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
79875622|NCT00453180|Drug|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
79857193|NCT00983970|Behavioral|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
80019956|NCT04693156|Procedure|unilateral ultrasound-guided posterior TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound (Esaote MyLab5) probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration.
80031639|NCT03108638|Behavioral|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
79397916|NCT01539512|Drug|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m^2, and 500 mg/m^2 thereafter
79559758|NCT05316116|Drug|Siltuximab|Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).
79397917|NCT01539512|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
79559759|NCT05314517|Drug|Namilumab|Namilumab administered subcutaneously
79722669|NCT04245553|Diagnostic Test|Abdominal Point of Care Ultrasound|Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
79722670|NCT04245631|Diagnostic Test|Recombinase aided amplification (RAA) assay|We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
79722671|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
79722672|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
79722673|NCT02828527|Other|Observational|
79722674|NCT04245007|Behavioral|Fasting|Doing fasting 2 days a week within 8 weeks
79722675|NCT05097469|Device|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
79722676|NCT05097469|Device|Sham laser treatment|3 consecutive sessions of sham laser treatment
79857194|NCT00983970|Behavioral|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
79857195|NCT00986700|Dietary Supplement|late night meal|Three different kinds of late night meal each for 2 days.
79397918|NCT01449955|Drug|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
79397919|NCT01449955|Drug|Placebo|Inactive
79559760|NCT05314517|Drug|Placebo|Placebo administered subcutaneously to match namilumab dosing
79559761|NCT05313321|Device|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
79559762|NCT05308654|Drug|ABBV-453|Oral; Tablet
79559763|NCT05308654|Drug|Dexamethasone|Oral Tablet
79559764|NCT05308654|Drug|Daratumumab|Subcutaneous Injection
79559765|NCT05308654|Drug|Lenalidomide|Oral Capsule
79722677|NCT02830789|Dietary Supplement|Calcium Carbonate|
79722678|NCT02830789|Dietary Supplement|Calcium Citrate|
79722679|NCT02830789|Dietary Supplement|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
79722680|NCT02830789|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
79857196|NCT00986778|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
79397920|NCT01574612|Drug|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
79397921|NCT01573910|Drug|Moxifloxacin ophthalmic solution, 0.5%|
79857197|NCT00986778|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
79857198|NCT00986778|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
80019957|NCT04693156|Procedure|unilateral ultrasound-guided posterior TAP block with %0.9 NaCl 30ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. %0.9 NaCl 30ml will be injected after negative aspiration.
80019958|NCT04677556|Other|Esogastric pressures measurement|"Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued."
79260301|NCT04938674|Device|ultrasonic guidance|Standard process for blood collection using Ultrasonic Guided puncture
79260302|NCT03227913|Other|Two samples of saliva|"Without stimulation: the first will be used to measure the flow of naturally secreted saliva~With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
79260303|NCT03227913|Other|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
79260304|NCT03227913|Other|Study of the food bolus|"Analysis by a compression and viscosity test~Evaluation of the quantity of saliva incorporated by drying"
79260305|NCT02079623|Procedure|Electroporation/ Nano knife treatment|
79397922|NCT01573910|Drug|Ofloxacin ophthalmic solution, 0.3%|
79397923|NCT01491919|Drug|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
79559766|NCT05304078|Behavioral|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
79722681|NCT04243993|Other|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
79722682|NCT04243603|Behavioral|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
79722683|NCT02828293|Other|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
79397924|NCT01573442|Drug|testosterone|10.4 mg
79397925|NCT01573442|Other|placebo|
80019959|NCT04670237|Device|Liberty677MTY Multifocal Toric IOL|multifocal, toric intraocular lens (IOL)
79722684|NCT04245163|Behavioral|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
79857199|NCT00429364|Drug|Losartan Potassium|Losartan .3 - 1.4 mg/kg
79857200|NCT00429364|Drug|Atenolol|Atenolol .5 - 4 mg/kg
79857201|NCT04758468|Behavioral|Telerehabilitation-based pelvic floor muscle training|"Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
79857202|NCT04758468|Behavioral|Home-based pelvic floor muscle training|"The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
79875623|NCT00453180|Drug|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
79875624|NCT00943709|Biological|insulin glargine recombinant|Given subcutaneously
79260306|NCT02079623|Device|NanoKnife|
79260307|NCT03235869|Drug|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
79260308|NCT03235869|Radiation|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
79397926|NCT02319369|Drug|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
79875625|NCT00943709|Drug|therapeutic insulin|Given subcutaneously
79875626|NCT00948545|Other|Observational study - there is no intervention|Observational study - there is no intervention
79857203|NCT04008342|Other|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
79857204|NCT00984048|Other|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
79857205|NCT00978354|Drug|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
80019960|NCT04647682|Other|physical activity program|"30 second chair test,~balance with joint-feet and semi-tandem stance~4 meters comfortable walking test were evaluated"
79559767|NCT05304078|Behavioral|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
79559768|NCT05301283|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.
79559769|NCT05301283|Diagnostic Test|MRI|Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
79559770|NCT05299554|Drug|Chronocort|Hydrocortisone modified-release capsule 5 mg and 10 mg
79559771|NCT05295771|Procedure|Gingival Phenotype Modification|Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
79559772|NCT05284552|Drug|Tinzaparin Injectable Solution|Subcutaneous injection
79559773|NCT05282277|Drug|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
79559774|NCT05282277|Drug|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
79559775|NCT05282277|Drug|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
79722685|NCT04245319|Drug|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
79722686|NCT04245319|Other|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
80019961|NCT04645979|Other|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
79397927|NCT02319369|Drug|AZA|AZA will be administered at 75 mg/m^2 subcutaneously or intravenously
79559776|NCT05282277|Drug|Raclopride C11|All Participants will receive two PET-MR scans using [11C]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
79559777|NCT05280821|Dietary Supplement|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
79559778|NCT05280821|Dietary Supplement|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
79559779|NCT05266703|Other|Isotopically labelled iron sulfate 15mg|test drink: water containing isotopic iron solution with vitamin C
79722687|NCT02828449|Behavioral|therapeutic education program|
79722688|NCT02828371|Device|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
79722689|NCT02828371|Other|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
79857206|NCT00978354|Drug|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
79857207|NCT00987012|Dietary Supplement|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
79857208|NCT00987012|Dietary Supplement|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
79857209|NCT00984360|Drug|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
80019962|NCT04617496|Behavioral|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features
80019963|NCT04617496|Behavioral|Health education|Provision of general information about a variety of topics
80019964|NCT04614558|Drug|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
79397928|NCT02319369|Drug|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
79397929|NCT01491841|Drug|Bendamustine + Rituximab + Pixantrone|Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
79397930|NCT01491841|Drug|Pegfilgrastim|6mg administered on Day 2 of each 21 day cycle
79857210|NCT03808350|Procedure|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
79857211|NCT03808350|Other|Placebo/Control|Family members will not be invited to remain in the ICU room
79559780|NCT05261633|Device|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
80019965|NCT04606030|Device|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
80019966|NCT04606030|Procedure|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
79559781|NCT05259150|Behavioral|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, & Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
79559782|NCT05259150|Behavioral|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool & Recognition.
79559783|NCT05259150|Behavioral|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
79722690|NCT02828215|Device|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
79722691|NCT05143099|Drug|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
79722692|NCT02828059|Drug|Ropivacaine|Surgical wound Infiltration over 48 hours
79722693|NCT02827903|Drug|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
79857212|NCT00414388|Drug|Sorafenib|400mg twice daily
80019967|NCT04589273|Dietary Supplement|Alginate|Volunteers will be asked to consume the alginate capsules with each of their three main meals per day.
80019968|NCT04589273|Other|Placebo|Volunteers will be asked to consume the placebo capsules with each of their three main meals per day.
80019969|NCT04578210|Biological|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
80019970|NCT04553341|Device|Navigated repetitive transcranial magnetic stimulation|In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
80019971|NCT04549454|Behavioral|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
80019972|NCT04549454|Behavioral|General Parenting Advice|General parenting advice
80019973|NCT04546451|Behavioral|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
79397931|NCT00486447|Device|64 Channel VCT|cardiac CT angiography exam
79857213|NCT00978588|Drug|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
79857214|NCT01037608|Drug|Sativex(Registered Trademark)|
79397932|NCT04081441|Device|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
79857215|NCT01037608|Drug|THC|
79857216|NCT04006080|Biological|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
79857217|NCT00984438|Drug|BCNU Wafer|Implantable during surgical resection into the tumor bed
79857218|NCT00984438|Drug|Irinotecan|IV every 2 weeks for up to one year
79857219|NCT00984438|Drug|Bevacizumab|IV every 2 weeks for up to one year
79857220|NCT01037686|Radiation|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
79857221|NCT01037686|Behavioral|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
80019974|NCT04546451|Behavioral|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
80019975|NCT04510532|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
80019976|NCT04504331|Drug|Infigratinib|Oral dose
80019977|NCT04504331|Drug|Tamoxifen|Oral Dose
80019978|NCT04504331|Drug|Omnipaque 350|IV contrast agent
79559784|NCT05259150|Other|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
79559785|NCT05254743|Drug|Pirtobrutinib|Administered orally.
79559786|NCT05254743|Drug|Ibrutinib|Administered orally.
79559787|NCT05251675|Behavioral|Physician Led Professional Coaching|This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.
79559788|NCT05251675|Behavioral|Delayed Physician Led Professional Coaching|This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
79559789|NCT05239000|Other|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
79559790|NCT05239000|Other|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
79559791|NCT05233956|Device|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
79559792|NCT05233956|Drug|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
79559793|NCT05225558|Drug|Delpazolid|BID, PO
79559794|NCT05225558|Drug|Vancomycin|IV infusion per 2020 IDSA guideline
79559795|NCT05225558|Drug|Placebo of Delpazolid|BID, PO
79559796|NCT05209737|Procedure|Trendelenburg position|A 10-degree head-down position will be used in this group
79559797|NCT05209737|Procedure|Semirecumbent position|A 30-degree head-up position will be used in this group
79559798|NCT05203445|Drug|Olaparib|Olaparib 300 mg orally BID
79559799|NCT05203445|Drug|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
79559800|NCT05195151|Dietary Supplement|Taking capsule containing probiotics or placebo|The probiotics capsule containing two strains of probiotics.
79559801|NCT05186740|Device|ProVee Urethral Expander System|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
79397933|NCT04081441|Behavioral|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
79559802|NCT05186740|Procedure|Urethral Access Sheath|The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
79559803|NCT05181540|Biological|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
79559804|NCT05181540|Other|Placebo|Placebo
79559805|NCT05162599|Device|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
79559806|NCT05147298|Other|eHealth phone program|The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
79559807|NCT05147298|Other|Environment program|The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
79559808|NCT05134831|Diagnostic Test|Rhinomanometry|"At Day 0, before the hyaluronic acid injection, the patient's nasal breathing is assessed by 4-phase rhinomanometry (bilaterally: right nostril AND left nostril).~At Month 1, the patient's nasal breathing is re-assessed by 4-phase rhinomanometry, in the same conditions as Day 0."
79559809|NCT05132933|Procedure|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
79559810|NCT05130216|Other|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
79857222|NCT01037686|Device|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
79559811|NCT05126238|Drug|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
79722694|NCT02827903|Drug|Metformin + placebo|Group II: Metformin + placebo,
79857223|NCT03920280|Device|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
79722695|NCT02827903|Drug|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
79722696|NCT05135923|Dietary Supplement|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
79722697|NCT02830945|Behavioral|Motivational Interviewing Intervention Arm|
79722698|NCT02830945|Other|Control Brochure Arm|
79857224|NCT03920280|Device|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
79397934|NCT00297063|Drug|Rosiglitazone|
79397935|NCT04408573|Other|Cycling deep brain stimulation|Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
79397936|NCT01553318|Drug|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
79397937|NCT01553318|Drug|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
79397938|NCT00486525|Procedure|Yoga Therapy|Patients will undergo yoga therapy
79857225|NCT03920280|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
79397939|NCT01572740|Drug|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
79559812|NCT05126238|Drug|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
79559813|NCT05117255|Behavioral|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
80019979|NCT04504331|Drug|Iopamidol|IV contrast agent
80019980|NCT04504331|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
79722699|NCT04247113|Behavioral|Parent-based prevention following bariatric surgery|PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
79857226|NCT00424372|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
79260309|NCT02079701|Biological|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
80019981|NCT04457102|Device|MANIV|mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac
80019982|NCT04457102|Other|Spontaneous DIBH|performed on Varian® Halcyon LINAC and Infinity Elekta® linac
79559814|NCT05117255|Behavioral|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
79857227|NCT00987090|Biological|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
79857228|NCT00987090|Radiation|MRI|intervention at the inclusion and 18 months after
79260310|NCT02079701|Biological|Placebo|
79397940|NCT01572740|Drug|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
79397941|NCT01572740|Drug|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
79559815|NCT05098210|Biological|Neoantigen Peptide Vaccine|Given IM
79559816|NCT05098210|Biological|Nivolumab|Given IV
79559817|NCT05098210|Drug|Poly ICLC|Given IM
79559818|NCT05096390|Drug|Axitinib Oral Tablet [Inlyta]|Axitinib 5 up to 10mg twice a day
79559819|NCT05096390|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
79722700|NCT00888433|Device|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
79722701|NCT01243424|Drug|linagliptin|linagliptin tablets 5mg QD
79722702|NCT01243424|Drug|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
79397942|NCT01491607|Biological|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
80019983|NCT04447911|Drug|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
79397943|NCT02338713|Drug|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
79397944|NCT02338713|Drug|Noncarbonated Water|Noncarbonated water 200 mL
80019984|NCT04447911|Drug|Placebo|Placebo per os once daily for 30 days
80019985|NCT04443452|Diagnostic Test|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
79857229|NCT00987090|Procedure|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
80019986|NCT04443452|Radiation|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
79559820|NCT05067283|Drug|MK-1084|Oral dose
79722703|NCT01243424|Drug|linagliptin placebo|linagliptin placebo
79857230|NCT00987090|Biological|Apolipoprotein E genotyping|genotyping at the inclusion
79857231|NCT00987090|Biological|Study of cerebrospinal fluid|intervention at the inclusion
79857232|NCT04006236|Other|Experimental Infant Formula|Feed Ad Libitum
79857233|NCT04006236|Other|Control Infant Formula|Feed Ad Libitum
79857234|NCT00988104|Behavioral|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
79260311|NCT03233919|Device|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
79260312|NCT02079779|Other|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
79559821|NCT05067283|Biological|Pembrolizumab|Intravenous infusion of 200 mg
79722704|NCT01243424|Drug|glimepiride placebo|glimepiride placebo
79857235|NCT00988104|Behavioral|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
79857236|NCT00978900|Dietary Supplement|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
79857237|NCT00978900|Dietary Supplement|Water|
79857238|NCT00988182|Other|dietary intervention|whey protein
79857239|NCT00988182|Other|water control|
79559822|NCT05067283|Drug|carboplatin|Per label
79559823|NCT05067283|Drug|pemetrexed|Per label
79559824|NCT05067283|Biological|cetuximab|Per label
79722705|NCT02831023|Drug|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
79722706|NCT02831023|Drug|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
79722707|NCT02831023|Drug|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
79857240|NCT00987168|Drug|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
79857241|NCT00978978|Drug|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
79857242|NCT00414310|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days.
79857243|NCT00414310|Drug|Valproic Acid|50 mg/kg orally daily for 7 days
79857244|NCT00542880|Drug|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
79857245|NCT00542880|Drug|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
79857246|NCT03726294|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
79857247|NCT00414076|Drug|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
79857248|NCT00987246|Drug|Placebo Gel|Topical
79857249|NCT00987246|Drug|LAS41005|Topical
79857250|NCT00987246|Drug|LAS106521|Topical
79857251|NCT01424098|Behavioral|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
79857252|NCT01033318|Drug|MK1809|single oral doses of MK1809
79559825|NCT05067283|Drug|oxaliplatin|Per label
79559826|NCT05067283|Drug|leucovorin|Per label
79559827|NCT05067283|Drug|5-fluorouracil|Per label
79722708|NCT02831023|Drug|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
79559828|NCT05065905|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
79857253|NCT01033318|Drug|Comparator: Losartan|single oral doses of 100 mg Losartan
79559829|NCT05056064|Other|Oral exercise|exercise remain tongue
79857254|NCT01033318|Drug|Comparator: Placebo|Placebo to MK1809
79857255|NCT04006158|Device|LED bed|Low risk FDA cleared full body LED bed
79857256|NCT00988338|Biological|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
79857257|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
79857258|NCT01033396|Drug|Allegra|Fexofenadine single dose 60 mg
79857259|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
79857260|NCT01033396|Drug|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
79857261|NCT01033396|Drug|Placebo|Placebo single dose
79857262|NCT00988416|Procedure|PET-CT|Pancreas Protocol PET-CT
79857263|NCT00979056|Drug|Rifaximin|400 mg per day, oral use, maximum duration 28 days
79857264|NCT00979056|Drug|Lactose|Coated Tablet, Oral Use
79857265|NCT04006314|Other|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
79857266|NCT00987324|Device|Taxus stent|Implantation of paclitaxel-eluting stent
79857267|NCT00987324|Device|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
80019987|NCT04443452|Procedure|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
79857268|NCT00987324|Device|Conventional Balloon Catheter|Ryuijin, Trek
79857269|NCT00092677|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
79559830|NCT05043389|Other|myofunctional therapy program|Exercise oral cavity muscle
79857270|NCT00092677|Drug|Comparator: Placebo|matching Placebo
79857271|NCT00988572|Other|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
79857272|NCT00979368|Drug|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
80019988|NCT04443452|Diagnostic Test|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
79397945|NCT00557349|Drug|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
79857273|NCT00979368|Drug|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
79857274|NCT00979368|Drug|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
79857275|NCT00979368|Drug|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
79857276|NCT00979368|Drug|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
79857277|NCT00979368|Drug|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
80019989|NCT04443452|Diagnostic Test|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
80019990|NCT04443452|Diagnostic Test|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
80019991|NCT04443452|Diagnostic Test|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
79559831|NCT05020873|Other|Crizanlizumab|Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
79559832|NCT05017571|Drug|Colchicine|Colchicine 1 capsule (0.6 mg) per day
79559833|NCT05017571|Drug|Placebo|Placebo 1 capsule per day
79559834|NCT05014724|Drug|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
79559835|NCT05003531|Drug|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
79722709|NCT02831023|Drug|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
79722710|NCT02830711|Other|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
79722711|NCT02826967|Procedure|Colonic Irrigation|
79857278|NCT04651920|Genetic|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
79857279|NCT00542178|Drug|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
79857280|NCT00542178|Drug|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
79857281|NCT00542178|Drug|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
79857282|NCT00542178|Drug|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
79857283|NCT00542178|Drug|Fenofibrate|Blinded fenofibrate
79857284|NCT00542178|Drug|Simvastatin|Simvastatin 20-40 mg/d
79857285|NCT00542178|Drug|Placebo|Placebo
79857286|NCT00987636|Drug|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients < 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients >= 18 years will receive a bodyweight-dependent dose:~Patients >40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
80019992|NCT04384835|Biological|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
79260313|NCT02079779|Other|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
79260315|NCT03559595|Behavioral|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
79260316|NCT03559439|Biological|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
79260317|NCT03236025|Combination Product|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
79559836|NCT05003531|Drug|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
79559837|NCT05003531|Drug|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
79559838|NCT05003531|Drug|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
79559839|NCT05003531|Drug|placebo|Participants will receive placebo SC
79559840|NCT04995003|Genetic|T cells or CAR T cells|"There are 2 dose levels:~Dose Level 1 (1x10^8 cells/m2) and Dose Level -1 (5x10^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
79722712|NCT04244539|Device|high-intensity laser Device.|Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of ~0.1%.
79722713|NCT02827825|Other|No intervention|No intervention. It's a study on retrospective Data
79722714|NCT02827669|Behavioral|One Drop Experts Program|
80019993|NCT04384835|Biological|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
79722715|NCT02827669|Behavioral|One Drop Experts Program + Apple Watch|
79722716|NCT04244695|Drug|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
79857287|NCT00987636|Drug|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: <9 kg= 1mg/kg BW 9 - <16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW >23 - 34 kg= 0.95 mg/kg BW >34 kg = 0.8 mg/kg BW
80019994|NCT04336215|Other|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
80019995|NCT04313985|Device|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
80019996|NCT04305782|Device|Release/Relock Socket - In Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.
79260318|NCT03236025|Combination Product|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
79260319|NCT03236025|Other|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
79559841|NCT04995003|Drug|Pembrolizumab Injectable Product|2 mg/kg/dose (max 200 mg/dose) every 3 weeks
79559842|NCT04995003|Drug|Nivolumab Injectable Product|3 mg/kg/dose (<40kg) or 124 mg (≥40 kg) every 2 weeks
79559843|NCT04983810|Drug|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
79559844|NCT04982445|Drug|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
79559845|NCT04975139|Device|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
79722717|NCT00887809|Drug|gemcitabine|
79559846|NCT04970966|Device|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
79722718|NCT00887809|Drug|docetaxel|
79722719|NCT00887809|Drug|bevacizumab|
79722720|NCT02830399|Device|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
79722721|NCT02830399|Device|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
79722722|NCT02826889|Device|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
79722723|NCT02826889|Device|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
79857288|NCT00987636|Drug|Treosulfan|12 g/m² d-5 to d-3
79857289|NCT00424294|Drug|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
79260320|NCT03057080|Procedure|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
79559847|NCT04970966|Device|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
79559848|NCT04967469|Drug|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
79722724|NCT04244617|Behavioral|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
79722725|NCT02827747|Other|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
79722726|NCT02827747|Other|Placebo|Placebo pill
79722727|NCT02827747|Dietary Supplement|Centrum|Centrum
79722728|NCT02827747|Combination Product|Dietary Sources|From dietary sources of vitamins.
79722729|NCT02830633|Procedure|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
79722730|NCT02830633|Procedure|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
79722731|NCT04244851|Other|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
79722732|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
79722733|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
79722734|NCT00958126|Biological|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
79722735|NCT02861560|Other|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
79722736|NCT04281394|Device|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
79722737|NCT04281394|Other|conventional gait training|even level gait training and range of motion exercises
79722738|NCT04281628|Drug|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
79722739|NCT04281628|Drug|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
79722740|NCT02859844|Device|Transcutaneous Tibial Nerve Stimulation (TTNS)|
79857290|NCT00424294|Drug|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
79857291|NCT00424294|Drug|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
79260321|NCT03558425|Drug|CKD-381|1 tablet administered before the breakfast during 7 days
79260322|NCT03558425|Drug|D026|1 tablet administered before the breakfast during 7 days
79260323|NCT03227835|Other|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR >29mL/min/1.73m2
79559849|NCT04967469|Drug|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
79857292|NCT00979446|Behavioral|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
79857293|NCT00979446|Behavioral|Self-directed|Received study materials but no phone coaching
79260324|NCT03236103|Other|Clinical Recommendations|"The clinical recommendations will regard the following:~Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~Optimizing volume status (avoidance of volume overload or depletion)~Optimizing electrolytes and acid-base status~Optimizing hemodynamics (Mean arterial BP>65mmHg)~Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
79559850|NCT04967001|Diagnostic Test|PSMA PET|68Ga-PSMA PET
79857294|NCT00988650|Other|isocaloric diet|
79857295|NCT00988650|Other|free living conditions|
79857296|NCT00988728|Drug|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
79857297|NCT00988728|Drug|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
79559855|NCT04958226|Drug|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
79559856|NCT04958226|Drug|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
79722741|NCT04280302|Behavioral|Virtual Reality-based Rehabilitation|VR-based eye stabilization exercises and balance exercises
79722742|NCT04280302|Behavioral|Conventional Therapy|Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
79260325|NCT02081495|Drug|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
79397946|NCT00557349|Drug|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
79559857|NCT04947722|Behavioral|PREVENT Program|A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.
79722743|NCT04279756|Other|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
79722744|NCT02861638|Device|Experimental group|Video of the exercises
79722745|NCT02861638|Device|Control group|video of nature scenes
79722746|NCT02861638|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
79722747|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
79722748|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
79722749|NCT04279600|Dietary Supplement|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
79722750|NCT04279600|Dietary Supplement|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
79260326|NCT02081495|Drug|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
79260327|NCT03056846|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
79260328|NCT03056846|Dietary Supplement|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
79397947|NCT01449721|Drug|Intravenous fluid|0.9% Sodium chloride intravenous fluid
79559858|NCT04938245|Device|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
79559859|NCT04923542|Radiation|Stereotactic Radiosurgery (SRS)|Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
79722751|NCT04279600|Other|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
79260329|NCT03056846|Dietary Supplement|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
79260330|NCT03056846|Dietary Supplement|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
79722752|NCT02830321|Other|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
79260331|NCT04431128|Behavioral|infant feeding position|correlation with allergy, GER or feeding position
79260332|NCT02087969|Procedure|Dry Needling|
79722753|NCT04246645|Other|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
79722754|NCT00886795|Drug|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
79722755|NCT02783482|Biological|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
79722756|NCT02827357|Other|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
79722757|NCT00889681|Device|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
79722758|NCT05048095|Other|AI cancer detection system|The use of AI as a third reader and as a decision support system during consensus meeting
79722759|NCT00957658|Device|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
79722760|NCT00953680|Drug|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
79722761|NCT00953680|Drug|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
79722762|NCT00953680|Drug|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
79260333|NCT02087969|Procedure|Stretching|
79260334|NCT02081651|Dietary Supplement|Parmigiano Reggiano cheese|
79260335|NCT03234075|Other|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~Helping to carry out the pre-graft assessments of patients by a care coordinator"
79559860|NCT04923542|Drug|Abemaciclib|Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
79559861|NCT04923542|Drug|Endocrine therapy|Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
79260336|NCT04431284|Other|Questionnaires|The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
79559862|NCT04912089|Behavioral|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
79559863|NCT04903795|Drug|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
79559864|NCT04897022|Drug|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
79559865|NCT04897022|Radiation|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
79559866|NCT04895761|Biological|DPX-Survivac|"DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5."
79722763|NCT00890929|Drug|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
79722764|NCT00890929|Drug|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
79722765|NCT04279366|Behavioral|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
79397948|NCT01553084|Drug|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
79397949|NCT01553084|Drug|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
79722766|NCT04246567|Procedure|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
79722767|NCT04246567|Drug|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
79722768|NCT04271566|Behavioral|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
79722769|NCT04243681|Combination Product|CD 34 and MSC infusion|Combination of stem cells
79722770|NCT04243681|Drug|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
79260337|NCT03545269|Drug|CartiLife®|CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
79722771|NCT00886639|Other|6MWT with oxygen|2 liter per minute as continuous-flow
79722772|NCT00886639|Other|6MWT with medical air|2 liters as continuous-flow
79722773|NCT04244383|Diagnostic Test|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
79722774|NCT04244305|Other|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
79722775|NCT02830243|Drug|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
79722776|NCT02830243|Drug|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
79857298|NCT00988728|Drug|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
79559867|NCT04895761|Drug|Letrozole 2.5mg|Aromatase inhibitor all arms will receive
79559868|NCT04895761|Drug|Cyclophosphamide 50mg|oral chemotherapy used in the neoadjuvant setting for Arm C only
79559869|NCT04895761|Radiation|XRT 10Gy x2|Directed radiation at week 4 for Arm B only
79559870|NCT04883970|Other|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
79559871|NCT04883346|Drug|Liraglutide|Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
79559872|NCT04874961|Dietary Supplement|Tensiofytol®|standardized olive extract
79559873|NCT04874961|Other|Placebo|contains excipients only
79559874|NCT04863417|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
79722777|NCT02830009|Other|Urines samples|24-hour urines will be collected
79857299|NCT00988806|Drug|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
79260338|NCT03545269|Procedure|Microfracture|The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
79559875|NCT04863417|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
79722778|NCT02830009|Other|Blood sample|
79260339|NCT02088125|Other|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
79559876|NCT04854096|Drug|NS-018|Experimental
79559877|NCT04854096|Drug|Best Available Therapy|Active Comparator
79559878|NCT04848688|Drug|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
79260340|NCT02088125|Other|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
79260341|NCT03227679|Other|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
79559879|NCT04848688|Drug|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
79559880|NCT04848688|Drug|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
79559883|NCT04822753|Procedure|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
79722779|NCT00889603|Drug|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
79559884|NCT04795661|Drug|Pembrolizumab|Administered intravenous (IV)
79559885|NCT04785586|Behavioral|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
79559886|NCT04785586|Behavioral|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
79559887|NCT04785586|Behavioral|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
79559888|NCT04776941|Behavioral|Behavioral Intervention|Read positive messages
79559889|NCT04776941|Behavioral|Behavioral Intervention|Write about positive experiences
79559890|NCT04776941|Behavioral|Behavioral Intervention|Write about neutral topics
79559891|NCT04776941|Behavioral|Behavioral Intervention|Read neutral messages
79559892|NCT04776941|Other|Quality-of-Life Assessment|Ancillary studies
79559893|NCT04776941|Other|Questionnaire Administration|Complete questionnaires
79722780|NCT04244071|Device|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
79722781|NCT04244071|Other|routine hospital care|routine hospital care
80019997|NCT04305782|Device|Release/Relock Socket - Out of Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine if the order of the re-lock mechanisms changes participant experience.
79559894|NCT04770870|Device|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
79260342|NCT03227679|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
79260343|NCT03227679|Drug|Bupropion|FDA-approved smoking cessation pharmacotherapy
79397950|NCT01553084|Drug|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
79722782|NCT04244149|Other|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
79722783|NCT04243135|Device|ESWT|Extracorporeal shock wave therapy
79397951|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
79722784|NCT02826577|Drug|Pregnenolone 175mg|Single Dose 175mg
79722785|NCT02826577|Drug|Pregnenolone 400mg|Single Dose 400mg
79722786|NCT02826577|Drug|Placebo|Single Dose
79722787|NCT00886483|Device|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
79857300|NCT00988806|Drug|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
79260344|NCT03227679|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
79397952|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
79397953|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
79260345|NCT03057548|Procedure|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
79397954|NCT01552928|Drug|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
79397955|NCT01552928|Drug|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
79397956|NCT01552928|Drug|Moxifloxacin|400 mg Moxifloxacin single oral dose
79397957|NCT01552928|Drug|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
79397958|NCT01448707|Drug|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
79397959|NCT01448707|Drug|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
79397960|NCT01536704|Drug|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
79397961|NCT01536704|Drug|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
79559895|NCT04763343|Drug|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
79722788|NCT00886483|Device|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
79722789|NCT00886015|Device|TT Clamp|trichiasis surgery performed with TT clamp
79722790|NCT00886015|Procedure|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
79722791|NCT02829853|Genetic|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo & HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
79722792|NCT00890695|Dietary Supplement|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
79857301|NCT04005768|Drug|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
79260346|NCT03057548|Procedure|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
79397962|NCT04108676|Drug|Fluzoparib|PARP inhibitor
79397963|NCT04108676|Drug|Omeprazole|proton pump inhibitor
79857302|NCT04005768|Drug|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
79260347|NCT04886167|Drug|AbobotulinumtoxinA|Injection of platysmal bands.
79722793|NCT02826655|Device|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
79397964|NCT04121546|Behavioral|Telecare Intervention|Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
79559896|NCT04763343|Drug|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
79559897|NCT04763343|Behavioral|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk < 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
79722794|NCT02826499|Device|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
79722795|NCT02826499|Other|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
79857303|NCT00987714|Procedure|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
79559898|NCT04761393|Procedure|Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI|Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
79857304|NCT00987792|Drug|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
79857305|NCT04459260|Behavioral|Cognitive Behavior Therapy|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change."
80019998|NCT04305782|Device|Release/Relock Socket & Control|The participants will operate the test socket in one of two test conditions: (1) release/relock mechanisms enabled and (2) release/relock mechanisms disabled. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine how the novel release/relock mechanisms compare against traditional socket release methods.
79559899|NCT04747795|Drug|Vitamin C|IV
79559900|NCT04747795|Drug|Normal saline|IV
79559901|NCT04731363|Dietary Supplement|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
79260348|NCT04937894|Drug|Tigecycline|Efficacy and safety of Tigecycline
79260349|NCT04882501|Other|QUEASEEase aromatherapy quick tab|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
79260350|NCT04882501|Other|Placebo product|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
79260351|NCT02088203|Dietary Supplement|Dose 1|Russian Tarragon Nutrasorb 0.3 g
79260352|NCT02088203|Dietary Supplement|Dose 2|Russian Tarragon Nutrasorb 1 g
79260353|NCT02088203|Dietary Supplement|Dose 0|Placebo
79260354|NCT02088203|Dietary Supplement|Dose 3|Russian Tarragon Nutrasorb 3 g
79260355|NCT02088203|Dietary Supplement|Dose 4|Russian Tarragon Nutrasorb 10 g
79260356|NCT02088203|Dietary Supplement|Dose 5|Russian Tarragon Nutrasorb 20 g
79260357|NCT02088203|Dietary Supplement|Dose 6|Russian Tarragon Nutrasorb 30 g
79260358|NCT04919486|Behavioral|visual feedback with non-weight bearing exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
79397965|NCT01552772|Drug|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
79397966|NCT01552694|Drug|Sitagliptin|Oral, 100 mg/day for 2 months
79857306|NCT04459260|Behavioral|Unified Protocol|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead."
79559902|NCT04731363|Dietary Supplement|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
79857307|NCT00987870|Drug|BFH772|
79857308|NCT00987870|Drug|Placebo|
79722796|NCT04242979|Behavioral|Questionnaire about albumin use in liver cirrhosis|"Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~A pilot study will be 10% done to test the clarity and feasibility of developed tool.~Each participant involved in the study will be assessed for his or her knowledge using (tool I).~Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
79857309|NCT00987870|Drug|BFH772|
79857310|NCT00987870|Drug|Placebo|
79857311|NCT00987870|Drug|calcipotriol/betamethasone|
79857312|NCT00988026|Drug|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
79857313|NCT00988962|Behavioral|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
79722797|NCT02829541|Drug|BIIB068|Administered as specified in the treatment arm.
79857314|NCT05578170|Drug|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
79857315|NCT00989040|Drug|usual treatment: Versatis|"To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
79857316|NCT00989118|Procedure|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
79857317|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
79722798|NCT02829541|Drug|Placebo|Administered as specified in the treatment arm
79722799|NCT02827123|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
79722800|NCT02827123|Drug|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
79722801|NCT00633607|Other|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
79722802|NCT05041543|Drug|NTX-101|Eye drops, topical administration
79857318|NCT00989274|Biological|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
79857319|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
79559903|NCT04731363|Dietary Supplement|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
79559904|NCT04731363|Dietary Supplement|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
79559905|NCT04715425|Procedure|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
79559906|NCT04715425|Procedure|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
79559907|NCT04710134|Biological|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
79722803|NCT05041543|Drug|Placebo|Placebo as eye drops
79857320|NCT03310944|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
79857321|NCT04804254|Drug|ABBV-623|Oral Tablets
79857322|NCT04804254|Drug|ABBV-992|Oral Tablets
79857323|NCT05712642|Drug|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
79260359|NCT04919486|Behavioral|elastic band exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
79857324|NCT00092521|Biological|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
79857325|NCT00092521|Biological|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
79857326|NCT00092521|Biological|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
79857327|NCT03908970|Drug|1% OPA-15406|Twice daily
79857328|NCT03908970|Drug|Placebos|Twice daily
79559908|NCT04708886|Drug|Romosozumab|Year 1 study drug
79559909|NCT04708886|Drug|Alendronate|Year 2 study drug
79857329|NCT05712330|Other|non invasive ventilation samples|machine samples for bacterial culture will be performed
79857330|NCT05712330|Other|patient samples|Patient samples for sputum culture
79857331|NCT05712330|Other|parent questionnaire|parent questionnaire
79857332|NCT00092443|Biological|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
79857333|NCT00092443|Biological|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
79857334|NCT04005924|Other|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
79857335|NCT01085149|Drug|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
79857336|NCT04691622|Biological|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
79857337|NCT04005612|Dietary Supplement|vitamin D3|50,000 IU VD3 / week for 8 weeks
79722804|NCT02826265|Device|multiple breath washout test (MBW)|
79559910|NCT04700137|Other|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
79397967|NCT01552694|Drug|Placebo|oral, matching placebo daily for 2 months
79397968|NCT01464931|Drug|Denosumab|Adminstered by subcutaneous injection
79397969|NCT00560859|Procedure|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
79397970|NCT00560859|Other|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
79397971|NCT03028376|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
79397972|NCT01536392|Drug|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
79397973|NCT01536392|Drug|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
79559911|NCT04700137|Other|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
79857338|NCT04005612|Dietary Supplement|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
79857339|NCT04005612|Dietary Supplement|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
79857340|NCT04005612|Other|control|no intervention
79857341|NCT00413920|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
79559912|NCT04693468|Drug|Axitinib|Given PO
79559913|NCT04693468|Drug|Crizotinib|Given PO
79559914|NCT04693468|Drug|Palbociclib Isethionate|Given PO
79722805|NCT02826265|Device|impulse oscillometry (IOS)|
79722806|NCT02826265|Device|body plethysmography (BP)|
79260360|NCT01570465|Other|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
79260361|NCT04919252|Drug|Vedolizumab|"Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
79260362|NCT03119961|Device|SONOCLOUD®|BBB opening by ultrasound
79260363|NCT04919174|Drug|Remimazolam|Sedation with remimazolam
79397974|NCT01536392|Behavioral|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
79397975|NCT01536392|Behavioral|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
79397976|NCT01464619|Other|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
79559915|NCT04693468|Drug|Talazoparib Tosylate|Given PO
79722807|NCT02826265|Device|quantitative computed tomography (qCT)|ultra-low-dose qCT
79722808|NCT04246411|Behavioral|Ultrasound-guided determination of cuffless RAE tube depth|"Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
79722809|NCT04246411|Behavioral|Auscultation-guided determination of cuffless RAE tube depth|"Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
79857342|NCT00413920|Drug|Prednisone|Oral tablets
79857343|NCT03993964|Drug|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
80019999|NCT04283578|Drug|OT|One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
80020000|NCT04283578|Drug|Placebo comparator|One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
79857344|NCT01037764|Procedure|alloHCT|"[ alloHCT arm ] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
79857345|NCT01033630|Drug|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
79857346|NCT01033630|Drug|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
79857347|NCT01033630|Drug|Placebo|Image-matched placebo, made with starch.
79857348|NCT00091819|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
79857349|NCT00091819|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
79857350|NCT01326871|Drug|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
79260364|NCT04919174|Drug|Dexmedetomidine|Sedation with dexmedetomidine
79260365|NCT02085239|Drug|Lidocaine Ropivacaine|"8-10 ml of Lidocaine given by subcutaneous injection~8-10 ml of Ropivacaine given by subcutaneous injection"
79559916|NCT04693169|Drug|11C-Choline|1、PSMA137 labeled with [Al18F] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the [Al18F]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
79559917|NCT04688593|Device|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
79260366|NCT02085239|Drug|Lidocaine alone|
79559918|NCT04678297|Behavioral|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
79857351|NCT01326871|Drug|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
79260367|NCT03233997|Other|FT21018|An electronic cigarette
79260368|NCT03233997|Other|FT21033|An electronic cigarette
79722810|NCT02829385|Drug|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
79722811|NCT02826109|Device|PeriAcryl®90 HV|
79722812|NCT02826343|Drug|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
79722813|NCT02826343|Drug|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
79857352|NCT01326871|Biological|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
79260369|NCT03233997|Other|FT21034|An electronic cigarette
79260370|NCT03233997|Other|FT21035|An electronic cigarette
79260371|NCT03056768|Behavioral|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
79260372|NCT03056768|Behavioral|Active control|Health promotion activities provided by local health bureau.
79260373|NCT02085317|Drug|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
79260374|NCT02085317|Drug|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
79260375|NCT03544645|Other|"Audiovisual material video"|an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
79857353|NCT01081405|Other|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
79857354|NCT01081483|Drug|ABT-072|See arm description for more information
79857355|NCT01081483|Drug|Placebo|See arm description for more information
79857356|NCT03964129|Procedure|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
79857357|NCT00540228|Biological|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
79857358|NCT00540228|Biological|Fluarix™|Single dose, Intramuscular injection
79559919|NCT04678297|Behavioral|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
79857359|NCT01081561|Drug|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
79260376|NCT03544645|Other|"Printed material brochure"|an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
79260377|NCT03234153|Drug|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
79260378|NCT03234153|Drug|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
79260379|NCT02085395|Drug|SR-T100 ® Gel|
79260380|NCT03056924|Biological|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
79260381|NCT03056924|Biological|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
79559920|NCT04675515|Behavioral|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
79857360|NCT04004754|Drug|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
79857361|NCT04567056|Diagnostic Test|Blood sample|A separate blood sample will be taken for methylation-analyses
79559921|NCT04667767|Other|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
79260382|NCT03056924|Biological|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
79857362|NCT05919901|Other|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
80020001|NCT04274998|Drug|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer [18F]NOS.
79260383|NCT03227367|Other|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
79260384|NCT02453061|Drug|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
79260385|NCT02453061|Drug|Placebo|Safflower oil orally administered at 1g/kg/day
79260386|NCT04918862|Drug|Granisetron|210 patients were enrolled, divided into two groups [Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
80020002|NCT04274998|Drug|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer [11C]PBR28 in comparison to [18F]NOS.
79260387|NCT03233763|Procedure|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
79260388|NCT02088281|Drug|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
79260389|NCT04918706|Genetic|Allogeneic MSC|These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC
79260390|NCT04918706|Drug|Placebo|The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
79260391|NCT03233685|Behavioral|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
79260392|NCT03233685|Behavioral|Normal Training|Normal training routine
79260393|NCT03559361|Dietary Supplement|EPA-rich|6 months omega 3 supplementation
79260394|NCT03559361|Dietary Supplement|DHA-rich|6 months omega 3 supplementation
79260395|NCT03559361|Dietary Supplement|Olive oil Placebo|6 months placebo supplementation
79260396|NCT02088359|Other|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
79260397|NCT02088359|Other|Continue near darkness|We covered the incubator with blanket all days.
79260398|NCT02452905|Drug|Nitazoxanide|
79260399|NCT02452905|Drug|Placebo (for Nitazoxanide)|
79260400|NCT04918550|Other|no drug and device|there is no intervention
79260401|NCT03780023|Other|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
80020003|NCT04271371|Other|Not yet developed|A prototype intervention will be developed over Phase 1 & 2 and piloted in Phase 3 of this study.
79260402|NCT04937426|Diagnostic Test|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|Diagnostic laboratory test for detection of helicobacter pylori
79260403|NCT03235401|Other|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
79260404|NCT02085629|Biological|Donor M reg (Mreg_UKR)|"Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description)."
79397977|NCT01464619|Other|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
79397978|NCT02123745|Device|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
79559922|NCT04667767|Other|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
79559923|NCT04662255|Drug|Pirtobrutinib|Oral
79559924|NCT04662255|Drug|Ibrutinib|Oral
80020004|NCT04267302|Other|Baby Bouncer|Fischer Price baby bouncer.
79260405|NCT04937114|Procedure|Barbed suture|Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
80020005|NCT04267302|Other|Infant t-shirts with Language Environment Analysis (LENA) audio recorders|Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.
80020006|NCT04267302|Other|Baby Carrier|Ergobaby Baby carrier.
79260406|NCT03227601|Device|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
79260407|NCT04918628|Drug|Sintilimab|A humanized anti-PD-1 monoclonal antibody
79260408|NCT02085707|Procedure|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
79260409|NCT02085707|Procedure|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
79260410|NCT03235167|Drug|CpG DNA|CpG DNA concentrate
79260411|NCT03235167|Procedure|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
79260412|NCT03235167|Drug|Placebo - Concentrate|CpG DNA vehicle
79260413|NCT04929782|Device|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
79397979|NCT04767295|Drug|Camrelizumab, Albumin Paclitaxel, Carboplatin|Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
79559925|NCT04662255|Drug|Acalabrutinib|Oral
79559926|NCT04662255|Drug|Zanubrutinib|Oral
79260414|NCT04929782|Device|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
79260415|NCT02452827|Other|Biomechanical parameters|
79260416|NCT02452827|Other|MRI|MRI of cervical spine
79397980|NCT00488865|Device|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
79397981|NCT02118441|Device|Ultrasound-guided Radial Artery Catheter Insertion|
79397982|NCT02118441|Device|Direct Palpation-guided Radial Artery Catheter insertion|
79397983|NCT02118831|Biological|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
79397984|NCT02118831|Drug|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
79397985|NCT02118831|Drug|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
79397986|NCT02118831|Drug|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
79397987|NCT03026179|Behavioral|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
79722814|NCT02826343|Drug|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
79722815|NCT04246255|Drug|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
79722816|NCT04246255|Drug|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
80020007|NCT04220255|Device|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
80020008|NCT04160130|Procedure|Transcatheter aortic valve replacement|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
80020009|NCT04157062|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
79397988|NCT02119455|Device|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
79559927|NCT04658771|Device|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
79559928|NCT04655404|Drug|Larotrectinib|"Larotrectinib monotherapy x2 cycles followed by disease evaluation~Larotrectinib with or without chemotherapy backbone"
79397989|NCT03026413|Procedure|pulmonary vein antrum modification|
79722817|NCT04246099|Other|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
79722818|NCT02824861|Behavioral|Bemobile|
79722819|NCT02825953|Drug|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
79722820|NCT02825953|Device|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
79857363|NCT05919875|Behavioral|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~Awareness and automatic pilot~Living in our heads~Being present in the body~Recognizing aversion~Allowing / Letting be~How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
79857364|NCT05919875|Behavioral|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~Introduction to the topic~Guided meditation~Brief inquiry and discussion~Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
79857365|NCT05919836|Procedure|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
79857366|NCT05919836|Procedure|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
79397990|NCT02120001|Device|ETT cleaning maneuver|"EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.~We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
79397991|NCT00490269|Drug|Placebo|
79397992|NCT00490269|Drug|Dronabinol|
79857367|NCT05919836|Procedure|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
79857368|NCT05919797|Drug|Naltrexone-Bupropion Combination|Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
79857369|NCT05919732|Drug|Bupivacaine and epinephrine infusion|"For caudal infusion group: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg) will be administered via the catheter.~For general anesthesia group: bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg) prior to start of the surgery."
80020010|NCT04143126|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
79277458|NCT03533153|Biological|WJ-MSC cells implantation|Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
79277459|NCT03533153|Drug|CTSTMD PBS without WJ-MSC|For Case-control study only.
79260417|NCT04929314|Behavioral|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
79559929|NCT04655404|Procedure|Larotrectinib surgical|"Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~Larotrectinib with or without chemotherapy backbone"
79559930|NCT04648358|Drug|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
79260418|NCT03233607|Procedure|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
79260419|NCT04918394|Other|Questionnaire of Mold / moisture exposure|"Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~Presence of visible mold~Impression of dampness~Apparent dampness~Existence of recent water damage in the last year~Presence of a moldy odor"
79260420|NCT02452749|Dietary Supplement|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
79559931|NCT04648358|Drug|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
79559932|NCT04633434|Behavioral|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
79559933|NCT04632238|Behavioral|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
79559934|NCT04629326|Other|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
79559935|NCT04623593|Procedure|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
80020011|NCT04143126|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
79260421|NCT04929860|Behavioral|social marketing campaign|social marketing campaign delivered over 4 weeks in 4 separate sessions
79397993|NCT05621499|Drug|HAIC|Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
79397994|NCT05621499|Drug|Sintilimab|200mg，iv，d1，q3w，a total of 3 cycles
79397995|NCT05621499|Drug|Lenvatinib|12 or 8mg/kg，po，qd，a total of 3 cycles
79397996|NCT05621421|Procedure|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
79397997|NCT01490125|Drug|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
79397998|NCT01490125|Drug|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
79397999|NCT01490125|Drug|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
79398000|NCT01490125|Drug|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
79398001|NCT01490125|Drug|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
79398002|NCT01446913|Device|Standard CPAP Intervention|
79398003|NCT01446913|Behavioral|Enhanced CPAP Intervention|
79398004|NCT00491751|Drug|atorvastatin|atorvastatin 40 or 80 mg/day
79398005|NCT00491751|Drug|ascorbic acid|ascorbic acid 500 mg/day
79398006|NCT00491751|Drug|Placebo|matching placebo
79398007|NCT01420549|Drug|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
79398008|NCT01420549|Drug|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
79857370|NCT05919719|Procedure|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
79857371|NCT05919667|Dietary Supplement|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
79722821|NCT02825953|Device|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
79857372|NCT05919641|Other|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
79857373|NCT05919615|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
79857374|NCT05919615|Drug|Normal saline|0.9% sodium chloride normal saline
79857375|NCT05919576|Device|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
79857376|NCT05919563|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
79722822|NCT02825953|Device|Neopuff|Fisher and Paykel, Auckland, New Zealand
79260422|NCT04918238|Other|Conventional program|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
79722823|NCT02825953|Device|neonatal ventilator|GE Healthcare, Madison, USA
79722824|NCT02826187|Other|Early complications data|"Early complications of interest are :~New arthroplasty for any reason~Related to the implant :~Wrong position of the implant~Early displacement of the implant~Related to the intervention :~Hematoma~Dislocation (or not causing the resumption of joint replacement)~Deep vein thrombosis~Pulmonary embolism~Acute Infection"
79398009|NCT00491829|Drug|50 mg qhs|flibanserin 50 mg
79398010|NCT00491829|Drug|100 mg|flibanserin 100mg
79722825|NCT02826187|Other|Late stage complications data|"Late complications taken into account are:~New arthroplasty for any reason~Aseptic loosening~Delayed hypersensitivity reaction type IV~Solid Tumors~Recurrent dislocation (causing or not the resumption of joint replacement)~Allergic reactions of any kind~Chronic infection"
79722826|NCT02826187|Other|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
79722827|NCT02826187|Other|Efficacity|Efficacity as evaluated by Harris HIP score
79722828|NCT02826187|Other|Radiographic evaluation|Bone reaction visible in radiography
79722829|NCT05210725|Drug|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
80020012|NCT04132544|Other|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
79398011|NCT00491829|Drug|placebo|placebo
79398012|NCT01440595|Drug|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
79398013|NCT01440595|Drug|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
79722830|NCT02826031|Drug|Sodium Hyaluronate Injection|
79722831|NCT02826031|Drug|DICL-SR|
79722832|NCT02829697|Drug|Ropivacaine|Perineural injection.
79722833|NCT04980469|Other|Vitex negundo + Zingiber officinale|200 mg/ Capsule
79722834|NCT04980469|Other|Placebo (MCC)|200 mg/ Capsule
79722835|NCT02829151|Drug|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
79722836|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
79857377|NCT05919550|Drug|search for a clozapine intake|search for a clozapine intake
79857378|NCT05919498|Other|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
79398014|NCT01440595|Drug|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
79398015|NCT01440595|Drug|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
79260423|NCT04918238|Other|Muscle energy technique|The patient was in the lateral recumbent position on the side opposite to his, her side-bending dysfunction while the physiotherapist stood facing the subject. The physiotherapist monitored the lumbar area with one hand while with the other hand flexed the subject's knees and hips until the barrier was engaged at the vertebral segment being treated.
79559936|NCT04623593|Procedure|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
79722837|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
79722838|NCT05207137|Behavioral|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
79722839|NCT02825719|Drug|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
79722840|NCT02825719|Other|Placebo pills|Placebo pills will be prescribed
79722841|NCT02825719|Drug|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
79722842|NCT02825719|Drug|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
79722843|NCT04241653|Procedure|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
79722844|NCT04241653|Procedure|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
79722845|NCT04241653|Procedure|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
79722846|NCT04241653|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
79722847|NCT04241653|Drug|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
79722848|NCT05199961|Behavioral|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
79559937|NCT04605380|Other|Virtual reality online world|Virtual patient with open fracture inside a virtual world
79722849|NCT04241731|Drug|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
79722850|NCT04241731|Drug|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
79722851|NCT02829073|Device|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
79260424|NCT03227133|Other|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
79260425|NCT03227133|Other|Psychiatric interview|
79260426|NCT03227133|Other|Cardiovascular risk assessment|
79398016|NCT05560347|Other|Hot water application|Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
79398017|NCT01440517|Drug|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
79559938|NCT04589468|Other|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
79722852|NCT02829073|Device|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
79722853|NCT02824159|Other|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
79722854|NCT02824159|Other|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
79722855|NCT02824159|Other|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
79722856|NCT02824159|Other|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
79260428|NCT02452281|Drug|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
79260429|NCT02452281|Drug|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
79398018|NCT05560269|Behavioral|Verbal coaching vs. Constraint based coaching|Providing verbal cues only to demonstrated proper form during a kettlebell swing exercise vs. the constraint of specific movements to enhance the kettle bell swing exercise.
79260430|NCT03558113|Diagnostic Test|light induced fluorescence intraoral camera|intraoral oral light induced fluorescence diagnostic camera
79398019|NCT01440283|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
79722857|NCT02824159|Genetic|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
79722858|NCT02824159|Genetic|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
79722859|NCT02824159|Other|Biological statement|"The following parameters will be assessed :~Complete blood count~Hemoglobin~Hepatic enzymes~Creatinine clearance~Lactate dehydrogenase rate~Total bilirubin rate~Cluster of differentiation 4 T lymphocytes rate~Total gamma-globulins rate"
79722860|NCT02824159|Other|Clinical examination|"The clinical examination are composed by :~Weigh, Height and body mass index measurement~Clinical state of patient during examination~Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~Presence of B symptomatology~Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
79857379|NCT05919498|Other|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
79857384|NCT05919407|Drug|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
79857385|NCT05919407|Drug|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
79857386|NCT05919407|Drug|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
79857387|NCT05919407|Drug|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
79857388|NCT05919394|Drug|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
79857389|NCT05919381|Drug|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
79857390|NCT05919381|Drug|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
79559939|NCT04562129|Drug|Interleukin-2|High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
79857391|NCT05919355|Other|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
79857392|NCT05919303|Radiation|CT Scan|CT scan study of abdomen
79398020|NCT05560035|Drug|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
79398021|NCT05560035|Other|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
79398022|NCT05559645|Drug|DZD9008|Daily dosing of DZD9008
79559940|NCT04562129|Drug|Ipilimumab|Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
79559941|NCT04562129|Drug|Nivolumab|Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
79559942|NCT04560725|Drug|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the [68Ga]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
80020013|NCT04132544|Other|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
79398023|NCT05459259|Other|Interviews and Delphi Survey|no intervention delivered
79277460|NCT03533153|Drug|Conventional drug therapy|All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
79277461|NCT03527797|Other|Titration of support level|Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
79277462|NCT02364765|Drug|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
79857394|NCT05919212|Diagnostic Test|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
79277463|NCT02206529|Behavioral|Social Network Engagement+Std Treatment|
79559943|NCT04560335|Behavioral|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
79559944|NCT04560335|Behavioral|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
79722861|NCT04241887|Procedure|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
79857395|NCT05919199|Other|No intervention|No intervention
79857396|NCT05919186|Drug|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
79857397|NCT05919186|Device|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
79857398|NCT05919186|Device|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
79857399|NCT05919121|Other|Therapeutic exercise|"Stretching exercise of posterior shoulder capsule~Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
80020014|NCT04132544|Other|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
80020015|NCT04132544|Other|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health [series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
79559945|NCT04557423|Behavioral|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
79559946|NCT04557423|Behavioral|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
79559947|NCT04557423|Behavioral|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
80020016|NCT04123873|Drug|Paracetamol|1g x 4 p.o.
79559948|NCT04554602|Diagnostic Test|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
79722862|NCT04241887|Procedure|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
80020017|NCT04123873|Drug|Ibuprofen|400mg x 4 p.o.
80020018|NCT04123873|Drug|Dexamethasone|24mg IV x 1 after induction om anaesthesia
80020019|NCT04123873|Drug|Placebo oral capsules|p.o. x 4
80020020|NCT04123873|Drug|Placebo IV|IV x 1
80020021|NCT04121585|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
80020022|NCT04117620|Other|Pediatric Vestibular Symptom Questionnaire|Subjects respond to the translated questionnaire twice with 15 days interval
80020023|NCT04116203|Drug|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
79260431|NCT04937348|Diagnostic Test|Acquisition and analysis of milk samples|"In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits."
79559949|NCT04553536|Drug|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
79857400|NCT05919121|Other|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
79260432|NCT04937348|Diagnostic Test|Collection, preparation and analysis of mother's blood samples.|Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.
79398024|NCT05418387|Behavioral|Social Support Network Intervention|The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
79559950|NCT04548219|Drug|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
79722863|NCT05660005|Other|Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
79722864|NCT05660005|Other|Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
79857401|NCT05919121|Other|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
79857402|NCT05919095|Drug|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
79559951|NCT04533750|Procedure|Computed Tomography|Undergo CT or PET/CT
79559952|NCT04533750|Other|Fludeoxyglucose F-18|Given IV
79559953|NCT04533750|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79559954|NCT04533750|Procedure|Magnetic Resonance Imaging|Undergo MRI
79559955|NCT04533750|Drug|Peposertib|Given PO
79559956|NCT04533750|Procedure|Positron Emission Tomography|Undergo PET/CT
79559957|NCT04523818|Drug|Capecitabine|Given PO
79559958|NCT04523818|Drug|Fluorouracil|Given IV
79722865|NCT05660005|Other|home exercises|The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
79722866|NCT04242745|Behavioral|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
79857403|NCT05919043|Other|Upper limb-based movement priming (UL-priming)|Repetitive upper limb movements administered to the beat of a metronome.
79857404|NCT05919043|Other|Stimulation-based priming (Stim priming)|Noninvasive brain stimulation.
79559959|NCT04523818|Radiation|Radiation Therapy|Undergo radiation therapy
79559960|NCT04523818|Procedure|Therapeutic Surgical Procedure|Undergo standard of care surgery
79559961|NCT04516967|Drug|Avatrombopag|Oral avatrombopag Tablet
79559962|NCT04516967|Drug|Placebo|Placebo comparator tablet
79260433|NCT04937348|Diagnostic Test|Body composition assessment|The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.
80020024|NCT04116203|Combination Product|Fish Oil and Metformin|Combo of 2 other arms
79398025|NCT05418387|Behavioral|Control (Patient Navigation Service)|The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
79722867|NCT04242745|Behavioral|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
79722868|NCT02825875|Drug|18F DCFPyL- Radiopharmaceutica|
79260434|NCT04937348|Other|Anthropometric measurements|"Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis."
79260435|NCT02452125|Dietary Supplement|Nicotine gum|Nicotine chewing gum
79260436|NCT04928924|Procedure|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
79260437|NCT03233451|Behavioral|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
79260438|NCT04936802|Device|Transcatheter tricuspid valve repair system (Trialign)|To assess the Trialign System to treat subjects with moderate to severe tricuspid regurgitation
79398026|NCT01440049|Other|Prospective Observational|this is an observational study non interventional
79559963|NCT04474847|Drug|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
79260439|NCT03226977|Device|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
79260440|NCT03226977|Device|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
79260441|NCT04936412|Device|Rehabilitation brace|Rehabilitation brace
79559964|NCT04474847|Drug|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
79559965|NCT04458766|Behavioral|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
79722869|NCT02828995|Other|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
79722870|NCT02825485|Procedure|Voiding cystourethrogram|
79260442|NCT04486053|Other|Screening|The patients who agreed to participate to the study were assessed with a survey which included age, gender, height, weight and hand dominancy questions. Sensory, motor and functional assessments of the bilateral hand were performed.
79260443|NCT03233373|Device|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
79260444|NCT02619812|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
79260445|NCT02619812|Drug|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
79398027|NCT00497055|Drug|Aripiprazole|
79398028|NCT00497055|Drug|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
79398029|NCT05559567|Device|Orthokeratology|The use of a specialty GP contact lens to temporarily correct myopia
79857405|NCT05919043|Other|Lower limb-based movement priming (LL-priming)|Aerobic exercise using a treadmill or recumbent stepper.
79857406|NCT05919043|Other|Sham priming|Auditory stimulation.
79857407|NCT05919017|Drug|Naltrexone implant|Naltrexone implant
79559969|NCT04417699|Drug|TAS 102|Oral medication over Days 1-5
79559970|NCT04417699|Drug|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
79722871|NCT02825563|Drug|Anlotinib|in the fasting state
79722872|NCT02825563|Drug|Anlotinib|in the high fat diet
79722873|NCT02825797|Drug|3BNC117|Intravenous infusion of 3BNC117
80020025|NCT04116203|Dietary Supplement|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
80020026|NCT04110795|Other|No Intervention|No Intervention
80020027|NCT04106362|Biological|Cetuximab|Given IV
80020028|NCT04106362|Drug|Cisplatin|Given IV
79398030|NCT00497289|Drug|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
79559971|NCT04414306|Other|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
79398031|NCT00497289|Drug|Lipidem 20%|daily i.v. infusion for up to 5 days
79559972|NCT04414306|Other|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
79559973|NCT04414306|Other|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
79722874|NCT02825797|Drug|10-1074|Intravenous infusion of 10-1074
79722875|NCT02825797|Other|Analytical treatment interruption|Analytical treatment interruption
79857408|NCT05919017|Drug|Placebo|Placebo
80020029|NCT04106362|Other|Quality-of-Life Assessment|Ancillary studies
80020030|NCT04106362|Other|Questionnaire Administration|Ancillary studies
79260446|NCT02619812|Other|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
79260447|NCT02451735|Behavioral|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
79260448|NCT02451735|Behavioral|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
79722876|NCT02825797|Drug|Placebo|Intravenous infusion of placebo (sterile saline)
79722877|NCT04241497|Behavioral|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
79722878|NCT02824315|Drug|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
80020031|NCT04106362|Radiation|Radiation Therapy|Undergo radiation therapy
80020032|NCT04101188|Other|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
80020033|NCT04101188|Other|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
80020034|NCT04101188|Other|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
80020035|NCT04100733|Diagnostic Test|Xpert Bladder Cancer Monitor|Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
80020036|NCT04100733|Diagnostic Test|Flexible cystoscopy (WL/NBI) and urinary cytology|Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
80020037|NCT04095117|Procedure|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
80020038|NCT04079088|Drug|Placebo|Administered as specified in the treatment arm.
80020039|NCT04079088|Drug|BIIB061|Administered as specified in the treatment arm.
80020040|NCT04079088|Biological|Interferon-beta1|Stable dose as prescribed by the physician.
79398032|NCT05559333|Procedure|class I restoration placement|zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
79722879|NCT02824315|Drug|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
79722880|NCT02824315|Drug|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
80020041|NCT04079088|Drug|Glatiramer acetate|Stable dose as prescribed by the physician.
80020042|NCT04060030|Drug|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
80020043|NCT04060030|Other|Placebo|Placebo
80020044|NCT04036071|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
80020045|NCT04033861|Drug|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
80020046|NCT04033861|Drug|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
80020047|NCT04012944|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)."
79260449|NCT03055754|Procedure|Argon randomized arm|Endoscopic argon plasma coagulation
79260450|NCT03055754|Procedure|Control arm|No Endoscopic procedure
79260451|NCT02451657|Other|No Intervention|No intervention was administered in this study
79260452|NCT03055676|Other|Early drain removal|Removing drain(s) on postoperative day 3
79260453|NCT03055676|Other|Late drain removal|Removing drain(s) on postoperative day 5 or later
79722881|NCT00633529|Drug|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
79559974|NCT04414306|Other|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
79559975|NCT04413097|Procedure|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
79559976|NCT04413097|Procedure|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
79722882|NCT02823613|Dietary Supplement|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
79722883|NCT02823613|Dietary Supplement|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
79559977|NCT04404075|Other|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
80020048|NCT03990870|Other|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
80020049|NCT03990870|Other|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
79260454|NCT03120117|Procedure|Cough Test following Sling Surgery|Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
79559978|NCT04390763|Biological|NIS793|anti-TGFb antibody
79559979|NCT04390763|Biological|Spartalizumab|anti-PD-1 antibody
79559980|NCT04390763|Drug|gemcitabine|SOC chemotherapy
79260455|NCT03222765|Drug|Placebo, metformin, linagliptin, linagliptin + metformin|
79260456|NCT04403126|Other|forgiveness education intervention|The forgiveness education intervention primarily teaches the concept of forgiveness through stories. We chose the kind of stories that should appeal to children ages 10 through 12. Each lesson is planned according to the following procedure: story-telling/movie-watching, discussion, and in-class activities.
79559981|NCT04390763|Drug|nab-paclitaxel|SOC chemotherapy
79559982|NCT04378075|Drug|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
79559983|NCT04378075|Other|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
79559984|NCT04339062|Drug|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
79559985|NCT04339062|Drug|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while eceiving Cemiplimab
79559986|NCT04339062|Drug|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
79559987|NCT04339062|Drug|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
79722884|NCT02824081|Biological|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
79260457|NCT04485897|Device|icare HOME device (Icare Oy, Vanda, Finland)|icare HOME device versus hospital based measurements
79722885|NCT04242433|Drug|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
79722886|NCT02825407|Dietary Supplement|Oral physiology|
79857409|NCT05918991|Behavioral|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
79875627|NCT00951743|Drug|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
79875628|NCT01065142|Procedure|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
79260458|NCT03055598|Drug|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
79260459|NCT03055520|Other|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
79398033|NCT00498615|Drug|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
79398034|NCT05559177|Biological|Chimeric exosomal tumor vaccines|Tumor cells (lesion site) were isolated from bladder cancer patients, and bladder cancer nuclei were extracted. Monocytes were isolated from peripheral blood of this patient and induced in vitro to obtain APC (DC or macrophage). Apc-tumor chimeric cells were constructed and stimulated with immune stimulator. Chimeric exosomal vaccines were extracted from cell supernatants by differential and hypervelocity centrifugation
79559988|NCT04330729|Drug|Acetylsalicylic acid|Se arm description
79559989|NCT04322383|Drug|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
79559990|NCT04318327|Biological|PHE885|Infusion
79559991|NCT04304066|Other|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
79722887|NCT04242511|Diagnostic Test|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
79722888|NCT02825173|Device|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
79722889|NCT02825329|Device|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
79722890|NCT02823925|Drug|Pamidronate or Zoledronate|
79722891|NCT05659771|Behavioral|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
79722892|NCT04242589|Radiation|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
79875629|NCT00464178|Drug|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
79260460|NCT03055520|Other|placebo|nonspecific recreation including befriending and free simple activities.
79875630|NCT00560105|Device|Lung Flute|8 weeks home use, twice daily
79875631|NCT00560105|Device|Acapella|8 weeks home use, twice daily
79260461|NCT04485585|Drug|BR9006-1|Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
79260462|NCT04485585|Drug|BR9006-2|"Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose"
79260463|NCT03222453|Biological|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
79277464|NCT02206529|Behavioral|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
79277465|NCT04547049|Drug|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
79398035|NCT00498927|Drug|temozolomide|
79398036|NCT00498927|Genetic|protein expression analysis|
79398037|NCT00498927|Genetic|reverse transcriptase-polymerase chain reaction|
79398038|NCT00498927|Other|diagnostic laboratory biomarker analysis|
79398039|NCT00498927|Other|immunoenzyme technique|
79398040|NCT00499473|Drug|sunitinib malate|Given orally
79398041|NCT00499473|Other|pharmacological study|Correlative studies
79398042|NCT01439971|Biological|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
79398043|NCT01439971|Biological|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
79398044|NCT01439971|Biological|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
79398045|NCT01439971|Biological|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
79398046|NCT01439971|Biological|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
79559992|NCT04260191|Drug|AMG 910|IV Infusion
79559993|NCT04248543|Device|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
79559994|NCT04236336|Device|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
79559995|NCT04205786|Dietary Supplement|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
79559996|NCT04205786|Other|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~Serum B12 levels~CRP~Homocysteine level~MMA"
79559997|NCT04205786|Other|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
79559998|NCT04205786|Other|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
79875632|NCT00467610|Drug|Panhematin|
79857410|NCT05918991|Other|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
79857411|NCT05918965|Device|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
79398047|NCT05555277|Other|No interventions - retrospective data collection|The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
79857412|NCT05918939|Biological|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
79857413|NCT05918939|Biological|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
79857414|NCT05918926|Behavioral|Exercise|Individualised remote exercise intervention
79857415|NCT05918874|Other|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
79559999|NCT04205786|Other|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
79560000|NCT04205786|Other|Demographics Questionnaire|Demographics Questionnaire
79857416|NCT05918848|Device|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
79857417|NCT05918770|Diagnostic Test|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
79398048|NCT03232671|Diagnostic Test|MIF ELISA|Blood sample
79560001|NCT04144517|Drug|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
79857418|NCT05918731|Behavioral|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
80020050|NCT03986411|Other|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
80020051|NCT03986411|Other|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
79560002|NCT04144517|Drug|Pembrolizumab|IV infusion over 30 minutes administered on Day 1 of each cycle
79560003|NCT04140942|Behavioral|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
79560004|NCT04140942|Behavioral|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
79560005|NCT04090567|Drug|Cediranib|Given PO
80020052|NCT03986411|Other|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
79722893|NCT04242589|Procedure|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
79722894|NCT04201249|Drug|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
79398049|NCT00501891|Drug|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
79398050|NCT00501891|Drug|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
79722895|NCT04201249|Device|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
79722896|NCT00633685|Drug|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
79722897|NCT00633685|Drug|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
79722898|NCT02823691|Drug|Lanreotide and Metformin|Lanreotide and Metformin
80020053|NCT03948893|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
80020054|NCT03948893|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
80020055|NCT03921333|Dietary Supplement|Low dose response efficacy of plant extracts|300mg
79398051|NCT01798017|Drug|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
79560006|NCT04090567|Drug|Ceralasertib|Given PO
79560007|NCT04090567|Drug|Olaparib|Given PO
79857419|NCT05918718|Drug|Letrozole|assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
79857420|NCT05918718|Drug|methotrexate|methotrexate
79722899|NCT04888195|Other|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
79857421|NCT05918627|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
79857422|NCT05918627|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
79857423|NCT05918614|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
79857424|NCT05918614|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
79857425|NCT05918588|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
79857426|NCT05918588|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
79260464|NCT03226743|Other|collaborative and stepped care model|"Including elements:~collaborative and stepped care of patients with mental disorders~treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~initial training of participating health care providers~formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~formalized ICD-diagnostics~guideline-oriented treatment recommendations~bibliotherapy or internet-based self-help for patient with mild to moderate disorders~online referral platform~case management for patients with severe disorders~systematic and regular monitoring~regular quality circles for participating health care providers"
80020056|NCT03921333|Dietary Supplement|Middle dose response efficacy of plant extracts|500mg
79722900|NCT02825095|Procedure|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
79722901|NCT02825095|Procedure|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
79857427|NCT05918562|Dietary Supplement|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
80020057|NCT03921333|Dietary Supplement|High Dose response efficacy of plant extracts|700mg
79857428|NCT05918562|Dietary Supplement|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
79560009|NCT04083378|Procedure|Ablation Therapy|Undergo standard of care ablation
79560010|NCT04083378|Procedure|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
79560011|NCT04083378|Other|Quality-of-Life Assessment|Ancillary studies
79560012|NCT04083378|Other|Questionnaire Administration|Ancillary studies
79722902|NCT02825095|Procedure|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
79857429|NCT05918536|Diagnostic Test|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
79857430|NCT05918471|Dietary Supplement|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~Consume 4 Optifast 900 packets each day~Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
79857431|NCT05918419|Drug|Serplulimab|PD-1 antibody
79277466|NCT04547049|Drug|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
79277467|NCT04547049|Drug|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
79277468|NCT04547049|Drug|Me-CCNU|250mg/m2 once administered orally on day -3.
79277469|NCT04547049|Drug|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
79857432|NCT05918393|Behavioral|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
79857433|NCT05918380|Behavioral|PAL2|"Low CVD risk participants (CAC < 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
79857434|NCT05918380|Other|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
79857435|NCT05918341|Drug|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
80020058|NCT03921333|Dietary Supplement|Placebo|Cellulose microcrystalline
80020059|NCT03913819|Drug|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
80020060|NCT03913819|Drug|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
80020061|NCT03913819|Drug|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
80020062|NCT03913819|Procedure|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
79560013|NCT04075799|Other|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
79722903|NCT02825095|Drug|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
79722904|NCT02825095|Procedure|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
79722905|NCT04241263|Device|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
79722906|NCT04241263|Device|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
79722907|NCT02823535|Behavioral|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
79722908|NCT02823379|Behavioral|Physical Activity|A Smartphone delivered physical activity program
79722909|NCT02823379|Behavioral|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
79857436|NCT05918315|Procedure|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
79857437|NCT05918289|Behavioral|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
79857438|NCT05918276|Drug|Orelabrutinib and BG|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2&d3 inC1, and then d1&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle."
79857439|NCT05918263|Behavioral|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
79857440|NCT05918237|Other|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
79857441|NCT05918172|Device|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
80020063|NCT03900273|Other|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
79722910|NCT02825017|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm*2 test application.(Formulation-SR15-79_Y73-161)
79722911|NCT02824939|Other|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
79722912|NCT02824939|Other|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
79722913|NCT04195009|Procedure|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
79722914|NCT02824549|Device|FreeStyle Libre Flash Glucose Monitoring|
79722915|NCT02824705|Procedure|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
79722916|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
79722917|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
80020064|NCT03900273|Other|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
80020065|NCT03865472|Other|Questionnaire Administration|Ancillary studies
79560014|NCT04074031|Device|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
79560015|NCT04073563|Device|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
79560016|NCT04073563|Device|Intervertebral body fusion device and Medtronic posterior Fixation Systems|Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
79560017|NCT04066361|Other|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
79560018|NCT04066361|Other|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
79560019|NCT04041310|Biological|GAd-209-FSP low dose|GAd20-209-FSP IM vaccine, low dose
79560020|NCT04041310|Biological|MVA-209-FSP low dose|MVA-209-FSP IM vaccine, low dose
79560021|NCT04041310|Biological|GAd-209-FSP high dose|GAd20-209-FSP IM vaccine, high dose
79560022|NCT04041310|Biological|MVA-209-FSP high dose|MVA-209-FSP IM vaccine, high dose
79722918|NCT02824393|Biological|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
79722919|NCT02824003|Drug|ISIS-GCGRRx|once weekly dosing for 13 weeks
79722920|NCT02824003|Drug|Placebo|once weekly dosing for 13 weeks
79857442|NCT05918172|Device|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
79857443|NCT05918068|Drug|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
79857444|NCT05918068|Combination Product|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
80020066|NCT03865472|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
79722921|NCT04240951|Other|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
79722922|NCT04241107|Procedure|Laparoscopic repair of Uterine niche|Repair of uterine niche through Laparoscopic approach.
79722923|NCT04241107|Procedure|Transvaginal repair of Uterine niche|Repair of uterine niche through Transvaginal approach.
79722924|NCT02822365|Procedure|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
79857445|NCT05918068|Other|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
79857446|NCT05918016|Diagnostic Test|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
79857447|NCT05917977|Behavioral|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
79857448|NCT05917977|Other|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
80020067|NCT03865472|Procedure|Sham Intervention|Undergo sham rTMS
80020068|NCT03819465|Drug|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
80020069|NCT03819465|Drug|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
80020070|NCT03819465|Drug|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
80020071|NCT03819465|Drug|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
80020072|NCT03819465|Drug|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
79722925|NCT02822365|Device|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
79722926|NCT02822365|Procedure|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
80020073|NCT03819465|Drug|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
80020074|NCT03819465|Drug|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
80020075|NCT03819465|Drug|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
79560023|NCT04041310|Biological|GAd20-209-FSP, RP2D|GAd20-209-FSP IM vaccine, RP2D
79560024|NCT04041310|Biological|MVA-209-FSP, RP2D|MVA-209-FSP IM vaccine, RP2D
79560025|NCT04033146|Device|Strengthening muscle contractions during walking|The investigators will use ankle-exoskeletons to systematically alter the behavior of participant muscle contractions. For example, participants will walk in a robotic device that adds a spring in parallel with their lower limb that will help the participants generate a stronger propulsive push-off and may reduce the effort of walking.
79560026|NCT04017546|Drug|CYC065|intravenous infusion
79560027|NCT04017546|Drug|Venetoclax|oral capsule
79857449|NCT05917925|Dietary Supplement|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
79722927|NCT02823301|Behavioral|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
79857450|NCT05917925|Dietary Supplement|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
79857451|NCT05917886|Other|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
79857452|NCT05917860|Drug|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
79857453|NCT05917860|Device|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
79857454|NCT05917847|Other|Awake intubation|Awake videolaryngoscopic intubation with dexmedetomidine for sedation
79857455|NCT05917834|Biological|Nipple sparing mastecomy with different incision placements|Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
80020076|NCT03819465|Drug|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
80020077|NCT03819465|Drug|AZD2936|AZD2936 IV
80020078|NCT03806764|Diagnostic Test|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
80020079|NCT03705286|Device|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
80020080|NCT03705286|Device|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
80020081|NCT03679117|Behavioral|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
79560028|NCT04013802|Biological|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
79722928|NCT04806607|Procedure|19G FNB|Biopsy specimen adequacy using the 19G FNB
79857456|NCT05917808|Other|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
79857457|NCT05917769|Other|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
80020082|NCT03637803|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
79722929|NCT04806607|Procedure|22G FNB|Biopsy specimen adequacy using the 22G FNB.
79277470|NCT04547049|Procedure|Allogeneic HSCT|Day 0
79277471|NCT04547049|Drug|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
79722930|NCT02822131|Dietary Supplement|sodium phosphate|
79722931|NCT02822131|Drug|sevelamer, sodium bicarbonate, sodium chloride|
79722932|NCT02820649|Other|Sleep deprivation|40 hours of continuous wakefullness
79857458|NCT05917769|Other|Postural correction exercises|"Posture correction exercises will be performed six times a day for six days.~Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
79857459|NCT05917756|Other|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
79875633|NCT00316186|Drug|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
79875634|NCT00316186|Drug|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
79875635|NCT04011761|Other|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
79875636|NCT00948623|Behavioral|physical activity counseling program|
79857460|NCT05917756|Other|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
79560029|NCT03981640|Other|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
79560030|NCT03981640|Other|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
80020083|NCT03637803|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
79722933|NCT04240873|Biological|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10^8 cells/DMEM 5cc into knee of patents with osteoarthritis
80020084|NCT03630289|Procedure|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
80020085|NCT03567720|Biological|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
79560031|NCT03981640|Other|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
79560032|NCT03979001|Other|complete ophthalmological examination|"collection:~ophthalmological history and current treatments~occular tension measurement~measurement of visual acuity (Snellen chart)~Axial length measurement~Photograph of the posterior segment of the eye~3x3 and 6x6 macular and papillary OCT angiography"
79560033|NCT03963960|Device|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
79560034|NCT03963960|Device|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
79560035|NCT03939637|Drug|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~Children 1 to 5 years: Initial: 25 mg once daily~Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity [e.g., Chinese, Japanese, Korean, Taiwanese])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
79722934|NCT04240873|Other|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
79722935|NCT02820805|Other|Meal Skipping|No meal
79722936|NCT02820805|Other|French fries|50g of available carbohydrates meal
79722937|NCT02820805|Other|Mashed potatoes|50g of available carbohydrates meal
79722938|NCT02820805|Other|Hash browns|50g of available carbohydrates meal
79722939|NCT02820805|Other|Rice|50g of available carbohydrates meal
79722940|NCT02820805|Other|Beans|50g of available carbohydrates meal
80020086|NCT03567720|Biological|Pembrolizumab|Intravenous 3 weekly treatments
79722941|NCT02821975|Other|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
79722942|NCT04239469|Drug|KL16-012|Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
79722943|NCT04239469|Drug|Placebo|Placebo
79722944|NCT04240795|Dietary Supplement|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
79722945|NCT02821897|Procedure|Target-controlled intravenous anaesthesia|
79722946|NCT02821897|Procedure|Total anaesthesia|
79722947|NCT04239547|Procedure|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
79875637|NCT00948623|Behavioral|sham counseling program|
79875638|NCT01065220|Drug|Testolactone undecanoate|4ml i.m.
79875639|NCT01065220|Drug|Lynestrenol|2/day
79875640|NCT01065220|Drug|Cyproterone Acetate|50mg per day
79875641|NCT01065220|Drug|Estradiol|100 microgram TTS twice a week
79875642|NCT01065220|Drug|5-alpha reductase inhibitor|1mg daily
79560036|NCT03939637|Drug|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
79560037|NCT03939637|Drug|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
79560038|NCT03939637|Drug|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
79560039|NCT03938324|Behavioral|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
79560040|NCT03938324|Behavioral|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
79560041|NCT03917927|Device|Eztetic dental implant|narrow diameter dental implant
79722948|NCT04239547|Procedure|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
79722949|NCT02822209|Behavioral|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
79722950|NCT02822209|Behavioral|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
79722951|NCT02822209|Behavioral|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
79722952|NCT02822209|Behavioral|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
79722953|NCT02690623|Other|Pediatric hospitalist program|In-house hospitalists available at all hours
79722954|NCT02690623|Other|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
79722955|NCT02823067|Other|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
79722956|NCT02820493|Drug|vedolizumab|
79722957|NCT02820415|Other|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
79722958|NCT02822053|Procedure|US-guided laser ablation for refractory neoplasms|
79722959|NCT02822989|Device|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
79722960|NCT02822989|Device|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
79722961|NCT04239391|Drug|Triferic|Ferric Pyrophosphate Citrate
79722962|NCT02820259|Drug|Tacrolimus|
79722963|NCT02823223|Device|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
79722964|NCT02821663|Behavioral|vocal intervention|10 x 60 min. sessions of vocal intervention
79722965|NCT02822755|Other|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
79722966|NCT02821585|Behavioral|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
79722967|NCT02821351|Device|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
79722968|NCT02820103|Behavioral|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
79857461|NCT05917743|Other|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
79277472|NCT04547049|Drug|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
79277473|NCT04547049|Drug|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
79277474|NCT02202395|Drug|LTS 0.25mg|use LTS 0.25mg/d
79857462|NCT05917743|Other|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
79260465|NCT04928768|Other|Questionnaire|A validated questionnaire (five-point Likert scale) through 10 items developed by Lee et al 2018 is employed to measure the level of orthodontic treatment satisfaction in 10 items; overall satisfaction, tooth alignment, facial appearance, eating and chewing, confident smile and self-image, retention state, treatment duration, treatment costs, intention to recommend, and relief of previous concerns. Total satisfaction is calculated by averaging the Likert scores from the 10 items
79560042|NCT03891602|Behavioral|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
79560043|NCT03891602|Behavioral|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
79560044|NCT03891602|Behavioral|Decision Conflict Scale - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
79560045|NCT03891602|Behavioral|Shared Decision Making Questionnaire - Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
79560046|NCT03891602|Behavioral|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
79560047|NCT03891602|Behavioral|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
79560048|NCT03878121|Biological|Ad4-Env145NFL|10^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
79722969|NCT02820103|Behavioral|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
79560049|NCT03878121|Biological|Ad4-Env150KN|10^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
79560050|NCT03878121|Biological|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
79560051|NCT03872908|Device|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
79560052|NCT03872908|Device|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
79560053|NCT03870802|Other|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
79560054|NCT03865589|Diagnostic Test|Ultrasound Elastography|Ultrasound shear wave elastography
79722970|NCT02820103|Behavioral|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
79260466|NCT03222687|Drug|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
80020087|NCT03567720|Device|Immunopulse|Device that administers electroporation
80020088|NCT03567720|Drug|nab paclitaxel|intravenous on days 1, 8 and 15 of each 28 day cycle
79277475|NCT02202395|Drug|LTS 0.5mg|use LTS 0.5mg/d
79277476|NCT02202395|Drug|LTS 1.0mg|use LTS 1.0mg/d
79277477|NCT02202395|Drug|Placebo|use placebo once daily
79560055|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
79560056|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
79560057|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
79560058|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
79560059|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
79560060|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
80020089|NCT03567720|Drug|gemcitabine plus carboplatin|intravenous on days 1 and 8 of every 21 days
79260467|NCT03222687|Drug|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
79857463|NCT05917730|Behavioral|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
79857464|NCT05917704|Other|Guitar then physical therapy|See arm/group descriptions
79857465|NCT05917704|Other|Physical therapy then guitar|See arm/group descriptions
79857466|NCT05917691|Procedure|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
79857467|NCT05917691|Drug|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
79857468|NCT05917691|Device|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
79857469|NCT05917652|Behavioral|Tool kit|The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
79260468|NCT03055442|Other|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
79560061|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
79560062|NCT03828513|Device|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
79560063|NCT03828513|Device|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
79722971|NCT05658991|Diagnostic Test|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
79857470|NCT05917600|Other|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~clinical and paraclinical examinations,~appraisal of patient's knowledge,~health education on hypertension and treatments,~setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
79857471|NCT05917561|Drug|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
79857472|NCT05917561|Drug|Placebo|Placebo once a month, infusion for 36 weeks
79857473|NCT05917535|Behavioral|Mentalizing course|6 hour mental health education course about mentalizing.
80020090|NCT03519906|Drug|Metoprolol|Patients are tested for their normal prescription metaprolol medication
80020091|NCT03519893|Drug|Losartan|Patients are tested for their normal prescription losartan medication
80020092|NCT03519256|Biological|Nivolumab|Specified dose on specified days
79260469|NCT03055442|Other|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
79260470|NCT03222375|Device|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
79560064|NCT03796767|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79560065|NCT03796767|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79560066|NCT03796767|Procedure|Metastasectomy|Undergo salvage oligometastasectomy
79560067|NCT03796767|Other|Quality-of-Life Assessment|Ancillary studies
79560068|NCT03796767|Other|Questionnaire Administration|Ancillary studies
79560069|NCT03796767|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79560070|NCT03785834|Procedure|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
79560071|NCT03780894|Drug|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
79722972|NCT02822833|Procedure|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
79260471|NCT03226587|Procedure|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
79260472|NCT03226587|Procedure|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
79560072|NCT03780894|Biological|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
79560073|NCT03780894|Drug|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
79560074|NCT03765073|Biological|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
79560075|NCT03765073|Biological|Placebo|Saline control
79722973|NCT02819947|Other|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
79722974|NCT02821429|Other|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
79560076|NCT03761095|Drug|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
79722975|NCT00633763|Drug|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
79857474|NCT05917093|Behavioral|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~Week 0 - Baseline enrollment.~Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
80020093|NCT03519256|Biological|BCG|Specified dose on specified days
79260473|NCT03226431|Drug|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
79260474|NCT04917770|Drug|Sintilimab in combination with Multimodality Radiotherapy|Participants will be treated with sintilimab in combination with multimodality radiotherapy
79260475|NCT03222297|Device|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
79260476|NCT03222297|Device|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
79260477|NCT04918004|Behavioral|Sleep Hygiene|"One-to-one sleep hygiene training, the content of which was created by the researchers,~A brochure containing 10 lifestyle changes related to sleep hygiene"
79260478|NCT02451579|Drug|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
79260479|NCT02451579|Other|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
79260480|NCT04935788|Dietary Supplement|milk protein|milk protein supplement
79560077|NCT03761095|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
79857475|NCT05914766|Behavioral|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of three components.
79857476|NCT05914766|Other|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
80020094|NCT03519256|Drug|BMS-986205|Specified dose on specified days
80020095|NCT03507608|Drug|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
80020096|NCT03507608|Other|Placebo|placebo prior to brachytherapy and prostatic biopsy
80020097|NCT03465579|Diagnostic Test|pelvic MRI|multi-parametric pelvic MRI
80020098|NCT03465579|Diagnostic Test|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
79260481|NCT04935788|Dietary Supplement|micellar casein|micellar casein supplement
79260482|NCT04935788|Dietary Supplement|pea protein|pea protein supplement
79260483|NCT04935788|Dietary Supplement|milk/pea protein blend|milk/pea protein supplement
79260484|NCT03233295|Drug|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
79560078|NCT03739723|Other|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
79722976|NCT00633763|Drug|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
80020099|NCT03458000|Device|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
80020100|NCT03458000|Other|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
80020101|NCT03453528|Drug|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
80020102|NCT03390413|Procedure|Robot|Renal cancer treated with robotic surgery
79560079|NCT03739554|Drug|CYC065|intravenous infusion
79560080|NCT03739554|Drug|Venetoclax|oral capsule
79560081|NCT03729271|Drug|Rifaximin|Rifaximin will be given during weeks 2-4
79560082|NCT03729271|Device|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
79560083|NCT03721822|Drug|[18F]NOS|[18F]NOS is an investigational radiotracer which each subject will have one [18F]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
80020103|NCT03390413|Procedure|Cryoablation|Renal cancer treated with cryoablation
80020104|NCT03375710|Device|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~myCordella™ Patient Management Portal~myCordella™ Hub~myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
79398052|NCT04808583|Procedure|TLH with uterine artery ligation at its origin at the beginning of the operation|After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery
79398053|NCT04808583|Procedure|conventional TLH with uterine artery ligation after the cornual pedicles|"Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides."
79398054|NCT02811003|Device|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
80020105|NCT03215927|Drug|Abatacept|Abatacept 125mg subcutaneous weekly
80020106|NCT03215927|Other|Placebo|Placebo
80020107|NCT03076034|Device|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of ~375 µm."
80020108|NCT03009110|Device|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
80020109|NCT03009110|Device|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
80020110|NCT02999230|Other|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
80020111|NCT02999230|Other|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
80020112|NCT02999230|Other|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
80020113|NCT02999230|Other|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
79560084|NCT03719768|Drug|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
79560085|NCT03719768|Radiation|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
79560086|NCT03701399|Drug|troriluzole|200 mg by mouth
79560087|NCT03701399|Drug|Placebos|200 mg by mouth
80020114|NCT02941315|Drug|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
80020115|NCT02941315|Drug|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
79260485|NCT03226665|Diagnostic Test|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
79260486|NCT04484805|Device|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
79260487|NCT04484805|Device|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
79260488|NCT02623322|Drug|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
79260489|NCT02623322|Drug|Placebo|Placebo will be administered as a single dose by IV administration.
79260490|NCT02452203|Behavioral|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
80020116|NCT02941315|Drug|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
79398055|NCT00502905|Drug|Busulfan|130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
79260491|NCT03222219|Procedure|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
79722977|NCT02822911|Behavioral|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
79857477|NCT05914636|Biological|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
79857478|NCT05914506|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
79857479|NCT05914480|Other|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
79857480|NCT05913817|Biological|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
79857481|NCT05912764|Other|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
79277478|NCT03533075|Behavioral|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
79398056|NCT00502905|Drug|Fludarabine|40 mg/m^2 through a central venous catheter over one hour, once a day, for four days.
79398057|NCT00505635|Drug|Temozolomide|250 mg/m^2 By Mouth Every 4 Hours x 3 Doses On Day 1
79398058|NCT00505635|Drug|Velban|1.5 mg/m^2 By Vein Over 15-30 Minutes On Days 1-4
79398059|NCT00505635|Drug|Cisplatin|20 mg/m^2 By Vein Over 45-120 Minutes On Days 1-4
79560088|NCT03699709|Behavioral|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
79398060|NCT00505635|Drug|Interleukin-2|9 MIU/m^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
79398061|NCT00505635|Drug|Intron-A|5 mu/m^2 Subcutaneously (Under the skin) Daily On Days 1-5
79398062|NCT00505635|Drug|Thalidomide|400 mg By Mouth Daily
79560089|NCT03689972|Drug|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
79560090|NCT03666845|Procedure|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
79560091|NCT03662100|Biological|LY3074828|Administered SC
79398063|NCT01842165|Drug|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
79398064|NCT00506025|Dietary Supplement|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
79560092|NCT03662100|Drug|LY3074828|Administered SC
79560093|NCT03662100|Device|Auto-injector (AI)|AI to administer LY3074828
79560094|NCT03662100|Device|Prefilled syringe (PFS)|PFS to administer LY3074828
79560095|NCT03656133|Radiation|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
79560096|NCT03648905|Drug|13N-Ammonia|a perfusion imaging agent
79560097|NCT03648905|Drug|18F-DOPA|is a positron-emitting analog of the catechol amino acid, levodopa
79560098|NCT03648905|Drug|11C-Methylreboxetine (11C-MRB)|11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
79722978|NCT02822911|Procedure|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
79857482|NCT05898386|Behavioral|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
79857483|NCT05897866|Procedure|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
79857484|NCT05896644|Other|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
79857485|NCT05890976|Drug|Semaglutide|Participants will receive semaglutide tablets orally once daily for 44 weeks.
79857486|NCT05890976|Drug|Semaglutide Placebo|Participants will receive placebo matched to semaglutide.
79857487|NCT05888805|Other|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
80020117|NCT02941315|Drug|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
80020118|NCT02920229|Drug|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
79857488|NCT05883241|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
79722979|NCT02822911|Procedure|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
79560099|NCT03648905|Drug|18F-Dopamine|is a positron-emitting analog of the catecholamine, dopamine
79722980|NCT02822911|Procedure|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
79260492|NCT03222063|Other|Play interventions|The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.
79857489|NCT05883241|Drug|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
79260493|NCT04917458|Drug|Cholecalciferol 4000 IU Oral Capsule, Liquid Filled|-Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.
79560100|NCT03616587|Drug|AZD9833|Part A: AZD9833 monotherapy dose escalation.
79560101|NCT03616587|Drug|AZD9833|Part B: AZD9833 monotherapy expansion.
79560102|NCT03616587|Drug|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
79560103|NCT03616587|Drug|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
79260494|NCT04917458|Drug|Placebo|Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
79260495|NCT04927910|Other|Ture self-acupressure|8-week intervention of self-acupressure on acupoints
79560104|NCT03616587|Drug|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
79722981|NCT02820025|Drug|doxapram|
79722982|NCT02820025|Other|saline|
79722983|NCT02819869|Drug|Statin and Metformin use|
79560105|NCT03616587|Drug|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
79722984|NCT02819713|Other|ultrasound gel|
79560106|NCT03616587|Drug|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
79260496|NCT04927910|Other|Sham self-acupressure|8-week intervention of self-acupressure on non-acupoints
79722985|NCT02819713|Other|Instillagel|
79722986|NCT02821117|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
79722987|NCT02820883|Biological|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
79260497|NCT04927910|Other|Usual care|routine care by hospitals
79277479|NCT05647291|Device|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
79277480|NCT05647291|Drug|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
79560107|NCT03616587|Drug|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
79560108|NCT03616587|Drug|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
79722988|NCT02820883|Biological|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
79722989|NCT02820883|Biological|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
79722990|NCT00633841|Biological|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
79722991|NCT05659615|Other|Study will not have intervention|Study will not have intervention
79560109|NCT03616587|Drug|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
79560110|NCT03616587|Drug|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
79560111|NCT03616587|Drug|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
79722992|NCT04811287|Device|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
79722993|NCT04811287|Procedure|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
79722994|NCT02819401|Other|pediatric formula|high-fiber enteral formula
79722995|NCT04200859|Other|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
79722996|NCT02819245|Procedure|posterior correction and fusion|
79722997|NCT04200703|Other|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
80020119|NCT02918721|Device|Restylane Lidocaine|Intradermal injection
79857493|NCT05882669|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
79857494|NCT05882656|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
79857495|NCT05880888|Biological|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
79857496|NCT05874245|Drug|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
80020120|NCT02918721|Device|Restylane|Intradermal injection
79560112|NCT03616587|Drug|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
79560113|NCT03616587|Drug|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
79560114|NCT03605550|Drug|PTC596|Oral tablets
79560115|NCT03605550|Radiation|Radiotherapy|Cycle1
79560116|NCT03593473|Drug|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
79857497|NCT05874245|Drug|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
80020121|NCT02884180|Drug|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
79560117|NCT03593473|Drug|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
79722998|NCT02819089|Drug|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
79722999|NCT02819089|Other|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
79398065|NCT00506025|Dietary Supplement|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
79398066|NCT05395689|Biological|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
79560118|NCT03552276|Drug|SUNPG18_07 I|injection
79560119|NCT03552276|Drug|SUNPG18_07 II|injection
79560120|NCT03552276|Drug|SUNPG18_07 III|injection
79560121|NCT03535688|Drug|D-cycloserine|200 mg twice daily
79560122|NCT03535688|Drug|Placebo|twice daily
79560123|NCT03511118|Drug|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723000|NCT02818699|Dietary Supplement|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
79723001|NCT02818699|Dietary Supplement|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
79560124|NCT03511118|Drug|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560125|NCT03511118|Drug|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560126|NCT03511118|Drug|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560127|NCT03511118|Drug|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723002|NCT02690311|Device|smartphone display|
80020122|NCT02884180|Drug|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
80020123|NCT02879682|Procedure|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
80020124|NCT02879682|Procedure|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
80020125|NCT02799602|Drug|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
80020126|NCT02799602|Drug|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
79398067|NCT05395689|Biological|Placebo|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
79398068|NCT05376657|Dietary Supplement|Cherry collagen drink|consume 1 sachet per day
79398069|NCT05376657|Dietary Supplement|Placebo drink|consume 1 sachet per day
79560128|NCT03511118|Drug|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560129|NCT03511118|Drug|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723003|NCT04191265|Diagnostic Test|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
80020127|NCT02799602|Drug|Docetaxel|As prescribed by the treating physician.
79857498|NCT05874245|Drug|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
79857499|NCT05873257|Device|Biatain Fiber Ag applied to participants|Intervention involving a wound gelling fiber dressing with silver
79723004|NCT04238923|Drug|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
79857500|NCT05870189|Behavioral|Remote CMR|12 weeks of remote CMR is done 3x/week, 45 min/session.
79857501|NCT05870189|Behavioral|Remote Exercise|12 weeks of remote exercise is done 3x/week, 45 min/session.
79857502|NCT05869318|Other|ECIG own|Participants will vape using their own ecig device
79857503|NCT05869318|Other|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
79857504|NCT05824143|Drug|Darigabat|Oral tablet
79857505|NCT05824143|Drug|Carbamazepine|Oral tablets
79857506|NCT05813769|Dietary Supplement|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
79560130|NCT03511118|Drug|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560131|NCT03511118|Drug|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
80020128|NCT02799602|Drug|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone [LHRH] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
79560132|NCT03511118|Drug|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560133|NCT03511118|Drug|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723005|NCT02819167|Other|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
79560134|NCT03511118|Drug|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560135|NCT03511118|Drug|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723006|NCT04239001|Drug|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
79723007|NCT04240015|Other|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
79723008|NCT02815657|Drug|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
79857507|NCT05813769|Dietary Supplement|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
79857508|NCT05789199|Drug|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
79857509|NCT05788965|Drug|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
79857510|NCT05774223|Device|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
79857511|NCT05774223|Device|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
79560136|NCT03511118|Drug|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560137|NCT03511118|Drug|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560138|NCT03511118|Drug|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79857512|NCT05763459|Drug|ABBV-CLS-7262|Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
80020129|NCT02792166|Procedure|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
79560139|NCT03511118|Drug|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560140|NCT03511118|Drug|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560141|NCT03511118|Drug|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
80020130|NCT02792166|Procedure|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
79560142|NCT03511118|Drug|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79398070|NCT05365503|Other|Shamiri Intervention|The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
79398071|NCT04479813|Drug|Moxonidine 0.2 MG|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
79560143|NCT03511118|Drug|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560144|NCT03511118|Drug|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560145|NCT03511118|Drug|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560146|NCT03511118|Drug|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560147|NCT03511118|Drug|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560148|NCT03511118|Drug|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560149|NCT03511118|Drug|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723009|NCT02815657|Drug|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
79398072|NCT04479813|Other|placebo|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
79398073|NCT04474899|Drug|Moxonidine 0.4 MG|Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
79560150|NCT03511118|Drug|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79398074|NCT04474899|Drug|Amlodipine 5mg|Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
79260498|NCT03233061|Diagnostic Test|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
79260499|NCT03225963|Radiation|Chemoradiation with temozolomide|
79857513|NCT05727332|Behavioral|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
80020131|NCT02788903|Other|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
79260500|NCT04935398|Other|Physiotherapy|The aim is to test two treatment techniques against each other to see how effective they are.
79398075|NCT00508521|Device|Functional Electrical Stimulation|commercially available surface electrical stimulator
79260501|NCT03232905|Drug|PF-06651600|PF-06651600 will be administered as tablet
79260502|NCT03232905|Drug|Placebo|Matching placebo will be administered as tablet
79398076|NCT00508521|Other|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
79560151|NCT03511118|Drug|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79260503|NCT03226041|Device|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
79260504|NCT04917536|Procedure|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
79260505|NCT03221907|Drug|GLA5PR GLARS-NF1|Pregabalin tablet
79398077|NCT04369989|Other|No intervention|No intervention
79560152|NCT03511118|Drug|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79260506|NCT03221907|Drug|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
79260507|NCT03221907|Drug|Pregabalin|Pregabalin capsule
79723010|NCT04597333|Drug|Dinoprostone|Dinoprostone vaginal insert.
79723011|NCT04597333|Device|Cervical ripening balloon.|Double lumen cervical ripening balloon.
80020132|NCT02770040|Drug|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
80020133|NCT02754297|Drug|177Lu-Octreotate|"The induction course will consist in 4 cycles at 8-10 weeks intervals.~Concomitant amino acids will be administered for renal protection.~Intra-arterial LuTate administration will be allowed in suitable cases.~Dosimetry will be based on quantitative SPECT/CT imaging.~In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
80020134|NCT02747459|Behavioral|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
80020135|NCT02663609|Other|No intervention|No treatment (intervention) was administered.
79560153|NCT03511118|Drug|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560154|NCT03511118|Drug|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560155|NCT03511118|Drug|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560156|NCT03511118|Drug|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560157|NCT03511118|Drug|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560158|NCT03511118|Drug|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560159|NCT03511118|Drug|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79560160|NCT03511118|Drug|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
79723012|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
79723013|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
79723014|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
80020136|NCT02472015|Procedure|telemedicine|psycho-behavioural care by telemedicine
80020137|NCT02291705|Procedure|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
79560161|NCT03446417|Drug|ZN-e4|Oral dose, tablet, daily dosing
79560162|NCT03445858|Drug|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
79857514|NCT05725863|Other|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
80020138|NCT02291705|Drug|Tramadol|tramadol 1 mg/kg iv
79560163|NCT03445858|Drug|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
79560164|NCT03445858|Radiation|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
79560165|NCT03442556|Drug|Carboplatin|Given IV
79560166|NCT03442556|Drug|Docetaxel|Given IV
79560167|NCT03442556|Other|Laboratory Biomarker Analysis|Correlative studies
79560168|NCT03442556|Drug|Rucaparib Camsylate|Given PO
79560169|NCT03442556|Drug|Rucaparib|Given PO
79560170|NCT03433274|Device|Tendyne Mitral Valve System|Mitral valve replacement
79560171|NCT03433274|Device|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
79723015|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
79857515|NCT05725616|Procedure|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
79857516|NCT05724875|Device|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
79857517|NCT05724875|Device|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
79857518|NCT05713981|Procedure|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
79857519|NCT05689749|Device|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
80020139|NCT02243709|Drug|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
79260508|NCT03221907|Drug|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
79260509|NCT03226119|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
79260510|NCT04917380|Other||Retrospective clinical study，no intervention
79560172|NCT03389802|Biological|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the MTD is reached or until dose level 3 (0.6 mg/kg) is complete without MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
79560173|NCT03389802|Biological|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the RP2D determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
79723016|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
79560174|NCT03377023|Drug|Nivolumab|Intravenous nivolumab every 2 weeks.
79560175|NCT03377023|Drug|Ipilimumab|Intravenous ipilimumab every 6 weeks.
79260511|NCT03221985|Other|questionnaires|questionnaire with application on smartphone
79260512|NCT03055130|Other|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
79560176|NCT03377023|Drug|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
79723017|NCT02817373|Other|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
79875643|NCT00943865|Behavioral|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
79260513|NCT03225885|Other|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
79560177|NCT03317392|Procedure|Biopsy|Undergo tissue biopsy
79560178|NCT03317392|Procedure|Biospecimen Collection|Undergo blood sample collection
79560179|NCT03317392|Procedure|Computed Tomography|Undergo CT
79560180|NCT03317392|Other|Laboratory Biomarker Analysis|Correlative studies
79560181|NCT03317392|Procedure|Magnetic Resonance Imaging|Undergo MRI
79560182|NCT03317392|Drug|Olaparib|Given PO
79560183|NCT03317392|Other|Quality-of-Life Assessment|Ancillary studies
79260514|NCT03225885|Other|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
79260515|NCT04484883|Other|Observational|Observational
79260516|NCT04934930|Drug|Bendamustin|Chemotherapy
79260517|NCT04934930|Drug|Obinutuzumab|Immunotherapy
79560184|NCT03317392|Radiation|Radium Ra 223 Dichloride|Given IV
79560185|NCT03311126|Drug|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of CLL and for indolent B cell NHLs progressing during or within 6 months of rituximab or a rituximab - containing regimen.
79560186|NCT03311126|Drug|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 mAb.
79560187|NCT03309033|Procedure|Biospecimen Collection|Undergo collection of blood samples
79560188|NCT03309033|Other|Questionnaire Administration|Complete questionnaire
79723018|NCT04279210|Device|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
79723019|NCT02817295|Other|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
79723020|NCT00957424|Behavioral|telephone-based intervention|10-15 minute web-based survey on a computer
79260518|NCT04934774|Biological|CD7 CAR T cells|Non-gene edited anti-CD7 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
79260519|NCT04484961|Device|Blood flow restriction (BFR)|The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
79723021|NCT00957424|Drug|nicotine replacement therapy|One week supply
79260520|NCT03057236|Behavioral|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
79260521|NCT03056612|Other|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
79260522|NCT03107481|Drug|Acetaminophen|Acetaminophen 1g IV
79260523|NCT03107481|Drug|Hydromorphone|Hydromorphone 1mg IV
79260524|NCT03107559|Diagnostic Test|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
79723022|NCT00957424|Other|informational intervention|
79560189|NCT03301064|Behavioral|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
79560190|NCT03301064|Other|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
79560191|NCT03300505|Drug|ARRx|Given intravenously (IV)
79560192|NCT03300505|Drug|Enzalutamide|Given by mouth (PO)
79723023|NCT00957424|Other|internet-based intervention|
79723024|NCT00957424|Other|questionnaire administration|Given out week 2, 3 and 4.
79723025|NCT02817061|Device|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
79857520|NCT05678595|Device|high-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
79857521|NCT05678595|Device|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
79857522|NCT05664568|Drug|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
79857523|NCT05664568|Drug|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
79857524|NCT05664568|Other|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
79857525|NCT05659303|Procedure|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
79857526|NCT05656768|Other|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
79857527|NCT05614323|Other|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
79857528|NCT05610124|Other|Ad libitum full-fat French fries with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
79857529|NCT05610124|Other|Ad libitum instant mashed potatoes with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
80020140|NCT02192931|Drug|Creatine monohydrate|
80020141|NCT02012153|Biological|Mesenchymal Stromal Cells|
80020142|NCT01896011|Biological|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
80020143|NCT01896011|Other|Placebo|Placebo 20 mcg injection pen
80020144|NCT01891396|Device|Hyaluronic Acid and TH (Cingal®)|Injection into knee
79723026|NCT02818855|Procedure|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
79723027|NCT02818855|Drug|Collagen Matrix|A new collagen membrane
79723028|NCT02818855|Procedure|Subepithelial connective tissue graft|Connective tissue graft
80020145|NCT01891396|Device|Hyaluronic Acid (Monovisc®)|Injection into knee
80020146|NCT01891396|Device|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
79260525|NCT04934852|Drug|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops >20% from the baseline value or <100 mmHg, or MAP <70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
79560193|NCT03295240|Drug|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
79723029|NCT04278976|Other|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
79723030|NCT02818621|Drug|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
79723031|NCT04642651|Drug|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
79723032|NCT04642651|Drug|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
79723033|NCT01061151|Drug|Zidovudine (ZDV)|300 mg twice daily
79723034|NCT01061151|Drug|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
79857530|NCT05610124|Other|Ad libitum macaroni pasta with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
79857531|NCT05610124|Other|Ad libitum full-fat French fries with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
79857532|NCT05610124|Other|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
79875644|NCT00943865|Behavioral|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
80020147|NCT01747304|Device|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
79560194|NCT03295240|Drug|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
79723035|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
79723036|NCT01061151|Drug|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
80020148|NCT01746225|Drug|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
79260526|NCT04934852|Drug|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops >20% from the baseline value or <100 mmHg, or MAP <70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
79260527|NCT04934852|Drug|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops >20% from the baseline value or <100 mmHg, or MAP <70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
79560195|NCT03280225|Other|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
79857533|NCT05610124|Other|Ad libitum macaroni pasta with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the vegetarian meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
79398078|NCT05209659|Other|Pragmatic Mobilization|"The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)"
79560196|NCT03264235|Device|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
79560197|NCT03264235|Other|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
79560198|NCT03223883|Drug|Curcumin|Oral supplement for 12 months
79560199|NCT03223883|Other|Placebo|Oral placebo for 12 months
79560200|NCT03188510|Biological|LY3074828|Administered SC
79560201|NCT03173937|Biological|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn (TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn (TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
79560202|NCT03173937|Device|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
79560203|NCT03129880|Behavioral|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
79857534|NCT05583695|Behavioral|mindfulness-based music therapy|eight weekly sessions with a combination of both mindfulness and music therapy
79560204|NCT03129880|Behavioral|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
79857535|NCT05583695|Behavioral|mindfulness-based therapy|eight weekly sessions of mindfulness
79857536|NCT05583695|Behavioral|routine care|eight weekly sessions of routine care
79857537|NCT05568004|Behavioral|Combined exercise|aerobic plus resistance exercise
79857538|NCT05568004|Behavioral|Aerobic exercise|Only aerobic exercise
79857539|NCT05537896|Drug|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~neutrophil recovery (ANC >500, post-nadir)~febrile neutropenia~breakthrough infection~any grade 3-4 toxicity related to eravacycline use"
80020149|NCT01730547|Biological|Autologous mesenchymal stem cells|
80020150|NCT01716806|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
79260528|NCT03119493|Behavioral|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
79260529|NCT04934618|Drug|Carelizumab Combined With Irinotecan and Apatinib|Three-drug regimen was used in second-line treatment of Advanced gastric cancer
79260530|NCT03107325|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
79260531|NCT03107325|Drug|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
79260532|NCT04916756|Drug|Baricitinib 2 MG|baricitinib 2mg per day for 24 weeks
79260533|NCT03221361|Device|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
79260534|NCT03221361|Device|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
79260535|NCT04916522|Drug|Colchicine|0.5 mg once daily
79560205|NCT03120780|Drug|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
79560206|NCT03120780|Drug|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
79260536|NCT04916522|Drug|Placebo|Once daily
79560207|NCT03120312|Procedure|total hip replacement|primary hip replacement patients during past 5 years．
79560208|NCT03118505|Device|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
79560209|NCT03118505|Device|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
80020151|NCT01716806|Drug|bendamustine|70 mg/m^2 by IV infusion on Days 1 and 2 of 3-week cycle
79857540|NCT05536908|Behavioral|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx & Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
79857541|NCT05536908|Behavioral|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
79857542|NCT05528939|Device|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
79857543|NCT05528939|Other|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
79857544|NCT05524584|Drug|Fulvestrant|Given intramuscularly
79560210|NCT03102125|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
79857545|NCT05524584|Drug|Anastrozole|Given orally
79857546|NCT05524584|Drug|Abemaciclib|Given orally
79560211|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (<) 65 kg.
79723037|NCT01061151|Drug|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at >= 14 weeks gestation; 600 mg/150 mg twice daily beginning at >= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
80020152|NCT01716806|Drug|dacarbazine|375 mg/m^2 every 3 weeks by IV infusion
80020153|NCT01716806|Drug|nivolumab|3 mg/kg every 3 weeks by IV infusion
79560212|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
79723038|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
80020154|NCT01650545|Drug|Liposomal aerosol cyclosporine|inhaled form of immune suppression
80020155|NCT01650545|Other|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
79260537|NCT03225729|Device|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots <6 mm which are previously selected by the investigator team.
79560213|NCT03100149|Drug|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
79560214|NCT03077841|Other|Laboratory Biomarker Analysis|Correlative studies
79560215|NCT03077841|Radiation|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
79560216|NCT03077841|Other|Questionnaire Administration|Ancillary studies
79560217|NCT03075527|Drug|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
79723039|NCT01061151|Drug|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
79723040|NCT01061151|Drug|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
79723041|NCT01061151|Other|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail."
79723042|NCT01061151|Other|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
79723043|NCT01061151|Other|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
79723044|NCT02818543|Drug|LYC-30937|
79260538|NCT03225729|Device|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots <6 mm a small amount of nitrogen liquid.
79260539|NCT03225495|Procedure|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
79260540|NCT03225495|Procedure|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
79560218|NCT03075527|Drug|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
79560219|NCT03068624|Biological|Aldesleukin|Given SC
79560220|NCT03068624|Biological|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
79560221|NCT03068624|Drug|Cyclophosphamide|Given IV
79560222|NCT03068624|Biological|Ipilimumab|Given IV
80020156|NCT01528189|Other|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
80020157|NCT01528189|Other|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
80020158|NCT01471522|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
80020159|NCT01471522|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
80020160|NCT01471522|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
79260541|NCT04934384|Diagnostic Test|prehospital extended focused assessment sonography for trauma|Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
79260542|NCT03221439|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
79560223|NCT02960022|Drug|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
79560224|NCT02960022|Drug|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
79723045|NCT02816047|Other|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
79723046|NCT04472143|Drug|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
79857547|NCT05510739|Behavioral|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
79857548|NCT05510739|Behavioral|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
80020161|NCT01471522|Behavioral|Lifestyle|diet, physical activity, smoking cessation
80020162|NCT01471522|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
79560225|NCT02960022|Drug|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
79560226|NCT02931253|Drug|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
79560227|NCT02926911|Other|Surgery|Surgery +/- radiation choice for endocrine therapy
79560228|NCT02926911|Other|Active Monitoring|Choice for endocrine therapy
79857549|NCT05495503|Device|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
79857550|NCT05495503|Device|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
79857551|NCT05495503|Device|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
79723047|NCT04303923|Procedure|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
79723048|NCT00634075|Drug|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
79857552|NCT05495503|Device|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
79857553|NCT05494437|Combination Product|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
79857554|NCT05494437|Combination Product|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
79857555|NCT05494437|Drug|Placebo|Placebo comparator
79857556|NCT05494437|Drug|Nabilone|CB1 receptor
79857557|NCT05494437|Drug|Gabapentin|GABAergic modulator
79857558|NCT05444504|Device|Cup|an insertable vaginal cup ('cup')
79857559|NCT05444504|Device|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
79857560|NCT05423600|Procedure|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
79857561|NCT05423600|Procedure|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
79857562|NCT05387187|Drug|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
79857563|NCT05387187|Drug|Pentoxifylline|Pentoxifylline 100mg TID
79857564|NCT05378139|Device|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
79560233|NCT02819882|Other|No intervention|
79560234|NCT02812524|Drug|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
79560235|NCT02796937|Biological|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
79560236|NCT02784496|Other|Long-term Follow-up|Undergo follow-up assessment
79857565|NCT05365893|Combination Product|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
79857566|NCT05365893|Other|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
79857567|NCT05330455|Drug|GSK3965193|GSK3965193 will be administered
79857568|NCT05330455|Drug|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
79857569|NCT05330455|Drug|Bepirovirsen|Bepirovirsen will be administered
79857570|NCT05312671|Drug|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
79857571|NCT05312671|Drug|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
79857572|NCT05312671|Drug|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
79857573|NCT05312671|Drug|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
79857574|NCT05312671|Procedure|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
79857575|NCT05306496|Device|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
79857576|NCT05304208|Biological|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
79857577|NCT05291351|Other|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
79560237|NCT02784496|Other|Quality-of-Life Assessment|Ancillary studies
79560238|NCT02784496|Drug|Ruxolitinib|Given PO
79560239|NCT02734004|Drug|Olaparib|Olaparib
79560240|NCT02734004|Drug|MEDI4736|MEDI4736
79560241|NCT02734004|Drug|Bevacizumab|Bevacizumab
79560242|NCT02697448|Drug|propofol|Participant receives propofol as anesthetic for cardiac ablation.
79560243|NCT02697448|Drug|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
79560244|NCT02688712|Drug|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
79560245|NCT02688712|Drug|Capecitabine|Antimetabolite chemotherapy
79560246|NCT02688712|Drug|Fluorouracil|Antimetabolite chemotherapy
79560247|NCT02688712|Procedure|Tumor specific mesorectal excision|Tumor specific mesorectal excision
79560248|NCT02687360|Device|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
79560249|NCT02687360|Device|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
79560250|NCT02677922|Drug|AG-120|Specified dose on specified days
79723049|NCT00634075|Drug|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
79723050|NCT01241552|Biological|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
79723051|NCT01241552|Biological|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
79723052|NCT01241552|Biological|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
79723053|NCT01241552|Biological|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
79723054|NCT01241552|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
79723055|NCT04748523|Drug|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
79723056|NCT04748523|Drug|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
79723057|NCT02817217|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
79560251|NCT02677922|Drug|Azacitidine|Specified dose on specified days
79560252|NCT02677922|Drug|AG-221|Specified dose on specified days
79560253|NCT02641847|Drug|docetaxel|
79560254|NCT02641847|Drug|doxorubicin or epirubicin|
79560255|NCT02641847|Drug|cyclophosphamide|
79560256|NCT02641847|Drug|gemcitabine|
79560257|NCT02641847|Drug|cisplatin|
79560258|NCT02567799|Drug|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
79857578|NCT05291351|Other|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
79857579|NCT05291351|Other|Porridge made with oat flour or oats|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
79723058|NCT02817217|Drug|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
79857580|NCT05254574|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
80020163|NCT01191008|Drug|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
80020164|NCT01155232|Drug|Teriparatide|Forteo (teriparatide)pen daily for 24 months
80020165|NCT01060371|Genetic|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
80020166|NCT00821587|Drug|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
79260543|NCT03221439|Other|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
79560259|NCT02567799|Drug|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
80020167|NCT00821587|Drug|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
80020168|NCT00751829|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
79260544|NCT03057392|Other|immersion|participants will sit in a 34-35C while receive dialysis
79260545|NCT03057392|Other|sham session|dialysis while sitting in the dialysis chair
79560260|NCT02567799|Drug|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg*min/mL will be administered by intravenous drip two times, 21 days apart."
79723059|NCT00948922|Drug|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
79723060|NCT00948922|Drug|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes.
80020169|NCT00751829|Drug|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
80020170|NCT00645801|Drug|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
79560261|NCT02567799|Radiation|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
79560262|NCT02552953|Drug|CYC065|
79723061|NCT00948922|Procedure|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
79723062|NCT00948922|Drug|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
79723063|NCT00948922|Procedure|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
79723064|NCT02817139|Device|TDCS|
79723065|NCT02858128|Other|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
80020171|NCT00645801|Drug|Placebo|Amitiza Placebo
80020172|NCT00424099|Drug|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
79560263|NCT02532452|Biological|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~Blood adenovirus PCR ≥ 1,000~Blood CMV PCR ≥ 500~Blood EBV PCR ≥ 9,000~Plasma BKV PCR >1,000~Plasma JC Virus PCR > 1,000~Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~Evidence of PML or other CNS infection due to JC virus"
79857581|NCT05254574|Device|Placebo Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the placebo SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% Diclofenac patches.
79723066|NCT04238065|Device|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
80020173|NCT00424099|Behavioral|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
79260546|NCT04934150|Device|navigated repetitive Transcranial Stimulation|High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
79260547|NCT02451501|Device|AKITA|
79560264|NCT02466321|Procedure|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
79560265|NCT02465398|Procedure|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
79560266|NCT02306954|Biological|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
79560267|NCT02306954|Radiation|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
79723067|NCT04238065|Device|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
79723068|NCT04238065|Device|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
79723069|NCT04237909|Biological|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
79723070|NCT04237831|Drug|BMS-986259|Specified Dose on Specified Days
80020174|NCT00424099|Drug|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
80020175|NCT00424099|Behavioral|Non NTI|Non NTI are calls from research staff 3 times weekly.
79260548|NCT04933994|Device|computed Tomography|All cases were detected with computed Tomography
79260549|NCT03221283|Behavioral|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
79260550|NCT04933604|Procedure|laparoscopic partial nephrectomy|Nephron sparing minimally invasive surgery
79260551|NCT04933604|Procedure|Laparoscopic radical nephrectomy|Completely removal of kidney by using laparoscopic surgery
79260552|NCT04926506|Drug|Xiyanping injection|Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
79560268|NCT02299141|Drug|Nintedanib|
79560269|NCT02088060|Drug|Cannabidiol|Cannabidiol capsules
79560270|NCT02088060|Drug|Olanzapine|Olanzapine capsules
79560271|NCT02088060|Drug|Placebo Cannabidiol|Placebo cannabidiol capsules
79560272|NCT02088060|Drug|Placebo Olanzapine|Placebo olanzapine capsules
79560273|NCT02078427|Biological|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
79723071|NCT00634309|Drug|Candesartan|
79723072|NCT00634309|Drug|Placebo|
79723073|NCT01239992|Drug|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
79723074|NCT02816905|Drug|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
79723075|NCT02816905|Drug|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
79857582|NCT05254574|Drug|1% Diclofenac Topical Gel|Topical pain-relief gel
79857583|NCT05225324|Drug|Equfina 50 mg|Equfina 50 mg tablets.
80020176|NCT00382213|Drug|Olmesartan medoxomil|
80020177|NCT00382213|Drug|Placebo|
79260553|NCT04927130|Diagnostic Test|ARNA Breast|A specific DNA fragments and globulins will be detected in blood plasma.
79260554|NCT03221205|Device|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
79560274|NCT02078427|Biological|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
79857584|NCT05219929|Drug|Tetracycline 500 Mg|500 mg three times daily
79857585|NCT05219929|Other|Placebo|Placebo for Tetracycline given same way as Tetracycline.
79857586|NCT05210530|Combination Product|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
79857587|NCT05205382|Other|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
79857588|NCT05205382|Other|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
79857589|NCT05205382|Other|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
80020178|NCT00176267|Radiation|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 & 36 of chemotherapy
79857590|NCT05203185|Other|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
79560275|NCT02073968|Drug|Carboplatin|Given IV
80020179|NCT00176267|Drug|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
79560276|NCT02073968|Procedure|Computed Tomography|Undergo PET-adjusted IMRT
79560277|NCT02073968|Radiation|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
79260555|NCT03221205|Device|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
79260556|NCT03225651|Biological|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
79260557|NCT03225651|Behavioral|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
79560278|NCT02073968|Drug|Paclitaxel|Given IV
79260558|NCT03225339|Dietary Supplement|Low Energy Diet|Low Energy Diet
79560279|NCT02073968|Procedure|Positron Emission Tomography|Undergo PET-adjusted IMRT
79560280|NCT02073968|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
79560281|NCT01983241|Biological|Alpha-1 MP|
79560282|NCT01983241|Other|0.9% Sodium Chloride for Injection, USP|
79560283|NCT01696994|Other|Laboratory Biomarker Analysis|Correlative studies
79857591|NCT05202847|Procedure|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
80020180|NCT00176267|Drug|Carboplatin|AUC of 6 on Days 1 & 22
80020181|NCT03102346|Other|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
79260559|NCT04407650|Drug|Metformin|"Patients will be randomized to each intervention using minimisation:~BMI category (Overweight/Obese),~Previous history of GDM,~Disease severity (baseline fasting glucose ≤6.2 or >6.2),~Recruitment centre"
79260560|NCT04407650|Drug|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~BMI category (Overweight/Obese),~Previous history of GDM,~Disease severity (baseline fasting glucose ≤6.2 or >6.2),~Recruitment centre"
79560284|NCT01696994|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
79560285|NCT01696994|Procedure|Ultrasound Imaging|Undergo TVU
79560286|NCT01696981|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
79560287|NCT01696981|Procedure|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
79560288|NCT01696968|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
79560289|NCT01696968|Procedure|X-Ray Imaging|Undergo a chest x-ray
79560290|NCT01247207|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
79560291|NCT01155050|Device|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
79857592|NCT05202847|Procedure|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
79857593|NCT05153148|Drug|NDI-034858|Randomized participants will receive NDI-034858 capsule orally
80020182|NCT02298764|Other|Standard back pain treatment|Standard back pain treatment
80020183|NCT02298764|Other|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
80020184|NCT05428501|Other|no treatment given|People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
79260561|NCT03225261|Dietary Supplement|Citrus extract|Citrus extract
79260562|NCT03225261|Dietary Supplement|Placebo|Maltodextrin
79560292|NCT01155050|Behavioral|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
79560293|NCT01155050|Device|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
79560294|NCT01148563|Device|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
79560295|NCT01050504|Other|Cytology Specimen Collection Procedure|Correlative studies
79560296|NCT01050504|Other|Laboratory Biomarker Analysis|Correlative studies
79560297|NCT00906997|Procedure|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
79560298|NCT00906997|Procedure|Colonoscopy|Every 10 years, with sedation.
79560299|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
79560300|NCT00587886|Behavioral|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
79560301|NCT00002540|Other|Laboratory Biomarker Analysis|Correlative studies
79260563|NCT03055052|Other|Standard formula for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
79560302|NCT00002540|Procedure|Medical Examination|Undergo DRE
79560303|NCT00002540|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
79560304|NCT01682486|Device|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
79560305|NCT01682486|Procedure|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
79560306|NCT01682577|Drug|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
79560307|NCT01682577|Drug|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
79560308|NCT01682707|Procedure|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
79560309|NCT01682707|Procedure|track light|
79560310|NCT01683227|Behavioral|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
79560311|NCT01683227|Behavioral|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
79560312|NCT01683240|Device|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
79560313|NCT01683357|Procedure|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
79560314|NCT01683578|Other|Variable Ventilation|
79560315|NCT01683643|Behavioral|SBIRT|Screening, brief intervention, and referral to treatment.
79857594|NCT05153148|Other|Placebo|Randomized participants will receive placebo orally
79560316|NCT01683643|Behavioral|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
79857595|NCT05132829|Drug|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
79260564|NCT03055052|Other|Formula with higher protein and new fat blend for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
79260565|NCT00105157|Drug|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
79260566|NCT00105157|Drug|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
79560317|NCT01683669|Other|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
79560318|NCT01683669|Other|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
79260567|NCT00105157|Drug|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
79260568|NCT00105157|Drug|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
79260569|NCT03221049|Diagnostic Test|radiomics|
79560319|NCT01683760|Drug|Fluconazole|Prophylactic fluconazole administration in VLBW infants
79560320|NCT01683851|Device|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
79560321|NCT01684124|Other|conservative O2 therapy|target lower O2 saturation
79560322|NCT01684124|Other|standard care|
79560323|NCT01684280|Genetic|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
79857596|NCT05132829|Drug|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
79857597|NCT05126355|Behavioral|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
79857598|NCT05122689|Dietary Supplement|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
79260570|NCT04916366|Other|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
79260571|NCT04916366|Other|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
79260572|NCT03220815|Procedure|Drilling at low speed|
79723076|NCT02816905|Drug|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
79723077|NCT02816827|Dietary Supplement|AG-01|Product to increase mental alertness
79857599|NCT05122689|Dietary Supplement|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
79857600|NCT05117450|Device|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
79857601|NCT05104450|Behavioral|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
79857602|NCT05102669|Other|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
79857603|NCT05102669|Diagnostic Test|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
79857604|NCT05099874|Device|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
79857605|NCT05063357|Drug|131I-Omburtamab|Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
79260573|NCT03220815|Procedure|Conventional drilling at high speed|
79723078|NCT02816827|Dietary Supplement|AG-05|Product to increase mental alertness
79723079|NCT02816827|Dietary Supplement|AG-06|Product to increase mental alertness
79723080|NCT02816827|Dietary Supplement|AG-07|Product to increase mental alertness
79857606|NCT05063357|Device|Convention Enhanced Delivery|The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
80020185|NCT03102112|Other|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
79723081|NCT01239680|Drug|Glutamine|Intravenous 25 grams once over 6 hours
79723082|NCT01239680|Drug|Ringer's Lactate|Intravenous 1 liter once over 6 hours
79723083|NCT01239680|Drug|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
79723084|NCT02816749|Procedure|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
79723085|NCT02816749|Procedure|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
79723086|NCT04211857|Device|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
79260574|NCT03232437|Device|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
79260575|NCT03232515|Combination Product|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
79260576|NCT04926428|Drug|tPA|Selectively catheter thrombolysis with alteplase in each main pulmonary
79260577|NCT03225027|Behavioral|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
79260578|NCT03225027|Behavioral|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
79260579|NCT03225027|Behavioral|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
79260580|NCT03225027|Behavioral|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
79260581|NCT03225027|Other|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
79723087|NCT05515094|Behavioral|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
79723088|NCT05654077|Biological|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10^6cells/kg、9.0 × 10^6cells/kg、1.5 × 10^7cells/kg。
79723089|NCT05654077|Drug|Fludarabine|Fludarabine 25~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
79260582|NCT03225027|Diagnostic Test|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
79560324|NCT01684488|Behavioral|YRI|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
79560325|NCT01684488|Other|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
79857607|NCT05050448|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
79857608|NCT05050448|Drug|1% Diclofenac Topical Gel|Topical pain-relief gel
79260583|NCT03225027|Diagnostic Test|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
79857609|NCT05030935|Device|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
79723090|NCT05654077|Drug|cyclophosphamide|250~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
79260584|NCT03225027|Other|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
79260585|NCT02254213|Other|EEG recording|A short EEG recording is performed 10 times over the span of three months.
79723091|NCT04303767|Drug|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
79723092|NCT04303767|Procedure|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
79723093|NCT02816671|Device|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
79857610|NCT05013385|Drug|Spesolimab|Spesolimab
79857611|NCT05013385|Drug|Placebo|Placebo
79857612|NCT05005650|Procedure|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
79857613|NCT04982198|Procedure|ROSA assisted TKA|Robotic assisted total knee arthroplasty
79260586|NCT04926350|Behavioral|Resistance Exercise|8 total resistance exercises that target all major muscle groups
79857614|NCT04956250|Other|Traffic Calming Curbs|Temporary curb extensions, placed at intersections.
79857615|NCT04956250|Other|In-Street Pedestrian Sign|Yield sign placed in middle of road at intersection.
79857616|NCT04946344|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
79260587|NCT03220659|Device|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
79260588|NCT03220659|Device|Standard settings|Normal bipolar LV pacing
79723094|NCT01238900|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
79723095|NCT04303299|Drug|Oral|Anti virus treatment
79857617|NCT04946344|Behavioral|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
79857618|NCT04922606|Diagnostic Test|US ot the GSV|Ultrasound of the Great Saphenous Vein
79857619|NCT04913701|Other|Observation group 1|Subjects will be followed with 3 swabs and serological test
79260589|NCT03224715|Other|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
79260590|NCT04913402|Other|Sufentanil administered by paramedics after the phone call consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
79260591|NCT04913402|Other|Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
79723096|NCT02874963|Procedure|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
79723097|NCT02874963|Device|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
79857620|NCT04899388|Procedure|Pericapsular Nerve Block|regional anaesthia
79857621|NCT04899388|Procedure|Lumbar Erector Spinae Plane Block|regional anaesthia
79857622|NCT04899388|Drug|Fentanyl|intavenous
79857623|NCT04887571|Other|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
79857624|NCT04880785|Drug|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
79857625|NCT04878601|Other|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
79560326|NCT01684514|Device|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
79857626|NCT04878601|Other|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
79857627|NCT04876586|Procedure|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
79857628|NCT04874246|Drug|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
79857629|NCT04865731|Drug|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
79857630|NCT04865731|Drug|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
80020186|NCT02292056|Behavioral|1-on-1 counseling|"Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
79260592|NCT03220971|Other|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
79260593|NCT04912934|Procedure|A survey form was applied to individuals included in the study face-to-face.|This study was completed with a descriptive, cross-sectional and relational screening model
79260594|NCT03232359|Diagnostic Test|immature platelets fraction|IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
79560327|NCT01684644|Behavioral|New Forest Parenting Programme|
79560328|NCT01684644|Behavioral|Treatment as usual|
79560329|NCT01684813|Drug|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
79560330|NCT01684813|Drug|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
79560331|NCT01684982|Device|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
79560332|NCT01684982|Device|sirolimus eluting stent|control arm of a comparison between drug eluting stents
79560333|NCT01685034|Biological|"Allergy immunotherapy (allergy shots)"|
79560334|NCT01685151|Drug|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
79560335|NCT01685151|Drug|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
79560336|NCT01685151|Drug|Placebo|Placebo
79560337|NCT01685307|Dietary Supplement|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
79560338|NCT01685489|Drug|Docetaxel, PSK®|
79560339|NCT01685489|Drug|Docetaxel, Placebo|
79560340|NCT01685775|Procedure|Transvaginal/transumbilical|
79560341|NCT01685775|Procedure|Needlescopic with 3 trocars|
79560342|NCT01686087|Behavioral|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
79560343|NCT01686087|Procedure|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
79560344|NCT01686100|Procedure|No touch technique|The vein graft is harvested with its surronding tissues.
79560345|NCT01686100|Procedure|Conventional technique|The vein graft is stripped from its surrounding tissues.
79560346|NCT01686139|Biological|ABMD-MSC|10-20 x 10^6 cells/20mL
79560347|NCT01686178|Behavioral|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
79560348|NCT01686204|Other|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
79560349|NCT01686204|Other|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
79560350|NCT01686386|Drug|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
79560351|NCT01686386|Drug|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
79560352|NCT01686386|Drug|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
79560353|NCT01686594|Drug|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
79560354|NCT01686776|Other|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
79560355|NCT01687192|Biological|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
79560356|NCT01687465|Procedure|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
79857631|NCT04813159|Device|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
79723098|NCT02874963|Drug|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
79560357|NCT01687465|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
79560358|NCT01687517|Drug|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
79723099|NCT02818465|Other|Vascular calcifications by Xray|
79723100|NCT02818465|Other|Vascular calcifications by tomodentimetry|
79723101|NCT02818465|Biological|Blood sample withdrawn|
79723102|NCT02818309|Drug|Lesogaberan|120 mg bid
79723103|NCT02818309|Drug|Placebo|Placebo
79723104|NCT01238822|Drug|Methylphenidate|18 mg methylphenidate
79723105|NCT01238822|Drug|placebo|Placebo
79723106|NCT01238822|Drug|Methylphenidate|36 mg methylphenidate
79723107|NCT01238822|Drug|Methylphenidate|54 mg methylphenidate
79723108|NCT04303455|Diagnostic Test|blood sampling|sampling serum renin
79723109|NCT02818387|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
79723110|NCT02818387|Drug|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
79857632|NCT04813159|Device|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
79723111|NCT02818387|Drug|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
79723112|NCT05296629|Drug|DFD-29|DFD-29 (40 mg) extended release capsules
79723113|NCT05296629|Drug|Doxycycline|Doxycycline 40 mg capsules
79857633|NCT04808869|Other|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
79857634|NCT04777006|Behavioral|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
80020187|NCT03643731|Device|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
79723114|NCT05296629|Drug|Placebo|Placebo capsules
79723115|NCT00634153|Other|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
79723116|NCT01238588|Drug|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
79723117|NCT04303143|Behavioral|Self-Hypnosis|Self-Hypnosis
79723118|NCT04303143|Behavioral|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
79723119|NCT02818231|Other|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
79723120|NCT00627003|Drug|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
79723121|NCT00627003|Other|Placebo|Placebo oral tablets administered daily for 5 weeks
79723122|NCT04238611|Device|Microneedle|Lactate microneedle applied on the skin of participant
79723123|NCT04238611|Diagnostic Test|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
79560359|NCT01687556|Other|topical EGCG application on acne|two times application of topical EGCG on acne lesion
79723124|NCT04238611|Other|Exercise regimen|Standardised aerobic exercise regimen
79723125|NCT02818153|Other|Self questionnaire for allergic rhinitis control|
79723126|NCT04238533|Other|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
79723127|NCT04238533|Other|Conventional training|Conventional training with Myoboy has been the only training available to users.
79857635|NCT04777006|Drug|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 < 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
79857636|NCT04766086|Biological|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
79857637|NCT04766086|Biological|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
80020188|NCT05431894|Behavioral|Laguna Coach Intervention Group|Behavioral and mental support was delivered through personal interactions with Laguna Coaches via phone, video, or web chat. Behavioral and mental support was individualized to best match each patient's needs and strengths. Support was provided to participants through human interactions over approximately 30 days.
80020189|NCT02298920|Drug|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
80020190|NCT05007366|Behavioral|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
79857638|NCT04766086|Biological|Placebo|Saline control
79857639|NCT04717986|Drug|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
80020191|NCT05007366|Behavioral|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
79560360|NCT01687751|Drug|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~The study drug will be started at a rate of 1.0 mL/hr.~The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
79560361|NCT01687751|Drug|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~The study drug will be started at a rate of 1.0 mL/hr.~The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
80020192|NCT05691907|Device|THE therapy|"THE therapy consisting of:~Heating Pad~Interferential Therapy"
80020193|NCT05691907|Procedure|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
80020194|NCT05691907|Procedure|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
80020195|NCT03517748|Device|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
79560362|NCT01687777|Biological|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
79260595|NCT04916288|Device|central venous cathterization|central venous catheterization through the right internal jugular vein
79260596|NCT04915586|Drug|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
79260597|NCT03232047|Device|Combined executive function and memory training|Computerized combined executive function and memory training
79560363|NCT01687777|Biological|OrthADAPT|
79560364|NCT01687881|Other|Chiropractic|Chiropractic Spinal Manipulative Therapy
79560365|NCT01687881|Other|Sham Chiropractic|Sham manipulation
79560366|NCT01688362|Biological|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
79723128|NCT05657509|Other|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 50 to 70% in the last weeks' intensity will be 60 to 70%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
79723129|NCT05657509|Other|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
79723130|NCT04238221|Drug|Doxofylline|Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
79723131|NCT02815423|Biological|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
79723132|NCT02815423|Biological|Percutaneous|Percutaneous injection
79723133|NCT01047501|Drug|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
79723134|NCT01047501|Drug|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
79857640|NCT04717986|Drug|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
79260598|NCT04925726|Other|Land based exercise|The patients who had land based exercise
79560367|NCT01688362|Drug|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
79857641|NCT04689529|Diagnostic Test|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
79560368|NCT01688375|Drug|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
79560369|NCT01688427|Behavioral|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
79723135|NCT01047501|Drug|Placebo|Placebo 4 capsules/day for 12 weeks
79723136|NCT01238120|Drug|Ibuprofen|200 mg BID and 8 hours apart
79723137|NCT01238120|Behavioral|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
79723138|NCT01238120|Drug|Placebo|200mg BID and 8 hours apart
79857642|NCT04687137|Drug|TAK-743 300 mg|TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
79857643|NCT04678102|Drug|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
79857644|NCT04648436|Other|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
79857645|NCT04648436|Other|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
79857646|NCT04643106|Procedure|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
79857647|NCT04643106|Procedure|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
79857648|NCT04636437|Drug|Doravirine 100 Mg|Participants will receive 100 mg tablet by mouth daily with or without food.
79857649|NCT04636437|Drug|Tenofovir alafenamide/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
79857650|NCT04636437|Drug|tenofovir alafenamide/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
79857651|NCT04636437|Drug|Integrase strand transfer inhibitors|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
79857652|NCT04636437|Drug|tenofovir disproxil fumarate/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
79857653|NCT04636437|Drug|tenofovir disproxil fumarate/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
79857654|NCT04622774|Drug|IMGC936|Antibody Drug Conjugate
79857655|NCT04615078|Device|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~An organizational solution relying on a nurse call center."
79857656|NCT04600648|Diagnostic Test|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
79857657|NCT04600648|Diagnostic Test|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
79857658|NCT04600180|Procedure|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
79857659|NCT04542161|Drug|NAC 900mg/day|self administer NAC 900mg/day caplets for a four week period
79857660|NCT04542161|Drug|NAC 3600mg/day|self administer NAC 3600mg/day caplets for a four week period
79857661|NCT04542161|Drug|NAC 0mg/day (Placebo)|self administer NAC 0mg/day (placebo) caplets for a four week period
79857662|NCT04469595|Drug|Iluvien 0.19 MG Drug Implant|0.19 mg Fluocinolone Acetonide Intravitreal Implant
79857663|NCT04469595|Drug|Aflibercept|2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
79857664|NCT04399460|Other|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
79857665|NCT04399460|Other|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
79260599|NCT04925726|Other|Water based exercise|The patients who had water based exercise
79260600|NCT03224559|Device|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
79560370|NCT01688427|Behavioral|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
79723139|NCT05655481|Other|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
79723140|NCT05655481|Other|Health education|Telehealth and guidelines for the practice of physical activity and health education
79723141|NCT01237340|Drug|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
80020196|NCT03517748|Device|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
79260601|NCT04915664|Device|Pessary|Use of Pessary as treatment of POP
79260602|NCT03232125|Drug|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
79260603|NCT03232125|Drug|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
79857666|NCT04370496|Procedure|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
79260604|NCT02143375|Device|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
79260605|NCT03220269|Other|Out-of-hospital cardiac arrest (OHCA)|Data collection
79857667|NCT04331340|Other|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
80020197|NCT03104686|Other|Short pasta (dry)|50g available carbohydrate of penne pasta
79260606|NCT03220269|Other|In-hospital cardiac arrest (IHCA)|Data collection
79260607|NCT04915820|Dietary Supplement|Ferinject|intravenous iron carboxymaltose
79260608|NCT02147743|Behavioral|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
79260609|NCT02147743|Behavioral|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
79260610|NCT03224793|Drug|BIIB059|Administered as specified in the treatment arm
79260611|NCT03224793|Drug|Placebo|Administered as specified in the treatment arm
79560371|NCT01688453|Behavioral|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
79560372|NCT01688453|Behavioral|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
80020198|NCT03104686|Other|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
80020199|NCT03104686|Other|Bread|50g available carbohydrate of bread
80020200|NCT03104686|Other|Glucose|50g available carbohydrate of glucose monohydrate
79260612|NCT04913324|Behavioral|Virtual Care|Infants randomized at 4 months of age to the intervention arm will participate in virtual care visits for 16 weeks in addition to standard of care in-hospital visits.
79260613|NCT03224637|Procedure|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
79260614|NCT03224637|Drug|Paracetamol (conventional)|
79260615|NCT03224637|Drug|Ketorolac Tromethamine (conventional)|
79560373|NCT01688778|Behavioral|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
79560374|NCT01689064|Procedure|Stamm Approach|
79260616|NCT02147821|Procedure|No Pleural Chest Tube|
79560375|NCT01689064|Procedure|Posterior Septectomy|
80020201|NCT02253498|Device|deep brain stimulation (DBS)|
80020202|NCT02298998|Other|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
80020203|NCT02298998|Other|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
79260617|NCT04912700|Biological|COVID-19 vaccine|Full or partial reception of vaccine
79260618|NCT00961831|Drug|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
79260619|NCT00961831|Drug|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
79277481|NCT05647291|Device|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
79857668|NCT04331340|Other|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
79857669|NCT04294407|Other|No intervention|no intervention in this study
79857670|NCT04254796|Behavioral|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
79857671|NCT04250636|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
79857672|NCT04250636|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
79857673|NCT04233749|Drug|Tranexamic acid tablets|325mg of tranexamic acid twice daily for six months
79857674|NCT04225897|Drug|RV521|RV521 is an RSV F protein inhibitor administered orally
79857675|NCT04225897|Drug|Placebo|vehicle administered orally
79260620|NCT03224871|Drug|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
79260621|NCT03224871|Drug|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
80020204|NCT03104608|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
79260622|NCT03224871|Drug|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
79560376|NCT01689077|Other|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
79560377|NCT01689753|Device|TEGO connector®|
79723142|NCT02818075|Other|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
79560378|NCT01689753|Drug|Trisodium citrate|
79723143|NCT02818075|Other|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
79723144|NCT04303533|Device|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
79723145|NCT02816593|Drug|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
79723146|NCT02816593|Drug|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
79857676|NCT04201561|Drug|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
79560379|NCT01690026|Behavioral|Motivation interviewing based brief intervention|
79560380|NCT01690026|Behavioral|Standard Intervention|
79560381|NCT01690039|Drug|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
79857677|NCT04201561|Drug|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
79857678|NCT04201561|Drug|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
79857679|NCT04190589|Device|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
79857680|NCT04151602|Behavioral|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
79857681|NCT04097184|Device|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
79857682|NCT04081220|Drug|IMG-7289|Single starting dose with individualized dose titrations throughout
79857683|NCT04061421|Drug|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
79857684|NCT04061421|Drug|Itacitinib|Taken by mouth daily during each 28-day cycle
79857685|NCT04046900|Biological|Vaginal microbiome transplant|Vaginal fluid from healthy donors
79857686|NCT04046900|Drug|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
79857687|NCT04046900|Other|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
79857688|NCT03989115|Drug|RMC-4630|RMC-4630 for oral administration
79857689|NCT03989115|Drug|Cobimetinib|Cobimetinib for oral administration
79857690|NCT03989115|Drug|Drug: Osimertinib|Osimertinib for oral administration
79857691|NCT03971071|Drug|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
79857692|NCT03971071|Drug|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
80020205|NCT03104608|Other|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
79857693|NCT03971071|Drug|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
79260623|NCT03224871|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
79260624|NCT02147977|Dietary Supplement|dietary supplement: n-3 PUFA|
79260625|NCT02147977|Dietary Supplement|olive oil|
79260626|NCT03220425|Drug|Insulin detemir|
79260627|NCT03220425|Drug|NPH insulin|
79723147|NCT02816593|Drug|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
79857694|NCT03946748|Drug|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
79560382|NCT01690065|Drug|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
79560383|NCT01690091|Drug|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
79857695|NCT03937843|Drug|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
80020206|NCT03517670|Other|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
79260628|NCT04912778|Other|Filling in an online survey|Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
79260629|NCT03544021|Biological|CART-19 cells|CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
79560384|NCT01690091|Drug|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
79260630|NCT04925258|Behavioral|SPACE Parenting Program|The program involves a two-arm randomized trial of differing parenting interventions which include: a service as usual (SAU) cohort, in which parents are provided with local and online parenting and family mental health resources; An intervention group called SPACE that includes weekly parenting materials (i.e., two online ~10-minute videos, ten parent-child activities that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program (NCT04347707 and NCT04639557) intervention group. Additionally, this group will receive weekly drop-in sessions with a facilitator-led (trained MA-level or higher psychology student or psychologist) interactive parenting group to re-enforce concepts and provide social support.
79560385|NCT01690104|Drug|Rifampicin|
79560386|NCT01690104|Drug|Placebo|
79560387|NCT01690169|Drug|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
79560388|NCT01690169|Drug|placebo|A single dose of oral placebo administered.
79560389|NCT01690182|Dietary Supplement|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
79857696|NCT03937843|Drug|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
79857697|NCT03937843|Drug|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
80020207|NCT03517670|Other|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
80020208|NCT03517670|Other|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
79560390|NCT01690182|Dietary Supplement|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
79560391|NCT01690182|Dietary Supplement|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
79560392|NCT01690195|Drug|ABT-126|See arm description
79560393|NCT01690208|Other|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
79723148|NCT04237987|Drug|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
79723149|NCT04237987|Drug|ciclosporin and corticosteroid|ciclosporin and corticosteroid
79723150|NCT01045707|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
79723151|NCT01045707|Drug|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
79723152|NCT02816125|Dietary Supplement|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
80020209|NCT03517670|Other|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
80020210|NCT03626155|Behavioral|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
80020211|NCT03626155|Behavioral|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
79723153|NCT02816437|Biological|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
79398079|NCT04234815|Behavioral|CETA Short Session (CSS)|CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
79398080|NCT04234815|Behavioral|Psychoeducation and Safety|This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
79398081|NCT00511095|Biological|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
79398082|NCT00511173|Genetic|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
79560394|NCT01690208|Other|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment & explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
79560395|NCT01690221|Drug|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
80020212|NCT04988880|Other|Multiple Sclerosis Expert Patient Program of Catalonia|It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
79560396|NCT01690221|Drug|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
79560397|NCT01690234|Procedure|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
79560398|NCT01690234|Procedure|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
80020213|NCT02295098|Other|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
80020214|NCT02295098|Other|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
79560399|NCT01690247|Drug|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
79560400|NCT01690247|Drug|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
79560401|NCT01690260|Drug|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
79560402|NCT01690260|Procedure|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
79560403|NCT01690286|Drug|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
79560404|NCT01690286|Drug|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
79560405|NCT01690286|Drug|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
79723154|NCT04303221|Other|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
79857698|NCT03896711|Behavioral|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
80020215|NCT05431504|Drug|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
80020216|NCT02292134|Device|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
79723155|NCT04238377|Procedure|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
80020217|NCT03104296|Diagnostic Test|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
80020218|NCT03626077|Other|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
80020219|NCT03626077|Device|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
79857699|NCT03896711|Other|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
80020220|NCT03626077|Combination Product|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
80020221|NCT03520634|Other|PD-L1 PET imaging|PD-L1 PET imaging
79260631|NCT02148055|Other|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
79560406|NCT01690286|Drug|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
79857700|NCT03839823|Combination Product|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
80020222|NCT03104530|Other|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
79260632|NCT04924868|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones
79260633|NCT04924868|Drug|Placebo|Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
79260634|NCT03220503|Procedure|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
79260635|NCT02451969|Biological|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
79260636|NCT02451969|Biological|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
80020223|NCT03514472|Dietary Supplement|Dried Moringa oleifera leaves|
80020224|NCT00109668|Drug|beclomethasone dipropionate (QVAR)|
79560407|NCT01690312|Dietary Supplement|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
79560408|NCT01690312|Dietary Supplement|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
79560409|NCT01690325|Drug|Docetaxel|
79260637|NCT04912310|Device|Argon laser peripheral iridoplasty|Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
79260638|NCT03224247|Procedure|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
79277482|NCT03105765|Drug|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
79277483|NCT03105765|Drug|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
79560410|NCT01690325|Drug|Trastuzumab|
79560411|NCT01690325|Drug|Bevacizumab|
79857701|NCT03839823|Combination Product|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day [oral] or (25 to 30 mg/m2 [IV infusion]"
79560412|NCT01690325|Drug|Epirubicin|
79723156|NCT04238377|Drug|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
79857702|NCT03839823|Combination Product|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
79857703|NCT03839823|Drug|Ribociclib|Dose: 600 mg (200 mg * 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
79260639|NCT03224247|Procedure|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
79260640|NCT04402502|Device|Ultrasound Imaging|The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
79260641|NCT02148133|Drug|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
79260642|NCT02148133|Drug|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
79260643|NCT03220191|Drug|Palbociclib|palbociclib tablet formulation
79260644|NCT03220191|Drug|Rabeprazole|rabeprazole as PPI
79560413|NCT01690325|Drug|Cyclophosphamid|
79560414|NCT01690338|Drug|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
79560415|NCT01690338|Drug|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
79560416|NCT01690338|Drug|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
79723157|NCT04302831|Behavioral|Strength training|weight lifting to increase muscle strength
79560417|NCT01690351|Drug|PF-05089771|Oral dispersion TS formulation- fasted
79560418|NCT01690351|Drug|PF-05089771|Capsules TS formulation- fasted
79723158|NCT04302831|Behavioral|Endurance training|treadmill walking to increase endurance
79857704|NCT03839823|Drug|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
79857705|NCT03839823|Drug|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
79260645|NCT03220113|Combination Product|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
79260646|NCT04915430|Other|Training|
79560419|NCT01690364|Other|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
79560420|NCT01690364|Other|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
79560421|NCT01690377|Biological|PDC or myDC|PDC or myDC; first patient 0.3 * 10E6 PDC; second and third 1 * 10E6 PDC; fourth and fifth 3 * 10E6 PDC.
79560422|NCT01690390|Drug|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
79560423|NCT01690390|Drug|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
79560424|NCT01690403|Drug|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
79857706|NCT03822702|Other|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
79560425|NCT01690403|Drug|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
79260647|NCT02143453|Other|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
79260648|NCT02143453|Other|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
79560426|NCT01690416|Procedure|Traditional palpation technique|
79560427|NCT01690416|Procedure|Ultrasound DNTP|
79560428|NCT01690429|Device|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
79560429|NCT01690442|Behavioral|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
79723159|NCT04302831|Behavioral|Flexibility training|stretches to improve flexibility
79723160|NCT04302831|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
79723161|NCT04302831|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
79723162|NCT02817685|Other|3 months|
79857707|NCT03822702|Other|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
79857708|NCT03805009|Device|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
79857709|NCT03800927|Device|Long duration ultrasound|Low-intensity long duration ultrasound treatment
79857710|NCT03797898|Other|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
79857711|NCT03787680|Drug|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
79857712|NCT03787680|Drug|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
79260649|NCT03219957|Drug|AT-527|Ascending doses of AT-527 administered orally.
79260650|NCT03219957|Other|Placebo Comparator|Matching placebo
79260651|NCT02254525|Drug|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
79560430|NCT01690442|Behavioral|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
79723163|NCT02817685|Other|6 months|
79857713|NCT03772899|Drug|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
79560431|NCT01690468|Drug|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
79560432|NCT01690468|Drug|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
79560433|NCT01690494|Behavioral|PACT|Couple-based behavioral HIV/STI preventive intervention
79857714|NCT03743636|Drug|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
79857715|NCT03743636|Drug|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
79260652|NCT02254525|Drug|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
79260653|NCT04915196|Dietary Supplement|Liposomally-bound Iron|Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
79260654|NCT03231813|Procedure|Sodium lauryl sulphate induced irritation|Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
79260655|NCT03231813|Other|Emollient, moisturizing cream|Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
79260656|NCT02254603|Device|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
79560434|NCT01690494|Behavioral|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
79560435|NCT01690507|Drug|Decitabine|20 mg/m²/day for 5 days
79260657|NCT02254603|Behavioral|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
79260658|NCT04914962|Other|glazed zirconium lithium silicate|monolithic glazed crown
79260659|NCT04914962|Other|polished zirconium lithium silicate|monolithic polishedcrowns
79560436|NCT01690507|Drug|Cytarabine|
79560437|NCT01690507|Drug|aclacinomycin|
79560438|NCT01690507|Drug|Granulocyte colony-stimulating factor|
79560439|NCT01690507|Other|HLA haploidentical mononuclear cells infusion|
79560440|NCT01690533|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
79723164|NCT02817685|Other|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
79723165|NCT02874807|Drug|Empagliflozin|
79723166|NCT02874807|Other|Placebo|
79723167|NCT02817529|Device|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
79857716|NCT03743636|Other|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
79857717|NCT03726775|Drug|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
79560441|NCT01690559|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
79260660|NCT04485351|Other|no intervention|no intervention
79260661|NCT02143531|Drug|4 mg of Ondansetron IV|
79260662|NCT02143531|Drug|1mg of Haloperidol IV|
79260663|NCT04914884|Diagnostic Test|intraocular fluid detection|This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
79260664|NCT03219411|Dietary Supplement|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
79260665|NCT03219411|Other|placebo|Placebo administered orally as capsules three times a day over 12 weeks
79723168|NCT02817529|Device|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
79260666|NCT02143609|Drug|oxygen|Nocturnal nasal oxygen during stay at 2048 m
79560442|NCT01690572|Device|Paclitaxel coated balloon catheter|Dilatation of the target lesion
79560443|NCT01690572|Device|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
79857718|NCT03718039|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
79857719|NCT03718039|Device|Luer Lock applicator|Applicator for instillation.
79857720|NCT03718039|Device|Vial access device|Device for withdrawal of drug product.
80020225|NCT03104140|Drug|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
79260667|NCT02143609|Drug|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
79260668|NCT04485117|Device|Bispectral Index Monitor|Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
79560444|NCT01690585|Drug|Ferinject 1000 mg|
79560445|NCT01690585|Drug|Sodium chlorure 0,9 %|
79857721|NCT03718039|Drug|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
80020226|NCT03104140|Drug|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
80020227|NCT05472883|Procedure|blood samples|- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
79260669|NCT04485117|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
79260670|NCT04485117|Drug|Sevoflurane|Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
79260671|NCT04485117|Drug|Propofol|Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
79260672|NCT03224169|Behavioral|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
79260673|NCT03218943|Device|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
79560446|NCT01690598|Drug|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
79560447|NCT01690598|Drug|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
79560448|NCT01690611|Procedure|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
79560449|NCT01690611|Other|Visual Feedback|Real time feedback regarding body motion while walking.
79560450|NCT01690624|Drug|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
79560451|NCT01690637|Drug|Oseltamivir phosphate suspension|
79560452|NCT01690637|Drug|Placebo|
79560453|NCT01690650|Drug|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
79560454|NCT01690676|Dietary Supplement|Epicatechin|
79560455|NCT01690676|Dietary Supplement|Microcrystalline cellulose|
79560456|NCT01690689|Device|Implant surgery|surgery
79560457|NCT01690702|Drug|Epirubicin|
79560458|NCT01690702|Drug|nab-Paclitaxel|
79560459|NCT01690702|Drug|Cyclophosphamide|
79560460|NCT01690702|Drug|Docetaxel|
79560461|NCT01690741|Drug|Nerofe|Nerofe administered intravenously 3x/week
79723169|NCT02875431|Procedure|Patients undergo ACDF or cervical vertebral body replacement|
79723170|NCT02817607|Procedure|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
80020228|NCT05472883|Procedure|collection of body tissues|removal of intra-abdominal fat and muscle tissue
80020229|NCT05472883|Procedure|routine care procedure|"Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~dosage of ß HCG for womens."
80020230|NCT03514316|Procedure|Scalpel Gingivectomy|The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
79260674|NCT03218943|Device|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
79260675|NCT00803569|Biological|ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine|The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
79260676|NCT00803569|Biological|Sargramostim|The GM-CSF sargramostim is administered at a dose of 100 μg SC.
79260677|NCT02451345|Behavioral|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
79723171|NCT00627159|Other|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
79723172|NCT00627159|Other|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
79723173|NCT02814097|Drug|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
79723174|NCT02814097|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
79857722|NCT03688165|Device|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
79857723|NCT03681080|Procedure|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
79857724|NCT03635164|Drug|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
79857725|NCT03635164|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
79260678|NCT02143687|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
79560462|NCT01690754|Other|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
79560463|NCT01690767|Drug|2% lidocaine gel|Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
79560464|NCT01690767|Drug|Health Care Lubricating Jelly|Non-medicinal lubrication gel
79560465|NCT01690780|Drug|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
79560466|NCT01690780|Drug|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
79723175|NCT02814331|Device|multimodal high-resolution EEG-NIRS|
79723176|NCT02875275|Other|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
79723177|NCT02875275|Other|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
79723178|NCT02875275|Other|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
79723179|NCT02875275|Other|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
79723180|NCT05636605|Diagnostic Test|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
79260679|NCT02143687|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
79398083|NCT05178771|Other|Platelet rich fibrin|"Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted."
79398084|NCT01447927|Drug|metformin hydrochloride|Given PO QD and BID
79398085|NCT01447927|Other|placebo|Given PO QD and BID
79260680|NCT02143687|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
79398086|NCT04111185|Device|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
79260681|NCT02143687|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
79260682|NCT03231579|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
79560467|NCT01690819|Procedure|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
79723181|NCT01054599|Drug|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
79723182|NCT01054599|Other|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
79723183|NCT01054599|Drug|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
79723184|NCT02813863|Drug|SP2086|
79723185|NCT02813863|Drug|Metformin|
79723186|NCT02874729|Procedure|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
79723187|NCT02874729|Procedure|Urine collection|Urine will be collected in appropriate sterile holders provided.
79723188|NCT02874729|Procedure|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
79560468|NCT01690819|Procedure|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
79560469|NCT01690832|Drug|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
79560470|NCT01690832|Drug|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
79560471|NCT01690845|Device|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
79723189|NCT02874729|Procedure|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
79723190|NCT04275661|Procedure|Ultrasound (US) bi-level erector spinae block|nerve block
79260683|NCT02451813|Procedure|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
79260684|NCT02143765|Drug|Mitiglinide|three times a day, orally, for 12 weeks
79260685|NCT02143765|Drug|Acarbose|three times a day, orally, for 12 weeks
79260686|NCT03231423|Other|Drainage|Using drain after operation
79560472|NCT01690858|Other|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
79723191|NCT04275661|Drug|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
79723192|NCT04275661|Drug|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
79723193|NCT04275661|Drug|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
79260687|NCT02143921|Behavioral|Training intervention|Intervention group service providers received intervention training
79260688|NCT03217695|Behavioral|Mindfulness-based Yoga Arm|
79398087|NCT04053387|Drug|tapinarof cream, 1%|Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
79560473|NCT01690871|Drug|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
79857726|NCT03635164|Procedure|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
79260689|NCT02148289|Dietary Supplement|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
79260690|NCT02148289|Dietary Supplement|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
79260691|NCT02451267|Other|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
79260692|NCT02451267|Other|physical therapy treatment|neck exercise strengthening program with neck massage
79277484|NCT03660371|Procedure|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
79277485|NCT03660371|Procedure|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
79398088|NCT04045743|Drug|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
79398089|NCT04045743|Drug|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
79398090|NCT01551758|Drug|FF/VI|FF/VI
79398091|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
79560474|NCT01690884|Drug|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
79560475|NCT01690897|Behavioral|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
79560476|NCT01690897|Behavioral|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
79560477|NCT01690936|Dietary Supplement|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
79560478|NCT01690949|Drug|PUR118|inhaled PUR118, BID
79560479|NCT01690962|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
79560480|NCT01690962|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
79560481|NCT01690975|Drug|Placebo|Placebo - single dose at start of each treatment period
79560482|NCT01690975|Drug|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
79560483|NCT01690975|Drug|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
79560484|NCT01691001|Drug|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
79560485|NCT01691001|Drug|normal saline|
79560486|NCT01691040|Drug|NOX-H94|intravenous injection
79560487|NCT01691040|Drug|Placebo solution|intravenous injection
79560488|NCT01691053|Drug|Spironolactone|50mg once daily
79560489|NCT01691053|Drug|Placebo|Placebo
79560490|NCT01691066|Behavioral|Infant Toddler Years PRT|
79560491|NCT01691118|Drug|Fimasartan|
79560492|NCT01691118|Drug|Antihypertensive treatment|
79560493|NCT01691131|Other|Exercise training|Comparison of high intensity exercise training on land versus water.
79560494|NCT01691157|Other|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
79560495|NCT01691157|Other|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
79560496|NCT01691170|Other|Stretching Hamstring|
79560497|NCT01691170|Other|Quadriceps Strengthening|
79560498|NCT01691209|Device|Phoenix (BAY81-2996)|Topical formulation applied to the skin
79560499|NCT01691209|Drug|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
79560500|NCT01691222|Device|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
79723194|NCT02813941|Other|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
79723195|NCT02813941|Other|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
79723196|NCT02813941|Other|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
79857727|NCT03602014|Drug|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
79857728|NCT03602014|Other|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
79560501|NCT01691235|Device|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
79560502|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, single, 1 day
79260693|NCT00629629|Behavioral|Dietary Advice|"Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness."
79277486|NCT03105609|Device|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
79398092|NCT00513747|Biological|rituximab|Given IV over 4 hours
79560503|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, twice a day, 14 days
79560504|NCT01691274|Drug|PF-04895162|Tablets, to be decided, twice a day, 14 days
79857729|NCT03559192|Drug|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
79857730|NCT03559192|Drug|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
79857731|NCT03552718|Biological|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
79277487|NCT03531307|Other|Data correlation|Correlation between lactate levels and Ki-67 index
79277488|NCT02202473|Drug|Lamivudine|
79398093|NCT00513747|Drug|fludarabine phosphate|Given IV over 30 minutes
79398094|NCT00514137|Drug|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
79398095|NCT00514215|Biological|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
79398096|NCT00514215|Other|flow cytometry|Days 1 & 32
79560505|NCT01691274|Drug|Placebo|Tablets, twice a day, 14 days
79398097|NCT00514215|Other|immunoenzyme technique|Days 1 & 32
79398098|NCT00514215|Procedure|biopsy|CT guided biopsy on days 1 & 32
79398099|NCT00514215|Procedure|cryosurgery|Days 1 and 32
79398100|NCT05070819|Diagnostic Test|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
79560506|NCT01691287|Behavioral|Michael Method|
79560507|NCT01691300|Other|ACT PET/CT|Old tracer but new indication
79560508|NCT01691352|Procedure|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
79560509|NCT01691352|Procedure|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
79560510|NCT01691365|Dietary Supplement|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
79560511|NCT01691365|Drug|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
79560512|NCT01691391|Behavioral|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two [18F-]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
79560513|NCT01691404|Dietary Supplement|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
79560514|NCT01691404|Dietary Supplement|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
79560515|NCT01691404|Dietary Supplement|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
79857732|NCT03552471|Other|Laboratory Biomarker Analysis|Correlative studies
79857733|NCT03552471|Biological|Mirvetuximab Soravtansine|Given IV
79857734|NCT03552471|Other|Pharmacokinetic Study|Correlative studies
79857735|NCT03552471|Drug|Rucaparib Camsylate|Given PO
79857736|NCT03542409|Other|MR Perfusion Scan|MR perfusion scan before and during surgery.
79857737|NCT03542409|Other|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
79857738|NCT03542409|Other|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
79857739|NCT03533946|Drug|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until PSA progression or intolerable toxicities.
79560516|NCT01691417|Device|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
79560517|NCT01691443|Procedure|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
79560518|NCT01691456|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
79560519|NCT01691469|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
79723197|NCT02875041|Device|Transcranial Magnetic Stimulation (TMS)|
79560520|NCT01691495|Drug|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
79560521|NCT01691547|Drug|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
79560522|NCT01691547|Drug|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
79723198|NCT02875041|Device|MAGSTIM Rapid2|
79723199|NCT02813707|Other|QoL questionnaire regarding the long term complication|Micronutrients evaluation
79723200|NCT04187521|Other|Meal A|A breakfast meal with a specific macronutrient proportions.
79723201|NCT04187521|Other|Meal B|A breakfast meal with a specific macronutrient proportions.
79723202|NCT00948766|Drug|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.
79723203|NCT00948766|Drug|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.
79723204|NCT00948766|Drug|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.
79723205|NCT00948766|Drug|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
79723206|NCT02813629|Device|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
79723207|NCT04206722|Device|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
79723208|NCT04206722|Device|Ultrasound|Ultrasound 0.7W/cm2
79723209|NCT01053663|Drug|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
79277489|NCT02202473|Drug|Lamivudine+Oxymatrine Capsules|
79560523|NCT01691547|Drug|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
79560524|NCT01691547|Drug|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
79560525|NCT01691586|Device|Remote patient monitoring|Remote monitoring of ICD and heart failure data
79723210|NCT00634387|Dietary Supplement|Anthocyans|Anthocyans
79723211|NCT00634387|Other|placebo|
79723212|NCT00634387|Dietary Supplement|Anthocyans|
79723213|NCT01235546|Drug|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
79723214|NCT01235546|Drug|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
79723215|NCT02813395|Device|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
79723216|NCT02813395|Device|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
79723217|NCT01053429|Drug|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
79560526|NCT01691586|Other|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
79560527|NCT01691625|Other|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
79560528|NCT01691625|Other|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
79398101|NCT03912909|Drug|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
79560529|NCT01691651|Procedure|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
79560530|NCT01691651|Drug|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
79560531|NCT01691664|Radiation|Only radiation therapy|Patients only radiation therapy after surgery
79560532|NCT01691664|Other|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
79560533|NCT01691677|Drug|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
79723218|NCT01233284|Drug|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
79560534|NCT01691677|Drug|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
79723219|NCT01233284|Drug|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
79723220|NCT01233284|Drug|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
79723221|NCT01233284|Drug|tiotropium bromide 1.25µg once daily|IMP
79723222|NCT00627237|Behavioral|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
79723223|NCT00627237|Behavioral|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
79723224|NCT00948688|Radiation|Radiation therapy|Once per day, 5 days a week for 6 weeks
79723225|NCT00948688|Drug|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
79723226|NCT00948688|Drug|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
79723227|NCT02857114|Other|massage|
79398102|NCT03912909|Drug|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
79398103|NCT03903471|Device|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
79560535|NCT01691703|Device|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
79723228|NCT01233050|Drug|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
79560536|NCT01691716|Drug|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
79723229|NCT01233050|Drug|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
79723230|NCT01232894|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
79723231|NCT01232894|Drug|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
79723232|NCT01049217|Drug|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
79723233|NCT01049217|Drug|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
79723234|NCT01232738|Drug|rasagiline|rasagiline 2 mg daily for 12 months
79723235|NCT04206644|Other|biological analysis|biological analysis of the Concentration of CCL18
79723236|NCT00957268|Drug|Alogliptin|Alogliptin tablets
79723237|NCT02888444|Drug|Varenicline|Two 0.5mg tablets taken twice daily
79723238|NCT02888444|Behavioral|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
79723239|NCT02888444|Drug|Placebo|Two 0.5mg tablets taken twice daily
79723240|NCT02888132|Procedure|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
79723241|NCT02888132|Procedure|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
79723242|NCT02158858|Drug|Pelabresib (CPI-0610)|
79723243|NCT02158858|Drug|Ruxolitinib|
79560537|NCT01691716|Behavioral|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
79560538|NCT01691742|Drug|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
79260694|NCT03224013|Procedure|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
79723244|NCT01230788|Drug|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
79723245|NCT04269694|Drug|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
79723246|NCT04269694|Device|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
79723247|NCT01230710|Drug|Erlotinib|Erlotinib was supplied as tablets.
79723248|NCT04269616|Behavioral|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
79398104|NCT03903471|Device|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
79723249|NCT04269616|Behavioral|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
79723250|NCT00627081|Drug|remifentanil|dosage
79723251|NCT01230554|Device|Daily disposable cosmetic tint lens|Bausch & Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
79723252|NCT04302909|Other|focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
79560539|NCT01691742|Drug|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
79723253|NCT04302909|Other|sham focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
79723254|NCT04302909|Other|night splint|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
79723255|NCT02888054|Drug|lesinurad/allopurinol 200/300 FDC tablet|
79723256|NCT02888054|Drug|lesinurad 200 mg|
79857740|NCT03525951|Behavioral|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
79857741|NCT03525951|Other|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
79857742|NCT03523585|Drug|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
79857743|NCT03523585|Drug|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
79560540|NCT01691742|Drug|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
79560541|NCT01691807|Drug|ofatumumab|treatment for NHL
79723257|NCT02888054|Drug|allopurinol 300 mg|
79723258|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
79857744|NCT03523585|Drug|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
79260695|NCT02254369|Drug|GC021109|
79260696|NCT02254369|Other|Placebo|
79260697|NCT03231501|Drug|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
79398105|NCT04992975|Other|MRI at 7T|MRI at 7T
79398106|NCT02130063|Drug|iron isomaltoside 1000 (Monofer®)|
79857745|NCT03523585|Drug|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
79398107|NCT02130063|Drug|iron sucrose (Venofer®)|
79398108|NCT00515697|Biological|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
79398109|NCT00516165|Drug|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
79398110|NCT04988061|Other|counselling|Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
79857746|NCT03495986|Device|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
79857747|NCT03495986|Behavioral|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
79857748|NCT03493581|Procedure|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
79857749|NCT03493581|Diagnostic Test|blood-sampled|"after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~after 6 weeks (V2),~after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
79857750|NCT03493581|Other|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
79857751|NCT03485911|Drug|BCX7353 capsules|BCX7353 oral capsules administered once daily
79857752|NCT03485911|Drug|Placebo oral capsule|Matching oral capsules administered once daily
79857753|NCT03470025|Other|Psychological Intervention|"F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
79857754|NCT03454256|Device|Virtual Reality|Virtual Reality Rehabilitation System
79857755|NCT03446690|Drug|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
80020231|NCT03514316|Procedure|Laser Gingivectomy|In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
80020232|NCT03514316|Procedure|Nonsurgical periodontal treatment|In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
79560542|NCT01691807|Drug|bendamustine|treatment for NHL
80020233|NCT02114242|Other|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
80020234|NCT02114242|Other|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
79277490|NCT02364531|Other|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
79723259|NCT05477810|Drug|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
79723260|NCT05477810|Drug|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
79723261|NCT02815969|Other|vena punction|vena punction and urine collection
79560543|NCT01691872|Drug|Retigabine|Retigabine
79560544|NCT01691911|Procedure|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
79560545|NCT01691924|Drug|PBF-509|
79560546|NCT01691924|Drug|Placebo|
80020235|NCT02253576|Other|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
80020236|NCT02253576|Other|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
80020237|NCT03520478|Drug|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
80020238|NCT03520478|Drug|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
80020239|NCT04412590|Other|Vermont Family Based Approach|Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
79260698|NCT02148367|Drug|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
79260699|NCT02451189|Dietary Supplement|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
79723262|NCT02811367|Device|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
79398111|NCT01798095|Biological|Aplisol@ PPD material|Determine equivalency of materials
79560547|NCT01691937|Procedure|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
79560548|NCT01691937|Procedure|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
79560549|NCT01691937|Procedure|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
79723263|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
80020240|NCT04412590|Other|Treatment as Usual|Pediatric care as usual.
79723264|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
79723265|NCT01040793|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
80020241|NCT05544864|Device|Drug eluting stent (DES)|DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
80020242|NCT05544864|Device|Drug coated ballloon (DCB)|DCB angioplasty with a paclitaxel-coated balloon (Agent, Boston Scientific)
80020243|NCT05691673|Other|No intervention|Observational during 16 weeks
79260700|NCT02451189|Dietary Supplement|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
79723266|NCT01040793|Drug|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
79723267|NCT01040793|Drug|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
79723268|NCT04204447|Other|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
79723269|NCT04204447|Other|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
79723270|NCT04155151|Other|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
79723271|NCT02690233|Procedure|Elective Surgery|Elective laparoscopic inguinal hernia repair
79398112|NCT01798095|Biological|Reference Standard|Reference standard material for comparison to newly produced materials.
79398113|NCT02130999|Drug|tasimelteon 20 mg capsule|
79398114|NCT02130999|Drug|tasimelteon 2 mg I.V.|
79398115|NCT00518349|Device|Passive bending function|Colonoscope with a passive bending function
79398116|NCT00518349|Device|No passive bending function|Examination using standard colonoscope without passive bending function
79398117|NCT02132169|Drug|Drug: AC-170 0.24%|
79398118|NCT02132169|Drug|AC-170 0%|
79398119|NCT04065321|Procedure|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
79857756|NCT03446690|Other|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
80020244|NCT05430880|Diagnostic Test|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
80020245|NCT00102648|Drug|Lonafarnib|Given PO
79398120|NCT04065321|Procedure|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
79398121|NCT03193125|Dietary Supplement|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
80020246|NCT00102648|Drug|Temozolomide|Given PO
80020247|NCT04216446|Behavioral|Mobile Health Intervention|A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
80020248|NCT05691361|Drug|ADX-324|siRNA duplex oligonucleotide
80020249|NCT05691361|Drug|Placebo|saline
80020250|NCT03517514|Other|Physical Therapy service|routine physical therapy care
79560550|NCT01691963|Device|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
79560551|NCT01691976|Drug|Oestrogen Patches|
79560552|NCT01691976|Drug|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
79560553|NCT01691989|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
79398122|NCT03193125|Dietary Supplement|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
79560554|NCT01691989|Drug|placebo|oral doses once a day for 26 weeks
79560555|NCT01692002|Dietary Supplement|Sodium propionate|Sodium propionate capsule or tablet
79560556|NCT01692002|Dietary Supplement|Sodium Chloride|Placebo capsule or tablet
79560557|NCT01692002|Procedure|Oral glucose tolerance test|
80020251|NCT01894282|Procedure|Manual Therapy|Manual Therapy Arm
80020252|NCT01894282|Procedure|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
80020253|NCT03545958|Behavioral|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
79560558|NCT01692002|Procedure|Intravenous glucose tolerance test.|
79560559|NCT01692015|Other|Questionnaire on dietary history|
79560560|NCT01692015|Other|Questionnaire on nosebleed severity|
79723272|NCT02811055|Biological|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
79723273|NCT02811055|Procedure|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
79723274|NCT02811055|Device|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
79723275|NCT02811055|Procedure|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
79723276|NCT02811055|Drug|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
79723277|NCT02811055|Drug|Administration of placebo|Administration of placebo once per day during 14 days
79723278|NCT02810977|Device|Ultrasound|Ultrasound assessment of gastric content and volume
79723279|NCT04192903|Drug|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
79560561|NCT01692015|Other|One week food diary generated by weighing foods|
79560562|NCT01692015|Procedure|Blood tests for full blood count, albumin, and indices of nutritional status|
79560563|NCT01692041|Drug|ivy leaves dry extract|5 ml twice daily po
79560564|NCT01692041|Drug|Placebo|5 ml per os twice daily
79560565|NCT01692080|Behavioral|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
79560566|NCT01692093|Dietary Supplement|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
79560567|NCT01692093|Dietary Supplement|Placebo|Placebo
79560568|NCT01692106|Procedure|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
79723280|NCT02810899|Drug|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
79723281|NCT02810899|Drug|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
79723282|NCT02810665|Behavioral|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
79723283|NCT04237129|Drug|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
79723284|NCT02810587|Drug|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
79723285|NCT02810353|Device|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
79723286|NCT02810353|Device|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
79723287|NCT04187365|Other|Duration of Indwelling Catheter|Foley catheter
79723288|NCT02810275|Drug|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
79723289|NCT02810275|Drug|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
79723290|NCT05646745|Procedure|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, ~1 cm× ~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
79857757|NCT03429413|Behavioral|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
79560569|NCT01692132|Drug|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
79560570|NCT01692145|Drug|KCT-0809|
79560571|NCT01692145|Drug|Placebo|
79560572|NCT01692184|Drug|50 mg AVL-292|
79560573|NCT01692184|Drug|100 mg AVL-292|
79560574|NCT01692184|Drug|200 mg AVL-292|
79560575|NCT01692184|Drug|350 mg AVL-292|
79560576|NCT01692184|Drug|Placebo capsules|
79560577|NCT01692210|Drug|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
79260701|NCT02451189|Dietary Supplement|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
79560578|NCT01692223|Behavioral|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety & Depression Scale (HADS), revised Impact of Events Scale (IES-R), & a questionnaire about their health behaviors, to establish baseline distress levels & health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider & discuss resultant therapeutic & management recommendations for the participants & their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
79560579|NCT01692249|Other|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
79560580|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
79560581|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
79723291|NCT02809807|Other|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
79723292|NCT02809807|Device|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
79723293|NCT00948064|Drug|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
79857758|NCT03429413|Behavioral|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
79857759|NCT03421964|Behavioral|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
79723294|NCT00948064|Drug|Azacitidine|75 mg/m^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
79723295|NCT02813239|Other|hCG|Oocyte maturation with hCG
79723296|NCT02813239|Other|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
79723297|NCT02815501|Biological|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
79723298|NCT02854930|Other|questioning|
79857760|NCT03421964|Behavioral|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
79857761|NCT03410823|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
79260702|NCT02451891|Biological|MVA-EBO Z|
79260703|NCT02451891|Biological|ChAd3-EBO Z|
79260704|NCT00482833|Drug|arsenic trioxide|"Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28)."
79723299|NCT02813161|Biological|cellular and tissue based therapy|
79723300|NCT02813161|Device|negative pressure wound therapy|
79723301|NCT02813161|Procedure|debridement|
79723302|NCT02813161|Procedure|advanced wound therapy|
79857762|NCT03410823|Dietary Supplement|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
79857763|NCT03410823|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
79857764|NCT03395717|Device|Exoskeleton-Assisted Gait Training|
79560582|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
79857765|NCT03395314|Drug|Ketamine|1 single dose of IV ketamine
79857766|NCT03395314|Drug|Midazolam|1 single dose of IV midazolam
79560583|NCT01692288|Behavioral|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
79560584|NCT01692314|Other|Resistance training|
79560585|NCT01692327|Dietary Supplement|High fat meal|
79723303|NCT02813161|Dietary Supplement|Nutritional screening|
79723304|NCT02813161|Device|off-loading|
79857767|NCT03329092|Drug|ATM-AVI|"(Creatinine clearance > 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
79857768|NCT03329092|Drug|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
79857769|NCT03329092|Drug|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance > 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance > 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
79260705|NCT00482833|Drug|idarubicin|"Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1."
79560586|NCT01692353|Other|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
79560587|NCT01692366|Drug|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
79560588|NCT01692379|Device|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
79723305|NCT02813161|Device|Hyperbaric oxygen Therapy|
79560589|NCT01692379|Other|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
79560590|NCT01692405|Device|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
79260706|NCT00482833|Drug|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
79260707|NCT00482833|Drug|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
79560591|NCT01692405|Procedure|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
79560592|NCT01692418|Drug|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
79560593|NCT01692418|Drug|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
79560594|NCT01692431|Dietary Supplement|EPA|High fat meal containing EPA
79560595|NCT01692431|Dietary Supplement|DHA|High fat meal containing DHA
79560596|NCT01692431|Dietary Supplement|Placebo|High fat meal containing negligible EPA/DHA content
80020254|NCT03545958|Behavioral|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
79560597|NCT01692457|Drug|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
79260708|NCT00482833|Drug|all-trans retinoic acid|"Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed."
79260709|NCT00482833|Drug|all-trans retinoic acid (ATRA)|"Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26)."
79560598|NCT01692470|Drug|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
79560599|NCT01692483|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
79560600|NCT01692483|Drug|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
79560601|NCT01692522|Procedure|Intubation|visualized blind intubation
79560602|NCT01692535|Procedure|Intubation|Intubation with one of the six videolaryngoscopes
79308688|NCT04851561|Diagnostic Test|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
80020255|NCT01827904|Device|Transcranial ExAblate|
79560603|NCT01692548|Other|Neurofeedback|
79560604|NCT01692574|Behavioral|Behavior Modification for Weight Loss|
80020256|NCT01827904|Device|Sham Transcranial ExAblate|
80020257|NCT03290287|Drug|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
80020258|NCT03290287|Drug|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
80020259|NCT02295176|Dietary Supplement|Armolipid Plus|
79560605|NCT01692574|Behavioral|Alternative Approach to Weight Loss|
80020260|NCT02295176|Dietary Supplement|Placebo|
80020261|NCT04211142|Procedure|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
79560606|NCT01692574|Behavioral|Cognitive-Behavior Therapy for Depression|
80020262|NCT04211142|Procedure|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
79560607|NCT01692574|Behavioral|Depression Support and Education|
79560608|NCT01692587|Other|Protein restrictive diet|To begin a reduced protein diet
79560609|NCT01692652|Drug|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
79560610|NCT01692652|Other|warm compress only group|
79560611|NCT01692678|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
79560612|NCT01692678|Drug|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
79560613|NCT01692704|Drug|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
80020263|NCT03104218|Other|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
79260710|NCT03223701|Combination Product|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
79260711|NCT03119727|Device|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
79260712|NCT02451033|Drug|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
79260713|NCT02451033|Drug|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
79260714|NCT02451033|Drug|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
79723306|NCT04271098|Procedure|Open-Heart Surgery for nine months duration|In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.
79723307|NCT04271098|Other|Relation between possible risk factors and hyperbilirubinemia|Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.
79723308|NCT04271098|Other|Follow-up period|All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
79560614|NCT01692769|Drug|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
79723309|NCT02813005|Procedure|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
79560615|NCT01692769|Drug|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
79560616|NCT01692808|Drug|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
79260715|NCT04485429|Drug|Methylprednisolone|Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
79723310|NCT02813005|Procedure|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
79723311|NCT02858206|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
79560617|NCT01692808|Drug|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
79560618|NCT01692821|Drug|100% oxygen breathing|100% oxygen breathing - 30 minutes
79723312|NCT02858206|Drug|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
79723313|NCT02858206|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
79723314|NCT02858206|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
79723315|NCT02858206|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
79260716|NCT04485429|Drug|Heparin|Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
79308689|NCT01668147|Drug|[11C] desmethyl-loperamide|IV administration of 10-14 mCi of [11C] desmethyl-loperamide with PET/CT imaging
79560619|NCT01692821|Drug|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
79560620|NCT01692821|Drug|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
79560621|NCT01692834|Drug|Sandimmune® Injection|
79560622|NCT01692834|Drug|NeuroSTAT®|
79857770|NCT03329092|Drug|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight < 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance > 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
79857771|NCT03293680|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
79857772|NCT03290261|Other|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
80020264|NCT03104218|Other|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
79260717|NCT03223857|Procedure|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
79398123|NCT03174405|Drug|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
79560623|NCT01692860|Other|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
79560624|NCT01692873|Procedure|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
79560625|NCT01692886|Biological|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
79723316|NCT05581615|Other|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
79723317|NCT02810119|Drug|LO2A|
79723318|NCT02810119|Drug|Placebo|
79723319|NCT02810041|Dietary Supplement|yoghurts enriched with XXS|
79723320|NCT02810041|Dietary Supplement|yoghurts non enriched with XXS|
79723321|NCT02809885|Biological|Hepatitis E serology|
79857773|NCT03205124|Procedure|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
80020265|NCT02253888|Drug|TPV - Room condition|
79260718|NCT03216057|Dietary Supplement|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
79260719|NCT03216057|Dietary Supplement|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
79260720|NCT03223467|Procedure|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
79560626|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
79723322|NCT02815189|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
79723323|NCT02815189|Drug|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
79723324|NCT02809963|Drug|Eplerenone|50 mg tablets, oral use.
79723325|NCT02809963|Drug|Placebo|50 mg tablets, oral use
79723326|NCT02815111|Drug|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
80020266|NCT02253888|Drug|TPV - Refrigerated conditions|
79398124|NCT00522171|Device|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
79398125|NCT00522795|Drug|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
79398126|NCT02913729|Radiation|partial breast irradiation|irradiation
80020267|NCT02253888|Drug|Ritonavir (RTV)|
80020268|NCT03520244|Behavioral|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
79857774|NCT03205124|Procedure|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
79857775|NCT03172975|Biological|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
79857776|NCT03172975|Biological|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
80020269|NCT05690737|Behavioral|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
79857777|NCT03172975|Biological|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
79857778|NCT03172975|Biological|Placebo|Physiological sterile saline solution
80020270|NCT05690737|Drug|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
80020271|NCT05430802|Drug|Furmonertinib+cisplating/pemetrexed|Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
80020272|NCT05524038|Drug|Bupivacaine Hydrochloride|20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
80020273|NCT05524038|Device|Ultrasound device|high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .
80020274|NCT05524038|Drug|Dexamethasone|injection of 4mg dexamethasone in each block
80020275|NCT05524038|Device|echogenic needle|22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
79560627|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
79723327|NCT02815111|Drug|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
79723328|NCT02815111|Drug|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
79260721|NCT02450955|Other|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
79398127|NCT02871687|Drug|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
79398128|NCT02871687|Drug|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
79398129|NCT02871687|Other|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
79398130|NCT00525057|Drug|Dalteparin|Given SC
79560628|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
79560629|NCT01692912|Other|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28<2.6
79560630|NCT01692925|Drug|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
79723329|NCT02815111|Drug|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
79723330|NCT04236895|Drug|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
79723331|NCT02809651|Device|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
79723332|NCT02809729|Drug|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
79723333|NCT02809729|Drug|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
79857779|NCT03172975|Drug|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
79857780|NCT03172975|Other|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
80020276|NCT04046731|Diagnostic Test|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
80020277|NCT02295254|Other|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
80020278|NCT03249727|Diagnostic Test|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
80020279|NCT04953312|Biological|Blood samples|blood
80020280|NCT02299154|Behavioral|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
80020281|NCT05686525|Procedure|Transurethral Microwave Thermotherapy|TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
80020282|NCT05686525|Procedure|Prostate Artery Embolisation|In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
79260722|NCT02450955|Other|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
79560631|NCT01692925|Drug|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
79560632|NCT01692977|Other|neuropsychological assessment|
79260723|NCT03215121|Procedure|One handed mask airway, switch to two hands|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
79308690|NCT01668147|Other|Control - no pretreatment|Session 1: IV administration of 10-14 mCi [11C] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI
79560633|NCT01692990|Dietary Supplement|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
79560634|NCT01693003|Drug|Indacaterol|150 µg d.o. during the first 3 weeks
79560635|NCT01693003|Drug|Tiotropium|150 µg d.o. during 3 weeks
79560636|NCT01693016|Device|non-invasive measurement of Hb|
79560637|NCT01693016|Procedure|taking blood samples|
79560638|NCT01693042|Biological|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area
79560639|NCT01693055|Device|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
79560640|NCT01693081|Drug|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
79560641|NCT01693081|Drug|placebo|
79560642|NCT01693133|Other|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
79723334|NCT02809729|Procedure|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
79723335|NCT02809729|Other|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
79723336|NCT04303377|Biological|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
79723337|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
79723338|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
79723339|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
79723340|NCT00953524|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
79560643|NCT01693133|Other|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
79560644|NCT01693146|Device|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
79560645|NCT01693146|Device|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
79857781|NCT03155022|Device|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of [1 min balloon inflation followed by 1 min balloon deflation] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
79857782|NCT03155022|Device|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
80020283|NCT03520166|Other|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
80020284|NCT03520166|Other|No treatment|No treatment
80020285|NCT03240835|Drug|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
79723341|NCT02809573|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
80020286|NCT03240835|Radiation|IMRT|intensity modulation radiation therapy
80020287|NCT03545880|Other|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
80020288|NCT03545880|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
80020289|NCT03517358|Other|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
79723342|NCT02809573|Drug|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m^2 in 5 minutes after chidamide administration
79723343|NCT02809573|Drug|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m^2 soon after cyclophosphamide administration.
80020290|NCT04067310|Other|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
80020291|NCT04067310|Other|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
80020292|NCT03514238|Behavioral|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
80020293|NCT03514238|Behavioral|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
80020294|NCT03514238|Behavioral|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
80020295|NCT03216109|Behavioral|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
80020296|NCT03133052|Behavioral|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
80020297|NCT03133052|Behavioral|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
79723344|NCT02809573|Drug|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m^2 after adriacin administration.
80020298|NCT05671783|Other|Hemodynamic observation of the patients.|"For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was <94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent."
80020299|NCT03133130|Drug|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
80020300|NCT03133130|Drug|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
80020301|NCT04172454|Biological|AK104|AK104, 6mg/kg, Q2W
79723345|NCT02809573|Drug|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
80020302|NCT03514160|Behavioral|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
80020303|NCT03545802|Behavioral|Home-HIT|Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
80020304|NCT03132974|Drug|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
80020305|NCT03132974|Other|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
80020306|NCT03132974|Other|Placebo with manipulation procedure|Placebo granule with manipulation procedure
80020307|NCT02295332|Drug|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
79723346|NCT02812927|Device|Edelvaiss Multiline-8|Optimised infusion line
79723347|NCT02812927|Device|Standard infusion line|
79857783|NCT03037879|Other|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
79857784|NCT03037879|Other|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
79857785|NCT03037879|Other|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
79857786|NCT03037879|Other|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
79857787|NCT03028103|Drug|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
79857788|NCT03028103|Drug|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
79857789|NCT03028103|Drug|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
79857790|NCT03028103|Drug|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
79857791|NCT03023163|Other|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
79857792|NCT03020589|Drug|Tacrolimus|See description in arm/group sections
79260724|NCT03215121|Procedure|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
79260725|NCT03215121|Procedure|Two handed mask airway, switch to one hand|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds."
79560646|NCT01693159|Device|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
79857793|NCT03010982|Drug|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
79857794|NCT02964208|Device|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
79560647|NCT01693159|Other|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
79560648|NCT01693172|Behavioral|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
79560649|NCT01693198|Procedure|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
79560650|NCT01693211|Device|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
79560651|NCT01693211|Device|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
79560652|NCT01693224|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
79560653|NCT01693224|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
79560654|NCT01693224|Device|Cepheid Xpert MTB/Rif assay|
79857795|NCT02932475|Drug|Metformin|1000 mg twice a day
79857796|NCT02932475|Drug|Placebo|Delivered to match active drug
79857797|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
79857798|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
79857799|NCT02893553|Drug|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
79857800|NCT02893553|Drug|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
79857801|NCT02893553|Drug|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
79560655|NCT01693237|Other|Group psychotherapy|20 sessions of systemic and narrative group therapy
79560656|NCT01693237|Other|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
79857802|NCT02893553|Other|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
79857803|NCT02886936|Device|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
79857804|NCT02886936|Device|iFIT Transfemoral Prosthesis|Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
80020308|NCT02295332|Drug|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
80020309|NCT04118868|Combination Product|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
80020310|NCT03514082|Device|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
79260726|NCT03214809|Diagnostic Test|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
79560657|NCT01693276|Drug|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
79723348|NCT04388683|Drug|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
79723349|NCT02809261|Procedure|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
79723350|NCT02809261|Procedure|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
79723351|NCT02809261|Drug|Normal Saline|Normal saline is safe for perineural injection.
80020311|NCT03514004|Behavioral|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
79260727|NCT00112957|Biological|rV-NY-ESO-1 vaccine|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10^7 PFU) on Day 1.
80020312|NCT03545178|Behavioral|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
80020313|NCT03545178|Diagnostic Test|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
79723352|NCT02809261|Drug|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
79723353|NCT05644639|Device|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
79723354|NCT01040403|Drug|olodaterol (BI 1744) low|olodaterol (BI 1744) low
79723355|NCT01040403|Drug|low tiotropium bromide|low tiotropium bromide
80020314|NCT03520088|Procedure|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
80020315|NCT03520088|Procedure|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
80020316|NCT03546504|Behavioral|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
79260728|NCT00112957|Biological|rF-NY-ESO-1 vaccine|Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
79260729|NCT03223389|Dietary Supplement|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
79560658|NCT01693276|Drug|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
79560659|NCT01693276|Radiation|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
79560660|NCT01693289|Drug|metformin plus letrozole|
79560661|NCT01693289|Procedure|ovarian drilling|
79560662|NCT01693302|Other|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
79560663|NCT01693315|Drug|AMA0076|
79560664|NCT01693315|Drug|Placebo|
79560665|NCT01693328|Drug|PecFent® (fentanyl) nasal spray|
79857805|NCT02756702|Device|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
80020317|NCT03513926|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
80020318|NCT04900350|Drug|AK117|Subjects receive AK117 intravenously.
80020319|NCT04900350|Drug|Azacitidine|Subjects receive Azacitidine subcutaneously.
79857806|NCT02734485|Device|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
79857807|NCT02734485|Device|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
79560666|NCT01693341|Other|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
79560667|NCT01693354|Device|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
79560668|NCT01693354|Device|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
79857808|NCT02507687|Drug|Bimatoprost SR|Up to two Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
79857809|NCT02507687|Drug|Sham Bimatoprost SR|Up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
79857810|NCT02507687|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
79857811|NCT02507687|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
79857812|NCT02383407|Device|Medtronic Deep Brain Stimulation|
79857813|NCT02321501|Drug|Ceritinib|Given PO
79857814|NCT02321501|Drug|Everolimus|Given PO
79857815|NCT02321501|Other|Laboratory Biomarker Analysis|Correlative studies
79857816|NCT02321501|Other|Pharmacological Study|Correlative studies
79857817|NCT02237079|Drug|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
79857818|NCT02237079|Drug|Placebo Oral Tablet|Daily placebo tablet
79857819|NCT02162511|Device|CliniMACS CD34+ cell enrichment and T-cell depletion|
79857820|NCT01992861|Procedure|Computed Tomography|Undergo FDG PET/CT
79857821|NCT01992861|Procedure|Diffusion Weighted Imaging|Undergo DW MRI
79857822|NCT01992861|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
79560669|NCT01693393|Drug|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
79560670|NCT01693419|Drug|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
79560671|NCT01693432|Drug|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
79560672|NCT01693445|Drug|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
79560673|NCT01693458|Behavioral|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
79560674|NCT01693497|Behavioral|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
79723356|NCT01040403|Drug|olodaterol (BI 1744) high|olodaterol (BI 1744) high
79723357|NCT01040403|Drug|medium tiotropium bromide|medium tiotropium bromide
79723358|NCT01040403|Drug|high tiotropium bromide|high tiotropium bromide
79723359|NCT01040403|Drug|Placebo|Placebo
79723360|NCT01040403|Device|Respimat|Respimat inhaler
79723361|NCT02809339|Other|Questionnaires|
79723362|NCT00957034|Drug|placebo|placebo patch
79723363|NCT00957034|Drug|testosterone|300 or 450 micrograms/day transdermal testosterone patch
79723364|NCT02812693|Drug|Imatinib Mesylate|Given PO
79857823|NCT01992861|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
79857824|NCT01992861|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
79857825|NCT01992861|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
79857826|NCT06271551|Drug|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
79723365|NCT02812693|Other|Laboratory Biomarker Analysis|Correlative studies
79260730|NCT03223389|Dietary Supplement|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
79560675|NCT01693497|Behavioral|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
79857827|NCT06271551|Drug|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
79857828|NCT06271551|Behavioral|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
79857829|NCT06271538|Combination Product|Skal Pro|One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10^10 CFU and GOS
79857830|NCT06271538|Other|Placebo|One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
79723366|NCT02812693|Biological|Pembrolizumab|Given IV
79723367|NCT02812459|Other|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
79723368|NCT02812459|Other|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
79857831|NCT06271525|Other|cupping therapy|"All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.~-Primary sucking~-Scarification 3- Bloodletting 4-Removal~5 -Dressing"
79857832|NCT06271512|Other|No Intervention|This is non-interventional study.
79857833|NCT06271499|Other|Radial artery catheterization with USG|Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of >50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
79857834|NCT06271499|Other|Radial artery catheterization with smart glasses integrated UGG|The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of >50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
79857835|NCT06271486|Drug|Pregabalin 75mg|Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
79857836|NCT06271486|Biological|An epidural blood patch (EBP)|Group B (EBP group) received active therapy in the form of an EBP
79857837|NCT06271486|Combination Product|conservative treatment.|Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.
79857838|NCT06271473|Procedure|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
79260731|NCT03223389|Dietary Supplement|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
79260732|NCT02140801|Drug|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
79260733|NCT02140801|Drug|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
79260734|NCT03223233|Other|procalcitonin level|serum procalcitonin level will be measured in both groups.
79260735|NCT02148601|Other|Fecal Microbiota Transplantation|
79260736|NCT02148601|Drug|Standard Antibiotic Therapy|
79723369|NCT02857972|Device|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
79723370|NCT04270552|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
79723371|NCT04270552|Drug|Placebo|Matched tablets without any active substance.
79723372|NCT04237597|Drug|K-877|K-877 tablets
79723373|NCT04237597|Drug|CSG452|CSG452 tablets
79723374|NCT02854462|Behavioral|Language comprehension intervention|
79723375|NCT02854462|Behavioral|Counting intervention|
79723376|NCT02812381|Procedure|KT|to aplicate neuromuscular bandage technique(KT)
79723377|NCT02812381|Procedure|SCS|To aplicate strain-counterstrain above trigger point
79723378|NCT02854774|Behavioral|Muscle activation exercises|Activation of either muscles activating the knee or hip.
79723379|NCT02812849|Drug|Cu-64 DOTATATE|
79260737|NCT02148601|Drug|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
79260738|NCT03231111|Other|Preventive Multimedia Teaching Program|Preventive Multimedia Teaching Program
79260739|NCT02141035|Drug|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
79398131|NCT00525135|Drug|Valproic Acid|"OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
79560676|NCT01693510|Behavioral|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
79560677|NCT01693536|Behavioral|Lifestyle counselling|as in Arm Description
79723380|NCT04117594|Diagnostic Test|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
79723381|NCT02812303|Other|Centralized support for population health management activities|
79723382|NCT02809495|Other|use of app in smartphone|
79857839|NCT06271460|Other|Traditional physiotherapy|All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.
79560678|NCT01693549|Drug|Cabazitaxel|
79398132|NCT00525525|Drug|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
79723383|NCT04236973|Device|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
79723384|NCT04236973|Other|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
79857840|NCT06271447|Other|Traditional therapy|"All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.~Since the questionnaires to be used in the study are related to fear of movement and pain, neuroscience education will be included in the treatment program of the patients. Patients will be informed about proper posture and movement regarding fear of movement and pain avoidance behaviors."
79723385|NCT02689999|Drug|Dexrabeprazole 10 mg Enteric-Coated Tablets|
79723386|NCT02808793|Drug|AK002|
79723387|NCT02809105|Drug|linaclotide|Oral administration once daily
79857841|NCT06271408|Drug|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Aerosolized albuterol
79723388|NCT02809105|Drug|Placebo|Oral administration once daily
79723389|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
79723390|NCT00953056|Biological|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
79723391|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
79857842|NCT06271408|Device|Vibrating Mesh Nebulizer|A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
79260740|NCT02141035|Drug|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
79308691|NCT01668147|Drug|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi [11C]dLop with PET/CT imaging and brain MRI
79398133|NCT00525525|Drug|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
79723392|NCT00953056|Biological|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
79723393|NCT02811289|Drug|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
79723394|NCT02811289|Other|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
79857843|NCT06271408|Device|Metered Dose Inhaler|A metered dose inhaler will be used to deliver aerosolized albuterol
80020320|NCT03982550|Behavioral|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
80020321|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
80020322|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
79723395|NCT02811289|Radiation|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
79308692|NCT01668147|Drug|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi [11C]dLop with PET/CT imaging and brain MRI
79581151|NCT01933308|Other|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
79723396|NCT02811289|Radiation|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
79723397|NCT02811289|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
79723398|NCT02811289|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
79857844|NCT06271408|Device|Jet Nebulizer|A jet nebulizer will be used to deliver aerosolized albuterol
79857845|NCT06271395|Drug|Injectable Type A Botulinum Toxin|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
80020323|NCT02292290|Drug|Sulfonylurea or Pioglitazone|Addition to Metformin
80020324|NCT02292290|Drug|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
79723399|NCT02811289|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
79723400|NCT02809027|Drug|Ginger|
79723401|NCT02809027|Drug|Placebo|
79723402|NCT02857660|Other|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
79723403|NCT02857660|Dietary Supplement|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
79723404|NCT02874495|Behavioral|Psychological tests|Related to affective and cognitive dimensions of pain.
80020325|NCT02295410|Behavioral|CPT|
80020326|NCT03943849|Other|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
80020327|NCT03943849|Other|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
80020328|NCT03943849|Other|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
80020329|NCT03943849|Other|Suture|Resorbable or non-resorbable suture material
80020330|NCT03545724|Device|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
80020331|NCT02299232|Drug|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
80020332|NCT03517124|Other|Ceramic tooth restoration|Dental restorations
80020333|NCT03517046|Drug|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
80020334|NCT02963493|Drug|Melphalan flufenamide (Melflufen)|
80020335|NCT02963493|Drug|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
80020336|NCT02299310|Drug|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
80020337|NCT02299310|Drug|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
80020338|NCT03516890|Procedure|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
80020339|NCT05657899|Procedure|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
79723405|NCT02874495|Device|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
79857846|NCT06271382|Other|Acupressure Group|"In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes."
79857847|NCT06271382|Other|Sham Acupressure Group|"Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention."
79857848|NCT06271382|Other|Foot Ankle Exercise Group|Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
80020340|NCT05657899|Procedure|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
80020341|NCT03644199|Other|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
80020342|NCT03644199|Other|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
79260741|NCT03214653|Drug|Propofol|Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
79857849|NCT06271356|Behavioral|BC-Navigate|BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
79857850|NCT06271330|Drug|Faricimab|switch from previous anti-VEGF agents to faricimab
79857851|NCT06271304|Device|Eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
79857852|NCT06271265|Drug|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
79857853|NCT06271265|Drug|bupivacaine|A single dose of 0.25% bupivacaine via LIA
79560679|NCT01693575|Device|Pupil expansion with APX 100 device|Patients with small pupils (<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
79723406|NCT02874495|Behavioral|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
79857854|NCT06271252|Drug|OriCAR-017|Anti-GPRC5D CAR-T cell product
79857855|NCT06271239|Other|Intervention group (ViviFrail)|The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
79260742|NCT03214653|Drug|Sevoflurane|Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
79260743|NCT02450877|Drug|Azacitidine|
79723407|NCT02808949|Drug|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
79723408|NCT02854306|Procedure|Bariatric surgery|With mindfulness programm
80020343|NCT02292524|Other|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
80020344|NCT04051489|Other|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
80020345|NCT03513692|Device|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
80020346|NCT03513536|Other|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
80020347|NCT03513536|Other|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
79260744|NCT02450877|Other|Control Arm|
79857856|NCT06271239|Other|Group Suggestions for a Healthy Life (CG)|The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
79857857|NCT06271226|Other|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
79857858|NCT06271226|Other|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
79857859|NCT06271226|Other|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
79857860|NCT06271213|Other|observational only - no interventions as part of study|Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
79857861|NCT06271200|Other|Intermittent fasting and 10,000 steps per day|"Reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis plus walking more than 10,000 steps per day."
79857862|NCT06271187|Device|Dynamic-orthosis|Engaging in motion training at home with the use of dynamic orthoses.
79857863|NCT06271187|Other|Traditional stroke occupational therapy training|Traditional post-stroke movement training arranged by an occupational therapist in a medical setting.
79857864|NCT06271174|Drug|Carbocaine|"After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance."
79857865|NCT06271174|Drug|Profofol and/or Suxaméthonium and/or Sévoflurane|"General anesthesia~Anesthetic induction is performed on a full stomach using :~Intravenous hypnotic Propofol 2-5 mg/kg~A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics."
79857866|NCT06271148|Other|Interview|We made multiple interviews with randomly selected surgical candidates
79857867|NCT06271135|Behavioral|CAPILLARY REPAIR SERUM 30ml|Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
80020348|NCT03513536|Other|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
80020349|NCT03513536|Other|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
80020350|NCT03641391|Procedure|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
79560680|NCT01693588|Other|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
79560681|NCT01693627|Device|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
79560682|NCT01693627|Device|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
79260745|NCT02148679|Other|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
79723409|NCT02854306|Procedure|Bariatric surgery|Without mindfulness programm
79723410|NCT02812147|Drug|L-DOPS|Added as described in the Arm/Group Descriptions.
79723411|NCT02812147|Drug|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
79723412|NCT02854150|Genetic|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
79723413|NCT04303065|Drug|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
79857868|NCT06271122|Other|Voluntary activation assessed by magnetic stimulation|"Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau."
79857869|NCT06271109|Procedure|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
79857870|NCT06271109|Procedure|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
79260746|NCT02148679|Other|Usual care|Standardized advice to restrict dietary sodium intake to < 2000 mg/day
79857871|NCT06271083|Behavioral|Exposure with response prevention|The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.
79857872|NCT06271083|Behavioral|Brief psychoeducation with general psychological support|Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
79560683|NCT01693627|Device|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
79857873|NCT06271070|Other|Non-intervention|Non
79857874|NCT06271057|Drug|golcadomide|golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
79857875|NCT06271044|Other|With radioiodine treatment|Postoperative radioiodine not given
79857876|NCT06271044|Procedure|With postoperative radioiodine treatment|Postoperative radioiodine given
79857877|NCT06271005|Dietary Supplement|NeuroTears|Over-the-counter supplement
79857878|NCT06271005|Dietary Supplement|Placebo|Oral placebo pill
79857879|NCT06270992|Diagnostic Test|NCCN (National Comprehensive Cancer Network) diagnosis|For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
79857880|NCT06270979|Device|ISHA|Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).
80020351|NCT03641391|Procedure|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
79260747|NCT03223545|Behavioral|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
79260748|NCT03223545|Behavioral|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
79560684|NCT01693627|Device|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
79560685|NCT01693640|Drug|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
79723414|NCT04303065|Drug|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
79723415|NCT02874417|Behavioral|CAST psychoeducation|
79723416|NCT02874417|Behavioral|PHET|
79723417|NCT02081248|Other|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
79260749|NCT02141113|Drug|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)"
79857881|NCT06270966|Device|Virtual Reality Cognitive Remediation|"Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions."
79260750|NCT02141113|Drug|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)"
79398134|NCT00525525|Drug|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
79260751|NCT03214107|Other|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
79260752|NCT03214107|Other|Snack|Full snack or Distributed snack
79260753|NCT03543709|Diagnostic Test|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
80020352|NCT03519776|Diagnostic Test|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
80020353|NCT03641235|Biological|Sputum collection|Analysis of Sputum collection
79260754|NCT03543709|Other|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
79260755|NCT03213873|Behavioral|HiBalance|Intervention of highly challenging balance training for 10 weeks.
79260756|NCT03213873|Behavioral|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
79260757|NCT02141191|Drug|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
79560686|NCT01693666|Behavioral|Lifestyle intervention|"To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
79560687|NCT01693679|Drug|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
79560688|NCT01693705|Procedure|Tracheostomy|
79260758|NCT03213639|Drug|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
79260759|NCT03213639|Drug|Placebo Oral Tablet|once daily oral tablets
79260760|NCT03231033|Drug|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
79260761|NCT02141347|Drug|Tremelimumab|Tremelimumab administered intravenously
79260762|NCT02141347|Drug|MEDI4736|MEDI4736 administered intravenously.
79260763|NCT03213327|Device|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
79398135|NCT00525603|Drug|Cyclophosphamide|200 mg/m^2/day 3-5 IV 5-30 minutes
79398136|NCT00525603|Drug|Fludarabine|20 mg/m^2/day 3-5 IV 5-30 minutes
79398137|NCT00525603|Drug|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
79398138|NCT00525603|Drug|Rituximab|375 mg/m^2/day 2 IV 4-6 hours
79560689|NCT01693770|Procedure|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
79560690|NCT01693809|Drug|Caffeine|
79560691|NCT01693874|Behavioral|MBSR|Mindfulness-Based Stress Reduction
79723418|NCT02081248|Other|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
79260764|NCT02254759|Drug|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
79260765|NCT02254759|Drug|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
79260766|NCT02254759|Drug|RO5186582|RO5186582 120 mg film-coated release tablet.
79260767|NCT03208257|Drug|Esmolol|Esmolol hydrochloride infusion
79260768|NCT02254837|Device|Zilver PTX Drug-Eluting Stent|
79260769|NCT02141425|Drug|ASP015K|oral
79260770|NCT02141425|Drug|Placebo|oral
79260771|NCT03212625|Drug|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
79560692|NCT01693874|Behavioral|control (health education)|health education
79857883|NCT06270940|Procedure|Pulsed Radiofrequency (PRF) Treatment|PRF treatment maintains a temperature below 42°C and does not produce structural tissue damage around the needle. PRF exposure to the Dorsal Root Ganglion (DRG) induces c-Fos gene expression in the dorsal horn, which suggests a cellular response to the electric forces generated within the DRG. PRF has been found to relieve neuropathic pain by inducing long-term depression of synaptic transmission in the spinal cord, leading to a decrease in allodynia and hyperalgesia. It also modulates the inflammatory response in the injured area by decreasing the expression of pro-inflammatory cytokines, such as TNF-α, in the peripheral nerve and spinal cord, which is a major player in the development and maintenance of neuropathic pain. PRF is characterized by a 500 kHz current applied for 2 pulses per second, with each pulse lasting 20 milliseconds.
79560693|NCT01693913|Behavioral|cognitive behavioral exercise and nutrition over|
79857884|NCT06270927|Diagnostic Test|MRI|neuroimaging using MRI scanner
79260772|NCT03212625|Drug|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
79723419|NCT02808715|Other|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
79560694|NCT01693913|Behavioral|nutrition and exercise education|
79260773|NCT02148757|Procedure|Doppler Ultrasound|
79260774|NCT03212547|Behavioral|Verbal Intervention|"Promotion of verbal interventions:~Detecting whether the infant has social withdrawal.~The physician will verbally intervene.~Positive response (+) from the infant, the evaluator will point out this to the parents.~Negative response (-) from the infant, the evaluator will include the parents in the interaction.~If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~If the infant does not establish positive contact (-)with the parents, repeat step 2.~If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
79260775|NCT03746899|Biological|PLX-PAD|PLX-PAD cell therapy to be administered via 30 IM injections (0.5 mL each) to the index leg leg per treatment, in each of two treatments, 8 weeks apart
79560695|NCT01693926|Behavioral|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
79857885|NCT06270927|Diagnostic Test|CT|neuroimaging using CT scanner
79260776|NCT03212157|Other|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
79260777|NCT03212157|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
79260778|NCT03212157|Diagnostic Test|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
79398139|NCT00398307|Drug|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
79260779|NCT02148913|Drug|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
79260780|NCT02148913|Drug|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
79260781|NCT02148913|Drug|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
79260782|NCT02148913|Drug|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
79560696|NCT01693926|Behavioral|placebo|
79398140|NCT00564447|Drug|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
79398141|NCT00564447|Drug|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
79398142|NCT00564681|Biological|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
79398143|NCT00564681|Biological|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
79398144|NCT00564681|Drug|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
79560697|NCT01693939|Device|FS200 Femtosecond Laser|
79560698|NCT01693952|Biological|blood draw|
79723420|NCT04302129|Procedure|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
79723421|NCT04302129|Drug|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
79398145|NCT00525837|Drug|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
79398146|NCT00525837|Drug|varenicline|up to 1 mg twice daily
79398147|NCT00527475|Drug|ranibizumab|0.5 mg. given as an intraocular injection
79723422|NCT02814877|Other|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
79723423|NCT02856958|Procedure|Nerve decompression|
80020354|NCT02988661|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
79260783|NCT03230721|Procedure|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
79260784|NCT03230721|Procedure|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
79260785|NCT03230721|Procedure|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
79398148|NCT00527475|Drug|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
79398149|NCT01798251|Drug|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
79398150|NCT01798251|Drug|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
79398151|NCT00566943|Device|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
79398152|NCT00566943|Procedure|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
79398153|NCT01449461|Drug|Brigatinib|Brigatinib tablets and capsules.
79398154|NCT05363241|Procedure|Cooled radiofrequency in classical targets (CRF-CT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
79398155|NCT05363241|Procedure|Cooled radiofrequency in revised targets (CRF-RT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
79260786|NCT03230799|Procedure|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
79398156|NCT02121483|Drug|empagliflozin medium dose|
79723424|NCT02856958|Other|Non-operative|Physical therapy
79723425|NCT00952822|Biological|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
79723426|NCT02857738|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79723427|NCT02857738|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79723428|NCT02854072|Drug|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
79857886|NCT06270914|Behavioral|Inclusive Positive Behavior Interventions and Supports|The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
79857887|NCT06270888|Radiation|Radiation|Radiation given for cancer treatment. Radiation is usually an outpatient procedure completed over the course of 1-6 weeks. High-energy radiation will be delivered to a focused area of the body using a treatment machine called a linear accelerator. Unlike surgery, there are no invasive procedures other than inserting an IV during the radiation planning session. Radiation uses a mold that is customized to fit your body. This mold will be made in the radiation planning session and be used during treatment to keep you from moving. The mold is necessary for very accurate targeting of your tumor. During the procedure, the radiation therapy team will also confirm the exact location that needs to be treated using x-rays.
79857888|NCT06270875|Behavioral|ADAPT HF|ADAPT is a multicomponent, lay palliative care coach-led or self-led supportive care intervention designed to improve pain of life in individuals with advanced heart failure. Participants will complete weekly sessions of the educational programs. This program includes the following modules: pain psychoeducation, self-care and relaxation tips, social support and communication, and spirituality and meaning coping. The sessions will either be self-guided or completed with a lay coach navigator.
79857889|NCT06270862|Behavioral|Resilience training|Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
79723429|NCT02854072|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
79857890|NCT06270862|Behavioral|cognitive training|Play games that trains attention, memory and planning using the services provided by CogniFit.
79857891|NCT06270862|Behavioral|physical exercise|Engage in age-appropriate physical exercises.
79857892|NCT06270862|Behavioral|social interaction|Engage in social discussion with peers in the group.
79857893|NCT06270862|Behavioral|workshop series|Watch a series of workshops targeting the older adult population.
79857894|NCT06270849|Other|Questionnaire|The questionnaire to assess severity of LUTS in women.
79857895|NCT06270836|Drug|Tarcocimab|Intravitreal injection
79723430|NCT02854072|Drug|Capecitabine|Capecitabine 830 mg/m^2 will be orally given in the morning and evening (total dose of 1660 mg/m^2) for 21 days followed by 7 days' rest.
79723431|NCT01038297|Drug|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
79857896|NCT06270836|Other|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
79857897|NCT06270823|Procedure|Knee-to-chest-flexion manoeuvre|The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
79857898|NCT06270797|Procedure|intubation for general anesthesia|routine intubation for general anesthesia
79857899|NCT06270784|Procedure|Traditional Extraction|Participants in this group will undergo traditional extraction method. This method involves uncovering the impacted tooth and extracting the tooth with or without dividing it.
80020355|NCT02292602|Behavioral|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
80020356|NCT05262933|Other|coffee|It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache
80020357|NCT05262933|Other|Water|It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
80020358|NCT03641157|Other|Easy Intubation|
79260787|NCT03230799|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
79260788|NCT03208101|Biological|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
79260789|NCT03208101|Biological|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
79723432|NCT01038297|Drug|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
79723433|NCT02537314|Drug|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
79398157|NCT02121483|Drug|empagliflozin high dose|
79398158|NCT02121483|Drug|empagliflozin low dose|
79723434|NCT02537314|Other|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
79723435|NCT00631150|Drug|Levetiracetam (Keppra)|
79723436|NCT02808559|Device|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
79723437|NCT04278040|Drug|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
79560699|NCT01693978|Behavioral|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, & Rothbaum, 2007)."
79857900|NCT06270784|Procedure|Orthodontic Extraction|"Participants in this group will undergo orthodontic extraction method. In this method, a two-stage surgical procedure will be performed. In the first operation, the impacted tooth will be uncovered, and then a button will be placed on the tooth. For anchorage purposes, orthodontic mini screws will be placed in the mandibular ramus or zygomaticomaxillary buttress area. Elastics and/or ligature wires fixed to the button will be attached to the mini screw to provide force for the traction of the tooth.~Patients will be called for check-up appointments every two weeks, and the movement of the impacted tooth will be monitored with panoramic x-rays. The second operation will be planned when the tooth moves away from the inferior alveolar nerve. In the second operation, the tooth will be extracted in a similar way to the traditional extraction group."
80020359|NCT02295488|Procedure|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
80020360|NCT02295488|Biological|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
79260790|NCT02149225|Drug|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
79308693|NCT04851639|Other|Wolverhampton Assessment Tool|a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
79398159|NCT01572038|Drug|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
79398160|NCT01572038|Drug|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
79398161|NCT01572038|Drug|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
79723438|NCT02812069|Device|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
79723439|NCT05641675|Diagnostic Test|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
79723440|NCT00955708|Device|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
79398162|NCT01572038|Drug|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
79398163|NCT01572038|Drug|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
79723441|NCT02811757|Procedure|tenotomy|
79723442|NCT02811757|Procedure|tenodesis|
79398164|NCT01448213|Drug|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
79723443|NCT02814799|Other|bone removal|
79723444|NCT02856724|Drug|PGE2|10 mg PGE2 vaginal ovul(Propess)
79723445|NCT02808637|Other|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
79723446|NCT02808637|Other|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
79723447|NCT02808637|Other|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
80020361|NCT02295566|Drug|Nitric Oxide|Not required
80020362|NCT02295566|Drug|Control|Not required
80020363|NCT05283681|Drug|Risankizumab|Subcutaneous Injection via Prefilled Syringe (PFS)
80020364|NCT05283681|Drug|Risankizumab|Subcutaneous Injection via Auto-Injector (AI)
80020365|NCT03513458|Biological|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
80020366|NCT03513458|Other|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
80020367|NCT03513458|Drug|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
79560700|NCT01693978|Behavioral|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
79560701|NCT01693991|Behavioral|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
79560702|NCT01693991|Behavioral|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
79560703|NCT01694017|Drug|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
79560704|NCT01694017|Drug|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
79560705|NCT01694030|Other|Attachment security priming|
79723448|NCT02808637|Other|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
79723449|NCT02808325|Drug|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
79260791|NCT02149225|Drug|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
79857901|NCT06270771|Device|OURA Ring|The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
79857902|NCT06270758|Diagnostic Test|CT scan at the femur|Additional CT scan which is not part of the standard clinical path
80020368|NCT03641079|Drug|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
79260792|NCT03230955|Behavioral|Psychological and psycho-educational support by phone|The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
79723450|NCT02808325|Drug|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
79723451|NCT01037985|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
79723452|NCT01037985|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
79260793|NCT03230955|Other|Brief counselling session|Brief counselling session
79260794|NCT03208335|Drug|recombinant human endostatin|The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
79260795|NCT02149381|Behavioral|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
79260796|NCT02149381|Behavioral|Befriending|Social support intervention, sessions once per week
79260797|NCT02149381|Other|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
79260798|NCT03211065|Drug|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
79260799|NCT02149459|Radiation|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
79260800|NCT02149459|Drug|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
79308694|NCT04833777|Drug|Local Anesthetics Lidocaine|10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
79723453|NCT00955474|Drug|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
80020369|NCT03760471|Other|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
79857903|NCT06270732|Behavioral|iMentalize Program (iMentalize)|"This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization."
80020370|NCT03643419|Procedure|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
79260801|NCT02149459|Behavioral|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
79560706|NCT01694043|Other|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
79560707|NCT01694043|Other|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
79723454|NCT00955474|Drug|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
79723455|NCT00955474|Drug|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
79723456|NCT00955474|Drug|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
80020371|NCT03643419|Device|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
79260802|NCT02376790|Drug|Etanercept|Etanercept was administered by subcutaneous injection once a week
79260803|NCT02376790|Drug|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
79560708|NCT01694056|Other|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
79560709|NCT01694056|Other|Control diet|4 weeks high mixed protein diet (20 en%)
79560710|NCT01694082|Behavioral|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
79560711|NCT01694082|Behavioral|Brief brochure and assessment control|
79723457|NCT02808247|Drug|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH & Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
79723458|NCT02808247|Drug|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
79723459|NCT02037334|Device|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
79723460|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
79723461|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
79723462|NCT02808091|Radiation|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
79723463|NCT02807935|Device|Optical coherence tomography imaging|
79723464|NCT02874183|Behavioral|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
79723465|NCT02808013|Drug|NDS-446|
79723466|NCT02808013|Drug|Placebo|
80020372|NCT03747835|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
80020373|NCT03747835|Behavioral|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
79560712|NCT05289778|Other|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
79560713|NCT05289726|Drug|Traditional chinese medicine TDX105|Experimental group Traditional chinese medicine TDX105
79560714|NCT05289726|Drug|Placebo|he control group received placebo granules mixed with dextrin and food coloring
79857904|NCT06270732|Behavioral|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.
79875645|NCT00943865|Behavioral|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
79875646|NCT00943865|Behavioral|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
80020374|NCT03516734|Dietary Supplement|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
80020375|NCT03516734|Other|Non Iron-fortified lentils|Non-fortified lentils will be provided
80020376|NCT03516734|Other|Usual Intake|No lentils will be provided.
79560715|NCT05289700|Device|HBOT in Hyperbaric chamber|HBOT is the administration of oxygen (FIO2 = 100%) at a pressure higher than atmospheric pressure (2 ATA). The pressure increase is achieved by introducing compressed air into the hyperbaric chamber. This study will use a hyperbaric chamber that is already marketed, licensed and used in other diseases.
80020377|NCT05260905|Behavioral|REHIT|REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
79560716|NCT05289700|Device|Hyperbaric chamber for placebo|Hyperbaric chamber is the same chamber used for HBOT, but here with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers. All other aspects of the procedure are identical to those of the intervention. As in the intervention arm, there will be a compression period (although shorter), of 5 min, followed by 85 min at 1.3 ATA, then a decompression period of 5 min (total duration of 95 min).
80020378|NCT03519698|Other|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
79560717|NCT05289609|Procedure|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
79723467|NCT04302519|Biological|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
79723468|NCT02811991|Drug|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
79723469|NCT02811991|Drug|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
80020379|NCT03519698|Other|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
80020380|NCT03519698|Other|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
79723470|NCT02811991|Drug|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose<25mg/4h.
79723471|NCT02873793|Genetic|Extraction of total RNA from healthy and tumour tissues|
79723472|NCT02873637|Device|under sartorial catheter|
80020381|NCT03513380|Behavioral|Exergaming|free access to the exergame PedalTanks during 6 months
80020382|NCT03516578|Other|Cardiac magnetic resonance imaging|
80020383|NCT02299544|Device|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
80020384|NCT03738397|Biological|Upadacitinib|Extended release tablet
80020385|NCT03738397|Biological|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
80020386|NCT03738397|Drug|Placebo to dupilumab|Placebo administered as a subcutaneous injection
80020387|NCT03738397|Drug|Placebo to upadacitinib|Tablet
79260804|NCT02376790|Drug|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
79260805|NCT02376790|Drug|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
79560718|NCT05289531|Procedure|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
79560719|NCT05289518|Device|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
79723473|NCT02873637|Device|femoral catheter|
79723474|NCT04237675|Procedure|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
79723475|NCT02807701|Procedure|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~dissection~reconstruction"
79723476|NCT02807701|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
79723477|NCT05638165|Drug|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
79723478|NCT05598853|Drug|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
80020388|NCT02295800|Other|Standard of care|
80020389|NCT02295800|Other|Semi-structured interviews|
80020390|NCT02292836|Other|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
79560720|NCT05289518|Device|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
79857905|NCT06270732|Behavioral|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|"This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment."
79857906|NCT06270719|Genetic|delandistrogene moxeparvovec|No study medication will be provided by the sponsor during this trial.
80020391|NCT02960217|Drug|UX007|liquid for oral (PO) administration
80020392|NCT02960217|Drug|Placebo|liquid safflower oil for PO administration
80020393|NCT02292914|Procedure|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
80020394|NCT02292914|Procedure|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
80020395|NCT02292992|Device|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
80020396|NCT02295878|Dietary Supplement|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
79723479|NCT04237285|Other|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
79723480|NCT04237363|Behavioral|Exercise|Underwater treadmill training and supplemental overground walk training
80020397|NCT02295878|Dietary Supplement|Placebo|
79260806|NCT03210987|Procedure|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
79260807|NCT03210987|Procedure|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
79260808|NCT02141737|Drug|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
79260809|NCT02141737|Drug|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
79260810|NCT02141737|Drug|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
79260811|NCT02141737|Drug|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
79560721|NCT05289466|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
79260812|NCT02141737|Drug|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
79560722|NCT05289466|Procedure|Oncoplastic partial mastectomy|Breast Conserving Therapy
79560723|NCT05289453|Procedure|lens extraction by phacoemulsification|lens extraction by phacoemulsification
79723481|NCT01229150|Drug|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
80020398|NCT02293070|Other|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
79723482|NCT01229150|Drug|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
80020399|NCT02293070|Procedure|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
80020400|NCT02299622|Genetic|Genetic test|Next-generation sequencing (AmpliSeq) & fusion analysis
79560724|NCT05289401|Other|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
79560725|NCT05289388|Diagnostic Test|Lactate/CRT index|index will be calculated as the product of multiplying the CRT and serum lactate
80020401|NCT03643497|Drug|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
80020402|NCT03519620|Other|SWWSV|Behaviours to prevent child obesity
80020403|NCT03643341|Behavioral|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
80020404|NCT02299700|Other|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
80020405|NCT02299778|Dietary Supplement|13C6-p-aminobenzoic acid|
79857907|NCT06270719|Drug|Standard of Care|No study medication will be provided by the sponsor during this trial.
79857908|NCT06270706|Drug|PLN-101095|PLN-101095
79260813|NCT02141737|Drug|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
79560726|NCT05289336|Procedure|Transoral Laser Microsurgery|
79560727|NCT05289219|Behavioral|EXPOBAR|Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
79560728|NCT05289128|Device|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
79560729|NCT05289128|Device|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
79723483|NCT01229150|Drug|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
79723484|NCT00634465|Device|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
79723485|NCT02807389|Drug|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
79723486|NCT02804737|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
79723487|NCT00952588|Drug|AZD1152|1200 mg, iv, 7 day infusion
79723488|NCT00952588|Drug|LDAC|20 mg, sc, bd, 10 days
79723489|NCT02814409|Drug|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|
79723490|NCT02814409|Drug|Intravenous Tenecteplase|
79723491|NCT02804893|Procedure|VATS|Thorax thoracoscopic surgery (lobectomy)
79723492|NCT02804893|Procedure|RATS|Thorax robotic surgery (lobectomy)
79723493|NCT02853916|Dietary Supplement|500 mg InSea2®|
79723494|NCT02853916|Dietary Supplement|250 mg InSea2®|
79723495|NCT02853916|Dietary Supplement|Placebo|
79723496|NCT02853838|Other|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
79723497|NCT02853838|Other|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
79857909|NCT06270706|Drug|Pembrolizumab|Pembrolizumab
79857910|NCT06270693|Procedure|Endodontic treatment|Root canal treatment
79260814|NCT02254447|Drug|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
79260815|NCT02254447|Drug|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
79723498|NCT02853838|Other|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
79723499|NCT05527717|Procedure|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
79723500|NCT05527717|Procedure|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
79857911|NCT06270680|Drug|Vision Edge Pro|Each dose will consist of one supplement capsule containing 10 mg lutein, 2 mg zeaxanthin, 10 mg mesozeaxanthin, 50mg EPA, 250mg DHA. Capsules are to be taken orally, once daily with a meal. Duration of supplementation will last approximately 2 - 5 months, depending on the length of the athletic seasons for the sports recruited.
79857912|NCT06270680|Other|Placebo|A sunflower oil placebo containing 380 mg of sunflower oil
79857913|NCT06270667|Behavioral|Aerobic Exercise|Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
79723501|NCT04236505|Behavioral|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
79560730|NCT05289115|Device|Experimental group/ Active HD-tDCS|Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
79560731|NCT05289115|Device|Control Group / Sham Group|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
79723502|NCT04236505|Behavioral|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
79723503|NCT04236505|Behavioral|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
79723504|NCT02804581|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
79857914|NCT06270667|Behavioral|Combined Aerobic and Resistance Exercise|Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
79723505|NCT01227902|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
79723506|NCT02804659|Other|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
79723507|NCT00946192|Drug|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
79723508|NCT00946192|Drug|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
79723509|NCT00946192|Dietary Supplement|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
79560732|NCT05289102|Other|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
79723510|NCT01037127|Drug|GSK1120212|Daily oral dosing
79723511|NCT02806999|Drug|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
79857915|NCT06270654|Procedure|Erector spinae plane block|"After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side."
79260816|NCT02254447|Drug|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
79260817|NCT03207711|Behavioral|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
79723512|NCT02806999|Drug|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
79723513|NCT02874261|Device|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
79723514|NCT02806921|Device|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
79857916|NCT06270654|Procedure|Skin infiltration LA|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
79857917|NCT06270628|Behavioral|Exercise group|Live-remote exercise sessions, personalized to the patients main side-effect
79260818|NCT03207711|Behavioral|Mindfulness|Mindful eating app-use and instruction
79260819|NCT02141815|Dietary Supplement|Arabinoxylan-oligosaccharides|
79260820|NCT02141815|Dietary Supplement|Maltodextrine|
79260821|NCT03209739|Other|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
79260822|NCT02149615|Other|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
79260823|NCT03209895|Dietary Supplement|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
79260824|NCT03209895|Dietary Supplement|Placebo|Palm oil Softgel capsule
79723515|NCT04292613|Other|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
79723516|NCT02807077|Drug|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
79723517|NCT04302363|Other|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
79723518|NCT00946114|Drug|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
79560733|NCT05289102|Other|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
79560734|NCT05289011|Other|Interviews and questionnaires|"Evaluation of inflammatory rheumatism~Dietary survey~International Physical Activity Questionnaire IPAQ~BASDAI self-questionnaire~Assessment of quality of life by ASQol questionnaire~Assessment of fatigue by FACIT questionnaire~Assessment of digestive symptoms~Collection of demographic and general data~Collection of treatment"
79560735|NCT05288959|Device|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
80020406|NCT05252169|Other|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
80020407|NCT05252169|Other|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~Passive stretching exercises~Weight bearing exercises~Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
79857918|NCT06270615|Other|Ambispective validation of machine learning-based predictive model|Retrospective and prospective validation of a machine learning model to predict major haemorrhage in trauma patients compared to clinician prediction
80020408|NCT03519542|Drug|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
79398165|NCT01448213|Drug|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
79560736|NCT05288959|Device|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
79560737|NCT05288881|Biological|ANX105|Participants will receive single-ascending doses of ANX105 administered by IV infusion.
79560738|NCT05288881|Drug|Placebo|Participants will receive matching placebo administered by IV infusion.
79857919|NCT06270602|Other|Data collection (retrospective)|Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
80020409|NCT03643029|Device|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
79560739|NCT05288738|Drug|Dexmedetomidine 1 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
80020410|NCT02295956|Behavioral|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
79560740|NCT05288738|Drug|Dexmedetomidine 2 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
79723519|NCT00946114|Drug|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
79723520|NCT02804503|Behavioral|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
79398166|NCT02122341|Device|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
79723521|NCT02804503|Behavioral|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
79723522|NCT02804503|Behavioral|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
79723523|NCT04302285|Other|PKU type meal and Exercise|"Exercise was conducted prior to PKU type meal.~PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
79260825|NCT03209895|Dietary Supplement|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
79260826|NCT02149693|Other|high-fidelity simulation and teamwork training|
79260827|NCT02149693|Other|traditional resuscitation training|
79260828|NCT03209817|Dietary Supplement|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
79260829|NCT03209817|Dietary Supplement|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
79308695|NCT04833777|Drug|Local Anesthetics Bupivacaine|5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
79308696|NCT03037047|Drug|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
80020411|NCT02295956|Other|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
79560741|NCT05288725|Biological|Bone Marrow Derived MSCs|Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
79723524|NCT04302285|Other|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
79723525|NCT02804425|Other|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
79723526|NCT00627471|Drug|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
79723527|NCT00627471|Drug|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
79723528|NCT04269382|Device|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
79723529|NCT02814721|Device|Sonic Window ultrasound device|
79723530|NCT04302441|Drug|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
79723531|NCT04302441|Drug|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
79723532|NCT04236427|Drug|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
79723533|NCT04236427|Drug|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
79723534|NCT02853682|Biological|plasma|assesment of glycocalyx protein
79723535|NCT02874027|Other|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
79857920|NCT06270602|Other|Data collection (prospective)|Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
80020412|NCT02295956|Other|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
79260830|NCT03119415|Behavioral|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
79723536|NCT02800447|Drug|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14
79260831|NCT02141893|Behavioral|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
79560742|NCT05288725|Drug|Corticosteroid|The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog [40 mg/dL], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
79560743|NCT05288725|Device|Bone Marrow Aspirate|The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
79857921|NCT06270589|Behavioral|MF-HIIT|A single bout of 20-min MF-HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s mindful intervals), and finally a 2-min cool-down.
79857922|NCT06270589|Behavioral|MF-only|A single bout of 20-min intervention mindfulness intervention that includes 5 x 90s mindful intervals separated by sitting rest
79857923|NCT06270589|Behavioral|HIIT-only|A single bout of 20-min HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s rest intervals), and finally a 2-min cool-down.
80020413|NCT02295956|Behavioral|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
80020414|NCT02295956|Other|Booklet|Exercise instructional booklet given to all participants describing all exercises.
80020415|NCT03642561|Device|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
80020416|NCT03642561|Device|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
80020417|NCT03516500|Drug|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
79260832|NCT02141893|Behavioral|CALMA|Family Education Intervention on management of pediatric asthma
79560744|NCT05288465|Drug|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
79560745|NCT05288426|Other|No intervention|This is an observational study, with no intervention.
79857924|NCT06270589|Behavioral|Sitting rest|Participants will sit in a comfortable chair, placed on the treadmill, while watching a HIIT video without mindfulness instructions for 20 minutes.
79723537|NCT02800447|Drug|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
79723538|NCT01038921|Drug|Melatonin|8 mg dose of Melatonin
79857925|NCT06270576|Drug|Lipopolysaccharides|LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.
79260833|NCT03230643|Device|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
79260834|NCT02149771|Procedure|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
79260835|NCT02149771|Device|endovascular stents implantation|Bare stents implant within portal vein.
79260836|NCT02149771|Procedure|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
79260837|NCT03207633|Procedure|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
79560746|NCT05288387|Procedure|Spinal cord stimulation|High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
79560747|NCT05288270|Device|Aramis|"ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality."
79560748|NCT05288270|Other|Conventional therapy|The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
79723539|NCT01038921|Drug|Placebo|Placebo
79723540|NCT01088542|Behavioral|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
79723541|NCT02804347|Device|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
79723542|NCT02804347|Device|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
79723543|NCT02804347|Other|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A & B, RAVLT
79723544|NCT02804191|Drug|LO2A|eye drop solution.
79857926|NCT06270563|Other|Postural advice|The patients received advice about maintaining good posture when sitting, standing, reading, driving, or lifting; taking breaks; sleeping on back or side with a pillow supporting head/neck; avoiding prolonged phone use; adjusting car seat; reading stand for upright posture; keeping objects close when lifting; and using pillows for support when breastfeeding.
80020418|NCT03642405|Diagnostic Test|Electrocardiogram examination|12-lead ECG monitored by Holter
80020419|NCT03642405|Diagnostic Test|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
80020420|NCT03642405|Procedure|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
80020421|NCT03642405|Behavioral|Questionnaire|Questionnaire regarding patients quality of life
80020422|NCT02299856|Other|Cardiac magnetic resonance scan|
80020423|NCT05283603|Diagnostic Test|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
79857927|NCT06270563|Other|Traditional exercise treatment|The exercise program included strengthening of deep flexor muscles and shoulder retractors while stretching of cervical extensors and pectoral muscles.
79857928|NCT06270563|Other|Scapular stabilization exercises|Scapular Stabilization exercise was composed of four exercise programs, including scapula retraction exercise, scapula mobilization exercise, and scapula dynamic stabilization exercise I and II.
80020424|NCT03513224|Other|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
79560749|NCT05288244|Other|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
79260838|NCT03207633|Procedure|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
79560750|NCT05288244|Other|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
79560751|NCT05288244|Other|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
79560752|NCT05288192|Drug|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
79560753|NCT05288179|Drug|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
79560754|NCT05288179|Drug|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
79560755|NCT05288127|Drug|Talazoparib|"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."
79260839|NCT03207633|Procedure|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
79560756|NCT05291585|Device|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
79560757|NCT05291585|Device|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
79723545|NCT02804191|Drug|Saline|Placebo
79723546|NCT02804113|Device|Supera Peripheral Stent System|
79723547|NCT02374372|Device|conventional hemodialysis|
79723548|NCT02374372|Device|hemodiafiltration On-line|
79723549|NCT04236349|Genetic|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
79723550|NCT01038687|Drug|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
79723551|NCT01038687|Drug|placebo|placebo
79723552|NCT02803957|Device|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
79723553|NCT02803957|Device|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
79875647|NCT00943865|Behavioral|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
79560758|NCT05291572|Behavioral|speech therapy only|fluency shaping technique
79560759|NCT05291572|Device|hyperbaric oxygen therapy|chamber system using oxygen with pressure
79560760|NCT05291572|Drug|medical treatment|brain stimulant
79875648|NCT02532712|Drug|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
79560761|NCT05291455|Drug|Lacosamide|lacosamide will be given
79560762|NCT05291455|Drug|Phenobarbital|phenobarbital will be given
79560763|NCT05291429|Device|OVR Health's VR experience|Virtual reality experience
79560764|NCT05291416|Diagnostic Test|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
79723554|NCT02856568|Drug|Cisplatin|Given IV
79723555|NCT02856568|Drug|Gemcitabine Hydrochloride|Given IV
79723556|NCT02856568|Other|Laboratory Biomarker Analysis|Correlative studies
79723557|NCT02856568|Other|Pharmacological Study|Correlative studies
79723558|NCT02856568|Drug|Ricolinostat|Given PO
79723559|NCT02804269|Other|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
79875649|NCT02532712|Drug|Placebo|Placebo with same shape and size
79875650|NCT00948701|Behavioral|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
79857929|NCT06270563|Other|High intensity Laser therapy|"There were two phases in every session, the wavelength is 1064 nm, size of spacer is 60 mm in both phases:~Phase I (analgesic phase): the application was made by moving the applicator perpendicular to the skin in continuous circular movements at trigger points detected by acupuncture, power was 8.00 w with a dosage of 5 J/cm2, surface area 50 cm2, frequency 25 HZ, treatment time in this phase was 3 minutes and total energy received at this phase was 250 J.~Phase II (bio stimulation): the application was made at the pain inflicting region by using continuous linear movements and prevent static application, The power was 8.00 w with a continuous frequency, dosage of 50 J/cm2, surface area 50 cm2, treatment time in this phase was 5 minutes and the total energy that was delivered to the patient during this phase was 2500 J."
80020425|NCT03644043|Device|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
79398167|NCT01448057|Drug|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
79560765|NCT05291312|Procedure|Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)|IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
79260840|NCT03230487|Drug|BI 1015550|Part 1 - single rising dose. Part 2 multiple rising dose
79260841|NCT03230487|Drug|Placebo|Part 1 - single rising dose. Part 2 multiple rising dose
79398168|NCT01448057|Drug|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
79560766|NCT05291195|Device|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
79560767|NCT05291195|Drug|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
79560768|NCT05291195|Drug|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
79723560|NCT02804269|Other|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
79723561|NCT04236583|Other|Telehealth|Post-discharge virtual visit
79723562|NCT02874105|Other|Group C: physiotherapy protocol with Conventional physiotherapy.|
79723563|NCT02874105|Other|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
79723564|NCT04081831|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
79723565|NCT02807155|Behavioral|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
79260842|NCT02142127|Drug|14C-labelled GFT505 120 mg|
79723566|NCT02807155|Behavioral|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
79723567|NCT02807155|Behavioral|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
79723568|NCT01081912|Drug|Placebo|Capsules, no active substance, shells identical to active comparator capsules
79723569|NCT01081912|Drug|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
79723570|NCT02800525|Device|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
80020426|NCT05283525|Dietary Supplement|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
80020427|NCT05283525|Dietary Supplement|Oxygen Saturation|0 - 90 Days of Treatment
80020428|NCT05283525|Dietary Supplement|Total Blood Chemistry|0 and 90 Days of Treatment
80020429|NCT05283525|Dietary Supplement|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
80020430|NCT05283525|Dietary Supplement|Body Weight Monitoring|0 - 90 Days of Treatment
79260843|NCT02376166|Drug|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade > 1 toxicities)
79260844|NCT03207165|Drug|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min [stage 1] and will be titrated according to a blinded protocol from stages 2 to 5 [0.250, 0.375, 0.5 and >0.5 ug/kg/min]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be [increased/decreased/maintained] at stage [1-5]' so as to ensure that treating physicians remain blinded to the allocated drug.
79398169|NCT05246631|Drug|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
80020431|NCT05283525|Dietary Supplement|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
79398170|NCT05246631|Drug|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
79560769|NCT05291104|Dietary Supplement|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
79857930|NCT06270550|Other|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
79398171|NCT05246553|Procedure|Electrical stimulation of the vestibular system|Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
79560770|NCT05291052|Drug|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
79560771|NCT05291052|Drug|Lenvatinib|Lenvatinib 8 mg (for patient weight < 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
79560772|NCT05291052|Drug|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
79560773|NCT05291052|Drug|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
79560774|NCT05291013|Procedure|Gastric byspass|Test will be before and 9-12 month after gastric bypass
79560775|NCT05291000|Behavioral|The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)|The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
79560776|NCT05290948|Drug|intravitreal injection of bevacizumab with acetazolamide tablets|intravitreal injection of bevacizumab with acetazolamide tablets
79560777|NCT05290948|Drug|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
79560778|NCT05290935|Drug|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
79723571|NCT02800525|Device|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
79723572|NCT01038609|Drug|Hydrocodone/Acetaminophen Extended Release|
79723573|NCT01038609|Drug|Acetaminophen|
79560779|NCT05290935|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
79560780|NCT05290922|Diagnostic Test|DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.
79723574|NCT01038609|Drug|Morphine Extended Release|
79723575|NCT01038609|Drug|Placebo|
79723576|NCT02803879|Device|Cardiogoniometry|
79723577|NCT02800759|Dietary Supplement|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
79723578|NCT02800759|Dietary Supplement|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
79723579|NCT02800759|Dietary Supplement|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
79723580|NCT02800759|Dietary Supplement|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
79857931|NCT06270537|Device|Stent-Graft Dominus® Endoprosthesis|Placement of the Dominus® Stent-Graft for endovascular repair of diseases of the Thoracic Aorta
79308697|NCT03037047|Drug|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
79723581|NCT02857582|Biological|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
79723582|NCT02857582|Drug|Vancomycin|Active comparator to treatment with ACHIM
79723583|NCT02857582|Drug|Metronidazole|Primary treatment for C diff in all treatment arms
79857932|NCT06270524|Procedure|Blood sampling|Blood sampling will be taken for further analysis
79857933|NCT06270511|Drug|S-337395|Administered as an oral suspension.
79857934|NCT06270511|Drug|Placebo|Administered as an oral suspension.
80020432|NCT03516422|Procedure|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
79857935|NCT06270498|Dietary Supplement|Sucrosomial iron|"Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 12 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-15 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 12 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 12 weeks"
80020433|NCT03516422|Other|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
80020434|NCT02293148|Drug|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
79560781|NCT05290909|Other|The protocol of blended and problem-based learning|The protocol of blended and problem-based learnin: The online platforms used in this research are the school's iLMS platform, online digital learning, and online opinion exchange platform. It will use online resources (Google, open educational resources, YouTube copyrighted medical micro-movies, and audio-visual materials), and the theme will be elderly care or emerging Multimedia resources on infectious themes, as well as real-time interaction with kahoot or Slido electronic whiteboards, will be uploaded to the office3655The One website. Drive is provided by the school (the school account is used to store course resources) and the system of digital theoretical course concepts in advance. Broadcasting, video (such as: values and conflicts; ethics and morality; patient rights and responsibilities; nurses' rights and responsibilities; ethical theory; basic ethical principles; ethical dilemmas and ethical decision-making; etc.), pre-recorded and stored on the Internet Road platform iLMS.
79857936|NCT06270498|Other|Placebo|"Placebo pills will be identical in shape, form and color of SI pills; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin D.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm."
79560782|NCT05290909|Other|The traditional problem-oriented teaching model|The traditional problem-oriented teaching model: There will be two PBL case introductions throughout the semester, with face-to-face teaching in physical classrooms.
79560783|NCT05290896|Device|Phacoemulsification|Phacoemulsification for senile cataract.
79857937|NCT06270485|Procedure|PEEP|Application of different PEEP-Levels during invasive mechanical ventilation
79260845|NCT03207165|Drug|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min [stage 1] and will be titrated according to a blinded protocol from stages 2 to 5 [5.0, 7.5, 10 and >10 ug/kg/min]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be [increased/decreased/maintained] at stage [1-5]' so as to ensure that treating physicians remain blinded to the allocated drug.
79260846|NCT03543475|Device|arabin pessary|arabin pessary: silicon device
79260847|NCT03543475|Device|no pessary|control group
79260848|NCT03744481|Other|Questionaire|"Evaluation of psychomotor development in children with mild EAI without indication of therapeutic hypothermia.~Precise analysis of the type (motor, sensory, language, epilepsy) and the severity of sequelae by sending a questionnaire to parents.~Investigation of early, clinical and paraclinical prognostic factors of good or bad neurodevelopmental outcome.~Evaluation of the height-weight growth and the cranial perimeter"
79260849|NCT02142205|Biological|BG00002|IV Infusion
79260850|NCT03209427|Drug|Morphine 100 μg|Intrathecal injection of morphine100 μg
79260851|NCT03209427|Drug|Morphine 200 μg|Intrathecal injection of morphine 200 μg
79560784|NCT05290831|Device|VitalPatch|The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
79560785|NCT05290649|Diagnostic Test|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
79723584|NCT04301973|Other|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
79723585|NCT02803801|Behavioral|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
79723586|NCT04301895|Behavioral|Continuous conversational interaction|Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
79723587|NCT04301895|Drug|Remifentanil infusion|10 minute remifentanil infusion
79723588|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow oxygen
79723589|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow air
79723590|NCT02357134|Other|Quality-of-Life Assessment|Ancillary studies
79723591|NCT02357134|Other|Questionnaire Administration|Ancillary studies
79723592|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow oxygen
80020435|NCT02293148|Drug|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
80020436|NCT02293148|Drug|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
80020437|NCT02293148|Drug|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
80020438|NCT02293148|Drug|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
79723593|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow air
80020439|NCT05283447|Other|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
79260852|NCT02311894|Drug|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus [+]/minus [-]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
79560786|NCT05290636|Other|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
79560787|NCT05290571|Other|Modified Otago Exercise Program with music|Our study attempts to establish a new home-based exercise option incorporating mOEP with video, music and lyrics. Our new approach shares the same aims with Exergames and video-supported methods - to increase the exercise motivation of elderlies, hence their physical performance. Based on the video-supported approach in one previous study, we add in the component of music therapy. Music-based exercise interventions could produce positive outcomes on both physical, such as gait, balance and fall risk and level of physical activities and psychological, including exercise adherence, perceived exertion, thus extending exercise duration. However, exact mechanisms have not been revealed and it may be limited by personal preferences on music. In our video, the music we chose is of brisk rhythm, slightly delightful melody and higher pitch, which all help to shape a cheerful and relaxing atmosphere for the elderlies.
79723594|NCT04200781|Drug|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
79723595|NCT04200781|Drug|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
79560788|NCT05290571|Other|Modified Otago Exercise Program|Otago Exercise Program (OEP) was developed by Otago Medical School in New Zealand as a tailor-made home-based fall prevention program to improve the balance performance of community-dwelling elderlies over 1 year. It comprises of 3 main components: 5 lower limb strengthening, 12 balance retraining and walking exercises. In the original program, the intensity was set as moderate with up to 4 difficulty levels for strengthening and balance exercises, in terms of ankle cuff weights and number of repetitions, and level of support respectively. It also stated that the frequency was at least 3 times a week for the former two exercises and at least 2 times per week for walking exercises; while the total duration was expected to make up to an hour, including 30-minute walking exercises.
79723596|NCT04302675|Behavioral|Prevention, Maternal Immunization|"This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study."
79723597|NCT02806765|Dietary Supplement|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol every day for 6 months
79723598|NCT02806765|Other|Control|Placebo in Softgel form
79260853|NCT03544723|Drug|Ad-p53|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
79260854|NCT03209661|Drug|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
79723599|NCT02853526|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
79723600|NCT02853526|Drug|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
79723601|NCT02853526|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
79260855|NCT03209661|Drug|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
79560789|NCT05290545|Other|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10^8 total nucleated cells/kg recipient ideal body weight.
79723602|NCT02853526|Drug|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
80020440|NCT05283447|Other|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
80020441|NCT02300090|Device|Test Group|Patients receive a mobile phone with the Me & My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
80020442|NCT02300090|Other|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
80020443|NCT03643887|Drug|FMT Capsule DE|30 capsule one-time oral dose
80020444|NCT03643887|Drug|Placebo oral capsule|30 capsule one-time oral dose
80020445|NCT03640923|Other|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
80020446|NCT03519152|Drug|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
80020447|NCT03516344|Procedure|Liver pumping and Spinal manipulation|Interventions are described in group descriptions
80020448|NCT02300168|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
80020449|NCT02959983|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
80020450|NCT02959983|Drug|Placebo|Placebo matching eluxadoline oral tablets BID with food.
79260856|NCT03209661|Drug|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
80020451|NCT02293226|Device|CoopDech|Video-laryngoscopy 1
80020452|NCT02293226|Device|CoPilot|video-laryngoscopy 2
79560790|NCT05290545|Other|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10^8 nucleated cells/kg and 0.15×10^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
79560791|NCT05290545|Other|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
79398172|NCT05246553|Procedure|Electrical stimulation of the auditory system|A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
79560792|NCT05290532|Other|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
79260857|NCT02142439|Behavioral|Strength training|Three times per week with strength training
79560793|NCT05290519|Other|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
79723603|NCT04200469|Diagnostic Test|Quantitative Flow Ratio (QFR) measurement|Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
79723604|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
79723605|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
79857938|NCT06270472|Procedure|hernioplasty|"The polysome repair was carried out as described by pelisse . In the case of a lateral hernia, the spermatic cord was mobilised and the cremasteric fibers were separated (in men). The hernia sac was dissected from the cord structures and reduced in the preperitoneal space through the internal ring. A dissection gauze was inserted through the internal ring to create the preperitoneal space. The medial border of the internal ring and the epigastric vessels were lifted with a refractor and blunt digital dissection was carried out in the preperitoneal space in all directions. A pocket was created to allow a complete expansion of the mesh. The conventional mesh was introduced with blunt forceps and, after the gauze has been removed, positioned in the preperitoneal space .~In the case of a medial hernia, the preperitoneal space was reached by incising the transversalis fascia around the base of the sac. Completion of the repair is the same as the lateral hernia procedure."
79857939|NCT06270459|Device|HMAN Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
80020453|NCT02293226|Device|Intubrite|Video-laryngoscopy 3
80020454|NCT02293226|Device|Vividtrack|video-laryngoscopy 4
80020455|NCT03513146|Procedure|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
80020456|NCT03518996|Device|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
80020457|NCT03518996|Device|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
80020458|NCT01344447|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
80020459|NCT03516188|Drug|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
79260858|NCT03209037|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
79260859|NCT02142517|Procedure|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
79560794|NCT05290506|Drug|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
79560795|NCT05290480|Other|expiratory muscle training|participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
80020460|NCT03516188|Drug|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
79260860|NCT02142517|Procedure|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
79560796|NCT05290480|Device|Insentive spirometry|participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
79560797|NCT05290441|Procedure|None involvement|No EGFR involvement
79560798|NCT05290428|Diagnostic Test|DNA methylation testing|All cervical cytology samples will be tested for PAX1 and JAM3 methylation
79260861|NCT03209115|Drug|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
79260862|NCT03209115|Drug|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
79260863|NCT03209193|Drug|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
79560799|NCT05290415|Diagnostic Test|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
79560800|NCT05290376|Procedure|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
79560801|NCT05290376|Device|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
79560802|NCT05290337|Drug|zanubrutinib|BTK inhibitor
79723606|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
79857940|NCT06270446|Other|Community based physiotherapy|Physiotherapy at community rehabilitation center
79260864|NCT03209193|Drug|Desflurane|Desflurane use as main anesthetic drug during the surgery
79857941|NCT06270446|Other|Outpatient physiotherapy|Physiotherapy at hospital
79260865|NCT02142595|Drug|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
79260866|NCT02142595|Drug|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
79260867|NCT02310646|Drug|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
79260868|NCT02310646|Drug|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
79260869|NCT03209271|Drug|Ringer's Acetate (warm)|Body temperature fluid
79260870|NCT03209271|Drug|Ringer's Acetate (cold)|Room temperature fluid
79560803|NCT05290324|Drug|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
79560804|NCT05290311|Behavioral|cognitive behavioural therapy|Cognitive behavioural therapy (CBT) was given according to the protocol of Safren (2004, 2005). Each participant followed one session of 60 minutes per week, for 10 to 16 weeks. Psychotherapists giving CBT had at least a master diploma.
79723607|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
79723608|NCT03898531|Procedure|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
79857942|NCT06270433|Drug|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
79857943|NCT06270433|Drug|Desvenlafaxine succinate sustained-release tablets|50 mg orally once daily dosing for 8 weeks
79857944|NCT06270420|Device|Technological Motor Rehabilitation|Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
79857945|NCT06270407|Drug|Tranexamic Acid 100 MG/ML|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
80020461|NCT03513068|Device|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
79560805|NCT05290298|Dietary Supplement|NITRATE|Multi-component nutritional formula
79560806|NCT05290298|Dietary Supplement|PLACEBO|Placebo
79560807|NCT05290272|Device|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
79857946|NCT06270407|Drug|0.9%sodium chloride|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
79260871|NCT02450721|Other|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
79560808|NCT05290051|Genetic|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
79857947|NCT06270394|Drug|68Ga-Fibroblast activation protein inhibitor|Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
79857948|NCT06270381|Other|EMPOWER|The EMPOWER intervention (Enhancing and Mobilizing the POtential for Wellness and Emotional Resilience) is a cognitive-behavioral and acceptance-based intervention divided into six modules.In the current application, this intervention is conducted in 6 in-presence or online 50-minute sessions and 2 booster sessions 2 and 4 weeks after the final intervention. It is a manualized treatment in which each session has a specific goal: 1st) Welcome, initial assessment and adherence to the intervention; 2nd) Psychoeducation and transmission of resources for stabilization; 3rd) Psychoeducation on Trauma, Grief and Cognitive-Behavioral Model; 4th)Promoting Experiential Acceptance; 5th) Imagined dialogue; 6th) Coping Training; and two final boosting sessions. In every session, the impact of the previous consultation and evolution is evaluated. This intervention was developed by Lichtenthal et al., 2022.
79560809|NCT05290051|Genetic|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
79560810|NCT05290012|Other|Dark Chocolate|A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
79560811|NCT05289921|Biological|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
79560812|NCT05289895|Other|No intervention|This study was an observational trial without any intervention
79560813|NCT05289843|Other|Rosmarinus Officinallis|Root canal Irrigants
80020462|NCT03516110|Other|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
79723609|NCT03898531|Procedure|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
79260872|NCT04898374|Drug|Gemcitabin/cisplatin|chemotherapy combination
79398173|NCT05246553|Diagnostic Test|Bilateral vestibulopathy Patients (BV)|Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
79723610|NCT03898531|Procedure|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
79723611|NCT02806531|Biological|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
79723612|NCT00630682|Drug|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
79723613|NCT00630682|Drug|Placebo|9 weeks of placebo 60mg capsules QD.
79398174|NCT05246553|Diagnostic Test|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
79398175|NCT01447433|Drug|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
79398176|NCT01447433|Behavioral|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
79398177|NCT03624699|Device|Glaukos iStent inject®|iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
79398178|NCT05363085|Other|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
79398179|NCT05246475|Diagnostic Test|PET-MRI|Simultaneous PET-MRI measurement
79398180|NCT01446965|Device|wearable defibrillator|LifeVest wearable defibrillator
79398181|NCT03578211|Behavioral|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
79398182|NCT01798875|Drug|oral metformin|
79398183|NCT01798875|Drug|oral contraceptive|
79398184|NCT05362851|Drug|YYC301-1 & YYC301-2 & YYC301-3|"YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day"
79398185|NCT05362851|Drug|YYC301 placebo & Celecoxib 200mg|comparator medication
79398186|NCT04408235|Drug|Enoxaparin|Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
79560814|NCT05293028|Drug|F527|0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
79560815|NCT05293015|Other|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
79560816|NCT05292924|Procedure|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
79260873|NCT03230409|Behavioral|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents >12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
79560817|NCT05292885|Diagnostic Test|Gadopentetate Dimeglumine Injection|Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).
80020463|NCT02293304|Other|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
80020464|NCT02293304|Other|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
80020465|NCT03621267|Other|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
79560818|NCT05292742|Drug|Pyrotinib+Trastuzumab+Capecitabine|Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
79398187|NCT03539133|Other|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
79398188|NCT05362617|Drug|FOLFIRI|FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
79560819|NCT05292742|Drug|Trastuzumab+Pertuzumab/Trastuzumab|Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
79560820|NCT05292677|Drug|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
79560821|NCT05292677|Drug|Placebo|2 mL of Normal Saline
79560822|NCT05292573|Drug|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
79560823|NCT05292495|Drug|HR17031 injection|HR17031 injection; administered subcutaneously.
79560824|NCT05292430|Other|Specimen Collection|collection of diseased and non-diseased tissue, blood, and other body fluids
79398189|NCT01446809|Drug|Doxorubicin Hydrochloride|Given IV
79398190|NCT01446809|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
79398191|NCT01446809|Drug|Ifosfamide|Given IV
79560825|NCT05292170|Other|Heat acclimation|10 consecutive days of heat acclimation
79560826|NCT05292157|Procedure|shoulder arthroplasty|range of motion (in degrees) measured in annual postoperative follow-up
79723614|NCT04236193|Diagnostic Test|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
79723615|NCT00745420|Biological|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~Fludarabine: 30 mg/m^2/day IV on Days -8 through -4~Melphalan: 140 mg/m^2 IV on Day -3~Rest on Days -2 and -1~Transplant occurs on Day 0~GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
79398192|NCT01446809|Other|Laboratory Biomarker Analysis|Correlative studies
79398193|NCT01446809|Drug|Pazopanib Hydrochloride|Given PO
79398194|NCT01446809|Other|Pharmacological Study|Correlative studies
79398195|NCT01446809|Other|Placebo|Given PO
79398196|NCT01446809|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79398197|NCT05246397|Drug|Sugammadex administration|Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
79398198|NCT05362539|Procedure|Cystoscopy|diagnostic cystoscopy for detection of any bladder lesions
79560827|NCT05292027|Radiation|low-dose radiotherapy|On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
79560828|NCT05291962|Other|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
79560829|NCT05291910|Drug|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
79560830|NCT05291910|Drug|Toripalimab|240mg intravenously every 3 weeks
79560831|NCT05291910|Drug|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
79857949|NCT06270381|Other|Treatment as usual (TAU)|The treatment as usual (TAU) consists of supportive psychotherapy based on a non-structured and integrative method that focuses on the development of more adaptive coping strategies, understanding and working on the patient's internal models of self, others, and the world. The TAU will be considered during the same period as the EMPOWER intervention.
79260874|NCT03230409|Behavioral|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
79260875|NCT03230409|Biological|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
79260876|NCT03230409|Behavioral|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
79560832|NCT05291793|Drug|Tenoxicam 20 Mg Powder for Solution for Injection Vial|Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
79560833|NCT05291793|Drug|Methylprednisolone|Methylprednisolone 40 Mg (suspension) administered intraarticularly
79560834|NCT05291793|Drug|Saline|2ml sterile saline administered intraarticularly
79723616|NCT02800681|Other|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
79723617|NCT02800681|Other|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
79723618|NCT02800681|Other|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
79723619|NCT02800681|Other|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
79723620|NCT02806609|Other|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
80020466|NCT03621267|Other|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
79260877|NCT03230253|Behavioral|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
79560835|NCT05291780|Radiation|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
79723621|NCT02806609|Other|immersion in water at room temperature|immersion in water at room temperature
79398199|NCT05362539|Diagnostic Test|Computed tomography|Computed tomography for patients to exclude bladder lesions
79398200|NCT05362539|Genetic|DNA hypermethylation assay|DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
79398201|NCT05362539|Diagnostic Test|Urine cytology|voided urine cytology for all patients
79398202|NCT05246319|Diagnostic Test|preoperative imaging|evaluation of preoperative imaging (versus nodes observed on pathology)
79398203|NCT01446419|Device|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
79398204|NCT01446419|Device|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
79560836|NCT05291702|Procedure|PCNL|Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
79560837|NCT05295134|Dietary Supplement|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
79260878|NCT03230253|Behavioral|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
79260879|NCT03230253|Behavioral|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
79260880|NCT03207321|Dietary Supplement|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
79260881|NCT02375698|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
79398205|NCT03353961|Behavioral|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
79398206|NCT03353961|Behavioral|Treatment as usual|Treatment as usual as provided in the community.
79560838|NCT05295134|Dietary Supplement|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
79560839|NCT05295134|Dietary Supplement|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
79560840|NCT05295134|Dietary Supplement|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
79560841|NCT05295069|Behavioral|A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.|Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
79857951|NCT06270342|Other|dual task assessment|The Minnesota Manual Dexterity Test was used to evaluate the upper extremity function of the participants in single and dual task conditions, and the Dual Task Questionnaire was used to evaluate the difficulties experienced during dual tasks. In the dual-task turning test, in addition to the single-task turning test, they were given a cognitive task, the task of counting the months of the year backwards from December to January. The dual-task turning test was continued by changing hands at the end of each turn until the last disk was turned. Meanwhile, verbal fluency and hand errors made while spinning the disc were recorded.
79857952|NCT06270329|Other|Neuromuscular training program|"Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase"
79857953|NCT06270329|Other|conventional physical therapy program|Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
80020467|NCT03512990|Procedure|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
79398207|NCT01736631|Behavioral|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark & Wells (Clark & Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
79398208|NCT04387929|Diagnostic Test|Detection of anti-COVID-19 antibody level|Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
79560842|NCT05294926|Drug|Rocuronium|After applying standard monitoring of pulse oximetry, ECG, noninvasive blood pressure, general anesthesia will be induced with fentanyl 1 µg/kg and propofol 2-3 mg/kg and Rocuronium 0.6 mg/kg will be administered for muscle relaxation after loss of consciousness, under the guidance of neuromuscular blockade monitoring. Tracheal intubation will be performed at a train-of-four count of 0. After that end-tidal carbon dioxide and temperature will be continuously monitored during the procedure. Mechanical ventilation will be instituted with o2:air of 4 L/min, tidal volume of 6-8 ml/kg and respiratory rate appropriate to achieving end-tidal carbon dioxide of 30-35 mmHg. no positive end-expiratory pressure; and inspiratory/expiratory ratio 1: 2. The patient's position will then be changed from supine to prone. Ephedrine 4 mg (if mean arterial pressure < 60 mmHg and heart rate < 40 bpm), or atropine 0.5 to 1.0 mg (if heart rate < 40 bpm) are used to prevent hypotension or bradycardia
79723622|NCT02806609|Other|active recovery - running|active recovery
79723623|NCT02806609|Other|rest in the chair|rest in the chair
79723624|NCT02857348|Behavioral|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
80020468|NCT05212935|Biological|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
80020469|NCT03642093|Combination Product|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
79260882|NCT02375698|Biological|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
79260883|NCT03207477|Diagnostic Test|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
79581152|NCT01933308|Other|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
79260884|NCT02374918|Device|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
79260885|NCT02374918|Device|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
79260886|NCT02374918|Device|HC wavelength-1 bright light|30 minutes of light exposure
79260887|NCT02374918|Device|HC wavelength-2 bright light|30 minutes of light exposure
79260888|NCT03206697|Other|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
79398209|NCT05361681|Other|Electromagnetic Field Exposure|All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
79723625|NCT02857348|Behavioral|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
79723626|NCT05095870|Other|No intervention|Pure observational study
79723627|NCT04269460|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]|preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
79723628|NCT04236037|Procedure|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
79723629|NCT04236037|Procedure|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
79723630|NCT04236115|Drug|Articaine 4%|Articaine 4% is dental local anaesthetic agent
79723631|NCT04236115|Drug|Prilocain 3%|prilocaine is dental local anaesthetic agent
79723632|NCT04236115|Drug|Adrenalin|adrenaline is a vasoconstrictor
79723633|NCT04236115|Drug|Felypressin|Felypressin is a vasoconstrictor
79723634|NCT02853370|Drug|Bendamustine and Rituximab|
79398210|NCT05361291|Drug|Lidocaine Hydrochloride|Inferior alveolar nerve block
79398211|NCT01445951|Drug|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
79398212|NCT01445951|Drug|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
79723635|NCT04044625|Device|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
80020470|NCT03642093|Behavioral|Physical Activity Intervention|Walking and Inspiratory Muscle Training
80020471|NCT02296268|Behavioral|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
79398213|NCT01445951|Drug|Insulin Aspart in combination with a basal insulin|Injectable insulin
80020472|NCT03512912|Device|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
79398214|NCT05355285|Procedure|Glucose Clamp|Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
79398215|NCT05245929|Device|Distalization|Distalizing the posterior maxillary segment
79398216|NCT05354973|Device|Consilium CareTM|This is an observational study using the Consilium CareTM smartphone ePRO application.
79560843|NCT05294926|Device|nerve stimulator|Neuromuscular blockade monitoring will be established and continuously monitored after induction using the Train Of Four (TOF) at the adductor pollicis muscle on the opposite hand and wrist to radial artery cannulation. Two surface electrocardiography electrodes will be placed on cleaned skin overlying the ulnar nerve, with one electrode positioned on the ulnar side of the flexor carpi radialis tendon and the other positioned 3cm proximal to the first. The transducer is then positioned with the flat side against the thumb. Supramaximal stimuli will be applied after autonomic calibration of acceleromyograph after an initial tetanic stimulus. After confirming a train-of-four ratio of 95 to 105%, neuromuscular blockade monitoring will start. The train-of-four mode of supramaximal stimulation (0.2 ms duration, frequency 2 Hz, two s duration) will be applied at 15 s intervals, which last until the end of anaesthesia.
79560844|NCT05294913|Behavioral|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
79723636|NCT04044625|Device|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
79398217|NCT03187743|Other|Blood samples|"Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
79723637|NCT02806219|Device|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
79857954|NCT06270316|Drug|AMT-191|"A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with FD."
79857955|NCT06270303|Procedure|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
79398218|NCT03169101|Drug|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
79857956|NCT06270303|Procedure|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
79857957|NCT06270290|Other|Exposure to contact sports or history of concussions|History of contact sports practices or of concussions
79857958|NCT06270264|Device|the Nociception level index monitoring|Nociception level index (NOL) monitoring (Medasense) is a non- invasive device differentiated from its alternatives by the use of five parameters: heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives.
79398219|NCT03169101|Behavioral|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
79857959|NCT06270251|Behavioral|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
79857960|NCT06270238|Device|Group 1-1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
80020473|NCT03512834|Drug|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
80020474|NCT03512834|Drug|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
79398220|NCT03130023|Device|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
79398221|NCT05344287|Other|Typical American Diet|Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
79398222|NCT05344287|Other|Plant-Based Diet|Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
79398223|NCT00513435|Drug|saracatinib|Given PO
79398224|NCT00513435|Other|laboratory biomarker analysis|Correlative studies
79560845|NCT05294913|Behavioral|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
79560846|NCT05294887|Drug|Bisoprolol|beta-adrenergic receptor blocker
79560847|NCT05294887|Drug|Diltiazem|calcium channel blocker
79560848|NCT05294887|Drug|Placebo|Placebo
79723638|NCT02806219|Device|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
79723639|NCT05491837|Other|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
79723640|NCT05491837|Other|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
79723641|NCT00954538|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
79398225|NCT03064737|Other|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use."
79260889|NCT03119337|Other|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
79723642|NCT02690155|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
79560849|NCT05294874|Other|gait training|walking forward, sideway and backward walking on balance board
79723643|NCT02690155|Drug|VKA (Vitamin K antagonist)|As prescribed by treating physicians
79560850|NCT05294861|Other|YesMdiet|In the YesMdiet, participants will consume Milk and Dairy products
79723644|NCT00630760|Drug|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
79723645|NCT02806375|Procedure|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
79723646|NCT02806375|Drug|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
79723647|NCT02806375|Drug|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
79857961|NCT06270238|Device|Group 1-2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
79857962|NCT06270238|Device|Group 2-1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
79857963|NCT06270238|Device|Group 2-2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
79857964|NCT06270238|Device|Group 3-1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
79398226|NCT03035097|Other|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
79560851|NCT05294861|Other|NoMdiet|In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
79398227|NCT05263791|Device|Airmod|Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
79560852|NCT05294822|Procedure|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
79560853|NCT05294783|Procedure|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
79560854|NCT05294744|Drug|N-acetylcysteine|"Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h."
79560855|NCT05294666|Drug|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
79723648|NCT02806375|Drug|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
79723649|NCT02806375|Drug|Ruxolitinib|Days -8 through -2 15 mg tid
79723650|NCT02806375|Drug|Ruxolitinib|Days +5 through +100: 7.5 mg bid
79723651|NCT02856256|Dietary Supplement|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
79723652|NCT02803489|Device|medical device intervention|
79723653|NCT02800603|Behavioral|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
79723654|NCT04269148|Other|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
80020475|NCT03642015|Behavioral|Music listening|listening the music 15 min
80020476|NCT03516032|Behavioral|exercises|
80020477|NCT03641781|Other|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
80020478|NCT03518762|Procedure|Sustained lung inflation (SLI)|SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
79560856|NCT05294666|Drug|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
79560857|NCT05294601|Other|High-Intensity Interval Training|high intensity exercise with games
79560858|NCT05294601|Other|Medium-Intensity Interval Training|medium intensity exercise with games
79723655|NCT04269226|Procedure|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
79723656|NCT04269226|Procedure|No recruitment maneuver|Usual ventilation procedures will be applied.
80020479|NCT03518762|Procedure|Continuous positive airway pressure (CPAP)|CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
80020480|NCT03641625|Device|Muscular tissue oxygen saturation guided care|Muscular tissue oxygen saturation monitored at flank and arm will be maintained > 70% (absolute measurement) and > baseline throughout the entire procedure.
80020481|NCT03518684|Drug|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
80020482|NCT05164640|Other|not required|This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
79260890|NCT02450643|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
79560859|NCT05294536|Drug|Liraglutide injection,RD12014|single dose, s.c. injection
79560860|NCT05294536|Drug|Liraglutide injection,Victoza|single dose, s.c. injection
79560861|NCT05294497|Other|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
79560862|NCT05294497|Other|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
79560863|NCT05294497|Other|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
79723657|NCT02803567|Behavioral|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
79260891|NCT02450643|Other|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
79260892|NCT03208881|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
80020483|NCT05201690|Drug|VV116 200 mg Group|Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
80020484|NCT05201690|Drug|VV116 400mg Group|Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
79260893|NCT02344576|Behavioral|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
79260894|NCT02452515|Drug|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
80020485|NCT05201690|Drug|VV116 600mg Group|Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
80020486|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
80020487|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
80020488|NCT01067859|Drug|Placebo|Infusion of placebo during 48 hours
79560864|NCT05294497|Other|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
79560865|NCT05294497|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
79560866|NCT05294497|Other|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
79560867|NCT05294484|Drug|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
79560868|NCT05294445|Procedure|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
79560869|NCT05294406|Drug|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
79723658|NCT04273984|Drug|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
79723659|NCT02806297|Procedure|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
80020489|NCT02296658|Radiation|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
80020490|NCT02296658|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
80020491|NCT03640689|Device|Endovenous ablation + iliac US +/- iliac stenting|Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
79723660|NCT02806297|Procedure|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
79723661|NCT02857504|Device|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
79723662|NCT02857504|Device|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
79723663|NCT02806453|Dietary Supplement|thickened formula|
79723664|NCT02806453|Dietary Supplement|Mg alginate|
80020492|NCT03640689|Device|Endovenous ablation of Great Saphenous Vein|Ablation of the Great Saphenous Vein and subsequent Graduated Compression
79260895|NCT02452515|Drug|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
79260896|NCT02452515|Drug|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
79723665|NCT02806453|Behavioral|reassurance with lifestyle changes|
79723666|NCT04235803|Other|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
79723667|NCT00943852|Drug|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
80020493|NCT02300246|Procedure|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
80020494|NCT03619239|Drug|GX-I7|During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
80020495|NCT02296736|Radiation|Computerised tomography (CT) scan|Retrospective review of CT scans
80020496|NCT03515954|Procedure|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
80020497|NCT02293616|Dietary Supplement|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
80020498|NCT02293616|Dietary Supplement|Placebo|
79260897|NCT02452515|Drug|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
79260898|NCT02452515|Drug|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
79260899|NCT03206931|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
79260900|NCT03208647|Other|AA or not|to study their risk factors
79560870|NCT05294393|Drug|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
79560871|NCT05294393|Drug|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
79560872|NCT05294393|Drug|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
79560873|NCT05294315|Procedure|Bi-level erector spinae block|erector spinae block at 4th and 6th transverse process
79560874|NCT05294315|Procedure|Single level erector spinae block|erector spinae block at 4th transverse process
79560875|NCT05294198|Dietary Supplement|Beetroot extract|Beetroot extract capsule
79560876|NCT05294094|Behavioral|blended learning|The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.
79723668|NCT00943852|Drug|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
79723669|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
79723670|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
79723671|NCT00943852|Drug|Comparator: Placebo|Single dose placebo only in one of five treatment periods
79723672|NCT02803645|Biological|blood sample|
79723673|NCT02853136|Drug|Fluvoxamine|single dose
79723674|NCT02853136|Drug|BI 409306|low single dose
79723675|NCT02853136|Drug|BI 409306|medium or high dose
80020499|NCT03640221|Drug|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
79560877|NCT05294094|Behavioral|teaching format as usual|The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
79560878|NCT05293990|Radiation|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
79560879|NCT05293977|Behavioral|Routine care by the dispensing pharmacist|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
79581153|NCT01933321|Biological|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
79723676|NCT02800369|Biological|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
79723677|NCT02803723|Procedure|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
79723678|NCT02803723|Procedure|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
79723679|NCT02803255|Device|MAHI Exo-II|
79723680|NCT02803099|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number-SR15-63-Z13-084).
79857965|NCT06270238|Device|Group 3-2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
79857966|NCT06270225|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
79857967|NCT06270225|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
79857968|NCT06270225|Drug|Colchicine 0.5 mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
79857969|NCT06270212|Device|STAIRWAY|Evaluation of STAIRWAY (new airway device) during sedation.
79857970|NCT06270212|Device|NO DEVICE|Evaluation of NO DEVICE during sedation
79857971|NCT06270199|Biological|Control|Standard treatment
79857972|NCT06270199|Biological|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|3 doses of 5 million MSC will be administered
79857973|NCT06270199|Biological|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|6 doses of 5 million MSC will be administered
79260901|NCT03206775|Behavioral|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~Visual Sweeps~Sustained Visual Attention~Associative Learning--Visual~Associative Learning--Auditory~Emotion Motion~Voice Choice"
79260902|NCT03206775|Behavioral|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~On trails: Learning~Line Length Discrimination~Tap the Emotion~Sound Sweeps~BIS/BAS~TEPS~Feasibility survey"
79723681|NCT02803177|Biological|BMC2012|
79723682|NCT02803177|Device|beta-TCP Chronos® Synthes|
79723683|NCT04236661|Device|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
79260903|NCT03206775|Behavioral|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~Visual Time Order Judgment~Target Tracker~Emotional Face~Auditory Sound Discrimination~BIS/BAS~TEPS~Feasiblity assessment"
79723684|NCT02806141|Drug|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
79723685|NCT02806141|Drug|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
79723686|NCT02805985|Device|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
79723687|NCT02806063|Procedure|intraoperative samples|
80020500|NCT03640221|Drug|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
79723688|NCT02805751|Device|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
79723689|NCT02805751|Other|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
79723690|NCT02805751|Other|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
79857974|NCT06270186|Diagnostic Test|Type 1 myotonic dystrophy|"To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients"
79260904|NCT03206775|Behavioral|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~Stroop 2AFC~Visual Task Switcher~Beep Seeker~Voice Choice~BIS/BAS~TEPS~Feasibility Survey"
80020501|NCT03640221|Device|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are <10% and < 5%, respectively."
79260905|NCT02344342|Device|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
79560880|NCT05293977|Behavioral|Pharmaceutical education/counseling about prescribed antibiotic|Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
79560881|NCT05293899|Diagnostic Test|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
79560882|NCT05293873|Biological|autologous bone marrow-derived mononuclear cell transplantation|Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation
79560883|NCT05293873|Other|Rehabilitation therapy|Rehabilitation therapy
79560884|NCT05293795|Behavioral|3D printed model|Mother is given 3D printed model of fetus' face
79560885|NCT05293795|Behavioral|Placebo|Mother is given a picture of 3D ultrasound of fetus
79560886|NCT05293704|Drug|Mizoribine|Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight & gt At 50 kg, the dosage was 100 mg each time.
79723691|NCT02803021|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - SR15-47-Z13-076)
79723692|NCT02802787|Other|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
79723693|NCT04235881|Behavioral|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
79723694|NCT04235881|Behavioral|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
79723695|NCT02805673|Procedure|Osteopathy|
79723696|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
79857975|NCT06270173|Device|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
79560887|NCT05293652|Other|Iontophoresis|Hydrocortisone iontophoresis
79857976|NCT06270160|Diagnostic Test|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
79260906|NCT02344342|Other|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
79723697|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
79723698|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
79723699|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
79723700|NCT00952276|Biological|Normal saline solution|0.5 mL, Intramuscular on Day 0
79723701|NCT02802709|Device|SB-061|delivered via intra-articular injection
79723702|NCT02802709|Other|Placebo|Placebo
79723703|NCT02805829|Drug|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
79260907|NCT02450565|Other|Questionnaire|
79260908|NCT02452437|Drug|Oxycodone|Controlled release oxycodone 40 mg twice daily
79308765|NCT04822779|Device|Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands|"Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
79560888|NCT05293652|Other|Phonophoresis|Hydrocortisone Phonophoresis
79560889|NCT05293652|Other|traditional PT program|Ultrasound and deep friction massage
79560890|NCT05293574|Drug|norethisterone acetate|Norethindrone, a progesterone agonist
79581154|NCT01933347|Drug|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
80020502|NCT03640221|Other|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
80020503|NCT03640221|Other|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
80020504|NCT03640221|Other|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
79723704|NCT02856178|Drug|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
79723705|NCT02856178|Drug|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
79723706|NCT02852980|Other|gestational diabetes women|No intervention.
79723707|NCT02800135|Drug|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
79723708|NCT02853058|Radiation|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
79723709|NCT02853058|Radiation|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
79723710|NCT00943384|Device|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
79723711|NCT04235647|Other|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
79723712|NCT04235647|Other|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
79260909|NCT03206619|Other|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
79560891|NCT05293301|Device|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
79723713|NCT02805205|Drug|PEG-rhG-CSF|
79723714|NCT02799979|Device|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
79723715|NCT02805439|Drug|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
79560892|NCT05293301|Device|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
79723716|NCT02805439|Drug|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
79723717|NCT02805439|Drug|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
79723718|NCT02802163|Drug|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
79723719|NCT02802163|Drug|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m^2 or 36 mg/m^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
79723720|NCT02802163|Drug|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
79560893|NCT05293275|Device|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
79560894|NCT05293262|Procedure|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
79560895|NCT05293119|Drug|JAK-2 inhibitor|In this trial, one group will receive the tofacitinib 5 mg twice daily
79398228|NCT05214339|Drug|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
80031640|NCT04896424|Procedure|cryoballoon-based pulmonary veins isolation|A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases < -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
79560896|NCT05293119|Drug|Topical corticosteroid|Mometasone furoate 0.1% ointment once daily
79560897|NCT05293054|Other|Application of autologous fibrin matrix (Obsidian)|"When the patient is anaesthetized, 120 ml venous blood is collected for preparation of the autologous fibrin matrix. The blood is processed in the Vivostat® unit for 30 minutes making a 5-6 ml concentrate ready for application by use of a specific endoscopic kit device.~When the rectal cancer resection is completed and the specimen is extracted, the Obsidian will be applied using minimal invasive technique and the endoscopic kit device.~Step 1: 1.5-2ml. Obsidian is applied onto the rectal stump, with the circular stapler device inserted into the rectal stump. The circular stapler is then closed, but not yet fired.~Step 2: 2.5-3ml Obsidian is applied 360 degrees around the anastomosis, while taking care not to increase tension on the anal intestine end. The circular stapler is then fired and removed. The water-air-leak test is performed according to standard clinical practice. Step 3: The remaining part of the Obsidian is then sealed 360 degrees around the anastomosis."
79560898|NCT05297006|Dietary Supplement|The infants who drank milk powder were given a dietary intervention four months before|The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients
79560899|NCT05296967|Behavioral|chewing|patients are asked to chew chewing gum X 3/ day
79560900|NCT05296863|Combination Product|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
79560901|NCT05296863|Combination Product|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
79560902|NCT05296863|Combination Product|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
79560903|NCT05296824|Procedure|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
79857977|NCT06270160|Device|mHealth|We are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
79398229|NCT03830463|Drug|CTP-692|Single oral dose
79560904|NCT05296811|Procedure|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
79560905|NCT05296499|Diagnostic Test|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing using cycle ergonomenter
79723721|NCT02802163|Drug|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
79723722|NCT02799511|Biological|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
79723723|NCT02802007|Device|Elipse Intragastric Balloon|
79723724|NCT02801773|Dietary Supplement|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
79723725|NCT02801773|Other|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
79857978|NCT06270160|Behavioral|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
79857979|NCT06270147|Drug|Bupivacaine-epinephrine|A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
79398230|NCT03830463|Drug|Placebo|Single oral dose
79560906|NCT05296499|Diagnostic Test|Exercise cardiac MRI|Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
79560907|NCT05296499|Other|6 minute walk test|6MWT
79560908|NCT05296499|Diagnostic Test|Blood tests|FBC, U&E, LFTS
79560909|NCT05296499|Other|Quality of life questionnaires|SF36, EQ5D, VEINES-QoL/Sym
79560910|NCT05296499|Other|Repeat baseline assessments|repeat baseline
79560911|NCT05296499|Diagnostic Test|MR venogram|MRI scan of venous system
79560912|NCT05296486|Procedure|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
79560913|NCT05296486|Procedure|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
79723726|NCT02802085|Device|VEGA Knee|TKA
79260910|NCT03229707|Device|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~Images are then opened into Photoshop.~The INFO panel must be open.~Click on the small eyedropper in the Info panel window and click on ''Lab Color.~Place the mouse over the center of the tooth to be measured for L value.~Click on the HSB Color option, which stands for hue, saturation, and brightness."
79560914|NCT05296486|Procedure|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
79560915|NCT05296486|Procedure|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
79560916|NCT05296369|Drug|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
79560917|NCT05296291|Device|High-translucent monolithic zirconia Bridge|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
79560918|NCT05296291|Device|Zirconium oxide ceramics Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
79723727|NCT02801851|Behavioral|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
79723728|NCT02801929|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - SR15-72_V27-010).
79723729|NCT02801461|Device|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
79723730|NCT00943306|Drug|lomitapide|5-60 mg po every day
79723731|NCT02805049|Drug|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
79723732|NCT02799589|Drug|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
79560919|NCT05296291|Device|Metal-ceramic Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
80020505|NCT03640221|Other|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
79560920|NCT05296200|Device|Hyperbuoyancy Floatation|Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
79560921|NCT05296174|Other|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
79560922|NCT05296174|Other|health education activities program|The control group was offered health education activities once a week.
79723733|NCT02799589|Drug|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
79723734|NCT02799589|Drug|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
79723735|NCT02801695|Drug|Citrulline|Citrulline supplementation
79723736|NCT02801695|Drug|Placebo|Placebo
79857980|NCT06270134|Other|Bicarbonate|Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
79560923|NCT05296044|Drug|JT-003|Subjects take the investigational products once a day for 24 weeks.
79560924|NCT05296044|Drug|JT-003 Placebo|Subjects take the investigational products once a day for 24 weeks.
79260911|NCT03229707|Device|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
79260912|NCT03230019|Procedure|chest tube|VATS with chest tube placement
79560925|NCT05296005|Drug|Capecitabine|Given PO
79723737|NCT02856100|Drug|18F DCFPyL- Radiopharmaceutical|
79723738|NCT02801539|Device|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
79723739|NCT02801539|Device|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
79723740|NCT04272970|Diagnostic Test|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
79723741|NCT02801383|Drug|Yallaferon®， the recombinant human interferon α-2b gel|
79723742|NCT02801383|Other|gel without active ingredient|
79857981|NCT06270121|Behavioral|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
80020506|NCT03640143|Other|venous blood lead|data about ve,nous blood lead
80020507|NCT02300324|Dietary Supplement|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
80020508|NCT02300324|Dietary Supplement|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
80020509|NCT02300324|Dietary Supplement|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
80020510|NCT03640767|Behavioral|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
79260913|NCT03230019|Procedure|two-lumen catheterization|VATS with two-lumen catheterization long the midclavicular line, second intercostal space
79260914|NCT03230019|Device|two-lumen catheter|central venous catheter(two-lumen 7-Fr-20cm)
79560926|NCT05296005|Drug|Docetaxel|Given IV
79260915|NCT03208491|Other|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
79260916|NCT03208491|Other|usual care|usual care of patient
79260917|NCT03208413|Drug|Thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
79560927|NCT05296005|Drug|Fluorouracil|Given IV
79560928|NCT05296005|Drug|Leucovorin|Given IV
79560929|NCT05296005|Drug|Oxaliplatin|Given IV
79560930|NCT05296005|Radiation|Radiation Therapy|Undergo radiotherapy
79560931|NCT05296005|Procedure|Surgical Procedure|Undergo surgical resection
79560932|NCT05295836|Other|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
79560933|NCT05295836|Dietary Supplement|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
79560934|NCT05295745|Behavioral|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
79560935|NCT05295719|Dietary Supplement|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
79560936|NCT05295719|Behavioral|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
79560937|NCT05295719|Dietary Supplement|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
79560938|NCT05295719|Behavioral|Flexibility training|30 min of stretching 3 days/week for 6 weeks
79560939|NCT05295680|Drug|Hymecromone|Hymecromone 400 mg 3 times daily by mouth.
79560940|NCT05295667|Diagnostic Test|Doppler measurement in combination with amniotic fluid volume|Ultrasonographic evaluation
79260918|NCT03206853|Procedure|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
79723743|NCT02799355|Drug|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
79857982|NCT06270108|Drug|Riluzole|50mg twice daily (100mg total daily) for 56 days.
80020511|NCT02300480|Procedure|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
80020512|NCT02300480|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
80020513|NCT03518528|Drug|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
80020514|NCT03518528|Drug|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
80020515|NCT03518450|Procedure|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
80020516|NCT03518450|Procedure|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
80020517|NCT03518450|Procedure|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
80020518|NCT01348425|Device|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
79723744|NCT02856022|Device|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
80020519|NCT01348425|Device|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
79560941|NCT05295576|Procedure|non surgical periodontal therapy|Scaling and root planing
79723745|NCT02856022|Procedure|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
79723746|NCT02801305|Drug|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
80020520|NCT02296814|Drug|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
80020521|NCT02296814|Drug|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
80020522|NCT03515798|Drug|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
80020523|NCT03515798|Drug|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
80020524|NCT03512600|Dietary Supplement|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
80020525|NCT03512600|Dietary Supplement|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
80031641|NCT03732339|Device|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
79398231|NCT02730507|Device|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
79560942|NCT05295563|Other|Evaluation|Gastrocnemius muscle morphology (cross-sectional area, muscle thickness, fascicle length, pennation angle), muscle stiffness, muscle vascularization and functionality of children with CP will be evaluated.
79560943|NCT05295381|Device|cough machine (CM)|Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
79560944|NCT05295381|Device|abdominal weight training (AWT)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
79560945|NCT05295329|Drug|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
79560946|NCT05295329|Drug|Placebo|use placebo
80031642|NCT03468842|Biological|Probiotic|Already described
80031643|NCT03468842|Biological|Placebo|Placebo
79560947|NCT05295316|Other|Life Stressor Checklist Revised (LSC-R) (Appendix 1)|Evaluation of stress factor as risk factor for fibromyalgia development
79581155|NCT01933360|Drug|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
79581156|NCT01933360|Drug|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
79581157|NCT01933360|Drug|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
79581158|NCT01933360|Drug|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
79581159|NCT01933360|Drug|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
79581160|NCT01933360|Drug|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
79581161|NCT01933360|Drug|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
79581162|NCT01933360|Drug|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
79581163|NCT01933373|Procedure|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
79581164|NCT01933373|Procedure|Dor|Anterior partial fundoplication plus myotomy.
79581165|NCT01933386|Device|SoundBite|Non-surgical removable bone conduction device via the teeth.
79581166|NCT01933412|Biological|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
79581167|NCT01933412|Biological|Engerix B Hepatitis B Vaccine|
79581168|NCT01933438|Other|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
79581169|NCT01933438|Other|Control|Standard treatment
79398232|NCT02730507|Device|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
79398233|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
80020526|NCT03512600|Dietary Supplement|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
79560948|NCT05295303|Device|Remote integrated post-MI management system|The home-based remote integrated post-MI management system comprises (1) a patch-based long-term Holter monitoring system HC3A250 (BISA Technologies (Hong Kong) Limited, Hong Kong SAR, China), (2) a handheld single-lead electrocardiogram (ECG) recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China), (3) a blood pressure monitor, (4) a patient-facing smartphone application specially designed for the study, and (5) a web-based clinical management system for clinicians
80020527|NCT03512600|Dietary Supplement|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
79260919|NCT03201471|Drug|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
79560949|NCT05294900|Drug|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~Paclitaxel 175mg/m2~Carboplatin AUC5"
79723747|NCT02801305|Drug|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
79723748|NCT02801305|Drug|Vaseline|This is used as the topical placebo agent.
79857983|NCT06270095|Diagnostic Test|Neurocognitive, neuromuscular and neurosensitive tests.|"At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated."
80020528|NCT03041701|Drug|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
80020529|NCT03041701|Drug|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
79260920|NCT03206385|Radiation|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
79560950|NCT05286398|Procedure|Palatoplasty|Surgical closure of palatal defect
80020530|NCT03041701|Drug|Ganitumab|Once every 2 weeks beginning on day 0.
80020531|NCT02296970|Procedure|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
79560951|NCT05286398|Diagnostic Test|Addition silicone impression|diagnostic impression for maxillary arch
79398234|NCT01444781|Biological|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
79398235|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
79398236|NCT05152641|Drug|BGE-117, 4mg|BGE-117, 4mg Capsules
79398237|NCT05152641|Dietary Supplement|Ferrous Sulfate|Ferrous Sulfate, 325mg Tablets
79581170|NCT01933451|Other|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
79581171|NCT01933490|Other|high carbohydrate test meal|
79260921|NCT03206385|Radiation|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
79581172|NCT01933490|Other|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
79723749|NCT02795845|Dietary Supplement|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
79723750|NCT02795845|Other|Placebo|capsule without active ingredient
79857984|NCT06270082|Drug|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
79260922|NCT03201237|Other|Action observation training|Each child observed a task video and then performed a task
79260923|NCT03206229|Drug|PEG-rhG-CSF|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
79260924|NCT03206229|Drug|Neulasta (PEG-rhG-CSF)|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
79723751|NCT00637975|Drug|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
79723752|NCT00637975|Drug|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
79723753|NCT02799433|Behavioral|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
79723754|NCT02799433|Behavioral|Usual services|Control condition
80020532|NCT04465058|Other|COVID19|viral infection
80020533|NCT03512522|Behavioral|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
80020534|NCT03512522|Behavioral|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
80020535|NCT04464902|Device|brace1|The brace1 can provide resistance when patients want to extend their knee.
80020536|NCT04464902|Device|brace2|The brace1 can't provide resistance when patients want to extend their knee.
79560952|NCT05281679|Other|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
79723755|NCT02801149|Procedure|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
79560953|NCT05281679|Other|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
79560954|NCT05276154|Other|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
79560955|NCT05275647|Drug|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
79560956|NCT05275647|Drug|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
79581173|NCT01933490|Other|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
79723756|NCT02801227|Drug|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
79857985|NCT06270069|Other|Excercise-based therapy|An individual 60-min motor training sessions twice a week for eight-week outpatient program, that included exercises aimed at improving postural control, strengthening and stabilizing the back muscles, and stretching
79857986|NCT06270056|Drug|Misoprostol|Self-administered misoprostol by clients obtaining medication abortion via telemedicine
79857987|NCT06270017|Drug|Chemotherapy drug|rsponse evaluation in zebrafish embryo model
79857988|NCT06270004|Other|nonsurgical periodontal therapy|sonic scaler for scaling and polishing. Graces curettes numbers(1-2,3-4,5-6,7-8,9-10,11-12,13-14)for root surfaces debridement(RSD), instructions and motivation for dental arch
79857989|NCT06269978|Procedure|Biopsy|Undergo biopsy
79857990|NCT06269978|Procedure|Biospecimen Collection|Undergo collection of blood and IP fluid samples
79857991|NCT06269978|Procedure|Computed Tomography|Undergo CT
79857992|NCT06269978|Procedure|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
79857993|NCT06269978|Drug|Fluorouracil|Given via IP infusion
79857994|NCT06269978|Procedure|Magnetic Resonance Imaging|Undergo MRI
79857995|NCT06269978|Drug|Oxaliplatin|Given via IP infusion
80020537|NCT04464902|Other|No Intervention|Control Group don't have any brace.
79857996|NCT06269978|Procedure|Surgical Procedure|Undergo placement of indwelling IP port
79857997|NCT06269965|Device|Regeneten® adding|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
79857998|NCT06269952|Other|No intervention|No intervention. The participants are asked questions from and questionnaire and later also interviewed guide by an interview-guide
80020538|NCT04464824|Other|no intervention|no intervention
80020539|NCT02293694|Drug|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
80020540|NCT02297048|Dietary Supplement|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
80020541|NCT02297126|Other|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
80020542|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
80020543|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
80020544|NCT02300636|Other|Training|Standard ACL rehabilitation
80020545|NCT02293772|Other|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
79560957|NCT05274126|Behavioral|Patient group/Passvers|"Passvers intervention aims at :~helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~allowing cooperation between health and social structures aiming at destigmatizing mental illness."
79581174|NCT01933503|Drug|OCA 5 mg|
79723757|NCT02801227|Drug|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
79857999|NCT06269939|Behavioral|STEM|Memory technique training
79858001|NCT06269900|Drug|Dexamethasone|Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
79858002|NCT06269900|Drug|Placebo|Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
79858003|NCT06269861|Device|patient transfer scale|patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
79858004|NCT06269835|Behavioral|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
79858005|NCT06269835|Device|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
79858006|NCT06269835|Device|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
79858007|NCT06269822|Diagnostic Test|Sympathetic skin response, heart rate variability test, quantitative EEG|Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
80020546|NCT02293772|Other|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
79398238|NCT05152641|Other|Matching Placebo|Matching Placebo to BGE-117 Capsules
79581175|NCT01933503|Drug|OCA 10 mg|
79858008|NCT06269809|Procedure|Temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
79723758|NCT02795611|Behavioral|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
79723759|NCT02795611|Behavioral|regular occupational therapy|regular occupational therapy
79723760|NCT02795611|Other|intervention done outside our hospital|intervention done outside our hospital
79723761|NCT02799121|Device|ReGenerCell™ Autologous Cell Harvesting Device|
79398239|NCT05152641|Drug|BGE-117, 12mg|BGE-117, 12mg Capsules
79398240|NCT01444391|Device|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
79398241|NCT02431845|Drug|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40~80 mg dose equivalents
79398242|NCT01443923|Drug|Boceprevir|
79398243|NCT01443923|Drug|Peg-Interferon-alfa 2B|
79398244|NCT01443923|Drug|Ribavirin|
79398245|NCT02196051|Other|Exercise Training|Six weeks of exercise
79398246|NCT02121639|Drug|Placebo|
80020547|NCT02293772|Other|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
80020548|NCT03512444|Device|Negative Pressure System|Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
80020549|NCT02956629|Drug|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
80020550|NCT02956629|Drug|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
79581176|NCT01933503|Drug|OCA 25 mg|
79581177|NCT01933516|Drug|GP2013|GP2013
79398247|NCT02121639|Drug|AZD5363|
79398248|NCT04847427|Other|Core exercises training|"Participants will perform:~Squats, 4 sets of 5 repetitions at 60% 1RM~Deadlifts, 4 sets of 5 repetitions at 60% 1RM~Lunges, 4 sets of 5 repetitions at 60% 1RM~Step ups, 4 sets of 5 repetitions at 60% 1RM"
79260925|NCT03201081|Other|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
79398249|NCT04847427|Other|Structural exercises training|"Participants will perform:~Snatch, 4 sets of 5 repetitions at 60% 1RM~Hang clean, 4 sets of 5 repetitions at 60% 1RM~Push jerk, 4 sets of 5 repetitions at 60% 1RM~Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
80020551|NCT02956629|Drug|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
79260926|NCT03201159|Drug|VLX103|150mg tablets
79560958|NCT05274035|Drug|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children <4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
79560959|NCT05273905|Diagnostic Test|Ultrasound derived Avi|Assess the Avi of carotid arteries, hepatic arteries, renal arteries and central retinal arteries.
79560960|NCT05273242|Drug|Artesunate Injection|"Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
79398250|NCT04847427|Other|Accentuated eccentric exercises training|"Participants will perform:~Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~Step down - squat jump, 4 sets of 5 repetitions at 30% BM~Step down - lunges, 4 sets of 5 repetitions at 30% BM~Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
79398251|NCT04847427|Other|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
79398252|NCT04460703|Other|Control message|2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
79260927|NCT03229785|Biological|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
79398253|NCT04460703|Other|Baseline message|3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
79560961|NCT05272995|Diagnostic Test|IIEF-5|The participants will be asked to complete a validated IIEF-5 questionnaire, an abridged version of the IIEF. The IIEF is a validated, brief and reliable self-administered questionnaire for assessing erectile function. Moreover, this tool is easily administered in clinical setting and demonstrates adequate sensitivity and specificity for detecting treatment-related changes in erectile function in patients with erectile dysfunction (ED).According to Rosen et al the abridged five-item version of the 15-item IIEF possesses favorable properties for detecting the presence and severity of ED for the preceding 6 months. The IIEF-5 consists of five questions, each of which is scored on a five-point ordinal scale and ED may be classified into five categories based on the calculated scores.
79260928|NCT02149927|Drug|Sevoflurane|
79260929|NCT02142673|Device|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
79260930|NCT02142673|Device|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
79581178|NCT01933529|Drug|ARA 290|ARA 290 is injected s.c. once daily during the study period
79581179|NCT01933542|Drug|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
79581180|NCT01933542|Drug|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
79858009|NCT06269809|Procedure|No temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
80020552|NCT02297204|Procedure|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
80020553|NCT02297204|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
80020554|NCT02300714|Procedure|oblique view approach|
79260931|NCT02142673|Device|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
79260932|NCT03205995|Biological|OMS721|Intravenous loading dose followed by daily subcutaneous injections
79260933|NCT02150005|Procedure|Periodontal treatment|
79398254|NCT04460703|Other|Personal freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
79398255|NCT04460703|Other|Economic freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
79260934|NCT03205917|Biological|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
79260935|NCT03205917|Biological|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
79260936|NCT03205917|Biological|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
79858010|NCT06269796|Diagnostic Test|Little Developmental Coordination Disorder Questionnaire (LDCDQ)|"The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75."
80020555|NCT03515642|Behavioral|HIIT group|Physical Training
80020556|NCT02293850|Biological|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
80020557|NCT02300792|Dietary Supplement|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
79723762|NCT02795455|Behavioral|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
79398256|NCT04460703|Other|Self-interest message|1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
79260937|NCT03205917|Biological|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
79560962|NCT05272800|Device|Spectroscopy Bioimpedance Analysis|Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
79581181|NCT01933542|Drug|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
79581182|NCT01933542|Drug|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
79723763|NCT02795455|Behavioral|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
80020558|NCT02300792|Dietary Supplement|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
80020559|NCT02297282|Behavioral|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
80020560|NCT02297360|Dietary Supplement|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
79723764|NCT02795455|Dietary Supplement|meal replacement shake|
79723765|NCT02795299|Drug|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
80020561|NCT02297360|Other|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
80020562|NCT02293928|Procedure|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
80020563|NCT02294006|Drug|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
79260938|NCT03205917|Biological|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
79260939|NCT03205917|Biological|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
79260940|NCT03205917|Biological|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
79260941|NCT03205917|Biological|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
79260942|NCT02142751|Drug|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
79260943|NCT02142751|Drug|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
79398257|NCT04460703|Other|Community interest message|1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
79398258|NCT04460703|Other|Economic benefit message|1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
79858011|NCT06269796|Diagnostic Test|Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)|The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
79560963|NCT05272800|Other|Clinical Examination alone|The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
79723766|NCT02795299|Drug|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
79723767|NCT02795299|Drug|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
79723768|NCT02795299|Drug|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
79723769|NCT03930277|Diagnostic Test|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
79723770|NCT02799043|Procedure|Standard PVI|Standard PVI procedure without FIRMap.
79858012|NCT06269757|Behavioral|Individualized Exercise Program|"The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~Running analysis;~Training program review;~Strength and flexibility assessment;~Review of running video;~Personalized final report."
79858013|NCT06269757|Behavioral|Standard Physical Therapy|Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
79858014|NCT06269744|Behavioral|Proactive Screening Outreach|Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
79858015|NCT06269731|Behavioral|Hamilton depression Rating Scale|also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.
80020564|NCT01348347|Drug|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
80020565|NCT01348347|Drug|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
79560964|NCT05271825|Device|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
79560965|NCT05271825|Device|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
79560966|NCT05271097|Other|MyLink2Care app full functionality|Participants will be shown how to download the app and use the assessment tool.
79560967|NCT05271097|Other|MyLink2Care app major intervention features inactivated|Participants will be shown how to download the app and use the assessment tool.
79560968|NCT05270850|Procedure|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
79723771|NCT02799043|Procedure|FIRM-Guided Procedure and PVI|
79560969|NCT05270850|Procedure|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
79560970|NCT05270317|Procedure|Bone Graft Cultivation and Harvesting|Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
79581183|NCT01933555|Behavioral|Empowerment Program|
79581184|NCT01933568|Radiation|SABR|combined CFRT and SABR with concurrent cisplatin
79581185|NCT01933568|Drug|Cisplatin|combined CFRT and SABR with concurrent cisplatin
79581186|NCT01933607|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
79581187|NCT01933633|Behavioral|Exercise|
79723772|NCT02801071|Drug|15g L-citrulline daily p.o.|
79723773|NCT02801071|Drug|Placebo|
79723774|NCT02790619|Device|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
79723775|NCT02790619|Device|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
79723776|NCT04233931|Behavioral|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
79723777|NCT03981757|Device|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
79723778|NCT02799277|Drug|Testosterone|Effect of testosterone on moral decision making
79723779|NCT02799277|Drug|Placebo|Effect of testosterone on moral decision making
79723780|NCT04235179|Radiation|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
79723781|NCT01198002|Drug|LY2127399|Administered Subcutaneously (SC)
79260944|NCT02142751|Drug|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
79560971|NCT05269797|Behavioral|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
80020566|NCT01348347|Drug|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
80020567|NCT02294084|Drug|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
80020568|NCT02294084|Drug|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
80020569|NCT03640533|Behavioral|Nanit-Insights|Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
80020570|NCT04464746|Other|implementation of a specific program to improve therapeutic adherence|"Discussion of risks associated with high BP;aims,healthy lifestyle options.~Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~Socio-psycho-affective interventions.~Reminder systems: phone,email,alarm on the mobile phone.~Simplification as far as possible of therapeutic scheme.~Explanation of prescribed medications (name&dosage), correct intake.~Explanation of possible side effects and what to do if they happen. Facilitate a contact.~Advise and training on home blood pressure self-measurement.~Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided."
79560972|NCT05269576|Other|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
79560973|NCT05269576|Other|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
79560974|NCT05269264|Diagnostic Test|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
79560975|NCT05269264|Diagnostic Test|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
79581188|NCT01933659|Drug|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
79723782|NCT01198002|Drug|Placebo Q2W|Administered SC
79723783|NCT01198002|Drug|Placebo Q4W|Administered SC
79723784|NCT01198002|Drug|Methotrexate|Methotrexate is a background therapy.
79723785|NCT02790307|Device|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
79723786|NCT02790151|Behavioral|Standard Therapy|Learning and practicing Memory strategies
79723787|NCT02790151|Behavioral|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
79723788|NCT02794909|Device|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
79723789|NCT02798887|Procedure|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
79723790|NCT02795065|Drug|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
79858016|NCT06269718|Other|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
80020571|NCT03640065|Drug|freeze-dried probiotic sachets|"The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~This procedure will be repeated once daily for the following 4 weeks.~4 weeks supply will be given to the participants."
80020572|NCT03640065|Dietary Supplement|fermented dairy product ( yogurt)|"The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
80020573|NCT03515486|Other|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
79560976|NCT05269264|Diagnostic Test|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
80020574|NCT03512366|Procedure|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
80020575|NCT03512366|Procedure|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
80020576|NCT02959671|Device|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
80020577|NCT03515408|Device|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
79308766|NCT04822779|Other|Placebo|"Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
79560977|NCT05269264|Diagnostic Test|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
79560978|NCT05269095|Procedure|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
79560979|NCT05269095|Biological|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
79723791|NCT02795065|Drug|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
79723792|NCT02794987|Device|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
79723793|NCT02789995|Procedure|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
79858017|NCT06269718|Other|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
79858018|NCT06269705|Drug|ZILRETTA|IA injection of 32 mg ZILRETTA
79858019|NCT06269705|Drug|TCA-IR|IA injection of 40 mg TCA-IR
79858020|NCT06269705|Other|Placebo|IA injection of placebo (normal saline)
79858021|NCT06269692|Device|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
79858022|NCT06269692|Device|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
79858023|NCT06269692|Device|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
80020578|NCT01597258|Drug|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
80020579|NCT02958267|Biological|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
80020580|NCT02958267|Biological|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
80020581|NCT02958267|Device|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution [10 mg/mL], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
80020582|NCT02302352|Other|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
80020583|NCT02302352|Other|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
79858024|NCT06269679|Diagnostic Test|CBCT|Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
79398259|NCT04460703|Other|Guilt message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
79398260|NCT04460703|Other|Embarrassment message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
80020584|NCT02302430|Drug|Oxytocin|20 International Units Intranasal Oxytocin
80020585|NCT02302430|Other|Placebo comparator|Saline nasal spray
79398261|NCT04460703|Other|Anger message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
79560980|NCT05269095|Biological|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
79560981|NCT05268783|Procedure|EORTC QLQ-C30|Quality of life questionnaire that has to be completed every 6 months
79560982|NCT05268783|Procedure|EORTC QLQ-GI.NET21|Quality of life questionnaire that has to be completed every 6 months
79560983|NCT05268783|Procedure|Satisfaction survey|Questionnaire regarding satisfaction of care that has to be completed on Day 1.
79560984|NCT05267938|Drug|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
79560985|NCT05267938|Drug|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
79560986|NCT05267431|Drug|Biological Drug|Different biological drugs
79723794|NCT02790229|Other|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
79560987|NCT05266248|Other|250 mg encapsulated caffeine|Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage
79560988|NCT05265585|Diagnostic Test|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~Parasternal window (Parasternal long axis, Parasternal minor axis)~Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
79560989|NCT05264584|Drug|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
79560990|NCT05264584|Drug|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
79560991|NCT05264584|Drug|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
79723795|NCT02790229|Other|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
79723796|NCT02798965|Biological|serodiagnosis|
79723797|NCT02798809|Other|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
79723798|NCT04233697|Drug|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
79723799|NCT04233697|Drug|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
79858025|NCT06269666|Device|P200TxE|SLO and OCT imaging
79858026|NCT06269614|Dietary Supplement|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
79858028|NCT06269588|Device|Nexpowder|Endoscopic hemostasis
80020586|NCT04485208|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
80020587|NCT03640299|Procedure|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
80031644|NCT02047539|Drug|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
80031645|NCT02047539|Drug|Placebo|
80031646|NCT05389748|Other|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
79858029|NCT06269575|Behavioral|SAFE NUTRITION PROGRAM|"Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment"
79560992|NCT05264155|Behavioral|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
79560993|NCT05263687|Diagnostic Test|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
79560994|NCT05263167|Drug|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
79560995|NCT05263167|Drug|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
80031647|NCT05389748|Biological|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
79560996|NCT05262959|Drug|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
79560997|NCT05262959|Procedure|TACE|TACE will be performed by the investigator based on the patient's tumor status.
79560998|NCT05262686|Drug|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
79723800|NCT04234009|Other|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
79723801|NCT02857036|Other|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
79723802|NCT02857036|Behavioral|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
79723803|NCT04234087|Other|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
79723804|NCT02794753|Behavioral|Working memory training|
79723805|NCT02794753|Behavioral|Game|
79723806|NCT02794519|Drug|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
79723807|NCT02794519|Drug|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
79560999|NCT05262686|Drug|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
79723808|NCT02794519|Drug|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
79723809|NCT05463523|Device|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
79723810|NCT03826303|Other|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
79561000|NCT05261334|Procedure|contour augmentation|early implant placement with contour bone augmentation
79561001|NCT05259540|Drug|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
79561002|NCT05258968|Other|Education on the Injeti Model of Self-Esteem|1 hour educational session
79561003|NCT05254028|Procedure|filiform needle|Manual acupuncture using filiform needles
79723811|NCT03826303|Other|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
79723812|NCT03826303|Other|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
79723813|NCT03826303|Other|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
79723814|NCT02794675|Drug|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
79858030|NCT06269562|Procedure|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
79858031|NCT06269536|Other|HRV biofeedback|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
80031648|NCT02047617|Device|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
79858032|NCT06269523|Other|Kinesio taping, Lymphatic drainage|Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
79858033|NCT06269523|Other|Lymphatic drainage|Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
79858034|NCT06269510|Behavioral|ENGAGE-ALD Application (APP)|"Participants randomized to this will complete the app at the time of enrollment.~If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app."
79303734|NCT05573321|Other|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
80020588|NCT02300948|Drug|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
79561004|NCT05238870|Other|Interviews for the needs analysis. No intervention.|To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.
79723815|NCT02798653|Drug|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
79561005|NCT05236608|Drug|Nivolumab|Administered together with ADG106 via intravenous infusion.
79561006|NCT05236608|Drug|ADG106|Administered as an intravenous infusion over 90 minutes.
79723816|NCT02798653|Drug|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
80031649|NCT02047617|Device|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
80031650|NCT04896190|Other|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
79561007|NCT05225402|Drug|Hemodynamic measurements during reduction in Norepinephrine and fluid boli.|"Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP<40.~While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV>10%.~As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP."
79723817|NCT02798653|Drug|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
79723818|NCT02794363|Biological|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
79723819|NCT04234789|Diagnostic Test|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
79723820|NCT04234789|Diagnostic Test|spirometry|test performed as recommended by ATS guidelines
79723821|NCT04234789|Diagnostic Test|pletysmography|test performed as recommended by ATS guidelines
79723822|NCT04234789|Diagnostic Test|forced oscillometry technique|test performed as recommended by ATS guidelines
79723823|NCT02794051|Behavioral|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
80020589|NCT02300948|Drug|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
80020590|NCT03103828|Behavioral|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
80020591|NCT03103828|Behavioral|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
79398262|NCT04460703|Other|Trust in science message|1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
79398263|NCT04460703|Other|Not bravery message|1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
79398264|NCT00569673|Biological|filgrastim|
79398265|NCT00569673|Biological|pegfilgrastim|
79561008|NCT05224232|Device|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
79561009|NCT05224232|Device|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
79561010|NCT05223517|Device|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
79561011|NCT05223517|Device|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
79723824|NCT02789683|Other|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
79723825|NCT02789683|Other|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
79723826|NCT02789683|Other|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
79858035|NCT06269510|Behavioral|Treatment Facilitation bundle|Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.
79858036|NCT06269510|Behavioral|Enhanced Usual Care|This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.
79858037|NCT06269497|Procedure|Scaffold placement|The scaffold is placed in the alveola following extraction
79858038|NCT06269497|Radiation|CBCT|A Cone Beam Computer Tomography (CBCT) is taken of the area of interest after surgery
79858039|NCT06269484|Drug|Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
79858040|NCT06269484|Drug|Zibotentan + placebo (placebo matching dapagliflozin tablet)|"zibotentan capsule~placebo tablet (matching dapagliflozin tablet)"
79858041|NCT06269484|Drug|Zibotentan + dapagliflozin|"zibotentan capsule~dapagliflozin 10 mg tablet"
79858042|NCT06269458|Behavioral|Baby Massage|In the baby massage application, mothers were trained on baby massage and the massage applied by the mother to her baby was observed once. The baby massage video prepared by the researchers was shared with mothers. Mothers were informed about the importan
79858043|NCT06269458|Behavioral|Monther-Baby Yoga|"Mothers were asked to choose the most suitable time of day for themselves and the baby, to ensure that the baby was fed at least 45 minutes before yoga, and to practice yoga in a calm and dimly lit environment, listening to music or white noise of their choice. One yoga session lasted approximately 20 minutes. Mothers and their babies did mother-baby yoga three times a week for four weeks. Mothers were informed about the importance of having the same treatment room for each treatment. All mothers were called once a week by a researcher to provide counseling and follow-up of the process.~At the end of four weeks, measurement tools were applied to all mothers and the groups were changed, massage was applied to the yoga group, and yoga intervention was applied to the massage group, as in the beginning of the research. At the end of four weeks, all mothers were evaluated for mother-infant attachment and the infant's sleep diary."
79858044|NCT06269445|Drug|Icaritin Combined With Bevacizumab and FOLFIRI|Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
80020592|NCT03103828|Behavioral|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
79398266|NCT00569673|Drug|docetaxel|
79561012|NCT05220826|Procedure|Post surgical embolization of middle meningeal artery with liquid embolic agents (ethylene vinyl alcohol copolymers as Onix, Squid, Phil or Libro)|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
79561013|NCT05217251|Other|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
79561014|NCT05213871|Other|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
79581189|NCT01933685|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
79581190|NCT01933685|Biological|AIDSVAX B/E Placebo|1 mL per injection
79723827|NCT02789761|Dietary Supplement|High-flavanol milk choocolate|
79723828|NCT02789761|Dietary Supplement|Low-flavanol milk chocolate|
79723829|NCT02798497|Other|Serum and Blood samples|
79723830|NCT02789917|Other|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
79398267|NCT00569673|Drug|trabectedin|
79398268|NCT01551212|Drug|Everolimus|tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
79398269|NCT01551212|Drug|Tacrolimus|capsule containing 0.5, 1.0, or 5.0mg
79398270|NCT01551212|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
79398271|NCT00573261|Drug|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
79581191|NCT01933698|Drug|amoxicillin|Comparison of pharmacokinetics of both formulations
79581192|NCT01933711|Drug|rituximab|
79723831|NCT02789917|Other|Triple Therapy|"HAS-BLED-Score <3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
79723832|NCT03863587|Biological|HLX12|healthy volunters receive HLX12 (8mg/kg) once
79723833|NCT03863587|Biological|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
79723834|NCT02789605|Drug|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
79723835|NCT02789605|Drug|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
79723836|NCT02789839|Procedure|Blood test|Blood test of 30mL
79723837|NCT02789839|Procedure|Medullar test|Medullar test for 2-5mL and a smear
79723838|NCT04233463|Dietary Supplement|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
79723839|NCT04233463|Drug|Budesonide|Standard treatment for mild Crohn Disease patients
79858045|NCT06269432|Drug|Precision Antiplatelet Therapy Trial Group|Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
80020593|NCT02302508|Drug|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
79260945|NCT03119259|Behavioral|ABC Clinical Program|"The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary."
79260946|NCT03119259|Behavioral|BCN|"BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others."
79260947|NCT02142829|Drug|EXPAREL|
79561015|NCT05213871|Other|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
79858046|NCT06269432|Drug|Traditional Antiplatelet Therapy Control Group|No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
80020594|NCT03103984|Other|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
79260948|NCT02142829|Drug|On-Q Pain Ball|bupivacaine HCl 0.25%
79260949|NCT03205683|Other|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
79260950|NCT03205683|Other|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
79260951|NCT02150083|Procedure|OR retrograde fill|
79260952|NCT03200691|Radiation|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
79260953|NCT03200691|Drug|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
79260954|NCT02150161|Drug|Lidocaine/ ketamine|
79561016|NCT05213871|Other|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
79561017|NCT05210413|Drug|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
79561018|NCT05210413|Drug|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
79723840|NCT02794129|Other|Functional Magnetic Resonance Imaging|
79723841|NCT02793973|Device|shoe lifts|
79723842|NCT02793895|Device|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
79260955|NCT02150161|Drug|Fentanyl|
79858047|NCT06269406|Dietary Supplement|ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 400 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
79858048|NCT06269406|Dietary Supplement|ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 200 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
80020595|NCT02297594|Drug|AK0529|AK0529 capsule for oral administration
80020596|NCT02297594|Drug|Placebo|Sugar placebo capsule for oral administration
79858049|NCT06269406|Other|The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure|The combination of ibuprofen 400 mg and placebo 100 mg in patients after 2-4 molars procedure
79858050|NCT06269393|Drug|Placebo|Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
79858051|NCT06269393|Drug|IBI311|IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
79858052|NCT06269354|Device|3D printed prostheses|3D printed prostheses
79858053|NCT06269341|Other|No intervention|No intervention
79260956|NCT03205839|Behavioral|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
79260957|NCT02144311|Procedure|PET/CT Scan|
79260958|NCT02144311|Procedure|MRI|
79260959|NCT03205527|Other|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
79398272|NCT00573261|Drug|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
79398273|NCT04514211|Drug|Propofol|General anesthesia using propofol infusion
79561019|NCT05210413|Drug|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
79561020|NCT05210413|Drug|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
79561021|NCT05208073|Behavioral|Cosmetic therapy|The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
79561022|NCT05208060|Biological|MV130|Treatment administered sublingually
79561023|NCT05208060|Other|Placebo|Treatment administered sublingually
79561024|NCT05205629|Drug|Donafenib combined with TACE|Donafenib(200mg bid po) combined with TACE
79561025|NCT05204784|Procedure|Rheopheresis treatment|After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.
79723843|NCT02793895|Other|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
79858056|NCT06269315|Other|Cleaning product exposure|Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
79561026|NCT05204784|Drug|Intravenous Infusion|Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
79561027|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 1, for 12 days
79398274|NCT04514211|Drug|Sevoflurane|General anesthesia using sevoflurane
79398275|NCT00574197|Drug|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
79398276|NCT00574587|Drug|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
79398277|NCT00574587|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
79561028|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 2, for 12 days
79561029|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 3, for 12 days
79561030|NCT05203705|Drug|SHR2285 tablet|SHR2285 tablet; dose 4, for 12 days
79561031|NCT05203705|Drug|Enoxaparin|Enoxaparin, for 12 days
79561032|NCT05202561|Biological|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
79561033|NCT05202561|Biological|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
79561034|NCT05196009|Behavioral|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
79858057|NCT06269289|Other|web based education|Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
79561035|NCT05193825|Device|Remote Programming|Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
79858058|NCT06269289|Other|Standard education brochure|The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.
79858059|NCT06269276|Behavioral|Caregiver Contribution to Self-Care in Ostomy Patient Index|This study was conducted to evaluate the Turkish validity and reliability of the Caregiver Contribution to Self-Care in Ostomy Patient Index, to evaluate the relatives of patients with stoma who contribute to their self-care in Turkish society, and to contribute to the nursing literature of the measurement tool.
79858060|NCT06269263|Behavioral|Home-based cardiac rehabilitation|Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
79858061|NCT06269250|Other|Policy Change|There will be a change with the digitalization in the health care system with the beginning of the year 2024 and between Wave 1 and Wave 2
79858062|NCT06269237|Device|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
80020597|NCT04484584|Other|complex decongestive therapy|Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
79260960|NCT03200613|Drug|Apixaban|2.5 mg orally twice daily
79398278|NCT00574587|Drug|Trastuzumab|Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
79398279|NCT00574587|Drug|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
79561036|NCT05193825|Device|Standard Programming|Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
79561037|NCT05192733|Other|Survey|This is a cross-sectional practice survey. There is no intervention.
79561038|NCT05192629|Drug|Dexmedetomidine|Premedication by intranasal dexmedetomidine
79561039|NCT05192629|Drug|Midazolam|Premedication by intranasal midazolam
79561040|NCT05191550|Behavioral|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
79561041|NCT05191121|Behavioral|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
79723844|NCT02793895|Device|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
80020598|NCT02301026|Drug|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
80020599|NCT01742026|Procedure|Aspergillus PCR technique|Aspergillus DNA PCR technique
80020600|NCT01742026|Procedure|Aspergillus AGA technique|Aspergillus AGA technique
80020601|NCT02297750|Procedure|double-wire technique in patients undergoing ERCP with biliary cannulation|
80020602|NCT02297750|Procedure|single-wire technique in patients undergoing ERCP with biliary cannulation|
80020603|NCT01682278|Device|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
80020604|NCT01952574|Drug|Erenumab|Administered by study site staff once a month (QM) as a subcutaneous injection
79260961|NCT03200613|Drug|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
79260962|NCT02150239|Procedure|operation|
79260963|NCT03118791|Dietary Supplement|anthocyanins|Acute intake of capsules
79260964|NCT02142985|Drug|Sodium Chloride 0.9% Intravenous|vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
79260965|NCT02150317|Procedure|TACE+Sorafenib|TACE followed by Sorafenib
79260966|NCT02150317|Procedure|TACE|TACE alone
79398280|NCT00574587|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
79398281|NCT00574587|Procedure|Surgery|Surgical excision of tumor from breast
79398282|NCT04120220|Other|Heavy Cream|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
79398283|NCT04120220|Other|Soybean Oil|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
79561042|NCT05191121|Behavioral|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
80020605|NCT01952574|Drug|Placebo|Administered by study site staff once a month (QM) as a subcutaneous injection
80020606|NCT01952574|Drug|Erenumab PFS|Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
79398284|NCT00603993|Biological|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
79561043|NCT05191121|Behavioral|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
79561044|NCT05189444|Drug|Vonoprazan|20mg bid
79561045|NCT05189444|Drug|Amoxicillin|0.75g tid
79561046|NCT05189444|Drug|Esomeprazole|20mg bid
79561047|NCT05189444|Drug|Amoxicillin|1.0g bid
79858063|NCT06269237|Device|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
79858064|NCT06269211|Drug|Toripalimab|240mg IV, Q3W
79858065|NCT06269198|Device|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
79858066|NCT06269172|Behavioral|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
79858067|NCT06269159|Other|Concept mapping: brainstorm|"Group health care providers:~Duration: 1.5 hour for HCP via zoom session~Brainstorm question: what would help your clients to change their sedentary behavior into more physical activity?~Group adults with overweight and obesity~Duration: online survey (REDCAP) of approx. 10 minutes~Brainstorm question via an online survey. What would help you to change your sedentary behavior into more physical activity?"
79858068|NCT06269159|Other|Concept mapping: clustering and rating|"The same participant of the brainstorm session are asked to join session 2 to complete the clustering and rating). All interested adults will get access to the online cluster and rate tool described below.~Duration: flexible use of the online tool (available for two weeks)~The clustering and rating of all needs mentioned in session 1 will be done online and individually via a web application. In this online tool, the final list of 'needs' generated in session 1 will be presented.~Individually sort the 'needs' into groups and give the group a theme. In addition, each need will be scored on effectiviness, feasibility, modifiability. Thhe participants have unlimited access for two weeks."
79858069|NCT06269146|Drug|Pramipexole Pill|The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
80020607|NCT01952574|Drug|Erenumab AI/Pen|Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
80020608|NCT02302586|Drug|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
80020609|NCT02302586|Drug|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
79398285|NCT00575367|Drug|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
79561048|NCT05189444|Drug|Clarithromycin|0.5g bid
79561049|NCT05189444|Drug|Bismuth potassium citrate|0.22g bid
79561050|NCT05186662|Other|patient education|patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
79561051|NCT05186662|Other|patient education|Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
79561052|NCT05185011|Drug|TPN171H|10 mg TPN171H tablets，single dose
79398286|NCT00575367|Drug|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
79561053|NCT05175274|Drug|Colchicine|Colchicine 0.5mg/tablet
79561054|NCT05175274|Drug|Placebo|matching placebo
79561055|NCT05165199|Drug|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
79561056|NCT05163015|Other|Data collection|Description: quality of life assessment
79561057|NCT05160194|Behavioral|Positive Parenting Intervention|"The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them."
79561058|NCT05157555|Other|Data collection|Description: quality of life assessment
79858070|NCT06269146|Drug|Placebo Pill|Placebo will match the study drug in mode of administration, color, size, and taste.
79858071|NCT06269133|Drug|REGN2810|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
80020610|NCT03512054|Procedure|Standardized 5-step weaning procedure|"Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver…) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation"
79858072|NCT06269133|Other|Platinum-doublet chemotherapy|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
79858073|NCT06269120|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
79561059|NCT05153278|Biological|Packed red blood cells|Standard treatment for iron deficiency anemia (control)
79858074|NCT06269094|Other|CGM|CGM use for 6 weeks during virtual focus groups
79260967|NCT02448147|Behavioral|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
79260968|NCT02448147|Behavioral|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
79858075|NCT06269068|Diagnostic Test|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
79260969|NCT02150395|Other|music therapy|
79858076|NCT06269068|Other|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
79858077|NCT06269068|Other|Oswestry Low Back Pain Disability Questionnaire|With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.
79260970|NCT02310568|Drug|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
79260971|NCT03205215|Other|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
79260972|NCT03205215|Other|Waitlist Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
79561060|NCT05153278|Drug|Intravenous drug|Experimental treatment for iron deficiency treatment
79858078|NCT06269068|Other|Douleur Neuropathique 4|The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.
79858079|NCT06269068|Other|Visual analogue scale|global pain score on a 0 to 10
79858080|NCT06269055|Drug|DTPA|Telephone interview and questionnaires about the results and side effects experienced
79858081|NCT06269042|Other|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
79858082|NCT06269029|Other|Chest mobility exercises|exercises were repeated 6 times on each side with rest of period for 30 seconds in between. The intervention will be carried out for one week with total of 7 sessions. Each Exercise will be accompanied by breathing pattern. In neutral position of exercises, subjects will be asked to exhale during flexion, turning or extension subject will be asked to do inhale.
80020611|NCT05430646|Device|Covered metal ureteral stents|The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.
80020612|NCT05430646|Device|Tandem DJ stents|Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
79260973|NCT02448069|Drug|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
79260974|NCT05234151|Other|NEWS|Newborn Early Warning Score
79260975|NCT02449863|Other|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
79260976|NCT02449941|Drug|PPI (proton pump inhibitor)|"Pre ESD (endoscopic submucosal dissection)~Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~Use of PPI for 2 months~Post ESD 1 (After 2 months)~Assess the distribution of helicobacter pylori after using PPI.~Stop of PPI~Post ESD 2 (After 4 months)~Assess the distribution of helicobacter pylori after stop of PPI."
79561061|NCT05150548|Other|No Intervention|Not applicable, non-interventional study
79561062|NCT05133427|Device|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
79561063|NCT05129137|Drug|nefopam hydrochloride 30mg X2|nefopam hydrochloride 30mg X2
79561064|NCT05129137|Drug|paracetamol 500 mg X2|paracetamol 500 mg X2
79561065|NCT05129137|Drug|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
79581193|NCT01933737|Device|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
79858083|NCT06269029|Other|proprioceptive neuromuscular facilitation|The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
79561066|NCT05126251|Drug|Tangningtongluo tablet|Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
79260977|NCT03205449|Behavioral|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
79561067|NCT05126251|Behavioral|lifestyle intervention|Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
79561068|NCT05121740|Drug|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
79561069|NCT05121740|Drug|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
79561070|NCT05121740|Drug|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
79561071|NCT05114473|Other|Workshops|Several face-to-face workshops given by a researcher
79723845|NCT04234711|Procedure|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
79561072|NCT05114473|Other|Online-accessed material|Access to a website containing the educational program
79561073|NCT05110898|Drug|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
79561074|NCT05110898|Drug|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
79561075|NCT05101590|Device|Monitored by HDA|Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
79561076|NCT05098730|Behavioral|Strategy Training|Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
79561077|NCT05096780|Other|Flavored caffeinated beverage|16.9 oz (500 cc), carbonated, zero calorie
79561078|NCT05096325|Device|YpsoPump® insulin pump system|The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
79858084|NCT06269016|Other|expremental pre and post test|effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
79561079|NCT05096065|Drug|Leuprolide Oral Tablet - 120 mg - QD- Treatment A|"If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level <20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions."
79723846|NCT02793427|Biological|blood sample collection|
79723847|NCT02793739|Procedure|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
79723848|NCT02793661|Device|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
79723849|NCT02793661|Other|Control|Hydration protocol following ESC Guidelines 2014
79723850|NCT03874039|Device|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
79858085|NCT06269003|Other|Expert|Participants will view a brief description of an expert source.
79723851|NCT03874039|Device|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
79561080|NCT05096065|Drug|Leuprolide Oral Tablet - 80 mg - QD - Treatment B|"If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level <20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
79561081|NCT05096065|Drug|Leuprolide Oral Tablet - 60 mg - QD - Treatment C|For up to 29 consecutive days with food-intake restrictions
79723852|NCT02798419|Drug|DFD05 Cream|
79858086|NCT06269003|Other|Peer|Participants will view a brief description of a peer source.
79260978|NCT03205449|Other|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. [12].
79723853|NCT02798419|Drug|Active01 Cream|
79858087|NCT06269003|Other|1 Sided|Participants will view e-cigarette education messages in two-sided.
79858088|NCT06269003|Other|2 Sided|Participants will view e-cigarette education messages in two-sided.
79858089|NCT06268990|Procedure|Fecal microbiota transplantation|FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
79858090|NCT06268977|Drug|SGLT2 inhibitor|a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
79858091|NCT06268964|Drug|Trimebutine|Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
79561082|NCT05096065|Drug|Leuprolide Oral Tablet - 60 mg - BID - Treatment D|"If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level <20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
79858092|NCT06268964|Dietary Supplement|Lactobacillus rhamnosus|Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.
79858093|NCT06268964|Other|Placebo|Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
79561083|NCT05096065|Drug|Leuprolide Oral Tablet - 40 mg - BID - Treatment E|For up to 29 consecutive days with food-intake restrictions
79561084|NCT05094544|Radiation|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
79561085|NCT05092789|Other|Kinesio taping group|"Participants in this group will receive treatment through standardised therapeutic kinesio taping along with conventional therapy.~Tape will place over the posterior cervical extensor muscle, from insertion to the origin, with the patient's neck in cervical contralateral side-bending and rotation.~Duration of kinesio tape will be of 48 hours with 50-100% tension.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions."
79581194|NCT01933737|Device|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
79581195|NCT01932879|Other|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
79581196|NCT01932879|Other|Jello|
79581197|NCT01933750|Device|PresVIEW Device Implantation|
79723854|NCT02793505|Drug|metformin|This is not an intervention but an observed exposure.
79723855|NCT02793505|Drug|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
79858094|NCT06268470|Drug|Desloratadine plus cilostazol and dipyridamole|Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
80020613|NCT02302664|Procedure|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
79581198|NCT01933763|Drug|REGN1193|
79723856|NCT02789371|Procedure|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
79723857|NCT02789371|Procedure|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
79858095|NCT06268470|Drug|Desloratadine|Desloratadine 20 mg/day
79858096|NCT06268418|Other|Artificial intelligence|Segmentation
79858097|NCT06268028|Behavioral|Training|Discharge training
79858098|NCT06267989|Procedure|Extraction of the primary canine teeth|Extraction of the primary teeth has show to be successful in some cases.
79858099|NCT06267989|Procedure|Expansion|Expansion of the maxilla with rapid maxillary expander with no extractions
80020614|NCT02302664|Procedure|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
79260979|NCT03200145|Other|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~- Attention to the person based on:~Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~Respect and acknowledge of the person.~Promotion of the autonomy.~Personalized treatment, with tailored attention and integrative cures~Protection of physical well-being, preventing damages and risks and promoting healthy habits.~Promotion of independence on daily activities.~Protection of privacy and personal matters~- Positive environment based on:~Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~Social relationships, with proximity and collaboration with families.~Friendly organization, with empathetic professionals empowering users."
79398287|NCT00604461|Drug|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
79398288|NCT04417569|Drug|hCG|human chorionic gonadotropin
79398289|NCT04417569|Diagnostic Test|Ultrasound|Endometrial thickness monitoring
79398290|NCT04417569|Other|Blood test|Progesterone, Luteinizing Hormone, Estradiol
79398291|NCT00576147|Device|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
79398292|NCT01550744|Drug|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
79398293|NCT01550744|Drug|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
79561086|NCT05092789|Other|Cervical thrust manipulation group|"Participants of this group will receive treatment via cervical thrust manipulation along with conventional therapy.~For mid cervical spine thrust manipulation, the patient will be in supine lying position,with cervical spine in neutral position.~The therapist will cradle the patients head with the other hand. Gentle ipsilateral cervical side flexion and contralateral rotation will introduce until tension will perceive in target tissues at contact point. A high velocity, low amplitude thrust manipulation, will direct upward and medially in direction of subject's contralateral eye.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This intervention protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions with 1 month follow up."
79561087|NCT05092789|Other|Conventional therapy group|"Participants of this group will receive only conventional therapy which will include:~Hot pack for 10 minutes Stretching Exercises of neck muscles. For sternocleidomastoid stretching, the subject will ask to sit or stand facing forward, exhale and slowly turn your head to right, by keeping shoulder relaxed and down,inhale and return to the center, then turn to look at your left shoulder, ask to hold this position for 30 seconds and do 3 repetitions.~For Trapezius stretching, patient is seated upright, therapist then passively move right ear to right shoulder.~This study includes interventional protocol of 6 weeks. The session will be given twice a week making it a total of 12 sessions with 1 month follow up."
79561088|NCT05087836|Device|Sensor at forehead area|NIRS sensor attached at forehead area.
79561089|NCT05087836|Device|Sensor at temporal area|NIRS sensor attached at temporal area.
79561090|NCT05083572|Drug|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
79723858|NCT02798575|Device|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
79723859|NCT02789293|Device|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
79723860|NCT02797873|Other|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
79723861|NCT02797873|Other|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
80020615|NCT01551472|Device|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
80020616|NCT03104062|Diagnostic Test|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
80020617|NCT03104062|Diagnostic Test|Platelet Aggregability|Obtained using Multiplate Analyzer
79398294|NCT01550744|Drug|Placebo|Form = Injection, route = subcutaneous
79398295|NCT00577083|Device|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
79398296|NCT00606489|Drug|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
79398297|NCT00606489|Drug|Placebo|Placebo
79398298|NCT00578331|Drug|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
79398299|NCT00578331|Drug|Placebo Nasal Spray|2 sprays each nostril twice daily
79398300|NCT00607113|Drug|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
79398301|NCT00607113|Drug|RAD001|10 mg By Mouth Daily For 21 Days
79561091|NCT05083572|Dietary Supplement|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
80020618|NCT03104062|Diagnostic Test|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
79260980|NCT03204825|Device|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
79561092|NCT05083572|Drug|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
79723862|NCT02797873|Behavioral|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
79723863|NCT02797873|Other|SCID-II|See Detailed Study Description.
79561093|NCT05076435|Drug|Isotonic crystalloids|"Types of fluids in both intervention groups:~Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
79723864|NCT02797873|Other|SDQ|See Detailed Study Description.
79723865|NCT02797873|Other|ASRS|See Detailed Study Description.
79723866|NCT02797873|Other|AQ|See Detailed Study Description.
80020619|NCT03515330|Other|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
80020620|NCT03103672|Procedure|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
79561094|NCT05075772|Drug|BI 765080|BI 765080
79723867|NCT02797873|Other|TAS-20|See Detailed Study Description.
79561095|NCT05074615|Other|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
79561096|NCT05074615|Other|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~Hot pack placed on the posterior neck for 15 minutes.~Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
79561097|NCT05070312|Biological|MEDI3506|MEDI3506
79723868|NCT02797873|Other|Raven's SPM|See Detailed Study Description.
79723869|NCT02797873|Other|Reading ability|See Detailed Study Description.
79723870|NCT02797873|Other|Ishihara's tests for colour deficiency|See Detailed Study Description.
79723871|NCT02797873|Other|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
79723872|NCT02797873|Other|Brown-ADD|See Detailed Study Description.
79723873|NCT02797873|Other|MFQ|See Detailed Study Description.
79723874|NCT02797873|Other|STAI-T|See Detailed Study Description.
79723875|NCT02797873|Other|BIS|See Detailed Study Description.
79723876|NCT02797873|Other|DAWBA|See Detailed Study Description.
79723877|NCT02797873|Other|STAI-S|See Detailed Study Description.
79723878|NCT02797873|Other|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
79723879|NCT02797873|Other|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
80020621|NCT03511898|Drug|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
80020622|NCT03511898|Drug|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
80020623|NCT03511898|Drug|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
80020624|NCT02254044|Drug|bivatuzumab mertansine|
80020625|NCT03103594|Drug|DMSO|DMSO will be instilled intravesically.
80020626|NCT03103594|Drug|Botox|Botox will be instilled intravesically with DMSO.
80020627|NCT03515252|Biological|Immune Killer Cells (IKC)|
79260981|NCT03204825|Behavioral|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
79723880|NCT02797873|Behavioral|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
79723881|NCT02797873|Other|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
79723882|NCT02797873|Other|Structural T2 MRI scan|See Detailed Study Description.
79723883|NCT02797873|Other|DTI MRI scan|See Detailed Study Description and Outcome Measures.
79723884|NCT02797873|Other|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
79858100|NCT06267703|Other|Metabolomic profiling|Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
80020628|NCT02143284|Device|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
79260982|NCT03204825|Device|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
79858101|NCT06267664|Drug|Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients will complete the study information in their smartphones, tablets or computers, using a QR code or a link that will redirect hem to the study questionnaires. RedCap will be used in the study.
79858102|NCT06267313|Behavioral|Attention Bias Modification|Training attention away from threat
79858103|NCT06267313|Behavioral|Attention Control Training|Training attention control
79858104|NCT06267313|Behavioral|Neutral training|Attention training with Neutral stimuli
79260983|NCT04484493|Drug|mometasone furoate nasal spray|dose of 2 puff in each nostril (100 µg once daily each nostril).
79723885|NCT02793193|Dietary Supplement|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
79723886|NCT02793193|Dietary Supplement|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
79723887|NCT02793193|Drug|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
79723888|NCT02793193|Dietary Supplement|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
79723889|NCT02793271|Behavioral|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
79260984|NCT03205059|Behavioral|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
79260985|NCT03205059|Behavioral|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
79561098|NCT05070312|Drug|Placebo|Placebo
79561099|NCT05058794|Other|Blood flow Restriction/Resistance Training|During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
79723890|NCT02793271|Behavioral|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
79723891|NCT02793349|Device|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
79723892|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily
79723893|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
79723894|NCT01197534|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
79858106|NCT06266806|Behavioral|Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources|Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
79858107|NCT06266793|Device|Holmium Laser|Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
79858108|NCT06266793|Device|Thulium Laser|Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
79858109|NCT06266728|Device|Total30 for Astigmatism Contact Lenses|Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
79858110|NCT06266715|Drug|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
80020629|NCT05430568|Procedure|robot-assisted surgery|"traditional sternotomy for coronary bypass graft or valvular replacement~robot-assisted surgery for coronary bypass graft or valvular replacement"
79561100|NCT05058794|Other|Conventional Therapy Group|Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
79581199|NCT01933763|Other|Placebo|
79561101|NCT05058547|Device|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
79561102|NCT05034068|Drug|0.15% bezaydamine hydrochloride.|0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
79561103|NCT05034068|Device|low power laser with a wavelength of 870 nm|the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
79561104|NCT05031195|Other|1st tertile, 2nd tertile, 3rd tertile|Patients will be divided into 3 groups according to the preoperative NLR value.
79723895|NCT04234321|Drug|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
79723896|NCT04234321|Drug|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
79260986|NCT03204903|Procedure|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
79260987|NCT03204903|Procedure|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
79260988|NCT03204747|Other|Observational study : gait speed|No intervention, only propose water and wait for need to void
79260989|NCT02310100|Device|TactiCath Quartz treatment|
79260990|NCT03200067|Behavioral|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
79260991|NCT03200223|Behavioral|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
79260992|NCT03199989|Drug|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
79260993|NCT03199989|Other|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
79260994|NCT03195933|Other|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
79260995|NCT03195933|Other|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
79260996|NCT03195621|Device|Stent implantation|Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
79260997|NCT03195543|Diagnostic Test|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
79260998|NCT03195543|Diagnostic Test|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
79260999|NCT03195543|Diagnostic Test|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
79261000|NCT03195543|Diagnostic Test|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
79261001|NCT03204669|Other|Trace elements replacement|
79261002|NCT03199833|Device|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
79561105|NCT05030870|Device|Capnography monitoring|Standard monitoring and capnographic monitoring.
79561106|NCT05030870|Device|Standard monitoring|Standard monitoring but no capnographic monitoring
79561107|NCT05030025|Combination Product|abacavir, dolutegravir and lamivudine dispersible tablets|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
79561108|NCT05030025|Combination Product|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
79561109|NCT05019924|Dietary Supplement|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
79723897|NCT04234321|Drug|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
79858111|NCT06266715|Drug|Placebo Group|Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
79858112|NCT06266702|Other|Experimental Oil with Phospholipids|Consumed on white bread
79858113|NCT06266702|Other|Control Polyunsaturated Oil Blend|Consumed on white bread
79561110|NCT05018026|Behavioral|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
79561111|NCT05016687|Drug|CUR-N399|CUR-N399 will be administered as oral capsules.
79561112|NCT05016687|Drug|Placebo|Placebo capsules matching CUR-N399 will administered.
79261003|NCT03199833|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~Upper limb passive motion~Arm Cycle ergometer with or without FES~Neuro Muscular Electrical Stimulation~Upper limb exercises using augmented or virtual reality environment~Occupational therapy exercises~Constraint induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training~Mirror therapy~Writing training~Chemodenervation Therapy"
79561113|NCT05014750|Other|None intervention|There is no intervention included in this study.
79561114|NCT05013567|Drug|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
79398302|NCT00607269|Behavioral|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol <0.05) urine sample."
79561115|NCT05013567|Other|Placebo|Placebo gel topically four times a day
79723898|NCT02793115|Behavioral|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
79398303|NCT01549964|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
79398304|NCT01549964|Drug|Sitagliptin|Sitagliptin tablets
79723899|NCT02793115|Behavioral|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
79723900|NCT02793115|Behavioral|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
79723901|NCT02793115|Behavioral|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
79723902|NCT02793115|Behavioral|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
79723903|NCT03832933|Behavioral|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
79723904|NCT03832933|Behavioral|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
79398305|NCT01549964|Drug|Placebo|Placebo-matching tablets
79398306|NCT00607815|Behavioral|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
79398307|NCT00607815|Behavioral|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
79561116|NCT05010408|Other|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
79561117|NCT05006014|Procedure|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement
79858114|NCT06266689|Behavioral|Personalized Diet Information|These participants will receive a report detailing their genomic food data based on the investigators' DNA metabarcoding technique in addition to standard dietary guidance to see if receiving the report modifies what they choose to feed their infant.
80031651|NCT02522858|Drug|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
79261004|NCT03204591|Other|No intervention|No intervention
79261005|NCT03199677|Drug|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
79561118|NCT04998708|Other|Relaxation technique|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
79581200|NCT01933802|Biological|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
79261006|NCT02780167|Drug|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
79261007|NCT02780167|Drug|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
79581201|NCT01933828|Procedure|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
79261008|NCT02780167|Drug|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
79561119|NCT04990505|Diagnostic Test|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
79398308|NCT00579111|Drug|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
79723905|NCT02797717|Radiation|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
79398309|NCT00579111|Drug|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
79398310|NCT00579111|Drug|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
79398311|NCT00579111|Procedure|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
79261009|NCT02780167|Drug|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
79261010|NCT02780167|Drug|Placebo|Placebo QD for 12 weeks
79261011|NCT02447757|Drug|remifentanil|Remifentanil analgesia during delivery
79261012|NCT03204435|Procedure|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
80020630|NCT02302820|Other|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
80020631|NCT02301104|Drug|TAS-102|
80020632|NCT02302898|Behavioral|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
80020633|NCT02302898|Other|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
80020634|NCT02302898|Other|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
79561120|NCT04989621|Drug|Orelabrutinib and Rituximab|Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
80020635|NCT02959437|Drug|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
80020636|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
79261013|NCT03204435|Procedure|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
80020637|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily.
79261014|NCT03204435|Procedure|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
79261015|NCT03204435|Procedure|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
79261016|NCT02447835|Drug|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)[1,5]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
79261017|NCT02447913|Behavioral|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
79561121|NCT04989621|Drug|Orelabrutinib|Orelabrutinib 150mg po qd
79561122|NCT04989049|Drug|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
79561123|NCT04989049|Other|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
79561124|NCT04988178|Other|Data extraction from medical files|Data extraction from medical files
79561125|NCT04984044|Dietary Supplement|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
79723906|NCT02797717|Drug|Vincristine|ARM A and ARM B
79723907|NCT02797717|Drug|Etoposide|ARM B , 100mg/m2/day
79723908|NCT02797717|Drug|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
80020638|NCT02959437|Drug|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
79561126|NCT04984044|Dietary Supplement|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
79723909|NCT02797717|Drug|Doxorubicin|ARM B , 25mg/m2
79261018|NCT02447679|Drug|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
79261019|NCT02447679|Drug|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
79561127|NCT04984031|Diagnostic Test|ELISA assessment of apoptosis markers in gingival crevicular fluid|Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
79561128|NCT04983979|Drug|Sodium Zirconium Cyclosilicate|sachets of 5g or 10g given OD titrated to serum potassium
79723910|NCT02797717|Drug|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
79723911|NCT02797717|Drug|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
79723912|NCT02793037|Device|Zirconia resin bonded bridge|
79723913|NCT02792725|Drug|Abemaciclib|Administered orally
79858115|NCT06266676|Other|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
79858116|NCT06266676|Other|slide presentation|Provide online presentations.
79858117|NCT06266663|Other|Survey|A cross-sectional survey of 400 IBD patients who will be actively recruited from the gastroenterology (GI) specialty clinics at Einstein-Montefiore Medical Center and Icahn School of Medicine at Mount Sinai Hospital. The survey will consist of validated screening measures on social domains known to affect health outcomes as well as measures of medication adherence and HRQoL.
79398312|NCT00579111|Drug|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
79723914|NCT04235569|Drug|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
79723915|NCT04235569|Drug|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
79723916|NCT04235569|Drug|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
79723917|NCT02789449|Other|assessment of DLNO and DLCO|
79858118|NCT06266637|Other|Conventional Physical Therapy Program|"Conventional Physical Therapy program:~trunk muscles strengthening exercises, trunk muscles endurance exercises, trunk proprioception exercises . postural correction exercises. Core exercise Spinal mobility exercises"
79858119|NCT06266637|Other|Physiotherapeutic Scoliosis-Specific Exercise (Schroth)|It uses exercises customized for each patient to return the curved spine to a more natural position. The spine is addressed in all three anatomical planes - sagittal, frontal and transverse. The purpose of the method is to create spinal balance and stability by improving body mechanics and spinal stabilization to prevent further curve progression
79723918|NCT01197378|Drug|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
79723919|NCT02797639|Other|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
79723920|NCT02797639|Other|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
79858120|NCT06266624|Diagnostic Test|Tourniquet Test|Tourniquet Test was performed in patients with HHT
79858121|NCT06266611|Drug|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
79858122|NCT06266611|Drug|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
80020639|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
80020640|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
79261020|NCT03199443|Diagnostic Test|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
79261021|NCT03203967|Procedure|Epidural morphine|2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
79398313|NCT04363437|Drug|Colchicine|People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
79398314|NCT04363437|Drug|Usual Care|COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
79398315|NCT01570244|Drug|levonorgestrel|multiple doses
79398316|NCT01570244|Drug|Ethinylestradiol|multiple doses
79398317|NCT01570244|Drug|levonorgestrel|multiple doses
79398318|NCT01570244|Drug|BI 201335|multiple doses
79398319|NCT01570244|Drug|Ethinylestradiol|multiple doses
79398320|NCT00579813|Drug|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
79398321|NCT00580671|Behavioral|MET/CBT|Weekly Individual Counseling Sessions
79561129|NCT04983979|Drug|Placebo|matched placebo given titrated according to potassium at a dose to 5 or 10g
79561130|NCT04976244|Procedure|Intravitreal injection|Intravitreal injection to the regimen pro re nata
79561131|NCT04976166|Behavioral|Education|More informed and detailed education
80020641|NCT02959437|Drug|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
80020642|NCT05179304|Procedure|Oncoplastic technique with a droplet-shaped glandular flap|"A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps."
79561132|NCT04976166|Behavioral|Education|Shared decision making
79561133|NCT04976166|Behavioral|Education|education as usual
79561134|NCT04975802|Other|Placebo|10 oz (296 ml) cherry flavored still beverage
79561135|NCT04975802|Dietary Supplement|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
79561136|NCT04975802|Dietary Supplement|Caffeine|10 oz (296 ml) cherry flavored still beverage
79723921|NCT02789527|Drug|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
79723922|NCT02789527|Genetic|Genotyping|DNA sampling from a saliva sample
79561137|NCT04972747|Other|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
79561138|NCT04971811|Other|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
79561139|NCT04971811|Other|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
79723923|NCT04233307|Diagnostic Test|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
79858123|NCT06266611|Drug|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
79398322|NCT00580671|Behavioral|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
79723924|NCT02789215|Behavioral|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
79723925|NCT02792647|Drug|Placebo|Administered orally
79723926|NCT02792647|Drug|IX-01|Administered orally
79858124|NCT06266572|Behavioral|Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)|Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
79858125|NCT06266559|Other|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
79398323|NCT00580671|Behavioral|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
79398324|NCT01535222|Drug|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
79398325|NCT01535222|Drug|Placebo|Commercially available NaCl
79398326|NCT01549886|Drug|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
79398327|NCT01549886|Drug|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
79398328|NCT01549886|Drug|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m^2 intravenous infusion
79398329|NCT00610311|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
79398330|NCT00610311|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
79398331|NCT00610311|Biological|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
79561140|NCT04971395|Drug|XTMAB-16 2mg/kg|Biological XTMAB-16 IV infusion single dose
79561141|NCT04971395|Drug|Placebo|Placebo; IV infusion single dose
79561142|NCT04971395|Drug|XTMAB-16 4mg/kg|Biological XTMAB-16 IV infusion single dose
79561143|NCT04969562|Behavioral|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
79561144|NCT04968782|Other|Patients with acute appendicitis|No intervention, single survey
79561145|NCT04964700|Drug|Natalizumab|Monthly Infusions
79561146|NCT04961372|Other|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
79581202|NCT01933828|Procedure|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
79581203|NCT01933828|Device|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
79581204|NCT01933841|Device|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
79723927|NCT02792491|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
79398332|NCT00610311|Biological|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL)
79398333|NCT00610311|Biological|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10^8 cells will be given.
79398334|NCT04767230|Other|Dietary Intervention|A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
80020643|NCT03102424|Device|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
79261022|NCT03203967|Procedure|Epidural placebo|5 ml normal saline is administered through the epidural catheter at the end of surgery.
79561147|NCT04960683|Device|Lokomat training|"Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~5 sessions of 45 minutes a week, each session includes:~5 minutes of stretching exercise~20 minutes of strengthening exercise~10 minutes of balance exercise~10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~5 sessions of 45 minutes of conventional therapy (same as above) per week~5 sessions of 45 minutes on Lokomat per week"
79723928|NCT02792803|Drug|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
79723929|NCT02792803|Drug|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
79858126|NCT06266520|Procedure|MNK therapy to release the superficial fascia|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
80020644|NCT03102424|Device|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
80020645|NCT02297906|Drug|Ketorolac|Non-steroidal anti-inflammatory drug
80020646|NCT03619161|Other|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
80020647|NCT03619161|Other|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
80020648|NCT03511820|Drug|Lipo-AB® (amphotericin B) liposome|"Name: Lipo-AB® (amphotericin B) liposome for injection~Dosage form: Lyophilized powder 50 mg/vial~Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
79398335|NCT00610701|Device|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
79398336|NCT00610701|Device|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
79723930|NCT02792803|Drug|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
79723931|NCT02792569|Procedure|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
79723932|NCT02797795|Drug|NEV801|Dose Escalation
79723933|NCT02789059|Other|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
79723934|NCT02797249|Drug|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
79723935|NCT02797249|Other|Blank|Routine examination during pregnancy.
79723936|NCT02792335|Drug|apixaban|
79723937|NCT02792335|Drug|dabigatran|
80020649|NCT02957331|Drug|Propranolol|
79261023|NCT03203967|Procedure|Single femoral nerve block|Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
79261024|NCT03203967|Drug|Intravenous morphine analgesia|Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
79723938|NCT02792335|Drug|rivaroxaban|
79723939|NCT02792335|Drug|warfarin|
79723940|NCT02792023|Other|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
79723941|NCT02792023|Device|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
79261025|NCT03204045|Drug|fentanyl|2 mL mixture of fentanyl with isotonic saline
79858127|NCT06266520|Procedure|acupuncture|Acupuncture treatment employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
79858128|NCT06266507|Behavioral|Ergotherapy Based Parent Coaching|Occupational Therapy Based Parent Coaching intervention will last 10 sessions and will be carried out on the online platform. Sessions are planned to last between 45-60 minutes. The interviews to be held during the sessions are considered as the basic principles of parent coaching; It will be carried out in line with the principles of joint planning, observation, implementation, reflection and feedback. This intervention aims to educate mothers on proper feeding strategies for their children and to enable them to carry out these practices independently.
79858129|NCT06266507|Other|Informative Brochure Distribution|No active intervention will be applied to mothers in the target group, and an informative brochure about nutritional problems will be distributed.
79858130|NCT06266494|Device|Long-Acting silver dressings|Mepilex Transfer Ag
79858131|NCT06266494|Other|Aloe Vera|Dermaid Aloe Vera
79858132|NCT06266494|Drug|Dalbavancin|1500mg IV dose
79858133|NCT06266481|Drug|Topical dexamethasone|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
79858134|NCT06266481|Drug|10% lidocaine was sprayed over the tube for the second group|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
79723942|NCT02792023|Device|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
79723943|NCT02792179|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of [18F]RO6958948 injected will be less than or equal to (</=) 10 micrograms (µg), injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie [mCi]).
79723944|NCT01197300|Drug|Zoledronic acid|intravenous infusion
79723945|NCT02797405|Radiation|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
79261026|NCT03204045|Drug|Oxycodone|2 mL mixture of oxycodone with isotonic saline
79261027|NCT03204045|Drug|control|isotonic saline 2 mL
79261028|NCT03199521|Other|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
79261029|NCT03195153|Drug|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
79858135|NCT06266468|Behavioral|Nutricity|Nutricity is a bilingual (English/Spanish) mobile website supplemented by an automated text-messaging system.
80020650|NCT03791008|Other|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
80020651|NCT03510806|Dietary Supplement|Supplement|dietary supplement contain protein from milk and fruit extract
80020652|NCT03510806|Other|Placebo|color, taste, and calorie-matched placebo
80031652|NCT02522858|Drug|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
79561148|NCT04956172|Device|NeuroCatch Platform 2|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
79561149|NCT04950868|Drug|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
79561150|NCT04947137|Drug|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
79561151|NCT04944667|Diagnostic Test|TAVR planning|TAVR planning without VR vs after VR
79261030|NCT03195153|Drug|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
79261031|NCT03195153|Drug|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
79261032|NCT03204201|Drug|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
79261033|NCT03195309|Drug|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
79261034|NCT03195309|Drug|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
79561152|NCT04941989|Drug|HTL0022562|HTL0022562
79561153|NCT04941989|Drug|Placebo|Placebo
79561154|NCT04939116|Drug|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
79561155|NCT04939116|Drug|Placebo|Orally administered placebo capsule
79561156|NCT04938804|Device|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
79561157|NCT04935593|Other|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
79261035|NCT03199131|Procedure|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
79261036|NCT03198975|Diagnostic Test|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
79261037|NCT03203811|Drug|HTI-2088|3 dose levels
79561158|NCT04929405|Behavioral|ADAPT|ADAPT, is multi-modal to promote a targeted approach to individual parental bereavement experiences and is not time or geographically limited. ADAPT is based on the theoretical foundations of the Adaptive Leadership (AL) framework. Our interdisciplinary team developed a web-based, multi-modal intervention, labeled ADAPT, that incorporates varied self-management strategies including: A: Asking for assistance (option to connect with child's healthcare team); DA: Developing Adaptive ability (self-management tools: e.g. stress reduction, legacy building); P: Accessing Pertinent online resources (grief support networks/websites); and T: Tracking one's health (self-administered surveys for grief, sleep, anxiety, and depression). Parents can download ADAPT on any digital device (phones/computers) using a Quick Response (QR) bar code or weblink.
79561159|NCT04928144|Drug|SHJ - Low concentration|Topical ophthalmic
79261038|NCT03203811|Drug|Placebo|placebo oral tablet
79723946|NCT02791867|Drug|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
79261039|NCT03203577|Procedure|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
79261040|NCT03198819|Drug|Local Rifampisin and İnrtravenous cefotaxime|
79261041|NCT03195231|Drug|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
79261042|NCT03195231|Drug|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
79723947|NCT04234243|Procedure|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
79723948|NCT04200235|Drug|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
79261043|NCT03195387|Drug|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
79858139|NCT06266442|Other|Whole genome sequencing testing|Whole genome sequencing
79858140|NCT06266429|Diagnostic Test|Blood collection|Collecting blood pre-op and post-op for metabolite levels.
79261044|NCT02447601|Drug|PEX168|200µg,injected subcutaneously,once a week.
79723949|NCT04200235|Drug|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
79723950|NCT02791789|Other|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
80020653|NCT02298062|Drug|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
79261045|NCT02447601|Drug|Simvastatin|40mg,oral,two times
79261046|NCT03203733|Device|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
79261047|NCT03203733|Other|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
79261048|NCT02447523|Procedure|Elective abdominal surgery|
79261049|NCT03118713|Drug|metformin|oral
79261050|NCT03118713|Drug|ipragliflozin|oral
79261051|NCT03118713|Drug|glimepiride|oral
79261052|NCT02450409|Procedure|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
79858141|NCT06266416|Behavioral|IMARA for Black Male Caregivers and Girls Empowerment|IMAGE is delivered by trained Black female facilitators to improve girls' SRH outcomes, prevention HIV/STIs, and reduce sexual violence. Over the two days, some components of the curriculum are delivered separately to male caregivers and girls, covering parallel content, and other sections are delivered jointly in a single group. The curriculum, extensively tailored for the target population and pilot tested, addresses Black girls' sexual development, risk for sexual violence, female anatomy, body positivity, HIV/STI knowledge and attitudes, and condom use. IMAGE is designed to strengthen bonds and communication between male caregivers and girls by encouraging perspective-taking (i.e., reverse role play) and conflict resolution.
79858142|NCT06266416|Behavioral|Time-matched control program|FUEL will engage Black male caregivers and girls to promote good nutrition, exercise, and informed consumer behavior. Topics include the impact of media on body image, evaluating nutritional labels to make healthy food choices, eating balanced meals, establishing regular exercise routines, and how families and communities can support healthy behavior. FUEL includes a brief video about HIV/AIDS and other STIs but otherwise does not otherwise address sexual health. Like IMAGE, FUEL is delivered in groups of 6-8 dyads over two workshop days (~10 hours total) in one weekend. Parts of the curriculum are delivered separately to girls and male caregivers covering parallel content and other components are delivered jointly.
79723951|NCT02791711|Other|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
79261053|NCT02450409|Procedure|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
79723952|NCT02791243|Drug|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
79723953|NCT02791243|Drug|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
79261054|NCT02449707|Procedure|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
79261055|NCT02449707|Device|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
79261056|NCT02449707|Device|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
79261057|NCT02449707|Device|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
79723954|NCT02791243|Drug|Negative Control|0.9% aqueous NaCl
79723955|NCT02791477|Device|Attune FB PS knee arthroplasty|
79723956|NCT04234165|Device|TURBT|different power sources ( bipolar vs monopolar)
79723957|NCT05393635|Biological|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
79723958|NCT02788825|Procedure|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
79261058|NCT02449707|Device|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
79261059|NCT02449707|Procedure|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
79261060|NCT02449707|Procedure|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
79261061|NCT03198585|Drug|Empagliflozin 10 MG|Capsule, once a day for 90 days
79261062|NCT03198585|Other|Placebo|Capsule, once a day for 90 days
79261063|NCT02447289|Drug|Intranasal ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
79261064|NCT02447289|Drug|Oral ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
79723959|NCT02797483|Other|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
79723960|NCT02797483|Other|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
79723961|NCT02797483|Other|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
79723962|NCT02791087|Other|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
79723963|NCT02791087|Other|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
79723964|NCT02797015|Drug|RPC1063|Oral capsule daily
79723965|NCT02791009|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
79261065|NCT02447289|Drug|Intranasal midazolam|Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
79858143|NCT06266403|Behavioral|Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
79858144|NCT06266403|Behavioral|Clear Speech|"PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the ___ this time. Participations will be instructed to overenunciate the critical words."
79858145|NCT06266403|Behavioral|Unstructured communicative interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
79858146|NCT06266403|Behavioral|Clear Speech Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success."
79858147|NCT06266390|Device|Transcranial Magnetic Stimulation (TMS)|The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
79561160|NCT04928144|Drug|SHJ - Mid concentration|Topical ophthalmic
79561161|NCT04928144|Drug|SHJ - High concentration|Topical ophthalmic
79561162|NCT04928144|Drug|SHJ - Maximum tolerated|SHJ - Maximum tolerated
79561163|NCT04927793|Drug|EDP-938|[14C]EDP-938
79561164|NCT04926701|Drug|ETD001 single dose|Single ascending doses of inhaled ETD001
79723966|NCT02791009|Other|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
79561165|NCT04926701|Drug|Placebo single dose|Single doses of inhaled placebo
79561166|NCT04926701|Drug|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
79723967|NCT02791009|Other|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
79723968|NCT02791009|Other|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
79723969|NCT02791009|Other|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
79723970|NCT02791009|Other|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
79723971|NCT02790775|Drug|Anti-VEGF in quadrant 1|
79723972|NCT02790775|Drug|Anti-VEGF in quadrant 2|
79723973|NCT02790775|Drug|Anti-VEGF in quadrant 3|
79561167|NCT04926701|Drug|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
79561168|NCT04926701|Drug|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
79561169|NCT04926701|Drug|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
79561170|NCT04919239|Biological|RUTI®|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
79561171|NCT04919239|Biological|Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
79561172|NCT04917367|Procedure|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
79561173|NCT04916743|Other|Intradialytic exercise group|Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
79561174|NCT04914377|Drug|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
79561175|NCT04911439|Other|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
79561176|NCT04911439|Other|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
79561177|NCT04911439|Other|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
79561178|NCT04911257|Device|Cervical or Lumbar Spinal fusion|This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
79561179|NCT04904172|Device|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
79561180|NCT04903821|Drug|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
79561181|NCT04902235|Drug|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
79561182|NCT04902235|Drug|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
79561183|NCT04900480|Other|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
79723974|NCT02790775|Drug|Anti-VEGF in quadrant 4|
79723975|NCT04010695|Diagnostic Test|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
79858148|NCT06266377|Other|Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder|"The AUT-MENU intervention study will be structured in two phases: a preliminary observation phase (T0), which will assess and describe the acceptance of standard meals in the context of collective catering in primary and high schools by the subjects enrolled in the study; and an intervention phase (T1) in which the acceptance of menus targeted to the nutritional and sensory needs of the same subjects enrolled at T0 will be assessed.~The revision of the standard menus will be carried 1) balancing energy and macronutrient content, 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population will be evaluated through meal evaluation forms. These results will be compared with the ones collected during the first observational phase (T0)."
79261066|NCT02447289|Drug|Oral midazolam|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
79723976|NCT04010695|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
79858149|NCT06266377|Other|Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder|A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity.
79858150|NCT06266351|Device|This is observational IOP measurement|IOP measurement of patients having LASIK with both CATS and GAT
79858151|NCT06266338|Drug|Pembrolizumab|200 mg IV q 3 weeks
79858152|NCT06266338|Drug|Lenvatinib|20 mg PO daily
79858153|NCT06266325|Other|There is no intervention. Exposures are predictor variables of mortality.|Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
79261067|NCT02447367|Drug|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
79261068|NCT02447367|Drug|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
79261069|NCT03203265|Other|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
79561184|NCT04899843|Dietary Supplement|Zinc sulphate tablet 20 mg|Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
79561185|NCT04899843|Dietary Supplement|Placebo tablet 20 mg|Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
79561186|NCT04897802|Drug|Experimental: GLP1-RA (exenatide) administration|a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
79561187|NCT04897802|Drug|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
79561188|NCT04892628|Other|Progressive resistance training|Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
79561189|NCT04892628|Other|Aerobic training|The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
79561190|NCT04891523|Dietary Supplement|Probiotics-O (Burgerstein)|Topical oral treatment with the probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein) in form of a lozenge, daily, during 3 weeks.
79858154|NCT06266312|Behavioral|A multimodal prehabilitation programme|"During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~5 min. warm-up~35 min. cycling at 40-60% of (HR reserve + resting HR)~5-10 min. cool-down~+ strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~3 min warm-up (20W)~14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week."
79398337|NCT04107506|Behavioral|Filming Interactions to Nurture Development|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
79561191|NCT04891523|Other|Placebo [inactivated Probiotics-O (Burgerstein)]|Topical oral treatment with the placebo [inactivated probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein)] in form of a lozenge, daily, during 3 weeks.
79723977|NCT04010695|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
79723978|NCT02790931|Other|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
79858155|NCT06266299|Drug|KK2269|KK2269 administered intravenously
79561192|NCT04889807|Other|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
79561193|NCT04882384|Procedure|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
79561194|NCT04882332|Other|sampling for diabetes control parameters|Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
80020654|NCT02298062|Drug|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
79561195|NCT04882332|Other|Sampling for vitamin B12 level|Intravenous blood sampling for a sample of vitamin B12 level
79561196|NCT04882189|Diagnostic Test|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
79723979|NCT02790697|Other|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
79723980|NCT02790385|Device|Negative Pressure Wound Therapy|
80020655|NCT03510728|Behavioral|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
79561197|NCT04880460|Dietary Supplement|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
79858156|NCT06266299|Drug|Docetaxel|antineoplastic drug administered intravenously
80020656|NCT03510728|Behavioral|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
79561198|NCT04880460|Dietary Supplement|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
80020657|NCT03510728|Behavioral|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
80020658|NCT03101956|Procedure|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
80031653|NCT02522858|Drug|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
79561199|NCT04876924|Drug|BBP-711|BBP-711, oral suspension
79561200|NCT04876924|Drug|Placebo|Placebo matching BBP-711
79561201|NCT04871425|Drug|Ketamine|IV ketamine
79723981|NCT02790385|Other|Standard Gauze Treatment|
79723982|NCT02788435|Behavioral|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
79723983|NCT04233151|Drug|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
79723984|NCT04233151|Drug|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
80020659|NCT03101956|Procedure|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
79261070|NCT03203265|Other|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
79261071|NCT03203265|Other|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
79261072|NCT03203655|Behavioral|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
79561202|NCT04871425|Drug|Fentanyl|IV fentanyl
79561203|NCT04871217|Diagnostic Test|68Ga-NODAGA-RGD PET-imaging|Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
79561204|NCT04869605|Diagnostic Test|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
79723985|NCT04233151|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m^2 on Days 1 and 5-fluorouracil 400 mg/m^2 IV bolus on day 1, then 1200 mg/m^2/dx2days(total 2400 mg/m^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
79723986|NCT04233541|Diagnostic Test|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
79858157|NCT06266286|Device|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more"
79723987|NCT02796703|Dietary Supplement|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
79723988|NCT02796703|Dietary Supplement|Placebo|2 cc of milk will be given to control group
79723989|NCT02796547|Drug|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
80020660|NCT03511508|Behavioral|ChroPreg + standard care|"Ongoing update of individual maternity care plan.~Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~Possibility for psychologist consultation.~Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
80020661|NCT02303054|Procedure|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
80020662|NCT02303132|Other|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
79261073|NCT03203655|Behavioral|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
79261074|NCT02447445|Procedure|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men < 27 kg and women <16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
79261075|NCT02447211|Drug|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
79561205|NCT04858750|Device|Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy|During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
79561206|NCT04855045|Drug|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
79561207|NCT04838197|Other|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
79261076|NCT02447211|Other|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
79723990|NCT02796547|Other|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
79858158|NCT06266286|Device|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
79858159|NCT06266273|Other|No intervention|No intervention
79858160|NCT06266260|Device|EUS PPG measurement|Direct EUS PPG measurement
79858161|NCT06266247|Diagnostic Test|Take blood samples|Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet&amp;#39;s disease using biological drugs and not using biological drugs
79858162|NCT06266221|Drug|Prednisone 20 Mg|Oral corticosteriods
79561208|NCT04835584|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
79723991|NCT01196988|Biological|Influenza vaccine GSK2321138A|intramuscular injections
79303735|NCT05573321|Other|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
79858163|NCT06266221|Drug|Oral Placebo|Oral placebo
79858164|NCT06266221|Drug|Methylprednisolone 120 Mg|IV corticosteriods
79723992|NCT01196988|Biological|FluarixTM|intramuscular injections
79723993|NCT01196988|Biological|Influenza vaccine GSK2604409A|intramuscular injections
80020663|NCT03515018|Drug|hydroxyurea|pulse therapy
79303736|NCT03067623|Drug|PRP|PRP intrauterine infusion
79303737|NCT03067623|Device|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
79561209|NCT04835584|Drug|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
79561210|NCT04835584|Drug|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
79561211|NCT04831502|Drug|TAK-906|TAK-906 Tablets.
79561212|NCT04831502|Drug|TAK-906|TAK-906 Capsules.
79561213|NCT04828434|Other|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
79561214|NCT04819854|Drug|EP395|capsule for oral treatment
79561215|NCT04819854|Drug|Placebo|capsule for oral treatment
79581205|NCT01933841|Procedure|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
79723994|NCT02790541|Device|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
79723995|NCT02796469|Drug|Pentoxifylline|
79723996|NCT02796469|Drug|Corticosteroid|
79723997|NCT02796469|Drug|Placebo|
79858165|NCT06266221|Drug|IV Placebo|IV placebo
79858166|NCT06266208|Procedure|Exostectomy|Patients diagnosed with dorsal osteophyte and experiencing pain were advised to proceed with osteophyte removal surgery during their initial visit.The surgical procedure, following protocol occurred during the second visit and involved the following steps: a 2-4 mm incision using a Beaver-64-MIS scalpel on the distal surface wall of the toe, parallel to its longitudinal axis, followed by careful osteophyte drilling; precise delineation of the osteophyte contour using a blunt elevator to prevent nailbed damage; resection executed through medial and lateral movements facilitated by a mini-Shannon drill; and finally, pressure application with a surgical spoon to extract the bone paste resulting from the drilling process.
79858167|NCT06266208|Procedure|Cut fingernail|Patients diagnosed with dorsal osteophyte and experiencing pain underwent nail cut fingernail
79858168|NCT06266195|Diagnostic Test|sierological test|sierological test: circulant vescicles
79858169|NCT06266169|Other|making artificial intelligence based decisions of gamete, embryo and endometrial potential|The method of Raman spectroscopy is based on the registration of inelastic scattering of photons. Each compound has its own spectral pattern when using a certain type of monochromatic radiation (laser). With this method, it is possible to obtain metabolic fingerprints from the objects being studied. Luminescent spectroscopy is a type of spectroscopy used to register emission from objects that occurred after absorbing the exciting (primary) radiation. Spectrophotometry is the detection of radiation in the visible area of the spectrum. Raman spectroscopy is used for the spent medium and semen to build artificial intelligence model and make prognosis of function for each object. For endometrium, luminescent spectroscopy and spectrophotometry are used to build the model and test its clinical relevance
80020664|NCT03515018|Drug|Imatinib|400mg qd PO per day
80020665|NCT03748966|Drug|Calcitriol|Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
80020666|NCT05891418|Behavioral|Two informational emails with plan information|Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
80020667|NCT05891418|Behavioral|Standard notice of eligibility determination|No extra outreach during intervention period.
79581206|NCT01933867|Procedure|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
79723998|NCT02796157|Device|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
79723999|NCT02796157|Device|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
79724000|NCT03328741|Behavioral|Online Osteoarthritis treatment|6 week online-program
79724001|NCT03328741|Behavioral|Face-to-face osteoarthritis treatment|3 months face-to-face program
79858170|NCT06266156|Behavioral|Score of anxiety questionnaire|All participants were answered the dental anxiety questionnaire.
79858171|NCT06266156|Diagnostic Test|Heart rate|All participants heart rate were measured with finger type pulse oxymeter.
79858172|NCT06266156|Diagnostic Test|Oxygen saturation|All participants oxygen saturation were measured with finger type pulse oxymeter.
79858173|NCT06266143|Drug|Y101D|Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.
79858174|NCT06266130|Device|Treatment Group Digital Bonding Tray|The Digital Bonding Tray is used in orthodontic treatment of misaligned teeth and provides a method to accurately position orthodontic brackets onto a patient's teeth simultaneously during a single procedure.
79561216|NCT04816747|Biological|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
79858175|NCT06266130|Device|Control Group Direct Bonding|The orthodontic brackets will be applied to Subject's teeth individually with direct bonding method.
79858176|NCT06266104|Procedure|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
79858177|NCT06266091|Drug|M701|Intra-peritoneal infusion of M701 combined with system therapy
79561217|NCT04809012|Biological|STI-3031|STI-3031 is an anti-PD-L1 antibody
79561218|NCT04807985|Device|JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
79561219|NCT04807725|Genetic|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
79858178|NCT06266091|Drug|paracentesis|paracentesis combined with system therapy
79858179|NCT06266078|Device|Innovative PPE|The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
79858180|NCT06266078|Device|Traditional PPE|The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
79261077|NCT03198429|Behavioral|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
79561220|NCT04807725|Other|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
79581207|NCT01933867|Procedure|Air insufflation insertion|
79581208|NCT01933906|Drug|P1101|
79858181|NCT06266052|Procedure|Triangular Flap|Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.
79858182|NCT06266052|Procedure|Berwick Flap|Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.
79858183|NCT06266052|Procedure|Saurez Flap|In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.
79858184|NCT06266052|Procedure|Heitz Flap|Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
79858185|NCT06266026|Diagnostic Test|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
80020668|NCT05891405|Procedure|Cardiac surgery|Operations for congenital heart diseases
79303738|NCT05729529|Other|Lipoid acid gel|Topic lipoid acid gel used with topic oral gel used on tongue
79581209|NCT01933945|Procedure|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
79581210|NCT01933945|Drug|Sorafenib (Nexavar, BAY43-9006)|
79858186|NCT06266013|Other|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the lower limbs.
79858187|NCT06266000|Drug|Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
80020669|NCT05891366|Drug|WAL0921|Investigational product WAL0921
80020670|NCT05891366|Drug|Placebo|Placebo product
80020671|NCT02297828|Device|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
79261078|NCT03198429|Behavioral|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
79398338|NCT04107506|Behavioral|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
79561221|NCT04801459|Procedure|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
80020672|NCT02297828|Device|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
79261079|NCT03198273|Other|Clinical pilates exercises|servical, lumbal, pelvic muscles
79398339|NCT00581061|Drug|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
79561222|NCT04799405|Device|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~First taper phase: three 30 minutes tDCS sessions applied every other day;~Second taper phase: three 30 minutes tDCS sessions applied one every third day;~Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
79261080|NCT03198273|Other|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
79261081|NCT03203499|Drug|ANS-6637 Oral Tablet|Ascending single doses administered orally.
79261082|NCT03203499|Drug|Placebo Oral Tablet|Placebo administered orally.
79261083|NCT03203343|Procedure|Operation - PIRS|Operation by its known design for PIRS group
79398340|NCT04107272|Device|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
79724002|NCT02786797|Behavioral|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
79858188|NCT06266000|Drug|Commercial Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
79858189|NCT06266000|Drug|Palm Oil capsule|Palm oil capsule
79858190|NCT06265961|Other|Education|"In line with the Papadopoulos Tilki Taylor cultural competence development model used in the research, a training presentation titled overview and basic concepts of intercultural nursing will be held at the beginning of the intervention in order to increase the cultural knowledge levels of nurses. In order to test the effectiveness of the bibliotherapy method, training will be given online via Google Meet to both groups (both study and control) at the beginning of the research."
80020673|NCT05891340|Other|Respiratory muscle exercise|respiratory muscle exercise with inspiratory muscle trainer (two times a day)
80020674|NCT05891340|Other|Endurance exercise|walking exercise 5000 steps/day
80020675|NCT05891288|Other|BioCoat® by Premier®|Bioactive pits and fissure sealant
80020676|NCT05891288|Other|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
80020677|NCT05891145|Drug|Remimazolam|Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
80020678|NCT05891145|Drug|midazolam|Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
79724003|NCT02786797|Behavioral|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
79561223|NCT04798131|Other|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
79561224|NCT04798131|Other|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
79398341|NCT04107272|Device|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
79561225|NCT04795440|Procedure|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
79561226|NCT04794036|Other|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
79724004|NCT04200001|Other|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30~EORTC QLQ-BR23~EORTC SHQ-C22~CUPIDON 2 specific questionnaire"
79398342|NCT01443845|Drug|Roflumilast|Roflumilast 500 µg, oral administration, once per day
79724005|NCT01196052|Drug|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
79561227|NCT04794036|Other|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
79561228|NCT04792957|Diagnostic Test|immunohistochemical methods|The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
79561229|NCT04790773|Other|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
79261084|NCT03203343|Procedure|Operation - MARCY|Operation by its known design for MARCY group
79398343|NCT01443845|Drug|Placebo|Dose-matched placebo, oral administration, once per day.
79398344|NCT04754204|Device|Arrhythmia Management System (AMS)|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
79398345|NCT01549652|Drug|Ondansetron|Ondansetron 8 mg oral tablet
79398346|NCT01549652|Drug|Placebo|Placebo to Match Ondansetron
79398347|NCT01549652|Drug|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
79724006|NCT02689921|Drug|Exemestane|Aromatase inhibitor
79724007|NCT02689921|Drug|Letrozole|Aromatase inhibitor
79724008|NCT02689921|Drug|Anastrozole|Aromatase inhibitor
79724009|NCT02689921|Drug|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
79724010|NCT02689921|Drug|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
79858191|NCT06265961|Other|Bibliotherapy|"The intervention consists of 1 online intercultural nursing training, 2 book and 2 short story reading activities and 1 film evaluation to be carried out over a 3-month period.~After the training, the nurses in the study group will be asked to read the introductions of the books on the reading list and choose 2 books that they feel close to and that they have not read before. Participants will complete readings and assignments (evaluation form, reflective thought essay) asynchronously in time periods convenient to them.~In addition to books, a supporting film will be used to raise awareness. At the end of the movie, they will be asked to write on their notes how they can relate to intercultural nursing, how they can behave when faced with similar situations, and what differences there are between their ideas about intercultural nursing before and after the movie."
79261085|NCT03198195|Procedure|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
79261086|NCT03203421|Biological|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
79261087|NCT03203421|Biological|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
79261088|NCT03198117|Drug|Huaier Granule|a Chinese traditional medicine
79261089|NCT03198117|Other|placebo|placebo
79398348|NCT01549652|Drug|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
79398349|NCT01549652|Drug|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
79398350|NCT04118504|Device|Mobile application|Lifestyle intervention on through mobile application
79561230|NCT04788329|Behavioral|"Prepare for Surgery, Heal Faster Program"|This NYU program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel. The program uses five steps to ease stress-related symptoms prior to surgery and improve help recovery time. By practicing deep relaxation, it is possible to reduce anxiety and promote a feeling of calmness. The patient swill be enrolled in the course preoperatively and will be ask to continue these meditations for ten weeks.
79581211|NCT01933971|Drug|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
79724011|NCT02689921|Drug|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
79303739|NCT05729529|Drug|Placebo|Placebo oral gel used on tongue
79261090|NCT03194997|Other|Dance|The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
79261091|NCT03194997|Other|Pilates|The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
79398351|NCT01569464|Drug|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
79561231|NCT04788329|Behavioral|Wim Hof Method|Patients will be enrolled in Wim Hof Method, a breathing/meditation program. This is a free online program, developed by a man named Wim Hof and his techniques. On this website, he explains the origins and methods behind his teachings ( https://www.wimhofmethod.com/iceman-wim-hof. ). Patients in this group will take the online free course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively. The three pillars of the WHM are 1) breathing/meditation, 2) stretching exercises and 3) gradual cold exposure. The patients will be told to concentrate on the breathing and meditation component, they may not be able to participate in the cold exposure (cold showers, ice baths) in the immediate post op period because of the open wounds.
79261092|NCT03203031|Procedure|General anesthesia|Standard general anesthesia
79261093|NCT03203031|Procedure|Quadratus lumborum block|Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
79261094|NCT03118323|Other|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
79398352|NCT01569464|Other|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
79858192|NCT06265935|Behavioral|Experimental Group|It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
79261095|NCT03118479|Drug|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
79261096|NCT03118479|Drug|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
79261097|NCT03118479|Drug|Placebo Oral Tablet|One tablet to be taken daily for 3 months
79261098|NCT03118401|Other|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
79858193|NCT06265922|Device|High frequency repetitive transcranial magnetic stimulation|High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.
79858194|NCT06265922|Device|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness
79858195|NCT06265909|Device|AmDTx|AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
80020679|NCT05891080|Drug|Toripalimab|Specified dose on specified days.
80020680|NCT05891080|Drug|JS004|Specified dose on specified days.
80020681|NCT05891080|Drug|Pemetrexed|Specified dose on specified days.
80020682|NCT05891080|Drug|Nab-paclitaxel|Specified dose on specified days.
79398353|NCT01534676|Procedure|Transfusion|A routine medical procedure to transfuse packed red blood cells.
79261099|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
79261100|NCT03197961|Combination Product|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
79261101|NCT03197961|Drug|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
79261102|NCT03202875|Drug|SAR341402|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79261103|NCT03202875|Drug|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79261104|NCT03202875|Drug|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79261105|NCT03202797|Other|audiometric tests|tone and speech audiometry
79261106|NCT03202797|Other|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
79398354|NCT01534676|Biological|Blood|"Processing of RBC for transfusion include the following:~Fresh~Stored~Washed~Frozen (Cryopreserved)"
79398355|NCT01534676|Procedure|Chelation therapy|(non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
79398356|NCT01442675|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
79724012|NCT03116425|Device|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
79724013|NCT03116425|Device|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
79724014|NCT03116425|Device|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
79858196|NCT06265883|Procedure|Len+DEB-TACE+HAIC|Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight <60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
79858197|NCT06265883|Procedure|Len+DEB-TACE|Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight <60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
79858198|NCT06265857|Device|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
79858199|NCT06265857|Device|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
79875651|NCT01065298|Biological|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
79261107|NCT03202797|Other|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
79261108|NCT03203109|Behavioral|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
79261109|NCT03202953|Procedure|ventilation strategy 1|"In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.~Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
79261110|NCT03202953|Procedure|ventilation strategy 2|"In group A, after trendelenburg position, patients will be applied autoflow VCV.~- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
79398357|NCT01534520|Drug|Lidocaine|Intravaginal insertion of 4mL 2% lidocaine gel
79561232|NCT04787653|Device|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
79561233|NCT04787653|Device|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
79581212|NCT01933971|Drug|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
79724015|NCT03116425|Procedure|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
79261111|NCT03197571|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
79261112|NCT03197571|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
79261113|NCT03197571|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79875652|NCT00943943|Drug|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
80020683|NCT05891080|Drug|Carboplatin|Specified dose on specified days.
79875653|NCT00943943|Drug|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
80020684|NCT05891080|Procedure|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
80020685|NCT05891067|Behavioral|SterkWerk|Classroom-based intervention program
79261114|NCT03197571|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
79261115|NCT03197571|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79561234|NCT04787380|Device|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
79561235|NCT04785781|Other|without masks|apply a bicycle ergometer test protocol to individuals without a mask
79561236|NCT04785781|Other|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
79581213|NCT01933997|Drug|Metadoxine (MG01CI )|
79724016|NCT03116425|Procedure|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
79724017|NCT03116425|Procedure|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
79724018|NCT02887638|Other|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~Analysis of the sitting-posture profile:~o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~Analysis of the dural profile before and after the provoking task:~o Determination of the dural sensitivity by the use of the slump-test~Analysis of the pain profile before and after the provoking task:~Determination of pressure pain sensitivity by the use of pressure algometry~Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
79724019|NCT02786485|Biological|rivogenlecleucel|T cells transduced with iCasp safety switch
79724020|NCT02786485|Drug|Rimiducid|administered to treat GVHD
79875654|NCT00943943|Drug|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
80020686|NCT05891067|Behavioral|Treatment-as-usual|Active control group
80020687|NCT05891054|Behavioral|Active breaks|Two active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity.
79261116|NCT03197571|Drug|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79261117|NCT03197571|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
79261118|NCT03197571|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
79261119|NCT03197571|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
79261120|NCT03197571|Drug|Lovaza|Omega-3-acid ethyl esters
79261121|NCT03197571|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
79261122|NCT03197571|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]
79261123|NCT03197571|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
79261124|NCT03197571|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
79261125|NCT03197571|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79261126|NCT03197571|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
79261127|NCT03197571|Biological|GI-4000|RAS yeast vaccine
79261128|NCT03197571|Biological|GI-6207|CEA yeast vaccine
79261129|NCT03197571|Biological|GI-6301|Brachyury yeast vaccine
79261130|NCT03197571|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
79303740|NCT02466815|Drug|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
79858200|NCT06265857|Behavioral|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
80020688|NCT05891054|Behavioral|Physically active learning|"The physically active learning is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
79561237|NCT04785781|Other|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\N95 mask
80020689|NCT05891002|Device|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
80020690|NCT05890989|Diagnostic Test|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
79724021|NCT04198753|Diagnostic Test|Skin tape stripping|Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
80020691|NCT05890937|Diagnostic Test|Oral and practical exam|Oral and practical exam that performed at the end of the semester
79858201|NCT06265844|Device|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
79858202|NCT06265844|Device|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
79261131|NCT03197805|Diagnostic Test|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
79261132|NCT02446977|Drug|Vitamin B2 Streuli®|4ml IV
79261133|NCT02446977|Other|Solution for injection|4ml IV
79261134|NCT02447055|Biological|Tocilizumab|
79261135|NCT02447055|Drug|Melphalan|
79261136|NCT02447055|Drug|Fludarabine|
79561238|NCT04780763|Other|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
79561239|NCT04777279|Behavioral|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
79561240|NCT04777279|Dietary Supplement|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
79581214|NCT01934023|Drug|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
79261137|NCT02447055|Drug|Cyclophosphamide|
79261138|NCT02447055|Drug|Tacrolimus|
79261139|NCT02447055|Drug|Mycophenolate mofetil|
79261140|NCT02447055|Drug|Filgrastim|
79261141|NCT03202563|Drug|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
79261142|NCT03202563|Drug|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
79398358|NCT01534520|Drug|Placebo|KY Jelly
79398359|NCT00611325|Drug|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
79398360|NCT00611325|Drug|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, & 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs & 2.5 mg/m2 for patients taking EIAEDs.
79398361|NCT04752098|Diagnostic Test|Vibro-acoustic analysis (VAA), based on ultrasound radiation force|The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
79398362|NCT01798719|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
80020692|NCT05890911|Diagnostic Test|Polysomnography|Each of the patients will undergo polysomnography
80020693|NCT05890911|Diagnostic Test|Blood dopamine level measurement|In each of the patients blood dopamine level will be measured
80020694|NCT05890911|Diagnostic Test|Genetical test|Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
80020695|NCT05890885|Procedure|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
80020696|NCT05890885|Procedure|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
80020697|NCT05890859|Diagnostic Test|DXA scan|The patients will undergo 5 DXA scans fro pre- to post treatment
80020698|NCT05890859|Behavioral|Physical testing|The patients will undergo tests for maximal muscle strength and functional performance before and after treatment
79261143|NCT03202563|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
79261144|NCT03202563|Device|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
79261145|NCT03202563|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
79261146|NCT02449785|Device|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
79261147|NCT02449785|Device|CT measurements of lung morphological changes in cystic fibrosis|
79561241|NCT04777279|Other|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
79561242|NCT04776382|Other|EMME (Eye Movement Modeling Examples)|Trainees of this group will watch an EMME (Eye Movement Modeling Examples)-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
79875655|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
79875656|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
79875657|NCT00453102|Drug|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
80020699|NCT05890820|Other|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
80020700|NCT05890781|Procedure|Skin biopsy|Skin biopsy
79398363|NCT01798719|Behavioral|General Advice|Only general advice about diet
80020701|NCT05890781|Procedure|Fresh tumor sample|Fresh tumor sample
80020702|NCT05890781|Biological|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
79398364|NCT00611403|Drug|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
79398365|NCT00611403|Drug|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
80020703|NCT05890781|Procedure|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
80020704|NCT05890781|Procedure|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
80020705|NCT05890768|Drug|Lumateperone|FDA approved antipsychotic drug
79398366|NCT01534208|Drug|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
79398367|NCT01548638|Drug|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
79561243|NCT04775537|Device|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
79561244|NCT04774315|Drug|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
79561245|NCT04769479|Drug|acoramidis|acoramidis
79561246|NCT04768361|Behavioral|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
79581215|NCT01934023|Drug|Placebo|
79581216|NCT01934036|Dietary Supplement|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
79581217|NCT01934036|Drug|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
79581218|NCT01934049|Procedure|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
79581219|NCT01934049|Drug|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
79581220|NCT01934062|Procedure|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.~--------------------------------------------------------------------------------"
79581221|NCT01934075|Behavioral|Mental health treatment|6 sessions of individual mental health counseling.
79581222|NCT01934088|Drug|Propofol|
79561247|NCT04768361|Behavioral|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
79858203|NCT06265844|Behavioral|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
79858204|NCT06265831|Other|Hand-fan application to the face|Hand fan application is one of the applications recommended in managing dyspnea in evidence-based guidelines. Hand fan application effectively reduces shortness of breath by stimulating cold airflow to the 2nd and 3rd trigeminal nerve branches, mucosa, and skin.
79858205|NCT06265818|Behavioral|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
79858206|NCT06265818|Behavioral|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
79858207|NCT06265805|Behavioral|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
79858208|NCT06265805|Device|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
79875658|NCT00453102|Drug|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
80020706|NCT05890768|Drug|Risperidone|FDA approved antipsychotic drug
80020707|NCT05890755|Other|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
79561248|NCT04768335|Behavioral|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
79561249|NCT04767802|Drug|PTG-300|Hepcidin mimetic
80020708|NCT05890742|Drug|IBI310|In arm 1，IBI310 will be used once
79561250|NCT04767503|Drug|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
79561251|NCT04767503|Drug|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
79561252|NCT04761263|Other|Task-oriented circuit training|The task-oriented circuit training program consisted of 14 workstations. Time spent at each station will be 1.5 minutes. The children will complete the activity at one station and move to another station. The whole circuit will be completed in 21 minutes and it will be repeated twice per session with 3 minutes rest interval between the 2 circuits. Children will be encouraged to work as hard as possible at each workstation and will also be given verbal feedback and instructions aimed at improving performance. The progression of the task will be considered according to each child's ability and progressed as tolerated. Progressions include increasing the number of repetitions and increasing complexity of the exercise performed at each workstation, such as the distance reached in standing, reducing the height of the chair during sit-to stand, changing the height of blocks or by increasing speed of movement.
79724022|NCT04198753|Device|Skin barrier assessment|A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
80020709|NCT05890742|Procedure|Radical surgery|Radical surgery after neoadjuvant therapy
79581223|NCT01934088|Drug|Midazolam|
79581224|NCT01934088|Drug|Fentanyl|
79581225|NCT01934101|Drug|CHR-5154|CHR-5154
79581226|NCT01934101|Drug|Placebo|Placebo
79724023|NCT04198753|Diagnostic Test|Blood draw|Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
79724024|NCT01195662|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
79261148|NCT03197727|Diagnostic Test|GC Saliva-Check BUFFER|Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
79261149|NCT03197493|Drug|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
79561253|NCT04761263|Other|Selected Physical therapy program|"Facilitation of balance reactions from standing position including; standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing and standing on balance board.~Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~Gait training activities including: walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~Facilitation of protective reaction from standing position by pushing the child in different directions.~Facilitation of rising mechanism through changing position as well as returning back to the original position e.g.: from lying to standing and from sitting to standing.~Strengthening exercises for back and abdominal muscles as well as upper and lower limbs.~Jumping in place and jumping a board."
79875659|NCT00944099|Behavioral|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
79261150|NCT02450175|Drug|Everolimus|10 mg of Everolimus daily (by mouth)
79261151|NCT02450175|Drug|Letrozole|2.5mg taken daily (by mouth)
79261152|NCT03202485|Device|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
79724025|NCT01195662|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
79724026|NCT02786407|Drug|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
79724027|NCT02786407|Drug|Placebo|In these studies,patients received placebo administered to 20 injection sites
79724028|NCT03028519|Drug|Vitamin D3|Vitamin D3
79724029|NCT02786641|Drug|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
79261153|NCT03202485|Device|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
79261154|NCT03202719|Biological|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
79261155|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
79261156|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
79261157|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
79261158|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
79261159|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
79724030|NCT02786641|Drug|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
79724031|NCT02786641|Drug|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
79724032|NCT02786641|Radiation|IMRT|IMRT for all patients
79724033|NCT02786641|Drug|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
79724034|NCT02787967|Drug|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
79724035|NCT02787967|Drug|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
79724036|NCT02788123|Drug|bismuth tripotassium dicitrate|oral
79724037|NCT02788123|Drug|pantoprazole|oral
79724038|NCT03631771|Drug|Iohexol|Iohexol administered intravascularly
79724039|NCT03631771|Drug|Iodixanol|Iodixanol administered intravascularly
79724040|NCT03631771|Drug|Iopromide|Iopromide administered intravascularly
79724041|NCT03631771|Drug|Ioversol|Ioversol administered intravascularly
79724042|NCT04317768|Behavioral|Basic oral health education and motivation|Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
79724043|NCT04317768|Behavioral|Intensive oral health education and motivation|Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
79724044|NCT02787889|Other|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
79724045|NCT02787889|Other|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
79724046|NCT04232995|Other|Balance Training|Balance enhancing exercises
79724047|NCT04232995|Other|General Exercises|General Exercises
79724048|NCT02796235|Other|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
79724049|NCT02787733|Dietary Supplement|Citrus flavonoid|Daily dose of 500mg divided over two capsules
79724050|NCT02787733|Dietary Supplement|Placebo|Daily dose of 500mg divided over two capsules
79724051|NCT02787577|Behavioral|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
79724052|NCT01195272|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
79724053|NCT02796079|Biological|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
79724054|NCT02796079|Biological|saline|saline injections
79724055|NCT01194804|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
79724056|NCT02785627|Other|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
79724057|NCT04232605|Other|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
79724058|NCT04232605|Other|Placebo|Receive intravenous infusion saline
79875660|NCT00949013|Other|immunohistochemistry staining method|
79875661|NCT00949013|Other|laboratory biomarker analysis|
80020710|NCT05890742|Drug|Sintilimab|In arm1&2，Sintilimab will be used twice ，q3w
80020711|NCT05890703|Drug|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
79858209|NCT06265805|Device|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
79561254|NCT04759898|Device|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
79261160|NCT03202407|Drug|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
79581227|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
79581228|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
79858210|NCT06265792|Behavioral|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
79581229|NCT01934127|Biological|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
80020712|NCT05890703|Drug|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
80020713|NCT05890651|Diagnostic Test|ECG|Describe the electrocardiography (ECG) changes 24 hours,1,6,12 months after VSD transcatheter device closure in a pediatric population.
80031654|NCT04455542|Other|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
79261161|NCT03202329|Other|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
79261162|NCT03202329|Other|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
79261163|NCT03197649|Procedure|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
79261164|NCT03197415|Other|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
79398368|NCT00581529|Radiation|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
79261165|NCT03202251|Other|It's is a cohort|It is a prospective, observational, cohort study
79398369|NCT00612339|Drug|Avastin and Temozolomide|This is Phase II study with the combination of Avastin & Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin & Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI & repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy & requests discontinuation, patients will receive up to 4 cycles of Avastin & Temozolomide, then proceed with standard XRT therapy, & future therapy after 4 cycles will be at discretion of patient & treating physicians.
79398370|NCT02134119|Dietary Supplement|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
79398371|NCT02134119|Drug|Placebo|Sugar pill manufactured to mimic dietary supplement
79261166|NCT03197337|Procedure|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
79724059|NCT00638053|Genetic|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
79858211|NCT06265792|Procedure|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
79858212|NCT06265779|Behavioral|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
79858213|NCT06265779|Device|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
79581230|NCT01934153|Drug|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
79261167|NCT03197181|Device|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
79261168|NCT02261077|Drug|Hyoscine butylbromide|
79261169|NCT02261077|Drug|Placebo|
79261170|NCT03196869|Device|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
79261171|NCT03196869|Device|Routine intravenous drip|Routine intravenous drip-chemotherap
79581231|NCT01934166|Drug|Nalmefene 18 mg|One single oral dose of 18 mg
80020714|NCT05890521|Biological|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
79261172|NCT03196869|Drug|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
79261173|NCT03196869|Drug|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
79261174|NCT03196869|Drug|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
79261175|NCT03196869|Drug|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
79261176|NCT03196869|Radiation|intensity-modulated radiation therapy|control group is similar to Experimental group
79261177|NCT02150473|Drug|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
79261178|NCT02150473|Drug|Placebo|Placebo the same amount as adalimumab
79261179|NCT02446587|Device|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
79261180|NCT02446509|Behavioral|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
79261181|NCT02446509|Behavioral|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
79261182|NCT02779075|Drug|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
79581232|NCT01934179|Other|cytology specimen collection procedure|Undergo blood sample collection
79581233|NCT01934179|Other|laboratory biomarker analysis|Correlative studies
79581234|NCT01934179|Other|questionnaire administration|Ancillary studies
79581235|NCT01934205|Drug|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
79581236|NCT01934205|Drug|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
79561255|NCT04759898|Device|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
80020715|NCT05890508|Device|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
79724060|NCT02787421|Device|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
79261183|NCT02779075|Drug|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
79303741|NCT02466815|Drug|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
79303742|NCT02466815|Drug|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
79561256|NCT04759898|Device|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
79561257|NCT04754477|Device|Active Osseointegrated Steady-State Implant System (OSI)|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
79398372|NCT01533428|Drug|Capsaicin 8%|Capsaicin 8% transdermal delivery system
79561258|NCT04749186|Device|Compuflo Epidural Training Instrument|The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
79724061|NCT03560635|Behavioral|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
79724062|NCT02771353|Radiation|WT_vDIBH|
79724063|NCT02771353|Radiation|VMAT_FB|
79398373|NCT01533428|Drug|Placebo|Placebo Patch
79398374|NCT04066725|Drug|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
79398375|NCT04066725|Drug|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
79398376|NCT04066725|Drug|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
79724064|NCT02785861|Behavioral|supervision of physical activity|
79724065|NCT02785861|Behavioral|distance supervised physical activity|
79724066|NCT02786017|Biological|Conventional therapy|Patients will receive the conventional therapy.
79724067|NCT02786017|Biological|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.
79724068|NCT02785549|Drug|Ibuprofen|600 mg/8hours
79724069|NCT02785549|Drug|Acetaminophen|1 g/8 hours
79724070|NCT02785549|Drug|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
79724071|NCT02720653|Procedure|Endoscopic sinus surgery|
79398377|NCT04047693|Drug|dose dense MVAC with pegylated GCSF|Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
79724072|NCT03429829|Device|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
79261184|NCT02446431|Drug|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
79261185|NCT02446431|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
79261186|NCT02446431|Drug|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
79261187|NCT02446431|Drug|Temsirolimus|Temsirolimus [an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
79261188|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
79875662|NCT00299182|Drug|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
79561259|NCT04748497|Other|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
79398378|NCT01517984|Drug|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
79561260|NCT04748458|Device|Conical tapered stem|Implantation of conical tapered stem
79561261|NCT04739956|Other|The Hospital and Anxiety Depression Scale|Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
80020716|NCT05890508|Device|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
79561262|NCT04739956|Other|Point of care testing (POCT)|Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
79561263|NCT04736875|Diagnostic Test|Doppler ultrasound study|Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
79561264|NCT04735315|Other|Preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term > 37-41 weeks)
79724073|NCT02785705|Biological|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
79875663|NCT00299182|Drug|Rituximab|375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.
79261189|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
79261190|NCT02151409|Drug|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
79398379|NCT01517984|Drug|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
79398380|NCT00612573|Drug|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
79398381|NCT00612573|Drug|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
79398382|NCT00612573|Drug|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
79398383|NCT00612573|Drug|Placebo|Placebo, 12 weeks
79561265|NCT04734444|Device|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
79724074|NCT02785783|Device|Standard colonoscopy|
79724075|NCT02785783|Device|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
79724076|NCT02821507|Drug|sirolimus and cyclophosphamide|
79724077|NCT02787265|Device|spinal cord stimulation|
79724078|NCT02785393|Drug|Sugar Pill|The administration of a sugar pill
79724079|NCT02785393|Drug|Doxazosin|The administration of the Doxazosin medication
80020717|NCT05890495|Drug|Lidocaine topical|4% aqueous solution
80020718|NCT05890495|Device|Tampon|Tampon with plastic applicator provided
80020719|NCT05890482|Behavioral|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
80020720|NCT05890456|Behavioral|Students with Involved Families and Teacher Program|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.
80020721|NCT05890456|Behavioral|Services As Usual|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
80020722|NCT05890443|Behavioral|Exercise|Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
79561266|NCT04726124|Device|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
79561267|NCT04725539|Procedure|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4*4min (FiO2 = 12%) and 3*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5*5min (FiO2 = 10%) and 4*3 min (FiO2 = 21%)~one night at 1900m"
79724080|NCT02787109|Biological|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
79724081|NCT02787109|Biological|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
79724082|NCT02787109|Biological|Placebo|Saline
79724083|NCT03427255|Behavioral|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
79724084|NCT03427255|Other|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
79724085|NCT04232527|Diagnostic Test|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
79724086|NCT04232527|Diagnostic Test|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
79858214|NCT06265779|Device|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
80020723|NCT05890391|Other|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
80020724|NCT05890391|Other|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
80020725|NCT05890339|Procedure|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
80020726|NCT05890339|Procedure|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
80031655|NCT04455542|Other|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
80031656|NCT04455542|Other|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
80031657|NCT02036697|Drug|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
80031658|NCT02036697|Drug|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
79561268|NCT04722744|Procedure|screwmented metal frameworks|Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
80020727|NCT05890326|Behavioral|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
80020728|NCT05890326|Behavioral|Motor imagery-based exercise protocol (MIEP)|"All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI)."
80020729|NCT05890326|Behavioral|Combination Group|Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
80020730|NCT05890287|Drug|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
80020731|NCT05890274|Other|AF and EKG Interpretation Project ECHO|The AF and EKG Interpretation Project ECHO program is delivered via Zoom videoconferencing technology and includes 12, 1-hour long sessions that involve education on best practice management of AF for primary care providers. Each session includes an EKG challenge, case presentation by a participant, didactic presentation, and time for open Q&A. Supplementary materials are made available to all participants.
80020732|NCT05890261|Device|Cold water-perfused cooling garment|Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
80020733|NCT05890235|Drug|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
79261191|NCT02446275|Other|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
79261192|NCT02446275|Other|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
79261193|NCT03543241|Diagnostic Test|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
79724087|NCT04232527|Diagnostic Test|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
79261194|NCT02446353|Drug|Apetrol ES / Megace|Sequences of administered drugs
79561269|NCT04722679|Drug|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
79398384|NCT01517750|Device|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
79561270|NCT04721730|Behavioral|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
79724088|NCT04232527|Diagnostic Test|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
79724089|NCT04232527|Diagnostic Test|S_CODS (change of direction speed) Test|S_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
79724090|NCT02787031|Procedure|Neuraxial anesthesia|
79724091|NCT02787031|Procedure|General anesthesia|
79724092|NCT03398395|Procedure|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
79724093|NCT03398395|Procedure|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
79858215|NCT06265766|Device|cTBS|10 sessions of cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
79398385|NCT01517750|Device|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
79398386|NCT03028064|Other|blood taking|in this cohort study, we will take blood to examine the platelet function
79398387|NCT00614445|Drug|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
79398388|NCT00614445|Drug|Placebo|2 to 4 tablets daily titrated according to the protocol
79261195|NCT02150551|Biological|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; <18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : >34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
79261196|NCT03202173|Diagnostic Test|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
79561271|NCT04721730|Behavioral|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
79561272|NCT04709042|Procedure|Chordal tension measurement|"The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length."
79561273|NCT04709042|Other|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
79561274|NCT04703010|Device|Electroencephalography-Near infrared spectroscopy|Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
79561275|NCT04703010|Device|Magnetic resonance imaging|Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
79858216|NCT06265753|Other|Gastrocinemius Function Massage|The purpose of gastrocnemius massage is to alleviate muscle stiffness in the gastrocnemius muscle and enhance mobility in the foot and ankle of the individuals involved. During the GFM application, the patient assumes a prone posture on a suitable treatment bed. The therapist positions themselves behind the patient's side and secures the patient's foot between their hip and ilium.The therapist firmly holds the gastrocnemius muscle using both hands and applies pressure to the ankle, causing it to move in the direction of dorsiflexion. Simultaneously, the therapist applies mobilisation in the cranial direction, following the same path as the gastrocnemius muscle fibres, using both hands. Afterwards, the therapist gently pulls the arm and trunk backwards until the foot and gastrocnemius muscle become relaxed. The application is sustained in a rhythmic manner . We will apply this massage aproximately 10 min to experimental group.
79858217|NCT06265753|Other|Sham application|The sham application was conducted when the patient was lying face down, with the hands placed on the gastrocnemius muscle without any movement. We will apply this application aproximately 10 min to experimental group.
80020734|NCT05890235|Drug|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
80020735|NCT05890209|Device|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
79261197|NCT03202095|Drug|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
79261198|NCT02446197|Other|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
79261199|NCT02144389|Drug|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
79261200|NCT02144389|Dietary Supplement|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
79261201|NCT02144389|Dietary Supplement|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
79261202|NCT02144545|Procedure|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
79261203|NCT02144545|Procedure|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
79261204|NCT02144545|Procedure|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
79261205|NCT02144545|Procedure|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
79261206|NCT03197103|Drug|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
79261207|NCT02144623|Drug|Valproate|
79261208|NCT03196947|Drug|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
79261209|NCT02151565|Device|HTEMS|
79261210|NCT02151565|Device|TENS|
79261211|NCT03195075|Procedure|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
79261212|NCT03195075|Procedure|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
79561276|NCT04703010|Behavioral|Psychometric testing|Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
79858218|NCT06265740|Other|vaginal swab|Any pregnant woman attending the obstetrics department of Clermont-Ferrand University Hospital who requires a vaginal swab (VS) for her clinical situation (routine care) will be offered the study. If she accepts, the usual swab will be doubled and performed simultaneously in a single procedure using two swabs. The first swab will be sent to the laboratory and used for diagnosis. The second swab will be used for microbiota analysis.
79858219|NCT06265727|Drug|CRB-701|Nectin-4 targeted Antibody Drug Conjugate (ADC)
80020736|NCT05890183|Behavioral|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
80020737|NCT05890183|Behavioral|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
79261213|NCT03118635|Behavioral|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
79261214|NCT03118557|Other|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
79261215|NCT03194919|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
79261216|NCT03201783|Other|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
79261217|NCT03201783|Other|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
79261218|NCT03201861|Drug|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
79561277|NCT04698096|Other|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
79561278|NCT04698096|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
79561279|NCT04698096|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
79858220|NCT06265701|Behavioral|Derailment-Focused Reflective Journaling|Experimental group aimed at decreasing anxiety symptoms
79561280|NCT04696380|Drug|Nicotine|Participants will sample high vs low nicotine.
79561281|NCT04696380|Device|JUUL e-cigarette|Participants will sample preferred vs non-preferred JUUL flavors.
79858221|NCT06265701|Other|Everyday Tasks Reflective Journaling|Control group
79858222|NCT06265688|Drug|CX-2051|Investigational drug monotherapy
79858223|NCT06265675|Drug|Phenol|Chemical neurolysis
79724094|NCT02784301|Device|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
79724095|NCT02784301|Behavioral|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
79858224|NCT06265675|Drug|Celestone|Chemical neurolysis with corticosteroid
79858225|NCT06265675|Drug|Lidocain|Chemical neurolysis with local anesthetic
79261219|NCT03201861|Drug|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
79261220|NCT03194841|Other|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
79261221|NCT02450097|Other|Caloric restriction|
79561283|NCT04694196|Device|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
79561284|NCT04681859|Device|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
79561285|NCT04681859|Device|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
79561286|NCT04677517|Device|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~on the cochlear implant processor;~on the antenna~in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
79561287|NCT04677517|Behavioral|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
79561288|NCT04677517|Behavioral|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
79561289|NCT04677517|Behavioral|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
79561290|NCT04677517|Behavioral|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
79561291|NCT04677348|Procedure|Pericapsular nerve group (PENG) block|ultrasound-guided PENG block with 0.3% ropivacaine 20cc
79561292|NCT04677348|Procedure|Fascia iliaca compartment block (FICB)|ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
79561293|NCT04672772|Drug|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
79561294|NCT04672772|Drug|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
79858226|NCT06265662|Behavioral|A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand|The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
79561295|NCT04671082|Drug|Tolperisone Hydrochloride|TID
79561296|NCT04671082|Drug|Placebo|TID
79561297|NCT04669587|Drug|ZB716|Pharmaceutical form: capsule Route of administration: oral
79561298|NCT04669587|Drug|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
79724096|NCT02784301|Behavioral|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
79724097|NCT02784223|Device|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
79261222|NCT03194685|Drug|FF-10101-01|FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached. In Phase 2a, subjects will be randomly assigned to 1 of 3 dose levels in a balanced fashion. The treatment will continue until, intolerable toxicity, or investigation/subject decision.
79261223|NCT03194451|Other|non-interventional study|teeth collection
79261224|NCT00105079|Drug|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
79261225|NCT00105079|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
79261226|NCT00105079|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
79261227|NCT00105079|Drug|Ritonavir|100 mg po bid
79261228|NCT02450019|Procedure|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
79561299|NCT04668092|Other|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
79561300|NCT04661592|Device|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
79561301|NCT04661410|Behavioral|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
79561302|NCT04661410|Behavioral|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
79724098|NCT05262751|Drug|Ofev®|Ofev®
79724099|NCT05262751|Drug|Nintedanib formulation 1|Nintedanib formulation 1
79724100|NCT05262751|Drug|Nintedanib formulation 2|Nintedanib formulation 2
79858227|NCT06265649|Other|NOM|Non-operative management (NOM) for ALCD consists of lab test monitoring, fluid therapy, antibiotic therapy, abscess drainage if >4cm, restoring a regular diet
79875664|NCT00299182|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, & 5.
80031659|NCT02036697|Drug|Morphine|morphine 150 mcg.
80020738|NCT05890183|Behavioral|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT&E group, involvement in our exercise program.
79261229|NCT02450019|Procedure|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
79261230|NCT03196713|Behavioral|Early Intensive Behavioral Intervention|
79261231|NCT03196557|Drug|Prenisolone|Specified dose on specified days
79261232|NCT03196557|Drug|Placebo|Specified dose on dose on specified days
79261233|NCT02144779|Behavioral|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
79261234|NCT02144779|Behavioral|Usual Care|usual hospital care, not assigned to palliative care team
80020739|NCT05890183|Behavioral|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT&E group.
79261235|NCT03196401|Drug|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
79261236|NCT03196401|Radiation|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
79261237|NCT03543163|Procedure|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap|A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures
79724101|NCT02785315|Behavioral|rehabilitation & remediation approach|The rehabilitation & remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
79724102|NCT02785315|Behavioral|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
79724103|NCT02785237|Device|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
79724104|NCT02785237|Device|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
79858228|NCT06265636|Procedure|Percutaneous nerve stimulation|Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.
79858229|NCT06265636|Other|Manual therapy|Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain
80020740|NCT05890183|Behavioral|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
79858230|NCT06265636|Other|exercise|Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
79858231|NCT06265623|Other|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
80020741|NCT05890170|Other|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
79261238|NCT03543163|Procedure|sub-epithelial connective tissue graft|a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
79261239|NCT02150707|Drug|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
79261240|NCT02150707|Drug|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
79261241|NCT03196479|Drug|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
79261242|NCT03196479|Drug|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
79261243|NCT03194529|Biological|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
79261244|NCT02777827|Drug|Abediterol 0.156 μg|Dry powder for inhalation
79261245|NCT02777827|Drug|Abediterol 2.5 μg|Dry powder for inhalation
79261246|NCT02777827|Drug|Abediterol 0.05 μg|Pressurised metered-dose inhaler
79261247|NCT02777827|Drug|Abediterol 0.156 μg|Pressurised metered-dose inhaler
79261248|NCT02777827|Drug|Abediterol 2.5 μg|Pressurised metered-dose inhaler
79261249|NCT02777827|Other|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
79261250|NCT02446041|Other|Non-Interventional Study|Non-Interventional Study
79858232|NCT06265610|Procedure|TIVA/TCI|: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
79875665|NCT00299182|Drug|Vincristine|1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,& 5.
80020742|NCT05890157|Other|PRF|Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
80020743|NCT05890144|Other|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
80020744|NCT05890144|Other|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
79875666|NCT00299182|Drug|Doxorubicin|50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,& 5.
80020745|NCT05890144|Other|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
80020746|NCT05890092|Other|Observation|Observing for disease prevalence - actual and self-reported
80020747|NCT05890053|Drug|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
80020748|NCT05890040|Other|questionnaire|assessment of anxiety
80020749|NCT05887687|Drug|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
80020750|NCT05887505|Other|Vitamin D|Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
79561303|NCT04659941|Biological|BCG vaccine|Using aseptic methods, 1 mL of Sterile Water for Injection, is added to one vial of vaccine. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Drop the immunizing dose of 0.1 mL of BCG VACCINE from the syringe and needle onto the cleansed surface of the skin.
79261251|NCT02446119|Device|EndoFLIP|Measurement of pyloric resistance and compliance
80020751|NCT05887505|Other|Placebo|Oral supplementation of placebo in 3 consecutive days.
80020752|NCT05886686|Device|Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device|Validation of the combined device measurements compared with standard of care devices
79261252|NCT03201627|Drug|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
79261253|NCT02151721|Drug|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
79561304|NCT04659941|Biological|0.9% sodium chloride (NaCl) saline solution|A 0.1 ml of 0.9% NaCl saline solution applied intradermally in the lower insertion of the deltoid muscle of the right arm will be used as placebo, except contraindications or impossibilities.
79875667|NCT00299182|Drug|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,& 5.
79261254|NCT02449083|Procedure|MRI|MRI
79261255|NCT02449083|Procedure|coronary angiography|coronary angiography
79261256|NCT02150941|Device|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
79261257|NCT02150941|Device|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
79261258|NCT03201705|Device|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
79261259|NCT02151799|Procedure|Abdominoplasty and liposuction|
79261260|NCT02449317|Other|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~extracellular water/total body water < 0.36 : 4 ml/kg/hr~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
79261261|NCT02449317|Other|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
79261262|NCT03194763|Diagnostic Test|coronary angiography|computed tomography acquisitions performed on a revolution CT
79875668|NCT00299182|Drug|Methotrexate|200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 & 6.
79875669|NCT00299182|Drug|Cytarabine|3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,& 6.
79875670|NCT00299182|Drug|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
79875671|NCT00467142|Biological|bevacizumab|
79875672|NCT00467142|Drug|fluorouracil|
79875673|NCT00467142|Drug|irinotecan hydrochloride|
79875674|NCT00467142|Drug|leucovorin calcium|
79875675|NCT00467142|Genetic|polymorphism analysis|
79858233|NCT06265597|Other|Healthy Nutrition and Yoga Program|"Healthy Nutrition Program~Providing individual counseling to children every 2 weeks from the start of the program, in cooperation with a nutritionist, in line with the basic healthy eating behavior goals.~In the 2nd, 4th, 6th, 8th and 10th weeks from the start of the program, children are asked to keep nutrition diaries for 2 weekdays and 1 weekend, and planning is made according to achieving basic healthy nutrition behavior goals.~Sending reminder messages regarding the basic healthy eating behavior target via Whatsapp every week in order to maintain interaction and ensure motivation.~Yoga Program Children's yoga is applied to each group twice a week for 12 weeks.~The time points at which outcome measures will be evaluated and data reported are as follows:~From the start of the program, on the 1st day,~From the start of the program, in the 2nd, 4th, 6th, 8th, 10th, and 12th weeks~3 months after completion of study"
79858234|NCT06265584|Drug|ATG dosing platform when combined with standard tacrolimus and mini methotrexate|On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
79261263|NCT02151955|Behavioral|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
79261264|NCT03201393|Drug|Low-dose naltrexone and acetaminophen combination|Twice a day
79858235|NCT06265571|Other|perineural injection|perineural injection of local anesthestetic for postoperative pain management
79858236|NCT06265558|Procedure|Negative pressure therapy (NPT)|Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.
79858237|NCT06265558|Procedure|Dressing|Fatty dressing or hydrocolloid dressing
79858238|NCT06265545|Drug|Ivosidenib,Venetoclax,gilteritinib,Selinexor|if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
79858239|NCT06265532|Drug|EGCG 300 mg|"Participants will be administered EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
79858240|NCT06265532|Drug|Placebo for EGCG 300 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
79875676|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
80020753|NCT05886387|Other|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
79261265|NCT03201393|Drug|Placebo|Twice a day
79261266|NCT03119103|Device|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
80031660|NCT02036697|Drug|Fentanyl|15 mcg
80031661|NCT04882462|Drug|Nimotuzumab|Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
79261267|NCT03118245|Device|AuraGain|After anesthetic induction, AuraGain is inserted in children
79561305|NCT04658953|Other|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
79561306|NCT04658953|Other|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
79398389|NCT01799187|Procedure|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
79398390|NCT01799187|Procedure|apexification|apexification uses calcium hydroxide as root medication
79261268|NCT03118245|Device|I-gel|After anesthetic induction, I-gel is inserted in children
79261269|NCT03196089|Procedure|Oxygen application|Supplemental oxygen via mask
79561307|NCT04658823|Drug|HOV-12020 (Palm tocotrienols complex)|Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
79561308|NCT04658823|Drug|Placebo|Oral Softgel capsule containing soybean oil; 1 capsule twice daily
79261270|NCT02445729|Other|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
79261271|NCT02445729|Other|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
79261272|NCT03192969|Drug|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
79261273|NCT03192969|Other|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
79261274|NCT03192969|Drug|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
79398391|NCT01548404|Drug|Placebo|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
79398392|NCT01548404|Drug|Dupilumab|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
79398393|NCT00614913|Radiation|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
79261275|NCT03194295|Behavioral|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
79261276|NCT03194295|Behavioral|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
79261277|NCT03194139|Drug|GC4711 30 mg IV|GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
79261278|NCT03194139|Drug|GC4711 50 mg IV|GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
79261279|NCT03194139|Drug|GC4419 45 mg IV|GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
79261280|NCT02448927|Device|balloon aortic valvuloplasty|
79261281|NCT02448927|Device|Transcatheter Aortic Valve Implantation|
79261282|NCT02448693|Device|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
79261283|NCT02448693|Device|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
79561309|NCT04657380|Behavioral|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
79561310|NCT04657380|Behavioral|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
79561311|NCT04655885|Behavioral|Optimization of cardiac flow by base water-electrolyte supply|optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
79724105|NCT04231123|Procedure|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
79724106|NCT04231123|Procedure|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
79724107|NCT04231279|Drug|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
79858241|NCT06265532|Drug|EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
80031662|NCT04882462|Drug|Sintilimab|Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
79261284|NCT02448849|Biological|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
79261285|NCT02448849|Other|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
79261286|NCT03192891|Diagnostic Test|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
79261287|NCT03192813|Device|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
79261288|NCT03192813|Device|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
79261289|NCT03118167|Dietary Supplement|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
79261290|NCT03118167|Dietary Supplement|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
79261291|NCT03118167|Other|Placebo|Edible starches 0.35g, edible capsule
79261292|NCT03118167|Other|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
79261293|NCT02445495|Device|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
79261294|NCT02445261|Radiation|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
80020754|NCT05886114|Behavioral|Structured Multi-domain Intervention|Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
79261295|NCT03118011|Other|No smoking|No smoking
79561312|NCT04655885|Behavioral|Control arm|increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
79561313|NCT04649515|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
79261296|NCT03118011|Other|Smoking|Ability to go out to smoke
79561314|NCT04649515|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
79561315|NCT04649515|Other|0.9% saline|Placebo
79561316|NCT04648371|Other|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
79561317|NCT04640818|Drug|Cladribine Oral Tablet|Treatment according to the label and medical prescription
79561318|NCT04640818|Drug|Rituximab|Treatment according to the label and medical prescription
79561319|NCT04640818|Drug|Ocrelizumab|Treatment according to the label and medical prescription
79561320|NCT04635449|Other|Age-specific information booklet and targeted telephone call|age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
79561321|NCT04625777|Behavioral|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
79561322|NCT04625777|Behavioral|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~Become aware of God's presence;~Give thanks to God for everything in your life;~Review the events of the day guided by the Holy Spirit;~Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
79561323|NCT04625777|Behavioral|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
79561324|NCT04624087|Behavioral|food-specific go/no-go computerized training|Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.
79561325|NCT04624087|Behavioral|nonfood-specific go/no-go computerized training|Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
79261297|NCT02445183|Other|None, N/A|
79858242|NCT06265532|Drug|Placebo for EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
80020755|NCT05886114|Behavioral|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
80020756|NCT05882162|Procedure|Coronectomy|Removal of crown part of the mandibular third molar
80020757|NCT05882162|Procedure|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
80020758|NCT05881486|Drug|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
80020759|NCT05881486|Drug|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
79261298|NCT02448459|Drug|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
79398394|NCT01547780|Drug|[11C]PBR28 and Positron Emission Tomography (PET)|Brain PET with [11C]PBR28. 11C]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
79398395|NCT00583011|Drug|Local Anesthesia|Local anesthesia: 2 cc of 1% Lidocaine
79398396|NCT00583011|Drug|Placebo Group|Placebo Group: 2cc Normal Saline
79398397|NCT01547390|Drug|Aspirin|
79398398|NCT01547390|Drug|placebo|
79398399|NCT01546922|Drug|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
79858243|NCT06265519|Procedure|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate is a minimally invasive procedure that uses pulses of laser beam to remove tissue from the inside of the prostate, which surrounds the urethra (the tube leading from the bladder to the urinary opening) in patients with BPH
79858244|NCT06265506|Behavioral|Contingency Management|Contingency Management (CM) is an intervention that uses positive reinforcement (e.g. gift cards) to reinforce a desired behavior (e.g. negative alcohol biomarker tests) on a frequent (e.g. weekly), escalating (e.g. $5/week) schedule (e.g. 26 weeks) in order to increase the occurrence of that behavior (e.g. long term alcohol abstinence or reduction in drinking).
79858245|NCT06265506|Behavioral|Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)|CBT4CBT is an evidence-based online intervention that teaches CBT principles and skills to help people with alcohol use disorder reduce their drinking. CBT4CBT teaches CBT principles through video, graphics, audio instruction, and interactive exercises. Modules include video-based examples to emphasize learning of behavioral, cognitive, and affective strategies, with an emphasis on learning from examples of individuals using skills in a range of situations. Skills taught include functional analysis, coping with craving and emotions, problem solving, decision making, challenging thoughts, and assertive alcohol refusal. Interactive exercises and homework are used to encourage skills learning and practice.
79858246|NCT06265480|Other|FallFitness intervention group|Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
79858247|NCT06265467|Procedure|Closed Sinus Elevation|using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor
79858248|NCT06265467|Procedure|Open Sinus Elevation|using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
79858249|NCT06265454|Drug|low dose atropine eye drops|Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
80020760|NCT05879575|Behavioral|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
79261299|NCT02712333|Behavioral|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
79261300|NCT02712333|Behavioral|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
79261301|NCT00189267|Drug|Imiquimod 5 % Cream|
80020761|NCT05869630|Other|Exercise Programme|All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
80020762|NCT05869630|Other|Experiments|The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
80020763|NCT05869240|Drug|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
79561326|NCT04622332|Drug|SIR1-365|Route of administration: oral
79561327|NCT04622332|Drug|Matching Placebo|Route of administration: oral
79561328|NCT04616027|Drug|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
79858250|NCT06265454|Drug|Placebo|placebo
79561329|NCT04614506|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
79858251|NCT06265428|Drug|DB-1303/BNT323|Administered I.V.
79858252|NCT06265428|Drug|T-DM1|Administered I.V.
79858253|NCT06265415|Drug|Labetalol|it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
79858254|NCT06265415|Drug|Nitroglycerine|a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
80020764|NCT05869123|Radiation|Online adaptive radiotherapy|PTV with 5 margins covers CTV
79561330|NCT04614506|Device|Electroencephalogram (EEG)|These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
79561331|NCT04611100|Device|ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)|Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
79858255|NCT06265415|Drug|Nifedipine|dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
80020765|NCT05866328|Other|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
80020766|NCT05858853|Drug|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
79561332|NCT04609657|Other|Flavored carbonated soft drink (CSD)|Beverage
79561333|NCT04608916|Procedure|Using surgical diathermy to make skin incision|Using surgical diathermy to make skin incision during shoulder arthroplasty
79561334|NCT04608916|Procedure|Using scalpel blade to make skin incision|Using scaple blade to make skin incision during shoulder arthroplasty
79561335|NCT04607876|Other|Technological Facilitator|See Enhanced Intervention Arm for full description.
79561336|NCT04607876|Other|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
79561337|NCT04606784|Biological|Ampion|Ampion, nebulized for inhalation
79561338|NCT04606784|Other|Standard of Care|Standard of Care
80020767|NCT05858853|Drug|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
80020768|NCT05858853|Drug|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
80020769|NCT05858853|Drug|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
79261302|NCT02440113|Device|Nellix|Nellix Implantation
80020770|NCT05852470|Device|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
80020771|NCT05852470|Device|Clareon/Clareon Toric Aspheric IOL|Ultraviolet-absorbing and blue light-filtering intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
80020772|NCT05851612|Procedure|constant PEEP|Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
80020773|NCT05851612|Procedure|Driving pressure guided PEEP|PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.
79261303|NCT04483869|Other|Thermography|thermographic image a 1, 3, 5 et 10 minutes of life
79261304|NCT02444949|Drug|endostar|
79261305|NCT02444949|Radiation|intensity modulated radiation|
79261306|NCT02444949|Drug|cisplatin|
79261307|NCT03192579|Drug|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
79561339|NCT04606160|Behavioral|Single Session Problem-Solving Intervention|The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
79561340|NCT04603690|Dietary Supplement|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
80020774|NCT05851612|Procedure|oxygenation method guided PEEP|PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
79561341|NCT04603690|Drug|Standard of care|This arm will receive standard of care as per the hospital guidelines
79561342|NCT04598360|Procedure|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
79858256|NCT06265402|Procedure|Tab block versus retrolaminar block in abdominal plastic surgery|i inject 20ml bupivacine either 4mg dead in each side
79858257|NCT06265389|Drug|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
79858258|NCT06265350|Drug|Cadonilimab|Cadonilimab, 375mg，Q3W， IV
79261308|NCT03192579|Drug|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
79261309|NCT03192657|Drug|Basiliximab|The first administration should be within 8 weeks after disease onset.
79261310|NCT03192657|Drug|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
79261311|NCT03192657|Drug|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
79261312|NCT03193983|Procedure|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
79261313|NCT03193983|Procedure|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
79561343|NCT04590651|Procedure|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
79858259|NCT06265350|Drug|Bevacizumab|Bevacizumab, 7.5mg/kg，Q3W， IV
79261314|NCT02444169|Device|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
79261315|NCT02444169|Drug|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
79858260|NCT06265350|Procedure|Cryoablation|Patients accepted Cryoablation of pulmanary metastases
79561344|NCT04590651|Procedure|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
79858261|NCT06265337|Dietary Supplement|Lactate|Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
79858262|NCT06265337|Other|Placebo|Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
79858263|NCT06265324|Device|Angioplasty|Drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions
79858264|NCT06265311|Procedure|IDUS examination|for patients with high risks of bile duct stones recurrence using IDUS during ERCP
79858265|NCT06265298|Procedure|Conjunctival reconstruction|Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
79858266|NCT06265285|Other|Home Health Encounter|Receive in-home visits by a home health nurse
79858267|NCT06265285|Biological|Nivolumab|Given SC
79858268|NCT06265285|Procedure|Patient Monitoring|Undergo remote patient monitoring
79858269|NCT06265285|Other|Questionnaire Administration|Ancillary studies
79858270|NCT06265272|Drug|Injection of a gadolinium contrast agen|"All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;"
79858271|NCT06265272|Drug|Radiotracer Injection|"All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~The catheter will be flushed post-injection with 0.9% saline solution~The injected dose and the time of injection will be recorded.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan"
79858272|NCT06265272|Diagnostic Test|Imaging|PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
79261316|NCT02444169|Device|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
79261317|NCT02444169|Device|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
79261318|NCT02444247|Other|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
79261319|NCT02444247|Other|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
79261320|NCT02444247|Other|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
79261321|NCT02444247|Other|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
79261322|NCT03194061|Radiation|Hypofractionated Radiotherapy|20 fractions of 275cGy 5 days/week
79561345|NCT04588857|Drug|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
79561346|NCT04588857|Drug|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
79858273|NCT06265259|Drug|Initiation of vasopressine as a first vasoconstrictive drug|The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
79858274|NCT06265259|Drug|Initiation of noradrenaline as a first vasoconstrictive drug|ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
79261323|NCT03194061|Drug|Weekly cisplatin|Concomitant weekly cisplatin 35mg/m2 x 4 weeks
79261324|NCT03190551|Other|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
79261325|NCT03190551|Other|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
80020775|NCT05837143|Biological|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10^11vg/kg，6×10^11vg/kg，or 2×10^12vg/kg.
79561347|NCT04580212|Behavioral|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
79561348|NCT04579081|Device|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
79561349|NCT04575467|Drug|CBL-514|CBL-514 will be administered via injection into the thigh subcutaneous adipose layer.
79261326|NCT02343406|Drug|Depatuxizumab mafodotin|Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
79261327|NCT02343406|Drug|Temozolomide|Capsules administered orally, 150 mg/m^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
79261328|NCT02343406|Drug|Lomustine|Capsules administered orally, 110 mg/m^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
79261329|NCT02444325|Behavioral|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
79261330|NCT02444091|Drug|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
79261331|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 4 weeks
79261332|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 24 weeks
79261333|NCT02439801|Procedure|PEEP 0|0 cmH2O positive end expiratory pressure
79261334|NCT02439801|Procedure|PEEP 5|5 cmH2O positive end expiratory pressure
79561350|NCT04569448|Drug|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
79561351|NCT04568733|Behavioral|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
79561352|NCT04568733|Behavioral|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
79561353|NCT04568733|Behavioral|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
80020776|NCT05825716|Other|Ifaa Basic|"PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
80031663|NCT04882462|Drug|Chemotherapy drug|Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
80031664|NCT03106688|Diagnostic Test|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
79261335|NCT02439801|Procedure|PEEP 8|8 cmH2O positive end expiratory pressure
79261336|NCT02439723|Drug|Regorafenib|
79561354|NCT04544930|Behavioral|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
79261337|NCT02440035|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 in Group 3.
79261338|NCT02440035|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 4.
79261339|NCT02440035|Drug|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
80020777|NCT05825716|Behavioral|Ifaa Enhanced|"PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
80031665|NCT03106688|Diagnostic Test|[11C]carfentanil PET scan|[11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
79561355|NCT04544891|Other|blood sampling|Blood will be collected every 3 days until Day 28, discharge, or death
79561356|NCT04543760|Other|Prone position|prone positioning in spontaneous ventilation
79561357|NCT04543760|Other|Supine position|supine positiong in spontaneous ventilation
79561358|NCT04542980|Diagnostic Test|SARS-CoV2 Autoantibody detection|Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
79561359|NCT04532619|Behavioral|Fathering Through Change|Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
79724108|NCT02782585|Other|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
80031666|NCT03106688|Diagnostic Test|[18F]FMPEP-d2 PET scan|[18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
79261340|NCT03193827|Device|In-line filtration|In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
79261341|NCT03193827|Device|Standard treatment|Patients are treated with standard intravenous solutions and vascular access management
79261342|NCT03193749|Drug|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
79561360|NCT04531085|Procedure|Operative treatment|Surgery
79561361|NCT04531085|Procedure|Long arm cast|cast immobilization
79561362|NCT04530435|Device|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
79561363|NCT04530279|Procedure|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
79561364|NCT04529499|Drug|AVIGAN|Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
79561365|NCT04529499|Drug|Placebo Comparator|Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
79724109|NCT02782585|Other|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
79724110|NCT02782585|Other|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
79561366|NCT04528433|Behavioral|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
79561367|NCT04528433|Behavioral|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
79561368|NCT04523428|Drug|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
79561369|NCT04508504|Procedure|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
79724111|NCT02605759|Device|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
80031667|NCT03106688|Diagnostic Test|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.
79261343|NCT03193749|Drug|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
79261344|NCT03193671|Diagnostic Test|Diagnosis|Improving diagnosis
79261345|NCT03193905|Procedure|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
79858275|NCT06265246|Other|Habitual Diet + Milk|1.5 servings of milk [providing approx. 500 mg Ca/day] per day (either 1% fat milk, or 2% fat milk)
79724112|NCT02782273|Drug|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
79724113|NCT02782273|Drug|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
79858276|NCT06265246|Other|Habitual Diet + Yogurt|2 servings of yogurt [providing approx. 500 mg Ca/day] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
79858277|NCT06265220|Drug|AB-101|NK Cell Therapy
79858278|NCT06265220|Drug|Cyclophosphamide|Lymphodepleting chemotherapy
79858279|NCT06265220|Drug|Fludarabine|Lymphodepleting chemotherapy
79858280|NCT06265220|Drug|Rituximab|Anti-CD20 antibody therapy
79858281|NCT06265207|Other|Virtual reality|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
79561370|NCT04508504|Procedure|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
79561371|NCT04508504|Drug|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
80020778|NCT05825716|Other|Ifaa Enhanced + Livelihoods|"Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
79261346|NCT03193905|Procedure|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
79561372|NCT04508504|Drug|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
79561373|NCT04507633|Behavioral|ROMA therapy(reminiacence therpy, orientation, music, and art)|An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
79561374|NCT04503382|Other|Kindness Media|As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
79561375|NCT04501094|Drug|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
79724114|NCT02782507|Behavioral|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon & Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
79724115|NCT02787811|Device|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
79724116|NCT05179135|Other|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
79858282|NCT06265207|Other|routine maintenance|routine maintenance
79858283|NCT06265194|Behavioral|EMDR|The fibromyalgia protocol applied to the patients in the study was developed specifically for fibromyalgia by Konuk, and colleagues (Konuk et al.). In addition to the article, the details of the protocol and the study sheet are presented supplementary. After a short introduction, the participants were informed about the protocol, their -consent was obtained for registration, and a visual, tactile and audio bilateral stimulus that will be used in the application was introduced.
79858284|NCT06265194|Behavioral|TAU|Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
79858285|NCT06265181|Behavioral|Diabetes coaching|Diabetes coaching intervention will be provided to the participants in the intervention group by the researcher, who is a specialist nurse who has received 140 hours of Level 2 Professional Coaching Training and 20 hours of diabetes coaching training. Since each individual's needs and values will be different, diabetes coaching interventions will be tailored specifically to the individual by the researcher within the general coaching framework, but by taking into account the individual's views, awareness, needs and current situation regarding self-management regarding diabetes. This flexibility, which supports the individual-specific approach within the coaching paradigm, is among the key elements in the success of coaching interventions (43). The individual will determine the coaching agenda according to his/her own needs.
79875677|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
79875678|NCT05300789|Other|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
79875679|NCT00949091|Drug|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
79875680|NCT00944177|Drug|Metformin HCl|
79261347|NCT03190629|Device|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
79858286|NCT06265168|Other|Simulation|Physicians will participate in a simulated scenario of an adult comatose patient. The intervention will be presented as a learning situation where the physician interacts with a high-fidelity mannequin. The mannequin simulating the patient will manifest a Glasgow Coma Score of 3 (improving over time to a GCS of 4) and a range of physiological and pathological symptoms. Physicians will have access to emergency equipment, including intubation equipment, a defibrillator, and medications. A trained nurse will be present to assist with the simulation. After 20 minutes the patient will regain consciousness in order to avoid a frustrating experience for the physicians. After simulation termination, a senior physician will join the resident and ask him to report the current scenario and will stop the simulation. The entire scenario will be video-recorded.
79858287|NCT06265142|Procedure|Bladder catheterization|Participant will undergo the standard bladder catheterization for urine collection
79561376|NCT04490707|Drug|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
79561377|NCT04490707|Drug|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
79858288|NCT06265142|Procedure|clean catch urine via bladder massage technique|Participant will undergo clean catch urine via bladder massage technique
79858289|NCT06265116|Other|One-step universal adhesive|Each patient will receive a class II restoration using the corresponding group adhesive
79561378|NCT04489485|Behavioral|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
79561379|NCT04488913|Other|RACE-IT Pathway|This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
79561380|NCT04488913|Other|Standard of Care|Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
79561381|NCT04486170|Other|Education provided via a video format|The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
79858290|NCT06265103|Other|Clinical care and quality improvement|All eligible patients at each center will be included in the registry for clinical care, quality improvement and other activities that do not meet the regulatory requirements of human subjects research. Use of data for these purposes is not considered to be a human subjects research activity and will be covered under a Business Associates Agreement and a Participation and Data Use Agreement.
79398400|NCT00615927|Drug|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant & must be taken in sitting position; mini of 2hrs should be allowed between last drug intake & going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 & continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
79398401|NCT01532648|Drug|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
79398402|NCT01532648|Drug|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
79858291|NCT06265090|Other|therapeutic exercises|Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.
79858292|NCT06265090|Other|exercises|"The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~Insert a ball measuring between four and six inches in diameter in the space between your knees.~Put your left hand upon a balloon and your right arm above your head.~Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
79858293|NCT06265077|Drug|Placebo|Placebo
79858294|NCT06265077|Drug|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
79858295|NCT06265064|Diagnostic Test|STOP-Bang score >= 3 with factors predicting difficult intubation|patients with STOP-Bang score >= 3 with Mallampati score ≥ 3 or neck circumference >42 cm or mentothyroid distance <6 cm
79858296|NCT06265051|Drug|Tirofiban|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
79875681|NCT00553475|Drug|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
79875682|NCT00553475|Drug|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
79875683|NCT00553475|Drug|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
79261348|NCT03190629|Device|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
79261349|NCT02444013|Drug|Folic acid|
79398403|NCT01532648|Drug|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
79398404|NCT00617097|Drug|lidocaine|paracervical block with lidocaine
79261350|NCT02444013|Drug|Placebo|
79261351|NCT02444637|Drug|Rivastigmine|
79261352|NCT02710071|Drug|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
79398405|NCT00617097|Drug|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
79398406|NCT00617175|Device|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
79398407|NCT00617175|Device|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
79261353|NCT02710071|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
79261354|NCT02443701|Other|Exercise|Warmup program, maximum isometric strengthening, and jump training
79261355|NCT02443701|Other|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
79261356|NCT02443701|Other|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
79261357|NCT02444403|Behavioral|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
79261358|NCT02439567|Device|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
79261359|NCT02443857|Device|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
79261360|NCT02443857|Device|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
79261361|NCT02443857|Device|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
79261362|NCT02443857|Device|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
79261363|NCT02443857|Device|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
79398408|NCT04022187|Other|Observational study : no intervention|Observational study : no intervention, only exporting data
79398409|NCT01532570|Drug|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
79398410|NCT00583713|Drug|BLI-800|BLI-800 oral solution (two doses)
79398411|NCT01532414|Drug|Androxal|oral, capsules, taken one time daily, for 3 months
79398412|NCT01532414|Drug|Placebo|Oral capsule taken one time daily for 3 months
79398413|NCT01441973|Biological|Elotuzumab (BMS-901608; HuLuc63)|
79398414|NCT02074709|Drug|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
79398415|NCT02074709|Drug|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
79398416|NCT03571191|Drug|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
79398417|NCT03475251|Biological|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
79858297|NCT06265051|Drug|Saline placebo|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
79261364|NCT02443857|Device|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
79261365|NCT02439333|Device|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
79261366|NCT02439333|Device|nasal catheter or Venturi mask|Conventional oxygen therapy
79261367|NCT02439489|Drug|BKM120-CIS|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
79261368|NCT02439489|Drug|BKM120-CARBO|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
79261369|NCT02444481|Drug|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
79261370|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
79261371|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Placebo|
79261372|NCT04484103|Other|Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.|"The following features will be retrieved from the CRFs of the patients included in the MRI-FIRST trial: age, DRE findings, PSA level, prostate volume, maximal PI-RADS score; the history of biopsy will be set to a default value of none since all patients included in the MRI-FIRST trial were biopsy naïve.~Then, the RPCRC will be used to calculate two different risks: the risk of detectable prostate cancer and of significant prostate cancer (ISUP ≥2) at subsequent biopsy.~The PI-RADS score (as a stand-alone) and the risks predicted by the RPCC will be compared to the results of the prostate biopsy performed during the MRI-FIRST trial.~Throughout the study, the version 2 of the PI-RADS score will be used."
79561382|NCT04482738|Other|High-calorie meal|Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
79261375|NCT02439177|Device|Blood glucose monitoring system (Omnitest 3)|
79398418|NCT03475251|Biological|CS1003|CS1003 to be intravenously administered at the dose level determined during the dose escalation part
79398419|NCT03475251|Drug|Regorafenib|Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
79561383|NCT04476433|Other|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
79261376|NCT02439177|Device|Blood glucose monitoring system (Omnitest 5)|
79561384|NCT04472468|Device|Percutaneous Balloon Pericardiotomy|"Subxiphoid approach under fluoroscopic guidance is used.~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
79561385|NCT04464577|Drug|Fluconazole|Specified Dose on Specified Days
79561386|NCT04464577|Drug|Bupropion|Specified Dose on Specified Days
79561387|NCT04464577|Drug|Itraconazole|Specified Dose on Specified Days
79561388|NCT04464577|Drug|BMS-986235|Specified Dose on Specified Days
79261377|NCT02440191|Radiation|3DCRT|conventional radiotherapy
79261378|NCT02439411|Drug|Trametinib|
79398420|NCT01575899|Drug|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
79398421|NCT01575899|Drug|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
79561389|NCT04453384|Drug|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
79561390|NCT04453384|Drug|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
79561391|NCT04440774|Biological|CHIK low dose|A single dose of 5x10^9 vp ChAdOx1 Chik
79561392|NCT04440774|Biological|CHIK mid dose|A single dose of 2.5x10^10 vp ChAdOx1 Chik
79875684|NCT00329602|Drug|Placebo|Matching Placebo
79875685|NCT00329602|Drug|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
79398422|NCT04122833|Other|Next generation sequencing|observational study
79561393|NCT04440774|Biological|CHIK high dose|A single dose of 5x10^10 vp ChAdOx1 Chik
79561394|NCT04440774|Biological|ZIKA low dose|A single dose of 5x10^9 vp ChAdOx1 Zika
79561395|NCT04440774|Biological|ZIKA mid dose|A single dose of 2.5x10^10 vp ChAdOx1 Zika
79561396|NCT04440774|Biological|ZIKA high dose|A single dose of 5x10^10 vp ChAdOx1 Zika
79561397|NCT04440774|Biological|Saline placebo|A single dose of isotonic saline solution (0.9%)
79875686|NCT01060696|Drug|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
79875687|NCT01065610|Drug|Oxytocin|
79875688|NCT01065610|Drug|Placebo|
79875689|NCT01062646|Behavioral|Multimodal music therapy|
79875690|NCT01062646|Behavioral|Community treatment as usual|
79875691|NCT00463866|Drug|Budesonide/formoterol|
79875692|NCT00313846|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
79858298|NCT06265038|Device|ReSpace TiCell Cage|"ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods."
79858299|NCT06265025|Drug|GM103 (Part A)|dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days [2 weeks]).
79561398|NCT04427397|Other|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
79858300|NCT06265025|Drug|GM103 (Part B)|dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease [HNC, CRC]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days [2 weeks]).
79858301|NCT06265025|Drug|GM103 and Pembrolizumab (Part C)|dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days [3 weeks]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days [3 weeks]).
79561399|NCT04418362|Other|Neurofeedback training|A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
79261379|NCT03192735|Drug|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
79561400|NCT04416867|Device|splint and home exercise|Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
79561401|NCT04416867|Device|RESWT|RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
79561402|NCT04416867|Device|physical therapy|20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks
79561403|NCT04414618|Drug|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
79561404|NCT04414618|Drug|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
79561405|NCT04412824|Drug|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
79561406|NCT04412057|Drug|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
79561407|NCT04412057|Drug|Placebo|Administered once subcutaneously
79561408|NCT04408807|Other|Speculum-free (SpF) fundoscopy|Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
79261380|NCT02439021|Device|COBRA|
79561409|NCT04408807|Other|Speculum (Sp) fundoscopy|Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
79724117|NCT05342545|Other|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
79724118|NCT05342389|Drug|Camrelizumab|a PD-1 antibody
79724119|NCT05342389|Drug|Apatinib Mesylate|an oral tyrosine kinase inhibitor
79724120|NCT04230655|Dietary Supplement|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
79261381|NCT02439021|Device|LMA|
79858302|NCT06264986|Dietary Supplement|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
79858303|NCT06264986|Other|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
79261382|NCT03796455|Dietary Supplement|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
79858304|NCT06264960|Behavioral|Music therapy|After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.
79858305|NCT06264960|Behavioral|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
79858306|NCT06264947|Device|laser acupuncture|wavelength: 808nm energy: 18j power: 100mw
79858307|NCT06264947|Device|sham laser acupuncture|wavelength: 0nm energy: 0j power: 0mw
79858309|NCT06264908|Behavioral|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~Disease pathology and Pain management~Joint protection and stretching exercise~Psychosocial education~Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
79858310|NCT06264895|Behavioral|Exercise|three times weekly exercise intervention with protein supplementation
79858311|NCT06264882|Drug|Degarelix|After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.
79858312|NCT06264882|Drug|Transdermal Estradiol Patch|Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to ~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
79858313|NCT06264882|Drug|Transdermal Placebo Patch|Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
79858314|NCT06264869|Procedure|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
79858315|NCT06264869|Procedure|Interdental guided creeping technique (IGCT) and collagen membrane (CM)|Interdental guided creeping technique (IGCT) and collagen membrane (CM)
79858316|NCT06264856|Procedure|bronchoscopic sputum suction|"Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument."
79858317|NCT06264856|Procedure|negative pressure aspiration suction|The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
79858318|NCT06264843|Device|Medistim MiraQ system with TTFM and L15 HFUS probes|MiraQ™ System with TTFM and L15 HFUS probes utilizes ultrasound to visualize blood flow and guide surgeons intraoperatively to successfully plan and accomplish surgical interventions.
79858319|NCT06264830|Device|Alcon-NGENUITY®(NG)-system|During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
79261383|NCT03796455|Other|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
79261384|NCT02443467|Other|No intervention|
79398423|NCT01440881|Drug|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
79398424|NCT01440881|Drug|Placebo|infuses at 0.01MCG/KG/min for 48 hours
79398425|NCT00620061|Drug|Lubiprostone 24|24 mcg capsules for oral administration
79724121|NCT04230655|Behavioral|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
79724122|NCT04230655|Device|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
79724123|NCT02784067|Drug|Sucraid|Study drug
79724124|NCT02784067|Drug|Placebo|Sucraid placebo
79261385|NCT02443311|Drug|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
79261386|NCT02443311|Drug|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
79261387|NCT02442999|Other|Screening for obstructive sleep apnea|
79261388|NCT02442999|Device|CPAP - continuous positive airway pressure|
79261389|NCT02373202|Drug|Sarilumab|Pharmaceutical form:solution
79858320|NCT06264830|Procedure|Standard cataract operation|Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
79858321|NCT06264817|Device|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
79261390|NCT02373202|Drug|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
79261391|NCT02373202|Drug|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
79261392|NCT02373202|Drug|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
79261393|NCT02373202|Drug|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
79858322|NCT06264817|Device|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
79261394|NCT02373202|Drug|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
79261395|NCT03192111|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
79261396|NCT02622074|Biological|Pembrolizumab|200 mg administered Q3W as an IV infusion.
79261397|NCT02622074|Drug|Nab-paclitaxel|125 mg/m^2 or 100 mg/m^2 administered weekly as an IV infusion, according to allocation.
79261398|NCT02622074|Drug|Anthracycline (doxorubicin)|60 mg/m^2 administered Q3W as an IV injection.
79261399|NCT02622074|Drug|Cyclophosphamide|600 mg/m^2 administered Q3W as an IV infusion.
79261400|NCT02622074|Drug|Carboplatin|AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.
79261401|NCT02622074|Drug|Paclitaxel|80 mg/m^2 or 70 mg/m^2 administered weekly as an IV infusion, according to allocation.
79261402|NCT02438709|Drug|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
79875693|NCT00313846|Drug|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
79875694|NCT00949247|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
79261403|NCT02438943|Other|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
79261404|NCT02438943|Other|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
79261405|NCT05438758|Behavioral|Almond Therapy|Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
79261406|NCT05438758|Drug|Intranasal ketamine (Esketamine)|Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
79261407|NCT05438758|Behavioral|Treatment as Usual|Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
79261408|NCT02442921|Drug|Colchicine|up to 2mg of Colchicine daily
79261409|NCT02442921|Drug|Placebo|Daily placebo
79261410|NCT04891510|Device|REVOLVE Advanced Adipose System|The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).
79261411|NCT04891510|Device|LipoGrafter|The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).
79261412|NCT04891510|Procedure|Standard Decantation technique|Traditional standard decantation technique for breast reconstruction.
79398428|NCT01575197|Biological|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 & 10 weeks of age, 10 & 14 weeks of age, or 6, 10, & 14 weeks of age, depending on study arm assignment.
79398429|NCT00587769|Drug|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
79398430|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
79398431|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
79724125|NCT05260099|Device|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
79261415|NCT02438865|Drug|Immediate instillation of intravesical chemotherapy-Epirubicin-|
79261416|NCT02438865|Drug|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
79261417|NCT04898140|Diagnostic Test|SARS-CoV-2 specific IgM and IgG detection|Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
79261418|NCT04898140|Diagnostic Test|ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins|Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
79724126|NCT02268175|Drug|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
79261419|NCT04898140|Diagnostic Test|Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes|Detection of peripheral blood T-helpers (CD45+CD3+CD4+)* and cytotoxic T cells (CD45+CD3+CD8+)* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. * CD, cluster of differentiation
79261420|NCT04924946|Other|Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs|"Time to monitor blood pressure values in target targets~Need for administration of another antihypertensive drug~Disappearance of organ failure attributable to hypertension~Weaning from an extra-renal purification~Weaning from mechanical ventilation~Improved kidney function~Iatrogenic hypotension~Need for suspension of treatment~Other side effect"
79261421|NCT03189771|Procedure|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
79261422|NCT02308696|Behavioral|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
79261423|NCT02308696|Behavioral|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
79261424|NCT03189927|Device|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
79261425|NCT04924478|Biological|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
79724127|NCT02268175|Drug|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
79724128|NCT02268175|Drug|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
79261426|NCT04924634|Diagnostic Test|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
79261427|NCT02442609|Other|questionaire|questionaire before surgery
79561411|NCT04402658|Drug|Inhaled salbutamol|Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately ~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
79724129|NCT02268175|Drug|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
79724130|NCT02207647|Other|no intervention|
79261428|NCT04923932|Drug|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib [Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight <50 kg] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
79561412|NCT04402060|Drug|APL-9|Complement (C3) Inhibitor
79561413|NCT04402060|Other|Vehicle Control|Normal saline of equal volume to active arm
79724131|NCT02783989|Other|white wine|A dietary beverage: a market white wine, 13º alcohol
79724132|NCT02783989|Dietary Supplement|tyrosol|tyrosol in capsules
79724133|NCT02783833|Drug|MMV390048 40mg|
79724134|NCT02783833|Drug|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
79724135|NCT02783755|Behavioral|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
79724136|NCT02783677|Procedure|Percutaneous balloon angioplasty|
79724137|NCT02782429|Drug|Ketamine|
79724138|NCT02782429|Other|Saline|
79724139|NCT04229719|Drug|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
79724140|NCT02782351|Biological|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
79261429|NCT02342704|Drug|natalizumab|Administered as specified in the treatment arm
79261430|NCT02342704|Drug|fingolimod|Administered as specified in the treatment arm
79261431|NCT02442843|Device|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
79261432|NCT02442843|Device|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
79261433|NCT04912154|Procedure|Rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture
79261434|NCT02438553|Device|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
79261435|NCT02438553|Device|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
79261436|NCT04911842|Device|HydroMID|Hydrophilic biomaterial
79261437|NCT04911842|Device|TPU|Thermoplastic polyurethane
79561414|NCT04393766|Drug|Normal Saline|normal saline(crystalloids)
79724141|NCT04231903|Device|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
79261438|NCT02442453|Drug|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
79858323|NCT06264791|Other|Stress|To manipulate stress, we follow the personalized imagery script procedure developed by Sinha and colleagues. Participants randomly assigned to the stress condition will be interviewed about one week prior to the lab session. They will share a detailed description of a stressful event from their life (last 12 months) with the interviewer. Based on this interview, the experimenter will write a script (~500 words), that will then be audiotaped. Participants will listen to this personalized audiotape during the experiment, and will be asked to imagine this event as vividly as possible. Participants randomly assigned to the no stress condition will listen to a generic audiotape that describes a non-stressful event (~500 words). They will not be interviewed. During the lab session, participants will first complete a 3-min color counting task. The participant will then listen to the audiotape (personalized stressful audiotape in stress condition, generic non-stressful audiotape in no stress c
79261439|NCT02442453|Drug|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
79261440|NCT04911764|Diagnostic Test|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
79261441|NCT02438397|Drug|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
79561415|NCT04391179|Drug|Dipyridamole 100 Milligram(mg)|Drug will be given for 14 days while in the hospital.
79561416|NCT04391179|Drug|Placebo oral tablet|Placebo will be given for 14 days while in the hospital.
79724142|NCT02784847|Drug|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
79724143|NCT04230889|Other|Usual Diet Group|three main meals and two snacks
79724144|NCT04230889|Other|Group 1 Nutritional Shake|2 servings per day
79261442|NCT02438397|Drug|metformin|500 mg tid by Merck
79261443|NCT02438397|Drug|Acarbose|100mg tid by Bayer
79261444|NCT04914104|Behavioral|Mindfulness Training - Headspace App|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
79261445|NCT02438319|Other|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
79261446|NCT02438319|Other|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
79261447|NCT02438163|Device|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
79398432|NCT03433833|Drug|Digoxin|Digoxin oral route once daily for 24 weeks.
79398433|NCT03366051|Procedure|Sentinel Node Mapping|At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
79398434|NCT03366051|Procedure|Lymphadenectomy|Systematic Pelvic and Para-Aortic Lymphadenectomy
79724145|NCT04230889|Other|Group 2 Nutritional Shake|2 servings per day
79724146|NCT01855867|Drug|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
79724147|NCT02689843|Drug|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
79398435|NCT01574651|Drug|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
79398436|NCT01574651|Drug|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
79724148|NCT02689843|Drug|Metformin|Metformin 500mg three times daily
79858324|NCT06264791|Other|Alcohol|Intoxication: Participants randomly assigned to the alcohol condition will be administered 100-proof Vodka mixed with orange juice (1:3 ratio) to induce a BAC of .06% (based on Widmark's formula). They will be breathalyzed every 5 minutes until they reach peak BAC, at which point they will continue with the experiment. Participants randomly assigned to the no alcohol condition will be administered water mixed with orange juice (1:3 ratio). Each participant in the no alcohol condition will be yoked to a participant in the alcohol condition and will complete the same number of breath tests. Once participants in the alcohol condition reach peak BAC and participants in the no alcohol condition performed the same number of breath tests as the participant they are yoked to, participants will continue to the stress induction.
79875695|NCT00949247|Biological|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
79561417|NCT04388228|Other|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~A low cognitive load of the feedback where the results will be presented with the help of graphs.~Action plans to improve the quality of registration~A push system to minimize the effort the GP must make to consult the feedback."
80020779|NCT05805111|Device|endovascular intervention|Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a new, minimally invasive technique, for treating extensive and/or recurrent aorto-iliac occlusive disease. The technique rebuilds the diseased aortic bifurcation and iliac arteries through the use of stent-grafts introduced through the groin or arm arteries.
79261448|NCT03193359|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
79561418|NCT04388150|Diagnostic Test|Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies
80020780|NCT05793307|Genetic|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
79398437|NCT01574651|Drug|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
79561419|NCT04386304|Drug|(+)-Epicatechin|(+)-Epicatechin is a synthetic flavanol
79561420|NCT04386096|Other|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
79724149|NCT02689843|Drug|Pioglitazone|Pioglitazone 30mg once daily
79724150|NCT02783365|Behavioral|Photo-elicitation and online group support|See above information.
79724151|NCT02783521|Behavioral|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
79875696|NCT00949247|Drug|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
79875697|NCT00949247|Drug|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
79398438|NCT01574651|Drug|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
79724152|NCT02783521|Behavioral|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
79724153|NCT02781961|Other|cellvizio|pCLE during gastroscopy
79875698|NCT00949247|Other|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
79875699|NCT00551135|Drug|Pregabalin|150 mg BID
79261449|NCT02442531|Drug|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
79261450|NCT04913792|Device|ZXR00|This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
79261451|NCT02438241|Procedure|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
79398439|NCT01574651|Drug|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
79398440|NCT01574651|Drug|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
80020781|NCT05779137|Behavioral|MBCT|Patients will join a mindfulness-based cognitive therapy course at the Radboudumc Center for Mindfulness. The course consists of eight weekly sessions of 2.5-hour and one 6-hour silence day between the 6th and 7th session. The sessions include meditation exercises (body-scan, sitting meditation, gentle movement exercises, three-minute breathing space, daily activities with attention), psychoeducation and group discussion. Psychoeducation includes information on cognitive techniques, like monitoring and scheduling of events and identification of negative automatic thoughts. In addition, all participants will be encouraged to perform daily practice assignments at home for about 30-45 minutes per day, mainly consisting of meditation exercises.
80020782|NCT05772988|Dietary Supplement|Beta-alanine|Beta-alanine
80020783|NCT05772988|Dietary Supplement|Maltodextrin|Maltodextrin
79561421|NCT04386096|Other|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
79561422|NCT04381169|Drug|Lactated Ringer Solution|Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
79261452|NCT02438241|Procedure|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
79261453|NCT02438241|Procedure|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
79261454|NCT02437929|Procedure|Mobilization|
79261455|NCT02437929|Procedure|Positioning|
79261456|NCT02437929|Procedure|Personal Hygiene Care|
79561423|NCT04376684|Biological|Otilimab|Otilimab will be administered once via IV route.
79561424|NCT04376684|Biological|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
79561425|NCT04376684|Biological|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
79561426|NCT04376684|Drug|Standard of care|All participants will receive standard of care as per institutional protocol.
79261457|NCT02437929|Procedure|Bladder catheterization|
79261458|NCT02437929|Procedure|Wound care|
79261459|NCT02437929|Procedure|Subcutaneous drugs administration|
79261460|NCT03054974|Other|Modern rehabilitation treatment|PT 1 hour per day and OT 30min per day
79561427|NCT04375683|Drug|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
79561428|NCT04368832|Other|Remote consultation|One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
79561429|NCT04367987|Diagnostic Test|Heart Rate Variability|Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
79561430|NCT04363905|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
79724154|NCT05171725|Diagnostic Test|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
79724155|NCT05171725|Diagnostic Test|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
79724156|NCT05171725|Diagnostic Test|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
79724157|NCT05171725|Diagnostic Test|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
79858325|NCT06264778|Drug|Dabrafenib|"Generic name: Dabrafenib mesylate capsules Dosage form: capsule Specifications: 50mg, calculated as C23H20F3N5O2S2 Usage: Orally The dose of dabrafenib is 150 mg twice daily (equivalent to a total daily dose of 300 mg), taken at least 1 hour before or 2 hours after a meal. If you miss a dose and it is less than 6 hours before the next dose, you should not take it.~Patients who undergo fenestrated decompression will be administered the drug for 8 weeks, with curettage performed between weeks 8 and 9. Patients undergoing curettage will continue to take dabrafenib preoperatively until a few hours before surgery, but ideally, patients will take dabrafenib within 12 hours before surgery."
79875700|NCT00551135|Drug|placebo|Placebo
79724158|NCT05171725|Diagnostic Test|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
79724159|NCT05341999|Other|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
79875701|NCT00551135|Drug|Pregabalin|75 mg BID
79261461|NCT03054974|Other|Modern rehabilitation &TCM|Traditional Chinese Medicine, including massage and medicated bath
79261462|NCT03054974|Other|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment with Baimai Ruangao and massage
79261463|NCT03054974|Other|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
79261464|NCT03193203|Drug|Etanercept|50 mg/mL PFS and AI
79261465|NCT04923698|Other|yoga training|All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
79858326|NCT06264765|Other|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
79858327|NCT06264765|Other|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
79858328|NCT06264752|Other|Level A|Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.
79261466|NCT02442063|Drug|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
79261467|NCT02442063|Drug|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
79261468|NCT04923152|Drug|moderate statin dose|5 mg rosuvastatin per day
79261469|NCT04923152|Drug|high dose statin|40 mg rosuvastatin per day
79261470|NCT03369717|Drug|Amoxi Clavulanate|Postoperative antibiotics
79261471|NCT03054662|Other|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
79261472|NCT03054662|Diagnostic Test|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
79261473|NCT03054662|Drug|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
79261474|NCT03054662|Other|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
79261475|NCT02441985|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
79261476|NCT02441985|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
79561431|NCT04363905|Dietary Supplement|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
79724160|NCT05341999|Drug|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
79724161|NCT05341999|Other|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
79261477|NCT02441985|Other|Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|All participants will receive a clinical assessment of tremor severity by using the TRS test.
79561432|NCT04362891|Procedure|Cosmetic lip augmentation|The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
79561433|NCT04356742|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
79561434|NCT04356742|Drug|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
79724162|NCT02781805|Drug|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
79724163|NCT02781493|Drug|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
79724164|NCT02781493|Drug|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
79724165|NCT02783287|Behavioral|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
79261478|NCT02441985|Other|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
79261479|NCT02441985|Other|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
79261480|NCT02441985|Other|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
79261481|NCT02441985|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
79261482|NCT04911686|Device|rod distraction|Our study entails the application of a simple method for correction of FKFD in younger children using a simple cast distraction technique. This conservative method aims at avoiding the complications of surgery in children while achieving a reasonable amount of correction.
79261483|NCT04911374|Other|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants
79261484|NCT04911374|Other|Aveeno Face Milk SPF 40+|Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
79261485|NCT04923074|Other|diffusion tensor imaging(DTI) evaluation|DTI is a new kind of MRI technique to evaluate peripheral neuropathy
79561435|NCT04356742|Drug|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
79561436|NCT04356742|Drug|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
79858329|NCT06264752|Other|Level B|The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.
79858330|NCT06264752|Other|Passive Alert|Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
79858331|NCT06264739|Drug|esp Dexmedetomidine (dekstomid)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
79875702|NCT00551135|Drug|Pregabalin|25 mg BID
79875703|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
80020784|NCT05772260|Procedure|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)"
79561437|NCT04353284|Drug|Camostat Mesilate|Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
79561438|NCT04353284|Other|Placebo|Placebo taken orally, 4 times daily, for 7 days.
79261486|NCT02437773|Behavioral|Cognitive Behavioral Therapy - Adolescents|"A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
79561439|NCT04350892|Procedure|Roux-en-Y Gastric Bypass (RYGB)|"This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.~If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass."
79261487|NCT02437773|Behavioral|Stress Management Therapy - Adolescents|An active control therapy with minimal effects on OCD symptoms.
79261488|NCT02437773|Behavioral|Optional CBT - Adolescents|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
79261489|NCT02437773|Behavioral|Cognitive Behavioral Therapy - Adults|"A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
79561440|NCT04350892|Procedure|Sleeve Gastrectomy (SG)|"Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.~If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy."
79561441|NCT04350892|Behavioral|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
79561442|NCT04348864|Diagnostic Test|COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|An immunodiagnostic rapid (5-20 minute) test detects circulating antibodies in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 as detected by rapid antigen test or LAMP/PCR-based molecular test taken from nasopharyngeal swab samples in the recent past.
79724166|NCT02783287|Behavioral|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
79724167|NCT02783053|Drug|Metformin|Metformin vs no metformin
79724168|NCT04230343|Behavioral|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
79724169|NCT04230343|Behavioral|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
79724170|NCT02783209|Procedure|Cataract surgery|
79875704|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
79875705|NCT01529801|Device|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
79875706|NCT01529801|Device|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
79875707|NCT01529801|Device|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
79875708|NCT00949481|Other|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
79261490|NCT02437773|Behavioral|Stress Management Therapy - Adults|An active control therapy with minimal effects on OCD symptoms.
79261491|NCT02437773|Behavioral|Optional CBT - Adults|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
79561443|NCT04348864|Other|Telemedicine|Imaging of the test using the software application COVIDscanDX and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).
79561444|NCT04338100|Procedure|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
79561445|NCT04330807|Other|Handgrip fatigability test|"Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest."
79561446|NCT04330807|Other|Questionnaires|Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
79561447|NCT04328012|Drug|Losartan|administered 14 days
79724171|NCT02689609|Radiation|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
79724172|NCT02783131|Device|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
79724173|NCT02782975|Drug|aducanumab|
79858332|NCT06264739|Drug|esp remifentanyl (ultiva)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
80020785|NCT05771623|Device|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
80020786|NCT05771623|Behavioral|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
79261492|NCT02437773|Other|fMRI only - Healthy Control Adults|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
79261493|NCT02437773|Other|fMRI only - Healthy Control Adolescents|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
79261494|NCT02342548|Drug|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
79561448|NCT04328012|Drug|Placebo|administered 14 days
79561449|NCT04322058|Other|The Dads' Club|The core intervention is Core 24/7 workshop attendance
79261495|NCT04911296|Other|Mock-RP|Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
79261496|NCT02437617|Procedure|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
79261497|NCT04431050|Diagnostic Test|Point of care testing of respiratory viruses.|Single use point of care diagnostic device.
79261498|NCT03190161|Behavioral|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level <6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
79261499|NCT04913714|Behavioral|3-month radio intervention on infant vaccination|Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
79561450|NCT04310150|Drug|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
79561451|NCT04310150|Device|Floseal|hemostatic agent that combine bovine-derived gelatin
79561452|NCT04307498|Behavioral|Intensive Outpatient Program - Prolonged Exposure|Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, & Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
79561453|NCT04306848|Device|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
79561454|NCT04303897|Device|XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
79561455|NCT04303663|Procedure|Fibular Plate|ORIF with Plating
79561456|NCT04303663|Procedure|Fibular Nail|CRIF +/- ORIF with Fibular nail
79858333|NCT06264726|Other|HealtheRx|CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support.
79261500|NCT03189615|Drug|Lu AF35700|Single oral dose of 10 mg Lu AF35700
79261501|NCT04913558|Other|Aerobic exercise|"The exercise will be performed by using the treadmill as the following:~- The first stage (warming up): It consists of 5 minutes warming up with the treadmill speed set at 1.0 mile per hour.~- The second stage (active stage): It consists of 20 minutes with the treadmill speed set at 3.0 miles per hour.~- Third stage (cooling down): It consists of 5 minutes of cooling down with the treadmill speed set at 1.0 miles per hour."
79261502|NCT04913558|Other|Traditional Treatment|"General advice for reducing fatigue and stress~Fluid and diet advice~Carrying the Baby~While Breastfeeding in a sitting position~Selecting Clothing"
79261503|NCT03142191|Drug|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
79561457|NCT04299061|Diagnostic Test|International Physical Activity Questionnaire|"This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs*min*days) + Mod (METs*min*days) + Vig (METs*min*days)~1. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week"
79261504|NCT03142191|Other|Placebo|Placebo
79261505|NCT04922996|Drug|Calcium Dobesilate|Dosage of calcium dobesilate in different tissues
79261506|NCT03056378|Biological|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
79724174|NCT01324531|Procedure|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
79261507|NCT04913480|Drug|Durvalumab|Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
79261508|NCT04913480|Radiation|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
79261509|NCT05233683|Drug|Caudal block|Caudal block will be performed in lateral position with 0.25% bupivacaine in the dose of 0.75 ml/kg containing 1 mic/kg dexmedetomidine. The patients will be turned back to the supine position after the block placement and the head of the patient will be placed in the neutral position. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
79261510|NCT05233683|Drug|Dorsal penile nerve block plus ring block|"It will be performed with the child in the supine position. Following skin preparation and palpation of the arch of the lower border of the symphysis pubis, the base of the penis will be gently pulled down, and a 25-G needle will be inserted at 10 and 2.0 O clock position to a depth of 0.25-0.5 cm (under Bucks' fascia) and 1 ml + 0.1ml X weight of the patient) of local anesthetic (0.25% bupivacaine) will be injected at each point after negative aspiration and then RB will be done in the form of a circumferential subcutaneous ring at the level of the base of the penis. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective."
79724175|NCT01324531|Procedure|Bankart repair|Bankart repair based on surgeon's preference
79724176|NCT02782819|Drug|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
79724177|NCT02782819|Drug|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
79261511|NCT05233683|Procedure|Circumcision with Plastibell|Circumcision with Plastibell
79724178|NCT04182217|Other|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
79261512|NCT05233683|Procedure|Conventional Dissection Method|Conventional Dissection Method
79261513|NCT03056066|Device|Plethysmograph|A full Body Plethysmography examination
79261514|NCT04922918|Biological|Ligilactobacillus salivarius MP101|Administration of the strain through a fermented milk
79261515|NCT02441907|Drug|aflibercept|
79261516|NCT04913090|Drug|XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
79261517|NCT04913090|Drug|Placebo to match XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
79261518|NCT04913090|Drug|XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
79261519|NCT04913090|Drug|Placebo to match XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
80020787|NCT05770297|Dietary Supplement|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
80020788|NCT05770297|Other|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
80020789|NCT05744635|Drug|Tacrolimus|Tacrolimus received as part of routine clinical care
80020790|NCT05736003|Procedure|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
79261520|NCT04913090|Drug|"XZP-5610 Tablet （for Part C1）"|Tablet(s) administered fasted orally once daily for 1 Day
79261521|NCT04913090|Drug|"XZP-5610 Tablet for Part C2"|Tablet(s) administered after a high-fat meal orally once daily for 1 Day
79561458|NCT04299061|Diagnostic Test|Pittsburgh Sleep Quality Index|"The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper."
79561459|NCT04299061|Other|Physical Activity Awareness Questionnaire - prepared by the researchers|It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.
79561460|NCT04299061|Diagnostic Test|Perceived Stress Scale|The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
79261522|NCT02437461|Drug|Triamcinolone hexacetonide|intraarticular knee injection
79724179|NCT02781415|Procedure|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
79724180|NCT02781415|Drug|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
79724181|NCT02785003|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
79261523|NCT04903886|Other|observational|observational
79261524|NCT04910516|Behavioral|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage fo
79261525|NCT02441829|Drug|Eleclazine|Eleclazine tablets administered orally in morning with food
79261526|NCT04910594|Drug|recombinant human erythropoietin|To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
79261527|NCT02441673|Drug|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
79261528|NCT02441673|Drug|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
79261529|NCT02441673|Drug|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
80020791|NCT05733689|Device|ctDNA Blood Test|Blood will be collected for ctDNA testing
80020792|NCT05733689|Combination Product|FLOT|"Oxaliplatin 85 mg/m2 IV on Day 1~Docetaxel 50 mg/m2 IV on Day 1~Leucovorin 200 mg/m2 IV on Day 1~Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
80020793|NCT05733689|Combination Product|FOLFOX|"Oxaliplatin 85 mg/m2 IV on Day 1~Leucovorin 400 mg/m2 IV on Day 1~Fluorouracil 400 mg/m2 IV Push on Day 1~Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
79261530|NCT02441673|Drug|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
79261531|NCT02441673|Drug|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
79261532|NCT02441673|Drug|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
79261533|NCT02441673|Drug|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
79261534|NCT04910828|Other|Common foods of varying glycemic indices|Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
79261535|NCT04910672|Other|Control Group|"Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression."
80020794|NCT05733689|Combination Product|FOLFIRI|"Irinotecan 180 mg/m2 IV on Day 1~Leucovorin 400 mg/m2 IV on Day 1~Fluorouracil 400 mg/m2 IV Push on Day 1~Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
80020795|NCT05733689|Combination Product|FOLFIRINOX|"Oxaliplatin 85 mg/m2 IV on Day 1~Irinotecan 150 mg/m2 IV on Day 1~Leucovorin 200 mg/m2 IV on Day 1~Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
80020796|NCT05733689|Combination Product|PACLITAXEL with or without CARBOPLATIN|"Paclitaxel 200 mg/m2 IV on Day 1~Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
79261536|NCT04910672|Other|Experimental Group|"Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion."
79561461|NCT04294914|Other|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
79561462|NCT04294914|Other|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
79858334|NCT06264700|Behavioral|Video Directly Observed Therapy (VDOT)|VDOT is an adherence-promoting intervention that involves partnering with an adolescent with SCD (or caregiver of a young patient with SCD) and observing the patient administer their hydroxyurea. In this study, VDOT will be delivered by a small business partner, Scene Health, via a smart phone app.
80020797|NCT05733689|Combination Product|DOCETAXEL and IRINOTECAN (alone or combined)|"Docetaxel 35 mg/m2 IV on Days 1 and 8~Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
79261537|NCT02437539|Drug|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
79261538|NCT02437539|Device|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
79261539|NCT02437227|Drug|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
79261540|NCT04910126|Drug|Camrelizumab|Camrelizumab 200mg q3w up to 2 years
79261541|NCT04910126|Drug|Adriamycin|adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
79261542|NCT02441361|Other|Exercise training|Exercise training will comprise aerobic and strength exercises
79261543|NCT04909892|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
79261544|NCT02436837|Other|sessions with virtual reality|sessions with virtual reality to improve the balance
79261545|NCT04922450|Drug|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/3weeks)
79561463|NCT04294147|Drug|Galcanezumab|Administered SC
79561464|NCT04294147|Drug|Erenumab|Administered SC
79724182|NCT02785003|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
79724183|NCT02785003|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
79261546|NCT04922450|Drug|Albumin Paclitaxel|Albumin Paclitaxel(260mg/m²),every 3 weeks
79261547|NCT04922450|Drug|Cisplatin|Cisplatin（80mg/m²）, every 3 weeks
79261548|NCT04903808|Drug|Allium Sativum Oil|Garlic oil Captain Company (CAP-PHARM)
79261549|NCT04903808|Drug|Mineral Tri-Oxide Aggregate|ProRoot MTA, Dentsply
79561465|NCT04289454|Other|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
79561466|NCT04269707|Drug|Ferric carboxymaltose|IV iron
79561467|NCT04264637|Drug|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
79561468|NCT04264637|Drug|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
79561469|NCT04264234|Diagnostic Test|Vaginal Ultrasonography|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
79561470|NCT04264234|Diagnostic Test|Magnetic Resonance Imaging|Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
79561471|NCT04263649|Device|Peripherally Inserted Central Catheter|insertion of a Peripherally Inserted Central Catheter (PICC)
79561472|NCT04263246|Dietary Supplement|PhytoDyNAmic|PhytoDyNAmic (6 capsules per day)
79561473|NCT04263246|Dietary Supplement|Inulin|Inulin (6 capsules per day)
79561474|NCT04245306|Other|computerized test for pragmatic inferences|Computerized tests
79561475|NCT04244240|Behavioral|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
79561476|NCT04240197|Device|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
79561477|NCT04239976|Device|FitBit|Wear FitBit for gait assessment test
79561478|NCT04239976|Other|Gait Assessment Test|Undergo gait assessment test
79561479|NCT04239976|Other|MC5-A Scrambler Therapy|Undergo scrambler therapy
79561480|NCT04239976|Other|Quality-of-Life Assessment|Ancillary studies
79561481|NCT04239976|Procedure|Quantitative Sensory Testing|Undergo quantitative sensory test
79724184|NCT02785003|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
80020798|NCT05733689|Drug|NIVOLUMAB (alone or when added to a regimen above)|"240 mg IV on Day 1 every 14 days, or~360 mg IV on Day 1 every 21 days, or~480 mg IV on Day 1 every 28 days"
79261550|NCT03189537|Drug|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
79858335|NCT06264700|Behavioral|Health Reminder Tip Alerts|"Participants randomized to this arm will receive an automated, daily, short health or safety tip alert (e.g. Time to get moving! You should be active for at least 30 minutes each day) to receive during the 180-day intervention period on their smartphone. The daily tip will be unrelated to hydroxyurea adherence. After the 180-day intervention period, participants complete a 180-day ongoing monitoring period where they will no longer receive these messages, but they will be reminded to continue to use their electronic adherence monitoring device. All participants will be offered a smart phone with a data plan at enrollment to ensure equal opportunity for participation."
79858336|NCT06264674|Drug|CHF5993 200/6/12.5 μg pMDI HFA-152a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
79561482|NCT04239976|Other|Questionnaire Administration|Ancillary studies
80020799|NCT05733689|Drug|PEMBROLIZUMAB (alone or when added to a regimen above)|"200 mg IV on Day 1 every 21 days, or~400 mg IV on Day 1 every 42 days"
80020800|NCT05733533|Drug|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
79261551|NCT03189537|Drug|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
79561483|NCT04238091|Drug|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
79561484|NCT04238091|Procedure|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
79561485|NCT04238091|Diagnostic Test|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
79724185|NCT02785003|Drug|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
79724186|NCT02781259|Procedure|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
79261552|NCT03052478|Drug|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
79261553|NCT04922372|Combination Product|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
79261554|NCT03054272|Behavioral|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
79261555|NCT03054194|Drug|E2730|capsules
79261556|NCT03054194|Drug|Placebo|capsules
79261557|NCT04922684|Behavioral|Mimic facial expressions|16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
79261558|NCT04922528|Procedure|Laparoscopic Cholecystectomy with Fluorescent Cholangiography|Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
79724187|NCT02781259|Drug|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
79724188|NCT02781259|Device|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
79724189|NCT05341531|Other|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery > 2 hours
79724190|NCT02782897|Drug|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
79858337|NCT06264674|Drug|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
80020801|NCT05733533|Drug|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
80020802|NCT05723874|Drug|BI 425809|BI 425809
80020803|NCT05723874|Drug|bosentan|bosentan
80020804|NCT05718817|Drug|XEN1101|XEN1101 capsules
80020805|NCT05699200|Other|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
80020806|NCT05699200|Diagnostic Test|Echocardiogram|We will collect limited ultrasound images of the heart.
80020807|NCT05699200|Diagnostic Test|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
79261559|NCT04922528|Procedure|Laparoscopic Cholecystectomy with White Light Imaging|As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
79561486|NCT04238091|Procedure|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
79561487|NCT04238091|Procedure|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
79261560|NCT04909814|Biological|The performance of colposcopy in vaccinated women|Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
79261561|NCT04909736|Other|Music Exposure|Music will be played for participants.
79261562|NCT04903418|Device|CBCT software|"Retrospective Data Analysis will be performed after the CBCT images are pooled from the computer database.~All the CBCT examinations will be obtained for patients who were scanned using CBCT Software (Planmeca Romexis® Viewer software).~CBCT images will be analysed in different planes."
79261563|NCT04894136|Procedure|ICSI-TESE; embryo-transfer|The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
79261564|NCT04397198|Diagnostic Test|Speckle Tracking echocardiography|"Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers"
79561488|NCT04238091|Drug|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
79561489|NCT04238091|Drug|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
79261565|NCT03053726|Procedure|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
79261566|NCT04893980|Drug|Recombinant human interleukin-2 (rhIL-2)|During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.
79261567|NCT04893980|Drug|Control group|During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
79261568|NCT04149470|Drug|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
79261569|NCT04430816|Procedure|double mesh modification of chevrel's technique|repair of midline incisional hernia by double mesh modification of chevrel's technique
79261570|NCT04430816|Procedure|on lay mesh hernioplasty|repair of midline incisional hernia by online mesh hernioplasty
79561490|NCT04237155|Other|Questionnaire|Subjects will complete a verbal material scoring questionnaire
79561491|NCT04237155|Other|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
79724191|NCT02782897|Other|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
79724192|NCT04229953|Device|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
79724193|NCT05280847|Procedure|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
79724194|NCT00638131|Drug|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
79724195|NCT05142475|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
79724196|NCT02781181|Device|CAS with CPD|using a neuroprotection device
79724197|NCT02781181|Other|CAS without CPD|No Neuroprotection
80020808|NCT05699200|Diagnostic Test|Elastography|We will measure the elastic properties of the arteries using elastography.
80020809|NCT05699200|Other|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
79398441|NCT05247411|Other|Educational intervention|"During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life."
79261571|NCT04902716|Behavioral|Design course|Precision nursing is a new trend in nursing in recent years. It is based on individual differences in disease type, gender, lifestyle, family, race, social and cultural factors, etc., to provide the most suitable empirical-based nursing treatment.Diverse courses include music, breathing exercises, cognitive training, hand-made knitting, etc.
79261572|NCT04894058|Procedure|Ureteroscopic lithotripsy|"After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz."
79398442|NCT03028649|Dietary Supplement|β-hydroxy-β-methylbutyrate and a placebo supplementation|
79398443|NCT03026231|Biological|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
79561492|NCT04236531|Other|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
79561493|NCT04231825|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
79261573|NCT04894292|Other|Non intervention|During the study there is no extra intervention planned for the participants.
79261574|NCT04893902|Device|medit intra oral scanner|ear scanning with intra oral scanner
79261575|NCT04902638|Procedure|Intraarticular injection of dexamethasone|Intraarticular injection of dexamethasone
79261576|NCT03054116|Diagnostic Test|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
79261577|NCT04893746|Dietary Supplement|Lactobacillus plantarum TWK10-L|Low dose: 2x1010 CFU/day
79261578|NCT04893746|Dietary Supplement|Maltodextrin|0x1010 CFU/day
79261579|NCT04893746|Dietary Supplement|Lactobacillus plantarum TWK10-H|High dose: 6x1010 CFU/day
79261580|NCT03053882|Other|mouthwash|mouthwash containing herbal peppermint or green tea
79261581|NCT03053804|Radiation|MR/PET|MR/PET with contrast media and FDG-18
79261582|NCT02617628|Drug|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
79561494|NCT04223479|Drug|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
79561495|NCT04223479|Drug|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
80020810|NCT05699200|Other|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
80020811|NCT05684315|Procedure|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
80031668|NCT03106688|Diagnostic Test|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
80031669|NCT03106688|Diagnostic Test|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
79261583|NCT03053648|Other|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
79261584|NCT03053648|Other|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
79261585|NCT03052244|Device|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
79261586|NCT03052244|Device|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
79261587|NCT03053336|Behavioral|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
79261588|NCT03053570|Device|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
79261589|NCT03053570|Device|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
79261590|NCT04893668|Other|Depression|Any participants who develop depression symptoms according to DSM 5 criteria
79261591|NCT04893668|Other|Anxiety|Any participants who develop anxiety symptoms according to DSM 5 criteria
79261592|NCT03053414|Dietary Supplement|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
79261593|NCT03053258|Device|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
79261594|NCT04901858|Diagnostic Test|Aspiration of haemarthrosis and high definition MRI|Aspiration of haemarthrosis and high definition MRI
79261595|NCT04892810|Procedure|Percutaneous ablation|Hepatic Percutaneous Ablation with radiofrequency or microwave
79261596|NCT02308540|Biological|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate [alum]) and preservative (thiomersal).
79398444|NCT03026231|Drug|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
79261597|NCT02308540|Biological|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
79398445|NCT02139969|Device|GreenLight XPS Laser System|
79581237|NCT01934244|Device|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
79581238|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
79581239|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
79724198|NCT02781103|Other|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
79261598|NCT02308540|Biological|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
79261599|NCT04909580|Behavioral|Decision coaching with a patient decision aid|Decision coaching guided by the Ottawa Decision Support Framework
79261600|NCT04893044|Behavioral|Video|"The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all."
79261601|NCT04909658|Behavioral|ACT Matrix|"The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action)."
79261602|NCT04909658|Behavioral|PT Protocol|The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
79261603|NCT04892576|Other|Physical Therapy|"The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks"
79261604|NCT04909268|Diagnostic Test|HIV testing|serology for HIV testing
79261605|NCT04909034|Drug|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
79261606|NCT04909034|Drug|Placebo|Oral solution without active ingredients
79398446|NCT03026309|Other|no intervantion|no intervention is being performed, only observational evaluations.
79398447|NCT01440803|Drug|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
79398448|NCT01440803|Drug|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
79398449|NCT05247177|Drug|dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia|co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
80031670|NCT03106688|Diagnostic Test|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
79581240|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
79581241|NCT01934270|Other|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
79261607|NCT04901780|Other|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
79261608|NCT04901780|Other|cross body stretch|crossbody stretch performed by an individual
79581242|NCT01934283|Device|urine folly catheter|
79724199|NCT02781103|Other|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
79261609|NCT02308228|Behavioral|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
79261610|NCT02308228|Drug|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
79724200|NCT04229251|Behavioral|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
79261611|NCT04901000|Procedure|Carotid endarterectomy|Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
79261612|NCT03051932|Drug|Ofiramev® (IV Acetaminophen)|Post -op pain medication
79261613|NCT03051932|Drug|Placebo IV administration|Post -op pain
79261614|NCT04900610|Dietary Supplement|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
79261615|NCT04900766|Drug|Mitoxantrone Hydrochloride Liposome Injection|20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
79261616|NCT04908566|Drug|PD-1 antibody combined with FOLFIRINOX regimen|Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。
79261617|NCT04908566|Drug|PD-1 antibody combined with SOX program|"Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles."
79261618|NCT03052946|Procedure|Bulking agent|Filling bulking agent in the anal canal
79261619|NCT03052946|Procedure|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
79261620|NCT03052868|Other|Cognitive Assessment|Cognitive testing session
79724201|NCT04229251|Behavioral|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
79261621|NCT03052790|Procedure|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
79303743|NCT03067779|Other|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
79724202|NCT02780245|Drug|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
79724203|NCT02780245|Procedure|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
79724204|NCT00634699|Procedure|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
79261622|NCT03052790|Device|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
79261623|NCT04892654|Drug|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
79261624|NCT04892654|Drug|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
79261625|NCT04892654|Other|Triple cART regimen|Participant standard triple cART regimen
79561496|NCT04186793|Behavioral|Guided Grocery Shopping (GGS)|"The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
79261626|NCT04900142|Procedure|Micropulsed laser trabeculoplasty|Trabeculoplasty
79724205|NCT05341063|Behavioral|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
79261627|NCT04891952|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|Functional precision medicine test to predict response to candidate chemotherapeutic agents
79724206|NCT05341063|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
79398450|NCT05247177|Drug|Conventional general anesthesia by administration of sevoflurane alone|Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
79398451|NCT01517282|Biological|MOR103|Anti-GM-CSF monoclonal antibody
79858338|NCT06264661|Behavioral|Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia|Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR.
79398452|NCT01517282|Other|Placebo|Placebo to anti-GM-CSF monoclonal antibody
79875709|NCT00949481|Other|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
79398453|NCT00624195|Drug|FDA Approved Antiretroviral Therapy (see list below)|"Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
79398454|NCT01440647|Procedure|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
79398455|NCT01440647|Procedure|Extubation to CPAP|After extubation infants were placed on CPAP
79398456|NCT01799031|Other|internet-based intervention|Receive access to the WISE web-based educational intervention
79398457|NCT01799031|Procedure|management of therapy complications|Receive standard of care
79398458|NCT01799031|Other|educational intervention|Receive access to the WISE web-based educational intervention
79398459|NCT01799031|Other|questionnaire administration|Ancillary studies
79398460|NCT01799031|Procedure|quality-of-life assessment|Ancillary studies
79724207|NCT05340985|Dietary Supplement|25(OH)D3|calcifediol
79724208|NCT05340985|Dietary Supplement|vitamin D3|Cholecalciferol
79724209|NCT05340829|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
79724210|NCT02780791|Other|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
79724211|NCT02780791|Other|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
79261628|NCT03052166|Device|QT Ultrasound scan|QT Ultrasound scan
79261629|NCT04892030|Behavioral|Whole Food Plant-Based Behavioral Weight Loss Treatment|Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
79261630|NCT04892108|Procedure|STARR (Stapled Trans Anal Rectal Resection)|Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)
79261631|NCT04892108|Procedure|LVR (Laparoscopic Ventral Rectopexy)|Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
79261632|NCT04891874|Radiation|Stereotactic radiotherapy|Radiation using stereotactic radiotherapy device.
79261633|NCT04899596|Other|No intervention|No intervention
79261634|NCT04899674|Drug|Elontril|Elontril
79261635|NCT04899674|Drug|BI 1358894|BI 1358894
79261636|NCT04891562|Other|interlimb coordination of the lower limbs and synchronization|4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)
79261637|NCT03051854|Behavioral|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
79261638|NCT04908098|Device|diode laser|It is the application of the laser tip parallel to the inner surface of the periodontal pocket
79724212|NCT02780947|Procedure|Ventricular tachycardia substrate ablation|"Study protocol~Baseline programmed ventricular stimulation performed from the LV~High density endocardial LV mapping using CARTO® 3 System~Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
79261639|NCT04908098|Procedure|scaling - root planning|Scaling is the removal of calculus and other deposits in the root of the tooth.Root planning is the removal of necrotic cementum on the tooth root surface. Scaler and gracey curettes are used for these operations.
79858339|NCT06264648|Other|Pressure sensitivity education|Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
79261640|NCT04908332|Behavioral|Kangaroo Baby Massage|The Kangaroo Baby Massage is an intervention that arose from nursing practice in 1996. It is a therapy that does not require an incubator, fuses massage, kangaroo position and music. KBM is available on video
79261641|NCT04907708|Drug|Metformin|Euglycemic agent
79261642|NCT04907708|Drug|Insulin|Hypoglycemic agent
79261643|NCT04890626|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Main randomization
79724213|NCT02784457|Drug|Cetrorelix|
79724214|NCT05338177|Other|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
79724215|NCT05338177|Other|No immunosuppression reduction|participants do not alter immunosuppresion
79858340|NCT06264635|Biological|Platelet-Rich-Plasma|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
79858341|NCT06264635|Other|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
79261644|NCT04890626|Drug|Baricitinib + dexamethasone|Rescue randomization
79261645|NCT04890626|Drug|Dexamethasone|Rescue randomization
79398461|NCT01516970|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
79724216|NCT02780323|Drug|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
79724217|NCT02780323|Drug|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
79724218|NCT02780323|Drug|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
79261646|NCT04908254|Device|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
79261647|NCT04907942|Device|EMA + Automated Text Message Intervention|Intervention includes 3 weeks of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of automated text messages delivered twice a day, which content follows constructs from The Transactional Model of Stress and Coping.
79261648|NCT04907942|Behavioral|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate momentary affects.
79261649|NCT04907864|Combination Product|Multi-modal intervention|Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
79261650|NCT04899128|Drug|Pyrotinib|Pyrotinib-based therapy
79303744|NCT05555069|Other|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
79398462|NCT01516970|Drug|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
79398463|NCT01516970|Drug|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
79261651|NCT03051542|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
79261652|NCT04898972|Behavioral|Mindfulness-based stress reduction intervention|The 8-group sessions of MBSR will be conducted once a week, lasting two and a half hours, with two additional sessions in the following two months. Between sessions, participants will have to practice at home for 45 minutes a day, 6 days a week. For the practice, patients and caregivers will be provided with audio files containing the meditations proposed in the classroom, readings, and the diary of the practice. During the sessions, the following mindfulness-based techniques will be introduced: body scan; sitting meditation; awareness movement exercises; and walking meditation.The sessions will be held face to face or online using common videoconferencing platforms, such as Skype or Zoom, based on the preferences of the participants. This will facilitate the participation of patients and caregivers, overcoming the obstacles related to travel. The course will be taught by certified mindfulness teachers with experience in MBSR interventions on patients with respiratory diseases.
79261653|NCT04898972|Behavioral|Information on stress reduction|"COPD patient-caregiver dyads will be delivered by hand, sent by email or by post an information booklet Coping with your chronic disease, targeting COPD patients, to teach them how to manage stress. This booklet, available in Italian, provides simple information on the meaning of stress and anxiety, and suggests some actions that people can implement at home to reduce stress."
79261654|NCT04890704|Drug|Curcuminoid|Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
79398464|NCT01516970|Drug|NRTIs|The NRTIs (including tenofovir/emtricitabine [Truvada], lamivudine/zidovudine [Combivir]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
79398465|NCT01516970|Drug|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
79858342|NCT06264622|Dietary Supplement|Low dose|2 tablets per day during the morning for 12 weeks.
79724219|NCT02780323|Drug|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
79724220|NCT05331859|Drug|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
79261655|NCT04890704|Drug|Placebo|Identical capsules were used for the placebo from the same manufacturer.
79303745|NCT05555069|Other|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
79858343|NCT06264622|Dietary Supplement|High dose|2 tablets per day during the morning for 12 weeks.
79858344|NCT06264622|Dietary Supplement|Placebo|2 tablets per day during the morning for 12 weeks.
79858345|NCT06264609|Drug|Alendronate|Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
79724221|NCT05331859|Drug|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
79858346|NCT06264609|Drug|Teriparatide|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
79398466|NCT00625989|Drug|Aeroallergen|
79724222|NCT05331859|Drug|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
79724223|NCT04229407|Dietary Supplement|Dietary supplement|MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
79858347|NCT06264609|Drug|Alendronate|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
79858348|NCT06264583|Other|HDV screening|1. Analyze the rate of HDV-testing and evaluate the prevalence of HDV-infection by testing.
79858349|NCT06264570|Dietary Supplement|B-TMG supplementation|B-TMG supplement (B2 riboflavin, B6 pyroxidine, B9 methylfolate, B12 methylcobalamine, S-adenosylmethionine, Trimethylglycerol (TMG), zinc sulfate) for subjects with normal COMT gene and MTHFR gene polymorphism
79858350|NCT06264570|Dietary Supplement|B-SAM supplementation|B-SAM supplement (B2 riboflavin, B6 pyroxidine, B9 folic acid, B12 adenosylcobalamin, magnesium, S-adenosylmethionine) for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
79858351|NCT06264570|Other|B-TMG placebo|B-TMG placebo for subjects with normal COMT gene and MTHFR gene polymorphism
79858352|NCT06264570|Other|B-SAM placebo|B-SAM placebo for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
79398467|NCT05247021|Procedure|erector spinae block for group E|. The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
79561497|NCT04186793|Other|Diet Provision Group|"This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
79561498|NCT04183621|Diagnostic Test|high resolution impedance manometry|Two detailed swallow assessments to be carried out at between 2-4 months and 8-10 months of age
79561499|NCT04182841|Device|RheOx|RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
79561500|NCT04181619|Dietary Supplement|Coffeeberry beverage|One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage prior to exercise session
79561501|NCT04181619|Other|Comparator beverage|One 300 ml still beverage, color and flavor matched to experimental beverage prior to exercise session
79561502|NCT04179565|Behavioral|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
79724224|NCT04229407|Dietary Supplement|vitamin B|MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
79724225|NCT05340595|Other|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
79724226|NCT04231435|Drug|Fedratinib|Oral
79303746|NCT03067701|Drug|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
79303747|NCT05548439|Biological|VBI-2901a|Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
79561503|NCT04178772|Device|Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens|JJVC Marketed Contact Lens
79561504|NCT04226976|Device|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
79561505|NCT04226976|Device|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
79724227|NCT04231435|Drug|Digoxin|Oral
79724228|NCT04231435|Drug|Rosuvastatin|Oral
79724229|NCT04231435|Drug|Metformin|Oral
79724230|NCT05340517|Procedure|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
79724231|NCT05340439|Drug|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
79858353|NCT06264544|Dietary Supplement|zinc, selenium, and L-tyrosine in SEPP1|zinc, selenium, and L-tyrosine in SEPP1 polymorphism
79858354|NCT06264544|Other|Placebo|placebo comparator in SEPP1 polymorphism group
79858355|NCT06264479|Procedure|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
79875710|NCT04012385|Behavioral|lifestyle counseling|Nutritional plan and Physical activity goals
79303748|NCT03069339|Drug|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
79261656|NCT04412330|Other|ICU Recovery + Physical Therapy|Physical therapy interventions will be supervised by a physical therapist (>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
79561506|NCT04178187|Drug|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
79261657|NCT04907474|Drug|tropicamide-phenylephrine fixed combination ophthalmic solution|Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis
79261658|NCT04907630|Behavioral|Antenatal Education|educational intervention
79261659|NCT04898738|Other|Alcohol based hand sanitizer|Provision of ABHS to randomly selected households
79261660|NCT04898582|Other|Mineral 89 Probiotic Fractions|The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
79261661|NCT04890392|Drug|PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)|S-1: 40~60mg Bid，d1~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
79261662|NCT04907318|Device|Cataract surgery|
79261663|NCT02616614|Drug|Onexton|Topical gel for treating acne
79261664|NCT02616614|Drug|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
79398468|NCT02140593|Drug|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
79398469|NCT02140593|Drug|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
79261665|NCT02616614|Drug|Placebo|Vehicle gel used as a placebo
79561507|NCT04178187|Drug|Caps Placebo|Caps Placebo
79561508|NCT04169490|Other|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
79858356|NCT06264466|Device|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
79261666|NCT04408040|Biological|Convalescent Plasma|200-425mL convalescent plasma donated by patients previously positive for COVID-19
79261667|NCT03050996|Procedure|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
79261668|NCT04898192|Other|questionnaire|questionnaire - the complex of 6 questionnaires aimed to recognize the fear of delivery, perinatal anxiety, depressive disorder, obsessive-compulsive disorder, general anxiety disorder, postpartal depression and domestic violence.
79261669|NCT04898426|Other|Enhanced bowel preparation instruction|Automated delivery of SMS, pre-recorded phone call, and link to an information website.
79261670|NCT04890080|Other|Pulmonary Rehabilitation|Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
79303749|NCT03069339|Procedure|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
79303750|NCT03069105|Other|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
79303751|NCT05542589|Other|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
79398470|NCT01516892|Biological|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
79398471|NCT02863029|Procedure|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
79561509|NCT04169490|Other|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
79561510|NCT04169490|Other|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
79561511|NCT04169490|Other|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
79561512|NCT04169490|Other|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
79561513|NCT04169451|Drug|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
79561514|NCT04169438|Other|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
79561515|NCT04169438|Other|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
79561516|NCT04161040|Behavioral|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
79858357|NCT06264453|Drug|KH001|3 topical applications of KH001
79858358|NCT06264453|Drug|Placebo|3 topical applications of Water for Injection
79858359|NCT06264440|Drug|BIIB122|Administered as specified in the treatment arm.
79858360|NCT06264440|Drug|Rabeprazole|Administered as specified in the treatment arm.
79858361|NCT06264427|Genetic|Whole genome sequencing|Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
79858362|NCT06264427|Diagnostic Test|VAGUS|To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
79858363|NCT06264427|Diagnostic Test|NightOwl|Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
79858364|NCT06264427|Device|CPAP|Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
79858365|NCT06264401|Other|Alendronate|control group received (Alendronate) 70 mg 1 tab every week.
79858366|NCT06264401|Other|treatment exercises|the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
79858367|NCT06264388|Drug|DB107-RRV|Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
79858368|NCT06264388|Drug|DB107-FC|Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
79858369|NCT06264375|Behavioral|Physical exercise|see group description
79858370|NCT06264362|Behavioral|Tailored Physical Activity Program|Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
79858372|NCT06264258|Behavioral|DVx-T1D™ app|The intervention group will be introduced to the DVx-T1D™ app and the participants will go home with the tablets that has the game installed. Participants will be asked to play the game for 20 mins or more daily. The aim of the app is to impart good behavioral changes in children with T1D in terms of diabetes education, on how to treat a low or a high blood sugar event and make healthy eating choices.
79261671|NCT04889768|Drug|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
79261672|NCT04906538|Procedure|all- inside anterior cruciate ligament reconstruction|all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
79561517|NCT04159818|Drug|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
79561518|NCT04159818|Drug|Cisplatin|40mg/m2, weekly for two weeks
79561519|NCT04159818|Drug|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
79561520|NCT04157881|Drug|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
79858373|NCT06264115|Procedure|Laparoscopic Cholecystectomy|Using Three Ports or Four Ports for Laparoscopic Cholecystectomy
79858374|NCT06263894|Other|Experimental group|Alexander technique will be applied to the experimental group.
79858375|NCT06263855|Other|CURE|A large language model (LLM) to help clinicians prepare discharge summaries for hospitalized patients.
79858376|NCT06263738|Procedure|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
79561521|NCT04157881|Drug|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
79858377|NCT06263738|Procedure|Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 49 degree (Fahrenheit) water, lasting up to 10 minutes.
79261673|NCT03050840|Behavioral|Way to Health|An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
80020812|NCT05681455|Device|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
80020813|NCT05663957|Drug|Evusheld|EVUSHELD users
79261674|NCT04898270|Drug|Flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity."
79261675|NCT04898270|Drug|Multi-acting receptor-targeted antipsychotics (MARTAs)|Multi-acting receptor-targeted antipsychotics (MARTAs)
79261676|NCT04889612|Procedure|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
79261677|NCT04889612|Procedure|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
79261678|NCT04889456|Procedure|Implementation standardised laparoscopic right hemicolectomy with proctoring|Implementation standardised laparoscopic right hemicolectomy with proctoring
79261679|NCT04889456|Procedure|Implementation standardised laparoscopic right hemicolectomy without proctoring|Implementation standardised laparoscopic right hemicolectomy without proctoring
79261680|NCT04897724|Other|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
79261681|NCT03051776|Other|Kinesio Taping|
79261682|NCT03051776|Other|Compression Garment|
79398472|NCT00668811|Drug|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
79398473|NCT02776605|Drug|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
79261683|NCT04897646|Other|SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm.|"In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.~The algorithm is exhasutively described in the following published article: Prigent, A., Gentina, T., Launois, S., et al. [Telemonitoring in continuous positive airway pressure-treated patients with obstructive sleep apnoea syndrome: An algorithm proposal]. Rev. Mal. Respir., 2020, 37: 550-560."
79261684|NCT03052712|Behavioral|social cognition|battery of tests of social cognition
79261685|NCT04906304|Drug|Everolimus Pill|standard dose versus low dose Sandimun
79261686|NCT04906304|Drug|Sandimmun (Neoral) dose plus cellcept|Sandimmun (Neoral) dose plus cellcept
79261687|NCT04889690|Drug|Danicopan|
79261688|NCT04889690|Drug|Placebo|
79724232|NCT05340361|Device|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
79261689|NCT04889534|Procedure|Analgesia|Patients will be observed during postoperative period,
79261690|NCT04398446|Drug|Hemp-based CBD|3x Daily dosing for 12 weeks
79261691|NCT04398446|Other|Placebo oral tablet|3x Daily dosing for 12 weeks
79261692|NCT04888910|Other|observational|observation of biomarkers in different asthma groups
79261693|NCT04905992|Other|Hypertonic saline at 6%|Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
79398474|NCT02776605|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
79398475|NCT02776605|Drug|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
79398476|NCT02776605|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
79261694|NCT04905992|Other|Airway clearance techniques (oscillating positive expiratory pressure therapy)|Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
79561522|NCT04148651|Device|The CO2RE® System|The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
79858378|NCT06263699|Procedure|ROM measurement of the MCP and PIP joints in digits 4 and 5|standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
79858379|NCT06263660|Dietary Supplement|Keto-like supplement|Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
80020814|NCT05654181|Drug|PF-07328948|investigational drug administered orally
80020815|NCT05654181|Drug|Placebo|Placebo matching active drug administered orally
79261695|NCT04897178|Diagnostic Test|Ultrasound|Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
79261696|NCT03050762|Other|Data Collection|Participant information collected from either source document or direct participant response.
79261697|NCT03050762|Behavioral|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
79261698|NCT04896710|Device|SD Biosensor|Nasal swab SD biosensor to be self administered
79261699|NCT03051698|Drug|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
79261700|NCT03051698|Other|Saline|0.9% NaCl
79261701|NCT03051698|Drug|Antibiotics|vancomycin, ciprofloxacin, metronidazole
79724233|NCT05340361|Device|Optical coherence tomography-guided Onyx expansion|"Expansion of 2.25, 3.0, and 4.0 mm Resolute Onyx @ nominal pressure~OCT pullback~Expansion with over 0.5mm sized non-compliant balloon of each stent~OCT pullback~Expansion with over 1.0mm sized non-compliant balloon of each stent~OCT pullback~Expansion with over 1.25~1.5mm sized non-compliant balloon of each stent~OCT pullback~Evaluation of polymer status with overexpansion assessed by an electric microscope"
79724234|NCT01194414|Drug|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
79858380|NCT06263660|Dietary Supplement|Placebo|Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
79858381|NCT06263582|Drug|Artesunate pessary|Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
79858382|NCT06263582|Diagnostic Test|blood draws for pharmacokinetics of the study drug|On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
79858383|NCT06263491|Drug|Rituximab|Given by PO
79858384|NCT06263491|Drug|Pirtobrutinib|Given by PO
79858385|NCT06263010|Drug|Allopregnanolone|Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
79858386|NCT06262607|Drug|CLE-400|Topical CLE400 gel 0.28% administered once daily
80020816|NCT05640557|Other|Physical Exercises|An original, noninvasive exercise program
80020817|NCT05638360|Drug|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
79398477|NCT02776605|Drug|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
79398478|NCT02776605|Drug|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
80020818|NCT05638360|Drug|Placebo|Each patch contains 13g starch and 10c.c. water.
79261702|NCT03052556|Procedure|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
79261703|NCT04905602|Drug|SHR-1905/placebo|"Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose"
79398479|NCT02776605|Drug|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
79398480|NCT02776605|Drug|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
79398481|NCT02776605|Drug|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
79398482|NCT02776605|Drug|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
79398483|NCT02776605|Drug|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
79724235|NCT01194414|Drug|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
79858387|NCT06262607|Drug|Vehicle|Topical vehicle gel administered once daily
79858388|NCT06262503|Device|Virtual Reality|Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
80020819|NCT05608837|Drug|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
80020820|NCT05607680|Drug|Placebo|Placebo administered subcutaneously (SC) once a week.
80020821|NCT05607680|Drug|IBI362|IBI362 administered subcutaneously (SC) once a week.
80020822|NCT05593887|Procedure|Hip reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
79261704|NCT04905680|Device|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
79561523|NCT04142736|Other|Prone Position|The best-fitting and most-tolerated oxygen interface will be used in the prone position--this could be different from patient to patient, and different from what is used in the supine position, and could differ between patients but also institutions (i.e., depending on the availability of masks with or without a reservoir bag and with or without the Venturi system, HFNO, CPAP or NIV). The patient will be placed in the prone position for at least 2 hours, which may be prolonged if the patient is comfortable or interrupted if the patient presents any criteria for prone position discontinuation. After the prone position period, the patient will be rotated to the semi-recumbent supine position for at least 2 hours and a maximum of 4 hours. This 2-hour time frame will depend on nursing availability, need for hygiene, complementary explorations, or diet.
79858389|NCT06262503|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
79261705|NCT04905368|Other|SS-POR11|Topical composition containing probiotic strains derived from human skin (SS-POR11). Participants will be instructed to apply it topically to face, twice weekly for the duration of the trial.
79261706|NCT04905758|Procedure|platform switching|reduced implant abutment interface
79261707|NCT04905758|Procedure|platform amtching|matched implant abutment interface
79261708|NCT04888520|Device|Adhesive elastic bandage|"The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist."
79858390|NCT06262503|Device|Mirroring Therapy|"Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb."
79858391|NCT06262503|Other|Phantom Exercises|The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
79858392|NCT06262425|Device|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
79858393|NCT06262425|Device|repetitive Transcranial Magnetic Stimulation over primary motor cortex|It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
79858394|NCT06262425|Device|sham repetitive Transcranial Magnetic Stimulation|It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated
79858395|NCT06262360|Procedure|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
79858396|NCT06262360|Procedure|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
79858397|NCT06262360|Procedure|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
79875711|NCT00956423|Behavioral|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
80020823|NCT05593887|Procedure|Proximal femoral resection|Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
79261709|NCT04888442|Biological|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
79561524|NCT04139252|Other|No intervention|No intervention
79261710|NCT04905056|Other|Ablation therapy|Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
79261711|NCT04888130|Genetic|Phylogenetic Analysis|The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
79561525|NCT04136990|Procedure|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
79261712|NCT04888130|Other|Data collection|Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
79261713|NCT04896788|Biological|Monitoring of the immune response|Blood sample at 3,6,12,18 and 24 months in order to assess the blood level of anti-S1 / RBD anticoprs
79261714|NCT04896554|Behavioral|Health literacy scale|"The Turkish version of The European Health Literacy Survey (HLS-EU) Health Literacy Questionnaire scale (ASOY-TR) was used to measure health literacy. This scale consists of 47 questions. Each item has 4 degrees such that 1 = Very difficult, 2 = Difficult, 3 = Easy, 4 = Very easy. Code 5 is used for the expression I don't know. The total score that can be obtained from the scale is between 47-188. For the sake of ease of calculation, the total score is standardized with the following formula to take a value between 0-50.~Formula = Index = (arithmetic mean-1) x [50/3] High score means better health literacy."
79858398|NCT06262347|Behavioral|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|The TOME intervention is a modified version of the personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND) intervention (Winhusen et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. Nov 1 2020;216:108265). Modifications include updating the knowledge assessment/education to reflect changes in the drug supply (i.e., the current high prevalence of fentanyl and increasing prevalence of xylazine) and the addition of items specific to pregnancy. Like PTOEND, TOME is a computer-guided intervention which utilizes REDCap to complete assessments and automatically generate personally-tailored feedback reports.
79858399|NCT06262347|Behavioral|Control|Participants randomized to the control condition will be offered three SAMHSA handouts.
79858400|NCT06261970|Behavioral|Connect|Community level enhancements
79858401|NCT06261619|Device|Adult Sotair Device|Adult Sotair® device employs a flow limiting valve mechanism.
79858402|NCT06261021|Drug|Ruxolitinib 1.5% cream|Topical application of Ruxolitinib 1.5% cream
79858403|NCT06261021|Procedure|Application without occlusion in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.
79858404|NCT06261021|Procedure|Application under occlusion at night in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.
79858405|NCT06261021|Procedure|Application under occlusion at night in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.
79858406|NCT06261021|Procedure|Application without occlusion in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
79858407|NCT06260995|Other|Social Prescribing Link Worker Intermediary Intervention|Social prescribing link workers [SPLW] receive referrals from healthcare professionals, community services, or through self-referral. Individuals are referred for social isolation or social needs, frequent healthcare attendance, or to address a pre-existing health issue. SPLW carry out an in-depth assessment of the individual's needs, and then work with the individual over weeks and months to connect them to community services and supports, which can include local physical activities. They use several strategies during this follow-up period, such as instrumental support (doing things for the individual), empowerment and motivation techniques and/or attending activities with the individual. After the SPLW establishes a connection to a local physical activity, the individual enrols and participates in the chosen activity. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi.
79858408|NCT06260995|Other|Local Sports Partnership Community Development Officer Intervention|Local sports partnership community development officers [LSPO] mainly receive self-referrals, or can receive referrals, to improve physical activity levels of individuals through participation in physical activity groups delivered by the partnership. LSPO do not carry out an in-depth assessment but may carry out screening before explaining/signposting to local physical activities. They use several strategies to connect the individual to local physical activities, such as attending the first session of the group, providing reassurance and practical support, and keeping the person updated and informed as to upcoming groups. After the LSPO establishes a connection to a local physical activity, the individual enrols and participated in the chosen activity. The LSPO continues to support this engagement during the follow-up period. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi amongst others.
79261715|NCT04888208|Behavioral|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
80020824|NCT05593887|Procedure|Proximal femoral valgus ostetomy|The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
80020825|NCT05580913|Behavioral|Resistance training|12 weeks of resistance-training performed two times per week
80020826|NCT05570435|Biological|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
80020827|NCT05560685|Other|Outcomes4Me|Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.
80020828|NCT05560685|Other|Semi-structured interview|Team member participants will complete a semi-structured interview.
80020829|NCT05542498|Behavioral|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
80020830|NCT05542498|Behavioral|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
80020831|NCT05505305|Behavioral|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at > 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
80020832|NCT05498454|Behavioral|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
79261716|NCT04888052|Device|Acute ACL injury|Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits > 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
79561526|NCT04136990|Procedure|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
79561527|NCT04136262|Drug|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
79561528|NCT04136262|Drug|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
79561529|NCT04136262|Other|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
79561530|NCT04133922|Drug|GLP-1|glucagon-like peptide 1
79561531|NCT04133922|Drug|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
79561532|NCT04133922|Drug|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
79561533|NCT04118049|Other|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
79561534|NCT04118049|Other|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
79561535|NCT04117516|Procedure|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
79561536|NCT04117516|Procedure|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
79561537|NCT04115761|Biological|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
79561538|NCT04115059|Drug|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
79561539|NCT04114890|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
79561540|NCT04113304|Behavioral|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
79261717|NCT04887818|Drug|2% Diltiazem ointment with 1.5% lidocaine|3 g of topical 2% diltiazem ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
79261718|NCT04887818|Drug|0.3% Nifedipine ointment with 1.5% lidocaine|3 g of topical 0.3% nifedipine ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
79261719|NCT04895774|Other|Probiotic strains|Fresh stools will be cultured in vitro in fermenters with adjunction of probiotic strains
79261720|NCT04895774|Other|Polyphenols|Fresh stools will be cultured in vitro in fermenters with adjunction of polyphenols
79261721|NCT04895774|Other|Fibers|Fresh stools will be cultured in vitro in fermenters with adjunction of fibers
79261722|NCT03050684|Procedure|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
79261723|NCT03050684|Procedure|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
79261724|NCT04904198|Behavioral|Care Management Intervention for non-cardiac chest pain|Multicomponent eight-week care management intervention involving a consultation visit with a cardiologist and nurse. Recommendations from the consultation visit are conveyed to the primary care physician. Following the visit, the participant has eight weekly phone calls with a nurse to provide support, introduce therapeutic principals, and assess symptoms. The study nurse is supervised by a psychiatrist.
79261725|NCT03050528|Behavioral|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
79561541|NCT04104828|Biological|Allergovit|Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis
79561542|NCT04104828|Biological|Polvac|Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis
79261726|NCT03050528|Behavioral|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
79261727|NCT04895540|Diagnostic Test|ECG|All study subjects will undergo ECG recording.
79561543|NCT04104828|Biological|Pollinex Quattro|Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
79561544|NCT04085042|Device|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
80020833|NCT05497687|Other|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
79261728|NCT04895540|Diagnostic Test|Echocardiography|All study subjects will undergo transthoracic echocardiography
79261729|NCT04895540|Diagnostic Test|Cardiac MRI|All ACM patients and SCD survivors will undergo cardiac MRI testing.
79561545|NCT04082676|Drug|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
79858409|NCT06260631|Device|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~strengthening exercises for abdominal and back muscles,~lumbar stabilization exercises.~stretching exercises."
80020834|NCT05490862|Behavioral|Lifestyle Modification|"An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months).~Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data"
79561546|NCT04082676|Drug|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
79261730|NCT04895540|Diagnostic Test|Ambulatory ECG recording|All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
79261731|NCT04895540|Diagnostic Test|Cardiac EP study|ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
79561547|NCT04073667|Behavioral|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~Teaching the correct scapular position, D. Postural correction exercises;~Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~a. Joint position sense:~Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
79561548|NCT04070131|Other|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
79561549|NCT04053569|Dietary Supplement|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
79561550|NCT04048642|Behavioral|DASH|7 days of a DASH diet
79261732|NCT04895540|Genetic|All study subjects will undergo sample collection for genetic testing.|Blood samples and buccal swab will be collected from study subjects for genetic testing.
79561551|NCT04048642|Behavioral|Whole-Food, Plant-Based|7 days of a WFPB diet
79561552|NCT04036994|Device|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
79561553|NCT04032782|Drug|HM15136|10 mg/mL as protein in prefilled syringes
79561554|NCT04032782|Drug|Placebo of HM15136|Placebo in prefilled syringes
79561555|NCT04030520|Behavioral|POPPi behavioral intervention|behavioral intervention with offer of HIV self test
79561556|NCT04030520|Behavioral|POPPi behavioral intervention|behavioral intervention
79561557|NCT04012177|Dietary Supplement|Balanced-energy protein (BEP)|Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
79561558|NCT04012177|Drug|Azithromycin Tablets|Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
79261733|NCT03050606|Other|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
79303752|NCT05542589|Other|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
79561559|NCT04012177|Drug|Choline Bitartrate|Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
79561560|NCT04012177|Drug|Nicotinamide|Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
79724236|NCT01194414|Drug|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
79724237|NCT01194414|Drug|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
79724238|NCT01194414|Drug|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
79724239|NCT05340283|Procedure|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
79724240|NCT02686411|Other|Survey Administration|Complete survey
79724241|NCT05340127|Device|CEREBO®|Usability Study
80020835|NCT05490862|Behavioral|Traditional Recommendations|The list of traditional diet and physical activity recommendations for patients with obesity
79858410|NCT06260631|Other|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~strengthening exercises for abdominal and back muscles,~lumbar stabilization exercises.~stretching exercises."
80020836|NCT05489887|Drug|Naxitamab|Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
80020837|NCT05489887|Drug|Ceritinib|Ceritinib is an inhibitor that selectively targets the ALK tyrosine kinase
80020838|NCT05487027|Behavioral|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
79858411|NCT06260618|Device|Gelfoam|GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.
79875712|NCT00956423|Behavioral|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
79261734|NCT03050606|Other|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
79261735|NCT04392908|Other|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
79398484|NCT02776605|Procedure|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
79398485|NCT02776605|Procedure|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
79398486|NCT00627861|Drug|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
79398487|NCT00627861|Drug|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
79875713|NCT00949559|Drug|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
80020839|NCT05480904|Other|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
80020840|NCT05480904|Diagnostic Test|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
80020841|NCT05480904|Other|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
79724242|NCT05327413|Other|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
80020842|NCT05480904|Diagnostic Test|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
79261736|NCT03051386|Biological|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
79261737|NCT03051308|Combination Product|NPT and UW Solution|Tissue preservation solutions for transplantation
79261738|NCT04884542|Device|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
79303753|NCT03069027|Procedure|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
79303754|NCT03069027|Drug|saline adrenaline|
79303755|NCT03069027|Drug|Xylocaine, adrenaline|
79303756|NCT05635071|Drug|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid *15 days orally after hysteroscopic surgery
79398488|NCT00669279|Drug|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
79398489|NCT00669279|Drug|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
79398490|NCT01516736|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
79398491|NCT01516736|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
79724243|NCT02784769|Other|measurement of skin autofluorescence|
79724244|NCT02784769|Other|skin biopsy collection|
79724245|NCT02173405|Drug|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
79724246|NCT02173405|Drug|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
79261739|NCT04884854|Device|Efferon LPS|Efferon LPS is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.
79261740|NCT04887974|Procedure|canine retraction|Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
79261743|NCT03051152|Procedure|D1 gastrectomy|Gastrectomy with limited lymph node dissection
79261744|NCT03051152|Procedure|D2 gastrectomy|Gastrectomy with extended lymph node dissection
79261745|NCT04887272|Other|Supervised Exercise Training Protocol|EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.
79261746|NCT04887272|Other|Inspiratory Muscle and Exercise Training|Inspiratory Muscle Training (IMT): All IMT sessions will be performed similar to EXT, with the exception of having 2-3-sessions of at-home IMT training depending on where in the exercise progression the individual is (i.e., Week1 vs week 6). On the days that IMT and exercise training overlap, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle and end of the session. Each week will include a measure of Maximal Inspiratory Pressure (MIP) and a Test of Inspiratory Respiratory Endurance (TIRE). The intensity of the IMT will be 50% of the weekly MIP, thus progressive increases in IMT threshold intensity will remain at 50% of the weekly MIP. In contrast, the TIRE protocol will assess respiratory endurance based on the relative baseline intensity. Thus TIRE testing will begin at a MIP intensity of 50% (weeks 1-2), and then progressing to 65% (weeks 3-4), and 80% (weeks 5-6).
79261747|NCT04884230|Procedure|Oversewing|Oversewing of the gastric remnant
79261748|NCT04884074|Procedure|Standard Sleeve Gastrectomy plus Anterior Crural Repair|The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
79261749|NCT04884074|Procedure|Standard sleeve gastrectomy (SSG, the control group)|"The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch."
79561561|NCT04011995|Behavioral|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
79561562|NCT04011995|Behavioral|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
79561563|NCT04011995|Behavioral|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
79561564|NCT04004910|Other|Plasma soluble TNF receptor pulldown|The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
79875714|NCT00949637|Behavioral|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
80020843|NCT05480904|Diagnostic Test|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
79261750|NCT04883996|Drug|1% EXP039|1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
79261751|NCT04883996|Other|Saline control|Saline
79858412|NCT06260618|Device|Chitodex|"The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile."
79858413|NCT06260215|Other|ST|Participants will perform a soccer training (ST) session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
79858414|NCT06259136|Procedure|A transitional palliative care intervention|The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
80020844|NCT05480904|Device|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
80020845|NCT05480904|Diagnostic Test|Physical Function|This is a test of how your heart and lungs respond to exercise.
80020846|NCT05466136|Behavioral|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
79261752|NCT04895228|Procedure|injection|triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
79724247|NCT04228939|Behavioral|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
79261753|NCT04392206|Drug|Adipose Derived Mesenchymal Stem Cells|The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
79261754|NCT04894604|Device|Avance® Solo NPWT System|Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
79724248|NCT04228939|Behavioral|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
79261755|NCT04884464|Device|Hyaluronic acid-based gel|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
79261756|NCT04884464|Drug|Chlorhexidine Gluconate|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
79261757|NCT04430270|Behavioral|Survey|Sequential Assignment
79398492|NCT01546688|Drug|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
79398493|NCT01546688|Drug|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
79724249|NCT05017051|Behavioral|Chocolate cake|The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
79724250|NCT05017051|Behavioral|Lego model|The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
79261758|NCT04883372|Other|continuous glucose monitoring|a continuous glucose monitoring CGM system through the ETAPES telemedicine program
79261759|NCT04886882|Other|placebo comparator|solution containing 0.9 % sodium chlorine
79261760|NCT04886882|Other|sham comparator|vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
79261761|NCT04886882|Other|Experimental drug 1|A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
79261762|NCT04886882|Other|Experimental drug 2|A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
79261763|NCT04886882|Drug|Centella asiatica|A cream containing Centella asiatica
79261764|NCT04886648|Behavioral|Music Therapy|
79303757|NCT05635071|Drug|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid *15 days orally after hysteroscopic surgery
79261765|NCT04886570|Device|hip arthroplasty|Hip arthroplasty is a kind of joint reconstruction surgery, which has been successfully utilized for treatment of osteoarthritis or hip fracture for decades. In this surgery, implants is applied to reconstruct hip joint, and usually comprised of four components, including femoral stem, femoral head, acetabular cup and liner.
79858415|NCT06258837|Procedure|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
79398494|NCT01516034|Device|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
79261766|NCT04883294|Diagnostic Test|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
79261767|NCT03048968|Procedure|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
79261768|NCT03048968|Procedure|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
79261769|NCT03048968|Device|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
79858416|NCT06258837|Procedure|Adenotonsillectomy|Tonsil and/or adenoid removal
79858417|NCT06258460|Other|psychotherapy training program intervention|The intervention group will receive a two-day multimodal-based intensive educational intervention of CBT with 8 weeks follow-up (supervision based online teaching).
79858418|NCT06258460|Other|the wail-list control intervention|The wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks.
79858419|NCT06257771|Drug|Alcohol (Ethanol)|Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.
80020847|NCT05466136|Behavioral|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
79261770|NCT03048968|Device|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
79398495|NCT04409522|Drug|Melatonin|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
79398496|NCT04409522|Drug|The usual treatment|Participants in this group will receive the usual treatment of COVID-19
79398497|NCT00672243|Drug|Erlotinib + sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
79398498|NCT04105946|Drug|Dexmedetomidine|dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
79398499|NCT04105946|Drug|Remifentanil|remifentanil administration intraoperatively in combination with other drugs used in TIVA
79398500|NCT01440569|Drug|COBI|150 mg tablet administered orally with food once daily
79398501|NCT01440569|Drug|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
79398502|NCT01440569|Drug|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
79724251|NCT05017051|Device|Measurement of sensorimotor abilities|The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
79724252|NCT05017051|Other|Measurement of facial expression of emotions|Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
79398503|NCT00629499|Drug|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
79724253|NCT05339971|Other|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
79724254|NCT02780557|Behavioral|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
80020848|NCT05453019|Device|Cochlear Implant|The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
80020849|NCT05446727|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine
79398504|NCT00629499|Drug|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
79398505|NCT00629499|Drug|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
79398506|NCT00631449|Drug|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
79398507|NCT00631449|Drug|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
79561565|NCT04004910|Other|Plasma soluble TNF receptor pulldown + chemotherapy|"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
79724255|NCT02780557|Behavioral|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
79724256|NCT04231045|Device|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
79724257|NCT04228471|Procedure|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
79724258|NCT04228471|Procedure|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
79858420|NCT06255873|Dietary Supplement|L- Carnitine|L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
79858421|NCT06255873|Other|ketogenic diet|ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
79858422|NCT06255301|Diagnostic Test|EYEPRIM|Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
80020850|NCT05444114|Behavioral|Mental Exercise|Participants perform a 10 minute mental exercise
79561566|NCT04004910|Drug|Chemotherapy Drugs, Cancer|Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
79724259|NCT02784145|Dietary Supplement|Resistant starch|
80020851|NCT05425511|Behavioral|sophrology / neurolinguistic programming intervention|"2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions."
79261771|NCT05028608|Drug|Elinzanetant (BAY3427080)|Elinzanetant given orally as a single dose in Period 1 and in Period 2.
79261772|NCT05028608|Drug|Midazolam|Midazolam given orally as single dose in Period 1 and in Period 2.
79261773|NCT05028608|Drug|Carbamazepine|Carbamazepine given orally twice daily in Period 2 .
79261774|NCT04886102|Other|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
79261775|NCT03048344|Drug|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
79261776|NCT03048344|Drug|ORH-2014|ORH-2014 capsule at recommended dose orally.
79261777|NCT04882826|Drug|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
79261778|NCT04882826|Drug|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
79398508|NCT01546142|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79398509|NCT01546142|Drug|Placebo|Phosphate buffered saline placebo for injection
79724260|NCT02784145|Other|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
79724261|NCT05322031|Drug|Aripiprazole|Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
79858423|NCT06253611|Drug|Nivolumab|Nivolumab 240 mg IV; every 2 weeks
79858424|NCT06253611|Drug|FOLFOX regimen|Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
79858425|NCT06253611|Biological|EXL01|Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
79261779|NCT04885088|Device|Wisdom bracelet|Wisdom bracelet
80020852|NCT05418764|Other|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
80020853|NCT05404139|Drug|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
80020854|NCT05404139|Other|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
80020855|NCT05398315|Behavioral|Empathic Statements/Reflections|Presence of Empathic Statements
80020856|NCT05398315|Behavioral|Narrator Backstory|Presence of a narrator backstory
79561567|NCT04002193|Other|volume expansion|To assess fluid responsiveness
79724262|NCT02779621|Procedure|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
79858426|NCT06253260|Drug|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
79858427|NCT06253260|Drug|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
79261780|NCT03049982|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
79261781|NCT04881968|Behavioral|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
79261782|NCT04734860|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
79261783|NCT04734860|Drug|Placebo|Diluent solution
79261784|NCT04729400|Device|Vacuum Myofascial Therapy device|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
79261785|NCT04729400|Other|physical therapy program|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
79261786|NCT04729400|Procedure|Therapeutic Percutaneous Electrolysis|Therapeutic Percutaneous Electrolysis
79261787|NCT04729400|Procedure|ultrasound pulsatil therapy (US) and massage|ultrasound pulsatil therapy (US) and massage
79261788|NCT04885868|Other|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.
79261789|NCT03048656|Other|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
79261790|NCT04886024|Other|Advanced Glycation End Products (AGEs)|Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
79261791|NCT04430504|Behavioral|multidisciplinary telerehabilitation|weekly video meetings to instruct and monitor self-exercises at home
79261792|NCT03049592|Other|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
79303758|NCT04489979|Other|Antibiotics|Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
79303759|NCT05634993|Other|Assessment|Assessment of disability level and trunk control
79724263|NCT02779621|Procedure|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
79875715|NCT00949637|Behavioral|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
79875716|NCT00299104|Drug|folate|Intravenous repeating dose
79875717|NCT00299104|Drug|methotrexate|Oral or parenteral repeating dose
79875718|NCT00299104|Drug|methylprednisolone|Intravenous repeating dose
79875719|NCT00299104|Drug|placebo|Intravenous repeating dose
79875720|NCT00299104|Drug|rituximab|Intravenous repeating dose
79875721|NCT03979690|Device|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
79875722|NCT03979456|Drug|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
79875723|NCT00313612|Drug|oxaliplatin|Given IV
79875724|NCT00313612|Drug|topotecan|Given IV
79875725|NCT00507416|Drug|Bortezomib|Bortezomib bolus intravenous (IV) injection
79875726|NCT00507416|Drug|Dexamethasone|Dexamethasone for oral administration
79875727|NCT00507416|Drug|Melphalan|Melphalan for oral administration
79261793|NCT03049904|Behavioral|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use & condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
79398510|NCT00632619|Behavioral|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
79398511|NCT00632619|Drug|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
79398512|NCT00632619|Behavioral|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
79398513|NCT03027518|Other|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
79398514|NCT00633009|Biological|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
79561568|NCT04000334|Other|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
79561569|NCT04000334|Other|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
79561570|NCT03998410|Device|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
79561571|NCT03993249|Biological|Nivolumab|standard of care chemoradiotherapy + Nivolumab
79561572|NCT03993249|Other|chemoradiotherapy|standard of care chemoradiotherapy
79561573|NCT03991611|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
79561574|NCT03991611|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
79561575|NCT03991611|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
79561576|NCT03991611|Other|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
79561577|NCT03991611|Other|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
79561578|NCT03990883|Device|Princess Filler Lidocaine|correction of nasolabial folds
79261794|NCT04885556|Device|Tampon-like device for absorption of sexual fluids|Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
79561579|NCT03984890|Drug|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
79261795|NCT04885478|Other|Immune response monitoring , blood samples|"In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~Covid-19 Symptoms, clinical monitoring"
79261796|NCT03049670|Device|latent available chlorine (LAC)|local application on the necrotic infected tissue
79261797|NCT04410770|Behavioral|Mood tracker ratings|The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
79561580|NCT03984890|Drug|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
79561581|NCT03982459|Behavioral|decision support tool|computerized online decision support tool
79561582|NCT03980834|Behavioral|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
79561583|NCT03980834|Behavioral|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
79724264|NCT02780011|Drug|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
79724265|NCT02780011|Drug|Alsertib|Aurora A kinase inhibitor
79724266|NCT02780479|Drug|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
79398515|NCT00633009|Biological|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
79398516|NCT01440101|Drug|Natalizumab (BG00002)|
79398517|NCT01440101|Drug|Placebo|
79398518|NCT01530464|Drug|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
79561584|NCT03980834|Behavioral|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
79561585|NCT03980834|Behavioral|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
79261798|NCT04436822|Device|Continuous Glucose Monitoring|CGM and frequent sample testing
79261799|NCT04309916|Drug|Tegoprazan|Tegoprazan 50mg tablet
79858429|NCT06251232|Drug|Prednisone|Placebo
79398519|NCT01530464|Drug|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
79261800|NCT04309916|Drug|Esomeprazole|Esomeprazole 40mg tablet
79398520|NCT01530464|Drug|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
79398521|NCT00633399|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
79398522|NCT00633399|Drug|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
79398523|NCT01077843|Drug|Etoricoxib|Cox-2 inhibitor
79398524|NCT01077843|Drug|Other Cox-2 inhibitors|Cox-2 inhibitor
79398525|NCT01077843|Drug|Other Non-selective NSAIDs|Non-selective NSAID
79261801|NCT04387448|Drug|GFB-887|Investigational Medicinal Product (IMP)
79398526|NCT01077843|Other|No anti-inflammatory treatment|No anti-inflammatory prescription
79398527|NCT00633867|Device|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
79398528|NCT00633867|Device|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
79398529|NCT00673959|Other|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
79398530|NCT00673959|Other|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
79398531|NCT04345809|Procedure|MESH WHIT OMEGA-3|Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
79261802|NCT04387448|Drug|Placebo|Matching
79261803|NCT01596062|Drug|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
79398532|NCT04345809|Procedure|MESH WITHOUT OMEGA-3|Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
79398533|NCT00635739|Dietary Supplement|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
79261804|NCT01596062|Drug|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
79261805|NCT01596062|Drug|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
79398534|NCT00635739|Dietary Supplement|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
79398535|NCT00635817|Drug|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
79398536|NCT00635817|Drug|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
79398537|NCT01439945|Drug|magnesium oxide|Given PO
79398538|NCT01439945|Other|placebo|Given PO
79398539|NCT00651963|Drug|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
79398540|NCT00674115|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
79398541|NCT00674115|Drug|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
79398542|NCT00674115|Drug|sodium bicarbonate|Sodium bicarbonate. Single dose.
79398543|NCT02142153|Drug|F901318|"Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile"
79398544|NCT02142153|Drug|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
79398545|NCT00674583|Biological|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
79398546|NCT00674583|Biological|Menjugate|Intramuscular administration, 1 dose
79398547|NCT00637299|Other|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
79398548|NCT00637299|Other|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
79398549|NCT01420081|Drug|PF-05212384|154mg IV weekly
79398550|NCT01420081|Drug|PF-05212384|154mg IV weekly
79398551|NCT01420081|Drug|PF-05212384|154mg IV weekly
79398552|NCT01439867|Drug|Cinacalcet hydrochloride|Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
79561586|NCT03978780|Procedure|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
79561587|NCT03978780|Procedure|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
79561588|NCT03978104|Dietary Supplement|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
79561589|NCT03978104|Dietary Supplement|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
79398553|NCT01439867|Drug|Standard of Care|Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
79398554|NCT00637923|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
79858430|NCT06251050|Drug|lithium-containing mouthwash|The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
79858431|NCT06251050|Drug|Plcacebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
79303760|NCT04568967|Diagnostic Test|Concentrated urine with Xpert Ultra|Molecular TB diagnostic test on urine
79303761|NCT04568967|Diagnostic Test|Stool with Xpert Ultra|Molecular TB diagnostic test on stool
79398555|NCT00637923|Drug|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
79561590|NCT03978104|Dietary Supplement|Control biscuits|Consumption of control biscuits together with habitual diet.
79561591|NCT03973528|Drug|traditional Chinese medicine: tonifying kidney Wan|traditional Chinese medicine : tonifying kidney Wan
79561592|NCT03968081|Behavioral|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
79398556|NCT00637923|Biological|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
79398557|NCT00637923|Drug|Ribavirin|Weight-based ribavirin for 48 weeks.
79561593|NCT03966742|Procedure|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
79561594|NCT03966638|Procedure|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
79398558|NCT01439711|Drug|letrozole|
79561595|NCT03965260|Biological|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
79561596|NCT03956498|Other|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
79561597|NCT03956394|Diagnostic Test|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
79858432|NCT06251050|Drug|lithium-containing mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
79303762|NCT02720081|Drug|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
79303763|NCT02720081|Drug|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
79303764|NCT02720081|Drug|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
79303765|NCT02720081|Drug|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
79398559|NCT01439711|Procedure|MRI|
79261806|NCT01596062|Drug|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
79398560|NCT01439711|Procedure|conventional surgery|
79398561|NCT01439555|Drug|Simvastatin|Simvastatin, 40 mg per day orally
79398562|NCT01439555|Drug|L-Arginine|L-Arginine, 2 Gm four times per day orally;
79261807|NCT01596062|Drug|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
79261808|NCT04090658|Biological|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
79398563|NCT01439555|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin 20 mg/kg/day orally
79398564|NCT00674739|Drug|Imiquimod|daily topical application for up to 8 weeks
79398565|NCT00674739|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
79261809|NCT04090658|Drug|Placebo|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
79398566|NCT00674739|Drug|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
79261810|NCT03987464|Behavioral|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
79261811|NCT03987464|Behavioral|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
79561598|NCT03952182|Other|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
79261812|NCT03987464|Behavioral|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
79261813|NCT03987464|Behavioral|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
79261814|NCT03987464|Behavioral|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
79261815|NCT04885010|Dietary Supplement|probiotics|participants will be given probiotics twice a day for 15 days
79261816|NCT04885010|Dietary Supplement|placebo|participants will be given a placebo twice a day for 15 days
79261817|NCT02614898|Other|Eculizumab|This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
79398567|NCT00675909|Drug|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
79398568|NCT00675909|Drug|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
79561599|NCT03952182|Other|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
79561600|NCT03929588|Device|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
79561601|NCT03929588|Device|Phoropter|Manual refraction and ETDRS chart
79561602|NCT03929588|Device|Autorefractor|Automated refraction
79398569|NCT00675909|Drug|Oral midazolam|oral midazolam 0.5mg/kg
79398570|NCT01439165|Biological|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
79398571|NCT01439165|Biological|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
79398572|NCT03027908|Other|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
79398573|NCT03027908|Other|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
79398574|NCT03027986|Behavioral|postural rehabilitation program|This program is based on sensory-motor control
79398575|NCT03027752|Procedure|Operation carotid endarterectomy with plastic of xenopericardial patch|Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
79561603|NCT03928678|Procedure|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
79561604|NCT03924700|Procedure|Biportal endoscopy|Biportal endoscopic spine surgery (BESS)
79561605|NCT03924700|Procedure|Microdiscectomy|Using microscope for discectomy
79561606|NCT03924427|Drug|BMS-986165|Oral tablet administration
79561607|NCT03922451|Drug|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
79561608|NCT03922451|Drug|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
79875728|NCT00507416|Drug|Prednisone|Prednisone for oral administration
79561609|NCT03908073|Device|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
79561610|NCT03907735|Other|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
79561611|NCT03907332|Other|Home visits|An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
79858434|NCT06250309|Dietary Supplement|Dietary assignment|A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
79875729|NCT00507416|Drug|Thalidomide|Thalidomide for oral administration
79875730|NCT00489476|Drug|Staccato Loxapine|
79561612|NCT05802732|Diagnostic Test|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
79561613|NCT05802706|Other|No intervention.|No intervention.
79561614|NCT05802667|Diagnostic Test|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
79561615|NCT05802641|Radiation|SBRT|Participants with early lung cancer receive single fraction (30Gy/1f) or multiple fractions of SBRT（36Gy/3f).
79561616|NCT05802537|Other|Home-based exergame program|The home-based exergame program was conducted at the participants' homes for 50 min, three times a week, for eight weeks. Online education on fall prevention and musculoskeletal health management was provided once a week for 50 minutes, one day a week, for 8 weeks.
79561617|NCT05802524|Diagnostic Test|Neurowave Group|"Neurosensory stimulation will consist in the administration of pairs of stimuli consisting of emotionally significant images and sounds in the personal life history (two rare stimuli) alternating with neutral images and sounds devoid of emotional significance (two distracting stimuli"
79261818|NCT04881734|Other|Overtime pancreaticoduodenectomy|Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
79875731|NCT00489476|Drug|Staccato Placebo|Placebo aerosol inhalation (0mg)
79875732|NCT00550745|Biological|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
79875733|NCT00550745|Biological|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
79875734|NCT00949793|Device|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
79561618|NCT05802511|Device|Exablate treatment|Exablate treatment for Neuropathic Pain
79561619|NCT05802498|Device|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
79561620|NCT05802485|Other|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~Before the start of treatment~Approximately 2 months after the start of induction chemotherapy~At the end of induction chemotherapy~Prior to local treatment (radiotherapy, surgery)~At the time of tumor progression~At the time of collection of tumor material:~During the initial diagnostic biopsy~On the operating room in case of surgery~During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
79875735|NCT00949871|Other|communication analysis|
79875736|NCT00949871|Other|questionnaire administration|
79261819|NCT04884932|Device|30 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
79261820|NCT04884932|Device|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
79561621|NCT05802472|Other|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
79561622|NCT05802472|Other|Placebo|During Visit 2. 250 ml of single potable water was administered orally.
79561623|NCT05802459|Other|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
79561624|NCT05802459|Other|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
79561625|NCT05802459|Other|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
79561626|NCT05802459|Other|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
79561627|NCT05802459|Procedure|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
79724267|NCT02780479|Drug|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
79724268|NCT05252923|Drug|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
79724269|NCT00634777|Other|pet scan|pet scan
79261821|NCT02145013|Procedure|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
79724270|NCT05097079|Drug|MYOBLOC Low Dose|Weight-based dose; 5.0 units/kg for submandibular gland and 25.0 units/kg for parotid gland
79724271|NCT05097079|Drug|MYOBLOC High Dose|Weight-based dose; 10.0 units/kg for submandibular gland and 40.0 units/kg for parotid gland
79724272|NCT05097079|Drug|Placebo|volume-matched placebo
79261822|NCT02145091|Drug|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
79261823|NCT02145091|Drug|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
79261824|NCT02145091|Drug|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
79261825|NCT02145091|Drug|Placebo|An oral placebo (lactose pill).
79858435|NCT06250088|Biological|Emdogain (EMD) - test|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the computer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, (Emdogain) EMD will be applied to the root surface of the donor tooth. Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
79875737|NCT00949871|Procedure|psychosocial assessment and care|
79875738|NCT00949871|Procedure|support group therapy|
79875739|NCT00952601|Dietary Supplement|Modified Atkins diet|Low carbohydrate diet
79261826|NCT02152111|Dietary Supplement|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
79261827|NCT02152111|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months.
79261828|NCT03544411|Biological|olive oil|the intervention consist of 15 ml / day of olive oil
79261829|NCT03544411|Biological|bran oil|the intervention consist of 15 ml / day of bran oil
79261830|NCT03811028|Drug|SOBI003|weekly i.v. infusion
79261831|NCT04872062|Device|NIV cards|Reading the data available on the NIV cards
79261832|NCT04872062|Other|Medical file|Using the data available in the medical file including clinical data, blood gas results, nocturnal oximetry results
79261833|NCT03441464|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
79261834|NCT02776033|Drug|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
79398576|NCT03027752|Procedure|New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA|Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
79561628|NCT05802446|Other|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
79398577|NCT00638937|Drug|saracatinib|Given PO
79561629|NCT05802433|Dietary Supplement|Vitamin D3 supplement|10µg vitamin D3 supplement per day for 90 days
79561630|NCT05802381|Dietary Supplement|protein supplement|20 gram protein supplement per day
79561631|NCT05802381|Behavioral|nutrition counseling|nutrition counseling for guidance of food intake
79561632|NCT05802368|Other|virtual reality group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
79561633|NCT05802368|Other|exercise group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
79561634|NCT05802355|Other|Manual Diaphragm Release|The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.
79724273|NCT05339737|Device|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values >25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
79875740|NCT00956735|Other|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
79875741|NCT04216043|Dietary Supplement|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
80020857|NCT05398315|Behavioral|Male Narrator|Presence of a male narrator
79303766|NCT04552197|Drug|JNJ-64251330|JNJ-64251330 tablet will be administered orally.
79303767|NCT04552197|Drug|Tofacitinib|Tofacitinib tablets will be administered orally.
79398578|NCT03027830|Device|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
79398579|NCT03027830|Device|Conventional|Other diagnostic devices (including FFR and angiography)
79261835|NCT02776033|Drug|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
79398580|NCT01529606|Other|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
79261836|NCT04881422|Behavioral|B-HIPE (Brief High Impact Preparatory Experience)|The intervention consists in a one-week intensive rehabilitation in which participants underwent to a multidimensional rehabilitation composed by physical rehabilitation, mental wellbeing, a proper diet and engaging physical activity (a sail course). Digital motivating reinforcements are proposed to the participants with the aim to maintain the correct lifestyle learned in the B-HIPE program.
79398581|NCT01529606|Procedure|Plasma treatment|plasma treatment after preparation and for caries prevention
79398582|NCT00639093|Behavioral|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
79398583|NCT00639093|Behavioral|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
79398584|NCT02985632|Drug|BMS-986141|
79398585|NCT01439009|Drug|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
79561635|NCT05802355|Other|control group|Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
79561636|NCT05802342|Drug|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
79398586|NCT01439009|Drug|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
79561637|NCT05802329|Drug|OCU200 Low Dose|Intravitreal Injection
79858436|NCT06250088|Procedure|Sham group|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
79858437|NCT06249841|Device|1.1mm flexible Cryoprobe SU|Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
80020858|NCT05398315|Behavioral|Female Narrator|Presence of a female narrator
79398587|NCT00675987|Drug|losartan|losartan 100 mg tablets 1 tab po QD
79561638|NCT05802329|Drug|OCU200 Medium Dose|Intravitreal Injection
80020859|NCT05398315|Behavioral|MI Techniques|Presence of MI techniques
79303768|NCT05729295|Procedure|Endovascular embolization or surgery|Endovascular embolization with embolizing agents (including glue, non-adhesive agents) or neurosurgical excision of the lesion.
79303769|NCT03067545|Other|Step rate increase|increase the step rate during running by 10% steps per minute
79398588|NCT00675987|Drug|Placebo control|Placebo 1 po QD
79303770|NCT05244473|Drug|brentuximab vedotin|Given into the vein (IV; intravenously)
79303771|NCT05244473|Drug|Placebo|Given by IV
79398589|NCT01572389|Behavioral|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
79398590|NCT01572389|Behavioral|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
79561639|NCT05802329|Drug|OCU200 High Dose|Intravitreal Injection
79561640|NCT05802316|Device|tracheal intubation using videolaryngoscope with a hyperangulated blade or standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)|In the awake group tracheal intubation performed by an videolaryngoscope with a hyperangulated blade. In the asleep group the standard intubation were performed by videolaryngoscopy (VL) and direct laryngoscopy (DL)
79303772|NCT05244473|Drug|ART|Daily use of a combination of HIV medicines
79398591|NCT00639717|Procedure|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
79398592|NCT00639717|Drug|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
79261837|NCT04881344|Procedure|laser hemorrhoidoplasty|"Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able."
79261838|NCT04881344|Procedure|mucopexy|"Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention)."
79261839|NCT02145325|Drug|Expanded Tregs|
79261840|NCT03352934|Drug|Avelumab|Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
79261841|NCT04871828|Drug|Leukotriene Receptor Antagonist|Zafirlukast
79398593|NCT00639717|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
79561641|NCT05802303|Drug|17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
79261842|NCT04871828|Other|Placebo|Placebo
79561642|NCT05802303|Drug|Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)|In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
79561643|NCT05802290|Drug|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
79261843|NCT02777125|Device|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
79303773|NCT03067389|Diagnostic Test|Diagnostic test|Genetic diagnostic test
79398594|NCT00639717|Drug|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
79398595|NCT00639717|Drug|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
79398596|NCT01571453|Drug|Vortioxetine (Lu AA21004)|10 mg/day
79398597|NCT01571453|Drug|Venlafaxine extended release|150 mg/day
79561645|NCT05802251|Diagnostic Test|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
79561646|NCT05802212|Drug|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
79561647|NCT05802186|Procedure|Computed Tomography|Undergo CT
79561648|NCT05802186|Procedure|Magnetic Resonance Imaging|Undergo MRI
79561649|NCT05802186|Procedure|Positron Emission Tomography|Undergo PET
79561650|NCT05802186|Other|Quality-of-Life Assessment|Ancillary studies
79561651|NCT05802186|Other|Radiology, Treatment Planning|Undergo radiation planning with AI-directed analysis for dose recommendation
79561652|NCT05802186|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79561653|NCT05802186|Procedure|X-Ray Imaging|Undergo x-ray imaging
79561654|NCT05802160|Behavioral|Good Start Matters - Parenting intervention|The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
79561655|NCT05802147|Behavioral|skin-to-skin contact|skin-to-skin contact
79561656|NCT05802134|Dietary Supplement|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
79561657|NCT05802134|Behavioral|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
79724274|NCT02779309|Procedure|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
79875742|NCT04216043|Dietary Supplement|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
79561658|NCT05802121|Drug|Apple Cider Vinegar|"Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months~https://www.webbernaturals.com/en-ca/apple-cider-vinegar-500-mg-capsules/"
79858438|NCT06248918|Behavioral|WATSOCPAP|Participants will receive an supervised and individualized exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory. Participants will be administered strengthening and aerobic exercise program, structured and individualized according to the person's individual capacity and needs, under the supervision of a physiotherapist. The activity tracker will provide real-time activity information about daily steps, time spent with MVPA (minutes/day) and sedentary time. The nurse-led physical activity coaching program was planned according to the Social Cognitive Theory (SCT) components such as self-regulation, outcome expectation, social support and perceived environment. The interventions will continue with online and the 12-week program will be completed.
79561659|NCT05802121|Drug|Placebo|Each patient will be instructed to take 6 placebo capsules per day for 3 months
79561660|NCT05802108|Drug|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
79261844|NCT02777125|Device|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
79261845|NCT04871906|Other|stretching exercises|Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
79261846|NCT02152189|Other|Screening for Fabry disease|
79261847|NCT04881110|Drug|Liraglutide|Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
79561661|NCT05802108|Drug|Statin|the control group was treated with statin only for lipid-lowering
79724275|NCT02780635|Behavioral|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
79858439|NCT06248411|Drug|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
79561662|NCT05802082|Other|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
80020860|NCT05386992|Diagnostic Test|Anthropometric study|Once the 5 models of lasts have been produced in phase 1, certain shoe models will be designed and manufactured based on these lasts at random and at the free choice of the designers of a footwear company. These models will then be physically tested on children to analyze their effects on walking and walking.
80020861|NCT05376059|Behavioral|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
80020862|NCT05376059|Behavioral|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
79261848|NCT04881110|Other|Control|Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
79261849|NCT02152267|Device|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
79261850|NCT04880954|Procedure|Soft Tissue Mobilization|Soft Tissue Mobilization will be provided to participants by Licensed Chiropractor focusing on structures of the lower and upper leg. This will be provided for 20 minutes, once per week for 12 weeks.
79561663|NCT05802043|Behavioral|Cognitive Stimulating Interventions|a quasi-experimental research design.The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderly club.
79561664|NCT05802017|Other|Allergen-specific substitute diet|Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.
79561665|NCT05801991|Device|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
79724276|NCT02780635|Behavioral|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
79724277|NCT02779387|Drug|Goserelin Acetate|
79724278|NCT04228315|Drug|Primaquine|radical cure dosing
79724279|NCT04228393|Drug|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
79724280|NCT04228393|Procedure|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
79858440|NCT06248411|Drug|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
79858441|NCT06244459|Other|VR Assessment Tool|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
79261851|NCT04880954|Other|Rehabilitation|Participants will engage in 20 minutes of prescribed at-home exercise 5 times per week, for 12 weeks.
79261852|NCT02145481|Behavioral|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
79261853|NCT02145481|Behavioral|CAD Education|Education for patients with coronary artery disease
79261854|NCT04880798|Diagnostic Test|124I PET/CT|The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin >100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.
79261855|NCT02152423|Drug|LOVENOX|LMWH
79561666|NCT05801991|Device|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
79261856|NCT02152423|Drug|ENOXAMED|LMWH
79261857|NCT02145559|Drug|Metformin XR|
79261858|NCT02145559|Drug|Delayed Metformin|
79261859|NCT02145559|Drug|Sirolimus|
79561667|NCT05801965|Device|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
79561668|NCT05801965|Other|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
79858442|NCT06243861|Behavioral|Mother-child bond|assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care
79261860|NCT02145637|Drug|Afatinib plus Ruxolitinib combination therapy|
79261861|NCT02155621|Genetic|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
79261862|NCT02152501|Other|Exercise Energy Expenditure 300 kcal/day|
79561669|NCT05801952|Device|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
79561670|NCT05801926|Device|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
79561671|NCT05801900|Drug|Ketorolac group|30 min preoperatively then every 8 hours postoperatively
79724281|NCT04228393|Procedure|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
79724282|NCT05246761|Device|Balloon catheter|In the two groups, if their bishop score <6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
79724283|NCT02779777|Drug|Tipifarnib|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
79724284|NCT05296915|Device|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
79858443|NCT06241963|Device|Active Comparator: Unilateral real High definition transcranial direct current stimulation|Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed
79858444|NCT06241963|Device|Active Comparator: Bilateral real High definition transcranial direct current stimulation|Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed
79261863|NCT02152501|Other|Exercise Energy Expenditure 600 kcal/day|
79858445|NCT06241963|Device|Sham Comparator: Sham High definition transcranial direct current stimulation|The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors
79261864|NCT03154580|Drug|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
79261865|NCT02145715|Drug|Velcade|
79261866|NCT02145715|Drug|Thalidomide|
79561672|NCT05801900|Drug|Ibuprofen group|30 min preoperatively then every 8 hours postoperatively
79561673|NCT05801887|Device|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
79261867|NCT02145715|Drug|Dexamethasone|
79261868|NCT02145715|Drug|Panobinostat|
79261869|NCT04871750|Dietary Supplement|Soy protein|Daily consumption for 24 weeks
79261870|NCT04871750|Dietary Supplement|Casein protein|Daily consumption for 24 weeks
79858446|NCT06241742|Drug|HT-6184|Single, oral dose of HT-6184
79858447|NCT06241742|Drug|HT-6184 Placebo|Single, oral dose of placebo
79261871|NCT04871126|Other|inflammatory indexes and CHA2DS2-VASc score|inflammatory indexes and CHA2DS2-VASc score
79261872|NCT03542929|Device|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
79261873|NCT02145793|Behavioral|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
79261874|NCT02155699|Behavioral|Exercise 1|65% of VO2max and 2 sessions per week
79261875|NCT02155699|Behavioral|Exercise 2|85% intensity and 3 sessions per peek
79261876|NCT01613144|Device|OsseoScrew Spinal Fixation System|Surgical intervention
79261877|NCT02152579|Drug|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
79875743|NCT04216043|Dietary Supplement|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
79398598|NCT04121195|Drug|Dose escalation|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
79398599|NCT04120961|Drug|prolonged continuous use of bivalirudin|prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
79398600|NCT04120961|Drug|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
79398601|NCT01446289|Biological|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
79398602|NCT01446289|Biological|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
79398603|NCT04120649|Procedure|hysterectomy|total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
79398604|NCT01438541|Device|Window|Dressing
79398605|NCT04410263|Diagnostic Test|Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)|"Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~Swabs (oral +/- nasal +/- nasopharyngeal)~Sublingual microscopy"
79561674|NCT05801887|Device|No ESWT|the osteoblast like cells are not exposed to shockwaves
79561675|NCT05801874|Diagnostic Test|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
79561676|NCT05801848|Diagnostic Test|[18F]NaF PET/CT scan|Patients will have their lower back scanned using [18F]NaF PET/CT
79561677|NCT05801822|Diagnostic Test|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
79561678|NCT05801783|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
79561679|NCT05801744|Behavioral|Operant conditioning|In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
79561680|NCT05801731|Other|Intervention|"The low GI snack is a biscuit with a Glycemic Index of 23.8 ± 3.3. The low GI snack contains plain flour, fibre, plant-based protein, vegetable oil and a low GI sweetener.~The interventional snacks (control, experimental) are matched for caloric content."
79561681|NCT05801731|Other|Control|The normal GI snack is a biscuit with a Glycemic Index of 54.4 ± 6.3. The control snack is formulated using basic ingredients for a biscuit recipe consisting of all-purpose flour, butter, sugar, vanilla flavour, baking soda, egg and salt.
80020863|NCT05376059|Behavioral|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
80020864|NCT05349890|Biological|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
80020865|NCT05349890|Drug|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
79561682|NCT05801718|Diagnostic Test|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference& skin fold thickness and measuring body mass index.
80020866|NCT05349890|Drug|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
79261878|NCT04880564|Drug|CN1, 0.5mg/kg and CN401, 400mg|CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
79261879|NCT04880564|Drug|CN1, 1mg/kg and CN401, 600mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
79561683|NCT05801692|Procedure|Weaning of mechanical ventilation|Weaning of mechanical ventilation is the time when the patient is ready for separation from ventilatory support until breathing without invasive support
79561684|NCT05801640|Other|Facilitated Tucking Position|The fetal position was given by the researcher. In the fetal position, the lower and upper extremities of the baby were kept in the flexed position by hand and placed in the side-lying position close to the midline.
79561685|NCT05801640|Other|Reiki|Reiki was applied to areas called chakras (forehead, throat, heart, stomach, feet and hands). A total of 15 minutes were applied in the form of 12 minutes touches in each chakra region.
79561686|NCT05801627|Drug|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
79561687|NCT05801627|Drug|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
79261880|NCT04880564|Drug|CN1, 1mg/kg and CN401, 800mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
79261881|NCT04880564|Drug|CN1, 3mg/kg and CN401, 800mg|CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
79261882|NCT04880564|Drug|CN1, 10mg/kg and CN401, 800mg|CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
79261883|NCT02155777|Drug|OrthoNovum 1/35|
79561688|NCT05801588|Other|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
79261884|NCT02155855|Other|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
79261885|NCT02155855|Other|Control|Routine care
79261886|NCT02152657|Other|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
79561689|NCT05801588|Other|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
79561690|NCT05801575|Drug|Chinese Herbal Medicine (CHM) teabag|Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
79261887|NCT04879784|Other|No intervention|No intervention
79561691|NCT05801536|Device|SCONE|This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
79561692|NCT05801523|Procedure|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
79724285|NCT05296915|Device|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
79261888|NCT04880018|Device|Capsular Tension Ring|Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
79724286|NCT05296915|Behavioral|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
79261889|NCT02145949|Drug|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
79261890|NCT02145949|Drug|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
79261891|NCT02152735|Procedure|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
79261892|NCT03047018|Behavioral|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
79261893|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks.
79261894|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
79724287|NCT02779933|Other|Epidemiology od HAP|no intervention
79724288|NCT05286697|Diagnostic Test|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
79724289|NCT05339425|Other|No additional intervention will be administered.|No additional intervention will be administered.
79875744|NCT04216043|Dietary Supplement|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
79261895|NCT00806390|Drug|Metoprolol|Metroprolol tartrate titrated up
79261896|NCT00566618|Drug|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
79261897|NCT00566618|Drug|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
79398606|NCT01419769|Device|AXIOS Stent & Delivery System|"The AXIOS Stent & Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
79398607|NCT01438307|Drug|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
79261898|NCT00095420|Behavioral|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
79261899|NCT00095420|Behavioral|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
79261900|NCT00095420|Behavioral|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
79261901|NCT00095420|Behavioral|Usual training|Participants will receive the usual training offered in their local school districts.
79261902|NCT04877600|Other|dual task performance|dual task performance measurement
79261903|NCT03046940|Other|Patient-centered style of communication|Different doctor-patient communication
79261904|NCT03046940|Other|Doctor-centered style of communication|Different doctor-patient communication
79261905|NCT02769481|Drug|Bexagliflozin|20 mg, tablet
79261906|NCT02769481|Drug|Placebo for Bexagliflozin|inactive tablet to match active comparator bexagliflozin
79261907|NCT02769481|Drug|Glimepiride|2, 4 or 6 mg, capsule
79261908|NCT02769481|Drug|Placebo for Glimepiride|inactive capsules to match active comparator glimepiride
79261909|NCT04410692|Other|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
79561693|NCT05801523|Procedure|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
79261910|NCT04879316|Other|Resting Energy Expenditure measurement|Resting Energy Expenditure measurement using indirect calorimetry
79261911|NCT02152813|Behavioral|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
79261912|NCT04877210|Drug|Topical Insulin|Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
79561694|NCT05801497|Procedure|Balneotherapy|"The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica."
79561695|NCT05801484|Other|Linezolid continuous infusion|Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
79724290|NCT05340049|Diagnostic Test|Online questionnaire of children's backgrounds|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children.
79724291|NCT05340049|Other|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
79875745|NCT00952679|Device|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
79261913|NCT02152891|Behavioral|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
79261914|NCT02146183|Dietary Supplement|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
79261915|NCT02146183|Dietary Supplement|Placebo Corn Starch|500 mg/day
79398608|NCT01438307|Drug|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
79398609|NCT01444651|Drug|Tadalafil|20 mg Tadalafil taken once a day for 3 months
79858448|NCT06240559|Device|External imaging panel|The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.
79858449|NCT06238297|Diagnostic Test|MRSA nasal swab based de-escalation|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
79261916|NCT02152969|Drug|Telmisartan|
79398610|NCT01444651|Drug|Placebo|Placebo tablet taken by mouth once a day for 3 months
79561696|NCT05801458|Procedure|Modeling Resin Insertion Technique|One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.
79398611|NCT01570751|Drug|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
79261917|NCT02152969|Drug|Amlodipine|
79261918|NCT02152969|Drug|Chlorthalidone|
79261919|NCT04876976|Drug|Cyanoacrylate, Isobutyl|using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
79261920|NCT04876976|Procedure|Classic surgical repair|classical repair of urethro-cutaneous fistula without the use of cyanoacryalte
79261921|NCT03544255|Procedure|Biopsy|Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
79261922|NCT04879004|Drug|Ropivacaine injection|Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
79261923|NCT04870736|Procedure|Mout-to-mouth ventilation|Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
79261924|NCT04870736|Procedure|Mout-to-mouth ventilation with quantitative analysis|Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
79261925|NCT02153125|Drug|Eplerenone|
79261926|NCT03046628|Device|TcPO2|
79261927|NCT03046628|Device|Green laser (at 532nm) and a fast camera|
79724292|NCT05340049|Procedure|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (placebo, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the therapies were expressed as percentages of satisfaction with the classifications of 25% (apparent changes less than half of the sample in each therapy group), 50% (apparent changes in half of the sample plus one in each therapy group) and 75-100% (apparent changes in all or almost all of the sample in each therapy group)."
79858450|NCT06237712|Dietary Supplement|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
79261928|NCT02156089|Other|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
79261929|NCT04879472|Procedure|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
79261930|NCT02255071|Device|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
79261931|NCT02255071|Device|Sham wristband|A wristband over wrist but no acupressure for seven days.
79261932|NCT04878926|Procedure|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
79398612|NCT01570751|Drug|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
79858451|NCT06237712|Dietary Supplement|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
79858452|NCT06237712|Dietary Supplement|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
79858453|NCT06237712|Dietary Supplement|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
79875746|NCT04416659|Device|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
79398613|NCT01419535|Drug|Mifepristone|Mifepristone 50mg tablet by mouth every six hours for nine days.
79398614|NCT01419535|Drug|Placebo|Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
80020867|NCT05335239|Other|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (> 4000 ppm) and relevant interproximal aids.
79561697|NCT05801458|Procedure|Conventional resin composite Incremental Placement Technique|A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
79561698|NCT05801393|Radiation|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
79561699|NCT05801380|Drug|AChE inhibitor monotherapy|This is a drug treatment using Donepezil only
80020868|NCT05313269|Other|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
79561700|NCT05801380|Drug|AChE inhibitor and NMDA receptor antagonist combination therapy|This is a drug treatment combining Donepezil and Memantine
79561701|NCT05801367|Drug|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
79561702|NCT05801367|Drug|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
79561703|NCT05801354|Drug|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
79261933|NCT04878926|Procedure|IV midazolam and propofol-based sedation with Local Anesthetic infiltration|IV midazolam and propofol-based sedation with Local Anesthetic infiltration
79561704|NCT05801354|Drug|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
79261934|NCT04879082|Other|Professional course, occupational exposures|"The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past."
79561705|NCT05801328|Device|Ending of the wires on Erich arch bar in the occlusal direction|The wires of the Erich arch bar will be placed on the occlusal direction
79561706|NCT05801302|Device|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
79561707|NCT05801302|Device|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
79561708|NCT05801289|Drug|Quetiapine|Giving the drug to group Q
79561709|NCT05801276|Diagnostic Test|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
79561710|NCT05801263|Diagnostic Test|CDO1 and HOXA9 methylation assay|CDO1 and HOXA9 methylation assay in plasma circulating tumor cells
79561711|NCT05801250|Behavioral|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
79561712|NCT05801185|Other|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
79561713|NCT05801133|Drug|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
79561714|NCT05801107|Drug|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
79561715|NCT05801094|Drug|QL1604|QL1604 3 mg/kg Q3W
79858454|NCT06237712|Dietary Supplement|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
79858455|NCT06237712|Dietary Supplement|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
79858456|NCT06237231|Drug|DIT112|DIT112 tablet
79858457|NCT06237231|Drug|DIPYRONE|Dipyrone tablet 1.000mg
79858458|NCT06237231|Drug|TRAMADOL|Tramadol tablet 50mg
79858459|NCT06237231|Drug|DIT112 Placebo|DIT112 placebo tablet
79858460|NCT06237231|Drug|Dipyrone Placebo|Dipyrone placebo tablet
80020869|NCT05313269|Other|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
80020870|NCT05310396|Other|Experimental formula|Cow's milk-based infant formula with a specific blend of nutrients at pre-defined levels
80020871|NCT05310396|Other|Control Formula|Cow's milk-based infant formula with standard nutritional composition
80020872|NCT05307055|Device|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
80020873|NCT05307055|Device|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
79561716|NCT05801068|Drug|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
79561717|NCT05801055|Drug|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
79561718|NCT05801016|Behavioral|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
79561719|NCT05801003|Device|Predilation with cutting balloon.|PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
79561720|NCT05801003|Device|Predilation with conventional balloon|PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
79561721|NCT05800977|Biological|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
79858461|NCT06237231|Drug|Tramadol Placebo|Tramadol placebo capsule
79561722|NCT05800912|Other|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
79561723|NCT05800912|Other|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
79561724|NCT05800899|Behavioral|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
79561725|NCT05800899|Behavioral|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
79561726|NCT05800886|Other|Early mobilization and tea consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
79561727|NCT05800886|Other|Early mobilization and coffee consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
79724293|NCT05339347|Device|Photoneuromodulation|Treatments were administered daily for a period of 2 weeks (10 sessions) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LED wavelength 850 nm) or with a placebo probe of the same appearance and display. The irradiation parameters created will be based on the disease, pain intensity and skin phototype. Each session has from 10 to 15 min, depending on skin phototype
79724294|NCT05044975|Behavioral|Sleep restriction|Participants will receive sleep restriction intervention
79724295|NCT05044975|Behavioral|Stimulus control|Participants will receive stimulus control intervention
79724296|NCT05044975|Behavioral|Systematic light exposure|Participants will receive systematic light exposure intervention
79724297|NCT05339191|Behavioral|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
79858462|NCT06236425|Biological|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
79858463|NCT06236425|Drug|Pembrolizumab|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
79858464|NCT06236425|Drug|Platinum based chemotherapy|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
79858465|NCT06236425|Drug|Cyclophosphamide|Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
79858466|NCT06236425|Drug|Fludarabine|Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
79858467|NCT06236425|Drug|Aldesleukin|After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
79561728|NCT05800886|Other|Early mobilization and warm water consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
79561729|NCT05800886|Other|Ongoing treatment|The first mobilization and oral intake of the patients in the control group started at the 8th hour.
79561730|NCT05800847|Drug|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
79724298|NCT05339035|Behavioral|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
79561731|NCT05800847|Drug|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
79561732|NCT05800808|Procedure|High Intensity Intervals|8x4 min cycling bouts at 85% of VO2peak
79561733|NCT05800808|Procedure|Moderate Exercise|81 minutes of cycling at 50% VO2peak
79561734|NCT05800795|Device|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
79561735|NCT05800795|Device|plasma spray|surface treatment with plasma spray for heating abutments
79561736|NCT05800756|Drug|pyrotinib combined with trastuzumab, dalpiciclib and letrozole|Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
79561737|NCT05800197|Drug|Tamoxifen 20mg|Selective estrogen receptor modulator
79858468|NCT06235892|Drug|TACROLIMUS|TACROLIMUS 2-3.5 ng/ml
79561738|NCT05800197|Drug|Anastrozole 1mg|Aromatase Inhibitor
79858469|NCT06230302|Dietary Supplement|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
79858470|NCT06230302|Dietary Supplement|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
79875747|NCT00956969|Behavioral|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
80020874|NCT05301517|Drug|SEPO®|SEPO® will be administered per dose and schedule specified in the arm description.
80020875|NCT05301517|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
79261935|NCT04878848|Other|Proprioceptive Neuromuscular Facilitation Exercises|Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
79261936|NCT04878848|Other|Conventional Rehabilitation Group|Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
79261937|NCT04876664|Device|measuring blood pressure with noninvasive blood pressure device|To measure blood pressure in different circumstances with noninvasive blood pressure device
79261938|NCT02156245|Other|conventional rehabilitation program (including concentric cycle ergometer)|
79261939|NCT02156245|Other|cycling included into a conventional rehabilitation program|
79261940|NCT04876898|Other|prospective cohort in high body mass index patient with covid 19|A cohort study included 114 adult patients with confirmed COVID-19 were categorized by BMI levels
79561739|NCT05800197|Drug|Letrozole 2.5mg|Aromatase Inhibitor
79561740|NCT05800197|Drug|Goserelin|Gonadotropin Releasing Hormone (GnRH) agonist
79561741|NCT05800197|Drug|Triptorelin|Gonadotropin Releasing Hormone (GnRH) agonist
79561742|NCT05798962|Procedure|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
79561743|NCT05798741|Procedure|Hardware removal|The surgery of hardware removal after an ORIF of an ankle fracture
79561744|NCT05798637|Other|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
79561745|NCT05797857|Other|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
79561746|NCT05797597|Drug|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
79561747|NCT05797597|Drug|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
79561748|NCT05797324|Other|Luminette|Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
79561749|NCT05797324|Other|Sham|Sham protocol (white light <100 lux equivalent).
79398615|NCT01438151|Drug|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
79261941|NCT02153203|Behavioral|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
79261942|NCT02153203|Other|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
79858471|NCT06229444|Behavioral|ILI Predictive Alerts, Reactive Content, and Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms, in addition they also receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
80020876|NCT05296304|Drug|Bexarotene|Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
79261943|NCT02146261|Drug|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
79261944|NCT02146261|Drug|Placebo|Subcutaneous administration of placebo
79261945|NCT02153281|Other|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
79398616|NCT02141451|Drug|Rituximab|Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
79724299|NCT01880359|Drug|Cisplatin|
79261946|NCT02146339|Other|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
79398617|NCT02141451|Drug|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
79398618|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
79398619|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
79724300|NCT01880359|Radiation|Radiotherapy|
79561750|NCT05796102|Procedure|PET-MRI|"A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment"
79858472|NCT06229444|Behavioral|ILI Predictive Alerts, Reactive Content|Participants receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
79561752|NCT05795335|Drug|CDK4/6 inhibitor|CDK4/6 inhibitors
79561753|NCT05794776|Device|BurstDR stimulation|BurstDR spinal cord stimulation
79724301|NCT01880359|Drug|Placebo|
79724302|NCT01880359|Drug|Nimorazole|
79724303|NCT05338489|Drug|Selpercatinib|Administered orally.
79724304|NCT05338489|Drug|Itraconazole|Administered orally.
79724305|NCT05338489|Drug|Rifampin|Administered orally.
79724306|NCT02779699|Drug|AL2846|AL2846 p.o. qd
79724307|NCT05266417|Drug|INS-GSH|Intranasal INS-GSH Twice Daily
79724308|NCT05266417|Drug|Matched Placebos|Intranasal Matched Placebos Twice Daily
79858473|NCT06229444|Behavioral|Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms.
79261947|NCT02146339|Other|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
79303774|NCT05501795|Device|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
79303775|NCT05634681|Radiation|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
79724309|NCT02779465|Drug|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
79858474|NCT06229444|Behavioral|No Intervention|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive IILI-related health educational content
79875748|NCT00956969|Behavioral|Relaxation Training|Teaches patients relaxation training
79875749|NCT00952835|Other|regular treatment|regular treatment
79875750|NCT00957125|Drug|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
79875751|NCT00957125|Drug|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
79875752|NCT00957125|Drug|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
80020877|NCT05296304|Radiation|Total Skin Electron Beam (TSEB)|At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
79561754|NCT05794776|Device|Tonic stimulation|Tonic spinal cord stimulation
79398620|NCT02075125|Drug|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
79398621|NCT02075125|Drug|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
79398622|NCT00678015|Drug|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
79398623|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
79261948|NCT02146339|Other|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
79261949|NCT02146339|Other|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
79261950|NCT02146339|Other|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
79561755|NCT05794776|Device|No stimulation|Stimulator is switched off
79261951|NCT02146339|Other|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
79261952|NCT02146417|Procedure|Low pressure pneumoperitoneum|
79261953|NCT02146417|Procedure|Normal pressure pneumoperitoneum (12 mmHg)|
79561756|NCT05794750|Drug|AK104 injection|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
79724310|NCT04985305|Behavioral|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
79724311|NCT04985305|Behavioral|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
79261954|NCT02146417|Procedure|Deep neuromuscular block|
79261955|NCT02146495|Device|EEG-NF|
79261956|NCT04845997|Biological|COVID-19 Vaccine|Patients with rheumatic diseases who have been vaccinated for COVID-19
79261957|NCT02156323|Drug|CMS|Multiple doses of CMS over 2.5 days
79261958|NCT02156323|Drug|RO7033877|Multiple doses of RO7033877 over 2.5 days
79561757|NCT05794750|Procedure|TME surgery|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
79261959|NCT02156323|Drug|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
79261960|NCT03542851|Drug|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
79261961|NCT03542851|Drug|Placebo oral capsule|Placebo will be presented as oral capsule.
79261962|NCT02769247|Drug|Naproxen|Oral naproxen vs placebo
79261963|NCT02769247|Drug|Lidocaine|Intrauterine lidocaine vs normal saline
79261964|NCT02769247|Drug|placebo|either normal saline or empty oral capsule
79398624|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
79398625|NCT01437995|Drug|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
79398626|NCT00640653|Behavioral|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
79398627|NCT00640653|Behavioral|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
79398628|NCT00640653|Behavioral|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
79398629|NCT00640653|Behavioral|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
79398630|NCT00640653|Behavioral|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
80020878|NCT05280301|Device|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
79398631|NCT04064879|Other|AD-SVF|Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
80020879|NCT05274763|Other|Quality-of-Life Assessment|Ancillary studies
79261965|NCT02146573|Behavioral|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
79398632|NCT00641745|Drug|Lurasidone HCl|40 - 120mg per day
79398633|NCT00641745|Drug|Risperidone|Risperidone
80020880|NCT05274763|Other|Questionnaire Administration|Ancillary studies
80020881|NCT05274763|Procedure|Spiritual Therapy|Deliver or undergo CCSH session
79261966|NCT02146573|Behavioral|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~Help patients/families navigate decisions in concert with preferences and beliefs~Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~Serve as point person for active intensivists on service and other specialists~Help resolve conflict when multiple providers have different opinions on course of action"
79398634|NCT01799109|Drug|Magnesium Sulfate & albuterol|
79261967|NCT02146651|Drug|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
79724312|NCT04985305|Behavioral|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
79561758|NCT05794750|Drug|Capecitabine|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
79261968|NCT02146651|Drug|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
79261969|NCT02146651|Drug|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
79398635|NCT01799109|Drug|albuterol|
79398636|NCT01799109|Drug|magnesium|
79398637|NCT00588159|Drug|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
79398638|NCT00588159|Drug|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
79261970|NCT02146651|Drug|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
79261971|NCT02153515|Other|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
79261972|NCT02773537|Drug|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
79303776|NCT05634681|Radiation|Standard plan|One treatment plan
79261973|NCT02773537|Drug|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
79261974|NCT02773537|Drug|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
79261975|NCT03542149|Drug|OZ439 + α-tocopherol polyethylene glycol 1000 succinate|Artefenomel (OZ439), is a novel trioxolane Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
79261976|NCT02146729|Procedure|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
79261977|NCT02146729|Procedure|Open Treatment|Midline posterior incision with instrumentation.
79398639|NCT01439347|Drug|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m^2 (without any dose cap) as an IV infusion over 60 minutes.
79398640|NCT01439347|Drug|Vincristine Sulfate Injection (VSI)|1.4 mg/m^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
79261978|NCT02153593|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
79398641|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
79398642|NCT00678249|Procedure|PTA|Percutaneous Transluminal Angioplasty
79561759|NCT05794750|Drug|Oxaliplatin|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
79561760|NCT05792293|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
79561761|NCT05792293|Other|Placebo|Placebo
79561762|NCT05788263|Other|neuroscience based aproach|exercise for pain
79261979|NCT02153593|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
79261980|NCT02153593|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
79261981|NCT03544177|Other|BFR-Walking|Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
79303777|NCT05728983|Other|Sleep levels|Sleep levels are what the experimenter prescribes to participants in the study.
79398643|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
79398644|NCT04066933|Combination Product|A2M enriched plasma|Plasma enriched for alpha2macroglobulin (A2M-PPP) was produced by a centrifugation and filtration process developed by Cytonics Corporation. Initially, 7 milliliters of Anticoagulant Citrate Dextrose Solution A, ubiquitous surface protein (USP) was drawn into a 60 cc syringe and then an additional 38 cc of autologous blood was drawn up through an antecubital vein. Two syringes were prepared in this manner and then centrifuged at 4000 rpm (1280G) for 4 minutes. The supernatant plasma fraction was then transferred to a roller pump system that circulates the fluid through a proprietary filter having a high molecular weight cutoff designed to trap larger molecules including alpha 2 macroglobulin (720 kDa).
79398645|NCT00680823|Drug|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
79398646|NCT00680823|Drug|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
79398647|NCT00589329|Drug|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
79398648|NCT00589329|Drug|placebo|IV and pill placebo
79561763|NCT05785689|Drug|Dexmedetomidine|To reduce postoperative agitation
79561764|NCT05785689|Drug|Placebo|Placebo bolus saline
79561765|NCT05784025|Device|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
79303778|NCT05233319|Other|There is no intervention|There is no intervention
79398649|NCT01438957|Drug|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
79398650|NCT01438957|Drug|Placebo|
79398651|NCT00589563|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
79561766|NCT05772117|Behavioral|Chatbot-delivered interventions tailored to stage of changes|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
79561767|NCT05772117|Behavioral|Chatbot-delivered standard interventions|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
79561768|NCT05770219|Drug|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
79561769|NCT05765864|Diagnostic Test|Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3|The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
79261982|NCT03544177|Other|Conventional therapy|Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
79398652|NCT00589563|Drug|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
79398653|NCT00589563|Drug|etoposide|60mg/kg on day -4 from stem cell transplant
79398654|NCT00589563|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
79398655|NCT00589563|Drug|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
79303779|NCT05634603|Dietary Supplement|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
79398656|NCT00589563|Drug|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
79561770|NCT05765864|Diagnostic Test|Columbia Suicide Severity Rating Scale (CSSRS)|"The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.~Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77."
79724313|NCT04985305|Behavioral|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
79398657|NCT00589563|Drug|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
79303780|NCT04809233|Drug|Tipifarnib|
79398658|NCT00589563|Drug|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
79398659|NCT00589563|Procedure|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
79398660|NCT00589563|Procedure|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
79398661|NCT00589563|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
79561771|NCT05765864|Diagnostic Test|The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)|"used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).~Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46."
79561772|NCT05765864|Diagnostic Test|Experiences in Close Relationships-Relationship Structures (ECR-RS)|"Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.~Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65."
79561773|NCT05765864|Diagnostic Test|Trauma Symptom Checklist for Children (TSCC)|"The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx"
79724314|NCT04985305|Behavioral|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
79724315|NCT02779231|Other|Bi-directional texting|
79398662|NCT00589563|Procedure|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
79398663|NCT00589563|Radiation|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
79398664|NCT00645333|Drug|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
79398665|NCT00646581|Drug|Placebo|Placebo
79398666|NCT00646581|Drug|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
79398667|NCT00681291|Device|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
79398668|NCT00681291|Device|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
79398669|NCT00648375|Drug|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
79398670|NCT00648375|Drug|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
79398671|NCT00648375|Behavioral|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
79398672|NCT01444417|Drug|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10^9/L and ≤ 200 x 10^9/L.
79398673|NCT01444417|Drug|Placebo|Matching placebo administered by subcutaneous injection
79398674|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 24%|transfusion
79858475|NCT06229431|Other|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~Introduction of the CSNAT tool as a conversation starter.~Time for the spousal caregiver to consider the questions in which more support is needed.~An assessment conversation takes place.~A shared action plan is formed based on the assessment conversation.~Continuous shared review of the action plan."
80020882|NCT05272280|Other|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
79261983|NCT02153749|Behavioral|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
79261984|NCT02153749|Behavioral|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
79261985|NCT02156557|Biological|Colon KCC Heptapeptide|"Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~We will obtain copies of your endoscopy report and any pathology reports."
79261986|NCT02780713|Drug|AZD9496 (Reference)|AZD9496 (Reference)
79261987|NCT02780713|Drug|AZD9496 Variant A|AZD9496 Variant A.
80020883|NCT05272280|Other|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
79261988|NCT02780713|Drug|AZD9496 Variant B|AZD9496 Variant B
79261989|NCT02780713|Drug|AZD9496 Variant C|AZD9496 Variant C
79398675|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 28%|transfusion
79398676|NCT00653133|Device|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
79398677|NCT00653133|Device|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
79398678|NCT01444027|Behavioral|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
79398679|NCT00654069|Drug|Placebo|2 tablets every 6 hours for 48 hours
79261990|NCT02780713|Drug|AZD9496 Variant D|AZD9496 Variant D
79398680|NCT00654069|Drug|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
79261991|NCT02146807|Device|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
79261992|NCT02154217|Drug|Bimatoprost|
79261993|NCT02154217|Drug|Latanoprost/Timolol|
79561774|NCT05765864|Diagnostic Test|Personality Assessment Inventory-Adolescent (PAI-A)|"An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx"
79858476|NCT06229236|Behavioral|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
79261994|NCT02147041|Drug|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
79261995|NCT02147041|Drug|Placebo|
79261996|NCT02147119|Procedure|Coronary angiography|
79261997|NCT02156635|Device|Transcranial direct current stimulation|
79261998|NCT02156635|Behavioral|Constraint-Induced Movement Therapy|
79261999|NCT02156635|Other|Placebo|
79262000|NCT02767765|Drug|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
79398681|NCT00654069|Drug|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
79398682|NCT00654147|Drug|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
79398683|NCT00654147|Drug|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
80020884|NCT05271448|Other|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
79262001|NCT02156713|Behavioral|CIMT Camp|
79262002|NCT02156791|Biological|gpASIT+TM|
79398684|NCT00654615|Device|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
79724316|NCT02776189|Drug|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
79724317|NCT02776189|Drug|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
79724318|NCT02776189|Drug|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
79724319|NCT04841707|Device|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
79262003|NCT02156869|Other|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
79262004|NCT02156947|Procedure|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
79262005|NCT02772757|Behavioral|standard hearing aid fitting|standard hearing aid, face-to-face fitting
79262006|NCT02772757|Behavioral|coupler-based fitting|coupler-based fitting using average RECDs
79262007|NCT02772757|Behavioral|coupler-based fitting|coupler-based fitting using measured RECDs
79262008|NCT02147431|Drug|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
79262009|NCT02147431|Drug|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
79262010|NCT02154295|Device|Infraredx Test Catheter|
79262011|NCT02147509|Drug|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
79262012|NCT02147509|Drug|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
79262013|NCT02147509|Other|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
79262014|NCT02147509|Drug|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
79262015|NCT00103207|Biological|cetuximab|
79262016|NCT02254915|Device|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
79262017|NCT02254915|Drug|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
79262018|NCT02154451|Device|Infrared Imaging Device- ALIAS|Infrared Camera
79561775|NCT05765864|Diagnostic Test|Inventory Of Statements About Self-Injury; ISAS|"A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669."
79561776|NCT05765864|Diagnostic Test|The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0|"A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.~Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14."
79262019|NCT02157181|Drug|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
79262020|NCT02147665|Other|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
79262021|NCT02159287|Drug|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
79262022|NCT02159287|Drug|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
79262023|NCT02154607|Device|CO2-Laser Treatment|
79858477|NCT06226974|Other|Static Stretching|"Shoulder extension - shoulder extension with the hand resting on a door;~Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~Shoulder flexion - arms above the head against a wall;~Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
79858478|NCT06226688|Procedure|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
79858479|NCT06226688|Procedure|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
79858480|NCT06223295|Procedure|Focal therapy|"Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring"
79858481|NCT06223295|Procedure|Usual care|standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
79262028|NCT02157337|Drug|Atorvastatin|80 mg (PO) once daily for 6 days
79262029|NCT02157337|Drug|placebo|80 mg (PO) once daily for 6 days
79262030|NCT02159599|Drug|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
79858482|NCT06220435|Radiation|Ultra-hypofractionated radiotherapy regimen.|"Prostate tumor(s): 49 Gray (Gy)/7 fractions~Prostate gland: 42.7 Gy/7 fractions~Elective lymph nodes: 29.4 Gy/7 fractions~Seminal vesicles: 31.15 Gy/7 fractions"
79858483|NCT06219668|Procedure|Omentopexy group|Omentopexy and Clips on staple line during LSG
79858484|NCT06219148|Behavioral|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
79262031|NCT02159599|Drug|Lamivudine|Lamivudine (300mg) : QD
79262032|NCT02159599|Drug|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
79262033|NCT05004571|Drug|EQU-001|EQU-001 in 10 and 20 mg capsules
79262034|NCT05004571|Drug|Placebo|Matched placebo
79262035|NCT02154685|Behavioral|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
79262036|NCT02154685|Behavioral|Non-Retrieval Extinction|Neutral cue exposure.
79262037|NCT03736057|Other|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at <1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
79262038|NCT03541681|Procedure|Glucocorticoid Injections|1 ml Dexamethasone + 0,5 ml Bupivacain
79581243|NCT01934322|Other|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
79262039|NCT03541681|Procedure|Anesthetic Injections|0,5 ml Bupivacain
79262040|NCT03542071|Other|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
79262041|NCT03542071|Other|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
79262042|NCT02154841|Behavioral|Questionnaire, taste test, visual food test|
79262043|NCT02157415|Device|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
79262044|NCT02154919|Procedure|Percutaneous coronary intervention|
79262045|NCT02157571|Drug|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
79262046|NCT02157571|Drug|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
79262047|NCT02157571|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
79262048|NCT02157571|Drug|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
79262049|NCT01369355|Drug|Placebo SC|Placebo will be administered subcutaneously.
79262050|NCT01369355|Drug|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
79262051|NCT01369355|Drug|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
79262052|NCT01369355|Drug|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
79262053|NCT01369355|Drug|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
79262054|NCT03541993|Dietary Supplement|Resveratrol|
79262055|NCT03541993|Other|Placebo|
79262056|NCT02157649|Drug|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
79262057|NCT02157649|Drug|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
79581244|NCT01934348|Behavioral|Psychological First Aid|
79262058|NCT02157649|Drug|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
79858485|NCT06219148|Behavioral|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
79262059|NCT02157727|Device|Infants hospitalized in health facilities performing Tele-expertise|
79262060|NCT02157805|Other|beef meat|"Meat cooking conditions~st condition : beef meat cooked during 5 minutes at 55°C~nd condition : beef meat cooked during 30 minutes à 90°C"
79262061|NCT02614196|Drug|Galcanezumab|Administered SC
79262062|NCT02614196|Drug|Placebo|Administered SC
79262063|NCT02159677|Device|EIM Measurements|
79262064|NCT02765035|Device|C-Leg 4|Microprocessor Controlled Knee
79262065|NCT02765035|Device|C-Leg 3|Microprocessor Controlled Knee
79262066|NCT02159833|Other|Intranasal challenge with active substance (food protein)|
79262067|NCT02159833|Other|Intranasal challenge with placebo|
79262068|NCT02088437|Other|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
79262069|NCT02088437|Other|Usual Care|once daily physiotherapy whilst acute hospital inpatient
79262070|NCT02159911|Drug|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
79262071|NCT04876508|Other|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
79561777|NCT05765864|Diagnostic Test|Borderline Personality Features Scale, BPFSC-11|"The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.~Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78."
79262072|NCT03542617|Drug|Dexamethasone|
79262073|NCT03542617|Drug|Normal Saline Solution|
79262074|NCT04878770|Drug|Topical corticosteroids|Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
79262075|NCT04878770|Drug|Systemic cyclosporine|"Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months."
80020885|NCT05271448|Other|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
79262076|NCT04878770|Drug|Systemic dupilumab|Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
79262077|NCT04878692|Drug|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
79262078|NCT04878692|Drug|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
79561778|NCT05765864|Other|Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)|"It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.~Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404."
79262079|NCT02086019|Drug|Conservative Arm|crossover to angiogram only if predefined criteria met
79262080|NCT02086019|Procedure|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
79262081|NCT02082197|Drug|ABT-SLV176|ABT-SLV176 administered daily
79262082|NCT03046706|Behavioral|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
79262083|NCT03046706|Behavioral|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
79262084|NCT02086097|Drug|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
79262085|NCT02086097|Drug|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
79262086|NCT02086097|Drug|PLACEBO|INACTIVE SUGAR PILLS
79262087|NCT03046784|Other|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
79262088|NCT02307682|Drug|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection
79561779|NCT05765864|Other|Adolescent Self-Harm Risk Scale; ASHRS|It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).
79581245|NCT01934348|Behavioral|Usual victim advocacy Services|
79581246|NCT01934361|Drug|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
80020886|NCT05268367|Behavioral|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
80020887|NCT05254405|Drug|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
80020888|NCT05252338|Biological|CVSQIV|Participants will receive an intramuscular injection by needle in the deltoid area.
80020889|NCT05252208|Other|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
79581247|NCT01934361|Drug|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
79262089|NCT02307682|Drug|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection
79398685|NCT00654615|Procedure|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
79398686|NCT01438489|Biological|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
79398687|NCT01438489|Biological|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
79398688|NCT01438489|Other|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
79262090|NCT02088515|Drug|Nedaplatin|
79581248|NCT01934361|Drug|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
79581249|NCT01934361|Drug|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
79262091|NCT02088515|Drug|Cisplatin|
79398689|NCT00654927|Drug|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
79262092|NCT02088515|Drug|Docetaxel|
79262093|NCT02615990|Device|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
79262094|NCT02615990|Other|Standard Physical Therapy|Patients receive standard physical therapy.
79262095|NCT03559283|Diagnostic Test|Walking and Record Cortical Activity|"The cortical activity of each patient is recorded by NIRS under the following conditions:~Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer."
79398690|NCT04407949|Other|CPAP Treatment|Comparing events from the CPAP device with the events scored in PSG
79398691|NCT00655083|Drug|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
79398692|NCT00655083|Drug|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
79398693|NCT01418209|Drug|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
79398694|NCT01418209|Drug|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
79398695|NCT01418209|Drug|Placebo|The placebo is an inactive pill that looks like the active medication.
79398696|NCT00655473|Drug|Dalcetrapib (RO4607381)|600mg po daily for 24 months
79398697|NCT00655473|Drug|Placebo|po daily for 24 months
79581250|NCT01934374|Behavioral|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
79724320|NCT04226287|Device|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
79858486|NCT06219148|Behavioral|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
80020890|NCT05252208|Other|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
79262096|NCT02082275|Other|OB Nest|"Reduction in the number of clinic office visits~Assignment to a specific nursing care team~Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~Augmentation of in-person visits between care providers and patients with video conversations.~Maternal outcomes will be monitored through surveys and questionnaires."
79398698|NCT01570361|Device|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
80020891|NCT05215106|Drug|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
80020892|NCT05212883|Behavioral|Behavioral questionaires|Behavioral surveys and questionnaires
80020893|NCT05206253|Dietary Supplement|Whole egg powder|Nutritional supplementation during a 12 week resistance training program
79262097|NCT04870814|Device|Tactical tourniquet set up|The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
79724321|NCT04228003|Dietary Supplement|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
79724322|NCT02776267|Device|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
79724323|NCT04225975|Diagnostic Test|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
79724324|NCT04225975|Diagnostic Test|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
79262098|NCT04870814|Diagnostic Test|Medical ultrasound|The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
79262099|NCT04870814|Other|Questionnaire|"The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter)."
79262100|NCT03558035|Drug|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
79262101|NCT03558035|Radiation|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
79262102|NCT04878146|Procedure|Sacro-spinous fixation|Uterine cervix will be attached to the sacro-spinous ligament
79262103|NCT04878146|Procedure|Subtotal hysterectomy|Done on both arms
79262104|NCT04878146|Procedure|Sacrocolpopexy|Uterine cervix is attached to sacral promontory with two synthetic meshes
79262105|NCT03558347|Device|short implants with splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns
79262106|NCT03558347|Device|short implants with non-splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
79724325|NCT02776345|Other|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
80020894|NCT05206253|Dietary Supplement|Whey protein powder|Nutritional supplementation during a 12 week resistance training program
79262107|NCT04877912|Diagnostic Test|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
79262108|NCT04877912|Diagnostic Test|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
79398699|NCT01570361|Drug|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
79398700|NCT01417195|Drug|Bravelle|
80020895|NCT05206253|Dietary Supplement|Maltodextrin placebo|Nutritional supplementation during a 12 week resistance training program
80020896|NCT05198713|Device|New hearing aid|Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
80020897|NCT05185843|Drug|Olezarsen|Olezarsen will be administered by SC injection.
80020898|NCT05177731|Drug|Venetoclax|Orally by mouth
80020899|NCT05177731|Drug|Decitabine for Injection|Intravenous infusion
80020900|NCT05177731|Drug|Cytarabine|Intravenous infusion
80020901|NCT05177731|Drug|Idarubicin|Intravenous infusion
80020902|NCT05177731|Drug|Gilteritinib|Orally by mouth
80020903|NCT05153811|Behavioral|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
79398701|NCT01417195|Drug|Menopur|
79398702|NCT00655707|Biological|Autologous Expanded CD34+ Haemopoietic cells|"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"
79398703|NCT00656487|Drug|rimonabant|double blind, placebo controlled, single 90 mg dose
79398704|NCT00656487|Drug|placebo|matched placebo
79262109|NCT04878068|Device|Theram COVID-19 Rapid Antigen Test|The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
79262110|NCT03559127|Procedure|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
79398705|NCT00657657|Biological|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
79561780|NCT05765864|Diagnostic Test|Lifetime Incidence of Traumatic Events questionnaire (LITE)|"Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.~Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:~development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315"
79561781|NCT05765864|Genetic|Genetic methods|DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).
79561782|NCT05758909|Device|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
79561783|NCT05753644|Procedure|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
79561784|NCT05753644|Drug|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
79262111|NCT03559127|Procedure|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
79262112|NCT03559127|Procedure|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
79262113|NCT04875962|Drug|UCB0599|Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
79262114|NCT04875962|Drug|Placebo|Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
79262115|NCT02086253|Drug|BQ-788 and/or BQ-123|
79262116|NCT04876118|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
79262117|NCT05502809|Drug|Deep-frozen platelets|Cryopreserved platelets
79262118|NCT04875650|Procedure|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
79262119|NCT04875650|Procedure|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
79262120|NCT03557879|Genetic|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
79303781|NCT03067233|Other|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
79561785|NCT05753644|Drug|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
79561786|NCT05735314|Other|consultation with a specialist|The intervention consists of consultation with a specialist, use of a nurse navigator to help patients with appointments and help them understand their condition, and use of a data query of the electronic health record (EHR) to identify abnormal test results to make sure they are appropriately addressed.
79561787|NCT05735314|Other|Usual care|Usual care involves primary care physicians ordering additional tests and referrals to evaluate patients with new anemia and decreased glomerular filtration rate (GFR) .
79858487|NCT06218706|Device|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
79858488|NCT06218615|Other|Educational Intervention (Video)|Watch video
79858489|NCT06218615|Other|Survey Administration|Answer survey questions
79303782|NCT05728905|Other|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
79303783|NCT05728905|Other|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
79398706|NCT01799499|Device|TC-3 hydrogel|
79303784|NCT02310269|Drug|SOM230|
79303785|NCT04489745|Radiation|SBRT|
79398707|NCT01799499|Device|TC-3 hydrogel|
79398708|NCT01799499|Device|TC-3 hydrogel|
79398709|NCT01443403|Drug|Placebo|Matching placebo tablets administered orally once a day.
79398710|NCT01443403|Drug|Naldemedine|Naldemedine tablets administered orally once a day.
79398711|NCT01438177|Drug|Velcade|
79398712|NCT01438177|Drug|Cyclophosphamide|
79398713|NCT01438177|Drug|Chloroquine|
79398714|NCT04747717|Procedure|chemotherapy/surgery|NEO chemotherapy/interval debulking surgery/AD chemotherapy
79858490|NCT06218602|Drug|Fecal Microbiota Transplantation|Given by PO
80020904|NCT05153811|Behavioral|mHealth|Participants will engage with an application designed to gamify drinking reduction.
79262121|NCT04870502|Drug|Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG|In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
79262122|NCT04870268|Procedure|percutaneous drainage|
79561788|NCT05733663|Diagnostic Test|Endoscopic procedure with duodenal biopsy|"In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram."
79561789|NCT05729243|Drug|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
79858491|NCT06218602|Procedure|Chemotherapy|Given by Infusion
79858492|NCT06218602|Procedure|CAR-T Therapy|Given by Infusion
80020905|NCT05153811|Behavioral|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
80020906|NCT05139290|Behavioral|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
80020907|NCT05127265|Other|Video Monitoring|continuous video monitoring
80020908|NCT05127265|Other|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
80020909|NCT05127265|Other|Noise Level Monitoring|continuous environmental noise monitoring
79858493|NCT06218121|Diagnostic Test|Instrumental and Functional Tests that Assess Functional Capacity|The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
79858494|NCT06217796|Combination Product|tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5%|1 metered spray
79858495|NCT06217250|Procedure|Hot EMR|Initial submucosal injection of physiological solution and methylene blue, followed by 'piece-meal' resection using a 10 or 15-millimeter diathermic snare and ablation of the margins with a snare tip
79858496|NCT06217250|Procedure|Cold EMR|Initial submucosal injection of physiological solution and methylene blue, followed by 'piece-meal' resection using a dedicated cold snare
79262123|NCT04870268|Procedure|endoscopic approach|
79262124|NCT04870268|Procedure|surgical internal derivation of WON|
79858497|NCT06216899|Other|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
79858498|NCT06216899|Other|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
79858499|NCT06216522|Other|Topical Sesame Oil|5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours
80020910|NCT05127265|Other|Light Level Monitoring|continuous environmental light monitoring
80020911|NCT05127265|Other|Air Quality Monitoring|continuous environmental air quality monitoring
80020912|NCT05127265|Other|EKG Monitoring|continuous EKG monitoring
79561790|NCT05729243|Other|Placebo|A placebo identical in appearance to cytisine will be used
80020913|NCT05127265|Other|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
80020914|NCT05127265|Other|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
80020915|NCT05127265|Other|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
79262125|NCT04870268|Procedure|surgical necrosectomy|
79303786|NCT04489745|Drug|Androgen deprivation therapy (ADT)|
79303787|NCT05728671|Drug|IP2015|Test drug
79303788|NCT03065907|Other|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
79561791|NCT05722132|Behavioral|One cycle|Message Design Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
79561792|NCT05722132|Behavioral|4 cycles|Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
80020916|NCT05120804|Behavioral|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
80020917|NCT05120804|Behavioral|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
79262126|NCT02088671|Drug|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
79561793|NCT05722132|Behavioral|5 Dollar Incentive|"Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program. The introductory message will mention that participants will receive $5 if they enroll in the program or that they should look out for messages with a $ sign at the beginning that will provide an incentive if they respond."
80020918|NCT05112315|Device|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
80020919|NCT05111288|Device|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
79262127|NCT02088671|Device|Recording of EEG using NeuroSENSE|"The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest."
79303789|NCT04392765|Device|eXciteOSA|eXciteOSA transoral neurostimulation device
79303790|NCT05180123|Procedure|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
79561794|NCT05722132|Behavioral|Raffle Incentive|"The incentive message (indicated with a leading $ sign) will invite participants to respond, and participants that do so will be included in a random drawing depending on the condition. The incentive message for the opportunity to win will contain a link to a website that provides full details of the timing of the drawing, the chances of winning, and when notification of winners will be made."
79561795|NCT05756504|Drug|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
79561796|NCT05756504|Drug|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
79561797|NCT05697510|Drug|Siltuximab|Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
79561798|NCT05691569|Other|doll therapy|empathy dolls
79561799|NCT05686980|Drug|ABBV-552|Oral Capsule
79561800|NCT05685095|Behavioral|Physical training|Supervised gait training program 3 times a week, 12 weeks
79561801|NCT05674266|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
79561802|NCT05674266|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
79561803|NCT05660187|Other|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
79561804|NCT05660187|Other|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
79561805|NCT05657925|Drug|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
79561806|NCT05657925|Drug|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
79561807|NCT05656495|Drug|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
79561808|NCT05656495|Drug|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
79561809|NCT05656495|Drug|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
79561810|NCT05653388|Other|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
80020920|NCT05111288|Device|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
80020921|NCT05110482|Drug|Syntocinon|uterotonic drugs
80020922|NCT05110482|Drug|Carbetocin|uterotonic drug
80020923|NCT05108623|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
79724326|NCT02776345|Other|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
79262128|NCT02088671|Other|Data collection|"Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information."
79262129|NCT02088671|Other|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
79262130|NCT03049124|Behavioral|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than < 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than < 60% of heart rate reserve) component.
79262131|NCT04870190|Drug|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
79262132|NCT04870190|Drug|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
79262133|NCT03049358|Other|Physiologic Testing|Undergo UPSIT smell test
79262134|NCT03049358|Other|Quality-of-Life Assessment|Ancillary studies
79262135|NCT03049358|Procedure|Sham Intervention|Undergo sham training
79262136|NCT03049358|Procedure|Therapeutic Procedure|Undergo olfactory training
79262137|NCT03049358|Other|rose essential oil|patient smells rose oil in vial
79262138|NCT03049358|Other|lemon essential oil|patient smells lemon oil in vial
79262139|NCT03049358|Other|clove essential oil|patient smells clove oil in vial
79262140|NCT03049358|Other|eucalyptus essential oil|patient smells eucalyptus oil in vial
79262141|NCT03049358|Other|canola oil placebo|patient smells canola oil in vial
79262142|NCT03049046|Drug|CC100|synthetic caffeic acid phenethylester
79262143|NCT03049046|Drug|Placebos|Diluent
79262144|NCT04385966|Procedure|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
79262145|NCT04385966|Drug|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
79262146|NCT04869800|Drug|CKD-398|Test Drug
79262147|NCT04869800|Drug|CKD-501, D745|Reference Drug
79262148|NCT04875572|Device|Analgesia Nociception Index (ANI) Monitor|The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
79858500|NCT06216522|Other|Liquid paraffin oil|5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
79262149|NCT04875182|Diagnostic Test|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
79262150|NCT04875494|Behavioral|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
79262151|NCT04875494|Behavioral|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
79262152|NCT05258006|Procedure|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
79262153|NCT02613884|Drug|Treatment|
79262154|NCT05257616|Other|Traction Mobilization technique|Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
79303791|NCT05179811|Procedure|Hypnosis sessions|"Physical examination~Psychiatric Assessment~VHI, SF-36, IPQ-R questionnaires~Standardized voice recording~3 Standardized Hypnotherapy sessions~CGI-I-Patient Questionnaire"
79398715|NCT01442779|Drug|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
79858501|NCT06216249|Procedure|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
79858502|NCT06216249|Other|Gallium Ga 68 Gozetotide|Given IV
79858503|NCT06216249|Drug|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
79262155|NCT05257616|Other|Traction Mobilization technique with SNAGS|Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
79262156|NCT03049436|Other|Program of adapted physical activity|
79561811|NCT05651893|Behavioral|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
79262157|NCT03046550|Drug|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
79262158|NCT03046550|Drug|Placebo|placebo
79398716|NCT01416805|Behavioral|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
79398717|NCT01416805|Behavioral|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
79398718|NCT01437943|Drug|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
79398719|NCT01437943|Drug|Placebo|Take 1 tablet (0 mg) daily for 180 days.
79398720|NCT01570283|Biological|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
79398721|NCT01570283|Biological|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
79561812|NCT05651893|Behavioral|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
79561813|NCT05650060|Drug|Secukinumab|all patients with psoriasis who received secukinumab
79858504|NCT06216249|Procedure|Positron Emission Tomography|Undergo PET/CT
80020924|NCT05108623|Drug|Approved ICIs|Nivolumab and pembrolizumab
79561814|NCT05649904|Device|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
79561815|NCT05649904|Device|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
79561816|NCT05634733|Other|Treatment of Sepsis|Patients will have standard care of sepsis
79561817|NCT05625321|Behavioral|Educational Group Weight Loss Classes|Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
79561818|NCT05625321|Behavioral|Home Gardening Intervention|Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
80020925|NCT05087810|Behavioral|Psychological stress induction|Subjects will undergo acute psychological stress induction by performing mental arithmetic tasks.
79561819|NCT05622604|Behavioral|pray.com app (autonomous use)|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
79561820|NCT05622604|Behavioral|pray.com app (meditative prayer condition)|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
79858505|NCT06216249|Procedure|PSMA PET Scan|Undergo PSMA PET/CT
79858506|NCT06216249|Other|Questionnaire Administration|Ancillary studies
80020926|NCT05087810|Other|Accelerated oral hydration|Participants will drink 2L of fluid in a short period of time to force diuresis and urine production.
79858507|NCT06216249|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
80020927|NCT05044663|Other|No intervention|This is an observational study
80031671|NCT03106688|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
79398722|NCT01570283|Biological|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
79398723|NCT04064489|Other|TRIPscore|TRIPcast score calculation
79561821|NCT05616637|Diagnostic Test|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
79724327|NCT02776345|Other|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
79858508|NCT06215703|Behavioral|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
79858509|NCT06215404|Other|Liberal group|Fluid challage to keep stroke volume variation < 10%
79858510|NCT06215404|Other|restrictive group|Fluid challage to keep stroke volume variation < 18%
79262159|NCT03046394|Device|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
80031672|NCT04882228|Drug|Entelon Tab.150mg|twice daily for 8 weeks
80031673|NCT04882228|Drug|Venitol Tab.|twice daily for 8 weeks
79262160|NCT03046394|Device|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
79262161|NCT03046394|Device|A-DER|Triton by Otto Bock, advertised for activity category 3-4
79262162|NCT05257226|Behavioral|frailty|questionaire
79398724|NCT01436357|Biological|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose, intramuscularly on day 0.
79398725|NCT01436357|Biological|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10^8 plaque forming units (pfu) intramuscularly on day 56.
79724328|NCT02776111|Other|Blood Sample|A one time blood sample will be provided.
79398726|NCT01436357|Other|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
79262163|NCT03046316|Other|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
79262164|NCT04874090|Other|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
79262165|NCT04874090|Other|Exercises|Patient will perform neck exercises
79398727|NCT04512053|Drug|TAS-303 18 mg/day|Oral administration for 12 weeks, once daily
79398728|NCT04512053|Drug|Placebo|Oral administration for 12 weeks, once daily
79398729|NCT01436201|Drug|Digoxin|Administered orally
79398730|NCT01436201|Biological|Dulaglutide|Administered as subcutaneous injection
79724329|NCT02775955|Drug|RX0041|Active
79858511|NCT06213454|Drug|TAP Anesthesia|ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
80031674|NCT04882228|Drug|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
79398731|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
79398732|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
79398733|NCT01437397|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
79398734|NCT01437397|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
79398735|NCT01437397|Drug|Placebo|Inhaled dose-matched placebo, twice per day
79398736|NCT01437319|Device|lotrafilcon A|To be used during run-in phase only.
79398737|NCT01437319|Device|comfilcon A|To be assigned at randomization at phase 2 only.
79398738|NCT01437319|Device|balafilcon A|To be assigned at randomization during phase 2 only.
79398739|NCT01437319|Other|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
79398740|NCT01416571|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
79398741|NCT04071691|Diagnostic Test|PET-MRI|SST2 PET-MRI scan
79398742|NCT04070833|Dietary Supplement|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
80031675|NCT04882228|Drug|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
80031676|NCT02037009|Other|Health care organization (anesthetic surveillance)|
79262166|NCT03046082|Drug|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
79262167|NCT04869722|Behavioral|Liquid Model|Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
79262168|NCT04869722|Behavioral|Solid Model|Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
79561822|NCT05616637|Other|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
79561823|NCT05616637|Other|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
79561824|NCT05611229|Drug|Nivolumab|Nivolumab
79561825|NCT05611229|Drug|Pembrolizumab|Pembrolizumab
79561826|NCT05611229|Combination Product|Dabrafenib+Trametinib|Dabrafenib+Trametinib
79561827|NCT05611229|Combination Product|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
79262169|NCT03048110|Drug|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
79561828|NCT05611229|Combination Product|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
79858512|NCT06213454|Drug|Surgeon-Initiated Local Anesthetic|266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
79262170|NCT03048110|Drug|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
79262171|NCT03048110|Drug|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
79262172|NCT03047876|Procedure|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
79262173|NCT05256758|Drug|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
79398743|NCT04070833|Drug|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
79262174|NCT05256758|Drug|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
79262175|NCT04869332|Device|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
79262176|NCT04869332|Device|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
79303792|NCT02464865|Drug|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
79398744|NCT04070833|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
79398745|NCT04070833|Drug|Fish oil placebo|Fish oil placebo
79398746|NCT01442155|Drug|Capecitabine|Administered according to the Summary of Product Characteristics.
79398747|NCT01442155|Biological|Oxaliplatin|Administered according to the Summary of Product Characteristics.
79398748|NCT01416181|Drug|natalizumab|Administered as specified in the treatment arm
79398749|NCT01416181|Drug|Placebo|Matched placebo in part 1
79398750|NCT04064983|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
79262177|NCT03047798|Drug|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
79262178|NCT02791763|Drug|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
79262179|NCT02791763|Drug|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
79398751|NCT03026023|Drug|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
79398752|NCT04064515|Diagnostic Test|Blood Assayed for CTCs|All study participants will have 15 mL of blood drawn for the purpose of the study.
79262180|NCT02791763|Drug|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
79262181|NCT02086409|Dietary Supplement|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
79262182|NCT02086409|Dietary Supplement|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
79262183|NCT02086487|Drug|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript > 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at > 12 months; i.e (BCR-ABL1 0.1 -1%)"
79262184|NCT02088827|Other|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
79262185|NCT02088827|Other|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
79262186|NCT02603471|Other|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
79398753|NCT01441765|Drug|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
79398754|NCT01441765|Biological|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
79398755|NCT01419665|Biological|GP2013|Type: Biological/Vaccine
79398756|NCT01419665|Biological|rituximab|Type: Biological/Vaccine
79561829|NCT05611229|Combination Product|Encorafenib+Binimetinib|Encorafenib+Binimetinib
79398757|NCT04064333|Device|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
79303793|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
79398758|NCT01436305|Drug|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
79398759|NCT01436305|Drug|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.~Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
79561830|NCT05599035|Device|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
79561831|NCT05580705|Other|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
79561832|NCT05580705|Other|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
79561833|NCT05574816|Device|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
79262187|NCT02603471|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
79262188|NCT03557723|Other|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~Cultural mediation workshop~Supervised visit and tour of the museum~Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
79398760|NCT01436305|Biological|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication[s])
79398761|NCT01436305|Drug|Short-term Tac|Short-term (3 months)
79398762|NCT01436305|Drug|tacrolimus|maintenance
79398763|NCT01436305|Biological|Belatacept|maintenance
79398764|NCT01436305|Drug|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
79398765|NCT01436149|Drug|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
79262189|NCT02613572|Drug|alpha lipoic acid|
79398766|NCT01436149|Drug|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
79262190|NCT02613572|Drug|Placebo|
79398767|NCT01415401|Drug|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
79398768|NCT01414855|Drug|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
79262191|NCT02088983|Dietary Supplement|CDP-Choline|Capsule
79262192|NCT02088983|Dietary Supplement|Cellulose|Capsule
79262193|NCT02089061|Drug|BMS-919373|
79262194|NCT02089061|Drug|Rosuvastatin|
79262195|NCT02089061|Drug|Atorvastatin|
79262196|NCT02086643|Procedure|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
79262197|NCT02086721|Drug|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
79262198|NCT03046160|Other|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
79858513|NCT06210776|Drug|Trastuzumab deruxtecan|Intravenous infusion
79262199|NCT03046160|Other|neck and scapular exercises.|A program of 12 neck and scapular exercises.
79262200|NCT03046160|Other|corrective tape|elastic tape used to correct the anterior tilt of the scapula
79262201|NCT02086799|Drug|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
79262202|NCT02086799|Drug|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
79262203|NCT02082665|Drug|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
79398769|NCT01414855|Drug|cyclophosphamide|750 mg/m^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
79398770|NCT01414855|Drug|doxorubicin|50 mg/m^2 IV, Day 1 of each 21-cycle, 6 cycles.
79398771|NCT01414855|Drug|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
79398772|NCT01414855|Drug|vincristine|1.4 mg/m^2 IV, Day 1 of each 21-day cycle, 6 cycles.
79398773|NCT01527500|Drug|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
79398774|NCT01527500|Drug|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
79398775|NCT01527500|Drug|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
79398776|NCT02074735|Drug|Placebo|Inactive ingredient matching the active comparator in appearance
79398777|NCT02074735|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
79398778|NCT01527110|Drug|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
79398779|NCT01441063|Drug|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
79398780|NCT01441063|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
79398781|NCT01441063|Drug|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
79858514|NCT06208878|Other|Non Interventional|Safety and Efficacy Assessment
79858515|NCT06207084|Behavioral|asynchronous content only|Receives asynchronous exercise content and no live training
79858516|NCT06207084|Behavioral|Asynchronous content and health coaching and no live training|Receives asynchronous content, health coaching and no live training.
79858517|NCT06207084|Behavioral|asynchronous content only and 1 on 1 live training|receives asynchronous content and live 1 on 1 training
79262204|NCT02082665|Drug|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
79262205|NCT02082665|Drug|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
79858518|NCT06207084|Behavioral|asynchronous content and health coaching and 1 on 1 training|receives asynchronous content, health coaching, and live training
79262206|NCT03046004|Other|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
79262207|NCT03046004|Other|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
79561834|NCT05566665|Diagnostic Test|Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol|"The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out ."
79561835|NCT05550454|Device|Automatic Mechanical Ventilation|"Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 ~ 1,000 ml"
79262208|NCT02082743|Behavioral|Outdoor activity in recess time|Outdoor activity in recess time
79262209|NCT05256524|Drug|The effect of LMWH|Quantified by aFXa-levels
79262210|NCT05256524|Diagnostic Test|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
79262211|NCT05256446|Drug|AMG 701|
79724330|NCT04931407|Other|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
79724331|NCT04947163|Device|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily [once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
79858519|NCT06207084|Behavioral|asynchronous content and group training|receives asynchronous content and live group training
79262212|NCT03047954|Drug|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
79262213|NCT03047954|Drug|Placebo - Cap|Matching Placebo capsule administered
79262214|NCT02086955|Behavioral|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
79561836|NCT05550454|Device|Manual Ventilation|Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel
79561837|NCT05529160|Device|FERTI LILY Conception Cup|The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
79561838|NCT05521984|Drug|Dapagliflozin|Commercially available
79561839|NCT05521984|Drug|Carmustine|Standard of care
79858520|NCT06207084|Behavioral|Asynchronous content and health coaching and group training|receives asynchronous content, health coaching, and live group training
79858521|NCT06207071|Dietary Supplement|DHA|DHA supplementation
79858522|NCT06206824|Drug|Leucettinib-21|See arm's description.
79262215|NCT03048032|Procedure|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
79303794|NCT02464865|Drug|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
79858523|NCT06206356|Device|PNS Injectrode F1|The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy. The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm. The device is placed in a minimally invasive procedure via a standard 18g needle. The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously. Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device. Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal. Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
79262216|NCT03048032|Procedure|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
79262217|NCT02089139|Device|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
79262218|NCT02089139|Other|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~medications (analgesics, NSAIDs, muscle relaxants),~physical therapy,~manual techniques,~transcutaneous electrical nerve stimulation (TENS),~blocks"
79398782|NCT01436071|Drug|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
79262219|NCT04869410|Procedure|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
79262220|NCT04869410|Procedure|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
79262221|NCT03558971|Drug|Cortisol|Participants determine when to administer 5-day regimens of cortisol
79262222|NCT04873544|Procedure|ERAS protocols for TKA|ERAS protocols for TKA
79262223|NCT05475509|Other|Virtually reality|Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
79561840|NCT05503823|Device|tACS or tRNS and TMS|A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
79561841|NCT05503485|Behavioral|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
79262224|NCT02087189|Device|First ICD/CRT-D implantation or upgrade from pacemaker|
79561842|NCT05503485|Behavioral|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
79561843|NCT05497323|Drug|Combination Cream|The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
79561844|NCT05497323|Drug|Adapalene 0,1% cream|Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
79262225|NCT02341456|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
79262226|NCT02341456|Drug|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
79262227|NCT02341456|Drug|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
79262228|NCT02082899|Drug|Active Comparator EBI-005 5 mg/mL|
79262229|NCT02082899|Drug|Placebo Comparator|
79262230|NCT02083055|Drug|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
79262231|NCT02083055|Drug|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
79398783|NCT01436071|Drug|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
79398784|NCT03025399|Drug|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
79398785|NCT03025399|Drug|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
79398786|NCT01514240|Drug|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
79262232|NCT02089295|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
79398787|NCT01514240|Drug|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
79262233|NCT02089295|Drug|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
79262234|NCT02089295|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
79398788|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
79398789|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
79398790|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
79398791|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
79398792|NCT01435759|Drug|Antidepressant + Placebo|oral, once daily for 8 weeks
79398793|NCT04048057|Other|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
79398794|NCT01393405|Drug|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
79398795|NCT01419197|Drug|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change > 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
79561845|NCT05495087|Device|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
79561846|NCT05495087|Other|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
79858524|NCT06206070|Behavioral|The Hong Kong version of Westmead Feeling Program 2|Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
79858525|NCT06202092|Device|Phonophoresis|Ultrasound using honey as a media over the knee joint
79262235|NCT02370784|Drug|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
79262236|NCT02370784|Drug|Placebo|oral drug of similar appearance to atorvastatin
79262237|NCT03558269|Biological|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
79262238|NCT04897750|Combination Product|CT001|Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
79262239|NCT02083211|Drug|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
79262240|NCT02083211|Device|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
79561847|NCT05494450|Device|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
79561848|NCT05490563|Drug|SLS-005|SLS-005
79561849|NCT05490563|Drug|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
79724332|NCT04947163|Device|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
79724333|NCT05045833|Drug|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
79858526|NCT06202092|Device|Ultrasound|ultrasound using gel as a media over the knee joint
79858527|NCT06202092|Procedure|conventional physiotherapy|TENS, Strengthening, and stretching exercises
79858528|NCT06200545|Other|PrEP eligibility assessment|PrEP eligibility assessment
79262241|NCT02307370|Device|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
79262242|NCT05483777|Procedure|PRF|Platelet-rich fibrin preparation and application technique will applied to the experimental group.
79262243|NCT03557645|Device|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
79724334|NCT02778217|Procedure|Culture media renwal|
79724335|NCT02777983|Behavioral|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
79398796|NCT01419197|Drug|Treatment of physician's choice|"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."
79561850|NCT05460130|Behavioral|Simplified Hepatitis C Virus (HCV) Treatment Protocol|A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.
79262244|NCT03557645|Device|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
79262245|NCT03557645|Device|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
79398797|NCT01414075|Drug|Roxadustat|Tiered, weight-based dosing per schedule specified in the arm.
79398798|NCT01414075|Drug|Oral Iron|Administered per oral dose and schedule specified in the arm.
79398799|NCT01414075|Drug|IV Iron|Administered per IV dose and schedule specified in the arm.
79398800|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for ketogenic diet
79262246|NCT02370394|Behavioral|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
79858529|NCT06200545|Diagnostic Test|Rapid HIV antibody testing prior to provision and/or refill of PrEP|Rapid HIV antibody testing prior to provision and/or refill of PrEP
79262247|NCT02089373|Procedure|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
79398801|NCT04766905|Procedure|Mini Lateral Shoulder Approach (MLSA)|"The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly."
79398802|NCT04408079|Drug|TQB3558|TQB3558 is a kinase inhibitor of the TRK protein family.
79398803|NCT01434823|Other|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
79398804|NCT01513460|Drug|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
79398805|NCT01513460|Drug|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
79398806|NCT01513460|Drug|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
79398807|NCT01513460|Drug|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
79398808|NCT01392547|Drug|vatreptacog alfa (activated)|1-3 doses per bleeding episode
79398809|NCT01392547|Drug|eptacog alfa (activated)|1-3 doses per bleeding episode
79398810|NCT01435655|Drug|tafamidis|tafamidis meglumine 20 mg QD
79561851|NCT05460026|Other|Routine Physical Therapy|Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).
79561852|NCT05460026|Other|Powerball Exercises|Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
79858530|NCT06200545|Other|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
79858531|NCT06200545|Behavioral|Evaluation of barriers and facilitators to ongoing PrEP use|Evaluation of barriers and facilitators to ongoing PrEP use
79858532|NCT06200545|Other|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
79858533|NCT06200545|Other|Tracing for any missed PrEP visits|Tracing for any missed PrEP visits
79398811|NCT01434667|Behavioral|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
79561853|NCT05446207|Other|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
79561854|NCT05446207|Other|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
79262248|NCT02089373|Procedure|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
79262249|NCT01595438|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
79262250|NCT01595438|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
79262251|NCT01595438|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
79262252|NCT01595438|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
79561855|NCT05431972|Device|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
79561856|NCT05431972|Device|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
79262253|NCT02089451|Drug|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
79262254|NCT02340520|Drug|Theophylline|Oral
79724336|NCT05214937|Behavioral|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action & coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
79262255|NCT02340520|Drug|Roflumilast|Oral
79262256|NCT02087579|Drug|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
79262257|NCT02087579|Drug|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
79262258|NCT02087579|Drug|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
79262259|NCT02087579|Drug|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
79262260|NCT02087579|Drug|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
79398812|NCT01434667|Behavioral|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
79398813|NCT01513148|Device|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
79561860|NCT05419310|Other|Rehabilitation - core strengthening|Physical rehabilitation based on core strengthening
79561861|NCT05419310|Other|Rehabilitation - rehabilitation pilates|Physical rehabilitation based on rehabilitation pilates
79561862|NCT05419310|Other|Elastic taping application|Application of elastic taping
79561863|NCT05404217|Other|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
79724337|NCT05214937|Behavioral|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
79724338|NCT01194258|Drug|Insulin lispro|
79724339|NCT01194258|Drug|Insulin aspart|
79724340|NCT01194258|Drug|Recombinant human hyaluronidase PH20|
79724341|NCT01194258|Drug|Insulin glulisine|
79724342|NCT01194258|Drug|Insulin glargine|
79262261|NCT02087579|Drug|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
79398814|NCT01418339|Drug|Aripiprazole|Aripiprazole tablet administered orally once a week.
79398815|NCT01418339|Drug|Placebo|Aripiprazole-matching placebo tablet administered orally once a week.
79262262|NCT02087579|Drug|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
79262263|NCT03777371|Other|Anti HIV Seropositive Pregnant Women|
79561864|NCT05404217|Other|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
79561865|NCT05375968|Diagnostic Test|Measurement of Splanchnic venous capacitance(SVC)|Effect of glucose on splanchnic venous capacitance in Postural Orthostatic Tachycardia Syndrome
79262264|NCT02339584|Drug|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
79561866|NCT05370378|Other|Hold Relax with Agonist Contraction|"Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~Passive sustained stretch to piriformis will be applied for 10 seconds.~The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
79561867|NCT05370378|Other|Active Release Therapy|"Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
79561868|NCT05345782|Drug|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
79262265|NCT02339584|Drug|Brinzolamide 10 mg/mL eye drops, suspension|
79262266|NCT02339584|Drug|Brimonidine 2 mg/mL eye drops, solution|
79262267|NCT02339584|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
79561869|NCT05345782|Drug|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
79561870|NCT05335473|Drug|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
79561871|NCT05300984|Other|Topical Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
79561872|NCT05300984|Other|Topical Cream with 0.5% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
79561873|NCT05300984|Other|Topical Cream with 1% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
79561874|NCT05300542|Other|Topical Placebo Cream|Application of test products before and after irradiation
79561875|NCT05300542|Other|Topical Cream with 0.5% Active|Application of test products before and after irradiation
79561876|NCT05300542|Other|Topical Cream with 1% Active|Application of test products before and after irradiation
79262268|NCT02087657|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
79561877|NCT05299814|Behavioral|Behavioral Parenting Intervention|8 session evidence based parenting intervention
79561878|NCT05286879|Behavioral|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
79561879|NCT05286879|Behavioral|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
79561880|NCT05270980|Other|Cohorting|"The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure."
79561881|NCT05268588|Behavioral|MESSSSAGE intervention|group mHealth education and social support intervention
79724343|NCT04883437|Drug|Acalabrutinib|Given PO
79724344|NCT04883437|Biological|Obinutuzumab|Given IV
79724345|NCT04883437|Other|Quality-of-Life Assessment|Ancillary studies
79724346|NCT04883437|Other|Questionnaire Administration|Ancillary studies
79262269|NCT02339506|Drug|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
79262270|NCT02339506|Drug|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
79262271|NCT02087735|Dietary Supplement|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
79262272|NCT02087813|Drug|Alpha1-antitrypsin|
79262273|NCT02087813|Drug|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
79262274|NCT03048812|Device|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
79262275|NCT03048812|Device|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
79262276|NCT02089529|Drug|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
79858534|NCT06200545|Other|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"
79398816|NCT01512368|Other|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
79262277|NCT02089529|Drug|Placebo|Placebo with no information, positive information and neutral information
79398817|NCT01412983|Device|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
79398818|NCT01412983|Device|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
79398819|NCT01417481|Dietary Supplement|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
79398820|NCT01417481|Dietary Supplement|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
79398821|NCT01392469|Drug|Imatinib|Film coated tablets, oral administration
79398822|NCT01392469|Drug|Sildenafil|Oral Administration
79724347|NCT02777905|Behavioral|Mindfulness Based Cognitive Therapy|
79858535|NCT06199999|Procedure|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block
79858536|NCT06199999|Procedure|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic:
79858537|NCT06199531|Genetic|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
79858538|NCT06198959|Device|Adult blanket plus, MA2220 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Adult Blanket plus, MA2220 blanket connected to the Mistral Air, Blower. MA1200-PM system for 30 minutes.
79858539|NCT06198959|Device|Premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.
79262278|NCT03048890|Behavioral|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
79262279|NCT03557567|Diagnostic Test|NGS molecular screening|
79262280|NCT03557489|Device|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
79262281|NCT04352738|Diagnostic Test|Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)|Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
79262282|NCT03557411|Drug|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
79262283|NCT02305888|Drug|LEO 43204|Treatment of actinic keratosis
79262284|NCT02090933|Drug|Celecoxib|Given PO
79262285|NCT02090933|Other|Laboratory Biomarker Analysis|Correlative studies
79398823|NCT01392469|Drug|Bosentan|Oral Administration
79398824|NCT01435577|Drug|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
79398825|NCT01435577|Drug|Matching Placebo|Maximum 12 administrations over 48 hours
79398826|NCT04039087|Drug|Sildenafil 40mg oral capsule|40 mg, sildenafil capsule taken by mouth thrice daily
79561882|NCT05268263|Device|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
79561883|NCT05265767|Biological|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
79561884|NCT05259904|Drug|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
79561885|NCT05259904|Drug|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
79561886|NCT05254015|Behavioral|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
79561887|NCT05254015|Behavioral|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
79561888|NCT05252130|Device|NoaScope|Smart digital stethoscope
79561889|NCT05242302|Procedure|nerve transfer|the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
79561890|NCT05232773|Procedure|Assessment|Evaluation of clinical and kinematic parameters
79724348|NCT01193556|Device|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
79724349|NCT01193556|Device|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
79724350|NCT02775877|Drug|Letrozole|
79724351|NCT02775877|Drug|clomiphene|
79724352|NCT02775877|Drug|HMG|
79398827|NCT04039087|Drug|Placebo Oral capsule|Placebo capsule taken by mouth thrice daily
79398828|NCT04061369|Other|Low fat meal|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
79398829|NCT04061369|Other|Moderate fat meal|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
79398830|NCT04061369|Other|High fat meal|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
79724353|NCT02775799|Other|Registration|Registration according to approved data sets
79724354|NCT02778763|Drug|CBLB612|4 μg CBLB612 SQ
79724355|NCT02778763|Drug|Placebo|
79262286|NCT02090933|Procedure|UV Light Therapy|Undergo UV-irradiation
79858540|NCT06198959|Device|Blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 system.
79724356|NCT04228159|Device|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
80020928|NCT05040841|Behavioral|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
79262287|NCT04349774|Drug|Control Group - ESP block with SAP block|None - Control Group
79262288|NCT04349774|Drug|Treatment Group - ESP block with SAP normal saline|Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
79262289|NCT02091323|Procedure|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 ~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
79262290|NCT02338882|Device|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
79262291|NCT02338882|Device|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
79262292|NCT03046238|Drug|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
79262293|NCT03046238|Drug|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
79262294|NCT05231096|Other|Aloe-vera gel|Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific & Industrial Research (PCSIR) laboratory.
79262295|NCT05231096|Other|sidr honey|Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
79262296|NCT05231096|Procedure|Scaling ans root Debridement|non-surgical periodontal therapy was given to all the participants of all the three groups
79262297|NCT02089763|Biological|pegylated recombinant human arginase|
79262298|NCT04884802|Procedure|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
79262299|NCT04884802|Procedure|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
79262300|NCT02089841|Drug|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
79561891|NCT05227339|Device|RAE|Subjects in the interventional group will have access to the RAE Health mobile app which receives continuous physiologic data from a wearable device. Algorithms embedded in the RAE app detect stress and craving events, and trigger mobile phone notifications when detected. Notifications are paired to real-time mindfulness based interventions.
79561892|NCT05224505|Other|GNT0006|Single intravenous infusion
79724357|NCT04228159|Other|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
79724358|NCT04226989|Biological|CT-RD06|CT-RD06 cell injection by intravenous infusion
79724359|NCT04875013|Device|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
79561893|NCT05224505|Other|Day 0: Placebo|Single intravenous infusion
79561894|NCT05224505|Other|Day 0: GNT0006|Single intravenous infusion
79561895|NCT05224505|Other|Day 365 (year 1): Placebo|Single intravenous infusion
79262301|NCT04873076|Device|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
79303795|NCT02466035|Dietary Supplement|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
79561896|NCT05224505|Other|Day 365 (year 1): GNT0006|Single intravenous infusion
79561897|NCT05215951|Drug|osimertinib|Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
79561898|NCT05205538|Other|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
79262302|NCT03045848|Device|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
79262303|NCT02250365|Other|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
79262304|NCT02250365|Other|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
79262305|NCT03045770|Drug|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
79262306|NCT03045770|Drug|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
79262307|NCT03045770|Drug|Irinotecan|Irinotecan was used as first line treatment with AGC.
79262308|NCT03045770|Drug|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
79398831|NCT04061369|Other|High fat liquid meal|Liquid meal that is high (60% of energy) in fat calories.
79561899|NCT05182294|Device|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
79561900|NCT05161468|Drug|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
79561901|NCT05161468|Drug|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
79724360|NCT05021107|Other|FDM with isometrics|FDM with isometrics will be done
79724361|NCT05021107|Other|FDM without isometrics|FDM without isometrics will be done
79724362|NCT02777359|Procedure|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
79724363|NCT02777671|Drug|BIA 2-093|
79724364|NCT02777671|Drug|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
79724365|NCT02777515|Behavioral|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~measurement of blood pressure~An electrocardiogram~A Holter-ECG 10 minutes~A transthoracic echocardiogram"
79724366|NCT02777437|Drug|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
79262309|NCT03045770|Drug|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
79262310|NCT04389086|Drug|Combination drug|"Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI."
79262311|NCT04389086|Radiation|Chemoradiotherapy|"Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy."
79398832|NCT01411891|Device|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
79398833|NCT01416389|Drug|LY2523355|Administered intravenously as a one hour infusion
79398834|NCT01416389|Drug|ixabepilone|Administered intravenously
79398835|NCT01416389|Drug|pegfilgrastim|Administered intravenously
79398836|NCT01416389|Drug|filgrastim|Administered intravenously
79398837|NCT04505969|Other|Questionnaire to assess needs|Two questionnaires have been developed to assess the specific needs of healthcare professionals working with SCD patients and of SCD patients or parents of children with SCD
79398838|NCT04497155|Drug|Norepinephrine|Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure <100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
79561902|NCT05161468|Drug|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
79398839|NCT01544348|Other|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
79398840|NCT01544348|Biological|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
79398841|NCT01544348|Biological|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
79398842|NCT01544348|Biological|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
79561903|NCT05153382|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
79561904|NCT05133726|Other|Text4Support|Daily supportive text messages
79561905|NCT05133726|Other|Peer support|Meeting with peers who have lived experiences with similar diagnoses but are in recovery
79561906|NCT05133544|Device|Endocuff with AI|Use of endocuff with computer assisted polyp detection
79561907|NCT05133544|Device|AI alone|Use of computer assisted polyp detection
79262312|NCT04389086|Procedure|Surgery locally recurrent rectal cancer|"Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional."
79262313|NCT02095847|Procedure|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
79262314|NCT02095847|Drug|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
79262315|NCT02091401|Device|Springfusor infusion pump|
79398843|NCT01544348|Biological|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
79398844|NCT01544348|Biological|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
79398845|NCT01544348|Biological|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
79398846|NCT01544348|Biological|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
79398847|NCT04059965|Other|Panel Management for Anticoagulation Therapy|Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
79561908|NCT05124886|Other|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
79561909|NCT05120947|Radiation|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
79561910|NCT05120947|Radiation|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
79262316|NCT02091401|Other|IV administration|
79561911|NCT05120947|Radiation|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
79262317|NCT02091401|Drug|Magnesium Sulfate|
79262318|NCT01594970|Drug|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
79561912|NCT05108389|Diagnostic Test|Viscoelastic haemostasis monitor output|Observational
79561913|NCT05104762|Device|plasmapheresis device|Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
79262319|NCT04387994|Other|Blood samples collection|Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
79262320|NCT02091557|Drug|GnRH-analogue|
79398848|NCT04059965|Other|Usual Care|Patients will receive standard, protocolized care in their respective anticoagulation clinics
79398849|NCT01416155|Drug|natalizumab|
79398850|NCT01415921|Drug|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
79398851|NCT01415531|Drug|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
79398852|NCT01415531|Drug|Placebo|Dose-match placebo
79398853|NCT01544114|Drug|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
79398854|NCT01544114|Drug|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
79398855|NCT01544114|Drug|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
79262321|NCT04869176|Diagnostic Test|Electrocardiogram|Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
79262322|NCT04869176|Diagnostic Test|Monitoring of vital functions|Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
79262323|NCT04869176|Drug|Caffeine Citrate 5 mg/kg|Caffeine in the form of suspension was given to the newborns.
79262324|NCT02089919|Biological|cancer stem cell vaccine|
79561914|NCT05104762|Drug|Intravenous immunoglobulin|group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
79262325|NCT03047408|Procedure|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
79262326|NCT02091635|Drug|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
79262327|NCT02091635|Drug|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
79398856|NCT01435265|Behavioral|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
79398857|NCT01435265|Behavioral|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
79561915|NCT05098665|Combination Product|Telemonitoring service|Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.
79561916|NCT05094297|Behavioral|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
79561917|NCT05084339|Diagnostic Test|CGM|blinded CGM used at 4 different time points in pregnancy
79561918|NCT05075941|Other|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
79561919|NCT05052112|Other|E-PR-01|Active arm
79561920|NCT05052112|Other|E- PR-02|Placebo arm
79561921|NCT05051618|Behavioral|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
79724367|NCT04226521|Procedure|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
79724368|NCT02775721|Other|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
79262328|NCT02338492|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
79858541|NCT06198959|Device|FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
79262329|NCT04869254|Other|Lower lymphocyte/ATG ratio|
79262330|NCT04869254|Other|Higher lymphocyte/ATG ratio|
79262331|NCT03557255|Drug|Levosimendan|Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.
79262332|NCT03557255|Drug|Saline|Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.
79262333|NCT03047564|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
79262334|NCT03047564|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
79262335|NCT02091713|Other|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
79398858|NCT01433263|Drug|BYM338 active drug|
79398859|NCT01433263|Drug|Placebo|
79398860|NCT01432951|Drug|Enzastaurin|Administered orally
79262336|NCT03047642|Diagnostic Test|Biomarker assay|There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
79262337|NCT02091791|Procedure|Traction sessions|
79398861|NCT01432327|Device|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
79398862|NCT01432327|Device|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
79398863|NCT01432327|Device|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
79262338|NCT03045692|Diagnostic Test|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
79398864|NCT01432327|Behavioral|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
79561922|NCT05051618|Behavioral|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
79561923|NCT05049070|Diagnostic Test|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
79262339|NCT03045692|Diagnostic Test|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
79262340|NCT02091947|Device|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
79561924|NCT05049070|Diagnostic Test|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
79561925|NCT05044455|Behavioral|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
79561926|NCT05037708|Procedure|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B** was applied to group 1 for 4 weeks.~*Treatment A consists of manual lymphatic drainage.~**Treatment B consists of no treatment"
79858542|NCT06198959|Device|Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
79858543|NCT06198712|Drug|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
79262341|NCT04868552|Other|Pre-hospital naloxone education|a 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone
79262342|NCT04872764|Other|duration of hospitalization, mortality rate|duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
79262343|NCT02092103|Procedure|Cord Milking|See description in cord milking arm.
79262344|NCT02090153|Drug|S-1|40~60mg bid，d1~7 q2W
79262345|NCT02090153|Drug|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
79262346|NCT04872530|Dietary Supplement|Pea-protein concentrate|Pea-protein concentrate
79262347|NCT04872530|Dietary Supplement|Fava-bean protein concentrate|Fava-bean protein concentrate
79262348|NCT04872530|Dietary Supplement|Chickpea protein concentrate|Chickpea protein concentrate
79262349|NCT04872530|Dietary Supplement|Red lentil protein concentrate|Red lentil protein concentrate
79262350|NCT04872530|Dietary Supplement|Non-essential amino acid blend|Non-essential amino acid blend
79262351|NCT04872530|Dietary Supplement|Whey protein concentrate|Whey protein concentrate
79262352|NCT03044756|Drug|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
79262353|NCT00358163|Drug|PTK787/ZK 222584|Taken in tablet form daily
79262354|NCT00358163|Drug|paclitaxel|Given as a 3-hour infusion once every 21 days
79398865|NCT01410799|Drug|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
79398866|NCT04407871|Other|Acupuncture and Chinese Herbal Medicine|1) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.
79398867|NCT01432171|Drug|Lacosamide|Given PO
79398868|NCT01432171|Other|Placebo|Given PO
79398869|NCT04046263|Drug|Sucroferric Oxyhydroxide Chewable Tablet|Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
79262355|NCT03044600|Other|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
79262356|NCT03044600|Other|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
79398870|NCT04034719|Other|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
79398871|NCT04034719|Other|usual practice|Parents will be carried their newborn as their usual practice.
79398872|NCT04496713|Other|Internet-connected computer tablet|An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.
79262357|NCT02096237|Device|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
79398873|NCT01435031|Device|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
79561927|NCT05037708|Procedure|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B** for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A* was applied to group 2 for 4 weeks.~*Treatment A consists of manual lymphatic drainage.~**Treatment B consists of no treatment"
79262358|NCT03044834|Other|PPB|Global current care
79262359|NCT02096315|Drug|POL7080|Intravenous infusion
79262360|NCT04868864|Diagnostic Test|CT scan|Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
79262361|NCT04868864|Diagnostic Test|Pulmonary Function Test|Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
79262362|NCT03556397|Procedure|Sentinel lymph node biopsy (SLNB)|Sentinel lymph node biopsy will be performed in the patients
79561928|NCT05032092|Diagnostic Test|Next Generation Sequencing|Molecular analysis of liquid biopsy.
79561929|NCT05032092|Diagnostic Test|Next Generation Sequencing|Molecular analysis of tissue biopsy.
79561930|NCT05032092|Genetic|Biomarker Monitoring|Biomarker Monitoring of study patients receiving matched therapy.
79262363|NCT03556397|Procedure|Axillary dissection|Axillary dissection procedure will be performed in the patients
79262364|NCT03045614|Other|No intervention|No intervention
79262365|NCT04865822|Behavioral|Single session pain education class|Pain education classes will be provided in person group or virtual settings
79561931|NCT05027425|Drug|Durvalumab|1500 mg IV, Q4W
79561932|NCT05027425|Drug|Tremelimumab|300 mg IV, 1 dose on day 1 of only the first cycle
79262366|NCT02249273|Other|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
79262367|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
79262368|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
79398874|NCT04490941|Other|Ophthalmologist-delivered health education|The educational intervention will be conducted on-site by a qualified, experienced ophthalmologist at an ophthalmic center with goals of building awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
79398875|NCT04490941|Other|Usual care|Usual care follows standard procedure on diabetes management similar to the routine service provision.
79398876|NCT04767581|Drug|KHK7791|oral administration
79398877|NCT04767581|Drug|Placebo|oral administration
79398878|NCT01433549|Device|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
79398879|NCT01433549|Device|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
79561933|NCT05027425|Procedure|Liver Transplant|minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.
79561934|NCT05025826|Other|Phycocare|Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)
79561935|NCT05025826|Other|Placebo|Placebo every day during 9 months (except days of chemotherapy = no Placebo)
79724369|NCT02775721|Other|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
79262369|NCT04868084|Behavioral|Physical literacy in the early years|Intervention nurseries received a 6-hour training session, covering the theory about FMS and practical demonstrations of age-appropriate ways to teach and develop FMS.
79262370|NCT02091479|Drug|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
79262371|NCT02091479|Drug|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
79398880|NCT01414205|Drug|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
79398881|NCT01414205|Drug|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
79398882|NCT01433471|Drug|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
79561936|NCT05012020|Device|mHealth Remote Monitoring platform|Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
79262372|NCT04865666|Device|movr mHealth App|The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
80020929|NCT05040841|Behavioral|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
79262373|NCT02090231|Device|rTMS, Magstim Rapid2|5 Hz rTMS
80020930|NCT05040841|Behavioral|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
79303796|NCT05728593|Other|parent-based occupational therapy|Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
79398883|NCT01433159|Drug|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
79561937|NCT05003648|Drug|Pramipexole|Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
79561938|NCT05003648|Drug|Placebo|Matching placebo
79561939|NCT04996849|Other|Data Capture|Data collected
79398884|NCT01433159|Drug|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
79561940|NCT04996849|Other|Questionnaire Administration|Ancillary studies
79561941|NCT04958460|Drug|Placebo|Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
79858544|NCT06194604|Device|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
79398885|NCT02076425|Behavioral|PCIT-ED|
79561942|NCT04958460|Other|BF688|Administrated 1 pack each morning and evening (5×109 CFUs per day)
79561943|NCT04952623|Other|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
79561944|NCT04943172|Device|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
79561945|NCT04913168|Other|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
79561946|NCT04898816|Procedure|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
79561947|NCT04898816|Procedure|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
79561948|NCT04880278|Drug|Nabilone|Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
79561949|NCT04880278|Drug|Placebo|Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
79561950|NCT04858425|Drug|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
79561951|NCT04858425|Drug|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
79561952|NCT04824820|Behavioral|Vibrator|Clitoral stimulation
79858545|NCT06194604|Other|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
79858546|NCT06193161|Behavioral|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
79858547|NCT06193070|Other|Educational Intervention|Play virtual misinformation escape room game
79858548|NCT06193070|Other|Interview|Ancillary studies
80020931|NCT05040841|Behavioral|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
79262374|NCT04865510|Procedure|Regional citrate anticoagulation|"The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6)."
79262375|NCT02090309|Drug|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
79262376|NCT02090309|Drug|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
79262377|NCT04865120|Other|cream cyclic merocyanine|cream long-UVA absorber
79262378|NCT04865120|Other|placebo|placebo
79858549|NCT06193070|Other|Survey Administration|Ancillary studies
79262379|NCT02092337|Other|computer-assisted speech training|
79262380|NCT03047252|Device|Home-based rehabilitation with a digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
79262381|NCT03047252|Other|Conventional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
79398886|NCT01413503|Radiation|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
79398887|NCT01413191|Biological|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
79398888|NCT01413191|Other|Laboratory biomarker analysis|Correlative studies
79398889|NCT05031000|Diagnostic Test|blood glucose measurement: POCT|measurement of blood glucose concentration using 5 different POCT glucometer
79561953|NCT04811365|Other|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
79561954|NCT04801771|Device|Inspire Upper Airway Stimulation (UAS) System|The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
79398890|NCT05031000|Diagnostic Test|blood glucose measurement: reference|measurement of blood glucose concentration using 2 different laboratory analyzer
79398891|NCT05069376|Device|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
79398892|NCT05069376|Device|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
79858550|NCT06193070|Other|Telemedicine|Play virtual misinformation escape room game
79858551|NCT06191965|Drug|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~CAS number: 444890-41-9 (phosphonium cation)~Molecular weight: 678.81~MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
79858552|NCT06191965|Drug|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
79262382|NCT03047096|Drug|hyaluronic acid|intra-Articular injection
79262383|NCT03047096|Drug|hyaluronic acid and corticosteroids|intra-Articular injection
79858553|NCT06191874|Other|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
79858554|NCT06191874|Other|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
79262384|NCT02092493|Device|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
79262385|NCT04872296|Device|Controlled Ankle Motion (CAM) boot|A CAM boot will be worn on the affected ankle to allow weight bearing
79262386|NCT04872296|Procedure|Physical Therapy|Standard physical therapy protocol will be started at 6 weeks after surgery
79262387|NCT04872374|Dietary Supplement|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
79262388|NCT04872374|Dietary Supplement|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
79262389|NCT02090387|Other|ONS without AN777|2 servings a day
79262390|NCT02090387|Other|ONS containing AN777|2 servings a day
79858555|NCT06191731|Other|biological samples collection|Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
80020932|NCT05040841|Behavioral|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
80020933|NCT05029960|Drug|Brivaracetam|Dose of 50 mg twice daily for 6 months
80020934|NCT05027217|Other|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
79262391|NCT02092727|Behavioral|Behavioral Interventions for Dialysis Facilities|"Educational seminars and monthly educational webinars~Peer-to-peer mentoring program~Bulletin boards about transplantation~Facility-specific feedback reports detailing transplant referral data for their center compared to state average~Formulate a facility-specific improvement plan to increase transplant referrals.~Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~Monthly monitoring and reporting of patient referrals to ESRD Network~Conduct a patient and family education session about transplantation~Host a movie day to show Living ACTS (About Choices in Transplantation & Sharing) video"
79262392|NCT04871984|Device|Ureteroscopy for upper tract stone treatment with Holmium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Holmium laser
79262393|NCT04871984|Device|Ureteroscopy for upper tract stone treatment with Thulium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Thulium laser
79262394|NCT02090465|Drug|Ingenol Mebutate|No intervention: observation of routine use of Picato®
79262395|NCT03045458|Device|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
79262396|NCT03045458|Device|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
79262397|NCT02090543|Drug|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
79398893|NCT04984512|Drug|Mitizodone Phosphate tablets|Mitizodone Phosphate tablets will be administered with food.
79398894|NCT04984512|Drug|Placebo-matching tablets|Placebo will be administered with food.
79561957|NCT04762758|Drug|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
79561958|NCT04762758|Drug|Placebo|liquid oral solution
79561959|NCT04717908|Drug|Bedaquiline|400 mg once daily for 2 weeks then 200mg 3 times per week;
79561960|NCT04717908|Drug|Pyrazinamide|1500 mg daily
79561961|NCT04717908|Drug|Linezolid|600 mg daily
79561962|NCT04717908|Drug|Cycloserine|≤50kg 500 mg daily, >50kg 750mg daily;
79858556|NCT06190249|Biological|LN-144|LN-144 is composed of autologous TIL, which are obtained from an individual participant's tumor and expanded ex vivo through cell culture in the presence of the cytokine IL-2 and muromonab CD3, a monoclonal antibody (mAb) to human CD3 (OKT3). Participants will be given LN-144 on day 0 of the study.
79858557|NCT06190249|Drug|Cyclophosphamide|60 mg/kg of cyclophosphamide will be given intravenously to participants on days -5 and -4 of the study as a part of the NMA-LD regimen
79858558|NCT06190249|Drug|Mesna|a total of 78 mg/kg Mesna will be given to participants on days -5 and -4 of the study to prevent hemorrhagic cystitis that can be caused by the cyclophosphamide used in the NMA-LD regimen
79561963|NCT04717908|Drug|Clofazimine|100 mg daily;
79858559|NCT06190249|Drug|Fludarabine|25 mg/m2 of fludarabine will be given intravenously to participants on days -5 through -1 of the study as a part of the NMA-LD regimen
79858560|NCT06190249|Biological|Interleukin-2 (IL-2)|IL-2 IV administrations at a dose of 600,000 IU/kg may begin as soon as 3 hours after, but no later than 24 hours after, completion of the LN-144 infusion on Day 0. Additional IL-2 doses will be given approximately every 8 to 12 hours for up to 6 total doses
80020935|NCT05021393|Other|Clinical Pharmacist Intervention|Medication review, patient education, counseling, and corresponding written recommendation will be performed by clinical pharmacists for all randomized patients.
80020936|NCT05005000|Biological|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
80020937|NCT05005000|Drug|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
79561964|NCT04715685|Behavioral|40 minute session|The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
79561965|NCT04715685|Behavioral|20 minute session|For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
79262398|NCT02090543|Drug|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
79262399|NCT04859036|Diagnostic Test|24 hours ambulatory Holter monitoring|
79262400|NCT02090621|Procedure|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
79262401|NCT03556241|Device|Case management|Case management consists keeping patient's current pacemaker mode during surgery
79262402|NCT03556163|Procedure|Modified vertical internal mattress sutures + MWF surgery.|Modified vertical internal mattress sutures were given after modified Widman flap surgery.
79561966|NCT04715685|Behavioral|home practice e-health|Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
79561967|NCT04715685|Behavioral|home practice handout|Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
79724370|NCT02775721|Other|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
79262403|NCT03556163|Procedure|Simple loop interrupted sutures + MWF surgery.|Simple loop interrupted sutures were given after modified Widman flap surgery.
79398895|NCT01412957|Other|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
79398896|NCT01412957|Drug|Panitumumab|Administered intravenously
79398897|NCT04973826|Drug|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
79398898|NCT05387616|Drug|Copanlisib|"Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle."
79858561|NCT06190249|Drug|Pembrolizumab|Up to 17 cycles of Pembrolizumab 200mg every 3 weeks starting at Week 12 will occur for up to 1 year during the post-treatment efficacy follow-up
79858562|NCT06189508|Drug|NXT007|In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
79858563|NCT06188559|Drug|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
79858564|NCT06187025|Other|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
79858565|NCT06187025|Other|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
79858566|NCT06186063|Other|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
79561968|NCT04715685|Behavioral|phone call|The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
79561969|NCT04712656|Device|CPAP therapy|CPAP treatment of obstructive sleep apnea.
79561970|NCT04711850|Drug|Imlifidase|Immunoglobulin G degrading enzyme of Streptococcus pyogenes
79724371|NCT02775721|Other|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
79724372|NCT02775721|Other|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
79858567|NCT06186063|Other|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
80020938|NCT04995055|Device|JJVC Investigational Multifocal Contact Lens TEST Lens|TEST Lens
79262404|NCT02092805|Procedure|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
79262405|NCT02092805|Procedure|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
79262406|NCT02092883|Drug|ACTH|PK PET scan before and after ACTH treatment
79262407|NCT03557021|Diagnostic Test|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
79262408|NCT02093039|Device|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
79262409|NCT02096783|Other|informational intervention|Given scripted intervention
79262410|NCT02096783|Other|counseling intervention|Given standard counseling
79262411|NCT02096783|Other|questionnaire administration|Ancillary studies
79262412|NCT02093117|Procedure|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
79561971|NCT04665895|Drug|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
79561972|NCT04665895|Drug|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
79724373|NCT04903951|Device|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
79262413|NCT02093117|Procedure|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
79262414|NCT02093195|Drug|Bosentan|
79262415|NCT02093195|Drug|Symbicort turbuhaler|
79262416|NCT02096939|Procedure|Adrenal extirpation|
79262417|NCT02096939|Drug|Antihypertensive medication|
79262418|NCT03555617|Drug|TD-1473|oral capsule/tablet, QD
79262419|NCT03555617|Drug|Itraconazole|oral solution, QD
79262420|NCT03555539|Drug|Danicopan|Oral tablet.
79262421|NCT02093273|Biological|tOPV pilot batch|the tOPV vaccine is given orally
79262422|NCT02093273|Biological|tOPV commercial batch|tOPV vaccine is given orally
79262423|NCT02098811|Device|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
79561973|NCT04665895|Drug|Placebo|twice daily inhalation throughout the study
79561974|NCT04643145|Procedure|Flexible ureteroscopy for renal calculi less than 20 mm|Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
79561975|NCT04638231|Other|Supportive messages|Daily supportive messages via SMS or email
79561976|NCT04617912|Device|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
79561977|NCT04607941|Other|Questionnaires|Self-administered questionnaires
79561978|NCT04607941|Other|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
79724374|NCT04903951|Other|Best medical treatment|Best medical treatment for stroke, including rehabilitation
79858568|NCT06184880|Behavioral|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
79858569|NCT06184880|Other|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods >30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
79262424|NCT02098811|Device|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
79724375|NCT02775565|Device|AngioVac|
79724376|NCT04811677|Other|radiology|image analysis
80020939|NCT04995055|Device|ACUVUE® OASYS Multifocal|CONTROL Lens
79262425|NCT02098889|Drug|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
79262426|NCT02098889|Drug|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
79262427|NCT01369199|Drug|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
79262428|NCT02093507|Other|parents manipulation|parents perform manipulation the child foot to correct the deformity
79262429|NCT02098967|Drug|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
79262430|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
79262431|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose </= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
79262432|NCT02097173|Drug|Methotrexate|
79262433|NCT03556865|Other|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
79262434|NCT02097251|Drug|UX003|Open Label
79262435|NCT03775967|Diagnostic Test|sialic acid|sialic acid level estimation in salivary samples
79262436|NCT03775967|Diagnostic Test|IL10|IL10 estimation in salivary samples
79262437|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
79262438|NCT02097329|Drug|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
79262439|NCT02097329|Drug|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
79262440|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
79262441|NCT02097329|Drug|antacid|30 mL orally once (2h before palbociclib)
79262442|NCT02097329|Drug|antacid|30 mL orally once (2h after palbociclib)
79398899|NCT05387616|Drug|Obinutuzumab|"Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks."
79398900|NCT03025841|Drug|Ceftaroline|
79561979|NCT04604743|Behavioral|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
79581251|NCT01934413|Behavioral|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
79875753|NCT04327583|Behavioral|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
80020940|NCT04987996|Drug|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
79262443|NCT02099201|Drug|ACT-389949 40 mg|
79262444|NCT02099201|Drug|ACT-389949 200 mg|Predicted dose
79262445|NCT02099201|Drug|ACT-389949 800 mg|Predicted dose
79262446|NCT02099201|Drug|ACT-389949 (Group C1 dose to be selected)|
79398901|NCT05387460|Diagnostic Test|radiomics|Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.
80020941|NCT04987996|Drug|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
80020942|NCT04987996|Drug|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
79398902|NCT05064774|Other|myofascial release technique|myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
79262447|NCT02099201|Drug|ACT-389949 (Group C2 dose to be selected)|
79262448|NCT02099201|Drug|Placebo|
79262449|NCT02099279|Device|echocardiography examination|patients underwent echocardiography examination
79262450|NCT02093585|Drug|abacavir (600 mg QD)|
79262451|NCT02093585|Drug|tenofovir (245 mg QD)|
79262452|NCT02099357|Dietary Supplement|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
79262453|NCT02099357|Dietary Supplement|Placebo|
79262454|NCT02099357|Dietary Supplement|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
79262455|NCT02093741|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
79262456|NCT02099435|Device|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
79262457|NCT02097407|Drug|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
79303797|NCT05728593|Other|Standard occupational therapy intervention|"The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities."
79561980|NCT04600479|Diagnostic Test|Evaluation of the prevalence of HCV, HBV and HIV viral infections|"Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up."
79858570|NCT06181279|Procedure|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
80020943|NCT04986670|Behavioral|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
79262458|NCT02097407|Drug|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
79262459|NCT02250053|Other|Exercise|
79262460|NCT02097563|Behavioral|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
79262461|NCT02097563|Behavioral|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
79262462|NCT01368965|Device|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
79262463|NCT02250599|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
79262464|NCT02250599|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
79262465|NCT02250599|Drug|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
79262466|NCT02093975|Device|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
79262467|NCT02099513|Device|The Mobile Health Platform|
79262468|NCT02094053|Drug|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
79262469|NCT02094053|Drug|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
79262470|NCT02094053|Drug|Placebo|placebo (oral) once daily, for 24 weeks
79262471|NCT02099669|Other|Red Blood Cell Transfusions|
79561981|NCT04559230|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
79858571|NCT06181279|Procedure|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
79858572|NCT06180356|Drug|Niraparib oral tablets|Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
79262472|NCT02099747|Drug|hATG|
79262473|NCT02099747|Drug|CsA|
79262474|NCT02099747|Drug|Eltrombopag|
79262475|NCT02097797|Other|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
79262476|NCT02097797|Other|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
79262477|NCT03555929|Drug|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
79262478|NCT03555929|Drug|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
79262479|NCT02097875|Drug|BLZ-100|
79262480|NCT02094131|Other|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
79303798|NCT05173337|Drug|Nefopam|"Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery."
79262481|NCT02094131|Other|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
79262482|NCT02099903|Device|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
79858573|NCT06179108|Drug|LB-102|LB-102 is a dopamine D2/3 and 5HT7 antagonist.
79262483|NCT02099981|Drug|Aminoguanidine|
79858574|NCT06179004|Drug|Liposomal bupivacaine|The medication liposomal bupivacaine of the dose of 133 mg in the form of a supraclavicular single shot injection perineural as a one-time administration
79262484|NCT02100059|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
80020944|NCT04986670|Other|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
79858575|NCT06179004|Drug|Bupivacaine Hydrochloride|The medication plain bupivacaine of the concentration of 0.25% will be administered as a perineural injection in the form of a one-time supraclavicular single shot injection.
79262485|NCT02100137|Other|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
79262486|NCT03555773|Procedure|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
80020945|NCT04986670|Behavioral|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
79262487|NCT02250209|Drug|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14~16 cycles.
79262488|NCT02250209|Drug|Capecitabine|"Capecitabine 800~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles."
79262489|NCT02250209|Drug|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles."
79262490|NCT02094209|Device|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
79262491|NCT02097953|Drug|Daptomycin|
79262492|NCT02097953|Drug|Rifampin|
79262493|NCT02098031|Other|Improving nutrition knowledge among mothers|
79262494|NCT03556787|Device|BPI 1000013 (Dr Scholls Insole)|Full length foam insole
79262495|NCT03556709|Device|Treadmill Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
79262496|NCT02094287|Drug|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
79262497|NCT02094287|Behavioral|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
79262498|NCT02094287|Other|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
79262499|NCT02094365|Drug|ALS-008176|
79858576|NCT06175546|Device|Compression socks|Wearing of compression sock in prescribed regimen
79858577|NCT06175026|Behavioral|Health messages|Participants view messages about the health impacts of certain dietary substitutions.
79858578|NCT06175026|Behavioral|Environmental messages|Participants view messages about the environmental impacts of certain dietary substitutions.
79262500|NCT02094365|Drug|vehicle|
79262501|NCT02100215|Other|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
79262502|NCT02100215|Other|Expert Modeling|70 minutes of expert modeling videos
79262503|NCT02100215|Other|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
79262504|NCT02100293|Drug|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
79398903|NCT05064774|Other|physiotherapy|patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
79858579|NCT06175026|Behavioral|Health and environmental messages|Participants view messages about the health and environmental impacts of certain dietary substitutions.
79858580|NCT06175026|Behavioral|Neutral messages|Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
79262505|NCT02100293|Drug|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
79262506|NCT02094521|Drug|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
79262507|NCT02100371|Drug|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
79262508|NCT02099045|Device|Point of Care Ultrasonography|
79262509|NCT02094599|Drug|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
79262510|NCT02094599|Drug|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
79262511|NCT02094599|Drug|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
79262512|NCT02094833|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
79262513|NCT02094833|Biological|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
79262514|NCT02100527|Drug|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
79262515|NCT02100527|Drug|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
79561982|NCT04549792|Drug|Ustekinumab|Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
79561983|NCT04545554|Drug|Romosozumab|Participants will receive 3 doses of romosozumab via a subcutaneous (SC) injection.
79858581|NCT06174948|Device|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
79262516|NCT02100605|Device|Phytosun, decongestant, nasal spray|one time application of the nasal spray
79262517|NCT02100761|Drug|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance <50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
79262518|NCT05420051|Behavioral|Positive Psychology + Motivational Interviewing|The 8-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage completion of PP activities and engagement in physical activity.
79561984|NCT04545554|Dietary Supplement|Calcium|All participants will receive daily supplements of elemental calcium.
79561985|NCT04545554|Dietary Supplement|Vitamin D|All participants will receive daily supplementation with vitamin D.
79858582|NCT06172348|Drug|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
79858583|NCT06171750|Drug|ANK-101|IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
79875754|NCT04295837|Other|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
80020946|NCT04986670|Other|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
79262519|NCT05420051|Behavioral|Motivational Interviewing|The 8-week MI-alone intervention focuses on providing education and enhancing motivation to engage in health behaviors (through MI). Each week, participants will complete an activity related to a health behavior (e.g., consider the pros and cons of behavior change, set a health behavior goal), then complete a phone session with a study trainer. This program will focus on assisting participants to improve health behavior adherence (including physical activity), resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Additional time in MI-alone phone sessions will be spent on review of core MI skills, problem-solving of barriers, and discussion of resources. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage engagement in health behaviors.
79262520|NCT02100917|Drug|DMB-3111|
79262521|NCT02100917|Drug|trastuzumab|
79561986|NCT04523519|Behavioral|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
79561987|NCT04523519|Behavioral|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
79561988|NCT04518657|Behavioral|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
79262522|NCT02098187|Drug|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
79561989|NCT04518657|Behavioral|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
79262523|NCT02098187|Drug|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
79262524|NCT02098187|Drug|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
79561990|NCT04500574|Drug|Latanoprost eluting contact lens|The latanoprost-contact lens will be worn in one eye for one week.
79561991|NCT04500574|Drug|Topical Latanoprost|A commercial contact lens with no drug will be worn in one eye for one week.
79561992|NCT04487457|Other|Blood samples|Blood samples
79561993|NCT04441593|Behavioral|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
79858584|NCT06171165|Diagnostic Test|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
79858585|NCT06168851|Drug|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
79561994|NCT04441593|Behavioral|Treatment as Usual|Psychoeducation and Information about Treatment Resources
79858586|NCT06167486|Drug|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
79561995|NCT04428736|Behavioral|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
79858587|NCT06166992|Drug|BI 1291583|BI 1291583
79858588|NCT06166992|Drug|[14C]-BI 1291583|[14C]-BI 1291583
79858589|NCT06165887|Other|No intervention|This is an observational study, no intervention will be implemented.
79858590|NCT06165887|Other|No intervention|This is an observational study, no intervention will be implemented.
79561996|NCT04416282|Drug|Terlipressin|Injection terlipressin 2 mg/24 hours infusion
79561997|NCT04416282|Biological|Albumin|i/v albumin 1g/Kg/day
79561998|NCT04395469|Drug|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
79561999|NCT04383886|Other|stress and anxiety questionnaire|Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
79858591|NCT06163404|Device|Implantation of Spirair Nasal Device using the Spirair delivery system.|The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
79262525|NCT02098187|Drug|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
79262526|NCT02098187|Device|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
79262527|NCT02098187|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
79262528|NCT02098421|Drug|Oxytocin|Use of oxytocin while the Foley bulb is in place
79562000|NCT04375150|Drug|Tyrosine kinase inhibitor (TKI)|TKIs
79562001|NCT04375150|Drug|Immuno-oncology (IO)|IOs
79562002|NCT04321291|Other|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
79562003|NCT04321291|Other|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
79858592|NCT06162052|Other|Tele-Rehabilitation|Technology will be used to enhance rehabilitation.
79858593|NCT06161584|Drug|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
79262529|NCT02098499|Drug|Haloperidol|5mg IV
79262530|NCT02098499|Drug|Metoclopramide 10mg|10mg IV
79262531|NCT02098499|Drug|Diphenhydramine|25mg IV
79262532|NCT02100995|Behavioral|Intervention Simultaneously Targeting Obesity and Pain|
79262533|NCT02100995|Behavioral|Weight Loss/Weight Self-Management|
79262534|NCT02100995|Behavioral|Chronic Pain Self-Management|
79562004|NCT04231513|Drug|E2814|E2814, intravenous infusion.
79562005|NCT04231513|Drug|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
79875755|NCT04295837|Other|Usual Care|Standard occupational therapy
79858594|NCT06159673|Drug|ACP-204|ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
80020947|NCT04986670|Behavioral|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
79562006|NCT04231032|Other|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
79562007|NCT04231032|Other|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
79562008|NCT04191538|Procedure|Conditioning electrical stimulation|Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
79562009|NCT04191538|Procedure|Postoperative electrical stimulation|Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
79262535|NCT02094911|Behavioral|Combined lifestyle intervention|"10-month intervention period with:~weekly group-based sports lessons supervised by a physiotherapist~individual dietary advice by a dietician~case management by practice nurse~maintenance programme to guide subjects to maintain lifestyle behaviour change"
79262536|NCT02094911|Other|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
79562010|NCT04191538|Procedure|No electrical stimulation|Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
79562011|NCT04169204|Diagnostic Test|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
79562012|NCT04152551|Drug|Risedronate Oral Tablet|Oral bisphosphonate
79858595|NCT06159673|Drug|Placebo|ACP-204 matching placebo
79858596|NCT06159062|Drug|162|The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
79858597|NCT06159062|Drug|Placebo|Placebo do not consist any active ingredients.
79262537|NCT02094989|Other|posture dependence of VCG-ECG-transformation|
79262538|NCT02097017|Drug|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
79858598|NCT06157944|Other|GPT-4|OpenAI's GPT-4 large language model with chat interface.
79858599|NCT06154863|Drug|RAI|Radioactive iodine
79858600|NCT06153966|Drug|ION717|ION717 will be administered by IT injection.
79858601|NCT06153966|Drug|Placebo|Placebo-matching ION717 will be administered by IT injection.
79858602|NCT06151769|Other|topical pomegranate seed oil|Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
79858603|NCT06151769|Other|Sesame oil|Sesame oil
79875756|NCT00957203|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
79875757|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
79875758|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
79875759|NCT00952913|Drug|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
79875760|NCT00952991|Drug|LAF237 = vildagliptin|
79875761|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 1
79875762|NCT00957437|Drug|AZD1305|ER formulation 1, bid for 5 days
79875763|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 2
79875764|NCT00957749|Drug|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
79262539|NCT02097017|Other|placebo comparator|
79303799|NCT03066921|Dietary Supplement|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
79398904|NCT01432457|Drug|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
79398905|NCT01432457|Drug|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
79398906|NCT01432457|Drug|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
79398907|NCT05062278|Drug|Vinblastine|Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).
79262540|NCT03555383|Diagnostic Test|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
79262541|NCT02095067|Device|Video consultation|
79262542|NCT02098577|Other|Crossover|Crossover cycle
79262543|NCT02098577|Other|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
79262544|NCT02095301|Other|Herbal Beverage|
79262545|NCT02095379|Other|oligosecretary|not abvailable
79858604|NCT06149975|Other|motor-cognitive training|"The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist."
79858605|NCT06149286|Drug|Odronextamab|Administered by intravenous (IV) infusion
79262546|NCT02095457|Behavioral|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
79262547|NCT02098655|Other|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
79562013|NCT04126161|Procedure|CT|standard of care CT prior to primary hip replacement
79562014|NCT04126161|Device|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
79562015|NCT04112498|Drug|relatlimab|Specified dose on Specified days
79562016|NCT04112498|Drug|nivolumab|Specified dose on Specified days
79562017|NCT04112498|Drug|rHuPH20|Specified dose on Specified days
79562018|NCT04104893|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
79562019|NCT04069533|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
79262548|NCT02101073|Biological|ALX-0061|single dose, intravenous
79858606|NCT06149286|Drug|Lenalidomide|Administered orally (PO)
79858607|NCT06149286|Drug|Rituximab|Administered by IV infusion
79858608|NCT06148870|Device|Myopia Control Lens-1 (MCL1)|The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
79858609|NCT06148870|Device|Myopia Control Lens-2 (MCL2)|The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
79262549|NCT02101073|Biological|ALX-0061|single dose, subcutaneous
79262550|NCT02101151|Dietary Supplement|Vitamin D3(cholecalciferol)|
79262551|NCT03556553|Device|Vertise Flow|Composite resin
79262552|NCT03556553|Device|LuxaFlow|Composite resin
79262553|NCT03556553|Device|Teco Adhesive|Adhesive system
79262554|NCT02101229|Drug|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
79262555|NCT02095613|Other|traditional food|
79262556|NCT02095613|Other|food that is nutrient dense|
79262557|NCT02106143|Device|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
79262558|NCT05402969|Procedure|Transimedance Matrix measurements|TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes
79262559|NCT05402969|Procedure|Depth sounding and spectroscopy|Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.
79262560|NCT05402969|Procedure|Cone Beam Computer Tomography|CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.
79262561|NCT03554603|Behavioral|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
79262562|NCT02106221|Other|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
79262563|NCT02106221|Other|Control|Will receive payments based on achievement in meeting goals.
79262564|NCT03554525|Dietary Supplement|Fat-binder damm|3 sticks every day during 12 months
79262565|NCT03554525|Dietary Supplement|Placebo|3 sticks every day during 12 months
79262566|NCT02102555|Drug|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
79262567|NCT02102555|Drug|placebo|placebo (IV normal saline)
79875765|NCT00953303|Drug|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
79858610|NCT06148090|Diagnostic Test|clobetasol decreasing measurement|"At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~Visit 1: 20-40 g clobetasol twice a week for at least 1 month~Visit 2: 20-40 g clobetasol once a week for at least 1 month"
80020948|NCT04986670|Behavioral|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
80020949|NCT04924205|Device|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
79262568|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
79262569|NCT02102633|Drug|Bosutinib|Bosutinib 500 mg orally
79262570|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
79262571|NCT02101463|Device|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
79562020|NCT04064749|Behavioral|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
79562021|NCT04057339|Behavioral|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
79562022|NCT04057339|Behavioral|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
79562023|NCT04042051|Drug|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 [according to the dose escalation scheme]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
79562024|NCT04042051|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
79562025|NCT04033991|Drug|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
79562026|NCT04033991|Drug|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
79724377|NCT04225741|Behavioral|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
79724378|NCT02775253|Other|Chronic cold acclimation|
79724379|NCT04227691|Device|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
79724380|NCT04227691|Device|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
79724381|NCT02775175|Behavioral|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
79262572|NCT02250755|Other|MRI T1 T2 sequences|MRI
79262573|NCT02101541|Procedure|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
79262574|NCT02106299|Device|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
79262575|NCT02106299|Device|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
79262576|NCT02106533|Other|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
79262577|NCT02101697|Behavioral|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
79724382|NCT02777203|Device|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag.
79724383|NCT02778841|Other|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
80020950|NCT04924088|Behavioral|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
80020951|NCT04924088|Behavioral|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
79262578|NCT02102711|Dietary Supplement|Vitamin A oral drops|
79262579|NCT02106767|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
79724384|NCT02775097|Device|OCT|OCT for all Arms
79724385|NCT01129687|Procedure|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
79262580|NCT02106767|Drug|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
79262581|NCT02102945|Procedure|Computed tomography perfusion|Computed tomography perfusion of the head
79562027|NCT04004741|Procedure|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
79262582|NCT02103023|Drug|Imiquimod ointment|5% 250mg imiquimod ointment
79262583|NCT02103023|Drug|Aqueous cream|aqueous cream
79262584|NCT02103023|Biological|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
79262585|NCT02103023|Biological|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
79262586|NCT02101931|Drug|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
79262587|NCT02102009|Dietary Supplement|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
79262588|NCT02102009|Other|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
79562028|NCT04004741|Procedure|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
79562029|NCT03961360|Drug|Aspirin 81 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
79562030|NCT03961360|Drug|Aspirin 162 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
79562031|NCT03941769|Biological|Recombinant Interleukin-7|Given IM or SC
79562032|NCT03924401|Drug|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
79562033|NCT03922386|Device|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
79724386|NCT01129687|Procedure|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
79724387|NCT02775019|Dietary Supplement|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
79724388|NCT02775019|Dietary Supplement|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
79724389|NCT04194853|Device|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
79724390|NCT04194853|Other|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
79724391|NCT02774863|Other|Home passages|Three home passages between the 2nd and 3rd months of follow up.
79724392|NCT02778919|Drug|KLH-2109|
79262589|NCT02106845|Drug|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
79262590|NCT02106845|Drug|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
79262591|NCT02106845|Drug|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
79262592|NCT02102087|Device|Initial Specimen Diversion Device (ISDD)|
79262593|NCT02102087|Device|Lab standard practice (LSP)|
79262594|NCT03554447|Drug|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
79262595|NCT03554447|Drug|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
79262596|NCT02103101|Other|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
79262597|NCT02103101|Genetic|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
79262598|NCT02103179|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
79724393|NCT02778919|Drug|Placebo|
79724394|NCT02778919|Drug|Leuprorelin acetate|
79724395|NCT02774629|Other|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
79724396|NCT00635011|Behavioral|psychotherapy|Cognitive Behavioral therapy
79858611|NCT06146959|Device|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
79262599|NCT02103257|Drug|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
79262600|NCT02103257|Drug|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
79262601|NCT02103335|Drug|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
79262602|NCT02103335|Drug|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
79262603|NCT02103335|Drug|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
79562034|NCT03865342|Behavioral|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
79262604|NCT02250911|Other|webcasts|
79262605|NCT02250911|Behavioral|Assessments|
79262606|NCT02250911|Other|Usual care|
79262607|NCT02103413|Device|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
79262608|NCT02103413|Device|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
79262609|NCT02610140|Drug|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
79262610|NCT02610140|Drug|Vinorelbine|Starting dose: 30mg/m^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
79562035|NCT03853915|Diagnostic Test|[18-F]- FDG - PET|[F-18]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, [F-18]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
79562036|NCT03849820|Device|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
79262611|NCT02102321|Drug|albendazole|
79262612|NCT02102321|Drug|placebo|
79262613|NCT03555227|Procedure|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
79262614|NCT03555227|Procedure|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
79562037|NCT03849820|Other|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
79562038|NCT03838510|Behavioral|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
79562039|NCT03813355|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
79562040|NCT03791216|Other|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
79562041|NCT03779490|Device|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
79262615|NCT03555227|Procedure|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
79262616|NCT03555227|Procedure|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
79562042|NCT03769285|Drug|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
79562043|NCT03769285|Drug|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
79562044|NCT03743051|Drug|Anamorelin Hydrochloride|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
79262617|NCT02103569|Drug|FDC of Daclatasvir, Asunaprevir and BMS-791325|
79262618|NCT02103569|Drug|FDC of Norethindrone and Ethinyl Estradiol|
79262619|NCT02103569|Drug|BMS-791325|
79262620|NCT03042338|Behavioral|CET: Central Executive Training|CET: Central Executive Training
79262621|NCT03042338|Behavioral|CET: Comparison Executive Training|CET: Comparison Executive Training
79262622|NCT02251067|Drug|VPI-2690B low dose|Comparison of different doses of study drug
79262623|NCT02251067|Drug|VPI-2690B medium dose|Comparison of different doses of study drug
79262624|NCT02251067|Drug|Placebo to match VPI-2690B|
79262625|NCT02251067|Drug|VPI-2690B high dose|Comparison of different doses of study drug
79262626|NCT04868162|Drug|MRG003|Administered intravenously
79262627|NCT02103647|Drug|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
79262628|NCT02103647|Drug|sustained release tablet|sustained release tablet
79398908|NCT05062278|Drug|Hydroxyurea capsules|Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
79398909|NCT05026788|Other|type of treatment|pathway of management for conservative treatment, operative treatment and type of anaesthesia used
79398910|NCT02823990|Biological|TG4010|Given SC
79398911|NCT02823990|Biological|Nivolumab|Given IV
79398912|NCT04873908|Other|modified constraint-induced therapy|Patients received conventional rehabilitation and modified constraint-induced therapy schedule
79398913|NCT04873908|Other|Proprioceptive Training|Patients received conventional rehabilitation and Proprioceptive Training schedule
79398914|NCT04873908|Other|conventional rehabilitation|Patients received conventional rehabilitation schedule
79262629|NCT02107001|Procedure|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
79262630|NCT02109965|Drug|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
79262631|NCT02109965|Drug|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
79562045|NCT03743051|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
79562046|NCT03710902|Diagnostic Test|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
79562047|NCT03710902|Other|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
79562048|NCT03707236|Behavioral|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
79562049|NCT03698201|Other|Non-interventional|Translational, observational study
79562050|NCT03642132|Drug|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
79262632|NCT02109965|Drug|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
79262633|NCT02789657|Drug|paclitaxel|80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
79562051|NCT03642132|Drug|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
79562052|NCT03642132|Drug|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
79562053|NCT03632330|Drug|Dexmedetomidine|Dexmedetomidine group
79562054|NCT03632330|Drug|Midazolam|Midazolam group
79562055|NCT03632330|Drug|Propofol|Propofol group
79562056|NCT03632330|Drug|Midazolam/Propofol|Midazolam/Propofol group
79562057|NCT03585946|Drug|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
79262634|NCT02789657|Drug|Trastuzumab|Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
79262635|NCT02789657|Drug|Pertuzumab|every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
79262636|NCT02789657|Drug|carboplatin|AUC 2 administered weekly with no planned treatment breaks
79262637|NCT02789657|Procedure|Breast surgery|breast conserving or mastectomy
79262638|NCT02789657|Drug|AC|"doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles"
79562058|NCT03575949|Procedure|Computed Tomography|Undergo FDG PET/CT
79562059|NCT03575949|Other|Fludeoxyglucose F-18|Given IV
79562060|NCT03575949|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
79562061|NCT03572764|Drug|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
79562062|NCT03572764|Procedure|Research skin biopsy|"-And/or buccal swab~Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
79562063|NCT03572764|Procedure|Research blood draw|"Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~Post-consolidation 1 (if applicable)~Post-consolidation 2 (if applicable)~Post-transplant Day 30 (if applicable)~Post-transplant Day 100 (if applicable)"
79562064|NCT03572764|Procedure|Research bone marrow aspirate|"Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~Post-consolidation 1 (if applicable)~Post-consolidation 2 (if applicable)~Post-transplant Day 30 (if applicable)~Post-transplant Day 100 (if applicable)"
79562065|NCT03568045|Device|standard light|usual care
79562066|NCT03568045|Device|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
79562067|NCT03568045|Device|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
79262639|NCT02110043|Device|tDCS|transcranial direct current stimulation (tDCS)
79562068|NCT03558802|Other|questionnaire|questionnaire
79262640|NCT02110043|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
79262641|NCT03555071|Biological|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
79262642|NCT03555071|Biological|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
79262643|NCT02609984|Biological|CMB305|A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
79262644|NCT02609984|Biological|atezolizumab|IV Infusion
79262645|NCT02107079|Drug|Melatonin|swallowing 1 piece, collecting saliva afterwards
79262646|NCT02107235|Drug|oral rigosertib|
79262647|NCT02107235|Drug|cisplatin|
79262648|NCT02107235|Radiation|Radiotherapy|
79262649|NCT04867772|Other|Home based rehabilitation|
79858612|NCT06146959|Device|Non corrective kinesiology tape|Non-corrective kinesiology tape is a form of biomechanical tape that is used without any tension
80020952|NCT04916509|Drug|Palbociclib plus an aromatase inhibitor|Palbociclib plus an aromatase inhibitor therapy
80020953|NCT04916509|Drug|Palbociclib plus fulvestrant|Palbociclib plus fulvestrant
79562069|NCT03558048|Diagnostic Test|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
79262650|NCT02103725|Drug|pimecrolimus 10 mg/g cream|
80020954|NCT04897581|Behavioral|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
80020955|NCT04897581|Behavioral|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
79262651|NCT02103725|Drug|Vehicle cream|
80020956|NCT04891380|Device|LUCAS 2 Active Decompression 2|Chest compression with active decompression of the chest. Measurement of physiological parameters.
80020957|NCT04891380|Other|Hypotension|measurement of physiological parameters
79262652|NCT03554993|Drug|CC-99677|CC-99677
79262653|NCT03554993|Other|Placebo|Placebo
79262654|NCT03042260|Drug|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
79562070|NCT03506061|Drug|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
79562071|NCT03486821|Radiation|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
80020958|NCT04891380|Other|Intensive care transport|Measurement of physiological parameters
80020959|NCT04884048|Diagnostic Test|Radiographs|Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
80020960|NCT04882774|Drug|Treprostinil Diolamine|Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
80020961|NCT04878887|Procedure|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
80020962|NCT04874558|Diagnostic Test|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
80020963|NCT04866134|Drug|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
80020964|NCT04866134|Drug|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
80020965|NCT04860700|Drug|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
80020966|NCT04846920|Drug|Belzutifan|40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
79262655|NCT03042260|Drug|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
79262656|NCT02110355|Drug|AMG 232|Given as an oral tablet in escalating doses
79262657|NCT02110355|Drug|Trametinib|Trametinib is an anti-cancer agent
79562072|NCT03453619|Drug|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
79562073|NCT03452930|Radiation|Radiation Therapy|Undergo RT
79262658|NCT02110355|Drug|Dabrafenib|Dabrafenib is an anti-cancer agent
79262659|NCT04864730|Other|No intervention|No intervention
79262660|NCT02107391|Biological|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
79262661|NCT02107391|Drug|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
79562074|NCT03452930|Drug|Tinostamustine|Given IV
79858613|NCT06146959|Other|Home exercise program|Intrinsic foot strengthening and stretching exercises
79262662|NCT02107391|Drug|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
79262663|NCT03045536|Device|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
79262664|NCT04864574|Other|Garden installation|"Garden installation: 6 raised planting beds (4x6x16) configured in a single line with direct sun at least 6 hrs./day, close to hose bib, sufficient distances to allow working from most sides, vegetable vines spill over space, and storage unit for tools.~Planting beds constructed from a standard kit. Beds filled with high quality growing medium.~Plants selection criteria: a) documented harvest success in NC Piedmont; b) able to be eaten raw, c) harvest times at the same time (except strawberries).~Designated beds and plants: Bed 1: 4 pepper, 2 tomato; Bed 2: 20 bean on 2 mini-teepees, 2 cucumber (trellised); Bed 3: 1 yellow squash, 1 zucchini; Bed 4: 2 blueberry bushes, 12 strawberry; Bed 5: 2 cantaloupe. Bed 6: 2 watermelon. 2 Blackberries planted at ground level on trellis."
79262665|NCT02110433|Device|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
79303800|NCT03066921|Dietary Supplement|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
79303801|NCT02464787|Dietary Supplement|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
79858614|NCT06146374|Other|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
79858615|NCT06146374|Drug|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
79262666|NCT02110433|Device|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
79262667|NCT02110433|Device|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP < 100 pg/ml or remaining stable (< 30% increase).
79398915|NCT04835688|Procedure|Transmyringeal ventilation tube insertion|"In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted."
79562075|NCT03396653|Behavioral|Peer-delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
79262668|NCT03045380|Other|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
79562076|NCT03396653|Behavioral|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
79262669|NCT03045380|Other|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
79262670|NCT02110511|Other|blended lentils|blended lentils burritto breakfast
79262671|NCT02110511|Other|whole lentils|whole lentils breakfast burritto
79262672|NCT02110511|Other|no lentils|No lentils control breakfast burritto
79262673|NCT04864340|Device|CE marked medical device|Tetanic stimulation
79262674|NCT04864340|Device|Algometer|Pressure stimulation
79562077|NCT03339908|Device|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
79562078|NCT03253289|Drug|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
79562079|NCT03227705|Drug|Prometrium|Intravaginal use, off label, of Prometrium
79262675|NCT04864340|Procedure|Comparator|Non-nociceptive procedure (fine touch)
79562080|NCT03227705|Device|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
79562081|NCT03178032|Biological|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
79562082|NCT03167307|Drug|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
79562083|NCT03167307|Drug|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
79724397|NCT02779153|Drug|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
79262676|NCT02103881|Drug|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
79262677|NCT02103881|Drug|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
79262678|NCT02103959|Drug|CMX-2043|Slow bolus IV administration of CMX-2043
79562084|NCT03150004|Drug|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~Cladribine 5 mg/m^2 IV over two hours on days 1-5;~Cytarabine 2 gm/m^2 IV over four hours on days 1-5~Mitoxantrone 10 mg/m^2 IV on days 1-3;~G-CSF at a dose of 300 μg on days 0-5."
79724398|NCT02779153|Drug|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
79562085|NCT03150004|Drug|Cladribine and Cytarabine (CLLDAC) Regimen|"Cladribine 5 mg/m^2 IV over two hours on days 1-5;~Cytarabine 20 mg/m^2 subcutaneous injection on days 1-10;"
79875766|NCT00953303|Drug|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
79262679|NCT02103959|Drug|Placebo comparator|Slow bolus IV administration of PBS
79262680|NCT04858646|Other|Experimental( Group A ): Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
79262681|NCT04858646|Other|Conventional( Group B): Conventional Physical therapy|The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes.Treatment duration for both groups will be 30 minutes. Each subject received total30sessions of the treatment, with 5 treatment sessions per week for 6 weeks
79262682|NCT02107469|Drug|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
79262683|NCT02107469|Drug|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
79398916|NCT04835688|Procedure|Sham-treatment|For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
79398917|NCT04957602|Other|Blood collection|Blood collection (4*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
79562086|NCT03082534|Drug|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
79562087|NCT03081663|Procedure|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
79724399|NCT04226443|Drug|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
79858618|NCT06142032|Behavioral|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~Introduction, check-in, ground rules;~Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~Encouragement of participants to share thoughts, ideas and experiences;~Psychoeducation on the topics;~Summary, takeaway, feedback."
80020967|NCT04785144|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
80020968|NCT04785144|Biological|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
80020969|NCT04780542|Behavioral|Yo Puedo Sentirme Bien- Clinician-Guided version|Internet delivered Cognitive Behavioral Therapy- Guided version
79262684|NCT02107469|Drug|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
79262685|NCT02107469|Drug|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
79262686|NCT02107469|Other|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
79262687|NCT02107469|Other|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
79303802|NCT05728515|Drug|68Ga-NY104|Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
79303803|NCT02464631|Drug|Sofosbuvir + Ribavirin 1|
79303804|NCT02464631|Drug|Sofosbuvir + Ribavirin 2|
79398918|NCT02427126|Drug|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
79398919|NCT02427126|Drug|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
79398920|NCT04917120|Device|Virtual Reality|The procedure will consist of a virtual reality program associated with suggestions of hypnoanalgesia, be added to usual care. Included patients will benefit from the Virtual Reality program combined with hypnoanalgesia suggestions for a period of 20 minutes. We will use a helmet with a built-in screen and an audio headset connected to a control room. Patients will watch an Virtual Reality sequence while listening to narratives designed for the hypnoanalgesia of the present pain.
79398921|NCT03143088|Behavioral|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
79562088|NCT03081663|Procedure|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
79262688|NCT03045146|Other|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
79562089|NCT03056339|Drug|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
79562090|NCT03056339|Drug|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
79562091|NCT03056339|Drug|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
79562092|NCT03056339|Biological|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
79562093|NCT03056339|Drug|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
79562094|NCT03008122|Other|Placebo|Placebo
79858619|NCT06142032|Behavioral|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~Introduction, check-in, ground rules;~Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~Encouragement of participants to share thoughts, ideas and experiences;~Psychoeducation on the topics;~Summary, takeaway, feedback."
79262689|NCT03554915|Other|Ketamine-based protocol|For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.
79262690|NCT03554915|Other|Midazolam-based protocol|For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
79562095|NCT03008122|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
79562096|NCT02977884|Behavioral|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
79562097|NCT02912897|Biological|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
79858620|NCT06140537|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10mg orally daily
80020970|NCT04780542|Behavioral|Yo Puedo Sentirme Bien- Self-Guided version|Internet delivered Cognitive Behavioral Therapy- Self-Guided version
79262691|NCT03044522|Other|Opioid Education|
79262692|NCT03044366|Other|general anesthesia management of preterm infants|general anesthesia management of preterm infants
79262693|NCT02110589|Device|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
79262694|NCT02107625|Behavioral|Diet A i.e. Low FODMAP diet|
79262695|NCT02107625|Behavioral|Diet B, i.e. Traditional IBS diet|
79262696|NCT02110667|Device|Transperineal Ultrasound|
79262697|NCT02104037|Procedure|Lumbar puncture|
79262698|NCT02250833|Drug|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
79262699|NCT02250833|Drug|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
79262700|NCT02250833|Drug|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
79262701|NCT04336670|Device|Immersive Virtual Reality exercise program|Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.
79262702|NCT04336670|Other|Usual care|Usual center therapies (Physical therapy, occupational therapy..)
79262703|NCT02107781|Device|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
79262704|NCT02609672|Other|Exercise|A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
79262705|NCT02609672|Other|No Exercise|A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
79262706|NCT02110745|Drug|Sevofluorane|Comparison of different induction drugs and techniques
79262707|NCT02110745|Drug|Propofol|Comparison of different induction drugs and techniques
79262708|NCT03553745|Behavioral|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
79262709|NCT03553745|Behavioral|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
79262710|NCT03553745|Behavioral|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
79303805|NCT02464631|Drug|Sofosbuvir + Ribavirin 3|
79398922|NCT04831554|Procedure|single chest tube drainage|place single chest tube after surgery of PSP
79398923|NCT04807920|Drug|OnabotulinumtoxinA 100 UNT|Intravesical injection
79398924|NCT04807920|Other|Injectable saline|Intravesical injection
79398925|NCT00658515|Drug|Dalcetrapib (RO4607381)|600mg po daily
79398926|NCT00658515|Drug|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
79398927|NCT00658515|Drug|Placebo|po daily
79262711|NCT04867304|Other|Patient education about chronic pancreatitis.|"Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters."
79262712|NCT03554213|Biological|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
79262713|NCT04857554|Other|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
79262714|NCT04857554|Other|White bread as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
79262715|NCT04857554|Other|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
79262716|NCT04857554|Other|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
79858621|NCT06140537|Drug|Placebo|Placebo one tablet orally daily
79858622|NCT06140290|Drug|Etrasimod Immediate Release (IR)|An immediate release tablet
79262717|NCT04857554|Other|Cocoa drink|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
79262718|NCT03554135|Other|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with < 6 months prognostic score attendance
79262719|NCT03553979|Behavioral|Stress management program (SM)|Participants follow the SM program.
79262720|NCT03553979|Behavioral|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
79262721|NCT02104115|Other|MRI scanners|
79858623|NCT06137534|Other|Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern|"Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~Bilateral symmetrical flexion-adduction-external rotation.~Bilateral symmetrical flexion-abduction-external rotation.~Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation."
79858624|NCT06137183|Drug|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
79262722|NCT02104115|Other|VAS Symptom scores|
79262723|NCT03041948|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
79262724|NCT03041948|Procedure|Caudal-epidural nerve block|See arm description
79262725|NCT03041948|Drug|Acetaminophen|See arm description
79262726|NCT03041948|Drug|Sevoflurane|See arm description
79262727|NCT03041948|Drug|Remifentanil|See arm description
79262728|NCT03041948|Drug|Propofol|See arm description
79262729|NCT03041948|Drug|Morphine|See arm description
79262730|NCT03041948|Drug|Ondansetron|See arm description
79262731|NCT03041948|Drug|Dexamethasone|See arm description
79262732|NCT03041948|Drug|Ketorolac|See arm description
79262733|NCT02108015|Procedure|Brain Imaging (PET)|
79262734|NCT02108015|Procedure|Aterial Line|
79262735|NCT02108015|Procedure|Blood Sampling|
79262736|NCT02104193|Drug|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
79262737|NCT02104193|Radiation|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
79262738|NCT03042182|Biological|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
79858625|NCT06137183|Drug|Placebo|Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
79858626|NCT06132958|Biological|MK-2870|4 mg/kg of MK-2870 by IV infusion
79858627|NCT06132958|Drug|Doxorubicin|60 mg/m^2 of doxorubicin by IV Infusion
79858628|NCT06132958|Drug|Paclitaxel|80 mg/m^2 of paclitaxel by IV infusion
79858629|NCT06132269|Dietary Supplement|AKK formula prebiotic sachet|"5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
79858630|NCT06132269|Dietary Supplement|Placebo sachet|"5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
79858631|NCT06132113|Drug|BI 764532|BI 764532
79858632|NCT06132113|Drug|Carboplatin|Standard of care
79858633|NCT06132113|Drug|Etoposide|Standard of care
79858634|NCT06132113|Drug|Cisplatin|Standard of care
79262739|NCT03044444|Dietary Supplement|citrus extract|Participants will receive either a low or high dose citrus extract
79262740|NCT03044444|Other|placebo|participants will receive 500mg of maltodextrin
79562098|NCT02847130|Other|Informational Intervention|Participate in focus group
79562099|NCT02847130|Other|Interview|Undergo one-on-one interviews
79562100|NCT02847130|Other|Medical Chart Review|Review of medical chart
79262741|NCT03041870|Device|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of [11C]DASB bolus.
79262742|NCT02104271|Procedure|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
79262743|NCT02104271|Procedure|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
79562101|NCT02847130|Other|Questionnaire Administration|Ancillary studies
79262744|NCT04429412|Behavioral|MCT+|Metacognitive training
79562102|NCT02764086|Radiation|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
79262745|NCT02104661|Drug|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
79262746|NCT02104661|Drug|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
79562103|NCT02759094|Device|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
79562104|NCT02758054|Behavioral|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
79562105|NCT02757911|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
79562106|NCT02732275|Drug|DS-3201b|
79562107|NCT02671305|Procedure|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
79562108|NCT02671305|Procedure|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
79562109|NCT02639754|Behavioral|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
79262747|NCT04863560|Other|Auditory Cueing|Metronome beat to step in time with
79262748|NCT04863560|Other|Visual Cueing|Lines on the floor to step over
79262749|NCT04863560|Other|tactile Cueing|Vibration to step in time with (metronome like)
79262750|NCT02104973|Behavioral|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
79262751|NCT04429490|Other|Adipose tissue sampling during surgery and urine sampling|Adipose tissue sampling during surgery and urine sampling
79262752|NCT02110979|Behavioral|Use of a PDA to assist shared decision making|
79262753|NCT02108093|Procedure|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
79262754|NCT02108249|Device|Annex™ Adjacent Level System|
79262755|NCT02108327|Procedure|surgical blade|Using surgical blade all the time of surgery
79262756|NCT02108327|Procedure|electrocautery|Using electrocautery all the time except at skin incision
79262757|NCT02105129|Drug|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
79262758|NCT02105129|Drug|Placebo|Oral administration
79262759|NCT02111135|Biological|b-OPV|
79262760|NCT02111135|Biological|m-OPV2|
79262761|NCT02111135|Biological|m-IPV HD|
79262762|NCT02111135|Biological|t-IPV|
79262763|NCT02611778|Biological|ranibizumab|
79262764|NCT04867538|Other|no intervention|No intervention
79262765|NCT04867226|Drug|Colchicine 0.5 MG|participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .
79262766|NCT04867226|Drug|usual care treatment|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
79262767|NCT03045224|Device|PTA, balloon angioplasty, stent|
79398928|NCT04797312|Drug|Opioid Free Anaesthesia protocol|"The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated."
80020971|NCT04774406|Drug|olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib|All patients treated at least with 1 PARPi (alone or in combination)
80020972|NCT04773730|Procedure|Posterior transversus abdominus plane block|Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
80020973|NCT04773730|Procedure|Quadratus lumborum block type 2|Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
80020974|NCT04768400|Drug|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
80020975|NCT04754100|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
79262768|NCT04856852|Other|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
79262769|NCT04856852|Other|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
79262770|NCT04856774|Drug|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."
79262771|NCT04867148|Device|Inertial measurement unit sensor-based gait analysis system|Gait analysis was performed on 20-m long corridor to collect gait data on more than 23 strides. The gait protocol was performed with an IMU sensor-based gait analysis system (DynaStab™, JEIOS, South Korea) consisting of a shoe-type data logger (Smart Balance1 SB-1, JEIOS, South Korea) and a data acquisition system (DynaStab-Spotfire1, Tibco Spotfire 7.10). The shoe-type data logger included an IMU sensor (IMU-3000™, InvenSense, USA) that measured tri-axial acceleration (up to ± 6 g) and tri-axial angular 136 velocity (up to ± 500˚ s-1) along three orthogonal axes.12,16 The IMU sensors were installed in both shoe outsoles, and the data were transmitted wirelessly to a data acquisition system via Bluetooth®. Shoe sizes were adapted to each participant, with available sizes ranging from 225 mm to 280 mm. The local coordinate system for the IMU sensors included the 140 anteroposterior, mediolateral, and vertical directions.
79262772|NCT04866836|Combination Product|Radiotherapy|Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
79262773|NCT04810130|Other|Soccer Kicking|Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
79562110|NCT02639754|Behavioral|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
79562111|NCT02553733|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
79398929|NCT04797312|Drug|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
79398930|NCT04814862|Behavioral|3 validated questionnaires (ADHD-RS, SRS, BRIEF) for the diagnosis of neurodevelopmental disorders|Completion of three validated questionnaires for the diagnosis of neurodevelopmental disorders
79398931|NCT05080374|Other|Spinal Manipulation + exercise program|high-speed, low-amplitude spinal manipulation plus a trunk exercise program
79398932|NCT05080374|Other|Spinal manipulation + Kinesiotaping|high-speed, low-amplitude spinal manipulation plus elastic bandage (Kinesiotaping) application to the trunk area
79562112|NCT02553733|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
79724400|NCT04226443|Drug|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
79724401|NCT02776891|Drug|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
79724402|NCT02776813|Biological|ACTR087|
79724403|NCT02776813|Biological|rituximab|
79724404|NCT02776657|Other|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
79724405|NCT02776657|Device|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
79724406|NCT02776657|Procedure|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
79562113|NCT02552394|Drug|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
79858635|NCT06131957|Combination Product|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
79858636|NCT06131957|Drug|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
79858637|NCT06129721|Procedure|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
79858638|NCT06128733|Biological|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
79858639|NCT06128733|Biological|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
79858640|NCT06128733|Biological|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
79858641|NCT06128733|Biological|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
79858642|NCT06128733|Biological|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
79562114|NCT02462187|Drug|NVN1000 8% Gel|once and twice daily
80020976|NCT04752813|Drug|BPM31510|Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
79858643|NCT06128733|Biological|MenACYW conjugate vaccine|Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
79262774|NCT04810130|Other|Soccer Heading (Frontal)|Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
79858644|NCT06128733|Biological|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
79858645|NCT06128642|Device|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
79858646|NCT06128642|Device|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
79858647|NCT06127797|Behavioral|Questionnaire/Interview|Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
79875767|NCT05300555|Drug|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
79875768|NCT05300555|Drug|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
79875769|NCT04010669|Drug|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
79398933|NCT05080374|Other|spinal manipulation + respiratory exercise|high-speed, low-amplitude spinal manipulation plus a breathing exercise program for the diaphragmatic muscles
79562115|NCT02462187|Drug|NVN1000 16%|once daily
79724407|NCT02774551|Behavioral|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
80020977|NCT04752813|Other|Vitamin K1|Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg Intramuscularly prior to the beginning of each week of BPM31510 therapy.
79562116|NCT02462187|Drug|Vehicle|placebo comparator
80020978|NCT04752813|Drug|Temozolomide (TMZ)|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.
79562117|NCT02462187|Drug|NVN1000 24%|once daily
79724408|NCT02774317|Biological|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
79724409|NCT02774161|Other|Ultrasound Tomography|Undergo B-mode ultrasound imaging
79724410|NCT04936243|Behavioral|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
79724411|NCT04936243|Behavioral|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
79724412|NCT02774083|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
79724413|NCT02774083|Behavioral|Adler Program|Social and emotional group program
79724414|NCT04175821|Radiation|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
79562118|NCT02351869|Drug|Nitrous Oxide|
79562119|NCT02351869|Drug|Midazolam|
79562120|NCT02342535|Behavioral|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
79562121|NCT02330289|Behavioral|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
79262775|NCT04810130|Other|Soccer Heading (Oblique)|Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
79858648|NCT06126211|Device|Assessment|"The hand grip strength of each individuals was measured by the Electronic Camry Dynamometer (Model EH101, Zhongs-han Camry Electronic Co. Ltd. China: 90 kg capacity, 356 g weight) and Jamar Hydraulic Hand Grip Dynamometer (Model J00105, Lafayette Instrument Com-pany. USA: 90 kg capacity, 727 g weight). The assessments of the upper extremity were performed bilaterally.~Camry Electronic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Camry Electronic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left).~Jamar Hydraulic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Jamar Hydraulic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left)."
79858649|NCT06124014|Device|At-Home Stimulation|The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions.
79858650|NCT06123611|Behavioral|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
79858651|NCT06123481|Procedure|Core Decompression|Standard core decompression procedure is performed by drilling into the necrotic bone of the femoral head. A sham bone marrow aspiration involves advancing a needle to the iliac crest (no bone penetration, no bone marrow aspiration) through a small skin incision.
79724415|NCT05157997|Drug|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
79858652|NCT06123481|Procedure|Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate|This involves bone marrow aspiration, concentrating the bone marrow aspirate, and injecting 6 milliliters of bone marrow aspirate concentrate into the necrotic femoral head through an opening created by the core decompression.
79858653|NCT06122779|Drug|BMS-986435|Specified dose on specified days
79858654|NCT06122779|Other|Placebo|Specified dose on specified days
79262776|NCT04866446|Device|endotracheal intubation and laringeal mask airway insertion|endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
79262777|NCT04863482|Procedure|IOC|intra-operative cholangiography near-infrared fluorescence cholangiography
79262778|NCT04863326|Behavioral|Making Proud Choices|
79262779|NCT04863326|Behavioral|Business as usual|
79262780|NCT02441595|Behavioral|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
79262781|NCT02441595|Behavioral|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
79858655|NCT06122350|Behavioral|Earthquake preparedness training|Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
79875770|NCT04010669|Drug|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
79262782|NCT03044132|Other|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
79262783|NCT02441049|Behavioral|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
79562122|NCT02311582|Biological|MK-3475|-Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
79562123|NCT02311582|Device|MRI-guided laser ablation|
79724416|NCT00635245|Biological|figitumumab|
79724417|NCT00635245|Other|imaging biomarker analysis|
79724418|NCT00635245|Other|laboratory biomarker analysis|
80020979|NCT04752813|Radiation|Radiation|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
80020980|NCT04743635|Device|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
80020981|NCT04735367|Drug|palbociclib plus letrozole|palbociclib plus letrozole
79262784|NCT01453179|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
79262785|NCT01453179|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
79562124|NCT02311582|Procedure|Surgical resection/debulking|"Optional~Standard of care"
79562125|NCT02311582|Procedure|Biopsy|"If no surgical resection/debulking~Phase II patients only"
79562126|NCT02311582|Procedure|Blood draw for research purposes|"Phase II patients only~Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment"
79562127|NCT02311582|Procedure|Cervical lymph node fine needle aspiration|"Optional~Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure"
79724419|NCT00635245|Other|pharmacological study|
79724420|NCT00635245|Procedure|conventional surgery|
79724421|NCT00635245|Procedure|magnetic resonance spectroscopic imaging|
79724422|NCT00635245|Procedure|neoadjuvant therapy|
79262786|NCT04866212|Behavioral|Beery- Buktenica Developmental Test of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
79262787|NCT04866212|Behavioral|Jebsen Taylor Hand Function Test|Investigation of hand skills by Jebsen Taylor Hand Function Test
79262788|NCT04866212|Diagnostic Test|Participation and Environment Measure - Children and Youth|Investigation of participation by Participation and Environment Measure - Children and Youth
79262789|NCT04856384|Other|synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
79262790|NCT02437149|Behavioral|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
79398934|NCT04470882|Behavioral|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
79562128|NCT02237820|Drug|Dexamethasone|6 mg/day of Oral Dexamethasone
79262791|NCT02437149|Behavioral|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
79262792|NCT02437149|Behavioral|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
79262793|NCT04856306|Other|Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure|See previous descriptions
79262794|NCT04856306|Drug|Elagolix Oral Product|See group 3 description
79562129|NCT02237820|Drug|Prednisone|40 mg/day of Oral Prednisone
79562130|NCT02225704|Drug|Radium-223 and enzalutamide|
79262795|NCT02441205|Behavioral|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
79262796|NCT04863170|Procedure|orthognathic surgery|surgical intervention of the maxilla and / or mandible that includes orthodontic treatment before and after surgery
79398935|NCT04470882|Behavioral|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
79398936|NCT04470882|Behavioral|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
79398937|NCT05080140|Drug|Ezetimibe 10mg|Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
79562131|NCT02186678|Other|PET-CT|
79562132|NCT02160353|Drug|Abiraterone acetate, Prednisolone|
79262797|NCT02441127|Device|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
79303806|NCT03066687|Drug|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet [G-024] and one 5-mg tablet [G-025]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
79303807|NCT04880577|Drug|TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|The study is designed to add on TAF to anti-CD20 therapies
79303808|NCT04880577|Drug|Placebo|Placebo arm
79398938|NCT03142230|Other|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
79562133|NCT02152358|Drug|Aciclovir|Intravenous 15 mg/kg/d during 14 days
79562134|NCT02152358|Drug|Ganciclovir|intravenous 10 mg/kg/d for 14 days
79562135|NCT02152358|Drug|Placebo|
79562136|NCT02151019|Radiation|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
79562137|NCT02150408|Other|PET-CT|
79562138|NCT02120040|Other|evaluation of anxiety with psychosocial scales|
79562139|NCT01916148|Drug|18F-DOPA|18F-DOPA is a PET scan radiotracer.
79562140|NCT01855685|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
79562141|NCT01851018|Radiation|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
79562142|NCT01851018|Radiation|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
79562143|NCT01822444|Other|Biomarker analysis|
79562144|NCT01819064|Drug|Atropine|intravenous atropine affect on heart rate
79562145|NCT01817751|Drug|sorafenib tosylate|Given by mouth
79562146|NCT01817751|Drug|valproic acid|Given by mouth
79562147|NCT01817751|Drug|sildenafil citrate|Given by mouth
79562148|NCT01810861|Other|There is no intervention in this study|This is a non-interventional study.
79562149|NCT02744053|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
79562150|NCT02744053|Other|Laboratory Biomarker Analysis|Correlative studies
79262798|NCT02441127|Procedure|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
79262799|NCT03192033|Other|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
79562151|NCT02744053|Radiation|Scintimammography|Undergo MBI
79562152|NCT02744053|Drug|Technetium Tc-99m Sestamibi|Given via injection
79398939|NCT03142230|Other|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
79562153|NCT01725633|Behavioral|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
79562154|NCT01725633|Behavioral|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
79262800|NCT03192033|Device|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
79262801|NCT03192033|Device|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
79262802|NCT03192033|Other|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
79262803|NCT04863404|Other|Face mask with hybrid-hyrax|Face mask with hybrid-hyrax
79262804|NCT04863404|Other|Face mask with conventional bonded RME|Face mask with conventional bonded RME
79398940|NCT04413318|Device|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
79262805|NCT04380896|Other|Blood test|Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
79562155|NCT01725633|Other|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
79562156|NCT01725633|Other|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
79562157|NCT01706913|Other|Dermatology consult|
79858656|NCT06121921|Other|Perioperative multi-component intervention|"Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~Rubber ball squeezes (3 sets of 12 reps, per hand)~Bicep curls (3 sets of 12 reps)~Leg extensions (3 sets of 12 reps)~Chair rises (3 sets of 12 reps)~Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~Formal dietician review if MUST score ≥ 2~IV ferritin if LVEF <45% and serum ferritin <100ng/mL or ferritin 100-299ng/mL with TSAT <20%"
79262806|NCT04380896|Other|Standardised questionnaires|It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
79262807|NCT02436603|Behavioral|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
79262808|NCT02709369|Device|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
79262809|NCT02436525|Device|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
80020982|NCT04715113|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262810|NCT02436525|Device|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
79262811|NCT02436525|Device|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
79262812|NCT02613182|Drug|NEOD001|NEOD001
79303809|NCT04353921|Other|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
79562158|NCT01604122|Other|No drug|No drug.
79562159|NCT01604122|Other|No drug|No drug.
79858658|NCT06120218|Procedure|Emergent Stenting|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
79303810|NCT04280211|Other|Respiratory Assessment|Spirometric measurement
79398941|NCT04413318|Device|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
79562160|NCT01564056|Drug|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
79858659|NCT06119841|Procedure|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
79858660|NCT06119841|Procedure|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
79858661|NCT06118502|Behavioral|Switching to a different medication|Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
79858662|NCT06118502|Behavioral|Continued use of the same medication|Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
79858663|NCT06118502|Behavioral|Switching to a harm reduction tobacco product|Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
80020983|NCT04715113|Other|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262813|NCT06101056|Behavioral|Junior Enlisted Component|"Junior Enlisted Airmen (E4 and below) will complete 10 online modules designed to train them on recognizing SH and SA, healthy and unhealthy relationships, and situations that may increase risk for SH and SA. Participants will adopt and practice a lifestyle paradigm of select-detect-protect, in which service members select their personal rule to have only healthy (non-abusive) relationships with their peers and romantic partners, detect signs and situations that might threaten their rules, and protect their rules using communication, management, and avoidance skills. They will be instructed to adopt a zero-tolerance approach to SH and SA and will receive skills training related to communication and conflict resolution for healthy relationships, reduction of SH and SA perpetration, consent communication, reporting incidents of SH and SA, and bystander intervention. Participants who have experienced SH or SA are encouraged to use the Get Help Now feature to access support 24/7."
79303811|NCT04280211|Other|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
79562161|NCT01564056|Drug|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~Docetaxel 75 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)~Myocet® 60 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
79562162|NCT01549730|Procedure|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
79562163|NCT01349322|Radiation|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
79724423|NCT02776501|Drug|Coppertone (BAY987521)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: Y49-103)
79724424|NCT02776423|Procedure|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
79858664|NCT06117592|Other|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
79858665|NCT06116591|Biological|mPnC candidate|monovalent pneumococcal conjugate candidate
80020984|NCT04715113|Other|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
80020985|NCT04715113|Other|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
79303812|NCT04280211|Other|Balance Assessment|Postural stability
79303813|NCT02465957|Biological|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
79398942|NCT01390441|Biological|MK-8808|MK-8808 500 mg/m^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
79398943|NCT01390441|Biological|MabThera® (rituximab)|MabThera® 500 mg/m^2 or 1000 mg administered by IV on Day 1 and Day 15
79398944|NCT01390441|Drug|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
79398945|NCT01390441|Biological|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
79398946|NCT01390441|Drug|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
79562164|NCT01349322|Radiation|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
79262814|NCT06101056|Behavioral|Leadership Component|"Mid- and advanced-level leaders (E5 and above) will complete 10 online modules designed to train them to recognize forms of SH and SA, how to respond to an incident of SH or SA, and how to create a safe work environment free of SH and SA. Leaders will also adopt and practice the paradigm select-detect-protect. Leaders will select their personal rule to enforce a healthy work environment (free of SH and SA), detect signs and situations that might threaten their rule (e.g., displaying inappropriate pictures on the computer), and protect their rules using communication and management skills. Leaders will also be given background material on SH and SA in the military (e.g., extent of the problem, DoD definitions, and policies) and installation resources for reporting incidents. As with the Junior Enlisted component, Leaders who may have experienced SH or SA are encouraged to use our Get Help Now feature to access support 24/7."
79858666|NCT06116591|Biological|mPnC control|monovalent pneumococcal conjugate control
79562165|NCT01349322|Radiation|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
79858667|NCT06115044|Procedure|Intermittent diurnal nutrition|Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast
79562166|NCT01349322|Radiation|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
79562167|NCT01326832|Device|Primoris|Total hip arthroplasty with the new Primoris femoral component
79562168|NCT01284829|Other|FDG-PET scan|
79562169|NCT01222390|Device|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
79562170|NCT01182415|Procedure|Autologous stem cell transplant|Autologous stem cell transplant following high-dose chemotherapy
79562171|NCT01182415|Drug|High-dose chemotherapy|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
79562172|NCT01164150|Radiation|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
79562173|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
79562174|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
79562175|NCT00951535|Other|questionnaire administration|
79562176|NCT00951535|Procedure|quality-of-life assessment|
79562177|NCT00951535|Radiation|image-guided radiation therapy|
79724425|NCT02776579|Other|Girls-only resistance training|
79724426|NCT02778373|Dietary Supplement|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
79724427|NCT02778373|Dietary Supplement|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
79724428|NCT02778373|Other|Placebo: Water|
79724429|NCT02772835|Device|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
79724430|NCT02773147|Drug|Cyanocobalamin|
79562178|NCT00951535|Radiation|intensity-modulated radiation therapy|
79562179|NCT00951535|Radiation|radiation therapy treatment planning/simulation|
79562180|NCT00812669|Biological|pegfilgrastim|
79562181|NCT00812669|Biological|rituximab|
79562182|NCT00812669|Drug|cyclophosphamide|
79562183|NCT00812669|Drug|fludarabine phosphate|
79562184|NCT00812669|Genetic|cytogenetic analysis|
79562185|NCT00812669|Genetic|fluorescence in situ hybridization|
79562186|NCT00812669|Genetic|gene expression analysis|
79562187|NCT00812669|Genetic|mutation analysis|
79562188|NCT00812669|Genetic|protein expression analysis|
79562189|NCT00812669|Other|flow cytometry|
79562190|NCT00812669|Other|laboratory biomarker analysis|
79562191|NCT00802711|Radiation|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
79724431|NCT02773147|Drug|Folate|
79724432|NCT02773147|Drug|Pyridoxine|
79724433|NCT02773927|Drug|Metformin|Metformin in tablet presentation of 500 mg
79724434|NCT02773927|Dietary Supplement|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
79724435|NCT02773927|Other|Placebo of agave inulin|Calcinated magnesia powder
79724436|NCT02773927|Other|Metformin placebo|Calcinated magnesia tablet
79724437|NCT02773771|Dietary Supplement|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive >3g of HMB/ day.
79724438|NCT02773771|Dietary Supplement|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
79858668|NCT06115044|Procedure|Continuous|Calculated daily nutritional requirement given over 24 hours
79858669|NCT06113939|Device|airway clearance|mechanical suctioning of airway secretions
79858670|NCT06113809|Drug|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
79858671|NCT06113809|Drug|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
79562192|NCT00802711|Radiation|brachytherapy|Given twice a day for 10 fractions
79562193|NCT00797719|Other|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
79562194|NCT00160979|Procedure|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
79562195|NCT03903315|Other|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
79562196|NCT03895541|Diagnostic Test|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
79858672|NCT06113614|Procedure|Physiotherapy|All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
79858673|NCT06113614|Device|Photobiomodulation|The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
79858674|NCT06113614|Device|Simulation of photobiomodulation|The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
79562197|NCT03893253|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
79562198|NCT03893253|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
79858675|NCT06111781|Drug|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
79858676|NCT06111781|Radiation|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
79858677|NCT06111547|Drug|TAK-279|TAK-279 oral tablet.
79724439|NCT02773771|Dietary Supplement|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
79858678|NCT06111547|Drug|Placebo|TAK-279 30 mg or 60 mg (2*30mg) matching placebo tablet.
79724440|NCT02773615|Procedure|Cardiac computed tomography|Non-invasive CT scan of the heart
79262815|NCT06101056|Behavioral|Social Marketing Campaign|"All participating Airmen (including Junior Enlisted Airmen and Leaders) will be exposed to X-CoRe's social marketing campaign, which includes posters, flyers, postcards, and digital content for social media. Messages are designed to increase awareness of consent and foster Wing-wide norms that are supportive of healthy relationships. Resources for Service members to receive support if they have experienced SH or SA will also be provided through the social marketing materials. Social marketing materials, such as posters, will be distributed at hot spots for SA (e.g., dorms)."
79724441|NCT04175275|Other|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
79562199|NCT03889314|Drug|Rosuvastatin 20mg|Statin Therapy
79724442|NCT02773693|Behavioral|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
79724443|NCT02773693|Behavioral|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
79724444|NCT02773693|Behavioral|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
79262816|NCT06101017|Diagnostic Test|Optical Coherence Tomography|Non-invasive imaging test that use light waves to take cross-section pictures of the eye.
79262817|NCT06101004|Device|CVA-Flow|CVA-FLOW Software Device is indicated for the detection of Stroke and LVO in patients with suspected stroke.
79262818|NCT06100926|Device|software|virtual reality scene
79262819|NCT06100900|Drug|BCX10013|Four dose levels may be tested in this study.
79262820|NCT06100848|Diagnostic Test|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
79562200|NCT03889314|Other|Placebo|Placebo
79562201|NCT03884166|Diagnostic Test|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
79562202|NCT03884153|Device|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
79562203|NCT03877575|Other|No specific intervention. Collection of clinical data|
79724445|NCT02773459|Drug|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
79858679|NCT06111313|Radiation|FTLEAD|In focal therapy lattice extreme ablative (FTLEAD) RT, the multiparametric-MRI (mpMRI) defined gross tumor volume (GTV) will receive 16-20 Gy in a single fraction of RT to the targeted area which is the tumor within the prostate, with or without uSTADT.
79562204|NCT03877211|Other|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
79562205|NCT03877211|Other|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
79262821|NCT06100848|Diagnostic Test|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
79262822|NCT06100809|Behavioral|Personalized coaching|Personalized fatigue mitigation coaching.
79262823|NCT06100809|Behavioral|Nutrition handout|Nutrition handout
79562206|NCT03877211|Other|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
79858680|NCT06111313|Drug|Ultra-Short-Term Androgen Deprivation Therapy with Relugolix|Ultra-Short-Term Androgen Deprivation Therapy (uSTADT) is hormone therapy that includes Relugolix. Patients will receive a loading dose of uSTADT for a total duration 4 weeks (28 days), with oral LHRH antagonist relugolix administered daily starting 2 weeks prior to LEAD RT and continuing until 2 weeks afterwards as per Study Calendar. Patients randomized to uSTADT will receive a loading dose of 360 mg of oral relugolix on Day 14 followed by 120 mg of oral relugolix daily from Day 13 to Day 14. Patients will be instructed to take relugolix orally once daily at approximately the same time each day. Patients may take relugolix with or without food and should swallow tablets whole and not crush or chew tablets.
79858681|NCT06111313|Radiation|HypoLEAD|In Hypofractionated LEAD (HypoLEAD), the multiparametric-MRI (mpMRI) defined GTV will receive 12-16 Gy in a single fraction on the first day of treatment, with or without uSTADT. Four weeks after LEAD RT, patients will begin whole prostate moderately hypoLEAD (67.5 Gy in 25 fractions) with pelvic nodal irradiation and further ADT at the discretion of the treating physician.
79858682|NCT06111313|Drug|ADT Standard of Care|Participants will receive ADT as per standard of care (SOC).
79858683|NCT06109155|Drug|Tranexamic acid|tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
79858684|NCT06108050|Drug|JZP898|Investigational drug monotherapy
79858685|NCT06108050|Drug|Pembrolizumab|Approved anti-PD1 antibody
79858686|NCT06107413|Drug|ABBV-400|Intravenous (IV) Infusion
80020986|NCT04713657|Other|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
79562207|NCT03877211|Other|Tonal audiometry|Tonal audiometry will be performed with headphones
79262824|NCT06100796|Combination Product|Pembrolizumab|Immune check inhibitor with OHA
79262825|NCT06100783|Device|Depot-medroxy Progesterone Acetate Injectable Contraceptives|Depot-medroxy progesterone acetate injectable contraceptives
79262826|NCT06100757|Device|Micra Transcatheter Pacing System (TPS°|Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
79262827|NCT06100757|Device|Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR|Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
79262828|NCT06100731|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
79262829|NCT06100679|Behavioral|Responsible Engaged and Loving (REAL) Fathers Initiative|REAL Fathers is a multilevel norms-shifting intervention among: young fathers (ages 16-25 whose oldest child is under the age of 3); couple dyads (fathers and wives); mentoring dyads and groups; and communities. Respected men in the community are identified by participating young fathers, their partners and community members to become mentors. Mentors participate in a training and mentor young fathers through home and group sessions on conflict resolution, non-violent discipline, family planning, and couple communication. Mentoring is supplemented with a monthly poster campaign designed to reinforce messages from the home and group mentoring sessions and a community celebration. REAL Fathers aims to build positive partnerships and parenting practices among young fathers to: 1) reduce incidence of intimate partner violence; 2) reduce harsh physical punishment of children; 3) improve early childhood development; 4) decrease unmet need for family planning.
79562208|NCT03877211|Other|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
79562209|NCT03874312|Diagnostic Test|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
79562210|NCT03873792|Diagnostic Test|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
79724446|NCT02773303|Device|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
79724447|NCT02773303|Device|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
79724448|NCT02773225|Drug|Eltrombopag|"CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> partial or complete remission Eltrombopag and slow tapering of CSA~12 month after therapy start --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
79262830|NCT06100666|Behavioral|Observational Tests|The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
79562211|NCT03873194|Other|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
79262831|NCT06100627|Drug|AP301|Orally administered
79398947|NCT01390441|Drug|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
79562212|NCT03873194|Other|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
79858687|NCT06107413|Drug|Bevacizumab|IV Infusion
79858688|NCT06107413|Drug|Folinic Acid|IV Infusion
79262832|NCT06100601|Behavioral|ANS regulation therapy|innovative intervention for functional dysphonia
80020987|NCT04713657|Other|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
79262833|NCT06100601|Behavioral|conventional voice therapy (CVT)|conventional voice therapy traditionally provided for functional dysphonia
79262834|NCT06100601|Behavioral|ANS regulation therapy + CVT|combination of ANS regulation therapy and CVT
79262835|NCT06100562|Behavioral|Adapted Dance Program|"Participants will attend a 2x/weekly adaptive dance session for 10 weeks. If participants miss a class due to illness or an unexpected event (loss of transportation, family emergency/need) they will receive a video of the content missed and can complete the session at home.~Each class will start with a 10 min warm-up that will include stretching and motor games.~Learn a section of choreography every session using action-based intervention for 30 minutes.~Break for 5 min.~Improvisation part of class for 10 min.~Cool-down for 5 min."
79262836|NCT06100536|Behavioral|Music-with-movement|The intervention group participants will receive 12 weekly music-with-movement interventions facilitated by trained staff in a community centre or a residential care home. The duration lasts 30 minutes to one hour. It can be carried out individually or with up to six persons in a group. The intervention will be supported by the standalone music-with-movement system.
79262837|NCT06100523|Behavioral|Visioconsulation|Meeting by videoconsultation with professionals adapted to the exposures highlighted by the questionnaires for patients who responded on the dedicated application (Arm A)
79398948|NCT01390441|Drug|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
79398949|NCT03142386|Other|Osteopathic manipulative treatment|
79398950|NCT03142386|Other|Physiotherapy|
79262838|NCT06100523|Behavioral|self-assessment questionnaire|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
79562213|NCT03870880|Drug|Risperidone ISM 75 mg|Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
79562214|NCT03870880|Drug|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
79562215|NCT03863782|Other|No intervention|No specific intervention. Collection of clinical data
79562216|NCT03862261|Other|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~Improvement of diagnosis capacities and their integration in all levels of care and all services."
79562217|NCT03861377|Drug|Remifentanil R2|0,7 microg/kg
79562218|NCT03861377|Drug|Remifentanil R4|1,1 microg/kg
79562219|NCT03861377|Drug|Remifentanil R8|1,7 microg/kg
79562220|NCT03858816|Other|Mixture probiotics|The mixture probiotics capsule
79562221|NCT03858816|Other|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
79858689|NCT06107413|Drug|Fluorouracil|IV Infusion
79262839|NCT06100523|Biological|hair sampling|hair sampling from the 2 members of the couple
79398951|NCT03142464|Other|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
79398952|NCT04280640|Other|Blood Draw|A blood sample will be collected once, prior to treatment.
79858690|NCT06107413|Drug|Irinotecan|IV Infusion
79858691|NCT06106945|Drug|AZD0305|AZD0305
79398953|NCT03142542|Drug|ZYDENA TAB.75mg(Udenafil 75mg)|ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
79398954|NCT03142542|Drug|Placebo Oral Tablet|Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
79262840|NCT06100523|Behavioral|self-assessment questionnaire on dedicated application|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
79262841|NCT06100523|Behavioral|Specialized follow-up|proactive healthcare pathway : active support of corrective measures implemented with couples by the platform, with the help of the application
79562222|NCT03858010|Diagnostic Test|Wheeze and me questionnaire|validation of questionnaire assessing disease control and quality of life in preschool children with recurrent wheeze
79562223|NCT03857893|Device|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
79562224|NCT03857893|Drug|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
79562225|NCT03854461|Behavioral|Personalised dietary advice and educational material|As within arm/group description
79562226|NCT03854461|Behavioral|Educational material|As within arm/group description
79562227|NCT03844100|Drug|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
79562228|NCT03836144|Dietary Supplement|Potassium citrate|
80020988|NCT04713657|Procedure|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in ToF/PS and is non-invasive.
79562229|NCT03817892|Other|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
79562230|NCT03817892|Other|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
79562231|NCT03811574|Drug|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
79858692|NCT06106919|Other|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
79858693|NCT06106477|Behavioral|Intermittent Fasting|"Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~An approximately fourteen-hour nightly fasting period that is followed by~An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM)."
79858694|NCT06105775|Dietary Supplement|Nitrate-enriched beetroot extract juice|Starting from the 16th week of gestation, participants will consume a daily 70 ml of nitrate-enriched beetroot extract (Beet-It Sport®, James White Drinks Co, UK) for 22 weeks or until delivery, whichever comes first. The extract contains approximately 6.5mmol of nitrate (~400mg). Participants will also continue with standard pre-eclampsia prophylaxis (acetylsalicylic acid 100mg nightly until the 36th week and calcium carbonate 1000mg daily) and their usual antihypertensive treatment.
80020989|NCT04713657|Procedure|Cardiac MRI|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
80020990|NCT04713657|Drug|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
80020991|NCT04713657|Drug|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
79262842|NCT06100523|Behavioral|self-assessment questionnaire for follow-up|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
79398955|NCT04133688|Device|ASC|mobile app
79398956|NCT03025867|Drug|Niraparib|
79398957|NCT04645290|Behavioral|"Intervention group: Educational Intervention KARER"|"Multicomponent and interdisciplinary intervention on the care ability and burden of family caregivers. It consists of:~Virtual componet~Module 0: the introduction~Module 1: called Identifying my role as a caregiver~Module 2: called Strategies to strengthen care~Module 3: called Strengthening my caring skills~Face-to-face componed - Two seasons of 4 hours each~Simulation component~- One season of practices abilities of 4 hours."
79398958|NCT02175576|Device|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
79262843|NCT06100510|Drug|Aspirin 325mg|Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.
79262844|NCT06100458|Other|Skin and leakage protocol|The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
79262845|NCT06100445|Behavioral|Semi structured interviews|Gaining qualitative data
79562232|NCT03811574|Drug|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
79562233|NCT03796416|Drug|Misoprostol|used at a rate of 25 mcg Q4hours for cervical ripening.
79562234|NCT03796221|Behavioral|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
79562235|NCT03796221|Behavioral|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
79562236|NCT03795558|Drug|Etelcalcetide|Up-Titration
79562237|NCT03790098|Behavioral|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
79562238|NCT03785457|Other|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
79562239|NCT03785457|Other|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
79562242|NCT03782142|Drug|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
79562243|NCT03782142|Drug|Rilpivirine|NNRTI
79562244|NCT03782142|Drug|Prezcobix|PI
79562245|NCT03782142|Drug|Dolutegravir|II
80020992|NCT04713657|Procedure|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
79262846|NCT06100406|Other|Biofield tuning|Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
79262847|NCT06100380|Other|Survey|Questionnaire
79262848|NCT06100354|Other|Answering preference|Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis
79562246|NCT03776695|Biological|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
79562247|NCT03776695|Other|Placebo|0.9% Saline
79562248|NCT03897920|Other|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
79562249|NCT03770299|Biological|Nivolumab|Specified dose on specified days
79562250|NCT03770299|Drug|Vinorelbine|Specified dose on specified days
79562251|NCT03770299|Drug|Gemcitabine|Specified dose on specified days
79562252|NCT03770299|Drug|Docetaxel|Specified dose on specified days
79562253|NCT03770299|Drug|Pemetrexed|Specified dose on specified days
79562254|NCT03770299|Drug|Cisplatin|Specified dose on specified days
79262849|NCT06100315|Drug|Nalbuphine|bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
79262850|NCT06100302|Other|no-intervention|no-intervention
79562255|NCT03770299|Drug|Carboplatin|Specified dose on specified days
79562256|NCT03770299|Drug|Paclitaxel|Specified dose on specified days
79562257|NCT03770299|Other|Observation|Observation by the investigator
79562258|NCT03760835|Drug|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
79562259|NCT03760835|Drug|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
79562260|NCT03759496|Biological|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
79562261|NCT03759184|Drug|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
79562262|NCT03759184|Drug|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
79562263|NCT03759184|Biological|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
79562264|NCT03747640|Device|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
79262851|NCT06100263|Other|Individualized exercise program|guided exercise program for 12 weeks
79262852|NCT06100263|Other|Control Arm|American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided
79262853|NCT06100159|Device|Tympanostomy tube insertion|Ventilation tube insertion in the tympanic membrane
79262854|NCT06100133|Dietary Supplement|Ketone ester|Up to 100g ketone ester daily for 56 days
79262855|NCT06100107|Other|Mirror Therapy exercise|Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
79262856|NCT06100094|Other|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~What were your expectations/state of mind before the group?~How would you describe your experience overall?~If you had to describe the group how would you do it?~Between two group sessions, how did it go for you?~What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
79262857|NCT06100081|Diagnostic Test|Detection of lesions using fluorescence molecular imaging|Using a fluorescence camera, lesions will be detected and biopsies will be taken to try and find cancer of unknown primary
79262858|NCT06100055|Device|Rectal Irrigation|"Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation."
79562265|NCT03747640|Behavioral|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
79724449|NCT02773225|Drug|Placebo (for Eltrombopag)|"CSA + Placebo, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --> dose escalation~12 month after start of eltrombopag --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
79724450|NCT02773381|Drug|semaglutide|Oral administration once-daily.
79724451|NCT02773381|Drug|placebo|Oral administration once-daily.
79724452|NCT04818229|Drug|CBP-307|CBP-307 capsules oral administration.
79724453|NCT04818229|Drug|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
79724454|NCT04818229|Drug|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
79724455|NCT04818229|Drug|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
79724456|NCT02772991|Other|troponin measurement|Cardiac catheterization (for patients with >50% lesions) or discharge or in patients with intermediate risk.
79724457|NCT02773069|Behavioral|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
79858695|NCT06105775|Dietary Supplement|Placebo juice|Starting from the 16th week of gestation and continuing for either 22 weeks (154 days) or until delivery, participants will consume a daily 70ml of placebo. This is designed to mimic the appearance and taste of the beetroot extract and will be bottled identically. Concurrently, participants will continue their standard pre-eclampsia prophylaxis, which includes acetylsalicylic acid 100mg nightly until the 36th week of gestation and calcium carbonate 1000mg daily until delivery, alongside their regular antihypertensive treatment.
80020993|NCT04713657|Other|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
79262859|NCT06100029|Drug|The modified GGLM decoction|"GGLM decoction, originally documented in the classic Chinese medical book Shang Han Lun (Treatise on Febrile Diseases), is a notable herbal formula traditionally used to calm the mind and alleviate insomnia. The modified GGLM decoction is built upon the original four herbs (Gui Zhi [Ramulus Cinnamomi], Gan Cao [Glycyrrhizae Radix et Rhizoma], Long Gu [Os Draconis], Mu Li [Ostreae Concha]) and includes targeted Chinese herbs. As soothing the mind and nourishing yin to restrain yang is the core TCM treatment principle for delirium in ICU patients, we chose targeted herbs, including Ye Jiao Teng [Fallopia multiflora], He Huan Pi [silktree (Albizia) bark], Suan Zao Ren [Ziziphi Spinosae Semen], Shi Chang Pu [Acori Tatarinowii Rhizoma], Yuan Zhi [Polygalae Radix], and Jue Ming Zi [Cassiae Semen]. The modified GGLM decoction will all be purchased by Chongqing Traditional Chinese Medicine Hospital and prepared by the Pharmacy Department, with each dose amounting to 200 g."
79398959|NCT02175576|Device|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
79398960|NCT01412879|Biological|rituximab|Given IV
79398961|NCT01412879|Drug|bendamustine hydrochloride|Given IV
79398962|NCT01412879|Drug|cyclophosphamide|Given IV
79398963|NCT01412879|Drug|cytarabine|Given IV
79398964|NCT01412879|Drug|dexamethasone|Given PO or IV
79398965|NCT01412879|Drug|doxorubicin hydrochloride|Given IV
79398966|NCT01412879|Drug|leucovorin calcium|Given PO or IV
79398967|NCT01412879|Drug|methotrexate|Given IV
79398968|NCT01412879|Drug|vincristine sulfate|Given IV
79262860|NCT06100029|Behavioral|A2F bundle|A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
79262861|NCT06099990|Drug|dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets|dalpiciclib+ abiraterone+ prednisone
79262862|NCT06099990|Drug|placebo; abiraterone acetate tablets; prednisone tablets|placebo+abirarerone+prenisone
79262863|NCT06099951|Drug|Serplulimab + FOLFOXIRI|Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
79724458|NCT02772523|Other|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
79724459|NCT04771741|Drug|Acetominophen|1,000 mg every 6 hours
79858696|NCT06105723|Behavioral|Pathway to Healthy Aging care|The ICOPE-based personalized care planning comprises two home visits. In 1st visit, a comprehensive assessment proposed by the WHO-ICOPE model is conducted to identify eight possible health problems including malnutrition, reduced physical fitness, fall risk, cognitive decline, insomnia, pain, psychological distress and social loneliness. After health problem identification, each participant receives a personalized care prescription. 2nd visit adopts a goal-oriented empowerment 3-step cycle to personalize the care planning: 1) communicating assessment results to increase healthy self-awareness; 2) supporting setting person-directed goals to address health problems; 3) identifying health actions and personalizing goal setting to participants' contexts. The 12-week healthy aging empowerment comprises three core activities for healthy aging promotion, including interactive health education, health message broadcasts, and three case conferences for goal monitoring and health counseling.
79262864|NCT06099951|Radiation|Radiation therapy|Radiation therapy
79262865|NCT06099938|Drug|sufentanil, ropivacaine|The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
79262866|NCT06099925|Drug|Hetrombopag|All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy
79262867|NCT06099899|Other|interview|conduct in-depth interviews
79262868|NCT06099873|Drug|ZX-7101A|Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
79562266|NCT03747640|Device|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
79562267|NCT03747640|Behavioral|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
79724460|NCT04771741|Drug|Toradol|10 mg every 6 hours, days 0-3
79724461|NCT04771741|Drug|Meloxicam|15 mg once daily, beginning post-op day 4
79724462|NCT04771741|Drug|Cyclobenzaprine|10 mg every 8 hours
79262869|NCT06099873|Drug|Placebo|Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
79262870|NCT06099860|Other|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
79262871|NCT06099860|Other|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
79262872|NCT06099860|Other|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
79262873|NCT06099847|Device|Sham TENS Stimulation|Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.
79262874|NCT06099847|Device|Sacral TENS Stimulation|Sacral TENS stimulation have been applied to directly the skin of sacral area.
79398969|NCT01431079|Behavioral|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
79398970|NCT03143010|Drug|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
79398971|NCT03143010|Drug|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
79724463|NCT04771741|Drug|Lyrica|75 mg every 12 hours
79724464|NCT02772445|Behavioral|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
79724465|NCT02772601|Drug|Caffeine|
79398972|NCT03143010|Drug|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
79724466|NCT02772601|Drug|Warfarin|
79724467|NCT02772601|Drug|Omeprazole|
79724468|NCT02772601|Drug|Metoprolol|
79262875|NCT06099808|Other|Audit and Feedback Emails|Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on >50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
79262876|NCT06099808|Other|Patient Specific Targets|Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
79562268|NCT03736876|Behavioral|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
79262877|NCT06099808|Other|Educational Resources|Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
79262878|NCT06099795|Device|eBAM Cov Testing|Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
79262879|NCT06099743|Behavioral|Psychosocial intervention|Intervention manual and six one-on-one coaching sessions.
79562269|NCT03736603|Behavioral|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~Pathway Implementation Toolkit~Local Multidisciplinary Champions~Audit and Feedback~Educational Seminars/Webinars~Practice Facilitation"
79562270|NCT03736603|Behavioral|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~Pathway Implementation Toolkit~Local Multidisciplinary Champions~Audit and Feedback~Educational Seminars/Webinars~Practice Facilitation~Mobile App"
79562271|NCT03727750|Drug|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
79562273|NCT03719417|Procedure|Unicompartmental Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery.
79562274|NCT03719417|Procedure|Extensive Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
79562275|NCT03719170|Behavioral|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
79562276|NCT03718052|Procedure|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
79562277|NCT03718052|Procedure|Conventional Care|Conventional care according to the 2015 European guidelines.
79562278|NCT03717428|Device|Daily Weighing Group|The Experimental group will weigh themselves everyday
79562279|NCT03717428|Device|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
79562280|NCT03715829|Drug|PF-06651600|Induction dose 1. Oral tablet taken QD
79562281|NCT03715829|Drug|PF-06651600|Induction dose 2. Oral tablet taken QD
79262880|NCT06099743|Other|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) as needed, upon request from the patient, caregiver, or clinician.
79262881|NCT06099717|Device|Dual-cantilevered implant bridge|A 3-unit supported by one implant in the middle
79262882|NCT06099717|Device|3-unit iFDP|3-unit fixed dental prosthesis supported by two implants
79262883|NCT06099626|Other|Different types of disease|Groups were observed according to disease type
79262884|NCT06099600|Procedure|Reconstructive surgery of the anterior cruciate ligament|surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
79262885|NCT06099587|Diagnostic Test|high-resolution diffusion MRI|The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
79262886|NCT06099561|Behavioral|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
79262887|NCT06099548|Device|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
79262888|NCT06099535|Drug|LNK01001 Dose A|Capsules taken orally
79724469|NCT02772601|Drug|Midazolam|
79262889|NCT06099535|Drug|LNK01001 Dose B|Capsules taken orally
79262890|NCT06099535|Drug|placebo|Capsules taken orally
79262891|NCT06099483|Other|Action observation and motor imagery|EEG recording was taken while watching a 10-minute video recording of specified breathing exercises and imagining the exercises.
79262892|NCT06099483|Other|Active breathing exercise|EEG recording was taken while the physiotherapist performed active breathing exercises for 10 minutes.
79262893|NCT06099483|Other|Control group|EEG recording was taken while resting with eyes closed for 10 minutes.
79262894|NCT06099470|Other|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
79262895|NCT06099470|Other|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
79398973|NCT03143010|Drug|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
79398974|NCT03142776|Procedure|periodontal debridement|
79398975|NCT03142776|Procedure|photodynamic therapy|
79262896|NCT06099470|Other|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
79262897|NCT06099431|Procedure|Mandibular marginal resection and reconstruction|Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.
79262898|NCT06099431|Device|mandibular osteosynthesis a 2.3mm reconstruction bone plate|a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
79262899|NCT06099418|Biological|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
79262900|NCT06099418|Drug|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
79262901|NCT06099418|Drug|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
79262902|NCT06099405|Behavioral|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
79262903|NCT06099405|Behavioral|Traditional yoga|Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
79398976|NCT03142776|Drug|systemic clarithromycin|
79398977|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
79858697|NCT06105008|Drug|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
79858698|NCT06105008|Drug|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
79262904|NCT06099392|Device|digital stimulators (SNM-FDC01, Ningbo MaidaMedical Device, Inc, Ningbo, China)|TEA at Zusanli(ST 36) 45 min when drinking Polyethylene Glycol Electrolytes Powder
79858699|NCT06104917|Drug|High Dose Maolactin|Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
80020994|NCT04712110|Biological|TAK-019|TAK-019 intramuscular injection
79262905|NCT06099379|Drug|∆9-tetrahydrocannabinol|Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
79262906|NCT06099366|Drug|induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate|vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
79262907|NCT06099366|Drug|Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
79262908|NCT06099366|Drug|Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
79262909|NCT06099366|Drug|Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
79398978|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
79398979|NCT03142698|Procedure|Quantification of hepatic steatosis|Quantification of hepatic steatosis (histology, and in MRI)
79398980|NCT05079438|Drug|Dendrobium Huoshanense Suppository|1.7g rectal administration per day for 5 weeks
79398981|NCT04053127|Device|RAVANS|Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
79398982|NCT03140826|Drug|meropenem|Antibiotics to treat infections.
79562282|NCT03715829|Drug|PF-06651600|Maintenance dose A. Oral tablet taken QD
79562283|NCT03715829|Drug|PF-06651600|Maintenance Dose B. Oral tablet taken QD
79858700|NCT06104917|Drug|Low Dose Maolactin|Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
80020995|NCT04712110|Biological|Placebo|Placebo intramuscular injection
79262910|NCT06099366|Drug|Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
79398983|NCT01409707|Behavioral|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
79398984|NCT01409707|Behavioral|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
79398985|NCT01409707|Behavioral|Healthy lifestyles sessions|
79398986|NCT05079048|Other|PEEK retentive elements|received implant-supported mandibular overdenture retained by PEEK retentive element and housings
79398987|NCT04477278|Behavioral|Mindfulness Meditation|The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
79562284|NCT03715829|Drug|PF-06651600|Maintenance Dose C. Oral tablet taken QD
79858701|NCT06104917|Drug|Maltodextrin|Once daily dose of 2 capsules
79562285|NCT03715829|Drug|placebo|placebo
79858702|NCT06101823|Biological|OpSCF|Monoclonal Antibody
80020996|NCT04706546|Other|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
80020997|NCT04706546|Other|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262911|NCT06099366|Drug|Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
79562286|NCT03715829|Drug|PF06700841|Oral tablet taken QD
79858703|NCT06101823|Biological|Placebo|Formulation buffer without active agent
79858704|NCT06101823|Biological|OpSCF (Open Label Extension)|Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
79724470|NCT02772601|Drug|Risankizumab|
80020998|NCT04704440|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262912|NCT06099366|Drug|Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
79262913|NCT06099366|Drug|Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
79262914|NCT06099340|Other|muscle-strengthening program|a muscle-strengthening program applied to the ankle muscles (triceps surae and dorsal flexors) in physiotherapy, as a complement to conventional rehabilitation
79562287|NCT03715829|Device|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
79724471|NCT02772055|Other|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
79262915|NCT06099314|Drug|Fruquintinib+PD-1 inhibitors|Third-line treatment with fruquintinib combined with PD-1 inhibitors. Fruquintinib: 5mg,Oral once daily,2 weeks on/1 week off,Q3W； PD-1 inhibitor：for example, Sintilimab,iv,200mg, Q3W.
79262916|NCT06099314|Drug|Fruquintinib+TAS-102|Fourth-line treatment with fruquintinib combined with TAS-102 . Fruquintinib: 3-5mg(Depending on the patient's physical condition), Oral once daily,3 weeks on/1 week off,Q4W； TAS-102:orally, 35mg/m2 twice daily (maximum dose 80mg in a single dose) for days 1-5, repeated every 14 days.
79562288|NCT03712254|Drug|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
79724472|NCT02772055|Other|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
79724473|NCT02772133|Procedure|Primary PCI|
79724474|NCT02772211|Drug|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
79724475|NCT02772211|Drug|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
79858705|NCT06101095|Drug|Dupilumab|Subcutaneous injection (SC) as per protocol
79398988|NCT04477278|Behavioral|History of Osteopathy|The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
79858706|NCT06101095|Drug|Placebo|SC injection as per protocol
79858707|NCT06101030|Device|Signal On|InSee monitor patient signals are on.
79398989|NCT05078814|Other|Observational research|Observational research
79398990|NCT01389973|Drug|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
79398991|NCT01389973|Drug|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
79858708|NCT06100913|Biological|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
79858709|NCT06100471|Other|Observational study|Observational study in different tissues in identifing new genetic markers related to endometriosis disease
80020999|NCT04704440|Other|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
80021000|NCT04704440|Other|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
80021001|NCT04704440|Other|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262918|NCT06099262|Behavioral|GenPMTO|GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
79262919|NCT06099249|Device|ASUS ECG App|The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
79262920|NCT06099210|Diagnostic Test|Glasgow coma scale|Closed tach brain injury due to external force was included according to the GCS score
79262921|NCT06099197|Behavioral|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
79262922|NCT06099197|Behavioral|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
79262923|NCT06099158|Other|HeartLogic|HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
79262924|NCT06099145|Device|Hephaï|Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
79262925|NCT06099132|Diagnostic Test|Electromyographic measurements|HD and bipolar EMG were assessed from gastrocnemius medialis (GM), soleus (SO) and tibialis anterior (TA) at seated position, ankle at 0°, during isometric submaximal effort and maximal effort, knee flexed (90°) and knee extended (0°)
79562289|NCT03712176|Behavioral|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
79562290|NCT03711175|Procedure|Subscapularis repair|Utilizing fiberwire, high tensile strength suture
79262926|NCT06099119|Drug|creon 35.000 Ph.U (R)|Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.
79262927|NCT06099119|Other|Best Standarard of Care|Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
79262928|NCT06099106|Device|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
79262929|NCT06099093|Drug|18F-DCFPyl|Fluorine-labeled small molecule, via intravenous infusion per protocol.
79262930|NCT06099067|Drug|Canagliflozin|Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
79262931|NCT06099067|Drug|DPP4 inhibitor|DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
79875771|NCT04010591|Device|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
80021002|NCT04697875|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262932|NCT06099067|Drug|Liraglutide|Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
79262933|NCT06099067|Drug|Saxagliptin|Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
79262934|NCT06099067|Drug|2nd generation Sulfonylurea|2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
79262935|NCT06099054|Device|Pigtail catheter|Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
79724476|NCT02772211|Drug|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
80021003|NCT04697875|Other|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
79262936|NCT06099054|Device|Intercostal tube|Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
79562291|NCT03711175|Device|Shoulder implant|Reverse shoulder arthroplasty device
80021004|NCT04697862|Other|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
79262937|NCT06099028|Other|no intervention|no intervention
79262938|NCT06099015|Device|Cera™ Vascular Plug System|The Cera™ Vascular Plug System is composed of Cera™ Vascular Plug and its accessory Introducer Kit. The Cera™ Vascular Plug is a self-expandable, cylindrical Ni-Ti wire mesh device.
79262939|NCT06098989|Procedure|Radio frequency ablation|Radio frequency ablation
79262940|NCT06098976|Device|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
79858710|NCT06099288|Behavioral|Home-Based Video and Motivational Interviewing Intervention|The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.
79262941|NCT06098976|Device|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
79262942|NCT06098963|Device|sacral neuromodulation|sacra neuromodulator implantation outcomes
80021005|NCT04697862|Other|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
80021006|NCT04696029|Drug|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
79262943|NCT06098950|Other|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
79262944|NCT06098950|Other|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
79262945|NCT06098950|Other|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
79262946|NCT06098950|Other|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
79262947|NCT06098950|Other|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
79398992|NCT01389973|Drug|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
79262948|NCT06098937|Device|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
79262949|NCT06098937|Device|Total1 for Astigmatism|Total1 for Astigmatism
79262950|NCT06098937|Device|Precision1 for Astigmatism|Precision1 for Astigmatism
79262951|NCT06098937|Device|MyDay Toric|MyDay Toric
79262952|NCT06098898|Drug|NK510|NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles.
79398993|NCT01389973|Drug|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
79398994|NCT03506568|Device|Devers Drop Device (D3) app|A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
79562292|NCT03704441|Drug|Bupivacaine|bupivacaine dose
79562293|NCT03678259|Drug|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
80021007|NCT04653597|Procedure|Close monitoring|surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS>8 or responds adequately to a simple order
80021008|NCT04653597|Procedure|Endotracheal intubation|invasive airway management in order to avoid risk of pulmonary aspiration
80021009|NCT04652544|Drug|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild & Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
80021010|NCT04652544|Other|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
80021011|NCT04642508|Procedure|Prepectoral reconstruction|Immediate prepectoral breast reconstruction in women requiring a mastectomy
80021012|NCT04635085|Behavioral|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
80021013|NCT04625699|Drug|Durvalumab|4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
79858711|NCT06099288|Behavioral|Read Educate and Develop Youth (READY) Comparison|The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
79562294|NCT03676153|Other|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
79858712|NCT06099275|Diagnostic Test|Transthoracic Echocardiography|Cardiac output measured by transthoracic echocardiography (TTE)
79858713|NCT06098118|Behavioral|MyMammogram decision aid|An online breast cancer screening decision aid that includes personalized risk assessment, information on benefits and risks of mammography screening, values clarification, outcome expectancies, and a summative document with participant responses.
79858714|NCT06098079|Drug|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
79858715|NCT06098079|Drug|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
79858716|NCT06097663|Drug|MAS825|Active MAS825 single dose
79858717|NCT06097663|Drug|MAS825 Placebo|MAS825 placebo single dose
79858718|NCT06097663|Drug|DFV890|Oral tablet of DFV890 active once daily
79858719|NCT06097663|Drug|DFV890 placebo|Oral tablet of DFV890 placebo once daily
79858720|NCT06097559|Diagnostic Test|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET."
79858721|NCT06097559|Diagnostic Test|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases."
79858722|NCT06097078|Device|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
80021014|NCT04625699|Drug|Tremelimumab|2 doses of Tremelimumab 300 mg IV Day 1, q56 days
79858723|NCT06095765|Drug|Colchicine 0.5 MG Oral Tablet|Oral intake of 0.5 mg colchicine once daily
79562295|NCT03676153|Other|Integrative medicine treatment program|Integrative medicine treatment program
79562296|NCT03660839|Drug|Artefenomel (OZ439)|Pharmaceutical form: Granules for oral suspension Route of administration: Oral
79858724|NCT06095765|Drug|Placebo|Oral intake of matching placebo once daily
80021015|NCT04606927|Other|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
79562297|NCT03660839|Drug|Ferroquine (SSR97193)|Pharmaceutical form: Capsule Route of administration: Oral
79562298|NCT03660241|Drug|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
80021016|NCT04562467|Drug|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
80021017|NCT04533698|Other|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
80021018|NCT04533698|Other|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
79562299|NCT03651102|Drug|Thalidomide and Hydroxyurea|Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
79262953|NCT06098898|Drug|Tislelizumab，atezolizumab or Trastuzumab|Administer according to the instructions.
79562300|NCT03649802|Dietary Supplement|Low dose vitamin D3|Low dose arm-800 IU given daily
79562301|NCT03649802|Dietary Supplement|High dose vitamin D3|High dose arm-5000 IU given daily
79562302|NCT03635385|Procedure|Apheresis technics|Blood draw will be performed for anti bodies dosages
79562303|NCT03634943|Other|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
79562304|NCT03626792|Other|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
79262954|NCT06098885|Other|extraction orthodontic treatment|bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
79562305|NCT03626792|Other|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
79562306|NCT03616041|Device|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
79398995|NCT03025633|Other|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
79858725|NCT06095115|Drug|JNJ-77242113|JNJ-77242113 will be administered orally.
79562307|NCT03607318|Behavioral|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
79562308|NCT03579628|Drug|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
79562309|NCT03579329|Procedure|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
79562310|NCT03575104|Drug|Daridorexant|Daridorexant will be administered as tablets, orally, once daily in the evening.
79858726|NCT06095115|Drug|Placebo|Placebo will be administered orally
80021019|NCT04510584|Drug|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
80021020|NCT04510584|Drug|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
80021021|NCT04500847|Drug|Emtriva Capsule|200mg daily oral dose
80021022|NCT04500847|Drug|Placebo|200mg daily oral dose
80021023|NCT04484532|Biological|Trivalent Influenza Vaccine|Given IM
80021024|NCT04483583|Drug|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
79562311|NCT03575104|Other|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
79562312|NCT03573557|Device|Pink Pad|Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.
79262955|NCT06098859|Procedure|Thoracic epidural analgesia|Thoracic epidural analgesia was started preoperatively and rest posoperative 48 hours
79262956|NCT06098859|Procedure|Erector spinae plane block|Erector spinae plane block was applied preoperatively using local anesthetic
79262957|NCT06098833|Drug|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
79262958|NCT06098833|Drug|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
79262959|NCT06098820|Other|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
79398996|NCT03502278|Behavioral|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
79562313|NCT03573557|Device|Bean Bag|Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
79562314|NCT03573557|Device|Gel Pad|Gel Pad used for patients in steep Trendelenburg position during surgery.
79562315|NCT03573115|Drug|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
79562316|NCT03569982|Other|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
79858727|NCT06094413|Behavioral|Multicomponent Training Intervention|The intervention will be implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session will consist of three phases: warm-up/initiation, conditioning, and cooldown. The intervention will be composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects will be informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention will be measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which will be documented during the session to measure immediate effect of the intervention. Progressions will be guided by individual responsiveness and measured by RPE. Progressions will be based on the training principles of specificity, adaptability, and overload.
79858728|NCT06093490|Device|Eysz Hyperventilation Recorder|App used to guide and record hyperventilation
80021025|NCT04483583|Drug|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
80021026|NCT04477681|Other|Data collection|In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, ATU / off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
79303814|NCT04248933|Behavioral|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
79398997|NCT01389817|Device|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
79398998|NCT04529460|Diagnostic Test|COVID-19 antibody point of care test kit|A disponible point of care test that identifies the presence of antibodies to COVID-19
79398999|NCT04032067|Drug|GV1001 placebo|0.9 % Normal Saline
79399000|NCT04032067|Drug|Proscar placebo|PO
79562317|NCT03569475|Drug|Levomilnacipran ER|Levomilnacipran extended-release oral capsules
79562318|NCT03569475|Drug|Fluoxetine|Fluoxetine oral capsules
79562319|NCT03569475|Drug|Placebo|Matching placebo oral capsules
79562320|NCT03565380|Other|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
80021027|NCT04447989|Drug|Sildenafil|Sildenafil citrate injection or powder for suspension
80021028|NCT04447989|Drug|Placebo|dextrose 5%
80021029|NCT04392960|Drug|[18F]Florbetaben|"Patients will undergo on the same day:~18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~standard assessment of clonal and organ disease;~echocardiography;~cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation."
80021030|NCT04385888|Behavioral|Low-calorie sweetener restriction|Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
80021031|NCT04380155|Other|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
80021032|NCT04378101|Other|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
80021033|NCT04375527|Drug|Binimetinib|Given PO
79562321|NCT03565380|Other|Usual post-operative care|No intervention will be provided
79562322|NCT03565380|Other|Untreated asymptomatic controls|No intervention will be provided
79562323|NCT03550144|Behavioral|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
79858729|NCT06089889|Other|ice application|"Group 1 will undergo the first intervention, which involves the application of ice.~Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential."
79858730|NCT06089889|Other|control group|"Group 2 will be control group, which involves no ice application~The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential."
79858731|NCT06088381|Other|Experimental Observation|Patients on the experimental arm will be under observation only.
80021034|NCT04375527|Biological|Nivolumab|Given IV
80021035|NCT04375527|Other|Questionnaire Administration|Ancillary studies
80021036|NCT04356027|Procedure|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
80021037|NCT04356027|Procedure|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
80021038|NCT04356027|Procedure|FFR|FFR will be measured
80021039|NCT04356027|Other|VFR Analysis|VFR will be calculated offline using the OCT pullback images
80021040|NCT04351711|Other|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
80021041|NCT04351711|Other|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
80021042|NCT04334343|Other|Additional Muscle Biopsy Collection|Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
79399001|NCT03141996|Other|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
79399002|NCT03141996|Other|Standard of Care|Standard of care treatment
79399003|NCT03140592|Procedure|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
79858732|NCT06088381|Other|Observation per Standard of Care|The low-risk group of patients will be observed per standard of care.
79858733|NCT06088381|Radiation|Adjuvant Treatment per Standard of Care|The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
79562324|NCT03550144|Behavioral|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
79399004|NCT00659295|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
79399005|NCT03142854|Drug|Polyethylene Glycol (PEG)|participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
79858734|NCT06088381|Diagnostic Test|Circulating Tumor DNA test (ctDNA test)|Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
79858735|NCT06082167|Drug|Zanzalintinib|Specified doses on specified days
79858736|NCT06082167|Drug|Zanzalintinib-matched Placebo|Specified doses on specified days
79858737|NCT06082167|Biological|Pembrolizumab|Specified doses on specified days
79858738|NCT06081894|Drug|Aficamten|Oral Tablet
79858739|NCT06081894|Drug|Placebo|Oral Tablet
79858740|NCT06080789|Drug|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
79858741|NCT06079281|Drug|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
79858742|NCT06079281|Drug|Placebo|Placebo will be administered via SC injection.
79858743|NCT06078761|Behavioral|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
79858744|NCT06077773|Drug|Oral EP262|Once daily
79858745|NCT06077773|Drug|Placebo|Once daily
79724477|NCT02767687|Other|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
79858746|NCT06076499|Device|NTX100|NTX100 Tonic Motor Activation (TOMAC) System - a non-invasive peripheral nerve stimulation device programmed to deliver active stimulation.
79724478|NCT02767297|Drug|FDL169|
79724479|NCT02772289|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
79858747|NCT06075264|Drug|Artesunate ointment|topical ointment, as a non-surgical treatment
79858748|NCT06075264|Drug|Placebo ointment|topical placebo ointment
79562325|NCT03549962|Procedure|TKA|Total Knee Arthroplasty
79303815|NCT04680689|Diagnostic Test|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
79303816|NCT04680689|Diagnostic Test|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
79399006|NCT03142854|Drug|Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
79562326|NCT03546556|Drug|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
79562327|NCT03545191|Drug|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
79562328|NCT03545191|Drug|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
79562329|NCT03545191|Other|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
79562330|NCT03543514|Other|TRIMODAL PREHABILITATION|"Trimodal prehabilitation application in the form of:~Control with the 6-minute walking test and podometer of physical activity~Dietary advice to be able to perform a hyperproteic diet~Mindfullnes to improve the emotional level."
79724480|NCT02772289|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
79724481|NCT02772289|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
79858749|NCT06075095|Drug|BGF MDI HFO 320/14.4/9.6μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
79858750|NCT06075095|Drug|BGF MDI HFA 320/14.4/9.6 μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
79858751|NCT06075095|Drug|Placebo MDI HFA|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
79858752|NCT06075043|Drug|AND017|Oral administration of AND017 capsules three times per week
79858753|NCT06075030|Drug|AND017|Oral administration of AND017 capsules three times per week
79858754|NCT06074549|Device|DynamX Novolimus-eluting Coronary Bioadaptor System|All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use
79858755|NCT06074380|Drug|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
79858756|NCT06071182|Device|Task-oriented Fruit ninja game|The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks
79303817|NCT04680689|Diagnostic Test|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
79303818|NCT04489901|Other|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
79399007|NCT01430455|Drug|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
79262960|NCT06098807|Behavioral|Family Centered Treatment for Problematic Gaming and Excessive Screen Use|Based on earlier implementation research with parents and children the treatment is likely to consist of a low number of sessions ;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
79562331|NCT03537365|Dietary Supplement|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
79262961|NCT06098794|Dietary Supplement|Sodium Bicarbonate|Capsules containing 0.3 g/kg of body weight of sodium bicarbonate were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
79262962|NCT06098794|Dietary Supplement|Placebo|Capsules containing 0.3 g/kg of body weight of celulose were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
79303819|NCT04656587|Device|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
79303820|NCT04656587|Other|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
79399008|NCT05078658|Other|Low-carbohydrate diet|The diet will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
80021043|NCT04322370|Procedure|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
79399009|NCT05078658|Other|Recommended-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with the amount of carbohydrates equal to 45% (+/- 5%) of the recommended energy a day.
79399010|NCT04051957|Drug|Isosorbide Mononitrate|The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
79562332|NCT03537365|Dietary Supplement|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
79724482|NCT04225195|Drug|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
79724483|NCT02771821|Other|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
79858757|NCT06071182|Other|sham-controlled therapy|The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
79858758|NCT06070649|Drug|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
79858759|NCT06070649|Drug|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
79858760|NCT06070649|Drug|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
80021044|NCT04322370|Device|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
79858761|NCT06070597|Drug|Iclepertin|Iclepertin
79858762|NCT06070597|Drug|Iclepertin Placebo|Placebo to Iclepertin
79858763|NCT06070597|Drug|Moxifloxacin|Moxifloxacin
79858764|NCT06070597|Drug|Moxifloxacin Placebo|Placebo Moxifloxacin
79858765|NCT06069726|Drug|Atezolizumab|One dose of atezolizumab will be given prior to resection.
80021045|NCT04296903|Device|MID-C System|Minimal invasive deformity correction system for the treatment of AIS
80021046|NCT04290520|Other|bioassay|Serum progesterone level (ng/ml)
80021047|NCT04271423|Procedure|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
79262963|NCT06098768|Behavioral|VR Social Skills|The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group. VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset. The VR interaction will be controlled and operated via linked iPad.
79562333|NCT03533712|Dietary Supplement|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~Total energy: 250-500 kcal per daily serving~Fat content: 10-60% of energy intake~Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~Trans Fats: <1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
79858766|NCT06068985|Drug|PHESGO|Subcutaneous formulation with pertuzumab and trastuzumab.
79858767|NCT06067984|Device|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
79562334|NCT03533712|Dietary Supplement|Fe and folic acid supplement|Routine iron and folic acid supplementation.
79858768|NCT06067737|Drug|Psilocybin|High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
79858769|NCT06067737|Drug|Psilocybin|A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
79858770|NCT06067230|Biological|mRNA-1345|Sterile liquid for injection
79858771|NCT06066424|Drug|Rimiducid|Given by (IV) vein
79858772|NCT06066424|Drug|TROP2-CAR-NK Cells|Given by (IV) vein
79858773|NCT06066424|Drug|Fludarabine phosphate|Given by (IV) vein
79858774|NCT06066424|Drug|Cyclophosphamide|Given by (IV) vein
79858775|NCT06066255|Drug|Thymoglobulin Injectable Product|single intravenous injection of thymoglobulin
79858776|NCT06066008|Drug|ZM-01-L|rAAV-hRS1 intravitreal injection of low dose
79562335|NCT03529838|Other|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
79562336|NCT03524911|Behavioral|CHFFF nutrition education|
79858777|NCT06066008|Drug|ZM-01-H|rAAV-hRS1 intravitreal injection of high dose
80021048|NCT04223999|Procedure|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
80021049|NCT04223999|Other|Control|Tumor treating fields combined with best medical treatment.
79562337|NCT03523520|Drug|Methylnaltrexone Bromide 150 mg Oral Tablet|Methylnaltrexone Bromide 150 mg Oral Tablet
79562338|NCT03523520|Drug|Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1|Methylnaltrexone Bromide 12 MG Subcutaneous Solution
79562339|NCT03523520|Drug|Naloxegol 25 MG Oral Tablet|Naloxegol 25 MG Oral Tablet
79562340|NCT03518242|Drug|Cyclophosphamide|Given PO
79562341|NCT03518242|Drug|Methotrexate|Given PO
79858782|NCT06062966|Drug|Anakinra|Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
79858783|NCT06062394|Behavioral|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
79858784|NCT06061991|Behavioral|Mobile instant messaging-based lifestyle intervention|Nurse-led personalised lifestyle intervention grounded in social cognitive theory via WhatsApp or WeChat from baseline to the 28th gestational week, which aims to maintain optimal gestational weight gain using dietary and exercise advice and behavioural change techniques.
79858785|NCT06061991|Behavioral|Text messaging reminders|Follow-up reminders via text messaging as attention control.
79262964|NCT06098703|Behavioral|CARD (Comfort Ask Relax Distract)|CARD is a vaccine delivery framework/protocol to plan and deliver vaccinations
79262965|NCT06098209|Drug|Dexmedetomidine|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
79262966|NCT06098209|Drug|Propofol|Patient will receive propofol 0.3-4 mg/kg/h.
79399011|NCT04051957|Drug|Placebo oral tablet|Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
79562342|NCT03518242|Drug|Capecitabine|Given PO
79562343|NCT03518242|Procedure|Biospecimen Collection|Undergo biospecimen collection
79858786|NCT06061991|Behavioral|Brief advice on GDM prevention|Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy
79562344|NCT03501719|Drug|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
79562345|NCT03500549|Drug|Pegcetacoplan|Complement (C3) Inhibitor
80021050|NCT04218799|Drug|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
80021051|NCT04189445|Drug|Futibatinib|Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle
80021052|NCT04183920|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
80021053|NCT04183920|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
80021054|NCT04179032|Combination Product|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
80021055|NCT04148703|Other|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
80021056|NCT04148703|Other|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
79399012|NCT00590889|Device|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
79562346|NCT03500549|Drug|Soliris|Complement (C5) Inhibitor
79562347|NCT03495557|Procedure|Control|Fascial closure with simple polydioxanone suture 2/0 stitches
79562348|NCT03495557|Device|Experimental|Onlay polypropylene mesh placement (MN mesh)
79562349|NCT03481608|Other|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
79724484|NCT02771899|Device|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
80021057|NCT04138953|Device|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process."
80021058|NCT04138953|Other|Sham TMS|Sham Transcranial Magnetic Stimulation (TMS) over premotor cortex
79399013|NCT05078424|Behavioral|Cognitive Behavioural Therapy|CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
79724485|NCT02771899|Device|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
79724486|NCT04227223|Diagnostic Test|biochemical measurements|TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
79858787|NCT06061991|Behavioral|Usual care|Usual care provided by the prenatal clinic.
79858788|NCT06060899|Procedure|Pneumoperitoneum 14mmHg|Performing surgery in 14mmHg pneumoperitoneum pressure
79858789|NCT06060899|Procedure|Pneumoperitoneum 10mmHg|Performing surgery in 10mmHg pneumoperitoneum pressure
79562350|NCT03481608|Other|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
79562351|NCT03480217|Behavioral|Multifaceted Implementation Strategy|"Key components include:~educational presentations to primary care providers at grand rounds~patient information materials on ABPM and HBPM~training registered nurses to assist providers with teaching patients to conduct HBPM~information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~an accessible, culturally-adapted and locally tailored ABPM service"
79858790|NCT06058442|Drug|NORTASE®|10-15 capsules of NORTASE® per day - over 6 months
79858791|NCT06058442|Drug|Placebo|10-15 capsules of placebo per day - over 6 months
79858792|NCT06058013|Drug|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
79858793|NCT06058013|Drug|Placebo|Placebo will be administered orally
79858794|NCT06057883|Dietary Supplement|Probiotic|A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
79262967|NCT06098105|Procedure|Ultrasound-guided transversus abdominis plane block|This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
79399014|NCT02859168|Behavioral|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
79399015|NCT02859168|Device|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
79562352|NCT03463018|Dietary Supplement|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
79562353|NCT03463018|Dietary Supplement|Placebo|Placebo tablet containing matching excipients to the active intervention
79562354|NCT03441776|Other|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
80021059|NCT04125992|Procedure|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
79724487|NCT02771509|Drug|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
79724488|NCT02771509|Drug|Placebo|Normal saline
79858795|NCT06057337|Behavioral|"Families with Pride (Familias con Orgullo)"|Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
79858796|NCT06056687|Drug|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha Lipoic Acid 600 MG Oral Tablet once daily
79858797|NCT06056687|Other|Placebo Tablet|Placebo Tablet once daily
79724489|NCT02697019|Behavioral|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
80021060|NCT04125992|Procedure|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
79724490|NCT02696941|Drug|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
80021061|NCT04100954|Device|Reinforced prosthesis|Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
79262968|NCT06098105|Procedure|Laparoscopic-assisted transversus abdominis plane block|Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
79303821|NCT02718131|Device|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
79724491|NCT02696941|Drug|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
79724492|NCT02771665|Other|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
79724493|NCT02767375|Drug|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 & 2 , IA，q4-6 Weeks
79399016|NCT02784600|Device|Bioinductive implant|
79399017|NCT02458560|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
79399018|NCT05387226|Biological|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
79724494|NCT02767375|Procedure|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
79858798|NCT06055920|Device|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
79399019|NCT04248114|Diagnostic Test|Ultrasound of the Neck|Anatomical measurements were performed on participants during an ultrasound exam
79399020|NCT04206150|Procedure|the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex|In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
79262969|NCT06098105|Procedure|Laparoscopic-assisted intraperitoneal instillation|This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
79262970|NCT06098105|Drug|Bupivacaine|bupivacaine
79858799|NCT06055920|Drug|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
80021062|NCT04100954|Device|Standard prosthesis|Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
80021063|NCT04093310|Device|Word Catheter|Use of the Word catheter to remove the Bartholin's abscess
79858800|NCT06055608|Drug|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight <40 kg will receive 3mg/m^ 2, with maintenance dose of 1 mg/m^2 divided BID - weight >= 40kg will receive 6mg/m^ 2, with maintenance dose of 2 mg daily
80021064|NCT04093310|Procedure|Incision-drainage|Incision-drainage to remove the Bartholin's abscess
79262971|NCT06097962|Drug|NK510|Intravenous infusion
79262972|NCT06097962|Drug|Tislelizumab，atezolizumab or sugemalimab|Administer according to the instructions
80021065|NCT04090476|Other|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
80021066|NCT04050293|Drug|SPN-538|Patients will receive SPN-538
79262973|NCT06097416|Drug|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
79562355|NCT03441776|Other|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
79562356|NCT03438838|Procedure|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
79724495|NCT02767453|Procedure|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
79724496|NCT02767453|Procedure|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
79724497|NCT02767141|Behavioral|Coping Strategies|Coping strategies for households in the US with food insecurity
80021067|NCT04050293|Drug|Placebo|Patients will receive Placebo
80021068|NCT04026776|Drug|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
80021069|NCT04026776|Other|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
79262974|NCT06097416|Drug|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
79262975|NCT06097039|Device|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
79303822|NCT02718131|Procedure|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
80021070|NCT03978871|Behavioral|Growth Mindset|Growth emotion mindset induction
80021071|NCT03978871|Behavioral|Control|Brain education
80021072|NCT03975855|Device|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
80021073|NCT03946449|Drug|Fazirsiran Injection (TAK-999, ARO-AAT)|solution for subcutaneous (sc) injection
80021074|NCT03916939|Other|osteopathy|osteopathy treatment
80021075|NCT03916939|Other|simulated osteopathy|simulated osteopathic sessions
79858801|NCT06055608|Biological|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
79562357|NCT03438838|Procedure|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
79562358|NCT03435185|Procedure|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
79562359|NCT03435185|Procedure|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
79724498|NCT02767219|Drug|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
79858802|NCT06055608|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m^2 BID
79858803|NCT06055608|Drug|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
79858804|NCT06055608|Drug|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
79858805|NCT06055608|Drug|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
79858806|NCT06055088|Other|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
80021076|NCT03913637|Behavioral|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
80021077|NCT03913637|Other|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
80021078|NCT03909854|Procedure|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
79399021|NCT04206150|Procedure|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location|In group 2, the adductor canal catheter is inserted femur length/15*2 cm above the location where the nerve block performed in group 1.
79399022|NCT04206150|Procedure|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location|In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
79562360|NCT03423069|Dietary Supplement|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
79262976|NCT06097039|Device|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
79562361|NCT03423069|Dietary Supplement|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
79562362|NCT03417349|Device|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
79724499|NCT02767219|Drug|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
79724500|NCT02767219|Drug|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
80021079|NCT03905668|Other|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
80021080|NCT03905668|Other|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
79399023|NCT05387070|Drug|TransCon PTH|TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
79399024|NCT05387070|Drug|placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
79399025|NCT00591123|Drug|FOLFOX|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
79858807|NCT06055075|Drug|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
79262977|NCT06096610|Other|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
79262978|NCT06096376|Diagnostic Test|Diaphragm Ultrasound|Diaphragm ultrasound to assess respiratory muscle function and respiratory efficiency
79399026|NCT00591123|Drug|5-FU|5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
79399027|NCT00591123|Drug|Erlotinib|All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
79262979|NCT06096363|Diagnostic Test|Transthoracic Echocardiography|Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
79262980|NCT06096298|Other|Vitamin B12 bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.
79562363|NCT03411889|Diagnostic Test|MRI scanning|MRI scanning during tear drainage
80021081|NCT03905668|Other|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
79858808|NCT06055075|Drug|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
79858809|NCT06055075|Drug|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
79562364|NCT03410342|Other|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
79562365|NCT03410342|Other|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
79562366|NCT03410342|Other|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
79562367|NCT03383380|Drug|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
79262981|NCT06096298|Other|Control bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.
79724501|NCT02766829|Procedure|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
79858810|NCT06054867|Device|Robotic Waterjet Treatment|"The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan."
79858811|NCT06052813|Drug|BN104|Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
79858812|NCT06052228|Other|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
79399028|NCT05311098|Device|cryoablation|Treatment of atrial fibrillation with cryoablation catheters
79399029|NCT01429441|Drug|Ocriplasmin|0.125 mg single intravitreal injection
79399030|NCT01429441|Other|Sham injection|Sham injection
79399031|NCT04149990|Drug|Valsartan+ sacubitril|Treatment with Entresto(valsartan+sacubitril)
79399032|NCT04149990|Drug|Placebo Oral Tablet|Matching placebo treatment
79399033|NCT00591825|Drug|D-cycloserine|D-cycloserine
79399034|NCT00591825|Drug|Placebo|Placebo
79399035|NCT04120038|Device|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
79399036|NCT01429285|Drug|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
79399037|NCT01429285|Drug|Usual care|Attending administers any IV opioid in any dose he chooses
79399038|NCT00592761|Behavioral|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
79724502|NCT02766829|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
79724503|NCT04711993|Other|Aerobic exercise|"Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine."
79262982|NCT06096142|Device|Solaris DE|Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
79262983|NCT06096142|Device|PTA|Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
79262984|NCT06096103|Dietary Supplement|placebo|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
79399039|NCT05084040|Other|90 days interval between catheter maintenance|Length of time between catheter maintenances extended from 60 days to 90 days
79858813|NCT06051994|Device|AI-guided VA ablation|Ablation of ventricular arrhythmia as guided by the ablation index, using Carto 3 electroanatomic mapping system, QDOT Micro ablation catheter, and multipolar mapping catheters (Optrell, Decanav)
79262985|NCT06096103|Dietary Supplement|Botanical Extract Standardized for Iron + Vitamin C|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
79262986|NCT06096103|Dietary Supplement|Botanical Extract Standardised for Iron|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
79562368|NCT03373097|Biological|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
79562369|NCT03366792|Device|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
79262987|NCT06095999|Behavioral|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including [re]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
79262988|NCT06094595|Diagnostic Test|MAS-p administration|Each patient will be assessed the first time at mealtime by two experienced speech therapists, and scores obtained on the MAS-p will be recorded independently and blinded to each other. The two scales selected for comparison will also be administered at the same time. The assessment with the MAS-p scale will be repeated 48 hours apart, a time considered optimal in order to avoid possible bias related to the clinical improvement of the patient undergoing rehabilitation treatment, by one of the two speech therapists.
79262989|NCT06093958|Diagnostic Test|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
79262990|NCT06093841|Biological|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
79262991|NCT06093841|Drug|Fludarabine|Administered according to package insert
79262992|NCT06093841|Drug|Cyclophosphamide|Administered according to package insert
79262993|NCT06093334|Diagnostic Test|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
79562370|NCT03350997|Behavioral|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
79562371|NCT03350997|Behavioral|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
79262994|NCT06093334|Diagnostic Test|Cardiopulmonary testing|Myocardial function (Strain-Analysis by echocardiography) and spiroergometry, capillary blood gases and lactate
79562372|NCT03348020|Procedure|Blood Donation|Subjects will donate blood within ~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
79562373|NCT03342053|Drug|RO7234292 (RG6042)|Intrathecal injection
79724504|NCT04711993|Other|Stretchin exercise|Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
79724505|NCT02771587|Dietary Supplement|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
79724506|NCT02771587|Dietary Supplement|Alcohol|Multiple oral dose of alcohol
79724507|NCT02771587|Dietary Supplement|Energy drink|Multiple oral dose of energy drink
79724508|NCT02771587|Dietary Supplement|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
79724509|NCT04742725|Drug|Placebo|Placebo
79724510|NCT04742725|Drug|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
79724511|NCT02778451|Other|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
79724512|NCT02771743|Drug|Cisplatin|
79724513|NCT02771743|Drug|Doxorubicin|
79724514|NCT02771743|Drug|Etoposide|
79724515|NCT02771743|Drug|Cyclophosphamide|
79724516|NCT02771743|Drug|Ifosfamide|
79724517|NCT02771743|Drug|Carboplatin|
80021082|NCT03905668|Other|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
79724518|NCT02771743|Procedure|Tandem HDCT/auto-SCT|
79262995|NCT06093334|Diagnostic Test|Pulmonary testing|Lung function (VC%, FEV1%)
79262996|NCT06093334|Diagnostic Test|Blood sample|Standard procedures/parameters routinely available in follow-up care after oncological treatment
79303823|NCT02465879|Other|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
79724519|NCT02771743|Radiation|Radiotherapy|
79724520|NCT02771743|Drug|Interleukin-2|
79724521|NCT02771743|Drug|Isotretinoin|
79724522|NCT02771743|Radiation|MIBG|
79724523|NCT02762851|Other|Sterile saline|0.5 ml dose injected intramuscularly
79262997|NCT06093178|Behavioral|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
79262998|NCT06091917|Dietary Supplement|Betaine supplementation in infant formula|Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.
79262999|NCT06091917|Dietary Supplement|Regular infant formula|Regular (unmodified) infant formula . The intervention will last for 12 weeks.
79263000|NCT06091501|Behavioral|Lev Livet|"The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention."
79263001|NCT06086470|Device|Qidni/D Hemodialysis System|Qidni/D is a hemodialysis device for patients with end-stage renal disease.
79263002|NCT06084091|Device|Myocardial spectrometric measurement|Myocardial spectrometric measurement during open-heart Surgery
79263003|NCT06077344|Procedure|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation
79858814|NCT06051942|Device|Robotic Waterjet Treatment|The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
79562374|NCT03325777|Behavioral|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
79263004|NCT06077344|Procedure|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment
79562375|NCT03325777|Behavioral|SHAM Training|SHAM Training
79562376|NCT03314506|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
79562377|NCT03302520|Device|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
79263005|NCT06077266|Other|Change of weight class to normal weight|The exposure is the change of weight class from obesity to normal weight during a follow-up period without known intervention.
79263006|NCT06073600|Drug|Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
79562378|NCT03302520|Device|PEEK cage|PEEK cage
79562379|NCT03297476|Diagnostic Test|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
79562380|NCT03285139|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
79562381|NCT03283241|Device|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
79724524|NCT02762851|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
79724525|NCT02771431|Other|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
79858815|NCT06051864|Device|Modius Mood Active Device|Battery powered non-invasive neurostimulation device
79858816|NCT06051864|Device|Sham Device|Placebo comparator sham device (no active stimulation)
79858817|NCT06050928|Drug|Oral EP262|Once daily
80021083|NCT03905668|Other|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
80021084|NCT03877510|Drug|IPX203|IPX203 extended release capsules
80021085|NCT03872778|Drug|[177Lu]-NeoB|[177Lu]-NeoB: peptide receptor radionuclide therapy
80021086|NCT03872778|Drug|[68Ga]-NeoB|[68Ga]-NeoB radioactive diagnostic agent
80021087|NCT03846427|Drug|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
79263007|NCT06073600|Drug|Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
79263008|NCT06069843|Drug|IV Ketamine|0.5 mg/kg IV Ketamine
79303824|NCT03066765|Device|Linguaflex Tongue Retractor|Tongue implant
79263009|NCT06066320|Behavioral|MMST|Participants randomised to the MMST group will complete the computer based paced auditory serial addition task (PASAT-C) in the presence of one observer and is informed that incorrect answers result in reduced monetary compensation. Simultaneously, the participant is exposed to emotionally evocative images and white noise via headphones
79263010|NCT06066320|Behavioral|TSST|Participants randomly assigned to the TSST condition will be exposed to a traditional TSST protocol. The TSST consists of a preparation phase (5 min), followed by a mock job interview and a mental arithmetic task (5 min each) in front of a panel consisting of two observers and a video recording device.
79562382|NCT03283241|Device|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
79399040|NCT00594009|Device|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
79562383|NCT03262909|Device|GelrinC|Patients will undergo GelrinC implantation.
79562384|NCT03262909|Other|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
79562385|NCT03261817|Behavioral|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
79562386|NCT03261817|Behavioral|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
79562387|NCT03259581|Combination Product|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
79858818|NCT06050681|Behavioral|Mindfulness Training|Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 & 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
79858819|NCT06050135|Other|Roadmap to Parenthood|web-based decision support
80021088|NCT03831113|Drug|Buprenorphine: Magnitude Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
80021089|NCT03831113|Drug|Buprenorphine: Frequency Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
79858820|NCT06050135|Other|Informational Booklet|web-based informational booklet about young adult cancer survivorship
79858821|NCT06049680|Drug|SMOFlipid® (lipid injectable emulsion)|"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
80021090|NCT03831113|Drug|Buprenorphine: Dosing Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
80021091|NCT03824561|Drug|Vedolizumab|Vedolizumab IV infusion
80021092|NCT03821857|Drug|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
80021093|NCT03818087|Behavioral|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
80021094|NCT04305236|Drug|Abemaciclib|Given PO
80021095|NCT04305236|Drug|Fulvestrant|Given Intramuscularly
79399041|NCT05083962|Behavioral|Healthy Lifestyle Program|An intensive behavior change curriculum designed to help create and sustain healthy habits
79399042|NCT03139812|Drug|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
80021096|NCT03761537|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
79263011|NCT06064656|Other|Non-Interventional|No study treatment will be administered on this study.
79263012|NCT06059222|Drug|Romosozumab|Romosozumab 210 mg/2.34 ml from baseline to month 11
79399043|NCT03139812|Device|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
79399044|NCT03141840|Device|ABL01|Experimental medical device
79263013|NCT06059222|Drug|Zoledronate|5 mg/100 ml at month 12
79263014|NCT06059222|Drug|Romosozumab|210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
79263015|NCT06059222|Drug|Zoledronate|5 mg/100 ml at month 6
79263016|NCT06059222|Drug|Romosozumab|210 mg/2.34 ml from baseline to month 5
79263017|NCT06059222|Drug|Zoledronate|5 mg/100 ml at month 5 and month 18
79399045|NCT03141840|Device|Placebo|ABL01 lacking active component
79399046|NCT00594945|Drug|Clonazepam|1 Dose
79399047|NCT03110874|Drug|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
79562388|NCT03242772|Drug|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
79263018|NCT06053450|Other|Oil Inhalation Patch|Each participant will wear a patch for a work week (3 worked shifts) and then no patch is worn for a week. This alternates for a total of a month.
79263019|NCT06043141|Diagnostic Test|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
79263020|NCT06043141|Diagnostic Test|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
79263021|NCT06043141|Diagnostic Test|Pressure pain threshold|Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
79263022|NCT06041997|Behavioral|Smartphone restriction|The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
79263023|NCT06031844|Drug|DFV890|oral film-coated tablets
79263024|NCT06031844|Drug|Placebo|oral film-coated tablets
79562389|NCT03242772|Behavioral|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
79562390|NCT03242772|Drug|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
79562391|NCT03236311|Drug|SAR407899|Pharmaceutical form: Capsule Route of administration: Oral
79562392|NCT03236311|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
79562393|NCT03236311|Drug|Adenosine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79562394|NCT03236311|Drug|Regadenoson|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79263025|NCT06028139|Behavioral|Continuous glucose monitoring and health coaching|"Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial.~Participants will interact with health coach throughout the study duration."
79263026|NCT06028139|Behavioral|EMPOWER mobile app|Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
79263027|NCT06027749|Device|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
79263028|NCT06019611|Device|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
79263029|NCT06017947|Procedure|Music care|20 min music listening during transportation to hospital
79263030|NCT06016075|Device|Hyperpolarised MRI|Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
79562395|NCT03236311|Drug|13N-ammonia|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79562396|NCT03236311|Drug|82Rubidium|Pharmaceutical form: Solution for injection Route of administration: Intravenous
79263031|NCT06016075|Device|Sodium MRI|MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
79263032|NCT06016075|Device|Deuterium metabolic imaging (DMI) MRI|Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
79858822|NCT06048406|Combination Product|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
79858823|NCT06047691|Behavioral|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format. Couples are provided with psychoeducation about PTSD and relationship functioning and are taught cognitive and behavioral skills to address the manifestation of PTSD in the couple relationship. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and once 1-2 weeks after the retreat.
80021097|NCT03761537|Other|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
80021098|NCT03733678|Behavioral|Price discounts for SARCs|SARCs are offered free to the client
80021099|NCT03733678|Behavioral|Price discounts for LARCs|LARCs are offered at lower prices to the client
80021100|NCT03733678|Behavioral|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
80021101|NCT03706079|Biological|Tezepelumab|Tezepelumab subcutaneous injection
79399048|NCT03110874|Drug|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
79399049|NCT05083728|Diagnostic Test|CT|Clinicians are free to choose the adult subjects in whom a non-contrast calibrated CT-scan will be performed as a part of routine clinical care. The decision to order a noncontrast CT-scan of the shoulder must be made prior to, and independently from, the decision to enroll the patient.
79399050|NCT00595101|Drug|PF-03187207|
79399051|NCT00595101|Drug|Latanoprost 0.005%|
79399052|NCT00595101|Drug|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
79399053|NCT00595101|Drug|Latanoprost Vehicle|
79399054|NCT05083650|Procedure|Macular hole closure with amniotic membrane with/without internal limiting membrane peeling|Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
79399055|NCT04063566|Procedure|Magnetic Resonance Imaging (MRI)|Prostate cancer screening MRI
79263033|NCT06014099|Behavioral|Long peripheral venous catheters for blood collection|used LPC for blood collection
79263034|NCT06014099|Behavioral|Midline catheter for blood collection|used MCs for blood collection
79263035|NCT06014099|Behavioral|SPCs for blood collection|used SPCs for blood collection
79263036|NCT06013722|Diagnostic Test|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
79263037|NCT05994378|Drug|SHR7280；Ganirelix Acetate Injection simulant|SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;
79263038|NCT05994378|Drug|SHR7280 simulant； Ganirelix Acetate Injection|SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
79562397|NCT03234686|Drug|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
79562398|NCT03234686|Drug|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
79562399|NCT03229629|Behavioral|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
79724526|NCT02770963|Procedure|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
79263039|NCT05979844|Drug|3,4-methyllenedioxymethamphetamine (MDMA)|2 MDMA sessions; PTSD+ Veteran partner only
79263040|NCT05979844|Behavioral|Brief Cognitive Behavioral Conjoint Therapy (bCBCT)|8 bCBCT sessions; sessions 1-3 massed with preparatory session; Both partners
79263041|NCT05978739|Drug|Orelabrutinib High dose|Orelabrutinib will be administered as 3 tablets once per day
79263042|NCT05978739|Drug|Orelabrutinib Low dose|Orelabrutinib will be administered as 1 tablet once per day
79263043|NCT05978583|Other|physical and occupational therapy consultation|Physical and occupational therapy consultation during the inpatient admission period. This information may be used in the future to provide targeted prehabilitation interventions.
79263044|NCT05964907|Device|Light Source B: Visible Light solar simulator (VL + UVA1)|Patients will be radiated with light source B (Visible light solar simulator)
79263045|NCT05964907|Device|Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)|Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
79562400|NCT03229629|Other|Food Voucher (Monetary)|Monthly voucher worth 200 birr(~$10) every month for the duration of 6 month
79562401|NCT03226795|Other|" Information-Motivation-Behavioral skills  intervention."|"information -> Reminders of medication: mobile application~Motivation -> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~Behavioral skills -> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
79562402|NCT03223974|Device|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for >30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
79562403|NCT03223974|Device|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
79562404|NCT03208153|Procedure|Invasive|Coronary angiogram and revascularization if anatomically feasible
79562405|NCT03208153|Procedure|Conservative|Conservative
79562406|NCT03194581|Device|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
79562407|NCT03192046|Device|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
79858824|NCT06047691|Behavioral|Prevention and Relationship Education Program|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.The content of PREP and workshop experiences focuses on helping couples communicate effectively, manage conflict without harming their relationship, preserve and act on commitment, improve relationship decision-making, increase understanding of differences between partners, and protect positive connections between partners. Approximately 12 hours of PREP content will be delivered over 2 consecutive days in a multi-couple group retreat format. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and will check in with a member of the study staff 1-2 weeks after the retreat.
79858825|NCT06046430|Other|Assessment|The same assessments will be made to participants in both groups.
79858826|NCT06046222|Drug|NS-229|Experimental
79858827|NCT06046222|Drug|Placebo|Placebo comparator
79858828|NCT06045806|Biological|idecabtagene vicleucel|Specified dose on specified days
79858829|NCT06045806|Drug|Lenalidomide|Specified dose on specified days
80021102|NCT03706079|Other|Placebo|Placebo subcutaneous injection
80021103|NCT03683030|Device|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
79858830|NCT06045806|Drug|Fludarabine|Specified dose on specified days
79263046|NCT05959200|Device|Serafilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
79858831|NCT06045806|Drug|Cyclophosphamide|Specified dose on specified days
79858832|NCT06044935|Other|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
79263047|NCT05959200|Device|Senofilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
79263048|NCT05959200|Device|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
79562408|NCT03192046|Other|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
79562409|NCT03191253|Other|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
79562410|NCT03190369|Device|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
79562411|NCT03190369|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
79562412|NCT05438342|Biological|Autologous Adoptive immune cells|Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
79562413|NCT05438342|Device|Thermotron RF-8EX|Hyperthermia for 40-50 minutes
79562414|NCT05438342|Drug|Chemotherapy，checkpoint immunotherapy, targeted therapy|The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
79562415|NCT05438108|Combination Product|SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab|SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
79562416|NCT05437952|Dietary Supplement|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
79724527|NCT02770963|Procedure|Sham acupuncture|"Specially designed sham needles (0.3*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
79263049|NCT05954468|Other|standardized and validated surveys|To evaluate the cognitive and psycho-social long term impact of a NMDAR encephalitis, we will collect the data using specific interview assessments such as the PROMS (Patient-reported Outcome Measures Information System) and PREMS (Patient-reported experiences measures) as well as we will check the cognitive performance in order to combine the expertise from clinical neurology, social & health psychology
79263050|NCT05946759|Device|Histolog Scanner|The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
79263051|NCT05939388|Device|Auricular Acupressure Pads|Pads containing seeds that are placed on specific sites of the ear that are thought to help with pain.
79263052|NCT05929768|Procedure|Biospecimen Collection|Undergo collection of blood samples
79263053|NCT05929768|Drug|Carboplatin|Given IV
79263054|NCT05929768|Drug|Cyclophosphamide|Given IV
79263055|NCT05929768|Drug|Docetaxel|Given IV
79399056|NCT04063566|Procedure|Prostate-specific antigen (PSA) test|Blood test for PSA levels
79263056|NCT05929768|Drug|Doxorubicin|Given IV
79263057|NCT05929768|Drug|Paclitaxel|Given IV
79858833|NCT06044935|Other|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
80021104|NCT03657160|Drug|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion.
80021105|NCT03657160|Drug|Vedolizumab|Vedolizumab IV infusion.
80021106|NCT03635320|Device|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
79263058|NCT05929768|Biological|Pembrolizumab|Given IV
79263059|NCT05929768|Other|Quality-of-Life Assessment|Ancillary studies
79263060|NCT05929768|Other|Questionnaire Administration|Ancillary studies
79263061|NCT05929768|Procedure|Surgical Procedure|Undergo surgery
79263062|NCT05928741|Behavioral|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
79399057|NCT00660075|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
79399058|NCT00660075|Drug|Placebo|Placebo for 6 weeks
79399059|NCT00682617|Behavioral|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
80021107|NCT03635320|Device|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
80021108|NCT03623620|Behavioral|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
79724528|NCT02771041|Procedure|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
79263063|NCT05911620|Device|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
79263064|NCT05905328|Drug|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
79263065|NCT05905328|Drug|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
79263066|NCT05905328|Drug|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
79263067|NCT05902767|Other|Nuts|"A mix of nuts containing 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~Dietary counselling on how to follow the Australian Dietary Guidelines"
79263068|NCT05902767|Other|Control|- Dietary counselling on how to follow the Australian Dietary Guidelines
79263069|NCT05885191|Other|2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture|Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
79263070|NCT05881135|Drug|Citicoline|i.v. bolus administration every 12 hours for 5 days.
79263071|NCT05881135|Drug|Saline/Placebo|i.v. administered every 12 hours as a 10 ml bolus for 5 days.
79263072|NCT05876442|Device|Extracorporeal Shock Wave Therapy.|Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.
79263073|NCT05876442|Device|High Intensity Laser Therapy|High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..
79263074|NCT05876442|Other|Traditional Physical Therapy Exercise Program|30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
79263075|NCT05867303|Drug|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
79263076|NCT05843149|Behavioral|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
79263077|NCT05843149|Behavioral|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
79263078|NCT05793281|Other|No Drug|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
79263079|NCT05786716|Drug|Trastuzumab|An initial loading dose of 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.
79263080|NCT05786716|Drug|Pertuzumab|An initial loading dose of 14 mg/kg administered intravenously every 21 days followed thereafter by a maintenance dose of 7 mg/kg.
79263081|NCT05781035|Procedure|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
79263082|NCT05781035|Procedure|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
79263083|NCT05768802|Device|Myoelectric Implantable Recording Array (MIRA)|The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
79263084|NCT05768178|Drug|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg orally on a twice daily schedule throughout a 28-day cycle.
79263085|NCT05768178|Drug|Cobimetinib|Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.
79263086|NCT05764824|Dietary Supplement|Blueberry powder|20 g per day of blueberry powder
79263087|NCT05764824|Other|Controlled and matched powder|20 g per day
79263088|NCT05755399|Device|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
79263089|NCT05750173|Other|Streamlining of the pre-procedural patient pathway|"Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety."
79303825|NCT02465723|Device|MRI with IVIM DW-MRI|
79303826|NCT02465723|Other|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
79399060|NCT00682617|Behavioral|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
79303827|NCT03069261|Device|Indocyanine green angiography|
79399061|NCT00595881|Device|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
79303828|NCT04490213|Other|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
79399062|NCT00682851|Device|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
79399063|NCT00682851|Device|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
79399064|NCT03140436|Drug|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
79399065|NCT03140436|Drug|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
79858834|NCT06044935|Dietary Supplement|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
79858835|NCT06044935|Dietary Supplement|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
79263090|NCT05748210|Other|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
79263091|NCT05748210|Other|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
79263092|NCT05732909|Dietary Supplement|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
79263093|NCT05726838|Other|Inclisiran|There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.
79263094|NCT05722886|Drug|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
79562417|NCT05437952|Other|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
79562418|NCT05437952|Dietary Supplement|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
79263095|NCT05722886|Drug|Atezolizumab|"Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
79263096|NCT05722886|Drug|Entrectinib|"Adult and paediatric participants with body surface area (BSA) ≥1.51 m^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
79263097|NCT05722886|Drug|Trastuzumab in combination with pertuzumab|"The initial loading dose of trastuzumab is 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.~The initial loading dose of pertuzumab is 840 mg administered intravenously every 21 days followed thereafter by a maintenance dose of 420 mg.~Participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
79263098|NCT05722886|Drug|Vemurafenib in combination with cobimetinib|"Participants will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
79399066|NCT01429051|Drug|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
79399067|NCT01429051|Drug|Placebo|Matching intranasal placebo spray
79399068|NCT03968562|Drug|2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor|2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
79399069|NCT03425292|Drug|Temozolomide|concomitant and 5-day adjuvant temozolomide
79399070|NCT03425292|Radiation|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
79562419|NCT05437952|Other|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
79562420|NCT05437913|Other|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
79724529|NCT04224805|Device|Bone-borne CAD/CAM splint|3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
79724530|NCT04224805|Device|3D interocclusal conventional splint|Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
79724531|NCT04710433|Device|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
79724532|NCT04710433|Other|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
79724533|NCT02767063|Drug|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.
79858836|NCT06044636|Other|Digi-physical breastfeeding support|"Breastfeeding support after birth is provided via chat~Extended home visits by a pediatric nurse after discharge from the maternity ward~Extra support from a lactation counselor when needed after discharge until one year after childbirth"
79858837|NCT06042478|Drug|Remibrutinib|Active treatment
79562421|NCT05437874|Drug|Natural Water|"355 ml of regular coke, diet coke or mineral water should be drunk.~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
79263099|NCT05711979|Behavioral|AARC|"There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting.~This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women."
79263100|NCT05710900|Other|Dietary intervention|Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
79263101|NCT05710770|Device|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
79263102|NCT05670964|Device|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
79263103|NCT05670964|Device|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
79263104|NCT05670821|Drug|Spesolimab|Spesolimab
79263105|NCT05668351|Radiation|SUPR-SABR treatment|SUPR-SABR prescription dose to the PTV_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
79263106|NCT05641103|Other|Patient with splenomegaly or splenectomy|No interventional study
79263107|NCT05638126|Drug|HRS-1780 table or placebo|HRS-1780 table or placebo single dose
79263108|NCT05638126|Drug|HRS-1780 table or placebo|HRS-1780 table or placebo single dose with food effect
79263109|NCT05638126|Drug|HRS-1780 table or placebo|HRS-1780 table or placebo multiple dose
79263110|NCT05627895|Other|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
79858838|NCT06042478|Drug|Placebo to remibrutinib|Placebo followed by active treatment
79263111|NCT05622955|Other|Peer Empowered Endometriosis Pain Support (PEEPS)|The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
79858839|NCT06042478|Drug|Placebo to omalizumab|Placebo followed by active comparator
79858840|NCT06042478|Drug|Omalizumab|Active comparator
79858841|NCT06042257|Drug|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
79858842|NCT06042257|Drug|Placebo|Matching placebo capsule
79858843|NCT06041555|Other|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
79263112|NCT05618912|Device|Hydrocolloid dressing|A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery
79399071|NCT03425292|Drug|Nivolumab|nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
79399072|NCT03425292|Drug|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
79399073|NCT03425292|Drug|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
79399074|NCT03425292|Drug|5-day Temozolomide|150 mg/m^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m^2 permitted)
79399075|NCT03425292|Drug|5-day Temozolomide|100 mg/m^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m^2 permitted)
79562422|NCT05437861|Behavioral|Brief Intervention|A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
79562423|NCT05437783|Drug|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
79562424|NCT05437744|Other|Cyanoacrylate glue|8 sockets that will be treated by immediate implant placement and sealed by a Cyanoacrylate glue.
79858844|NCT06040762|Other|Best Practice|Receive SOC educational materials
79858845|NCT06040762|Other|Exercise Intervention|Receive (P)REHAB exercise program
79858846|NCT06040762|Other|App-Based Intervention|Use ExerciseRx app
79858847|NCT06040762|Other|App-Based Intervention|Use FitBit app
79263113|NCT05618912|Other|Petrolatum jelly dressing|The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
79263114|NCT05618587|Drug|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
79263115|NCT05618587|Drug|Placebo|Inactive pill
79263116|NCT05617040|Biological|ChAdOx1-PCAQ|Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
79263117|NCT05617040|Biological|MVA-PCAQ|Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))
79399076|NCT03425292|Drug|Lomustine|100 mg/m^2 oral, on Day 1 of each 6 week course
79399077|NCT03425292|Drug|Nivolumab monotherapy|nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
79562425|NCT05437744|Other|Platelet-rich fibrin (PRF)|8 sockets that will be treated by immediate implant placement and sealed by PRF.
79263118|NCT05607472|Other|blood sampling|blood samples for bio collection
79399078|NCT00596271|Biological|IC51|
79724534|NCT02767063|Drug|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
79263119|NCT05607472|Other|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
79724535|NCT02766751|Behavioral|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
79263120|NCT05593484|Other|Standard Referral|Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
79263121|NCT05593484|Other|Specialty Telemedicine Access for Referrals (STAR)|The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.
79263122|NCT05583604|Drug|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
79263123|NCT05565625|Other|Sunscreen A|Participants will topically apply Sunscreen A at Visit 1.
79263124|NCT05565625|Other|Sunscreen B|Participants will apply Sunscreen B at Visit 1.
79263125|NCT05565625|Other|Sunscreen C|Participants will apply Sunscreen C at Visit 1.
79263126|NCT05565625|Other|Sunscreen D|Participants will apply Sunscreen D at Visit 1.
79263127|NCT05565625|Other|Sunscreen E|Participants will apply Sunscreen E at Visit 1.
79263128|NCT05565625|Other|Sunscreen F|Participants will apply Sunscreen F at Visit 1.
79399079|NCT00596271|Biological|HAVRIX|
79724536|NCT02766751|Behavioral|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
79724537|NCT02766595|Other|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
79858848|NCT06040762|Other|Interview|Ancillary studies
79858849|NCT06040762|Other|Wearable Activity Tracker|Wear FitBit
79399080|NCT00596271|Other|Placebo|
79399081|NCT03139656|Behavioral|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
79562426|NCT05437731|Other|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
79562427|NCT05437731|Other|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
79858850|NCT06040762|Other|Physical Performance Testing|Ancillary studies
79858851|NCT06040762|Other|Questionnaire Administration|Ancillary studies
79562428|NCT05437718|Other|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
79858852|NCT06039371|Procedure|Biopsy|Undergo a biopsy
79858853|NCT06039371|Procedure|Biospecimen Collection|Undergo blood sample collection
79858854|NCT06039371|Procedure|Bone Scan|Undergo bone scan
79858855|NCT06039371|Drug|Carboplatin|Given IV
79858856|NCT06039371|Procedure|Computed Tomography|Undergo CT
79858857|NCT06039371|Drug|Etoposide|Given PO
79858858|NCT06039371|Other|Quality-of-Life Assessment|Ancillary studies
79858859|NCT06039371|Other|Questionnaire Administration|Ancillary studies
79858860|NCT06039371|Drug|Testosterone Cypionate|Given IM
79858861|NCT06038903|Other|caffeine consumption expectation|The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
79858862|NCT06038630|Drug|Hyperpolarized Xe129|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
79858863|NCT06038630|Other|Oxygen Administration|Oxygen administration
79263129|NCT05562128|Behavioral|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
79263130|NCT05562128|Behavioral|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
79263131|NCT05561517|Other|5 K running|The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
79263132|NCT05561387|Drug|Bortezomib|Given SC
79263133|NCT05561387|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
79858864|NCT06038292|Radiation|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
79858865|NCT06038136|Behavioral|Decreased Neuro Checks overnight|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
79858866|NCT06034743|Drug|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~1 mg per tablet for 1 mg baxdrostat Arm;~2 mg per tablet for 2 mg baxdrostat Arm."
79858867|NCT06034743|Drug|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
79858868|NCT06033196|Drug|Tocilizumab|"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
79263134|NCT05561387|Drug|Dexamethasone|Given PO
80021109|NCT03587870|Other|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
80021110|NCT03576274|Behavioral|Technology Enhanced Home Exercise (TEHE)|A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
80021111|NCT03576274|Behavioral|Auricular Point Acupressure (APA)|A non invasive complementary method to provide pressure on the ear points.
80021112|NCT03576274|Behavioral|Mindfulness body scan (MBI)|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
79263135|NCT05561387|Drug|Lenalidomide|Given PO
79263136|NCT05561387|Other|Quality-of-Life Assessment|Ancillary studies
79263137|NCT05561387|Other|Questionnaire Administration|Ancillary studies
79263138|NCT05559489|Drug|Oral Rehydration Solution|Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
79858869|NCT06033196|Drug|Placebo for Tocilizumab|"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
79858870|NCT06031441|Drug|RO7566802|RO7566802 solution for infusion will be administered as specified in each treatment arm.
79858871|NCT06031441|Drug|Atezolizumab|Atezolizumab solution for infusion will be administered as specified in each treatment arm.
80021113|NCT03539068|Behavioral|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
79263139|NCT05559489|Drug|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
79263140|NCT05520359|Device|Mobility Device|Use of mobility device during session.
79263141|NCT05520359|Device|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
79858872|NCT06029972|Drug|Tilpisertib Fosmecarbil|Tablets administered orally
79858873|NCT06029972|Drug|Placebo|Tablets administered orally
79858874|NCT06029452|Other|Machine learning algorithm|Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features
79263142|NCT05517655|Drug|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
79263143|NCT05511948|Drug|DBI-102|Topical application on dorsal hand and upper volar arm
79263144|NCT05511948|Drug|Vehicle gel|Inactive comparator
79263145|NCT05511948|Drug|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
79263146|NCT05499728|Other|Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)|Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
79263147|NCT05468008|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is an outpatient procedure to remove deep tumors from the gastrointestinal (GI) tract
79263148|NCT05465655|Other|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
79858875|NCT06026228|Dietary Supplement|Limosilactobacillus reuteri|"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10^8 CFU*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~*Colony forming Unit"
79263149|NCT05461092|Drug|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
80021114|NCT03508726|Drug|Ascorbate|"Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV"
80021115|NCT03499964|Device|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
80021116|NCT03499964|Device|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
80021117|NCT03437694|Other|Medication optimization intervention|Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
79263150|NCT05461092|Diagnostic Test|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, IL-8, IL-6, TNFa
79263151|NCT05461092|Other|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
79263152|NCT05461092|Other|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
79263153|NCT05461092|Other|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
79562429|NCT05437666|Other|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
79562430|NCT05437666|Other|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
79562431|NCT05437653|Other|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
79858876|NCT06026228|Other|Placebo|The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
80021118|NCT03404661|Drug|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
80021119|NCT03370172|Drug|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
80021120|NCT03351803|Other|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
80021121|NCT03328130|Biological|AAV2/5-hPDE6B|Subretinal administration in one eye
79562432|NCT05437653|Other|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
79562433|NCT05437627|Diagnostic Test|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
79858877|NCT06026111|Behavioral|High-Intensity Interval Training|Home-based, virtually supervised, aerobic exercise intervention with trained exercise specialist. Exercise is high intensity in an interval fashion. Participants will be provided with home stationary bike, heart-rate monitor/watch, and automatic blood pressure cuff.
79858878|NCT06026111|Behavioral|Moderate-Intensity Continuous Training|Home-based, virtually supervised, aerobic exercise intervention with trained exercise specialist. Exercise is moderate intensity in a continuous fashion. Participants will be provided with home stationary bike, heart-rate monitor/watch, and automatic blood pressure cuff.
79263154|NCT05461092|Other|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
79263155|NCT05461092|Other|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
79263156|NCT05461092|Other|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
79562434|NCT05437614|Procedure|Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
79562435|NCT05437614|Procedure|Cyclocryoablation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by cyclocryoablation
79562436|NCT05437549|Procedure|MRI|MRI prior to PVI, acutely after PVI, and 3 months after PVI
79858879|NCT06024109|Device|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
79263157|NCT05461092|Other|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
79263158|NCT05461092|Other|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
79263159|NCT05461092|Other|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
79263160|NCT05461092|Other|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
79858880|NCT06021795|Device|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
80021122|NCT03319537|Drug|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
79263161|NCT05461092|Other|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
79263162|NCT05461092|Other|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
79263163|NCT05461092|Other|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
79263164|NCT05461092|Other|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
79263165|NCT05461092|Other|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
79562437|NCT05437523|Other|Constipation Action Plan|The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
79562438|NCT05437523|Other|Standard of care without constipation action plan|Standard of care without constipation action plan
79562439|NCT05437497|Drug|Remimazolam Injection|The experimental group was sedated with remimazolam
79263166|NCT05461092|Other|Quality of Recovery 15|Questionnaire assessing postoperative quality of recovery
79562440|NCT05437497|Drug|Propofol Injection|The control group was sedated with propofol
79724538|NCT04224103|Drug|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
79724539|NCT02766439|Drug|etanercept|25-mg etanercept injection subcutaneously twice a week
79724540|NCT04651075|Other|music listening|The music selected by the participants was played to the music listening group.
79858881|NCT06021548|Other|Blood sample|Finger stick blood spots will be collected at V0 and M12
79858882|NCT06021548|Other|Saliva sample|Saliva sample will be collected at V0
79858883|NCT06021548|Other|Hair sample|Hair sample will be collected at V0 (optional)
79858884|NCT06020898|Drug|Sodium valproate|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
80021123|NCT03319537|Drug|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
80021124|NCT03279692|Drug|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
80021125|NCT03276702|Procedure|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
80021126|NCT03276702|Other|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
80021127|NCT03152929|Drug|Paravertebral Block|20-30 mL 0.5% Ropivacaine
80021128|NCT03152929|Drug|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
79263167|NCT05456841|Behavioral|Empathic Communication Skills (ECS) training|"The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others"
79263168|NCT05456841|Other|Standard of Care participant interaction|Standard of Care participant interaction
79263169|NCT05451212|Biological|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
79263170|NCT05424913|Other|research-specific blood sample|blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
79724541|NCT04651075|Other|individual training|Individual training group was trained on coronary angiography.
79263171|NCT05422079|Other|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week.
79263172|NCT05422079|Other|motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program.
79263173|NCT05422079|Other|motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
79263174|NCT05420935|Diagnostic Test|IgG group|"Will be performed :~a blood sampling of 5 ml (for realization of a basophil activation test)~a blood sampling of 250 ml"
79263175|NCT05420935|Diagnostic Test|IgE group|"Will be performed :~a blood sampling of 5 ml (for realization of a basophil activation test)~a bone marrow sampling"
79724542|NCT04223869|Other|non-surgical periodontal treatment|scaling and root planing were performed
79263176|NCT05420935|Diagnostic Test|IgG group + IgE group|"a blood sampling of 5 ml (for realization of a basophil activation test)~a blood sampling of 250 ml~a bone marrow sampling"
79263177|NCT05414032|Biological|AZD2936|AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
79263178|NCT05413720|Other|two additional blood samples specific to research|proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
79263179|NCT05409846|Diagnostic Test|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
79263180|NCT05395767|Procedure|Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor|The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
79263181|NCT05374447|Procedure|Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy|Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
79263182|NCT05373641|Other|Repeated feedback|Repeated feedback monthly based on previous month pain documentation audit results.
79263183|NCT05373641|Other|Pain documentation audit|Monthly pain documentation audit
79263184|NCT05371288|Dietary Supplement|NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH)|Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
79263185|NCT05366465|Other|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
79263186|NCT05355012|Other|5A organizational innovation|"This project is based on three strategic axes:~A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
79562441|NCT05437484|Behavioral|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
79562442|NCT05437471|Drug|GNRH Analoge, Duphaston, Letrozole|GNRH Analoge, Duphaston, Letrozole
79562443|NCT05437432|Procedure|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
79724543|NCT02766361|Behavioral|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
79724544|NCT02766361|Other|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
79724545|NCT02766127|Other|Veritise Flow|Self-adhering composite
79724546|NCT02766127|Other|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
79724547|NCT02766127|Other|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
79724548|NCT02766127|Other|Flor-Opal® Varnish|fluoride-based varnish
79724549|NCT02766049|Biological|DC|Autologous dendritic cells (3x10e7)
79724550|NCT02766049|Biological|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
79724551|NCT02766049|Biological|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
79858885|NCT06020898|Drug|Normal saline|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
79858886|NCT06020183|Device|Hybrid hyrax|these patents will be treated using Four mini-screws supported hybrid hyrax
79858887|NCT06019000|Combination Product|CYR-064|CYR-064 is a nasal solution.
79263187|NCT05346887|Behavioral|Home-based Therapy|The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
79263188|NCT05345184|Behavioral|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)|Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
79263189|NCT05345184|Behavioral|Services as Usual (SAU)|Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
79263190|NCT05328856|Device|Hansgrohe prototype|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out with a mixing function for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
79562444|NCT05437432|Procedure|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
79263191|NCT05325853|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
79263192|NCT05325853|Drug|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
79562445|NCT05437367|Other|Scapular Stabilization exercises|Therapeutic exercises
79263193|NCT05321615|Device|Palpator|Palpator for tumor localization
79858888|NCT06018428|Drug|ADX-914|Subcutaneous administration of ADX-914
79858889|NCT06018428|Drug|Placebo|Subcutaneous administration of placebo
79263194|NCT05321615|Device|Grasper|Atraumatic lung grasper
79263195|NCT05321615|Device|Ultrasound|VATS ultrasound
79263196|NCT05321615|Other|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
79263197|NCT05320809|Biological|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
79263198|NCT05312255|Behavioral|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
79263199|NCT05312255|Drug|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
79263200|NCT05312255|Drug|Propranolol|Given PO
79562446|NCT05437367|Other|Postural correction exercises|Therapeutic exercises
79858890|NCT06018350|Behavioral|Clinician-led adherence intervention|The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
79263201|NCT05312255|Other|Quality-of-Life Assessment|Ancillary studies
79263202|NCT05312255|Other|Questionnaire Administration|Ancillary studies
79263203|NCT05312255|Other|Resistance Training|Undergo strength training for 6 months
79263204|NCT05312255|Other|Short-Term Fasting|Participate in intermittent fasting
79562447|NCT05437341|Biological|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10^6 cells/kg body weight via IV
79562448|NCT05437328|Biological|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10^6 cells/kg body weight via IV
79562449|NCT05437315|Biological|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10^6 cells/kg body weight via IV
79562450|NCT05437302|Device|prism spectacle|a prism is dispensed in prescription glasses
79562451|NCT05437237|Diagnostic Test|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
79562452|NCT05437224|Drug|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
79562453|NCT05437185|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
79724552|NCT02765971|Other|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
79724553|NCT02765971|Drug|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
79724554|NCT02765971|Drug|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
79724555|NCT02765815|Drug|Liposomal bupivacaine, 266mg|
79724556|NCT02765815|Drug|Bupivacaine 0.5 % with Epinephrine|
79724557|NCT02765815|Drug|Ketorolac 30mg|
79724558|NCT02765815|Drug|Morphine 10mg|
79724559|NCT02765815|Drug|Bupivacaine 0.25% with Epinephrine|
79724560|NCT02765893|Other|No Foley|Patients will have Foley catheter removed 6 hours post-op.
79858891|NCT06018194|Device|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
79858892|NCT06015620|Procedure|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
79858893|NCT06014827|Procedure|Biospecimen Collection|Undergo blood sample collection
79858894|NCT06014827|Procedure|Computed Tomography|Undergo CT or PET/CT scan
79263205|NCT05310578|Procedure|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
79858895|NCT06014827|Drug|Osimertinib|Given PO
79263206|NCT05304819|Device|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
79858896|NCT06014827|Procedure|Positron Emission Tomography|Undergo PET/CT
79263207|NCT05283018|Device|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
79263208|NCT05283018|Other|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
79562454|NCT05437185|Device|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
79562455|NCT05437133|Device|Custom fabricated elbow extension orthosis|custom low temperature thermoplastic orthosis (Splint) holding the elbow in maximum extension at night
79562456|NCT05437081|Behavioral|Latino Emerging Adults (LEA)|The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
79562457|NCT05436990|Drug|Pembrolizumab, Vactosertib|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
79562458|NCT05436977|Diagnostic Test|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
79562459|NCT05436977|Diagnostic Test|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
79562460|NCT05436938|Combination Product|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
79562461|NCT05436847|Other|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
79562462|NCT05436847|Other|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
79562463|NCT05436821|Device|Auricular vagus nerve stimulation|Autonomic nerve system regulation
79562464|NCT05436821|Device|Sham Auricular Vagus Nerve Stimulation (AVNS)|Sham Auricular Vagus Nerve Stimulation (AVNS)
79562465|NCT05436782|Other|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
79562466|NCT05436782|Other|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
79724561|NCT02765581|Device|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
80021129|NCT03139266|Behavioral|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
80021130|NCT03139266|Behavioral|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
80021131|NCT03100786|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
79858897|NCT06014827|Radiation|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
79858898|NCT06014827|Other|Survey Administration|Ancillary study
79858899|NCT06013475|Drug|Apalutamide|Decision by the treating physician
79858900|NCT06013475|Drug|Darolutamide (BAY 1841788)|Decision by the treating physician
79858901|NCT06013475|Drug|Enzalutamide|Decision by treating physician
79858902|NCT06013423|Procedure|Biospecimen Collection|Undergo blood sample collection
79858903|NCT06013423|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
79858904|NCT06013423|Drug|Cyclophosphamide|Receive IV
79858905|NCT06013423|Drug|Cyclosporine|Receive IV or PO
79858906|NCT06013423|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
79858907|NCT06013423|Procedure|Echocardiography|Undergo ECHO
79858908|NCT06013423|Drug|Fludarabine Phosphate|Receive IV
79858909|NCT06013423|Procedure|Multigated Acquisition Scan|Undergo MUGA
79858910|NCT06013423|Drug|Mycophenolate Mofetil|Receive IV
79858911|NCT06013423|Other|Survey Administration|Ancillary studies
79858912|NCT06013423|Drug|Thiotepa|Receive IV
79724562|NCT02765581|Device|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
79263209|NCT05283018|Device|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
79724563|NCT02765581|Behavioral|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
79263210|NCT05283018|Device|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
79724564|NCT02765347|Drug|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
79858913|NCT06013423|Radiation|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
80021132|NCT03100786|Other|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
79263211|NCT05276219|Drug|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
79263212|NCT05276219|Drug|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
79263213|NCT05276219|Drug|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
80021133|NCT03047239|Device|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
79724565|NCT02765347|Drug|Insulin|For arm 2, just accept insulin for 24 weeks
79724566|NCT02765425|Device|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
79724567|NCT04223713|Procedure|TriRec|Trileaflet Reconstruction of the Aortic Valve
79724568|NCT04223713|Procedure|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
79724569|NCT02764957|Dietary Supplement|green coffee extract|
79724570|NCT02764957|Dietary Supplement|placebo|
79858914|NCT06013423|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
79562467|NCT05436743|Drug|K-Y Jelly, Topical Gel soaked packs|Topical Gel used as lubricant
79562468|NCT05436743|Other|Water soaked packs|Water soaked packs for reduction of postoperative sore throat
79562469|NCT05436730|Device|Ambulatory blood pressure measurement device|Assessment of the 24-h blood pressure profile
79263214|NCT05272488|Other|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
79263215|NCT05272488|Other|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
79263216|NCT05268055|Other|"Sign Here training intervention"|Training film to educate healthcare providers to competently and sensitively interact with Deaf patients in healthcare settings.
79724571|NCT02765113|Procedure|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
79724572|NCT02765113|Procedure|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
79858915|NCT06013111|Biological|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10^7 CAR-T cells/kg, 1×10^7 CAR-T cells/kg, and 3×10^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
79858916|NCT06007547|Drug|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
79562470|NCT05436730|Device|Sphygmocor|Assessment of the arterial stiffness
79562471|NCT05436730|Device|VaSera-VS|Assessment of the arterial stiffness
79263217|NCT05268055|Other|Intervention as usual|"Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
79858917|NCT06004921|Drug|AB801|Administered as specified in the treatment arm
79858918|NCT06004921|Drug|Placebo|Administered as specified in the treatment arm
79858919|NCT06004245|Drug|RO7589831|RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
79263218|NCT05265052|Drug|3D1002 (50 mg)(Phase IIa)|1 tablet of 3D1002 per oral dose
79263219|NCT05265052|Drug|3D1002 (100 mg)(Phase IIa)|2 tablets of 3D1002 per oral dose
79562472|NCT05436730|Device|Somnocheck|Assessment of the sleep breath disturbances
79562473|NCT05436704|Procedure|EUS-FNB|EUS-FNB
79263220|NCT05265052|Drug|3D1002 (150 mg)(Phase IIa)|3 tablets of 3D1002 per oral dose
79263221|NCT05265052|Drug|3D1002 monotherapy (Phase IIb)|3D1002 is administered at recommended dose with mimic OxyContin tablets.
79858920|NCT06003699|Behavioral|Search Inside Yourself (SIY) program|The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
79858921|NCT06001775|Behavioral|Patient Priorities Care|According to patientprioritiescare.org a Patient Priorities Care conversation helps to align healthcare decision-making and care by all clinicians with patients' own health priorities. Patient Priorities Care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare.
79263222|NCT05265052|Drug|OxyContin monotherapy (Phase IIb)|OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
79263223|NCT05265052|Drug|3D1002 + OxyContin (Phase IIb)|3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
79263224|NCT05255484|Drug|LM-108|Administered intravenously
79562474|NCT05436691|Other|Information and Coping with Anxiety Training|Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
79858922|NCT06000670|Procedure|stromal vascular fraction injection in the osteoarthritic knee|stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
79858923|NCT06000072|Other|Core Exercise Program|Core exercises
79858924|NCT05999149|Drug|Camrelizumab Plus Chemotherapy and Famitinib|camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
79858925|NCT05999149|Drug|Camrelizumab Plus Chemotherapy|Camrelizumab Plus Chemotherapy
79562475|NCT05436574|Other|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
79562476|NCT05436509|Biological|bi-4SCAR CD19/79b T cells|Infusion of bi-4SCAR-CD19/79b T cells at 10^6 cells/kg body weight via IV
79858926|NCT05998304|Drug|[14C] Yiqibuvir|600 mg suspension containing 100µCi of [14C] Yiqibuvir
79858927|NCT05998135|Drug|Atovaquone|Given PO
79858928|NCT05998135|Procedure|Biopsy|Undergo biopsy
79858929|NCT05998135|Procedure|Computed Tomography|Undergo CT
79858930|NCT05998135|Procedure|Paracentesis|Undergo paracentesis
80021134|NCT03011541|Procedure|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
80021135|NCT03001882|Biological|Nivolumab|Specified dose on specified days
80021136|NCT03001882|Biological|Ipilimumab|Specified dose on specified days
80021137|NCT02985151|Device|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
80021138|NCT02981966|Drug|Dapagliflozin|dapagliflozin, 10mg tablet
80021139|NCT02981966|Drug|Placebo|Placebo for dapagliflozin
80021140|NCT02932956|Genetic|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10^7/m2~DL2: 3x10^7/m2~DL3: 1x10^8/m2~DL4: 3x10^8/m2~DL5: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
79263225|NCT05255484|Drug|An Anti-PD-1 Antibody|Administered intravenously
79263226|NCT05254678|Behavioral|general exercise|A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
79562477|NCT05436496|Biological|bi-4SCAR CD19/70 T cells|Infusion of bi-4SCAR CD19/70 T cells at 10^6 cells/kg body weight via IV
79858931|NCT05997914|Behavioral|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
79858932|NCT05997446|Device|Left atrial appendage occlusion (LAAO)|Implantation of an Amplatzer Amulet left atrial appendage occluder
79858933|NCT05995171|Other|Questionnaire|Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
79581252|NCT01934413|Other|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
79263227|NCT05243368|Dietary Supplement|Personalized Nutritional Intervention|Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
79263228|NCT05223816|Drug|VG161|"Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, <5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections."
80021141|NCT02932956|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
80021142|NCT02932956|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
79581253|NCT01934439|Device|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
79581254|NCT01934491|Behavioral|Cognitive Training A|
80021143|NCT02891148|Drug|BI 690517|
79724573|NCT04686175|Drug|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
79724574|NCT02764879|Dietary Supplement|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
79724575|NCT02764879|Procedure|scaling and root planing|
79724576|NCT02764879|Other|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
79724577|NCT02764645|Device|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
79858934|NCT05993377|Other|Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .|we will use robust machine learning approaches, such as Random Forest and XGBoost.
79858935|NCT05993104|Diagnostic Test|Intrachamber ultrasound|Ultrasound left atrial geometry collecting using AcQMap.
79858936|NCT05993104|Other|Statistical shape analysis|Statistical shape analysis tools used to investigate left atrial geometry
79263229|NCT05223816|Drug|Nivolumab Injection [Opdivo]|immunotherapy treatment
79724578|NCT02764645|Device|22Fr curved Cannula|arterial cannula for use in cardiac surgery
79858937|NCT05989581|Drug|BP <130/80mmHg|The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs <130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.
79263230|NCT05211401|Drug|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
79724579|NCT02770885|Drug|Dulaglutide|Treatment with dulaglutide for 3 weeks.
79724580|NCT02770885|Drug|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
79724581|NCT02770651|Device|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
79724582|NCT02770651|Device|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
80021144|NCT02843165|Drug|Checkpoint blockade immunotherapy|Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
80021145|NCT02843165|Radiation|Checkpoint blockade immunotherapy plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
80021146|NCT02807467|Drug|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
80021147|NCT02807467|Drug|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
79263231|NCT05211401|Drug|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
79263232|NCT05211401|Drug|Placebo arm|Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
79263233|NCT05203939|Drug|OCU400 Low Dose|subretinal injection of up to 1.66 × 10^10 vg/mL
79263234|NCT05203939|Drug|OCU400 Med Dose|subretinal injection of upto 3.33 × 10^10 vg/mL
79263235|NCT05203939|Drug|OCU400 High Dose|subretinal injection of upto 1.66 × 10^11 vg/mL
79263236|NCT05199714|Drug|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
79263237|NCT05199714|Device|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
79263238|NCT05199714|Drug|Pramlintide|Pramlintide delivered in a basal-bolus manner.
79724583|NCT02770573|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
79263239|NCT05199714|Drug|Aspart|Aspart insulin delivered in a basal-bolus manner.
80021148|NCT02795052|Procedure|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
79263240|NCT05197231|Procedure|Resisted knee extension exercise|Patients in the intervention group will perform a seated knee extension exercise in three sets. Resistance will be adjusted using ankle weights, targeting 8-12 repetitions per set.
79263241|NCT05197231|Drug|IV amino acids|IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
79562478|NCT05436405|Procedure|Trans-pedal access for endovascular revascularization in complex infra-popliteal lesions in critically ischemic limb|"Briefly, conventional femoral access will be conducted in the traditional manner and involve the sheath while the catheter was introduced close to the proximal degree of lesion.~Access to a pedal vessel: Using a 21-guage needle or by utilizing a micro puncture access set. Such vessel is recognized using the US probe. such approach performed in 54 patients.a fluoroscopy might enable a good possibility for efficient access. In addition, it was suggested to utilize micro-puncture needle supposed to have echogenic pattern as the tip of regular needle is very hard to visualize utilizing the duplex US probe. Also, use of straight fluoroscopy or road mapping may offer a better chance for successful access, this method is done in 31 cases . Another method is open method (cut down) on tibial vessels, this method is done in 11 cases."
79724584|NCT02770573|Other|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
79724585|NCT02770573|Other|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
79724586|NCT02770729|Drug|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
79263242|NCT05196919|Biological|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
79263243|NCT05196919|Biological|Placebo|Phosphate-buffered saline for injection
79263244|NCT05164705|Other|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
79263245|NCT05164705|Other|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
79263246|NCT05150093|Procedure|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
79263247|NCT05149573|Device|Pulsed Electromagnetic Field (PEMF) Device|BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
79562479|NCT05431738|Device|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
79562480|NCT05429229|Drug|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
79562481|NCT05429229|Drug|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
79562482|NCT05429229|Drug|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
79562483|NCT05427643|Procedure|study group|dental implant procedure under local anesthesia
79562484|NCT05427643|Procedure|control group|dental implant procedure under local anesthesia
79562485|NCT05426811|Drug|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
79562486|NCT05426811|Drug|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
79562487|NCT05426369|Biological|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
79263248|NCT05149573|Device|Sham Pulsed Electromagnetic Field (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
79263249|NCT05139147|Device|DAISe Thrombectomy System|DAISe Thrombectomy System for mechanical thrombectomy
79562488|NCT05426148|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
79562489|NCT05422352|Dietary Supplement|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
79562490|NCT05419765|Diagnostic Test|Peripheral blood withdrawn|"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"
79562491|NCT05400304|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
79562492|NCT05393089|Drug|AGN-190584|Eye drops
79562493|NCT05393089|Drug|Vehicle|Eye drops
79724587|NCT02770729|Drug|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
79724588|NCT02770807|Drug|EDS-EP dose range of ~5-10 mg DSP/infusion|infusion
79724589|NCT02770807|Drug|EDS-EP dose range of ~14-22 mg DSP/infusion|infusion
79263250|NCT05139069|Behavioral|Trauma-Informed Toolkit|Staff in this intervention will be trained to conducting intimate partner violence screening, and providing support to women through referrals to local community resources; to help African American women identify and understand HIV risk factors (e.g., unprotected condom less sex with a male partner who is HIV-positive or unknown HIV status); and to communicate with their African American women patients in a respectful way in order to build trust and facilitate shared decision making.
79263251|NCT05137392|Other|oral hygiene instruction|The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
79263252|NCT05124860|Diagnostic Test|Indirect calorimetry|Measurement of metabolic rate (kcal/day) by respiratory gas analysis.
79263253|NCT05121974|Drug|Tebipenem Pivoxil|Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.
79263254|NCT05121974|Drug|Azithromycin|Oral Azithromycin antibiotic (Macrolides)
80021149|NCT02794428|Drug|Eflornithine|Eflornithine*, 2 tablets, Oral, Daily for 18 months
79562494|NCT05360524|Procedure|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
79263255|NCT05121974|Drug|Ceftriaxon|IV Ceftriaxone (Cephalosporin)
79263256|NCT05103280|Other|Assistive tennis shoes|Assistive shoes include carbon-fiber and spring loaded shoes.
79562495|NCT05304182|Device|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
79562496|NCT05304182|Device|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
79562497|NCT05195099|Other|respiratory treatment|Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
79724590|NCT02770807|Drug|Placebo|infusion
79263257|NCT05085704|Device|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
79263258|NCT05080842|Drug|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
79263259|NCT05080101|Other|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
79581255|NCT01934491|Behavioral|Cognitive Training B|
79724591|NCT02770495|Other|blood sample|
79724592|NCT02770417|Dietary Supplement|beta-alanine|Patients receive beta-alanine
79724593|NCT02770417|Dietary Supplement|placebo|Patients receive placebo
79724594|NCT02770417|Other|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
79724595|NCT02770105|Other|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
79724596|NCT02770105|Other|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
79724597|NCT02770105|Other|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
79724598|NCT02770105|Other|Placebo|Oral administration of 200ml of distilled water
79724599|NCT02770027|Drug|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
79724600|NCT02770027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
79724601|NCT02769871|Behavioral|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
80021150|NCT02794428|Other|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
79263260|NCT05080101|Other|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
79858938|NCT05989451|Behavioral|Dialectical behavior therapy (DBT)|The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
79263262|NCT05041257|Drug|Mirvetuximab soravtansine|Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
79263263|NCT05036642|Device|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
79263264|NCT05026996|Drug|Pelacarsen|Single subcutaneous injection of pelacarsen
79263265|NCT05025267|Other|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
79263266|NCT04995562|Drug|129Xe|Inhaled contrast for MRI
79562498|NCT05019482|Behavioral|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~Design-based innovative workshops during the first week;~8-weeks program of Physical Activity constructed by users~Information session focusing on the promotion of active behaviors~Feedback provided to the users with an individualized report"
79562499|NCT04970381|Drug|Rivaroxaban|Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks
79562500|NCT04932226|Device|cloth mask|Buff bandana double layer worn over nose and mouth
79562501|NCT04932226|Device|surgical mask|standard surgical mask
79562502|NCT04932226|Device|FFP2 respirator|filtering facepiece 2 respirator
79858939|NCT05988567|Dietary Supplement|Placebo candy|consume 2 tablets per day
79858940|NCT05988567|Dietary Supplement|melon and oil olive pressed candy|consume 2 tablets per day
79858941|NCT05988554|Dietary Supplement|Placebo sachet|Consume 1 sachet daily
79263267|NCT04984811|Drug|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
79263268|NCT04984811|Drug|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
79263269|NCT04975711|Drug|HIP2105|Test drug
79263270|NCT04975711|Drug|RLD2104|Reference drug
79263271|NCT04942067|Drug|APG-2575+ Pd|APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients > 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
79263272|NCT04942067|Drug|APG-2575 + DRd|APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients > 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
79263273|NCT04922255|Device|Reusable Underwear|Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
79263274|NCT04922255|Device|Disposable urethral support|The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
79562503|NCT04915560|Device|Connected T-shirt|Ware of a connected T-shirt
79562504|NCT04895046|Drug|Niraparib|300 mg taken orally (all cycles)
79562505|NCT04895046|Drug|Dostarlimab|500 mg (cycles 1-4) intravenously
79562506|NCT04895046|Drug|Dostarlimab|1000 mg (cycle 5+) intravenously
79562507|NCT04837105|Other|Serious game ARROW CP|"ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session."
79263275|NCT04922255|Behavioral|Pelvic floor physical therapy|Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
79263276|NCT04897139|Drug|Flu-Bu-Mel-E|Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
79263277|NCT04895813|Behavioral|Education|The patient will be given pre-colonoscopy training and guidance by telephone.
79263278|NCT04891497|Drug|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
79263279|NCT04891497|Drug|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
79263280|NCT04890379|Drug|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
79263281|NCT04890379|Drug|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
79263282|NCT04890353|Drug|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
79562508|NCT04837105|Other|Treadmill|Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
79562509|NCT04805398|Biological|CM310|300 mg every two weeks
79562510|NCT04805398|Biological|Placebo|300 mg every two weeks
79562511|NCT04721444|Diagnostic Test|Machine Learning Classification of parenchymal lung change cause|Arms A & B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
79263283|NCT04887298|Drug|Liposomal Annamycin (L-Annamycin)|2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
79263284|NCT04843579|Drug|Selinexor|Given as 60 mg oral capsule
79263285|NCT04843579|Drug|Clarithromycin|Given as 500 mg oral capsule
79263286|NCT04843579|Drug|Pomalidomide|Given as 4 mg oral capsule
79562512|NCT04721444|Diagnostic Test|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
79562513|NCT04704011|Other|2-1-1 United Way Healthy Missouri Hotline|This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.
79263287|NCT04843579|Drug|Dexamethasone|Given as 40 mg oral capsule
79858942|NCT05988554|Dietary Supplement|Hibiscus sabdariffa extract and collagen products|Consume 1 sachet daily
79263288|NCT04837833|Diagnostic Test|ultrasound|Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
79263289|NCT04827446|Other|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
79263290|NCT04827446|Other|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
79562514|NCT04704011|Other|National Comprehensive Cancer Network (NCCN) Distress Thermometer|Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.
79562515|NCT04704011|Other|Basic needs survey|11-item survey with questions regarding safety, housing, food, and financial needs
79562516|NCT04704011|Other|2-1-1 survey|This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.
79562517|NCT04704011|Other|Usual Care Reminder Call|-Automated phone call two weeks before their colposcopy appointment
79562518|NCT04677829|Biological|PNT001|30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg
79562519|NCT04677829|Biological|%5 dextrose for infusion|30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg
79858943|NCT05986188|Other|Pathways to Potential|Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
79858944|NCT05985473|Other|audiological measurements|audiological measurements
79858945|NCT05985473|Other|Objective and subjective audiological measurements|Objective and subjective audiological measurements
79562520|NCT04672551|Behavioral|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
79858946|NCT05985473|Other|Evaluation of the denoising methods REFINED|Evaluation of the denoising methods REFINED
79263291|NCT04827446|Other|Clear glasses|Patient is given glasses that block no visible light.
79263292|NCT04827446|Other|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
79263293|NCT04827446|Other|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
79263294|NCT04794777|Combination Product|Individualised therapy|"Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention."
79562521|NCT04657198|Biological|RSVPreF3 OA investigational vaccine (GSK3844766A)|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
79858947|NCT05984992|Drug|SRN-001|siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
79858948|NCT05984992|Drug|Placebo|0.9% Sodium Chloride(Normal saline)
79858949|NCT05984199|Biological|VCAR33|Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
79858950|NCT05984069|Other|observational prospective data collection|Collection of data from medical records.
79858951|NCT05983770|Drug|AT-1501|IV infusions of AT-1501 20 mg/kg over 1 hour.
79263295|NCT04794777|Radiation|Standard salvage therapy|Standard salvage radiotherapy
79263296|NCT04781491|Behavioral|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
79263297|NCT04780646|Behavioral|Nature therapy in urban nature|Nature therapy means visits in nature, actively perceiving the flora and fauna
79263298|NCT04780646|Behavioral|City Walk|City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
79263299|NCT04768244|Other|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
79263300|NCT04751734|Biological|Covid vaccines|women within Priority groups for coronavirus (COVID-19) vaccination
79263301|NCT04723147|Drug|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
79263302|NCT04723147|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
79562522|NCT04645836|Behavioral|New management mode|"New management mode intervention: Pharmaceutical care~SMS text messages and Phone Calls~Behavioural Educational leaflet~Self-Administered Therapy A financial incentive for mobile use"
79562523|NCT04599647|Biological|PVSRIPO|PVSRIPO (5x10^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
79562524|NCT04590586|Drug|Standard of care|Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
79562525|NCT04590586|Drug|Apremilast|Apremilast administered orally as a tablet.
79562526|NCT04590586|Drug|Apremilast placebo|Matching apremilast placebo administered orally as a tablet.
79562527|NCT04590586|Drug|Lanadelumab|Lanadelumab administered as an intravenous (IV) infusion.
79562528|NCT04590586|Drug|Lanadelumab placebo|Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
79263303|NCT04669158|Drug|Idebenone|Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.
79263304|NCT04669158|Drug|Placebo|Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
79263305|NCT04667559|Device|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
79263306|NCT04661176|Diagnostic Test|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
79263307|NCT04649359|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
79562529|NCT04590586|Drug|Zilucoplan|Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
79562530|NCT04590586|Drug|Zilucoplan placebo|Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
79562531|NCT04588012|Behavioral|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
79562532|NCT04588012|Behavioral|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
79562533|NCT04564209|Other|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
79263308|NCT04646200|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
79308841|NCT04813341|Other|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
79562534|NCT04477707|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
79562535|NCT04312009|Drug|Losartan|Losartan; 50 mg daily; oral administration
79562536|NCT04312009|Other|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
79562537|NCT04252573|Device|Chimney Endovascular Aortic Sealing (ChEVAS) System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
79562538|NCT04232696|Device|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
79562539|NCT04100096|Drug|Brexpiprazole|Tablet
79562540|NCT04100096|Other|Placebo|Tablet
79562541|NCT03964337|Drug|Cabozantinib|Cabozantinib 40 mg by mouth daily for 4 weeks.
79562542|NCT03964337|Procedure|Radical Prostatectomy|Radical prostatectomy as part of routine medical care.
79562543|NCT03957226|Device|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
79858952|NCT05983770|Drug|Tacrolimus|Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
79263309|NCT04646200|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
79263310|NCT04635865|Device|3D-printed patient-specific plate|"We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder."
79263311|NCT04635865|Device|Conventional commercial reconstruction plate|Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.[
79263312|NCT04632030|Behavioral|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
79263313|NCT04613154|Dietary Supplement|magnesiumcitrate|Magnesiumcitrate 250 mg, Apoteket AB, Sweden
79263314|NCT04613154|Dietary Supplement|Placebo|Ester-c
79263315|NCT04600544|Other|Non-interventional|Translational, observational study
79858953|NCT05983692|Device|Magnesium based wire|Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
79858954|NCT05981521|Diagnostic Test|Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21
79858955|NCT05981456|Other|patient safety competency|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.
79263316|NCT04594980|Procedure|lumbar fusion|Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
79263317|NCT04572230|Device|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
79263318|NCT04567693|Other|Early spaced-out appointments|Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
79263319|NCT04566731|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
79263320|NCT04566731|Device|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
79562544|NCT03937466|Device|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
79858956|NCT05981456|Other|satisfaction with the training method|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
79858957|NCT05979389|Drug|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
79858958|NCT05979389|Drug|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
80021151|NCT02741986|Other|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
79858959|NCT05978908|Drug|FC-12738|Retro enversio pentapeptide of thymopentin
79858960|NCT05978908|Drug|Saline|placebo
79858961|NCT05978804|Other|Computerized Cognitive Training via BrainHQ|Computerized Cognitive training (BrainHQ)
79858962|NCT05978804|Device|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
80021152|NCT02740179|Drug|Eplerenone|Eplerenone 50mg by mouth twice daily
80021153|NCT02740179|Drug|Placebo|Placebo by mouth twice daily
80021154|NCT02740179|Behavioral|Lifestyle Modification|Counseling regarding diet and healthy activity
79263321|NCT04566731|Behavioral|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
79263322|NCT04526106|Drug|RLY-4008|RLY-4008 is an oral inhibitor of FGFR2
79858963|NCT05977660|Diagnostic Test|Cumberland ankle instability tool for diagnose to determine ankle instability and its severity|CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.
79858964|NCT05976698|Drug|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
79858965|NCT05976698|Drug|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
79858966|NCT05976698|Drug|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
79858967|NCT05965544|Drug|Bupivacain (preoperative)|After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
79858968|NCT05965544|Drug|Bupivacaine-fentanyl|The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
79858969|NCT05965544|Drug|Bupivacain (Postoperative)|After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
79858970|NCT05961033|Device|Virtual Reality based exercises|Play VR games
79858971|NCT05960773|Drug|Decitabine/cedazuridine|Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
79263323|NCT04484740|Drug|Gepotidacin|Single oral dose of 1500 mg gepotidacin
79263324|NCT04481347|Device|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
79263325|NCT04481347|Other|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
79263326|NCT04481347|Device|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
79263327|NCT04475146|Other|video vizualisation|video vizualisation
79724602|NCT02769871|Behavioral|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
79263328|NCT04472065|Dietary Supplement|Lactobacillus reuteri|1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
79263329|NCT04472065|Other|Placebo|1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
79308842|NCT02601573|Drug|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
79562545|NCT03863639|Diagnostic Test|Neuroimaging Procedures|"Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures."
79724603|NCT02769637|Drug|PPI treatment|PPI treatment or no PPI treatment
79724604|NCT02769559|Procedure|Reduction mammaplasty|Surgical removal of excess breast tissue
79724605|NCT02696707|Procedure|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
79724606|NCT02696707|Procedure|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
80021155|NCT02679144|Drug|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
80021156|NCT02650986|Drug|Cyclophosphamide|Given IV
80021157|NCT02650986|Drug|Decitabine|Given IV
79562546|NCT03863639|Diagnostic Test|Neuropsychological Assessment Procedures|Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
79858972|NCT05958017|Behavioral|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
79858973|NCT05958017|Other|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
79263330|NCT04469530|Drug|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
79858974|NCT05957718|Drug|TKTX cream|TKTX cream was used in several studies on Tatto and laser
80021158|NCT02650986|Other|Laboratory Biomarker Analysis|Correlative studies
80021159|NCT02650986|Procedure|Leukapheresis|Undergo leukapheresis
80021160|NCT02650986|Biological|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
80021161|NCT02619409|Drug|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
80021162|NCT02619409|Drug|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
79562547|NCT03850483|Drug|PF-06700841|PF-06700841 topical cream
80021163|NCT02619409|Drug|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
80021164|NCT02619409|Drug|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
80021165|NCT02619409|Drug|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
80021166|NCT02603432|Biological|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
80021167|NCT02603432|Other|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
79263331|NCT04469530|Drug|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
79263332|NCT04469530|Drug|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
79263333|NCT04469530|Drug|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
79308843|NCT02601573|Drug|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
79858975|NCT05954312|Drug|VVD-130037|Oral tablets
79858976|NCT05953584|Drug|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
80021168|NCT02603432|Biological|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
80021169|NCT02582866|Drug|Lacosamide|"Pharmaceutical Form: Oral tablets~Concentration: 50 mg~Route of Administration: Oral administration"
80021170|NCT02559778|Drug|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
80021171|NCT02559778|Drug|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
80021172|NCT02559778|Drug|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
79562548|NCT03850483|Drug|Vehicle (Placebo)|Vehicle topical cream
79562549|NCT03612479|Behavioral|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
80021173|NCT02559778|Drug|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
80021174|NCT02559778|Drug|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
79263334|NCT04445740|Behavioral|i♥rhythm project|behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
80021175|NCT02512432|Device|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
79263335|NCT04443023|Device|chosen TAVI valve|chosen TAVI valve
80021176|NCT02491476|Device|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
79263336|NCT04423679|Device|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
79263337|NCT04401761|Drug|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
79263338|NCT04401761|Drug|Acetylsalicylic acid|75 - 100 mg once daily at the discretion of the investigator
79263339|NCT04329975|Drug|Desmopressin|Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
79263340|NCT04324905|Drug|HIP1802|Test drug
79263341|NCT04324905|Drug|HGP1705|Reference drug
79263342|NCT04313634|Drug|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
79263343|NCT04313634|Drug|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
79263344|NCT04313634|Drug|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
79263345|NCT04303078|Other|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
79724607|NCT02769715|Device|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
79263346|NCT04288869|Other|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
79263347|NCT04288869|Other|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
79263348|NCT04288869|Other|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
79263349|NCT04288869|Other|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
79724608|NCT02769715|Other|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
80021177|NCT02465307|Behavioral|Confusion Assessment Method|Confusion Assessment Method (CAM) score
79263350|NCT04269811|Drug|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
79263351|NCT04260217|Drug|APG2575 400 mg|APG2575 400 mg
79263352|NCT04260217|Drug|APG2575 600 mg|APG2575 600 mg
79263353|NCT04260217|Drug|APG2575 800 mg|APG2575 800 mg
79263354|NCT04248569|Drug|DNAJB1-PRKACA peptide vaccine|"DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and Day 1 of cycle 2, 3, 4 and 5 (priming phase). Boost vaccinations: every 3 cycles beginning C6D1. For Cohort A-(Initial) only: Patients with FLC cancer with no prior checkpoint inhibitor therapy treatment.~DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~Cohort A-(Expansion): Patients with FLC cancer with no prior checkpoint inhibitor treatment.~Cohort B: Patients with FLC cancer with prior checkpoint inhibitor treatment.~Cohort C: Patients with non-FLC cancer (solid tumors) with prior checkpoint inhibitor treatment eligible.~Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
79263355|NCT04248569|Drug|Nivolumab|"Cohort A (Initial): Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 2-5 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 6.~Cohort A (Expansion), B and C: Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~Drug: 3mg/kg and 480mg IV"
79858977|NCT05953584|Drug|Hydroxyurea|Participants will receive a stable dose of HU.
79858978|NCT05953428|Other|Opioid Sparing Anesthesia Protocol (OSA)|OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
79858979|NCT05953428|Other|Opioid Based Anesthesia Protocol (OBA)|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
79858980|NCT05951296|Drug|Leramistat|Drug: Leramistat
79858981|NCT05951296|Drug|Placebo|Placebo comparator
79263356|NCT04248569|Drug|Ipilimumab|"Cohort A (Initial): Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 2, 3, 4 and 5 of the study, every 3 weeks of the priming phase.~Cohort A (Expansion), B and C: Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~Drug: 1mg/kg IV"
79263357|NCT04238663|Drug|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
79263358|NCT04238663|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
79263359|NCT04238663|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
79263360|NCT04235660|Radiation|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
79263361|NCT04235660|Radiation|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
79263362|NCT04227977|Device|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
79263363|NCT04192929|Device|Narrow band imaging|Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
79263364|NCT04192929|Other|Chromoendoscopy|Indigo carmine will be sprayed during withdrawal phase of colonoscopy
79263365|NCT04192929|Other|High definition white light endoscopy|High definition equipment will be used to perform colonoscopy
79263366|NCT04180423|Device|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
79263367|NCT04180423|Device|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
79263368|NCT04142957|Other|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
79399082|NCT03139656|Behavioral|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
79562550|NCT03612479|Behavioral|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
79308844|NCT02601573|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
79308845|NCT02601573|Drug|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
79562551|NCT03563742|Drug|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
79858982|NCT05947136|Behavioral|Interpretation of the results from the detection visit|"- An interpretation of the results of the detection tests concerning~the 7 complications of interest assessed at T1, T2, T3 and T4 ;~the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
79562552|NCT03563742|Drug|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
79562553|NCT03529799|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
79562554|NCT03513237|Procedure|Cervical dilation|manual dilatation of the cervix using surgeon's finger.
80021178|NCT02465307|Device|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
80021179|NCT02465307|Device|Commercially available camera|As part of facial recognition video system
80021180|NCT02465307|Device|Internet Pod (iPod)|Monitors noise levels in the room
79263369|NCT04139642|Device|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
79263370|NCT04136912|Drug|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
79263371|NCT04136912|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
79263372|NCT04129580|Device|reSET-O app|The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
79263373|NCT04102020|Drug|Venetoclax|Tablet: Oral
79263374|NCT04102020|Drug|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
80021181|NCT02465307|Diagnostic Test|Cortisol Swab|Cortisol level collected through self administered salivary swab
79263375|NCT04102020|Drug|CC-486|Tablet; Oral
79263376|NCT04090502|Other|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
79263377|NCT04090502|Other|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
79263378|NCT04060017|Drug|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
79263379|NCT04060017|Other|Placebo|Placebo
79263380|NCT04052698|Drug|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
79858983|NCT05947136|Behavioral|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~Clearly explain the results of the detection visit and the action to be taken for each referral;~Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
79263381|NCT04046991|Device|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
79858984|NCT05947136|Behavioral|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
79858985|NCT05947136|Behavioral|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
79858986|NCT05944601|Behavioral|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
80021182|NCT02453373|Device|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
80021183|NCT02453373|Drug|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
80021184|NCT02453373|Drug|tPA|tPA will be administered intravenously if indicated
80021185|NCT02453373|Drug|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
80021186|NCT02453373|Drug|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
80021187|NCT02453373|Procedure|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
80021188|NCT02452008|Drug|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
79399083|NCT03139656|Behavioral|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
79399084|NCT02320227|Device|Miami w/o frag Personal lubricant|
79399085|NCT03139422|Drug|Tranexamic Acid 500 MG|oral tablets
79399086|NCT03139422|Drug|Calcium Dobesilate|oral tablets
79562555|NCT03473925|Drug|Navarixin|Oral capsules
79562556|NCT03473925|Biological|Pembrolizumab|Intravenous infusion
79562557|NCT03424122|Drug|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
79263382|NCT04046991|Behavioral|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
79263383|NCT04039568|Behavioral|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
79263384|NCT04039568|Behavioral|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
79399087|NCT01428661|Drug|tasimelteon|20 mg once daily
79399088|NCT01428661|Drug|placebo|once daily
79562558|NCT03424122|Drug|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
79562559|NCT03424122|Drug|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
79562560|NCT03424122|Drug|Ibrutinib|Ibrutinib administered orally once daily.
79562561|NCT03230097|Drug|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
79263385|NCT03980483|Biological|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
79263386|NCT03980483|Drug|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
79263387|NCT03980483|Drug|Placebo|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
79263388|NCT03980483|Drug|Placebo|Placebo cap (containing lactose) to be administered orally.
79399089|NCT05168670|Combination Product|Protection of eyes with tinted soft scleral eye shields|In subjects with dry eye disease due to meibomian gland dysfunction, protection of eyes with tinted soft scleral eye shields followed by IPL administration on eyelids
79399090|NCT01799577|Procedure|Laparoscopic surgery|Two methods will be compare
79399091|NCT02721381|Behavioral|ImPACT Online|ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
79399092|NCT05083104|Diagnostic Test|laboratory investigations on coagulation profiles|CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
79399093|NCT05163600|Other|Blod flow restriction training|includes one strength and one endurance training
79399094|NCT05144802|Procedure|acute hypoxia|Participants will be exposed to a 3-hour acute hypoxia
79399095|NCT01428583|Drug|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
79399096|NCT05125848|Device|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
79562562|NCT03230097|Drug|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
79562563|NCT03226067|Drug|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
79562564|NCT03226067|Drug|Placebo oral capsule|Matching capsules.
79562565|NCT03190525|Other|Quality of life questionnaires|QLQ-C30
79562566|NCT02993211|Device|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
79562567|NCT02993211|Device|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
79562568|NCT02968940|Biological|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
79562569|NCT02968940|Radiation|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
79399097|NCT00683085|Biological|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
79858987|NCT05944081|Device|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
79858988|NCT05941507|Drug|LCB84|TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
80021189|NCT02452008|Drug|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
79263389|NCT03935269|Device|Cereset Research Wearable|CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
79858989|NCT05941507|Drug|Anti-PD-1 monoclonal antibody|anti-PD-1 Ab
79858990|NCT05939895|Device|Medtronic G3 sensor|A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
80021190|NCT02450318|Other|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
79263390|NCT03935269|Procedure|Stress management therapy|Undergo Cereset research office intervention
79263391|NCT03935269|Other|Questionnaire administration|Ancillary studies
79263392|NCT03935269|Other|Quality of Life Assessment|Ancillary studies
79562570|NCT02846350|Behavioral|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
79562571|NCT02803593|Behavioral|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
79263393|NCT03862716|Drug|IDegLira|Dose is titrated to achieve fasting normoglycemia
79263394|NCT03862716|Drug|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
79858991|NCT05935930|Drug|Propofol 10 MG/ML Injection|Propofol infusion
79858992|NCT05935930|Drug|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
79858993|NCT05934110|Drug|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
79858994|NCT05934110|Drug|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
79858995|NCT05934110|Drug|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
80021191|NCT02447874|Drug|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~Loading dose: 200 mg/kg once~Continuous IV: 300 mg/kg/24 hours"
80021192|NCT02447874|Drug|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 200 mg/kg once
80021193|NCT02447874|Drug|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
79263395|NCT03862716|Drug|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
79263396|NCT03862716|Behavioral|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
79263397|NCT03840239|Drug|Capecitabine, Oxaliplatin|Drug: Capecitabine, Oxaliplatin
79263398|NCT03840239|Radiation|External beam radiotherapy|External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
79263399|NCT03840239|Procedure|Surgery|'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
79263400|NCT03840239|Other|Watch and wait strategy|Watch and wait strategy recommendation and discussion for cCR patients
79263401|NCT03833661|Drug|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
79263402|NCT03824808|Drug|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
79263403|NCT03824808|Drug|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
80021194|NCT02402582|Other|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
79263404|NCT03813537|Other|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
80021195|NCT02402582|Other|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
79263405|NCT03804060|Device|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
79263406|NCT03804060|Procedure|Recanalization only|Standard of Care for recanalization
79263407|NCT03798691|Biological|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
79263408|NCT03769116|Genetic|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
80021196|NCT02365051|Behavioral|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
80021197|NCT02098161|Other|Laboratory Biomarker Analysis|Correlative studies
79263409|NCT03769116|Genetic|placebo|Single IV infusion of matching placebo
79263410|NCT03768492|Drug|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
79263411|NCT03768492|Other|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
79263412|NCT03738462|Device|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
79263413|NCT03737383|Behavioral|Narrative Exposure Therapy|brief, trauma-focused treatment.
79562572|NCT02803593|Behavioral|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
79724609|NCT02769793|Drug|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
79724610|NCT02769793|Drug|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
79263414|NCT03733691|Drug|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
79562573|NCT02772068|Drug|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
80021198|NCT02098161|Other|Questionnaire Administration|Ancillary studies
80021199|NCT02098161|Drug|Smac Mimetic LCL161|Given PO
80021200|NCT01734928|Drug|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
80021201|NCT01734928|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
79263415|NCT03733691|Drug|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
79263416|NCT03686124|Biological|IMA203 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
79263417|NCT03686124|Biological|IMA203CD8 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
79263418|NCT03686124|Device|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials. IMADetect® is intended for investigational use only.
79263419|NCT03686124|Drug|nivolumab (Opdivo®)|Nivolumab will be given post IMA203 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
79263420|NCT03657693|Diagnostic Test|NICU MRI|MRI device that is not FDA approved.
79562574|NCT02772068|Other|Exercise|
79562575|NCT02755948|Biological|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
79562576|NCT02755948|Biological|Influenza A/California/04/2009|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
79562577|NCT02663908|Drug|Degarelix|
79562578|NCT02663908|Drug|Leuprolide|
79562579|NCT02650284|Device|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
79562580|NCT02650284|Device|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
79724611|NCT02769325|Drug|Atropine|IV atropine 0.1%, 10 ml
79724612|NCT02769325|Drug|Placebo|IV saline, 10 ml
79724613|NCT02769325|Drug|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
79263421|NCT03657693|Diagnostic Test|Polysomnography|Polysomnography to better determine obstruction index in the airway.
79263422|NCT03632863|Behavioral|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
79263423|NCT03632863|Behavioral|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
79858996|NCT05934110|Drug|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
79858997|NCT05934110|Drug|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
79562581|NCT02554487|Device|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI > 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI < 5) following stroke serve as a control group
79562582|NCT02333292|Drug|Telaprevir|Initiation of a regimen containing TVR
79562583|NCT02333292|Drug|Boceprevir|Initiation of a regimen containing BOC
79562584|NCT02333292|Drug|Sofosbuvir|Initiation of a regimen containing SOF
79562585|NCT02333292|Drug|Simeprevir|Initiation of a regimen containing SMV
79724614|NCT02769325|Drug|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
80021202|NCT01734928|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [>75 years old] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
79263427|NCT03528187|Other|MRI|"MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher"
79263428|NCT03528187|Other|Written Consent|Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
79263429|NCT03527927|Drug|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
79263430|NCT03510468|Drug|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
79263431|NCT03510468|Drug|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to < 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
79263432|NCT03510468|Drug|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
79263433|NCT03510468|Dietary Supplement|Pyridoxine|Each tablet contains 50 mg of pyridoxine
79562586|NCT02333292|Drug|Daclatasvir|Initiation of a regimen containing DCV
79724615|NCT02769325|Drug|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
79724616|NCT02769325|Drug|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
79724617|NCT02769325|Drug|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
79724618|NCT02769325|Drug|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
79724619|NCT02770261|Drug|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
79724620|NCT02770261|Drug|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
79724621|NCT02770261|Drug|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
79724622|NCT02770261|Drug|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
79562587|NCT02333292|Drug|Ledipasvir|Initiation of a regimen containing LDV
79263434|NCT03472599|Other|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
79263435|NCT03374202|Genetic|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
79263437|NCT03312920|Device|active anodal tDCS|active anodal tDCS with memory task
79263438|NCT03312920|Device|sham tDCS|sham tDCS with memory task
79263439|NCT03312920|Device|active cathodal tDCS|active cathodal tDCS with memory task
79562588|NCT02333292|Drug|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
79562589|NCT02333292|Drug|Dasabuvir|Initiation of a regimen containing DBV
79562590|NCT02333292|Drug|Velpatasvir|Initiation of a regimen containing VPV
79562591|NCT02333292|Drug|Elbasvir|Initiation of a regimen containing EBV
79562592|NCT02333292|Drug|Grazoprevir|Initiation of a regimen containing GZR
79562593|NCT02203773|Drug|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
79562594|NCT02203773|Drug|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
79858998|NCT05933239|Drug|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
79263440|NCT03289754|Device|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
79562595|NCT02203773|Drug|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
80021203|NCT01682616|Drug|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
80021204|NCT01682616|Drug|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
79263441|NCT03289000|Device|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
79263442|NCT03266653|Drug|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
79263443|NCT03266640|Drug|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
79263444|NCT03266627|Drug|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
79263445|NCT03248739|Device|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
79263446|NCT03248739|Device|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
79263447|NCT03218826|Drug|Docetaxel|Given IV
79263448|NCT03218826|Other|Laboratory Biomarker Analysis|Correlative studies
79263449|NCT03218826|Other|Pharmacological Study|Correlative studies
79263450|NCT03218826|Drug|PI3Kbeta Inhibitor AZD8186|Given PO
79263451|NCT03192501|Drug|inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.|Choose appropriate targeted drugs according to NGS/IHC results.
79263452|NCT03152357|Device|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
79263453|NCT03152162|Device|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
79263454|NCT03149809|Drug|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
79263455|NCT03149809|Behavioral|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
79263456|NCT03146819|Device|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
79263457|NCT03146819|Device|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
79263458|NCT03075215|Device|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
79263459|NCT03063632|Biological|Interferon Gamma-1b|Given SC
79399098|NCT05110950|Procedure|No suction EBUS-TBNA|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
79263460|NCT03063632|Other|Laboratory Biomarker Analysis|Ancillary studies
79263461|NCT03063632|Biological|Pembrolizumab|Given IV
79263462|NCT03042975|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
79263463|NCT03042975|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
79263464|NCT03037632|Behavioral|Family Heart Talk Booklet|
79263465|NCT03016169|Device|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
79263466|NCT03001830|Biological|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
79263467|NCT02955082|Drug|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
79263468|NCT02947750|Drug|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
79263469|NCT02947750|Other|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
79399099|NCT05110950|Procedure|Passive suction through dedicated EBUS-TBNA syringe|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
79399100|NCT05110950|Procedure|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.."
79399101|NCT00660543|Drug|Gadolinium|Given IV
79399102|NCT00660543|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
79399103|NCT00660543|Other|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
79399104|NCT00660543|Other|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
79399105|NCT00660543|Other|Diffusion Weighted Imaging|Undergo DWI
79399106|NCT00660543|Other|MRI-Based Angiogram|Undergo TOF MR angiography
79263470|NCT02947750|Dietary Supplement|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
79562596|NCT02203773|Drug|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
79263471|NCT02947750|Other|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
79263472|NCT02947750|Other|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
79263473|NCT02947750|Dietary Supplement|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
79263474|NCT02947750|Other|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
79263475|NCT02891603|Drug|Pacritinib|Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
79263476|NCT02891603|Drug|Sirolimus|Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
79263477|NCT02891603|Drug|Tacrolimus|Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
79562597|NCT02175030|Drug|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
79562598|NCT02175030|Drug|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
79263478|NCT02891603|Procedure|Allogenic hematopoietic cell transplant (alloHCT)|Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.
79263479|NCT02890160|Device|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
79263480|NCT02890160|Device|XIENCE|Everolimus Eluting Coronary Stent System
79263481|NCT02862418|Other|UTE MRI|One MRI with UTE settings will be acquired.
79263482|NCT02848560|Drug|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
79263483|NCT02839915|Drug|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
79263484|NCT02839915|Other|Placebo|Inactive placebo comparator
79263485|NCT02792257|Drug|Dronabinol (Marinol®)|5mg - 10mg daily dose
79263486|NCT02792257|Drug|Placebo|Daily dose
79263487|NCT02767778|Device|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
79263488|NCT02767778|Device|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
79562599|NCT01555541|Drug|Ofatumumab|1000 mg IV days 0, 7, 14, 21
79562600|NCT01555541|Drug|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
79562601|NCT01555541|Drug|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
79562602|NCT01398852|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
79562603|NCT01398852|Device|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
79724623|NCT02770261|Drug|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
79724624|NCT02770261|Drug|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
79724625|NCT02769403|Device|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
79724626|NCT02769403|Other|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
79724627|NCT02769403|Other|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
79724628|NCT02769403|Other|Sick Days|Sick days during the 12 week study period will be collected
79399107|NCT01428193|Drug|Flutamide|Subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day.
79263489|NCT02759731|Drug|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
79263490|NCT02756962|Drug|Cytarabine|
79858999|NCT05933122|Other|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
79263491|NCT02756962|Procedure|Allogeneic stem cell transplant|
79399108|NCT01428193|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
79263492|NCT02756962|Procedure|Bone marrow aspiration|"Baseline~Approximately 30 days after cytotoxic induction therapy~End of treatment"
79263493|NCT02756962|Procedure|Punch skin biopsy|"The first will be obtained with the initial blood and bone marrow collections, whenever possible.~The second will be obtained at the time of re-biopsy to confirm remission."
79399109|NCT01428193|Drug|estrace|0.5-1 mg once a day for seven days
79724629|NCT02769403|Other|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) & Physician Assistants [advance practice clinicians], and nurses) and will be linked to the consented research participant.
79724630|NCT04224649|Device|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
79724631|NCT04224649|Device|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
79724632|NCT02769169|Drug|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
79859000|NCT05933122|Other|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
79263494|NCT02756962|Device|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
79263495|NCT02703493|Radiation|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
79263496|NCT02665117|Drug|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
79263497|NCT02665117|Drug|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
79263498|NCT02665117|Drug|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
79263499|NCT02659254|Device|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
79263500|NCT02617485|Drug|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
79263501|NCT02617485|Drug|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
79263502|NCT02617485|Drug|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
79263503|NCT02617485|Drug|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
79399110|NCT03864276|Drug|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
79399111|NCT03864276|Drug|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
79399112|NCT05082792|Diagnostic Test|doppler ultrasound|"Doppler ultrasound evaluation of AVF:~pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks"
79399113|NCT03141918|Dietary Supplement|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
79399114|NCT03141918|Other|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
79399115|NCT01427803|Drug|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
79263504|NCT02617485|Drug|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
79263505|NCT02589522|Drug|Berzosertib|Given IV
79263506|NCT02589522|Other|Quality-of-Life Assessment|Ancillary studies
79263507|NCT02589522|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79263508|NCT02589522|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
79263509|NCT02543905|Procedure|Prostate MRI and Biopsy|All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
79263510|NCT02514278|Drug|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~5FU: 2400 mg/m2"
79263511|NCT02514278|Radiation|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
79263512|NCT02514278|Procedure|Local excision in good responders|"If local excision:~Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
79562604|NCT01398839|Device|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
79562605|NCT01398839|Drug|Riboflavin|Both treatment and sham groups will receive riboflavin
79263513|NCT02514278|Procedure|Rectal excision in bad responders|
79263514|NCT02514278|Drug|Capecitabine|1600 mg/m2 daily 5 days/7
79263515|NCT02485860|Device|Melectis G|
79263516|NCT02403453|Device|Rhine Cervical Disc|RHINE Cervical Disc
79263517|NCT02385123|Biological|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
79263518|NCT02337686|Other|Laboratory Biomarker Analysis|Correlative studies
79263519|NCT02337686|Biological|Pembrolizumab|Given IV
79263520|NCT02337686|Other|Pharmacological Study|Correlative studies
79263521|NCT02337686|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79263522|NCT02251522|Device|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
79263523|NCT02251522|Device|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
79562606|NCT00501176|Procedure|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
79562607|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
79562608|NCT03178786|Behavioral|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
79724633|NCT02769169|Drug|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
79724634|NCT02768857|Behavioral|Sensorimotor reeducation programs|
79724635|NCT02769013|Other|Pre-treatment follow up|No active intervention; medical support provided if needed
79724636|NCT02769013|Other|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
79399116|NCT05082558|Other|No intervention, as this was retrospective study.|No intervention performed. Participants were entolled retrospectively and medical records were accessed for data.
79263524|NCT02138357|Drug|buprenorphine transdermal delivery system (BTDS)|
79263525|NCT02138357|Drug|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
79263526|NCT02115295|Drug|Cladribine|Given IV
79263527|NCT02115295|Drug|Cytarabine|Given IV
79399117|NCT04973202|Other|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
79399118|NCT01408537|Biological|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
79399119|NCT03139500|Drug|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
79263528|NCT02115295|Drug|Gilteritinib|Given PO
79263529|NCT02115295|Drug|Idarubicin|Given IV
79263530|NCT02115295|Other|Laboratory Biomarker Analysis|Correlative studies
79263531|NCT02115295|Drug|Midostaurin|Given PO
79263532|NCT02115295|Drug|Venetoclax|Given PO
79263533|NCT02109614|Drug|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
79263534|NCT02109614|Drug|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
79263535|NCT02097420|Device|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
79263536|NCT02000115|Device|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
79263537|NCT02000115|Device|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
79263538|NCT01899417|Device|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
79263539|NCT01882751|Device|Conformis CR Total Knee Replacement|iTotal CR by Conformis
79263540|NCT01882751|Device|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
79263541|NCT01820676|Device|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
79724637|NCT02769013|Other|Post treatment follow up|No active intervention; medical support provided if needed.
79724638|NCT02769013|Other|Olfactometer experiment|No active intervention; medical support provided if needed.
79562609|NCT03174379|Procedure|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
79562610|NCT03174379|Procedure|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
79263542|NCT01820650|Device|iTotal G2 CR Knee Replacement System|Total Knee replacement
79263543|NCT01564654|Device|iTotal KRS|Total Knee Replacement System
79263544|NCT01564641|Device|iDuo G2|single comparator
79263545|NCT01541761|Behavioral|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
79277491|NCT05346133|Behavioral|Suicide Prevention Intervention for Adolescents|Suicide Safety Planning Intervention (SPI). SPI is a very brief intervention (20-45 minutes) that provides patients with specific strategies to use to decrease the risk of suicidal behavior. SPI begins with psychoeducation about suicide risk, then the clinician and patient collaboratively create a stepwise plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; and 6) reducing access to means. SPI providers work with caregivers to help them monitor warning signs of suicide risk, encourage the use of the safety plan by their adolescent, and reduce access to lethal means in the home.
79277492|NCT02206763|Drug|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
79562611|NCT03164889|Drug|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
79277493|NCT02206763|Drug|Erlotinib|Tablet(s) administered orally once daily.
79399120|NCT03139500|Drug|Placebo|Participants will receive matching placebo.
79399121|NCT03139500|Drug|Midazolam|Participants will receive single oral dose of midazolam.
79399122|NCT00661479|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
79399123|NCT00661479|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
79859001|NCT05930665|Drug|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
79562612|NCT03164889|Drug|Entecavir|Antiviral drug for hepatitis b virus (HBV)
79277494|NCT03531229|Drug|Placebo|Placebo to Lu AF76432 oral solution
79277495|NCT03531229|Drug|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
79277496|NCT02202629|Other|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
79277497|NCT02367963|Behavioral|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
79277498|NCT02367963|Behavioral|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
79277499|NCT05724355|Drug|Dalpiciclib Isetionate Tablets, Camrelizumab|Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
79277500|NCT02202707|Drug|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
79277501|NCT02367807|Drug|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
79277502|NCT05724277|Behavioral|Mindfulness meditation and virtual reality|Mindfulness meditation and virtual reality
79399124|NCT00661479|Drug|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
79399125|NCT00661479|Other|Sham (no implant)|Sham in the fellow eye on Day 1.
79399126|NCT01408459|Dietary Supplement|Tomato Product|Motivational Telephone Counseling weekly
79562613|NCT03161444|Other|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
79562614|NCT03141190|Behavioral|Mindfulness Based Stress Reduction - modified|already described
79562615|NCT03141190|Behavioral|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
79562616|NCT03133260|Diagnostic Test|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
79859002|NCT05930483|Behavioral|Behavioral Dietary Intervention|Receive delivered groceries
79859003|NCT05930483|Behavioral|Behavioral Intervention|Participate in ¡Vida! program
79859004|NCT05930483|Procedure|Biospecimen Collection|Undergo blood sample collection
79263546|NCT01480154|Drug|Akt Inhibitor MK2206|Given PO
79562617|NCT03133260|Drug|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
79859005|NCT05930483|Other|Dietary Intervention|Receive dietary modifications
79859006|NCT05930483|Other|Educational Intervention|Attend online health education sessions
79859007|NCT05930483|Other|Exercise Intervention|Perform home-based exercise sessions
79562618|NCT03133260|Drug|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
79562619|NCT03121235|Diagnostic Test|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
79562620|NCT03097146|Other|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
79562621|NCT03096834|Biological|AMG334 (70 mg) Pre-Filled Syringe (PFS)|Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
79562622|NCT03096834|Biological|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of matching placebo
79562623|NCT03065465|Device|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
79859008|NCT05930483|Other|Health Promotion and Education|Receive written instructions and website link to instructional video
79859009|NCT05930483|Other|Internet-Based Intervention|Use Fitbit app
80021205|NCT01644747|Device|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
79859010|NCT05930483|Other|Interview|Ancillary studies
79859011|NCT05930483|Behavioral|Lifestyle Counseling|Attend remote lifestyle health education sessions
79399127|NCT01408459|Dietary Supplement|Control|No Motivational telephone Counseling
80021206|NCT01430572|Drug|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
79859012|NCT05930483|Other|Medical Device Usage and Evaluation|Use measuring tape, Aria Wifi-enable scale, and Actigraph accelerometer
80021207|NCT01430572|Drug|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
79399128|NCT03139110|Behavioral|Presence of a mediator in the emergency departments|"The mediator tasks are :~Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~Have a proactive attitude towards patients showing nervousness signs~Report patients expressing the will to leave the emergency departments before medical care~Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
79399129|NCT04476966|Drug|Bladogra|1 tablet contains 25 mg Mirabegron
80021208|NCT01224288|Procedure|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
80021209|NCT00950430|Drug|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
80021210|NCT00950430|Drug|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
80021211|NCT00950430|Drug|Tau (18-F-AV-1451)|"PIB PET scan, Tau PET scan and/or FDG PET scan~Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
80021212|NCT00909051|Drug|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
79263547|NCT01480154|Drug|Hydroxychloroquine|Given PO
79562624|NCT03065465|Other|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
79859013|NCT05930483|Other|Medical Device Usage and Evaluation|Use Fitbit scale and Fitbit Luxe (or latest model)
79859014|NCT05930483|Other|Nutritional Intervention|Use Cook for Your Life website
79859015|NCT05930483|Other|Questionnaire Administration|Ancillary studies
79263548|NCT01117571|Device|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
79399130|NCT04476966|Drug|Myrbetriq (first dosing)|1 tablet contains 25 mg Mirabegron
79859016|NCT05930483|Behavioral|Telephone-Based Intervention|Participate in individualized health coaching sessions
79263549|NCT01006798|Other|Placebo|enteric coated capsule containing no vaccine virus
79263550|NCT01006798|Biological|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
79263551|NCT01006798|Biological|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
79859017|NCT05926661|Other|NCC Support Toolkit|"Pre-discharge intervention-~Set expectations for parents/caregivers to spend time bedside and attend rounds~iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~Download Nemours App and teach them how to use it~Education materials- to ease the use of medications, Oxygen and feeding~Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding."
79859020|NCT05924997|Drug|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
80021213|NCT00667459|Device|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
79263552|NCT00893516|Biological|CHOP + CD4|
79859021|NCT05919511|Other|Non-Interventional|This is an observational study
79399131|NCT04476966|Drug|Myrbetriq (second dosing)|1 tablet contains 25 mg Mirabegron
79399132|NCT00661557|Biological|Meningococcal vaccine GSK134612 (Nimenrix)|one dose, as intramuscular injection
79399133|NCT01408303|Drug|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
79562625|NCT03065192|Drug|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
79562626|NCT03056014|Drug|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
79859022|NCT05918861|Drug|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
79859023|NCT05918861|Drug|Placebo|matching placebo tablets
79859024|NCT05918640|Drug|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
79562627|NCT03056014|Dietary Supplement|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
79562628|NCT03056014|Dietary Supplement|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
79562629|NCT03126812|Drug|Carboplatin|Carboplatin AUC=6
79562630|NCT03126812|Drug|Paclitaxel|paclitaxel 80 mg/m2
79859025|NCT05918055|Drug|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
79562631|NCT03126812|Drug|Pembrolizumab|200 mg flat dose, starting cycle 2
79859026|NCT05918055|Drug|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
79859027|NCT05905471|Other|Interview|Interview study
79859028|NCT05901298|Device|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
79263553|NCT00893516|Drug|CHOP|
79263554|NCT00877656|Biological|HuMax-CD4|Active treatment
79263555|NCT00601939|Behavioral|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
79263556|NCT00601939|Behavioral|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
79263557|NCT00113360|Drug|RAD001|Starting dose of 5 or 10 mg by mouth daily.
80021214|NCT00667459|Device|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
80021215|NCT00546429|Device|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
79263558|NCT00113360|Drug|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
79263559|NCT00087685|Drug|RAD001|10 mg by mouth Daily
79263560|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
79263561|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
79263562|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
79399134|NCT01408303|Drug|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
79399135|NCT01408303|Drug|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
79399136|NCT00597675|Biological|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
79399137|NCT00597675|Biological|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
79399138|NCT03821610|Drug|Fludarabine|IV
79399139|NCT03821610|Drug|Melphalan|IV
79399140|NCT03821610|Drug|Alemtuzumab|IV
79263563|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
79859029|NCT05897242|Behavioral|Smartphone app|Use ACT on Vaping smartphone app
80021216|NCT00453544|Other|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
80021217|NCT00453544|Other|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
79724639|NCT02768779|Other|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
79263564|NCT04855994|Procedure|paravertebral block|The investigators performed Paravertebral block to that patient group for postoperative analgesia
79263565|NCT04855994|Procedure|pectoral block|The investigators performed pectoral block to that patient group for postoperative analgesia
80021218|NCT00280657|Drug|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
80021219|NCT00280657|Drug|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
79263566|NCT03188445|Drug|Iron Isomaltoside 1000|Administered iv
79263567|NCT03188445|Drug|ferrous fumarate with ascorbic acid|Oral administration
79263568|NCT04379960|Other|Peptides|Peptides will be added to PBMCs in in vitro cell culture.
79263569|NCT02440893|Diagnostic Test|Corus CAD (ASGES)|
79263570|NCT04866368|Procedure|The ultrasound-guided Sacral Erector spinae plane block|postoperative pain procedure
79263571|NCT04866368|Procedure|The dorsal penile block|postoperative pain procedure
79263572|NCT03044288|Other|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
79263573|NCT03044288|Other|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
79263574|NCT04483635|Dietary Supplement|Placebo|Weekly oral dose of placebo
79263575|NCT04483635|Dietary Supplement|Vitamin D|Weekly oral dose of Vitamin D
79263576|NCT04855916|Device|ABLE Exoskeleton|Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
79263577|NCT04855916|Device|KAFO Orthosis|Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
79724640|NCT02765503|Radiation|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
79724641|NCT02768545|Drug|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
79263578|NCT03041558|Behavioral|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
79724642|NCT02768623|Other|Pharmacist led Asthma Management|
79859030|NCT05897242|Other|Text Message|Receive text messages
79263579|NCT03041558|Behavioral|SafeCare (SC)|SafeCare intervention as usual
79263580|NCT02436291|Device|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
79263581|NCT04855682|Other|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
79263582|NCT04855682|Other|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
79263583|NCT04855682|Other|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
79263584|NCT03191877|Dietary Supplement|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
79263585|NCT04865900|Diagnostic Test|Laboratory Blood Tests|Blood tests to determine liver and kidney functioning, total blood count, and troponin levels
79263586|NCT04865900|Diagnostic Test|ECG|ECG to determine heart rate and functioning
79263587|NCT04865900|Diagnostic Test|PCR|PCR test to determine whether patient has Covid19
79263588|NCT04865900|Diagnostic Test|Antibody test|Antibody test to determine level of antibodies to Covid19
79399141|NCT03821610|Drug|Cyclophosphamide|IV
79399142|NCT03821610|Drug|Mesna|IV
79724643|NCT02768623|Other|Pharmacist Intervention (when requested by patient)|
79724644|NCT04224259|Procedure|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
79859031|NCT05897242|Other|Survey Administration|Ancillary studies
79859032|NCT05894356|Other|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
80021220|NCT00280657|Drug|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
80021221|NCT03514940|Diagnostic Test|ultrasound|second trimester us scan will be made to pregnant women
80021222|NCT05421520|Device|Artificial intelligence assisted system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
80021223|NCT03514862|Behavioral|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
80021224|NCT03514862|Behavioral|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
79562633|NCT03026972|Biological|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
79263589|NCT04865900|Diagnostic Test|Echocardiography|If Troponin level elevated echocardiography to determine heart function
79263590|NCT04865900|Diagnostic Test|MRI|If Troponin level elevated MRI to determine heart function
79263591|NCT02440971|Device|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
79263592|NCT04855448|Device|Micro Hand S robot and da Vinci robot|The surgeries are performed with the Micro Hand S robot and da Vinci robot
79263593|NCT04855448|Device|da Vinci robot|The surgeries are performed with the da Vinci robot
79263594|NCT03191721|Procedure|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
79263595|NCT03191721|Procedure|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
79263596|NCT03191721|Procedure|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
80021225|NCT03514862|Behavioral|Self-Practice|4 weeks of self-practice after the MBI training.
79263597|NCT03191721|Drug|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
79263598|NCT03191721|Drug|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
79263599|NCT03191721|Procedure|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
79562634|NCT03026972|Biological|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
79399143|NCT03821610|Radiation|Total Body Irradiation (8Gy)|TBI (8Gy)
79399144|NCT01408147|Behavioral|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
79399145|NCT00683163|Drug|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
79399146|NCT00683163|Drug|Ibandronate|150mg by mouth once monthly
79562635|NCT03026972|Biological|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
79562636|NCT03026972|Biological|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
79724645|NCT04224259|Procedure|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
79399147|NCT00683163|Other|Placebo injection|Daily injections as placebo for PTS 1-84
79399148|NCT00683163|Other|Placebo pills|Monthly pills as placebo for oral ibandronate
79562637|NCT03026972|Biological|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
79562638|NCT03012815|Drug|Gabapentin|Gabapentin administered as a taper
79724646|NCT02764723|Drug|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
79724647|NCT02764723|Drug|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
79724648|NCT02764567|Other|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
80021226|NCT03103516|Procedure|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
80021227|NCT03103516|Procedure|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
79399149|NCT04044001|Drug|BTZ-043|BTZ-043 (250mg per tablet)
79399150|NCT04044001|Drug|Rifafour e-275®|Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
79562639|NCT03012815|Drug|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
79562640|NCT03012815|Drug|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
79263600|NCT04855292|Drug|TG103 injection|TG103 injection, SC, once weekly
79263601|NCT04855292|Drug|Placebo|Placebo control, SC, once weekly
79263602|NCT04864496|Drug|Prescribe N-acetylcysteine tablets|N-acetylcysteine tablets ,1200 mg two times daily
79724649|NCT04664959|Drug|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
79263603|NCT04864496|Drug|Prescribe placebo tablets|manufactured by Daroo Salamat Pharmed, two times daily
79263604|NCT02434887|Device|KL029 Intimate Lubricant Gel|
79263605|NCT04855214|Other|Qualitative Analysis|Mixed methods analysis of the user's experience with upper limb prosthetics.
79263606|NCT02440815|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
79263607|NCT04862546|Device|Laser Acupoint|Step 1: The subject was in sitting position and exposure area for applying laser then therapist use tap measurement to find the point. Parameters was used in this study : PROBE :ML A1\25 TIME:01:00 FREQUENCY: 10000Hz (25mw), DUTY-CYCLE:100% DENESITY: 1J\CM2 AREA :1CM2 Step 2: Apply laser on acupuncture points by using 10000HZ for 1 minute for every point. Totally cession: 10 minutes Step 3: ensure that all point done Repeat all steps for every subject
79399151|NCT04044001|Drug|Probe Drug Cocktail|"A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~Caffeine: 1 tablet à 150mg~Tolbutamide: 1/4 tablet à 500mg~Dextromethorphan: 10 ml syrup à 15mg/5ml~Midazolam:2 ml solution à 5mg/5ml~Digoxin: 2 tablets à 0.25mg"
79399152|NCT04044001|Drug|Dolutegravir 50mg Tab|1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
79399153|NCT00684723|Drug|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
79399154|NCT00684723|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
79399155|NCT00598689|Drug|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
79399156|NCT01405027|Procedure|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
79399157|NCT01405027|Other|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
79724650|NCT04664959|Drug|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
79724651|NCT02762695|Other|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
79399158|NCT00663039|Drug|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
79724652|NCT02762695|Other|Usual Care|Usual Care at Primary Health Care Center
79724653|NCT00951496|Biological|Bevacizumab|Given IV
79724654|NCT00951496|Drug|Carboplatin|Given IV
79724655|NCT00951496|Drug|Carboplatin|Given IP
79724656|NCT00951496|Drug|Cisplatin|Given IP
79263608|NCT04862546|Device|Tap water iontophoresis|"Enough tap water is placed in the pans, then the generator is plugged in and switched on. After that, the patient's hands are placed in the pans.~The treatment is administrated by slowly increased intensity to tell the patient to feel a tingling sensation or up to 20 milliamperes and continue with this polarity for 10 minutes. After that, the polarity reversed and intensity increased again to the desired level for another 10 minutes."
79263609|NCT03188289|Drug|Placebo gel|Placebo is the control group treated with a placebo gel.
79263610|NCT03188289|Drug|Clorhexidine gel|Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
79263611|NCT03188289|Drug|Clorhexidine-Chitosan gel|Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
79263612|NCT03188289|Drug|Hyaluronic Acid gel|Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
79263613|NCT03044912|Drug|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
79263614|NCT03044678|Behavioral|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
79263615|NCT03044678|Behavioral|Self-Study|Books for youth about anxiety management
79263616|NCT02436057|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
79263617|NCT04849286|Drug|HTL0016878|Oral solution
79724657|NCT00951496|Other|Laboratory Biomarker Analysis|Correlative studies
79724658|NCT00951496|Drug|Paclitaxel|Given IV
79724659|NCT00951496|Drug|Paclitaxel|Given IP
79724660|NCT00951496|Other|Quality-of-Life Assessment|Ancillary studies
79263618|NCT02440737|Other|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
80021228|NCT02298140|Other|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
79263619|NCT02440737|Other|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
79263620|NCT02440737|Procedure|Psychosocial Assessment and Care|Undergo the NEST intervention
79263621|NCT02440737|Other|Questionnaire Administration|Ancillary studies
79263622|NCT02436369|Dietary Supplement|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
79263623|NCT02436369|Dietary Supplement|low fat yogurt|daily intake of low fat yogurt for 8 weeks
79263624|NCT04862702|Device|mechanical instrumentation using rotary file system|the mechanical preparation will be performed using rotary file system
79263625|NCT02435979|Other|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
79263626|NCT02435979|Other|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
79263627|NCT02610842|Other|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
79263628|NCT03188211|Other|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
79263629|NCT03188211|Other|Control|Any educational program will be delivered to clinicians assigned to control arm
79263630|NCT03041480|Diagnostic Test|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
79263631|NCT03041402|Other|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
79562641|NCT03001011|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79724661|NCT02764177|Dietary Supplement|Protein drink|The protein drink was administered during this trial
79724662|NCT02764177|Dietary Supplement|Carbohydrate drink|The carbohydrate drink was administered in this trial
79263632|NCT03041402|Other|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
79263633|NCT03041402|Other|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
79263634|NCT03188367|Diagnostic Test|Gluten or placebo capsules|Administration of gluten or placebo capsules
79263635|NCT03041246|Procedure|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
79263636|NCT02435823|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
79263637|NCT04849208|Other|Presentation of fast and slow trials|"In each task trial participants will solve a reasoning problem. Half of the trials will be traditional Slow trials in which participants get ample time to deliberate (i.e., 20 s). The other half of the trials will be Fast trials in which people do not get sufficient time to deliberate (i.e., 4 s deadline) and need to rely on intuitive processing"
79399159|NCT00663039|Drug|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
79399160|NCT04387539|Drug|SOF/SMV/DCV/RBV|SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
79399161|NCT01412801|Biological|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
79399162|NCT00663819|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
79562642|NCT03001011|Drug|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
79562643|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
79562644|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
79562645|NCT02993757|Biological|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
79562646|NCT02980068|Drug|15N Nitrate|1,000 mg/11.8 mmol, oral, on day one, hour zero
79562647|NCT02980068|Drug|14N Nitrate|1,000 mg/11.18 mmol, oral, on day hour, hour zero
79562648|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
79263638|NCT03191487|Other|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
79263639|NCT03191487|Other|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
79263640|NCT04849754|Diagnostic Test|bone scintigraphy|Bone scintigraphy
79263641|NCT02435667|Other|Resistance Exercise Training|"Aerobic Exercise~a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
79263642|NCT02435667|Radiation|DEXA bone scan|A DEXA scan that provides bone density measures.
79263643|NCT02435667|Other|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
80021229|NCT05089396|Other|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
80021230|NCT02303210|Device|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
79263644|NCT02435667|Other|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
79263645|NCT02435667|Other|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
79562649|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
79724663|NCT02696629|Procedure|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
79263646|NCT02435667|Other|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
79859033|NCT05893342|Diagnostic Test|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
79859034|NCT05887466|Drug|A9-DPC|"IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~Main ingredients and quantities: A9-DPC~7.0X10^6 cells (Use 3.15X10^6 cells of this)~1.4X10^7 cells (Use 6.30X10^6 cells of this)~Formulation: milky white cell suspension~Storage method: Refrigerated storage (5±3℃)~Expiration date: within 36 hours of manufacture~Dosage:~1st Stage Dosage: 3.15X10^6 cells/body (6 tracks in total, 52.5X10^4 cells per track)~2nd Stage Dosage: 6.30X10^6 cells/body (6 tracks in total, 105X10^4 cells per track)~Frequency: single dosing~Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
79562650|NCT02979535|Biological|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
79263647|NCT03041012|Drug|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
79263648|NCT03041012|Drug|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
79263649|NCT03041012|Drug|Antiretrovirals|Combination antiretroviral therapy
79562651|NCT02979535|Biological|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
79562652|NCT02978911|Procedure|preoperative cerebral MRI and operative findings|
79562653|NCT02978716|Drug|Trilaciclib|G1T28
79562654|NCT02978716|Drug|Gemcitabine|Gemcitabine
79562655|NCT02978716|Drug|Carboplatin|Carboplatin
79724664|NCT02696629|Device|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
79724665|NCT02696629|Behavioral|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
79724666|NCT02696551|Other|Medical education|
79859035|NCT05886842|Other|Test-retest|Test-retest
80021231|NCT02303210|Device|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
80021232|NCT05076994|Other|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
80021233|NCT05076994|Other|Standard Care|An exercise prescription and verbal instructions in clinic
80021234|NCT03510572|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
79724667|NCT02764411|Drug|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
79263650|NCT03188133|Other|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
79859036|NCT05884372|Drug|Eldecalcitol|the same as arm descriptions.
80021235|NCT03511274|Behavioral|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
80021236|NCT05030896|Other|Invasive treatment and exercise therapy|The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
80021237|NCT03510494|Behavioral|Augmented physical education program|Augmented physical education program
79562656|NCT02976220|Other|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
79562657|NCT02973321|Drug|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
79263651|NCT04804202|Other|Bicycling with and without virtual reality|In one session: Exercise intensity and enjoyment are measured while participants bicycle in a virtual compared to non-virtual environment. Cycling takes places in two modes continous and interval. In a second session exercise intensity and enjoyment are compared during bicycling with virtual reality presented in two different ways.
79263652|NCT03191565|Other|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
79263653|NCT03191565|Device|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
80021238|NCT05015608|Drug|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
80021239|NCT05015608|Drug|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
79859037|NCT05884372|Drug|Native Vitamin D|the same as arm descriptions.
79859038|NCT05884372|Drug|Denosumab|the same as arm descriptions.
79399163|NCT00663819|Procedure|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
79263654|NCT03189225|Other|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
79263655|NCT02435589|Other|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
79263656|NCT02435589|Other|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
79859039|NCT05884372|Drug|Calcium|the same as arm descriptions.
79263657|NCT04861532|Diagnostic Test|Imaging|MRI scanning using new protocols
79263658|NCT03187899|Drug|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
79859040|NCT05879614|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
79263659|NCT03187899|Drug|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
79263660|NCT01648582|Drug|Dulaglutide|Administered SC
79859041|NCT05878860|Biological|ATSN-201|AAV.SPR-hGRK1-hRS1syn
79859042|NCT05878769|Drug|Astegolimab|Participants will receive SC astegolimab Q2W
79859043|NCT05876351|Drug|Eculizumab|Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
80021240|NCT02301260|Behavioral|Speed of Processing Training (SPT)|
80021241|NCT02301260|Behavioral|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
79263661|NCT01648582|Drug|Insulin glargine|Administered SC per dosing titration schedule
79263662|NCT01648582|Drug|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
79263663|NCT01648582|Drug|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
79263664|NCT02440347|Device|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
79263665|NCT02440347|Device|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
79263666|NCT04848818|Procedure|Distal radial metaphyseal fracture fixation with percutaneous K-wires|Pediatric distal metaphyseal fractures which are severly displaced will be operated with percutaneous K-wires..
79399164|NCT00664755|Drug|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
79399165|NCT00664755|Device|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
79399166|NCT01525628|Drug|midazolam|CYP3A probe drug
79399167|NCT01525628|Drug|BI 201335|HCV protease inhibitor
79399168|NCT01525628|Drug|tenofovir|nucleoside analogue
79399169|NCT01525628|Drug|caffeine|CYP1A2 probe drug
79399170|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
79859044|NCT05875272|Procedure|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
79859045|NCT05874986|Other|Resistance training|12-week resistance training intervention
79859046|NCT05869786|Device|Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)|In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
79859047|NCT05869786|Other|conventional rehabilitation program|conventional rehabilitation program
79263667|NCT04848818|Procedure|Distal radial and/or ulnar metaphyseal fracture fixation with bidegradable PLGA-based (Activa Im-Nail) implants|Pediatric distal metaphyseal radial and /or ulnar fractures which are severly displaced will be operated with percutaneous bidegradable PLGA-based (Activa Im-Nail) implants.
79263668|NCT03191331|Behavioral|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
79859048|NCT05869786|Behavioral|Exercise|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
79859049|NCT05868148|Device|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
79263669|NCT03043742|Drug|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
79263670|NCT03043898|Other|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
79562658|NCT02973321|Drug|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
79562659|NCT02973321|Drug|Liraglutide|Self-administered by SC injection using a pre-filled pen.
79562660|NCT02973321|Drug|Metformin|Orally administered at a stable dose , >=1500 mg daily stable dose or maximal tolerated dose.
79562661|NCT02967250|Drug|ursodeoxycholic acid|Subjects will be provided ~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over ~2 weeks to a stable dose for 4 weeks.
79859050|NCT05867888|Other|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
79859051|NCT05867888|Other|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
79859052|NCT05867888|Other|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
79263671|NCT03043898|Other|Lung sound recording|Lung sounds are recorded using a sensor array.
79263672|NCT03187821|Procedure|Laser peripheral iridotomy|location of laser peripheral iridotomy
79263673|NCT03043820|Drug|Raloxifene|Oral selective estrogen receptor modulator (SERM).
79263674|NCT03043820|Drug|Placebo|Tablets identical in form and color to intervention.
79562662|NCT02963844|Other|Inspiratory Muscle Training|
79859053|NCT05867121|Drug|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
79859054|NCT05867121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
79859055|NCT05867121|Drug|Capecitabine|Capecitabine will be administered as per the schedules specified in the respective arms
79859056|NCT05867121|Drug|S-1|S-1 will be administered as per the schedules specified in the respective arms.
79859057|NCT05867121|Drug|Nivolumab|Nivolumab will be administered as per the schedules specified in the respective arms.
79859058|NCT05867121|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedules specified in the respective arms.
79859059|NCT05867121|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
79859060|NCT05867121|Drug|Gemcitabine|Gemcitabine will be administered as per the schedules specified in the respective arms.
79859061|NCT05865678|Other|Not an intervention study|This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors.
79263675|NCT02435355|Behavioral|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
79399171|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
79399172|NCT01525628|Drug|midazolam|CYP3A probe drug
79399173|NCT01525628|Drug|caffeine|CYP1A2 probe drug
79399174|NCT01525628|Drug|pegylated interferon|HCV treatment
79399175|NCT01525628|Drug|BI 201335|HCV protease inhibitor
79399176|NCT01525628|Drug|BI 201335|HCV protease inhibitor
79399177|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
79399178|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
79399179|NCT01525628|Drug|BI 201335|HCV protease inhibitor
79399180|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
79399181|NCT01525628|Drug|ribavirin|HCV treatment
79859062|NCT05864274|Behavioral|Cognitive training application|Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
79859063|NCT05864235|Behavioral|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
79859064|NCT05864235|Behavioral|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment & confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
79859065|NCT05864235|Behavioral|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
79859066|NCT05861349|Diagnostic Test|Nerve conduction study|Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
79562663|NCT02963844|Other|Inspiratory Muscle Training Sham|
79263676|NCT02435043|Other|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
79562664|NCT02944188|Procedure|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
79562665|NCT02944188|Procedure|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
79562666|NCT02943785|Drug|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
79859067|NCT05861349|Diagnostic Test|Ultrasound|Ultrasound of the median nerve on the affected side (sides).
79562667|NCT02943785|Drug|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
79724668|NCT02764099|Behavioral|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
79859068|NCT05859165|Dietary Supplement|Nutren Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
79859069|NCT05859165|Dietary Supplement|Fresubin Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
79859070|NCT05858905|Device|Intravascular Lithotripsy|The Shockwave Medical IVL System is intended for lithotripsy-enhanced treatment of lesions, including calcified lesions, to increase luminal diameter, allowing for further treatment (e.g. post-dilatation) in the peripheral arterial vasculature. Not for use in the coronary or cerebral vasculature.
79562668|NCT02938143|Procedure|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
79859071|NCT05858671|Other|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
79859072|NCT05858671|Other|Black Tea|A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
79263677|NCT02435043|Other|standard management after stroke|standard management after stroke is individualised.
79859073|NCT05857878|Drug|BI 1815368|BI 1815368
79859074|NCT05857878|Drug|Matching placebo|Matching placebo
79859075|NCT05856773|Radiation|Proton Therapy|Pencil Beam Scanning (PBS)
79859076|NCT05855668|Behavioral|CBT|12 weeks of group CBT for AUD or CUD
79263678|NCT04854902|Procedure|Free gingival graft|1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
79263679|NCT04854902|Procedure|Cyanoacrylate|N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
79263680|NCT04854902|Procedure|Suture|The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
79263681|NCT03191175|Other|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
79263682|NCT03040622|Device|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
79263683|NCT03191097|Drug|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
79263684|NCT03191097|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
79263685|NCT04420234|Drug|narfurine hydrochloride orally disintegrating tablets|Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
79562669|NCT02938143|Procedure|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
79562670|NCT02936947|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
79562671|NCT02936947|Other|Free breathing|Free breathing
79562672|NCT02936947|Other|Active Breathing Control|Active Breathing Control
79562673|NCT02927990|Other|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
79724669|NCT02768077|Drug|Melatonin(Circadin®)|
79724670|NCT02768077|Drug|Placebo|
79263686|NCT04884022|Procedure|Miniplates in mandibular symphysis & infrazygomatic|Fixed functional appliance (pushing orthopedic force) in conjunction with direct skeletal anchorage
79562674|NCT02923674|Behavioral|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
79859077|NCT05853068|Device|Mechanical ventilation|Need for endotracheal intubation and invasive mechanical ventilation
79859078|NCT05853055|Procedure|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
80021242|NCT05009836|Drug|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
79263687|NCT04884022|Procedure|Miniplates in external oblique ridge & anterior maxillary region|Coil spring (pulling orthopedic force) in conjunction with direct skeletal anchorage
79263688|NCT02435199|Drug|EMA401 600mg|
79263689|NCT02435199|Drug|Placebo|
79263690|NCT04848350|Other|Lavender essential oil|Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
79263691|NCT02434965|Drug|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
79263692|NCT02434965|Drug|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
79263693|NCT04854356|Other|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
79263694|NCT03189069|Drug|Apixaban|Treatment for NVAF patients
80021243|NCT05009836|Drug|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
79263695|NCT03189069|Drug|Dabigatran|Treatment for NVAF patients
79263696|NCT03189069|Drug|Rivaroxaban|Treatment for NVAF patients
79724671|NCT01193244|Drug|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
79724672|NCT01193244|Drug|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
79263697|NCT03189069|Drug|Warfarin|Treatment for NVAF patients
79263698|NCT03040934|Device|Firehawk sirolimus target eluting coronary stent system|98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
79263699|NCT03040934|Device|XIENCE Everolimus-Eluting Coronary Stent System|98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
79263700|NCT03189147|Procedure|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
79263701|NCT03189147|Procedure|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
79263702|NCT04861376|Drug|Pueraria lobata|The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
79263703|NCT04861376|Drug|Pueraria thomsoni|The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
79263704|NCT04861376|Other|Placebo|The placebo group will take the same dose as the other two groups.
79263705|NCT03187587|Device|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
79263706|NCT03187587|Drug|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
79263707|NCT04861142|Drug|Anti-osteoporotic medication( alendronate or denosumab)|Initiation of anti-osteoporotic medication (alendronate or denosumab)
79263708|NCT03187665|Device|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
79399182|NCT01525628|Drug|ribavirin|HCV treatment
79399183|NCT01525628|Drug|ribavirin|HCV treatment
79399184|NCT01525628|Drug|pegylated interferon|HCV treatment
79399185|NCT01525628|Drug|ribavirin|HCV treatment
79399186|NCT01525628|Drug|caffeine|CYP1A2 probe drug
79399187|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
79399188|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
79399189|NCT01525628|Drug|midazolam|CYP3A probe drug
79399190|NCT01525628|Drug|BI 201335|HCV protease inhibitor
79399191|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
79399192|NCT01525628|Drug|ribavirin|HCV treatment
79263709|NCT03187665|Device|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
79263710|NCT02434731|Device|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
79263711|NCT03117855|Drug|Capecitabine|Given PO
79399193|NCT03709134|Diagnostic Test|Genomic Markers (CTC/ctDNA)|This is a non-interventional study.
79399194|NCT04387383|Device|Acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
79399195|NCT04387383|Device|Sham-acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
79399196|NCT01426789|Drug|Placebo|Matching placebo to secukinumab I.V.
79399197|NCT01426789|Drug|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
79562675|NCT02923674|Behavioral|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
79562676|NCT02923674|Behavioral|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).
79263712|NCT03117855|Other|Laboratory Biomarker Analysis|Correlative studies
79263713|NCT03117855|Radiation|Radioembolization|Undergo yttrium Y-90 radioembolization
79263714|NCT02434419|Device|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
79263715|NCT02434419|Other|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
79263716|NCT02607800|Drug|SOF/VEL/VOX|400/100/100 mg tablet administered orally once daily with food
79263717|NCT02607800|Drug|SOF/VEL|400/100 mg tablet administered orally once daily with or without food
79263718|NCT02433951|Other|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
79263719|NCT02304484|Biological|Evolocumab|Administered by subcutaneous injection once a month
79263720|NCT03190707|Behavioral|Intervention|"Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~Strengthen parenting skills through:~Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~Teaching the woman/couple on the importance of breast-feeding and how to succeed."
79263721|NCT02433873|Dietary Supplement|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
79263722|NCT02434029|Drug|Budesonide 1mg orodispersible tablet twice daily|
79263723|NCT02434029|Drug|Placebo orodispersible tablet twice daily|
79263724|NCT03043352|Dietary Supplement|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
79399198|NCT04388007|Other|Thoracic spinal manipulation|High velocity, low amplitude force manipulation
79562677|NCT02921971|Drug|SAR156597|Pharmaceutical form: Solution Route of administration: Subcutaneous
79562678|NCT02921971|Drug|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous
79562679|NCT02908334|Drug|Sertraline|400 mg/day sertraline
79562680|NCT02906397|Drug|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
79562681|NCT02906397|Radiation|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
79399199|NCT03141294|Procedure|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
79399200|NCT02320695|Drug|Saline|
79399201|NCT02320695|Drug|Isopropyl Alcohol|
79399202|NCT02320695|Drug|Pain Relieving Cream|
79399203|NCT02320695|Drug|Antibiotic/Pain Relieving Ointment|
79399204|NCT02320695|Drug|Original Ointment|
79399205|NCT02320695|Drug|Pain Relief Ointment|
79399206|NCT03632850|Other|web-based interactive tool|an online tool to assist users in decision-making in choice of treatment for advanced cancer
79399207|NCT02078557|Drug|MK-8892|
79562682|NCT02905669|Device|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
80021244|NCT03510416|Drug|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
79263725|NCT03043352|Dietary Supplement|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
79263726|NCT03187431|Biological|autologous bone marrow mesenchymal stem cells|intravenous infusion
79263727|NCT03043508|Other|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
79263728|NCT03043508|Behavioral|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
79263729|NCT02708355|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
80021245|NCT03510416|Radiation|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
79263730|NCT02708355|Drug|Placebo|Placebo capsules
79263731|NCT04854044|Drug|Akt/ERK Inhibitor ONC201|Given orally
79263732|NCT04854044|Radiation|Radiation Therapy|Undergo radiation therapy
79399208|NCT03554226|Behavioral|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
79263733|NCT04854044|Procedure|Resection|Undergo surgical resection
79399209|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
79399210|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
79263734|NCT03187275|Other|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
79399211|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
79562683|NCT02903615|Other|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
79724673|NCT01193244|Drug|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
79859079|NCT05852353|Other|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear & Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
79263735|NCT03187275|Other|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
79263736|NCT02708277|Device|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
79263737|NCT02708277|Device|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
79399212|NCT01426009|Drug|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
79399213|NCT01426009|Drug|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
79562684|NCT02903615|Other|Standard diet|Standard diabetes diet recommendations
79562685|NCT02895906|Drug|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
79562686|NCT02887651|Radiation|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
79724674|NCT02768467|Procedure|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
79724675|NCT02768467|Procedure|No Stitches|Subject will not receive stitches post buccal mucosa removal.
79724676|NCT04224337|Drug|Durvalumab + doxorubicin + ifosfamide|Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
79724677|NCT02768311|Procedure|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
79263738|NCT04847570|Other|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
79562687|NCT02886286|Drug|Bupivacaine|Patient-activated intrathecal bolus for incident pain
79263739|NCT02337478|Drug|Vincristine Sulfate Liposome|Given via injection
79263740|NCT02337478|Other|Laboratory Biomarker Analysis|Correlative studies
79263741|NCT03117387|Other|no intervention|This study contains no interventions
79263742|NCT02303704|Procedure|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
79263743|NCT02303704|Procedure|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
79562688|NCT02886286|Drug|Opioid|Patient-activated intrathecal bolus for incident pain
79263744|NCT04860908|Other|no intervention, observation only|no intervention, observation only
79562689|NCT02865187|Dietary Supplement|Vitamin D|Vitamin D 600IU/day
79263745|NCT03187041|Other|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
79263746|NCT04376918|Device|Begin with BVGA|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
79263747|NCT04376918|Device|Begin with Face-mask|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
79263748|NCT04483401|Behavioral|Cognitive Orientation to Occupational Performance (CO-OP)|"Intervention: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. CO-OP intervention will be administered by occupational therapists who have been trained in the CO-OP approach. Children will be seen once weekly for one hour over 12 weeks at as per published protocol (Polatajko et al., 2001b). Parents or caregivers will be encouraged to attend treatment sessions so that therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
79263749|NCT02608892|Behavioral|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
79859080|NCT05852262|Drug|Cephalexin|1000 mg PO QID for 7 days
79859081|NCT05852262|Drug|Cephalexin|500 mg PO QID plus oral placebo for 7 days
79859082|NCT05851859|Other|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
79263750|NCT03186963|Procedure|No immobilization|Conventional wrist dressing
79263751|NCT03186963|Procedure|Volar splint|Volar plaster splint
79263752|NCT04854200|Device|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
79399214|NCT01426009|Drug|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
79399215|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
79399216|NCT00685659|Other|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
79562690|NCT02865187|Drug|Hormonal contraception|Hormonal contraceptives
79724678|NCT02768311|Procedure|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
79724679|NCT02768311|Procedure|hand files k-files|Procedure: hand files k-files
79724680|NCT02768233|Behavioral|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
79875772|NCT04263311|Behavioral|CHW|Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
79399217|NCT00685659|Other|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
79859083|NCT05848713|Drug|Heparin|"Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement."
79859084|NCT05847504|Behavioral|mSTARS|mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
80021246|NCT02303288|Device|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
80021247|NCT03507920|Other|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
80021248|NCT03507920|Other|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
79562691|NCT02861885|Other|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
79562692|NCT02826707|Behavioral|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
79562693|NCT02824198|Biological|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
79859085|NCT05845918|Behavioral|PRISEM CEP|Participants in PRISEM CEP will undergo assessment and goal setting during the intake process to ensure that the program meets their needs. All participants partake in lifestyle programs in individual or group-based in-person activities that address cognitive, physical, social, and functional independence, education, and well-being goals.
80021249|NCT02301338|Other|Usual care|
80021250|NCT02301338|Other|Phone Calls|
79263753|NCT03186885|Behavioral|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
79399218|NCT00685659|Other|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
79399219|NCT01411319|Radiation|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
79875773|NCT00957983|Drug|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
80021251|NCT03720262|Combination Product|Mesh reinforcement|Reinforcement of the abdominal wall with Ultrapro Advanced.
80021252|NCT03720262|Other|No reinforcement|Suturing the abdominal wall without mesh reinforcement
79399220|NCT01411319|Radiation|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
79399221|NCT03538860|Behavioral|Active comparator: Human interpreter|A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.
79562694|NCT02824198|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
79875774|NCT05299463|Diagnostic Test|Exercise Testing|"Tele-Six-minute walk test (T6MWT)~1 Minute Sit-to-stand test (STS)~2-minute symptom-limited Step test (ST)~3-metre Timed up and go test (TUG)."
80021253|NCT02306486|Other|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
79562695|NCT02817126|Procedure|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
79562696|NCT02817126|Procedure|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
79562697|NCT02817074|Behavioral|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
79875775|NCT00452790|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
79875776|NCT00452790|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
80021254|NCT03103360|Device|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
79875777|NCT00953381|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
79263754|NCT03186885|Behavioral|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
80021255|NCT03103360|Procedure|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
79263755|NCT03186885|Behavioral|Control|Participants receive standard of care
79859086|NCT05845918|Behavioral|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
80021256|NCT03511040|Device|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
79263756|NCT03186573|Dietary Supplement|Grape juice|400ml diary of grape juice
79859087|NCT05845814|Biological|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
80021257|NCT03671122|Diagnostic Test|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
80021258|NCT03671122|Other|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
80021259|NCT03671122|Procedure|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
80021260|NCT03510962|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
80021261|NCT03510962|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
80021262|NCT03510962|Drug|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
79562698|NCT02817074|Behavioral|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
80021263|NCT03510962|Other|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
80021264|NCT03510962|Other|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
79263757|NCT03186573|Dietary Supplement|Maltodextrin|400ml diary of maltodextrin
79399222|NCT03538860|Behavioral|Intervention: Asynchronous Telepsychiatry|A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
79399223|NCT01543958|Drug|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
79562699|NCT02801045|Behavioral|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~humanistic phenomenological focus~transpersonal therapeutic bound~transdisciplinarity in the artistic approach~integrative-relational specialized counseling of the grief, loss and trauma aspects."
79399224|NCT01543958|Device|Sevelamer carbonate|
79562700|NCT02789098|Other|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
79562701|NCT02787551|Drug|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79562702|NCT02787551|Drug|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79562703|NCT02787551|Drug|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79399225|NCT03537222|Diagnostic Test|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
79399226|NCT04054895|Device|Lead placed in the His-Purkinje system in order to achieve QRS shortening.|Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
79859088|NCT05845814|Biological|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
79859089|NCT05845814|Combination Product|EV|1.25 mg/kg IV infusion
79859090|NCT05845814|Biological|Pembrolizumab|200 mg IV infusion
79859091|NCT05845710|Device|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
80021265|NCT03510962|Other|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
80021266|NCT02646124|Drug|Naproxen|Naproxen 500mg by mouth two times a day, #20
80021267|NCT02646124|Drug|Placebo|28 placebo capsules
79263758|NCT04847492|Procedure|Traditional corticotomy|A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
79263759|NCT04847492|Procedure|Flapless corticotomy|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
79562704|NCT02787551|Drug|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79859092|NCT05843721|Device|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
79859093|NCT05843578|Drug|AGMB-129|Oral capsule
79859094|NCT05843578|Drug|Placebo|Matching oral capsule
79859095|NCT05841095|Drug|ISA104|SLP vaccine
79859096|NCT05841095|Drug|Placebo|Saline solution (0.9% NaCl)
79859097|NCT05839847|Device|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
79859098|NCT05839847|Device|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
80021268|NCT02646124|Drug|Diazepam|Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
80021269|NCT02306564|Drug|Cabergoline|given to patients at high risk for OHSS
80021270|NCT02301494|Drug|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
80021271|NCT02301494|Drug|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
79263760|NCT02434653|Other|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
79263761|NCT02434653|Other|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
79263762|NCT03043196|Drug|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
79263763|NCT03043196|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
79562705|NCT02787551|Drug|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79562706|NCT02787551|Drug|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79562707|NCT02787551|Drug|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
79859099|NCT05837117|Behavioral|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
79859100|NCT05837091|Drug|Low Sodium Oxybate|Titrated according to standard of care and continued on stable dose for 3 months
79859101|NCT05837091|Diagnostic Test|24-hour polysomnography|Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
79859102|NCT05837091|Device|Nextsense EEG earbuds|Ear buds used to record sleep staging worn for a 24-hours period
79859103|NCT05837091|Device|Axivity device|Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
79859104|NCT05828173|Device|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
79859105|NCT05827861|Behavioral|HeartAge|HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
79859106|NCT05827861|Behavioral|HOPE-CVD Mobile App|The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
79263764|NCT03040544|Procedure|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
79263765|NCT03040544|Procedure|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
79263766|NCT03188835|Dietary Supplement|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
79263767|NCT03188835|Other|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
79263768|NCT03188835|Radiation|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
79263769|NCT03188835|Radiation|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
79263770|NCT03188835|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
79263771|NCT03188835|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
79562708|NCT02782871|Device|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
79562709|NCT02763228|Behavioral|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
79263772|NCT03188835|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
79263773|NCT03188835|Device|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
79263774|NCT03188835|Device|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
79263775|NCT03188835|Device|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
79562710|NCT02763228|Behavioral|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
79263776|NCT03188835|Device|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
79263777|NCT04847414|Diagnostic Test|HbA1C, other investigations|we will do some necessary investigations for prospective group
79263778|NCT04847180|Procedure|Biopsy|The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
79562711|NCT02763228|Behavioral|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
79263779|NCT04847024|Drug|Parecoxib|40 mg IV
79263780|NCT04847024|Drug|Dexketoprofen|50 mg IV
79263781|NCT03188757|Other|hyperglycaemic clamp|2h hyperglyceamic clamp
79562712|NCT02763228|Behavioral|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
79859107|NCT05827861|Behavioral|Genetic Risk Score|Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
79562713|NCT02763228|Behavioral|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
79562714|NCT02763228|Behavioral|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
79562715|NCT02763228|Behavioral|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
79724681|NCT02768155|Other|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
79859108|NCT05827133|Other|No intervention|No intervention
80021272|NCT03101800|Drug|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
79724682|NCT02768155|Other|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
79724683|NCT02768155|Other|Placebo Control|Normal Saline
79724684|NCT04223167|Dietary Supplement|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
79263782|NCT04860674|Drug|PD-1 inhibitor +ICE|PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
79263783|NCT03188679|Device|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
79263784|NCT04847336|Other|No intervention is planned|No intervention is planned
79263785|NCT03188913|Diagnostic Test|Coagulation tests|The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether
79263786|NCT04853342|Drug|Drug: Furmonertinib 80 mg|The initial dose of Furmonertinib 80 mg once daily
79263787|NCT04853342|Drug|Furmonertinib 80 mg placebo|The initial dose of Furmonertinib 80 mg once daily
79263788|NCT02430285|Procedure|Endoscopic Ultrasound|Endoscopic Ultrasound
79263789|NCT02430285|Device|Olympus 180 series echoendoscope|
79263790|NCT02430207|Procedure|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
79263791|NCT02430207|Procedure|temporary pacing subclavian vein|
79263792|NCT04853030|Drug|Fiasp|Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)
79263793|NCT04853030|Drug|Novorapid|Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid
79263794|NCT02430519|Procedure|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
79263795|NCT02430519|Procedure|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
79724685|NCT04223167|Dietary Supplement|Water|473 ml Water
79263796|NCT02430519|Device|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
79263797|NCT02430519|Device|autologous platelet-rich fibrin|
79859109|NCT05823532|Drug|Infliximab|"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
79859110|NCT05823532|Drug|Placebo|Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
79859111|NCT05820620|Procedure|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
79859112|NCT05820620|Procedure|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
79859113|NCT05820620|Other|Control Group|Control Group + Patient Control Analgesia (PCA)
79859114|NCT05819021|Device|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
80021273|NCT03101800|Drug|Azathioprine|Standard weight based azathioprine dosage
80021274|NCT03507842|Drug|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
79263798|NCT03040700|Other|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
79263799|NCT03040700|Other|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
79263800|NCT02430363|Drug|MK - 3475|Administered Intravenously
79263801|NCT02430363|Biological|Suppressor of the PI3K/Akt pathways|Capsules orally with food
79263802|NCT04852406|Drug|Protocol-based management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
79562716|NCT02747121|Behavioral|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
79562717|NCT02736136|Behavioral|joint observation and video feedback|
79263803|NCT04852406|Drug|Routine management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to current routine practice.
79263804|NCT02430051|Behavioral|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
79263805|NCT03042806|Behavioral|questionnaire|all the COPD patients will be ask to complete the questionnaire
79399227|NCT04054895|Device|Lead is placed in a tributary of the coronary sinus.|Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
79399228|NCT04880928|Drug|Eye injection (Mydrane)|"Mydrane 0.2 mg/ml + 3.1 mg/ml~+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride"
79562718|NCT02735044|Drug|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter [mmol/L])
80021275|NCT03507842|Drug|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
80021276|NCT03507842|Drug|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
80021277|NCT04464044|Device|verofilcon A toric contact lenses|Daily disposable toric soft contact lenses
79399229|NCT04880928|Drug|eye drops (Phenylephrin)|Phenylephrine 10%
79399230|NCT04880928|Drug|eye drops (Tropicamid)|Tropicamid 0,5%
79399231|NCT03496038|Procedure|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
79263806|NCT04860440|Device|GeneActiv wrist worn accelerometer|Wrist worn device worn for 7 days
79263807|NCT02429973|Drug|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
79263808|NCT03043040|Behavioral|Telephone follow up|Already described in previous page
79263809|NCT03043040|Behavioral|Treatment as usual|Already described in previous page
79263810|NCT03186651|Device|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
79263811|NCT04860284|Drug|Hydroxychloroquine tablets|Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
79263812|NCT04846634|Drug|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
79263813|NCT04846634|Drug|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
79263814|NCT04846634|Drug|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
79263815|NCT03190395|Procedure|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
79263816|NCT03190395|Procedure|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
79263817|NCT04860362|Behavioral|PEERS|Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
79562719|NCT02735044|Drug|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
79263818|NCT02429895|Drug|ABT-122|Injection
79562720|NCT02735044|Drug|Background therapy|Fast-acting mealtime insulin analogs
79263819|NCT03043118|Other|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
79263820|NCT02425371|Other|Screening and treatment of comorbidities|Screening and treatment of comorbidities
79263821|NCT02425371|Other|Placebo Comparator|No screening of comorbidities
79263822|NCT04852250|Other|Virtual centralized multidisciplinary tumour board|Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
79263823|NCT02429739|Behavioral|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo"
79263824|NCT04851938|Device|transcutaneous electrical nerve stimulation device|The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
79263825|NCT02429661|Behavioral|Peer support groups|
79263826|NCT02433717|Drug|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
79263827|NCT04846166|Diagnostic Test|Periodontally healthy group|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) < 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
79263828|NCT04846166|Diagnostic Test|Periodontitis|: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
79263829|NCT02433561|Procedure|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
79263830|NCT02433561|Procedure|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
79263831|NCT03042884|Behavioral|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
79263832|NCT03042884|Device|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
79263833|NCT02429817|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
79263834|NCT02429817|Device|Aeroneb Solo|
79263835|NCT02429817|Device|Jet Nebulizer|
79263836|NCT02429817|Other|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
79263837|NCT02429817|Other|Spirometry|FEV1, FVC assessment
79562721|NCT02720744|Drug|FT218|
79562722|NCT02720744|Drug|Placebo|
79562723|NCT02699515|Drug|MSB0011359C|Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
79562724|NCT02695160|Biological|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
79263838|NCT03042728|Behavioral|Dog Interaction|A therapy dog will visit the patients.
79263839|NCT03042728|Behavioral|Human Interaction|A human will visit the patients.
79399232|NCT03496038|Procedure|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
79859115|NCT05818540|Device|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
79859116|NCT05818540|Device|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
79263840|NCT04851782|Device|ivEAD tubing kit|ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
79263841|NCT04852094|Other|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
79263842|NCT04846010|Combination Product|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
79263843|NCT04846010|Combination Product|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
79263844|NCT04846010|Combination Product|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
79263845|NCT04846010|Combination Product|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
79263846|NCT04846010|Combination Product|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
79263847|NCT04846010|Combination Product|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
79399233|NCT01411085|Drug|Risperidone + Desipramine|
79562725|NCT02692651|Drug|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
79263848|NCT04846010|Combination Product|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
79263849|NCT04851860|Drug|sublingual immunotherapy|sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
79724686|NCT02763943|Behavioral|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
79724687|NCT02764021|Dietary Supplement|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
79263850|NCT04851548|Procedure|hyaluronic acid|after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
79399234|NCT01543490|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
79399235|NCT01543490|Other|Vehicle|Vehicle twice daily for 2 weeks
79399236|NCT01404949|Drug|Tretinoin and Arsenic Trioxide|See Detailed Description
79562726|NCT02692651|Drug|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
79562727|NCT02690246|Other|questionnaire|a questionnaire based study
79399237|NCT03273816|Behavioral|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
79562728|NCT02688855|Device|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
79859117|NCT05813873|Other|Triflow|Triflow
79859118|NCT05813873|Other|Control|Exercise
79859119|NCT05810870|Drug|MEN1611|MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
79399238|NCT04758780|Drug|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
79562729|NCT02688855|Device|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
79562730|NCT02677688|Biological|Autologous EBV specific CTL infusion|
79724688|NCT02764021|Dietary Supplement|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
79859120|NCT05810870|Drug|Eribulin|Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
79859121|NCT05808764|Drug|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
79859122|NCT05807139|Other|Placebo|Placebo
79875778|NCT00953381|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
79875779|NCT00953381|Drug|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
79263851|NCT03042572|Drug|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5*10^6 MSC per site; total 150*10^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
79562731|NCT02675699|Behavioral|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
79562732|NCT02675699|Behavioral|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
79263852|NCT03042572|Other|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
79263853|NCT04845698|Device|i-Dashboard|i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
79263854|NCT04851626|Other|Hypnotic intervention for persistent pelvic pain.|Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.
79562733|NCT02674061|Biological|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
79859123|NCT05807139|Drug|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
79859124|NCT05805501|Drug|Tobemstomig|Participants will receive IV tobemstomig Q3W.
79859125|NCT05805501|Drug|Tiragolumab|Participants will receive IV tiragolumab Q3W.
79263855|NCT04851626|Other|Control group persistent pelvic pain no intervention.|Control group no hypnotic intervention. Waitlist control.
79263856|NCT04851392|Drug|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
79859126|NCT05805501|Drug|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
79859127|NCT05805501|Drug|Axitinib|Participants will receive axitinib PO BID.
79859128|NCT05805189|Procedure|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
79263857|NCT04851392|Drug|Cannabis with THC without CBD|Cannabis with THC without CBD - inhaled and vaporised cannabis flower
79399239|NCT01431521|Drug|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
79399240|NCT01431521|Drug|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
79263858|NCT04851392|Drug|Placebo cannabis|Placebo cannabis, without THC and without CBD - inhaled and vaporised
79263859|NCT04859894|Diagnostic Test|Physiological testing|Cardiopulmonary exercise testing, Lung Function Testing and in some cases echocardiography. 20 subjects will perform DNA-methylation testing.
79263860|NCT03185325|Other|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
79263861|NCT03185325|Other|venous blood samples|venous blood samples are collected in healthy voulnteers
79263862|NCT04845464|Other|Cognitive Assessment (not diagnostic)|Sleep quality and cognition will be assessed in young adults
79263863|NCT02429193|Drug|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
79263864|NCT02429193|Drug|Enzalutamide|Enzalutamide (160 mg/day p.o.)
79399241|NCT01431521|Drug|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
79399242|NCT01431521|Drug|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
79399243|NCT04877652|Other|Standard of care|Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
80021278|NCT04435132|Device|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
80021279|NCT03132584|Drug|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3"
80021280|NCT03132584|Drug|Alemtuzumab|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~Alemtuzumab will be administered as follows:~IV Day 1~IV Day 2~Target dose IV on Day 3 and 4"
80021281|NCT03507764|Other|Use of the treadmill workstation at work|"During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions."
80021282|NCT02301650|Drug|Lamivudine|mothers use Lamivudine in late pregnancy
80021283|NCT02301650|Drug|Telbivudine|mothers use Telbivudine in late pregnancy
80021284|NCT02301650|Drug|Tenofovir|mothers use Tenofovir in late pregnancy
79562734|NCT02672982|Other|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
79562735|NCT02672982|Other|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
79859129|NCT05804266|Procedure|Coventional coagulation|Coventional coagulation
80021285|NCT03600844|Behavioral|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
80021286|NCT03510338|Drug|Sublingual sildenafil|100 mg biphasic sildenafil tablet
80021287|NCT03510338|Drug|Oral sildenafil|50 mg oral sildenafil (Viagra)
80021288|NCT02301728|Other|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
80021289|NCT03510260|Other|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
80021290|NCT03510260|Other|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
79263865|NCT04859738|Drug|Lidocaine Spray|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
79399244|NCT04855188|Device|YVOIRE Y-Solution 540|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
79399245|NCT04855188|Device|YVOIRE volume plus|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
79399246|NCT05393856|Drug|CG-549|"PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state."
80021291|NCT03510260|Other|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
79399247|NCT00601731|Biological|MenACWY-CRM197|Blood test, 40-months and 60-months children
79399248|NCT00601731|Biological|Blood test|Blood test, 40-months and 60-months children
79562736|NCT02659124|Device|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
80021292|NCT02303366|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
80021293|NCT02303366|Drug|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
80021294|NCT02301806|Other|dieting|
80021295|NCT02301806|Drug|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
79562737|NCT02659124|Procedure|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
79859130|NCT05804266|Procedure|Underwater coagulation|Underwater coagulation
79859131|NCT05804266|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy
80021296|NCT02301806|Drug|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
79859132|NCT05800665|Drug|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
79263866|NCT04859738|Drug|Benzokain Sprey|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
79263867|NCT04859738|Other|Alcohol|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~In patients in the placebo group, alcohol was sprayed 60 seconds before the area where the peripheral intravenous catheter will be applied. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
79263868|NCT02429271|Drug|Ticagrelor|
79562738|NCT02654314|Drug|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
79562739|NCT02654314|Other|Placebo|Blue capsule matching the melatonin arm
79562740|NCT02652611|Procedure|SI Screw Removal Surgery|
79859133|NCT05800392|Drug|DEC103|The intervention is composed by two medications: An active sublingual pill and an active oral one.
79724689|NCT02762617|Drug|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
80021297|NCT03103204|Combination Product|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
79724690|NCT02762617|Drug|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
80021298|NCT03507530|Other|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
79263869|NCT02429271|Drug|Clopidogrel|
79562741|NCT02652611|Procedure|Non-screw removal treatment (non-operative management)|
79562742|NCT02634905|Other|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
79562743|NCT02634905|Other|Phone Call|
79562744|NCT02628444|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
79562745|NCT02628444|Biological|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
79562746|NCT02626962|Drug|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
79724691|NCT02696473|Dietary Supplement|Carrot|
79562747|NCT02626962|Drug|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
79724692|NCT02696395|Device|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
79724693|NCT02696395|Device|DePuy Corail® femoral stem + Deltamotion® acetabular component|
79724694|NCT01192152|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
79724695|NCT01192152|Drug|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
79724696|NCT01192152|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
79859134|NCT05800392|Drug|Placebo DEC103|The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
79859135|NCT05800015|Drug|fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
79859136|NCT05800015|Drug|cemiplimab|Administered IV Q3W
79859137|NCT05800015|Drug|Pemetrexed|IV Infusion, Q3W
79859138|NCT05800015|Drug|Paclitaxel|IV Infusion, Q3W
79263870|NCT02429271|Procedure|Percutaneous Coronary Intervention (PCI)|
79263871|NCT02429271|Procedure|Coronary Angiography|
79263872|NCT02429505|Drug|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
79562748|NCT02623998|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
79562749|NCT02623998|Drug|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
79859139|NCT05800015|Drug|Carboplatin|IV Infusion, Q3W
79859140|NCT05800015|Drug|Cisplatin|IV infusion, Q3W
79859141|NCT05800015|Drug|Placebo|IV infusion, Q3W
79859142|NCT05799092|Diagnostic Test|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
79859143|NCT05799092|Diagnostic Test|Non-invasive functional test|Standard non-invasive functional testing will be performed.
80021299|NCT02301884|Biological|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
80021300|NCT04724512|Device|suture|a type of suture used in entropion surgery
79263873|NCT04850924|Other|evaluation psychological trauma|9 classes of symptoms to be evaluated
79562750|NCT02623998|Behavioral|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
79263874|NCT04851002|Procedure|Application of concentrated growth factor with dental implants|Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
79263875|NCT04851002|Procedure|Application of advanced platelet rich fibrin with dental implants|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
79263876|NCT04851002|Procedure|Control side of concentrated growth factor study group|Traditional implant methods applied
79263877|NCT04851002|Procedure|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied
79263878|NCT02708121|Behavioral|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
79263879|NCT02708121|Other|Comparator Intervention|Participants informed that they have access to weight loss treatment.
79263880|NCT04844996|Procedure|Surgical induction of endometriotic explants|"Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively"
79263881|NCT02433639|Drug|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
79875780|NCT00953381|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
79263882|NCT02425293|Behavioral|asthma patient education|
79263883|NCT04851080|Device|Heart Rate Variability|"Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health."
79263884|NCT04851080|Device|Spirometry|Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
79263885|NCT04851080|Behavioral|Testing of psycho-physiological functions using four questionnaires|Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
79263886|NCT02433405|Biological|Fetuin-A|Acute phase protein
79562751|NCT02623725|Biological|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
79562752|NCT02623725|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
79562753|NCT02608684|Drug|Pembrolizumab|Pembrolizumab IV solution
79263887|NCT02433405|Biological|Serum Amyloid A|Acute phase protein
79263888|NCT02425059|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
79562754|NCT02608684|Drug|Gemcitabine|Gemcitabine IV solution
79562755|NCT02608684|Drug|Cisplatin|Cisplatin IV solution
79562756|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 milliliter (mL), Intramuscular
79724697|NCT02763553|Dietary Supplement|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
79724698|NCT02763553|Dietary Supplement|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
79724699|NCT04317924|Device|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
79724700|NCT04317924|Other|Standard of care|Standard of care after air leak post lung resection
79724701|NCT04222933|Device|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
79724702|NCT04222933|Device|Classical cryotherapy|application of an ice bag
79263889|NCT02425059|Device|NanoKnife|
79562757|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
79562758|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
79724703|NCT02758249|Drug|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
79724704|NCT02758249|Drug|propofol|patients are anesthetized by using propofol infusion
79724705|NCT02758405|Drug|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
79859144|NCT05798585|Procedure|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
79859145|NCT05798520|Drug|BIIB091|Administered as specified in the treatment arm.
80021301|NCT02301962|Drug|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
80021302|NCT04702438|Behavioral|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
79263890|NCT02425137|Drug|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
79263891|NCT02429349|Procedure|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
79562759|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
79562760|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
79562761|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
79562762|NCT02584829|Drug|Avelumab|Given IV
79724706|NCT02758405|Drug|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
79724707|NCT02758405|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
79859146|NCT05798520|Drug|DRF|Administered as specified in the treatment arm.
79263892|NCT04859348|Other|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
79263893|NCT04859348|Other|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
79263894|NCT02424981|Device|Threshold inspiratory muscle training|Inspiratory muscle training
79859147|NCT05798520|Drug|Placebo|Administered as specified in the treatment arm.
79859148|NCT05797805|Drug|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
79263895|NCT03184857|Procedure|open maxillary sinus lifting|biopsy of the region 6 months later
79263896|NCT03185169|Combination Product|Replens and coconut oil|
79859149|NCT05797805|Drug|Pembrolizumab|"In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus pembrolizumab combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 of a 21-day cycle; Pembrolizumab will be administered on Day 1 of a 21- day cycle"
79859150|NCT05797610|Drug|RO7434656|RO7434656 will be administered subcutaneously per schedule as specified.
79263897|NCT02433249|Behavioral|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
79562763|NCT02584829|Other|Laboratory Biomarker Analysis|Correlative studies
79859151|NCT05797610|Drug|Placebo|Matching placebo will be administered subcutaneously per schedule as specified.
79562764|NCT02584829|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
79562765|NCT02584829|Radiation|Radiation Therapy|Undergo radiation therapy
79724708|NCT02763787|Drug|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
79724709|NCT02763787|Drug|Placebo|Identical placebo
79562766|NCT02584829|Biological|Recombinant Interferon Beta|Given via intra-tumor injection
79562767|NCT02581306|Other|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
79562768|NCT02570308|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
79562769|NCT02540200|Device|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
79562770|NCT02540200|Procedure|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
79562771|NCT02536898|Other|Fracture Liaison Service|
79562772|NCT02536898|Other|Current treatment|
79562773|NCT02512172|Drug|Oral CC-486|
79562774|NCT02512172|Drug|Romidepsin|
79562775|NCT02512172|Drug|MK-3475|
79562776|NCT02510703|Other|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
79724710|NCT02763631|Other|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
79263898|NCT02433249|Behavioral|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
79562777|NCT02502396|Other|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
79562778|NCT02499367|Drug|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
79562779|NCT02499367|Radiation|Radiation therapy|20 Gy to metastatic lesion
79562780|NCT02499367|Drug|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
79724711|NCT02763631|Other|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
79724712|NCT02763631|Other|Sham Comparator: Stand Care Arm|No change will be made to participants care
79724713|NCT02762305|Other|RSVP Bone Builders Group Exercise|
79724714|NCT04223011|Behavioral|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
79263899|NCT02433249|Behavioral|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
79263900|NCT04850690|Diagnostic Test|2D Gait analysis|"The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~Single: Walking without task at a self-selected speed~Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~Motor Task (MT): Walking while carrying an empty box~CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes"
79263901|NCT02433327|Other|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
79263902|NCT02433327|Other|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
79263903|NCT04850768|Other|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
79263904|NCT04850768|Other|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
79562781|NCT02499367|Drug|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
79562782|NCT02499367|Drug|Cisplatin|40 mg/m2, weekly for 2 weeks
79562783|NCT02497612|Drug|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
80021303|NCT03507374|Drug|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
79562784|NCT02497612|Drug|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
79562785|NCT02497612|Other|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
79562786|NCT02497131|Drug|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
79562787|NCT02491333|Other|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
79724715|NCT02758327|Drug|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
79875781|NCT05300477|Drug|Acetazolamide|Carbonic Anhydrase Inhibitor
79875782|NCT05300477|Drug|Erythropoietin|Hormone for red blood cell
80021304|NCT03507374|Drug|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
80021305|NCT05141890|Dietary Supplement|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
79263905|NCT04483323|Procedure|Erector Spinae Plane Block|"The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected."
79399249|NCT04759326|Other|Hippotherapy|Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.
79263906|NCT04483323|Procedure|Intraarticular Injection|Intraarticular injection of local anesthetic through the surgical port
79263907|NCT03182595|Drug|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
79263908|NCT02428959|Drug|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
79263909|NCT02429037|Drug|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10^12 viral particles (VP) in a 21-days cycle.
79562788|NCT02491333|Other|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
79562789|NCT02491333|Drug|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
79859152|NCT05797311|Other|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques are a therapeutic exercise approach developed based on functional activities in daily life. At the stage of regaining movement and function, it creates models similar to functional activities.
79859153|NCT05797311|Other|Shoulder Stabilization Exercises|Scapular stabilization exercise and stabilization exercise for the shoulder joints
79859154|NCT05797233|Biological|Anti-CD19 and anti-CD20 bicistronic CAR T- cells|0.66x10^6 CAR+ T - 10x10^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
79263910|NCT02429037|Radiation|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
79263911|NCT02429037|Drug|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
79562790|NCT02491333|Drug|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
79859155|NCT05797233|Drug|Cyclophosphamide|500 mg/m^2 IV infusion over 30 minutes on days -5, -4 and -3
79859156|NCT05797233|Drug|Fludarabine|30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
79562791|NCT02490943|Other|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
79562792|NCT02490943|Other|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
79562793|NCT02470286|Drug|SA001 60mg or Placebo|"Study Drug: SA001 60mg~Comparator: Placebo~Cohort 1 in the part 1 (Dose escalation study)"
79562794|NCT02470286|Drug|SA001 120mg or Placebo|"Study Drug: SA001 120mg~Comparator: Placebo~Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)"
79562795|NCT02470286|Drug|SA001 180mg or Placebo|"Study Drug: SA001 180mg~Comparator: Placebo~Cohort 3 in the part 1 (Dose escalation study)"
79859157|NCT05795439|Behavioral|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
79562796|NCT02470286|Drug|SA001 240mg or Placebo|"Study Drug: SA001 240mg~Comparator: Placebo~Cohort 4 in the part 1 (Dose escalation study)"
79562797|NCT02470286|Drug|SA001 300mg or Placebo|"Study Drug: SA001 300mg~Comparator: Placebo~Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)"
79562798|NCT02469987|Drug|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
79263912|NCT04833530|Diagnostic Test|Gastric Ultrasound|"In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again."
79263913|NCT04833608|Device|Vktory insoles|Patients were randomized into either the Carbon fiber insole group or Morton's extension group.
79263914|NCT04833608|Device|Morton's extension insoles|Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
79263915|NCT03182439|Device|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
79263916|NCT03182439|Device|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
79562799|NCT02469987|Drug|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
79562800|NCT02469987|Drug|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
79859159|NCT05793060|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
79263917|NCT03182439|Device|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
79562801|NCT02460458|Drug|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
79263918|NCT03182439|Device|Apple Watch|Apple Watch Heart Rate Monitoring Device
79263919|NCT03040232|Other|biomechanical assessment|biomechanical and strength assessment of both groups
79562802|NCT02457559|Drug|Tirabrutinib|Tablets or capsules administered orally
79562803|NCT02439307|Drug|Rifaximin|1200 mg of rifaximin for 2 weeks.
79263920|NCT02428803|Other|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
79263921|NCT04833686|Behavioral|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
79263922|NCT04833686|Behavioral|Instrumental music|Instrumental music , a musical piece 24 minutes long
79263923|NCT04833686|Behavioral|Silence|Silence, a piece 24 minutes long.
79263924|NCT02428881|Drug|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
79263925|NCT02428725|Other|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
79562804|NCT02439307|Drug|Placebo|Placebo for 2 weeks
79562805|NCT02437175|Dietary Supplement|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
79562806|NCT02437175|Dietary Supplement|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
79562807|NCT02424409|Behavioral|2: Intervention|"The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~A written action plan with formalized recommendations for the patient~A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~The ED doctor at discharge will explain all these documents orally~Recommendations for an early contact with the general practitioner;~Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
79562808|NCT02424409|Behavioral|1: Control|patients without discharge protocol
79724716|NCT02758093|Behavioral|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
79724717|NCT02758093|Other|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
79724718|NCT02763475|Drug|cyclophosphamide|60mg/kg by vein on day -6
79859160|NCT05793060|Drug|Dexamethasone Phosphate|Dexamethasone 4 mg
79724719|NCT02763475|Drug|Fludarabine|25mg/m2 iv daily on day -5 to -1
79724720|NCT02763475|Procedure|NK cell infusion|"First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
79724721|NCT02763475|Drug|IL-2|1x10^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
79875783|NCT00953459|Drug|sunitinib malate|
79875784|NCT00953459|Other|laboratory biomarker analysis|
79875785|NCT00953459|Radiation|fludeoxyglucose F 18|
79875786|NCT00953537|Drug|capecitabine|
79875787|NCT00953537|Other|laboratory biomarker analysis|
79875788|NCT00953537|Other|pharmacological study|
79875789|NCT00463788|Drug|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m^2) followed by weekly doses of 250 mg/m^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
79724722|NCT02762383|Drug|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
79859161|NCT05790811|Other|Physician-oriented Video|previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
80021306|NCT03510026|Device|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
80021307|NCT02302040|Behavioral|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
80021308|NCT02302040|Behavioral|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
79562809|NCT02418039|Dietary Supplement|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
79859162|NCT05790811|Other|Patient-oriented video|"The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council."
79263926|NCT02433093|Drug|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
79562810|NCT02418039|Dietary Supplement|Normal protein|A normal protein diet will be administrated in patients with MHE.
79859163|NCT05789524|Drug|SerpinPC|Administered as SC injection.
79859164|NCT05785767|Drug|fianlimab|Every three weeks (Q3W) as intravenous (IV) co-infusion
80021309|NCT02639650|Drug|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
79859165|NCT05785767|Drug|cemiplimab|Q3W as IV co-infusion
80021310|NCT02639650|Drug|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
80021311|NCT02639650|Drug|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
80021312|NCT02639650|Drug|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
79859166|NCT05785767|Drug|Placebo|Q3W as IV co-infusion
79859167|NCT05785611|Drug|Filgotinib|Tablets administered orally once daily
79859168|NCT05785611|Drug|Placebo|Tablets administered orally once daily
80021313|NCT02639650|Drug|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
79859169|NCT05784844|Drug|Meropenem|Carbapenem antibiotic
79859170|NCT05784844|Drug|Micafungin|Echinocandin antifungal
80021314|NCT02639650|Drug|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
80021315|NCT02639650|Drug|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
79859171|NCT05784363|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
79859172|NCT05784363|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
80021316|NCT02639650|Drug|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
80021317|NCT03509870|Biological|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
80021318|NCT03581734|Biological|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
80021319|NCT03581734|Biological|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
79263927|NCT02433093|Drug|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
79263928|NCT02433171|Procedure|Standard of Care FDG-PET Imaging|[11C]Methionine [11]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. [11C]PBR28 [12]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
79562811|NCT02417974|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
79724723|NCT02763163|Behavioral|Sun exposure routine|
79724724|NCT02763241|Drug|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
79724725|NCT02763241|Drug|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
79724726|NCT02763397|Device|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
79724727|NCT02763397|Device|DBS|DBS will be switched off
79724728|NCT04223245|Behavioral|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
79724729|NCT04223245|Behavioral|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
79263929|NCT02433015|Other|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
79263930|NCT02433015|Other|Tobacco Cigarette|Smoke own brand of cigarette as previously
79263931|NCT04833842|Other|Web-based childbirth preparation program developed based on health belief model and supported by motivational interview|In the three-month study, primigravida women in the initiative group will be given a web-based childbirth preparation program, which is prepared based on the Health Belief Model and supported by motivational interviews. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
79724730|NCT02758015|Other|Standardized Meal|
79724731|NCT02758015|Dietary Supplement|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
79724732|NCT02758015|Dietary Supplement|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
79724733|NCT02758015|Dietary Supplement|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
79724734|NCT02757937|Behavioral|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
79724735|NCT02757937|Other|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
79724736|NCT04221685|Other|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
79724737|NCT04221685|Other|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
79724738|NCT02762461|Procedure|IVF or ICSI|
79724739|NCT02762539|Drug|omega-3 enriched SMOF lipid emusion|
79859173|NCT05783310|Behavioral|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
79859174|NCT05782712|Biological|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
79859175|NCT05782647|Device|HeartGuide cuffless BP monitor|Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
79859176|NCT05782491|Procedure|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
79263932|NCT04833842|Other|Web-based childbirth preparation program based on health belief model|In the three-month study, a web-based childbirth preparation program based on the Health Belief Model will be applied to primigravida women in the control group. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
79263933|NCT02428569|Behavioral|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
79263934|NCT04833452|Procedure|Endoscopic dacryocystorhinostomy|Endoscopic DCR
79263935|NCT02424669|Other|ALS Functional rating Scale-revised (ALS FRS-R)|
79263936|NCT02424669|Other|slow vital capacity|
79263937|NCT02424669|Other|Blood sample|
79263938|NCT02424669|Other|Cerebrospinal Fluid (CSF) sample|
79263939|NCT03040310|Other|Back Rx program|The Back Rx program can be viewed via a smartphone app.
79562812|NCT02385786|Behavioral|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
79562813|NCT02381652|Combination Product|Cingal|Injection into the knee
79562814|NCT02381652|Combination Product|Cingal|Injection into the knee
79562815|NCT02381652|Combination Product|Cingal|Injection into the knee
79562816|NCT02378259|Procedure|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
79562817|NCT02378259|Procedure|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
79724740|NCT02757703|Drug|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
79724741|NCT02757703|Drug|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
79859177|NCT05782491|Procedure|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
80021320|NCT02306798|Drug|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
79263940|NCT03186807|Diagnostic Test|ultrasonographic scan of fetal brain|"Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~specific measurements as follow:~Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
79562818|NCT02367794|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
79562819|NCT02367794|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
79562820|NCT02367794|Drug|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
79562821|NCT02367794|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.
79724742|NCT02757703|Drug|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
79724743|NCT02757703|Device|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
79859178|NCT05782491|Procedure|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
79859179|NCT05777863|Behavioral|Multidomain lifestyle intervention|A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
79859180|NCT05776225|Procedure|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
79859181|NCT05775445|Procedure|Blood draw|2 6ml blood tubes will be collected from patient
79859182|NCT05775406|Drug|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
79859183|NCT05774678|Radiation|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
79859184|NCT05774678|Other|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
79859185|NCT05773157|Behavioral|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
79263941|NCT02432859|Procedure|Electrical Stimulation|Direct current with sensory intensity for one hour
79263942|NCT02432859|Procedure|Placebo|Direct current with zero intensity for one hour
80021321|NCT04980430|Device|Virtual Reality|Virtual Reality Demonstration
80021322|NCT02306876|Drug|PF-06412562 3mg BID|PF-06412562
80021323|NCT02306876|Drug|PF-06412562 15mg BID|PF-06412562
80021324|NCT02306876|Other|Placebo|Placebo
80021325|NCT04347226|Drug|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
79263943|NCT04833218|Drug|Propranolol|Test of catecholamines level in moderate traumatic brain injury
79263944|NCT02424747|Other|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
80021326|NCT02302118|Procedure|Esophagogastrectomy|Esophagogastrectomy
80021327|NCT04962178|Procedure|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
79399250|NCT04759326|Other|Conventional Neurorehabilitation|The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
79399251|NCT00601965|Drug|Escitalopram|20 mg daily oral escitalopram
79399252|NCT00601965|Drug|Placebo|Placebo pill of daily oral escitalopram
79399253|NCT00601965|Behavioral|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
79399254|NCT05393778|Procedure|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
79399255|NCT05393778|Procedure|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
79399256|NCT04751994|Dietary Supplement|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
79399257|NCT04751994|Dietary Supplement|Placebo drops|Participants will consume daily drops of placebo
79263945|NCT03182127|Radiation|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
80021328|NCT04962178|Other|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
80021329|NCT02302196|Procedure|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
79263946|NCT03182127|Device|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
79263947|NCT04843748|Device|cataract surgery and intraocular lens implantation - both eyes|cataract surgery and intraocular lens implantation for both eyes
79562822|NCT02364323|Behavioral|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
79562823|NCT02364323|Other|Normal usual care|General education on diabetes and diabetic complications
79562824|NCT02363998|Drug|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
80021330|NCT02302196|Other|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
79562825|NCT02353832|Device|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
79263948|NCT04840160|Dietary Supplement|Cherry juice|A tart cherry juice intervention
79562826|NCT02353728|Drug|Nilotinib|
79724744|NCT02757781|Behavioral|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
79562827|NCT02351583|Device|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
79724745|NCT02763007|Drug|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
80021331|NCT03509714|Dietary Supplement|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
79263949|NCT04840160|Dietary Supplement|Placebo|A tart cherry juice placebo
79562828|NCT02351583|Device|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
79562829|NCT02345070|Drug|SAR156597|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79562830|NCT02345070|Drug|placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79263950|NCT04833374|Drug|Methylprednisolone|Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
79263951|NCT03036410|Device|standard telephone setting|without streaming function
79263952|NCT03036410|Device|DECT|cordless telephone (streaming to both hearing devices)
79562831|NCT02325466|Drug|Aspirin|Aspirin 81mg
79562832|NCT02325466|Drug|Ticagrelor|ticagrelor 90 mg
80021332|NCT03509714|Dietary Supplement|rice flour (Placebo)|250 mg rice flour (Placebo)
80021333|NCT02303522|Other|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
79263953|NCT03036410|Device|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
79724746|NCT02763007|Drug|alogliptin|nesina add on metformin
79724747|NCT02763007|Drug|pioglitazone|actos add on metformin
79724748|NCT02753101|Drug|[18F]-FTC-146|10 mCi± 1 mCi of [18F]FTC-146 intravenously
79263954|NCT03036410|Device|DuoPhone|streaming function, which provides the speech signal to both ears
79562833|NCT02325466|Drug|Aspirin Placebo|
79562834|NCT02325466|Drug|Ticagrelor Placebo|
79562835|NCT02323100|Drug|Ravicti low dose|8 am, 4pm and midnight
79562836|NCT02323100|Drug|Ravicti high dose|8 am, 4pm and midnight
79562837|NCT02323100|Drug|Placebo|8 am, 4pm and midnight
79562838|NCT02322710|Device|Urgotul: Low-adherent dressing|
79724749|NCT02762227|Device|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
79875790|NCT00463788|Drug|cisplatin|"Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
79875791|NCT00548249|Device|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
79263955|NCT04843826|Procedure|papilla reconstruction|subepithelial connective tissue graft for interdental papillary reconstruction around delayed
79562839|NCT02322710|Device|TulleGras M.S.: Vaseline gauze|
79263956|NCT04843670|Procedure|duodenopancreatectomy|resection of the head of the pancreas, the mower part of the biliary duct, and antrectomy
79724750|NCT02762227|Device|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
79724751|NCT02762227|Procedure|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
79724752|NCT00635323|Drug|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
79562840|NCT02303548|Drug|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
79562841|NCT02303548|Drug|Normal saline|Placebo
79562842|NCT02300493|Behavioral|Experimental|Asked to weigh themselves
79724753|NCT01191840|Drug|Vancomycin|Duration
79562843|NCT02292654|Drug|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
79724754|NCT01191840|Drug|Vancomycin|Duration
79724755|NCT02752711|Procedure|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
79724756|NCT04534543|Radiation|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
79724757|NCT05656950|Procedure|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
79724758|NCT02752555|Other|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
79724759|NCT04472377|Device|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
79263957|NCT04840082|Diagnostic Test|Nasopharyngeal swab for COVID-19 testing|A nasopharyngeal swab was performed endoscopically video guided to measure the actual length from to the mid turbinate and the posterior nasopharyngeal wall
79724760|NCT00624546|Drug|Prevacid Solutabs|BID Prevacid Solutabs
79724761|NCT00624546|Procedure|Antireflux surgery|Lap Nissen
80021334|NCT03101878|Drug|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
80021335|NCT03101878|Drug|Placebo|Saline .9%
79263958|NCT04833062|Diagnostic Test|Ultrasound|In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.
79399258|NCT05393700|Behavioral|Action Observation Therapy|Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
79399259|NCT00602043|Radiation|F-18 16 alpha-fluoroestradiol|Undergo [^18F] FES PET
79399260|NCT00602043|Radiation|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
79399261|NCT00602043|Procedure|positron emission tomography|Undergo [^18F] FES PET
79399262|NCT00602043|Procedure|positron emission tomography|Undergo standard clinical FDG PET/CT
79399263|NCT00602043|Procedure|computed tomography|Undergo standard clinical FDG PET/CT
79562846|NCT02257749|Other|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
79724762|NCT05656872|Procedure|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
79875792|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
79875793|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
79875794|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
80021336|NCT02302274|Drug|flecainide iv|infusion over 10 min
80021337|NCT05245318|Other|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
79263959|NCT04833062|Other|Survey|"The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI."
79263960|NCT04843592|Device|SOKARY Mobile|Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
79263961|NCT02707965|Drug|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263962|NCT02707965|Drug|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263963|NCT02707965|Drug|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263964|NCT02707965|Drug|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263965|NCT02707965|Drug|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263966|NCT02707965|Drug|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79399264|NCT00602043|Other|laboratory biomarker analysis|Correlative studies
79724763|NCT05656872|Procedure|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
79724764|NCT02757469|Drug|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
79875795|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
79875796|NCT00463476|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
79875797|NCT01025466|Drug|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
79875798|NCT01025466|Drug|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
80021338|NCT05245318|Device|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
79859186|NCT05772715|Other|orthosis + exercise therapy|The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).
80021339|NCT02303600|Drug|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
80021340|NCT02303600|Other|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
80021341|NCT05245240|Procedure|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
80021342|NCT02307110|Other|cross-sectional observation|cross-sectional opthalmic examination
79263967|NCT02707965|Drug|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263968|NCT02707965|Drug|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
79263969|NCT04839926|Drug|0.5mg CY150112|single oral CY150112 while fasting on day 1.
79263970|NCT04839926|Drug|1.5mg CY150112|single oral CY150112 while fasting on day 1.
79263971|NCT04839926|Drug|4.5mg CY150112|single oral CY150112 while fasting on day 1.
79724765|NCT05656716|Behavioral|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
79263972|NCT04839926|Drug|10mg CY150112|single oral CY150112 while fasting on day 1.
79724766|NCT05656716|Behavioral|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
79263973|NCT04839926|Drug|18mg CY150112|single oral CY150112 while fasting on day 1.
79263974|NCT04839926|Drug|24mg CY150112|single oral CY150112 while fasting on day 1.
79263975|NCT04839536|Drug|Sevoflurane inhalant product|Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
79263976|NCT02428257|Procedure|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
79263977|NCT02428257|Drug|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
79263978|NCT02428257|Drug|isobaric bupivacaine|0.5% isobaric bupivacaine
79263979|NCT02428257|Drug|ephedrine|
79263980|NCT04839224|Drug|carbogen|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
79263981|NCT04839224|Drug|phenylephrine|Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
79263982|NCT03182283|Behavioral|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
79263983|NCT03036644|Device|e-cigarette (PG+VG without nicotine; low temperature)|
79263984|NCT03036644|Device|e-cigarette (PG+VG with nicotine; low temperature)|
79263985|NCT03036644|Device|e-cigarette (PG+VG without nicotine; high temperature)|
79263986|NCT03036644|Device|e-cigarette (PG+VG with nicotine; high temperature)|
79562847|NCT02257749|Other|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
79562848|NCT02243033|Device|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
79562849|NCT02239354|Combination Product|VC-01™ Combination Product|Biologic and Device
79562850|NCT02234310|Biological|rFIXFc|Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
79562851|NCT02162563|Drug|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
79562852|NCT02162563|Drug|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
79562853|NCT02162563|Drug|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
79562854|NCT02158403|Other|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
79724767|NCT02762149|Device|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
79724768|NCT02757391|Biological|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
79724769|NCT02757391|Biological|Aldesleukin|Given SC
79875799|NCT03910296|Behavioral|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
79263987|NCT03036644|Other|tobacco cigarette|
79263988|NCT02424825|Behavioral|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
79263989|NCT03184779|Other|Ski and Snowboard Safety Video|The ski and snowboard safety video (~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
79263990|NCT03184467|Drug|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
79263991|NCT03184467|Drug|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
79399265|NCT02998437|Drug|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
79399266|NCT02998437|Drug|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
79263992|NCT03184467|Drug|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
79263993|NCT03186495|Drug|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
79263994|NCT02424513|Radiation|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
79399267|NCT02998437|Drug|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
79399268|NCT02618148|Drug|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
79399269|NCT02618148|Drug|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
79859187|NCT05772715|Other|Orthosis|The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
79859188|NCT05772338|Drug|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
79859189|NCT05772338|Other|Placebo|Placebo. Up to six applications per day.
79859190|NCT05770908|Other|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~Scaption with elastic band.~External rotation at 0º of abduction with elastic band.~Internal rotation at 0º of abduction with elastic band.~Shoulder protraction in supine position with weights.~Low row with elastic band.~Horizontal adduction stretching."
79859191|NCT05770908|Other|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
79859192|NCT05770908|Other|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
79859193|NCT05770895|Biological|GS-2829|Administered intramuscularly
79263995|NCT02424201|Drug|Misoprostol|experimental
79263996|NCT02424201|Drug|vitamin c|control
79562855|NCT02154568|Drug|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
79263997|NCT03186105|Other|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
79263998|NCT03186183|Behavioral|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
79263999|NCT02428179|Procedure|StOP? - Control group|Control group - Surgical procedure without Study Intervention
79562856|NCT02139436|Other|FES-row-training|
79562857|NCT02139436|Other|Arms-only-row training|
79724770|NCT02757391|Drug|Cyclophosphamide|Given IV
79859194|NCT05770895|Biological|GS-6779|Administered intramuscularly
79859195|NCT05770895|Biological|Placebo for GS-2829|Administered intramuscularly
79562858|NCT02139436|Other|Time Control|
79562859|NCT02127086|Other|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
79562860|NCT02120079|Drug|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
79562861|NCT02120079|Drug|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
79562862|NCT02120079|Diagnostic Test|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
79562863|NCT02106195|Drug|Belumosudil|
79724771|NCT02757391|Other|Laboratory Biomarker Analysis|Correlative studies
79724772|NCT02757391|Biological|Pembrolizumab|Given IV
79724773|NCT02757157|Behavioral|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
79859196|NCT05770895|Biological|Placebo for GS-6779|Administered intramuscularly
79859197|NCT05767034|Drug|Secukinumab 300 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
79859198|NCT05767034|Drug|Secukinumab 150 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
79859199|NCT05767034|Other|Placebo to secukinumab|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
79859200|NCT05765721|Behavioral|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
79264000|NCT02428179|Procedure|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
79264001|NCT04440423|Drug|Clotiazepam 5 mg Test Product Coated Tablets|Investigational Medicinal Product
79264002|NCT04440423|Drug|Clotiazepam 5 mg Reference Product Coated Tablets|Rize (Trademark)
79264003|NCT03117231|Device|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
79859201|NCT05763875|Drug|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
79859202|NCT05763875|Drug|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
79264004|NCT03117231|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
79264005|NCT02427945|Behavioral|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
79264006|NCT02427945|Behavioral|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
79264007|NCT02427789|Other|Physical Exercise|physical exercise
79264008|NCT02432781|Dietary Supplement|Carbohydrate-rich drink|
79264009|NCT02432781|Dietary Supplement|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
79264010|NCT01667900|Drug|Dulaglutide|
79264011|NCT01667900|Drug|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
79264012|NCT02432937|Drug|Corever|Corever
79562864|NCT02104180|Device|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
79562865|NCT02104180|Device|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
79562866|NCT02097550|Other|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
79264013|NCT03116919|Other|Potato|Participants will be given an extra serving of potato a day
79264014|NCT03116919|Other|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
79562867|NCT02075177|Drug|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
79562868|NCT02075177|Drug|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
79562869|NCT02059681|Other|Autologous bone marrow derived-CD133+ cells|Cell therapy
79562870|NCT02050919|Drug|Epirubicin Hydrochloride|Given IV
79562871|NCT02050919|Radiation|External Beam Radiation Therapy|Undergo EBRT
79562872|NCT02050919|Drug|Ifosfamide|Given IV
79562873|NCT02050919|Other|Laboratory Biomarker Analysis|Correlative studies
79562874|NCT02050919|Drug|Sorafenib Tosylate|Given PO
79562875|NCT02050919|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79562876|NCT02001142|Other|Exercise|single session of exercise
79562877|NCT01997463|Drug|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
79562878|NCT01976754|Drug|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
79562879|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
79562880|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
79562881|NCT01943825|Biological|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
79562882|NCT01943825|Biological|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
79562883|NCT01913457|Radiation|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
79562884|NCT01863186|Drug|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
79562885|NCT01863186|Drug|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
79562886|NCT01863186|Drug|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
79562887|NCT01828840|Drug|epidural morphine via PCEA|
79859203|NCT05763875|Drug|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
79859204|NCT05763875|Drug|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
79562888|NCT01828840|Drug|epidural fentanyl via PCEA|
79562889|NCT01828840|Drug|epidural methadone via PCEA|
79562890|NCT01828840|Drug|intravenous morphine via PCA|
79562891|NCT01817426|Drug|Infliximab|
79562892|NCT01817426|Other|Placebo|
79562893|NCT01741103|Drug|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
79562894|NCT01741103|Drug|Placebo|Take one by mouth daily for 12 weeks
79562895|NCT01722331|Drug|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
79562896|NCT01722331|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
79562897|NCT01722331|Drug|Matching Placebo|Matching placebo to tildrakizumab PFS
79562898|NCT01630590|Drug|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
79562899|NCT01630590|Drug|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
79562900|NCT01619085|Drug|Nintedanib|Nintedanib twice a day
79859205|NCT05759156|Drug|Tranexamic acid injection|The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
79859206|NCT05755256|Dietary Supplement|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
79859207|NCT05755256|Dietary Supplement|Placebo|After randomization, participants will consume the placebo for 12 weeks.
79859208|NCT05753319|Other|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
79264015|NCT03040076|Behavioral|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
79399270|NCT02998281|Device|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
79724774|NCT02757157|Behavioral|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
79399271|NCT02998359|Device|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
80021343|NCT05244928|Other|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
79562901|NCT01612663|Device|Pain relief by Acupuncture needle at non-specific site|
80021344|NCT03505034|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
79399272|NCT02998359|Device|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
79859209|NCT05751369|Behavioral|Education plus Support|Brief behavioral support for using TECW Tracker
79399273|NCT04692714|Device|Knee prosthesis implementation with additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot with additional cement.
79399274|NCT04692714|Device|Knee prosthesis implementation without additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot without additional cement.
79562902|NCT01612663|Device|Acupuncture needle|
79562903|NCT01612663|Device|Acupuncture needle|
79562904|NCT01612663|Device|Acupuncture needle|
79562905|NCT01499095|Drug|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
79859210|NCT05747456|Device|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
79859211|NCT05747456|Device|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
79859212|NCT05743114|Device|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
79859213|NCT05742711|Device|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
79859214|NCT05742711|Device|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
80021345|NCT05244850|Other|Test|Measurements
80021346|NCT02817178|Other|Additional biological samples|blood and tumor tissue samples
80021347|NCT02303756|Device|Pillcam® COLON Capsule|colonoscopy
80021348|NCT04730986|Behavioral|ED GOAL Nursing|A brief (<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
79562906|NCT01499095|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
80021349|NCT04463342|Combination Product|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
80021350|NCT04463342|Combination Product|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
79264016|NCT03040076|Behavioral|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
79264017|NCT03184623|Other|muscle mass measurement|measurement of muscle mass by echocardiography
79264018|NCT03181581|Biological|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
79264019|NCT03181581|Biological|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
79264020|NCT04843280|Procedure|FORCE therapeutics (physical therapy)|6 weeks of internet based physical therapy following arthroscopic knee surgery
79264021|NCT04843280|Procedure|Traditional Outpatient Physical Therapy|6 weeks of outpatient physical therapy following arthroscopic knee surgery
79264022|NCT03184389|Behavioral|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
79264023|NCT04833296|Drug|Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
79264024|NCT04832828|Diagnostic Test|Roth´s Test|Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
79562907|NCT01499082|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
79562908|NCT01499082|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
79264025|NCT03181737|Behavioral|Covivio/Relaxio|Informations already included in arm/group descriptions.
79562909|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
79562910|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
79724775|NCT02757079|Drug|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
79724776|NCT04221217|Drug|Icosapent|Icosapent (MND-2119) capsules.
79724777|NCT02696161|Other|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
79724778|NCT02696161|Other|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
79724779|NCT02887560|Procedure|transoesophageal echocardiography|
79724780|NCT04220749|Radiation|Radiation|Standard of Care: Radiation +/- Chemotherapy
79724781|NCT04220749|Procedure|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
79724782|NCT05655858|Other|Management of allergic rhinitis|Collection of patient data in real-life
79724783|NCT02752321|Device|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
79264026|NCT04832906|Drug|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
79264027|NCT04832906|Procedure|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
79724784|NCT02768389|Drug|Bevacizumab|Subjects receive Bevacizumab as standard of care
79724785|NCT02768389|Behavioral|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (< 20gm/day).
79724786|NCT04529005|Drug|Angiotensin II|If intraoperative or postoperative hypotension occurs (e.g. SBP < 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
79724787|NCT05357040|Drug|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
80021351|NCT05244772|Other|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
79264028|NCT03182205|Other|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
79264029|NCT03182205|Other|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
79562911|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
79562912|NCT01488890|Biological|Yellow Fever|0.5 mL, Subcutaneous
79724788|NCT05357040|Drug|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
79562913|NCT01480206|Other|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
79562914|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
79562915|NCT01436396|Biological|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
79724789|NCT05655390|Behavioral|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
79562916|NCT01436396|Biological|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
79562917|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
79562918|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
79562919|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
79562920|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
79562921|NCT01436396|Biological|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
79562922|NCT01436396|Biological|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
79562923|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
79562924|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
79724790|NCT00943072|Biological|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
79724791|NCT00943072|Drug|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
79724792|NCT02757001|Other|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
79724793|NCT04222855|Drug|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
79724794|NCT00942994|Drug|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
79724795|NCT00942994|Drug|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
79724796|NCT02756767|Other|Survey|
79724797|NCT02761525|Other|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
79724798|NCT02761525|Other|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
79724799|NCT04317222|Device|eCRRT|"eCRRT was define as:~Initiated within the first 24 post-transplant hours;~High volume (35-50ml/kg) hemofiltration;~Continuous at least 12 hours per day for 3 days;~Standard treatment"
79724800|NCT04268602|Other|local anesthetic injection|1% lidocaine
79724801|NCT05658354|Other|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
79724802|NCT02756455|Other|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
79724803|NCT00942604|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
79724804|NCT00942604|Drug|Vehicle gel|two day treatment
79724805|NCT04314336|Drug|Public procurement|Cost minimisation study through public procurement
79859215|NCT05738278|Behavioral|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~revised personal hygiene procedure."
79859216|NCT05738278|Behavioral|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~revised personal hygiene procedure."
79399275|NCT04683588|Other|Nursing Coaching|Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
79562925|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
79264030|NCT04843358|Behavioral|Emotional Disclosure|"The trial member will deliver instructions For the next three days, I want you to write about your experience with cancer. In your writing, I want you to really let go and explore your very deepest emotions and thoughts. It is critical that you delve deeply. Ideally, I would like you to write about those parts of the experience you found hard to share with others. Perhaps this will provide an opportunity to really examine those thoughts and emotions. You might tie your personal experiences to other parts of your life. How is it related to your family life, relationship with your spouse, your children, your sexuality, daily activities, hobbies, your past, your childhood, your work? These are just some examples."
79562926|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
79264031|NCT04843358|Behavioral|Non-Emotional Writing|"The trial member will deliver instructions were as follows. For the next three days, I want you to write about how you use your time. We are interested in everything you do during the course of a day. In your writing I want you to be completely objective. We are not interested in your emotions or opinions. Feel free to be as detailed as possible"
79264032|NCT03182049|Procedure|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
79562927|NCT01414777|Drug|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
79724806|NCT04314336|Drug|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
79859217|NCT05737979|Other|Study chart review|Evaluation of the IVF cycle using the prescribed medication
79859218|NCT05736107|Drug|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
79859219|NCT05736107|Other|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
79562928|NCT01414777|Drug|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
79562929|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
79859220|NCT05735236|Device|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
80021352|NCT02303834|Device|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
79264033|NCT03182049|Procedure|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
79264034|NCT04839068|Device|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
79562930|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
79562931|NCT01411241|Biological|Placebo|0.5 mL, subcutaneous
79562932|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
79562933|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
79724807|NCT02756221|Dietary Supplement|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
79724808|NCT02756221|Other|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
79724809|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
80021353|NCT02303912|Drug|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
79562934|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
79562935|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
79562936|NCT01411241|Biological|Placebo|0.5 mL, subcutaneously
79562937|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
79562938|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
79724810|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
79859221|NCT05735041|Behavioral|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
79859222|NCT05735041|Behavioral|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
80021354|NCT03507140|Other|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
80021355|NCT01597492|Biological|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
80021356|NCT01597492|Biological|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
80021357|NCT04483726|Procedure|minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
79264035|NCT00702273|Drug|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
79724811|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
80021358|NCT04483726|Procedure|open distal pancreatectomy|open distal pancreatectomy
80021359|NCT03423602|Device|PerQseal®|Large hole closure system
79264036|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79264037|NCT00702273|Drug|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
79264038|NCT00702273|Drug|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
79264039|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
79264040|NCT00702273|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
79264041|NCT00702273|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
79724812|NCT00624702|Drug|Placebo|
79264042|NCT00702273|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
79264043|NCT04842812|Biological|TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3|TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
79724813|NCT02857192|Biological|Blood samples|
79562939|NCT01380938|Drug|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight < or > 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
79562940|NCT01374516|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
79562941|NCT01374516|Biological|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
79562942|NCT01373281|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
79562943|NCT01373281|Biological|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
79562944|NCT01340105|Procedure|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
79562945|NCT01340105|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
79562946|NCT01254422|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
79724814|NCT02756377|Drug|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
79724815|NCT02756377|Drug|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
79724816|NCT02852824|Drug|BI 655130|
79724817|NCT02852824|Drug|Placebo|
79724818|NCT02752009|Procedure|Axillary Lymph Node Sampling Clip|
80021360|NCT04051645|Device|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
79724819|NCT04220437|Other|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
80021361|NCT04569994|Drug|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
79264044|NCT03181659|Procedure|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
79264045|NCT03181659|Procedure|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
79264046|NCT04842656|Other|Post isometric relaxation|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions
79562947|NCT01254422|Biological|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
79562948|NCT01204242|Drug|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
79562949|NCT01204242|Drug|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
79562950|NCT01187433|Biological|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
79562951|NCT01187433|Biological|NaCl 0.9%|0.5 mL, Subcutaneous
79562952|NCT01187433|Biological|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
79724820|NCT02752477|Drug|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
79724821|NCT02752477|Drug|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
79724822|NCT02761681|Behavioral|ACT-CL Web-based guided self-help|
79724823|NCT02761681|Behavioral|Control Web-based guided self-help|
79562953|NCT01187433|Biological|Meningococcal A+C vaccine|0.5 mL, Intramuscular
79724824|NCT04220593|Other|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
79724825|NCT04204096|Biological|Vi-DT (Multi-dose formulation)|"Manufacturer: SK bioscience Co., Ltd.~Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~Storage Conditions: +2 to +8°C"
79562954|NCT01150045|Drug|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
79562955|NCT01150045|Drug|5-fluorouracil|Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
79562956|NCT01150045|Other|placebo|Patients receive placebo administered by mouth, once daily.
79562957|NCT01150045|Drug|oxaliplatin|Patients receive 85 mg/m^2 intravenous over two hours.
79562958|NCT01150045|Drug|leucovorin|Patients receive 400 mg/m^2 intravenous over two hours.
79724826|NCT04204096|Biological|Vi-DT (Single dose formulation)|"Manufacturer: SK bioscience Co., Ltd.~Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~Storage Conditions: +2 to +8°C"
80021362|NCT04569994|Drug|Placebo (NNC0363-0845)|A single dose administered s.c.
80021363|NCT04569994|Drug|Insulin degludec|A single dose administered s.c.
80021364|NCT02307344|Dietary Supplement|Nigella Sativa|
80021365|NCT02307344|Dietary Supplement|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
80021366|NCT05243992|Other|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
80021367|NCT05374096|Other|Patient-Chosen Music|Music played into headphones.
80021368|NCT05374096|Other|Placebo|Silence into headphones.
79562959|NCT01098032|Device|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate >300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
79562960|NCT01098032|Drug|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
80021369|NCT02307422|Genetic|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
80021370|NCT03509480|Procedure|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
80021371|NCT04457206|Behavioral|SCI Group and one-on-one services through student led occupational therapy clinic|The Collaborative Community Clinic (CCC) students collaborate with Dr. Walker to conduct the spinal cord injury/disease (SCI/D) Health and Participation Program, which consists of a combination of groups and one-on-one OT sessions serving persons with spinal cord injury and disease who are un- or under-insured. The program includes a pre-assessment session, four groups, optional individual sessions and a post-survey. Group topics include bowel/bladder management, community mobility, advocacy, transportation, promoting intimacy, adaptive parenting and finding resources. Students are involved in recruiting participants, co-leading group sessions, treatment planning and implementation for individual sessions, and development of topic-specific materials.
80021372|NCT03509402|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
80021373|NCT03509402|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
80021374|NCT05243758|Device|Group video fiberscope of experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopyvideo fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
80021375|NCT05243758|Device|Group video laryngoscope of experienced practitioner|Intubation Pending Difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.
79264047|NCT04842656|Other|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
79562961|NCT01034306|Drug|CF101|orally q12h
79264048|NCT02433795|Drug|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
79562962|NCT01034306|Drug|Placebo control|orally q12 hours
79562963|NCT01013857|Behavioral|Health coaching|Calling patients every week to discuss medication adherence
79562964|NCT01013857|Behavioral|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
79724827|NCT04204096|Biological|Control Vaccine|"For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
79724828|NCT05376852|Combination Product|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
79724829|NCT02756143|Behavioral|Exercise|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
79562965|NCT00993447|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
79724830|NCT05657730|Dietary Supplement|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
79724831|NCT02756299|Other|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
79724832|NCT02756299|Other|Standard Support|General information about OSA and PAP treatment at baseline
79724833|NCT05657574|Drug|D377|oral, once daily, 8 weeks
79724834|NCT05657574|Drug|CKD-331|oral, once daily, 8 weeks
79724835|NCT05657574|Drug|D086|oral, once daily, 8 weeks
79724836|NCT05657574|Drug|Placebo (for D377)|oral, once daily, 8 weeks
79724837|NCT05657574|Drug|Placebo (for CKD-331)|oral, once daily, 8 weeks
79724838|NCT05657574|Drug|Placebo (for D086)|oral, once daily, 8 weeks
79724839|NCT02761447|Other|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
79724840|NCT02761447|Other|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
79724841|NCT00061282|Drug|Clotrimazole|One retention enema, administered nightly
79724842|NCT02756065|Other|no intervention|no intervention is used
79724843|NCT04268524|Combination Product|drug: miltefosine with thermotherapy|see previous
79724844|NCT05657418|Drug|JS107|JS107, i.v., q3w
79399276|NCT03140124|Behavioral|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
79724845|NCT05657418|Combination Product|JS107 combination with Toripalimab|JS107 i.v., q3w combine with Toripalimab
79724846|NCT02695693|Behavioral|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
79724847|NCT02695693|Behavioral|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
79724848|NCT02695693|Behavioral|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
79724849|NCT02695693|Behavioral|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
79859224|NCT05733208|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
79859225|NCT05733208|Procedure|Sham-remote ischemic preconditioning|The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
79859226|NCT05733143|Other|cardiopulmonary exercise stress test (CPEST)|The study is observational and purely exploratory. We will utilise cardiopulmonary exercise stress testing to assess levels of fitness and causes for symptoms in proposed groups.
79399277|NCT03140124|Behavioral|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
79399278|NCT04680936|Drug|Dextrose 5% in water|low dose dextrose solution
79399279|NCT04680936|Drug|Dextrose 15 % in Water|high dose dextrose solution
79724850|NCT02855632|Drug|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
79724851|NCT02855632|Drug|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
79859227|NCT05730712|Procedure|Biopsy|Undergo biopsy
79859228|NCT05730712|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79724852|NCT02855632|Drug|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
79859229|NCT05730712|Procedure|Computed Tomography|Undergo CT
79859230|NCT05730712|Procedure|Echocardiography|Undergo ECHO
79859231|NCT05730712|Drug|Enzalutamide|Given PO
79859232|NCT05730712|Drug|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
79399280|NCT04680936|Drug|Isotonic sodium chloride solution|isotonic saline solution
79859233|NCT05730712|Procedure|Magnetic Resonance Imaging|Undergo MRI
79859234|NCT05730712|Other|Questionnaire Administration|Ancillary studies
79859235|NCT05728255|Diagnostic Test|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
79562966|NCT00993447|Biological|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
80021376|NCT05243758|Device|Group video fiberscope of less experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopy video fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
80021377|NCT05243758|Device|Group video laryngoscope of less experienced practitioner|Entubation pending difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.Storz DCI Video Laryngoscope (Karl Storz GmbH &Co. KG, Tuttlingen, Germany)
80021378|NCT02311556|Device|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
79264049|NCT03038516|Drug|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
79264050|NCT03038516|Device|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
79399281|NCT05393544|Behavioral|Digitally assisted peer recovery coach|The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
79562967|NCT00945009|Biological|Dactinomycin|Given IV
79562968|NCT00945009|Drug|Doxorubicin Hydrochloride|Given IV
79562969|NCT00945009|Radiation|Radiation Therapy|Undergo radiation therapy
79724853|NCT02855632|Other|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
79724854|NCT05657340|Diagnostic Test|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
79399282|NCT03140046|Procedure|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
79724855|NCT02761213|Drug|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
79724856|NCT02761213|Drug|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
79859236|NCT05728242|Diagnostic Test|Gastric ultrasound|Preoperative gastric antrum examination to detect gastric content (empty, liquid, or solid) and measure gastric volume
79859237|NCT05720156|Other|Contrast-enhanced CCTA|Allows for non-invasive assessment of atherosclerotic plaque burden and morphology
79859238|NCT05720156|Other|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
79859239|NCT05718323|Drug|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
79859241|NCT05710692|Drug|PRX-102 1 mg/kg every 2 weeks|PRX-102 1 mg/kg every 2 weeks
79859242|NCT05710692|Drug|PRX-102 2 mg/kg every 4 weeks|PRX-102 2 mg/kg every 4 weeks
80021379|NCT04372030|Other|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
79264051|NCT02424279|Procedure|Splanchnicectomy|
79399283|NCT01404325|Drug|standard therapy|centre specific CNI-based triple drug immunosuppression
79399284|NCT01404325|Drug|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
79399285|NCT04407559|Other|Serological analyses to be lead on a pre-existing biobank|"3 immunoassays will be used according to the procedure described (Demey-2020; Tuaillon-2020) :~WuHan UNscience Biotechnology Co., Ltd (Chine). COVID-19 IgG/IgM Rapid Test Kit, (Wuhan, China), will be refered as UNscience~Chongqing iSIA BIO-Technology Co., Ltd (Chine). 2019-nCoV IgM/IgG Diagnostic Test Kit ; (Chongqing, China), will be refered as iSIA~Xiamen Biotime Biotechnology Co. Ldt (Chine). (SARS-CoV-2) IgM/IgG Rapid Qualitative Test Kit, will be refered as Biotime."
79562970|NCT00945009|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
79562971|NCT00945009|Drug|Vincristine Sulfate|Given IV
79562972|NCT00942877|Drug|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
79859243|NCT05708924|Drug|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
79859244|NCT05708924|Biological|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
79859245|NCT05708300|Drug|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
79859246|NCT05706922|Other|Venous blood sample, vaginal swab|Venous blood samples and vaginal swab will be obtained on the same day.
80021380|NCT02311634|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
79562973|NCT00896389|Procedure|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
79562974|NCT00896389|Drug|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
79562975|NCT00880893|Biological|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
79264052|NCT02432469|Behavioral|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
79562976|NCT00880893|Biological|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
79724857|NCT02852746|Behavioral|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
79859247|NCT05703945|Other|Progressive training program|The intervention consists of progressive training program : toe plantar flexion isometric at 30° of dorsal flexion of the metatarsophalangeal joint (0° is considered the anatomical position). The training will be performed in the same customized device used for the measurement. Each session consists of four sets at 80% of the maximal voluntary contraction performed until task failure. Between the sets, 2 minutes of rest will be allowed. Maximal voluntary contraction estimate will be updated every session of training, testing it before the start. The test is considered part of the training intervention. The total impulse performed during the single session will be recorded. Participants will train twice a week for 8 weeks. Training will be performed with both the feet.
79859248|NCT05703945|Other|Control group|The control group will not perform the progressive training program after visit 2 and will continue all of their daily activities during the 8-week intervention period.
79859249|NCT05703607|Biological|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
79859250|NCT05703607|Biological|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
79859251|NCT05703607|Biological|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
80021381|NCT02311634|Device|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
80021382|NCT00109590|Drug|Didanosine, enteric-coated|once daily
79264053|NCT04832126|Genetic|Genetic analysis|Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood & Tissue Kit (QIAGEN).
79264054|NCT02424435|Drug|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
79724858|NCT05657262|Other|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
79724859|NCT05657262|Behavioral|experimental group|The experiment group will be applied with the Z technique.
79724860|NCT00635635|Behavioral|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
79724861|NCT00635635|Behavioral|Music Audio|Music only audio to be listened to 5x per week
79724862|NCT02852668|Other|Power Training|This experimental groups underwent an intervention period of power training
80021383|NCT00109590|Drug|Lopinavir/ritonavir|twice daily
80021384|NCT00109590|Drug|Nevirapine|single-dose at the onset of labor
80021385|NCT00109590|Drug|Zidovudine|twice daily
79724863|NCT02852668|Other|Strength Training|This experimental groups underwent an intervention period of strength training
79724864|NCT04220281|Drug|Propofol|propofol infusion during surgery
79859252|NCT05703607|Biological|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
79859253|NCT05703607|Biological|Shingrix|Intramuscular injection
79859254|NCT05703607|Biological|Selected Vaccine Candidate group (Dose level, Schedule)|Intramuscular injection
79859255|NCT05703607|Biological|Shingrix - SSB|Intramuscular injection
79859256|NCT05700643|Dietary Supplement|Montmorency cherry supplement|Montmorency cherry supplement
79859257|NCT05700643|Dietary Supplement|Control|Placebo
80021386|NCT05243446|Drug|Losartan|losartan treatment
79724865|NCT04220281|Drug|Nitroglycerin|nitroglycerin infusion during surgery
79859258|NCT05697406|Drug|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
79264055|NCT04832048|Other|Therapeutic physical exercise|"The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF)."
79562977|NCT00875901|Radiation|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
79562978|NCT00875901|Radiation|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
79562979|NCT00779961|Procedure|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
79264056|NCT04832048|Other|No physical exercise|No programmed physical exercise
79562980|NCT00779961|Procedure|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
79562981|NCT00770380|Behavioral|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
79562982|NCT00770380|Other|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
79859259|NCT05696912|Genetic|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
80021387|NCT02311712|Device|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
79859260|NCT05696912|Genetic|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
79264057|NCT02427711|Device|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
79562983|NCT00587301|Device|Lap-Band|Obesity and adolescents
79562984|NCT00579527|Biological|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
79724866|NCT02852512|Procedure|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
79724867|NCT02751619|Drug|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
79724868|NCT02751619|Drug|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
79859261|NCT05696678|Drug|Intrathecal Morphine|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
80031677|NCT04882306|Device|Bilateral MARIA scan|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.
80031678|NCT02047383|Other|Respiratory infection|An assessment of the patients included in the study will be conducted
79264058|NCT04842968|Other|Methylene blue injection|Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
79264059|NCT02423967|Biological|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
79264060|NCT02423967|Biological|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
79264061|NCT04832204|Drug|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
79264062|NCT02427633|Other|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
79264063|NCT02427633|Other|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
79264064|NCT04842578|Other|Cross- Section of CT Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.
79264065|NCT04842578|Other|3D simulation Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
79562985|NCT00579527|Other|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
79562986|NCT00579527|Procedure|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
79562987|NCT00579527|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
79562988|NCT00579527|Drug|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses >50,000 cpm, or atypical cDGA with PHA response <75,000cpm (when not on immunosuppression) or <40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
79562989|NCT00579527|Drug|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
79562990|NCT00579527|Drug|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells >4,000cumm. Steroids are weaned as per protocol.
79562991|NCT00579527|Drug|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
79562992|NCT00579527|Drug|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
79562993|NCT01904123|Other|Laboratory Biomarker Analysis|Correlative studies
79562994|NCT01904123|Other|Pharmacological Study|Correlative studies
79562995|NCT01904123|Drug|STAT3 Inhibitor WP1066|Given PO
79562996|NCT00576836|Biological|Cultured Thymus Tissue Implantation (CTTI)|Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not >18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
79724869|NCT04316988|Diagnostic Test|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
79724870|NCT02751541|Drug|Sunscreen Sport Spray (BAY987519)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
79724871|NCT02751541|Other|Untreated Skin|This site is patched without treatment as irradiated control.
79724872|NCT02755753|Drug|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
79724873|NCT02755753|Drug|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
79724874|NCT02755753|Drug|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
79264066|NCT02427555|Other|Barley kernel bread|3 days intervention with barley kernel bread
79264067|NCT02427555|Other|white wheat bread|3 days intervention with white wheat bread
79724875|NCT02755987|Drug|ANG1005|
80031679|NCT04886674|Dietary Supplement|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for < 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
80031680|NCT02260011|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
80031681|NCT02260011|Drug|Atrovent® CFC inhalation aerosol|
79264068|NCT03038282|Dietary Supplement|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
79264069|NCT03038282|Other|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
79724876|NCT01188564|Drug|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
79724877|NCT01188564|Drug|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
79859262|NCT05696678|Drug|Ropivacaine 0.2%|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
79859263|NCT05695521|Biological|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
79859264|NCT05695521|Other|Excipient|Excipient
79859265|NCT05695222|Other|This is not an interventional study|This is not an interventional study
79859266|NCT05695001|Device|Efferon CT|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
79859267|NCT05694988|Device|Efferon CT|Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
79859268|NCT05694455|Diagnostic Test|Starling Stroke Volume (Starling SV)- Passive Leg Raise|All septic patients will have a passive leg raise performed with the assistance of an Starling SV device to look at Stroke Volume change. This will be performed at admission and 4 hours after admission. This intervention will not be performed on healthy controls
79859269|NCT05694455|Diagnostic Test|Microscan Sublingual Microscopy|All septic patients will have sublingual microscopic images performed at admission, 8-16 hours, 48 hours and 72 hours. Control patients will have a sublingual microscope imaging performed after intubation for the elective procedure. This is a process of a 2cm probe tip gently placed on patients' mouth and 3 different images of 5-8 seconds are recorded.
79264070|NCT02424045|Drug|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
79264071|NCT02427321|Device|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
79264072|NCT03038204|Procedure|The papillary muscle approximation|"Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.~After coronary anastomosis, the mitral valve is exposed by a transseptal incision.~The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.~Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured."
79562997|NCT00576836|Other|Cultured Thymus Tissue Implantation with Parathyroid Transplantation|Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest & transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced & placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
79724878|NCT02755909|Behavioral|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
79724879|NCT04222777|Diagnostic Test|Cinematographic Recording|A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
79724880|NCT04316598|Drug|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol <1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
79724881|NCT04316598|Drug|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC <0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids <0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
79724882|NCT02761369|Device|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
79859270|NCT05694455|Diagnostic Test|Venous Excess Ultrasound Scoring (VExUS)|All septic Patients will have this performed on all patients at admission, 8-16 hours, 48 hours and 72 hours. Ultrasound images and blood flow waves will be collected of the Inferior Vena Cava diameter, hepatic vein, portal vein, renal veins and scored using the Venous Excess Ultrasound (VExUS scale). Healthy controls will not have ultrasound performed
80031682|NCT02260011|Drug|Placebo|
79724883|NCT02761291|Drug|Gemcitabine|Gemcitabine will be administrated 600~1250 mg/m^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m^2. If no subject suffered the dose limit toxicity, 1000 mg/m^2 and even 1250 mg/m^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m^2, the 600 mg/m^2 will be started.
79724884|NCT02761291|Drug|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
79724885|NCT02761291|Drug|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and < 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
79724886|NCT01187550|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.
79724887|NCT02755363|Other|osteopathic manual therapy|"suboccipital decompression - atlanto-occipital joint relaxation technique.~deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
79724888|NCT02755363|Other|control group|"manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
79724889|NCT00602368|Other|histological technique|
79859271|NCT05694455|Other|Urine Collection|The urine assay is collected passively from the patient will be ran through a Dimethylmethylene blue (DMMB assay)- could provide future beneficial information to resuscitation efforts. This will be performed on all septic patients at admission, 8-16 hours, 48 hours and 72 hours. Urine will be collected on healthy controls at time of intubation for elective procedure.
79859272|NCT05691218|Device|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
79859273|NCT05691218|Device|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
79859274|NCT05691218|Device|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
79859275|NCT05689450|Other|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
79264073|NCT02432391|Behavioral|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
79264074|NCT04842344|Device|ECCO2R|extracorporeal carbon dioxide removal
79264075|NCT02432313|Drug|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
79264076|NCT04831814|Diagnostic Test|Near Focus NBI|Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
79264077|NCT04831814|Diagnostic Test|Standard Focus NBI|Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
79264078|NCT02432157|Drug|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
79264079|NCT02432157|Drug|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
79264080|NCT04842188|Procedure|L-PRF with aPDT|surgical open flap debridement followed by L-PRF with aPDT
79264081|NCT04842188|Procedure|L-PRF|surgical open flap debridement followed by L-PRF alone
79264082|NCT03183999|Dietary Supplement|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
79724890|NCT00602368|Other|laboratory biomarker analysis|
79724891|NCT00602368|Procedure|colposcopic biopsy|
79724892|NCT00602368|Procedure|colposcopy|
79724893|NCT00602368|Procedure|light-scattering spectroscopy|
79724894|NCT00602368|Procedure|loop electrosurgical excision procedure|
79264083|NCT03183999|Dietary Supplement|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
79264084|NCT03037970|Drug|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
79264085|NCT03037970|Other|Placebo|Collagen Wound Dressing wetted with buffer.
79859276|NCT05686044|Drug|Buntanetap/Posiphen|HPMC (vegetarian source) capsule shells
79859277|NCT05686044|Drug|Placebo|HPMC (vegetarian source) capsule shells
79264086|NCT04842110|Device|Experimental: eonTM FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
79264087|NCT02423889|Radiation|Radiotherapy|
79264088|NCT02427087|Behavioral|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
79264089|NCT02427087|Behavioral|Healthy Diet|Diet group (21) Recommendation for healthy diet.
79264090|NCT04841720|Drug|HSK16149|HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
79264091|NCT04841720|Drug|Metformin Hydrochloride tablet|Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
79264092|NCT04841720|Drug|HSK16149+Metformin（phase 3）|Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
79264093|NCT04831346|Other|Low level laser|940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
79264094|NCT04831346|Device|Soft occlusive splint|"A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene."
79264095|NCT03181347|Procedure|RYGB|Roux-en-Y Gastric Bypass
79264096|NCT03181347|Procedure|SG|Sleeve Gastrectomy
79264097|NCT03181347|Behavioral|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
79562998|NCT00576407|Biological|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, & thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
79562999|NCT00543348|Procedure|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
79563000|NCT00543348|Procedure|Balloon angioplasty|HIGH PRESSURE BALLOON
79563001|NCT00531232|Drug|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
79563002|NCT00389844|Behavioral|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
79563003|NCT00389844|Behavioral|Plus component (motivation) of the Exercise Plus Program|Motivation only
79563004|NCT00389844|Behavioral|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
79563005|NCT00365326|Biological|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
79563006|NCT00265525|Behavioral|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
79563007|NCT00066950|Drug|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
79563008|NCT00066950|Device|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
79724895|NCT00602212|Behavioral|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
79724896|NCT00602212|Behavioral|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
79264098|NCT03036020|Radiation|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
79264099|NCT03181269|Other|Intervention education|An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
79264100|NCT03181269|Other|Placebo Education|An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
79563009|NCT01694134|Drug|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
79724897|NCT02755675|Other|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
79724898|NCT02855866|Procedure|thyroidectomy|
79724899|NCT02855866|Other|cryotherapy|
79724900|NCT02855866|Drug|cortisone aerosol|
79724901|NCT02855866|Drug|Dexamethasone acetate|
79724902|NCT02855866|Drug|paracetamol|
79724903|NCT02751463|Drug|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
79724904|NCT02751463|Other|Untreated skin|One site is patched without treatment as control
79724905|NCT04316520|Dietary Supplement|Ketogenic diet|Ketogenic diet 2:1
79724906|NCT02751307|Drug|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
79859278|NCT05685472|Biological|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
79859279|NCT05683470|Drug|RBS2418|RBS2418 will be administered orally at 200 mg two times per day (BID).
79859280|NCT05683132|Behavioral|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
79859281|NCT05683132|Behavioral|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
79859282|NCT05680142|Drug|superficial cervical plexus block|The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
79859283|NCT05680142|Drug|cervical erector spinae plane block|The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
79264101|NCT03039842|Drug|Dextromethorphan|
79264102|NCT03039842|Drug|Memantine|
79264103|NCT03039842|Drug|dextromethorphan+memantine|
79264104|NCT03039842|Drug|placebo+valproate|
79563010|NCT01694134|Drug|Lidocaine|
79563011|NCT01694147|Device|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
79563012|NCT01694160|Drug|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
79563013|NCT01694173|Other|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
79563014|NCT01694173|Other|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
79563015|NCT01694173|Other|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
79563016|NCT01694173|Other|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
79563017|NCT01694212|Drug|Perioperative Diclofenac eye-drops administration|
79563018|NCT01694212|Drug|placebo|
79724907|NCT02751307|Drug|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
79264105|NCT03181815|Drug|Cladribine|5mg/㎡ d1-5
79264106|NCT03181815|Drug|G-CSF|300ug d0-9
79264107|NCT03181815|Drug|Aclarubicin|10mg d3-6
79264108|NCT03181815|Drug|Cytarabine|10mg/㎡ q12h SC d3-9
79563019|NCT01694225|Other|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
79563020|NCT01694238|Procedure|Cruciate incision|
79563021|NCT01694238|Procedure|Circular incision|
79563022|NCT01694238|Other|Mesh enforced cruciate incision|
79563023|NCT01694264|Drug|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
79859284|NCT05679362|Behavioral|online brief CBT intervention|Cognitive behavioral therapy
79859285|NCT05676749|Biological|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
79859286|NCT05670587|Device|A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection|A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
79264109|NCT04369040|Device|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
79264110|NCT04369040|Device|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
79264111|NCT05115669|Device|Wortie freeze plus|treatment of common and plantar warts
79264112|NCT03038048|Procedure|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
79563024|NCT01694264|Drug|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
79563025|NCT01694290|Other|Chemical Cold Pack|
79724908|NCT05356494|Other|Postural drainage|(Group A will be treated with postural drainage)
79724909|NCT05356494|Other|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
79724910|NCT04220359|Device|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
79724911|NCT00638209|Drug|Human insulin|
79724912|NCT00638209|Drug|Saline|
79724913|NCT02760745|Other|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
79724914|NCT04220047|Procedure|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
79724915|NCT05429749|Drug|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
79724916|NCT05429749|Drug|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
79264113|NCT03185871|Drug|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
79563026|NCT01694303|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
79563027|NCT01694316|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
79563028|NCT01694355|Drug|Vitamin D|
79563029|NCT01694381|Drug|M5|single point mutant of serine protease prourokinase
79563030|NCT01694381|Drug|C1-inhibitor|a protease inhibitor belonging to the serpin superfamily.
79563031|NCT01694394|Device|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
79563032|NCT01694407|Drug|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
79563033|NCT01694407|Drug|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
80021388|NCT05234008|Other|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from >3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
79563034|NCT01694407|Drug|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
79563035|NCT01694407|Drug|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
79563036|NCT01694446|Other|Intraduodenal glucose or fructose|
79563037|NCT01694459|Drug|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
79563038|NCT01694459|Drug|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
79563039|NCT01694472|Biological|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
79563040|NCT01694498|Drug|A: Desmopressin 25 µg|
79724917|NCT05429671|Procedure|total knee arthroplasty|Participants will have total knee arthroplasty
79724918|NCT05429671|Drug|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
79724919|NCT05429671|Drug|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
79724920|NCT05429671|Device|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
79859287|NCT05666713|Device|TELLTALE BASILICA procedure|The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
79859288|NCT05665283|Drug|Ensartinib Hydrochloride|oral ALK inhibitor
79859289|NCT05664477|Dietary Supplement|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
79563041|NCT01694498|Drug|B. Desmopressin 50 µg|
79563042|NCT01694498|Drug|Placebo|
79563043|NCT01694511|Procedure|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
79724921|NCT02754973|Behavioral|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
79724922|NCT02754973|Behavioral|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
79724923|NCT04222621|Other|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
79724924|NCT01186770|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
79563044|NCT01694511|Procedure|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
80021389|NCT03506984|Device|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
79264114|NCT04831268|Other|Glucose as reference food|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
79724925|NCT01186770|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
79859290|NCT05664477|Drug|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
79859291|NCT05658185|Behavioral|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~Adjustment to the disease:~Self-esteem/self-concept:~Coping with fear:~Emotional self-regulation:~Social area and enjoyment:~Decision making and problem solving:~Communication and listening skills:"
79859292|NCT05655364|Other|Mobile application|Breastfeeding Supportive Mobile Application
79859293|NCT05653726|Other|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
80021390|NCT03506984|Device|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
79264115|NCT04831268|Other|Lentils and lupins mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
79264116|NCT04831268|Other|Trahanas with tomato sauce mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
79264117|NCT04831268|Other|Halva with currants mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
79264118|NCT03181191|Other|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
79264119|NCT03181113|Drug|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
79264120|NCT03181113|Drug|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
79264121|NCT03036176|Behavioral|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
79264122|NCT03036176|Other|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
79563045|NCT01694537|Drug|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
79563046|NCT01694537|Drug|placebo|Placebo is made with same size and shape with study drug.
79724926|NCT02754817|Drug|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
79859294|NCT05653466|Behavioral|Adaptive Spacing Condition|"Each of the 200 target words for practice are presented on a schedule determined by an algorithm that relies on the pattern of correct vs. incorrect responses for each item. Items in the active learning state need to be answered correctly a certain number of times before being categorized as learned. Each item must be answered correctly 3 times in a row (immediately, then at one-minute and five-minute intervals) before it is categorized as learned. Then, it will be scheduled at ever-increasing intervals, until answered incorrectly, at which point the item would be returned to the active learning state, requiring three correct responses in a row to return again to the learned expanding interval state."
79859295|NCT05653466|Behavioral|High-Item Non-Adaptive Spacing Condition|Each of the 200 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
79264123|NCT03183921|Other|No intervention|No Interventions
79563047|NCT01694576|Drug|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
79563048|NCT01694589|Drug|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
79563049|NCT01694602|Biological|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
79563050|NCT01694615|Procedure|Cryoprobe biopsy|
79563051|NCT01694615|Procedure|Forceps Biopsy|
79724927|NCT02755051|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~Sleep education~Sleep scheduling, limit setting, and stimulus control~Teaching relaxation strategies and other adaptive coping skills~Parenting strategies (differential attention, rewards, consequences)~Identification of maladaptive & adaptive cognitions~Problem solving & communication skills~Sleep restriction; bright light to change circadian rhythms~Review gains and plan for long-term maintenance"
79724928|NCT05429515|Procedure|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
79724929|NCT05429515|Procedure|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
79724930|NCT05429515|Drug|Chemotherapy|chemotherapy protocol will be made by hematologists.
79264124|NCT02605928|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
79724931|NCT01186692|Device|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
79724932|NCT04230031|Drug|Daratumumab|Experimental
79563052|NCT01694628|Behavioral|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
79724933|NCT01186458|Drug|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
79859296|NCT05653466|Behavioral|Low-Item Non-Adaptive Spacing Condition|Each of the 40 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
79859297|NCT05653440|Behavioral|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
79859298|NCT05653440|Behavioral|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
79859299|NCT05653440|Behavioral|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
79563053|NCT01694680|Dietary Supplement|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
79724934|NCT01186458|Drug|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
79859300|NCT05650996|Behavioral|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
79859301|NCT05650996|Behavioral|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
79859302|NCT05650021|Device|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
80021391|NCT02143362|Drug|Anesthesia induction,propofol, remifentanil ,cisatracurium|"Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~Intermittent injection cisatracurium (0.15mg/kg).~A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
79264125|NCT03180957|Drug|Adalimumab|
79264126|NCT03180957|Drug|Saline|
79264127|NCT04830644|Drug|Iguratimod|Iguratimod orally twice a day
79724935|NCT01186458|Drug|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
79724936|NCT01185834|Device|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
79724937|NCT01185600|Biological|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
79724938|NCT01185600|Biological|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
79859303|NCT05649722|Drug|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
79859304|NCT05649722|Drug|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
79859305|NCT05647447|Drug|Osanetant|Osanetant 200 mg orally, twice per day
79859306|NCT05647343|Drug|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
79264128|NCT04830644|Drug|Placebo|Placebo orally twice a day
79264129|NCT02432001|Procedure|Image-Guided Biopsies|
79264130|NCT02427165|Drug|RPL554|A dual PDE3 and PDE4 inhibitor
79264131|NCT02427165|Drug|Salbutamol|a beta-2 receptor agonist
79264132|NCT02427165|Drug|Placebo|RPL554 placebo containing no active ingredients
79264133|NCT04830722|Device|Sculptra Aesthetic|One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
79563054|NCT01694680|Dietary Supplement|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
79563055|NCT01694693|Drug|Orencia|No Intervention
79563056|NCT01694719|Behavioral|Brief Behavioral Activation Treatment for Depression|
79563057|NCT01694719|Behavioral|Cognitive Control Training|
79563058|NCT01694732|Drug|Varenicline|
79563059|NCT01694732|Drug|placebo|
79724939|NCT02754895|Other|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
79264134|NCT04838366|Dietary Supplement|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
79563060|NCT01694784|Behavioral|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
79563061|NCT01694784|Behavioral|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
79859307|NCT05647343|Other|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
79859308|NCT05643209|Procedure|ablation|epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
79563062|NCT01694784|Behavioral|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
79563063|NCT01694784|Behavioral|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
79563064|NCT01694797|Drug|Metoprolol Succinate|
79563065|NCT01694810|Drug|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
79563066|NCT01694810|Drug|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel applied once daily 4 weeks
79859309|NCT05643118|Genetic|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
79859310|NCT05641597|Other|Actimetric measurement|"Evaluation during 7 days in real life condition Carried out during the pre-operative evaluation (M0), the post-operative evaluation (M1) and the post-operative evaluation (M6)"
79859311|NCT05641597|Other|Evaluation of plantar flexion, dorsal flexion and ankle eversion forces|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
79859312|NCT05641597|Other|Assessment of static and dynamic balance and quality of life|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
79859313|NCT05641597|Other|Functional gait assessment (TM6)|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
79859314|NCT05639751|Drug|PRT3789|PRT3789 will be administered by intravenous infusion
79859315|NCT05639751|Drug|Docetaxel|Docetaxel will be administered by intravenous infusion
79264135|NCT03039764|Device|Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
79264136|NCT02706717|Drug|Visbiome Extra Strength|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
79264137|NCT02706717|Drug|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
79264138|NCT03037736|Drug|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
79264139|NCT03037736|Drug|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
79264140|NCT03037736|Drug|Normal saline|Normal saline will be used as the placebo.
79859318|NCT05638841|Other|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
79859319|NCT05635292|Behavioral|Tele-CBT|8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
79563067|NCT01694810|Drug|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
79563068|NCT01694810|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
79724940|NCT02754895|Other|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
79563069|NCT01694823|Drug|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
79563070|NCT01694836|Biological|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
79563071|NCT01694862|Procedure|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
79859320|NCT05634707|Drug|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
79563072|NCT01694875|Device|APTIMA HPV Assay|In Vitro Diagnostics Assay
79859321|NCT05634707|Drug|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
79859322|NCT05633667|Drug|Zimberelimab (ZIM)|Administered intravenously
79859323|NCT05633667|Drug|Domvanalimab (DOM)|Administered intravenously
79859324|NCT05633667|Drug|Sacituzumab govitecan-hziy (SG)|Administered intravenously
79859325|NCT05633667|Drug|Etrumadenant (ETRUMA)|Administered orally
79859326|NCT05633667|Drug|Carboplatin|Administered intravenously
79859327|NCT05633667|Drug|Cisplatin|Administered intravenously
79859328|NCT05633667|Drug|Pemetrexed|Administered intravenously
79859329|NCT05633667|Drug|Paclitaxel|Administered intravenously
79859330|NCT05633667|Drug|Nab-paclitaxel|Administered intravenously
79859331|NCT05633667|Drug|Docetaxel|Administered intravenously
79264141|NCT04838132|Procedure|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
79563073|NCT01694888|Other|lecture|Teaching documentation skill using lecture method
79563074|NCT01694914|Procedure|corneal graft|
79563075|NCT01694927|Procedure|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
79563076|NCT01694979|Other|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
79563077|NCT01694979|Other|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
79563078|NCT01694979|Other|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
79724941|NCT01185366|Drug|Everolimus|10 mg by mouth once a day.
79724942|NCT01185366|Drug|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
79724943|NCT01185288|Biological|Adalimumab|Adalimumab in pre-filled syringes
79859332|NCT05633667|Drug|Nivolumab|Administered intravenously
79859333|NCT05630092|Diagnostic Test|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
79859334|NCT05630092|Diagnostic Test|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
79859335|NCT05626790|Other|Exercise|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
79859336|NCT05626790|Other|PNF Stretching|"In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~Biceps: Flex-Add-ER repositioned half pattern~Brachioradialis: Flex-Abd-ER repositioned half pattern~Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches."
79859337|NCT05626790|Other|Prolonged Stretching|"In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched."
79859338|NCT05622643|Other|MRI|Comparison between groups
79859339|NCT05621746|Drug|Esperoct|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
79859340|NCT05620719|Behavioral|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
79859341|NCT05620719|Other|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
79859342|NCT05620719|Other|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
79859343|NCT05619692|Drug|SAGE-718|Softgel lipid capsules.
79859344|NCT05619692|Drug|SAGE-718-matching Placebo|Softgel lipid capsules.
79264142|NCT04838132|Procedure|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
79563079|NCT01694992|Other|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
79563080|NCT01695005|Drug|LY3039478|Administered orally
79563081|NCT01695005|Drug|Prednisone|Administered orally
79563082|NCT01695031|Behavioral|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
79724944|NCT01185288|Drug|Methotrexate|Methotrexate capsule
79724945|NCT01184508|Drug|Placebo|Administered orally, once daily, for 12 weeks
79724946|NCT01184508|Drug|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
79724947|NCT02887014|Procedure|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
79724948|NCT01184118|Drug|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
80021392|NCT02143362|Drug|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~Target Controlled Infusion remifentanil , targeted plasma concentrations are 3~6ng/ml ,maintain heart rate to 60~100 beats per minute and mean blood pressure to 70~105 mmHg.~Intermittent injection cisatracurium (0.05mg/kg)."
79563083|NCT01695031|Behavioral|Generic web-based education|Generic, web-based asthma education
79563084|NCT01695057|Drug|vorinostat|Given PO
79563085|NCT01695057|Procedure|therapeutic conventional surgery|Undergo surgery
79563086|NCT01695057|Other|laboratory biomarker analysis|Correlative studies
79563087|NCT01695070|Drug|Melatonin|4mg prolonged release melatonin oral tablets twice daily
79563088|NCT01695096|Other|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
79563089|NCT01695096|Other|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
79563090|NCT01695109|Drug|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
79563091|NCT01695109|Drug|Placebo|0.9% NaCl, 0.2 ml
79563092|NCT01695122|Drug|Valproic Acid|
79563093|NCT01695148|Dietary Supplement|β-Carotene Biofortified Maize Flour|
79563094|NCT01695148|Dietary Supplement|White Maize Flour|
80021393|NCT02143362|Procedure|Awaken test|"Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~Patients will receive initial anesthesia after finish awaken test."
80021394|NCT03509324|Drug|Insulin LISPRO|receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
79724949|NCT01183884|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
80021395|NCT02304068|Other|Home monitoring|
80021396|NCT02304068|Other|Hospital assessment|
80021397|NCT02143440|Behavioral|The initial assessment of daily insulin dose.|
80021398|NCT04906564|Other|Identification of genetic variants|Identification of genetic variants
79264143|NCT03037892|Drug|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
79563095|NCT01695174|Drug|Xifaxan|
79563096|NCT01695187|Drug|NB-001 (0.3%)|Topical administration at least five times throughout the day
79563097|NCT01695187|Drug|Placebo|
79563098|NCT01695200|Dietary Supplement|Omega-3 fatty acids|
79563099|NCT01695213|Procedure|uncemented total hip arthroplasty|
79563100|NCT01695226|Drug|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
79563101|NCT01695226|Drug|Placebo|pre-operative placebo twice daily for two to three weeks
79724950|NCT05344248|Biological|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
79724951|NCT05344248|Biological|JS005 placebo|Subcutaneous injection
79724952|NCT01183260|Device|Trabecular Metal Revision Cup|Revision of the acetabular cup
79724953|NCT01183260|Device|Trabecular Metal Modular Cup|Revision of the acetabular cup
79724954|NCT01191762|Drug|sevelamer carbonate|2400 mg with each meal for 4 weeks
79724955|NCT01191762|Drug|placebo|3 tablets with each meal
79724956|NCT04315974|Drug|Rivaroxaban|Rivaroxaban therapy for at least 4 weeks.
79724957|NCT04315974|Procedure|Catheter ablation|Radiofrequency catheter ablation or cryoballoon ablation.
79724958|NCT04316208|Procedure|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
79724959|NCT02855788|Drug|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
79724960|NCT02852278|Other|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
79724961|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
79724962|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
79724963|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
79724964|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
79724965|NCT02852356|Device|MIRI-TL Incubator|MIRI-TL Timelapse incubator
79724966|NCT02886858|Device|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
79724967|NCT02886858|Device|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
79724968|NCT04268290|Combination Product|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
79724969|NCT00604318|Drug|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
79724970|NCT01190436|Drug|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
79563102|NCT01695252|Other|MEMOS|Patient informed clinical outcomes supervision
79563103|NCT01695265|Other|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
79563104|NCT01695265|Device|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
79859345|NCT05618834|Behavioral|Promoting Positive Care Interactions (PPCI)|"The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living."
79859346|NCT05618834|Behavioral|PPCI-Staff Education Only (EO)|The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
79859347|NCT05618678|Behavioral|DIGNITY|DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.
79859348|NCT05618678|Behavioral|Infection Control|This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
79859349|NCT05616650|Drug|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
79859350|NCT05616650|Radiation|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
79859351|NCT05615870|Other|Winix 5500-2 HEPA filtration units|To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
79859352|NCT05611853|Drug|BN301|BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
79859353|NCT05607550|Drug|furmonertinib 240 mg oral, daily|furmonertinib tablet
80021399|NCT02311790|Dietary Supplement|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
79399286|NCT00602355|Drug|Sertraline|"Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care."
79563105|NCT01695278|Behavioral|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
79563106|NCT01695343|Biological|KB001-A|
79563107|NCT01695343|Drug|Placebo Comparator|
79724971|NCT02852122|Drug|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA > 20 ng/mL, or Gleason score 8-10, or clinical stage >T2c) would be included.
79724972|NCT01035255|Drug|LCZ696 200 mg BID|LCZ696 200 mg BID
79724973|NCT01035255|Drug|Enalapril 10 mg BID|Enalapril 10 mg BID
79724974|NCT04268056|Diagnostic Test|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
80021400|NCT02311790|Dietary Supplement|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
79399287|NCT00602355|Drug|Placebo|"Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline."
79724975|NCT00631072|Biological|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
79724976|NCT00631072|Drug|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
79724977|NCT00602524|Drug|Pilocarpine|
79859354|NCT05607550|Drug|furmonertinib 160 mg oral, daily|furmonertinib tablet
79563108|NCT01695356|Drug|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
79563109|NCT01695356|Drug|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
79563110|NCT01695382|Behavioral|Navigation|As per Arm description
79563111|NCT01695421|Procedure|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
79264144|NCT03037892|Drug|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
79264145|NCT03037892|Drug|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
79563112|NCT01695421|Procedure|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
79724978|NCT01189890|Drug|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
79724979|NCT01189890|Drug|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
79724980|NCT01189890|Drug|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
79724981|NCT01189890|Drug|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
79724982|NCT01189812|Drug|Lithium Carbonate|300 mg one time per day for 4 weeks
79724983|NCT01189812|Drug|Placebo|Take one time daily for 4 weeks
79724984|NCT01189812|Drug|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
79724985|NCT00950950|Drug|Romosozumab|Administered by subcutaneous injection
79724986|NCT00950950|Drug|Placebo|Administered by subcutaneous injection
79724987|NCT00950872|Device|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
79724988|NCT04302597|Procedure|Staples|Skin closure using surgical stapler.
79724989|NCT04302597|Procedure|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
79724990|NCT01189500|Drug|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
79264146|NCT03183765|Drug|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
79399288|NCT00602355|Behavioral|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
79399289|NCT00602355|Behavioral|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
79399290|NCT00602355|Behavioral|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
79724991|NCT01189500|Drug|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
79859355|NCT05607550|Drug|platinum-based chemotherapy|(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
79859356|NCT05607342|Drug|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
79859357|NCT05606965|Biological|mRNA-1010|Sterile liquid for injection
79859358|NCT05606965|Biological|Egg-based Quadrivalent Influenza Vaccine|Sterile suspension for injection
79399291|NCT01425463|Drug|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
79399292|NCT01425463|Drug|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
79399293|NCT01425463|Other|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
79859359|NCT05606965|Biological|Adjuvanted Quadrivalent Influenza Vaccine|Sterile injectable emulsion
79264147|NCT03183765|Procedure|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
79724992|NCT02874339|Device|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
79859360|NCT05606965|Biological|Inactivated Influenza Vaccine|Sterile suspension for injection
79563113|NCT01695421|Procedure|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
79563114|NCT01695421|Procedure|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
79563115|NCT01695434|Other|MRI|All subjects will undergo a MRI.
79563116|NCT01695447|Procedure|duct-to-mucosa|
79563117|NCT01695447|Procedure|invagination|
80021401|NCT02143518|Biological|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
79724993|NCT02874339|Device|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
79724994|NCT00627315|Procedure|Gastric bypass|NOTE: Surgery will not be paid by the study
79724995|NCT00627315|Procedure|Gastric banding|NOTE: Surgery will not be paid by the study
79724996|NCT00938860|Drug|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
79859361|NCT05606887|Other|Wearable Device and Ecological Momentary Assessments|"The intervention will consist of three components:~Completion of brief text-message based surveys 2-3 times per week~Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~Individual biweekly reports of survey response trends and curated resources intended to support participant well-being"
79859362|NCT05605678|Other|No Intervention|This is a non-interventional study.
79859363|NCT05601726|Drug|ABD-3001|Each patient will receive a single and fixed 4 hours-intravenous infusion dose of ABD-3001. The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m².
79264148|NCT04830176|Other|dentifrice|use of dentifrices for brushing
79264149|NCT04841174|Other|Abdominal massage|The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
79399294|NCT01425463|Other|Placebo to Polyferose|Administered orally with water.
79399295|NCT02144259|Drug|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
79399296|NCT02144259|Drug|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
79399297|NCT04655586|Drug|rNAPc2|two dose levels of rNAPc2
79399298|NCT04655586|Drug|Heparin|standard of care heparin per institution (therapeutic or prophylactic regimen)
79399299|NCT00689091|Device|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
79399300|NCT00689091|Device|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
79399301|NCT05082246|Other|Conscious Breathing|During the Conscious Breathing session, participants will be asked to sit comfortably and with gently closed eyes. Participants will be guided through several different kinds of breathing techniques, where the will focus will be on the expansion of the chest or abdomen, releasing all tension from the body, and visualizing breathing light into the body.
79859364|NCT05601726|Drug|ABD-3001|"Based on PK data gathered during the SAD, a dose regimen optimization will be done using population Pharmacokinetic modelling in order to set the optimal frequency of infusion per week to achieve sustained exposition throughout treatment period. Based on this analysis, the Sponsor will, in accordance with the Safety review Committee, define the occurrence of infusion to 1, 2 or 3 times per week, during 4 weeks (28 days ± 3 days).~Number of infusions given per week and dose increase between each dose will be set so that, whatever the initial dose used in the MAD part, total dose increase will never get above the MTD determined in the SAD part or a dose defined by the SRC, if no MTD is determined during the SAD part."
79264150|NCT03183843|Drug|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
79563118|NCT01695447|Device|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
79563119|NCT01695460|Drug|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
79563120|NCT01695460|Drug|Placebo|
79563121|NCT01695525|Other|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
79563122|NCT01695538|Other|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
79563123|NCT01695551|Other|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
79563124|NCT01695564|Device|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
79724997|NCT00938860|Drug|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
79724998|NCT05381584|Procedure|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
79859365|NCT05599295|Drug|Oritavancin|Oritavancin for IV infusion
79859366|NCT05591053|Device|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
79264151|NCT03183843|Drug|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
79264152|NCT04830332|Diagnostic Test|abdominal fluid CA-125 levels test|One hundred milliliters of normal saline was used as the abdominal washing liquid to obtain the sample for CA-125 measurement. Serum and abdominal washing fluid CA-125 levels were measured with a double antibody sandwich immunoenzymatic method, using Beckman Coulter DXI (Ireland) analyzer. I
79563125|NCT01695564|Device|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
79563126|NCT01695577|Other|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
79563127|NCT01695577|Other|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
79563128|NCT01695590|Drug|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
79563129|NCT01695603|Device|Intellivent|
79563130|NCT01695616|Drug|Placebo|
79563131|NCT01695616|Drug|Active drug|
79563132|NCT01695681|Other|Gluten-free diet|Dietary advice by clinical dietitian
79563133|NCT01695694|Behavioral|supporting positive and healthy relationships|
79563134|NCT01695694|Behavioral|community support group|
79563135|NCT01695707|Drug|Pioglitazone|see Arm Description
79563136|NCT01695707|Drug|Placebo (for pioglitazone)|see Arm Description
79563137|NCT01695720|Procedure|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam [the system itself] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
79563138|NCT01695733|Biological|trivalent influenza vaccine|
79563139|NCT01695759|Drug|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
79563140|NCT01695759|Drug|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
79563141|NCT01695798|Biological|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
79724999|NCT00604396|Drug|insulin detemir|
79725000|NCT00604396|Drug|insulin NPH|
79725001|NCT00938470|Drug|capecitabine|Given PO
79725002|NCT00938470|Drug|docetaxel|Given IV
79725003|NCT00938470|Drug|fluorouracil|Given IV
79725004|NCT00938470|Drug|oxaliplatin|Given IV
79725005|NCT00938470|Radiation|radiation therapy|Undergo radiation therapy
79725006|NCT00938470|Procedure|therapeutic conventional surgery|Undergo surgery
79725007|NCT00602680|Drug|SSR180711C|duration of treatment: 4 weeks
79725008|NCT00602680|Drug|donepezil|duration of treatment: 4 weeks
79725009|NCT00602680|Drug|placebo|duration of treatment: 4 weeks
79725010|NCT02852200|Other|SEGAm|
79264153|NCT04830254|Device|Transcutaneous Electrical Nerve Stimulation(TENS) device|The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
79859367|NCT05588700|Behavioral|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
79859368|NCT05588700|Behavioral|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
79264154|NCT02431689|Procedure|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
79264155|NCT03180879|Drug|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
79264156|NCT03180879|Drug|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
79264157|NCT03180879|Drug|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
79399302|NCT05082246|Other|Heartfulness Meditation|During the Heartfulness Meditation session, participants will be asked to sit comfortably and with gently closed eyes. Starting with the feet and working towards the head, participants will be asked to relax each part of the body. Then participants will focus on the heart and imagine it filled with light and love. Participants will sit in this relaxed state for a few minutes to allow all stress and cares to be released.
79725011|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
80021402|NCT02143518|Biological|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
80021403|NCT03504878|Procedure|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
79725012|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
79725013|NCT00602758|Behavioral|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
79725014|NCT00602758|Behavioral|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
79859369|NCT05588700|Behavioral|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
80021404|NCT03504878|Procedure|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
80021405|NCT02254590|Procedure|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
80021406|NCT03506906|Diagnostic Test|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
79725015|NCT02851888|Drug|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
79725016|NCT02851888|Other|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
79725017|NCT02851888|Procedure|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
79264158|NCT04830098|Other|Spinal stabilization exercises|It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
79264159|NCT04830098|Other|Chiropractic manipulation|It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
79725018|NCT05381428|Drug|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
79725019|NCT05381428|Combination Product|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
79725020|NCT00604474|Device|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
80021407|NCT03506906|Diagnostic Test|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
79264160|NCT04829708|Other|MRI Surveillance|Receive MRI surveillance
79264161|NCT04829708|Radiation|Prophylactic Cranial Irradiation|Receive PCI
79264162|NCT03185715|Behavioral|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
79264163|NCT03037814|Device|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
79264164|NCT03037814|Device|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
79264165|NCT03037814|Device|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
79264166|NCT03037814|Device|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
79264167|NCT03180723|Drug|Rituximab|Intravenous injection
79264168|NCT03180723|Drug|Cyclosporin|Oral tablets
79859370|NCT05587439|Genetic|Data and Specimen Collection|"Provide blood and/or saliva sample~Answer short questionnaires~Consider consenting to other optional parts of the research such as:~use stored tissue samples related to prior cancer treatment~Allow access to deceased relatives' medical records and stored specimens~Provide blood 1x per year for up to 5 years~Provide contact information of family members"
79859371|NCT05584384|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
79264169|NCT02427009|Other|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
79264170|NCT02427009|Procedure|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
79264171|NCT03180567|Diagnostic Test|Genetic Mutations|By next generation sequencing
79264172|NCT02427243|Drug|Crenezumab|
79264173|NCT02427243|Drug|Crenezumab|
79264174|NCT03037658|Other|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
79264175|NCT02426853|Behavioral|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
79264176|NCT02426853|Other|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
79264177|NCT02426853|Behavioral|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
79264178|NCT03039920|Other|Electronic cigarette|Smoking of electronic cigarette
79264179|NCT03039920|Other|Conventional cigarette|Smoking tobacco cigarette
79859372|NCT05584384|Device|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
79725021|NCT02852044|Behavioral|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
79725022|NCT02852044|Behavioral|Exercise|One hour of cycling at 50% of maximal power output
79725023|NCT02852044|Other|Dorsal Hand Vein Cannulation (heated hand technique)|
79725024|NCT02852044|Other|Venous Cannulation|
79859373|NCT05583838|Drug|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 ~ 600U/kg every other day depends on platelet count.
79859374|NCT05583838|Drug|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 ~ 75mg daily or every other day depends on platelet count.
80021408|NCT03506828|Procedure|Surgical sympathectomy|thoracoscopic sympathectomy
80021409|NCT03506828|Procedure|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
80021410|NCT00546598|Device|Total hip replacement/arthroplasty|Hip replacement
79264180|NCT03037502|Behavioral|Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
79725025|NCT02851654|Device|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
79725026|NCT02851966|Procedure|mTESE|mTESE time may be postponed or advanced.
79725027|NCT02851732|Behavioral|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
79725028|NCT02855320|Other|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
79859375|NCT05583591|Device|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
79264181|NCT02431611|Behavioral|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
79264182|NCT02431611|Behavioral|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
79563142|NCT01695824|Device|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
79563143|NCT01695824|Procedure|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
79725029|NCT04204174|Dietary Supplement|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
79725030|NCT01022853|Drug|BI 6727|intravenous each 21 days
79264183|NCT03037268|Device|Lytro Plenoptic Camera and 28D lens|"visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~screened and consented for study~subjected to bilateral plenoptic ophthalmoscopy~mydriatic, single-field fundus images obtained~images reviewed for quality and diagnostic utility by a masked grader"
79859376|NCT05583591|Device|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
79859377|NCT05583227|Biological|Tezepelumab|Tezepelumab subcutaneous injection
79264184|NCT03180333|Drug|PNA|
79264185|NCT03180333|Drug|PNA placebo|
79264186|NCT04829942|Behavioral|positive health behavior|Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
79859378|NCT05583227|Biological|Tezepelumab|Tezepelumab subcutaneous injection
79859379|NCT05583227|Other|Placebo|Placebo subcutaneous injection
79264187|NCT02431377|Other|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
79264188|NCT04829786|Drug|palovarotene low-dose|oral capsules
79264189|NCT04829786|Drug|palovarotene high-dose|oral capsules
79264190|NCT02426697|Drug|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
79563144|NCT01695824|Drug|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
79725031|NCT01022853|Drug|BIBF 1120|oral continuously
79725032|NCT00937768|Drug|Goserelin Acetate|Given SC
79725033|NCT00937768|Other|Laboratory Biomarker Analysis|Correlative studies
79725034|NCT00937768|Drug|Leuprolide Acetate|Given IM
79725035|NCT00937768|Other|Quality-of-Life Assessment|Ancillary studies
79725036|NCT04204018|Other|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
79725037|NCT02851810|Behavioral|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
79725038|NCT02851810|Behavioral|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
79859380|NCT05581121|Other|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
79859381|NCT05581121|Procedure|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.
79264191|NCT02426697|Drug|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
79264192|NCT03039608|Drug|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
79859382|NCT05581004|Drug|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
79859383|NCT05581004|Drug|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
79859384|NCT05579197|Device|Lower-limb robotic intervention|"The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~The Optogait system; for a markerless gait analysis;~The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients."
79725039|NCT02851810|Behavioral|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
79264193|NCT03039608|Drug|oral steroid administration（prednisone）|oral steroid
79264194|NCT02423811|Dietary Supplement|Fursultiamine|Use of Fursultiamine in addition to CCRT
79264195|NCT04837664|Drug|Curcumin|Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
79264196|NCT04837664|Drug|Rose Bengal|Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
79264197|NCT04837664|Drug|Nystatin|Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
79264198|NCT03039374|Other|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
79859385|NCT05573919|Device|VivAer Stylus|This device will be used to complete its corresponding procedure, which involves reshaping a patient's nasal sidewall tissue through the delivery of radiofrequency heating.
79859386|NCT05572437|Device|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
79859387|NCT05568784|Other|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
79859388|NCT05568524|Other|BFRT|Low-load (30% 1RM) resistance exercise with blood flow restriction
79264199|NCT02423733|Other|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
79264200|NCT04837898|Dietary Supplement|Haskapa|Haskapa Ltd, Oxford, UK
79264201|NCT04837898|Dietary Supplement|Placebo|isocaloric to the haskap powder
79264202|NCT04841330|Device|Securis™ Stabilization Device|A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
79264203|NCT01331837|Drug|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
79563145|NCT01695837|Behavioral|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
79563146|NCT01695850|Drug|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
79563147|NCT01695850|Drug|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
79563148|NCT01695850|Drug|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
79563149|NCT01695876|Drug|AMG 357|Oral administration available in varying dose strength.
79563150|NCT01695876|Drug|Placebo|Matching placebo to AMG 357 containing no active drug
79563151|NCT01695902|Drug|Levosert-20|
79563152|NCT01695902|Drug|Mirena|
79563153|NCT01695915|Procedure|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
79725040|NCT02851810|Behavioral|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
79859389|NCT05568524|Other|Control|Moderate-to-high load (60%-80% 1RM) resistance exercise
79859390|NCT05567796|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously.
79725041|NCT02851810|Behavioral|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
79725042|NCT00602914|Device|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
79725043|NCT00602914|Device|MicronJet|MicronJet, Intradermal Injection
79725044|NCT00940888|Device|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
79563154|NCT01695928|Device|Extracorporeal shockwave therapy|1000 impulses
79563155|NCT01695928|Device|ESWT placebo|0 impulses, acoustic effect
79563156|NCT01695967|Procedure|turbinate cauterization|
79563157|NCT01696019|Other|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
79563158|NCT01696019|Other|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
79563159|NCT01696019|Other|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
79563160|NCT01696019|Other|Contact and testing only|
79563161|NCT01696097|Behavioral|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
79563162|NCT01696110|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
79563163|NCT01696110|Drug|heparin|heparin monotherapy
79563164|NCT01696110|Drug|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
79563165|NCT01696123|Drug|MLC601|It was described
79859391|NCT05567796|Drug|Semaglutide|Participants will recieve semaglutide subcutaneously.
79859392|NCT05567796|Drug|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
79264204|NCT01331837|Drug|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
79264205|NCT02706483|Drug|Plecanatide|
79563166|NCT01696136|Device|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
79264206|NCT04837274|Dietary Supplement|Placebo|Dextrose (480 mg)
79563167|NCT01696149|Device|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
79264207|NCT04837274|Dietary Supplement|Active|Tary Cherry (480 mg)
79264208|NCT03037424|Drug|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
79563168|NCT01696162|Other|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
79725047|NCT00631228|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
79725048|NCT02851576|Other|Infusion of ADV specific T cells|Cell engineering
79725049|NCT05381038|Device|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
79264209|NCT03037424|Drug|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
79264210|NCT04829396|Other|placebo|Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.
79264211|NCT04829396|Dietary Supplement|Fibre mixture|The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
79399303|NCT05082246|Other|Emotional Freedom Technique|"During the Emotional Freedom Technique session, participants will be asked to tap lightly on several acupressure points while saying a variety of statements regarding pain, anxiety, depression or stress. As participants tap on the acupressure points, participants will repeat phrases of affirmation and acceptance, and also talk through how pain, anxiety, depression or stress may cause distress but can learn to release these feelings. participants will be given a picture of where each of the acupressure points lie on the face, chest or head, and will also be given a script of what to say while tapping on each acupressure point. In addition, participants will be given a description of what each acupressure point means - its associated organ and what emotion that point helps to release."
79563169|NCT01696162|Other|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
79563170|NCT01696162|Other|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
79859393|NCT05567796|Drug|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
79859394|NCT05565378|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion.
79859395|NCT05565378|Drug|Dostarlimab|Dostarlimab will be administered as an IV infusion.
79859396|NCT05565378|Drug|Belrestotug|Belrestotug will be administered as an IV infusion.
79563171|NCT01696201|Behavioral|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
79859397|NCT05565378|Drug|GSK6097608|GSK6097608 will be administered as an IV infusion.
79859398|NCT05560009|Drug|Fluorodopa F 18|Given IV
79725050|NCT05381038|Device|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
79725051|NCT05381038|Drug|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
79399304|NCT04629690|Other|SOLAR|The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
79725052|NCT05381038|Drug|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
79725053|NCT05381038|Drug|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
79725054|NCT00603070|Other|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
79725055|NCT00603070|Other|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
79859399|NCT05560009|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79264212|NCT03183375|Drug|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
79859400|NCT05560009|Procedure|Positron Emission Tomography|Undergo PET/MRI
79859401|NCT05560009|Radiation|Radiation Therapy|Receive standard of care radiation therapy
79859402|NCT05560009|Procedure|Surgical Procedure|Undergo standard of care surgery
79859403|NCT05559866|Device|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
79859404|NCT05559866|Device|Apollo ESG|Using only Apollo ESG as approved per label.
79859405|NCT05559671|Biological|Herpes Zoster Subunit (HZ/su) Vaccine|Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
79859406|NCT05559671|Biological|Placebo|Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
79859407|NCT05555862|Drug|Artesunate|artesunate formulated as intra-anal suppositories
79264213|NCT03183297|Drug|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
79264214|NCT03183297|Drug|Naproxen|Naproxen sodium 220mg
79264215|NCT03183297|Drug|Fexofenadine|Fexofenadine 60mg
79264216|NCT03183297|Drug|placebo|placebo comparator
79399305|NCT05393154|Device|Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner|Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
79563172|NCT01696227|Drug|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
79859408|NCT05555862|Drug|Placebo|placebo intra-anal suppository
79859409|NCT05555251|Drug|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
79264217|NCT04829162|Other|Mother with obesity, daughter with obesity|Participants in this group were shown an image of a mother with obesity and a daughter with obesity.
79264218|NCT04829162|Other|Mother with obesity, daughter without obesity|Participants in this group were shown an image of a mother with obesity and a daughter without obesity.
79264219|NCT04829162|Other|Mother without obesity, daughter with obesity|Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
79859410|NCT05555251|Drug|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
79264220|NCT04829162|Other|Mother without obesity, daughter without obesity|Participants in this group were shown an image of a mother without obesity and a daughter without obesity.
79264221|NCT04829162|Other|Mother with obesity, son with obesity|Participants in this group were shown an image of a mother with obesity and a son with obesity.
79399306|NCT05392998|Device|Cataract surgery with Vivity intraocular lens implantation|Cataract surgery with Vivity intraocular lens implantation
79859411|NCT05555251|Drug|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
79859412|NCT05554406|Drug|Azacitidine|Given SC or IV
79859413|NCT05554406|Procedure|Biospecimen Collection|Undergo collection of blood
79859414|NCT05554406|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79859415|NCT05554406|Drug|Cytarabine|Given IV
79859416|NCT05554406|Drug|Daunorubicin Hydrochloride|Given IV
79859417|NCT05554406|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79859418|NCT05554406|Drug|Venetoclax|Given PO
79399307|NCT03141216|Device|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
79399308|NCT03141216|Device|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
79264222|NCT04829162|Other|Mother with obesity, son without obesity|Participants in this group were shown an image of a mother with obesity and a son without obesity.
79264223|NCT04829162|Other|Mother without obesity, son with obesity|Participants in this group were shown an image of a mother without obesity and a son with obesity.
79264224|NCT04829162|Other|Mother without obesity, son without obesity|Participants in this group were shown an image of a mother without obesity and a son without obesity.
79399309|NCT01388647|Drug|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
79264225|NCT04829162|Other|Father with obesity, daughter with obesity|Participants in this group were shown an image of a father with obesity and a daughter with obesity.
79264226|NCT04829162|Other|Father with obesity, daughter without obesity|Participants in this group were shown an image of a father with obesity and a daughter without obesity.
79264227|NCT04829162|Other|Father without obesity, daughter with obesity|Participants in this group were shown an image of a father without obesity and a daughter with obesity.
79264228|NCT04829162|Other|Father without obesity, daughter without obesity|Participants in this group were shown an image of a father without obesity and a daughter without obesity.
79264229|NCT04829162|Other|Father with obesity, son with obesity|Participants in this group were shown an image of a father with obesity and a son with obesity.
79563173|NCT01696240|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
79563174|NCT01696240|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
79563175|NCT01696266|Other|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
79563176|NCT01696305|Device|Hyalobarrier|
79563177|NCT01696305|Device|Guardix-SG|
79399310|NCT01388647|Drug|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
79399311|NCT01388647|Drug|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
79859419|NCT05552976|Drug|Mezigdomide|Specified dose on specified days
79264230|NCT04829162|Other|Father with obesity, son without obesity|Participants in this group were shown an image of a father with obesity and a son without obesity.
79264231|NCT04829162|Other|Father without obesity, son with obesity|Participants in this group were shown an image of a father without obesity and a son with obesity.
79399312|NCT03141138|Biological|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
79563178|NCT01696318|Behavioral|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
79563179|NCT01696331|Behavioral|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
79563180|NCT01696344|Procedure|PVAI|
79563181|NCT01696344|Procedure|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
79859420|NCT05552976|Drug|Carfilzomib|Specified dose on specified days
79859421|NCT05552976|Drug|Dexamethasone|Specified dose on specified days
79859422|NCT05551741|Biological|IBC-Ab002|An anti-PD-L1 monoclonal antibody
79859423|NCT05551741|Other|Placebo|Normal Saline
79264232|NCT04829162|Other|Father without obesity, son without obesity|Participants in this group were shown an image of a father without obesity and a son without obesity.
79264233|NCT02426775|Drug|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
79264234|NCT03039452|Behavioral|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
79264235|NCT02426931|Device|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
79264236|NCT02426931|Device|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
79264237|NCT03039218|Device|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
79264238|NCT03039218|Device|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
79264239|NCT03037190|Other|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
79725056|NCT05380960|Device|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
79859424|NCT05550064|Other|Structured contraceptive counseling|"Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
79859425|NCT05549297|Drug|Tebentafusp|soluble gp100-specific T cell receptor with anti-CD3 scFV
79859426|NCT05549297|Drug|Tebentafusp with Pembrolizumab|soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with Pembrolizumab
80021411|NCT02307734|Behavioral|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
79859427|NCT05549297|Drug|Investigators Choice|Investigators choice of therapy
79859428|NCT05547984|Device|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
79859429|NCT05547984|Device|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
79859430|NCT05546580|Drug|Iadademstat|iadademstat oral solution
79859431|NCT05546580|Drug|Gilteritinib Oral Tablet|120 mg Gilteritinib
79264240|NCT03185559|Device|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
79264241|NCT03185559|Device|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
79264242|NCT03117153|Other|DA-5502 liquid toothpaste|6 weeks study, brush three times daily, liquid toothpaste
79563182|NCT01696370|Drug|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
79563183|NCT01696370|Other|Placebo capsule|one capsule three times per day for 3 months
79264243|NCT03117153|Other|placebo|same flavor solution, brush three times daily
79563184|NCT01696383|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
79859432|NCT05544344|Behavioral|Healthy ReStart|In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
79859433|NCT05544344|Other|Services as Usual|Subjects receive mental health services as usual.
79875800|NCT04857918|Behavioral|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
79264244|NCT02426619|Device|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
79563185|NCT01696409|Dietary Supplement|400 IU vitamin D3|Take 400 IU once/day for 2 months
79563186|NCT01696409|Dietary Supplement|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
79563187|NCT01696422|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
79563188|NCT01696422|Biological|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
79563189|NCT01696422|Other|Placebo|Route:subcutaneous
79563190|NCT01696448|Dietary Supplement|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
79563191|NCT01696448|Other|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
79563192|NCT01696474|Drug|Bortezomib|
80021412|NCT02307734|Behavioral|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
80021413|NCT04653454|Device|Continuous Glucose Monitor (CGM)|CGM data will be downloaded prior to discharge and it will be compared with hospital glucometer readings taken at the same time.
79563193|NCT01696487|Dietary Supplement|High oral Fructose challenge (150g per day for 28 days)|
79725057|NCT02851498|Other|Food product: high-protein pasta and cereal|
80021414|NCT03506750|Drug|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
79563194|NCT01696500|Drug|Intravenous immunoglobulin|
79264245|NCT02426619|Device|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
79563195|NCT01696526|Other|vitamin D fortified fish|fish containing vitamin D3
79563196|NCT01696526|Other|conventional fish|fish containing low concentrations of vitamin D3
79563197|NCT01696539|Behavioral|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
79563198|NCT01696539|Other|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
79563199|NCT01696552|Procedure|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
79563200|NCT01696552|Procedure|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
79563201|NCT01696578|Behavioral|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
79563202|NCT01696591|Biological|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
79563203|NCT01696604|Drug|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
79563204|NCT01696604|Drug|Placebo|Matching placebo capsules will be available.
79563205|NCT01696617|Drug|Aripiprazole 6-week group|
79563206|NCT01696617|Drug|Aripiprazole 8-week group|
79563207|NCT01696630|Drug|Xenon|
79563208|NCT01696630|Drug|Desflurane|
79563209|NCT01696656|Drug|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
79725058|NCT02690272|Behavioral|Psychic processes|Quantitative and qualitative aprroche of the psychic process
79725059|NCT02851420|Other|spectroscopy|
79725060|NCT00604630|Drug|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
79725061|NCT00604630|Drug|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
79725062|NCT05380882|Drug|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
79725063|NCT01189266|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
79725064|NCT01189266|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
79725065|NCT01189266|Other|Laboratory Biomarker Analysis|Correlative studies
79725066|NCT01189266|Drug|Vorinostat|Given PO
79725067|NCT01189032|Drug|DE-089 ophthalmic solution|
79725068|NCT01189032|Drug|DE-089 ophthalmic solution|
79725069|NCT01189032|Drug|Placebo ophthalmic solution|
79725070|NCT01188798|Drug|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
79264246|NCT02108483|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
79264247|NCT02108483|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
79264248|NCT04828616|Drug|DP303c injection|DP303c injection, every 3 weeks (Q3W)
79264249|NCT03117075|Device|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
79725071|NCT01188798|Drug|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
79725072|NCT04316052|Other|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
79725073|NCT04316052|Other|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
79725074|NCT01183104|Drug|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=< <50).
79725075|NCT01183104|Drug|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
79725076|NCT02886468|Other|skin ultrasound|
79725077|NCT04188132|Other|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
79725078|NCT04187664|Behavioral|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
79859434|NCT05541913|Other|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
79859435|NCT05541822|Drug|ABN401|"Tablets~Route of Administration: Oral"
80021415|NCT03506750|Procedure|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
80021416|NCT03506750|Procedure|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
80021417|NCT03506750|Procedure|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
79563210|NCT01696669|Drug|Chemotherapy|"Vincristine, 2 mg/m^2 IV bolus, day 1.~Doxorubicin: 75 mg/m^2 per cycle, or 25 mg/m^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~Cyclophosphamide: 2100 mg/m^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm^3/L.~Ifosfamide: 1800 mg/m^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~Gemcitabine: 1000 mg/m^2 IV, 90 minutes on day 1 and 8.~Docetaxel 100 mg/m^2, 2-3 hour infusion on day 8."
80021418|NCT00054964|Drug|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
80021419|NCT00054964|Drug|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
80021420|NCT02781558|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
79563211|NCT01696669|Procedure|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
79563212|NCT01696669|Radiation|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
80021421|NCT02781558|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
79725079|NCT04187664|Diagnostic Test|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
79725080|NCT02885532|Other|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
79725081|NCT02885688|Dietary Supplement|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
79725082|NCT02885688|Procedure|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
79859436|NCT05537727|Device|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
79859437|NCT05537727|Device|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
79859438|NCT05537727|Device|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
80021422|NCT05073796|Device|Cochlea Implant|"examination and documentation of vital signs and concomitant medication~application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~attraction of an special mask to determine the subjective visual vertical (SVV)~assessment of the vertical spatial axis with all electrodes turned off~assessment of the vertical spatial axis with all electrodes turned on~assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
80021423|NCT05073640|Drug|Oxopurin|Subjects will receive two capsules per day.
80021424|NCT02304224|Other|eye masks|eye masks from 21:00 to 6:00 each night during admission
80021425|NCT02143596|Other|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
80021426|NCT05073094|Drug|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
80021427|NCT05073094|Drug|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
79399313|NCT03141138|Biological|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
79399314|NCT03140982|Diagnostic Test|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
79399315|NCT05392686|Drug|PD-1 inhibitor|Tirelizumab
79859439|NCT05536297|Drug|Avacincaptad pegol 2 mg intravitreal injection|Avacincaptad pegol is a complement C5 inhibitor
79859440|NCT05534620|Drug|Treosulfan|IV infusion
79859441|NCT05534620|Drug|Fludarabine|IV infusion
79859442|NCT05529849|Drug|TCMCB07|Subcutaneous injection of TCMCB07
79859443|NCT05529849|Drug|Placebo|Matching subcutaneous placebo
79399316|NCT05392686|Drug|PARP inhibitor|Fluzopari capsule
79725083|NCT00950248|Drug|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
79725084|NCT00950248|Other|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
80021428|NCT03509246|Drug|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
80021429|NCT03509168|Drug|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
79859444|NCT05528861|Drug|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
80021430|NCT03509168|Other|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
80021431|NCT04330534|Drug|BCX9930|BCX9930 capsules for oral administration
80021432|NCT04330534|Drug|Placebo|placebo to match BCX9930 capsules for oral administration
80021433|NCT03509090|Procedure|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
80021434|NCT03509090|Procedure|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
80021435|NCT05072938|Drug|Mucotra SR Tablet 150mg|Rebamipide/Nizatidine Combination Therapy
80021436|NCT05072938|Drug|Axid Capsule 150mg|Nizatidine Monotherapy
80021437|NCT03041311|Drug|Trilaciclib|Trilaciclib IV
80021438|NCT03041311|Drug|Placebo|Placebo IV
79264250|NCT01648348|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
79725085|NCT04269928|Procedure|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
79859445|NCT05528861|Other|Placebo|Placebo
79859446|NCT05526781|Device|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
79859447|NCT05526326|Device|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
79859448|NCT05524571|Drug|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
79859449|NCT05524571|Drug|Placebo|Matching Placebo
79264251|NCT01648348|Biological|Bevacizumab|Given IV
79264252|NCT01648348|Other|Laboratory Biomarker Analysis|Correlative studies
79264253|NCT01648348|Other|Pharmacological Study|Correlative studies
80021439|NCT03041311|Drug|Carboplatin|Carboplatin IV
80021440|NCT03041311|Drug|Etoposide|Etoposide IV
80021441|NCT03041311|Drug|Atezolizumab|Atezolizumab IV
80021442|NCT02311868|Dietary Supplement|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
80021443|NCT02311868|Dietary Supplement|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
80021444|NCT05072860|Drug|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
80021445|NCT05072860|Other|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
80021446|NCT02311946|Drug|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
79264254|NCT01648348|Other|Quality-of-Life Assessment|Ancillary studies
79264255|NCT03039530|Behavioral|Group Cognitive Behavioral Therapy|9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
79264256|NCT03039530|Behavioral|Postnatal Care As Usual|Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
79563213|NCT01696682|Procedure|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
79563214|NCT01696682|Procedure|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
79563215|NCT01696708|Other|31-Phosphorus RMN Spectroscopy|
79563216|NCT01696786|Procedure|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
79563217|NCT01696799|Drug|Econazole Nitrate|
79563218|NCT01696799|Drug|placebo|
79563219|NCT01696812|Procedure|electrode position|
79563220|NCT01696825|Drug|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
79563221|NCT01696825|Drug|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
79563222|NCT01696825|Drug|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
79563223|NCT01696838|Other|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
80021447|NCT02311946|Drug|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
79859450|NCT05523635|Device|Gamma4 Nailing System|The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
79859451|NCT05523583|Other|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
79859452|NCT05523375|Behavioral|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
79859453|NCT05520515|Other|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
79875801|NCT04857918|Behavioral|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
80021448|NCT05072392|Device|Foley catheter|"Using a 16G Foley catheter to cover the tip of the endotracheal tube as it passes through the nose. This is done in comparison to the standard practice of directly passing an endotracheal tube through the nose without a cover.~Both groups use warmed endotracheal tubes and the use of topical vasoconstrictor (4 sprays of 0.1% xylometazoline to each nare)."
80021449|NCT02312024|Device|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
80021450|NCT04302766|Drug|Remdesivir|Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
79264257|NCT02108561|Other|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
80021451|NCT02312102|Drug|Lenalidomide|Chemotherapy
79725086|NCT00950170|Procedure|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
79264258|NCT03180255|Combination Product|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
79264259|NCT03180255|Other|Placebo|Ocular iontophoretic delivery of a placebo
79264260|NCT02431221|Drug|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
79264261|NCT02431221|Drug|Placebo|
79264262|NCT02108639|Drug|DCV 3DAA FDC|
79875802|NCT01025544|Biological|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
79875803|NCT01025544|Biological|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
79875804|NCT03839940|Drug|Dexamethasone|Given as mouthwash
79875805|NCT03839940|Other|Placebo|Given as mouthwash
80021452|NCT02312102|Drug|Velcade|Chemotherapy
80021453|NCT02304536|Drug|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
79399317|NCT05082168|Device|Capnodynamic monitoring|"In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x [(FACO2(n)-FACO2(n-1)] = delta(n) x EPBF [CvCO2(n)] - VTCO2."
79399318|NCT00603291|Drug|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
80021454|NCT02304536|Procedure|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
80021455|NCT05408221|Drug|Rulonilimab+Lenvatinib|Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
79859454|NCT05520515|Other|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
80021456|NCT05408221|Drug|Rulonilimab placebo +Lenvatinib|Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
80021457|NCT02644096|Other|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
80021458|NCT03504722|Behavioral|RESCUE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
80021459|NCT03504722|Behavioral|Prolonged Exposure|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
80021460|NCT05072002|Other|no intervention / observational study|no intervention / observational study
80021461|NCT02304614|Other|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
80021462|NCT02304614|Other|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
80021463|NCT02304614|Other|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
79264263|NCT02108639|Drug|BMS-791325|
79264264|NCT04795466|Biological|Canakinumab|Biological sub-cutaneous injection
79264265|NCT04795466|Other|Placebo|Matching placebo subcutaneous injection
79264266|NCT02426385|Device|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
79563224|NCT01696838|Other|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
80021464|NCT02304614|Other|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
79563225|NCT01696851|Other|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
79563226|NCT01696864|Device|Hand tutor rehabilitation device|A rehabilitation device for the hand
79563227|NCT01696864|Device|Arm tutor rehabilitation device|A rehabilitation device for the arm
79563228|NCT01696890|Device|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
79725087|NCT05380804|Diagnostic Test|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
79264267|NCT02111291|Biological|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
79875806|NCT03839940|Other|Questionnaire|Ancillary studies
79875807|NCT03839940|Other|Quality-of-Life Assessment|Ancillary studies
79875808|NCT03839940|Drug|Everolimus|Standard of care
79875809|NCT01025622|Biological|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
79875810|NCT01027494|Drug|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
79875811|NCT01027572|Device|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
79264268|NCT02111291|Biological|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
79264269|NCT03180099|Drug|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
79264270|NCT03180099|Drug|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
79563229|NCT01696890|Device|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
79563230|NCT01696903|Procedure|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
79563231|NCT01696916|Procedure|6-minute walking test|submaximum exercise test
79563232|NCT01697007|Biological|HIVIS DNA vaccine|
79563233|NCT01697007|Device|Zetajet|
79563234|NCT01697007|Device|Derma Vax Electroporation|
79563235|NCT01697007|Biological|Modified Vaccinia Ankara (MVA-CDMR)|
79563236|NCT01697020|Drug|Mercaptopurine 20mg/ml oral suspension|50mg
79264271|NCT03180177|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m^2, 43°C, 90min.
79264272|NCT03180177|Procedure|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
79563237|NCT01697020|Drug|Mercaptopurine 50mg tablet|50mg
79563238|NCT01697046|Drug|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
79725088|NCT02851030|Behavioral|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
79264273|NCT03180177|Drug|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
79875812|NCT03839628|Other|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
79264274|NCT03180177|Drug|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
79264275|NCT02108717|Device|Remote CT reading using the iPhone|
79264276|NCT02108717|Device|CT reading using LCD monitor|
79264277|NCT03179709|Behavioral|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
79875813|NCT00462462|Drug|Ethanol 96% Gel|
79264278|NCT04794608|Device|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each session of hypnosis, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
79399319|NCT00603291|Drug|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
79399320|NCT00603291|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
79399321|NCT03140202|Device|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
79563239|NCT01697059|Drug|Piperacillin + Amoxicillin|
79563240|NCT01697085|Dietary Supplement|Sea buckthorn oil|
79399322|NCT03140202|Device|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
79399323|NCT03110796|Device|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
79399324|NCT03110796|Device|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
79399325|NCT03110796|Device|Dressing without LU3103209|Dressing without LU3103209
79563241|NCT01697085|Dietary Supplement|Placebo oil|
79563242|NCT01697098|Drug|Dexamethasone 24 hours|
79563243|NCT01697098|Drug|Dexamethasone 12|
80021465|NCT03625999|Behavioral|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
79264279|NCT03180021|Procedure|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
79264280|NCT02251145|Drug|Tipranavir low dose|
79563244|NCT01697111|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
79725089|NCT04267666|Device|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
79264281|NCT02251145|Drug|Tipranavir high dose|
79264282|NCT02251145|Drug|Ritonavir low dose|
79264283|NCT02251145|Drug|Ritonavir high dose|
79725090|NCT04267666|Other|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
79725091|NCT00604864|Drug|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
79725092|NCT00604864|Drug|placebo|Placebo
79725093|NCT01227824|Drug|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
80021466|NCT04211194|Procedure|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
80021467|NCT04196842|Device|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
80021468|NCT03508856|Drug|Ingenol Mebutate (Picato®) 0.015% gel|
80021469|NCT03132428|Drug|INOmax|Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
80021470|NCT02643628|Procedure|Microneedling|
80021471|NCT02643628|Device|Microneedling followed by Bellafill treatment|
80021472|NCT03508778|Device|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
80021473|NCT03508778|Device|AcrySof IQ PanOptix Trifocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
80021474|NCT03508778|Procedure|Cataract surgery|Cataract surgery per investigator's standard practice
79264284|NCT02251145|Drug|Tenofovir disoproxil fumarate|
79264285|NCT04792424|Other|Regional citrate anticoagulation|Starting RCA 4 mmol/L (adjust the rate by BFR)
79264286|NCT04792424|Drug|Vasopressor|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
79264287|NCT04792424|Drug|Antibiotic|Antibacterial agents deemed appropriate by physicians in the ICU
79264288|NCT04792424|Device|Dialysis with continuous renal replacement therapy|Prismaflex
79264289|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
79264290|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
79264291|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
79264292|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
79563245|NCT01697111|Drug|Placebo|One tablet (no active ingredient) / day and one tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day, for the first 24 weeks and the later 28 weeks, respectively
79563246|NCT01697111|Drug|Dienogest|Dienogest 1mg twice a day (bid)
79563247|NCT01697124|Behavioral|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
79563248|NCT01697137|Behavioral|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
80021475|NCT02643472|Behavioral|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
80021476|NCT02643472|Behavioral|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
80021477|NCT02738840|Procedure|MRI scan|MRI scan
80021478|NCT03508700|Drug|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
80021479|NCT04038736|Device|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
80021480|NCT02304692|Device|Bone anchored hearing aid|
79264293|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
79399326|NCT00705003|Drug|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
79563249|NCT01697150|Device|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
79563250|NCT01697189|Behavioral|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
79563251|NCT01697215|Other|AirWave|
79563252|NCT01697228|Dietary Supplement|Vitamin D|
79563253|NCT01697241|Other|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
79563254|NCT01697241|Other|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
79563255|NCT01697280|Behavioral|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~Vaccines can save a child's life~Children who are immunized on time are less likely to become ill~Unimmunized children can become disabled for life~Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
79563256|NCT01697280|Other|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
79563257|NCT01697280|Other|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
79563258|NCT01697293|Drug|Cyclophosphamide|Given IV
79563259|NCT01697293|Drug|Doxorubicin Hydrochloride|Given IV
79725094|NCT01227824|Drug|raltegravir|raltegravir 400mg taken twice daily
79725095|NCT01227824|Other|GSK1349572 Placebo|GSK1349572 placebo taken once daily
79725096|NCT01227824|Other|ABC/3TC|Abacavir/Lamivudine background therapy once daily
79725097|NCT01227824|Other|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
79264294|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
79264295|NCT03553901|Procedure|Acupressure|Acupressure was performed before the injection onto GB30 point
79264296|NCT03553667|Device|Standard group|Use radial arterial line to monitor mean arterial pressure
79264297|NCT03553667|Device|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
79399327|NCT00705003|Drug|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
79399328|NCT00705003|Drug|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
79399329|NCT05081856|Other|mobilization with moduler medical equipment carring vehicle|Mobilization of the patients was carried out with the vehicle in their modular vehicle.
79725098|NCT01227824|Other|raltegravir Placebo|raltegravir placebo taken twice daily
79264298|NCT04790630|Other|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|computerized experimental brain-training treatment
79725099|NCT00949702|Drug|vemurafenib|960 mg b.i.d. continuous oral dosing
79859455|NCT05520515|Other|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
79264299|NCT04790630|Other|Active Control|computerized intervention that follows recommendations for cognitive fitness
79264300|NCT02426463|Drug|propofol|
79264301|NCT02426463|Drug|oxycodone|
79264302|NCT02105207|Other|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
79264303|NCT02105207|Other|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
79264304|NCT02426229|Drug|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
79264305|NCT01648270|Drug|buprenorphine|Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
79563260|NCT01697293|Other|Laboratory Biomarker Analysis|Correlative studies
79563261|NCT01697293|Drug|Paclitaxel|Given IV
79563262|NCT01697293|Procedure|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
79563263|NCT01697293|Drug|Triciribine Phosphate|Given IV
79563264|NCT01697306|Drug|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
79725100|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
79725101|NCT01034631|Drug|BNC105P|BNC105P, up to 16 mg/m^2
79859456|NCT05518422|Drug|Hyperinsulinemic, euglycemic infusion|60 minute infusion
79264306|NCT05619380|Procedure|physiotherapy treatment|Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
79264307|NCT02108795|Drug|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
79264308|NCT02108795|Drug|Placebo|
79264309|NCT02431143|Drug|Miltefosine|
79264310|NCT04825340|Biological|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine|0.2 ml/vial, 0.2ml/dose/per person
79264311|NCT02302846|Drug|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
79264312|NCT02105363|Other|measure of skin movement on surface of the back|
79264313|NCT02105363|Other|Measurement of skin movement on surface of back|
79264314|NCT02431065|Procedure|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
79563265|NCT01697306|Drug|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
79563266|NCT01697410|Drug|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
79563267|NCT01697410|Drug|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
79563268|NCT01697423|Drug|platelet-rich plasma|
79563269|NCT01697423|Drug|durolane|
79563270|NCT01697436|Drug|ribavirin [Copegus]|tablet under fed condition
79563271|NCT01697436|Drug|ribavirin [Copegus]|tablet under fasted condition
79563272|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fed condition
79563273|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fasted condition
79563274|NCT01697475|Behavioral|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
79725102|NCT01227668|Drug|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
79725103|NCT01227668|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
79725104|NCT00603460|Biological|DCVax-L and T Cells|"Arm A~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~End of study visit~Arm B~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~End of study visit"
79725105|NCT02851186|Device|Acupuncture|
79725106|NCT02851186|Device|Sham acupuncture|
79725107|NCT04319432|Behavioral|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
79725108|NCT01227512|Drug|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
79859457|NCT05517668|Drug|Intravenous infusion of N-acetylcysteine|If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.
79264315|NCT02431065|Drug|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
79264316|NCT02431065|Other|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
79264317|NCT04836806|Drug|Cetirizine and Famotidine|Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
79264318|NCT04836806|Drug|Placebo|Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
79264319|NCT04836728|Biological|CIK cell injection|CIK cells, more than 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.
79264320|NCT04836728|Drug|Sintilimab Injection|Sintilimab Injection intravenous infusion 200mg d1
79264321|NCT04836728|Drug|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d2
79264322|NCT04836728|Drug|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d2
79264323|NCT04836728|Drug|Carboplatin|Carboplatin intravenous infusion AUC5 d2
79264324|NCT02430831|Dietary Supplement|Nidina|
79264325|NCT02430831|Dietary Supplement|Placebo|
79399330|NCT03110718|Device|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
79399331|NCT00690339|Device|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
79859458|NCT05517668|Drug|Intravenous infusion of Fomepizole (4-MP)|If randomized to fomepizole, the proposed infusion schedule for fomepizole closely mirrors the dosing outlined in the medication's package insert. Specifically, the Antizol (fomepizole) doses (bags) #1-5 allocated for the study will precisely adhere to the manufacturer's recommendations from the package insert. This entails an initial loading dose of 15 mg/kg followed by four subsequent doses of 10 mg/kg. The dose of fomepizole will not be adjusted based on age, presence of liver injury or renal insufficiency.
79859459|NCT05517447|Other|Observational cohort study|Observational cohort study
79399332|NCT03110640|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
79264326|NCT02426151|Drug|BEPO-A|BEPO-A (Bioreactor manufacturing process)
79399333|NCT03110640|Drug|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
79399334|NCT03110640|Drug|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
79399335|NCT04368936|Genetic|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
79399336|NCT00690495|Drug|Propofol|Propofol (drug), intravenous, induction of anesthesia
79563275|NCT01697514|Drug|LY2940680|Capsule administered orally.
79563276|NCT01697514|Drug|LY2940680|Powder administered orally (may be sprinkled on soft food).
79563277|NCT01697553|Other|home automation pack coupled to teleassistance service|
79563278|NCT01697553|Other|Home without automation pack coupled to teleassistance service|
79563279|NCT01697605|Drug|BGJ398|
79875814|NCT00462462|Drug|Ethanol 98% Solution|
79399337|NCT00690495|Drug|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
79563280|NCT01697618|Drug|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
79563281|NCT01697618|Drug|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
79563282|NCT01697631|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
79563283|NCT01697631|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
79563284|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
79859460|NCT05517447|Drug|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
79859461|NCT05517421|Drug|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
79264327|NCT02426151|Drug|REPO-A|REPO-A (Roller bottle manufacturing process)
79563285|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
79563286|NCT01697657|Drug|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
79563287|NCT01697657|Drug|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
79563288|NCT01697657|Drug|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
79859462|NCT05517421|Drug|Placebo|Matching Placebo
79859463|NCT05515705|Device|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
79859464|NCT05513586|Drug|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
79859465|NCT05511987|Device|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
79859466|NCT05511987|Device|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
79563289|NCT01697670|Drug|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
79563290|NCT01697683|Drug|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
79563291|NCT01697683|Drug|Placebo|
79563292|NCT01697722|Drug|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
79725109|NCT01227512|Other|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
79725110|NCT01227278|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
79725111|NCT01227278|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
79725112|NCT01034397|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
79859467|NCT05509894|Drug|Ngenla|As provided in real world practice
79725113|NCT01034397|Drug|placebo|iv every 4 weeks for 24 weeks
79859468|NCT05509725|Drug|Probiotic formulation|Participants will be asked to take 2 doses daily
79859469|NCT05509725|Drug|Placebo|Participants will be asked to take 2 doses daily
79859470|NCT05509400|Drug|Rimegepant|DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
79264328|NCT04836572|Other|3M 1529 Adhesive Tape|5-12 hour adhesive wear
79859471|NCT05509400|Drug|Placebo|DB Phase: matching placebo
79859472|NCT05509400|Drug|Rimegepant|OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
79859473|NCT05509023|Drug|ADX-914|Subcutaneous administration of ADX-914
79859474|NCT05509023|Drug|Placebo|Subcutaneous administration of Placebo
79859475|NCT05505110|Procedure|Vaginal Seeding|Following delivery by C-section, participating infants randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
79859476|NCT05505110|Procedure|Sterile Swab|Following delivery by C-section, participating infants randomized to the control group will have their nasal cavity swabbed with a sterile swab.
79859477|NCT05501119|Behavioral|A Program of SUPPORT-D (dementia)|The SUPPORT-D intervention consists educational materials will be presented in a format with enhanced content (face-to-face virtually delivered by nurse interventionist via telehealth (e.g., MS Teams), with printed booklet, and identical digital content (electronic pdf and recorded videos of printed content). The SUPPORT-D intervention will be addressed in four sequential sections including: 1) understanding the disease 2) caring for myself; 3) information for the caregiver; and 4) planning for the future. Within the four sections of the intervention seven topics are addressed included symptom management, understanding your disease, putting safety first, ongoing conversations, respite care, palliative care, and alternative treatments. Participants will attend a total of 4 study visits across 8 weeks (approximately every 2 weeks).
79859478|NCT05501093|Other|sample collection|Blood, plaque, and other oral samples
79264329|NCT02109185|Drug|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
79264330|NCT02109185|Drug|Nasonex® Nasal Spray, 50 μg/actuation|
79264331|NCT02109185|Drug|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
79264332|NCT02109185|Drug|Placebo Nasal Spray, 50 μL/actuation|
79264333|NCT04824950|Other|Circulating tumor DNA monitoring|Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
79859479|NCT05500066|Device|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~A replacement of shoulder joints in primary anatomic or in primary reverse~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
80021481|NCT05071378|Behavioral|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
80021482|NCT02307968|Other|insulin injection site|insulin injected site between inner thigh and out thigh
80021483|NCT02312180|Biological|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
80021484|NCT05070832|Procedure|Deep Hyperthermia|Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
79264334|NCT02105441|Device|Cochlear implant|Implantable hearing device
79563293|NCT01697722|Drug|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
79563294|NCT01697735|Drug|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
79563295|NCT01697735|Drug|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
79563296|NCT01697761|Other|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
79563297|NCT01697761|Other|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
80021485|NCT03504566|Drug|Linagliptin|Linagliptin
80021486|NCT03504566|Drug|Empagliflozin|Empagliflozin
80021487|NCT03504566|Drug|Telmisartan|Telmisartan
80021488|NCT03504566|Drug|Sulodexide|Sulodexide
80021489|NCT05070520|Drug|Artemether-lumefantrine|Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
80021490|NCT03508544|Procedure|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
80021491|NCT03508544|Procedure|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
79264335|NCT02425995|Procedure|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
79264336|NCT04824716|Procedure|Postconditioning|The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
79264337|NCT04824716|Device|Percutaneous coronary intervention|Percutaneous coronary intervention as per European Society of Cardiology guidelines.
79264338|NCT02430909|Biological|Bimekizumab|"Pharmaceutical form: Solution for infusion~Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~Route of administration: iv infustion"
79264339|NCT02430909|Biological|Certolizumab Pegol|"Pharmaceutical form: Prefilled syringes~Concentration: 200 mg/ml~Route of administration: Subcutaneous injection"
79725114|NCT01034397|Drug|non-biological DMARDs|stable dose at investigator's prescription
79725115|NCT01227044|Drug|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
79725116|NCT01227044|Other|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
79725117|NCT02872779|Procedure|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
79725118|NCT01225952|Device|Crystalens AO|Bausch & Lomb model silicone multi-piece accommodating IOL.
80031683|NCT02047773|Other|Duration|If bacterial load checked on day 7 is less than 10^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
79563298|NCT01697787|Drug|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
79725119|NCT01225952|Device|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
79725120|NCT01225952|Device|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
79725121|NCT01034163|Drug|Panobinostat|
79725122|NCT01034163|Drug|Placebo|Placebo
79725123|NCT01033851|Behavioral|Mindfulness Based Stress Reduction|8 week course
79725124|NCT01033851|Behavioral|Stress Management Education|8 week course
79264340|NCT02430909|Other|Placebo|"Pharmaceutical form: Solution for infusion~Concentration: 0.9% saline~Route of administration: Intravenous infusion"
79264341|NCT02105519|Biological|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
79563299|NCT01697787|Drug|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
79725125|NCT01162122|Biological|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
79725126|NCT01162122|Biological|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
79725127|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
79725128|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
79725129|NCT01033071|Drug|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
79725130|NCT04313946|Diagnostic Test|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
79725131|NCT04125030|Other|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
79725132|NCT01032915|Biological|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
79859480|NCT05498480|Biological|Relatlimab|Specified dose on specified days
79859481|NCT05498480|Biological|Nivolumab|Specified dose on specified days
79859483|NCT05492500|Drug|Main cohort: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
79399338|NCT04273386|Other|Evaluation|The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
79399339|NCT00691197|Device|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
79399340|NCT00691197|Device|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
79859484|NCT05492500|Drug|Main cohort: Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
79859485|NCT05492500|Drug|Main cohort: ponsegromab high dose|Ponsegromab high dose subcutaneous injection
79859486|NCT05492500|Other|Main cohort: Matched placebo|Matched placebo subcutaneous injection
79859487|NCT05492500|Drug|Open-label, PK Cohort: ponsegromab low dose|ponsegromab low dose subcutaneous injection
79859488|NCT05492500|Drug|Open-label, PK Cohort: ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
79859489|NCT05492500|Drug|Open-label, PK Cohort: ponsegromab high dose|Ponsegromab high dose subcutaneous injection
79859490|NCT05485376|Device|Pulmonary Artery Catheter|The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
79859491|NCT05485051|Other|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
79859492|NCT05485051|Other|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
79859493|NCT05483010|Drug|Atorvastatin|Atorvastatin is commercially available.
79859494|NCT05483010|Drug|Rosuvastatin|Rosuvastatin is commercially available.
79859495|NCT05481970|Drug|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
79859496|NCT05481970|Drug|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
79859497|NCT05480995|Drug|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
79859498|NCT05479344|Behavioral|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
80031684|NCT02047773|Drug|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
79859499|NCT05477875|Drug|oral cannabinoid|dronabinol
79264342|NCT04836650|Diagnostic Test|Postural stability assessment with a force platform.|The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.
79859500|NCT05477875|Combination Product|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
80031685|NCT02047773|Drug|Meropenem|
80031686|NCT03562299|Device|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
80031687|NCT04886830|Procedure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
79264343|NCT04836650|Diagnostic Test|Muscular assessment with a electromyograph|The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.
79264344|NCT02109263|Procedure|saccharose versus breast-feeding|saccharose versus breast-feeding
79563300|NCT01697826|Drug|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
79563301|NCT01697826|Drug|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
79563302|NCT01697852|Other|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
79563303|NCT01697852|Other|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
79563304|NCT01697865|Procedure|Transfer group|
79563305|NCT01697865|Procedure|Control group|
79563306|NCT01697878|Procedure|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
79563307|NCT01697878|Procedure|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
79725133|NCT01032915|Biological|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
79725134|NCT01032915|Biological|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
79725135|NCT01032915|Drug|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
79725136|NCT00627783|Other|a bicycle exercise test|
79725137|NCT01161498|Biological|Talimogene Laherparepvec|Administered by intratumoral injection
79725138|NCT01161498|Radiation|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
79725139|NCT01161498|Drug|Cisplatin|Administered by intravenous infusion
79725140|NCT02873559|Drug|testosterone|Testosterone supplemented in 5 months
79725141|NCT02873559|Other|Progressive muscle training|Progressive muscle training during 4 months
79859501|NCT05477563|Biological|CTX001|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
79859502|NCT05471622|Behavioral|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
80031688|NCT04886830|Procedure|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
79264345|NCT02423655|Other|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
80031689|NCT04886830|Procedure|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
79264346|NCT02423655|Other|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
79264347|NCT04825028|Device|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
79264348|NCT02105597|Other|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
79264349|NCT02425761|Procedure|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
79264350|NCT04836338|Device|orotracheal intubation|orotracheal intubation
79264351|NCT02105675|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
79399341|NCT02997969|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
79563308|NCT01697891|Device|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
79563309|NCT01697904|Procedure|Titration of oxygen during newborn resuscitation in delivery room|
79563310|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
79563311|NCT01697943|Procedure|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
79399342|NCT02997969|Biological|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
79399343|NCT02997969|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
79399344|NCT04351230|Drug|Abemaciclib|Given IV
79563312|NCT01697982|Behavioral|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
79563313|NCT01697982|Behavioral|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
79563314|NCT01698034|Behavioral|Volunteering|Weekly volunteering with elementary school children in after school programs
79563315|NCT01698047|Behavioral|Resiliency Class|See Arm Description
79563316|NCT01698047|Other|Case Management|See Case Management description
79563317|NCT01698060|Biological|ND1.1|
79399345|NCT04351230|Biological|Trastuzumab Emtansine|Given PO
79563318|NCT01698073|Behavioral|mCOL|
79563319|NCT01698073|Other|AS+|
79725142|NCT01180998|Device|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
79725143|NCT01180998|Device|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
79725144|NCT01029795|Drug|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
79725145|NCT01029795|Drug|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
79725146|NCT01029795|Drug|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
79725147|NCT04124874|Other|There will be no intervention|There will be no intervention
79725148|NCT02885766|Drug|PF-114|
79725149|NCT02885454|Drug|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
79725150|NCT02885454|Drug|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
79725151|NCT02885454|Drug|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
79264352|NCT02105675|Drug|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
79399346|NCT02997891|Diagnostic Test|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
79725152|NCT02885454|Drug|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
79725153|NCT02885610|Biological|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
79399347|NCT02997891|Diagnostic Test|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
79563320|NCT01698086|Other|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
79563321|NCT01698112|Dietary Supplement|Flaxseed High Dose|26 gram flaxseed intervention
79563322|NCT01698112|Dietary Supplement|Flaxseed Low Dose|13 grams flaxseed
79563323|NCT01698125|Procedure|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
79725154|NCT02885610|Biological|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
79725155|NCT02885610|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
79725156|NCT02885610|Biological|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
79725157|NCT04314180|Device|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
79264353|NCT02336230|Drug|remestemcel-L|Participants were treated with IV remestemcel-L at a dose of 2 x 10^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
79264354|NCT04836260|Drug|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
79264355|NCT02105753|Device|1210nm Diode Laser treatments|
79264356|NCT04835948|Drug|single dose of Anti-thymocyte globulin|Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period
79563324|NCT01698164|Drug|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
79264357|NCT02111759|Procedure|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
79264358|NCT02111759|Procedure|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
79264359|NCT02302222|Device|Customizable Dressing with ActiV.A.C. Therapy Unit|
79563325|NCT01698164|Drug|Ximingting Tablet|Participants are given phytoestrogen.
79563326|NCT01698164|Drug|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
79563327|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
79563328|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
79725158|NCT01032837|Drug|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
79725159|NCT01032837|Drug|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
79264360|NCT02302222|Device|Standard of Care Dressing|
79264361|NCT02111837|Other|Standard infant formula|
79264362|NCT02111837|Other|Standard infant formula with PL1|
79264363|NCT02111837|Other|Standard infant formula with PL2|
79399348|NCT05392374|Drug|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2
79725160|NCT01032837|Drug|Placebo|Matching placebo provided as capsules and as a suspension.
79725161|NCT04314102|Other|No intervention will be made.|No intervention will be made. Only checks will be made
79725162|NCT01180296|Drug|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
79725163|NCT01180296|Drug|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
79725164|NCT01160640|Drug|Ceftriaxone|ceftrixone 250mg IM single dose
79725165|NCT01160640|Drug|Doxycycline|Doxycycline 100 mg PO bid x 14 days
79725166|NCT01160640|Drug|Metronidazole|metronidazole 500 mg PO bid x 14 days
79725167|NCT01160640|Drug|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
79725168|NCT01160484|Drug|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
79725169|NCT01032291|Drug|cetuximab|Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
79725170|NCT01032291|Drug|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
80021492|NCT03508544|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
80021493|NCT04435054|Diagnostic Test|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
80021494|NCT02304770|Drug|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
79725171|NCT01159938|Drug|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
79859503|NCT05469009|Drug|Aducanumab|Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening
79563329|NCT01698190|Procedure|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
79859504|NCT05469009|Device|Exablate Model 4000 Type 2|The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.
79859505|NCT05469009|Drug|Lecanemab|Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening
80021495|NCT03101410|Behavioral|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
80021496|NCT03101410|Behavioral|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
79563330|NCT01698203|Drug|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
79563331|NCT01698203|Drug|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
79563332|NCT01698203|Drug|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
79563333|NCT01698229|Other|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
79725172|NCT02873871|Device|Standardized compressive dressing|Standardized compressive dressing
79725173|NCT02873871|Device|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
79725174|NCT04301739|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
79725175|NCT04301739|Drug|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
79725176|NCT04301739|Drug|Placebo|Placebo
79725177|NCT04301583|Dietary Supplement|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
79859506|NCT05462106|Biological|Placebo|Administration of Placebo
79859507|NCT05462106|Biological|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
79859508|NCT05462106|Biological|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
79859509|NCT05462106|Biological|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
79859510|NCT05462106|Biological|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
79859511|NCT05462106|Biological|Placebo|Administration of Placebo
79859512|NCT05462106|Biological|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
79859513|NCT05462106|Biological|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
79859514|NCT05459701|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
79859515|NCT05459701|Other|Placebo|Placebo
79859516|NCT05458765|Drug|emtricitabine/tenofovir alafenamide|200mg/25mg tablet, once daily dosing for 24 weeks
79859517|NCT05458765|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|200mg/300mg tablet, once daily dosing for 24 weeks
79563334|NCT01698242|Behavioral|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
79859518|NCT05458700|Other|Collect information|Collect information from the patients to support the design of innovate clinical trials
79264364|NCT04827524|Other|Anthropometric measurement|The demographic information and birth histories of the subjects included in the study will be taken first. Anthropometric measurements of all subjects will be measured with the Star Scanner device. The Star Scanner 3 dimensional data collection system is a scanning system that enables the anthropometric head measurements of the baby to be taken in just 2 seconds. The advantages of this device is that it does not emit any harmful beams during evaluation, it does not have any harmful effects on health, and that it is an application that will not disturb babies.
79859519|NCT05451004|Other|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
79264365|NCT04824560|Behavioral|Blood pressure education|One page teaching protocol performed by pharmacy students; phone follow-up
79264366|NCT02111915|Behavioral|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
79264367|NCT02111915|Other|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
79264368|NCT04824404|Behavioral|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
79399349|NCT00713427|Device|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
79399350|NCT04186650|Biological|COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
79581256|NCT01934530|Procedure|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
79264369|NCT02109341|Drug|Paclitaxel bound albumine|
79264370|NCT03553589|Other|Blood sampling|Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
79264371|NCT04835792|Other|Stool and blood collection|One-time stool and blood collection
79399351|NCT04175184|Other|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
79725178|NCT01029405|Drug|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
79725179|NCT01029405|Drug|Placebo|Ointment B Vehicle applied once or twice daily
79725180|NCT02872623|Radiation|Enterography-MRI without enteroclysis|
79725181|NCT02872623|Radiation|enteroCT with enteroclysis|
79725182|NCT01021683|Drug|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
79725183|NCT01021293|Biological|Poliorix™|3 doses, intramuscular administration
80021497|NCT03504332|Procedure|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
79725184|NCT01021293|Biological|Oral Poliovirus vaccine|3 doses, oral administration
79859520|NCT05451004|Radiation|Ipsilateral and Contralateral Neck|Radiotherapy
79859521|NCT05450731|Other|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
80021498|NCT05070676|Diagnostic Test|newly developed mobile application|"The application will be developed in native Android, using Java (backend) and XML (front-end) as the programming language. The program of choice will be Android Studio®, YouTube® (video reproduction) and Firebase® (database) will be used as external APIs (Application Programming Interfaces).~The layout of the application will be developed using:~Adobe Illustrator® software. The logo, brand, objects, and shapes of the mobile application will be designed to enable to resize of the images without any loss of quality, due to the wide range of scales available in current smartphones"
80021499|NCT02304848|Other|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
80021500|NCT03919864|Behavioral|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
80021501|NCT03919864|Behavioral|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
80021502|NCT05070598|Drug|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
79563335|NCT01698242|Behavioral|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
79725185|NCT04625725|Drug|AZD7442|"Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
79725186|NCT04625725|Drug|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
80021503|NCT02308436|Device|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries & acidic challenges
79859522|NCT05449691|Procedure|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
80021504|NCT02308514|Device|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
80021505|NCT02308514|Other|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
80021506|NCT03884452|Drug|Atorvastatin|Tablets taken orally once daily in the morning
80021507|NCT03884452|Drug|Simvastatin|Tablets taken orally once daily in the morning or evening
79725187|NCT01021215|Drug|Zileuton|1200 mg twice daily given orally (PO) for 6 days
79725188|NCT01021215|Drug|Celecoxib|200 mg twice daily given orally for 6 days
79725189|NCT01021215|Other|laboratory biomarker analysis|Correlative studies
79725190|NCT02760979|Drug|Denosumab|Denosumab treatment one year after surgery
80021508|NCT03884452|Drug|Ezetimibe|Tablet taken orally once daily in the morning or evening
79264372|NCT02112071|Behavioral|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
79725191|NCT02760979|Drug|Placebo|Serum one year after surgery
79725192|NCT04301115|Other|attachment|unilateral attachment from rehine 83
80021509|NCT03884452|Drug|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
80021510|NCT02308592|Behavioral|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
80021511|NCT02308592|Behavioral|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
79725193|NCT04301115|Other|bridge|tooth implant supported bridge
79725194|NCT04301115|Other|CONVENTIONAL|conventional metalic partial denture
79725195|NCT05429281|Other|Pilates-based Core Strengthening Exercises|The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.
79859523|NCT05448326|Other|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
79859524|NCT05448326|Other|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
79859525|NCT05448326|Biological|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
79859526|NCT05447923|Other|Educational Intervention|Undergo education for colorectal cancer screening
79859527|NCT05447923|Other|Fecal Immunochemical Test|Undergo FIT testing
79859528|NCT05447923|Behavioral|Patient Navigation|Undergo patient navigation for positive FIT results
79563336|NCT01698255|Behavioral|ENGAGE|
79725196|NCT05429281|Other|Plyometric-based Muscle Loading Exercises|The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
79725197|NCT05429281|Other|Combined Pilates and Plyometrics|The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
80021512|NCT02305082|Other|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
79399352|NCT04175184|Other|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
79563337|NCT01698255|Behavioral|Standard of Care Psychotherapy|
79563338|NCT01698346|Biological|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
79563339|NCT01698372|Device|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
79563340|NCT01698385|Other|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
79563341|NCT01698398|Device|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
79563342|NCT01698437|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
79563343|NCT01698450|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
79563344|NCT01698476|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
79563345|NCT01698476|Drug|Placebo tablets|
79725198|NCT02873325|Other|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
79725199|NCT02873403|Device|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
79725200|NCT02873403|Device|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
79859529|NCT05447923|Other|Questionnaire Administration|Complete questionnaire about colorectal cancer screening and healthcare
79859530|NCT05445635|Device|Iriscope|The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
79859531|NCT05441618|Device|Lyoplant®|replacement and extension of connective tissue structures in neurosurgery
79859532|NCT05440734|Drug|Melatonin|2 Mg Oral Tablet, slow release
80021513|NCT03882892|Drug|Ezetimibe|Ezetimibe 10 mg tablets
79563346|NCT01698541|Drug|Tacrolimus|Tested generic
79563347|NCT01698541|Drug|Tacrolimus|Original formulation used as comparator
79563348|NCT01698567|Drug|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
79563349|NCT01698567|Drug|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
79563350|NCT01698580|Other|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
79859533|NCT05440734|Drug|Placebo|placebo pill identical to the treatment pill
79859534|NCT05436249|Device|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~Overt finger tapping in time with a flashing cue.~Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
80021514|NCT03882892|Drug|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
80021515|NCT03882892|Drug|Placebo|Placebo tablets matched to ezetimibe
80021516|NCT02305160|Drug|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
79581257|NCT01934543|Other|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
79581258|NCT01934543|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
79563351|NCT01698580|Other|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
79399353|NCT02991183|Behavioral|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
79563352|NCT01698580|Other|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
79563353|NCT01698580|Other|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
79563354|NCT01698580|Other|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
79563355|NCT01698593|Drug|Bupivacaine 0.5%|
79563356|NCT01698593|Drug|Bupivacaine 0.5% + Epinephrine (1:200,000)|
79581259|NCT01934569|Drug|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
79725201|NCT02754505|Other|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
79725202|NCT02754505|Other|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
79725203|NCT04301193|Device|Quantra Analyzer|Subjects blood will be manipulated in the lab and will be tested with the Quantra Analyzer
79725204|NCT02760901|Drug|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
79725205|NCT02760901|Drug|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
79725206|NCT02760901|Drug|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
79725207|NCT02760901|Drug|saline|saline hydration 2500 ml before cisplatin therapy
80021517|NCT02305160|Drug|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
79725208|NCT02760901|Drug|Cisplatin|patients with tumours already prescribed cisplatin
79725209|NCT04301427|Other|Bone mineral density|Bone mineral density will be measured twice in all included patients.
79725210|NCT00635713|Drug|Fulvestrant|125mg
79725211|NCT00635713|Drug|Anastrozole|ARIMIDEX
79725212|NCT00635713|Drug|Fulvestrant|250mg
79725213|NCT02760823|Drug|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
79725214|NCT02760823|Drug|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
80021518|NCT03101332|Behavioral|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
80021519|NCT03504176|Other|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures <28-32cmH2O PEEP-FiO2 titration tables
79399354|NCT05392218|Behavioral|motivational interviewing|consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
79399355|NCT05392218|Behavioral|general health education|rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
79725215|NCT04222543|Combination Product|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
79725216|NCT01020747|Drug|Avastin® (bevacizumab)|Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
80021520|NCT05069506|Other|Glucose as reference food|Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79859535|NCT05436249|Behavioral|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~Group 1: Imagery only.~Group 2: Overt finger tapping only.~Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
80021521|NCT05069506|Other|Goat milk as test food|Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79563357|NCT01698606|Behavioral|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
79563358|NCT01698645|Drug|PecFent® (fentanyl) nasal spray|
79563359|NCT01698671|Device|InterGard Synergy Vascular Graft|
79725217|NCT01020747|Drug|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
80021522|NCT05069506|Other|Goat milk and currants as test food|Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79264373|NCT04824170|Other|Neural Glide|hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient & affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved
80021523|NCT05069506|Other|Currants as test food|Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
79264374|NCT04824170|Other|Rhythmic stabilization technique|"This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control"
79264375|NCT02105831|Other|Contrast ultrasound skeletal muscle perfusion imaging|1. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
79399356|NCT04028388|Drug|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
79399357|NCT04028388|Drug|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
79563360|NCT01698697|Drug|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
79563361|NCT01698723|Drug|Ribavirin|
79725218|NCT02760511|Dietary Supplement|Anthocyanin|Capsules with different anthocyanin content
79725219|NCT02760511|Dietary Supplement|Placebo|Placebo capsules
80031690|NCT04886752|Dietary Supplement|vitamin C without liposome|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
79563362|NCT01698723|Drug|Placebo|
79563363|NCT01698736|Device|Membrane filtration|Membrane filtration (Polysulfone)
79563364|NCT01698736|Device|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
79859536|NCT05429632|Drug|mocravimod|S1PR modulator
79859537|NCT05422235|Other|Routine Medical Treatment|Subjects will continue their routine medical treatment.
79563365|NCT01698749|Drug|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
79563366|NCT01698762|Other|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
79725220|NCT05428579|Procedure|Retroperitoneal Liposarcoma resection|Retroperitoneal Liposarcoma resection
79725221|NCT02754739|Drug|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
79725222|NCT02754739|Drug|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
80021524|NCT05069506|Other|Sultanina raisins as test food|Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
80021525|NCT05069506|Other|Goat milk yogurt as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
80031691|NCT04886752|Dietary Supplement|liposomal process A vitamin C|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
79264376|NCT02335450|Behavioral|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
79264377|NCT02335450|Device|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
79725223|NCT02754739|Behavioral|Nutritional education only|Only nutritional education by a nutritionist
79264378|NCT03037112|Behavioral|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
79264379|NCT03037112|Behavioral|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
79725224|NCT04300101|Other|molecular characterization|"immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off>50%), MUM1/IRF4, c-myc (cut off>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis"
79725225|NCT01020435|Other|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
79725226|NCT01020435|Other|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
79725227|NCT02754349|Device|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
79725228|NCT02873949|Biological|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
79725229|NCT02873949|Biological|Saliva samples (1ml)|
79725230|NCT02873949|Other|Etiologic treatment|education on oral hygiene, scaling and root planing
79725231|NCT02873949|Other|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
79725232|NCT02754271|Other|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
79725233|NCT01031979|Drug|Yohimbine|alpha-2 adrenergic receptor antagonist
79725234|NCT01031979|Drug|Placebo|Placebo
79264380|NCT02105909|Other|GWAS|
79725235|NCT04502173|Device|Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
79725236|NCT02754193|Other|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
79725237|NCT02753803|Drug|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
80031692|NCT04886752|Dietary Supplement|liposomal process B vitamin C (Double Nutri™)|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
79725238|NCT02753803|Drug|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
79725239|NCT02753803|Drug|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
79859538|NCT05422235|Other|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
79859539|NCT05422235|Other|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
79859540|NCT05419388|Drug|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
79859541|NCT05416151|Other|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
79859542|NCT05416151|Other|Maltodextrin|2 sticks of 3g consumed daily for 28 days
79859543|NCT05412095|Other|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
79859544|NCT05412095|Other|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
79859545|NCT05412095|Other|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
79264381|NCT04428710|Other|assessment with psychometric questionnaire|"At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing."
79264382|NCT03554759|Drug|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
79264383|NCT03013517|Drug|Viaskin Peanut 250µg|DBV712 250 µg, once daily
79859546|NCT05412095|Other|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
79859547|NCT05412095|Other|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
79859548|NCT05408637|Device|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
79563367|NCT01698762|Other|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
79725240|NCT02753803|Drug|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
79725241|NCT02753803|Drug|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
79859549|NCT05407129|Behavioral|Family safety reporting intervention|Family safety reporting intervention for patients/families
79859550|NCT05401799|Device|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
80031693|NCT02047851|Other|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
80031694|NCT03051490|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
80031695|NCT03051490|Drug|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
79264384|NCT02113709|Device|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
79264385|NCT02113709|Device|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
79264386|NCT04824326|Behavioral|PSAI-CA|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
79563368|NCT01698762|Behavioral|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
79563369|NCT01698788|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
79563370|NCT01698827|Other|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
79563371|NCT01698866|Biological|Vaccin GenHevac B Pasteur|
79563372|NCT01698931|Drug|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
80031696|NCT03816813|Other|blood and saliva sampling|blood and saliva sampling
79725242|NCT02753803|Drug|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
79725243|NCT04219579|Drug|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
80021526|NCT05069506|Other|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
80021527|NCT02312336|Other|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
79725244|NCT04219579|Drug|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
80021528|NCT02312336|Other|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
80021529|NCT03504098|Behavioral|nutrition consult|Post-lung cancer operation diet pattern
80021530|NCT04434742|Other|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
79725245|NCT04613947|Behavioral|Informed consent|The style of informing patients about the procedure they will undergo
79725246|NCT04613947|Procedure|Third molar surgery|Surgical extraction of the third molar tooth
79725247|NCT00635401|Drug|Varenicline|0.5 mg BID for 7 weeks
79859551|NCT05401799|Procedure|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
80021531|NCT04434742|Other|Usual care|Social call was given to this group.
79264387|NCT02113787|Procedure|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
79859552|NCT05399108|Procedure|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
79725248|NCT04199065|Other|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
79859553|NCT05399108|Procedure|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
80031697|NCT04895800|Dietary Supplement|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
79264388|NCT04367168|Drug|Colchicine|Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
79264389|NCT04367168|Drug|Placebo oral tablet|Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
79264390|NCT02113943|Drug|Citalopram 30mg|
79399358|NCT04216056|Behavioral|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
79399359|NCT04205760|Combination Product|Nutrition + exercise|Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
79399360|NCT01402063|Drug|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
79563373|NCT01698931|Drug|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
79563374|NCT01698931|Drug|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
79563375|NCT01698944|Drug|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
79563376|NCT01698957|Other|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
80021532|NCT02312414|Drug|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
80021533|NCT05069272|Other|Bakuchiol and Ethyl Linoleate|A synergistic combination of Bakuchiol and Ethyl Linoleate
80021534|NCT05069272|Other|Vehicle|No actives
80021535|NCT02305394|Drug|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
80021536|NCT02305394|Drug|propofol and normal saline|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.
80021537|NCT02305472|Device|NeoVas BCS|Subjects receiving NeoVas BCS
80021538|NCT02305550|Device|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
79563377|NCT01698970|Other|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
79563378|NCT01698970|Other|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
79563379|NCT01698996|Procedure|Packing vs No Packing|
79725249|NCT05424055|Behavioral|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
79725250|NCT02753959|Other|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
80021539|NCT03673852|Behavioral|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
80021540|NCT03673852|Behavioral|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
80021541|NCT03506516|Dietary Supplement|Mixing alcohol|Alcoholic beverages, different types
80021542|NCT03506516|Dietary Supplement|Single type alcohol|Alcoholic beverages, different types
79264391|NCT04823936|Other|core stability training|core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
79399361|NCT01402063|Drug|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
79399362|NCT05392140|Behavioral|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
79399363|NCT05392140|Behavioral|Standart care|Standart care
79399364|NCT05392062|Other|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
79399365|NCT01796301|Drug|Romozosumab|Administered by subcutaneous injection once a month.
79563380|NCT01699009|Other|Plant based diet|
79399366|NCT01796301|Drug|Teriparatide|Administered by subcutaneous injection once a day.
79399367|NCT03361410|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
79399368|NCT03361410|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
79563381|NCT01699009|Other|an unrestricted diet|
79563382|NCT01699048|Procedure|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
79563383|NCT01699048|Procedure|PCI|Multi-vessel PCI with DES
79563384|NCT01699048|Procedure|CABG|Coronary artery bypass graft (CABG) treatment
80021543|NCT02312492|Other|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
80021544|NCT02312492|Other|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
80031698|NCT04895800|Dietary Supplement|Placebo|Natural Flavors [Chocolate, Caramel, Vanilla Cream], Silica, Inulin, Sucralose)
79725251|NCT02753959|Other|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
80031699|NCT04895800|Dietary Supplement|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine [20% natural caf-feine])
79725252|NCT02753725|Drug|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
80031700|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment|Compound level meeting
79725253|NCT02753725|Drug|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
79725254|NCT01020123|Drug|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
79563385|NCT01699061|Drug|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
79563386|NCT01699061|Drug|Placebo|Placebo tablet administered with a meal twice a day on Day 1
79563387|NCT01699074|Dietary Supplement|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
79725255|NCT01020123|Drug|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
79725256|NCT01020123|Drug|Glipizide|Glipizide administered to 1 group of patients
79725257|NCT04603027|Drug|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
79725258|NCT04603027|Drug|Placebo|Placebo oral capsule
79725259|NCT04300959|Drug|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
79725260|NCT04300959|Drug|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
79725261|NCT04299711|Other|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
79725262|NCT02753569|Other|Imaging - DW-MRI|
80031701|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
80031702|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
79725263|NCT02753569|Radiation|FDG PET-CT|
79725264|NCT02760355|Drug|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
79399369|NCT04118790|Other|Clinical Assessment|"Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
79399370|NCT04118790|Procedure|MRI scan|1. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
79399371|NCT04095936|Drug|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
79399372|NCT00868179|Drug|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
79563388|NCT01699074|Dietary Supplement|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
79563389|NCT01699074|Dietary Supplement|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
79563390|NCT01699074|Dietary Supplement|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
79563391|NCT01699074|Dietary Supplement|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
79581260|NCT01934595|Dietary Supplement|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
79264392|NCT02114021|Drug|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
79264393|NCT02114021|Drug|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
79581261|NCT01934608|Behavioral|Refill synch|
79581262|NCT01934621|Behavioral|Strategy Training|
79581263|NCT01934621|Behavioral|Attention Control|
79725265|NCT02760355|Drug|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks.
79563392|NCT01699100|Other|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
79725266|NCT01028391|Drug|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
79725267|NCT01028391|Drug|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
79725268|NCT01028391|Drug|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
79725269|NCT02753491|Behavioral|Motivational short interview|New designed motivational short interview model
79725270|NCT01179672|Drug|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
79725271|NCT01179672|Drug|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
79725272|NCT02872545|Procedure|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
79859554|NCT05398809|Drug|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
79859555|NCT05388357|Other|Intervention Procedure: PCI|Percutaneous Coronary Intervention
79581264|NCT01934634|Drug|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
79859556|NCT05377905|Drug|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
79859557|NCT05377749|Behavioral|FACT|Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
79859558|NCT05377658|Drug|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
79859559|NCT05377658|Drug|Albumin-Bound Paclitaxel|260mg/m^2 via intravenous infusion on Day 1 of each 21-day cycle.
80021545|NCT02312492|Other|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
80021546|NCT02312570|Device|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
80021547|NCT02312570|Other|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
79725273|NCT02872545|Procedure|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
79725274|NCT02872545|Procedure|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
79725275|NCT04321915|Other|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
79859560|NCT05377658|Drug|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
79859561|NCT05372549|Other|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
79859562|NCT05372549|Other|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
79859563|NCT05372549|Other|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
79859564|NCT05364411|Radiation|HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)|20 daily fractions, 5 times per week
79859565|NCT05364411|Radiation|conventional fractionated radiotherapy|35 daily fractions, 5 times per week
79859566|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
79859567|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
79859568|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
79859569|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
79859570|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
80031703|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
80031704|NCT04886362|Drug|Ivermectin|Treatment with Ivermectin in the first 7 days from symptoms onset.
80031705|NCT04886362|Drug|Placebo|Treatment with Placebo in the first 7 days from symptoms onset.
79264394|NCT02114021|Drug|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
79399373|NCT01204905|Drug|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, ~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, ~12 hours (10 to 14 hours) apart"
79563393|NCT01699113|Drug|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~YF476 100 mg; or~rabeprazole 20 mg; or~a combination of YF476 100 mg and rabeprazole 20 mg."
79563394|NCT01699113|Drug|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~YF476 100 mg; or~rabeprazole 20 mg; or~a combination of YF476 100 mg and rabeprazole 20 mg."
79563395|NCT01699126|Device|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
79563396|NCT01699126|Drug|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
79563397|NCT01699139|Device|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
80031706|NCT02050035|Other|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
79725276|NCT04321915|Other|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
79725277|NCT04301349|Drug|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
79725278|NCT04301349|Drug|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
79859571|NCT05358431|Other|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
79859572|NCT05357586|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
79859573|NCT05356117|Behavioral|Resistance Training (RT) and Protein Supplementation (PS)|Aerobic and resistance exercise with orally consumed pre-packed protein supplement
79859574|NCT05356117|Behavioral|Resistance Training (RT)|Aerobic and resistance exercise
79859575|NCT05356117|Behavioral|Attention Control (AC|Stretching
79859576|NCT05355454|Device|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
79563398|NCT01699139|Device|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
79563399|NCT01699152|Drug|TG02 citrate|TG02 citrate capsules
79563400|NCT01699165|Device|Nasal filter|Active nasal filter
79563401|NCT01699165|Device|Placebo nasal filter|Placebo nasal filter
79725279|NCT04301349|Drug|placebo|two tablets of placebo given 3 hours prior to IUD insertion
79725280|NCT02753647|Drug|Rituximab|
79725281|NCT02753647|Drug|Cyclophosphamide|
79725282|NCT02753647|Drug|Doxorubicin|
79725283|NCT02753647|Drug|Vincristine|
79725284|NCT02753647|Drug|Prednisone|
79725285|NCT02753647|Drug|Chidamide|
79725286|NCT02872389|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
79725287|NCT02872389|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
79725288|NCT02760199|Drug|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
79725289|NCT02760199|Device|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
79725290|NCT02695927|Device|Computer rehabilitation glasses|
79875815|NCT00462384|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
79875816|NCT00452400|Drug|BI 1744CL|
79875817|NCT00462306|Procedure|Survey: Berlin questionnaire|Completion of questionnaire
79264395|NCT04826822|Drug|Spironolactone + Dexamethasone|Low doses of orally administered spironolactone and dexamethasone
79264396|NCT04826822|Drug|Standard-of-care SARS-CoV-2 treatment|Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
79264397|NCT02251457|Drug|Ranolazine|Ranexa is FDA approved for chronic angina
79399374|NCT03137940|Device|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
79399375|NCT03137940|Device|sham tDCS|one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
79399376|NCT03137706|Procedure|Biospecimen Collection|Undergo fresh tumor tissue collection
79399377|NCT03137706|Other|Laboratory Biomarker Analysis|Correlative studies
79875818|NCT00461682|Drug|SB-705498|
79875819|NCT03776370|Procedure|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
79875820|NCT03776370|Procedure|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
79563402|NCT01699191|Dietary Supplement|Probiotic|
79859577|NCT05355454|Device|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
79264398|NCT04835246|Device|Spectra IMDx system|The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
79563403|NCT01699191|Dietary Supplement|Placebo|
79563404|NCT01699204|Dietary Supplement|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
79563405|NCT01699204|Other|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
79563406|NCT01699204|Other|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
79563407|NCT01699230|Dietary Supplement|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
79264399|NCT02112149|Behavioral|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
79563408|NCT01699256|Behavioral|Guideline implementation as usual|Newsletters and Invitation to Meetings
79563409|NCT01699256|Behavioral|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
79264400|NCT03553511|Procedure|Vaginal vault suspension to the uterosacral ligaments|Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments
79264401|NCT03553511|Procedure|McCall culdoplasty|Vaginal hysterectomy with McCall culdoplasty
79725291|NCT04307251|Device|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
79725292|NCT04307251|Device|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
79725293|NCT01030965|Drug|GSK573719 125mcg|125mcg once-daily
79264402|NCT02112227|Other|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
79264403|NCT02112305|Drug|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
79264404|NCT02112305|Drug|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
79399378|NCT03137706|Other|Laboratory Procedure|Tissue stiffness and cell viability analysis
79399379|NCT00691665|Drug|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
79399380|NCT00691665|Drug|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
79563410|NCT01699269|Other|peritumoral glial cell infiltration|
79563411|NCT01699282|Behavioral|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
79563412|NCT01699282|Behavioral|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
79563413|NCT01699295|Behavioral|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
79725294|NCT01030965|Drug|GSK573719 250mcg|250mcg once-daily
79725295|NCT01030965|Drug|GSK573719 500mcg|500mcg once-daily
79725296|NCT01030965|Drug|Placebo|once-daily
79875821|NCT01566474|Drug|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
79875822|NCT01566474|Drug|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
79399381|NCT01388335|Drug|warfarin|Administered orally
79399382|NCT01388335|Drug|enzastaurin|Administered orally
79399383|NCT03402282|Procedure|embolization|upper rectal artery embolization with coils
79399384|NCT03402282|Procedure|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
79399385|NCT00713583|Drug|levodopa|800mg levodopa and 200mg carbidopa per day
79875823|NCT01025778|Drug|Clofarabine for remission induction|
79875824|NCT01025778|Drug|Etoposide for remission induction|
79875825|NCT01025778|Drug|Cyclophosphamide for remission induction|
79859578|NCT05353296|Behavioral|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
80021548|NCT03670446|Other|Pharmacists' intervention|"Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~Establish a medical record and remind their follow-up by message, phone every 2 weeks.~Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months."
79563414|NCT01699295|Behavioral|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
80021549|NCT02643394|Drug|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
80021550|NCT02643394|Drug|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
79264405|NCT02112383|Behavioral|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
79264406|NCT02112383|Behavioral|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
79264407|NCT02109575|Diagnostic Test|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
79264408|NCT02112461|Behavioral|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
79264409|NCT02114099|Drug|Atorvastatin|10 mg qd x1 year
79264410|NCT02114255|Other|Placebo|Administration of 0.9% NaCl.
79563415|NCT01699308|Drug|Genotropin|
79563416|NCT01699321|Behavioral|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
79264411|NCT02114255|Biological|BCG|Vaccination with the live attenuated BCG vaccine.
79264412|NCT02251223|Drug|Tipranavir low dose|
79725297|NCT02753179|Other|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
79725298|NCT02753179|Other|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
79563417|NCT01699321|Other|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
79563418|NCT01699334|Behavioral|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
79581265|NCT01934634|Drug|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
79264413|NCT02251223|Drug|Tipranavir medium dose|
79264414|NCT02251223|Drug|Tipranavir high dose|
79264415|NCT02251223|Drug|Ritonavir low dose|
79264416|NCT02251223|Drug|Ritonavir high dose|
79264417|NCT02112539|Other|platelet aggregation measurement|
79264418|NCT02109653|Drug|LGX818|Oral LGX818 300mg daily
79264419|NCT02114333|Biological|Zostavax|0.65ml, subcutaneous
79264420|NCT02114333|Biological|HZ/su vaccine|0.5ml, intramuscular
79264421|NCT02114333|Biological|Placebo|0.65ml, subcutaneous
79399386|NCT00713583|Drug|Placebo|Placebo
79399387|NCT00713583|Behavioral|Cognitive Behavioral Therapy|Participants received individual cognitive behavioral therapy (CBT) in 50-minute weekly sessions. These sessions were manual-driven and based on the relapse prevention model proposed by Marlatt and Gordon (1985). Trained masters-level therapists, under the supervision of senior therapists and the principal investigator, worked with participants to teach them how to recognize and cope with risky situations that could influence their cocaine use through self-monitoring of situational craving and drug use stimuli, coping skills training, and lifestyle modifications.
79264422|NCT02114411|Procedure|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
79859579|NCT05353296|Behavioral|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
79859580|NCT05353296|Device|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
79563419|NCT01699334|Other|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
79563420|NCT01699347|Drug|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
79725299|NCT02753179|Other|VEMPs & VEMPo|VEMPs & VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
79725300|NCT02753179|Other|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
79725301|NCT02753179|Other|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
79725302|NCT02753257|Other|Non-Interventional|Non-Interventional
79859581|NCT05350072|Biological|VAY736|ianalumab s.c.
79859582|NCT05350072|Other|Placebo|placebo s.c.
79563421|NCT01699360|Drug|Cyclosporine A, Tacrolimus, Sirolimus|
79563422|NCT01699386|Other|Control Study Formula|feed as lib
79859583|NCT05349422|Behavioral|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
79264423|NCT02114411|Procedure|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
79264424|NCT02114489|Drug|ibandronate|Unique perfusion of ibandronate 3 mg IV
79264425|NCT02114489|Drug|Placebo|
79563423|NCT01699386|Other|Experimental Study Formula|feed as lib
79563424|NCT01699399|Procedure|water immersion|
79563425|NCT01699399|Procedure|water exchange|
79563426|NCT01699399|Procedure|air insufflation|
79563427|NCT01699412|Drug|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
79563428|NCT01699412|Drug|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
79563429|NCT01699425|Device|Ajust sling|
79563430|NCT01699425|Device|Classical transobturator sling|Control group
79563431|NCT01699438|Drug|Mesalazine|2400 mg q.d. for 8 weeks
79859587|NCT05347927|Device|water resistante padding|"Delta-Dry® Softliner~Tensoban®~Delta-Dry®"
79859588|NCT05347927|Device|non water resistante padding|"Delta-Net® Stockinette~Delta-Rol®"
79859589|NCT05347446|Procedure|Hybrid ESD|Method of removing colon lesion
79264426|NCT02114567|Other|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
79264427|NCT02114645|Drug|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
79264428|NCT02114645|Drug|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
79264429|NCT02114645|Drug|4 mg oral estradiol valerate|estrofem is given twice a day
79563432|NCT01699438|Drug|Placebo|3 tablets q.d. for 8 weeks
79563433|NCT01699477|Device|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
79563434|NCT01699490|Drug|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
79563435|NCT01699490|Drug|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
79563436|NCT01699529|Device|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
79563437|NCT01699555|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
79563438|NCT01699555|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
79725303|NCT02752867|Drug|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
79859590|NCT05347446|Procedure|Non-hybrid ESD|Method of removing colon lesion
79859591|NCT05346042|Other|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
79859592|NCT05330975|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79859593|NCT05330975|Biological|mRNA-1345|Sterile liquid for injection
79859594|NCT05330975|Biological|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
79859595|NCT05330975|Biological|mRNA-1273.214|Sterile liquid for injection
79859596|NCT05329649|Biological|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
80021551|NCT02143674|Other|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
79725304|NCT02752867|Other|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
79725305|NCT01179516|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
80021552|NCT02143674|Other|Educated about physical exercises|
79264430|NCT02114723|Device|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
79264431|NCT02112617|Radiation|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
79264432|NCT02112695|Other|[11C]diprenorphine|3 micrograms [11C]diprenorphine - intravenous use - 1 time
79264433|NCT02251301|Dietary Supplement|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
79264434|NCT02251301|Behavioral|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
79563439|NCT01699568|Device|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
79563440|NCT01699581|Dietary Supplement|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
79563441|NCT01699594|Drug|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
79563442|NCT01699594|Drug|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
79563443|NCT01699620|Procedure|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
79859597|NCT05326477|Behavioral|Behavioral weight loss treatment|The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
79875826|NCT01025778|Drug|Clofarabine in conditioning before transplantation|
79875827|NCT01025778|Drug|Thiotepa in conditioning before transplantation|
79264435|NCT02251301|Other|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
79264436|NCT02251301|Dietary Supplement|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
79264437|NCT02114801|Device|manual brushing|Tooth brushing
79264438|NCT02114801|Device|electric toothbrush linked|Tooth brushing
79264439|NCT02114801|Device|off electric toothbrush|Tooth brushing
79264440|NCT04834856|Drug|ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
79264441|NCT04823624|Drug|MBG453|intravenous infusion
79563444|NCT01699646|Device|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
79563445|NCT01699646|Procedure|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
79725306|NCT01179516|Drug|Placebo|Vortioxetine placebo-matching capsules
79725307|NCT02752945|Other|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
79725308|NCT02752945|Other|Usual care|Usual care afforded by local CAMHS services
79725309|NCT01018953|Drug|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
79725310|NCT04219657|Biological|mesenchymal stem cell application|
79725311|NCT04315740|Other|Particles from candles|Generating fine and ultrafine particles from lit candles
79875828|NCT01025778|Drug|Melfalan in conditioning before transplantation|
79875829|NCT01025778|Procedure|Haploidentical transplantation of T-cell depleted graft|
79875830|NCT01025778|Procedure|Donor lymphocyte infusion|
79563446|NCT01699659|Other|allergen immunotherapy|allergy shots
79875831|NCT00443430|Drug|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
79875832|NCT00443430|Drug|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
80021553|NCT02308904|Other|Blood Draw/Semen Exam|"Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
79859598|NCT05326386|Behavioral|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
79875833|NCT01022658|Drug|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
80021554|NCT02308904|Other|Retrospective data/Chart Review/Relevant Clinical Results|"1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2* MRI. 4. Ferritin levels.~NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
80021555|NCT02308904|Other|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
79399388|NCT00713583|Behavioral|Contingency Management|An abstinence-based contingency management (CM) procedure was used. Participants earned vouchers according to the reward schedule recommended by Budney and Higgins (1998), beginning at $2.50 for the first cocaine-negative urine. For each consecutive cocaine-negative urine, voucher values increased by $1.25 with a $10 bonus given for provision of three consecutive cocaine-negative urines within a week. A cocaine-positive urine or failure to provide a scheduled urine sample resulted in a reset of the schedule to the initial value of $2.50. After provision of five negative urines, the voucher returned to the value prior to the reset. Participants were able to redeem their vouchers for small amounts of cash (≤$25) or gift cards for goods and services.
79264442|NCT04823546|Other|activity based therapy|Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;
79563447|NCT01699672|Other|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
79264443|NCT04823546|Other|Strength Training|Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
79264444|NCT04361162|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
79264445|NCT04361162|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
79399389|NCT03359460|Drug|Ibrutinib|Given PO
79264446|NCT04361162|Radiation|Radiation|3D Conformal Radiotherapy to shrink or kill tumors
79264447|NCT04826978|Behavioral|Auditory environment|Auditory environment
79399390|NCT03359460|Drug|Lenalidomide|Given PO
79563448|NCT01699711|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
79563449|NCT01699724|Drug|JZoloft|50 mg tablet on Day 1 of each period
79875834|NCT01025856|Other|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
79875835|NCT01025856|Other|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
79875836|NCT01025856|Other|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
79875837|NCT01025856|Other|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
79875838|NCT01022736|Drug|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
79725312|NCT04315740|Other|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
79725313|NCT04315740|Other|Clean Air|Nothing but clean air
79399391|NCT03025243|Device|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
79563450|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
79563451|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
79399392|NCT00692211|Other|Mailed fecal occult blood tests|Stool blood test
79563452|NCT01699776|Drug|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
79399393|NCT00692211|Other|Mailed fecal immunochemical tests|Stool blood test
79725314|NCT04314024|Drug|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
79725315|NCT00635791|Drug|Sorafenib|Given by mouth
79725316|NCT00635791|Drug|Vorinostat|Given by mouth
79859599|NCT05321459|Other|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
79725317|NCT04219501|Other|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
79859600|NCT05319015|Drug|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
79859601|NCT05319015|Drug|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
79264448|NCT03036878|Other|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
79264449|NCT04835012|Other|Medical debt forgiveness|A non-profit charity, RIP Medical Debt, bought and retired medical debt for individuals that were assigned to the treatment group.
79399394|NCT03025477|Drug|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
79399395|NCT03025477|Drug|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
79725318|NCT02753023|Other|no intervention|No intervention related
79725319|NCT01158924|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
79725320|NCT02760121|Drug|Acetazolamide|
79859602|NCT05319015|Procedure|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
79399396|NCT03025477|Drug|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"carboplatin (IV) - paclitaxel (IV) (3 cycles)~Interval surgery~Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
79399397|NCT03025477|Drug|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"Cisplatin (IV) - Epirubicin (IV) (3 cycles)~Interval surgery :~if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~if CC>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
79563453|NCT01699776|Drug|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
79563454|NCT01699802|Other|Inhaled anaesthetic agent|
79563455|NCT01699828|Drug|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
79859603|NCT05319015|Drug|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
79563456|NCT01699828|Drug|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
79563457|NCT01699854|Drug|capsaicin patch (qutenza)|
79859604|NCT05317416|Drug|Elranatamab|BCMA-CD3 bispecific antibody
79859605|NCT05317416|Drug|Lenalidomide|Immunomodulatory drug
79859606|NCT05317416|Drug|Lenalidomide|Immunomodulatory drug
79264450|NCT04835090|Other|screening test|using three screening tools
79264451|NCT04823390|Drug|Midazolam-Fentanyl combination|Sedation is given to patients undergoing cataract surgery under local anesthesia
79264452|NCT04823234|Diagnostic Test|Lung ultrasound|Lung ultrasound signs in Covid 19 positive pregnant patients
79264453|NCT02302066|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
79563458|NCT01699854|Drug|Placebo|
79563459|NCT01699893|Other|unique arm|blood, nasal swab, skin biopsy, stool samples
79563460|NCT01699906|Other|Diet regimen to induce weight loss|Diet regimen to induce weight loss
79725321|NCT02760121|Drug|Methazolamide|
79725322|NCT02760121|Drug|Placebo|
79859607|NCT05317416|Drug|Elranatamab|BCMA-CD3 bispecific antibody
79859608|NCT05315349|Other|Complete ophthalmological check-up|Preoperatively, 3 to 7 days after surgery and 1 to 2 months after surgery: fundus, optical coherence tomography angiography (OCT-A)
79859609|NCT05315349|Biological|Blood sampling|Preoperatively and on Day 1 of surgery: 6 tubes of approximately 5 ml each, i.e. 30 ml
79859610|NCT05315297|Device|PEMF device|PEMF device wear overnight daily for four weeks
79859611|NCT05315297|Device|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
79859612|NCT05312970|Drug|Varithena®|Varithena® (polidocanol injectable foam) 1%
80021556|NCT03545646|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
80021557|NCT03101644|Drug|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
80021558|NCT03115918|Device|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
80021559|NCT03115918|Other|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
79859613|NCT05312970|Device|FDA-approved Endothermal Ablation (ETA) systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
80021560|NCT03508466|Behavioral|hypersensitivity reaction|Previous hypersensitivity reaction
80021561|NCT03545100|Other|motor control therapy|scapular muscle progressive resistive exercise(PRE)
79563461|NCT01699919|Drug|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
79859614|NCT05312892|Drug|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
79859615|NCT05312892|Drug|Moxonidine|Moxonidine
79563462|NCT01699932|Drug|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
79859616|NCT05312892|Drug|Placebo|Placebo
79563463|NCT01699945|Other|This is an observational study being conducted as a substudy of antoher trial.|
79563464|NCT01699958|Behavioral|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
79563465|NCT01699971|Procedure|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
80021562|NCT03545100|Other|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
80021563|NCT03132272|Device|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
79859617|NCT05312164|Device|HF-OCT Imaging|Subjects undergo HF-OCT imaging of stenosed coronary arteries
79859618|NCT05312164|Device|FFR Pressure Wire|Subjects undergo FFR physiology assessment of stenosed coronary arteries
79859619|NCT05312164|Device|Angiography|Subjects undergo angiography imaging of stenosed coronary arteries
79859620|NCT05310422|Drug|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
80021564|NCT03627234|Behavioral|Same Day Discharge|Patients will be randomized to same day discharge
80021565|NCT03627234|Behavioral|Overnight Stay|Patients will be randomized to stay overnight
80021566|NCT02305706|Procedure|starting position in colonoscopy|
79563466|NCT01699971|Procedure|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
79563467|NCT01699971|Procedure|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
79725323|NCT05218447|Device|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
80021567|NCT02623309|Biological|Allogeneic (Allo) hematopoietic stem cell transplantation|
80021568|NCT05068804|Procedure|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
79563468|NCT01699997|Drug|Oxytocin|Intranasal spray with 40 IU of OXT
79563469|NCT01699997|Drug|Placebo|Intranasal spray with placebo solution
79581266|NCT01934634|Drug|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
79581267|NCT01934673|Other|No treatment given|Patients will fill out a questionnaire by interview.
79581268|NCT01934686|Other|No treatment given|Patients will fill out a questionnaire by interview.
79859621|NCT05310422|Drug|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
79859622|NCT05310279|Other|GAIMplank|The GAIMplank video game controller will be used to play active video games.
79859623|NCT05309642|Behavioral|Intermittent calorie restriction|Recipes will be provided with suggestions of meals that would not exceed the calorie restriction. For the remaining 5 days of the week, they will receive instructions and recipes that follows the Korean Dietary Reference Intakes (KDRIs), with an intake limit of 2,000 kcal/day for women and 2,500 kcal/day for men. The percentage of energy (E%) from different macronutrients in the recipes will be 45-60 E% carbohydrates, 25 E% fat and 10-20 E% protein.
79875839|NCT01022814|Device|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
79875840|NCT01025934|Drug|Bevacizumab|
79875841|NCT01025934|Other|sham|
79875842|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training.
79875843|NCT01026090|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
79875844|NCT01026090|Drug|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
79875845|NCT01028040|Drug|AZD3043|Intravenous, single dose
79875846|NCT01028040|Drug|AZD3043|Infusion, single dose
80021569|NCT05068804|Other|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
79859624|NCT05309642|Behavioral|Standard of care|They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
79859625|NCT05306756|Diagnostic Test|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
79859626|NCT05306756|Diagnostic Test|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
79859627|NCT05305846|Device|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
79859628|NCT05305820|Behavioral|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
79859629|NCT05305820|Behavioral|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
80021570|NCT03545022|Procedure|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
79264454|NCT02302066|Biological|TDV Placebo|Placebo-matching vaccine
79264455|NCT04834700|Other|online group|In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.
79264456|NCT04834544|Combination Product|DCVAC/OvCa|An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines
79563470|NCT01700010|Drug|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
79563471|NCT01700062|Dietary Supplement|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
79875847|NCT01028118|Other|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
79875848|NCT03891654|Diagnostic Test|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
79875849|NCT00460746|Drug|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
79264457|NCT04834544|Combination Product|Placebo|Placebo
79264458|NCT04823000|Biological|Mesenchymal Stem Cells (MSC)|Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
79264459|NCT04823312|Device|Experimental prospective single arm evaluating the Medtronic Duo Extended Set|Subjects will be using 4 Duo extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
79264460|NCT04823078|Other|Activity base therapy|"activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching."
79264461|NCT04823078|Other|Strength training|Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
79264462|NCT04822922|Genetic|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4*10^5 cells/kg/each time, and medium dose: 8*10^5 cells/kg/each time, high dose 12*10^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
79264463|NCT04826510|Drug|Perospirone hydrochloride tablets|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
79264464|NCT04826510|Drug|Lithium carbonate + perospirone hydrochloride|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
79264465|NCT04826510|Drug|Lithium Carbonate Pill|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
79264466|NCT04834466|Behavioral|Pain Level experience during orthodontic treatment|A questionnaire was given to patients who have started their orthodontic treatment to assess their pain level experience
79875850|NCT01026246|Drug|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
79264467|NCT04834232|Device|compression therapy|compression bandaging or graduated compression hosiery consists of applying a type of elastic device, mainly on the limbs, to exert a controlled pressure on the lower limbs. The controlled pressure exerted by medical compression stockings reduces the diameter of major veins, thereby increasing the velocity and volume of blood flow, along with conditions beneficial for the healing of chronic inflammatory disorders (e.g. cellulitis, erysipelas, venous leg ulcers, etc.), through reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokines.
79725324|NCT05218447|Other|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
79859630|NCT05304975|Behavioral|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
80021571|NCT05068180|Drug|low-dose neuroleptanalgesia|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
80021572|NCT05068180|Drug|Placebo|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
79399398|NCT03356652|Procedure|Noninvasive electrical dyssynchrony study|"Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations."
80021573|NCT02143908|Dietary Supplement|lysine supplementation|
80021574|NCT02143908|Dietary Supplement|Placebo|
79264468|NCT04834232|Procedure|iliac vein stenting|using x-ray guidance (fluoroscopy) to place a an expandable metal mesh tube against the vein walls, acting as a scaffold to keep the veins open and improve blood flow
79264469|NCT05618288|Behavioral|mobile Health Breastfeeding Counseling|a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.
79264470|NCT05618288|Behavioral|Standard of care breastfeeding counseling|The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
79563472|NCT01700075|Drug|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
80021575|NCT02847364|Dietary Supplement|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
79264471|NCT04833998|Drug|Extremecare|The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
79399399|NCT05391594|Device|customized posture support|We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
79399400|NCT03025321|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
79563473|NCT01700075|Dietary Supplement|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
79563474|NCT01700114|Device|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
79563475|NCT01700127|Other|Breastfeeding|breastfeeding encouraged versus withheld
79563476|NCT01700153|Other|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
79563477|NCT01700153|Other|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
79563478|NCT01700166|Biological|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
79563479|NCT01700218|Other|telemonitoring|
80021576|NCT02308982|Drug|Immunoglobulins, Intravenous (Privigen)|
80021577|NCT02308982|Drug|Placebo|
79563480|NCT01700218|Other|control|
79563481|NCT01700231|Procedure|Liver resection|Liver resection of patient with neoplastic hepatic tumors
79563482|NCT01700244|Device|Pacemaker implant|
79563483|NCT01700257|Radiation|CT scan & Early CDT Lung test|
79725325|NCT00635869|Behavioral|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
79399401|NCT03147378|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
79859631|NCT05304975|Behavioral|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
80021578|NCT05515627|Drug|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
79264472|NCT04833998|Drug|Placebo|Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
79264473|NCT03036800|Drug|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
79264474|NCT03036800|Other|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
79563484|NCT01700257|Other|CT scan & Early CDT Lung test|
79264475|NCT02301988|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
79264476|NCT02301988|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.
80021579|NCT03503708|Drug|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
79264477|NCT02301988|Drug|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
79264478|NCT02114957|Dietary Supplement|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
79264479|NCT04326920|Drug|Sargramostim|Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
79264480|NCT04326920|Other|Control|Standard of care
79563485|NCT01700270|Drug|dovitinib (TKI258)|
80021580|NCT02144064|Drug|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
79563486|NCT01700270|Drug|fluvoxamine|perpetrator drug; 7 days of dosing
79563487|NCT01700283|Behavioral|exercise education and walking program|12-week moderate intensity walking program
79581269|NCT01934699|Device|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
79725326|NCT00635869|Behavioral|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
79264481|NCT02112851|Other|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
79264482|NCT05369884|Drug|WPQW granule|WPQW granule, 2 sachets / time, 3 times / day.
79264483|NCT05369884|Drug|WPQW granule simulant|WPQW granule simulant, 2 sachets / time, 3 times / day.
79399402|NCT04466137|Drug|YPEG-rhG-CSF|YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
79399403|NCT04466137|Drug|YPEG-rhG-CSF|YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
79399404|NCT04466137|Drug|rhG-CSF/PEG-rhG-CSF|rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
79399405|NCT00713661|Drug|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
79399406|NCT00159744|Drug|Asenapine|Asenapine, 3 weeks
79399407|NCT00159744|Drug|Olanzapine|Olanzapine, 3 weeks
79399408|NCT00159744|Drug|Placebo|placebo, 3 weeks
79399409|NCT04041973|Drug|Artemether-lumefantrine|"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
79581270|NCT01934699|Device|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
79725327|NCT00635869|Behavioral|Placebo|didactic education sessions on physical assessment
79725328|NCT05215873|Drug|Misoprostol|a synthetic prostaglandin E1 analogue
79725329|NCT05215873|Drug|Syntocinon|synthetic oxytocin
79725330|NCT02759887|Procedure|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
79725331|NCT02759887|Other|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
79563488|NCT01700296|Behavioral|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
79859632|NCT05304975|Behavioral|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
79725332|NCT02759887|Other|caregiver questionnaire|
79725333|NCT02759887|Procedure|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
79725334|NCT02759887|Procedure|MRI|Magnetic resonance imaging of the head and brain.
79725335|NCT02759887|Procedure|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
79859633|NCT05304975|Other|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
79859634|NCT05296902|Device|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
79859635|NCT05296889|Device|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
79859636|NCT05296707|Other|Inspiratory muscle training|"The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day."
80021581|NCT02312648|Other|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
80021582|NCT02312648|Other|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
80021583|NCT02090530|Other|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
80021584|NCT02144142|Biological|Moisturizer with each subject's own antimicrobial bacteria|
80021585|NCT02309060|Behavioral|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
80021586|NCT03101098|Procedure|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
79581271|NCT01934712|Drug|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
79581272|NCT01934712|Drug|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
79725336|NCT02759887|Procedure|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
79725337|NCT02759887|Procedure|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
79725338|NCT02750917|Drug|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
79725339|NCT02750917|Drug|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
79725340|NCT02750839|Procedure|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
79725341|NCT02759809|Other|Pasteurized donor human breastmilk|
79725342|NCT02759809|Other|Preterm formula|
79725343|NCT02750995|Biological|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
79563489|NCT01700309|Behavioral|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
79563490|NCT01700322|Procedure|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
79563491|NCT01700322|Drug|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
80021587|NCT03101098|Procedure|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
79563492|NCT01700322|Drug|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
79859637|NCT05296707|Other|Used routine medicine|After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
79859638|NCT05296707|Other|Control group|A healthy child compatible with the age and sex of the patient group was evaluated once.
79264484|NCT02118779|Behavioral|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
79563493|NCT01700322|Drug|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
79264485|NCT04825808|Other|usual care|according to recommendations
79859639|NCT05295498|Device|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
80021588|NCT02447120|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
80021589|NCT05067322|Device|Minecraft|A game played within the videogame Minecraft
80021590|NCT02254356|Device|Zilver Flex Bare Metal Stent|
79264486|NCT02112929|Drug|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
79264487|NCT04826120|Procedure|PCEA Infusion|Patients of this group Had PCEA during the second stage of labor
79563494|NCT01700400|Drug|Everolimus|
79264488|NCT04826120|Procedure|Continuous epidural infusion|Patients of this group Had continuous epidural infusion during the second stage of labor
79264489|NCT02334748|Drug|canakinumab|canakinumab
79563495|NCT01700400|Drug|Pemetrexed|
79264490|NCT03553355|Device|Infrared Laser Moxibustion|We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
79563496|NCT01700400|Drug|Carboplatin|
79859640|NCT05295498|Device|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
79859641|NCT05294276|Other|no intervention related|no intervention related
79264491|NCT03553355|Device|Sham Infrared Laser Moxibustion|The sham laser moxibustion instrument appears to be identical as the real one.
79399410|NCT04041973|Dietary Supplement|Multivitamin|"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
79563497|NCT01700400|Drug|Bevacizumab|
79563498|NCT01700413|Drug|Idarubicin|
79563499|NCT01700426|Drug|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
79563500|NCT01700426|Other|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
79563501|NCT01700478|Drug|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
79563502|NCT01700478|Drug|Vasopressin|Vasopressin was used in all patients during surgery.
79563503|NCT01700491|Drug|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
79563504|NCT01700491|Drug|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
79563505|NCT01700504|Drug|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
79859642|NCT05288062|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
79859643|NCT05288062|Drug|Dexamethasone|Given orally
80021591|NCT01405066|Behavioral|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
79264492|NCT04825418|Device|Artic Sun|"Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃"
79859644|NCT05288062|Drug|Lenalidomide|Given orally
79264493|NCT04308122|Device|Cervical Orthosis (CO)|Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.
79264494|NCT04308122|Device|No Orthosis|The NO group will have no specific precautions applied to their neck range of motion.
79563506|NCT01700556|Other|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
79563507|NCT01700556|Other|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
79563508|NCT01700556|Other|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
79859645|NCT05288062|Drug|Pomalidomide|Given orally
79859646|NCT05283226|Drug|NRC-2694-A|300 mg orally once daily
79859647|NCT05283226|Drug|Paclitaxel|175 mg/m² IV infusion over approximately 3 hours
79859648|NCT05280314|Drug|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
79859649|NCT05280314|Drug|Pembrolizumab KEYTRUDA®|Pembrolizumab KEYTRUDA® administered intravenously
79859650|NCT05275231|Behavioral|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
79859651|NCT05273151|Device|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
79264495|NCT02118857|Other|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
79264496|NCT02118935|Other|Previously marketed cow's mlik-based infant formula|
79264497|NCT02118935|Other|Marketed cow's milk-based infant formula with prebiotics|
79725344|NCT02750995|Drug|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
79725345|NCT01027845|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
79725346|NCT01027845|Biological|DTPa|Subcutaneous injection, 4 doses
79725347|NCT04219345|Device|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
79725348|NCT05113225|Procedure|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
79859652|NCT05268445|Procedure|Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis|Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
79859653|NCT05266638|Other|Data collection (radiological parameters, outcome information) from electronic patient files in hospital data system|Collection of medical data and medical images (MRI, radiographs) of the lumbar spine and pelvis of patients having received TLIF with degenerative spinal diseases from the years 2015-2020 and statistical analysis of the coded data.
79859654|NCT05265728|Drug|Natalizumab|Administered as specified in the treatment arm
79859655|NCT05264623|Device|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
79859656|NCT05261984|Procedure|Resistance exercise|Knee extensions in flywheel inertia machine in four sets of 10 repetitions.
79859657|NCT05261984|Dietary Supplement|Oral protein supplementation|24 grams of hydrolyzed whey protein.
79264498|NCT04822532|Genetic|GSTA1 genotyping|Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene
79264499|NCT02113085|Behavioral|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
79264500|NCT02119013|Drug|Octeotride|
79264501|NCT02119013|Drug|Placebo|
79264502|NCT02119091|Drug|Moxifloxacin|
79264503|NCT02332876|Behavioral|Exercise|
79264504|NCT02332876|Behavioral|Control|
79264505|NCT02115035|Drug|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
79264506|NCT05618522|Procedure|vacuum-dehydrated amnion membrane (omnigen)|applying the lens loaded with Omnigen on the cornea
79563509|NCT01700556|Other|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
79563510|NCT01700595|Procedure|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
79264507|NCT05618522|Device|the lens loaded with Omnigen|the lens loaded with Omnigen
79264508|NCT02119169|Device|Pigtail catheter|pigtail catheter for pleural drainage
79563511|NCT01700608|Drug|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
79563512|NCT01700647|Other|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
79563513|NCT01700647|Other|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
79563514|NCT01700686|Other|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
79563515|NCT01700712|Dietary Supplement|Probiotic Lactobacilli reuteri|
79563516|NCT01700712|Dietary Supplement|Placebo|
79563517|NCT01700738|Procedure|gastric ring surgery|
79563518|NCT01700738|Other|nutritional help|
79563519|NCT01700751|Drug|brentuximab vedotin|
79563520|NCT01700777|Other|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
79563521|NCT01700790|Drug|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
79563522|NCT01700803|Drug|Povidone Iodine 10% vand cesarean section wound infections|
79563523|NCT01700803|Drug|Povidone Iodine 7.5% vand cesarean section wound infections|
79563524|NCT01700855|Procedure|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
79563525|NCT01700855|Procedure|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
79563526|NCT01700868|Other|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
79563527|NCT01700868|Other|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
79563528|NCT01700881|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
79563529|NCT01700881|Other|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
79563530|NCT01700894|Behavioral|Walking Program + Motivational Interviewing Calls|
79563531|NCT01700894|Behavioral|Walking Program + Automated Calls|
79563532|NCT01700894|Behavioral|Walking Program|
79563533|NCT01700920|Procedure|bone marrow aspirate|
79563534|NCT01700933|Other|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
79563535|NCT01700933|Other|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
79563536|NCT01700972|Procedure|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
79563537|NCT01700998|Drug|Magnesium|
79563538|NCT01700998|Drug|Placebo|
79563539|NCT01701050|Other|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
79563540|NCT01701076|Drug|Bendamustine|"Induction treatment phase (cycle 1-6):~Bendamustine 75 mg/m2 i.v day 1 and 2~Lenalidomide 25 mg p.o. day 1-21~Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~Lenalidomide 25 mg p.o. day 1-21~Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
79563541|NCT01701089|Drug|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
79563542|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for 14 days
79563543|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for up to 17 days
79563544|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
80021592|NCT01405066|Behavioral|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
79725349|NCT04221919|Drug|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
79725350|NCT04299633|Drug|Vadadustat|2 x 150 mg oral tablets
79859658|NCT05259033|Drug|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
80021593|NCT02309216|Other|Whol-Body MRI scan|
79264509|NCT03037034|Device|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
79264510|NCT03036722|Other|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
79264511|NCT03036722|Other|Placebo control porridge|control porridge matched for energy and fat content.
79264512|NCT02113319|Drug|dasatinib|dasatinib 50 mg and 20 mg During one year
79264513|NCT03036332|Behavioral|Aerobic interval training|Carried out 3 times per week for 16 weeks
79264514|NCT04822454|Other|Night shift shadowing program|Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
79264515|NCT02119247|Device|CHF 6001 dry powder for inhalation via NEXThaler®|
79264516|NCT02119247|Device|CHF 6001 DPI capsules for inhalation via Aerolizer|
79264517|NCT04822844|Other|Lavender Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
79264518|NCT04822844|Other|Ginger Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
79264519|NCT02113397|Drug|TOBI™ Podhaler™ 112 mg inhaled twice daily|
79264520|NCT02113397|Drug|Colistimethate 75 mg inhaled two times daily|
79859659|NCT05259033|Drug|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
80021594|NCT04475770|Other|Real Sustained Natural Apophyseal Glides (SNAGS)|"Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment."
80021595|NCT04475770|Other|Sham Sustained Natural Apophyseal Glides (SNAGS)|The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
79264521|NCT02332798|Drug|PF-04958242|Administered as specified in the treatment arm
79264522|NCT02332798|Drug|Placebo|Administered as specified in the treatment arm
79264523|NCT04833920|Device|transcranial dirrect current brain stimuation|tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
79264524|NCT04428242|Device|RHMS-RTM|Assessment of retinal thickness.
79264525|NCT04428242|Diagnostic Test|SD-OCT|Assessment of retinal structure.
79264526|NCT02790437|Drug|IdeS|One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.
79264527|NCT02790437|Procedure|Kidney transplantation|Performed following IdeS treatment
79581273|NCT01934738|Drug|PF-06273340|Tablets, 100 mg TID, 14 days
79264528|NCT03553433|Drug|Apremilast 30mg|Anti-psoriatic drug
79581274|NCT01934738|Drug|Placebo|Tablets, TID, 14 days
79581275|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
79581276|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
79581277|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
79581278|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
79581279|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
79581280|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
79581281|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
79581282|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
79581283|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
79581284|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
79725351|NCT04299633|Drug|Sevelamer carbonate|2 x 800 mg oral tablets
79725352|NCT04299633|Drug|Calcium acetate|2 x 667 mg oral gelcaps
80021596|NCT03538158|Behavioral|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
80021597|NCT03538158|Behavioral|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
80021598|NCT02305862|Drug|Rosuvastatin 5mg|drug intervention
80021599|NCT02305862|Drug|Rosuvastatin 20mg|drug intervention
80021600|NCT03101176|Drug|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
79563545|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
79725353|NCT04299633|Drug|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
80021601|NCT02305940|Drug|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
80021602|NCT02305940|Drug|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
79264529|NCT03553433|Drug|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
79264530|NCT02115425|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
79264531|NCT02115425|Other|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
79725354|NCT02695459|Drug|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
79725355|NCT04288713|Drug|Eculizumab|A distal complement inhibitor.
80021603|NCT03099460|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
80021604|NCT03099460|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
79725356|NCT02759497|Other|serum amyloid A level|serum amyloid A level (SAA)
79725357|NCT00627549|Procedure|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
79725358|NCT00627549|Procedure|Conventional surgery (anterior repair)|Anterior repair surgery
79725359|NCT04299789|Other|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
79725360|NCT04217863|Behavioral|GDP|Guided Disclosure Protocol
79563546|NCT01701128|Other|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
79563547|NCT01701180|Drug|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
80021605|NCT03099460|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
80021606|NCT03544554|Behavioral|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
80021607|NCT03099772|Behavioral|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
80021608|NCT02312804|Drug|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
80021609|NCT02312804|Drug|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
80021610|NCT02312804|Drug|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
79563548|NCT01701180|Drug|Placebo|
79563549|NCT01701206|Behavioral|HIV knowledge Intervention|
79725361|NCT02872233|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79725362|NCT02872233|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79725363|NCT04219423|Behavioral|Multimodal physical therapy|see description in arm/group description
79725364|NCT04599231|Diagnostic Test|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
79725365|NCT04219267|Behavioral|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
80021611|NCT03100630|Drug|RO7239361|Specified dose on specified days
80021612|NCT02306018|Device|EV1000™/volumeView™|
80021613|NCT03099616|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
79859660|NCT05257031|Drug|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
79859661|NCT05256069|Drug|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
79859662|NCT05256069|Drug|Placebo|Participants will receive a placebo in pill form.
79399411|NCT03125304|Other|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
79859666|NCT05255965|Diagnostic Test|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
79859667|NCT05255900|Drug|Metyrapone Capsules|Exposure to 24 weeks of treatment with metyrapone
79859668|NCT05255679|Device|Early FES|FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
79563550|NCT01701219|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
79563551|NCT01701232|Biological|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
79563552|NCT01701297|Drug|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
79563553|NCT01701297|Drug|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
79859669|NCT05255679|Device|Delayed FES|FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
79859670|NCT05252273|Other|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
79859671|NCT05248074|Other|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
79859672|NCT05248074|Drug|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
79859673|NCT05240898|Drug|KSQ-4279 Monotherapy (Dose Escalation and Expansion)|Administered orally in capsule
80021614|NCT03099616|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
80021615|NCT04463966|Drug|Tranexamic acid injection|1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
79563554|NCT01701297|Drug|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
79563555|NCT01701310|Drug|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
79563556|NCT01701310|Drug|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
79563557|NCT01701323|Biological|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
79563558|NCT01701323|Drug|Cytarabine|Given IV
79563559|NCT01701323|Drug|Filgrastim|Given SC or IV
79859674|NCT05240898|Drug|KSQ-4279 Combination Therapy (Dose Escalation and Expansion)|KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor) and combination with a platinum-based chemotherapy.
79859675|NCT05238142|Device|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
79859676|NCT05236595|Other|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
79859677|NCT05236062|Behavioral|Exercise|aerobic and resistance exercise
80021616|NCT00794248|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
80021617|NCT00794248|Drug|fexofenadine|Allegra 180 mg daily x 7 days
79399412|NCT01401361|Device|Treatment Arm|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
79399413|NCT01401283|Device|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
79563560|NCT01701323|Drug|Fludarabine Phosphate|Given IV
79563561|NCT01701336|Biological|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
79563562|NCT01701349|Drug|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
79563563|NCT01701349|Drug|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
79563564|NCT01701440|Device|Biofusionary Bebe|
79859678|NCT05236062|Behavioral|Attention control|stretching
79725366|NCT04219267|Behavioral|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
79725367|NCT01017549|Radiation|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
79859679|NCT05233774|Drug|Allogeneic MSC|An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
79859680|NCT05233774|Other|Placebo|Placebo
79859681|NCT05233189|Other|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
79859682|NCT05233189|Other|No intervention|Patients will be followed up until 18 months only
79859683|NCT05232825|Drug|Ocrelizumab IV|IV Injection
79859684|NCT05232825|Drug|Ocrelizumab SC|SC Injection
79859685|NCT05232825|Drug|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
79563565|NCT01701453|Drug|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
80021618|NCT04463732|Other|Loaded inspiratory muscle test and cardiopulmonary exercise test|This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
80031707|NCT04886206|Biological|DLI|the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.
79399414|NCT00693303|Behavioral|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
80031708|NCT02048007|Drug|Azithromycin|Biannual mass oral azithromycin to children
79563566|NCT01701466|Other|Aveeno cream|Twice a day
79563567|NCT01701466|Other|Flamazine cream|Twice a day, when there is dry desquamation
79859686|NCT05232825|Drug|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
79859687|NCT05232825|Drug|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
79859688|NCT05232825|Drug|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
79859689|NCT05231304|Procedure|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
80031709|NCT02048007|Drug|Placebo|Biannual mass oral placebo to children
80031710|NCT04881994|Drug|Finerenone (BAY94-8862)|Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
79859690|NCT05231304|Procedure|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
79399415|NCT02914470|Drug|carbplatin, cyclophophamide, atezolizumab|
79399416|NCT00694473|Device|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
79399417|NCT05383950|Device|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
79563568|NCT01701466|Other|NeoVIDERM cream|Three times a day
79563569|NCT01701479|Drug|ch14.18/CHO|
79859691|NCT05231304|Procedure|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
79859692|NCT05231304|Procedure|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
79563570|NCT01701479|Drug|Aldesleukin|
79563571|NCT01701479|Drug|Isotretinoin|
79563572|NCT01701492|Other|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
79563573|NCT01701492|Other|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
79563574|NCT01701518|Drug|Ozurdex|biodegradable 0.7mg dexamethasone implant
79725368|NCT00635947|Other|isotonic solution|1.5 L- during 2-4hours
79725369|NCT00635947|Other|water|1.5 L- during 2-4hours
79725370|NCT00635947|Other|water|200mL- during 2-4hours
79725371|NCT04299243|Device|Contact Lenses|Contact lenses for vision correction
79725372|NCT01030341|Device|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
79725373|NCT02750449|Drug|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
79725374|NCT02750449|Other|Untreated skin|This site is patched without treatment as control
79859693|NCT05224869|Device|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
79725375|NCT04301037|Procedure|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
79859694|NCT05224869|Procedure|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
79859695|NCT05224869|Procedure|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
79264532|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
80021619|NCT05066542|Behavioral|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
80021620|NCT05066542|Behavioral|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
79264533|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
79264534|NCT02115425|Other|add name here|
79563575|NCT01701531|Drug|RBCPF|
79563576|NCT01701544|Device|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
80021621|NCT02309450|Drug|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
80021622|NCT04475224|Drug|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
79563577|NCT01701557|Other|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
79563578|NCT01701557|Other|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
79563579|NCT01701583|Drug|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
79563580|NCT01701596|Procedure|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
79859696|NCT05224869|Radiation|Brachytherapy|one month after completing SBRT
80031711|NCT02048085|Drug|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
79859697|NCT05224869|Procedure|Post-implant dosimetry scan|one month after brachytherapy
79563581|NCT01701596|Procedure|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
79563582|NCT01701609|Behavioral|Cognitive Remediation Therapy|
79563583|NCT01701635|Behavioral|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
79563584|NCT01701635|Behavioral|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
79563585|NCT01701648|Other|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
79563586|NCT01701661|Procedure|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
79563587|NCT01701661|Other|conservative treatment|Compression stockings class II
79859698|NCT05223335|Drug|Clopidogrel|75 mg/day
79859699|NCT05223335|Drug|Prasugrel|60 mg bolus then 10 mg daily
79859700|NCT05223335|Drug|Tricagrelor|180 mg bolus then 90 mg twice daily
79859701|NCT05222789|Procedure|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
79859702|NCT05219799|Drug|Propranolol Hydrochloride|Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
79264535|NCT03553277|Other|transfluthrin|passive emanator with formulated transfluthrin
79859703|NCT05219799|Drug|Isoproterenol|Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
79563588|NCT01701700|Procedure|portable electronic magnifier|
79859704|NCT05219799|Drug|Phentolamine Mesylate|This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
79859705|NCT05219799|Drug|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
80021623|NCT05401201|Device|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
80021624|NCT05401201|Other|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
80021625|NCT03506126|Other|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
79859706|NCT05219591|Device|EPR|application of EPR technology during CPAP treatment
79859707|NCT05219513|Drug|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
79859708|NCT05219513|Drug|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
79859709|NCT05219513|Drug|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
79859710|NCT05219513|Drug|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
80021626|NCT05066620|Drug|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
80021627|NCT02309528|Other|Educational computerized digital stories|computerized digital stories made by American Indians
79264536|NCT03553277|Other|placebo|passive emanator with formulated inert ingredients
79399418|NCT03137628|Other|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance [sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
80021628|NCT03498781|Other|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
80021629|NCT03498781|Other|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
80021630|NCT05066152|Dietary Supplement|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
79264537|NCT02119403|Other|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
79264538|NCT02119481|Behavioral|Mindfulness-based stress reduction|
79264539|NCT02119481|Behavioral|Expressive writing condition|
79264540|NCT02119559|Other|Blood analysis by EPISPOT and CellSearch®|
79563589|NCT01701700|Procedure|optical aids|
79563590|NCT01701713|Device|DKI ED2011|
79264541|NCT02604212|Drug|ARC-520|
79264542|NCT02604212|Other|Placebo|
79264543|NCT02604212|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
79264544|NCT02604212|Drug|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
79264545|NCT02604212|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
79563591|NCT01701713|Device|Sham-TDCS|
79859711|NCT05218655|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
79859712|NCT05217927|Drug|Rimegepant 75mg daily dosing|Daily
79859713|NCT05217927|Drug|Rimegepant 75mg every other day dosing|Every other day
79859714|NCT05217927|Drug|Placebo comparator dosing|Placebo comparator
79859715|NCT05216406|Dietary Supplement|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
79859716|NCT05216406|Other|Placebo|Maltodextrin capsule
79859717|NCT05215756|Device|transcutaneous vagal nerve stimulation|The tVNS device will be attached to the left concha of the ear to stimulate the auricular branch of the vagal nerve. Each stimulation will last for 2 minutes.
79859718|NCT05214482|Drug|AK112|IV infusion,Specified dose on specified days
79859719|NCT05214482|Drug|AK117|IV infusion,Specified dose on specified days
80021631|NCT05066152|Dietary Supplement|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
80021632|NCT02309606|Other|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
80021633|NCT05066464|Other|Fluid Resuscitation|Fluid Resuscitation for Suspected Sepsis in Paediatric Emergency Departments
79859720|NCT05214482|Drug|Chemotherapy|IV infusion,Specified dose on specified days
79859721|NCT05213260|Other|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
79859722|NCT05209984|Drug|ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg|Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.
79859723|NCT05209984|Drug|ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg|Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
79859724|NCT05209984|Drug|SIB Group Sibus (Sibutramine) 15mg|Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
79563592|NCT01701726|Other|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
79859725|NCT05209984|Drug|Placebo Group|participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
79563593|NCT01701726|Other|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
79563594|NCT01701739|Drug|aleglitazar|Multiple doses of aleglitazar
79563595|NCT01701739|Drug|digoxin|Single dose of digoxin
79563596|NCT01701752|Biological|FP-01.1 + Placebo|
79859726|NCT05207033|Other|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
79859727|NCT05207033|Other|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
79859728|NCT05205967|Other|MCED|Multi-cancer early detection (MCED) test
79859729|NCT05205967|Other|SOC|Standard of care cancer screening
79859730|NCT05205733|Other|Mail-in semen analysis kit|Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
79399419|NCT00856479|Device|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
79399420|NCT00856479|Procedure|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
79563597|NCT01701752|Biological|FP-01.1 + TIV|
79563598|NCT01701752|Biological|FP-01.1-Adjuvant + Placebo|
79563599|NCT01701752|Biological|FP-01.1-Adjuvant + TIV|
79563600|NCT01701752|Biological|Adjuvant + TIV|
79563601|NCT01701752|Biological|Placebo + TIV|
79563602|NCT01701752|Biological|FP-01.1|
79563603|NCT01701752|Biological|FP-01.1-Adjuvant|
79563604|NCT01701752|Other|Placebo|
79563605|NCT01701778|Drug|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
79563606|NCT01701778|Drug|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
79563607|NCT01701778|Drug|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
79563608|NCT01701778|Drug|sevoflurane|Induction and maintain anaesthesia
79563609|NCT01701791|Other|Computerized Decision Support System|
79563610|NCT01701804|Drug|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
80021634|NCT05066386|Other|Modified RCRI risk stratification|"The objective of the study is to compare the predictive value of RCRI and substitution of the DM on insulin component with HH ratio for 30- and 90-day mortality, and postoperative acute myocardial injury(AMI) and acute kidney injury(AKI)."
79859731|NCT05203822|Drug|Tepotinib (HydroChloride hydrate)|Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
79264546|NCT02115659|Drug|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
79264547|NCT02115659|Drug|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
79264548|NCT02113631|Drug|Telaprevir|
79725376|NCT04301037|Procedure|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
79399421|NCT02409654|Other|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
79859732|NCT05203822|Drug|Itraconazole|Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
79859733|NCT05196113|Behavioral|sipIT|Participants receive education and digital tools to monitor their fluid intake and just-in-time text messages to remind them when they have lapsed in regular fluid intake.
79859734|NCT05194345|Behavioral|Autism Eats nutrition intervention|The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).
80021635|NCT03100708|Procedure|PIPAC|"Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
80021636|NCT05493085|Procedure|Quadratus lumborum block|Ultrasound-guided quadratus lumborum block
80021637|NCT05493085|Procedure|Caudal epidural injection|Single Caudal epidural injection
80021638|NCT02306252|Other|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
79264549|NCT02113631|Drug|Boceprevir|
79399422|NCT02409654|Other|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
79399423|NCT02990871|Other|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
79264550|NCT02113631|Drug|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
79264551|NCT02113631|Drug|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
79264552|NCT02119637|Device|Transcranial magnetic stimulation (TMS)|1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
79264553|NCT02119637|Device|MRI|Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
79264554|NCT04428320|Procedure|Pelvic floor injection|Injection of 10 cc of bupivacaine
79264555|NCT02123069|Device|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
79264556|NCT02123069|Drug|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
79264557|NCT02123069|Drug|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
79264558|NCT02123069|Drug|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
79563611|NCT01701804|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
79563612|NCT01701804|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10~20 acupoints once a week for 16 weeks.
79725377|NCT02750293|Drug|Cholecalciferol|Vitamin D preparation
79725378|NCT02750293|Drug|Placebo|placebo
79725379|NCT04217785|Drug|Optive, Ophthalmic Solution|6 drops per day, for 8 weeks
79725380|NCT04217785|Biological|Umbilical Cord Serum eye drops|UCS eye drops (6 drops per day, for 8 weeks)
79399424|NCT02990871|Other|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
79264559|NCT02123069|Drug|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
79399425|NCT05088330|Drug|Daratumumab|treatment with D-VRD in NDMM
79264560|NCT04428632|Drug|Berotralstat|One 150mg capsule administered orally once daily
79563613|NCT01701804|Procedure|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
79264561|NCT02115737|Behavioral|Dialectical Behavior Therapy Skills Group|
80021639|NCT02313116|Device|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
79399426|NCT03750006|Behavioral|Short session HIIT|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
79399427|NCT03678324|Other|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
79399428|NCT00695097|Drug|Rituximab|Rituximab infusion on Day 1 and Day 15
79399429|NCT00695097|Drug|No Rituximab|No Rituximab
79399430|NCT03139734|Device|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
79399431|NCT02997267|Procedure|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
80021640|NCT05395585|Procedure|Manual placental separation|Manual separation of the placenta from uterus
80021641|NCT03508310|Other|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
80021642|NCT02306330|Device|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
80021643|NCT02306330|Other|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
80021644|NCT02643082|Drug|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
79264562|NCT02115737|Behavioral|Psychoeducation group treatment|
79264563|NCT02115893|Dietary Supplement|Sodium Nitrate|
79264564|NCT02115893|Dietary Supplement|Sodium Chloride|
79399432|NCT03138642|Radiation|RT|All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
79563614|NCT01701817|Other|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
79563615|NCT01701843|Drug|Cromoglicate|Twice daily topical treatment for 14 days
79563616|NCT01701843|Drug|Placebo|Twice daily topical treatment for 14 days
79563617|NCT01701856|Drug|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
79563618|NCT01701882|Drug|tenofovir/emtricitabine/rilpivirine|
79264565|NCT04807634|Drug|Intravenous Lipid Emulsion (Intralipid 20%)|Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
79264566|NCT04816370|Diagnostic Test|FSFI|2 group and 2 subgroup
79264567|NCT02789111|Drug|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
79264568|NCT02789111|Drug|Placebo|Placebo twice daily up to 15 doses
79563619|NCT01701921|Drug|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
79563620|NCT01701921|Drug|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
79563621|NCT01701921|Drug|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
79563622|NCT01701934|Drug|Roflumilast|500 mcg, oral, once daily for 6 months
79563623|NCT01701934|Drug|Placebo|One placebo pill daily, for 6 months
79563624|NCT01701947|Biological|Hemoleven|Replacement therapy
79399433|NCT01795911|Biological|Pegylated Interferon Lambda|
79399434|NCT01795911|Drug|Ribasphere|
79399435|NCT01795911|Drug|Daclatasvir|
79725381|NCT04217785|Drug|Genteal lubricant gel|Genteal lubricant gel (2 drops per day, for 8 weeks)
79725382|NCT01026831|Drug|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
79725383|NCT01026831|Drug|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
79725384|NCT04299165|Device|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
79725385|NCT04299165|Other|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
79725386|NCT05103943|Other|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
79859735|NCT05194345|Behavioral|We Can! enhanced usual care|We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
79859736|NCT05188469|Drug|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
79859737|NCT05188469|Drug|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
79859738|NCT05188469|Drug|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
79859739|NCT05188469|Drug|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
79859740|NCT05188469|Drug|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
79859741|NCT05184296|Procedure|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
79264569|NCT04807010|Procedure|Prostate Artery Embolization|Prostate artery embolization reduces symptoms from benign prostatic hyperplasia by delivering embolic materials to the prostate through the prostatic arteries.
79264570|NCT04807010|Procedure|Sham Prostate Artery Embolization|Angiogram without embolization initially. At 6 months patients will be allowed to crossover to prostate artery embolization.
79264571|NCT02119715|Drug|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
79725387|NCT02759341|Other|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
79725388|NCT02759341|Other|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
79264572|NCT02119715|Drug|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
79264573|NCT02119715|Drug|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
79264574|NCT04816292|Procedure|Active Comparator: Hot Snare Polypectomy|Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
79264575|NCT04816292|Procedure|Experimental: Cold Snare Polypectomy|Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
79399436|NCT03138408|Drug|SC-004|Intravenous
79399437|NCT03138408|Drug|ABBV-181|Intravenous
79399438|NCT03137316|Diagnostic Test|intact parathyroid hormone level|obtain intact parathyroid hormone level from patients records.
79399439|NCT03139890|Other|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
79725389|NCT02759341|Other|State-Trait Anxiety Inventory form Y (STAI-Y)|
79725390|NCT02759341|Other|SF-36 Health-Related Quality of Life|
79725391|NCT02759341|Other|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
79725392|NCT05052385|Drug|Ruxolitinib|As per treating physician's decision - non interventional study
79725393|NCT05052385|Device|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
79725394|NCT05052385|Drug|Ibrutinib|As per treating physician's decision - non interventional study
79725395|NCT01016067|Device|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
79725396|NCT01016067|Procedure|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
79725397|NCT04905511|Biological|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
79725398|NCT04843891|Drug|[64]Cu Macrin|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
79264576|NCT02119793|Device|YVOIRE contour|YVOIRE contour injection into the anteromedial malar region
79399440|NCT03139890|Other|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
79399441|NCT03139890|Other|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
79399442|NCT03137238|Other|Investigation of self-perception in Parkinson's disease|There is no therapeutic intervention.
79399443|NCT01422889|Device|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
79399444|NCT03137082|Drug|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
79399445|NCT03137082|Drug|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
79399446|NCT03549468|Device|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
79264577|NCT02115971|Other|Jumping exercise|Total 120min exercise
79563625|NCT01702012|Dietary Supplement|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
79859742|NCT05181982|Other|FIT contract with global treatment budget|Several SHI funds have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT hospital, Pfalzklinikum). This contract encourages the model hospital an alternative treatment of their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment. The contract is based on a global treatment budget (pre-defined fix budget for a specified number of patients independent from the setting of treatment in the hospital).
79859743|NCT05181657|Behavioral|COVID-19 education|This session will be completed within 45 minutes. The LinkUP intervention will be available in English and Spanish.
79563626|NCT01702012|Behavioral|Group-Based Lifestyle Intervention|
79859744|NCT05180825|Drug|Trametinib|Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
79859745|NCT05180825|Drug|Vinblastine|weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
79563627|NCT01702038|Drug|Rituximab|1000 mg administered intravenously
79563628|NCT01702064|Drug|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.~Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
79859746|NCT05179928|Procedure|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
79264578|NCT02115971|Other|Strength exercise|Total 120 min exercise
79264579|NCT04807166|Drug|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
79563629|NCT01702064|Drug|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
79563630|NCT01702077|Procedure|Neurofeedback|
79563631|NCT01702077|Procedure|Sham feedback|
79563632|NCT01702090|Drug|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
79563633|NCT01702103|Drug|Mometasone furoate|
79563634|NCT01702129|Drug|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
79563635|NCT01702155|Drug|DFP-10917|
79264580|NCT04807166|Drug|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
79563636|NCT01702168|Other|Provider training: Cognitive Processing Therapy (CPT)|
79563637|NCT01702181|Drug|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
79563638|NCT01702181|Drug|Tacrolimus|0.1% concentration of tacrolimus.
79563639|NCT01702181|Drug|Placebo|
79563640|NCT01702194|Drug|TD-1211 IV [C14]|
79563641|NCT01702194|Drug|TD-1211 PO [C14]|
79563642|NCT01702207|Drug|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
79563643|NCT01702207|Drug|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
79563644|NCT01702220|Behavioral|CBT|6-12 sessions of CBT in person or over the phone
79725399|NCT04830475|Device|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
79725400|NCT04830475|Device|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
79725401|NCT00636103|Drug|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
79725402|NCT00636103|Other|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
79563645|NCT01702220|Other|ECC|6 biweekly sessions of ECC over the telephone
79859747|NCT05179928|Procedure|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
79264581|NCT02116049|Behavioral|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
79563646|NCT01702272|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
79563647|NCT01702285|Drug|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
79563648|NCT01702324|Drug|DD-25|A topical DD-25 cream at 0.025% concentration.
80021645|NCT02643082|Drug|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
79725403|NCT04423393|Biological|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
79725404|NCT04423393|Other|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
79859748|NCT05175794|Diagnostic Test|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
79264582|NCT02116049|Behavioral|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
79563649|NCT01702337|Other|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
79264583|NCT02116127|Device|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
79264584|NCT02116127|Device|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
79264585|NCT04821596|Other|biological collection|"Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...)."
79399447|NCT05230446|Device|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
79399448|NCT05088174|Drug|Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule|"Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule"
79399449|NCT03136614|Device|Arteriograph|
79399450|NCT03455634|Device|Twin Block|functional appliances for the stimulation of the mandibular growth
79563650|NCT01702350|Drug|GSK2251052|Oral formulation of an an antibacterial
79859749|NCT05174312|Device|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
79399451|NCT03455634|Device|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
79399452|NCT00695409|Biological|rituximab|Given IV
79399453|NCT00695409|Drug|carmustine|Given IV
79399454|NCT00695409|Drug|cytarabine|Given IV
79399455|NCT00695409|Drug|etoposide|Given IV
79563651|NCT01702376|Drug|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
79563652|NCT01702376|Drug|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
79563653|NCT01702376|Drug|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
79563654|NCT01702376|Drug|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
79399456|NCT00695409|Drug|melphalan|Given IV
79399457|NCT00695409|Procedure|ASCT|Undergo autologous peripheral blood stem cell transplant
79399458|NCT00695409|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
79399459|NCT03469050|Drug|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
79563655|NCT01702389|Drug|Remifentanil|
79581285|NCT01934751|Other|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
79725405|NCT02750137|Drug|Tetracaine|Application of Ametop prior to intravenous cannulation
79399460|NCT03469050|Other|Placebo|Placebo BID + Placebo BID
79581286|NCT01934751|Other|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
79725406|NCT04687735|Other|Intervention after nerve block|Brachial plexus block + Physical therapy
79725407|NCT02760043|Drug|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
79725408|NCT02760043|Other|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
79725409|NCT02760043|Drug|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
79725410|NCT02696005|Other|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
79725411|NCT02750059|Drug|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
79264586|NCT04807322|Procedure|Reverse Total Shoulder Arthroplasty (RTSA)|Implantation of a Reverse Total Shoulder Arthroplasty
79725412|NCT02750059|Drug|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
80021646|NCT00353496|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
79264587|NCT04807244|Procedure|Selective Caries Removal with Biodentine™|"Rubber dam placement~Cleaning of the tooth and rubber dam with ethanol 98%~Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)"
79264588|NCT04807244|Procedure|Partial Pulpotomy with Biodentine™|"Rubber dam placement~Cleaning of the tooth and rubber dam with ethanol 98%~Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
79264589|NCT04807244|Procedure|Full Pulpotomy with Biodentine™|"Rubber dam placement~Cleaning of the tooth and rubber dam with ethanol 98%~Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
79264590|NCT04807244|Procedure|Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy|"Dentin cleaning with a low-speed round bur~Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation"
79264591|NCT04815980|Other|Exercise|Home-based mat-based Pilates intervention 3 times a week for 12 weeks prepared by a certified Pilates instructor.
79399461|NCT01400893|Device|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
79399462|NCT03243318|Diagnostic Test|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
79399463|NCT01794663|Drug|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
79399464|NCT01794663|Drug|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
79399465|NCT05087706|Drug|Pyrotinib|Pyrotinib 400mg qd po
79399466|NCT05087706|Drug|Bicalutamide|Bicalutamide was administered orally at a daily dose of 50 mg
79399467|NCT05087706|Drug|Leuprorelin|Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
79399468|NCT02990637|Dietary Supplement|OLECOL|Olive leaf extract
79399469|NCT02990637|Dietary Supplement|Placebo|Maltodextrin
79563656|NCT01702402|Behavioral|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
79725413|NCT02759029|Drug|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
79859750|NCT05174312|Drug|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
80021647|NCT00353496|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
80021648|NCT03411746|Other|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
80021649|NCT00389896|Drug|MK0733 / Duration of Treatment: 18 Weeks|
79725414|NCT02759263|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
79725415|NCT02749825|Drug|Trelstar|As labeled
79725416|NCT02749825|Drug|Lupron|As labeled
79725417|NCT02749825|Drug|Zoladex|As labeled
79859751|NCT05171387|Drug|Darolutamide 600 mg twice daily|The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
79859752|NCT05171387|Drug|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
79859753|NCT05168943|Device|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
79859754|NCT05168943|Device|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
79859755|NCT05163314|Drug|Soticlestat|Soticlestat mini-tablets or tablets
79859756|NCT05157581|Device|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
79859757|NCT05157581|Drug|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
79859758|NCT05156398|Drug|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
80021650|NCT00389896|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
80021651|NCT03508154|Other|Control Meal 1|carbohydrate test meal
79859759|NCT05156398|Drug|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
79859760|NCT05156151|Other|Relex-Smile|
80021652|NCT03508154|Other|Control Meal 2|carbohydrate test meal
80021653|NCT03508154|Other|Experimental Nutritional Product|ready to drink nutritional formulation
80021654|NCT05313373|Other|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
79264592|NCT02251925|Biological|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
79399470|NCT03393936|Biological|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
79563657|NCT01702402|Other|Comparison Group|A comparison area received standard government health services.
79725418|NCT02758873|Genetic|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
79859761|NCT05155085|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
79859762|NCT05155085|Other|Placebo|Placebo
79859763|NCT05154929|Behavioral|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
80021655|NCT05065996|Diagnostic Test|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
80021656|NCT03478579|Other|observational|No intervention, it is observational study
80021657|NCT05065606|Diagnostic Test|Dual-energy computed tomography|Dual-energy scanner examinations stored in the PACS (medical imagery) at Lariboisière Hospital are to be analyzed retrospectively and prospectively
80021658|NCT05065138|Behavioral|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
80021659|NCT02309762|Drug|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
80021660|NCT02309762|Drug|Placebo|Solution containing no active ingredients
80021661|NCT04463888|Other|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
80021662|NCT03508076|Device|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
79264593|NCT02251925|Drug|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
79563658|NCT01702415|Drug|Zoledronic acid|Single dose, intravenous solution 5mg
79563659|NCT01702415|Drug|Placebo|
79563660|NCT01702467|Drug|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
79563661|NCT01702467|Drug|Placebo|Matching placebo capsules.
79563662|NCT01702480|Drug|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
79264594|NCT02251925|Drug|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
79264595|NCT02251925|Drug|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
79859764|NCT05154929|Other|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
79859765|NCT05150210|Device|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
79264596|NCT03552653|Dietary Supplement|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
79264597|NCT02116283|Behavioral|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
79264598|NCT02116283|Other|Smartphone|Participants will use an Android-based smartphone as their own for one month
79264599|NCT02119949|Behavioral|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
79264600|NCT02119949|Behavioral|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
79264601|NCT03552497|Diagnostic Test|Radiomics|The high-throughput extraction of large amounts of quantitative image features from radiographic medical images
80021663|NCT03508076|Device|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
79264602|NCT02116517|Dietary Supplement|green tea extract|500 mg three times per day
79264603|NCT02116517|Dietary Supplement|Placebo|cellulose 500mg three times a day for 6 weeks
79264604|NCT02116595|Other|high or low acid diet|high or low acid diets
80021664|NCT03473977|Biological|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
80021665|NCT03473977|Biological|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
79264605|NCT02116673|Other|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
79264606|NCT02116673|Other|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
79264607|NCT01359644|Drug|PSI-7977|Tablets, oral, 400 mg, once daily
79563663|NCT01702480|Drug|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
79563664|NCT01702493|Drug|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
79264608|NCT01359644|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily
79563665|NCT01702493|Drug|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
79563666|NCT01702493|Drug|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
79563667|NCT01702493|Drug|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
79563668|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
79563669|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
79563670|NCT01702506|Drug|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
79563671|NCT01702506|Drug|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
79563672|NCT01702506|Drug|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
79859766|NCT05148390|Device|Cutimed® Gelling Fiber|application of dressing
79859767|NCT05147805|Drug|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
79859768|NCT05147805|Drug|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
79859769|NCT05147103|Device|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
80021666|NCT03503084|Behavioral|Classical Yang's TCC exercise|
80021667|NCT03507998|Drug|CGX1321|CGX1321 capsules for oral administration
79859770|NCT05142462|Device|Hip arthroplasty|Hip prosthesis surgical implantation
80021668|NCT01361464|Drug|Tipifarnib|Given PO
80021669|NCT01361464|Other|Laboratory Biomarker Analysis|Correlative studies
80021670|NCT03424213|Other|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
79264609|NCT01359644|Drug|Ribavirin|Tablets, oral, 200 mg
79264610|NCT04821206|Drug|DMARDs|New Initiation of a DMARDs
79264611|NCT04821206|Drug|biologic DMARDs|New Initiation of a biologic DMARDs
79264612|NCT04821206|Drug|JAK Inhibitor|New Initiation of a JAK Inhibitor
79399471|NCT03393936|Biological|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
79399472|NCT01799733|Other|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
79859771|NCT05140330|Behavioral|ALAPAGE workshop|7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
79859772|NCT05140330|Behavioral|control workshop|3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
79859773|NCT05140148|Drug|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
79859774|NCT05140148|Drug|Placebo|placebo pills
79859775|NCT05130073|Procedure|Computed Tomography|Undergo PET/CT
79859776|NCT05130073|Other|Electronic Health Record Review|Review of medical records
79859777|NCT05130073|Procedure|Follow-Up|Undergo follow-up
79264613|NCT04806932|Procedure|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
79264614|NCT04806932|Procedure|The conventional approach|The conventional approach
79399473|NCT01799733|Other|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
79859778|NCT05130073|Procedure|Positron Emission Tomography|Undergo PET/CT
79264615|NCT04806698|Device|Menicon Z Night|Children wearing Menicon Z Night orthokeratology contact lenses
79563673|NCT01702584|Procedure|stent assisted embolization|stent assisted embolization and anti-thrombotic management
79563674|NCT01702597|Device|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
79563675|NCT01702597|Other|Physiotherapy|Patients will receive a standardized physical therapy.
79563676|NCT01702610|Radiation|IMRT Technique|
79859779|NCT05128903|Drug|[18F]DPA714|"Intravenous injection~Before or within 2 weeks of starting radiation therapy~Before starting chemotherapy~1 year after the start of radiation therapy Timing cont.~1.5 to 2 years after the start of radiation therapy"
79859780|NCT05126992|Biological|AZD1222|Covid-19 AstraZeneca Vaccine
79859781|NCT05126290|Other|Collection of personal and family history from CAFÉ Study participants|Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system
79859782|NCT05123014|Other|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
79859783|NCT05120648|Behavioral|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
79859784|NCT05117515|Device|Vascular reconstruction|Vascular reconstructions in the carotid, profunda, femoral and iliac arteries
79859785|NCT05115058|Other|relex Smile module|
79859786|NCT05109351|Behavioral|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
79264616|NCT04806698|Device|Control|Children wearing distance single-vision glasses or distance single-vision soft contact lenses
79264617|NCT04807088|Procedure|Tactile-kinesthetic Stimulation|
79264618|NCT04807088|Other|Placebo|
79264619|NCT04806542|Behavioral|TMR-group|A mindfulness-based 8 week program.
79264620|NCT04806542|Behavioral|Treatment as usual|Individual counselling.
79264621|NCT04806308|Behavioral|Otolaryngology stretching micro-breaks (OSMB)|Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
79264622|NCT04806464|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
79264623|NCT04806230|Drug|sertraline, mirtazapine, venlafaxine, citalopram, escitalopram|Naturalistic treatment
79264624|NCT04816136|Other|Sleep recording (already done)|Sleep recording (already done)
79563677|NCT01702610|Radiation|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
79563678|NCT01702610|Radiation|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
79563679|NCT01702610|Drug|Temozolomide and Accelerated Hypofractionation RT|
79563680|NCT01702623|Drug|Oxcarbazepine|
79563681|NCT01702636|Drug|Tranexamic Acid|
79563682|NCT01702636|Drug|Placebo|
79563683|NCT01702649|Drug|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
79859787|NCT05105087|Drug|Perflubutane Microbubble|Given subdermally
79859788|NCT05105087|Procedure|Contrast-Enhanced Ultrasound|Undergo ultrasound
79859789|NCT05104567|Drug|THOR-707|Solution for infusion: intravenous infusion
79859790|NCT05104567|Drug|Pembrolizumab|Solution for infusion: intravenous infusion
79859791|NCT05104567|Drug|Cetuximab|Solution for infusion: intravenous infusion
80021671|NCT03099226|Drug|Placebo|Placebo blue hard gelatine capsules
80021672|NCT03099226|Drug|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
79264625|NCT05617274|Procedure|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
79264626|NCT04815512|Diagnostic Test|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
79264627|NCT04815512|Diagnostic Test|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
79264628|NCT01532258|Behavioral|Go! Foods for You without Weekly MA Support.|"Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
80021673|NCT03505970|Dietary Supplement|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
79264629|NCT01532258|Behavioral|Go! Foods for You with Weekly MA Support.|"Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
79264630|NCT04821050|Device|Sacral nerve stimulation|"A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
79264631|NCT04821050|Device|Sham stimulation|"Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
79399474|NCT05087316|Device|biomimetic oral appliance therapy (BOAT)|BOAT appliance is designed to correct maxillo-mandibular underdevelopment in both children and adults (Singh and Lipka, 2009). However, adults will only use for this study. Typically, a BOAT appliance consists of 6 patented, anterior 3-D Axial Springs™, a midline actuator (such as omega loops or screws), posterior occlusal rests, and a round labial bow (Figure 1). Patients will be trained on activation of the screw
79399475|NCT05087316|Device|Standard hospital treatment|Use of CPAP and similar methods
79563684|NCT01702649|Drug|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
79563685|NCT01702662|Device|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
79399476|NCT05087160|Other|mitigation measures against COVID 19|no intervention
79399477|NCT02990403|Drug|Aspirin|
79399478|NCT02990403|Drug|Heparin|
80021674|NCT03505970|Dietary Supplement|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
79264632|NCT04412174|Biological|GC022F|GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.
79399479|NCT02990403|Drug|Prednisone|
79399480|NCT02990403|Drug|Immunoglobulin|
79563686|NCT01702675|Drug|ACH15 50 mg|ACH15 50mg capsule
79859792|NCT05104268|Device|Bocaliner|Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
79563687|NCT01702675|Drug|ACH15 250 mg|ACH15 250mg capsule
79563688|NCT01702675|Drug|ACH15 500mg|ACH15 500 mg capsule
79859793|NCT05101161|Behavioral|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
79859794|NCT05098834|Device|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
79399481|NCT02990403|Drug|Dydrogesterone|
79399482|NCT05087004|Behavioral|Teen Council|Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
79399483|NCT05086926|Combination Product|Exercises and CSI|"Corticosteroid injection:~The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline. The procedure will be performed aseptically.~Home exercise program:~The exercise programis based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of 8 weeks. Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled."
79399484|NCT03138174|Device|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
79399485|NCT00697203|Drug|Placebo|po daily for 12 weeks
79399486|NCT00697203|Drug|Pravastatin|40mg po daily for 12 weeks
79399487|NCT00697203|Drug|Dalcetrapib|300mg po daily for 12 weeks
79563689|NCT01702675|Drug|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
79563690|NCT01702675|Drug|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
79264633|NCT04806152|Other|High intensity exercise|Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
79859795|NCT05097534|Other|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
79859796|NCT05097534|Other|Standard of Care|Standard of Care for patients with type 2 diabetes
79563691|NCT01702675|Drug|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
79264634|NCT04806152|Other|Usual care home exercise|Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
79264635|NCT04821128|Other|Radiologic and pathological review.|"We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses.~The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon).~Then we will analyse the correlation between the radiological and the pathological analysis."
79264636|NCT02603120|Drug|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
79264637|NCT02603120|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
79264638|NCT02603120|Drug|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
79859797|NCT05095207|Drug|Abemaciclib|100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
80021675|NCT03317743|Drug|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
80021676|NCT04078828|Procedure|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
79399488|NCT00697203|Drug|Dalcetrapib|600mg po daily for 12 weeks
79399489|NCT00697203|Drug|Dalcetrapib|900mg po daily for 12 weeks
79563692|NCT01702675|Drug|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
79264639|NCT02603120|Drug|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
79264640|NCT04805684|Device|LUS Twelve area|Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
79264641|NCT04805684|Device|LUS Fourteen area|Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
79264642|NCT04820504|Device|Augmented Infant Resuscitator (AIR)|Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths
79264643|NCT04820504|Device|AIR device without feedback|Device provides no visual feedback to clinician but records data on ventilation effectiveness
79264644|NCT04820816|Other|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
79399490|NCT03325842|Diagnostic Test|ASKp|30 items questionnaire
79399491|NCT05086848|Drug|Irinotecan liposome、5-fluorouracil、Leucovorin|Irinotecan liposome、5-fluorouracil、Leucovorin
79399492|NCT03295500|Radiation|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
79399493|NCT00830895|Drug|RAD001|RAD001 10mg/day
79563693|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
79563694|NCT01702675|Drug|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
79563695|NCT01702675|Drug|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
79563696|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
79399494|NCT03136224|Device|Thermocautery|
79399495|NCT03136224|Device|Plastic Clamping|
79399496|NCT03136224|Device|Surgical Circumcision|
79399497|NCT01158417|Drug|Placebo|oral
79399498|NCT01158417|Drug|Resveratrol 40 mg oral three times a day|Drug
79399499|NCT01158417|Drug|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
79399500|NCT05086614|Drug|Thymosin Alpha1|Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
79563697|NCT01702688|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
79563698|NCT01702688|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
79563699|NCT01702701|Drug|Montelukast|montelukast 10mg po pill q day for 12 weeks
79563700|NCT01702701|Drug|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
79563701|NCT01702714|Drug|RO5083945|multiple ascending doses
79563702|NCT01702714|Drug|carboplatin|up to 6 cycles
79563703|NCT01702714|Drug|cisplatin|up to 6 cycles
79563704|NCT01702714|Drug|gemcitabine|up to 6 cycles
79563705|NCT01702714|Drug|paclitaxel|up to 6 cycles
79563706|NCT01702727|Device|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
79859798|NCT05095207|Drug|Bicalutamide|150 mg orally daily, day 1 to 28.
79859799|NCT05090150|Other|Home delivery of ART|Home ART refill and monitoring, adherence support
79859800|NCT05090150|Other|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
80021677|NCT03505814|Device|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
79264645|NCT04805372|Other|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
79563707|NCT01702727|Device|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
79264646|NCT04805372|Other|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
79563708|NCT01702727|Device|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
79859801|NCT05090150|Other|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
79859802|NCT05090150|Other|Best clinic practices|Continue with best clinic practices
79264647|NCT05617976|Procedure|caudal block|caudal block
79859803|NCT05088356|Drug|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg"
79264648|NCT04805606|Drug|CKD-843 A|Single Dose
79563709|NCT01702740|Drug|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
79563710|NCT01702740|Drug|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
79859804|NCT05088356|Drug|Fludarabine|Fludarabine (160 mg/m2)
79859805|NCT05088356|Drug|Melphalan|Melphalan (50 mg/m2)
79264649|NCT04805606|Drug|CKD-843 B|Single Dose
79563711|NCT01702740|Drug|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
79563712|NCT01702740|Drug|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
79563713|NCT01702753|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
79264650|NCT04805606|Drug|CKD-843-R|QD, PO
79264651|NCT04360226|Other|Non-interventional|Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.
79563714|NCT01702766|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
79563715|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
79563716|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
79563717|NCT01702792|Biological|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
79563718|NCT01702857|Biological|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
79563719|NCT01702857|Biological|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
79563720|NCT01702857|Other|Phosphate buffered saline|
79563721|NCT01702857|Biological|1 µg TDENV-PIV with Alum adjuvant|
79563722|NCT01702857|Biological|1 µg TDENV-PIV with AS01E adjuvant|
79563723|NCT01702870|Procedure|Magnetic Resonance Imaging|
79563724|NCT01702974|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
79563725|NCT01702974|Drug|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
79563726|NCT01703052|Drug|CHF 6001 SD or placebo|Dry Powder Inhaler
79563727|NCT01703052|Drug|CHF 6001 MD or placebo|Dry Powder Inhaler
79859806|NCT05088356|Device|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
79859807|NCT05088356|Drug|Tacrolimus|4-6ng/mL
79859808|NCT05088356|Drug|Cyclophosphamide|40mg/kg
79859809|NCT05088356|Drug|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
79859810|NCT05088356|Drug|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
79264652|NCT04820738|Other|Sensorimotor training exercises|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking
79264653|NCT04820738|Other|Without Sensorimotor training exercises|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
79563728|NCT01703078|Drug|Ingenol once daily for two consecutive days|
79563729|NCT01702116|Procedure|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
79563730|NCT01702116|Procedure|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
79563731|NCT01703104|Drug|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
79563732|NCT01703104|Dietary Supplement|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
79563733|NCT01703130|Procedure|Dose of of ropivacaine 0.75% used in block procedure|
79563734|NCT01703143|Procedure|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
79563735|NCT01703156|Procedure|Stress Test|
79563736|NCT01703156|Procedure|No Stress Test|
79563737|NCT01703195|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
79859811|NCT05088356|Drug|Thiotepa|Thiotepa 10 mg/kg
79725419|NCT02758873|Genetic|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
79264654|NCT04805060|Drug|TQB2858 injection|TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline [0.9% (w/v) sodium chloride solution], and the infusion time is 60 ± 10 min.
79563738|NCT01703195|Procedure|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
79563739|NCT01703234|Drug|Ramipril|ramipril 10 mg/day during 3 months
79725420|NCT02758873|Other|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
80021678|NCT03505814|Device|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
79264655|NCT04815434|Other|Interview|Interviews will be conducted.
79264656|NCT04815122|Radiation|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical [99mTC] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
79725421|NCT02749747|Drug|Sulpiride use|50mg sulpiride once a day use for 60 days
79725422|NCT02749747|Drug|Placebo|50mg placebo once a day use for 60 days
79725423|NCT02749591|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
80021679|NCT02012179|Other|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
80021680|NCT02309918|Drug|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
79264657|NCT02599688|Other|Observation only|No intervention in this study.
79264658|NCT04820660|Other|Task orientated strengthening training|"Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~forward step-up onto blocks of various heights to strengthen the lower limb muscles;~heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy."
79563740|NCT01703247|Procedure|Pulmonary vein isolation|
79563741|NCT01703247|Procedure|Ganglionated plexi ablation|
79563742|NCT01703247|Procedure|Linear Lesion Ablation|
79563743|NCT01703273|Behavioral|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
79563744|NCT01703273|Behavioral|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
79563745|NCT01703312|Drug|QGE031|Drug administered by subcutaneous injection
79563746|NCT01703312|Drug|omalizumab|Drug administered by subcutaneous injection
79563747|NCT01703312|Drug|placebo|Drug administered by subcutaneous injection
79581287|NCT01934777|Drug|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
79581288|NCT01934777|Drug|placebo pearls|placebo
79725424|NCT02749591|Other|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
79725425|NCT02749591|Other|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
79725426|NCT02749591|Other|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
79725427|NCT04460833|Device|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
79725428|NCT04359979|Drug|Tamsulosin|selective alpha1 receptor antagonist
79725429|NCT04218955|Combination Product|Silver Diamine Flouride|Material used to arrest caries in children
79725430|NCT04180813|Drug|Linagliptin|drug
79725431|NCT04180813|Drug|Acarbose|drug
79725432|NCT04221607|Other|Sensate Focus exercise|Structured exercise to enhance intimacy
79725433|NCT04148443|Other|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
79725434|NCT04148443|Other|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
79859812|NCT05088356|Drug|Mycophenolate Mofetil (MMF)|MMF 1000 mg BID
80021681|NCT03098914|Other|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
79264659|NCT04820660|Other|Balance training exercises|"Stepping forward, backward, and sideways on the exercise step;~Stepping over blocks of various heights;~Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~Arms; bending the trunk forward and side to side);~Performing double-legged stance for 10 s;~Performing tandem stance for 10 s;~Rising from a chair without the use of the arms;~Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~Performing single- legged stance for 10 s."
79725435|NCT04116775|Biological|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
79563748|NCT01703325|Drug|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~Group C: Controlled group"
79725436|NCT04116775|Drug|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
79725437|NCT04116775|Drug|Enzalutamide|Daily oral dose.
79859813|NCT05088356|Drug|Ruxolitinib|Ruxolitinib 5 mg BID
79859814|NCT05086692|Drug|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
79859815|NCT05086692|Drug|Pembrolizumab|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
79859816|NCT05086510|Procedure|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
79859817|NCT05083390|Drug|norUrsodeoxycholic acid|500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
79859818|NCT05078203|Behavioral|Exercise|36 minutes of Exercise
79859819|NCT05075824|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight >= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight >= 100 kg). Dosing schedule will be as per Arm Description.
79859820|NCT05075824|Drug|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
79859821|NCT05074303|Biological|Influenza Vaccine|All subjects will receive the influenza vaccine.
79859822|NCT05074303|Dietary Supplement|Beta-glucan|2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
80031712|NCT02048085|Drug|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
79264660|NCT04804670|Device|Power device A|Oral hygiene regimen completed daily
79563749|NCT01703351|Drug|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
79563750|NCT01703351|Drug|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
79264661|NCT04804670|Device|Power device B|Oral hygiene regimen completed daily
79264662|NCT04804670|Device|Routine Oral Hygiene|Oral hygiene regimen completed daily
79264663|NCT04820270|Other|Autologous T regulatory cells|Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
79264664|NCT04426760|Procedure|Transcervical resection of fibroids|Transcervical resection of fibroids
79264665|NCT04426760|Procedure|Myomectomy per laparoscopy or laparotomy|Myomectomy per laparoscopy or laparotomy
79563751|NCT01703364|Drug|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
79563752|NCT01703390|Drug|FOLFIRI + Cetuximab|
79725438|NCT04172857|Procedure|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch & Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
79859823|NCT05074303|Dietary Supplement|Placebo|2 - 250 mg capsules/day of cellulose
79859824|NCT05071131|Dietary Supplement|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
79859825|NCT05071131|Dietary Supplement|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
80031713|NCT04430374|Other|No interverntion|No intervention will be done, registry only
80031714|NCT03051412|Other|No Intervention|No intervention
79563753|NCT01703390|Drug|modifiedFOLFOX6 + Cetuximab|
79563754|NCT01703468|Drug|Oxcarbazepine|
79563755|NCT01703481|Drug|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
79563756|NCT01703481|Drug|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
79859826|NCT05064709|Device|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
79859827|NCT05064709|Device|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
79859828|NCT05064436|Drug|11C-BMS-986196|Specified dose on specified days
79725439|NCT02749435|Other|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
79859829|NCT05064293|Behavioral|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
79859830|NCT05064293|Behavioral|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
79859831|NCT05064124|Device|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"CADDIE assisted polyp detection~CADDIE assisted polyp characterisation"
79563757|NCT01703481|Drug|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
79563758|NCT01703481|Drug|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
79264666|NCT04804436|Genetic|Genetic analysis|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
79563759|NCT01703494|Biological|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
79581289|NCT01934803|Dietary Supplement|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
79725440|NCT04217083|Diagnostic Test|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
79859843|NCT05061888|Other|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
79859844|NCT05061888|Other|Smart Intervention for Stress Managment|Will receive a Smart Intervention on stress management practices and strategies.
79859845|NCT05057429|Device|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
80031715|NCT03051334|Other|diagnosed as bicuspid aortic valve|
79859846|NCT05057429|Other|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
79264667|NCT04427696|Behavioral|Aerobic walking intervention|Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
79725441|NCT04216849|Biological|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
79725442|NCT04216849|Other|saline|Saline solution containing human serum albumin will be infused to the control group
79725443|NCT02749357|Device|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
79859847|NCT05056545|Behavioral|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
79859848|NCT05056363|Other|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
79859849|NCT05056363|Other|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
79859850|NCT05048459|Other|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
79859851|NCT05048459|Other|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
79859852|NCT05048459|Other|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
79859853|NCT05041309|Biological|Axicabtagene Ciloleucel|No investigational product will be administered
79859854|NCT05041309|Biological|Brexucabtagene Autoleucel|No investigational product will be administered
79264668|NCT04815200|Device|Copper Nickel titanium arch wire|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
79264669|NCT04820114|Other|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
79563760|NCT01703494|Biological|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
79725444|NCT02749357|Device|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
79725445|NCT03933553|Other|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
79859855|NCT05041309|Biological|KITE-585|No investigational product will be administered
79859856|NCT05041309|Biological|KITE-718|No investigational product will be administered
79859857|NCT05041309|Biological|KITE-439|No investigational product will be administered
79264670|NCT04820114|Other|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
79563761|NCT01703546|Procedure|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band & Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
79563762|NCT01703559|Drug|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
79563763|NCT01703559|Drug|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
79563764|NCT01703559|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
79563765|NCT01703572|Drug|OMP-52M51|
79725446|NCT02758561|Behavioral|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
79264671|NCT04803968|Other|bicycle ergometer and arm ergometer exercise|"After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm."
79563766|NCT01703611|Other|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
79264672|NCT04803968|Other|bicycle ergometer exercise|All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
79264673|NCT04426916|Other|Spondylolisthesis|Spondylolisthesis at a single level
79563767|NCT01703611|Other|Usual Nutrition Care|Usual nutrition care in India
79563768|NCT01703624|Drug|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
79563769|NCT01703637|Drug|Sitagliptin|"before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
79563770|NCT01703637|Drug|Vildagliptin|"before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
79563771|NCT01703637|Drug|Saxagliptin|"before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
79563772|NCT01703650|Drug|iopromide|"iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight[BW] <50kg) or 35 mL (50kg ≤BW <70kg) or 40 mL (70 kg≤BW <90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~Injection rate is as follows; 6.0mL/sec if BW is <50kg, 7.0 mL/sec if BW is 50kg≤and <70kg, 8.0 mL/sec if BW is 70≤and<90kg and 9.0mL/sec if BW is 90kg≤."
79563773|NCT01703650|Procedure|CT|"Perfusion CT will be performed by using a 320 channel MDCT~Patients are requested for fasting for at least 8 hours before CT scan.~Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
79563774|NCT01703689|Behavioral|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
79563775|NCT01703689|Behavioral|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
79563776|NCT01703715|Device|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
79563777|NCT01703728|Other|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
79563778|NCT01703754|Genetic|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
79563779|NCT01703754|Drug|Palifosfamide|Small molecule chemotherapy, IV administration
79563780|NCT01703767|Behavioral|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
79725447|NCT03913741|Drug|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
79725448|NCT02758639|Behavioral|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
79725449|NCT02749669|Other|Qualitative research|Semi-structured Interviews
79563781|NCT01703793|Drug|Test Product 49778|
79563782|NCT01703793|Drug|Test Product 10156|
79563783|NCT01703793|Drug|Vehicle (placebo)|
79725450|NCT02758795|Dietary Supplement|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
79581290|NCT01934803|Dietary Supplement|Placebo|
79563784|NCT01703884|Drug|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
79859858|NCT05041309|Biological|KITE-222|No investigational product will be administered
79264674|NCT04426994|Drug|proton pump inhibitor use|Patients using long term proton pump inhibitor
79563785|NCT01703897|Device|Manometry and Impedance analysis|
79264675|NCT04814576|Behavioral|Collaborative cares|The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
79859859|NCT05041309|Biological|KITE-363|No investigational product will be administered
79859860|NCT05034432|Procedure|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
79264676|NCT04427774|Drug|Surufatinib plus Sintilimab|Surufatinib will be given orally. Sintilimab will be given intravenously
79264677|NCT04803890|Procedure|"No-Touch Radiofrequency Ablation"|"No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode"
79264678|NCT04820192|Other|Craniosacral Therapy|The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
79563786|NCT01703910|Drug|Arm A chemotherapy|
79264679|NCT04427852|Dietary Supplement|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
79859861|NCT05034432|Other|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
79859862|NCT05031325|Device|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
79859863|NCT05022810|Drug|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
79859864|NCT05022810|Drug|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
79859865|NCT05018585|Biological|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
79859866|NCT05018585|Dietary Supplement|Colecalciferol 2000 IU|Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).
79859867|NCT05018585|Biological|Placebo for recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Placebo for Diamyd, Alhydrogel® only
79264680|NCT04427852|Dietary Supplement|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
79563787|NCT01703910|Drug|arm B chemotherapy|
80031716|NCT02808975|Drug|Placebo|Subcutaneous injections administered as described in arm description
79264681|NCT04803656|Other|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
79308889|NCT05618769|Combination Product|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
79563788|NCT01703936|Other|Agricultural and life skills training program|
79563789|NCT01703975|Other|Training in pairs (Dyad training)|
79563790|NCT01704001|Drug|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
79563791|NCT01704027|Radiation|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~Pelvis : 55,5 Gy (1,85 Gy/fr)~Seminal vesicles : 66 Gy (2,2 Gy/fr)~Prostate : 72 Gy (2,4 Gy/fr)"
79563792|NCT01704027|Drug|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
79563793|NCT01704040|Drug|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
79563794|NCT01704040|Drug|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
79563795|NCT01704040|Drug|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
79264682|NCT05617196|Behavioral|Virtual PREHAB|The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
79563796|NCT01704040|Drug|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
79563797|NCT01704040|Other|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
79264683|NCT05617196|Behavioral|Standard care|In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
79725451|NCT02758795|Dietary Supplement|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
79563798|NCT01704066|Other|Training and education|
79563799|NCT01704092|Drug|Dexmedetomidine|
79563800|NCT01704105|Behavioral|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
79725452|NCT02749123|Drug|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
79875851|NCT01026246|Biological|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
79875852|NCT01028274|Dietary Supplement|Placebo|Two capsules, twice daily with meals for 12 weeks.
79264684|NCT04819802|Other|Measurement of sublingual microcirculation|Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.
79264685|NCT04819802|Other|Plasma sampling|Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
80021682|NCT04051255|Drug|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
79264686|NCT04819412|Biological|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
79264687|NCT04819412|Biological|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
79725453|NCT02749123|Drug|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
79264688|NCT04819412|Biological|ROTAVAC 5C -F2|ROTAVAC 5C formulation BBIL-R2014-2
79563801|NCT01704105|Behavioral|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
79563802|NCT01704105|Behavioral|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
79581291|NCT01934816|Other|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
79725454|NCT02749123|Drug|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
79725455|NCT02758483|Other|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
80021683|NCT03538834|Dietary Supplement|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
80021684|NCT03538834|Dietary Supplement|Control|Placebo
79725456|NCT02758483|Other|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
79264689|NCT04814030|Drug|PD-1 inhibitor|Transarterial hepatic chemoembolization and FOLFOX-based infusion
79264690|NCT04819724|Diagnostic Test|3D motion analysis|30° arm abduction in the scapular plane will be performed with and without a handheld weight of 1, 2, 3, and 4 kg. All movements will be done bilaterally. Electromyographic (EMG) data of arm and trunk muscles will be recorded using surface electrodes. Participants will be asked to perform full arm abduction with different rotations (internal, neutral and external rotation), flexion and internal-/external rotations movements (without additional handheld weight).
79264691|NCT04819724|Diagnostic Test|isometric shoulder strength by dynamometer|isometric shoulder strength for abduction and internal/external rotation will be assessed with a isometric shoulder strength for abduction and internal/external rotation will be assessed with a dynamometer
79264692|NCT04819724|Diagnostic Test|fluoroscopic images of each shoulder|fluoroscopic images (Multitom Rax, Siemens Healthineers, Erlangen, Germany) of each shoulder will be taken during the 30° arm abduction test with and without a handheld weight (0, 2, and 4kg)
79264693|NCT04819724|Diagnostic Test|Bilateral shoulder Magnetic Resonance Imaging (MRI)|MRI of both shoulders will be taken
79264694|NCT04819724|Other|data collection by health questionnaires|data collection by health questionnaires
79264695|NCT04412252|Drug|Tofacitinib|10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
79264696|NCT04412252|Other|Placebo|Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
79859868|NCT05016791|Device|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
79264697|NCT05617586|Other|In-depth parental interview|A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
79581292|NCT01934829|Drug|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
79859869|NCT05006027|Procedure|Percutaneous coronary intervention via the snuffbox approach|Percutaneous coronary intervention using a 7-Fr thin wall sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the snuffbox approach
79859870|NCT05000502|Behavioral|Home-based exercise intervention|A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
79859871|NCT04998812|Drug|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
79859872|NCT04998019|Behavioral|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
79859873|NCT04997096|Other|Exercise|16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
79859874|NCT04997096|Other|Attention Control|Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
79859875|NCT04995822|Device|hip arthroplasty|Hip prosthesis surgery
79859876|NCT04995419|Drug|Enfortumab vedotin|Intravenous Infusion
79859877|NCT04993638|Device|hip arthroplasty|Hip prosthesis surgery
79859878|NCT04990323|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single UM171-Expanded CB transplant (CD34+: 2.5-50x10^5/kg, CD3+>1x10^6/kg)
79859879|NCT04987723|Other|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
79581293|NCT01934842|Device|TAP20-C|
79581294|NCT01934842|Device|SAFE-T-FILL|
79581295|NCT01934907|Other|Washing of packed RBC by normal saline|
79859880|NCT04987723|Other|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
79875853|NCT01028274|Dietary Supplement|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
79875854|NCT01028274|Dietary Supplement|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
79264698|NCT05617586|Other|Developmental Coordination Disorder Questionnaire (DCD-Q)|Parents will be asked to complete the DCD-Q. This will help us describe the sample.
79264699|NCT04813952|Drug|Sevoflurane inhalant product|The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
79264700|NCT04813874|Drug|Nitrous Oxide|Nitrous Oxide Inhalational Agent
79264701|NCT04813874|Procedure|Neuraxial analgesia|Epidural Labor Analgesia Placement
79581296|NCT01934933|Drug|celebrex|
79581297|NCT01934933|Drug|Enbrel|
79563803|NCT01704105|Dietary Supplement|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
79264702|NCT04803578|Other|Conventional physiotherapy|The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
79264703|NCT04803500|Drug|Simvastatin|single injection of simvastatin gel in the gap around immediately placed implant
79264704|NCT04803500|Drug|Placebo|single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
79264705|NCT04803188|Diagnostic Test|Magnetic Resonance|"Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy."
79563804|NCT01704118|Device|I-gel|Supraglottic airway device
79264706|NCT04803266|Radiation|Internal mammary node irradiation|Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
79264707|NCT04803266|Radiation|No internal mammary node irradiation|Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
79264708|NCT04803344|Behavioral|Expressive Writing tecnique|Expressive Writing (EW), is a simple, potentially inexpensive, therapeutic intervention which involves writing daily for 15-20 min over 3-4 consecutive days. EW can be completed at home without the need for facilitation, a specialist therapist or a dedicated facility.
79264709|NCT04803344|Behavioral|Neutral Writing|Participants were asked to write on neutral objects or events.
79264710|NCT04426682|Diagnostic Test|urodynamics parameters|"Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure."
79563805|NCT01704118|Device|ProSeal Laryngeal mask|Supraglottic airway device
79725457|NCT04172545|Procedure|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
79725458|NCT04218253|Dietary Supplement|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
79725459|NCT04218253|Behavioral|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
79725460|NCT02748811|Other|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
79725461|NCT02748733|Other|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
79859881|NCT04987723|Other|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
80021685|NCT03920072|Drug|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
80021686|NCT03534154|Diagnostic Test|MRI|Magnetic Resonance Imaging
80021687|NCT03534154|Diagnostic Test|Blood Sampling|Sampling of serum
80021688|NCT03534154|Diagnostic Test|Microdialysis|Monitoring of cerebral fluid protein levels
79264711|NCT02120183|Behavioral|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)"
80021689|NCT03534154|Diagnostic Test|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
80021690|NCT03534154|Diagnostic Test|MRI (advanced)|Advanced MRI
80021691|NCT03502928|Other|Motor Control|Neck Motor Control
80021692|NCT03502928|Other|Manual Therapy|Massage + Joint Mobilizations
79264712|NCT04803032|Procedure|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
79399501|NCT00698139|Device|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
79563806|NCT01704170|Device|Kona Externally Focused Ultrasound Therapy|
79725462|NCT02748733|Other|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
79725463|NCT02748967|Drug|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
80021693|NCT03502928|Other|Dry Needling|Dry Needling in Neck Muscles
79399502|NCT01400815|Drug|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
80021694|NCT03505736|Biological|Adenosine|Given IV
79264713|NCT04813640|Device|Spectacles|Novel spectacles for myopia control
79264714|NCT04813406|Drug|Anlotinib + Sintilimab|"Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle."
79264715|NCT01331291|Drug|bosutinib|Taken orally
79264716|NCT02120339|Drug|Carvedilol|
79399503|NCT01400815|Drug|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
79399504|NCT02990169|Device|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
79399505|NCT02990169|Device|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
79399506|NCT05086536|Other|no intervention|This is a retrospective and observational study.
79725464|NCT02748967|Drug|Placebo|Participant will receive single dose of Placebo on Day 1.
79399507|NCT02990325|Drug|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
79399508|NCT02990325|Drug|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
79399509|NCT02990325|Drug|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
79563807|NCT01704235|Other|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
79725465|NCT02748655|Other|Alkaline ionized water|
79725466|NCT02748655|Other|Tap water|
79264717|NCT03553199|Device|TRS, Tissue Retraction System|Tissue Retraction System
79264718|NCT02123381|Radiation|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
79399510|NCT01793025|Biological|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
79725467|NCT00635557|Drug|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
79725468|NCT02748499|Other|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
79725469|NCT02748499|Other|Control|Participants maintain their daily acitvities.
79725470|NCT02748577|Other|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
79725471|NCT02748577|Other|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
80021695|NCT03505736|Procedure|Magnetic Resonance Imaging|Undergo CMR imaging
80021696|NCT03505736|Drug|Regadenoson|Given IV
80021697|NCT03505736|Procedure|Stress Management Therapy|Undergo stress test
80031717|NCT02808975|Drug|Adalimumab|Subcutaneous injections administered as described in arm description
79399511|NCT05086458|Dietary Supplement|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
79399512|NCT01795131|Dietary Supplement|Vitamin B12|
79399513|NCT01795131|Dietary Supplement|Placebo|
79399514|NCT02990247|Device|anharmonic morphological analysis of the respiratory signals (AMARS)|
79399515|NCT03136458|Procedure|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
79563808|NCT01704248|Device|Eye Drop Guide technique|"Wash the hands.~Shake and then uncap the bottle.~Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~Then place the upper lip down to cover the whole orbital rim area.~Tilt the head back if seated or standing.~Insert the bottle in the device all the way. Hold the bottle gently.~Look upward.~Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
79563809|NCT01704248|Behavioral|Routine self-instillation technique|"Wash the hands.~Shake and then uncap the bottle.~Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~Lie down or tilt the head back if seated or standing.~Using the other hand, pull the lower lid down.~Hold the bottle over the eye and look up.~Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
79563810|NCT01704313|Procedure|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
79725472|NCT02748187|Other|CBASP|Interpersonal psychotherapy for chronic depression
79264719|NCT02123381|Drug|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
79264720|NCT02123537|Device|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
79399516|NCT03136458|Drug|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
79581298|NCT01934933|Drug|Enbrel plus Celebrex|
79725473|NCT02748421|Procedure|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
79725474|NCT02748421|Procedure|Conventional Microscope|macular membrane dissection without OCT RESCAN
79725475|NCT02748265|Drug|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
79725476|NCT02748265|Drug|Sevoflurane|Volatile maintenance anesthesia
79725477|NCT02748265|Drug|Propofol|Intravenous maintenance anesthesia
79725478|NCT01015833|Drug|Doxorubicin Hydrochloride|Given IV
79859882|NCT04987723|Other|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
79859883|NCT04987060|Device|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
79859884|NCT04987021|Device|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
79725479|NCT01015833|Other|Laboratory Biomarker Analysis|Correlative studies
79725480|NCT01015833|Other|Pharmacogenomic Study|Correlative studies
79859885|NCT04975997|Drug|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
79264721|NCT02120495|Procedure|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
79264722|NCT02120573|Other|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
79264723|NCT02120573|Other|Workshop using Educational Film|workshops using film review about CPR
79264724|NCT02120573|Other|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
79264725|NCT02120573|Other|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
79264726|NCT02116829|Other|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
79264727|NCT02116829|Other|Olive oil|
79399517|NCT02996643|Device|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
79399518|NCT01115283|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
79399519|NCT01115283|Behavioral|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
79725481|NCT01015833|Drug|Sorafenib Tosylate|Given PO
79264728|NCT02123615|Drug|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
79264729|NCT02123615|Drug|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
79859886|NCT04975997|Drug|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7 of a 28-day cycle
79859887|NCT04975997|Drug|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
79859888|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
79859889|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
79859890|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
79859891|NCT04974892|Diagnostic Test|Blood test|Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
79563811|NCT01704313|Procedure|Continuous|Continuous suturing technique used for the anastomosis
79563812|NCT01704339|Drug|QUTENZA|Single treatment with topical capsaicin 8%
79725482|NCT04218175|Other|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
79725483|NCT03523273|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
79264730|NCT02123615|Drug|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
79725484|NCT03523273|Drug|Placebo|Placebo administration will match the study drug.
79399520|NCT01115283|Behavioral|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
79859892|NCT04974086|Other|Sexually transmitted infection (STI) testing clinical decision support (CDS) tool|The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
79859896|NCT04970992|Drug|DZ-002|DZ-002 Injection
79859897|NCT04967287|Device|MyopiaX|MyopiaX treatment twice a day
79859898|NCT04967287|Device|Myopia control spectacles|To be used all as prescribed
79859899|NCT04964765|Diagnostic Test|Mapping|CardioInsightTM Cardiac Mapping System is a non-invasive single beat cardiac mapping system that provides three-dimensional electroanatomic maps of the heart. The CIT vest is attached to the patient's torso for non-invasive mapping. To ensure correct and rapid mapping of the NOAF by the CIT device, it is essential to briefly slow down the patient's heart rate below 50bpm for a few seconds. Therefore 6mg adenosine as a rapid i.v. bolus will be administered. The adenosine application will slow down the patient's heart rate and allow for correct mapping by the CIT device. Medical therapy of atrial fibrillation is started immediately according to local protocol. Since non-invasive mapping is performed within a few minutes, the therapy of atrial fibrillation will not be critically delayed. Consecutively, a low-dose thoracic computed tomography (CT) scan (neck to upper abdomen) will be performed independent from the patient's rhythm.
79875855|NCT00443118|Device|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
79264731|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
79399521|NCT03137004|Drug|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
79399522|NCT03137004|Drug|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
79563813|NCT01704352|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
79563814|NCT01704378|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
79264732|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
79563815|NCT01704417|Drug|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
79563816|NCT01704417|Drug|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
79563817|NCT01704430|Dietary Supplement|Glutamine|Enteric L-Glutamine
79563818|NCT01704430|Dietary Supplement|Maltodextrin|Enteric Maltodextrin
79581299|NCT01934946|Other|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
79581300|NCT01934946|Other|home rehabilitation|6 times home rehabilitation services within 3 months
79581301|NCT01934959|Drug|Bifico|
79581302|NCT01935011|Other|PD, DBS|PD DBS frequency on swallowing function
79264733|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
79264734|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
79399523|NCT00706407|Device|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
79264735|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
79264736|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
79725485|NCT02746939|Behavioral|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
79859900|NCT04964765|Diagnostic Test|Computed tomography scan|The CT scans will follow a standardised protocol as predefined by the manufacturer of the CIT vest, Medtronic (Dublin, Ireland). After the sensor array has been placed on the patient, the patient is ready to undergo a CT scan to register each electrode's locations with respect to the body surface. All CT scans cover a body region from neck to the upper abdomen, have no cardiac gating performed or any contrast agent given. The CT scans are acquired on 3 CT scanners manufactured by Siemens Corporation (Berlin, Germany) with a fixed tube voltage of 80 kVp and 250 effective mAs (=mAs/pitch). The reconstruction parameters are of 3 mm slice thickness and of 1.5 mm increment (slice overlap) The estimated effective dose (ED) is 3.2 mSv per patient.
79725486|NCT04217941|Procedure|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
79725487|NCT04217941|Drug|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
79563819|NCT01704443|Behavioral|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
79264737|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
79399524|NCT03113994|Drug|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
79725488|NCT04217629|Drug|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
79399525|NCT03113994|Drug|Placebo Oral Tablet|Placebo, daily for 12 months
79399526|NCT03113994|Dietary Supplement|Coenzyme Q10|100mg CoQ10, daily for 12 months
79399527|NCT03113994|Dietary Supplement|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
79399528|NCT03113994|Dietary Supplement|Vitamin D|2000IU Vitamin D, daily for 12 months
79399529|NCT00706485|Device|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
79399530|NCT02003742|Drug|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
79563820|NCT01704443|Other|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
79399531|NCT02003742|Drug|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
79399532|NCT01101555|Drug|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
79399533|NCT01101555|Other|Placebo|Placebo will be given to one member of each cohort.
79399534|NCT03110016|Device|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
79399535|NCT03134118|Drug|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
79399536|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
79563821|NCT01704469|Procedure|The local anesthetic injection|
79563822|NCT01704482|Drug|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
79264738|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
79399537|NCT05085912|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
79563823|NCT01704482|Drug|placebo|
79563824|NCT01704508|Drug|Artemether-lumefantrine|
79563825|NCT01704508|Drug|Dihydroartemisinin-piperaquine|
79859901|NCT04961996|Drug|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
79563826|NCT01704534|Drug|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
80021698|NCT03532750|Device|Particle|"300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
79563827|NCT01704560|Other|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
79563828|NCT01704573|Drug|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-[18F]FA radioligand. The 2-[18F]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-[18F]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-[18F]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-[18F]FA from the FDA."
79563829|NCT01704586|Radiation|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
79563830|NCT01704586|Radiation|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
79563831|NCT01704612|Drug|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
79859902|NCT04961996|Drug|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
79859903|NCT04961996|Drug|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
79859904|NCT04961996|Drug|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
80021699|NCT03532750|Device|Coil|Ruby or Interlock detachable coils
80021700|NCT04027114|Behavioral|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
80021701|NCT02309996|Behavioral|Supervisor Training Program|
79725489|NCT02748343|Device|allograft bone|Use of the allograft bone to treat the bone defect in patients
79725490|NCT02748343|Device|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
79725491|NCT02695381|Drug|Etodolac-lidocaine topical patch|Once daily
79875856|NCT00443118|Device|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
80021702|NCT03103126|Behavioral|Combined resistance exercise and walking|Combined resistance exercise and walking
79264739|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
79264740|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
79264741|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
79264742|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
79264743|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
79725492|NCT02695381|Drug|Placebo|Once daily
79725493|NCT02748109|Behavioral|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
79725494|NCT02748109|Behavioral|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
79875857|NCT00443118|Device|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
79875858|NCT00460434|Device|TVT|Prophylactic TVT
79875859|NCT00460434|Other|Sham|Sham TVT
79859905|NCT04958265|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing 40 to <100 kg) or 1500 mg IV (for participants weighing >=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing 40 to <100 kg) or 1020 mg SC (for participants weighing >=100 kg). Enrollment of participants weighing <40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing >=20 kg to <40 kg, followed by Group 2 participants weighing >=5 kg to <20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
79563832|NCT01704625|Procedure|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
79563833|NCT01704625|Procedure|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
79875860|NCT01023048|Other|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
79875861|NCT01026558|Drug|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
79875862|NCT01023126|Behavioral|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
80021703|NCT02313350|Device|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
80021704|NCT02313350|Procedure|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
80021705|NCT05064748|Drug|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
79264744|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
79264745|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
79264746|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
79264747|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
79264748|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
79875863|NCT01025700|Drug|Cesemat|1 mg capsule per day for 21 days
79875864|NCT00373425|Drug|Erlotinib|150 mg tablet
79875865|NCT00373425|Drug|Placebo|Placebo tablet
79875866|NCT00459342|Drug|dasatinib|Given orally
79875867|NCT03510156|Behavioral|Behavior analytic treatment|Function-based treatment
80021706|NCT02316626|Drug|Subcutaneous progesterone|25 mg daily for 14 days
80021707|NCT02316626|Drug|Vaginal progesterone|90 mg daily for 14 days
80021708|NCT05065060|Other|Observation|Observation
79264749|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
79563834|NCT01704638|Drug|fluvoxamine|
79563835|NCT01704638|Drug|Digoxin|
79563836|NCT01704664|Dietary Supplement|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
79581303|NCT01935024|Other|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
79725495|NCT02746861|Behavioral|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
79725496|NCT02746783|Drug|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
79264750|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
79264751|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
79264752|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
79264753|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
79264754|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
79264755|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
79264756|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
79264757|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
79725497|NCT02746783|Drug|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
79725498|NCT02748031|Procedure|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
79264758|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
79563837|NCT01704664|Drug|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
79264759|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
79264760|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
79725499|NCT02747953|Drug|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
79725500|NCT02747797|Drug|Lucitanib|10 mg orally daily
79264761|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
79725501|NCT02747719|Behavioral|Light and exercise|Exposure to light and exercise
79725502|NCT02747641|Procedure|Pixel CO2 Laser System|
79725503|NCT02747563|Other|Blood test (PSA)|Measurement of blood PSA levels
79725504|NCT02735239|Drug|Durvalumab|
79875868|NCT00443040|Drug|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
79875869|NCT00443040|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
79875870|NCT00442962|Drug|Efavirenz|600-mg tablet taken orally daily
79264762|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
79264763|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
79264764|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
79264765|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
79264766|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
79264767|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
79399538|NCT05085912|Procedure|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
79399539|NCT05085912|Procedure|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
79399540|NCT02339415|Drug|Edoxaban 30mg daily|
79399541|NCT02339415|Drug|Matching placebo|
79581304|NCT01935050|Behavioral|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
79725505|NCT02735239|Drug|Tremelimumab|
79264768|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
79264769|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
79264770|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
79264771|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
79725506|NCT02735239|Drug|Oxaliplatin|IV administered Chemotherapy
79725507|NCT02735239|Drug|Capecitabine|orally-administered chemotherapy
79725508|NCT02735239|Radiation|Radiotherapy|
79725509|NCT02735239|Drug|Paclitaxel|IV administered Chemotherapy
79725510|NCT02735239|Drug|Carboplatin|IV administered Chemotherapy
79725511|NCT02735239|Drug|5-fluorouracil (5-FU)|IV administered Chemotherapy
79725512|NCT02735239|Drug|Leucovorin|orally-administered chemo-protective agent
79725513|NCT02735239|Drug|docetaxel|IV administered Chemotherapy
79725514|NCT02655523|Drug|Triamcinolone|1 mL of 40 mg of Triamcinolone
79725515|NCT02655523|Drug|Dexamethasone|1 mL of 4mg of Dexamethasone
79725516|NCT02655523|Drug|Normal Saline|1 mL of preservative free normal saline
79725517|NCT02655523|Drug|Bupivacaine|2 mL of 0.5% bupivacaine
79725518|NCT02644291|Drug|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
79725519|NCT01015677|Drug|MK-6913|
79725520|NCT01015677|Drug|17-β estradiol|
79725521|NCT01015677|Drug|Placebo to MK-6913|
79725522|NCT01015677|Drug|Placebo to 17-β estradiol|
79725523|NCT01015677|Drug|MK-6913 25 mg|
79725524|NCT02281981|Dietary Supplement|Curcumin|333mg CurcuWin OAHTCUR002-2014
79725525|NCT02281981|Dietary Supplement|Placebo|OAHTCUR005-2014
79875871|NCT00442962|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
79875872|NCT03995160|Procedure|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
79563838|NCT01704664|Dietary Supplement|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
79264772|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
79264773|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
79725526|NCT00628017|Dietary Supplement|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
79725527|NCT04298619|Diagnostic Test|Standard cohort: Clinical lab follow-up|
79725528|NCT04298619|Diagnostic Test|Imaging cohort: integrated imaging follow-up|
79725529|NCT04297839|Drug|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
79725530|NCT04297839|Drug|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
79725531|NCT02746549|Other|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
79859906|NCT04956549|Behavioral|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
79859907|NCT04956549|Behavioral|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
79859908|NCT04955743|Drug|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
79859909|NCT04955743|Drug|Lenvatinib|20 mg orally (PO) is administered daily
79859910|NCT04950075|Drug|INBRX-109|Tetravalent DR5 Agonist Antibody
79859911|NCT04950075|Drug|Placebo|Placebo
79859912|NCT04945018|Biological|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
79859913|NCT04945018|Device|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
80021709|NCT03502850|Drug|ASK120067|patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
80021710|NCT03100162|Dietary Supplement|Probiotic|
80021711|NCT03100162|Dietary Supplement|Placebo|
80021712|NCT03505658|Behavioral|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
79264774|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
79264775|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
80021713|NCT05063890|Procedure|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
80021714|NCT05063890|Procedure|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
79264776|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
79264777|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
79264778|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
79859914|NCT04943328|Device|Total Hip Arthroplasty|cemented hip arthroplasty
80021715|NCT05063890|Procedure|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
80021716|NCT05063890|Procedure|Heating and TENS|Heating and TENS for 10 minutes
79264779|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
79399542|NCT05085444|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
79399543|NCT02998047|Drug|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of multiple myeloma.
79399544|NCT03110172|Drug|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
79399545|NCT02964546|Other|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
79399546|NCT00706563|Biological|Fluarix™|Single intramuscular dose on Day 0
79563839|NCT01704664|Drug|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
79563840|NCT01704677|Procedure|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
79859915|NCT04940078|Drug|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
79859916|NCT04940078|Drug|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
79859917|NCT04940078|Drug|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
79563841|NCT01704677|Behavioral|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
79859918|NCT04938362|Other|FDG-PET|[18F]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
80021717|NCT03502772|Other|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
79563842|NCT01704690|Drug|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
79563843|NCT01704690|Drug|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
79725532|NCT02751229|Behavioral|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~Considering pros and cons of disclosing:~hurtful and helpful attitudes about mental illness~identify beliefs participants hold about themselves~explore five-step process to challenge their personally hurtful beliefs~weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~Different ways to disclose:~different levels of (non-) disclosure and how to weigh the cons and pros~disclosure via social media versus disclosing face to face~how to find people that are better to disclose to than others and how to 'test them out'~participants will discuss how others might respond to their disclosure and how that will affect them~Telling your story:~how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
79859919|NCT04938362|Other|EEG|Electroencephalography (EEG) at 0-10 years after brain abscess
79399547|NCT05084898|Other|Far-UVC light as an additional method of disinfection|Far-UVC light is a form of ultraviolet light with an extremely short wavelength (207-222 nm)
79563844|NCT01704690|Drug|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
80021718|NCT03502772|Other|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
80031718|NCT04881136|Device|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
79264780|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
79264781|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
79264782|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
79563845|NCT01704703|Drug|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
79563846|NCT01704703|Drug|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
79563847|NCT01704716|Drug|Vincristine|given during Rapid COJEC and modified N7 therapy
79563848|NCT01704716|Drug|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
79563849|NCT01704716|Drug|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
79563850|NCT01704716|Drug|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
79859920|NCT04936035|Drug|Placebo|Placebo administered by SC injection
79859921|NCT04936035|Drug|ALN-AGT01|ALN-AGT01 administered by SC injection
79399548|NCT05084898|Other|Placebo fluorescent light|"Inactive fluorescent light (no additional disinfection)"
79399549|NCT05084820|Combination Product|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
79859922|NCT04934839|Diagnostic Test|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
80021719|NCT03505502|Drug|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
80021720|NCT03977896|Procedure|11C-MET PET/MRI|"Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL)."
80021721|NCT03501758|Diagnostic Test|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
79725533|NCT02751151|Other|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
79725534|NCT02747251|Other|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
79725535|NCT02747251|Other|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
79725536|NCT04216537|Diagnostic Test|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
79399550|NCT05084820|Combination Product|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
79399551|NCT01400503|Drug|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
79399552|NCT05082324|Other|Adapted physical activity|Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
79399553|NCT00706719|Drug|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
79399554|NCT00706719|Drug|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
79399555|NCT05079672|Drug|Dexmedetomidine|Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
79399556|NCT05079672|Drug|0,9% Saline|Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
79399557|NCT03138018|Diagnostic Test|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
79399558|NCT03138018|Diagnostic Test|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
79399559|NCT01400425|Drug|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose
79399560|NCT03137862|Other|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
79399561|NCT03137862|Dietary Supplement|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
79399562|NCT03137862|Dietary Supplement|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
79399563|NCT02996331|Other|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
79563851|NCT01704716|Drug|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
79563852|NCT01704716|Drug|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
79563853|NCT01704716|Drug|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
79725537|NCT02695303|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
79725538|NCT04216459|Drug|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR < 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
79563854|NCT01704716|Drug|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
79725539|NCT04216459|Drug|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
79725540|NCT02747485|Device|Cardiac MRI|
79725541|NCT02747485|Biological|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
79725542|NCT02747485|Procedure|myocardial biopsy|
79563855|NCT01704716|Drug|G-CSF|G-CSF is given during Induction Treatment
79725543|NCT02747485|Genetic|blood samples|extract DNA to look for genomic mutations associated with the disease.
79725544|NCT04216771|Drug|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
79859923|NCT04931342|Drug|Ipatasertib|Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
79859924|NCT04931342|Drug|Cobimetinib|Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
79859925|NCT04931342|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
79725545|NCT04216771|Drug|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
79725546|NCT02747095|Device|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
79859926|NCT04931342|Drug|Atezolizumab|Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
79859927|NCT04931342|Drug|Bevacizumab|Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
79859928|NCT04931342|Drug|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
79725547|NCT00636259|Drug|Bicalutamide (Casodex)|150mg
79859929|NCT04931342|Drug|Giredestrant|Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
79859930|NCT04931342|Drug|Abemaciclib|Abemaciclib will be administered by mouth twice a day during each 28-day cycle
79859931|NCT04931342|Drug|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
79859932|NCT04931342|Drug|Palbociclib|Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
79859933|NCT04931342|Drug|Letrozole|Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
79563856|NCT01704716|Drug|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
79563857|NCT01704716|Drug|Melphalan|Melphalan is given during MAT treatment
79563858|NCT01704729|Procedure|group1|Non-cycloplegic self-refraction +conventional glasses
79563859|NCT01704729|Procedure|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
79563860|NCT01704729|Procedure|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
79563861|NCT01704729|Procedure|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
79725548|NCT02737033|Drug|Rhodiola|Rhodiola rosea 800mg
79725549|NCT02737033|Drug|Placebo|innocuous pill manufactured to mimic Rhodiola
79725550|NCT02736799|Device|Sham vibrating capsule|Sham device without vibration
79725551|NCT02736799|Device|Vibrant Capsule (1 vibration)|1 vibration/min
79725552|NCT02736799|Device|Vibrant Capsule (3 vibration)|3 vibration/min
79725553|NCT02736799|Device|Vibrant Capsule (5 vibration)|5 vibration/min
79725554|NCT02736487|Device|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
79725555|NCT02736487|Device|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
79725556|NCT03565939|Biological|Trichuris suis ova|Eggs from the pig whipworm
79725557|NCT03565939|Biological|Placebo|Solution without TSO
79725558|NCT02736331|Dietary Supplement|Treatment 1|Treatment 1 Beverage
79725559|NCT02736331|Dietary Supplement|Treatment 2|Treatment 2 Beverage
79725560|NCT02736019|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
79725561|NCT02736019|Drug|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
79859934|NCT04931342|Drug|Olaparib|Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
79859935|NCT04931342|Drug|Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
79859936|NCT04931342|Drug|Cyclophosphamide|Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
79859937|NCT04931342|Drug|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
79264783|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
79563862|NCT01704768|Behavioral|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
79563863|NCT01704768|Behavioral|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
79563864|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
79725562|NCT02736019|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
79725563|NCT02736019|Drug|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
79725564|NCT02735863|Drug|ABX464|50 mg or 150mg once daily for 28 days
79725565|NCT02735863|Drug|Placebo|ABX464 matching placebo
79725566|NCT02735785|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
79725567|NCT04286581|Device|I-Gel Laryngeal Mask Airway|The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
79725568|NCT04286581|Device|Ambu Auragain Laryngeal Mask Airway|The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
79725569|NCT05595889|Drug|Surufatinib|250 mg/day p.o. QD
79725570|NCT05595889|Drug|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
80021722|NCT03501758|Diagnostic Test|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
80021723|NCT02316704|Device|THA with G7 PPS coted acetabular component|
80021724|NCT02316704|Device|THA with G7 OsseoTi coted acetabular component|
80021725|NCT03501680|Drug|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
80021726|NCT03501680|Device|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
80021727|NCT03502694|Drug|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
80021728|NCT03502694|Drug|Placebo|Participants will receive matching placebo tablets orally.
79264784|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
79264785|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
79264786|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
79264787|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
79264788|NCT02123693|Other|Osteopathic manipulative treatment|
79264789|NCT02123693|Other|Sham Therapy|
79264790|NCT02123693|Other|No Intervention|
79725571|NCT02735629|Drug|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
79725572|NCT02735629|Drug|CX1739 - 600 mg|CX1739 - 600 mg
79725573|NCT02735629|Drug|CX1739 - 900 mg|CX1739 - 900 mg
79725574|NCT02735629|Drug|Placebo|Placebo to 300 mg CX1739
79725575|NCT02735395|Procedure|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
79725576|NCT02735395|Drug|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
80021729|NCT05059756|Device|PTNS|PTNS and PFR
80021730|NCT05059756|Device|Sham PTNS|Sham PTNS and PFR
79264791|NCT02116907|Drug|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
79264792|NCT02116985|Device|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
79725577|NCT02735395|Drug|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
80021731|NCT03486912|Drug|BMS-986036|Specified dose on specified days.
79725578|NCT02735395|Drug|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
79859938|NCT04930406|Other|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
79859939|NCT04925427|Behavioral|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
79859940|NCT04925427|Behavioral|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
79859941|NCT04922333|Drug|Risedronate|150mg over-encapsulated risedronate
79563865|NCT01704794|Drug|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
79563866|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
79725579|NCT02735395|Drug|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
80021732|NCT03486912|Other|Placebo|Specified dose on specified days.
80021733|NCT02310074|Drug|Pulsatile Gonadotropin Releasing Hormone|
79725580|NCT02735395|Drug|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
79725581|NCT02735395|Other|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
79725582|NCT02735395|Other|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
79725583|NCT02735395|Other|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
79725584|NCT02735395|Other|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
80021734|NCT02310074|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
79725585|NCT02741947|Drug|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
79725586|NCT02741947|Drug|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
79725587|NCT05629195|Device|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
80021735|NCT02310074|Drug|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
80021736|NCT05059912|Biological|Humanized CD7 CAR-T cells|Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
80021737|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
80021738|NCT05063968|Drug|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
80021739|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
80021740|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
80021741|NCT05063968|Drug|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
80021742|NCT05063968|Drug|Placebo|Tablet is administered orally once daily for 14 Days continuously
80021743|NCT02313584|Drug|dabigatran|
79725588|NCT02741869|Device|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
79859942|NCT04922333|Drug|Placebo|Capsules containing placebo tablets
79859943|NCT04916002|Drug|vidutolimod|Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
80021744|NCT02313584|Drug|placebo|
80021745|NCT02310152|Behavioral|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
80021746|NCT02310152|Behavioral|CBT|Cognitive Behavioral Therapy
80021747|NCT05063578|Drug|Lidocaine 2% Injectable Solution|Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
80021748|NCT02310230|Device|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
80021749|NCT02667652|Procedure|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
80021750|NCT02667652|Procedure|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
80031719|NCT04885738|Other|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
80031720|NCT02050191|Behavioral|www.princetonlivingwell.com|
79563867|NCT01704807|Device|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
79563868|NCT01704807|Device|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
79563869|NCT01704820|Procedure|Retroflexion in the right colon|
79725589|NCT02741557|Drug|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
79725590|NCT02741557|Drug|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
79725591|NCT02741557|Drug|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
79399564|NCT02996331|Other|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
79399565|NCT02996331|Other|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
79399566|NCT04766827|Drug|albumin-bound paclitaxel|Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
79399567|NCT02960568|Drug|Primaquine|30 mg oral primaquine one time
79399568|NCT02996175|Behavioral|Behavioral Sleep Treatment|"Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~Information on healthy sleep hygiene, preventative techniques, and use of visual supports~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~Information on procedures for delayed sleep onset and problematic sleep associations~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
79859944|NCT04916002|Drug|cemiplimab|Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
79264793|NCT02116985|Device|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
79399569|NCT02996175|Behavioral|Standard of care sleep treatment enhanced with psychoeducation|"Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~Introduction to understanding and interpreting results from clinical evaluations~Introduction to educational planning, expectations, and transition planning~Introduction to lifespan development and advocacy and support services available~Feedback on current concerns and methods for obtaining services to manage concerns"
80021751|NCT02310308|Dietary Supplement|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
80031721|NCT02976038|Drug|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
79399570|NCT02948790|Device|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
79264794|NCT03553121|Other|walking|walking and not walking
79264795|NCT02120651|Procedure|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
79399571|NCT02948790|Device|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
79399572|NCT02996409|Drug|HVIGI|High Volume Image-Guided Injection with a saline/lidocain solution
79563870|NCT01704833|Behavioral|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
79399573|NCT02996409|Drug|LVIGI|Placebo control with injection of a saline/lidocain solution (low volume)
79399574|NCT02996409|Other|Progressive exercise program|A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
79399575|NCT02997111|Device|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
79399576|NCT02996565|Other|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~Improved recognition of uncontrolled BP at primary care encounters,~Therapeutic action to address uncontrolled BP at primary care encounters,~Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
79563871|NCT01704872|Drug|ch14.18/CHO|
79563872|NCT01704885|Behavioral|Play Intervention|
79563873|NCT01704885|Other|Questionnaires|
79859945|NCT04915924|Device|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
79859946|NCT04914234|Drug|Atenolol Succinate Oral Tablet|Atenolol 50 mg
79859947|NCT04914234|Drug|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
79859948|NCT04913311|Procedure|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
79859949|NCT04913311|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
79859950|NCT04913311|Other|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
79859951|NCT04913311|Procedure|Computed Tomography|Undergo computed tomography scan
79859952|NCT04913311|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79264796|NCT02120651|Procedure|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
79563874|NCT01704898|Drug|Efavirenz 600 Test-Stocrin 600 Reference|
79563875|NCT01704898|Drug|Stocrin 600 Reference-Efavirenz 600 Test|
79859953|NCT04913311|Drug|Immune Checkpoint Inhibitor|Receive CPI per standard of care
79563876|NCT01704911|Procedure|Transradial Coronary Intervention|
79563877|NCT01704911|Procedure|Transfemoral Coronary Intervention|
79563878|NCT01704911|Device|Coronary Stent System|Any kind of coronary stent system
79859954|NCT04913311|Procedure|Nasal Wash and Collection|Undergo nasal wash
79859955|NCT04913311|Other|Quality-of-Life Assessment|Ancillary studies
79859956|NCT04913311|Other|Questionnaire Administration|Ancillary studies
79859957|NCT04913311|Procedure|Spirometry|Under lung spirometry tests
80021752|NCT04412434|Diagnostic Test|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
80021753|NCT02316782|Device|Blinded IVUS assessment|Only the angiogram is used for stent placement
80021754|NCT02316782|Device|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
80021755|NCT03545568|Other|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
80021756|NCT03845374|Device|Hyper-CL™ lens|Use of the Hyper-CL™
80021757|NCT02140710|Procedure|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
80021758|NCT05063422|Drug|polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose|3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges
79725592|NCT02741479|Other|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
80031722|NCT02669511|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
79264797|NCT02117219|Biological|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
79563879|NCT01704924|Device|Prevena|Device will be applied at end of procedure over closed incision
79563880|NCT01704924|Procedure|Standard of Care Dressing|Dressing applied as Standard of Care
79563881|NCT01704937|Drug|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
79563882|NCT01704989|Procedure|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
79725593|NCT02741401|Other|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
79725594|NCT02741401|Other|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
79725595|NCT02741167|Procedure|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
79725596|NCT02740933|Drug|Demeclocycline|
79859958|NCT04913220|Drug|THOR-707|Solution for infusion: intravenous infusion
79859959|NCT04913220|Drug|Cemiplimab|Solution for infusion: intravenous infusion
79859960|NCT04912960|Device|Mechanical ventilation|Optimum PEEP
79859961|NCT04904588|Drug|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
79859962|NCT04904588|Drug|Busulfan|Given IV pre-transplant as part of conditioning regimen
79859963|NCT04904588|Drug|Fludarabine|Given IV pre-transplant as part of conditioning regimen
79859964|NCT04904588|Radiation|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
79859965|NCT04904588|Drug|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
79859966|NCT04904588|Drug|Melphalan|Given IV pre-transplant as part of conditioning regimen
79859967|NCT04904588|Procedure|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
79859968|NCT04904588|Procedure|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
79859969|NCT04904588|Drug|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
79859970|NCT04904588|Drug|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
79859971|NCT04904588|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
79859972|NCT04904588|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
79859973|NCT04904588|Other|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
79264798|NCT02117219|Drug|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
79725597|NCT02741089|Procedure|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
79399577|NCT02996565|Other|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~Systematic home BP telemonitoring with data transmitted into patient medical record~Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email"
79563883|NCT01704989|Drug|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
79264799|NCT02117219|Biological|tremelimumab|tremelimumab will be administered by IV infusion
79264800|NCT03553043|Behavioral|Intervention|Energy label condition.
79264801|NCT03553043|Behavioral|Control|No label
79859974|NCT04897243|Drug|Biktarvy|B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
79563884|NCT01705002|Drug|Promitil|2 mg/kg dose IV
79563885|NCT01705002|Drug|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
79563886|NCT01705002|Drug|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
79264802|NCT02117375|Device|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
79563887|NCT01705015|Behavioral|direct feedback about exercise|
79563888|NCT01705015|Behavioral|PLacebo|UCFit plus encouraged exercise
79725598|NCT02740855|Device|Alcomed 3011®|Endtidal ethanol measurement
79725599|NCT02694991|Other|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
79563889|NCT01705041|Device|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
79563890|NCT01705093|Dietary Supplement|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
79859975|NCT04897243|Behavioral|Patient Experience|To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
79399578|NCT01421719|Drug|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
79399579|NCT01421641|Drug|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
79399580|NCT01421641|Drug|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
79399581|NCT02591082|Device|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
79563891|NCT01705093|Dietary Supplement|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
79859976|NCT04896372|Other|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
79264803|NCT02117375|Other|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
79264804|NCT02117375|Other|brain MRI follow-up|
79264805|NCT02117453|Drug|Rosuvastatin|Rosuvastatin 20 mg/day
79264806|NCT02117453|Drug|Placebo|Placebo
79264807|NCT02117609|Dietary Supplement|New DELICAL formula|3 months with the option of continuing until 6 months.
79264808|NCT02117609|Dietary Supplement|Standard DELICAL formula|3 months with the option of continuing until 6 months.
79264809|NCT02123927|Drug|TAK-438|TAK-438 tablets
79264810|NCT02123927|Drug|Placebo|TAK-438 placebo-matching tablets
79264811|NCT02124005|Drug|Bupivacaine|
79264812|NCT03551873|Drug|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
79859977|NCT04896372|Other|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
79859978|NCT04895709|Drug|BMS-986340|Specified dose on specified days
79859979|NCT04895709|Drug|BMS-936558-01|Specified dose on specified days
80031723|NCT04885894|Drug|Zeposia|Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
80031724|NCT04885660|Drug|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
79264813|NCT02120729|Other|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
79264814|NCT02120885|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
79264815|NCT02117765|Drug|Ustekinumab|
79264816|NCT02251535|Device|ATTUNE® Knee System|
79264817|NCT02251535|Device|PFC® SIGMA® Knee System|
79399582|NCT01385995|Device|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
79399583|NCT01385995|Device|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
79563892|NCT01705197|Drug|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
79563893|NCT01705223|Biological|DNA vaccine|4mg/dose, three doses at week 0,4,8
79399584|NCT05068206|Drug|AK105 injection|AK105 is programmed death 1（PD-1） monoclonal antibody
79399585|NCT05068206|Drug|Anlotinib hydrochloride capsule|Anlotinib is small molecule multi-target tyrosine kinase inhibitor.
79725600|NCT02741011|Other|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
79859980|NCT04895709|Drug|Docetaxel|Specified dose on specified days
79264818|NCT02120963|Behavioral|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
79264819|NCT02121119|Drug|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
79563894|NCT01705223|Biological|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
79563895|NCT01705223|Biological|rTV boost|at week 16
79563896|NCT01705223|Biological|rTV boost|at week 24
79563897|NCT01705223|Biological|rTV boost|at week 32
79563898|NCT01705249|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
79264820|NCT02121119|Drug|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
79264821|NCT02124239|Drug|Ingenol mebutate|
79563899|NCT01705275|Drug|ONO-8539|ONO-8539
79563900|NCT01705275|Other|Placebo|Identical to ONO-8539 tablet but without active ingedient
79859981|NCT04894110|Biological|EO2002|EO2002 (magnetic human corneal endothelial cells [HCECs]) with and without endothelial brushing (EB) or Descemet Stripping (DS)
79859982|NCT04894110|Biological|EO2002 low dose|Low dose of EO2002 (magnetic human corneal endothelial cells)
79859983|NCT04894110|Biological|EO2002 mid dose|Mid dose of EO2002 (magnetic human corneal endothelial cells)
79264822|NCT02121197|Drug|Ozurdex|
79264823|NCT02124317|Drug|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
79399586|NCT05068206|Drug|CapeOX|CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
79399587|NCT05068206|Drug|Bevacizumab|Bevacizumab is a recombinant human monoclonal antibody.
79399588|NCT05063370|Drug|Levosimendan|Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
79725601|NCT02740465|Behavioral|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
79725602|NCT02740465|Behavioral|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
79725603|NCT00636337|Behavioral|Attention Training|Computer program training for attention difficulties.
79725604|NCT00636337|Behavioral|Placebo|Comparison computer program
79725605|NCT02740387|Drug|OTO-104|
79725606|NCT03699163|Diagnostic Test|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
79725607|NCT02746393|Other|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
79725608|NCT02746393|Other|211 Information Sheet|Receive a printed list of community resources to address social needs.
79725609|NCT02740309|Behavioral|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
79725610|NCT02740309|Behavioral|Treatment as usual|Facilitated community referral for mental health treatment
79725611|NCT02746237|Drug|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
79725612|NCT02746237|Drug|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
79725613|NCT02739841|Other|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
79725614|NCT02739841|Other|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
79725615|NCT02739763|Biological|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
79725616|NCT02739685|Device|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
79725617|NCT02739685|Device|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
79725618|NCT02735317|Drug|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
79264824|NCT02124317|Drug|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
79264825|NCT02601560|Biological|MEDI6012|Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
79264826|NCT02601560|Biological|Placebo SC|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
79264827|NCT02601560|Biological|Placebo IV|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
79399589|NCT05063370|Drug|Standard Care|Patients will not receive Levosimendan and will receive standard care according to the institution protocol
79399590|NCT02590380|Device|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
79399591|NCT02590380|Device|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
79859984|NCT04894110|Biological|EO2002 high dose|High dose of EO2002 (magnetic human corneal endothelial cells)
79859985|NCT04892186|Drug|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
79859986|NCT04892186|Drug|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
79875873|NCT03995160|Procedure|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
79563901|NCT01705301|Device|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
79563902|NCT01704963|Drug|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
79563903|NCT01705314|Dietary Supplement|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
79563904|NCT01705314|Dietary Supplement|placebo|7mls of placebo drops per week for 8 months.
79563905|NCT01705340|Drug|Akt inhibitor MK2206|Given PO
79563906|NCT01705340|Biological|trastuzumab|Given IV
79563907|NCT01705340|Drug|lapatinib ditosylate|Given PO
80031725|NCT04885660|Drug|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
80031726|NCT02050269|Drug|Iohexol|Iohexol, 300 mg/mL
79725619|NCT02735317|Drug|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
79563908|NCT01705340|Other|laboratory biomarker analysis|Optional correlative studies
79725620|NCT02735161|Other|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
79725621|NCT02735161|Other|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
79725622|NCT02746315|Drug|HS-20004|
79725623|NCT02746315|Drug|Placebo|
79725624|NCT05548621|Other|Decision aid|Online interactive decision aid for RCC
79725625|NCT02739529|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
79725626|NCT02739607|Behavioral|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
79725627|NCT05629975|Dietary Supplement|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum& bifidobacterium (500 mg) every day for 7 days."
79725628|NCT02739451|Procedure|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~low-flow oxygen [including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask]~or medium-flow oxygen [Venturi masks and medium-flow facemasks]"
79859987|NCT04890652|Behavioral|4-week intervention|All participants will receive a digital intervention to reduce drinking for 4 weeks. There will be two sessions each week using an alcohol intervention combined with breathing-based stress management.
79859988|NCT04886999|Behavioral|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
79875874|NCT01028508|Drug|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
79875875|NCT01028508|Procedure|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
79264828|NCT02117843|Device|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
79264829|NCT05345483|Device|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter
79563909|NCT01705366|Procedure|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
79563910|NCT01705366|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
79563911|NCT01705366|Procedure|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
79399592|NCT02553954|Procedure|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
79264830|NCT02117921|Behavioral|One-on-one interview and educational sessions. Reading material for educational series provided.|A one-on-one interview with the patient and the principal investigator and group educational sessions.
79875876|NCT01026636|Drug|Ceftobiprole|
79875877|NCT00313300|Drug|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
79264831|NCT02121353|Drug|Lucentis|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
79399593|NCT05377866|Other|Remote proctoring using HoloLens|Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
79399594|NCT01421017|Radiation|Radiation|
79875878|NCT00313300|Drug|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
79399595|NCT01421017|Drug|Imiquimod|
79399596|NCT01421017|Drug|Cyclophosphamide|
79725629|NCT02739451|Procedure|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher&Paykel, Courtaboeuf, France).
79725630|NCT02734927|Other|realization of computerized exercises|
79875879|NCT00313300|Drug|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
79875880|NCT00313300|Drug|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
79725631|NCT05629819|Device|Non-invasive phrenic nerve stimulation|Some studies have shown that PNS can relieve diaphragmatic atrophy and reverse diaphragmatic dysfunction.
79875881|NCT01023282|Drug|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
79264832|NCT02121353|Drug|PF582|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
79264833|NCT04812938|Diagnostic Test|Patients with Ovarian cancer and pap test available|Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.
79264834|NCT02118077|Biological|G17DT|
79563912|NCT01705366|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
79563913|NCT01705366|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
79563914|NCT01705366|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
79563915|NCT01705379|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
79563916|NCT01705392|Drug|Bevacizumab|Bevacizumab 10 mg/kg q3w
79563917|NCT01705392|Drug|Propranolol|Propranolol 80 mg x 1
79563918|NCT01705392|Drug|Enalapril|Enalapril 5 mg x 1
79563919|NCT01705392|Drug|Dacarbazine|dacarbazine 1000 mg/m2 q3w
79563920|NCT01705405|Device|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
79563921|NCT01705431|Behavioral|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
79563922|NCT01705444|Device|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
79563923|NCT01705457|Drug|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
79563924|NCT01705457|Drug|placebo|
79563925|NCT01705470|Drug|furosemide|
79563926|NCT01705470|Drug|placebo normal saline|
79563927|NCT01705483|Drug|ASP9853|oral
79563928|NCT01705483|Drug|Docetaxel|intravenous (IV)
79563929|NCT01705483|Drug|Paclitaxel|Taxol
79725632|NCT02735005|Other|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
79725633|NCT04257097|Device|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
79875882|NCT01023282|Drug|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
79875883|NCT00459186|Drug|RAD001|Daily for two weeks
79875884|NCT00459186|Drug|Docetaxel|Infusion once per cycle
79875885|NCT00459186|Drug|Prednisone|Prednisone 5 mg by mouth twice daily
79264835|NCT02124473|Other|Homeopathy|
79264836|NCT02124473|Other|Placebo|
79563930|NCT01705535|Behavioral|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
79875886|NCT01026714|Drug|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
79875887|NCT01026714|Drug|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
79875888|NCT01026714|Drug|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
79264837|NCT04350008|Device|Renamic Neo programmer device, including software; PK-222-L ECG cable|Patients were enrolled either for implantation including subsequent pre-hospital discharge or for a follow-up visit only. ICM patients were included for follow-ups only. Implants were programmed and interrogated by using the investigational devices.
79308890|NCT04428099|Behavioral|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
79875889|NCT03996252|Drug|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
79725634|NCT04257097|Device|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
79859989|NCT04886635|Other|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
79859990|NCT04886115|Other|Neuromuscular evaluation|"Before and after training.~Muscle function:~voluntary maximal isometric force of the knee extensors~evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~level of voluntary activation~voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~squat jump and counter-movement jump"
79859991|NCT04886115|Other|Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task|"Before and after training.~Cardiovascular-respiratory function:~Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~heart rate during pedaling tasks~Muscle architecture:~- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling"
79264838|NCT02121431|Behavioral|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
79859992|NCT04886115|Other|Pedaling at 15 rpm|3 training sessions per week for 6 weeks
79563931|NCT01705535|Other|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
79563932|NCT01705535|Behavioral|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
79859993|NCT04886115|Other|No pedaling, usual activity|Maintain usual physical activity and diet for a period of 6 weeks.
79859994|NCT04886115|Other|Pedaling at 60rpm|3 sessions per week of training for 6 weeks
79264839|NCT03551717|Other|Optical Coherence Tomography angiography|At the inclusion visit for all patients and at M3 only for 50 patients.
79264840|NCT03551717|Other|Fundus|At the inclusion visit for all patients and at M3 only for 50 patients.
79264841|NCT03551717|Other|cardiac ultrasound scan|Only for 50 patients, 3 months after the initial cardiovascular event
79725636|NCT02739217|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
79725637|NCT02739373|Drug|BMS-986189|
79725638|NCT02739373|Other|Placebo|
79725639|NCT02738983|Drug|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
79725640|NCT02738983|Radiation|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
79264842|NCT05617430|Drug|HAIC|"Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W"
79725641|NCT02739139|Dietary Supplement|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
79264843|NCT05617430|Drug|Sintilimab|200mg IV d1, Q3W
79563933|NCT01705600|Behavioral|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
79563934|NCT01705639|Drug|Melatonin|All subjects receive the same dose of melatonin
79563935|NCT01705678|Dietary Supplement|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
79563936|NCT01705678|Dietary Supplement|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
79563937|NCT01705743|Drug|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
79563938|NCT01705743|Drug|Sevoflurane|100% oxygen+ Sevoflurane
79725642|NCT02739061|Behavioral|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
79725643|NCT02739061|Drug|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
79725644|NCT02739061|Other|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
79859995|NCT04884035|Drug|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
79399597|NCT05377710|Procedure|sinus lift with lateral approach|Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material
80021759|NCT03501602|Device|LMA protector|In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
79563939|NCT01705756|Drug|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
79264844|NCT05617430|Drug|Bevacizumab Biosimilar IBI305|7.5mg/kg IV d1, Q3W
79563940|NCT01705769|Other|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
79563941|NCT01705769|Other|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
79563942|NCT01705769|Other|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
79725645|NCT02746003|Other|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
79859996|NCT04884035|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
79859997|NCT04884035|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
79859998|NCT04884035|Drug|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
79264845|NCT03552887|Procedure|Cardiac Surgery|Any type of cardiac surgery
79563943|NCT01705782|Biological|E. coli endotoxin, US standard|
79563944|NCT01705795|Drug|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
79563945|NCT01705795|Drug|Placebo|Nacl four times over four months
79563946|NCT01705808|Drug|Protein C concentrate|
79563947|NCT01705821|Device|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
79563948|NCT01705821|Procedure|Removal of pituitary tumor using modified curette|
79563949|NCT01705847|Drug|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
79563950|NCT01705860|Biological|Santyl|
79725646|NCT02745925|Drug|Ibuprofen|
79725647|NCT04374253|Drug|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
79859999|NCT04884035|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
79860000|NCT04884035|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
79860001|NCT04884035|Drug|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
79860002|NCT04884035|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
79264846|NCT03552887|Procedure|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
79264847|NCT04813094|Other|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
79264848|NCT04813094|Other|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
79264849|NCT02118155|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
79264850|NCT04802642|Other|Survey|Survey
79264851|NCT02251691|Drug|Advagraf|Compare the drug compliance between once daily or twice daily regimen
79399598|NCT04988802|Dietary Supplement|Prenatal Nutrients Solgar|Patients will take dietary supplement Prenatal Nutrients from Solgar
79399599|NCT04988802|Other|Placebo|Placebo capsules based on starch.
79399600|NCT00703053|Biological|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
79399601|NCT00703053|Biological|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
79399602|NCT04980534|Dietary Supplement|Viusid and Asbrip|Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
79399603|NCT04980534|Drug|COVID-19 Standard Therapy|Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
79563951|NCT01705912|Other|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
79725648|NCT04374253|Drug|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
79725649|NCT02738905|Drug|Rifaximin|One 550 mg tablet taken orally two times a day.
79725650|NCT02738827|Procedure|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
79563952|NCT01705912|Other|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
79563953|NCT01705938|Drug|SP-333|
79725651|NCT02738749|Device|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
79725652|NCT02738671|Behavioral|Cognitive assessment|
79563954|NCT01705951|Other|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
79563955|NCT01705951|Biological|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
79563956|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
79725653|NCT02738671|Other|functional magnetic resonance imaging|
79563957|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
79563958|NCT01705990|Biological|Ad35-GRIN (0.5mL)|(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection
79563959|NCT01706016|Procedure|Thermic destruction of tissue by Laser using the Novilase device|
79725654|NCT02738671|Other|olfactory function measurement|
79860003|NCT04884035|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
79860004|NCT04879628|Drug|SAR441344 IV|Pharmaceutical form: Solution Route of administration: IV infusion
79860005|NCT04879628|Drug|placebo IV|Pharmaceutical form: Solution Route of administration: IV infusion
79860006|NCT04879628|Drug|SAR441344 SC|Pharmaceutical form: Solution Route of administration: SC injection
79563960|NCT01706042|Other|legume meal|
79725655|NCT02738671|Procedure|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
79725656|NCT02738437|Device|Kryptonite-bone cement|
79725657|NCT02734459|Drug|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
79725658|NCT02745613|Other|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
79725659|NCT02745691|Other|Surgery|Thoracic surgery for lung cancer
79725660|NCT02745691|Other|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
79860007|NCT04879628|Drug|placebo SC|Pharmaceutical form: Solution Route of administration: SC injection
79860008|NCT04879628|Drug|MRI contrast-enhancing preparations|gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
79264852|NCT02251691|Drug|Prograf|Compare the drug compliance between once daily or twice daily regimen
79725661|NCT02745691|Other|Targeted therapy|New targeted therapies for lung cancer
79860009|NCT04877756|Drug|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
79860010|NCT04876729|Behavioral|Otago Exercise Program|Otago Exercise program implemented including education on fall risk reduction, instruction on strength and balance exercises and walking program. Perform a home safety assessment and provide recommendations to reduce trip hazards. CHRs will engage local housing authority services to complete the modifications (such as grab bar installation). CHRs will complete approximately 10 home visits during 12 months with reassessment at 3, 6, and 12 months.
79264853|NCT02595398|Drug|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
79264854|NCT02595398|Drug|Sham Procedure|Sham procedure administered at 2 timepoints
79264855|NCT02251769|Drug|Tipranavir|
79264856|NCT02251769|Drug|Ritonavir|
79725662|NCT02745691|Other|Immunotherapy|New immunotherapies for lung cancer
79725663|NCT02734381|Other|Elderly patients|Elderly patients who visited the Emergency Department
79264857|NCT02251769|Drug|Clarithromycin|
79264858|NCT02251769|Other|High-Fat Test Meal|
79563961|NCT01706042|Other|white bread|
79563962|NCT01706055|Biological|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
79725664|NCT02745769|Drug|Ramucirumab|Administered IV
79725665|NCT02745769|Drug|Merestinib|Administered orally
79725666|NCT02745769|Drug|Abemaciclib|Administered orally
79725667|NCT04370041|Device|Dokimos Plus aortic valve|Dokimos Plus aortic valve
79725668|NCT05629663|Device|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
79725669|NCT03636607|Diagnostic Test|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
79725670|NCT02737969|Device|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
79725671|NCT02734225|Other|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
79860011|NCT04861259|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg).
79563963|NCT01706094|Other|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
79563964|NCT01706133|Other|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
79563965|NCT01706172|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
79860012|NCT04860479|Device|ultrasound|ultrasonography to inguinal region
79860013|NCT04860336|Other|Observational|Observational
79860014|NCT04858698|Device|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
79860015|NCT04853758|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
79860016|NCT04853758|Drug|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
79860017|NCT04840121|Diagnostic Test|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R&D scientists, helps to predict the endometrial receptivity and embryo implantation.
79860018|NCT04837820|Procedure|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
80021760|NCT03501602|Device|I-gel LMA|In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
79264859|NCT03552809|Device|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
79563966|NCT01706172|Other|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
79563967|NCT01706185|Other|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
79563968|NCT01706211|Drug|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
79563969|NCT01706211|Drug|Placebo|
79563970|NCT01706224|Procedure|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
79860019|NCT04837820|Procedure|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
79860020|NCT04837820|Other|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
79860021|NCT04837820|Other|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
80021761|NCT05063188|Other|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
79725672|NCT02734225|Other|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
79725673|NCT02734225|Other|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
79725674|NCT02745223|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
79563971|NCT01706224|Other|Data collection|Electronic Case Report Forms (eCRF)
79725675|NCT02745223|Drug|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
79860022|NCT04837053|Other|Digital decision aid for physicians and patients|The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.
79860023|NCT04837053|Other|Routine care|Care as usual within the included study sites.
79264860|NCT03552809|Procedure|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
79264861|NCT02121587|Behavioral|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
79264862|NCT04818710|Procedure|skin incision with a scalpel|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)"
79264863|NCT04818710|Procedure|skin incision with diathermy|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)"
79563972|NCT01706224|Other|Data collection|Questionnaires, active questioning.
79725676|NCT02737813|Drug|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
79725677|NCT02737813|Drug|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
79860024|NCT04835805|Drug|Belvarafenib|Twice daily (BID), continuous dosing
79860025|NCT04835805|Drug|Cobimetinib|Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
79860026|NCT04835805|Drug|Nivolumab|Once every 4 weeks (Q4W)
79563973|NCT01706237|Device|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
79860027|NCT04832958|Drug|99m-TC-PSMA-I&S|"99mTc-PSMA-I&S intravenous injection the day before surgery~99mTc-PSMA-I&S SPECT/CT imaging~99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations"
79264864|NCT04813250|Other|ventilation mode setting|Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
79264865|NCT02118311|Biological|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
79264866|NCT02118311|Drug|Fludarabine|Fludarabine 30mg/m^2 IV over 1 hour on days -6 through -2 from transplant
79563974|NCT01706302|Other|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD [recently re-named Clinical Practice Research Datalink (CPRD)], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
79563975|NCT01706315|Drug|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
79725678|NCT03630913|Procedure|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
79725679|NCT02745379|Procedure|BFPSCs+ DFDBA+ PRF|
79725680|NCT02745379|Procedure|DFDBA + PRF|
79725681|NCT02745301|Other|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
79725682|NCT02737735|Drug|standard chemotherapy medicine combined with Chinese herbs|
79860028|NCT04823650|Device|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
79860029|NCT04823650|Device|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
79860030|NCT04823585|Drug|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
79860031|NCT04823585|Drug|Placebo|Solution. Subcutaneous.
79725683|NCT02737735|Drug|standard chemotherapy medicine|
79725684|NCT02738515|Drug|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
79725685|NCT02738515|Drug|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
79725686|NCT02744599|Device|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
79860032|NCT04821349|Device|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
79860033|NCT04821271|Other|Placebo|Arm 1 and 2 Control Intervention
79860034|NCT04821271|Drug|TS-161 (50 - 100 mg)|Arm 1 and 2 Experimental Intervention
79860035|NCT04819893|Biological|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
79264867|NCT02118311|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
79264868|NCT02118311|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
79264869|NCT04812782|Dietary Supplement|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
79563976|NCT01706315|Drug|Placebo|Matching placebo will be available
79563977|NCT01706341|Drug|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
79563978|NCT01706341|Drug|acetate Ringer's solution containing no glucose|
79563979|NCT01706341|Drug|acetate Ringer's solution containing 1% glucose|
79725687|NCT00636415|Drug|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
79264870|NCT04812782|Dietary Supplement|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
79264871|NCT04818788|Drug|Biological Drug|we will give biological drugs to indicated ulcerative colitis patients and we will investigate the predictive ability of fecal calprotectin and hematological indices to histological remission
79264872|NCT02121665|Drug|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
79563980|NCT01706354|Procedure|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
79725688|NCT02733835|Drug|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
79725689|NCT02737423|Drug|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
79725690|NCT02694913|Other|Non Interventional|This is a non therapeutic, pilot study.
79725691|NCT02737345|Other|Rotem|
79725692|NCT05629507|Device|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
79860036|NCT04819893|Biological|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
79264873|NCT02121665|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
79264874|NCT02118389|Dietary Supplement|Glucerna|Glucerna 52g meal replacement
79264875|NCT03552263|Drug|T89 capsule|T89 capsules (75mg), orally, twice daily.
79264876|NCT03552263|Drug|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
79725693|NCT02737267|Behavioral|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
79725694|NCT02737267|Behavioral|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
79860037|NCT04819893|Biological|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
79860038|NCT04819893|Other|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
79860039|NCT04819269|Drug|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
79860040|NCT04819269|Drug|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
79860041|NCT04817839|Behavioral|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
79860042|NCT04817839|Behavioral|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
79875890|NCT03996252|Drug|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
79875891|NCT00328510|Device|GTC frame|
79875892|NCT00328510|Device|Thermoplastic facemask|
79875893|NCT00328510|Radiation|Stereotactic radiation therapy|
79725695|NCT02744911|Device|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
79264877|NCT04802486|Other|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
79860043|NCT04814628|Procedure|scenario 1 : pre-oxygenation with a face mask held by the anaesthetist|"the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~Patient lying on the operating table, start of the stopwatch~Opening of the computerized anaesthesia file~Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~Preparation of the hypnotic (propofol or thiopental, as desired)~Preparation of curare (succinylcholine or rocuronium, as desired)~Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~Waiting for an ORI which has reached a plateau value for more than 10 seconds~Conditions for general anaesthesia met for the participating anaesthetist~End of simulation, stopwatch stop"
79563981|NCT01706354|Procedure|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
79563982|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
79725696|NCT02744911|Behavioral|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
79860044|NCT04814628|Procedure|scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation|"one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~Patient entering the operating room, patient lying on the operating table, start of the stopwatch~Opening of the computerized anaesthesia file~Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~Preparation of the hypnotic (propofol or thiopental, as desired)~Preparation of curare (succinylcholine or rocuronium, as desired)~Face mask held by the patient for pre-oxygenation~Waiting for an ORI which has reached a plateau value for more than 10 seconds~Conditions for general anaesthesia met for the participating anaesthetist~End of simulation, stopwatch stop"
79875894|NCT00313144|Drug|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
79725697|NCT02744911|Behavioral|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
79725698|NCT02737111|Behavioral|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
79875895|NCT00459108|Drug|dasatinib|Given orally
79875896|NCT00458484|Radiation|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
79875897|NCT00458484|Procedure|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
80021762|NCT05063188|Other|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
79563983|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
79563984|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
79563985|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
79563986|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
79563987|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
79563988|NCT01706380|Behavioral|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
79563989|NCT01706380|Behavioral|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
79563990|NCT01706393|Dietary Supplement|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
79264878|NCT04818476|Procedure|diagnostic endoscopic resection|diagnostic endoscopic resection
79264879|NCT01368497|Drug|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
79264880|NCT04802330|Other|Questionnaire|Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
79264881|NCT02595008|Drug|DSXS|Active treatment
79264882|NCT04812704|Dietary Supplement|Whey protein|Patient receive protein supplement in liquid form after each exercice session
79563991|NCT01706393|Dietary Supplement|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
79563992|NCT01706406|Behavioral|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
79563993|NCT01706419|Dietary Supplement|Fortified rice cold extruded kernel|
79563994|NCT01706419|Dietary Supplement|fortified rice warm extruded kernel|
79860045|NCT04814628|Procedure|scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~Patient entering the operating room, patient lying on the operating table, start of the stopwatch~Opening of the computerized anaesthesia file~Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~Preparation of the hypnotic (propofol or thiopental, as desired)~Preparation of curare (succinylcholine or rocuronium, as desired)~THRIVE for pre-oxygenation~Waiting for an ORI which has reached a plateau value for more than 10 seconds~Conditions for general anaesthesia met for the participating anaesthetist~End of simulation, stopwatch stop"
79860046|NCT04814628|Procedure|scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~Patient entering the operating room, patient lying on the operating table, start of the stopwatch~Opening of the computerized anaesthesia file~Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~Preparation of the hypnotic (propofol or thiopental, as desired)~Preparation of curare (succinylcholine or rocuronium, as desired)~Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~Waiting for an ORI which has reached a plateau value for more than 10 seconds~Conditions for general anaesthesia met for the participating anaesthetist~End of simulation, stopwatch stop"
79563995|NCT01706419|Dietary Supplement|fortiified rice hot extruded kernel|
79563996|NCT01706445|Other|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
79860047|NCT04803058|Biological|TCD601|Investigational Product
79860048|NCT04802057|Drug|SAR445088|"Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)"
79563997|NCT01706471|Drug|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
79563998|NCT01706471|Drug|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
79563999|NCT01706484|Drug|BNO 1016|comparison of different dosages of drug and placebo
79564000|NCT01706510|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
79564001|NCT01706510|Drug|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
79564002|NCT01706523|Drug|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
79564003|NCT01706562|Drug|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
79564004|NCT01706627|Drug|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
79564005|NCT01706627|Drug|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
79564006|NCT01706627|Drug|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
79564007|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
79725699|NCT02737111|Behavioral|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
79860049|NCT04799301|Behavioral|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
80021763|NCT02316860|Other|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
80021764|NCT05063266|Other|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
80021765|NCT05063266|Other|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
80021766|NCT03501524|Device|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
80021767|NCT03501524|Device|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
79308891|NCT04428099|Behavioral|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
79308892|NCT04428099|Behavioral|Written Information|Written information about lifestyle change suggestions
79308893|NCT02598297|Drug|Ruxolitinib|5 mg tablet for oral use
79308894|NCT02598297|Drug|Ruxolitinib Placebo|5 mg placebo tablet for oral use
79564008|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - medium|
79564009|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
79564010|NCT01706653|Dietary Supplement|Very low polyphenol fruit based drink (control)|
79564011|NCT01706679|Drug|ATX-101 (10 mg/ml)|
79564012|NCT01706679|Drug|ATX-101 (20 mg/ml)|
79564013|NCT01706679|Drug|Moxifloxacin (400 mg)|
79564014|NCT01706679|Drug|Placebo vehicle (PBS)|
79564015|NCT01706718|Dietary Supplement|Bread|
79564016|NCT01706731|Behavioral|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
79308895|NCT04812561|Dietary Supplement|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
79860050|NCT04799301|Behavioral|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
80021768|NCT02313662|Device|NBI and PDD|
79564017|NCT01706731|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
79564018|NCT01706744|Other|Intermediate care unit|
79564019|NCT01706744|Other|Local health care 1|
79564020|NCT01706744|Other|Local health care 2|
79564021|NCT01706757|Device|go-cart|conducts exercises with the help of a go-cart
79564022|NCT01706783|Drug|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
79725700|NCT02737111|Behavioral|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
79725701|NCT02737111|Behavioral|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
79860051|NCT04799301|Behavioral|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
79860052|NCT04793893|Device|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
79860053|NCT04792502|Drug|Mosunetuzumab|Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.
79860054|NCT04792502|Drug|Lenalidomide|Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.
79860055|NCT04791969|Drug|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
79860056|NCT04791969|Drug|Placebo|Intermittent Oral Placebo
79860057|NCT04791969|Behavioral|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
79860058|NCT04790344|Device|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
79860059|NCT04789304|Drug|BI 1595043|BI 1595043
79860060|NCT04789304|Drug|Placebo|Placebo
79860061|NCT04789304|Drug|Midazolam|Midazolam
79860062|NCT04774952|Drug|RMC-5552|RMC-5552 for IV administration
79860063|NCT04772079|Drug|Deucravacitinib|Specified dose on specified days
79860064|NCT04772079|Other|Placebo matching deucravacitinib|Specified dose on specified days
79860065|NCT04756063|Drug|Ascorbic acid|Intravenous vitamin C
80021769|NCT03782350|Drug|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
79860066|NCT04756063|Other|Placebo|Normal Saline
79860067|NCT04747314|Drug|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
80021770|NCT03782350|Drug|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
80021771|NCT02310386|Device|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
80021772|NCT02313740|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
80021773|NCT02310542|Device|MARS albumin dialysis system|
80021774|NCT02310542|Device|SPAD albumin dialysis system|
79308896|NCT04812561|Dietary Supplement|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
79308897|NCT04825977|Other|RISK STRATIFICATION USING AIMS65 SCORE AND RDW|Risk Statification of patients presenting with upper gastrointestinal bleeding to the emergency department using AIMS65 score and Red cell Distribution Width.
79564023|NCT01706783|Drug|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
79564024|NCT01706796|Drug|PF-06273340|Oral solution, single dose, fasted
79564025|NCT01706796|Drug|PF-06273340|Immediate Release Tablet, single dose, fasted
79564026|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
79564027|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
79564028|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
79564029|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
79564030|NCT01706809|Other|blood sampels from vena rectalis superior and vena cubiti|
79564031|NCT01706848|Other|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
79564032|NCT01706848|Other|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
80021775|NCT03098680|Drug|Albuterol Sulfate|see arm/group descriptions
79860068|NCT04747314|Other|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
79860069|NCT04745871|Diagnostic Test|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA will be performed to patient by a single intravenous injection.
79860070|NCT04745026|Drug|GWP42003-P|GWP42003-P oral solution (100 milligrams per milliliter [mg/mL] cannabidiol [CBD] in sesame oil with anhydrous ethanol, ethanol [10% v/v] sweetener [sucralose], and strawberry flavoring), administered twice a day (morning and evening)
79860071|NCT04745026|Drug|Placebo|Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
79860072|NCT04744883|Other|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
79860073|NCT04744883|Drug|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
79564033|NCT01706861|Device|Celotres|Celotres following surgical removal of earlobe keloid.
79564034|NCT01706874|Other|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
79860074|NCT04744883|Drug|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
79860075|NCT04744883|Behavioral|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
79860076|NCT04743141|Drug|Rimegepant / BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
79860077|NCT04731649|Behavioral|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
79860078|NCT04730843|Drug|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
79860079|NCT04727619|Behavioral|SLEEP program|SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
79875898|NCT00458484|Procedure|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
80021776|NCT03098680|Drug|Nicardipine Hydrochloride|see arm/group descriptions
80021777|NCT03098680|Drug|Dobutamine Hydrochloride|see arm/group descriptions
79264883|NCT02118623|Behavioral|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
79308898|NCT04812405|Diagnostic Test|Trios4|Examination of occlusal surfaces with 3D scanner and optical criteria
79308899|NCT04816929|Other|Bobath Method|Neurodevelopmental Treatment
80021778|NCT03098680|Drug|Phenylephrine Hydrochloride|see arm/group descriptions
80021779|NCT03098680|Drug|Verapamil Hydrochloride|see arm/group descriptions
79564035|NCT01706887|Other|Diet Amiloride|only arm of the trial
79564036|NCT01706900|Other|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
79308900|NCT04816929|Other|Task-Oriented Approach|Task-Oriented Treatment
79564037|NCT01706900|Other|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
79564038|NCT01706991|Device|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
79564039|NCT01707017|Other|Strength training|
80021780|NCT03098680|Drug|Phentolamine Mesylate|see arm/group descriptions
79564040|NCT01707056|Other|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
79564041|NCT01707056|Other|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
79860080|NCT04727359|Other|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
79860081|NCT04725656|Procedure|Smoking cessation counseling|Smoking cessation counseling at baseline, week 1, and week 4.
79860082|NCT04725656|Other|Open system vape device and nicotine salt e-liquids|Ad libitum use of nicotine salt e-liquids during three months.
79860083|NCT04720625|Behavioral|Adapt2Quit|Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.
79564042|NCT01707056|Other|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
79564043|NCT01707056|Other|Water|Taking Synthroid with water for a period of 6 weeks.
79564044|NCT01707069|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
79564045|NCT01707082|Drug|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
79564046|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
79860084|NCT04720625|Behavioral|Control|Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
79860085|NCT04719156|Drug|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
79860086|NCT04719156|Device|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
79860087|NCT04718974|Other|mHealth call for life system/ tool using IVR ( interactive voice response)|The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
80021781|NCT03098680|Drug|Placebo|see arm/group descriptions
80021782|NCT02317094|Other|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
80021783|NCT02317094|Drug|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
79264884|NCT02118623|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~What is bipolar disorder? - Content about symptoms and diagnosis~Stress and triggers of illness~Medication and the biological basis of bipolar disorder~Depression - Symptoms, early detection and helpful strategies~Mania and hypomania - Symptoms, early detection and helpful strategies."
79308901|NCT04825899|Other||
79399604|NCT04962204|Behavioral|Virtual meeting between patients/physicians and caregiver|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
79564047|NCT01707082|Drug|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
79564048|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
79564049|NCT01707082|Drug|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
79564050|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
79564051|NCT01707082|Drug|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
79564052|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
79564053|NCT01707082|Drug|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
79564054|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
79564055|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
79399605|NCT05089890|Device|Sorbact® Compress|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
79399606|NCT05089890|Device|Sorbact® Gel Dressing|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
79564056|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
79564057|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
79564058|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
79564059|NCT01707134|Drug|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
79564060|NCT01707134|Drug|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
79564061|NCT01707134|Drug|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
79564062|NCT01707160|Drug|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
79860088|NCT04716309|Procedure|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
79860089|NCT04712422|Other|Healthy subjects|"Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant."
79860090|NCT04712422|Other|Pathologic group|"Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt."
79860091|NCT04712097|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
79860092|NCT04712097|Drug|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
79860093|NCT04712097|Drug|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
79564063|NCT01707160|Drug|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
79564064|NCT01707173|Behavioral|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
79564065|NCT01707173|Behavioral|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
79264885|NCT02118623|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
79564066|NCT01707199|Drug|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
79564067|NCT01707212|Behavioral|Pain management education|Education about pain management during infant immunization
79725702|NCT02737111|Behavioral|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
79860094|NCT04712097|Drug|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
79264886|NCT04812860|Drug|HR18042|Tablet, Dosing frequency: once daily, Route of administration: oral
79564068|NCT01707212|Behavioral|No pain management education|Control - no education about pain management during infant immunization
79564069|NCT01707251|Drug|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
79564070|NCT01707251|Drug|Saline|Placebo control
79564071|NCT01707277|Other|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
79564072|NCT01707277|Other|Usual care|Usual pahramacological treatment
79725703|NCT02733679|Drug|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
79860095|NCT04710628|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
79860096|NCT04710628|Drug|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
79860097|NCT04704934|Drug|Trastuzumab deruxtecan|6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
79264887|NCT04812860|Drug|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
79564073|NCT01707303|Other|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
79725704|NCT02733679|Drug|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
79725705|NCT02736877|Procedure|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
79860098|NCT04704934|Drug|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
79860099|NCT04704934|Drug|Paclitaxel|80 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
79860100|NCT04703075|Drug|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
79860101|NCT04703075|Drug|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
79564074|NCT01707303|Other|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
79860102|NCT04692012|Other|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
79860103|NCT04691297|Other|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
79860104|NCT04691297|Other|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
79564075|NCT01707316|Drug|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
79860105|NCT04682704|Device|Parasym|Tragus stimulation
79860106|NCT04681729|Drug|Dupilumab SAR231893|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79564076|NCT01707316|Drug|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
79564077|NCT01707316|Other|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
79860107|NCT04681729|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
79264888|NCT04812860|Drug|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
79564078|NCT01707329|Drug|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
79564079|NCT01707329|Drug|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
79564080|NCT01707342|Drug|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
79564081|NCT01707355|Behavioral|intervention - poster|
79564082|NCT01707394|Drug|Apixaban|Specified dose on specified days
79725706|NCT02736877|Procedure|Conventional Microscope|corneal transplantation guided by Conventional Microscope
79725707|NCT02695147|Procedure|TAVI|
79725708|NCT02744443|Dietary Supplement|Leucine|
79725709|NCT02744443|Dietary Supplement|Placebo|
79725710|NCT02732353|Dietary Supplement|Minced beef|Cow meat protein supplement
79725711|NCT02732353|Dietary Supplement|Hydrolyzed beef|Cow meat protein supplement
79725712|NCT02731963|Drug|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
79725713|NCT02731807|Dietary Supplement|Dose A: TA-65 24mg, powder|
79725714|NCT02731807|Dietary Supplement|Dose B: TA-65, 8mg, powder|
79725715|NCT02731807|Dietary Supplement|Dose C: TA-65 3.2mg, capsule|
79725716|NCT02731807|Dietary Supplement|Dose D: TA-65 8mg, capsule|
79725717|NCT02731807|Dietary Supplement|Dose E: TA-65 32mg, capsule|
79860108|NCT04681729|Drug|Non sedating H1-antihistamine|Pharmaceutical form: Tablet Route of administration: Oral
79860109|NCT04679857|Other|TKA|Total Knee Arthroplasty
79860110|NCT04678336|Biological|CART123 cells; cyclophosphamide; fludarabine|CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML. Subjects will be treated with a single IV dose of CART123 cells on Day 0.
79860111|NCT04676009|Other|Exercise arm :|"Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration."
79860112|NCT04674969|Device|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
79860113|NCT04671862|Device|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
79564083|NCT01707407|Drug|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
79264889|NCT04812860|Drug|Tramadol hydrochloride ER|Tablet,Dosing frequency: once daily, Route of administration: oral
79860114|NCT04668001|Device|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
79564084|NCT01707407|Drug|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
79860115|NCT04668001|Device|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
79860116|NCT04665739|Drug|Everolimus|Given PO
79860117|NCT04665739|Drug|Lutetium Lu 177 Dotatate|Given IV
79860118|NCT04665271|Behavioral|Zemedy App|Digital smart phone app that delivers cognitive-behavioral therapy for IBS
79860119|NCT04660344|Drug|Atezolizumab|Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
79860120|NCT04660344|Other|Placebo|Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
79860121|NCT04658199|Drug|UCB0107 (bepranemab)|UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
79860122|NCT04649242|Drug|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
79860123|NCT04649242|Drug|Matching placebo|Matching 75 mg or 50 mg ODT placebo
79564085|NCT01707407|Drug|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
79564086|NCT01707407|Drug|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
79564087|NCT01707433|Other|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
79725718|NCT02744521|Other|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
79860124|NCT04644731|Device|Aquadex™ System|Ultrafiltration for fluid removal
79860125|NCT04642729|Procedure|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
79264890|NCT04812860|Drug|Placebo|Tablet,Dosing frequency: once daily, Route of administration: oral
79264891|NCT02118701|Other|Shared Decision-Making educational training|
79264892|NCT04812236|Drug|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
79564088|NCT01707446|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
79564089|NCT01707446|Other|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of < 75% from baseline is reached for > 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
79564090|NCT01707498|Procedure|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
79564091|NCT01707498|Procedure|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
79564092|NCT01707524|Procedure|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
79564093|NCT01707537|Biological|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
79564094|NCT01707563|Procedure|skin punch biopsy and molecular biology|
79564095|NCT01707563|Other|fibroblast culture and molecular biology|
79564096|NCT01707576|Behavioral|consultation 10 days later|new depression screening
79564097|NCT01707589|Device|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
79564098|NCT01707602|Biological|INTANZA® 15|intradermal vaccination
79725719|NCT04189705|Drug|MCT-SR|Rebamipide 150mg
79725720|NCT04189705|Drug|Mucosta Tab.|Rebamipide 100mg
79725721|NCT02731651|Procedure|open hysterectomy|Hysterectomy with laparotomy incision.
79725722|NCT02731651|Procedure|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
80021784|NCT03098446|Behavioral|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
79564099|NCT01707602|Biological|Vaxigrip®|Intramuscular vaccination
79564100|NCT01707602|Biological|INTANZA® 15 T|transcutaneous vaccination
79725723|NCT02744131|Drug|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
79725724|NCT02744131|Drug|Metformin 1500mgs per day|
79725725|NCT02731885|Drug|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
79725726|NCT02731885|Drug|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
79725727|NCT05468749|Drug|CTP-543|Single 12 mg oral dose administered on Day 1
79725728|NCT02731495|Dietary Supplement|EGCG|EGCG (Epigallocatechin -3-gallate)
79725729|NCT02731495|Dietary Supplement|Placebo (deionized water)|
79860126|NCT04632628|Behavioral|Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
79860127|NCT04632043|Other|Endotracheal intubation|Endotracheal intubation
79860128|NCT04630574|Other|Speech evaluation with the clinical evaluation of dysarthria|A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
80021785|NCT03098446|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
80021786|NCT02313818|Behavioral|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
80021787|NCT03098524|Procedure|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
80021788|NCT03098524|Procedure|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
79264893|NCT04812236|Drug|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
79264894|NCT04812236|Drug|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
79264895|NCT04812236|Drug|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
79564101|NCT01707615|Drug|GSPE|GSPE 240 mg/day (120mg bid)
79264896|NCT04817930|Device|Polyetheretherketone patient specific implant|a customized peek patient specific implant is place to augment the chin
79264897|NCT04817930|Device|Computer guided advancement genioplasty|advancement genioplasty using patient specific cutting and positioning surgical stents
79264898|NCT02126813|Procedure|increased interventional threshold for urinary bladder catheterization (800 ml)|
79264899|NCT02126813|Procedure|Current used interventional threshold for urinary bladder catheterization (500 ml)|
79264900|NCT02126813|Device|Intermittent bladder catheter|
79564102|NCT01707615|Other|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
79264901|NCT04817852|Other|CBCT data of c-shaped canal in mandibular second molar.|Detection of variation in root canal morphology in mandibular second molar by using CBCT.
79564103|NCT01707628|Biological|influenza vaccination with influenza vaccine|
79564104|NCT01707641|Dietary Supplement|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
79564105|NCT01707641|Other|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
79564106|NCT01707680|Other|SOC|Patient are given standard of care
79725730|NCT02731573|Drug|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
79725731|NCT02731573|Procedure|Open heart surgery|Subject will undergo open heart surgery according to standard of care
79725732|NCT02733523|Behavioral|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
79725733|NCT02743975|Drug|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
79725734|NCT02743663|Procedure|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
79725735|NCT02743663|Procedure|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
79264902|NCT03551561|Drug|CSAAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
79264903|NCT03551561|Drug|CSAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
79860129|NCT04630574|Other|complete assessment of the MonPaGe computerized protocol|The application records directly and anonymously stores speech productions made by the patient.
79399607|NCT05089890|Device|Sorbact® Ribbon Gauze|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
79399608|NCT04931238|Drug|JS016|Single Intravenous Injection of JS016 with a dose of 50mg/kg
79564107|NCT01707706|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
79564108|NCT01707732|Drug|Enoxaparin|Administration of Enoxaparin
79564109|NCT01707745|Procedure|Intravitreal Bevacizumab|
79860130|NCT04629105|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
79860131|NCT04629105|Other|Placebo|Placebo
79860132|NCT04628793|Drug|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
79860133|NCT04628793|Drug|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
79860134|NCT04628767|Procedure|Biopsy|Undergo tissue biopsy
79860135|NCT04628767|Procedure|Biospecimen Collection|Undergo blood sample collection
79264904|NCT02598128|Device|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
79264905|NCT02598128|Device|Placebo|Sham device
79264906|NCT02124785|Procedure|Blood sampling|At Years 21 to 25 after their second vaccine dose.
79264907|NCT04817384|Other|Graston technique|For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
79399609|NCT04543500|Other|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
79399610|NCT05089578|Other|focus interview|"The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes."
79564110|NCT01707771|Procedure|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
79564111|NCT01707771|Behavioral|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
79564112|NCT01707810|Procedure|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
79564113|NCT01707810|Procedure|conventional method|
79564114|NCT01707823|Drug|acetylsalicylic acid|Given PO
79564115|NCT01707823|Other|laboratory biomarker analysis|Correlative studies
79564116|NCT01707849|Drug|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
79564117|NCT01707849|Drug|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
79564118|NCT01707875|Other|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
79564119|NCT01707888|Procedure|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
79564120|NCT01707901|Drug|ONO-8539|Treatment
79564121|NCT01707901|Other|Placebo|Placebo
79564122|NCT01707914|Dietary Supplement|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
79860136|NCT04628767|Drug|Cisplatin|Given IV
79860137|NCT04628767|Procedure|Computed Tomography|Undergo CT
79860138|NCT04628767|Drug|Doxorubicin Hydrochloride|Given Iv
79860139|NCT04628767|Biological|Durvalumab|Given IV
79860140|NCT04628767|Drug|Gemcitabine Hydrochloride|Given IV
79860141|NCT04628767|Procedure|Magnetic Resonance Imaging|Undergo MRI
79860142|NCT04628767|Drug|Methotrexate|Given IV
79860143|NCT04628767|Biological|Pegfilgrastim|Given via injection
79860144|NCT04628767|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79564123|NCT01707914|Dietary Supplement|placebo|
79564124|NCT01707940|Drug|Ketoconazole|Ketoconazole 400 mg / day
79564125|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
79725736|NCT02743663|Procedure|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach ~2%. Each test in duplicate and average is calculated.
79725737|NCT02743663|Procedure|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
79725738|NCT02743663|Procedure|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
79725739|NCT02743663|Drug|salbutamol|Given during bronchodilator response.
79725740|NCT02743663|Procedure|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
79725741|NCT02743663|Procedure|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
79725742|NCT02743663|Procedure|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
79564126|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
80021789|NCT03098524|Procedure|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
79564127|NCT01707953|Drug|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
79725743|NCT02743663|Procedure|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
80021790|NCT02313896|Behavioral|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
80021791|NCT03098368|Drug|Rotigotine|
80021792|NCT03098368|Drug|Placebo|Placebo of rotigotine patch
80021793|NCT02310854|Procedure|ACL Repair|augmented suture of acute ACL rupture (<3 weeks after injury)
80021794|NCT02310854|Procedure|ACL reconstruction|reconstruction hamstring autograft
79264908|NCT04817384|Other|Classical Massage|In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
80021795|NCT02313974|Procedure|Renal Biopsy|
79264909|NCT02121821|Behavioral|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
79264910|NCT04427540|Drug|Oxytocin|Oxytocin 10 micrograms IM
79564128|NCT01707953|Drug|Placebo|Placebo capsule to mimic midodrine
79564129|NCT01707966|Drug|Orteronel|
79564130|NCT01707966|Drug|Placebo|
79564131|NCT01708005|Drug|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
79564132|NCT01708005|Drug|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
79581305|NCT01935063|Behavioral|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
79725744|NCT02731417|Other|acupuncture|Acupuncture for women with post partum urinary retention
80021796|NCT04434820|Device|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
79725745|NCT02731417|Device|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
79725746|NCT02731339|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
80021797|NCT02310932|Behavioral|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
79725747|NCT02731339|Behavioral|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
79860145|NCT04628767|Drug|Vinblastine Sulfate|Given Iv
79564133|NCT01708018|Procedure|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
79860146|NCT04624113|Drug|Tazemetostat|Epizyme will supply the study agent, which will be provided free of charge to the patient.
79860147|NCT04624113|Drug|Pembrolizumab|Pembrolizumab is commercially available
79860148|NCT04612556|Drug|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
79860149|NCT04607733|Drug|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
80021798|NCT05062486|Drug|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
79264911|NCT02125097|Device|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
79564134|NCT01708031|Other|physiological signals|
79564135|NCT01708044|Drug|Pramlintide acetate|
79860150|NCT04607733|Drug|Mirikizumab Autoinjector|Administered SC by autoinjector
80021799|NCT05062486|Drug|Curcumin|1000 mg curcumin BID
79564136|NCT01708044|Other|Placebo|Placebo Comparator
79564137|NCT01708070|Behavioral|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
79564138|NCT01708096|Dietary Supplement|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
79564139|NCT01708096|Dietary Supplement|Normal diet|normal diet 2 weeks before gastric by-pass
79564140|NCT01708109|Other|no measures taken to clear bile ductus|biliary calculus remain
79564141|NCT01708109|Procedure|clearance of bile ductus|biliary calculus removed at surgery
80021800|NCT02317172|Other|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
79264912|NCT05616962|Dietary Supplement|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
79264913|NCT02126891|Procedure|Tests|Individual parameters of echocardiography and heart rate variability
79264914|NCT02252003|Other|Pain scales testing|
79264915|NCT04801940|Drug|Apixaban|Apixaban 2.5mg orally twice daily for 14 days.
79264916|NCT04801940|Drug|Atorvastatin|Atorvastatin 40mg orally once daily for 12 months.
79564142|NCT01708135|Behavioral|Use of smartphone app|
79564143|NCT01708148|Dietary Supplement|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
79564144|NCT01708148|Other|Placebo|control group would receive a oral lactose placebo
79564145|NCT01708200|Other|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
79725748|NCT02731339|Behavioral|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
79860151|NCT04605549|Drug|CIN-107 2 mg dosing|One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
79264917|NCT02251847|Drug|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
79564146|NCT01708226|Behavioral|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
79725749|NCT02731339|Behavioral|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
79725750|NCT02733211|Device|MD- Logic Closed Loop System|Closed Loop System
79725751|NCT02733211|Device|sensor augmented pump therapy|Sensor augmented pump therapy
79860152|NCT04605549|Drug|CIN-107 4 mg dosing|Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
79860153|NCT04605549|Drug|CIN-107 8 mg dosing|Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
80021801|NCT02314130|Dietary Supplement|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
80021802|NCT02314208|Drug|Xenbilox|
80021803|NCT02314208|Dietary Supplement|Resveratrol|
80021804|NCT02314208|Drug|Tahor|
80021805|NCT03098212|Other|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
80021806|NCT02317250|Procedure|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
80021807|NCT02317250|Procedure|FDG-PET|[F-18] FDG-PET brain scans are administered once to all arms.
80021808|NCT05059288|Device|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
80021809|NCT03502538|Device|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
79264918|NCT04801706|Diagnostic Test|Ultrasound|Association of each ultrasonographic parameter with FIGO clinical grading of placenta accreta and with histopathological diagnosis of placenta accreta in hysterectomy specimens
79564147|NCT01708239|Other|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
79264919|NCT04811846|Device|Bipolar transurethral resection of bladder tumor (TURBT)|Standard resection in piecemeal technique with standard bipolar cutting loop. (Storz medical, 27040 GP1)
79264920|NCT04811846|Device|Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)|Vaporization of bladder tumor with standard bipolar vaporization electrode. (Storz medical, 27040 NB)
79264921|NCT06173609|Procedure|CABG|"During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then, the surgeon uses that piece of blood vessel (called a graft) to reroute blood around the blocked artery."
79564148|NCT01708252|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564149|NCT01708265|Other|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
79564150|NCT01708265|Procedure|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
79564151|NCT01708304|Behavioral|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
79564152|NCT01708330|Drug|Lidocaine|2% Lidocaine gel
79564153|NCT01708330|Drug|Placebo gel|odorless, colorless gel will be used as a placebo
79564154|NCT01708343|Procedure|DIMMST|
79564155|NCT01708356|Behavioral|Cycling on a residential route|
79564156|NCT01708369|Drug|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
79564157|NCT01708369|Drug|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
79564158|NCT01708369|Drug|Oseltamivir|Oseltamivir 150 mg orally
79860154|NCT04599088|Other|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
80021810|NCT03502538|Device|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
80021811|NCT03100318|Drug|FYU-981|Oral daily dosing for 14 weeks
80021812|NCT03100318|Drug|Benzbromarone|Oral daily dosing for 14 weeks
79264922|NCT06173570|Drug|AZD0780|3 tablets once daily, orally, for 12 weeks
79264923|NCT06173570|Drug|Placebo|3 tablets once daily, orally, for 12 weeks
79264924|NCT06173557|Procedure|entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic i|technique of intraoperative measurement of the femoral offset and limb length was used, entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic imaging data and surgical reports
79264925|NCT06173479|Behavioral|HeBSaPU|HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
79264926|NCT06173414|Other|No intervention measures|No intervention measures
79264927|NCT06173388|Other|Structured exercise training program + The swallow resistance exercise program.|Structured exercise training program + The swallow resistance exercise program.
79264928|NCT06173388|Other|Only the swallow resistance exercise program.|Only the swallow resistance exercise program.
79264929|NCT06173362|Drug|Abiraterone|Given abiraterone
79264930|NCT06173362|Procedure|Biospecimen Collection|Undergo collection of blood samples
79264931|NCT06173362|Drug|Darolutamide|Given darolutamide
79564159|NCT01708369|Drug|Aspirin|Aspirin 650 mg orally will be given
79564160|NCT01708382|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564161|NCT01708434|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
79564162|NCT01708447|Drug|L.M.X.4.® cream|A lidocaine topical anesthetic cream
79564163|NCT01708447|Other|A placebo cream|Placebo cream containing no anesthetic properties.
79564164|NCT01708447|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564165|NCT01708460|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
79564166|NCT01708473|Drug|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
79564167|NCT01708473|Drug|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
79564168|NCT01708473|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564169|NCT01708499|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564170|NCT01708512|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564171|NCT01708564|Biological|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
80021813|NCT04463420|Drug|PHR160 Spray|One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
79564172|NCT01708577|Device|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
79725752|NCT02743585|Device|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in < 1 - 1.5 hours
79564173|NCT01708616|Drug|RO5285119|multiple doses
79860155|NCT04596540|Drug|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
79860156|NCT04596540|Drug|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
79860157|NCT04596540|Other|Placebo|Normal saline
80021814|NCT04463420|Drug|Placebo|participants will receive a placebo spray every hour. This process will continue for 10 days.
80021815|NCT04463420|Drug|Standard treatment|: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
79564174|NCT01708616|Drug|RO5285119 placebo|multiple doses
80021816|NCT02311010|Drug|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
80021817|NCT02314286|Drug|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
79564175|NCT01708616|Drug|risperidone|single dose
79264932|NCT06173362|Drug|Prednisone|Given prednisone
79264933|NCT06173349|Drug|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
79264934|NCT06173336|Procedure|gastric per-oral endoscopic myotomy (G-POEM)|Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.
79860158|NCT04591587|Procedure|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
79564176|NCT01708616|Drug|risperidone placebo|single dose
79564177|NCT01708642|Drug|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
79564178|NCT01708642|Drug|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
79564179|NCT01708655|Other|Sweat Evaporimeter measurement|"The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~intracutaneous injection of 0.2 ml of atropine~Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
79564180|NCT01708668|Procedure|Epidural analgesia|
79564181|NCT01708668|Procedure|Combined spinal-epidural analgesia|
79564182|NCT01708668|Procedure|Continuous epidural infusion|
79860159|NCT04591184|Biological|Covigenix VAX-001 placebo|Placebo vaccine
79564183|NCT01708668|Procedure|Intermittent epidural bolus|
79564184|NCT01708681|Dietary Supplement|Lean seafood|
79564185|NCT01708681|Dietary Supplement|Meat, egg, milk|
79564186|NCT01708694|Dietary Supplement|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
79564187|NCT01708694|Dietary Supplement|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
79564188|NCT01708707|Drug|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
79725753|NCT02743585|Device|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
79725754|NCT02733445|Drug|dasatinib|
79725755|NCT02733445|Drug|nilotinib|
79860160|NCT04591184|Biological|Covigenix VAX-001|Active Covigenix VAX-001
79860161|NCT04586010|Drug|Fenebrutinib|Participants will receive fenebrutinib.
79860162|NCT04586010|Drug|Teriflunomide|Participants will receive teriflunomide.
79860163|NCT04586010|Drug|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
79860164|NCT04585958|Procedure|Biopsy|Undergo biopsy
79860165|NCT04585958|Procedure|Biospecimen Collection|Undergo collection of blood samples
79860166|NCT04585958|Procedure|Computed Tomography|Undergo CT
79860167|NCT04585958|Procedure|Echocardiography|Undergo echocardiography
79860168|NCT04585958|Drug|Olaparib|Given PO
79860169|NCT04585958|Biological|Trastuzumab Deruxtecan|Given IV
80021818|NCT02314286|Drug|Placebo|
79725756|NCT02731261|Other|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
79264936|NCT06173271|Dietary Supplement|multi-intervention program and protein foods supplementation|This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
79725757|NCT02731105|Drug|Acnatac® Gel left face|topical application
79725758|NCT02731105|Drug|Epiduo® Gel right face|topical application
79725759|NCT02731105|Drug|Acnatac® Gel right face|topical application
79725760|NCT02731105|Drug|Epiduo® Gel left face|topical application
79725761|NCT02743429|Drug|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
80021819|NCT02317406|Drug|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
80021820|NCT02317406|Drug|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
79399611|NCT04927182|Other|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
80021821|NCT05061784|Procedure|Routine thymectomy, which has been performed|There is no intervention
80021822|NCT03132194|Drug|DPSG 7.5%|topical gel
79264937|NCT06173245|Procedure|Intravitreal injection of ranibizumab|"These patients were received three intravitreal injection of ranibizumab with one month interval. 3D-OCT by enhanced depth spectral-domain imaging (EDI-OCT) was done preoperative and a month after every injection.~All patients recieved topical anesthesia as 0.5 mg/0.05 ml , ranibizumab is injected 4 mm (3.5 mm in Pseudophakia) from the limbus intravitreally (in the lower temporal quadrant) by a needle (27gauge)."
79264938|NCT06173232|Device|Camera Imaging|Camera Imaging
79564189|NCT01708707|Drug|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
79564190|NCT01708720|Drug|IPV|
79264939|NCT06173206|Drug|SP (Macleods Pharmaceuticals Ltd)|Children who weigh <10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh >10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
79264940|NCT06173206|Drug|SPAQ (Guilin Pharmaceuticals)|Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
79399612|NCT04927182|Other|Moderate Exercise Training (Age Group 2; 31 to 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
79399613|NCT04927182|Other|Moderate Exercise Training (Age Group 3; Above 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
79564191|NCT01708720|Drug|Sabin-IPV|
79564192|NCT01708720|Drug|Adjuvanted Sabin-IPV|
79564193|NCT01708733|Drug|KSY|Chinese herbal formula
79564194|NCT01708785|Behavioral|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
79725762|NCT05454553|Other|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
79725763|NCT02730949|Dietary Supplement|D-chiro-inositol|Treated group
79725764|NCT02730949|Dietary Supplement|Folic Acid|Control group
79725765|NCT04205929|Drug|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
79725766|NCT04205929|Drug|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
79725767|NCT03856645|Drug|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
79725768|NCT02695069|Procedure|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
79725769|NCT04190797|Device|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
79725770|NCT04190797|Device|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
79725771|NCT02743195|Dietary Supplement|Polyphenol/prebiotic blend|
79725772|NCT02743039|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
80021823|NCT03132194|Drug|Aczone|topical gel
80021824|NCT03132194|Drug|Placebo|topical gel
80021825|NCT05061628|Drug|JS006 as Monotherapy|"JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
79564195|NCT01708785|Behavioral|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
79264941|NCT06173206|Drug|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
79264942|NCT06173193|Behavioral|Multicomponent exercise regimen|"A multicomponent exercise regimen applied is comprised of the step-aerobic and resistance training programs alternating every two weeks. The trainees participate in supervised training sessions 3 times a week for 8 months. Each session will include a 10-minutes warm-up, 30-minutes of effective training part and a 10-minutes period for cooling down.~Step-aerobic: The program includes accelerating and decelerating through forwards and sideways movements with stops and turns to music. The degree of difficulty of movements and steps as well as training intensity will be gradually increased by increasing the height of the step benches.~Resistance training: The participants will undergo a progressive resistance training program. Resistance training will emphasize training of following muscle groups: Quadriceps and hamstrings, hip abductors, adductors and extensors, and calf muscles. In addition to lower limb exercises, trunk and upper body exercises will be applied at intervals."
79264943|NCT06173193|Behavioral|Standard rehabilitative management|The treatments that will be provided to the members of a reference group represent the standard rehabilitative management for knee OA patients. The home exercises focus on functional exercises maintaining lower extremity flexibility and muscle function. The home exercises are instructed to be carried out three times a week, each work-out lasting 30 minutes.
79564196|NCT01708785|Behavioral|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
79564197|NCT01708785|Behavioral|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
79564198|NCT01708798|Drug|Eplerenone|
80021826|NCT05061628|Drug|JS006 in combination with Toripalimab|"JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
79399614|NCT05089500|Other|Endoscopic injection sclerotherapy|Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.
79564199|NCT01708798|Drug|Placebo|
79564200|NCT01708824|Behavioral|Dietary|"Dietary intervention to meet the target of~<5 servings of red/processed meat weekly; <2 servings would be processed meat~2 servings of refined grains daily"
79564201|NCT01708824|Behavioral|Physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
79564202|NCT01708837|Drug|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
79564203|NCT01708850|Drug|Rivaroxaban|All specified in arm description. One arm study.
79725773|NCT03308773|Other|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
79564204|NCT01708876|Drug|Artesunate-mefloquine|
79564205|NCT01708876|Drug|Chloroquine|
79564206|NCT01708876|Drug|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
79564207|NCT01708889|Biological|BMS-914143 (Peginterferon Lambda-1a)|
79564208|NCT01708928|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564209|NCT01708980|Other|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
79564210|NCT01709006|Radiation|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
79564211|NCT01709019|Biological|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
79564212|NCT01709019|Biological|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
79564213|NCT01709019|Biological|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
79725774|NCT02731183|Procedure|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
79725775|NCT00636493|Device|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
79725776|NCT02742961|Other|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
79860170|NCT04585074|Procedure|Robotic or endoscopic nipple sparing mastectomy|Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
79860171|NCT04585074|Procedure|Conventional mastectomy (including nipple sparing mastectomy, skin sparing mastectomy)|Cases or Patients who underwent conventional mastectomy and immediate reconstruction are enrolled in this arm. Conventional mastectomy should not be performed using robotic or endoscopic surgical systems. Any incisions can be performed for this procedure. Conventional mastectomy includes also Nipple-sparing mastectomy and Skin sparing mastectomy. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases without immediate reconstruction are excluded.
80021827|NCT05010616|Device|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
80021828|NCT02314442|Drug|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
80021829|NCT02314442|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
80021830|NCT03614572|Behavioral|Group MI|refer to the arm description
79264944|NCT06173180|Device|TOT|In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.
79399615|NCT05089500|Other|Endoscopic Band Ligation|Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
79564214|NCT01709019|Biological|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
79564215|NCT01709019|Biological|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
80021831|NCT03501290|Dietary Supplement|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
79564216|NCT01709058|Drug|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
79725777|NCT02730637|Other|Early nephrologist consultation|
79725778|NCT02730559|Other|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
79860172|NCT04585035|Drug|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
79860173|NCT04585035|Drug|D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other|Standard treatment of solid tumor, NSCLC or CRC
79860174|NCT04585009|Drug|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
80021832|NCT05058586|Other|The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients|Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
80021833|NCT03505268|Behavioral|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
79725779|NCT02730481|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
79725780|NCT05423353|Device|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
79725781|NCT05423353|Device|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
79725782|NCT02733055|Other|posturographic evaluation|subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
79725783|NCT02732977|Other|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
79860175|NCT04585009|Drug|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
79860176|NCT04585009|Device|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
79399616|NCT05089422|Procedure|Squint surgery|Lateral rectus recession and /or medial rectus resection
79860177|NCT04581408|Drug|Lumacaftor / Ivacaftor, Orkambi® Oral Tablet|"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"
79860178|NCT04560998|Drug|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
79860179|NCT04560998|Drug|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
79564217|NCT01709058|Other|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
79564218|NCT01709071|Drug|IPV|
79564219|NCT01709071|Drug|Low dose Sabin-IPV|
79564220|NCT01709071|Drug|Low dose adjuvanted Sabin-IPV|
79564221|NCT01709071|Drug|Middle dose Sabin-IPV|
79564222|NCT01709071|Drug|Middle dose adjuvanted Sabin-IPV|
79564223|NCT01709071|Drug|High dose Sabin-IPV|
79564224|NCT01709071|Drug|High dose adjuvanted Sabin-IPV|
79725784|NCT02732821|Procedure|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
79860180|NCT04559802|Procedure|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
79860181|NCT04559802|Procedure|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
80021834|NCT03423862|Other|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
79264945|NCT06173180|Device|VACS-D|The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
79264946|NCT06173167|Device|Crowns self-adhesively luted|After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm^2).
79399617|NCT04476888|Biological|Convalescent Plasma (CP)|500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.
79399618|NCT04476888|Other|Drugs and supportive care|This will include drugs like steroids, tocilizumab, azithromycin and supportive care
79399619|NCT05089344|Drug|Growth Hormone|growth hormone
79564225|NCT01709175|Behavioral|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
79725785|NCT02742727|Biological|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
79725786|NCT02730091|Drug|Letrozole|Letrozole 2.5 mg daily
79725787|NCT02730091|Drug|Anastrozole|anastrozole 1 mg daily
79725788|NCT02730091|Drug|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
79725789|NCT02730013|Behavioral|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
79860182|NCT04557735|Drug|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
79860183|NCT04557735|Other|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
79860184|NCT04549467|Drug|Lamivudine 300 MG|Experimental arm
79860185|NCT04549467|Drug|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
79860186|NCT04545242|Drug|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
80021835|NCT02311088|Drug|Caffeine|
80021836|NCT02311088|Drug|Placebo|
79564226|NCT01709188|Behavioral|Musical Dual Task Training|
79564227|NCT01709188|Behavioral|Walking and Talking|
79564228|NCT01709201|Behavioral|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
79564229|NCT01709240|Device|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
79725790|NCT02742805|Dietary Supplement|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
79725791|NCT02742805|Dietary Supplement|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
79725792|NCT02742805|Drug|Omalizumab|Standard of care dose.
79860187|NCT04544618|Device|Virtual reality operating room simulation|The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
79860188|NCT04544098|Drug|177Lu-DOTATATE|The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
80021837|NCT05058352|Drug|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
79725793|NCT02742571|Other|non applicable|
80021838|NCT02314676|Biological|PEG-somatropin|
79860189|NCT04533503|Device|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
79564230|NCT01709253|Radiation|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
80021839|NCT05060770|Genetic|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
79264947|NCT06173167|Device|Crowns conventionally cemented|After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
79399620|NCT05089344|Drug|Clomiphene citrate daily and recombinant FSH (Gonal-F®)|Clomiphene citrate daily and recombinant FSH (Gonal-F®)
80021840|NCT03501212|Drug|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
80021841|NCT03501212|Drug|Placebo|Placebo Cream 2.5gr applied to both wrist
80021842|NCT02317484|Drug|Ipragliflozin (SGLT2 inhibitor)|
80021843|NCT02140866|Other|Hand Exercise|
80021844|NCT02140866|Other|Compensatory Intervention Program (CIP)|
80021845|NCT03502460|Other|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
80021846|NCT02141022|Other|plasticity-based computerized cognitive remediation program|
79264948|NCT06173141|Other|low- to moderate-continuous intensity cycling exercises:|"aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
79264949|NCT06173141|Other|moderate- to high-interval intensity cycling exercises|"aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
79264950|NCT06173141|Other|hemodialysis sessions only|hemodialysis sessions only
79264951|NCT06173102|Device|Cranial Orthosis|Early versus usual reception of orthosis.
79399621|NCT01420627|Biological|EZN-2279|Weekly administration of EZN-2279 via IM injection
79399622|NCT01420627|Biological|Adagen|
79564231|NCT01709266|Dietary Supplement|Probiotics|
80021847|NCT02141022|Drug|Gileyna|
80021848|NCT02642614|Drug|BI 1026706|
80021849|NCT02642614|Drug|Placebo|
79564232|NCT01709266|Dietary Supplement|Placebo|
79564233|NCT01709279|Biological|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
79564234|NCT01709344|Behavioral|PS-OT|
79564235|NCT01709344|Other|Usual care|Supportive and rehabilitation services available at DHMC
79564236|NCT01709357|Other|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
79725794|NCT03204643|Behavioral|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
79725795|NCT02729779|Other|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
80021850|NCT02642614|Drug|Placebo|For blinding purposes
80021851|NCT03501134|Device|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
80021852|NCT02781324|Procedure|Posterior Spinal Fusion|
80021853|NCT02781324|Device|Ultrasonic Bone Scalpel|
79564237|NCT01709357|Other|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
79725796|NCT02729779|Other|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
79564238|NCT01709357|Other|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
79860190|NCT04530292|Behavioral|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
79860191|NCT04526938|Device|Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft|Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
80021854|NCT04435210|Drug|Hydralazine|Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
80021855|NCT04435210|Drug|Nifedipine|Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
79725797|NCT02729857|Dietary Supplement|SFA muffin|Muffin rich in saturated fat.
79564239|NCT01709357|Other|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
79564240|NCT01709370|Drug|Letrozole, PD 0332991|
79564241|NCT01709396|Radiation|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
79564242|NCT01709487|Procedure|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
79564243|NCT01709526|Behavioral|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
79564244|NCT01709552|Behavioral|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
79725798|NCT02729857|Dietary Supplement|PUFA muffin|Muffin rich in polyunsaturated fat.
79860192|NCT04520698|Behavioral|UPLIFT-AD|Access to palliative care needs screening, advance care planning conversations, palliative care consultations
79860193|NCT04513366|Drug|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
79860194|NCT04513366|Drug|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
79860195|NCT04513366|Other|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
80021856|NCT03501056|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
79264952|NCT06173089|Device|Remote monitoring|Remote monitoring for patients with an ICD/CRT device
79264953|NCT06173063|Device|Mobility+ Enteral Feeding System|Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
79264954|NCT06173050|Device|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
79264955|NCT06173050|Device|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
79264956|NCT06173037|Drug|RC88|2.0mg/kg Q3W IV
79264957|NCT06173011|Drug|QL2107|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
79264958|NCT06173011|Drug|Keytruda®(china)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
79264959|NCT06173011|Drug|Keytruda®(US)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
79264960|NCT06172998|Drug|Phentolamine Injection|Under patient safety, Phentolamine will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent sympathetic overactivity. Under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.
79564245|NCT01709552|Behavioral|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
79264961|NCT06172985|Other|No intervention|Due to observational study
79264962|NCT06172972|Behavioral|Atraumatic nursing care|Children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure
79860196|NCT04505553|Procedure|Acupuncture Therapy|Undergo acupuncture
79564246|NCT01709591|Behavioral|Prenatal education|
79264963|NCT06172946|Device|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
80021857|NCT03501056|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
79264964|NCT06172946|Device|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
79264965|NCT06172920|Drug|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
79264966|NCT06172920|Drug|Aldolan|Patients are receiving meperidine under thoracic surgery
79264967|NCT06172920|Drug|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
79564247|NCT01709604|Procedure|CVVH|Ultrafiltration at 35ml/h/Kg
79564248|NCT01709604|Procedure|Standardized therapy regimens|"Standardized therapy regimens included the followings:~Remove all contaminated clothing~Gastric lavage~Receive activated charcoal as quickly as possible~Hemoperfusion with activated charcoal(160g)~Immunosuppression with methylprednisolone~Antioxidants (glutathione,1.2 gram iv twice a day)~Supportive care"
79725799|NCT02732743|Dietary Supplement|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
79725800|NCT02732431|Other|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
80021858|NCT03100084|Other|Blood sampling|Maternal blood sampling
80021859|NCT03502382|Diagnostic Test|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
79264968|NCT06172842|Diagnostic Test|Echocardiography|Multi-modality echocardiography
79264969|NCT06172829|Device|Advantage MX Module|no intervention will be provided.
79264970|NCT06172816|Other|SARS-CoV-2|a virus infection
79264971|NCT06172803|Behavioral|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
79264972|NCT06172803|Behavioral|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
79264973|NCT06172777|Diagnostic Test|suspected asthma|enrollment 200 asthma patients
80021860|NCT03292146|Drug|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
79264974|NCT06172777|Diagnostic Test|suspected COPD|enrollment 200 COPD patients
79264975|NCT06172777|Diagnostic Test|confirmed asthma|enrollment 200 patients
79264976|NCT06172777|Diagnostic Test|confirmed COPD|enrollment 200 patients
79264977|NCT06172751|Other|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
79264978|NCT06172751|Other|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
79264979|NCT06172738|Procedure|the left atrial appendage closure through surgery.|Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
79264980|NCT06172725|Other|Dietary and exercise intervention|"The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians."
79564249|NCT01709617|Dietary Supplement|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
79564250|NCT01709630|Drug|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
79564251|NCT01709643|Dietary Supplement|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
79564252|NCT01709643|Dietary Supplement|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
79564253|NCT01709656|Biological|MSC|"human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
79564254|NCT01709656|Drug|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
80021861|NCT03292146|Drug|Placebo Injection|Placebo Injection at baseline and 6 months
79264981|NCT06172686|Drug|Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).|The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
79399623|NCT04413630|Other|family workshop|The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
79399624|NCT03136770|Dietary Supplement|CK-30|Compound K 600 mg
79725801|NCT02742259|Device|Blood Draw|Blood draws only - non-diagnostic, non-treatment
79725802|NCT02729623|Drug|Kite Systems cannaHALER cannabis Inhaler.|
79725803|NCT04189549|Diagnostic Test|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
79860197|NCT04505553|Procedure|Acupressure Therapy|Undergo acupressure
79860198|NCT04505553|Procedure|Oral Cryotherapy|Undergo oral cryotherapy
79860199|NCT04505553|Other|Questionnaire Administration|Ancillary studies
79860200|NCT04505553|Other|Quality-of-Life Assessment|Ancillary studies
80021862|NCT03292146|Drug|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at Month 12 through 24 months.
79564255|NCT01709682|Drug|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
79564256|NCT01709682|Procedure|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
79564257|NCT01709682|Procedure|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
79564258|NCT01709760|Drug|Methotrexate|Methotrexate 15-25 mg/week
79564259|NCT01709760|Drug|ENIA11|ENIA11 25 mg, sc twice weekly
79564260|NCT01709760|Drug|Placebo|Placebo, sc twice weekly
79564261|NCT01709773|Procedure|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
79564262|NCT01709812|Other|individualized patient support program|individualized patient support with compliance supporting tools
79564263|NCT01709812|Other|Standard care|
79564264|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
79564265|NCT01709825|Dietary Supplement|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
79564266|NCT01709825|Dietary Supplement|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
79564267|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
79725804|NCT04190719|Other|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
79264982|NCT06172686|Drug|Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
79264983|NCT06172660|Drug|Nirsevimab|Immunoprophylaxis against RSV
79264984|NCT06172647|Diagnostic Test|Colonoscopy|Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
79264985|NCT06172634|Drug|dentritic cell infusion and immunecheckpoint inhibitor|dentritic cell infusion and immunecheckpoint inhibitor
79264986|NCT06172595|Diagnostic Test|FET PET|There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
79564268|NCT01709851|Device|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
79564269|NCT01709851|Device|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
79725805|NCT02690389|Drug|Flumazenil|used alone or with acupuncture
79725806|NCT02690389|Procedure|Acupuncture|used alone or with flumazenil
79860201|NCT04504422|Device|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
80021863|NCT03132506|Other|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
80021864|NCT02144376|Dietary Supplement|Ispaghula|
80021865|NCT02144376|Dietary Supplement|Maltodextrin|
80021866|NCT03249532|Device|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
79399625|NCT03136770|Dietary Supplement|Red ginseng extracts|Red ginseng extracts 2.94 g
79399626|NCT01400113|Drug|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
79564270|NCT01709877|Procedure|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
79564271|NCT01709890|Device|YO2(R) catheter|
79564272|NCT01709929|Drug|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
80021867|NCT03249532|Device|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
80021868|NCT03249532|Device|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
80021869|NCT03249532|Device|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
80021870|NCT02254122|Drug|BEA 2180 BR|
80021871|NCT02254122|Drug|Placebo|
79725807|NCT03838861|Behavioral|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
79264987|NCT06172569|Device|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
79264988|NCT06172543|Dietary Supplement|Creatine Monohydrate|Participants were assigned to ingest a single serving daily of either A) a 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb); or B) a 25-gram dose of Whey Protein Isolate + 25-gram dose of carbohydrate powder + 5-gram dose of creatine monohydrate (Creatine) for a 17-21-day period.
79725808|NCT02732197|Drug|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
79725809|NCT02732197|Drug|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
79264989|NCT06172543|Dietary Supplement|Control|A 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb)
79264990|NCT06172517|Other|Orthosis intervention|Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
79264991|NCT06172478|Drug|HER3-DXd|Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
79264994|NCT06172439|Other|acupressure|Women in the intervention group will receive acupressure for 12 minutes.The acupressure pressure points related to the gynecologic surgery to be performed are named as the large intestine (LI4), stomach (ST36) and spleen (SP6) meridians, respectively. These points are determined by expert opinion and are used for pain control.
79264995|NCT06172387|Drug|intra-arterial infusion albumin|The experimental group would inject 20% human blood albumin solution into the responsible blood vessel supply area by catheter artery at a dose of 0.6g/kg. The infusion time is 20-30 minutes. All participant will receive mechanical thrombectomy and a standard clinical therapy.
79399627|NCT01400113|Drug|Placebo|Placebo Sublingual Tablet, single-dose
79399628|NCT05089188|Other|Immunomarkers|immunohistochemical expression profile of ambiguous melanocytic proliferation.
79399629|NCT05088954|Procedure|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
79399630|NCT01399723|Drug|Amoxicillin|Oral 45mg/kg 12 hourly
79725810|NCT02729935|Drug|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
79725811|NCT02729935|Drug|Placebo|An equal volume of saline
79725812|NCT02742415|Behavioral|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
79725813|NCT02721667|Device|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
80021872|NCT02254122|Device|Respimat®|
80021873|NCT02314754|Drug|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
80021874|NCT02144454|Dietary Supplement|Saturated fat|
80021875|NCT02144454|Dietary Supplement|Monounsaturated fat|
80021876|NCT02144454|Dietary Supplement|n-6 polyunsaturated fat|
80021877|NCT02317640|Drug|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
80021878|NCT02317640|Other|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
80021879|NCT02317640|Device|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
79399631|NCT01399723|Drug|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
79399632|NCT04787094|Other|Yoga|Yoga
79399633|NCT04787094|Other|Spinal Stabilization Exercise|Spinal Stabilization Exercise
79725814|NCT02721667|Other|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
79725815|NCT02729389|Behavioral|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
79725816|NCT02729389|Behavioral|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
80021880|NCT05060614|Procedure|Hip fracture surgery|Hip fracture surgery
80021881|NCT05058118|Drug|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
80021882|NCT05058118|Drug|Placebo|empty bottle
79860202|NCT04502823|Procedure|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~Fetuses with sFlt-1/PlGF <38 weekly follow up will be recommended and delivery at ≥40 weeks."
79399634|NCT04726098|Drug|Dexamethasone high dose|High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
79399635|NCT04726098|Drug|Dexamethasone low dose|Low doses: dexamethasone 6 mg/day 10 days.
79264996|NCT06172387|Other|mechanical thrombectomy and a standard clinical therapy|mechanical thrombectomy and a standard clinical therapy
79399636|NCT04712838|Drug|SHR0302|Group A subjects were given oral F1 、F2 and F3 version SHR0302
79860203|NCT04491136|Drug|ACEI/ARB|initative ACE/ARB drug for 6 months in this study
79860204|NCT04491136|Drug|ARNI|initative ARNI drug for next 6 months in this study
79564273|NCT01709942|Drug|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
79564274|NCT01709942|Drug|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
79564275|NCT01709955|Dietary Supplement|Glucomannan|750 MG of Glucomannan in capsule form
79564276|NCT01709955|Other|Placebo|750 mg of Cellulose powder in a capsule form
79564277|NCT01709968|Drug|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
79564278|NCT01709968|Drug|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
79564279|NCT01709994|Drug|Aspirin|100 mg/day of aspirin
79725817|NCT02729233|Other|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
79725818|NCT02729467|Drug|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
79725819|NCT02729467|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
79725820|NCT02729467|Drug|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
79725821|NCT02727205|Drug|Rotigotine Transdermal System|
79725822|NCT02721433|Drug|Pamidronate|Bone-targeted agent as standard of care
79860205|NCT04489199|Other|Questionnaire and semi-structured interview|questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
79860206|NCT04487067|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
79860207|NCT04487067|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV Q3W
80021883|NCT02144532|Device|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
80021884|NCT03500978|Behavioral|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
80021885|NCT02716948|Other|Laboratory Biomarker Analysis|Correlative studies
80021886|NCT02716948|Biological|Nivolumab|Given IV
80021887|NCT02716948|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
79264997|NCT06172361|Drug|Prednisone+Tofacitinib|"Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage."
79399637|NCT04712838|Drug|SHR0302|Group B subjects were given oral F1 、F3 and F2 version SHR0302
79399638|NCT04712838|Drug|SHR0302|Group C subjects were given oral F2 、F1 and F3 version SHR0302
79399639|NCT04712838|Drug|SHR0302|Group D subjects were given oral F2 、F3 and F1 version SHR0302
79399640|NCT04712838|Drug|SHR0302|Group E subjects were given oral F3 、F1 and F2 version SHR0302
79399641|NCT04712838|Drug|SHR0302|Group F subjects were given oral F3 、F2 and F1 version SHR0302
79725823|NCT02721433|Drug|Denosumab|Bone-targeted agent as standard of care
79725824|NCT02721433|Drug|Zoledronate|Bone-targeted agent as standard of care
79725825|NCT02726893|Other|no intervention|
79725826|NCT02729155|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
79725827|NCT02729155|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
79725828|NCT02729155|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
79725829|NCT02729155|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
79860208|NCT04485104|Drug|GWP42003-P|Oral Solution
79860209|NCT04474509|Behavioral|FACT Module Engagement|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
79860210|NCT04474509|Behavioral|FACT Module Openness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
79860211|NCT04474509|Behavioral|FACT Module Awareness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
80021888|NCT03500900|Drug|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
80021889|NCT03500900|Drug|Placebo Oral Tablet|Acute administration of placebo tablet
80021890|NCT02144688|Drug|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
80021891|NCT02320760|Behavioral|Physical activity on prescription|
79399642|NCT01385371|Biological|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
79725830|NCT02721199|Other|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
80021892|NCT05046652|Biological|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
80021893|NCT04463186|Other|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
80021894|NCT02141100|Drug|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
79264998|NCT06172361|Drug|Prednisone|Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
79564280|NCT01710059|Behavioral|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
79564281|NCT01710059|Behavioral|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
79725831|NCT02721043|Biological|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
79860212|NCT04473820|Drug|Vapocoolant spray|The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
79264999|NCT06172322|Drug|NTQ1062 with Fulvestrant|"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."
79564282|NCT01710059|Behavioral|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
79564283|NCT01710059|Behavioral|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
79564284|NCT01710072|Drug|aspirin|
79725832|NCT02721043|Drug|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
79725833|NCT02721043|Drug|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
79725834|NCT02721121|Procedure|circumferential pulmonary vein isolation|
79725835|NCT02721121|Procedure|Linear ablation in addiction to circumferential pulmonary vein isolation|
79860213|NCT04473820|Drug|Lidocaine-Prilocaine cream|A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
79860214|NCT04467658|Diagnostic Test|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
80021895|NCT05057650|Dietary Supplement|Vegan diet|Provide
79265000|NCT06172309|Drug|NTQ1062|tablet(s) PO
79265001|NCT06172296|Procedure|Biospecimen Collection|Undergo blood sample collection
79265002|NCT06172296|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79265003|NCT06172296|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79399643|NCT01385371|Biological|Placebo for SCH 697243|One dissolving tablet sublingually once daily
79265004|NCT06172296|Procedure|Bone Scan|Undergo MIBG scan
79265005|NCT06172296|Drug|Carboplatin|Given IV
79265006|NCT06172296|Drug|Cisplatin|Given IV
79265007|NCT06172296|Procedure|Computed Tomography|Undergo CT scan
79265008|NCT06172296|Drug|Cyclophosphamide|Given IV
79265009|NCT06172296|Drug|Dexrazoxane|Given IV
79265010|NCT06172296|Biological|Dinutuximab|Given IV
79265011|NCT06172296|Drug|Doxorubicin|Given IV
79265012|NCT06172296|Drug|Etoposide|Given IV
79564285|NCT01710085|Device|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
79564286|NCT01710098|Drug|Degarelix|subcutaneous injection
79725836|NCT02729311|Behavioral|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
79265013|NCT06172296|Procedure|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG PET
79564287|NCT01710111|Device|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
79564288|NCT01710124|Other|Financial incentives|
79564289|NCT01710150|Procedure|CTI ablation alone|
79564290|NCT01710150|Procedure|CTI ablation and Pulmonary vein isolation (PVI)|
79564291|NCT01710163|Drug|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
79564292|NCT01710163|Drug|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
79564293|NCT01710189|Drug|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
79564294|NCT01710202|Drug|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
79725837|NCT02729077|Device|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
79725838|NCT02728999|Procedure|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
79860215|NCT04467658|Diagnostic Test|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79265014|NCT06172296|Procedure|Hematopoietic Cell Transplantation|Undergo stem cell infusion
79564295|NCT01710215|Other|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
79564296|NCT01710215|Other|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
79564297|NCT01710228|Drug|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
79564298|NCT01710280|Dietary Supplement|High-fat meal containing native palm olein|
79564299|NCT01710280|Dietary Supplement|High-fat meal containing interesterified palm olein|
79564300|NCT01710293|Behavioral|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
79725839|NCT02728999|Procedure|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
79265015|NCT06172296|Drug|Irinotecan|Given IV
79265016|NCT06172296|Drug|Isotretinoin|Given PO
79265017|NCT06172296|Procedure|Leukapheresis|Undergo apheresis
79265018|NCT06172296|Procedure|Magnetic Resonance Imaging|Undergo MRI
79265019|NCT06172296|Drug|Melphalan|Given IV
79564301|NCT01710319|Other|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
79564302|NCT01710371|Drug|18F-AV-133|296 MBq (8 mCi)
79564303|NCT01710371|Drug|10% Arginine Hydrochloride-R-Gene 10|
79564304|NCT01710384|Drug|betamethasone|
79265020|NCT06172296|Radiation|Radiation Therapy|Undergo radiation therapy
79265021|NCT06172296|Other|Survey Administration|Ancillary studies
79265022|NCT06172296|Drug|Temozolomide|Given PO or via NG or G tube
79265023|NCT06172296|Drug|Thiotepa|Given IV
79265024|NCT06172296|Drug|Topotecan|Given IV
80021896|NCT04462718|Other|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
80021897|NCT04462718|Other|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
80021898|NCT02141178|Drug|Bupivacaine|
80021899|NCT02141178|Drug|Exparel|
80021900|NCT05057338|Behavioral|CoreDISTparticipation|CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
80021901|NCT05057338|Behavioral|Standard care|The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist. Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity. These will be registered.
80021902|NCT02314832|Procedure|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
79564305|NCT01710397|Other|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
79564306|NCT01710410|Device|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
79564307|NCT01710410|Device|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
79564308|NCT01710423|Behavioral|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
79564309|NCT01710449|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
79564310|NCT01710462|Drug|Pantoprazole + Domperidone|
79564311|NCT01710462|Drug|Pantozol®|
79860216|NCT04467658|Diagnostic Test|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79875899|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
80021903|NCT02314832|Procedure|femoral nerve block|ultrasound guided femoral nerve block
80021904|NCT02141256|Dietary Supplement|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
80021905|NCT03500822|Procedure|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
80021906|NCT03500822|Procedure|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
79725840|NCT02727049|Other|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
79725841|NCT02720887|Procedure|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
79725842|NCT02728921|Drug|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
79725843|NCT02728921|Drug|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
79725844|NCT02728843|Drug|Deferiprone|600 mg tablets
79725845|NCT02728843|Drug|Placebo|Tablets that match the deferiprone tablets in appearance
80021907|NCT02141412|Drug|dexmedetomidine 0.25 µg/kg IV|
80021908|NCT02141412|Drug|dexmedetomidine 0.5 µg/kg IV|
80021909|NCT02141412|Drug|dexmedetomidine 1 µg/kg IV|
80021910|NCT02141412|Drug|Placebo Comparator|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
79265025|NCT06172296|Procedure|Tumor Resection|Undergo tumor resection surgery
79265026|NCT06172296|Drug|Vincristine|Given IV
79564312|NCT01710488|Drug|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
79860217|NCT04467658|Diagnostic Test|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
80021911|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
80021912|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
79564313|NCT01710488|Drug|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
79564314|NCT01710540|Other|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
79564315|NCT01710540|Other|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
79564316|NCT01710553|Other|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
79725846|NCT02726503|Drug|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
79725847|NCT02720965|Other|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
79725848|NCT02726815|Other|Questionnaire|Questionnaire based study using a symptom assessment tool
79725849|NCT02728765|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
80021913|NCT04463264|Drug|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
80021914|NCT04463264|Drug|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
80021915|NCT03210558|Drug|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
80021916|NCT03210558|Drug|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
80021917|NCT05060224|Device|EasyLaser: Low Level Laser therapy|
79265027|NCT06172283|Other|Intermittent Fasting|Dietary intervention
79265028|NCT06172257|Drug|Dexamethasone ophthalmic suspension (OCS-01)|"The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
79399644|NCT01399099|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
80021918|NCT02317718|Other|monitor reproductive outcome|
80021919|NCT05046262|Drug|Calcium chloride|Calcium electroporation
80021920|NCT03502226|Behavioral|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
80021921|NCT05036824|Drug|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
80021922|NCT03544476|Behavioral|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
79860218|NCT04467658|Diagnostic Test|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79725850|NCT02720497|Behavioral|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
79725851|NCT02720497|Behavioral|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
79725852|NCT05372107|Drug|AG-80308|AG-80308 Eye Drop Solution
79725853|NCT02726737|Drug|sodium bicarbonate|
79860219|NCT04467658|Diagnostic Test|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
80021923|NCT03544476|Other|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
79564317|NCT01710553|Other|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
80021924|NCT03500666|Device|Robot|Robot lateral neck lymph node dissection
79564318|NCT01710566|Drug|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
79564319|NCT01710566|Drug|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
79564320|NCT01710579|Procedure|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
79564321|NCT01710579|Procedure|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
79725854|NCT02726737|Drug|Lidocaine|
79725855|NCT02726737|Drug|sterile distilled water|
80021925|NCT03500666|Device|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
80021926|NCT04462250|Device|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
79265029|NCT06172257|Drug|Vehicle|"The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
79265030|NCT06172244|Other|whole body vibration|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
79725856|NCT02720575|Other|Consumption of capsule/bread with vitamin D|
79725857|NCT02720341|Device|ARMin|single sessions of about one hour each
79725858|NCT02726425|Behavioral|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
79725859|NCT02726191|Behavioral|Spatial Match Exercise|
79725860|NCT02726191|Behavioral|Temporal Sequence Reconstruction Exercise|
79725861|NCT02726191|Behavioral|Token Task Exercise|
79725862|NCT02726191|Behavioral|Story Recall Exercise|
79725863|NCT02726191|Behavioral|Sample-Match (Within Modality) Exercise|
79725864|NCT02726191|Behavioral|Pair-Match (Across-Modality) Exercise|
79725865|NCT02726191|Behavioral|Triad-FiguresExercise|
79725866|NCT02726191|Behavioral|Monster Garden Exercise|
79725867|NCT02726191|Behavioral|Memory Match Exercise|
79725868|NCT02726191|Behavioral|Memory Matrix Exercise|
79725869|NCT02726191|Behavioral|Familiar Faces Exercises|
79725870|NCT02726191|Behavioral|Lost in Migration Exercise|
79725871|NCT02726191|Behavioral|Playing Koi Exercise|
79725872|NCT02728609|Device|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
79860220|NCT04467658|Diagnostic Test|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79725873|NCT02728609|Device|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
79265031|NCT06172231|Procedure|Instrument Assisted Soft tissue mobilization|The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific. Frequency: 4 sessions in 4-week period. Duration: 15_35 min each session.
80021927|NCT03095560|Device|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
79265032|NCT06172231|Procedure|Conventional therapy|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15_ 35 min each session.
79265033|NCT06172218|Other|Flo|sterile, micronized human amniotic membrane product derived from placenta and umbilical cord
79265034|NCT06172218|Other|Saline|sterile, preservative free 0.9% NaCl
79265035|NCT06172205|Drug|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
79265036|NCT06172205|Drug|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
79308902|NCT04816851|Procedure|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
79399645|NCT01398787|Device|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
80021928|NCT02315222|Dietary Supplement|Regenium|
80021929|NCT02315222|Dietary Supplement|Placebo|
79399646|NCT01398787|Device|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
79725874|NCT02728453|Drug|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
79725875|NCT02728453|Drug|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
79725876|NCT02728687|Drug|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
79725877|NCT02728687|Drug|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
79725878|NCT00636571|Behavioral|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
79725879|NCT02720263|Drug|ASP4345|Oral
79725880|NCT02720263|Drug|Matching Placebo|Oral
79725881|NCT02726269|Drug|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
79725882|NCT02726269|Drug|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
79725883|NCT02720029|Device|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
80021930|NCT02315222|Procedure|Full Mouth Disinfection|
80021931|NCT02144766|Drug|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
80021932|NCT02144766|Drug|saline|caudal block with 1 ml/kg of saline
80021933|NCT05035966|Other|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
80021934|NCT03502304|Behavioral|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
80021935|NCT03498482|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
79564322|NCT01710579|Procedure|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
79564323|NCT01710592|Drug|Epirubicin|
79564324|NCT01710592|Drug|Oxaliplatin|
79265037|NCT06172192|Procedure|Core Strengthening|"Warm up phase Following exercise would be performed in warm up. Jump rope, Cross jacks, Standing side crunch, Mountain climbers, Scissor skier, Criss cross crunches, Reverse lunge high kick, Inchworm, Hip circles, Bent over.~Core Strengthening:~Abdominal bracing, Bracing with heel slides, Bracing with leg lifts, Bracing with bridging, Bracing in standing, Bracing with standing row exercise, Quadruped arm lifts with bracing, Quadruped leg lifts with bracing, Quadruped alternate arm and leg lifts with bracing , Oblique abdominals~Cool down phase: Following exercise would be performed for cood down: child pose, Ab stretch, cat cow stretch, hip stretch, oblique stretch, standing forward bend.~After performance of core strengthening protocol, group A will perform self-diaphragmatic breathing exercises while group B will perform resistive diaphragmatic breathing exercise."
79265038|NCT06172192|Procedure|Self-Diaphragm breathing exercises|"Participants will place one hand on the chest and other on the abdomen, feeling the swelling of the stomach and the movement of the chest. It will be performed in supine position.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
79399647|NCT04041115|Dietary Supplement|Non-alcoholic beer|Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
79564325|NCT01710592|Drug|Capecitabine|
79399648|NCT04041115|Other|control|Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
79564326|NCT01710592|Drug|Docetaxel|
79564327|NCT01710605|Biological|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
79564328|NCT01710631|Drug|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
79564329|NCT01710631|Drug|placebo|placebo
79564330|NCT01710670|Drug|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
79564331|NCT01710670|Other|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
79860221|NCT04467658|Diagnostic Test|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79399649|NCT05088720|Drug|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
79399650|NCT05088720|Drug|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
79399651|NCT05365945|Other|NDT Bobath therapy|Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
79564332|NCT01710670|Other|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
79564333|NCT01710670|Other|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
79564334|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid
79564335|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid.
79564336|NCT01710696|Drug|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
79564337|NCT01710696|Drug|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
79564338|NCT01710722|Drug|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
79564339|NCT01710722|Drug|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
79564340|NCT01710722|Drug|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
79564341|NCT01710735|Procedure|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
79308903|NCT04807959|Other|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
79564342|NCT01710748|Device|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
79564343|NCT01710748|Device|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
79564344|NCT01710774|Procedure|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
79564345|NCT01710813|Biological|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
79564346|NCT01710826|Biological|Genz-682452|Capsules for oral administration.
79564347|NCT01710826|Biological|Placebo|Placebo capsules matching the Genz-682452 capsules.
79564348|NCT01710852|Drug|ISIS CRP Rx|
79564349|NCT01710852|Drug|Placebo|
79564350|NCT01710865|Other|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
79564351|NCT01710865|Other|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
79564352|NCT01710878|Device|Intergard Synergy Graft|
79564353|NCT01710904|Drug|Targinact® (oxycodone/naloxone)|
79564354|NCT01710917|Drug|Targinact® (oxycodon/naloxon)|
79564355|NCT01710930|Other|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
79564356|NCT01710943|Behavioral|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
79564357|NCT01710956|Radiation|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
79564358|NCT01710969|Behavioral|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
79725884|NCT02728375|Other|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
79725885|NCT02728375|Other|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
79725886|NCT02719951|Drug|[18F]FPEB PET imaging|PET exam
79725887|NCT02719951|Other|Biological samples|blood sample and urine sample
79725888|NCT02719951|Other|MRI|MRI exam
79725889|NCT02719717|Device|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
79860222|NCT04467658|Diagnostic Test|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79564359|NCT01710969|Behavioral|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
79564360|NCT01710982|Drug|TZP-101|
79564361|NCT01710982|Other|Placebo|
79564362|NCT01710995|Drug|Zegerid|
79564363|NCT01710995|Drug|Losec|
79564364|NCT01711008|Dietary Supplement|Cereal|
79564365|NCT01711008|Dietary Supplement|No breakfast|
79564366|NCT01711034|Drug|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
79564367|NCT01711047|Procedure|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
79725890|NCT02728219|Procedure|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
79725891|NCT02728219|Procedure|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
79860223|NCT04467658|Diagnostic Test|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
79860224|NCT04467658|Diagnostic Test|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
79860225|NCT04467658|Diagnostic Test|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
79860226|NCT04467593|Device|Whole body hyperthermia|Whole body hyperthermia to treat stage IV cancer patients
79564368|NCT01711047|Procedure|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
79860227|NCT04467593|Drug|Standard of Care (SOC) chemotherapy according to the NCCN guidelines.|Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
79860228|NCT04455503|Drug|EVX-02A|Up to 8 patients will receive EVX-02A administered IM.
79860229|NCT04455503|Drug|EVX-02B|Up to 8 patients will receive EVX-02B administered IM.
79860230|NCT04455503|Drug|EVX-02A OR EVX-02B|EVX-02A or EVX-02B will be used. Patients: 24 to 30
79860231|NCT04452149|Device|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
79860232|NCT04452149|Other|Medication intervention|Risk status guided medication intervention.
79860233|NCT04447313|Other|Survey Administration|Ancillary studies
79265039|NCT06172192|Procedure|Resistive-Diaphragm breathing exercises|"Participants will place one hand on the chest and another on the sand bag placed over abdomen. This sand bag weighing 3-5 Kgs will provide resistance to breathing. These exercises will be performed in supine position. We will adjust the weight of the sandbag as per individual's level of 11-13 of 'Rating of Perceived Exercise (RPE)'.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
79265040|NCT06172179|Other|No interventions|All procedures are observation. No intervention in this study.
79725892|NCT02728297|Procedure|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
79725893|NCT02694289|Drug|Metformin|Treatment/continuation of metformin therapy during admission
79725894|NCT02694289|Drug|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
79725895|NCT02728063|Dietary Supplement|Lactibiane Tolerance|probiotics
79860234|NCT04447313|Behavioral|Telephone-Based Intervention|Receive ACT telephone coaching
79860235|NCT04447313|Behavioral|Telephone-Based Intervention|Receive SBT telephone coaching
79860236|NCT04447027|Drug|Romidepsin|Romidepsin (12mg/ m2 ) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.
80021936|NCT05056636|Diagnostic Test|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~Female patient will first screened by lyso-GB3 (Cutoff: > 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: > 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
79564369|NCT01711060|Drug|oxytocin|
79564370|NCT01711060|Procedure|balloon catheter|
79564371|NCT01711073|Drug|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
79564372|NCT01711086|Device|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
79564373|NCT01711086|Device|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
79564374|NCT01711099|Device|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
79564375|NCT01711112|Drug|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
79564376|NCT01711125|Drug|Baclofen 30mg/day|30mg/day 10 mg t.i.d
79725896|NCT02719873|Other|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
79725897|NCT02727985|Procedure|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
79308904|NCT04807569|Other|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
79308905|NCT04807569|Drug|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
79564377|NCT01711125|Drug|Baclofen 75mg/day|75mg/day 25 mg t.i.d
79564378|NCT01711125|Drug|Placebo|Placebo 3 matched tabs/day
79725898|NCT02728141|Other|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
79860237|NCT04447027|Drug|Lenalidomide|Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.
79860238|NCT04447027|Drug|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.
79860239|NCT04447027|Drug|Dexamethasone|Dexamethasone, 40mg, PO, will be given on days 1 and 10 of each cycle.
79860240|NCT04440176|Biological|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
79564379|NCT01711190|Procedure|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
79860241|NCT04440176|Biological|Saline|Placebo
79860242|NCT04439838|Drug|BI 1595043|BI 1595043
79564380|NCT01711203|Other|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
79564381|NCT01711203|Other|General Strengthening|General abdominal and lower quarter musculature strengthening
79564382|NCT01711229|Drug|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
79564383|NCT01711229|Drug|oral acetaminophen|oral acetaminophen will be given preoperatively
79564384|NCT01711281|Device|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
79860243|NCT04439838|Drug|Placebo|Placebo
80021937|NCT02144844|Behavioral|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
80021938|NCT03498404|Radiation|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
79265041|NCT06172166|Behavioral|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
79265042|NCT06172153|Other|No interventions|No intervention
79564385|NCT01711307|Procedure|operative|
79564386|NCT01711307|Procedure|non-operative|casting within 48 hrs
79564387|NCT01711320|Drug|Placebo|
79564388|NCT01711320|Drug|Omeprazole|
79564389|NCT01711385|Behavioral|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
79564390|NCT01711398|Drug|Drug|
79564391|NCT01711411|Device|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
79564392|NCT01711437|Device|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
79725899|NCT02728141|Other|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
79725900|NCT02719795|Drug|Ropivacaine|Local injection of local anesthetic into the fascial spaces
79725901|NCT02719795|Drug|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
79725902|NCT02719561|Behavioral|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
79725903|NCT02727829|Device|pefusion index measurement|perfusion index measurement using massimo radical 7 device
79725904|NCT02726347|Biological|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
79725905|NCT02726035|Drug|Naltrexone|oral naltrexone 50 mg daily
79725906|NCT02726035|Other|Placebo|oral placebo (appearing identical to naltrexone) once daily
79725907|NCT02719405|Dietary Supplement|Lactobacillus GG|Lactobacillus GG
79725908|NCT02719405|Dietary Supplement|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
79860244|NCT04432584|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
79860245|NCT04432584|Drug|Eculizumab|Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
79860246|NCT04427137|Device|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
79265043|NCT06172140|Drug|Ciprofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
79265044|NCT06172140|Drug|Propofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
79265045|NCT06172127|Drug|Trastuzumab deruxtecan|10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
79265046|NCT06172127|Drug|Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
79860247|NCT04424927|Biological|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
79860248|NCT04424927|Other|Placebo|Placebo
79860249|NCT04421573|Procedure|BCPHD with D5W|D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
79265047|NCT06172127|Drug|Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection|15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
79265048|NCT06172114|Procedure|Alveolar ridge preservation using sticky bone|In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
79265049|NCT06172101|Other|Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment
79564393|NCT01711437|Device|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
79564394|NCT01711437|Device|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
79564395|NCT01711437|Device|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
79564396|NCT01711450|Procedure|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
79860250|NCT04421573|Procedure|Waiting period with usual care|Same as previous group description
79564397|NCT01711450|Procedure|Control sham procedure|Injection of Normal saline into the paravertebral space
79725909|NCT02719405|Dietary Supplement|Amino Acid Formula|Amino Acid Formula
79725910|NCT02725957|Drug|Trehalose for IV Infusion|
79725911|NCT02725957|Drug|Saline 0.9% IV|
79725912|NCT02719483|Device|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
79725913|NCT02719483|Procedure|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
79725914|NCT02719249|Other|Dried blood spot test|
79860251|NCT04418414|Drug|Gene therapy|CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
79860252|NCT04418414|Other|Biological|G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
79860253|NCT04417803|Biological|Blood sampling|plasmatic sampling
79860254|NCT04416646|Drug|Cabozantinib|The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.
79860255|NCT04411823|Device|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
79265050|NCT06172088|Other|Fasting|Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
79265051|NCT06172062|Other|laparoscopic pancreaticoduodenectomy|we recorded the surgical videos of laparoscopic pancreaticoduodenectomy, and labeled the information in the video to build and test the algorithms.
79564398|NCT01711463|Drug|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
79564399|NCT01711463|Drug|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
79564400|NCT01711476|Behavioral|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
79564401|NCT01711476|Other|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
79564402|NCT01711489|Drug|isavuconazole|oral
79564403|NCT01711489|Drug|Mycophenolate mofetil|oral
79564404|NCT01711515|Drug|Cisplatin|Given IV
79564405|NCT01711515|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
79564406|NCT01711515|Radiation|Internal Radiation Therapy|Undergo intracavitary brachytherapy
79564407|NCT01711515|Biological|Ipilimumab|Given IV
79564408|NCT01711515|Other|Laboratory Biomarker Analysis|Correlative studies
79564409|NCT01711528|Drug|Bortezomib|Given SC
79564410|NCT01711528|Drug|Dexamethasone|Given PO
80021939|NCT03498404|Other|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
80021940|NCT05056558|Drug|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
79265052|NCT06172049|Other|treatment|the actual treatment CRC patients have reveived
79265053|NCT06172036|Drug|irinotecan liposome + oxaliplatin + 5-FU / LV|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
79265054|NCT06172036|Drug|Adebellizumab|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
79265055|NCT06172023|Drug|Silver Nanoparticles Irrigant|Nanosilver irrigant solution
79265056|NCT06172023|Drug|Chitosan Nanoparticles Irrigant|Chitosan nanoparticles irrigant solution
79265057|NCT06172010|Drug|Clindamycin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
79564411|NCT01711528|Drug|Dinaciclib|Given IV
79564412|NCT01711528|Other|Laboratory Biomarker Analysis|Correlative studies
79564413|NCT01711567|Drug|tenofovir|tenofovir 300 mg qd
79564414|NCT01711567|Drug|entecavir|entecavir 0.5 mg qd
79564415|NCT01711580|Other|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
79265058|NCT06172010|Drug|Rifampicin and levofloxacin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
79564416|NCT01711580|Other|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
79564417|NCT01711580|Other|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
79564418|NCT01711580|Other|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
79564419|NCT01711580|Other|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
79564420|NCT01711580|Other|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
79564421|NCT01711580|Other|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
79564422|NCT01711580|Other|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
80021941|NCT05056558|Drug|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
79265059|NCT06171997|Other|Swaddling after bath group|"The babies were bathed in the bathtub. Then swaddling was done. The baby was taken into the incubator and waited for 15 minutes. At the end of 15 minutes, the swaddle was opened quietly and slowly, without disturbing the body posture. Stress and comfort scores were given by two observers by video recording the babies before bathing, before swaddling and after swaddling.~Newborns' stress will be assessed with the Newborn Stress Scale and their comfort with the Newborn Comfort Behavior Scale."
79265060|NCT06171958|Drug|Iodine-containing Contrast Media|Patients will receive or not receive ICM depending on their medical need.
79265061|NCT06171932|Drug|Methylprednisolone,|No intervention required
79860256|NCT04403022|Device|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
79860257|NCT04397185|Device|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
79860258|NCT04397185|Device|Wire Localized (WL) partial mastectomy|Standard of care procedure
79860259|NCT04394858|Procedure|Biospecimen Collection|Undergo collection of blood samples
79860260|NCT04394858|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
79860261|NCT04394858|Procedure|Magnetic Resonance Imaging|Undergo MRI
79860262|NCT04394858|Drug|Olaparib|Given PO
79725915|NCT05130385|Device|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
80021942|NCT02317796|Drug|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
79860263|NCT04394858|Other|Quality-of-Life Assessment|Ancillary studies
79265062|NCT06171919|Other|Organizational Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.
79265063|NCT06171919|Other|HIV Continuum Care|Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
79860264|NCT04394858|Drug|Temozolomide|Given PO
80021943|NCT05055700|Behavioral|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
80021944|NCT02317952|Other|Experimental Extensively Hydrolyzed Formula|
79265064|NCT06171906|Biological|mesenchymal stromal cells|On the basis of conventional PGF treatment for poor implantation, the enrolled patients were injected with 1×10^6/kg mesenchymal stem cells of cord blood weekly for 4 consecutive weeks
79725916|NCT05130385|Device|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
79399652|NCT05365945|Other|The classic exercises.|"They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes."
79725917|NCT02725723|Device|Therm-AppTM TH, thermographic camera|
79725918|NCT02725723|Drug|epidural injection|
79860265|NCT04392622|Drug|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
79860266|NCT04392622|Radiation|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
79265065|NCT06171880|Drug|JLP-1901|administration of JLP-1901
79265066|NCT06171880|Drug|JC-001(active comparator)|administration of JC-001(tenofovir)
79725919|NCT02727595|Device|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
79860267|NCT04392622|Drug|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
79725920|NCT02727517|Procedure|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
79725921|NCT02727517|Procedure|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
79725922|NCT02719093|Drug|recombinant FSH|Subcutaneous injection
79725923|NCT02727439|Other|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
79725924|NCT02725255|Dietary Supplement|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
79725925|NCT02725255|Drug|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
79860268|NCT04392622|Other|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
79860269|NCT04392388|Biological|Non applicable|to collect data from questionnaires and to collect serological samples
79860270|NCT04388839|Drug|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
79564423|NCT01711593|Biological|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
79564424|NCT01711593|Procedure|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
79725926|NCT02725255|Dietary Supplement|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
79265068|NCT06171828|Device|Head-Mounted Display (HMD) to communicate with a supervisor remotely|Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
79564425|NCT01711671|Drug|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
79564426|NCT01711671|Drug|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
79564427|NCT01711671|Drug|Standard of Care|Current approved standard of care
79265069|NCT06171815|Behavioral|Scenario-based simulation|Scenario-based simulation prepared for Respiratory Activity and Diabetes Management topics in the course curriculum
79564428|NCT01711684|Drug|Diphenylcyclopropenone (DPCP)|Topical application of study drug
79564429|NCT01711697|Radiation|stereotactic body radiation therapy|Undergo SBRT
79564430|NCT01711697|Drug|carboplatin|
79564431|NCT01711697|Drug|paclitaxel|
79564432|NCT01711697|Radiation|radiation therapy|Undergo radiation therapy
79860271|NCT04388839|Drug|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
79860272|NCT04388839|Drug|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
79265070|NCT06171776|Drug|RetroMTA|calcium silicate lining material work as dentin substitute
79564433|NCT01711723|Drug|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
79860273|NCT04388839|Drug|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
79860274|NCT04388839|Drug|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
79860275|NCT04387474|Device|Brain-computer interface|brain-computer interface rehabilitation training.
79265071|NCT06171776|Drug|TheraCal|calcium silicat material light cured
79265072|NCT06171776|Drug|Fuji IX|filling material bonded chemically to the tooth structure
79265073|NCT06171737|Behavioral|Decision Aid|The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
79265074|NCT06171737|Behavioral|Shared Decision Making Skills Training|60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
79265075|NCT06171685|Drug|Teclistamab|Comparing treatment regimens
79265076|NCT06171685|Drug|Investigational Agent|Comparing Treatment Regimens
79265077|NCT06171672|Other|Semi-structured interview|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
79265078|NCT06170437|Behavioral|Smoke-free home resident intervention|Study staff delivered intervention on how to adopt a smoke free home using a pamphlet
79564434|NCT01711749|Drug|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
79564435|NCT01711749|Drug|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
79564436|NCT01711762|Drug|GDC-0973|Single oral dose of [14C]-GDC-0973
79564437|NCT01711775|Drug|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
79564438|NCT01711788|Procedure|Intrabone infusion of umbilical cord blood stem cells|
79564439|NCT01711801|Drug|Placebo|Single ascending dose
79564440|NCT01711801|Drug|RO5545965|Single ascending dose
79564441|NCT01711801|Drug|RO5545965|Single dose, in fed and fasted state
79564442|NCT01711814|Drug|peficitinib|oral
79564443|NCT01711827|Drug|Isavuconazole|oral
79564444|NCT01711827|Drug|Prednisone|oral
79564445|NCT01711892|Behavioral|Soccer training|
79725927|NCT02718859|Biological|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
79725928|NCT02718859|Procedure|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
79725929|NCT00636727|Procedure|arthrocentesis|Irrigate the TMJ with lactated ringers
79725930|NCT00636727|Procedure|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
79860276|NCT04387474|Other|Traditional rehabilitation|traditional rehabilitation training.
80021945|NCT02317952|Other|Active Comparator Formula|
80021946|NCT05045248|Drug|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
80021947|NCT02144922|Drug|Pitavastatin|statin
80021948|NCT02144922|Other|Control|Life style modification alone
79564446|NCT01711905|Dietary Supplement|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
79725931|NCT00636727|Procedure|arthroplasty|The disc will be surgically repositioned with open surgery
79725932|NCT02727361|Radiation|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
79725933|NCT02727361|Other|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
79265079|NCT06170437|Behavioral|Lay Health Worker coaching|Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
79725934|NCT02719015|Drug|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10^11 vp. Subsequently enrolled patients injected at the same dose of 1x10^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10^10 up to three separate sites/lesions if patients have > 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
79725935|NCT02719015|Drug|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
79265080|NCT06169098|Procedure|Auricular acupressure on the left ear|Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
79564447|NCT01711931|Device|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
79860277|NCT04384965|Device|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~3 minutes) at a target of 110% of the subject's resting MT.
79860278|NCT04384692|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
79860279|NCT04384692|Drug|Busulfan|Given IV
79860280|NCT04384692|Drug|Cyclophosphamide|Given IV
79265081|NCT06169098|Procedure|Auricular acupressure on the right ear|Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
79265082|NCT06169098|Procedure|Sham auricular acupressure|Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
79265084|NCT06166745|Device|Sensi-IP toothpaste|Brushing daily with the Sensi-PI or sodium fluoride toothpaste for 14 days to decrease dentinal hypersensitivity
79564448|NCT01711931|Device|Implantation of everolimus-eluting stents|
79564449|NCT01711931|Device|Implantation of biolimus-eluting stents|
79564450|NCT01711944|Behavioral|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
79860281|NCT04384692|Drug|Fludarabine|Given IV
79860282|NCT04384692|Drug|Melphalan|Given IV
79860283|NCT04384692|Drug|Methotrexate|Given IV
79860284|NCT04384692|Drug|Mycophenolate Mofetil|Given IV or PO
79564451|NCT01711957|Procedure|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
79564452|NCT01711970|Drug|Paclitaxel|
79725936|NCT02727283|Drug|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
79725937|NCT02727283|Drug|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
79860285|NCT04384692|Drug|Ruxolitinib|Given PO
79860286|NCT04384692|Drug|Tacrolimus|Given IV and PO
79860287|NCT04384692|Radiation|Total-Body Irradiation|Undergo TBI
79860288|NCT04384367|Drug|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
79860289|NCT04384367|Drug|Maxalt 10Mg Tablet|oral - single dose
79860290|NCT04384367|Drug|Flanax 550mg|oral - single dose
79860291|NCT04384367|Drug|Placebo oral tablet|oral - single dose
79860292|NCT04381130|Drug|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
79564453|NCT01712048|Procedure|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
79564454|NCT01712048|Procedure|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
79564455|NCT01712087|Device|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
79564456|NCT01712100|Drug|Irbesartan|
79564457|NCT01712100|Drug|Avapro|
79860293|NCT04379596|Drug|Fluorouracil (5-FU)|5-FU: administered as an IV infusion
79860294|NCT04379596|Drug|Capecitabine|Capecitabine: administered orally
79860295|NCT04379596|Biological|Durvalumab|Durvalumab: administered as an IV infusion
79860296|NCT04379596|Drug|Oxaliplatin|Oxaliplatin: administered as an IV infusion
79860297|NCT04379596|Biological|Trastuzumab|Trastuzumab: administered as an IV infusion
79860298|NCT04379596|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
79860299|NCT04379596|Drug|Cisplatin|Cisplatin: administered as an IV infusion
79860300|NCT04379596|Biological|Pembrolizumab|Pembrolizumab: administered as an IV infusion
79860301|NCT04379596|Biological|Volrustomig|Volrustomig: administered as an IV infusion
79860302|NCT04379596|Biological|Rilvegostomig|Rilvegostomig: administered as an IV infusion
79399653|NCT05377632|Procedure|Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)|laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
79860303|NCT04377555|Drug|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
79725938|NCT02725333|Procedure|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
79860304|NCT04374175|Biological|Blood sample|Blood sample will be performed
79265085|NCT06166693|Device|"MINDLiNG Digital Mental Health Intervention"|The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
79564458|NCT01712113|Drug|Irbesartan|
80021949|NCT05055310|Diagnostic Test|MicRNAs test|plasma micRNAs concentration
79860305|NCT04370756|Dietary Supplement|Beetroot Juice|Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.
79860306|NCT04370756|Other|Exercise Training|Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
79564459|NCT01712113|Drug|Avapro|
79265086|NCT06166602|Drug|PENG block with 0.25% bupivacaine.|Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
79725939|NCT02718937|Drug|BTA-C585 oral capsule|
79725940|NCT02718937|Drug|Matching placebo capsules|
79399654|NCT05088642|Drug|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet
79399655|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
79564460|NCT01712126|Drug|Irbesartan and Hydrochlorothiazide|
79725941|NCT04189237|Other|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
79860307|NCT04350463|Drug|CC-90011|CC-90011
79860308|NCT04350463|Drug|Nivolumab|Nivolumab
79265087|NCT06166537|Other|Graduated compression stockings|Graduated compression stockings are standard care (control)
79265088|NCT06166537|Other|No Graduated compression stockings|No Graduated compression stockings is the intervention
79564461|NCT01712126|Drug|Avalide|
79564462|NCT01712139|Drug|Irbesartan and Hydrochlorothiazide|
79564463|NCT01712139|Drug|Avalide|
79564464|NCT01712165|Dietary Supplement|ANMUM Materna|
79564465|NCT01712165|Dietary Supplement|Control (milk powder)|
79564466|NCT01712243|Other|Light|
79564467|NCT01712269|Procedure|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
79860309|NCT04347629|Behavioral|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
79860310|NCT04322448|Device|Mechanomyography (MMG)|MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.
79860311|NCT04315285|Behavioral|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
79860312|NCT04312178|Other|cash incentive|cash incentive (20€ gift card)
79860313|NCT04312178|Other|no intervention|no intervention
79564468|NCT01712282|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
80021950|NCT02315300|Device|medilog® DARWIN FD12|
80021951|NCT02315300|Device|Continuous Glucose Monitoring|
80021952|NCT02141568|Other|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
79564469|NCT01712295|Drug|17% Salicylate with ethyl pyruvate|
79860314|NCT04312178|Other|return vaginal self-swab kit in person|hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
79564470|NCT01712295|Drug|Salicylates|
79860315|NCT04311632|Biological|TCD601|Investigational Product
79860316|NCT04311632|Drug|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
79860317|NCT04311632|Drug|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
80021953|NCT05036200|Device|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
80021954|NCT02318108|Other|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
79860318|NCT04311632|Drug|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
79265089|NCT06165458|Other|6% hydrogen peroxide gel + violet LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
79265090|NCT06165458|Other|6% hydrogen peroxide gel + blue LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
79860319|NCT04311632|Drug|ATG|Standard of Care induction therapy in solid organ transplantation
79860320|NCT04255966|Device|Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
79860321|NCT04255784|Device|Active iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
79860322|NCT04255784|Device|Sham iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
79564471|NCT01712321|Drug|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
79564472|NCT01712321|Drug|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
79564473|NCT01712347|Drug|Bevacizumab|Bevacizumab will be administered as per approved label.
79564474|NCT01712347|Drug|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
79860323|NCT04223115|Behavioral|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
79860324|NCT04223115|Other|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
79860325|NCT04221542|Drug|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
79265091|NCT06165458|Other|35% hydrogen peroxide gel + violet LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
79265092|NCT06165458|Other|35% hydrogen peroxide gel + blue LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
79860326|NCT04221542|Drug|Abiraterone|Abiraterone administered as oral tablets.
79860327|NCT04221542|Drug|Enzalutamide|Enzalutamide administered as oral tablets.
79860328|NCT04217005|Device|Sensory Feedback|Subjects will receive a sensory feedback provided by electrical stimulation
79860329|NCT04213885|Combination Product|PXL 330 Platinum device/Riboflavin|30mW, 5 sec, 5 sec off, 10 minutes of illumination
79860330|NCT04203160|Drug|CPI 613|Given intravenously
79265093|NCT06165380|Drug|Cardenilimab Combined With Chemotherapy|Cardenilimab Combined With Chemotherapy
79860331|NCT04203160|Drug|Gemcitabine|Given intravenously
79860332|NCT04203160|Drug|Cisplatin|Given intravenously
79399656|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
79399657|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
79564475|NCT01712373|Drug|Ginseng|it is kind of drug
79564476|NCT01712373|Drug|Placebo|it is placebo
79564477|NCT01712386|Dietary Supplement|Beetroot|
79564478|NCT01712386|Dietary Supplement|Beetroot placebo|
79564479|NCT01712425|Biological|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
79564480|NCT01712425|Biological|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
79564481|NCT01712464|Drug|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
79564482|NCT01712477|Drug|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
79564483|NCT01712477|Drug|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
79564484|NCT01712503|Device|Phacoemulsfication cataract surgery and intra-ocular lens implant|
79564485|NCT01710761|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
79564486|NCT01710761|Dietary Supplement|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
79725942|NCT02725489|Biological|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
79725943|NCT02725489|Drug|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
79725944|NCT02693899|Other|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
79725945|NCT02718781|Behavioral|Health talk|Health talk on zero-time exercise.
79725946|NCT02718781|Behavioral|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
79860333|NCT04199702|Other|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
79860334|NCT04187053|Procedure|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
79564487|NCT01712529|Behavioral|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
79860335|NCT04187053|Drug|Saline|Sham group will receive saline as a sham for methylene blue
79860336|NCT04187053|Drug|Methylene Blue|Experimental arm will receive methylene blue
79265094|NCT06165263|Behavioral|Mobile earthquake education|The mobile earthquake education application was developed to increase high school students&#39; knowledge about earthquakes through videos, activities or games. In the mobile earthquake education application, there are 4 modules that provide general information about the earthquake and what to do before, during and after the earthquake.
79265095|NCT06165068|Drug|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
79265096|NCT06165068|Drug|Clopidogrel|Patients take clopidogrel 75 mg per day.
79265097|NCT06165068|Drug|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
79265098|NCT06164795|Drug|Zoledronate|intravenous infusion
79564488|NCT01712555|Procedure|autologous fat grafting with PRP to anophthalmic orbits|
79265099|NCT06164795|Drug|Denosumab|subcutaneous injection
79725947|NCT02718781|Device|Handgrip|This is a home-based equipment
79725948|NCT02716519|Biological|Santyl|Collagenase ointment applied topically once per day for up to six weeks
79265100|NCT06164795|Drug|Teriparatide|subcutaneous injection
79265101|NCT06164795|Drug|Romosozumab|subcutaneous injection
79265102|NCT06164769|Procedure|blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
79265103|NCT06164444|Other|Intervention: Reusable drapes and gowns|Reusable drapes and gowns used during surgery.
79265104|NCT06164444|Other|Comparator: Disposable (single-use) drapes and gowns|Disposable drapes and gowns used during surgery.
79265105|NCT06164301|Dietary Supplement|Elemental amino-acids|mono peptide oral protein formula
79265106|NCT06164119|Other|manual treatment with osteopathic techniques and nutritional treatment|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
79265107|NCT06164119|Other|manual treatment with osteopathic techniques|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
79265108|NCT06164119|Other|nutritional treatment|nutritional treatment (personalized Mediterranean Diet)
79860337|NCT04187053|Device|Light emitting laser|Experimental arm will receive Light emitting laser
79860338|NCT04187053|Device|Non-light emitting laser|Sham group will receive Non-light emitting laser
79860339|NCT04184895|Biological|ASP2390|Intradermal
79265109|NCT06163651|Behavioral|Parent-Child Assistance Program - One-Year Version|Case managers work closely with mothers over the course of one year, meeting the mothers in their own homes when possible, to help them set goals and take advantage of available resources.
79265110|NCT06163443|Dietary Supplement|Vitamin B|MTHFR, MTR, and MTRR polymorphysm based L-methylfolate (1 mg), P5P (pyridoxal-5-phosphate, 50 mg), and Methylcobalamin (500 mcg) prescription
79564489|NCT01712568|Drug|Test Product (Ropinirole)|"one Tablet at 0 hour"
79564490|NCT01712568|Drug|Reference Product (REQUIP )|"one Tablet at 0 hour"
79564491|NCT01712581|Other|Magnetic Resonance Imaging|
79725949|NCT02716519|Other|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
79725950|NCT02716831|Behavioral|Nutritional Counseling & Acceptance-based Therapy|
79265111|NCT06163443|Dietary Supplement|Placebo|MTHFR, MTR, and MTRR polymorphysm based placebo prescription
79265112|NCT06162013|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside 3000mg/day
79265113|NCT06162013|Other|Placebo|Placebo. Identical in taste and appearance as the intervention.
79265114|NCT06161844|Drug|semaglutide injection (HD1916)|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
79265115|NCT06161844|Drug|Ozempic|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
79564492|NCT01712594|Device|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
79564493|NCT01712607|Other|Preoperative Warm-Up training|Preoperative Warm-Up training
79564494|NCT01712646|Drug|Intranasal Oxytocin|
79725951|NCT02716831|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|
79725952|NCT02339233|Device|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
79725953|NCT04124263|Other|Educational short message texts|Educational messages for patient engagement
79725954|NCT04124263|Other|Adherence short message texts|Reminder messages of medication use time
79725955|NCT02718547|Drug|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
79725956|NCT02725099|Drug|Chewing Ticagrelor|180 mg Chewing Ticagrelor
79860340|NCT04184895|Biological|Placebo|Intradermal; normal saline solution
80021955|NCT02318108|Other|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
80021956|NCT03095482|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
79725957|NCT02725099|Drug|Oral Ticagrelor|180 mg oral Ticagrelor
79725958|NCT02718703|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
79564495|NCT01712724|Other|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
79564496|NCT01712737|Other|Dietary intervention|
79564497|NCT01712802|Other|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
79564498|NCT01712802|Other|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
79399658|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
79725959|NCT02325427|Device|tDCS|tDCS could deliver either real or sham stimulation.
79725960|NCT02724865|Device|Somnodent® (Oral appliance therapy)|
79265116|NCT06161675|Behavioral|QuitAid|Participants will receive the QuitAid intervention, based on a medication adherence intervention, which addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician. Smokers not ready to quit will receive up to two sessions focused on using NRT to cut down cigarette use. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the full QuitAid intervention.
79265117|NCT06161675|Behavioral|SmokefreeTXT|All participants will receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment. For smokers not ready to quit, participants will receive two week-long pre-quit modules, Practice Quit and Daily Challenges. These modules will help the smoker become comfortable with not smoking for short periods of time and build skills before they attempt to quit. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the ready to quit treatment.
79725961|NCT02724865|Device|Herbst® (Oral appliance therapy)|
79265118|NCT06161675|Drug|Nicotine Replacement Therapy Patch|All participants will receive up to 8 weeks of NRT in the form of patch. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
79564499|NCT01712802|Other|Saline|work as control for Denture Adhesives: Cream and Powder
79725962|NCT01225211|Drug|Lumacaftor|Tablet
79725963|NCT01225211|Drug|Ivacaftor|Tablet.
79725964|NCT01225211|Drug|Lumacaftor Placebo|Matching placebo tablet.
79725965|NCT01225211|Drug|Ivacaftor Placebo|Matching placebo tablet.
79725966|NCT02685709|Drug|Octreotide capsules|
79265119|NCT06161675|Drug|Nicotine lozenge|All participants will receive up to 8 weeks of NRT in the form of lozenge. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
79725967|NCT02265367|Drug|Levomilnacipran|
79399659|NCT05084118|Drug|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
79399660|NCT05084118|Drug|Placebo|continous application of isotone saline solution for 72 hours
79399661|NCT03025009|Drug|LY3192767|Administered SC.
79399662|NCT03025009|Drug|Basal Insulin Peglispro|Administered SC.
79399663|NCT03025009|Drug|Insulin Glargine|Administered SC.
79725968|NCT02265367|Drug|Placebo|
79564500|NCT01712828|Drug|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
79564501|NCT01712828|Drug|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
79564502|NCT01712828|Drug|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
79564503|NCT01712828|Drug|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
79725969|NCT02718469|Biological|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
79725970|NCT02718469|Biological|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
79725971|NCT02718469|Biological|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
79725972|NCT02718469|Biological|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
80021957|NCT03095482|Behavioral|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
80021958|NCT02261064|Drug|Telmisartan/Amlodipine low dose|
79399664|NCT03025009|Drug|Placebo|Administered SC.
79399665|NCT05075070|Biological|Inactivated COVID-19 vaccine|two doses inactivated COVID-19 vaccine
79399666|NCT03024853|Behavioral|BPS PAST|
79399667|NCT03024853|Behavioral|BPS PRESENT|
79725973|NCT02716363|Device|Rotational Atherectomy by Rotablator|
79725974|NCT02716285|Drug|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
79725975|NCT02716285|Drug|Placebo|Placebo capsule, containing microcrystalline cellulose
79725976|NCT02716285|Drug|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
79725977|NCT02725021|Behavioral|Education Against Tobacco school-based intervention by medical students|
80021959|NCT02261064|Drug|Telmisartan/Amlodipine high dose|
80021960|NCT02261064|Other|Japanese meal|
79265120|NCT06156371|Other|lymphatic drainage massage|"Before the application, the patient will be placed in a supine position and the feet will be elevated to 45 degrees by the researcher. After the infraclavicular lymph node, located at the point where the veins in the neck area meet the thymus gland, is stimulated with a pumping action, lower extremity applications will be started in the form of upper legs, lower legs and feet; By stimulating the inguinal lymph node in the upper leg application, the popliteal lymph node in the lower leg application, and the medial malleolus lymph node in the foot application, the mobility of the lymph fluid in the direction of the stimulated lymph node is used using stroking, pumping, circular movements or rolling movements according to the weight characteristic, body type and preference of the patient. will be provided. Finally, passive exercise will be performed 5 times, repeating both legs in flexion and extension positions, and the infraclavicular lymph node will be stimulated."
79725978|NCT01224821|Biological|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
79725979|NCT02684851|Drug|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
79725980|NCT02684851|Drug|Placebo|Placebo
79725981|NCT01224431|Drug|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
79725982|NCT02724943|Behavioral|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
79725983|NCT02724943|Behavioral|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
79860341|NCT04160065|Biological|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~Immunomodulatory Agent~Route of Administration:~Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
79265121|NCT06156371|Other|classic massage|The application will be done by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration will be used. The application will start with efflorescence and end with the same technique. To the upper leg; Starting from the knee to the groin, to the lower leg; The application will be made in the direction of the muscle fibers, starting from the ankle to the knee. Appropriate techniques will be used depending on the characteristics of the application areas, and each technique will be repeated 5-10 times. In the final stage, passive exercise will be performed by moving to the foot and applying flexion and extension to the ankle 5 times. The application will be completed by applying similar applications to the upper and lower legs on the back of the foot and the outer and lower surface of the foot. Olive oil will be used as essential oil during application.
79564504|NCT01712867|Other|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
80031727|NCT03468764|Procedure|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
80031728|NCT02037633|Drug|Fentanyl|Fentanyl IV
80031729|NCT02037633|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
79725984|NCT02724943|Behavioral|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
79725985|NCT02724943|Behavioral|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
79725986|NCT02724943|Behavioral|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
79860342|NCT04155073|Behavioral|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
79564505|NCT01712867|Other|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
79564506|NCT01712880|Procedure|open debridement with modular exchange|
79564507|NCT01712880|Procedure|one stage exchange|
79564508|NCT01712893|Drug|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
79564509|NCT01712412|Drug|IW-9179|
79564510|NCT01712412|Drug|Placebo|
79564511|NCT01712919|Radiation|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
79860343|NCT04155073|Other|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
79725987|NCT02716129|Drug|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
79725988|NCT02716129|Drug|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
79725989|NCT01223183|Drug|hypertonic saline (7%)|single treatment by inhalation
79265122|NCT06156007|Behavioral|progressive muscle relaxation exercises|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
79265123|NCT06155409|Device|Anterior cervical interbody fusion|Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.
79725990|NCT01223183|Drug|isotonic saline|single treatment by inhalation
79564512|NCT01712919|Drug|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
79860344|NCT04154332|Other|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
79725991|NCT02718391|Biological|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
79725992|NCT02718235|Other|Overall survival|Observation of overall and disease free survival
79725993|NCT02724709|Procedure|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
79725994|NCT02724709|Procedure|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
79564513|NCT01712919|Biological|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
79860345|NCT04153721|Behavioral|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
79860346|NCT04145466|Behavioral|High-fat diet|"The high-fat diet will consist of ~40% energy from fat and ~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
80021961|NCT05044858|Procedure|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
79399668|NCT03024853|Behavioral|BPS FUTURE|
79399669|NCT03024853|Behavioral|CONTROL|
79399670|NCT03135912|Drug|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
79399671|NCT03135912|Drug|Placebo|Dosage method of SESC 01, without active ingredients.
79564514|NCT01712945|Drug|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
79860347|NCT04145466|Behavioral|High-carbohydrate diet|"The high-carbohydrate diet will consist of ~20% of energy from fat and ~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
79860348|NCT04130022|Device|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
79860349|NCT04128228|Behavioral|8-week outpatient treatment|Individuals with alcohol use disorder will receive an 8-week outpatient treatment, involving two sessions per week that integrate cognitive behavioral therapy with breathing-based stress management.
80021962|NCT05044858|Procedure|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
80031730|NCT02037633|Drug|ropivacaine|
79265124|NCT06155357|Behavioral|Multicomponent lifestyle intervention program|The multicomponent lifestyle intervention program is targeted at risk factor management, increased exercise capacity, and weight loss. The program will commence upon order/referral for ablation. Ablation would occur during the lifestyle program and the program will be continued after the ablation to complete 12 weeks or up to 36 exercise sessions.
79399672|NCT03135912|Drug|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
79564515|NCT01712945|Drug|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
79564516|NCT01712997|Drug|Iloprost|
79564517|NCT01712997|Drug|Bosentan|
79725995|NCT02920333|Procedure|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
79725996|NCT02920333|Device|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
79725997|NCT02920333|Device|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
80021963|NCT02320916|Procedure|23Gauge|Arterial puncture will be made using a 23Gauge needle
79265125|NCT06155045|Procedure|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
79860350|NCT04124406|Device|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
79860351|NCT04121364|Device|Tetranite|Dental Adhesive for increased implant stability
79265126|NCT06155045|Procedure|Conventional Arm|This technique uses only the electrocautery as conventional model
79265127|NCT06154408|Dietary Supplement|omega-3 fatty acids|The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
79265128|NCT06154408|Dietary Supplement|Placebo|placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
79265129|NCT06154148|Procedure|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
79399673|NCT05365321|Drug|WP1122|Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
79860352|NCT04111991|Behavioral|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
79860353|NCT04111991|Behavioral|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
79564518|NCT01713010|Other|Predictive indexes of weaning from mechanical ventilation|
79564519|NCT01713023|Dietary Supplement|Glucose|The same described in Arm description
79564520|NCT01713023|Dietary Supplement|Fructose|The same described in Arm description
79564521|NCT01713049|Drug|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
79564522|NCT01713088|Other|Multisystemic therapy|
79564523|NCT01713088|Other|YOT (usual services)|
79564524|NCT01713101|Drug|Early intravenous tranexamic acid administration|Initial history taking and physical examination --> enrollment --> 1g bolus over 10 minutes followed slow infusion over 8 hours.
79564525|NCT01713101|Drug|placebo|
79564526|NCT01713114|Other|Acute measures of satiety and food intake at next meal|
79564527|NCT01713127|Drug|remifentanil infusion|
80021964|NCT02320916|Procedure|25Gauge|Arterial puncture will be made using a 25Gauge needle
79725998|NCT02920333|Device|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
79725999|NCT02724553|Device|Acrylic lens implantation|
79726000|NCT02718079|Biological|Plasma Exchange|
79726001|NCT02718079|Other|Management of cerebral edema/intracranial hypertension:|
79726002|NCT02718079|Other|Transfer to Intensive Care Unit|
79726003|NCT02718079|Drug|Prophylactic Antibiotics|
79726004|NCT02718079|Other|Intubation of trachea|
79726005|NCT02718079|Other|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
79726006|NCT02718079|Other|Volume Replacement|
79726007|NCT02718079|Other|Pressor Support|
79726008|NCT02718079|Drug|N-acetyl-L-cysteine|
79726009|NCT02718079|Other|Correction of metabolic parameters|
80021965|NCT02955966|Device|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
80021966|NCT02955966|Biological|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
80021967|NCT03498326|Drug|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
80031731|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
80031732|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
79726010|NCT02718079|Dietary Supplement|Correction of nutrition|
79726011|NCT02717923|Other|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
79860354|NCT04111770|Device|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
79726012|NCT02724475|Procedure|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
79860355|NCT04111770|Device|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
80021968|NCT03498326|Drug|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
79564528|NCT01713127|Drug|Placebo|
79860356|NCT04103879|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
79860357|NCT04098744|Drug|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
80021969|NCT02141724|Other|Positioning consultation|Assessment of pain,bedsores and postural troubles
80021970|NCT03498248|Drug|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
79860358|NCT04098744|Drug|Placebo vaginal insert|Placebo for artesunate vaginal inserts
79860359|NCT04096417|Drug|Pemigatinib|Given PO
79860360|NCT04096417|Other|Quality-of-Life Assessment|Ancillary studies
79564529|NCT01713140|Other|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
79564530|NCT01713153|Drug|Misoprostol|600 mcg misoprostol oral
79860361|NCT04096274|Behavioral|Leadership for Organization Change and Implementation (LOCI)|LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
79265130|NCT06154148|Procedure|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
79265131|NCT06151431|Drug|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
79265132|NCT06151431|Drug|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
79564531|NCT01713153|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
79564532|NCT01713166|Drug|plasmalyte solution|plasmalyte solution
79564533|NCT01713166|Drug|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
79726013|NCT02724475|Procedure|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
79726014|NCT02716207|Device|CyberKnife|Radiation Therapy
79860362|NCT04096274|Behavioral|Training and Technical Assistance Only|"All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback."
79860363|NCT04095689|Drug|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
79860364|NCT04095689|Drug|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
79265133|NCT06147193|Other|with baseline intervention and power training interventions|"Group A (with power training ) will be treated with~squats jump,~change of direction speed,~countermovement jump,~bench press,~Romanian deadlift~barbell squats,~resistance band sprints,~stair sprints~weighted sled pulls"
79564534|NCT01713179|Drug|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
79564535|NCT01713218|Drug|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
79726015|NCT02716051|Device|MRI|Whole body MRI with cardiac and pulmonary synchronization
79726016|NCT02716051|Device|PET|
79726017|NCT02717845|Device|Ellipse|diagnostic CT scan imaging
79726018|NCT02717845|Device|Tomofix|diagnostic CT scan imaging
80021971|NCT02141802|Behavioral|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
80021972|NCT02141802|Behavioral|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
80021973|NCT01360996|Drug|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
79265134|NCT06147193|Other|baseline interventions and without power training interventions|"Group B (without power training) will be treated with~squats jump~change of direction speed~countermovement jump~barbell squats~resistance band sprints~stair sprints~Weighted sled pulls."
79564536|NCT01713218|Drug|Vismodegib|150 mg capsule, oral, once daily
79564537|NCT01713218|Procedure|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
79265135|NCT06145997|Other|Acupuncture therapy|Acupuncture therapy (AT) is delivered by Licensed Acupuncturists (LAcs). Treatment plans are determined according to each patient's presentation and resulting traditional East Asian medicine (TEAM) differential diagnosis. TEAM therapeutics include AT, Chinese herbal medicine (CHM), Kampo herbal medicine, gua sha, tui na, cupping and lifestyle advice. All TEAM therapeutics are allowed in this study because it is a pragmatic, effectiveness study.
79860365|NCT04095689|Drug|IL-12 gene therapy|Adenoviral-mediated IL-12
79265136|NCT06145893|Drug|Hemay005|Hemay005 tables 60mg bid p.o;
79265137|NCT06145893|Drug|Hemay005|Hemay005 tables 45mg bid p.o;
79564538|NCT01713231|Dietary Supplement|standard-dose vitamin D (400IU per day)|
79564539|NCT01713231|Dietary Supplement|high-dose vitamin D (2000 IU per day)|
79265138|NCT06145893|Drug|Placebo|placebo to Hemay005 tables bid p.o
79265139|NCT06137742|Drug|PF-07868489|Experimental Treatment
79564540|NCT01713244|Procedure|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
79564541|NCT01713244|Procedure|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
79564542|NCT01713257|Dietary Supplement|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
79564543|NCT01713257|Dietary Supplement|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
79726019|NCT02715973|Dietary Supplement|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
79726020|NCT02715973|Dietary Supplement|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
80021974|NCT02254434|Drug|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
79265140|NCT06137742|Drug|Placebo for PF-07868489|Placebo
79265141|NCT06135961|Device|eCTG monitoring with the NFMS|Device: Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands)
79265142|NCT06135298|Procedure|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
79564544|NCT01713270|Procedure|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
79726021|NCT02724397|Device|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
79726022|NCT02724397|Device|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
79726023|NCT02717533|Other|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
79564545|NCT01713270|Drug|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
79860366|NCT04092257|Procedure|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
80021975|NCT03498170|Drug|BCT197|Single dose of BCT197
80021976|NCT03498170|Drug|Itraconazole 200 mg|Single dose of itraconazole
80021977|NCT03544944|Drug|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
80021978|NCT03544944|Drug|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
80021979|NCT03544944|Drug|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
80021980|NCT05055544|Drug|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
80021981|NCT05055544|Drug|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
80021982|NCT02315456|Procedure|capsulorhexis|
79564546|NCT01713270|Procedure|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
79564547|NCT01713296|Drug|Pazopanib|
79265143|NCT06135298|Drug|Zoledronic acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
79265144|NCT06135298|Device|CERAMENT BONE VOID FILLER (BVF)|In addition to the standard surgical procedure, in the study group, after creating the canal with 10 mm drill bit and partly insertion of the helical blade, the synthetic bone void filler CaS/HA will be injected. The helical blade will be inserted partially with gentle blows with a hammer, 2.5 cm from its final intended position. The injectable CaS/HA biomaterial will be mixed as per the manufacturer guidelines and the paste will be transferred into an injection syringe. At t = 2.5 min from the start of mixing, 2-3 mL of BVF paste will be injected by a CE marked Introducer Needle connected to the injection syringe, through the hollow helical blade. Finally, the helical blade will be inserted to its end position with gentle blows with a hammer. Remaining material approximately 2 mL still being moldable will be manually deposited in the trochanteric fracture void.
79265145|NCT06132568|Device|VITALYST System|The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
79265146|NCT06129929|Behavioral|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
79265147|NCT06121791|Other|Normal values of abdominal level muscle areas of Turkish children|age, sex, L3-L4 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area, L4-L5 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area
79399674|NCT03025555|Other|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
79564548|NCT01713309|Drug|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
79564549|NCT01713322|Behavioral|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
79564550|NCT01713322|Behavioral|No pain management education|Control - parents receive general information about childhood immunization.
79564551|NCT01713361|Drug|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
79564552|NCT01713361|Drug|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
79564553|NCT01713361|Drug|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). [Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.]
79564554|NCT01713374|Procedure|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
79564555|NCT01713374|Other|no intervention|control visit
79564556|NCT01713374|Procedure|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
79564557|NCT01713374|Procedure|Cold pressure test|A hand will be placed in ice-cold water.
79564558|NCT01713387|Drug|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
79564559|NCT01713413|Device|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
79564560|NCT01713413|Device|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
79564561|NCT01713426|Drug|Qutenza|Cutaneous patch
79564562|NCT01713426|Drug|Pregabalin|Oral capsule
79564563|NCT01713452|Procedure|Purse string closure|"An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~Diameter of the skin defect should then be measured.~A postoperative photo will then be taken."
79564564|NCT01713452|Procedure|Primary closure|"An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (<1.5cm). No subcutaneous drains will be placed.~Length of the incision should be measured in centimeters.~A postoperative photo will then be taken."
79564565|NCT01713465|Other|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
79564566|NCT01713478|Other|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
79564567|NCT01713504|Biological|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
79726024|NCT02715817|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
79726025|NCT02715817|Other|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
79860367|NCT04086485|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
79860368|NCT04086485|Drug|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
79860369|NCT04086485|Diagnostic Test|Ga dotatate scanning|Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
79860370|NCT04086485|Diagnostic Test|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
79860371|NCT04086485|Drug|Amino Acid infusion|Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
79564568|NCT01713517|Other|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
79726026|NCT02715817|Other|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
79564569|NCT01713517|Device|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
79564570|NCT01713543|Other|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
79564571|NCT01713556|Drug|Propranolol|
79564572|NCT01713556|Other|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
79726027|NCT02717689|Other|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
79860372|NCT04086056|Other|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
79308906|NCT04807491|Other|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
79564573|NCT01713556|Drug|placebo|
79564574|NCT01713569|Device|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
79564575|NCT01713595|Drug|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
79564576|NCT01713634|Other|Preflight|4-d controlled diet sessions will occur twice before flight.
79726028|NCT02717065|Other|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
79860373|NCT04081350|Drug|LY3471851|Administered SC
79860374|NCT04081350|Drug|Placebo|Administered SC
79860375|NCT04081233|Procedure|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
80021983|NCT03498092|Drug|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
79564577|NCT01713634|Other|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
79564578|NCT01713647|Drug|Amlodipin, losartan, HCTZ|
79564579|NCT01713673|Drug|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564580|NCT01713673|Drug|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
79564581|NCT01713699|Procedure|lumbar puncture|
79726029|NCT02717065|Other|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
79726030|NCT02694367|Other|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
79726031|NCT04864171|Device|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
79726032|NCT02715739|Other|No intervention|
79726033|NCT02715661|Other|exercise|six-month interval of exercise
79860376|NCT04081233|Procedure|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
79860377|NCT04080531|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
79860378|NCT04080531|Biological|Trivalent Influenza Vaccine|Given IM
79860379|NCT04078555|Drug|ENERGI-F703 GEL|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
79860380|NCT04078555|Drug|ENERGI-F703 GEL matched vehicle|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
80021984|NCT03498092|Drug|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
80021985|NCT03498092|Drug|General anesthesia|Normal saline in a volume of 0.5 ml/kg
80021986|NCT05055388|Other|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
80021987|NCT02145234|Drug|BMS-986089|
79726034|NCT04860817|Biological|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~Dose level one: 0.6×10^7 cells/kg;~Dose level two: 1×10^7 cells/kg;~Dose level three: 1.5×10^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m^2×6d, Cyclophosphamide 300 mg/m^2×6d or Cyclophosphamide 600 mg/m^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
79860381|NCT04078282|Behavioral|Intervention group|see above
79860382|NCT04068727|Other|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
79265148|NCT06113666|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
79564582|NCT01713712|Behavioral|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
79860383|NCT04067011|Drug|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
80021988|NCT02145234|Drug|Placebo matching with BMS-986089|
79265149|NCT06113666|Behavioral|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
79265150|NCT06112093|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.
79265151|NCT06112093|Device|Sham Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
79265152|NCT06103721|Drug|Dexmedetomidine Injection [Precedex]|Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
79564583|NCT01713725|Biological|Omalizumab|"Two injections will be administered the first two weeks~The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
79564584|NCT01713725|Biological|Placebo|"Two injections will be administered the first two weeks~The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
79726035|NCT02717221|Other|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
79564585|NCT01713738|Drug|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
79564586|NCT01713751|Other|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
79726036|NCT02715895|Dietary Supplement|Friso|Friso formula feeding on demand for 3 months
79726037|NCT02715895|Dietary Supplement|Wyeth|Wyeth formula feeding on demand for 3 months
79726038|NCT02715895|Dietary Supplement|Breast milk|Breast milk feeding on demand
80021989|NCT03501914|Behavioral|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome & introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
79726039|NCT02717299|Device|Verasense|Verasense will collect balancing data on all patients in this trial.
79860384|NCT04067011|Drug|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
80021990|NCT05055154|Device|Very low calorie diet|In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
80021991|NCT03500588|Diagnostic Test|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
79860385|NCT04067011|Biological|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
79860386|NCT04064242|Drug|CMK389|single i.v. dose every 4 weeks
80021992|NCT03500588|Device|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
80021993|NCT05044624|Procedure|retroperitoneal mass excision|retroperitoneal mass excision
79265153|NCT06103721|Drug|Normal Saline|Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
79564587|NCT01713751|Other|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene [Prolene®]
79564588|NCT01713764|Behavioral|Low Carbohydrate Diet|
79564589|NCT01713764|Behavioral|American Diabetes Association Diet|
79564590|NCT01713764|Behavioral|Mindfulness and Positive Affect Skills|
79564591|NCT01713777|Drug|"Lamotrigine Generic A"|
79564592|NCT01713777|Drug|"Lamotrigine generic B"|
79564593|NCT01713790|Device|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
79564594|NCT01713790|Device|Exergame|training program over 10 weeks, three times a week.
79564595|NCT01713790|Device|Leg press|training program over 10 weeks, three times a week.
79564596|NCT01713803|Drug|Buprenorphine and naloxone|
79564597|NCT01713829|Other|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
79564598|NCT01713829|Other|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
79564599|NCT01713842|Drug|TCZ|Tocilizumab at week 0, 4 and 8.
79564600|NCT01713855|Biological|Inactivated Trivalent Influenza vaccine|
79564601|NCT01713894|Other|Decision Aid|
79860387|NCT04064242|Drug|Placebo|single i.v. dose every 4 weeks
79265154|NCT06099522|Behavioral|Internet-based cognitive behavioral therapy (iCBT)|The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.
79265155|NCT06092957|Drug|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
79564602|NCT01713894|Other|Standard|
79564603|NCT01713907|Device|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
79564604|NCT01713920|Drug|SEVIKAR|
79564605|NCT01713959|Device|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
79564606|NCT01713959|Device|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
79564607|NCT01713972|Drug|dabrafenib|Given PO
79564608|NCT01713972|Drug|pazopanib hydrochloride|Given PO
79564609|NCT01713972|Other|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
79860388|NCT04062396|Device|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
79564610|NCT01713985|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
79564611|NCT01713985|Device|Thermage|Radiofrequency treatment focusing radiofrequency energy
79564612|NCT01714011|Drug|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
79564613|NCT01714011|Drug|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
79564614|NCT01714037|Drug|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
79564615|NCT01714037|Drug|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
79564616|NCT01714037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
79564617|NCT01714037|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
80021994|NCT03501836|Device|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
80021995|NCT05055232|Drug|XZP-3621|tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
80021996|NCT02145312|Drug|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
79860389|NCT04062396|Device|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
80021997|NCT03500432|Procedure|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
79265156|NCT06092957|Drug|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
79265157|NCT06092957|Radiation|Reduced-dose IMRT|GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
79265158|NCT06092957|Radiation|Standard-dose IMRT|GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
79265159|NCT06092957|Drug|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
79265160|NCT06086522|Drug|QN-302|dose escalation/dose expansion
79265161|NCT06070688|Diagnostic Test|MeMed BV® biomarker test|one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
79265162|NCT06070688|Diagnostic Test|Usual care|Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
79564618|NCT01714037|Drug|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
79564619|NCT01714076|Other|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
79564620|NCT01714089|Drug|RNS60 125 ml|
79564621|NCT01714089|Drug|RNS60 250 ml|
79726040|NCT04189315|Drug|asfotase alfa|Asfotase alfa is administered subcutaneously.
79860390|NCT04054557|Other|Telemedicine|Participate in virtual visits with oncologist
79265163|NCT06069570|Biological|KB-GDT-01|KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
79265164|NCT06066216|Drug|Cadonilimab|Injectable solution
79265165|NCT06066216|Drug|Carboplatin|Injectable solution
79265166|NCT06066216|Drug|Cisplatin|Injectable solution
79265167|NCT06066216|Drug|Paclitaxel|Injectable solutionS
79265168|NCT06064006|Drug|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
79265169|NCT06064006|Drug|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
79564622|NCT01714089|Drug|Interferon beta 1a|
79564623|NCT01714102|Dietary Supplement|Placebo|Placebo manufactured to mimic resveratrol tablet
79564624|NCT01714102|Dietary Supplement|Resveratrol|Resveratrol PO BID for 30 days
79564625|NCT01714115|Drug|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
79564626|NCT01714128|Drug|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
79564627|NCT01714141|Behavioral|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
79564628|NCT01714141|Behavioral|Asthma education active control|
79564629|NCT01714154|Drug|danoprevir|100 mg orally every 12 hours
79564630|NCT01714154|Drug|ritonavir|100 mg orally every 12 hours
79564631|NCT01714154|Drug|setrobuvir|200 mg orally every 12 hours
79564632|NCT01714167|Genetic|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
79564633|NCT01714193|Drug|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
79726041|NCT02724163|Drug|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
79726042|NCT02724163|Drug|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
79726043|NCT02724163|Drug|Mitoxantrone|DNA-reactive agent
79726044|NCT02724163|Drug|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
79726045|NCT02724163|Drug|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
79860391|NCT04054557|Other|Best Practice|Receive 4 in-office visits with oncologist
79860392|NCT04054557|Other|Questionnaire Administration|Ancillary studies
79860393|NCT04054557|Other|Quality-of-Life Assessment|Ancillary studies
79860394|NCT04054557|Other|Survey Administration|Complete electronic survey
79860395|NCT04054557|Behavioral|Behavioral Intervention|Use smart pill bottle
79860396|NCT04054557|Other|Educational Intervention|Receives time-specific reminders and messages
80021998|NCT05035108|Biological|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 24-48 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 6-9h.
80021999|NCT02318420|Other|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
80022000|NCT05044702|Other|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
79564634|NCT01714193|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
80022001|NCT05044702|Other|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~prone leg extension~prone lying chest elevation~prone extension with alternate arm and leg lift~supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
79265170|NCT06061471|Drug|AK111|AK111 regimen 1-subcutaneous injection,until week 24.
79265171|NCT06061471|Drug|AK111|AK111 regimen 2-subcutaneous injection,until week 24.
79564635|NCT01714206|Drug|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
79564636|NCT01714206|Drug|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
79726046|NCT02724163|Drug|Busulfan|Alkylsulfonate
79726047|NCT02724163|Drug|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
79726048|NCT02723851|Device|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
79860397|NCT04053816|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
79860398|NCT04053634|Biological|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
79860399|NCT04053634|Biological|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
80022002|NCT03497858|Other|Coconut Water|participants will consume coconut water and complete a simulated basketball game
79265172|NCT06051162|Device|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
79265173|NCT06048952|Behavioral|Music Therapy|Huseyni maqam, Pentatonic music
79265174|NCT06047977|Biological|Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2|Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)
79265175|NCT06044324|Device|Repetitive Transcranial Magnetic Stimulation|"Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
79265176|NCT06038123|Device|China market released 3.0T Magnetic resonance (MR) conditional CIED systems|To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)
79265177|NCT06026319|Drug|CD79b-19 CAR T cells|Intravenous infusion
79564637|NCT01714206|Drug|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
79564638|NCT01714219|Procedure|Posterior reconstruction|
79564639|NCT01714258|Procedure|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
79564640|NCT01714284|Behavioral|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
79265178|NCT06026319|Drug|Cyclophosphamide|Intravenous infusion
79564641|NCT01714284|Behavioral|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
79564642|NCT01714297|Drug|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
79265179|NCT06026319|Drug|Fludarabine|Intravenous infusion
79581306|NCT01935063|Other|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
79581307|NCT01935076|Behavioral|Neonatal exposure to maternal obesity|
79726049|NCT02717377|Behavioral|physical activity|
79726050|NCT02486965|Device|thermode (TSA-II model)|thermal stimulation with test thermode
79726051|NCT02486965|Other|Adapted Physical Activity|
79726052|NCT02486965|Other|Physical activity|
79726053|NCT02723539|Drug|MBN-101|Topical application
79726054|NCT02723539|Drug|Placebo|Topical application
79726055|NCT02723617|Other|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
79726056|NCT02723617|Other|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
79726057|NCT02723617|Other|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
79726058|NCT02723617|Other|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
79726059|NCT02902003|Behavioral|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
79265180|NCT06025877|Other|PrecivityAD2(TM) blood test|The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
79399675|NCT03025555|Other|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
79564643|NCT01714375|Device|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
79564644|NCT01714388|Drug|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
79564645|NCT01714401|Drug|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
79726060|NCT02715427|Other|Conventional care|
79726061|NCT02715427|Other|Enhanced recovery|
79726062|NCT02715349|Behavioral|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
79726063|NCT02715505|Drug|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
79726064|NCT02716909|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
79726065|NCT02723695|Other|Evaluation of postural performances|Postural tests
79860400|NCT04052971|Drug|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
79860401|NCT04052971|Drug|ABN401- Expansion Phase|"Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal."
79860402|NCT04047797|Drug|Ixazomib|Given by mouth
79860403|NCT04047797|Drug|Ixazomib Citrate|Given by mouth
79860404|NCT04047797|Biological|Rituximab|Given Intravenous
79860405|NCT04044768|Genetic|afamitresgene autoleucel (previously ADP-A2M4)|Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
79860406|NCT04039971|Procedure|ACL Reconstruction|Surgical techniques
79860407|NCT04019275|Behavioral|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
79860408|NCT04018040|Other|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
79265181|NCT06019637|Other|Onasemnogene Abeparvovec|Retrospective and prospective observational study. There is no treatment allocation.
79265182|NCT06017336|Other|Inspiratory Muscle Training Group|Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.
79564646|NCT01714401|Drug|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
79564647|NCT01714414|Drug|FZD|
79564648|NCT01714414|Drug|3TC|
79564649|NCT01714414|Drug|EFV|
79564650|NCT01714414|Drug|AZT|
79564651|NCT01714427|Drug|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
79564652|NCT01714427|Drug|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
79564653|NCT01714466|Drug|NER1006|
79564654|NCT01714466|Drug|MOVIPREP|
79564655|NCT01714479|Other|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
79726066|NCT02723461|Drug|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
79564656|NCT01714479|Other|Placebo|
79726067|NCT02723461|Drug|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
79860409|NCT04012723|Device|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
79860410|NCT04011722|Device|Portico™ NG (Navitor) Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
79726068|NCT02715037|Other|Throat swabbing|
79860411|NCT04011722|Device|Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
79860412|NCT04009499|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
79860413|NCT04007523|Behavioral|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
79860414|NCT04007523|Behavioral|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
80022003|NCT03497858|Other|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
79265183|NCT06017336|Other|Control Group (breathing exercises)|Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
79265184|NCT06006156|Procedure|Dental implants placement|surgery for placement of two one-piece trans gingival implants
79265185|NCT06001047|Procedure|Group A|Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.
79564657|NCT01714531|Behavioral|Telephone-Based Goal Management Training|
79564658|NCT01714531|Behavioral|Telephone-Based Attention-Control|
79564659|NCT01714557|Drug|Piperacillin|4.0g q8h 3-5 days
79860415|NCT04002947|Drug|DA-EPOCH|Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
79860416|NCT04002947|Biological|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
79564660|NCT01714557|Drug|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
79564661|NCT01714570|Drug|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
79564662|NCT01714570|Drug|Imipenem|0.5g q6h, 5-10 days
79564663|NCT01714596|Other|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
79564664|NCT01714622|Procedure|subtotal gastrectomy with gastroduodenostomy|
79564665|NCT01714622|Procedure|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
79564666|NCT01714622|Procedure|total gastrectomy with Rou-en-Y esophagojejunostomy|
79564667|NCT01714648|Drug|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
79564668|NCT01714661|Drug|EVP-6124|Arms 1, 2
79564669|NCT01714661|Drug|Placebo|Arm 3
79564670|NCT01714674|Dietary Supplement|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
79726069|NCT02723227|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
79726070|NCT02723227|Behavioral|Referral to Social Services|
79726071|NCT02716597|Drug|25% Albumin|
79726072|NCT02716597|Drug|Placebo|
79726073|NCT04857619|Other|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
79726074|NCT02715193|Biological|REMD-477|
79726075|NCT02715193|Biological|Placebo Comparator|
79860417|NCT04002947|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
79860418|NCT04002947|Drug|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
80022004|NCT03497858|Other|Sports drink|participants will consume a sports drink and complete a simulated basketball game
80022005|NCT02321072|Drug|Oxygen|
80022006|NCT02315690|Drug|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
79265186|NCT06001047|Drug|Group B|"The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol."
79265187|NCT05999708|Drug|GSK4381406|GSK4381406 will be administered.
79265188|NCT05999708|Drug|Placebo|Placebo will be administered.
79265189|NCT05999708|Drug|Indomethacin|Indomethacin will be administered.
79265190|NCT05990387|Drug|Mirabegron|Dose-response effect on thermogenesis
79265191|NCT05990387|Drug|Placebo|Placebo control condition
79265192|NCT05989152|Radiation|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
79265193|NCT05984979|Other|Standardized meal|The participants will receive a standardized meal for breakfast
79564671|NCT01714674|Dietary Supplement|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
79564672|NCT01714700|Behavioral|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
79564673|NCT01714700|Behavioral|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
79726076|NCT01223027|Drug|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
79726077|NCT01223027|Drug|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
79726078|NCT02714959|Drug|Proleukin|
79726079|NCT02714647|Behavioral|Attentional prime|
79726080|NCT02714647|Behavioral|Sham prime|
79726081|NCT02714725|Drug|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
79860419|NCT04002401|Biological|Axicabtagene Ciloleucel|A single infusion of CAR-transduced autologous T cells administered intravenously
79265194|NCT05977959|Behavioral|Mentoring Program|Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.
79265195|NCT05977959|Behavioral|Enhanced Resources|Schools in this group will receive extra resources such as program incentives to aid in program implementation.
79265196|NCT05977959|Behavioral|Enhanced Engagement|Schools in this group will participate in program contests to aid program implementation.
79265197|NCT05974280|Drug|Alofisel|Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
79860420|NCT04002401|Drug|Rituximab|Administered intravenously
79265198|NCT05974280|Drug|Fat stem cell|mesenchymal stem cells from adipose (fat) tissue injection
79265199|NCT05973565|Other|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
79564674|NCT01714713|Drug|EVP-6124|Arm 1, 2
79564675|NCT01714752|Procedure|measure of left ventricular and diastolic pressure at exercise|
79860421|NCT04002401|Drug|Fludarabine|Administered according to package insert
79564676|NCT01714765|Drug|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
79726082|NCT02714725|Drug|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
79726083|NCT02714725|Drug|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
79860422|NCT04002401|Drug|Cyclophosphamide|Administered according to package insert
79860423|NCT04000880|Behavioral|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
79860424|NCT04000880|Other|Diet-Exercise|Diet-Exercise
79265200|NCT05967403|Drug|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
79726084|NCT01015287|Drug|Placebo|Administered once orally
79860425|NCT04000880|Other|Exercise-Diet|Exercise-Diet
79860426|NCT04000880|Other|Combined Diet and Exercise|Combined Diet and Exercise
80022007|NCT02315690|Procedure|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
79564677|NCT01714765|Drug|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
79265201|NCT05967403|Drug|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
79265202|NCT05953285|Other|Sleep restriction|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.
79265203|NCT05935683|Other|Severe Uncontrolled Chronic Rhinosinusitis patients (CRS)|Obsertvation
79564678|NCT01714778|Other|e-Cigarette|
79564679|NCT01714791|Other|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
79564680|NCT01714791|Other|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~Structural High Velocity Low Amplitude-techniques.~Muscle Energy Techniques.~General osteopathic mobilisations.~Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.~Fascia techniques.~Soft tissue- and connective tissue techniques.~Neurovisceral and neurolymphatic reflex techniques.~Fluidal techniques (lymphatic manipulative techniques,...).~Visceral manipulations.~Neurocranial and viscerocranial techniques."
79564681|NCT01714817|Biological|BMS-188667|
79564682|NCT01714817|Drug|Mycophenolate mofetil|
79564683|NCT01714817|Drug|Prednisone|
79564684|NCT01714817|Biological|Placebo matching with BMS-188667|
79564685|NCT01714830|Device|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
79564686|NCT01714830|Device|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
79564687|NCT01714843|Drug|linaclotide|oral
79564688|NCT01714843|Drug|placebo|oral
79564689|NCT01714856|Drug|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
79564690|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
79564691|NCT01714882|Behavioral|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
79564692|NCT01714882|Behavioral|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
79564693|NCT01714895|Other|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
79564694|NCT01714895|Other|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
79564695|NCT01714908|Other|Erlotinib w Concurrent Radiotherapy|
79860427|NCT04000724|Behavioral|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
79860428|NCT04000724|Behavioral|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
79265204|NCT05933616|Device|Device: Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
79265205|NCT05932290|Drug|Elranatamab|BCMA-CD3 bispecific antibody
79265206|NCT05932290|Drug|Standard of care|Standard of care
79265207|NCT05920109|Procedure|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence < 5% of the total experimental group), patients will be switched to the control group.
79265208|NCT05917132|Other|Nutritionnal intervention|Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
79399676|NCT04507308|Behavioral|Single-session sleep intervention drawn from principles of the TranS-C youth protocol|We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
79399677|NCT01397461|Drug|ozenoxacin placebo|cream
79399678|NCT01397461|Drug|retapamulin 1% ointment|ointment
79564696|NCT01714908|Other|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
79564697|NCT01714960|Drug|MRZ-99030 eye drops 5mg/mL|
79564698|NCT01714960|Drug|MRZ-99030 eye drops 20mg/mL|
79564699|NCT01714960|Drug|Placebo to MRZ-99030 eye drops|
79564700|NCT01714973|Biological|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
79564701|NCT01714986|Behavioral|Affect School|
79564702|NCT01714986|Behavioral|Body Awareness Therapy|
79265209|NCT05910749|Device|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
79564703|NCT01714999|Procedure|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
79564704|NCT01714999|Procedure|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
79564705|NCT01715025|Drug|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
79564706|NCT01715038|Dietary Supplement|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
79564707|NCT01715038|Dietary Supplement|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
79564708|NCT01715038|Dietary Supplement|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
79564709|NCT01715038|Dietary Supplement|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
79564710|NCT01715051|Drug|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
79564711|NCT01715051|Behavioral|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
79564712|NCT01715051|Drug|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
79564713|NCT01715077|Drug|Ipilimumab at 3 mg/kg dose|
79564714|NCT01715090|Device|Web-based insulin titration|
79564715|NCT01715103|Procedure|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
79564716|NCT01715116|Device|Enhanced ICD programming|"VT monitor: > 166/min~fVT: > 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~VF: > 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~SVT/VT discrimination is turned on, high rate time out is OFF~SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~T wave-oversensing and lead noise discrimination is turned on in all devices."
79564717|NCT01715142|Drug|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
79564718|NCT01715142|Drug|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
79564719|NCT01715168|Drug|DOXIL/CAELYX|
79564720|NCT01715168|Drug|ATI-0918|
79564721|NCT01715181|Other|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
79564722|NCT01715194|Device|Telemedicine intervention|Patients undergoing telemedicine intervention
79564723|NCT01715220|Drug|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
79399679|NCT01397461|Drug|ozenoxacin 1% cream|1% cream
79564724|NCT01715246|Other|Infant Formula|
79564725|NCT01715259|Drug|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
79564726|NCT01715259|Drug|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
79564727|NCT01715272|Device|TF037|
79564728|NCT01715272|Drug|Fleet enema|
79564729|NCT01715311|Drug|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
79581308|NCT01935115|Drug|Propofol|Propofol anesthesia for ECT
79564730|NCT01715311|Drug|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
79265210|NCT05901662|Other|Competence training program|A 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
79265211|NCT05901662|Other|Control|This group provided their routine services at senior activity centers.
79265212|NCT05897632|Behavioral|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
79564731|NCT01715311|Drug|Tiotropium|Tiotropium capsules for inhalation once daily
79564732|NCT01715311|Drug|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
79564733|NCT01715337|Other|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
79564734|NCT01715350|Drug|PM012|"The drug will be taken with water within 30 minutes after breakfast and supper.~650mg/1 tablet, PO, 12weeks"
79564735|NCT01715350|Drug|Placebo|"The drug will be taken with water within 30 minutes after breakfast and supper.~650mg/1 tablet, PO, 12weeks"
79564736|NCT01715363|Drug|Oxaliplatin|
79564737|NCT01715363|Drug|Folinic Acid|
79564738|NCT01715363|Drug|Fluorouracile|
79564739|NCT01715389|Other|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
79564740|NCT01715402|Procedure|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
79726085|NCT01015287|Drug|Prasugrel|Administered orally
79265213|NCT05897632|Behavioral|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
79265214|NCT05892718|Drug|HCB101|HCB101 administered via. intravenous (IV) infusion.
79265215|NCT05892133|Behavioral|Maximal strength training|3 sessions/ week. leg press at ~85% of one repetition maximum for 8 weeks
79265216|NCT05878457|Device|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System|Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
79265217|NCT05872347|Drug|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
79265218|NCT05866198|Diagnostic Test|Actigraph CP Insight Watch|"CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist. The watch captures and records continuous high-resolution raw acceleration data to provide objective, real-world physical activity, mobility, and sleep measures, in near real time. That data is then processed by ActiLife software into what is called Epoch data (i.e. turning it into activity counts so that things such as moderate vigorous physical activity can be found). The device also passively scores every minute of recorded data as Sleep or Wake based on the amount of activity taking place."
79265219|NCT05865522|Other|Trapezius Massage|The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
79265220|NCT05865522|Other|Foot Massage|The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
79399680|NCT04429464|Device|AcQBlate Force Sensing Ablation Catheter|Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
79399681|NCT04335084|Drug|Hydroxychloroquine|Prophylaxis treatment for COVID-19
79399682|NCT04335084|Dietary Supplement|Vitamin C|Prophylaxis treatment for COVID-19
79726086|NCT02714803|Behavioral|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
79726087|NCT02714803|Behavioral|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
79726088|NCT02714803|Behavioral|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
79564741|NCT01715441|Drug|Sorafenib and irinotecan combination|
79564742|NCT01715441|Drug|Sorafenib monotherapy|
79564743|NCT01715441|Drug|Irinotecan monotherapy|
79564744|NCT01715480|Dietary Supplement|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
79564745|NCT01715493|Drug|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
79564746|NCT01715493|Drug|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
79564747|NCT01715506|Behavioral|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
79265221|NCT05865327|Procedure|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
79399683|NCT04335084|Dietary Supplement|Vitamin D|Prophylaxis treatment for COVID-19
79564748|NCT01715519|Drug|Treatment (Viibryd)|
79564749|NCT01715532|Drug|Huachansu|
79564750|NCT01715532|Other|TACE|
79564751|NCT01715584|Other|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
79564752|NCT01715597|Drug|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
79564753|NCT01715597|Drug|Normal saline|normal saline 500ml IV
79564754|NCT01715610|Drug|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
79564755|NCT01715610|Drug|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
79564756|NCT01715610|Drug|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
79564757|NCT01715623|Biological|a blood sample|Dosage of Ig
79564758|NCT01715636|Drug|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
79564759|NCT01715649|Behavioral|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
79564760|NCT01715662|Device|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
79564761|NCT01715662|Device|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
79564762|NCT01715675|Dietary Supplement|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
79564763|NCT01715675|Dietary Supplement|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
79564764|NCT01715688|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
79564765|NCT01715688|Drug|Saline|Administration of saline in the endotracheal tube cuff
79564766|NCT01715701|Procedure|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
79564767|NCT01715701|Procedure|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
79564768|NCT01715701|Procedure|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
79564769|NCT01715740|Drug|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
79564770|NCT01715740|Drug|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
79726089|NCT04028713|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
79726090|NCT04028713|Procedure|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
79726091|NCT04028713|Drug|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
79726092|NCT04772365|Drug|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
79726093|NCT04772365|Drug|Placebo|Placebo will be subcutaneously administered with different dose levels;
79726094|NCT02714491|Other|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
79726095|NCT02714491|Other|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
79726096|NCT02714491|Other|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
79726097|NCT02714179|Drug|Paracetamol was given intravenously in both group at different times|
79726098|NCT02714413|Dietary Supplement|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
79581309|NCT01935115|Drug|Ketamine|Ketamine anesthesia for ECT
79726099|NCT02714413|Dietary Supplement|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
79564771|NCT01715753|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
79564772|NCT01715753|Behavioral|Diet counseling and group education lessons|Individual and group diet counseling to achieve a >10% weight loss
79564773|NCT01715779|Drug|Eltrombopag|Eltrombopag exposure
79564774|NCT01715792|Other|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
79265222|NCT05865327|Procedure|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
79564775|NCT01715818|Drug|Placebo|matching aleglitazar placebo tablet orally daily
79399684|NCT04335084|Dietary Supplement|Zinc|Prophylaxis treatment for COVID-19
79564776|NCT01715818|Drug|aleglitazar|150 mcg orally daily
79564777|NCT01715844|Dietary Supplement|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
79564778|NCT01715870|Behavioral|Life style and food habits questionnaire|
79564779|NCT01715909|Drug|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams [mg]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for </= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
79564780|NCT01715922|Drug|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
79726100|NCT02714413|Other|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
79860429|NCT04000724|Behavioral|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
79564781|NCT01715922|Drug|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
79564782|NCT01715922|Procedure|lumbar punctures|lumbar punctures to control intracranial pressure
79564783|NCT01715935|Drug|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
79564784|NCT01715961|Procedure|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
79564785|NCT01715987|Drug|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
79564786|NCT01715987|Drug|Entecavir|0.5mg oral daily for two years.
79564787|NCT01716000|Other|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
79564788|NCT01716000|Behavioral|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
79564789|NCT01716091|Procedure|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
79564790|NCT01716143|Procedure|radiofrequency catheter ablation|
79564791|NCT01716247|Other|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
79564792|NCT01716273|Other|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
79726101|NCT01015131|Radiation|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
79726102|NCT02714101|Other|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
79726103|NCT02714023|Procedure|Normal Saline|Intra-operative irrigation with normal saline
79726104|NCT02714023|Procedure|Sterile Water|Intra-operative irrigation with sterile water
79860430|NCT03997448|Drug|Pembrolizumab|Pembrolizumab 200mg IV
79860431|NCT03997448|Drug|Abemaciclib|Abemiciclib 150mg PO
79860432|NCT03993717|Biological|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
79860433|NCT03988283|Biological|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
79860434|NCT03988283|Device|Papivax Biotech TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
79860435|NCT03988283|Procedure|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
79265223|NCT05861895|Drug|HF158K1 /Arm 2 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
79726105|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
80022008|NCT02639338|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
79564793|NCT01716273|Other|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
79564794|NCT01716286|Dietary Supplement|low fat vs. essence yoghurt|
79564795|NCT01716299|Other|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
79564796|NCT01716299|Other|application of a confirmation test|use of rapid confirmation test
79564797|NCT01716338|Drug|Glyburide|
79564798|NCT01716338|Drug|Placebo|
79726106|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
79726107|NCT02723383|Drug|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
79860436|NCT03986034|Drug|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
79564799|NCT01716351|Behavioral|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
79860437|NCT03981705|Radiation|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
79860438|NCT03971253|Drug|Peficitinib|Oral
79265224|NCT05861895|Drug|HF158K1 /Arm 6 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
79265225|NCT05861895|Drug|HF158K1 /Arm 15 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
79265226|NCT05861895|Drug|HF158K1 /Arm 30 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
79860439|NCT03964090|Drug|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
79860440|NCT03964090|Drug|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
79860441|NCT03964090|Drug|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
80022009|NCT02639338|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
79265227|NCT05861895|Drug|HF158K1 /Arm 45 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
79564800|NCT01716364|Biological|Anti-LeY- scFv-CD28-ζ vector,.|
79564801|NCT01716377|Drug|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
79564802|NCT01716390|Dietary Supplement|Drink that contains plant stanols|
79564803|NCT01716390|Dietary Supplement|Placebo drink|
79564804|NCT01716403|Biological|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
79564805|NCT01716416|Drug|Pazopanib|
79564806|NCT01716416|Drug|Cetuximab|
79564807|NCT01716429|Behavioral|Vegan diet|Vegan dietary approaches for weight loss
79564808|NCT01716429|Behavioral|Low calorie diet|Reduced calorie diet for weight loss
79564809|NCT01716442|Drug|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
79564810|NCT01716442|Drug|Placebo|
80022010|NCT01754857|Drug|Bendamustine|Given IV
80022011|NCT01754857|Drug|Rituximab|Given IV
80022012|NCT01754857|Drug|Lenalidomide|Given PO
80022013|NCT03497702|Drug|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
80022014|NCT03497702|Drug|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
80022015|NCT03497702|Drug|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
80022016|NCT03497702|Drug|Letrozole|2.5 mg once daily preoperably
80022017|NCT03497702|Drug|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
79265228|NCT05861895|Drug|HF158K1 /Arm 60 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
79564811|NCT01716481|Other|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
79564812|NCT01716507|Procedure|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
79564813|NCT01716546|Drug|Pazopanib|
79860442|NCT03964090|Drug|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
79860443|NCT03964090|Drug|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
79860444|NCT03964090|Drug|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
79860445|NCT03950414|Biological|CMV specific T-cells|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~Low Dose Tier - Viral-Specific T cell infusion 5 x10^3 cells/kg body weight(BW)~Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10^4 cells/kg BW~High Dose Tier - Viral-Specific T cell infusion 2.5 x10^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection."
79860446|NCT03947840|Behavioral|Physical activity|Se their physical activity level
79860447|NCT03941093|Drug|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
79860448|NCT03941093|Drug|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
80022018|NCT02321150|Procedure|Cautery|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~Conjunctiva undermined at the recipient site.~Relaxing incisions placed at the corners of the recipient site.~Graft is slid into place~Graft / host interface is gently dried with a Qtip~Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~Power setting: 25.~Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~Cautery is applied at the 4 apices of the graft then in between these points."
80022019|NCT02321150|Procedure|Sutures|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~Conjunctiva undermined at the recipient site.~Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
79726108|NCT02723383|Drug|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
79726109|NCT02723149|Behavioral|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
79564814|NCT01716572|Drug|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
79564815|NCT01716572|Procedure|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
79726110|NCT02722915|Procedure|fMRI|collection of functional brain data for 1 hour per day
79265229|NCT05860465|Drug|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
79265230|NCT05860465|Drug|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
79265231|NCT05858593|Behavioral|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
79564816|NCT01716598|Device|IPS System|TLD Therapy will be achieved bronchoscopically.
79564817|NCT01716611|Drug|Tolvaptan|15 - 60 mg/day for 28 days
79564818|NCT01716611|Drug|placebo|
79564819|NCT01716624|Drug|Oxybutynin|standard oral therapy
79564820|NCT01716624|Drug|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
79564821|NCT01716637|Biological|Etanercept|
79564822|NCT01716637|Dietary Supplement|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
79564823|NCT01716676|Other|Telemedicine CPAP monitoring (webpage and televisit)|
79564824|NCT01716676|Other|Standard CPAP monitoring|
79564825|NCT01716689|Drug|oral cyclophosphamide|50mg daily
79581310|NCT01935141|Procedure|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
79564826|NCT01716702|Behavioral|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
79564827|NCT01716728|Other|enzyme analysis|
79564828|NCT01716741|Other|Enzyme analysis|
79564829|NCT01716767|Other|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
79564830|NCT01716767|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
79860449|NCT03925038|Behavioral|Augmented Care: Electronic Media Dashboard|A participant-specific dashboard that highlights patterns of patient electronic communication usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
80022020|NCT03097744|Device|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
80022021|NCT02900352|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
80022022|NCT02900352|Drug|Placebo|Placebo
80022023|NCT02318498|Procedure|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
79265232|NCT05858593|Behavioral|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
79564831|NCT01716780|Other|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
79564832|NCT01716793|Drug|Ara-C|"Intermediate dose during induction phase to remission.~High-dose during consolidation phase in patients with favorable cytogenetics."
79564833|NCT01716793|Other|Autologous transplantation|"In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~In patients with other cytogenetics without HLA-Identical sibling."
79564834|NCT01716793|Other|Allogeneic HLA-identical sibling transplantation|"Patients without favorable or normal karyotype(and one course to CR).~Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
79564835|NCT01716793|Other|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
79564836|NCT01716819|Other|Urine sample|dosages on one spot and 24h collection
79564837|NCT01716819|Other|Blood sample|dosages
79564838|NCT01716819|Other|Assessment of sleep apnea syndrome|
79564839|NCT01716819|Other|Electrocardiogram|
79726111|NCT02722915|Behavioral|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 & 4; controls without AVH: Days 2 & 3)
79726112|NCT02722915|Other|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
79564840|NCT01716819|Other|Glucose tolerance test|
79726113|NCT02722915|Other|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
79265233|NCT05854381|Biological|VIR-1388|VIR-1388 is given by subcutaneous injection
79265234|NCT05854381|Biological|Placebo|The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection
79265235|NCT05846633|Device|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
79564841|NCT01716819|Other|Echocardiography|
79564842|NCT01716819|Other|cardiac and abdominal magnetic resonance imaging|
79564843|NCT01716819|Other|Ambulatory blood pressure monitoring|
79564844|NCT01716819|Other|Echotracking|
79564845|NCT01716819|Other|Pulse wave velocity|
79564846|NCT01716819|Other|Composition of body mass by Dual x-ray absorptiometry|
79564847|NCT01716832|Behavioral|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
79564848|NCT01716858|Dietary Supplement|Sulforaphane-rich Broccoli Sprout Extract|
79564849|NCT01716871|Device|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
79581311|NCT01935141|Device|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
79581312|NCT01935141|Drug|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
79860450|NCT03925038|Behavioral|Treatment as Usual|Participants will receive psychotherapy as treatment as usual.
80022024|NCT05034406|Drug|2% Lidocaine|6 mL of 2% lidocaine injected at the trocar insertion site.
80022025|NCT05034406|Drug|0.5% levobupivacaine|6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
80022026|NCT02318576|Other|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
79399685|NCT04386369|Other|Airway pressure release ventilation|Ventilator management strategy
80022027|NCT02254668|Other|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
80022028|NCT02254668|Other|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
80022029|NCT03097978|Device|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
79265236|NCT05840978|Dietary Supplement|Probiotics|Oral capsules
80022030|NCT03097978|Device|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
80022031|NCT03097978|Other|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
79564850|NCT01716871|Device|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
79564851|NCT01716897|Drug|E2609|
79564852|NCT01716910|Dietary Supplement|Combination of Lactobacillus acidophilus NCFM and cellobiose|
79726114|NCT02722915|Other|SF36|questionnaire about life quality after 1 week during a telephone interview
79726115|NCT05269537|Radiation|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
79726116|NCT05269537|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
79726117|NCT05269537|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
79726118|NCT05269537|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
79726119|NCT05269537|Drug|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
80022032|NCT03097978|Other|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
80022033|NCT02315924|Other|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
80022034|NCT02315924|Other|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
79399686|NCT02996019|Drug|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
79399687|NCT02996019|Device|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
79399688|NCT02996019|Device|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
79564853|NCT01716923|Biological|S-303 Red Blood Cells (RBCs) - Test|
79726120|NCT05269537|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
79726121|NCT05269537|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
79726122|NCT05269537|Drug|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
79726123|NCT02722993|Dietary Supplement|Probiotics|
79726124|NCT02722993|Dietary Supplement|Placebo|
79726125|NCT01222715|Biological|Bevacizumab|Given IV
79726126|NCT01222715|Drug|Cyclophosphamide|Given IV
79265237|NCT05840978|Dietary Supplement|Placebo|Oral capsules
79265238|NCT05833126|Drug|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
79265239|NCT05823727|Dietary Supplement|SOLUGEL|Bovine collagen peptide supplement
79265240|NCT05823727|Dietary Supplement|Placebo|Maltodextrin
79265241|NCT05819658|Drug|GV1001 Placebo|0.9% normal saline
79265242|NCT05819658|Drug|GV1001 0.56mg|Lyophilized peptide from hTERT
79265243|NCT05819658|Drug|GV1001 1.12mg|Lyophilized peptide from hTERT
79564854|NCT01716923|Biological|Conventional, untreated red blood cells (RBCs) - Control|
79564855|NCT01716949|Radiation|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
79564856|NCT01716949|Procedure|Hyperthermia|10 sessions, therapeutic time 60 min
79564857|NCT01716949|Drug|5-Fluorouracil|250 mg/m^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
79564858|NCT01716949|Drug|Capecitabine|1650 mg/m^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
79564859|NCT01716949|Drug|Oxaliplatin|50 mg/m^2/d as 2-hour bolus infusion on d2, 9, 23, 30
79726127|NCT01222715|Other|Laboratory Biomarker Analysis|Correlative studies
79726128|NCT01222715|Drug|Temsirolimus|Given IV
79726129|NCT01222715|Drug|Vinorelbine Tartrate|Given IV
79726130|NCT02723071|Drug|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
79726131|NCT02722759|Other|hemoglobin measurement|
79726132|NCT02722681|Procedure|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
79726133|NCT02722681|Procedure|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
79726134|NCT02722447|Drug|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
79860451|NCT03922100|Drug|NMS-03592088|Route of administration: Oral
79564860|NCT01716962|Other|Infusion of 6% tetrastarch for a total of 500 ml|
79564861|NCT01716975|Drug|EVP-6124|Arms 1, 2
79564862|NCT01716975|Drug|Placebo|Arm 3
79860452|NCT03920007|Drug|ATSN-101|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
79860453|NCT03920007|Drug|ATSN-101 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
80022035|NCT03040687|Biological|Anti CS6 BSIgG product (Lot PD1601105CS)|
80022036|NCT03040687|Biological|Anti B7A BSIgG product (Lot PD1601132ET)|
79564863|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
79564864|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
79399689|NCT02995785|Other|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
79564865|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
79726135|NCT02722447|Drug|Placebo|Placebo for 6 weeks
79726136|NCT01222403|Biological|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
79726137|NCT01222403|Biological|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
79726138|NCT02722369|Drug|Gemcitabine|Chemotherapy
79726139|NCT02722369|Drug|Carboplatin|Chemotherapy
79860454|NCT03920007|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
79860455|NCT03920007|Drug|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
79860456|NCT03920007|Drug|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
79860457|NCT03920007|Drug|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
80022037|NCT03040687|Biological|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
80022038|NCT03040687|Biological|B7A- CS6-expressing ETEC challenge strain|
80022039|NCT03544398|Other|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
80022040|NCT03500276|Behavioral|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
80022041|NCT03500276|Behavioral|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
79399690|NCT02995785|Other|traditional training|traditional training:Give TMS online lecture(15-min).
79399691|NCT02994537|Other|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
79564866|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
79564867|NCT01717066|Drug|the ginsenoside Rg3|
79564868|NCT01717066|Drug|Placebo|
79564869|NCT01717079|Procedure|Sham rTMS|120 pulses 0.2Hz
79564870|NCT01717079|Procedure|rTMS|120 pulses 0.2Hz
79564871|NCT01717118|Biological|Bivalent Vaccines|
79564872|NCT01717118|Biological|Tetravalent Vaccine|
79564873|NCT01717144|Behavioral|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
79564874|NCT01717157|Drug|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
79564875|NCT01717157|Drug|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
79564876|NCT01717157|Drug|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
79564877|NCT01717157|Drug|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
79564878|NCT01717157|Drug|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
79726140|NCT02722369|Drug|Etoposide|Chemotherapy
79726141|NCT02722369|Drug|Hydroxychloroquine|Maintenance Agent
79726142|NCT04657393|Procedure|mechanical ventilation|change of ventilation frequency
79726143|NCT02722291|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
79726144|NCT02694211|Behavioral|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
79726145|NCT02694133|Procedure|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
79726146|NCT02694133|Procedure|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
79860458|NCT03916276|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
79564879|NCT01717170|Drug|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
79564880|NCT01717183|Device|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
79726147|NCT01222247|Drug|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
79726148|NCT01222247|Drug|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
79726149|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
79726150|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
79726151|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
79726152|NCT02713555|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
79399692|NCT02995395|Device|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
79564881|NCT01717183|Device|Placebo URGO 310 3113 dressing|
79564882|NCT01717196|Other|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
80022042|NCT03098134|Behavioral|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
79860459|NCT03916276|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
79564883|NCT01717222|Drug|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
79564884|NCT01717222|Drug|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
79564885|NCT01717235|Drug|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
79726153|NCT02713555|Procedure|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
79399693|NCT02992041|Drug|VVZ-149 Injections|IV infusion of 900 or 1100 mg of VVZ-149
79265244|NCT05818735|Other|electroacupuncture (EA) treatment|The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
79399694|NCT02992041|Drug|Placebo|IV infusion of 0 mg of VVZ-149
79399695|NCT02997501|Procedure|T790M+ Testing|The patient will need to have T790M+ testing
80022043|NCT03098134|Other|Health Education|Video based health education covering common myths and false believes about dental surgeries
79399696|NCT02997501|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
80031733|NCT05106218|Device|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
80031734|NCT05106218|Device|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
79564886|NCT01717248|Drug|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
79564887|NCT01717274|Procedure|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
79564888|NCT01717300|Drug|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
79399697|NCT02997501|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
79399698|NCT02997501|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
79399699|NCT02997501|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
79399700|NCT02997501|Procedure|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
79564889|NCT01717300|Drug|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
79564890|NCT01717300|Drug|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
79564891|NCT01717300|Drug|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
79564892|NCT01717339|Other|Sleep Study|
79564893|NCT01717352|Behavioral|Weight Loss Education|
79564894|NCT01717352|Behavioral|Sleep and Eating Routine|
79581313|NCT01935154|Drug|Vx-001|
79726154|NCT00628173|Procedure|AGV implantation|
79726155|NCT00611065|Device|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
79726156|NCT04299477|Procedure|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
80022044|NCT05270785|Other|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
80022045|NCT05270785|Other|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
79265245|NCT05818735|Other|sham acupuncture (SA) treatment|The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
79564895|NCT01717404|Drug|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
79564896|NCT01717417|Device|miniscrew|
79564897|NCT01717417|Device|TPA|
79564898|NCT01717469|Device|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
79564899|NCT01717469|Device|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
79564900|NCT01717508|Behavioral|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
79564901|NCT01717534|Dietary Supplement|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
79726157|NCT03982537|Drug|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
79726158|NCT03982537|Radiation|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
79726159|NCT05260593|Device|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
79399701|NCT01396525|Device|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
79399702|NCT02998827|Drug|Thalidomide|
79399703|NCT02998827|Drug|infliximab, azathioprine|other treatment include infliximab, azathioprine
79399704|NCT02998827|Other|enteral nutrition|
79399705|NCT02991027|Device|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
79399706|NCT02991027|Device|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
79564902|NCT01717547|Behavioral|Yoga-based treatment|
79564903|NCT01717560|Other|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
79564904|NCT01717573|Procedure|Deferred stenting|
79564905|NCT01717573|Procedure|Conventional treatment|
79564906|NCT01717599|Drug|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
79564907|NCT01717599|Drug|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
79399707|NCT02995707|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
79399708|NCT02849652|Behavioral|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
79564908|NCT01717612|Drug|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
79564909|NCT01717612|Drug|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
79564910|NCT01717625|Drug|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
79564911|NCT01717664|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
79564912|NCT01717677|Procedure|radical prostatectomy|
79564913|NCT01717677|Radiation|percutaneous radiation therapy|
79564914|NCT01717677|Radiation|permanent seed implantation|
79564915|NCT01717677|Procedure|Active Surveillance|
79581314|NCT01935154|Drug|Placebo|
79581315|NCT01935167|Drug|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
79860460|NCT03916276|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
80022046|NCT03097354|Other|no intervention/observational survey study design|no intervention/observational survey study design
79265246|NCT05818735|Drug|Escitalopram 10mg|Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
79399709|NCT02849652|Behavioral|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
79564916|NCT01717690|Drug|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
79564917|NCT01717703|Dietary Supplement|Water|
79399710|NCT02995473|Drug|NP000888|270 µg/g topical (BID) for 24 weeks
79564918|NCT01717703|Dietary Supplement|Fruit drink|
79564919|NCT01717703|Dietary Supplement|Cola|
79564920|NCT01717703|Dietary Supplement|1% chocolate milk|
79564921|NCT01717716|Dietary Supplement|water with Sucralose|
79564922|NCT01717716|Dietary Supplement|water with HFCS|
79564923|NCT01717716|Dietary Supplement|water with glucose|
79564924|NCT01717716|Dietary Supplement|water with sucrose|
79564925|NCT01717729|Procedure|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
79564926|NCT01717729|Radiation|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
79726160|NCT05260593|Device|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
79860461|NCT03903224|Procedure|Combined Modified Pectoralis and Transversus Plane Blocks|"Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region"
80022047|NCT02321306|Drug|LUM001|LUM001 administered orally once each day.
80022048|NCT05034094|Other|VEMP recording|"Clinical evaluation: All participants will undergo detailed medical and neurological histories and examinations.~The severity of manifestations of PD will be assessed using the Movement Disorder Society (MDS)-sponsored new version of Unified PD Rating Scale (MDS-UPDRS)."
80022049|NCT02316080|Other|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
79564927|NCT01717755|Other|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
79564928|NCT01717781|Procedure|Thunderbeat technology|
79726161|NCT05260593|Device|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
80022050|NCT02316080|Other|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
80022051|NCT03095404|Drug|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
79564929|NCT01717781|Procedure|Standard bipolar electrosurgery|
79564930|NCT01716260|Drug|Chloroquine|
80022052|NCT03095404|Drug|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
80022053|NCT02145546|Drug|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
80022054|NCT02145546|Drug|Propafenone|150mg per 8 hours, 3 times per day
79726162|NCT05260593|Other|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
79726163|NCT02713477|Drug|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79564931|NCT01716260|Drug|Primaquine|
79564932|NCT01716325|Other|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
79564933|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
79564934|NCT01717794|Procedure|Thunderbeat technology|
79564935|NCT01717794|Procedure|Standard bipolar electrosurgery|
79726164|NCT02713477|Drug|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79726165|NCT02713477|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79726166|NCT00611299|Dietary Supplement|BB-12 and CRL 431|
80022055|NCT02145546|Drug|Sotalol|80mg twice per day.
80022056|NCT03039673|Drug|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
80022057|NCT03039673|Drug|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
80022058|NCT03039673|Drug|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
79726167|NCT01221623|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
79860462|NCT03903224|Procedure|Erector Spinae block|The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
79860463|NCT03888105|Drug|Odronextamab|Administered by intravenous (IV) infusion
80022059|NCT02316158|Other|Web-based support|Comparison between the efficacy between webb-based support and informational support
80022060|NCT03097432|Drug|ORALVAC COMPACT BÄUME|
80022061|NCT04461782|Dietary Supplement|Lactobacillus plantarum|Oral food supplement
80022062|NCT02145624|Drug|Repevax|vaccine
79726168|NCT01221623|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
79726169|NCT02722213|Behavioral|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
79399711|NCT02995473|Drug|Vehicle|Topical (BID) for 24 weeks
79564936|NCT01717807|Other|C11-Erlotinib PET/CT|
79564937|NCT01717820|Dietary Supplement|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
79564938|NCT01717833|Procedure|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
79564939|NCT01717833|Procedure|Sham|Sham sessions of neuromuscular electrical stimulation
79564940|NCT01717846|Drug|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
79564941|NCT01717846|Other|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
79564942|NCT01717911|Drug|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
79564943|NCT01717911|Drug|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
79581316|NCT01935167|Drug|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
79265247|NCT05818735|Drug|Placebo|Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
79399712|NCT02995161|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-106)
79399713|NCT02995161|Drug|SPF control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
79564944|NCT01717911|Drug|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
79564945|NCT01717937|Procedure|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
79564946|NCT01717950|Biological|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
79564947|NCT01717950|Biological|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
79564948|NCT01717963|Drug|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
79564949|NCT01717963|Drug|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
79564950|NCT01718002|Behavioral|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
79564951|NCT01718054|Dietary Supplement|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
79726170|NCT02693587|Drug|Misodel and Angusta|
79726171|NCT01014585|Drug|Placebo|Placebo tablets administered orally twice daily
79726172|NCT01014585|Drug|Milnacipran|Milnacipran tablets administered orally twice daily
79726173|NCT02722135|Drug|Volasertib|
79726174|NCT00611143|Drug|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
79860464|NCT03878979|Drug|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
79860465|NCT03873363|Device|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
79860466|NCT03873363|Device|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
79265248|NCT05817240|Drug|taladegib|100 mg per tablet, dosed once daily
79265249|NCT05817240|Drug|nintedanib|100 mg per capsule, dosed once daily
79265250|NCT05810259|Device|Caravan Wellness app|Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
79399714|NCT02990949|Other|Timing of trigger|
79399715|NCT04234854|Diagnostic Test|Intravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent|IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
79564952|NCT01718054|Dietary Supplement|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
79564953|NCT01718054|Drug|Chloroquine|
79564954|NCT01718067|Device|VAKÜM system|15 minutes, twice a day.
79564955|NCT01718067|Other|conventional manual ELTGOL technique|20 minutes twice a day
79726175|NCT01221233|Other|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
79860467|NCT03872401|Drug|Evolocumab|Administered subcutaneously using an autoinjector pen.
79860468|NCT03872401|Drug|Placebo|Administered subcutaneously using an autoinjector pen.
79860469|NCT03866187|Biological|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
80022063|NCT02145624|Drug|Boostrix-IPV|vaccine
79860470|NCT03866187|Biological|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
79860471|NCT03866187|Biological|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
79564956|NCT01718093|Drug|Sitagliptin|up to 50 mg twice a day
79399716|NCT02990715|Device|C-Scan System|"To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~To evaluate the safety of the C-Scan Capsule System procedure"
79564957|NCT01718093|Drug|Metformin|up to 1000 mg twice a day
80031735|NCT05684211|Drug|Ametumumab|A recombinant fully human anti-EGFR monoclonal antibody
79564958|NCT01718093|Drug|Sitagliptin + Metformin|up to 50/1000 mg twice a day
79564959|NCT01718106|Device|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
79564960|NCT01718119|Drug|r-hCG|r-hCG(250mcg) injection subcutaneously
79564961|NCT01718184|Procedure|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
79564962|NCT01718184|Procedure|Sulcoflex intraocular lens implantation|
79564963|NCT01718210|Drug|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
79564964|NCT01718210|Drug|CONTROL|group of controls treated with a standard IVF medium
79564965|NCT01718223|Drug|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
79726176|NCT01221233|Other|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
79726177|NCT04300569|Other|Non-interventional|No intervention will be administered.
79726178|NCT04488393|Device|MaterniT21 PLUS and GENOME Laboratory-Developed Tests|Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
79726179|NCT02713165|Other|Raisins|Participants will consume 84g of raisins per day for 14 days.
79860472|NCT03866187|Biological|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
79860473|NCT03866187|Biological|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
80031736|NCT05684211|Drug|Anti-PD-1 monoclonal antibody|Toripalimab 3 mg/kg，Intravenous titration，Q2W
80031737|NCT05684211|Drug|Cetuximab|Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
80031738|NCT05684211|Drug|FOLFIRI|Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
80031739|NCT04894942|Other|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
79399717|NCT01270035|Drug|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
79399718|NCT01396447|Drug|Placebo|Placebo was supplied in capsules.
79399719|NCT01396447|Drug|Cariprazine|Cariprazine was supplied in capsules.
79399720|NCT01270113|Behavioral|contingency management|
79399721|NCT04792788|Procedure|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
79399722|NCT00704379|Drug|Placebo|an inactive substance
79564966|NCT01718223|Procedure|therapeutic conventional surgery|Undergo surgical resection
79564967|NCT01718223|Other|laboratory biomarker analysis|Correlative studies
79564968|NCT01718223|Drug|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
79564969|NCT01718236|Drug|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
79564970|NCT01718236|Drug|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
79564971|NCT01718249|Other|Implantable neurostimulation system|
79581317|NCT01935167|Drug|Placebo|Placebo 2 tablets b.i.d.
79581318|NCT01935193|Drug|lysine acetylsalicylate|
79581319|NCT01935206|Drug|Naloxone (2 mg/kg)|
79581320|NCT01935206|Drug|Placebo|
79726180|NCT02712619|Drug|Metformin|
80022064|NCT03042559|Device|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
80031740|NCT03130634|Drug|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
80031741|NCT02050425|Device|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
79399723|NCT00704379|Drug|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
80031742|NCT02050425|Device|CPAP|Patients continue therapeutic CPAP therapy
80031743|NCT04885582|Other|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
80031744|NCT02124824|Drug|BQ-123|Endothelin subtype A antagonist
79265251|NCT05804773|Diagnostic Test|Non-invasive Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s)|"Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s) (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk. For neuro-injured patients with intracranial pressure monitoring (ICP), the lower limit of cerebral perfusion pressure (CPP = MAP - ICP) will be set at 50 mmHg"
79399724|NCT03110406|Other|whole-body vibration training|Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
79399725|NCT02991495|Biological|Stamaril, Sanofi Pasteur|"Full dose~Fractional dose: one fifth (1/5)"
79399726|NCT02991495|Biological|Yellow fever vaccine, Bio-Manguinhos|"Full dose~Fractional dose: one fifth (1/5)"
79399727|NCT02991495|Biological|Yellow fever vaccine, Institut Pasteur|"Full dose~Fractional dose: one fifth (1/5)"
79564972|NCT01718288|Drug|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
79564973|NCT01718288|Drug|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
79564974|NCT01718301|Drug|boceprevir|
79564975|NCT01718301|Drug|Ribavirin|
79265252|NCT05803876|Other|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
79265253|NCT05801237|Drug|PE0116&PE0105|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
79564976|NCT01718301|Drug|Peginterferon alfa-2a|
79564977|NCT01718301|Drug|Peginterferon alfa-2b|
79265254|NCT05796661|Other|Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration|"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."
79564978|NCT01718314|Drug|Sublingual Misoprostol|
79564979|NCT01718314|Drug|Lidocaine pump spray|
79265255|NCT05782881|Behavioral|phone calls and encouraging patients' lifestyle change and medication adherence|Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
79265256|NCT05782881|Drug|Statin|Treatment and management according to the guidelines
79860474|NCT03866187|Biological|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
79860475|NCT03866187|Drug|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
80031745|NCT04895020|Biological|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
79265257|NCT05780073|Drug|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
79726181|NCT00611221|Procedure|Massage|Massage therapy by an RMT during labour
79726182|NCT00611221|Procedure|Massage|Massage by anyone else, eg. husband, nurse, doula
79726183|NCT01220609|Drug|Ixabepilone|Given IV
79726184|NCT01220609|Other|Laboratory Biomarker Analysis|Correlative studies
79726185|NCT02713087|Drug|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
79726186|NCT02713087|Drug|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
79726187|NCT02722603|Drug|gabapentin|75 mg/ml gabapentin syrup
79726188|NCT02722603|Drug|tramadol|100 mg/ml tramadol oral drops
79726189|NCT02722603|Other|placebo tramadol|placebo tramadol oral drops
79726190|NCT02722603|Other|placebo gabapentin|placebo gabapentin syrup
79726191|NCT03975517|Behavioral|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
79726192|NCT02712853|Other|Saliva collection|Collection of saliva via swab for miRNA processing
79726193|NCT02712853|Other|Vineland Adaptive Behavior Scale-II Assessment|
79726194|NCT02712697|Drug|WM (Shentong Granules)|Shentong Granules with Prednisone
79726195|NCT02712697|Drug|Hormone (prednisone)|Oral prednisone
79726196|NCT02708563|Procedure|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
79726197|NCT02708563|Procedure|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
79860476|NCT03853707|Drug|Atezolizumab|Given IV
79860477|NCT03853707|Drug|Capecitabine|Given PO
79860478|NCT03853707|Drug|Carboplatin|Given IV
79860479|NCT03853707|Drug|Ipatasertib|Given PO
79265258|NCT05780073|Other|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
79265259|NCT05779345|Procedure|surgery|short implant placement
79265260|NCT05777525|Combination Product|"application of cream La Chinata"|application of cream enriched with essential oil
79265261|NCT05774340|Drug|CM326|CM326 injection
79265262|NCT05774340|Other|Placebo|Placebo
79265263|NCT05771064|Behavioral|Gentle Moves|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position; and two movements in the standing position. The intervention will be delivered by a research coach.
79265264|NCT05770609|Drug|SPH3127 Tablets with Dose A|See Arm description
79265265|NCT05770609|Drug|SPH3127 Tablets with Dose B|See Arm description
79265266|NCT05770609|Drug|SPH3127 Tablets placebo|See Arm description
79265267|NCT05766943|Device|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
79265268|NCT05766943|Device|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
79265269|NCT05761028|Drug|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
79265270|NCT05761028|Other|Placebo|Placebo
79265271|NCT05755789|Drug|Loading bolus of cefoxitin|Cefoxitin [2g] at least 30 min before incision
79265272|NCT05755789|Drug|Intermittent cefoxitin|Additional bolus of cefoxitin [1g] every 2 hours until the end of surgical closure
79265273|NCT05755789|Drug|Continuous infusion of placebo|Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
79265274|NCT05755789|Drug|Continuous infusion of cefoxitin|Continuous infusion of cefoxitin [0.5g/h] from the end of the loading bolus until the end of surgical closure
79726198|NCT02708797|Other|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
79726199|NCT02708797|Other|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
79726200|NCT02708719|Procedure|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
79726201|NCT01220297|Drug|Sirolimus|"Immunosuppressant administered orally to:~Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~Children < 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
79726202|NCT01220297|Drug|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
79726203|NCT01220297|Drug|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
79860480|NCT03853707|Drug|Paclitaxel|Given IV
79860481|NCT03853707|Other|Quality-of-Life Assessment|Ancillary studies
79399728|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose~Fractional dose: one fifth (1/5)"
79564980|NCT01718314|Drug|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
79564981|NCT01718314|Drug|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
79564982|NCT01718327|Drug|Sunitinib|sunitinib dose :37.5mg/day
79726204|NCT01220297|Drug|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
79726205|NCT01220297|Drug|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
79726206|NCT01220297|Drug|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
80022065|NCT03042559|Device|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
80022066|NCT05033938|Procedure|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
79726207|NCT02721901|Behavioral|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
79860482|NCT03853707|Other|Questionnaire Administration|Ancillary studies
79860483|NCT03850678|Device|Hearing Aid|Hearing Aid
79860484|NCT03845166|Drug|XL092|oral doses of XL092
79860485|NCT03845166|Drug|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
79265275|NCT05755789|Drug|Intermittent placebo|Additional bolus of placebo every 2 hours until the end of surgical closure
79265276|NCT05745077|Behavioral|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
79265277|NCT05745077|Behavioral|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
79399729|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose~Fractional dose: one fifth (1/5)"
79399730|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose~Fractional dose: one fifth (1/5)"
79860486|NCT03845166|Drug|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
79860487|NCT03843918|Drug|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
79399731|NCT02994693|Device|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
79564983|NCT01718340|Drug|Metformin|metformin tablet 500mg three time per day
79564984|NCT01718366|Drug|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
79564985|NCT01718379|Drug|Lenalidomide|Lenalidomide:10 mg per day during 21 days
79564986|NCT01718379|Drug|Epoetin beta|Epoetin beta: 60,000 Units/week.
79564987|NCT01718392|Behavioral|Training|
79564988|NCT01718405|Other|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
79564989|NCT01718405|Genetic|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
79564990|NCT01718418|Other|test meal|
79564991|NCT01718418|Other|reference|
79564992|NCT01718431|Other|test meal|
79564993|NCT01718431|Other|reference meal|
79564994|NCT01718457|Device|Endobarrier|
79564995|NCT01718470|Procedure|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
79581321|NCT01935219|Behavioral|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
79265278|NCT05738239|Device|Laser therapy|Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).
79265279|NCT05731687|Other|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and < TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
79265280|NCT05731687|Other|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
79265281|NCT05724823|Other|Virtual Physical Activity Seated Exercises (V-PASE)|The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
79399732|NCT04541706|Drug|Lorlatinib|Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
79399733|NCT02997345|Other|There is no intervention associated with this study.|There is no intervention associated with this study.
79399734|NCT04345185|Other|Infant egg consumption (i.e., age of introduction and frequency of intake)|
79399735|NCT05738070|Diagnostic Test|Magnetic resonance imaging|MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
79564996|NCT01718470|Procedure|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
79564997|NCT01718496|Drug|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
79564998|NCT01718496|Drug|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
79564999|NCT01718548|Dietary Supplement|Cordyceps Sinensis (CS) and Lingzhi|
79565000|NCT01718548|Dietary Supplement|Tea and Flour|Placebo
79565001|NCT01718561|Procedure|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
79565002|NCT01718574|Other|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
79565003|NCT01718587|Procedure|stem cell transplantation through interventional procedure|interventional procedure once
79565004|NCT01718587|Drug|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
79565005|NCT01718613|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
79565006|NCT01718613|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
79565007|NCT01718626|Drug|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
79565008|NCT01718626|Drug|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
79565009|NCT01718639|Device|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
79726208|NCT02721901|Behavioral|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
79726209|NCT02888015|Other|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
79726210|NCT02712775|Drug|Minocycline (yes/no)|
79726211|NCT02712775|Drug|Placebo|Saline
79860492|NCT03840967|Drug|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
79860493|NCT03825757|Drug|Placebo Oral Tablet|Placebo Oral Tablet
79860494|NCT03825757|Drug|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
80031746|NCT04880746|Drug|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
79860495|NCT03817021|Behavioral|CORE NAP SACC|Modify the food environment following a self-assessment of current food conditions
80022067|NCT05033938|Procedure|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
79265282|NCT05706311|Behavioral|Clinical Decision Support Tool (Moderate Risk)|Moderate risk patients will get brief motivational intervention for medication misuse and an offer of naloxone dispensation.
79265283|NCT05706311|Behavioral|Clinical Decision Support Tool (High Risk)|Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation.
80022068|NCT02321384|Drug|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
79860496|NCT03817021|Behavioral|ECE Provider|Provide online training for Head Start educators
79860497|NCT03817021|Behavioral|Parent Intervention|Coach parents remotely to educate them on responsive feeding and parenting
80022069|NCT02321384|Drug|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
80022070|NCT02321384|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
80022071|NCT02321384|Drug|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
79265284|NCT05706311|Other|Standard of Care|Ohio State law requires pharmacist to not dispense an opioid supply >90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
79565010|NCT01718639|Device|IQP-LH-101 liquid|Oral medical device in the form of a liquid
79265285|NCT05702970|Drug|Sucrosomial iron|Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.
80022072|NCT03095326|Dietary Supplement|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
79860498|NCT03817021|Behavioral|Child intervention|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
79860499|NCT03812562|Biological|Nivolumab|Given IV
79860500|NCT03812562|Radiation|Yttrium Y 90 Glass Microspheres|Given IV
79860501|NCT03812224|Drug|Erenumab|Administered by subcutaneous injection once a month
79860502|NCT03812224|Drug|Placebo|Administered by subcutaneous injection once a month
79860503|NCT03809624|Drug|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
79860504|NCT03809624|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
80022073|NCT03095326|Drug|Sucrose|Placebo of sucrose syrup
80022074|NCT03095326|Biological|PCV Vaccine|Pneumococcal conjugate vaccine
79265286|NCT05702970|Drug|Vitamin D|administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group
79265287|NCT05702970|Drug|Ferric Carboxymaltose 50 MG/ML|Control group [standard of care]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
79265288|NCT05689619|Dietary Supplement|Silibinin|Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
79265289|NCT05689619|Other|Placebo|Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
79265290|NCT05686798|Biological|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)|Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
79399736|NCT05737914|Procedure|Endoscopic thoracic T3 sympathectomy|Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy
79565011|NCT01718639|Other|Placebo|
79565012|NCT01718652|Drug|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
79860505|NCT03799003|Drug|ASP1951|Intravenously (IV)
79860506|NCT03799003|Drug|pembrolizumab|Intravenously (IV)
79860507|NCT03796559|Device|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
79860508|NCT03786016|Behavioral|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
79860509|NCT03778229|Drug|osimertinib|osimertinib (80 mg oral OD).
79860510|NCT03778229|Drug|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
79860511|NCT03778229|Drug|placebo|placebo to osimertinib (oral OD)
79860512|NCT03773159|Biological|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
79860513|NCT03768349|Drug|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
79860514|NCT03768349|Drug|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
80022075|NCT03095326|Biological|PPV Vaccine|Pneumococcal polysaccharide vaccine
80031747|NCT04880746|Drug|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
79565013|NCT01718652|Drug|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
79860515|NCT03768063|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
79860516|NCT03768063|Drug|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
79860517|NCT03768063|Drug|Alectinib|Alectinib will be administered as directed per the parent study.
79860518|NCT03768063|Drug|Cobimetinib|Cobimetinib will be administered as directed per the parent study.
79860519|NCT03768063|Drug|Vemurafenib|Vemurafenib will be administered as directed per the parent study.
79860520|NCT03768063|Drug|FAP IL2V|FAP IL2V will be administered as directed per the parent study.
79860521|NCT03768063|Drug|Venetoclax|Venetoclax will be administered as directed per the parent study.
79860522|NCT03768063|Drug|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
79860523|NCT03768063|Drug|Pembrolizumab|Pembrolizumab will be administered as directed per the parent study.
79860524|NCT03768063|Drug|Sunitinib|Sunitinib will be administered as directed per the parent study.
79860525|NCT03768063|Drug|Niraparib|Niraparib will be administered as directed per the parent study.
79860526|NCT03768063|Drug|Cabozantinib|Cabozantinib will be administered as directed per the parent study.
79860527|NCT03768063|Drug|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
80022076|NCT02780856|Device|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black & white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
79399737|NCT05737914|Procedure|ThoracicT3 radiofrequency ablation|radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
79399738|NCT00714753|Radiation|brachytherapy|
79565014|NCT01718678|Drug|Melatonin|it is kind of drug
79565015|NCT01718678|Drug|Placebo|It is Placebo
79565016|NCT01718704|Device|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
79565017|NCT01718717|Other|Thoracic Epidural Analgesia (TEA)|
79860528|NCT03768063|Drug|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
79860529|NCT03768063|Drug|Emactuzumab|Emactuzumab will be administered as directed per the parent study.
79860530|NCT03768063|Drug|Rucaparib|Rucaparib will be administered as directed per the parent study.
79860531|NCT03761173|Device|FlowTriever System|Thrombectomy
79860532|NCT03761173|Drug|Anticoagulation Agents|Anticoagulation medication
79860533|NCT03746964|Procedure|Cardiac MRI|Preoperative cardiac MRI
79860534|NCT03746964|Other|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
80022077|NCT03497624|Other|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
80022078|NCT03095092|Drug|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
80022079|NCT02318810|Drug|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
80022080|NCT02318810|Drug|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
80022081|NCT02318810|Drug|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
80022082|NCT02318810|Drug|Placebo|Patients receive saline
79399739|NCT00714753|Radiation|hypofractionated radiation therapy|
79565018|NCT01718717|Other|TEA followed by Intravenous morphine|
79565019|NCT01718730|Device|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
79565020|NCT01718730|Device|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
79565021|NCT01718756|Drug|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
79860535|NCT03743610|Other|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
79860536|NCT03743610|Other|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
79860537|NCT03741673|Other|Quality-of-Life Assessment|Ancillary studies
79860538|NCT03741673|Other|Questionnaire Administration|Ancillary studies
79860539|NCT03741673|Radiation|Stereotactic Radiosurgery|Undergo SRS
79860540|NCT03740542|Procedure|Esophagectomy|Surgical removal of part of esophagus
79860541|NCT03740542|Procedure|Pyloroplasty|pyloric drainage procedure
79860542|NCT03740256|Biological|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
79860543|NCT03735667|Device|ACURATE neo2™ Transfemoral TAVR System|ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
79860544|NCT03735667|Device|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
79860545|NCT03735667|Device|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
79860546|NCT03735667|Device|ACURATE Prime™ Transfemoral TAVR System XL|ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
79860547|NCT03732521|Other|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
80022083|NCT03766477|Diagnostic Test|Pittsburgh Sleep Quality Index (IQSP) and Johansson|All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
79860548|NCT03725592|Other|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
79860549|NCT03725592|Behavioral|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
79265291|NCT05681078|Behavioral|A Matter of Balance: Managing Concerns about Falls|A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
79399740|NCT00714753|Radiation|image-guided radiation therapy|
79399741|NCT00714753|Radiation|intensity-modulated radiation therapy|
79565022|NCT01718756|Drug|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
79860550|NCT03711448|Drug|prednisone treatment|tapering prednisone regimen
79399742|NCT04449042|Procedure|airway management during sedation or general anesthesia|airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
79860551|NCT03711448|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
79860552|NCT03711448|Other|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
79860553|NCT03711448|Biological|Blood samples|Additional blood samples for immunomonitoring
80022084|NCT03766477|Diagnostic Test|Smartphone APP|All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
79565023|NCT01718756|Drug|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
80022085|NCT03766477|Diagnostic Test|Polysomnography|All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
80031748|NCT03050086|Drug|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
79565024|NCT01718769|Other|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
79565025|NCT01718782|Device|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
79565026|NCT01718782|Device|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
79565027|NCT01718795|Device|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
79860554|NCT03709680|Drug|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
79565028|NCT01718808|Drug|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
79565029|NCT01718808|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
79565030|NCT01718834|Biological|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
79860555|NCT03709680|Drug|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
79860556|NCT03709680|Drug|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
79860557|NCT03709680|Drug|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
79860558|NCT03709680|Drug|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
80031749|NCT03050086|Drug|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
79565031|NCT01718834|Biological|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
79565032|NCT01718847|Drug|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
79565033|NCT01718860|Procedure|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
79860559|NCT03708159|Device|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
79860560|NCT03708159|Other|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
79860561|NCT03705559|Drug|Vaporized Marijuana|Active Marijuana or Placebo, administered through vaporizer
79565034|NCT01718886|Device|Obalon Gastric Balloon|
79565035|NCT01718899|Biological|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
79860562|NCT03705559|Drug|Opioid Agonist|Active Opioid Agonist or Placebo, administered intranasally
79860563|NCT03697408|Drug|Itacitinib|A JAK 1 selective small molecule inhibitor
79565036|NCT01718912|Drug|metronidazole-nystatin oral rinse|
79860564|NCT03697408|Drug|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
79860565|NCT03685305|Behavioral|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
79860566|NCT03685305|Behavioral|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
79860567|NCT03685110|Device|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
79860568|NCT03684980|Drug|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2 (Cohort E) will receive standard of care
79860569|NCT03684980|Drug|Rituximab|Patients will be treated with rituximab 500 mg/m^2.
79860570|NCT03684980|Drug|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
79860571|NCT03684980|Drug|Glucarpidase|Glucarpidase 2000 units. Arm E 1000 units.
79303970|NCT05419557|Behavioral|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
79565037|NCT01718951|Drug|golimumab|golimumab
79565038|NCT01718951|Drug|Pamidronate|pamidronate
79565039|NCT01718964|Drug|Cortisol 20 mg|
79860572|NCT03677986|Behavioral|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
79565040|NCT01718964|Drug|Mannitol|Mannitol used as placebo
80031750|NCT03050086|Drug|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
79565041|NCT01718977|Other|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
79565042|NCT01718977|Other|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
79565043|NCT01719029|Other|Low-Carbohydrate/Higher Fat Diet|
79565044|NCT01719029|Other|High Carbohydrate/Low fat diet|
79565045|NCT01719042|Drug|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
79581322|NCT01935219|Behavioral|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
79565046|NCT01719042|Dietary Supplement|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
80022086|NCT03098056|Other|PROG2|"Nutritional Supplements to be administered:~Protein Shakes: one shake po twice daily~Phytosterol supplement: one capsule po twice daily~Cinnamon: one tablet twice daily~Fiber supplement; one shake twice daily~Antioxidant supplement: 2 capsules daily with dinner~Fish Oil supplement: 1 capsule twice daily with food~Probiotic supplement: 1 capsule twice daily with food"
79565047|NCT01719081|Procedure|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
79565048|NCT01719107|Dietary Supplement|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
79565049|NCT01719107|Dietary Supplement|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
79565050|NCT01719120|Behavioral|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
79565051|NCT01719133|Drug|placebo|saline solution
79565052|NCT01719133|Drug|Histamine|positive control
79726212|NCT01219985|Other|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
79726213|NCT04318847|Drug|Ondansetron 4 MG|Administration of ondansetron 4 mg or 8 mg according to weight
79726214|NCT02721823|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
79860573|NCT03661255|Behavioral|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
80022087|NCT03544788|Device|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
80022088|NCT03500120|Diagnostic Test|Seated saline infusion test|"Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge."
80022089|NCT05054764|Device|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
80022090|NCT02141958|Drug|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
80022091|NCT02141958|Drug|Placebo|A matching placebo will be used to keep the study double-blind.
79565053|NCT01719133|Drug|AllerT1|synthetic peptide T1
79726215|NCT02721823|Behavioral|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
79726216|NCT02691221|Behavioral|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
79726217|NCT02721745|Behavioral|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
79565054|NCT01719133|Drug|AllerT2|synthetic peptide T2
79565055|NCT01719133|Drug|AllerT3|synthetic peptide T3
79565056|NCT01719133|Drug|AllerT4|synthetic peptide T4
79565057|NCT01719133|Drug|AllerT5|synthetic peptide T5
79565058|NCT01719133|Drug|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
79565059|NCT01719133|Drug|mix of AllerT4-T5|mix T4-T5
79565060|NCT01719159|Drug|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
79565061|NCT01719185|Drug|Phentermine and B12|
79565062|NCT01719185|Drug|Phentermine|
79565063|NCT01719250|Drug|Buparlisib|Given PO
79565064|NCT01719250|Other|Laboratory Biomarker Analysis|Correlative studies
79565065|NCT01719250|Other|Questionnaire Administration|Ancillary studies
80022092|NCT03500042|Device|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
79265292|NCT05674994|Drug|Methylprednisone/Prednisone|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~From day 4 to Day 30: Oral Prednisone slow tappering~1 mg/kg/d for 7 days~0.5 mg/kg/d for 7 days~0.25 mg/kg/d for 7 days,~10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
79565066|NCT01719263|Device|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
79726218|NCT02721745|Device|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
79726219|NCT02721745|Device|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
80022093|NCT02142036|Drug|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
79726220|NCT02721511|Drug|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
79726221|NCT02708329|Procedure|T-provisional stenting|Standard endovascular T-provisional stenting technique
79726222|NCT02708329|Procedure|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
79726223|NCT02708329|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
80022094|NCT05501743|Drug|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
80022095|NCT05501743|Procedure|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
80022096|NCT05053984|Procedure|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
80022097|NCT03494582|Procedure|Sacral Hysteropexy|Abdominal approach for uterine suspension
80022098|NCT03494582|Procedure|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
80022099|NCT05053594|Drug|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
80022100|NCT05053594|Drug|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
80022101|NCT05053594|Drug|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
80022102|NCT05053594|Other|Placebo|Once the third response to TOF is obtained, saline will be administered
80022103|NCT04462016|Other|Calamansi|250 ml of a commercially sourced calamansi drink
79399743|NCT02999997|Behavioral|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
79565067|NCT01719263|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
79565068|NCT01719276|Other|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
80022104|NCT04462016|Other|Glucose|75 g of glucose dissolved in 250 ml of drinking water
80022105|NCT02324426|Drug|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
80022106|NCT03097510|Behavioral|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
79860574|NCT03655132|Behavioral|Veteran Acceptance and Commitment Therapy for Chronic Pain|Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
80022107|NCT02142114|Device|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
80022108|NCT05053516|Other|A standardized training program for social workers|A standardized training program for social workers who work with drug addicts / drug users based on industry needs
79565069|NCT01719276|Other|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
80022109|NCT02318888|Procedure|Surgery|
80022110|NCT02318888|Drug|Icodextrin|
80022111|NCT02142192|Drug|natalizumab|Administered as specified in the treatment arm
80022112|NCT05053906|Device|Endoscope|effect of FESS on eustachian tube function
80022113|NCT02145702|Other|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
80022114|NCT02145702|Procedure|Standard Care Dialysis|12 weeks of standard of care.
79399744|NCT03222648|Other|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
79399745|NCT03222648|Other|Usual Care|Continuation of usual care
79565070|NCT01719289|Behavioral|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
79565071|NCT01719302|Drug|Gemcitabine|1500 mg/m^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
79565072|NCT01719302|Drug|Docetaxel|50 mg/m^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
79726224|NCT02708407|Procedure|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
79726225|NCT02712307|Drug|Phenoxymethylpenicillin|
79726226|NCT02708251|Drug|glyceryl trinitrate cream|
79726227|NCT02708251|Drug|lidocaine cream|
79726228|NCT02708251|Drug|placebo cream|
79860575|NCT03651830|Device|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
79860576|NCT03651830|Device|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
79860577|NCT03646123|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion
80022115|NCT05033860|Other|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
80022116|NCT02145780|Dietary Supplement|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
80022117|NCT02145780|Dietary Supplement|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
80022118|NCT02749045|Radiation|SPECT imaging|myocardial perfusion imaging
79565073|NCT01719302|Drug|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
79581323|NCT01935219|Behavioral|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
79726229|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
79726230|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
79726231|NCT00611611|Biological|fluzone|once
79726232|NCT00611611|Biological|pneumovax|once
80022119|NCT02321540|Drug|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
80022120|NCT03544320|Device|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
80022121|NCT03544320|Device|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
80022122|NCT02321618|Behavioral|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
80022123|NCT02321618|Behavioral|BP educational materials|Exposure to hypertension educational materials
80022124|NCT02324582|Drug|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
80022125|NCT01255891|Radiation|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
80022126|NCT02321696|Device|Acupuncture|
79265293|NCT05674994|Other|Placebo|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Placebo Group:~Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes.~For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL."
79565074|NCT01719315|Other|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
79399746|NCT00707343|Radiation|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-[F-18]fluorothymidine, [F-18]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
79399747|NCT04373616|Biological|ACI-24|injections
79860578|NCT03646123|Drug|doxorubicin|25 mg/m^2 by IV infusion
79399748|NCT04373616|Biological|Placebo|injections
79399749|NCT04341090|Drug|Apatinib Mesylate|Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
80022127|NCT02321696|Other|Physiotherapy and eccentric exercise|
80022128|NCT02321696|Other|Watchful waiting and eccentric exercise|
80022129|NCT02321696|Other|eccentric exercise|
80022130|NCT02777190|Drug|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
80022131|NCT03494426|Procedure|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
79399750|NCT04273854|Device|OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
79399751|NCT02999607|Other|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
79399752|NCT04413396|Procedure|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
79860579|NCT03646123|Drug|vinblastine|6 mg/m^2 by IV infusion
79860580|NCT03646123|Drug|dacarbazine|375 mg/m^2 by IV infusion
80022132|NCT03494426|Drug|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
80022133|NCT03494270|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
80022134|NCT03494270|Drug|Monorova|Rosuvastatin 20mg
80022135|NCT02145858|Device|Blood drainage post cardiac surgery using PleuraFlow System|
80022136|NCT03497468|Other|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
80022137|NCT03497468|Other|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
80022138|NCT03497312|Procedure|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
80022139|NCT02319122|Other|High Intensity Interval Training|See arm description
80022140|NCT02319122|Other|Progressive Resistance Training|See arm description
80022141|NCT02432209|Other|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
80022142|NCT02432209|Drug|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
79265294|NCT05669014|Drug|Daxdilimab|Participants will be administered daxdilimab by subcutaneous (SC) injection
79860581|NCT03646123|Drug|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
80022143|NCT02432209|Other|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
80022144|NCT00108732|Drug|Bicalutamide|Given orally
80022145|NCT00108732|Drug|Goserelin Acetate|Given SC
79265295|NCT05669014|Drug|Placebo|Participants will be administered identically matching placebo by SC injection over a total of 24 weeks, then participants will be given active treatment for the remainder of the study.
79265296|NCT05666700|Biological|Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent|Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis
79265297|NCT05666687|Drug|MIJ821|MIJ821 will be administered as an i.v. infusion
79265298|NCT05654870|Drug|Valbenazine|Oral treatment
79265299|NCT05654870|Drug|Placebo|Placebo matching valbenazine
79565075|NCT01719328|Behavioral|Vinyasa yoga|
79265304|NCT05649137|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
79265305|NCT05649137|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
79565076|NCT01719354|Other|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
79565077|NCT01719354|Other|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
79726233|NCT04188925|Device|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
79726234|NCT04188925|Device|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
79726235|NCT03906643|Drug|HS-201|HS-201 will be administered intravenously as a single dose
80022146|NCT00108732|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
80022147|NCT00108732|Biological|Recombinant Vaccinia-TRICOM Vaccine|Given SC
80022148|NCT00108732|Biological|Sargramostim|Given SC
80022149|NCT02319200|Drug|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
79265306|NCT05649137|Drug|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
79265307|NCT05635383|Other|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
79265308|NCT05626244|Behavioral|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
79565078|NCT01719406|Behavioral|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
79565079|NCT01719419|Drug|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
79565080|NCT01719419|Drug|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
79726236|NCT01218659|Drug|migalastat hydrochloride|150-mg capsule administered orally QOD
79726237|NCT01218659|Biological|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
79860582|NCT03646123|Drug|nivolumab|240 mg by IV infusion
79860583|NCT03635073|Drug|Soticlestat|Soticlestat tablets or mini-tablets.
79860584|NCT03622775|Biological|Daratumumab|Given IV
79860585|NCT03598309|Drug|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
79860586|NCT03598309|Drug|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
80022150|NCT02319200|Drug|placebo tablet|4 tablets per day for 36 months
80022151|NCT02145936|Other|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
80022152|NCT02319278|Drug|Ferumoxytol|Infusion following between paired MRI scans
79860587|NCT03598309|Other|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
79860588|NCT03597503|Drug|SPN-810|Flexible dose
79726238|NCT02712229|Behavioral|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
80022153|NCT02324738|Drug|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
80022154|NCT02324738|Other|Wash-out period|
80022155|NCT02324738|Drug|Mefloquine|2 tablets of Mefloquine single dose
79265309|NCT05625971|Other|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
79565081|NCT01719510|Other|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~one swab for GBS detection by real-time PCR~the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding."
79565082|NCT01719523|Drug|EPI-743|
79565083|NCT01719536|Drug|Icotinib|Icotinib: 125 mg is administered orally three times per day.
79565084|NCT01719536|Drug|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
80022156|NCT03497234|Diagnostic Test|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
79565085|NCT01719549|Drug|Dovitinib|"Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~Study drug: TKI258 capsule~Dose: 500mg p.o. qd~Every 3 weeks"
80022157|NCT02146014|Other|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off."
79265310|NCT05621538|Behavioral|Realtime fMRI Neurofeedback - Active|fMRI aided reinforcement of craving regulation
79265311|NCT05621538|Device|TMS - Active|rTMS to right dorsolateral prefrontal cortex to reduce craving
79265312|NCT05621538|Behavioral|Realtime fMRI Neurofeedback - Yoked Sham|Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation
79265313|NCT05621538|Device|TMS - Sham|rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex
79565086|NCT01719575|Drug|Motilitone|
80022158|NCT02146014|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
80022159|NCT02321852|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
79265314|NCT05620290|Drug|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
79726239|NCT05172037|Biological|Novaferon|a novel recombinant antiviral protein drug
79726240|NCT05172037|Biological|Placebo|Saline
80022160|NCT02321852|Drug|Placebo|Once daily oral administration of placebo mannitol for 7 days
79265315|NCT05620290|Device|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
79265316|NCT05616689|Other|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
79265317|NCT05611502|Device|TMS|TMS will be administered in a pattern that is either excitatory or inhibitory.
79265318|NCT05611268|Drug|Pentoxifylline|Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
79265319|NCT05607719|Drug|Bevespi|Two puffs twice a day
79265320|NCT05607719|Drug|Bretzri|Two puffs twice a day
79265321|NCT05604482|Diagnostic Test|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
79265322|NCT05603312|Genetic|AAV-GAD Dose 1|Bilateral infusion of AAV-GAD Dose 1
79265323|NCT05603312|Genetic|AAV-GAD Dose 2|Bilateral infusion of AAV-GAD Dose 2
79265324|NCT05603312|Procedure|Sham Surgery|Sham infusion
79265325|NCT05593458|Drug|Oxaliplatin by arterial infusion plus S-1|3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
79565087|NCT01719575|Drug|Placebo|
79565088|NCT01719588|Drug|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
79860589|NCT03597503|Drug|Placebo|Placebo
79860590|NCT03593590|Drug|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
79860591|NCT03589703|Other|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
79726241|NCT02708017|Procedure|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
80022161|NCT02146092|Procedure|Incentive spirometry|
80022162|NCT02146092|Other|Physiotherapy|Standard of care exercise training and supervision
79265326|NCT05593458|Drug|SOX neoadjuvant|3 cycles of SOX neoadjuvant chemotherapy every 21 days.
79265327|NCT05593458|Drug|Sintilimab neoadjuvant|3 cycles of neoadjuvant immunotherapy every 21 days.
79265328|NCT05593458|Procedure|gastrectomy plus D2 lymph node dissection|All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
79265329|NCT05593458|Drug|SOX adjuvant, Sequential S-1|"3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation."
79265330|NCT05593458|Drug|Sintilimab adjuvant|3 cycles of adjuvant immunotherapy every 21 days.
79399753|NCT04097964|Behavioral|brief intervention|1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.
79565089|NCT01719601|Drug|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
79565090|NCT01719614|Drug|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
79565091|NCT01719614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
79303971|NCT03065673|Procedure|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
79565092|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 300mg
79565093|NCT01719627|Drug|TVD 300/200 QD|TVD 300/200 QD during 7 days
79399754|NCT04097964|Behavioral|treatment as usual|standard care conducted by primary care providers during clinic visits
79399755|NCT04089150|Radiation|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
79399756|NCT04089150|Drug|mFOLFIRINOX|"Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~14-day cycle, 6 cycles"
79565094|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 600mg
79565095|NCT01719679|Behavioral|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
79399757|NCT04089150|Drug|Gemcitabine + Nab-paclitaxel|"Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~28-day cycle, 3 cycles"
80022163|NCT03499886|Drug|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
80022164|NCT03499886|Drug|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
80022165|NCT02319356|Dietary Supplement|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
80022166|NCT02319356|Dietary Supplement|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
79565096|NCT01719692|Drug|Rituximab|
79565097|NCT01719705|Drug|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
79565098|NCT01719705|Drug|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
79565099|NCT01719705|Drug|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
79565100|NCT01719731|Behavioral|Education|This group will receive the psychoeducation
79565101|NCT01719731|Behavioral|Non-Education|This group will not receive the psychoeducation
79565102|NCT01719770|Drug|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
79565103|NCT01719770|Other|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
79565104|NCT01719796|Procedure|Regional analgesia infusion|
79565105|NCT01719822|Device|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
79726242|NCT02708017|Procedure|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
79860592|NCT03589703|Other|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
79265331|NCT05593302|Behavioral|Trauma-Focused Art Therapy (TFAT)|"Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session)."
79399758|NCT04089150|Drug|Gemcitabine + Capecitabine|"Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~28-day cycle, 3 cycles"
79399759|NCT04089150|Procedure|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
79399760|NCT02076919|Drug|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
79399761|NCT02076919|Drug|LHA510 Vehicle|Inactive ingredients used for masking purposes
79399762|NCT01678560|Device|Monitoring every 3 months by face-to-face visits|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
79726243|NCT00612625|Drug|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
79726244|NCT00612625|Drug|Saline|continuous infusion of saline
79726245|NCT02712073|Other|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
79726246|NCT00612001|Biological|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
79726247|NCT02711761|Device|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
79726248|NCT02711917|Drug|MAC 0.5|0.5 MAC Sevoflurane
79726249|NCT02711917|Drug|MAC 0.75|0.75 MAC Sevoflurane
79860593|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
80022167|NCT02324894|Procedure|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
79399763|NCT01678560|Device|Frequent remote monitoring|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
79399764|NCT02076997|Drug|Methotrexate|"Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
79399765|NCT03980574|Dietary Supplement|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
79399766|NCT05365165|Drug|Sevoflurane|Sevoflurane will be applied during aortic cross- clamping in cardiac surgery
79399767|NCT03925350|Drug|Niraparib|300 mg PO daily
79399768|NCT04890912|Radiation|Conventional Fractionation|Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
79399769|NCT04890912|Radiation|Hypofractionation|Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
79399770|NCT00707967|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
79399771|NCT00707967|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
79726250|NCT02711917|Drug|MAC 1.0|1.0 MAC Sevoflurane
79726251|NCT02711917|Drug|Propofol|Propofol consumption
79726252|NCT02711917|Drug|Etomidate|Etomidate consumption
79860594|NCT03589547|Drug|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
79860595|NCT03589547|Radiation|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~*3 fractions are allowed for centrally located tumors"
79860596|NCT03568630|Diagnostic Test|Mixed Meal Tolerance Test|The goal of the test is to determine hormone secretion from the pancreas and small intestine in response to the mixed meal.
79726253|NCT02711917|Drug|Rocuronium|Consumption of Rocuronium
79726254|NCT02707783|Device|Bioresorbable vascular scaffold (BVS) implantation|
79726255|NCT02711449|Drug|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
79265332|NCT05587517|Behavioral|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
79860597|NCT03568630|Diagnostic Test|Hemoglobin A1c|This test provides the average level of blood glucose over the last 3 months.
79860598|NCT03568630|Diagnostic Test|Other exploratory blood biomarkers|Other exploratory blood biomarkers including cell free DNA and other markers in development
79860599|NCT03564873|Drug|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
79860600|NCT03564873|Drug|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
79726256|NCT02711449|Drug|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
79726257|NCT04419103|Other|no intervention|Natural exposure of iodine.
79726258|NCT02707705|Device|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
79726259|NCT02707705|Device|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
79726260|NCT02707705|Procedure|Disinfection|The ear is disinfected by applying Chlorhexidine®.
79860601|NCT03564873|Drug|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
79860602|NCT03564873|Drug|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
79265333|NCT05587517|Other|Supportive Conversation|The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
79265334|NCT05580692|Procedure|Biospecimen Collection|Biospecimen Sample Collection
79265335|NCT05577754|Drug|Alpelisib (BYL719)|Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
79399772|NCT00707967|Biological|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
79860603|NCT03564288|Drug|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
79860604|NCT03564067|Device|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
79860605|NCT03564067|Behavioral|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
79265336|NCT05577754|Drug|Matching placebo|During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
79265337|NCT05577754|Procedure|Optional lumbar puncture + blood sample|Between 6 and 24 months of treatment with Alpelisib
79565106|NCT01719835|Drug|Cyclophosphamide|750mg/m2 IV every 21 days
79565107|NCT01719835|Drug|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
79565108|NCT01719835|Drug|Doxorubicin|50mg/m2 IV every 21 days
79565109|NCT01719835|Drug|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
79565110|NCT01719835|Drug|Prednisolone|100mg PO Days 1-5 every 21 days
79565111|NCT01719835|Drug|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
79265338|NCT05567562|Combination Product|dual anti-platelet therapy|dual anti-platelet therapy
79265339|NCT05567562|Drug|Placebo|Placebo
79565112|NCT01719835|Drug|Cisplatin|100mg/m2 IV Day 15 every 28 days
79565113|NCT01719848|Other|Measurements of parameters related with physical examinations for difficult airway prediction|
79565114|NCT01719874|Biological|TCN-032|
79565115|NCT01719874|Biological|Placebo (saline)|
79565116|NCT01719913|Other|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
79726261|NCT00612079|Drug|Sertindole|oral 3 x 4mg
79726262|NCT00612079|Drug|Placebo|3 x 4mg Placebo
79726263|NCT00940498|Drug|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
79265340|NCT05566431|Other|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
79726264|NCT03820531|Diagnostic Test|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
79726265|NCT03820531|Diagnostic Test|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA > 192 ng/ml and lipase > 200 U/l = mucinous cyst"
79265341|NCT05566431|Other|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
79860606|NCT03554317|Drug|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
80022168|NCT02142582|Dietary Supplement|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
79265342|NCT05565339|Device|PMEIs|"To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated."
79265343|NCT05560516|Drug|Qutenza|Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
79265344|NCT05560516|Drug|Duloxetine|Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
79265345|NCT05554419|Drug|Azacitidine|Given IV or SC
79726266|NCT03820531|Diagnostic Test|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
79726267|NCT03820531|Diagnostic Test|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
79726268|NCT02711527|Other|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
79860607|NCT03554317|Drug|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
79860608|NCT03550391|Drug|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
79860609|NCT03550391|Radiation|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
79860610|NCT03550391|Procedure|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
79565117|NCT01719913|Other|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
79860611|NCT03548285|Radiation|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
80022169|NCT02142582|Dietary Supplement|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
80022170|NCT02319434|Device|Ostom-i Alert Sensor|Sensor on ostomy bag.
80022171|NCT02142660|Procedure|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
80022172|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
80022173|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp).
80022174|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
79565118|NCT01719926|Drug|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
80022175|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 1*10^11 viral particles (vp).
80022176|NCT02325050|Other|Placebo|One 0.5 mL IM injection of 0.9% saline.
79565119|NCT01719952|Drug|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
79565120|NCT01719952|Drug|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
79565121|NCT01719965|Other|Interviews and Focus Group Discussions|
79565122|NCT01719978|Drug|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
79726269|NCT02711527|Other|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
79860612|NCT03537963|Other|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
79726270|NCT05115721|Other|no intervention|It's only observational study. No interventions.
79860613|NCT03537963|Other|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
79860614|NCT03537963|Other|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
79860615|NCT03537963|Other|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
79860616|NCT03537963|Other|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
79399773|NCT04875780|Behavioral|Digital diabetes prevention app intervention|"16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
79860617|NCT03537963|Other|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
79860618|NCT03512132|Biological|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
79860619|NCT03512132|Biological|Urine sample|Urine sample on an empty stomach
79860620|NCT03511196|Drug|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
79860621|NCT03511196|Drug|Abiraterone|Prednisone 5 mg once a day with food.
79399774|NCT04875780|Behavioral|Digital weight loss tracking app intervention|"All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
79399775|NCT04875780|Behavioral|Wait-list control (usual care)|Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
79399776|NCT02994381|Drug|RPC1063|
79399777|NCT04874766|Other|Wingate exercise test and on-ice testing while wearing a face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
79399778|NCT04874766|Other|Wingate exercise test and on-ice testing while wearing a sham face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
79565123|NCT01719978|Procedure|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
79565124|NCT01719978|Drug|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
79565125|NCT01719978|Drug|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
79565126|NCT01719991|Other|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
79726271|NCT02850718|Drug|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
79726272|NCT02850718|Drug|Oral Sildenafil|50 mg oral sildenafil (Viagra)
79726273|NCT02707393|Drug|Fludarabine|infusion
79860622|NCT03511196|Drug|Prednisone|Abiraterone 1000 mg daily with empty stomach.
79860623|NCT03498001|Drug|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
79265346|NCT05554419|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
79265347|NCT05554419|Drug|Cytarabine|Given IV
79265348|NCT05554419|Procedure|Echocardiography|Undergo ECHO
79265349|NCT05554419|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79265350|NCT05554419|Procedure|Multigated Acquisition Scan|Undergo MUGA
79265351|NCT05554419|Drug|Venetoclax|Given PO
79265352|NCT05548634|Drug|TAVO412|Biologic
79265353|NCT05545956|Procedure|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
79860624|NCT03498001|Procedure|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides ([TG] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
79860625|NCT03498001|Other|Follow up by phone|at 2 and 4 mois
79860626|NCT03477396|Drug|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
79860627|NCT03477396|Other|Laboratory Biomarker Analysis|Correlative studies
79860628|NCT03477396|Other|Pharmacokinetic Study|Correlative studies
79860629|NCT03477396|Other|Questionnaire Administration|Ancillary studies
79726274|NCT02707393|Drug|Thiotepa|infusion
79860630|NCT03477396|Drug|Ribociclib|Given PO
79860631|NCT03476954|Other|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
79726275|NCT02707393|Drug|Melphalan|infusion
79726276|NCT02707393|Drug|ATG|infusion
79265354|NCT05545956|Device|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
79265355|NCT05545930|Procedure|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
79726277|NCT02707393|Drug|Cyclosporine A|infusion, orally if possible
79726278|NCT02707393|Drug|Mycophenolate mofetil|infusion
79860632|NCT03475888|Device|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
79860633|NCT03475186|Drug|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
79265356|NCT05545930|Device|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
79265357|NCT05542485|Diagnostic Test|ctDNA liquid biopsy - Roche Avenio Assay|The intervention will involve plasma ctDNA testing for patients with a radiological suspicion for newly diagnosed advanced NSCLC
79565127|NCT01720199|Other|Diario della Salute (DDS)|"DDS is composed by~tools for children and their parents on health and social and emotional well-being issues:~a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
79565128|NCT01720459|Dietary Supplement|Micronized trans-resveratrol|
79565129|NCT01720459|Dietary Supplement|Placebo|
79265358|NCT05542264|Drug|SEP-363856|SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
79265359|NCT05542264|Drug|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
79399779|NCT00716079|Other|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
79565130|NCT01720537|Biological|PF-05335810 Dose A|Single SC Injection
79565131|NCT01720537|Biological|PF-05335810 Dose B|Single Subcutaneous Injection(s)
79565132|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
79565133|NCT01720537|Biological|PF-05335810 Dose B|Single Intravenous Infusion
79565134|NCT01720537|Biological|Placebo|Single Intravenous Infusion
79565135|NCT01720537|Biological|PF-04950615 Dose A|Single Subcutaneous Injection(s)
79565136|NCT01720537|Biological|PF-04950615 Dose A|Single Intravenous Infusion
79726279|NCT02707393|Biological|bone marrow or peripheral blood stem cells|infusion
79726280|NCT02711605|Device|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
79726281|NCT00940342|Drug|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
79726282|NCT00940342|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly for four weeks
79726283|NCT02707549|Drug|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
79726284|NCT02707549|Drug|0.9% sodium chloride|
79726285|NCT00936910|Drug|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome [2 mg/ml]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
79726286|NCT02707627|Device|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
79726287|NCT02707315|Drug|Gemcitabine|
79726288|NCT02707315|Radiation|Stereotactic Radiosurgery|
79726289|NCT00604942|Procedure|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
79726290|NCT00604942|Procedure|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
79726291|NCT00604942|Drug|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
79860634|NCT03459287|Device|INTERCEPT|Pathogen reduced RBCs
79860635|NCT03459287|Device|Control|Conventional RBCs
80022177|NCT02687646|Drug|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
80022178|NCT02319512|Other|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
79860636|NCT03458611|Behavioral|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent & Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
79860637|NCT03458611|Behavioral|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
79860638|NCT03458546|Drug|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
79860639|NCT03442231|Device|Journey UNI Unicompartmental Knee System|Lateral or medial knee compartment replacement
79565137|NCT01720537|Biological|PF-05335810 Dose C|Single Subcutaneous Injection(s)
79565138|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
79860640|NCT03439891|Biological|Nivolumab|Given IV
79860641|NCT03439891|Drug|Sorafenib|Given PO
79860642|NCT03439345|Drug|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
79860643|NCT03439345|Drug|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
79565139|NCT01720537|Biological|PF-05335810 Dose C|Single Intravenous Infusion
79565140|NCT01720537|Biological|Placebo|Single Intravenous Infusion
79565141|NCT01720537|Biological|PF-04950615|Single Subcutaneous Injection(s)
79565142|NCT01720537|Biological|PF-05335810 Dose D|Single Subcutaneous Injection(s)
79265360|NCT05541536|Other|Consultation meeting|Study team member will approach mothers < 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
79399780|NCT04683510|Other|Navigation - Study Specific - Researcher Voice|The intervention is delivered over the telephone
79399781|NCT04683510|Other|Navigation - Study Specific - Cancer Survivor Voice|The intervention is delivered over the telephone
80022179|NCT02319512|Other|Glucose|12ml glucose solution (13,6g) per day
79265361|NCT05541536|Other|Pamphlet|Study team member will distribute pamphlet to beside nurse to give to mother. The pamphlet provides information about Learning Health Care (LHC) and clinical research.
79399782|NCT04683510|Other|Navigation - Research General - Researcher Voice|The intervention is delivered over the telephone
79399783|NCT04683510|Other|Navigation - Research General - Cancer Survivor Voice|The intervention is delivered over the telephone
79565143|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
79565144|NCT01720537|Biological|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
79565145|NCT01720537|Biological|PF-05335810 Dose D|Single Intravenous Infusion
79565146|NCT01720537|Biological|Placebo|Single Intravenous Infusion
79565147|NCT01720719|Drug|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
79565148|NCT01720719|Drug|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
79565149|NCT01721005|Other|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
79565150|NCT01721213|Drug|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
79860644|NCT03424005|Drug|Capecitabine|Capecitabine will be administered 1250 mg/m^2 orally twice daily on Days 1-14, of each 21 day cycle.
79860645|NCT03424005|Drug|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
79860646|NCT03424005|Drug|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
79265362|NCT05541536|Other|Usual Care|Study participants will not receive the general information pamphlet or consultation.
79265363|NCT05500144|Other|Not applicable- no intervention administered|Not applicable- no intervention administered
79399784|NCT04683510|Other|Brochure - Study Specific - Researcher Voice|The invention is mailed to the participant in a brochure.
79399785|NCT04683510|Other|Brochure - Study Specific - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
79399786|NCT04683510|Other|Brochure - Research General - Researcher Voice|The invention is mailed to the participant in a brochure.
79565151|NCT01721551|Other|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
79565152|NCT01721551|Other|Usual Treatment|The CON group received no intervention but the usual treatment
79565153|NCT01721785|Drug|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
80022180|NCT02142816|Device|Doppler|Fluid therapy guided by doppler
80022181|NCT02142816|Other|PVI'|Fluid therapy guided by PVI
79860647|NCT03424005|Drug|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
80022182|NCT02442050|Other|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
80022183|NCT02442050|Other|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
79565154|NCT01721824|Behavioral|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
79565155|NCT01721928|Device|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
79265364|NCT05492578|Drug|Amlitelimab|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
79265365|NCT05492578|Other|Topical corticosteroids|Pharmaceutical form: Topical Route of administration: Topical
79565156|NCT01722214|Biological|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
79565157|NCT01722214|Other|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
79565158|NCT01722344|Behavioral|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
79565159|NCT01722344|Behavioral|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
79565160|NCT01722422|Drug|oxygen and saline|
79565161|NCT01722474|Device|ASI Device|
79565162|NCT01722526|Drug|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
79565163|NCT01722578|Drug|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
79726292|NCT00604942|Drug|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
79726293|NCT02711683|Drug|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
79565164|NCT01722578|Drug|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
79565165|NCT01723007|Other|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
79565166|NCT01723280|Drug|Oxygen|During and 2 hrs after surgery
79726294|NCT02711683|Drug|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
79726295|NCT02854618|Other|additional blood sample|
79726296|NCT04266808|Device|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
79860648|NCT03424005|Drug|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
79860649|NCT03424005|Drug|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m^2 on days 1 and 8 of each 21 day cycle."
79860650|NCT03424005|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
79860651|NCT03424005|Drug|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
79265366|NCT05492578|Other|Topical calcineurin inhibitors|Pharmaceutical form: Topical Route of administration: Topical
79265367|NCT05492578|Other|Oral corticosteroids|Pharmaceutical form: Oral Route of administration: Oral
79265368|NCT05490875|Procedure|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
79265369|NCT05490875|Other|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
79265370|NCT05490875|Other|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
79399787|NCT04683510|Other|Brochure - Research General - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
79726297|NCT04266808|Behavioral|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
79860652|NCT03424005|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m^2, on Days 1, 8, and 15 of each 28-day cycle.
79860653|NCT03424005|Drug|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
79860654|NCT03424005|Drug|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
79860655|NCT03424005|Drug|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
79860656|NCT03424005|Drug|Ribociclib|Ribociclib tablets of 400 mg will be administered by mouth on Days 1-21 of each 28-day cycle.
80022184|NCT03544710|Other|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
80022185|NCT02322008|Biological|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
80022186|NCT02647554|Drug|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
80022187|NCT02647554|Drug|Placebo|matching placebo every 8 hours for 10 days
80022188|NCT02325128|Behavioral|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
80022189|NCT02322086|Drug|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
79565167|NCT01723475|Biological|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
79565168|NCT01723475|Biological|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
79565169|NCT01723852|Dietary Supplement|Vitamin D at 30 ug/day|
79265371|NCT05489445|Device|KODEX - EPD|A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
79565170|NCT01723852|Dietary Supplement|Vitamin D at 10 ug/day|
79565171|NCT01724229|Drug|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
79565172|NCT01724450|Drug|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
79565173|NCT01724450|Drug|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
79565174|NCT01724463|Other|Severe Sepsis Management Bundle|"Management Bundle includes:~Securing Intravenous Access~Obtaining Blood Culture~Antibiotic Administration~Goal Directed Fluid Bolus Therapy~Oxygen Administration~Measuring Serum Lactate Levels"
79726298|NCT05079061|Drug|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
79726299|NCT00605800|Other|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
79860657|NCT03424005|Drug|Inavolisib|Inavolisib tablets will be administered at a dose of 9 mg by mouth on Days 1-28 of each cycle (cycle = 28 days).
79860658|NCT03424005|Drug|Inavolisib (9 mg)|Inavolisib tablets will be administered at a dose of 9 mg by mouth on Days 1-21 of each cycle (cycle = 21 days).
79860659|NCT03424005|Drug|Inavolisib (6 mg)|Inavolisib tablets will be administered at a dose of 6 mg by mouth on Days 1-21 of each cycle (cycle = 21 days).
79860660|NCT03424005|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
79860661|NCT03422822|Drug|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
79860662|NCT03422822|Drug|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
79860663|NCT03422822|Drug|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
79860664|NCT03422822|Drug|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
79860665|NCT03422822|Drug|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
80022190|NCT03499730|Drug|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
80022191|NCT03499652|Diagnostic Test|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
80022192|NCT02325206|Drug|dapagliflozin|one administration in the morning
80022193|NCT02325206|Drug|Placebo|one administration in the morning
79860666|NCT03422822|Drug|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
79565175|NCT01724567|Other|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
79726300|NCT00605800|Other|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
79860667|NCT03414905|Device|Aspira Catheter|"15.5Fr catheter~Standard of care"
79860668|NCT03414905|Procedure|Ultrasound|Standard of care
79860669|NCT03374670|Drug|Zimura|Zimura in combination with Eylea
79860670|NCT03374670|Drug|Eylea|Zimura in combination with Eylea
80022194|NCT03499574|Behavioral|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
80022195|NCT03499574|Behavioral|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
80022196|NCT03499496|Diagnostic Test|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
80022197|NCT02325284|Device|Pressure Algometer Testing|
79565176|NCT01724567|Other|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
79565177|NCT01724684|Other|Telehealth program|
79565178|NCT01724684|Other|Usual care|
80022198|NCT02322398|Drug|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
80022199|NCT02322398|Drug|hMG|150-300 IU/d hMG
79565179|NCT01724723|Drug|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
79565180|NCT01724762|Other|Nursing Orientation|"Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
79565181|NCT01724892|Drug|Dexamethasone|
79565182|NCT01724892|Drug|Loteprednol etabonate|
79565183|NCT01725139|Drug|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
79565184|NCT01725139|Drug|Placebo|Matching placebo will be available
79565185|NCT01725256|Drug|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
79565186|NCT01725269|Drug|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
79565187|NCT01725438|Other|sample blood|
79565188|NCT01725828|Device|Ultrasound|Using the Ultrasound to determine the location of the CTM.
79860671|NCT03364153|Drug|Zimura|Zimura Intravitreal Injection
80022200|NCT02325362|Drug|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
79565189|NCT01725828|Other|External Palpation|Using External Palpation to identify cricothyoid membrane
79565190|NCT01726660|Device|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
79265372|NCT05464615|Drug|Amoxicillin|We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
79565191|NCT01726751|Device|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
79860672|NCT03364153|Other|Sham|Sham Intravitreal Injection
79860673|NCT03360201|Behavioral|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
80022201|NCT02325362|Drug|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
80022202|NCT03499340|Behavioral|text-only PWL|control condition (no image)
80022203|NCT03499340|Behavioral|low arousal graphic PWL|pictorial warning
80022204|NCT03499340|Behavioral|high arousal graphic PWL|pictorial warning
79565192|NCT01726751|Device|Spinal cord nerve stimulation|
79565193|NCT01727245|Other|Obese|gastric bypass
79860674|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
79860675|NCT03351712|Behavioral|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
79860676|NCT03351712|Behavioral|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
79860677|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
79860678|NCT03345095|Drug|Marizomib|Intravenous administration of Marizomib
79860679|NCT03345095|Drug|Temozolomide|Oral Administration of Temozolomide
79860680|NCT03345095|Radiation|radiotherapy|60 Gy in 30 fractions over 6 weeks
79265373|NCT05458401|Drug|Trastuzumab deruxtecan|No drug will be administered during this study.
80022205|NCT03499340|Behavioral|absolute risk|Percentage risk information for smoking-related diseases for smokers
80022206|NCT03499340|Behavioral|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
80022207|NCT02322476|Other|No intervention will be performed|No intervention will be performed
79265374|NCT05457842|Drug|pudexacianinium chloride|Subcutaneous or subareolar (breast cancer) or intradermal or peritumoral (melanoma)
79860681|NCT03344965|Drug|Olaparib|olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
79860682|NCT03324646|Drug|[11C]PS13|A novel PET ligand to selectively image COX-1
79399788|NCT04557696|Other|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
79860683|NCT03320252|Device|Endurant Chimney Graft Technique|Medtronic Endurant II and Endurant IIs Stent Graft Systems and balloon-expandable covered stent graft systems approved for use in the renal arteries. These devices will be utilized in a chimney graft configuration.
79399789|NCT01270191|Drug|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
79860684|NCT03316560|Biological|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
79860685|NCT03315871|Biological|PROSTVAC-V|Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
79860686|NCT03315871|Biological|PROSTVAC-F|Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
80022208|NCT03004664|Behavioral|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
80022209|NCT03004664|Behavioral|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
79265375|NCT05432206|Drug|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
79399790|NCT01270191|Drug|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
79399791|NCT02999919|Procedure|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
79860687|NCT03315871|Drug|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
79860688|NCT03315871|Biological|CV301|Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
79265376|NCT05432206|Drug|Placebo|Hemp virgin seed oil
79265377|NCT05417412|Behavioral|Brief Behavioral Therapy|8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
80022210|NCT02322554|Biological|Cellular and tissue based products|Procedure: Application of device or biological to wounds
80022211|NCT03499262|Behavioral|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
79265378|NCT05404932|Drug|Aliquoted allogeneic donor plasma in patient's conjunctiva|1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
79860689|NCT03310489|Behavioral|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
79265379|NCT05403827|Drug|K-161|K-161 Ophthalmic Solution
79265380|NCT05403827|Drug|Placebo|Vehicle Solution
79265381|NCT05369975|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
79265382|NCT05369975|Other|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
79399792|NCT04526652|Drug|Dexmedetomidine|Evaluating anxiety score in both arms
79399793|NCT04526652|Drug|Placebo|Evaluating anxiety score in both arms
79399794|NCT01270269|Behavioral|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
79565194|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
79565195|NCT01727362|Other|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
79565196|NCT01727362|Other|Usual care|Patients of this group receive usual care only
79565197|NCT01727427|Drug|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
79565198|NCT01727609|Dietary Supplement|Milk feed (breast milk or formula milk)|
79565199|NCT01727661|Behavioral|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
79860690|NCT03310489|Behavioral|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
79726301|NCT02693431|Other|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
79265383|NCT05363891|Drug|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
79399795|NCT01270269|Behavioral|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
79565200|NCT01727661|Behavioral|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
79565201|NCT01727661|Behavioral|quality of life|assessing quality of life using short-forum 36 (questionnaire)
79565202|NCT01727778|Biological|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
79565203|NCT01728025|Drug|Ranolazine|
79565204|NCT01728207|Drug|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
79565205|NCT01728389|Procedure|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
79565206|NCT01728415|Other|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
79565207|NCT01728675|Other|Exercise|Participants will perform two isokinetic eccentric exercise bouts
79565208|NCT01728870|Other|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
79565209|NCT01728870|Other|Exclusive Enteral Nutrition (Modulen)|
79726302|NCT00605020|Drug|insulin detemir|
79860691|NCT03297606|Drug|Olaparib|300mg taken twice daily
79860692|NCT03297606|Drug|Dasatinib|100mg administered orally once daily
79860693|NCT03297606|Drug|Nivolumab plus Ipilimumab|"Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
79860694|NCT03297606|Drug|Axitinib|5mg orally twice daily
79860695|NCT03297606|Drug|Bosutinib|500mg orally once daily
79860696|NCT03297606|Drug|Crizotinib|250mg orally twice daily
79860697|NCT03297606|Drug|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
79860698|NCT03297606|Drug|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
79860699|NCT03297606|Drug|Temsirolimus|25mg infused over a 30-60 minute period once a week
79265384|NCT05363891|Drug|Placebo|Placebo
79265385|NCT05361616|Device|PBM Ortho|The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
79265386|NCT05360537|Drug|Insulin Degludec / Liraglutide Injectable Product|administration of Insulin Degludec/Liraglutide
79265387|NCT05360537|Drug|Insulin Glargine|Administration of glargine insulin
79565210|NCT01729195|Procedure|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
79565211|NCT01729741|Procedure|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
79565212|NCT01729780|Device|EEG-NF|
79726303|NCT00605020|Drug|insulin aspart|
79726304|NCT00605020|Device|biphasic insulin aspart|
79726305|NCT02707081|Drug|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
79860700|NCT03297606|Drug|Erlotinib|150mg orally, once daily
79860701|NCT03297606|Drug|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
79726306|NCT02707081|Drug|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
79726307|NCT02707081|Drug|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
79860702|NCT03297606|Drug|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
79860703|NCT03297606|Drug|Vismodegib|150mg taken orally, once daily
79860704|NCT03297606|Drug|Tucatinib|300mg taken orally, twice daily
79860705|NCT03294759|Other|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
79860706|NCT03294759|Other|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
79265388|NCT05355363|Diagnostic Test|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
79265389|NCT05344521|Device|Integra®|A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
79265390|NCT05344521|Device|Integra®-SC|A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
79265391|NCT05334784|Device|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
79265392|NCT05329883|Procedure|Double-J stent removal|Outpatient ureteral stent removal without antibiotic prophylaxis
79265393|NCT05326191|Diagnostic Test|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
79565213|NCT01729910|Behavioral|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
79565214|NCT01729910|Behavioral|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
79565215|NCT01729936|Behavioral|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
79565216|NCT01730001|Procedure|Early Intubation|
79565217|NCT01730001|Procedure|Late intubation|
79565218|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
79565219|NCT01730014|Drug|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
79565220|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
79565221|NCT01730014|Drug|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
79565222|NCT01730014|Drug|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
79565223|NCT01730014|Drug|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
79726308|NCT02707081|Drug|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
79726309|NCT02711371|Other|fMRI|
79726310|NCT02707237|Other|Verbal counseling|Verbal counseling done by physician
79726311|NCT02707237|Other|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
79726312|NCT00605098|Drug|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
79860711|NCT03283254|Behavioral|Practical Resources for Effective Postpartum Parenting (PREPP)|A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
79860712|NCT03283254|Behavioral|Enhanced Treatment As Usual (ETAU)|"Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate."
80022212|NCT04462094|Drug|Ketamine 0.3 mg/kg at end-of-surgery|Ketamine 0.3 mg/kg at end-of-surgery (intravenously)
79860713|NCT03265574|Drug|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
79860714|NCT03236428|Drug|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
79860715|NCT03235232|Drug|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
79860716|NCT03235232|Drug|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
79860717|NCT03229941|Procedure|Blood Transfusion|Blood Transfusion
79565224|NCT01730066|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
80022213|NCT04462094|Drug|Ketamine 0.3 mg/kg at anesthesia induction|Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
79399796|NCT04500210|Dietary Supplement|Placebo|Placebo in gelatin capsules
79565225|NCT01730157|Biological|ipilimumab|Given IV
79565226|NCT01730157|Radiation|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
79565227|NCT01730157|Other|laboratory biomarker analysis|Correlative studies
79565228|NCT01730183|Other|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
79726313|NCT00605098|Drug|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
79860718|NCT03225664|Biological|Pembrolizumab|Given IV
79860719|NCT03225664|Other|Pharmacokinetic Study|Correlative studies
79860720|NCT03225664|Drug|Trametinib|Given PO
79860721|NCT03223610|Drug|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
79860722|NCT03223610|Drug|Ibrutinib|Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
79860723|NCT03223610|Drug|Prednisone|Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
79860724|NCT03223610|Biological|Obinutuzumab|Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
79860725|NCT03223610|Drug|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
79399797|NCT04500210|Dietary Supplement|Turmeric|Turmeric in gelatin capsules
79565229|NCT01730196|Behavioral|Fit Body and Soul|
79565230|NCT01730196|Behavioral|Wellness Education|
79860726|NCT03213834|Procedure|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
79860727|NCT03213834|Procedure|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
79860728|NCT03213834|Drug|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
79860729|NCT03213834|Drug|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
80022214|NCT02325440|Drug|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
80022215|NCT02325440|Drug|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
80022216|NCT02319746|Behavioral|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
80022217|NCT02319746|Behavioral|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
79565231|NCT01730209|Drug|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
80022218|NCT03499184|Dietary Supplement|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
79565232|NCT01730209|Drug|Placebo|
79565233|NCT01730222|Drug|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
79565234|NCT01730222|Drug|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
79565235|NCT01730222|Drug|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
79565236|NCT01730222|Drug|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
79726314|NCT02711215|Diagnostic Test|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
79726315|NCT02711215|Drug|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
79565237|NCT01730235|Other|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
79726316|NCT02711215|Drug|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
79726317|NCT02711215|Drug|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
79565238|NCT01730248|Drug|INC424|5 mg tablets administered orally twice daily
79565239|NCT01730248|Drug|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
79726318|NCT04254406|Other|Descriptive study|Evaluation of routine treatment
79726319|NCT04310215|Biological|CARTISTEM®|"*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~Procedure: Microfracture~Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
79565240|NCT01730261|Behavioral|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
79860732|NCT03198533|Device|Triathlon PA|Implantation of Knee Prosthesis
79860733|NCT03198533|Device|Triathlon Pressfit|Implantation of Knee Prosthesis
79860734|NCT03179904|Drug|Anastrozole|Given PO
79860735|NCT03179904|Drug|Denifanstat|Given PO
80022219|NCT03499184|Dietary Supplement|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
79860736|NCT03179904|Drug|Exemestane|Given PO
79565241|NCT01730287|Drug|Control|The teeth in this group restored only by filling material,without liner application.
79265394|NCT05319925|Other|Patient reported outcome measure|Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
79860737|NCT03179904|Drug|Fulvestrant|Given IM
79860738|NCT03179904|Procedure|Echocardiography|Undergo ECHO
79860739|NCT03179904|Drug|Letrozole|Given PO
79565242|NCT01730287|Drug|Calcium Hydroxide|Calcium Hydroxide paste applied.
79565243|NCT01730287|Drug|Mineral Trioxide Aggregate(MTA)|MTA applied .
79860740|NCT03179904|Drug|Paclitaxel|Given IV
79860741|NCT03179904|Biological|Trastuzumab|Given IV
79860742|NCT03179904|Procedure|Computed Tomography|Undergo CT
79265395|NCT05309200|Drug|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
79265396|NCT05309200|Drug|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
80022220|NCT03499184|Drug|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
80022221|NCT03499184|Drug|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
79265397|NCT05304715|Drug|Bezlotoxumab|Single intravenous infusion of bezlotoxumab
79265398|NCT05304715|Drug|Normal saline 0.9% or 5% dextrose water|Single intravenous infusion - Placebo arm
79565244|NCT01730287|Drug|CEM cement|CEM cement applied .
79565245|NCT01730326|Drug|Paracetamol|1000 mg
79565246|NCT01730326|Drug|Dexketoprofen|50 mg
79726320|NCT04310215|Procedure|Microfracture|"*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture"
79726321|NCT00603772|Drug|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
79726322|NCT02706613|Behavioral|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
79726323|NCT02706613|Behavioral|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
79726324|NCT00605332|Device|inferior vena cava filter|Crux Biomedical IVC Filter
79726325|NCT02706769|Drug|Placebo|Study medication contains blinded placebo
79726326|NCT02706769|Drug|Paracetamol|Study medication contains blinded paracetamol
79726327|NCT05044117|Drug|Capecitabine|Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
79726328|NCT05031715|Dietary Supplement|Berberine Phytosome|2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
79860743|NCT03179904|Procedure|Magnetic Resonance Imaging|Undergo MRI
79860744|NCT03179904|Procedure|Biospecimen Collection|Undergo blood sample collection
79860745|NCT03179904|Procedure|Biopsy|Undergo biopsy
79860746|NCT03165734|Drug|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
79860747|NCT03165734|Drug|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
79860748|NCT03133780|Drug|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
79860749|NCT03133780|Drug|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
79860750|NCT03115983|Device|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
80022222|NCT03497078|Other|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
80022223|NCT03497000|Procedure|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
80022224|NCT03497000|Procedure|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
80022225|NCT03494114|Drug|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
79860751|NCT03115983|Device|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
79860752|NCT03115983|Procedure|Decompression|Surgical decompression at one or two contiguous levels from L1 to S1.
80022226|NCT02322632|Drug|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
79860753|NCT03115983|Procedure|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
79860754|NCT03113500|Drug|Brentuximab Vedotin|Given IV
80022227|NCT00107952|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
80022228|NCT00107952|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
79265399|NCT05299021|Procedure|Double-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
80022229|NCT03499106|Drug|IW-1973|Oral Tablet
80022230|NCT03499106|Drug|Itraconazole|Oral Capsule
79303972|NCT03065673|Procedure|Placebo gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
79565247|NCT01730352|Drug|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
79565248|NCT01730365|Procedure|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
79565249|NCT01730391|Other|Data collection|Collection of demographic data and vaccination history
79565250|NCT01730391|Other|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
79565251|NCT01730404|Drug|CHF6001 DPI|
79565252|NCT01730404|Drug|Roflumilast|
79565253|NCT01730404|Drug|Placebo|
80022231|NCT02325596|Genetic|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
80022232|NCT02146404|Other|hypoglycemia|Blood glucose levels will be kept at ~3.0 mmol/l
79565254|NCT01730417|Drug|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
79565255|NCT01730456|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
79860755|NCT03113500|Drug|Cyclophosphamide|Given IV
79860756|NCT03113500|Drug|Doxorubicin|Given IV
79860757|NCT03113500|Drug|Doxorubicin Hydrochloride|Given IV
79860758|NCT03113500|Drug|Etoposide|Given IV
79860759|NCT03113500|Drug|Etoposide Phosphate|Given IV
80022233|NCT02146404|Other|euglycemia|Blood glucose levels will be kept at ~5.0 mmol/l
80022234|NCT02319902|Device|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
80022235|NCT02319902|Device|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
80022236|NCT03494036|Dietary Supplement|Synbiotic|capsule
80022237|NCT03494036|Dietary Supplement|Placebo|capsule
80022238|NCT02146638|Drug|Morphine|
80022239|NCT02146638|Drug|Fentanyl|
80022240|NCT03498950|Other|laser therapy|laser irradiation on the taste papillae
80022241|NCT02146716|Other|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
79565256|NCT01730469|Drug|AT1001 150 mg|AT1001 150mg is available as a capsule
79860760|NCT03113500|Other|Laboratory Biomarker Analysis|Correlative studies
79860761|NCT03113500|Drug|Prednisone|Given PO
79860762|NCT03092518|Procedure|Surgery|Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
79860763|NCT03092518|Drug|Cisplatin|Cisplatin (90 mg/m2) will be administered via circuit to the peritoneal cavity
79860764|NCT03092518|Drug|Mitomycin C|Mitomycin C 10 mg/m2 will be administered via circuit to the peritoneal cavity
79860765|NCT03092518|Drug|Sodium Thiosulfate|Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
79860766|NCT03088514|Dietary Supplement|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
79860767|NCT03085758|Biological|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
79860768|NCT03085758|Biological|Placebo|Single i.v. dose of placebo (control group)
79860769|NCT03071406|Drug|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
79860770|NCT03071406|Drug|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
79399798|NCT04493190|Procedure|Scapular control training|Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
79565257|NCT01730482|Drug|[14C] AT1001|150 mg of [14C] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
79860771|NCT03071406|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
79565258|NCT01730495|Drug|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
79860772|NCT03059940|Behavioral|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
79860773|NCT03059940|Procedure|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
79860774|NCT03059940|Other|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
79565259|NCT01730508|Drug|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
79565260|NCT01730521|Behavioral|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
79860775|NCT03059940|Behavioral|Cessation Counseling|Brief cessation counseling given by LDCT provider.
79860776|NCT03059940|Behavioral|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
80022242|NCT02322944|Behavioral|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
80022243|NCT02322944|Behavioral|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
80022244|NCT02550522|Device|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
79399799|NCT04493190|Procedure|General exercise|Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
79399800|NCT01381549|Drug|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
79399801|NCT01381549|Drug|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
79399802|NCT01381549|Other|Placebo|saline placebo
79399803|NCT00159432|Drug|Oxaliplatin|
79565261|NCT01730560|Other|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~two visits in pre-tests evaluation (V1 and V2),~one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~two visits after treatment (V4 at one week and V5 at one month)."
79860777|NCT03059940|Behavioral|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
79860778|NCT03059940|Drug|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
79860779|NCT03059940|Drug|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
79860780|NCT03059940|Behavioral|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
79860781|NCT03059940|Other|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
79860782|NCT03053622|Biological|Mirikizumab Test|Administered SC
79860783|NCT03053622|Biological|Mirikizumab Test|Administered IV
79860784|NCT03053622|Biological|Mirikizumab Reference|Administered SC
80022245|NCT02325752|Other|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~Post discharge surveillance of the patient to ensure adherence to care plans.~Coordination of follow-up visits with specialist care providers.~Patent education and care giver training.~Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
79565262|NCT01730560|Other|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~two visits in pre-tests evaluation (V1 and V2),~one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~two visits after treatment (V4 at one week and V5 at one month)."
79860785|NCT03047837|Drug|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
79726329|NCT05029609|Drug|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
79726330|NCT05029609|Drug|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
79726331|NCT02693197|Drug|T-817MA|A single oral dose of 448 mg
79860786|NCT03047837|Drug|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
79860787|NCT03047837|Other|Placebo|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
79860788|NCT03037515|Drug|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
79860789|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
80022246|NCT02254200|Other|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
80022247|NCT02254200|Other|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of ~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
79265400|NCT05299021|Procedure|Single-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
80022248|NCT03498872|Device|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
79265401|NCT05297565|Biological|Nivolumab/rHuPH20|Specified dose on specified days
79265402|NCT05297565|Biological|Nivolumab|Specified dose on specified days
79399804|NCT00159432|Drug|Bevacizumab|
79860790|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
79860791|NCT03009786|Other|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
79399805|NCT00159432|Drug|Capecitabine|
79399806|NCT05737368|Radiation|fractionated radiotherapy|fractionated radiotherapy (500cGy *5F, 600cGy*5F, 350cGy*10F, according to the tumor volume)
79565263|NCT01730573|Procedure|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
79565264|NCT01730573|Procedure|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
79860792|NCT02998580|Device|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
79860793|NCT02998580|Device|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
79565265|NCT01730599|Other|neurological exam|motor and cognitive functions
79860794|NCT02991677|Behavioral|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
80022249|NCT03498872|Other|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
79565266|NCT01726400|Drug|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
79399807|NCT05737368|Drug|cadonilimab|Cardunizumab (10mg/kg, Q3W, d1)
79399808|NCT02969850|Dietary Supplement|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
79565267|NCT01726400|Drug|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
79565268|NCT01730612|Drug|TF2 - 68 Ga-IMP-288:|ImmunoTEP
80022250|NCT02354118|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
79565269|NCT01730625|Behavioral|Cognitive behavioral therapy for anxiety|
79726332|NCT02711293|Other|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count >350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been >350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
79726333|NCT02711293|Other|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
79726334|NCT03961165|Drug|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
79726335|NCT03961165|Drug|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
79860795|NCT02991677|Other|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
79860796|NCT02991677|Behavioral|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
79860797|NCT02979522|Drug|Brentuximab vedotin|Brentuximab vedotin infusion
79860798|NCT02979522|Drug|Doxorubicin|Doxorubicin infusion
79860799|NCT02979522|Drug|Vinblastine|Vinblastine infusion
79726336|NCT02706457|Other|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
79726337|NCT02706535|Drug|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
79860800|NCT02979522|Drug|Dacarbazine|Dacarbazine infusion
80022251|NCT02354118|Other|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
79265403|NCT05268744|Drug|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
79265404|NCT05254873|Other|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
79399809|NCT02969850|Other|Placebo|Subjects in this group will receive a placebo.
79565270|NCT01730625|Behavioral|Attention Bias Modification Treatment|
79565271|NCT01730651|Radiation|Tomotherapy|"IMRT boost of gross LNs~Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
79565272|NCT01730664|Drug|ertapenem|single dose of 2000mg ertapenem IV
79860801|NCT02971761|Drug|Enobosarm|Given PO
79860802|NCT02971761|Other|Laboratory Biomarker Analysis|Correlative studies
79860803|NCT02971761|Biological|Pembrolizumab|Given IV
79860804|NCT02954341|Device|CardioMEMS HF System|
79860805|NCT02943746|Dietary Supplement|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
79860806|NCT02943746|Dietary Supplement|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
79860807|NCT02922777|Drug|BGB324|75 mg/m2 every 21 days
79860808|NCT02922777|Drug|Docetaxel|75 mg/m2 given IV every 21 days
79860809|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
79860810|NCT02915575|Other|Usual Care|Participants will be discharged as per usual ward discharge protocols.
79860811|NCT02911103|Procedure|DBS surgery|Unilateral thalamic DBS therapy
79860812|NCT02906007|Drug|Bedaquiline|100 mg oral tablets. In Cohorts 2 and 3 only under protocol Version 2.0, 20 mg oral dispersible tablet may alternatively be used. Doses will vary based on the participant's age and weight.
79860813|NCT02887820|Device|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
79860814|NCT02884271|Procedure|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
79860815|NCT02881320|Drug|B/F/TAF (Adult Strength)|50/200/25 mg FDC tablets administered orally once daily without regard to food.
79265405|NCT05251129|Drug|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
79265406|NCT05214963|Device|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
79265407|NCT05214963|Device|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
79565273|NCT01730677|Drug|Lapatinib|lapatinib 1000mg, once daily
79565274|NCT01730677|Drug|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
79565275|NCT01730716|Device|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
79565276|NCT01730742|Behavioral|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
79565277|NCT01730742|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
79860816|NCT02881320|Drug|B/F/TAF (Low Dose)|30/120/15 mg FDC tablets administered orally once daily without regard to food.
79860817|NCT02881320|Drug|B/F/TAF (TOS)|2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.
79726338|NCT02706535|Drug|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
79565278|NCT01730742|Procedure|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
79565279|NCT01730755|Drug|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
79726339|NCT02706535|Drug|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
79860818|NCT02881320|Drug|B/F/TAF (TOS)|2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.
79265408|NCT05211713|Device|Opp|Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
79265409|NCT05203926|Procedure|MRI scan|Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
79565280|NCT01730794|Other|NAVA ventilation|Neurally adjusted ventilatory assist
79565281|NCT01730794|Other|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
79399810|NCT02969850|Dietary Supplement|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
79265410|NCT05184023|Device|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
79726340|NCT02711059|Procedure|parathyroidectomy|surgical treatment of hyperparathyroidism
79399811|NCT02339766|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
79860819|NCT02881320|Drug|B/F/TAF (TOS)|1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.
79860820|NCT02881320|Drug|B/F/TAF (TOS)|1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
79399812|NCT02339766|Procedure|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
79399813|NCT02339766|Drug|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
79399814|NCT02339766|Drug|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
79399815|NCT05092464|Device|Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
79565282|NCT01730807|Device|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
79565283|NCT01730859|Other|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
79726341|NCT02706223|Other|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
80022252|NCT03498794|Procedure|Ureteral stent|"Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively."
80022253|NCT03496688|Procedure|Sinus floor augmentation|
80022254|NCT03544164|Other|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
79265411|NCT05184023|Device|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
79565284|NCT01730885|Other|Comparison of different Blood Glucose Meters|
79726342|NCT02706223|Other|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
79726343|NCT02706379|Other|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
79726344|NCT03960073|Dietary Supplement|MitoQ|4 week 20mg oral daily dose of Mito Q
79726345|NCT03960073|Dietary Supplement|Placebo|4 week oral daily dose of TTP placebo
79726346|NCT02706301|Behavioral|Telephone-Based Coping Skills Training (CST)|
79265412|NCT05179356|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg given once daily for three months
79265413|NCT05179356|Drug|Placebo|Matching placebo
79399816|NCT04287660|Drug|clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells|"clarithromycin: 500mg, PO, twice daily, on days 1~21 for a 28-day cycle.~lenalidomide: 25mg, PO, on days 1~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~Doses should be adjusted according to renal function."
79565285|NCT01730898|Other|Study product containing lutein|delivered in capsule form
79565286|NCT01730898|Other|Study product containing lutein|delivered in capsule form
79565287|NCT01730911|Other|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
79565288|NCT01730924|Procedure|Pulmonary vein isolation using contact force sensing catheter|
79565289|NCT01730976|Dietary Supplement|Vitamin D 2,000 I.U.|
79565290|NCT01730989|Dietary Supplement|Estromineral Serena Plus|
79565291|NCT01730989|Dietary Supplement|Estromineral|
79860821|NCT02859753|Other|Percutaneous Radiofrequency Ablation|
79860822|NCT02859753|Other|Percutaneous Microwave Ablation|
79265414|NCT05153226|Drug|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
79265415|NCT05153226|Biological|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
79399817|NCT04280016|Behavioral|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
79399818|NCT04069104|Behavioral|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
79565292|NCT01731015|Drug|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
79726347|NCT02710825|Other|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
79726348|NCT02710825|Other|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
80022255|NCT02325830|Device|CARILLON Mitral Contour System|Percutaneous mitral valve repair
79265416|NCT05150236|Drug|177Lu-PSMA-617|Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.
79265417|NCT05150236|Drug|Ipilimumab|Patients will be given 3mg/kg of Ipilimumab every 6 weeks up to 4 doses unless there is unacceptable toxicity, concurrently with Lu-PSMA and Nivolumab.
79265418|NCT05150236|Drug|Nivolumab|Patients will be given 1mg/kg of Nivolumab every 3 weeks up to 8 doses, concurrently with Lu-PSMA and Ipilimumab unless there is unacceptable toxicity. Followed by 480mg nivolumab monotherapy commencing at week 32. Nivolumab monotherapy will be given to patients every 4 weeks up to 18 doses, or until disease progression or unacceptable toxicity.
79303973|NCT04006223|Diagnostic Test|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
79303974|NCT04006223|Diagnostic Test|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
79399819|NCT04069104|Behavioral|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
79399820|NCT04069104|Behavioral|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
79399821|NCT04069104|Behavioral|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
79399822|NCT01396057|Drug|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
79399823|NCT01396057|Other|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
79565293|NCT01731028|Drug|Somatropin|Somatropin powder and solvent for solution for injection
79860823|NCT02852213|Drug|AAV2-hAADC|Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged >/= 13 yo) will be dosed (1.6 x 10^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
79860824|NCT02846376|Drug|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
79860825|NCT02846376|Drug|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
80022256|NCT02146794|Device|Renal denervation|Renal denervation
80022257|NCT03496532|Device|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
79565294|NCT01731067|Drug|Cocktail probe drugs|
79565295|NCT01731093|Drug|AT-001|
79565296|NCT01731093|Drug|Placebo|
79726349|NCT00612703|Drug|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
79265419|NCT05141266|Behavioral|Patient Navigation|PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable
79565297|NCT01731132|Drug|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
79860826|NCT02830594|Radiation|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
79565298|NCT01731145|Device|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
79265420|NCT05141266|Other|Standard Medication Counseling (SMC)|SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
79265421|NCT05137730|Drug|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
79265422|NCT05120531|Other|Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia|Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
79265423|NCT05088616|Behavioral|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
79399824|NCT01396057|Other|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
80022258|NCT03496532|Device|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
79565299|NCT01731158|Drug|Avastin in combination with Roferon-A|
80022259|NCT03496532|Device|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
79860827|NCT02830594|Other|Laboratory Biomarker Analysis|Correlative studies
80022260|NCT03496532|Device|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
80022261|NCT03496532|Device|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
80022262|NCT03496454|Other|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
79565300|NCT01731158|Drug|Afinitor|
79565301|NCT01731158|Drug|TKI: Sutent, Nexavar or Votrient|TKI
79565302|NCT01731184|Drug|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
79726350|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
79860828|NCT02830594|Biological|Pembrolizumab|Given IV
79860829|NCT02829684|Other|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
79399825|NCT02419560|Drug|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
79565303|NCT01731197|Dietary Supplement|Dry-Blended Beverage|
79565304|NCT01731210|Device|implantation of the new LV lead: NANO system.|
79565305|NCT01731223|Behavioral|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
79565306|NCT01731249|Biological|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
79565307|NCT01731249|Biological|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
79726351|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
79726352|NCT00612157|Drug|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
79726353|NCT00612157|Drug|Placebo control|Matching placebo
79726354|NCT05265559|Procedure|Partial Indirect Restoration|Dental restorative treatment
79726355|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
79726356|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
79860830|NCT02827877|Radiation|Copper Cu 64-DOTA-Trastuzumab|Given IV
79860831|NCT02827877|Other|Laboratory Biomarker Analysis|Correlative studies
79860832|NCT02827877|Biological|Pertuzumab|Given IV
79860833|NCT02827877|Procedure|Positron Emission Tomography|Undergo PET
79860834|NCT02827877|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79860835|NCT02827877|Biological|Trastuzumab|Given IV
79860836|NCT02823769|Device|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
79265424|NCT05087446|Behavioral|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
79565308|NCT01731275|Drug|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
79265425|NCT05087446|Behavioral|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
79860837|NCT02823769|Device|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
79265426|NCT05070624|Behavioral|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content & Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
79565309|NCT01731275|Drug|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
79265427|NCT05070156|Biological|Biological/Vaccine: Low-dose group|1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
79265428|NCT05070156|Biological|Biological/Vaccine: Mid-dose group|2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
79265429|NCT05070156|Biological|Biological/Vaccine: High-dose group|3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
79565310|NCT01731301|Drug|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
79726357|NCT02710903|Procedure|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
79726358|NCT05265403|Drug|Commercially-available energy storage and return prosthetic foot|Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
79726359|NCT05265403|Device|MIT-Lower Leg Trajectory Error (LLTE) customized prosthetic feet|Each patient will walk in prosthetic feet designed by the researchers at MIT. These feet will be customized for the user based on their body size (ie, height, foot length) and weight.
79860838|NCT02822092|Drug|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
79860839|NCT02806882|Drug|Ceftaroline fosamil|600mg IV infusion
80022263|NCT02319980|Procedure|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
80022264|NCT02320370|Device|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
80022265|NCT02320448|Drug|PIPAC|
79565311|NCT01731301|Drug|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
79860840|NCT02782104|Drug|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
79860841|NCT02776735|Drug|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
79860842|NCT02774746|Other|35-week delivery|Induction at 35 weeks gestational age
79860843|NCT02774746|Other|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
79565312|NCT01731301|Drug|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
79860844|NCT02758717|Drug|Brentuximab Vedotin|Given IV
79860845|NCT02758717|Biological|Nivolumab|Given IV
79860846|NCT02755610|Other|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
79860847|NCT02738606|Drug|Chemotherapy|
79860848|NCT02738606|Other|Laboratory Biomarker Analysis|Correlative studies
79860849|NCT02738606|Procedure|Metastasectomy|Undergo lung metastasectomy
79565313|NCT01731314|Behavioral|Learning and Memory of Pain|
79565314|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
79565315|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
79860850|NCT02738606|Other|Quality-of-Life Assessment|Ancillary studies
79860851|NCT02738606|Procedure|Therapeutic Conventional Surgery|Undergo hepatectomy
79860852|NCT02728830|Drug|Pembrolizumab|Pembrolizumab 200mg IV
79860853|NCT02704234|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
79860854|NCT02704234|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
79860855|NCT02694874|Drug|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
79860856|NCT02694874|Drug|Placebo|This is the placebo control
79265430|NCT05068219|Procedure|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~EFA (Expiratory Flow Acceleration) at the upper thoracic level.~PEP (Positive Expiratory Pressure).~Expectoration if necessary (coughing up and spitting out)"
79565316|NCT01731340|Dietary Supplement|Calcium Citrate|750mg
79565317|NCT01731340|Other|Low Dietary Calcium|450 mg
79399826|NCT04540224|Diagnostic Test|Flow-Cytometric analysis|Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
79565318|NCT01731340|Other|High Dietary Calcium|1200 mg
79565319|NCT01731366|Other|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
79565320|NCT01731366|Other|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
79565321|NCT01731379|Procedure|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
79565322|NCT01731392|Dietary Supplement|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
79565323|NCT01731392|Dietary Supplement|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
79860857|NCT02681302|Drug|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
79860858|NCT02681302|Drug|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
79860859|NCT02677896|Drug|Enzalutamide|Oral
79860860|NCT02677896|Drug|Placebo|Oral
79565324|NCT01731392|Dietary Supplement|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
79565325|NCT01731418|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, & Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
79565326|NCT01731418|Other|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
79726360|NCT04971655|Other|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
79726361|NCT04612699|Drug|Jaktinib|Administered orally
79726362|NCT04612699|Drug|Placebo|Administered orally
79565327|NCT01731431|Other|Insulin|
79565328|NCT01731431|Drug|Glyburide|
79565329|NCT01731457|Drug|etanercept|adding appropriate dose of etanercept to the perfusion fluid
79565330|NCT01731496|Other|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
79726363|NCT04267432|Dietary Supplement|Placebo|Blank
79860861|NCT02654171|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
79860862|NCT02654171|Drug|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
79860863|NCT02651948|Procedure|Transperineal, MRI-guided, prostate biopsy|
79860864|NCT02651948|Procedure|Transrectal prostate biopsy (TRB):|
79860865|NCT02625961|Biological|Pembrolizumab|Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
79860866|NCT02625961|Biological|Pembrolizumab/vibostolimab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
79565331|NCT01731496|Other|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
79565332|NCT01731509|Other|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
79565333|NCT01731548|Radiation|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
79565334|NCT01731561|Drug|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
79726364|NCT04267432|Dietary Supplement|TCI633|Probiotics
79860867|NCT02625961|Biological|Favezelimab/pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
79860868|NCT02624869|Biological|Evolocumab|Administered by subcutaneous injection
79860869|NCT02601417|Other|Ignoring result of bile culture|Patients in the trial arm will do bile cultures which will not be considered when choosing antibiotics.
79860870|NCT02590393|Combination Product|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
79860871|NCT02588651|Drug|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
79860872|NCT02573779|Other|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
79860873|NCT02565498|Radiation|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
79565335|NCT01731561|Drug|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
79565336|NCT01731574|Drug|dapivirine|
79565337|NCT01731574|Drug|miconazole|
79565338|NCT01731587|Other|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
79565339|NCT01731587|Drug|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
79565340|NCT01731613|Dietary Supplement|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
79565341|NCT01731639|Other|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form > 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
79565342|NCT01731652|Drug|TMX-101|
79726365|NCT04267432|Drug|Type 2 collagen|Positive control group
79726366|NCT04970173|Other|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
79726367|NCT04267354|Other|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
79565343|NCT01731704|Radiation|Stereotactic radiosurgery (SRS)|
79726368|NCT05382988|Drug|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
79860874|NCT02565498|Radiation|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
80022266|NCT03496376|Other|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
80022267|NCT03496376|Other|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
79726369|NCT05379868|Procedure|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
79726370|NCT05379868|Procedure|No osteotomies|Standard treatment
79726371|NCT02710747|Genetic|CYP2C9;VKORC1|
79726372|NCT05382832|Combination Product|SCS|SCS-experimental treatment
79860875|NCT02531932|Drug|Carboplatin|Carboplatin will be administered if ANC > 1.0 and platelets are >75k
79565344|NCT01731704|Radiation|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
79565345|NCT01731717|Behavioral|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
80022268|NCT02323022|Drug|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
79565346|NCT01731717|Behavioral|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
80022269|NCT02323022|Drug|High-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
80022270|NCT02323022|Drug|Intermediate-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 10mg/msq/d (d1-3)
79565347|NCT01731717|Behavioral|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
79565348|NCT01731717|Behavioral|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
79565349|NCT01731717|Procedure|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
79565350|NCT01731717|Behavioral|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
79565351|NCT01731717|Other|Control group: treatment as usual|treatment as usual
79726373|NCT05382832|Combination Product|SCS|SCS-placebo
79726374|NCT00936598|Drug|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
79726375|NCT00936598|Drug|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
79726376|NCT04159441|Other|None intervetion|None intervetion
79726377|NCT01025817|Drug|Everolimus and tacrolimus|"Everolimus:~Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~Dose: 1.5 mg per day~Frequency: 0.75 mg twice daily~Tacrolimus:~Dose adjusted to maintain specific blood levels"
79726378|NCT01025817|Drug|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
79726379|NCT02710513|Dietary Supplement|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
79726380|NCT00939640|Behavioral|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
79860876|NCT02531932|Drug|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
79860877|NCT02506153|Procedure|Biospecimen Collection|Undergo blood sample collection
79860878|NCT02506153|Procedure|Computed Tomography|Undergo CT scan
79860879|NCT02506153|Biological|Ipilimumab|Given IV
79860880|NCT02506153|Procedure|Magnetic Resonance Imaging|Undergo MRI
79860881|NCT02506153|Biological|Pembrolizumab|Given IV
79860882|NCT02506153|Procedure|Positron Emission Tomography|Undergo PET scan
79265431|NCT05068219|Procedure|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~Maximum inspiration against resistance, then maximum expiration with increased pressure.~Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
79860883|NCT02506153|Other|Quality-of-Life Assessment|Ancillary studies
79860884|NCT02506153|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
79265432|NCT05050188|Drug|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
79860885|NCT02475434|Dietary Supplement|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
80022271|NCT03493724|Other|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
79565352|NCT01731743|Device|AT LISA tri 839MP|
79399827|NCT05091996|Procedure|Post-isometric muscle relaxation technique|"1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier."
79565353|NCT01731756|Other|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
80022272|NCT03496142|Procedure|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
80022273|NCT03496142|Procedure|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
79265433|NCT05050188|Drug|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
79265434|NCT05050188|Drug|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
79265435|NCT05045196|Behavioral|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
79265436|NCT05041439|Behavioral|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
79726381|NCT05264545|Device|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
79860886|NCT02444741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
79860887|NCT02444741|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79265437|NCT05037409|Drug|PF-06823859|low dose or high dose intravenous infusion
79265438|NCT05037409|Drug|Placebo|Intravenous infusion
79265439|NCT05030038|Biological|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
79565354|NCT01731756|Drug|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
79860888|NCT02444741|Other|Laboratory Biomarker Analysis|Correlative studies
79565355|NCT01731756|Other|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
79565356|NCT01731769|Procedure|vacuum assisted closure in experimental arm|
79265440|NCT05030038|Biological|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
79265441|NCT05029791|Other|Tumor biopsy|2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)
79265442|NCT05029791|Other|Blood sample|1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
79265443|NCT05017103|Biological|Sintilimab|Given IV
79565357|NCT01731769|Procedure|Axillary dissection|
79565358|NCT01731795|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
79726382|NCT00636883|Drug|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
79860889|NCT02444741|Biological|Pembrolizumab|Given IV
79860890|NCT02444741|Radiation|Proton Beam Radiation Therapy|Undergo PBRT
79860891|NCT02444741|Radiation|Radiation Therapy|Undergo low dose radiation therapy
79860892|NCT02444741|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79726383|NCT02872155|Other|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
79726384|NCT02872155|Drug|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
79726385|NCT02872155|Drug|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
79726386|NCT00605956|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
79565359|NCT01731808|Behavioral|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
79726387|NCT00605956|Drug|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
79726388|NCT00605956|Drug|Blank Patch|Blank Patch
79726389|NCT02710357|Procedure|Mandibular Overdenture|Placement of an implant in the mandibular midline.
79726390|NCT02710357|Procedure|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
80022274|NCT03496064|Other|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
79726391|NCT02871999|Device|Acupuncture therapy|
80022275|NCT02320526|Behavioral|Control|
80022276|NCT02320526|Behavioral|Continuous walking|
79726392|NCT02871999|Procedure|Laparoscopic Surgery|
80022277|NCT02320526|Behavioral|Interval walking|
80022278|NCT02320604|Drug|Administration of study drug|i.v. administration of Ambisome in two different dossages
80022279|NCT01366638|Drug|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
80022280|NCT01366638|Drug|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
80022281|NCT01366638|Drug|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
79265444|NCT05003115|Behavioral|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
79265445|NCT04999111|Biological|Ad26.COV2.S|Participants will receive IM injection of Ad26.COV2.S.
79265446|NCT04986969|Behavioral|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
79726393|NCT05382676|Device|Eyeswift Pro|assessment of visual function parameters
79726394|NCT01218113|Biological|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
79726395|NCT01218113|Drug|Placebo|1 or 3 doses according to protocol schedule
79726396|NCT05264467|Biological|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
79726397|NCT02871453|Device|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
79726398|NCT02871453|Other|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
79726399|NCT00605410|Drug|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
79726400|NCT00605410|Drug|placebo|Matched placebo
79726401|NCT02710201|Behavioral|Descriptive Social Norm|
79726402|NCT02710201|Behavioral|Descriptive-plus-Injunctive Social Norm|
79726403|NCT04300881|Drug|Eplerenone|Following intravitreal ocriplasmin therapy
79726404|NCT04203940|Procedure|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
79726405|NCT04203940|Procedure|Suture|mesh fixation was done with polypropylene 2/0 sutures
80022282|NCT02320682|Device|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
80022283|NCT02147028|Radiation|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
79860893|NCT02422147|Procedure|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
79860894|NCT02415621|Drug|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
79860895|NCT02414789|Procedure|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
79860896|NCT02407405|Drug|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
79860897|NCT02401685|Other|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
79860898|NCT02401685|Procedure|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
79860899|NCT02397083|Drug|Everolimus|Given PO
79860900|NCT02397083|Other|Laboratory Biomarker Analysis|Correlative studies
79860901|NCT02397083|Device|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
79860902|NCT02396134|Biological|CMVpp65-A*0201 peptide vaccine|Given SC
79860903|NCT02396134|Other|Placebo|Given SC
79860904|NCT02396134|Other|Laboratory Biomarker Analysis|Correlative studies
79860905|NCT02393924|Other|No intervention|
79860906|NCT02393859|Drug|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
79860907|NCT02393859|Drug|Dexamethasone|10 mg/m^2/day intravenous (IV) on Days 1-6
79565360|NCT01731821|Procedure|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
79565361|NCT01731834|Other|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
79565362|NCT01731847|Procedure|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
79565363|NCT01731860|Device|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
79565364|NCT01731899|Drug|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
79565365|NCT01731925|Drug|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
79860908|NCT02393859|Drug|Vincrisitne|1.5 mg/m^2/day IV on Days 1 and 6
79860909|NCT02393859|Drug|Daunorubicin|30 mg/m^2 IV over 24 hours on Day 5
79565366|NCT01731925|Drug|Placebo (for sunitinib)|
79565367|NCT01731925|Drug|Sunitinib|Sunitinib 37.5 mg daily
79565368|NCT01731964|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
79860910|NCT02393859|Drug|Methotrexate|1 g/m^2 IV over 36 hours on Day 1
79860911|NCT02393859|Drug|Ifosfamide|800 mg/m^2 IV for 1 hour on Days 2-4
79860912|NCT02393859|Drug|PEG-asparaginase|1000 U/m^2 IV for 2 hours or intramuscularly (IM) on Day 6
79860913|NCT02393859|Drug|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
79860914|NCT02391324|Procedure|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
79860915|NCT02391324|Procedure|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
79860916|NCT02391324|Procedure|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
79860917|NCT02365766|Drug|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
79860918|NCT02365766|Drug|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
79860919|NCT02365766|Drug|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
79565369|NCT01731964|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
79565370|NCT01731977|Behavioral|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
79726406|NCT00603850|Device|ForeseeHome|human factor
79726407|NCT03873493|Drug|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
79860920|NCT02365766|Procedure|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
79265447|NCT04981795|Drug|Tafasitamab|Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
79726408|NCT03873493|Drug|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
79399828|NCT05091996|Procedure|Myofascial release technique|The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
79399829|NCT05091840|Other|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
79860921|NCT02294461|Drug|Enzalutamide|Oral
79860922|NCT02294461|Drug|Placebo|Oral
79860923|NCT02216032|Other|TMW Curriculum|
79860924|NCT02216032|Other|Nutrition Curriculum|
79265448|NCT04978818|Drug|Vaxelis|Eligible infants will be block randomized to one of two study arms.
79265449|NCT04978818|Drug|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
79265450|NCT04978766|Behavioral|Interactive Book Reading|"The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~Two videos of child development experts explaining the benefits of interactive reading.~Thirty written text messages strengthening content provided in the videos.~Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification."
79265451|NCT04974125|Procedure|Drain|A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
79265452|NCT04974125|Procedure|Manual exsufflation|Exsufflation through the trocar opening.
79265453|NCT04970082|Diagnostic Test|FFR DWP|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
79265454|NCT04970082|Diagnostic Test|FFR|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
79565371|NCT01732003|Dietary Supplement|Omega-3 Complete|
79860925|NCT02205034|Drug|oxytocin|Intranasal administration
79265455|NCT04964557|Drug|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
79265456|NCT04964557|Drug|Placebo|Placebo solution
79265457|NCT04959565|Behavioral|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
79265458|NCT04959565|Behavioral|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
79399830|NCT00704847|Drug|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
79399831|NCT00704847|Drug|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
79399832|NCT01380769|Drug|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
80022284|NCT02147028|Radiation|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
79399833|NCT01380769|Other|Best Supportive Care|best supportive care
79399834|NCT05091762|Behavioral|exercise|Upper limb resistance training with blood flow obstruction
79565372|NCT01732003|Dietary Supplement|Placebo Pill|
79565373|NCT01732016|Other|Normobaric hypoxia chamber|
79565374|NCT01732029|Other|Normobaric hypoxia chamber|
79565375|NCT01732055|Behavioral|Partner-Assisted Interpersonal Psychotherapy|
79860926|NCT02194387|Dietary Supplement|Dietary Intervention|Record dietary intake 4-7 days per week
79860927|NCT02194387|Dietary Supplement|Dietary Intervention|Record dietary intake 1 day per week
79860928|NCT02194387|Other|Internet-Based Intervention|Receive email coaching
79860929|NCT02194387|Other|Internet-Based Intervention|Participate in social networking
79860930|NCT02194387|Other|Laboratory Biomarker Analysis|Correlative studies
79860931|NCT02194387|Other|Questionnaire Administration|Ancillary studies
79860932|NCT02194387|Behavioral|Telephone-Based Intervention|Receive telephone coaching
79860933|NCT02194387|Behavioral|Telephone-Based Intervention|Receive text messages
79726409|NCT05264311|Other|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study [31]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
79726410|NCT05264233|Dietary Supplement|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
79860934|NCT02192021|Drug|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
79860935|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
79860936|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
79860937|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube|
80022285|NCT02323178|Drug|eltrombopag|initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
79265459|NCT04951063|Radiation|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
79265460|NCT04951063|Drug|Concurrent chemotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
79860938|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes|
79860939|NCT02133196|Drug|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
79860940|NCT02133196|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
79860941|NCT02133196|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
79860942|NCT02133196|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
79860943|NCT02103140|Behavioral|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
79860944|NCT02103140|Behavioral|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
79860945|NCT02085772|Other|Blood samples at 37-38 Weeks of amenorrhea|
79860946|NCT02085772|Other|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
79860947|NCT02085772|Other|Blood samples at the time of delivery|
79860948|NCT02080741|Other|Blood sample of 12 ml|
80022286|NCT02147808|Drug|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
80022287|NCT02147808|Drug|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup [2mg/mL]).
80022288|NCT02323256|Other|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
80022289|NCT02323256|Other|Speech-ABR|
79265461|NCT04951063|Drug|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
79565376|NCT01732055|Other|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
79565377|NCT01732068|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
80022290|NCT02323256|Other|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
80022291|NCT02323256|Other|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
79565378|NCT01732068|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
79726411|NCT05264233|Dietary Supplement|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
80022292|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
80022293|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|
80022294|NCT03543072|Drug|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
80022295|NCT02147964|Drug|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months [all subjects]
80022296|NCT02147964|Drug|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]
79265462|NCT04947501|Drug|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 & 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~******* Administration of CDV - cycle 3 Days 1 & 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
79265463|NCT04947501|Drug|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 & 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
79399835|NCT03393468|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
79399836|NCT05091606|Procedure|Perfusion İndex in Patients with Spinal Anesthesia|Comparison of lower and upper extremity perfusion index values
79399837|NCT02999685|Behavioral|Home-base Pulmonary Rehab with Health Coaching|
79565379|NCT01732068|Drug|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
79565380|NCT01732094|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
80022297|NCT02147964|Drug|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
80022298|NCT02147964|Drug|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
80022299|NCT02147964|Drug|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
80022300|NCT02147964|Drug|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
80022301|NCT02147964|Drug|placebo ketoconazole|placebo ketoconazole daily for 4 months
79399838|NCT02999529|Other|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
80022302|NCT03491852|Behavioral|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
79399839|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
79399840|NCT01012557|Biological|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
79565381|NCT01732094|Drug|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
79565382|NCT01732094|Drug|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
79565383|NCT01732133|Device|Nexfin|
79565384|NCT01732146|Drug|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
79565385|NCT01732146|Drug|Placebo|
79565386|NCT01732159|Other|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
79399841|NCT01012557|Biological|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
79399842|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
79399843|NCT01395901|Drug|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
79565387|NCT01732172|Other|Sperm sample|Sperm sample
79565388|NCT01732185|Genetic|Patient|Blood and histological samples will be done at day of the inclusion.
79565389|NCT01732198|Biological|NU300|
79565390|NCT01732198|Biological|ActHIB|
79565391|NCT01732198|Biological|Prevnar 13|
79565392|NCT01732224|Drug|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
79565393|NCT01732224|Drug|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
79565394|NCT01732237|Drug|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
79565395|NCT01732237|Drug|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
79565396|NCT01732237|Drug|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
79565397|NCT01732250|Drug|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
79565398|NCT01732250|Drug|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
79565399|NCT01732276|Drug|gefitinib|
79565400|NCT01732289|Genetic|genes|Draw blood for genetic screening
79726412|NCT05264233|Dietary Supplement|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
79726413|NCT00611689|Drug|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in < 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
80022303|NCT03491852|Behavioral|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
79860949|NCT02077335|Radiation|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~V100 > 95%~V150 30-35%~V200 < 15%~D90 > 90% (12,15Gy)~Bladder~• V75 < 1cc~Rectum~• V75 < 1cc~Urethra~V125 = 0cc D10 < 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
79265464|NCT04947501|Drug|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 & 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
79565401|NCT01732302|Other|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
79565402|NCT01732315|Behavioral|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
79565403|NCT01732328|Dietary Supplement|Calcium plus vitamin D|
79860950|NCT02048189|Drug|LEVEMIR|
79265465|NCT04947501|Drug|Doxorubicin|"Administration of CDV - cycle 3 Days 1 & 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
79399844|NCT01395901|Drug|Ondansetron|"Single dose Ondansetron IV:~0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for >40 kg;~13 years to less than 17 years dose: 4 mg"
79399845|NCT01395901|Drug|Placebo to Ondansetron|
79565404|NCT01732341|Device|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
79726414|NCT05264077|Drug|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
79726415|NCT04892641|Drug|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
79726416|NCT04892641|Drug|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
79726417|NCT03757819|Device|tDCS|Brain Stimulation
79726418|NCT03757819|Device|SHAM|Placebo device
79726419|NCT04160845|Procedure|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
79726420|NCT00612859|Drug|levetiracetam|
79860951|NCT02048189|Drug|APIDRA|
79860952|NCT02045563|Other|prise de sang|
79399846|NCT01395901|Drug|Placebo to Palonosetron|
79565405|NCT01732341|Device|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~--------------------------------------------------------------------------------"
79726421|NCT04866901|Behavioral|Slow-Paced Breathing (SPB)|see arm description
79726422|NCT04866901|Behavioral|Mindfulness (M)|see arm description
79860953|NCT02045563|Other|magnetic resonance imaging and magnetic resonance spectroscopy|
79860954|NCT02042573|Device|rTMS|
79726423|NCT04866901|Behavioral|Yogic Breathing (SPB+M)|see arm description
79726424|NCT00612391|Procedure|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
79860955|NCT02042573|Drug|SSRI (SEROPLEX ou ZOLOFT)|
79860956|NCT02042573|Other|Genetic samples|
79860957|NCT02019849|Device|Plasmafit® Total Hip Arthroplasty|
79399847|NCT02994147|Drug|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
79399848|NCT02994147|Drug|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
79399849|NCT03030534|Combination Product|Educational package and software package|Using Information and communication technology to deliver health promoting activities
79399850|NCT03030534|Other|Health promotion tips|Give general information on health promotion
79565406|NCT01732367|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
79565407|NCT01732367|Drug|Tenofovir|Tenofovir 300mg QD for 96 weeks
79565408|NCT01732380|Drug|Raltitrexed|
79565409|NCT01732380|Drug|Oxaliplatin|
79565410|NCT01732380|Radiation|Radiotherapy|
79860958|NCT02016924|Drug|ATV|Capsules administered once daily according to dosing recommendations per product monograph
79860959|NCT02016924|Drug|DRV|Tablets administered once daily according to dosing recommendations per product monograph
79860960|NCT02016924|Drug|Cobicistat|Tablets administered orally once daily with food
79860961|NCT02016924|Drug|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
79565411|NCT01732393|Drug|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
79565412|NCT01732393|Drug|Placebo|
79860962|NCT02016924|Drug|F/TAF|Tablets administered orally once daily
79860963|NCT02016924|Drug|LPV/r|Solution administered orally
79860964|NCT02016924|Drug|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
79565413|NCT01732497|Device|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
79565414|NCT01732562|Other|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
79565415|NCT01732575|Behavioral|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
79860965|NCT02016924|Drug|Cobicistat TOS|Tablets for oral suspension
80022304|NCT03493334|Other|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
80022305|NCT03493334|Other|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
79265466|NCT04947501|Drug|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is <10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is <10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is <10 kg), IV over 2 hrs.
79265467|NCT04947501|Drug|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is <10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is <10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is <10 kg), IV over 2 hrs."
79265468|NCT04947501|Drug|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is <10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is <10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is <10 kg), IV over 2 hrs."
79399851|NCT04270539|Behavioral|Nap|Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
79399852|NCT02995239|Drug|CJ-12420 formulation 2|CJ-12420 formulation 2
79565416|NCT01732601|Behavioral|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
79565417|NCT01732601|Behavioral|Standard Care|Treatment at step-down facilities
79565418|NCT01732614|Procedure|Topcon Endpoint Management laser|
79565419|NCT01732653|Other|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
79565420|NCT01732653|Other|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
79565421|NCT01732666|Drug|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
79565422|NCT01732666|Drug|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
79565423|NCT01732666|Drug|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
79565424|NCT01732679|Other|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
79565425|NCT01732705|Behavioral|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
79565426|NCT01732731|Other|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
79860966|NCT02016924|Drug|F/TAF TOS|Tablets for oral suspension
79860967|NCT02004028|Drug|VS-6063|
79860969|NCT01950975|Biological|Peripheral blood samples in EDTA tubes|
79860970|NCT01950975|Procedure|Skin biopsies|
79860971|NCT01950754|Behavioral|standing with both feet|
79860972|NCT01950754|Behavioral|descent of the platform|
79860973|NCT01950754|Behavioral|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
80022306|NCT02147106|Other|Videoconsultation|
79860974|NCT01950520|Drug|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
79860975|NCT01950520|Drug|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
79265469|NCT04947501|Drug|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
79265470|NCT04939272|Drug|Copanlisib Hydrochloride|"Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level."
79265471|NCT04939272|Drug|Venetoclax|Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
79265472|NCT04936178|Drug|NB003 tablets|NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
79860976|NCT01950520|Drug|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
79860977|NCT01950520|Drug|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
79860978|NCT01950520|Drug|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
79860979|NCT01950520|Drug|Qysmia|Qysmia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
79860980|NCT01950520|Drug|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
80022307|NCT03495830|Procedure|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
80022308|NCT02780700|Drug|Nintedanib|
79265473|NCT04916496|Behavioral|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
79399853|NCT02995239|Drug|CJ-12420 formulation 1|CJ-12420 formulation 1
79399854|NCT02570100|Procedure|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~1 tumor specimen (under echographic control)~4 blood collections~Biological collection during treatment :~1 tumor specimen after 3 cycles~4 blood collections after 3 and 6 cycles"
79399855|NCT01395823|Dietary Supplement|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
79399856|NCT01395823|Other|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
79399857|NCT02993991|Drug|Mocetinostat|Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
79399858|NCT02993991|Biological|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
79399859|NCT00158184|Drug|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
79565427|NCT01732744|Other|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
79565428|NCT01732744|Other|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
79565429|NCT01732744|Other|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
79860981|NCT01950520|Behavioral|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
79860982|NCT01950520|Drug|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
79860983|NCT01950520|Drug|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
79860984|NCT01950520|Drug|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
79860985|NCT01950520|Drug|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
79860986|NCT01950520|Drug|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
79860987|NCT01950520|Drug|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
80022309|NCT02780700|Drug|Capecitabine|
80022310|NCT03493256|Other|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
80022311|NCT02151396|Behavioral|Working memory training|
80022312|NCT02151396|Device|Functional magnetic resonance imaging (fMRI)|
80022313|NCT03495752|Other|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
80022314|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 14 days|
79265474|NCT04916496|Behavioral|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
79399860|NCT00158184|Drug|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
79399861|NCT00158184|Drug|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
80022315|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 28 days|
80022316|NCT02447276|Drug|REGN475|
79565430|NCT01732744|Other|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
79399862|NCT02993913|Drug|Simmiparib|Simmiparib Tablets, oral administration
79399863|NCT02405520|Biological|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
79565431|NCT01732848|Drug|BMS-986094/INX-08189|
79565432|NCT01732848|Drug|Placebo matching BMS-986094/INX-08189|
79565433|NCT01732861|Drug|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
79726425|NCT00612391|Procedure|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
79860988|NCT01921062|Behavioral|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
79860989|NCT01911195|Drug|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
79860990|NCT01911195|Other|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
79726426|NCT02709811|Drug|Electrochemotherapy|
79726427|NCT04216147|Other|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
79860991|NCT01909102|Behavioral|ACT-based intervention|
79860992|NCT01909102|Behavioral|usual care|
79860993|NCT01907425|Other|Blood samples|
79860994|NCT01785641|Drug|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
79860995|NCT01785641|Drug|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
79860996|NCT01785641|Drug|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
79565434|NCT01732861|Drug|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
79565435|NCT01732887|Other|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~General training applications~Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
79565436|NCT01732900|Other|Morphology|Embryos selected for transfer will be based upon morphology alone.
79565437|NCT01732900|Other|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
79565438|NCT01732965|Other|Phototherapy|
79860997|NCT01785641|Drug|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
79860998|NCT01772771|Procedure|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
79860999|NCT01772771|Other|Genetic Testing|Correlative studies
79861000|NCT01772771|Other|Medical Chart Review|Review of medical records
80022317|NCT02447276|Drug|Placebo|
80022318|NCT03544008|Other|The use of AXIOS in Endoscopic transmural drainage|
80022319|NCT02151552|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
79565439|NCT01732965|Other|Phototherapy and Photochemotherapy|
79565440|NCT01732978|Behavioral|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
79726428|NCT04216147|Procedure|Surgery for CTS|Median nerve release
80022320|NCT02151552|Drug|[18F](+/-)NOS|7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
79726429|NCT05261035|Behavioral|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos & pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
79565441|NCT01732991|Device|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
79265476|NCT04896775|Behavioral|NiteCAPP CARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
79726430|NCT05261035|Other|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
79861003|NCT01760226|Drug|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
79861004|NCT01760226|Drug|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~2+ extranodal sites~elevated LDH,~MYC rearrangement OR~bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
79861005|NCT01760226|Drug|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
79861006|NCT01760226|Drug|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
79861007|NCT01760226|Drug|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
79265477|NCT04896775|Behavioral|NiteCAPP SHARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
79265478|NCT04891705|Device|Lung Ultrasound Scan|Ultrasound scan of subjects in up to 14 lung zones
79399864|NCT02405520|Biological|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
79399865|NCT02405520|Biological|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
79565442|NCT01733004|Drug|MM-141|
79565443|NCT01733017|Behavioral|Sodium reduction|Teaching and skill building to reduce dietary sodium
79565444|NCT01733017|Dietary Supplement|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
79565445|NCT01733017|Dietary Supplement|rice bran oil capsules|placebo capsules
79565446|NCT01733017|Behavioral|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
79726431|NCT04848805|Procedure|liver transplantation|total hepatectomy material was examined by pathology laboratory
79861008|NCT01760226|Drug|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
79861009|NCT01760226|Drug|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
79861010|NCT01760226|Drug|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
79565447|NCT01733030|Drug|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
79565448|NCT01733030|Drug|Seromycin|
79565449|NCT01733043|Drug|Dexmedetomidine|
79565450|NCT01733043|Drug|Placebo|
79565451|NCT01733095|Drug|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
79565452|NCT01733108|Drug|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
79565453|NCT01733108|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
79265479|NCT04882254|Procedure|Normothermic machine perfusion|Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
79861011|NCT01760226|Drug|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
79265480|NCT04882085|Drug|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
79265481|NCT04882085|Drug|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
79265482|NCT04870112|Drug|Durvalumab|Anti-PD-L1 antibody
79265483|NCT04870112|Drug|Cisplatin|Chemotherapy
79265484|NCT04870112|Drug|Carboplatin|Chemotherapy
79565454|NCT01733134|Drug|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
79565455|NCT01733134|Drug|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
79565456|NCT01733173|Procedure|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
79861012|NCT01712490|Drug|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
79861013|NCT01712490|Drug|doxorubicin|Doxorubicin: 25 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
79265485|NCT04870112|Drug|Etoposide|Chemotherapy
79565457|NCT01733199|Other|questionnaires|Summons of patients and filling questionnaire.
79565458|NCT01733290|Drug|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
79565459|NCT01733290|Drug|Normal saline instillation|Normal saline instillation
79265486|NCT04857112|Drug|Low Dose MT-1303|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
79265487|NCT04857112|Drug|High Dose MT-1303|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
79265488|NCT04857112|Drug|Placebo|Matching placebo, QD (Day 1-85)
79265489|NCT04855201|Drug|Bocidelpar|Oral
79265490|NCT04855201|Drug|Placebo|Oral
79265491|NCT04838288|Drug|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
79265492|NCT04827745|Drug|BLINCYTO (Blinatumomab)|Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
79265493|NCT04821739|Device|AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
79265494|NCT04812275|Procedure|Skin closure|Skin closure
79265495|NCT04798027|Biological|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
79265496|NCT04798027|Biological|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
79565460|NCT01733303|Behavioral|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
79565461|NCT01733342|Device|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
79565462|NCT01733342|Procedure|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
79565463|NCT01733342|Device|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
79565464|NCT01733355|Radiation|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
79565465|NCT01733394|Drug|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
79565466|NCT01733394|Drug|lamotrigine|
79565467|NCT01733446|Other|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
79565468|NCT01733459|Drug|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
79565469|NCT01733459|Drug|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
79565470|NCT01733459|Drug|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
79565471|NCT01733459|Drug|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
79565472|NCT01733485|Drug|Aspirin|500 mg/8 h for 5 days
79565473|NCT01733485|Drug|Indomethacin|25 mg/8 h for 5 days
79565474|NCT01733524|Behavioral|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
80022321|NCT03491774|Behavioral|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
80022322|NCT05064644|Other|Product that contains plant stanol ester|Product with active ingredient
80022323|NCT05064644|Other|Placebo product|Product without active ingredient
79565475|NCT01733524|Behavioral|Picture of a fish|Participants will receive a picture of a betta fish.
79265497|NCT04798027|Biological|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
79265498|NCT04798027|Biological|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
80022324|NCT04926272|Drug|18F-92|Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
79565476|NCT01733537|Other|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
79565477|NCT01733537|Behavioral|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
79565478|NCT01733550|Device|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
79565479|NCT01733550|Device|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
79565480|NCT01733550|Device|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
79565481|NCT01733563|Procedure|Soft drink consumption|
80022325|NCT03495518|Other|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
79265499|NCT04796766|Diagnostic Test|High frequency stimulation (HFS)|Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
79265500|NCT04796766|Diagnostic Test|Low-frequency sinusoidal transcutaneous stimulation (sLFS)|Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
79265501|NCT04793880|Behavioral|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
79265502|NCT04793880|Behavioral|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
79565482|NCT01733576|Device|HD-tDCS|
79565483|NCT01733589|Drug|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
79861014|NCT01712490|Drug|bleomycin|Bleomycin: 10 units/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
79861015|NCT01712490|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
80022326|NCT03495518|Other|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
80022327|NCT03495362|Dietary Supplement|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
79565484|NCT01733589|Drug|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
79565485|NCT01733589|Drug|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
79565486|NCT01733589|Other|laboratory biomarker analysis|
79565487|NCT01733589|Other|CT perfusion imaging|
79565488|NCT01733602|Device|transcranial direct current stimulation|
79565489|NCT01733654|Biological|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
79565490|NCT01733667|Device|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
79861016|NCT01712490|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
79861017|NCT01698840|Dietary Supplement|Vitamin D|
80022328|NCT03495362|Other|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
80022329|NCT03493100|Dietary Supplement|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
80022330|NCT03493100|Other|Usual care|The control group will receive treatment according to usual care.
79265503|NCT04788667|Other|A health education programme using a telerehabilitation platform|All patients enrolled in the study will receive information through the tele rehabilitation platform, although the experimental group will have specific training/education whereas the control group will only receive some general recommendations as control/sham
79265504|NCT04778397|Drug|Magrolimab|Administered intravenously (IV).
79265505|NCT04778397|Drug|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
79265506|NCT04778397|Drug|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
79265507|NCT04778397|Drug|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
79265508|NCT04778397|Drug|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
79565491|NCT01733667|Device|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
79726432|NCT04841005|Other|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 * 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
79861018|NCT01698840|Dietary Supplement|Placebo|
79861019|NCT01592968|Other|Cognitive Assessment|Ancillary studies
79861020|NCT01592968|Other|Quality-of-Life Assessment|Ancillary studies
79861021|NCT01592968|Radiation|Stereotactic Radiosurgery|Undergo SRS
79861022|NCT01592968|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
79861023|NCT01563731|Drug|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
80022331|NCT02323412|Drug|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
80022332|NCT02323412|Drug|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
80022333|NCT03493022|Other|Test Granola|50.5 Test Granola
79265509|NCT04778397|Drug|Idarubicin|Administered IV, 12 mg/m^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
79265510|NCT04778397|Drug|Steroidal Eye Drops|Administered per institutional standard during consolidation.
80022334|NCT03493022|Other|Control Granola|54.3 Control Granola
80022335|NCT02323490|Procedure|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
79303975|NCT03108365|Device|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
79303976|NCT03108365|Device|Cotton Gauze|Size: 1 x 1 cm
79581324|NCT01935245|Device|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
79581325|NCT01935245|Device|Conventional extracorporeal circulation|
79861026|NCT01534819|Device|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
79861027|NCT01534819|Procedure|endovascular treament|implantation of a device inserted through an artery
79861028|NCT01525966|Drug|carboplatin|Given IV
79861029|NCT01525966|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
79861030|NCT01525966|Other|laboratory biomarker analysis|Correlative studies
79861031|NCT01487928|Dietary Supplement|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
79861032|NCT01463072|Other|Laboratory Biomarker Analysis|Correlative studies
79861033|NCT01463072|Drug|Nab-paclitaxel|Given IV
79861034|NCT01463072|Other|Questionnaire Administration|Ancillary studies
80022336|NCT02323490|Procedure|without microfractures|standard procedure meniscal repair without augmentation.
80022337|NCT04960514|Diagnostic Test|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
80022338|NCT02323568|Other|Gynecological consultation|
80022339|NCT04537910|Drug|LY3819253|Administered SC.
79265511|NCT04776278|Behavioral|Brief Alcohol Intervention (BAI)|This session includes a discussion related to harm reduction and the participant's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the participant's perception of how much he or she drinks and actual norms, (b) a comparison of the participant's alcohol consumption vs. norms, (c) an estimate of the participant's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
80022340|NCT04537910|Drug|Placebo|Administered SC.
79303977|NCT02628873|Device|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
79565492|NCT01733706|Device|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
79565493|NCT01733706|Other|Standard counseling|standard counseling
79565494|NCT01733719|Procedure|ER plus RFA|
79565495|NCT01733719|Procedure|ER plus APC|2 litres/minute, 70 watts
79861035|NCT01445509|Drug|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
79861036|NCT01445509|Drug|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
79565496|NCT01733771|Other|CAM treatments|CAM treatments last 10-30 minutes
79565497|NCT01733784|Other|Induced central apneas|
79861037|NCT01419561|Drug|Zidovudine|Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
79861038|NCT01419561|Drug|Liposomal Doxorubicin|Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
79861039|NCT01419561|Drug|Valganiclovir|Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
79565498|NCT01733797|Device|Wooden spatula|Lollipop sticks placed between incisors
79861040|NCT01419561|Drug|Rituximab|"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
79861041|NCT01419561|Other|Standard Therapies|Standard of Care drugs
79861042|NCT01419561|Other|Cohort 1|Participants who are infected with KSHV who meet criteria for inflammatory cytokine syndrome (KICS)
80022341|NCT04821362|Device|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
80022342|NCT04821362|Device|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
79565499|NCT01733797|Device|Therabite|Hand held device placed in mouth that exercises the jaw
79565500|NCT01733810|Other|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
79565501|NCT01733823|Radiation|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
79565502|NCT01733836|Drug|Metformin|
79565503|NCT01733836|Drug|placebo|
79565504|NCT01733849|Other|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
79565505|NCT01733849|Other|Data collection|Log books
79565506|NCT01733862|Other|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
79565507|NCT01733875|Drug|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
79565508|NCT01733875|Drug|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
79565509|NCT01733875|Drug|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
79565510|NCT01733875|Drug|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
79565511|NCT01733875|Drug|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
79565512|NCT01733875|Drug|Placebo|A single dose of placebo will be administered orally once a day.
79565513|NCT01733875|Drug|CC-220|CC-220 4 mg will be administered orally once a day
79565514|NCT01733875|Drug|CC-220|CC-220 6 mg will be administered orally once a day
79565515|NCT01733875|Drug|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
79565516|NCT01733901|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
79726433|NCT04841005|Other|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
79726434|NCT02709733|Behavioral|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
79726435|NCT00939484|Other|Pharmacological Study|Correlative studies
79726436|NCT00939484|Drug|Vismodegib|Given PO
79726437|NCT01010217|Drug|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
79726438|NCT01010217|Drug|Fludarabine|40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.
79726439|NCT01010217|Drug|Melphalan|140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
79726440|NCT01010217|Drug|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
79726441|NCT01010217|Drug|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
79861043|NCT01362803|Drug|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
79265512|NCT04776278|Behavioral|Substance-free Activity Session (SFAS)|The SFAS session includes : a) discussion of life goals, b) discussion of associations between alcohol and drug use, goals, and substance-free activities; c) a graph depicting the participant's ratings of the relative importance of various aspects of their life and how their actions in the past week have been consistent with these priorities; d) personalized feedback on recent time allocation to activities across life domains, and a discussion of any changes the participant would like to make; e) feedback on symptoms of stress, anxiety and discussion of adaptive coping strategies; f) discussion of enjoyable substance-free activities and hobbies and substance-free recreational activity suggestions tailored to individual's interests and neighborhood; g) a goal setting exercise for specific behavior change plans; h) a Future Thinking Writing Exercise. Participants will receive weekly text-message based booster prompts for four weeks after their SFAS session.
79303978|NCT02463149|Behavioral|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
79861044|NCT01266642|Radiation|External Beam Radiation Therapy|Undergo HF-WBI
79565517|NCT01733901|Procedure|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
79565518|NCT01733914|Procedure|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
79861045|NCT01266642|Radiation|External Beam Radiation Therapy|Undergo CF-WBI
79861046|NCT01266642|Radiation|Hypofractionated Radiation Therapy|Undergo HF-WBI
79861047|NCT01266642|Other|Laboratory Biomarker Analysis|Optional correlative studies
79861048|NCT01266642|Other|Quality-of-Life Assessment|Ancillary studies
79861049|NCT01266642|Other|Questionnaire Administration|Ancillary studies
80022343|NCT04692584|Behavioral|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
80022344|NCT03109730|Drug|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
79303979|NCT02462993|Drug|Aloe Vera|Local drug delivery of aloe vera gel
79726442|NCT01010217|Procedure|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
79726443|NCT01010217|Drug|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
79726444|NCT01010217|Drug|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
79726445|NCT01010217|Drug|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
79726446|NCT01010217|Drug|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
80022345|NCT03109730|Drug|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
80022346|NCT03109730|Drug|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
79726447|NCT00605488|Procedure|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
79861050|NCT01266642|Radiation|Whole Breast Irradiation|Undergo HF-WBI
79726448|NCT04268212|Dietary Supplement|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
80022347|NCT03109730|Drug|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
80022348|NCT03109730|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
80022349|NCT02323724|Genetic|BRAF V600E mutation by pyrosequencing technique|
80022350|NCT02323802|Behavioral|educational group intervention|
80022351|NCT02323802|Behavioral|prescriptive diet|
79565519|NCT01733914|Other|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
79565520|NCT01733927|Device|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
79565521|NCT01733940|Device|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
79861051|NCT01266642|Radiation|Whole Breast Irradiation|Undergo CF-WBI
80022352|NCT03495206|Drug|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
80022353|NCT04230122|Drug|LY3478006 - IV|Administered IV
80022354|NCT04230122|Drug|LY3478006 - SC|Administered SC
79565522|NCT01733940|Device|Application of a dressing without clorhexidine gluconate|
80022355|NCT04230122|Drug|Placebo - IV|Administered IV
80022356|NCT04230122|Drug|Placebo - SC|Administered SC
79303980|NCT03063333|Other|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
79565523|NCT01733966|Drug|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
80022357|NCT04223024|Drug|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
80022358|NCT04223024|Drug|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
80022359|NCT04202354|Drug|ARO-HSD Injection|single or multiple doses of ARO-HSD by subcutaneous (sc) injections
80022360|NCT04202354|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment, by sc injection
80022361|NCT03491696|Drug|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
79303981|NCT03063333|Other|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
79303982|NCT02935283|Procedure|MRI|MRI, fMRI, 1H MRS, DTI
79303983|NCT02935283|Behavioral|Behavioral|Battery of executive function tasks
79565524|NCT01733966|Drug|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
80022362|NCT04077086|Device|Spectacles|Intervention group children in middle school Years 1 and 2 will receive spectacles at the beginning of the academic year (September 2021). Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone either 22 months (September 2021 to July 2023 for those recruited in Year 2) or 34 months (September 2021 to July 2024 for those recruited in Year 1) of treatment by the endpoint of the trial.
80022363|NCT03492866|Drug|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
80022364|NCT03492788|Other|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
79565525|NCT01733979|Dietary Supplement|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
79565526|NCT01733979|Dietary Supplement|Placebo|Placebo (1g/day)
79565527|NCT01733979|Dietary Supplement|Heme-Iron|Heme-Iron (1g/day)
79565528|NCT01733979|Dietary Supplement|Organic Iron|Organic Iron (1g/day)
79565529|NCT01733992|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
79565530|NCT01733992|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
79565531|NCT01733992|Drug|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
79565532|NCT01733992|Drug|Placebo|Placebo, single and multiple ascending dose
79565533|NCT01734005|Dietary Supplement|Red Ginseng|Red Ginseng (1.4g/day)
79565534|NCT01734005|Dietary Supplement|Placebo|Placebo (1.4g/day)
79726449|NCT04268212|Behavioral|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
79726450|NCT00604006|Drug|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
79726451|NCT00604006|Drug|Placebo|Placebo (lactose in capsules for blinding) once daily
80022365|NCT03492788|Other|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
80022366|NCT03491618|Other|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
80022367|NCT02323958|Other|acupoint stimulation|stimulation is given at acupoints
80022368|NCT02323958|Other|non-acupoint stimulation|stimulation is given at acupoints
80022369|NCT02323958|Other|electrode attached|electrodes are attached to skin
79726452|NCT00604084|Drug|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
79726453|NCT00604084|Drug|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
79565535|NCT01734044|Drug|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
79726454|NCT02691052|Other|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
79861052|NCT01218854|Device|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
79861053|NCT01176006|Procedure|Reduced-intensity hematopoietic stem cell|stem cell transplant
79861054|NCT01176006|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
80022370|NCT02323958|Device|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
79861055|NCT01176006|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
80022371|NCT02324036|Device|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
80022372|NCT02324036|Behavioral|Coached Care|Community health worker provides participation training to patient
80022373|NCT03492710|Biological|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
80022374|NCT02780388|Drug|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
80022375|NCT02780388|Other|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
80022376|NCT02324114|Device|Hsp90|Detect plasma Hsp90α concentration
80022377|NCT03954938|Behavioral|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
80022378|NCT03954938|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
80022379|NCT03954938|Drug|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
80022380|NCT02148120|Drug|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
79399866|NCT02405520|Biological|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
79399867|NCT02356302|Device|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
79565536|NCT01734044|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
79565537|NCT01734057|Drug|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day)
79565538|NCT01734057|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
79565539|NCT01734070|Other|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
79726455|NCT05379478|Diagnostic Test|Laboratory assessment of antibody profiles|Antibody profiles will be determined on submitted plasma samples
79726456|NCT04267042|Drug|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
80022381|NCT02148120|Drug|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
80022382|NCT02148120|Drug|Placebo|
80022383|NCT03543930|Device|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
79726457|NCT04267042|Device|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
79726458|NCT04267042|Device|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
79726459|NCT04266652|Procedure|tooth block|tooth root blocks were used to increase the bone width
79726460|NCT04266652|Procedure|autogenous bone block|autogenous bone block were used to increase the bone width
80022384|NCT03901820|Device|Medication Interaction System of Dr App (SIMDA)|A module for the electronic clinical records allowing detection of the potential drug interactions
80022385|NCT02148198|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
79399868|NCT02356302|Device|MK-2048 IVR|Contains 30 mg MK-2048.
79726461|NCT01217957|Drug|Ixazomib|Ixazomib capsules
79726462|NCT01217957|Drug|Lenalidomide|Lenalidomide capsules
79861056|NCT01176006|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
79861057|NCT01176006|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
80022386|NCT02148198|Dietary Supplement|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
80022387|NCT03495050|Device|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
80022388|NCT03492632|Other|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
80022389|NCT02324192|Other|Ultrasonography|imaging findings
80022390|NCT03491462|Drug|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
79265513|NCT04776278|Behavioral|Relaxation Training (RT)|The clinician will begin by establishing the credibility of the session by providing the participant with the rationale that developing relaxation or mindfulness training strategies can reduce stress and enhance wellness. The clinician will then lead the participant through a diaphragmatic breathing exercise, followed by a progressive muscle RT protocol, and then a brief breath-counting (mindfulness) exercise. The session will conclude with a brief discussion of additional stress and anxiety management strategies (e.g., apps to monitor heartrate and breathing). Participants will be asked about their reaction to the techniques and, if interested, encouraged to commit to a specific plan for practicing these techniques.
79565540|NCT01734083|Device|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
79565541|NCT01734083|Behavioral|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
79565542|NCT01734096|Other|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
79565543|NCT01734096|Drug|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
79565544|NCT01734109|Device|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
79565545|NCT01734135|Other|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
79565546|NCT01734148|Behavioral|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
79726463|NCT01217957|Drug|Dexamethasone|Dexamethasone tablets
79726464|NCT00939094|Drug|AZD2066|Capsule, once daily
79726465|NCT00939094|Drug|Placebo|Capsule, once daily
79726466|NCT04297371|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
79726467|NCT01217801|Drug|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
79726468|NCT01217801|Drug|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
79726469|NCT00935818|Drug|Varenicline|varenicline - 1 mg bid for 12 weeks
79726470|NCT00935818|Drug|placebo|placebo for 12 weeks
79861058|NCT01176006|Procedure|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
79861059|NCT01176006|Procedure|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
79861060|NCT01174108|Device|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
79861061|NCT01174108|Other|Donor derived G-CSF mobilized PBC|Cell Therapy
79861062|NCT01154920|Drug|Paclitaxel|135 mg/m^2 weekly, Weeks 1 - 6
79861063|NCT01154920|Drug|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
79861064|NCT01154920|Drug|Cetuximab|"PCC Arm: 400 mg/m^2 by vein over about 1-2 hours on Day 1; 250 mg/m^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
79303984|NCT02871167|Procedure|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
79399869|NCT02356302|Device|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
80022391|NCT03491462|Drug|Placebo|2 matched placebo capsules taken 3 times daily
79726471|NCT00935818|Drug|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
79726472|NCT01216319|Device|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
79726473|NCT00607516|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
79726474|NCT00607516|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
79726475|NCT04804345|Other|standard of care|retrospective study: standard of care
79726476|NCT02709265|Drug|amikacin/fosfomycin|single aerosolized dose
80022392|NCT02147496|Other|Dietary Intervention|
79399870|NCT02356302|Device|Placebo IVR|
79726477|NCT00611845|Drug|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
79726478|NCT02709499|Device|0J LLLT|perform with the machine off
79726479|NCT02709499|Device|6J LLLT|irradiation will be perform with 4J
80022393|NCT02147574|Procedure|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
80022394|NCT02147652|Other|Personalized music|
80022395|NCT04584554|Behavioral|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
79565547|NCT01734174|Procedure|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
79565548|NCT01734174|Procedure|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
79726480|NCT01216163|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
79726481|NCT01216163|Drug|Acetaminophen|Single-dose of acetaminophen (1000mg)
80022396|NCT02147730|Procedure|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
79861065|NCT01154920|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
80022397|NCT02147730|Procedure|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
80022398|NCT03109808|Other|e-health strategy|"First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
80022399|NCT03109808|Other|Traditional Oral Hygiene Education|traditional oral hygiene education
79861066|NCT01154920|Drug|Cisplatin|100 mg/m^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
80022400|NCT02151630|Drug|Pyruvic acid|
79303985|NCT02871167|Procedure|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
79565549|NCT01734174|Procedure|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
79565550|NCT01734187|Dietary Supplement|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
79726482|NCT01216163|Drug|Placebo|Single-dose of placebo
79726483|NCT05260411|Biological|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
80022401|NCT02151630|Drug|Salicylic Acid|
80022402|NCT03494972|Drug|Tetracyclin ointment|During 3rd molar surgery
79399871|NCT04270461|Biological|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
79565551|NCT01734187|Dietary Supplement|Placebo|Placebo (30g/day)
79726484|NCT05260411|Biological|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
79726485|NCT05260411|Drug|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
79726486|NCT05260255|Drug|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
79726487|NCT05260255|Drug|Placebo|add on placebo ( 2 cap ) for 12 weeks
79726488|NCT00612469|Drug|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
79726489|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
79726490|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
79726491|NCT00612469|Drug|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
79726492|NCT00933244|Dietary Supplement|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
79861067|NCT01154920|Drug|Fluorouracil|700 mg/m^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
79861068|NCT01154920|Radiation|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
80022403|NCT02148354|Behavioral|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
79565552|NCT01734200|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
79265514|NCT04776278|Other|Education Control|This condition will not include any clinical contact other than a brief (2-3 minute) discussion with the research assistant (RA) who completed the assessment session and who will describe the educational handout. This condition is meant to approximate a low-threshold public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or MI/clinical contact. Thus, participants will receive information on risks associated with alcohol and drug misuse, strategies for reducing use/problems, and strategies for managing stress and setting and follow-through with achievable goals. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact.
79565553|NCT01734200|Dietary Supplement|Placebo|Placebo (1.5g/day)
79565554|NCT01734213|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
79265515|NCT04753346|Other|Physical Activity Level|International Physical Activity Questionnaire
79265516|NCT04753346|Other|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
79265517|NCT04753346|Diagnostic Test|Exercise Capacity|6 Minute Walk Test
79565555|NCT01734213|Dietary Supplement|Placebo|Placebo (1.5g/day)
79565556|NCT01734226|Dietary Supplement|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
79265518|NCT04753346|Diagnostic Test|Pulmonary Function Test|Spirometry
79565557|NCT01734226|Dietary Supplement|Placebo|Placebo (3.94g/day)
79565558|NCT01734252|Drug|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
79565559|NCT01734265|Drug|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
79565560|NCT01734265|Drug|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
79565561|NCT01734278|Other|No intervention|This is a non-interventional study.
79565562|NCT01734291|Behavioral|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
79265519|NCT04753346|Diagnostic Test|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
79265520|NCT04753346|Other|Cognitive Assessment|Montreal Cognitive Assessment
79565563|NCT01734304|Biological|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
79565564|NCT01734330|Behavioral|Cognitive behavioral therapy in group|
79565565|NCT01734330|Drug|Nicotine replacement|
79565566|NCT01734343|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
79565567|NCT01734343|Device|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
79265521|NCT04739072|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79265522|NCT04739072|Other|Electronic Health Record Review|Review of medical records
79265523|NCT04707625|Drug|Aflibercept Ophthalmic|Anti-vascular endothelial growth factor intraocular injection
79265524|NCT04702893|Drug|Nintedanib|Nintedanib
79565568|NCT01734356|Other|Skin biopsies|
79726493|NCT00933244|Dietary Supplement|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
79726494|NCT00933244|Dietary Supplement|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
79565569|NCT01734408|Biological|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
79565570|NCT01734408|Biological|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
79565571|NCT01734408|Biological|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
79726495|NCT02709187|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
79726496|NCT02709187|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
79265525|NCT04682405|Drug|Uproleselan|Provided by study
79265526|NCT04682405|Drug|Placebo|Provided by study
79265527|NCT04682405|Drug|Melphalan|-Standard of care
79265528|NCT04671940|Other|DNA Analysis|Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies & subsequent resections
79265529|NCT04663334|Other|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
79565572|NCT01734408|Biological|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
79565573|NCT01734408|Biological|0/0.5ml placebo|0/0.5ml placebo
79565574|NCT01734421|Other|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
79565575|NCT01734421|Device|Cell phone Aplication for Smarth Phone|
79565576|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
79565577|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
79565578|NCT01734447|Drug|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
79565579|NCT01734473|Dietary Supplement|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
79565580|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
79565581|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
79565582|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
79726497|NCT02709187|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
80022404|NCT03494894|Diagnostic Test|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
79399872|NCT05091216|Other|Traditional Chinese Medicine mouthwash|The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.
79399873|NCT05091216|Other|Dilute 50 times of Traditional Chinese Medicine mouthwash|Dilute 50 times of traditional Chinese medicine mouthwash.
79265530|NCT04655313|Drug|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
79399874|NCT02999451|Device|snare-assisted POEM|"POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~The mucosal incision is closed with endoclips."
79726498|NCT02708953|Procedure|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
79726499|NCT02708953|Procedure|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
79399875|NCT02999451|Device|knife-assisted POEM|"POEM is performed by using a conventional endoscopic knife.~After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~The mucosal incision is closed with endoclips."
79399876|NCT02993835|Other|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
79861069|NCT01154920|Other|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
79861070|NCT01038193|Other|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
79399877|NCT02993835|Other|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
79861071|NCT01034670|Device|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
79861072|NCT01034670|Device|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
79861073|NCT01034670|Device|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
79399878|NCT02993835|Other|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
79861074|NCT01034670|Drug|fluorescent Peptide|microdosing; Topical through the endoscope
79861075|NCT01034670|Drug|fluorescein|100 mcg topical
79861076|NCT01034670|Drug|indocyanine green|100 mcg topical
79861077|NCT01019343|Procedure|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
79565583|NCT01734473|Dietary Supplement|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
79565584|NCT01734486|Drug|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
79565585|NCT01734486|Drug|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
79581326|NCT01935258|Other|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
79581327|NCT01935258|Other|care as usual|usual care of the general practitioner
79581328|NCT01935271|Dietary Supplement|Muscle Armor Supplement|
79726500|NCT04262830|Diagnostic Test|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
79726501|NCT04262830|Diagnostic Test|Echocardiography|Echocardiography, heart ultrasound, will be performed in conjunction with cardiac MRI.
80022405|NCT02224573|Drug|GWP42003-P|
80022406|NCT04520750|Drug|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
79277503|NCT05261789|Other|Turkish Get Up exercise|"Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes."
79581329|NCT01935271|Dietary Supplement|Placebo|
80022407|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent [%] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
79565586|NCT01734499|Behavioral|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
79565587|NCT01734499|Behavioral|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
79565588|NCT01734499|Behavioral|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
79565589|NCT01734538|Dietary Supplement|Omega-3 Complete|
79565590|NCT01734538|Dietary Supplement|Placebo capsule|
79565591|NCT01734564|Biological|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
79565592|NCT01734564|Radiation|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
80022408|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
80022409|NCT01360840|Other|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
80022410|NCT01360840|Other|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
80022411|NCT03529292|Device|AmeaCell|Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
80022412|NCT02151708|Drug|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
80022413|NCT02151708|Drug|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
80022414|NCT03490058|Drug|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
80022415|NCT02148432|Drug|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
80022416|NCT02148432|Drug|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
80022417|NCT01976455|Other|20% fewer calories|
80022418|NCT01976455|Other|40% fewer calories|
79265531|NCT04647760|Behavioral|JOIN for ME|JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
79565593|NCT01734577|Procedure|Dry needling|Sterile monofilament needles
79565594|NCT01734577|Procedure|Sham needling|Applicator tubes from the sterile monofilament needles
79565595|NCT01734590|Dietary Supplement|Carbohydrate based food mix 1|Carbohydrate based food
79565596|NCT01734590|Dietary Supplement|Carbohydrate based food mix 2|Carbohydrate based food
79565597|NCT01734590|Dietary Supplement|Control carbohydrate based food|Carbohydrate based food
80022419|NCT03096964|Other|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
80022420|NCT03096964|Other|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
80022421|NCT02151864|Drug|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
80022422|NCT03350984|Drug|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL.
80022423|NCT03350984|Drug|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
80022424|NCT02148510|Device|Monobloc|Construction fitted to upper and lower jaw
80022425|NCT02148510|Device|Bibloc|Biblock construction
80022426|NCT03504423|Drug|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
80022427|NCT03504423|Drug|Folfirinox|Folfirinox
80022428|NCT05053048|Device|SL-PLUS-Stem for total hip arthroplasty|Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
80022429|NCT04461548|Behavioral|Thinking, writing and imagining|All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
80022430|NCT05176717|Drug|QR-421a|RNA antisense oligonucleotide for intravitreal injection
79265532|NCT04643587|Biological|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
79265533|NCT04643587|Drug|Placebo|Normal saline (0.9% NaCl)
79565598|NCT01734603|Procedure|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
79861078|NCT01019343|Device|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
79861079|NCT01019343|Device|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
80022431|NCT05176717|Other|Sham-procedure|Sham-procedure (no experimental drug administered)
79265534|NCT04631016|Biological|MEDI3506|Dose 1
79265535|NCT04631016|Other|Placebo|Dose 1
79265536|NCT04622046|Drug|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
80022432|NCT03097198|Other|Plum-blossom Needle|"acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
79581330|NCT01935297|Behavioral|Exercise|endurance and resistance exercise 3x/week for 8 weeks
79726502|NCT04262830|Diagnostic Test|Electrocardiogram|Measuring conduction abnormalities
79726503|NCT05258929|Other|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
79726504|NCT00930046|Device|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
79726505|NCT00930046|Device|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
80022433|NCT03097198|Drug|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
80022434|NCT02324348|Procedure|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
79265537|NCT04621006|Diagnostic Test|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
79265538|NCT04618653|Other|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
79265539|NCT04613414|Other|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
79265540|NCT04607980|Drug|ABP 654|Participants will receive SC injection of ABP 654.
79265541|NCT04607980|Drug|Ustekinumab|Participants will receive SC injection of ustekinumab.
79726506|NCT05244031|Procedure|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
79726507|NCT05244031|Procedure|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
79726508|NCT05155306|Drug|BI 1358894, intended Commercial Formulation (iCF) (T)|Test Treatment (T)
79399879|NCT05091138|Drug|Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
79861080|NCT01019343|Other|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
79265542|NCT04605146|Behavioral|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
79277504|NCT05261789|Other|Core Stability exercise|"After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied"
79565599|NCT01734603|Procedure|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
79565600|NCT01734616|Behavioral|Old Exercise|
79861081|NCT01019343|Other|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
79861082|NCT01019343|Device|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
80022435|NCT02324348|Procedure|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
80022436|NCT02770248|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
80022437|NCT02770248|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
80022438|NCT05053282|Other|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
80022439|NCT04459130|Behavioral|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
79565601|NCT01734616|Dietary Supplement|Old Acute Cocoa|
79565602|NCT01734616|Dietary Supplement|Old 7 Day Cocoa|
79861083|NCT01019343|Device|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
79861084|NCT01019343|Diagnostic Test|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
80022440|NCT05044390|Procedure|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
80022441|NCT03619005|Drug|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
79565603|NCT01734668|Device|In Vitro Diagnostic device to aid in diagnosis|
80022442|NCT03619005|Drug|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
80022443|NCT02686346|Drug|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
79565604|NCT01734681|Drug|G-202|
79565605|NCT01734707|Dietary Supplement|Allicor|
80022444|NCT02686346|Drug|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
80022445|NCT02686346|Drug|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
80022446|NCT02686346|Drug|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
79565606|NCT01734707|Drug|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
79565607|NCT01734733|Other|NTCELL|
79265543|NCT04574609|Device|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
79265544|NCT04544917|Behavioral|SmartManage for HIV+ cancer survivors|Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
79265545|NCT04544917|Behavioral|Educational Control|Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
79565608|NCT01734759|Drug|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
79565609|NCT01734798|Radiation|Radiation|
79565610|NCT01734798|Drug|gemcitabine and cisplatin|
79565611|NCT01734798|Other|Radiotherapy and Drug|
79565612|NCT01734824|Drug|Denosumab|sc RANKL-inhibitor
79565613|NCT01734824|Drug|Teriparatide|daily subcutaneous injection of teriparatide
79565614|NCT01734824|Drug|Placebo Denosumab|one subcutaneous injection denosumab placebo
79565615|NCT01734824|Drug|Placebo Teriparatide|daily subcutaneous placebo injection
79565616|NCT01734837|Device|DS-Ligature Clip|
79565617|NCT01734863|Radiation|External Beam Radiotherapy|
79565618|NCT01734876|Behavioral|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
79565619|NCT01734876|Behavioral|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
79565620|NCT01734915|Device|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
79565621|NCT01734941|Drug|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
79565622|NCT01734941|Drug|Placebo|
79565623|NCT01734954|Procedure|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
79565624|NCT01734954|Procedure|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
79565625|NCT01734954|Drug|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
79565626|NCT01734954|Device|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
79565627|NCT01734954|Device|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
79565628|NCT01734954|Drug|supplemental oxygen|supplemental oxygen during the block and/or during surgery
79565629|NCT01734954|Drug|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
79565630|NCT01734954|Drug|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
79726509|NCT05155306|Drug|BI 1358894, Trial Formulation 2 (TFII) (R)|Reference Treatment (R)
80022447|NCT03618927|Behavioral|Daily physical activity intervention|
80022448|NCT03489044|Drug|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
80022449|NCT03489044|Drug|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
80022450|NCT02630654|Other|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
80022451|NCT01344369|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
80022452|NCT01344369|Drug|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
79399880|NCT05091138|Drug|Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
79265546|NCT04543279|Drug|Fostamatinib|Fostamatinib will be supplied by Rigel Pharmaceuticals.
79399881|NCT02993679|Procedure|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
79399882|NCT02989818|Other|Endoscopic Submucosal Dissection|This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
79399883|NCT02999295|Biological|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
79399884|NCT02999295|Biological|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
79565631|NCT01734954|Procedure|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
79565632|NCT01734967|Device|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
79265547|NCT04543279|Drug|Ruxolitinib|Ruxolitinib is commercially available.
79265548|NCT04541433|Drug|AZD9833|AZD9833 taken orally
79265549|NCT04540913|Device|RHA 3|Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.
79265550|NCT04540913|Device|Restylane-L|Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.
79265551|NCT04540133|Drug|dexamethasone 0.5mg/5ml solution|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
79265552|NCT04540133|Drug|dexamethasone 0.5mg/5ml solution in Mucolox™|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
79277505|NCT05261789|Other|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
79399885|NCT05094726|Radiation|photobiomodulation|Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying.
79399886|NCT05094726|Other|placebo intervention by photobiomodulation device|placebo intervention while the photobiomodulation device is on the off mode
79399887|NCT05094648|Other|high flow nasal therapy|effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
79399888|NCT02998905|Drug|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
79565633|NCT01734967|Procedure|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
79399889|NCT02998905|Drug|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
79399890|NCT02993367|Drug|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
79399891|NCT02993367|Drug|Placebo Butylphthalide Soft Capsules|
79399892|NCT05094492|Combination Product|Curodont Repair Fluoride Plus|P11-4 self assembling peptide combined with fluoride
79399893|NCT05094492|Other|Bifluorid 10 fluoride varnish|5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
79565634|NCT01734980|Procedure|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
79565635|NCT01735006|Biological|HPV Vaccine|3 doses at month 0,1 and 6
79565636|NCT01735006|Biological|HEV vaccine|3 doses at month 0,1 and 6
79565637|NCT01735019|Drug|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
79399894|NCT01380691|Drug|LY2216684|Administered orally
79399895|NCT01380691|Drug|Placebo-matching LY2216684|Administered orally
79565638|NCT01735045|Device|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
79565639|NCT01735045|Device|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
79265553|NCT04523376|Device|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
80022453|NCT03491306|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
79399896|NCT01380691|Drug|Placebo-matching alcoholic beverage|Administered orally
79265554|NCT04521647|Drug|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
79265555|NCT04520633|Other|biologic initiation|introduction or modification of biotherapy at M0
79265556|NCT04515875|Behavioral|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
79265557|NCT04515875|Behavioral|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
79265558|NCT04494880|Drug|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
79265559|NCT04494633|Other|Clinical Encounters Medical School 3D Simulation|A 3D simulation related to coping with the stresses of medical school and burnout.
79265560|NCT04482816|Device|Physiological pacing|Pacing of the his bundle or the left bundle branch
79861085|NCT01019343|Device|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
79861086|NCT01019343|Procedure|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
79861087|NCT01019343|Other|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
79399897|NCT01380691|Drug|Alcoholic beverage|Administered orally
79565640|NCT01735058|Drug|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
79565641|NCT01735058|Drug|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
79861088|NCT01019343|Procedure|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
79861089|NCT01019343|Procedure|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
79265561|NCT04482816|Device|Right ventricular pacing|Conventional pacing; right ventricular pacing
79265562|NCT04477291|Drug|CG-806|CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
79265563|NCT04456608|Drug|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
79399898|NCT01270893|Drug|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
79399899|NCT05094414|Drug|Valacyclovir|oral valacyclovir 500 mg twice per day for 4 weeks
79399900|NCT02998515|Device|Companion (Liquid oxygen device)|
79565642|NCT01735071|Drug|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
79726510|NCT04262752|Device|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
80022454|NCT03491306|Other|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
80022455|NCT03491072|Device|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
79265564|NCT04436978|Drug|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
79265565|NCT04436978|Drug|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
79861090|NCT01019343|Procedure|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
79861091|NCT01019343|Procedure|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
79861092|NCT01019343|Procedure|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
80022456|NCT03491072|Drug|Fentanyl|Patients will receive IV fentanyl
80022457|NCT03503409|Drug|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
80022458|NCT03490994|Drug|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
79265566|NCT04405349|Biological|VB10.16|Vaccination
79265567|NCT04405349|Biological|Atezolizumab|Intravenously infusion
79265568|NCT04401553|Drug|cephalosporin|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
79265569|NCT04401553|Drug|Second tier antibiotic (Vancomycin)|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
79265570|NCT04393298|Drug|ginisortamab|Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
79265571|NCT04393298|Drug|trifluridine/tipiracil|Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
79265572|NCT04393298|Drug|mFOLFOX6|Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
79399901|NCT02998515|Device|Activox (concentrator)|
80022459|NCT03490994|Drug|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
79399902|NCT01271049|Other|Novel Food Product|Novel food product containing essential oil blend
79399903|NCT01271049|Other|Control Food Product|Control food product
79399904|NCT02998593|Drug|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
79399905|NCT02998593|Drug|Placebo|Oral use of placebo capsules by patients for 3 months.
79565643|NCT01735071|Drug|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
79265573|NCT04372875|Behavioral|SHS-derived CDS|This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
79277506|NCT02364609|Drug|Afatinib Dimaleate|Given PO
79399906|NCT02993289|Other|Different well-known treatments|
79265574|NCT04363853|Drug|Tocilizumab 20 MG/ML|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
79565644|NCT01735084|Biological|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
79565645|NCT01735084|Biological|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
79726511|NCT03823651|Behavioral|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
79726512|NCT03823651|Behavioral|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
79726513|NCT03823651|Behavioral|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
79861093|NCT01019343|Procedure|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
79726514|NCT03823651|Behavioral|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
79726515|NCT04712071|Drug|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
79726516|NCT02708875|Other|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
79265575|NCT04291703|Drug|Antithymocyte Globulin|Thymoglobulin
79265576|NCT04291703|Drug|Placebo (for ATG)|Normal Saline administered by IV infusion to mimic ATG
79265577|NCT04289142|Drug|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
79265578|NCT04284852|Drug|Niraparib|PARP inhibitor
79565646|NCT01735097|Dietary Supplement|Vitamin E|Vitamin E (200 mg, soft capsule)
79726517|NCT02708875|Other|Glucose Challenge|Glucose drink (50g glucose)
79861094|NCT01019343|Procedure|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
79265579|NCT04277104|Other|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
79265580|NCT04277104|Other|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
79565647|NCT01735097|Dietary Supplement|Nigella sativa|Nigella sativa (200 mg, soft capsule)
79565648|NCT01735097|Dietary Supplement|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
79265581|NCT04262596|Other|Interactive Consulting System|Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
79265582|NCT04262596|Other|A traditional patient decision aid brochure|Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
79277507|NCT02364609|Biological|Pembrolizumab|Given IV
79565649|NCT01735110|Procedure|transfemoral intervention (TFI)|
79726518|NCT00609388|Drug|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
79726519|NCT00609388|Other|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
79861095|NCT00950001|Radiation|Stereotactic Radiosurgery|Undergo SRS
79861096|NCT00947531|Drug|Cerebrolysin|
79861097|NCT00947531|Drug|0.9% Saline Solution|
79565650|NCT01735110|Procedure|Transradial intervention|
79861098|NCT00942981|Drug|PET|Brain dopamine D1 and D2/3 receptor regional binding potentials measured by [11C]NNC-112 and [18F]Fallypride PET.
79861099|NCT00941473|Drug|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
80022460|NCT03179462|Dietary Supplement|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
80022461|NCT03179462|Dietary Supplement|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
80022462|NCT03179462|Dietary Supplement|Tofu intake|Each participant will consume 2 ounces of tofu.
79726520|NCT02709031|Drug|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
79565651|NCT01735123|Dietary Supplement|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
79399907|NCT04386447|Drug|Oxytocin|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
79565652|NCT01735136|Dietary Supplement|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
79565653|NCT01735136|Dietary Supplement|Placebo|Placebo (10g/day)
79565654|NCT01735149|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
79565655|NCT01735149|Dietary Supplement|Placebo|Placebo (34.5g/day)
79565656|NCT01735227|Drug|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
79565657|NCT01735227|Drug|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
79565658|NCT01735240|Drug|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
79565659|NCT01735240|Drug|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
79726521|NCT02709031|Drug|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
79565660|NCT01735253|Procedure|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
79726522|NCT05233111|Behavioral|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
79726523|NCT05233111|Behavioral|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
79726524|NCT04262674|Other|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
79265583|NCT04257110|Drug|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
79265584|NCT04243005|Procedure|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
79265585|NCT04243005|Procedure|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
79265586|NCT04236180|Other|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
79265587|NCT04233801|Drug|Empagliflozin|Empagliflozin
79265588|NCT04233801|Drug|Placebo|Placebo
79265589|NCT04227899|Device|Esprit BTK Device|Participants will receive Esprit BTK Device
79265590|NCT04227899|Device|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
79265591|NCT04225039|Drug|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
79265592|NCT04225039|Drug|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
79265593|NCT04225039|Drug|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
79265594|NCT04225039|Procedure|Brain surgery|maximal safe surgical resection of the tumor.
79565661|NCT01735266|Other|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
79565662|NCT01735266|Other|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
79565663|NCT01735292|Device|Automatic Respiration Transfer System- Timer|
79565664|NCT01735318|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
79565665|NCT01735318|Drug|Lisinopril|40 mg tablet once a day
79565666|NCT01735344|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
79565667|NCT01735344|Drug|Lisinopril|40 mg tablet once a day
79565668|NCT01735357|Dietary Supplement|EPA-rich triacylglycerol oil|
79565669|NCT01735357|Dietary Supplement|Placebo - olive oil (BP specification)|
79861100|NCT00881920|Biological|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10^7 cells/m^2 CAR-Kappa~Group 2: 1x10^8 cells/m^2 CAR-Kappa~Group 3: 2x10^8 cells/m^2 CAR-Kappa"
79861101|NCT00855036|Other|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
79861102|NCT00782093|Drug|volociximab|volociximab intravitreal injection
79565670|NCT01735357|Dietary Supplement|DHA-rich triacylglycerol oil|
79565671|NCT01735370|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
79726525|NCT02887937|Drug|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
79726526|NCT00606112|Drug|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
79726527|NCT05232955|Device|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
79265595|NCT04198012|Device|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
79265596|NCT04184843|Other|iWalk Toolkit|"Intervention period: 5 months~Intervention:~A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~Access to a clinical expert by email or phone"
79861103|NCT00766584|Other|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
79861104|NCT00687115|Behavioral|Weight Loss|liquid diet at 50% of weight maintaining intake
79265597|NCT04181333|Drug|TRASTUZUMAB BS|"Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) [Trastuzumab Biosimilar 3] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) [Trastuzumab Biosimilar 3] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes."
79565672|NCT01735370|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
79565673|NCT01735383|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
79565674|NCT01735383|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
79565675|NCT01735409|Drug|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
79861105|NCT00687115|Behavioral|Overfeeding|Overfeeding at 150% of weight maintaining intake
79565676|NCT01735409|Drug|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
79565677|NCT01735409|Drug|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
79565678|NCT01735422|Drug|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
79565679|NCT01735422|Drug|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
79726528|NCT00606190|Procedure|Retrograde brain perfusion|observational
79726529|NCT00606190|Procedure|Antegrade brain perfusion|observational
79861106|NCT00687115|Behavioral|Overfeeding Low Pro|Overfeeding 150% of normal intake at <5% protein
79861108|NCT00673335|Drug|letrozole|
79861109|NCT00673335|Drug|Placebo|
79565680|NCT01735422|Drug|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
79726530|NCT04168957|Drug|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
79861110|NCT00630032|Drug|cyclophosphamide|500 mg/m² every 3 weeks
79861111|NCT00630032|Drug|Docetaxel|100 mg/m² every 3 weeks
79861112|NCT00630032|Drug|epirubicin hydrochloride|100 mg/m² every 3 weeks
79861113|NCT00630032|Drug|fluorouracil|500 mg/m² every 3 weeks
79861114|NCT00630032|Drug|ixabepilone|40 mg/m² every 3 weeks
79861115|NCT00609791|Drug|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
79726531|NCT00935584|Behavioral|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
79565681|NCT01735435|Other|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
79565682|NCT01735448|Other|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
80022463|NCT02031705|Procedure|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
80022464|NCT02031705|Procedure|control group|Control group was performed no additional cavotricuspid isthmus ablation.
79565683|NCT01735448|Other|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
79565684|NCT01735448|Other|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
79565685|NCT01735474|Other|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
79565686|NCT01735474|Other|Placebo|Usual care
79726532|NCT05201443|Device|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
80022465|NCT03618459|Other|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
80022466|NCT02031783|Dietary Supplement|Mixture of glucose and fructose|
79861116|NCT00609791|Other|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
79861117|NCT00609791|Other|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
79861118|NCT00609791|Other|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
79861119|NCT00609791|Other|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
79861120|NCT00609791|Procedure|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
79265598|NCT04130659|Combination Product|MARIAL® + PPI (generic Omeprazole)|"MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28"
79265599|NCT04130659|Drug|PPI alone (generic omeprazole)|Omeprazole administration: 20 mg cps once daily from day 1 to day 28
79565687|NCT01735487|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
79565688|NCT01735487|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
79726533|NCT05201443|Device|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
79726534|NCT00612547|Drug|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
80022467|NCT02031783|Dietary Supplement|glucose|
80022468|NCT01314703|Drug|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
80022469|NCT01314703|Drug|70% isopropyl alcohol|10.5 ml applicator
80022470|NCT03618069|Diagnostic Test|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
79265600|NCT04130659|Device|MARIAL® alone|MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
80022471|NCT01360762|Drug|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
80022472|NCT04382924|Drug|NP-120 (Ifenprodil)|Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
80022473|NCT05034016|Device|High Myopic Posterior Scleral Fixation System|Implant HM into the eye through posterior scleral reinforcement
80022474|NCT05693233|Device|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
79861121|NCT00609791|Procedure|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
80022475|NCT02816996|Procedure|Hand-holding|Subject will have their hand held.
79565689|NCT01735487|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
79565690|NCT01735487|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
79565691|NCT01735487|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
80022476|NCT02816996|Procedure|Stress Ball|Subject will be given a stress ball to hold.
79565692|NCT01735513|Device|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
79565693|NCT01735539|Dietary Supplement|15g EAA bolus|Oral; in aqueous solution
79861122|NCT00569140|Drug|E10030|Intravitreal injection
79861123|NCT00544830|Drug|Bicalutamide|Given PO
79861124|NCT00544830|Drug|Goserelin Acetate|Given SC
79861125|NCT00544830|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79861126|NCT00544830|Other|Laboratory Biomarker Analysis|Correlative studies
79565694|NCT01735539|Dietary Supplement|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
80022477|NCT05439343|Other|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
79861127|NCT00544830|Drug|Leuprolide Acetate|Given via injection
79861128|NCT00534430|Drug|busulfan|
79861129|NCT00534430|Drug|cyclosporine|
80022478|NCT05439343|Other|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
79565695|NCT01735539|Dietary Supplement|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
80022479|NCT03097042|Procedure|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
79565696|NCT01735591|Dietary Supplement|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
79565697|NCT01735591|Dietary Supplement|Probiotic|Capsules with 3x10^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
79565698|NCT01735604|Biological|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
79565699|NCT01735604|Other|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
79565700|NCT01735643|Device|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
79565701|NCT01735643|Other|waiting|waiting for 12 weeks
79861130|NCT00534430|Drug|etoposide|
79861131|NCT00534430|Drug|mycophenolate mofetil|
79565702|NCT01735669|Drug|Remifentanil|
79565703|NCT01735669|Drug|Nitrous Oxide|
79565704|NCT01735682|Device|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
79565705|NCT01735682|Behavioral|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
79565706|NCT01735682|Behavioral|Control|The control treatment involves exercises of the upper limbs.
79565707|NCT01735708|Behavioral|HIVPASS|
79565708|NCT01735708|Other|Health Education|
79581331|NCT01935310|Drug|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
79861132|NCT00534430|Procedure|allogeneic bone marrow transplantation|
79861133|NCT00534430|Procedure|allogeneic hematopoietic stem cell transplantation|
79861134|NCT00534430|Procedure|peripheral blood stem cell transplantation|
79861135|NCT00534430|Radiation|total-body irradiation|
79861136|NCT00492050|Drug|Bortezomib|1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22.
79861137|NCT00492050|Drug|Rituximab|375 mg/m^2 IV on Day 8 and 22.
79861138|NCT00492050|Drug|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
79861139|NCT00456963|Behavioral|Diet|total fat < 5%, saturated fat < 10%, vegetables, fruit
80022480|NCT03097042|Procedure|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
80022481|NCT00002601|Biological|filgrastim|5 ug/kg daily following stem cell reinfusion
80022482|NCT00002601|Drug|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
80022483|NCT00002601|Drug|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
80022484|NCT00002601|Drug|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
80022485|NCT00002601|Drug|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
80022486|NCT00002601|Procedure|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
79861140|NCT00456963|Behavioral|Moderate exercise|30 min at least 5 times/week
79861141|NCT00456963|Drug|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
79565709|NCT01735721|Procedure|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
79861142|NCT00456963|Drug|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
79565710|NCT01735734|Device|Air cooling to CM site|
79861143|NCT00456963|Drug|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
79861144|NCT00418821|Biological|Laronidase|dose of 0.58mg/kg body weight intravenously (IV) every week
80022487|NCT05033704|Drug|5% human plasma protein fraction (PPF)|"Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium)."
80022488|NCT03044431|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
80022489|NCT03618303|Diagnostic Test|PET-MRI scan|Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
80022490|NCT03492320|Other|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
80022491|NCT04335032|Drug|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
80022492|NCT04335032|Drug|Placebo|same as in arm/group description
80022493|NCT03094936|Procedure|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
80022494|NCT03094936|Device|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
80022495|NCT03490526|Device|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
79861145|NCT00280189|Procedure|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
79565711|NCT01735747|Radiation|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
79565712|NCT01735747|Drug|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
79565713|NCT01735747|Drug|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
79565714|NCT01735747|Drug|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
79565715|NCT01735786|Device|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
79565716|NCT01735851|Drug|Thoracic epidural analgesia|
79565717|NCT01735851|Procedure|Bilateral Paravertebral block|
79565718|NCT01735864|Drug|Indirubin 200μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment containing 200 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
79565719|NCT01735864|Drug|Indirubin 100 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 100 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
79565720|NCT01735864|Drug|Indirubin 50 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 50 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
79565721|NCT01735864|Drug|Indirubin 10 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 10 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
79565722|NCT01735890|Drug|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
79581332|NCT01935323|Other|High Intensity Interval Training|
79581333|NCT01935323|Other|Moderate Intensity Training|
79581334|NCT01935362|Dietary Supplement|Citrus supplement|
79581335|NCT01935362|Dietary Supplement|Placebo|
79581336|NCT01935375|Behavioral|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
79581337|NCT01935375|Behavioral|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
79861146|NCT00280189|Behavioral|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
79861147|NCT00280189|Behavioral|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
79861148|NCT00260585|Procedure|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
79565723|NCT01735903|Procedure|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.~Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
79565724|NCT01735968|Drug|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
79861149|NCT00260585|Procedure|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
79861150|NCT00260585|Procedure|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
79565725|NCT01736007|Device|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
79565726|NCT01736007|Device|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
79565727|NCT01736020|Drug|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
79565728|NCT01736020|Drug|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
79565729|NCT01736020|Drug|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
79565730|NCT01736020|Drug|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
79861151|NCT00260585|Procedure|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
79861152|NCT00260572|Behavioral|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
79861153|NCT00260572|Behavioral|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
79861154|NCT00260572|Behavioral|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
79861155|NCT00260572|Behavioral|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
79861156|NCT00260559|Procedure|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
79861157|NCT00177268|Other|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
79861158|NCT00024622|Drug|18F-Fluoro-L-dopa|
79861159|NCT00024622|Drug|O-15 Water|
79861160|NCT00001481|Drug|Estradiol|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
79861161|NCT00001481|Other|Placebo|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
79861162|NCT00001481|Drug|Progesterone|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
79861163|NCT00001379|Biological|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
79861164|NCT00001379|Drug|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
79861165|NCT01897610|Drug|Immuncell-LC|intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour
79565731|NCT01736020|Drug|Placebo|Placebo
79565732|NCT01736033|Drug|Tamsulosin|1 tablet(0.2mg) orally q.d.
79565733|NCT01736033|Drug|Finasteride|1 tablet(5mg) orally q.d.
79565734|NCT01736033|Drug|Placebo|1 tablet(0.2mg) orally q.d.
79565735|NCT01736046|Radiation|CT Enterography|"Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
79565736|NCT01736098|Other|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
79565737|NCT01736111|Behavioral|one way text|
79565738|NCT01736111|Behavioral|Personal feedback|
79581338|NCT01935388|Other|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
79581339|NCT01935440|Behavioral|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
79581340|NCT01935440|Behavioral|Prevention & Testing Control|7 group sessions
79565739|NCT01736137|Other|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
79565740|NCT01736150|Drug|Placebo|"Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
79565741|NCT01736150|Drug|Sevelamer carbonate|"Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
79565742|NCT01736163|Drug|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
79565743|NCT01736163|Drug|131I|28 mCi or ≥ 1.036 GBq.
79726535|NCT04266262|Behavioral|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
79726536|NCT04266262|Behavioral|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
79726537|NCT00606268|Drug|Micafungin|IV
79861166|NCT01895517|Other|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
79861167|NCT01895517|Other|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
79861168|NCT01572532|Other|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
79861169|NCT01439659|Behavioral|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
80022496|NCT03490526|Device|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
80022497|NCT03095014|Procedure|Cesarean Myomectomy|Myomectomy was done during Cesarean section
80022498|NCT03095014|Procedure|Cesarean section|Cesarean delivery
80022499|NCT04247438|Other|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
79565744|NCT01736163|Other|Thyroid Hormone Withdrawal|Stop taking hormone therapy
79565745|NCT01736228|Device|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
79565746|NCT01736280|Other|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
79565747|NCT01736332|Drug|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
79565748|NCT01736332|Other|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
79565749|NCT01736371|Drug|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
79565750|NCT01736371|Drug|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
79565751|NCT01736371|Drug|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
79565752|NCT01736384|Procedure|Gastric bypass or cholecystectomy|
79581341|NCT01935453|Biological|Recombinant hGM-CSF Herpes Simplex Virus Injection|
79581342|NCT01935479|Drug|AK159|transdermal administration of teriparatide acetate
79726538|NCT05194189|Drug|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
79726539|NCT05194189|Drug|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
79726540|NCT05342935|Device|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
80022500|NCT02770170|Drug|BI 655064 dose 1|
79265601|NCT04123847|Other|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
79565753|NCT01736410|Drug|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
79565754|NCT01736423|Drug|YM060|oral
79565755|NCT01736436|Drug|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
79565756|NCT01736436|Procedure|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
79565757|NCT01736436|Procedure|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
79565758|NCT01736449|Drug|Bevacizumab|
79565759|NCT01736462|Drug|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
79565760|NCT01736488|Drug|Fimasartan|Fimasartan 60mg
79565761|NCT01736488|Drug|Atenolol|Atenolol 50mg
80022501|NCT02770170|Drug|BI 655064 dose 2|
79726541|NCT04262518|Device|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
79726542|NCT05342857|Drug|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T&E criteria in Taiwan local consensus
79726543|NCT04264624|Device|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
79726544|NCT04264624|Device|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
80022502|NCT02770170|Drug|BI 655064 dose 3|
80022503|NCT02770170|Drug|Placebo|
79565762|NCT01736501|Other|Genetics education at baseline|
79565763|NCT01736501|Other|Hypothetical genomic scenarios at follow-up|
79565764|NCT01736514|Drug|febuxostat|oral
80022504|NCT03618615|Biological|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
80022505|NCT03490448|Behavioral|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
80022506|NCT02031861|Drug|nifedipine CR tablets (Xin Ran)|
80022507|NCT02031861|Drug|nifedipine CR tablets (Adalat)|
80022508|NCT03617991|Other|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
79265602|NCT04123847|Device|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
79303986|NCT03981549|Biological|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
79565765|NCT01736514|Drug|Allopurinol|oral
79565766|NCT01736605|Procedure|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
79565767|NCT01736605|Procedure|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
79565768|NCT01736644|Device|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
79565769|NCT01736644|Device|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
79565770|NCT01736670|Drug|Triamcinolone Acetonide spray|
79565771|NCT01736670|Drug|Triamcinolone acetonide cream|
79565772|NCT01736670|Drug|Alcohol spray|
79581343|NCT01935479|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
79581344|NCT01935479|Drug|Placebo|Placebo AK159
79726545|NCT05342779|Procedure|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
79726546|NCT00606424|Drug|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
79565773|NCT01736709|Biological|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
79565774|NCT01736722|Device|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
79565775|NCT01736735|Drug|CLP|
79565776|NCT01736735|Drug|placebo|
79565777|NCT01736761|Drug|Darunavir, Ritonavir and Rilpivirine|
79565778|NCT01736774|Other|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
79565779|NCT01736774|Other|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
79565780|NCT01736787|Dietary Supplement|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
79565781|NCT01736787|Dietary Supplement|Placebo|Placebo (1g/day)
79565782|NCT01736800|Drug|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
79565783|NCT01736800|Drug|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
79565784|NCT01736813|Drug|Maraviroc|Twelve patients with 300 mg/bid
79565785|NCT01736826|Biological|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
79726547|NCT04266184|Other|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
79726548|NCT04266184|Other|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
79726549|NCT04266184|Other|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
79265603|NCT04117100|Procedure|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
79265604|NCT04109066|Biological|nivolumab|Specified Dose on Specified days
79726550|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
79265605|NCT04109066|Drug|paclitaxel (PTX)|Specified dose on Specified days
79265606|NCT04109066|Other|nivolumab placebo|Specified dose on Specified days
79265607|NCT04109066|Drug|anthracycline|Specified dose on Specified days
79565786|NCT01736826|Biological|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 & 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
79265608|NCT04109066|Drug|cyclophosphamide|Specified dose on Specified days
79565787|NCT01736826|Biological|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
79265609|NCT04109066|Drug|Endocrine Therapy|Variable endocrine therapy of investigators choice
79565788|NCT01736878|Drug|Sorafenib|
79265610|NCT04109066|Procedure|Surgery|Surgery for breast cancer
79565789|NCT01736891|Drug|Rasagiline|Tablets, qd
79565790|NCT01736891|Drug|Placebo|Tablets, qd
79565791|NCT01736904|Drug|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
79565792|NCT01736904|Drug|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
79565793|NCT01736969|Device|RD047-023|Experimental hydrogel
79565794|NCT01736969|Device|Predicate Device|
79565795|NCT01736982|Behavioral|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
80022509|NCT03938402|Other|Positive end-expiratory pressure|Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
79265611|NCT04098146|Procedure|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
79265612|NCT04097730|Drug|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
80022510|NCT05052424|Diagnostic Test|Analysis of cytokines and immun cell related markers|blood samples
79265613|NCT04097730|Drug|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
79565796|NCT01736982|Other|Standard of Care|Standard smoking cessation counseling
79565797|NCT01736982|Other|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)]
79565798|NCT01736982|Other|Standard of Care|Breath sample monitoring
79565799|NCT01736995|Behavioral|Functional Family Therapy|
79565800|NCT01736995|Behavioral|Motivational Enhancement Tx/Cognitive Behavioral Tx|
79726551|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
79726552|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
79726553|NCT04188691|Biological|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
79726554|NCT04188691|Biological|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
79565801|NCT01736995|Behavioral|Contingency Management|
79726555|NCT04264546|Biological|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
79726556|NCT02691208|Other|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
79726557|NCT02691208|Other|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
79861170|NCT01439659|Dietary Supplement|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
79565802|NCT01737008|Drug|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
79861171|NCT01267448|Drug|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
79861172|NCT01267448|Drug|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
79861173|NCT01267448|Drug|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
79861174|NCT01265030|Drug|Sirolimus|"Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
79303987|NCT03981549|Biological|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does penetrate the bone followed by sham intravitreal injection without penetration of the eye
79565803|NCT01737008|Radiation|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
79565804|NCT01737008|Drug|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
79565805|NCT01737034|Other|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
79565806|NCT01737073|Behavioral|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
79565807|NCT01737073|Behavioral|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
79726558|NCT01215851|Drug|PA-824|200 mg tablet, once daily for 14 days
79726559|NCT01215851|Drug|Pyrazinamide|Dosed by Weight
79726560|NCT01215851|Drug|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
79726561|NCT01215851|Drug|Rifafour|Rifafour e-275
79726562|NCT01215851|Drug|Moxifloxacin|moxifloxacin 400 mg
79726563|NCT05378698|Drug|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
79861175|NCT00901511|Procedure|Baseline WLL|Scheduled bilateral WLL
79861176|NCT00901511|Drug|Sargramostim|Inhaled GM-CSF
79861177|NCT00901511|Procedure|Rescue WLL|Unscheduled bilateral WLL
79726564|NCT00613093|Drug|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
79726565|NCT00933166|Device|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
79726566|NCT03696277|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
79565808|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tip and usual clinical care
79565809|NCT01737086|Dietary Supplement|Lactobacillus reuteri DSM 17938 and zinc sulphate|
79726567|NCT04262362|Procedure|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
79726568|NCT00607750|Drug|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
79861178|NCT00534196|Radiation|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
79861179|NCT00500500|Drug|EGb 761® (Tanakan®)|
79861180|NCT00202813|Device|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
79861181|NCT00117143|Drug|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
79861182|NCT00004180|Drug|rosiglitazone maleate|
79861183|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
79861184|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
79861185|NCT00988494|Drug|Placebo ophthalmic solution|Topical ocular application
79861186|NCT05347290|Device|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
80022511|NCT02645474|Procedure|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
79277508|NCT02202863|Dietary Supplement|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
79277509|NCT05328115|Biological|ALZ-101|Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
79277510|NCT05328115|Other|Placebo|Intramuscular injections of adjuvanted placebo.
79565810|NCT01737086|Dietary Supplement|placebo|
79565811|NCT01737099|Dietary Supplement|DHA-O|
79565812|NCT01737099|Dietary Supplement|Fish oil|
79565813|NCT01737099|Dietary Supplement|Placebo|
79565814|NCT01737112|Drug|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
79565815|NCT01737125|Radiation|Magnetic Resonance Imaging (MRI)|"spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
79565816|NCT01737138|Procedure|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
79565817|NCT01737138|Drug|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
79565818|NCT01737151|Radiation|stereotactic body radiation therapy|Undergo SBRT
79565819|NCT01737151|Radiation|four fraction split-course SBRT|four fraction split-course SBRT
79565820|NCT01737164|Behavioral|Aerobic Exercise|
79726569|NCT00607750|Drug|Placebo|Placebo eyedrops, BID, 48 weeks
79726570|NCT04262050|Device|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
79726571|NCT05271955|Device|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
79726572|NCT05271955|Behavioral|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
79726573|NCT00609544|Drug|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
79726574|NCT04908475|Drug|Risankizumab|Subcutaneous injection
79726575|NCT04908475|Drug|Apremilast|Oral Tablets
79399908|NCT04386447|Drug|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%~Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~Prophylaxis for deep vein thrombosis~Steroids are not routinely recommended but may be considered in selected patients."
79399909|NCT02993133|Drug|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
79399910|NCT02993055|Drug|Ulimorelin|
79565821|NCT01737177|Drug|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~Bendamustine: 70 mg/m2 on day 2 and 3 every 28~Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
79565822|NCT01737190|Other|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
79565823|NCT01737203|Drug|Viagra|50 mg tablet on Day 1 of each period
79399911|NCT02993055|Other|Placebo|
79565824|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
79265614|NCT04097730|Drug|Riboflavin Ophthalmic|All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
79565825|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
79265615|NCT04097730|Other|Topical Placebo|Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
79565826|NCT01737216|Drug|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
79565827|NCT01737216|Drug|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
79265616|NCT04075136|Drug|Ranibizumab|Intravitreal injection 0.5 MG Per 0.05 ML Injection.
79265617|NCT04075136|Device|Photodynamic laser treatment (PDT)|PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
79265618|NCT04075136|Drug|Triamcinolone Acetonide|Intravitreal injection of 0.5ml-2mg
80022512|NCT02645474|Procedure|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
79265619|NCT04075136|Drug|verteporfin|Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
79265620|NCT04069897|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
79399912|NCT02992977|Biological|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
79399913|NCT02114814|Behavioral|Diabetes self-management program for Hispanics and their families|The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
79565828|NCT01737229|Device|Application of Biodentine™ (RD94), dentin substitute|
79565829|NCT01737294|Drug|Qutenza exposure|Cutaneous patch
79565830|NCT01737307|Drug|Fluoride varnish|Fluoride Varnish (NaF 5%)
79565831|NCT01737307|Other|Oral Hygiene|Oral hygiene followed.
79565832|NCT01737307|Drug|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
79565833|NCT01737320|Drug|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~Intervention group - antibiotic treatment stopped on day 7~Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
79565834|NCT01737320|Drug|accepted prolonged antibiotic treatment|
79565835|NCT01737346|Drug|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
80022513|NCT02645474|Drug|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
80022514|NCT05052814|Other|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
79726576|NCT04261816|Procedure|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
79565836|NCT01737359|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
79726577|NCT04261816|Procedure|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
79265621|NCT04069897|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
79726578|NCT05127070|Device|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
79726579|NCT04611139|Drug|SP-2577|Daily oral doses
79726580|NCT04611139|Drug|Pembrolizumab|200mg Q3W by IV infusion
79726581|NCT00935272|Device|Restylane®|Restylane® injections in the lips
79726582|NCT00935272|Device|Non-Treatment|Non- Treatment
79861187|NCT05347290|Device|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
80022515|NCT05052814|Other|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
80022516|NCT05052814|Other|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
79565837|NCT01737359|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
79565838|NCT01737359|Drug|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
79726583|NCT04570501|Drug|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
79726584|NCT04570501|Drug|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
79726585|NCT04114747|Other|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
79861188|NCT05347290|Device|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
79265622|NCT04069156|Device|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
79265623|NCT04069156|Drug|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
79265624|NCT04069156|Drug|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
79265625|NCT04059042|Behavioral|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
79265626|NCT04033328|Drug|ORIC-101|ORIC-101 once daily in each 28-day cycle
79265627|NCT04033328|Drug|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
79726586|NCT00607906|Drug|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
79726587|NCT00607906|Drug|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
79726588|NCT00607906|Drug|Placebo|Subjects will also receive placebo capsules.
79726589|NCT02692963|Biological|BCG vaccination|BCG vaccine InterVax
79726590|NCT04266106|Drug|SuperBio probiotic|One capsule po BID for 28 days
79861189|NCT00539994|Drug|retapamulin|200mg BID retapamulin 3 days
79861190|NCT00539994|Drug|Retapamulin|200mg BID retapamulin 5 days
79861191|NCT00539994|Drug|Placebo|200mg BID placebo 5 days
79565839|NCT01737385|Procedure|Measurement with O2C|Measurement of microcirculation using O2C light probes.
79565840|NCT01737411|Drug|solifenacin|
79565841|NCT01737411|Procedure|cesa/vasa|surgical repair of USL
79565842|NCT01737424|Drug|LC28-0126|LC28-0126
79565843|NCT01737424|Drug|Placebo|Placebo
79565844|NCT01737437|Drug|group C|0.9% normal saline was applied to trachea and laryngoscope blade
79565845|NCT01737437|Drug|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
79565846|NCT01737437|Drug|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
79565847|NCT01737437|Drug|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
79565848|NCT01737450|Drug|BKM120|
79726591|NCT04266106|Drug|Placebo|One capsule po BID for 28 days
79861192|NCT05711706|Other|Su Jok Application|Su Jok massage appplication
79399914|NCT02114814|Behavioral|General health educational program for Hispanics and their families|The attention control group received 8-weekly education program on general health information
79861193|NCT04004676|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
79399915|NCT01380535|Drug|ECP Methoxsalen|Methoxsalen delivered by ECP
80022517|NCT03615417|Device|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
80022518|NCT03615417|Device|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
79726592|NCT04264468|Combination Product|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
79726593|NCT05198791|Drug|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
79861194|NCT04004676|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
80022519|NCT03490370|Device|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
79861195|NCT05711550|Device|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
80022520|NCT02155530|Drug|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
79861196|NCT05711550|Device|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
79861197|NCT04005222|Drug|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
79861198|NCT04005222|Drug|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
79861199|NCT05711472|Other|birth ball exercise|birth ball exercise used in childbirth
80022521|NCT02155530|Drug|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
80022522|NCT03617835|Drug|Spesolimab|single-dose
79399916|NCT01380535|Drug|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
79399917|NCT00725361|Drug|Ambrisentan|
79399918|NCT05721612|Other|Flapless transcrestal sinus lift approach with TPRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.
79399919|NCT05721612|Other|Flapless transcrestal sinus lift approach with PRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
79399920|NCT04385979|Other|Gel|containing herbal Curcumin or NanoCurcumin
79399921|NCT05094024|Dietary Supplement|Central kitchen-prepared version of MDCF-2|Kitchen-prepared MDCF-2 containing chickpea flour, peanut flour, soybean flour, green banana pulp, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be freshly prepared in central kitchens on a daily basis and provided to participants on the same day. Every child in this arm will be offered 25g of the MDCF-2 formulation twice daily.
79565849|NCT01737463|Procedure|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
79565850|NCT01737476|Procedure|Transcranial Magnetic Stimulation. PFC|
79565851|NCT01737489|Behavioral|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
79399922|NCT05094024|Dietary Supplement|MDCF-2 shelf-stable foil pouch prototype with green banana powder|This shelf-stable foil pouch prototype of MDCF-2 contains chickpea flour, peanut flour, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix, prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 21.77g of the formulation twice daily.
79399923|NCT05094024|Dietary Supplement|MDCF-2 shelf-stable foil pouch prototype with sweet potato|This shelf-stable MDCF prototype contains chickpea flour, peanut flour, soybean flour, sweet potato, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 23.34g of the MDCF formulation twice daily.
79399924|NCT05094024|Dietary Supplement|Freshly reconstituted MDCF-2 ingredients|This version of MDCF-2 is comprised of its individually packaged ingredients. Separate premeasured sachets of chickpea flour, peanut paste, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix will be combined and reconstituted prior to each feeding session. Every child in this arm will be offered 21.72g of the formulation twice daily.
79565852|NCT01737489|Behavioral|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
79565853|NCT01737515|Other|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
79565854|NCT01737541|Drug|Fluoxetine|
79861200|NCT04441710|Other|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
79861201|NCT01563744|Procedure|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
79861202|NCT01563744|Procedure|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
79861203|NCT00098839|Drug|L-asparaginase|Given IM
79861204|NCT00098839|Drug|doxorubicin hydrochloride|Given IV
79861205|NCT00098839|Drug|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
79861206|NCT00098839|Drug|vincristine sulfate|Given IV
79861207|NCT00098839|Biological|epratuzumab|Given IV
79265628|NCT04033003|Behavioral|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
79265629|NCT04019015|Drug|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
79265630|NCT04019015|Drug|Placebo|Normal saline solution
79265631|NCT04013555|Drug|N-acetylcysteine (NAC)|Flavored effervescent formulation
79265632|NCT04013555|Drug|Placebo|Flavored effervescent formulation designed to mimic NAC
79265633|NCT04013555|Drug|Tryptophan|Oral slurry form
79565855|NCT01737541|Drug|Placebo|
79565856|NCT01737554|Other|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
79565857|NCT01737580|Drug|resiquimod|
79565858|NCT01737580|Drug|placebo gel|
79565859|NCT01737606|Device|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
79565860|NCT01737632|Behavioral|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
79565861|NCT01737632|Behavioral|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
79565862|NCT01737658|Other|Exercise Program|Exercise Program for Obese Adolescents
79265634|NCT03980314|Drug|Nivolumab|Specified dose on specified days
79565863|NCT01737671|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
79565864|NCT01737671|Drug|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
79565865|NCT01737671|Drug|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
79565866|NCT01737723|Device|Neurokeeper stroke detector|Monitoring stroke patients
79565867|NCT01737736|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
79565868|NCT01737749|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
79861208|NCT00098839|Drug|cytarabine|Given IT
79861209|NCT00098839|Drug|prednisone|Given orally
79861210|NCT00098839|Drug|pegaspargase|Given IM
79861211|NCT00098839|Drug|dexrazoxane hydrochloride|Given IV
79861212|NCT00098839|Drug|methotrexate|Given IT
79861213|NCT00098839|Drug|etoposide|Given IV
79861214|NCT00098839|Drug|cyclophosphamide|Given IV
79861215|NCT00098839|Drug|leucovorin calcium|Given IV
79861216|NCT00098839|Biological|filgrastim|Given SC
79861217|NCT02531191|Drug|peficitinib|oral
79399925|NCT05094024|Dietary Supplement|Ready-to-use supplementary food (RUSF) arm|Locally-produced ready-to-use supplementary food (RUSF) is used as part of a nutritional program to treat moderate acute malnutrition in children over 6 months-of-age. RUSF is eaten directly from the package with no dilution, mixing or cooking. RUSF contains rice, lentil, powdered low-fat milk, soybean flour, sugar, and micronutrient mix. Every child in this arm will be offered 25g of the formulation twice daily.
79399926|NCT02816424|Behavioral|Teens Exploring and Managing Prevention Options (TEMPO)|
79399927|NCT01275885|Dietary Supplement|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
79399928|NCT01275885|Dietary Supplement|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
79399929|NCT01275885|Dietary Supplement|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
79265635|NCT03979781|Drug|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
79399930|NCT01380379|Behavioral|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
79399931|NCT02794896|Drug|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
79399932|NCT02794896|Drug|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
79265636|NCT03979781|Drug|standard of care|antiplatelet selection using standard of care
79265637|NCT03976843|Drug|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
79399933|NCT01271283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79399934|NCT01271283|Drug|Lenalidomide|Given orally
79861218|NCT01087177|Other|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
79265638|NCT03967470|Biological|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
79265639|NCT03958630|Drug|11C-ER176|PET biomarker for inflammation
79265640|NCT03958630|Drug|11C-PIB|PET biomarker for amyloid
79265641|NCT03956680|Drug|BMS-986301|Specified dose on specified days
79399935|NCT02985307|Behavioral|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
79399936|NCT02985307|Behavioral|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
79399937|NCT05090670|Other|Incrediwear Germanium-Embedded Knee Brace following Knee Arthroscopy|Germanium-Embedded Knee Brace will be applied to the effected limb following Knee Arthroscopy
79399938|NCT05090670|Other|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following Knee Arthroscopy
79399939|NCT05376618|Other|no intervention|no intervention
79399940|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
79565869|NCT01737775|Procedure|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
79565870|NCT01737788|Procedure|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
79565871|NCT01737801|Procedure|Lung function test|Lung function test.
79565872|NCT01737814|Drug|Saline|
79565873|NCT01737814|Drug|MST-188|
80022523|NCT03933254|Diagnostic Test|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
79265642|NCT03956680|Biological|Nivolumab|Specified dose on specified days
79399941|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
79399942|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single sc injection
79399943|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
79399944|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
79399945|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single sc injection
79399946|NCT01271439|Drug|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
79399947|NCT01271517|Drug|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
79265643|NCT03956680|Biological|Ipilimumab|Specified dose on specified days
79265644|NCT03955146|Drug|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
79265645|NCT03955146|Drug|Placebo|Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
79265646|NCT03952078|Drug|CPI-818|Interleukin-2 inducible T-cell Kinase Inhibitor
79265647|NCT03940560|Device|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
79399948|NCT01271517|Drug|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
79399949|NCT01271517|Drug|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
79399950|NCT05090592|Device|orthokeratology|orthokeratology wearing for myopia control
79399951|NCT05090592|Drug|0.01 atropine|0.01% atropine eye drop prevent myopic progression
79399952|NCT02992665|Drug|Ca Ionophore A23187|Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
79399953|NCT02992665|Other|Placebo|Placebo is used to control Ca ionophore group
79265648|NCT03928314|Drug|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
79399954|NCT05082636|Other|Observational Study ( Tissue Biopsy )|control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
79399955|NCT02992353|Procedure|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
79399956|NCT02992353|Procedure|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
79399957|NCT05093478|Drug|Intranasal capsaicin|Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
79399958|NCT05093478|Drug|topical lidocaine|The nose will be pre-treated with topical lidocaine 15 minutes before each application
79565874|NCT01737853|Drug|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
79565875|NCT01737853|Drug|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
79565876|NCT01737866|Drug|AMG 423|omecamtiv mecarbil
79565877|NCT01737918|Procedure|TOT|
79565878|NCT01737918|Drug|solifenacin|
79565879|NCT01737957|Device|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
79861219|NCT01081639|Drug|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
79861220|NCT01081639|Drug|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
79861221|NCT01081717|Drug|systemic non-biological treatments|as prescribed
79265649|NCT03928314|Drug|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
79265650|NCT03925987|Behavioral|Exposure therapy|10 weekly sessions of group-based exposure therapy
79265651|NCT03924869|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT
79265652|NCT03924869|Biological|Pembrolizumab|IV infusion
79265653|NCT03924869|Drug|Placebo|IV infusion
79565880|NCT01737957|Device|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
79565881|NCT01737983|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10^10 colony-forming units) for 6 months.
79565882|NCT01737983|Dietary Supplement|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
79565883|NCT01738022|Other|Administration of gas mixtures|
79565884|NCT01738035|Drug|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
79565885|NCT01738035|Other|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
79565886|NCT01738048|Procedure|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
79565887|NCT01738061|Behavioral|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
79265654|NCT03916185|Biological|RSV ΔNS2/Δ1313/I1314L Vaccine|10^6 plaque-forming units (PFU); administered as nose drops
79265655|NCT03916185|Biological|RSV 6120/ΔNS2/1030s Vaccine|10^5 plaque-forming units (PFU); administered as nose drops
79265656|NCT03916185|Biological|RSV 276 Vaccine|10^5 plaque-forming units (PFU); administered as nose drops
79265657|NCT03916185|Biological|Placebo|Administered as nose drops
79265658|NCT03913078|Behavioral|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
79265659|NCT03913078|Behavioral|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
79265660|NCT03908788|Device|Intplex test|Blood sample at each tumor assessment
79265661|NCT03893682|Drug|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
79277511|NCT02367651|Drug|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
79277512|NCT02367651|Drug|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
79399959|NCT01380145|Biological|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
79565888|NCT01738074|Biological|trivalent rotavirus genetic reassortment vaccine|
79565889|NCT01738074|Biological|Placebo|
79565890|NCT01738087|Drug|NEXThaler 100/6 mcg DPI|
79565891|NCT01738087|Drug|Flixotide Accuhaler 500 mcg|Active comparator
79565892|NCT01738087|Drug|NEXThaler 200/6 mcg DPI|
79565893|NCT01738087|Drug|NEXThaler placebo|Placebo comparator
79565894|NCT01738100|Drug|Ticagrelor|
79565895|NCT01738100|Drug|Clopidogrel|
79565896|NCT01738100|Drug|Morphine Sulfate|
79565897|NCT01738100|Drug|Saline|
79861222|NCT01081717|Biological|anti-TNF biologics|as prescribed
79861223|NCT01081717|Biological|golimumab|as prescribed
79399960|NCT05376072|Other|Electromyographic Biofeedback|"The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial."
79565898|NCT01738113|Other|Open Kinetic Chain exercise|"Hamstrings strengthening exercise~Quadriceps strengthening exercise~Hamstrings stretch~Hip extensors and abductors strengthening~Calf-muscles stretching~Strength exercise of ankle dorsiflexors & plantar flexors"
79565899|NCT01738113|Other|Closed kinetic chain exercise|"Foot sliding from sitting~Seated Toe Raises~Hamstrings and quadriceps co-contraction from sitting~Bridging exercise~Sitting-to-standing~Side-to side, forward and backwards weight shifting~Lunge exercise~Squatting exercise~Standing Toe Raises~Standing Hamstrings Stretch"
79726594|NCT05198791|Other|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
79726595|NCT04261660|Other|NO intervention|NO INTERVENTION
79726596|NCT01010061|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
79726597|NCT01010061|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
79861224|NCT01081717|Biological|non-anti-TNF biologics|as prescribed
79861225|NCT01081717|Other|general population|non-treated cohort
79265662|NCT03869970|Behavioral|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
79861226|NCT03963973|Drug|RDN-929 oral capsule|low, medium and high dose
79861227|NCT03963973|Drug|Placebo oral capsule|matching placebo dose
79265663|NCT03869970|Behavioral|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
79265664|NCT03869970|Behavioral|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
79399961|NCT05695170|Behavioral|PreventT2 (Individual intervention)|"PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has full recognition from the CDC based on outcome data over the course of a number of years."
79399962|NCT05695170|Behavioral|PreventT2 Together (Couple-based intervention)|PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
79399963|NCT05367193|Procedure|pars plana vitrectomy|pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
79399964|NCT05367193|Device|NGENUITY® 3D Visualization System (Alcon, TX, USA)|Injection of ICG to stain internal limiting membrane
79399965|NCT00725751|Biological|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
79861228|NCT01085305|Behavioral|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
79861229|NCT01085305|Behavioral|TAU|Usual treatment for behavioral disorders
80022524|NCT05043844|Device|abdominal binder|Wearing an abdominal binder postoperatively
80022525|NCT03845738|Device|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
80022526|NCT05051956|Drug|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
80022527|NCT02769858|Device|Light therapy|Light therapy glasses
79399966|NCT00725751|Drug|Ribavirin|Ribavirin administered according to European labeling.
79399967|NCT05364385|Drug|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
79399968|NCT05364385|Drug|Infants in the control group (S/P group) receive placebo (Normal saline 1mL)|Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
79399969|NCT00726375|Drug|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
79399970|NCT05368597|Procedure|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
79565900|NCT01738152|Other|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
79581345|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"st line:~Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~Bevacizumab until PD or unacceptable toxicity~At PD patients will go to the 2nd treatment line.~nd line:~Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
79265665|NCT03860168|Other|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
79265666|NCT03854058|Diagnostic Test|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
79265667|NCT03816891|Drug|vixarelimab|solution for injection
79265668|NCT03816891|Drug|Placebo|solution for injection
79265669|NCT03800121|Biological|Blood samples|"Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)"
79265670|NCT03740113|Behavioral|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
79399971|NCT01276275|Drug|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
79399972|NCT00710931|Device|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
79399973|NCT05363059|Drug|Hypoglycemic drugs|drug
80022528|NCT03490214|Device|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
79726598|NCT01010061|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
79726599|NCT00607984|Drug|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
80022529|NCT05051488|Procedure|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
80022530|NCT05051488|Device|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
80022531|NCT02152020|Behavioral|Survey|
79265671|NCT03736993|Other|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
79265672|NCT03719924|Drug|Onivyde|onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
79265673|NCT03719924|Drug|Paclitaxel|Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
79399974|NCT05363059|Procedure|Bariatric surgery|surgery
79399975|NCT01271595|Other|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
79399976|NCT03420222|Drug|AVP-786|oral capsules
79399977|NCT03420222|Drug|Placebo|oral capsules
79399978|NCT04766593|Other|Oncological functional reeducation program|"It will consist of the following actions:~Prescription of multimodal physical exercise.~Retraining in activities of daily living."
79399979|NCT04386291|Behavioral|Anxiety Reduction Training|Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
79399980|NCT04386291|Behavioral|Kundalini Yoga and Anxiety Reduction Training|Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
79399981|NCT04386291|Behavioral|Meditation and Anxiety Reduction Training|Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
79265674|NCT03713879|Device|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
79265675|NCT03713879|Drug|Indomethacin|rectally administered indomethacin before or after ERCP
79265676|NCT03713775|Other|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
79399982|NCT01394185|Drug|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
79399983|NCT01394185|Drug|Placebo|Participants receive placebo
79399984|NCT01394185|Drug|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
79565901|NCT01738152|Behavioral|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
79565902|NCT01738178|Drug|Caffeine|
79565903|NCT01738178|Drug|Placebo|
79565904|NCT01738217|Procedure|Fluobeam|
79565905|NCT01738243|Drug|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
79565906|NCT01738243|Drug|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
79265677|NCT03713775|Other|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min), together with supporting written information.
79265678|NCT03687359|Other|Standard of care|Treatment as per standard practice
79399985|NCT05032014|Other|M9|one times a day during the whole treatment
79399986|NCT05032014|Other|placebo|placebo
79399987|NCT00711711|Other|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
79565907|NCT01738256|Behavioral|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
79565908|NCT01738256|Behavioral|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
79565909|NCT01738256|Behavioral|No intervention|No intervention
79565910|NCT01738282|Drug|Baclofen|
79565911|NCT01738282|Drug|Placebo (for baclofen)|
79565912|NCT01738295|Drug|Donepezil administration|
79565913|NCT01738295|Drug|Placebo administration|
79265679|NCT03679598|Drug|Alvelestat (MPH966)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
79265680|NCT03679598|Other|Placebo|Placebo is a pill or tablet that does not contain any study drug.
79265681|NCT03655015|Procedure|Lung Tumor Resection|Lung Tumor Resection
79265682|NCT03635788|Drug|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
79265683|NCT03635788|Drug|Oral RPV|RPV 25 mg tablets
79265684|NCT03635788|Drug|Oral CAB|CAB 30 mg tablets
79265685|NCT03635788|Drug|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
79265686|NCT03635788|Drug|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
79399988|NCT00711711|Other|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
79399989|NCT05030376|Dietary Supplement|intraileal infusion|intraileal glucose or intraileal saline infusion
79399990|NCT04039165|Behavioral|PP-MI Intervention|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
79399991|NCT04000399|Behavioral|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
79399992|NCT01677936|Other|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
79265687|NCT03635788|Drug|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
79265688|NCT03635788|Drug|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
80022532|NCT05051800|Behavioral|Online Program to Support Coping and Communication in Families|Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
79265689|NCT03597620|Drug|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
79399993|NCT01677936|Other|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
79399994|NCT05089110|Procedure|blood sample|5 cm blood sample from COVID-19 patients
79399995|NCT04361851|Drug|Pembrolizumab|Experimental
79399996|NCT04352179|Behavioral|Virtual Education Simulation|"The simulations will be developed using Kognito's proprietary Conversation Platform.~In this pilot study, the simulations will be a bundle of four topic-based conversations with Linda, a virtual peer with a chronic disease. The four wellness topics are:~Fitness & Nutrition~Smoking Cessation~Alcohol Use~Distress & Anxiety"
79726600|NCT04019353|Genetic|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
79726601|NCT00609778|Device|LUCAS|Mechanical chest compression
79861230|NCT01085383|Drug|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
79861231|NCT03811093|Device|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
79265690|NCT03562494|Biological|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
79265691|NCT03562494|Other|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
79399997|NCT04407715|Procedure|The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater|The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
79399998|NCT00727857|Drug|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
79399999|NCT00727857|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
79726602|NCT00609778|Other|Conventional manual resuscitation method|Manual compression
79861232|NCT03811093|Device|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
79861233|NCT01087255|Device|Electronic Pillbox Monitoring System|Daily exposure for six months
79265692|NCT03560323|Drug|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
79400000|NCT00727857|Drug|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
79400001|NCT05361421|Drug|Intensive targeting group|Intensive lipid lowering therapy with LDL-cholesterol goal of <55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
79726603|NCT05143801|Device|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
79861234|NCT01087411|Behavioral|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
79861235|NCT01087411|Behavioral|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
79861236|NCT01087411|Dietary Supplement|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
80022533|NCT05051410|Procedure|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
79400002|NCT05361421|Drug|Conventional therapy group|Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
79400003|NCT05095194|Procedure|Cataract surgery with IOL implantation and with/without capsular tension ring implatation|Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation
79400004|NCT00217165|Drug|taurine|taurine 2mg BID po
79400005|NCT04537728|Behavioral|My Healthy Brain Version 2|multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
79861237|NCT01087411|Dietary Supplement|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
79265693|NCT03531463|Procedure|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
79265694|NCT03529565|Procedure|Biospecimen Collection|Undergo collection of blood
79265695|NCT03529565|Other|Laboratory Biomarker Analysis|Correlative studies
79861238|NCT00485589|Drug|Methotrexate|Oral repeating dose
79400006|NCT05092152|Drug|Esketamine hydrochloride|2 mg per kilogram of body weight
79400007|NCT05092152|Drug|Propofol|1.5 mg per kilogram of body weight
79565914|NCT01738308|Procedure|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
79565915|NCT01738308|Procedure|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
79565916|NCT01738334|Behavioral|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
79565917|NCT01738334|Behavioral|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
79565918|NCT01738347|Drug|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
79726604|NCT05143801|Device|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
79726605|NCT05143801|Other|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
79861239|NCT00485589|Drug|Ocrelizumab|Intravenous repeating dose
79861240|NCT00485589|Drug|Placebo|Intravenous repeating dose
79861241|NCT01014273|Procedure|Percutaneous Coronary Intervention|
80022534|NCT02769624|Drug|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
80022535|NCT02769624|Drug|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
79265696|NCT03529565|Other|Quality-of-Life Assessment|Ancillary studies
79400008|NCT05081700|Drug|All patients in the study will be treated with ocrelizumab|300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
79726606|NCT05143801|Other|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
79726607|NCT00929734|Drug|Rosuvastatin|10mg tablets, once daily in three months
79726608|NCT00929734|Drug|Placebo|1 tablet, once daily in three months
79726609|NCT05378542|Behavioral|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
79265697|NCT03529565|Other|Questionnaire Administration|Ancillary studies
79265698|NCT03495180|Other|Standard EEG or SSEP|The gamma frequency range (30 -100 Hz) of standard EEG or somatosensory evoked potential (SSEP) correlate with intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
79400009|NCT05019066|Dietary Supplement|Herbal Supplementation|A proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa.
79726610|NCT04251676|Other|Observational study|Observational study
79726611|NCT04248634|Procedure|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
79861242|NCT01018797|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
79861243|NCT01015599|Behavioral|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
79861244|NCT00490971|Drug|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
80022536|NCT02228954|Procedure|Molecular imaging|
79565919|NCT01738360|Drug|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~Pre-inclusion between D-35 and D-15~Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~A telephone contact between D32 and D34~A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
79726612|NCT00609856|Drug|pioglitazone|tablet, 30 mg, once daily, 26 weeks
79565920|NCT01738373|Drug|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
80022537|NCT05032924|Combination Product|PPR group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy) (3000 impulse, each point, 24 KV, 0.32 mJ/mm2) one week after PRP or HA injection
79861245|NCT00490971|Drug|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
80022538|NCT05032924|Combination Product|PPR group without ESWT|PRP or HA injection only
79565921|NCT01738399|Dietary Supplement|Coffee|
79726613|NCT00609856|Drug|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
79726614|NCT02873169|Other|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
79726615|NCT05116813|Drug|Dipraglurant|Oral 50 mg and 100 mg tablet
79726616|NCT04527757|Procedure|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
79861246|NCT00490971|Drug|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
79861247|NCT00686075|Biological|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
80022539|NCT05032924|Combination Product|HA group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy)
80022540|NCT05032924|Combination Product|HA group without ESWT|PRP or HA injection only
80022541|NCT03446768|Other|Peer support|Access to educational and informational support by a trained peer coach
80022542|NCT03446768|Other|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
79726617|NCT04527757|Procedure|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
79726618|NCT00613249|Drug|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
79726619|NCT00613249|Drug|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
79861248|NCT00686075|Other|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
79861249|NCT00686075|Biological|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
79861250|NCT00686075|Other|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
79861251|NCT00686075|Biological|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
79861252|NCT00686075|Other|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
80022543|NCT03446768|Other|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
80022544|NCT03543774|Drug|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
79565922|NCT01738399|Dietary Supplement|Placebo|
79565923|NCT01738412|Device|Neurokeeper stroke detector|Monitoring stroke patients
79565924|NCT01738425|Drug|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
79565925|NCT01738425|Drug|GIC-1001 matching placebo|"Single ascending doses (SAD) [equivalent to active arm, 125 mg to 1000 mg]~Multiple ascending doses, TID over 7 successive days [equivalent to the active arm, 125 mg to 500 mg]"
79565926|NCT01738451|Drug|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
79565927|NCT01738451|Drug|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
79726620|NCT00613249|Drug|HEC-based Placebo Gel|intravaginal gel, dosed daily
79726621|NCT00613561|Drug|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
79726622|NCT01009983|Biological|panitumumab|Given IV
79861253|NCT00686075|Biological|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
79861254|NCT00686075|Other|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
80022545|NCT03543774|Drug|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
80022546|NCT03543774|Drug|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
80022547|NCT05032768|Radiation|post-operative radiotherapy|Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
80022548|NCT02152098|Procedure|Acute Early onset of rehabilitation|Early onset of rehabilitation
80022549|NCT02152098|Procedure|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
80022550|NCT02152098|Procedure|Chronic Exercise|Exercise
80022551|NCT02152098|Procedure|Chronic Control|Control
79565928|NCT01738490|Device|Bone anchored hearing implant|
79726623|NCT01009983|Drug|paclitaxel|Given IV
79861255|NCT00686075|Biological|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
79861256|NCT00686075|Other|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
79565929|NCT01738529|Device|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
79565930|NCT01738542|Drug|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
79565931|NCT01738542|Drug|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
79565932|NCT01738542|Drug|Statins|
79565933|NCT01738542|Drug|Antihypertensive therapy|
79726624|NCT01009983|Drug|carboplatin|Given IV
79726625|NCT01009983|Procedure|laboratory biomarker analysis|Correlative study
79861257|NCT02562677|Device|Transcutaneous Trigeminal Nerve Stimulation|
79861258|NCT02563613|Behavioral|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
79861259|NCT02563613|Behavioral|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
79861260|NCT02563613|Other|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
79861261|NCT00750347|Drug|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
79861262|NCT00750425|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
79861263|NCT02563457|Other|periodontal manual treatment|periodontal manual treatment
79861264|NCT02563457|Other|no periodontal manual treatment|blood sampling
79565934|NCT01738555|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
79565935|NCT01738555|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
79565936|NCT01738568|Behavioral|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at ~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
79565937|NCT01738568|Behavioral|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
79565938|NCT01738620|Behavioral|psychological counseling|
79565939|NCT01738620|Behavioral|prevention of sleep disorders in ICU|
79565940|NCT01738633|Behavioral|nutritional counseling|
79565941|NCT01738633|Behavioral|respirology counseling|
79565942|NCT01738659|Dietary Supplement|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
79565943|NCT01738685|Behavioral|Behavioral Intervention.|
79565944|NCT01738685|Other|Nutritional Education.|
79565945|NCT01738711|Behavioral|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
79565946|NCT01738724|Drug|Dienogest|Dienogest 2mg pills daily during 6 months
79565947|NCT01738724|Drug|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
79565948|NCT01738724|Drug|Desogestrel|Desogestrel 75mcg pills daily during six months
79565949|NCT01738763|Dietary Supplement|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
79726626|NCT01009983|Procedure|immunohistochemistry staining method|Correlative study
79861265|NCT00745589|Drug|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
79861266|NCT00750503|Behavioral|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
79861267|NCT00750581|Drug|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
79861268|NCT00685763|Radiation|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
79861269|NCT00745667|Procedure|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
79861270|NCT00745667|Procedure|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
79861271|NCT00745745|Device|Device Implantation|ICD lead implantation
79400010|NCT05001360|Drug|XBI-302 + Nivolumab|After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
79861272|NCT00750659|Drug|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
79861273|NCT02561663|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
79861274|NCT02561663|Other|Placebo|
79861275|NCT00098293|Drug|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
79400011|NCT01276665|Procedure|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
79861276|NCT00098293|Drug|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
80022552|NCT03096574|Other|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
79265699|NCT03478878|Drug|Vitamin A Palmitate|Provide vitamin A to participants with pre/post assessments of vision.
79400012|NCT01276665|Procedure|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
79565950|NCT01738802|Dietary Supplement|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
79565951|NCT01738802|Drug|Placebo|This group will take a placebo.
79565952|NCT01738815|Drug|Valproic Acid|500 mg orally, once daily for up to 30 days
79565953|NCT01738841|Biological|Priorix-Tetra™|Single dose, subcutaneous injection
79565954|NCT01738841|Other|Safety data collection|Recording of adverse events, using diary cards
79565955|NCT01738854|Procedure|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
79565956|NCT01738867|Drug|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
79861277|NCT00098293|Drug|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
79861278|NCT04056065|Drug|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
80022553|NCT02676284|Device|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
80022554|NCT05032222|Other|Uroflowmetry|Diagnostic test
79265700|NCT03475212|Biological|Virus Specific T-cell (VST) infusion|Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
79265701|NCT03426748|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
79265702|NCT03426748|Radiation|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
79265703|NCT03415854|Drug|Paricalcitol (Zemplar)|combination therapy
79265704|NCT03404505|Behavioral|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
79265705|NCT03404505|Behavioral|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
79265706|NCT03397966|Drug|recombinant human BNP(1-32)|Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
79565957|NCT01738867|Drug|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
79565958|NCT01738867|Drug|Placebo|Matching placebo capsules to GSK1521498 or NTX
79565959|NCT01738880|Drug|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
79565960|NCT01738880|Drug|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
79565961|NCT01738893|Drug|Gabapentin 300 mg|Test product
79861279|NCT04056065|Drug|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
79861280|NCT00923741|Drug|Talactoferrin|
79861281|NCT00923741|Procedure|Apheresis|
79861282|NCT04055285|Procedure|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
79565962|NCT01738893|Drug|Gabapentin 300 mg|Reference product
79565963|NCT01738906|Other|Orange juice|
79265707|NCT03397966|Drug|placebo (control, normal saline)|Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
79265708|NCT03374657|Biological|CPK850|In one of 4 dose levels administered via subretinal injection under anesthesia
79265709|NCT03260920|Drug|Syntocinon|Intranasal Oxytocin
79265710|NCT03250247|Device|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices > 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
79565964|NCT01738906|Other|maltodextrin|
79565965|NCT01738906|Other|Vodka|
79565966|NCT01738906|Other|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
79565967|NCT01738906|Other|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
79565968|NCT01738945|Drug|Amlodipine|10 mg/day for 12 weeks
79565969|NCT01738958|Biological|L. retueri|two tablets a day for 6 weeks
79565970|NCT01738958|Biological|Placebo|
79565971|NCT01738997|Device|Dilation 10 sec|
79565972|NCT01738997|Device|Dilation 2 min|
79400013|NCT04986150|Other|Resistance exercise|Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
79565973|NCT01739023|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
79565974|NCT01739036|Biological|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
79565975|NCT01739036|Biological|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
79565976|NCT01739036|Biological|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
79565977|NCT01739036|Biological|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
79565978|NCT01739036|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
79565979|NCT01739049|Drug|Liraglutide|liraglutide
79861283|NCT04055285|Device|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
79861284|NCT00685685|Drug|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
79861285|NCT00685685|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
79861286|NCT01087567|Drug|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
79861287|NCT01087567|Drug|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
79400014|NCT00711867|Device|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
79400015|NCT00711867|Device|Bair Hugger|Arizant Bair Hugger temperature management system.
79400016|NCT01525550|Drug|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
79565980|NCT01739049|Behavioral|Diet and Exercise|diet and exercise
79565981|NCT01739088|Other|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
79565982|NCT01739088|Other|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
79565983|NCT01739101|Behavioral|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
79565984|NCT01739114|Procedure|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
79861288|NCT00684671|Biological|Twinrix|Intramuscular injection, single dose in left deltoid.
79861289|NCT00684671|Biological|Engerix-B|Intramuscular injection, single dose in left deltoid.
79861290|NCT00684671|Biological|Havrix|Intramuscular injection, single dose in right deltoid.
79861291|NCT00684671|Biological|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
79861292|NCT00684671|Biological|Vaqta|Intramuscular injection, single dose in right deltoid.
79861293|NCT03859323|Drug|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
79565985|NCT01739114|Procedure|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
80022555|NCT02155686|Device|Biosensors|Device: Biometric sensors; Home automation; telecare
80022556|NCT02155686|Device|Home automation|
80022557|NCT05032300|Device|Focused shockwave|Procedure: Focused shockwave therapy received shock wave therapy once a week: first locate, touch on the heel of the patient Tenderness points, take tenderness points as treatment points;Then ask the patient to take the lower limbs straight sitting or prone position, Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, Total of 3000 pulses; rest for 20 minutes after the treatment
79265711|NCT03248063|Drug|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
79265712|NCT03248063|Drug|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
79265713|NCT03221257|Drug|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
79400017|NCT02991963|Other|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
79565986|NCT01739127|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
80022558|NCT05032300|Other|Home therapy|Stretching and ice massage
80022559|NCT02155764|Device|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
79565987|NCT01739127|Drug|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
79565988|NCT01739140|Behavioral|Yoga|
80022560|NCT02155764|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
80022561|NCT02155764|Device|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
80022562|NCT01829750|Genetic|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
80022563|NCT05032456|Device|Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system|The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
80022564|NCT02152176|Device|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
80022565|NCT03617055|Diagnostic Test|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
80022566|NCT02155842|Behavioral|High intensity endurance exercise|
79565989|NCT01739153|Other|Dietary intervention: CHEESE (High cheese intake)|
79565990|NCT01739153|Other|Dietary intervention: MEAT (High Meat intake)|
79565991|NCT01739153|Other|Dietary intervention: CARB (High Carbohydrate intake)|
79861294|NCT03859323|Other|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
80022567|NCT02155842|Behavioral|Moderate continuous endurance exercise|
80022568|NCT03094780|Behavioral|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
79265714|NCT03221257|Drug|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
79265715|NCT03221257|Drug|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
79265716|NCT03221140|Drug|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
79400018|NCT02991963|Other|Blood collection (Dried Blood Spot)|Dried Blood Spot
79861295|NCT00750971|Procedure|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
79861296|NCT00751049|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
79861297|NCT00751049|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
79400019|NCT02991963|Other|Blood Collection (Venous Blood collection)|Venous Blood collection
79400020|NCT02991963|Other|Blood Smear|Slide blood smear
79565992|NCT01739166|Other|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
79565993|NCT01739179|Procedure|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
79565994|NCT01739179|Procedure|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
79565995|NCT01739192|Drug|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
79265717|NCT03182465|Diagnostic Test|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
79265718|NCT03047746|Device|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
79265719|NCT02981173|Drug|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
79265720|NCT02981173|Drug|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
80022569|NCT03094780|Other|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
79581346|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~st line~Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~Bevacizumab until PD or unacceptable toxicity~At PD < 3 months after last paclitaxel start 2nd treatment line.~At PD ≥ 3 months after last paclitaxel, start another 4 cycles~Bevacizumab until the next PD or unacceptable toxicity~At the next PD start the 2nd treatment line.~nd line:~Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~At PD < 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~At the next PD start 3rd treatment line."
80022570|NCT03488888|Drug|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
80022571|NCT03488888|Drug|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
79400021|NCT05016570|Behavioral|Picture narrative information format|Lung screening information formatted as picture narratives
79400022|NCT05016570|Behavioral|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
79400023|NCT05016570|Behavioral|Text-only information format|Lung screening information formatted as text with no pictures
79400024|NCT04730232|Drug|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
79400025|NCT04730232|Drug|Nab-paclitaxel|Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
79400026|NCT04701918|Drug|Pembrolizumab|Intravenous injection through a vein (IV) every 3 weeks
79400027|NCT04701918|Procedure|Cryoablation|Needle inserted through the skin and into the tumor using CT guidance
79400028|NCT04279197|Drug|Fuzheng Huayu Tablet|FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
80022572|NCT05031676|Other|opioid free anesthesia|Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
79400029|NCT04279197|Drug|Vitamin C tablets|Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
79400030|NCT04279197|Drug|Placebo|Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
79265721|NCT02981173|Drug|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
79265722|NCT02980341|Drug|Patritumab Deruxtecan|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
79265723|NCT02978326|Drug|SAGE-217 15/20 mg Oral Solution|SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
79400031|NCT04279197|Other|respiratory function rehabilitation training|Health exercise, once a day
79400032|NCT04699032|Drug|Apraglutide|Single dose of apraglutide 5 mg.
79400033|NCT04540848|Drug|Group A (Exparel plus supraclavicular block)|"Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
79400034|NCT04540848|Drug|Group B (Bupivacaine HCL plus supraclavicular block)|"Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
79400035|NCT04540848|Drug|Group C(supraclavicular block only)|"In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
79400036|NCT01271751|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
79400037|NCT01271751|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
79565996|NCT01739205|Behavioral|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
79265724|NCT02978326|Drug|Placebo|SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
80022573|NCT05149430|Other|Observational Quality of life and functional capacity|Observational Quality of life and functional capacity
80022574|NCT03615339|Dietary Supplement|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
80022575|NCT02769312|Device|Theta burst stimulation|Theta burst transcranial magnetic stimulation
79400038|NCT00211237|Device|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
79565997|NCT01739218|Drug|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula ([participant's glomerular filtration rate + 25] multiplied by the target area under the concentration-time curve [AUC] of 5 milligrams per milliliter per minute [mg/mL/min]), as intravenous [IV] infusion over 30-60 minutes [min] every 3 weeks).
79565998|NCT01739218|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared [mg/m^2] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
80022576|NCT02769312|Device|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
79400039|NCT00211237|Other|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
79400040|NCT01271829|Dietary Supplement|Avocado supplement|Calories from avocados replace calories of the control lunch
79400041|NCT01271829|Dietary Supplement|Avocado included|Calories from avocados will be added to calories from the control lunch
79400042|NCT04774146|Procedure|pars plana vitrectomy|silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
79400043|NCT01489358|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
79565999|NCT01739218|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram [mg/kg] as IV infusion over 30-90 min every 3 weeks.
79566000|NCT01739244|Drug|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
79566001|NCT01739244|Drug|Placebo|Ocular topical administration of placebo for 14 consecutive days
79566002|NCT01739257|Behavioral|Medical Lecture|
79566003|NCT01739257|Behavioral|Dramatic Reading|
79566004|NCT01739270|Procedure|supraclavicular brachial plexus block|
79566005|NCT01739283|Other|GIP|
79566006|NCT01739283|Other|GLP-1|
79400044|NCT04760028|Procedure|Adjusting the depth of anesthesia|After the main procedure, the depth of anesthesia can be adjusted as needed
79566007|NCT01739283|Other|Saline|
79566008|NCT01739296|Other|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
79566009|NCT01739296|Other|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
79265725|NCT02978326|Drug|SAGE 217 30 mg Capsules|SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
79265726|NCT02967172|Drug|Ropivacaine|
79265727|NCT02967172|Drug|Epinephrine|
79265728|NCT02967172|Drug|Morphine|
79265729|NCT02967172|Drug|0.9% sodium chloride solution|
79265730|NCT02916316|Drug|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
79277513|NCT03533621|Dietary Supplement|Probiotic - VSL#3|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
80022577|NCT03616743|Behavioral|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
80022578|NCT03616743|Behavioral|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
80022579|NCT03489902|Procedure|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
80022580|NCT03489902|Procedure|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
80022581|NCT03617757|Diagnostic Test|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
80022582|NCT03617757|Diagnostic Test|HbA1c|2mL blood will be taken for analysis of HbA1c.
79726627|NCT04474795|Behavioral|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
79400045|NCT05366101|Drug|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
79861298|NCT00751985|Other|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
80022583|NCT03489824|Procedure|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
79566010|NCT01739322|Biological|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
80022584|NCT03543696|Radiation|Single Dose Radiotherapy (SDRT)|
80022585|NCT03615261|Behavioral|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
80022586|NCT02148744|Biological|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
79566011|NCT01739374|Other|reduced mesh implants|mesh for pelvic floor reinforcement
80022587|NCT02148744|Biological|Placebo|
79265731|NCT02879864|Device|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
79277514|NCT03533621|Dietary Supplement|Placebo pill - soy protein powder|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
79277515|NCT02364453|Drug|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
79566012|NCT01739387|Device|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
79566013|NCT01739413|Procedure|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
79566014|NCT01739426|Device|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
80022588|NCT01632644|Other|Survey/Interview|Each group will be surveyed and interviewed.
80022589|NCT05034510|Device|Deep Brain Stimulation|modification in stimulation parameters
80022590|NCT03488810|Other|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
80022591|NCT03488810|Drug|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
80022592|NCT03488810|Drug|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
79400046|NCT05366101|Behavioral|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
79566015|NCT01739439|Drug|gemcitabine hydrochloride|Given IV
79566016|NCT01739439|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
79566017|NCT01739439|Radiation|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
79726628|NCT00628485|Device|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
79566018|NCT01739439|Radiation|radiosurgery|Undergo radiosurgery boost
79566019|NCT01739439|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
79726629|NCT00628485|Device|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
79566020|NCT01739465|Procedure|Self expanding metallic stent (SEMS)|Self expanding metallic stent
79566021|NCT01739465|Procedure|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
79566022|NCT01739465|Procedure|Photodynamic therapy (PDT)|Photodynamic therapy
79566023|NCT01739478|Other|Packing of abscess cavity|
79566024|NCT01739478|Other|External dressing|Application of external dressing whilst abscess cavity heals
79566025|NCT01739491|Drug|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
79566026|NCT01739504|Procedure|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
79566027|NCT01739504|Biological|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
79566028|NCT01739517|Drug|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
80022593|NCT03488810|Drug|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
79277516|NCT02258009|Drug|Ranibizumab|0.5 mg intravitreal injections
79400047|NCT04993560|Biological|BBIBP-CorV|Inactivated virus COVID-19 vaccine
79566029|NCT01739530|Biological|Repaircell|allogenic differentiated adipocyte
79566030|NCT01739543|Device|Hem-Avert|Application of Hem-Avert
79566031|NCT01739556|Drug|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
79566032|NCT01739582|Drug|Androxal|
79277517|NCT02258009|Drug|Aflibercept|2 mg intravitreal injections
79566033|NCT01739608|Other|Invitation to screening|Invitation to screening
79566034|NCT01739621|Drug|Proellex 12 mg|
79566035|NCT01739621|Drug|Proellex 24 mg|
79566036|NCT01739634|Drug|CASAD|CASAD is provided in 500mg capsules.
79566037|NCT01739647|Drug|AZD3293|Oral solution
79566038|NCT01739647|Drug|Placebo|Oral solution
79566039|NCT01739660|Drug|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
79566040|NCT01739673|Other|Ultraviolet-A and riboflavin|
79566041|NCT01739686|Other|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
79566042|NCT01739712|Behavioral|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
79566043|NCT01739712|Behavioral|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
79566044|NCT01739725|Device|Stent insertion|The patient will receive the helical stent
79277518|NCT02364219|Other|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
79277519|NCT02364219|Device|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
79566045|NCT01739738|Device|Ureteral Stent|patients who need to receive stent as per standard of care
79566046|NCT01739751|Device|pedometers|portable device that estimate the number of steps walked daily
79566047|NCT01739777|Biological|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
79566048|NCT01739777|Other|Controls|Autologous Serum will administrated as placebo
79566049|NCT01739816|Behavioral|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
79566050|NCT01739829|Device|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
79726630|NCT00628485|Device|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
79726631|NCT04471363|Behavioral|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
80022594|NCT03615027|Behavioral|Dementia-specific advance care planning|see detailed description
79400048|NCT04993560|Biological|BNT162b2|mRNA-based COVID-19 vaccine
79566051|NCT01739829|Device|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
79400049|NCT05365555|Procedure|Fascia Iliaca Compartment Block|Blind technique.
79400050|NCT05365555|Procedure|Femoral Nerve Block|Ultrasound guided.
79400051|NCT05365555|Drug|Ropivacaine|Ropivacaine dosed according to local guidelines.
79400052|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
79400053|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
79566052|NCT01739842|Dietary Supplement|Kudzu extract|
79566053|NCT01739855|Drug|Calciferol, calcium carbonate|
79566054|NCT01739868|Other|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~1 visit the first year (inclusion visit)~1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~1 intermediary visit (in 3 years) or activated by the following conditions:~Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~Normalization of the glycemia (fasting blood glucose < 1 g/l)"
79566055|NCT01739881|Device|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
79566056|NCT01739894|Drug|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
79566057|NCT01739907|Other|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
79400054|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
79400055|NCT05374356|Drug|Intrathecal bupivacaine and morphine|Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
79566058|NCT01739920|Other|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
79566059|NCT01739920|Other|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
79566060|NCT01739972|Drug|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
79566061|NCT01739972|Drug|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
79566062|NCT01739985|Drug|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
79726632|NCT04297215|Device|DermaCura® Chitosan based antimicrobial therapeutic clothing|"DermaCura® antimicrobial therapeutic clothing (D&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
79726633|NCT04297215|Device|Binamed® silver based antimicrobial therapeutic clothing|"The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
79400056|NCT00717405|Drug|Standard chemotherapy|As prescribed
79400057|NCT00717405|Drug|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
79400058|NCT00717405|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
79400059|NCT01276977|Drug|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
79400060|NCT01276977|Drug|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
79400061|NCT01271985|Drug|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
79400062|NCT01271985|Other|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
79400063|NCT03832699|Drug|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
79400064|NCT03832699|Drug|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
79400065|NCT03024619|Other|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
79400066|NCT00717873|Device|Airway clearance Device|Provided by the Vest Airway clearance system
79400067|NCT02991885|Biological|HAL-MPE1|Weekly subcutaneous administrations of HAL-MPE1
79400068|NCT02991885|Drug|HAL-MPE1 placebo|Weekly subcutaneous administrations of HAL-MPE1 placebo
79400069|NCT03997513|Behavioral|Pulmonary Telerehabilitation|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
79400070|NCT05369767|Drug|SAD, SHR-2004|Ascending dose
79400071|NCT05369767|Drug|SAD, SHR-2004 placebo|Ascending dose
79400072|NCT05366803|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
79400073|NCT01277289|Drug|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
79400074|NCT05630287|Drug|[14C] Selpercatinib|Administered as an oral solution
80022595|NCT03492242|Drug|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
79400075|NCT05630287|Drug|Selpercatinib|Administered orally
79400076|NCT05630287|Drug|[14C] Selpercatinib|Administered intravenously
79400077|NCT04386915|Drug|GST-HG141 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
79566063|NCT01739985|Drug|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
79566064|NCT01739998|Dietary Supplement|functional oil|
79566065|NCT01739998|Dietary Supplement|Placebo|
79726634|NCT04297215|Device|Binamed® therapeutic clothing without antimicrobial agents|"The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
79726635|NCT04850989|Device|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
79726636|NCT02873091|Procedure|Epidural analgesia|
79726637|NCT02873091|Procedure|Continuous epidural infusion|
80022596|NCT03572283|Drug|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
80022597|NCT02254824|Drug|Xuezhikang|Xuezhikang
80022598|NCT02254824|Drug|Atorvastatin|Atorvastatin
79400078|NCT04386915|Drug|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
79400079|NCT03599791|Drug|Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Dymista Nasal spray suspension
79400080|NCT03599791|Drug|Azelastine Hydrochloride 0.137 MG/ACTUAT|AZEP Nasal spray solution
79400081|NCT03599791|Drug|Fluticasone Propionate 0.05 MG/ACTUAT|Fluticasone propionate nasal spray suspension
79400082|NCT04386681|Behavioral|Reentry Continuum for Brain Injury (RCBI)|"Pre-Release RCBI Treatment Procedures (BICS and ICAN). BICS: consists of 12 weekly two- hour sessions. Sessions focus on brain injury education, coping skills for the various symptoms of brain injury, depression management, stress management, and self- advocacy.~ICAN: delivered once a week for 6 weeks for 2 hours per session. ICAN primarily focuses on poor perspective-taking and inability to make social inferences about others' behaviors that are related to negative attributions, and employs role playing exercises and a novel perspective-positioning technique to elicit affective and cognitive empathy to alter negative attributions and reduce anger.~Post-Release RCBI Resource Facilitation. Working with their resource facilitator, alongside their corrections case manager, to work on brain injury specific reentry planning, resource, and needs identification."
79566066|NCT01740011|Procedure|Laparoscopic surgery|
79566067|NCT01740024|Biological|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
79566068|NCT01740037|Other|Specialized outpatient AF Clinic|
79566069|NCT01740037|Other|Usual Care|
79566070|NCT01740050|Dietary Supplement|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
79566071|NCT01740050|Procedure|RYGB|
79726638|NCT02873091|Procedure|Intermittent epidural bolus|
80022599|NCT02254824|Behavioral|Lifestyle modification|Lifestyle modification
80022600|NCT03617601|Diagnostic Test|MET|Testing of the metabolic equivalent of task before aortic procedure
79400083|NCT04386525|Dietary Supplement|Omega-3 fish oil|soft gels,1000gm, 84% of DHA and EPA
80022601|NCT01525316|Dietary Supplement|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
80022602|NCT01525316|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
80022603|NCT03616665|Other|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
79726639|NCT02873091|Drug|ropivacaine|
80022604|NCT03488732|Device|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
79265732|NCT02879864|Device|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
79566072|NCT01740050|Procedure|LAGB|
79566073|NCT01740063|Drug|DAS181-F02 formulation|
79566074|NCT01740063|Drug|DAS181-F04 formulation|
79277520|NCT03532997|Other|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
79400084|NCT01488578|Drug|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
79566075|NCT01740063|Drug|Placebo|
79861299|NCT00751985|Other|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
79861300|NCT00751985|Other|Control|The participant is being informed about their allocation to the control group.
79726640|NCT02873091|Drug|sufentanil|
79400085|NCT05632705|Other|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
79400086|NCT00720369|Drug|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
79726641|NCT03905083|Other|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
79726642|NCT04298775|Procedure|spinal anesthesia with morphine|
79861301|NCT03857841|Biological|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
79861302|NCT03857841|Biological|Phosphate-buffered saline|Phosphate-buffered saline
79861303|NCT01014429|Drug|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
79400087|NCT01277367|Behavioral|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
79566076|NCT01740076|Other|soy nuts|
79566077|NCT01740102|Procedure|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
79861304|NCT00500331|Drug|GSK189075|Experimental Drug
79861305|NCT00500331|Drug|pioglitazone|Active Control
79861306|NCT00500331|Other|Placebo|Placebo Comparator
79861307|NCT01015755|Behavioral|combined therapy treatment|mouth care
80022605|NCT01673386|Drug|Tivozanib|
80022606|NCT01673386|Drug|Sunitinib|
80022607|NCT00103740|Drug|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
79277521|NCT02374827|Procedure|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
79566078|NCT01740141|Procedure|Plexus brachialis block|
79566079|NCT01740167|Behavioral|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
79566080|NCT01740180|Other|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF."
79726643|NCT04298775|Procedure|spinal anesthesia without morphine + peripheral nerve block|
79726644|NCT04285359|Procedure|Intracranial Interventions|Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.
79726645|NCT01215227|Drug|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
79400088|NCT01277367|Behavioral|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
79400089|NCT01277367|Behavioral|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
79566081|NCT01740193|Procedure|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
79566082|NCT01740193|Procedure|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
79566083|NCT01740219|Behavioral|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
79726646|NCT01215227|Drug|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
79566084|NCT01740219|Behavioral|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
79566085|NCT01740232|Procedure|trephination|Artroscopic meniskal repair with trephination.
79400090|NCT01277367|Behavioral|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
79400091|NCT01277367|Behavioral|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
79400092|NCT01277367|Behavioral|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
79566086|NCT01740232|Procedure|Normal meniscal repair|Artroscopic meniskal repair without trephination.
79726647|NCT01215227|Drug|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
79566087|NCT01740245|Device|Chlorhexidine vaginal suppositories|
79566088|NCT01740245|Device|Polyhexamethylene biguanide vaginal suppositories|
79726648|NCT01215227|Drug|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
79726649|NCT05429957|Other|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~MET of the Iliopsoas~MET of Piriformis muscle~MET of Quadratus Lumborum muscle~MET of Erector Spinae muscle"
79265733|NCT02853214|Genetic|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
79566089|NCT01740271|Drug|Epirubicin|
79566090|NCT01740284|Drug|Grazax + Aerius|
79566091|NCT01740284|Drug|Grazax + placebo|
79726650|NCT05429957|Other|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
79726651|NCT01009515|Drug|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
79726652|NCT04550481|Procedure|Biospecimen Collection|Undergo blood sample collection
79726653|NCT04550481|Drug|Lisinopril|Given PO
79726654|NCT04550481|Procedure|Liver Ultrasonographic Elastography|Undergo transient elastography (Fibroscan)
79726655|NCT04550481|Procedure|Magnetic Resonance Elastography|Undergo PDFF MRE
79726656|NCT04550481|Procedure|Magnetic Resonance Imaging|Undergo PDFF MRI
79726657|NCT04550481|Procedure|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
79726658|NCT04550481|Other|Questionnaire Administration|Ancillary studies
79726659|NCT01214915|Drug|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
80022608|NCT00103740|Drug|placebo to zoledronic acid|5 mL of sterile water for infusion
80022609|NCT00103740|Drug|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
80022610|NCT00103740|Drug|Placebo to risedronate|oral capsules
80022611|NCT00103740|Drug|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
79566092|NCT01740310|Behavioral|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
80022612|NCT03131804|Other|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
79566093|NCT01740336|Drug|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
80022613|NCT03616509|Drug|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
79566094|NCT01740336|Drug|Placebo|Placebo matching to GDC-0941
79566095|NCT01740336|Drug|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
80022614|NCT03616509|Drug|Placebo|2 months on placebo, sodium chloride 0,9% injections
79265734|NCT02834403|Drug|L-NMMA|Nitric oxide synthase inhibitor
80022615|NCT03488654|Diagnostic Test|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
80022616|NCT03616353|Procedure|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
80022617|NCT03616353|Procedure|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
79265735|NCT02834403|Drug|Docetaxel|Mitotic inhibitor, cytotoxic
79265736|NCT02834403|Drug|Amlodipine|Long-acting calcium channel blocker
79265737|NCT02834403|Drug|Pegfilgrastim|Colony-stimulating factor
79265738|NCT02834403|Drug|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
79265740|NCT02682511|Drug|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
79566096|NCT01740375|Procedure|esophagectomy|esophagectomy
79566097|NCT01740453|Drug|ropivacaine 2 mg/ml|single
79566098|NCT01740479|Procedure|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
79566099|NCT01740505|Behavioral|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
79566100|NCT01740505|Behavioral|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
79566101|NCT01740505|Behavioral|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
79566102|NCT01740518|Drug|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
79566103|NCT01740531|Biological|S-303 Treated Red Blood Cells (RBCs)|
79566104|NCT01740531|Biological|Conventional, untreated Red Blood Cells|
79566105|NCT01740544|Other|Cathodal tDCS|Cathodal tDCS applied over the right PPC
79861308|NCT01019109|Device|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
80022618|NCT03488576|Procedure|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
79265741|NCT02682511|Drug|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
79265742|NCT02620852|Other|Complete a health questionnaire|Complete a health history questionnaire.
79265743|NCT02620852|Device|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
79265744|NCT02620852|Other|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
79265745|NCT02620852|Other|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
80022619|NCT03488576|Procedure|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
79265746|NCT02576795|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
79265747|NCT02456974|Procedure|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
79265748|NCT02456974|Procedure|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
79265749|NCT02456974|Procedure|blood sampling in patients receiving vancomycin as part of routine clinical care.|
79566106|NCT01740544|Other|Sham tDCS|Sham tDCS applied over the right PPC
79566107|NCT01740570|Drug|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
79265750|NCT02456974|Procedure|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
79726660|NCT04297527|Procedure|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
79726661|NCT04297527|Procedure|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
79861309|NCT00499863|Drug|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
79861310|NCT00499863|Drug|Placebo|Placebo patch
79861311|NCT04475835|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
79861312|NCT04475835|Drug|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
79861313|NCT01014507|Drug|8 cycles BEACOPPesc plus oral contraceptive|
80022620|NCT03094858|Device|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
79265751|NCT02456974|Procedure|blood sampling in patients receiving meropenem as part of routine clinical care.|
79265752|NCT02456974|Procedure|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
79265753|NCT02456974|Procedure|blood sampling in patients receiving amikacin as part of routine clinical care.|
79265754|NCT02414477|Drug|Deuterated NNN|Smokeless tobacco study product
79265755|NCT02411656|Other|Laboratory Biomarker Analysis|Correlative studies
79265756|NCT02411656|Biological|Pembrolizumab|Given IV
79400093|NCT01524770|Biological|Dulaglutide|Administered by subcutaneous (SC) injection
79400094|NCT01277445|Dietary Supplement|Prebiotic|Inulin-fructan 15mg/day for 28days
79400095|NCT01277445|Dietary Supplement|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
79566108|NCT01740583|Device|percutaneous annuloplasty|plication of the mitral valve annulus
79726662|NCT01009281|Drug|AIN457|
79726663|NCT01009203|Drug|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
79861314|NCT01014507|Drug|8 cycles BEACOPPesc plus Goserelin|
79265757|NCT02392455|Drug|treatment|Docetaxel plus nintedanib until progression or intolerability
79265758|NCT02300961|Behavioral|Cognitive rehabilitation program|
79265759|NCT02091245|Drug|KPT-330|
79265760|NCT02060188|Drug|Ipilimumab|Specified dose on specified days
79265761|NCT02060188|Drug|Nivolumab|Specified dose on specified days
79265762|NCT02060188|Drug|Cobimetinib|Specified dose on specified days
79265763|NCT02060188|Drug|Daratumumab|Specified dose on specified days
79566109|NCT01740609|Drug|Placebo|Placebo
79566110|NCT01740609|Biological|PF-06342674 Dose A|Single SC Dose
79566111|NCT01740609|Biological|PF-06342674 Dose B|Single SC Dose
79566112|NCT01740609|Biological|PF-06342674 Dose C|Single SC Dose
79566113|NCT01740609|Biological|PF-06342674 Dose D|Single SC Dose
79566114|NCT01740609|Biological|PF-06342674 Dose E|Single SC Dose
79566115|NCT01740609|Biological|PF-06342674 Dose F|Single IV Dose
79566116|NCT01740609|Biological|PF-06342674 Dose G|Single SC Dose
79566117|NCT01740609|Biological|PF-06342674 Dose H|Single IV Dose
79566118|NCT01740609|Biological|PF-06342674 Dose I|Single SC Dose
79566119|NCT01740609|Biological|PF-06342674 Dose J|Single IV Dose
79566120|NCT01740622|Other|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
79861315|NCT00484185|Drug|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
80022621|NCT03094858|Device|Wristband|Wristband will monitor activity of all participants
80022622|NCT03094858|Device|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
80022623|NCT03746730|Device|ultrasound|gray scale and doppler ultrasound
80022624|NCT01281644|Device|Diode Laser|810 nm diode laser
80022625|NCT02869893|Drug|Secretin|
80022626|NCT00202826|Procedure|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
79566121|NCT01740635|Device|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
79400096|NCT03598231|Device|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
79566122|NCT01740661|Other|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
80022627|NCT03616275|Other|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
79400097|NCT02991261|Drug|SPARC001 type I|Treatment type I
79400098|NCT02991261|Drug|SPARC001 type II|Treatment type II
79400099|NCT02991261|Drug|Reference001 type I|Hydrocodone-acetaminophen
80022628|NCT05119790|Drug|[14C] BIIB122 ([14C] DNL151)|Oral dose
79400100|NCT02991261|Drug|Reference001 type II|Hydrocodone Acetaminophen
79400101|NCT02991339|Drug|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
79400102|NCT04018495|Device|Fitbit Tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
79566123|NCT01740661|Other|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
79566124|NCT01740674|Other|Electronic data collection|
79566125|NCT01740700|Device|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
79566126|NCT01740752|Behavioral|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
79566127|NCT01740752|Behavioral|CBT|"weekly manualized higher dose of individual CBT"
79566128|NCT01740765|Other|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
79566129|NCT01740830|Device|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
79265764|NCT02060188|Drug|BMS-986016|Specified dose on specified days
79566130|NCT01740843|Device|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
79566131|NCT01740856|Other|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
79566132|NCT01740856|Other|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
79566133|NCT01740869|Other|Stem cells|
79566134|NCT01740908|Other|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
79566135|NCT01740921|Drug|Liraglutide|Administered once daily
79566136|NCT01740921|Other|diet|reduction of caloric intake to promote weight loss
79265765|NCT02027818|Drug|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
79265766|NCT02003950|Other|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
79726664|NCT01009203|Drug|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
80022629|NCT05050786|Device|Negative Wound Pressure Therapy (Prevena(TM))|After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.
79566137|NCT01740921|Drug|Aspirin|300mg of Aspirin per day
79726665|NCT01009047|Drug|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
80022630|NCT05050786|Other|Standard Wound Dressing|After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
79265767|NCT01966731|Drug|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
79277522|NCT02374827|Procedure|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
79277523|NCT02202941|Other|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
79566138|NCT01740934|Other|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
79566139|NCT01740934|Other|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
79566140|NCT01740947|Drug|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
79566141|NCT01740960|Drug|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
79566142|NCT01740960|Drug|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
79566143|NCT01740986|Drug|SA09012 Low dose|Tablet, b.i.d
79566144|NCT01740986|Drug|SA09012 High dose|Tablet, b.i.d
79726666|NCT01009047|Drug|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
79726667|NCT04205097|Drug|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
79726668|NCT04205097|Drug|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
79566145|NCT01740986|Drug|Placebo|Tablet, b.i.d
79566146|NCT01741025|Device|iFuse Implant System|Placement of iFuse implant system via surgery
79566147|NCT01741025|Other|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
79566148|NCT01741038|Biological|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
79726669|NCT04285047|Other|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
79566149|NCT01741038|Procedure|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
79566150|NCT01741038|Other|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
79861316|NCT00097981|Drug|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
79861317|NCT00097981|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
79861318|NCT00097981|Drug|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
79861319|NCT01015911|Drug|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
79566151|NCT01741051|Device|HEPA Filter|
79566152|NCT01741077|Dietary Supplement|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
80022631|NCT03614871|Other|Epidemiological study|
80022632|NCT02152332|Drug|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
79265768|NCT01958307|Behavioral|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
79566153|NCT01741090|Biological|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
79265769|NCT01946074|Drug|paclitaxel|Paclitaxel will be administered by intravenous infusion.
79265770|NCT01946074|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
79265771|NCT01946074|Drug|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
79566154|NCT01741116|Drug|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
79566155|NCT01741129|Device|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
79566156|NCT01741129|Device|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
79726670|NCT04283955|Drug|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
79726671|NCT04205253|Diagnostic Test|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
79726672|NCT04297059|Other|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
79726673|NCT04300725|Other|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
79566157|NCT01741142|Drug|ABT-436|Subjects receiving ABT-436
79566158|NCT01741142|Drug|Escitalopram|Subjects receiving escitalopram
79726674|NCT04300491|Other|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
79726675|NCT04296669|Device|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
79726676|NCT01025193|Drug|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
79726677|NCT01025037|Device|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
79265772|NCT01946074|Drug|ABBV-181|ABBV-181 will be administered by intravenous infusion.
79265773|NCT01856478|Drug|methotrexate|intravenous bolus injection, once weekly
79265774|NCT01856478|Drug|afatinib|oral intake, once daily
79566159|NCT01741142|Drug|Placebo|Subject receiving placebo
79566160|NCT01741168|Other|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
79726678|NCT01214837|Biological|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
79265775|NCT01813968|Procedure|Ischemic postconditioning|
79265776|NCT01791556|Other|HIV-1 viral load testing|
79265777|NCT01736059|Drug|CD34+ bone marrow stem cells intravitreal|
79265778|NCT01484730|Device|Multi-Spectral and Laser Speckle Imaging|Changes in skin tissue and blood flow.
79265779|NCT01397851|Device|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
79265780|NCT01254864|Drug|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
79265781|NCT01254864|Drug|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
79265782|NCT01254864|Drug|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
79265783|NCT01254864|Drug|Dasatinib|100 mg by mouth each day of a 28 day cycle.
79566161|NCT01741168|Other|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
79566162|NCT01741181|Drug|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
79566163|NCT01741181|Drug|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
79566164|NCT01741207|Drug|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
79566165|NCT01741233|Genetic|VitDgen|
79566166|NCT01741285|Drug|Beclomethasone (QVAR)|Small particle treatment
79566167|NCT01741285|Drug|Beclomethasone (Clenil)|Course particle beclomethasone
79726679|NCT01214837|Biological|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
79566168|NCT01741285|Drug|Fluticasone|Course particle treatment
79726680|NCT01214837|Biological|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
79726681|NCT01024959|Other|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
79400103|NCT06123546|Other|Patient oriented discharge summary|"The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge."
79581347|NCT01935505|Behavioral|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
79265784|NCT01166893|Device|Modulated Imaging and Laser Speckle Imaging|wound healing
79265785|NCT01070212|Other|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
79726682|NCT01008423|Drug|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
79265786|NCT01070212|Other|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
79265787|NCT01070212|Other|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
79400104|NCT06123533|Other|No intervention|There is no intervention.
79400105|NCT06123520|Procedure|Ho-YAG Laser Visual internal urethrotomy|"the operations will be performed by an expert surgeon and operative time will be considered. The procedure will be performed under spinal or general anaesthesia in lithotomy position. Antibiotic will be given just before and 12 h after procedure and continued for next 5 days.~Normal saline will be used for irrigation during the procedure. A Holmium laser at an energy of 1,200 to 2.000 mJ with a frequency of 10 to 15 Hz will be used By use of a 22 F cystoscope and Ho:YAG laser, the stricture site will be completely incised while sparing healthy mucosa. a fiber will be positioned about 1 mm away from the tissue and the laser will be fired.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
79400106|NCT06123520|Procedure|Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel|"The investigators will follow the same interversion protocol in the first group then paclitaxel is going to be injected via Williams cystoscopic injection needle (5 F size and 23 G needle size) through the cystoscope after laser ablation of the stricture in the submucosa with an assumed dose of 3.5µg/mm2 (reaching a urethral diameter of 30 Fr and a total length of 2 cm a total dose of 2.2 mg divided along 3 injection is to be injected). the dose is divided at 12,4 and 8 o'clock respectively along the length of the stricture.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
79277524|NCT02202941|Other|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
79303988|NCT04657133|Device|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
79400107|NCT06123507|Behavioral|Student practitioner perspective-taking intervention|This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.
79581348|NCT01935505|Drug|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
79726683|NCT01008423|Drug|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
79726684|NCT02872077|Other|Auricular acupuncture|
79726685|NCT04296825|Dietary Supplement|Camel milk containing Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
79726686|NCT04296825|Dietary Supplement|Camel milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
79726687|NCT04296825|Dietary Supplement|Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
79400108|NCT06123455|Dietary Supplement|Taurine|Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day.
79400109|NCT06123455|Biological|Sintilimab|Sintilimab
79400110|NCT06123455|Drug|XELOX regimen|Oxaliplatin + capecitabine
79400111|NCT06123455|Drug|SOX regimen|Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)
79400112|NCT06123455|Drug|FOLFOX regimen|Oxaliplatin + leucovorin + fluorouracil
79400113|NCT06123429|Behavioral|Mindfulness Based Stress reduction|"The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection.~Mindfulness-Based Stress Reduction (MBSR) is a structured program designed to help individuals manage stress, increase self-awareness, and promote overall well-being. Developed by Dr. Jon Kabat-Zinn in the late 1970s, MBSR combines elements of mindfulness meditation and cognitive-behavioral techniques. MBSR is a comprehensive program that equips individuals with practical skills to better manage stress and enhance their mental and emotional well-being. Its emphasis on mindfulness, self-awareness, and the integration of these practices into daily life makes it a valuable resource for those seeking to reduce stress and improve their overall quality of life."
79400114|NCT06123403|Diagnostic Test|blood methotrexate level and Cystatin C level|blood methotrexate level and Cystatin C level
79400115|NCT06123377|Diagnostic Test|Angiogenic factor|sFLt-1/PGIF below or equal to 33
79265788|NCT00968266|Behavioral|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
79265789|NCT00868283|Drug|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
79265790|NCT00868283|Drug|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
79400116|NCT06123312|Diagnostic Test|Tri-modality biopsy|When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
79265791|NCT00641238|Device|Radiofrequency ablation|Radiofrequency ablation
79265792|NCT00289068|Procedure|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
79265793|NCT00289068|Procedure|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
79400118|NCT06123273|Behavioral|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
79400119|NCT06123260|Diagnostic Test|renal function tests|BUN, eGFR , CBC , Electrolytes , Liver function tests
79400120|NCT06123234|Dietary Supplement|Verum 408|Food supplement in single-dose vials
79400121|NCT06123234|Other|Placebo 407|Food supplement in single-dose vials
79400122|NCT06123221|Procedure|Osseodensification with Versah system|Access to the bone crest will be performed through a slightly palatinized crestal incision, and a full-thickness mucoperiosteal flap will be elevated. Implant site preparation will be performed according to the bone densification drilling sequence established by the Densah® technique protocol
79581349|NCT01935505|Behavioral|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
79581350|NCT01935505|Behavioral|Consulting+Telephone+Drug intervention|Include all the above interventions
79265794|NCT00289068|Procedure|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
79265795|NCT00280345|Procedure|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
79265796|NCT00280345|Procedure|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
79265797|NCT00280345|Procedure|Cataract surgery|Removal of the cataract from the eye
79265798|NCT05615792|Other|No intervention|No intervention
79265799|NCT04817306|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
79265800|NCT02121977|Device|Elevate Anterior and Apical|
79265801|NCT02121977|Procedure|Native Tissue Repair for pelvic organ prolapse|
79265802|NCT02125175|Radiation|Hypofractionated IMRT boost Radiotherapy|
79400123|NCT06123221|Procedure|Lateral window|A full-thickness mucoperiosteal flap will be elevated. The lateral window will be made with a spherical diamond drill (number 8) at 20,000 rpm. The mesiodistal and apicocoronal dimensions of the lateral access window to the sinus will be measured in all the participants using a caliper. Sinus membrane elevation will be performed with manual instruments.
79400124|NCT06123182|Behavioral|Episodic Future Thinking|During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.
79400125|NCT06123182|Behavioral|Episodic Recent Thinking|During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.
79581351|NCT01935518|Drug|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
79265803|NCT04817150|Procedure|Laparoscopic ventral mesh rectopexy|Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
79400126|NCT06123182|Behavioral|Positive Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
79400127|NCT06123182|Behavioral|Neutral Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the physical sensations associated with an exercise bout.
79400128|NCT06123182|Behavioral|HIIT Exercise Intervention|"The high intensity interval training (HIIT) will be conducted 2 times per week for 6 weeks. The duration of each individual exercise session will last about 45 minutes. After the 5-minute warm-up at 30% peak workload, HIIT will consist of repeated 1-minute high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 80% of peak watts (range: 75%-85%) followed by the off interval at 10% of peak watts. The session will end with up to 10 minute cool-down at 20% peak workload."
79400129|NCT06123169|Drug|Antibioprophylaxis (Piperacillin-tazobactam)|antibiotic prophylaxis during surgery
79400130|NCT06123169|Drug|5 days Antibiotherapy (Piperacillin-tazobactam)|5 days Antibiotherapy from surgery
79400131|NCT06123156|Drug|Sildenafil|Sildénafil during 10 months (50mg daily), start 30 days after surgery
79400132|NCT06123156|Other|Placebo|1 platelet during 10 months (daily), start 30 days after surgery
79400133|NCT06123104|Device|Occlusion of blood flow|Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
79400134|NCT06123091|Other|Questionnaires with patient reported outcome measures|Questionnaires to gain insight of the prevalence of extracutaneous manifestations and the impact of the disease on the quality of life.
79566169|NCT01741298|Behavioral|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
79566170|NCT01741324|Dietary Supplement|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
79566171|NCT01741324|Dietary Supplement|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
79566172|NCT01741324|Dietary Supplement|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
79726688|NCT04296825|Dietary Supplement|Cow milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
79726689|NCT01012947|Behavioral|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
79726690|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
79726691|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
79726692|NCT01012947|Behavioral|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
79265804|NCT02127047|Drug|Sitagliptin|
79265805|NCT02127047|Drug|Exercise|
79400135|NCT06123078|Behavioral|CaCBT|Culturally adapted Self help guide and modules total eight 80 hour session per week
79265806|NCT04811690|Behavioral|front-of-package modification|testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
79400136|NCT06123065|Behavioral|Yoga|8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
79400137|NCT06123026|Drug|Cabergoline|1mg oral cabergoline given to participants once
79566173|NCT01741337|Procedure|Adaptive servo-ventilation post-operative treatment for 6 months|
79566174|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
79566175|NCT01741363|Other|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
79566176|NCT01741363|Other|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
79566177|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
79566178|NCT01741363|Other|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
79566179|NCT01741376|Drug|Progesterone|Progesterone 200 mg twice daily
79726693|NCT01012947|Behavioral|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
79726694|NCT00627627|Drug|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
79265807|NCT02122055|Drug|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
79265808|NCT02122055|Procedure|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
79400138|NCT06123026|Drug|Placebo|1 encapsulated placebo tablet given to participants after procedure
79400139|NCT06122987|Drug|Angiotensin II and hydrocortisone sodium succinate|Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
79400140|NCT06122935|Device|Aurora Xi New Nomogram Software 2.0|Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
79400141|NCT06122935|Device|Aurora Xi Currently Approved Software 1.3|Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
80022633|NCT02152332|Drug|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
80022634|NCT02152332|Drug|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
80022635|NCT02152332|Drug|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
79265809|NCT02122055|Procedure|Screen of weaning|1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
79265810|NCT02122055|Drug|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
79265811|NCT02122055|Drug|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
79265812|NCT02122055|Drug|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
79265813|NCT04801628|Device|Active Tecar|Active Tecar
79265814|NCT04801628|Device|Placebo Tecar|Placebo Tecar
79265815|NCT04801082|Drug|Alcohol injection|Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)
79566180|NCT01741376|Drug|Placebo|
79566181|NCT01741389|Drug|"Melatonin (Circadin)"|
80022636|NCT02152332|Drug|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
80022637|NCT03488498|Other|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
80022638|NCT05050708|Other|Patient interview|Patient will be interviewed pre-operatively and at 24 hrs post-opartively
80022639|NCT03492086|Dietary Supplement|Dietary supplementation with capsules containing rosemary and alkylglycerol|
79566182|NCT01741402|Device|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
79265816|NCT04801082|Device|Radiofrequency Ablation|coeliac plexus is identified and punctured with 19G EUSRA RFA needle with 10W-30W of energy for 10-50s bilaterally or unilaterally depends on individual anatomical characteristics.
79265817|NCT04816994|Drug|Single-dose of cannabis oil|Single-dose of cannabis oil in order to treat acute radicular pain
79726695|NCT04296513|Diagnostic Test|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
79726696|NCT04296513|Diagnostic Test|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
80022640|NCT03492086|Dietary Supplement|Dietary supplementation with control capsules|
79566183|NCT01741402|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
79566184|NCT01741415|Behavioral|SIDI|
79265818|NCT04816994|Drug|Control|Giving a sub-linguistic olive oil that is similar in appearance and taste to cannabis oil
79265819|NCT02125409|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
79265820|NCT02125409|Procedure|Screening colonoscopy|
79265821|NCT02125487|Behavioral|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
79265822|NCT02125487|Behavioral|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
79265823|NCT04811768|Procedure|Maxillary sinus augmentation|The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
79265824|NCT02122133|Device|PC 400|
79566185|NCT01741415|Behavioral|SC|
79581352|NCT01935531|Drug|3% diclofenac in 2.5% hyaluronic acid gel|
79581353|NCT01935544|Device|Botulinum toxin injection|
80022641|NCT03616197|Procedure|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
79566186|NCT01741428|Behavioral|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
80022642|NCT05050630|Drug|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
80022643|NCT05118308|Procedure|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
79726697|NCT03832153|Procedure|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
80022644|NCT05118308|Procedure|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
79265825|NCT04816760|Biological|Peripheral blood samples|Peripheral blood samples at Day 0, Day 7, Day 14, Day 28, Day 90 and Day 180.
79265826|NCT04816838|Drug|Osimertinib|"* Osimertinib 80mg once a day(QD) oral(PO)~Neoadjuvant Period -If there is no disease progression or unacceptable toxicity, treatment is performed for 2cycles at 1 cycle (28 days) interval~Adjuvant Period~- If there is no disease progression of unacceptable toxicity, treatment fis performed for 3years at intervals of 1cycle(28days)"
79566187|NCT01741441|Procedure|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
79265827|NCT04816448|Other|cervical mobilization (Headache SNAG)|For cervical mobilization the patient's position is sitting on a chair in the erect posture. The therapist handled C2 spinous process with the middle phalanx of one hand. With the other hand, he performed ventral glide asked the patient to move neck in all directions (Flexion, Extension, Side bending and rotation) one by one and then slowly move the neck back to its starting position while the therapist maintained the ventral glide.
79726698|NCT04735861|Drug|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
79861320|NCT03997149|Behavioral|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
79566188|NCT01741467|Behavioral|RT-CGM|Dexcom Seven+
79566189|NCT01741493|Drug|ABT-494|Oral administration of ABT-494 capsules
79861321|NCT03997149|Behavioral|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
79861322|NCT01016145|Drug|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
79861323|NCT01016145|Drug|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
79566190|NCT01741493|Drug|Placebo|Oral administration of placebo capsules
79566191|NCT01741493|Drug|Tofacitinib|Oral administration
79566192|NCT01741506|Drug|Dalteparin (Fragmin®)|
79566193|NCT01741519|Drug|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
79566194|NCT01741519|Drug|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
79726699|NCT04735861|Drug|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
79726700|NCT04395859|Procedure|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
79726701|NCT04395859|Other|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
79726702|NCT02693275|Device|Quotient® System iPad Test|See arm/group description
79726703|NCT04152031|Other|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
79726704|NCT03717571|Diagnostic Test|Glenohumeral translation assessment|amount of glenohumeral translation under load
79726705|NCT03685747|Drug|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
79566195|NCT01741558|Drug|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
79861324|NCT03741283|Other|Optimisation of nutrition and medication|"Inter-professional optimisation of medication prescribing:~Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~Dysphagia: occupational therapy intervention.~Oral cavity problems: odontological intervention.~Depression: geriatric intervention.~Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
80022645|NCT03617289|Drug|Magnesium Sulfate|
79566196|NCT01741558|Drug|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
79566197|NCT01741571|Device|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
79566198|NCT01741584|Behavioral|stationary bike exercise|
79566199|NCT01741584|Behavioral|aerobic|
79566200|NCT01741597|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
79566201|NCT01741597|Other|pharmacological study|Correlative studies
79566202|NCT01741597|Biological|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
79566203|NCT01741610|Biological|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
79566204|NCT01741623|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
79566205|NCT01741623|Drug|Bisoprolol|10 mg tablet once a day
79566206|NCT01741636|Other|educational intervention|Undergo Survivorship Care Planning
79861325|NCT01016223|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
79861326|NCT01016223|Drug|placebo|Matched placebo swallowed two puffs twice daily
80022646|NCT03617289|Drug|D5W|
80022647|NCT05050552|Device|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
80022648|NCT02152410|Device|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
80022649|NCT02152410|Drug|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS> 30).
80022650|NCT02236845|Device|Lacrima Medical Device and sham comparator|
80022651|NCT05050396|Procedure|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). [16, 17] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation [20]
80022652|NCT03615963|Diagnostic Test|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
79265828|NCT04816448|Other|Sub-occipital myofascial release|"For the application of the technique , the patient position is supine lying with the head fully supported on therapist's hands and therapist places 3 middle fingers just inferior to the nuchal line, lifts the fingers tips towards the ceiling while resting the head on the table and then therapist will apply a gentle upward pull. This procedure done for 2 to 3 minutes and 5 to 7 repetitions, 3 sessions per week on alternate days were given for 6 weeks.~Evaluation was done before treatment, during treatment at 4th week and after treatment at 6th week. Outcomes will be measured by NDI, PNRS and Universal Goniometer."
79265829|NCT04811612|Diagnostic Test|Warmed heel stick|One heel will be warmed before sampling with the other heel will not be warmed
79566207|NCT01741636|Other|questionnaire administration|Ancillary studies
79566208|NCT01741636|Procedure|quality-of-life assessment|Ancillary studies
79566209|NCT01741649|Procedure|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
79566210|NCT01741649|Procedure|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
79566211|NCT01741662|Other|neuropsychological evaluation|
79566212|NCT01741675|Behavioral|Questionnaire and monetary incentive|
79566213|NCT01741675|Behavioral|Questionnaire only|
79566214|NCT01741714|Other|Sham chiropractic manipulative therapy|Sham manipulation
79566215|NCT01741714|Other|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
79566216|NCT01741727|Drug|ABT-414|ABT-414 will be administered by intravenous infusion.
79566217|NCT01741753|Drug|BKM120|Orally, every morning
79566218|NCT01741753|Drug|Abiraterone|Orally, 1000 mg, every morning
79566219|NCT01741753|Drug|Prednisone|Orally, 5 mg, every morning
79566220|NCT01741766|Other|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
79581354|NCT01935557|Drug|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
79581355|NCT01935557|Drug|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
79265830|NCT02788175|Biological|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
79566221|NCT01741779|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
79566222|NCT01741779|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
79726706|NCT00614341|Device|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
79265831|NCT04811534|Behavioral|Interview|Mixed exploratory study, mixing a mainly qualitative study (semi-directed interviews) with a descriptive observational study (short self-questionnaire of the interviewees).
79726707|NCT02692573|Other|positioning|prone positioning for the initial 5 minutes of life
79726708|NCT02692573|Other|positioning|supine positioning for the initial 5 minutes of life
79861327|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
79265832|NCT04811456|Other|multisystem inflammatory syndrome in children (MIS-C)|as in group description
79265833|NCT03551171|Drug|ZL-2306 (niraparib)|"About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose."
79566223|NCT01741779|Other|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
79265834|NCT04811300|Other|There is no intervention|There is no intervention
79265835|NCT02787083|Drug|Mirabegron|
79265836|NCT02787083|Drug|Placebo|
79265837|NCT04800848|Device|Mask|Physical Fitness is evaluated with the use of a face mask
79265838|NCT02122211|Drug|Betaine supplement|
80022653|NCT05043688|Drug|SHR-1210|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: immunotherapy combined with neoadjuvant chemotherapy, immunotherapy combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
80022654|NCT03615885|Dietary Supplement|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
79861328|NCT01087645|Drug|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
79861329|NCT01087645|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
79861330|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
80022655|NCT03615885|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
79265839|NCT04800926|Device|Xavier wheelchair controller|Controlling a wheelchair using the Xavier surface EMG system
79265840|NCT02125565|Other|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
79265841|NCT04800770|Diagnostic Test|4C mortality score|4C mortality score and phosphate levels
79265842|NCT04800380|Other|Edpuzzle interactive videos|The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
79265843|NCT02122289|Device|Application of Smartphone|Weekly questionnaire on smartphone
79265844|NCT02122289|Other|No application Smartphone|No weekly questionnaire on smartphone
79265845|NCT02125643|Drug|Caffeine|
79265846|NCT02125643|Other|Flour|Flour will be administered as the placebo.
79265847|NCT04811144|Device|Er:YAG dental laser|To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp
79581356|NCT01935570|Drug|Magnesium chloride (ChronoMag Smart Tablet®)|
79726709|NCT04327921|Behavioral|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
79726710|NCT04327921|Behavioral|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
79861331|NCT01087645|Drug|placebo|Subjects will be randomised to receive a single dose of placebo
79861332|NCT04151121|Behavioral|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
79861333|NCT04151017|Other|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
79861334|NCT04151017|Other|Suture|Graft fixation using 10.0 mononylon
79861335|NCT01019265|Drug|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
80022656|NCT03615885|Dietary Supplement|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
80022657|NCT03614715|Drug|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
80022658|NCT05131802|Device|upper GIT endescopy|Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
80022659|NCT00363038|Drug|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
80022660|NCT00363038|Drug|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
79265848|NCT02122367|Other|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
79265849|NCT04797806|Drug|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
79265850|NCT04797806|Drug|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
79566224|NCT01741805|Other|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
79265851|NCT02122523|Procedure|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
79265852|NCT04811378|Other|HaemoCer|Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
80022661|NCT00363038|Drug|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
80022662|NCT00363038|Drug|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
79861336|NCT03963661|Behavioral|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
80022663|NCT03614637|Other|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
79265853|NCT03551483|Device|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
79265854|NCT03551483|Device|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
79265855|NCT04811222|Diagnostic Test|Ga-DOTATATE PETMRI scan|Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan
79265856|NCT02127437|Drug|Lanreotide|120 mg, subcutaneously, once every 4 weeks
79265857|NCT02127437|Drug|saline|0,5 ml, subcutaneously, once every 4 weeks
79265858|NCT04797494|Device|acrylic removable appliance|"Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating."
79566225|NCT01741818|Other|Measuring IVC collapsibility index by bedside ultrasonography|
79861337|NCT01087879|Drug|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
79861338|NCT01087879|Drug|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
79566226|NCT01741831|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
79566227|NCT01741844|Drug|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
79566228|NCT01741857|Biological|human umbilical cord derived MSC transplantation for SLE|
79566229|NCT01741870|Dietary Supplement|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
79581357|NCT01935570|Drug|Magnesium carbonate (Mag2® Tablet)|
80022664|NCT04876352|Other|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
79265859|NCT02127515|Procedure|Non Invasive Prenatal Testing|
79566230|NCT01741883|Behavioral|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
79566231|NCT01741883|Behavioral|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
79265860|NCT02127515|Procedure|Invasive Prenatal Testing|
79726711|NCT04154761|Procedure|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
79726712|NCT03586687|Drug|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
79726713|NCT04324099|Other|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
79726714|NCT04324099|Other|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
79726715|NCT04324099|Other|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
79861339|NCT01087879|Drug|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
79861340|NCT01019421|Drug|Lu AE58054|Add-on treatment to donepezil
79861341|NCT01019421|Drug|Placebo|Add-on treatment to donepezil
79861342|NCT01085695|Drug|rabeprazole|10 mg normal tablet
79861343|NCT01085695|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
79861344|NCT01085695|Drug|rabeprazole|Type 2 granule containing rabeprazole 10 mg
79861345|NCT01085695|Drug|rabeprazole|Type 3 granule containing rabeprazole 10 mg
79861346|NCT00572195|Device|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
79265861|NCT04799678|Other|Recording voice samples|A maximum of 9 voice sample recording session will be carried out on their phones and take less than 2 minutes each
79265862|NCT04799600|Other|BRESCİA-COVİD Respiratory Severity Scale|KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
79265863|NCT02122601|Drug|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
79265864|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
79265865|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
79265866|NCT04810832|Other|Evoked related potentials|"Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~with scalp electrodes in the department of neurophysiology~with intracranial electrodes in the department of neurosurgery."
79566232|NCT01741896|Procedure|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
79566233|NCT01741909|Behavioral|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
79861347|NCT01088035|Drug|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
79861348|NCT03961477|Other|Interferential therapy|Exercise therapy
79861349|NCT01085851|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
80022665|NCT04876352|Other|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
79861350|NCT01085851|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
80022666|NCT04876352|Other|No intervention|Only baseline evaluations, without longitudinal assessment
79265867|NCT02125799|Device|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
79265868|NCT04812158|Other|standard ankle physiotherapy or rehabilitation for chronic ankle instability|6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
79265869|NCT02122679|Drug|Tranexamic Acid|
79265870|NCT02122679|Drug|placebo|
79265871|NCT02127671|Other|IDEAL intervention|
79566234|NCT01741922|Drug|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
79726716|NCT04324099|Other|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
79265872|NCT02127671|Other|Control|
79726717|NCT04324099|Other|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
79726718|NCT04324099|Other|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
79861351|NCT00751127|Drug|PhXA41|One drop in the affected eye once daily for six months.
79861352|NCT00751127|Drug|timolol|One drop in the affected eye twice daily for six months.
79861353|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
80022667|NCT03489668|Drug|MetFORMIN 500 Mg Oral Tablet|metformin administration 1500mg per day
79265873|NCT04810754|Drug|Daratumumab Injection|1800 mg per injection; 8 consecutive injections once a week; subcutaneous application in abdomen
79265874|NCT02122757|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
79265875|NCT02122757|Device|sham Cefaly tDCS|2mA during 30sec
80022668|NCT02872311|Biological|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
80022669|NCT02872311|Biological|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
79265876|NCT04810286|Procedure|3d-Printing Myofunctional Appliance|To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
80022670|NCT02872311|Biological|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
80022671|NCT02872311|Biological|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
80022672|NCT04461470|Genetic|epigenetic longitudinal waves|force - inducing energies using electromagnetic field(s)
79265877|NCT02127749|Drug|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
79265878|NCT02127749|Drug|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
79265879|NCT02125955|Dietary Supplement|Prebiotic fiber|Dissolved in water.
79265880|NCT02125955|Dietary Supplement|Placebo|Dissolved in water
79265881|NCT04810442|Other|Nap|45-minute nap between scanning procedures
79265882|NCT02126033|Procedure|take blood samples|
80022673|NCT05120336|Device|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
80022674|NCT05120336|Device|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
80022675|NCT03488342|Procedure|Repair for primary inguinal hernia|Repair for primary inguinal hernia
80022676|NCT03614403|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
80022677|NCT04461314|Behavioral|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
79566235|NCT01741922|Drug|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
80022678|NCT02871375|Device|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
80022679|NCT02871375|Device|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
80022680|NCT04691414|Genetic|NGS|next-generation sequencing on preexisting samples
80022681|NCT02032017|Procedure|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
80022682|NCT02032017|Procedure|Percutaneous assisted approach|
80022683|NCT02032017|Procedure|Anterolateral approach|
80022684|NCT02032017|Other|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
79566236|NCT01741922|Drug|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
79566237|NCT01741922|Drug|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
80022685|NCT03492008|Other|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
80022686|NCT03492008|Other|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
79581358|NCT01935583|Behavioral|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
79581359|NCT01935596|Drug|ropivacaïne|spinal anesthesia.
79581360|NCT01935596|Drug|lévobupivacaïne|
79726719|NCT04324099|Other|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
80022687|NCT03492008|Other|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
80022688|NCT03488186|Drug|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
80022689|NCT05103644|Drug|Atorvastatin 80mg|patients received statin experimental group
80022690|NCT05103644|Other|placebo|patients received placebo control group
80022691|NCT03614325|Other|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
79726720|NCT04324099|Other|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
80022692|NCT03615651|Dietary Supplement|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
80022693|NCT03615651|Other|Placebo|Placebo intervention.
80022694|NCT03491930|Device|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
79265883|NCT04797338|Drug|Synarel, 0.2 Mg/Inh Nasal Spray|Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
80022695|NCT03491930|Behavioral|Telephone Coaching|Weekly Telephone Coaching
79726721|NCT04324099|Other|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
79861354|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
79861355|NCT00572039|Behavioral|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
79861356|NCT00572039|Behavioral|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
79861357|NCT00751283|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
79861358|NCT00752063|Drug|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
79861359|NCT00751361|Device|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
79861360|NCT00684593|Drug|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
79861361|NCT00684593|Other|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
80022696|NCT03491930|Behavioral|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~Vioscreen food frequency assessment and bionutritionist consult.~Healthy eating nutritional pamphlets (during consult)~Decrease daily caloric intake by 500 cal/day~Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~Dietary counseling by Clinician (monthly)"
80022697|NCT03614091|Procedure|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
79861362|NCT00752141|Drug|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
80022698|NCT03614091|Procedure|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
80022699|NCT03887624|Drug|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
79265884|NCT04797338|Drug|Estrofem|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
79265885|NCT04797338|Drug|Utrogestan|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
79566238|NCT01741948|Drug|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
79566239|NCT01741961|Procedure|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
79861363|NCT00752141|Drug|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
79861364|NCT00752141|Other|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
79265886|NCT04797338|Drug|Hydroxyprogesterone Caproate|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
79265887|NCT05272865|Drug|Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator|Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
79566240|NCT01741974|Dietary Supplement|Karinat|
79566241|NCT01741974|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
79861365|NCT03879317|Device|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
79861366|NCT00752375|Drug|Trimethoprim Sulfamethoxazole|"Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
79566242|NCT01741987|Other|Optive ®|instilation of 1 drop each eye 4 times per day
79566243|NCT01741987|Other|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
79566244|NCT01742000|Dietary Supplement|Karinat|
79566245|NCT01742000|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
79265888|NCT04810676|Drug|CKD-501, D745, D150|QD, PO
79861367|NCT00752375|Drug|placebo|"Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
79861368|NCT00751517|Drug|Methotrexate|
79861369|NCT00751517|Drug|Cyclophosphamide|
80022700|NCT03887624|Drug|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
79566246|NCT01742013|Drug|GCJBP Laennec Inj.|Test drug
79726722|NCT04324099|Other|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
80022701|NCT03887624|Drug|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
79265889|NCT04810676|Drug|CKD-383|QD, PO
79566247|NCT01742013|Drug|Placebo|Comparator
79566248|NCT01742052|Drug|MT-1303-Low|
79566249|NCT01742052|Drug|MT-1303-Middle|
79566250|NCT01742052|Drug|MT-1303-High|
79566251|NCT01742052|Drug|Placebo|
79566252|NCT01742130|Drug|sodium bicarbonate solution|
79566253|NCT01742130|Drug|Isotonic saline|
79566254|NCT01742169|Behavioral|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
79726723|NCT04324099|Other|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
79861370|NCT00751595|Biological|Tat protein|Biologically active recombinant Tat protein
79861371|NCT00685373|Drug|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
79861372|NCT02561117|Drug|Metronidazole|Administration once daily
79265890|NCT03552107|Drug|Lorcaserin|Treatment initiation with Lorcaserin
79265891|NCT04798976|Drug|neoadjuvant/adjuvant therapy|chemotherapy/endocrine therapy/surgery/radiotherapy
79265892|NCT04797182|Drug|avatrombopag|avatrombopag,60 mg/d,po
79265893|NCT02787863|Biological|Prevenar-13|Conjugate 13 serotype pneumococcal vaccine
79265894|NCT02787863|Biological|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
79265895|NCT04809818|Drug|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
79265896|NCT04809818|Drug|Placebo|Multiple doses of Placebo administered by intravenous infusion
79265897|NCT04809818|Drug|Aspirin|Loading and maintenance doses of Aspirin administered by oral
79265898|NCT04809818|Drug|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
79566255|NCT01742182|Other|Light exposure|
79566256|NCT01742195|Procedure|Oral EBUS insertion|
79566257|NCT01742195|Procedure|Nasal EBUS insertion|
79566258|NCT01742221|Biological|HemaMax|single subcutaneous 12 microgram dose of HemaMax
79566259|NCT01742221|Drug|Placebo|single subcutaneous dose
79566260|NCT01742234|Procedure|Organ Donation|People in this study will donate either a lung or kidney
79566261|NCT01742247|Other|Physiogel|Application of moisturizer on laser-treated area
80022702|NCT03614247|Procedure|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
79265899|NCT04809818|Drug|Apixaban|Multiple doses of Apixaban administered by oral
79265900|NCT04809818|Drug|Dabigatran|Multiple doses of Dabigatran administered by oral
79566262|NCT01742247|Other|Moisturizer|Application of moisturizer on laser-treated area
79566263|NCT01740999|Procedure|silicone arthroplasty|silicone arthroplasty
79400150|NCT06122805|Device|Toothbrush|We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
79566264|NCT01740999|Procedure|arthrodesis|arthrodesis
79566265|NCT01742260|Procedure|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
79726724|NCT04324099|Other|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
79726725|NCT04324099|Other|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~Aggressive Behavior~Anxious/Depressed~Attention Problems~Rule-Breaking Behavior~Somatic Complaints~Social Problems~Thought Problems~Withdrawn/Depressed. Higher scores indicate greater Problems."
79861373|NCT00684515|Drug|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
79861374|NCT00684515|Drug|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
79566266|NCT01742273|Drug|Vitamin K1|Vitamin K1 to slow vascular calcification
79566267|NCT01742312|Radiation|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
79566268|NCT01742312|Procedure|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
79566269|NCT01742312|Other|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
79566270|NCT01742325|Behavioral|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
79861375|NCT00684515|Drug|Placebo|oral tablets; once daily for 60 days
79861376|NCT00684515|Drug|Aspirin 75-150 mg|oral tablets; once daily for 60 days
79265901|NCT04797416|Device|FGM infiltration 1 hour group|The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
79265902|NCT04797416|Device|FGM infiltration 6-hour group|Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
79265903|NCT04797416|Device|FGM infiltration 12-hour group|Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
79265904|NCT02126111|Biological|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
79265905|NCT02126111|Biological|DEPIGOID Placebo|Placebo for subcutaneous administration
79265906|NCT04796480|Dietary Supplement|YOGURT|Group 1 was given yogurt
79566271|NCT01742338|Drug|Low Dose Corticosteroids|
79566272|NCT01742338|Drug|High Dose Corticosteroids|
79726726|NCT04324099|Other|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
79861377|NCT00751751|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
79861378|NCT00751751|Drug|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
79861379|NCT00490815|Drug|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
79265907|NCT04796480|Dietary Supplement|LACTOSE FREE FORMULA MILK|Group 2 was given lactose free formula milk
79265908|NCT02127827|Device|Automated Ambulatory Glycemic Controller (AAGC)|
79265909|NCT02127905|Biological|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
79861380|NCT00490815|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
79400151|NCT06122792|Procedure|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
79400152|NCT06122792|Procedure|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic injection of tissue adhesives will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new endoscopic injection of tissue adhesives will be performed."
79400153|NCT06122753|Procedure|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
79566273|NCT01742351|Behavioral|Guided internet-based cognitive behavior therapy|
79400154|NCT06122753|Procedure|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
79566274|NCT01742377|Procedure|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
79566275|NCT01742377|Procedure|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
79566276|NCT01742377|Procedure|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
79566277|NCT01742390|Drug|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
79566278|NCT01742390|Drug|risperidone or paliperidone|
79566279|NCT01742416|Procedure|Ultrasound|Arterial cannulation facilitated by ultrasound.
79566280|NCT01742416|Procedure|Palpation Method|Arterial cannulation by palpation method.
79566281|NCT01742429|Drug|Proton pump inhibitor|
79861381|NCT01016301|Other|Pharmacist service|Medication Review, medication report
79566282|NCT01742429|Drug|Bismuth subsalicylate|
79861382|NCT01014663|Behavioral|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
79861383|NCT01014663|Behavioral|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
79861384|NCT01019499|Other|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
79861385|NCT01019499|Other|control products|two portions daily
79861386|NCT04453137|Biological|Adalimumab originator|Subcutaneous injection every other week
79861387|NCT04453137|Biological|Adalimumab biosimilar|Subcutaneous injection every other week
79566283|NCT01742429|Drug|Metronidazole|antibiotic
79861388|NCT03855189|Drug|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
79861389|NCT03855189|Drug|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) [336 mcg total dose per day] for 4 weeks.
79265910|NCT04798742|Procedure|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
79265911|NCT04796402|Biological|Bamlanivimab|700 mg/20mL IV over at least one hour OD
79265912|NCT04796402|Other|Standard of Care|Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
79265913|NCT02127983|Behavioral|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
79566284|NCT01742429|Drug|Tetracycline|antibiotic
79861390|NCT03855189|Drug|Placebo|Placebo nasal spray administered for 4 weeks.
79861391|NCT03853551|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
80022703|NCT03614247|Procedure|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
80022704|NCT03614247|Procedure|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
80022705|NCT03614247|Procedure|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
80022706|NCT03614247|Procedure|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
80022707|NCT03486002|Device|Cleansweep|The Cleansweep closed suction system
80022708|NCT03486002|Device|Halyard|Halyard Closed Suction System
80022709|NCT03489590|Drug|PFP|"Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
80022710|NCT02867709|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
80022711|NCT02867709|Drug|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
80022712|NCT02446028|Drug|BIOD-531|
80022713|NCT02446028|Drug|Humalog® Mix 75/25|
79566285|NCT01742429|Drug|Amoxicillin|antibiotic
80022714|NCT03485846|Drug|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
80022715|NCT03485846|Drug|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
80022716|NCT03485846|Drug|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
80022717|NCT04461392|Diagnostic Test|Cardiorespiratory exercise test|"Cardiorespiratory exercise test to evaluate the exercise tolerance~Cardiac imaging for the assessment of the left atrium anatomy and function."
80022718|NCT04909671|Device|Gi Genius, Medtronic|GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.
80022719|NCT04909671|Other|White light standart colonoscopy|High definition white light endoscopy will be used during the scope withdrawal
80022720|NCT02032095|Drug|GB-0998|
79861392|NCT00423670|Drug|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
80022721|NCT03614169|Procedure|Implantation of a HIS-pacing lead|This intervention is attempted first
80022722|NCT03614169|Procedure|Implantation of a LV-pacing lead|This intervention is attempted first
80022723|NCT03613857|Drug|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
79566286|NCT01742429|Drug|Levofloxacin|antibiotic
79566287|NCT01742468|Dietary Supplement|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
79566288|NCT01742468|Dietary Supplement|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
79566289|NCT01742481|Behavioral|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
79861393|NCT00423670|Drug|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
79566290|NCT01742494|Procedure|Water-jet POEM|Water-jet assisted POEM procedure was performed
79861394|NCT00423670|Drug|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
79861395|NCT00423670|Drug|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
79566291|NCT01742494|Procedure|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
79566292|NCT01742507|Device|Resolute Integrity Stent|Resolute Integrity Stent
79566293|NCT01742507|Device|Biomatrix stent|Biomatrix stent
79566294|NCT01742520|Drug|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
79566295|NCT01742520|Drug|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
79566296|NCT01742533|Biological|human umbilical cord mesenchymal stem cells|
79566297|NCT01742533|Biological|hUCMSCs and hCBMNCs|
79861396|NCT03996759|Diagnostic Test|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
79861397|NCT01016379|Genetic|DNA analysis|
79861398|NCT01016379|Other|biologic sample preservation procedure|
79861399|NCT01016379|Other|laboratory biomarker analysis|
79861400|NCT01019577|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
79861401|NCT05072535|Drug|HA121-28 tablet B|HA121-28 tablet B 200 mg
79861402|NCT05072535|Drug|HA121-28 tablet A|HA121-28 tablet A 200 mg
79861403|NCT03996681|Drug|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
79861404|NCT01019655|Drug|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
79861405|NCT01019733|Procedure|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
79861406|NCT00483717|Drug|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
79861407|NCT00483717|Drug|Placebo|Intranasal (IN) placebo
80022724|NCT03613857|Drug|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
79861408|NCT00406354|Drug|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
79861409|NCT00406354|Drug|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
79566298|NCT01742533|Biological|human cord blood mononuclear cells|
79566299|NCT01742533|Drug|Hormone Replacement Therapy|
79861410|NCT01037842|Drug|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
79861411|NCT01037842|Drug|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
79566300|NCT01742546|Device|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
79566301|NCT01742559|Procedure|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman & Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
79566302|NCT01742559|Procedure|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
79566303|NCT01742572|Behavioral|Diet|Change in dietary intake
79566304|NCT01742585|Drug|ASP1585|oral
79566305|NCT01742585|Drug|placebo|oral
79566306|NCT01742598|Device|Portico Transapical Aortic Valve System|
79566307|NCT01742611|Drug|ASP1585|oral
79566308|NCT01742624|Drug|Advagraf|oral
79566309|NCT01742624|Drug|Prograf|oral
79566310|NCT01742624|Drug|Corticosteroid|oral
79566311|NCT01742624|Drug|Mycophenolate mofetil|oral
79566312|NCT01742637|Drug|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
79566313|NCT01742637|Drug|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
79566314|NCT01742637|Drug|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
79566315|NCT01742650|Procedure|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
79566316|NCT01742650|Procedure|TightRope|TightRope transfixation of syndesmosis
79566317|NCT01742663|Drug|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
79566318|NCT01742663|Drug|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
80022725|NCT03613389|Dietary Supplement|oral topical vitamin E|Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
80022726|NCT03613779|Combination Product|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
79566319|NCT01742663|Drug|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
80022727|NCT03613779|Other|Standard of Care|Standard of care will be provided.
80022728|NCT03044353|Drug|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
80022729|NCT03044353|Biological|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
79265914|NCT02127983|Behavioral|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
79265915|NCT04798508|Other|Evoked related potential - P3 paradigm|Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
79265916|NCT03551093|Device|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
79566320|NCT01742676|Drug|ADVAGRAF|oral
79566321|NCT01742676|Drug|PROGRAF|oral
79861412|NCT01037920|Behavioral|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
79566322|NCT01742689|Drug|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
80022730|NCT03614013|Other|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
79566323|NCT01742689|Drug|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
79861413|NCT01037920|Behavioral|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
80022731|NCT03613311|Diagnostic Test|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
80022732|NCT02032329|Device|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
80022733|NCT02259777|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
80022734|NCT02259777|Other|high fat, high caloric meal|
79566324|NCT01742689|Drug|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
79861414|NCT00483405|Biological|cetuximab|250 mg/m2, intravenously, once per week
80022735|NCT03613935|Other|Product 1|Comparison with products 2, 3, and 4
79566325|NCT01742702|Drug|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
79566326|NCT01742702|Drug|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
79566327|NCT01742702|Drug|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
79566328|NCT01742702|Dietary Supplement|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
79861415|NCT00483405|Drug|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
79861416|NCT00483405|Drug|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
79861417|NCT00483327|Drug|Megestrol Acetate|
80022736|NCT03613935|Other|Product 2|Comparison with products 1, 3, and 4
80022737|NCT03613935|Other|Product 3|Comparison with products 1, 2, and 4
80022738|NCT03613935|Other|Product 4|Comparison with products 1, 2, and 3
80022739|NCT03261375|Device|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
80022740|NCT03261375|Drug|Antihypertensive Agents|Calcium channel blocker, Diuretic
80022741|NCT03261375|Device|Sham Procedure|Catheterization without renal denervation
80022742|NCT03613233|Procedure|Glaucoma surgery|phacoemulsification
80022743|NCT03613545|Procedure|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
80022744|NCT03613545|Procedure|Infusion of sham|Infusion of sham
80022745|NCT03613545|Drug|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
80022746|NCT01361308|Drug|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
79265917|NCT04809584|Drug|F18-DCFPyL|Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL
79265918|NCT04809584|Drug|Gadolinium|Contrast agent
79265919|NCT04809584|Procedure|Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan|Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)
80022747|NCT01361308|Drug|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
80022748|NCT03613467|Procedure|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
80022749|NCT03613467|Procedure|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
80022750|NCT03613155|Other|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
80022751|NCT02032251|Drug|oral administration of ginger|Oral administration of ginger in patients with infertility.
80022752|NCT02032251|Drug|Placebo|
80022753|NCT03612765|Behavioral|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
80022754|NCT03612999|Device|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
80022755|NCT03612999|Device|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
80022756|NCT03612999|Behavioral|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
79400155|NCT06122727|Procedure|total knee arthroplasty|In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.
79861418|NCT01019811|Procedure|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
79566329|NCT01742702|Dietary Supplement|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
79861419|NCT00684203|Drug|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
79861420|NCT00684203|Drug|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
79861421|NCT00684203|Drug|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
79861422|NCT00684203|Drug|Clopidogrel|100 mg two or three times daily for 60 days.
80022757|NCT03612999|Behavioral|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
80022758|NCT05043142|Diagnostic Test|ELISA test for the antibodies to COVID-2019.|Each subject will be assigned an individual number, which will be used for conduction of a rapid ELISA test for the antibodies to COVID-2019. Subjects will be notified of the test results.
80022759|NCT03612297|Diagnostic Test|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
80022760|NCT02872935|Drug|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
80022761|NCT02872935|Drug|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
79566330|NCT01742702|Drug|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
79861423|NCT00423592|Drug|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
79861424|NCT04055987|Behavioral|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
79861425|NCT01037998|Drug|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
79861426|NCT00752687|Drug|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
79861427|NCT00752687|Drug|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
79861428|NCT02561429|Procedure|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
79861429|NCT00751907|Drug|atorvastatin|40mg daily for 4 months
79861430|NCT00751907|Drug|Placebo|Matching placebo daily for 4 months
79861431|NCT00752843|Drug|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
79566331|NCT01742715|Other|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
79566332|NCT01742715|Other|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
79566333|NCT01742715|Other|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
79726727|NCT04324099|Other|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
79726728|NCT03584737|Diagnostic Test|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
79726729|NCT03584737|Diagnostic Test|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
79726730|NCT03584737|Diagnostic Test|PCR assay|Semiquantitative real-time PCR assay
79726731|NCT01214603|Drug|LY2090314|Administered intravenously
79726732|NCT02692729|Procedure|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
79726733|NCT02692729|Procedure|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
79726734|NCT02692807|Procedure|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
79726735|NCT04308889|Drug|Lovaza|Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
79861432|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
79861433|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
80022762|NCT00103662|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
79726736|NCT04308889|Other|Cantharone|Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
79726737|NCT04308889|Other|Phlebotomy|Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
79726738|NCT01212185|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
79726739|NCT01212185|Other|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
79861434|NCT00752921|Drug|etoricoxib|120 mg
79861435|NCT00752921|Drug|placebo|placebo
79861436|NCT00683657|Drug|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
79861437|NCT00683657|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
79861438|NCT00755885|Drug|abiraterone acetate|
79861439|NCT00755885|Other|laboratory biomarker analysis|
79861440|NCT00755885|Other|pharmacogenomic studies|
79861441|NCT00755963|Drug|estradiol valerate|Progynova® 21; 2mg/d
79861442|NCT00755963|Drug|micronized progesterone|Utrogestan®; 200mg/d
79861443|NCT00755963|Drug|placebo|maltodextrin
79861444|NCT00752999|Drug|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
79861445|NCT00752999|Drug|Placebo|Placebo tablet, oral, twice-a-day
79861446|NCT00756041|Drug|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
79861447|NCT00753155|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
79861448|NCT00756197|Device|Cryo Spray Ablation Group 1|Cryo Spray Ablation
79265920|NCT04809428|Procedure|vNOTES salpingectomy|Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.
80022763|NCT00103662|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
79400156|NCT06122701|Dietary Supplement|Thiamin|"A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
79400157|NCT06122688|Behavioral|Navigator Plus App Intervention|Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
79566334|NCT01742741|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
80022764|NCT03612219|Drug|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
79566335|NCT01742754|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
80022765|NCT03612219|Radiation|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
80022766|NCT03612219|Drug|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
79400158|NCT06122675|Device|DBS|Implanted in the cerebellum.
79566336|NCT01742767|Drug|Cisplatinum|
79566337|NCT01742767|Drug|Pemetrexed|
79566338|NCT01742780|Procedure|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
79566339|NCT01742793|Drug|lenalidomide (Revlimid) and romidepsin (Istodax)|
79726740|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
79861449|NCT00756197|Device|Cryo Spray Ablation Group 2|cryo spray ablation
79861450|NCT00753311|Drug|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
79265921|NCT04809428|Procedure|Laparoscopic salpingectomy|Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
79265922|NCT02126267|Procedure|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
79265923|NCT02126267|Procedure|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
79265924|NCT02126267|Drug|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
79265925|NCT02126267|Drug|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
79265926|NCT02126267|Drug|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
79303989|NCT04657133|Device|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
79400159|NCT06122597|Other|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
79400160|NCT06122584|Drug|[18F]PSMA-1007|Diagnostic radiopharmaceutical for PET scan
79566340|NCT01742806|Device|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
79566341|NCT01742845|Other|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
79566342|NCT01742845|Other|landmark based superfical ropivacaine 4.75 mg/ml injection|
79566343|NCT01742884|Other|Thealoz|Instillation of 1 drop of Thealoz
79566344|NCT01742884|Other|Vehicle|1 drop of the vehicle will be instillated in the eye
79566345|NCT01742910|Procedure|intraocular lens implantation|
79566346|NCT01742923|Behavioral|Complex tailored intervention|
79566347|NCT01742923|Behavioral|Usual care|
79265927|NCT02131103|Other|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
79265928|NCT04796090|Other|Clinical assessment|FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
79265929|NCT02126345|Device|MASTER SL femoral stem and DELTA TT acetabular cup|
79265930|NCT02126423|Other|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
80022767|NCT03612843|Other|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
79566348|NCT01742962|Procedure|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
79566349|NCT01742975|Device|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
79566350|NCT01742988|Drug|fimepinostat|
79861451|NCT00756431|Device|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
79861452|NCT00756431|Device|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
79566351|NCT01742988|Drug|Rituximab|
79265931|NCT04808960|Diagnostic Test|clinical Computed Tomography|Clinical CT was acquired (scanned at 1.25mm x 1.25mm on a standard algorithm and then reformatted into an axial, coronal and sagittal series at 3mm x 2mm) on all fully intact cadavers prior to the onset of this study by the Schulich School of Medicine & Dentistry at the University of Western Ontario, in accordance with the Anatomy Act of Ontario and guidelines of Western's Committee for Cadaveric Use in Research.
79265932|NCT02128061|Drug|Lenalidomide|
79400161|NCT06122571|Other|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
79861453|NCT00756587|Device|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
79861454|NCT00756587|Device|Bottle Feeding|receiving all feeding by bottle
79400162|NCT06122558|Dietary Supplement|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
79566352|NCT01742988|Drug|venetoclax|
79566353|NCT01743014|Drug|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
79861455|NCT00756743|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
79861456|NCT00756743|Drug|Placebo|Placebo capsules q12 hours for 10 days
79400163|NCT06122558|Dietary Supplement|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
79566354|NCT01743014|Drug|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
79566355|NCT01743053|Device|Standard Care plus ReCell|
79566356|NCT01743053|Other|Standard Care|
79566357|NCT01743066|Dietary Supplement|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
79566358|NCT01743079|Drug|Telbivudine|LdT 600mg QD
79566359|NCT01743079|Drug|Lamivudine|LAM 100mg QD
79566360|NCT01743105|Procedure|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
79861457|NCT00753389|Other|None (anesthesia)|anesthesia
79861458|NCT00753467|Drug|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
79861459|NCT00753467|Drug|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
79861460|NCT00753467|Drug|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
79861461|NCT00482703|Drug|Dasatinib|tablets, Oral, 100 mg, once daily
79861462|NCT00482703|Drug|dasatinib|tablets, Oral, 50 mg, twice daily
79861463|NCT00757055|Drug|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
79861464|NCT00757055|Drug|Placebo|No active treatment given
79861465|NCT04052867|Drug|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
79861466|NCT04052867|Drug|Normal saline|An equivalent volume of normal saline is given
79861467|NCT00757133|Procedure|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
79861468|NCT00757133|Procedure|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
79566361|NCT01743105|Procedure|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
80022768|NCT05030116|Drug|Shenqu Xiaoshi oral liquid|Shenqu Xiaoshi oral liquid
80022769|NCT05030116|Drug|Domperidone suspension|Domperidone suspension
80022770|NCT05049304|Other|Functional olive oil|Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
80022771|NCT05049304|Other|Olive oil|Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
79726741|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
80022772|NCT02255058|Other|No intervention|The study is a Prospective observational cohort study
79566362|NCT01743118|Drug|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
79566363|NCT01743118|Drug|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
79726742|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
79726743|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
79726744|NCT03626233|Other|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
79726745|NCT04460131|Diagnostic Test|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
79726746|NCT04424797|Other|Prone Positioning|Intervention is patient in prone positioning
79726747|NCT04424797|Other|Supine Positioning|Intervention is patient in supine positioning
79726748|NCT03369301|Drug|Gammanorm|Gammanorm given per standard of care
80022773|NCT02148978|Drug|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
79726749|NCT03369301|Drug|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
79726750|NCT00614419|Device|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
79726751|NCT00614419|Device|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
79726752|NCT03229915|Behavioral|cognitive processing therapy|Group therapy for PTSD patients
80022774|NCT04470154|Drug|Stage I:HSK21542 0.05 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
79861469|NCT00482391|Biological|trastuzumab|
80022775|NCT04470154|Drug|Stage I:HSK21542 0.15 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
80022776|NCT04470154|Drug|Stage I:HSK21542 0.30 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
80022777|NCT04470154|Drug|Stage I:HSK21542 0.80 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
80022778|NCT04470154|Drug|Stage II:HSK21542 0.3 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
80022779|NCT04470154|Drug|Stage II:HSK21542 0.6 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
79265933|NCT02128061|Drug|Rituximab|
79265934|NCT05615558|Other|Dietary Intervention|Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
79265935|NCT02128295|Device|Electric breast pump - A|
79265936|NCT02128295|Device|Electric breast pump - B|
79265937|NCT03551015|Other|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
79265938|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with IUD
79265939|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with EUD
79265940|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with IUD
79265941|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with EUD
79265942|NCT02252393|Other|quality-of-life assessment|Ancillary studies
79265943|NCT02596958|Drug|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
79861470|NCT00482391|Drug|cyclophosphamide|
79861471|NCT00482391|Drug|doxorubicin hydrochloride|
79861472|NCT00482391|Drug|lapatinib ditosylate|
79265944|NCT03550625|Diagnostic Test|Computer program|No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
79861473|NCT00482391|Drug|paclitaxel|
79861474|NCT00482391|Other|laboratory biomarker analysis|
79861475|NCT00753779|Drug|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
79265945|NCT02128373|Procedure|Usual care|Health care provided by physician, physician's nurse, and social worker
79265946|NCT02128373|Other|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
79265947|NCT02128373|Other|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
79566364|NCT01743118|Drug|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
79566365|NCT01743144|Drug|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
79566366|NCT01743144|Drug|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
79566367|NCT01743157|Drug|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, & 4)
79566368|NCT01743170|Other|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
79566369|NCT01743183|Device|Threshold|The load adjustment was done weekly by a single examiner.
79566370|NCT01743222|Genetic|eASC|"First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
79566371|NCT01743222|Drug|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
79566372|NCT01743235|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
79566373|NCT01743235|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
79566374|NCT01743235|Drug|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
79861476|NCT00753779|Drug|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
79265948|NCT02128373|Other|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
79265949|NCT02128373|Other|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
79265950|NCT02128373|Other|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
79265951|NCT04764422|Biological|Normal Saline|0.9% normal saline for injection
79265952|NCT04764422|Biological|NDV-HXP-S vaccine|Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
79265953|NCT02126501|Other|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
79265954|NCT04794998|Drug|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
79566375|NCT01743261|Other|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
79566376|NCT01743261|Other|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
79566377|NCT01743274|Procedure|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
79566378|NCT01743287|Drug|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
79861477|NCT00757211|Genetic|polymorphism analysis|
79861478|NCT00757211|Other|laboratory biomarker analysis|
79861479|NCT00757211|Other|questionnaire administration|
79861480|NCT00757289|Biological|PRP Injection|PRP Injection
79861481|NCT00757289|Biological|Corticosteroid Injection|Corticosteroid Injection
79566379|NCT01743287|Drug|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
79566380|NCT01743300|Drug|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
79566381|NCT01743300|Drug|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
79566382|NCT01743300|Other|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
79726753|NCT05345431|Device|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
79861482|NCT00757367|Drug|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
79265955|NCT04794998|Drug|Control treatment schedule|Treatment regimens different from the recommended one according to family phisicians personal practice.
79265956|NCT04808726|Behavioral|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
80022780|NCT03612609|Biological|blood, urine and semen sample|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
80022781|NCT05048914|Drug|Ibuprofen|treatment of acute migraine attack
80022782|NCT02255136|Other|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
80022783|NCT02255136|Other|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
80022784|NCT04715529|Drug|FZJ-003|Subjects will receive FZJ-003 oral capsules in a dose escalation format.
80022785|NCT04715529|Drug|Placebo|Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
80022786|NCT03094624|Other|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
80022787|NCT03094624|Other|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
79566383|NCT01743300|Other|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
79566384|NCT01743326|Procedure|Radio Frequency Denervation|
79861483|NCT00757523|Drug|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
79265957|NCT04808648|Drug|SH-1028|tablet, oral, 200 mg once daily for day 1 and day 12
79265958|NCT04808648|Drug|Itraconazole|capsule, oral, 200 mg twice daily for day 8 to day 14
79265959|NCT04808648|Drug|Rifampicin|capsule, oral, 600 mg once daily for day 8 to day 16
79265960|NCT03550547|Other|Educational workshops|1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
79265961|NCT03550547|Other|Spa Therapy|Approved Spa therapy of knee osteoarthritis patients
79265962|NCT04808804|Diagnostic Test|Optical Coherence Tomography (OCT)|a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
79265963|NCT02131337|Other|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
79265964|NCT04786652|Device|estimated stroke volume variation (esSVV, Nihon Kohden, Japan)|Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
79303990|NCT04657133|Drug|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
79566385|NCT01743326|Procedure|Local Anesthesia|
79566386|NCT01743339|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
79566387|NCT01743339|Behavioral|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
79566388|NCT01743365|Drug|Cisplatin-5FU-Afatinib|
79566389|NCT01743378|Procedure|TAP Block Ropivacaine 0,75 %|
79566390|NCT01743378|Procedure|TAP Block Saline 0,9 %|
79566391|NCT01743404|Dietary Supplement|Inflaminat|
79566392|NCT01743404|Drug|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
79726754|NCT05345431|Device|PTA|Treating with balloon dilation or stent implantation
79726755|NCT05345275|Other|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
79566393|NCT01743417|Behavioral|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
79566394|NCT01743430|Other|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
79566395|NCT01743443|Other|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
79566396|NCT01743456|Other|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
79726756|NCT01995175|Procedure|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
79726757|NCT01995175|Procedure|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
79861484|NCT00757523|Drug|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
79861485|NCT00753857|Other|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
79861486|NCT00753857|Other|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
79861487|NCT00423046|Biological|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
79861488|NCT00423046|Biological|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
79566397|NCT01743482|Drug|Pazopanib|
79265965|NCT04786652|Diagnostic Test|Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB|In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
79265966|NCT04786652|Diagnostic Test|Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period|2) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
79566398|NCT01743495|Behavioral|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
79566399|NCT01743508|Procedure|Misoprostol treatment by midwife|Misoprostol treatment by midwife
79566400|NCT01743547|Other|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
79566401|NCT01743573|Other|yoga|
79265967|NCT02126657|Drug|70% glycolic acid|
79265968|NCT04786418|Other|Standard of care|Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.
79566402|NCT01743586|Other|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
79566403|NCT01743612|Procedure|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
79566404|NCT01743612|Procedure|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
79566405|NCT01743638|Procedure|MR-Guided Laser Ablation|
79566406|NCT01743664|Behavioral|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
79566407|NCT01743664|Behavioral|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
79726758|NCT01995175|Other|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
79726759|NCT03611101|Combination Product|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
79566408|NCT01743690|Biological|Probiotic lactobacilli reuteri|
79566409|NCT01743690|Drug|Nystatin|
79566410|NCT01743690|Drug|fluocinolone|
79726760|NCT03611101|Drug|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
79861489|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
79861490|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
79861491|NCT00757679|Drug|Milnacipran|capsules
79861492|NCT00757679|Drug|Placebo|capsules
79861493|NCT02561351|Other|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
79861494|NCT00754091|Device|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
79566411|NCT01743755|Drug|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
79861495|NCT00496587|Drug|Capecitabine|800 mg/m^2 By Mouth Twice Daily On Days 1-21.
79861496|NCT00496587|Drug|Gemcitabine|900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15.
79726761|NCT03611101|Device|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
79861497|NCT00496587|Drug|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
79861498|NCT00757835|Drug|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
79861499|NCT00757835|Drug|latanoprost/timolol fixed combination drops|once in the evening
79566412|NCT01743755|Drug|Placebo|Placebo tablet, once daily for four consecutive days
79566413|NCT01743781|Behavioral|video|view a 10-minute informational video about comprehensive eye examination
79566414|NCT01743794|Drug|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
79566415|NCT01743794|Drug|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
79861500|NCT04052633|Radiation|intraoperative cholangiography|success or failure of cholangiography
79726762|NCT05345119|Drug|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
79726763|NCT05345119|Drug|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
79726764|NCT03529123|Drug|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
79726765|NCT03529123|Drug|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
79726766|NCT03529123|Drug|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
80022788|NCT03094624|Other|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
79265969|NCT04786418|Dietary Supplement|Low-calorie diet|The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.
79726767|NCT03529123|Drug|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
79726768|NCT04074187|Drug|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
79726769|NCT04074187|Drug|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
79861501|NCT01038076|Behavioral|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
80022789|NCT03094624|Other|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
80022790|NCT03094624|Other|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
79303991|NCT05345457|Drug|Azithromycin Pill|Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
79566416|NCT01743807|Drug|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
79566417|NCT01743820|Drug|dihydroartemisinin-piperaquine|
79566418|NCT01743820|Drug|0.125 mg/kg Primaquine|
79566419|NCT01743820|Drug|0.5 mg/kg Primaquine|
79566420|NCT01743820|Drug|0.25 mg/kg Primaquine|
79566421|NCT01743820|Drug|0.0625 mg/kg Primaquine|
79726770|NCT04074187|Drug|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
79726771|NCT04074187|Drug|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
79726772|NCT02670031|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
79861502|NCT00757913|Dietary Supplement|n-3 enriched nutrition|
79861503|NCT01038154|Drug|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
79861504|NCT02560727|Device|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
79861505|NCT02560727|Device|colonoscope|FMT via colonoscope is the most common approach.
79861506|NCT00757991|Genetic|polymorphism analysis|
79861507|NCT00757991|Other|laboratory biomarker analysis|
79861508|NCT00757991|Other|questionnaire administration|
79861509|NCT00405652|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
79566422|NCT01743833|Other|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
79861510|NCT04052321|Other|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
79265970|NCT03551405|Radiation|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
79265971|NCT04786496|Behavioral|ITP+SA Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).
79265972|NCT04786496|Behavioral|ITP Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.
79303992|NCT05345457|Drug|Amoxicillin Pill|Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
79400164|NCT06122545|Procedure|Greater Occipital Nerve Block|"Patients will receive Greater Occipital Nerve Block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided GONB will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
79861511|NCT01324180|Drug|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
79861512|NCT01324180|Drug|Vincristine|1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
79861513|NCT01324180|Drug|Dexamethasone|"10 mg/m^2/day divided BID~Take dexamethasone by mouth days 2-15"
79861514|NCT01324180|Drug|PEG-asparaginase|"2500 IU's/m^2/day~Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
79400165|NCT06122545|Other|Medical Treatment|Patients who will receive medical treatment
79566423|NCT01743833|Other|Scapular High Velocity, Low Amplitude Thrust Maneuver|
79861515|NCT01324180|Drug|Doxorubicin|60 mg/m^2/day IV over 15 minutes on day 2
79861516|NCT01324180|Drug|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
79400166|NCT06122545|Drug|bupivacaine or onabotulinum toxin A injection.|bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
79400167|NCT06122532|Procedure|Stem cell preparation combined with Reticular skin|The dose of transplanted stem cells per wound (100cm2) is 1×10^6, then cover the wound with autologous regular skin.
79400168|NCT06122532|Procedure|Stem cell preparation combined with MEEK skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 ^ 6, then cover the wound with autologous MEEK skin.
79400169|NCT06122532|Procedure|Stem cell preparation combined with split-thickness skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 ^ 6, then cover the wound with autologous split-thickness skin.
79566424|NCT01743885|Drug|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
79566425|NCT01743885|Drug|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
79566426|NCT01743898|Drug|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
79566427|NCT01743898|Other|no anticoagulation|
79566428|NCT01743911|Other|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
79566429|NCT01743911|Drug|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
79566430|NCT01743924|Other|raw broccoli|To eat this plant material
79566431|NCT01743937|Procedure|Coronary occlusion with balloon inflation|
79726773|NCT02670031|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
79726774|NCT02670031|Other|Electrocardiogram|To examine specific function of the heart.
79726775|NCT02670031|Device|Ambulatory Blood Pressure Monitoring|A 24-hour test.
79726776|NCT02670031|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
79566432|NCT01744002|Other|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
79566433|NCT01744002|Other|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
80022791|NCT03046017|Device|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
80022792|NCT03046017|Other|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
80022793|NCT03046017|Other|Control cream|A neutral cream will be applied as a control.
80022794|NCT05383989|Behavioral|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
80022795|NCT05383989|Behavioral|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
80022796|NCT05383989|Behavioral|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
79566434|NCT01744015|Behavioral|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
80022797|NCT05383989|Behavioral|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
80022798|NCT05383989|Behavioral|Service as usual provided by the University|It is the regular university-provided well-being services.
80022799|NCT03542370|Other|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
79581361|NCT01935609|Behavioral|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
79726777|NCT03128905|Drug|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
79726778|NCT03128905|Drug|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
79861517|NCT02560649|Drug|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
79861518|NCT02560649|Drug|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
79861519|NCT02560649|Drug|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
79861520|NCT02560649|Drug|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
79861521|NCT02560649|Drug|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
79861522|NCT02560649|Drug|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
79861523|NCT02560649|Drug|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
80022800|NCT03542292|Diagnostic Test|placental drainage|
80022801|NCT03736278|Other|No intervention|We group the patients according to the outcome (survival vs mortality)
80022802|NCT05043610|Biological|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|Cell Tech Pharmed Company (Tehran, Iran) will provide us with cGMP grade WJ-MSCs. 10^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
80022803|NCT05043610|Other|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
80022804|NCT02149056|Behavioral|observation|
80022805|NCT02149056|Other|Impaired Glucose Tolerance|Impaired Glucose Tolerance
80022806|NCT02149134|Dietary Supplement|TeHF2013-01|
79265973|NCT04786496|Behavioral|Control condition|The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
80022807|NCT05042752|Procedure|CLINICAL ULTRASOUND|The intervention group will receive the standard care of treatment in AHF and the performance of CU.
80022808|NCT02149212|Drug|Phlebotonic|Aminaftone -- 75 mg BID
80022809|NCT02149212|Device|Stent|Iliac Vein Stenting
80022810|NCT02149212|Procedure|Limb elastic compression support|CEAP 3-5 > 20-30 mmHg compression stockings CEAP 6 > elastic bandages
80022811|NCT02149212|Procedure|Unna boot dressing|CEAP 6 > Unna boot dressing
80022812|NCT03612063|Device|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
80022813|NCT03612063|Device|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
80022814|NCT03612063|Device|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
80022815|NCT03612063|Device|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
80022816|NCT03612063|Device|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
80022817|NCT03612063|Device|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
80022818|NCT05048290|Other|Communication Skills Training|Participate in communication workshops
80022819|NCT05048290|Other|Communication Skills Training|Participate in generic communication skills workshops
79566435|NCT01744015|Other|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
79566436|NCT01744028|Device|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
79861524|NCT02560649|Drug|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
79861525|NCT00758147|Device|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
79861526|NCT04052165|Procedure|Glaucoma Implant|
79861527|NCT04052009|Other|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
79566437|NCT01744028|Other|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
79861528|NCT04052009|Other|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
80022820|NCT05048290|Other|Educational Intervention|Develop a video
80022821|NCT05048290|Other|Survey Administration|Complete surveys
80022822|NCT03611985|Drug|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
80022823|NCT03611985|Drug|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
79566438|NCT01744054|Device|PET/MR|
79566439|NCT01744054|Device|PET/CT|
79566440|NCT01744067|Drug|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
79861529|NCT04052009|Other|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
79566441|NCT01744067|Drug|Placebo|Placebo capsules 3 times a day (oral administration)
79566442|NCT01744080|Other|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
79566443|NCT01744080|Other|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
79566444|NCT01744106|Drug|pseudoephedrine hydrochloride 30 mg tablets|
79726779|NCT00613795|Dietary Supplement|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
79726780|NCT00613795|Dietary Supplement|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
79861530|NCT00754403|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
79861531|NCT00754403|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
79861532|NCT00754481|Other|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature < 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
80022824|NCT05029804|Other|Education|This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
80022825|NCT03611517|Behavioral|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
80022826|NCT05029492|Other|Low-calorie diet|Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.
79303993|NCT03922139|Drug|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
79400170|NCT06122532|Procedure|autologous skin grafting|After cleaning the wound, use autologous skin (Reticular skin/MEEK skin/split-thickness skin) grafting and cover the wound surface。
80022827|NCT05029492|Other|Visceral manipulation with diet|Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).
79566445|NCT01744106|Drug|Placebo tablets|
80022828|NCT02865915|Drug|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
80022829|NCT02865915|Drug|Placebo|Placebo to match active drug
80022830|NCT05029648|Other|Cohort|Cohort
80022831|NCT05029258|Procedure|Biopsy of tumour|Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
80022832|NCT05029258|Diagnostic Test|MRI scans|Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
80022833|NCT03097900|Drug|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
79566446|NCT01744119|Device|Vascutek Anaconda™ Stent Graft System|
79726781|NCT02430181|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
79726782|NCT02430181|Drug|peginterferon alfa-2a|immunomodulator
79726783|NCT02430181|Drug|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
79726784|NCT03100591|Drug|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie [μCi]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
79566447|NCT01744132|Behavioral|Aim 3: Contract|
79566448|NCT01744158|Other|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~measurement of severity of spasticity using the modified Ashworth score~description of presence of chorea or athetosis~classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~classification of fine motor abilities using the manual ability classification system (MACS)~collection of demographic data and associated medical history"
79566449|NCT01744184|Drug|Entonox|Entonox arm
80022834|NCT03097900|Other|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
80022835|NCT03096652|Procedure|Approach for cancer resection|
79400171|NCT06122493|Drug|Tirelizumab|immunotherapy, 200 mg on day 1 per 3 weeks
79566450|NCT01744184|Drug|Midazolam|up to 5mg midazolam as appropriate
79566451|NCT01744236|Drug|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
79566452|NCT01744236|Drug|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
79566453|NCT01744236|Drug|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
79566454|NCT01744236|Drug|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
79566455|NCT01744236|Drug|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
79566456|NCT01744236|Drug|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
79726785|NCT00613873|Procedure|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
79726786|NCT00614653|Drug|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
79726787|NCT00614653|Drug|Erlotinib|100 mg by mouth Once Daily on days with radiation.
79726788|NCT00614653|Drug|Capecitabine|400 mg/m^2 PO Twice Daily on days with radiation.
80022836|NCT03096496|Other|QoL questionnaires|Quality of life questionnaires
80022837|NCT02149446|Device|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
80022838|NCT03543618|Device|Sloped|Placement of implant with sloped design
80022839|NCT03543618|Device|Control|Placement of implant with conventional design
80022840|NCT02149602|Radiation|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
80022841|NCT05047276|Biological|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
80022842|NCT00354835|Drug|Cyclophosphamide|Given IV
80022843|NCT00354835|Biological|Dactinomycin|Given IV
80022844|NCT00354835|Drug|Irinotecan Hydrochloride|Given IV
79400172|NCT06122493|Drug|Nab paclitaxel|chemotherapy, 175 mg/m² on day 1 per 3 weeks
79400173|NCT06122493|Drug|Carboplatin|chemotherapy, AUC=5 on day 1 per 3 weeks
79400174|NCT06122493|Radiation|Radiotherapy|Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
79566457|NCT01744236|Drug|L-NMMA|
79566458|NCT01744249|Drug|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
79566459|NCT01744249|Drug|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
79400175|NCT06122467|Other|EQ Exfoliating Cleanser|Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).
79726789|NCT00614653|Radiation|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
79400176|NCT06122467|Other|EQ Gel|Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.
79726790|NCT05344807|Diagnostic Test|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
79726791|NCT05344729|Drug|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
79726792|NCT03909451|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79726793|NCT03909451|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79726794|NCT03463135|Drug|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
79726795|NCT03463135|Drug|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
79726796|NCT03463135|Drug|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
79726797|NCT03463135|Drug|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
80022845|NCT00354835|Other|Laboratory Biomarker Analysis|Correlative studies
80022846|NCT00354835|Other|Questionnaire Administration|Ancillary studies
80022847|NCT00354835|Radiation|Radiation Therapy|Undergo radiotherapy
80022848|NCT00354835|Drug|Vincristine Sulfate|Given IV
80022849|NCT02768298|Drug|LCZ696|LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
80022850|NCT02768298|Drug|Enalapril|"Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
80022851|NCT02768298|Drug|Placebo matching enalapril|Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
79400177|NCT06122467|Other|EQ Moisturizer|Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.
79400178|NCT06122454|Drug|Hepenofovir Fumarate Tablets|Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations
79400179|NCT06122441|Behavioral|Complex lifestyle intervention|The complex lifestyle intervention comprise high-intensity aerobic and strength exercise, behavioral counselling based on Acceptance and Commitment Theory (ACT), and dietary counselling based on Norwegian nutritional guidelines. The different intervention elements are introduced step-wise to reduce initial overload. Participants are progressively transitioned over to the Tromsø municipality and local NGO's, who delivers activities harmonized with the intervention elements. Participants are at this stage also supported by an eTool which digitally reinforces the intervention through web-based information and videos.
79566460|NCT01744249|Drug|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
79566461|NCT01744275|Dietary Supplement|Omega 3 fatty acids|
79726798|NCT03859765|Behavioral|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
79726799|NCT03596125|Drug|N-acetylcysteine|N-acetylcysteine supplementation
79726800|NCT03596125|Drug|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
79726801|NCT02118727|Drug|Memantine|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
79726802|NCT02118727|Drug|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
79726803|NCT05343637|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
79726804|NCT03776227|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79861533|NCT00754481|Other|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
79861534|NCT02560571|Device|ultrasound|
79861535|NCT02560571|Other|blood test|
79566462|NCT01744275|Dietary Supplement|corn oil|Placebo
80022852|NCT02768298|Drug|Placebo matching LCZ696|Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
80022853|NCT05028478|Drug|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
79566463|NCT01744288|Drug|Ticagrelor|Oral single loading dose 180ng
79566464|NCT01744288|Drug|Clopidogrel|Oral single loading dose 600mg
79726805|NCT03369613|Device|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
79726806|NCT00614809|Drug|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
79726807|NCT03562741|Procedure|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
79726808|NCT01752907|Other|General Education DVD|A general chemotherapy side effects education DVD
79726809|NCT01752907|Other|Bone Pain Education DVD|
79726810|NCT00614731|Biological|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
79726811|NCT02692261|Procedure|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
80022854|NCT05028322|Drug|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
79566465|NCT01744288|Drug|ASA|81mg once daily from day -2 up to platelet transfusion
79566466|NCT01744301|Drug|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
79566467|NCT01744314|Drug|Indomethacin and Pantoprazole|
79566468|NCT01744314|Drug|microcrystalline cellulose powder tablets|
79566469|NCT01744366|Drug|Degarelix|
79566470|NCT01744366|Drug|Goserelin|
79726812|NCT02692261|Procedure|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
79861536|NCT00758225|Drug|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
79861537|NCT00754715|Drug|AZD2516|Solution administered once orally
79861538|NCT00754715|Drug|Placebo|Solution administered only once
80022855|NCT05028322|Biological|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
80022856|NCT03096340|Drug|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
80022857|NCT05041894|Other|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
80022858|NCT05028244|Diagnostic Test|venous ultrasound of lower extremity|Patients inbed are explored for deep vein thrombosis in femoral-popliteal and distal veins of the legs with ultrasound compresión and doppler flow evaluation
79861539|NCT02561039|Drug|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
80022859|NCT02152800|Drug|valacyclovir hydrocholoride|
80022860|NCT03543540|Biological|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
79265974|NCT04795310|Device|Pulsed dye laser|"PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment."
79400180|NCT06122441|Behavioral|Physical activity monitoring and recommendations|Wrist-worn activity trackers that are worn throughout the trial, which monitors steps, activity intensity and energy expenditure. Access to Norwegian physical activity guidelines via the Directorate of Health.
79566471|NCT01744379|Drug|Lesinurad|
79566472|NCT01744379|Drug|Placebo|
79861540|NCT00422734|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
79861541|NCT00422734|Drug|Placebo|placebo tablet taken by mouth once a day for 12 weeks
79566473|NCT01744444|Drug|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
80022861|NCT03543540|Biological|Placebo|Placebo injections: 14 in total at twice weekly intervals
80022862|NCT03096106|Device||the investigators just observe the pressure time curve on the ventilation
79566474|NCT01744444|Drug|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
79566475|NCT01744457|Device|Measurement of tear film osmolarity with the TearLab® instrument|
79566476|NCT01744457|Other|Schirmer I test|
80022863|NCT02149758|Drug|Etoricoxib|
80022864|NCT03094546|Dietary Supplement|Polyamine|12 months of polyamine supplementation (6 capsules/day)
80022865|NCT03094546|Dietary Supplement|Placebo|12 months of placebo intake (6 capsules/day)
80022866|NCT03542214|Combination Product|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
80022867|NCT03094468|Drug|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
80022868|NCT03094468|Drug|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
80022869|NCT02156388|Biological|GW003|freeze-dried powder；single SC injection
80022870|NCT05029024|Other|30-minute mindful breathing|The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
80022871|NCT05029024|Other|control group|standard care alone
80022872|NCT02152878|Device|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
80022873|NCT02152878|Device|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
79400181|NCT06122428|Drug|modified hyaluronic acid 0.1% covalently linked to Riboflavin|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
79400182|NCT06122428|Drug|hyaluronic acid 0.1%|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
79566477|NCT01744457|Other|Tear break up time|
79566478|NCT01744457|Device|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
79566479|NCT01744457|Other|Ocular Surface Disease Index|
79566480|NCT01744470|Drug|Tacrolimus targeted half-dose|
79566481|NCT01744470|Drug|Tacrolimus targeted plain dose|
79566482|NCT01744509|Device|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
79566483|NCT01744522|Procedure|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
79861542|NCT02560415|Device|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
79861543|NCT02560415|Behavioral|Comparator|Treatment as usual
79861544|NCT03916198|Drug|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
79726813|NCT03181087|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
80022874|NCT05026216|Drug|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
80022875|NCT03542136|Device|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
80022876|NCT05025982|Procedure|combination of lymphaticovenular anastomosis and liposuction|Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
79566484|NCT01744535|Behavioral|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
79726814|NCT02704663|Procedure|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
79566485|NCT01744535|Behavioral|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
79566486|NCT01744535|Behavioral|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
80022877|NCT02156544|Drug|CKD-519|
80022878|NCT02156544|Drug|placebo|
79861545|NCT03916198|Drug|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
79861546|NCT00422422|Drug|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~~0.4 mg/kg bid for Week 1~~0.8 mg/kg bid for Week 2~~1.6 mg/kg bid for Week 3~For subjects <8 years:~~0.5 mg/kg bid for Week 1~~1.0 mg/kg bid for Week 2~~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~~0.8 mg/kg bid for Week 4~~0.4 mg/kg bid for Week 5~For subjects <8 years:~~1.0 mg/kg bid for Week 4~~0.5 mg/kg bid for Week 5"
79861547|NCT00413374|Drug|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
80022879|NCT05025904|Behavioral|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
80022880|NCT05025904|Behavioral|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
80022881|NCT05025904|Behavioral|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
80022882|NCT03543462|Device|thoracic Drain Tube 24 Fr.|Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
80022883|NCT03095950|Other|News items with spin|Interpretation of news items with spin
79581362|NCT01935635|Biological|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;
79265975|NCT03551327|Behavioral|Experimental: Intervention plus information|The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.
79581363|NCT01935648|Drug|Ropivacaine|
80022884|NCT03095950|Other|News items without spin|Interpretation of news items without spin
79265976|NCT03551327|Other|Active Comparator: Information only|Participants in this arm will be provided with information about fatigue.
79265977|NCT02128451|Drug|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
79726815|NCT02704663|Procedure|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
79726816|NCT02526355|Behavioral|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
79726817|NCT03439189|Combination Product|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
79726818|NCT03439189|Drug|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
79726819|NCT03439189|Drug|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
79726820|NCT01211483|Drug|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
79726821|NCT01211483|Drug|Erlotinib|Tablet 150 mg for oral administration
80022885|NCT03744546|Drug|ABBV-8E12|Solution for infusion
80022886|NCT05025592|Drug|Regorafenib|patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not
80022887|NCT05025592|Device|cTACE/DEB-TACE-HAIC|conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
80022888|NCT04467034|Behavioral|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
79400183|NCT06122402|Other|SECURE Care Bundle|The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including 2-octyl-cyanoacrylate tissue adhesive, CHG dressing and silicone based remover.
79400184|NCT06122402|Procedure|Standart Care|It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
79400185|NCT06122376|Device|U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
79400186|NCT06122376|Device|Soft Manual Toothbrush|Twice daily brushing for two minutes with fluoride toothpaste
79400187|NCT06122324|Drug|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
79566487|NCT01744548|Behavioral|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
79265978|NCT02128451|Drug|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
79265979|NCT04291040|Behavioral|Decision Aid|Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.
79566488|NCT01744561|Behavioral|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
79265980|NCT04291040|Behavioral|Routine Care|The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
79726822|NCT01211483|Drug|Placebo|Placebo liquid matching U3-1287 for IV infusion
79400188|NCT06122298|Other|fMRI|A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.
79400189|NCT06122298|Other|Ecological Momentary Assessment|studies people's thoughts and behaviour in their daily lives by repeatedly collecting data in an individual's normal environment, at or close to the time they carry out that behaviour
79400190|NCT06122285|Drug|Bulevirtide|dose of 2 mg/day subcutaneously
79400191|NCT06122246|Behavioral|Community Health Worker (CHW)|Participants will receive the additional support of a Community Health Worker (CHW).
79726823|NCT00615823|Drug|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
79861548|NCT00682643|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray
79400192|NCT06122246|Other|Remote Blood Pressure (BP) Management Program (RBPM)|Participants will receive a medical model of remote BP management (RBPM).
79861549|NCT00682643|Drug|vehicle placebo nasal spray|placebo
79861550|NCT00758381|Drug|Sorafenib 400 mg po bid, continuously|"NEXAVAR*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
79861551|NCT00758381|Drug|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
79861552|NCT05436119|Dietary Supplement|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
79400193|NCT06122233|Behavioral|Pulmonary Fibrosis self-management package and smartphone application|"The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants track their health over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data and physical activity via the phone's step count and has links to ILD-related educational resources."
79400194|NCT06122220|Procedure|ONSD+AF|Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index
79400195|NCT06122181|Drug|HS-10384 tablets|Multiple dosing of HS-10384 orally in a fasting state
79861553|NCT00754871|Drug|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
79265981|NCT04808336|Other|PRP injection.|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
79861554|NCT00754871|Drug|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
80022889|NCT02775864|Drug|Antipsychotic|New initiation of any antipsychotic medication
79265982|NCT04808336|Procedure|fixation surgical procedure|Group 2: thirty patients underwent surgery
79265983|NCT02128607|Device|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
79265984|NCT02128607|Device|Sham|
79265985|NCT04808102|Device|IER AG|The game is a web-based single-player adventure game with 3 levels created with the RPG Maker MV. Playtime is approximately 3 hours.
79566489|NCT01744587|Other|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
79566490|NCT01744587|Dietary Supplement|Placebo|Placebo qd (2# bid) for 3 years
79566491|NCT01744600|Behavioral|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
79566492|NCT01744639|Behavioral|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
79566493|NCT01744678|Behavioral|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
79861555|NCT00754871|Drug|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
79861556|NCT00754871|Drug|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
79861557|NCT00755027|Drug|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
79861558|NCT05435807|Behavioral|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
79861559|NCT00421408|Dietary Supplement|Whey protein supplement|40-g whey protein supplement daily for 18 months
79265986|NCT04808102|Device|BubbleShooter|A free-to-play arcade browser puzzle game called BubbleShooter.
79265987|NCT04785716|Drug|Niraparib|Niraparib provided through the patient access program
79566494|NCT01744678|Behavioral|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
79566495|NCT01744717|Other|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~TURNING / POSITIONING (moving side to side or up or down in bed)~ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
79566496|NCT01744262|Drug|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5~4 µg/mL and remifentanil effect site concentration 2~5 ng/mL.
79861560|NCT00421408|Dietary Supplement|Placebo|Placebo supplement daily for 18 months
79861561|NCT02560337|Drug|Cabazitaxel|
79861562|NCT01038388|Drug|Bortezomib|1.3mg/m² given IV or subcutaneously
79861563|NCT01038388|Drug|Lenalidomide|25 mg given PO
79861564|NCT01038388|Drug|Dexamethasone|20 mg given PO
79861565|NCT01038388|Drug|Vorinostat|100, 200, or 300 mg given PO
79861566|NCT02560259|Other|Physiotherapy|Physiotherapy
79861567|NCT02560259|Other|Conservative treatment|Conservative treatment
80022890|NCT02775864|Drug|Antidepressant|New initiation of any antidepressant medications
79265988|NCT01367249|Drug|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
79265989|NCT01367249|Drug|Placebo|Sterile ophthalmic solution
79265990|NCT04795154|Other|Yoga excercise|Yoga exercise in pre-eclampsia >20 weeks of pregnancy woman, treatment number was 4 times.
79566497|NCT01744262|Drug|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5~2.0 % and remifentanil effect site concentration 2~5 ng/mL.
79566498|NCT01744743|Procedure|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
79265991|NCT02131727|Behavioral|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
79265992|NCT02131727|Behavioral|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
79265993|NCT02128685|Drug|Dydrogesterone|
79566499|NCT01744756|Drug|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
79566500|NCT01744795|Other|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
79566501|NCT01744808|Drug|EB-1020 IR|Immediate release
79566502|NCT01744808|Drug|EB-1020 SR1|sustained release
79566503|NCT01744808|Drug|EB-1020 SR2|Sustained release
79566504|NCT01744808|Drug|EB-1020 SR3|Sustained release
79726824|NCT00615823|Drug|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
79726825|NCT02704195|Procedure|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
79265994|NCT02128685|Drug|Placebo|
79265995|NCT04808024|Procedure|SelfMyofascial Release|Myofascial auto-release consisted of rolling the roller on a group of knee flexors for 3.5 minutes between the sciatic tumor and the knee joint in both directions, omitting the popliteal fossa. Before and after the intervention, sEMG of the biceps and gluteal muscles will be performed.
79265996|NCT02131883|Behavioral|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
79265997|NCT02131883|Other|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
79726826|NCT02704195|Procedure|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
79726827|NCT02699281|Drug|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
79861568|NCT05435183|Device|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
79861569|NCT05435183|Device|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
79861570|NCT04050059|Drug|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
79566505|NCT01744808|Other|Placebo|Placebo formulation
79265998|NCT04808258|Device|C3+ Holter Monitor|Long-Term ECG monitoring (up to 7 days)
79861571|NCT04050059|Drug|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
79861572|NCT05435105|Behavioral|Virtual reality|Distraction method
79861573|NCT05435105|Behavioral|Local cold-vibration|Distraction method
79861574|NCT00679913|Procedure|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
79265999|NCT02252315|Other|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
79566506|NCT01744847|Device|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
79566507|NCT01744873|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
79566508|NCT01744873|Drug|Bisoprolol|10 mg tablet once a day
79566509|NCT01744886|Procedure|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
79566510|NCT01744899|Other|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
79566511|NCT01744925|Drug|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
79566512|NCT01744925|Drug|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
79726828|NCT02699281|Drug|Placebo|um-PEA like placebo twice a day
79726829|NCT04320485|Diagnostic Test|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
79726830|NCT02699359|Device|HS-1000 recording|
79861575|NCT00679913|Procedure|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
79861576|NCT02560103|Other|Transmeridian travel across multiple time zones|
79861577|NCT00482001|Drug|donepezil|
79566513|NCT01744938|Procedure|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
79266000|NCT02252315|Other|Verbal education module|A structured in-person education module about mild traumatic brain injury.
79400196|NCT06122181|Drug|HS-10384-matched placebo tablets|Multiple dosing of HS-10384-matched placebo orally in a fasting state
79400197|NCT06122168|Other|Mandala|verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
79400198|NCT06122168|Other|Standard care|verbal interview and standard health care
79400199|NCT06122090|Drug|Bimatoprost|Bimatoprost will be delivered with laser
79400200|NCT06122090|Drug|Saline|Saline control will be delivered with laser
79566514|NCT01744626|Drug|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
79566515|NCT01744626|Drug|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
79861578|NCT00482001|Drug|Placebo (cornstarch)|
79861579|NCT00490035|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
79861580|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
79581364|NCT01935674|Drug|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
79726831|NCT00615979|Device|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
79726832|NCT02704507|Drug|Triamcinolone|topical application nightly to half the face for 4 weeks
79726833|NCT02704507|Drug|Tretinoin|topical application nightly for 8 weeks
79726834|NCT02704507|Drug|Emollient|topical application nightly to half the face for 4 weeks
79861581|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
79861582|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
79726835|NCT02699203|Behavioral|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
79726836|NCT02699203|Behavioral|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
79861583|NCT01014897|Device|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
79566516|NCT01744951|Behavioral|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
79726837|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 low dose
79726838|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
79726839|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
79726840|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
79726841|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
79861584|NCT01016457|Device|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
79861585|NCT00404248|Drug|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
79861586|NCT00404248|Other|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
79861587|NCT00421174|Drug|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
79861588|NCT00421174|Drug|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
80022891|NCT02775864|Drug|Benzodiazepine|New initiation of any benzodiazepine
80022892|NCT02775864|Drug|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
79566517|NCT01744964|Drug|Apomorphine|1.5 mg Apomorphine
79566518|NCT01744990|Other|Oral food challenges to multiple nuts|
79726842|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
79726843|NCT02699047|Dietary Supplement|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
80022893|NCT03095872|Device|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
79566519|NCT01745003|Procedure|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
79566520|NCT01745016|Dietary Supplement|Placebo|
79726844|NCT02699047|Dietary Supplement|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
79566521|NCT01745016|Dietary Supplement|Beta-alanine|
79566522|NCT01745029|Device|Motilis-3D-transit|
79566523|NCT01743768|Drug|SB010|Treatment group (n=19), receiving the active drug substance.
79566524|NCT01743768|Drug|Placebo|Treatment group (n=19), receiving placebo.
79566525|NCT01745042|Other|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
79566526|NCT01745068|Other|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
79566527|NCT01745081|Drug|20% mannitol bolus administration|
79566528|NCT01745081|Drug|Hypertonic saline 3% bolus administration|
79726845|NCT00624455|Drug|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
79726846|NCT00624455|Drug|Placebo|Placebo
79726847|NCT01127659|Drug|testosterone|intramuscular every 2 weeks
79726848|NCT01127659|Drug|placebo|saline intramuscular every 2 weeks
79726849|NCT01209689|Drug|Tocilizumab|
79726850|NCT01209689|Drug|Placebo|
79726851|NCT02698969|Drug|Sugammadex|
79566529|NCT01745107|Radiation|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
79566530|NCT01745159|Drug|tacrolimus|
79566531|NCT01745172|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
79726852|NCT02698969|Device|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
79566532|NCT01745224|Device|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
79566533|NCT01745224|Device|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
79726853|NCT02698969|Drug|Neostigmine|
79726854|NCT02698969|Drug|Atropine|
79726855|NCT02698969|Device|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
79566534|NCT01745263|Drug|Vitamin D3|2000 IU/d
79566535|NCT01745263|Drug|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
79566536|NCT01745263|Procedure|Strength Home Exercise|
79726856|NCT02698969|Drug|Rocuronium|Rocuronium will be administered 0.6 mg*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
79861589|NCT00496197|Drug|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
79861590|NCT00496197|Drug|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
79861591|NCT00496197|Drug|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
79861592|NCT03996993|Drug|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
79861593|NCT03996993|Radiation|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
79861594|NCT01019889|Drug|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
79861595|NCT01019889|Drug|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
79566537|NCT01745263|Procedure|Flexibility Home Exercise|
79566538|NCT01745276|Device|Biphosfonate|External pins coated by biphosfonate.
79566539|NCT01745276|Device|Hydroxylapatit|External pins coated by Hydroxylapatit.
79566540|NCT01745302|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
79566541|NCT01745302|Drug|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
79566542|NCT01745315|Device|Advanced bipolar devices|
79566543|NCT01745328|Drug|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
79566544|NCT01745328|Drug|TCM|Subject is treated with TCM for 4 weeks.
79566545|NCT01745328|Drug|LVX-AMX|treatment with placebo from 2 to 4 weeks.
79566546|NCT01745354|Drug|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
79566547|NCT01745354|Radiation|Local Radiation|
79726857|NCT02698969|Drug|Fentanyl|Fentanest will be administered 2 mcg*kg-1 at the induction of general anesthesia and titrated 0.5 mcg*kg-1 every 30 minutes
79726858|NCT02698969|Drug|Propofol|Propofol will be administered 2 mg*kg-1 at the induction of general anesthesia
79726859|NCT02698969|Drug|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
79861596|NCT01019889|Drug|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
79861597|NCT01015053|Procedure|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
79861598|NCT01015053|Procedure|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
79861599|NCT00495495|Device|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
79566548|NCT01745432|Device|ADBLOCK|Laparoscopic surgery
79581365|NCT01935674|Drug|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
79861600|NCT00495495|Device|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
79861601|NCT00404092|Drug|caspofungin|i.v.
79726860|NCT00848731|Drug|nitric oxide|nitric oxide gas is delivered by facemask
79726861|NCT00537589|Procedure|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
79726862|NCT01209143|Drug|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
79861602|NCT00481767|Biological|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
79400201|NCT06122051|Radiation|Dynamic chest x-ray|Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
79400202|NCT06122051|Diagnostic Test|Spirometry|Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
79566549|NCT01745445|Other|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
79266001|NCT04807946|Procedure|lower third molar extraction|"All surgeries were performed by the same expert surgeon (RP), with the buccal approach using local anesthesia, and included the following maneuvers:~luxation of the coronal portion of the tooth/root in an ipsilateral or parallel direction with respect to the IAN position and running, in order to minimize nerve compression;~post-extraction residual bone cavity inspection using a Zeiss 4x300 magnification optical system to better identify intra-operative nerve exposure.~No material was inserted into the residual cavity, neither by regeneration nor by haemostasis.~After one week, sensitivity was tested on both sides with the tactile test using a 27-gauge needle tip and, if a difference was found, the patient was followed up once a week for the first month and every two weeks thereafter, until he/she reported to perceive the pin-prick test in the affected side the same way as the healthy side."
79400203|NCT06122038|Dietary Supplement|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
79400204|NCT06122038|Dietary Supplement|Placebo|Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
79566550|NCT01745458|Drug|SB-659032|
79566551|NCT01745458|Drug|Placebo|Matched placebo
79566552|NCT01745484|Other|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
79566553|NCT01745510|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
79726863|NCT01209143|Drug|Rosiglitazone|Rosiglitazone was supplied in tablets.
80022894|NCT03095872|Drug|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
80022895|NCT03095872|Drug|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
80022896|NCT02156700|Procedure|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
79400205|NCT06122025|Device|Patient Access|A 6-month pilot prospective interventional study with an independent groups design.
79400206|NCT06122012|Drug|HSK16149 20mg BID|HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；
79726864|NCT01209143|Drug|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
79726865|NCT00454285|Drug|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
79726866|NCT00614965|Drug|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
79726867|NCT00614965|Drug|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
79726868|NCT00614965|Drug|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
79726869|NCT00405613|Drug|Aspirin|
79726870|NCT02703883|Device|BWST|BWST (six weeks, 3 times/week)
79726871|NCT02703805|Other|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
79726872|NCT02703805|Other|Standard YMCA membership|A 12 week standard YMCA membership.
79726873|NCT02703961|Drug|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
79726874|NCT02703961|Drug|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
79861603|NCT00481767|Drug|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
79861604|NCT04261491|Procedure|scaling and root planing|scaling and root planing
79861605|NCT00489489|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
79566554|NCT01745510|Dietary Supplement|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
79726875|NCT02703961|Radiation|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
79726876|NCT02703961|Radiation|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
79726877|NCT02703961|Drug|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
79726878|NCT02703649|Drug|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
79266002|NCT02252627|Drug|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
79726879|NCT02703571|Drug|ribociclib|Combination treatment with LEE and TMT
79726880|NCT02703571|Drug|Trametinib|Combination treatment with LEE and TMT
79726881|NCT00615355|Radiation|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
79726882|NCT00615355|Device|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
79726883|NCT02703727|Behavioral|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
79726884|NCT02703415|Drug|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
79726885|NCT02703415|Drug|Tramadol|caudal block with tramadol 1 mg/kg
79726886|NCT02703181|Drug|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
79861606|NCT00489489|Drug|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
79861607|NCT00489489|Drug|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
79566555|NCT01745523|Procedure|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
79726887|NCT02703181|Drug|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
79726888|NCT03297697|Procedure|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
79861608|NCT00489411|Drug|duloxetine hydrochloride|Given orally
80022897|NCT03096184|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
80022898|NCT03096184|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
79266003|NCT02252627|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
79266004|NCT02252627|Other|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
79266005|NCT02252627|Drug|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
79566556|NCT01745523|Procedure|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
79566557|NCT01745536|Procedure|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
79566558|NCT01745536|Procedure|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
79566559|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
79566560|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
79566561|NCT01745562|Drug|Alprazolam 0.5 mg|Reference product
79566562|NCT01745562|Drug|Alprazolam 0.5 mg|Test product
79566563|NCT01745575|Drug|Alprazolam 2mg tablets|Reference product
79566564|NCT01745575|Drug|Alprazolam 2 mg tablets|Test product
79726889|NCT03297697|Procedure|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
79861609|NCT00489411|Other|placebo|Given orally
79861610|NCT00420784|Drug|Telaprevir|tablet
79861611|NCT00420784|Drug|Ribavirin|tablet
79861612|NCT00420784|Drug|Pegylated Interferon Alfa 2a|Solution for injection
79861613|NCT00420784|Drug|Matching Placebo|Tablet
79861614|NCT00420628|Drug|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
79726890|NCT03297697|Procedure|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
79726891|NCT04215835|Drug|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
79726892|NCT04215835|Drug|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
79726893|NCT01023789|Device|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
79726894|NCT02702947|Dietary Supplement|Prunus domestica extract|Prosman 1 capsule twice a day
79726895|NCT00637039|Drug|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
79726896|NCT02703103|Other|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
79726897|NCT02703103|Device|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
79726898|NCT01208207|Drug|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
79726899|NCT01208207|Drug|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
79861615|NCT00420628|Drug|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
79861616|NCT03993808|Behavioral|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
79266006|NCT04807790|Other|Telerehabilitation based structured home program applications|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
79861617|NCT03993808|Behavioral|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
80031751|NCT04885348|Behavioral|Intervention Group (Dental Home Visits + Dental Home Education Leaflets)|No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
79266007|NCT02135939|Behavioral|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
79566565|NCT01745601|Drug|escitalopram 10 mg|Reference product
79566566|NCT01745601|Drug|escitalopram 10 mg|Test product
79566567|NCT01745614|Drug|Nimesulide 100 mg tablets|Reference product
79566568|NCT01745614|Drug|Nimesulide 100 mg tablets|Test product
79566569|NCT01745640|Drug|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
79566570|NCT01745640|Drug|Dexamethasone|40mg (if patient <75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
79566571|NCT01745653|Device|Low level laser therapy|
79566572|NCT01745653|Procedure|sham procedure|
79726900|NCT01208207|Drug|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
79726901|NCT01208207|Drug|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
79726902|NCT01208207|Drug|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
79726903|NCT01208207|Drug|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
79726904|NCT01208207|Drug|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
79566573|NCT01745666|Other|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
79566574|NCT01745666|Other|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
79566575|NCT01745679|Drug|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
79726905|NCT01208207|Drug|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
79726906|NCT01208207|Drug|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
79566576|NCT01745692|Device|Mechanical thrombectomy|
79566577|NCT01745692|Drug|Intravenous rtPA|All patients receive IV alteplase
79726907|NCT01208207|Drug|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
79726908|NCT01208207|Drug|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
79266008|NCT02131961|Drug|Collagenase ointment|250 collagenase units/g
79266009|NCT02131961|Device|Modified Contact Cast System|1 Unit
79726909|NCT01208207|Drug|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
79266010|NCT02136095|Procedure|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
79861618|NCT03993808|Behavioral|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
79266011|NCT02128841|Drug|Rivaroxaban|Direct Factor Xa Inhibitor
79266012|NCT02132039|Other|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
79861619|NCT03993808|Behavioral|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
79566578|NCT01745705|Other|Cervical Spine Manipulation|
79861620|NCT03993808|Behavioral|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
80022899|NCT02156778|Behavioral|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
80022900|NCT02156778|Behavioral|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
80031752|NCT04885348|Behavioral|Control Group (Dental Home Education Leaflets)|Only Dental Home Education Leaflets were provided every six months for 2 years.
79266013|NCT02132039|Other|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
79566579|NCT01745705|Other|Manual Contact|
79266014|NCT03550859|Drug|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
79266015|NCT03550859|Drug|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
79266016|NCT03768011|Combination Product|transdermal cream and or patch|transdermal cream and/or transdermal patch(s) with or without oral medication
79266017|NCT03550781|Drug|Prednisone, cyclophosphamide|Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
79266018|NCT02136173|Device|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
79266019|NCT02260583|Device|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
79566580|NCT01745718|Other|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
79726910|NCT02703025|Dietary Supplement|GCB-70|green coffee bean extract
79266020|NCT02260661|Drug|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
79266021|NCT02260661|Drug|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
79566581|NCT01745731|Other|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
79566582|NCT01745744|Other|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
79566583|NCT01745770|Drug|Mesalazine - TID 1000 mg|
79566584|NCT01745770|Drug|Mesalazine - TID 2x 500 mg|
79581366|NCT01935687|Device|Using of instrumented wheel|Using of instrumented wheel
79581367|NCT01935687|Device|Using of ergometer roller|Using of ergometer roller
79726911|NCT03292471|Device|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
79726912|NCT05420285|Drug|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
79726913|NCT04147663|Other|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
79726914|NCT01012713|Drug|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
79726915|NCT01012713|Drug|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
79266022|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
79266023|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
79266024|NCT02136329|Drug|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
79566585|NCT01745809|Procedure|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
79566586|NCT01745835|Drug|2L Coolprep®|* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
79566587|NCT01745835|Drug|1L Coolprep® and Bisacodyl|"Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) * composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
79566588|NCT01745861|Dietary Supplement|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
79566589|NCT01745861|Dietary Supplement|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
79566590|NCT01745887|Drug|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
79566591|NCT01745926|Device|MECHANICAL CHEST COMPRESSION|
79566592|NCT01745939|Other|Lumbar Manipulation|Manual therapy intervention
79566593|NCT01745939|Other|Sham manipulation|Manual therapy intervention
79566594|NCT01745978|Procedure|Precut papillotomy|
79566595|NCT01745991|Device|CoSeal spray|
79861621|NCT00489255|Drug|Tigan®|Oral capsule, 300mg three times daily
79861622|NCT00489255|Drug|Placebo|Oral capsule, three times daily
79861623|NCT00413218|Drug|Isavuconazole|Administered by intravenous infusion.
79566596|NCT01746004|Drug|[^14C]-LY2157299|[^14C]-LY2157299 monohydrate administered as oral solution
79566597|NCT01746069|Behavioral|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
79566598|NCT01746069|Behavioral|health advice|routine clinical practice
79566599|NCT01746121|Genetic|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
79566600|NCT01746147|Other|No intervention and study treatment|
79566601|NCT01746199|Drug|cotrimoxazole daily prophylaxis|
79566602|NCT01746199|Drug|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
79566603|NCT01746212|Procedure|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
79566604|NCT01746212|Biological|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
79566605|NCT01746212|Device|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
79566606|NCT01746251|Drug|Afatinib|
79566607|NCT01746277|Drug|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
79566608|NCT01746277|Drug|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
79566609|NCT01746290|Other|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
79566610|NCT01746303|Dietary Supplement|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
79581368|NCT01935752|Other|blood samples|blood samples
79861624|NCT00413218|Drug|Caspofungin|Administered by intravenous infusion.
79861625|NCT00413218|Drug|Voriconazole|Administered by intravenous infusion.
79861626|NCT02303392|Drug|Selinexor|Given PO
79861627|NCT02303392|Drug|Ibrutinib|Given PO
79861628|NCT02303392|Other|Pharmacological Study|Correlative studies
79861629|NCT02303392|Other|Laboratory Biomarker Analysis|Correlative studies
79861630|NCT03994042|Device|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
79726916|NCT01012713|Procedure|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
79726917|NCT02702713|Dietary Supplement|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
79726918|NCT02702713|Dietary Supplement|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
79726919|NCT02702713|Dietary Supplement|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
79566611|NCT01746303|Dietary Supplement|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
79566612|NCT01746303|Other|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
79566613|NCT01746303|Other|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
79566614|NCT01746329|Other|Tea|Oral intake of tea containing 75 grams of glucose
79566615|NCT01746329|Other|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
79726920|NCT02702713|Dietary Supplement|Bakery placebo|Bakery placebo: Biscuits without enrichment
79266025|NCT02129153|Behavioral|LIFT (Parent Information)|"Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
79566616|NCT01746329|Other|Placebo|Oral intake of 75 grams of glucose in water
79566617|NCT01746342|Device|Effective continuous positive airway pressure (CPAP)|
79566618|NCT01746342|Device|Sham continuous positive airway pressure (CPAP)|
79566619|NCT01746355|Procedure|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
79726921|NCT02702713|Dietary Supplement|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
79266026|NCT02129231|Drug|calcined magnesia|We ensured the patient took the drug at night before meals
79266027|NCT02129231|Drug|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
79726922|NCT02702713|Dietary Supplement|Egg placebo|Egg placebo: Frozen pancakes without enrichment
79726923|NCT02698813|Biological|umbilical cord mesenchymal stem cells and hyaluronic acid|
79726924|NCT02698813|Drug|hyaluronic acid|
79266028|NCT02129231|Drug|Rosuvastatin|We ensured the patient took the drug at night before meals
79266029|NCT02136485|Behavioral|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
79266030|NCT02136485|Other|waiting list control|
79566620|NCT01746381|Device|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
79566621|NCT01746394|Behavioral|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
79566622|NCT01746394|Behavioral|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
79566623|NCT01746433|Other|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
79566624|NCT01746446|Other|Care team|Provides additional support to patients, family, and friends.
79566625|NCT01746459|Other|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
79726925|NCT04205331|Device|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
79726926|NCT02702635|Procedure|DCE MRI of the brain|An MRI of the brain including a DCE sequence
79726927|NCT02871531|Procedure|Pneumatic retinopexy|
79726928|NCT02871531|Procedure|Vitrectomy|
79726929|NCT02702791|Behavioral|Telecoaching|Pedeometer based goals and telecoaching support
79726930|NCT02702791|Other|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
79726931|NCT02702557|Other|Elastic Band Exercises|
79726932|NCT02702479|Other|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
79726933|NCT02702479|Other|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
79566626|NCT01746459|Other|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
79861631|NCT00420316|Biological|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
79861632|NCT00420316|Biological|Placebo (primary vaccination study)|Two liquid oral doses of placebo
79566627|NCT01746472|Behavioral|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
79266031|NCT03550079|Procedure|fixation|treated with different fixation method
79566628|NCT01746472|Behavioral|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
79861633|NCT03993886|Device|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
79861634|NCT03993886|Other|Activity Monitor|commercially available accelerometer to be worn on wrist
80022901|NCT05028010|Behavioral|Capacity building|Four days of training on the promotion of maternal and child nutrition will be given. The training will be based on Pender's health promotion model. Supportive supervision will be conducted.
80022902|NCT05027854|Other|TMS or tES|Transcranial magnetic or electric stimulation
80022903|NCT05027854|Other|sham TMS or tES|Sham transcranial magnetic or electric stimulation
79266032|NCT03550001|Procedure|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
79266033|NCT02132273|Other|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
79266034|NCT02136641|Drug|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
79566629|NCT01746472|Behavioral|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
79566630|NCT01746472|Behavioral|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
79861635|NCT03993886|Other|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
79566631|NCT01746485|Drug|UT-15C|
79266035|NCT02136641|Drug|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
79266036|NCT02136641|Drug|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
79266037|NCT02136719|Procedure|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
79266038|NCT02129309|Procedure|Forearm plethysmography|Dose response study
79266039|NCT02129309|Procedure|Haemodynamic studies|Dose response study
79266040|NCT03550703|Biological|V3-Myoma|Once daily oral pill of V3-Myoma
79566632|NCT01746498|Procedure|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
79566633|NCT01746498|Procedure|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
79566634|NCT01746498|Procedure|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
79566635|NCT01746524|Device|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
79566636|NCT01746550|Device|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
79566637|NCT01746563|Drug|Ranibizumab|Intravitreal injection
79566638|NCT01746563|Procedure|Laser therapy|Laser therapy
79566639|NCT01746576|Other|Use of impedance threshold device during spontaneous ventilation|
79566640|NCT01746589|Device|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
79566641|NCT01746602|Drug|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
79566642|NCT01746602|Drug|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
79861636|NCT03993886|Other|ECG|Commercially available electrocardiogram machine
79861637|NCT03993886|Other|respiratory rate sensor|Commercially available respiratory rate sensor.
80022904|NCT03542916|Drug|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
80022905|NCT03542916|Drug|NESP 60ug|NESP 60ug SC, IV injection
80022906|NCT05025202|Other|Isometric exercise training|A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
80022907|NCT05028088|Drug|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
80022908|NCT02156934|Biological|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
80022909|NCT02157012|Drug|The effectiveness of Xeljanz in rheumatoid arthritis patients|
80022910|NCT03096028|Other|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18&28 weeks of pregnancy is the primary exposure of interest
80022911|NCT02149914|Device|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
80022912|NCT02149914|Device|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
79726934|NCT04422093|Device|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
79726935|NCT02702323|Drug|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
79726936|NCT02702323|Procedure|TACE|one times every 4-6 weeks.
79726937|NCT01007253|Drug|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
79861638|NCT00494871|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
79861639|NCT00494871|Drug|Warfarin|Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients <70 years)
79861640|NCT00494871|Drug|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
79861641|NCT00494871|Drug|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
79861642|NCT00420238|Drug|Etanercept (Enbrel)|50 mg injection once weekly
79861643|NCT00420238|Other|Placebo|placebo
79861644|NCT01016925|Procedure|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
79861645|NCT03994432|Behavioral|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
79861646|NCT00420004|Drug|LY2216684|3-mg and 6-mg tablets
79266041|NCT02786927|Drug|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
79566643|NCT01746602|Device|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
79861647|NCT00420004|Drug|Placebo|
79566644|NCT01746602|Device|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
79861648|NCT00420004|Drug|Escitalopram|10-mg capsules
79861649|NCT00494481|Drug|Vandetanib (ZD6474)|once daily oral dose
79861650|NCT00494481|Drug|Docetaxel|intravenous infusion
79861651|NCT01040494|Drug|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
79861652|NCT01040494|Drug|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
79861653|NCT01017081|Other|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
79266042|NCT02786927|Drug|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
79566645|NCT01746602|Device|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
79566646|NCT01746628|Procedure|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
79566647|NCT01746641|Drug|Remifentanil|
79566648|NCT01746641|Drug|Propofol|
79566649|NCT01746654|Drug|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
79566650|NCT01746654|Drug|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
79566651|NCT01746654|Drug|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
79566652|NCT01746654|Drug|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
79566653|NCT01746667|Behavioral|Exposure in vivo|
79566654|NCT01746667|Behavioral|Virtual Reality Exposure Therapy|
79726938|NCT01007253|Drug|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
79726939|NCT01007253|Drug|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
79726940|NCT01007253|Drug|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
79726941|NCT02702167|Device|High-frequency rTMS|10 Hz active stimulation, once daily
79726942|NCT02702167|Device|Low-frequency rTMS|1 Hz active stimulation, once daily
79726943|NCT02702167|Device|Sham rTMS|Sham stimulation, once daily
79726944|NCT02691949|Drug|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
79726945|NCT04146961|Device|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
79726946|NCT02698501|Drug|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
79726947|NCT02698501|Drug|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
79861654|NCT01017081|Other|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
79861655|NCT01038544|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
79861656|NCT01038544|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
79861657|NCT00097591|Drug|Prasugrel|Administered orally
79861658|NCT00097591|Drug|Clopidogrel|Administered orally
79861659|NCT01082029|Drug|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
79861660|NCT01082029|Drug|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
80022913|NCT02149914|Device|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
79266043|NCT02786927|Other|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
79266044|NCT02786927|Other|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
79266045|NCT03549689|Drug|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
79266046|NCT03549689|Drug|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
79861661|NCT00419926|Drug|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
79566655|NCT01746680|Drug|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week
79566656|NCT01746706|Device|PET amyloid tracer (Florbetapir F18 AV45 F18|
79861662|NCT00419926|Drug|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
79726948|NCT02702245|Dietary Supplement|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
79726949|NCT02702245|Dietary Supplement|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
79726950|NCT02702245|Other|Placebo Comparator: Control|75 g pure glucose.
79861663|NCT00419926|Drug|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
79861664|NCT01038622|Drug|L-arginine|5-day L-arginine treatment
79861665|NCT01038622|Drug|placebo|5-day placebo treatment
79861666|NCT00080119|Drug|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
79861667|NCT00080119|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
79861668|NCT00080119|Drug|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
79861669|NCT00419380|Drug|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment [dornase alfa (Pulmozyme®)]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
79861670|NCT03961633|Behavioral|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
79861671|NCT01082107|Other|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
79566657|NCT01746719|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
79266047|NCT02132429|Drug|AMG 333|Oral administration available in varying dose strength.
79566658|NCT01746719|Drug|Etodolac|500 mg tablet once a day
79566659|NCT01746758|Behavioral|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
79566660|NCT01746771|Drug|HM781-36B(Poziotinib)|QD*2weeks/3weeks
79566661|NCT01746771|Drug|Paclitaxel|175mg/m2
79566662|NCT01746771|Drug|Trastuzumab|8mg/kg
79726951|NCT04296747|Drug|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
79566663|NCT01746810|Radiation|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
79566664|NCT01746823|Drug|Cyclosporins|
79566665|NCT01746875|Drug|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
79566666|NCT01746875|Drug|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
79566667|NCT01746927|Other|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
79566668|NCT01746992|Drug|Cyclophosphamide 750mg/m2|day 1 in both arms
79566669|NCT01746992|Drug|Vincristine 1.4mg/m2|day 1
79566670|NCT01746992|Drug|Doxorubicin 50mg/m2|day 1
79566671|NCT01746992|Drug|prednisone 60mg/m2|day1-day5
79566672|NCT01746992|Drug|ifosfamide 2000mg/m2|day 22-day 24
79726952|NCT04296747|Procedure|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
79266048|NCT02132429|Drug|Placebo|Placebo containing no active drug
79566673|NCT01746992|Drug|pirarubicin 50mg/m2|day 1
79566674|NCT01746992|Drug|pirarubicin 25mg/m2|day 22
79566675|NCT01746992|Drug|Etoposide phosphate 100mg/m2|day 22-day 24
79566676|NCT01746992|Drug|methotrexate 1500mg/m2|day 43
79566677|NCT01747018|Biological|Platelet-rich Plasma|
79266049|NCT02129621|Procedure|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
80022914|NCT02149914|Other|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
79566678|NCT01747031|Device|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
79861672|NCT01085929|Procedure|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
79861673|NCT01085929|Procedure|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
79566679|NCT01747044|Drug|Milnacipran|100mg/day
79566680|NCT01747044|Drug|Placebo|
79566681|NCT01747057|Behavioral|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation* and with sinus rhythm.~PPV >12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ [(PPmax+PPmin)/2] x100 (during 5 respiratory cycles)~SVV > 12% (15). SVV: Stroke volume variation~A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV < 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP>12).~● Non-preload responsive patients (defined as PPV or SVV < 12%) will resume the same protocol as responders when fluid response parameters are negative."
79726953|NCT04296747|Radiation|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
79726954|NCT04298931|Other|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
79726955|NCT02686879|Device|Multifocal contact lenses|
79266050|NCT02129621|Drug|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
79266051|NCT02129699|Drug|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
79266052|NCT02129699|Other|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
79266053|NCT03549923|Device|Simultaneous CRRT|The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
79266054|NCT03549923|Device|Conventional-indication CRRT|The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
79726956|NCT02686879|Device|Single vision contact lenses|
79861674|NCT00413062|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
79266055|NCT03549923|Drug|Esmolol|The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
79266056|NCT03549923|Drug|Standard care|The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
79266057|NCT02132585|Procedure|Speckle tracking echocardiography|
79266058|NCT02136875|Drug|Double dose of Salmeterol + Fluticasone Propionate|
79566682|NCT01747057|Behavioral|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (> 65mmHg) or CVP > 12mmHg. If CVP reaches > 12 mmHg and MAP remains < 65mmHg, norepinephrine should be started to reach MAP > 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output < 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
79861675|NCT00413062|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
79566683|NCT01747070|Other|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
79566684|NCT01747070|Other|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
79566685|NCT01747070|Other|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
79581369|NCT01935752|Other|vascular echotracking|endothelial function study and virtual histology study
80022915|NCT02149914|Drug|PPI|
80031753|NCT03050242|Drug|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
79266059|NCT02136875|Behavioral|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
79266060|NCT02136875|Drug|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
79861676|NCT01082185|Device|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
79861677|NCT01034878|Drug|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
79861678|NCT01082263|Drug|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
79566686|NCT01747070|Other|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
79861679|NCT02208544|Procedure|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
79861680|NCT02208544|Device|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
79861681|NCT02208544|Radiation|FDG-PET/CT|Head and Neck FDG-PET/CT
79861682|NCT00494091|Drug|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
79266061|NCT02132663|Other|Control: Marketed routine infant formula|
79266062|NCT02132663|Other|An investigational infant formula containing an alternate source of DHA|
79566687|NCT01747083|Drug|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
79566688|NCT01747109|Device|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
79566689|NCT01747109|Procedure|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
79861683|NCT00494091|Drug|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
79861684|NCT01017159|Drug|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
79861685|NCT00494013|Drug|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
79861686|NCT00494013|Drug|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
79861687|NCT00079339|Radiation|radiation therapy|Undergo radiotherapy
79861688|NCT00079339|Drug|tipifarnib|Given orally
79861689|NCT00493779|Procedure|Blood Collection|4 weeks
79861690|NCT01088191|Biological|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
79266063|NCT05212493|Drug|Cannabis oil|Cannabis oil 20:1 CBD:THC ratio
79266064|NCT02136953|Behavioral|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
79566690|NCT01747122|Device|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
79566691|NCT01747122|Device|Epidural|
79566692|NCT01747135|Drug|VTS-270|
79566693|NCT01747148|Drug|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
79566694|NCT01747161|Drug|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
79566695|NCT01747161|Drug|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
79861691|NCT01088191|Drug|Hyaluronan|Hyaluronan alone
79861692|NCT01082341|Biological|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
79861693|NCT01017315|Drug|Baby talcum|50 grams apply locally prior cast application
80022916|NCT03095794|Other|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
79266065|NCT02136953|Behavioral|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
79861694|NCT00541866|Drug|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous [IV] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
79861695|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
79266066|NCT02129933|Drug|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
79861696|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
79861697|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
79566696|NCT01747174|Drug|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
79566697|NCT01747174|Drug|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
79566698|NCT01747174|Procedure|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
79266067|NCT02129933|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
79266068|NCT02132819|Other|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
79566699|NCT01747200|Procedure|Sham rTMS|
79566700|NCT01747200|Procedure|Bilateral rTMS at same frequency and in phase|
79566701|NCT01747200|Procedure|Bilateral rTMS at different frequencies|
79266069|NCT02132819|Other|feeding during transfusion|The feeding process will be continued during the transfusion
79266070|NCT02132897|Drug|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
79566702|NCT01747200|Procedure|Bilateral rTMSat same frequency and out of phase|
79566703|NCT01747200|Procedure|rTMS over TP8|
79566704|NCT01747200|Procedure|rTMS over TP7|
79566705|NCT01747226|Other|Fluoride rinse|rinse with 15 ml for 1 minute
79726957|NCT04296591|Diagnostic Test|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
79726958|NCT01006707|Drug|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
79266071|NCT02132897|Drug|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
79266072|NCT02130011|Other|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
79566706|NCT01747226|Other|Halita|rinsing with 15 ml for 1 minute
79566707|NCT01747226|Other|Meridol Halitosis|rinsing with 15 ml for 1 minute
79566708|NCT01747226|Other|Water|rinsing with 15ml for 1 minute
79566709|NCT01747239|Drug|Cabazitaxel|25 mg/m2 IV every three weeks
79566710|NCT01747252|Dietary Supplement|RGC|
79566711|NCT01747252|Dietary Supplement|RGC|
79566712|NCT01747252|Dietary Supplement|Resveratrol|The equivalent of 150 mg resveratrol
79566713|NCT01747278|Drug|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
79566714|NCT01747317|Device|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
79726959|NCT02698657|Drug|ASP5094|Intravenous (IV)
79726960|NCT02698657|Drug|Placebo|Intravenous (IV)
79726961|NCT04298385|Other|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
79726962|NCT04216615|Behavioral|preoperative anxiety|patients who are anxious
79726963|NCT04296279|Drug|FMP014|Falciparum Malaria Protein-14
80022917|NCT03095794|Other|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
79566715|NCT01747356|Device|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
79726964|NCT04296279|Drug|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
79726965|NCT00616057|Dietary Supplement|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
79566716|NCT01747382|Procedure|Renal denervation|
79726966|NCT00616057|Dietary Supplement|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
79566717|NCT01747395|Other|Exercise training|The heart failure patients are subjected to differents protocols of physical training
79861698|NCT00493467|Drug|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
79861699|NCT00493467|Drug|Rituximab|250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
79861700|NCT00090493|Biological|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
79861701|NCT00090493|Biological|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
79861702|NCT01088347|Drug|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
79861703|NCT01088347|Drug|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
80022918|NCT03095794|Other|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
79266073|NCT02132975|Device|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
79266074|NCT02132975|Procedure|Biopsies using UroStation® (image fusion)|
79266075|NCT02252471|Behavioral|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
79266076|NCT02252549|Device|SPIES+WLI assisted TURB|
79266077|NCT02252549|Device|WLI assisted TURB|
79566718|NCT01747408|Drug|Human Albumin|"25% human albumin given in four escalating doses:~Group 1: .625g/kg infused over 3hrs daily X 7day~Group 2: 1.25g/kg infused over 3hrs daily X 7day~Group 3: 1.875g/kg infused over 3hrs daily X 7day~Group 4: 2.5g/kg infused over 3hrs daily X 7day"
79566719|NCT01747512|Drug|C-PERT|Patients with thyroid and Head and Neck cancer
79566720|NCT01747512|Drug|G-PERT|Patients with thyroid and Head and Neck cancer
79566721|NCT01747525|Device|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
79566722|NCT01747538|Drug|Placebo|Solution for subcutaneous injection
79566723|NCT01747538|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
79566724|NCT01747538|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
79566725|NCT01747564|Drug|YM178 (mirabegron)|oral
79566726|NCT01747590|Drug|Zolpidem|
79266078|NCT02137031|Device|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
79266079|NCT02133053|Other|Medical Device, drug-like|Ectoin Allergy Nasal Spray
79266080|NCT02133053|Drug|Beclomethasone|Beclomethasone nasal spray
79266081|NCT02137109|Drug|natalizumab|Administered as specified in the treatment arm.
79566727|NCT01747590|Drug|Alprazolam|
79566728|NCT01747590|Drug|Caffeine|
79566729|NCT01747590|Other|Placebo|
79566730|NCT01747603|Other|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
79566731|NCT01747616|Device|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
79566732|NCT01747616|Other|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
79726967|NCT04296201|Device|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
79726968|NCT00615511|Dietary Supplement|placebo pregnenolone|Sugar pill, taken twice a day
79726969|NCT00615511|Dietary Supplement|pregnenolone|500mg in tablet form taken orally twice a day
79726970|NCT04215133|Other|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
79726971|NCT02702089|Procedure|Rectal cancer surgery|Rectal cancer resection
79726972|NCT01006629|Biological|palivizumab|palivizumab 15 mg/kg intramuscularly
80022919|NCT03095794|Other|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
79566733|NCT01747642|Dietary Supplement|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
79726973|NCT04215055|Device|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
79861704|NCT01088347|Radiation|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
80022920|NCT04976218|Biological|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10^5/kg, dose 2 will be 1×10^6/kg，and dose 3 will be 1×10^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
80022921|NCT02153190|Device|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
79266082|NCT02130089|Behavioral|Intensive Tailored Education|
79266083|NCT02130167|Drug|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
79566734|NCT01747642|Drug|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
79566735|NCT01747668|Dietary Supplement|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
79566736|NCT01747668|Dietary Supplement|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
79566737|NCT01747681|Procedure|Microfracture|
79726974|NCT04214977|Procedure|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
79726975|NCT04214977|Procedure|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
79726976|NCT02701933|Drug|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
79566738|NCT01747694|Behavioral|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
79566739|NCT01747707|Drug|Docetaxel|
79726977|NCT02701933|Drug|Saline|Saline, intravenous infusion
79726978|NCT04295967|Other|formalin fixed paraffin embedded blocks|The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
79861705|NCT04329702|Behavioral|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
79861706|NCT04329702|Behavioral|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
80022922|NCT02153190|Device|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
79566740|NCT01747707|Drug|Cisplatin|
79266084|NCT02133209|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
79266085|NCT02133209|Behavioral|Stress Management for Headaches|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
79266086|NCT02130245|Procedure|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
79266087|NCT02130245|Procedure|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
79266088|NCT02130323|Drug|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
79566741|NCT01747707|Drug|S-1|
79566742|NCT01747720|Dietary Supplement|Vitamin D3|Given orally
79566743|NCT01747720|Dietary Supplement|Placebo|
79566744|NCT01747733|Device|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
79266089|NCT02130323|Procedure|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
79566745|NCT01747746|Drug|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
79726979|NCT01012323|Biological|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
79726980|NCT02871765|Other|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
79266090|NCT03549611|Drug|Multimodal Oral Drug Regimen|Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
79266091|NCT03549611|Drug|Acetaminophen|Acetaminophen 975mg
79266092|NCT02253017|Other|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
79726981|NCT02870751|Biological|TW11681 or TW10722|
79726982|NCT01011933|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79726983|NCT01011933|Drug|Selumetinib|Given PO
79726984|NCT02549209|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
79861707|NCT05220930|Other|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
79861708|NCT05220930|Other|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
79266093|NCT02133287|Device|AVI® Arsenic trioxide drug eluting stent delivery system|
79266094|NCT02133287|Device|Firebird2® sirolimus eluting stent system|
79266095|NCT02137187|Procedure|AV junction ablation|AV junction ablation
79266096|NCT02137187|Device|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
79266097|NCT02137187|Drug|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
79266098|NCT02137187|Device|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
79861709|NCT04302558|Behavioral|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
79400209|NCT06121973|Behavioral|educational group|Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
79400210|NCT06121960|Diagnostic Test|spirometry|"Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance"
79400211|NCT06121947|Procedure|The DBS electrodes are implanted into MLR.|MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
79566746|NCT01747746|Drug|Warfarin and Enoxaparin|Historical Control
79861710|NCT04302558|Behavioral|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
79861711|NCT05692440|Device|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
79861712|NCT05692050|Drug|Epcoritamab|Subcutaneous Injection
79861713|NCT04004832|Diagnostic Test|there is not any intervention procedure|there is not any intervention procedure
80022923|NCT05041738|Procedure|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
80022924|NCT05041738|Procedure|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
79266099|NCT02130401|Device|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
79266100|NCT02130479|Behavioral|Contingency Management-Family Engagement|
79266101|NCT02130479|Behavioral|Treatment as Usual|
79266102|NCT02137265|Drug|Clomiphene|Clomiphene citrate 50 mg orally daily
79266103|NCT02137265|Drug|Placebo|One pill every other day
79566747|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|
79566748|NCT01747785|Other|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
79566749|NCT01747785|Other|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
79726985|NCT02549209|Drug|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
80022925|NCT02149992|Dietary Supplement|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
79566750|NCT01747785|Other|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
79566751|NCT01747798|Drug|auranofin|Given PO
80022926|NCT02149992|Device|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
80022927|NCT02149992|Device|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
79861714|NCT04221828|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
80022928|NCT05041660|Other|Virtual-reality-based training|Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
79566752|NCT01747798|Other|laboratory biomarker analysis|Correlative studies
80022929|NCT05041660|Other|Inhibitory Control Training|"Uses an active inhibitory control training which includes a stop signal."
79566753|NCT01747863|Other|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at </= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
79400212|NCT06121947|Procedure|The electrodes are implanted into the patient's vagus nerve|A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
79400213|NCT06121895|Other|Video Laryngeal Mask|Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.
79400214|NCT06121895|Other|Fastrack Laryngeal Mask|Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
79566754|NCT01747889|Device|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
80022930|NCT05041660|Other|Sham Inhibitory Control Training|"Uses an inhibitory control training which does not include a stop signal."
80022931|NCT05041660|Other|Computerized training|Uses a relatively simplistic computerized training.
80022932|NCT04833582|Drug|ZN-c3|ZN-c3 is an investigational drug.
79400215|NCT06121869|Dietary Supplement|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
79400216|NCT06121869|Dietary Supplement|Leucine|Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
79566755|NCT01747902|Procedure|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
79566756|NCT01747902|Procedure|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
79566757|NCT01747941|Drug|PF-06305591|single dose, solution
79400217|NCT06121869|Dietary Supplement|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
79566758|NCT01747941|Drug|Placebo|matching placebo
79566759|NCT01747941|Drug|PF-06305591|single dose, solution
79566760|NCT01747941|Drug|Placebo|matching placebo
79566761|NCT01747941|Drug|PF-06305591|single dose, solution
79566762|NCT01747941|Drug|Placebo|matching placebo
79581370|NCT01935765|Other|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
79581371|NCT01935765|Other|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
79726986|NCT02549209|Drug|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
79726987|NCT03405883|Other|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
80022933|NCT04833582|Drug|Gemcitabine|Gemcitabine is an approved drug
79861715|NCT05138328|Device|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
80022934|NCT02157090|Other|Herpes Patch SOS (Hansaplast®)|
80022935|NCT02157090|Other|Herpes vesicle patch of Compeed®|
80022936|NCT02153268|Procedure|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
80022937|NCT05041582|Device|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
80022938|NCT05041582|Drug|Citalopram|total 3 months, since 2-4 weeks after stroke
80022939|NCT05041582|Behavioral|Rehabilitation|hospitalized rehabilitation, 3 hours daily
80022940|NCT02157246|Other|Pimonidazole|
80022941|NCT02157246|Other|F-MISO PET|
79566763|NCT01747954|Other|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
79581372|NCT01935765|Other|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
79726988|NCT03278587|Other|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
79861716|NCT04221750|Behavioral|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced ~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
79861717|NCT04221750|Drug|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
79861718|NCT04221750|Drug|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
79400218|NCT06121856|Device|VerioVue Enhancements BGMS|Blood glucose monitoring system
79400219|NCT06121830|Drug|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
79400220|NCT06121830|Drug|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
79861719|NCT04221750|Behavioral|Healthy Lifesylte|Group educational sessions that focus on healthy diet, exercise, and social support once a month
79861720|NCT04182126|Other|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
79861721|NCT04182126|Other|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
79400221|NCT06121830|Drug|Placebo|Placebo, tablet, orally, once daily for up to 4 weeks
79861722|NCT04182126|Other|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
80022942|NCT02157246|Other|pCT|
80022943|NCT02157246|Other|Functional MRI|
80022944|NCT02157246|Procedure|Biopsy|
80022945|NCT02157246|Procedure|Blood sample|
80022946|NCT04966156|Behavioral|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
80022947|NCT02150070|Drug|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
80022948|NCT02150070|Drug|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
80022949|NCT02150148|Behavioral|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
80022950|NCT03542838|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
80022951|NCT03542838|Drug|Saline|Saline is a normal physiological solution
80022952|NCT05027776|Biological|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
80022953|NCT05027776|Biological|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
80022954|NCT05027776|Biological|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
79266104|NCT02133365|Behavioral|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
79566764|NCT01747954|Other|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
79566765|NCT01747967|Other|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
79726989|NCT03278587|Other|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
79726990|NCT03278587|Other|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
79726991|NCT02698267|Drug|BIIB074|Administered as specified in the treatment arm
79726992|NCT02698267|Drug|Itraconazole|200 mg twice daily [BID] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
79266105|NCT02133443|Device|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
79266106|NCT02133443|Device|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
79308907|NCT04807491|Other|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
79400222|NCT06121817|Other|Food/meal intervention|2 types of exotic fruits, durian and banana, are the study test meals. Both isocaloric test meals are performed at breakfast. All subjects are required to consume the entire meal within 10 minutes.
79400223|NCT06121804|Drug|Immunosuppressive Agents|Prescribing immunosuppressive agents
79400224|NCT06121778|Other|Home|There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
79400225|NCT06121765|Other|Tyrosine kinase inhibitor|Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI
79566766|NCT01747980|Drug|PRX-112|Single dose level, four doses per cohort
79726993|NCT01011465|Drug|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
79726994|NCT01011465|Drug|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
79726995|NCT01011465|Behavioral|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
79566767|NCT01747993|Drug|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
79566768|NCT01747993|Drug|Placebo|(1 tablet / day for 6 days)
79566769|NCT01748006|Other|Standard of care therapy for severe decompensated heart failure|
79566770|NCT01748019|Drug|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
79566771|NCT01748032|Behavioral|Cognitive training|20 minutes/day for 5 sequential working days
79566772|NCT01748058|Behavioral|Exercise based on active video gaming|
79566773|NCT01748084|Drug|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
79566774|NCT01748084|Drug|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
79566775|NCT01748097|Drug|sodium bicarbonate 4.2%|
79566776|NCT01748110|Behavioral|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
80022955|NCT02150226|Device|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
79726996|NCT01011465|Behavioral|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
79726997|NCT02701855|Behavioral|Cognitive tests|"Cognitive tests include:~The MMSE (Mini Mental State Examination)~Free and Cued Selective Recall Reminding Test (FCSRT).~Executive functions (fluencies, TMT A and B, span).~Tests of verbal fluency (literal and category)~Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~The Clinical Dementia Rating Scale~The IADL scale evaluates autonomy.~Geriatric Depression screening Scale (GDS)"
79726998|NCT02701855|Biological|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
79861723|NCT04182126|Other|Indoor residual spraying with micro-encapsulated pirimiphos-methyl|each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year
80022956|NCT02153424|Drug|Apixaban|
79861724|NCT00481065|Biological|MF59-eH5N1|
79266107|NCT02592434|Drug|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet [BID] or solution [BID]):~5<7kg (2mg or 2mL); 7<10kg(2.5mg or 2. mL); 10 <15kg (3mg or 3mL); 15<25kg (3.5mg or 3.5mL); 25<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects <40 kg. Oral tablets (5 mg) are used for subjects >=40 kg."
79566777|NCT01748110|Behavioral|TRIMM|text message intervention.
79861725|NCT00481065|Biological|eTIV_a|
79861726|NCT00481065|Biological|MF59-eH5N1 + eTIV_a|
80022957|NCT05025436|Device|Acupoint stimulation with low energy laser (Erger laser pen)|Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
79566778|NCT01748123|Drug|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
79566779|NCT01748123|Drug|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
79566780|NCT01748136|Device|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
79566781|NCT01748188|Procedure|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
79566782|NCT01748188|Procedure|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
79566783|NCT01748188|Procedure|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
79566784|NCT01748188|Procedure|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
79566785|NCT01748188|Procedure|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
79566786|NCT01748201|Procedure|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
79566787|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
79566788|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
79726999|NCT02701855|Radiation|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
79861727|NCT01017393|Drug|Ketamine|
79861728|NCT01017393|Drug|ketamine free|
79861729|NCT00493311|Drug|IV Placebo|IV Placebo
79861730|NCT00493311|Drug|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
80022958|NCT02157402|Behavioral|Social marketing activities and pop-up events to promote healthy lifestyles|
79861731|NCT00493311|Biological|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
79861732|NCT00571649|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
79861733|NCT00571649|Drug|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
79861734|NCT00571649|Drug|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
79566789|NCT01748266|Other|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
79861735|NCT00571649|Drug|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
79861736|NCT05434793|Device|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
79861737|NCT05434715|Procedure|Thyroidectomy|removal of the thyroid gland
79861738|NCT05434403|Device|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
79861739|NCT05434403|Device|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
79566790|NCT01748279|Drug|Atorvastatin|
79861740|NCT00546572|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
79861741|NCT00546572|Biological|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
79861742|NCT03917472|Drug|Brolucizumab|Intravitreal injection
79566791|NCT01748279|Drug|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
79727000|NCT02701855|Other|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
79861743|NCT03917472|Drug|Aflibercept|Intravitreal injection
79861744|NCT00681863|Drug|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
79861745|NCT00681863|Drug|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
79861746|NCT00681863|Drug|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
79566792|NCT01748279|Drug|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
79727001|NCT04294485|Behavioral|Physical therapy|Electrostimulation combined with exercise
79727002|NCT02494141|Drug|Curcumin|Dietary Supplement
79727003|NCT02494141|Other|Placebo|
79861747|NCT00681863|Drug|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
79861748|NCT00681863|Drug|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
79861749|NCT02559791|Biological|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
79266108|NCT02592434|Other|placebo|matching placebo tablet or solution for tofacitinib
79566793|NCT01748305|Behavioral|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
79566794|NCT01748318|Drug|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
79566795|NCT01748318|Drug|Bactrim DS|Bactrim DS
79566796|NCT01748331|Other|Fluid restriction|Patients will be randomized to strict fluid restriction < 1 L/day versus moderate fluid restriction < 2.5 L/day
79566797|NCT01748344|Drug|Cetirizine|10mg tablets
79566798|NCT01748344|Drug|High dose ONO-4053|Experimental
79566799|NCT01748344|Drug|Low dose ONO-4053|Experimental
79566800|NCT01748344|Drug|Placebo|None active
79566801|NCT01748370|Drug|Vitamin D supplementation in hypogonadal men|
79566802|NCT01748370|Drug|Vitamin D supplementation in eugonadal men|
79566803|NCT01748370|Drug|Placebo hypogonadal|
79566804|NCT01748370|Drug|Placebo eugonadal|
79581373|NCT01935765|Other|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
79727004|NCT01011387|Procedure|NPWT System|Dressing change 3 times per week
79727005|NCT01011387|Device|NPWT system|3 dressing changes/week for maximum 4 weeks.
79727006|NCT02701621|Other|MIRT-AT|Aquatic therapy
79727007|NCT02701621|Other|MIRT|Land-based Therapy
79727008|NCT02698345|Device|drug-eluting balloon (In.PACT Admiral, Medtronic)|
79727009|NCT04215211|Diagnostic Test|Survival prediction for glioma patients|Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
79861750|NCT02559791|Drug|Placebo|Matching placebo once monthly for 2 months
79861751|NCT05677620|Radiation|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
79861752|NCT05677620|Drug|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
79861753|NCT05677620|Device|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
79861754|NCT00681629|Drug|Quetiapine XR|400-800 mg, oral, bid
79861755|NCT00681629|Other|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
79566805|NCT01748383|Procedure|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
79727010|NCT02701465|Other|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
79727011|NCT02701465|Other|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
79861756|NCT00969176|Drug|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
79566806|NCT01748383|Procedure|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
79566807|NCT01748383|Procedure|stenting of IRA|The only stent implantation
79566808|NCT01748396|Drug|Calcitriol|
79566809|NCT01748396|Drug|Calcium Carbonate|
79566810|NCT01748409|Other|Biopsies of peripheral autonomic nervous system|
79566811|NCT01748409|Other|Autonomic dysfunction questionnaires|
79566812|NCT01748409|Other|Electrophysiological tests|
79566813|NCT01748422|Drug|Qutenza|Transdermal patch
79566814|NCT01748435|Drug|Qutenza|Single treatment with Qutenza
79566815|NCT01748461|Behavioral|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
79266109|NCT02130713|Drug|Third generation fluoroquinolone|Prulifloxacin 600 mg
79266110|NCT02130713|Dietary Supplement|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
79266111|NCT02133599|Drug|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
79266112|NCT02130791|Behavioral|Sleep|
79566816|NCT01748461|Behavioral|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
79566817|NCT01748474|Procedure|Supplemental oxygen via a mask|
79566818|NCT01748487|Drug|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
79566819|NCT01748500|Drug|Pantoprazole|
79566820|NCT01748513|Other|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
79566821|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
79566822|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
79566823|NCT01748539|Drug|KHK4827|
79266113|NCT02137421|Dietary Supplement|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
79266114|NCT02260739|Other|Blood samples|
79266115|NCT02137577|Procedure|DEB catheter|DEB catheter (trade name: Litos/Tulip)
79266116|NCT02137577|Procedure|common PTA balloon catheter|common PTA balloon catheter
79266117|NCT02260895|Dietary Supplement|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
79266118|NCT02133677|Drug|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
79266119|NCT02137733|Drug|Bisoprolol|
79566824|NCT01748539|Drug|Placebo|
79266120|NCT02137733|Drug|Carvedilol|
79566825|NCT01748578|Drug|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
79566826|NCT01748578|Drug|EBI-005-1 Placebo|
79566827|NCT01748604|Other|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
79566828|NCT01748604|Device|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
79566829|NCT01748604|Other|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
79566830|NCT01748604|Device|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
79566831|NCT01748617|Other|Controlled diet|1 week of controlled diet
79566832|NCT01748630|Drug|dexmedetomidine|
79566833|NCT01748630|Drug|Midazolam|
79566834|NCT01748630|Drug|fentanyl|
79566835|NCT01748656|Device|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
79566836|NCT01748656|Device|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
79566837|NCT01748669|Dietary Supplement|Garlic oil|Oral administration
79566838|NCT01748682|Other|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
79566839|NCT01748708|Device|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
79581374|NCT01935765|Other|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
79581375|NCT01935765|Other|Electrocardiogram (ECG)|Electrocardiogram (ECG)
79861757|NCT05669586|Drug|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
79266121|NCT02137811|Other|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
79566840|NCT01748708|Device|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
79566841|NCT01748721|Biological|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
79566842|NCT01748721|Other|pharmacological study|Correlative studies
79566843|NCT01748721|Other|laboratory biomarker analysis|Optional correlative studies
79566844|NCT01748734|Procedure|quality-of-life assessment|Ancillary studies
79727012|NCT00616135|Procedure|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
80022959|NCT05027152|Other|Resistance training|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.
79266122|NCT04371458|Drug|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
79266123|NCT02137889|Drug|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
79266124|NCT04794452|Device|Battery operated toothbrush|Device on plaque removal efficacy
79400226|NCT06121739|Behavioral|Child Mental Health Literacy Program|The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
79566845|NCT01748734|Other|questionnaire administration|Ancillary studies
79566846|NCT01748734|Other|counseling intervention|Undergo cognitive behavioral therapy
80022960|NCT05027152|Other|Repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
80022961|NCT04434430|Drug|Gabapentin|Oral Gabapentin 600 mg
79566847|NCT01748734|Behavioral|behavioral intervention|Undergo cognitive behavioral therapy
80022962|NCT04434430|Other|Placebo|Oral NaCl 500 mg
80022963|NCT03094156|Drug|Placebo|1 capsule of placebo [to be taken orally, with 240 mL of potable water]
80022964|NCT03094156|Drug|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg [to be taken orally, with 240 mL of potable water]
79266125|NCT04794452|Device|Manual toothbrush|Device on plaque removal efficacy
79266126|NCT02133755|Drug|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
79308908|NCT04807413|Drug|Nitric Oxide|The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
79308909|NCT04807413|Other|standard of care treatment|standard of care treatment
79308910|NCT05617053|Device|DAART|
79308911|NCT05617053|Device|ATP/Supera stenting|
79308912|NCT04825665|Other|Continuous force|"A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period."
79566848|NCT01748747|Drug|Montanide ISA 51 VG|Given SC
79566849|NCT01748747|Biological|MART-1 antigen|Given SC
79566850|NCT01748747|Other|laboratory biomarker analysis|Correlative studies
79566851|NCT01748747|Biological|Gag:267-274 peptide vaccine|Given SC
79566852|NCT01748747|Drug|resiquimod|Applied topically
79566853|NCT01748773|Drug|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m^2 IV on Day 1 of Cycles 1-3.
79566854|NCT01748773|Radiation|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
79727013|NCT01011309|Biological|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
79727014|NCT01011309|Drug|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
79727015|NCT04214821|Drug|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
80022965|NCT03094156|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg [to be taken orally, with 240 mL of potable water]
80022966|NCT03094156|Drug|Comtan®|Entacapone 200 mg tablets [to be taken orally, with 240 mL of potable water]
80022967|NCT02964273|Drug|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
80022968|NCT02964273|Drug|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
80022969|NCT05025046|Diagnostic Test|Thyroscan|To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
80022970|NCT02773446|Biological|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
80022971|NCT05040724|Drug|Ivermectin|ivermectin placebo
80022972|NCT03542058|Drug|Carvedilol|Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
79861758|NCT00969254|Drug|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
79861759|NCT00969254|Drug|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
79861760|NCT00921791|Device|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
79266127|NCT02130869|Biological|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
79566855|NCT01748773|Drug|Capecitabine|Participants will receive capecitabine 850 mg/m^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
79400227|NCT06121726|Other|Ilioinguinal-Iliohypogastric nerve block|local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
79566856|NCT01748773|Drug|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
79566857|NCT01748786|Behavioral|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
79727016|NCT04214821|Drug|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
79861761|NCT00921791|Device|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
79861762|NCT00921791|Behavioral|Pharmaceutical care|consultations with the pharmacists
79266128|NCT02130869|Biological|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
79266129|NCT02130869|Biological|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
79266130|NCT02130869|Drug|Busulfan|Given IV - Group A only.
79400228|NCT06121726|Drug|Local anesthetic|Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
79566858|NCT01748786|Other|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
79566859|NCT01748812|Drug|Osteomalacia|
79727017|NCT00616213|Biological|filgrastim|filgrastim will be administered at a standard dose and schedule
79727018|NCT00616213|Drug|PR104|PR104 is administered intravenously once every 21 days
79861763|NCT00921791|Other|Usual care|Consultation with the physician.
79861764|NCT04503252|Other|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
79861765|NCT04503252|Other|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
79861766|NCT04503252|Other|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
79861767|NCT04503252|Other|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
79266131|NCT02130869|Drug|Melphalan|Given IV - All groups.
79266132|NCT02130869|Biological|GM-CSF|Given SQ - All groups.
79266133|NCT02130869|Drug|Bendamustine|Given IV - Group B only.
79266134|NCT02130869|Drug|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
79266135|NCT02130869|Drug|Cytarabine|Given IV - Group B only.
79266136|NCT02130869|Drug|Carboplatin|Given IV - Group C only.
79400229|NCT06121700|Radiation|Radiotherapy targeted to the primary lesion|5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
79566860|NCT01748838|Drug|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
79566861|NCT01748838|Other|Mannitol|excipient blended with CTX-4430 in capsules
79727019|NCT00616213|Other|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
79727020|NCT00615667|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
79566862|NCT01748838|Drug|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
79566863|NCT01748838|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
79566864|NCT01748838|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
79566865|NCT01748838|Other|Mannitol|excipient blended with CTX-4430
79566866|NCT01748851|Drug|XELOX|capecitabine 1000mg/m2 bid po D1-D14
80022973|NCT03611439|Dietary Supplement|ReBuilder|8-component botanical dietary supplement
80022974|NCT03611439|Dietary Supplement|Placebo|Inactive Placebo Capsule
80022975|NCT05040412|Device|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
79727021|NCT00615043|Procedure|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
79400230|NCT06121700|Radiation|Radiotherapy targeted to the metastatic lesions|Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
79861768|NCT04503252|Other|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
79400231|NCT06121700|Biological|Anti-PD-1 monoclonal antibody|"The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W."
79400232|NCT06121700|Biological|Trastuzumab|For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.
79400233|NCT06121700|Drug|Chemotherapy|"The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks."
79400234|NCT06121700|Procedure|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
79566867|NCT01748851|Drug|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
79566868|NCT01748864|Drug|Etarfolatide (EC20)|
79566869|NCT01748877|Drug|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
80031754|NCT04894630|Other|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
79566870|NCT01748877|Drug|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
79566871|NCT01748903|Device|Target 360°, 2D Coils, Nano Coils|
79566872|NCT01748929|Drug|Albendazole|
79566873|NCT01748929|Drug|Placebo|
79566874|NCT01748981|Other|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
79727022|NCT04295655|Other|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
80031755|NCT04880902|Procedure|sleeve gastrectomy|Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
79727023|NCT04295655|Other|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
79727024|NCT04295655|Other|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
79727025|NCT02697955|Drug|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
79727026|NCT02697955|Other|Placebo|9 mg sodium chloride pr. ml (0,9 %)
79727027|NCT04294329|Procedure|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
79727028|NCT04294329|Drug|Bupivacaine|Bupivacaine
79727029|NCT04294329|Drug|Saline|normal saline
79727030|NCT02871609|Other|Stent examination, urinary analysis, USSQ questionnaire|
79727031|NCT02701309|Device|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
79566875|NCT01748981|Other|As usual|Controls, not training
79727032|NCT03250507|Drug|Bupivacaine|0.25% bupivacaine for TAP block
79727033|NCT03250507|Drug|Liposomal bupivacaine|Exparel for TAP block
79727034|NCT03250507|Drug|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
79727035|NCT00997893|Dietary Supplement|Soy Phytoestrogen|Novasoy® pill (55 mg)
79727036|NCT00997893|Drug|Estradiol|Estradiol pill (1 mg)
79727037|NCT00997893|Drug|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
79727038|NCT00997893|Drug|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
79266137|NCT02130869|Device|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
79400235|NCT06121700|Procedure|Metastasectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
79566876|NCT01749020|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
79566877|NCT01749020|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
79566878|NCT01749046|Drug|Remegal|Remegal 1500 mg for 12 weeks
79566879|NCT01749072|Drug|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
79566880|NCT01749072|Drug|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
79727039|NCT00997893|Drug|MPA Placebo|oral placebo pill (0mg MPA)
79727040|NCT02697877|Drug|Regadenoson|
79400236|NCT06121700|Procedure|Local ablative therapies|Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
79566881|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
79566882|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
79727041|NCT04214665|Drug|Alpha Lipoic acid 600 mg HR film coated tablets|
79727042|NCT02870673|Drug|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
79727043|NCT02870673|Drug|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
79266138|NCT02130869|Biological|G-CSF|Given SQ - All Groups.
79266139|NCT02130869|Drug|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
79266140|NCT02130869|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
79566883|NCT01749098|Drug|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
79566884|NCT01749098|Drug|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
79566885|NCT01749098|Drug|Placebo|Placebo capsule orally administered on Days 1 - 5
79566886|NCT01749098|Drug|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
79566887|NCT01749111|Drug|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
79566888|NCT01749111|Drug|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
79727044|NCT02870673|Device|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
79727045|NCT02870673|Device|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
79727046|NCT02701231|Device|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
79861769|NCT00969410|Biological|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
79861770|NCT00969488|Other|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
79861771|NCT03485430|Behavioral|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
79861772|NCT00679367|Drug|dexamethasone|40 mg once weekly
79566889|NCT01749124|Device|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
79566890|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
79266141|NCT04785404|Procedure|primary skin closure|skin will be stitched after stoma reversal to heal by primary intention
79566891|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
79566892|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
79566893|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
79566894|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
79566895|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
79566896|NCT01749163|Biological|Saline|
79566897|NCT01749163|Biological|GIP|
79861773|NCT00679367|Drug|lenalidomide|10 mg/day D1-21
79861774|NCT00679367|Drug|melphalan|5 mg/m2 D1-4
79266142|NCT02130947|Behavioral|Exercise|
79566898|NCT01749163|Biological|GLP-1|
79566899|NCT01749176|Behavioral|SMS texting intervention|
79566900|NCT01749176|Behavioral|Control-Usual Care|
79861775|NCT00969566|Drug|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
79861776|NCT00973544|Other|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
79266143|NCT04785248|Procedure|Three-step disinfection|"Three step disinfection method can be divide in three part. The first step of disinfection: scalp dandruff removal + disinfection The second step of disinfection: whole head Use 2% iodine tincture to smear the whole head skin, the assistant helps to lift the head to expose the surgical field, from both eyebrows to the occipital hairline, from both sides to the neck, after the iodine tincture dry out, use 75% alcohol to deionize. Then placing more than 4 layers of operation towel under the head.~The third step of disinfection: neck chest abdomen disinfection."
79566901|NCT01749189|Dietary Supplement|Blend|22 grams of protein/day
79566902|NCT01749189|Dietary Supplement|Whey|22 grams of protein/day
79566903|NCT01749189|Dietary Supplement|Placebo|22 grams of carbohydrate/day
79566904|NCT01749202|Dietary Supplement|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
79566905|NCT01749202|Dietary Supplement|EPA softgels|3 x 500 mg softgel capsules/day
79566906|NCT01749202|Other|Sunflower Oil Food|3 servings/day
79566907|NCT01749202|Other|SDA soybean Oil Food|3 servings/day
79566908|NCT01749228|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
79566909|NCT01749228|Drug|Etodolac|500 mg tablet once a day
79566910|NCT01749241|Drug|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
79566911|NCT01749241|Drug|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
79566912|NCT01749267|Procedure|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
79566913|NCT01749306|Biological|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
79581376|NCT01935765|Other|Carotid echography|Carotid echography
79581377|NCT01935765|Other|Blood pressure|Blood pressure
79861777|NCT00755495|Drug|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
79861778|NCT00755495|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
79861779|NCT00755495|Drug|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
79861780|NCT00755495|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
79861781|NCT00964184|Drug|Metformin|
79861782|NCT00964184|Behavioral|Lifestyle modification|
79861783|NCT04005300|Dietary Supplement|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
79861784|NCT04005300|Dietary Supplement|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
79861785|NCT00969644|Drug|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
80022976|NCT03321513|Drug|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
79266144|NCT02133833|Device|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
79266145|NCT02137967|Procedure|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
79566914|NCT01749306|Other|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
79566915|NCT01749319|Drug|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
79566916|NCT01749319|Drug|Intervenous baclofen|
79566917|NCT01749332|Other|Perihepatic Phlebotomy|
79566918|NCT01749358|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
79566919|NCT01749358|Behavioral|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
79566920|NCT01749371|Drug|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
79566921|NCT01749384|Biological|Bevacizumab|Given IV
79566922|NCT01749384|Other|Laboratory Biomarker Analysis|Correlative studies
79727047|NCT02701231|Drug|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
79727048|NCT02701231|Device|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
79861786|NCT00969644|Drug|Pegvisomant|s.c. injections once daily (10-15 mg/day)
79861787|NCT05646420|Other|Blood sampling|A blood sample of 15 ml will be collected for each patient.
80022977|NCT03321513|Drug|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
79266146|NCT02137967|Procedure|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
79266147|NCT02137967|Drug|2.5% NaOCl|
79266148|NCT02137967|Drug|20% Formocresol|
79400237|NCT06121687|Procedure|Shaeer-I|Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.
79400238|NCT06121687|Procedure|PPI|Penile prosthesis implantation (PPI) will be performed
79400239|NCT06121674|Procedure|Shaeer-II|"SHAEER-I targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
79400240|NCT06121674|Procedure|PPI|Penile Prosthesis Implantation will be performed
79566923|NCT01749384|Other|Pharmacological Study|Correlative studies
79566924|NCT01749384|Drug|Tivantinib|Given PO
79566925|NCT01749397|Drug|Floxuridine|Given IP
79566926|NCT01749397|Other|Laboratory Biomarker Analysis|Correlative studies
79566927|NCT01749397|Other|Pharmacological Study|Correlative studies
79566928|NCT01749397|Drug|Veliparib|Given IV
79566929|NCT01749423|Biological|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
79566930|NCT01749436|Other|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
79566931|NCT01749449|Other|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
79861788|NCT00969800|Device|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
79861789|NCT00969800|Device|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
79266149|NCT04785170|Drug|Amino Acid|"A novel non-protein amino acid secreted by skeletal muscles which aids the cross-talk between skeletal muscles, liver, and adipose tissue at molecular levels. amino acid is generated by catabolism of the branched-chain amino acid valine. Existing literature states, amino acid induces body fat loss by increasing energy expenditure, stimulating free fatty acid (FFA) oxidation in the liver and skeletal muscle cell, and by enhancing oxygen consumption by adipose tissue and hepatocytes. It was observed that amino acid stimulated differentiation of energy storing white adipose tissue preadipocytes to an energy burning beige (brown to white) phenotype."
79727049|NCT02701075|Device|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
79727050|NCT02701075|Device|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
79861790|NCT04008914|Other|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
79861791|NCT04073394|Behavioral|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
79861792|NCT04073394|Behavioral|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
79266150|NCT02133911|Drug|Ranolazine|
79266151|NCT02133989|Drug|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
79266152|NCT02133989|Drug|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
79266153|NCT02138045|Drug|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
79266154|NCT02138045|Drug|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
79400241|NCT06121570|Procedure|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
79400242|NCT06121570|Drug|Doxorubicin|Doxorubicin will be administered at 60 mg/m^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
79566932|NCT01749475|Drug|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
79266156|NCT02138123|Procedure|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
79266157|NCT02138123|Procedure|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
79266158|NCT02134067|Drug|TAS-119|
79266159|NCT02134067|Drug|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
79400243|NCT06121570|Drug|Epirubicin|Epirubicin will be administered at 100 mg/m^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
79400244|NCT06121570|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
79400245|NCT06121570|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
79566933|NCT01749475|Other|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
79566934|NCT01749488|Other|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
79566935|NCT01749514|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
79566936|NCT01749527|Behavioral|minimal activity|Pad test with minimal activity
79727051|NCT00615745|Drug|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
79861793|NCT00964262|Drug|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
79861794|NCT00964262|Drug|Placebo|Plcacebo of each doasage, single subcutanoeus injection
79861795|NCT00973778|Other|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
79861796|NCT05623410|Biological|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
79861797|NCT05623410|Biological|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
79861798|NCT00964340|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
79861799|NCT00964340|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
80022978|NCT05024110|Other|High intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
79566937|NCT01749540|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
80022979|NCT05024110|Other|Moderate intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
79566938|NCT01749553|Other|Sleeper Stretch|Posterior shoulder stretch technique
79566939|NCT01749566|Drug|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
79566940|NCT01749579|Drug|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
79566941|NCT01749579|Drug|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
79727052|NCT04216069|Other|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
79861800|NCT04004598|Behavioral|golf training|12 weeks of training by Professional Golf Association professional
79861801|NCT00973934|Device|Magstim Theta|
79861802|NCT00973934|Device|Thymatron System IV|
80022980|NCT03093376|Behavioral|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
79861803|NCT00970112|Procedure|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
79861804|NCT00964418|Drug|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
80022981|NCT02032797|Drug|Progesterone|
80022982|NCT05024266|Drug|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
80022983|NCT03094078|Other|News item with spin|Interpretation of news item with spin
80022984|NCT03094078|Other|News item without spin|Interpretation of news item without spin
79861805|NCT00964418|Drug|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
79566942|NCT01749579|Drug|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
79566943|NCT01749592|Device|cochlear implant|Surgical implantation of a cochlear implant device
79566944|NCT01749618|Behavioral|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
79566945|NCT01749722|Device|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
79566946|NCT01749748|Procedure|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
79581378|NCT01935804|Drug|Pioglitazone|30 mg/daily for 12 months
79861806|NCT00974012|Drug|Divalproex Sodium|500 mg ER Tablet
79861807|NCT00974012|Drug|Depakote®|500 mg ER Tablet
79861808|NCT04009226|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
79266160|NCT02253329|Procedure|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
79266161|NCT02253329|Procedure|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
79266162|NCT05614154|Other|hypochlorous active substance|Poviodin iyot
79581379|NCT01935804|Drug|Metformin|850 mg/daily for 12 months
79581380|NCT01935817|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
79861809|NCT00964574|Drug|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
79727053|NCT04216069|Other|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
79861810|NCT00964574|Drug|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
79308913|NCT04825665|Other|Intermittent force|"A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period."
79400246|NCT06121570|Drug|Fludarabine|Fludarabine will be administered at 30 mg/m^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
79861811|NCT04008680|Other|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
79861812|NCT00970346|Drug|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
79566947|NCT01749761|Other|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
79861813|NCT03937778|Behavioral|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
79861814|NCT03935126|Diagnostic Test|Diagnostics|Diagnostics
79400247|NCT06121570|Biological|Tumor-draining lymph node-derived lymphocyte (LNL)|Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
79566948|NCT01749761|Other|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
79861815|NCT00964652|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
79400248|NCT06121570|Biological|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
79400249|NCT06121570|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
79400250|NCT06121557|Procedure|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
79566949|NCT01749774|Behavioral|Physical activity counseling|
79861816|NCT00970580|Drug|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
79861817|NCT00974168|Radiation|Cumulative BED ≤ 100|Radiation
79861818|NCT00974168|Radiation|Cumulative BED ≤ 130 Gy2|Radiation
79861819|NCT04009304|Behavioral|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
79861820|NCT00974324|Drug|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
79861821|NCT00545714|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
79861822|NCT00545714|Drug|Fludarabine|Fludarabine 25 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
79400251|NCT06121557|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
79400252|NCT06121557|Drug|Fludarabine|Fludarabine will be administered at 30 mg/m^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
79400253|NCT06121557|Biological|Tumor-draining lymph node-derived lymphocyte (LNL)|In the dose-escalation portion, participants receive ascending dose (1×10^9~18×10^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
79566950|NCT01749787|Drug|PRTX-100 at 1.5 mcg/kg|
79566951|NCT01749787|Drug|PRTX-100 at 3.0 mcg/kg|
79566952|NCT01749787|Drug|PRTX-100 at 6.0 mcg/kg|
79566953|NCT01749787|Drug|PRTX-100 at 12.0 mcg/kg|
79861823|NCT00545714|Drug|Rituximab|Rituximab 375 mg/m^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
79861824|NCT00970658|Drug|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
79861825|NCT00970658|Drug|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
79861826|NCT00964730|Drug|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
79861827|NCT00964730|Drug|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
79727054|NCT02697721|Behavioral|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
79727055|NCT02697721|Other|Control with delayed intervention|Control with delayed intervention
79727056|NCT04215367|Dietary Supplement|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
79727057|NCT04215367|Dietary Supplement|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
79566954|NCT01749787|Drug|PRTX-100 at 240 mcg|
79566955|NCT01749787|Drug|Placebo|Placebo administered via infusion once per week for 5 weeks
79566956|NCT01749787|Drug|PRTX-100 at 420 mcg|
79566957|NCT01749852|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
79566958|NCT01749852|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
79566959|NCT01749865|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
79566960|NCT01749878|Drug|REGN1500|
79727058|NCT02697799|Behavioral|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
79727059|NCT02697799|Behavioral|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
79727060|NCT02700607|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
79727061|NCT02700607|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
79266163|NCT03767699|Behavioral|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never < 1,500 kcal).
79400254|NCT06121557|Biological|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
79400255|NCT06121557|Biological|Camrelizumab|Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
79400256|NCT06121557|Drug|Chemotherapeutic drug, ADC or PARP inhibitor|Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
79400257|NCT06121531|Device|Soft Contact Lens|Vision Correction
79566961|NCT01749878|Drug|placebo|
79566962|NCT01749891|Drug|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
79566963|NCT01749917|Other|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
79566964|NCT01749917|Other|Control intervention|Active upper limb range of movement exercises for 15 minutes.
79566965|NCT01750008|Procedure|Global Fibroid Ablation|
79566966|NCT01750008|Procedure|Myomectomy|
79566967|NCT01750021|Dietary Supplement|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
79727062|NCT04782739|Other|None - Descriptive study|Descriptive study
79727063|NCT04215913|Other|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
79566968|NCT01750021|Dietary Supplement|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
79566969|NCT01750034|Procedure|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
79566970|NCT01750034|Procedure|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
79566971|NCT01750060|Drug|Fentanyl|
79566972|NCT01750060|Drug|Naltrexone|
79566973|NCT01750099|Procedure|Combined Spinal-epidural|See arm description
79566974|NCT01750099|Procedure|Continuous Lumbar epidural|See arm description
79566975|NCT01749657|Device|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
79566976|NCT06176599|Drug|Shenxiao Yuning decoction|Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
79581381|NCT01935817|Drug|Placebo|
79581382|NCT01935830|Radiation|[11c] LAAM|intravenous administration of 15-20 mCi of [11c] LAAM.
79581383|NCT01935830|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
79581384|NCT01935830|Drug|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
79581385|NCT01935843|Biological|CART-HER-2|
79727064|NCT02697643|Behavioral|BHCDS-based recommendations|
79727065|NCT02697643|Behavioral|Non-tailored recommendations|
79727066|NCT05324839|Drug|Botulinum toxin type A|injecting different dosage to different group
79861828|NCT00964730|Drug|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
79266164|NCT04794140|Procedure|different number of passes|Each patient's operation process is the same, that is, after obtaining enough specimens for diagnosis by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique, additional three passes are performed. One of which is randomly selected as the one pass group, and the other two passes automatically as the two pass group. Please refer to the literature for EUS-FNB wet technique (Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.)
79266165|NCT04091126|Drug|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as intravenous infusion.
79266166|NCT04091126|Drug|Bortezomib|Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
79266167|NCT04091126|Drug|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
79400258|NCT06121518|Drug|D064 and D702, QD|Experimental Group Subjects assigned to this group are treated with D064, D702
79400259|NCT06121518|Drug|D064 and Placebo of D702, QD|Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
79266168|NCT04091126|Drug|Dexamethasone|Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
79727067|NCT02700685|Dietary Supplement|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
79266169|NCT04785014|Procedure|interventional|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
79266170|NCT02785913|Other|Laboratory Biomarker Analysis|Correlative studies
79266171|NCT02785913|Drug|Taselisib|Given PO
79581386|NCT01935856|Drug|KHK7580|Oral administration
79727068|NCT02700685|Drug|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
79727069|NCT02700685|Other|Placebo|Placebo treatment (identical capsules containing excipients only)
79266172|NCT04793672|Other|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
79266173|NCT04784468|Other|No intervention|Case-control design, one single investigation
79266174|NCT04085900|Biological|Blood and saliva|Collect blood and saliva samples from participants
79266175|NCT04085900|Diagnostic Test|P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA|Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
79266176|NCT04085900|Diagnostic Test|Fiberoptic endoscopy and biopsy|Screening participants will refer to fiberoptic endoscopy and biospy
79266177|NCT04784156|Procedure|Subtalar (Talocalcaneal) Arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
79266178|NCT04784156|Device|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
79266179|NCT04793594|Other|Berg Balance Test|Patients evaluate with Berg Balance Test for balance
79266180|NCT04793594|Other|Tinetti Balance And Gait Test|Patients evaluate with Tinetti Balance And Gait Test for balance
79266181|NCT04793594|Other|Time Up And Go Test|Patients evaluate with Time Up And Go Test for balance
79400260|NCT06121518|Drug|Placebo of D064 and D702, QD|Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
79400261|NCT06121492|Drug|Branched-chain amino acid|In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
79400262|NCT06121492|Drug|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
79400263|NCT06121453|Behavioral|Multicomponent Adherence Intervention|multi-part intervention to reduce barriers to medication use
79400264|NCT06121154|Diagnostic Test|SARC-F questionnaire|"The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia."
79400265|NCT06121154|Diagnostic Test|Gait speed|Low gait speed was defined as walking below than 0.8 meters per second.
79400266|NCT06121154|Diagnostic Test|The chair rise test|the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
79581387|NCT01935869|Drug|LEO 90100|
79581388|NCT01935869|Drug|Vehicle|
79581389|NCT01935869|Drug|Petrolatum ointment|
79581390|NCT01935882|Drug|Artemether-lumefantrine combination|
79581391|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
79581392|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
79727070|NCT02700763|Other|[18F]dabrafenib molecular imaging|A [18F]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
79727071|NCT04188613|Device|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
79727072|NCT00616291|Biological|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
79727073|NCT03151681|Drug|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
79266182|NCT05613998|Other|GPR Group|"6-week treatment using the GPR method. 1 weekly session (45 min) with frog on the ground and sitting postures + daily home self-postures (10 min)"
80022985|NCT03611361|Device|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
79566977|NCT06176599|Drug|Symptomatic treatment|(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure &gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
79566978|NCT06176586|Other|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
79861829|NCT00974402|Behavioral|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
79566979|NCT06176573|Procedure|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
79566980|NCT06176560|Drug|Mesalazine|Oral Formulation
80022986|NCT03094000|Behavioral|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
80022987|NCT03094000|Behavioral|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
79566981|NCT06176534|Drug|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
79566982|NCT06176534|Drug|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
79566983|NCT06176521|Procedure|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
79566984|NCT06176508|Drug|HS-10374|Administered orally QD for 16 weeks
79566985|NCT06176508|Drug|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
79566986|NCT06176508|Drug|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
79566987|NCT06176482|Device|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
79566988|NCT06176456|Diagnostic Test|rTMS|Active regiment
79566989|NCT06176456|Other|Placebo|Tactile artefacts without magnetic pulses
79727074|NCT05324605|Procedure|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
79727075|NCT02700373|Drug|PDC-APB|
79727076|NCT02700373|Drug|Placebo|
79727077|NCT04215445|Drug|Empagliflozin 25 MG|Tab.empagliflozin 25mg once daily for 28 days
79266183|NCT05613998|Other|Aerobic Exercice Group|6-week nonspecific aerobic exercise treatment. Participants will take a daily walk (20 min)
79266184|NCT03962114|Dietary Supplement|Vitamin B3|capsules with niagen
79266185|NCT04346186|Diagnostic Test|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
79727078|NCT04215445|Device|OCT-A|Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
79727079|NCT01032265|Behavioral|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
79861830|NCT00539838|Drug|Prednisone|Oral repeating dose
79727080|NCT01032265|Behavioral|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
80022988|NCT05026762|Other|Treatment|Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
79566990|NCT06176417|Procedure|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
79727081|NCT00951457|Drug|Bendamustine|
79727082|NCT00951457|Drug|Alemtuzumab|
79727083|NCT05324527|Other|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
79727084|NCT02691871|Drug|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
80022989|NCT03611283|Other|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
79400267|NCT06121154|Diagnostic Test|Grip strength|Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females
79566991|NCT06176417|Procedure|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
79727085|NCT02691871|Drug|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
79727086|NCT02691871|Drug|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
79727087|NCT02700217|Procedure|Bupivacaine and Diamorphine|
80022990|NCT03611283|Other|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
80022991|NCT03611283|Other|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
80022992|NCT03611283|Other|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
79400268|NCT06121154|Diagnostic Test|Visual analog scale|The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
79400269|NCT06121037|Procedure|proximal ultrasound-guided GON radiofrequency ablation|proximal GON radiofrequency
79400270|NCT06121037|Procedure|distal ultrasound-guided GON radiofrequency ablation|distal GON radiofrequency
79566992|NCT06176391|Device|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
79727088|NCT02700217|Procedure|Remifentanil, Propofol and Cistracurium|
79727089|NCT02700217|Procedure|Bupivacaine and Rectus Sheath injection|
80022993|NCT05040490|Drug|sugammadex as reversal drugs|use sugammadex to reverse neuromuscular blockade
80022994|NCT02773368|Drug|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
79861831|NCT00539838|Drug|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
80022995|NCT02773368|Drug|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
80022996|NCT02032563|Drug|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
80022997|NCT03093532|Other|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
80022998|NCT03093532|Other|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
79861832|NCT00539838|Drug|Methylprednisolone|Intravenous repeating dose
79861833|NCT00539838|Drug|Ocrelizumab|Intravenous repeating dose
79566996|NCT06176339|Drug|Pentoxifylline Oral Tablet|Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
79566997|NCT06176339|Drug|Placebo|Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
79727090|NCT02690467|Device|Insupen G34x3,5mm|
79727091|NCT02690467|Device|Insupen G32x4mm|
79727092|NCT02700139|Device|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
79727093|NCT02699827|Drug|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
79727094|NCT02699827|Drug|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
79727095|NCT02699827|Drug|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
79727096|NCT02700061|Procedure|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
79727097|NCT02700061|Procedure|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
79727098|NCT02705989|Drug|BMS-986195|Specified dose on specified day
79727099|NCT02705989|Other|Placebo|Specified dose on specified day
79861834|NCT00539838|Drug|Placebo|Intravenous repeating dose
79861835|NCT00970892|Drug|Warfarin dose titration|Dosage
79861836|NCT00964808|Drug|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
79861837|NCT00964808|Drug|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg * 2 pr. day until time to discharge from the Hospital or latest at day 12.
79861838|NCT00970970|Other|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
79566998|NCT06176326|Other|Ethics Education Program in Nursing|In the 7-session training program, each session, lasting 2 hours, presented to students the topic headings determined through the needs analysis of the program development study. This education program consists of sessions on the Introduction to Ethics-Bioethics, Principles of Beneficence and Non-maleficence, Autonomy and Responsibility, Informed Consent and Those Lacking Capacity for Consent, Respect for Human Vulnerability and Individual Integrity, Respect for Private Life and Ensuring Confidentiality, Discrimination, Stigmatization, and Cultural Diversity.
80022999|NCT02032485|Drug|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
79566999|NCT06176313|Other|Mandala Group|"The Mandala activity lasts approximately 60 minutes.~• A calm environment is provided during the Mandala activity, and participants are ensured not to be disturbed by external stimuli or individuals unless they request assistance.~Each student's last menstrual date is recorded in an Excel table.~Two days before the intervention day, students will be contacted and invited to participate in the study.~Monitoring each student's menstrual cycle, the Mandala activity intervention is scheduled during the late luteal phase of each student's menstrual cycle. The intervention is planned within the 5 days before the expected start of menstrual bleeding on days and hours convenient for the student's class schedule.~After each session, on the 4th day of the expected menstrual bleeding, students are subjected to PMSÖ.~On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
79727100|NCT00616447|Device|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
79266186|NCT04346186|Diagnostic Test|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
79727101|NCT00616447|Device|placebo sham|Sham treatment will mimic active treatment mentioned above.
79727102|NCT05323747|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
79727103|NCT02706067|Drug|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent [%] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
79727104|NCT05323669|Diagnostic Test|Molecular testing|Molecular testing of thyroid nodules
79861839|NCT03765450|Drug|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
79861840|NCT00974558|Device|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
79861841|NCT05258084|Behavioral|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
79861842|NCT00974636|Dietary Supplement|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
79861843|NCT00974636|Dietary Supplement|Usual Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
79727105|NCT04215757|Procedure|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
79861844|NCT00974714|Drug|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
79727106|NCT02699905|Other|phlebotomy|phlebotomy
79727107|NCT02699671|Device|Bioresorbable Vascular Scaffold|
79727108|NCT00615277|Dietary Supplement|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
79727109|NCT05323201|Biological|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10^6/kg), dose Level 2 (3×10^6/kg) and dose Level 3 (5×10^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10^6/kg /infusion) will be evaluated.
79727110|NCT05323201|Drug|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5~Day -3)
79727111|NCT05323201|Drug|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
79861845|NCT00974714|Other|placebo|oral placebo 2 g twice a day for 14 weeks
79861846|NCT00971126|Drug|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
79266187|NCT03720158|Dietary Supplement|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
79266188|NCT03720158|Dietary Supplement|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
79304344|NCT03289091|Behavioral|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
79861847|NCT00971360|Other|conversion disorder|Proinflammatory cytokine levels in conversion disorder
79861848|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
79400271|NCT06120803|Drug|Esomeprazole 40 mg|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
79567000|NCT06176313|Other|Coping with Premenstrual Symptoms Education Group|"The education will be conducted through face-to-face interviews in the master's course classroom at the Faculty of Health Sciences at Bilecik Şeyh Edebali University. The education was conducted using PowerPoint presentations projected onto a white smartboard.~One month after the completion of the education, a 1st Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~One month after the 1st Reminder training, a 2nd Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
79567001|NCT06176313|Other|Control Group|"No intervention will be applied to the control group throughout the research. However, students in this group who cope with premenstrual syndrome using medication or non-medication methods will be monitored during the three-month menstrual cycle.~Each student's menstrual cycle in the control group has been recorded in the Excel table. The estimated end of menstruation for each student has been noted.~At the estimated end of menstruation, the researcher contacts the students in the control group to inquire whether they have used any medication or non-medication methods to cope with premenstrual syndrome.~Those who use medication or non-medication methods to reduce premenstrual symptoms are excluded from the study.~On the 4th day of the 4th menstrual period bleeding, the post-test with PMSÖ will be applied to the students."
79727112|NCT02905825|Device|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
79567002|NCT06176300|Behavioral|PAR - the SEED Method|The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.
79727113|NCT02905825|Drug|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
79727114|NCT02905825|Diagnostic Test|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
79727115|NCT01208051|Drug|Cediranib|Given PO
79727116|NCT01208051|Drug|Cediranib Maleate|Given PO
79727117|NCT01208051|Other|Laboratory Biomarker Analysis|Correlative studies
79727118|NCT01208051|Drug|Lenalidomide|Given PO
79727119|NCT00616837|Other|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
79266189|NCT05473052|Behavioral|Preoperative home-based exercise training|"1) Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~Type: Walking~Frequency: 3 sessions per week~Duration: 30 minutes~Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~Frequency: 2 sessions per week~Duration: 2 sets x 15 repetitions~Rest in-between sets: 45 seconds~Intensity:Rate of perceived exertion on Borg Category Ratio-10 (3-5)~Progression: Increase the number of sets (3 sets of 15 repetitions after week~2) Weekly telephone supervision: A physical therapist carried out weekly telephone calls with all participants to monitor adverse events, give positive reinforcement and recommend strategies to overcome barriers that arise during the exercise program."
79266190|NCT05472896|Procedure|cTACE|transcatheter arterial chemoembolization with
80023000|NCT05026918|Other|MCPT|Postural Drainagewith percussion and vibration
80023001|NCT05026918|Other|ACBT|ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
79400272|NCT06120270|Device|CeraFlex PFO Closure System|The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
79727120|NCT00616837|Other|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
79727121|NCT04214197|Drug|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
79727122|NCT04214275|Other|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
79727123|NCT05322889|Drug|Telmisartan tablets|12 weeks treatment
79727124|NCT04214431|Behavioral|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
79727125|NCT02705521|Device|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
79727126|NCT00616915|Drug|Wellbutrin XL|Wellbutrin XL 300mg daily
79727127|NCT01207583|Other|Non-interventional observational study|Non-interventional observational study
80023002|NCT05040022|Drug|Pneumoperitoneum pressure 10 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
80023003|NCT05040022|Drug|Pneumoperitoneum pressure 14 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
79304345|NCT03061851|Behavioral|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
79400273|NCT06119438|Other|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
79727128|NCT01207427|Drug|Placebo|
79727129|NCT01207427|Drug|ADL5945 0.1 mg|
79727130|NCT01207427|Drug|ADL5945 0.25 mg|
79861849|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
79861850|NCT00964964|Drug|placebo|Placebo injected s.c. (under the skin) four times weekly
79266191|NCT05472896|Drug|Dicycloplatin (TP21)|the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
79567003|NCT06176300|Behavioral|PAR-Youth Voices|Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.
79727131|NCT05410223|Drug|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
79861851|NCT04183998|Other|Trans-spinal Electrical Stimulation (tsES)|Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
80023004|NCT03611205|Procedure|Computed Tomography|Undergo dPET/CT
79266192|NCT05472896|Drug|Epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
79266193|NCT05579171|Device|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
79266194|NCT05579171|Device|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
79266195|NCT04793048|Device|a noninvasive intraoral electrotherapy device|a noninvasive intraoral electrotherapy device to treat periodontal disease at-home for 20 minutes a day
79266196|NCT04793048|Device|a sham device|a sham device to be used at-home for 20 minutes a day
79266197|NCT05472428|Combination Product|Autologous bone marrow mononuclear cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
79266198|NCT03596918|Biological|Bleomycin Sulfate|Given IV
79266199|NCT03596918|Other|Laboratory Biomarker Analysis|Correlative studies
79266200|NCT03596918|Other|Quality-of-Life Assessment|Ancillary studies
79266201|NCT03596918|Other|Questionnaire Administration|Ancillary studies
79567004|NCT06176300|Behavioral|Emerging Leaders hospital-based intervention|Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
79567005|NCT06176287|Procedure|Dental Implantation with high torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
79266202|NCT03596918|Drug|Vincristine Sulfate|Given IV
79727132|NCT05410223|Drug|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
79266203|NCT02261051|Other|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
79266204|NCT04793438|Behavioral|Motive-specific intervention|Three appointments are made with the patients of the intervention group within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. The time frame of 45 minutes for each intervention must be strictly adhered to. Patients are additionally asked to complete tasks between the sessions. All appointments take place in the Psychiatric University Hospital directly on the ward.
79567006|NCT06176287|Procedure|Dental Implantation with low torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
79861852|NCT00965042|Drug|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
80023005|NCT03611205|Procedure|Positron Emission Tomography|Undergo dPET/CT
80023006|NCT03093298|Other|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
80023007|NCT02254902|Behavioral|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
79727133|NCT05410223|Drug|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
79727134|NCT05410223|Drug|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
79727135|NCT04713553|Biological|BNT162b2|Intramuscular injection
79727136|NCT04713553|Biological|BNT162b2.B.1.351|Intramuscular injection
79266205|NCT04793438|Behavioral|Supportive conversations|Since we want to check whether the patients benefit from the specific intervention and not only from getting more speaking time, patients without the motive-specific intervention should also be given three sessions, in which no intervention takes place. They will be carried out in the sense of supportive conversations (i.e. conversations that do not follow a specific psychotherapy concept). All appointments take place in the Psychiatric University Hospital directly on the ward.
79266206|NCT04793126|Diagnostic Test|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
79266207|NCT05472350|Drug|Breztri Aerosphere|Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
79266208|NCT05472350|Other|Placebo|placebo is 0.9% normal saline
79567007|NCT06176274|Other|Prehabilition program|this program includes nutrition, physical activity, medical optimization and psychological support interventions.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. it will be applied for 4 weeks before surgery. the first meeting is scheduled for 40 minutes. the program compliance process will be monitored by phone weekly. postoperative recovery and functional capacity measurements will be performed.
79567008|NCT06176261|Drug|Datopotamab Deruxtecan|Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
79567009|NCT06176248|Drug|Triamcinolone Acetonide|1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
79567010|NCT06176248|Drug|saline solution|intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
79567011|NCT06176222|Drug|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
79567012|NCT06176222|Drug|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
79567013|NCT06176209|Diagnostic Test|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
79567014|NCT06176157|Dietary Supplement|vitamin D2, vitamin D3|comparing parentral D2, D3, to oral D2, D3
79567015|NCT06176144|Drug|Desflurane|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
79727137|NCT01206101|Drug|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
79727138|NCT01206101|Drug|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
79727139|NCT01205165|Drug|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
79727140|NCT00997503|Device|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
79266209|NCT02134223|Behavioral|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
79727141|NCT00997503|Drug|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
79727142|NCT00997503|Drug|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
79727143|NCT00997503|Drug|aspirin|"Oral, as prescribed by physician through end of study.~."
79727144|NCT02705443|Other|No Intervention|Standard of Care Only
79727145|NCT02705053|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
79400274|NCT06119425|Diagnostic Test|blood-based CRC screening|For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
79727146|NCT02705053|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
79400275|NCT06119412|Device|blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.|Each participant will have their blood pressure measured with two different techniques.
79400276|NCT06119399|Other|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
79727147|NCT01204775|Drug|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
79567016|NCT06176144|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
80023008|NCT05383443|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
80023009|NCT05383443|Behavioral|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
79266210|NCT02134223|Other|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
79400277|NCT06119399|Other|Pursed Lip Breathing Exercise|Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
79567017|NCT06176118|Dietary Supplement|2-HOBA|2-HOBA supplement take three times daily for 12-weeks
79567018|NCT06176079|Drug|Hyperpolarized (HP) 13C|A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
79266211|NCT02138435|Other|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
79266212|NCT02138435|Other|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
79567019|NCT06176079|Drug|Hyperpolarized 13C-Urea|Given intravenously (IV)
79567020|NCT06176079|Procedure|Magnetic Resonance Imaging|Imaging procedure
79567021|NCT06176079|Procedure|Saline Flush|A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
79567022|NCT06176053|Other|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
79567023|NCT06176040|Drug|TAVO101|TAVO101 IV Infusion.
79727148|NCT01204775|Drug|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
79727149|NCT01204775|Drug|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
79727150|NCT01204775|Drug|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
79727151|NCT01204775|Drug|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
79727152|NCT02705131|Device|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
79861853|NCT00974792|Biological|pegfilgrastim|
79861854|NCT00974792|Biological|rituximab|
79861855|NCT00974792|Drug|cyclophosphamide|
79861856|NCT00974792|Drug|cytarabine|
79861857|NCT00974792|Drug|doxorubicin hydrochloride|
79266213|NCT02134379|Device|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
79266214|NCT04792658|Behavioral|Detailed interview with personal demographic data|, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
79266215|NCT04792658|Behavioral|Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)|the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
79727153|NCT02705131|Device|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
79727154|NCT02844907|Drug|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
79727155|NCT02844907|Drug|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
79266216|NCT04792658|Behavioral|The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)|it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
79861858|NCT00974792|Drug|etoposide phosphate|
79861859|NCT00974792|Drug|ifosfamide|
79266217|NCT04792658|Behavioral|the Hamilton Depression Rating Scale|it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
79266218|NCT04792658|Behavioral|The Hamilton Anxiety Rating Scale|it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
79266219|NCT04792658|Behavioral|The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)|It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic
79567024|NCT06176014|Procedure|implant placement|5 implant were placed in intraforaminal area using surgical guide
79567025|NCT06176001|Other|psychoeducation in groups|Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
79567026|NCT06175988|Other|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
79567027|NCT06175975|Other|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
79567028|NCT06175949|Drug|HRS-7085 Tablets|HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
79727156|NCT02844907|Other|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
79727157|NCT00628719|Drug|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
79861860|NCT00974792|Drug|leucovorin calcium|
79266220|NCT02138513|Behavioral|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
79266221|NCT02134457|Biological|ranibizumab|
79266222|NCT02138591|Procedure|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
79727158|NCT00628719|Drug|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
79861861|NCT00974792|Drug|methotrexate|
79861862|NCT00974792|Drug|vincristine sulfate|
79861863|NCT03659214|Behavioral|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
79727159|NCT00616993|Drug|Difluprednate|Difluprednate
79727160|NCT00616993|Other|Placebo|Vehicle
79727161|NCT02870361|Drug|intranasal insulin|
79861864|NCT00971438|Procedure|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
79727162|NCT02870361|Drug|Placebo|
79727163|NCT00617071|Other|medical chart review|
79727164|NCT00617071|Other|survey administration|
79727165|NCT00617071|Procedure|fecal occult blood test|
79727166|NCT00617071|Procedure|screening colonoscopy|
79727167|NCT00616681|Drug|Oxcarbazepine|
79861865|NCT03657888|Behavioral|Family Club Denmark (FCD)|Participation in Family Club Denmark
79861866|NCT03657888|Other|Wait-list control|Participants on the waiting list
79861867|NCT00965120|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
79861868|NCT00965120|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
79861869|NCT00965120|Drug|Placebo (saline)|Systemic infusion of placebo (saline).
79861870|NCT00971516|Procedure|Implant placement|dental implant placement
79861871|NCT00971516|Procedure|Implants surgery|dental implant surgery
79861872|NCT00971594|Behavioral|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk
79861873|NCT00971594|Behavioral|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
79727168|NCT00997035|Drug|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
79567029|NCT06175949|Drug|HRS-7085 simulant|PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
79567030|NCT06175936|Other|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
79567031|NCT06175910|Procedure|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
79727169|NCT00997035|Drug|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
79727170|NCT00617149|Behavioral|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
79727171|NCT01204697|Drug|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
79727172|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
79727173|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally as monotherapy
79727174|NCT02705209|Other|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
79727175|NCT02705209|Other|Placebo Cataplasm|Poultice of Kaolin and Water
79727176|NCT01001325|Biological|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
79861874|NCT00971672|Other|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
79861875|NCT00679289|Drug|HDI|20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression
79861876|NCT00679289|Drug|KW2871|5 mg/m^2 IV every 2 weeks until disease progression
79861877|NCT00679289|Drug|KW2871|10 mg/m^2 IV every 2 weeks until disease progression
79266223|NCT02138591|Procedure|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
79266224|NCT02138591|Procedure|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
79727177|NCT01001325|Biological|Normal saline|0.5 mL intramuscular
79727178|NCT02968459|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
79727179|NCT02968459|Other|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
79727180|NCT02870595|Device|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
79727181|NCT02870595|Device|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
79861878|NCT00679289|Drug|KW2871|20 mg/m^2 IV every 2 weeks until disease progression
79861879|NCT00679211|Drug|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
79861880|NCT00545948|Drug|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
79861881|NCT00545948|Drug|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
79861882|NCT00755573|Drug|Pregabalin|Pregabalin 300 mg - 600 mg BID
79861883|NCT00755573|Drug|placebo|Regime as described for pregabalin
79266225|NCT05613920|Behavioral|diet management program based on the nudge strategy|The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
79727182|NCT02704975|Device|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
79861884|NCT00971906|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant,or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups
79861885|NCT00755651|Procedure|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
79567032|NCT06175910|Procedure|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
79567033|NCT06175897|Procedure|Deep Brain Stimulation|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.~Device: STN-DBS devices DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
79567034|NCT06175897|Procedure|non-Deep Brain Stimulation|Patients with PD were given their original drug dose and did not receive DBS.
79567035|NCT06175871|Other|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
79567036|NCT06175871|Other|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
79727183|NCT02704975|Device|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
79727184|NCT01203917|Drug|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
79861886|NCT00974948|Procedure|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
79861887|NCT02559869|Drug|[18F] GE-180|PET Tracer Ligand
79266226|NCT05471804|Dietary Supplement|Sceletium tortuosum|Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
79266227|NCT02134613|Other|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
79727185|NCT02704741|Device|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
79861888|NCT00975026|Procedure|Massages ± Stretches|Chair Massage
79861889|NCT00971984|Other|Medical records summary|Summary of Medical files and laboratory results.
79861890|NCT00975104|Drug|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
79861891|NCT00975104|Drug|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
79861892|NCT00975104|Drug|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
79861893|NCT00975104|Drug|Placebo|Placebo IV QW
79861894|NCT00679055|Drug|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
79861895|NCT00679055|Drug|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
79861896|NCT04008290|Drug|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
79861897|NCT04008290|Drug|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
79266228|NCT04792736|Diagnostic Test|Blood lactate level|Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48
79861898|NCT02559167|Drug|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
79861899|NCT00975182|Drug|GDC-0941|Oral repeating dose
79861900|NCT00975182|Drug|erlotinib HCl|Oral repeating dose
79861901|NCT05271071|Diagnostic Test|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
79861902|NCT00972062|Other|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
79861903|NCT00972062|Other|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
79861904|NCT05270291|Procedure|rectal swab|rectal swab
79266229|NCT05578625|Other|plasma circulation DNA methylation sequencing|10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
79727186|NCT02704819|Other|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
79727187|NCT02704819|Other|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
79567037|NCT06175858|Diagnostic Test|CMR|We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
79567038|NCT06175845|Procedure|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
79567039|NCT06175819|Other|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
79567040|NCT06175806|Drug|Ondansetron Oral Film|5-hydroxytryptamine (5-HT) receptor antagonist
79567041|NCT06175806|Drug|Granisetron Oral Liquid Product|5-hydroxytryptamine (5-HT) receptor antagonist
79567042|NCT06175767|Drug|MT101-5|Tablet
79727188|NCT02704819|Other|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
79727189|NCT02704819|Other|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
79727190|NCT02704819|Other|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
79567043|NCT06175754|Procedure|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
79567044|NCT06175754|Procedure|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
79727191|NCT04318379|Biological|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
79861905|NCT00972140|Drug|Formoterol|Formoterol-HFA pMDI 12µg twice daily
79861906|NCT00972140|Drug|Formoterol|Formoterol-DPI 12 µg twice daily
79266230|NCT02134691|Behavioral|Prolonged Exposure|
79266231|NCT02134691|Behavioral|Applied Relaxation|
79266232|NCT02590562|Other|Routine clinical practice|
79567045|NCT06175754|Procedure|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
79266233|NCT05578469|Procedure|surgical treatment of Marfan Syndrome with subluxation lens|different surgical treatment of Marfan Syndrome with subluxation lens
79266234|NCT02138903|Other|trans thoracic echocardiography|
79266235|NCT02138981|Procedure|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
79266236|NCT02138981|Procedure|Immediate Resection|patients received immediate surgical resection.
79266237|NCT02134769|Device|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
79266238|NCT05613686|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
79567046|NCT06175741|Procedure|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in three levels (T3,T4 and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
79567047|NCT06175728|Device|S-Press|Leg Strengthening Device that can be used in supine and seated positions
79567048|NCT06175715|Procedure|carotid endarterectomy|carotid endarterectomy under local or general anethesia
79567049|NCT06175702|Drug|Vincristine|dose 1.5 mg/m2 at days 1, 8, 15 and 22
79567050|NCT06175702|Drug|Dexamethasone|40 mg on days 1-2, 8-9,15-16 and 22-23
79567051|NCT06175702|Drug|Imatinib|600 mg per day from 1 to up to 5 years
79266239|NCT05578391|Biological|Convalescent plasma|Admistration of one unit of convalescent plasma
79727192|NCT04213651|Other|No intervention|There is no intervention for this study
79727193|NCT04213495|Other|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
79727194|NCT02688517|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
79266240|NCT04792346|Radiation|breast/chest wall radiotherapy|34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery
79727195|NCT02688517|Other|Laboratory Biomarker Analysis|Correlative studies
79266241|NCT02253407|Biological|MMR vaccine|
79567052|NCT06175702|Drug|Cytarabine|1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
79567053|NCT06175702|Drug|Mercaptopurine|50 mg/m2 on days 1 to 28 of maintenance
79266242|NCT03549767|Device|Springfusor|Springfusor for administration of magnesium sulphate
79266243|NCT03549767|Procedure|Standard of care|Pritchard regimen. Magnesium sulphate is administered using hospital practice
79727196|NCT04318223|Drug|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
79727197|NCT02704897|Other|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
79266244|NCT04090190|Drug|Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
79266245|NCT05578313|Drug|Medical Cannabis|Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
79266246|NCT05471570|Device|tDCS stimulation|The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.
79266247|NCT04792034|Drug|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
79727198|NCT01202903|Drug|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
79727199|NCT01202903|Drug|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
79727200|NCT01001169|Biological|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
79266248|NCT02253095|Drug|Albendazole|
79266249|NCT02253095|Dietary Supplement|Zinc|
79266250|NCT02253095|Dietary Supplement|Multiple Micronutrient Supplement|
79266251|NCT02253095|Drug|Placebo|
79266252|NCT02134847|Other|SCS intervention schedule|
79266253|NCT03549455|Behavioral|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 & 4 will have Exposure therapy with Self-Distancing; Weeks 5 & 6 will have Exposure therapy only; Weeks 7 & 8 will have Exposure therapy with Self-Distancing;
79266254|NCT05578157|Diagnostic Test|Feeling Hot sensor|The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
79567054|NCT06175702|Drug|Methotrexate|1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
79567055|NCT06175702|Drug|Ponatinib|15 mg per day from consolidation start up to 5 years
79567056|NCT06175702|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
79567057|NCT06175702|Procedure|Total body irradiation|Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
79567058|NCT06175702|Drug|Cyclophosphamide|60 mg/kg on days -6 and -5 before alloSCT
79567059|NCT06175702|Drug|Fludarabine|30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
79567060|NCT06175676|Drug|Hydroxybutyl chitosan|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
79727201|NCT00618631|Drug|Nicotine|
79727202|NCT00618631|Drug|Carfentanil|
79727203|NCT01202747|Device|LipiFlow System|In-office treatment for meibomian gland dysfunction
79727204|NCT04213339|Behavioral|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~Squeeze the muscles in anus like holding a bowel movement focus penile area~Relax the pelvic floor muscles after each attempt.~Repeat this exercise 10 to 20 times.~While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
79567061|NCT06175676|Drug|5-Fluorouracil|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
79567062|NCT06175676|Drug|Gelatin Sponge Sheet|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
79727205|NCT04213573|Drug|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
79727206|NCT04213573|Drug|MI Varnish|topical fluoride varnish with calcium and phosphate
79727207|NCT05154175|Device|Ottobock helmet|Patients treated in current practice
79567063|NCT06175663|Drug|Antihypertensive medication withdrawal|To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
79567064|NCT06175650|Procedure|Cardiac surgery|Cardiac surgery of all types
79567065|NCT06175624|Other|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
79266255|NCT03548597|Device|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
79266256|NCT02135003|Other|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
79727208|NCT04395027|Device|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
79727209|NCT04294173|Behavioral|video education|tracheostomy care will be given to student nurses with video training
79861907|NCT05261945|Other|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
79861908|NCT05261945|Other|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
79861909|NCT05261945|Other|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
79861910|NCT00972218|Biological|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
79861911|NCT05230901|Other|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
79861912|NCT05230901|Drug|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
79266257|NCT02139059|Procedure|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
79266258|NCT02139059|Procedure|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
79266259|NCT03283982|Device|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
79266260|NCT03283982|Device|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
79266261|NCT04791800|Diagnostic Test|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
79266262|NCT04791332|Drug|JNJ-67953964|JNJ-67953964 capsule will be administered orally.
79266263|NCT04791332|Drug|Placebo|Matching placebo will be administered orally.
79567066|NCT06175624|Other|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
79727210|NCT02869659|Behavioral|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 & 2 & 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
79727211|NCT02869659|Behavioral|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
79727212|NCT04210063|Other|Inspiratory Muscle Training (IMT)|IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
79727213|NCT02870439|Other|Blood drawn|
79727214|NCT04209751|Diagnostic Test|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
79567067|NCT06175624|Other|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
79861913|NCT05230901|Drug|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
79861914|NCT02559557|Other|Educational Intervention|Participate in focus groups
79861915|NCT02559557|Other|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
79567068|NCT06175585|Other|narrative nursing|"The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient ."
79567069|NCT06175585|Other|traditional nursing|Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
79567070|NCT06175572|Device|coronary physiological indices|coronary physiological indices
79567071|NCT06175559|Combination Product|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
79727215|NCT00618709|Drug|ATX-101|ATX-101 single dose
79727216|NCT00620269|Drug|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
80023010|NCT05383443|Behavioral|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
79266264|NCT04791410|Procedure|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
79266265|NCT04791020|Drug|Lidocain topical + paracervical blockade|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
79266266|NCT04791020|Drug|Lidocaine topical|5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
79266267|NCT02531906|Drug|Gabapentin|Given PO
79266268|NCT02531906|Drug|Methadone Hydrochloride|Given PO
79727217|NCT00620269|Drug|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
79727218|NCT00620269|Drug|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 & 8 every 3 weeks X 2 cycles
79727219|NCT00620269|Radiation|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
79727220|NCT04213417|Other|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
79727221|NCT04213417|Other|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
79727222|NCT00618865|Dietary Supplement|Omega-3 fatty acids|
79266269|NCT02531906|Drug|Oxycodone Hydrochloride|Given PO
79266270|NCT02531906|Other|Quality-of-Life Assessment|Ancillary studies
79266271|NCT02531906|Other|Questionnaire Administration|Ancillary studies
79266272|NCT02783729|Drug|Lemborexant|Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
79266273|NCT02783729|Drug|Lemborexant|Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
79266274|NCT02783729|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
79266275|NCT02783729|Drug|Zolpidem tartrate|Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
79266276|NCT02783729|Drug|Zolpidem-matched placebo|Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
79727223|NCT04213183|Diagnostic Test|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
79567072|NCT06175533|Procedure|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
79861916|NCT02559557|Other|Quality-of-Life Assessment|Answer questionnaires
79861917|NCT02559557|Other|Questionnaire Administration|Answer questionnaires
79567073|NCT06175520|Behavioral|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
79567074|NCT06175507|Drug|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
79567075|NCT06175507|Drug|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
79567076|NCT06175481|Other|Popliteal Vein Compliance|Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
79567077|NCT06175468|Drug|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
79567078|NCT06175468|Drug|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
79727224|NCT00617617|Dietary Supplement|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
79727225|NCT00617617|Other|Placebo|Control Group - Control Group participants will receive an identical placebo.
79567079|NCT06174883|Dietary Supplement|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
79861918|NCT00972296|Device|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
79861919|NCT03908099|Behavioral|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
79861920|NCT03908099|Other|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
80023011|NCT05383443|Behavioral|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
80023012|NCT05383443|Other|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
79266277|NCT02443766|Other|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
79266278|NCT04790942|Drug|berberine hydrochloride|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
79266279|NCT04790942|Behavioral|lifestyle intervention group|The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
79567080|NCT06174051|Behavioral|Flashforward EMDR|The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
79727226|NCT05104957|Other|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
79861921|NCT03927950|Drug|escitalopram|escitalopram 10-20mg per day 12 weeks
79861922|NCT03927950|Drug|bupropion|bupropion 150-300mg per day 6 weeks
79861923|NCT00678899|Device|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
79861924|NCT00965432|Drug|STX107|Single dose of an oral suspension
79266280|NCT04791098|Other|Specific infectious diseases consultation|"Specific infectious diseases consultation at Clermont Ferrand Hospital with a specialist doctor :~Update vaccinations~Advice to travelers~Diagnostic and treatment of latent tuberculosis infection"
79727227|NCT05104957|Other|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
79266281|NCT04344080|Device|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
79266282|NCT02324504|Device|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
79266283|NCT02227940|Drug|Ceritinib|Given PO
79727228|NCT04212637|Other|MRI|Examine BOLD activity in relation to eye movements measures
79567081|NCT06174051|Behavioral|Flashback EMDR|The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
79567082|NCT06170840|Drug|QY101Placebo/QY101 ointment|External use for BID
79727229|NCT04212403|Drug|Levofloxacin|The control group receives AMP.
79727230|NCT00618943|Behavioral|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
79727231|NCT00637117|Biological|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
79727232|NCT02052193|Drug|Dabrafenib|Measurement of toxicity related to UV exposure
79727233|NCT02052193|Drug|Vemurafenib|Measurement of toxicity related to UV exposure
79727234|NCT00617695|Drug|Zolmitriptan|5mg nasal spray
79727235|NCT00617695|Drug|Placebo|
79727236|NCT02704585|Device|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
79727237|NCT02704585|Device|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
79861925|NCT03827993|Behavioral|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
79266284|NCT02227940|Drug|Cisplatin|Given IV
79266285|NCT02227940|Drug|Gemcitabine Hydrochloride|Given IV
79266286|NCT02227940|Other|Laboratory Biomarker Analysis|Correlative studies
79266287|NCT02227940|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
79567083|NCT06169800|Device|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
79727238|NCT00619021|Drug|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m^2, 800 mg/m^2, 1000 mg/m^2, 1200 mg/m^2
79727239|NCT00620347|Drug|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
79266288|NCT02227940|Other|Pharmacological Study|Correlative studies
79266289|NCT02135159|Drug|TDM1|administration of the TDM1 by IV perfusion
79266290|NCT02135159|Radiation|Brain Sequential RT|local RT
79266291|NCT02072486|Other|Laboratory Biomarker Analysis|Correlative studies
79266292|NCT02072486|Drug|Sorafenib Tosylate|Given PO
79266293|NCT03548441|Procedure|Surgery|Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.
79266294|NCT03548441|Other|Non-surgical management|Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
79266295|NCT03548363|Dietary Supplement|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
79266296|NCT03548363|Dietary Supplement|Placebo|200 mg/d maltodextrin
79266297|NCT00988364|Drug|Simvastatin|Simvastatin 20mg daily for 3 months.
79727240|NCT01918735|Drug|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
79266298|NCT00988364|Drug|Vytorin|Vytorin 20/10mg daily for 3 months.
79266299|NCT00988364|Drug|Placebo|Placebo one tablet daily times 3 months.
79727241|NCT01918735|Drug|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
79861926|NCT00972452|Behavioral|Exercise|short period of exercise training (5-10 days)
79727242|NCT04213105|Drug|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
79727243|NCT04213105|Drug|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
79727244|NCT01887301|Drug|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
80023013|NCT05383443|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
79400278|NCT06119399|Other|Doming of the diaphragm|"The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~The patient is instructed to inhale, and the physiotherapist gently resists this motion.~The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation."
79861927|NCT00965510|Behavioral|care coordination|patients receive care coordination to improve their type II diabetes
79861928|NCT00972686|Drug|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
80023014|NCT05383443|Behavioral|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
79266300|NCT00988364|Drug|Ezetimibe|Ezetimibe 10mg daily for 3 months.
79266301|NCT05578001|Drug|Pilocarpine Ophthalmic|1 drop of Pilocarpine 1%
79266302|NCT05577923|Drug|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks
79400279|NCT06119399|Other|Conventional exercise program for chronic neck pain|"Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks."
79581393|NCT01935895|Behavioral|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
79727245|NCT00618085|Behavioral|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
79727246|NCT00618085|Other|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
79727247|NCT00996801|Drug|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
79861929|NCT00921869|Drug|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
79581394|NCT01935908|Drug|levetiracetam|
79727248|NCT00996801|Drug|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
79727249|NCT00996801|Drug|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
79727250|NCT00996801|Drug|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
79861930|NCT00965588|Biological|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
79727251|NCT00996801|Drug|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
79861931|NCT04008992|Drug|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
79861932|NCT04008992|Other|Placebo|Placebo matching BMS-986259
79861933|NCT04008992|Diagnostic Test|P-Aminohippurate|Diagnostic Agent
79266303|NCT05577923|Drug|pyrotinib|Pyrotinib 320mg, PO daily, continuously
79266304|NCT05577923|Drug|Dalpiciclib|Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks
79266305|NCT05577923|Drug|fulvestrant|Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
79266306|NCT04790708|Radiation|Lutetium-177 (177Lu)-DOTATOC|5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
79266307|NCT04790708|Radiation|Yttrium-90 (90Y)-DOTATOC|5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
79727252|NCT00996801|Drug|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
79861934|NCT04008992|Diagnostic Test|Iohexol|Diagnostic Agent
79861935|NCT05248490|Other|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
79266308|NCT04790708|Radiation|177Lu-DOTATOC + 90Y-DOTATOC|"3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC"
79266309|NCT04790708|Radiation|Re-treatment 177Lu-DOTATOC|3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
79400280|NCT06119386|Device|Rexon-Eye|In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
79727253|NCT00619333|Drug|follitropin and lutropin|follitropin and lutropin
79727254|NCT02692027|Other|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
79861936|NCT00972842|Drug|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
79861937|NCT00972920|Procedure|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
79861938|NCT00975494|Drug|Sildenafil|
79861939|NCT00975494|Drug|Placebo|
79861940|NCT00975572|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
79861941|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
79861942|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
79861943|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
79861944|NCT00975572|Biological|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
79861945|NCT00975572|Biological|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
79861946|NCT00678587|Drug|Eltrombopag|75 mg, once daily, oral
79861947|NCT00678587|Drug|Placebo|placebo, once daily, oral
79861948|NCT00972998|Drug|Phenyephrine|Phenyephrine coated suppositories
79861949|NCT00965666|Drug|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
79266310|NCT04790708|Radiation|Re-treatment 90Y-DOTATOC|3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
79266311|NCT05577689|Other|Tissue|Tissue will be derived from patients during a standard of care procedure
79266312|NCT05577611|Combination Product|Basic chemotherapy + UCB transplantation|"The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC > 1.5 * 10 ^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation."
79266313|NCT05475314|Dietary Supplement|ReFerm(R)|Enemas of approx 250 mL twice daily
79266314|NCT04426604|Diagnostic Test|Light induced fluorescence intraoral camera|Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations
79266315|NCT04426604|Diagnostic Test|Laser-induced fluorescence device|Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
79861950|NCT00965744|Device|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
79861951|NCT00973076|Drug|AZD8055|Tablets, orally administered, twice daily
79861952|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 18%-protein diet|
79861953|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 35%-protein diet|
79861954|NCT00975728|Dietary Supplement|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
79861955|NCT04049747|Procedure|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]
79861956|NCT04049747|Procedure|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
79266316|NCT04426604|Diagnostic Test|Visual-tactile assessment method according to FDI criteria|Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations
79400281|NCT06119373|Other|Single daily icodextrin exchange|PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
79567084|NCT06169761|Other|Assessment of motor skills of the tongue and others muscles, see below) and risk for sleep apnea|"The following items will be assessed:~Risk for sleep apnea, through the STOP-BANG Questionnaire.~Anthropometric data: Height, weight, neck circumference, maximal mouth opening and maximal mouth opening with tongue to palate (with the Quick Tongue-Tie Assessment tool).~Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb in kPa) during 3 sec. of tongue protrusion and elevation.~Tongue endurance (i.e., the time to task failure in maintaining a pressure equal to a fixed percentage of Pmax against the IOPI bulb) during tongue protrusion and elevation~Tongue mobility restriction measured with the Quick Tongue-Tie Assessment Tool~Maximum inspiratory and expiratory pressures measured with MicroRPM in cmH2O~Handgrip strength (measured with a JAMAR dynamometer in kg)~Tongue skills measurements will be repeated 2 to 4 weeks after baseline to assess the reliability of these measurements."
79727255|NCT02692027|Other|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
79727256|NCT04212871|Other|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
79266317|NCT05224856|Biological|CT-P63 and CT-P66 / Placebo|Inhalation
79266318|NCT02139293|Device|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
79400282|NCT06119373|Other|Conventional PD group|PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.
79400283|NCT06119360|Procedure|Face-to-face approach|A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
79861957|NCT04049747|Procedure|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
79861958|NCT04049747|Procedure|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
79861959|NCT00973154|Drug|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
79861960|NCT00965822|Other|North American ginseng|3 day, once daily, dosing
79266319|NCT05615168|Diagnostic Test|"Acumen IQ guided hemodynamic optimization"|"Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions."
79266320|NCT05615168|Diagnostic Test|"Flotrac guided hemodynamic optimization"|"Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor."
79266321|NCT02139371|Other|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
79266322|NCT04790552|Other|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
79266323|NCT04790552|Other|Fasting|Subjects will be asked to fast overnight for approximately 15 hours.
79266324|NCT04790552|Other|Fast Bar|Subjects will be asked to consume a Fast Bar.
79266325|NCT04790552|Other|Bar with Coffee|Subjects will be asked to consume a Fast Bar with coffee.
79266326|NCT04790552|Other|Bar with Tea|Subjects will be asked to consume a Fast Bar with tea.
79400284|NCT06119360|Procedure|Conventional approach|Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
79567085|NCT06168617|Diagnostic Test|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
79567086|NCT06168214|Drug|Rabeprazloe+bismuth+amoxicillin+clarithromycin|PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
79567087|NCT06168214|Drug|Vonoprazan+amoxicillin+clarithromycin 14 days|VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
79567088|NCT06168214|Drug|Vonoprazan+amoxicillin+clarithromycin 7 days|VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
79861961|NCT00965822|Other|Placebo|3 day, once daily dosing
79861962|NCT04822025|Biological|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
79861963|NCT04822025|Biological|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
80023015|NCT05383443|Behavioral|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
79266327|NCT02139449|Procedure|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
79266328|NCT04790006|Drug|TG103|Administered SC
79567089|NCT06168214|Drug|Vonoprazan+tetracycline+furazolidone 14 days|VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
79727257|NCT04212871|Other|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
79727258|NCT04212871|Other|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
79861964|NCT00965900|Procedure|Endoscopic band ligation|"Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
79861965|NCT00965900|Drug|Propranolol|"start with 20 mg of propranolol b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
80023016|NCT05383443|Behavioral|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
79266329|NCT04790006|Drug|Placebo|Administered SC
79266330|NCT02139527|Device|Total Disc Replacement|
79266331|NCT02784431|Device|Contour Neurovascular System placement|Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
79266332|NCT02590406|Procedure|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
79266333|NCT02590406|Procedure|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
79567090|NCT06168214|Drug|Vonoprazan+tetracycline+furazolidone 7 days|VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
79727259|NCT04924621|Device|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
79727260|NCT04924621|Device|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
80023017|NCT05383443|Behavioral|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
80023018|NCT03093142|Device|tDCS & neurofeedback|tDCs and neurofeedback
80023019|NCT03093142|Device|neurofeedback|Neurofeedback
79266334|NCT02135237|Behavioral|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
79266335|NCT02135237|Behavioral|Standard Care|
79266336|NCT02139683|Device|HIFU treatment|HIFU treatment in patients with fibroadenoma
79266337|NCT05577377|Behavioral|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
79266338|NCT05614934|Drug|standard Clarithromycin triple therapy|Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
79266339|NCT05614934|Drug|Vonoprazan triple therapy|Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
79266340|NCT05614934|Drug|Vonoprazan dual therapy|Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days
79308914|NCT05618535|Device|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
79308915|NCT04807023|Biological|blood sampling|blood sampling
79567091|NCT06168214|Drug|Vonoprazan+amoxicillin+furazolidone 7 days|hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
79567092|NCT06168214|Drug|Vonoprazan+amoxicillin+tetracycline 14 days|hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
79567093|NCT06168214|Drug|Vonoprazan+amoxicillin 7 days|hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
79567094|NCT06168214|Drug|Vonoprazan+amoxicillin 14 days|hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
79581395|NCT01935960|Other|Laboratory Biomarker Analysis|Correlative studies
80023020|NCT03093142|Device|sham neurofeedback|sham neurofeedback
79727261|NCT04924621|Drug|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
79567095|NCT06167876|Radiation|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
79567096|NCT06167876|Other|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
79567097|NCT06166914|Drug|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
79567098|NCT06166914|Drug|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
79567099|NCT06166407|Other|no intervention|no intervention
79567100|NCT06166355|Behavioral|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
79861966|NCT00965900|Procedure|EBL+Propranolol|"EBL~Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~Propranolol~start with 20 mg b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
79861967|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
79861968|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
79266341|NCT02135393|Dietary Supplement|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
79266342|NCT05577299|Device|PET/CT|18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.
79567101|NCT06166355|Behavioral|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
79567102|NCT06166355|Behavioral|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
79567103|NCT06165978|Behavioral|Self-monitoring|pedometer/activity band provided to each participant
79861969|NCT00973232|Drug|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
80023021|NCT05026840|Procedure|GDM screening criteria|difference in risk factors and clinical outcomes between groups
79727262|NCT04924621|Drug|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
79727263|NCT04924621|Drug|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
79727264|NCT04924621|Drug|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
79727265|NCT04924621|Drug|Drug use target(T group)|Make BIS < 60 .
79727266|NCT04924621|Drug|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
79727267|NCT04924621|Drug|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
79727268|NCT04924621|Drug|Propofol|Propofol 1-2ug/ml, intravenous injection
79727269|NCT04924621|Drug|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
80023022|NCT02033109|Drug|PC-1005|Intravaginal use
79727270|NCT04924621|Drug|Drug use target|Make the BIS between 70 and 80.
79727271|NCT02869737|Device|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
79727272|NCT00619411|Behavioral|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
79266343|NCT04426448|Behavioral|Brief Relaxation, Education And Trauma HEaling|A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
79266344|NCT02139761|Drug|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
79266345|NCT02139761|Drug|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
79266346|NCT04426370|Other|Observational|Physical examination and questionnaires
79266347|NCT02139839|Other|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
79266348|NCT02139839|Drug|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
79266349|NCT05150600|Procedure|Inverse Ratio Ventilation|The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
79400285|NCT06119347|Drug|AntiVEGF|anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
79400286|NCT06119347|Drug|ICIs|immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
79567104|NCT06165978|Behavioral|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
79567105|NCT06165978|Behavioral|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
79567106|NCT06165978|Behavioral|Feedback|Daily or weekly feedback for patients (emotional/social support)
79727273|NCT04293705|Device|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
79727274|NCT04211467|Other|No Intervention|There is no intervention for this study
79727275|NCT00996489|Device|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
79400287|NCT06119334|Behavioral|Online intervention|Phone counselling for 1 hour/week over 16 weeks and access to the online platform with health promotion materials (videos, text, audios)
79400288|NCT06119321|Other|Pentacam, Corvis ST and Scansys|morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
79400289|NCT06119308|Other|Benzodiazepine Medication Taper with Cognitive Behavioral Therapy|Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing (led by pharmacist/clinician/psychologist) over a 10-week Trial.
79400290|NCT06119282|Other|inhaler|Experimental: After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
79567107|NCT06165978|Behavioral|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
79567108|NCT06165978|Behavioral|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2>88%, HRmax<96%, Borg<9)
79567109|NCT06165978|Behavioral|Report|Daily or weekly reporting for therapists (messages)
79567110|NCT06165978|Behavioral|Social support|Support meetings (in-person), parallel to educational sessions
79727276|NCT00618163|Drug|Meloxicam|
79861970|NCT00973232|Drug|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
79861971|NCT00973232|Drug|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
80023023|NCT02033109|Drug|HEC gel|
79266350|NCT04790084|Other|no intervention|no intervention
79266351|NCT02139917|Behavioral|Transitional community based palliative care|"transitional palliative care include:-~telephone follow up for early identification of signs and symptoms~relief of signs and symptoms encountered~home visit with spiritual support"
79266352|NCT05144438|Diagnostic Test|Toxseek test|Hair taking
79308916|NCT04427319|Dietary Supplement|β-alanine|7 days of consumption
79308917|NCT04427319|Dietary Supplement|wheat semolina|7 days of consumption
79400291|NCT06119282|Other|Control Group|Control Group Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
79567111|NCT06165978|Behavioral|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
79266353|NCT02135471|Drug|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
79266354|NCT02135471|Drug|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
79266355|NCT05614778|Other|Zoledronic Acid injection, 5mg/100mL|Zoledronic Acid injection, 5mg/100mL
79266356|NCT02139995|Behavioral|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
79266357|NCT05614700|Radiation|Brachytherapy|High Dose-Rate Brachytherapy
79727277|NCT04295343|Diagnostic Test|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
79861972|NCT00973232|Drug|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
79861973|NCT00973232|Drug|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
79266358|NCT05614700|Radiation|Sterotactic Body Radiotherapy|Hypofractionated External Beam Radiotherapy
79567112|NCT06165978|Behavioral|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
79266359|NCT02252783|Drug|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
79266360|NCT05474924|Drug|Budesonide intrapolyp injection|intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
79266361|NCT05474924|Drug|Budesonide nasal wash|Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
79266362|NCT05474924|Drug|Prednisolone tablets|oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
79266363|NCT02135549|Dietary Supplement|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
79266364|NCT02135549|Drug|Placebo Oral Tablet|Placebo comparator
79567113|NCT06163690|Combination Product|Endourage Targeted Wellness Formula C™, a full hemp flower extract|A hemp-derived formulation designed as a daily use adjunctive therapy to help improve Long COVID symptoms. Endourage Targeted Wellness Formula C™ are used as sublingual drops held under the tongue for 60 to 90 seconds.
79567114|NCT06162637|Device|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
79266365|NCT04789772|Device|Laser acupuncture|The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
79266366|NCT05576987|Behavioral|Education|Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
79266367|NCT02135627|Drug|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
79266368|NCT02135627|Other|Current standard therapy|
79266369|NCT05576909|Drug|Donafenib|"0.2g BID for downstaging treatment;~0.1g BID for adjuvant therapy"
79567115|NCT06162637|Device|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
79567116|NCT06162611|Drug|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
79567117|NCT06162611|Device|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
79567118|NCT06161181|Device|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
79567119|NCT06157749|Other|Gait analysis|It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
79727278|NCT04295343|Diagnostic Test|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
80023024|NCT02153658|Procedure|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
79266370|NCT05576909|Procedure|TACE|For downstaging treatment
79266371|NCT02252861|Other|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
79308918|NCT05616975|Other|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
79400292|NCT06119282|Other|massage|Experimental: Test Massage When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
79727279|NCT04212949|Device|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
79727280|NCT04212949|Drug|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
79861974|NCT03440099|Other|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
79266372|NCT02135783|Procedure|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
79400293|NCT06119269|Diagnostic Test|Therapeutic drug monitoring|At each follow up visit, plasma concentrations of ponatinib will be measured and compared with therapeutic range (according to a lower concentration equal to 21 nM)
79266373|NCT02135783|Procedure|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
79567120|NCT06157697|Behavioral|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Based on the monthly minimum wage in Brazil and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately 100 USD would fairly subsidize women's breastfeeding efforts. Therefore, all social transfer options equate to approximately 100 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
79567121|NCT06156722|Procedure|Sperm selection by IMSI|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
79727281|NCT02187601|Device|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
79400294|NCT06119269|Diagnostic Test|Molecular Response|BCR-ABl transcript levels will be assessed to evaluate molecular response to ponatinib
79567122|NCT06156722|Procedure|Sperm selection by IMSI and spermslow|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
79727282|NCT02187601|Device|BreathID|BreathID is the name of the original Exalenz breath analyzer system
79727283|NCT00628797|Radiation|UVA1|intraindividual half body irradiation
79727284|NCT00628797|Other|UVA1|60 J/cm2 at least 36 tx
79861975|NCT04049435|Device|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
79861976|NCT00973310|Other|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
79861977|NCT00973388|Drug|Telaprevir; Moxifloxacin; Placebo|
79266374|NCT05614622|Drug|Cyclopentolate Hydrochloride 1.0% eye drops|A short-acting mydriatic agent
79266375|NCT03548129|Drug|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
79400295|NCT06119256|Biological|EBV-TCR-T cells|The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10^5/kg to 1×10^6/kg EBV-TCR-T cells per dose.
79567123|NCT06155656|Other|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
79727285|NCT00618241|Drug|lamotrigine|100 mg
79727286|NCT00618241|Drug|Raltegravir|400 mg BD
79861978|NCT04762823|Device|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
79266376|NCT03548129|Drug|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
79266377|NCT03548129|Diagnostic Test|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
79266378|NCT03548129|Diagnostic Test|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
79266379|NCT03548129|Diagnostic Test|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
79266380|NCT05474768|Other|no intervention|no intervention
79567124|NCT06155656|Other|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
79861979|NCT04762823|Device|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
79861980|NCT04728815|Behavioral|TAU - Phase 1|4-8 weeks of TAU treatment
79266381|NCT02140073|Drug|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
79266382|NCT02140073|Drug|omeprazole|40mg in the morning
79266383|NCT04788290|Other|Observational|Rabone D®, Once daily administered per the locally approved product information
79861981|NCT04728815|Behavioral|CAMS - Phase 1|4-8 weeks of CAMS treatment
79861982|NCT04728815|Behavioral|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
79861983|NCT04728815|Behavioral|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
79861984|NCT04728815|Behavioral|DBT - Phase 2|Up to 8 weeks of DBT treatment
79727287|NCT04213027|Procedure|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
79727288|NCT00619567|Behavioral|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
79727289|NCT04212715|Radiation|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
79727290|NCT04211623|Other|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~10 degrees active wrist extension on the affected hand,~10 degrees active thumb abduction,~10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~using fork or a spoon,~combing hair~brushing teeth~writing~dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
79861985|NCT00965978|Drug|ONO-5920 / YM529|oral
79861986|NCT00975962|Drug|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
79861987|NCT00975962|Procedure|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
79861988|NCT00966056|Drug|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
79861989|NCT00966056|Device|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
79861990|NCT00976040|Other|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
79861991|NCT04008212|Other|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
79861992|NCT03523728|Drug|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
79567125|NCT06155656|Other|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
79400296|NCT06119243|Device|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
79861993|NCT03523728|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
79861994|NCT00979706|Drug|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
79861995|NCT00979706|Drug|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
79861996|NCT00979784|Behavioral|Better Weight|Standard cognitive behavioral treatment focused on dietary & exercise behavior
79400297|NCT06119230|Behavioral|Activity Counselling|Participants will receive a one hour goal setting session with a physiotherapist where they will use the feedback forms to create activity goals for the upcoming week of collection.
79400298|NCT06119217|Combination Product|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
79400299|NCT06119217|Combination Product|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
79400300|NCT06119217|Combination Product|Nab-Paclitaxel and gemcitabine|Dose and schedule per protocol
79567126|NCT06155656|Other|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
79861997|NCT00979784|Behavioral|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
79861998|NCT00979862|Drug|Cediranib Maleate|Given PO
79861999|NCT00979862|Drug|Cilengitide|Given IV
79862000|NCT00979862|Other|Laboratory Biomarker Analysis|Correlative studies
79400301|NCT06119204|Other|Oviva programme|Total diet replacement for insulin-treated patients
79400302|NCT06119204|Other|Usual care|NHS 12 week weight loss programme
79862001|NCT00966134|Other|exposure to high altitude|
79862002|NCT00976118|Drug|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
79862003|NCT00976118|Drug|placebo|matching placebo to masitinib
79400303|NCT06119152|Behavioral|DESA|Intervention group is monitored via remote bp monitoring and telehealth device.
79567127|NCT06152172|Drug|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
79567128|NCT06152172|Drug|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2 and fludarabine (FLU) 30 mg/m2 intravenously (IV)
79567129|NCT06152172|Drug|Fludarabine|Fludarabine (FLU) 30 mg/m2 intravenously (IV)
79567130|NCT06148662|Other|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
79581396|NCT01935960|Other|Pharmacological Study|Correlative studies
79266386|NCT03549377|Behavioral|Deception|Participants will be deceived during delayed gratification task.
79567131|NCT06148662|Other|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
79266387|NCT05474612|Other|kinesiology taping with conventional therapy|Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.
79266388|NCT05474612|Other|Instrument assisted soft tissue mobilization with conventional therapy|IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
79266389|NCT02140229|Device|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
79567132|NCT06148662|Drug|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
79567133|NCT06148662|Drug|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
79567134|NCT06148662|Drug|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
79266390|NCT02140229|Other|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
79266391|NCT02140229|Other|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
79266393|NCT05575973|Drug|Mitoxantrone Hydrochloride Liposome|Drug: Mitoxantrone hydrochloride liposome (20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
79400304|NCT06119139|Drug|3.6 ml 4% Articaine hydrochloride|3.6 ml 4% articaine buccal infiltration
79567135|NCT06145789|Other|standing powered wheelchair evaluation|standing powered wheelchair evaluation
79567136|NCT06144281|Behavioral|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
79567137|NCT06138054|Behavioral|MI-CBTech|"Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources."
79581397|NCT01935960|Other|Placebo|Given PO
79581398|NCT01935960|Drug|Retinoid 9cUAB30|Given PO
79581399|NCT01935973|Other|Laboratory Biomarker Analysis|Correlative studies
79581400|NCT01935973|Drug|Trametinib|Given PO
79581401|NCT01935973|Drug|Uprosertib|Given PO
79266394|NCT05575973|Drug|Rituximab|Drug: Rituximab (375 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
79266395|NCT05575973|Drug|Lenalidomide|Drug: Lenalidomide (25 mg) will be taken orally from day 1 to day 8 of each 28-day cycle.
79266396|NCT05474222|Other|Horizon Eagle Fatherhood Program - classroom instruction|The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
79266397|NCT03547895|Drug|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
79266398|NCT03547895|Drug|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
79266399|NCT01359254|Drug|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
79266400|NCT01359254|Drug|Fludarabine|Fludarabine is given through the vein daily for 5 days.
79266401|NCT01359254|Drug|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
79266402|NCT01359254|Drug|Busulfan|Busulfan is given daily for 4 days.
79266403|NCT01359254|Drug|Total Body Irradiation (TBI)|TBI is given twice on the last day.
79308919|NCT05616975|Other|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
79581402|NCT01935986|Dietary Supplement|probiotic|
79581403|NCT01935986|Dietary Supplement|placebo|
79862004|NCT00966212|Behavioral|parent education|Especially for Daughters audio-cd parent education
79308920|NCT05616975|Other|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
79308921|NCT04807335|Drug|CT001|nasal spray
79308922|NCT04807335|Drug|Ketamine|iv single dose
79400305|NCT06119139|Drug|1.8 ml 4% Articaine hydrochloride|1.8 ml 4% articaine buccal infiltration
79400306|NCT06119113|Other|Evaluation of the wound infection at the 10th day post-op check-up among all groups|Discharge, redness, increased temperature, and dehiscence were accepted as wound infection.
80023025|NCT02153658|Procedure|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
79727291|NCT04211623|Other|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~carrying a tray,~cutting a fruit with a knife,~holding and cutting the paper with scissor,~buttoning and~Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
79266404|NCT05474144|Dietary Supplement|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
79862005|NCT00980252|Behavioral|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
79567138|NCT06138054|Behavioral|Mindfulness control|"Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources."
79862006|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
79862007|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
79862008|NCT04004052|Other|Ultrasound guided injection|
79266405|NCT05474144|Dietary Supplement|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
79266406|NCT05575739|Diagnostic Test|Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )|Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.
79266407|NCT05035862|Drug|Albuterol Sulfate|Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.
79727292|NCT00618397|Drug|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
79308923|NCT04807335|Drug|sufentanil|iv single dose
80023026|NCT05026294|Other|plyometric exercises|Exercises for strength and flexibility
79581404|NCT01935999|Device|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
79727293|NCT04857151|Behavioral|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
79727294|NCT04211779|Device|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
79727295|NCT04211779|Device|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
79727296|NCT04211779|Other|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
79727297|NCT00618475|Behavioral|Cognitive behavioral therapy|"10 sessions~1 hour per week"
79862009|NCT04004052|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
79862010|NCT04004052|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
79862011|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
79862012|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
79862013|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
79862014|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
79862015|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
79862016|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
80023027|NCT05026294|Other|Exercises for flat feet rehabilitation|Exercises for intrinsic muscles strength
80023028|NCT04962607|Other|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
80023029|NCT05040100|Other|3D Mediastinum Model|The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
79266408|NCT05035862|Drug|Interferon gamma-primed mesenchymal stromal cells (MSCs)|IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg
79862017|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
79862018|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
79727298|NCT04211545|Drug|Rabeprazole|Rabeprazole
79727299|NCT04211545|Drug|CC-92480|CC-92480
79567139|NCT06135714|Drug|Systemic therapy for 12 weeks after primary registration|"Luminal BC~Denovo stage IV~Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~Postmenopausal(POST): AI + CDK~Recurrence after completion of postoperative endocrine therapy~PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~POST: AI + CDK, or FUL + CDK~Recurrence during postoperative endocrine therapy~PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~POST: FUL + CDK~HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~PD-L1 negative - following a) or b)~Taxane (naive for taxane)~S-1 or Capecitabine or Eriblin (previously treated with taxane)~PD-L1 positive - following a) or b)~Pembrolizumab + Gemcitabine + Carboplatin~Atezolizumab + Nab-paclitaxel~BRCA-mutation positive Olaparib"
79567140|NCT06135714|Procedure|Radiation therapy (SBRT/conventional RT)|Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.
79567141|NCT06135714|Procedure|Surgery|Surgery for the oligometastases
79727300|NCT00620581|Drug|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
79727301|NCT01739569|Other|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
79862019|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
79266409|NCT05035862|Drug|Prednisone|Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
79304346|NCT03061851|Other|Maltose app|"Weekly diabetes-related science articles.~Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~Personalize the development of diet, exercise program.~different insulin and oral hypoglycemic drug medication time to remind.~hypoglycemic drug side effects query."
79567142|NCT06135714|Drug|Same systemic therapy after secondary registration|"Luminal BC~Denovo stage IV~Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~Postmenopausal(POST): AI + CDK~Recurrence after completion of postoperative endocrine therapy~PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~POST: AI + CDK, or FUL + CDK~Recurrence during postoperative endocrine therapy~PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~POST: FUL + CDK~HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~PD-L1 negative - following a) or b)~Taxane (naive for taxane)~S-1 or Capecitabine or Eriblin (previously treated with taxane)~PD-L1 positive - following a) or b)~Pembrolizumab + Gemcitabine + Carboplatin~Atezolizumab + Nab-paclitaxel~BRCA-mutation positive Olaparib"
79862020|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
79567144|NCT06127342|Behavioral|Moderate Intensity Exercise|Participants will wear a heartrate monitor and walk on a treadmill at a slow speed for 5 minutes, then slowly jog on a treadmill for 30 minutes, then walk on the treadmill at a slow speed for 5 minutes.
79727302|NCT04211311|Other|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
79727303|NCT01000311|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
79862021|NCT01563822|Biological|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
79862022|NCT04007822|Behavioral|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
79862023|NCT04007978|Genetic|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
79862024|NCT00980876|Drug|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
80023030|NCT01336647|Drug|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
80023031|NCT01336647|Drug|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
79862025|NCT00980876|Drug|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
80023032|NCT01336647|Drug|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
80023033|NCT02157558|Drug|Fexofenadine|All subjects will receive 180 mg fexofenadine
80023034|NCT02157558|Drug|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
80023035|NCT05018182|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery
80023036|NCT05018182|Drug|Irinotecan|Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection
80023037|NCT05018182|Drug|Folinic Acid|Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection
79727304|NCT01000311|Biological|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
79862026|NCT04004130|Other|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
79862027|NCT00981032|Behavioral|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
79862028|NCT00981032|Behavioral|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
80023038|NCT05018182|Drug|5FU|5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
79727305|NCT01000311|Biological|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
79266410|NCT05033210|Behavioral|Psychological First Aid (PFA)|PFA is a WHO developed support strategy that involves humane, supportive and practical help for individuals living in a serious humanitarian crisis. PFA does not necessarily involve a discussion of the event(s) that cause the distress but aims particularly at five basic elements that are crucial to promote in the aftermath of crises, i.e. a sense of safety, calm, self- and community efficacy, connectedness, and hope (Hobfoll et al., 2007). It consists of a conversation (approximately 30-45 minutes) that a helper has with a participant which can be provided remotely (e.g. videoconferencing or telephone). It has various themes; the helper provides non-intruding practical care and support, listen to needs and concerns, helps people to address basic needs (e.g. information), listens to people without pressuring them to talk, comforts people and helps them to feel calm, helps people to connect to information, services, and social support, and protects people from further harm (WHO, 2011).
79266411|NCT05033210|Behavioral|Care as Usual (CAU)|In addition to PFA, both arms will be allowed to receive any usual care (CAU). CAU ranges from community care to specialised psychological treatments.
79304347|NCT03289013|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
79304348|NCT03289013|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
79567145|NCT06127342|Behavioral|Low Intensity Exercise|Participants will wear a heartrate monitor and walk on a treadmill at a slow speed for 40 minutes.
79567146|NCT06123988|Behavioral|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
79727306|NCT01000311|Biological|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
79727307|NCT01000311|Biological|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
79727308|NCT04211701|Procedure|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
80023039|NCT05018182|Drug|Capecitabine|Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
79727309|NCT04211701|Procedure|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
79727310|NCT04209439|Drug|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
80023040|NCT01336569|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
79304349|NCT03289013|Other|LT-2|Newly developed adhesive
79727311|NCT04209439|Drug|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
79304350|NCT03289013|Other|LT-21|Newly developed adhesive
79304351|NCT03289013|Other|LT-25|Newly developed adhesive
79304352|NCT03289013|Other|33-20|Newly developed adhesive
79862029|NCT00981110|Device|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
79862030|NCT00981110|Device|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
79581405|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
79266412|NCT05033210|Behavioral|Doing What Matters in Times of Stress (DWM)|DWM is based on the acceptance and commitment therapy (ACT), a form of cognitive-behavioural therapy, with distinct features (Hayes, Levin, Plumb-Vilardaga, Villatte & Pistorello, 2013). ACT is based on the concept that ongoing attempts to suppress unwanted thoughts and feelings can make these problems worse, so instead it emphasises on learning new ways to accommodate these thoughts and feelings without letting them dominate. ACT has been shown to be useful for a range of mental health issues (Tjak et al., 2015) and has been used successfully in a guided self-help format (Hayes et al., 2013). DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, will be adapted for use on a smartphone or other device with internet access.
79567147|NCT06123988|Behavioral|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
79266413|NCT05033210|Behavioral|Problem Management Plus (PM+)|PM+ is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011). The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. In these 90-minute sessions participants may talk to trained non-professional helpers (who are supervised by registered (clinical) psychologists). PM+ has four core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic thereby addressing depression, anxiety, PTSD, stress and problems as defined by people themselves; and originally designed for people in low-income country communities but easily adaptable to different (vulnerable) populations, cultures and languages.
79567148|NCT06123988|Behavioral|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
79266414|NCT02140307|Behavioral|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
79266415|NCT02973269|Biological|daxibotulinumtoxin type A|Intramuscular injection
79266416|NCT02973269|Biological|Placebo|Intramuscular injection
79266417|NCT03549221|Drug|0.6 mg 1:1000 epinephrine (0.6 ml)|In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
79266418|NCT05185505|Drug|Atezolizumab|1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
79266419|NCT05185505|Drug|Bevacizumab|15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
79266420|NCT01667432|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
79727312|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
79862031|NCT00981266|Device|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
79862032|NCT00976430|Procedure|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
79862033|NCT00976742|Behavioral|Endurance exercise training|
79266421|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
79266422|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
79266423|NCT02140385|Device|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
79266424|NCT02140385|Device|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
79727313|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
79727314|NCT00619879|Other|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
79862034|NCT00989898|Other|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
79862035|NCT05400954|Procedure|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
79727315|NCT00619879|Radiation|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
79266425|NCT02140385|Device|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
79266426|NCT05614466|Other|The Simply B Study|"This study will be conducted in three parts:~Part A: A prospective open label pilot intervention study, comparing the proportion of people with hepatitis B who are managed by their GP in primary care clinics before, 12 months and 24 months after implementation of the Simply B electronic hepatitis B support package.~Part B: A nested qualitative health services feasibility study using semi -structured interviews and thematic analysis Part C: A mathematical modelling study using a Markov model to determine cost effectiveness of Simply B for increasing hepatitis B treatment uptake compared to status quo of hospital care."
79567149|NCT06123000|Procedure|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
79862036|NCT05400954|Procedure|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
79266427|NCT05575271|Procedure|Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network|The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
79567150|NCT06123000|Procedure|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
79581406|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
79581407|NCT01936025|Drug|Dextromethorphan|
79581408|NCT01936025|Drug|Sitagliptin|
79581409|NCT01936025|Drug|Placebo|
79581410|NCT01936038|Other|CPAP|CPAP
79581411|NCT01936038|Procedure|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
79862037|NCT05400954|Procedure|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
79862038|NCT00989976|Behavioral|normal sleep times|8.5 h bedtimes
79862039|NCT00989976|Behavioral|bedtime restriction|4.5 h restricted bedtimes
79862040|NCT00990054|Drug|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
79862041|NCT00990132|Device|Home mechanical ventilation|Nocturnal non-invasive ventilation
79862042|NCT00990132|Device|Long term oxygen therapy|LTOT established as per national guidelines
79862043|NCT05361564|Drug|Brigatinib|After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
79862044|NCT05399472|Diagnostic Test|Dorsiflexion lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the participant stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The participant is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The participant steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
80023041|NCT05018572|Behavioral|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
79400307|NCT06119113|Other|Evaluation of the cosmetic results of the incision line at the 2nd month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
79567151|NCT06118359|Behavioral|Intervention to Support Interhospital Transfer Decisions (SITe)|The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
79567152|NCT06111742|Device|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
79567153|NCT06111079|Drug|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
79727316|NCT04212559|Other|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
79727317|NCT05228041|Drug|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
79727318|NCT01003899|Drug|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
79727319|NCT04160377|Drug|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
79266428|NCT05575115|Behavioral|Peer Comparison|"Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers."
79266429|NCT04750460|Drug|Teriparatide|Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.
79266430|NCT04966364|Device|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
79266431|NCT04966364|Device|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
79727320|NCT04150393|Drug|MaaT033 capsule|Oral capsule
79727321|NCT04142203|Other|23 h surgery|Patients were treated in 23 surgical unit
79727322|NCT01000155|Drug|vorinostat|
79727323|NCT00621595|Dietary Supplement|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
79727324|NCT00318487|Procedure|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
79727325|NCT00999921|Drug|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
79727326|NCT00999921|Drug|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
79727327|NCT02869581|Other|Data collection|
79567154|NCT06111079|Drug|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
79727328|NCT00620737|Biological|Autologous Human Fibroblasts (Isolagen TherapyTM)|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
79862045|NCT05399472|Diagnostic Test|Jack Test|The Jack Test will be used to measure the first toe dorsiflexion under load. The examiner pulled the proximal phalanx of the hallux to dorsiflexion with his hand until the maximal amount of mobility was reached with the subject standing. The static arm of the goniometer was placed along the first metatarsal longitudinal axis while the free movable arm followed the proximal phalanx of the hallux axes.
79862046|NCT05360004|Drug|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
79266434|NCT04426526|Device|BTL 799-2|High power magnet system
79266435|NCT04788212|Behavioral|Group Behavioral Activation Therapy for Autism Spectrum Disorder|This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
79862047|NCT05359926|Other|Experimental|Early urethral foley removal after the surgery
79567155|NCT06109402|Drug|TQB2450|Specified dose on specified days
79567156|NCT06109402|Drug|Carboplatin|Specified dose on specified days
79862048|NCT05359926|Other|Active comparator|Delayed urethral foley removal after the surgery
79567157|NCT06109402|Drug|Pemetrexed|Specified dose on specified days
79862049|NCT05361408|Drug|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
79862050|NCT05361408|Drug|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
79727329|NCT00620737|Biological|Placebo|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
79862051|NCT03227406|Behavioral|Sleep deprivation|Subjects are kept awake all night.
79862052|NCT03227406|Behavioral|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
80023042|NCT04899505|Other|Evaluation on appearance of unpleasant body odors|Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
79266440|NCT01563107|Radiation|Plasma Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
79567158|NCT06109402|Drug|Nab-paclitaxel|Specified dose on specified days
79567159|NCT06109402|Procedure|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
79567160|NCT06108999|Device|Connettivina BIO cream and gauze|Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
79567161|NCT06100432|Drug|DLBS5055 200mg|1x1 caplet
79567162|NCT06100432|Drug|Placebo DLBS5055|1x1 caplet
79727330|NCT02869347|Drug|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
79727331|NCT02869347|Drug|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
79266441|NCT01563107|Procedure|Exercise Capacity Test - Bicycle|subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
79266442|NCT01563107|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
79567163|NCT06100432|Drug|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
79567164|NCT06100432|Drug|Placebo Multivitamin|1x2 caplets
79727332|NCT00621673|Drug|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
79727333|NCT05008393|Drug|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
79727334|NCT05008393|Drug|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
79727335|NCT05008393|Drug|Placebo|Patients will receive placebo daily for 10 days.
79266443|NCT04787900|Device|iPhone measurement application|The iPhone measurement application will be used to ensure validity and reliability.
79266444|NCT04787900|Device|Bubble inclinometer|Bubble inclinometer with proven validity and reliability will be used for this study.
79567165|NCT06095297|Behavioral|Speed of Processing Training|"Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. In the first level of difficulty, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. This intervention aims to improve the mental processing speed of participants. Trainees receive immediate feedback at the end of each trial, and rest will be provided after trials if necessary. These games will be implemented during training, and participants are also encouraged to practice at home."
79567166|NCT06095297|Behavioral|In-lab Instrumental Activities of Daily Living Training|Participant will receive shaping on IADLS. Participants will receive training on everyday tasks with important cognitive components, in which the difficulty is increased in small steps over the course of treatment.
79727336|NCT02869503|Other|Data collection|
79862053|NCT03069690|Behavioral|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
79266445|NCT04788056|Procedure|Parasternal Subpectoral Plane Block|Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
79400308|NCT06119113|Other|Evaluation of the cosmetic results of the incision line at the 6th month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
79400309|NCT06119100|Diagnostic Test|Ultrasound characterization of stenotic lesion type|Target lesion type will be classified as restrictive, hyperplastic or mixed using high frequency Duplex ultrasound, before the angioplasty procedure and at 6 months follow up.
79567167|NCT06095297|Behavioral|In-lab Brain Health Training|Participants will receive training on healthy eating, sleeping, and relaxation techniques that have been shown to improve brain health.
79567168|NCT06095297|Behavioral|Transfer Package|"The Transfer Package was designed to try and bridge the gap between what is trained in the lab and what the participant does outside of the treatment setting. This components includes negotiation of a behavioral contract with participants at the outset of treatment regarding the responsibilities of the participant, family caregivers, if available, and the treatment team, self-monitoring, assignment of homework, review of homework by the trainer, and support of problem-solving by the participant."
79567169|NCT06095297|Behavioral|Follow Up Phone Calls|After completing training, participants will receive four follow up phone calls in the first month of training. Each call will separated by about a week. The focus of the calls will incorporating the lessons learnt during treatment into daily life.
79567170|NCT06095297|Behavioral|Vocational Rehabilitation|In partnership with the Alabama Department of Rehabilitation Services (ADRS), participants who are eligible may receive vocational rehabilitation. Participants will receive typical services offered by the ADRS. These could include career counseling, guidance regarding job retention or return-to-work, and guidance regarding workplace accommodations.
79266446|NCT05574803|Device|Active-tDCS|Active-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (20 minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program.
79567171|NCT06095297|Behavioral|Peer Mentoring|Participants who are eligible for vocational rehabilitation, and agree will also have a peer mentor, a co-worker that will be trained by our team, to reinforce strategies the participant learned during training, and to help the participant problem solve issues that may arise on the job during the first month after treatment. Peer mentors will meet with trainers during the month after treatment to make sure procedures are being followed and address any issues that may arise.
79567172|NCT06093893|Drug|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
79727337|NCT04210921|Device|Acupuncture|"The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi ."
79727338|NCT04210921|Device|The park sham needle|When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
79727339|NCT05662657|Diagnostic Test|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
79727340|NCT01002573|Drug|ibuprofen|Ibuprofen, 10 mg/kg
79727341|NCT01002573|Drug|acetaminophen|Acetaminophen, 10mg/kg
80023043|NCT03092986|Drug|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
79567173|NCT06093893|Drug|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
79567174|NCT06093893|Drug|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
79581412|NCT01936064|Dietary Supplement|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
79727342|NCT00620893|Drug|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
79727343|NCT00620893|Drug|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
80023044|NCT03092986|Drug|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
79266447|NCT05574803|Device|Sham-tDCS|Sham-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (one minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program. Participants will receive initial stimulation for one minute, eliciting a tingling sensation on the scalp then it will be discontinued.
79727344|NCT04211233|Device|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
79266448|NCT04788134|Diagnostic Test|Post-rotatory nystagmus test|The test is administrated with the person sit down with cross legs at a rotatory board, with the head positioned by the examiner in 30° of forward flexion. The position was maintained by the administration of the test. The administration consist in two administrations separate by one minute. Each administration consist in rotate the person 10 times in 20 seconds (the first 10 rotations in a counterclockwise direction in 20 s and the second 10 rotations in a clockwise direction in 20 s). After each administration the examiner counts the duration of the reflex in seconds.
79862054|NCT03069690|Behavioral|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
79567175|NCT06093386|Other|Intensive Transition Support|Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
79727345|NCT04211233|Other|Control arm|Standard Treatment based on Brain Trauma Foundation
79727346|NCT00999687|Drug|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
79727347|NCT00999687|Other|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
79727348|NCT04211077|Other|Date collection|Data collection from national SNIIRAM and PMSI database
79862055|NCT00990366|Device|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
79862056|NCT05590572|Drug|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
79266449|NCT05614310|Other|Magnetic Resonance Imaging (MRI)|Participants will be asked to lie in the MRI scanner while we collect 3D T1- and T2-weighted images and a 3D FLAIR image to exclude pathology (e.g. stroke). Participants will ingest a glucose solution (75 g Dextrose) so dynamic glucoCEST images can be acquired to measure glucose uptake and clearance.
79581413|NCT01936064|Drug|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
79581414|NCT01936077|Drug|Recombinant LH (Luveris)|150 IU recombinant LH daily.
79581415|NCT01936090|Drug|Bortezomib|Given IV
79266450|NCT05614310|Other|Blood Glucose Assessment|A blood testing meter will be used to measure the blood sugar levels before and after the scans. Normal reading for a nondiabetic person after fasting is 70-99 mg/dl (3.9-6 mmol/L). If abnormal blood sugar levels are detected (sugar levels outside the above normal range), the participant will no longer be eligible for the study and they will be withdrawn.
79862057|NCT05590572|Drug|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
79862058|NCT05590572|Drug|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
79862059|NCT05359614|Device|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
79862060|NCT05359614|Device|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
80023045|NCT03092986|Drug|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
80023046|NCT03092986|Drug|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
80023047|NCT03092986|Radiation|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
80023048|NCT03739086|Procedure|erector spinae plane block|unilateral or bilateral or bilevel erector spinae plane block performance for postoperative pain or acute pain
80023049|NCT04867759|Procedure|Endometrial Biopsy|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
80023050|NCT03092908|Dietary Supplement|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
80023051|NCT03092908|Dietary Supplement|placebo (water)|Administer 5 ml placebo (water) three times a day.
80023052|NCT03543306|Drug|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
80023053|NCT05039398|Behavioral|Treatment as usual|The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
79266451|NCT05614310|Other|Positron Emission Tomography (PET)|Participants will be administered a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG) through a canula inserted into a vein in the arm or hand and asked to sit quietly for 1 h. After 1 h they will be asked to lie quietly and without talking in the PET scanner and a PET brain scan will be performed.
79266452|NCT05614310|Other|Cognitive Assessment|Participants will be asked to undertake two cognitive tests (the Alzheimer's Disease Assessment Scale ADAS-cog test and the Mini Mental State Examination test - MMSE). These are standard clinical tests used to determine cognitive dysfunction in Alzheimer's disease.
79862061|NCT03050502|Device|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
79862062|NCT03050502|Other|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
79266453|NCT03549143|Other|IBS|No intervention, description of routine practice only
79266454|NCT04787510|Drug|low molecular weight Heparin as standard of care treatment|STANDARD OF CARE
79862063|NCT00990444|Drug|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
79862064|NCT00990522|Procedure|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
79567176|NCT06085495|Procedure|mechanical thrombectomy (PMT)|After the establishment of the pathway, Angiojet (Boco, USA) was used to infuse urokinase into the blood vessels of the thrombotic segment. After waiting for 15 minutes, mechanical thrombectomy was performed. After thrombectomy, the effectiveness of thrombectomy was evaluated through angiography. For residual thrombi, repeated thrombectomy was performed, with a maximum thrombectomy volume of 480ml. After thrombectomy, antegrade angiography of the dorsal vein of the foot was performed again. If iliac vein stenosis was found to be greater than 50%, Then, Mustang balloons (Boko, USA) that match the normal blood vessel diameter are used for dilation. If the residual stenosis after dilation is greater than 30%, Wallsten stents that match the normal blood vessel diameter are inserted (Boko, USA). After all operations are completed, a dorsalis pedis venography is performed again to evaluate the thrombus burden and calculate the immediate thrombus clearance rate and thrombus clearance level.
80023054|NCT05039398|Behavioral|Dialogue and guidance over telephone|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone."
79308924|NCT05616507|Dietary Supplement|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
79308925|NCT04806945|Drug|HLX10|IV infusion.
79308926|NCT04806945|Drug|Paclitaxel|IV infusion
79567177|NCT06083064|Diagnostic Test|Abdominal imaging|Abdominal ultrasound and/or abdominal CT
79567178|NCT06083064|Other|Score based selective abdominal imaging|Abdominal imaging is done selectively based on Adult Appendicitis Score
79567179|NCT06083064|Other|Score based selective observation combined with selective abdominal imaging|Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
79567180|NCT06080529|Other|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
79567181|NCT06080516|Other|Kettlebell exercise|Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
79862065|NCT00990600|Other|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
80023055|NCT05039398|Behavioral|Dialogue and guidance at physical meeting|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting."
79567182|NCT06069778|Drug|BNT321 Dose Level 1|Intravenous infusion
80023056|NCT02157714|Drug|PRX002|
80023057|NCT02157714|Other|Placebo|
80023058|NCT02342665|Drug|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
80023059|NCT03090724|Drug|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
80023060|NCT02153892|Device|GDS Accucinch System|Percutaneous Coronary Intervention
79567183|NCT06069778|Drug|BNT321 Dose Level 2|Intravenous infusion
79567184|NCT06069778|Drug|mFOLFIRINOX|Intravenous infusion
79308927|NCT04806945|Drug|Cisplatin|IV infusion
79308928|NCT04806945|Drug|Carboplatin|IV infusion
79567185|NCT06069778|Drug|BNT321 RP2D|Intravenous infusion
79581416|NCT01936090|Radiation|Total-Body Irradiation|Undergo TBI
79862066|NCT02897076|Drug|betamethasone 24 mg|
79862067|NCT02897076|Drug|12mg betamethasone +placebo|
79862068|NCT05590182|Device|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
79862069|NCT00990678|Drug|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
79862070|NCT00990678|Drug|Vitamin D|tablets, vitamin D3, 30 microgram daily
79862071|NCT00990678|Drug|Calcium|tablets, 400 mg calcium, 3 times daily
79862072|NCT05265468|Other|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
79862073|NCT05265468|Other|Lewit Group|Isometric muscular exercise acompained with stretching technique
80023061|NCT03090568|Drug|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
79567186|NCT06068270|Procedure|Micro-ostoperforations (MOPs)|3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
79567187|NCT06066151|Dietary Supplement|Minayo Yeast Drink Product|Participants need to drink one piece of the products each day, for 4 consecutive weeks.
79567188|NCT06060847|Procedure|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
80023062|NCT02157792|Drug|M6620|
79266455|NCT03549065|Device|Brain Stimulation|"Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George & Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008)."
79266456|NCT04787432|Behavioral|Salutogenic Frailty Prevention Program|"Laughter yoga: The first component of intervention is the laughter yoga that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Each session of laughter yoga will be offered twice a weekly and 40 minutes each time.~Health education: The second component of intervention consisted of six health issues which are health, frailty and generalized sources of resistance for frailty, the most common medical condition and medication use, physical activity, healthy diet, falls prevention and cognitive and psychosocial well-being.~Case management: The third component of intervention is activities that determine each participant's health needs with the Omaha System and support them for the use of appropriate resources."
79727349|NCT04293315|Behavioral|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
79727350|NCT04293549|Drug|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
79727351|NCT02691715|Procedure|Endometrial saline plus curettage|
79727352|NCT02691715|Procedure|Endometrial curettage|
79567189|NCT06060847|Procedure|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
79567190|NCT06037148|Biological|DM-101PX|subcutaneous injection of DM-101PX
79567191|NCT06037148|Biological|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
79862074|NCT05265468|Other|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
79862075|NCT05265468|Other|Placebo Group|No pain positioning of participants
79862076|NCT05359458|Behavioral|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
79308929|NCT04806945|Drug|Placebo to HLX10|IV infusion
79567192|NCT06028464|Drug|BI 1810631|BI 1810631
79567193|NCT06028464|Drug|Carbamazepine|Carbamazepine
79567194|NCT06026540|Behavioral|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
79581417|NCT01936090|Drug|Melphalan|Given IV
79581418|NCT01936090|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
79581419|NCT01936090|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
79727353|NCT00996333|Drug|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
79862077|NCT05590104|Procedure|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
79862078|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
79862079|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
79862080|NCT00538590|Device|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
80023063|NCT02157792|Drug|Gemcitabine|
80023064|NCT02157792|Drug|Cisplatin|
80023065|NCT02157792|Drug|Etoposide|
80023066|NCT02157792|Drug|Carboplatin|
80023067|NCT02157792|Drug|Irinotecan|
79862081|NCT00538590|Drug|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
79862082|NCT00990834|Drug|simvastatin|simvastatin 80 mg PO daily for one to eight months.
79862083|NCT05589636|Dietary Supplement|Bergamot Juice|Bergamot Juice (35% in water)
79862084|NCT00990990|Drug|PNU-100480|100 mg BID for 14 days
80023068|NCT03095716|Other|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
79400310|NCT06119087|Device|Mechanical insufflation|"Mechanical insufflation (MI) is a chest physiotherapy exercise that will be performed using a type of mechanical insufflator-exsufflator (MI-E) known as the BiWaze Cough device. The device connects to a tube that can interface with a patient using either a facemask or mouthpiece.~Mechanical insufflation is a chest physiotherapy exercise that passively inflates the chest with positive pressure that is delivered in coordination with the patient's own inspiratory timing until maximal inflation capacity (MIC), determined by the patient or maximal chest rise on visual inspection. At MIC, the patient passively exhales, which completes one cycle. Prior literature has used a dose of 5 sets of 5 cycles once or twice daily. The maneuver is usually performed with assistance of a caregiver to hold the mask or mouthpiece in place."
80023069|NCT05175391|Other|Meat based protein with added spice; Plant based protein with added spice|Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.
80023070|NCT05023954|Diagnostic Test|Blood test|Drop of blood for RNA and metabolic analysis
79567195|NCT06026306|Behavioral|Problem Management Plus (PM+)|PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session
79567196|NCT06018272|Behavioral|Mentalization-Based Treatment (MBT)|Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
80023071|NCT02150538|Device|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
80023072|NCT02150538|Device|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
79567197|NCT06018272|Behavioral|Bona-Fide Treatment in Germany (BFT)|Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (<24 sessions) or long-term psychotherapy (>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
79567198|NCT06018233|Other|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
79567199|NCT06016335|Diagnostic Test|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
79567200|NCT06016335|Diagnostic Test|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
79266457|NCT05424263|Drug|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
79266458|NCT05424263|Drug|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
79862085|NCT00990990|Drug|Placebo|to match 100 mg BID for 14 days
79862086|NCT00990990|Drug|PNU-100480|300 mg BID for 14 days
79862087|NCT00990990|Drug|Placebo|to match 300 mg BID for 14 days
79862088|NCT00990990|Drug|PNU-100480|600 mg BID for 14 days
79862089|NCT00990990|Drug|Placebo|to match 600 mg BID for 14 days
79266459|NCT04722614|Other|Music|Classic music hearing at amplitude approximately 60-80 dB using MP3 player connected to headphone with noise canceling property
79266460|NCT04722614|Other|Essential oil|Bergamot oil inhalation through a piece of cotton gauze (2 × 2 cm square shape) with 0.5 cc of bergamot oil. It will be attached to the collar of the patient's clothes gown, approximately 15 cm below their nose.
79266461|NCT04722614|Other|Control|The routine intensive care unit sedation protocol
79308930|NCT04806711|Device|Menicon Z Night|Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children
79862090|NCT00990990|Drug|PNU-100480|1200 mg QD for 14 days
79862091|NCT00990990|Drug|Placebo|to match 1200 mg QD for 14 days
79862092|NCT00990990|Drug|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
79862093|NCT00990990|Drug|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
79862094|NCT00990990|Drug|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
79862095|NCT00990990|Drug|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
79862096|NCT00990990|Drug|Linezolid|300 mg QD for 4 days (open label)
80023073|NCT05023798|Device|ATD (device test)|Medical device test (no intervention)
79400311|NCT06119022|Procedure|Invasive coronary angiography|Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
79400312|NCT06119022|Other|routine medical treatment|Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
79400313|NCT06119009|Other|non interventions|
79266462|NCT03547817|Device|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
79400314|NCT06118996|Device|3D Ultrasound Image Acquisition|A custom device will be used with a clinical ultrasound machine to acquire ultrasound images of the breast.
79567201|NCT06016335|Other|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
79567202|NCT06015529|Diagnostic Test|4PEPS strategy|"Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. Using 12 variables, 4PEPS defines four levels of CP that rule out a PE, namely~based only on clinical data (very low CP: PEPS < 0),~based on a D-dimer level < 1000 μg/L (low CP: PEPS ≥ 0 and < 5),~based on a D-dimer level with an age-adjusted cut-off value (moderate CP: PEPS ≥ 5 and <12), or~the diagnosis cannot reliably be ruled out based on a D-dimer test (high CP: PEPS ≥ 12)"
79567203|NCT06011629|Device|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
79567204|NCT06011603|Device|Prineo dressing|Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
79862097|NCT05361096|Other|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
79862098|NCT05589558|Procedure|consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)|TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
79862099|NCT04003662|Device|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
79862100|NCT00991146|Drug|canakinumab|canakinumab
79862101|NCT05589324|Behavioral|3D-printed writing aids task|Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
79266463|NCT05472974|Device|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of pressure injury, without pressure injury, up during the day, will ly a on a specific P-APAM (DOMUS 4 /AUTO)
79266464|NCT04787120|Device|SQUIDperi|Liquid embolic delivery syringes and micro-catheter
80023074|NCT03742830|Device|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
80023075|NCT05038774|Other|Face to face Educational Training|"Key points of current hypertension guidelines.~10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~checklists to assist in the diagnosis of secondary hypertension.~Patient information leaflet about hypertension."
79266465|NCT05614232|Radiation|Chest X-ray|Chest radiographs
79266466|NCT04787276|Dietary Supplement|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
79266467|NCT04787276|Drug|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
79266468|NCT04787276|Drug|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
79266469|NCT04686734|Other|No active intervention (observational only)|No active intervention (observational only)
79266470|NCT01564979|Drug|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
79400315|NCT06118970|Other|Neuropsychological tasks and self-report questionnaires|Being a cross-sectional observational study, no intervention will be administered. Subjects will be assessed with neuropsychological tasks and self-report questionnaires.
79400316|NCT06118944|Device|ICB00 IOL|Bilateral implantation of ICB00 IOL
79400317|NCT06118944|Device|ZCB00 IOL|Bilateral implantation of ZCB00 IOL
79400318|NCT06118944|Device|CNA0T0 IOL|Bilateral implantation of CNA0T0 IOL
79400319|NCT06118931|Behavioral|Early (7:00 - 16:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.
79400320|NCT06118931|Behavioral|Mid (9:30 - 18:30) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.
80023076|NCT05038774|Other|Printed Education Material|"Key points of current hypertension guidelines.~10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~checklists to assist in the diagnosis of secondary hypertension.~Patient information leaflet about hypertension."
80023077|NCT02154126|Device|Continuous Glucose Monitoring Device (Senseonics)|
80023078|NCT05023408|Drug|Bleomycin Injection|Intralesional Bleomycin used for treatment of cutaneous warts.
80023079|NCT05023408|Procedure|Cryotherapy|Cryotherapy used for comparison of efficacy.
79266471|NCT01564979|Drug|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
79266472|NCT05613140|Drug|sacubitril/valsartan|Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
79266473|NCT02253719|Procedure|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
79266474|NCT02140619|Behavioral|multiple health education interventions|
79266475|NCT04786886|Other|VIrtual Reality Visual Field Exam|Virtual reality visual field exam will be administered using the virtual reality headset. Exams can take up to 20 minutes.
79266476|NCT02260973|Dietary Supplement|Omega-3 (Triglyceride form)|
79400321|NCT06118931|Behavioral|Late (12:00 - 21:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.
79567205|NCT06010693|Drug|Daridorexant|Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.
79862102|NCT00991224|Biological|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
79567206|NCT06010693|Drug|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
79567207|NCT06008301|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
79862103|NCT00991224|Biological|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
79862104|NCT00991224|Other|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
79862105|NCT00466947|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
80023080|NCT02772978|Drug|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
80023081|NCT02772978|Drug|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
80023082|NCT03090490|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
79266477|NCT03548909|Diagnostic Test|VITROS Immunodiagnostic Products|NT-proBNP II assay
79266478|NCT03547505|Procedure|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
79266479|NCT03547505|Procedure|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
79266480|NCT03547505|Procedure|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
79266481|NCT04335578|Drug|Zampilimab|Participants will receive zampilimab (UCB7858) at pre-specified time-points.
79266482|NCT04335578|Drug|Placebo|Participants will receive matching placebo (PBO) at pre-specified time-points.
79266483|NCT05279183|Dietary Supplement|Erythritol|Subject specific dose of erythritol dissolved in 300 mL tap water.
79567208|NCT05996133|Drug|Bupivacain|30 mL of 0.25% bupivacaine
79567209|NCT05996133|Drug|Dexamethasone|0.5 mL (5 mg) preservative-free dexamethasone
79567210|NCT05996133|Drug|Epinephrine|0.1 mL epinephrine 1:400,000.
79567211|NCT05996133|Drug|Normal saline|3 mL normal saline
79581420|NCT01936090|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
79581421|NCT01936090|Other|Laboratory Biomarker Analysis|Correlative studies
79581422|NCT01936103|Drug|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
79862106|NCT00466947|Biological|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
79862107|NCT00466947|Biological|Engerix-B|Intramuscular injection, 3 doses
79862108|NCT00466947|Biological|Infanrix hexa|Intramuscular injection,3 doses
79862109|NCT00466947|Biological|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
79862110|NCT00991380|Behavioral|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
79862111|NCT00991380|Behavioral|Usual Care|Control
79862112|NCT00537810|Drug|Sibutramine|15 mg daily
79862113|NCT00537810|Drug|Placebo|Daily
79862114|NCT00537810|Behavioral|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
79862115|NCT00537810|Behavioral|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
80023083|NCT03090490|Other|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
80023084|NCT05038696|Biological|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
79862116|NCT05589246|Device|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
79266484|NCT05279183|Dietary Supplement|Sucrose|30 g sucrose dissolved in 300 mL tap water.
79266485|NCT05279183|Dietary Supplement|Sucralose|Subject specific dose of sucralose dissolved in 300 mL tap water.
79266486|NCT05568485|Other|Telerehabilitation was applied to the group with rheumatism|Telerehabilitation was applied to the group with rheumatism in 3 sessions a week for 24 weeks via a social texting program. The intervention sessions consisted of 10 minutes of dance therapy-authentic movement, 40 minutes of exercises, and 10 more minutes of dance therap
79266487|NCT05143346|Device|Intubation|Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.
79266488|NCT05567003|Procedure|Percutaneous transhepatic cholangioscopic (PTCS) laser incision|Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
79567212|NCT05993507|Behavioral|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
79581423|NCT01936103|Drug|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
79727354|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
80023085|NCT05300971|Other|Heat therapy|36 sessions (~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
79727355|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
79727356|NCT00621907|Drug|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
79727357|NCT00621907|Drug|sodium chloride|sodium chloride : 0,9% 30 ml
79266489|NCT04462952|Drug|Adavosertib (AZD1775)|Adavosertib taken orally
79727358|NCT04140799|Device|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
80023086|NCT05300971|Other|Thermoneutral water immersion|36 sessions (~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature >0.2°C, and 12 weeks of follow-up.
79266490|NCT05263427|Device|TOCONAUTE|"This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.~For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient."
79266491|NCT05563259|Radiation|Cognitive assessment, functional magnetic resonance imaging|Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
79308931|NCT04806711|Device|Control|Distance, single-vision glasses were used as a control
79727359|NCT04717219|Other|Blood drawing|Blood will be drawn after inclusion of the participants.
79727360|NCT02870985|Device|Coronary Stent|
79727361|NCT01349101|Radiation|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
79727362|NCT01349101|Drug|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
79727363|NCT01349101|Drug|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
79727364|NCT01349101|Drug|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
79727365|NCT01349101|Drug|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
79727366|NCT01349101|Drug|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
79727367|NCT01349101|Genetic|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
79727368|NCT02870049|Behavioral|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
79727369|NCT02870049|Behavioral|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
79862117|NCT05589168|Behavioral|Triage nurse|Triage nurse joins 911 call
79862118|NCT05589168|Behavioral|No triage nurse|Triage nurse does not join 911 call (business as usual)
79862119|NCT01017471|Procedure|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
80023087|NCT03543228|Diagnostic Test|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
80023088|NCT03090334|Diagnostic Test|De-escalation|Antifungal therapy will be stopped according with BG results
80023089|NCT03090178|Other|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
80023090|NCT05290363|Other|Blood sampling|A 51 mL blood sample will be collected during the study
79567213|NCT05991934|Behavioral|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
79567214|NCT05988229|Other|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
79567215|NCT05982730|Behavioral|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
79567216|NCT05977816|Device|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
79567217|NCT05977816|Other|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
79727370|NCT02870049|Behavioral|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
79862120|NCT05589012|Biological|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
79727371|NCT02870049|Behavioral|Usual care|Usual care: FIT kit delivery as part of usual care
79727372|NCT04295109|Drug|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
79862121|NCT05589012|Biological|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
79862122|NCT05589012|Biological|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
79862123|NCT01355094|Device|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
79266492|NCT02253485|Drug|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
79727373|NCT00620971|Drug|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
79266493|NCT02253563|Behavioral|Resistance Training|
79266494|NCT02253563|Behavioral|Balance Training|
79727374|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
79308932|NCT02596893|Drug|GED-0301|
79567218|NCT05975307|Drug|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
79567219|NCT05975307|Drug|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
79567220|NCT05975307|Drug|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
80023091|NCT05290363|Other|synovial aspiration|If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
80023092|NCT03092830|Genetic|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
80023093|NCT00104052|Biological|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
79400322|NCT06118918|Behavioral|Phase II comprehensive cardiac rehabilitation program|the program extends over 3 months after cardiac surgery. The program includes exercise, health education, and stress management. all content will be delivered to the participants through the WhatsApp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation …etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. Phone call follow-ups once weekly will be made by one of the research team to evaluate the adherence and answer potential questions All interventions are guided by universal guidelines like the Australian Cardiovascular Health and Rehabilitation Association (ACRA) and American Heart Association (AHA
79400323|NCT06118879|Device|Transcutaneous electrical stimulation|sensory level stimulation, one-leg standing and Y-balance training
79400324|NCT06118866|Drug|placebo-Q2W|placebo, 0mg，SC，Q2W，12 cycles
79567221|NCT05975307|Drug|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate < 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
79567222|NCT05975307|Radiation|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
79567223|NCT05971173|Drug|Juven|Nutritional supplements
79567224|NCT05971173|Drug|Centrum Silver 50+|Over the counter nutritional supplement
79567225|NCT05970042|Behavioral|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
79567226|NCT05970042|Behavioral|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
79567227|NCT05956730|Other|Physical Activity (AUD)|Home training of patients with severe low vision managed through audio-guides (AUD).
79567228|NCT05956730|Other|Physical Activity (SUP)|Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
79567229|NCT05932992|Other|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
79727375|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
79727376|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
79727377|NCT00620971|Drug|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
79266495|NCT05131256|Behavioral|Neurofunctional characterization of emotional regulation (fMRI)|Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
79266496|NCT02253641|Behavioral|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
79266497|NCT02253641|Behavioral|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
79266498|NCT05612516|Procedure|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
79400325|NCT06118866|Drug|HMI-115-120mg-Q4W|HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
79266499|NCT05612516|Procedure|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
79308933|NCT02596893|Drug|Placebo|
79308934|NCT04806633|Drug|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
79400326|NCT06118866|Drug|HMI-115-240mg-Q4W|HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
79400327|NCT06118866|Drug|HMI-115, 240mg-Q2W|HMI-115, 240mg，SC，Q2W，12 cycles
79567230|NCT05924971|Drug|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
79567231|NCT05924815|Drug|Aficamten|Oral Tablet
79567232|NCT05924815|Drug|Aficamten-matching Placebo|Oral Tablet
79567233|NCT05924815|Drug|Moxifloxacin|Oral Tablet
79567234|NCT05924412|Drug|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
79567235|NCT05924412|Other|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
79727378|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
79727379|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
79727380|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
79727381|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
80023094|NCT00104052|Drug|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
80023095|NCT03092596|Behavioral|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
80023096|NCT03092596|Behavioral|Patient health navigator-administered screening tool|patient health navigator-administered screener
80023097|NCT03092596|Behavioral|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
80023098|NCT04434508|Procedure|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
80023099|NCT04434508|Procedure|Open right hemicolectomy with CME and central v|Open right hemicolectomy with CME and central v
80023100|NCT05038072|Drug|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
79400328|NCT06118840|Device|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
79567236|NCT05923437|Other|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
79567237|NCT05922930|Drug|TROP2-CAR-NK|Given by IV (vein)
79567238|NCT05922930|Drug|Cyclophosphamide|Given by IV (vein)
79567239|NCT05922930|Drug|Fludarabine|Given by IV (vein)
79727382|NCT04673773|Behavioral|A Massive Open Online Course|Same as intervention
79862124|NCT01355094|Device|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
79862125|NCT05588232|Procedure|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
80023101|NCT02777970|Drug|Tramadol Hydrochloride/Dexketoprofen Trometamol|
80023102|NCT02777970|Drug|Tramadol Hydrochloride/Paracetamol|
79308935|NCT04806633|Drug|Placebo|Patients randomized in this arm will receive placebo.
79727383|NCT00995865|Biological|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10^8 VE/0.5mL and Mid dose = 2.2 x 10^7 VE/0.5mL
79727384|NCT00995865|Biological|Placebo|NaCl Injectable 0.9%
79727385|NCT04210531|Dietary Supplement|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
79862126|NCT00991614|Device|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
80023103|NCT02777970|Drug|Placebo|
80023104|NCT03037489|Drug|MIV-711|MIV-711 administered orally once daily
80023105|NCT02150616|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
80023106|NCT02150616|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
80023107|NCT02150616|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
80023108|NCT02150616|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
80023109|NCT01336023|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
80023110|NCT01336023|Drug|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
80023111|NCT01336023|Drug|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
80023112|NCT05037916|Other|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
79862127|NCT05358054|Other|Mobilization with movement lateral Glides and Conventional Physiotherapy|"(The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching"
79567240|NCT05921903|Biological|RSVPreF3 OA Investigational Vaccine|The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).
79862128|NCT05358054|Other|Progressive Resistance Exercises and Conventional Physiotherapy|4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
79862129|NCT01287936|Biological|SB623|SB623, a modified stem-cell product
79567241|NCT05911516|Dietary Supplement|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
79862130|NCT05586984|Procedure|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
80023113|NCT05151445|Behavioral|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
80023114|NCT02255292|Drug|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study
79400329|NCT06118840|Device|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
79567242|NCT05911516|Dietary Supplement|Placebo|Placebo
79567243|NCT05911165|Other|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
79727386|NCT04210531|Dietary Supplement|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
79727387|NCT04223661|Drug|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
79727388|NCT04223661|Drug|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
79400330|NCT06118827|Drug|HS-10518|QD, orally for 7 days
79400331|NCT06118827|Drug|Placebo|QD, orally for 7 days
79400332|NCT06118814|Other|Body Awareness Therapy Exercise|Body awareness therapy exercises were applied to the subjects in this group.
79400333|NCT06118814|Other|Virtual Reality Exercise|Virtual reality exercises were applied to the subjects in this group.
79400334|NCT06118814|Other|Core Stability Exercise|Core stabilization exercises were applied to the subjects in this group.
79400335|NCT06118814|Other|Home Exercise|Subjects in this group implemented a home exercise program.
79567244|NCT05911165|Other|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
79567245|NCT05898724|Procedure|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
79727389|NCT04223661|Drug|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
79581424|NCT01936116|Device|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
79862131|NCT05586984|Procedure|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
79862132|NCT00991692|Other|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
79266500|NCT05612438|Device|RADIX 2 Stent|RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis > 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.
79266501|NCT05558072|Genetic|Toll-like receptor 4|Toll-like receptor 4
79266502|NCT05557994|Other|Method|treatment of mature teeth with apical periodontitis
79266503|NCT02589626|Drug|empagliflozin 10mg|
79266504|NCT02589626|Drug|empagliflozin 25 mg|
79567246|NCT05898724|Procedure|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
79567247|NCT05898724|Procedure|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
79727390|NCT04208503|Diagnostic Test|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
79727391|NCT04220853|Diagnostic Test|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
79862133|NCT05583786|Diagnostic Test|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
79400336|NCT06118801|Dietary Supplement|Probiotic Product Supplement|Mothers of preterm babies who feed their babies only with breast milk will be given a probiotic product supplement once a day (80 ml probiotic product support containing the Actregularis (5×106 CFU\mL) (lactobacillus bulgaricus, streptococcus thermophilus, lactococcus lactis and bifidobacterium lactis) strain)
79862134|NCT00991770|Other|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
79862135|NCT00991770|Other|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
79862136|NCT00989352|Drug|Methotrexate|3g/m² i.v. max. 9 times
79862137|NCT00989352|Drug|Lomustine|110 mg/m² p.o., max. 3 times
79862138|NCT00989352|Drug|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
79266505|NCT02589626|Drug|Placebo|For blinding purposes
79266506|NCT04816175|Behavioral|Acquire Therapy|This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
79266507|NCT04976036|Drug|Nintedanib|150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
79266508|NCT04976036|Drug|Placebo|150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
79266509|NCT05557916|Other|Standard rehab|Standard rehab protocol including knee orthosis following meniscal repair
79400337|NCT06118788|Biological|BG1805|A single infusion of BG1805 Injection administered intravenously.
79400338|NCT06118775|Procedure|EaDyn Weaning Arm:|In the intervention group, where the EaDyn-guided weaning strategy is applied, the norepinephrine dosage will be systematically reduced every 15 minutes. Weaning will continue until the EaDyn value, measured through TPTD, reaches or exceeds 0.94, indicating improved hemodynamic stability. Weaning will cease if EaDyn falls below 0.94, ensuring patient safety. If the patient's Mean Arterial Pressure (MAP) is below 70 mmHg, yet the EaDyn value is 0.94 or higher, a 250 ml crystalloid infusion will be administered to maintain adequate perfusion. Additionally, for patients showing preload dependence, characterized by a more than 15% increase in Systolic Volume after Passive Leg Raising measured by TPTP, a fluid challenge with 250 ml of lactated Ringer's solution will be administered, optimizing preload and patient's hemodynamic status.
79727392|NCT04220853|Diagnostic Test|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
79727393|NCT04210453|Drug|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
79862139|NCT00989352|Drug|Rituximab|375 mg/m² i.v., max. 10 times
79862140|NCT05566626|Device|Hyperspectral retinal image|Hyperspectral image of both eyes
79567248|NCT05897073|Behavioral|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
79862141|NCT05566626|Drug|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
79862142|NCT00989430|Behavioral|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
79266510|NCT05557916|Other|accelerated rehab group|accelerated rehab group, no orthosis
79266511|NCT05557682|Other|composite restorative treatment|Restorative treatment using dental materials
79266512|NCT05557604|Drug|Decapeptyl|STAD androgen deprivation
79266513|NCT05292716|Device|MitraClip|MitraClip
79862143|NCT00989508|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
79862144|NCT00989508|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
79862145|NCT05408442|Other|No intervention|No intervention
80023115|NCT03092206|Drug|F/TAF|antiretroviral therapy
79266514|NCT05612282|Diagnostic Test|body composition analysis|A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
79567249|NCT05897073|Behavioral|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
79727394|NCT04210453|Drug|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
79266515|NCT05612282|Other|anthropometric measurements|An assessment of the status of nutrition based on anthropometric measurements was carried out.
79567250|NCT05897073|Behavioral|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
79567251|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
79567252|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 2
79727395|NCT00622141|Drug|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
79727396|NCT04210765|Drug|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
79727397|NCT00622219|Other|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
79727398|NCT05662267|Other|Pancreatic islet transplantation after kidney transplantation|Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
79862146|NCT05408364|Dietary Supplement|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
79862147|NCT05408364|Procedure|SRP|Scalling and root planing
79862148|NCT05408286|Behavioral|administration of questionnaires|administration of questionnaires
79862149|NCT05360394|Device|Paclitaxel Coated Balloon|CAS treated with PCB only
79266516|NCT05612282|Other|Interview questionnaire|An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
79567253|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 3
79567254|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 4
79567255|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks
79567256|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks
79862150|NCT05360394|Device|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
79266517|NCT05612282|Diagnostic Test|biochemical parameters|The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
79862151|NCT00090259|Drug|Losartan 50 mg|50-mg losartan oral tablet
79862152|NCT00090259|Drug|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
80023116|NCT03092206|Drug|E/C/F/TAF|antiretroviral therapy
80023117|NCT03092206|Drug|R/F/TAF|antiretroviral therapy
79266518|NCT05612282|Diagnostic Test|cardiopulmonary fitness test|Cardiopulmonary fitness was assessed using the Modified Bruce protocol
79266519|NCT05612282|Other|nutritional interview|A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
79266520|NCT05556278|Diagnostic Test|Ultrasound study|based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)
79567257|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks
79567258|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
79567259|NCT05881213|Drug|CKD-378 (low-dose)|Quaque day (QD), PO
79567260|NCT05880199|Device|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
79567261|NCT05856890|Biological|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
79567262|NCT05856890|Other|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
79727399|NCT00621205|Behavioral|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
79567263|NCT05854628|Procedure|skin biopsy|Skin biopsies will be obtained at different time points.
79567264|NCT05851625|Device|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
79567265|NCT05851625|Device|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
79567266|NCT05849441|Behavioral|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
79567267|NCT05847712|Other|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of ~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of ~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
79567268|NCT05846789|Drug|Carboplatin|Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
79567269|NCT05846789|Drug|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
79567270|NCT05840900|Behavioral|Digital Mindfulness Training|Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
79727400|NCT04210609|Device|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
79727401|NCT00621283|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
79727402|NCT00138853|Device|Tibial component|Tibial component inserted at the time of surgery
79727403|NCT00995709|Drug|AIN457|
79266521|NCT05556278|Diagnostic Test|Neurophysiological test|ultrasound protocol described by Chen et al. (2)
79727404|NCT00995709|Drug|AIN457|
79862153|NCT01082497|Behavioral|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
79862154|NCT03961711|Procedure|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
79862155|NCT03961711|Procedure|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
79862156|NCT00079183|Drug|sirolimus|Given PO
79862157|NCT03961243|Biological|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
79862158|NCT01589341|Other|laboratory biomarker analysis|Correlative studies
79862159|NCT01086085|Drug|Adefovir|Adefovir 10 mg po once daily for 36 weeks
79862160|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
79862161|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
80023118|NCT02154282|Behavioral|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
80023119|NCT05289427|Procedure|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
79727405|NCT00995709|Drug|Placebo|
79567271|NCT05835219|Drug|REBYOTA™|REBYOTA™ is administered in the rectum
79567272|NCT05829070|Behavioral|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
79862162|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
79862163|NCT01088425|Other|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
79862164|NCT01086163|Drug|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
79862165|NCT01589419|Drug|veliparib|see arm description
79862166|NCT01589419|Drug|capecitabine|see arm description
79862167|NCT01589419|Radiation|radiation|see arm description
79862168|NCT00676403|Drug|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
79862169|NCT00676403|Drug|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
79862170|NCT00676403|Drug|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
79862171|NCT00676403|Drug|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
79862172|NCT00676403|Drug|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
79862173|NCT00676403|Drug|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
79862174|NCT01086241|Procedure|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
80023120|NCT05289427|Procedure|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
79567273|NCT05829070|Behavioral|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
79862175|NCT01086241|Procedure|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
79862176|NCT00078325|Drug|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
79862177|NCT00078325|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
79567274|NCT05819047|Device|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
79567275|NCT05814510|Behavioral|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
79567276|NCT05814510|Behavioral|Asthma CHAMPS Wait List Control|Stepped wedge design
79862178|NCT00078325|Drug|Placebo|Matching placebo tablets once daily in the morning
79727406|NCT04208113|Behavioral|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
79727407|NCT00629031|Drug|Paromomycin|11 mg/kg for 14 days
79862179|NCT03963271|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
79862180|NCT03963193|Drug|Etoposide|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days.
79862181|NCT03963193|Drug|Irinotecan|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days.
79862182|NCT01088581|Drug|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
79862183|NCT01082653|Biological|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
79727408|NCT00629031|Drug|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
79727409|NCT04295265|Device|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
79862184|NCT03961867|Drug|Docetaxel|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
79862185|NCT03961867|Drug|Oxaliplatin|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
79862186|NCT03962179|Device|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
79862187|NCT00077857|Drug|capecitabine (Xeloda®)|825 mg/m^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
79862188|NCT00077857|Drug|docetaxel (Taxotere®)|75 mg/m^2 intravenous on day 1 of each 3 week cycle
79862189|NCT01086397|Procedure|Urine sample collection|All subjects have non-invasive urine sample collection performed
79862190|NCT00545402|Drug|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
79862191|NCT00545402|Drug|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
79400339|NCT06118775|Procedure|PAM Weaning Arm:|A gradual reduction of norepinephrine dosage by 0.01 mcg/kg/min will be implemented every 15 minutes in both study groups. In the control group, this reduction will persist until Mean Arterial Pressure (MAP) remains above or equal to 70 mmHg. Weaning will pause if MAP drops below 70 mmHg. In such cases, the patient's preload status will be assessed using a Passive Leg Raising (PLR) test. If the patient exhibits preload dependence, defined as a more than 15% increase in systolic volume after PLR measured by TPTD, a fluid challenge with 250 ml of lactated Ringer's solution will be administered. For patients with adequate preload, no fluids will be given, and the norepinephrine dosage will be increased to the level used before the decrease in MAP occurred.
79567277|NCT05810038|Drug|Rimegepant|Rimegepant
79567278|NCT05810038|Drug|Placebo|matching placebo
79727410|NCT00621361|Drug|AZD2171|Oral
79727411|NCT00621361|Drug|Etoposide|Intravenous
79727412|NCT00621361|Drug|Cisplatin|Intravenous
79862192|NCT00545402|Drug|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
79862193|NCT00545402|Drug|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
79862194|NCT00545402|Drug|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
79862195|NCT03963115|Drug|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
79862196|NCT01583023|Drug|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
79862197|NCT01583023|Device|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
79862198|NCT01583023|Other|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
79862199|NCT01583023|Device|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
79567279|NCT05806515|Procedure|Biospecimen Collection|Undergo collection of blood samples
79567280|NCT05806515|Drug|Carboplatin|Given IV
79567281|NCT05806515|Procedure|Chest Radiography|Undergo chest X-ray
79727413|NCT05661565|Other|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
79727414|NCT04208581|Drug|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
79727415|NCT04208581|Drug|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
79727416|NCT03551899|Other|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
79862200|NCT00976976|Drug|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
79862201|NCT00977054|Drug|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
79862202|NCT00977054|Drug|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
79862203|NCT00966524|Procedure|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
79862204|NCT00977132|Drug|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
79862205|NCT00977132|Drug|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
79862206|NCT00977210|Drug|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
79862207|NCT00545792|Drug|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
79266522|NCT05611814|Other|Osteopathic Manipulative Treatment|Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.
79862208|NCT00977288|Drug|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
80023121|NCT03092440|Other|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
80023122|NCT05017714|Drug|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
79266523|NCT05611814|Other|Sham treatment|"Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5"
79567282|NCT05806515|Procedure|Computed Tomography|Undergo CT
79567283|NCT05806515|Procedure|Magnetic Resonance Imaging|Undergo MRI
79567284|NCT05806515|Procedure|PSMA PET Scan|Undergo PSMA PET
79567285|NCT05806515|Procedure|Surgical Procedure|Undergo surgery
79567286|NCT05799313|Other|At home removal|Removal of PNE lead at home
79567287|NCT05799313|Other|In office removal|Removal of PNE lead in the office
79567288|NCT05793957|Other|Questionnaire Administration|Ancillary studies
79567289|NCT05793957|Behavioral|Telephone-Based Intervention|Use smartphone
79567290|NCT05793957|Other|Virtual Technology Intervention|Use VR headset
79567291|NCT05782075|Other|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
79727417|NCT02696863|Behavioral|questionnaire|
79862209|NCT00977288|Drug|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
79862210|NCT00977288|Drug|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
79862211|NCT00966602|Drug|VX-809|VX-809 capsule, once daily for 14 days
79862212|NCT00966602|Drug|VX-770|VX-770 tablet, once every 12 hours for 14 days
79862213|NCT00966602|Drug|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
79862214|NCT00966602|Drug|Placebo|Matching Placebo
79862215|NCT00977366|Other|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
79862216|NCT00977366|Other|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
79567292|NCT05781620|Dietary Supplement|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
79727418|NCT05368831|Drug|1024|Drug Drug interactions between 1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
79727419|NCT05368675|Drug|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
79862217|NCT00966680|Other|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
79567293|NCT05781620|Dietary Supplement|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
79862218|NCT00977444|Drug|kondrium|intraarticular injections once month
79862219|NCT00977444|Drug|kondrium f|intraarticular injections once month
79567294|NCT05769881|Procedure|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
79567295|NCT05769881|Procedure|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
79567296|NCT05760781|Drug|STSG-0002 Injection|Intravenous infusion
79862220|NCT00977444|Drug|methyl prednisolone (corticosteroid)|intraarticular injections once month
79862221|NCT04093934|Behavioral|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
79862222|NCT00966758|Procedure|Computed Tomography|1 low dose CT scan is taken
80023123|NCT02254980|Device|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
80023124|NCT02254980|Device|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
80023125|NCT05017636|Device|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
80023126|NCT02150694|Procedure|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
80023127|NCT02150694|Procedure|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
79266524|NCT05556122|Other|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
79266525|NCT05556122|Other|lateral intercostal nerve block|lateral intercostal nerve block
79266526|NCT05556122|Drug|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
79567297|NCT05760703|Drug|STSG-0002 Injection|Intravenous infusion
80023128|NCT02150694|Other|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
80023129|NCT02150694|Other|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
79266527|NCT04880720|Other|Blood sampling|Blood sampling - 10mL
79266528|NCT05555966|Device|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
79266529|NCT04865198|Diagnostic Test|Neurl1 gene expression|This observational case control study. The gene expression was examined.
79266530|NCT04865198|Diagnostic Test|RGS14 gene expression|This observational case control study. The gene expression was examined.
79567298|NCT05758337|Device|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
79567299|NCT05758194|Other|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
79567300|NCT05758194|Other|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
79567301|NCT05757466|Drug|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
79862223|NCT00966758|Procedure|Single Photon Emission Computed Tomography|1 SPECT scan is taken
79567302|NCT05757466|Drug|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
79727420|NCT04208425|Behavioral|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
79266531|NCT05555810|Procedure|clipping or ligation of the cystic duct and the cystic artery in Laparoscopic cholecystectomy|The investigators will make a comparison between clipping and ligation of cystic duct and cystic artery during Laparoscopic cholecystectomy and trying to know advantages and disadvantages of each technique .
79266532|NCT04842734|Other|Physical exercise|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
79567303|NCT05754216|Device|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
79727421|NCT04208425|Behavioral|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
79727422|NCT04208269|Other|postcard campaign|Post card sent to parent only
79727423|NCT04208269|Other|Health Information Technology system|Accessed by adolescent and provider only
79727424|NCT05368051|Combination Product|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
79727425|NCT02648113|Procedure|Restrictive transfusion|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
80023130|NCT05281003|Drug|Pembrolizumab|Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
80023131|NCT05281003|Drug|Paclitaxel|Drug: Paclitaxel 150 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
79567304|NCT05753189|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
79567305|NCT05753189|Drug|Placebo|Placebo: Proprietary Vehicle Solution
79567306|NCT05753189|Drug|Aceclidine Ophthalmic Solution|Aceclidine
79567307|NCT05746208|Drug|Lenvatinib|Given orally
79567308|NCT05746208|Drug|Pembrolizumab|Given IV
79567309|NCT05746208|Drug|Hyperpolarized 13C-Pyruvate|Given IV
79567310|NCT05744167|Behavioral|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
79567311|NCT05744167|Behavioral|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
79567312|NCT05735067|Other|Blood sample collection|5 ml of blood samples were withdrawn from RRMS patients
79727426|NCT02648113|Procedure|Liberal transfusion|transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL
79727427|NCT02648113|Biological|red blood transfusion|
79727428|NCT02641873|Drug|BBI608|240 mg twice daily (480 mg total daily dose)
79727429|NCT02641873|Drug|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
79727430|NCT02641873|Drug|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
79727431|NCT02641873|Drug|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
79727432|NCT02641873|Drug|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
79727433|NCT00998985|Drug|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
79727434|NCT00998985|Drug|Placebo|Placebo tablet, orally, once a day for 7 days
79727435|NCT05240391|Drug|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
79727436|NCT05240391|Drug|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
79567313|NCT05724095|Other|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
79567314|NCT05724095|Other|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
79567315|NCT05724095|Other|electrodes attached|electrodes are attached to area of acupoints
79567316|NCT05723614|Behavioral|TRUE HAVEN|The two components of the TRUE HAVEN intervention are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
79727437|NCT00628953|Drug|Esomeprazole|40mg twice a day
79266533|NCT04842734|Other|Physical exercise and computerized cognitive training|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
79727438|NCT00628953|Drug|Placebo|40mg twice a day
79266534|NCT04817228|Drug|EscharEx (EX-02 formulation)|EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
79400340|NCT06118762|Drug|Fruquintinib|Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
79727439|NCT04294875|Drug|MPT0B640|PO, every 3 days. dose escalation per MTD
79727440|NCT02870127|Other|blood sample|
79727441|NCT04294953|Drug|Duloxetine|Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
79727442|NCT04294953|Drug|Placebo oral tablet|Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
79727443|NCT04293861|Device|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
79727444|NCT02869815|Procedure|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
79862224|NCT00977600|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
79862225|NCT00977600|Drug|Ammonul|
79862226|NCT00977600|Drug|Buphenyl|
80023132|NCT05281003|Drug|Cisplatin|Drug: Cisplatin 80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
80023133|NCT05017792|Biological|Astrazenica vaccine|COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
79266535|NCT05555498|Device|Virtual Reality glasses|The intervention used are Virtual Reality glasses. The VR-glasses used are designed by SyncVR medical (Utrecht, the Netherlands), and are applicable specifically for medical use. By distracting the patients' cognition from the procedure, using images and sounds, the patient hopefully experiences less pain and anxiety. Women can choose between relaxation excersises and nature films
79400341|NCT06118749|Diagnostic Test|Antigen detection Rapid Diagnostic Test prototype|The study will focus on the usability and diagnostic performance of the RDT in blood and/or urine from patients with visceral leishmaniasis.
79266536|NCT05611658|Other|MR, PET CT|diagnostic method
79266537|NCT05549882|Other|no intervention|no intervention
79400342|NCT06118736|Procedure|Temporary Medial Hemi-epiphysiodesis of the proximal femur|Temporary Medial Hemi-epiphysiodesis of the proximal femur
79400343|NCT06118710|Drug|Dexamethasone|Dexamethasone prior to paclitaxel infusion according to local care standards.
79567319|NCT05715814|Drug|Empagliflozin 25 MG|PO once daily
79581425|NCT01936116|Device|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
79581426|NCT01936129|Drug|Copaxone|
79581427|NCT01936129|Drug|Placebo (buffered normal saline w/v)|
79581428|NCT01936142|Device|Use of RenalGuard|
79727445|NCT04293081|Drug|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
79727446|NCT04293081|Drug|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
79862227|NCT00966836|Drug|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
79862228|NCT00966836|Drug|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
79862229|NCT00966836|Drug|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
80023134|NCT03039283|Device|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
80023135|NCT02150772|Procedure|Shear Wave Elastography (SWE)|
80023136|NCT03089476|Other|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
80023137|NCT03089476|Other|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
80023138|NCT02158104|Procedure|Deep dry needling|
80023139|NCT05037604|Other|Questionnaire about associated factors|Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.
80023140|NCT05037604|Diagnostic Test|Self questionnaire diagnostic tool|Self questionnaire of physical characteristics
79727447|NCT00995553|Behavioral|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
79266538|NCT05549804|Drug|KL340399 Intratumoral|KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
79266539|NCT05549570|Drug|Sitagliptin/Metformin HCl 50/850 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
79862230|NCT00966836|Drug|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
79400344|NCT06118710|Drug|H1 Antihistaminics|Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards
79400345|NCT06118697|Procedure|Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy|Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
79266540|NCT05549492|Drug|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present."
79266541|NCT04331132|Drug|Tolvaptan 15 MG|vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
79581429|NCT01936155|Device|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
79581430|NCT01936168|Device|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
79862231|NCT00967070|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
80023141|NCT05037604|Other|Physical Examination|Physical Examination made by a dermatologist
80023142|NCT02158182|Drug|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
80023143|NCT02158182|Drug|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
80023144|NCT02158182|Drug|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
80023145|NCT02158182|Drug|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
79581431|NCT01936168|Procedure|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
79581432|NCT01936194|Dietary Supplement|DHA+EPA|
79266542|NCT05555420|Device|SRP+Laser|Non-surgical periodontal therapy in combination with Laser
79266543|NCT05555108|Behavioral|ACTCOM-I Intervention|ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.
79266544|NCT05555108|Behavioral|Standard CBT-I Intervention|Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)
79581433|NCT01936194|Dietary Supplement|High Olive Oil|
79581434|NCT01936194|Dietary Supplement|DHA|
79727448|NCT00995553|Behavioral|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
79727449|NCT04293003|Other|fasting|6-hour fasting
79727450|NCT04293003|Other|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
79727451|NCT04293003|Other|Mediterranean|Consumption of a Mediterranean-type breakfast
80023146|NCT02033187|Other|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
79567320|NCT05711758|Procedure|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
79266545|NCT05549336|Drug|PD-1 inhibitor|PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
79567321|NCT05704868|Behavioral|UniVRse + TAU|"UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~Attending a lecture;~Group work in a seminar;~Delivering a presentation;~Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company."
79567322|NCT05701527|Drug|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-90-minute intravenous (IV) fusion.
79727452|NCT04295187|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
79727453|NCT04295187|Other|Physical development and General Health|Physical development and General health examination
79567323|NCT05701527|Drug|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
79727454|NCT04295187|Other|Developmental Red flags|Developmental Red flags Questionnaires
79727455|NCT02868723|Other|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
79727456|NCT02869269|Device|Early stage|patients who classed as clinical stage 1 and 2
79567324|NCT05677594|Diagnostic Test|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
79727457|NCT02869269|Device|Late stage|patients who classed as clinical stage 3 and 4
79727458|NCT04291833|Behavioral|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
79727459|NCT04291833|Behavioral|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
79862232|NCT00967070|Drug|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
79862233|NCT00977678|Other|open access gastroscopy|access to gastroscopy without preceding appointment
79862234|NCT00977678|Other|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
79862235|NCT00977756|Drug|Raltegravir (RAL)|400 mg twice daily (BID)
79862236|NCT00977756|Drug|Atazanavir (ATV)|300 mg daily
79862237|NCT00977756|Drug|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
79266546|NCT04323722|Procedure|Empty Bladder planning CT scan and CBCTs|Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
79266547|NCT05554952|Combination Product|MTA|Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
79266548|NCT04753034|Drug|TER-101|Active Comparator
79266549|NCT04753034|Drug|Vehicle|Placebo Comparator
79727460|NCT04291833|Behavioral|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
79727461|NCT02868801|Drug|Placebo|same intervention as the experimental group
79727462|NCT02868801|Drug|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
79727463|NCT02868801|Drug|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
79727464|NCT02868801|Drug|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
79862238|NCT00977756|Drug|Tenofovir (TDF)|300 mg daily
79862239|NCT00977756|Drug|Etravirine (ETV)|200 mg BID
79862240|NCT00977756|Drug|Darunavir (DRV)|Dosing by weight
79862241|NCT00977756|Drug|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
79862242|NCT00977756|Drug|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
79862243|NCT00981344|Other|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
79727465|NCT00991887|Radiation|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
79266550|NCT05611190|Diagnostic Test|CT-FFR|CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.
79862244|NCT04938206|Procedure|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
79862245|NCT00981500|Procedure|gastric bypass|Roux-en-Y gastric bypass
79727466|NCT01002339|Drug|Tacrolimus with rapid steroid withdrawal|"Basiliximab induction (4 mg i.v., days 0 and 4).~Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
79727467|NCT01002339|Drug|Tacrolimus with steroids minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
80023147|NCT02033187|Other|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
79567325|NCT05674175|Biological|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
79266551|NCT05611190|Diagnostic Test|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice.
79727468|NCT01002339|Drug|CsA with steroid minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~Mycophenolate mofetil 1 gr b.i.d"
79266552|NCT05554718|Behavioral|Self-help Smartphone App|The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.
79266553|NCT05554718|Behavioral|Therapist-guided App Use|In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
79266554|NCT05549024|Drug|68Ga-RM26-RGD|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
79266555|NCT05549024|Drug|18F-FDG|18F-FDG injection
79567326|NCT05674175|Biological|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
79567327|NCT05674149|Device|camera|photographs using multi-spectral camera
79727469|NCT01002105|Drug|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
79727470|NCT01002105|Other|Control group|psychosocial intervention and placebo for 12 weeks
79727471|NCT02605993|Biological|Ravulizumab|All treatments were given as IV infusions.
79862246|NCT00981500|Procedure|gastric banding|laparoscopic adjustable gastric banding
79862247|NCT00981500|Procedure|sleeve gastrectomy|vertical sleeve gastrectomy
79266556|NCT05549024|Drug|68Ga-RM26|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
79266557|NCT05549024|Drug|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
79266558|NCT04666844|Other|no intervention|Observational Study
79266559|NCT05548868|Device|E4W mobile app|Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.
79266560|NCT05548868|Behavioral|Standard Care|Patients will receive standard dietary counselling as part of the weight management program.
79266561|NCT05548790|Behavioral|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
79308936|NCT04806867|Other|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
79266562|NCT05548790|Behavioral|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
79567328|NCT05671302|Behavioral|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
79567329|NCT05661461|Drug|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
79567330|NCT05656105|Drug|DPA-714 PET/MRI|DPA-714 PET/MRI
79567331|NCT05651802|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
79727472|NCT00995085|Drug|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
79727473|NCT02867787|Drug|Botox arm|
79862248|NCT00967148|Drug|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
79862249|NCT00981734|Other|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
79862250|NCT04007588|Drug|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
79266563|NCT05548790|Behavioral|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
79266564|NCT05548790|Behavioral|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
79266565|NCT01666730|Drug|metformin hydrochloride|Given PO
79266566|NCT01666730|Drug|oxaliplatin|Given IV
79266567|NCT01666730|Drug|leucovorin calcium|Given IV
79266568|NCT01666730|Drug|fluorouracil|Given IV
79266569|NCT01666730|Other|laboratory biomarker analysis|Correlative studies
79567332|NCT05651802|Radiation|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
79567333|NCT05651802|Drug|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
79862251|NCT04007588|Drug|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
79862252|NCT04007588|Drug|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
79266570|NCT05554484|Biological|Autologous peripheral blood-derived tolerogenic dendritic cells|AMI-DC, autologous dendritic cell product Inject 7.5 x 106 cells hypodermically to 1~4 sites in the left axillary lymph node between 5-7 days after PCI and 12-14 days after PCI. . The administration must be done within 30 minutes after fully liquified.
79266571|NCT05554094|Drug|Psilocybin|Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
79266572|NCT04434560|Drug|Nivolumab|Nivolumab will be given at the FDA-approved dose of 3 mg/kg.
79266573|NCT04434560|Drug|Ipilimumab|Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.
79266574|NCT05700656|Drug|Galunisertib plus capecitabine|Combination therapy with galunisertib plus capecitabine
79266575|NCT05548478|Procedure|Transepithelial PRK/MMC|transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
79581435|NCT01936220|Behavioral|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
79581436|NCT01936220|Behavioral|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
79727474|NCT02868489|Dietary Supplement|LactoWise®|blend of bacillus coagulans and galactomannans
79727475|NCT02868489|Other|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
79727476|NCT04209049|Drug|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
79727477|NCT02868645|Biological|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
79727478|NCT00136123|Procedure|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
79862253|NCT00977912|Dietary Supplement|Probiotic supplementation|one capsule containing probiotics per day added to milk
79727479|NCT04208893|Behavioral|Exercise training|See description of Arms
79727480|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
79862254|NCT00977912|Dietary Supplement|Milk containing placebo|one capsule containing placebo per day added to milk
79400350|NCT06118671|Behavioral|personalized lifestyle intervention by AI|The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
79266576|NCT05548478|Procedure|Alcohol-Assisted PRK/MMC|photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
79266577|NCT00103285|Radiation|3-Dimensional Conformal Radiation Therapy|Some patients undergo cranial radiotherapy
79400351|NCT06118658|Drug|tislelizumab|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
79400352|NCT06118645|Drug|cadonilimab combined +paclitaxel (albumin-bound)|"In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase"
79400353|NCT06118632|Other|Observational|Observational
79862255|NCT00967304|Other|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
80023148|NCT05037838|Procedure|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
79400354|NCT06118580|Drug|Alcohol (Ethanol)|95% Ethanol diluted in Grape-flavored drink
79400355|NCT06118580|Drug|Placebo|Grape-flavored drink
79400356|NCT06118567|Drug|Nitrous oxide|Nitrous oxide gas.
79400357|NCT06118567|Drug|Room Air|Room Air
79727481|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet
79727482|NCT02478151|Device|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
79727483|NCT02471911|Drug|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
79727484|NCT02471911|Drug|Rituximab|IV Rituximab 375 mg/m2 on D1
79727485|NCT02471911|Drug|Etoposide|IV Etoposide 100 mg/m2 on D1-3
79727486|NCT02471911|Drug|Carboplatin|IV Carboplatin AUC 5 on D2
79400358|NCT06118554|Other|Irrigation head position|Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
79400359|NCT06118541|Behavioral|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~Eye-Head Coordination exercise~Sitting balance exercises~Standing Static balance exercises~Standing Dynamic balance exercises~Ambulation exercises"
79400360|NCT06118528|Device|Blur Obfuscation|Blurring is applied to the RGB images.
79400361|NCT06118528|Device|Avatar Obfuscation|Cartoonization and avatars are applied to the RGB images.
79400362|NCT06118528|Device|Edge Obfuscation|A black background and simple outlines of objects/people are applied to the RGB images.
79400363|NCT06118528|Device|No Obfuscation (raw)|No editing is performed on the RGB images.
79727487|NCT02471911|Drug|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
79727488|NCT02471911|Drug|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
79727489|NCT02323321|Device|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
79727490|NCT00622375|Drug|mesalamine|encapsulated mesalamine granules
79862256|NCT00978146|Drug|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
79862257|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
79266578|NCT00103285|Drug|Cyclophosphamide|Given IV
79266579|NCT00103285|Drug|Cytarabine|Given IV or SC
79266580|NCT00103285|Drug|Dexamethasone|Given IV or PO
79266581|NCT00103285|Drug|Doxorubicin Hydrochloride|Given IV or IT
79266582|NCT00103285|Drug|Leucovorin Calcium|Given PO
79266583|NCT00103285|Drug|Mercaptopurine|Given PO
79266584|NCT00103285|Drug|Methotrexate|Given IM or IT
79266585|NCT00103285|Drug|Pegaspargase|Given IM
79266586|NCT00103285|Drug|Thioguanine|Given PO
79266587|NCT00103285|Drug|Vincristine Sulfate|Given IV
79308937|NCT05616897|Behavioral|Physiological responses during sustained CPR|
79400364|NCT06118515|Drug|Letermovir|Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
79400365|NCT06118476|Behavioral|3D animation|Education with 3D animation videos
79400366|NCT06118450|Other|Non-intervention|non-intervention
79727491|NCT02239861|Biological|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
80023149|NCT02154360|Drug|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
80023150|NCT02740257|Other|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
80023151|NCT05017870|Drug|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1~5 day) eyedrops recieved one drop to both eyes four times a day
79266588|NCT02155075|Device|MIRA device imaging|MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
79266589|NCT03541915|Drug|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
79400367|NCT06118424|Behavioral|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
79567334|NCT05651659|Other|TIME model in the prevention and treatment of crises in frail community-dwelling people|TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
79567335|NCT05650710|Device|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
79862258|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
79862259|NCT00982046|Device|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
79862260|NCT00982046|Device|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
79862261|NCT00982046|Device|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
80023152|NCT05017870|Drug|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1~5 day) eyedrops recieved one drop to both eyes four times a day
79862262|NCT00982046|Device|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
80023153|NCT05017870|Drug|KSR-001-02|KSR-001-02
80023154|NCT05017870|Drug|KSR-001-03|KSR-001-03
80023155|NCT02158260|Behavioral|Position changing|
80023156|NCT02033031|Drug|Lucentis intravitreal injection|Lucentis intravitreal injection
80023157|NCT02033031|Drug|Avastin intravitreal injection|Avastin intravitreal injection
80023158|NCT05017402|Drug|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: >25 mg/kg every other week.
80023159|NCT02158338|Other|Asthma|mothers who have children that have been diagnosed with respiratory issues
80023160|NCT02158338|Other|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
80023161|NCT02033343|Radiation|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
80023162|NCT05034367|Diagnostic Test|Mannitol challenge|Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
80023163|NCT02033265|Procedure|Brachial plexus block|Ultrasound guided axillary brachial plexus block
79266590|NCT03541915|Drug|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
79266591|NCT03541837|Drug|Ropivacaine|ESP catheter
79266592|NCT02155153|Other|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
79266593|NCT02783573|Drug|Lanabecestat|Administered orally
79400368|NCT06118398|Drug|Intravenous methylprednisolone (IVMP) and Efgartigimod|IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)
79400369|NCT06118398|Drug|IVMP|IVMP 800-1000mg/day for 3-5 days.
79400370|NCT06118372|Drug|Recombinant von Willebrand Factor|Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
79862263|NCT00982046|Device|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
79567336|NCT05646784|Drug|Cerebiome|Evaluate the effect of oral intake of a probiotic agent, on clinical and plasma inflammatory markers, in a subgroup of target patients versus a subgroup treated with placebo, in combination with conventional treatment, during the patient's stay in the hospital, and after his discharge, for a total duration of 12 weeks
79567337|NCT05646784|Drug|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment, during the patient's stay in the hospital, and after his discharge, for a total duration of 12 weeks
79567338|NCT05646095|Behavioral|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
79727492|NCT02691559|Device|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
79727493|NCT02691325|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
79727494|NCT02691325|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
79727495|NCT02691325|Drug|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
79727496|NCT02689687|Behavioral|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
79727497|NCT02689687|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
79727498|NCT02689687|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
79727499|NCT02689687|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
79727500|NCT00621439|Drug|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
79727501|NCT00621439|Drug|Placebo|Patients will receive placebo.
79266594|NCT02783573|Drug|Placebo|Administered orally
79727502|NCT00622453|Other|Screening|Electrocardiography Blood Test
79727503|NCT02689765|Dietary Supplement|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
79727504|NCT02689765|Dietary Supplement|Placebo|Placebo capsules is identically packaged.
79727505|NCT00622531|Device|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
79727506|NCT00622531|Other|hidden BNP value|no intervention
79727507|NCT05661877|Other|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
79727508|NCT05661877|Other|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
79727509|NCT04631107|Drug|AD109 dose1- A|Oral administration at bedtime
80023164|NCT02150928|Drug|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
80023165|NCT03611127|Other|pulmonary rehabilitation|pulmonary rehabilitation standardized program
79266595|NCT02158117|Drug|nasal naloxone|one puff in one nostril with the subject is lying down
79266596|NCT02160067|Drug|Second generation BTDS patch|
79266597|NCT02160067|Drug|First generation BuTrans patch|
79266598|NCT03541603|Drug|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
79727510|NCT04631107|Drug|AD109 dose2- B|Oral administration at bedtime
79727511|NCT04631107|Drug|Placebo- C|Oral administration at bedtime
79727512|NCT02691481|Dietary Supplement|Oatmeal breakfast|
80023166|NCT04964518|Drug|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
80023167|NCT03543150|Drug|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
79266599|NCT03541603|Drug|Matching Placebo|A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
79862264|NCT00982046|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
79266600|NCT02160223|Drug|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
79862265|NCT00967382|Drug|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
79862266|NCT00982124|Drug|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
79862267|NCT04007354|Other|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
80023168|NCT03611049|Dietary Supplement|High dose Vitamin D3|High dose arm- 5000IU given daily
80023169|NCT03611049|Dietary Supplement|Low dose Vitamin D3|Low dose arm-800 IU given daily
80023170|NCT05037448|Behavioral|Me & My Wishes|Me & My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me & My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
80023171|NCT02151006|Drug|DHEA|
80023172|NCT03610503|Other|Music|Participants in this arm will listen to music during the EMG testing
79266601|NCT02160223|Drug|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
79266602|NCT04829617|Behavioral|PP-MI Intervention|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and promoting adherence to physical activity, diet, and medications (through MI). Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to monitor health behavior adherence, resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in health behaviors.
79567339|NCT05641077|Other|Virtual Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
79567340|NCT05641077|Other|Office Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
79567341|NCT05636514|Drug|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
79567342|NCT05636514|Drug|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
79567343|NCT05630170|Device|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
79727513|NCT02691481|Dietary Supplement|Glucerna formula|
79727514|NCT02691481|Dietary Supplement|Ultra Glucose Control formula|
79727515|NCT01449409|Other|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
79727516|NCT00622609|Drug|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
79727517|NCT00622609|Drug|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
79727518|NCT04187287|Other|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
79862268|NCT00982202|Drug|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
79862269|NCT00982202|Drug|Placebo|1 to 3 tablets daily for ~18 months
79862270|NCT00967460|Behavioral|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
79862271|NCT00978224|Dietary Supplement|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
79862272|NCT00978224|Dietary Supplement|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
79862273|NCT00967538|Drug|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
79862274|NCT00978302|Drug|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
79862275|NCT00978302|Drug|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
80023173|NCT05037058|Other|Quality improvement activities|Quality improvement activities
80023174|NCT03610893|Drug|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
79567344|NCT05627713|Other|Blood sample collection|Blood sample collection between inclusion and 12 months after inclusion
79567345|NCT05627713|Other|urine sample collection|urine sample collection at inclusion
79862276|NCT00978302|Drug|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
79567346|NCT05620186|Other|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
79862277|NCT00978302|Drug|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
79567349|NCT05610033|Device|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
79567350|NCT05604560|Drug|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
79862278|NCT00978302|Drug|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
80023175|NCT03610893|Drug|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
79727519|NCT04187287|Other|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
79727520|NCT04208737|Procedure|recruitment maneuver|30 cmH2O pressure 15 seconds
79727521|NCT05661799|Behavioral|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
79862279|NCT00978302|Drug|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
79308938|NCT04427475|Drug|pabolizumab|100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
79308939|NCT04427475|Drug|nafulizumab|nafulizumab
79567351|NCT05604560|Drug|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
79567352|NCT05604287|Drug|ID119031166M|The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
79567353|NCT05604287|Drug|Placebo|The participant will receive a oral dose of Placebo.
79567354|NCT05602649|Drug|Cannabis|Cannabis will be orally ingested
79567355|NCT05602649|Drug|Placebo|Placebo will be orally ingested
79567356|NCT05601180|Other|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
79567357|NCT05601180|Other|Standard of care|standard treatment is prescribed by the treating physician.
79567358|NCT05594992|Drug|JR-141|IV infusion, 2.0 mg/kg/week
79567359|NCT05590377|Drug|Modakafusp Alfa|Modakafusp alfa intravenous infusion
79567360|NCT05590377|Drug|Daratumumab|Daratumumab SC injection
79862280|NCT00978302|Drug|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
79862281|NCT00984776|Other|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
79862282|NCT00978536|Other|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
79862283|NCT00978614|Drug|Neramexane|"Dosage form:~25 mg immediate release [IR] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
79862284|NCT00982358|Drug|Valsartan|
79308940|NCT04812249|Other|Clinical assessment|Clinical assessment and follow up of oral feeding ability
79567361|NCT05588193|Behavioral|PVO|post-visit outreach
79567362|NCT05588193|Behavioral|TS|tele-sexual health visit during the ED visit
79567363|NCT05584644|Drug|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
79567364|NCT05584644|Drug|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
79862285|NCT00982358|Other|Placebo|
79862286|NCT00982436|Drug|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
79862287|NCT00982436|Radiation|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
79862288|NCT00982436|Drug|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
79862289|NCT00982748|Behavioral|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
79400371|NCT06118320|Drug|Potassium sodium hydrogen citrate|"Medication: Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/package).~Method: Preprandial urine pH was monitored to maintain an effective range of 6.2 to 6.8. One package should be taken after breakfast, one after lunch, and two after dinner. If the pH falls below 6.2, a half-package dose should be added; if it exceeds 6.8, a half-package dose should be reduced accordingly. Oral medication will be administered for a duration of three months.~Medication requirements: Abstain from alcohol and smoking during treatment period and avoid using any probiotics or drugs that lower uric acid levels."
79400372|NCT06118294|Dietary Supplement|probiotics|>30 billion CFU/capsule
79862290|NCT00982826|Drug|ABT-072|See Arms information for a detailed description.
79400373|NCT06118294|Dietary Supplement|Placebo|Placebo
79567365|NCT05574101|Drug|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
79567366|NCT05574101|Radiation|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
79567367|NCT05563103|Other|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
79266603|NCT04829617|Behavioral|MI-alone Intervention|The time- and attention-matched MI-alone intervention focuses on providing education about heart failure (HF) and promoting adherence to physical activity, diet, and medications. Each week, participants will independently complete an activity related to HF education or adherence to a health behavior, then complete a phone session with a study trainer. HF educational topics will include the causes and types of HF, risk factors for cardiovascular disease, methods for monitoring risk factors and symptoms, and the importance of adherence to physical activity, diet, and medications. For each health behavior, study trainers will assist participants to monitor adherence, identify realistic behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) that provide education and encourage engagement in health behaviors.
79567368|NCT05563103|Other|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
79567369|NCT05563103|Other|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
79727522|NCT05661799|Behavioral|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
79727523|NCT04548037|Other|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
79862291|NCT00982826|Drug|Placebo|See Arms information for a detailed description.
79862292|NCT00978692|Device|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
79266604|NCT04809701|Procedure|Temporary implantation of defibrillation coils and pulse generator|Each subject will undergo temporary implantation of defibrillation coils and pulse generator according to the NV-ICD electrode configurations.
79266605|NCT04809701|Procedure|Defibrillation following induction of VA (Configuration A first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration A. Then up to two defibrillation energies will be tested for Configuration B.
79567370|NCT05563103|Other|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
79862293|NCT00978692|Device|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
79862294|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
79400374|NCT06118268|Device|iTBS (Active)|"The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands)."
79400375|NCT06118268|Device|iTBS (Sham)|DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
79400376|NCT06118242|Other|Use of oral care solutions|Oral care solutions to be used: Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid
79567371|NCT05560659|Drug|177Lu-PSMA|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
79567372|NCT05559853|Diagnostic Test|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
79266606|NCT04809701|Procedure|Defibrillation following induction of VA (Configuration B first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration B. Then up to two defibrillation energies will be tested for Configuration A.
79266607|NCT04809701|Procedure|Removal of defibrillation coils and pulse generator|Defibrillation coils and pulse generator will be removed from the subject after the defibrillation tests are completed.
79567373|NCT05558358|Device|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- > 6 months of sham stimulation
79567374|NCT05558358|Device|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- > 6 months of active stimulation
79727524|NCT04325737|Drug|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
79266608|NCT02163031|Device|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
79862295|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
79862296|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
79266609|NCT05537987|Drug|ICP-723|3+3 dose escalation
79266610|NCT02158351|Procedure|liver and white adipose tissue biopsies|
79266611|NCT05258825|Drug|Monoferric|A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
79266612|NCT02158429|Other|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
79266613|NCT02160301|Drug|Gabapentin|PO
79266614|NCT02160301|Drug|Acetaminophen|PO
79266615|NCT02160301|Drug|Acetaminophen|IV
79266616|NCT02160301|Drug|Celecoxib|PO
79266617|NCT02160301|Drug|Dexamethasone|IV
79266618|NCT02160301|Drug|Oxycodone|PO
79266619|NCT05531981|Other|detect HPV E7 ctDNA|Peripheral blood was collected from the patients, and the copy number of HPV E7 gene in ctDNA was accurately detected by ddPCR
79266620|NCT02160379|Other|standard test meal|
79266621|NCT02160457|Other|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~Impairment-Focused Interpretation~Recommendation for interdisciplinary interventions~Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
79266622|NCT02160613|Procedure|Open flap debridement|an access flap
79567375|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
79567376|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
79567377|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
79567378|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose|Injection in the muscle
79862297|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
79862298|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
79266623|NCT03541759|Drug|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS > 5.
79266624|NCT03541759|Drug|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS > 5.
79266625|NCT04064021|Procedure|Acupunture|Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
79400377|NCT06118229|Device|Wearable smart devices and PROs|Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
79567379|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose|Injection in the muscle
79567380|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose|Injection in the muscle
79567381|NCT05543616|Biological|Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose|injection in the muscle
79862299|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
80023176|NCT05022940|Other|Usual gold-standard multidisciplinary rehabilitation for TBI|In individual and group interventions within a holistic interdisciplinary rehabilitation program focusing on resumption of daily activities and social roles. Interventions could include physiotherapy or physical training, occupational therapy, speech therapy, and neuropsychology/psychology, which aimed at reducing the impacts of cognitive difficulties in daily life by using self-guided and environmental strategies.
80023177|NCT02032719|Behavioral|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
80023178|NCT02032719|Behavioral|Lifestyle counseling|Lifestyle counseling
80023179|NCT03079492|Device|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
80023180|NCT05137093|Device|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
79308941|NCT04797975|Biological|KDS-1000|"Non-randomized part of study:~At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~Cohort 1: Low Dose, 2x10E8 cells/dose~Cohort 2: High Dose, 1x10E9 cells/dose"
79567382|NCT05543382|Device|Axonics System|The Axonics System will be implanted as standard care
79567383|NCT05541510|Biological|AD17002 + Formulation buffer|Intranasal innate immune modulator
79567384|NCT05541510|Biological|Placebo|Formulation buffer
79567385|NCT05538663|Drug|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
79567386|NCT05538663|Drug|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
79727525|NCT04325737|Drug|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
79727526|NCT00457873|Drug|0.9% saline in 5% dextrose (intravenous)|
80023181|NCT02154438|Drug|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
80023182|NCT05022628|Drug|Donafenib|"Donafenib treatment regimen.~Donafenib started on the day of the first radiation treatment.~starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment."
79727527|NCT00457873|Drug|0.45% saline in 5% dextrose (intravenous)|
79727528|NCT02689375|Device|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
80023183|NCT02154594|Drug|Acacia catechu|
80023184|NCT02154594|Drug|Chlorhexidine gluconate|
79567387|NCT05538663|Drug|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
79567388|NCT05533892|Drug|Nocardia rubra cell wall skeleton|Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
79567389|NCT05533892|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
79567390|NCT05533892|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
79567391|NCT05533892|Drug|Tislelizumab|200mg intravenously every 3 weeks
79727532|NCT02697565|Behavioral|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
80023185|NCT02154594|Other|Distilled water|
80023186|NCT03610347|Device|Bare metal Stent plus Paclitaxel Balloon|
80023187|NCT03610347|Device|Drug Eluting Stent|
80023188|NCT05022706|Other|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
79567392|NCT05533502|Dietary Supplement|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
80023189|NCT05022706|Behavioral|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
79727533|NCT02697565|Behavioral|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
80023190|NCT05022706|Behavioral|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
80023191|NCT03541824|Behavioral|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
80023192|NCT05016934|Biological|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
80023193|NCT02151162|Behavioral|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
80023194|NCT02151162|Dietary Supplement|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
80023195|NCT02151162|Behavioral|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
80023196|NCT02151162|Dietary Supplement|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
80023197|NCT05016544|Drug|inetetamab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
80023198|NCT05016544|Drug|Pytotinib|"Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w."
80023199|NCT05016466|Other|Standard Care|Patients will followed during 5 years, and only 2 visits , baseline and 5 years
79567393|NCT05533502|Dietary Supplement|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
79727534|NCT04208191|Behavioral|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
79727535|NCT02697409|Behavioral|Education Against Tobacco intervention|
79308942|NCT04797975|Other|Placebo|0.9% Normal Saline
79308943|NCT04806477|Other|Telemedicine Consultation|Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.
79308944|NCT04806477|Other|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
79308945|NCT05616819|Other|Blue light exposure|Blue light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
79567394|NCT05525598|Behavioral|"One step at a time"|[see 'arms' section for full description]
79567395|NCT05525598|Behavioral|"Get started"|[see 'arms' section for full description]
79567396|NCT05520788|Genetic|precise medicine|During screening stage, all patients should accept next-generation sequencing (NGS) test.
79567397|NCT05515406|Drug|ONO-7018|ONO-7018 tablet(s) are administered orally
79567398|NCT05515406|Drug|ONO-7018|ONO-7018 tablet(s) are administered orally
79567399|NCT05511272|Biological|blood test|four blood samples will be withdrawn from the participants during the day of their frozen embryo transfer cycle
79567400|NCT05501665|Procedure|Biospecimen Collection|Correlative studies
79567401|NCT05501665|Drug|Carboplatin|Given carboplatin
79567402|NCT05501665|Procedure|Computed Tomography|Undergo PET/CT
79567403|NCT05501665|Other|Fludeoxyglucose F-18|Given IV
79567404|NCT05501665|Drug|Nab-paclitaxel|Given nab-paclitaxel
79567405|NCT05501665|Biological|Pembrolizumab|Given pembrolizumab
79567406|NCT05501665|Drug|Pemetrexed|Given pemetrexed
79567407|NCT05501665|Procedure|Positron Emission Tomography|Undergo PET/CT
79727536|NCT02697331|Drug|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
79727537|NCT02697331|Other|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
79727538|NCT02697175|Device|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
79727539|NCT02697175|Other|No Live Video-Colposcopy|The TV will be shut off during colposcopy
79862300|NCT00984854|Drug|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
80023200|NCT05016466|Other|Standard Care plus oxidative stress study plus inflammation biomarkers study|Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
79567408|NCT05501665|Radiation|Radiation Therapy|Undergo radiation therapy
80023201|NCT05016154|Behavioral|Online Group CBT intervention|Group of participants complete 10 weeks of Online Group CBT intervention
80023202|NCT05016154|Behavioral|SilverCloud guided|Group of participants make use of the SilverCloud guided app
80023203|NCT05016154|Behavioral|SilverCloud Unguided|Group of participants make use of the SilverCloud Unguided app
80023204|NCT05016154|Behavioral|Mood Flow|Group of participants make use of the Mood Flow app
79567409|NCT05501665|Other|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
79727540|NCT04187911|Behavioral|Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
80023205|NCT05016388|Other|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
80023206|NCT05016388|Other|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
79727541|NCT04187911|Behavioral|Services as Usual (SAU)|"SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites."
79727542|NCT04278625|Drug|Acetaminophen|IV acetaminophen given as part of standard of care.
79862301|NCT00978770|Drug|systemic chemotherapy|
79862302|NCT00978770|Procedure|diffusion-weighted magnetic resonance imaging|
79862303|NCT00978770|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
79862304|NCT00978770|Procedure|magnetic resonance spectroscopic imaging|
79862305|NCT00978770|Procedure|neoadjuvant therapy|
79862306|NCT00545168|Drug|Spinosad|10 minute topical application of product, followed by a complete rinse off.
80023207|NCT05022160|Drug|pudendal nerve block|All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine
80023208|NCT05009446|Procedure|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
80023209|NCT05009446|Radiation|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
80023210|NCT05009446|Drug|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
80023211|NCT01518517|Drug|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
80023212|NCT01518517|Drug|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
80023213|NCT02863575|Drug|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
80023214|NCT02863575|Drug|Ibuprofen|Ibuprofen capsule
80023215|NCT02863575|Drug|Placebo|Placebo treatment
79567410|NCT05501665|Biological|Ipilimumab|Given Ipilimumab
79567411|NCT05501665|Biological|Nivolumab|Given Nivolumab
79567412|NCT05501301|Other|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
79567413|NCT05501236|Device|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
79567414|NCT05496205|Drug|iN1011-N17|"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."
79567415|NCT05496205|Drug|Placebo|Matching Placebo for each formulations
79567416|NCT05481827|Genetic|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
79862307|NCT00545168|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
79400378|NCT06118216|Procedure|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
79400379|NCT06118216|Procedure|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
79400380|NCT06118203|Drug|Semaglutide|Semaglutide in addition to standard of care
79400381|NCT06118190|Drug|Lidocain|All participants treated with procaine and lidocaine injection for treatment.
79400382|NCT06118177|Procedure|connective tissue harvesting|The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of canine and the mesial of first molar in the palate. Connective tissue dimensions were approximately 10 × 5 × 2 mm. Finally, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture
79567417|NCT05480449|Biological|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
79567418|NCT05473767|Behavioral|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
79727543|NCT02689141|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
79727544|NCT02689141|Drug|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
80023216|NCT05021770|Drug|Orelabrutinib|150mg or 200mg orally daily
79727545|NCT02689141|Drug|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
79727546|NCT00622687|Drug|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
79862308|NCT00545168|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
79862309|NCT00982904|Drug|Fexinidazole/Placebo|
80023217|NCT05021770|Drug|Orelabrutinib|RP2D
80023218|NCT05021770|Drug|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
80023219|NCT05008978|Other|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
79400383|NCT06118177|Diagnostic Test|ultrasonography|A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the donor site in the palatal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit: Pulsality index (PI) = (Vmax-Vmin)/(Vmean) (Vmax is peak systolic flow velocity, Vmin is diastolic flow velocity and Vmean is mean flow velocity). The mean PI values of each patient were measured.
79400384|NCT06118177|Other|autolog platelet rich fibrin application|Leukocyte rich PRF (L-PRF) was obtained with the centrifugation of the two tubes at 2800 rpm for 12 minutes. After centrifugation, L-PRF clots were taken from the tubes using sterile tweezers, separated from the red blood cell base using scissors. Then L-PRF membrane was placed into the donor site.
79400385|NCT06118151|Biological|Influenza Hemagglutinin mRNA vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
79400386|NCT06118151|Biological|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
79727547|NCT00622687|Drug|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
79862310|NCT04869020|Device|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
79862311|NCT04869020|Device|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
79862312|NCT04869020|Device|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
79862313|NCT00984932|Drug|Rosuvastatin|40 mg of rosuvastatin daily
79862314|NCT00983138|Drug|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
79862315|NCT00544544|Drug|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
79862316|NCT05015270|Diagnostic Test|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
80023220|NCT05008978|Other|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
80023221|NCT05008978|Other|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
80023222|NCT05008978|Other|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
79862317|NCT04810364|Radiation|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
79862318|NCT00979160|Drug|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
80023223|NCT05008978|Other|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
80023224|NCT05021692|Behavioral|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
79567419|NCT05473767|Behavioral|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
80023225|NCT05009056|Device|Postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
80023226|NCT03619525|Procedure|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
80023227|NCT05230303|Dietary Supplement|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
79727548|NCT00622687|Drug|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
79727549|NCT04432051|Behavioral|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
79727550|NCT02687659|Device|TEMIS system|Wearing TEMIS system over the day during one week
79727551|NCT05662735|Device|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
79727552|NCT05662735|Procedure|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
79727553|NCT02691403|Drug|levo-bupivacaine|
79727554|NCT02691403|Drug|normal saline|
79727555|NCT02685319|Procedure|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
80023228|NCT05230303|Dietary Supplement|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
79727556|NCT04184713|Dietary Supplement|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
79727557|NCT04184713|Dietary Supplement|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
79862319|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
79862320|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
79308946|NCT05616819|Other|Amber light exposure|Amber light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
79727558|NCT00995007|Drug|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
79727559|NCT00995007|Drug|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
79727560|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
79727561|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
79862321|NCT00979316|Drug|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
79862322|NCT00979316|Drug|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
79304353|NCT04971603|Other|Acupuncture|"All acupuncture operations were done by registered Chinese medicine practitioner. Sterile, disposable acupuncture needles (0.25mmin diameter and 40mmin length) were used, which were purchased from HuaTuo acupuncture instrument.~Principal points: Neiguan (PC 6) *, Sanyinjia (SP 6) *, Weizhong (BL 40) *, Baihui (GV 20), Shuigou (GV 26) *, Zusanli (ST 36) *, Quchi (LI 11) *, Waiguan (TE 5) *, Hegu (LI 4) *, Huantiao (GB 30) *, Yanglingquan (GB 34)* (Grading of recommendation: C, level of evidence: IV).~Supplementary points: If upper limbs hemiplegia occurs, add Jianliao (TE 14) and Shousanli (LI 10); if lower limbs hemiplegia occurs, add Xuanzhong (GB 39) and Taichong (LR 3); if a deviation of the mouth or tongue occurs, add Dicang (ST 4) and Jiache (ST 6)."
79567420|NCT05469139|Diagnostic Test|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
79727562|NCT02685475|Drug|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
79727563|NCT00909883|Drug|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
79727564|NCT00909883|Drug|Placebo|Placebo injection
79727565|NCT00639925|Biological|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
79862323|NCT00983450|Other|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
79862324|NCT00983450|Other|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity [Celnik et al., 2008]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
79862325|NCT00983684|Device|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
79862326|NCT00983684|Radiation|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
79862327|NCT00983840|Other|Family Eats|8-session web-based program on healthy eating for African American families
79862328|NCT00983996|Drug|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
79862329|NCT00983996|Drug|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
79862330|NCT00984074|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
80023229|NCT04287790|Behavioral|audit and feedback, educational meetings, and academic detailing to promote medication receipt|Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
79567421|NCT05466448|Drug|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
79862331|NCT00984074|Procedure|diffusion tensor imaging|
79567422|NCT05464719|Drug|Loncastuximab Tesirine|Given by IV
79567423|NCT05456555|Procedure|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
79567424|NCT05456555|Procedure|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
79727566|NCT00994461|Drug|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
79727567|NCT00994461|Drug|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
79727568|NCT00994461|Drug|Placebo|Placebo tablet three times a day with meal for 2 weeks
79727569|NCT02685553|Device|NIR|Laparoscopic use of NIR
79727570|NCT04185961|Device|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
79727571|NCT04185961|Device|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
79727572|NCT00993915|Drug|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
79727573|NCT04174911|Drug|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
79727574|NCT04174911|Drug|Placebo|sublingual drops
79727575|NCT01202591|Drug|AZD4547|Tablet oral twice daily
79727576|NCT01202591|Drug|Exemestane|Tablet oral once daily
79727577|NCT01202591|Drug|Placebo|Tablet oral twice daily
79862332|NCT00984074|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
80023230|NCT04287790|Drug|Acamprosate, naltrexone, or disulfiram|Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
80023231|NCT01408615|Drug|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
79266626|NCT05149235|Other|early mobilization group|Participants will perform exercises using only the cycle ergometer and ambulation. In this group, participants will be instructed to turn the pedals continuously, without any weight added to the equipment (only on 1st post-operative day) and training load will be determined by a fatigue level maintenance of 4 or 5 on the modified Borg scale with a maximum HR elevation of 20% on 2nd and 3rd post-operative days. Duration of exercise will be of 10 minutes (five minutes with the upper limbs and five minutes with the lower limbs). For the arm exercises, the individuals will be positioned with the head end of the bed raised to 60° above the horizontal, while ensuring that all the equipment responsible for measuring the patient's vital signs remained connected. For the leg exercises, the head end of the bed will be lowered to a 30° angle to provide better access to the pedals and avoid compensatory hip movements. Ambulation will be performed only on 3rd post-operative day (40 meters).
79862333|NCT00984074|Procedure|functional magnetic resonance imaging|
79862334|NCT00984074|Radiation|intensity-modulated radiation therapy|
80023232|NCT04466332|Device|LifeCath-CT PICC easy™ (Vygon)|"ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position."
79567425|NCT05453136|Drug|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
79727578|NCT01202591|Drug|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
79862335|NCT00984074|Radiation|radiation therapy treatment planning/simulation|
79862336|NCT00985244|Drug|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
80023233|NCT04466332|Device|PowerPICC-SOLO® (C.R. Bard)|"ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position."
80023234|NCT05015842|Other|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
79266627|NCT05149235|Device|physio adventure|The protocol applied to the experimental group will be the same of that applied to the early mobilization group with the use of smart move instead of cycle ergometer.
79304354|NCT03293693|Other|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
79304355|NCT03293693|Other|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
79304356|NCT03293693|Other|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
79567426|NCT05453136|Drug|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
79727579|NCT00639067|Device|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
79304357|NCT04979325|Other||
79308947|NCT04797819|Diagnostic Test|Coronary plaque components|Coronary plaque components were detected by CCTA method
79567427|NCT05453136|Drug|Placebo to TS-142|Participants received repeated doses of placebo to TS-142 (oral tablet)
79567428|NCT05445336|Behavioral|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
79727580|NCT02687503|Dietary Supplement|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
79727581|NCT01202279|Drug|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
79727582|NCT01202279|Device|Placebo|Placebo bid for 7 days
79862337|NCT00985244|Drug|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
79727583|NCT03877315|Device|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
79727584|NCT03877315|Device|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
79727585|NCT02687347|Drug|oral methadone|Oral methadone is the study drug
79727586|NCT02687347|Drug|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
79727587|NCT01201967|Other|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
79862338|NCT00979472|Drug|Solifenacin|oral
79862339|NCT04007120|Drug|RVT-1601|Inhaled RVT-1601 administered once daily over two days
79862340|NCT00984152|Drug|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
79862341|NCT00984152|Drug|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
79266628|NCT05149235|Other|placebo|Participants allocated to the Control group will perform respiratory physiotherapy (Flow-oriented incentive spirometer (3×15), active exercises for lower and upper limbs, with each movement being repeated 10 times in an open kinetic chain. For the upper limbs, movements of anterior flexion of the shoulder will be performed until achieving maximum range of motion, using diagonal movements starting at the contralateral iliac crest up to the maximum range of anterior flexion of the shoulder associated with supination. For the lower limbs, exercises will consist of straight leg raises, hip and knee flexion-extension exercise and ankle pumps. Sessions will be of 10 minutes duration.
79266629|NCT01666652|Biological|4 µg TDENV-PIV with Alum adjuvant|
79266630|NCT01666652|Biological|1 µg TDENV-PIV with AS03B1 adjuvant|
79266631|NCT01666652|Other|Phosphate buffered saline|
79727588|NCT01201967|Other|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
79266632|NCT01666652|Biological|1 µg TDENV-PIV with Alum adjuvant|
79567429|NCT05431699|Diagnostic Test|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
79862342|NCT00985322|Drug|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
80023235|NCT05015842|Other|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
80023236|NCT03723967|Drug|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
80023237|NCT05009212|Procedure|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (<5 cm)
79266633|NCT01666652|Biological|1 µg TDENV-PIV with AS01E1 adjuvant|
79266634|NCT03545789|Drug|[18F]MNI-958|Subjects will undergo PET imaging using [18F]MNI-958, a PET radioligand for imaging tau.
79581437|NCT01936220|Behavioral|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
79862343|NCT00985322|Drug|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
79862344|NCT00984230|Other|BSF|feeding amount according to individual baby need
80023238|NCT05009212|Procedure|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (<5 cm)
79266636|NCT05548322|Device|Different surfaces to be touched|The participant will touch various different surfaces and textures, including ones of different temperature and including solids and liquids.
79266637|NCT05548322|Behavioral|Emotional state change|The emotional state of the participant will be modulated by listening to music.
79266638|NCT05548322|Device|Electrical stimulation|The participant will receive electrical stimulation of single nerve fibers (a few microamps) to artificially excite an individual afferent.
79266639|NCT05174585|Biological|JAB-BX102 (anti-CD73 monoclonal antibody)|Administered by intravenous infusion (IV)
79266640|NCT05174585|Biological|pembrolizumab (anti-PD-1 monoclonal antibody)|Administered by intravenous infusion (IV)
79727589|NCT02687425|Drug|Pioglitazone|15mg/day,po
79727590|NCT02687425|Drug|imatinib mesylate|400mg/day,po
79727591|NCT02537665|Other|heating precondition|
79727592|NCT02687269|Drug|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
79727593|NCT02687269|Drug|Placebo|Patients receive Placebo twice daily in the three days before surgery
79862345|NCT00984230|Other|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
79862346|NCT00984230|Other|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
79862347|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
79862348|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
79862349|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
79862350|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
79862351|NCT00984386|Drug|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
79862352|NCT00984464|Biological|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
80023239|NCT05132569|Drug|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
80023240|NCT05132569|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
80023241|NCT05008666|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~Exploring biomarkers that may have predictive effects."
80023242|NCT05008666|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~Exploring biomarkers that may have predictive effects."
80023243|NCT05008666|Drug|Azacitidine|"To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~Exploring biomarkers that may have predictive effects."
80023244|NCT05008666|Drug|L-DEP|L-DEP
80023245|NCT05021380|Other|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
80023246|NCT03079648|Dietary Supplement|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
79567430|NCT05431699|Diagnostic Test|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
79727594|NCT02689297|Other|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
79862353|NCT00984464|Drug|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
79567431|NCT05431699|Procedure|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
80023247|NCT03079648|Dietary Supplement|Placebo|Placebo for 12 weeks
80023248|NCT03659461|Drug|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
80023249|NCT03088618|Procedure|Nasal septoplasty|Type of surgery
80023250|NCT01227187|Drug|Drotrecogin alfa activated (Xigris)|We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains <65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
79266641|NCT04428086|Drug|Apatinib in arm1|Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
79266642|NCT04428086|Drug|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
79581438|NCT01936233|Drug|Aspirin|Aspirin 0.1 QD po
79581439|NCT01936233|Drug|Lamivudine|LAminvudine 0.1 QD po
79727595|NCT02689297|Other|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
79727596|NCT04186741|Drug|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
79727597|NCT04185805|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
79727598|NCT04185805|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
79862354|NCT00984464|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
79266643|NCT04428086|Drug|Apatinib in arm2|Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
79266644|NCT04428086|Drug|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
79727599|NCT03758755|Device|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
79266645|NCT04416386|Other|Vitamin C|Pre and post-operative blood plasma levels of vitamin C will be investigated
79266646|NCT05548166|Other|Interview and scale development|Interview and scale development
79266647|NCT05700110|Other|Non-Interventional|Non-interventional
79862355|NCT00988130|Other|laboratory biomarker analysis|
79862356|NCT00988130|Other|questionnaire administration|
79862357|NCT00988130|Procedure|assessment of therapy complications|
79862358|NCT00988130|Procedure|high-intensity focused ultrasound ablation|
79862359|NCT00988130|Procedure|quality-of-life assessment|
79862360|NCT00985478|Drug|SLV342|25 mg once daily - Maximal Tolerated Dose
80023251|NCT03088072|Drug|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl >50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow <5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
80023252|NCT03088072|Device|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
80023253|NCT03088072|Drug|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
79727600|NCT03758755|Other|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
79862361|NCT00985478|Drug|placebo|matching placebo
80023254|NCT03088072|Drug|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
80023255|NCT05008042|Drug|Mecobalamin 5 MG|The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
80023256|NCT05008042|Other|Placebo Comparator : NaCl 9 mg/ml|Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
80023257|NCT03619447|Drug|ESP block group|USG guided Erector spinae block (ESP) will perform bilaterally.
80023258|NCT03619447|Drug|serratus block group|USG guided serratus plane block will perform bilaterally
79400387|NCT06118138|Combination Product|Hyperbaric oxygen therapy (HBOT)|"HBOT is a medical treatment employed for various conditions. It entails breathing 100% oxygen within a pressurized chamber known as a hyperbaric chamber. This oxygen-rich environment promotes healing and aids in combating specific infections.~In this study, the investigators will administer HBOT using a hyperbaric chamber set to 2 times the normal atmospheric pressure, indicated as 2 atmosphere absolute (ATA). This pressure surge enhances oxygen dissolution into the bloodstream, surpassing levels achievable at sea level. The pressure will be raised incrementally, followed by HBOT sessions lasting for a total of 90 minutes. The 90-minute sessions include brief 5-minute intervals for ambient air every 20 minutes to ensure safety and comfort. Treatment will be conducted five days a week over eight weeks.~Supervised by competent healthcare professionals, HBOT is considered safe, with potential side effects primarily stemming from heightened pressure and, in rare cases, oxygen toxicity."
79567432|NCT05431699|Procedure|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
80023259|NCT05015140|Other|musıc therapy|calm music with nature sounds set by the music therapist
79266648|NCT03929549|Device|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
79266649|NCT04355858|Drug|SHR7390|MEK1/2 inhibitor
79581440|NCT01936246|Dietary Supplement|Increased protein|
79727601|NCT01201811|Drug|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
79727602|NCT04186897|Procedure|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
79862362|NCT00988286|Procedure|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
79862363|NCT05593250|Drug|SHR-1905|subcutaneous
79266650|NCT04355858|Drug|Famitinib|Multi-target tyrosine kinase inhibitor
79266651|NCT04355858|Drug|SHR3162|PARP inhibitor
79266652|NCT04355858|Drug|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
79266653|NCT04355858|Drug|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
80023260|NCT05021302|Procedure|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
79581441|NCT01936285|Drug|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
79581442|NCT01936285|Drug|Placebo|
79727603|NCT04186897|Procedure|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
79727604|NCT05400785|Other|Circadian Rhythms for Mood (CRM) application - Active|The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.
79862364|NCT05593250|Drug|placebo|subcutaneous ,placebo
80023261|NCT05021302|Behavioral|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
79400388|NCT06118073|Other|Headspace|Headspace is a smartphone-based application that guides individuals through various mindfulness sessions and has been shown to reduce symptoms of depression, anxiety, and pain. Participants will be required to answer questions regarding anxiety levels and pain for 6 weeks after surgery.
79266654|NCT04355858|Drug|SHR1210|PD-1 antibody
79266655|NCT04355858|Drug|Everolimus|mTOR inhibitor
79266656|NCT04355858|Drug|Nab paclitaxel|Albumin bound paclitaxel
79266657|NCT04355858|Drug|SHR2554|EZH2 inhibitor
79266658|NCT04355858|Drug|SHR3680|AR inhibitor
79266659|NCT04355858|Drug|SHR6390|CDK4/6 inhibitor
79266660|NCT04355858|Drug|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
79400389|NCT06118073|Procedure|Total Knee Replacement|Participant will have total knee replacement surgery
79400390|NCT06118060|Other|Acupressure|In this study, the frequency of acupressure was twice a day (the interval between each acupressure was more than 6 hours, 6:00 to 9:00 in the morning and 1:00 to 4:00 in the afternoon); the acupressure was applied from the first day after surgery for a total of 5 days, that is, each patient received a total of 10 acupressure; the duration was 5 minutes, and the bilateral acupressure required 10 minutes.
79400391|NCT06118047|Drug|Crisaborole Ointment|Crisaborole ointment to be applied twice daily.
79567433|NCT05431699|Procedure|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
79567434|NCT05427383|Drug|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
79567435|NCT05427383|Drug|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
79400392|NCT06118047|Drug|Cetuximab|Cetuximab
79400393|NCT06118021|Drug|HS-20094|Administered SC
79567436|NCT05427383|Drug|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
79567437|NCT05427383|Drug|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
79567438|NCT05427045|Other|home - exercise program|Home exercise program
79567439|NCT05426252|Drug|Abatacept|Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
79727605|NCT05400785|Other|Circadian Rhythms for Mood (CRM) application - Sham|The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
79727606|NCT05392127|Drug|SHR0302 Tablets|SHR0302 Tablets once daily
79727607|NCT05392127|Drug|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
79727608|NCT05392127|Drug|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
79727609|NCT05392127|Drug|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
79266661|NCT04355858|Drug|SERD|Fulvestrant
79266662|NCT04355858|Drug|AI|aromatase inhibitor
79266663|NCT04355858|Drug|VEGFi|Bevacizumab
79567440|NCT05426252|Drug|Sirolimus|Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
79567441|NCT05420207|Other|No intervention|No intervention included
79567442|NCT05410574|Behavioral|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
79567443|NCT05396807|Device|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
79727610|NCT05392127|Drug|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
79727611|NCT05392127|Drug|Repaglinide Tablets|Repaglinide Tablets single dose
79727612|NCT05378399|Drug|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
79266664|NCT03917225|Drug|MIN-102|Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
79266665|NCT03917225|Drug|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
79266666|NCT05548088|Biological|LILRB4 STAR-T cells|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg。
79266667|NCT03913013|Behavioral|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
79266668|NCT05700500|Procedure|shockwave therapy, barbotage and infiltration|ultrasound guided interventions
79400394|NCT06118021|Drug|Placebo|Administered SC
79400395|NCT06118008|Drug|HS-20094 5mg|Administrated by subcutaneous injection
79400396|NCT06118008|Drug|HS-20094 10mg|Administrated by subcutaneous injection
79727613|NCT05378399|Device|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
79727614|NCT05378399|Device|Beiwe|Digital phenotyping app
79727615|NCT02687113|Device|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
79727616|NCT02685163|Other|Antioxidant ice-cream|Narutal Antioxidant ice-cream
80023262|NCT03079258|Other|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
80023263|NCT05021068|Other|Postural Assessment|Spinal mouse measurement
79266669|NCT03894995|Other|Installation of ventilation|The intervention is installation of a ventilating structure, in this case a window in the house roof.
79567444|NCT05393128|Procedure|Control group (Supine Position)|"In this group the patients will be given supine position.~Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~The patient will be given supine position.~The arms and the hands will be elevated and supported, the legs will be elevated and supported.~The patient will be covered.~The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
79400397|NCT06118008|Drug|HS-20094 15mg|Administrated by subcutaneous injection
79567445|NCT05393128|Procedure|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~The patient will be positioned supine and the bed will be straightened.~Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~Between the legs will be supported with pillows.~The patient's head will be elevated with 45-60 degrees.~The patient will be covered :~The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
80023264|NCT05125081|Drug|Liuwei Dihuang Pill (marketed product in China)|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
80023265|NCT05125081|Drug|Liuwei Dihuang Pill（placebo ）|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
80023266|NCT03091972|Procedure|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
79400398|NCT06118008|Drug|HS-20094 20mg|Administrated by subcutaneous injection
80023267|NCT03091972|Procedure|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
79400399|NCT06117995|Other|Assessment the pre-washed sperm motility before IUI|The pre-washed sperm motility will be assessed by using WHO 2021 guidelines, stratified into four groups.
79567446|NCT05393128|Procedure|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~The patient will be positioned supine and the bed will be straightened.~Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~Between the legs will be supported with pillows.~The patient's head will be elevated with 45-60 degrees.~The patient will be covered :~The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
79727617|NCT02685163|Other|Control Ice-cream|Natural Control Ice-cream
79727618|NCT00638599|Device|LMA®|LMA® is placed after anesthesia induction and removed after the operation
79727619|NCT00638599|Device|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
79727620|NCT00640003|Drug|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
79727621|NCT00640003|Drug|Placebo|placebo drug
79400400|NCT06117956|Diagnostic Test|Rapid urease test for h pylori|"Tonsillectomy will be done with the dissection method and one tonsil per patient will be collected. A 2 mm gross specimen will be washed with normal saline. The specimen will be placed in a test tube well containing Rapid Urease Enzyme (GASTRO CURE SYSTEM RUT DRY TEST Batch No. A1060).~The initial color will be read at 0 min. Subsequent color changes will be read at 30 min, 6 hours, and 24 hours. Any color change from the initial yellow color to either pink or red will be recorded as positive. Any test that will be remained yellow after 24 hours will be recorded as negative.~Tonsillar tissue samples will be fixed in 10% formalin for 24 h Each slide will be separately evaluated for the presence or absence of Helicobacter-like organisms at a high-power magnification"
79400401|NCT06117943|Other|data collection|Pregnant women who smoke personally or are passively exposed to cigarette smoke
79266670|NCT05553782|Combination Product|Implantable Microdevice (IMD)|"Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine"
79727622|NCT01201343|Drug|Interferon beta-1a|
79567447|NCT05386797|Procedure|Geniculate Artery Embolization|The GAE procedure involves the use of an embolization agent to block blood flow to specific areas of the knee. Under sedo-analgesia, access to the target vessels is gained through the femoral or radial artery. GAE is performed with angiography to visualize blood vessels to assess the affected knee joint and ensure successful treatment.
79862365|NCT04454372|Other|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
79266671|NCT03890627|Device|Thoracic bio-reactance|Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
79400402|NCT06117917|Drug|S-ketamine and pregabalin|"Drug: Pregabalin~150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~Drug: S-ketamine infusion~0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
79400403|NCT06117917|Drug|Normal saline and placebo capsule|"Drug: Placebo capsules~Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~Drug: Normal saline~0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
79400404|NCT06117878|Drug|NK510|NK510 will be administered through intravenous infusion.once a week，for a total of six times.
79400405|NCT06117878|Drug|NK510|NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
79567448|NCT05366777|Drug|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
79567449|NCT05366777|Drug|Saline|100 ml of normal saline
79567450|NCT05363605|Drug|[225Ac]-FPI-1966|[225Ac]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
79727623|NCT04185727|Other|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
79727624|NCT04185649|Biological|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
79727625|NCT04185649|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
79862366|NCT00985556|Drug|capecitabine|Given orally
79862367|NCT00985556|Drug|oxaliplatin|Given IV
79862368|NCT00985556|Drug|tegafur-gimeracil-oteracil potassium|Given orally
79862369|NCT04780490|Other|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
79862370|NCT04780490|Other|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
79567451|NCT05363605|Drug|[111In]-FPI-1967|[111In]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive [111In]-FPI-1967 Injection of 185 MBq for imaging.
79727626|NCT04185649|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
79727627|NCT01201265|Drug|Bevacizumab|15 mg/kg iv every 3 weeks
79862371|NCT04445246|Drug|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
79862372|NCT00541346|Drug|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
79862373|NCT00988520|Drug|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
79862374|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
79266672|NCT05553626|Device|Left bundle branch pacing|Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
79266673|NCT05553626|Device|Bi-ventricular pacing|Bi-ventricular pacing by a CRT/CRTD device
79266674|NCT05553548|Procedure|biologically oriented alveolar ridge preservation|xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
79266675|NCT05553548|Procedure|xenogenic bone graft in entire (apico-coronal) extension|xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
79400406|NCT06117865|Behavioral|Module 1|Module 1: Introduction to IBS by a gastroenterologist.
79400407|NCT06117865|Behavioral|Module 2|Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.
79400408|NCT06117865|Behavioral|Module 3|Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.
79400409|NCT06117865|Behavioral|Module 4|Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).
79400410|NCT06117865|Behavioral|Module 5|Module 5: Intervention: The low FODMAP diet.
79727628|NCT01201265|Drug|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
79727629|NCT01201265|Drug|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
79862375|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
79862376|NCT00988520|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
79862377|NCT00988520|Drug|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
79862378|NCT00985634|Device|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
79727630|NCT02688673|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
80023268|NCT03091972|Procedure|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
79862379|NCT00985634|Device|Control|Vessel loops
80023269|NCT05020834|Other|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
80023270|NCT05020834|Other|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
80023271|NCT05020756|Dietary Supplement|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
80023272|NCT01077817|Drug|Alendronate|
80023273|NCT01077817|Drug|Etidronate|
79266676|NCT05610956|Drug|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
79567452|NCT05363605|Biological|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
79862380|NCT00985868|Drug|multikinase inhibitor AT9283|
79727631|NCT00624533|Behavioral|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
79727632|NCT00624533|Behavioral|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
79727633|NCT04246801|Drug|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
79727634|NCT04246801|Drug|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
79862381|NCT00985868|Other|enzyme-linked immunosorbent assay|
79862382|NCT00985868|Other|immunohistochemistry staining method|
79862383|NCT00985868|Other|laboratory biomarker analysis|
79862384|NCT00985868|Other|pharmacological study|
79862385|NCT05498090|Drug|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
79862386|NCT00077623|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
79862387|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
79862388|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
79862389|NCT00541034|Biological|rituximab|
80023274|NCT01077817|Drug|Ibandronate|
80023275|NCT01077817|Drug|Risedronate|
80023276|NCT01077817|Drug|Raloxifene|
80023277|NCT03086902|Device|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
79266677|NCT05610956|Drug|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
79567453|NCT05357781|Diagnostic Test|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
79567454|NCT05356260|Device|URincontrol4men|The intervention is built as an app
79567455|NCT05356260|Other|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
79862390|NCT00541034|Drug|cyclophosphamide|
79862391|NCT00541034|Drug|pentostatin|
79862392|NCT00986024|Behavioral|aerobic exercise|carried out 3 times per week for 12 weeks
79862393|NCT00986024|Behavioral|strength training|carried out 3 times per week for 12 weeks
79862394|NCT01090375|Other|Exercise|
79862395|NCT01090375|Other|Non Exercise|
79862396|NCT00540644|Drug|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
79862397|NCT00540644|Drug|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
79862398|NCT00540644|Drug|Prednisone|50 mg p.o. Q.O.D.
79862399|NCT05450900|Drug|Choriogonadotropin Alpha|drug, active
79862400|NCT05450900|Dietary Supplement|biotin|supplement, oral
79862401|NCT05450900|Other|Microcellulose filler|supplement, oral
79862402|NCT04004858|Radiation|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
80023278|NCT03086902|Device|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
80023279|NCT04433962|Other|Exercise training|
80023280|NCT03085498|Other|No intervention|no intervention
80023281|NCT02638012|Drug|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
79862403|NCT00988754|Behavioral|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
80023282|NCT02638012|Other|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
80023283|NCT05014906|Drug|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
80023284|NCT05014906|Drug|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
79266678|NCT00109733|Biological|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
79400411|NCT06117800|Other|TeamSTEPPS|Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
79266679|NCT00109733|Biological|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
79266680|NCT05699876|Drug|Melatonin 6 MG|melatonin will be administered orally preoperatively as premedication
79266681|NCT05699876|Drug|Gabapentin|melatonin will be administered orally preoperatively as premedication
79400412|NCT06117709|Behavioral|I-STAMP|A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
79400413|NCT06117696|Other|Animated video|delivery of written and oral information, supported by animated videos.
79400414|NCT06117657|Drug|Low dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10^11 vg/kg.
79400415|NCT06117657|Drug|Middle dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10^11 vg/kg.
79400416|NCT06117657|Drug|High dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10^12 vg/kg.
79567456|NCT05339477|Other|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
79567457|NCT05335915|Other|Nicotine|Nicotine pouches will be self-administered
79727635|NCT02686567|Procedure|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
79727636|NCT02686567|Procedure|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
79727637|NCT01200797|Drug|SJG-136|Given IV
79727638|NCT01200797|Other|laboratory biomarker analysis|Correlative studies
79727639|NCT00638677|Dietary Supplement|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
79727640|NCT00638677|Dietary Supplement|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
79727641|NCT00638677|Dietary Supplement|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
79727642|NCT02686723|Other|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
79727643|NCT01200485|Drug|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
79567458|NCT05335915|Other|Cigarette|Cigarette will be smoked
79862404|NCT00988910|Drug|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
79862405|NCT00988910|Drug|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
79862406|NCT00986336|Drug|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
79862407|NCT00986336|Drug|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
79862408|NCT00986336|Drug|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
80023285|NCT03085420|Diagnostic Test|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
79266682|NCT05610878|Biological|Cultured ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
79400417|NCT06117644|Drug|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
79567459|NCT05328037|Diagnostic Test|Blood sample collection|Blood sample collection for dosage of vitamin C
80023286|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
80023287|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
79400418|NCT06117631|Behavioral|Centering Parenting|See Arm description.
79400419|NCT06117631|Behavioral|Bright by Text|See Arm description.
79400420|NCT06117566|Drug|WX390|WX390 tablet, once a day
79400421|NCT06117566|Drug|Toripalimab|240 mg, Day 1, every 3 weeks
79266683|NCT05610878|Biological|Curcumin-preconditioned ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
79400422|NCT06117540|Drug|WX390|WX390 tablet, 1.1 mg once a day
79400423|NCT06117514|Drug|Sudapyridine 30mg|Sudapyridine capsule 30mg, orally, single dose
79400424|NCT06117514|Drug|Sudapyridine 100mg SAD|Sudapyridine tablet, 100mg orally, single dose
79400425|NCT06117514|Drug|Sudapyridine 200mg SAD|Sudapyridine tablet, 200mg orally, single dose
79567460|NCT05317533|Procedure|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
79862409|NCT00986336|Drug|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
79400426|NCT06117514|Drug|Sudapyridine 200mg MAD|Sudapyridine tablet, 200mg orally once a day for 14 days
79862410|NCT00989222|Procedure|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
79567461|NCT05303883|Other|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
79727644|NCT01200485|Drug|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
79727645|NCT02688907|Drug|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first & second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
80023288|NCT00103506|Drug|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
80023289|NCT03541746|Biological|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
80023290|NCT03541746|Device|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
80023291|NCT04992780|Radiation|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
80023292|NCT04992780|Radiation|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
80023293|NCT02158650|Behavioral|Video-Based Informed Consent|
80023294|NCT02151240|Drug|Foscarnet Sodium|
79266684|NCT05610878|Other|Conventional fat grafting|Patients will undergo conventional fat harvesting and grafting of fat into recipient site
79400427|NCT06117514|Drug|Sudapyridine 300mg MAD|Sudapyridine tablet, 300mg orally once a day for 14 days
79400428|NCT06117514|Other|Placebo tablet SAD|Placebo tablet, 100mg orally, single dose
79400429|NCT06117514|Other|Placebo 200mg SAD|Placebo tablet, 200mg orally, single dose
79400430|NCT06117514|Other|Placebo tablet MAD|Placebo tablet, 200mg orally once a day for 14 days
79400431|NCT06117514|Other|Placebo tablet MAD|Placebo tablet, 300mg orally once a day for 14 days
79862411|NCT00989222|Procedure|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
79862412|NCT00989300|Drug|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
79727646|NCT02686645|Biological|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
79727647|NCT02686645|Drug|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
79266686|NCT02706405|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Given IV
79266687|NCT02706405|Drug|Cyclophosphamide|Given IV
79266688|NCT02706405|Biological|Durvalumab|Given IV
79567464|NCT05295784|Drug|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
79567465|NCT05293925|Behavioral|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
79567466|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
79862413|NCT00989300|Drug|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
79862414|NCT00989300|Other|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
79862415|NCT04005014|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
79862416|NCT03437720|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
79862417|NCT03437720|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
79266689|NCT02706405|Drug|Fludarabine|Given IV
79400432|NCT06117501|Device|Axoguard HA+ Nerve Protector™|Axoguard HA+ Nerve Protector™ is a surgical implant that provides non-constricting protection for non-transected peripheral nerve injuries where there is no gap. Axoguard HA+ Nerve Protector™ is designed to be an interface between the nerve and the surrounding tissue.
79400433|NCT06117475|Procedure|Posterior corpectomy|Removal of posterior portion of vertebrae by posterior approach
80023295|NCT02151240|Drug|Acyclovir|
80023296|NCT02154750|Device|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
80023297|NCT02154750|Device|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
80023298|NCT02154828|Behavioral|Integrative practices|
80023299|NCT04807530|Device|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
79567467|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
79567468|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~Methotrexate 15 mg, IT, Days 36, 56"
79567469|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
79567470|NCT05284435|Behavioral|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
79581443|NCT01936298|Device|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
79727648|NCT02686645|Drug|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
79862418|NCT03393182|Procedure|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
79862419|NCT03393182|Procedure|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
80023300|NCT03736902|Other|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
80023301|NCT02159430|Other|Clinical and psychopathological assessment of HAE patients|
80023302|NCT02154984|Behavioral|behavioral dietary intervention|Follow tRD
80023303|NCT02154984|Behavioral|telephone-based intervention|Receive coaching calls
80023304|NCT02154984|Other|laboratory biomarker analysis|Correlative studies
80023305|NCT02158962|Behavioral|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
80023306|NCT03542604|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
80023307|NCT03542604|Behavioral|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
80023308|NCT02159196|Drug|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
79727649|NCT02686645|Drug|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
79727650|NCT04318067|Drug|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
79727651|NCT04185181|Other|virtual reality|wii video game based exercise
79727652|NCT04185181|Other|proprioceptive neuromuscular facilitation|PNF with breathing
79727653|NCT04185181|Other|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
79862420|NCT04005950|Device|Scalpel Bougie technique|ScalpelCric Set
79862421|NCT04005950|Device|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
79862422|NCT00986414|Drug|AFQ056|
79862423|NCT00986414|Drug|AFQ056|
79862424|NCT00986414|Drug|AFQ056|
79862425|NCT00986414|Drug|AFQ056|
80023309|NCT02159196|Drug|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
80023310|NCT02159196|Drug|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
80023311|NCT02765490|Drug|AL-335|AL-335 800 mg (2*400) tablet will be administered once daily.
80023312|NCT02765490|Drug|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
80023313|NCT02765490|Drug|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
79862426|NCT00986414|Drug|AFQ056|
79862427|NCT00986414|Drug|Placebo|
79862428|NCT05712668|Behavioral|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
80023314|NCT02159508|Behavioral|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
79400434|NCT06117462|Other|Assesment of CFS|Assesment of CFS
79862429|NCT05712668|Behavioral|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
79862430|NCT01563614|Radiation|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
79862431|NCT01563614|Drug|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
79727654|NCT01200407|Drug|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
79862432|NCT01563614|Drug|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
79862433|NCT00543296|Drug|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
79567471|NCT05284435|Behavioral|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
80023315|NCT02155062|Other|Whole grain rye|
80023316|NCT02155062|Other|Whole grain wheat|
79266690|NCT04857359|Drug|Dipraglurant|Oral 50mg and 100mg tablet
79266691|NCT04857359|Drug|Placebo|Oral matching placebo tablet
79581444|NCT01936298|Device|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
79727655|NCT04186975|Device|Non-Invasive fetal ECG|Non-Invasive fetal ECG
80023317|NCT02155062|Other|Refined cereal|
80023318|NCT03542526|Device|electrogradiogram|12 lead ecg ambulatory blood prussre
80023319|NCT03542526|Device|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
80023320|NCT02163018|Drug|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
79266692|NCT02761993|Biological|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
79266693|NCT02761993|Drug|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
79400435|NCT06117436|Drug|Cilostazol|Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
79400436|NCT06117436|Drug|Selenium|Selenium 200 mcg oral tablet once daily
79400437|NCT06117423|Drug|Adalimumab-680LT|First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.
79400438|NCT06117423|Other|Control|Fluorescence Molecular Imaging was performed to enable the visualisation and detection of fluorescence signals.
79727656|NCT04186975|Device|Fetal heart rate monitor|Fetal heart rate monitor
79727657|NCT02685085|Drug|Misoprostol ( Prostaglandin E2)|
79727658|NCT02685085|Device|Foley's catheter|
79266694|NCT05547776|Behavioral|Mindfulness app|The mindfulness app contains 6 modules with a variety of features to help caregivers reduce their stress.
79400439|NCT06117397|Other|Text Messaging Intervention|A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
79400440|NCT06117384|Genetic|Biomolecular profiling|Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
79727659|NCT02688595|Device|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
79727660|NCT02688595|Other|General anesthesia|Scheduled operation under general anesthesia
79727661|NCT01200329|Drug|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
79727662|NCT01200329|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
79727663|NCT01200329|Drug|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
79727664|NCT01200329|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
79727665|NCT01200329|Drug|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
79862434|NCT00543140|Device|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
79862435|NCT00543062|Drug|Inhaled placebo|Inhaled Staccato placebo (0 mg)
79862436|NCT00543062|Drug|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
79862437|NCT00543062|Drug|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
79862438|NCT00543062|Drug|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
79862439|NCT00543062|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
79862440|NCT05235074|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
79862441|NCT03911960|Behavioral|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
79862442|NCT03911960|Behavioral|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
79862443|NCT04005092|Device|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
79862444|NCT04004624|Device|Ablation|Cardiac Ablation
79862445|NCT03360578|Device|Garmin|A commercial grade health wearable
79862446|NCT04006574|Other|Exercises|Core stabilization
79862447|NCT05192720|Dietary Supplement|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
80023321|NCT02163018|Drug|Placebo|Subcutaneous administration of increasing doses of placebo
80023322|NCT02639182|Drug|AGS-16C3F|Intravenous (IV) infusion
80023323|NCT02639182|Drug|Axitinib|Oral
79400441|NCT06117371|Drug|BEBT-607Tablets|"PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle."
80023324|NCT02863419|Drug|semaglutide|Oral semaglutide once-daily.
80023325|NCT02863419|Drug|liraglutide|Subcutaneous (s.c.) injection once-daily.
79567472|NCT05282225|Behavioral|MI- Safety Plan|"The MI-enhanced safety plan (MI-SP) component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy"
80023326|NCT02863419|Drug|placebo|Placebo once-daily.
80023327|NCT03541668|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
79567473|NCT05282225|Behavioral|Texts messages|For participants randomized to receive supportive text messages (Texts), text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
79581445|NCT01936311|Behavioral|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
79581446|NCT01936337|Drug|DLX105 Hydrogel|topical administration on psoriatic plaque
79727666|NCT04185493|Diagnostic Test|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
79727667|NCT04186273|Drug|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
79727668|NCT04186273|Other|Vehicle moisture balancing base|Vehicle base without FS2.
79727669|NCT01199939|Drug|Etravirine|400mg once daily orally for 48 weeks
79727670|NCT01199939|Drug|Ritonavir|100mg once daily orally for 48 weeks
79727671|NCT01199939|Drug|Darunavir|800mg once daily orally for 48 weeks
79727672|NCT02688439|Other|Sciatic Nerve block|
79862448|NCT05192720|Dietary Supplement|Placebo|drinking water with food colour
79862449|NCT04006184|Other|Chart review|Retrospective review of medical records at a single site with six physicians
80023328|NCT03541668|Drug|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
80023329|NCT02155140|Dietary Supplement|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
80023330|NCT05019898|Diagnostic Test|pupillometry|"Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~The quantification of their anxiety~An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain."
80023331|NCT02155218|Other|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
79727673|NCT02688439|Other|Leg raised 30°|
79862450|NCT00986804|Drug|Decitabine|
79862451|NCT05712122|Procedure|stellate block|stellate blockade effect on Ventricular arrytmia
79862452|NCT00676091|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
79862453|NCT00676091|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
80023332|NCT02155218|Other|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
80023333|NCT02155218|Other|gadolinium contrast|
80023334|NCT03079180|Other|Strength training at 80% 1RM|Detailed in Arms section's
80023335|NCT03079180|Other|Strength training at 55% 1RM|Detailed in Arms section's
80023336|NCT02155296|Behavioral|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
80023337|NCT05020288|Drug|Orelabrutinib|Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
79862454|NCT02558933|Dietary Supplement|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
79862455|NCT02558855|Other|Thrust Joint Manipulation of the Lumbar Spine|
79862456|NCT02558855|Other|Non-thrust Joint Manipulation of the Lumbar Spine|
79727674|NCT02688439|Other|Distal tourniquet placed on the lower part of the leg|
79727675|NCT02688439|Other|Leg in a neutral position|
80023338|NCT02155374|Drug|Sliding scale insulin|
79727676|NCT02688361|Drug|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
80023339|NCT02155374|Drug|Intermediate acting insulin|
79266695|NCT04425980|Other|Modified Constraint-Induced Movement Therapy|intensive use of more affected arm in structured setting
79266696|NCT05114759|Drug|SHR-A2009|"In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
79266697|NCT05553158|Device|Compression pants|Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.
79266698|NCT05553158|Device|Embolization coils|Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.
79266699|NCT04193150|Diagnostic Test|Full pulmonary specialist assessment|Please see description for the intervention arm.
79266700|NCT02425839|Device|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
79266701|NCT02425839|Device|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
79400442|NCT06117358|Other||Descriptive cross section study
79400443|NCT06117332|Device|Visual prosthesis|"In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information."
79400444|NCT06117319|Other|Individual assistance Virtual reality training sessions|5 virtual reality training sessions where feedback will be provided to each individual by the research team
79400445|NCT06117319|Other|Collective assistance Virtual reality training sessions|4 virtual reality training sessions where feedback will be provided to the whole group by the research team and 1 session where feedback will be individual.
79400446|NCT06117306|Drug|3,4 Methylenedioxymethamphetamine|1 MDMA session
79400447|NCT06117306|Behavioral|Prolonged Exposure|11 90-minute PE sessions; initial two sessions both occurring during the first treatment visit and the remaining sessions occurring daily or every other day
79400448|NCT06117293|Device|Mosaic|1550 Fractional Laser System
79727677|NCT02688361|Drug|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
79727678|NCT02686489|Other|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher & Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
79727679|NCT02686489|Other|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
79727680|NCT01199861|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
79727681|NCT01199861|Drug|Placebo|Matching placebo capsules for oral administration.
79727682|NCT01199861|Biological|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
79727683|NCT01199861|Biological|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
79727684|NCT03196219|Drug|C16G2|C16G2
79727685|NCT03196219|Drug|Placebo|Varnish Placebo
79727686|NCT02684929|Dietary Supplement|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
79862457|NCT00812201|Device|No intervention is used. Collection of signals only.|Device received per standard of care.
79862458|NCT00678041|Drug|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
79862459|NCT00678041|Drug|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
79862460|NCT04331561|Behavioral|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
80023340|NCT02155374|Behavioral|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
79266702|NCT03546257|Device|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
79266703|NCT05553002|Other|Deneroll cervical extension traction|"Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~In the upper cervical region (C2-C4) region.~The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region."
79567474|NCT05282225|Behavioral|Monitoring|Adolescent participants will complete daily surveys for 4 weeks (including assessment of suicidal ideation, behavior, and other relevant risk and protective factors) and these will be monitored daily to identify presence of heightened suicidal ideation and presence of suicidal behavior. In addition, daily surveys will be used to determine if adolescents are sufficient responders to Phase 1 intervention.
79266704|NCT05553002|Other|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
79266705|NCT02423421|Other|Faecal microbiota transplantation|Human Stool.
79581447|NCT01936337|Drug|Placebo|topical administration on psoriatic plaque
79581448|NCT01936350|Drug|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
79266706|NCT03183219|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
79400449|NCT06117280|Other|Paraxanthine 200 mg|For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
79727687|NCT05398211|Behavioral|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
79862461|NCT03903822|Drug|PF-06700841|PF-06700841 topical cream
79862462|NCT03903822|Drug|Vehicle (Placebo)|Vehicle topical cream
79400450|NCT06117280|Other|Paraxanthine 300 mg|For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
79400451|NCT06117280|Other|Placebo|The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
79400452|NCT06117267|Device|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
79400453|NCT06116747|Behavioral|Intervention|Support for fathers of preterm infants
79862463|NCT00677807|Drug|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
79862464|NCT00677807|Drug|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
79862465|NCT04003350|Drug|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
79473359|NCT04087343|Behavioral|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
80023341|NCT02155374|Drug|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
80023342|NCT02155374|Drug|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
80023343|NCT03078712|Other|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
79581449|NCT01936350|Drug|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
79727688|NCT05398211|Behavioral|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
79266707|NCT03183219|Biological|γδ T cell|γδ T cells will be used against Liver Cancer
79400454|NCT06116292|Device|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~MESSAGING, it is a bidirectional contact area."
79581450|NCT01936402|Behavioral|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
79727689|NCT02684773|Procedure|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
79400455|NCT06116032|Diagnostic Test|Methylation Cytometry|Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
79400456|NCT06115980|Device|lead extraction (Xtrac O.S. system)|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction.~A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications"
79400457|NCT06115759|Behavioral|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
79400458|NCT06115759|Behavioral|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
79727690|NCT02684773|Procedure|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
79727691|NCT00640081|Biological|cetuximab|
79727692|NCT00640081|Drug|capecitabine|
79727693|NCT00640081|Drug|fluorouracil|
79727694|NCT00640081|Drug|leucovorin calcium|
79727695|NCT00640081|Drug|oxaliplatin|
79727696|NCT00640081|Other|immunohistochemistry staining method|
79727697|NCT00640081|Other|laboratory biomarker analysis|
79727698|NCT01199705|Biological|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
79727699|NCT02688127|Drug|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
79862466|NCT04003350|Drug|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
79862467|NCT04003350|Drug|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
80023344|NCT03078712|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
79266708|NCT03183219|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
79266709|NCT03545711|Drug|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
79400459|NCT06115720|Other|Video assisted consent|The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA. This video will aim to communicate the same information as that found in the traditional verbal consent, using an actor undergoing an anaesthetic to provide context.
79862468|NCT04003350|Drug|Meloxicam|Meloxicam 15 mg as need once per day
79862469|NCT04003350|Drug|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
79862470|NCT04003350|Drug|Metaxalone|Metaxalone 800mg TID
79862471|NCT04003350|Drug|Esomeprazole 20mg|Esomeprazole 20mg daily
79862472|NCT00748007|Drug|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
79862473|NCT00748163|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
80023345|NCT02033577|Procedure|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
80023346|NCT02033577|Procedure|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
80023347|NCT03542448|Device|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
80023348|NCT03610191|Diagnostic Test|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
79266710|NCT05552846|Radiation|thoracic radiotherapy|Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 4 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
79727700|NCT02686333|Other|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
79266711|NCT05134233|Device|Low-intensity Focused Ultrasound|LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
79266712|NCT03546959|Other|Lycra sleeve|custom-fitted lycra sleeve extending from axilla to wrist
79400460|NCT06115473|Drug|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
79400461|NCT06115473|Drug|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
79727701|NCT02688283|Other|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
79727702|NCT04185571|Device|PEPA|
79727703|NCT02686255|Other|complete blood count|complete blood count during follow up in the heart institute
79727704|NCT04185025|Drug|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
79727705|NCT04295239|Procedure|MRI|Pre and Post operative MRI
80023349|NCT03610191|Behavioral|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
79400462|NCT06115460|Drug|oral sitagliptin supplementation|oral sitagliptin supplementation for three months
79727706|NCT02688205|Other|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
79727707|NCT02688205|Device|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
79727708|NCT04136665|Other|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
79727709|NCT02684695|Other|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
79727710|NCT02684695|Other|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
79862474|NCT00748163|Drug|sunitinib malate|
79862475|NCT00748319|Other|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
80023350|NCT03610191|Procedure|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
80023351|NCT04434118|Drug|Traditional antirheumatic drugs|Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
80023352|NCT02765100|Drug|Minocycline|Minocycline 100 mg twice a day
80023353|NCT05007574|Device|Microphone MI-305|Remote data collection
80023354|NCT02033655|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
80023355|NCT02033655|Behavioral|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
79266713|NCT03546959|Other|Rehabilitation|Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
79266714|NCT03546959|Drug|Botulinum Toxin|Botulinum toxin injection for upper limb spasticity after stroke
79266715|NCT04164836|Diagnostic Test|rhinoscope|more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
79304358|NCT03288935|Behavioral|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R&P service period (i.e., 60 days).
79400463|NCT06114836|Drug|Omeprazole|Omeprazole will be the PPI prescribed for 4 weeks.
79400464|NCT06114836|Other|AR formula|Added rice formula will be ordered for 4 weeks.
79400465|NCT06114810|Biological|polio vaccines: nOPV2, bOPV, IPV|Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
79862476|NCT00748397|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
80023356|NCT02159664|Other|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
80023357|NCT03091894|Drug|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
79266716|NCT03791645|Behavioral|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (~3 hours/day), followed by 4 weekly follow-ups (~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
79400466|NCT06114602|Behavioral|E-Mail Reminder|Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.
79400467|NCT06114472|Drug|aromatherapy blend containing Lavender|hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
79400468|NCT06114446|Other|simulation group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
79400469|NCT06114446|Other|immersive virtual reality|Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
79400470|NCT06114446|Other|observation|All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
79400471|NCT06114368|Procedure|Surgery for the treatment of Acute Achilles tendon rupture|Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
79400472|NCT06114329|Drug|AL01211|AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
79400473|NCT06114277|Other|ETCO2 levels|Intraoperative ETCO2 values between 26 and 34 in laparoscopic robotic prostatectomy patients were included in group 1.
79400474|NCT06114277|Other|Patients with high ETCO2 levels|Intraoperative ETCO2 values between 35 and 45 in laparoscopic robotic prostatectomy patients were included in group 2.
79400475|NCT06113744|Biological|Placebo|saline
79400476|NCT06113744|Biological|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
79400477|NCT06113744|Biological|COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|Low-dose
79400478|NCT06113744|Biological|COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|Mid-dose
79400479|NCT06113744|Biological|COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg|High-dose
79400480|NCT06113731|Biological|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
79400481|NCT06113731|Biological|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
79727711|NCT04184947|Drug|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
79862477|NCT00687401|Biological|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
79862478|NCT00485693|Drug|Bupivacaine HCl|150 mg Bupivacaine HCl
79862479|NCT00485693|Drug|SKY0402|600 mg SKY0402 (study drug)
79862480|NCT00748475|Behavioral|Neurofeedback|
79400482|NCT06113731|Biological|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
79400483|NCT06113432|Diagnostic Test|Arterial blood gases|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
80023358|NCT03091894|Drug|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
79400484|NCT06113432|Diagnostic Test|Respiratory rate (RR)|Measurement of respiratory rate by waveform analysis using a ventilator
79400485|NCT06113432|Diagnostic Test|Pulseoximeter|Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
79400486|NCT06113432|Diagnostic Test|Assessment of accessory respiratory muscles work|Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
79400487|NCT06113432|Diagnostic Test|Esophageal pressure measurement|Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
79400488|NCT06113432|Diagnostic Test|Discomfort Visual Analog Scale (VAS)|From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
79400489|NCT06113432|Diagnostic Test|Noninvasive blood pressure|Noninvasive blood pressure
79727712|NCT04184947|Drug|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
79862481|NCT00538902|Biological|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
79862482|NCT00538902|Biological|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
79862483|NCT00538902|Biological|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
79862484|NCT00541970|Biological|Cervarix|Intramuscular injection, different dosing /schedule
79862485|NCT00541970|Drug|Placebo|Intramuscular injection, different dosing /schedule
79862486|NCT00687323|Drug|temozolomide|
79862487|NCT00989742|Drug|Doxycycline|50mg od
79862488|NCT00989742|Drug|Placebo|50mg od
79266717|NCT03183531|Diagnostic Test|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
79400490|NCT06113432|Diagnostic Test|Heart rate|Heart rate calculation using electrocardiogram monitoring
79400491|NCT06112860|Device|Over the counter hearing aid|An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.
79266718|NCT05552768|Procedure|Bone level-driven placement|The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
79266719|NCT05552768|Procedure|Biological width-driven placement guidelines|Biological width-driven placement guidelines
79727713|NCT04186507|Combination Product|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
79862489|NCT05408208|Drug|Intralesional Injection of Methotrexate|"One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment ."
79567475|NCT05282225|Behavioral|Portal follow-up|This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.
79581451|NCT01936415|Device|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
79727714|NCT02684383|Biological|rDEN3∆30|10^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
79862490|NCT05408208|Drug|Triamcinolone Acetonid|One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
79727715|NCT02684383|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
79862491|NCT02559245|Other|Descurainia Sophia|
79862492|NCT02559245|Other|Ficus carica|
79862493|NCT05358756|Drug|SACT-1|Single administartion of 150mg SACT-1
80023359|NCT05014594|Drug|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
79266720|NCT01569659|Drug|Lurasidone|80 mg/day for up to 30 weeks
79266721|NCT01569659|Drug|Lurasidone|Up to 240 mg/day for up to 30 weeks
79266722|NCT02423187|Other|No Intervention|
79266723|NCT04111406|Drug|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
79304359|NCT03288935|Behavioral|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation & resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
79304360|NCT04971369|Diagnostic Test|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
79400492|NCT06112860|Behavioral|Communication Strategies Information/Counseling|Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.
79400493|NCT06109961|Drug|Oxygen Gas for Inhalation|The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
79862494|NCT05358756|Drug|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
79862495|NCT00758615|Behavioral|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
79862496|NCT00758693|Drug|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
79862497|NCT00758693|Drug|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
79862498|NCT01564212|Other|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
79862499|NCT01564212|Other|laminar airflow with surgical drapes|
79727716|NCT04186351|Behavioral|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call & care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
79862500|NCT01564212|Other|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
79266724|NCT04111406|Drug|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~insertion at mid-level of surgical insertion~insertion depth is 3-5 cm in space, not more than 5 cm~using benzoin tincture and transparent dressing to fix catheter~test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
79862501|NCT01564212|Other|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
79862502|NCT05407896|Other|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
79862503|NCT00989820|Drug|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
79862504|NCT00748631|Device|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
79266725|NCT03183453|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
79266726|NCT05547308|Device|3D myoelectric prosthetic device|All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
79266727|NCT02253953|Drug|BILR 355 BS, D1|
79266728|NCT02253953|Drug|BILR 355 BS, D2|
79567476|NCT05282225|Behavioral|Booster call|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
79567477|NCT05278962|Drug|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
79567478|NCT05278962|Other|No SGLT2i|No SGLT2i
79567479|NCT05278130|Other|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
79727717|NCT00638833|Drug|Memantine|Memantine 30 mg/day (20-10-0)
79862505|NCT04742114|Device|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
79862506|NCT04742114|Device|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
79862507|NCT00758849|Drug|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
79266729|NCT02253953|Drug|BILR 355 BS, D3|
79266730|NCT02253953|Drug|BILR 355 BS, D4|
79266731|NCT02253953|Drug|BILR 355 BS, D5|
79266732|NCT02253953|Drug|BILR 355 BS, D6|
79266733|NCT02253953|Drug|BILR 355 BS, D7|
79266734|NCT02253953|Drug|BILR 355 BS, D8|
79266735|NCT02253953|Drug|BILR 355 BS, D10|
79266736|NCT02253953|Drug|Placebo|
79266737|NCT02253953|Other|high-fat breakfast|
79400494|NCT06109961|Other|Standard of care|The accepted standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission.
79266738|NCT02253953|Drug|Ritonavir|
79266739|NCT05547230|Other|questionnaires|The same tests will be applied to all participants in an objective way.
79567481|NCT05268107|Drug|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
79727718|NCT00638833|Drug|Placebo|Placebo pills
79266740|NCT03546803|Other|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
79266741|NCT02422953|Dietary Supplement|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
79567482|NCT05259722|Drug|Delgocitinib|Cream for topical application 20 mg/g
79727719|NCT01198145|Drug|sulfasalazine|Given orally
79567483|NCT05259722|Drug|Toctino|1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
79727720|NCT01198145|Other|placebo|Given orally
79266742|NCT02422953|Dietary Supplement|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
79567484|NCT05249959|Drug|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~Rituximab 375 mg/m2 i.v. Day 1~Bendamustine 70 mg/m2, Days 2 and 3~Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
79567485|NCT05249959|Drug|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~Rituximab 375 mg/m2 i.v. Day 1~Bendamustine 70 mg/m2, Days 2 and 3~Cytarabine 500 mg/m2, Day 2 and 3~or~Rituximab 375 mg/m2 i.v. Day 1~Bendamustine 100 mg, Days 2 and 3~Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
79567486|NCT05247255|Drug|Active Comparator|QL block with 0.25% ropivacaine
79727721|NCT02684539|Device|tilt table Erigo®|tilting table with onset of syncope
79727722|NCT02687737|Procedure|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
79266743|NCT02422953|Dietary Supplement|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
79266744|NCT02422953|Behavioral|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
79266745|NCT04053140|Device|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
79266746|NCT04053140|Device|Microneedle array and closed-loop control of penicillin delivery|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
79567487|NCT05247255|Drug|Placebo Comparator|QL block with saline
79727723|NCT02687737|Procedure|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
79727724|NCT02687737|Procedure|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
79266747|NCT04053140|Drug|Penicillin G_1200mg|Benzylpenicillin IV 1200mg administered every 4 hours.
79266748|NCT04053140|Drug|Penicillin G_2400mg|Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
79266749|NCT04053140|Drug|Penicillin G_600mg/hr|Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
79266750|NCT02766283|Drug|iodinated contrast agents|Intravascular application
79567488|NCT05236699|Combination Product|DEB-TACE combined with Surufatinib and Camrelizumab|"All patients will be treated with standard DEB-TACE on the first day (D1).~After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
79581452|NCT01936415|Device|Regenerex|
79581453|NCT01936428|Other|interview|
79862508|NCT00758849|Drug|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
79862509|NCT05334186|Behavioral|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
79266751|NCT05547152|Other|massages|The experimental rehabilitation protocol includes massages
79266752|NCT05547152|Other|motor stimulation and stretching|motor stimulation and stretching
79266753|NCT05547152|Other|virtual reality|Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
79727725|NCT02687737|Behavioral|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
79266754|NCT04597541|Drug|AK112|AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
79400495|NCT06106360|Device|Locus Health iPhone App|In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
79266755|NCT03182985|Behavioral|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
79400496|NCT06105216|Other|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
79567489|NCT05231629|Drug|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
79567490|NCT05231629|Drug|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
79567491|NCT05231629|Drug|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
79567492|NCT05231629|Drug|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
79266756|NCT03118089|Dietary Supplement|Biscuit style oral nutritional supplement|
79567493|NCT05231629|Drug|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
79567494|NCT05229263|Diagnostic Test|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
79567495|NCT05180110|Diagnostic Test|Venepuncture|Venous blood draw
79567496|NCT05180110|Diagnostic Test|Fingerstick|Capillary blood draw
79567497|NCT05173298|Drug|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
79862510|NCT05070884|Other|The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer|Evaluate response to neoadjuvant treatment in advanced breast cancer
79266757|NCT03106935|Drug|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
79266758|NCT03106857|Other|Group A|Group A Physical activity and low caloric diet for
79266759|NCT02422407|Procedure|Biopsy|Salivary Gland
79400497|NCT06104527|Combination Product|Standard protein enteral nutrition with enteral tracer|Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-[1-13C]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
79567498|NCT05165485|Drug|Revefenacin|Revefenacin DoseA
79567499|NCT05165485|Drug|Tiotropium|Tiotropium DoseB
79567500|NCT05165485|Drug|Revefenacin Placebo|Placebo for Revefenacin administered with Tiotropium
79727726|NCT02686099|Device|SternaLock 360|Sternal closure with SternaLock 360
79727727|NCT02686099|Device|Wire Cerclage|Sternal closure with standard wire cerclage
79862511|NCT05357820|Drug|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14~Day28, single dose AB-106 at Day17
79266760|NCT03985904|Other|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
79266761|NCT03107169|Other|FMT|Patients in the FMT group received FMT-FURM
79266762|NCT03107169|Drug|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
79266763|NCT05552300|Procedure|SAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
79266764|NCT05552300|Drug|traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
79567501|NCT05165485|Drug|Tiotropium Placebo|Placebo for Tiotropium administered with Revefenacin
79567502|NCT05165381|Device|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
79567503|NCT05163964|Behavioral|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
79727728|NCT02688049|Biological|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
79727729|NCT02688049|Biological|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
79727730|NCT02687893|Behavioral|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
79727731|NCT02687893|Behavioral|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
79727732|NCT04317677|Other|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
79727733|NCT01197911|Drug|aleglitazar|single oral dose
79567504|NCT05159388|Drug|PRS-344/S095012|PRS-344/S095012 Monotherapy
79727734|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily
79266765|NCT02425683|Drug|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
79567505|NCT05150990|Behavioral|Virtual Reality|Older adults (residents of senior living communities) will engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions will include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children will be participating remotely from their own homes.
79567506|NCT05150990|Behavioral|Video Chat|Older adults (residents of senior living communities) will engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children will be participating remotely from their own homes.
79727735|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
79727736|NCT01197755|Drug|placebo|Placebo twice daily
79727737|NCT01179048|Drug|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
79727738|NCT01179048|Drug|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
79727739|NCT00603265|Drug|ADL5859|
79727740|NCT00603265|Drug|Duloxetine|
79727741|NCT00603265|Drug|Placebo|
79727742|NCT02686177|Drug|Liraglutide|
79727743|NCT02686177|Drug|Metformin or sulfonylurea|
79862512|NCT05357820|Drug|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14~Day32, single dose AB-106 at Day21
80023360|NCT05014594|Drug|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
79266766|NCT05547074|Procedure|pancreatic cancer surgery|Surgical resection of pancreatic cancer，including radical or palliative surgery
79266767|NCT02425917|Device|geko|neuromuscular electrostimulator
79567507|NCT05148078|Other|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
79862513|NCT00748787|Drug|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
79862514|NCT00748787|Drug|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
79862515|NCT05712044|Drug|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
79862516|NCT05360316|Device|ESWT|extracorporeal shock wave therapy
79727744|NCT04010227|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
79727745|NCT04010227|Behavioral|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
79727746|NCT02885298|Procedure|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
79727747|NCT00639613|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
79862517|NCT04059731|Dietary Supplement|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
79266768|NCT02425917|Device|IPC-Calf|IPC used on calf with or without geko
79567508|NCT05140525|Drug|Macitentan Tablets|10 mg oral once daily
79567509|NCT05140525|Drug|Riociguat|1 mg to 2.5mg oral three times daily
79862518|NCT05407740|Other|no intervention study|no intervention study
79862519|NCT00986960|Drug|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
79862520|NCT00986960|Drug|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
79862521|NCT00758927|Drug|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
79862522|NCT00758927|Drug|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
79862523|NCT05711966|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
79862524|NCT05711966|Device|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
80023361|NCT03609645|Procedure|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
79266769|NCT02425527|Behavioral|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
79304361|NCT03293537|Diagnostic Test|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
80023362|NCT03609645|Procedure|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
79304362|NCT04979091|Diagnostic Test|Sex Hormones|A panel of 13 hormones was measured in plasma samples of COVID-19 patients (total testosterone, free testosterone, dihydrotestosterone, androstenedione, 17-β-estradiol, estrone, sex hormone-binding globulin, thyroid-stimulating hormone, free triiodothyronine (T3), free thyroxine (T4), luteinizing hormone, follicle-stimulating hormone and cortisol).
79304363|NCT03288857|Device|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
79567510|NCT05140525|Device|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
79567511|NCT05136027|Other|Combined training|Low-intensity interval training and resistance exercise
79567512|NCT05130658|Device|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
79567513|NCT05130658|Other|Treadmill Training|Conventional gait and balance training using treadmill.
79567514|NCT05129787|Procedure|Surgical resection|Resection of metastasis
79567515|NCT05129787|Procedure|Thermal ablation|Ablation of metastasis
79581454|NCT01936441|Behavioral|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
79581455|NCT01936441|Behavioral|Menopause Education Control (MEC)|See Experimental Arm Description
79862525|NCT05407506|Diagnostic Test|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
79727748|NCT00639613|Other|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
79727749|NCT02686021|Drug|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
79862526|NCT00759005|Drug|propranolol and cortisol|
79400498|NCT06104527|Combination Product|High protein enteral nutrition with enteral tracer|Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-[1-13C]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
79266770|NCT02425527|Behavioral|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
80023363|NCT02761980|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
79304364|NCT04979013|Other|Smoking Abstinence|Smokers will be switched to smoking abstinence for 14 days
79400499|NCT06102980|Device|Transparietal ultrasound (US)-based shear wave elastography (SWE)|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
79727750|NCT02686021|Drug|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
79727751|NCT02686021|Drug|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
79727752|NCT02886390|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
79727753|NCT02685787|Behavioral|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
79727754|NCT02685787|Behavioral|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
79727755|NCT04186039|Diagnostic Test|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
79567516|NCT05110313|Biological|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
79567517|NCT05106296|Drug|Ibrutinib|Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
79567518|NCT05106296|Drug|Indoximod|Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
79567519|NCT05106296|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
79567520|NCT05106296|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
79581456|NCT01936493|Genetic|DNA analysis|At a future time DNA analysis will be performed
79727756|NCT01158534|Drug|celecoxib|Given orally
79727757|NCT01158534|Biological|recombinant interferon alfa-2b|Given subcutaneously
79727758|NCT01158534|Other|polymerase chain reaction|Correlative studies
79727759|NCT01158534|Other|laboratory biomarker analysis|Correlative studies
79862527|NCT04360070|Drug|Ketamine Hydrochloride|Parenteral General Anesthetic
79862528|NCT00748943|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
79862529|NCT04354688|Device|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
79862530|NCT00749021|Drug|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
79862531|NCT00749021|Drug|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
79862532|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
79727760|NCT01158534|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
79567521|NCT05106192|Device|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
79567522|NCT05106192|Drug|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
79567523|NCT05106192|Drug|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
79266771|NCT03985202|Other|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
79567524|NCT05106192|Drug|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
79727761|NCT01158534|Other|immunologic technique|Correlative studies
79727762|NCT01158534|Other|immunohistochemistry staining method|Correlative studies
79727763|NCT01158534|Other|flow cytometry|Correlative studies
79727764|NCT02687971|Drug|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
79727765|NCT02685631|Other|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
79727766|NCT02683213|Drug|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
79727767|NCT02683213|Drug|Placebo|Matching placebo.
79727768|NCT04185103|Drug|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
79727769|NCT04033939|Drug|HSK3486|
79727770|NCT04033939|Drug|Propofol|
79727771|NCT04033939|Drug|Placebo|
79727772|NCT02685943|Behavioral|Psychotherapy|
79862533|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
79862534|NCT04733846|Other|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
79862535|NCT05407350|Diagnostic Test|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine [DICOM] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
80023364|NCT02761980|Drug|Ibuprofen 250 mg|Ibuprofen 250 mg
79727773|NCT00639691|Biological|omalizumab|sc
80023365|NCT02761980|Drug|Acetaminophen 500 mg|1 APAP 500 mg caplet
79266772|NCT02425605|Radiation|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
79266773|NCT02425605|Drug|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
79567525|NCT05106192|Device|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
79567526|NCT05103007|Procedure|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
79567527|NCT05103007|Procedure|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
79727774|NCT02684149|Procedure|relational touch|
79727775|NCT02684071|Drug|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
79727776|NCT02684071|Drug|topotecan|To be administered in conjunction with methotrexate
79727777|NCT02684071|Drug|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
79727778|NCT01158378|Device|Adherus Dural Sealant|In situ polymerizing sealant
79727779|NCT00640861|Biological|CpG oligodeoxynucleotide|
79727780|NCT00640861|Biological|HER-2/neu peptide vaccine|
79727781|NCT00640861|Biological|MUC-1 peptide vaccine|
79727782|NCT00640861|Biological|incomplete Freund's adjuvant|
79727783|NCT00640861|Biological|sargramostim|
79727784|NCT00640861|Other|immunoenzyme technique|
79727785|NCT00640861|Other|immunologic technique|
80023366|NCT02761980|Drug|Placebo|Placebo tablet
79266774|NCT03117465|Other|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
79727786|NCT04184011|Device|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
79727787|NCT04183855|Dietary Supplement|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
79266775|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
79727788|NCT04183855|Dietary Supplement|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
79727789|NCT04183855|Behavioral|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
79862536|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
79567528|NCT05100966|Other|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
79567529|NCT05096611|Behavioral|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
79567530|NCT05096611|Behavioral|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
79862537|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
79862538|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
79266776|NCT03978806|Behavioral|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
79266777|NCT03978806|Other|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
79567531|NCT05094128|Drug|Upadacitinib|Tablet; Oral
79727790|NCT04184089|Device|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
79727791|NCT04184089|Device|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
79862539|NCT04005560|Other|no interventional study|no interventional study
79862540|NCT04901442|Device|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body & help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
79727792|NCT04184089|Device|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
79727793|NCT01158222|Drug|sunitinib malate|Given orally
79862541|NCT00987038|Drug|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
79862542|NCT00987038|Drug|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
79266778|NCT02422563|Procedure|hysterectomy|radical hysterectomy
79266779|NCT02422563|Radiation|Radiation|
79266780|NCT02422563|Drug|Cisplatin|
79266781|NCT02422563|Drug|Paclitaxel|
79266782|NCT02422563|Drug|Carboplatin|
79266783|NCT02422563|Drug|Ifosfamide|
79266784|NCT03545633|Device|Treatment with High Intensity Focused ElectroMagnetic system.|"The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area.~Visible contractions will be induced by the device."
79266785|NCT03185403|Other|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
79727794|NCT02682979|Other|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
79862543|NCT00761033|Behavioral|music|
79862544|NCT05711810|Drug|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
79266786|NCT03185403|Other|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
79266787|NCT03185403|Drug|ropivacaine|
79266788|NCT03185403|Drug|Sufentanil|
79727795|NCT02886780|Behavioral|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
79727796|NCT02886780|Behavioral|Self-help|
79727797|NCT02684305|Drug|Administration of Propess|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
79727798|NCT02684305|Device|balloon|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
79727799|NCT02684305|Drug|Intravenous oxytocin infusion|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
79727800|NCT02885376|Device|Dentoxol|Mouthrinse
79727801|NCT02885376|Device|Placebo|Mouthrinse
79862545|NCT05711810|Diagnostic Test|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
79862546|NCT05711810|Behavioral|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
79266789|NCT02422485|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
79567532|NCT05092880|Device|radioembolization|holmium-166 microspheres
79266790|NCT05551910|Drug|Esketamine|The patients in the test group were given esmketamine (50mg / 2ml * branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was < 3 points. The dose of esketamine was adjusted according to the cpot score.
79266791|NCT05551910|Drug|Remifentanil|Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
79567533|NCT05092880|Drug|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
79567534|NCT05087030|Drug|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
79567535|NCT05087030|Drug|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
79727802|NCT02940769|Device|light glasses|light glasses
79727803|NCT02940769|Device|sham glasses (placebo)|sham light glasses
79727804|NCT04315584|Procedure|Positron Emission Tomography|Undergo PET/CT Scans
79862547|NCT05711810|Drug|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
79862548|NCT05711810|Drug|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
79862549|NCT05711810|Drug|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
79266792|NCT05551910|Drug|propofol|propofol
79567536|NCT05081479|Drug|N-Acetylcysteine|N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients <45kg will be adjusted to weight based dosing.
79567537|NCT05071209|Drug|Elimusertib|Given PO
79567538|NCT05050214|Drug|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
79862550|NCT05711810|Dietary Supplement|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
79567539|NCT05044273|Device|Synergy XD stent or Synergy Megatron™ Stent|Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
79567540|NCT05042687|Drug|Tc99m sestamibi|Given by IV
79567541|NCT05035173|Other|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
79727805|NCT04315584|Procedure|Computed Tomography|Undergo PET/CT Scans
79567542|NCT05035173|Other|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
79727806|NCT04315584|Procedure|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
79862551|NCT05711810|Dietary Supplement|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
79862552|NCT05711810|Dietary Supplement|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
79862553|NCT05711810|Drug|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
79862554|NCT05711810|Drug|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
79862555|NCT00759083|Drug|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
79862556|NCT04864236|Device|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
79862557|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
79862558|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
79862559|NCT00761111|Behavioral|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
79862560|NCT03899064|Drug|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79862561|NCT03899064|Drug|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79862562|NCT03899064|Drug|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79581457|NCT01936493|Other|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
79581458|NCT01936506|Behavioral|Cognitive Training A|
79862563|NCT03899064|Drug|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
79266793|NCT03608423|Device|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
79727807|NCT04315584|Radiation|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
79581459|NCT01936506|Behavioral|Cognitive Training B|
79727808|NCT04315584|Radiation|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
79727809|NCT02683993|Device|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
79727810|NCT02683291|Drug|sirolimus|
79727811|NCT02683291|Drug|tacrolimus|
79727812|NCT02683291|Drug|mycophenolate|
79727813|NCT02683291|Drug|Prednisone|Prednisone 30mg/day
79727814|NCT02683291|Drug|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
79727815|NCT02683291|Drug|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
79727816|NCT02685865|Device|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
79727817|NCT02685865|Device|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
79727818|NCT02685397|Drug|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
79727819|NCT02685397|Drug|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
79862564|NCT03899064|Drug|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
79862565|NCT03899064|Drug|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
79862566|NCT03899064|Drug|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
79727820|NCT02685397|Drug|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
79567543|NCT05035173|Other|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
79266794|NCT02430753|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
79266795|NCT02430753|Device|NanoKnife|
79266796|NCT03546179|Other|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded.
79266797|NCT03546179|Other|Volume loading|After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight).
79266798|NCT05551676|Procedure|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
79862567|NCT03899064|Drug|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
79266799|NCT05551676|Procedure|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
79862568|NCT03899064|Drug|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
79862569|NCT03742908|Drug|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
79862570|NCT05357274|Diagnostic Test|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
79266800|NCT02430675|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
79266801|NCT02430675|Device|NanoKnife|
79266802|NCT05039567|Behavioral|optimal heart team protocol|Heart teams in the experimental group will be established and trained based on the optimal heart team implementation protocol. The protocol included instructions on specialist selection, specialist training, team composition, team training and formal implementation precess.
79266803|NCT05699720|Drug|Nebulized Magnesium Sulphate|Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
79266804|NCT02421471|Drug|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
79266805|NCT04578509|Diagnostic Test|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
79266806|NCT04578509|Diagnostic Test|Saliva sample|Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
79266807|NCT04578509|Diagnostic Test|axillary sweat sample|Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
79266808|NCT04578509|Other|Data collection|Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
79567544|NCT05031949|Combination Product|hyperbaric oxygen therapy plus Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
79727821|NCT02685397|Drug|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
79727822|NCT02685397|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
79266809|NCT05546762|Drug|Povidone-iodine solution|Pleural irrigation with 2% povidone iodine
79266810|NCT05546762|Drug|Normal saline|Pleural irrigation with normal saline
79266811|NCT02421549|Device|Unpaired remote monitoring transmitter|
79266812|NCT05546684|Other|footbath|footbath for patients before sleeping
79727823|NCT02682745|Drug|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
79727824|NCT02682745|Drug|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
79727825|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily
79727826|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
79266813|NCT02422719|Drug|Radotinib|Radotinib 400mg bid
79567545|NCT05018806|Drug|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
79567546|NCT05018806|Drug|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
79567547|NCT05003895|Drug|Cyclophosphamide|Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
79567548|NCT05003895|Biological|CAR-T cell|Single infusion on Day 0
79567549|NCT05003895|Drug|Fludarabine|Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
79567550|NCT05000138|Diagnostic Test|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
79567551|NCT04996966|Biological|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
79727827|NCT01197521|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
79862571|NCT05407116|Other|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
79862572|NCT04003194|Other|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
79862573|NCT04003194|Other|Green Beans - control|The control was 1/2 cup of green beans each day.
79862574|NCT05406960|Dietary Supplement|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
79862575|NCT05406882|Drug|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
79862576|NCT01564134|Biological|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
79567552|NCT04996966|Other|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
79567553|NCT04987957|Other|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
79727828|NCT02683915|Procedure|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
79862577|NCT05357196|Drug|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
79862579|NCT03902574|Drug|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
79862580|NCT03902574|Drug|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
79567554|NCT04966455|Dietary Supplement|Raisins|Daily supplementation of 50 g of rainsins for 3 months
79727829|NCT02683837|Drug|Remifentanil|
79727830|NCT02683837|Device|Pupillometry|Pupillary diameter measured every 5 minutes
79727831|NCT02683837|Drug|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
79567555|NCT04965155|Drug|Isatuximab-dexamethasone|Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
79567556|NCT04958707|Other|Information including knowledge and skills related to dementia patient care|The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
79727832|NCT02002507|Other|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
79727833|NCT01157676|Procedure|Open radical cystectomy|Standard of care removal of urinary bladder.
79567557|NCT04958707|Other|Usual care|Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
79567558|NCT04957147|Other|12 months of guideline-directed heart failure therapy|Standard guideline-directed heart failure drug +/- device therapy
79567559|NCT04946734|Device|PFO closure device|Device PFO closure.
79567560|NCT04946734|Drug|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
79567561|NCT04946734|Drug|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
79567562|NCT04944888|Drug|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
79567563|NCT04944888|Drug|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
79581460|NCT01936545|Drug|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
79581461|NCT01936545|Drug|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
79567564|NCT04934176|Other|Psychosocial scales/questionnaires|We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
79727834|NCT01157676|Procedure|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
79862581|NCT03902574|Drug|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
79567565|NCT04934176|Other|3D Facial Measurements|3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
79727835|NCT01157676|Device|DaVinci robot|DaVinci robotic surgical system.
79862582|NCT04646850|Other|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
79862583|NCT01564290|Dietary Supplement|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
79862584|NCT01564290|Drug|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
79862585|NCT01004874|Drug|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
79862586|NCT01004874|Drug|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
79862587|NCT01004874|Radiation|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
79862588|NCT01004874|Drug|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
79862589|NCT05356026|Other|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
80023367|NCT04577157|Behavioral|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~Daily notes for medication reminders,~Daily a voice message with the same content will be delivered.~Daily Graphics-based Reminder (GBR).~Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~Once-weekly lifestyle advice through video~Hypertension at a glance, complete information will be provided(Optional)~24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
80023368|NCT05007496|Biological|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
80023369|NCT03609567|Other|Aromatherapy|Aromatherapy using essential oils
79727836|NCT02680873|Other|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
79727837|NCT04183543|Device|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
79862590|NCT04002804|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
79862591|NCT05355948|Device|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
80023370|NCT03609567|Other|Placebo|Aromatherapy using odorless placebo oil
79727838|NCT04183543|Device|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
79727839|NCT02680951|Drug|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
79567566|NCT04924101|Biological|Pembrolizumab|IV infusion
79567567|NCT04924101|Biological|MK-4830|IV infusion
79567568|NCT04924101|Biological|Boserolimab|IV infusion
79567569|NCT04924101|Drug|Lenvatinib|Oral capsule
79567570|NCT04924101|Drug|Etoposide|IV infusion
79567571|NCT04924101|Drug|Cisplatin|IV infusion
79727840|NCT02680951|Drug|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
79862592|NCT05355948|Device|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days ~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
79567572|NCT04924101|Drug|Carboplatin|IV infusion
79727841|NCT02680951|Drug|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
79862593|NCT04302818|Behavioral|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
79862594|NCT04302818|Behavioral|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
79862595|NCT00987116|Drug|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
79862596|NCT04866680|Procedure|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
79266814|NCT05026775|Behavioral|Initial Medication Adherence (IMA)|"The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals."
79862597|NCT05711732|Diagnostic Test|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
79862598|NCT04006340|Combination Product|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
79862599|NCT04006340|Combination Product|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
79862600|NCT04006340|Diagnostic Test|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
79862601|NCT05711654|Behavioral|Health coaching|Coaching interview will be held with patients at regular intervals.
79862602|NCT04005326|Procedure|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
79862603|NCT04005326|Procedure|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest & iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
79862604|NCT04005326|Procedure|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
79266815|NCT05026775|Other|Usual care|Health professionals in the usual care group will prescribe medication and provide information as usual.
79266816|NCT02422329|Behavioral|Questionnaires|Participants complete questionnaires at baseline and after intervention.
79266817|NCT02422329|Behavioral|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
79266818|NCT02422329|Behavioral|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
79567573|NCT04921943|Drug|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
79567574|NCT04921943|Drug|Azithromycin|Standard of care
79567575|NCT04921943|Drug|Ethambutol|Standard of care
79567576|NCT04921943|Drug|Rifampin|Standard of care
79567577|NCT04919382|Biological|Atezolizumab|Given IV
79727842|NCT02680951|Drug|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
79567578|NCT04919382|Drug|Temozolomide|Given PO
79581462|NCT01936558|Other|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
79266819|NCT05551598|Drug|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 12 weeks (Q12W)
79400500|NCT06102980|Device|Vibration-controlled transient elastography (VCTE)|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an XL probe will be based on a VCTE automatic probe selection tool prompt.
79266820|NCT02421393|Other|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
79266821|NCT02421315|Behavioral|CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment|CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
79400501|NCT06102980|Device|Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE)|EUS-SWE will be performed by an experienced endoscopist, who will be blinded to any clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). The patient must be lying in the supine position. Based on the premise that as fibrosis progresses the distribution becomes heterogeneous, both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. After the patient suspended respiration for a few seconds, the elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kPa measurements will be obtained.
79400502|NCT06102720|Drug|Colchicine|Oral colchicine will be initiated with a dose of 0.5 mg per day during 14 days. Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).
79400503|NCT06102720|Drug|Clopidogrel|Dual antiplatelet therapy includes ASA (300 mg on days 1 and continuing with 100 mg/day) and clopidogrel (300 mg on days 1 and continuing with 75 mg/day).
79567579|NCT04907045|Behavioral|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
79727843|NCT02680951|Drug|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~30 mg for patients age 1 - 1.99~50 mg for patients age 2 - 2.99~70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
79727844|NCT02680717|Drug|Clobetasol|ointment, twice daily (alternating weeks)
79727845|NCT02680717|Drug|Calcipotriene|ointment, twice daily
79862605|NCT04004702|Drug|Levetiracetam|Levetiracetam 500mg twice a day
79862606|NCT00542828|Biological|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
79862607|NCT04533074|Biological|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
80023371|NCT05007340|Other|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
79400504|NCT06100692|Drug|Vitamin D|the patients will receive a 30 pts a combination of oral vit D and zinc
79567580|NCT04907045|Behavioral|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
79567581|NCT04907045|Behavioral|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
79727846|NCT02680717|Drug|Tacrolimus|ointment, 0.1%, twice daily
79727847|NCT05663983|Behavioral|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
79727848|NCT04182529|Device|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
79266822|NCT02422251|Device|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
79567582|NCT04905290|Device|Left ventricular coronary sinus configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle.
79266823|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
79727849|NCT04182529|Other|Sham|Sham, no active stimulation will be given to subjects
79727850|NCT02680795|Drug|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
79727851|NCT00640237|Dietary Supplement|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
79727852|NCT02683759|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
79727853|NCT02683759|Drug|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
79862608|NCT04533074|Biological|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
79266824|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
79266825|NCT02421081|Procedure|vessel microsurgery|That is a surgery ro repair artery laceration.
79266826|NCT02421081|Procedure|tendon repair|That is a surgery ro repair tendon cut.
79266827|NCT02421081|Procedure|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
79266828|NCT03758222|Device|XFLO Expander System|Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)
79266829|NCT03179007|Biological|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
79400505|NCT06100185|Device|PeakSleep|The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of <14 minutes with a maximum dose of 1mA (500uA per electrode pair).
79567583|NCT04905290|Device|Conduction system pacing-only configuration|Conduction system pacing (CSP) of the left bundle branch.
79266830|NCT02421237|Behavioral|Narrative Enhancement and Cognitive Therapy|
79266831|NCT02421237|Behavioral|Supportive Group Therapy|
79266832|NCT05551442|Procedure|To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.|The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
79266833|NCT05551442|Device|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
79567584|NCT04905290|Device|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of left ventricle (LV) pacing and conduction system pacing (CSP) of the left bundle branch.
79567585|NCT04891640|Other|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
79567586|NCT04891640|Other|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~Adalimumab- from every 2 to 3 weeks~Certolizumab- from every 2 to 4 weeks~Etanercept- from every 1 to 2 weeks~Golimumab- from every 4 to 6 weeks~Infliximab- from baseline to baseline + 2 weeks"
79727854|NCT02682589|Procedure|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
79727855|NCT02682589|Procedure|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
79727856|NCT03072433|Behavioral|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
79266834|NCT03185793|Drug|Placebo|Placebo once daily for 5 weeks
79266835|NCT03185793|Drug|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
79567587|NCT04891640|Other|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
79567588|NCT04891237|Biological|10,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
79727857|NCT03072433|Behavioral|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
79727858|NCT00991341|Biological|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored <=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
79567589|NCT04891237|Biological|30,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
79567590|NCT04891237|Other|Placebo|The same solution and presentation as the active treatment, but without active ingredients
79567591|NCT04889716|Drug|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
79862609|NCT04722692|Diagnostic Test|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~Transcutaneous signal~Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~SLN identification in situ~SLN excision and signal ex vivo~Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
79862610|NCT04722692|Diagnostic Test|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~Transcutaneous signal~Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~SLN identification in situ~SLN excision and signal ex vivo~Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
79862611|NCT05711342|Behavioral|Aggression|"The intervention consists of 10 lessons:~Motivation - where are you now?~Where do you want to go?~Circle of aggression.~Thoughts.~Emotions.~Bodily sensations.~Techniques for self-control.~Asking for help.~Assertiveness.~Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
79266836|NCT03185793|Drug|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
79567592|NCT04889716|Drug|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
79567593|NCT04889716|Drug|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
79727859|NCT00991341|Biological|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
79727860|NCT04291989|Device|Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device|This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
79266837|NCT03185637|Procedure|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
79266838|NCT03660488|Drug|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
79727861|NCT04291677|Other|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
79727862|NCT04291677|Other|Without intervention musical|Control group with standard treatment without musical intervention.
79727863|NCT04292691|Drug|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
79727864|NCT04292691|Drug|40ml of Ringer's Lactate|already outlined in the arm/group description
79727865|NCT00990249|Drug|Busulfan|Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
79266839|NCT03660488|Drug|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
79266840|NCT03185091|Other|rapid ventricular pacing|
79266841|NCT03185091|Procedure|Surgery|
79581463|NCT06071780|Other|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
79727866|NCT00990249|Drug|Clofarabine|40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3
79266842|NCT02421003|Procedure|heart surgery|
79266843|NCT03185247|Behavioral|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
79567594|NCT04874714|Biological|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
79567595|NCT04874714|Biological|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
79862612|NCT05711342|Behavioral|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
79567596|NCT04874714|Biological|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
79727867|NCT00990249|Drug|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
79862613|NCT05710796|Behavioral|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
79266844|NCT02422017|Drug|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
79266845|NCT02422017|Other|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
79400506|NCT06100185|Device|Sham|Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
79567597|NCT04874714|Biological|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
79567598|NCT04868656|Other|Implementation Strategy: Foundational Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.
79567599|NCT04868656|Other|Implementation Strategy: Enhanced Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
79567600|NCT04867603|Drug|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) [Ga-68]PSMA at the time of injection and is administered to subjects by intravenous injection.
79567601|NCT04867603|Device|PET/CT imaging|PET/CT imaging procedure
79727868|NCT00990249|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
79727869|NCT02846545|Biological|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
79727870|NCT02846545|Biological|Placebo|Matching Placebo to golimumab.
79727871|NCT04291755|Drug|Pembrolizumab Injection|Any checkpoint inhibitor is acceptable
79266846|NCT02761915|Other|Leukapheresis|
79266847|NCT02761915|Drug|Cyclophosphamide|
79266848|NCT02761915|Drug|Fludarabine|
79266849|NCT02761915|Genetic|1RG-CART|
79266850|NCT02706327|Device|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
79400507|NCT06099834|Other|Patients selection|Patient selection were selected according to selected criteria.
79400508|NCT06099834|Other|Implnat placement|dental implants were applied as recommended by the manufacturer.
79727872|NCT05663827|Drug|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
79727873|NCT04292769|Drug|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
79727874|NCT04292769|Biological|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
79400509|NCT06099834|Other|Recall visits|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W&H, Sweden) devices.
79266851|NCT02706327|Device|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
79400510|NCT06098872|Drug|Trametinib tablet|Drug is supplied in 2mg and 0.5 mg tablets
79400511|NCT06096740|Behavioral|Cognitive Processing Therapy|"Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms."
79567602|NCT04856826|Device|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
79862614|NCT04266470|Device|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
79400512|NCT06095908|Drug|Bupivacain|Bupivacain administered with two different ways to the patients, postoperative pain recorded
79400513|NCT06092593|Device|Upper endoscopy|Evaluation of upper gastrointestinal tract lesions in ulcerative colitis patients
79400514|NCT06085833|Diagnostic Test|Nanomechanical Phenotype Test|The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
79400515|NCT06083857|Drug|Amivantamab|Given by IV (vein)
79862615|NCT04266470|Diagnostic Test|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
80023372|NCT05007340|Other|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
79266852|NCT02706327|Other|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
79400516|NCT06083857|Drug|Tepotinib|Given by PO
79400517|NCT06080659|Diagnostic Test|fMRI|functional MRI
79400518|NCT06080659|Diagnostic Test|CONFMEM|The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
79266853|NCT03619148|Device|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
79400519|NCT06080425|Behavioral|Medical Nutrition Therapy|Counselling
79400520|NCT06077630|Other|No intervention|There is no intervention, observational study
79400521|NCT06074003|Other|Seated Rest (Non-exercise control)|Sitting for 30 minutes
79567603|NCT04849884|Device|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
79567604|NCT04828304|Device|PLASOMA|Treatment with cold plasma device
79567605|NCT04826224|Biological|Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.|Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
79567606|NCT04817670|Drug|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
79567607|NCT04817670|Drug|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
79567608|NCT04817670|Drug|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
79567609|NCT04817670|Drug|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
79567610|NCT04817670|Drug|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
79567611|NCT04816643|Biological|Biological/Vaccine: BNT162b2 10mcg|BNT162b2 Low/Mid-Dose (10mcg) level
79567612|NCT04816643|Biological|BNT162b2 20mcg|BNT162b2 Mid-Dose (20mcg) level
80023373|NCT05007340|Other|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
80023374|NCT05007340|Other|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
79266854|NCT02422095|Procedure|Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections|Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
79266855|NCT02422095|Procedure|EUS of pancreatic cysts|Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
79266856|NCT03464084|Drug|placebo|Capsules containing microcrystalline cellulose
79266857|NCT03464084|Dietary Supplement|melatonin|5 mg of melatonin per os.
79266858|NCT03464084|Other|bright light|room light will be bright
79266859|NCT03464084|Other|dim light|room light will be dim
79266860|NCT05551208|Drug|fluzopanib and bevacizumab|fluzopanib and bevacizumab were used for maintenance treatment
79400522|NCT06074003|Other|High-intensity interval exercise|Performing a single session of high-intensity interval exercise on a cycle ergometer
79400523|NCT06073509|Diagnostic Test|Screening for atrial fibrillation and other cardiac arrhythmias and diseases|"In addition to retrospective data collection based on a medical questionnaire, a 5-year post-RT cardiovascular screening will include:~connected smartwatches for atrial fibrillation screening~complete ECG for other cardiac arrhythmias~echocardiography for other cardiac diseases (including cardiac dysfunction, cardiomyopathy, valvulopathy, ...)"
79400524|NCT06068218|Other|Biopsy for the patient group|The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet. For vitiligo patients, the biopsies will be taken on a non-depigmented skin.
79400525|NCT06068218|Other|biopsy for the volunteer group|A publicity in the hospital will announce the study, and will be use to recruit the healthy volunteers. The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet.
79400526|NCT06066697|Behavioral|SOVA Ambassador|"The SOVA Ambassador intervention includes:~adolescents will have access to the website specifically for adolescents: sova.pitt.edu These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion.~Participants that receive this intervention will contribute monthly articles and regular comments."
79567613|NCT04816643|Biological|BNT162b2 30mcg|BNT162b2 High-Dose (30mcg) level
79567614|NCT04816643|Other|Placebo|Intramuscular injection
79567615|NCT04816643|Biological|Biological/Vaccine: BNT162b2 3mcg|BNT162b2 Low-Dose (3mcg) level
79567616|NCT04809467|Drug|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
79567617|NCT04809467|Drug|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
80023375|NCT03609957|Other|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
80023376|NCT03609957|Other|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
79400527|NCT06066697|Behavioral|Self-Reflection|Participant will be given an article from the sova.pitt.edu website and a prompt to write about privately.
79581465|NCT06071676|Other|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
79581466|NCT06071676|Other|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
79727875|NCT00640939|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
79727876|NCT00640939|Drug|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
79727877|NCT04291443|Procedure|Heavy Force (225g)|Orthodontic Force
79727878|NCT04291443|Procedure|Light Force (25g)|Orthodontic Force
79727879|NCT05663749|Drug|Metformin|1000mg for 8 weeks
79727880|NCT05663749|Drug|Topiramate|50mg for 8 weeks
79727881|NCT02682433|Device|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
79862616|NCT00987350|Device|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
79266861|NCT02161003|Procedure|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
79266862|NCT02161003|Procedure|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
79400528|NCT06066580|Drug|EDG-5506|EDG-5506 is administered orally once per day
79862617|NCT00987350|Device|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
79862618|NCT00987350|Biological|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
79266863|NCT05551130|Other|Restoration|Restorations completed with these materials.
79266864|NCT02764333|Biological|TPIV200|
79266865|NCT02764333|Biological|Durvalumab|
79400529|NCT06064071|Device|Nordlys SWT IPL|Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
79400530|NCT06064071|Procedure|Meibomian Gland Expression (MGX)|Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
79400531|NCT06064071|Device|Sham Nordlys SWT IPL|Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
79567618|NCT04799834|Other|Questionnaire administration,blood sampling and genetic analyses.|"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."
79862619|NCT00987428|Procedure|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
79266866|NCT02158741|Behavioral|Home Visits and Lifestyle Education Support|
79266867|NCT02705625|Drug|MIV-711|MIV-711 administered orally once daily
79400532|NCT06063954|Other|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
79400533|NCT06063460|Diagnostic Test|Periodontal examination|Periodontal Examination Routine In routine periodontal examination, measurements of plaque score, gingival score, pocket depths, and attachment loss will be utilized.
79581467|NCT06071663|Procedure|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
79581468|NCT06071650|Behavioral|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
79862620|NCT00987428|Procedure|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
79862621|NCT00987506|Device|XIENCE V®|Participants with placement of a XIENCE V® EESS
79862622|NCT04567082|Diagnostic Test|Examination of saliva|Collection of saliva samples
79862623|NCT04518722|Radiation|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
79862624|NCT04518722|Radiation|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
79862625|NCT04518722|Other|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
79266868|NCT02705625|Drug|Placebo|Placebo manufactured to mimic MIV-711 capsule.
79266869|NCT05550974|Device|Minimally Invasive Surgery|gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures
79266870|NCT02161081|Procedure|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
79266871|NCT02422173|Device|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
79266872|NCT02422173|Device|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
79266873|NCT02422173|Device|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
79266874|NCT02422173|Device|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
79862626|NCT00987662|Drug|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg.
79862627|NCT00987662|Drug|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg
80023377|NCT03083938|Procedure|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
79567619|NCT04795999|Behavioral|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
79400534|NCT06063460|Other|baseline questionnaire about sociodemographic characteristics, smoking habits, oral hygiene habits, halitosis, smell and taste perception|"Each patient participating in the study will complete a questionnaire detailing their age, gender, height, weight, smoking status, frequency of dental brushing, diabetes status, total annual household income, and Covid-19 history. In addition, a visual analogue scale and self-reported periodontal status questionnaire will be completed.~Personal Periodontal Condition Questionnaire This questionnaire comprises of eight questions regarding the participants' periodontal condition.~Graphical Analog Scale Patients were asked to rate their perception of taste, smell, and bad breath between 0 and 100 on this scale. Sense of smell (0-I cannot smell at all, 100-I can smell perfectly), sense of taste (0-I cannot taste at all, 100-I can smell perfectly), mouth. The odor will be graded from 0 (no bad breath) to 100 (extremely awful breath)."
79567620|NCT04794517|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
79727882|NCT02682433|Device|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
79862628|NCT00987740|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
79567621|NCT04794517|Other|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
79266875|NCT05546216|Other|Determination of the Effect of Raised Supine Position and Back Support on Back Pain, Anxiety and Comfort Level in Coronary Angiography Patients|The study was conducted between 01 September 2021 and 30 January 2022 as a randomized single-blind interventional study with a pre-test post-test control group. The sample of the study consisted of patients who underwent coronary angiography. Data; The patient information form was collected with the visual analog scale, state anxiety and immobilization comfort scale. Back support was provided to the intervention group with a pillow at the exit of the angiography and the head of the bed was raised 30 degrees. Back pain intensity at 0, 2 and 4 hours, anxiety and comfort level at 0 and 4 hours were measured. The control group was given routine nursing care.
79400535|NCT06063460|Other|phase I periodontal treatment|Phase I periodontal treatment will be applied by same expert.
79862629|NCT00987818|Other|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
79400536|NCT06063460|Other|1. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.
79567622|NCT04786548|Drug|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
79567623|NCT04775914|Procedure|PCI + Ischemic conditioning|IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
79567624|NCT04775914|Procedure|Stent with ultrasound|IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
79862630|NCT05690126|Dietary Supplement|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
79567625|NCT04757519|Behavioral|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
79862631|NCT05690126|Dietary Supplement|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
79862632|NCT00987896|Device|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
79862633|NCT00090103|Drug|dutasteride 0.5mg once daily for 4 years|combination or single agent
79862634|NCT00090103|Drug|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
79862635|NCT01088659|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
80023378|NCT02166684|Device|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
80023379|NCT05007184|Behavioral|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
79266876|NCT02161159|Biological|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
79567626|NCT04757519|Behavioral|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
79266877|NCT02421861|Behavioral|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
79266878|NCT02421861|Other|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C&L service; (2) referral to psychiatry C&L service; or (3) pharmacologic management.
79266879|NCT05546138|Diagnostic Test|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
79266880|NCT05546138|Diagnostic Test|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
79266881|NCT05546138|Diagnostic Test|Thermal perception thresholds|Heat and cold perception thresholds
79266882|NCT05546138|Diagnostic Test|Corneal confocal Microscopy|Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density
79266883|NCT05546138|Diagnostic Test|MRI|Functional and structural MRI pictures of peripheral nerves and CNS
79266884|NCT05546138|Diagnostic Test|Nerve conduction studies|Nerve conduction and amplitude of Sural nerve
79266885|NCT05546138|Other|Composite scores and questionnaires|Composite scores and questionnaires
79266886|NCT02160925|Other|Preoperative 99mTc-Sestamibi SPECT/CT|
79266887|NCT02161237|Drug|Advagraf®|oral
79400537|NCT06063460|Other|3. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
79400538|NCT06060691|Drug|Kaempferol|Kaempferol
79567627|NCT04755725|Device|Epidural catheter|epidural catheter inserted pre induction
79567628|NCT04755725|Device|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
79567629|NCT04733547|Procedure|Placement of a central venous catheter|The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
79727883|NCT00990093|Device|test intermittent catheter|CH 12 hydrophilic coated catheter
79862636|NCT01088659|Drug|placebo|orally daily, 96 weeks
79862637|NCT01088659|Drug|tenofovir|245mg po daily, 96 weeks
79862638|NCT03962257|Other|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
79862639|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
79862640|NCT00087607|Drug|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
79862641|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
79862642|NCT00087607|Drug|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
80023380|NCT05007184|Behavioral|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
79862643|NCT01088737|Drug|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
79266888|NCT03326336|Combination Product|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
79266889|NCT03116607|Other|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
79567630|NCT04733547|Device|Monitoring of central venous pressure|Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
79567631|NCT04733547|Drug|Furosemide-induced hypovolemia before graft procurement|Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is <1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces >1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
79266890|NCT02430597|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
79266891|NCT02430597|Device|NanoKnife|
79862644|NCT00069823|Drug|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
79862645|NCT00069823|Drug|Placebo proton pump inhibitor|Placebo proton pump inhibitor
79862646|NCT01088815|Drug|Gemcitabine, nab-Paclitaxel, GDC-0449|"One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
79266892|NCT03173066|Drug|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
79266893|NCT03540823|Biological|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
79266894|NCT02421627|Device|moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
79266895|NCT02421627|Device|Sham moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
79266896|NCT05546060|Drug|Venetoclax|Venetoclax 100mg qd d1，200mg qd d2，400mg qd d3-56
79266897|NCT05546060|Drug|Dexamethasone|Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56
79581469|NCT06071637|Procedure|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
79727884|NCT00990093|Device|Intermittent catheterization|CH 12 hydrophilic catheter
79727885|NCT04184167|Other|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
79727886|NCT02867553|Drug|rituximab|
79727887|NCT02867553|Radiation|Multi-fields radiotherapy|
79862647|NCT00086515|Drug|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
79862648|NCT00086515|Drug|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
79862649|NCT00086515|Drug|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
79862650|NCT00086515|Drug|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)
79862651|NCT01090609|Device|Stent implantation|Stent implantation
79862652|NCT00541658|Drug|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
79567632|NCT04733547|Drug|Replacement of fluid loss after graft procurement|Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
80023381|NCT04570605|Device|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
80023382|NCT04570605|Other|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
80023383|NCT02163174|Drug|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
79266898|NCT05546060|Drug|Etoposide|Etoposide 75mg/m2 qw d1-56
80023384|NCT02163174|Drug|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
80023385|NCT01744912|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
80023386|NCT01744912|Drug|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
79266899|NCT02161393|Behavioral|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
80023387|NCT03609879|Device|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
80023388|NCT03609879|Device|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
79266900|NCT02161393|Behavioral|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
79266901|NCT02416869|Procedure|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
79266902|NCT02416869|Procedure|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
79567633|NCT04733547|Device|Monitoring of stroke volume variation|Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
79567634|NCT04725604|Device|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
79567635|NCT04725071|Dietary Supplement|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
79567636|NCT04725071|Dietary Supplement|Boost High Protein|conventional supplement
80023389|NCT03609879|Device|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
79266903|NCT02416869|Drug|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
79266904|NCT02416869|Drug|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
79266905|NCT02416869|Procedure|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
79266906|NCT02416869|Procedure|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
79266907|NCT02163265|Procedure|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
79567637|NCT04723056|Device|Use of Zemedy Application|8 weeks of CBT via the Zemedy Application.
79567638|NCT04711005|Drug|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
79567639|NCT04711005|Drug|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
79567640|NCT04696406|Device|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
80023390|NCT03609879|Device|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
80023391|NCT03609879|Device|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
80023392|NCT03540810|Drug|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
80023393|NCT03540810|Drug|Placebo|The patients will receive placebo with their usual treatment
80023394|NCT03078400|Drug|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
80023395|NCT03609723|Procedure|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
80023396|NCT02159820|Drug|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
80023397|NCT02159820|Drug|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve [AUC] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
79266908|NCT03107013|Drug|[14C]-BTD-001|Carbon-14 labeled BTD-001
79266909|NCT02410395|Procedure|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
79266910|NCT02410395|Procedure|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
79266911|NCT03178929|Drug|S-Adenosyl Methionine|2000mg, po
79567641|NCT04659954|Other|Application O'DIDE|The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
79567642|NCT04646733|Other|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
79567643|NCT04646733|Other|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
79862653|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
79862654|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
79862655|NCT04384952|Other|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
79862656|NCT04384952|Other|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
79862657|NCT04334174|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
79862658|NCT00987974|Drug|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
80023398|NCT05013658|Behavioral|pressure measurement|pressure measurement with pilot balloon palpation
80023399|NCT02862171|Drug|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
80023400|NCT05013814|Diagnostic Test|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
80023401|NCT05013814|Diagnostic Test|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
79266912|NCT02161861|Other|cFFE increase the fusiogenic capacities of a gamete|
79266913|NCT02416557|Procedure|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
79266914|NCT02588612|Drug|letetresgene autoleucel (GSK3377794)|letetresgene autoleucel (GSK3377794) as an IV infusion.
79266915|NCT02588612|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
79266916|NCT02588612|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
79266917|NCT02161939|Drug|Daclatasvir (BMS-790052)|
79266918|NCT02161939|Drug|Sofosbuvir|
79400539|NCT06059508|Drug|SHR-5495 for injection|SHR-5495 for injection
79400540|NCT06048965|Other|No intervention to be performed|No intervention to be performed. Anonymous survey only.
79862659|NCT00987974|Drug|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
79862660|NCT00987974|Drug|placebo|placebo for 3 days.
79862661|NCT00987974|Drug|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
79862662|NCT00987974|Drug|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
79862663|NCT00987974|Drug|placebo 7 days|placebo 7 days
79862664|NCT04324580|Other|Splint|Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.
80023402|NCT05013814|Diagnostic Test|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
80023403|NCT05013814|Diagnostic Test|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
80023404|NCT05013814|Diagnostic Test|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
80023405|NCT05013814|Diagnostic Test|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
80023406|NCT03083626|Other|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
80023407|NCT05013346|Other|No intervention needed|No intervention required. Not a clinical trial
79266919|NCT02416479|Behavioral|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
79567644|NCT04636710|Procedure|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
80023408|NCT04405791|Procedure|Active stimulation group Sham stimluation group|"Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week."
80023409|NCT03083314|Procedure|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
80023410|NCT03083314|Procedure|COMPLETE AXILLARY DISSECTION (ALND)|
79266920|NCT02416479|Behavioral|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
79266921|NCT03540979|Procedure|endometrial preparation for frozen blastocyst transfer|medical endometrial preparation for frozen blastocyte transfer
79727888|NCT05663671|Diagnostic Test|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
79727889|NCT02682277|Device|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
79727890|NCT02682277|Other|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
79727891|NCT00909961|Drug|Zoledronic acid|
80023411|NCT05013112|Drug|SGLT2 inhibitor|Empagliflozin 20mg once daily from discharge
80023412|NCT05013112|Drug|Metformin|Metformin 500mg twice daily from discharge
80023413|NCT05013112|Other|Placebo|Placebo group
80023414|NCT03082144|Drug|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
80023415|NCT03082144|Drug|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
79266922|NCT03540979|Drug|Letrozole|Aromatase inhibitor - 2.5mg/d for 5 days
79266923|NCT03540979|Drug|Ovidrel|recommbinant hCG 250 mcg- single sc injection to induce ovulation
79567645|NCT04635228|Device|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
79567646|NCT04632992|Drug|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
79727892|NCT05663593|Drug|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
79727893|NCT05663593|Drug|Placebo, tablet|Matching placebo
79567647|NCT04632992|Drug|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
79862665|NCT04324580|Behavioral|Formal Physical Therapy|Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.
79862666|NCT04324580|Behavioral|Self directed physical therapy|Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
79862667|NCT04324580|Other|Soft dressing (No Splint)|Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
79862668|NCT04229888|Device|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
79862669|NCT04229888|Device|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
79862670|NCT04004546|Behavioral|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
79862671|NCT04236284|Device|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 _ 7 cm saline-soaked surface sponge electrodes.
80023416|NCT03082144|Radiation|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
79567648|NCT04632992|Drug|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
79567649|NCT04632992|Drug|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
79567650|NCT04632992|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
79567651|NCT04632992|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
79567652|NCT04632992|Drug|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
79567653|NCT04632992|Drug|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
79567654|NCT04632992|Drug|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
79567655|NCT04632992|Drug|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
79727894|NCT02680249|Drug|CTP-656|
79727895|NCT04184557|Behavioral|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
79727896|NCT00641017|Biological|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
79727897|NCT00641017|Biological|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
79727898|NCT00642577|Drug|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
79727899|NCT00642577|Drug|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
79727900|NCT00642577|Drug|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
79727901|NCT00642577|Drug|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
79727902|NCT02679937|Behavioral|Fit4Duty|Small (<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
79862672|NCT04236284|Behavioral|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
79862673|NCT04005248|Diagnostic Test|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
79862674|NCT03519074|Drug|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
79862675|NCT02661542|Drug|FF-10502-01|
79862676|NCT05659316|Other|MRI imaging|Knee MRI imaging
79567656|NCT04632992|Drug|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
79862677|NCT03907280|Drug|BI 1265162 (T1)|oral solution
79862678|NCT03907280|Drug|BI 1265162 (T2)|Solution for inhalation
79862679|NCT03907280|Drug|BI 1265162 (R)|concentrate for i.v. solution
79862680|NCT03907280|Drug|BI 1265162 (T3)|Solution for inhalation
79567657|NCT04632992|Drug|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
79862681|NCT04004468|Behavioral|Resistance Training|Standard barbell resistance training programs
80023417|NCT05013034|Drug|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
80023418|NCT05013034|Drug|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
80023419|NCT02638948|Drug|BMS-986142|BMS986142 specific dose on specific days
80023420|NCT02638948|Drug|Placebo|Placebo of BMS-986142 specific dose on specific days
79862682|NCT03730454|Device|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
79862683|NCT03730454|Other|No Transanastomotic Tube|No transanastomotic tube used during repair
79862684|NCT04120376|Behavioral|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
79862685|NCT03644732|Procedure|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
79862686|NCT04108130|Other|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
80023421|NCT02638948|Drug|Methotrexate|Methotrexate specific dose on specific days
80023422|NCT03091582|Behavioral|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
79266924|NCT03540979|Drug|Estrofem|Estrofem 2mg*3/d for endometrial preparation
79567658|NCT04622319|Drug|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
79862687|NCT04108130|Procedure|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
79862688|NCT04108130|Other|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
79727903|NCT02679937|Other|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
80023423|NCT03091582|Behavioral|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
79727904|NCT02682121|Drug|Metformin|Metformin 850 mg twice daily
79266925|NCT03540979|Drug|Endometrin 100Mg Vaginal Insert|vaginal tab for lutheal support
79266926|NCT02416401|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
79266927|NCT02416401|Other|Commercially available computerized training|
79567659|NCT04622319|Drug|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
79567660|NCT04621188|Drug|Lorlatinib|100 mg once daily
79727905|NCT02682121|Drug|Placebo|Placebo twice daily
79862689|NCT04108130|Procedure|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
79862690|NCT04108130|Behavioral|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
79862691|NCT03905642|Drug|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
79862692|NCT04499300|Other|Data collection from medical files|Data collection from medical files
79862693|NCT03518294|Behavioral|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
79862694|NCT05613374|Device|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
79862695|NCT05613374|Other|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
80023424|NCT03091582|Behavioral|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
80023425|NCT03091426|Drug|Omiganan|Omiganan 1%
79862696|NCT03743012|Other|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
80023426|NCT03091426|Drug|Omiganan|Omiganan 1.75%
80023427|NCT03091426|Drug|Omiganan|Omiganan 2.5%
79266928|NCT02158819|Device|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
79400541|NCT06042166|Behavioral|Connecting and Reflecting Experience (CARE) Program|The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
79400542|NCT06039787|Behavioral|single bout of moderate intensity continuous training (MICT)|the MICT consists of 60 min continuous cycling
79400543|NCT06039787|Behavioral|single bout of High Intensity Interval Training (HIIT)|HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover
79400544|NCT06039787|Behavioral|waiting control|sitting in a waiting room for 60 min
79400545|NCT06028646|Device|Dynamic Airway CT scan (DA-CT)|Patient will be asked to perform movements during the scan.
79567661|NCT04579653|Device|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
79567662|NCT04574895|Other|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
79862697|NCT03743012|Other|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
79727906|NCT02680405|Procedure|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
79862698|NCT04004156|Device|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
79862699|NCT03504020|Device|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
80023428|NCT03091426|Drug|Placebo|Vehicle
79266929|NCT03174873|Procedure|laparoscopy|Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
79400546|NCT06028347|Biological|sa-mRNA vaccine Dose 1|self-amplifying mRNA vaccine
79400547|NCT06028347|Biological|sa-mRNA vaccine Dose 2|self-amplifying mRNA vaccine
79400548|NCT06028347|Biological|sa-mRNA vaccine Dose 3|self-amplifying mRNA vaccine
79581470|NCT06071598|Other|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
79266930|NCT02946788|Drug|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
79400549|NCT06028347|Biological|sa-mRNA vaccine Dose 4|self-amplifying mRNA vaccine
79400550|NCT06028347|Biological|Placebo|Saline for injection
79400551|NCT06026514|Biological|B/HPIV3/S-6P|Intranasal vaccine.
79400552|NCT06025123|Device|Early transnasal evaporative cooling with the RhinoChill device|Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
79400553|NCT06023719|Device|DISC Care|Medical device to prevent disc herniation recurrence
79581471|NCT06071585|Other|Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis|We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
79727907|NCT02680405|Procedure|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
79727908|NCT02680405|Procedure|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
79727909|NCT02537587|Other|Control 1|67g of control bar
79727910|NCT02537587|Other|Control 2|86g of control bar
79727911|NCT02537587|Other|15/0|66g of experimental bar 15/0
79727912|NCT02537587|Other|15/0LS|84g of experimental bar 15/0LS
79727913|NCT02537587|Other|15/5|75g of experimental bar 15/5
79727914|NCT02537587|Other|10/5|72g of experimental bar 10/5
79727915|NCT02537587|Other|10/10|80g of experimental bar 10/10
80023429|NCT05020054|Device|Tecartherapy Intervention|therapeutic therapy with effective application, connected equipment
80023430|NCT05020054|Device|placebo tecartherapy|tecartherapy with equipment turned off
80023431|NCT05019820|Other|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
80023432|NCT05019820|Other|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
80023433|NCT04465864|Drug|Intracanalicular Dexamethasone, 0.4 mg insert|Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
79862700|NCT04126538|Drug|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
79862701|NCT04126538|Drug|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
79862702|NCT04004234|Drug|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
79567663|NCT04571814|Behavioral|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
79862703|NCT04004234|Drug|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
79567664|NCT04543591|Biological|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
79567665|NCT04543591|Other|Placebo|Matching placebo
79567666|NCT04543591|Other|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
79862704|NCT04004234|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
79862705|NCT04004234|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
80023434|NCT03091504|Device|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
80023435|NCT03091504|Drug|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
80023436|NCT03091036|Other|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
80023437|NCT05019586|Drug|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
79727916|NCT02683603|Drug|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
79862706|NCT04095416|Device|ACE compression wrap|Bilateral lower extremity ACE compression wraps
79862707|NCT00990080|Biological|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
79862708|NCT00990158|Drug|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
79862709|NCT00990158|Drug|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
79862710|NCT02736344|Device|BioNIR Ridaforolimus Eluting Coronary Stent|
79862711|NCT02682992|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
79862712|NCT05279066|Device|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
79581472|NCT06071572|Other|Biological samples collected specifically for the IBD Biobank|Biological samples will include: material intestinal biological waste (surgical leftover), 30 ml of peripheral blood, one sample stool standards and a saliva sample.
79581473|NCT06071559|Procedure|Laparoscopic Roux-en-y gastric bypass|Obesity surgery
79727917|NCT02683603|Drug|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
79727918|NCT02683603|Drug|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
79727919|NCT02683603|Drug|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
79727920|NCT02683603|Drug|AS colistin and imipenem|IV imipenem 1 g three times per day.
79727921|NCT02683603|Drug|IV colistin and imipenem|IV imipenem 1 g three times per day
79727922|NCT00641095|Biological|rituximab|concentrate for solution for infusion
79727923|NCT00641095|Drug|Cyclophosphamide|Tablets
79862713|NCT01563770|Dietary Supplement|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
79862714|NCT01563770|Dietary Supplement|Placebo|3 placebo capsules, twice daily for four consecutive weeks
79862715|NCT00412984|Drug|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
79862716|NCT00412984|Drug|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
79862717|NCT00539864|Biological|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
79862718|NCT00539864|Biological|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
79862719|NCT04003376|Device|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
79862720|NCT04003376|Drug|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
80023438|NCT03078634|Other|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
80023439|NCT03078634|Other|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
80023440|NCT03081676|Drug|Glimepiride 1Mg Tablet|Glimepiride
80023441|NCT03081676|Drug|Glucagon-like Peptide-1|GLP-1 infusion
79266931|NCT02420925|Procedure|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
79567667|NCT04521712|Diagnostic Test|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
79567668|NCT04518306|Drug|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
79727924|NCT00641095|Drug|Fludarabine|Film coated tablet
79727925|NCT00984165|Procedure|Single fraction radiation|8-Gy fraction of radiation
79727926|NCT00984165|Biological|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
79727927|NCT00984165|Procedure|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
79727928|NCT02869113|Drug|BAY98751 (Y65-110)|10 µL in one eye
79727929|NCT02869113|Drug|BAY 98751 (Y65-102)|10 µL in one eye
79727930|NCT02869113|Drug|BAY 98751 (Y65-106)|10 µL in one eye
79862721|NCT04003376|Biological|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
79862722|NCT04003376|Drug|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
80023442|NCT03081676|Drug|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
79266932|NCT02158897|Other|Prolon diet|3 cycles of a 5-day Prolon diet very month
79266933|NCT05550740|Device|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
79266934|NCT02159131|Drug|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
79266935|NCT02159131|Drug|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
80023443|NCT03081676|Drug|Placebo Oral Tablet|Placebo
79266936|NCT02159131|Drug|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
79266937|NCT05550506|Drug|Duloxetine|Patients who use duloxetine for chronic pain or fibromyalgia
80023444|NCT03081676|Drug|Placebo infusion|Placebo (saline)
80023445|NCT05013268|Drug|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
79266938|NCT03178695|Other|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
79266939|NCT05545982|Procedure|Video laryngoscope with Miller approach|Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
79567669|NCT04518306|Drug|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
79567670|NCT04518306|Drug|Placebo|Placebo
79567671|NCT04512547|Drug|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
79567672|NCT04502043|Other|Exercise therapy|"Education~Hip-specific strengthening exercises~Functional lower limb strengthening exercises~Core stability exercises~Postural balance exercises"
79727931|NCT02869113|Drug|Standard shampoo mixture (Control)|10 µL in other eye
80023446|NCT05005858|Procedure|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
80023447|NCT05005858|Device|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
79727932|NCT00993291|Procedure|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
79727933|NCT00993291|Procedure|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
79727934|NCT02867631|Behavioral|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
79727935|NCT01196975|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
79727936|NCT01196975|Biological|FluLavalTM-VB|Single intramuscular dose
79727937|NCT01196975|Biological|FluLavalTM-YB|Single intramuscular dose
80023448|NCT03081208|Drug|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
80023449|NCT03081208|Drug|Placebo|Placebo dispersible tablets for single oral administration
79727938|NCT00992589|Drug|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
79727939|NCT00992589|Drug|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
80023450|NCT00102960|Drug|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
79567673|NCT04477187|Device|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
79727940|NCT00992589|Drug|Placebo|Matching placebo capsules once daily in the morning.
79727941|NCT01196741|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
79727942|NCT01196741|Drug|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
79727943|NCT01196741|Drug|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
79727944|NCT02868255|Procedure|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
79567674|NCT04450758|Procedure|Bridge to Surgery (stent or stoma)|The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
79727945|NCT00629187|Drug|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
79727946|NCT04291287|Drug|Antithrombotic Agent|"Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~Clopidogrel (Plavix®)~Prasugrel (Efient®)~Ticagrelor (Brilique®)~DOACs therapy include:~Apixaban (Eliquis®)~Dabigatran (Pradaxa®)~Edoxaban (Lixiana®)~Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~Warfarin (Counmadin®)~Acenocumarol (Sintrom®)"
79727947|NCT04291365|Diagnostic Test|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
79862723|NCT01563848|Procedure|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
79862724|NCT01563848|Procedure|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
79862725|NCT01563848|Procedure|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
79862726|NCT04086212|Drug|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
79862727|NCT04086212|Drug|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
79862728|NCT05404490|Drug|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
79862729|NCT05404490|Drug|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
80023451|NCT00102960|Drug|Didanosine|Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
80023452|NCT00102960|Drug|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
80023453|NCT00102960|Drug|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
80023454|NCT00102960|Drug|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
80023455|NCT00102960|Drug|Nevirapine|Second Line Regimen: 150 - 200 mg/m^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
80023456|NCT00102960|Drug|Zidovudine|First Line Regimen: 240 mg/m^2 taken orally twice daily
79567675|NCT04450212|Genetic|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
79727948|NCT00983385|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
79862730|NCT05359874|Drug|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
79727949|NCT00983385|Other|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
79862731|NCT05359796|Biological|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
79862732|NCT05359796|Biological|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
79862733|NCT05359796|Genetic|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
79862734|NCT05359796|Dietary Supplement|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
79862735|NCT05359796|Genetic|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
79862736|NCT05359796|Biological|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
79862737|NCT05359796|Biological|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
79862738|NCT00990392|Drug|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
79862739|NCT00990392|Other|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
80023457|NCT05019118|Other|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
80023458|NCT05019118|Other|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
79567676|NCT04450212|Dietary Supplement|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
79862740|NCT05590988|Other|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
79862741|NCT05590988|Other|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
79862742|NCT05590910|Other|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
79862743|NCT03335072|Drug|Azithromycin|Mass Drug Administration
80023459|NCT05019118|Other|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
79567677|NCT04447339|Procedure|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
79400554|NCT06023524|Device|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
79567678|NCT04441307|Behavioral|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
79862744|NCT01563926|Drug|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
79862745|NCT05590520|Procedure|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
79862746|NCT05590520|Drug|GTN OINTMENT|0.2%GTN applied on anal canal.
79862747|NCT05590442|Other|Tests|Cognitive assessments and olfactory tests
79862748|NCT01034956|Device|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
79862749|NCT01040884|Other|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
79862750|NCT05590052|Device|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
79862751|NCT05590052|Device|Thermocautery|achievement of hemostasis using thermocautery
79862752|NCT01580878|Drug|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
79862753|NCT01580878|Drug|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
79862754|NCT01580878|Drug|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
79581474|NCT06071546|Device|MAIA|MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
79727950|NCT00983385|Drug|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
79727951|NCT02867475|Other|Physical activity motivation|Physical activity motivation
79727952|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
79727953|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
79862755|NCT05589974|Drug|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
80023460|NCT05019118|Other|Placebo milk|Conventional milk
80023461|NCT05019118|Other|Placebo yogur|Conventional yogur
80023462|NCT05019118|Other|Placebo fresh cheese|Conventional fresh cheese
79266940|NCT02162017|Other|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
80023463|NCT05005702|Other|Inspiratory Muscle training|"Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure."
80023464|NCT03078790|Device|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
79727954|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
80023465|NCT02166762|Procedure|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
80023466|NCT02163252|Behavioral|Standard|
80023467|NCT02163252|Behavioral|Early Intervention|
80023468|NCT05012800|Biological|COVID-19 Vaccine|Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
80023469|NCT02166840|Procedure|Plastic stent (7-10Fr)|
79727955|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
79266941|NCT02162017|Other|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
79727956|NCT02868177|Dietary Supplement|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
80023470|NCT02166840|Procedure|Self Expanding Metal Stent|
79266942|NCT02416323|Other|AIM HI Training|
79567679|NCT04441307|Behavioral|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
79727957|NCT02868177|Dietary Supplement|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
79266943|NCT05545904|Behavioral|Substance use brief intervention (BI)|The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
79400555|NCT06023524|Device|Sham Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
80023471|NCT02858895|Drug|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
80023472|NCT04712136|Other|MRI|MRI cardiac
80023473|NCT04939714|Behavioral|Psychoeducational Intervention|The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
80023474|NCT05018962|Device|Cutting balloon followed by paclitaxel coated balloon|Cutting balloon followed by paclitaxel coated balloon
80023475|NCT02160054|Drug|Graceptor®|oral
79567680|NCT04437264|Dietary Supplement|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
80023476|NCT03078322|Drug|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
79567681|NCT04437264|Dietary Supplement|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
79567682|NCT04433182|Drug|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~Rituximab (R): 375 mg/sqm i.v. day 1*~Bendamustine (B): 90 mg/sqm i.v. days 1-2*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
79567683|NCT04408118|Drug|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
79567684|NCT04408118|Drug|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
80023477|NCT03078322|Drug|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
80023478|NCT03609489|Drug|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
79473360|NCT04087343|Behavioral|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
79567685|NCT04408118|Drug|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
79567686|NCT04404595|Biological|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
79567687|NCT04385368|Drug|Durvalumab + SoC chemotherapy|Experimental Treatment
79567688|NCT04385368|Other|Placebo + SoC chemotherapy|Placebo Comparator
80023479|NCT03609489|Drug|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
80023480|NCT05019196|Device|GE 3.0T MRI|using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
79266944|NCT05545904|Behavioral|substance use education intervention|This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
79266945|NCT03174951|Drug|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
79473361|NCT02249689|Other|Definitive 65|
79473362|NCT02249689|Other|Definitive 74|
79567689|NCT04380636|Biological|Pembrolizumab|intravenous (IV) infusion
79567690|NCT04380636|Drug|Olaparib|oral tablets
79567691|NCT04380636|Drug|Placebo for olaparib|oral tablets
79473363|NCT05423132|Drug|Ropivacaine injection|The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
79473364|NCT05423132|Drug|Physiological serum injection|The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
79567692|NCT04380636|Drug|Etoposide|IV infusion
79567693|NCT04380636|Drug|Carboplatin|IV infusion
79567694|NCT04380636|Drug|Cisplatin|IV infusion
79567695|NCT04380636|Drug|Paclitaxel|IV infusion
79567696|NCT04380636|Drug|Pemetrexed|IV infusion
79567697|NCT04380636|Radiation|Thoracic Radiotherapy|external beam radiation
79567698|NCT04380636|Drug|Durvalumab|IV infusion
79567699|NCT04372953|Procedure|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
79727958|NCT02868099|Drug|Romiplostim|
79727959|NCT02868099|Drug|Placebo|
79727960|NCT02868021|Device|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
79727961|NCT02868021|Behavioral|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
79727962|NCT02868021|Behavioral|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
79727963|NCT02868021|Behavioral|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
79473365|NCT03681977|Device|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
79473366|NCT03681977|Device|Zimmer Persona Knee-PS|Persona the personalized knee system
79473367|NCT05739500|Other||no intervention, just observation
79473368|NCT02975219|Drug|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
79473369|NCT05688956|Dietary Supplement|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine & 10 µg Vitamin D.
79567700|NCT04370054|Biological|PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy|Single IV infusion
79567701|NCT04362826|Biological|Novel probiotic|Investigational novel probiotic
79567702|NCT04362826|Other|Placebo|Placebo for probiotic
79567703|NCT04349436|Biological|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
79567704|NCT04341948|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
79727964|NCT02868021|Behavioral|Self-assessed function|Using the Late Life Function and Disability Instrument.
79567705|NCT04325607|Procedure|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
79567706|NCT04325607|Procedure|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
79266946|NCT05700968|Other|validity and reability study|Validity and reliability assessment of the Turkish version of the Multidimensional Outcome Expectations For Exercise Scale (MOEES).
79266947|NCT03174795|Drug|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
79266948|NCT03174795|Drug|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
79567707|NCT04323280|Drug|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
79567708|NCT04323280|Drug|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
79567709|NCT04318548|Combination Product|Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)|rMenB+OMV will be administered intramuscularly as 1 dose each at day 1 and 61 to subjects in MenB+MenACWY group and MenB group and as 1 dose at day 91 to subjects in MenACWY group, to the deltoid region of the non-dominant arm.
79567710|NCT04318548|Biological|Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)|MenACWY will be administered intramuscularly as 1 dose at day 1 to subjects in MenB+MenACWY group, 1 dose at day 91 for MenB group and as 1 dose at day 1 to subjects in MenACWY group, to the deltoid region of the non-dominant arm.
79266949|NCT02163655|Drug|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
79862756|NCT00673049|Drug|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
80023481|NCT02033967|Procedure|vasodilator induced hypovolemia|
79266950|NCT02163655|Drug|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
79266951|NCT02410083|Drug|Clopirin 1|
79266952|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 1|
79266953|NCT02410083|Drug|Clopirin 2|
79567711|NCT04318548|Combination Product|Placebo|Placebo will be administered intramuscularly as 1 dose at day 91 to subjects in MenB+MenACWY group, 1 dose at day 1 to subjects in MenB group and MenACWY group, to the deltoid region of the non-dominant arm.
79567712|NCT04307134|Drug|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
79567713|NCT04307004|Other|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
79266954|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 2|
79266955|NCT02162173|Procedure|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
79567714|NCT04307004|Other|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
79567715|NCT04307004|Other|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
79567716|NCT04307004|Other|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
79567717|NCT04289870|Device|Trillium™|Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
79567718|NCT04281498|Drug|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
79567719|NCT04281498|Drug|Enasidenib|50mg -100mg daily
79567720|NCT04276870|Biological|Murine CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
79567721|NCT04263025|Biological|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue [43]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
79567722|NCT04263025|Procedure|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
79567723|NCT04242667|Behavioral|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
79567724|NCT04242667|Behavioral|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
79567725|NCT04221438|Drug|Binimetinib|Given PO
79567726|NCT04221438|Procedure|Computed Tomography|Undergo PET/CT
79567727|NCT04221438|Procedure|Conventional Surgery|Undergo surgery
79567728|NCT04221438|Drug|Encorafenib|Given PO
79567729|NCT04221438|Other|Fluorothymidine F-18|Given IV
79567730|NCT04221438|Procedure|Positron Emission Tomography|Undergo PET/CT
79862757|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
79862758|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
80023482|NCT03541590|Procedure|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
79567731|NCT04218370|Procedure|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
79567732|NCT04196218|Other|Driving simulator|Computer simulated driving assessment
79727965|NCT02868021|Procedure|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
79727966|NCT02868021|Device|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
79727967|NCT02868021|Device|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
79727968|NCT02868021|Behavioral|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
79862759|NCT04003844|Drug|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
79862760|NCT04003844|Drug|Acetylsalicylic acid|Coadministration
79862761|NCT05589584|Drug|N acetyl cysteine with weight reduction|high dose 2400mg/day
79266956|NCT02416245|Dietary Supplement|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
79862762|NCT05359484|Diagnostic Test|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
79862763|NCT00412750|Drug|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
79862764|NCT00412750|Drug|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
80023483|NCT03090802|Behavioral|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
80023484|NCT04765956|Device|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
80023485|NCT03610113|Device|Reverse shoulder arthroplasty|The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
79266957|NCT02416245|Other|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
79266958|NCT02716376|Device|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
79567733|NCT04181749|Drug|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
79567734|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
79567735|NCT04165317|Drug|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
79567736|NCT04165317|Drug|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
79567737|NCT04163289|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
79567738|NCT04161898|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet
79567739|NCT04161898|Drug|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
79567740|NCT04161898|Drug|Prednisolone|Prednisolone will be administered as oral tablet
79567741|NCT04161755|Drug|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
79567742|NCT04161755|Biological|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
80023486|NCT03081130|Procedure|Intravenous laser irradiation treatment|control group
80023487|NCT02163330|Drug|Acetazolamide|
80023488|NCT02163330|Drug|sugar pill|
80023489|NCT04186845|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
79567743|NCT04161755|Drug|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
79567744|NCT04151563|Biological|nivolumab|Specified dose on Specified days
79567745|NCT04151563|Biological|ipilimumab|Specified dose on Specified days
79567746|NCT04151563|Drug|cabozantinib|Specified dose on Specified days
79567747|NCT04151563|Biological|docetaxel|Specified dose on Specified days
79567748|NCT04151563|Biological|ramucirumab|Specified dose on Specified days
79567749|NCT04151563|Drug|lucitanib|Specified dose on Specified days
79567750|NCT04151368|Procedure|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
80023490|NCT02166996|Procedure|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
79266959|NCT03730441|Device|Colonoscopy|Endoscopic examination of large bowel
79727969|NCT02868879|Other|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
79727970|NCT02867319|Biological|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
80023491|NCT02166996|Procedure|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
79473370|NCT05688956|Other|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
79727971|NCT02869035|Drug|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
79727972|NCT02869035|Drug|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
79862765|NCT05361278|Other|Chlorhexidine solution|"Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the solution after using the last file.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
79862766|NCT05361278|Other|Activated chlorhexidine solution|"Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
79862767|NCT05361278|Other|Chlorhexidine gel|"Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the gel after using the last file.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
80023492|NCT03080272|Other|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
79473371|NCT05688956|Other|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
79727973|NCT04121871|Other|No intervention|Not required
80023493|NCT03610035|Drug|NPT189|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
80023494|NCT03610035|Drug|Placebo|Placebo
80023495|NCT02163564|Behavioral|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
80023496|NCT03078244|Other|N/A, observational study|
79567751|NCT04142242|Biological|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
79266960|NCT02416167|Drug|FYU-981|
79567752|NCT04142242|Other|Blood sample|Blood sample for assessment of antibody persistence.
79727974|NCT02868957|Other|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
80023497|NCT03609411|Procedure|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
80023498|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
80023499|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
80023500|NCT05005468|Drug|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
79266961|NCT02416167|Drug|Placebo|
79266962|NCT05550350|Drug|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
79567753|NCT04126018|Diagnostic Test|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
79266963|NCT05550350|Other|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
79727975|NCT02868957|Device|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
79862768|NCT05361278|Other|Activated chlorhexidine gel|"Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
80023501|NCT05005468|Drug|Famitinib|Famitinib is administered orally, once a day.
79266964|NCT02166619|Device|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy"
79266965|NCT02416089|Device|Tampostat|
79727976|NCT02868957|Device|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
79727977|NCT04290819|Dietary Supplement|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
79727978|NCT04290819|Dietary Supplement|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
79727979|NCT04290819|Dietary Supplement|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
79727980|NCT04290819|Dietary Supplement|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
79727981|NCT02867943|Other|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
79727982|NCT01196429|Drug|Carboplatin|Given IV
79727983|NCT01196429|Drug|Docetaxel|Given IV
79727984|NCT01196429|Other|Laboratory Biomarker Analysis|Correlative studies
80023502|NCT02034201|Drug|Lisdexamfetamine|
79727985|NCT01196429|Drug|Paclitaxel|Given IV
79727986|NCT01196429|Drug|Temsirolimus|Given IV
79727987|NCT02887703|Behavioral|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
79727988|NCT01157364|Drug|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
79727989|NCT01157364|Drug|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
79266966|NCT02416089|Device|Condom catheter tamponade|
80023503|NCT02034201|Drug|Placebo|
80023504|NCT03609333|Device|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
79266967|NCT02420535|Behavioral|Immediately Receive Tool|
79266968|NCT02420535|Behavioral|One Month Delay|
79266969|NCT02420457|Procedure|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
79473372|NCT01686451|Drug|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
79473373|NCT01686451|Drug|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
79473374|NCT00361751|Drug|fenofibrate|
79473375|NCT05682638|Biological|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
79473376|NCT05682638|Other|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
79473377|NCT04899297|Other|Questionnaire|All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
79473378|NCT05681702|Drug|aspirin plus clopidogrel|After at least 30 days of DAPT [with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
79473379|NCT05681702|Drug|prasugrel or ticagrelor|After at least 30 days of DAPT [with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
79473380|NCT04675983|Drug|Sintilimab|Administered IV
79473381|NCT04675983|Drug|Ramucirumab|Administered IV
79473382|NCT04675983|Drug|Cisplatin|Administered IV
79473383|NCT04675983|Drug|5-fluorouracil|Administered IV
79473384|NCT04675983|Drug|Oxaliplatin|Administered IV
79473385|NCT04675983|Drug|Capecitabine|Administered orally
79473386|NCT03668951|Drug|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
79473387|NCT03668951|Drug|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
79400556|NCT06022913|Behavioral|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
80023505|NCT02034357|Other|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
80023506|NCT02034357|Other|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
79266970|NCT02420457|Drug|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
79567754|NCT04126018|Diagnostic Test|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
79727990|NCT01157364|Drug|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
79266971|NCT02166853|Drug|sevoflurane|Sedation with inhaled sevoflurane
79473388|NCT03668951|Drug|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
79567755|NCT04123535|Device|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
79567756|NCT04123366|Drug|Olaparib|Oral tablet
80023507|NCT03608943|Other|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
79727991|NCT01157364|Drug|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
79727992|NCT01157364|Drug|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
79727993|NCT01157364|Drug|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
79862769|NCT05361278|Other|Sodium hypochlorite solution|"Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the solution after using the last file.~Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
80023508|NCT02637856|Drug|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
80023509|NCT02637856|Drug|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
79567757|NCT04123366|Biological|Pembrolizumab|Intravenous infusion
79567758|NCT04109950|Drug|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
79473389|NCT05739344|Behavioral|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
79567759|NCT04097158|Other|Sample Collection|The investigators will be collecting blood, urine, and spinal fluid samples.
79567760|NCT04092634|Device|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
80023510|NCT02858037|Combination Product|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
79567761|NCT04092634|Device|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
80023511|NCT04433884|Device|Endotracheal intubation using a laryngoscope|Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
80023512|NCT03078088|Drug|Tham|alkalinizer
80023513|NCT03078088|Drug|Saline|Placebo
80023514|NCT05001334|Behavioral|Kangaroo care training|During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
79266972|NCT02166853|Drug|midazolam|Sedation with intravenous midazolam
79266973|NCT02704689|Device|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
79266974|NCT02162251|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
79266975|NCT02164045|Drug|BMS-663068|BMS-663068
79266976|NCT02704143|Other|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
79727994|NCT01157364|Drug|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
80023515|NCT05011942|Device|Irrisept Irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
79266977|NCT02586506|Drug|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
79567762|NCT04086589|Other|Observational study without intervention|Observational study without intervention
80023516|NCT05011786|Procedure|hernia repair/ligation of the hernial sac|the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
79567763|NCT04049669|Drug|Indoximod|Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
79727995|NCT01195415|Drug|Gemcitabine Hydrochloride|Given IV
79727996|NCT01195415|Other|Laboratory Biomarker Analysis|Correlative studies
79727997|NCT01195415|Drug|Vismodegib|Given PO
79727998|NCT01195103|Drug|Fospropofol disodium|10 mg/kg bolus
79727999|NCT01195103|Drug|Fospropofol disodium|6.5 mg/kg bolus
79728000|NCT01195103|Drug|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients <60 kg; 1.5 mg for patients ≥60 kg to <90 kg; or 2 mg for patients ≥90 kg
79728001|NCT01195103|Drug|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients <60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
79728002|NCT01194869|Drug|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
79728003|NCT01194869|Drug|Cisplatin|75 mg/m² given IV
79266978|NCT02586506|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
79567764|NCT04049669|Radiation|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
79567765|NCT04049669|Radiation|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine).
79728004|NCT01194869|Drug|Paclitaxel|175 mg/m² given IV
79728005|NCT04317833|Drug|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
80023517|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
80023518|NCT05011630|Other|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
80023519|NCT05011474|Biological|administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3|Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
79567766|NCT04049669|Drug|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
79567767|NCT04049669|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
79567768|NCT04049669|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
79728006|NCT04317833|Drug|Placebo|matched placebo
79728007|NCT01177800|Drug|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
79728008|NCT01177800|Drug|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
79728009|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
79728010|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
79728011|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
79728012|NCT01177722|Biological|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
80023520|NCT03076528|Other|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
79567769|NCT04049669|Drug|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
79567770|NCT04041401|Other|PICU storybook|Narrative and developmentally appropriate intervention
79567771|NCT04029454|Biological|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~training on hepatitis B awareness and management~training on EPI vaccination and cold chain~training on the modalities for the birth dose administration~the use of a monovalent unidose vaccine against Hepatitis B"
79728013|NCT02884986|Drug|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
79728014|NCT02884986|Drug|Placebo|120mg of placebo
79400557|NCT06021301|Other|Platelet-Rich Fibrin and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
79567772|NCT04028674|Device|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
79728015|NCT04124562|Other|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
79862770|NCT00764855|Procedure|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
79567773|NCT04023331|Drug|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
79567774|NCT04023331|Drug|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
79862771|NCT05589506|Device|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
79862772|NCT00759317|Drug|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
79862773|NCT00764933|Behavioral|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
80023521|NCT03076528|Other|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
80023522|NCT03077854|Radiation|Functional Lung Avoidance Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
80023523|NCT03077854|Radiation|Standard Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
79567775|NCT04023305|Drug|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
79567776|NCT04014712|Drug|Tetrahydrobiopterin|Oral, Single dose
79567777|NCT04014712|Drug|Placebo oral tablet|Single dose
79567778|NCT03967158|Device|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
79567779|NCT03915184|Biological|zevor-cel|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
79567780|NCT03912259|Drug|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
79567781|NCT03912259|Drug|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
79567782|NCT03912259|Drug|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
79728016|NCT01177410|Drug|Placebo|placebo capsules once daily for 12 weeks
79728017|NCT01177410|Drug|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
79728018|NCT01177410|Drug|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
79728019|NCT02884596|Drug|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
79728020|NCT05264220|Behavioral|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
79728021|NCT01156116|Device|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________"
79728022|NCT01156116|Drug|Placebo|oral placebo tablet
79728023|NCT01155726|Device|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
79728024|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
79567783|NCT03871829|Drug|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m^2 will be administered intravenously (IV).
79728025|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
79862774|NCT00764933|Other|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
80023524|NCT05005156|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
80023525|NCT05010928|Combination Product|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
79266979|NCT05550116|Other|Giomer|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
79266980|NCT05550116|Other|Two composite resin sealants|Unfilled composite resin sealants
79567784|NCT03871829|Drug|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m^2 will be administered IV.
79567785|NCT03871829|Drug|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
79728026|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
79728027|NCT01155726|Device|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
79728028|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
79728029|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
79728030|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
80023526|NCT05001100|Other|rehabilitation|rehabilitation
79266981|NCT02410005|Dietary Supplement|Calcitriol|
79728031|NCT04205916|Drug|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
79728032|NCT04205916|Other|Standard of care surgery|Standard method used for surgery and the use of post operative drops
79728033|NCT02886546|Procedure|pneumoperitoneum|
79728034|NCT02886546|Device|oesophageal Doppler monitor|
79728035|NCT04315428|Behavioral|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
79728036|NCT04315428|Behavioral|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
80023527|NCT04266340|Drug|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
80023528|NCT04266340|Drug|midazolam|0.5mg/kg oral midazolam
79266982|NCT02410005|Drug|Losartan|
79266983|NCT02166931|Dietary Supplement|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
79266984|NCT02420145|Behavioral|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
79862775|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
79862776|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
79862777|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
79862778|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
79862779|NCT01041040|Drug|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
80023529|NCT04266340|Drug|midazolam|0.05mg/kg intravenous injection midazolam
80023530|NCT04266340|Drug|Saline|no premedication
80023531|NCT04338945|Behavioral|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
80023532|NCT03079804|Other|Experimental MWM|Mobilization with Movement
79266985|NCT02410239|Biological|Mesenchymal Stem Cells|
79266986|NCT02255617|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
79266987|NCT05543330|Drug|M701 pleural infusion|M701 pleural infusion on Days 1,4,7 and 10.
79567786|NCT03871829|Drug|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
79567787|NCT03871829|Drug|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
79567789|NCT03845270|Drug|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
79567790|NCT03831464|Drug|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
79567791|NCT03831464|Drug|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
79862780|NCT00765011|Drug|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
79567792|NCT03799991|Behavioral|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
80023533|NCT03079804|Other|Experimental Thrust|Mobilization grade 5 (Thrust)
79728037|NCT04315662|Other|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
79862781|NCT00765011|Procedure|H&N surgery|Rescue surgery
80023534|NCT03079804|Other|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
80023535|NCT03609255|Behavioral|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
80023536|NCT03609255|Behavioral|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
79862782|NCT01035034|Procedure|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
80023537|NCT03609255|Behavioral|Control|An educational handout for sedentary behavior and weekly neutral topic videos
80023538|NCT03077464|Behavioral|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
80023539|NCT03079960|Device|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
80023540|NCT05000554|Procedure|Neoadjuvant Therapy|"Drug:~Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa<1.25m2,40mg/time，twice a day；bsa1.25~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14；~Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection"
80023541|NCT02856555|Drug|Firsocostat|Capsules orally once daily.
80023542|NCT02856555|Drug|Placebo|Placebo matched to firsocostat orally once daily.
80023543|NCT05000476|Other|eye mask and earplugs|Materials similar to those offered on long commercial flights
80023544|NCT05000476|Other|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
79266988|NCT05543330|Procedure|Pleural drainage|Pleural effusion drainage via Ultra-sound guidance on Day 1.
79266989|NCT05543330|Drug|Cisplatin pleural infusion|Cisplatin pleural infusion (30-50mg/m2) on Day 1.
79266990|NCT03174561|Dietary Supplement|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
79266991|NCT03174561|Other|diet restriction|diet restriction for 28 days
79862783|NCT01035034|Procedure|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
79862784|NCT00765089|Procedure|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
79862785|NCT00765167|Drug|Fluoride|Brush half mouth twice daily for four days
80023545|NCT03076450|Device|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
79266992|NCT02164123|Other|Spinal mobilization|Experimental group
79266993|NCT02164123|Other|Spinal Mobilization II|Active comparator group
79266994|NCT02164123|Other|Placebo|Placebo group
79567793|NCT03799991|Behavioral|Active control|Strength and flexibility exercises that do not involve head movements.
79567794|NCT03783936|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2
79567795|NCT03783936|Drug|Leucovorin|Leucovorin 400 mg/m2
79567796|NCT03783936|Drug|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
80023546|NCT03076450|Diagnostic Test|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
79567797|NCT03783936|Drug|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
79567798|NCT03783936|Drug|Avelumab|Avelumab 800 mg
79567799|NCT03755414|Procedure|Stem cell transplantation|Standard of care
80023547|NCT03608787|Behavioral|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
80023548|NCT03076138|Device|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
80023549|NCT03077308|Procedure|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual [every 10-14 months]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
80023550|NCT02237235|Drug|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
80023551|NCT02237235|Drug|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
79567800|NCT03755414|Drug|Itacitinib|Itacitinib may be taken without regard to food.
79567801|NCT03755414|Other|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|"Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
79728038|NCT04315662|Other|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
79862786|NCT00765167|Drug|Triclosan|Brush half mouth daily for four days
79862787|NCT00765167|Drug|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
79862788|NCT00765167|Drug|Fluoride|Brush half mouth daily for four days
80023552|NCT03609099|Drug|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
80023553|NCT03609099|Drug|Placebo|once a day oral treatment during 3 days.
79567802|NCT03755414|Other|Human Activity Profile|"Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
79567803|NCT03754114|Other|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
80023554|NCT03077230|Behavioral|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
80023555|NCT04463290|Other|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
80023556|NCT05004844|Diagnostic Test|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
80023557|NCT05000398|Other|Stretching the intrinsic muscles|Participants will be asked to dorsiflex the foot and stretch for 30 seconds. It will be done with 5 repetitions.
80023558|NCT05000398|Other|Thumb Abduction with MTF Joint Traction|participants will be held for 30 seconds by passively abducting the thumb within the limits of pain, and will be applied with 5 repetitions.
80023559|NCT05000398|Other|Thumb active extension exercise|An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. It will be desired to move the feet away from each other without moving the heels from the ground and the extension movement of the thumbs.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
79581475|NCT06071520|Drug|Fostamatinib|Patient treated with fostamatinib in the period described
79728039|NCT01155024|Device|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
79862789|NCT00759551|Drug|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
79862790|NCT00759551|Drug|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
79862791|NCT00759551|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
79862792|NCT00759551|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
79862793|NCT00759551|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
79862794|NCT00759551|Drug|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
79862795|NCT00759551|Drug|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
79862796|NCT03905096|Drug|BI 425809|Film coated tablet
79862797|NCT03905096|Drug|Donepezil|Film coated tablet
79862798|NCT02557919|Other|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
79862799|NCT02557919|Other|Usual Best Practice|.5 day training on tobacco control and emerging products.
79567804|NCT03754114|Other|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
79862800|NCT00412360|Biological|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
79567805|NCT03742986|Drug|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
79728040|NCT01155024|Device|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
79728041|NCT01176240|Drug|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
79728042|NCT01176240|Other|Placebo|Placebo
79862801|NCT00412360|Biological|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
79567806|NCT03742986|Drug|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
79567807|NCT03742986|Drug|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
79567808|NCT03742986|Drug|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m^2 on Day 1 of every 14 day cycle (Cycle 5-8)
79567809|NCT03742986|Drug|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m^2 on Day 1 of every 21 day cycle (Cycle 1-4)
79862802|NCT00412360|Radiation|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
79862803|NCT00412360|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
79862804|NCT00412360|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
79266995|NCT02420301|Other|Tuina exercises|
79567810|NCT03742986|Drug|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
79567811|NCT03742986|Drug|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
79567812|NCT03736720|Drug|Fluorouracil|Given IV
79567813|NCT03736720|Drug|Leucovorin|Given IV
79567814|NCT03736720|Drug|Liposomal Irinotecan|Given IV
79567815|NCT03736720|Procedure|Quality-of-Life Assessment|Correlative studies
79567816|NCT03708328|Drug|Lomvastomig|Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
79567817|NCT03703167|Drug|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
79567818|NCT03703167|Drug|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 & 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
79567819|NCT03703167|Drug|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
79567820|NCT03676465|Other|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
79567821|NCT03676465|Other|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
79728043|NCT00988221|Drug|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
79728044|NCT00988221|Drug|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
79728045|NCT02884830|Device|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
79728046|NCT02886312|Device|Supplemental Oxygen Delivery System|
79728047|NCT01149096|Procedure|Bone Marrow Donation|Undergo bone marrow harvest
79728048|NCT01149096|Biological|Filgrastim|Given subcutaneously
79728049|NCT01149096|Other|Laboratory Biomarker Analysis|Optional correlative studies
79728050|NCT02867397|Drug|Teysuno (S1) in combination with epirubicin and oxaliplatin|
79728051|NCT04291053|Drug|Huaier Granule|standard treatment + Huaier Granule 20g po tid for 2weeks
79728052|NCT02884518|Device|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
79728053|NCT02884518|Behavioral|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
79728054|NCT02866851|Other|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
79728055|NCT01175382|Behavioral|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
79862805|NCT00412360|Drug|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
79862806|NCT00412360|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if < 50 kg beginning the morning of Day -3.
79567822|NCT03674528|Other|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
79567823|NCT03674528|Diagnostic Test|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
79567824|NCT03672630|Drug|Azithromycin|Azithromycin 500 MG Oral Tablet [ZITHROMAX]
79862807|NCT00761423|Biological|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
79862808|NCT00761423|Biological|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
79567825|NCT03672630|Drug|Ethambutol|Ethambutol 25 mg/kg [MYAMBUTOL]
79567826|NCT03672630|Drug|Rifampin|Rifampin 600 MG [RIFADIN]
80023560|NCT05000398|Other|Toe spread out|In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
79567827|NCT03659734|Behavioral|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
79567828|NCT03659734|Behavioral|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
79567829|NCT03642028|Drug|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
79728056|NCT01175382|Drug|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
79728057|NCT01175382|Other|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
79728058|NCT01194245|Drug|Insulin lispro|
79728059|NCT01194245|Drug|recombinant human hyaluronidase PH20|
79567830|NCT03642028|Other|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
79567831|NCT03639753|Behavioral|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
79728060|NCT01194245|Drug|Insulin aspart|
79728061|NCT01194245|Drug|Insulin glulisine|
79862809|NCT03957967|Other|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
79728062|NCT01194245|Drug|Insulin glargine|
79728063|NCT02887547|Procedure|micro-osteoperforation|
79728064|NCT04311528|Biological|9-valent HPV vaccine|9-valent HPV vaccine
79728065|NCT00979407|Biological|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
79862810|NCT00761501|Drug|PN400|Oral
79862811|NCT00761501|Drug|Naproxen (Proxen S)|Oral
79862812|NCT00761501|Drug|Naproxen (Naprosyn E)|Oral
79266996|NCT02420301|Other|Placebo Tuina exercises|
79266997|NCT05545592|Other|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
79728066|NCT00979407|Biological|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
79862813|NCT01564160|Dietary Supplement|Fish Oil|Source of omega-3 fatty acids.
80023561|NCT05000398|Other|Short foot|While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
79266998|NCT02167087|Procedure|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
79862814|NCT01564160|Dietary Supplement|PCSO-524|Extract of Greenshell Mussel
79862815|NCT01088893|Drug|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
79862816|NCT03026036|Radiation|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
79862817|NCT00759629|Other|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
79862818|NCT00759629|Other|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
79862819|NCT01088971|Dietary Supplement|Duolac7S|1 capsule two times everyday for 6 weeks
79862820|NCT01088971|Dietary Supplement|starch|1capsule two times everyday for 6 weeks
79862821|NCT00990860|Drug|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
79862822|NCT00990860|Procedure|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
79862823|NCT02558543|Drug|Stromal Vascular fraction|
79862824|NCT02558543|Drug|Ringer lactate|
80023562|NCT05000398|Other|Heel rise|After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
80023563|NCT05000398|Other|Towel toe curl|Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
79266999|NCT05545436|Drug|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
79267000|NCT03174639|Procedure|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
79267001|NCT02164279|Other|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)
79862825|NCT01035190|Drug|Budesonide|Inhalation, 200 µg/puff
79862826|NCT01090687|Radiation|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
79862827|NCT01090687|Device|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
79862828|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
79862829|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
79862830|NCT02557841|Device|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
79862831|NCT00765479|Dietary Supplement|soy protein isolate|Given orally
79862832|NCT00765479|Other|placebo|Given orally
79862833|NCT01035268|Procedure|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
79862834|NCT00571103|Drug|acamprosate|Two 333mg tablets taken three times daily.
79862835|NCT03742934|Other|Short peptide|Short peptide formula during bowel preparation
79862836|NCT03742934|Other|Liquid diet|Liquid diet during bowel preparation
79862837|NCT00991016|Drug|PF-04805712|ascending single and multiple doses starting at 30 mg
79862838|NCT03993652|Behavioral|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
79862839|NCT02558777|Other|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
79567832|NCT03639753|Other|Usual Practice|Standard care for teens who get licensed in the state of PA
79728067|NCT01148862|Device|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
79862840|NCT01089049|Dietary Supplement|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
79567833|NCT03636295|Drug|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
79567834|NCT03630107|Other|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
79728068|NCT02884674|Device|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
79728069|NCT02884674|Device|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
79862841|NCT01038934|Procedure|samples collected by buccal cytobrush|
79862842|NCT00765557|Drug|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
79862843|NCT00765557|Drug|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
79862844|NCT02828618|Procedure|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
79862845|NCT02828618|Procedure|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
79862846|NCT02828618|Procedure|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
79862847|NCT02828618|Procedure|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
79267002|NCT05545358|Other|Questionnaires|Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
79567835|NCT03609177|Other|Clinician Communication Skills Training|Communication skills training
79567836|NCT03609177|Other|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
79567837|NCT03609177|Other|Video Declarations (ViDec)|Recording of patient advance care planning videos
79567838|NCT03603210|Device|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
79567839|NCT03589846|Device|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
79567840|NCT03588481|Device|DESyne X2|Novolimus-eluting stent
79567841|NCT03586102|Dietary Supplement|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive > 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
79862848|NCT02828618|Drug|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
79862849|NCT01086553|Drug|budesonide|9mg budesonide OD
79862850|NCT01086553|Drug|budesonide|3mg budesonide TID
79862851|NCT01041352|Device|laryngeal mask|LMA Proseal
79862852|NCT01041352|Device|endotracheal tube|Unomedical endotracheal tube
79862853|NCT00765635|Drug|drops intilation (Taponoto ® )|four drops, unique doses
79862854|NCT00765635|Drug|drops intilation (Otocerum®)|four drops, unique doses
79862855|NCT00765635|Drug|drops intilation (Placebo)|Placebo
79728070|NCT02866773|Behavioral|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
80023564|NCT05000398|Other|Gastrocnemius active static stretching exercise|The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
79267003|NCT05545358|Device|Brain and Spinal Cord functional Magnetic Resonance Imaging|Brain and Spinal Cord functional Magnetic Resonance Imaging
79267004|NCT05545358|Other|Proprioceptive training|Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
79728071|NCT02866773|Behavioral|PA2: Education sessions, Reminders|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
79267005|NCT02167165|Drug|Digoxin Injection|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
79728072|NCT02866773|Behavioral|PA3: Education sessions, Whataps group|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
79267006|NCT05545124|Drug|Donafenib + Tislelizumab|Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
79267007|NCT02409849|Drug|Octreotide lar|
79308986|NCT04351815|Other|No specific intervention|"Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~Patients will be asked to maintain regular physical activity without support~2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
79728073|NCT02866773|Behavioral|PA4: Education sessions|"The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
79728074|NCT02866773|Behavioral|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
79728075|NCT02866773|Behavioral|HD2: Education sessions, Reminders|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
79728076|NCT02866773|Behavioral|HD3:Education sessions, Whataps group|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
79728077|NCT02866773|Behavioral|HD4: Education sessions|"The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
79728078|NCT00975975|Drug|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
79728080|NCT01193153|Drug|Placebo|monthly by i.m. injection for 15 months
79728081|NCT01193153|Drug|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
79728082|NCT02867007|Drug|KHK2455|oral dosing
79728083|NCT02867007|Drug|Mogamulizumab|i.v. administration
79728084|NCT04289883|Combination Product|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
80023565|NCT05000398|Other|Plantar fascia and gastrocnemius stretching exercise on step|The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
80023566|NCT04925440|Dietary Supplement|Bifidobacterium longum 1714® strain|Probiotic capsules containing 5 x 10^9 CFUs, corn-starch and magnesium stearate.
80023567|NCT04925440|Dietary Supplement|Placebo|Capsules containing corn-starch and magnesium stearate only.
80023568|NCT05000086|Drug|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
79567842|NCT03586102|Dietary Supplement|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (< 4.5 g/kg/day of enteral protein)
79728085|NCT04289883|Combination Product|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
79862856|NCT02810990|Drug|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 > 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
79267008|NCT00664040|Other|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
79567843|NCT03562793|Behavioral|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
79567844|NCT03556826|Behavioral|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
79267009|NCT00664040|Other|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
79728086|NCT04289337|Dietary Supplement|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
79567845|NCT03551691|Drug|Omeprazole 40mg Capsule|Omeprazole 40mg daily for 28 days
79728087|NCT04289337|Dietary Supplement|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
79862857|NCT01041430|Other|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
79862858|NCT01041430|Other|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
79862859|NCT00069277|Drug|E7389|
79567846|NCT03551691|Drug|Placebo oral capsule|Identically-appearing capsule to omeprazole for 28 days
79567847|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
80023569|NCT03077074|Other|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
79581476|NCT06071481|Drug|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
79728088|NCT04289337|Dietary Supplement|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
79728089|NCT04289337|Dietary Supplement|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
79728090|NCT04289337|Dietary Supplement|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
79728091|NCT04289337|Dietary Supplement|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
79728092|NCT02865369|Drug|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
79728093|NCT04290585|Other|Questionnaire Administration|Ancillary studies
79728094|NCT04290585|Behavioral|Telephone-Based Intervention|Receive text message reminders
79862860|NCT00765713|Device|Nasal continuous positive airway pressure|Nocturnal
79862861|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
80023570|NCT05000008|Other|Exercises|Moderate aerobic and resistance exercise programe
80023571|NCT05004922|Other|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
80023572|NCT05004922|Other|Embryo transfer into midcavity|Transfer of embryos in mid cavity
80023573|NCT05010382|Procedure|Implant placement surgery|Under local anaesthesia, full-thickness mucoperiosteal flaps were elevated, the alveolar ridge measured, and a proper implant dimension (3.75 mm and 4.25 mm diameter; 8 mm, 10 mm and 11.5 mm length) and position selected. After site preparation, each patient was randomly allocated to the test or the control group. Patients in the test group received a modified implant design with the coronal third presenting a machined surface (hybrid surface (HS) group), while in the control group the same implant design with a titanium rough surface up to the implant shoulder was used (rough surface (RS) group). Implants were placed 1 mm sub-crestally. In the case of dehiscence or fenestrations around the implant, the patient was excluded from the study. Once inserted, healing abutments (ranging between 3 -5 mm) were placed, and flaps sutured around the abutments to allow for a transmucosal healing.
79862862|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
79862863|NCT00765869|Other|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
79862864|NCT00766025|Drug|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
79862865|NCT01039012|Other|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
79862866|NCT01039012|Other|Standard Care|Participant follow the standard care recommended by their physician.
79862867|NCT04049357|Device|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
79862868|NCT00766103|Other|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
79728095|NCT01192295|Drug|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
79728096|NCT02866929|Procedure|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
79862869|NCT05577572|Dietary Supplement|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1~10 and Probiotics packets is taken from day 1~56.
79862870|NCT05577572|Dietary Supplement|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1~10 and Placebo packets is taken from day 1~56.
79400558|NCT06018545|Other|Ground truthing|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration.
79728097|NCT02866929|Device|Orthodontics|Self-ligation brackets in upper and lower teeth
79728098|NCT02866929|Drug|Mucograft|Porcine naturally cross-linked collagen matrix
79728099|NCT04289181|Other|Medically Tailored Meals|4 weeks of medically tailored meals
79728100|NCT02865291|Device|ForConti device|
79728101|NCT04317365|Other|Women receiving extra remembering by healthcare|Women receiving extra remembering by healthcare in covid infection
79728102|NCT04289103|Biological|Inolimomab (Leukotac)|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~Treatment phase - Leukotac will be given up to D28~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
79267010|NCT00664040|Other|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
79308987|NCT04796025|Drug|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
79728103|NCT04316897|Device|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
79862871|NCT00760097|Device|Transcranial direct stimulation|sessions of 20 minutes each
79862872|NCT00766181|Behavioral|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
79862873|NCT05358002|Procedure|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
79862874|NCT04048577|Drug|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
79862875|NCT00991250|Biological|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
79728104|NCT04272879|Other|Observational Group|Those requiring NIV following an acute exacerbation of COPD
79728105|NCT01154166|Drug|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
79728106|NCT01154166|Drug|Placebo|Placebo
79862876|NCT00991250|Drug|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
79862877|NCT00762047|Device|Durasphere FI|Durasphere Injection
79862878|NCT00762047|Device|Sham|Sham injection with anesthesia
79862879|NCT00418522|Drug|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
79267011|NCT00664040|Other|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
79267012|NCT02162407|Drug|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
79400559|NCT06018545|Other|Reading|All 30 readers will review all 150 cases, in each of two study phases. The readers will provide their opinion on the presence or absence of some acute abnormalities, including intracranial haemorrhage, infarct, midline shift and fracture. They will provide a confidence in their diagnosis (10-point visual analogue scale), and a single click point to mark the location of each abnormality that they consider as being present. The time taken for each scan will be automatically recorded.
79400560|NCT06017102|Device|wired magnetic assisted capsule endoscopy|once
79400561|NCT06017102|Device|esophagogastroduodenoscopy|once
79567848|NCT03508518|Other|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
79728107|NCT04290195|Drug|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
79728108|NCT05656937|Procedure|internal jugular venous cannulation|internal jugular venous cannulation
79728109|NCT04317131|Diagnostic Test|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
79400562|NCT06014164|Diagnostic Test|Interview|An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
79400563|NCT06013982|Behavioral|Anxiety Reduction Bundle|"The Anxiety Reduction Bundle intervention comprises the following resources:~Stroke Support Group~Anxiety Reduction Sheet~Understanding Anxiety Disorder sheet~Your body's response to anxiety sheet~Relaxation Tip sheet~Breathing Tip sheet and video~A sigh of Relief video"
79400564|NCT06011928|Other|MOPEX Exercise|"Exercises to be done in order:~Pelvic tilt in supine position~Bridge building~Pelvic stretching~Ball spin~Cat-camel exercise~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds"
79473390|NCT04890327|Other|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
79473391|NCT05400356|Procedure|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
79567849|NCT03508518|Other|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
79567850|NCT03508427|Other|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
79728110|NCT04317131|Device|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
79473392|NCT04889703|Drug|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
79862880|NCT00418522|Drug|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
79267013|NCT02162407|Drug|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
79267014|NCT02409693|Procedure|Myringotomy with tube insertion|
79567851|NCT03501303|Procedure|No touch technique|Veins for CABG is harvested with the no touch technique
79567852|NCT03501303|Procedure|Control technique|Veins for CABG is harvested with the Control technique.
79567853|NCT03494881|Drug|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
79728111|NCT04317131|Device|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
79728112|NCT04317131|Device|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
79728113|NCT04317131|Device|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
79728114|NCT02865603|Behavioral|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
79267015|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler|
79267016|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
79267017|NCT02162485|Drug|Seretide Diskus|
79267018|NCT02162485|Drug|Seretide Diskus with charcoal|
79267019|NCT02415777|Drug|Ursodeoxycholic acid, thiamine, riboflavin|
79728115|NCT05656859|Behavioral|Single group|Survey
79728116|NCT04289259|Other|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
79862881|NCT00991328|Procedure|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
79862882|NCT00762125|Behavioral|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
79267020|NCT02409771|Device|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
79267021|NCT05543018|Diagnostic Test|Electroretinogram|Retinal function assessment using electroretinogram
79267022|NCT05543018|Procedure|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
79267023|NCT02409615|Other|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
79267024|NCT02409615|Other|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
79267025|NCT05542940|Other|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
79267026|NCT03178539|Drug|diclofenac|non steroidal anti-inflammatory drug
79267027|NCT03178539|Drug|ketorolac|non steroidal anti-inflammatory drug
79267028|NCT03178305|Behavioral|Do CHANGE|"Besides the behavior change programme (Do Something Different)~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
79267029|NCT03174717|Behavioral|Music performance|residents of LTC will learn and perform songs with musicians from the community
79567854|NCT03493425|Drug|Carboplatin|Given IV
79567855|NCT03493425|Drug|Cisplatin|Given IV
79567856|NCT03493425|Drug|Docetaxel|Given IV
79567857|NCT03493425|Radiation|Image Guided Radiation Therapy|Undergo image guided IMRT
79567858|NCT03493425|Radiation|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
79567859|NCT03493425|Other|Laboratory Biomarker Analysis|Correlative studies
79567860|NCT03493425|Other|Questionnaire Administration|Ancillary studies
79567861|NCT03493425|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
79567862|NCT03490929|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
79567863|NCT03490929|Device|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
79567864|NCT03477058|Other|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
79567865|NCT03468634|Diagnostic Test|endoscopy|Oesophageal endoscopy with biopsy
79567866|NCT03451123|Drug|FET PET/MRI|FET PET/MRI scan before and after surgery
79567867|NCT03429582|Device|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
79728117|NCT04313556|Procedure|Lateral patellar release|Arthroscopic lateral patellar reticular release
79728118|NCT05656703|Device|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
79728119|NCT05656703|Other|Standard of Care|Anesthesia is administered as usual
79567868|NCT03429582|Device|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
79728120|NCT02866617|Device|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
79728121|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
79728122|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
79728123|NCT02865213|Device|OBA|"The intrusion of posterior teeth using removable appliance OBA."
79862883|NCT00762125|Behavioral|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
79862884|NCT00762125|Behavioral|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
79862885|NCT00762281|Device|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
79862886|NCT00760175|Biological|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
79862887|NCT02703662|Device|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
79862888|NCT02703662|Device|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
79862889|NCT00762437|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
79862890|NCT02557763|Device|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
79400565|NCT06011928|Other|Relaxation Exercise|Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened.
79473393|NCT04889703|Drug|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
79473394|NCT05739266|Behavioral|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
79473395|NCT00421811|Drug|ADH-1|4 gm IV Days 1 and 8
79473396|NCT00421811|Drug|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
79473397|NCT04884477|Biological|Convalescent Plasma|Convalescent Plasma
79567869|NCT03429582|Device|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
79567870|NCT03382145|Other|No intervention|No intervention
79567871|NCT03373383|Drug|Padsevonil|Padsevonil in different dosages.
79862891|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
79862892|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
79862893|NCT00766337|Drug|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
79862894|NCT01564004|Other|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
79567872|NCT03373383|Other|Placebo|Placebo will be provided matching Padsevonil.
79567873|NCT03348566|Other|fish|fish intkae
79567874|NCT03332797|Drug|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
79567875|NCT03332797|Drug|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
79581477|NCT06071403|Other|(enteral feeding volume/ total fluid volume)*100%|(enteral feeding volume/ total fluid volume)*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
79862895|NCT00762593|Device|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
79862896|NCT00762593|Device|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
79862897|NCT00991562|Drug|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
79862898|NCT00762671|Drug|Ebselen|150 mg BID for 2 weeks
79862899|NCT00762671|Drug|Placebo|Placebo 1 po BID for 2 weeks
80023574|NCT01242267|Drug|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
80023575|NCT03076294|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
79862900|NCT05306483|Procedure|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
80023576|NCT03076294|Other|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
80023577|NCT03608553|Device|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
79567876|NCT03332797|Drug|LHRH Agonist|The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
79567877|NCT03320018|Drug|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
79567878|NCT03320018|Drug|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
79862901|NCT05306483|Procedure|Ventricular septal defect closure catheter|Catheter closure of VSD
79567879|NCT03320018|Other|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
79567880|NCT03320018|Other|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
79728124|NCT02865213|Device|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
79728125|NCT02865213|Device|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
79862902|NCT02558387|Drug|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
79862903|NCT00766805|Drug|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
80023578|NCT01741480|Other|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
80023579|NCT01741480|Other|routine care|
80023580|NCT03608085|Behavioral|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~Online material for home self-study (10 contact hours);~Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~Monthly coaching conference calls/webinars with URI and Brown Faculty;"
79567881|NCT03306082|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
79567882|NCT03276559|Behavioral|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
79728126|NCT05656079|Drug|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
79862904|NCT00766805|Other|EVL alone|
79728127|NCT05656079|Drug|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79728128|NCT05656079|Drug|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79728129|NCT05656079|Drug|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79862905|NCT00766883|Behavioral|Problem Solving Education|
79862906|NCT00766961|Procedure|Trans-catheter arterial embolization|Trans-catheter arterial embolization
79862907|NCT00766961|Procedure|Surgery|Surgery
79728130|NCT05656079|Drug|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79728131|NCT05656079|Drug|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
79567883|NCT03276559|Other|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
79567884|NCT03274492|Drug|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
79728132|NCT00975585|Device|senofilcon A|soft contact lens, 2-week replacement indicated
79728133|NCT00975585|Device|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
79728134|NCT01181921|Drug|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
79728135|NCT02883894|Other|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
79728136|NCT05655923|Biological|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
79728137|NCT05655923|Biological|xenograft bone substitute|Xenograft bone substitutes in all Groups
79267030|NCT03178461|Other|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
79567885|NCT03274492|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
79728138|NCT02867241|Behavioral|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
79567886|NCT03274492|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
79567887|NCT03274492|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
79728139|NCT02867241|Behavioral|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
79728140|NCT02867085|Other|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
79728141|NCT05655767|Other|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
79728142|NCT04317443|Procedure|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
79728143|NCT04317443|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
79862908|NCT00762749|Drug|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
79862909|NCT00403546|Drug|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
79862910|NCT00403546|Drug|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
79267031|NCT05558930|Device|iTBS stimulation|standard iTBS burst pattern:3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals. 600 pulses on both side of cerebellar with an interval of 5 minutes.
79267032|NCT05558930|Device|sham stimulation|Participants receive a sound stimulation with the same pattern with iTBS stimulation,but without magnetic field
79567888|NCT03274492|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
79728144|NCT01174446|Biological|BAX 326|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
79567889|NCT03274492|Drug|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
79567890|NCT03274492|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
79862911|NCT00403546|Drug|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
79862912|NCT00767117|Drug|Etravirine; Lopinavir; Ritonavir|
79862913|NCT02558621|Device|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
79862914|NCT00760565|Drug|RO4905417|3mg/kg iv every 28 days for 3 infusions
79862915|NCT00760565|Drug|RO4905417|20mg/kg iv every 28 days for 3 infusions
79862916|NCT00760565|Drug|RO4905417|7mg/kg iv every 28 days for 3 infusions
79862917|NCT00760565|Drug|placebo|3mg/kg iv every 28 days for 3 infusions
79862918|NCT00760565|Drug|placebo|7mg/kg iv every 28 days for 3 infusions
79862919|NCT00760565|Drug|placebo|20mg/kg iv every 28 days for 3 infusions
79728145|NCT01174446|Biological|BeneFIX|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~BeneFIX only used in Part 1 of this study.~Study Part 2 and 3 only utilized BAX326"
79567891|NCT03274492|Drug|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
79567892|NCT03271034|Dietary Supplement|Weight loss|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for ~4 months.
79267033|NCT03178227|Behavioral|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
80023581|NCT03608085|Behavioral|Patient Heart failure MTM intervention|"The baseline visit will take place >= 7 but <= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
79567893|NCT03257384|Other|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
79567894|NCT03255577|Procedure|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
79267034|NCT03174483|Drug|Hypertonic saline|nasal spray
79728146|NCT04316273|Other|colonic surgery|resection of duplicated colon
79728147|NCT00932698|Drug|Ixazomib|Ixazomib capsules
79862920|NCT00403390|Drug|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
79862921|NCT00403390|Drug|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
79862922|NCT00767273|Procedure|PET Scan|
79862923|NCT00767273|Drug|FLT|
80023582|NCT04994158|Combination Product|Drugs, procedures|standard of care only. non interventional registry.
79728148|NCT00978627|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
79728149|NCT00978627|Drug|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
79862924|NCT00767273|Drug|FDG|
79862925|NCT00762905|Device|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
80023583|NCT05004766|Other|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
79267035|NCT03174483|Drug|Fluticasone Nasal|nasal spray
79400566|NCT06011928|Other|Combine Exercise|"Exercises to be done in order:~Pelvic tilt in supine position Bridge building Pelvic stretching Ball spin Cat-camel exercise Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds.~Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened."
79728150|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
79728151|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
79728152|NCT01181609|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
79728153|NCT01154010|Device|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
79728154|NCT01154010|Device|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
79728155|NCT02866305|Procedure|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
79728156|NCT02866305|Procedure|Chest tube insertion|Conventional chest tube insertion.
79862926|NCT00762905|Device|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
79862927|NCT00762983|Drug|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
79862928|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
79728157|NCT02866305|Drug|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
79862929|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
79862930|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
79862931|NCT00403234|Drug|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
79567895|NCT03250975|Drug|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
79567896|NCT03250975|Other|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
79567897|NCT03230318|Drug|derazantinib|Derazantinib was administered orally at 300 mg once daily
79567898|NCT03191162|Drug|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
79567899|NCT03169972|Biological|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
79567900|NCT03142958|Device|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
79567901|NCT03132337|Other|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
79567902|NCT03090633|Device|Fetoscopy|Minimally invasive in-utero surgery
79862932|NCT00767429|Device|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
79862933|NCT00760721|Behavioral|Educational Small Group Session|1 hour small group health-related discussion
80023584|NCT04066413|Other|Standard infant formula|Standard infant formula
80023585|NCT04066413|Other|Infant formula supplemented with HMO|Infant formula supplemented with HMO
80023586|NCT02637232|Other|Mirvaso® / Onreltea TM|
79400567|NCT06010875|Biological|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
79728158|NCT02866305|Radiation|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
79728159|NCT04261426|Drug|Intravenous Immunoglobulin|IVIG 0.5g/kg/d for 5 days
79728160|NCT04261426|Other|Standard care|Standard care
79728161|NCT04264078|Biological|CD7 UCAR-T cells|Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
79400568|NCT06010875|Biological|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
79400569|NCT06010862|Biological|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
79728162|NCT04264078|Drug|Fludarabine|30mg/m^2 per day for 6 days
79862934|NCT04049201|Procedure|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
79862935|NCT04049201|Drug|Midazolam|Oral Midazolam
80023587|NCT02715375|Device|CREON2000A|
79567903|NCT03085316|Device|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
79567904|NCT03080883|Drug|Apixaban|Given PO
79567905|NCT03060291|Behavioral|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
80023588|NCT04993690|Drug|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
80023589|NCT02855541|Device|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
79400570|NCT06010862|Biological|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
79567906|NCT03060291|Behavioral|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
79567907|NCT03058627|Procedure|PCI|FFR guided PCI
79567908|NCT03025035|Drug|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
79567909|NCT03025035|Drug|Olaparib|Olaparib administered orally twice a day
79567910|NCT02956291|Device|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
79728163|NCT04264078|Drug|Cytoxan|600mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
79862936|NCT04049201|Device|Interactive Tablet|interactive Tablet containing many cartoon's videos
79862937|NCT00767663|Drug|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
79862938|NCT00767663|Drug|placebo|placebo twice daily, minimal three days pretreatment
79728164|NCT04264078|Drug|Melphalan|50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
79728165|NCT04290273|Diagnostic Test|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
79267036|NCT05542784|Procedure|Modified LERV|"Patients routinely underwent LC. The ligature clamp clamps the distal end of the capsule tube. In this case, you need to perform two steps:~Laparoscopic operation: proximal incision, anterograde placement of guide wire into the duodenum. The catheter was removed and the balloon dilated. The balloon was released and removed when the ERCP was initiated for cannulation. After successful ERCP retrograde placement, the anterograde guide wire was pulled out and the gallbladder was removed.~ERCP procedure: After the anterograde guide wire was observed by duodenoscope, duodenal papilla was placed through a retrograde incision along the anterograde guide wire, and a retrograde cannula was inserted into the common bile duct. Remove stones by dragging them with a net basket or/and balloon. Angiography confirmed that there was no filling defect in the extrahepatic bile duct, and ENBD was indwelled."
79862939|NCT00767741|Device|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
79862940|NCT00763295|Other|T-Spot.TB test|diagnostic test
79267037|NCT05699174|Drug|Standard of Care PO (oral) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to PO (oral) antibiotics for up to 6 weeks post hospitalization. The exact type of oral antibiotic will be depended on the patient's infection diagnosis.
79862941|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
79267038|NCT05699174|Drug|Standard of Care Intravenous (IV) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. The exact type of IV antibiotic will be depended on the patient's infection diagnosis.
79567911|NCT02953509|Drug|Magrolimab|Administered intravenously
79567912|NCT02953509|Drug|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
79567913|NCT02953509|Drug|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
79862942|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
79567914|NCT02953509|Drug|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
79567915|NCT02939872|Drug|aspirin and clopidogrel|at the discretion of investigator
79728166|NCT04290273|Device|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
79728167|NCT00608218|Drug|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
79728168|NCT01174368|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
79728169|NCT02884050|Drug|Topiramate|antiepilepsy drug
79862943|NCT00402688|Drug|levofloxacin|500mg tablet once daily for 4 weeks.
79862944|NCT04049045|Drug|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
79862945|NCT04049045|Drug|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
79862946|NCT00763373|Other|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
79567916|NCT02939872|Drug|Clopidogrel only|at the discretion of investigator
79728170|NCT02884050|Drug|Placebo|non-active placebo
79728171|NCT00609934|Drug|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
79728172|NCT00609934|Radiation|external beam radiotherapy|3000cGy in 10 fractions
79728173|NCT01147926|Drug|Placebo|Placebo matched to Prucalopride tablet orally once daily.
79728174|NCT01147926|Drug|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
79728175|NCT05115136|Drug|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
79728176|NCT05115136|Drug|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
79862947|NCT00760799|Procedure|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
79862948|NCT01035580|Drug|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
79567917|NCT02856438|Drug|Elotuzumab|Specified dose on specified days
79567918|NCT02856438|Drug|Lenalidomide|Specified dose on specified days
79567919|NCT02856438|Drug|Dexamethasone|Specified dose on specified days
79728177|NCT00608374|Drug|chlorambucil|
79728178|NCT00608374|Drug|fludarabine phosphate|
79728179|NCT00608374|Procedure|quality-of-life assessment|
79862949|NCT01035580|Drug|curcumin|all patients received the drug
79862950|NCT03993730|Device|ICD|Insertion of ICD in patients with LVEF <45% and LGE on CMR.
79862951|NCT03993730|Device|ILR|Insertion of ILR in patients with LVEF <45% and LGE on CMR.
79862952|NCT01041586|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
79862953|NCT00671879|Drug|Carisoprodol SR 700 mg|700 mg twice daily tablet
79862954|NCT00671879|Drug|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
79862955|NCT00671879|Drug|Placebo|placebo tablet
79862956|NCT01039168|Behavioral|Workplace dialogue|
79862957|NCT01039168|Other|Care as usual|
79267039|NCT02419833|Procedure|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
79862958|NCT00770393|Procedure|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
79862959|NCT00770393|Procedure|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
79862960|NCT03994276|Dietary Supplement|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
79862961|NCT01036048|Device|drug eluting stent|pts with cabg disease treated with drug eluting stent
79862962|NCT01036048|Device|bare metal stent|pts with cabg disease treated with bare metal stent
79267040|NCT02419833|Procedure|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
79567921|NCT02803190|Behavioral|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
79567922|NCT02803190|Behavioral|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
79267041|NCT02419833|Device|Coronary artery stenting|Implantation of coronary stents
79728180|NCT00975507|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
79728181|NCT00975507|Biological|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
79728182|NCT00975507|Biological|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
79728183|NCT00975507|Biological|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
79267042|NCT04320914|Other|High Intensity LASER Therapy|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks."
79728184|NCT00625014|Drug|Haloperidol|Haloperidol 3 mg/day for 8 days
79567923|NCT02764801|Drug|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
79567924|NCT02764801|Device|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
79728185|NCT04261348|Other|No intervention|There is no intervention
79862963|NCT00767897|Drug|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
79862964|NCT00767975|Drug|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
79862965|NCT00767975|Drug|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
79862966|NCT00768131|Drug|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
79862967|NCT00768131|Drug|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
79862968|NCT00768131|Drug|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
79862969|NCT00401830|Drug|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
79862970|NCT00401830|Other|Placebo|Matching placebo tablet administered twice daily
79862971|NCT05285033|Drug|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
79862972|NCT00768209|Drug|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
80023590|NCT02635984|Drug|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
80023591|NCT02635984|Drug|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
79862973|NCT02557685|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
79728186|NCT04271163|Device|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
80023592|NCT03608319|Drug|A4250|9.6 mg
80023593|NCT03076216|Device|OncoSil™|The implantation of OncoSil™ under EUS
80023594|NCT03076918|Device|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
79728187|NCT04083339|Drug|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
79728188|NCT04083339|Drug|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
80023595|NCT03076918|Device|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
79728189|NCT01147848|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
80023596|NCT03076372|Drug|MM-310|MM-310
79567925|NCT02723929|Device|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
79581478|NCT06071390|Behavioral|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
79728190|NCT01147848|Drug|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
79728191|NCT01147848|Drug|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
79728192|NCT01147848|Drug|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
79728193|NCT00610090|Device|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
80023597|NCT03076060|Behavioral|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
80023598|NCT03076060|Behavioral|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
80023599|NCT03073408|Drug|Propofol|Closed loop control for propofol administration guided by the BIS.
79267043|NCT04320914|Other|Ibuprofen gel phonophoresis|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
79728194|NCT00606658|Procedure|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
79728195|NCT02864823|Procedure|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
79728196|NCT00929656|Procedure|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
79728197|NCT00929656|Procedure|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
79728198|NCT00929656|Procedure|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
79862974|NCT00401752|Drug|Esomeprazole|
79862975|NCT00401752|Drug|Ranitidine|
79862976|NCT04048967|Behavioral|Professional development|professional development of preschool staff
79862977|NCT00770471|Drug|temozolomide|
79862978|NCT00770471|Drug|veliparib|
79862979|NCT00770471|Genetic|DNA methylation analysis|
79862980|NCT00770471|Genetic|gene expression analysis|
80023600|NCT03073408|Drug|Propofol|Manual control group: Propofol administration adjusted manually.
80023601|NCT04993222|Drug|Amphotericin B liposome for injection|IV infusion
80023602|NCT04993222|Drug|AmBisome®|IV infusion
80023603|NCT01147653|Biological|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
80023604|NCT01147653|Other|Placebo|Placebo
80023605|NCT04993378|Device|EV-array|"Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
80023606|NCT04065087|Biological|GX-I7|Investigational drug
80023607|NCT04065087|Other|Placebo|Placebo drug
80023608|NCT03076762|Drug|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
79728199|NCT00629577|Genetic|microarray analysis|
79862981|NCT00770471|Genetic|mutation analysis|
79267044|NCT02415543|Procedure|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
79728200|NCT00629577|Other|flow cytometry|
79267045|NCT02415543|Procedure|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
79267046|NCT05544812|Drug|Sintilimab ，bevcizumab/cetuximab，XELOX|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
79267047|NCT02415699|Drug|Fluorouracil|
79267048|NCT02415699|Drug|Oxaliplatin|
79267049|NCT02415699|Drug|Leucovorin|
79267050|NCT02415699|Biological|DC-CIK|
79567926|NCT02723929|Device|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
79567927|NCT02709226|Radiation|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
79728201|NCT00629577|Procedure|biopsy|
79728202|NCT00629577|Procedure|colposcopy|
79728203|NCT02866539|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
79728204|NCT02866539|Drug|Placebo|Similar looking inactive powder
79728205|NCT04261270|Drug|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
79728206|NCT04261270|Drug|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
79728207|NCT04261270|Drug|Oseltamivir|75mg ,once a day
79728208|NCT00977613|Behavioral|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
79728209|NCT01152996|Drug|Vortioxetine|Vortioxetine tablets
79728210|NCT04265716|Other|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
79728211|NCT00608452|Other|Symptom Assessment Scale|"Memorial Symptom Assessment Scale~History and neurologic examination"
79728212|NCT00624936|Drug|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
79267051|NCT05544656|Drug|Tolperisone Hydrochloride|Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
79267052|NCT05544656|Drug|Placebo|matching placebo administered three times a day
79267053|NCT03116451|Behavioral|Foot Health Promoting Program|An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
79728213|NCT00624936|Drug|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
79728214|NCT00979953|Drug|ADL5859|
79862982|NCT00770471|Genetic|proteomic profiling|
80023609|NCT03073252|Other|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
79267054|NCT05542472|Other|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
79267055|NCT02409537|Dietary Supplement|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
79728215|NCT00979953|Drug|ADL5747|
79728216|NCT00979953|Drug|Oxycodone CR|
79728217|NCT00979953|Drug|Placebo|
79728218|NCT05086198|Behavioral|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
79728219|NCT05086198|Behavioral|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
79862983|NCT00770471|Other|high performance liquid chromatography|
79862984|NCT00770471|Other|immunoenzyme technique|
79862985|NCT00770471|Other|laboratory biomarker analysis|
79862986|NCT00770471|Other|mass spectrometry|
79862987|NCT00770471|Other|pharmacogenomic studies|
79862988|NCT00770471|Other|pharmacological study|
79862989|NCT00770471|Procedure|adjuvant therapy|
79862990|NCT00770471|Radiation|radiation therapy|
79567928|NCT02670447|Procedure|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
79567929|NCT02670408|Procedure|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
79728220|NCT01181531|Drug|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
79728221|NCT01181531|Drug|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
79728222|NCT01152450|Drug|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
79567930|NCT02647099|Drug|Acetylsalicylic acid|
79567931|NCT02647099|Drug|Placebo|
79567932|NCT02626715|Drug|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
79567933|NCT02626715|Drug|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
79567934|NCT02593994|Device|Onyx Drug Eluting Stent group|
79567935|NCT02585622|Biological|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
79567936|NCT02585622|Other|Placebo|Volume total of fluid infused: 40 ml
79567937|NCT02531854|Drug|ADXS11-001|ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.
79567938|NCT02531854|Drug|Pemetrexed|Chemotherapy
79567939|NCT02530658|Other|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
79567940|NCT02530658|Other|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
79567941|NCT02530658|Other|Informed Consent Follow-Up Visit|Within 2-4 weeks following the Informed Consent Visit, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
79567942|NCT02530658|Other|Return of Results Conversation|Participants will complete the assessment questionnaires.
79728223|NCT01152450|Drug|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
79728224|NCT01152450|Drug|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
79728225|NCT05085262|Diagnostic Test|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
79267056|NCT02409537|Dietary Supplement|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
79267057|NCT02409537|Other|placebo|the individuals were given placebo for 1 month
79567943|NCT02530658|Other|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 32±8 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
79567944|NCT02530658|Procedure|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
79567945|NCT02530658|Procedure|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
79567946|NCT02524834|Procedure|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
79567947|NCT02524834|Device|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
79567948|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
79728226|NCT05085262|Diagnostic Test|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
79862991|NCT01039324|Other|Reports|Primary care event reports and patient letters
79567949|NCT02487966|Behavioral|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
79267058|NCT05558540|Device|spinal cord stimulator|By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
79567950|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
79567951|NCT02487966|Behavioral|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
79567952|NCT02471690|Drug|Oritavancin|IV - Single dose 1200 mg Oritavancin
79567953|NCT02471690|Drug|Dextrose|D5W 5% in Water
79567954|NCT02470702|Drug|Oritavancin|
79567955|NCT02470702|Drug|Placebo (D5W)|
79862992|NCT01039324|Other|Reports and Notices|Primary care event reports, patient letters and care manager notices
79862993|NCT01039324|Other|Usual care|This is the study's control group
79862994|NCT00539240|Drug|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
79862995|NCT00539240|Drug|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast & Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
79862996|NCT00539240|Drug|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
79862997|NCT00770627|Dietary Supplement|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
79267059|NCT03177993|Drug|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~allergy to ivermectin, diethylcarbamazine or albendazole;~pregnant;~breastfeeding within 7 days of delivery;~less than 2 years old; OR~less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~allergy to permethrin~crusted scabies"
79567956|NCT02407145|Other|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
79567957|NCT02392442|Other|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
79567958|NCT02392442|Biological|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
79581479|NCT06071377|Other|Biologic Specimen Collection|Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
79581480|NCT06071338|Diagnostic Test|Clinical Periodontal Examination|No details will be published from the clinical assessment.
79728227|NCT00610246|Drug|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
79728228|NCT04265560|Other|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
79862998|NCT00417976|Drug|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
79862999|NCT00417976|Drug|Bevacizumab|10 mg/kg every 2 weeks.
79863000|NCT00417976|Drug|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
79863001|NCT00770705|Drug|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
79863002|NCT00770705|Other|Standard surgical approach|Historical controls
79863003|NCT00991718|Drug|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
79863004|NCT00991718|Drug|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
79728229|NCT01181141|Drug|DU-176b (edoxaban)|
79863005|NCT00991718|Drug|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
79863006|NCT01036282|Behavioral|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
79863007|NCT01036282|Behavioral|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
79863008|NCT04048733|Device|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
79863009|NCT01036360|Other|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
79863010|NCT00991796|Drug|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
79267060|NCT03177993|Drug|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~allergy to ivermectin, diethylcarbamazine or albendazole;~pregnant;~breastfeeding within 7 days of delivery;~less than 2 years old; OR~less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~allergy to permethrin~crusted scabies"
79567959|NCT02373189|Device|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
79567960|NCT02357524|Drug|Oritavancin|
79567961|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
79728230|NCT01181141|Drug|Enoxaparin sodium 20mg|
79567962|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
79567963|NCT02235610|Procedure|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
79567964|NCT02201589|Device|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
79567965|NCT02153437|Drug|BMS-919373|
79567966|NCT02153437|Drug|Sotalol|
79308988|NCT02592447|Other|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
79567967|NCT02153437|Drug|Placebo for BMS-919373|
79567968|NCT02051088|Procedure|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
79728231|NCT00606814|Drug|IPI-504, docetaxel|"IPI-504 administered IV at a dose of 300mg/m2~Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
79728232|NCT01173120|Device|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
79728233|NCT05332691|Procedure|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
79728234|NCT00977379|Radiation|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
79863011|NCT00991796|Drug|Placebo|Placebo
79863012|NCT00991796|Drug|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
79863013|NCT00991796|Drug|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
79863014|NCT00673673|Drug|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
79863015|NCT00673673|Drug|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
79863016|NCT00770783|Device|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
80023610|NCT03073252|Other|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
80023611|NCT04993456|Procedure|Caridac surgery|Cardiac surgery
80023612|NCT02747043|Biological|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
79567969|NCT02051088|Procedure|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
80023613|NCT02747043|Biological|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
79267061|NCT03177993|Drug|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~allergy to diethylcarbamazine or albendazole;~pregnant;~breastfeeding within 7 days of delivery;~less than 2 years old; OR~less than 15 kg~Exclusion criteria for permethrin:~allergy to permethrin~crusted scabies"
79728235|NCT00977379|Drug|Capecitabine|825 mg/m^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
79400571|NCT06003309|Device|Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
79728236|NCT00977379|Drug|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
80023614|NCT03075514|Other|MKD|Modified ketogenic diet
79567970|NCT02051088|Device|drug-coated balloons and/or drug-eluting stents|
79567971|NCT01901965|Behavioral|Neuromuscular electrical stimulation|
79567972|NCT01901965|Behavioral|eccentric training|
79567973|NCT01884038|Drug|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
79567974|NCT01884038|Drug|Placebo|
79728237|NCT04263844|Drug|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
79567975|NCT01801072|Drug|Levetiracetam|Details covered in Arm Descriptions.
79567976|NCT01784536|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
79567977|NCT01718743|Drug|Ixazomib Citrate|Given PO
79567978|NCT01718743|Drug|Lenalidomide|Given PO
79567979|NCT01718743|Other|Questionnaire Administration|Ancillary studies
79567980|NCT01605084|Drug|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
79567981|NCT01605084|Drug|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
79567982|NCT01605084|Drug|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
79567983|NCT01605084|Drug|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~Didanosine + Stavudine~Zidovudine + Stavudine~Lamivudine + Emtricitabine"
79728238|NCT04263844|Drug|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
79728239|NCT01180985|Device|galyfilcon A prototype lens|silicone hydrogel contact lens
79728240|NCT01180985|Device|comfilcon A|silicone hydrogel contact lens
79728241|NCT00610324|Drug|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
79728242|NCT00610324|Drug|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
79728243|NCT01147536|Biological|HSPPC-96|
79728244|NCT01154088|Biological|Mencevax ACWY|One dose, Subcutaneous injection
79863017|NCT00770783|Device|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
80023615|NCT03075514|Other|MCT|Medium chain triglyceride ketogenic diet
80023616|NCT05004142|Drug|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
80023617|NCT05004142|Drug|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
80023618|NCT03076684|Other|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
80023619|NCT03076684|Drug|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
80023620|NCT02034903|Other|Feedings warmed with commercial warmer|
80023621|NCT04999930|Device|Aerochamber|efficacy and patients satisfaction
79863018|NCT00763685|Drug|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
79863019|NCT04048655|Drug|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
79863020|NCT02557997|Other|Blood tube bottom analyses|
79863021|NCT00768677|Drug|topiramate|
79863022|NCT00770939|Device|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
79863023|NCT04003064|Diagnostic Test|Blood|3ml blood
79863024|NCT05257694|Procedure|Surgery|hepatectomy
79863025|NCT05257694|Procedure|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
80023622|NCT03607851|Drug|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
79277525|NCT02374983|Other|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
79567984|NCT01514864|Drug|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
79567985|NCT01502917|Drug|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide & liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations & PET/CT or PET/MRI scans of the brain & other organs. Clinical observations, intensive care unit monitoring, routine blood & interval imaging studies (MRI & PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
80023623|NCT03607851|Drug|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
79863026|NCT02557451|Other|Surgery|
79728245|NCT01154088|Biological|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
79863027|NCT02557451|Other|Intravitreal injections of gas|
79863028|NCT02557451|Procedure|injections of an antiangiogenic|
79863029|NCT05408936|Drug|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
80023624|NCT03607851|Drug|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
80023625|NCT04999540|Drug|Tucidinostat|30 mg, administered orally twice per week (BIW)
80023626|NCT04999540|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
80023627|NCT03607773|Behavioral|Mindfulness Behavioural Intervention (MBI) group|While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
79728246|NCT02864901|Drug|KSL-W|Plaque reducing gum
79728247|NCT02864901|Drug|Chewing Gum Placebo|
79728248|NCT04288791|Other|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
79728249|NCT04288791|Other|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
79863030|NCT02558153|Device|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
79863031|NCT02558153|Device|standard PTA|Percutaneous angioplasty performed with a standard balloon
79863032|NCT04048187|Device|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
79863033|NCT05408858|Behavioral|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
79863034|NCT01041742|Procedure|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
79863035|NCT00763763|Drug|Imatinib mesylate|imatinib 600 mg/day for 2 years
79863036|NCT00763763|Drug|Interferon|45 micrograms per week during 2 years
79863037|NCT00763763|Drug|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
79863038|NCT00763763|Drug|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
79863039|NCT04003298|Device|Electric toothbrush|Electric toothbrush and power interdental device
79863040|NCT04003298|Device|Control|Oscillating-rotating
79863041|NCT01041820|Behavioral|Exercise|Children will be exposed to a 10-week exercise intervention
79863042|NCT00763841|Device|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
79863043|NCT00763841|Device|Sham|
79863044|NCT01037140|Drug|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
79863045|NCT01037140|Drug|placebo|oral placebo tablets similar to active comparator
79728250|NCT04260724|Device|TMS|"stimulation intensity : motor threshold 100%~stimulation frequency : 1600 pulses for 20 minutes~stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
79728251|NCT04260724|Device|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
79863046|NCT05357456|Behavioral|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
79863047|NCT05357456|Procedure|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
79863048|NCT00069121|Drug|Capecitabine|1000 milligrams per square metre of body surface area (mg/m^2) orally twice daily on days 1-15 of each 3-week cycle.
80023628|NCT03608007|Drug|X-396 Capsule|225 mg once daily
80023629|NCT02637076|Drug|Xyrem|single 3.0 gram dose
79567986|NCT01502917|Radiation|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
79567987|NCT01458366|Drug|Bendamustine|"Phase 1: Given via IV at the following dose levels:~Level 1: 70 mg/m2~Level -1: 50 mg/m2~Level 2: 90 mg/m2~Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
79863049|NCT00069121|Drug|Oxaliplatin|130 mg/m^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
79863050|NCT00069121|Drug|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
79863051|NCT00069121|Drug|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
80023630|NCT02034669|Device|Laminectomy|surgical laminectomy with glial scar resection
80023631|NCT02034669|Device|Intradural space|ADSCs injection into Intradural space at damage site
80023632|NCT02034669|Device|Intrathecal|ADSCs Intrathecal into lumbar puncture
79277526|NCT02203097|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
79277527|NCT02203097|Drug|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
79400572|NCT06003309|Device|Transcranial Magnetic Stimulation (TMS) - targeted-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
79567988|NCT01458366|Drug|Ofatumumab|"Phase II~Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~Cycles 2 and 3: 1000 mg via IV on Day 1"
79567989|NCT01458366|Drug|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
79567990|NCT01458366|Drug|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
79728252|NCT04313322|Biological|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
79728253|NCT02884284|Other|clinical biological database collection|
79728254|NCT02884128|Drug|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
79863052|NCT00768911|Drug|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
79863053|NCT00768911|Drug|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
79863054|NCT00768911|Procedure|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
79863055|NCT01860404|Drug|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
80023633|NCT02034669|Device|Intravenous|ADSCs intravenous
80023634|NCT02237391|Other|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
80023635|NCT02237391|Other|Treatment as Usual (TAU)|Control group
80023636|NCT03075358|Drug|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
79567991|NCT01458366|Procedure|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
79567992|NCT01458366|Procedure|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
79567993|NCT01458366|Genetic|Stem Cell Transplant (STC)|"For potential transplant candidates:~Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
79567994|NCT01126723|Other|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
79863056|NCT01860404|Drug|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
79863057|NCT00769145|Drug|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
79863058|NCT00399802|Drug|ZA|Single ZA 4 mg IV infusion at the start of treatment
79863059|NCT00399802|Drug|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
79863060|NCT00399802|Drug|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
79863061|NCT00399802|Drug|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
80023637|NCT03075358|Other|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
80023638|NCT05003284|Device|acupressure wristband|acupressure after surgery
79728255|NCT02884128|Drug|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
79728256|NCT02884128|Drug|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
80023639|NCT05003284|Device|placebo wristband|acupressure after surgery
80023640|NCT04999150|Procedure|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced ~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
79267062|NCT05544578|Behavioral|Nurses Taking On Readiness Measures (N- TORM)|The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
79400573|NCT06003309|Device|Transcranial Magnetic Stimulation (TMS) - Standard-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
79567995|NCT01126723|Other|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
79567996|NCT00968760|Procedure|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
79567997|NCT00968760|Procedure|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
79567998|NCT00968760|Procedure|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
79567999|NCT00968760|Drug|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10^6 U/m^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
79728257|NCT00629343|Drug|Azacitidine In Combination With Temozolomide|mg, oral
79728258|NCT02864745|Device|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
79728259|NCT02864745|Other|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
79728260|NCT01180049|Drug|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
79728261|NCT01180049|Drug|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
79728262|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
79728263|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
79863062|NCT00763997|Drug|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
79568000|NCT00968760|Drug|Carmustine|300 mg/m^2 IV over 1 hour on Day -6
79568001|NCT00968760|Drug|Etoposide|200 mg/m^2 IV over 3 hours every 12 hours on Days -5 to -2
79863063|NCT00763997|Drug|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
79863064|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
79863065|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
79863066|NCT00763997|Drug|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
79863067|NCT00763997|Other|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
79863068|NCT00771095|Behavioral|podcasting|
79863069|NCT00771251|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
79863070|NCT00771251|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
79863071|NCT00399568|Drug|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
79863072|NCT00399568|Drug|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
79863073|NCT03960853|Procedure|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
79267063|NCT02167009|Device|Embosphere Microspheres|Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
79863074|NCT03960853|Procedure|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
79863075|NCT01326949|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
79863076|NCT01326949|Procedure|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
79568002|NCT00968760|Drug|Cytarabine|200 mg/m^2 by vein over 1 hour every 12 hours on Days -5 to -2.
79863077|NCT00764075|Device|Beutel TM|application of BeutelTM
79863078|NCT00764075|Other|standard|standard procedure will be applied but no Beutel TM software
79863079|NCT00764075|Device|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
80023641|NCT04999150|Procedure|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
80023642|NCT04999072|Procedure|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
80023643|NCT03073330|Diagnostic Test|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
79568003|NCT00968760|Drug|Melphalan|140 mg/m^2 IV over 30 minutes on Day -1
79568004|NCT00967733|Dietary Supplement|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
79728264|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
79728265|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
79728266|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
79863080|NCT01039558|Drug|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
79863081|NCT01039558|Drug|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
79728267|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
79728268|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
79863082|NCT01039558|Drug|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
80023644|NCT03073330|Diagnostic Test|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
80023645|NCT02854605|Drug|GS-9674|Tablet administered orally once daily
80023646|NCT02854605|Drug|Placebo to match GS-9674|Tablet(s) administered orally once daily
80023647|NCT04992910|Device|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
80023648|NCT04992910|Other|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
79267064|NCT02409381|Drug|Motore|250 mg
79267065|NCT02409381|Drug|Alivium|600 mg
79568005|NCT00967733|Dietary Supplement|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
79568006|NCT00967733|Dietary Supplement|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
79568007|NCT00967733|Dietary Supplement|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
79568008|NCT00769223|Other|medical chart review|
79568009|NCT00769223|Other|questionnaire administration|
79728269|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
79728270|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
79728271|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
79728272|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
79863083|NCT03900728|Device|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
80023649|NCT04992988|Drug|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
79568010|NCT00769223|Procedure|quality-of-life assessment|
79568011|NCT00769223|Radiation|brachytherapy|
79568012|NCT00769223|Radiation|radiation therapy|
79568013|NCT00415233|Biological|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
80023650|NCT03073096|Procedure|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
79568014|NCT00415233|Radiation|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
79568015|NCT00364286|Drug|Dasatinib (BMS-354825)|50mg Orally twice daily
79568016|NCT00328614|Drug|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
79568017|NCT00328614|Drug|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
79568018|NCT00328614|Drug|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
79568019|NCT00328614|Device|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
80023651|NCT05003596|Drug|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
79568021|NCT01750125|Device|measure ascending aortic blood flow with pulse wave Doppler|
79568022|NCT01750138|Drug|Glutamine|
79568023|NCT01750138|Drug|Dextrose powder|
79568024|NCT01750151|Dietary Supplement|Glucose Beverage|
79568025|NCT01750151|Behavioral|Video Game Playing|
79568026|NCT01750151|Dietary Supplement|Control Beverage|
79568027|NCT01750177|Behavioral|Television Viewing before mealtime|
79568028|NCT01750177|Behavioral|Video Game Playing|
79568029|NCT01750177|Behavioral|Computer Use|
79267066|NCT03178071|Drug|Lorlatinib|oral tablets, administered daily, continuously
79267067|NCT05544422|Other|The Timed Up & Go Test and 30second Chair-Stand Test'|"Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other."
79267068|NCT02415231|Behavioral|humor|
79568030|NCT01750177|Behavioral|Sitting quietly|
79568031|NCT01750203|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
79568032|NCT01750307|Dietary Supplement|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
79568033|NCT01750307|Dietary Supplement|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
79568034|NCT01750320|Device|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
79568035|NCT01750359|Drug|curcumin|500 mg/day for 6 week
79568036|NCT01750385|Drug|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
79568037|NCT01750385|Drug|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
79568038|NCT01750424|Procedure|Autologous Fat Grafting|
79728273|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
79728274|NCT01172808|Drug|Placebo|Placebo that represents comparator
79728275|NCT01172808|Drug|tiotropium Respimat® low dose|IMP
79267069|NCT05698862|Dietary Supplement|Probiotic|Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
79267070|NCT05698862|Dietary Supplement|Placebo|Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
79267071|NCT02408991|Drug|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
79568039|NCT01750424|Other|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
79568040|NCT01750437|Drug|YH1885L(Revaprazan)|
79568041|NCT01750437|Drug|Esomeprazole 20mg|
79568042|NCT01750437|Drug|placebo|
79568043|NCT01750463|Other|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
79568044|NCT01750463|Other|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
79568045|NCT01750476|Drug|Mirena|
79568046|NCT01750476|Drug|Oral contraception|
79568047|NCT01750476|Drug|Depo-Provera|
79568048|NCT01750489|Device|non-invasive ventilation (NIV)|
79728276|NCT01172808|Drug|Placebo|Placebo that represents comparator
79728277|NCT01172808|Drug|Placebo|Placebo that represents comparator
79728278|NCT01172808|Drug|tiotropium Respimat® high dose|IMP
79728279|NCT01172808|Drug|50 mcg salmeterol HFA MDI|Active comparator
79728280|NCT01172808|Drug|Placebo|Placebo that represents BI drug
79728281|NCT01172808|Drug|Placebo|Placebo that represents BI drug
80023652|NCT05003596|Other|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
79568049|NCT01750515|Device|Acupuncture|
79568050|NCT01750541|Drug|Haloperidol|
79267072|NCT02408991|Device|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
79267073|NCT05558306|Procedure|Surgery of distal radius fracture|Surgery of distal radius fracture for displaced fractures
79267074|NCT05558306|Procedure|Reduction and cast treatment of distal radius fracture|Reduction and cast treatment of distal radius fracture for minimally displaced fractures
79267075|NCT02419677|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
79568051|NCT01750541|Drug|Valproate|
79568052|NCT01750554|Other|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
79568053|NCT01750580|Drug|Lirilumab|
79568054|NCT01750580|Drug|Ipilimumab|
79568055|NCT01750593|Procedure|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
79568056|NCT01750632|Procedure|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
79568057|NCT01750645|Drug|Intradetrusor Injection of Type-A Botulinum Toxin|
79568058|NCT01750645|Other|Other interventions analyzed according to protocol|"Placebo~Different dosage of Type-A Botulinum Toxin injected~Anticholinergic drugs"
79568059|NCT01750723|Drug|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
79568060|NCT01750736|Other|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
79728282|NCT04315194|Drug|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
79728283|NCT01151280|Device|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
79568061|NCT01750736|Other|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
79568062|NCT01750749|Biological|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
79728284|NCT02884362|Other|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
79728285|NCT01149486|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
79728286|NCT01149486|Drug|Hyzaar®|100/25 mg Tablets
79728287|NCT00601705|Drug|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
79728288|NCT00601705|Drug|epirubicin hydrochloride|50 mg/m2 IV bolus
79728289|NCT00601705|Drug|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
79728290|NCT00601705|Drug|oxaliplatin|130 mg/m2 IV infusion over 2 hours
79728291|NCT00601705|Procedure|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
79728292|NCT00601705|Procedure|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
79728293|NCT02680093|Other|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
79728294|NCT01179737|Drug|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
79728295|NCT01179737|Drug|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
79728296|NCT04033705|Device|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
79728297|NCT02679859|Other|BNP guided medical therapy optimisation|
79728298|NCT05664529|Diagnostic Test|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
79728299|NCT03125083|Biological|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
79728300|NCT00641173|Drug|paroxetine|treatment with SSRI paroxetine
79568063|NCT01750762|Drug|Lenalidomide|
79568064|NCT01750775|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
79568065|NCT01750775|Drug|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
79863084|NCT03900728|Device|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
79568066|NCT01750788|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
79863085|NCT03900728|Device|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
79863086|NCT04994912|Drug|EI-001|EI-001 IV infusion
80023653|NCT04998994|Dietary Supplement|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
79267076|NCT02419677|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
79267077|NCT04425590|Drug|DLBS1033|DLBS 1033 490 mg tablet 3 times daily
79728301|NCT00641173|Drug|placebo|treatment with placebo
79568067|NCT01750801|Drug|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
79267078|NCT04425590|Drug|Aspirin|Aspirin 100 mg tablet once daily
79267079|NCT04425590|Drug|Statin|Atorvastatin 20 mg tablet once daily
79267080|NCT04425590|Drug|Vit B12|Vit B12 100 mg tablet three times daily
79267081|NCT02419599|Other|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
79568068|NCT01750801|Drug|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
79568069|NCT01750814|Biological|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
79568070|NCT01750814|Biological|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
80023654|NCT03607929|Procedure|optimal|Physiological Saline Solution
80023655|NCT03607929|Procedure|variability|Other solutions
80023656|NCT04433572|Drug|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
79267082|NCT02419599|Other|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
79267083|NCT02419911|Procedure|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
79267084|NCT02419911|Device|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
79267085|NCT02419911|Device|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
79267086|NCT05535686|Other|Rheumatoid Arthritis|Rheumatoid Arthritis Disease (R.A)
79568071|NCT01750827|Drug|SB659032|single dose
79728302|NCT05664373|Procedure|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
79728303|NCT02679625|Device|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
79863087|NCT04994912|Other|Placebo|Placebo IV infusion
79863088|NCT01324258|Drug|GSK1120212|Part1 and Part2
79728304|NCT02679703|Device|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
79728305|NCT02679703|Device|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
79863089|NCT01324258|Drug|Gemcitabine|Part2
79863090|NCT00769457|Device|Access Arm|Active OptiVol-System with CareAlert via CareLink
79863091|NCT01037296|Procedure|catheter ablation|ablation procedure performed with Hansen robotic navigation system
80023657|NCT04433572|Drug|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
80023658|NCT03606135|Other|The Pneumonia Group|
80023659|NCT03606135|Other|The Control Group|
80023660|NCT03072940|Other|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
80023661|NCT03073018|Drug|Fosinopril|oral administration, capsules
80023662|NCT03073018|Drug|Pravastatin|oral administration, capsules
79267087|NCT02409069|Device|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
79728306|NCT02679703|Other|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
79267088|NCT02409069|Device|Sham stimulation (Nemos®, Cerbomed GmbH)|
79728307|NCT02681965|Behavioral|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
79728308|NCT00641875|Procedure|Nocturnal Hemodialysis|
79728309|NCT00929110|Drug|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
79267089|NCT00707889|Drug|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
79267090|NCT00707889|Drug|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
79267091|NCT00707889|Drug|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
79267092|NCT00707889|Drug|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
79267093|NCT00707889|Drug|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
79267094|NCT00707889|Drug|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
79568072|NCT01750853|Drug|LY3045697|Administered orally
79568073|NCT01750853|Drug|Placebo|Administered orally
79568074|NCT01750866|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
79568075|NCT01750866|Drug|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
79568076|NCT01750866|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
79728310|NCT00929110|Drug|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
79728311|NCT00929110|Drug|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
79728312|NCT00922519|Other|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
79728313|NCT00640549|Drug|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
79728314|NCT00640549|Drug|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
79728315|NCT02683369|Dietary Supplement|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~15 mg of Vitamin C~400 mcg of Folate~30 mcg Vitamin of B-12~26 mg of Iron~125 mg of Beet Root"
79728316|NCT01147068|Biological|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
79863092|NCT01037296|Procedure|catheter ablation|Ablation will be performed as normal treatment
79863093|NCT05120999|Device|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
79267095|NCT00109031|Drug|palifermin|Administered as one daily intravenous bolus.
79267096|NCT00109031|Radiation|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
79267097|NCT00109031|Drug|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
79568077|NCT01750905|Drug|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
79568078|NCT01750905|Drug|Placebo|Vehicle (D5W) SQ
79568079|NCT01750944|Procedure|Ankle first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~A 15 minute walking test (WT) is performed.~BBP-LR and BPA-LR are re-measured.~2 hours of rest.~BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~WT is reperformed.~BBP-LR and BPT-LR are re-measured."
79568080|NCT01750944|Procedure|Toe first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~A 15 minute walking test (WT) is performed.~BBP-LR and BPT-LR are re-measured.~2 hours of rest.~BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~WT is reperformed.~BBP-LR and BPA-LR are re-measured."
79568081|NCT01750970|Other|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
79568082|NCT01750983|Drug|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
79267098|NCT00109031|Drug|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
79267099|NCT00109031|Drug|Placebo|Administered as one daily intravenous bolus.
79267100|NCT02419443|Drug|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
79863094|NCT00068419|Drug|tamoxifen citrate|Given orally
79267101|NCT02419443|Drug|Placebo|Control group
79267102|NCT05535608|Dietary Supplement|SRW Cel System|Dietary supplement
80023663|NCT03073018|Drug|Fosinopril Placebo|oral administration, capsules
79267103|NCT05535530|Device|Active PSIO|new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
79568083|NCT01750983|Drug|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
79267104|NCT02415465|Procedure|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
79267105|NCT02415465|Procedure|General|General Intraoperative Anesthesia
79568084|NCT01750996|Behavioral|Strongest Families|Behavioural intervention
79728317|NCT02683135|Behavioral|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
79728318|NCT02683135|Behavioral|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
79267106|NCT02415465|Procedure|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
79863095|NCT00068419|Drug|sulindac|Given orally
79863096|NCT00068419|Other|laboratory biomarker analysis|Correlative studies
79863097|NCT01039636|Drug|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
79863098|NCT00769535|Genetic|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
79863099|NCT00769613|Biological|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
79267107|NCT02415465|Procedure|Spinal|Spinal Intraoperative Anesthesia
79267108|NCT05542082|Device|CHILLS Procedure|Cryotherapy
79267109|NCT03521999|Behavioral|AboutFace|AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
79267110|NCT03521999|Other|Enhanced Usual Care (eUC)|Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
79267111|NCT05698082|Diagnostic Test|Immunohistochemical staining with anti-FOS|The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
79267112|NCT02409225|Device|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
79267113|NCT02409225|Device|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
79267114|NCT02408913|Biological|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
79267115|NCT02408913|Biological|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
79568085|NCT01751009|Dietary Supplement|Vitamin A supplements|Sprinkles with Vitamin A
79568086|NCT01751009|Dietary Supplement|Sprinkles without Vitamin A|Active comparator
79581481|NCT06071234|Procedure|3D printed technology|Preoperative application of 3D printing technology to evaluate the breast blood supply of patients and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to conventional non preoperative evaluation.
79581482|NCT06071169|Other|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
79863100|NCT00769613|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
79863101|NCT00769613|Biological|therapeutic allogeneic lymphocytes|
79863102|NCT00769613|Genetic|polymerase chain reaction|
79863103|NCT00769613|Other|flow cytometry|
79863104|NCT00769613|Other|immunological diagnostic method|
79863105|NCT00769613|Other|laboratory biomarker analysis|
79863106|NCT01037374|Other|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
79863107|NCT00764153|Procedure|Bipolar hemiarthroplasty|Lateral approach. FWB.
79863108|NCT00764153|Procedure|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
79863109|NCT01042054|Other|Standard optimised recovery protocol.|"Epidural analgesia for the first 48 hours postoperatively.~Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
80023664|NCT03073018|Drug|Pravastatin Placebo|oral administration, capsules
80023665|NCT03607617|Other|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
80023666|NCT05003206|Other|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
80023667|NCT05003206|Device|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
79568087|NCT01751035|Behavioral|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
79728319|NCT02683135|Behavioral|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning ~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
79728320|NCT00640627|Drug|Celecoxib|200 mg oral capsule once daily for 6 weeks
79728321|NCT00640627|Drug|Placebo|Matched oral placebo for 6 weeks
79863110|NCT01042054|Other|Wound catheter plus patient-controlled analgesia.|"Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~Sham epidural catheter applied to the patient's back for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
79863111|NCT02557373|Dietary Supplement|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
79863112|NCT02557373|Dietary Supplement|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
80023668|NCT03607461|Device|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
79568088|NCT01751035|Behavioral|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
79568089|NCT01751048|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
79863113|NCT01757626|Biological|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 & 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m^2/day (day -4 to day 0), & at 500 mcg/m^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
80023669|NCT03607461|Combination Product|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
80023670|NCT06205277|Procedure|Second TURBt|Second TURBt for pT1 NMIBC as per current EAU Guidelines.
80023671|NCT06205264|Other|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
80023672|NCT06205238|Other|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
80023673|NCT06205212|Other|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
80023674|NCT06205212|Other|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
80023675|NCT06205173|Other|Hot compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
79267116|NCT05542004|Behavioral|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
79277528|NCT02367573|Procedure|2D laparoscopic TAPP inguinal hernia repair|
79568090|NCT01751048|Biological|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
79728322|NCT01146912|Other|Text Message|Text message vaccine reminders
79728323|NCT01146912|Other|automated call|Automated call
79863114|NCT01757626|Biological|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
79863115|NCT00764231|Behavioral|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
79863116|NCT00764231|Behavioral|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
79863117|NCT05408234|Other|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
80023676|NCT06205173|Other|Cold compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
79568091|NCT01751048|Biological|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
80023677|NCT06205160|Device|SOFT ECoG subdural grid electrode|"Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making."
79568092|NCT01751048|Drug|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
79267117|NCT02414919|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
79267118|NCT02414919|Drug|ParaGard|Copper T380A
79400574|NCT06003075|Combination Product|Nivolumab and Chemotherapy|3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks
79400575|NCT06003075|Drug|Nivolumab|Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation
79568093|NCT01751074|Drug|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
79568094|NCT01751074|Drug|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
79568095|NCT01751100|Behavioral|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
79568096|NCT01751100|Behavioral|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
79863118|NCT01042132|Procedure|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
79863119|NCT01042132|Procedure|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
79267119|NCT02414919|Drug|Implanon/Nexplanon|Etonorgestrel contraceptive implant
80023678|NCT06205147|Device|Elastic Band|Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.
80023679|NCT06205134|Drug|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
80023680|NCT06205134|Drug|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
80023681|NCT06205134|Drug|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
79568097|NCT01751204|Dietary Supplement|Calcium tablet|
79568098|NCT01751204|Dietary Supplement|Calcium ion water (250mg)|
79568099|NCT01751204|Dietary Supplement|Calcium ion water (125mg)|
79728324|NCT00641251|Other|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
79728325|NCT00641251|Other|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
79728326|NCT02682043|Device|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
79863120|NCT00068107|Drug|Replagal|enzyme replacement therapy
79863121|NCT04048811|Drug|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
80023682|NCT06205121|Drug|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
80023683|NCT06205121|Drug|Placebo|Matching placebo tablets
80023684|NCT06205108|Device|taVNS stimulation|Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.
79728327|NCT02679547|Other|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
80023685|NCT06205108|Device|sham stimulation|Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
80023686|NCT06205095|Drug|Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII|Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
80023687|NCT06205095|Other|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
80023688|NCT06205082|Drug|LIT-00814|LIT-00814 is an oral tablet.
79267120|NCT05005559|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
79267121|NCT05005559|Biological|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
79267122|NCT05535452|Device|Photobiomodulation through LED board|The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
79267123|NCT02419053|Other|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
79267124|NCT05543954|Drug|68Ga-FAPI-RGD|Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
79267125|NCT05543954|Drug|18F-FDG|Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
79267126|NCT05543954|Drug|68Ga-FAPI|Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
79267127|NCT05543954|Drug|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
79568100|NCT01751217|Behavioral|Functional Family Tx|
79568101|NCT01751217|Behavioral|Services as Usual|
79568102|NCT01751243|Other|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
79568103|NCT01751243|Other|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
79568104|NCT01751256|Device|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
79568105|NCT01751269|Drug|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
79568106|NCT01751269|Drug|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
79568107|NCT01751282|Genetic|Stem Cell|
79568108|NCT01751295|Drug|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
79568109|NCT01751321|Drug|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
79568110|NCT01751334|Device|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
79267128|NCT02419131|Behavioral|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
79863122|NCT04048811|Drug|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
79568111|NCT01751334|Device|total knee arthroplasty|Fixed Total Knee Arthroplasty
79568112|NCT01751347|Drug|Bupivacaine|Local anesthetics
79568113|NCT01751347|Drug|Lidocaine|Local anesthetics
79728328|NCT00641953|Drug|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
79863123|NCT04048811|Drug|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
80023689|NCT06205069|Device|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
80023690|NCT06205056|Biological|Ad26.Mos4.HIV [Arm 1]|Participants in Arm 1 will receive dose-consistent injections (5x10^10 vp/0.5 mL) at each product administration visit (Days 1, 57, and 169)
79568114|NCT01751373|Behavioral|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
79728329|NCT00641953|Drug|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
80023691|NCT06205056|Biological|Ad26.Mos4.HIV [Arm 2]|Participants in Arm 2 will initially receive a lower dose (2.5x10^10 vp/0.25 mL) on Day 1, which will increase to the Arm 1 dose (5x10^10 vp/0.5 mL) when subsequently administered on Days 57 and 169.
80023692|NCT06205056|Biological|CH505 TF chTrimer+ALFQ [Arm 1]|Participants in Arm 1 will receive dose-consistent injections of CH505 TF chTrimer (300 µg) mixed with ALFQ (200 µg MPLA/ 100 µg QS 21) at each product administration visit on Days 1, 57, and 169
80023693|NCT06205056|Biological|CH505 TF chTrimer+ALFQ [Arm 2]|"Participants in Arm 2 will receive 30 µg, 100 µg, 150 µg, and 300 µg doses of CH505 TF chTrimer mixed with ALFQ.~Day 1: CH505 (30 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 4: CH505 (100 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 8: CH505 (150 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 15: CH505 (300 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 57: CH505 (300 µg) +ALFQ (200 µg MPLA/ 100 µg QS 21)~Day 169: CH505 (300 µg) +ALFQ (200 µg MPLA/ 100 µg QS 21)"
80023694|NCT06205056|Biological|ALFQ [Arm 1]|Participants in Arm 1 will receive dose-consistent injections of ALFQ (200 µg MPLA/100 µg QS-21) mixed with CH505 TF chTrimer on Days 1, 57, and 169
79267129|NCT02419131|Behavioral|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
79267130|NCT02419131|Behavioral|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
79267131|NCT02419209|Other|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
79267132|NCT02408679|Procedure|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
79267133|NCT02408679|Other|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
79267134|NCT05698004|Other|prone positioning|The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
79568115|NCT01751373|Behavioral|Standard Therapy|
79728330|NCT00641953|Drug|Placebo|0.5 g topically BID to each foot for 4 weeks
79728331|NCT02681887|Drug|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
79728332|NCT02681887|Drug|Placebo|placebo tablet identical to circadian
79728333|NCT01134042|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
79728334|NCT01134042|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
79728335|NCT01134042|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
79728336|NCT01134042|Other|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
79728337|NCT01134042|Other|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
79863124|NCT01564082|Device|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
79863125|NCT00764387|Drug|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
79863126|NCT00764387|Drug|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
79863127|NCT03957889|Other|Educational simulation|
79863128|NCT01086631|Drug|Rituximab|
79863129|NCT04909502|Drug|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
79863130|NCT04909502|Drug|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
79568116|NCT01751464|Behavioral|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
79863131|NCT04909502|Drug|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
79863132|NCT04909502|Drug|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
79728338|NCT02681419|Procedure|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
79863133|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
79863134|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
79568117|NCT01751503|Procedure|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
79568118|NCT01751503|Procedure|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
80023695|NCT06205056|Biological|ALFQ [Arm 2]|"Participants in Arm 2 will receive a lower dose of ALFQ (50 µg MPLA/25 µg QS-21) mixed with CH505 TF chTrimer during the rapid, dose-escalating injections on Days 1, 4, 8, and 15~and a dose of ALFQ similar to that used in Arm 1 (200 µg MPLA/100 µg QS-21) mixed with CH505 TF chTrimer at subsequent injections on Days 57 and 169"
79267135|NCT04486781|Drug|Pembrolizumab + sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
79568119|NCT01751529|Procedure|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
79728339|NCT02681419|Procedure|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
79863135|NCT00769847|Procedure|Endoscopic strip craniectomy|Surgery
80023696|NCT06205017|Dietary Supplement|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
79267136|NCT02408601|Other|Helioseal - F|"Helioseal -F ( Resin based sealant)~isolate the tooth surface~etch the fissure anatomy with 37% phosphoric acid for 20 seconds~wash the tooth surface and dry it. No salivary contamination is accepeted~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~light cure the sealant~check for high points and the occlusion"
79267137|NCT02408601|Other|ART sealant|"Fuji IX extra strength~isolate the tooth surface~condition the fissure anatomy using a GC conditioner for 10 seconds~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~dry the tooth surface~mix the GIC according to the standard powder: liquid ratio~place the mix onto the fissures using a plastic spatula~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~apply pressure for 10-15 sec and withdraw the finger in a sideways motion~scrap out the excess material~check for the high points and the occlusion~apply petroleum jelly onto the GIC mix~advice patient not to eat or drink for 30 minutes."
79277529|NCT02367573|Procedure|3D laparoscopic TAPP inguinal hernia repair|
79400576|NCT06003075|Procedure|Post Induction Surgery|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles
79400577|NCT06003075|Radiation|Post Induction XRT|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.
79728340|NCT00642031|Drug|Triciribine|15 mg/m^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
79728341|NCT01179347|Drug|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
79728342|NCT01179347|Drug|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
79863136|NCT00394654|Biological|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
79863137|NCT00394654|Other|Placebo|Placebo administered as a single intravenous infusion
79863138|NCT01086787|Other|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
80023697|NCT06205004|Other|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
80023698|NCT06204991|Biological|ADP-TILIL7|Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement
80023699|NCT06204991|Drug|Cyclophosphamide|Lymphodepleting Chemotherapy
80023700|NCT06204991|Drug|Fludarabine Phosphate|Lymphodepleting Chemotherapy
80023701|NCT06204991|Drug|Proleukin|IL-2
79568120|NCT01751529|Drug|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
80023702|NCT06204952|Drug|Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)|In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
80023703|NCT06204952|Drug|Placebo|In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
79568121|NCT01751542|Behavioral|Mindfulness + Residential Treatment|
79400578|NCT06002087|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
79568122|NCT01751542|Behavioral|Residential treatment alone|
79728343|NCT04182295|Device|acupuncture|A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
79728344|NCT04182295|Device|Park Sham Needle|A Park Sham Needle (Meridius Medical Ltd. & DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
80023704|NCT06204939|Procedure|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
79728345|NCT04182139|Other|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
79728346|NCT04104373|Other|Observational Cohort|
79728347|NCT01146288|Drug|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
79400579|NCT05994261|Device|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
79400580|NCT05993546|Device|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
79400581|NCT05993546|Device|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
79400582|NCT05990478|Diagnostic Test|Contrast-Enhanced Mammography|Participants will have pre- and post-treatment CEM of the affected breast
79400583|NCT05990478|Diagnostic Test|Breast MRI|Pre- and post-NAT breast MRI will be performed for all participants
79568123|NCT01751555|Drug|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
79568124|NCT01751581|Behavioral|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
79568125|NCT01751581|Behavioral|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
79728348|NCT01146288|Drug|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
79728349|NCT02683057|Other|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
79267138|NCT05541692|Behavioral|Sleep Hygiene Toolkit|The sleep hygiene toolkit includes multiple resources including assistive devices (ie. eye masks and ear plugs), sensory-based tools (ie. aromatherapy, music, meditation, and breathing techniques), cognitive behavioral therapy (CBT) activities (ie. addressing anxiety and worry), and education and training on sleep hygiene.
79267139|NCT05543798|Device|Vision-MR Ablation Catheter 2.0|Catheter ablation of ventricular tachycardia
79267140|NCT02408835|Device|PICO™|Negative pressure wound therapy device for closed surgical wounds.
79267141|NCT04467359|Other|ERAS|Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
79267142|NCT04467359|Other|Perioperative routine rehabilitation nursing|Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
79728350|NCT01146054|Device|CyberKnife based stereotactic radiotherapy|"Initial orthogonal images will be obtained to confirm location of fiducial seeds.~Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~Quality assurance will be performed as per standard practice at each participating institution."
79728351|NCT01146054|Drug|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
79267143|NCT05543564|Procedure|PRP|Single session prophylactic early Pan-retinal Photocoagulation
79267144|NCT02418975|Other|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
79728352|NCT01146054|Drug|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
79568126|NCT01751594|Behavioral|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
79728353|NCT00640705|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
79568127|NCT01751594|Behavioral|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
79728354|NCT00640705|Drug|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
79728355|NCT01145898|Drug|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
79267145|NCT02418975|Other|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
79267146|NCT05543486|Device|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.
79400584|NCT05989256|Diagnostic Test|EndoTool|EndoTool is a vendor based glucose management software
79728356|NCT04181905|Other|Questionnaire|Firstly, demographic information (name-surname, date of birth, gender, age, height, body weight, dominant hand, family structure, social security, educational status, occupation, smoking, alcohol use, assistive device drug use, resume, surname, complaints). Data collection tools will then be applied to patients by face to face interview technique. Evaluation of kinesiophobia Assessment of quality of life in asthma patients with TAMPA questionnaire Assessment of physical activity level with Asthma Quality of Life Questionnaire (AQLQ) Assessment of physical activity level with International Physical Activity Questionnaire-Short Form (IPAQ) is planned.
79728357|NCT02681653|Drug|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
79728358|NCT02681653|Drug|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
79728359|NCT04181983|Other|Personalized exercise program|Home-based personalized exercise program using a smart phone app
79728360|NCT04181983|Other|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
79728361|NCT04315116|Drug|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 & day10 .
79728362|NCT04315116|Drug|Loperamide|Loperamide 4 mg bid from day 7 to day 13
80023705|NCT06204939|Procedure|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
80023706|NCT06204926|Diagnostic Test|AI diagnostic algorithm|The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
80023707|NCT06204913|Other|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
79728363|NCT02886078|Procedure|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
80023708|NCT06204900|Device|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
80023709|NCT06204874|Procedure|Pulsed radiofrequency ablation|See left.
80023710|NCT06204874|Procedure|Sham ablation|See left.
80023711|NCT06204861|Other|Capacitive and Resistive Electric Transfer Therapy|In the initial phase, administer a 60% dosage using the capacitance mode with a 65mm treatment head, targeting the musculature surrounding the ankle joint through a 10-minute session of mobile therapy. Subsequently, transition to the resistance mode, maintaining a 65mm treatment head, and apply a 20% dosage for a further session of mobile therapy.
80023712|NCT06204861|Other|Functional Training|The training program consists of four exercises: one-legged stand, one-legged heel lift, one-legged squat, and one-legged standing catch. Each exercise is performed for two sets. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
79728364|NCT02886078|Procedure|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
80023713|NCT06204861|Other|Capacitive and Resistive Electric Transfer Therapy Combined with Functional Training|The training exercises mirror those of the functional training group, and the treatment protocol similarly commences with the application of a 60% dosage using the capacitance mode with a 65mm treatment head. This phase involves a 10-minute session of mobile therapy targeting the musculature surrounding the ankle joint. Subsequently, the intervention diverges as the treatment transitions to the resistance mode, maintaining a 65mm treatment head, and employs a 20% dosage for a focused, fixed-point therapy session.
79267147|NCT05543486|Device|Knee sleeve|Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
79728365|NCT04183933|Other|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
79863139|NCT04048265|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
80023714|NCT06204861|Other|Control Group|Control group received no intervention.
79267148|NCT05089565|Diagnostic Test|Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation|Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
79267149|NCT02415075|Behavioral|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
79267150|NCT05543408|Behavioral|EXERCISE|individualized, progressive, exercise program
79267151|NCT02414997|Procedure|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
79267152|NCT02414997|Procedure|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
79400585|NCT05989256|Other|glucose management team|comparison group will be services that have not yet implemented EndoTool
79400586|NCT05989256|Other|standard of care glucose management|providers adjusting insulin and consulting the Glucose Management Team at their discretion
79568128|NCT01751620|Behavioral|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
79568129|NCT01751620|Behavioral|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
79568130|NCT01751633|Procedure|Surgical|
79568131|NCT01751633|Procedure|Conservative treatment|
79728366|NCT04183933|Other|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
79728367|NCT02883114|Drug|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
79728368|NCT02883114|Drug|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
79728369|NCT00640783|Behavioral|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
79568132|NCT01751698|Behavioral|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
79568133|NCT01751698|Behavioral|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
79568134|NCT01751737|Procedure|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
79568135|NCT01751750|Other|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
79568136|NCT01751763|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
79568137|NCT01751776|Drug|BI 655064 medium dose|Medium dose
79568138|NCT01751776|Drug|BI 655064 high dose|High dose
79568139|NCT01751776|Drug|BI 655064 high dose|High dose
79568140|NCT01751776|Drug|Placebo|Placebo
79568141|NCT01751776|Drug|BI 655064 low dose|Low dose
79728370|NCT00640783|Behavioral|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, <30%).
79267153|NCT05697926|Other|No intervention|This is a preclinical study. No intervention will be performed.
79267154|NCT03174171|Drug|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
79267155|NCT05541302|Device|TMS|Transcranial Magnetic Stimulation
79267156|NCT02418663|Drug|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
79267157|NCT03116373|Other|mandible fixation|Intubation device will be fixed on mandible
79267158|NCT03116373|Other|Maxilla fixation|Intubation device will be fixed on maxilla
79267159|NCT03174249|Behavioral|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
79568142|NCT01751776|Drug|Placebo|Placebo
79568143|NCT01751776|Drug|BI 655064 medium dose|Medium dose
79568144|NCT01751789|Behavioral|Linkage|
79568145|NCT01751789|Other|Treatment as Usual|
79568146|NCT01751815|Procedure|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
79568147|NCT01751815|Procedure|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
79568148|NCT01751828|Drug|Sertraline|
79568149|NCT01751854|Drug|SSRI|SSRI alone or with training
79568150|NCT01751854|Drug|Placebo|Placebo alone or with training
79568151|NCT01751880|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
79568152|NCT01751893|Drug|Henna|natural henna in the form of paste
79568153|NCT01751893|Drug|Placebo|placebo
79568154|NCT01751919|Drug|Imatinib mesylate tablet 400 mg, 1 Tablet|
79568155|NCT01751919|Drug|Glivec film-coated tablet 100 mg, 4 Tablets|
79568156|NCT01751932|Device|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
79568157|NCT01751945|Behavioral|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
79568158|NCT01751958|Radiation|Epidural steroid injection|Epidural steroid injection
79728371|NCT04183387|Drug|Simvastatin 40mg|
79863140|NCT03900416|Behavioral|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
79267160|NCT02418741|Other|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
79267161|NCT02418507|Dietary Supplement|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
79267162|NCT02418507|Other|Placebo|The placebo is administered to randomized healthy participants
79568159|NCT01751997|Drug|Transplants from 8/8-matched Unrelated donors|"Myeloablative conditioning~Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~Reduced-intensity conditioning; older patients (age > 55 years) and/or patients with comorbidities~Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m^2)~Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~GVHD prophylaxis~Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
79568160|NCT01751997|Drug|Transplants from family-mismatched/haploidentical donors|"Reduced-intensity conditioning~Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m^2)~Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~GVHD prophylaxis~Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
79581483|NCT06071130|Behavioral|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F&S! cycles at each center (totaling 8 F&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F&S! for 3 sessions a week for 8 weeks.
79728372|NCT01133418|Other|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
79728373|NCT01133418|Other|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
79728374|NCT02677909|Device|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
79267163|NCT05696210|Other|Transfusion rate of red blood cells|Transfusion rate of red blood cells greater than 7
79728375|NCT02679313|Device|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
79728376|NCT04314804|Combination Product|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
79728377|NCT04314804|Combination Product|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
79728378|NCT02678065|Device|InPact Admiral DEB|
79267164|NCT02414763|Behavioral|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
79728379|NCT04183153|Device|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
79728380|NCT00625092|Drug|fluorouracil|Post-operative day 1 and day 2, 600mg/m^2 intraperitoneal (IP) held for 23 hours
79728381|NCT00625092|Drug|leucovorin calcium|Day 0 200 mg/m^2 intraperitoneal held for 2 hours
79728382|NCT00625092|Drug|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m^2
80023715|NCT06204835|Drug|RD-Cy7 fluorophore|Fluorophore targeting ITGA6 that is overexpressed in HCC cells
79267165|NCT03174093|Behavioral|MATCh AFib application|The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
79267166|NCT05592470|Diagnostic Test|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).|Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
79400587|NCT05988749|Other|Biofourmis Digital Platform|The intervention is a combination of the American Heart Association's Digital Heart Failure CarePlans and Education Content, delivered through and combined with the Biofourmis Platform. Patients enrolled in this arm will wear the device for 90 days and provide data to the participant's care team.
79400588|NCT05986942|Drug|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
79267167|NCT02414529|Drug|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
79400589|NCT05986942|Drug|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
79267168|NCT02414529|Drug|Placebo|
79400590|NCT05986253|Dietary Supplement|Seaweed protein|Novel protein extracted from seaweed
79400591|NCT05986253|Dietary Supplement|Maltodextrin|maltodextrin solution
79400592|NCT05985850|Drug|Aurora 1:1 Drops (Indica)|Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
79400593|NCT05985850|Drug|Placebo|Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
79568161|NCT01752010|Other|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
79568162|NCT01752010|Device|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
79728383|NCT00625092|Procedure|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
79728384|NCT00931918|Drug|Bortezomib|Bortezomib IV
79400594|NCT05980767|Device|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
79728385|NCT00931918|Drug|Rituximab|Rituximab IV
79728386|NCT00931918|Drug|Cyclophosphamide|Cyclophosphamide IV
79267169|NCT05541068|Device|Bioimpedance analysis|Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
79728387|NCT00931918|Drug|Doxorubicin|Doxorubicin IV solution
79728388|NCT00931918|Drug|Vincristine|Vincristine IV
79728389|NCT00931918|Drug|Prednisone|Prednisone tablet
79728390|NCT04183075|Dietary Supplement|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
79728391|NCT04183075|Dietary Supplement|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
79267170|NCT02418273|Drug|denosumab|These subjects will receive two doses of denosumab.
79400595|NCT05977894|Other|Reduced Environmental Stimulation Therapy|"During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation."
79400596|NCT05973955|Behavioral|Insomnia Treatment|The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
79400597|NCT05973955|Behavioral|Education Control|The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
79400598|NCT05970289|Biological|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
79728392|NCT00642109|Procedure|midurethral sling procedure|quality of life, voiding dysfunction
79728393|NCT02681575|Behavioral|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
79728394|NCT02679001|Drug|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
79728395|NCT02678221|Drug|Sildenafil citrate|
79728396|NCT02678221|Drug|Aspirin|
79728397|NCT04033783|Other|6MWT - accompanied|Assessor walks behind the patient
79267171|NCT02418429|Other|waxy maize starch|pancake test meal with waxy maize starch only
79267172|NCT02418429|Other|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
79267173|NCT02418429|Other|Resistant Starch|pancake test meal with resistant starch only
79267174|NCT02418429|Other|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
79267175|NCT03724526|Behavioral|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
79863141|NCT02557607|Device|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
79728398|NCT04033783|Other|6MWT - not accompanied|Assessor does not walk behind the patient
79728399|NCT00641329|Drug|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
79728400|NCT00641329|Drug|Placebo|Matching placebo tablets
79728401|NCT02681107|Radiation|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
79267176|NCT03174015|Behavioral|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
79267177|NCT05592314|Other|No intervention|No intervention
79267178|NCT02414685|Drug|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
79568163|NCT01752010|Device|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
79568164|NCT01752075|Drug|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
79728402|NCT01179191|Drug|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
79728403|NCT01169844|Biological|AIN457A|
79728404|NCT01169844|Other|Other|
79728405|NCT00642421|Drug|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
79728406|NCT00642421|Drug|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
79728407|NCT00642187|Drug|budesonide|
79728408|NCT00642187|Drug|Placebo|
79728409|NCT05663125|Procedure|Laser interstitial thermal therapy|Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.
79728410|NCT05663125|Drug|Temozolomide|Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
79863142|NCT00769925|Behavioral|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
79863143|NCT00769925|Behavioral|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
79267179|NCT02414685|Drug|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
79267180|NCT02414685|Drug|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
79400599|NCT05970289|Drug|BRII-835|BRII-835 will be given via subcutaneous injection
79863144|NCT00770003|Drug|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
79863145|NCT00770003|Drug|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
79863146|NCT00771329|Drug|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
79863147|NCT00771329|Other|Placebo (sterile normal saline)|Single IV dose of Placebo
79863148|NCT00771485|Drug|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
79863149|NCT00771485|Drug|Marketed Bowel Cleanser|Marketed bowel cleanser
79728411|NCT05655533|Diagnostic Test|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
79728412|NCT01132482|Drug|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
79267181|NCT04425824|Drug|Toripalimab combine with Rituximab|"Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC)."
79728413|NCT01132482|Drug|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
79267182|NCT02408367|Behavioral|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
79267183|NCT02408367|Behavioral|Relaxation|30
79728414|NCT02678767|Drug|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
79728415|NCT02678455|Biological|TV005 vaccine|Delivered by subcutaneous injection; contains 10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31, and 10^3 PFU of rDEN4Δ30.
79267184|NCT02414451|Drug|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
79267185|NCT02414451|Drug|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
79267186|NCT02418117|Other|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
79267187|NCT02408289|Dietary Supplement|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
79568165|NCT01752127|Procedure|percutaneous coronary intervention using drug eluting stent|"1. Intracoronary stenting~The procedure could be conducted via brachial, radial or femoral approaches.~There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~Direct stenting or bifurcation stenting is allowed.~Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
79568166|NCT01752140|Procedure|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
79568167|NCT01752140|Procedure|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
79728416|NCT02678455|Biological|Placebo|Delivered by subcutaneous injection
79728417|NCT02678845|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
79400600|NCT05965336|Other|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
79400601|NCT05965336|Other|Evaluation of Passive Ankle Stiffness|Participants will be seated in a dynamometer with their trunk and thigh stabilized to the dynamometer chair, ankle joint aligned with the rotational axis of the dynamometer, and foot stabilized to the foot plate. EMG activity will be recorded from lower limb muscles (gastrocnemius, soleus, tibialis anterior) during all isolated contractions. Participants will first perform three maximum voluntary isometric contractions (MVIC) while seated in a dynamometer. Participants will then perform three isokinetic dorsiflexion tasks while using electromyographic biofeedback at a prescribed level of 50% MVIC soleus activation. The slope of the linear best fit line from the ankle moment vs. angle plot will yield total ankle joint stiffness (i.e., active + passive) at a fixed activation. In three additional trials, the dynamometer will move the ankle joint through the same motion without active subject resistance and the same analytical procedures will derive passive ankle joint stiffness.
79728418|NCT00931762|Drug|Panobinostat|Panobinostat oral capsules
79728419|NCT02886455|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
79728420|NCT02886455|Other|New adhesive strip|This a newly developed adhesive strip.
79728421|NCT00641407|Drug|NPL insulin|Starting dose 10 IU bedtime and then titration
80023716|NCT06204796|Drug|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
79863150|NCT04002752|Drug|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
80023717|NCT06204796|Drug|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
79568168|NCT01752153|Drug|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
79728422|NCT00641407|Drug|Insulin glargine|10 IU bedtime and then titration
80023718|NCT06204783|Other|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
80023719|NCT06204770|Other|extensive hydrolyzed protein formula|NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
80023720|NCT06204757|Other|questionary|questionary relating to birth trauma are completed by midwives and patients
80023721|NCT06204744|Other|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
80023722|NCT06204744|Other|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
80023723|NCT06204731|Other|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
80023724|NCT06204718|Other|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
79400602|NCT05965336|Other|Gait Biomechanics|Three-dimensional gait analysis is performed as participants walk at a self-selected speed on an instrumented treadmill. Reflective markers are attached to lower extremity segments. Elastic bands are wrapped around the thighs, calves, and pelvis to which small, thermoplastic shells containing reflective markers are attached. Additional markers are taped to the participant's shoes and on the upper back, shoulder, hip, knee, and ankle joints with adhesive skin tape. Marker data is collected using a 7-camera motion analysis system (Vicon Inc., USA). Vicon motion analysis cameras will collect the location of the retroreflective markers in Vicon Nexus software.
79568169|NCT01752153|Drug|Silymarin (Legalon)|
79728423|NCT00624689|Dietary Supplement|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
79728424|NCT02677597|Drug|Cisplatin Combined With S-1|
79728425|NCT02677597|Drug|Cisplatin Combined With Paclitaxel|
79728426|NCT00606970|Dietary Supplement|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
79728427|NCT00606970|Dietary Supplement|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
80023725|NCT06204718|Other|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
80023726|NCT06204692|Procedure|dental implant|consisted of 6 patients where computer guided dental implant placement
80023727|NCT06204679|Drug|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
79568170|NCT01752179|Procedure|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~puts the base of tape over the contralateral of sacrum with no tension.~attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
79728428|NCT02681029|Procedure|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
79863151|NCT04002752|Drug|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
79568171|NCT01752192|Device|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
79728429|NCT02681029|Procedure|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
79267188|NCT02408289|Dietary Supplement|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
79267189|NCT02408289|Dietary Supplement|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
79728430|NCT05662969|Device|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
79728431|NCT05372146|Procedure|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
79728432|NCT02882880|Device|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
79728433|NCT02677675|Behavioral|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
79728434|NCT04260568|Other|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
79728435|NCT00642343|Behavioral|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
79728436|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
79728437|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
79728438|NCT00642343|Behavioral|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
79728439|NCT01178411|Drug|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
80023728|NCT06204679|Drug|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
79267190|NCT02408289|Dietary Supplement|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
80023729|NCT06204679|Drug|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
80023730|NCT06204666|Dietary Supplement|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
79267191|NCT02417883|Drug|Furosemide|Evaluate urinary excretion rate fo furosemide
79728440|NCT01178411|Drug|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
79728441|NCT04263688|Other|Non-Intervention|Non-Intervention
79728442|NCT02681263|Drug|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
79728443|NCT00608686|Dietary Supplement|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
79728444|NCT02675803|Biological|VAY736|VAY736 treatment
79728445|NCT02675803|Biological|VAY736 placebo|VAY736 placebo
80023731|NCT06204666|Dietary Supplement|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
80023732|NCT06204666|Dietary Supplement|Placebo|Placebo bar with other ingredients
80023733|NCT06204653|Device|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
80023734|NCT06204653|Device|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
79267192|NCT03173859|Drug|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
79267193|NCT03173859|Drug|Apalutamide|apalutamide 240mg qD orally
79267194|NCT04482465|Diagnostic Test|blood sample|blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
79267195|NCT01664624|Drug|Roflumilast|Roflumilast tablets
79267196|NCT01664624|Drug|Alogliptin|Alogliptin tablets
79267197|NCT01664624|Drug|Exenatide|Exenatide solution
79267198|NCT01664624|Drug|Placebo to roflumilast|Placebo-matching roflumilast tablets
79267199|NCT01664624|Drug|Placebo to alogliptin|Placebo-matching alogliptin tablets
79267200|NCT02414061|Dietary Supplement|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
79728446|NCT02678611|Dietary Supplement|Basis 250|
79728447|NCT02678611|Dietary Supplement|Basis 500|
79728448|NCT02678611|Dietary Supplement|Placebo|
79728449|NCT02677519|Drug|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
79728450|NCT01145508|Drug|Docetaxel|Given IV
79728451|NCT01145508|Other|Laboratory Biomarker Analysis|Correlative studies
79728452|NCT01145508|Drug|Prednisone|Given PO
79728453|NCT01145508|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
79728454|NCT01145508|Biological|Rilimogene Galvacirepvec|Given SC
79728455|NCT02675881|Device|DSM|Monopolar RFA using dual switching mode (DSM)
79863152|NCT00770159|Drug|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
79267201|NCT02414061|Other|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
79267202|NCT05079399|Other|Blood draw|Blood samples will be collected via venipuncture
79568172|NCT01752205|Drug|Paclitaxel|45mg/m2/w,total 6 weeks
79568173|NCT01752205|Drug|Erlotinib|150mg/d,days 1-42,total 6 weeks
80023735|NCT06204640|Drug|Spironolactone|Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
79568174|NCT01752205|Radiation|Radiation therapy|
79568175|NCT01752218|Device|arcuate incision|
79568176|NCT01752244|Dietary Supplement|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
79728456|NCT02675881|Device|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
79728457|NCT00931528|Drug|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
79728458|NCT00931528|Other|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
79863153|NCT00770159|Drug|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
79863154|NCT00399490|Drug|RN624 (PF-04383119)|50 mcg/kg
79863155|NCT00770237|Behavioral|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
79400603|NCT05965336|Other|Gait Biofeedback|Audio-visual biofeedback will be provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map will represent the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target will be provided using the heat map colors of red and target line on the bar graph. For propulsion biofeedback, a visual display with a marker will represent the current propulsion (peak AGRF) and a target provided to modulate propulsion. The plantar pressure and AGRF measurements from the participant's baseline walking trials will be used to determine customized biofeedback targets.
79568177|NCT01752244|Dietary Supplement|Alfacalcidol|Alfacalcidol
79568178|NCT01752257|Drug|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
79568179|NCT01752270|Drug|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
79728459|NCT04312152|Dietary Supplement|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
79728460|NCT04312152|Dietary Supplement|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
79728461|NCT04312152|Dietary Supplement|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
79728462|NCT00975195|Drug|tiotropium inhalation|
79728463|NCT00975195|Drug|salmeterol xinafoate|
79728464|NCT00975195|Drug|fluticasone propionate|
79728465|NCT00975195|Drug|placebo matched for fluticasone propionate|
79728466|NCT00642499|Drug|Dronabinol|2.5 mg to 40 mg
79728467|NCT00642499|Drug|Placebo|placebo
80023736|NCT06204627|Device|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
80023737|NCT06204627|Device|Recognise (hand)- Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
79568180|NCT01752270|Drug|Diane-35 pretreatment|
79267203|NCT03173781|Drug|droxidopa|medication
79267204|NCT03173781|Drug|Placebo|medication
79267205|NCT05540912|Drug|D064+D701|Reference
79267206|NCT05540912|Drug|CKD-828 Formulation 1|Test 1
79267207|NCT05540912|Drug|CKD-828 Formulation 2|Test 2
79568181|NCT01752283|Procedure|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
79568182|NCT01752283|Procedure|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
79568183|NCT01752322|Drug|Lidocaine 5% medicated plaster|
79568184|NCT01752322|Drug|Placebo plaster|
79568185|NCT01752335|Other|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
79568186|NCT01752348|Other|Endotoxin, US standard reference E.coli|
79568187|NCT01752361|Device|Motilis-3D transit|
79568188|NCT01752439|Device|Anodal transcranial direct current stimulation|
79568189|NCT01752439|Device|Sham transcranial direct current stimulation|
79728468|NCT00644215|Drug|5-FU and Mitomycin|"5-FU injection 5mg~Mitomycin drop 0.02%"
79728469|NCT01145352|Drug|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
79863156|NCT00770237|Behavioral|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
79568190|NCT01752465|Behavioral|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
79267208|NCT02408133|Other|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
79728470|NCT01178099|Drug|Prasugrel|Oral, daily for 12 days
79728471|NCT04016545|Device|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
79728472|NCT05323188|Other|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
79728473|NCT02673463|Drug|Spironolactone|25 mg once daily
79863157|NCT02557529|Behavioral|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
79863158|NCT02557529|Behavioral|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
80023738|NCT06204627|Other|TDCS sham|TDCS sham: The device remains inactive for 20 minutes.
80023739|NCT06204627|Other|landscape recognition|Image recognition training that does not refer to right/left discrimination.
80023740|NCT06204614|Device|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
79267209|NCT05540834|Drug|Alteplase|The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
79267210|NCT05696132|Drug|Betadine|Nasal decolonization with betadine gel
79568191|NCT01752465|Behavioral|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
79267211|NCT02407899|Drug|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
79267212|NCT02407899|Drug|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
79728474|NCT02673463|Drug|Placebo|Visually identical to spironolactone, once daily
79728475|NCT00610636|Procedure|Hepatic resection|Hepatic resection
79728476|NCT01169532|Drug|ridaforolimus|Given PO
79728477|NCT01169532|Drug|vorinostat|Given PO
79728478|NCT01169532|Procedure|biopsy|Optional correlative studies
79728479|NCT01169532|Other|pharmacological study|Correlative studies
79728480|NCT01169532|Other|laboratory biomarker analysis|Correlative studies
79728481|NCT02537353|Device|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
79728482|NCT02537353|Drug|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
79863159|NCT02557529|Behavioral|Diet diary|Weekly diet diary during the 12-weeks intervention
79728483|NCT02537353|Procedure|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
79728484|NCT02537353|Drug|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
79863160|NCT00764543|Device|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
79863161|NCT00398866|Drug|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
79863162|NCT00398866|Drug|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
79863163|NCT00398866|Drug|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
79863164|NCT00771563|Drug|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
79863165|NCT00771563|Drug|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
79728485|NCT04181671|Other|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
79728486|NCT04181671|Other|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
79728487|NCT00928564|Drug|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
79728488|NCT00928564|Drug|Placebo|5ml of saline at each block site.
79863166|NCT04780802|Procedure|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
79863167|NCT00775073|Drug|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
79863168|NCT00398632|Drug|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
79863169|NCT03993418|Dietary Supplement|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
79863170|NCT04048031|Dietary Supplement|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
79728489|NCT02883036|Other|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
79863171|NCT04048031|Other|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
79863172|NCT04734548|Drug|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
79863173|NCT04734548|Other|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
79863174|NCT01589146|Drug|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
80023741|NCT06204614|Drug|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
80023742|NCT06204614|Drug|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
80023743|NCT06204614|Drug|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
79267213|NCT02407899|Drug|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
79863175|NCT00775151|Drug|amlodipine 10 mg tablet|
79863176|NCT04694300|Drug|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
80023744|NCT06204614|Drug|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
80023745|NCT06204614|Drug|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
80023746|NCT06204614|Drug|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
80023747|NCT06204614|Drug|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
80023748|NCT06204614|Drug|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
80023749|NCT06204614|Drug|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
80023750|NCT06204614|Drug|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
79267214|NCT02407899|Drug|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
79267215|NCT05592080|Radiation|MRI|MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
79267216|NCT02417493|Behavioral|Simulation of epinephrine self-injection|
79267217|NCT05540600|Drug|Digoxin 0.25 mg|Patients will have the dose of one tablet of 0.25mg per day
79267218|NCT05540600|Drug|Bisoprolol|Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
79728490|NCT02883036|Other|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
79728491|NCT00643357|Drug|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
79728492|NCT00643357|Drug|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
79728493|NCT01177943|Drug|Atomoxetine|Administered orally, once.
79728494|NCT00608920|Other|Single Photon Emission Computed Tomography (SPECT)|
80023751|NCT06204614|Drug|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
80023752|NCT06204614|Drug|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
79267219|NCT03373448|Device|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
79728495|NCT01131312|Device|Thinprep|Pap test
79728496|NCT01131312|Device|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
79728497|NCT01131312|Procedure|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
79728498|NCT04181281|Diagnostic Test|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
80023753|NCT06204614|Drug|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
80023754|NCT06204614|Drug|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
80023755|NCT06204614|Drug|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
79267220|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
79267221|NCT02417649|Biological|Placebo|"The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~Three months of rest, according to the indications, will be allowed.~A second cycle (the same as point 1.) will be performed~A second three month rest (according to point 2.) will be provided."
79400604|NCT05965336|Other|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target.
79728499|NCT04181281|Diagnostic Test|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
79728500|NCT02865057|Procedure|Vaginal assessment|Vaginal assessment of position prior to delivery
79728501|NCT04314960|Device|Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)|Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
79728502|NCT04178785|Drug|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
79728503|NCT01177787|Device|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
79728504|NCT01177787|Device|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
79863177|NCT04694300|Drug|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
79863178|NCT04694300|Drug|Tramadol|50 mg by mouth every 6 hours as needed for pain
80023756|NCT06204614|Drug|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
80023757|NCT06204614|Drug|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
80023758|NCT06204614|Drug|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
80023759|NCT06204614|Drug|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
80023760|NCT06204614|Drug|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
80023761|NCT06204601|Other|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
80023762|NCT06204575|Other|Data collection|Data collection
79267222|NCT02417649|Biological|Ismigen|"The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~Three months of rest, according to the indications, will be allowed.~A second cycle (the same as point 1.) will be performed~A second three month rest (according to point 2.) will be provided."
79267223|NCT03173625|Drug|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
79728505|NCT02864589|Behavioral|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
79863179|NCT02556983|Radiation|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
79267224|NCT03173625|Drug|Placebo|Sterile 0.9% w/v sodium chloride solution
79863180|NCT04002596|Device|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
79267225|NCT02417571|Device|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A&D Company, Tokyo, Japan)
79267226|NCT03177837|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
79267227|NCT03177837|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
79267228|NCT02414295|Drug|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
79267229|NCT05591768|Procedure|Monopolar radiofrequency|In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be < 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
79728506|NCT02864589|Behavioral|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual & workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
79728507|NCT02676037|Device|foot pressure plate form|
79728508|NCT00928486|Drug|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
79728509|NCT00928486|Drug|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
79863181|NCT00764621|Procedure|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
79267230|NCT05591768|Procedure|Bipolar radiofrequency|a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
79267231|NCT02414373|Drug|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
79267232|NCT02414373|Drug|Bupivacaine|local anesthetics, which will epidurally administered
79267233|NCT02414373|Device|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
79267234|NCT02414373|Device|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
79473398|NCT04670523|Procedure|Early postoperative day 0 (POD 0) chest tube removal.|Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow <20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
79863182|NCT00764621|Procedure|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
79863183|NCT00764621|Procedure|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
79863184|NCT01043770|Behavioral|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
79863185|NCT00771641|Procedure|conventional surgery|
79863186|NCT00771641|Radiation|low-LET cobalt-60 gamma ray therapy|
79863187|NCT00771641|Radiation|low-LET electron therapy|
79863188|NCT00771641|Radiation|low-LET photon therapy|
79568192|NCT01752504|Behavioral|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
79568193|NCT01752517|Drug|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
79568194|NCT01752530|Other|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
79568195|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
79728510|NCT05528029|Device|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
79728511|NCT02887391|Other|No intervention - observational study|No intervention - observational study
79728512|NCT04056117|Biological|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
79863189|NCT00771641|Radiation|radiation therapy|
79863190|NCT05408078|Device|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
79568196|NCT01752543|Drug|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
80023763|NCT06204562|Behavioral|imitated laughter practice|"To imitate laughter, participants will practice Duchenne smile, which is reported to associate with positive emotion in people producing it If participants cannot imitate a Duchenne smile, they can hold a chopstick horizontally in their mouth tightly. To help timing the 3-minute and to enhance adherence, an audio recording with joyous music and vocal instruction will be played alongside the practice. Versions with or without laugh voice will be prepared for their preferences. A logbook will be given to each participant to record their practice. To remind participants to practise, a reminder will be made each day through the public announcement system of the respective nursing home, and the audio guide will be played."
79267235|NCT04320290|Drug|Direct Acting Antivirals|8 weeks of DAA treatment
79568197|NCT01752543|Drug|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
79568198|NCT01752556|Procedure|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
79568199|NCT01752556|Procedure|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
79728513|NCT04056117|Biological|MenACWY|Control vaccine administrated to adults and infants
79728514|NCT04056117|Biological|Rabies|Control vaccine administrated to children
79728515|NCT04056117|Biological|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
79728516|NCT04056117|Biological|Placebo|Control administrated to adults
79728517|NCT05655221|Drug|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
79728518|NCT05655221|Other|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
79728519|NCT00610792|Drug|bortezomib|1.3 mg/m2 on Days 1, 4, 8 & 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
79728520|NCT00610792|Drug|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
79728521|NCT02677441|Procedure|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
79728522|NCT02677441|Procedure|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
79728523|NCT00610870|Drug|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
79728524|NCT05655143|Behavioral|Balance training|Participants will undergo a 4-week balance training protocol modified from that described by McKeon et al.15 Participants will undergo supervised exercise three times per week for approximately 30 minutes per session, The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task.
79863191|NCT05408078|Other|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
79863192|NCT05408000|Drug|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
79863193|NCT00771719|Drug|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
79863194|NCT05407922|Procedure|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
79728525|NCT04181593|Drug|Omega 3 fatty acid|Omega 3 fatty acid Softgels
79728526|NCT04181593|Drug|Placebos|Mineral oil Softgels
79728527|NCT04265326|Other|Measurement of Quality of Life|Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
79863195|NCT00771797|Dietary Supplement|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
79863196|NCT00771797|Dietary Supplement|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
79863197|NCT00673361|Drug|Concurrent decrescendo biochemotherapy regimen|"Temozolomide: 200mg/m^2, daily, PO, days 1-4~Vinblastine: 1.5mg/m^2, daily, IV, days 1-4~Cisplatin: 20mg/m^2, daily IV, days 1-4~IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1~9 MIU/m^2, IVCI, day 2~4.5 MIU/m^2, IVCI, days 3 & 4~Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5~5-day inpatient regimen, to be repeated every 21 days"
79568200|NCT01752569|Drug|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
79863198|NCT00673361|Drug|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
79863199|NCT00393718|Drug|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
79863200|NCT00393718|Drug|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
79863201|NCT00393718|Drug|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
79863202|NCT00393718|Drug|placebo|glibenclamide placebo. Given orally once or twice daily.
80023764|NCT06204549|Other|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~Fill in cardiovascular risk assessment score: Life's simple 7~Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
79568201|NCT01752582|Device|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
80023765|NCT06204536|Other|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
79568202|NCT01752582|Device|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
79863203|NCT00669071|Drug|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
79863204|NCT00669071|Drug|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
79863205|NCT00398320|Drug|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
79863206|NCT00398320|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
79863207|NCT00398320|Drug|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
79267236|NCT03173235|Diagnostic Test|Plasma level of vitamin D|messurement of plasma level of vitamin D
79728528|NCT01168596|Drug|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
79728529|NCT01168596|Drug|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
79728530|NCT02537275|Device|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
79728531|NCT02537275|Device|EyeLIKe Shine, Koryo Eyetech Co|clear lens
79728532|NCT05658419|Procedure|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
79728533|NCT02675647|Drug|Heparin, IV route, based on patients body weights (UI/kg)|
79728534|NCT02675647|Procedure|Cardiopulmonary bypass|
79728535|NCT02675647|Drug|Protamin administration|
79728536|NCT05370898|Drug|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
79863208|NCT00670007|Biological|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
79863209|NCT00775307|Drug|PAZOPANIB|400 mg/day (24 weeks)
79863210|NCT00775307|Drug|Placebo|Placebo 400 mg/day (24 weeks)
79728537|NCT05370898|Drug|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
79728538|NCT05370898|Drug|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
79728539|NCT04315805|Other|Integrative Yoga Therapy|Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
79728540|NCT02677363|Other|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
79863211|NCT05407298|Other|Non applicable|Non Applicable
79863212|NCT00775385|Drug|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
79267237|NCT05697692|Drug|Heparin sodium|Lung transplantation on central veno-arterial ECMO with standard additional heparin
79267238|NCT05697692|Drug|Placebo|Lung transplantation on central veno-arterial ECMO without additional heparin
79267239|NCT02702193|Behavioral|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
79267240|NCT02761057|Drug|Cabozantinib S-malate|Given PO
79267241|NCT02761057|Drug|Crizotinib|Given PO
79728541|NCT00610948|Biological|panitumumab|Given IV
79728542|NCT00610948|Drug|everolimus|Given orally
79728543|NCT00610948|Drug|fluorouracil|Given IV
79863213|NCT00775385|Drug|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~ERCC1 high : no treatment~ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
79267242|NCT02761057|Drug|Savolitinib|Given PO
79267243|NCT02761057|Drug|Sunitinib Malate|Given PO
79267244|NCT02414217|Behavioral|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
79267245|NCT02414217|Behavioral|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
79728544|NCT00610948|Drug|leucovorin calcium|Given IV
79728545|NCT00610948|Drug|oxaliplatin|Given IV
79728546|NCT04206137|Other|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
79728547|NCT04206137|Other|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
79728548|NCT04314726|Drug|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
79728549|NCT04314726|Drug|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
79863214|NCT05407220|Drug|HCP1904-1|take it once per period
79863215|NCT05407220|Drug|HCP1904-3|take it once per period
79863216|NCT04003688|Drug|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
79863217|NCT04003688|Drug|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
79863218|NCT04003688|Drug|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
79863219|NCT00775541|Dietary Supplement|Vitamin C|One IV infusion of 2 gm vitamin C
79863220|NCT05406986|Other|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
79863221|NCT00764777|Device|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
79863222|NCT00779129|Drug|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
79863223|NCT00779129|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
79863224|NCT00779207|Behavioral|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
79728550|NCT04178395|Device|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
79267246|NCT02417181|Other|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
79267247|NCT03173391|Drug|HMS5552|BID Oral administration
79267248|NCT03173391|Drug|Placebo|BID Oral administration
79267249|NCT03173469|Other|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
79568203|NCT01752595|Behavioral|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
79568204|NCT01752595|Other|Preference Based Music Intervention|
79568205|NCT01752608|Behavioral|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
79267250|NCT02413983|Procedure|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
79267251|NCT02413983|Procedure|hepatectomy midline incision|
79267252|NCT02413983|Procedure|hepatectomy transverse incision|
79863225|NCT00779207|Behavioral|weight loss|10 percent weight loss through diet and behavioral modification
79863226|NCT00779363|Device|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
80023766|NCT06204497|Procedure|Stent-based Diverting Technique|The stent-based diverting technique (SDT) contains two parts to achieve feces diversion One is a degradable solid intestinal stent to be implanted 20 cm from the terminal ileum and could be gradually degraded within 3-4 weeks. Another part is a drainage tube to be placed at the proximal 5-10 cm of the aforementioned stent. Given this SDT, intestinal contents could be diverted through the drainage tube, and the stent prevents the feces from entering the distal intestinal. After removing the drainage tube after 3-4 weeks, intestinal contents will freely access the distal intestinal space following the degradation of the stent. For patients, stoma reversal is avoided.
80023767|NCT06204484|Other|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
79267253|NCT03172923|Device|sliding hip screw|fixation of the fracture with a sliding hip screw
79568206|NCT01752647|Procedure|Low dose computed tomography|Low dose computed tomography scan
79568207|NCT01752660|Behavioral|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
79267254|NCT03172923|Device|intramedullary nial|fixation of the fracture with an intramedullary nail
79267255|NCT03177915|Drug|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
79267256|NCT03177915|Drug|Saline|median nerve hydro-dissection using 10 cc saline injection
79267257|NCT03173157|Other|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
79267258|NCT02407977|Other|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
79267259|NCT02413905|Biological|Stool samples|Stool samples
79568208|NCT01752660|Behavioral|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
79568209|NCT01752673|Other|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
79568210|NCT01752673|Other|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
79568211|NCT01752686|Drug|carboplatin|carboplatin as adjuvant chemotherapy
79568212|NCT01752699|Drug|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
79568213|NCT01752699|Drug|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
79863227|NCT00535496|Drug|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
79267260|NCT03176355|Procedure|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
79728551|NCT01177553|Procedure|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
79728552|NCT01177553|Device|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
79863228|NCT00772187|Drug|morphine|Single dose: 0.1-0.5 mg
79863229|NCT00772187|Drug|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
79863230|NCT00772187|Drug|general anesthesia (fentanyl)|general anesthesia alone
79863231|NCT00772265|Biological|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
79863232|NCT00772265|Biological|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
79568214|NCT01752725|Device|BiCision®|
79728553|NCT04178239|Diagnostic Test|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
79863233|NCT04002128|Other|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
79728554|NCT04260178|Other|An Education-Based Intervention Program and handbook (EBIP, hospital and home)|A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
79863234|NCT00779441|Drug|Zolpidem 10mg tablets|
79863235|NCT00989378|Behavioral|baseline study|normal bedtimes
79267261|NCT02407821|Drug|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
79728555|NCT04260178|Other|PFT, BMI, BDI, SCMP-G|pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
79267262|NCT02407821|Drug|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
79267263|NCT02167243|Behavioral|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
79568215|NCT01752725|Device|Ultracision® Har-monic Scalpel(Ethicon)|
79568216|NCT01752764|Other|Test product: Salad with a high dosage fat|
79568217|NCT01752764|Other|Control product: Salad with low dosage fat|
79728556|NCT02675413|Drug|Dimethyl Fumarate|Open-label
79267264|NCT02167243|Other|Standard of care|Subjects receive standard of care
79267265|NCT02408055|Drug|TA-8995|
79267266|NCT02164357|Procedure|EVT (endovascular treatment )|
79267267|NCT02164357|Procedure|IVT (intravenous thrombolytic therapy)|
79863236|NCT02556437|Drug|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
79863237|NCT02556437|Drug|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
79863238|NCT04946006|Drug|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
79863239|NCT00779597|Behavioral|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
79863240|NCT00775619|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
79863241|NCT00775697|Drug|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
79863242|NCT00775697|Drug|Montelukast|montelukast 4 mg day for 4 weeks
80023768|NCT06204484|Other|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
79568218|NCT01752777|Behavioral|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
79568219|NCT01752777|Behavioral|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
79267268|NCT03540745|Device|TES Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
79863243|NCT05357066|Drug|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
79267269|NCT03540745|Device|TES-SHAM Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
79267270|NCT02407665|Behavioral|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
79267271|NCT02417337|Procedure|Root Canal Treatment|A standardized endodontic procedures performed.
79267272|NCT02417337|Drug|Paracetamol|
79267273|NCT02417337|Drug|Ibuprofen|
79267274|NCT02417337|Drug|Mefenamic acid|
79400605|NCT05965336|Other|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
79728557|NCT02675725|Device|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
79728558|NCT00928408|Drug|Cinacalcet|
79728559|NCT04179877|Behavioral|IPS|Occupational rehabilitation and support Integrated with clinical treatment
79728560|NCT02675257|Behavioral|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
79728561|NCT02675257|Behavioral|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
79863244|NCT05357066|Drug|Placebo|Administration of the placebo (oxygen-air mixture [FiO2 ≈0.3]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
79863245|NCT02556905|Drug|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
79267275|NCT02417337|Drug|Diclofenac|
79473399|NCT04670523|Procedure|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
79863246|NCT02556905|Drug|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
79473400|NCT05663840|Behavioral|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
79267276|NCT02164435|Procedure|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
79267277|NCT02417025|Behavioral|PE|Prolonged Exposure
79267278|NCT02167321|Drug|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
79473401|NCT05663840|Behavioral|Standard of care|Subjects will receive SOC therapy only
79473402|NCT02974829|Other|follow-up|
79473403|NCT03029468|Behavioral|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
79863247|NCT00772421|Device|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
80023769|NCT06204484|Other|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
80023770|NCT06204471|Device|Helite hip protector|hip protector
80023771|NCT06204471|Device|Wolk hip protector|Hip protectdor
80023772|NCT06204458|Other|mild hyperthermia group|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of two weeks, according to the manufacturer's instructions. For better tolerability, the application takes place under administration of 10L/min oxygen. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
80023773|NCT06204458|Other|sham group|Within the application, patients in the Sham group will undergo a hyperthermia application with virtually no overheating. To achieve this, the patients are positioned on the hyperthermia device in the same way as the intervention group. An insulating foil applied beforehand prevents direct irradiation with water-filtered infrared-A radiation. This prevents an increase in temperature. Due to the insulating blanket and the natural heat from the device and body, patients in the Sham group experience a gentle warmth that cannot be compared with regular whole-body hyperthermia and an increase in core body temperature of around 1.5°C. The number of treatments, the lighting conditions and procedures including 10L/min oxygen supply, is equal to the treatments in the intervention group.
80023774|NCT06204445|Dietary Supplement|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
79728562|NCT02675257|Behavioral|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
79728563|NCT02675257|Behavioral|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
79728564|NCT02675257|Behavioral|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
79863248|NCT00539006|Drug|FPNS|fluticasone propionate nasal spray
80023775|NCT06204445|Dietary Supplement|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
79400606|NCT05963672|Device|EEG-guided sleep protection|"The tablet will display a specific picture prioritize sleep or prioritize care depending on the patient status determined by the algorithm. When the picture favor/prioritize sleep is displayed, all caregivers and visiting family are asked to follow the sleep protection rules: refrain to enter the room for not urgent reasons, switch off television, reduced light in the room/corridor, reduce noise in front of the door, close curtain (if any), and delay non urgent care…etc; if caregivers have to enter the room, headlight and/or additional light will be favored. All these rules will be established collegially by nurses and doctors. Obviously, urgent care and reactions to alarms are maintained.~When the picture favor/prioritize care is displayed, all caregivers and visiting family are invited to perform non urgent care, cleaning, restocking perfusion needles, comfort care, visiting."
79728565|NCT02675257|Behavioral|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
80023776|NCT06204432|Drug|Sodium Citrate|Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
80023777|NCT06204432|Drug|Normal Saline|Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
80023778|NCT06204432|Other|"Olfactory Training Kit - The Olfactory Kit, by AdvancedRx"|All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
79400607|NCT05963672|Other|Control condition|the recording device will be placed on the patient to record sleep but the tablet will be masked and placed face down on the bench in the room, invisible from the door.
79473404|NCT03029468|Behavioral|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
79473405|NCT02974751|Procedure|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
79728566|NCT02675257|Behavioral|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
79863249|NCT00539006|Drug|FFNS|fluticasone furoate nasal spray
79863250|NCT00539006|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
79863251|NCT00539006|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
79863252|NCT00776087|Device|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
79473406|NCT04872387|Drug|BAY2586116|Nasal administration
79473407|NCT04872387|Drug|Placebo|Matching placebo
79473408|NCT02411357|Behavioral|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
79473409|NCT02411357|Behavioral|WHO contraception protocol|World Health Organization's contraception protocol
79473410|NCT02411357|Behavioral|Incentives|Financial incentives contingent on follow-up visit attendance
79473411|NCT01687387|Drug|IPH2102 at 0.1 mg/kg|every 3 months
79863253|NCT00776087|Device|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
79863254|NCT00776165|Biological|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
80023779|NCT06204419|Drug|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
79568220|NCT01752790|Drug|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
79568221|NCT01752790|Drug|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
79568222|NCT01752803|Dietary Supplement|Probiotic|mix probiotic
79568223|NCT01752803|Dietary Supplement|Placebo|placebo
79267279|NCT02167321|Drug|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
79267280|NCT03176589|Device|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
79568224|NCT01752816|Behavioral|exercise training|
79863255|NCT00776165|Biological|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
79728567|NCT02675257|Behavioral|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
79267281|NCT03176589|Device|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
79267282|NCT03176589|Other|Deep breathing maneuvers|deep breathing maneuvers 3 times 10 breahs without any device at expiration
79568225|NCT01752868|Dietary Supplement|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
79568226|NCT01752881|Biological|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
79568227|NCT01752881|Biological|AdimFlu-S|
79863256|NCT00989456|Behavioral|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
79863257|NCT00989456|Behavioral|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
79863258|NCT04521374|Behavioral|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
80023780|NCT06204419|Other|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
80023781|NCT06204406|Other|Observational|This is a prospective observational study with observation only and no intervention
80023782|NCT06204393|Other|Thyroid metabolic index|The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.
79267283|NCT02162641|Procedure|Sentinel lymph node biopsy|
79267284|NCT02407743|Behavioral|Surgical patients' clinical progression|Study the dynamic nature of pain
79267285|NCT02407743|Genetic|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
79267286|NCT04733833|Drug|VB-201 + Standard of care|Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
79267287|NCT04733833|Drug|Standard of care|Standard of care
79728568|NCT02675257|Behavioral|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
79728569|NCT02675257|Behavioral|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
79728570|NCT02675257|Behavioral|Sports, activities and exercise|Education on sports, activities and exercise
79267288|NCT02416635|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
79267289|NCT02416635|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
79568228|NCT01752894|Device|Angio-guided PCI with EES or BES|Angio-guided intervention
79568229|NCT01752894|Device|OCT-guided PCI with EES or BES|OCT-guided intervention
79568230|NCT01752894|Device|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
79863259|NCT04047329|Other|general anesthesia or neuraxial anesthesia|
79267290|NCT02162797|Dietary Supplement|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
79568231|NCT01752894|Device|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
79568232|NCT01752894|Drug|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (>6%) at 3months OCT follow up after stent implantation.
79568233|NCT01752894|Drug|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
79863260|NCT00779753|Dietary Supplement|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
79863261|NCT00537056|Procedure|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
79568234|NCT01752959|Drug|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
79568235|NCT01752959|Drug|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
79568236|NCT01752972|Dietary Supplement|Spirulina|10 g/day orally for 12 weeks
79267291|NCT02162797|Dietary Supplement|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
79568237|NCT01752998|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|
79568238|NCT01752998|Behavioral|Health Education|
79568239|NCT01753024|Dietary Supplement|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
79728571|NCT02675257|Behavioral|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
79728572|NCT02675257|Behavioral|Diabetes complications|Education on diabetes complications
79728573|NCT02675257|Behavioral|Social aspects of living with diabetes|Education on social aspects of living with diabetes
80023783|NCT06204367|Diagnostic Test|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
80023784|NCT06204341|Radiation|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
79267292|NCT02407587|Device|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
79267293|NCT02162875|Drug|Praziquantel|Six different treatment strategies with praziquantel
79267294|NCT02413671|Dietary Supplement|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
79728574|NCT00928252|Drug|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
79728575|NCT02673073|Other|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
79728576|NCT02673073|Other|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
79728577|NCT02673229|Drug|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
79728578|NCT02673229|Drug|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
79863262|NCT00537056|Procedure|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
79863263|NCT00537056|Drug|F-18 Fluoro-deoxi-glucose|15 mCi iv
79863264|NCT00537056|Drug|Gadolinium-DTPA|0.1 mmol/kg iv
79863265|NCT00537056|Drug|Sunitinib|50 mg/day po
79568240|NCT01753037|Dietary Supplement|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
79568241|NCT01753037|Other|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
79568242|NCT01753050|Device|Stroke volume monitoring|Pulse contour stroke volume monitoring
79568243|NCT01753063|Behavioral|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
79568244|NCT01753063|Behavioral|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
79568245|NCT01753102|Drug|Estradiol|one tablet will be inserted daily for 14 days
79568246|NCT01753128|Drug|imipramine|
79568247|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation|
79863266|NCT00779831|Drug|120 mg Pseudoephedrine hydrochloride extended release tablets|
79863267|NCT00776321|Drug|Eprotirome|
79863268|NCT00776321|Drug|Placebo|
79863269|NCT00535262|Drug|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
79568248|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
79728579|NCT00644293|Drug|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
79568249|NCT01753154|Drug|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
79728580|NCT00644293|Drug|placebo|placebo
79728581|NCT00644293|Drug|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
79267295|NCT02413671|Dietary Supplement|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
79267296|NCT02413671|Other|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
79728582|NCT00644293|Drug|placebo|placebo
79728583|NCT01177007|Device|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
80023785|NCT06204328|Other|Benson relaxation technique and mHealth psychoeducation|"Benson relaxation technique & mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions."
80023786|NCT06204315|Radiation|Stereotactic Radiosurgery|Given by RTx
80023787|NCT06204289|Behavioral|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
80023788|NCT06204263|Other|finger feeding|The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
79267297|NCT02407353|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
79267298|NCT02407353|Drug|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
79267299|NCT03177447|Behavioral|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
79267300|NCT03177135|Device|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
79568250|NCT01753154|Drug|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
79728584|NCT00930982|Drug|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
79728585|NCT00930982|Drug|Placebo|Inhalation of matching placebo twice a day
79728586|NCT02673307|Behavioral|1 chewing gum over 45 minutes|
79728587|NCT02677285|Other|Different type of wound|
79267301|NCT02167555|Dietary Supplement|Active Comparator|Wild Blueberry Beverage
79267302|NCT02167555|Dietary Supplement|Placebo Comparator|Placebo Beverage
79267303|NCT03177057|Behavioral|Compliance Monitoring|Record behavior
79267304|NCT03177057|Other|Health Telemonitoring|Receive health monitoring text messages
79267305|NCT03177057|Other|Questionnaire Administration|Ancillary studies
79267306|NCT02164747|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
79267307|NCT03176901|Behavioral|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
79568251|NCT01753180|Biological|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
79568252|NCT01753180|Drug|saline|Local intra-coronary administration of saline at or into the CTO
79568253|NCT01753219|Procedure|Onstep|
79568254|NCT01753219|Procedure|Lichtenstein|
79568255|NCT01753232|Device|DALI-adsorber|Recording of treatment data. No extra interventional treatment
79568256|NCT01753232|Device|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
79568257|NCT01753271|Other|thoracic mobilization & shoulder mobilization & exercise|
79568258|NCT01753271|Other|shoulder mobilization & exercise|
79568259|NCT01753349|Biological|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
79568260|NCT01753375|Dietary Supplement|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
79863270|NCT00776399|Device|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
79863271|NCT00989534|Behavioral|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
79863272|NCT00989534|Behavioral|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
79568261|NCT01753375|Dietary Supplement|Placebo|Placebo to be given orally on weekly basis
79728588|NCT05662891|Other|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
79728589|NCT01176773|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
79267308|NCT03176901|Behavioral|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
79568262|NCT01753388|Device|Liberty Stent|
79568263|NCT01753440|Procedure|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
79568264|NCT01753453|Drug|Plerixafor|240mcg/kg, solution, subcutaneous injection
79568265|NCT01753453|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
79728590|NCT04102033|Drug|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
79728591|NCT05029180|Other|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
79728592|NCT04180111|Device|CATS Tonometer|CATS Tonometer Prism
79728593|NCT02887625|Drug|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
79728594|NCT02887625|Drug|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c <7.0%
79863273|NCT00772499|Drug|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
79863274|NCT00772499|Drug|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
79267309|NCT03176745|Diagnostic Test|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
79400608|NCT05962346|Device|BALT GOLDBALL 2 detachable latex ballon|Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
79400609|NCT05962346|Device|BALTACCIBDPE100 Microcatheter|Used to deliver the detachable balloon
79473412|NCT01687387|Drug|IPH2102 at 1 mg/kg|every 4 weeks
79473413|NCT01687387|Drug|Placebo (normal saline solution)|every 4 weeks
79473414|NCT05739110|Behavioral|tumor micronecrosis|whether HCC patients have tumor micronecrosis or not
79473415|NCT04638699|Other|OptiScreen training|Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
79473416|NCT01706263|Drug|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
79473417|NCT01706263|Drug|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
79473418|NCT01706263|Drug|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
79473419|NCT05738876|Procedure|CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access
79473420|NCT05738798|Dietary Supplement|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
79568266|NCT01753466|Dietary Supplement|Hydration|
79568267|NCT01753479|Other|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
79568268|NCT01753492|Device|Ologen|
79568269|NCT01753505|Other|64-slice Multidetector coronary CT angiography|
79568270|NCT01753531|Device|Flu Symptoms|
79568271|NCT01753583|Device|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
79568272|NCT01753583|Other|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
79863275|NCT00989690|Drug|docetaxel|
79863276|NCT00989690|Drug|erlotinib hydrochloride|
79863277|NCT00989690|Drug|pemetrexed disodium|
79863278|NCT00989690|Genetic|fluorescence in situ hybridization|
79863279|NCT00989690|Genetic|mutation analysis|
79863280|NCT00989690|Genetic|proteomic profiling|
79863281|NCT00989690|Other|immunohistochemistry staining method|
79863282|NCT00989690|Other|laboratory biomarker analysis|
79863283|NCT00989690|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
79863284|NCT00989690|Procedure|breath test|
79863285|NCT00779987|Drug|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
79863286|NCT00779987|Drug|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
79863287|NCT04819022|Device|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
79863288|NCT04819022|Device|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
80023789|NCT06204211|Diagnostic Test|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
79267310|NCT03176667|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
79568273|NCT01753596|Device|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
79568274|NCT01753596|Other|Physiological Sodium Chloride solution (0,9%)|Placebo
79568275|NCT01753609|Device|Tulip capsule|swallowing Tulip capsule for up to 29 days
79568276|NCT01753622|Behavioral|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
79728595|NCT04180033|Diagnostic Test|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
79728596|NCT02886377|Biological|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
79863289|NCT04819022|Device|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
79863290|NCT03875027|Procedure|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
79863291|NCT00074581|Drug|Atazanavir|300 mg taken orally once daily
79863292|NCT00074581|Drug|Didanosine|400 mg taken orally once daily
80023790|NCT06204198|Other|No intervention|No intervention
80023791|NCT06204185|Drug|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
79728597|NCT05662813|Drug|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
79728598|NCT02675335|Drug|Sitagliptin|
79728599|NCT02675335|Drug|Placebo|
79728600|NCT02675101|Other|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
79728601|NCT02675101|Other|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
79863293|NCT00074581|Drug|Efavirenz|600 mg taken orally once daily
79863294|NCT00074581|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
79863295|NCT00074581|Drug|Lamivudine|300 mg taken orally once daily
79863296|NCT00074581|Drug|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
80023792|NCT06204185|Drug|Placebo|Placebo gel consist of drug without the active component.
79568277|NCT01753635|Device|supraglottic airway placement and use|
79568278|NCT01753661|Behavioral|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
80023793|NCT06204172|Device|Intensive Neurowave Emotional Stimulation (INES)|Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
80023794|NCT06204172|Other|Intensive Sensorial Emotional Stimulation (ISES)|The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
80023795|NCT06204146|Behavioral|massage|stressn level and preterm growth
80023796|NCT06204133|Other|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
80023797|NCT06204120|Drug|LPM3480392 Injection|PCA administration
80023798|NCT06204120|Drug|Placebo|PCA administration
80023799|NCT06204120|Drug|morphine hydrochloride injection|PCA administration
80023800|NCT06204107|Drug|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
79267311|NCT03176667|Procedure|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
79267312|NCT03727399|Other|blood withdrawal|Blood withdrawal
79728602|NCT02675101|Other|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
79267313|NCT02167633|Procedure|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
79863297|NCT00074581|Drug|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
79863298|NCT00074581|Drug|Stavudine|Dosage depends on weight
79267314|NCT02167633|Radiation|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
79267315|NCT02167633|Radiation|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
79728603|NCT00928018|Drug|Sirolimus|Taken orally for at least 12 months
80023801|NCT06204107|Drug|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
80023802|NCT06204094|Radiation|node-sparing short-course radiotherapy|5Gy*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes
80023803|NCT06204094|Drug|Sintilimab|200mg intravenous infusion d1 of each cycle*8cycles
79267316|NCT02167633|Drug|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
79267317|NCT02167633|Drug|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
79728604|NCT00928018|Drug|Methotrexate|Given intravenously on the first, third and sixth day after transplant
79863299|NCT00074581|Drug|Tenofovir disoproxil fumarate|300 mg taken orally once daily
79863300|NCT00074581|Drug|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
79863301|NCT00776477|Drug|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
79863302|NCT00776477|Drug|aspirin|aspirin 100mg daily
79863303|NCT04692116|Device|ExAblate treatment|Subthalamotomy using the ExAblate
79267318|NCT02416947|Dietary Supplement|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
79267319|NCT02416947|Dietary Supplement|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
79267320|NCT02416947|Dietary Supplement|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
79863304|NCT00772655|Drug|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 [if platelets are below 150000/µl only 11 MBq/kg are administered).
79267321|NCT02413281|Drug|ALKS 5461|Sublingual tablets, single administration
79267322|NCT02413281|Drug|Buprenorphine|Sublingual tablets, single administration
79400610|NCT05962346|Device|Storz fetoscopic operating sheath and miniature telescope/fetoscope|Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
79728605|NCT00928018|Drug|Tacrolimus|Taken orally or given intravenously for at least 6 months
79863305|NCT00772655|Drug|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
79267323|NCT02413281|Drug|Placebo|Sublingual tablets, single administration
79267324|NCT02170909|Drug|BIBR 1048 MS low dose|
79863306|NCT04299542|Procedure|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
80023804|NCT06204094|Drug|Capecitabine|1000mg/m2, PO, BID, d1-14 of each cycle*8cycles
80023805|NCT06204094|Drug|Oxaliplatin|130mg/m2, intravenous infusion,d1 of each cycle*8cycles
80023806|NCT06204094|Procedure|TME surgery|laparoscopic or robotic TME surgery for non-cCR patients
80023807|NCT06204094|Procedure|watch and wait|WW for cCR patients
80023808|NCT06204081|Device|CSO_without cueing|The sole is worn without using the cueing application
80023809|NCT06204081|Device|CSO_cueing|The sole is worn with using the cueing application
79267325|NCT02170909|Drug|BIBR 1048 MS medium dose|
79267326|NCT02170909|Drug|BIBR 1048 MS high dose|
79400611|NCT05962008|Dietary Supplement|DHAPS® product|Take 4 capsules per day after breakfast with warm water.
79568279|NCT01753661|Behavioral|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
79568280|NCT01753661|Behavioral|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
79568281|NCT01753674|Dietary Supplement|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
79568282|NCT01753674|Dietary Supplement|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
79568283|NCT01753687|Other|Ocular scattering of the tear film|
79568284|NCT01753687|Other|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
79568285|NCT01753687|Other|Measurement of tear film osmolarity|
79568286|NCT01753700|Dietary Supplement|UHT treated milk|
79568287|NCT01753726|Other|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
79728606|NCT00928018|Drug|Cyclosporine|Taken orally or given intravenously for at least 6 months
80023810|NCT06204068|Device|Spica cast|Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.
80023811|NCT06204068|Device|Rhino brace|Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
80023812|NCT06204055|Other|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
80023813|NCT06204003|Drug|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
79267327|NCT03176433|Device|Normothermic Machine Liver Perfusion|Liver Preservation Method
79267328|NCT02164825|Drug|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
79728607|NCT00928018|Drug|MMF|Taken orally for about 2 months
79728608|NCT04099225|Diagnostic Test|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
80023814|NCT06203990|Behavioral|Barre exercise|Group barre exercise class
80023815|NCT06203977|Drug|Colchicine|0.3mg and 0.6mg tablets
80023816|NCT06203964|Other|No intervention|No intervention
79400612|NCT05962008|Dietary Supplement|BioPS® product|Take 4 capsules per day after breakfast with warm water.
79400613|NCT05962008|Dietary Supplement|Placebo|Take 4 capsules per day after breakfast with warm water.
79400614|NCT05946382|Behavioral|RNT-ACT Protocol|Swedish Translation of the 2*60 minute Acceptance and Commitment Protocol for Repetitive Negative Thinking.
79728609|NCT02672839|Drug|LGD-6972 Solution|15 mg of LGD-6972
79728610|NCT02672839|Drug|LGD-6972 Capsules|15 mg LGD-6972
79400615|NCT05946382|Behavioral|iCBT Treatment|Internet-based Cognitive Behavioral Therapy as mandatory routine care in Swedish Primary care and therefore considered Treatment as usual.
79568288|NCT01753726|Other|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
79863307|NCT04299542|Procedure|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
79568289|NCT01753752|Drug|Chitosan- N- Acetylcysteine eye drops|
79267329|NCT02164825|Drug|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
79568290|NCT01753752|Drug|Placebo|
79267330|NCT03176511|Behavioral|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
79267331|NCT03176511|Behavioral|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
79267332|NCT02170987|Drug|Dabigatran etexilate low|
79267333|NCT02170987|Drug|Dabigatran etexilate high|
79568291|NCT01753778|Device|Cryo-Touch III Device|Treatment with Cryo-Touch III
79267334|NCT02170987|Drug|Moxifloxacin|
79267335|NCT02170987|Drug|Placebo|
79568292|NCT01753791|Drug|80 mg PF-06473871|80 mg of PF-06473871 or placebo
79568293|NCT01753791|Drug|160 mg PF-06473871|160 mg of PF-06473871 or placebo
79568294|NCT01753791|Drug|320 mg PF-06473871|320 mg of PF-06473871 or placebo
79568295|NCT01753791|Drug|480 mg PF-06473871|480 mg of PF-06473871 or placebo
79728611|NCT00643435|Behavioral|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
79728612|NCT00643435|Behavioral|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
79728613|NCT00927940|Device|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
79728614|NCT02677129|Other|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
79568296|NCT01753804|Other|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
79728617|NCT00910117|Drug|nimotuzumab|nimotuzumab 400 mg d1
79728618|NCT00910117|Drug|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
79728619|NCT04264936|Drug|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
79728620|NCT04181437|Drug|NVP-1203-R1|1 tablet, Single oral dosing
79728621|NCT04181437|Drug|NVP-1203-R2|1 tablet, Single oral dosing
79728622|NCT04181437|Drug|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
79728623|NCT04181125|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
79728624|NCT04181125|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
79267336|NCT03176121|Drug|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
79267337|NCT02261155|Procedure|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
79267338|NCT02171143|Drug|ASP2409|intravenous (IV)
79267339|NCT02171143|Drug|Placebo|intravenous (IV)
79267340|NCT03176199|Drug|Oxycodone|Every 12 hours for control-released oxycodone (OxyContin®)
79267341|NCT03176199|Drug|Oxycodone|Every 6 hours for immediate-released oxycodone (OxyNorm®)
79267342|NCT05697614|Drug|Valproic acid|valproic acid is used for general epilepsy type, used in experimental group
79267343|NCT05697614|Drug|Carbamazepin|carbamazepine is used for focal type epilepsy, used in experimental group
79568297|NCT01753843|Procedure|early cord clamping|early ( <20 seconds)
79568298|NCT01753843|Procedure|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
79568299|NCT01753869|Procedure|Airways clearance and Hypertonic saline inhalation|
79568300|NCT01753882|Drug|Lexapro|Agent + training vs Placebo + training
79568301|NCT01753882|Drug|Placebo|Agent + training vs Placebo + training
79568302|NCT01753908|Drug|Broccoli Sprout Extract|Given PO
79568303|NCT01753908|Other|Laboratory Biomarker Analysis|Correlative studies
79568304|NCT01753908|Other|Pharmacological Study|Urinary ITCs and metabolites measured
79568305|NCT01753908|Other|Placebo|Given PO
79728625|NCT00927862|Genetic|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
79728626|NCT00927862|Genetic|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
79863308|NCT01086865|Drug|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
80023817|NCT06203951|Diagnostic Test|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
80023818|NCT06203938|Device|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
80023819|NCT06203938|Device|Sham|Identical to TILS, but with lights off
80023820|NCT06203925|Diagnostic Test|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
80023821|NCT06203925|Diagnostic Test|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
80023822|NCT06203899|Behavioral|Op Volle Kracht|This is a preventive group training based on cognitive behavioural therapy for depression.
80023823|NCT06203899|Behavioral|Gatekeeperstraining|This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
80023824|NCT06203886|Device|LumbaCure|LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
80023825|NCT06203873|Device|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
80023826|NCT06203873|Device|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
80023827|NCT06203860|Other|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~Lipid management~Blood pressure management~Antithrombotic therapy~Glycemic targets~Prevention of diabetes-related complications~Treatment of vascular disease affecting the lower extremities~Evaluation of cardioprotective drugs~Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~Guidance on vaccinations"
79267344|NCT05697614|Drug|Phenytoin|phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
79267345|NCT05697614|Drug|Lamotrigine|lamotrigine is used for general epilepsy type, used in control group
79267346|NCT05697614|Drug|Clobazam|clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
79400616|NCT05945797|Drug|Dexamethasone 4mg|An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
79400617|NCT05940935|Procedure|Arterial Blood Gas Base Deficit|The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
79400618|NCT05940285|Diagnostic Test|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after STEMI Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
79400619|NCT05934955|Drug|BI 1839100|BI 1839100
79400620|NCT05934955|Drug|Placebo matching BI 1839100|Placebo matching BI 1839100
79568306|NCT01753921|Other|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
79568307|NCT01753921|Other|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
79568308|NCT01753921|Device|MRI|MRI study of the brain will be performed at t=3months.
79267347|NCT05697614|Drug|Oxcarbazepine|oxcarbazepine is used for focal type epilepsy, used in control group
79267348|NCT03539185|Device|Videolaryngoscope Airtraq|Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation
79267349|NCT03539185|Device|Fiberoptic bronchoscope|Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
79267350|NCT02407275|Other|Biological sample|
79267351|NCT02171221|Drug|Oral DFP-11207|
79267352|NCT02413515|Drug|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
79267353|NCT02167789|Device|Paradym CRT 8770|
79568309|NCT01753947|Other|Deliberate Practice|
80023828|NCT06203834|Dietary Supplement|I-Fiber Pearl|Eat 200g for once, and once a day.
80023829|NCT06203834|Dietary Supplement|placebo|Eat 200g for once, and once a day.
79728627|NCT00927862|Other|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
79728628|NCT02672527|Drug|Trabectedin|
79863309|NCT01090843|Procedure|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
79863310|NCT01090843|Device|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
79863311|NCT01090843|Device|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
79863312|NCT00780299|Device|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
79863313|NCT00780299|Procedure|CVVH|hemofiltration intermittent dialysis
80023830|NCT06203795|Other|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
79267354|NCT02413437|Other|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
79267355|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided.
79267356|NCT02413437|Device|Ultrasound|
79267357|NCT03194906|Drug|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
79267358|NCT03194906|Other|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
80023831|NCT06203795|Other|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
80023832|NCT06203795|Other|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
80023833|NCT06203795|Device|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
79728629|NCT02672527|Drug|Dexamethasone|
79267359|NCT03194906|Other|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
79267360|NCT03540589|Device|Buzzy specific vibration device|It is a device that produces vibration
79267361|NCT03540589|Behavioral|Distraction|The distraction will be obtained through tablet with videos
79267362|NCT03171987|Drug|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
79267363|NCT03171987|Drug|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
79267364|NCT02164903|Other|QoL Survey Booklet|
79267365|NCT03172065|Drug|Normal saline|intravenous flluid
79728630|NCT04263220|Device|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
79728631|NCT04263220|Other|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
79728632|NCT00976989|Drug|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
79728633|NCT00976989|Drug|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
79728634|NCT00976989|Drug|FEC|5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
79728635|NCT00976989|Drug|Docetaxel|75 mg/m^2 for the first dose; 100 mg/m^2 if no dose limiting toxicity occurs.
79863314|NCT03895034|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
79728636|NCT00976989|Drug|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m^2. All treatments were given every three weeks by the IV route.
79267366|NCT03172065|Drug|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
79728637|NCT00927784|Biological|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
79728638|NCT00927784|Drug|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
79728639|NCT02675023|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
79728640|NCT04290117|Behavioral|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
79728641|NCT04290117|Behavioral|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
79728642|NCT02672605|Other|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
79863315|NCT03960931|Other|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
79863316|NCT03960931|Other|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
79267367|NCT06110650|Drug|Surufatinib|Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
79267368|NCT06110611|Device|Astra Tech Osseospeed EV® dental implant|Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
79267369|NCT06110585|Procedure|Transcranial Magnetic Stimulation (TMS)|The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.
79267370|NCT06110585|Procedure|Sham|A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
79728643|NCT04260100|Behavioral|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
79568310|NCT01753986|Behavioral|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
79728644|NCT04179487|Diagnostic Test|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
79728645|NCT04270227|Other|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
79728646|NCT05331352|Behavioral|Semi-structured interviews|Interview
79728647|NCT05331352|Behavioral|Projective methode|Rorschach + thematic aperception test
79728648|NCT05331352|Behavioral|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
79728649|NCT00644371|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~Rituximab, 250 mg/m2 on days -21 and -14.~Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
79728650|NCT04963972|Behavioral|Behavioral Intervention|Participate in Lucid Lane therapy program
79568311|NCT01753986|Behavioral|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
79568312|NCT01754012|Dietary Supplement|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
79568313|NCT01754051|Device|PC 400 coils|
79568314|NCT01754064|Device|Cardiac Rhythm Management device|
79267371|NCT06110546|Drug|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or >200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or >3mg/hr).
79863317|NCT03960931|Other|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
79267372|NCT06110546|Drug|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
79267373|NCT06110494|Drug|Iron oxide nanoparticles treatment Ferumoxytol/H2O2|Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
79863318|NCT00776633|Drug|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
79863319|NCT00776633|Drug|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
79863320|NCT00776633|Drug|oral anticoagulation|
79863321|NCT01093963|Drug|Lisdexamfetamine|oral; 20-70mg/day
79267374|NCT06110494|Drug|NaOCl|Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
79267375|NCT06110494|Drug|NaCl|Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
79267376|NCT06110468|Other|CoreDISTParticipation|CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
79568315|NCT01754077|Behavioral|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
79568316|NCT01754077|Behavioral|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
79568317|NCT01754077|Behavioral|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
79728651|NCT04963972|Other|Best Practice|Receive standard of care opioid education
79728652|NCT04963972|Other|Questionnaire Administration|Ancillary studies
79728653|NCT02677207|Drug|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
79728654|NCT02677207|Drug|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
79728655|NCT02864199|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
79728656|NCT02864199|Drug|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
79728657|NCT05911191|Other|Exercise based prehabilitation|A peripheral muscle strengthening program
79728658|NCT05911178|Radiation|[11C]-UCB-J|"PET tracer binding to SV2A protein, used to study synaptic vesiscle density."
79728659|NCT05911178|Radiation|[18F]-DPA-714|"PET tracer binding to TSPO protein, used to study microglial activation."
79863322|NCT01093963|Drug|Placebo|oral; 20-70mg/day
79863323|NCT03956563|Device|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
79267377|NCT06110455|Other|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
79267378|NCT06110455|Other|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
79267379|NCT06110429|Drug|Lactate, Sodium|Isovolemic and osmotic infusion Comparison of osmotic agent
79267380|NCT06110429|Drug|Hypertonic saline|Isovolemic and osmotic infusion Comparison of osmotic agent
79267381|NCT06110416|Other|nausea relief inhaler|Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
79267382|NCT06110403|Drug|TRIXEO AEROSPHERE|BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
79863324|NCT03956563|Device|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
79863325|NCT00776711|Drug|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
80023834|NCT06203782|Procedure|endoscopic stricturoplasty|Experimental Group: In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
80023835|NCT06203782|Procedure|endoscopic balloon dilation|Control Group: In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
80023836|NCT06203769|Drug|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
79863326|NCT00776711|Drug|VRC-AViDNA036-00-VP|
79863327|NCT00336128|Behavioral|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
79863328|NCT00336128|Behavioral|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
80023837|NCT06203769|Drug|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
80023838|NCT06203756|Device|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
79473421|NCT04858737|Behavioral|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
79568318|NCT01754090|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
79568319|NCT01754090|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
79728660|NCT05911178|Radiation|[18F]-RO-948|"PET tracer binding to tau protein, used to study the topograhpy of tau deposition."
80023839|NCT06203756|Device|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
79728661|NCT05911178|Radiation|[11C]-PiB|PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
80023840|NCT06203756|Device|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
80023841|NCT06203743|Procedure|caudal block group|PI, PVI measurements and hemodynamic data will be compared between groups
79728662|NCT05911126|Drug|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
79728663|NCT05911087|Biological|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
79728664|NCT05911087|Biological|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
79863329|NCT03956485|Other|Type of center|Tertiary versus non-tertiary
79863330|NCT03743090|Diagnostic Test|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
79863331|NCT00772811|Drug|Flu-Mel|"Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~Melphalan will be administered following the completion of Fludarabine infusion at day -2."
79863332|NCT03961087|Drug|Coenzyme Q10|Coenzyme Q10 will be given twice
79863333|NCT03961087|Drug|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
80023842|NCT06203743|Procedure|ilioinguinal-iliohypogastric nerve block group|PI, PVI measurements and hemodynamic data will be compared between groups
80023843|NCT06203691|Dietary Supplement|Supplementation with Nirvana Super Pro Liquid Supplements|Intervention will measure strength pre & post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
80023844|NCT06203691|Dietary Supplement|Non-Supplementation Group|Intervention will measure strength pre & post operatively. Intervention group will not receive liquid supplements.
80023845|NCT06203678|Other|Kinesio taping|therapeutic tape application
80023846|NCT06203678|Other|Exercise|Cervical stretching and strengthening exercises home program
80023847|NCT06203678|Other|Sham taping|patch tape application
79863334|NCT03960775|Drug|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
79728665|NCT05911087|Biological|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
79568320|NCT01754090|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
79728666|NCT05911087|Biological|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
79568321|NCT01754103|Other|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
79568322|NCT01754116|Drug|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
79568323|NCT01754116|Drug|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
79863335|NCT03960775|Drug|saline|Saline infusion during same time period.
79728667|NCT05908565|Behavioral|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
79728668|NCT05908565|Behavioral|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
79863336|NCT00536978|Drug|ARA-C|100 mg/m^2 IV Daily Over 1 Hour for 4 Days
80023848|NCT06203665|Diagnostic Test|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
80023849|NCT06203652|Other|Real-world regimen|The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
79568324|NCT01754116|Drug|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
79568325|NCT01754116|Drug|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
79568326|NCT01754116|Drug|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
79728669|NCT05908539|Behavioral|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
79728670|NCT05908539|Behavioral|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
79728671|NCT05908539|Behavioral|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
79863337|NCT00536978|Drug|BCNU|300 mg/m^2 IV Over 1 Hour for 1 Day
79863338|NCT00536978|Drug|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
79863339|NCT00536978|Drug|Cyclophosphamide|1000 mg/m^2 IV Daily Over 1 Hour for 3 Days
79863340|NCT00536978|Drug|Etoposide|100 mg/m^2 IV Daily Over 3 Hours for 4 Days
79863341|NCT00536978|Drug|Fludarabine|30 mg/m^2 IV Daily Over 1 Hour for 3 Days
79863342|NCT00536978|Drug|Melphalan|100 mg/m^2 IV Over 30 Minutes for 1 Day.
79568327|NCT01754155|Radiation|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
79863343|NCT00536978|Drug|Rituximab|375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks.
79863344|NCT00536978|Other|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
79863345|NCT00536978|Radiation|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
79863346|NCT00536978|Drug|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
79863347|NCT00536978|Drug|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
79728672|NCT05908539|Behavioral|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
79728673|NCT05908513|Drug|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
79568328|NCT01754181|Drug|Insulin|the intervention is applied only at the dose of insulin
79863348|NCT00536978|Procedure|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
79568329|NCT01754220|Drug|Montelukast|Montelukast is a leukotriene receptor antagonist
79568330|NCT01754233|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
79728674|NCT05908513|Drug|Placebo|Similar chemical structure of NAC but without function
79267383|NCT06110390|Device|High flow nasal oxygen|An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0
79267384|NCT06110364|Device|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
79267385|NCT06110364|Behavioral|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
79267386|NCT06110364|Other|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
79267387|NCT06110338|Drug|placebo|placebo iv. once.
79267388|NCT06110338|Drug|IBI355|IBI355 iv. once.
79728675|NCT05908500|Other|CPR Training|Various methods of CPR training are implemented and compared
79863349|NCT05356832|Diagnostic Test|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
79863350|NCT03809611|Drug|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
79863351|NCT03809611|Drug|Placebo|placebo
79267389|NCT06110312|Behavioral|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
79267390|NCT06110299|Diagnostic Test|air injection|delination of the ureter and pelvis by injecting air under C-ARM
79728676|NCT05908422|Device|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
79728677|NCT05908370|Procedure|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
79728678|NCT05908318|Behavioral|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
79728679|NCT05908305|Drug|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
79267391|NCT06110286|Other|Photorefractive keratectomy|Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
79473422|NCT04858737|Other|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
79568331|NCT01754246|Device|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
79568332|NCT01754285|Drug|LF-PB and Placebo|
79568333|NCT01754285|Drug|Placebo|
79863352|NCT05360342|Drug|Vitamin K supplement|Single dose of vitamin K supplement
79863353|NCT00989846|Other|biomarker|measuring serum-biomarkers
79863354|NCT05356754|Device|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
79863355|NCT03807739|Drug|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
79473423|NCT01690117|Behavioral|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
79473424|NCT02330978|Procedure|Intravitreal transplantation of mesenchymal stem cell|
79473425|NCT02330978|Biological|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
79568334|NCT01754285|Drug|LF-PB|
79863356|NCT03807739|Drug|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
79863357|NCT03807739|Drug|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
79863358|NCT05290220|Drug|HLX07|1500 mg
79863359|NCT05290220|Drug|HLX10|300 mg
79863360|NCT05290220|Drug|HLX04|15mg/kg
79863361|NCT05290220|Drug|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW <60 kg)
79863362|NCT01583257|Behavioral|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
79568335|NCT01754298|Procedure|Retro-articular drilling|"Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~Use a 0.045 K-wire for drilling.~Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
79568336|NCT01754298|Procedure|Trans-articular drilling|"Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~Use a 0.045 K-wire for drilling~A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
79728680|NCT02672995|Radiation|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
79728681|NCT02672995|Drug|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
79728682|NCT05908279|Other|Walking test|Walk with and without a metronome
79863363|NCT03956329|Other|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
79267392|NCT06110260|Dietary Supplement|AstraGin (Ginseng and Astragalus Saponin Extract)|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
79267393|NCT06110260|Dietary Supplement|Placebo|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
79267394|NCT06110234|Behavioral|Episodic Specificity Induction|Recalling complex scenes using the Episodic Specificity Induction
79568337|NCT01754324|Drug|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
79568338|NCT01754337|Other|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
79267395|NCT06110234|Behavioral|Associative Memory|Recalling word/picture pairs
79267396|NCT06110221|Other|Periodontal clinical measurements, GCF and saliva sampling|"Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
79267397|NCT06110208|Drug|CLL1 and CD38 dual-target CAR-T injection|CLL1 and CD38 dual-target CAR-T injection
79568339|NCT01754415|Device|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
79568340|NCT01754454|Biological|Human Umbilical Cord Derived MSC|1×10^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
79568341|NCT01754506|Dietary Supplement|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
79568342|NCT01754532|Biological|Hair Sample|Analysis of hair cortisol levels
79728683|NCT05908279|Other|Disease assessement|Disease stage assessed by a doctor
79728684|NCT05908266|Other|Reaching movements|Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
79728685|NCT05908266|Other|Disease Assessment|Disease stage assessed by trained professionals
79728686|NCT05908201|Behavioral|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
79728687|NCT05908175|Other|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
79728688|NCT05908162|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
79728689|NCT05908019|Other|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
79728690|NCT05908006|Device|Velacur|Imaging Procedures Comparison
79400621|NCT05931874|Behavioral|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the study self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the study. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the study app and provide Fitbit data to the study team in real-time.~The core study app will support BCS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
79400622|NCT05931874|Behavioral|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
79400623|NCT05931874|Behavioral|Buddy|"Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the study app modules the participant has access to for their assigned condition.~The study app include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcast (one every 3 weeks) during the first 24 weeks of the intervention. Each webinar will provide social support training and peer discussion of challenges and successes in providing BCS with MVPA support."
79267398|NCT06110195|Drug|Xevinapant|Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
79568343|NCT01754545|Drug|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
79267399|NCT06110195|Drug|Carboplatin|Given with radiation weekly for 7 doses.
79267400|NCT06110195|Drug|Paclitaxel|Given with radiation weekly for 7 doses.
79267401|NCT06110195|Radiation|Radiation Therapy|Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
79568344|NCT01754545|Drug|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
79728691|NCT05907941|Device|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system [V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
79267402|NCT06110182|Dietary Supplement|enteral or parenteral nutritional support|Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.
79863364|NCT03956329|Other|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
79568345|NCT01754558|Procedure|Ajust system|The use of Ajust system for stress incontinence
79568346|NCT01754558|Procedure|TVT/TVT-O|sling surgery
79568347|NCT01754571|Behavioral|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
79568348|NCT01754597|Drug|Peptide Natriurétique de type B|Peptide Natriurétique de type B
79568349|NCT01754636|Other|No intervention|
79568350|NCT01754649|Drug|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
79568351|NCT01754662|Dietary Supplement|Soy protein|2 bars daily for 8 weeks.
79568352|NCT01754662|Dietary Supplement|Isoflavones|2 bars daily for 8 weeks.
79568353|NCT01754662|Dietary Supplement|Cocoa|2 bars daily for 8 weeks.
79568354|NCT01754662|Dietary Supplement|Placebo|
79568355|NCT01754675|Behavioral|Soccer|Watching the soccer match at the time that the favorite team is playing
79568356|NCT01754675|Behavioral|Movie|Watching a movie at the time that the favorite team is playing
79568357|NCT01754701|Dietary Supplement|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
79568358|NCT01754701|Dietary Supplement|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
79267403|NCT06110104|Other|routine physiotherapy program for knee osteoarthritis|The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
79267404|NCT06110104|Other|Retro-walking program|Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
79267405|NCT06110104|Other|whole body vibration training|whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
79568359|NCT01754740|Drug|Uréia|"The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
79728692|NCT05907941|Other|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
79728693|NCT05907941|Procedure|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
79400624|NCT05931874|Behavioral|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the study app.
79400625|NCT05931874|Behavioral|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the study app.
79568360|NCT01754740|Drug|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
79863365|NCT01583413|Procedure|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
79863366|NCT00536744|Device|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
79863367|NCT00536744|Other|Sham|Non-energized (inactive - Sham) application + standard of care
79863368|NCT01094041|Other|Gluten free diet|A 4-week gluten free diet provided
79863369|NCT01094041|Other|Gluten rich diet|A 4-week gluten rich diet is provided
80023850|NCT06203574|Radiation|[18F]F/[68Ga]Ga-NOTA-T4|The dose of [18F]F/[68Ga]Ga-NOTA-T4 was calculated based on the patient's body weight to be 3.7 MBq [0.1 MCi]/kg, and the method of administration was intravenous push, with one single imaging administration.
80023851|NCT06203548|Behavioral|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
79267406|NCT06110078|Drug|Acetazolamide|Oral rinse with acetazolamide (not taken orally)
79267407|NCT06110065|Drug|CT-guided Pudendal Nerve Cryoneurolysis|CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
79568361|NCT01754805|Drug|peficitinib|oral
79568362|NCT01754805|Drug|methotrexate|oral
79568363|NCT01754818|Drug|Bendavia 10mg|
79568364|NCT01754818|Drug|Bendavia 50mg|
79568365|NCT01754818|Drug|Bendavia 100mg|
79863370|NCT04076072|Device|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
79267408|NCT06110065|Drug|Percutaneous image-guided cryoneurolysis|Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
79568366|NCT01754818|Drug|Placebo|
79568367|NCT01754831|Device|Fluoride varnish|Topical application of fluoride varnish on present teeth
79863371|NCT04076072|Device|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
79568368|NCT01754844|Drug|AZD7624|Single dose inhaled IMP via a nebulizer
79568369|NCT01754844|Drug|Placebo to match|Single dose inhaled Placebo via a nebulizer
79863372|NCT04026230|Drug|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
79863373|NCT04026230|Drug|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
79863374|NCT03884504|Device|Ventricular Assist Device System|Ventricular Assist Device System
79568370|NCT01754870|Drug|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
79863375|NCT00536510|Drug|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
79863376|NCT00536510|Drug|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
79863377|NCT04526600|Other|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
80023852|NCT06203509|Behavioral|Thrive Intervention|• The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
80023853|NCT06203496|Diagnostic Test|Blood sample|Blood sample
79267409|NCT06110052|Other|prospective follow up|compare preoperative and postoperative visual analog scale VAS of maximum perceived pain in ladies with OMAs
79267410|NCT06110039|Other|Cervicothoracic Junction Mobilization|The therapist stood in back of the subject, who was seated straight on a chair. The therapist positioned the medial side of one hand's thumb. The desired level of vertebra can be strengthened by placing the index finger of the opposite hand on the spinous process. A pure transverse glide was executed from the affected side to the unaffected side.
79400626|NCT05928182|Behavioral|El Faro Treatment Intervention|"Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. [All rating scales are parent-report unless noted otherwise]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. [All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise]."
79400627|NCT05925075|Diagnostic Test|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
79568371|NCT01754883|Drug|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
79568372|NCT01754896|Other|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
79400628|NCT05923125|Behavioral|Graded-Intensity Treadmill Exercise Protocol|The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
79473426|NCT02330276|Drug|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
79473427|NCT04632303|Other|Early Palliative Care|Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
79473428|NCT01690273|Other|mobility exercise|30 minutes, twice a week
79568373|NCT01754896|Other|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
79568374|NCT01754896|Other|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
79568375|NCT01754896|Other|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
79568376|NCT01754961|Drug|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
79728694|NCT05907928|Other|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
79728695|NCT05907928|Other|Single bond Universal|Radiolucent universal adhesive
79728696|NCT05907915|Device|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
79728697|NCT05907915|Behavioral|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
79728698|NCT05907902|Drug|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
80023854|NCT06203470|Drug|Botulinum Toxin-A|Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
80023855|NCT06203470|Drug|calcipotriol|topical vitamin D3 analogues
80023856|NCT06203457|Biological|Efgartigimod|Patients receiving efgartigimod infusions
80023857|NCT06203444|Drug|Tenapanor|The study drug will be administered in dose of 50 mg bid
79568377|NCT01754961|Drug|Placebo|Placebo given orally on Day 1
79728699|NCT05907863|Other|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
79728700|NCT05907798|Procedure|LIMA Blood flow|30 minutes after induction
79728701|NCT05907772|Other|No intervention|No intervention
79863378|NCT04496258|Behavioral|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
80023858|NCT06203431|Drug|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
80023859|NCT06203431|Drug|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
79728702|NCT05907733|Diagnostic Test|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
79728703|NCT05907642|Other|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
79728704|NCT05907603|Drug|RD13-02 cell infusion|CAR-T cells
79728705|NCT05907590|Other|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
79728706|NCT05907590|Other|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
79267411|NCT06110039|Other|Upper Thoracic Spine Manipulation:|The therapist placed one hand on the patient's head and the hypothenar or thenar eminence of the other hand was placed over the T1 transverse process (the therapist's left hand was used for thrusting and vice versa for treating the left T1 Transverse process). As the tissue deficiency is taken up localizing the forces, the patient was urged to breathe in and out multiple times. While holding the hand on the head steady, a minor relative rotation in the opposite direction was caused, which led to the introduction of the postero-anterior force on the transverse process of T1(29). Patients will receive three sessions a week on alternate days for three weeks and follow up data will be taken once after completion of all three sessions using data collection tools
79267412|NCT06110026|Other|Brunkow Exercise Program|The brunkow exercise program will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
79267413|NCT06110026|Other|Lumbar Stabilization Exercises|The lumbar stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
79473429|NCT01690273|Other|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
79728707|NCT05907590|Other|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
79728708|NCT05907590|Other|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
79728709|NCT05907590|Other|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
79728710|NCT05907577|Other|Observational|No interventions.
79728711|NCT05907538|Other|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
79728712|NCT05907538|Other|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
79863379|NCT04496258|Behavioral|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
79568378|NCT01754974|Biological|Peginterferon Lambda-1a|
79568379|NCT01754974|Drug|Ribavirin|
79568380|NCT01754974|Biological|Peginterferon alfa-2a|
79568381|NCT01755000|Procedure|USCOM scan|
79863380|NCT04424264|Drug|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600*/300 mg daily from screening until enrolment (days -15 to 0)
79568382|NCT01755000|Procedure|Fluid Bolus|
79568383|NCT01755013|Procedure|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
79568384|NCT01755078|Drug|Sevelamer HCl|Non-metal phosphate binder
79568385|NCT01755078|Drug|Calcium-based phosphate binder|
79863381|NCT04424264|Drug|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/*300 mg daily (days 1 to ≤ 56)
79267414|NCT06110013|Device|Electrical cardiometry|"All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management"
79267415|NCT06110000|Other|pragmatic set of interventipons|"The pragmatic set included 6 interventions as follows.~Pragmatic posterior capsular stretch (PPCS)~Serratus anterior stretch (SAS)~Rotator cuff facilitation (RCF)~Acromioclavicular joint mobilization.~Pectoralis minor stretch~Thoracic manipulation Five to ten sweeps per minute are administered three to four times. The applied force is combined with deep breathing. The subject is asked to report discomfort and the applied force is adjusted."
79267416|NCT06110000|Other|scapular strengthening exercise.|• Subjects in Group B receive strengthening exercises (exercise will perform with 15 repetitions for each set- 3sets/day, 3 days /week for 6 weeks. In Scapular strengthening exercises, treatment protocol will involve the individualized for focus muscle Serratus anterior (Dynamic hug, Scaption with external rotation, Diagonal PNF (shoulder flexion horizontal flexion, external rotation),Trapezius - Upper trapezius (unilateral shoulder shrug, rowing, forward shoulder flexion, shoulder abduction in scapular plane above 120 degrees, Middle trapezius (prone shoulder horizontal abduction, scaption, horizontal abduction with external rotation), Lower trapezius (Unilateral scapular retraction, prone bilateral shoulder external rotation at 90 degrees of abduction, prone shoulder abduction), Levator Scapulae (horizontal abduction with shrug, horizontal abduction with ER, prone shoulder extension, Rhomboids (ER at 90° of abduction, ER at 0° of abduction, Horizontal abduction, Shoulder extension)
79267417|NCT06109987|Other|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
79267418|NCT06109948|Drug|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
79267419|NCT06109948|Drug|Placebo injection for IV infusion|placebo saline injection
79728713|NCT05907538|Other|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
79863382|NCT04424264|Drug|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg <70kg, 750mg >70kg
79728714|NCT05907499|Drug|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
79728715|NCT05907499|Drug|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
79728716|NCT05907499|Drug|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
79728717|NCT05907499|Drug|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
79863383|NCT05355662|Other|Age|The study was retrospective and did not involve the application of interventions.
79863384|NCT00398086|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
79863385|NCT00398086|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
79267420|NCT06109935|Drug|Somapacitan|Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
79568386|NCT01755104|Dietary Supplement|Stablor|
79568387|NCT01755104|Dietary Supplement|Placebo|
79568388|NCT01755117|Other|Sciatic, femoral, obturator nerve blocks|
79728718|NCT05907486|Drug|N-acetyl-cysteine|8g/d (>=45kg); 200mg/kg.d (<45kg), intravenously for at least 4 hours, day -9 to day +45
79728719|NCT05907486|Drug|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
79568389|NCT01755117|Other|Sciatic nerve block, posterior lumbar plexus block|
79728720|NCT05907486|Drug|Cytarabine|2g/m2, day -8, intravenously
79728721|NCT05907486|Drug|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
79568390|NCT01755130|Procedure|Photoacoustic Imaging|Undergo LOUISA 3D
79568391|NCT01755182|Drug|approved pharmacologic therapy|
79568392|NCT01755182|Procedure|TAE|after randomization, and after 3 months
79728724|NCT05907447|Other|No interventions need to be specified for this study|No interventions need to be specified for this study
79728725|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
79728726|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
79728727|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
79728728|NCT05907382|Drug|Placebo in Cohorts 1 to 5|oral once
79863386|NCT05280860|Procedure|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
79863387|NCT04364360|Dietary Supplement|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
80023860|NCT06203418|Behavioral|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
79568393|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|All subjects will have a pH probe placed at their initial clinic visit and will have the probe removed 24 hours later. They will start on PPI medication (as per the standard of care) after probe removal. Subjects will have a follow up clinic visit 8-12 weeks after the initial visit. At the follow up visit, all subjects will have the option of a second probe placement to assess the effects of PPI therapy on reflux events.
79568394|NCT01755247|Drug|Topical Gel Vehicle|
79568395|NCT01755247|Drug|8% NVN1000 Topical Gel|
79568396|NCT01755247|Drug|8% NVN1000 Topical Gel and moisturizer|
79568397|NCT01755260|Other|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
79568398|NCT01755273|Procedure|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
79568399|NCT01755286|Drug|OTO-201|Single intra-operative injection
79568400|NCT01755286|Drug|Placebo|Single intratympanic injection
79568401|NCT01755286|Drug|Sham|Simulated single intratympanic injection
79568402|NCT01755299|Other|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
79728729|NCT05907382|Drug|Placebo in 2 Cohorts|oral once
80023861|NCT06203405|Procedure|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~Then sedation adjustment will be guided by P0.1 measurement.~If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~If P0.1 value <1.5, sedation will be reduced.~If P0.1 value >3.5, sedation will be increased.~If P0.1 value is still >3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value <3.5 cmH2O.~The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
79568403|NCT01755299|Other|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
79728730|NCT05907330|Drug|CU104|CU104 will administer the study drug once a day after a meal
80023862|NCT06203405|Drug|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
80023863|NCT06203405|Drug|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
80023864|NCT06203405|Drug|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
80023865|NCT06203405|Drug|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
80023866|NCT06203405|Drug|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
80023867|NCT06203392|Other|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
80023868|NCT06203392|Other|Mediterranean diet|Mediterranean diet provided for six weeks
80023869|NCT06203379|Other|Neuromuscular Exercise Training|Neuromuscular Exercise Training
80023870|NCT06203379|Other|control exercise|Exercise Training
79568404|NCT01755299|Other|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
79568405|NCT01755299|Other|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
79568406|NCT01755312|Device|Medication reminder|Medication reminder
79568407|NCT01755325|Drug|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
79568408|NCT01755325|Drug|placebo|
79568409|NCT01755338|Drug|Methylprednisolone|Methylprednisolone 15mg/kg
79568410|NCT01755338|Drug|Placebo|Placebo
79568411|NCT01755364|Biological|AdimFlu-V|
79568412|NCT01755377|Drug|Benznidazole|
79568413|NCT01755390|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
79568414|NCT01755403|Drug|Benznidazole|
79568415|NCT01755442|Other|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
79568416|NCT01755442|Drug|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
79568417|NCT01755468|Drug|Intermittent insulin therapy|
79568418|NCT01755468|Drug|Continuous metformin|
79568419|NCT01755481|Other|Probiotic|
79568420|NCT01755481|Other|Whey protein concentrate|
79728731|NCT05907330|Drug|Placebo|Placebo will administer the study drug once a day after a meal
79728732|NCT05907265|Behavioral|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
79728733|NCT05907265|Behavioral|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
80023871|NCT06203366|Procedure|Vojta therapy|Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
80023872|NCT06203353|Diagnostic Test|diaphragm ultrasound monitoring|Ultrasound measure the diaphragm excursion, thickening fraction and maximal contraction and relaxation velocities
79568421|NCT01755494|Drug|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
80023873|NCT06203340|Other|Core stabilizasyon and lumbal back school|Lumbal back schooL
80023874|NCT06203314|Other|Diagnostic test: EBV antibody tests|Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
80023875|NCT06203301|Behavioral|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
79728734|NCT05907187|Behavioral|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
79267421|NCT06109896|Other|Self Report Questionaires|Collection and analysis of information from patient self-report assessments and integration with clinical information from assessments performed routinely during cancer treatment.
79728735|NCT05907109|Behavioral|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~Infants will receive outcome evaluations within a 42-month follow-up clinic."
79728736|NCT05907083|Radiation|cone beam computer tomography|Cone Beam CT Radiation
79568422|NCT01755494|Drug|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
79568423|NCT01755494|Drug|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
79568424|NCT01755494|Drug|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
79568425|NCT01755494|Drug|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
79728737|NCT05906992|Biological|CT-P53|Intravenous(IV) infusion
79728738|NCT05906992|Biological|US-Ocrevus|Intravenous(IV) infusion
79728739|NCT05906992|Biological|EU-Ocrevus|Intravenous(IV) infusion
79728740|NCT05906966|Other|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
79728741|NCT05906901|Other|Cranial listening technique|5 minutes
79728742|NCT05906901|Other|Suboccipital muscles inhibition technique|6 minutes
79728743|NCT05906823|Other|Detection of pleural effusion|Detection of pleural effusion
79728744|NCT05906758|Procedure|Angiography|Coronary angiography with less than 20cc of contrast materials
79728745|NCT05906719|Other|video recording|Patients' performance of MDS-UPDRS III will be recorded.
79728746|NCT05906680|Procedure|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
79728747|NCT05906667|Behavioral|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
80023876|NCT06203275|Drug|Paroxetine|intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
80023877|NCT06203275|Drug|Placebo|Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
79568426|NCT01755507|Drug|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
79568427|NCT01755507|Drug|Placebo|
79568428|NCT01755520|Drug|Ticagrelor|90mg twice daily dose
79568429|NCT01755520|Drug|Aspirin|Aspirin 100mg once daily
79568430|NCT01755520|Drug|Placebo - Ticagrelor|Placebo
79568431|NCT01755520|Drug|Placebo - Aspirin|Placebo
79568432|NCT01755533|Other|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
79568433|NCT01755533|Other|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
79568434|NCT01755559|Drug|Artesunate-amodiaquine|antimalarial ACT
79568435|NCT01755559|Drug|Dihydroartemisinin-piperaquine|antimalarial ACT
79568436|NCT01755559|Drug|Artemether-lumefantrine|antimalarial ACT
80023878|NCT06203262|Device|Catheter Ablation Ventricular Tachicardia|Catheter ablation is s minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
80023879|NCT06203262|Device|Catheter Ablation Premature Ventricular Contractions|Catheter ablation is s minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
79568437|NCT01755572|Drug|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
80023880|NCT06203236|Drug|Furosemide 20 MG|"The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
80023881|NCT06203236|Other|diuretic therapy|diuretic therapy
80023882|NCT06203223|Other|Ova-max|use Ova-max 3 months prior to treatment initiation
80023883|NCT06203223|Other|placebo|use placebo 3 months prior to treatment initiation
80023884|NCT06203210|Drug|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
80023885|NCT06203210|Drug|Topotecan|Topotecan will be administered per local SoC.
79568438|NCT01755572|Drug|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
79267422|NCT06109857|Other|Non-Interventional Study|Non-interventional study
79728748|NCT05906654|Behavioral|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
79728749|NCT05906576|Drug|Infliximab|Infliximab in the treatment of Crohn's disease in children
79728750|NCT05906563|Drug|Melatonin gel|local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
79728751|NCT05906563|Drug|Metformin and melatonin gel|local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
79728752|NCT05906563|Drug|placebo gel|Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
79267423|NCT06109844|Other|Standard of Care|Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.
79568439|NCT01755611|Drug|Minocycline 100mg|Test product
79568440|NCT01755611|Drug|Minocycline 100mg|Reference product
79728753|NCT05906563|Procedure|scaling and root planning|full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
80023886|NCT06203210|Drug|Amrubicin|Amrubicin will be administered per local SoC.
80023887|NCT06203210|Drug|Lurbinectedin|Lurbinectedin will be administered per local SoC
80023888|NCT06203197|Other|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
80023889|NCT06203184|Other|video based exercises|Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
80023890|NCT06203145|Drug|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
80023891|NCT06203132|Drug|Doravirine + tenofovir DF + lamivudine|Oral administration
80023892|NCT06203132|Drug|Dolutegravir + tenofovir DF + lamivudine or emtricitabine|Oral administration
79267424|NCT06109805|Other|Gastric cancer|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
79267425|NCT06109792|Procedure|implant supported mandibular overdenture|In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.
79568441|NCT01755624|Device|NovoTTF-100A device|
79568442|NCT01755624|Other|Best Standard of Care|
79568443|NCT01755663|Drug|Ivabradine and Metoprolol|
79568444|NCT01754792|Dietary Supplement|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
79568445|NCT01755676|Drug|Orlistat 60 mg|1 tablet 3 times a day
79568446|NCT01755676|Other|Placebo|1 tablet 3 times a day
79568447|NCT01755689|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
79568448|NCT01755689|Biological|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
79568449|NCT01755689|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
80023893|NCT06203106|Other|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
80023894|NCT06203093|Other|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
80023895|NCT06203080|Drug|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
80023896|NCT06203080|Drug|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
80023897|NCT06203015|Diagnostic Test|The Cambridge Neuropsychological Test Automated Battery.|to determine cognitive dysfunction
80023898|NCT06203015|Diagnostic Test|Venous blood samples|to measure levels of cytokines, endotoxin, and genetic markers.
80023899|NCT06203015|Diagnostic Test|brain MRI|to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
80023900|NCT06203015|Diagnostic Test|the Montgomery-Åsberg Depression Rating Scale|to measure severity of depressive symptoms
79267426|NCT06109766|Behavioral|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
79267427|NCT06109753|Procedure|Robotically Assisted Laparoscopic Surgery|robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
79728754|NCT05906550|Diagnostic Test|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
79728755|NCT05906550|Diagnostic Test|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume <500mL/min.
79728756|NCT05906537|Drug|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
79728757|NCT05906524|Drug|KD6001|KD6001 will be administered intravenously.
79728758|NCT05906524|Drug|Tislelizumab|Tislelizumab will be administered intravenously.
79728759|NCT05906524|Drug|Bevacizumab|Bevacizumab will be administered intravenously.
79728760|NCT05906498|Drug|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
80023901|NCT06203015|Other|questionnaire prepared by the researchers|collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
79400629|NCT05921552|Behavioral|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
79728761|NCT05906498|Drug|Vitamin E|vitamin E possessing an anti-inflammatory action
79728762|NCT05906485|Behavioral|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
80023902|NCT06202989|Drug|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ [ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)] Dose: 1.0g, 3 times per day for 3 months after surgery
80023903|NCT06202989|Other|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients
80023904|NCT06202976|Other|Secondary data collection|clinical data
80023905|NCT06202963|Drug|Triamcinolone Acetonide|"group will receive ultrasound-guided hydrodilatation~group will receive ultarsound-guided coracohumeral hydrorelease in addition to the ultrasound-guided hydrodilaltation of shoulder"
80023906|NCT06202937|Behavioral|Mother Baby Yoga|Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
80023907|NCT06202937|Other|No intervention:control|the control group received the usual care
79728763|NCT05906485|Behavioral|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
79728764|NCT05906472|Other|Feeds continued|Enteral feeds are continued up until time of surgery
79728765|NCT05906472|Other|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
79728766|NCT05905796|Other|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
79728767|NCT05904639|Genetic|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
79728768|NCT05903911|Other|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
80023908|NCT06202911|Drug|oral n-acetyl cysteine|the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
80023909|NCT06202911|Other|placebo|the control group will receive placebo
80023910|NCT06202898|Other|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
80023911|NCT06202898|Other|ENTRSUT|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
80023912|NCT06202898|Other|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
80023913|NCT06202885|Drug|Immunotherapy|Immunotherapy
79728769|NCT05902156|Behavioral|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
80023914|NCT06202872|Device|Gamma (40 Hz) tACS at the precuneus region|40 Hz tACS applied at a current of 3 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
80023915|NCT06202872|Device|Sham tACS at the precuneus region|Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
79400630|NCT05921552|Behavioral|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
79728770|NCT05902156|Behavioral|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
79728771|NCT05901961|Drug|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
79728772|NCT05901961|Drug|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
79728773|NCT05901961|Drug|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
79728774|NCT05901584|Drug|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
79728775|NCT05900765|Drug|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
79728776|NCT05896358|Behavioral|ketogenic diet|a low calorie ketogenic diet
79728777|NCT05892510|Drug|Intra-arterial tenecteplase injection at the completion of thrombectomy|Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus
79568450|NCT01755715|Procedure|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
79568451|NCT01755728|Drug|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
79568452|NCT01755728|Drug|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
79568453|NCT01755728|Procedure|Closure of PDA|Open surgery for closure of PDA
79568454|NCT01755741|Combination Product|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
79568455|NCT01755741|Device|Condom|Male condom
79568456|NCT01755754|Combination Product|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
79728778|NCT05892510|Drug|Placebo|intra-arterial bolus of 0.9% Sodium Chloride solution
79863388|NCT00536198|Drug|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
79863389|NCT00536198|Drug|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
79863390|NCT00393484|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
79863391|NCT00393484|Drug|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
79863392|NCT00393484|Drug|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
79863393|NCT00393484|Drug|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
79863394|NCT00667823|Drug|Macitentan|Tablet, oral administration, 10 mg dose once daily
79863395|NCT00397930|Procedure|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
79863396|NCT00397930|Procedure|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
80023916|NCT06202859|Device|MIE|Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
79267428|NCT06109753|Procedure|Conventional Laparoscopic Surgery|conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
79728779|NCT05887414|Other|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
79863397|NCT05356676|Other|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
80023917|NCT06202846|Genetic|cfDNA analysis|"In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH."
79267429|NCT06109740|Dietary Supplement|lactobacillus GG|probiotic
79568457|NCT01755754|Device|Female Condom|Female condom
79728780|NCT05887414|Other|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
79728781|NCT05886270|Other|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
79267430|NCT06109727|Device|cerebellar transcranial electrical stimulation|Cerebellar transcranial electrical stimulation - 20 mA - 20 min
79267431|NCT06109714|Other|Goal Directed Fluid Therapy|Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor
79267432|NCT06109688|Dietary Supplement|Bovine Lactoferrin|Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
79267433|NCT06109688|Dietary Supplement|placebo|Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
79267434|NCT06109675|Behavioral|Nutrition Education|All mothers in this group will be given 3 nutrition education sessions including detailed informations on Nutrition Therapy in Cystic Fibrosis. In addition to the education sessions, an informational booklet and a high-energy sample recipe booklet will be given.
79568458|NCT01755780|Other|Left interscalene block|
79568459|NCT01755780|Other|Right interscalene block|
79568460|NCT01755819|Device|Biocomposite interference screw|
79568461|NCT01755819|Device|Extracortical ACL Tightrope fixation|
79568462|NCT01755832|Procedure|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
79568463|NCT01755845|Drug|paclitaxel|
79568464|NCT01755845|Drug|cisplatin|
79568465|NCT01755845|Radiation|radiotherapy|
79568466|NCT01755871|Drug|Fingolimod|0,5mg Fingolimod once a day
79568467|NCT01755884|Dietary Supplement|Wheat oral immunotherapy|Cooked spaghetti
79568468|NCT01755910|Other|Left thoracic paravertebral block|
79568469|NCT01755910|Other|Right thoracic paravertebral block|
79568470|NCT01755923|Drug|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
79568471|NCT01755923|Drug|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
79728782|NCT05881551|Device|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
79863398|NCT05356676|Other|Combination Therapy|"In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
80023918|NCT06202833|Device|Acupuncture with regulating immunity as the core of treatment|The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
80023919|NCT06202833|Device|Needles that are not on acupoints|In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
80023920|NCT06202820|Behavioral|CV Care Program|Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
80023921|NCT06202781|Drug|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
80023922|NCT06202781|Procedure|Gastroscopic biopsy|Gastroscopy and biopsy
79568472|NCT01755936|Other|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
79728783|NCT05881551|Other|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
79728784|NCT05871853|Behavioral|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
79728785|NCT05871164|Procedure|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
79728786|NCT05866718|Behavioral|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (<20-second/day personal practice) via video recording.
79863399|NCT00397540|Procedure|PEIT|Percutaneous Ethanol Injection Therapy
79863400|NCT00397540|Procedure|RFTA|Radiofrequency Thermal Ablation
80023923|NCT06202768|Other|data collection|data collection : age, gestational age, BMI, history of vaginal delivery after cesarean section, indication for cesarean section, preeclampsia for this pregnancy, the cervix dilatation, position in the pelvis, cervix consistency
79267435|NCT06109649|Drug|Afamelanotide and NB-UVB Light|Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.
79267436|NCT06109649|Procedure|NB-UVB Light|Patients will receive NB-UVB light twice per week for 20 weeks.
79568473|NCT01755936|Other|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
79267437|NCT06109636|Other|Pentacam, Corvis ST and Casia2|scleral and ciliary muscle thickness were obtained by Casia2, biomechanical parameters were obtained by Pentacam and Corvis ST
79267438|NCT06109623|Other|observation|To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
79267439|NCT06109623|Other|sex hormone|Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
79267440|NCT06109610|Behavioral|Cognitive Behavioral Therapy|The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).
79568474|NCT01755936|Other|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
79568475|NCT01755962|Other|Glycemic Load|
79568476|NCT01755962|Other|Resistance Training|
79568477|NCT01755988|Other|Educational website (in addition to usual care).|
79568478|NCT01755988|Other|Website and interactive platform with telemonitoring.|
79728787|NCT05866718|Behavioral|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
79568479|NCT01756001|Device|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
79568480|NCT01756001|Behavioral|Daily email, text message, or phone call reminders|
79568481|NCT01756001|Behavioral|Paid for adherence|
79728788|NCT05833490|Other|Repetitive Peripheral Magnetic Stimulation (rPMS)|Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at ~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
79728789|NCT05833490|Other|Sham Priming|Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
79728790|NCT05831800|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
79728791|NCT05827341|Other|No intervention|No intervention needed
79863401|NCT03993496|Diagnostic Test|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~Prior to EVAR deployment~After EVAR deployment, but before balloon affixation to the aortic wall~After EVAR deployment and after affixation"
79863402|NCT00536120|Biological|BG00002 (natalizumab)|
79863403|NCT00536120|Biological|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
79863404|NCT00536120|Biological|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
79863405|NCT00057811|Drug|doxorubicin hydrochloride|Given IV, IT, or orally
79728792|NCT05816447|Behavioral|interview|Interview patient's perception
79863406|NCT00057811|Drug|cyclophosphamide|Given IV
79568482|NCT01756027|Device|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
79863407|NCT00057811|Drug|methotrexate|Given IV or IT
79863408|NCT00057811|Drug|rasburicase|Given IV
79863409|NCT00057811|Drug|leucovorin calcium|Given IV or orally
79863410|NCT00057811|Drug|prednisone|Given IV or orally
79863411|NCT00057811|Drug|methylprednisolone|Given IV or orally
79863412|NCT00057811|Biological|filgrastim|Given subcutaneously
79863413|NCT00057811|Biological|rituximab|Given IV
79863414|NCT00057811|Drug|cytarabine|Given IT
79267441|NCT06109597|Other|75 g glucose tolerance test|Pregnant patient who visited obstetric clinic , who did 75 g glucose tolerance test
79267442|NCT06109584|Device|Insertion of central venous catheter|Central venous catheter verified by ultrasound and then verified by radiography.
79267443|NCT06109545|Procedure|Laparoscopy|Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed
79568483|NCT01756027|Device|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
79863415|NCT00057811|Drug|etoposide|Given IV
79863416|NCT00057811|Drug|vincristine sulfate|Given IV
79863417|NCT00057811|Drug|hydrocortisone sodium succinate|Given IT
79863418|NCT00057811|Other|laboratory biomarker analysis|Correlative studies
79267444|NCT06109519|Procedure|implant supported overdenture|patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
79568484|NCT01756066|Behavioral|Different levels of cost sharing|
79568485|NCT01756092|Procedure|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
79568486|NCT01756105|Drug|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
79728793|NCT05806593|Behavioral|Get Back pilot|A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
79728794|NCT05802589|Procedure|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
79728795|NCT05802589|Procedure|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
79863419|NCT03502148|Drug|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
79863420|NCT03957811|Other|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
79267445|NCT06109493|Behavioral|ACT|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
79267446|NCT06109467|Drug|Neratinib|All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
79568487|NCT01756105|Drug|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
79568488|NCT01756131|Drug|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
79568489|NCT01756131|Other|Placebo to match injectable suspension|placebo
79568490|NCT01756144|Device|rhBMP-2|
79568491|NCT01756170|Drug|paclitaxel|
79568492|NCT01756170|Drug|cisplatin|
79568493|NCT01756170|Radiation|Radiotherapy|
79568494|NCT01756183|Drug|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
79568495|NCT01756196|Drug|Spinal Steroid Injection|Steroid Injection
79568496|NCT01756261|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
79568497|NCT01756287|Other|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
79728796|NCT05802589|Procedure|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
79728797|NCT05767619|Diagnostic Test|Troponin hs-cTnI|One sample of Troponin (hs-cTnI) is obtained and analyzed at the scene. Capillary blood sample or venous (lithium heparin) if peripheral venous catheter is inserted for standard care reasons. The sample is disposed after the result has been recorded in the clinical report form. The clinicians participating in the study are instructed and have been educated about the study to only collect the data (report form with measurements) and provide care as constituted by the guidelines. Patients will be monitored by board members that standard clinical care is provided.
79728798|NCT05767619|Diagnostic Test|Plasma glucose|One sample of plasma glucose is obtained and analyzed at the scene. The sample is then disposed and the measured value is recorded in the clinical report form. P-glucose measurement is clinical practice in standard care and is measured on all patients with diabetes and patients with altered mental status or at the ambulance nurse discretion.
79728799|NCT05760807|Drug|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
79728800|NCT05746442|Behavioral|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
79728801|NCT05746442|Drug|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
79728802|NCT05746442|Behavioral|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
79863421|NCT01090999|Other|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
79863422|NCT02530801|Drug|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
79863423|NCT02530801|Drug|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
79863424|NCT01091077|Dietary Supplement|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
79863425|NCT01094275|Drug|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
79267447|NCT06109467|Drug|Trastuzumab|All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
79267448|NCT06109467|Drug|Oxaliplatin|All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
79568498|NCT01756313|Procedure|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
79568499|NCT01756326|Drug|PREOB® Implantation|
79568500|NCT01756326|Procedure|Bone Autograft|
79568501|NCT01756378|Procedure|joint mobilization with movement|
79568502|NCT01756378|Procedure|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
79568503|NCT01756404|Drug|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
79568504|NCT01756404|Drug|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
79568505|NCT01756417|Drug|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
79568506|NCT01756417|Drug|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
79568507|NCT01756430|Drug|Carvedilol SR 32mg, QD|"Carvedilol SR 32mg QD for 4 weeks~With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
79728803|NCT05746442|Behavioral|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
79863426|NCT05355506|Device|Application|Knowledge & record
79863427|NCT01094353|Procedure|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
79728804|NCT05736874|Drug|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
79728805|NCT05736874|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
79728806|NCT05712460|Drug|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
79863428|NCT01094353|Procedure|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
79728807|NCT05712460|Drug|Placebo|Placebo for sisunatovir
79728808|NCT05710380|Other|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
79863429|NCT01089205|Drug|Metformin|
79400631|NCT05920681|Procedure|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
79400632|NCT05920681|Combination Product|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
79400633|NCT05920408|Drug|EXS21546|EXS21546 Granule in Capsule
79568508|NCT01756430|Drug|Carvedilol SR 64mg, QD|"Carvedilol SR 64mg QD for 4 weeks~With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
79863430|NCT02866682|Drug|Prograf|Brand Drug for the duration of the study.
79863431|NCT02866682|Drug|Tacrolimus|Generic
80023924|NCT06202651|Device|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
80023925|NCT06202638|Device|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
80023926|NCT06201923|Drug|Honey Mouthwash|0.2% thyme honey mouth rinse
80023927|NCT06201923|Drug|Normal saline|0.9% sodium chloride
79400634|NCT05914142|Device|Proton radiation therapy|Radiation: Proton Therapy System (ProBeam)
79568509|NCT01756430|Drug|Carvedilol IR 25mg, QD|"Carvedilol IR 25mg QD for 4 weeks~With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
79728809|NCT05710380|Radiation|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
79728810|NCT05710380|Procedure|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
79400635|NCT05909059|Drug|Fludarabine|Received IV on Days -5 to -3 before CAR T cell therapy
79400636|NCT05909059|Drug|Cyclophosphamide|Received IV on Days -5 to -3 before CAR T cell therapy
79400637|NCT05905523|Other|Assessing prewriting skills in children|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
79400638|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79568510|NCT01756430|Drug|Carvedilol IR 25mg, BID|"Carvedilol IR 25mg BID for 4 weeks~With the others investigation product placebo 2 capsules QD for 4 weeks."
79568511|NCT01756443|Drug|2% lidocaine/adrenaline and 0.5% bupivacaine|
79400639|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
79400640|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79400641|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
79400642|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79568512|NCT01756469|Behavioral|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
79568513|NCT01756495|Drug|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
79728811|NCT05699655|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
79728812|NCT05699655|Drug|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
79728813|NCT05699655|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
79728814|NCT05699655|Drug|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
79728815|NCT05697042|Behavioral|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
79728816|NCT05695079|Other|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
79728817|NCT05695079|Other|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
79728818|NCT05695079|Other|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
79728819|NCT05687500|Drug|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
79728820|NCT05687500|Biological|Pharmacokinetics study|"0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution"
79728821|NCT05687500|Biological|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio
79728822|NCT05687500|Biological|Blood glucose on fluorinated tube|0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.
79728823|NCT05687500|Biological|Routine biological monitoring|If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.
80023928|NCT06201871|Drug|Lidocaine Hydrochloride|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
79728824|NCT05687500|Biological|glycose holter monitor|glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
79728825|NCT05683184|Drug|[11C]OMAR|For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.
80023929|NCT06201845|Other|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
79400643|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
79568514|NCT01756495|Drug|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
79568515|NCT01756495|Drug|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
79728826|NCT05680064|Behavioral|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
80023930|NCT06201845|Other|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
80023931|NCT06201546|Procedure|TAP block group|TAP block will be administrated after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
79400644|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79400645|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
79400646|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79400647|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
79568516|NCT01756495|Drug|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
79568517|NCT01756508|Drug|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
79568518|NCT01756521|Drug|Moxifloxacin|
79400648|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79400649|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
79267449|NCT06109467|Drug|5-Fluorouracil + leucovorin|All participants will receive 400 mg/m^2 5-Fluorouracil (5FU)+ 400 mg/m^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
79267450|NCT06109467|Drug|Pembrolizumab|All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
79267451|NCT06109428|Drug|HTX-011|400 mg
79400650|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
79728827|NCT05676073|Drug|SHEN26 dose 1|Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
80023932|NCT06201546|Procedure|m-TAPA block group|m-TAPA block will be administrated after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region
80023933|NCT06201507|Drug|Brentuximab vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
80023934|NCT06201507|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
80023935|NCT06201507|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
79267452|NCT06109428|Drug|Bupivacaine Hydrochloride|125 mg
79267453|NCT06109428|Drug|Ibuprofen|400 mg
79267454|NCT06109428|Drug|Acetaminophen|1 g
79568519|NCT01756534|Device|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
79568520|NCT01756547|Drug|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
79863432|NCT02822924|Procedure|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
79267455|NCT06109428|Device|Luer lock applicator|Applicator for instillation
79863433|NCT01089439|Drug|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
79863434|NCT01089439|Drug|Placebo|placebo
79267456|NCT06109415|Drug|HTX-011|400 mg
79400651|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
80023936|NCT06201507|Drug|Vincristine|1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
79267457|NCT06109415|Drug|Bupivacaine Hydrochloride|100 mg
79267458|NCT06109415|Drug|Ibuprofen|400 mg
79267459|NCT06109415|Drug|Acetaminophen|1 g
79267460|NCT06109415|Device|Luer lock applicator|Applicator for instillation
79267461|NCT06109389|Drug|Lidocaine IV|LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
79267462|NCT06109376|Procedure|hypothermia|In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
79267463|NCT06109376|Procedure|thrombectomy|Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
79267464|NCT06109363|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I intervention will be provided to participants once their districts are exposed.
79267465|NCT06109350|Other|Supporting play exploration and early developmental intervention(SPEEDI)|SPEEDI will be performed by the parents
79267466|NCT06109350|Other|Standard care|Standard care will be performed by the parents
79400652|NCT05896332|Device|Active, Open Label iTBS-rTMS|Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
79400653|NCT05887700|Device|CeraFlex™ Atrial Septal Defect (ASD) Closure System|The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
79568521|NCT01756547|Drug|Placebo|
79568522|NCT01756599|Biological|blood samples|
79568523|NCT01756612|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
79568524|NCT01756638|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
79568525|NCT01756638|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
79728828|NCT05676073|Drug|SHEN26 dose 2|Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
79728829|NCT05676073|Drug|SHEN26 placebo|Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
79728830|NCT05675163|Dietary Supplement|Vitamin K2|(K2VITAL® 1% MCT Oil)
79728831|NCT05675163|Dietary Supplement|Placebo|Sunflower oil
80023937|NCT06201507|Drug|Dacarbazine|375 mg/m2 will be administered on days 1 and 15
79863435|NCT02774642|Behavioral|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
79728832|NCT05672589|Diagnostic Test|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
79728833|NCT05672589|Diagnostic Test|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
79728834|NCT05664334|Biological|IVX-121|75 mcg of IVX-121 without MF59®
79568526|NCT01756651|Drug|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
79568527|NCT01756664|Other|Sunscreen|
79728835|NCT05664334|Biological|IVX-241|75 mcg of IVX-241 without MF59®
79728836|NCT05664334|Biological|Placebo|Diluent
79728837|NCT05664334|Biological|IVX-121|75 mcg of IVX-121, without MF59®
79863436|NCT02774642|Behavioral|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
79863437|NCT00992030|Drug|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
79568528|NCT01756664|Other|Vaseline|
79568529|NCT01756703|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
79568530|NCT01756703|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
79863438|NCT00992030|Radiation|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
79863439|NCT00992342|Drug|PF-03893787|oral solution, 5 mg, QD for 14 days
79863440|NCT00992342|Drug|PF-03893787|oral solution, 15 mg, QD for 14 days
79863441|NCT00992342|Drug|PF-03893787|oral solution, 50 mg, QD for 14 days
79568531|NCT01756703|Drug|Placebo|Placebo for 8 weeks
79863442|NCT01976390|Drug|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
79863443|NCT01976390|Drug|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
79568532|NCT01756716|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
79568533|NCT01756716|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
79568534|NCT01756716|Drug|Placebo|Placebo for 8 weeks
79863444|NCT00570713|Drug|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
79863445|NCT00570713|Drug|Placebo|As per package insert.
79863446|NCT00570713|Drug|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
79863447|NCT04002440|Combination Product|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
79863448|NCT04002440|Device|HomeChoice PRO|Usual care
79863449|NCT05294939|Dietary Supplement|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
79863450|NCT05294939|Dietary Supplement|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
79400655|NCT05882734|Drug|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
79568535|NCT01756729|Device|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
79568536|NCT01756742|Other|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
79568537|NCT01756742|Other|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
79568538|NCT01756755|Device|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
79568539|NCT01756768|Radiation|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of [14C]-PD-0332991.
79728838|NCT05664334|Biological|IVX-241|150 mcg IVX-241, without MF59®
79728839|NCT05664334|Biological|IVX-241|225 mcg of IVX-241, without MF59®
79728840|NCT05664334|Biological|IVX-121|75 mcg of IVX-121, with MF59®
79728841|NCT05664334|Biological|IVX-241|75 mcg of IVX-241, with MF59®
79728842|NCT05664334|Biological|IVX-241|150 mcg IVX-241, with MF59®
79728843|NCT05664334|Other|MF59®|MF59® as an adjuvant
79863451|NCT00773045|Other|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
79863452|NCT00556946|Drug|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
79863453|NCT00776867|Drug|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
79400656|NCT05882734|Drug|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
79568540|NCT01756781|Drug|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
79568541|NCT01756781|Drug|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
79863454|NCT02556515|Procedure|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
79863455|NCT02556515|Procedure|Total joint replacement|Total joint replacement
79863456|NCT02556515|Device|Elektra prosthesis|Elektra prosthesis
79863457|NCT05356286|Device|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
79863458|NCT00780377|Drug|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
79863459|NCT05219942|Drug|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR > 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR <60 dose = 0.19 IU/kg/day.
79863460|NCT05219942|Other|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
79267468|NCT06109324|Other|Robotic Rehabilitation of the upper limb|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
79568542|NCT01756781|Drug|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
79400657|NCT05880225|Behavioral|Reciprocal Imitation Training|As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
79728844|NCT05655156|Device|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~Size 5~- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 6~- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 8~Primary ACL reconstruction where autograft tissue is not suitable~Revision ACL reconstruction~Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 10~Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
79863461|NCT04002206|Other|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
80023938|NCT06201377|Other|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
79728845|NCT05636449|Other|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
80023939|NCT06201377|Other|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
79400658|NCT05880225|Behavioral|music-enhanced Reciprocal Imitation Training|Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
79400659|NCT05874401|Drug|Trilaciclib|Participants will receive intravenous trilaciclib infusion
79400660|NCT05874401|Drug|Placebo|Participants will receive intravenous placebo infusion
79400661|NCT05874401|Drug|Topotecan|Participants will receive intravenous topotecan infusion
79400662|NCT05873205|Biological|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
79400663|NCT05868668|Device|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
79400664|NCT05868668|Device|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
79568543|NCT01756781|Drug|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
79568544|NCT01756794|Procedure|Liver transplantation|
79568545|NCT01756807|Device|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
79568546|NCT01756820|Procedure|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
79863462|NCT04002206|Other|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
79863463|NCT04002284|Drug|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
79267469|NCT06109324|Other|Conventional Rehabilitation of the upper limb|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
79568547|NCT01756820|Procedure|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
79568548|NCT01756859|Procedure|MRI Scan|
79267470|NCT06109311|Drug|Orforglipron|Administered orally.
79568549|NCT01756872|Procedure|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
79568550|NCT01756911|Device|MFM|Implantation of the MFM
79568551|NCT01756937|Drug|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
79728846|NCT05636449|Other|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
79728847|NCT05618509|Device|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
79728848|NCT05618509|Other|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
79863464|NCT00669617|Drug|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
79267471|NCT06109311|Drug|Placebo|Administered orally.
79267472|NCT06109298|Other|Cold spray|Cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedu
79267473|NCT06109298|Other|Refrigerated gel ice|Refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated.
79267474|NCT06109285|Device|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
79267475|NCT06109259|Drug|DWJ1567|One tablet of DWJ1567
79728849|NCT05618509|Other|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
79863465|NCT00669617|Drug|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
79863466|NCT00669617|Drug|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
79863467|NCT00669617|Drug|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
79267476|NCT06109259|Drug|DWC202312|One tablet of DWC202312
79568552|NCT01756937|Drug|Placebo|1 capsule once daily for 24 weeks
79267477|NCT06109220|Behavioral|Stromal vascular fraction,SVF|SVF was injected into the knee cavity
79267478|NCT06109207|Drug|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
79267479|NCT06109207|Drug|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
79568553|NCT01756950|Biological|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
79568554|NCT01756950|Biological|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
79568555|NCT01756950|Biological|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
79728850|NCT05618509|Device|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
79728851|NCT05616793|Biological|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
79863468|NCT00669617|Drug|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
79863469|NCT00669617|Drug|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
79863470|NCT03979352|Drug|empagliflozin|Treatment with empagliflozin 25mg orally once a day
79267480|NCT06109207|Drug|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
79568556|NCT01756950|Biological|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
79863471|NCT03979352|Device|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
79863472|NCT00780767|Device|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
79863473|NCT00773201|Drug|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
79863474|NCT05355194|Other|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
79863475|NCT05355194|Other|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
79863476|NCT03905174|Device|custom made device|surgical intervention to place custom made orthopaedic device
79728852|NCT05601843|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
79728853|NCT05596786|Drug|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
79728854|NCT05596786|Other|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
79267481|NCT06109103|Procedure|telerehabilitation-based motor imagery training|"Motor imagery is defined as the mental thinking of a movement without actual movement being revealed. Many of the currently available physiotherapy and rehabilitation approaches are designed to stimulate damaged motor neural connections through neuroplasticity.~based on real movements. Studies have shown that similar brain regions are activated during motor imagery and real movement. By repeatedly visualizing the same movement, people can improve their motor activity skills such as lifting weights, playing the piano or performing surgery. These findings suggest that motor imagery provides motor learning by strengthening synaptic connections depending on activity."
79267482|NCT06109103|Procedure|telerehabilitation-based physiotheraphy training|The telerehabilitation application will be carried out by video conference method, one of the image-based telerehabilitation technologies. The telerehabilitation-based physiotherapy program will be administered to both Group 1 and Group 2 children by a physiotherapist experienced in the physiotherapy of neuromuscular diseases, excluding the researchers who performed the randomization and evaluations.
79400665|NCT05868668|Device|Sham treatment|Handheld sham probe
79400666|NCT05867472|Drug|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
79400667|NCT05867472|Drug|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
79400668|NCT05866692|Drug|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
79400669|NCT05863325|Drug|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
79400670|NCT05863325|Drug|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
79400671|NCT05857943|Device|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
79568557|NCT01756950|Biological|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
79568558|NCT01756950|Biological|Placebo|administered as a single 2-hour intravenous infusion
79568559|NCT01756989|Drug|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
79568560|NCT01757002|Behavioral|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
79568561|NCT01757002|Behavioral|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
79568562|NCT01757015|Drug|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
79568563|NCT01757015|Drug|Placebo to NVA237|Placebo to NVA237
79568564|NCT01757054|Dietary Supplement|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
79568565|NCT01757080|Other|Cardiorespiratory performance assessment with ergospirometry test|
79568566|NCT01757080|Other|Biochemical analysis|
79568567|NCT01757093|Device|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
79568568|NCT01757093|Device|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
79568569|NCT01757106|Drug|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
79568570|NCT01757106|Drug|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
79568571|NCT01757132|Device|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
79277530|NCT02364141|Other|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
79568572|NCT01757145|Drug|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count >50,000/microliter will be reached again)."
79568573|NCT01757158|Radiation|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
79728855|NCT05582707|Drug|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
79728856|NCT05571306|Other|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
79568574|NCT01757223|Biological|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
79728857|NCT05566392|Diagnostic Test|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
79728858|NCT05564611|Drug|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
79728859|NCT05559164|Drug|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
79568575|NCT01757223|Biological|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
79568576|NCT01757236|Drug|VANCOMYCIN|
79568577|NCT01757236|Drug|CEFTRIAXONE|
79728860|NCT05553405|Drug|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
79728861|NCT05544760|Other|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
79863477|NCT05064527|Device|wearable biosensor|The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
79863478|NCT05064527|Behavioral|Treatment as usual (TAU)|Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
79568578|NCT01757236|Drug|CLINDAMYCIN|
79568579|NCT01757236|Drug|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
79568580|NCT01757236|Drug|FLUOROQUINOLONE|
79568581|NCT01757236|Drug|LINEZOLID|
79863479|NCT05064527|Behavioral|Exposure and response prevention (ERP)|One ERP session will be offered in Week 0 and Week 8.
79568582|NCT01757236|Drug|RIFAMPIN|
79863480|NCT05355038|Behavioral|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
79863481|NCT05355038|Behavioral|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
79863482|NCT05355038|Behavioral|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
79863483|NCT00777413|Drug|Minocycline 100mg Tablets|
79863484|NCT05199974|Procedure|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
79568583|NCT01757249|Drug|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
79568584|NCT01757262|Drug|90 mg Ticagrelor|Morning and Evening dose for 5 days
79568585|NCT01757262|Drug|75mg Clopidogrel|Morning dose for 5 days
79568586|NCT01757314|Behavioral|ultrasound technique|instruction in the ultrasound technique
79568587|NCT01757314|Other|palpation technique|placement of a line via palpation technique
79568588|NCT01757327|Drug|Erismodegib|
79568589|NCT01757327|Drug|Placebo|
79568590|NCT01757340|Behavioral|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
79568591|NCT01757340|Behavioral|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
79728862|NCT05543083|Behavioral|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
79863485|NCT05189912|Device|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
79863486|NCT05189912|Behavioral|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
79568592|NCT01757353|Behavioral|BASICS motivational interview|
79568593|NCT01757353|Behavioral|BASICS plus normative enhancement motivational interview|
79568594|NCT01757353|Behavioral|Self-directed: Information only|
79568595|NCT01757366|Drug|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
79568596|NCT01757366|Drug|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
79568597|NCT01757379|Dietary Supplement|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
79568598|NCT01757379|Dietary Supplement|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
79568599|NCT01757379|Dietary Supplement|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
79568600|NCT01757379|Dietary Supplement|Inulin|15 g of inulin dissolved in 200 ml of water
79568601|NCT01757431|Drug|Eculizumab|
79568602|NCT01757444|Device|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
79568603|NCT01757444|Device|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
79728863|NCT05543083|Behavioral|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
79728864|NCT05543083|Behavioral|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
79400672|NCT05857371|Procedure|lipoaspiration|The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
79400673|NCT05857371|Procedure|urethrotomy|The urologist will perform an endoscopic urethrotomy (standard care).
79267483|NCT06109090|Other|Neuropsychological testing|"In this study, the Vineland Adaptive Behavior Scale is administered, which evaluates the child's adaptive functioning, particularly in four areas: communication, socialization, daily living skills, and motor activities. The Child Behavior Checklist (CBCL) questionnaire is also administered, which is a questionnaire given to parents that highlights elements related to internalizing and externalizing behavioral disorders.~For the assessment of executive functions, a series of tests are administered to evaluate specific functions. These tests are chosen from a list of available tests according to the document from the Italian Society of Child Neuropsychiatry, titled Assessment of attention and executive functions in developmental age: review of Italian instruments and proposal of a battery for in-depth analysis."
79863487|NCT02556827|Other|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
79863488|NCT02556827|Device|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
79863489|NCT02556827|Device|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
79267484|NCT06109077|Other|Levator ani release|Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).
79267485|NCT06109077|Other|Post isometric relaxion|Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks
79568604|NCT01757457|Drug|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
79568605|NCT01757457|Drug|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
79267486|NCT06109064|Biological|Unrelated Umbilical Cord Blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
79568606|NCT01757496|Device|Cough Assist|
79728865|NCT05543083|Behavioral|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
79728866|NCT05541848|Other|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
79728867|NCT05541848|Other|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
79863490|NCT02556827|Device|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
79267487|NCT06109064|Drug|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
79267488|NCT06109064|Drug|Decetabine|Patients will be treated with Decetabine (20mg/m^2/d on days 1 to 5) or Azacitidine (75mg/m^2/d on days 1 to 7)
79863491|NCT05162690|Drug|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
79863492|NCT05162690|Other|Placebo|Metformin DPP4 inhibitors
79863493|NCT00773435|Biological|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
79863494|NCT00773435|Other|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
79863495|NCT00992576|Drug|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
79863496|NCT00992576|Drug|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
79863497|NCT00777569|Drug|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
79568607|NCT01757509|Other|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
79568608|NCT01757548|Procedure|open operation|high ligation of spermatic vein by open operation
79568609|NCT01757548|Procedure|microsurgery|high ligation of spermatic vein by microsurgery
79568610|NCT01757574|Drug|Alemtuzumab infusion|
79568611|NCT01757587|Drug|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
79728868|NCT05539937|Other|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
79728869|NCT05526768|Device|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
79728870|NCT05511701|Behavioral|CHW Care Model|The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is > 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
79863498|NCT00777569|Drug|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
79863499|NCT00777569|Drug|Nicotine Lozenge|4 mg nicotine lozenge
79863500|NCT00777647|Other|Sugar-sweetened soft drink|One litre a day for six months.
79863501|NCT00777647|Other|Aspartame-sweetened soft drink|One litre a day for six months.
79863502|NCT00777647|Other|Semi-skimmed milk|One litre a day for six months
79863503|NCT00777647|Other|Water|One litre a day for six months.
79863504|NCT00777725|Device|FibroScan|Liver scan, similar to an ultrasound.
79568612|NCT01757587|Drug|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
79568613|NCT01757600|Other|Microperimetry|
79568614|NCT01757613|Drug|AK 3012|cutaneous use twice a day
79863505|NCT02556593|Radiation|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
79863506|NCT02556593|Radiation|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
79863507|NCT02556593|Drug|erlotinib|erlotinib 150mg daily
79863508|NCT00535730|Biological|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
79863509|NCT00535730|Biological|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
79863510|NCT00535730|Biological|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
80023940|NCT06201364|Procedure|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
80023941|NCT06201364|Procedure|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
79863511|NCT00780923|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
79863512|NCT02556125|Device|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
79863513|NCT05354960|Other|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
79863514|NCT00781001|Drug|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
79863515|NCT00992654|Drug|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
80023942|NCT06201260|Other|intermittent pneumatic compression protocol|A 30 min IPC protocol at about 200mmHg
79568615|NCT01757639|Biological|Ipilimumab|Given IV
79568616|NCT01757639|Other|Laboratory Biomarker Analysis|Correlative studies
79568617|NCT01757756|Drug|Pf-05175157|200-mg administered twice daily for 14 days
79568618|NCT01757756|Drug|placebo|placebo administered twice daily for 14 days
79568619|NCT01757756|Drug|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
79568620|NCT01757769|Drug|Silodosin|8 mg daily for 24 weeks
79568621|NCT01757795|Drug|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
79568622|NCT01757795|Drug|Placebo|Placebo will be intravenously administered
79568623|NCT01757808|Drug|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
79568624|NCT01757808|Drug|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
79568625|NCT01757834|Device|SWUS Elastography|
79568626|NCT01757860|Drug|CARD-024|Comparison of different dosages of drug
79568627|NCT01757860|Other|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
79568628|NCT01757873|Drug|Z160|
79568629|NCT01757873|Drug|Placebo|
79863516|NCT02556047|Device|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&S
79863517|NCT05252234|Other|Observation of hemodynamic status and post operative pain|No intervention
79863518|NCT00773591|Drug|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
79728871|NCT05511701|Behavioral|Usual Care Model|All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is > 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
80023943|NCT06201260|Other|Placebo treatment|The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
80023944|NCT06201169|Procedure|implant placement|All patients received four implants in the lower arch
80023945|NCT06201117|Behavioral|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
80023946|NCT06201117|Behavioral|Usual information|Preoperative information that is given to patients before having cardiac surgery
80023947|NCT06201026|Other|Traditional exercise|Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
80023948|NCT06201026|Other|Individualized exercise|Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
80023949|NCT06200948|Other|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
80023950|NCT06200948|Other|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
79728872|NCT05510726|Device|shearwave elastography|shearwave elastography on upper or lower limb
80023951|NCT06200831|Procedure|Staged resection|Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
80023952|NCT06200831|Procedure|Simultaneous resection|In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
80023953|NCT06200727|Procedure|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
80023954|NCT06200727|Procedure|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
80023955|NCT06200727|Procedure|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
80023956|NCT06200727|Procedure|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
80023957|NCT06200727|Procedure|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
79728873|NCT05494177|Diagnostic Test|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~Binocular uncorrected near reading acuity (bUNVA) at 40 cm~Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity & Reading Test (DDART)."
79728874|NCT05494177|Diagnostic Test|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
79728875|NCT05487261|Drug|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
79728876|NCT05487261|Drug|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
79728877|NCT05487261|Drug|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
79728878|NCT05487261|Drug|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
79728879|NCT05479240|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
79728880|NCT05479240|Drug|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
79728881|NCT05479240|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
79863519|NCT00992810|Procedure|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
79863520|NCT00992810|Procedure|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
79863521|NCT00995306|Drug|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
79267489|NCT06109064|Drug|Azacitidine|Patients will be treated with Decetabine (20mg/m^2/d on days 1 to 5) or Azacitidine (75mg/m^2/d on days 1 to 7)
79568630|NCT01757886|Other|Biomarkers to analyze both intracoronary thrombi as blood|
80023958|NCT06200727|Procedure|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
79568631|NCT01757899|Drug|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
79568632|NCT01757899|Drug|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
79568633|NCT01757912|Procedure|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
79568634|NCT01757925|Behavioral|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
79568635|NCT01757925|Other|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
79568636|NCT01757938|Procedure|Shang Ring Guided Circumcision|
79568637|NCT01757938|Procedure|Forceps Guided Circumcision|
79568638|NCT01757951|Procedure|Unimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
79568639|NCT01757951|Procedure|Bimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
79728882|NCT05479240|Radiation|short-range radiotherapy|5*5Gy，d1-d5
79728883|NCT05454462|Drug|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
79728884|NCT05454462|Diagnostic Test|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
79728885|NCT05454462|Diagnostic Test|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
79728886|NCT05454462|Diagnostic Test|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
79728887|NCT05454462|Diagnostic Test|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
79728888|NCT05454462|Diagnostic Test|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
79863522|NCT00992888|Device|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
79863523|NCT05351372|Radiation|Ultra-low dose protocol|
79863524|NCT05351372|Radiation|Standard dose protocol|
79568640|NCT01757119|Drug|Tardyferon 80 mg|Oral administration (2 tablets)
79568641|NCT01757977|Device|double lumen endotracheal tube placement and use|
79863525|NCT00666965|Drug|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
79863526|NCT05350358|Device|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
80023959|NCT06200727|Procedure|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
79728889|NCT05454462|Diagnostic Test|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
79728890|NCT05454462|Diagnostic Test|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
79728891|NCT05454462|Procedure|Physical Examination|patients will undergo a physical examination on all the clinical visits
79728892|NCT05454462|Procedure|Vital signa|patient's vital signs will be measured on all the clinical visits
79728893|NCT05454462|Diagnostic Test|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
79728894|NCT05454462|Diagnostic Test|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
79728895|NCT05454462|Other|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
79728896|NCT05449457|Other|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
79728897|NCT05447247|Other|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
79728898|NCT05442684|Biological|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
80023960|NCT06200727|Procedure|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
80023961|NCT06200233|Drug|Rivoceranib|700mg once daily
80023962|NCT06200064|Other|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
80023963|NCT06200064|Other|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
80023964|NCT06199245|Other|emotional freedom technique experimental group|Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
79568642|NCT01757990|Dietary Supplement|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
79568643|NCT01758029|Drug|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
79568644|NCT01758055|Biological|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
79568645|NCT01758068|Procedure|Coconut Oil Application|Coconut oil - 4 ml
79568646|NCT01758094|Drug|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
79267490|NCT06109051|Device|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
79568647|NCT01758107|Other|Withdraw cyclosporine|
79568648|NCT01758120|Drug|prednisone plus cyclophosphamide|"prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
79568649|NCT01758120|Drug|Prednisone alone|"prednisone alone: prednisone(0.5mg/kg/day*6 months);~supportive care,including ACE-I or ARBs and blood pressure control"
79568650|NCT01758133|Behavioral|Exposure to medical clown activities|
79568651|NCT01758146|Drug|Tamoxifen|20 mg once daily for 5 years
79568652|NCT01758146|Drug|Letrozole|Letroz, Femara, Letronat
79568653|NCT01758159|Dietary Supplement|Iron supplementation|
79568654|NCT01758159|Other|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
79568655|NCT01758172|Drug|6% hydroxyethyl starch 130/0.4|
79728899|NCT05442684|Biological|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
79728900|NCT05442684|Biological|mRNA-based COVID-19 vaccine|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
79568656|NCT01758172|Drug|Albumin|
79568657|NCT01758185|Biological|recombinant hepatitis b vaccine|0.5ml intramuscular
79568658|NCT01758185|Biological|Aleph influenza vaccine|0.5ml intramuscular
79568659|NCT01758198|Biological|Abatacept|
79568660|NCT01758198|Drug|Placebo matching with Abatacept|
79568661|NCT01758198|Drug|Methotrexate|
79568662|NCT01758211|Procedure|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
79568663|NCT01758211|Procedure|conventional resection|conventional resection in AVM patients
79728901|NCT05435859|Behavioral|Speech Tasks|Listen to 25-minutes of speech sounds in English.
79728902|NCT05434936|Procedure|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
79728903|NCT05431114|Diagnostic Test|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
79728904|NCT05566496|Diagnostic Test|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
79568664|NCT01758224|Other|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
79568665|NCT01758224|Other|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
79568666|NCT01758237|Device|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
79568667|NCT01758237|Procedure|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
79568668|NCT01758250|Other|Acoustic Radiation Force Impulse (ARFI)|
79568669|NCT01758250|Other|Laser Doppler Flowmetry (LDF)|
79728905|NCT05415735|Behavioral|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
79728906|NCT05396469|Diagnostic Test|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
79728907|NCT05380388|Biological|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
79728908|NCT05380388|Biological|HBV vaccine|HBV Vaccine
79728909|NCT05374616|Genetic|Observation|Retrospective and prospective Natural History Study
79728910|NCT05370157|Behavioral|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
79728911|NCT05365334|Behavioral|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
79728912|NCT05365334|Behavioral|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
79728913|NCT05365334|Behavioral|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
79728914|NCT05365113|Procedure|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
79728915|NCT05364957|Device|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
79728916|NCT05364957|Procedure|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
79728917|NCT05364957|Procedure|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
79728918|NCT05358106|Biological|AntiBKV|AntiBKV neutralising antibody
80023965|NCT06198920|Procedure|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
80023966|NCT06198868|Procedure|Operable|Enrolled patients capable of surgical treatment
80023967|NCT06198660|Other|positional release technique|positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
80023968|NCT06198660|Other|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
80023969|NCT06198660|Other|conventional therapy only|conventional therapy two sessions for 6 weeks
79568670|NCT01758250|Other|Laser Doppler Perfusion Imaging (LDI)|
79568671|NCT01758250|Other|Optical Coherence Tomography (OCT)|
79568672|NCT01758250|Other|Orthogonal Polarization Spectral Imaging (OPSI)|
79568673|NCT01758250|Other|Nail fold video capillaroscopy (NVC)|
79568674|NCT01758263|Drug|Metoprolol|Metoprolol, oral administration
79568675|NCT01758263|Drug|Nebivolol|Nebivolol, oral administration
79568676|NCT01758302|Behavioral|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
79568677|NCT01758302|Behavioral|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
79568678|NCT01758302|Other|Cookies|Participants are asked to taste test chocolate chip cookies
79568679|NCT01758302|Other|Vegetables|Participants are asked to taste test raw celery or radishes
79568680|NCT01758302|Behavioral|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
79568681|NCT01758315|Other|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
79568682|NCT01758341|Procedure|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
79568683|NCT01758341|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
79568684|NCT01758341|Device|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
79568685|NCT01758354|Other|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
79568686|NCT01758367|Drug|Deciatbine(DAC)|
80023970|NCT06197035|Procedure|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
80023971|NCT06197035|Procedure|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
79568687|NCT01758380|Drug|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
79568688|NCT01758380|Drug|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
79568689|NCT01758380|Drug|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
79568690|NCT01758380|Drug|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
79568691|NCT01758380|Drug|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
79728919|NCT05358106|Biological|Placebo|Solution with no active ingredients
79728920|NCT05356949|Behavioral|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
79728921|NCT05332444|Drug|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
79728922|NCT05332444|Drug|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
79267494|NCT06109012|Procedure|duct diversion|the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock
79568692|NCT01758393|Drug|Prednisone|
79728923|NCT05328570|Diagnostic Test|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
79728924|NCT05323825|Dietary Supplement|Probiotic|Fermented milk product containing a probiotic
79728925|NCT05323825|Dietary Supplement|Placebo|Product with identical characteristics to the experimental product.
79728926|NCT05314491|Device|Multigen Plus CCK|Total Knee Arthroplasty
79728927|NCT05314491|Device|AMF TT cones|To fill a proximal tibia or distal femur defect
79728928|NCT05291481|Behavioral|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
79568693|NCT01758406|Biological|Intracoronary injection|stem cell transplantation
79568694|NCT01758406|Biological|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
79568695|NCT01758419|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
79568696|NCT01758471|Drug|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
80023972|NCT06196385|Device|intensive Cervical Traction|A 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. The main objective will be the evaluation of depression, insomnia, and quality of life. We evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life.
80023973|NCT06196359|Procedure|Combined Femoral and Popliteal nerve block|Patients who receive a combined femoral and popliteal nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
80023974|NCT06195995|Device|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
80023975|NCT06195813|Dietary Supplement|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
79863527|NCT00781157|Drug|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
80023976|NCT06195813|Other|Placebo capsule|Placebo capsule is categorized as other.
80023977|NCT06194981|Drug|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
80023978|NCT06194838|Device|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
79267495|NCT06108986|Other|tabata training|this include tabata training thrice a week for six weeks
79267496|NCT06108986|Other|plyometric training|this include plyometric training thrice a week for six weeks
79267497|NCT06108973|Device|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
79267498|NCT06108960|Other|Proprioceptive neuromuscular facilitation|Group A (Proprioceptive neuromuscular facilitation.) will be treated with Proprioceptive neuromuscular facilitation, before applying exercise, Hot pack will be applied for 15 minutes. (8 weeks, 4 sessions per week) The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
79267499|NCT06108960|Other|Pelvic stabilization exercises|"Group B (Pelvic stabilization exercises) will be treated with Pelvic Stabilization Exercise, before applying exercise we will apply Hot pack for 15minutes (8 weeks, 3 sessions per week).~All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first be taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks."
79568697|NCT01758471|Drug|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
79728929|NCT05290740|Drug|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
79728930|NCT05290740|Drug|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
79728931|NCT05269186|Device|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
79568698|NCT01758484|Other|palliative care|Undergo supportive care intervention
79728932|NCT05241665|Device|SpectraWAVE Imaging System|Coronary imaging
79728933|NCT05234554|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
79728934|NCT05234554|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
79728935|NCT05233800|Behavioral|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
80023979|NCT06194838|Device|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
80023980|NCT06194045|Dietary Supplement|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
79568699|NCT01758484|Other|questionnaire administration|Ancillary studies
79568700|NCT01758484|Procedure|quality-of-life assessment|Ancillary studies
79568701|NCT01758497|Procedure|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
79568702|NCT01758497|Procedure|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
79568703|NCT01758510|Genetic|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10^6 cells/kg, 0.5 X 10^6 cells/kg, 1 X 10^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10^6 cells/kg dose cohort.
79568704|NCT01758536|Drug|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
80023981|NCT06194045|Dietary Supplement|Placebo|2 x 1 g capsules containing corn oil
80023982|NCT06193317|Device|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
80023983|NCT06191588|Procedure|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
80023984|NCT06191263|Drug|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
79568705|NCT01758549|Other|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
79863528|NCT00995462|Behavioral|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
79568706|NCT01758549|Other|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
79568707|NCT01758562|Device|Caphosol|
79568708|NCT01758601|Other|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
79568709|NCT01758601|Other|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
79728936|NCT05233800|Behavioral|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
80023985|NCT06191263|Drug|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
80023986|NCT06190665|Device|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
80023987|NCT06190665|Device|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
80023988|NCT06190275|Biological|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced (HNSCC)
79267500|NCT06108934|Device|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
79267501|NCT06108921|Drug|Xylitol Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.
79267502|NCT06108921|Drug|Salt Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
79267503|NCT06108908|Behavioral|Reminder|1. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.
79267504|NCT06108882|Other|Experimental: Manual Ischemic Compression with Strain Counter Strain technique|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
79568710|NCT01758627|Drug|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
79568711|NCT01758640|Drug|Warfarin|Low dose warfarin of 5mg or less per day
79568712|NCT01758640|Drug|phenindione|Phenindione of 100mg or less per day
79568713|NCT01758666|Drug|Methotrexate,Calcium folinate|
79568714|NCT01758679|Biological|Licartin and CIK|Licartin and CIK
79568715|NCT01758718|Procedure|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
79568716|NCT01758744|Drug|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
79568717|NCT01758757|Procedure|Vitrectomy|
79568718|NCT01758783|Drug|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
79568719|NCT01758809|Procedure|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
79728937|NCT05231655|Diagnostic Test|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
79728938|NCT05214378|Device|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
79728939|NCT05212311|Device|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
79568720|NCT01758809|Procedure|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
79568721|NCT01758822|Other|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
79568722|NCT01758835|Other|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
79568723|NCT01758835|Other|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
79568724|NCT01758835|Other|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
79568725|NCT01758861|Drug|EPO group|
79568726|NCT01758861|Drug|Placebo|
79568727|NCT01758874|Procedure|phlebotomy|repeated phlebotomy for 4 weeks
79863529|NCT00777959|Drug|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
79863530|NCT00777959|Drug|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
79728940|NCT05212311|Device|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
79863531|NCT00777959|Drug|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
79728941|NCT05212311|Device|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
79863532|NCT00995540|Drug|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
79568728|NCT01758913|Drug|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
79863533|NCT00995540|Drug|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
80023989|NCT06188663|Dietary Supplement|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
80023990|NCT06185764|Drug|VX-670|Solution for intravenous administration.
80023991|NCT06185764|Drug|Placebo|Solution for intravenous administration.
80023992|NCT06183788|Behavioral|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent [PCT/ES2008/00677]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
80023993|NCT06183489|Drug|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
79863534|NCT00995540|Drug|Placebo|Placebo tid subcutaneous injection for 12 weeks
79863535|NCT00778037|Drug|Cyclobenzaprine hydrochloride 10 mg tablet|
80023994|NCT06183398|Other|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
79863536|NCT00778115|Drug|Loperamide HCl 2 mg and simethicone 125 mg tablets|
79863537|NCT02557217|Drug|NP202|Active
80023995|NCT06181773|Behavioral|EPO Feeding Program|The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
80023996|NCT06179992|Device|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
79267505|NCT06108882|Other|Active Comparator: Manual Ischemic Compression|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
79568729|NCT01758965|Other|PPI|monotherapy of PPI
79400674|NCT05857371|Drug|autologous ADSVF administration|ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
79568730|NCT01758965|Other|H2RA and surgicel|combination therapy of H2RA and surgicel
79568731|NCT01758978|Drug|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
79568732|NCT01759004|Other|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
79728942|NCT05212311|Other|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
79863538|NCT02557217|Other|Placebo|Placebo
79863539|NCT03474224|Device|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
79863540|NCT00993122|Drug|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
79863541|NCT00778193|Drug|Naproxen|1 tablet 500mg BID for 8 days
79863542|NCT00778193|Drug|Aspirin|1 tablet 81mg QD for 8 days
79863543|NCT00778193|Drug|Celecoxib|1 capsule 200mg QD for 8 days
79568733|NCT01759030|Drug|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
79568734|NCT01759043|Procedure|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
79568735|NCT01759043|Procedure|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
79863544|NCT00778193|Drug|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
80023997|NCT06166342|Dietary Supplement|Placebo sachet|Consume 1 sachet daily
80023998|NCT06166342|Dietary Supplement|TCI153 probiotic sachet|Consume 1 sachet daily
80023999|NCT06165601|Procedure|Follow-up at D14|A blood test and urinary test will be performed at D14.
80024000|NCT06165601|Procedure|Follow-up at M1|A blood test and urinary test will be performed at M1.
80024001|NCT06165354|Drug|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
79267506|NCT06108869|Other|ABT Online Programme|"When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~A short ABT practice~An educational component related to the development of our ABT practice~A group discussion on the week's topic and how it relates to you and your diagnosis"
79568736|NCT01759056|Drug|AVX 470|active comparator
79568737|NCT01759056|Drug|Placebo|
79568738|NCT01759069|Procedure|Surgical treatment with microscope|
79728943|NCT05201404|Drug|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
79728944|NCT05201404|Drug|Placebo|Control arm
79728945|NCT05179837|Device|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
79728946|NCT05176353|Other|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
79863545|NCT00778193|Drug|Placebo|1 capsule BID for 8 days
79568739|NCT01759095|Device|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
79568740|NCT01759108|Drug|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
79568741|NCT01759121|Radiation|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
79568742|NCT01759121|Radiation|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
79568743|NCT01759134|Other|Post discharge formula|Babies will be given either materna sensitive or similac neosure
79568744|NCT01759147|Procedure|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
79568745|NCT01759199|Procedure|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
79568746|NCT01759303|Drug|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
79568747|NCT01759316|Other|heliox|heliox or oxygen is used in the two groups respectively
79568748|NCT01759329|Dietary Supplement|test coffee|test coffee with higher alkyl pyridine content
79728947|NCT05174416|Drug|Mavacamten|Mavacamten Capsules
79863546|NCT00778271|Drug|Gabapentin 400mg capsules|
80024002|NCT06165354|Combination Product|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
79267507|NCT06108869|Other|Delayed Control group|Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
79267508|NCT06108856|Device|Hemodialysis machine|machine by which people undergo dialysis on it.
79267509|NCT06108843|Other|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
79728948|NCT05174416|Drug|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
79863547|NCT00778349|Drug|Metformin solution 100 mg/mL|
79863548|NCT00995618|Drug|Tranilast|Tranilast tablets, 300 mg, QD
79863549|NCT00995618|Drug|Febuxostat|Febuxostat Tablets, 40 mg, QD
79863550|NCT00995618|Drug|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
79863551|NCT00778427|Drug|metformin hydrochloride 1000 mg tablets|
80024003|NCT06162377|Drug|Methylnaltrexone|Given by SC (injection)
79863552|NCT00773981|Procedure|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
80024004|NCT06162091|Other|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~Cognitive functioning (Levels of Cognitive Functioning, LCF);~disability (Disability Rating Scale, DRS);~level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
80024005|NCT06159335|Radiation|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
80024006|NCT06156904|Device|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
79568749|NCT01759329|Dietary Supplement|control coffee|control coffee with regular alkyl pyridine content
79400675|NCT05857254|Other|Patient with chronic intestinal failure|"The negociation component will be assessed during an office visit with the help of forms, by the difference between  ideal  parenteral nutrition prescription proposed by prescriber and the  final  prescription, that the patient ultimately receives at the end of the office visit.~The compliance component will be assessed by a telephone interview, 8 weeks after the office visit."
79568750|NCT01759342|Behavioral|Aerobic exercise|
79267510|NCT06108843|Other|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
79267511|NCT06108804|Other|mulligan pain release phenomenon with tapping|Participants in Group A will receive mulligan pain release phenomenon with tapping.First, demographic information will be gathered, pain severity will be measured using NPRS, knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.Two sessions of treatment per week with a total of eight session will be given in four weeks
79728949|NCT05159752|Drug|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
79863553|NCT03889886|Drug|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
79863554|NCT03889886|Drug|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
79863555|NCT03889886|Drug|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
79267512|NCT06108804|Other|mulligan pain release phenomenon|Two sessions of treatment per week with a total of eight session will be given in four weeks.Group B will receive mulligan pain release phenomenon only. First, demographic information will be gathered, pain severity will be measured using NPRS. knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.
79568751|NCT01759342|Behavioral|Resistance exercise|
79568752|NCT01759342|Behavioral|Flexibility and postural exercise|
79568753|NCT01759342|Behavioral|Balance exercise|
79267513|NCT06108791|Drug|FIO2=0.8|the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
79568754|NCT01759355|Procedure|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
79568755|NCT01759394|Drug|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~Fed, Fed, Fasted; or~Fed, Fasted, Fed; or~Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
79267514|NCT06108791|Drug|FIO2=0.33|the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
79568756|NCT01759485|Drug|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
79568757|NCT01759485|Drug|placebo|
79568758|NCT01759498|Dietary Supplement|HYDRO|
79568759|NCT01759498|Dietary Supplement|ACTIVE|
79568760|NCT01759498|Dietary Supplement|HYDRO 2|
79863556|NCT03889886|Drug|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
79863557|NCT00774059|Device|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
79863558|NCT03888482|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
79728951|NCT05155267|Other|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
79863559|NCT03888482|Device|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
79863560|NCT00995696|Behavioral|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
79863561|NCT00993278|Dietary Supplement|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
79267515|NCT06108739|Drug|Cyclophosphamid|A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
79568761|NCT01759524|Drug|Bupivacaine|
79728952|NCT05130762|Device|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
79728953|NCT05126381|Behavioral|Smoking|The Study contains patients who are allowed to smoke
79728954|NCT05126381|Behavioral|non-somking|The Study contains patients who are not allowed to smoke
79728955|NCT05124561|Biological|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
79863562|NCT00993278|Dietary Supplement|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
79568762|NCT01759524|Drug|Lidocaine|
79863563|NCT00667355|Biological|adalimumab|40 mg or 80 mg every other week, subcutaneous
79863564|NCT00778505|Drug|Propofol|closed-loop administration using bispectral index as the controller
80024007|NCT06154707|Drug|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
79267516|NCT06108739|Drug|ATG|A total of 10mg/kg ATG was administered.
79267517|NCT06108726|Drug|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
79568763|NCT01759563|Device|nasopharyngeal targeted brain cooling|
79568764|NCT01759576|Drug|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
79568765|NCT01759589|Drug|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
79568766|NCT01759589|Drug|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
79568767|NCT01759589|Drug|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
79568768|NCT01759615|Other|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
80024008|NCT06154707|Other|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
80024009|NCT06136442|Drug|Atogepant|atogepant in real life in Italy
80024010|NCT06129760|Device|Apple Watch|The wearable sensor device is the Apple Watch Series 6 or newer
79267518|NCT06108713|Other|Addition of juggling|Participants will not change ther daily activities, and participate in juggling intervention lasted 4 weeks and consisted of 12 meetings (3 trainings per week), each lasting 45 minutes.
79568769|NCT01759615|Other|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
79568770|NCT01759628|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
79267519|NCT06108661|Procedure|Conventional Physical Therapy|"Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks."
79863565|NCT00778505|Drug|remifentanil|closed-loop administration using bispectral index as the controller
79267520|NCT06108661|Procedure|Slump Stretching|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
79863566|NCT00778505|Drug|Propofol|manual administration according bispectral index values
79863567|NCT00778505|Drug|Remifentanil|manual administration according bispectral index values
79863568|NCT00532844|Drug|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
79863569|NCT00532844|Drug|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
79863570|NCT00778583|Drug|Nitrofurantoin 100 mg capsules|
79863571|NCT00778661|Drug|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
80024011|NCT06126887|Device|Incrediwear Daytime Back Brace|Incrediwear Daytime Back Brace
80024012|NCT06126887|Device|Incrediwear Sham Daytime Back Brace|Incrediwear Sham Daytime Back Brace
80024013|NCT06126887|Device|Control Daytime Back Brace|Control Daytime Back Brace
79568771|NCT01759641|Device|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
79568772|NCT01759654|Biological|AdimFlu-V|
80024014|NCT06126887|Device|Incrediwear 24 Hour Back Brace|Incrediwear 24 Hour Back Brace
79728956|NCT05124561|Biological|Placebo|Nebulized inhalation through the mouth
80024015|NCT06121986|Behavioral|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
79267521|NCT06108661|Procedure|ELDOA|"ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides."
79267522|NCT06108648|Drug|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
79863572|NCT00993356|Drug|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
80024016|NCT06121986|Behavioral|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
80024017|NCT06115811|Behavioral|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
79267523|NCT06108648|Other|Control|Standard care according to national standards.
79568773|NCT01759667|Other|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
79728957|NCT05115890|Other|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
79568774|NCT01759680|Device|Vibrosphère device|Vertical Sinusoidal vibration
79568775|NCT01759693|Procedure|Blood sampling|Blood sampling
79728958|NCT05085561|Drug|REC-994|REC-994 200 mg tablets
79728959|NCT05085561|Drug|Placebo|Placebo Tablets
80024018|NCT06114628|Drug|GSK3036656|Oral daily dosage of 20mg.
79863573|NCT00993356|Procedure|Transsphenoidal surgery|
80024019|NCT06114628|Drug|BTZ-043|Oral daily dosage of 1000mg.
80024020|NCT06114628|Drug|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
80024021|NCT06114628|Drug|Delamanid (D)|Oral daily dosage of 300mg.
79568776|NCT01759706|Behavioral|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
79863574|NCT00781547|Drug|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
79728960|NCT05071586|Device|Soterix 1x1 tDCS LTE Stimulator Device Model 1401|Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
79728961|NCT05056987|Device|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
79728962|NCT05056987|Device|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
79728963|NCT05056987|Device|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
79728964|NCT05053035|Drug|AL001|Administered via intravenous (IV) infusion
80024022|NCT06114628|Drug|Pretomanid (Pa)|Oral daily dosage of 200mg.
80024023|NCT06114628|Drug|Moxifloxacin (M)|Oral daily dosage of 400mg.
80024024|NCT06114628|Drug|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
80024025|NCT06114628|Drug|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
80024026|NCT06114628|Drug|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
80024027|NCT06114628|Drug|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
80024028|NCT06114628|Drug|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
79863575|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
80024029|NCT06114108|Other|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
79267524|NCT06108635|Procedure|McKenzie Exercises|"These can be performed in sitting and the protocol includes,~Retraction and extension~Retraction and extension with rotation~Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds."
80024030|NCT06114108|Other|Surgery|Surgery
79568777|NCT01759706|Procedure|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
79568778|NCT01759706|Drug|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
80024031|NCT06114108|Radiation|Radiotherapy|Radiotherapy
80024032|NCT06112431|Behavioral|Telehealth-Based Intervention|Participants randomized to the Telehealth-Based Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide telehealth-based support with scheduling an in-office glaucoma evaluation at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Participants will also receive telehealth-based support from a Peer Ambassador, who are individuals from the community with glaucoma or other eye diseases who have expressed interest in sharing their experiences. Each referred participant will receive several telehealth-based calls from a Peer Ambassador over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office glaucoma evaluation.
80024033|NCT06104319|Drug|GSK4532990|GSK4532990 will be administered
79568779|NCT01759706|Other|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
79568780|NCT01759706|Drug|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
79728965|NCT05053035|Drug|Placebo|Administered via intravenous (IV) infusion
79728966|NCT05051046|Procedure|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
79728967|NCT05043441|Behavioral|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
79568781|NCT01759706|Drug|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
79728968|NCT05043441|Behavioral|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
80024034|NCT06102824|Drug|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
79267525|NCT06108635|Procedure|Maitland mobilization|The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2
79267526|NCT06108635|Procedure|Heat Therapy|Moist heat therapy with hot pack.
79267527|NCT06108622|Diagnostic Test|cbc ,u\s renalor hepatic function test if needed|just blood sample if the case needed
80024035|NCT06102824|Drug|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
80024036|NCT06102824|Drug|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
79267528|NCT06108609|Other|Administration of the French version of the COSI and IOI-HA questionnaires|"Inclusion (D0):~Audiometry (as part of treatment)~Clinical evaluation (as part of treatment)~Passing the French version of the COSI and IOI-HA questionnaires Visit 1 (D0 +3±1 week): only for 35 patients Second administration of the French version of the COSI and IOI-HA questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame."
79277531|NCT02364141|Other|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
79277532|NCT05618977|Behavioral|Dramatization simulation|Ethical attitudes of nursing students will be evaluated with dramatization simulation application.
79728969|NCT05023096|Other|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
79728970|NCT05014555|Biological|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
79267529|NCT06108583|Behavioral|TEAlimento : a multicomponent parent training behavioral program to treat feeding difficulties in children with Autism Spectrum Disorder|The program focuses on parent training. Additionally, intervention on sensory integration is implemented directly with children. The program is made up of 12 sessions, which are held weekly, combining group (1.5 hour parent training and child sensory desensitization) with individual sessions. Parent training group sessions (1,3,4,5,7,8), are focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Strategies involve functional behavioral assessment, antecedent-based interventions, extinction of disruptive behaviors, positive reinforcement, modeling and visual supports. Additionally, parents were trained in methods of introducing new foods, such as modifying food presentation or textures. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions (2,6,9) are focused on specific characteristics of each child.
79863576|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
79863577|NCT00774293|Drug|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
79863578|NCT00774293|Drug|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
79863579|NCT04000958|Drug|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
79863580|NCT04000958|Drug|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
79863581|NCT00778739|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
79863582|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
79863583|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
79863584|NCT00781625|Dietary Supplement|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
79863585|NCT03190460|Other|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
80024037|NCT06102824|Drug|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
80024038|NCT06102824|Drug|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
80024039|NCT06102824|Drug|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
80024040|NCT06102824|Drug|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
80024041|NCT06102824|Drug|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
79267530|NCT06108557|Diagnostic Test|Serum Pararoxonase -1 level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
79568782|NCT01759706|Behavioral|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
80024042|NCT06102824|Drug|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
80024043|NCT06102824|Drug|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
79277533|NCT05618977|Behavioral|In-class case studies|In-class case studies will be conducted with the control group students.
79277534|NCT02367183|Drug|GED-0301|
79568783|NCT01759706|Drug|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
80024044|NCT06102824|Drug|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
79568784|NCT01759719|Device|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
79568785|NCT01759732|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -4
79568786|NCT01759732|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
79568787|NCT01759732|Biological|anti-thymocyte globulin|
79568788|NCT01759732|Biological|filgrastim|
80024045|NCT06097702|Drug|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
79568789|NCT01759732|Radiation|Total body irradiation|200 cGy per day on D-5 & -4
80024046|NCT06097702|Drug|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 7 sequential days in one of the three doses based on body weight and followed up for 14 days.
79568790|NCT01759732|Procedure|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
79568791|NCT01759758|Other|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
79568792|NCT01759758|Other|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
79568793|NCT01759771|Drug|Vitamin D3|4,000 IU of VD3 for at least one year
79568794|NCT01759771|Drug|Placebo|Placebo for at least one year
79568795|NCT01759784|Biological|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
79568796|NCT01759797|Biological|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
79568797|NCT01759810|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
79568798|NCT01759810|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
79568799|NCT01759823|Biological|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
79568800|NCT01759823|Other|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
79568801|NCT01759823|Biological|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
79568802|NCT01759849|Other|Allergen|Allergen extract is administered by inhalation.
79568803|NCT01759875|Drug|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
79863586|NCT03190460|Other|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
79863587|NCT00993434|Behavioral|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
79863588|NCT00993434|Behavioral|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
80024047|NCT06097702|Drug|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
80024048|NCT06084598|Drug|BMS-986446|Specified dose on specified days
80024049|NCT06084598|Other|Placebo|Specified dose on specified days
80024050|NCT06083454|Drug|Durvalumab|Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
79267531|NCT06108557|Diagnostic Test|Diagnostic Test: Serum pseudocholinesterase enzyme level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
79267532|NCT06108531|Other||
79267533|NCT06108518|Drug|Carvedilol|Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
79267534|NCT06108505|Other|Lacticaseibacillus with oats|Subjects will receive 7.5 gr of oats containing Lacticaseibacillus
79267535|NCT06108505|Other|Plain oats|Subjects will receive 7.5 gr of plain oats
79267536|NCT06108453|Drug|Methotrexate Sodium|Methotrexate oral administration alone
79863589|NCT00781703|Other|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
79863590|NCT02557061|Procedure|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
79863591|NCT02557061|Biological|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
79863592|NCT00781781|Drug|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
79863593|NCT00666263|Biological|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
79863594|NCT00666263|Biological|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
79863595|NCT00667277|Drug|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
79728971|NCT05014009|Behavioral|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
79568804|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
79568805|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
79400676|NCT05852054|Behavioral|OB Provider Clinical Decision Support (CDS)|When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.
79728972|NCT05014009|Behavioral|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
79863596|NCT00774527|Drug|Cyclophosphamide-fludarabine-anti thymocyte globulin|"Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
79728973|NCT05006417|Drug|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
79863597|NCT00778973|Drug|sertraline 100 mg tablets|
79863598|NCT00774605|Drug|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
79863599|NCT00774605|Drug|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
79863600|NCT00779051|Drug|Zolpidem 10mg tablets|
79863601|NCT00774683|Drug|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
79863602|NCT02556281|Biological|Blood sampling|Blood sampling is done for patient with colorectal cancer
79863603|NCT00782015|Dietary Supplement|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
79863604|NCT00782015|Dietary Supplement|Placebo Comparator:|NCEP Step 2 diet
79863605|NCT00774839|Behavioral|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
79267537|NCT06108453|Drug|Rifampicin|Co-administration of methotrexate and rifampicin
79267538|NCT06108440|Other|action observation training|Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks.
79568806|NCT01759888|Drug|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
79863606|NCT00784433|Dietary Supplement|alcohol|150 cc
79863607|NCT00774917|Device|Numen|Numen Co-Cr coronary stent implant
79863608|NCT00784511|Dietary Supplement|cholecalciferol|4000 IU/d
79568807|NCT01759914|Drug|Potent topical steroid|
79568808|NCT01759914|Drug|Superpotent topical steroid|
79863609|NCT00784511|Other|microcrystalline cellulose|1/d
80024051|NCT06083454|Drug|Pharmacological ascorbate|Given intravenously in combination with Durvalumab
80024052|NCT06083454|Procedure|Surgery (SOC)|Surgery SOC
80024053|NCT06082102|Drug|Orelabrutinib|Orelabrutinib Tablets
80024054|NCT06082102|Drug|Lenalidomide|Lenalidomide Capsules
79267539|NCT06108440|Other|motor imagery training|Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.
79267540|NCT06108414|Drug|low-dose rivaroxaban|Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance <50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
79267541|NCT06108414|Drug|Standard-dose rivaroxaban|Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance <50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
79277535|NCT02367183|Drug|Placebo|
79863610|NCT00784589|Drug|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
79863611|NCT00784589|Drug|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
80024055|NCT06082102|Drug|Rituximab|Rituximab Injection
79728974|NCT05001152|Drug|Ozanimod|Taste assessment
79728975|NCT05000632|Behavioral|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
79728976|NCT05000632|Behavioral|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
80024056|NCT06082102|Drug|Orelabrutinib Placebo|Orelabrutinib Placebo Tablets
80024057|NCT06082037|Drug|Belumosudil|Tablet, Oral
79728977|NCT04999956|Procedure|dynamic navigation surgery|immediate implant placement using dynamic navigation
80024058|NCT06082037|Drug|Azithromycin|Tablet, Oral
80024059|NCT06082037|Drug|Placebo|Tablet, Oral
80024060|NCT06081049|Drug|Colchicine|0.5 mg once daily
80024061|NCT06081049|Drug|Placebo|Once daily
79267542|NCT06108401|Dietary Supplement|Goat milk-based infant formula|Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.
79267543|NCT06108401|Dietary Supplement|Cow milk-based infant formula|Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
79267544|NCT06108362|Drug|Terlipressin|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
79267545|NCT06108362|Drug|normal saline|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
79568809|NCT01759927|Behavioral|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
79568810|NCT01759940|Drug|ropivacaine 0,375%|
79568811|NCT01759940|Drug|ropivacaine 0,75%|
79568812|NCT01759953|Other|Game|InsuOnline game, on the web, in the player´s own time and rhythm
79568813|NCT01759953|Other|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
79568814|NCT01759979|Procedure|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
79568815|NCT01759979|Procedure|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
79568816|NCT01759992|Device|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
79568817|NCT01760018|Drug|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
79728978|NCT04999956|Procedure|freehand surgery|immediate implant placement using freehand surgery
80024062|NCT06080698|Drug|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
80024063|NCT06080698|Drug|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
79267546|NCT06108349|Drug|Cannabidiol|Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
79267547|NCT06108297|Dietary Supplement|Lithium|Elemental lithium as lithium aspartate.
79267548|NCT06107647|Device|COVIDIEN WarmTouch|"COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia."
79267549|NCT06107569|Other|Fecal microbiota transplant (Promicrobioma)|Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)
79267550|NCT06107569|Drug|Antibiotic|Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.
79863612|NCT00789893|Device|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis & assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st & 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, & the 2nd will be one month ± 2 weeks from last day of radiation.
79568818|NCT01760018|Drug|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
79863613|NCT00784667|Drug|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
79863614|NCT00784667|Drug|Erlotinib|100mg orally daily continuously
79863615|NCT00784745|Drug|Dexamethasone|2mg morning and night for 5 days.
79863616|NCT00534638|Biological|Cervarix|Intramuscular injection, 3 doses
79863617|NCT00534638|Biological|Engerix-B|Intramuscular injection, 3 doses
79267551|NCT06107504|Drug|Sucralfate|2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
79267552|NCT06106763|Other|Mandala coloring|Mandala coloring page
79267553|NCT06105619|Drug|PLB1001|PLB1001 is a capsule in the form of 300mg,twice daily.
79267554|NCT06105619|Drug|Temozolomide|100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle
79267555|NCT06105619|Drug|Cisplatin combined with Etoposide|Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
79267556|NCT06105463|Other|Strength training sessions and High-interval intensity training sessions|"During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer."
79267557|NCT06105060|Drug|Rosuvastatin 20mg|40 patients will receive 20mg/day orally for 3 months.
79267558|NCT06105060|Drug|N-acetyl cysteine|40 patients will receive high dose 2400 mg /day for 3 months.
79267559|NCT06105060|Drug|Rosuvastatin and N-acetyl cysteine|40 patients will receive NAC dose 2400 mg and Rosuvastatin 20mg /day for 3 months.
79267560|NCT06105060|Drug|Vita-E|40 patients will receive Vitamin E 400 mg twice daily for 3 months.
79728979|NCT04999306|Behavioral|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
79728980|NCT04999306|Behavioral|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
79728981|NCT04979078|Device|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
79863618|NCT00996008|Drug|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
79863619|NCT00996008|Drug|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
79863620|NCT00993512|Drug|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
79863621|NCT00993512|Drug|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
79863622|NCT00993512|Other|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
79863623|NCT00996086|Device|CRT device implant|CRT device-recipients
79267561|NCT06104865|Behavioral|Tinnitus Sound Therapy using (Resound Tinnitus relief) mobile application|Patient exposure to relieving sound(wind, rain, ocean waves, etc) of his own choice from the mobile phone application and using this effect with time to accommodate the brain to neglect the negative effects of tinnitus.
79267562|NCT06104410|Radiation|Standard fractioned dose|Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.
79267563|NCT06104410|Radiation|Experimental single dose|Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
79267564|NCT06104254|Other|education|we will give an education to experimental group about pain and pain management.
79267565|NCT06104098|Device|D005 vaginal mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
79267566|NCT06103682|Device|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
79267567|NCT06103396|Biological|Transplantation of autologous MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
79568819|NCT01760031|Other|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
79568820|NCT01760044|Device|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
79568821|NCT01760057|Behavioral|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
79568822|NCT01760057|Behavioral|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
79568823|NCT01760070|Device|Hybrid knife|Use Hybrid knife in ESD procedure
79568824|NCT01760070|Device|IT knife|Use IT knife in ESD procedure.
79728982|NCT04978636|Other|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
79863624|NCT00993590|Behavioral|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
79863625|NCT00662129|Biological|bevacizumab|
79568825|NCT01760083|Device|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
80024064|NCT06070441|Other|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
79728983|NCT04978636|Other|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
79863626|NCT00662129|Drug|gemcitabine hydrochloride|
79863627|NCT00662129|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
80024065|NCT06070441|Device|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
80024066|NCT06070441|Other|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
79863628|NCT00996242|Drug|L-lysine|6 g/day for four weeks
79863629|NCT00996320|Other|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
79863630|NCT00993746|Drug|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
80024067|NCT06070428|Other|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
80024068|NCT06070428|Other|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
80024069|NCT06063317|Biological|CF33-CD19 IT|"Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28-day cycle."
80024070|NCT06063317|Biological|CF33-CD19 IV|"Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28-day cycle."
80024071|NCT06063317|Biological|Blinatumomab|Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
80024072|NCT06061939|Other|Blood Flow Restriction training with Oclussion Cuff.|A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
79267568|NCT06103396|Biological|Transplantation of allogeneic MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
79267569|NCT06102681|Other|intervention group|we will measure, consider and compare patients pain level, quality of life and recovery process. For these aims we will use numeric pain scale, nottingham health profile and postoperative recovery index.
79267570|NCT06102577|Dietary Supplement|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
79568826|NCT01760096|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
79863631|NCT00993746|Drug|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
79863632|NCT00789971|Drug|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
79863633|NCT00789971|Drug|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
79863634|NCT00996398|Other|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
79267571|NCT06102577|Other|1gr Placebo|ake 1g. of placebo at the end of an osteopathic manual treatment
79267572|NCT06102577|Other|control group|control
79277536|NCT03527641|Behavioral|CookingMatters|Nutrition education and hands-on cooking lessons for the whole family
79568827|NCT01760096|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
79568828|NCT01760096|Drug|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
79568829|NCT01760109|Drug|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
79568830|NCT01760122|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
79568831|NCT01760122|Drug|Pegasys|sc, qw, 48 weeks.
79568832|NCT01760135|Dietary Supplement|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
79568833|NCT01760135|Dietary Supplement|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
79728984|NCT04978636|Other|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
79728985|NCT04967391|Procedure|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
79728986|NCT04930653|Procedure|Extracorporeal Photopheresis|Undergo ECP
79863635|NCT00782405|Drug|quetiapine|XR, 150-300mg
79863636|NCT00782405|Drug|mirtazapine|30-45 mg
79863637|NCT04000646|Other|standard care|standard care non-pharmacologic interventions during anesthesia induction
79863638|NCT04000646|Other|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
79863639|NCT05250362|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
79267573|NCT06101992|Drug|Mesoglycan|Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
79267574|NCT06101992|Other|Placebo|placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
79267575|NCT06101862|Procedure|CCTA|Participants will be examined during admission.
79568834|NCT01760148|Drug|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
79568835|NCT01760161|Drug|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
79267576|NCT06101862|Procedure|Conventional ICA|Standard-of-care with conventional ICA.
79267577|NCT06101862|Other|Team-based interventional triage|If the CCTA suggests a potential requirement for revascularization, the CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
79267578|NCT06101277|Device|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
79728987|NCT04930653|Biological|Mogamulizumab|Given IV
79728988|NCT04930653|Other|Quality-of-Life Assessment|Ancillary studies
79728989|NCT04930653|Other|Questionnaire Administration|Ancillary studies
79728990|NCT04922268|Other|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
79728991|NCT04922268|Other|External focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
79728992|NCT04902170|Procedure|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
79863640|NCT00790283|Device|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
79863641|NCT00996554|Procedure|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
79267579|NCT06101147|Drug|Vitamin D3|These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
79267580|NCT06101147|Drug|Placebo Oral Tablet|These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
79568836|NCT01760161|Drug|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
79568837|NCT01760174|Drug|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
79728993|NCT04889079|Behavioral|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
79267581|NCT06095128|Drug|Vedolizumab|Vedolizumab IV infusions
79267582|NCT06095128|Drug|Tofacitinib|Tofacitinib Tablets
79267583|NCT06094998|Diagnostic Test|hemogram examination|It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
79267584|NCT06094582|Other|questionnaire|Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.
79267585|NCT06093048|Procedure|Endoscopic retrograde cholangiopancreatography|saftey and outcome in patients older than 65 years old
79267586|NCT06087380|Procedure|auricular acupressure|Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.
79267587|NCT06087380|Other|standard ward care|standard ward care
79267588|NCT06082778|Behavioral|Fermented food intake above habitual level|Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
79277537|NCT03527641|Behavioral|Parent Education|Parenting, physical activity and nutrition education, and family health education for parents
79728994|NCT04881487|Radiation|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
79728995|NCT04874402|Procedure|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
79728996|NCT04874402|Procedure|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
79728997|NCT04869202|Diagnostic Test|COVID-19 test|Naso-pharyngeal swab test
79728998|NCT04841057|Procedure|50 cm BP limb length|50 cm biliopancreatic limb length
79863642|NCT00996554|Procedure|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
79863643|NCT00782561|Drug|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
79863644|NCT02996396|Device|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
79568838|NCT01760174|Drug|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
79568839|NCT01760213|Other|CBT delivered via Internet|
79863645|NCT00785135|Device|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
79863646|NCT00785135|Device|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
79863647|NCT00993902|Procedure|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
79267589|NCT06079970|Device|Neelde Based Confocal Laser Endomicroscopy|Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)
79267590|NCT06079970|Procedure|Conventional diagnostic bronchoscopy|Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
79267591|NCT06074692|Combination Product|Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)|Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
79267592|NCT06073470|Drug|methylphenidate|The patients with ADHD will receive 12-week treatment with methylphenidate.
79568840|NCT01760252|Drug|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
79568841|NCT01760278|Drug|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
79568842|NCT01760317|Procedure|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
79568843|NCT01760330|Drug|IV acetaminophen|
79568844|NCT01760330|Drug|Placebo|
79728999|NCT04841057|Procedure|100 cm BP limb length|100 cm biliopancreatic limb length
79729000|NCT04841057|Procedure|150 cm BP limb length|150 cm BP limb length
79729001|NCT04839679|Behavioral|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
79729002|NCT04839679|Behavioral|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
79729003|NCT04839549|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
79729004|NCT04839549|Drug|Fluoromethalone .01%|Fluoromethalone .01%
79729005|NCT04837404|Procedure|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
79729006|NCT04837404|Procedure|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
79729007|NCT04836221|Behavioral|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
79729008|NCT04829292|Behavioral|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
79729009|NCT04826185|Drug|IMB-1018972|Modified release (MR) oral tablet
79729010|NCT04826185|Drug|Placebo|Matching oral tablet
79729011|NCT04812314|Behavioral|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
79863648|NCT00993902|Procedure|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
79863649|NCT02555735|Drug|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
79568845|NCT01760343|Biological|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
79568846|NCT01760343|Biological|CSL830|CSL830 is a formulation of Berinert.
80024073|NCT06058923|Procedure|M-MIST|This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.
79568847|NCT01760382|Device|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
79568848|NCT01760408|Other|all patients on Home Parenteral Nutrition|
80024074|NCT06058923|Procedure|MIST|A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
79863650|NCT05343260|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
79267598|NCT06070233|Radiation|stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation|"Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax <100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system"
79267599|NCT06070233|Other|Sham|Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
79267600|NCT06069193|Behavioral|Touch Intervention|"The participants will be examined, with various areas in the neck and upper back being palpated. Subsequently, the exercises to be performed at home will be demonstrated by the experimenter. The experimenter will ensure correct execution by touching specific areas in the neck and upper back of the participants. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
79568849|NCT01760421|Drug|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
79568850|NCT01760434|Other|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
79568851|NCT01760460|Drug|Anacetrapib|
79568852|NCT01760460|Drug|Placebo for anacetrapib|
79568853|NCT01760486|Behavioral|Shape Up Rhode Island|
79568854|NCT01760486|Behavioral|Shape Up Rhode Island + Professional Coach + Incentives|
79568855|NCT01760486|Behavioral|Shape Up Rhode Island + Peer Coach + Incentives|
79568856|NCT01760499|Drug|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
79729012|NCT04812314|Behavioral|No exercise|Participants will remain sedentary throughout the duration of the study.
79729013|NCT04807179|Device|Experimental: RF Device Arm|Non-invasive radiofrequency Alexandrite laser
79729014|NCT04794569|Drug|tinzaparin|low molecular weight heparin
79729015|NCT04794569|Drug|Rivaroxaban|direct oral anticoagulant
79729016|NCT04787042|Biological|ST-067|ST-067 is an engineered variant of human interleukin-18.
79729017|NCT04787042|Biological|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
79863651|NCT05343260|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
79267601|NCT06069193|Behavioral|Control|"The participants will be examined, and they will be asked to describe as accurately as possible the regions where they experience pain. Subsequently, the experimenter will demonstrate the exercises to be performed at home. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
79277538|NCT03527641|Behavioral|Physical Activity|Physical fitness activities for teens
79568857|NCT01760499|Procedure|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
79863652|NCT01564472|Other|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
79863653|NCT04001660|Procedure|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
79863654|NCT04001816|Other|Orthodontic Brackets|Self ligating and Conventional brackets
79568858|NCT01760512|Procedure|Gastric bypass|Gastric bypass
79277539|NCT03527641|Behavioral|Health Education|Health knowledge curriculum for adolescents
79277540|NCT03527641|Behavioral|Mindfulness-based Stress Reduction|Adolescent mindfulness curriculum
79277541|NCT03527641|Behavioral|Brief Mindfulness Intervention|Parent-based education and experiential learning of mindfulness-based tools
79277542|NCT02364297|Device|Early TIPS|TIPS (first 5 days)
79277543|NCT02364375|Device|Menai mask (full face)|Prototype mask system (full face variant) with novel vent and humidification system
79568859|NCT01760525|Drug|CGM097|Patients treated with CGM097
79729018|NCT04787042|Biological|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
79729019|NCT04779931|Behavioral|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
79568860|NCT01760538|Behavioral|Exercise training|exercise training
79568861|NCT01760538|Behavioral|usual care|received usual medical care after heart transplantation
79568862|NCT01760564|Drug|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
79568863|NCT01760577|Drug|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
79729020|NCT04737577|Procedure|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
79729021|NCT04737577|Procedure|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
79729022|NCT04725903|Radiation|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
79729023|NCT04725903|Radiation|Proton Beam Radiation Therapy|Undergo proton beam therapy
79729024|NCT04725903|Other|Quality-of-Life Assessment|Ancillary studies
79729025|NCT04725903|Other|Survey Administration|Ancillary studies
79729026|NCT04697810|Drug|Namodenoson|25 mg q12hours x 36 weeks
79729027|NCT04697810|Drug|Placebo|Matching capsules q12hours x 36 weeks
79568864|NCT01760577|Drug|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
79568865|NCT01760590|Procedure|Manual Manipulation|A grade 5 thrust to the thoracic spine
79568866|NCT01760590|Procedure|Mobilization|A grade 1-4 mobilization directed at thoracic spine
79729028|NCT04682301|Behavioral|Behavioral Intervention|Receive SDM intervention
79729029|NCT04682301|Other|Discussion (focus group)|Attend focus group
79729030|NCT04682301|Other|Discussion (feedback on SDM)|Provide feedback on SDM
79729031|NCT04682301|Other|Interview|Attend a telephone interview
79729032|NCT04682301|Other|Survey Administration|Ancillary studies
79729033|NCT04679194|Biological|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
79568867|NCT01760603|Procedure|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
79568868|NCT01760616|Drug|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
79568869|NCT01760629|Device|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
79568870|NCT01760642|Drug|Midazolam|Midazolam 3 mg IV
80024075|NCT06053827|Other|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
79568871|NCT01760642|Drug|Ketoconazole|ketoconazole 400 mg PO
79863655|NCT00664859|Drug|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
80024076|NCT06039397|Behavioral|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
80024077|NCT06038812|Diagnostic Test|GCF sample collection|collecting GCF from deepest sites by paper points
79863656|NCT00996788|Drug|Rebamipide|Rebamipide 100 mg tid for 28 days
80024078|NCT06038812|Procedure|non-surgical periodontal treatment|performing scaling and root planning using ultrasonic device and manual curettes
80024079|NCT06037031|Drug|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
80024080|NCT06034275|Drug|VIP943|VIP943 will be administered by IV Infusion weekly
79267602|NCT06068322|Other|Exercise training on a stationary bicycle|"Training is performed two to three times per week for a total of 30 sessions using a group format.~Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power [MAP]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM).~All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional.~The different types of exercise training is described under the specific arm.~Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: Home, Outpatient, or Mix setting."
79568872|NCT01760642|Drug|Rifampicin|Rifampicin 600 mg PO
79277544|NCT02364375|Device|Menai Standard mask (full face)|Prototype mask system (full face variant) with conventional vent and humidification system
79277545|NCT02364375|Device|Menai mask (nasal)|Prototype mask system (nasal variant) with novel vent and humidification system
79568873|NCT01760681|Device|H- Coil DTMS|20 daily deep rTMS treatments
79568874|NCT01760681|Device|Sham|
79729034|NCT04672720|Drug|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
79568875|NCT01760694|Other|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
79568876|NCT01760707|Behavioral|exercise training|
79568877|NCT01760707|Behavioral|usual care|
79729035|NCT04647448|Diagnostic Test|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
79729036|NCT04644224|Other|Educational Activity|Attend health coaching session
79729037|NCT04644224|Other|Educational Intervention|Attend resource navigation session
79729038|NCT04644224|Other|Informational Intervention|Receive handbook
79729039|NCT04644224|Other|Questionnaire Administration|Ancillary studies
79729040|NCT04644224|Procedure|Support Group Therapy|Attend support group
79729041|NCT04629417|Device|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
79729042|NCT04624178|Drug|Rucaparib|Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
79863657|NCT00785369|Device|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
80024081|NCT06030700|Other|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
80024082|NCT06030687|Other|Ad libitum data collection|Food purchase, prep, eat and toss data
80024083|NCT06030635|Device|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
79568878|NCT01760720|Behavioral|MMT CARE|
79568879|NCT01760746|Other|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
79568880|NCT01760759|Behavioral|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
79729043|NCT04624178|Drug|Nivolumab|Nivolumab 480mg intravenously on day 1 of every four-week cycle.
79863658|NCT01564550|Drug|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
79863659|NCT01564550|Drug|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
79863660|NCT01564550|Other|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
79863661|NCT01564550|Other|no diet|The subjects will ingest a non-restricted diet prior to the study day.
80024084|NCT06028022|Dietary Supplement|Mushroom|Given Reishi mushroom extract PO
80024085|NCT06028022|Drug|Placebo Administration|Given PO
80024086|NCT06028022|Other|Quality-of-Life Assessment|Ancillary studies
80024087|NCT06028022|Other|Questionnaire Administration|Ancillary studies
80024088|NCT06027255|Diagnostic Test|IL-6|"Compare IL-6 level , as a marker of inflammation in all the 3 groups:~POTS patients~post-COVID-19 POTS~gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae."
80024089|NCT06027255|Diagnostic Test|cytokines (IL-17, and IFN-ɣ)|"Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~POTS patients~post-COVID-19 POTS~gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae"
80024090|NCT06027255|Behavioral|Compass 31|Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
80024091|NCT06013176|Other|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
80024092|NCT06013176|Other|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
79267603|NCT06067165|Behavioral|POET feeling|"POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961).~POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions."
79729044|NCT04563338|Drug|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
79729045|NCT04563338|Drug|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
79267604|NCT06067165|Behavioral|Supportive treatment|The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends. The parent component will include educative material and self reflection in how to support their adolescent.
79277546|NCT02364375|Device|Menai Standard mask (nasal)|Prototype mask system (nasal variant) with conventional vent and humidification system
79277547|NCT02364375|Device|Menai mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
79568881|NCT01760759|Behavioral|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
79568882|NCT01760772|Drug|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
79568883|NCT01760772|Drug|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
79568884|NCT01760772|Other|saline|Constant infusion
79729046|NCT04562610|Drug|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
79729047|NCT04562610|Drug|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
79729048|NCT04558957|Device|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
79863662|NCT00785447|Other|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
79863663|NCT00790439|Drug|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
79863664|NCT00790439|Drug|Heparin|Anticoagulant
79568885|NCT01760798|Drug|Teriparatide|
79568886|NCT01760811|Drug|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
79568887|NCT01760824|Drug|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
79267605|NCT06065020|Behavioral|VIDACTIVA sessions|"Community health workers (CHWs) will delivered VIDACTIVA intervention that consists in 8 home-sessions, one hour duration, within a period of 14 weeks + 2 follow-up calls (monthly). In total, a period of 22 weeks.~The multicomponent intervention consist in the following:~Problem-Solving Exercises: These are basic structured exercises aimed at training older individuals in problem-solving. This activity is centered around the older adult, meaning the older adults guides this activity, and the CHWs is a facilitator.~Physical Activation: This component involves planning and scheduling enjoyable activities (physical or social) that the older adult chooses based on their preferences and capabilities.~Education on Depressive Symptoms (psychoeducation)"
79568888|NCT01760824|Drug|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
79729049|NCT04524910|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
79729050|NCT04518917|Behavioral|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
79729051|NCT04518917|Behavioral|Listening to music|Participants listen to their song and match their footfalls to the beat.
79729052|NCT04518917|Behavioral|Singing|Participants will sing their song out loud and match their footfalls to the beat.
79729053|NCT04506424|Other|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
79863665|NCT00790439|Drug|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
80024093|NCT06010758|Drug|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
80024094|NCT06010758|Drug|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
79400677|NCT05852054|Behavioral|Patient Education (OB Visit)|A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.
79863666|NCT00790439|Drug|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
79729054|NCT04505501|Drug|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
79863667|NCT00790439|Drug|Tacrolimus|Calcineurin inhibitor
80024095|NCT06010758|Drug|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
80024096|NCT06010758|Other|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
79400678|NCT05852054|Behavioral|Text messaging|At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a <5th grade reading level.
79400679|NCT05852054|Behavioral|Patient Outreach|Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.
79568889|NCT01760837|Other|Baked milk products to cow's milk allergic patients|
79568890|NCT01760863|Other|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
79568891|NCT01760902|Behavioral|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
79568892|NCT01760967|Drug|Dexmedetomidine|intervention to administer dexmedetomidine or not
79863668|NCT00790439|Drug|Cyclosporine|Calcineurin inhibitor, immunosuppressant
79863669|NCT00790439|Drug|Daclizumab|Monoclonal IL-2 receptor blocker
79863670|NCT00790439|Drug|Basiliximab|Monoclonal IL-2 receptor blocker
79863671|NCT00790439|Biological|Allogeneic Pancreatic Islet Cells|
79863672|NCT00785603|Drug|Paroxetine|tablets of 20 mg paroxetine
79863673|NCT00785603|Drug|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
79863674|NCT00785603|Drug|Tramadol|Capsules of 50 mg tramadol
79863675|NCT00570401|Drug|dasatinib|
80024097|NCT06010641|Other|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
80024098|NCT06004856|Drug|Orelabrutinib|Orelabrutinib once daily (QD)
80024099|NCT06004856|Drug|Placebo|Placebo once daily (QD)
79568893|NCT01760980|Drug|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
79568894|NCT01760980|Drug|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
79568895|NCT01761006|Device|NIOX MINO®|
79568896|NCT01761032|Device|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
79568897|NCT01761045|Dietary Supplement|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
79568898|NCT01761045|Dietary Supplement|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
79568899|NCT01761045|Dietary Supplement|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
79863676|NCT00785681|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
79863677|NCT00785759|Drug|AH110690 (18F) Injection|All subjects will receive an I.V. dose of [18F]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of [18F]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
79863678|NCT00785837|Other|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
79863679|NCT00785915|Drug|AZD6765|single administration and once daily for 5 days
80024100|NCT06001840|Behavioral|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
80024101|NCT06001840|Behavioral|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
80024102|NCT06000228|Procedure|Recession coverage with CTG using minimally invasive access technique in shallow vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
79729055|NCT04486586|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm^2; estimated total charge 0.048 C/cm^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
79267606|NCT06065020|Behavioral|Standard Care|Study fieldworkers will provide 2 educational sessions (45-60 min) about mental health at old age and participant will be guided to mental health community services (primary care centers). One session after the enrolment (week 1) and one at the 14th week.
79400680|NCT05852054|Behavioral|Primary Care Provider Clinical Decision Support (CDS)|The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.
79729056|NCT04486586|Device|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
79267607|NCT06061653|Combination Product|IPT plus HD-tDCS|psychotherapy plus device
79267608|NCT06061653|Combination Product|IPT plus sham HD-tDCS|psychotherapy plus sham device
79267609|NCT06061159|Drug|Remimazolam besylate|initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
79267610|NCT06058559|Dietary Supplement|Sunflower lecithin|Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function
79267611|NCT06058559|Dietary Supplement|Olive oil|Extra virgin olive oil
79267612|NCT06050850|Behavioral|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
79267613|NCT06047405|Device|Average Volume-Assured Pressure Support (AVAPS)|A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.
79400681|NCT05852054|Behavioral|Patient Education (Primary Care Visit)|A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
79400682|NCT05844475|Procedure|Conventional Free Gingival Graft Approach (FGG)|Conventional Free Gingival Graft Approach involving palatal soft tissue harvesting
79729057|NCT04465955|Biological|NGM621|NGM621 Dose 1
79729058|NCT04465955|Biological|NGM621|NGM621 Dose 2
79729059|NCT04465955|Other|Sham Comparator|Sham Comparator
79729060|NCT04457193|Device|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
79863680|NCT00785915|Drug|Placebo|single administration and once daily for 5 days
79863681|NCT00785993|Other|Vitrification of oocytes for IVF treatment|
79863682|NCT00785993|Other|Protocolary IVF treatment with fresh donor oocytes|
79267614|NCT06047405|Device|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
79267615|NCT06046976|Procedure|piesosurgical extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
79267616|NCT06046976|Procedure|conventional extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
79267617|NCT06045078|Other|Elequil Lavender-peppermint Aromatabs|100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
79267618|NCT06045078|Other|Elequil Almond-Oil Aromatabs|100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
79267619|NCT06043830|Drug|Acetazolamide|Acetazolamide 250 mg 2 capsules by mouth nightly
79400683|NCT05844475|Procedure|Buccal Strip Graft with a collagen matrix (bSG + CM)|A small strip of keratinized gingiva is harvested from the buccal gingiva of a site showing abundant keratinized gingiva, and combined with a xenogeneic collagen matrix
80024103|NCT06000228|Procedure|Recession coverage with CTG using minimally invasive access technique in deep vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
79568900|NCT01761071|Drug|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
80024104|NCT05999136|Other|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
79267620|NCT06043830|Other|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide 2 capsules by mouth nightly
79400684|NCT05841199|Diagnostic Test|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
79400685|NCT05841004|Device|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
79400686|NCT05841004|Device|Comparator device|Hollister Infyna Chic, single-use compact catheter.
79568901|NCT01761071|Drug|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
79863683|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
79568902|NCT01761097|Device|Endocuff attachment|Endocuff
79568903|NCT01761110|Behavioral|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
80024105|NCT05999136|Other|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
80024106|NCT05999136|Other|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
79267621|NCT06042946|Procedure|Microsurgical resection of ISCM|Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
79729061|NCT04450368|Device|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
79863684|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
79267622|NCT06040918|Drug|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
79863685|NCT00532298|Biological|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
79267623|NCT06038643|Behavioral|Motivational behavioural intervention and daily activities monitoring|Social motivation manipulation, self-transcendence daily messaging, and daily activities monitoring through accelerometry. Participants in this arm will have a study partner who receives daily feedback on the main participant's daily step count.
79267624|NCT06038643|Behavioral|Active Control|Daily activities monitored through accelerometry.
79277548|NCT02364375|Device|Menai Standard mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
80024107|NCT05998902|Procedure|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
80024108|NCT05998902|Procedure|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
80024109|NCT05997615|Drug|AMX-500 (SAR446329)|Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
79267625|NCT06038318|Behavioral|PRISM Program Video Coach|A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
79267626|NCT06038318|Behavioral|PRISM Program Text Coach|A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
79400687|NCT05837676|Behavioral|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
79400688|NCT05837676|Other|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
79568904|NCT01761123|Biological|VXA-A1.1|
79568905|NCT01761136|Biological|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
79568906|NCT01761136|Biological|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
79267627|NCT06038318|Behavioral|mPRISM Program App|6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
79568907|NCT01761149|Drug|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
79568908|NCT01761188|Procedure|Ablation|electrophysiology substrate mapping is the critical difference between both groups
79729062|NCT04444895|Drug|Lanadelumab|Rollover participants will receive 300 mg of lanadelumab solution in a PFS SC injection once Q2W or Q4W for 26 consecutive weeks.
79729063|NCT04410653|Drug|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
79729064|NCT04377087|Drug|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
79729065|NCT04341779|Combination Product|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
79729066|NCT04322994|Device|Transnasal Humidified Rapid-Insufflation Ventilatory Echange|The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
79729067|NCT04319367|Drug|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
79729068|NCT04286776|Other|Direct electrical stimulation|Stimulation lasting from 500 to 2000 milliseconds on bipolar target electrode pairs at one of two target frequencies (e.g. 10 Hz and 200 Hz), up to 1.5 milliamperes in amplitude on depth contacts and 3.5 milliamperes in amplitude on surface contacts. (Pulse shape - Charge-balanced biphasic rectangular pulses with pulse width of 300 microseconds in duration per phase).
79267628|NCT06037382|Other|Mood Triggers App|"The current intervention will deploy a smartphone application called Mood Triggers. Mood Triggers was designed to provide personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction."
79400689|NCT05832307|Other|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
79568909|NCT01761201|Drug|Levofloxacin|Levofloxacin
79568910|NCT01761201|Drug|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
79568911|NCT01761214|Drug|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
79568912|NCT01761214|Drug|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
79568913|NCT01761227|Drug|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
79568914|NCT01761227|Drug|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
79568915|NCT01761240|Drug|MORAb-066|
79729069|NCT04272996|Procedure|Craniotomy only|evacuation of SDH
79729070|NCT04272996|Procedure|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
79729071|NCT04258436|Procedure|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
79267629|NCT06032104|Dietary Supplement|Bush's Best Cannellini Beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention.
79400690|NCT05832307|Other|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
79400691|NCT05829291|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
79863686|NCT00532298|Biological|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
79267630|NCT06032104|Dietary Supplement|Usual diet|Usual diet without adding the bean smoothie
79267631|NCT06026345|Device|Affera Platform|A cardiac ablation will be performed using the Affera Platform
79267632|NCT06014996|Device|Pulsed Field Ablation (PFA) Therapy|Patients randomized to thePulsed Field Ablation group will undergo PVI using the PFA system (Insight Medtech).
79267633|NCT06014996|Device|Radiofrequency Ablation（RAF）Therapy|Patients randomized to Radiofrequency Ablation group will undergo PVI using the RFA system (Biosense Webster).
79267634|NCT06013137|Other|Therabot|The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
79400692|NCT05829135|Device|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
79400693|NCT05829083|Device|Asymmetric nasal cannula - DUET|"DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions"
79568916|NCT01761318|Drug|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
79568917|NCT01761318|Drug|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
79729072|NCT04257214|Behavioral|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
79863687|NCT04047017|Drug|Apatinib|250mg, po, qd
79267635|NCT06008015|Drug|BR1015|One tablet administered alone
79267636|NCT06008015|Drug|BR1015-1|One tablet administered alone
79267637|NCT06008015|Drug|BR1015-2|One tablet administered alone
79267638|NCT06004609|Device|Low-level laser therapy (LLLT)|Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.
79729073|NCT04814732|Drug|Surufatinib|HMP-012
79729074|NCT04252859|Drug|[18F]Fluoroestradiol (FES) PET/CT|[18F]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
79863688|NCT04047017|Drug|Camrelizumab|200mg, q2w
79863689|NCT00997022|Drug|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
79267639|NCT06004609|Other|Conventional physical therapy|Conventional physical therapy will be applied three time each week, for 12 weeks
79267640|NCT06003829|Drug|Sinsunatovir|Single dose, to be spit out after tasting
79267641|NCT06003829|Other|Bitrex|Single dose, to be spit out after tasting
79400694|NCT05829083|Device|Conventional nasal high flow cannula|"Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions"
79400695|NCT05826600|Drug|OMX-0407|Dose escalation
79400696|NCT05822544|Drug|TLC-6740 Oral Solution|Oral solution of TLC-6740
79400697|NCT05822544|Other|Placebo|Placebo-to-match
79400698|NCT05822544|Drug|TLC-6740 Tablet|Tablet formulation of TLC-6740
79400699|NCT05820672|Other|No intervention|No intervention
79729075|NCT04247711|Behavioral|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
79863690|NCT00786149|Other|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
79863691|NCT00786149|Other|Varenicline without counseling|Brief advice, one time during initial session
79863692|NCT00997100|Drug|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
79267642|NCT05999292|Drug|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
79568918|NCT01761331|Other|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
79863693|NCT02555501|Other|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
79267643|NCT05999292|Drug|68Ga-R8760 injection|PET/CT imaging at a single timepoint
79267644|NCT05993975|Drug|Bupivacain 0.5%|Bupivacaine hydrochloride was given without any adjuvant
79267645|NCT05993975|Drug|Dexmedetomidine Hydrochloride|Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
79267646|NCT05993013|Other|LudoFit|Game-based, technology-enabled home exercise software, done at least 3 times per week. Video games for a variety of exercises that promote balance, strength, endurance, and coordination.
79267647|NCT05991713|Behavioral|Modifying Exploration|Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
79400700|NCT05819138|Drug|Semaglutide Pen Injector|Semaglutide injection
79568919|NCT01761344|Other|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
79568920|NCT01761357|Other|answering to questionnaires of quality of live|
79568921|NCT01761370|Procedure|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
79729076|NCT04247711|Behavioral|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
79568922|NCT01761370|Procedure|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
79729077|NCT04246476|Behavioral|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
79729078|NCT04246476|Behavioral|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
79729079|NCT04205838|Biological|Anakinra|Given SC
79729080|NCT04205838|Biological|Axicabtagene Ciloleucel|Given via infusion
79729081|NCT04205838|Drug|Cyclophosphamide|Given via infusion
79729082|NCT04205838|Drug|Fludarabine|Given via infusion
79400701|NCT05819138|Drug|Placebo|Semaglutide placebo injection
79267648|NCT05981417|Other|Therapeutic exercise|Therapeutic exercise sessions will be guided by a physiotherapist.
79267649|NCT05981417|Other|Therapeutic exercise|Therapeutic exercise sessions will be performed at home.
79400702|NCT05818904|Other|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
79400703|NCT05817968|Device|intelligent Esophageal Pressure Catheter (iEPC)|"Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent)."
79568923|NCT01761383|Other|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
79568924|NCT01761396|Behavioral|CBT|
79568925|NCT01761396|Behavioral|UC|
79568926|NCT01761435|Biological|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
79729083|NCT04205838|Drug|Fludarabine Phosphate|Given via infusion
79729084|NCT04170543|Drug|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
79729085|NCT04170543|Drug|Placebo|Placebo
79729086|NCT04170543|Drug|Dapagliflozin|Dapagliflozin 10 mg
79729087|NCT04163016|Drug|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
79729088|NCT04161391|Drug|TPX-0046|Oral TPX-0046 capsules
79729089|NCT04147013|Drug|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
79267650|NCT05981040|Drug|ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
79729090|NCT04147013|Drug|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
79267651|NCT05981040|Drug|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
79568927|NCT01761448|Device|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
79267652|NCT05981040|Drug|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
79267653|NCT05981040|Drug|Matching placebo 25 mg and Matching placebo 50 mg|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
79729091|NCT04121182|Other|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
79729092|NCT04121182|Other|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
79267654|NCT05977140|Drug|CDI-988|SARS-CoV-2 3CL protease inhibitor
79729093|NCT04111900|Behavioral|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
79729094|NCT04084717|Drug|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
79267655|NCT05977140|Drug|Placebo|matching placebo
79729095|NCT04081038|Diagnostic Test|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
79729096|NCT04079868|Behavioral|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
79729097|NCT04061070|Other|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
79729098|NCT04061070|Other|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
79729099|NCT04039841|Diagnostic Test|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
79729100|NCT04029922|Drug|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
79729101|NCT04020575|Biological|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
79729102|NCT04020575|Biological|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
79729103|NCT04007510|Combination Product|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
79267656|NCT05976971|Other|7T MRI|Subjects will have a 7T MRI and questionnaires on the only day of clinical study.
79267658|NCT05966025|Drug|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
79267659|NCT05966025|Drug|conventional therapy|will taken by patient in control group
79267660|NCT05965531|Drug|Trifluridine/Tipiracil|TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
79568928|NCT01761448|Device|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
79568929|NCT01761448|Device|Control group training without Guided Exercise system at home|
79568930|NCT01761461|Drug|TS-1, oxaliplatin|
80024110|NCT05997381|Device|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
79267661|NCT05965531|Radiation|intensity-modulated radiotherapy|intensity-modulated radiotherapy
79568931|NCT01761487|Device|Gentamicin and polymyxin E|
79568932|NCT01761500|Other|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
79863694|NCT02555501|Radiation|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
79863695|NCT04001738|Other|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
79863696|NCT00993980|Procedure|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
80024111|NCT05997381|Procedure|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
80024112|NCT05996913|Other|Imagery rescripting|The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz & Weertman, 1999).
79267662|NCT05960942|Drug|propofol combined with esketamine|In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
79267663|NCT05960942|Drug|propofol-sufentanil|In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
79267664|NCT05959005|Other|No intervention|There is no intervention.
79267665|NCT05957042|Drug|Lumason|Up to 4.8mL administered intravenously
79267666|NCT05953610|Drug|Acetazolamide 500 MG QHS|Acetazolamide
79267667|NCT05953610|Drug|Eszopiclone 3 mg QHS|Eszopiclone
79267668|NCT05951946|Drug|BR3006-1|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
79729104|NCT04007510|Diagnostic Test|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
79729105|NCT03991819|Drug|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
79267669|NCT05951946|Drug|BR3006-2|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
79267670|NCT05951946|Drug|BR3006-3|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
79568933|NCT01761513|Drug|YH4808|"Group1~adminitration of YH4808 dose1, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose2, qd for 2weeks"
79568934|NCT01761513|Drug|YH4808|"Group2~adminitration of YH4808 dose2, qd for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose1, bid for 2weeks"
79729106|NCT03991819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
79729107|NCT03919552|Drug|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
79729108|NCT03919552|Drug|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
79729109|NCT03919552|Radiation|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
79729110|NCT03919552|Radiation|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
79863697|NCT00993980|Procedure|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
79863698|NCT02725814|Other|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
80024113|NCT05993559|Radiation|Arm I (No PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
80024114|NCT05993559|Radiation|Arm II (PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
80024115|NCT05989074|Device|ALLEGRA TAVI System TF|Patients receive ALLEGRA TAVI System TF. Patient will receive medication according to routine practice of the hospital
79568935|NCT01761513|Drug|YH4808|"Group3~adminitration of YH4808 dose2, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of Nexium tab 40mg, bid for 2weeks"
79568936|NCT01761513|Drug|YH4808|"Group 4~adminitration of Nexium tab 40mg, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose2, bid for 2weeks"
79568937|NCT01761526|Drug|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
79568938|NCT01761539|Other|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
79863699|NCT00410410|Drug|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
80024116|NCT05989074|Device|Ballon-expandable valve system|Patients receive any kind of CE-marked balloon expandable valve system, used at the hospital. Patient will receive medication according to routine practice of the hospital.
79863700|NCT00410410|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
79863701|NCT00410410|Drug|abatacept|"~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
79863702|NCT00997178|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
80024117|NCT05988580|Other|Pasta dish with resistant starch|Pasta dish with 20-22% of resistant starch
79400704|NCT05814549|Diagnostic Test|NavDx|"Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase."
79568939|NCT01761539|Other|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
79568940|NCT01761552|Drug|Sugammadex Reversal|
79863703|NCT00997178|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
79863704|NCT00782951|Drug|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
79863705|NCT00782951|Drug|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
79863706|NCT00782951|Drug|Placebo|single IV dose of placebo after dental impaction surgery
80024118|NCT05988580|Other|Original version of pasta dish|Original pasta dish, not reinforced with resistant starch
80024119|NCT05988216|Biological|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
80024120|NCT05986864|Genetic|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
80024121|NCT05984680|Other|Surveys and Interviews - Arm A|For Arm A, this outpatient study will administer surveys, interviews, concept mapping exercises, guided tours of oncology clinics, design team workshops, and phone calls for follow-up questions
80024122|NCT05984680|Other|COPD Care Pathway|The COPD care pathway will consist of an initial assessment followed by monthly follow-up assessments, which occur during regularly scheduled immunotherapy infusions. At each of these three visits, the study team will administer symptom measures, counsel participants on the management of COPD, and give algorithm-generated general recommendations to the patient and provider regarding possible options for COPD-directed care.
80024123|NCT05978817|Device|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
80024124|NCT05970978|Drug|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
80024125|NCT05970978|Drug|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
79568941|NCT01761552|Drug|Atropine/Neostigmine|
79568942|NCT01761578|Device|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
79568943|NCT01761591|Device|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
79568944|NCT01761591|Device|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
79568945|NCT01761604|Device|Nasal ganglion block for TN|
79568946|NCT01761617|Behavioral|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
79863707|NCT00997256|Drug|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
79863708|NCT00997256|Drug|film-coated sugar-pill|3 x 2 tablets / day over 3 days
80024126|NCT05970016|Drug|TCC1727 tablet|TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
79568947|NCT01761617|Behavioral|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
79729111|NCT03900845|Device|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
79863709|NCT02555813|Drug|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
80024127|NCT05962827|Diagnostic Test|lipoprotein (a)|dosage of lipoprotein (a)
80024128|NCT05962398|Genetic|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).
80024129|NCT05961085|Procedure|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
80024130|NCT05959733|Procedure|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
80024131|NCT05959733|Procedure|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
80024132|NCT05956964|Behavioral|Sleep Restriction|5 hours of sleep for 3 days
80024133|NCT05956964|Behavioral|Sleep Adequate|9 hours of sleep for 3 days
80024134|NCT05956041|Drug|Pembrolizumab|400mg Intravenously
80024135|NCT05956041|Drug|Mogamulizumab|1mg/kg Intravenously
80024136|NCT05955365|Drug|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
80024137|NCT05955365|Drug|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
79267671|NCT05946707|Drug|restrictive oxygen supply|Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.
79863710|NCT02555813|Drug|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
79863711|NCT00994058|Device|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
79863712|NCT00997412|Drug|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
80024138|NCT05955365|Drug|DOAC|The choice of DOAC is left at investigator's discretion.
80024139|NCT05955339|Other|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
80024140|NCT05955339|Other|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
79267672|NCT05946707|Drug|liberal oxygen supply|Oxygen supply will be maximized to 100% at the beginning of OLV
79267673|NCT05933083|Behavioral|In-person cardiac rehabilitation|In-person exercise training, health education, and counseling
79267674|NCT05933083|Behavioral|Telehealth cardiac rehabilitation|Telehealth exercise training, health education, and counseling
79267675|NCT05931627|Procedure|Patients undergoing ACL reconstruction with or without a tourniquet|Patients undergoing ACL reconstruction with or without a tourniquet
79568948|NCT01761656|Drug|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
79568949|NCT01761656|Drug|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
79568950|NCT01761669|Drug|Vitamin D|
79568951|NCT01761682|Other|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
79863713|NCT00997412|Drug|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
79267676|NCT05925114|Drug|S-309309|Administered as oral capsules
79267677|NCT05925114|Drug|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
79400705|NCT05813717|Drug|BMS-986325|Specified dose on specified days
80024141|NCT05954559|Drug|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
80024142|NCT05948436|Procedure|Clamping the uterine artery bilaterally during Cesarean section|We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
80024143|NCT05943431|Device|paired taVNS|The stimulator will be placed on the left ear of the patient. While the patient performs the action training, the EMG signal feature evoked by the action will trigger an electrical stimulation of the transcutaneous auricular vagus nerve. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
80024144|NCT05943431|Device|Unpaired taVNS|The stimulator will be placed on the patient's left ear. Patients will receive taVNS with pulses every 5-7 seconds. Following the stimulation, motor training will be performed. The motor training will be identical to that of the paired group. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
80024145|NCT05943431|Device|Sham taVNS|The stimulator will be placed on the patient's left ear. The amplitude of the electrical stimulation will be adjusted at 0 mA. The intervention will be performed daily for 14 days.
80024146|NCT05920083|Other|CPAP withdrawal|2 weeks of CPAP withdrawal
80024147|NCT05915767|Dietary Supplement|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
80024148|NCT05912231|Radiation|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
79568952|NCT01761695|Other|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
79568953|NCT01761708|Procedure|primary ventral hernia repair with mesh|
79568954|NCT01761734|Behavioral|text message|
80024149|NCT05912231|Radiation|Accelerated Photon Radiation Therapy (XRT)|per protocol
80024150|NCT05911334|Behavioral|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
80024151|NCT05910411|Device|Inelastic compression|Inelastic compression used in the treatment of lymphedema
80024152|NCT05909176|Behavioral|GYN Residency Training|The combined care model will be implemented and during months 5-14.
80024153|NCT05909176|Behavioral|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
80024154|NCT05905458|Drug|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
80024155|NCT05905458|Drug|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
80024156|NCT05905458|Drug|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
79267678|NCT05922462|Dietary Supplement|Greek yogurt|For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
79400706|NCT05813717|Drug|Placebo|Specified dose on specified days
79568955|NCT01761760|Behavioral|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
79568956|NCT01761773|Drug|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
79568957|NCT01761786|Genetic|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with *1/*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (*2 or *3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
80024157|NCT05901610|Behavioral|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
80024158|NCT05901610|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
80024159|NCT05901610|Device|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
80024160|NCT05901610|Device|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
80024161|NCT05900895|Drug|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
80024162|NCT05900895|Drug|17b-estradiol|17b-estradiol will be taken orally three times per day.
80024163|NCT05895292|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
80024164|NCT05895292|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
80024165|NCT05888870|Drug|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
80024166|NCT05888870|Drug|SCT800|SCT800 50IU/kg TIW alone
80024167|NCT05886400|Other|SCAT6|The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
80024168|NCT05886400|Other|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
79568958|NCT01761799|Behavioral|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
79729112|NCT03900845|Device|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
79729113|NCT03900845|Device|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
79729114|NCT03897595|Device|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
79729115|NCT03897530|Behavioral|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
79267679|NCT05922462|Dietary Supplement|Whey protein|For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, ~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
79863714|NCT04047407|Device|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
80024169|NCT05885464|Biological|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
79568959|NCT01761812|Other|MRI with gadofosveset and MR elastography|
79568960|NCT01761825|Drug|ivabradine|
79729116|NCT03897530|Other|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
79729117|NCT03897530|Other|Questionnaire Administration|Ancillary studies
79729118|NCT03758950|Drug|Placebo|Once daily inhaled placebo for 48 weeks
79863715|NCT00997490|Drug|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
79863716|NCT00997490|Drug|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
79267680|NCT05920759|Diagnostic Test|Cerebral blood flow|Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
79267681|NCT05919329|Drug|Piflufolastat|Given IV
79267682|NCT05919329|Procedure|PSMA PET/CT Scan|Undergo PSMA PET/CT
79267683|NCT05919329|Procedure|PSMA PET/MRI scan|Undergo PET/MRI
79568961|NCT01761838|Other|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
79568962|NCT01761838|Other|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
79568963|NCT01761838|Other|Low back pain participants without SMT|No treatment
79568964|NCT01761864|Behavioral|academic detailing intervention|
79729119|NCT03758950|Drug|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
79863717|NCT00783107|Drug|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
79863718|NCT00783107|Drug|Placebo|
79267684|NCT05919329|Procedure|Biospecimen Collection|Undergo collection of blood samples
79267685|NCT05919329|Other|Electronic Health Record Review|Ancillary studies
79400707|NCT05809986|Other|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
79863719|NCT00997568|Device|PET-511BTM|Transesophageal Transducer
79863720|NCT00783185|Behavioral|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
80024170|NCT05874635|Device|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
79267686|NCT05917782|Biological|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
79400708|NCT05809921|Drug|alteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
79400709|NCT05809921|Drug|Alteplase + possible complementary IVT with tenecteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
79400710|NCT05809622|Behavioral|Elbow focused rehabilitation|"Patient education~Activity modification~2 days/week, 8 weeks in total~Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
79863721|NCT00783185|Behavioral|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
79400711|NCT05809622|Behavioral|Scapular and rotator cuff muscles strengthening|"Patient education~Activity modification~2 days/week, 8 weeks in total~Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~Scapular stabilizer muscle + rotator cuff (RM) strengthening"
79400712|NCT05805826|Biological|C. difficile vaccine (previously studied formulation)|Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
79400713|NCT05805826|Biological|C. difficile vaccine formulation 1|C. difficile vaccine formulation 1 given as an intramuscular injection
79568965|NCT01761916|Drug|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
79568966|NCT01761916|Drug|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
79568967|NCT01761942|Dietary Supplement|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
79568968|NCT01761955|Other|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
79729120|NCT03751371|Device|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
79568969|NCT01761968|Drug|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
79568970|NCT01761994|Drug|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
79267687|NCT05917782|Biological|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|subcutaneous injection of 1 dose on Day 1
79267688|NCT05917782|Biological|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
79568971|NCT01762020|Device|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
79568972|NCT01762020|Drug|Standard Preparation|standard creams
79863722|NCT00783341|Drug|GAP-134|
79863723|NCT00783341|Drug|placebo|
79863724|NCT00534404|Drug|Nicotine patches|Participants will wear nicotine patches.
79863725|NCT00534404|Behavioral|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
79267689|NCT05912959|Other|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
79400714|NCT05805826|Biological|C. difficile vaccine formulation 2|C. difficile vaccine formulation 2 given as an intramuscular injection
79400715|NCT05805826|Biological|C. difficile vaccine formulation 3|C. difficile vaccine formulation 3 given as an intramuscular injection
79400716|NCT05805826|Other|Saline Placebo|0.9% sodium chloride solution given as an intramuscular injection
79400717|NCT05805800|Drug|5HT3RA+Olanzapine|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner."
79568973|NCT01762033|Drug|ASONEP|Intravenous infusion
79568974|NCT01762046|Drug|Glipizide|
79568975|NCT01762046|Drug|Metformin|
79568976|NCT01762046|Other|Oral Glucose Tolerance Test|
79568977|NCT01762072|Dietary Supplement|Fish oil|
79863726|NCT00534404|Behavioral|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
79863727|NCT00393094|Biological|Bevacizumab|10 mg/kg intravenous injection
80024171|NCT05873348|Procedure|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
80024172|NCT05865496|Drug|611|611 subcutaneous (SC) injection.
79568978|NCT01762072|Dietary Supplement|vitaminB12|
80024173|NCT05865496|Drug|Placebo|Placebo subcutaneous (SC) injection.
80024174|NCT05860972|Device|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
80024175|NCT05826990|Drug|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
80024176|NCT05821478|Drug|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
79267690|NCT05908344|Device|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
79267691|NCT05908344|Device|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
79267692|NCT05906238|Behavioral|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
79267693|NCT05906238|Behavioral|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
79308989|NCT02592447|Other|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
79400718|NCT05805800|Drug|5HT3RA+Olanzapine+Dexamethasone|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered.~Other Names:~Acidocont; Deronil; Dexacortal; Desameton; Fluprednisolone; (11β，16α-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione"
79568979|NCT01762085|Procedure|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
79568980|NCT01762124|Device|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
79568981|NCT01762137|Procedure|Flow Diversion|Endovascular flow diverter placement
79568982|NCT01762137|Procedure|Coiling|Endovascular coil placement
79568983|NCT01762150|Drug|Sorafenib|Sorafenib 400mg BID by oral until progressed;
79568984|NCT01762150|Drug|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30~60min on Day 1 and 8,for 4 cycles;
79729121|NCT03751371|Other|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
79729122|NCT03738410|Behavioral|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
79729123|NCT03738410|Other|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
79729124|NCT03711279|Drug|SHR-1210 plus Apatinib|SHR-1210 (200mg lyophilized powder in a single-dose vial for reconstitution) q3w+ Apatinib (250mg/375mg tablets) qd
79729125|NCT03711279|Drug|ADM plus IFO or IFO alone|ADM 60mg/m2 D1 + IFO 2mg/m2 D1-D4 q3w；if the cumulative doses of ADM is beyond 450mg/m2, the monotherapy of IFO (2mg/m2 D1-D5 q3w) will be used.
79729126|NCT03658538|Device|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
79863728|NCT00393094|Drug|Irinotecan hydrochloride|125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
79568985|NCT01762150|Drug|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
79568986|NCT01762163|Drug|Qizhitongluo Capsule|
79568987|NCT01762163|Drug|Naoxintong Capsule|
79568988|NCT01762163|Drug|Aspirin Enteric-coated Tablets|
79568989|NCT01762163|Behavioral|the routine recovery training|
79568990|NCT01762163|Drug|placebo|
79568991|NCT01762189|Procedure|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
79568992|NCT01762202|Drug|Cyclophosphamide|
80024177|NCT05821478|Drug|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
79568993|NCT01762202|Drug|Fludarabine|
79568994|NCT01762202|Drug|Ofatumumab|
79863729|NCT04047485|Diagnostic Test|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
79568995|NCT01762215|Behavioral|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
79568996|NCT01762228|Device|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
79863730|NCT04047485|Diagnostic Test|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
79863731|NCT04047485|Diagnostic Test|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
79863732|NCT04047485|Diagnostic Test|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
79863733|NCT04047485|Diagnostic Test|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
79267694|NCT05885282|Device|paraspinal vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
79267695|NCT05885282|Device|gastrosoleus muscle complex vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
79267696|NCT05885282|Other|Control Exercise|Lumbar spinal stabilization exerciseswill be given. Lumbar spinal stabilization exercises; Diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
79267697|NCT05881707|Drug|CKD-828, D064, D702|QD, PO
79568997|NCT01762228|Dietary Supplement|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
79568998|NCT01762241|Behavioral|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
79729127|NCT03658538|Behavioral|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
79729128|NCT03658538|Device|Sham Air Cleaner|The Control arm will receive sham air cleaners
79729129|NCT03657368|Procedure|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
79729130|NCT03657368|Procedure|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
79729131|NCT03657368|Procedure|Low PEEP|PEEP = 5 cm H2O
79729132|NCT03657368|Procedure|High PEEP|PEEP = 8 cm H2O
79863734|NCT04047485|Diagnostic Test|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
79863735|NCT04047485|Diagnostic Test|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
79863736|NCT01043848|Procedure|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
79863737|NCT00783653|Drug|Sunitinib|25 mg or 37,5 mg daily dose until DLT
79863738|NCT00409786|Behavioral|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
79863739|NCT00786305|Drug|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
79863740|NCT00786305|Drug|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
79863741|NCT00790517|Behavioral|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
79863742|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
79400719|NCT05803304|Behavioral|PATH Intervention|The PATH intervention guides participants in making changes in their lifestyle and PA habits to support long-term adherence to the minimum threshold of PA Guidelines (150 MVPA minutes per week). The health coach provides participants with access the PATH website and a detailed orientation on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA by about 10 minutes per week. The PA prescription process begins by identifying a suitable PATH level for each participant. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week. The coach also guides participants to select activities with intensity to help them progress along the PA continuum (i.e., from inactive to light PA and then MVPA).
79863743|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
79267698|NCT05866523|Behavioral|Team Based Inpatient ARTAS|Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
79267699|NCT05866523|Behavioral|Standard of Care|Subject admitted and seen by routine inpatient medical service.
79267700|NCT05866016|Behavioral|Skill birth attendant training|It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
79863744|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
79267701|NCT05865392|Behavioral|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
79400720|NCT05803304|Behavioral|Attention Control Intervention|"A health coach will have a zoom meeting with each control group participant where they will be provided with an electronic copy of the Be Active Your Way booklet, developed by the Centers for Disease Control and Prevention (CDC) to help individuals integrate PA into their daily lives. The coach will orient the participant to the key strategies used in the booklet and encouraged them to use it regularly and to self-monitor PA using the Fitbit during the entire course of the study. In addition, the group will be introduced to www.health.com, a jargon free website that focuses on general health topics and latest medical news. At the end of the meeting, the participants will be asked to provide a schedule for zoom meetings the study team twice per month during the 6 month study. The meetings will focus on their progress in using the Be Active Your Way handout and the health.com website."
79267702|NCT05860647|Device|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
79267703|NCT05835908|Other|Phone questionnaire|Patients will be contacted by the investigator to collect information regarding follow-up from the initial call to the Emergency call center until the patient is taken care of in the health care facility to which he/she has been admitted.
79400721|NCT05803304|Other|Physical activity tracker|Participants will be asked to wear Fitbit Charge 5 on their non-dominant hand for the entire duration of the study using a 24hr wear protocol.
79568999|NCT01762254|Procedure|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
79569000|NCT01762254|Procedure|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
79569001|NCT01762267|Other|nutrition intervention|DASH diet control diet
79569002|NCT01762280|Drug|Famitinib Malate Capsule|
79569003|NCT01762293|Drug|Famitinib|Famitinib 25 mg p.o. qd
79569004|NCT01762293|Other|placebo|p.o. qd
79569005|NCT01762306|Drug|Diclofenac Potassium|
79569006|NCT01762306|Drug|Folic Acid|
79729133|NCT03645590|Behavioral|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
80024178|NCT05820087|Device|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
79863745|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
79863746|NCT00786383|Biological|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
79863747|NCT00786383|Biological|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
79863748|NCT00786383|Biological|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
79863749|NCT00786383|Biological|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
79863750|NCT00786383|Biological|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
79863751|NCT01042444|Device|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
79863752|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
79863753|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
79729134|NCT03641456|Drug|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
79729135|NCT03641456|Drug|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
79400722|NCT05803304|Behavioral|Dietary education|Diet quality and barriers to healthy eating will be evaluated at baseline, and then all study participants will be provided with educational materials that are curated to promote diet quality. Participants will receive a monthly email with a brief PDF addressing a diet component focused on improving diet quality to reduce CVD risk and improve general health.
79473430|NCT02384993|Behavioral|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
79569007|NCT01762319|Drug|Misoprostol|
79267704|NCT05833958|Drug|GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin|As described previously
79267705|NCT05833958|Drug|Metformin|As described previously - Experimental Arm, 175mg at night
79267706|NCT05833958|Drug|Metformin|As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
79267707|NCT05830071|Drug|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
79569008|NCT01762319|Drug|Vitamin B6|
79569009|NCT01762332|Drug|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
79569010|NCT01762332|Drug|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
79569011|NCT01762332|Other|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
79569012|NCT01762358|Other|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
79569013|NCT01762358|Other|Physiotherapy|Twelve times standardized Physiotherapy
79729136|NCT03641456|Drug|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
79729137|NCT03639688|Procedure|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
79729138|NCT03639688|Procedure|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
79267708|NCT05830071|Drug|CHF5259|GB 12.5 μg pMDI
79569014|NCT01762371|Other|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
79863754|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
79863755|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
79863756|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
79863757|NCT00783731|Drug|Low dose midazolam|
79863758|NCT00409708|Drug|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
79863759|NCT00409708|Behavioral|Behavior Therapy|
80024179|NCT05817786|Device|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
79569015|NCT01762384|Procedure|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
79569016|NCT01762384|Procedure|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
80024180|NCT05817786|Other|sham stimulation|treated by sham stimulation
80024181|NCT05800782|Behavioral|Face Memory Training|Computer-based training using faces targeting face memory
79267709|NCT05830071|Drug|Moxifloxacin 400mg|400 mg Oral Tablets
79267710|NCT05830071|Drug|CHF5993 Placebo|placebo pMDI
79267711|NCT05828836|Drug|Allopurinol Tablet|allopurinol300mg once daily
79267712|NCT05828836|Drug|Placebo|placebo once daily
79308990|NCT05616351|Other|Data collection in patients with diabetic foot syndrome and infections in the area of the foot|Data collection: on (surgical and antibiotic) treatment and implementation of the recommendations published 2019 with regard to the duration of antibiotic therapy.
79569017|NCT01762384|Device|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
79569018|NCT01762397|Drug|PMK-S005|
79863760|NCT00790985|Dietary Supplement|flavocoxid|medical food
79863761|NCT00790985|Drug|Naproxen|antiinflammatory drug
79863762|NCT01044082|Procedure|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
79863763|NCT01044082|Procedure|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
79863764|NCT01324336|Drug|6-Mercaptopurine|75 mg/m2/dose/day
79863765|NCT00783887|Other|Blood sample|Blood sample of 5 ml
80024182|NCT05800782|Behavioral|Face Perception Training|Computer-based training using faces targeting improving face perception
79569019|NCT01762410|Drug|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
79569020|NCT01762423|Device|Active Device (IVIVI SofPulse)|
79569021|NCT01762423|Device|Sham Device|
80024183|NCT05800782|Behavioral|Placebo control training|Computer-based training using faces not targeting improving face perception or memory
79729139|NCT03572660|Biological|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
79729140|NCT03564626|Other|Health-IT +/- Scheduled Follow Up|"Training patient and caregiver on Patient Buddy and EncephalApp~Counseling regarding readmission~Daily contact through app~Standard of care counseling regarding readmission and discharge instructions~Follow up phone calls at Week 1 and Week 3~In-person follow up visits at Week 2 and Week 4"
80024184|NCT05796492|Device|Pulsed splenic ultrasound|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
80024185|NCT05796492|Device|Ultrasound probe (no energy applied)|A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
80024186|NCT05787678|Biological|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
80024187|NCT05781399|Drug|JNT-517 Suspension|JNT-517 in on-site compounded suspension
80024188|NCT05781399|Drug|Placebo Suspension|On-site compounded placebo suspension
80024189|NCT05781399|Drug|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
80024190|NCT05781399|Drug|Placebo Tablet|Matching film-coated placebo tablet
80024191|NCT05781009|Drug|Pregnenolone|300mg
79267713|NCT05822479|Procedure|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
80024192|NCT05781009|Drug|Placebo|placebo
80024193|NCT05775380|Drug|Pioglitazone 45 mg|We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
79308991|NCT04810455|Other|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
80024194|NCT05755568|Other|No Intervention|As this is an observational study, no intervention will be administered.
80024195|NCT05752448|Behavioral|POSTCare Survivorship transition process|Survivorship coaching intervention
79569022|NCT01762436|Drug|bisoprolol|
79569023|NCT01762436|Drug|atenolol|
79729141|NCT03493152|Drug|Everolimus|mTOR inhibitor
79569024|NCT01762449|Other|Followup survey|
79569025|NCT01762462|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
79569026|NCT01762475|Drug|Sildenafil|
79729142|NCT03492671|Drug|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
79863766|NCT01039870|Procedure|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
80024196|NCT05751720|Drug|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
79569027|NCT01762488|Procedure|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
79569028|NCT01762488|Procedure|Renal angiography|Renal angiography by femoral access
79569029|NCT01762514|Drug|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
79569030|NCT01762514|Drug|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
79569031|NCT01762527|Radiation|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
79569032|NCT01762540|Drug|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
79569033|NCT01762540|Drug|Calcium Supplement|Placebo
79729143|NCT03492671|Drug|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
79863767|NCT01039870|Procedure|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
79863768|NCT00784121|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
79863769|NCT04047173|Radiation|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 33-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
80024197|NCT05736705|Procedure|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
79863770|NCT04047173|Procedure|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 2 times.
79863771|NCT01324492|Drug|RAD001|
80024198|NCT05736705|Device|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
79400723|NCT05798468|Other|Augmented reality|The intervention will be carried out in the Physiotherapy Degree of the Universities of Malaga and Cadiz. It will consist of the use of software and a platform that works with augmented reality. Previously a study of the demographic variable of the population that conforms the study will be carried out. During the intervention, teaching will be carried out with the support and enhancement of the use of augmented reality through Zapworks and Aumentaty. A study and analysis of the variables of the qualifications and usability of the study population will be carried out. For the qualification variable, the academic performance of the students will be taken into account and for the usability variable, the System Usability Scale will be used. Subsequently, an analysis and interpretation will be carried out to assess the correlation between both variables.
80024199|NCT05727657|Drug|Satralizumab|120mg subcutaneous Day 0 and Day 14
79267714|NCT05822479|Other|Control|"Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg (IBW) iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
79267715|NCT05821075|Drug|Prednisolone|prednisolone 60mg tablet once daily for 5 days then tapering dose
79267716|NCT05821075|Drug|Cerebrolysin|intramuscular Cerebrolysin 10 mg daily for 3 weeks
79267717|NCT05815485|Drug|Azeliragon|30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).
79267718|NCT05815485|Drug|Placebo|Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
79267719|NCT05814172|Other|no intervention|no intervention
79267720|NCT05789758|Other|No Intervention|Administered as specified in the treatment arm.
79267721|NCT05786131|Procedure|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
80024200|NCT05725668|Behavioral|dual-task tai ji quan|dual-task tai ji quan training
80024201|NCT05725668|Behavioral|standard tai ji quan|standard tai ji quan training
79569034|NCT01762553|Behavioral|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
79569035|NCT01762566|Dietary Supplement|wheat|wheat is administered blindly versus placebo in capsules once
79267722|NCT05786131|Procedure|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
79267723|NCT05785325|Drug|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
79267724|NCT05784597|Drug|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
79267725|NCT05765513|Drug|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
79267726|NCT05758402|Diagnostic Test|Routine practice groups|Routine practice groups
79267727|NCT05758402|Diagnostic Test|EARP group|EARP group
79400724|NCT05798468|Other|Control group|Traditional education will be carried out
79400725|NCT05794503|Drug|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
80024202|NCT05725668|Behavioral|stretching|stretching exercise
79267728|NCT05743595|Biological|Personalized Neoantigen DNA vaccine|The sites of immunization may be rotated for each of the immunizations.
79267729|NCT05743595|Biological|Retifanlimab|Retifanlimab will be supplied by Incyte.
79400726|NCT05794503|Drug|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
79400727|NCT05792553|Device|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
79400728|NCT05792553|Device|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
79569036|NCT01762566|Dietary Supplement|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
79569037|NCT01762592|Drug|Iodine (124I) Girentuximab|i.v.
79569038|NCT01762618|Behavioral|Cognitive Behavioral Therapy Group|Therapy Groups
79569039|NCT01762644|Drug|Oral Cyclosporine and Oral Omeprazole|
80024203|NCT05723653|Behavioral|Project nGage|"Project nGage (nGage) is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men. The nGage intervention consists of (1) selection and invitation of a Support Confidant (SC), (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference."
80024204|NCT05717140|Biological|Aerosol Sargramostim|Given via inhalation with nebulizer
80024205|NCT05717140|Procedure|Biospecimen Collection|Undergo collection of blood samples
80024206|NCT05717140|Procedure|Computed Tomography|Undergo CT
80024207|NCT05717140|Procedure|Magnetic Resonance Imaging|Undergo MRI
79569040|NCT01762644|Drug|Oral Omeprazole|
79400729|NCT05792553|Device|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
80024208|NCT05717140|Other|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
79267730|NCT05743595|Device|TDS-IM v 2.0 electroporation device|Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
79267731|NCT05737056|Other|Management of rheumatoid purpura|Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).
79267732|NCT05736588|Behavioral|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
79267733|NCT05728047|Procedure|Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam)|The 'Cytocam' is a hand held computer-controlled device, a third generation video-microscope, which enables real time visualisation of the in vivo microcirculation, based upon the principle of incident dark field (IDF) illumination.
79569041|NCT01762657|Drug|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
79569042|NCT01762657|Drug|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
79569043|NCT01762670|Drug|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
79267734|NCT05727137|Procedure|Single shot adductor canal block|Single shot adductor canal block on the the first and second postoperative day.
79267735|NCT05727137|Procedure|Continuous adductor canal block|A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
79267736|NCT05725265|Device|Large-area low-level laser therapy(Venusure)|The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
79569044|NCT01762670|Drug|Metronidazole|500 mg twice daily for 7 days
79729144|NCT03492671|Radiation|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
79729145|NCT03442322|Other|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
79729146|NCT03442322|Other|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
79729147|NCT03439852|Behavioral|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
79729148|NCT03401385|Drug|Datopotamab Deruxtecan (Dato-DXd)|A total anti-TROP2 antibody and MAAA-1181a
79729149|NCT03401385|Drug|Steroid Containing Mouthwash|A mouthwash containing a steroid ingredient administered in sub-study
79729150|NCT03401385|Other|Non-Steroid Containing Mouthwash|A mouthwash containing a non-steroid ingredient administered in sub-study
79267737|NCT05725265|Device|Conventional low-level laser therapy|The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
79569045|NCT01762683|Other|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
79569046|NCT01762696|Behavioral|MET|Motivational Enhancement Therapy only
79729151|NCT03355300|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
79729152|NCT03350529|Device|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
79729153|NCT03333031|Drug|HS-196|HS-196 will be administered intravenously as a single dose
80024209|NCT05717140|Biological|Nivolumab|Given IV
79569047|NCT01762696|Behavioral|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
79569048|NCT01762709|Procedure|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
79729154|NCT03332056|Drug|Belladonna and Opium|
80024210|NCT05714059|Device|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
80024211|NCT05713955|Device|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
80024212|NCT05712889|Drug|VIP236|VIP236 will be administered by IV infusion once every 3 weeks.
80024213|NCT05707377|Drug|Zanubrutinib|Participants will receive zanubrutinib once daily
80024214|NCT05707377|Drug|Tacrolimus|Participants will receive tacrolimus twice daily
79267738|NCT05719831|Drug|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
79569049|NCT01762709|Procedure|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
79569050|NCT01762709|Procedure|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
79267739|NCT05719831|Drug|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
79267740|NCT05719831|Drug|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
79569051|NCT01762735|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
79569052|NCT01762735|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
79569053|NCT01762748|Drug|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
79569054|NCT01762761|Drug|eltrombopag|TPO-R agonist
79569055|NCT01762761|Drug|placebo|placebo
79569056|NCT01762774|Drug|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
79569057|NCT01762774|Drug|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
79569058|NCT01762787|Drug|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
79569059|NCT01762787|Drug|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
79569060|NCT01762787|Drug|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
79729155|NCT03332056|Other|Placebo suppository|
79729156|NCT03255434|Drug|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
79729157|NCT03255434|Drug|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
79729158|NCT03136393|Behavioral|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
79729159|NCT03136393|Behavioral|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
79309033|NCT04426617|Procedure|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
80024215|NCT05707377|Drug|Zanubrutinib|Participants will receive zanubrutinib twice daily
79400730|NCT05778695|Dietary Supplement|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
79400731|NCT05777330|Diagnostic Test|Oral glucose tolerance test (OGTT)|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
79400732|NCT05777330|Diagnostic Test|Hyperglycemic clamp test|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years."
79400733|NCT05777330|Diagnostic Test|Continuous glucose monitoring|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
79400734|NCT05766891|Behavioral|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
79569061|NCT01762787|Drug|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
79569062|NCT01762787|Drug|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
79569063|NCT01762813|Procedure|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
79569064|NCT01762826|Dietary Supplement|Myo-inositol|Dietary control plus Myo-inositol
79569065|NCT01762826|Dietary Supplement|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
79569066|NCT01762826|Dietary Supplement|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
79569067|NCT01762826|Dietary Supplement|Placebo|Dietary control plus folic acid 400 mcg daily
79569068|NCT01762852|Drug|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
80024216|NCT05703477|Procedure|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
79569069|NCT01762852|Drug|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
79729160|NCT03115359|Behavioral|Mindfulness Meditation|"The Mindfulness Meditation intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
79729161|NCT03115359|Behavioral|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
79863772|NCT01042834|Other|Air pollution study on healthy volunteers.|"The subjects are examined three times:~First the volunteers get used to equipments.~Second and third the volunteers sleep in a pollution or purified air."
79863773|NCT01039948|Biological|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
80024217|NCT05702437|Other|assessment of cognitive performance|evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time
79267741|NCT05704400|Drug|Rituximab Biosimilar ABP 798|Rituximab IV: the dose is standard for pediatric nephrotic syndrome; for dosage between 100 and 250 mg rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
79267742|NCT05704400|Drug|Daratumumab|Daratumumab vials 20 mg 1 ml will be collected to reach the desired dose of 16 mg /Kg, the dose is standard recommend to treat myeloma; diluted in 1000 ml of normal saline and infused at the constant speed of 50 ml/h. This will be reduced in case of cutaneous allergic reactions
79267743|NCT05698550|Drug|Erzhi Tiangui Granule|The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
79267744|NCT05698550|Drug|Erzhi Tiangui Placebo|The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
79267745|NCT05686421|Device|OCT Imaging Using Device N|Standard conventional OCT imaging device equipped with extendable and comfortable chin and forehead rest.
79267746|NCT05686421|Device|OCT Imaging Using Device C|Standard conventional OCT imaging device.
79569070|NCT01762878|Drug|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
79569071|NCT01762878|Drug|Placebo|Dry powder for oral inhalation once daily using DIKUS device
79863774|NCT01039948|Drug|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
79863775|NCT00391846|Drug|Captopril|
79863776|NCT00391846|Drug|Enalapril|
79863777|NCT00391846|Drug|Lisinopril|
79863778|NCT00391846|Drug|Ramipril|
79863779|NCT00391846|Drug|Trandolapril|
79863780|NCT00391846|Drug|Bisoprolol|
79863781|NCT00391846|Drug|Carvedilol|
79863782|NCT00391846|Drug|Metoprolol succinate|
79863783|NCT00391846|Drug|Candesartan|
79863784|NCT00391846|Drug|Valsartan|
79863785|NCT00391846|Drug|Eplerenone|
79863786|NCT00391846|Drug|Spironolactone|
79863787|NCT00391846|Drug|Diuretics|
79863788|NCT00391846|Drug|HF treatment according to Swedish guidelines|
79863789|NCT00391846|Procedure|Blood samples|
80024218|NCT05695898|Drug|XmAb22841|Given intravenously (IV)
80024219|NCT05695898|Drug|XmAb23104|Given intravenously (IV)
80024220|NCT05694650|Behavioral|Focus Group|Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
80024221|NCT05694650|Behavioral|Interview|Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
80024222|NCT05689840|Procedure|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
80024223|NCT05689736|Behavioral|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (<70th %ile).~Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
80024224|NCT05689736|Behavioral|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
80024225|NCT05689736|Behavioral|Gamification|"Gamification will include four features:~Game-like graphical environment (e.g., avatars to represent the participant).~Digital rewards. Parents will receive points and badges for completing intervention activities.~Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
79267747|NCT05684367|Behavioral|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
79400735|NCT05766891|Behavioral|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
79400736|NCT05766891|Behavioral|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
79569072|NCT01762891|Drug|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
79569073|NCT01762891|Drug|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
79569074|NCT01762891|Drug|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
79569075|NCT01762891|Drug|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
79569076|NCT01762930|Drug|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
79863790|NCT00391846|Procedure|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
79863791|NCT00448630|Other|No intervention|Non-interventional study
79729162|NCT03093350|Biological|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10^7 cells/m2~Day 28: 2 x 10^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
79863792|NCT01042990|Other|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
79863793|NCT00534248|Biological|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
79863794|NCT00534248|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
79863795|NCT00994136|Drug|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
79569077|NCT01762956|Other|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
79863796|NCT00997724|Procedure|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
79729163|NCT03087903|Dietary Supplement|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
79267748|NCT05684367|Behavioral|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
80024226|NCT05689736|Behavioral|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
79267749|NCT05681104|Diagnostic Test|Waist-height ratio|Waist-height ratio as early predictors of metabolic syndrome in primary school obese children
79267750|NCT05681104|Diagnostic Test|body mass index|Body mass index as early predictors of metabolic syndrome in primary school obese children
79267751|NCT05681104|Diagnostic Test|Bio-electrical impedance analysis|Bio-electrical impedance analysis as early predictors of metabolic syndrome in primary school obese children
79267752|NCT05663502|Procedure|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
79267753|NCT05662137|Behavioral|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
79729164|NCT03074045|Drug|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
79863797|NCT00997802|Device|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
79863798|NCT00391768|Drug|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
79267754|NCT05660941|Drug|Lispro|Ultra rapid Lispro
79863799|NCT00391222|Drug|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
80024227|NCT05689736|Behavioral|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
79267755|NCT05660941|Drug|Lispro|Conventional Lispro
79267756|NCT05643248|Drug|NEX-20A|Subcutaneous prolonged-release injection
79267757|NCT05642806|Biological|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
79267758|NCT05642806|Other|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
79267759|NCT05640648|Behavioral|User-Centered Implementation Strategy|"4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
79863800|NCT00391222|Drug|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
79863801|NCT00391222|Drug|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
80024228|NCT05685004|Biological|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
80024229|NCT05685004|Procedure|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
80024230|NCT05685004|Radiation|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
79863802|NCT01043068|Drug|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
79569078|NCT01762969|Other|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
79863803|NCT00409006|Drug|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
79863804|NCT00409006|Drug|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
79863805|NCT00409006|Drug|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
79863806|NCT00534092|Device|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
79863807|NCT00997880|Drug|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
79267760|NCT05640648|Behavioral|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
79400737|NCT05763550|Drug|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
79569079|NCT01762995|Drug|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
79569080|NCT01762995|Drug|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
79729165|NCT03074045|Drug|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
79729166|NCT03003052|Procedure|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
79729167|NCT02982564|Behavioral|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
79729168|NCT02982564|Behavioral|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
80024231|NCT05685004|Drug|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
79267761|NCT05629546|Biological|Memory-like natural killer cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
79400738|NCT05763550|Drug|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
79400739|NCT05763550|Drug|Pregabalin 150mg|pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
79267762|NCT05629546|Biological|Relatilmab|Standard of care
79400740|NCT05762211|Drug|Pooled allogeneic fecal microbiotherapy|Capsule for oral use
79400741|NCT05762211|Drug|Placebo|Capsule for oral use
79569081|NCT01762995|Drug|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
79729169|NCT02948543|Biological|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
79863808|NCT00997880|Drug|Rosuvastatin calcium10mg|Rosuvastatin 10mg
79863809|NCT00408928|Drug|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
79863810|NCT00997958|Drug|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
79473431|NCT00382707|Device|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
79473432|NCT04342247|Drug|external testosteron|external testosteron
79473433|NCT04620369|Drug|Placebo Administration|Instill isotonic nasal saline intranasally
79473434|NCT04620369|Other|Questionnaire Administration|Ancillary studies
79473435|NCT04620369|Drug|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
79473436|NCT03628313|Other|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
79863811|NCT00998036|Drug|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
79569082|NCT01763008|Drug|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
79569083|NCT01763021|Drug|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
79569084|NCT01763021|Drug|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
79267763|NCT05629546|Biological|Nivolumab|Standard of care
79267764|NCT05629143|Procedure|de-prescription of PPI via intermittent scheme|The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.
79267765|NCT05629143|Procedure|de-prescription of PPI via on-demand scheme|The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.
79400742|NCT05761522|Other|transthoracic echocardiography|"Concerning the main judgment criterion and the secondary judgment criteria:~Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~Tricuspid Annular Systolic Excursion (TAPSE) (mm)~S wave at the tricuspid ring (cm/s)~Other parameters collected systematically:~Surface of the left ventricle (end-systolic and end-diastolic),~Global strain of the left ventricle~Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
79400743|NCT05759910|Dietary Supplement|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
79569085|NCT01763034|Procedure|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
79863812|NCT00998036|Drug|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
79569086|NCT01763060|Radiation|CT scan|
79569087|NCT01763060|Behavioral|Cognitive function|
79569088|NCT01763060|Radiation|MRI|
79729170|NCT02948543|Drug|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
79863813|NCT00998036|Drug|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
79863814|NCT05309876|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
79267766|NCT05629143|Drug|Alginate|The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
79267767|NCT05624866|Drug|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
79267768|NCT05624866|Drug|Triamcinolone|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
79267769|NCT05613361|Drug|Colistin|added for infection with multi drug resistant bacteria
79267770|NCT05613361|Drug|Curcumin|added for the possible nephroprotective effect
79267771|NCT05598359|Dietary Supplement|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
79569089|NCT01763086|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
79729171|NCT02925780|Device|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
79729172|NCT02925780|Device|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
79729173|NCT02901041|Drug|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
79863815|NCT05254808|Drug|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
80024232|NCT05679011|Other|4 and 6 meters walking test|A 10-meter and other 6-meter flats pathways were identified. Two-meter are provided for the acceleration zone and two-meter for deceleration for 6-meter walk test. One meter to acceleration and another to deceleration for 4-meter walk test. The participants are randomly to perform 3-time to comfortable speed and 3-time faster speed for 4-meter and 6-meter.
80024233|NCT05678673|Drug|XL092|Specified doses on specified days
79569090|NCT01763099|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
79569091|NCT01763099|Biological|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
79569092|NCT01763112|Device|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
79569093|NCT01763138|Behavioral|oral health education|oral health education in the form of a pictorial pamphlet.
79863816|NCT05254808|Drug|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
80024234|NCT05678673|Drug|Nivolumab|Specified doses on specified days
79267772|NCT05598359|Other|Placebo|Inactive formulation
79569094|NCT01763138|Behavioral|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
79569095|NCT01763151|Device|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
80024235|NCT05678673|Drug|Sunitinib Malate|Specified doses on specified days
79267773|NCT05591092|Procedure|Computed Tomography|Undergo a SPECT/CT scan
79569096|NCT01763151|Procedure|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
79267774|NCT05591092|Radiation|Iodine I-123|Given PO
79569097|NCT01763177|Other|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
79569098|NCT01763190|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
79569099|NCT01763216|Other|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
79729174|NCT02901041|Behavioral|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
79729175|NCT02901041|Drug|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
79729176|NCT02840227|Procedure|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
79729177|NCT02840227|Procedure|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
79729178|NCT02797964|Drug|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
79729179|NCT02717403|Behavioral|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
79729180|NCT02717403|Behavioral|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
80024236|NCT05677711|Device|ultimaster|Subjects who received Ultimaster stent will be included.
80024237|NCT05675631|Other|Suspension training|This group will perform training using suspension devices.
80024238|NCT05675631|Other|Strength training|This group will perform training using weights and elastic bands.
79569100|NCT01763216|Other|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
80024239|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
80024240|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
80024241|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
80024242|NCT05668312|Other|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
79569101|NCT01763229|Procedure|transthoracic echocardiography|
79569102|NCT01763242|Other|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
79569103|NCT01763255|Biological|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
80024243|NCT05668312|Other|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
79569104|NCT01763268|Biological|Trivivac vaccine|Trivalent MMR vaccine
79569105|NCT01763281|Drug|CRH|
79569106|NCT01763281|Drug|Placebo|
79267775|NCT05591092|Procedure|Planar Imaging|Undergo planar imaging
79569107|NCT01763294|Device|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
79267776|NCT05591092|Procedure|Single Photon Emission Computed Tomography|Undergo a SPECT/CT scan
79569108|NCT01763294|Device|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
79569109|NCT01763294|Device|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
79569110|NCT01763294|Device|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
79569111|NCT01763294|Device|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
79569112|NCT01763307|Drug|RECONVAL CREAM|
79569113|NCT01763307|Drug|PLACEBO|
79569114|NCT01763385|Drug|Erlotinib|
79569115|NCT01763385|Radiation|concurrent brain radiotherapy|
79569116|NCT01763385|Radiation|secondary brain radiotherapy|
79569117|NCT01763437|Drug|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
79569118|NCT01763450|Drug|bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
79569119|NCT01763463|Drug|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
79729181|NCT02717403|Behavioral|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
79729182|NCT02717403|Behavioral|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
79729183|NCT02705508|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
79729184|NCT02705508|Drug|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
79863817|NCT02275286|Drug|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
79267777|NCT05579665|Biological|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
79267778|NCT05579665|Biological|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
79267779|NCT05579665|Drug|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
79304365|NCT03293459|Procedure|Shunt Occlusion|Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.
79569120|NCT01763463|Drug|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
79569121|NCT01763476|Procedure|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
79729185|NCT02705508|Drug|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
79569122|NCT01763476|Procedure|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
79569123|NCT01763489|Behavioral|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
79863818|NCT02275286|Radiation|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
79863819|NCT04000412|Device|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
79267780|NCT05571280|Dietary Supplement|Nutritional Supplementation|"The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt."
79569124|NCT01763502|Other|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
79569125|NCT01763502|Other|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
79569126|NCT01763515|Procedure|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
79569127|NCT01763528|Other|nutrition intervention|high protein diet
79569128|NCT01763541|Drug|leuprolide acetate|Given to both arms to induce hypogonadism
79863820|NCT00998114|Behavioral|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
79863821|NCT00998192|Biological|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
79569129|NCT01763541|Drug|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
79569130|NCT01763619|Device|Freedom Cervical Disc|
79569131|NCT01763632|Device|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
79569132|NCT01763658|Drug|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
79569133|NCT01763658|Other|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
79569134|NCT01763697|Behavioral|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
79569135|NCT01763697|Behavioral|Recorded meal|
79569136|NCT01763710|Drug|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
79569137|NCT01763710|Drug|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
79569138|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
79569139|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
79569140|NCT01763723|Device|IPL-home use device|A light based home use device for hair removal
79729186|NCT02705508|Radiation|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
79729187|NCT02673398|Other|Comprehensive Geriatric Assessment|Ancillary studies
79729188|NCT02673398|Other|Laboratory Biomarker Analysis|Correlative studies
79729189|NCT02673398|Drug|Neratinib|Given PO
79729190|NCT02673398|Other|Pharmacological Study|Correlative studies
79729191|NCT02636322|Drug|Cyclophosphamide|Given IV
79729192|NCT02636322|Drug|Doxorubicin Hydrochloride|Given IV
79729193|NCT02636322|Drug|Etoposide|Given IV
79729194|NCT02636322|Drug|Ibrutinib|Given PO
79729195|NCT02636322|Drug|Lenalidomide|Given PO
79729196|NCT02636322|Drug|Prednisone|Given PO
79729197|NCT02636322|Biological|Rituximab|Given IV
79729198|NCT02636322|Drug|Vincristine Sulfate|Given IV
79729199|NCT02547987|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
79729200|NCT02547987|Drug|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
79729201|NCT02523040|Drug|Lenalidomide|
79729202|NCT02513199|Radiation|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
79863822|NCT00998192|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
79729203|NCT02513199|Drug|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
79729204|NCT02440672|Device|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
79729205|NCT02396043|Drug|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
79729206|NCT02396043|Drug|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
79863823|NCT00998192|Drug|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
79863824|NCT00998270|Procedure|Autologous bone marrow transplantation|"Autologous transplantation:~Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
79863825|NCT00998270|Procedure|Allogeneic bone marrow transplantation|"Allogeneic~Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
79569141|NCT01763736|Behavioral|Music|playlist per patient preference
79267781|NCT05571280|Behavioral|Money transfers|The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
79400744|NCT05759910|Dietary Supplement|Placebo|Participants will take placebo capsules during 3 months
79569142|NCT01763749|Drug|Closone|Closone 75mg/100mg, 4weeks, PO
79267782|NCT05571280|Behavioral|Standard intervention|"The activities included are the following:~Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~Biannual supplementation with vitamin A for children from 6 to 24 months of age.~Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy."
79569143|NCT01763749|Drug|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
79569144|NCT01763762|Behavioral|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
79569145|NCT01763762|Behavioral|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
79569146|NCT01763762|Behavioral|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
79569147|NCT01763775|Device|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
79569148|NCT01763775|Device|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
79569149|NCT01763788|Drug|Necitumumab|Administered IV
79267783|NCT05559359|Drug|Lebrikizumab|Administered SC
79267784|NCT05559359|Drug|Placebo|Placebo given SC
79267785|NCT05559359|Drug|Topical corticosteroid|Topical corticosteroid
79569150|NCT01763788|Drug|Gemcitabine|Administered IV
79569151|NCT01763788|Drug|Cisplatin|Administered IV
79569152|NCT01763801|Device|P-Max|tip placement in correspondence to the P-Max on the ECG
79569153|NCT01763801|Device|P-Submax|tip placement in correspondence to the P-Submax on the ECG
79569154|NCT01763814|Procedure|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
79569155|NCT01763814|Procedure|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
79267786|NCT05558098|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
79400745|NCT05756777|Drug|Gilteritinib|Dose level (-1) 80mg, (1) 120mg, (2) 120mg
79569156|NCT01763814|Procedure|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
79569157|NCT01763840|Drug|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
79569158|NCT01763853|Drug|4% albumin|
79569159|NCT01763879|Other|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
79569160|NCT01763879|Other|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
79569161|NCT01763944|Behavioral|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
79729207|NCT02396043|Drug|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
79267787|NCT05558098|Other|Standard of Care|Current standard of care for management of critically ill patients
79267788|NCT05556824|Drug|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
79400746|NCT05756777|Drug|Ivosidenib|Dose level (-1) 250mg, (1) 250mg, (2) 500mg
79400747|NCT05756777|Drug|Enasidenib|Dose level (-1) 50mg, (1) 50mg, (2) 100mg
79400748|NCT05755204|Drug|LA-CAB|Intramuscular LA-CAB for PrEP
79400749|NCT05755204|Drug|TDF/FTC|Oral TDF/FTC for PrEP
79267789|NCT05556824|Other|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
79267790|NCT05556733|Procedure|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
79569162|NCT01763957|Behavioral|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
79569163|NCT01763957|Behavioral|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
79569164|NCT01763983|Behavioral|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
79729208|NCT02396043|Drug|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
79729209|NCT02396043|Drug|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
79729210|NCT02396043|Drug|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
79729211|NCT02396043|Drug|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
79729212|NCT02258919|Procedure|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
79729213|NCT02258919|Procedure|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
79863826|NCT00998348|Behavioral|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
79863827|NCT03742856|Combination Product|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
79863828|NCT00994526|Other|Ham|Ham : 180 g per day during 4 days
79863829|NCT00994526|Other|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
79267791|NCT05535712|Device|Lung Anatomic Resection (Da Vinci SP)|To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection
79267792|NCT05510115|Drug|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3furanyl]oxy]phenyl]methyl]phenyl]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
79267793|NCT05510115|Drug|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
79729214|NCT02232191|Biological|Pneumovax-23|
79729215|NCT02143752|Behavioral|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
79729216|NCT02143752|Behavioral|Quit Line|see arm
79729217|NCT02141828|Drug|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
79729218|NCT02015871|Drug|Degarelix|
79729219|NCT02000050|Drug|FOLFOX4|FOLFOX4
79729220|NCT02000050|Radiation|Tomotherapy|Tomotherapy
79729221|NCT02000050|Procedure|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
79863830|NCT00994526|Other|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
79863831|NCT00998504|Dietary Supplement|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
79863832|NCT00998504|Dietary Supplement|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
79863833|NCT00788684|Drug|rituximab|IV infusion once weekly for four doses
79863834|NCT00788684|Drug|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
79863835|NCT00454220|Other|Placebo|33 patients to placebo + 131-I arm
79863836|NCT00454220|Drug|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
79863837|NCT00454220|Drug|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
80024244|NCT05666622|Other|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
79267794|NCT05506371|Drug|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
79267795|NCT05506371|Drug|SRP|Scaling and root planning (SRP) treatment of periodontitis
79267796|NCT05506371|Drug|No interventions|Diagnostocs to confirm the healthy state of the gingiva
79569165|NCT01763983|Behavioral|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
79267797|NCT05505513|Device|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
79863838|NCT00998972|Drug|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
79569166|NCT01764009|Biological|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
79569167|NCT01764035|Behavioral|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
79729222|NCT01765491|Other|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
79729223|NCT01765491|Other|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
79729224|NCT01684150|Drug|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
79729225|NCT01273610|Drug|Lapatinib|250 mg tablets
79863839|NCT00390910|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
79729226|NCT01273610|Drug|Trastuzumab|Intravenous injection
79729227|NCT01273610|Other|laboratory biomarker analysis|
79863840|NCT00390910|Biological|Infanrix hexa|Intramuscular injection, 3 doses
79729228|NCT01273610|Other|pharmacological study|
79729229|NCT01165762|Drug|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
79729230|NCT00999804|Drug|Lapatinib|1000 mg of Lapatinib by mouth daily
79729231|NCT00999804|Drug|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
79729232|NCT00999804|Drug|Trastuzumab|6 mg/kg intravenously, every 3 weeks
79729233|NCT00797888|Behavioral|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
79729234|NCT00349869|Behavioral|yoga|8-week yoga program.
79729235|NCT00309933|Procedure|cognitive assessment|
79729236|NCT00309933|Procedure|psychosocial assessment and care|
79863841|NCT00998816|Drug|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
80024245|NCT05664113|Drug|Fecal microbiota transplant (FMT)|FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
79267798|NCT05501548|Drug|Olaparib|Olaparib 300mg by mouth twice daily
79267799|NCT05501548|Dietary Supplement|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
79267800|NCT05484089|Device|CapFlex PIP implant|Patients receive the CapFlex PIP implant based on regular care. During surgery tantalum markers are placed in the bone surrounding the implant.
80024246|NCT05657106|Behavioral|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
79304366|NCT03293459|Dietary Supplement|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
79304367|NCT04971291|Drug|AXS-05|AXS-05 taken twice daily for 6 weeks
79729237|NCT00309933|Procedure|quality-of-life assessment|
79729238|NCT00303914|Procedure|assessment of therapy complications|
79729239|NCT00303914|Procedure|cognitive assessment|
79729240|NCT00303914|Procedure|psychosocial assessment and care|
79729241|NCT00130221|Drug|2% chlorhexidine gluconate impregnated cloth|
79729242|NCT00130221|Other|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
79863842|NCT05219084|Drug|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
79863843|NCT05219084|Drug|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
79863844|NCT05219084|Drug|Combined group|hip denervation and intra-articular hydration were conducted together
79863845|NCT05219084|Drug|Control group|Normal; saline was injected subcutaneously
79863846|NCT05133908|Behavioral|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
79863847|NCT05133908|Behavioral|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
80024247|NCT05653778|Device|Scrambler therapy|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
79267801|NCT05473897|Device|Catalyst Cryohelmet|The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
79569168|NCT01764035|Behavioral|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
79569169|NCT01764048|Drug|Fix protocol|Please see arm description
79569170|NCT01764048|Drug|medications following demand protocol|Please see arm description
79569171|NCT01764074|Behavioral|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
79569172|NCT01764087|Drug|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
79569173|NCT01764100|Genetic|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
79569174|NCT01764113|Behavioral|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
79569175|NCT01764113|Behavioral|Standard dietary counselling|
79304368|NCT04971291|Drug|Bupropion SR|Bupropion taken twice daily for 6 weeks
79729243|NCT00077129|Drug|carboplatin|
79729244|NCT00077129|Drug|paclitaxel|
80024248|NCT05653778|Device|TENS treatment|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
80024249|NCT05650554|Biological|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
79569176|NCT01764126|Drug|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
79729245|NCT00052884|Biological|filgrastim|
79569177|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
79569178|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
79569179|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
79569180|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
79569181|NCT01764139|Procedure|Blood sampling|
79569182|NCT01764152|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
79569183|NCT01764165|Other|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
79569184|NCT01764165|Other|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
79729246|NCT00052884|Drug|amifostine trihydrate|
79729247|NCT00052884|Drug|melphalan|
79400751|NCT05747352|Other|closed-loop hybrid insulin administration|observational non-interventional study
79729248|NCT00052884|Procedure|bone marrow ablation with stem cell support|
79729249|NCT00052884|Procedure|peripheral blood stem cell transplantation|
79729250|NCT00040807|Drug|docetaxel|
79729251|NCT00040807|Drug|irinotecan hydrochloride|
79729252|NCT00028678|Drug|dalteparin|
79729253|NCT00028678|Radiation|radiation therapy|
79729254|NCT00005095|Other|Ca-125|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
79729255|NCT00005095|Other|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
79729256|NCT00005095|Procedure|Surgery|Subjects will be assessed for high risk factors.
79729257|NCT00004223|Drug|docetaxel|
79729258|NCT00004223|Drug|gemcitabine hydrochloride|
79400752|NCT05746819|Other|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
79400753|NCT05746585|Behavioral|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
79400754|NCT05738746|Dietary Supplement|Pasteurized Akkermansia muciniphila|PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
79569185|NCT01764178|Drug|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
79569186|NCT01764178|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
79569187|NCT01764204|Drug|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
79569188|NCT01764230|Drug|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
79569189|NCT01764243|Drug|MT-4666|low dose, high dose
79569190|NCT01764243|Drug|Placebo|
79729259|NCT00003764|Drug|cyclophosphamide|
79729260|NCT00003764|Drug|fludarabine phosphate|
79729261|NCT00003601|Drug|fenretinide|
79729262|NCT00003601|Drug|tretinoin|
79729263|NCT00003266|Drug|methylphenidate hydrochloride|
79729264|NCT00003266|Procedure|quality-of-life assessment|
79863848|NCT00999050|Procedure|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
79863849|NCT00533702|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
80024250|NCT05650554|Biological|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
80024251|NCT05650554|Biological|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
79729265|NCT00003236|Biological|ISIS 3521|
79729266|NCT00003236|Drug|ISIS 5132|
79729267|NCT00003057|Drug|loperamide hydrochloride|
79729268|NCT00003057|Drug|octreotide acetate|
79729269|NCT00002922|Drug|paclitaxel|
79729270|NCT00002514|Biological|sargramostim|
79729271|NCT00002514|Drug|asparaginase|
79729272|NCT00002514|Drug|cyclophosphamide|
80024252|NCT05650554|Biological|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
79304369|NCT03288701|Device|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
79309034|NCT04263441|Behavioral|NICE Intervention|Subjects enrolled in the intervention arm will be offered assistance in enrolling in healthcare coverage and provided assistance on where they can go for care immediately. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review.
79569191|NCT01764269|Other|text message surveillance for fever|
79569192|NCT01764282|Behavioral|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
79569193|NCT01764295|Drug|DWJ1276|
79569194|NCT01764295|Drug|Olmesartan|
79569195|NCT01764295|Drug|Rosuvastatin|
79569196|NCT01764295|Drug|Placebo|
79569197|NCT01764308|Dietary Supplement|Omega-3|1200mg twice a day for 24 weeks
79569198|NCT01764308|Dietary Supplement|Placebo|4 tablets twice a day for 24 weeks
79729273|NCT00002514|Drug|cytarabine|
79729274|NCT00002514|Drug|daunorubicin hydrochloride|
79729275|NCT00002514|Drug|dexamethasone|
79729276|NCT00002514|Drug|etoposide|
79729277|NCT00002514|Drug|imatinib mesylate|
79729278|NCT00002514|Drug|leucovorin calcium|
79729279|NCT00002514|Drug|mercaptopurine|
79729280|NCT00002514|Drug|methotrexate|
79729281|NCT00002514|Drug|prednisone|
79729282|NCT00002514|Drug|thioguanine|
79729283|NCT00002514|Drug|vincristine sulfate|
79729284|NCT00002514|Procedure|allogeneic bone marrow transplantation|
79729285|NCT00002514|Procedure|autologous bone marrow transplantation|
79729286|NCT00002514|Procedure|peripheral blood stem cell transplantation|
79729287|NCT00002514|Radiation|radiation therapy|
79729288|NCT05448469|Procedure|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
79729289|NCT05448469|Procedure|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
79729290|NCT05448469|Drug|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
79729291|NCT00607282|Drug|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
79729292|NCT02674789|Behavioral|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
79729293|NCT00609310|Dietary Supplement|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
79729294|NCT02674867|Other|Blood draw|
79267802|NCT05472961|Behavioral|Target and Stimulus|The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
79569199|NCT01764334|Device|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
79729295|NCT04265248|Device|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
79729296|NCT04265248|Behavioral|Exercise|The subjects will perform evidence-based exercises for the neck.
79729297|NCT00643591|Other|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
79863850|NCT00533702|Drug|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
79863851|NCT00408694|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
79863852|NCT00408694|Biological|Bevacizumab|Given IV
79863853|NCT00408694|Drug|Cisplatin|Given IV
79863854|NCT00408694|Drug|Fluorouracil|Given IV
79267803|NCT05464849|Diagnostic Test|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
79267804|NCT05455840|Device|Da Vinci SP surgical platform|using Da Vinci SP platform in thymothymectomy or extended thymectomy
79267805|NCT05422885|Drug|Dasatinib|Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
79267806|NCT05422885|Drug|Quercetin|Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
79267807|NCT05417438|Behavioral|Wearable device deployment|Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
79729298|NCT05437705|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
79863855|NCT00408694|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79863856|NCT03993340|Device|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
79863857|NCT00999128|Drug|GDC-0941|Oral repeating dose
79267808|NCT05407233|Device|Does not reuse the syringe for insulin application|Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.
79309035|NCT04802889|Other|scanning electron microscopy|scanning electron microscopy of the сentral retina and preretinal structures
79569200|NCT01764347|Procedure|therapeutic conventional surgery|Undergo robotic radical prostatectomy
79569201|NCT01764347|Procedure|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
79569202|NCT01764347|Procedure|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
79863858|NCT00999128|Drug|rabeprazole|Oral repeating dose
80024253|NCT05650437|Device|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
80024254|NCT05650437|Behavioral|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
80024255|NCT05650437|Dietary Supplement|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A&B)
79309036|NCT05616117|Other|Intrauterine 90µg D-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
79729299|NCT00927472|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
79863859|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
79569203|NCT01764373|Other|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
79729300|NCT00927472|Drug|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
79569204|NCT01764425|Drug|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
79569205|NCT01764438|Procedure|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
79729301|NCT00642655|Drug|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
79729302|NCT00643747|Biological|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
79729303|NCT00642733|Drug|erlotinib [Tarceva]|100mg po daily
79729304|NCT00642733|Drug|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
79729305|NCT02672371|Device|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
79729306|NCT02672371|Device|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
79729307|NCT00927394|Drug|Aliskiren|Aliskiren 150 mg tablet
79729308|NCT00927394|Drug|Valsartan|Valsartan 160 mg capsules
79729309|NCT00927394|Drug|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
79863860|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
80024256|NCT05644418|Device|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
80024257|NCT05635227|Drug|Dexamethasone phosphate|See description of arms
79267809|NCT05407233|Device|Uses the syringe for insulin delivery five times|Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
80024258|NCT05635227|Drug|Isotonic sodium chloride (0.9%)|See description of arms
79729310|NCT00927394|Drug|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
79400755|NCT05738746|Dietary Supplement|Placebo|PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
79569206|NCT01764451|Drug|Simvastatin|
80024259|NCT05635227|Drug|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
80024260|NCT05635227|Drug|Placebo capsule|capsule identical to capsule containing olanzapine
79569207|NCT01764477|Drug|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
79569208|NCT01764542|Procedure|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
79729311|NCT04179253|Diagnostic Test|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
79729312|NCT05014126|Behavioral|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
79729313|NCT00643825|Drug|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
79729314|NCT00643825|Drug|Temozolomide|Observation till Progression then rechallenging with TMZ
79729315|NCT04178863|Device|CATS Tonometer|latanoprost vs. timolol
79729316|NCT04178863|Drug|Latanoprost|latanoprost IOP reduction
79729317|NCT05329636|Other|FMT|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
79729318|NCT05329636|Other|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
79863861|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
79863862|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
79863863|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
79863864|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
79863865|NCT00999284|Drug|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
80024261|NCT05635227|Procedure|Flow-targeted hemodynamic management|See description of arms
80024262|NCT05635227|Procedure|Pressure-targeted hemodynamic management|See description of arms
80024263|NCT05635227|Procedure|Low tidal-volume ventilation|See description of arms
80024264|NCT05635227|Procedure|No ventilation|See description of arms
80024265|NCT05634746|Drug|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
80024266|NCT05634746|Drug|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
80024267|NCT05634746|Procedure|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
80024268|NCT05625867|Other|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
80024269|NCT05625867|Other|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
80024270|NCT05625191|Diagnostic Test|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
80024271|NCT05625191|Diagnostic Test|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
80024272|NCT05624879|Behavioral|Accelerated Resolution Therapy|A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.
80024273|NCT05624879|Other|Information and Support|4 sessions of a standardized social work intervention. Standard of care including education and active listening.
80024274|NCT05624281|Drug|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
79569209|NCT01763424|Drug|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
79267810|NCT05394844|Device|Dexcom G6|Dexcom G6 CGM device
79267811|NCT05391893|Drug|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
79267812|NCT05391893|Drug|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
79569210|NCT01763424|Drug|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
79569211|NCT01764555|Drug|acetaminophen 2 g|
79569212|NCT01764568|Behavioral|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz & Woodward 2007a; Moritz & Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
79729319|NCT05329636|Other|FMT- enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
79729320|NCT04264858|Drug|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
79729321|NCT04264858|Drug|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
79729322|NCT04178473|Procedure|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
79863866|NCT01043224|Drug|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
79863867|NCT01044238|Drug|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
79863868|NCT01044238|Drug|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
80024275|NCT05607017|Drug|Losartan|Taken Orally
80024276|NCT05607017|Radiation|Radiation Therapy|Photon Radiation Therapy
80024277|NCT05585840|Device|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
80024278|NCT05582889|Behavioral|Fitbit Intervention|Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
79729323|NCT04178473|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
79729324|NCT00976911|Drug|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
79729325|NCT00976911|Drug|liposomal doxorubicin|40mg/m2 iv every 4 weeks
79729326|NCT00976911|Drug|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
79729327|NCT00976911|Drug|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
79863869|NCT01043380|Drug|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
79267813|NCT05384132|Other|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
79729328|NCT04177927|Device|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
80024279|NCT05581498|Behavioral|Exercise, Bike exercise and muscle strength exercise.|"Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks."
79569213|NCT01764568|Behavioral|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
80024280|NCT05578612|Procedure|Dorsal Spanning Bridge Plate Fixation|Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.
79400756|NCT05734313|Behavioral|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
79400757|NCT05734313|Device|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
79400758|NCT05733507|Procedure|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
79400759|NCT05733507|Procedure|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
79400760|NCT05728736|Drug|Lemborexant 25 mg|Lemborexant 25mg will be taken nightly for two consecutive nights.
79400761|NCT05728736|Drug|Placebo|Placebo will be taken nightly for two consecutive nights
79569214|NCT01764581|Procedure|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
79569215|NCT01764594|Biological|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
79729329|NCT04177927|Device|Rutine monitoring|peripheric Oxygen saturation is monitored.
79729330|NCT05336968|Drug|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
79400762|NCT05720312|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
79569216|NCT01764594|Other|Placebo|Placebo comparator
79729331|NCT04178161|Device|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
79729332|NCT02674555|Drug|radio-labeled naquotinib|Oral administration
79729333|NCT02674555|Drug|naquotinib|Oral administration
79729334|NCT00934648|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
79729335|NCT00934648|Drug|methotrexate|10-25mg weekly
79863870|NCT01043380|Drug|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
79863871|NCT01044316|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
80024281|NCT05578612|Procedure|Dorsal Spanning Bridge Plate Removal|Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
80024282|NCT05556265|Drug|Deucravacitinib|Specified dose on specified days
80024283|NCT05556265|Other|Placebo|Specified dose on specified days
79863872|NCT01044394|Drug|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
79863873|NCT01040104|Other|Skin sample|Taken from regularly discarded tissue during routine operation
79267814|NCT05384132|Other|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
79267815|NCT05381766|Other|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
80024284|NCT05545306|Dietary Supplement|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
79400763|NCT05718687|Drug|GBT021601|Single oral dose of 200 mg GBT021601, containing ~74 kBq (~2 µCi) of [14C]-GBT021601
79400764|NCT05708014|Behavioral|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
79400765|NCT05708014|Behavioral|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
79400766|NCT05706701|Other|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
79569217|NCT01764620|Other|Elastic taping applied with tension|
80024285|NCT05545306|Dietary Supplement|fasting|Fasting for at least 24 hours
80024286|NCT05545306|Dietary Supplement|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
79400767|NCT05706701|Other|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
79400768|NCT05706701|Other|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
79400769|NCT05706701|Other|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
79569218|NCT01764620|Other|Elastic taping applied without tension|
79569219|NCT01764620|Other|Fatigue protocol|
79569220|NCT01764646|Radiation|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
79569221|NCT01764646|Radiation|Volumetric modulated arc therapy|Highly conformational dose distribution
79569222|NCT01764646|Radiation|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
79569223|NCT01764672|Drug|Methylphenidate|Oral dose 40mg (2 x 20mg)
79569224|NCT01764672|Other|Placebo|Oral intake of 2 placebo tablets
79729336|NCT00643903|Behavioral|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
80024287|NCT05545306|Dietary Supplement|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
79729337|NCT00643903|Behavioral|Standard care|Participants will receive standard of care for HIV infections.
79729338|NCT00643903|Behavioral|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
79729339|NCT04178083|Diagnostic Test|medical examination|medical examination
79863874|NCT01040104|Other|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
79863875|NCT01040104|Other|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
79863876|NCT01040104|Other|Blood taking|Blood taking on day 0
79863877|NCT01040104|Other|Blood taking|Blood taking on day 90
79863878|NCT01043458|Drug|ABT-126|ABT-126 Low Dose & ABT-126 High Dose
79863879|NCT01043458|Drug|Placebo for ABT-126|Matching Placebo for Arms 1 & 2
79863880|NCT00396136|Device|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
79863881|NCT00530894|Device|Edwards SAPIEN Transcatheter Heart Valve|
79863882|NCT00530894|Device|Surgical Valve Replacement|
79863883|NCT00530894|Other|medical management and/or balloon aortic valvuloplasty|
79863884|NCT00300898|Procedure|Nucleoplasty|
79863885|NCT00300898|Procedure|Percutaneous decompression|
79863886|NCT00300898|Procedure|Intervertebral electrothermal disc decompression (IDET)|
79863887|NCT00300898|Behavioral|Conservative treatment|
79863888|NCT03474094|Combination Product|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 & W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
79267816|NCT05373173|Behavioral|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
79267817|NCT05373082|Other|questionnaire completion|Questionnaire to be completed by patients
79267818|NCT05367336|Drug|Morphine|second group will be receiving morphine
79267819|NCT05367336|Drug|Fentanyl|third group receiving fentanyl
79863889|NCT03474094|Combination Product|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 & W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
79863890|NCT03474094|Combination Product|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 & W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
80024288|NCT05545306|Dietary Supplement|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
80024289|NCT05545306|Dietary Supplement|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
80024290|NCT05545306|Dietary Supplement|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
79267820|NCT05359133|Drug|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
79267821|NCT05359133|Drug|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
79267822|NCT05356637|Device|Werewolf Fastseal 6.0|bi-polar hemostatic wand
79267823|NCT05353595|Dietary Supplement|Insect protein|Insect protein concentrate retrieved from lesser mealworms.
79267824|NCT05353595|Behavioral|Running exercise|40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
79267825|NCT05351502|Drug|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
79267826|NCT05351502|Drug|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
79400770|NCT05706428|Device|NHFOV|The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
79400771|NCT05706428|Device|NCPAP|The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
79400772|NCT05705414|Drug|Valine|A medical food intended for use under medical supervision
79400773|NCT05705414|Drug|EEA|A medical food intended for use under medical supervision
79400774|NCT05694156|Other|Music-based cognitive training|8-week music-based cognitive training
79400775|NCT05689424|Drug|HDV-Insulin Lispro|The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
79400776|NCT05689021|Drug|Abiraterone Acetate/Niraparib|Given PO
79400777|NCT05689021|Procedure|Biospecimen Collection|Undergo blood specimen collection
79863891|NCT01004120|Dietary Supplement|Bimuno|5.5g daily intake
79863892|NCT01004120|Dietary Supplement|Maltodextrin|5.5g daily intake
79569225|NCT01764698|Behavioral|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
79569226|NCT01764698|Behavioral|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
79863893|NCT01043536|Radiation|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
79569227|NCT01764724|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
79267827|NCT05351502|Drug|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
79267828|NCT05351502|Drug|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
79569228|NCT01764737|Drug|VX15/2503|single dose intravenous administration
79569229|NCT01764737|Drug|Placebo|single dose intravenous administration
79569230|NCT01764750|Drug|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
79729340|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
79729341|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
79863894|NCT01043536|Drug|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
79267829|NCT05337423|Device|Photobiomodulation|Group 1 will receive 630 nm LED and group 2 will receive sham treatment twice a week in the palmo-plantar areas of the hands and feet (4 J/cm2) for 4 weeks.
79267830|NCT05337423|Other|Moisturizer|Both groups will receive moisturizer.
79267831|NCT05297461|Other|Medication review|Community pharmacy benchmarking guideline Pharmaceutical Services Division provides guidelines for medication review in community pharmacy settings in Malaysia
79267832|NCT05297305|Device|Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
79267833|NCT05297305|Device|Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
79267834|NCT05289024|Behavioral|Mindful Awareness in Body-Oriented Therapy|Up to 8 individually delivered clinical sessions
79267835|NCT05280223|Drug|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
79400778|NCT05689021|Procedure|Bone Scan|Undergo technetium-99m bone scan
79569231|NCT01764750|Drug|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
79400779|NCT05689021|Procedure|Computed Tomography|Undergo CT scan
79400780|NCT05689021|Procedure|Magnetic Resonance Imaging|Undergo MRI
79729342|NCT01175213|Biological|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
79863895|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
79863896|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
79863897|NCT01004198|Drug|Ringers Lactate solution|Ringers Lactate solution for Injection
79863898|NCT01004276|Other|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
79863899|NCT03742778|Behavioral|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
79863900|NCT03742778|Behavioral|Incentivizing exercise|Participants receive bonus incentives for exercising
79863901|NCT01004588|Dietary Supplement|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
79863902|NCT01004588|Dietary Supplement|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
80024291|NCT05544019|Drug|SGR-1505|SGR-1505 will be administered orally.
80024292|NCT05529316|Drug|Botensilimab|An anti-CTLA-4 monoclonal antibody
80024293|NCT05529316|Drug|Balstilimab|An anti-PD-1 monoclonal antibody
79267836|NCT05280223|Drug|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
79400781|NCT05689021|Drug|Prednisone|Given PO
79400782|NCT05687838|Other|Music|Music medicine
79569232|NCT01764776|Drug|LDE225|LDE225
79569233|NCT01764789|Other|questionnaire administration|Ancillary studies
79863903|NCT00056407|Drug|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
79569234|NCT01764789|Procedure|quality-of-life assessment|Patients will participate in a quality life assessment.
79569235|NCT01764789|Procedure|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
79267837|NCT05248503|Behavioral|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
79569236|NCT01764789|Behavioral|behavioral intervention|Participate in multi-component biobehavioral intervention
79569237|NCT01764789|Other|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
79569238|NCT01764789|Other|educational intervention|Participate in multi-component biobehavioral intervention
79569239|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in enhanced standard care
79729343|NCT02865837|Other|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
79729344|NCT00643981|Biological|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
79729345|NCT04287699|Other|labor dance|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
79729346|NCT00644449|Other|placebo|placebo
79729347|NCT00644449|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
79863904|NCT00056407|Drug|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
79267838|NCT05246254|Diagnostic Test|Frailty index scale|There are clinically common scales for assessing weakness and delirium.
79267839|NCT05238506|Drug|Intravenous lidocaine|Intraoperative intravenous lidocaine infusion.
79267840|NCT05238506|Drug|Normal saline infusion|Intraoperative intravenous normal saline infusion.
79267841|NCT05216991|Other|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
79267842|NCT05216991|Other|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
79267843|NCT05216796|Behavioral|Diet Intervention|Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
79267844|NCT05216328|Drug|Macrogol Only Product in Oral Dose Form|Information already included in arm/group description.
79267845|NCT05216328|Drug|Magnesium hydroxide 724mg|Information already included in arm/group description.
79309037|NCT05616117|Other|Intrauterine 10µg D-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
79569240|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in psychological intervention
79569241|NCT01764815|Device|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
79569242|NCT01764828|Drug|Refametinib (BAY86-9766)|
79729348|NCT00644449|Other|placebo|placebo
79569243|NCT01764828|Drug|Gemcitabine|
79569244|NCT01764867|Drug|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
79569245|NCT01764867|Drug|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
79569246|NCT01764867|Other|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
79729349|NCT00644449|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
79729350|NCT04287777|Drug|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
79863905|NCT00388726|Drug|E7389|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
79863906|NCT00388726|Drug|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
79863907|NCT01043614|Behavioral|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
79863908|NCT01043692|Other|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
79569247|NCT01764867|Other|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
79569248|NCT01764867|Drug|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569249|NCT01764867|Drug|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569250|NCT01764867|Drug|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79729351|NCT04287777|Drug|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
79569251|NCT01764867|Drug|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569252|NCT01764867|Drug|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569253|NCT01764867|Drug|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79729352|NCT04287777|Drug|Placebo|Topical administration of Placebo (ointment) TID during 7 days
79863909|NCT03957655|Biological|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
79863910|NCT01091233|Procedure|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
79863911|NCT02530723|Other|power training|Resistance training machines with CAM devices will be used for training.
79863912|NCT00387790|Drug|motexafin gadolinium|Given IV
79863913|NCT00387790|Radiation|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
79863914|NCT00073021|Drug|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
79863915|NCT00073021|Drug|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
80024294|NCT05527600|Diagnostic Test|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
79729353|NCT04180657|Genetic|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
79729354|NCT02676583|Procedure|Tonsillectomy|Closure or not closure of tonsil fossa
79863916|NCT01091311|Device|Blephasteam|Eye lid warming goggles
80024295|NCT05523726|Behavioral|pCBT-I|Telehealth coaching
79309038|NCT04802421|Procedure|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
79309039|NCT05615961|Dietary Supplement|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
79569254|NCT01764867|Drug|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569255|NCT01764867|Drug|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569256|NCT01764867|Drug|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79569257|NCT01764867|Drug|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79729355|NCT00642889|Drug|Safinamide|
79729356|NCT00642889|Drug|Safinamide|
79729357|NCT00642889|Drug|Placebo|
79729358|NCT00629655|Other|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
79729359|NCT03920163|Other|Enhanced Recovery Measures|Perioperative measures
79863917|NCT00407758|Drug|enzastaurin hydrochloride|
79863918|NCT01583725|Procedure|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
79863919|NCT01583725|Behavioral|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
79863920|NCT01094509|Behavioral|Tai Chi|Tai Chi classes and exercises
79863921|NCT01094509|Behavioral|Guided autobiography|Autobiographical writing in class and at home
79863922|NCT01094509|Behavioral|Qigong|Qigong classes and exercises (exploratory)
79863923|NCT01094509|Behavioral|Successful aging|Seminar series on the theme of successful aging
79863924|NCT01094509|Behavioral|Combination|Combination of Tai Chi exercises and autobiographical writing
79863925|NCT01094509|Behavioral|Comparison|No assigned behavioral activity (exploratory)
79863926|NCT01094587|Procedure|Gastroschisis closure with suture|
79863927|NCT01094587|Procedure|Gastroschisis closure without suture|
79863928|NCT01584115|Biological|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
79863929|NCT01584115|Biological|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
79863930|NCT01089673|Other|data collection|retrospective data collection
79863931|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
79863932|NCT00531752|Drug|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
80024296|NCT05521685|Procedure|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
80024297|NCT05514496|Drug|NX-019|NX-019 will be administered orally.
80024298|NCT05509166|Behavioral|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
79863933|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
79863934|NCT00395746|Drug|sulfonylurea|SU agent
79863935|NCT00395746|Drug|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
79863936|NCT00395746|Drug|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
79863937|NCT00994838|Other|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
79863938|NCT00055471|Drug|ZD4054 10 mg|1 x 10 mg oral tablets once daily
79863939|NCT00055471|Drug|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
79863940|NCT00055471|Drug|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
79863941|NCT01004900|Procedure|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
79863942|NCT01004900|Drug|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
79863943|NCT01583491|Procedure|autologous platlet rich fibrin|one dose immediate after surgery
79267846|NCT05214144|Other|PRO Instruments assessment questionnaire|"Patient Reported Outcome (PRO) questionnaire consisting of:~PRO-CTCAE (approximately 11 questions plus free text)~Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~PRO ECOG question (1 question)~EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)"
79863944|NCT01583491|Procedure|one side in control group|control group insert any things after surgery
79267847|NCT05214144|Other|Baseline Survey Clinician- reported (ClinRO) ECOG|Baseline Survey completed prior to initiation of chemotherapy
79569258|NCT01764867|Drug|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
79863945|NCT04001348|Device|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79267848|NCT05214144|Device|Fitbit|wearable device
79267849|NCT05214144|Other|"Hugo Health (Hugo)"|an electronic platform that aggregates real world EHR data with patient's wearable and PRO data
79267850|NCT05214144|Other|6 Minute Walk Test (6MWT)|A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
79267851|NCT05208099|Biological|Blood tests|"For patients, it will be performed:~a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study."
79309040|NCT05615961|Dietary Supplement|Placebo|Placebo Tablets
79309041|NCT02594163|Drug|Brentuximab Vedotin|
79309042|NCT02594163|Drug|Rituximab|
79569259|NCT01764880|Drug|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
79569260|NCT01764893|Other|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
79569261|NCT01764893|Other|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
79729360|NCT00974259|Device|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
79729361|NCT00974259|Device|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
80024299|NCT05509166|Behavioral|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
79309043|NCT02594163|Drug|Bendamustine|
79569262|NCT01764906|Device|Novosis|
79569263|NCT01764906|Procedure|Iliac crest bone graft|
79569264|NCT01764932|Procedure|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
79569265|NCT01764971|Other|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
79569266|NCT01764971|Other|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
79569267|NCT01764984|Device|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
79569268|NCT01765010|Drug|Calcitriol|
79569269|NCT01765010|Drug|Alfacalcidol|
79569270|NCT01765010|Drug|Cholecalciferol|
79569271|NCT01765010|Drug|Placebo|
79569272|NCT01765023|Drug|Period I : atorvastatin, Period II : atorvastatin and metformin|
79729362|NCT04177615|Procedure|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
79729363|NCT00927082|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
79729364|NCT02672137|Behavioral|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
79729365|NCT02864511|Procedure|Nefertiti lift|
79729366|NCT04287933|Device|Drain insertion|insertion of a drain
79729367|NCT02674243|Drug|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
79729368|NCT02674243|Drug|Talc|In this group, Talc will be used as pleurodesis substance
79400784|NCT05673629|Drug|Utidelone Injection in combination with AC|"The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
79569273|NCT01765023|Drug|Period I : metformin, Period II : atorvastatin and metformin|
79569274|NCT01765036|Drug|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
79569275|NCT01765088|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
79729369|NCT04256200|Drug|Dienogest 2 MG Oral Tablet|Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
79729370|NCT04256200|Drug|Yasmin|0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
79729371|NCT05294029|Other|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
79863946|NCT04001348|Device|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79569276|NCT01765088|Drug|α-IFN|3mIU (3million) D1，3，5
79569277|NCT01765101|Other|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
79569278|NCT01765101|Other|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
79569279|NCT01765114|Drug|PEG-Formulation|
79729372|NCT04265014|Other|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
79729373|NCT04265014|Other|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
79729374|NCT02674009|Drug|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
79729375|NCT00976677|Drug|erlotinib hydrochloride|Given PO
79729376|NCT00976677|Drug|paclitaxel|Given IV
79729377|NCT00976677|Drug|carboplatin|Given IV
79729378|NCT00976677|Biological|bevacizumab|Given IV
79729379|NCT05329480|Dietary Supplement|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
79729380|NCT05329480|Dietary Supplement|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
79729381|NCT04179331|Other|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
79729382|NCT04179331|Other|Saline|Isotonic saline will serve as a placebo.
79729383|NCT02676271|Procedure|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
79729384|NCT02674165|Behavioral|HART|Skills based sexual education intervention plus PTSD awareness
79729385|NCT04288167|Diagnostic Test|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
79863947|NCT04001348|Device|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79729386|NCT00642967|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
79863948|NCT04001348|Device|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863949|NCT04001348|Device|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863950|NCT04001348|Device|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
80024300|NCT05503875|Biological|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
80024301|NCT05493215|Drug|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
79569280|NCT01765166|Behavioral|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
79569281|NCT01765205|Device|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
80024302|NCT05492682|Drug|PeptiCRAd-1|All patients will receive 6 doses of PeptiCRAd-1.
79569282|NCT01765231|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
79569283|NCT01765231|Drug|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
80024303|NCT05492682|Drug|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
80024304|NCT05492682|Drug|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
80024305|NCT05490329|Behavioral|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
79569284|NCT01765244|Drug|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
79569285|NCT01765244|Other|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
79569286|NCT01765257|Drug|AZILECT®|
79569287|NCT01765257|Drug|Placebo|
79569288|NCT01765283|Biological|HepaStem|
79569289|NCT01765309|Procedure|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
79729387|NCT00926536|Device|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
79729388|NCT00926536|Device|DSA only|DSA imaging only
79729389|NCT02864043|Device|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
79729390|NCT02864043|Procedure|esophagogastroduodenoscopy (EGD)|Standard of care EGD
80024306|NCT05488847|Drug|Celecoxib|preoperative pain medication given to all patients
79729391|NCT04287231|Device|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
80024307|NCT05488847|Drug|Pregabalin|preoperative and discharge pain medication given to all patients
80024308|NCT05488847|Drug|Tramadol|preoperative pain medication given to all patients
80024309|NCT05488847|Drug|Dexamethasone|Intraoperative and discharge pain medication given to all patients
80024310|NCT05488847|Drug|Acetaminophen|Intraoperative and discharge pain medication given to all patients
80024311|NCT05488847|Drug|Ropivicaine|Intraoperative pain medication given to all patients
80024312|NCT05488847|Drug|Epinephrine|Intraoperative pain medication given to all patients
80024313|NCT05488847|Drug|Ketorolac|Intraoperative pain medication given to all patients
80024314|NCT05488847|Drug|Tizanidine|Discharge pain medication given to all patients
80024315|NCT05488847|Drug|Magnesium|Discharge pain medication given to all patients
79569290|NCT01765322|Device|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
79569291|NCT01765335|Device|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
79569292|NCT01765348|Behavioral|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
80024316|NCT05488847|Drug|Ibuprofen|Discharge pain medication given to all patients
79729392|NCT00607360|Behavioral|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
80024317|NCT05488847|Drug|Oxycodone Hydrochloride 5 Mg|Only given to active comparator group
79400785|NCT05673629|Drug|Docetaxel Injection in combination with AC|"The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
80024318|NCT05485662|Other|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
80024319|NCT05485662|Other|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
80024320|NCT05483400|Drug|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
79569293|NCT01765348|Behavioral|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
79569294|NCT01765374|Device|ESAOTE MyLab60|US evaluation at different time points
79569295|NCT01765374|Drug|Rituximab|
79569296|NCT01765387|Behavioral|Spa session|
79569297|NCT01765413|Biological|Varicella-zoster virus|
79863951|NCT04001348|Device|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863952|NCT04001348|Device|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863953|NCT04001348|Device|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863954|NCT04001348|Device|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863955|NCT04001348|Device|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
80024321|NCT05456880|Biological|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
80024322|NCT05446376|Drug|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
80024323|NCT05437510|Biological|Nirsevimab|Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
79569298|NCT01765413|Biological|Yellow Fever Vaccine|
79569299|NCT01765413|Biological|Placebo|
79569300|NCT01765452|Drug|Closone|75mg/100mg, 8weeks, PO
79569301|NCT01765452|Drug|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
79729393|NCT02865993|Other|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
79729394|NCT02865993|Other|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
80024324|NCT05435664|Behavioral|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
80024325|NCT05432284|Drug|Placebo|Placebo (ambient air)
80024326|NCT05432284|Drug|THC|Pure THC vapor
80024327|NCT05432284|Drug|Beta-Myrcene|Pure beta-myrcene vapor
79569302|NCT01765478|Drug|HM71224 single ascending dose|
79569303|NCT01765478|Drug|HM71224 food effect|
79569304|NCT01765478|Drug|HM71224 Multiple ascending dose|
79569305|NCT01765517|Dietary Supplement|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
79569306|NCT01765517|Dietary Supplement|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
79569307|NCT01765556|Drug|ketoconazole|multiple doses of ketoconazole in Period B and C
79569308|NCT01765556|Drug|vemurafenib|single dose of vemurafenib in Period A and C
79569309|NCT01765595|Other|DDI+|
79729395|NCT02865759|Behavioral|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
79863956|NCT04001348|Device|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863957|NCT04001348|Device|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863958|NCT04001348|Device|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863959|NCT04001348|Device|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
80024328|NCT05430035|Drug|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
80024329|NCT05427695|Drug|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
79267852|NCT05208099|Procedure|exeresis|"For patients, it will be performed:~- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue."
79267853|NCT05208099|Procedure|abdominoplasty|"For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~four in the center,~two in the margin"
79267854|NCT05207982|Behavioral|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
79400786|NCT05673590|Drug|Utidelone Injection|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities."
79400787|NCT05673590|Drug|Docetaxel Injection|"Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs."
79400788|NCT05669924|Drug|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
79400789|NCT05669924|Drug|Placebo|Placebo for methylphenidate
79569310|NCT01765608|Drug|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
79569311|NCT01765608|Drug|Placebo|
79863960|NCT04001348|Device|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
79863961|NCT03956251|Procedure|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
79863962|NCT03956251|Procedure|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
79569312|NCT01765608|Device|nCPAP|
79569313|NCT01765621|Other|DDI+ System and Pharmacogenetic Data|
79569314|NCT01765634|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) each week, four times for a cycle.
79569315|NCT01765634|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
79863963|NCT00395512|Drug|Alogliptin|Alogliptin tablets.
79863964|NCT00395512|Drug|Pioglitazone|Pioglitazone tablets.
79863965|NCT00395512|Drug|Placebo|Matching placebo tablets.
79863966|NCT03956017|Drug|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
79569316|NCT01765660|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
79863967|NCT03956017|Drug|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
79863968|NCT00994916|Drug|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
79267855|NCT05203302|Other|Single-Electrode Pulse Train|AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.
79267856|NCT05203302|Other|Modulation Detection Threshold (MDT) and Gap Detection Tasks|AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
79267857|NCT05203302|Other|Sound coding strategy.|Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL
79267858|NCT05203302|Other|Electric-only spectral resolution|Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
79400790|NCT05662124|Other|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
79569317|NCT01765660|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
79863969|NCT01005212|Drug|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
79569318|NCT01765686|Device|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
79569319|NCT01765686|Device|Ligasure Small Jaw (Covidien, USA)|
79569320|NCT01765699|Device|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
79569321|NCT01765725|Behavioral|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
79863970|NCT00999440|Drug|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
79863971|NCT00054691|Drug|Iressa|250 mg by mouth daily
79863972|NCT02530879|Drug|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
79863973|NCT02530879|Behavioral|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
79863974|NCT02530879|Other|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
79863975|NCT03957499|Drug|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
79863976|NCT03957499|Drug|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
79569322|NCT01765738|Device|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
79569323|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing every 2 weeks~Intravenous injection"
79569324|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing weekly~Intravenous injection"
79863977|NCT03957499|Drug|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
79863978|NCT00387712|Other|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
79863979|NCT00387712|Other|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
79267859|NCT05190913|Other|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
79267860|NCT05190913|Other|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
79267861|NCT05190679|Other|None/Observational Studies|This is an observational study and there is no intervention.
79569325|NCT01765816|Behavioral|high intensity interval training|
79569326|NCT01765816|Behavioral|moderate intensity training|
79863980|NCT01091389|Procedure|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
79863981|NCT01040338|Drug|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
79863982|NCT01089829|Other|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
79863983|NCT01091545|Radiation|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
79863984|NCT03955939|Drug|LY3295668 Erbumine|Administered orally.
79863985|NCT03955939|Drug|Endocrine therapy|Administered according to label instructions.
79863986|NCT03955939|Drug|Midazolam|Administered orally.
79863987|NCT01094665|Procedure|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
79863988|NCT01091623|Other|training|
79267862|NCT05177991|Drug|Liposomal Bupivacaine|20cc of Liposomal Bupivacaine for TAP block
79267863|NCT05177991|Drug|Bupivacaine|20cc of Bupivacaine for TAP block
79267864|NCT05168319|Device|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
79267865|NCT05168319|Device|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
79267866|NCT05168319|Device|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
79267867|NCT05161000|Other|Oral Nutritional Supplement|ONS plus dietary counseling
79267868|NCT05161000|Other|Dietary counseling|dietary counseling
79267869|NCT05141877|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
79267870|NCT05141877|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
79267871|NCT05128578|Behavioral|Liver Education About Pain (LEAP)|LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
79267872|NCT05128578|Behavioral|Usual Care|"Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
79569327|NCT01765829|Drug|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
79267873|NCT05120622|Drug|Tremelimumab|"Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy."
79267874|NCT05112120|Drug|Olumiant|Olumiant (4mg) will be administered in line with standard of care guidance.
79267875|NCT05100147|Procedure|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
79569328|NCT01765829|Drug|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
79569329|NCT01765842|Biological|Rituximab|Only one cycle of rituximab will be administered in this arm.
79569330|NCT01765881|Drug|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
79569331|NCT01765881|Drug|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
79569332|NCT01765894|Other|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
79569333|NCT01765907|Device|HIFU|
79569334|NCT01765933|Dietary Supplement|DMAA|no placebo
79569335|NCT01765946|Drug|Metformin|Metformin tablets 500 mg tris in die (tid)
79569336|NCT01765946|Drug|placebo|
79863989|NCT01091623|Other|training|
79863990|NCT01091623|Other|training|
79863991|NCT01094821|Drug|ATI-7505|3 mg three times daily for 9 days
79863992|NCT01094821|Drug|Placebo|Placebo capsule three times daily for 9 days
79863993|NCT01094821|Drug|ATI-7505|10 mg ATI-7505 three times daily for 9 days
79863994|NCT01094821|Drug|ATI-7505|20 mg ATI-7505 three times daily for 9 days
79863995|NCT00072475|Drug|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
79863996|NCT02530645|Behavioral|OnTrack|
79863997|NCT02530645|Behavioral|Treatment as Usual|
79863998|NCT02530645|Behavioral|Brief Motivational Interviewing|
79863999|NCT01094899|Radiation|Radiography|Radiography, microscanner, osteodensitometry
79864000|NCT01094899|Other|Urine and Blood sampling|mainly dosage of bones metabolism
79864001|NCT01094899|Other|Echography|body bones echography
79864002|NCT01091701|Biological|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
80024330|NCT05427695|Other|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
80024331|NCT05421169|Diagnostic Test|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
79569337|NCT01765959|Other|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
79569338|NCT01765959|Other|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
79569339|NCT01765985|Device|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
79864003|NCT01091701|Other|Plasmalyte-A|Single IV dose of Plasmalyte-A
79864004|NCT03960229|Other|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
79864005|NCT03960229|Other|Gradient-Density Centrifugation|sperm selection of IVF treatment
79267876|NCT05099666|Drug|Lurbinectedin|Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
79267877|NCT05099666|Drug|Doxorubicin|Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
79267878|NCT05092763|Behavioral|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
79864006|NCT00066469|Biological|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: < 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: < 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
79864007|NCT00066469|Drug|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
79864008|NCT00066469|Drug|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
80024332|NCT05408832|Behavioral|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
80024333|NCT05408832|Behavioral|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
80024334|NCT05408832|Behavioral|Stress Management Techniques with No Randomization Sequence (or order)|Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
80024335|NCT05406713|Drug|Pembrolizumab|400 mg intravenously
80024336|NCT05403853|Diagnostic Test|Venepuncture|Venous blood draw
80024337|NCT05403853|Diagnostic Test|Fingerstick|Capillary Blood Draw
80024338|NCT05400200|Diagnostic Test|questionnary administration|questionary
79864009|NCT00066469|Drug|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
79864010|NCT01094977|Drug|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
79864011|NCT01094977|Drug|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
80024339|NCT05395299|Procedure|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
80024340|NCT05383170|Drug|CyPep-1|Intratumoral injection
80024341|NCT05383170|Drug|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
80024342|NCT05382520|Diagnostic Test|Questionares and practice|Questionares and practice
79864012|NCT01094977|Drug|Saline Placebo|
79864013|NCT01095055|Biological|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly
79864014|NCT01095055|Biological|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly
79864015|NCT01095133|Drug|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
79864016|NCT01095133|Drug|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
79864017|NCT01092013|Behavioral|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
79864018|NCT01092013|Behavioral|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
79864019|NCT01092013|Behavioral|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
79267879|NCT05092763|Behavioral|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
79267880|NCT05090124|Drug|Adalimumab|Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
79267881|NCT05090124|Drug|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
79267882|NCT05086263|Device|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
79267883|NCT05085730|Device|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
79267884|NCT05084716|Behavioral|Enhanced PrEP provision|The intervention will train health care providers to facilitate workshops at outreach events where attendees can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter. Check-in reminder calls will be conducted systematically with PrEP users.
79267885|NCT05069961|Procedure|ESPB|Ropivacaine is injected near the nerves in the back
79267886|NCT05069961|Procedure|TEA|Bupivacaine is injected into the space around the spinal cord.
79267887|NCT05056038|Procedure|Lateral Quadratus Lumborum block|Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
79400791|NCT05656573|Drug|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~cohort 1： CART-PSMA cells 1-3x10^7 on Day 0;~cohort 2： CART-PSMA cells 1-3x10^8 on Day 0;~cohort 3： CART-PSMA cells 1-3x10^7 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days;~cohort 4： CART-PSMA cells 1-3x10^8 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days;~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation)."
79400792|NCT05653700|Behavioral|Arena Strive|This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience.
79400793|NCT05653700|Device|WHOOP Sensor|The WHOOP sensor collects data on heart rate (HR), heart rate variability (HRV), and sleep data
79400794|NCT05653700|Behavioral|Survey|survey at baseline and end of the study
79864020|NCT00387088|Device|Respimat|
79864021|NCT00387088|Drug|Tiotropium|
79864022|NCT01095211|Drug|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
80024343|NCT05378100|Drug|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
80024344|NCT05378100|Drug|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
80024345|NCT05351593|Drug|Tafasitamab|Given IV
80024346|NCT05351593|Drug|Lenalidomide|Given Orally
80024347|NCT05350150|Device|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
80024348|NCT05337137|Drug|Relatlimab|Specified dose on specified days
80024349|NCT05337137|Drug|Nivolumab|Specified dose on specified days
80024350|NCT05337137|Drug|Bevacizumab|Specified dose on specified days
80024351|NCT05337137|Other|Placebo|Specified dose on specified days
80024352|NCT05334004|Drug|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
80024353|NCT05307094|Behavioral|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
79729396|NCT00923260|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
79864023|NCT01089985|Drug|Autologous serum eyedrops|3 times a day for the duration of the study
79569340|NCT01765985|Device|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
79569341|NCT01765998|Drug|Probiotic|Clinical evaluation according to the Crohn's activity scale
79569342|NCT01765998|Drug|Placebo|
79569343|NCT01766011|Other|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
79569344|NCT01766063|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
79729397|NCT00923260|Procedure|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
79729398|NCT04180735|Procedure|Liver transplantation|Liver transplantation
79729399|NCT04256278|Other|Spermotrend|oral administration of antioxidants for three months
79729400|NCT04287543|Drug|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
79729401|NCT04287543|Drug|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
79864024|NCT00053365|Drug|irofulven|Given IV
79864025|NCT00387010|Drug|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
80024354|NCT05304442|Drug|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
79267888|NCT05056038|Procedure|Posterior Quadratus Lumborum Block|In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
79267889|NCT05055011|Other|Electronic Health Record Review|Review of medical records
79400795|NCT05650736|Drug|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
79569345|NCT01766089|Drug|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
79569346|NCT01766089|Drug|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
79569347|NCT01766115|Drug|Telaprevir|HCV Protease Inhibitor
79569348|NCT01766141|Other|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
79569349|NCT01766154|Drug|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
79729402|NCT04100395|Device|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
79729403|NCT02676505|Behavioral|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
79864026|NCT01092091|Biological|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
79864027|NCT01092169|Other|No intervention|
79864028|NCT03960385|Biological|CYD-TDV|Dengue vaccine
79267890|NCT05055011|Other|Survey Administration|Complete survey
79569350|NCT01766167|Drug|MP-424|Low
79569351|NCT01766167|Drug|MP-424|Middle
79569352|NCT01766167|Drug|MP-424|High
79569353|NCT01766167|Drug|MP-424|Multiple
79569354|NCT01766180|Drug|Fruitflow-II|150 mg/day for 3 months, orally
79569355|NCT01766180|Drug|resVida|150 mg/day for 3 months, orally
79569356|NCT01766193|Procedure|vaginal delivery|
79569357|NCT01766193|Procedure|forceps extraction|vaginal delivery by forceps extraction
79569358|NCT01766193|Procedure|vacuum extraction|vaginal delivery by vacuum extraction
79569359|NCT01766193|Procedure|cesarean section|
79569360|NCT01766245|Drug|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
79267891|NCT05048862|Diagnostic Test|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
79267892|NCT05048862|Diagnostic Test|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
79729404|NCT02676505|Behavioral|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
79569361|NCT01766258|Drug|ODM-101 65mg Carbidopa|
79864029|NCT00386776|Other|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
79569362|NCT01766258|Drug|ODM-101 105mg Carbidopa|
79864030|NCT01092247|Other|Nutritional support with Standard diet|Nutritional support with Standard diet
79864031|NCT01092247|Other|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
79864032|NCT00065065|Drug|Rosiglitazone|4mg orally twice daily for 12 weeks
79864033|NCT00065065|Drug|Placebo|pill that looks identical to rosiglitazone
79864034|NCT00386308|Drug|Tranexamic acid tablets|3900 mg/Day
79864035|NCT00386308|Drug|Placebo tablets|
79864036|NCT00064987|Procedure|Testicular biopsy|Outpatient surgical procedure.
79864037|NCT00064987|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
79864038|NCT00064987|Drug|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
79864039|NCT00374452|Other|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
79267893|NCT05048862|Diagnostic Test|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
79569363|NCT01766258|Drug|Stalevo|
79569364|NCT01766271|Behavioral|Health Coaching|biweekly health coaching for 5 months
79569365|NCT01766271|Genetic|9p21|Genetic testing results of 9p21
79569366|NCT01766271|Other|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
79729405|NCT04287387|Drug|Glucophage 500Mg Tablet|0.5g three times daily
79729406|NCT04287387|Drug|Acarbose Tablets|50mg three times daily
79729407|NCT04287387|Drug|Sitagliptin tablet|100mg once daily
79569367|NCT01766284|Device|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
79569368|NCT01766323|Drug|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
79864040|NCT00374452|Other|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
79864041|NCT00064753|Drug|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
79569369|NCT01766323|Drug|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
79864042|NCT00064753|Device|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
79864043|NCT00374140|Drug|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
79309044|NCT04801875|Other|Selected Exercise|The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
79569370|NCT01766349|Behavioral|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
79569371|NCT01766362|Procedure|PRPC using Pascal laser|
79729408|NCT04287387|Drug|Dapagliflozin Tablet|10mg once daily
79729409|NCT04287387|Drug|Pioglitazone Tablets|30mg once daily
79729410|NCT04287387|Drug|Glimepiride Tablets|2mg once daily
79729411|NCT00644527|Other|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
79729412|NCT00644527|Other|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
79729413|NCT04287153|Device|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
79400796|NCT05646706|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
79729414|NCT00644605|Drug|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
79729415|NCT00644605|Drug|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
79729416|NCT00644605|Drug|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
79569372|NCT01766375|Drug|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
79569373|NCT01766414|Drug|C1-esterase inhibitor|intravenously
79569374|NCT01766414|Drug|Endotoxin|intravenously
79729417|NCT00644605|Drug|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
79729418|NCT02865681|Drug|Menopur|Nasal versus injectable
79729419|NCT02865681|Drug|Synarel|nasal
79864044|NCT00665561|Drug|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
79864045|NCT00665561|Drug|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
79864046|NCT03955705|Drug|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
79864047|NCT03955705|Drug|Normal saline|0.9% Sodium chloride (normal saline or NSS)
79864048|NCT03154138|Device|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
80024355|NCT05304442|Drug|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
79400797|NCT05646706|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
79400798|NCT05646706|Drug|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
79569375|NCT01766453|Behavioral|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
79729420|NCT02865681|Drug|HCG trigger|injectable
80024356|NCT05302375|Other|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
80024357|NCT05297825|Behavioral|Vegan diet|Healthy vegan diet.
80024358|NCT05297825|Behavioral|Omnivore diet|Healthy omnivore diet.
79729421|NCT02865681|Drug|Clomiphene citrate|oral
79729422|NCT02865681|Drug|Letrozole|Oral
79729423|NCT04287309|Other|CAR-T cells|CD19 targeted CAR-T treatment
79729424|NCT00644137|Drug|pregabalin|Help stop smoking
79400799|NCT05639413|Other|Collection of blood samples|A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
79729425|NCT00644137|Other|cigarettes|help stop smoking with study medication
79729426|NCT04286997|Device|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
79729427|NCT02672059|Other|Observation|No intervention
80024359|NCT05291091|Drug|EDG-5506 10 mg|EDG-5506 is administered orally once per day
79400800|NCT05636618|Drug|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of [212Pb]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
79569376|NCT01766453|Behavioral|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
79569377|NCT01766479|Radiation|CT colonography|
79569378|NCT01766518|Drug|Mycophenolate mofetil|MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
79569379|NCT01766531|Device|body bioelectrical impedance|
79729428|NCT04256356|Dietary Supplement|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
79267894|NCT05048862|Diagnostic Test|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
79267895|NCT05048862|Diagnostic Test|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
79267896|NCT05048862|Diagnostic Test|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
79400801|NCT05636618|Drug|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of [212Pb]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
79569380|NCT01766544|Other|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
79267897|NCT05048862|Diagnostic Test|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS & Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics & Protein Function Core Lab in National Taiwan University.
79267898|NCT05048862|Diagnostic Test|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
79569381|NCT01766544|Other|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
79267899|NCT05048862|Diagnostic Test|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
79729429|NCT04256356|Dietary Supplement|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
79729430|NCT04256356|Other|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
79729431|NCT04256356|Other|Breastfeeding infants|reference group
79729432|NCT02864121|Other|all patients included in IDAHO study|
79729433|NCT04177537|Device|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
79729434|NCT00934102|Device|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
79729435|NCT00934102|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
79400802|NCT05630300|Diagnostic Test|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
79729436|NCT00934102|Device|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
79729437|NCT05587153|Other|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
79729438|NCT03760419|Behavioral|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
79729439|NCT00910195|Device|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
79729440|NCT00910195|Device|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
80024360|NCT05291091|Drug|EDG-5506 5 mg|EDG-5506 is administered orally once per day
80024361|NCT05291091|Drug|EDG-5506 12.5 mg|EDG-5506 is administered orally once per day
80024362|NCT05291091|Drug|Placebo|Placebo is administered orally once per day
80024363|NCT05286112|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
80024364|NCT05286112|Behavioral|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
80024365|NCT05282550|Drug|Trazodone|50mg of trazodone administered for 4 weeks.
79569382|NCT01766557|Other|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
79729441|NCT04285905|Other|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
79729442|NCT04285905|Other|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
79729443|NCT04285905|Other|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
79729444|NCT04285905|Other|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
79729445|NCT04285905|Other|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
79864049|NCT03154138|Device|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
79864050|NCT01090219|Procedure|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
80024366|NCT05282550|Drug|Placebo|Placebo administered for 4 weeks.
80024367|NCT05272878|Drug|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
79267900|NCT05048862|Diagnostic Test|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at >32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
79267901|NCT05048862|Diagnostic Test|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
79267902|NCT05048862|Diagnostic Test|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
79729446|NCT04203784|Other|Plasma concentration measurements|Plasma concentration measurements
79267903|NCT05036577|Drug|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
79729447|NCT02671825|Drug|PUR0200|PUR0200 dry powder inhalation
79729448|NCT02671825|Drug|Reference Product|Dry Powder Inhalation Reference Product
80024368|NCT05272878|Drug|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
80024369|NCT05268562|Drug|Ketamine|1-2 mg/kg induction with additional medication administered as needed to achieve intubating conditions
80024370|NCT05268562|Drug|Propofol|0.5-1 mg/kg induction with additional medication administered as needed to achieve intubating conditions
80024371|NCT05256199|Behavioral|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
80024372|NCT05252832|Procedure|Superficial Cervical Plexus Block|Location of injection for block.
79267904|NCT05036577|Drug|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
79569383|NCT01766557|Other|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
79569384|NCT01766570|Other|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
79569385|NCT01766570|Other|Placebo|
79569386|NCT01766583|Drug|CC-292 + lenalidomide|CC-292 + lenalidomide
79569387|NCT01766596|Procedure|Optical Coherence Tomography|
79729449|NCT04256122|Other|No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.|evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
79729450|NCT04176367|Drug|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
79729451|NCT04176367|Drug|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
79729452|NCT04259476|Drug|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
79729453|NCT04177147|Other|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
79729454|NCT04255732|Device|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
79729455|NCT04255732|Device|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
79729456|NCT04177459|Behavioral|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
79729457|NCT04177459|Other|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
79729458|NCT00970281|Drug|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
79729459|NCT00970281|Drug|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
79729460|NCT00607438|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
80024373|NCT05252832|Procedure|Local Infiltrate|Local infiltration location.
80024374|NCT05242250|Device|Catheter Ablation|Ablation RF technologies manufactured by Abbott.
79267905|NCT05036577|Drug|Methotrexate (MTX)|high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
79267906|NCT05036577|Drug|Dexamethasone|Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
79267907|NCT05024097|Drug|Etrumadenant (AB928)|Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
79729461|NCT00607438|Drug|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
79729462|NCT00643045|Drug|Safinamide|
79729463|NCT00643045|Drug|Safinamide|
79729464|NCT00643045|Drug|Placebo|
79729465|NCT04203706|Other|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
79729466|NCT02670733|Procedure|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
80024375|NCT05239039|Drug|spesolimab|spesolimab
79267908|NCT05024097|Radiation|Radiation therapy|Patients will receive a radiation therapy dose of 25Gy in 5fx
79267909|NCT05024097|Drug|FOLFOX regimen|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
79569388|NCT01766609|Drug|Triamcinolone Acetonide|
79569389|NCT01766622|Drug|[18F]-CP18|7mCi, IV (in the vein) at baseline
79267910|NCT05024097|Drug|Zimberelimab (AB122)|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
79267911|NCT05017116|Drug|RBD1016|subcutaneous injection
79267912|NCT05017116|Drug|Placebo|subcutaneous injection
79729467|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
79267913|NCT05017116|Drug|Entecavir|Take orally.
79400803|NCT05630300|Diagnostic Test|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
79569390|NCT01766622|Procedure|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third [18F]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
79569391|NCT01766661|Procedure|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
79729468|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
79729469|NCT02676427|Procedure|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
79729470|NCT03747627|Diagnostic Test|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
79729471|NCT05275465|Drug|HH-006|Different dose levels of HH-006
79400804|NCT05629234|Drug|Osimertinib|Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
79729472|NCT05275465|Drug|Placebo|Different dose levels of placebo
79729473|NCT02862639|Device|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
79400805|NCT05624580|Drug|NNC0582-0001|Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.
79400806|NCT05624580|Drug|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
79400807|NCT05616676|Behavioral|Brief digital imagery-competing task|"First session guided by a researcher: A memory cue followed by playing a computer game with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session."
79569392|NCT01766661|Procedure|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
79569393|NCT01766661|Procedure|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
79729474|NCT02862639|Device|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
79729475|NCT04177069|Dietary Supplement|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
79729476|NCT03746301|Drug|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
79267914|NCT05015881|Dietary Supplement|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|Drink a single dose of ketone ester 1.9 kcal/kg
79569394|NCT01766674|Behavioral|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
79569395|NCT01766687|Dietary Supplement|Hydration|
79569396|NCT01766700|Behavioral|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
79569397|NCT01766700|Behavioral|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
79569398|NCT01766752|Device|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
79569399|NCT01766765|Procedure|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
79569400|NCT01766765|Other|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
79729477|NCT00925990|Drug|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
79267915|NCT05015881|Drug|FDG|Echocardiogram, and 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) PET scan.
79267916|NCT05002413|Diagnostic Test|Resistell AST|The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.
79400808|NCT05616676|Behavioral|Brief digital music-listening task|"First session guided by a researcher: Information about the composer's music followed by listening to classical music.~Option to engage in self-administered/guided sessions after the first session."
79400809|NCT05616676|Other|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events.
79729478|NCT00925990|Drug|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
79729479|NCT00925990|Drug|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
79729480|NCT02670655|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
79729481|NCT02670655|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
79729482|NCT02670655|Drug|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
79729483|NCT02670655|Device|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
79729484|NCT02670655|Device|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
79729485|NCT04176991|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
79729486|NCT04176991|Biological|Placebo|Placebo Comparator
79729487|NCT03744351|Other|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
79864051|NCT01090297|Device|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
79569401|NCT01766791|Other|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM
79569402|NCT01766791|Other|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - < 75 1RM
79569403|NCT01766791|Other|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM and Protein Supplementation
79569404|NCT01766791|Other|Control|control group, no intervention, maintenance of physical activity
79864052|NCT01090297|Device|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
79864053|NCT01090297|Device|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
79569405|NCT01766804|Dietary Supplement|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
79569406|NCT01766804|Dietary Supplement|placebo|
79569407|NCT01766830|Device|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
79569408|NCT01766830|Device|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
79569409|NCT01766830|Device|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
79729488|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
79729489|NCT03744351|Other|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
79729490|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
79729491|NCT01131078|Drug|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
79729492|NCT01131078|Drug|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m^2 twice daily (Day 2 to 15) or as 650 mg/m^2 twice daily on Days 1 to 21.
79729493|NCT01131078|Drug|Irinotecan|Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
79864054|NCT03955549|Behavioral|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
80024376|NCT05208125|Biological|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
80024377|NCT05208125|Other|Normal saline solution|Intramuscular administration of normal saline solution
80024378|NCT05201079|Biological|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
79569410|NCT01766830|Device|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
79569411|NCT01766830|Device|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
79569412|NCT01766830|Device|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
79400810|NCT05612945|Other|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
79729494|NCT03738501|Other|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
79864055|NCT03955549|Behavioral|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
79864056|NCT03955549|Drug|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
79267917|NCT04981392|Behavioral|Health System Vaccination Text Messages and Provider Education|"Patients: Eligible patients will receive a series of text messages from their PCP recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: will receive educational materials to support their conversations with patients about the COVID-19 vaccines."
79569413|NCT01766830|Device|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
79864057|NCT00786461|Procedure|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
79864058|NCT00786461|Procedure|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
79864059|NCT00786695|Drug|esomeprazole|esomeprazole (40 mg o d) for 14 days
79267918|NCT04979676|Behavioral|Cognitive Therapy|Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
79569414|NCT01766830|Device|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
79569415|NCT01766830|Device|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
79729495|NCT03738501|Other|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
79729496|NCT04180501|Combination Product|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
79864060|NCT00786695|Drug|Placebo|Identical looking Placebo, same regimen, for 14 days
80024379|NCT05201079|Drug|Dificlir|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
79267919|NCT04979676|Behavioral|Compassion-focused Therapy|Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
79267920|NCT04979676|Behavioral|Acceptance and Commitment Therapy|Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
79569416|NCT01766830|Device|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
79569417|NCT01766843|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
79569418|NCT01766843|Drug|Seretide Diskus|2 inhalations as a single dose
79569419|NCT01766843|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
79569420|NCT01766843|Drug|SF Easyhaler|2 inhalations as a single dose
79569421|NCT01766856|Other|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
79729497|NCT04286061|Other|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
79729498|NCT02670499|Device|CPM|Used to aid in recovery from TKR
79267921|NCT04965285|Behavioral|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
79267922|NCT04946396|Drug|dexmedetomidine intravenous infusion|Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
79267923|NCT04946396|Drug|0.9%sodium chloride|0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
79267924|NCT04932135|Diagnostic Test|Continuous heart rate monitoring|Continuous heart rate monitoring with a wrist worn fitnesstracker
79267925|NCT04910750|Device|Pulse oximetry|Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
79267926|NCT04910750|Device|Clinical Decision Support Algorithm|Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
79267927|NCT04905134|Device|Nasopharyngoscope|Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
79267928|NCT04903314|Drug|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
79729499|NCT02670499|Device|GAPFLEX|Used to aid in the recovery of TKR
79729500|NCT04180345|Other|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
79729501|NCT03709017|Drug|Ponatinib|Iclusig 45mg, 15mg
79729502|NCT02671903|Device|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
79267929|NCT04892875|Drug|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
79267930|NCT04892875|Drug|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
79569422|NCT01766882|Behavioral|Lower sodium intervention|"1. Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately >180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
79729503|NCT01167582|Biological|Red blood cell transfusion|Liberal versus restrictive transfusion
79729504|NCT03695445|Drug|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
79267931|NCT04892875|Drug|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
79267932|NCT04892875|Radiation|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
79267933|NCT04886596|Biological|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV_1 dose group.
79729505|NCT04204551|Behavioral|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 [rpm], but preferably at 80-90 [rpm] (fast phase of interval) and 2-minutes cycling at ≤ 60 [rpm] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, [bpm]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
79729506|NCT04204551|Behavioral|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
80024380|NCT05200247|Drug|spesolimab|solution for infusion
79267934|NCT04886596|Biological|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV_annual group.
79267935|NCT04881045|Biological|PF-07257876|CD47-PDL-1 bispecific antibody
79729507|NCT04177303|Drug|Metformin|Participants will be randomized to metformin 2000 mg
79267936|NCT04864665|Dietary Supplement|a formula with prebiotics and milk fat|Provided in a formula added with prebiotics and milk fat for 1 month
79267937|NCT04845685|Device|Continuous Glucose Monitor (CGM)|A device that measures blood sugar levels every 1-5 minutes
79267938|NCT04839380|Drug|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
79729508|NCT04177303|Drug|Placebo|Participants will be randomized to placebo
80024381|NCT05197621|Biological|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
79267939|NCT04836585|Other|eMBC Intervention|"The treating psychiatrist sets a flag in the patient's electronic chart that prompts them to complete self-report scales prior to each appointment:~Edinburgh Postnatal Depression Scale (EPDS) for symptoms of depression and anxiety~PROMIS Neuro-QOL and PROMIS ASCQ-Me Social Functioning Short form for measures of functional capacity~Adapted Frequency, Intensity, and Burden Side Effects Rating (FIBSER) Scale for participants taking antidepressant medication to measure side effects~Patient participants and providers can view the questionnaire results over time in the electronic chart item by item, and/or see them in graphical format. During the clinical encounter, the provider and patient participant review the results of the scales, as part of a collaborative re-evaluation of the treatment plan."
79729509|NCT04177225|Procedure|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
79569423|NCT01766882|Other|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
79569424|NCT01766895|Other|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
79569425|NCT01766908|Other|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
79569426|NCT01766947|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
79569427|NCT01766960|Other|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
79569428|NCT01766960|Drug|Morphine|Five milligrams of intravenous morphine will be administered.
79569429|NCT01767012|Device|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
79569430|NCT01767012|Device|Polylens EC-Y10-PAL (uncoated)|
79729510|NCT04177225|Other|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
79729511|NCT01167426|Drug|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
79729512|NCT01167426|Drug|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
79729513|NCT04091035|Other|To describe the incidence of disease and evaluate risk factors|Se above
79729514|NCT04204785|Behavioral|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
79729515|NCT04286919|Behavioral|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
79729516|NCT04090333|Other|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
79729517|NCT04089475|Device|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
79729518|NCT02862873|Procedure|Spinal anaesthesia|
79729519|NCT02862873|Drug|Ondansetron|
79267940|NCT04828980|Device|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
79569431|NCT01767025|Drug|Oxytocin|
79569432|NCT01767025|Drug|Sea water|
79569433|NCT01767038|Procedure|OCT Spectralis|
79569434|NCT01767038|Procedure|microperimetry|
79569435|NCT01767077|Dietary Supplement|Butter oil|Daily intake of 40 g butter oil
79569436|NCT01767077|Dietary Supplement|Cream|Daily intake of 100 g cream (40%)
79569437|NCT01767090|Drug|ASP1707|Oral
79569438|NCT01767090|Drug|Placebo|Oral
79569439|NCT01767090|Drug|Leuprorelin acetate|subcutaneous
79729520|NCT02862873|Other|saline solution|
79729521|NCT02671513|Drug|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
79569440|NCT01767168|Other|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
79569441|NCT01767181|Other|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
79569442|NCT01767181|Other|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
79569443|NCT01767207|Other|mental disorders|mental disorders
79569444|NCT01767207|Behavioral|screening for mental disorders|screening for mental disorders
79729522|NCT04266951|Behavioral|Singstrong:|Group singing and breathing control training
79729523|NCT02671669|Behavioral|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
79729524|NCT02671669|Behavioral|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
79864061|NCT00786851|Drug|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
79729525|NCT03814005|Drug|Azacitidine|Azacitidine subcutaneous or intravenous injection.
79729526|NCT03814005|Drug|Pevonedistat|Pevonedistat intravenous infusion.
79267941|NCT04828980|Device|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
79267942|NCT04828109|Device|Virtual Reality|Use of any virtual reality experiences available
79400811|NCT05612945|Other|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
79400812|NCT05610280|Drug|Olezarsen|Olezarsen will be administered by SC injection.
79569445|NCT01767220|Procedure|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
79729527|NCT03814005|Drug|Docetaxel|Docetaxel intravenous infusion.
79729528|NCT03814005|Drug|Paclitaxel|Paclitaxel intravenous infusion.
79729529|NCT03814005|Drug|Carboplatin|Carboplatin intravenous infusion.
79864062|NCT00786929|Procedure|Catheter drainage|
79729530|NCT02676115|Other|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
79267943|NCT04828109|Device|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
79267944|NCT04818866|Diagnostic Test|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
79267945|NCT04817826|Drug|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
79267946|NCT04817826|Drug|Tremelimumab|tremelimumab 300 mg single administration (day 1)
79267947|NCT04798248|Behavioral|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
79729531|NCT02676115|Other|Medipore Tape|"One layer of Medipore tape will be placed across the incision.~Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
79864063|NCT00786929|Drug|Conservative treatment|
79267948|NCT04798248|Behavioral|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to ~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
79267949|NCT04794842|Drug|Tetracaine 5% drops|same as information in the arm/group description
79864064|NCT00663923|Procedure|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
79864065|NCT00787007|Drug|S-equol|capsule, oral, single dose
79864066|NCT00787007|Drug|Placebo|capsule, oral, single dose
79267950|NCT04794842|Drug|Phenol 90% concentration|same as information in the arm/group description
79267951|NCT04794647|Other|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
79400813|NCT05610280|Drug|Placebo|Olezarsen-matching placebo will be administered by SC injection.
79400814|NCT05609344|Behavioral|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
79864067|NCT00787163|Procedure|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
79864068|NCT00791063|Other|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
79864069|NCT00784355|Procedure|Laparoscopic cholecystectomy|Surgery
79267952|NCT04794647|Other|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
79267953|NCT04788147|Device|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
79267954|NCT04786262|Biological|VX-880|Infused into the hepatic portal vein.
79267955|NCT04776694|Drug|Dupilumab|
79267956|NCT04773041|Procedure|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
79569446|NCT01767220|Procedure|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
79569447|NCT01767233|Procedure|ERCP and pancreatic stenting|
79569448|NCT01767246|Other|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
79569449|NCT01767246|Other|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
79569450|NCT01767259|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
79569451|NCT01767259|Drug|Valsartan|Valsartan alone
79569452|NCT01767259|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
79569453|NCT01767272|Drug|fexofenadine|fexofenadine brand name
79569454|NCT01767298|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
79864070|NCT00795119|Device|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
79864071|NCT00787397|Behavioral|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
79267957|NCT04770155|Dietary Supplement|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
79267958|NCT04770155|Dietary Supplement|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
79267959|NCT04770155|Drug|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
79267960|NCT04770155|Drug|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
79267961|NCT04757402|Other|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
79267962|NCT04754256|Behavioral|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients and for correlation of scores with lung function, CAT-score and other
79267963|NCT04753931|Other|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
79267964|NCT04753931|Other|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
79267965|NCT04753203|Drug|Alpelisib plus Capecitabine combination|Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
79569455|NCT01767298|Drug|Valsartan|Valsartan alone
79569456|NCT01767298|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
79569457|NCT01767324|Device|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
79569458|NCT01767324|Device|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
79569459|NCT01767324|Device|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
79569460|NCT01767337|Device|FLUGEN 101.2 device|
79569461|NCT01767350|Procedure|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
79569462|NCT01767363|Other|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
79569463|NCT01767363|Other|Alpha-blockers|Use of alpha-blockers over the study period.
79569464|NCT01767389|Other|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
79569465|NCT01767389|Other|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
79569466|NCT01767389|Other|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
79569467|NCT01767402|Biological|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
79569468|NCT01767402|Biological|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
79729532|NCT02863887|Behavioral|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
79729533|NCT05552131|Device|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
79569469|NCT01767402|Biological|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
79729534|NCT02668471|Procedure|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
79729535|NCT02668471|Procedure|traditional method|Radial artery catheters will be placed by the palpation technique only.
79267966|NCT04751955|Drug|Olinvacimab added to Capecitabine|Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
79267967|NCT04734080|Drug|Dronabinol 5mg Cap|Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
79729536|NCT02668549|Other|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
79729537|NCT04175353|Dietary Supplement|Dairy snack|The effects of dairy snack are compared with orange juice.
79729538|NCT04175353|Dietary Supplement|Berry snack|The effects of two berry snacks are compared with berry soup.
79729539|NCT04175743|Drug|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
79729540|NCT04016233|Drug|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
79864072|NCT00791141|Drug|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
79864073|NCT04046783|Device|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
79864074|NCT04046393|Device|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
79267968|NCT04734080|Other|Placebo oral tablet|Non-active placebo
79267969|NCT04731662|Behavioral|Short sleep|6-hours time-in-bed during weeknights
79267970|NCT04731662|Behavioral|Variable short sleep|Variable hours of time-in bed during weeknights
79864075|NCT04046393|Device|Meridian Energy Analysis Device(MEAD)|measure meridian energy
79400815|NCT05608681|Drug|EP-104IAR|Long-acting fluticasone propionate for injection
79569470|NCT01767428|Drug|Paracetamol|500 mg immediate release paracetamol formulations
79569471|NCT01767441|Procedure|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
79729541|NCT04175899|Other|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
79729542|NCT02671591|Behavioral|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
79864076|NCT04046393|Procedure|bacteria culture|use culture swab to culture nasal discharge
79864077|NCT04046393|Procedure|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
79864078|NCT04046393|Combination Product|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
79864079|NCT00386152|Drug|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
79569472|NCT01767441|Procedure|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
79267971|NCT04723186|Drug|MT1002 for Injection|MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
79729543|NCT02671591|Behavioral|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
79267972|NCT04709276|Drug|Nivolumab|360 mg intravenously every 3 weeks
79267973|NCT04709276|Drug|Ipilimumab|1 mg/kg intravenously every 6 weeks
79267974|NCT04709276|Drug|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
79400816|NCT05605756|Drug|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
79400817|NCT05593497|Drug|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
79267975|NCT04709276|Drug|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
79267976|NCT04706533|Diagnostic Test|Biomarkers of inflammation|Biomarkers were measured on blood samples collected within 48 hours of admission
79267977|NCT04696731|Genetic|ALLO-316|ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
79267978|NCT04696731|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
79569473|NCT01767441|Procedure|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
79267979|NCT04696731|Drug|Fludarabine|Chemotherapy for lymphodepletion
79267980|NCT04696731|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
79400818|NCT05593497|Drug|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
79400819|NCT05592145|Device|ViOptix|ViOptix machine
79569474|NCT01767441|Other|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
79569475|NCT01767454|Drug|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
79569476|NCT01767454|Drug|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
79569477|NCT01767454|Drug|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
79729544|NCT02671747|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
79729545|NCT04033471|Drug|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
79729546|NCT02670421|Behavioral|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
79729547|NCT02670421|Behavioral|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
79729548|NCT02670421|Behavioral|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
79729549|NCT02671279|Dietary Supplement|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
79729550|NCT02671201|Other|Education|Different methods in education of emergency ultrasound
79729551|NCT02668081|Procedure|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
79729552|NCT02668081|Procedure|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
79267981|NCT04681339|Other|Antibiotic treatment|Antibiotic treatment
79267982|NCT04681339|Other|No antibiotic treatment|No antibiotic treatment
79267983|NCT04645719|Other|Lactate ringer group|General anesthesia only
79267984|NCT04645719|Drug|Magnesium sulfate dose through real weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's real weight
79267985|NCT04645719|Drug|Magnesium sulfate dose through corrected ideal weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's corrected ideal weight
79729553|NCT00910351|Drug|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
79569478|NCT01767480|Device|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
79569479|NCT01767480|Behavioral|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
79267986|NCT04626882|Procedure|Staged in-hospital or Immediate complete revascularization|Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
79569480|NCT01767532|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
80024382|NCT05191446|Behavioral|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|"Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement."
80024383|NCT05191446|Other|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
80024384|NCT05174767|Device|AMDS|AMDS Implantation
80024385|NCT05161767|Diagnostic Test|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
80024386|NCT05156827|Drug|TB006|TB006 diluted in normal saline, administered through IV infusion over an hour
80024387|NCT05156827|Drug|Placebo|Normal saline administered through IV infusion over an hour
80024388|NCT05136651|Behavioral|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
80024389|NCT05129371|Other|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
80024390|NCT05129371|Other|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
80024391|NCT05124912|Procedure|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
79267987|NCT04621604|Other|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
79267988|NCT04601324|Drug|Fluticasone Propionate|Participants will be required to use fluticasone propionate nasal spray twice daily.
79729554|NCT02671357|Procedure|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
79729555|NCT04175665|Drug|Semaglutide|Prescription for semaglutide as part of usual clinical practice
79729556|NCT02671123|Procedure|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
79864080|NCT00386152|Drug|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
79267989|NCT04601324|Drug|Azelastine hydrochloride and fluticasone propionate|Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.
79267990|NCT04601324|Drug|Rupatadine|Rupatadine once daily for a total of 2 weeks.
79267991|NCT04596800|Other|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
79267992|NCT04596800|Other|Enhanced Recovery After Surgery|ERAS
79267993|NCT04576988|Biological|Sotatercept|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
79569481|NCT01767532|Drug|Cephalexin 125 mg/5ml|Test product 20 ml
79569482|NCT01767545|Drug|Dexamethasone implant|
79864081|NCT00787475|Other|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
79267994|NCT04576988|Drug|Placebo|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
79267995|NCT04576988|Drug|Background PAH Therapy|Background PAH therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5(PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
79267996|NCT04576871|Drug|225Ac-J591|In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial planned dose level will be determined based upon prior radioactivity exposure level. Those with moderate exposure (up to 30 GBq of 177Lu) will start with 65 KBq/Kg and those with heavy prior exposure (more than 30 Gbq of 177Lu or any 225Ac) will start with 50 KBq/Kg.
79267997|NCT04575935|Drug|Chemotherapy|Receive standard of care chemotherapy
79729557|NCT02671123|Procedure|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
79267998|NCT04575935|Procedure|Laparotomy|Undergo laparotomy
79729558|NCT04174729|Device|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
79267999|NCT04575935|Procedure|Minimally Invasive Surgery|Undergo MIS
79729559|NCT04174729|Device|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
79729560|NCT04174729|Device|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
79729561|NCT04174729|Device|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
79864082|NCT00787553|Drug|cefazolin|2.0 g, IV, 2 hours before surgery
79864083|NCT00787553|Drug|tinidazole|2.0 g orally, 12 hours before surgery
79864084|NCT00787553|Drug|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
79864085|NCT00795353|Drug|Amevive exposure|Commercial alefacept prescribed by Physician
80024392|NCT05124912|Drug|Steroid Therapy|Best medical management with steroid therapy
79268000|NCT04575935|Other|Quality-of-Life Assessment|Ancillary studies
79268001|NCT04575935|Other|Questionnaire Administration|Ancillary studies
79268002|NCT04570878|Procedure|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
79268003|NCT04570878|Procedure|Control|No regional block is provided at the end of surgery.
79400820|NCT05587842|Procedure|Early Weightbearing management post operation|Subjects will be instructed to be weightbearing, as tolerated, on their ankle starting at two weeks post operation.
79569483|NCT01767545|Drug|Bevacizumab|
79569484|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
79569485|NCT01767571|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
79569486|NCT01767571|Drug|Cephalexin 250mg/5ml|Test product 10 ml
79569487|NCT01767584|Drug|Cephalexin 1g tablets|Reference product
79729562|NCT04174729|Device|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
79729563|NCT04174729|Device|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
79864086|NCT00791297|Drug|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
79864087|NCT00385918|Device|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
79569488|NCT01767584|Drug|Cephalexin 1g tablets|Test product
79569489|NCT01767623|Drug|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
79569490|NCT01767649|Other|Caesarean|Collection of tissues and blood
79569491|NCT01767649|Other|Vaginal delivery|Collection of tissues and blood
79569492|NCT01767662|Procedure|manipulation|home programme
79569493|NCT01767662|Procedure|No intervention|observation
79569494|NCT01767714|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
79569495|NCT01767714|Drug|Plerixafor|0.24 mg/kg/day subcutaneous injection
79569496|NCT01767714|Drug|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
79569497|NCT01767727|Procedure|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
80024393|NCT05124912|Procedure|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
80024394|NCT05123001|Device|Biostrap arm band|The Biostrap mobile app will connect with the Biostrap arm band and temperature sensor.
80024395|NCT05114876|Other|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~Direct-to-Patient Education Program~Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~Reinforce CHASM best practices with regular educational sessions for nurses."
80024396|NCT05107674|Drug|NX-1607|Oral NX-1607
79268004|NCT04561739|Device|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size<2um."
79729564|NCT02670265|Dietary Supplement|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
79268005|NCT04561739|Device|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
79268006|NCT04550845|Behavioral|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
79268007|NCT04547439|Drug|Melatonin|Melatonin 3 mg will be taken nightly for 8 weeks
79268008|NCT04547439|Other|Placebo|Placebo will be given nightly for 8 weeks
79268009|NCT04519476|Drug|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
79569498|NCT01767740|Device|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
79729565|NCT02670265|Dietary Supplement|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
79268010|NCT04519476|Drug|Lenalidomide|Immunomodulatory drug
79268011|NCT04519476|Drug|Methylprednisolone|Glucocorticoid, steroid
79268012|NCT04508049|Device|qMT-MRI to detect fibrosis.|The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
79268013|NCT04498234|Procedure|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
79268014|NCT04471207|Device|Therapist Guided Prolonged Exposure with BioWare Device|"Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during in vivo exposures (IVEs) (galvanic skin response [GSR], heart rate [HR], and subjective units of distress [SUDS]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
79268015|NCT04471207|Device|Record Only Prolonged Exposure with BioWare Device|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
79400821|NCT05587842|Procedure|Delayed Weightbearing management post operation (Traditional)|Subjects will be instructed to be non-weightbearing on their ankle until at least 6 weeks. After 6 weeks, the subject will be instructed to be weightbearing as tolerated.
79569499|NCT01767740|Device|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
79268016|NCT04451707|Other|non-cholera Vibrio infection|Epidemiology of patients diagnosed with non-cholera Vibrio infection
79268017|NCT04446351|Drug|GSK6097608|GSK6097608 will be administered as an IV infusion.
79268018|NCT04446351|Drug|Dostarlimab|Dostarlimab will be administered as an IV infusion.
79268019|NCT04446351|Drug|Cobolimab|Cobolimab will be administered as an IV infusion.
79268020|NCT04446351|Drug|Belrestotug|Belrestotug will be administered as an IV infusion.
79268021|NCT04418232|Combination Product|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
79569500|NCT01767753|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
79569501|NCT01767766|Drug|TGR-1202|TGR-1202 Daily Oral Dose
79400822|NCT05586269|Behavioral|Meal Kit Delivery|Families receive 6 weeks of healthy meal kit delivery. Meal kits come with embedded nutrition education and access to online cooking demonstrations.
79569502|NCT01767805|Procedure|Standard incubator|
79569503|NCT01767805|Procedure|Mini incubator|
79569504|NCT01767805|Procedure|5% oxygen|
79569505|NCT01767805|Procedure|20% oxygen|
79729566|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
79729567|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 alone
79729568|NCT04175587|Drug|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
79729569|NCT02668159|Dietary Supplement|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
79729570|NCT02668159|Dietary Supplement|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
79729571|NCT02668159|Dietary Supplement|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
79729572|NCT02668159|Dietary Supplement|Placebo|7 tablets of placebos administered prior to one the OGTT
79729573|NCT02670109|Drug|Carmustine|300mg/m2, IV, in 3 hours, during day -4
79729574|NCT02670109|Drug|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
79729575|NCT02670109|Drug|Carboplatin|1400/m2, IV, in 1 hour, during day -3
79729576|NCT02670109|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
79268022|NCT04417725|Other|Not applicable - this is a non-interventional, observational study.|Not applicable - this is a non-interventional, observational study.
79569506|NCT01767831|Behavioral|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
79569507|NCT01767844|Dietary Supplement|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
79569508|NCT01767844|Dietary Supplement|Placebo|
79569509|NCT01767870|Procedure|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
79569510|NCT01767870|Procedure|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
79864088|NCT00385918|Other|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
79569511|NCT01767883|Other|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation~Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
79729577|NCT02670109|Drug|Busulfan|16mg/kg, Oral, during day -4
79729578|NCT02670187|Biological|GLS-5300|
79864089|NCT02554409|Biological|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
79729579|NCT00922636|Drug|LY2216684|Taken in tablet form QD po.
79864090|NCT00791375|Behavioral|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
79864091|NCT00385840|Biological|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
79864092|NCT00385840|Biological|FluarixTM|Single dose, intramuscular injection
79864093|NCT01045876|Drug|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
79864094|NCT01045876|Other|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
79864095|NCT01044550|Procedure|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
79864096|NCT01044550|Other|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
79268023|NCT04414787|Behavioral|PCplanner|PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
79268024|NCT04410224|Drug|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
79268025|NCT04405024|Diagnostic Test|Hepatitis C testing|Hepatitis C Screening
79400823|NCT05585775|Behavioral|Mindfulness-Based Cognitive Therapy|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
79569512|NCT01767883|Other|Clinical Decision Support Only|"CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms"
79864097|NCT00385762|Drug|paroxetine|paroxetine 10-40mg daily x 5 weeks
79569513|NCT01767896|Biological|ASP7374|subcutaneous (sc)
79864098|NCT00385684|Drug|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
80024397|NCT05107674|Drug|Paclitaxel|Paclitaxel IV
80024398|NCT05104736|Drug|PT-112|PT-112 will be administered intravenously on Days 1, 8 and 15 of a 28-day cycle at a dose of 360 mg/m2
80024399|NCT05098132|Drug|STK-012|pegylated alpha/beta-biased engineered interleukin-2
80024400|NCT05098132|Drug|Pembrolizumab|anti-PD-1 humanized monoclonal antibody
79268026|NCT04381663|Procedure|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
79268027|NCT04381663|Procedure|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
79569514|NCT01767896|Biological|approved egg-derived TIV|subcutaneous (sc)
79569515|NCT01767922|Dietary Supplement|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~visit V1, so-called inclusion visit (D0),~visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
79569516|NCT01767922|Dietary Supplement|Placebo - Excipient only|
79729580|NCT00922636|Drug|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
79729581|NCT00922636|Drug|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
79729582|NCT00922636|Drug|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
79729583|NCT02667925|Drug|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
79864099|NCT00385684|Drug|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
79729584|NCT02669719|Biological|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
80024401|NCT05095779|Behavioral|Standard Care + Financial Incentives|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
79569517|NCT01767948|Drug|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
80024402|NCT05095779|Other|Standard Care|Financial Incentives participants will receive standard care for completing counseling calls.
80024403|NCT05095116|Drug|APT-1011 3 mg HS|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
79729585|NCT02669719|Drug|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
79729586|NCT00644761|Drug|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
79864100|NCT00385684|Drug|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
79864101|NCT01044628|Device|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
79864102|NCT01044628|Device|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
80024404|NCT05092412|Radiation|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
80024405|NCT05092412|Drug|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
79268028|NCT04367233|Other|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
79268029|NCT04367233|Other|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
79268030|NCT04367233|Other|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
79268031|NCT04363164|Drug|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
79473437|NCT05738642|Drug|4 factor Prothrombin Complex Concentrates|Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
79473438|NCT01690663|Drug|Bupivacaine 0.25%|
79729587|NCT05330728|Other|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
79473439|NCT01690663|Drug|Dexamethasone|
79473440|NCT01690663|Drug|normal saline|placebo
79569518|NCT01767961|Procedure|diagnostic imaging|Undergo MBS
79729588|NCT05330728|Other|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
80024406|NCT05092412|Drug|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide [80 to 100mg/m2] via intravenous infusion and carboplatin [ The area under the curve (AUC) is 5-6] by intravenous infusion or cisplatin [75-80 mg/m2] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
80024407|NCT05072158|Other|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
80024408|NCT05059977|Biological|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
80024409|NCT05051384|Diagnostic Test|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
79569519|NCT01767961|Other|questionnaire administration|Correlative studies
79569520|NCT01767961|Procedure|quality-of-life assessment|Correlative studies
79569521|NCT01768039|Drug|Vitamin D|
79569522|NCT01768039|Drug|Placebo|
79569523|NCT01768052|Device|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
79569524|NCT01767610|Drug|micronized fenofibrate 160mg|
79569525|NCT01767610|Drug|pitavastatin Ca 2mg|
79569526|NCT01767610|Drug|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
80024410|NCT05037851|Drug|Opelconazole|Nebulizer suspension
80024411|NCT05037851|Drug|Standard of Care|Standard of Care
79729589|NCT05330728|Other|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
79729590|NCT00645073|Drug|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
79729591|NCT00645073|Drug|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
79729592|NCT04259008|Other|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
79729593|NCT04259008|Other|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
79729594|NCT04258930|Other|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
79729595|NCT04258930|Device|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
79864103|NCT00661661|Drug|CP-690,550|5 mg BID up to 10 mg BID until launch
79729596|NCT04258930|Device|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
79729597|NCT02669875|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
79729598|NCT02669875|Drug|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
79729599|NCT04176289|Diagnostic Test|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
79569527|NCT01768065|Device|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
79729600|NCT02671045|Genetic|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
79729601|NCT02671045|Genetic|Genomic profile by other methods|Genomic profiling by other testing methods.
79569528|NCT01768065|Device|placebo sham|
79729602|NCT04084327|Other|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
79729603|NCT01175135|Drug|PF-02545920|5 mg tablet every 12 hours for 28 days
79729604|NCT01175135|Drug|PF-02545920|15 mg tablet every 12 hours for 28 days
79729605|NCT01175135|Drug|Placebo|One tablet/capsule every 12 hours for 28 days
79729606|NCT01175135|Drug|Risperidone|3 mg capsule every 12 hours for 28 days
79729607|NCT02667613|Other|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
79864104|NCT00791453|Behavioral|Education|Patients will receive literacy appropriate health information.
79864105|NCT00038467|Drug|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
79864106|NCT00038467|Drug|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
79569529|NCT01768078|Procedure|Intravitreal injection of Betamethasone + antibiotics|
79729608|NCT02667613|Other|Control|Usual customary care
79729609|NCT00645541|Procedure|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
79729610|NCT02667769|Other|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose <55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
79729611|NCT02667691|Dietary Supplement|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
79729612|NCT02667691|Dietary Supplement|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
79729613|NCT02667691|Other|caloric restriction|Caloric recommendation reduced by 20%
79729614|NCT05098561|Other|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
79864107|NCT01095367|Procedure|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
79569530|NCT01768078|Procedure|Intravitreal injection of antibiotics|
79569531|NCT01768091|Procedure|POEM|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
79569532|NCT01768091|Procedure|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
79569533|NCT01768104|Procedure|ESTD|"A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~Dissection was done along the margin of the tumor.~After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
79569534|NCT01768104|Procedure|VATS|"General anesthesia with double lumen intubation.~Three to four cameras or working ports are placed over the chest wall.~After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~The mass is exposed after the overlying muscle is split longitudinally.~The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
79569535|NCT01768143|Behavioral|unexperienced endoscopy nurses|
79569536|NCT01768143|Behavioral|Experienced endoscopy nurses|
79569537|NCT01768156|Other|Experimental arm|"Serum samples are collected:~at time of diagnosis of recurrence (before 1st chemotherapy)~during each cycle of chemotherapy~after the end of chemotherapy~every 3 month until treatment failure (3-6 samples)~stop at the progression or after 18 months post chemotherapy"
79569538|NCT01768169|Dietary Supplement|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
79569539|NCT01768182|Dietary Supplement|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
79569540|NCT01768182|Other|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
79569541|NCT01768195|Drug|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
79569542|NCT01768208|Drug|Saxagliptin|
79569543|NCT01768221|Behavioral|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
79569544|NCT01768234|Other|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
79569545|NCT01768247|Drug|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
79569546|NCT01768260|Device|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
79569547|NCT01768260|Drug|Aspirin|Standard drug therapy
79569548|NCT01768273|Drug|Midazolam|
79569549|NCT01768273|Drug|PA-824|
79569550|NCT01766505|Drug|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure."
79729615|NCT02669641|Dietary Supplement|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
79864108|NCT00051025|Drug|ONTAK|
79864109|NCT01095445|Drug|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
79864110|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
79569551|NCT01766505|Drug|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
79569552|NCT01768299|Drug|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
79864111|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
79864112|NCT00660179|Drug|placebo|Matching placebo, once daily
79864113|NCT00050167|Drug|Paclitaxel|80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
79864114|NCT00050167|Drug|Docetaxel|75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
79864115|NCT00050167|Drug|Capecitabine|1500 mg/m^2 by mouth Twice Daily x 2 Weeks
79569553|NCT01768299|Drug|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
79569554|NCT01768312|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
79569555|NCT01768351|Drug|Paricalcitol|Zemplar cp 1 mcg/day per os
79569556|NCT01768351|Drug|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
79569557|NCT01768364|Drug|Trimetoprim-Sulfa (Bactrim)|
79569558|NCT01768364|Other|No antibiotics|
79569559|NCT01768377|Drug|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
79569560|NCT01768377|Drug|Fentanyl|Fentanyl 2 microgram/Kg BW IV
79569561|NCT01768377|Drug|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
79864116|NCT01095523|Procedure|Laparotomy+ HIPEC +/- CRS|
79864117|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
79864118|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
79864119|NCT01092325|Drug|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
79569562|NCT01768390|Other|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
79729616|NCT02886221|Procedure|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
79729617|NCT02669485|Drug|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
79569563|NCT01768390|Other|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
79569564|NCT01768429|Behavioral|Fatty fish|
79569565|NCT01768429|Behavioral|Lean Fish|
79569566|NCT01768429|Behavioral|Alpha-linolenic acid|
79569567|NCT01768429|Behavioral|Control|
79569568|NCT01768455|Drug|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
79729618|NCT02669485|Device|Fluorescence imaging|
79729619|NCT00922480|Drug|Fimasartan|Fimasartan 60 ~ 120mg/po take one tablets once a day
79729620|NCT00922480|Drug|Losartan (Control)|Losartan 50 mg ~ 100 mg/po, take one tablets once a day
79729621|NCT04174885|Procedure|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
79864120|NCT01092325|Drug|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
79864121|NCT01092325|Drug|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
79864122|NCT01092325|Drug|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
79864123|NCT03957265|Procedure|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
79864124|NCT01096927|Drug|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
79864125|NCT01092403|Drug|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
79864126|NCT01092403|Drug|Placebo|Placebo once daily by inhalation
79268032|NCT04363164|Drug|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
79268033|NCT04363164|Drug|Testosterone enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
79268034|NCT04356040|Device|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
79569569|NCT01768455|Drug|Glimepiride|Glimepiride 4mg (qd) on Day1
79569570|NCT01768468|Drug|LAYLA tablet|1 tablet twice a day
79569571|NCT01768468|Drug|JOINS tablet|1 tablet at each time, 3 times a day
79569572|NCT01768481|Drug|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
79569573|NCT01768481|Drug|sugar pill|placebo controlled arm receives similarly looking placebo.
79569574|NCT01768507|Dietary Supplement|Resveratrol|5 g (10 capsules) as single oral dose on day 1
79569575|NCT01768546|Behavioral|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
79569576|NCT01768546|Behavioral|Interactive tracking and problem solving web portal|
79569577|NCT01768585|Drug|Ivabradine|Please see description of Intervention Arm
79569578|NCT01768585|Drug|Placebo|
79569579|NCT01768598|Other|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
79569580|NCT01768598|Other|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
79569581|NCT01768598|Other|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
79569582|NCT01768598|Other|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
79569583|NCT01768624|Procedure|dialysis, kidney transplant|
79729622|NCT02886143|Procedure|Active Voiding Trial|"Nursing protocol:~Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~Clamp the Foley~Deflate the catheter balloon and remove the catheter from the bladder.~Record the amount of saline that was instilled into the bladder.~Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
79729623|NCT02886143|Procedure|Passive Voiding Trial|"Nursing protocol:~Deflate the catheter balloon and remove the catheter from the bladder.~Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~5. If the patient has not voided within 5 hours, assist the patient to try to void.~6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
80024412|NCT05035771|Device|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
79268035|NCT04356040|Device|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
79569584|NCT01768650|Behavioral|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
79729624|NCT02670967|Dietary Supplement|Soluble Fibre|
79729625|NCT04258618|Behavioral|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
79729626|NCT04258618|Device|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
79729627|NCT02669563|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
79729628|NCT02669563|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
79729629|NCT02669563|Drug|[13N]ammonia|IV injection of [13N]ammonia
79569585|NCT01768650|Behavioral|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
79864127|NCT00660023|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
80024413|NCT05032157|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
79268036|NCT04349631|Biological|HB-adMSCs|Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
79268037|NCT04331873|Diagnostic Test|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
79268038|NCT04331236|Behavioral|Cognitive Behavioral Therapy|CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
79268039|NCT04331236|Other|Yoga|Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
79268040|NCT04288258|Behavioral|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
79729630|NCT02669563|Drug|[11C]HED|IV injection of [11C]HED
80024414|NCT05032157|Drug|Placebo|Placebo
80024415|NCT05032157|Drug|LOU064 (open-label)|LOU064 (open -label) active treatment
80024416|NCT05024851|Other|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
79569586|NCT01768663|Drug|Lumacaftor|tablet, 200mg taken every 12 hours
79268041|NCT04279392|Drug|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zoledronic acid infusion
79864128|NCT03953521|Device|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
79268042|NCT04279392|Drug|Placebos|Saline infusion
79400824|NCT05585775|Behavioral|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
79569587|NCT01768663|Drug|Ivacaftor|tablet, 250mg taken every 12 hours
79729631|NCT04963036|Other|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
79268043|NCT04262778|Diagnostic Test|electrochemical skin conductance measurement|electrochemical skin conductance measurement
79569588|NCT01768663|Drug|Ciprofloxacin|750 mg taken every 12 hours
79569589|NCT01768663|Drug|Itraconazole|200mg taken once daily
79729632|NCT04963036|Other|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate…), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
79729633|NCT02537119|Procedure|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
79729634|NCT02537119|Procedure|Massage therapy|Rubbing on hamstrings
79729635|NCT04255420|Procedure|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
79729636|NCT04255420|Drug|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
79268044|NCT04257955|Behavioral|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
79569590|NCT01768663|Drug|Rifampin|600mg taken once daily
79569591|NCT01768689|Behavioral|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
79569592|NCT01768689|Behavioral|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
79569593|NCT01768689|Behavioral|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
79729637|NCT00973479|Drug|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
79729638|NCT00973479|Other|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
79304370|NCT04360811|Diagnostic Test|COVID 19 diagnostic test by PCR|"Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~Pathological study of placentas and fetal autopsies~Histology of positive COVID-19 placentas~Brain and visceral histology of positive COVID-19 fetuses autopsied~Analysis of patient comorbidities and comparison in the different groups~Final statistical analysis"
79304371|NCT04971135|Drug|SAN711|SAN711 liquid formulation
79729639|NCT00973479|Drug|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
79729640|NCT04082221|Other|no intervention|no intervention
79569594|NCT01768702|Biological|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
79729641|NCT04174183|Device|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
79864129|NCT00787709|Behavioral|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
79569595|NCT01768702|Biological|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
79569596|NCT01768728|Procedure|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
79569597|NCT01768728|Procedure|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
79569598|NCT01768741|Procedure|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
79569599|NCT01768741|Procedure|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
80024417|NCT05022472|Behavioral|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration [2-dose series and importance of vaccine completion]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
80024418|NCT05022472|Behavioral|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
80024419|NCT05022472|Behavioral|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
79400825|NCT05582473|Behavioral|LST-LC Education|"Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain"
79729642|NCT04174495|Diagnostic Test|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
79729643|NCT04315493|Drug|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
79268045|NCT04225130|Behavioral|Written Exposure Therapy -for Suicide|The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
79569600|NCT01768754|Behavioral|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
79864130|NCT02554955|Drug|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
79864131|NCT02554955|Drug|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
79864132|NCT02554955|Drug|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
79864133|NCT00062647|Drug|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
79729644|NCT04315493|Drug|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
79304372|NCT04971135|Other|Placebo|Matching placebo
79729645|NCT04173871|Device|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
79729646|NCT02862483|Drug|Tamsulosin 0.2mg|
79729647|NCT02862483|Drug|Tadalafil 5mg|
79729648|NCT02862483|Drug|Placebo for Tamsulosin|
79729649|NCT01173653|Other|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
79729650|NCT01173653|Other|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
79864134|NCT00062647|Drug|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
79864135|NCT00570323|Drug|Arimidex|Aromatase inhibitors
79864136|NCT00570323|Drug|Faslodex|Hormone Receptor
79864137|NCT00791531|Drug|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
79864138|NCT00788099|Drug|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
79304373|NCT04978623|Other|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
79729651|NCT02667535|Drug|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
79268046|NCT04225130|Behavioral|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
79268047|NCT04204408|Drug|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
79268048|NCT04204408|Drug|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
79268049|NCT04199728|Drug|Liraglutide Pen Injector|Liraglutide will be provided using an injection pen provided by the manufacturer
79569601|NCT01768780|Device|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
79864139|NCT00788099|Drug|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
79864140|NCT00795587|Drug|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
79569602|NCT01768793|Behavioral|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
80024420|NCT05022472|Biological|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
80024421|NCT05018416|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
79268050|NCT04199728|Drug|Placebo|Placebo injection pen
79729652|NCT04284735|Other|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
79864141|NCT00788177|Drug|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
80024422|NCT05016310|Dietary Supplement|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
80024423|NCT05016310|Dietary Supplement|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of >30 ng/mL according to Endocrine Society Practice Guidelines.
79268051|NCT04165460|Other|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
79268052|NCT04165460|Other|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
79268053|NCT04165460|Other|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
79268054|NCT04165460|Other|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
79268055|NCT04156347|Drug|Episcleral Topotecan|Transscleral Topotecan
79268056|NCT04141514|Other|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
79864142|NCT00661505|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
79864143|NCT04047095|Dietary Supplement|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
79864144|NCT04047095|Dietary Supplement|Normal daily meal|Normal daily meal (75-80 g protein)
80024424|NCT05014828|Drug|lenvatinib|Capsules administered orally
79268057|NCT04115514|Drug|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~Method: Instilled via a catheter through the ETT directly into the airway."
79268058|NCT04115514|Other|Non-intervention|Standard of Care (SOC)
79400826|NCT05582083|Drug|Momelotinib|Momelitinib available as tablets.
80024425|NCT05014828|Drug|Tislelizumab|intravenous (iv) infusion
80024426|NCT05013736|Device|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
79268059|NCT04105868|Other|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
79569603|NCT01768793|Behavioral|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
79569604|NCT01768806|Behavioral|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
79569605|NCT01768806|Behavioral|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
79569606|NCT01768819|Behavioral|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
79569607|NCT01768884|Drug|Nitric Oxide|
79569608|NCT01768884|Drug|Placebo|
79569609|NCT01768897|Drug|CPI-613|Given IV
79729653|NCT05657951|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
79864145|NCT00788333|Drug|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
79864146|NCT00788333|Drug|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
79864147|NCT00922103|Procedure|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
79864148|NCT00922103|Procedure|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
79864149|NCT00795899|Drug|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
79864150|NCT00795977|Biological|dendritic cells, OK-432|Single Group Assignment
79864151|NCT00796055|Drug|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
79864152|NCT00796133|Drug|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
79864153|NCT00796211|Drug|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
79400827|NCT05581056|Drug|CFTR modulators|Introduction of CFTR modulators by pneumologists for pneumologic issues
79569610|NCT01768897|Drug|cytarabine|Given IV
79569611|NCT01768897|Drug|mitoxantrone hydrochloride|Given IV
79569612|NCT01768897|Other|laboratory biomarker analysis|Optional correlative studies
79864154|NCT00796211|Drug|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
79864155|NCT00796211|Drug|Nortriptyline|0.1% nortriptyline HCl topical cream
79569613|NCT01768897|Other|pharmacological study|Correlative studies
79569614|NCT01768910|Other|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
79569615|NCT01768910|Other|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
79569616|NCT01768910|Other|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
79569617|NCT01768910|Other|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
79864156|NCT00796211|Drug|Calcipotriol|0.005% calcipotriol topical cream
79864157|NCT00796211|Other|Placebo|Vehicle of CRx-197 topical cream (placebo)
79864158|NCT00792233|Other|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
79864159|NCT00788567|Drug|mycophenolate mofetil|1
79569618|NCT01768923|Procedure|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)
79864160|NCT00792311|Procedure|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
79569619|NCT01768923|Procedure|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28<2.6) (minimal disease activity group)
79569620|NCT01768949|Device|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
79569621|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
79569622|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
80024427|NCT05013736|Behavioral|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
79569623|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
79569624|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
79569625|NCT01768988|Drug|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~Paracetamol 1g/8h~Weak opioid (tramadol at maximal doses of 400 mg/24h)~Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
79729654|NCT02667145|Other|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
79864161|NCT00788645|Behavioral|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
80024428|NCT05013736|Device|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
80024429|NCT05011123|Biological|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection - Subcutaneous
79268060|NCT04097002|Biological|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
79268061|NCT04095091|Device|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
80024430|NCT05011123|Biological|Yellow fever vaccine|Powder and diluent for suspension for injection - Subcutaneous
80024431|NCT04985773|Device|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
79400828|NCT05580523|Drug|75 mg acetylsalicylic acid|75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
79864162|NCT00788645|Behavioral|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
79864163|NCT00792389|Other|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
79864164|NCT00792389|Other|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
79864165|NCT00788723|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
79864166|NCT00788801|Drug|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
79864167|NCT00662909|Drug|Mirabegron|Oral
79729655|NCT04316819|Other|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
80024432|NCT04968808|Procedure|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
79569626|NCT01768988|Drug|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~Paracetamol 1g/8h~Weak opioid (tramadol at maximal doses of 400 mg/24h)~Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
79569627|NCT01769040|Drug|Rifaximin|550 mg two times daily for 28 days
79569628|NCT01769040|Drug|placebo|
79268062|NCT04083456|Behavioral|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
79304374|NCT03107507|Drug|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
79569629|NCT01769053|Other|Variable Ventilation|
79569630|NCT01769066|Drug|Sequential Gefitinib With Pemetrexed/Platinum|
80024433|NCT04968808|Procedure|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
79569631|NCT01769066|Drug|Pemetrexed/Platinum|
79569632|NCT01769079|Drug|Nitrate|Two arms: placebo and nitrate
79569633|NCT01769079|Drug|Placebo|
79569634|NCT01769118|Drug|Caffeine|Caffeine will be given according to departmental protocol
79569635|NCT01769144|Device|Acticoat Absorbent|wound dressing
79569636|NCT01769144|Device|BCT|wound dressing
79569637|NCT01769157|Drug|L-carnitine|
79569638|NCT01769157|Drug|Placebo|
79569639|NCT01769183|Drug|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
79569640|NCT01769235|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
79569641|NCT01769235|Drug|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
79569642|NCT01769235|Drug|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
79569643|NCT01769261|Other|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
79569644|NCT01769261|Other|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
79569645|NCT01769261|Other|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
79569646|NCT01769300|Behavioral|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
79569647|NCT01769313|Device|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
79569648|NCT01769313|Device|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
79569649|NCT01769417|Drug|Placebo|Placebo
79569650|NCT01769417|Drug|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
79569651|NCT01769482|Drug|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
79268063|NCT04083456|Other|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
79268064|NCT04078061|Behavioral|MABA|Adaptive, modular, behavioral intervention.
79400829|NCT05580523|Drug|1.5g Metformin|up to 1.5 g metformin (C4H11N5, CAS number 657-24-9) daily, Oral Dose increases from 0.5g to 1.0g to 1.5g
79400830|NCT05580523|Drug|150 mg acetylsalicylic acid|150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
79400831|NCT05580523|Drug|Placebo of acetylsalicylic acid and Metformin|Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
79400832|NCT05575830|Biological|Recombinant Zoster Vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
79569652|NCT01769482|Drug|placebo|
79400833|NCT05570838|Device|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
79729656|NCT04286841|Drug|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
79729657|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
79729658|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
79268065|NCT04078061|Behavioral|EIBI|Early Intensive Behavioral Intervention
79268066|NCT04053517|Other|Medical Chart Review|Medical chart is reviewed
79400834|NCT05570838|Device|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
79400835|NCT05568173|Other|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
79268067|NCT04053517|Other|Quality-of-Life Assessment|Ancillary studies
79268068|NCT04053517|Other|Questionnaire Administration|Ancillary studies
79268069|NCT04044534|Drug|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
79268070|NCT04044534|Drug|Placebo|Subjects in this arm will receive placebo.
79400836|NCT05568173|Other|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
79569653|NCT01769495|Other|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
79569654|NCT01769521|Device|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
79569655|NCT01769547|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
79569656|NCT01769560|Behavioral|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
79569657|NCT01769625|Drug|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
79729659|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
79864168|NCT00662909|Drug|Placebo|Oral
79864169|NCT00050011|Drug|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
80024434|NCT04963413|Biological|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
80024435|NCT04956640|Drug|LY3537982|Oral
80024436|NCT04956640|Drug|Pembrolizumab|Intravenous
79400837|NCT05565521|Radiation|Dose escalation + Reduced Margin Adaptive Radiotherapy|Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40 Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of minimum 5 mm and a weekly online adaptive approach.
79400838|NCT05564390|Drug|Azacitidine|Given IV or SC
79569658|NCT01769638|Drug|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
79569659|NCT01769638|Drug|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
79569660|NCT01769651|Other|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
79569661|NCT01769664|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
79569662|NCT01769664|Drug|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
79569663|NCT01769664|Drug|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
79569664|NCT01769677|Drug|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
79729660|NCT00645229|Drug|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
79729661|NCT01172873|Drug|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
79729662|NCT01172873|Behavioral|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
79729663|NCT02886299|Drug|Fenofibrate|
79729664|NCT02886299|Drug|Simvastatin|
80024437|NCT04956640|Drug|Cetuximab|Intravenous
79729665|NCT02667379|Other|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
80024438|NCT04956640|Drug|Pemetrexed|Intravenous
79268071|NCT04039464|Drug|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
79268072|NCT04039464|Drug|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
79268073|NCT03989141|Procedure|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
79268074|NCT03989141|Procedure|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
79400839|NCT05564390|Procedure|Biospecimen Collection|Undergo collection of blood samples
79729666|NCT05261659|Behavioral|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
79729667|NCT05261659|Behavioral|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
79729668|NCT00925600|Biological|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
79729669|NCT00925600|Biological|Placebo|Prefilled syringe for subcutaneous (SC) injection
79400840|NCT05564390|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79729670|NCT00645307|Drug|Extended Release OROS® Paliperidone|
80024439|NCT04956640|Drug|Cisplatin|Intravenous
80024440|NCT04956640|Drug|Carboplatin|Intravenous
80024441|NCT04943536|Drug|bicalutamide|localized anti-androgen therapy
80024442|NCT04943536|Radiation|Stereotactic body radiation therapy|localized radiation therapy
80024443|NCT04942483|Diagnostic Test|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
80024444|NCT04942483|Diagnostic Test|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
80024445|NCT04942483|Diagnostic Test|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
80024446|NCT04941898|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
80024447|NCT04935372|Other|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
80024448|NCT04925219|Behavioral|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
80024449|NCT04925219|Behavioral|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
80024450|NCT04920812|Genetic|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
80024451|NCT04911816|Drug|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
80024452|NCT04865133|Procedure|Biospecimen Collection|Undergo blood sample collection
79569665|NCT01769690|Other|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
79729671|NCT02666287|Drug|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
79729672|NCT02666287|Drug|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
79729673|NCT02666287|Drug|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
79729674|NCT02666287|Drug|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
79729675|NCT02666287|Drug|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
79729676|NCT02668861|Drug|Vitamin D|Vitamin D 4000IU/day for 8 weeks
79729677|NCT02668861|Drug|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
79729678|NCT02668861|Other|placebo|placebo for 8 weeks
79729679|NCT05330650|Drug|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
79729680|NCT05330650|Drug|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
80024453|NCT04865133|Other|Electronic Health Record Review|Medical record reviewed
80024454|NCT04864782|Drug|QL1604|Intravenous Infusion
79268075|NCT03974139|Drug|Metformin Oral Tablet|Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
79729681|NCT02668705|Other|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
79729682|NCT04879654|Procedure|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
79729683|NCT04997005|Device|AMIStem-P|Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant
79729684|NCT04255888|Procedure|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
79268076|NCT03968822|Drug|Lidocaine 2%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
79268077|NCT03968822|Drug|Lidocaine 1%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
79268078|NCT03968822|Drug|Bupivacaine 0.25%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
79268079|NCT03968822|Drug|Bupivacaine 0.5%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
79268080|NCT03968822|Drug|Intralipid, 20% Intravenous|a 250ml bag administered intravenously
79268081|NCT03968822|Other|Saline intravenously|a 250ml bag administered intravenously
79268082|NCT03968822|Other|Saline|3 mL of test solution to a skin area on the thigh, 2cm in diameter
79268083|NCT03961204|Other|Data Collection|No study treatment was administered as part of this study
79268084|NCT03946800|Biological|MEDI1191|Subjects will receive MEDI1191 (at least twice)
79268085|NCT03946800|Biological|Durvalumab|Subject will receive durvalumab every 4 weeks
79268086|NCT03935971|Drug|Dupilumab|See arm/group description
80024455|NCT04864782|Drug|Paclitaxel injection|Intravenous Infusion
79864170|NCT00050011|Drug|Letrozole|Participants received Letrozole 2.5 mg daily.
79268087|NCT03932136|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
79268088|NCT03932136|Combination Product|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
79569666|NCT01769690|Other|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
79569667|NCT01769703|Drug|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
79569668|NCT01769716|Procedure|Umbilical cord blood transplantation|
79569669|NCT01769729|Behavioral|PEPP|
79569670|NCT01769729|Behavioral|Care management|
79569671|NCT01769742|Behavioral|Early mobility bundle|
79569672|NCT01769755|Biological|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
79569673|NCT01769755|Drug|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
79569674|NCT01769768|Drug|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
79729685|NCT04255888|Procedure|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
79729686|NCT02668627|Procedure|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
79729687|NCT00968253|Drug|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
79729688|NCT00968253|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
79729689|NCT00968253|Drug|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
79729690|NCT00968253|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
79864171|NCT00661427|Biological|cetuximab|Cetuximab 500 mg/m^2 IV over 2 hours every other week
79864172|NCT00661427|Biological|cetuximab|Cetuximab 750 mg/m^2 IV over 3 hours every other week
80024456|NCT04864782|Drug|Cisplatin/Carboplatin|Intravenous Infusion
80024457|NCT04862780|Drug|BLU-945|Oral administration
80024458|NCT04862780|Drug|osimertinib|Osimertinib tablets for oral administration
79268089|NCT03918057|Behavioral|Cognitive Behavioural Therapy for Insomnia|Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
79569675|NCT01769768|Drug|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
80024459|NCT04842331|Drug|RESP301 (a nitric oxide generating solution)|Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.
80024460|NCT04842331|Drug|Standard of Care (SOC)|Participants will receive institutional SOC for the treatment.
80024461|NCT04835831|Other|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
80024462|NCT04829578|Other|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
80024463|NCT04827862|Drug|Pembrolizumab|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
79569676|NCT01769768|Drug|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
79569677|NCT01769781|Drug|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
79569678|NCT01769781|Drug|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
79864173|NCT00049543|Drug|gefitinib|Given PO
79864174|NCT00049543|Other|placebo|Given PO
79864175|NCT00049543|Other|laboratory biomarker analysis|Correlative studies
80024464|NCT04804735|Device|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
80024465|NCT04804735|Device|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
80024466|NCT04803305|Drug|PF-06946860|subcutaneous injection
80024467|NCT04803305|Drug|Placebo for PF-06946860|subcutaneous injection
80024468|NCT04801329|Drug|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
80024469|NCT04795908|Device|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
80024470|NCT04795908|Behavioral|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
80024471|NCT04782687|Drug|Selinexor|oral drug that comes in 20 mg tablets
79864176|NCT03955393|Other|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
79569679|NCT01769794|Drug|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
79729691|NCT00968253|Drug|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
79864177|NCT00048997|Radiation|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
79268090|NCT03918057|Other|Active Control|Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
79569680|NCT01769794|Drug|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
79729692|NCT00968253|Drug|Mesna|600 mg/m^2 IV continuous infusion daily for 24 hours days 1-3.
79268091|NCT03891251|Other|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
79268092|NCT03841019|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
79729693|NCT00968253|Drug|Methotrexate|200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 IV over 22 hours day 1.
79864178|NCT00048997|Other|Observation|
79864179|NCT01092481|Drug|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
79864180|NCT01097083|Drug|Coriolus Versicolor|
79400841|NCT05564390|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
79400842|NCT05564390|Drug|Cytarabine|Given
79864181|NCT01097161|Behavioral|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
79400843|NCT05564390|Drug|Daunorubicin Hydrochloride|Given IV
79864182|NCT01097239|Device|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
79864183|NCT03955315|Biological|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
79400844|NCT05564390|Procedure|Echocardiography|Undergo ECHO
79569681|NCT01769794|Drug|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
79569682|NCT01769807|Device|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
79729694|NCT00968253|Drug|Ara-C (Cytarabine)|3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
79400845|NCT05564390|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79400846|NCT05564390|Procedure|Multigated Acquisition Scan|Undergo MUGA
79400847|NCT05564390|Procedure|Mutation Carrier Screening|Undergo rapid genetic testing
79400848|NCT05564390|Drug|Venetoclax|Given PO
79400849|NCT05563974|Other|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
79400850|NCT05558137|Drug|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
79569683|NCT01769820|Drug|Dexamethasone|studies 1&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
79864184|NCT03955315|Procedure|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
79864185|NCT00035815|Drug|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
79864186|NCT00035815|Drug|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
79864187|NCT00662831|Drug|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
79864188|NCT00662831|Drug|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
79569684|NCT01769820|Drug|placebo|
79569685|NCT01769833|Drug|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
79569686|NCT01769833|Drug|Nucleosides|
79729695|NCT00968253|Drug|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
79729696|NCT00968253|Drug|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
79729697|NCT04258540|Behavioral|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
79729698|NCT04258540|Behavioral|yoga course|yoga course
79729699|NCT00646009|Drug|budesonide/formoterol|
79729700|NCT00646009|Drug|fluticasone/salmeterol|
79729701|NCT00646009|Drug|albuterol|
79729702|NCT04069663|Other|No interventional study|Retrospective data analysis
80024472|NCT04782687|Drug|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those >75 years old may be administered a weekly dose of 20 mg dexamethasone.
80024473|NCT04782687|Drug|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
79268093|NCT03841019|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
79268094|NCT03816007|Behavioral|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
79268095|NCT03816007|Behavioral|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
80024474|NCT04782687|Drug|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
79400851|NCT05556850|Behavioral|STABL Virtual Rehabilitation|"STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner."
80024475|NCT04781907|Procedure|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
79864189|NCT00788879|Behavioral|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
79400852|NCT05554393|Drug|Azacitidine|Given IV or SC
79400853|NCT05554393|Procedure|Biospecimen Collection|Undergo collection of blood samples
79400854|NCT05554393|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspiration
79569687|NCT01769846|Other|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
79569688|NCT01769872|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
79569689|NCT01769898|Drug|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
79569690|NCT01769898|Drug|Theophylline|Theophylline 0.1 Q12H
79569691|NCT01769898|Drug|Placebo|Placebo for theophylline 0.1 Q12H
79569692|NCT01769911|Drug|carmustine|Given IV
79569693|NCT01769911|Drug|cytarabine|Given IV
79268096|NCT03804229|Drug|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
79268097|NCT03804229|Drug|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
79268098|NCT03797326|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
79268099|NCT03797326|Drug|Lenvatinib|Administered orally once a day during each 21-day cycle.
79268100|NCT03781700|Drug|Prednisolone|Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
79268101|NCT03781700|Drug|Placebo Oral Tablet|Placebo tablets with identical appearance to the experimental drug
79268102|NCT03771417|Behavioral|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
79268103|NCT03749018|Drug|Cyclophosphamide|Given IV
79268104|NCT03749018|Drug|Doxorubicin Hydrochloride|Given IV
79400855|NCT05554393|Drug|Cytarabine|Given IV
79400856|NCT05554393|Drug|Daunorubicin Hydrochloride|Given IV
79400857|NCT05554393|Drug|Venetoclax|Given PO
79400858|NCT05553743|Biological|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
79400859|NCT05553743|Drug|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
79400860|NCT05553314|Drug|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
79400861|NCT05553314|Drug|Placebo|patients randomized to placebo group will receive placebo.
79400862|NCT05546346|Device|wearable magnet tracking system|In this group, wearable magnet tracking system was used.
79400863|NCT05544071|Device|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
79569694|NCT01769911|Drug|melphalan|Given IV
79569695|NCT01769911|Drug|etoposide|Given IV
79569696|NCT01769911|Drug|O6-benzylguanine|Given IV
79569697|NCT01769911|Procedure|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
79268105|NCT03749018|Drug|Etoposide|Given IV
79268106|NCT03749018|Biological|Nivolumab|Given IV
79729703|NCT00646087|Drug|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
79729704|NCT00646087|Drug|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
79729705|NCT04255576|Dietary Supplement|Dietary Supplement: Calcium/Vitamin D|All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
79864190|NCT00788879|Behavioral|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
79864191|NCT00796601|Drug|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
79864192|NCT00796601|Drug|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
79864193|NCT00796679|Drug|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH <500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
79864194|NCT02554643|Other|Diet|Nutrition intervention, once a week during 12 weeks
79268107|NCT03749018|Drug|Prednisone|Given PO
79400864|NCT05544045|Device|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio < 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
79569698|NCT01769911|Procedure|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
79729706|NCT02668315|Biological|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
79569699|NCT01769911|Other|laboratory biomarker analysis|Correlative studies
79729707|NCT05309434|Behavioral|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
79729708|NCT04175197|Device|Drug Coated Balloon|Legflow Drug Coated Balloon
79729709|NCT02862405|Other|vision tests|
79864195|NCT02554643|Other|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
79864196|NCT02554643|Other|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
79864197|NCT02555423|Drug|Local anaesthetic - chirocaine|
79268108|NCT03749018|Biological|Rituximab|Given IV
79569700|NCT01769937|Drug|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
79864198|NCT00792779|Drug|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
79864199|NCT00662363|Drug|Lubiprostone|24 µg po BID given with meals for 6 days
79864200|NCT00662363|Drug|Senna|2 tabs daily for 6 days
79864201|NCT02555033|Other|Resistance training|traditional resistance training
79864202|NCT02555033|Other|Instability resistance training|training under unstable conditions
79268109|NCT03749018|Drug|Vincristine Sulfate|Give IV
79268110|NCT03712449|Device|JUVÉDERM®|Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
79268111|NCT03712449|Drug|BOTOX Cosmetic®|BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
79400865|NCT05542420|Other|No treatment given|The study will be based on data already recorded in the medical record
79400866|NCT05539443|Behavioral|Intensive Clinic Management (ICM)|An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial
79569701|NCT01769950|Other|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
79569702|NCT01769963|Other|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
79569703|NCT01769976|Other|Periodic fasting|
79864203|NCT00796835|Drug|ER OROS Paliperidone|
79864204|NCT04887155|Behavioral|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
79864205|NCT00792857|Drug|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
79268112|NCT03712449|Drug|BELKYRA®|BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
79729710|NCT04258696|Device|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
79864206|NCT00792857|Drug|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
79268113|NCT03712449|Other|SkinMedica|SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
79569704|NCT01769976|Other|Energy restriction|
79268114|NCT03691376|Biological|Aldesleukin|Given SC
79268115|NCT03691376|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
79569705|NCT01769976|Other|Energy balance diet|
79569706|NCT01769989|Procedure|Electrodermabrasion|
79729711|NCT04258696|Device|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
79729712|NCT05180565|Device|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
79268116|NCT03691376|Other|Cellular Therapy|Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV
79268117|NCT03691376|Drug|Melphalan|Given IV
79268118|NCT03671226|Other|Questionnaire Administration|Given questionnaire
79268119|NCT03649178|Other|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
79268120|NCT03637400|Drug|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
79268121|NCT03637400|Drug|DOXY|DOXY will be administered over a period of 7 days.
79569707|NCT01769989|Procedure|Dermabrasion|
79569708|NCT01770002|Procedure|Everted suture technique|
79569709|NCT01770002|Procedure|Non-everted suture technique|
79569710|NCT01770041|Other|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
79569711|NCT01770054|Other|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
79864207|NCT00796913|Other|Stop medication|Stop medication Stop medication + se supplement
79864208|NCT02554175|Drug|Propofol|Propofol was administered to achieve target propofol Ce
79864209|NCT00789269|Drug|rhubarb|14 days of rhubarb
79864210|NCT00789269|Drug|placebo|14 days of placebo
80024476|NCT04775472|Procedure|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
79268122|NCT03620539|Other|Lifestyle intervention|Sauna bathing
79268123|NCT03619655|Procedure|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
79268124|NCT03619655|Drug|18F-DCFPyL PET/CT|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
79268125|NCT03619655|Drug|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
79268126|NCT03619655|Procedure|WB-MRI|Whole body MRI exam (total examination time < 50 minutes)
79268127|NCT03607552|Device|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
79268128|NCT03607552|Device|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
79569712|NCT01770080|Drug|Euminz®|3 to 5 time topical use of study drug.
79569713|NCT01770080|Drug|Placebo|3 to 5 time topical use of study drug.
79569714|NCT01770093|Other|Questionnaire|
79569715|NCT01770106|Drug|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
79569716|NCT01770106|Drug|Alendronate|Alendronate 70mg once weekly
79569717|NCT01770119|Biological|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
79569718|NCT01770132|Drug|porfimer sodium|Given IV
79569719|NCT01770132|Procedure|endoscopic ultrasonography|Undergo EUS-PDT
79569720|NCT01770132|Procedure|photodynamic therapy|Undergo EUS-PDT
79569721|NCT01770132|Drug|gemcitabine hydrochloride|Given IV
79569722|NCT01770171|Drug|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
79569723|NCT01770171|Drug|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
79569724|NCT01770184|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
79569725|NCT01770197|Drug|IV rt-PA|IV rt-PA treatment
79569726|NCT01770210|Drug|Patients on atorvastatin treatment|Statins Therapy
79569727|NCT01770223|Drug|boceprevir|
79569728|NCT01770223|Biological|PegIFN-2b|
79569729|NCT01770223|Drug|RBV|
79569730|NCT01770236|Drug|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
79569731|NCT01770288|Other|Anaerobic wingate test|
79569732|NCT01770301|Drug|Paclitaxel|
79569733|NCT01770301|Drug|Bevacizumab|
79729713|NCT04255498|Drug|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
79729714|NCT04255498|Drug|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
79729715|NCT00645775|Dietary Supplement|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
79864211|NCT00793013|Device|Volume-Cycled Assist-Control (AC) mode|"Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40%~Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~Inspiratory to Expiratory ratio set at 1:1 to 1:3~If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~Mgmt of PEEP will be conducted as per the ARDSnet Protocol~Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
79864212|NCT00793013|Device|Airway Pressure Release Ventilation (APRV) mode|"Ventilation uses Drager Model X1~Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~Time periods for the high & low pressure levels can be set independently~Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~Spontaneous frequency will be targeted for 6 to 18 breaths/per min~If spontaneous breathing is achieved,level of sedation will be decreased~If spontaneous respirations are >20 breaths/min, sedation will be increased~If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
79268129|NCT03586453|Drug|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~Osimertinib: Oral, Daily 28 day cycle.~Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~Tumor biopsy between C4 and C8 and at disease progression"
79268130|NCT03583255|Drug|Dexamethasone|Given PO
79268131|NCT03583255|Behavioral|Exercise Intervention|Complete resistance training and moderate intensity walking
79268132|NCT03583255|Other|Placebo Administration|Given PO
79569734|NCT01770327|Behavioral|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
79569735|NCT01770340|Biological|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
79569736|NCT01770340|Procedure|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
79569737|NCT01770405|Device|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
79569738|NCT01770444|Other|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~Prospective gating~Range: dedicated imaging (below carina to heart base)"
79569739|NCT01770444|Other|Conventional cardiac CT protocol|"Conventional CCTA protocol~Retrospective gating with tube current modulation~Range: dedicated imaging (below carina to heart base)"
79569740|NCT01770470|Dietary Supplement|Chitosan|The product chitosan is contained in a chewing gum formulation
79569741|NCT01770496|Behavioral|Childhood vaccination reminder / recall notification|
79569742|NCT01770548|Genetic|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
79569743|NCT01770548|Genetic|DNA collection|DNA collection
79569744|NCT01770548|Other|Auditory evoked potentials|auditory evoked potentials
79569745|NCT01770561|Device|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
79569746|NCT01770574|Device|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
79569747|NCT01770574|Procedure|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
79569748|NCT01770587|Behavioral|Behavioral Insomnia Treatment|
79569749|NCT01770600|Other|placebo|placebo pill administered daily for 5 days
79569750|NCT01770600|Drug|Riperidone|1 mg risperidone administered orally for 5 days
79569751|NCT01770613|Biological|Stem cells|Allogeneic mesenchymal stem cells
79569752|NCT01770626|Other|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
79569753|NCT01770639|Procedure|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
79569754|NCT01770678|Other|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
79268133|NCT03526874|Drug|Lidocaine 4% Topical Application Cream [LMX 4]|Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
79268134|NCT03526874|Drug|Lidocaine Hydrochloride 2 mg/mL Injectable Solution|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
79268135|NCT03526874|Drug|Normal Saline|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
79268136|NCT03523559|Genetic|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
79729716|NCT02862249|Biological|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
79729717|NCT02862249|Biological|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
79729718|NCT04258384|Other|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
79729719|NCT02666209|Drug|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
79864213|NCT00789425|Dietary Supplement|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
79569755|NCT01770730|Device|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
79569756|NCT01770769|Device|Hemi - arthroplasty|modular hemiarthroplasty
79864214|NCT00789425|Dietary Supplement|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
79864215|NCT00793091|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
79864216|NCT00793091|Drug|Placebo|4 drops applied daily for 120 days
79268137|NCT03505424|Other|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~a welcome packet from the nursing staff~access to their infant's medical team including doctors and nurse~opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
79268138|NCT03505424|Other|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
79268139|NCT03505424|Other|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
79268140|NCT03502603|Diagnostic Test|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
79268141|NCT03502603|Diagnostic Test|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
79268142|NCT03502603|Diagnostic Test|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
79268143|NCT03502603|Diagnostic Test|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
79268144|NCT03502603|Diagnostic Test|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
79569757|NCT01770769|Device|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
79569758|NCT01770782|Procedure|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
79569759|NCT01770782|Other|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
79569760|NCT01770795|Drug|Genexol-PM/Gemcitabine|
79569761|NCT01770808|Dietary Supplement|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
79729720|NCT02666209|Drug|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
79864217|NCT00789503|Dietary Supplement|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
79864218|NCT00789659|Other|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
79864219|NCT00797069|Other|standard nutritional product (medical food)|once during crossover
79864220|NCT00797069|Other|nutritional product for diabetes (medical food)|once during crossover
79864221|NCT00797069|Other|diabetes specific experimental nutritional product (medical food)|once during crossover
79864222|NCT00793247|Drug|PRU-PLA-PRU-PLA|
79864223|NCT00793247|Drug|PLA-PRU-PLA-PRU|
79569762|NCT01770808|Dietary Supplement|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
79864224|NCT00793247|Drug|PLA-PRU-PRU-PLA|
79864225|NCT00793247|Drug|PRU-PLA-PLA-PRU|
79864226|NCT00797303|Drug|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
79864227|NCT00800579|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
79864228|NCT00800579|Drug|Placebo|Inhaled volume-matched placebo in sterile saline
79864229|NCT00661271|Behavioral|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
79864230|NCT00661271|Behavioral|Healthy topics|8 week health education program with one retreat session
79864231|NCT00800657|Procedure|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
79864232|NCT00800657|Procedure|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
79864233|NCT00922181|Device|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
79864234|NCT00922181|Device|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
79864235|NCT00661193|Drug|carboplatin|given IV
79864236|NCT00661193|Drug|erlotinib hydrochloride|given orally
80024477|NCT04775472|Procedure|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
79268145|NCT03502603|Diagnostic Test|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
79268146|NCT03502603|Diagnostic Test|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
79569763|NCT01770808|Dietary Supplement|Placebo|Subjects swallowed 4 capsules/day for six weeks.
79569764|NCT01770821|Other|Dietary supplement and/or physical training|
79729721|NCT02666209|Drug|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
79864237|NCT00661193|Drug|paclitaxel|given IV
79569765|NCT01770873|Behavioral|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
79569766|NCT01770886|Drug|UE2343|Oral capsule
79569767|NCT01770886|Drug|Placebo|Oral capsule
79569768|NCT01770899|Drug|Montelukast|
79569769|NCT01770899|Drug|Placebo|Gelatin capsule given every 24 hours
79729722|NCT02666209|Drug|Dexamethasone|steroid given at physician discretion on a 28 day cycles
79729723|NCT00964743|Drug|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
79729724|NCT00964743|Drug|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
79729725|NCT04258774|Other|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
79729726|NCT02537041|Procedure|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
79729727|NCT02537041|Procedure|MRI|
79729728|NCT02862327|Drug|intravenous dexamethasone|intravenous injection of dexamethasone
79864238|NCT04046315|Diagnostic Test|CMR|GLS measurement with CMR
79864239|NCT00797537|Procedure|Echography|Echography
79864240|NCT00800813|Behavioral|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
79864241|NCT00793481|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
79864242|NCT00800969|Procedure|FDG-PET-CT|Radiologic standard procedure
79864243|NCT00801047|Drug|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
79864244|NCT00801047|Drug|Remifentanil|40-50 mic per 1-2 min via PCA
79864245|NCT00801125|Drug|natalizumab|
79864246|NCT00801203|Drug|IRCT|Up to two administrations of the IRCT during a single cough testing session
79864247|NCT00801281|Drug|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
79864248|NCT00801281|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
79864249|NCT00801281|Drug|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
79864250|NCT00801281|Drug|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
79864251|NCT00801281|Drug|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
79864252|NCT00801281|Drug|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
79864253|NCT00801359|Procedure|Phacoemulsification|
80024478|NCT04765137|Drug|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
80024479|NCT04760691|Drug|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
79268147|NCT03502603|Diagnostic Test|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
79268148|NCT03502603|Diagnostic Test|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
79268149|NCT03502603|Diagnostic Test|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
79268150|NCT03471143|Drug|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
79400867|NCT05539443|Behavioral|Intensive tailored telehealth management (ITTM)|A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial
79569770|NCT01770925|Device|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
79569771|NCT01770925|Device|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
79569772|NCT01770925|Device|NIPPV|The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
79729729|NCT02862327|Drug|intravenous placebo|intravenous injection of placebo
79729730|NCT02862327|Drug|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
79729731|NCT02862327|Other|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
80024480|NCT04760691|Drug|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
79268151|NCT03468530|Procedure|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
79268152|NCT03409432|Drug|Brentuximab Vedotin|Given IV
79569773|NCT01770938|Device|Effective light-emitting diode therapy|
79569774|NCT01770938|Device|Placebo light-emitting diode therapy|
79569775|NCT01770964|Drug|Pregabalin|
79569776|NCT01770964|Drug|placebo|
79569777|NCT01770964|Behavioral|Training Type A|
79729732|NCT04945720|Procedure|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
79729733|NCT04945720|Drug|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
79268153|NCT03409432|Other|Laboratory Biomarker Analysis|Correlative studies
79268154|NCT03409432|Drug|Lenalidomide|Given PO
79569778|NCT01770964|Behavioral|Training Type B|
79569779|NCT01770977|Device|Light-emitting diode therapy|
79729734|NCT02666365|Procedure|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
79729735|NCT02666365|Procedure|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
79864254|NCT00801359|Drug|BSSPlus solution|
79864255|NCT00801359|Drug|Lactated Ringer's solution|
79864256|NCT00801437|Drug|Xalacom|Xalacom 1 drop into the affected eye daily
80024481|NCT04760691|Drug|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
80024482|NCT04760691|Drug|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
79569780|NCT01770977|Device|Placebo light-emitting diode therapy|
79729736|NCT03423303|Diagnostic Test|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
79729737|NCT04268433|Other|N/A - Non-interventional study|"Stages:~Patient information and written informed consent (3 Copies. To be carried out >24 hours after receiving the patient information sheet)~Physiological recording set up (ECG, BP, sensor and respiratory band)~Control period - no music played~Series of pieces of music without tempo control~Repeat series of pieces of music with tempo control~Participant leaves the study"
79729738|NCT00645385|Other|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
79729739|NCT02862093|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
79729740|NCT02666443|Drug|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
79729741|NCT02666443|Drug|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
79729742|NCT02666443|Drug|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
79729743|NCT00925522|Device|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
80024483|NCT04760691|Drug|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
80024484|NCT04741230|Device|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
79729744|NCT01130532|Drug|Tadalafil|Administer orally
79729745|NCT01130532|Drug|Placebo|Administer orally
79864257|NCT00801515|Drug|Maraviroc|150 mg twice per day
79864258|NCT00797615|Behavioral|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
79864259|NCT00797615|Behavioral|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
80024485|NCT04711915|Drug|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
80024486|NCT04711915|Drug|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
80024487|NCT04700098|Behavioral|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
80024488|NCT04700098|Behavioral|Online insomnia patient education|Online insomnia patient education
80024489|NCT04668157|Drug|TAK-536|TAK-536 granule formulation
80024490|NCT04660721|Combination Product|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
80024491|NCT04660721|Combination Product|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
80024492|NCT04617457|Drug|nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)|preoperative chemotherapy
80024493|NCT04607135|Device|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
79268155|NCT03407833|Other|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
79569781|NCT01770990|Behavioral|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
79569782|NCT01770990|Behavioral|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
80024494|NCT04607135|Device|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
80024495|NCT04599140|Drug|CXCR1/2 Inhibitor SX-682|Given PO
80024496|NCT04599140|Biological|Nivolumab|Given IV
79569783|NCT01771003|Device|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
79569784|NCT01771042|Other|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
79729746|NCT04258306|Dietary Supplement|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
79729747|NCT04258306|Dietary Supplement|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
79864260|NCT00797693|Drug|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
79268156|NCT03407833|Other|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
79268157|NCT03407833|Other|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
79268158|NCT03407833|Other|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
79268159|NCT03374826|Diagnostic Test|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
79268160|NCT03343483|Behavioral|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
79268161|NCT03343483|Behavioral|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
79268162|NCT03323476|Other|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
79268163|NCT03323476|Drug|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
79569785|NCT01771068|Behavioral|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
79729748|NCT04068961|Other|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
79729749|NCT04284501|Behavioral|Non|questionnaire
79268164|NCT03315312|Drug|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
79268165|NCT03315312|Drug|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
79569786|NCT01771081|Drug|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
79569787|NCT01771094|Behavioral|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
79864261|NCT00797771|Device|"Adi Insulin pump"|insulin delivery will be defined by the physician
79864262|NCT00797849|Device|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
79729750|NCT00646165|Drug|Forodesine|
79864263|NCT00797849|Device|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
79729751|NCT04253158|Behavioral|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
79864264|NCT00793559|Drug|terlipressin|1 mg of terlipressin one time only
79864265|NCT00793559|Drug|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
79864266|NCT00797927|Drug|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
79864267|NCT00797927|Other|no intervention|keep the original conventional antipsychotic agent for 28 days
79864268|NCT00798005|Drug|XRP0038 (NV1FGF)|
79729752|NCT04253158|Behavioral|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
79864269|NCT00801593|Procedure|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
79864270|NCT02554097|Procedure|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
79864271|NCT02554097|Procedure|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
80024497|NCT04591093|Device|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
79268166|NCT03289325|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
79268167|NCT03289325|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation."
79268168|NCT03259763|Device|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
79268169|NCT03259763|Device|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
79569788|NCT01771120|Other|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
80024498|NCT04590885|Behavioral|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
79268170|NCT03204123|Drug|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
79304375|NCT03107507|Drug|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
79400882|NCT05534880|Other|Binaural beats|Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
79400883|NCT05533463|Drug|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
79400884|NCT05524051|Drug|TIN816|TIN816
79400885|NCT05524051|Other|Placebo|Placebo
79569789|NCT01771133|Behavioral|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
79729753|NCT04253158|Behavioral|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
79729754|NCT04253158|Behavioral|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
79729755|NCT04253158|Behavioral|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
79729756|NCT04253158|Behavioral|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
79729757|NCT04253158|Behavioral|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
79729758|NCT04253158|Behavioral|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
79729759|NCT04068415|Other|Constipation risk assessment scale|questionnaires
79729760|NCT04912804|Other|Questionnaires|SF-12, GHQ-12 and HAQ
79729761|NCT02668237|Other|OptiPAC|Molecular and urinary tests.
79729762|NCT02668237|Other|Usual care|Antibiotics for prevention.
79729763|NCT04856800|Dietary Supplement|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
79729764|NCT04856800|Dietary Supplement|Placebo|The placebo contains <1 kcal and 0 g protein
79729765|NCT00646711|Drug|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
80024499|NCT04590885|Behavioral|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
80024500|NCT04586127|Other|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
80024501|NCT04574778|Drug|Acetaminophen|1000 mg of oral acetaminophen preoperatively administered
79268171|NCT03204123|Diagnostic Test|PET/CT|PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
79864272|NCT02554097|Procedure|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
79864273|NCT02554097|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
79569790|NCT01771146|Drug|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
80024502|NCT04568564|Other|Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|The exercise program includes breathing exercises (chest-abdominal-lateral basal breathing; 10 repetitions), use of intensive spirometry (20 repetitions) and assisted coughing. Apart from this, a progressive mobilization program will be applied considering patient tolerance and hemodynamic parameters, starting after the patient is taken to the service room. The teleconference exercise call will be continued from the postop 1st day until discharge, twice a day.
79729766|NCT00646711|Drug|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
79864274|NCT00793715|Procedure|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
79268172|NCT03204123|Diagnostic Test|MRI|Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
79268173|NCT03197454|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
79268174|NCT03197454|Other|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
79268175|NCT03190954|Drug|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
79268176|NCT03190954|Drug|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
79729767|NCT04255186|Device|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
79569791|NCT01771159|Device|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor [bladder] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
79729768|NCT04255186|Device|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
79729769|NCT04255186|Device|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
79729770|NCT00972777|Drug|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
79729771|NCT00972777|Drug|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
79729772|NCT04254874|Drug|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
79729773|NCT04254874|Drug|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
79729774|NCT02667223|Biological|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
79729775|NCT02667223|Biological|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
79729776|NCT02667223|Biological|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
79729777|NCT02667223|Biological|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
79864275|NCT00793715|Procedure|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
79864276|NCT00801671|Procedure|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
80024503|NCT04568564|Other|Exercise booklet|Patients will be interviewed by videoconferencing method at least 1 day before the operation, their first evaluation will be taken and an exercise booklet will be given.
80024504|NCT04567537|Device|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
80024505|NCT04566315|Procedure|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
80024506|NCT04554485|Drug|Blinatumomab|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
79864277|NCT04045925|Other|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
79864278|NCT00801749|Behavioral|sleep|
79864279|NCT02553785|Device|Revivent TC|
79864280|NCT00798083|Drug|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
79864281|NCT00794027|Behavioral|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
80024507|NCT04543331|Drug|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
80024508|NCT04539392|Other|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
79569792|NCT01771185|Procedure|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
79569793|NCT01771185|Drug|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
79569794|NCT01771198|Drug|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
79569795|NCT01771211|Device|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
79569796|NCT01771224|Dietary Supplement|Palmitoleic acid|Palmitoleic acid and 5-ASA
79569797|NCT01771237|Behavioral|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
79729778|NCT02667223|Biological|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
79729779|NCT04240912|Device|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
79729780|NCT02883660|Genetic|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
79864282|NCT00794027|Behavioral|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
79864283|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
80024509|NCT04529772|Drug|acalabrutinib|Investigational Product
79569798|NCT01771237|Behavioral|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
79569799|NCT01771263|Device|iControl-RP|
79569800|NCT01771276|Device|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
79569801|NCT01771289|Drug|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
79729781|NCT02882724|Behavioral|Exercise|8-week aquatic exercise training program
79729782|NCT02882724|Behavioral|Control|Control group did not do the exercise training.
79729783|NCT04173091|Diagnostic Test|No Intervention|No Intervention planed
79729784|NCT00918736|Drug|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
79729785|NCT02666053|Drug|BMS-663068|BMS-663068
79569802|NCT01771289|Radiation|Radiation|chemoradiation
79569803|NCT01771302|Device|Bio-Oss|It is a bone substitute of bovine origin
79864284|NCT00798239|Other|Iliac crest autograft|autograft
79864285|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
79864286|NCT00798395|Drug|Org 50081|1.5 mg on day 1-7
79864287|NCT00798395|Drug|Org 50081|4.5 mg on Day 1-7
79864288|NCT00798395|Drug|Placebo|Once daily on Day 1-7
79864289|NCT00798395|Drug|zopiclone|Single dose of 7.5 mg
79864290|NCT00801905|Drug|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
79864291|NCT00801905|Other|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
79864292|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
79864293|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
79864294|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|2.5mg po daily
79864295|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
80024510|NCT04529772|Drug|placebo|Placebo comparator
80024511|NCT04529772|Drug|Prednisone|Investigational Product
80024512|NCT04529772|Drug|Rituximab|Investigational Product
80024513|NCT04529772|Drug|Cyclophosphamide|Investigational Product
80024514|NCT04529772|Drug|Vincristine|Investigational Product
80024515|NCT04529772|Drug|Doxorubicin|Investigational Product
80024516|NCT04525885|Drug|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
79569804|NCT01771302|Device|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
79729786|NCT04257838|Drug|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~Just before the antibiotic infusion (T0)~In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
79569805|NCT01771315|Behavioral|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
79569806|NCT01771328|Drug|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
79729787|NCT01172639|Drug|Methotrexate|Methotrexate tablet
79569807|NCT01771328|Drug|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
79729788|NCT01172639|Drug|Sulfasalazine|Sulfasalazine tablet
79569808|NCT01771341|Device|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
79729789|NCT01172639|Drug|Leflunomide|Leflunomide tablet
79729790|NCT01172639|Drug|Prednisone|Prednisone tablet
79729791|NCT01144182|Behavioral|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
79729792|NCT00646789|Drug|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
79864296|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
80024517|NCT04525885|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
79729793|NCT01225562|Drug|Ticagrelor 90 mg|Oral dose twice a day
79729794|NCT01225562|Drug|Ticagrelor 60 mg|Oral dose twice a day
79729795|NCT01225562|Drug|Ticagrelor Placebo|Oral dose twice a day
79729796|NCT04203628|Diagnostic Test|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~Standard sucrose flotation method~Optimized sucrose flotation~Stool processing kit (SPK)~Simple One-step method (SOS)"
79729797|NCT04203628|Diagnostic Test|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
79400886|NCT05523323|Drug|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
79569809|NCT01771341|Device|MAQUET SERVOi ventilator|Pressure Support
79569810|NCT01771354|Biological|Engerix B Vaccine|
79569811|NCT01771354|Biological|Placebo|
79569812|NCT01771367|Biological|Fluad|
79569813|NCT01771367|Biological|Agrippal|
79569814|NCT01771367|Biological|Placebo|
79569815|NCT01771393|Device|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
79569816|NCT01771393|Device|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
79569817|NCT01771406|Drug|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
79569818|NCT01771406|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
79569819|NCT01771432|Drug|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
79569820|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
79729798|NCT04067557|Diagnostic Test|molecuar test of BV|diagnosis of BV
79864297|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|150mg po monthly
79864298|NCT00048061|Dietary Supplement|Calcium|500 mg/day
79864299|NCT00048061|Dietary Supplement|Vitamin D|400 IU/day
79864300|NCT00802061|Behavioral|Sleeping position in glaucoma patient|
79864301|NCT00802139|Drug|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
79864302|NCT00802139|Drug|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
79864303|NCT00802217|Drug|Civamide|5 mg liquid filled softgel capsules
79864304|NCT00802217|Drug|Civamide|5 mg x 2 liquid softgel capsules
80024518|NCT04525885|Drug|Placebo|Placebo tablet administered orally BID
79569821|NCT01771445|Drug|IL-1Ra|100mg, s.c, once only
79569822|NCT01771445|Drug|Placebo|100mg, s.c., once only
79569823|NCT01771458|Drug|Targeted therapy based on molecular profiling : Imatinib|
79569824|NCT01771458|Procedure|Tumor biopsy|
80024519|NCT04525885|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
80024520|NCT04517149|Biological|4D-125 IVT Injection|4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
80024521|NCT04517149|Other|Observational|Natural History
80024522|NCT04496726|Other|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
80024523|NCT04489823|Device|Amplatzer Valvular Plug III|Transcatheter closure of a paravalvular leak using Amplatzer Valvular Plug III
79400887|NCT05523323|Drug|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
79729799|NCT02665819|Other|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
79400888|NCT05523323|Drug|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
79569825|NCT01771458|Drug|Standard Chemotherapy|
79864305|NCT04808141|Device|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
79569826|NCT01771458|Drug|Targeted therapy based on molecular profiling : Everolimus|
79864306|NCT04808141|Other|Conventional PT|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.
79569827|NCT01771458|Drug|Targeted therapy based on molecular profiling : Vemurafenib|
79569828|NCT01771458|Drug|Targeted therapy based on molecular profiling : Sorafenib|
79569829|NCT01771458|Drug|Targeted therapy based on molecular profiling : Erlotinib|
79729800|NCT00925288|Biological|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
79729801|NCT04174573|Other|GTO|"Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
79729802|NCT04174573|Other|GT-tDCS|"Group therapy~Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
79864307|NCT03955159|Dietary Supplement|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
79864308|NCT00802295|Drug|Gonadotrophins|Administration of standard ovarian stimulation protocol
80024524|NCT04482660|Procedure|Positron emission tomography with 18F-RO6958948|tau PET ()
80024525|NCT04473378|Device|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
79400889|NCT05522868|Drug|SB17170|SB17170 capsules, Oral administration 21days/cycle
79400890|NCT05521919|Behavioral|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
79864309|NCT00802295|Drug|Low dosis Gonadotrophin|
79400891|NCT05521919|Behavioral|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
79400892|NCT05520762|Procedure|A strategy of first choice supraglottic airway|See description in Arms section
79569830|NCT01771458|Drug|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
79569831|NCT01771458|Drug|Targeted therapy based on molecular profiling : Dasatinib|
79569832|NCT01771458|Drug|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
79569833|NCT01771458|Drug|Targeted therapy based on molecular profiling : Abiraterone|
79569834|NCT01771471|Biological|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
80024526|NCT04466527|Device|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
80024527|NCT04459559|Device|Tactile Cueing Device|Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
79400893|NCT05520762|Procedure|A strategy of first choice endotracheal intubation|See description in Arms section
79569835|NCT01771471|Other|Placebo|0.9% w/v Sodium Chloride for Injection, USP
79569836|NCT01771484|Device|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
79569837|NCT01771419|Device|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
79569838|NCT01771419|Device|Cannulotome CT-25mm Cook Medical|
79569839|NCT01771497|Device|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
79569840|NCT01771523|Procedure|Thyroidectomy|total thyroidectomy or lobectomy
79569841|NCT01771523|Device|use of drain|drain will be used
79569842|NCT01771575|Other|Placebo device|Placebo device
79729803|NCT01143714|Drug|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
79729804|NCT01143714|Other|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
79864310|NCT03954925|Procedure|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
79268177|NCT03190954|Drug|[11C]NNC-112|[11C]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
79268178|NCT03150433|Behavioral|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
79268179|NCT03150433|Other|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
79268180|NCT03146442|Behavioral|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
79400894|NCT05518812|Drug|Carboprost Tromethamine|During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
79569843|NCT01771575|Device|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance & gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
79569844|NCT01771588|Dietary Supplement|Human milk fortifier|
79569845|NCT01771614|Behavioral|Exercise|
79569846|NCT01771614|Procedure|Hyperglycemia|
79569847|NCT01771640|Biological|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
79569848|NCT01771692|Other|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
79569849|NCT01771692|Other|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
79569850|NCT01771705|Other|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
79569851|NCT05318365|Drug|Polyethylene Glycol 3350|PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
79569852|NCT05318365|Behavioral|Urotherapy|Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
79729805|NCT04800757|Behavioral|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
79864311|NCT03954925|Procedure|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
79864312|NCT00802373|Drug|Solifenacin succinate|oral
79864313|NCT00802373|Drug|Tolterodine|Oral
79864314|NCT01092715|Procedure|Spinal mobilization|Non thrust mobilization to the cervical spine
79569853|NCT01771783|Drug|ACEI-ARB-RI|
79864315|NCT01092715|Procedure|Massage|Sedative massage to cervical paraspinal muscles
79864316|NCT01092715|Procedure|Neck exercises|Range of motion exercises to include foraminal opening
79268181|NCT03122717|Drug|Gefitinib|gefitinib is a EGFR inhibitor
79268182|NCT03122717|Drug|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
79400895|NCT05516979|Drug|100 mg AP1189|AP1189 tablets for oral use
79569854|NCT01771783|Drug|ARB-RI-ACEI|
79569855|NCT01771783|Drug|RI-ACEI-ARB|
79569856|NCT01771796|Behavioral|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
79864317|NCT03957109|Procedure|general anesthesia|
79864318|NCT03952975|Other|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
79864319|NCT00802451|Drug|Mesalamine|
79864320|NCT03956953|Drug|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
80024528|NCT04446962|Drug|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
80024529|NCT04446962|Drug|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
80024530|NCT04438824|Drug|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
79400896|NCT05516979|Drug|Placebo|Matching placebo for oral use
79400897|NCT05514288|Procedure|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
79400898|NCT05513378|Device|Needle guide|Please see the arm/group description
79569857|NCT01771822|Drug|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
79268183|NCT03104972|Device|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
79268184|NCT03104972|Device|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
79569858|NCT01771822|Drug|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
79569859|NCT01771822|Drug|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
79569860|NCT01771822|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
79569861|NCT01771848|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
79569862|NCT01771861|Other|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
79569863|NCT01771874|Drug|MDMA|125 mg per os, single dose
79569864|NCT01771874|Drug|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
79569865|NCT01771874|Drug|Placebo|per os
79569866|NCT01771887|Behavioral|education program|education program in 6 hours and monitoring phone every 15 days
79569867|NCT01771926|Other|potatoes|Daily intake of assigned treatment for 8 weeks
79569868|NCT01771926|Other|other carbohydrate|Daily intake of assigned treatment for 8 weeks
79729806|NCT04800757|Behavioral|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
79569869|NCT01771939|Procedure|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
79864321|NCT03956953|Other|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
79569870|NCT01771939|Procedure|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
79569871|NCT01771978|Drug|Placebo|Received 250 ml of a 5% dextrose solution as placebo
79864322|NCT00798473|Drug|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
79864323|NCT00798473|Other|IV saline infusion|
79864324|NCT01583881|Procedure|renal denervation|Renal denervation
79569872|NCT01771978|Drug|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
79569873|NCT01771978|Drug|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
79864325|NCT03955003|Behavioral|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
79864326|NCT03955003|Other|Attention Control|This is intended to control for time, place, and group affect.
79864327|NCT03955237|Procedure|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
79569874|NCT01771978|Drug|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
79569875|NCT01772017|Device|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
79569876|NCT01772030|Other|Use of the Achieve catheter followed by ICE-guided mapping catheter|
79569877|NCT01772056|Drug|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
79569878|NCT01772056|Drug|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
79569879|NCT01772082|Behavioral|Internet mediated walking program|
79569880|NCT01772108|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
79569881|NCT01772173|Other|Vessel measurements|Measurement of retinal vessels
79864328|NCT04045769|Drug|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
79864329|NCT04045769|Drug|Placebos|5 tablets of placebo to be administered orally
79864330|NCT04045769|Drug|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
79864331|NCT04045769|Drug|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
79729807|NCT04800757|Behavioral|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
79729808|NCT04257916|Other|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
79729809|NCT04257916|Other|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
79864332|NCT01095601|Drug|Avanafil|"Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~Treatment B: 2x100 mg Formulation II avanafil tablet, fed~Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
79569882|NCT01772186|Device|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
80024531|NCT04438824|Drug|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
80024532|NCT04431401|Device|Magstim rTMS|The device is made in London,UK
80024533|NCT04426006|Other|PRO-SERO-COV|"At inclusion, 3 months and 12 months :~blood sample (2 x 5ml)~self-administered questionnaire"
80024534|NCT04418713|Other|active video-games|An intervention with active video-games to increase physical activity and improve body composition
80024535|NCT04413123|Drug|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
80024536|NCT04413123|Drug|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
80024537|NCT04413123|Drug|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
79268185|NCT03104972|Device|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
79268186|NCT03035409|Drug|Anamorelin Hydrochloride|Given PO
79268187|NCT03035409|Behavioral|Exercise Intervention|Undergo physical activity
79268188|NCT03035409|Other|Laboratory Biomarker Analysis|Correlative studies
79268189|NCT03035409|Other|Nutritional Assessment|Undergo nutritional counseling
79569883|NCT01772199|Drug|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
79268190|NCT03035409|Other|Quality-of-Life Assessment|Ancillary studies
79569884|NCT01772199|Drug|Placebo|White to almost white, round tablets. Once daily orally.
79569885|NCT01772212|Drug|Terbinafine 250 mg|Test product
79729810|NCT04920682|Drug|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4
79864333|NCT03953365|Procedure|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
79864334|NCT00798629|Biological|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
79864335|NCT01097317|Drug|carboplatin|
79864336|NCT01097317|Drug|vinorelbine tartrate|
79864337|NCT01097317|Other|neuromuscular electrical stimulation|
79864338|NCT01097317|Other|physiologic testing|
79864339|NCT01097317|Procedure|fatigue assessment and management|
79864340|NCT01097317|Procedure|quality-of-life assessment|
80024538|NCT04408066|Diagnostic Test|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~Whole Venous Blood"
80024539|NCT04408066|Diagnostic Test|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~Whole Venous Blood~Fingerstick Capillary Sample"
80024540|NCT04343924|Other|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
79268191|NCT03035409|Other|Questionnaire Administration|Ancillary studies
79268192|NCT03006068|Drug|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
79268193|NCT03006068|Drug|Placebo|Placebo will be administered orally.
79268194|NCT02965703|Drug|Aspirin|Given PO
79268195|NCT02965703|Procedure|Biospecimen Collection|Undergo collection of blood, urine, stool, and rectal swab samples
79268196|NCT02965703|Other|Placebo Administration|Given PO
79268197|NCT02965703|Other|Questionnaire Administration|Ancillary studies
79268198|NCT02965703|Procedure|Rectal Biopsy|Undergo rectal biopsy
79268199|NCT02943915|Device|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
79268200|NCT02943915|Device|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
79569886|NCT01772212|Drug|Terbinafine 250 mg|Reference product
79864341|NCT04046705|Procedure|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
79864342|NCT04046705|Other|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
80024541|NCT04343924|Other|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
79268201|NCT02926196|Drug|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
79569887|NCT01772225|Other|Data collection|Medical record abstraction form and patient survey questionnaire.
79569888|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
79729811|NCT04920682|Drug|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
79729812|NCT04920682|Drug|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
80024542|NCT04343313|Device|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
80024543|NCT04341350|Drug|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
80024544|NCT04341350|Drug|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
80024545|NCT04322084|Other|Wearable Sensors|To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
80024546|NCT04318366|Other|Observational Study|Not required
80024547|NCT04305795|Biological|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
80024548|NCT04305795|Biological|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
80024549|NCT04305795|Combination Product|ASP-1929|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
80024550|NCT04296006|Drug|Sustained Release d-amphetamine|Twice daily administration of active or placebo d-amphetamine
80024551|NCT04296006|Behavioral|Money|Three money values offered as alternatives to cocaine
79268202|NCT02824185|Device|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
79268203|NCT02795442|Other|Even protein|5 day intake of even protein 3 day rotating menu.
79268204|NCT02795442|Other|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
79569889|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
79864343|NCT01097473|Procedure|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
79864344|NCT00802763|Device|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
80024552|NCT04292054|Drug|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
79268205|NCT02772003|Biological|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
79268206|NCT02772003|Biological|HCV DNA Vaccine INO-8000|Given IM
79268207|NCT02772003|Other|Laboratory Biomarker Analysis|Correlative studies
79268208|NCT02772003|Other|Quality-of-Life Assessment|Ancillary studies
79268209|NCT02772003|Biological|Rocakinogene Sifuplasmid|Given IM
79268210|NCT02763384|Drug|BL-8040|
79268211|NCT02763384|Drug|Nelarabine|
79268212|NCT02708394|Drug|olanzapine|atypical antipsychotic
79268213|NCT02708394|Drug|placebo|placebo control
79268214|NCT02662062|Drug|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
79268215|NCT02662062|Drug|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
79569890|NCT01772251|Drug|Oshadi Icp|
79569891|NCT01772264|Drug|PF-05089771|titration from 150mg BID to 450mg BID
79569892|NCT01772264|Drug|Placebo|matched placebo
79569893|NCT01772290|Drug|fluconazole|Multiple oral doses
79569894|NCT01772290|Drug|itraconazole|Multiple oral doses
79569895|NCT01772290|Drug|rabeprazole|Multiple oral doses
79569896|NCT01772290|Drug|vismodegib|Multiple oral doses
79569897|NCT01772303|Drug|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
79569898|NCT01772342|Other|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
79569899|NCT01772342|Other|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
79729813|NCT04920682|Drug|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4
79729814|NCT04174339|Drug|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
79729815|NCT04174339|Drug|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
79729816|NCT04174339|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
79569900|NCT01772355|Device|semi automated core needle biopsy of orbital tumors|
79569901|NCT01772381|Drug|Dexamethasone|Long acting corticosteroid
79569902|NCT01772394|Behavioral|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
79569903|NCT01772394|Behavioral|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
79729817|NCT00972543|Biological|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
79729818|NCT00972543|Biological|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
79729819|NCT04173481|Other|Rood's Group|"ROOD'S sensory motor training~Brushing & strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
79729820|NCT04173481|Other|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
79729821|NCT00925132|Drug|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
79569904|NCT01772433|Dietary Supplement|Olive oil|Phonophoresis with Olive oil for 10 day, daily
79569905|NCT01772433|Drug|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
79569906|NCT01772446|Behavioral|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
79569907|NCT01772485|Behavioral|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
79729822|NCT02862015|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
79729823|NCT02862015|Drug|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
79569908|NCT01772485|Behavioral|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
79729824|NCT00646867|Device|Tetrix|Twice daily topical application
79729825|NCT00646867|Device|Placebo|Twice daily topical application
79729826|NCT02863653|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
79729827|NCT04254718|Behavioral|Digital Storytelling|Creation of a digital story about the infant with video and music selected by parents
79729828|NCT02664805|Drug|LEO 124249 ointment|Ointment
79268216|NCT02662062|Radiation|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
79729829|NCT02664805|Drug|LEO 124249 ointment vehicle|Ointment vehicle
79729830|NCT04285593|Other|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
79729831|NCT01143402|Drug|Dacarbazine|Given IV
79729832|NCT01143402|Other|Laboratory Biomarker Analysis|Correlative studies
79729833|NCT01143402|Other|Quality-of-Life Assessment|Ancillary studies
79268217|NCT02649855|Biological|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
79729834|NCT01143402|Drug|Selumetinib|Given PO
79268218|NCT02649855|Biological|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
79268219|NCT02649855|Drug|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
79268220|NCT02619682|Drug|Ixazomib Citrate|Given PO
79268221|NCT02619682|Other|Laboratory Biomarker Analysis|Correlative studies
79569909|NCT01772498|Behavioral|heart rate variability biofeedback|
79729835|NCT01143402|Drug|Temozolomide|Given PO
79268222|NCT02619682|Drug|Lenalidomide|Given PO
79569910|NCT01772511|Behavioral|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
79569911|NCT01772524|Biological|ALD403|
79569912|NCT01772524|Drug|Placebo|
79569913|NCT01772589|Procedure|New saw blade|
79569914|NCT01772589|Procedure|Reprocessed saw blade|
79569915|NCT01772615|Drug|Ciprofloxacin|Antibiotic
79569916|NCT01772615|Dietary Supplement|E. coli Nissle|Probiotic
79569917|NCT01772628|Behavioral|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
79569918|NCT01772628|Behavioral|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
79729836|NCT00646945|Drug|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
79729837|NCT00646945|Drug|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
79864345|NCT01095679|Drug|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
79268223|NCT02613507|Drug|Nivolumab|
79268224|NCT02613507|Drug|Docetaxel|
79268225|NCT02592382|Dietary Supplement|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for three months
79569919|NCT01772628|Behavioral|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
79569920|NCT01772628|Behavioral|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
79569921|NCT01772641|Other|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
79569922|NCT01772641|Other|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
79569923|NCT01772641|Other|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
79569924|NCT01772641|Other|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
79569925|NCT01772667|Procedure|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
79569926|NCT01772680|Dietary Supplement|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
79569927|NCT01772706|Procedure|low level laser therapy|
79569928|NCT01772706|Procedure|placebo (laser low level energy nonfunctional)|
79569929|NCT01772732|Drug|Simotinib Hydrochloride|
79268226|NCT02539407|Other|Pharmacokinetics|
79268227|NCT02538510|Other|Laboratory Biomarker Analysis|Correlative studies
79569930|NCT01772745|Procedure|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
79569931|NCT01772745|Procedure|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
79729838|NCT01171625|Device|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
79729839|NCT00629889|Drug|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
79864346|NCT01095679|Drug|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
79268228|NCT02538510|Biological|Pembrolizumab|Given IV
79268229|NCT02538510|Drug|Vorinostat|Given PO or via PEG
79268230|NCT02521285|Drug|Aspirin|Given PO
79268231|NCT02521285|Other|Laboratory Biomarker Analysis|Correlative studies
79268232|NCT02521285|Other|Placebo Administration|Given PO
79268233|NCT02521285|Other|Questionnaire Administration|Ancillary studies
79569932|NCT01772784|Other|Phenolic acids|Phenolic acids
79729840|NCT00629889|Drug|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
79729841|NCT04898686|Biological|Probiotic chewables|chewables containing Lacticaseibacillus rhamnosus GG
79569933|NCT01772797|Drug|LDK378|LDK378 is a capsule to be taken daily by mouth.
80024553|NCT04292054|Other|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
79569934|NCT01772797|Drug|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
79569935|NCT01772810|Drug|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
80024554|NCT04285372|Procedure|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
79569936|NCT01772836|Drug|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
79729842|NCT04898686|Biological|Placebo chewables|chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
79729843|NCT04257604|Drug|Perampanel|Perampanel tablets.
79569937|NCT01772836|Drug|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
79569938|NCT01772836|Drug|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
79569939|NCT01772849|Behavioral|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
79729844|NCT03381261|Drug|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
79729845|NCT05224752|Other|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
79729846|NCT04315259|Device|Diode laser|irrigation activated by diode laser versus soft tissue laser application therapy
79729847|NCT04849936|Diagnostic Test|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
79729848|NCT00630045|Drug|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
79729849|NCT00630045|Procedure|resection of liver metastasis|surgery with the aim of R0 resection
79729850|NCT04315103|Combination Product|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
79729851|NCT02861859|Drug|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
79729852|NCT02861859|Drug|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
79729853|NCT00910507|Behavioral|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
79864347|NCT00794183|Device|CRT device settings|Comparision of A-V delay settings
79864348|NCT01092793|Dietary Supplement|Krill|Encapsulated oil from the antarctic crustacean Krill
79864349|NCT01092793|Dietary Supplement|Fish oil|Encapsulated, raffined cod-oil
80024555|NCT04285372|Procedure|No side branch protection/ballooning|No intervention on the side branch
80024556|NCT04279847|Drug|INCB057643|INCB057643 dose escalation and dose expansion.
80024557|NCT04279847|Drug|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
79268234|NCT02436226|Drug|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
79268235|NCT02436226|Drug|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
79268236|NCT02421380|Drug|Hyperpolarized Pyruvate|
79268237|NCT02419040|Procedure|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
79864350|NCT00794261|Drug|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
79864351|NCT00794261|Drug|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
79864352|NCT03953287|Drug|Paracetamol|A randomized, cross over design
79864353|NCT02554565|Procedure|Tumor biopsy|Tumor biopsy before treatment
79864354|NCT02554565|Procedure|Blood sampling|Blood sample before, during and after treatment
79864355|NCT01092949|Device|MRI|MRI, 45 minutes
79729854|NCT00910507|Behavioral|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
79864356|NCT00803075|Device|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
79864357|NCT03952819|Diagnostic Test|serum sclerostin|blood samples obtained
79864358|NCT00803153|Procedure|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
79864359|NCT02530333|Other|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
79569940|NCT01772862|Behavioral|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
79864360|NCT01097551|Drug|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
80024558|NCT04276584|Device|Positive expiratory pressure|Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
80024559|NCT04276584|Other|Speaking loudly during about 3 minutes|A specified swedish text
79400899|NCT05512871|Behavioral|Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)|The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
79569941|NCT01772875|Procedure|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
80024560|NCT04276493|Biological|ZW25|Administered as specified in the treatment arm
79268238|NCT02419040|Procedure|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
79729855|NCT05657795|Device|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
80024561|NCT04276493|Drug|Docetaxel|Administered as specified in the treatment arm
79729856|NCT00910585|Behavioral|Coaching, providing social support|Active telephone and in person coaching
79864361|NCT01097551|Drug|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
79268239|NCT02419040|Procedure|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
79268240|NCT02407171|Drug|MK-3475|200 mg every 2 weeks by IV infusion
80024562|NCT04276493|Biological|Tislelizumab|Administered as specified in the treatment arm
80024563|NCT04276493|Drug|Capecitabine|Administered as specified in the treatment arm
79400900|NCT05512364|Drug|Elacestrant|400mg QD orally on a continuous dosing schedule
79729857|NCT04317209|Drug|SHR0410|administered intravenously
79729858|NCT04317209|Drug|Placebo|administered intravenously
79729859|NCT04255654|Other|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
79864362|NCT01097551|Drug|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
79864363|NCT01097551|Device|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
79864364|NCT00803309|Drug|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
79864365|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
79864366|NCT00803309|Drug|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
79864367|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
79864368|NCT03953209|Drug|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
79864369|NCT03953209|Drug|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
79864370|NCT03953209|Drug|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
80024564|NCT04276493|Drug|Oxaliplatin|Administered as specified in the treatment arm
80024565|NCT04273022|Other|Exercise|A single bout of standardized, moderate exercise
79569942|NCT01772901|Other|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
79268241|NCT02407171|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
79569943|NCT01772927|Dietary Supplement|Parenteral Nutrition|Protein and energy intakes
79569944|NCT01772940|Drug|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
79729860|NCT00647023|Drug|metformin|1000 mg metformin x 2 daily during 8 months
79569945|NCT01772940|Drug|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
79569946|NCT01772940|Drug|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
79569947|NCT01772940|Drug|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
79569948|NCT01772953|Drug|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
79569949|NCT01772966|Procedure|Spinal manipulation|
79569950|NCT01772979|Drug|Trabectedin|
79569951|NCT01772992|Behavioral|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
79864371|NCT01583959|Drug|Folic Acid|Folic acid tablets 5 mg
80024566|NCT04269239|Behavioral|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
79569952|NCT01773005|Drug|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
79569953|NCT01773005|Drug|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
79569954|NCT01773018|Drug|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
79569955|NCT01773044|Drug|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
79569956|NCT01773044|Drug|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
79729861|NCT05657717|Drug|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
79729862|NCT00924898|Drug|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
79729863|NCT01167192|Drug|Cisplatin|
79729864|NCT01167192|Drug|Carboplatin|
79729865|NCT01167192|Radiation|Radiation therapy|
79729866|NCT01167192|Procedure|Mastectomy (recommended but not mandatory)|
79729867|NCT00646321|Drug|budesonide/formoterol (Symbicort)|
79729868|NCT00646321|Drug|budesonide|
79729869|NCT00647101|Drug|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
79864372|NCT01583959|Drug|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
80024567|NCT04269239|Behavioral|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
80024568|NCT04258293|Diagnostic Test|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
80024569|NCT04257058|Behavioral|Electronic educational material|Electronic media via email
79268242|NCT02381561|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79268243|NCT02381561|Other|Laboratory Biomarker Analysis|Correlative studies
79268244|NCT02381561|Other|Pharmacological Study|Correlative studies
79268245|NCT02381561|Drug|Ropidoxuridine|Given PO
79268246|NCT02381535|Drug|Cisplatin|Given IV
79569957|NCT01773044|Drug|Placebo (for alcalinized lidocaine)|
79569958|NCT01773057|Other|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
79569959|NCT01773096|Drug|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
79729870|NCT01166958|Drug|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
79864373|NCT00803387|Drug|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
79864374|NCT03952897|Other|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
79569960|NCT01773096|Drug|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
79569961|NCT01773148|Device|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
79864375|NCT02553551|Drug|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
79864376|NCT02553551|Drug|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
79864377|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
79864378|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
79864379|NCT00803621|Other|Toxoplasma PCR assay|Toxoplasma PCR assay
79569962|NCT01773161|Procedure|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
79569963|NCT01773174|Drug|dabigatran etexilate|age & weight adjusted equivalent of adult dose
79569964|NCT01773213|Procedure|Ice-water-test|
79569965|NCT01773239|Behavioral|TARA computer-based exercises|
79569966|NCT01773252|Device|Flow Detection System|
79569967|NCT01773304|Other|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
79569968|NCT01773317|Other|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
79569969|NCT01773317|Other|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
79864380|NCT01095913|Drug|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
79864381|NCT00803699|Dietary Supplement|placebo|daily placebo capsules for 12 months
79864382|NCT00803699|Dietary Supplement|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
79864383|NCT03952741|Behavioral|Physical Therapy|
79864384|NCT00798785|Drug|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
79864385|NCT00798785|Drug|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
80024570|NCT04253262|Drug|Rucaparib|Rucaparib (PO twice daily continuous)
79268247|NCT02381535|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79268248|NCT02381535|Other|Laboratory Biomarker Analysis|Correlative studies
79400901|NCT05512364|Drug|Tamoxifen|20 mg QD orally on a continuous dosing schedule
79569970|NCT01773330|Procedure|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
79569971|NCT01773330|Dietary Supplement|Gatorade|The patient will be given Gatorade to drink at various times during the study.
80024571|NCT04253262|Drug|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
80024572|NCT04251936|Behavioral|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
79268249|NCT02381535|Drug|Onalespib|Given IV
79268250|NCT02381535|Other|Pharmacological Study|Correlative studies
79268251|NCT02358083|Behavioral|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
79268252|NCT02331134|Drug|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
79268253|NCT02303171|Drug|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
79268254|NCT02303171|Drug|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
79268255|NCT02243605|Drug|Cabozantinib S-malate|Given PO
79268256|NCT02243605|Other|Laboratory Biomarker Analysis|Correlative studies
79268257|NCT02243592|Other|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
79400902|NCT05512364|Drug|Letrozole 2.5mg|2.5 mg QD orally on a continuous dosing schedule
79400903|NCT05512364|Drug|Anastrozole 1mg|1 mg QD orally on a continuous dosing schedule
79400904|NCT05512364|Drug|Exemestane 25 MG|25 mg QD orally on a continuous dosing schedule
79400905|NCT05502770|Diagnostic Test|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
79400906|NCT05502770|Other|Physical development and General Health|Physical development and General health examination
79864386|NCT00798785|Drug|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
80024573|NCT04251936|Behavioral|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
80024574|NCT04245150|Other|Stool sample|Stool sample
80024575|NCT04245150|Other|Skin Swab Sample|Skin Swab Sample
79268258|NCT02217735|Behavioral|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
79268259|NCT02170103|Procedure|percutaneous intervention (PCI)|Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
79268260|NCT02170103|Drug|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
79268261|NCT02170103|Procedure|Ultrasound|Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
79268262|NCT02135042|Drug|Cisplatin|Given IV
79400907|NCT05502770|Diagnostic Test|Developmental Red flags|Developmental Red flags Questionnaires
79400908|NCT05491720|Drug|RisperiDONE 1 MG/ML|Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
79400909|NCT05491720|Device|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
79569972|NCT01773330|Other|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
79569973|NCT01773330|Other|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
79569974|NCT01773330|Procedure|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
79400910|NCT05491720|Drug|Placebo|Patients will receive placebo tablet (Galenus pharmaceutical company)
79400911|NCT05491720|Device|sham transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
79569975|NCT01773330|Procedure|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
79569976|NCT01773343|Procedure|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
79729871|NCT01166958|Drug|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
79400912|NCT05491226|Drug|Pembrolizumab|Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
79400913|NCT05491226|Radiation|Radiation Therapy|Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.
79400914|NCT05491226|Drug|Axatilimab|Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
79400915|NCT05490485|Drug|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
79400916|NCT05485467|Diagnostic Test|coronary CT angiography|Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
79569977|NCT01773356|Dietary Supplement|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
79729872|NCT01170221|Drug|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
79729873|NCT01170221|Drug|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
79729874|NCT04849624|Other|No Intervention|This is an observational study and involved no intervention
79729875|NCT04254640|Drug|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
79729876|NCT04254640|Drug|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
79729877|NCT04254640|Drug|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
79729878|NCT04254640|Drug|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
79729879|NCT01166646|Drug|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
80024576|NCT04243837|Drug|LYT-100 MAD|"LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.~HV subjects will receive multiple ascending doses, starting at 100 mg BID up to 1000 mg, with food for 5-days."
80024577|NCT04243837|Other|Matching Placebo for MAD|Inactive capsule(s)
79569978|NCT01773369|Behavioral|Early leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
79569979|NCT01773369|Behavioral|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur ~3 months after recruitment.
79400917|NCT05482334|Drug|Sargramostim for Injection|Recombinant human GM-CSF
79569980|NCT01773369|Behavioral|Parent leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
79569981|NCT01773382|Behavioral|weight reduction|"Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~Daily body weight measurement.~Record food diary"
79569982|NCT01773408|Drug|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
79569983|NCT01773408|Drug|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
79569984|NCT01773408|Drug|Idarubicin|Idarubicin will be administered as per standard clinical practice.
79569985|NCT01773408|Drug|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
79569986|NCT01773408|Drug|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m^2 IV infusion daily.
79569987|NCT01773434|Drug|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
79569988|NCT01773447|Procedure|Set-back suture|
79569989|NCT01773447|Procedure|Vertical mattress suture|
79569990|NCT01773460|Drug|Everolimus|Everolimus is given beyond progress (comparison with placebo)
79569991|NCT01773460|Drug|Everolimus-placebo|Everolimus-placebo
79569992|NCT01773512|Drug|Rosuvastatin|All patients will be using rosuvastatin 40 mg
79729880|NCT01166646|Drug|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
80024578|NCT04243837|Drug|LYT-100 Food Effect|"LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.~HV subjects will receive one dose of LYT-100 or Placebo"
80024579|NCT04243837|Drug|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
79569993|NCT01773538|Drug|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
79729881|NCT04203394|Other|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
80024580|NCT04243837|Drug|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
80024581|NCT04243837|Drug|Placebo Food Effect|inactive capsules
79569994|NCT01773538|Dietary Supplement|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
79569995|NCT01773538|Other|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
79569996|NCT01773551|Other|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
79569997|NCT01773564|Device|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
79569998|NCT01773564|Device|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
79569999|NCT01773590|Other|Rhinovirus Infection|
79570000|NCT01773603|Device|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
79570001|NCT01773616|Drug|Oral prednisolone|
79570002|NCT01773616|Drug|Rituximab|
79570003|NCT01773616|Drug|Mycophenolate mofetil|
79570004|NCT01773616|Drug|Methyl prednisolone|
79570005|NCT01773629|Other|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
79729882|NCT04203394|Other|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
79729883|NCT00647179|Procedure|Transsphenoidal adenomectomy|Surgery
79729884|NCT04909840|Other|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
79729885|NCT04909840|Other|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
79729886|NCT04065763|Other|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
79400918|NCT05482334|Drug|Saline Placebo|Bacteriostatic Saline
79400919|NCT05482321|Drug|Definity Suspension for Injection|"DEFINITY is administered as per manufactures instructions~1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~Following imaging, provide a 10 mL flush of preservative-free saline~Wait at least 30minutes until second dose (if provided)."
79268263|NCT02135042|Other|Clinical Observation|Undergo clinical observation
79268264|NCT02135042|Drug|Fluorouracil|Given IV
79268265|NCT02135042|Drug|Gemcitabine Hydrochloride|Given IV
79268266|NCT02135042|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79268267|NCT02135042|Other|Laboratory Biomarker Analysis|Correlative studies
79268268|NCT02135042|Drug|Paclitaxel|Given IV
79729887|NCT01129284|Drug|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
79864387|NCT00798785|Procedure|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
79864388|NCT01095991|Drug|AZD1656|Oral tablet bd,
79864389|NCT01095991|Drug|Sitagliptin|Oral tablet od
80024582|NCT04242147|Drug|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
79268269|NCT02135042|Other|Quality-of-Life Assessment|Ancillary studies
79268270|NCT02013479|Dietary Supplement|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
79268271|NCT02013479|Dietary Supplement|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
79268272|NCT01725165|Other|Clinical Observation|Undergo clinical observation
79268273|NCT01725165|Radiation|External Beam Radiation Therapy|Undergo EBRT
79268274|NCT01725165|Other|Laboratory Biomarker Analysis|Optional correlative studies
79268275|NCT01725165|Other|Quality-of-Life Assessment|Ancillary studies
79268276|NCT01725165|Procedure|Standard Follow-Up Care|Undergo standard maintenance therapy
79268277|NCT01725165|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79400920|NCT05479812|Drug|WTX-124|Investigation Product Monotherapy
79400921|NCT05479812|Drug|Pembrolizumab|Investigation Product in combination with approved therapy
79400922|NCT05478863|Drug|Oral Placebo|Placebo will be orally self-administered by study participants.
79570006|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
79570007|NCT01773642|Behavioral|Cognitive behavioral intervention to support pediatric HIV disclosure|
79729888|NCT04065607|Procedure|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
79729889|NCT00647257|Drug|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
79729890|NCT00647257|Drug|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
79729891|NCT04033393|Other|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
79268278|NCT01693601|Drug|Panobinostat|PO TIW QOW or PO TIW QW
79268279|NCT01693601|Drug|Ruxolitinib|PO BID x 28 days
79268280|NCT01671982|Other|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to <50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
79400923|NCT05478863|Drug|Oral THC|THC will be orally self-administered by study participants.
79268281|NCT01508312|Drug|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
79268282|NCT01508312|Drug|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
79400924|NCT05478863|Drug|Oral CBD|CBD will be orally self-administered by study participants.
79400925|NCT05478863|Drug|Oral Caffeine|Caffeine will be orally self-administered by study participants.
79400926|NCT05478499|Drug|Deucravacitinib|Specified dose on specified days
79729892|NCT04033393|Other|Treadmill training|Participants in the control group will receive treadmill training
79729893|NCT01166568|Device|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
80024583|NCT04215978|Drug|BGB-A445|Administered as specified in the treatment arm
79268283|NCT01408511|Drug|Mapracorat|Application of the investigational product on the affected skin areas
79268284|NCT01284348|Drug|Sotatercept 15 mg|Sotatercept 15 mg SC injection once every 42 days, up to four doses
79400927|NCT05478499|Other|Placebo|Specified dose on specified days
79400928|NCT05476523|Other|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
79729894|NCT02664727|Behavioral|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
79570008|NCT01773655|Other|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
79864390|NCT00798863|Procedure|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
80024584|NCT04215978|Drug|tislelizumab|Administered as specified in the treatment arm
79570009|NCT01773668|Device|Integrated sensor and infusion set.|
79570010|NCT01773681|Drug|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
80024585|NCT04185337|Procedure|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
80024586|NCT04185337|Procedure|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
80024587|NCT04185337|Procedure|Photoacoustic Imaging|Undergo ultrasound-guided PAI
80024588|NCT04185337|Procedure|Ultrasound|Undergo ultrasound
80024589|NCT04185337|Device|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
79570011|NCT01773681|Device|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
79570012|NCT01773681|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
79570013|NCT01773694|Behavioral|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
79570014|NCT01773746|Other|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
79729895|NCT02664727|Behavioral|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
79729896|NCT02666989|Drug|placebo|2 placebo pills twice a day
79570015|NCT01773759|Behavioral|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
79729897|NCT04742179|Other|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
79729898|NCT01166178|Drug|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
79729899|NCT01166178|Drug|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
79729900|NCT01166178|Dietary Supplement|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
79864391|NCT00798941|Behavioral|mouth care|mouth spray, mouth swab, moisturizer
79864392|NCT00798941|Behavioral|pain intervention|music and massage
79864393|NCT00803855|Drug|AZD1446|oral, single dose
80024590|NCT04178005|Drug|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
80024591|NCT04174742|Drug|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
80024592|NCT04163315|Other|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
80024593|NCT04153422|Drug|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
80024594|NCT04153422|Drug|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
80024595|NCT04137289|Drug|BI 905711|BI 905711
79570016|NCT01773772|Drug|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those or = to 42 kg.
79729901|NCT00646477|Device|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
79729902|NCT00924820|Drug|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
80024596|NCT04115033|Device|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
79268285|NCT01284348|Drug|Sotatercept 30 mg|Sotatercept 30 mg SC injection once every 42 days, up to four doses
79268286|NCT01099644|Biological|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
79570017|NCT01773772|Drug|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
79570018|NCT01773798|Drug|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
79400929|NCT05474274|Other|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
79400930|NCT05473702|Device|Nanowear SimpleSense Wearable monitoring device|The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
79729903|NCT01225172|Drug|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
80024597|NCT04105530|Device|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
79268287|NCT00727025|Device|wound closure device (Steri-Strip™)|wound closure with steri-strip S
79268288|NCT00488241|Device|Zarzenda|Topically applied daily for 2 weeks
79268289|NCT00082706|Drug|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
79268290|NCT00082706|Drug|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
79729904|NCT01225172|Drug|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
79729905|NCT02665039|Drug|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min"
80024598|NCT04105530|Device|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
80024599|NCT04105530|Device|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
79729906|NCT02665039|Drug|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
79729907|NCT02665039|Drug|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
79268291|NCT00082706|Drug|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
79268292|NCT00082706|Drug|Gemcitabine|Day: 1 & 5 Dose: 200 mg/m2 (Two doses only)
79400931|NCT05472584|Other|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
79400932|NCT05472584|Other|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
79400933|NCT05472584|Other|Electrophysiology assessment - spinal motoneuron|Kinematics and spinal motoneuron excitability
79400934|NCT05472584|Other|Activity-based training|Motor task
79400935|NCT05472584|Other|Transcutaneous spinal cord stimulation|Non-invasive spinal cord stimulation
79570019|NCT01773798|Drug|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
79268293|NCT00020345|Drug|fluorouracil|
79268294|NCT00020345|Drug|gemcitabine|
79268295|NCT00020046|Drug|docetaxel|
79268296|NCT00020046|Drug|thalidomide|
79570020|NCT01773798|Drug|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
79570021|NCT01773798|Drug|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
79729908|NCT02665663|Device|medical device|
79570022|NCT01773798|Drug|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
79570023|NCT01773811|Behavioral|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
79570024|NCT01773811|Behavioral|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
79570025|NCT01773824|Behavioral|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
79570026|NCT01773824|Behavioral|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
79570027|NCT01773837|Drug|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
79570028|NCT01773837|Drug|placebo|placebo (pill) p.o.
79570029|NCT01773850|Device|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
79570030|NCT01773876|Drug|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
79570031|NCT01773876|Drug|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
79570032|NCT01773902|Dietary Supplement|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
79570033|NCT01773902|Dietary Supplement|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
79729909|NCT04844086|Biological|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
79729910|NCT05329870|Other|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
79729911|NCT01143324|Device|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
79729912|NCT04172935|Device|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
80024600|NCT04105530|Other|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
79268297|NCT00019968|Drug|melphalan|
79729913|NCT04254016|Dietary Supplement|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
79729914|NCT02665585|Procedure|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
79729915|NCT04252924|Other|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
79570034|NCT01773902|Dietary Supplement|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
79570035|NCT01773980|Other|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
79570036|NCT01773980|Other|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
79570037|NCT01774006|Other|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
79729916|NCT02883816|Other|assessment of lung function|measurement of lung volumes and flow rates of bronchial
79864394|NCT00794807|Drug|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
79268298|NCT00019968|Drug|tumor necrosis factor|
79268299|NCT00019760|Drug|floxuridine|
79268300|NCT00019760|Drug|leucovorin calcium|
79268301|NCT00019760|Drug|melphalan|
79268302|NCT00019578|Procedure|Sterotactic radiosurgery|
79268303|NCT03172143|Procedure|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
79268304|NCT03172143|Procedure|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
79570038|NCT01774032|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
79268305|NCT02168023|Device|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
79570039|NCT01774058|Drug|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
79729917|NCT00647413|Behavioral|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
79570040|NCT01774136|Behavioral|Enhanced HIV and MCH training for CHW|
79864395|NCT00794885|Drug|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
79864396|NCT00794885|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
79729918|NCT00647491|Biological|adalimumab|20 mg sc eow
79729919|NCT00647491|Biological|adalimumab|40 mg sc eow
79729920|NCT00647491|Biological|adalimumab|80 mg sc eow
79729921|NCT00647491|Biological|placebo|placebo sc eow
79729922|NCT04253704|Combination Product|IDL lotion|IDL lotion is water-based (> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
79729923|NCT04253704|Combination Product|Control lotion|Control lotion is water-based (> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
80024601|NCT04105530|Other|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
79268306|NCT02168023|Device|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
79268307|NCT02406963|Other|Digital Photograph|A digital photograph sent by the family of the surgical site
79570041|NCT01774162|Device|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
79570042|NCT01774162|Device|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
79570043|NCT01774201|Other|Breathing exercises|Breathing exercises with positive expiratory pressure.
79729924|NCT04252456|Procedure|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
79729925|NCT01224158|Device|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
79729926|NCT01224158|Device|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
79864397|NCT00803933|Drug|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
79864398|NCT00803933|Drug|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
79864399|NCT02553707|Drug|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
79268308|NCT02406963|Other|Telephone Call|Standard telephone call with the nurse practitioner
79268309|NCT05698472|Other|questionnaire|"Use the Questionnaire on physical exercise of the elderly in Beijing community to collect the related information of the elderly."
79268310|NCT02171299|Procedure|Wound infiltration with local anaesthetic|
79268311|NCT02171299|Drug|Ropivacaine|
79729927|NCT02665351|Drug|Peramivir|The two regimens of Peramivir were compared
79864400|NCT00804011|Other|ATC|Automatic tube compensation
79864401|NCT00804011|Other|PSV|Pressure support ventilation
79864402|NCT00799175|Drug|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
79864403|NCT00799175|Drug|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
79268312|NCT02171377|Device|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
79268313|NCT02171377|Other|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
79268314|NCT02171377|Device|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
79268315|NCT02171377|Other|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
79268316|NCT03171831|Drug|Busulfan|Busulfan（4 mg/kg/day,4 days）
79268317|NCT03171831|Drug|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
79268318|NCT03171831|Drug|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
79268319|NCT03171831|Drug|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
79400936|NCT05466539|Drug|AbobotulinumtoxinA|Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
79729928|NCT02666911|Procedure|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
79864404|NCT00799331|Drug|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
80024602|NCT04105530|Other|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
79268320|NCT03171831|Drug|Tacrolimus|Tacrolimus（0.03mg/kg/day）
79268321|NCT03171831|Drug|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
79268322|NCT03171831|Drug|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
79268323|NCT03171831|Drug|Basiliximab|Basiliximab（10mg on day 0 and +4）
79268324|NCT02171455|Drug|Dabigatran etexilate low dose|
79268325|NCT02171455|Drug|Dabigatran etexilate medium dose|
79268326|NCT02171455|Drug|Dabigatran etexilate high dose|
79268327|NCT02171455|Drug|Placebo|
79268328|NCT03171753|Diagnostic Test|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
79268329|NCT03171753|Diagnostic Test|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
79268330|NCT03171753|Diagnostic Test|cardiac monitoring|the cardiac monitoring will be performed through study period
79268331|NCT03171753|Diagnostic Test|skin resistance|the skin resistance monitoring will be performed through study period
79268332|NCT03171753|Device|Music listening|Listening prerecorded music through an individual headset for 30 min
79400937|NCT05466539|Drug|Placebo|Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
79268333|NCT03171753|Device|No sound|No sound through an individual headset for 30 min
79268334|NCT02255851|Device|SENTINEL (Cerebral Protection System)|
79268335|NCT02406417|Device|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
79268336|NCT02406417|Device|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
79268337|NCT02171533|Drug|dabigatran|
79268338|NCT02171533|Drug|Verapamil|
79268339|NCT02171533|Drug|Verapamil ER|
79268340|NCT04482543|Drug|Methotrexate|Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
79268341|NCT03173079|Other|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
79864405|NCT00799331|Drug|placebo|Oral suspension.
79864406|NCT00804089|Procedure|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
79864407|NCT00804089|Procedure|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
79864408|NCT00804089|Procedure|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
79864409|NCT00656513|Drug|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
79864410|NCT00656513|Procedure|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
79864411|NCT04017221|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
79864412|NCT04017221|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
79864413|NCT04017221|Drug|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
79729929|NCT02666911|Procedure|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
79268342|NCT02406807|Other|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
79729930|NCT04253860|Device|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
79729931|NCT01129128|Biological|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
79729932|NCT01129128|Biological|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
79864414|NCT00804245|Procedure|needle biopsy|Biopsy of positive findings found on CT scan
79864415|NCT00804245|Drug|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
79864416|NCT00805883|Procedure|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
79864417|NCT00804323|Procedure|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
80024603|NCT04105530|Other|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
80024604|NCT04103593|Behavioral|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
79268343|NCT02406807|Other|Sham Spinal lumbar manipulation|Sham manipulation
79268344|NCT02413125|Device|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
79400938|NCT05465486|Device|Brain-Computer Interface control of robotic arms with augmented reality|"The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics & Digital Innovation Lab."
79400939|NCT05465486|Device|Serious game with augmented reality|"The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket & gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics & Digital Innovation Lab"
79729933|NCT01129128|Biological|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
79729934|NCT04172389|Procedure|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
79864418|NCT04045847|Biological|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
79864419|NCT00804401|Drug|Naproxen Tablets, 500 mg|
79864420|NCT00804479|Other|No intervention.|
79864421|NCT00655889|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of biopsy from palate~Papillary priming procedure~Seven injection treatments to target sites~Performance of study assessments (investigator and subject)"
79864422|NCT00806039|Other|Early Renal Involvement|Renal Consultation
79570044|NCT01774214|Procedure|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
79729935|NCT01222520|Drug|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
79729936|NCT01222520|Drug|Telmisartan|80 mg once a daily
79729937|NCT04252222|Device|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
79729938|NCT05312424|Dietary Supplement|Placebo|300 mg olive oil
79268345|NCT02413125|Drug|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
79570045|NCT01774214|Procedure|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
79729939|NCT05312424|Dietary Supplement|Low GG|150 mg GG
79729940|NCT05312424|Dietary Supplement|High GG|300 mg GG
79729941|NCT02888210|Device|MD-15 Intraocular Lens|
79729942|NCT04172233|Biological|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
79729943|NCT04172233|Biological|placebo|matching placebo
79729944|NCT01221350|Dietary Supplement|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
79729945|NCT01221350|Dietary Supplement|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
79729946|NCT02665429|Behavioral|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
79729947|NCT00646633|Procedure|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
79729948|NCT00647569|Procedure|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
79729949|NCT00647569|Procedure|Conventional facial closure|The abdominal facia is closed with with continuous running suture
79864423|NCT00804791|Other|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
80024605|NCT04078997|Other|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
79268346|NCT02406339|Device|NMES|Neuromuscular Electrical Stimulation
79268347|NCT02406339|Device|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
79864424|NCT00804791|Other|Unisol 4 Saline Solution|saline solution for irrigating the cornea
79864425|NCT02553239|Device|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
80024606|NCT04062812|Other|the same citrate dosification in both types|match concentrated and dilute citrate protocol
80024607|NCT04051619|Drug|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
80024608|NCT04042402|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
79268348|NCT03172845|Procedure|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
79268349|NCT02406183|Radiation|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
79268350|NCT02406183|Drug|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
79268351|NCT02412969|Procedure|Lumbar Epidural|control group will receive lumbar puncture epidural
79268352|NCT02412969|Procedure|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
79864426|NCT00806117|Radiation|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~Lateral: 2 cm lateral to the bony margin of the pelvis~Superior: Between L5 and S1~Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
79864427|NCT00806117|Other|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
79268353|NCT05539820|Other|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
79570046|NCT01774227|Procedure|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
79729950|NCT00647647|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
79268354|NCT02412891|Device|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
79268355|NCT02412891|Device|Sham UroShield device|
79570047|NCT01774227|Procedure|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
79570048|NCT01774279|Other|Tissue, blood and clinical data collection|
79570049|NCT01774292|Procedure|Endotracheal intubation with injection of liquid in the cuff|
79570050|NCT01774318|Other|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
79570051|NCT01774370|Drug|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
79570052|NCT01774396|Drug|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
79570053|NCT01774396|Drug|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
79570054|NCT01774422|Device|Extracorporeal CO2 removal device|
79570055|NCT01774435|Drug|EN3342|
79570056|NCT01774448|Behavioral|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
79729951|NCT00647647|Drug|Lamisil® Tablets 250 mg|250mg, single dose fasting
79570057|NCT01774461|Other|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
79729952|NCT01221272|Drug|Ranolazine|"One 500 mg tablet in the evening on Day 1 of the period~One 500 mg tablet, twice daily on Days 2-3 of the period~Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
79729953|NCT01221272|Drug|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
79729954|NCT01221272|Procedure|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
79864428|NCT00806117|Other|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2
79268356|NCT04723472|Drug|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
79570058|NCT01774474|Drug|Bromfenac|
79570059|NCT01774474|Drug|Dexamethasone|
79570060|NCT01774474|Drug|Bevacizumab|
79570061|NCT01774474|Drug|Triamcinolone Acetonide|
79729955|NCT01221272|Behavioral|Exercise|Treadmill stress test
79864429|NCT00804869|Device|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
79864430|NCT00804869|Device|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
79864431|NCT02553083|Drug|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
79268357|NCT04723472|Drug|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
79268358|NCT03176043|Procedure|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
79570062|NCT01774513|Device|Procore-Needle|
79570063|NCT01774526|Other|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
79570064|NCT01774539|Other|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
79570065|NCT01774565|Device|Fully Automated Closed-Loop Insulin Delivery|
79570066|NCT01774565|Device|Conventional insulin therapy|
79570067|NCT01774656|Drug|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
79570068|NCT01774669|Device|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
79570069|NCT01774669|Other|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
79864432|NCT02553083|Drug|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
80024609|NCT04038203|Device|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
80024610|NCT04028765|Drug|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
80024611|NCT04028765|Drug|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
80024612|NCT03993054|Behavioral|Cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 4 weeks.
79570070|NCT01774682|Procedure|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
79570071|NCT01774695|Behavioral|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
79570072|NCT01774708|Device|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
79570073|NCT01774734|Other|Physical therapy|"Physical therapy~Provided by 2 experienced physiotherapist~Applied to every patients 3 times weekly"
79570074|NCT01774734|Device|Neck Strength Exerciser (NSE)|"Neck strength exerciser use 10-20 minutes daily at home~Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
79570075|NCT01774747|Drug|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
79570076|NCT01774747|Drug|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
79729956|NCT00647725|Procedure|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
79729957|NCT00647725|Procedure|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
79729958|NCT01220414|Drug|Naltrexone, then placebo|50 mg of naltrexone
79729959|NCT01220414|Drug|Placebo, then Naltrexone|sugar pill
79729960|NCT01128894|Biological|albiglutide|albiglutide weekly subcutaneous injection
80024613|NCT03993054|Behavioral|Culturally-tailored cognitive behavioral stress management|This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
79729961|NCT01128894|Drug|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
79729962|NCT01128816|Device|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
79729963|NCT01220180|Drug|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
79729964|NCT01220180|Drug|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
79729965|NCT01220180|Drug|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
79729966|NCT01220024|Drug|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
79729967|NCT01220024|Drug|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
79729968|NCT01128738|Drug|GSK1358820|Onabotulinum toxin type A
79729969|NCT01128738|Drug|Placebo|Placebo
79729970|NCT00625248|Drug|Antithrombotics|With or without or discontinuted use of Antithrombotics
79864433|NCT02553083|Drug|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
79864434|NCT02553083|Drug|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
79864435|NCT02553083|Drug|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
79864436|NCT02553083|Drug|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
79864437|NCT00804947|Drug|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
80024614|NCT03974750|Device|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
79729971|NCT01143090|Drug|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
79268359|NCT04425668|Behavioral|Academic detailing (AD)|In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
79268360|NCT04425668|Other|Continuing educational|"Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah."
79268361|NCT02406105|Radiation|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
79400940|NCT05461495|Behavioral|Treatment Group|"This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
79268362|NCT02406105|Drug|CyberKnife|
79268363|NCT02412813|Device|LEGION OXINIUM|Investigational Group
79268364|NCT02412813|Device|LEGION Cobalt Chrome|Control Group
79268365|NCT02013128|Drug|Ublituximab|Ublituximab (IV infusion)
79268366|NCT02013128|Drug|Ibrutinib|Ibrutinib oral daily dose
79729972|NCT05125146|Behavioral|e-CBTi|See arm/group description
79400941|NCT05459064|Device|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
79400942|NCT05456685|Drug|Mirvetuximab soravtansine|Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed for the treatment of subjects with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
79400943|NCT05456685|Drug|Carboplatin|Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
79729973|NCT05125146|Drug|Trazodone|See arm/group edescription
79400944|NCT05456360|Device|ViSi Mobile device|Participants will wear the device on your wrist like a watch, and it will continuously (non-stop) monitor your pulse, blood pressure, temperature, breathing rate, heart rate, and pulse rate
79400945|NCT05456360|Drug|Sleep enhancement intervention|Participants will receive a medication administration will be limited to before bedtime.
79729974|NCT01165554|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
79729975|NCT01218308|Biological|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
79729976|NCT01218308|Biological|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
79729977|NCT02887976|Drug|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
79729978|NCT02887976|Drug|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
80024615|NCT03960463|Device|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
79729979|NCT01165320|Drug|Caspofungin|
79729980|NCT01217606|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
79729981|NCT01217606|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
80024616|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
79400946|NCT05456100|Behavioral|Expressive Helping|Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
79729982|NCT05463146|Other|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
79864438|NCT02553005|Procedure|Acupuncture|
79400947|NCT05456100|Behavioral|Expressive Writing|Expressive writing involves emotional disclosure writing over four weeks.
79400948|NCT05456100|Behavioral|Factual Writing|Factual writing involves writing facts about cancer treatment and experiences over four weeks.
79400949|NCT05449990|Other|Participation in PFCC-IR|Patient-and-family-centered-care interdisciplinary rounds (PFCC-IR) with the critical care team are standard practice in the ICU but it doesn't usually include family members. The intervention for this study is PFCC-IR that include one family member of the patient.
79400950|NCT05448170|Drug|Linerixibat|open label investigational product
79400951|NCT05447988|Device|Breast Tissue Expander|tissue expander based breast reconstruction
79400952|NCT05446168|Drug|tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
79400953|NCT05444881|Behavioral|Mindfulness-based Intervention (Headspace TM)|"A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages)."
79400954|NCT05438134|Behavioral|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~An understanding of stress physiology and the physiology of the relaxation response;~A regular practice of eliciting the relaxation response; and~Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
79729983|NCT05463146|Other|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
79268367|NCT04482075|Other|segmental stability training|SEGMENTAL STABILISATION TRAINING (SST): This part of the therapy shall involve Isometric co-contraction of Lumbar Transversus abdominis and Lumbar Multifidus. The patient shall perform 10 repetitions of abdominal drawing-in manoeuvre with 30-40% Maximal Voluntary Contraction (MVC) with a 10-second hold in specific prescribed positions.
79729984|NCT05463146|Other|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
79729985|NCT05460962|Other|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
79729986|NCT05460962|Other|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
79729987|NCT01128114|Drug|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
79729988|NCT05458544|Drug|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of [177Lu]Ludotadipep~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 3.7 GBq~Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of [177Lu]Ludotadipep every 8 [±1] weeks (4 to 6 times)~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 4 to 6 x 3.7 GBq~Dosage form: solution for injection"
79729989|NCT01217060|Drug|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
79729990|NCT01217060|Drug|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
79268368|NCT05591378|Other|core stability exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise"
79400955|NCT05437848|Drug|Experimental: Cotadutide|Cotadutide: subcutaneous (SC) injection
79400956|NCT05437848|Other|Placebo|Placebo subcutaneous injection
79400957|NCT05428163|Other|Biological sampling|3ml of blood
79400958|NCT05426356|Device|Surgical Intervention|Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
79400959|NCT05426356|Other|Non-Surgical Management|Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
80024617|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
79268369|NCT05591378|Other|otago exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without"
79570077|NCT01774773|Drug|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
79570078|NCT01774773|Drug|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
79570079|NCT01774773|Drug|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
79729991|NCT01217060|Radiation|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
79268370|NCT02405949|Genetic|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
79268371|NCT02405559|Drug|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
79268372|NCT03116061|Other|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
79268373|NCT05539664|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
79268374|NCT05539664|Device|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
79268375|NCT02405637|Drug|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
79729992|NCT01217060|Procedure|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
79729993|NCT01217060|Drug|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
79729994|NCT04816669|Biological|BNT162b2|Intramuscular injection
79729995|NCT01165242|Biological|Meningococcal vaccine GSK 134612|One intramuscular injection
79729996|NCT01165242|Biological|Menactra®|One intramuscular injection
79729997|NCT01170065|Drug|BIBF 1120|Intermediate dose BIBF 1120 twice daily
79729998|NCT01170065|Drug|BIBF 1120|High dose BIBF 1120 twice daily
79729999|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 twice daily
79730000|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 once daily
79730001|NCT02885922|Drug|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
79730002|NCT04174417|Procedure|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
79268376|NCT02405637|Drug|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
79268377|NCT04425512|Diagnostic Test|Complete Blood Count|Complete Blood Count samples
79268378|NCT03116295|Drug|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
79268379|NCT00548756|Procedure|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
79570080|NCT01774812|Dietary Supplement|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
79570081|NCT01774812|Dietary Supplement|Ergocalciferol|50,000IU 1x per week for 6 weeks
80024618|NCT03959241|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
80024619|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
79570082|NCT01774825|Dietary Supplement|IQP-CL-101|2 softgels twice a day
79570083|NCT01774825|Other|Placebo|2 softgels twice a day
79570084|NCT01774838|Drug|Prasugrel|3 months treatment
79570085|NCT01774838|Drug|Clopidogrel|3 months treatment
79570086|NCT01774864|Drug|DA-8159 (Udenafil)|
79570087|NCT01774864|Drug|Placebo|
79570088|NCT01774877|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
79570089|NCT01774877|Drug|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
79570090|NCT01774916|Genetic|blood samples|
79570091|NCT01774942|Procedure|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
79570092|NCT01774994|Other|stable isotope infusion for measurement of metabolism|
79570093|NCT01775020|Dietary Supplement|L-arginine|
79730003|NCT04174417|Procedure|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
79864439|NCT00806273|Device|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
80024620|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
79570094|NCT01775033|Other|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
79570095|NCT01775059|Device|Integrated sensor and infusion set.|
79570096|NCT01775098|Drug|allopurinol|No arms will not be change as the study as been closed.
79570097|NCT01775111|Behavioral|Cognitive Training|
79570098|NCT01775111|Behavioral|Strength Training|
79570099|NCT01775111|Dietary Supplement|FortiFit|
79570100|NCT01775150|Other|health education|Health education via text messaging
79570101|NCT01775215|Radiation|Cardiac I123-MIBG Scintigraphy|
79730004|NCT02885844|Procedure|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
79730005|NCT02885844|Procedure|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
79730006|NCT00966693|Drug|Dexamethasone|Given PO
79730007|NCT00966693|Drug|Lenalidomide|Given PO
79730008|NCT00966693|Drug|Thalidomide|Given PO
79730009|NCT01215968|Biological|LY2189265|1.5 mg administered subcutaneously
79730010|NCT01215968|Drug|Placebo|Administered subcutaneously
79730011|NCT02663713|Drug|Ticagrelor|Ticagrelor 60mg twice daily
79268380|NCT00548756|Other|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
79268381|NCT00548756|Behavioral|Questionnaire|Questionnaire taking 40 minutes to complete.
79268382|NCT05586542|Combination Product|DERMASEAL|a novel skin substitute formulated as planar, thin film
79268383|NCT05586542|Biological|Plasma Film|a planar, thin film made from human plasma
79268384|NCT05586542|Other|Standard of Care|standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
79268385|NCT02405715|Drug|Oxytocin nasal spray or placebo|
79864440|NCT00806273|Device|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
80024621|NCT03959241|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
79400960|NCT05420753|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
79570102|NCT01775215|Other|Cardiac MRI|
79864441|NCT00805103|Radiation|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
79570103|NCT01775215|Other|Stress and rest Echocardiogram|
79570104|NCT01775215|Other|High Sensitivity Troponin I|
79864442|NCT00655733|Drug|HMPL-004|HMPL-004 1200 mg/d
79570105|NCT01775215|Other|Brain Natriuretic Peptide|
79570106|NCT01775228|Behavioral|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
79730012|NCT02663713|Drug|Clopidogrel|Clopidogrel 75 mg once daily
79730013|NCT02664649|Drug|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
79730014|NCT02664649|Drug|Standard of care|VKA or Antiplatelet therapy
79570107|NCT01775267|Procedure|Associating liver partition and portal vein ligation for staged hepatectomy|
79864443|NCT00655733|Drug|Placebo|Placebo 1200 mg/d
80024622|NCT03959241|Drug|Cyclophosphamide|Cyclophosphamide [50 mg/kg ideal body weight (IBW); if actual body weight (ABW) < IBW, use ABW] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
80024623|NCT03958474|Drug|Oxycodone|Participants receive oxycodone or placebo.
80024624|NCT03958474|Drug|Remifentanil|Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
80024625|NCT03907488|Procedure|Biospecimen Collection|Undergo peripheral blood collection
80024626|NCT03907488|Drug|Brentuximab Vedotin|Given IV
80024627|NCT03907488|Procedure|Computed Tomography|Undergo PET/CT or CT scan
80024628|NCT03907488|Drug|Dacarbazine|Given IV
79570108|NCT01775267|Procedure|Portal vein embolization or ligation|
79730015|NCT02664493|Drug|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
80024629|NCT03907488|Drug|Doxorubicin Hydrochloride|Given IV
80024630|NCT03907488|Biological|Filgrastim|Given SC or IV
79570109|NCT01775280|Radiation|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
79570110|NCT01775293|Device|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
79570111|NCT01775319|Dietary Supplement|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
79570112|NCT01775319|Dietary Supplement|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
79570113|NCT01775319|Dietary Supplement|Placebo|
79570114|NCT01775332|Other|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
79570115|NCT01775345|Procedure|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
79730016|NCT00963807|Drug|Cisplatin|Given IV
79730017|NCT00963807|Procedure|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
79730018|NCT00963807|Drug|Docetaxel|Given IV
79730019|NCT00963807|Drug|FDG|Undergo FDG PET/CT
79730020|NCT00963807|Drug|FLT|Undergo FLT PET/CT
79730021|NCT00963807|Procedure|PET/CT|Undergo FDG PET/CT and FLT PET/CT
79730022|NCT00963807|Procedure|Surgery|Undergo surgery
79864444|NCT00806429|Procedure|transvaginal appendectomy|patient undergoes transvaginal appendectomy
79864445|NCT00657371|Device|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
79864446|NCT00805259|Behavioral|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
79864447|NCT00806507|Procedure|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
79864448|NCT00806507|Procedure|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
80024631|NCT03907488|Procedure|Magnetic Resonance Imaging|Undergo MRI
79570116|NCT01775345|Procedure|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
79268386|NCT03171519|Behavioral|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
79570117|NCT01775345|Procedure|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
79570118|NCT01775345|Procedure|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
79570119|NCT01775358|Drug|ALRN-5281 0.015 mg/kg|
79570120|NCT01775358|Drug|ALRN-5281 0.05 mg/kg|
79400961|NCT05419193|Drug|Propranolol Hydrochloride|"Day of randomization:~propranolol IV vp for 7 days after randomization"
80024632|NCT03907488|Biological|Nivolumab|Given IV
80024633|NCT03907488|Biological|Pegfilgrastim|Given SC
80024634|NCT03907488|Procedure|Positron Emission Tomography|Undergo PET/CT scan
80024635|NCT03907488|Other|Quality-of-Life Assessment|Ancillary studies
80024636|NCT03907488|Other|Questionnaire Administration|Ancillary studies
79268387|NCT03171519|Behavioral|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
79268388|NCT04482387|Device|DigiVis visual acuity app|Self-testing of visual acuity app on two occasions
79268389|NCT02412423|Drug|post-transplantation cyclophosphamide|
79268390|NCT05679206|Diagnostic Test|Echocardiography images|"Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~Left ventricular ejection fraction,~Left ventricular mass index,~Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~Tricuspid annular plane systolic excursion,~Left atrial volume index,~Right ventricle to right atrium (RV/RA) gradient"
79268391|NCT05679206|Diagnostic Test|24-hour ambulatory blood pressure monitoring|Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
79268392|NCT02412345|Procedure|Extracorporeal shockwave therapy|
79268393|NCT02412345|Procedure|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
79570121|NCT01775358|Drug|ALRN-5281 0.15 mg/kg|
79570122|NCT01775358|Drug|Placebo 0.015 mg/kg|
79570123|NCT01775358|Drug|Placebo 0.05mg/kg|
79570124|NCT01775358|Drug|Placebo 0.15mg/kg|
79400962|NCT05419193|Other|control group|Patients will receive usual care and drug use in hospital
79570125|NCT01775384|Dietary Supplement|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
79570126|NCT01775384|Dietary Supplement|Placebo|
79400963|NCT05417971|Other|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
79864449|NCT04017065|Device|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
79400965|NCT05409183|Drug|CRD-740|Tablets administered orally.
79400966|NCT05409183|Drug|Placebo|Tablets administered orally.
79400967|NCT05407428|Other|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients
79570127|NCT01775397|Drug|Fidaxomicin|capsule
79570128|NCT01775397|Drug|Vancomycin|capsule
79570129|NCT01775397|Drug|Placebo|Capsule
80024637|NCT03907488|Radiation|Radiation Therapy|Receive radiation therapy
80024638|NCT03907488|Drug|Vinblastine Sulfate|Given IV
80024639|NCT03888950|Diagnostic Test|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
80024640|NCT03878485|Device|MRIdian Linac System from ViewRay|"0.35T MRI combined with a linear accelerator~This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
80024641|NCT03878485|Radiation|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
79268394|NCT02412345|Other|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
79268395|NCT05679128|Diagnostic Test|identification of the cricothyroid membrane using Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
79268396|NCT05679128|Diagnostic Test|Identification of the cricothyroid membrane using ultrasonography|identification of the cricothyroid membrane, using ULTRASONOGRAPHY, a procedure used to prepare for front of neck airway access
80024642|NCT03856515|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
80024643|NCT03856515|Other|Questionnaire Administration|Ancillary studies
80024644|NCT03856515|Device|Electronic Cigarette|Electronic Cigarette - with Nicotine
80024645|NCT03856515|Device|Electronic Cigarette|Electronic Cigarette -without Nicotine
80024646|NCT03851523|Other|No intervention|No intervention
80024647|NCT03847272|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
79400968|NCT05406349|Behavioral|Self-navigation task|Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.
79268397|NCT03172611|Other|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
79268398|NCT05679050|Drug|AG Followed by FOLFIRINOX|"AG（every 28 days) Nab-paclitaxel 125 mg/m2 i.v. over 30 min, gemcitabine hydrochloride 1g/m2 i.v. over 30 min, D1, 8 and 15 ; FOLFIRINOX(every 42 days) Oxaliplatin: 65 mg/m2 i.v. over 2h on D1, 15, 29; Tetrahydrofolate: 400 mg/m2 i.v.2h on D1, 15, 29; Irinotecan: 150 mg/m2 i.v. over 90 min every 42 days on D1, 15, 29; 5-FU: 2400 mg/m2 i.v. over 46h /14 days on D1-3, 15-17, and 29-31; After one round of above therapy, patients achieving stable disease and above without disease progression or unacceptable toxicity underwent pancreatectomy within 4-8 weeks; Patients who did not achieve stable disease and above were treated another round , and patients who achieved stable disease and above underwent pancreatectomy at 4-8 weeks.~Following pancreatectomy, patients underwent AG regimen (2 rounds, 56 days) followed by FOLFIRINOX regimen (42 days) in the absence of disease progression or unacceptable toxicity, and AG and FOLFIRINOX dosing as the preoperative therapy."
79268399|NCT02412267|Drug|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
79268400|NCT05539586|Other|Tecartherapy|Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.
79268401|NCT05539586|Other|Sham|Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
79400969|NCT05406349|Behavioral|Observation task|Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
79570130|NCT01775436|Behavioral|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
79570131|NCT01775436|Behavioral|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
79570132|NCT01775449|Behavioral|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
79570133|NCT01775462|Drug|EDI200|3 or 10 mg/kg of EDI200
79570134|NCT01775488|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
79570135|NCT01775527|Other|blood test|
79570136|NCT01775540|Drug|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
79570137|NCT01775540|Drug|Saline solution|Saline solution,1 drop used QID for 4 weeks
79400970|NCT05405660|Biological|barzolvolimab|Subcutaneous Administration
79268402|NCT05539508|Behavioral|Psychophysical evaluation|All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
79400971|NCT05405660|Drug|Matching Placebo|Subcutaneous Administration
79400972|NCT05403307|Biological|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
79570138|NCT01775540|Drug|Maxidex|Eyedrop-1 drop QID for 4 weeks
79864450|NCT00805337|Device|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
79864451|NCT00806663|Drug|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
79570139|NCT01775579|Drug|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
79570140|NCT01775592|Drug|Arterakin (DHA-PPQ)|
79570141|NCT01775605|Drug|Synera|Synera Pain Patch
79570142|NCT01775618|Biological|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months
79570143|NCT01775618|Biological|BAY94-9027|Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks
79570144|NCT01775618|Biological|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug
79570145|NCT01775631|Biological|Urelumab|
79570146|NCT01775631|Biological|Rituximab|
79864452|NCT00805415|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
79268403|NCT03172455|Drug|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
79268404|NCT03171597|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
79268405|NCT03171597|Drug|Lipid Regulating Drugs|Mainly including statins
79268406|NCT03171597|Drug|Coronary Vasodilator|Mainly including nitrates
79268407|NCT03171597|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
79268408|NCT03171597|Drug|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
79268409|NCT03171597|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
79268410|NCT05698394|Drug|Esketamine|0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
79268411|NCT05698394|Drug|Placebo|20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
79268412|NCT03171363|Behavioral|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
79268413|NCT05539274|Diagnostic Test|human papilloma virus testing and genotyping in cervical cancer cases|an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
79268414|NCT03171285|Other|Less than 35 years old|Clinical and laboratory evaluations
79268415|NCT03171285|Other|Greater than or equal to 35 years|Clinical and laboratory evaluations
79268416|NCT05539118|Drug|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
79268417|NCT05539118|Drug|Toripalimab|Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
79400973|NCT05403307|Biological|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
79400974|NCT05396001|Behavioral|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
79570147|NCT01775748|Other|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
79730023|NCT01142466|Drug|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
79730024|NCT02663635|Device|Safe'N'Sound|
79730025|NCT00648505|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
79730026|NCT00648505|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
79730027|NCT01215734|Biological|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
79730028|NCT01215734|Biological|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
79730029|NCT04172311|Other|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
79268418|NCT05539118|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
79268419|NCT03171441|Diagnostic Test|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
79268420|NCT03171441|Diagnostic Test|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
79400975|NCT05396001|Behavioral|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
79400976|NCT05389800|Other|Upper Extremity Aerobic Exercise|Using a cycle-ergometer (Monark 881E)
79570148|NCT01775748|Other|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
79570149|NCT01775761|Drug|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
79570150|NCT01775761|Drug|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
79570151|NCT01775761|Drug|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
79570152|NCT01775826|Other|Measurement|Measured usual (day-to-day) behavior with body-worn sensors.
79570153|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
79570154|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
79864453|NCT00805415|Drug|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
79864454|NCT02553863|Procedure|Acupuncture|Acupuncture for 30min [twice weekly for 8 weeks]
79864455|NCT02553863|Procedure|Standard care|Standard care
79864456|NCT00799565|Genetic|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
79570155|NCT01775878|Device|Telemonitoring Device|Telemonitoring device was installed in patients' homes
79864457|NCT00806741|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
79268421|NCT02405793|Drug|Meloxicam Test Capsules|
79570156|NCT01775891|Drug|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
79864458|NCT00806741|Drug|Phenylephrine|1μg/kg/min, infusion period 20 minutes
79864459|NCT00806741|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
79864460|NCT00806741|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
80024648|NCT03847272|Other|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
80024649|NCT03847272|Other|Questionnaires|VFQ-25 and SF-36
80024650|NCT03847272|Biological|Blood samples|Additional blood samples for immunomonitoring
80024651|NCT03833180|Drug|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
80024652|NCT03813615|Behavioral|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
80024653|NCT03813615|Behavioral|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk & 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity & duration) or non-linear (i.e., exercise dose is continually altered & progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented & may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
80024654|NCT03805464|Other|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
80024655|NCT03788837|Drug|Ilomedin|The patient will receive treatment with intravenous Ilomedin therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
79268422|NCT02405793|Drug|Meloxicam Test Capsules|
79268423|NCT02405793|Drug|Meloxicam Tablets|
79268424|NCT05579912|Procedure|Esophageal and gastric resections requiring an anastomosis|Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
79268425|NCT02405481|Behavioral|SEPA III|
79268426|NCT05575622|Device|CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection|Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
79268427|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
79268428|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
79268429|NCT00702741|Drug|Placebo|Intra-articular injection of Hyaluronan
79268430|NCT05695664|Drug|Ibuprofen 800 mg|Intravenous injection of ibuprofen 800 mg
79268431|NCT05695664|Drug|Ketorolac Injection|Intravenous injection of Ketorolac 30 mg
79268432|NCT02412189|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
79268433|NCT02412189|Drug|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
79570157|NCT01775891|Drug|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
79570158|NCT01775969|Other|Text Message|A text message with instructions is sent to the patient
79570159|NCT01775969|Other|Voicemail|A voicemail with instructions is sent to the patient
79864461|NCT00806741|Device|Goldmann applanation tonometer|intraocular pressure measurements
79864462|NCT00806741|Other|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
79864463|NCT00806897|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
79864464|NCT00805649|Procedure|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
79864465|NCT00805649|Procedure|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
79864466|NCT00805649|Drug|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
79864467|NCT00805649|Drug|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
79864468|NCT00805649|Procedure|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
79864469|NCT00805649|Drug|triamcincolone|intravitreal injection of 8 mg triamcincolone
79864470|NCT00799799|Biological|NK cells|NK cells infusion after immunosuppressive chemotherapy
79864471|NCT00806975|Device|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
79864472|NCT00809315|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
79400977|NCT05389488|Device|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
79570160|NCT01775982|Other|Psychiatric evaluation|"This evaluation is carried out in several stages:~Assessment of cognitive functioning;~Interview with a relative;~Interview with caregivers;~Evaluation of the presence of delirium according to DSM-IV criteria;~Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
80024656|NCT03788837|Drug|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
79730030|NCT04172311|Drug|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
80024657|NCT03785262|Device|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
80024658|NCT03785262|Device|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
80024659|NCT03775096|Drug|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
80024660|NCT03769454|Drug|PP-001|PP-001 eye drops
80024661|NCT03769454|Other|Placebo|Placebo eye drops
80024662|NCT03752697|Behavioral|metacognitive performance|Paper and pencil/computerized tests of metacognition
80024663|NCT03744910|Biological|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
80024664|NCT03744910|Drug|Physiologic saline solution|Normal saline
80024665|NCT03734731|Device|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
79400978|NCT05389488|Device|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
79570161|NCT01775982|Other|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
79570162|NCT01776021|Other|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
79730031|NCT02863185|Drug|Pitavastatin|
79730032|NCT02863185|Drug|Atorvastatin|
79730033|NCT02666833|Device|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
79730034|NCT01215422|Procedure|timed intubation|timed intubation
79730035|NCT04315025|Biological|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
79730036|NCT04315025|Biological|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
79730037|NCT02664571|Device|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
79730038|NCT02664571|Device|MRI scan|Subjects will have an MRI scan at inclusion.
79730039|NCT02664571|Biological|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
79730040|NCT00972153|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
79730041|NCT00972153|Device|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
79730042|NCT04736485|Drug|perioperative treatment|FLOT + Spartalizumab
79730043|NCT00647881|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
79730044|NCT00647881|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fed
79730045|NCT02861625|Behavioral|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
79730046|NCT04174261|Drug|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
79730047|NCT04174261|Procedure|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
79730048|NCT04174261|Drug|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
79730049|NCT00971997|Drug|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
79864473|NCT00809315|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
79864474|NCT03870971|Other|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
79864475|NCT00807053|Drug|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
79864476|NCT00807053|Drug|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
80024666|NCT03734731|Device|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
79400979|NCT05387889|Behavioral|Mindfulness Meditation for Pulmonary Hypertension (MMPH)|Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.
79400980|NCT05380583|Behavioral|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
79570163|NCT01776021|Other|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
79864477|NCT00807053|Drug|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
79864478|NCT00807053|Drug|Placebo|Placebo
80024667|NCT03734731|Drug|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
79730050|NCT04171609|Behavioral|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
79730051|NCT00910741|Drug|Nanoplatin (NC-6004) and Gemcitabine|
79730052|NCT02863731|Other|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
80024668|NCT03734731|Drug|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
80024669|NCT03720990|Drug|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
80024670|NCT03709264|Drug|Amino Acids|Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
80024671|NCT03709264|Drug|Placebos|Placebo: standard treatment
80024672|NCT03705169|Biological|SAR441236|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
80024673|NCT03705169|Biological|Placebo|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
80024674|NCT03695939|Biological|realSKIN (skin xenotransplant)|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
80024675|NCT03695939|Biological|Human Cadaver Allograft|HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
80024676|NCT03687957|Drug|rhIL-7-hyFc|-Given by intramuscular injection
80024677|NCT03687957|Drug|Placebo|-Given by intramuscular injection
80024678|NCT03687957|Drug|Temozolomide|-Standard of care
79570164|NCT01776047|Drug|Exforge®|
79570165|NCT01776047|Drug|G-0081|
79570166|NCT01776060|Other|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
79864479|NCT00809393|Drug|tranexamic acid|10 mg/kg
79864480|NCT00809393|Drug|tranexamic acid|30 mg/kg
79864481|NCT00799955|Procedure|Placebo block|100 micrograms of spinal morphine
79864482|NCT00799955|Procedure|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
79864483|NCT00807131|Behavioral|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
79864484|NCT00807131|Behavioral|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
80024679|NCT03687957|Radiation|Radiation therapy|-Standard of care
80024680|NCT03687957|Procedure|Blood sample|"Week 1 (prior to the 1st dose of rhIL-7-hyFc)~Week 2 (one week after rhIL-7-hyFc)~Week 3 (two weeks after rhIL-7-hyFc)~Week 4 (three weeks after rhIL-7-hyFc)~Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~Week 14 (one week after rhIL-7-hyFc)~Week 16 (three weeks after rhIL-7-hyFc) - optional~Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~At the time of tumor progression"
80024681|NCT03684109|Device|3T MRI Scanner|3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
80024682|NCT03677037|Other|Short-term MBT|Short-term mentalization-based therapy
79570167|NCT01776073|Behavioral|Patient Navigation|
79570168|NCT01776086|Behavioral|Neurological testing|
79570169|NCT01776099|Dietary Supplement|Dietary supplement (4 arms, 2 active, 2 placebo)|
79570170|NCT01776112|Other|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
79570171|NCT01776112|Other|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
79864485|NCT00807131|Behavioral|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
79268434|NCT05695586|Behavioral|Mindful Self-Compassion (MSC) training|8-week Mindful Self-Compassion (MSC) intervention protocol, developed by Germer and Neff (2013, 2019). After the training, participants will enter a 12-month phase of regular MSC-based supervised practice.
79268435|NCT05695586|Behavioral|Mindfulness Based Stress Reduction (MBSR) training|8-week Mindfulness Based Stress Reduction (MBSR) intervention protocol, as developed by Stahl & Goldstein (2010). After the training, participants will enter a 12-month phase of regular MBSR-based supervised practice.
79268436|NCT02411955|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
79268437|NCT02411955|Drug|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
79268438|NCT02411955|Drug|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
79570172|NCT01776125|Other|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
79570173|NCT01776138|Other|Collect Blood and Survey Instruments|
79570174|NCT01776203|Drug|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
79730053|NCT02863731|Other|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
79730054|NCT02863497|Behavioral|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
79730055|NCT00647959|Drug|Doxycycline Tablets, 150mg|150mg, single dose fasting
79730056|NCT00647959|Drug|Adoxa Tablets 150 mg|150mg, single dose fasting
79730057|NCT00648583|Drug|Ondansetron Tablets 24 mg|24mg, single dose fed
80024683|NCT03677037|Other|Long-term MBT|Long-term mentalization-based therapy
80024684|NCT03672487|Drug|Benznidazole|Benznidazole tablet
80024685|NCT03672487|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
79570175|NCT01776216|Other|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
79570176|NCT01776216|Other|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
79730058|NCT00648583|Drug|Zofran® Tablets 24 mg|24mg, single dose fed
79730059|NCT04284579|Device|IV cannula|We measure the time duration needed for IV cannulation
79730060|NCT02882334|Device|Finger Force Manipulandum|
79864486|NCT00807131|Behavioral|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
79864487|NCT00658775|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
80024686|NCT03656835|Procedure|Molecular Nanotechnology|Undergo ILN biochip testing
80024687|NCT03655769|Device|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
80024688|NCT03655769|Device|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
80024689|NCT03590288|Procedure|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
79730061|NCT02882334|Other|Conventional physiotherapy|
79730062|NCT02664259|Procedure|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
79864488|NCT00658775|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
79864489|NCT00807287|Procedure|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
79864490|NCT00807287|Procedure|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
79268439|NCT03175887|Device|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
79268440|NCT03172533|Drug|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
79268441|NCT03172533|Drug|Placebo oral capsule|placebo
79268442|NCT05678894|Other|Scanner and EOS imaging|Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
79730063|NCT02664259|Procedure|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
79730064|NCT02664259|Procedure|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
79730065|NCT04285749|Drug|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
79400981|NCT05380583|Behavioral|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
79570177|NCT01776255|Behavioral|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
79570178|NCT01776255|Behavioral|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
79864491|NCT00800033|Behavioral|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
79570179|NCT01776281|Behavioral|Kangaroo Mother Care|
79570180|NCT01776281|Behavioral|Standard Care|
79570181|NCT01776320|Drug|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
79570182|NCT01776333|Behavioral|video decision aid|
79570183|NCT01776359|Dietary Supplement|High Protein|2.4g/kg of protein
79570184|NCT01776359|Dietary Supplement|Low Protein|1.2g/kg of protein
79570185|NCT01776372|Device|Medela Thopaz Thoracic Drainage System|
79570186|NCT01776372|Device|Atrium Express Dry Seal Chest Drain|
79864492|NCT00800033|Dietary Supplement|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
79570187|NCT01776385|Other|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
79864493|NCT00800111|Procedure|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
79864494|NCT00488631|Biological|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
79570188|NCT01776385|Other|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
79864495|NCT00488631|Biological|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
79864496|NCT00488631|Biological|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
80024690|NCT03588260|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
79570189|NCT01776411|Drug|forodesine hydrochloride|
79570190|NCT01776437|Drug|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
79570191|NCT01776450|Device|Endovascular AAA repair|
79570192|NCT01776463|Drug|Z-360|
80024691|NCT03556228|Drug|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|Taken orally once daily
79400982|NCT05375760|Biological|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region."
79570193|NCT01776463|Drug|placebo|
79570194|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
79570195|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
79570196|NCT01776528|Biological|NGM282|
79570197|NCT01776528|Biological|Placebo|
79570198|NCT01776567|Device|Everolimus eluting stents|
79570199|NCT01776619|Drug|PF-06305591|14 day repeated 20mg BID doses
79570200|NCT01776619|Drug|Placebo|14 day repeated BID doses
79570201|NCT01776619|Drug|PF-06305591|14 day repeated 80mg BID doses
79730066|NCT04285749|Other|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
79730067|NCT04285749|Other|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
79730068|NCT03809481|Drug|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
79268443|NCT03172221|Diagnostic Test|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
79570202|NCT01776619|Drug|Placebo|14 day repeated BID doses
79570203|NCT01776619|Drug|PF-06305591|14 day repeated 40mg BID doses
79570204|NCT01776619|Drug|Placebo|14 day repeated BID doses
79570205|NCT01776619|Drug|PF-06305591|14 day repeated BID doses
79570206|NCT01776619|Drug|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
79570207|NCT01776658|Drug|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
79570208|NCT01776658|Drug|Placebo|Ocular topical administration of placebo for 10 consecutive days
79730069|NCT03809481|Drug|Argatroban|Synthetic direct thrombin inhibitor
79730070|NCT00649129|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
79400983|NCT05375760|Biological|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab [AZD8895] and 600 mg cilgavimab [AZD1061]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region."
79730071|NCT00649129|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
79400984|NCT05372614|Procedure|Biopsy|Correlative studies
79400985|NCT05372614|Procedure|Biospecimen Collection|Undergo blood sample collection
79400986|NCT05372614|Procedure|Computed Tomography|Undergo CT scan
79400987|NCT05372614|Procedure|Echocardiography|Undergo echocardiography
79570209|NCT01776671|Drug|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
79730072|NCT01127646|Drug|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
79864497|NCT00488631|Biological|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
79730073|NCT01127646|Drug|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
79730074|NCT01127646|Drug|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
79730075|NCT04284423|Diagnostic Test|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
79864498|NCT00809549|Drug|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
80024692|NCT03555851|Drug|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
79400988|NCT05372614|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
79570210|NCT01776684|Drug|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
79570211|NCT01776697|Drug|pelubiprofen (30mg) tablet IR|
79570212|NCT01776697|Drug|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
79730076|NCT02660047|Drug|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
79864499|NCT00809627|Drug|Caffeine|Caffeine 500 mg IV
79864500|NCT00809627|Drug|saline|Normal saline
79400989|NCT05372614|Drug|Neratinib Maleate|Given PO
79864501|NCT00809705|Drug|Placebo|sc once weekly for 12 weeks
79268444|NCT03175965|Device|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
79268445|NCT02405247|Other|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
79268446|NCT02405403|Drug|[18F]DPA-714 PET|[18F]DPA-714 Positron Emission Tomography
79400990|NCT05372614|Biological|Trastuzumab Deruxtecan|Given IV
79268447|NCT05488574|Other|Deep breathing with Yoga positioning|Deep breathing with yoga positioning 10min in morning, 1 minute noon, and 1 minute evening (diner)
79268448|NCT02401893|Biological|Influenza Vaccine|Everyone immunized as recommended by current guidelines
79400991|NCT05370352|Behavioral|Standard smoking cessation treatment|Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation
79570213|NCT01776710|Behavioral|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
79864502|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
79864503|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 12 weeks
79864504|NCT00655499|Drug|Panitumumab|6 mg/kg
79864505|NCT00655499|Drug|Irinotecan hydrochloride|180 mg/kg
79864506|NCT00655499|Genetic|Chromogenic in situ hybridization|
79864507|NCT00655499|Genetic|Fluorescence in situ hybridization|
79864508|NCT00655499|Genetic|Gene expression analysis|
79864509|NCT00655499|Other|Laboratory biomarker analysis|
79864510|NCT00809861|Procedure|volar locking plating|open reduction and internal fixation
79864511|NCT00809861|Procedure|external immobilisation|closed reduction and external fixation
79864512|NCT00800189|Radiation|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
79864513|NCT00654875|Drug|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
79864514|NCT00654875|Drug|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
79864515|NCT00800267|Drug|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
79864516|NCT00800267|Drug|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
79864517|NCT00800267|Drug|timolol 0.5%|one drop in the morning and evening
80024693|NCT03555851|Other|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
80024694|NCT03519971|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
80024695|NCT03519971|Other|Placebo|Placebo IV (intravenous infusion)
80024696|NCT03519971|Drug|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
80024697|NCT03519971|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
79730077|NCT02660047|Drug|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
79864518|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
79864519|NCT00809939|Drug|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
79864520|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
79400992|NCT05370352|Behavioral|Personalised chat messaging|Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).
79570214|NCT01776749|Device|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
79570215|NCT01776775|Device|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
79730078|NCT04285437|Behavioral|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
79730079|NCT00648661|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
79730080|NCT00648661|Drug|Lexapro® Tablets 20 mg|20mg, single dose fed
79730081|NCT05367414|Other|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
79730082|NCT05367414|Other|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
79730083|NCT04284111|Device|Orthokeratology lenses|Orthokeratology lenses
80024698|NCT03519971|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
79730084|NCT04171687|Drug|Clopidogrel 75mg|Clopidogrel 75 mg tablet
79730085|NCT04171687|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
79730086|NCT04171687|Drug|RAPA113|RAPA113 tablet
80024699|NCT03519971|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
79730087|NCT03556215|Device|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
79730088|NCT03556215|Procedure|Myringotomy|Myringotomy will be performed using a standard procedure.
79730089|NCT00648817|Drug|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
79730090|NCT00648817|Drug|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
79730091|NCT02664025|Procedure|vaginal examination simulator|
79730092|NCT04284033|Device|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
79730093|NCT04284033|Device|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
79730094|NCT02663479|Dietary Supplement|Cardiopressin|
79730095|NCT02663479|Dietary Supplement|Placebo|
79730096|NCT02663401|Behavioral|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
79730097|NCT02862561|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
79864521|NCT00809939|Drug|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
79864522|NCT00807443|Drug|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp & Dohme. A dose of 400 mg will be administered every 12 hours
79864523|NCT00807521|Drug|Dexamethasone|Single high dose bolus of dexamethasone before surgery
79864524|NCT00807521|Drug|Placebo|Placebo for dexamethasone
79864525|NCT00810173|Behavioral|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
79864526|NCT00922259|Biological|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
80024700|NCT03519971|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
80024701|NCT03493945|Biological|M7824|1,200 mg IV once every 2 weeks
80024702|NCT03493945|Drug|N-803|8-15 mcg/kg subcutaneous every 2 weeks
80024703|NCT03493945|Biological|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
80024704|NCT03493945|Biological|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
80024705|NCT03493945|Drug|Epacadostat|600 mg orally twice daily (1200 MG total)
80024706|NCT03484702|Drug|JCAR017|Specified dose on specified days
79730098|NCT02862561|Biological|Precision Cells|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
79730099|NCT02663323|Device|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
79730100|NCT01215188|Biological|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
79864527|NCT00800423|Drug|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
79730101|NCT01215188|Biological|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
79864528|NCT00800423|Drug|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
79570216|NCT01776788|Drug|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
79570217|NCT01776788|Drug|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
79730102|NCT01215188|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
79730103|NCT04285281|Drug|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
79730104|NCT02663245|Other|Intervention 1|"Diabetes specific consultation~Basic training in clinical guidelines~Platform of communication for professionals~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
79864529|NCT00800501|Drug|sNN0029|Continuous ICV infusion at one of three dose levels
80024707|NCT03480061|Drug|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
79730105|NCT02663245|Other|Intervention 2|"7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~Basic training in clinical guidelines.~Platform of communication for professionals.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
80024708|NCT03440450|Drug|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
80024709|NCT03435510|Behavioral|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
79730106|NCT00629733|Drug|RO-14|
79730107|NCT02659657|Drug|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
79730108|NCT02861547|Other|death|
79730109|NCT02659891|Biological|IVIg|
79730110|NCT02659891|Other|Placebo|
79730111|NCT02863341|Other|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
79730112|NCT02659735|Drug|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
79730113|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
79864530|NCT00800501|Drug|Placebo|Continuous ICV infusion
79864531|NCT00807677|Drug|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
79864532|NCT00651755|Drug|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
79864533|NCT00651755|Drug|Cyclophosphamide|750 mg/m^2 By Vein On Day 1
79864534|NCT00651755|Drug|Doxorubicin|25 mg/m^2 By Vein Over 48 Hours On Days 1-2
79864535|NCT00651755|Drug|Vincristine|2 mg By Vein On Day 1
79864536|NCT00651755|Drug|Prednisone|100 mg PO for 5 Days
79864537|NCT00651755|Drug|Rituximab|375 mg/m^2 By Vein On Day 1.
79730114|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
79864538|NCT00651755|Drug|Ondansetron|8 mg daily for 2 days
79570218|NCT01776801|Other|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
79570219|NCT01776853|Dietary Supplement|Glucose|
79730115|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
79730116|NCT04283799|Dietary Supplement|A new human milk fortifier|Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
79730117|NCT04286763|Diagnostic Test|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
79730118|NCT00648193|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
79864539|NCT02552381|Other|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
79864540|NCT02552771|Procedure|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
80024710|NCT03414684|Drug|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
80024711|NCT03414684|Drug|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
80024712|NCT03400085|Other|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
80024713|NCT03374449|Procedure|continuation of the RAS-inhibitors|drug intake
79268449|NCT05678816|Device|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
79730119|NCT00648193|Drug|Paxil® 40 mg Table|40mg, single dose fasting
80024714|NCT03374449|Procedure|discontinuation of the RAS-inhibitors|no drug intake
79268450|NCT05678816|Other|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~Passive stretching exercise, strengthening exercise.~Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~Gait training."
79570220|NCT01776853|Dietary Supplement|Fructose|
79730120|NCT04283721|Other|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
79864541|NCT02552771|Procedure|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
80024715|NCT03357536|Procedure|Human biological samples|"Blood sample~Skin biopsy~Saliva"
80024716|NCT03346083|Drug|Betrixaban|Factor Xa inhibitor.
80024717|NCT03298451|Drug|Durvalumab|Durvalumab IV (intravenous infusion).
80024718|NCT03298451|Drug|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
79570221|NCT01776853|Dietary Supplement|Fructans|
79570222|NCT01776866|Procedure|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
79570223|NCT01776892|Drug|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
79864542|NCT00810251|Device|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
79864543|NCT00807755|Drug|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
79864544|NCT00807755|Drug|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
79864545|NCT00807755|Drug|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
79864546|NCT00813527|Drug|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
79864547|NCT00813527|Drug|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
79864548|NCT00654641|Procedure|Negative pressure wound closure|Applying negative pressure to primary wound closure
79864549|NCT00654641|Procedure|Standard wound closure|Standard wound closure
79864550|NCT00810485|Drug|ADX10059|oral administration
79864551|NCT00810485|Drug|ADX10059|oral administration
79864552|NCT00810485|Drug|ADX10059|oral administration
80024719|NCT03298451|Drug|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
80024720|NCT03298451|Drug|Sorafenib|Sorafenib, as per standard of care
80024721|NCT03298451|Drug|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
79570224|NCT01776892|Procedure|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
79570225|NCT01776931|Dietary Supplement|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
79570226|NCT01776957|Device|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
79864553|NCT00810485|Drug|ADX10059 Matching Placebo|oral administration
79570227|NCT01776970|Drug|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
79268451|NCT02701413|Device|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
79570228|NCT01776983|Device|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
79400993|NCT05370352|Behavioral|SMS text messaging|SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.
79268452|NCT02701413|Device|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
79400994|NCT05370196|Device|Test Product|Synthetic Male Condom
79400995|NCT05370196|Device|Control Product|Latex Male Condom
79400996|NCT05366933|Drug|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
79730121|NCT01215032|Drug|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
79730122|NCT02659579|Behavioral|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
80024722|NCT03298451|Drug|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
79268453|NCT02412033|Drug|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
79268454|NCT02412033|Drug|Placebo|This group will receive placebo
79400997|NCT05363865|Behavioral|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
79400998|NCT05363865|Behavioral|Standard of Care|health websites and county information provided to participants
79400999|NCT05360784|Drug|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
79401000|NCT05360784|Drug|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
79401001|NCT05359016|Behavioral|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
79401002|NCT05356715|Procedure|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
79730123|NCT02659579|Behavioral|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
79730124|NCT00962247|Device|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
79730125|NCT02659423|Behavioral|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
79730126|NCT02659423|Behavioral|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
79730127|NCT02659423|Behavioral|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
79730128|NCT02663089|Drug|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of [14C]-GSK961081 (approximately 6.2 kilobecquerel [kBq]) intravenously as a single dose over 1 hour.
79730129|NCT02663089|Drug|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of [14C]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
79730130|NCT02663089|Drug|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
79864554|NCT00810563|Drug|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
79864555|NCT00810563|Drug|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
79401003|NCT05355701|Drug|PF-07799933|Tablet
79570229|NCT01776996|Drug|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
79730131|NCT02663167|Behavioral|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
79864556|NCT00807911|Drug|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
80024723|NCT03279081|Drug|Cx601|Cx601 eASCs intralesional injection.
79268455|NCT05538494|Other|BFR intervention|"Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~Rest between series: Duration of 45 seconds.~Workload: 30% of 1RM.~Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps."
79570230|NCT01777009|Procedure|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
79570231|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
79570232|NCT01777048|Dietary Supplement|Omega-3 Fatty Acids Supplementation|
79730132|NCT02664103|Drug|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
79730133|NCT02663011|Other|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
79730134|NCT02659345|Behavioral|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
79730135|NCT02659345|Behavioral|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
79864557|NCT00807911|Drug|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
80024724|NCT03279081|Other|Placebo|Cx601 placebo-matching eASCs intralesional injection.
80024725|NCT03243513|Other|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
80024726|NCT03173976|Drug|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
80024727|NCT03156946|Behavioral|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
80024728|NCT03156946|Behavioral|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
80024729|NCT03073967|Drug|Pritelivir|100 mg oral tablets
79268456|NCT05538494|Other|High load intervention|"A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~Training: 4 series of 12 repetitions of squats.~Rest between series: Duration 2 minutes.~Workload: 70% of 1RM."
79268457|NCT04481685|Drug|ATI-450|50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.
79570233|NCT01777048|Dietary Supplement|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
79570234|NCT01777061|Drug|[11C]Acetate|intravenous injection of an average of 40 mCi of [11C]Acetate
79570235|NCT01777074|Other|Data collection|Questionnaire, Vaccination book
79864558|NCT00808145|Drug|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
79864559|NCT00922337|Device|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
80024730|NCT03073967|Drug|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
79570236|NCT01777087|Other|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
79570237|NCT01777100|Drug|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
79864560|NCT02552459|Drug|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
79864561|NCT02552459|Drug|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
79570238|NCT01777113|Other|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
79730136|NCT00918580|Biological|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
79864562|NCT02552459|Drug|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
79864563|NCT02552459|Drug|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
79730137|NCT02662855|Other|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
79730138|NCT02662855|Drug|Favipiravir|oral administration of Favipiravir tablets
79730139|NCT00648271|Drug|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
79730140|NCT00648271|Drug|Lopressor® Tablets 50 mg|1x50mg, single dose fed
79864564|NCT00810953|Drug|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
79864565|NCT00811031|Drug|Taxotere|75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
79730141|NCT04170127|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
79730142|NCT00648349|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
79864566|NCT00811031|Drug|Prednisone|5 mg twice a day by mouth.
80024731|NCT02988375|Behavioral|dCBTI|
80024732|NCT02988375|Behavioral|Sleep Education|
80024733|NCT02965950|Drug|Cyclophosphamide|I.v. infusion
80024734|NCT02876757|Drug|5ARI|Exposure to finasteride/dutasteride
80024735|NCT02843035|Drug|venglustat (GZ402671)|"Pharmaceutical form: capsule~Route of administration: oral"
80024736|NCT02843035|Drug|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
79268458|NCT04481685|Drug|Placebo|Placebo pill will be taken twice daily preferably spaced 12 hours apart.
79730143|NCT00648349|Drug|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
79730144|NCT04253938|Other|Education|Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
79730145|NCT00649207|Drug|ABT-888|Oral Capsules
79864567|NCT02552537|Drug|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
79268459|NCT02401971|Drug|Thalidomide|Given orally
79730146|NCT00649207|Radiation|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
79730147|NCT02662621|Other|blood samples|
79730148|NCT02662621|Other|Urine samples|
79864568|NCT02552537|Drug|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
79864569|NCT00811109|Device|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
79864570|NCT00811109|Device|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
80024737|NCT02841930|Other|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
80024738|NCT02728817|Procedure|End-cephalic vein to side-radial artery fistula creation|"Circumferential dissection of the cephalic vein (4-5cm long)~Longitudinal arteriotomy (~10mm)~End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
79268460|NCT02401971|Drug|CPT-11|Given Ivgtt
79268461|NCT05538416|Procedure|Posterior Lumbar Interbody Fusion (PLIF)|Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
79268462|NCT00701883|Drug|Placebo|2 capsules, once a day for 8 weeks
79268463|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
79268464|NCT00701883|Drug|MBX-8025|2 capsule, once daily for 8 weeks
79268465|NCT00701883|Drug|Atorvastatin|2 capsules, once daily for 8 weeks
79401004|NCT05355701|Drug|binimetinib|Tablet
79864571|NCT00811109|Device|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
79864572|NCT00811265|Device|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
79864573|NCT00808223|Biological|alefacept|IM injection
79864574|NCT00811343|Biological|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
80024739|NCT02728817|Procedure|RADAR fistula creation|"Dissection of the anterior-medial aspect of the cephalic vein (~15mm) without grasping or clamping the venous wall~Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~Ligation and section of the radial artery (distal)~Longitudinal venotomy (~10mm)~End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
80024740|NCT02723994|Drug|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
80024741|NCT02723994|Drug|Asparaginase Erwinia Chrysanthemi|
80024742|NCT02723994|Drug|Cyclophosphamide|
80024743|NCT02723994|Drug|Cytarabine|
80024744|NCT02723994|Drug|Dexamethasone|
80024745|NCT02723994|Drug|Doxorubicin|
80024746|NCT02723994|Drug|Leucovorin Calcium|
80024747|NCT02723994|Drug|Mercaptopurine|
79268466|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
79570239|NCT01777113|Other|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
79570240|NCT01777113|Other|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
79268467|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
79401005|NCT05355701|Biological|cetuximab|Injection for intravenous use
79570241|NCT01777178|Other|Low bicarbonate dialysis|
79730149|NCT02663947|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
79730150|NCT00920686|Drug|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
79570242|NCT01777230|Procedure|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
79268468|NCT05678738|Dietary Supplement|Antioxidant Berry Supplementation|Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.
80024748|NCT02723994|Drug|Methotrexate|
79570243|NCT01777230|Procedure|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
79268469|NCT05678738|Other|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
79268470|NCT05678738|Dietary Supplement|Placebo (non-juice) Supplementation|Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
79401006|NCT05336812|Drug|Acalabrutinib|Given PO
79570244|NCT01777230|Procedure|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
79570245|NCT01777243|Drug|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg [approximately equivalent to 0.1 mg/ kg]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
79570246|NCT01777243|Drug|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
79570247|NCT01777256|Drug|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
79570248|NCT01777256|Drug|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
79730151|NCT00920686|Drug|placebo|administered as 3 placebo hard gelatin capsules
80024749|NCT02723994|Drug|Pegaspargase|
80024750|NCT02723994|Drug|Prednisone|
79268471|NCT02401659|Device|CareLinK|
79401007|NCT05336812|Biological|Obinutuzumab|Given IV
79401008|NCT05336812|Drug|Venetoclax|Given PO
80024751|NCT02723994|Drug|Thioguanine|
80024752|NCT02723994|Drug|Vincristine Sulfate|
79401009|NCT05333250|Drug|Modafinil|Modafinil
79401010|NCT05333250|Other|Placebo|Placebo
80024753|NCT02685969|Procedure|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
80024754|NCT02586857|Drug|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
80024755|NCT02512926|Drug|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
79401011|NCT05332899|Biological|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device or by natural exposure to infected participants. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
80024756|NCT02512926|Drug|Cyclophosphamide|
80024757|NCT02512926|Drug|Etoposide|
80024758|NCT02502318|Procedure|Video-thoracoscopy|
80024759|NCT02502318|Procedure|thoracotomy|
80024760|NCT02427451|Drug|Bcl-2 Inhibitor GDC-0199|Given PO
80024761|NCT02427451|Biological|Obinutuzumab|Given IV
80024762|NCT02427451|Drug|Ibrutinib|Given PO
80024763|NCT02427451|Other|Pharmacological Study|Correlative studies
79401012|NCT05324579|Behavioral|Behavioral testing during neuronal recordings|Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
79401013|NCT05322213|Drug|THC|2-Week, once daily, flexible dose, inhaled THC
79401014|NCT05322213|Drug|Placebo|2-Week, once daily, flexible dose, inhaled placebo
79401015|NCT05321706|Drug|Dapagliflozin 10 mg|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
80024764|NCT02427451|Other|Laboratory Biomarker Analysis|Correlative studies
80024765|NCT02427451|Other|Quality-of-Life Assessment|Ancillary studies
80024766|NCT02293980|Drug|MK-3795|Oral administration
80024767|NCT02293980|Drug|Nivolumab|IV infusion
80024768|NCT02293980|Drug|Cabozantinib|Oral administration
79268472|NCT03175653|Other|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
79268473|NCT03175653|Other|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
79268474|NCT02401737|Drug|NVR 3-778|
79401016|NCT05321706|Drug|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
79570249|NCT01777256|Drug|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
79570250|NCT01777256|Drug|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
79570251|NCT01777256|Drug|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
79570252|NCT01777295|Biological|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79268475|NCT02401737|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
79268476|NCT02401737|Drug|Pegasys|
79268477|NCT02401581|Other|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
79730152|NCT00920686|Drug|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
79730153|NCT00648427|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
79730154|NCT00648427|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
79268478|NCT05678504|Device|The phlebotomy procedure|The process of blood collection with a vascular imaging device
79268479|NCT05538260|Procedure|Repair of ocular trauma in children below 16 years old|Diagnosis and repair of pediatric ocular trauma
79730155|NCT02656225|Drug|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
79730156|NCT02656225|Drug|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
80024769|NCT02291848|Biological|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10^6 cells/m2 and Day 14: 5 x 10^6 cells/m2~Dose Level Two:~Day 0: 1 x 10^7 cells/m2 and Day 14: 1 x 10^7 cells/m2~Dose Level Three:~Day 0 2 x 10^7 cells/m2 and Day 14 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
79268480|NCT03175497|Drug|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
79268481|NCT03175341|Drug|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
79268482|NCT03175341|Drug|Placebos|100 ml normal saline 0.9%
79268483|NCT05538026|Drug|Mesalazine|daily dose of 3 g (2 g orally + 1 g rectally)
79268484|NCT05538026|Biological|Fecal transplantation|Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.
79268485|NCT03175575|Behavioral|Access to a community garden in deprived neighborhoods|
79730157|NCT04253470|Other|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
79730158|NCT04170751|Drug|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
79268486|NCT02401425|Drug|Letrozole|
79268487|NCT02401425|Drug|Misoprostol|
79268488|NCT02401425|Other|Placebo|
79401017|NCT05313438|Device|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
79401018|NCT05309382|Diagnostic Test|Prospera|Monthly testing and results provided
79401019|NCT05306938|Behavioral|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
79401020|NCT05298124|Device|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
79401021|NCT05298124|Other|Medical therapy|Medical treatment in an intensive care unit
79401022|NCT05292222|Device|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
79570253|NCT01777295|Biological|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79570254|NCT01777295|Biological|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
79570255|NCT01777347|Drug|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
79570256|NCT01777347|Drug|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
79570257|NCT01777360|Device|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
79401023|NCT05289791|Other|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
79570258|NCT01777386|Procedure|preexpanded perforator flap surgery|
79570259|NCT01777451|Other|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
79864575|NCT04045535|Other|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
79864576|NCT04045535|Other|Usual care|Usual clinical care based on current clinical practice guidelines.
79864577|NCT00811421|Drug|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
79864578|NCT00811421|Drug|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
79864579|NCT00811421|Drug|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
79401024|NCT05283928|Device|OsseoDensification (OD) protocol|Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.
79401025|NCT05283928|Device|standard drilling (SD) protocol (NobelReplace® Conical)|osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
79401026|NCT05276973|Procedure|Biopsy|Undergo biopsy
79401027|NCT05276973|Drug|Carboplatin|Given IV
79401028|NCT05276973|Drug|Ipatasertib|Given PO
79570260|NCT01777464|Biological|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
79864580|NCT00811421|Drug|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
79864581|NCT00811421|Drug|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
79864582|NCT00808301|Other|Gluten-free products|Gluten-free bakery products containing oatmeal.
79401029|NCT05276973|Drug|Paclitaxel|Given IV
79401030|NCT05275855|Drug|EDI048|Oral Liquid
79401031|NCT05275855|Other|Placebo|Oral Liquid
79401032|NCT05272826|Drug|Iberdomide|Available as formulated capsules and administered as oral medication
79401033|NCT05272826|Drug|Bortezomib|Administered as subcutaneous injection
79401034|NCT05272826|Drug|Dexamethasone|Administered as oral medication
79401035|NCT05269667|Drug|Satralizumab 120 mg|Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
79401036|NCT05267535|Drug|Piromelatine 20 mg|Tablets
79570261|NCT01777464|Biological|sham|sham solution
79570262|NCT01777477|Drug|Chloroquine|Addition of Chloroquine to Gemcitabine
79401037|NCT05267535|Drug|Placebo|Tablets
79401038|NCT05258630|Behavioral|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
79864583|NCT00808379|Drug|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
79570263|NCT01777477|Drug|Gemcitabine|
79730159|NCT04170751|Drug|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
79730160|NCT04865536|Drug|1800 mg TBI-223|3 x 600 mg SR1 tablets
79730161|NCT04865536|Drug|2400mg TBI-223|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
79730162|NCT04865536|Drug|3000mg TBI-223|4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
79730163|NCT04865536|Drug|TBI-223 Placebo|3 x Placebo tablets
79730164|NCT04865536|Drug|TBI-223 Placebo|4 x Placebo tablets
79730165|NCT04865536|Drug|TBI-223 Placebo|5 x Placebo tablets
79570264|NCT01777503|Drug|prasugrel|prasugrel 5 mg o.d.
79570265|NCT01777503|Drug|Clopidogrel|75 mg o.d.
79570266|NCT01777529|Biological|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
79570267|NCT01777607|Device|IMPELLA® RP|
79570268|NCT01777633|Radiation|Palliative re-irradiation for progressive DIPG in children|
79570269|NCT01777646|Biological|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
79864584|NCT00808379|Radiation|Additional Radiation boost to the primary tumor volume|15-20Gy
79570270|NCT01777659|Device|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
79730166|NCT02662465|Procedure|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
79730167|NCT02659111|Other|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
79864585|NCT00569777|Device|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
79864586|NCT00569777|Device|Placebo Lens|contact lens without drug
80024770|NCT02291848|Biological|TAA-specific CTLs- fixed dose|"Fixed dose of 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
79864587|NCT00808535|Procedure|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
80024771|NCT02255799|Drug|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
79401039|NCT05258630|Behavioral|Enhanced usual care|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
79570271|NCT01777672|Behavioral|Dietary and oral hygiene recommendations|
79570272|NCT01777672|Dietary Supplement|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
79309045|NCT04801719|Device|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
79309046|NCT04801407|Procedure|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
79730168|NCT02659111|Other|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
79730169|NCT02656147|Biological|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
79864588|NCT00811811|Behavioral|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
79864589|NCT00811811|Behavioral|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
79864590|NCT00569231|Drug|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
79864591|NCT00654095|Drug|Ezetimibe|Ezetimibe 10 mg once daily
80024772|NCT02255799|Drug|Placebo|Placebo capsule once daily for 70 days.
80024773|NCT02244463|Drug|MLN0128|
80024774|NCT02234388|Other|Observation|There are no interventions associated with this registry as it is purely observational.
80024775|NCT02181257|Combination Product|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
80024776|NCT02176902|Behavioral|behavioral dietary intervention|Receive dietary counseling
79864592|NCT00654095|Drug|atorvastatin|atorvastatin 20 mg once daily
80024777|NCT02176902|Behavioral|behavioral dietary intervention|Receive guidelines for low-fat diet
79309047|NCT04801407|Procedure|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
79309048|NCT05615883|Other|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
79309049|NCT05615883|Other|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
79309050|NCT02712983|Drug|TIP|TIP dose regimen
79309051|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
79309052|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
80024778|NCT02176902|Dietary Supplement|omega-3 fatty acid|Given PO
80024779|NCT02176902|Other|laboratory biomarker analysis|Correlative studies
80024780|NCT02139397|Drug|DFMO|
80024781|NCT02139397|Drug|Bortezomib|
80024782|NCT02079740|Procedure|Biopsy|Undergo biopsy
80024783|NCT02079740|Procedure|Biospecimen Collection|Undergo collection of blood samples
80024784|NCT02079740|Procedure|Computed Tomography|Undergo conventional CT or PET/CT
80024785|NCT02079740|Procedure|Magnetic Resonance Imaging|Undergo MRI
80024786|NCT02079740|Biological|Navitoclax|Given PO
80024787|NCT02079740|Procedure|Positron Emission Tomography|Undergo PET/CT
79730170|NCT04170049|Behavioral|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
80024788|NCT02079740|Drug|Trametinib|Given PO
79570273|NCT01777672|Device|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
80024789|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
79570274|NCT01777672|Device|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
79570275|NCT01777685|Drug|Sulpiride|
79570276|NCT01777711|Behavioral|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
79570277|NCT01777711|Behavioral|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
79570278|NCT01777724|Behavioral|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
79570279|NCT01777737|Drug|Cotrimoxazole|24 weeks of treatment
79570280|NCT01777737|Drug|Placebo|Identical capsules to cotrimoxazole
80024790|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
80024791|NCT02038777|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
80024792|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
80024793|NCT02038777|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
80024794|NCT02038777|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
80024795|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
80024796|NCT02038777|Drug|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
80024797|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
79401040|NCT05257811|Device|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
79401041|NCT05253755|Biological|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
79401042|NCT05253755|Biological|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
79401043|NCT05247281|Diagnostic Test|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
79570281|NCT01777750|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
79570282|NCT01777815|Device|NeoChord DS1000 Artificial Chordae Delivery System|
79570283|NCT01777841|Other|Electronic Care plan delivery|
79570284|NCT01777841|Other|Standard care|
79864593|NCT04016831|Behavioral|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
80024798|NCT02038777|Drug|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
80024799|NCT01991457|Drug|Fludarabine|
80024800|NCT01991457|Procedure|Total Body Irradiation|
79401044|NCT05247281|Diagnostic Test|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
79401045|NCT05246514|Drug|Trastuzumab deruxtecan|administered as an IV infusion
79401046|NCT05238311|Drug|Elranatamab|
79401047|NCT05234658|Biological|PHITAH|Tissue Engineered Human Artificial Skin: Fibrin-Hyaluronic Acid
79401048|NCT05234658|Biological|PHIT|Human artificial skin created by tissue engineering: fibrin-agarose
79730171|NCT02659267|Behavioral|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
79730172|NCT02659033|Drug|ceftriaxone|ceftriaxone (1 gram per day)
79864594|NCT04016831|Other|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
79864595|NCT00808691|Other|Critical care|Standard care for each group of patients
80024801|NCT01943994|Drug|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
80024802|NCT01943994|Drug|Nicotine Replacement Therapy (NRT)|
80024803|NCT01899989|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
80024804|NCT01899989|Drug|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
80024805|NCT01817166|Drug|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
79570285|NCT01777867|Procedure|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
79570286|NCT01777867|Procedure|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
79570287|NCT01777893|Behavioral|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
79570288|NCT01777893|Behavioral|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
79570289|NCT01777893|Behavioral|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
79570290|NCT01777893|Behavioral|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
79570291|NCT01777919|Drug|Temozolomide|
79570292|NCT01777919|Drug|Disulfiram|
79570293|NCT01777919|Drug|Copper|
79730173|NCT02659033|Drug|Cefotaxime|cefotaxime (1 gram every 8 hours)
79730174|NCT04170595|Biological|GB221,2 mg/kg|Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
79730175|NCT04170595|Biological|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
79730176|NCT04170595|Biological|Herceptin,6 mg/kg|Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
79864596|NCT00811967|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
79864597|NCT00811967|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
79864598|NCT02552615|Other|body awareness therapy|
80024806|NCT01817166|Drug|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
80024807|NCT01817166|Other|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
80024808|NCT01817166|Biological|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
79268491|NCT05537870|Behavioral|cancer nurse navigator care|oncology case manager care combined with cancer nurse navigator care
79268492|NCT05537870|Behavioral|case manager care|case manager care (usual care)
79268493|NCT02401269|Drug|Aspirin|
79268494|NCT02401269|Drug|Placebo|
79864599|NCT02552615|Other|core stabilization exercises|
79864600|NCT02552615|Other|traditional exercises|
79864601|NCT00812045|Drug|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
79864602|NCT00812045|Drug|Placebo|
79864603|NCT04046159|Drug|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
79864604|NCT04046159|Radiation|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
79864605|NCT00650585|Behavioral|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
79864606|NCT02552069|Device|Tritanium® cup|
79570294|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
79570295|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
79570296|NCT01778088|Drug|I-131-CLR1404 Injection|
79864607|NCT00653939|Drug|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
79268495|NCT02168179|Procedure|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
79268496|NCT02168179|Other|questionnaire administration|Ancillary studies
79268497|NCT04480905|Device|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
79268498|NCT04480905|Device|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
79268499|NCT02168257|Device|RAM Cannula|
79268500|NCT02168257|Device|Binasal Prong CPAP|
79401049|NCT05234658|Biological|Skin Autograft|Skin Autograft
79401050|NCT05225792|Behavioral|Promis Physical Function Questionnaire|Patient reported physical function outcomes
79401051|NCT05225792|Behavioral|L Test|Performance based measure assessing general physical function and balance ability.
79401052|NCT05225792|Behavioral|Narrowing Beam Walking Test|Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
79401053|NCT05225792|Behavioral|PEQ-A|Survey on confidence, stumbles and falls.
79570297|NCT01778101|Drug|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
79570298|NCT01778114|Dietary Supplement|Vitamin D2 in orange juice|1000 IU dose
79730177|NCT04170595|Biological|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
79730178|NCT04170595|Biological|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
79730179|NCT04170595|Biological|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
79864608|NCT00653939|Drug|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
79864609|NCT00653939|Drug|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
79864610|NCT00653939|Drug|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
79864611|NCT00812123|Drug|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
79268501|NCT04480827|Drug|Aramchol 600mg single dose|aramchol acid tablet 600mg, single dose
79268502|NCT04480827|Drug|Aramchol 300mg, bid|aramchol acid tablet 300mg, bid for 12 days
79268503|NCT02582684|Drug|Dolutegravir|Participants were prescribed 50 mg of DTG orally daily
79268504|NCT02582684|Drug|Lamivudine|Participants were prescribed 300 mg of 3TC orally daily.
79268505|NCT02400957|Other|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
79473441|NCT05360186|Device|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
79473442|NCT02290574|Radiation|Hyperthermia with concurrent chemo-radiation therapy|
79473443|NCT01706497|Device|Cerebral tissue oxygen saturation monitoring, blinded|
79473444|NCT05356052|Combination Product|INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula
79570299|NCT01778114|Dietary Supplement|Vitamin D3 in orange juice|1000 IU
79570300|NCT01778114|Dietary Supplement|Vitamin D2|capsule, 1000 IU
79570301|NCT01778114|Dietary Supplement|Vitamin D3|capsule, 1000 IU
79864612|NCT00812123|Drug|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
79864613|NCT00812123|Drug|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
79864614|NCT00812123|Drug|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
79730180|NCT04511533|Drug|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
79730181|NCT02662231|Procedure|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
79570302|NCT01778114|Other|Placebo|Placebo
79864615|NCT00812123|Procedure|Protocol biopsies|protocol kidney biopsies at month one and three
79570303|NCT01778140|Other|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
79570304|NCT01778140|Other|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
79864616|NCT00808925|Other|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
79864617|NCT00809081|Procedure|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
79864618|NCT00646451|Drug|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
80024809|NCT01817166|Biological|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
79268506|NCT02400957|Other|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
79570305|NCT01778153|Behavioral|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
79570306|NCT01778166|Drug|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
79570307|NCT01778166|Drug|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
79570308|NCT01778192|Drug|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
79570309|NCT01778192|Drug|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
79570310|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
79730182|NCT00648973|Drug|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
79730183|NCT00648973|Drug|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
79570311|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
79570312|NCT01778205|Other|Observational|
79730184|NCT00648973|Drug|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
79864619|NCT00646451|Drug|placebo|up to 4 capsules bid as tolerated
79864620|NCT02552849|Other|No intervention|
80024810|NCT01817166|Biological|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
80024811|NCT01590862|Device|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
80024812|NCT01571986|Procedure|Non-invasive ventilation|Non-invasive ventilation
80024813|NCT00902044|Genetic|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
80024814|NCT00902044|Drug|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~>10 kg: 25 mg/m2/day;~<10 kg: 1 mg/kg/day IV over 30 minutes"
79570313|NCT01778218|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
79570314|NCT01778231|Dietary Supplement|Nutrof Total|Antioxidant and trace element supplement
79570315|NCT01778231|Dietary Supplement|Placebo|
79730185|NCT02662309|Drug|MPDL3280A|Intravenous infusion
79730186|NCT02658955|Procedure|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
79730187|NCT02655835|Behavioral|Internet Mindfulness Meditation|
79730188|NCT02655835|Behavioral|Access|
79864621|NCT02552927|Device|Chest shield with aluminum foil (CALF)|
79864622|NCT02552927|Device|SHIELD|
79864623|NCT00813683|Other|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
79864624|NCT00813683|Other|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
79864625|NCT00809237|Drug|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
79730189|NCT02662075|Device|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
79864626|NCT00813839|Other|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
79268507|NCT02411877|Procedure|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
79268508|NCT02411877|Procedure|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
79730190|NCT02661919|Device|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
79268509|NCT02411877|Device|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
79268510|NCT02411877|Device|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
79730191|NCT04032691|Drug|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
79268511|NCT04721288|Other|Active communication through Reboot application|Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
79570316|NCT01778244|Drug|metformin|1000mg/day for 24 weeks
79268512|NCT04721288|Other|Generic communication through Reboot application|Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
79401055|NCT05221385|Drug|Gentulizumab|Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.
79401056|NCT05218096|Drug|ALXN2050|Oral tablet.
79570317|NCT01778257|Dietary Supplement|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
79570318|NCT01778257|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Mate extracts.
79570319|NCT01778270|Device|Body Bioimpedance Sensor|
79570320|NCT01778283|Biological|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
79864627|NCT02552693|Other|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
79268513|NCT02401191|Drug|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
79268514|NCT04714970|Device|iTBS|Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
79268515|NCT04714970|Device|Shame stimulation|TMS coil vertical to the brain surface, with same protocol as iTBS
79268516|NCT04892901|Procedure|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
79268517|NCT04892901|Procedure|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
79401057|NCT05218096|Drug|Placebo|Oral tablet.
79401058|NCT05206877|Drug|Insulin, 4 units|Topical insulin 100 U/ml, 1 drop per day
79570321|NCT01778309|Dietary Supplement|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
79570322|NCT01778335|Procedure|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
79570323|NCT01778348|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
79570324|NCT01778348|Device|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
79570325|NCT01778374|Other|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
79570326|NCT01778374|Other|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
79864628|NCT02551913|Behavioral|Control|the adolescents will not receive any specific intervention
79864629|NCT02551913|Behavioral|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
79864630|NCT00817505|Drug|AZD1656|Single dose oral tablet
79864631|NCT00817505|Drug|AZD1656|Single dose oral suspension
79730192|NCT02658799|Drug|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
79864632|NCT00817583|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
79401059|NCT05206877|Drug|Insulin, 20 units|Topical insulin 500 U/ml, 1 drop per day
79570327|NCT01778387|Procedure|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
79570328|NCT01778400|Procedure|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
79570329|NCT01778400|Procedure|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
79570330|NCT01778413|Drug|ATRIPLA|
79570331|NCT01778439|Drug|OMP-52M51|
79864633|NCT00817583|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
79268518|NCT04892901|Procedure|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
79268519|NCT03169491|Device|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
79268520|NCT02411721|Behavioral|Animal Assisted Intervention|"Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
79401060|NCT05194358|Drug|Stabilized Isoamyl Nitrite (SIAN)|"SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs."
79401061|NCT05190588|Other|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
79570332|NCT01778452|Procedure|endometrial biopsy|endometrial biopsy
79473445|NCT05738564|Drug|Epinephrine Inhalation Solution|epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
79473446|NCT01706965|Drug|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
79570333|NCT01778517|Other|Group Psychotherapy|
79570334|NCT01778517|Other|Cognitive behavior therapy based on self help|
79268521|NCT03115437|Other|Hard cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by hard cushioning.
79268522|NCT03115437|Other|Soft cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by soft cushioning.
79570335|NCT01778621|Device|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
79570336|NCT01778660|Other|Type of Counselling (Mnemonic)|
79570337|NCT01778660|Other|Standard|
79570338|NCT01778673|Procedure|Cast immobilization|
79570339|NCT01778686|Drug|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
79570340|NCT01778686|Other|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
79570341|NCT01778686|Dietary Supplement|Acute tryptophan depletion|
79570342|NCT01778699|Dietary Supplement|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
79570343|NCT01778712|Behavioral|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
79864634|NCT00817661|Dietary Supplement|Vitamin A|10000 IU Vitamin A or placebo per week
79864635|NCT00817661|Dietary Supplement|Placebo|10000 IU Vitamin A or placebo per week
79864636|NCT00642707|Drug|PRO 140 (humanized monoclonal antibody to CCR5)|
79864637|NCT00642707|Drug|Placebo Comparator|
79864638|NCT02551523|Drug|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
79864639|NCT02551523|Drug|Standard of care combinational antiretroviral therapy|
79730193|NCT02658799|Drug|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
79730194|NCT02536885|Procedure|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
80024815|NCT00902044|Drug|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes"
79730195|NCT02536885|Procedure|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
79730196|NCT02655757|Drug|Sitagliptin|5 mg, 1 tablet per day for 12 months
79730197|NCT02655757|Drug|Placebo|Placebo,1 tablet per day for 12 months
79730198|NCT02661841|Other|LI-Guided Therapy|Preemptive treatment according to LI monitoring
79730199|NCT02661841|Other|Heart Failure Guidelines|Treatment according to clinical signs
79864640|NCT00814151|Other|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
79864641|NCT00817739|Drug|Leuprorelin|Leuprorelin injection
79864642|NCT00817739|Drug|Flutamide|Flutamide tablets
79864643|NCT00817895|Drug|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
79268523|NCT03169569|Procedure|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
79730200|NCT01214720|Drug|bevacizumab [Avastin]|Intervenous repeating dose
79730201|NCT02655991|Behavioral|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
79864644|NCT00817895|Drug|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
79864645|NCT00817895|Procedure|TACE|All patients will accept TACE one month after tumor was resected.
79864646|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
79268524|NCT03169569|Procedure|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
79730202|NCT02655991|Behavioral|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
79730203|NCT02655913|Drug|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
79268525|NCT03170037|Procedure|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
79268526|NCT03170037|Procedure|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
79268527|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
79864647|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
79864648|NCT00814229|Biological|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
79268528|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Standard treatment
79268529|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Intensified treatment
79268530|NCT03169413|Genetic|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
79864649|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
79864650|NCT00814229|Biological|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
80024816|NCT00902044|Genetic|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
79570344|NCT01778790|Device|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
79570345|NCT01778803|Drug|defactinib|
79730204|NCT02655913|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
79730205|NCT02655913|Other|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
80024817|NCT00250809|Procedure|Placement of a central venous catheter|Placement of a central venous catheter
80024818|NCT00187473|Procedure|liver biopsy|Liver biopsy every 5 years
80024819|NCT04992364|Other|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
79401062|NCT05190549|Procedure|CAV regimen bridging to HSCT|The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
79401063|NCT05171803|Other|No intervention|No intervention, prospective, cohort study.
79570346|NCT01778803|Drug|Paclitaxel|
79570347|NCT01778829|Procedure|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
79570348|NCT01778829|Procedure|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
79473447|NCT01706965|Drug|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
79473448|NCT04350086|Drug|Treatment with Dexmedetomidine|Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
79570349|NCT01778842|Drug|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
79730206|NCT00649285|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
79473449|NCT05620238|Drug|Carfilzomib|Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
79570350|NCT01778842|Drug|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
79570351|NCT01778881|Other|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
79730207|NCT00649285|Drug|Macrobid® Capsules 100 mg|100mg, single dose fed
79730208|NCT04318574|Other|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
79864651|NCT00814229|Biological|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
79864652|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
79864653|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
79864654|NCT00814229|Biological|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
79864655|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
79864656|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
80024820|NCT03608241|Drug|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
80024821|NCT03608241|Drug|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
80024822|NCT03072784|Procedure|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
80024823|NCT03606057|Drug|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
80024824|NCT03606057|Drug|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
80024825|NCT03606057|Drug|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
80024826|NCT03606057|Drug|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
80024827|NCT04998760|Drug|ATG-008|ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.
80024828|NCT04998760|Drug|ATG-010|ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
80024829|NCT03607383|Drug|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
80024830|NCT03607383|Drug|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
79730209|NCT02661685|Biological|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
80024831|NCT04998526|Other|Experimental group|The cold gel pack will be applied to the nape.
80024832|NCT04998526|Other|Placebo group|The gel pack kept at room temperature will be applied to the nape.
80024833|NCT03607305|Procedure|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
80024834|NCT03607305|Procedure|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
79401064|NCT05167227|Other|Extension for Community Healthcare Outcomes|ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
79401065|NCT05166876|Drug|Brequinar Sodium|50 mg, 100 mg, 150 mg, 200 mg x 5 days
79401066|NCT05166876|Drug|Dipyridamole 75 MG|75 mg TID for 5 days
79570352|NCT01778881|Other|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
79570353|NCT01778881|Other|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
79570354|NCT01778881|Other|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
79570355|NCT01778907|Other|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
79268531|NCT03169335|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
79401067|NCT05166876|Drug|Placebo|50 mg, 100 mg, 150 mg, 200 mg x 5 days
79401068|NCT05162586|Drug|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
79570356|NCT01778920|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
79570357|NCT01778933|Drug|EC17|
79570358|NCT01778959|Device|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
79570359|NCT01778959|Device|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
79570360|NCT01778959|Device|standard OVD|use of a standard cohesive OVD during cataract surgery
79730210|NCT04169269|Drug|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
79730211|NCT04169269|Drug|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
79730212|NCT02655367|Other|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
79730213|NCT02655367|Other|Milled oats|Test meal consisting of 264g porridge made with milled oats
79268532|NCT03169335|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
79268533|NCT03169335|Drug|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
79268534|NCT03169335|Drug|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
79268535|NCT03169179|Behavioral|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
79401069|NCT05162586|Drug|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
79401070|NCT05162586|Drug|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
79401071|NCT05162586|Drug|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
79401072|NCT05161078|Device|CARPEDIEM|CARPEDIEM treatment as per local standard of care
79401073|NCT05159700|Drug|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
79401074|NCT05144386|Biological|EBT-101|EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
79401075|NCT05143307|Biological|EBT-101|Long term follow up of participants who received EBT-101
79570361|NCT01778959|Device|OVD|use of a highly cohesive OVD during cataract surgery
79570362|NCT01778972|Other|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
79730214|NCT02661529|Procedure|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
79864657|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
79864658|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
80024835|NCT05002894|Other|Pilates exercises|Pilates exercises for flexibility and stability
80024836|NCT05002894|Dietary Supplement|medical standard care for fatigue|supplements and medical care
80024837|NCT02696499|Drug|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
80024838|NCT02696499|Drug|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
80024839|NCT05003128|Device|LED screen (InnoLux, Taiwan)|Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
79570363|NCT01778972|Other|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
79730215|NCT02661529|Procedure|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
79864659|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
79864660|NCT00568685|Drug|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
79864661|NCT00568685|Drug|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
79401076|NCT05126459|Combination Product|Regimen 1|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
80024840|NCT03607227|Drug|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
79570364|NCT01778998|Procedure|MICS-group|Micro incision cataract surgery is done
79570365|NCT01778998|Procedure|SICS-group|small incision cataract surgery is done
79730216|NCT02661529|Other|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
79730217|NCT02661529|Other|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
80024841|NCT03607227|Drug|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
79570366|NCT01778998|Procedure|SICS pre-cut|Small incision cataract surgery with pre-cut is done
79570367|NCT01778998|Procedure|SICS stab-incision|Small incision cataract surgery with stab-incision is done
79570368|NCT01779063|Behavioral|web based multimedia intervention|cognitive therapy based web intervention
79570369|NCT01779063|Other|educational booklet|patient education booklet
79570370|NCT01779076|Procedure|30% oxygen|
80024842|NCT03607149|Drug|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
79570371|NCT01779076|Procedure|100% oxygen|
79730218|NCT02661373|Drug|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
79730219|NCT02661373|Drug|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
79730220|NCT00649051|Drug|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
80024843|NCT04998292|Device|Piezo-surgery with low level laser therapy|Low level laser therapy
80024844|NCT04998292|Device|Piezo-surgery only|Piezo-surgery only
79570372|NCT01779089|Drug|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
79570373|NCT01779089|Drug|placebo|
79570374|NCT01779102|Biological|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
79730221|NCT00649051|Drug|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
79730222|NCT02536573|Other|Radlink Surgical Positioning Software|
79730223|NCT02655289|Device|Modulated TENS|"Frequency: 100 Hz~Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~Mode: intensity modulation (40% decrease every 0.5 seconds)~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
79864662|NCT00568685|Drug|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
80024845|NCT02035293|Other|PEP|
79570375|NCT01779102|Biological|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
79570376|NCT01779102|Biological|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
79570377|NCT01779128|Procedure|PET-CT|
79570378|NCT01779128|Procedure|MR-PET|
79570379|NCT01779193|Dietary Supplement|lactic acid bacteria|oral lactobacillus capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
79570380|NCT01779193|Dietary Supplement|cranberry|oral cranberry capsule, one pill daily
79570381|NCT01779193|Dietary Supplement|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
79570382|NCT01779232|Drug|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
79570383|NCT01779232|Drug|placebo|administered daily like the active comparator
79570384|NCT01779245|Dietary Supplement|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
79570385|NCT01779245|Dietary Supplement|Placebo|
79570386|NCT01779258|Drug|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
79570387|NCT01779258|Device|Atopiclair®|1 application in the morning, in the afternoon and in the evening
79570388|NCT01779258|Drug|Locatop@|"During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days"
80024846|NCT04998838|Drug|Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)|Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
80024847|NCT04998838|Drug|Regular Myanmar treatment|Treated according to normal Myanmar processes for HBV positive patients
79268536|NCT02401113|Dietary Supplement|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
79570389|NCT01779258|Drug|Locapred@|"During the 3 months study treatment:~1 application in the evening in case of flare "
79730224|NCT02655289|Device|Placebo TENS|"Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~Mode: continuous~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
79268537|NCT03106623|Drug|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
79268538|NCT03106623|Drug|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
79570390|NCT01779271|Drug|Pelubiprofen|
79730225|NCT04169971|Other|Music|Played through headphones during the operation under spinal anaesthesia
79730226|NCT02661607|Procedure|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
80024848|NCT03605823|Device|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
80024849|NCT03607071|Drug|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
79268539|NCT03106623|Drug|Placebo|Oral administration of Placebo once a daily for 4 weeks
79730227|NCT02661607|Device|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
79730228|NCT02661607|Procedure|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
79730229|NCT04170829|Biological|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
79730230|NCT02655211|Procedure|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
80024850|NCT02035215|Drug|Atorvastatin 20mg|
80024851|NCT02035215|Drug|Omega-3-acids ethylesters 90 4g|
79268540|NCT02411175|Other|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
79268541|NCT02411175|Drug|20% ethanol|
79268542|NCT05537558|Drug|Antidepressant|Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
79730231|NCT02655211|Procedure|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
79730232|NCT02655211|Other|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
79730233|NCT02655445|Procedure|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
79864663|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
79864664|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
79864665|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
79864666|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
79268543|NCT03169023|Behavioral|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
79268544|NCT03169023|Behavioral|Enhanced Usual Care Packets|-From the American Cancer Society Website
79268545|NCT03169023|Other|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
79570391|NCT01779271|Drug|Loxoprofen|
79570392|NCT01779284|Drug|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
79570393|NCT01779284|Drug|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
79570394|NCT01779336|Drug|PL225B|"Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~This 21 day administration will define a treatment cycle.~Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
79570395|NCT01779349|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
79570396|NCT01779362|Drug|Metformin|Titrated to 1000 mg BID
79570397|NCT01779362|Drug|Liraglutide|Titrated to 1.8 mg/day
79570398|NCT01779362|Drug|Glargine|Titrated to target fasting glucose <90 mg/dl
79570399|NCT01779362|Drug|Placebo|Matching to metformin 1000 mg BI
79570400|NCT01779401|Drug|Clopidogrel 75mg|
79570401|NCT01779401|Drug|Clopidogrel 150mg|
79570402|NCT01779401|Drug|Aspirin 100mg|
79570403|NCT01779401|Drug|Cilostazol 100mg|
79268546|NCT03169023|Other|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
79730234|NCT02655445|Procedure|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
79268547|NCT03169023|Other|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
79268548|NCT03169023|Other|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
79268549|NCT03169023|Other|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
79401077|NCT05126459|Combination Product|Regimen #2|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
79401078|NCT05126459|Combination Product|Regimen #3|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
79401079|NCT05123118|Behavioral|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
79570404|NCT01779414|Other|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
79401080|NCT05123118|Behavioral|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
79570405|NCT01779427|Behavioral|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
79401081|NCT05120128|Device|Acuvue® Oasys 1-Day|TEST Lens
79570406|NCT01779466|Drug|Desmopressin|
79730235|NCT02655445|Procedure|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
79730236|NCT00649987|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
79730237|NCT00649987|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
79864667|NCT00814385|Biological|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
79864668|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
79864669|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
80024852|NCT02035215|Other|Placebo(Omega-3-acids ethylesters 90)|
80024853|NCT04992442|Drug|TAK-935 Oral Tablet|TAK-935 tablet
79401082|NCT05114057|Other|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
79401083|NCT05113771|Drug|Liafensine|Liafensine
79268550|NCT03169023|Behavioral|iOTA|-Washington University based intervention
79401084|NCT05113771|Drug|Placebo|Placebo
79401085|NCT05109195|Other|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
79473450|NCT05738408|Behavioral|Financial Incentives (FI) and Nicotine Replacement Therapy (NRT)|: In the intervention condition, patients will receive both NRT plus a 12-week program of monetary incentives for verified smoking abstinence that will be implemented by our clinic staff
79570407|NCT01779466|Drug|Placebo (not active)|
79570408|NCT01779479|Drug|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
79864670|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
79864671|NCT00814385|Biological|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
80024854|NCT04992442|Drug|[14C]TAK-935 IV Infusion|[14C]TAK-935 IV infusion
79473451|NCT01352117|Drug|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
79473452|NCT01352117|Drug|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
79864672|NCT04044911|Behavioral|Task model (CogWatch)|
79864673|NCT04045457|Procedure|dry needling|insertion of needle into active myofascial trigger point
79864674|NCT02551601|Other|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
79864675|NCT00061945|Drug|allopurinol|Given PO
79864676|NCT00061945|Drug|cyclophosphamide|Given IV
79864677|NCT00061945|Drug|daunorubicin hydrochloride|Given IV
79864678|NCT00061945|Drug|vincristine sulfate|Given IV
80024855|NCT04992442|Drug|[14C]TAK-935 Oral Solution|[14C]TAK-935 oral solution
79570409|NCT01779479|Drug|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
79570410|NCT01779492|Drug|GL2907|once a day
79730238|NCT04169035|Device|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
80024856|NCT03606993|Other|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one ~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
80024857|NCT03605589|Drug|Blinatumomab|Continuous IV infusion
80024858|NCT03605589|Drug|Pembrolizumab|IV infusion
79570411|NCT01779492|Drug|Oxycontine CR 10mg|twice a day
79730239|NCT04169035|Procedure|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
80024859|NCT04992130|Behavioral|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
80024860|NCT03072472|Device|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
80024861|NCT03075436|Behavioral|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
80024862|NCT03075436|Behavioral|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
80024863|NCT03075124|Device|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
80024864|NCT05002036|Device|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
80024865|NCT03074968|Drug|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
80024866|NCT03074968|Drug|Normal saline|normal saline application
79268551|NCT05678426|Behavioral|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
79268552|NCT05678426|Behavioral|Intermittent fasting|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
79268553|NCT05678426|Behavioral|Intermittent fasting with ketogenic supplement|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
79268554|NCT02411331|Drug|Ethanol 40% + Enoxaparine 400UI/ml|
79268555|NCT02411331|Drug|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
79268556|NCT02411097|Procedure|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
79268557|NCT03540511|Diagnostic Test|postoperative troponin|assess postoperative troponin levels after cardiac surgery in patients with renal dysfunction
79570412|NCT01779505|Biological|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
79570413|NCT01779518|Drug|Sofosbuvir|
79570414|NCT01779518|Drug|Ribavirin|
79570415|NCT01779518|Drug|Pegylated Interferon|
79570416|NCT01779544|Other|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
79730240|NCT01142232|Drug|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
79864679|NCT00061945|Drug|dexamethasone|Given PO and as eye drops
79864680|NCT00061945|Drug|asparaginase|Given SC
79570417|NCT01779544|Other|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
79730241|NCT01142232|Drug|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
79730242|NCT04169659|Device|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
79864681|NCT00061945|Biological|filgrastim|Given SC
79570418|NCT01779570|Drug|Macrolide treatment|
79268558|NCT02411019|Biological|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
80024867|NCT05002348|Device|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
80024868|NCT03075202|Device|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
80024869|NCT04991584|Drug|Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
80024870|NCT03072706|Device|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
80024871|NCT03072706|Other|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
79401086|NCT05103475|Behavioral|Rage Against the Pain (RAP)|The RAP program curriculum will mirror that of the Hatha Yoga classes, but will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the poses/movements (rather, poses will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the typical relaxation/meditation exercise used in yoga, referred to as savasana).
80024872|NCT04997746|Behavioral|Multiprofessional educational interventions|Preventive educational interventions
80024873|NCT04997746|Other|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
79570419|NCT01779596|Drug|Bosentan|
79864682|NCT00061945|Drug|imatinib mesylate|Given PO
79570420|NCT01779596|Drug|Placebo|
80024874|NCT05001412|Drug|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
80024875|NCT04997590|Biological|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
80024876|NCT04997590|Drug|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
80024877|NCT04997512|Device|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
80024878|NCT04997512|Other|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
80024879|NCT04997122|Other|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
79268559|NCT02168335|Other|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
79268560|NCT02168335|Other|Sea salt|Unmedicated sea salt
79268561|NCT05151926|Procedure|Full weight-bearing|Instruction for full and immediate weight-bearing postoperatively
79473453|NCT03379207|Other|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
79473454|NCT03379207|Other|Tracheal Aspirates|Only for mechanically ventilated participants.
79473455|NCT03379207|Other|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
79473456|NCT03377569|Other|Sleep, PD and DBS|Sleep, PD and DBS
79570421|NCT01779609|Drug|Bosentan|
79570422|NCT01779609|Drug|Placebo|
79570423|NCT01779609|Behavioral|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
79570424|NCT01779622|Other|Mixed meal|Ingestion of mixed meal
79864683|NCT00061945|Drug|methotrexate|Given IT, IV, and PO
79864684|NCT00061945|Drug|cytarabine|Given IV
79864685|NCT00061945|Drug|trimethoprim-sulfamethoxazole|Given PO
79864686|NCT00061945|Drug|mercaptopurine|Given PO
79864687|NCT00061945|Drug|leucovorin calcium|Given IV and PO
79864688|NCT00061945|Biological|alemtuzumab|Given SC
79864689|NCT00061945|Drug|acyclovir|Given PO
79864690|NCT00061945|Other|laboratory biomarker analysis|Correlative studies
79864691|NCT00061945|Other|pharmacological study|Correlative studies
79864692|NCT00817973|Dietary Supplement|Casein|
79268562|NCT05151926|Procedure|Partial weight-bearing|Instruction for partial weight-bearing for 6 weeks postoperatively
79864693|NCT00817973|Dietary Supplement|Whey|
79570425|NCT01779635|Device|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
79864694|NCT00817973|Dietary Supplement|Cod|
79268563|NCT05151926|Procedure|Intramedullary nailing|Intramedullary nailing of the fractured tibial shaft.
79268564|NCT05695430|Behavioral|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
79268565|NCT02699463|Device|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
79268566|NCT02699463|Other|Control Group|Standard sleep hygiene counseling as per published guidelines
79268567|NCT05537480|Device|Continuous glucose monitoring device|Continuous glucose monitoring device will be worn by participants during several periods.
79864695|NCT00817973|Dietary Supplement|Gluten|
80024880|NCT04997122|Other|High oleic acid sunflower oil|Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
80024881|NCT04996810|Biological|PROTOXIN|Botulinum toxin Type A
80024882|NCT04996810|Biological|Botox®|Botulinum toxin Type A
79268568|NCT00100789|Drug|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
79268569|NCT00100789|Drug|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
79401087|NCT05103475|Behavioral|Treatment as Usual|The 'treatment as usual' class will be conducted in the style of the yoga classes currently being offered to Veterans at the Hines VA Hospital, which is a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
79401088|NCT05100199|Drug|OnabotulinumtoxinA X|Injection
79401089|NCT05100199|Drug|Placebo|Injection
79268570|NCT02410863|Drug|Dabrafenib|150 mg twice daily
79401090|NCT05096156|Device|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
79401091|NCT05081661|Other|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
79570426|NCT01779635|Device|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
79268571|NCT02410863|Drug|Trametinib|2 mg daily
79268572|NCT05537324|Other|Brazil nut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
79268573|NCT05537324|Other|Coconut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
79268574|NCT03168945|Other|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
79570427|NCT01779661|Other|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
79570428|NCT01779661|Other|Infant Massage|Infant Massage
79268575|NCT03168945|Other|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
79268576|NCT05678192|Drug|oral menopausal hormone therapy|Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
79268577|NCT05678192|Drug|transdermal menopausal hormone therapy|Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
79268578|NCT00708123|Drug|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
79268579|NCT00708123|Drug|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
79268580|NCT05678036|Drug|Opioid maintenance treatment|A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
79268581|NCT03168789|Behavioral|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
79268582|NCT03168789|Behavioral|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
79570429|NCT01779687|Drug|raltegravir|Raltegravir 400 mg BID for 7 days
79570430|NCT01779687|Drug|Atorvastatin|Atorvastatin 20 mg QD for 7 days
79570431|NCT01779713|Genetic|Case-control transcriptomic study|No intervention
79864696|NCT00818051|Radiation|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
79864697|NCT01097941|Biological|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
79864698|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
79864699|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
79864700|NCT00642473|Drug|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
79864701|NCT00642473|Drug|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
79570432|NCT01779726|Radiation|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
80024883|NCT04991896|Drug|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
80024884|NCT03072394|Drug|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
80024885|NCT03072394|Drug|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
79730243|NCT04169659|Device|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
79730244|NCT02655133|Drug|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
79730245|NCT02655133|Drug|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
79730246|NCT02536807|Drug|Hyaluronan|HA gel injection
79730247|NCT02883738|Other|tremor|evaluation of the intensity of the tremor
79730248|NCT04395547|Dietary Supplement|JointAlive™|Combination herbal extract
79730249|NCT04395547|Dietary Supplement|Placebo|Combination placebo product
79730250|NCT02660671|Behavioral|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
79730251|NCT02660671|Behavioral|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
79730252|NCT02660671|Behavioral|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
80024886|NCT04991428|Other|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
79730253|NCT02536495|Drug|Docetaxel|Given IV
79730254|NCT02536495|Other|Laboratory Biomarker Analysis|Correlative studies
80024887|NCT03072004|Device|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
80024888|NCT03072004|Device|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
80024889|NCT03072082|Drug|Danlou Tablet|Conventional western medicine & Danlou Tablet
79730255|NCT02536495|Other|Pharmacological Study|Correlative studies
79268583|NCT05677958|Dietary Supplement|125 mL Fortimel/Nutridrink Compact Protein|125 mL Fortimel/Nutridrink Compact Protein®* two servings per day (300 kcal, 18 g protein per serving).
79730256|NCT02536495|Drug|Selinexor|Given PO
80024890|NCT03072082|Drug|DanLou Tablet placebo|Conventional western medicine & placebo (for Danlou Tablet)
79268584|NCT02410785|Device|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
79268585|NCT02410785|Other|Placebo|Placebo tablet
79570433|NCT01779726|Radiation|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
79570434|NCT01779739|Procedure|Perineorrhaphy|Procedure to build up the vaginal opening
79570435|NCT01779765|Dietary Supplement|PHGG|
79570436|NCT01779765|Dietary Supplement|Maltodextrin|
79570437|NCT01779791|Drug|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
79268586|NCT02410941|Behavioral|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
79570438|NCT01779804|Procedure|OFAR|OFAR
79570439|NCT01779817|Behavioral|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
79730257|NCT02536417|Drug|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
79730258|NCT02536417|Drug|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
79730259|NCT01140906|Drug|Placebo|capsules, daily, orally
79730260|NCT01140906|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
79730261|NCT01140906|Drug|Duloxetine|encapsulated capsules, daily, orally
79730262|NCT00650065|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
79730263|NCT00650065|Drug|Zyrtec® Tablets 10 mg|10mg, single dose fasting
79730264|NCT02654821|Biological|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
79730265|NCT02654821|Procedure|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
79730266|NCT02654821|Procedure|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
79730267|NCT02882412|Other|observational|
79730268|NCT04170439|Drug|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
79570440|NCT01779830|Drug|LY2624803 - Capsules|Administered orally as capsules.
79864702|NCT00642473|Other|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
79730269|NCT04170439|Drug|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
79730270|NCT04170439|Drug|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
79570441|NCT01779830|Drug|Zolpidem - Tablets|Administered orally as tablets.
79864703|NCT00818129|Drug|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
79864704|NCT00818129|Drug|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
79864705|NCT00645671|Drug|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
79864706|NCT00645671|Drug|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
79864707|NCT00366340|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
79864708|NCT00366340|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
79864709|NCT03992326|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
79864710|NCT03992326|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
79864711|NCT03992326|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
79864712|NCT03992326|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
79570442|NCT01779830|Drug|Placebo - Capsules|Administered orally as capsules.
79570443|NCT01779830|Drug|Placebo - Tablets|Administered orally as tablets.
79864713|NCT03992326|Other|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
79864714|NCT01049386|Other|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
79570444|NCT01779843|Drug|Cytarabine|
79570445|NCT01779843|Drug|Idarubicin|
79864715|NCT01049386|Procedure|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
79864716|NCT01045954|Drug|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
79864717|NCT01046032|Drug|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
79570446|NCT01779843|Drug|Alisertib|
79570447|NCT01779882|Drug|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
79570448|NCT01779882|Drug|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
79570449|NCT01779895|Dietary Supplement|Lactobacillus paracasei probiotic strain|
79570450|NCT01779895|Dietary Supplement|Placebo|maltodextrin
79570451|NCT01779908|Dietary Supplement|Vitamin D|
79570452|NCT01779908|Other|Placebo|
79570453|NCT01779921|Drug|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
79864718|NCT01046032|Drug|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
79864719|NCT01046188|Other|Knowledge Questionnaire|Administered before and after teaching intervention
79864720|NCT01046188|Other|Perceived Stress Scale|Administered before and after teaching intervention
79570454|NCT01779921|Drug|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
79864721|NCT01046188|Other|Satisfaction questionnaire|Administered after the intervention and at study completion
79864722|NCT01046188|Other|Web-based IVF teaching|Web-based IVF teaching
79864723|NCT01046188|Other|Didactic lecture|Didactic lecture
79864724|NCT00061633|Drug|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
79864725|NCT00061633|Drug|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
79864726|NCT00645593|Drug|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
79864727|NCT00645593|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
79570455|NCT01779921|Drug|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
79570456|NCT01779921|Drug|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
79864728|NCT00645593|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
80024891|NCT03072082|Drug|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
80024892|NCT03072082|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
79730271|NCT05188092|Other|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
79730272|NCT02660515|Procedure|Additional wrist arthroscopy|
80024893|NCT03072082|Drug|Atorvastatin calcium|10 mg tablet, two tablets each night.
79730273|NCT02660515|Procedure|ORIF|
79864729|NCT01093261|Drug|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
80024894|NCT03072082|Drug|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
79570457|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
79570458|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
79570459|NCT01779960|Other|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
79730274|NCT02883504|Procedure|Echo-Doppler examination and left heart catheterization|
79730275|NCT02660593|Dietary Supplement|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
79730276|NCT00962091|Drug|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
79864730|NCT01093261|Drug|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
79864731|NCT02550977|Drug|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
80024895|NCT03072082|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
79730277|NCT02660437|Other|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; ~30min).
79864732|NCT03832738|Drug|JTE-451 Tablets|Active drug tablets containing JTE-451
79864733|NCT03832738|Drug|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
79864734|NCT01045018|Drug|Placebo|placebo 400 mg
79864735|NCT01045018|Drug|Mesalamine|
79864736|NCT01045018|Drug|Mesalamine|
79864737|NCT00267904|Other|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
79864738|NCT00267904|Other|Banana|Banana ingestion
79864739|NCT00267904|Other|Olives|Olives ingestion
79864740|NCT00267904|Other|Temp. manip.|Manipulate temperature at skin of the back
79864741|NCT01049464|Drug|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
79864742|NCT01049464|Drug|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
80024896|NCT03072082|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
80024897|NCT03072316|Other|3D surface imaging|3D photography
79864743|NCT01046266|Drug|RO5083945|700mg iv weekly
79864744|NCT01046266|Drug|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
80024898|NCT03072316|Other|semi-structured interview|qualitative analysis using semi structured interview
80024899|NCT03072316|Other|applanation tonometry|measurement of breast compressibility
80024900|NCT03076840|Other|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
80024901|NCT04990960|Other|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
80024902|NCT04996732|Procedure|hospitalization|Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
80024903|NCT04934020|Other|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
80024904|NCT04934020|Other|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
80024905|NCT03074890|Device|Application Protocol|Application lMassive Transfusion Protocol
79864745|NCT00046891|Drug|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
79864746|NCT00046891|Other|Placebo|Patients will take 1 tablet BID
79864747|NCT01045330|Behavioral|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
79864748|NCT00365794|Drug|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
79730278|NCT02536651|Procedure|Ankle surgery|Plastic or orthopedic surgery of the ankle
80024906|NCT04931914|Other|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
79730279|NCT00649363|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
80024907|NCT04987450|Drug|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
80024908|NCT03074656|Other|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
80024909|NCT03074656|Other|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
80024910|NCT03074578|Behavioral|Watching Video-clip 1|Video -clip 1 contains violent images and text
80024911|NCT03074578|Behavioral|Watching Video-clip 2|Video -clip 2 contains neutral images and text
80024912|NCT04996888|Device|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
80024913|NCT03071848|Other|No Intervention|This was an observational study.
80024914|NCT03070210|Procedure|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
79473457|NCT02987426|Behavioral|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
79570460|NCT01779960|Other|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
79570461|NCT01779973|Behavioral|Remote Observed Dosing|
79570462|NCT01779999|Other|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
79570463|NCT01780012|Behavioral|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
80024915|NCT03070210|Procedure|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
80024916|NCT03074422|Procedure|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
80024917|NCT03071614|Other|News items with spin|Interpretation of news items with spin
80024918|NCT03071614|Other|News items without spin|Interpretation of news items without spin
79473458|NCT02974673|Procedure|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
79570464|NCT01780038|Behavioral|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
79570465|NCT01780038|Behavioral|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
79730280|NCT00649363|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
79730281|NCT04285203|Other|Educational Video Intervention|Educational videos
80024919|NCT04991194|Drug|BIA 5-1058|Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours [Day (D)2 to D9] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
80024920|NCT04990648|Device|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
80024921|NCT04920058|Device|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
79570466|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
79730282|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
79730283|NCT02654899|Other|Placebo|Placebo
79730284|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
79730285|NCT02654743|Dietary Supplement|Sulforaphane|Children with ASD will receive Sulforaphane in this study
79730286|NCT04314258|Dietary Supplement|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
79730287|NCT02862795|Procedure|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
79730288|NCT04168723|Drug|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
79730289|NCT04168723|Drug|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
80024922|NCT04920058|Other|<Active Comparator?>|<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (<50g/day) and associated education >
79730290|NCT04168723|Drug|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
79730291|NCT04168723|Drug|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
79864749|NCT03954457|Behavioral|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
79864750|NCT03954457|Behavioral|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
80024923|NCT02853435|Drug|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
80024924|NCT02853435|Drug|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
80024925|NCT02853435|Drug|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
80024926|NCT04996186|Other|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
80024927|NCT03071770|Drug|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
79570467|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
79730292|NCT04168801|Dietary Supplement|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
79730293|NCT00649441|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
79730294|NCT00649441|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
79864751|NCT00383500|Device|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
80024928|NCT04986982|Drug|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI) (L-dopa/DDCI).
79570468|NCT01780064|Behavioral|interviews with a psychologist|interviews with a psychologist
79473459|NCT02974439|Drug|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
79570469|NCT01780064|Behavioral|Questionnaires|Questionnaires
79570470|NCT01780077|Drug|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
79570471|NCT01780077|Drug|Placebo|Multiple intradermal injections of placebo at incision sites
80024929|NCT04986982|Other|Matching placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
79730295|NCT01122576|Device|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
79473460|NCT02974439|Drug|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
79473461|NCT05275712|Other|Audiological evaluation|Questionnaire for parents about their children behavior after implantation, audiological evaluation and speech perception test .
79473462|NCT02974517|Device|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
79473463|NCT05736614|Behavioral|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
79473464|NCT05736614|Behavioral|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
79473465|NCT03340727|Drug|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
80024930|NCT04990570|Other|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship & encounter."
80024931|NCT03606915|Behavioral|pain evaluation|collect CSF during spinal anesthesia
80024932|NCT03074344|Device|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
80024933|NCT03074344|Device|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
80024934|NCT03605511|Diagnostic Test|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
80024935|NCT03069898|Behavioral|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
80024936|NCT02035371|Drug|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
80024937|NCT02035371|Drug|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
79401092|NCT05081661|Other|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
79570472|NCT01780090|Other|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
79570473|NCT01780116|Behavioral|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
79864752|NCT00383500|Device|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
79864753|NCT03954301|Diagnostic Test|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
79864754|NCT01098019|Drug|Xeomin|Patients will receive Xeomin only at Day 0.
79401093|NCT05080244|Dietary Supplement|Probiotics|2 strains 10x10^9 UFC/capsule
79401094|NCT05080244|Dietary Supplement|Placebo|Potato starch and magnesium stearate
79401095|NCT05080218|Drug|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
79401096|NCT05080218|Drug|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
79401097|NCT05080218|Drug|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
79401098|NCT05080218|Drug|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
79401099|NCT05080218|Drug|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
79401100|NCT05080218|Drug|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
79401101|NCT05080218|Drug|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
79401102|NCT05080218|Drug|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
79570474|NCT01780129|Drug|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
79570475|NCT01780181|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
79864755|NCT01098019|Drug|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
80024938|NCT03274947|Device|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
80024939|NCT03274947|Device|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
80024940|NCT04990414|Other|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
79401103|NCT05071911|Procedure|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
79401104|NCT05068843|Procedure|arthroscopic partial meniscectomy|In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
79570476|NCT01780181|Drug|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
79570477|NCT01780207|Device|PFO Closure|
80024941|NCT03069820|Drug|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
79570478|NCT01780233|Drug|Fentanyl 400 µg sublingual spray|
79864756|NCT03956641|Other|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
79864757|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
79864758|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
79864759|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
79864760|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
80024942|NCT03605433|Drug|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
80024943|NCT03071302|Other|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
79268587|NCT05537012|Diagnostic Test|clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.
79864761|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
79864762|NCT01049542|Drug|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
80024944|NCT03606681|Drug|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
80024945|NCT03606681|Drug|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
79401105|NCT05068843|Other|Physical therapy|The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
79401106|NCT05065619|Biological|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
79401107|NCT05065619|Drug|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
79401108|NCT05065619|Biological|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
79401109|NCT05061862|Device|cardiac implantable electronic devices (CIEDs)|Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure
79473466|NCT03340727|Drug|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
79570479|NCT01780233|Drug|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
80024946|NCT03606681|Drug|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
80024947|NCT03071380|Drug|Repatoxaban|1 tablet contains 10 mg rivaroxaban
80024948|NCT03071380|Drug|Xarelto|1 tablet contains 10 mg rivaroxaban
79473467|NCT04612179|Device|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
79473468|NCT04843995|Procedure|Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling
80024949|NCT03070990|Drug|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
79864763|NCT01049620|Drug|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
79864764|NCT00059839|Drug|doxorubicin hydrochloride|Given IV
79570480|NCT01780233|Drug|Fentanyl citrate injection 100 µg intravenously|
79864765|NCT00059839|Drug|mercaptopurine|Given by mouth
79864766|NCT00059839|Drug|methotrexate|Given IV and intrathecally
79864767|NCT00059839|Drug|prednisone|Given by mouth
79730296|NCT01122576|Device|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
79864768|NCT00059839|Drug|vinblastine sulfate|Given IV
79864769|NCT00059839|Drug|vincristine sulfate|Given IV
79864770|NCT00059215|Drug|Prasugrel (CS-747)|Administered orally
80024950|NCT04995718|Other|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
79473471|NCT01707043|Drug|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
79570481|NCT01780233|Drug|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
79570482|NCT01780246|Drug|nusinersen|Administered by intrathecal (IT) injection
79730297|NCT01122576|Device|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
79730298|NCT02660203|Procedure|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
79864771|NCT00059215|Drug|Clopidogrel|Administered orally
79864772|NCT01096147|Device|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
79864773|NCT00058825|Biological|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
79864774|NCT00058825|Drug|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
79864775|NCT00058825|Procedure|Stem Cell Transplant|Day 0: Donor stem cells infused.
79864776|NCT00058825|Radiation|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
79730299|NCT02654665|Behavioral|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
79730300|NCT02654665|Drug|Liraglutide|GLP-1 agonist
79730301|NCT02654509|Biological|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
79730302|NCT04168333|Biological|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
79730303|NCT04168333|Biological|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
79730304|NCT02654431|Procedure|Breast Cancer patient|Samples
79730305|NCT02654431|Procedure|Cancer patients|Samples
79864777|NCT00058825|Drug|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
79864778|NCT00364858|Drug|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
79864779|NCT01098409|Drug|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
79864780|NCT01098409|Drug|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
79864781|NCT03956719|Drug|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
79473472|NCT05736380|Device|Cerebellar rTMS|250 pulses at 10 Hertz over the cerebellum
79473473|NCT05736380|Device|Sham cerebellar rTMS|Sham cerebellar rTMS
79473474|NCT03294499|Other|Questionnaire|Patients will be asked to complete one off questionnaire.
79473475|NCT04350164|Drug|Romiplostim|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
79473476|NCT01708213|Device|Aline HA|Implantable dermal filler
79864782|NCT03956719|Procedure|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
80024951|NCT03605199|Drug|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
80024952|NCT04986436|Drug|HS-10360|Single or multiple dose(s) of HS-10360
80024953|NCT04986436|Drug|Placebo|Single or multiple dose(s) of Placebo
79401110|NCT05058911|Behavioral|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
79730306|NCT04167865|Other|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
79730307|NCT02658643|Procedure|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
79730308|NCT02658643|Procedure|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
79730309|NCT02658721|Drug|Lidocaine|
79401111|NCT05058911|Behavioral|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
79401112|NCT05042102|Combination Product|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
79570483|NCT01780259|Drug|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
79730310|NCT02658721|Drug|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
79730311|NCT02658721|Drug|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
79401113|NCT05042102|Combination Product|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
79570484|NCT01780259|Drug|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
79730312|NCT02658721|Drug|Fentanyl|If the patient had a VAS score of >4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
79730313|NCT02658721|Drug|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR <50/min), 0.5 mg intravenous atropine was administered."
79730314|NCT02658721|Drug|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
80024954|NCT03605121|Procedure|cardiac surgery|The relationship between body mass index or waist circumference and clinical outcome in patients undergoing cardiac surgery will be assessed
79730315|NCT02658721|Drug|Diclofenac sodium|The patients with a VAS score of >4 were administered with 75 mg diclofenac sodium via intramuscular route.
79730316|NCT02658721|Drug|Ephedrine|In the event of hypotension (systolic arterial pressure <90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
79730317|NCT02658721|Drug|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
79730318|NCT00965523|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
79730319|NCT02652013|Other|cognitive evaluation|
79730320|NCT00629967|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
79730321|NCT00629967|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
79730322|NCT04283643|Other|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
79268588|NCT03168633|Behavioral|web-based DM2 information pages|"Each email will include information on one of the following topics:~The importance of physical activity~Correct nutrition~The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies.…"
79730323|NCT04283643|Other|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
79730324|NCT02861703|Behavioral|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
79268589|NCT05536934|Drug|Nω-hydroxy-nor-arginine|
79268590|NCT02400879|Drug|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
79268591|NCT02400879|Drug|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
79730325|NCT02861313|Device|CM LOC attachment|CM LOC attachment
79730326|NCT02861313|Device|ball attachment|Ball attachment
79864783|NCT02535208|Other|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR < 0.73.
79401114|NCT05042102|Combination Product|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
79730327|NCT02654353|Procedure|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
79730328|NCT01122264|Drug|Tadalafil|Administered orally for 24 weeks.
79730329|NCT01122264|Drug|Sildenafil Citrate|Administered orally for 24 weeks.
79730330|NCT04311294|Drug|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
79730331|NCT04311294|Drug|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
79730332|NCT04311294|Drug|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
79730333|NCT04265131|Other|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
79730334|NCT00920218|Biological|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
79730335|NCT00920218|Biological|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
79730336|NCT02861235|Other|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
79864784|NCT02535208|Other|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
79401115|NCT05042102|Combination Product|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
79864785|NCT01093495|Device|CPAP|CPAP
79864786|NCT01093495|Device|Nasal Cannula|Nasal Cannula
79401116|NCT05041101|Drug|Eribulin Mesylate|Given IV
79401117|NCT05041101|Drug|Grapiprant|Given PO
79401118|NCT05039632|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally
79401119|NCT05039632|Radiation|Radiation Therapy|Undergo Abscopal radiation therapy
79401120|NCT05039632|Radiation|Radiation Therapy|Undergo RadScopal radiation therapy
79401121|NCT05029583|Other|routine screening|routine screening for advanced NASH
79401122|NCT05029583|Other|physician-driven screening|physician-driven screening for advanced NASH
79401123|NCT05023551|Drug|DSP-0390|DSP-0390 administered orally
79730337|NCT02861235|Other|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
79730338|NCT02861235|Other|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
79730339|NCT02861235|Other|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
79864787|NCT02535052|Biological|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
79864788|NCT03741205|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
79864789|NCT02534974|Device|NOSTEN|
79864790|NCT03953989|Drug|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
79401124|NCT05023161|Biological|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
79730340|NCT02861235|Other|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
79730341|NCT02861235|Other|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
79730342|NCT00649519|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
79730343|NCT00649519|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
79864791|NCT01096225|Biological|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
79864792|NCT01049698|Behavioral|Resistance Training|3 d/wk resistance training
79864793|NCT01049698|Behavioral|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
79864794|NCT02535130|Device|Positive expiratory pressure|
79864795|NCT02535130|Drug|amikacine nebulization|
79864796|NCT03803059|Device|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
79268592|NCT05034692|Procedure|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
79309053|NCT03201107|Other|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
79570485|NCT01780259|Drug|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
79730344|NCT00629811|Drug|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
79864797|NCT01046500|Dietary Supplement|myo-inositol|2 grams twice a day
79864798|NCT01046500|Drug|Metformin|pill, 250 mg, twice a day
79864799|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
79864800|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
79268593|NCT05034692|Procedure|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
79864801|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
79570486|NCT01780272|Other|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
79570487|NCT01780285|Device|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
79864802|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
79570488|NCT01780285|Device|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
79570489|NCT01780311|Drug|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
79570490|NCT01780311|Procedure|Catheter Ablation|
79570491|NCT01780376|Procedure|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
79730345|NCT00629811|Drug|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
79730346|NCT02654275|Other|Proprioceptive Intervention|
79864803|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
79864804|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
79864805|NCT01098565|Device|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
79864806|NCT03956875|Other|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
79570492|NCT01780402|Behavioral|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
79864807|NCT01098643|Other|computer-assisted intervention|
79864808|NCT01098643|Other|medical chart review|
79864809|NCT01098643|Other|questionnaire administration|
79864810|NCT01098643|Other|survey administration|
79268594|NCT03175107|Device|Exergaming|
79268595|NCT04133480|Drug|GWP42003-P|oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
79268596|NCT02400645|Procedure|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
79570493|NCT01780415|Other|blastocoele aspiration|
79570494|NCT01780467|Behavioral|Role of dopamine|
79864811|NCT01096381|Other|laboratory biomarker analysis|Blood collection
79864812|NCT01096381|Other|questionnaire administration|Survey regarding baseline health and activity level.
79570495|NCT01780480|Drug|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
79570496|NCT01780480|Drug|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
79570497|NCT01780480|Procedure|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
80024955|NCT04995250|Other|corrective exercise training for knee|All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
80024956|NCT03606525|Procedure|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
79268597|NCT02400645|Procedure|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
79864813|NCT00372424|Drug|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
79864814|NCT00372424|Drug|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
79864815|NCT00372424|Drug|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
79401125|NCT05019131|Behavioral|Training|trainings to reduce conscious bias and stress
79570498|NCT01780493|Procedure|The Direct Nipple Ureteroneocystostomy Technique|
79570499|NCT01780519|Drug|lorazepam|single dose of 1 mg lorazepam
79570500|NCT01780532|Procedure|Photoacoustic Imaging (PAI)|Standard of Care
79570501|NCT01780558|Other|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
79730347|NCT02882256|Other|Video discharge instructions|Discharge instructions provided in video form
79730348|NCT02652091|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
79864816|NCT01098721|Drug|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
79864817|NCT03952507|Drug|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
79268598|NCT02400645|Drug|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
79268599|NCT02400645|Drug|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
79730349|NCT02652091|Device|BETACONNECT device|Used to apply Betaseron.
79730350|NCT00625560|Drug|Entecavir|entecavir 1.0 mg QD
79864818|NCT03952507|Drug|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
79268600|NCT02400645|Drug|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
79268601|NCT02165215|Drug|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
79268602|NCT02165215|Drug|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
79268603|NCT02400801|Drug|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
79401126|NCT05019131|Behavioral|Peer support and mentorship|facilitated peer and mentorship opportunities
80024957|NCT03606447|Drug|Uproleselan|[14C]-Uproleselan
79268604|NCT02400801|Drug|ethinylestradiol + dienogest|oral oestroprogestogen
79268605|NCT05677802|Procedure|Biospecimen Collection|Undergo blood sample collection
79268606|NCT05677802|Other|Medical Chart Review|Undergo medical cart review
79268607|NCT05677802|Procedure|Stress Management Therapy|Receive biobehavioral stress reduction intervention
79268608|NCT05677802|Other|Survey Administration|Ancillary studies
79309054|NCT02449967|Procedure|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
79309055|NCT03206255|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
79309056|NCT03206255|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
79309057|NCT03206411|Diagnostic Test|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
79730351|NCT00625560|Drug|Lamivudine|lamivudine 100 mg QD
79730352|NCT02651857|Device|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
79730353|NCT02651857|Device|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
79730354|NCT04167709|Other|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
79864819|NCT02872792|Device|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
79864820|NCT02872792|Other|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
79864821|NCT02530411|Drug|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
79864822|NCT02530411|Drug|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
79864823|NCT00372190|Device|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
79401127|NCT05019131|Behavioral|Leadership engagement|Engaged leadership at the county and facility levels
79401128|NCT05019131|Behavioral|Embedded champions|Facilitate local champions to promote intervention
80024958|NCT03074266|Diagnostic Test|GEM Hemochron 100 ACT|Activated Clotting Time
79268609|NCT05677724|Diagnostic Test|HBV DNA Sequencing|"Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed."
79268610|NCT02400177|Behavioral|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
79268611|NCT03175029|Drug|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
79570502|NCT01780558|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
79570503|NCT01780571|Procedure|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
79570504|NCT01780610|Drug|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
79570505|NCT01780610|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
79570506|NCT01780623|Device|Bright white light|
79570507|NCT01780623|Device|Dim red light|
79570508|NCT01780649|Procedure|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
79570509|NCT01780649|Procedure|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
79570510|NCT01780688|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
79730355|NCT04310982|Device|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
79730356|NCT02651935|Device|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
79864824|NCT00372190|Procedure|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
79864825|NCT01096459|Procedure|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
79864826|NCT01093729|Drug|HM11260C|HM11260C 0.5mcg/kg or Placebo
79864827|NCT01093729|Drug|HM11260C|HM11260C 2mcg/kg or Placebo
79864828|NCT01093729|Drug|HM11260C|HM11260C 4mcg/kg or Placebo
79864829|NCT01093729|Drug|HM11260C|HM11260C 8mcg/kg or Placebo
79864830|NCT01093729|Drug|HM11260C|HM11260C 14mcg/kg or Placebo
79864831|NCT03992794|Diagnostic Test|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
79864832|NCT01327027|Drug|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
79864833|NCT01327027|Drug|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
79864834|NCT01046656|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
80024959|NCT03605043|Other|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
80024960|NCT03606369|Drug|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
80024961|NCT03606369|Drug|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
80024962|NCT03604965|Drug|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
80024963|NCT03604965|Drug|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
79730357|NCT04311138|Other|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
79730358|NCT04311138|Other|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
80024964|NCT02237313|Behavioral|psychological support and therapeutic education program|
79268612|NCT03175029|Drug|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
79268613|NCT02400411|Other|Wheat bread|
79730359|NCT00650455|Drug|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
79268614|NCT02400411|Other|margarine|
79401129|NCT05011825|Behavioral|Pregnant Moms' Empowerment Program|The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
79401130|NCT05005689|Drug|Fluoride mouthwash (0.05%; 225ppm).|Mouthwash
79570511|NCT01780688|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
79570512|NCT01780701|Procedure|Magnetic Resonance Spectroscopy Imaging with rectal probe|
79570513|NCT01780714|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
79570514|NCT01780714|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
79570515|NCT01780740|Drug|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
79730360|NCT00650455|Drug|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
79730361|NCT00650455|Drug|placebo|placebo tablet every morning and capsule every evening for 12 weeks
79730362|NCT02654041|Drug|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
79730363|NCT02651779|Procedure|Open reduction and internal plate fixation|
79730364|NCT02651779|Other|Closed reduction and plasterimmobilisation|
79730365|NCT02658409|Biological|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
79730366|NCT02658409|Biological|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
79730367|NCT02653885|Other|Red red cell distribution width|Results from hemogram
79730368|NCT02653807|Other|mobilization with movement|manual therapy intervention
79730369|NCT02653807|Other|osteopathic mobilization|manual therapy intervention
79730370|NCT01121562|Drug|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
79730371|NCT04169425|Procedure|elective diverting ileostomy|
80024965|NCT02635204|Drug|DFD06 Cream|Twice daily topical application for 14 days.
80024966|NCT02635204|Drug|Vehicle Cream|Twice daily topical application for 14 days.
80024967|NCT03604887|Diagnostic Test|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~1 point will be given for each quadrant where the umbilical cord was observed.~0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
79268615|NCT02400411|Other|ham|
79268616|NCT02400411|Other|soup|
79268617|NCT02400411|Other|rye bread|
79268618|NCT02168569|Drug|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
79268619|NCT02168569|Drug|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
79570516|NCT01780740|Drug|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
79268620|NCT02165293|Drug|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
79570517|NCT01780753|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
79864835|NCT01093807|Drug|Placebo|once daily for 10 weeks
80024968|NCT03069430|Behavioral|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
80024969|NCT03074032|Drug|ONC1-0013B|ONC1-0013B per os daily
80024970|NCT00102804|Drug|Pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression
80024971|NCT00102804|Drug|Placebo|IV administration, q 21 days
80024972|NCT00102804|Other|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
79268621|NCT05536622|Diagnostic Test|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
79268622|NCT02171689|Drug|[14C]- BIBW 2992 MA2|
79401131|NCT05005689|Drug|Tooth Mousse Plus|Tooth Mousse
79401132|NCT05004129|Drug|Tideglusib|All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
79570518|NCT01780779|Other|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
79570519|NCT01780792|Other|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
80024973|NCT04989634|Behavioral|Intensive dietary and weight management|health education , nutritional analysis and individualized dietary guidance
80024974|NCT04989634|Behavioral|Standard care|Standard prenatal education on diet, nutrition and physical activity
80024975|NCT01814072|Behavioral|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
80024976|NCT01814072|Behavioral|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
80024977|NCT01814072|Behavioral|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
80024978|NCT01814072|Behavioral|Text Messages|Participants will receive regular text messages
80024979|NCT01814072|Behavioral|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
80024980|NCT01814072|Behavioral|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
80024981|NCT04986124|Other|treatment as usual|No inervention. Treatment regime remains unchanged.
79268623|NCT05536544|Other|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
79268624|NCT05536544|Other|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
79268625|NCT02396901|Other|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
79401137|NCT04998916|Device|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
79401138|NCT04998916|Device|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
79401139|NCT04998344|Biological|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
79401140|NCT04998344|Biological|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
79730372|NCT02658253|Biological|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
79864836|NCT01093807|Drug|Lercanidipine|10 mg once daily for 10 weeks
79864837|NCT01093807|Drug|Lercanidipine|20 mg once daily for 10 weeks
79864838|NCT01093807|Drug|Enalapril|10 mg once daily for 10 weeks
79864839|NCT01093807|Drug|Enalapril|20 mg once daily for 10 weeks
79864840|NCT01093807|Drug|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
79864841|NCT01093807|Drug|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
80024982|NCT02167152|Other|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
79864842|NCT01093807|Drug|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
79268626|NCT02165371|Behavioral|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
79864843|NCT01093807|Drug|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
79864844|NCT01046812|Drug|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
79268627|NCT02171767|Drug|BIBW 2992 MA2 - single rising dose|
79268628|NCT02400021|Drug|Prometrium|
79570520|NCT01780818|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
79268629|NCT04757246|Other|MouthLab Device|Use of MouthLab system
79268630|NCT02255539|Device|Geelong Prototype Mask|A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
79401141|NCT04997473|Behavioral|W8L2G mobile health (mHealth) app|Weight loss phone app based on addiction principles. This intervention has been validated in two prior studies. Participants will also interact with coaches throughout the intervention
79570521|NCT01780818|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
79730373|NCT02658253|Biological|GLA-SE|2.56 µg of GLA content
79730374|NCT02658253|Biological|Alhydrogel|0.85 mg og Aluminium content
79730375|NCT02658253|Biological|Placebo|0.9% Na cl
79730376|NCT04311060|Diagnostic Test|Molecular panel|"Detection of CBF rearrangements using PCR: CBFB-MYH11 [inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
79730377|NCT02651623|Drug|Sertraline|Multiple doses of sertraline for 14 days
79864845|NCT01046890|Drug|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
79864846|NCT01096615|Dietary Supplement|Placebo|"Description:~- capsule size 3~Composition of the product:~45 mg of microcristalline cellulose,~132 mg of maltodextrin,~3 mg of magnesium stearate.~Composition of the capsule:~46 mg of hypromellose,~1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
79268631|NCT02396667|Other|5D ultrasound|Measure the femur length by 5DLB to calculate fetal weight
79268632|NCT02396589|Behavioral|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
79401142|NCT04996498|Drug|Oxytocin|intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy
79401143|NCT04996498|Other|sterile bacteriostatic water ampule|a placebo drug similar in shape to oxytocin ampules
79730378|NCT02651623|Drug|Moxifloxacin|A single dose of 400 mg Moxifloxacin
79730379|NCT02651623|Drug|Drug - Placebo|Placebo administered for 14 days
79864847|NCT01096615|Dietary Supplement|Lactobacillus paracasei LP-33|"Description:~minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~capsule size 3 1 capsule daily together with a meal, with a glass of water."
79864848|NCT01046968|Dietary Supplement|Lepticore|300 mg twice daily
79401144|NCT04995081|Biological|Biological/Vaccine: Allogeneic HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
79401145|NCT04995081|Other|Placebo|Sterile Saline Solution 0.9%
79401146|NCT04992520|Biological|S. sonnei 53G|Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast
79401147|NCT04992520|Biological|S. flexneri 2a 2457T|Shigella flexneri strain 2457T (Lot 1617) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
79401148|NCT04987372|Drug|Dexmedetomidine|The use of multimodal painkillers pre, per and postoperative
79730380|NCT02651701|Procedure|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
79730381|NCT04167475|Dietary Supplement|Probiotic capsule|Each probiotic capsule contains 1 x 10^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
79730382|NCT04167475|Dietary Supplement|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
79730383|NCT01121484|Drug|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
79730384|NCT01121484|Drug|placebo|Placebo tablets taken orally once daily.
79730385|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release oral tablet
79730386|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release tablet
79730387|NCT01169675|Drug|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
79730388|NCT01169675|Drug|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
79730389|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
79730390|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
79570522|NCT01780818|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
79570523|NCT01780909|Drug|Paromomycin Sulfate Fasted State|
79730391|NCT01169675|Drug|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
79570524|NCT01780909|Drug|Paromomycin Sulfate Fed State|
79730392|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
79730393|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
79730394|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
79730395|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
79730396|NCT01169675|Drug|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
79730397|NCT01169675|Drug|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
79730398|NCT01169675|Drug|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
79730399|NCT00650533|Drug|Glimepiride Tablets 1 mg|1mg, single dose fed
79730400|NCT00650533|Drug|Amaryl® Tablets 1 mg|1mg, single dose fed
80024983|NCT03038113|Drug|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
79268633|NCT02396589|Behavioral|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
79730401|NCT02653729|Behavioral|cognitive behaviour therapy|
79268634|NCT02165449|Drug|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
79268635|NCT02400099|Dietary Supplement|High-protein low calorie diet|
79268636|NCT02400099|Dietary Supplement|Control low calorie diet|
79730402|NCT02653729|Drug|Espidone|
79730403|NCT02653729|Drug|Olepra|
79730404|NCT02653729|Drug|Donu|
79730405|NCT02881866|Drug|Furosemide|
79730406|NCT02881866|Drug|Saline|
79730407|NCT00924664|Biological|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
79730408|NCT00924664|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
79730409|NCT04314869|Procedure|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
79401149|NCT04977375|Drug|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
79730410|NCT05252611|Other|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
79268637|NCT02400099|Other|Anthropometrical measurements|
79268638|NCT02400099|Other|Body composition|
79268639|NCT02400099|Other|8-h metabolic profile|
79401150|NCT04977375|Radiation|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
79401151|NCT04977375|Procedure|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
79570525|NCT01780909|Drug|Paromomycin Sulfate w/ domperidone|
79730411|NCT02653651|Drug|Ketamine|Ketamine infused at 0.1 mg/kg/hour
79730412|NCT02653651|Drug|Lidocaine|Lidocaine infused at 1 mg/kg/hour
79730413|NCT02653651|Drug|Placebo|An equal volume of saline
79730414|NCT02653573|Behavioral|Coaching|Self-management education
79730415|NCT02887469|Drug|3% hypertonic saline|The same as above
79730416|NCT02651233|Other|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
79730417|NCT05376839|Drug|Cedirogant|Capsule, Oral
79730418|NCT02651311|Other|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
79730419|NCT02651311|Drug|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
79730420|NCT02651311|Drug|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
79730421|NCT04168177|Procedure|PCA|Patient controlled analgesia
79730422|NCT04168177|Procedure|ESP|erector spinae plane block
79864849|NCT01047046|Other|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
80024984|NCT03038113|Drug|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
79268640|NCT02400099|Other|Liver biopsy|
79570526|NCT01780909|Drug|Paromomycin Sulfate w/ loperamide HCl|
79570527|NCT01780948|Drug|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
79570528|NCT01780948|Drug|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
79570529|NCT01781000|Behavioral|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
79570530|NCT01781000|Behavioral|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
80024985|NCT03038113|Drug|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
80024986|NCT02160210|Device|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
79570531|NCT01781000|Behavioral|Treatment as usual|standard treatment protocol of schizophrenia ward
79570532|NCT01781013|Other|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
79570533|NCT01781052|Drug|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
79570534|NCT01781065|Device|transcranial direct current stimulation|
79570535|NCT01781091|Device|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
79570536|NCT01781091|Device|Conventionals Modes|
79570537|NCT01779323|Other|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
79730423|NCT02653261|Drug|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
79730424|NCT02653261|Drug|Placebo|An equal volume of saline
79730425|NCT04252378|Procedure|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
79730426|NCT04252378|Procedure|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
79864850|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose
80024987|NCT02163642|Device|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
79730427|NCT02657941|Behavioral|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
79864851|NCT01098877|Drug|PF-04634817|Oral solution, 1mg, single dose
80024988|NCT02163720|Drug|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
79401152|NCT04977024|Biological|COVID-19 Vaccine|Receive SOC mRNA SARS-CoV-2 vaccine IM
79401153|NCT04977024|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
80024989|NCT04995640|Procedure|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
80024990|NCT03487952|Other|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
79268641|NCT05536466|Procedure|bariatric surgery|bariatric surgery
79268642|NCT02168647|Behavioral|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
79730428|NCT02657941|Behavioral|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
79864852|NCT01098877|Drug|PF-04634817|Oral solution, 3mg, single dose
79864853|NCT01098877|Drug|PF-04634817|Oral solution, 10mg, single dose
79570538|NCT01781117|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
79570539|NCT01781117|Device|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
79864854|NCT01098877|Drug|PF-04634817|Oral solution, 30mg, single dose
79570540|NCT01781130|Procedure|Steroid injection|
79730429|NCT02653339|Drug|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
79730430|NCT02653339|Drug|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
79730431|NCT04169503|Drug|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
79730432|NCT00649597|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
79730433|NCT00649597|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
79730434|NCT02653105|Biological|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
79730435|NCT02657785|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
79730436|NCT02653027|Drug|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
79730437|NCT02653027|Other|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
79730438|NCT04168255|Procedure|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
79730439|NCT02650765|Other|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
79730440|NCT02652793|Drug|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
79730441|NCT02652793|Drug|Lamivudine|Lamivudine 300 mg once dailly
79730442|NCT02650687|Procedure|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
79730443|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
79864855|NCT01098877|Drug|PF-04634817|Oral solution, 100mg, single dose
79730444|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
79730445|NCT00600067|Drug|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
79730446|NCT00600067|Drug|Placebo|Oral placebo capsules, once daily, 28 weeks
79730447|NCT02650609|Drug|Methylprednisolone|
79730448|NCT02650609|Drug|Placebo|
79864856|NCT01098877|Drug|PF-04634817|Oral solution, 300mg, single dose
79864857|NCT01098877|Drug|PF-04634817|Oral solution, 600mg, single dose
79864858|NCT01098877|Drug|PF-04634817|Oral solution, 900mg, single dose
79570541|NCT01781221|Device|Alpha-Bio's GRAFT Natural Bovine Bone|
79570542|NCT01781221|Device|Bio-Oss xenograft|
79864859|NCT01098877|Drug|PF-04634817|Oral solution, up to 900mg, single dose after food
79864860|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose after food
79864861|NCT00044083|Other|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
79864862|NCT00044083|Drug|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
79864863|NCT00058123|Drug|poly ICLC|
79864864|NCT00022633|Drug|gemcitabine hydrochloride|
79570543|NCT01781247|Behavioral|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
79570544|NCT01781247|Behavioral|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
79864865|NCT00022633|Drug|paclitaxel|
79864866|NCT00021541|Drug|tipifarnib|Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
79864867|NCT00021541|Other|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
79864868|NCT01100827|Other|EGFR mutation status in patients|
79730449|NCT02652871|Drug|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
79730450|NCT02652871|Drug|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
80024991|NCT02163798|Behavioral|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
80024992|NCT02163798|Behavioral|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
80024993|NCT04461002|Other|Retrospective analysis|Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
79864869|NCT00021229|Drug|imatinib mesylate|"Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
79401154|NCT04977024|Biological|Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1|Given IM
79570545|NCT01781273|Other|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
79730451|NCT02652871|Drug|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
80024994|NCT04985578|Other|Dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
80024995|NCT04985578|Other|Sham dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds with a sham needle without tip.
79730452|NCT00650299|Drug|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
79730453|NCT00650299|Drug|Xanax XR® Tablets 3 mg|3mg, single dose fed
79268643|NCT02168647|Other|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
79730454|NCT00970593|Drug|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
80024996|NCT03487874|Procedure|Conventional interscalene block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
80024997|NCT03487874|Procedure|Interscalene block with C8 root block|Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
80024998|NCT03487874|Drug|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
79268644|NCT02399865|Other|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
79268645|NCT02168725|Drug|briciclib|
79401155|NCT04974671|Radiation|Stereotactic Body Radiation Therapy|1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
79401156|NCT04968548|Procedure|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
79570546|NCT01781273|Other|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
79570547|NCT01781312|Dietary Supplement|ProTectis|
79570548|NCT01781312|Dietary Supplement|Gastrus|
79864870|NCT00021229|Radiation|local irradiation therapy|"Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
79864871|NCT00372112|Drug|GW642444|GW642444H
79864872|NCT00372112|Other|Placebo|Placebo administered twice daily
79864873|NCT02746588|Other|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
79864874|NCT02731144|Other|Peptamen intense|
80024999|NCT03074110|Device|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
80025000|NCT02160366|Other|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
79570549|NCT01781325|Device|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
79730455|NCT00970593|Drug|placebo comparator|Group 1 & 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
79730456|NCT04167553|Drug|HM15136|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
79730457|NCT04167553|Drug|Placebo|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
79730458|NCT02657395|Device|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
79268646|NCT02399787|Other|blastocyst biopsy|Performed on day 5
79730459|NCT04168411|Procedure|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
79730460|NCT02861469|Other|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
79864875|NCT02731144|Other|Novasource senior|
79864876|NCT02688790|Drug|Dalbavancin|
79864877|NCT01047124|Other|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
80025001|NCT04989400|Drug|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
80025002|NCT04989400|Drug|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
79268647|NCT02172001|Drug|Iron isomaltoside 1000|
79570550|NCT01781351|Other|Taping the ankle|
79570551|NCT01781364|Behavioral|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
79268648|NCT02172001|Drug|Natrium Chloride 0,9%|100 ml or 5 ml
79268649|NCT02165527|Procedure|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
79309058|NCT03200873|Device|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
79570552|NCT01781377|Drug|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
79570553|NCT01781377|Drug|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
79570554|NCT01781377|Drug|PLACEBO|SALINE INFUSION
79570555|NCT01781442|Drug|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
79570556|NCT01781494|Procedure|Immobilization followed by protected range of motion|
79570557|NCT01781494|Procedure|Immediate range of motion|
79570558|NCT01781507|Drug|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
80025003|NCT02167230|Procedure|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
80025004|NCT02167230|Procedure|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
80025005|NCT04989088|Device|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
80025006|NCT04989088|Device|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
79268650|NCT05535998|Procedure|TACE-HAIC|The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.
79570559|NCT01781507|Drug|Placebo|This placebo ( sugar pill) will provide the negative control for this study
79570560|NCT01781520|Biological|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
80025007|NCT03485768|Procedure|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
79570561|NCT01781520|Drug|S1|The dose of S-1 is determined according to the body surface area as follows: <1.25 m2, 40 mg; 1.25-<1.5 m2, 50 mg; and >1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
79570562|NCT01781520|Other|Best supportive care|Best supportive care
79730461|NCT04168099|Drug|Cefotaxime|Cefotaxime IV
79730462|NCT04168099|Drug|Gemifloxacin|Gemifloxacin oral
79730463|NCT04283877|Drug|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
79730464|NCT04283877|Drug|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
79730465|NCT02650453|Procedure|Deep venous reconstruction|PTA & stenting with/without endophlebectomy and/or arteriovenous fistula creation
79730466|NCT00962013|Device|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
80025008|NCT03485768|Procedure|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
79309059|NCT03200951|Drug|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
79570563|NCT01781533|Procedure|algorithm|
79570564|NCT01781546|Procedure|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is >20mm or stent malapposition is suspected).
79730467|NCT02650375|Drug|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
79730468|NCT02652715|Other|Laboratory Biomarker Analysis|Correlative studies
79730469|NCT02652715|Other|Quality-of-Life Assessment|Ancillary studies
79730470|NCT02652715|Other|Questionnaire Administration|Ancillary studies
79730471|NCT02652715|Dietary Supplement|Salvia hispanica Seed|Given PO
79730472|NCT04283487|Dietary Supplement|Fructans|500ml 0.9% normal saline containing 40g fructans
79730473|NCT04283487|Dietary Supplement|Glucose|500ml 0.9% normal saline containing 40g glucose
79730474|NCT04283487|Dietary Supplement|Saline|500ml 0.9% normal saline
79730475|NCT02657317|Behavioral|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
79570565|NCT01781546|Procedure|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length >20mm or stent malapposition is suspected).
79570566|NCT01781559|Dietary Supplement|phenolic acid|phenolic acid
79730476|NCT02657317|Other|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
79864878|NCT00488475|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
79730477|NCT04283331|Drug|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
79730478|NCT02657473|Drug|tobramycin inhalation solution|
79730479|NCT02657473|Drug|Saline 0.9% inhalation solution|
79730480|NCT04281459|Other|HIV Treatment Satisfaction Questionnaire status|Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
79864879|NCT01020279|Drug|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
79864880|NCT01020279|Drug|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
79864881|NCT01020357|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
80025009|NCT02163954|Drug|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
79309060|NCT03200951|Drug|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
79730481|NCT02652637|Drug|neomycin, metronidazole, polyethylene glycol (PEG)|
79730482|NCT02861079|Device|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
79730483|NCT02861079|Drug|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
79730484|NCT02652403|Device|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
79730485|NCT02652403|Device|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
79864882|NCT01020357|Drug|placebo|normal saline
79864883|NCT01017627|Other|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
79864884|NCT01017627|Other|No change from normal routine|Normal unit policy for labs and anemia treatment
79864885|NCT00042991|Drug|gefitinib|Given orally
79309061|NCT03206021|Drug|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
79570567|NCT01781585|Procedure|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
79570568|NCT01781598|Device|Total knee arthroplasty (TKA) (Smith &Nephew®)|
79570569|NCT01781624|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
79570570|NCT01781650|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
79570571|NCT01781650|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
79864886|NCT00042991|Radiation|radiation therapy|Undergo standard brain irradiation
79864887|NCT00042991|Other|pharmacological study|Correlative studies
79864888|NCT00042991|Other|laboratory biomarker analysis|Correlative studies
79864889|NCT01022385|Dietary Supplement|24-hour low-residual diet|
79864890|NCT01017783|Behavioral|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
79864891|NCT01017783|Behavioral|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
79864892|NCT01017783|Behavioral|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
79864893|NCT00466167|Drug|Pramipexol Extended Release|
79864894|NCT00466167|Drug|Pramipexol Immediate Release|
79864895|NCT00466167|Drug|Placebo|
79730486|NCT02861157|Behavioral|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
79864896|NCT01017939|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
79864897|NCT01017939|Drug|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
79864898|NCT01017939|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
79864899|NCT01017939|Drug|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
80025010|NCT02163954|Drug|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
80025011|NCT04985656|Drug|Pevonedistat|Pevonedistat IV infusion
79570572|NCT01781650|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
79570573|NCT01781663|Device|KAM2904 Face Cream|
79570574|NCT01781663|Device|KAM3008 Body Lotion|
79570575|NCT01781663|Other|petrolatum-based moisturizer|
79570576|NCT01781702|Drug|Pelubiprofen 30 mg|
79570577|NCT01781702|Drug|Celebrex 200 mg|
79730487|NCT00649675|Drug|Meloxicam Tablets 15 mg|15mg, single dose fed
79730488|NCT00649675|Drug|Mobic® Tablets 15 mg|15mg, single dose fed
79730489|NCT04283565|Other|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2*2 factorial design in order to obtain 4 arms
79730490|NCT04283565|Other|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2*2 factorial design in order to obtain 4 arms
79730491|NCT02652559|Device|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
79730492|NCT02652559|Device|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
79730493|NCT02652559|Device|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
79864900|NCT00480441|Drug|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
79864901|NCT00480441|Behavioral|BRENDA therapy|weekly therapy sessions for 6 weeks
79864902|NCT00480441|Drug|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
80025012|NCT04985656|Drug|Decitabine|Decitabine tablets
79570578|NCT01781715|Device|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
79570579|NCT01781754|Procedure|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
79570580|NCT01781780|Behavioral|General Nutrition Recommendations|
79570581|NCT01781780|Behavioral|Breakfast Recommendation|
79570582|NCT01781780|Behavioral|No Breakfast Recommendation|
79570583|NCT01781793|Other|Room air|Humidified room air (21% oxygen) will be inspired
79570584|NCT01781793|Other|Hyperoxia|60% oxygen will be inspired
79570585|NCT01781819|Procedure|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
79570586|NCT01781845|Procedure|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
79730494|NCT02652559|Other|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
79730495|NCT02652559|Other|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
79730496|NCT02860923|Drug|Exenatide|
79730497|NCT02860923|Drug|Placebo|
79730498|NCT02861001|Device|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
79730499|NCT02861001|Device|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
79730500|NCT04168021|Behavioral|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
79864903|NCT01022463|Drug|Ivabradine|Ivabradine 5 mg BId for 4 weeks
79864904|NCT01022463|Drug|Atenolol|50 mg od for 4 weeks
79864905|NCT00488319|Drug|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
80025013|NCT04985656|Drug|Cedazuridine|Cedazuridine tablets
80025014|NCT02167308|Device|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
80025015|NCT03071224|Drug|[18F] MNI-946|Subjects will undergo PET imaging using [18F]MNI-946, a PET radioligand for imaging tau.
80025016|NCT03071224|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-946.
79730501|NCT04032769|Other|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
80025017|NCT04682990|Device|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
80025018|NCT04682990|Other|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
80025019|NCT04682990|Diagnostic Test|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
80025020|NCT04682990|Other|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
80025021|NCT04682990|Other|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
79268651|NCT05535998|Procedure|TACE|TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.
79570587|NCT01781871|Biological|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
79730502|NCT00970359|Biological|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
79570588|NCT01781871|Biological|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
79864906|NCT01018017|Drug|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
79864907|NCT01018017|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
79570589|NCT01781884|Drug|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
79570590|NCT01781884|Drug|Placebo|
79570591|NCT01781897|Device|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
79570592|NCT01781897|Drug|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
79570593|NCT01781910|Dietary Supplement|Branched Chain Amino Acid drink supplement|
79570594|NCT01781910|Dietary Supplement|Placebo|
79570595|NCT01781923|Behavioral|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
79864908|NCT01018251|Other|3'-deoxy-3'-[18F]fluorothymidine|Given IV
79864909|NCT01018251|Procedure|Positron Emission Tomography/computed tomography|
79864910|NCT01018251|Radiation|FLT-PET/CT|
79570596|NCT01781923|Behavioral|Small group social skills training|Meet once per week for duration of 40 weeks.
79570597|NCT01781936|Drug|Fluocinolone Acetonide|
79570598|NCT01781949|Other|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
79570599|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS <30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
79730503|NCT01121406|Drug|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
79730504|NCT01121406|Drug|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
79730505|NCT01121406|Drug|Topotecan|Patients receive topotecan in 3 or 4 week schedule
79730506|NCT01121406|Drug|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
79730507|NCT01121406|Drug|BI 6727|Patients receive BI 6727 infusion every 3 weeks
79864911|NCT01018329|Procedure|Magnetic Resonance Imaging|
79864912|NCT01018329|Procedure|Diffusion Tensor Imaging|
79864913|NCT01018329|Procedure|Magnetic Resonance Spectroscopic Imaging|
79864914|NCT01018329|Procedure|Dynamic Contract-Enhanced magnetic resonance imaging|
79864915|NCT01018329|Procedure|Diffusion-weighted magnetic resonance imaging|
80025022|NCT04682990|Other|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
80025023|NCT04682990|Other|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
80025024|NCT04682990|Other|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
79730508|NCT02650141|Drug|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
79268652|NCT05535998|Drug|Targeted therapy|The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight <60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
79570600|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
79570601|NCT01781988|Drug|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
79730509|NCT02650141|Drug|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
79730510|NCT02657239|Behavioral|MOVE UP|Weight management behavioral program
79730511|NCT02652325|Drug|Saline|
79864916|NCT00463047|Drug|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
79570602|NCT01782001|Dietary Supplement|vitamin A|vitamin A with placebo
79730512|NCT02652325|Drug|Povidone-Iodine|
79730513|NCT02652325|Drug|5% Povidone-Iodine USP swabs|
79864917|NCT00487695|Device|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
80025025|NCT02164032|Drug|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
79730514|NCT00960687|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
79730515|NCT00960687|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
79730516|NCT00920140|Drug|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
79730517|NCT00920140|Drug|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
79730518|NCT00649753|Procedure|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
79864918|NCT00487695|Device|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
79864919|NCT00487539|Biological|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
79864920|NCT00487539|Biological|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
79268653|NCT05535998|Drug|PD-1 inhibitors|PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
79730519|NCT00649753|Procedure|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
79730520|NCT00649753|Procedure|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
79730521|NCT01120782|Device|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
79730522|NCT01120782|Device|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
79730523|NCT02650297|Other|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
79864921|NCT00487539|Biological|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
79730524|NCT02650297|Device|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
79730525|NCT04203862|Drug|NPC-22|Single administration of low dose NPC-22
79730526|NCT04203862|Drug|NPC-22|Single administration of low/middle dose NPC-22
79730527|NCT04203862|Drug|NPC-22|Single administration of middle dose NPC-22
79730528|NCT04203862|Drug|NPC-22|Single administration of middle/high dose NPC-22
79730529|NCT04203862|Drug|NPC-22|Single administration of high dose NPC-22
79730530|NCT04203862|Drug|NPC-22 Placebo|Single administration of NPC-22 Placebo
79730531|NCT01120626|Drug|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
79730532|NCT01120626|Drug|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
79730533|NCT04252534|Combination Product|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
79730534|NCT04252534|Biological|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
79730535|NCT00650377|Drug|Finasteride Tablets 5 mg|5mg, single dose fed
79570603|NCT01782001|Dietary Supplement|vitamin A and zinc|combination of vitamin A and zinc supplements
79730536|NCT00650377|Drug|Proscar® Tablets 5 mg|5mg, single dose fed
79730537|NCT05115370|Other|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
79730538|NCT02649985|Drug|[F-18]PBR06|PET radiopharmaceutical
79864922|NCT00487539|Biological|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
79864923|NCT00487539|Biological|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
80025026|NCT02164032|Drug|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
79730539|NCT02649985|Drug|[C-11]PBR28|PET radiopharmaceutical
79730540|NCT02650063|Drug|DE-117|
79730541|NCT02649751|Drug|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
79730542|NCT02649751|Drug|Placebo|The placebo treatment is lactose capsule.
79309095|NCT02596971|Drug|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
79570604|NCT01782014|Procedure|colonoscopy|colonoscopy using different methods of insufflation
79730543|NCT04252300|Drug|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
79730544|NCT04252300|Drug|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
79730545|NCT02649595|Other|Red Cross Respite care|See detailed description.
79730546|NCT04256746|Other|Boiled Rice|
79730547|NCT04256746|Other|Boiled Rice+0.37 gr mulberry fruit powdered extract|
79730548|NCT04256746|Other|Boiled Rice+0.75 gr mulberry fruit powdered extract|
79730549|NCT04256746|Other|Boiled Rice+1.12 gr mulberry fruit powdered extract|
79730550|NCT04256746|Other|Boiled Rice+1.50 gr mulberry fruit powdered extract|
79730551|NCT04256746|Other|Rice Porridge|
79730552|NCT04256746|Other|Rice porridge+1.50 gr mulberry fruit powdered extract|
79730553|NCT04167319|Other|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
79730554|NCT04256668|Diagnostic Test|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
79730555|NCT02649517|Procedure|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
79730556|NCT00924508|Device|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
79570605|NCT01782040|Other|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
79570606|NCT01782053|Behavioral|Picture warning|Warning contains picture proposed for each text statement by FDA
79570607|NCT01782053|Behavioral|Control|
79730557|NCT00924508|Drug|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
79864924|NCT01018407|Behavioral|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen & Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
79864925|NCT01018407|Behavioral|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
79864926|NCT00486837|Drug|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
79401157|NCT04952532|Other|Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)|The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
79401158|NCT04947254|Drug|Abiraterone Acetate|Given PO
79570608|NCT01782066|Biological|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
79570609|NCT01782079|Dietary Supplement|L. brevis|
79570610|NCT01782092|Other|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
79570611|NCT01782105|Behavioral|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
79864927|NCT04199247|Behavioral|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
79864928|NCT00486759|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
79570612|NCT01782105|Behavioral|Control group|Evaluation of nutritional and physcial activity habits
79570613|NCT01782118|Dietary Supplement|Lactobacillus GG|
79570614|NCT01782144|Other|NutriSystem portion-controlled pre-packaged meals|
79570615|NCT01782170|Drug|Iocide Oral Rinse|
79570616|NCT01782170|Drug|Placebo|
79570617|NCT01782183|Device|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
79570618|NCT01782196|Device|Enhanced one piece drainable pouch with Type A mouldable adhesive|
79730558|NCT00650923|Drug|ziv-aflibercept|Given IV
79730559|NCT00650923|Procedure|radiation therapy|Undergo RT
79730560|NCT00650923|Drug|temozolomide|Given PO
79730561|NCT00650923|Procedure|pharmacological study|Correlative studies
79304376|NCT04978935|Other|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
79304377|NCT03293303|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
79304378|NCT02711137|Drug|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
79570619|NCT01782196|Device|Enhanced one piece drainable pouch with Type B mouldable adhesive|
79570620|NCT01782235|Drug|Tocilizumab|
79570621|NCT01782235|Drug|Placebo|
79570622|NCT01782248|Other|Questionnary and IRM|
79570623|NCT01782261|Drug|Liraglutide|once daily subcutaneous injection
79730562|NCT00650923|Procedure|laboratory biomarker analysis|Correlative studies
79401159|NCT04947254|Drug|Antiandrogen Therapy|Given ADT
79401160|NCT04947254|Drug|Apalutamide|Given PO
79401161|NCT04947254|Procedure|Biopsy|Undergo biopsy
79401162|NCT04947254|Drug|Niraparib|Given PO
79401163|NCT04947254|Drug|Prednisone|Given PO
79401164|NCT04947254|Radiation|Radiation Therapy|Undergo radiation therapy
79570624|NCT01782261|Drug|Saxagliptin|once daily tablet
79570625|NCT01782274|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
79570626|NCT01782274|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
79730563|NCT04241926|Diagnostic Test|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
79730564|NCT02649205|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
79730565|NCT04256590|Diagnostic Test|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
79730566|NCT00637858|Dietary Supplement|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
79864929|NCT00486759|Drug|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
79864930|NCT00486759|Drug|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
79864931|NCT00486759|Drug|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
79864932|NCT00486603|Drug|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
79864933|NCT00486603|Drug|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
79864934|NCT00486603|Other|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
79304379|NCT02711137|Drug|Gemcitabine|Standard of Care (SOC) agents
79304380|NCT02711137|Drug|Paclitaxel|Standard of Care (SOC) agents
79304381|NCT02711137|Drug|Rucaparib|Standard of Care (SOC) agents
79401165|NCT04942353|Behavioral|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
79401166|NCT04942353|Behavioral|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
79401167|NCT04939701|Drug|ASP0739|Intravenous (IV)
79401168|NCT04939701|Drug|Pembrolizumab|Intravenous (IV)
79401169|NCT04937868|Other|There are no interventions associated with this study|This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
79401170|NCT04925817|Other|Electronic Health Record Review|Medical record reviewed
79401171|NCT04925817|Procedure|Ultrasound Microvessel Imaging|Undergo 3D ultrasound microvessel imaging
79570627|NCT01782287|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
79570628|NCT01782287|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
79570629|NCT01782300|Biological|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
79864935|NCT00486603|Radiation|Radiation|Radiation during the first six weeks of treatment Monday-Friday
79304382|NCT02711137|Drug|Abiraterone|Standard of Care (SOC) agents
79304383|NCT02711137|Drug|Ruxolitinib|Standard of Care (SOC) agents
79304384|NCT02711137|Drug|Azacitidine|Standard of Care (SOC) agents
79304385|NCT03288623|Dietary Supplement|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
79304386|NCT03288623|Dietary Supplement|White/Milk chocolate (<35% cocoa)|white or milk chocolate (<35% cocoa) in tablet
79304387|NCT04970979|Other|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
79304388|NCT04970823|Device|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
79570630|NCT01782300|Biological|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
79864936|NCT00486291|Drug|VI-0521|phentermine 15mg/topiramate 100mg
79864937|NCT00486291|Drug|Placebo|matched placebo
79864938|NCT00474045|Drug|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
79864939|NCT00474045|Drug|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
79864940|NCT00474045|Drug|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
79864941|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
79864942|NCT01020825|Drug|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
79864943|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
79864944|NCT01018485|Drug|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
79401172|NCT04917055|Drug|ropivacaine 0.25% with epinephrine and 6mg dexamethasone|Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
80025027|NCT02164032|Other|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
80025028|NCT04985734|Diagnostic Test|Specific diagnostic work-up for ATTR-CM patients|Technetium-scintigraphy
80025029|NCT04682288|Drug|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
80025030|NCT00968149|Drug|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
79268654|NCT02255695|Other|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
79401173|NCT04917055|Drug|Saline|Injection of Saline behind knee using ultrasound guidance
79864945|NCT00462501|Biological|bevacizumab|
79401174|NCT04917042|Drug|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
79401175|NCT04911907|Drug|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
79401176|NCT04909801|Drug|Abatacept|Abatacept SC (125 mg) once weekly
79730567|NCT00637858|Dietary Supplement|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
79864946|NCT00462501|Drug|fluorouracil|
79864947|NCT00462501|Drug|leucovorin calcium|
79864948|NCT00462501|Drug|oxaliplatin|
80025031|NCT00968149|Drug|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
79401177|NCT04909801|Drug|Adalimumab|Adalimumab SC (40 mg) once every 2 weeks
79401178|NCT04909801|Drug|Methotrexate|Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
79570631|NCT01782339|Drug|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
79401179|NCT04889144|Other|Communication Intervention|Participate in PLAN intervention
79401180|NCT04889144|Other|Best Practice|Receive usual care
79401181|NCT04889144|Other|Questionnaire Administration|Ancillary studies
79570632|NCT01782365|Device|SHAM stimulation|no stimulation
79570633|NCT01782365|Device|0,75 Hz stimulation|
79570634|NCT01782391|Device|Stimulation|
79864949|NCT00462501|Procedure|conventional surgery|
79401182|NCT04878276|Device|Dimet 5|The application is carried out according to the enclosed instructions for use.
79401183|NCT04877821|Drug|Sintilimab|200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
79401184|NCT04877821|Drug|Anlotinib|12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
79730568|NCT00637858|Dietary Supplement|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
79730569|NCT00637858|Dietary Supplement|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
79730570|NCT00637858|Other|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
79730571|NCT04167241|Diagnostic Test|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
79730572|NCT02649127|Behavioral|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
79864950|NCT00462501|Radiation|radiation therapy|
79864951|NCT03996603|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
80025032|NCT02160444|Behavioral|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
80025033|NCT02160522|Device|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
80025034|NCT02167386|Behavioral|Enhanced PrEP Adherence|
80025035|NCT02167386|Behavioral|Standard PrEP Adherence|
80025036|NCT03989882|Other|Wheat germ energy ball|wheat germ mixed other ingredients to make an energy ball
80025037|NCT03989882|Other|Control|corresponding control without wheat germ
79268655|NCT03540199|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
79268656|NCT03540199|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
79730573|NCT02649127|Behavioral|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity [i. e., >60% of oxygen uptake reserve (VO2R)], and a time of 20-25 minutes each bout of training
79401185|NCT04877821|Drug|Nab paclitaxel|100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
79401186|NCT04877821|Drug|Carboplatin|AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
79730574|NCT02649127|Behavioral|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
79730575|NCT04251598|Behavioral|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
79864952|NCT01018641|Biological|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
79864953|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
79570635|NCT01782391|Device|SHAM|no stimulation
79864954|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
79864955|NCT01018641|Biological|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
79570636|NCT01782404|Device|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
79570637|NCT01782417|Behavioral|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
79570638|NCT01782430|Procedure|- standard oxygenation|
79730576|NCT04251598|Behavioral|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
79730577|NCT02657161|Biological|RABIPUR®|Biological rabies vaccine
79864956|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
79864957|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
79268657|NCT04313582|Behavioral|SmartPrompt smartphone application|The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
79864958|NCT01018641|Biological|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
79864959|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
79864960|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
79268658|NCT03540043|Drug|Administration of Placebo|Botanical Drug Phase 2 clinical study
79268659|NCT03540043|Drug|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
79268660|NCT03540043|Drug|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
79268661|NCT03540043|Drug|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
79268662|NCT02172079|Other|Real mobilization-with-movement (MWM)|
79268663|NCT02172079|Other|Sham mobilization-with-movement (MWM)|
79268664|NCT02261233|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
79268665|NCT02261311|Other|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
79268666|NCT05694962|Radiation|Low-Dose Radiation Therapy|1.5Gy single treatment of whole-lung radiation therapy
79401187|NCT04877821|Drug|Epirubicin|90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
79401188|NCT04877821|Drug|Cyclophosphamide|600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
79401189|NCT04877288|Biological|Belatacept|Specified dose on specified days
79401190|NCT04877288|Drug|Tacrolimus|Specified dose on specified days
79401191|NCT04877288|Drug|Cyclosporine A|Specified dose on specified days
79401192|NCT04877288|Drug|Mycophenolate Mofetil|Specified dose on specified days
79401193|NCT04877288|Drug|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
79401194|NCT04877288|Drug|Corticosteroids|Specified dose on Specified days
79570639|NCT01782456|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
79570640|NCT01782508|Drug|imatinib|a selectively inhibits the KIT protein tyrosine
79730578|NCT02657161|Biological|PIKA rabies vaccine|Biological rabies vaccine
79730579|NCT02657161|Biological|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
79730580|NCT01139580|Drug|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
79730581|NCT01139580|Drug|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
79730582|NCT02657083|Device|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
79268667|NCT02165917|Procedure|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
79268668|NCT02165917|Procedure|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
79570641|NCT01782508|Drug|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
79864961|NCT01018641|Biological|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
79864962|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
79570642|NCT01782521|Procedure|No primer|Primer not used when bonding orthodontic brackets
79268669|NCT05696756|Behavioral|Personalized Web-based training for EMMA app|Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
79268670|NCT05696756|Behavioral|Motivational Interviewing: Clinician Support|Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
79730583|NCT02657083|Device|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
79730584|NCT04686760|Drug|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
79730585|NCT04312698|Drug|D013, D326, D337|Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
79864963|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
79864964|NCT01018641|Procedure|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
79864965|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
79864966|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
79268671|NCT03539107|Procedure|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
79401195|NCT04873037|Device|BTL Emsella Chair|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
79570643|NCT01782547|Behavioral|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
79730586|NCT04312698|Drug|placebo of D013, D326, D337|Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
79730587|NCT04312698|Drug|D013, placebo of D326, placebo of D337|Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
79730588|NCT04251832|Drug|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
79268672|NCT03539107|Other|spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
79570644|NCT01782547|Other|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
79570645|NCT01782560|Drug|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
79570646|NCT01782560|Drug|Placebo|
79730589|NCT04312464|Other|non|no intervention
79730590|NCT02656927|Behavioral|Yoga Condition|
79864967|NCT01018719|Device|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
80025038|NCT02164110|Biological|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
79401196|NCT04873037|Device|Sham BTL Emsella Chair|The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
79570647|NCT01782573|Drug|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
79570648|NCT01782573|Drug|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
79730591|NCT04251988|Device|Oculus Go VR|virtual reality headset
79730592|NCT04312776|Other|none intervention|
79730593|NCT02656849|Drug|BAY 1000394|
79730594|NCT04313010|Other|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
79730595|NCT04313010|Other|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
79864968|NCT00383188|Drug|placebo|Capsule, once daily (QD) for 12 weeks
79864969|NCT00383188|Drug|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
79864970|NCT00383188|Drug|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
79864971|NCT00383188|Drug|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
79864972|NCT00383188|Drug|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
79864973|NCT01021059|Biological|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
79864974|NCT00462345|Drug|rituximab|1000 mg i.v. on Days 1 and 15
79864975|NCT00462345|Drug|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
79864976|NCT00462345|Drug|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
79864977|NCT00462345|Dietary Supplement|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
79864978|NCT01025115|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
79864979|NCT01025115|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
79864980|NCT01022541|Drug|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
79864981|NCT01022541|Drug|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
79730596|NCT05252260|Procedure|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
79730597|NCT05252260|Procedure|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
79864982|NCT01022541|Drug|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
80025039|NCT02164110|Biological|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
80025040|NCT03489512|Drug|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
80025041|NCT03489512|Drug|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
79268673|NCT02168881|Drug|Misoprostol|
79401197|NCT04861896|Behavioral|"My Guide (psychoeducation & self-management program)"|12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
79401198|NCT04860986|Device|EarliPoint|EarliPoint is a non-invasive diagnostic device for ASD
79401199|NCT04858529|Drug|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
79864983|NCT01022541|Procedure|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
79864984|NCT01045408|Dietary Supplement|Berry extract|Berry extract for weeks
80025042|NCT02167464|Drug|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
80025043|NCT02167464|Other|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
79401200|NCT04858529|Drug|investigator-selected taxane/trastuzumab/pertuzumab (THP)|investigator-selected taxane/trastuzumab/pertuzumab (THP)
79864985|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
79401201|NCT04857606|Drug|AMG 609|Single dose of AMG 609 administered as a subcutaneous injection.
79401202|NCT04857606|Drug|Placebo|Single dose of placebo administered as a subcutaneous injection.
79401203|NCT04855136|Biological|BB2121|CAR T Cell Therapy
79570649|NCT01782612|Procedure|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
79730598|NCT05252260|Other|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
79864986|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
79864987|NCT01047202|Biological|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
79864988|NCT01047280|Dietary Supplement|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
79864989|NCT01047280|Dietary Supplement|Safflower oil|3.5 g/d of safflower oil
79864990|NCT01047280|Dietary Supplement|G-c9, t11|3.5 g/day of c9, t11 CLA
79864991|NCT02672956|Procedure|Ten mm trocar|
79864992|NCT01047514|Behavioral|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
79864993|NCT01047592|Drug|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
79864994|NCT01047592|Drug|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
79570650|NCT01782612|Procedure|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
79570651|NCT01782625|Other|NO exercise at depth|Subjects will NOT exercise while at depth
79570652|NCT01782625|Other|exercise at depth|Subjects will exercise while at depth
79570653|NCT01782651|Drug|Lapatinib plus capecitabine|Lapatinib plus capecitabine
79864995|NCT01047592|Drug|placebo|placebo,oral, for 12 weeks
80025044|NCT02167464|Drug|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
80025045|NCT03485612|Diagnostic Test|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
80025046|NCT05200351|Behavioral|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
80025047|NCT02164188|Behavioral|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
79268674|NCT02168881|Drug|Dinoprostone|
79401204|NCT04855136|Drug|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
79401205|NCT04855136|Drug|BMS-986405|gamma secretase inhibitor (GSI)
79570654|NCT01782677|Procedure|Bilateral Surgical Resection of Carotid Bodies|
79401206|NCT04852783|Device|Contour Neurovascular System|Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
79401207|NCT04823884|Procedure|open distal chevron osteotomy|Through a 4-cm-long dorsomedial skin incision the V-shaped osteotomy with the apex 1-2 mm superior to the center of the metatarsal head is performed. The angle of the chevron is 60° to 90°. The direction of the osteotomy is angled toward the center of the third metatarsal head. After shifting the metatarsal head laterally, fixation is achieved by usage of one cannulated screw (3.0 mm or 2.5mm). Prominent bone ridges are resected with a saw. A distal soft tissue procedure is performed in every case through the same skin incision. The adductor hallucis tendon is detached from its insertion at the phalangeal bone and from the lateral border of the fibular sesamoid. The transverse intermetatarsal ligament is released and a T-shaped capsulotomy is performed to allow reposition of the sesamoids. Sesamoid position is controlled by sight. After closing of the medial capsula skin is closed with nylon sutures.
79570655|NCT01782755|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
79570656|NCT01782755|Other|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
79730599|NCT02536729|Drug|Oral Sodium Phosphate - Normal preparation|
79730600|NCT02536729|Drug|Oral sodium phosphate - Modified Preparation|
79730601|NCT02536729|Drug|polyethylene glycol + Electrolytes|
79730602|NCT02656771|Device|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
79268675|NCT02165995|Procedure|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
80025048|NCT03485456|Drug|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
79730603|NCT02883582|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
79730604|NCT02883582|Device|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
79570657|NCT01782768|Device|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
79570658|NCT01782781|Drug|ropivacaine, ketorelac and epinephrine|Active group
79570659|NCT01782781|Drug|Placebo|Placebo group
79864996|NCT01049854|Drug|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
79864997|NCT01049854|Drug|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
79864998|NCT01049854|Drug|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
79864999|NCT01049854|Drug|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
79268676|NCT02165995|Procedure|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
79570660|NCT01782794|Other|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
79570661|NCT01782807|Procedure|Salpingectomy or Fimbriectomy|
79268677|NCT02168959|Drug|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
79268678|NCT02169037|Procedure|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
79730605|NCT02656537|Device|EnSite™ HD Grid Catheter mapping system|
79730606|NCT00917644|Drug|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
79730607|NCT00917644|Genetic|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
79268679|NCT02169037|Procedure|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
79570662|NCT01782846|Drug|Ixprim®|
79570663|NCT01782846|Drug|Dafalgan-Codeine®|
79570664|NCT01782911|Dietary Supplement|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
79570665|NCT01782911|Dietary Supplement|Placebo pills|The patients will take placebo for 40 days.
79570666|NCT01782924|Drug|KHK4827|
79730608|NCT02649283|Device|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
79570667|NCT01782937|Drug|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
79570668|NCT01782950|Drug|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
79570669|NCT01782976|Drug|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
79570670|NCT01782976|Drug|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
79730609|NCT02649283|Procedure|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
79730610|NCT01137786|Drug|Non ionic contrast media comparator|One time administration for PCI
79730611|NCT01137786|Drug|Non ionic contrast media comparator|one time administration for PCI
79730612|NCT00631774|Dietary Supplement|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
79865000|NCT01045486|Drug|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
79865001|NCT01045486|Drug|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
79865002|NCT01045564|Biological|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
80025049|NCT03487562|Drug|DWP14012 Amg|DWP14012 Amg
79865003|NCT00453999|Drug|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
79865004|NCT00453999|Drug|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
80025050|NCT03487562|Drug|DWP14012 Bmg|DWP14012 Bmg
80025051|NCT03487562|Drug|Clarithromycin|Clarithromycin 500 mg
79268680|NCT05450822|Drug|Levetiracetam|"Healthy subjects and patients in Cohort III will undergo a 120 min. [11C]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. [11C]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models."
79570671|NCT01782976|Behavioral|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
79570672|NCT01783002|Radiation|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
79570673|NCT01783002|Radiation|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
79730613|NCT05367258|Other|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
79730614|NCT05252104|Diagnostic Test|CORE-TOS diagnostic tool|Collection of clinical findings from clinical examination, subdivided into 5 sub-categories. Positivity in 4 or 5 of these subcategories is considered diagnostic for thoracic outlet syndrome (TOS).
79865005|NCT00453999|Drug|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
79865006|NCT00453921|Drug|Methylphenidate|Dosage dependent on weight
79865007|NCT00453921|Behavioral|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
79865008|NCT00453921|Other|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
79865009|NCT03995745|Behavioral|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
79865010|NCT00382720|Drug|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
79865011|NCT00382720|Drug|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
79865012|NCT00382720|Drug|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
79865013|NCT01025349|Drug|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
80025052|NCT03487562|Drug|Amoxicillin|Amoxicillin 1 g
80025053|NCT03487562|Drug|Lansoprazole|Lansoprazole 30 mg
80025054|NCT02160600|Other|Standard multiphase CT|
80025055|NCT02160600|Other|split bolus Dual energy CT|
79865014|NCT01022697|Other|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
80025056|NCT03541434|Diagnostic Test|Complete Blood Count|White blood cell subgroups count
80025057|NCT03541434|Diagnostic Test|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
80025058|NCT03541434|Procedure|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
80025059|NCT05150522|Biological|BCMA CAR-T cells|BCMA CAR-T cells infusion
79865015|NCT01021371|Behavioral|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
79730615|NCT00625170|Drug|olanzapine|olanzapine 10 mg/day for 8 days
79730616|NCT00625170|Drug|Haloperidol|haloperidol 3 mg/day for 8 days
79730617|NCT00599755|Radiation|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
79268681|NCT05450822|Drug|Levetiracetam Tablets|Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
79268682|NCT05450822|Drug|Lamotrigine tablet|Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
79268683|NCT03539029|Procedure|Surgery|Surgical fracture fixation
79401208|NCT04823884|Procedure|minimally invasive distal chevron osteotomy|The osteotomy is performed percutaneously through a dorsomedial incision of 3-5 mm. An electric motor-driven machine used for the osteotomy. To prevent overheating the reamer is frequently rinsed with sterile saline. The medial eminence is excised and the V-shaped osteotomy is performed. The apex of the osteotomy is identified by fluoroscopy and centered 1-2 mm superior to the center of the metatarsal head. The angle of the osteotomy amounts to 60-90 degrees as well. Bone debris is washed out with sterile saline. A lateral soft-tissue release is undertaken through a separate lateral incision of 3-5 mm. The distal fragment is shifted laterally and fixed with a canulated screw of 3.5mm. Residual bone ridges are reamed. Position of the metatarsal head and the K-wire is controlled by fluoroscopy. The skin is closed with a nylon sutures.
79570674|NCT01783002|Radiation|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
79730618|NCT00599755|Drug|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
79730619|NCT04251364|Drug|Acetazolamide|Daily acetazolamide pill intake
79730620|NCT04251364|Drug|Atorvastatin|Daily atorvastatin pill intake
79730621|NCT04251364|Drug|Placebo oral tablet|Daily placebo pill intake
79730622|NCT00637260|Device|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
79730623|NCT00637260|Device|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
79730624|NCT02648425|Drug|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
79730625|NCT02648425|Drug|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
79730626|NCT02648425|Drug|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
79865016|NCT01022775|Procedure|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
79268684|NCT03539029|Procedure|Conservative treatment|immobilisation with plaster cast
79268685|NCT02172157|Drug|BI 1744 CL i.v.|
79268686|NCT02172157|Drug|BI 1744 CL oral|
79730627|NCT00637338|Biological|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
79865017|NCT01022775|Procedure|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
79730628|NCT00637338|Biological|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
79730629|NCT00625482|Biological|OPV|
79730630|NCT00625482|Biological|OPV plus BCG|
79730631|NCT00625482|Biological|OPV|
79730632|NCT00625482|Biological|OPV plus BCG|
79730633|NCT02648503|Drug|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
79730634|NCT02648503|Drug|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
79268687|NCT02166151|Drug|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
79268688|NCT02172235|Drug|Pioglitazone|
79268689|NCT02172235|Drug|Pioglitazone - low dose|
79268690|NCT02172235|Drug|BI 10773 - low dose|
79268691|NCT02172235|Drug|BI 10773 - medium dose|
79268692|NCT02172235|Drug|BI 10773 - high dose|
79401209|NCT04821830|Drug|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
79268693|NCT03725371|Other|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
79570675|NCT01783028|Behavioral|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
79570676|NCT01783067|Other|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
79268694|NCT05689346|Device|high tone power therapy|high tone power therapy
79268695|NCT05689346|Other|traditional physical therapy exercises|traditional physical therapy exercises for improving balance
79268696|NCT02169193|Radiation|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
79570677|NCT01783067|Other|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
79570678|NCT01783093|Other|Data Collection|Collection of data from existing medical records
79268697|NCT02166229|Drug|Divalproex sodium|
79570679|NCT01783106|Drug|Ciprofloxacin|experimental
79730635|NCT04787614|Other|No intervention|No intervention
79865018|NCT00453063|Drug|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
79865019|NCT00453063|Drug|Placebo|Two sprays in each nostril once daily in the morning
79268698|NCT04474964|Radiation|Low dose Craniospinal Irradiation plus Focal Radiotherapy|The intervention arm of the study is to prospectively evaluate disease-related outcomes of low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy in WNT-pathway medulloblastoma.
79570680|NCT01783106|Drug|Doxycycline|experimental
79268699|NCT04410926|Other|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
79268700|NCT04410926|Other|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
79268701|NCT04375514|Drug|ARO-ENaC|single or multiple doses of ARO-ENaC by inhalation of nebulized solution
79570681|NCT01783106|Drug|Hydroxychloroquine|oral
79570682|NCT01783106|Drug|Budesonide|active comparator
79570683|NCT01783119|Dietary Supplement|Aloe Barbadensis Miller|
79570684|NCT01783119|Dietary Supplement|placebo water|
79570685|NCT01783132|Device|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
79570686|NCT01783158|Procedure|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
79570687|NCT01783171|Drug|Akt Inhibitor MK2206|Given PO
79570688|NCT01783171|Drug|Dinaciclib|Given IV
79570689|NCT01783171|Other|Laboratory Biomarker Analysis|Correlative studies
79570690|NCT01783171|Other|Pharmacological Study|Correlative studies
79730636|NCT04250896|Other|Control group|Standard child care in health unit plus exposure to EsIAN
79730637|NCT04250896|Behavioral|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
79730638|NCT05253508|Drug|Lidocaine 2% Injectable Solution|A digital nerve block by injections to the base of the finger
79865020|NCT00371566|Drug|Lapatinib oral tablets|
79730639|NCT04524130|Drug|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
79865021|NCT00371566|Drug|Placebo|
79865022|NCT00382408|Biological|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
79865023|NCT00382408|Other|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
79865024|NCT00371254|Drug|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg <6 months)
79865025|NCT00371254|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg <6 months)
80025060|NCT02167542|Device|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
79401210|NCT04802187|Other|RADx CHCs testing intervention strategy|The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
79268702|NCT04375514|Drug|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
79401211|NCT04802187|Other|Usual care control|CHCs implement testing strategies in accordance with their usual supports.
79570691|NCT01783210|Behavioral|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
79865026|NCT00452673|Drug|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
80025061|NCT02167542|Device|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2>92%."
79268703|NCT05677178|Other|observational|This study is an observational study without any intervention.
79268704|NCT05677022|Other|Adapted motor activity|15-month adapted motor activity program based on a postural and functional analysis
79268705|NCT05696600|Procedure|Scaling and root planing and open flap debridement|"Scaling and root planing involves removal of plaque and calculus.~Open Flap debridement involves reflection of full thickness mucoperiosteal flap, thorough debridement of the surgical site and approximation and suturing of the flap at the original position."
79268706|NCT05696522|Radiation|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
79268707|NCT02757625|Drug|Dexmedetomidine hydrochloride|"45 weeks CGA to < 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~6 years old to < 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
79268708|NCT04231058|Device|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
79268709|NCT04112186|Behavioral|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
79401212|NCT04795648|Device|Transfluthrin|Passive emanator with formulated transfluthrin
79401213|NCT04795648|Device|Placebo|Passive emanator with formulated inert ingredients
79401214|NCT04793035|Device|Omega-Cuff|An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
79570692|NCT01783210|Behavioral|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
79570693|NCT01783249|Other|Stationary Exercise cycling|Stationary exercise cycling
79865027|NCT00452673|Drug|Capecitabine|Tablets, Oral, 660 - 1250 mg/m^2 twice a day (BID). Treatment may continue until disease progression.
79865028|NCT00461253|Device|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
79865029|NCT00461253|Device|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
79865030|NCT00469833|Drug|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
79865031|NCT00382174|Drug|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
79865032|NCT00382174|Drug|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
80025062|NCT02167620|Drug|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
80025063|NCT02167620|Drug|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
80025064|NCT03485300|Diagnostic Test|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
79268710|NCT04112186|Behavioral|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
79570694|NCT01783262|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
79570695|NCT01783262|Device|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
79570696|NCT01783275|Behavioral|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
79570697|NCT01783301|Drug|FSH|
79570698|NCT01783314|Procedure|MRI of liver|MRI of liver with intravenous gadoxetate disodium
79570699|NCT01783327|Behavioral|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
79570700|NCT01783327|Behavioral|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
79570701|NCT01783340|Drug|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
79730640|NCT04524130|Drug|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
79730641|NCT04524130|Drug|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
79865033|NCT00641537|Drug|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
79865034|NCT00641537|Drug|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
79865035|NCT00641537|Drug|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
79865036|NCT00641537|Drug|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
80025065|NCT03485300|Behavioral|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
79268711|NCT02169349|Other|laboratory biomarker analysis|
79268712|NCT02169349|Other|Next Generation Sequencing|
79268713|NCT02169349|Genetic|DNA Analysis|
79268714|NCT05693324|Behavioral|Minority stress|Intervention based on Cognitive Behavioural and Compassion Focused Treatments
79268715|NCT02256007|Other|Paper and Pencil Assessments|Videogame Assessments
79401215|NCT04787848|Drug|Relistor Injectable Product|Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
79401216|NCT04787731|Drug|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
79401217|NCT04787523|Radiation|Radiotherapy|Patients have received neoadjuvant radiotherapy
79570702|NCT01783340|Drug|Placebo|Placebo capsules will be administered at each immunization
79570703|NCT01783340|Biological|Immunization with falciparum|three inoculations with 5 infected mosquito bites
79570704|NCT01783353|Dietary Supplement|Zinc gluconate|
79570705|NCT01783353|Dietary Supplement|Corn starch pill|
79570706|NCT01783366|Device|TUBE EXCHANGER|
79730642|NCT00600613|Radiation|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
79730643|NCT00649831|Drug|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
79730644|NCT00649831|Drug|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
79730645|NCT05251870|Drug|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
79268716|NCT05692232|Other|Pressure biofeedback guided DCFM strength training|A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.
79401218|NCT04783168|Other|Best Practice|Receive usual care
79268717|NCT05692232|Other|Manual therapy|A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
79570707|NCT01783379|Drug|micafungin|100mg/day infusion in 1 hour
79268718|NCT05692232|Other|Conventional intervention|A hot pads was applied for 20minutes underneath the cervical spine covering either side of shoulder in a relaxed supine position.
79570708|NCT01783392|Procedure|Transcutaneous Electrical Nerve Stimulation|
79570709|NCT01783431|Drug|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
79570710|NCT01783431|Procedure|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
79570711|NCT01783457|Other|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
79570712|NCT01783457|Other|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
79570713|NCT01783587|Drug|Afatinib|Taken orally once per day
79268719|NCT02166541|Procedure|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
79570714|NCT01783587|Drug|Docetaxel|15 mg/m2, given intravenously once per week
79730646|NCT05117944|Other|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
79268720|NCT02166541|Procedure|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
79268721|NCT02166541|Procedure|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
79268722|NCT05691920|Procedure|Pectointercostal plane block and external oblique intercostal plane block|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
79268723|NCT05691920|Procedure|Fentanyl infusion|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
79268724|NCT02172313|Drug|semaglutide|For oral administration.
79570715|NCT01783587|Radiation|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
79401219|NCT04783168|Other|Health Promotion and Education|Install and use Fitbit app
79401220|NCT04783168|Other|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
79570716|NCT01783600|Device|NanoCross .014 balloon catheter|
79401221|NCT04783168|Other|Quality-of-Life Assessment|Ancillary studies
79570717|NCT01783613|Dietary Supplement|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
79570718|NCT01783613|Dietary Supplement|Placebo: 50 mg/kg/day during 12 months|
79730647|NCT02648659|Drug|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
79730648|NCT02648659|Drug|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
79730649|NCT02648659|Drug|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
79570719|NCT01783626|Device|Evodial|
79570720|NCT01783626|Device|Evodial+ Condition B1|
79570721|NCT01783626|Device|Evodial+ Condition B2|
79570722|NCT01783626|Device|Evodial+ Condition C|
79401222|NCT04783168|Other|Questionnaire Administration|Ancillary studies
79401223|NCT04774926|Drug|Brolucizumab|120 mg/ml solution for intravitreal injection
79401224|NCT04767347|Other|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
79401225|NCT04767347|Other|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
79570723|NCT01783665|Other|aerobic exercise|
79570724|NCT01783665|Other|home exercise program|
79570725|NCT01783691|Drug|NKTT120|
79570726|NCT01783717|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
79570727|NCT01783756|Drug|lapatinib ditosylate|Given PO
79570728|NCT01783756|Drug|everolimus|Given PO
79570729|NCT01783756|Drug|capecitabine|Given PO
79570730|NCT01783756|Other|laboratory biomarker analysis|Correlative studies
79570731|NCT01783769|Behavioral|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
79570732|NCT01783782|Behavioral|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
79570733|NCT01783782|Drug|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
79570734|NCT01783782|Drug|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
79865037|NCT00641537|Drug|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
79570735|NCT01783795|Other|Genetic Analysis|
79570736|NCT01783834|Drug|Gefitinib|compare progression free survivla rate and safety to both drugs
79401226|NCT04767347|Other|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
80025066|NCT03485300|Drug|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
80025067|NCT02160756|Drug|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
79268725|NCT03539809|Dietary Supplement|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
79570737|NCT01783834|Drug|Pemetrexed|compare PFS rate, safety to both drugs
79570738|NCT01783873|Other|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
79730650|NCT02648659|Drug|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
79268726|NCT05650346|Other|Deep Cervical Training|The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
79730651|NCT04567888|Behavioral|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
79730652|NCT01125930|Drug|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
79730653|NCT01125930|Drug|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
79730654|NCT02656615|Drug|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
79730655|NCT05253430|Procedure|Lymphadenectomy type|D1 vs D2 lymph node dissection
80025068|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
80025069|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
80025070|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
79730656|NCT03946579|Other|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
79730657|NCT05031988|Other|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
80025071|NCT00963469|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
80025072|NCT00963469|Drug|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
80025073|NCT00963469|Drug|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
80025074|NCT05150366|Procedure|Trans thoracic echocardiography|trans thoracic echocardiography at the beggining and at the end of the placement of the Saint Jude Medical AMULET type prosthesis
80025075|NCT03733392|Device|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
80025076|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
79304389|NCT04970823|Device|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
79304390|NCT04488653|Dietary Supplement|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
79304391|NCT04488653|Dietary Supplement|Placebo|Maltodextrin
79304392|NCT04970745|Other|Transcranial parenchymal color Doppler ultrasound (TCS)|tracing the nigrostriatal echogenic area
79401227|NCT04767347|Other|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
79570739|NCT01783899|Device|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
80025077|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
79730658|NCT00651235|Drug|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
79865038|NCT01025583|Dietary Supplement|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
79304393|NCT04970745|Other|Electromyography (EMG) tremor analysis|observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
79865039|NCT01025583|Dietary Supplement|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
79304394|NCT03292835|Device|LeiProtect®|Filmogenic dressing gel
79570740|NCT01783951|Biological|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
79570741|NCT01783951|Drug|S-1|The dose of S-1 is determined according to the body surface area as follows: <1.25 m2, 40 mg; 1.25 to <1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
79570742|NCT01783951|Drug|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
79730659|NCT00651235|Drug|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
79730660|NCT02656459|Other|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
79865040|NCT03840135|Drug|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
79865041|NCT03840135|Other|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
79304395|NCT04970589|Other|Mango|400g of mango/day
79304396|NCT04970589|Dietary Supplement|Probiotics|1 probiotics capsule/day
79304397|NCT04970589|Other|Placebo|1 Placebo capsule/day
79570743|NCT01783964|Drug|[14C]-Elacytarabine|Single intravenous administration
79304398|NCT03193099|Other|Brain imaging|Volume, DWS and DTI
79570744|NCT01783977|Biological|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
79304399|NCT03193099|Other|Neurological assessments|UHDRS
79570745|NCT01783977|Biological|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10^8 PFU/ml; administered as 1 mL IM in participant's deltoid
79570746|NCT01783977|Biological|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10^6 PFU/ml for a planned maximum dose of 1.1x10^7 PFU/ml; administered as 1 mL IM in participant's deltoid
79730661|NCT04015219|Device|Self retained cryopreserved amniotic membrane|PROKERA SLIM
79730662|NCT04015219|Other|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
79304400|NCT03193099|Behavioral|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
79304401|NCT03193099|Behavioral|Behavioural assessments|Computerized game
79304402|NCT02460653|Device|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
79730663|NCT02648269|Drug|SEL-110|
79730664|NCT02648269|Biological|SEL-212|
79730665|NCT02648269|Biological|SEL-037|
79730666|NCT00918346|Drug|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
79865042|NCT00814541|Drug|Bortezomib|
79865043|NCT00814541|Drug|Doxorubicin|
79865044|NCT00814541|Drug|Dexamethasone|
79865045|NCT01021527|Other|Comparator: Treatment A|No Treatment
80025078|NCT03487484|Behavioral|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
80025079|NCT03487484|Behavioral|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
80025080|NCT03487484|Behavioral|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
80025081|NCT02164266|Drug|Placebo|Matching placebo daily oral administration
79570747|NCT01783977|Biological|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
79268727|NCT05650346|Other|Deep cervical training + Upper cervical mobilization group|"the patient in supine crook lying with the neck in a neutral position.The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg~The therapist will cover the rear of the cervical part of the participant with his right hand for stabilization, and will place his thumb and index fingers on the atlas of the participant. To conduct the atlanto-occipital mobilization, the therapist will place his left hand at the right side of the participant and at the same time will place his fifth finger under the occipital area and will pull the participant's head toward his trunk."
80025082|NCT02164266|Drug|RO6799477|Daily oral administration of RO6799477
80025083|NCT05150288|Other|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
79268728|NCT05650346|Other|Deep cervical training + Upper thoracic mobilization group|"The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.~The participants will be placed in the prone position and the therapist will stand facing the joint where the mobilization will be applied to improve the extension of the upper thoracic spine (T1-2)."
79401228|NCT04767347|Other|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
79570748|NCT01783977|Biological|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
79570749|NCT01783977|Biological|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
79570750|NCT01784003|Device|Powered ankle-foot prosthesis|
79730667|NCT02649361|Drug|Anlotinib|Anlotinib p.o. qd
79570751|NCT01784016|Radiation|[11C]-PHNO|[11C]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
79730668|NCT02649361|Drug|Placebo|Placebo p.o. qd
79730669|NCT02648815|Procedure|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
79865046|NCT01021527|Drug|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
79865047|NCT01021527|Drug|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
79865048|NCT01021527|Procedure|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
79865049|NCT00814619|Biological|panitumumab|Given IV
79865050|NCT00814619|Drug|capecitabine|Given orally
79865051|NCT00814619|Procedure|therapeutic conventional surgery|Patients undergo surgical resection
80025084|NCT02163876|Drug|HuCNS-SC cells|surgery arm
80025085|NCT00897949|Drug|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
80025086|NCT00897949|Drug|Comparator: placebo|Placebo to rizatriptan
79268729|NCT02174809|Behavioral|Use of 5As to discuss gestational weight gain|
79570752|NCT01784042|Drug|Placebo|placebo
79570753|NCT01784042|Drug|Lovaza|
79570754|NCT01784042|Other|Dietary energy restriction|
79570755|NCT01784081|Other|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
79570756|NCT01784094|Device|StromaGlide|
79570757|NCT01784107|Drug|Belotecan and Ifosfamide|
79570758|NCT01784120|Drug|Doxorubicin/Genexol-PM|
79730670|NCT02648815|Procedure|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
79865052|NCT00814619|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
79865053|NCT01023009|Procedure|vitrectomy|
80025087|NCT04260776|Behavioral|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
80025088|NCT04260776|Behavioral|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
80025089|NCT04260776|Behavioral|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
80025090|NCT04260776|Behavioral|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
79268730|NCT02174809|Behavioral|Usual care|
79268731|NCT05696366|Drug|Sotagliflozin|Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
79570759|NCT01784146|Other|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
79570760|NCT01784146|Other|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
79730671|NCT00913978|Device|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
79730672|NCT00913978|Device|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
79730673|NCT02648893|Other|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
79570761|NCT01784146|Other|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
79865054|NCT01025661|Other|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
79570762|NCT01784172|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
80025091|NCT03541278|Procedure|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
79268732|NCT05696366|Drug|Volagidemab|Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
79268733|NCT05696288|Procedure|Respiratory Gas Delivery System|Oxygen therapy during general anesthesia for ENT panendoscopy
79268734|NCT02169583|Drug|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
79268735|NCT02169583|Drug|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
79268736|NCT02169583|Drug|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
79268737|NCT02169583|Drug|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
79730674|NCT02648893|Other|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
79730675|NCT02649049|Other|there is no intervention|
79730676|NCT04687540|Drug|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
79730677|NCT04687540|Drug|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
80025092|NCT03541278|Procedure|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
79268738|NCT02169661|Other|Burger and Beetroot Study|50% fat, 10% beetroot extract
79268739|NCT02172391|Drug|Tiotropium inhalation powder capsules|
79268740|NCT02172391|Drug|Placebo inhalation powder capsules|
79268741|NCT00109681|Drug|Iloprost Inhalation Solution (Ventavis)|
79268742|NCT05606120|Device|CL TRAUMA femoral stem|Hip arthroplasty according to the instruction for use.
79268743|NCT02172469|Drug|Tiotropium inhalation powder capsule|
79268744|NCT02172469|Drug|Placebo Metered Dose Inhaler|
79268745|NCT02172469|Drug|Ipratropium Bromide Metered Dose Inhaler|
79268746|NCT02172469|Drug|Placebo inhalation powder capsule|
80025093|NCT03489200|Other|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
80025094|NCT03489200|Other|Placebo|No intervention- placebo
80025095|NCT03540342|Procedure|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
79268747|NCT02172547|Drug|Spiriva|
79730678|NCT01137474|Drug|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
79268748|NCT02174887|Drug|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"
79268749|NCT05173376|Behavioral|Portion size manipulation|The intervention was administered via changing portion sizes of foods served to participants.
79570763|NCT01784172|Device|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
79865055|NCT01025739|Device|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
79268750|NCT04373564|Procedure|Motor Tests|To assess motor function annually
79865056|NCT00641147|Drug|Curcumin|Given PO
79268751|NCT04373564|Procedure|Cognitive Tests|To assess cognitive function annually
79570764|NCT01784185|Procedure|virtual bronchoscopy guided transbronchial needle aspiration|
79730679|NCT01137474|Drug|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
79865057|NCT00641147|Other|Laboratory Biomarker Analysis|Correlative studies
79865058|NCT00641147|Other|Placebo|Given PO
79865059|NCT00460239|Drug|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
79865060|NCT00460239|Drug|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
80025096|NCT04952636|Procedure|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
80025097|NCT04952636|Procedure|open Cuistow|peforming the Cuistow Procedure with the traditional open process
80025098|NCT03732456|Procedure|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
79268752|NCT04373564|Procedure|Unenhanced-MRI of the brain|The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
79268753|NCT04373564|Procedure|Gadolinium Measurements|Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
79268754|NCT04373564|Drug|Gadoxetate disodium|Administered as defined by the treating physician as part of routine clinical practice
79730680|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
79730681|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
79730682|NCT04791436|Diagnostic Test|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
79730683|NCT04791436|Diagnostic Test|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
79865061|NCT00460239|Drug|Placebo|Intramuscular; double blind; once per week
79865062|NCT01021605|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
79865063|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
80025099|NCT03487406|Drug|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
80025100|NCT03487406|Drug|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
79268755|NCT04373564|Drug|Gadobenate dimeglumine|Administered as defined by the treating physician as part of routine clinical practice
79268756|NCT04373564|Drug|Gadodiamide|Administered as defined by the treating physician as part of routine clinical practice
79268757|NCT04373564|Drug|Gadoterate meglumine|Administered as defined by the treating physician as part of routine clinical practice
79268758|NCT04373564|Drug|Gadobutrol|Administered as defined by the treating physician as part of routine clinical practice
79304403|NCT04155411|Drug|Dasatinib|70 mg of Dasatinib orally daily for 12 months
80025101|NCT03487406|Drug|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
80025102|NCT03487406|Drug|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
80025103|NCT02164344|Dietary Supplement|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
79730684|NCT04790188|Dietary Supplement|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
80025104|NCT04653571|Other|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
80025105|NCT02097758|Device|Transcatheter device closure|"Closure of atrial septal defect with device~choosing device size with 3D image and the formula~we do not use sizing balloon for choosing of the device size"
80025106|NCT02760810|Device|Marketed Contact Lens|Narafilcon A
80025107|NCT04574869|Drug|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
80025108|NCT04574869|Drug|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
80025109|NCT04574869|Drug|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia [USP]).
79865064|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
79865065|NCT03839355|Drug|Apixaban|Dosage either 5mg or 2.5mg for 2 years
79865066|NCT03839355|Drug|Warfarin|Dosage assessed by your treating physician for 2 years
79268759|NCT04373564|Drug|Gadoteridol|Administered as defined by the treating physician as part of routine clinical practice
79570765|NCT01784185|Procedure|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
79268760|NCT02169817|Drug|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
79401229|NCT04767347|Other|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
79570766|NCT01784198|Dietary Supplement|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
79570767|NCT01784224|Procedure|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
79730685|NCT04790188|Dietary Supplement|Placebo|10g of maltodextrin lemon flavor (HSN®).
79730686|NCT02648737|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch & Craske, 2009; Craske, 2010).
79730687|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
79730688|NCT02645305|Biological|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
79865067|NCT00382018|Drug|chemotherapy|No administration details available
79730689|NCT04609696|Drug|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
79865068|NCT00640601|Drug|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
79730690|NCT04609696|Drug|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
79865069|NCT03838731|Drug|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
79865070|NCT03838731|Drug|Placebo|Single subcutaneous (SC) dose of matching placebo
79865071|NCT02551133|Drug|dexamethasone|1 hour before surgery
80025110|NCT04574869|Drug|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
80025111|NCT04574869|Drug|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
79268761|NCT02169817|Drug|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
79268762|NCT02174965|Device|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
79268763|NCT02174965|Device|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
79268764|NCT05142319|Biological|Homologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
79268765|NCT05142319|Biological|Heterologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
79268766|NCT05142319|Biological|Non-mRNA booster vaccine A|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
80025112|NCT04047056|Other|Labor Kinesiotherapy|"The intervention group will perform 5 minutes of warm-up with free active exercises, 10 minutes of specific resistance exercises for the cervical and upper limbs and 5 minutes of stretching and muscle relaxation.The initial free active exercises will be performed in 3 sets of 15 repetitions; Resistance exercises will be performed in 3 sets of 10 repetitions and stretching will be performed in 3 sets of 30 seconds.~Regarding the intervals between exercises, active recovery will be adopted to counteract the effects of muscle fatigue."
80025113|NCT02760654|Device|Proactive Self Management Program for Effects of Cancer Treatment|
79401230|NCT04767347|Other|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
79401231|NCT04767347|Other|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
79401232|NCT04766879|Device|Transfluthrin|Passive emanator with formulated transfluthrin
79570768|NCT01784237|Procedure|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
79730691|NCT04609696|Drug|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
79730692|NCT01168973|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
79865072|NCT00814853|Device|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
79865073|NCT00818285|Device|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
79268767|NCT05142319|Biological|Non-mRNA booster vaccine B|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
79268768|NCT05142319|Biological|Non-mRNA booster vaccine C|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
79268769|NCT02169973|Drug|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
79268770|NCT02169973|Drug|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
79730693|NCT01168973|Drug|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
79730694|NCT01168973|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
79730695|NCT00631462|Drug|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
79730696|NCT03918109|Drug|OTO-313|single intratympanic injection of gacyclidine
79730697|NCT03918109|Drug|Placebo|single intratympanic injection of placebo
79865074|NCT00452439|Drug|Actonel (Risedronate)|35 mg (pill) by mouth weekly
79730698|NCT04187430|Behavioral|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
79730699|NCT04187430|Behavioral|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
79865075|NCT00452439|Dietary Supplement|Calcium|500 mg by mouth twice a day for a total of 24 months.
79865076|NCT00452439|Dietary Supplement|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
79865077|NCT02550899|Procedure|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
80025114|NCT00725491|Drug|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
80025115|NCT00725491|Drug|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 <= 50 pg/ml (<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
79268771|NCT04373174|Device|Regional oximetry probe|Regional oximetry probe will be placed in the frontal area of the head
79268772|NCT04373174|Procedure|Thoracic Epidural block|Thoracic epidural block will be applied to the patients before the operation begins
79304404|NCT03292757|Drug|Indocyanine Green|Fluorescent dye - indocyanine green
79401233|NCT04766879|Device|Placebo|Passive emanator with formulated inert ingredients
79401234|NCT04745910|Drug|Pegloticase|Given IV
79401235|NCT04745910|Drug|Rasburicase|Given IV
79401236|NCT04742361|Drug|[18F]PSMA-1007|diagnostic radiopharmaceutical for PET scan
79401237|NCT04740034|Drug|AMG 340|AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
80025116|NCT03487328|Procedure|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
80025117|NCT00724789|Drug|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
80025118|NCT00724789|Drug|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
80025119|NCT03485144|Biological|TV003|Live attenuated virus vaccine-TetraVax-DV
80025120|NCT03485144|Biological|Placebo for TV003|Placebo
80025121|NCT02164500|Drug|Ruxolitinib|
80025122|NCT03489356|Behavioral|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
79268773|NCT02172703|Device|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
79401238|NCT04729114|Drug|PRL-02 injection|abiraterone decanoate for intramuscular injection
79570769|NCT01784237|Procedure|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
79570770|NCT01784250|Drug|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
79570771|NCT01784250|Drug|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
79570772|NCT01784250|Drug|Placebo|Sugar pill manufactured to mimic a drug
79570773|NCT01784263|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
79730700|NCT02648035|Biological|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
79570774|NCT01784263|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
79730701|NCT04311372|Behavioral|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
79730702|NCT04311372|Behavioral|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
79730703|NCT04744012|Procedure|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
79730704|NCT02644993|Radiation|Proton therapy|
80025123|NCT03925142|Other|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
80025124|NCT03925142|Other|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
80025125|NCT00711607|Drug|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
80025126|NCT03893318|Drug|IV lidocaine|an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.
80025127|NCT03893318|Drug|Placebos|Saline
80025128|NCT03625531|Other|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
79401239|NCT04729114|Drug|prednisone|5 mg once daily or twice daily
79401240|NCT04729114|Drug|dexamethasone|0.5 mg administered once daily
79401241|NCT04729114|Drug|docetaxel infusion|docetaxel administered via intravenous infusion
79401242|NCT04728087|Device|ACCEL® Absorbable Hemostat Powder|Up to 2 bellows (10 grams nominal) of ACCEL®
80025129|NCT03625531|Drug|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
80025130|NCT03625531|Drug|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
80025131|NCT02161224|Drug|FG-4592|Oral
80025132|NCT02167698|Device|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
80025133|NCT02167698|Other|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
80025134|NCT02167698|Drug|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
79730705|NCT04117438|Other|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
79730706|NCT00652561|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
80025135|NCT02167698|Other|Restrictive fluid therapy|Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols
80025136|NCT02167698|Drug|sedo-analgesia titration|
80025137|NCT02167698|Other|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
80025138|NCT02167698|Other|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
80025139|NCT02167698|Other|Biomarker Assay|Biomarker Assay for patients in both arms
79268774|NCT04298528|Drug|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
79730707|NCT01168427|Device|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
79730708|NCT00653497|Behavioral|Aquatic exercise|"Arthritis Foundation Aquatics Program~community-based aquatic exercise program~participants asked to attend 2 classes per week for 20 weeks~each class 45-60 minutes in duration"
80025140|NCT04050943|Other|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
79401243|NCT04728087|Device|Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)|Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
79401244|NCT04722276|Other|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
79401245|NCT04722276|Other|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
79730709|NCT05251168|Procedure|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
80025141|NCT02164656|Behavioral|mindfulness for smokers|
80025142|NCT02634580|Biological|Evolocumab|Administered by subcutaneous injection
80025143|NCT02634580|Drug|Ezetimibe|Tablet for oral administration
79401246|NCT04721405|Device|Observational Study: No intervention|Observational Study: No intervention
79401247|NCT04717024|Device|Observational Study - no intervention|Observational Study - no intervention
79730710|NCT05251168|Procedure|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
80025144|NCT02634580|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
80025145|NCT02634580|Drug|Placebo Ezetimibe|Tablet for oral administration
80025146|NCT02225366|Biological|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
79268775|NCT04298528|Other|Placebo|2 times a day for 30 days after total knee replacement
79268776|NCT02170129|Device|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface."
79309096|NCT02596971|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
79309097|NCT02596971|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
79309098|NCT02596971|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
79268777|NCT02170129|Device|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
79268778|NCT00100711|Drug|Motexafin Gadolinium|
79570775|NCT01784276|Behavioral|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
79570776|NCT01784302|Dietary Supplement|Multivitamins|
79730711|NCT03206437|Behavioral|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
79268779|NCT02175043|Procedure|atrial electrogram and liner ablation|"The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
79730712|NCT03206437|Behavioral|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
79730713|NCT01124916|Procedure|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
79730714|NCT01124916|Procedure|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
79730715|NCT00631618|Drug|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
79401248|NCT04702750|Behavioral|Targeted memory reactivation (odors)|I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).
79401249|NCT04702750|Behavioral|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
79570777|NCT01784302|Dietary Supplement|Sodium bicarbonate|
79570778|NCT01784302|Drug|Maalox Plus extra|
79570779|NCT01784302|Drug|Raltegravir 400 mg|
79570780|NCT01784315|Drug|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
79570781|NCT01784315|Drug|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
79730716|NCT02647801|Behavioral|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
79730717|NCT04777630|Diagnostic Test|None, neuroimaging|Observation only to observe differences in neuroimaging
79730718|NCT04714060|Biological|UB-621|mAb by SC administration
79730719|NCT04431778|Drug|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
79268780|NCT02581202|Drug|lopinavir/ritonavir|tablet
79268781|NCT02581202|Drug|lamivudine|tablet
79268782|NCT02758171|Drug|Empagliflozin|
79268783|NCT02758171|Drug|Linagliptin|
79268784|NCT05662826|Behavioral|Avatar-based Social Physical Activity|Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
79304405|NCT03192865|Procedure|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
79304406|NCT04970667|Drug|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
79570782|NCT01784328|Device|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
79570783|NCT01784354|Other|Acupressure|
79570784|NCT01784354|Other|Acupressure dilatation|
79570785|NCT01784354|Behavioral|education|
79730720|NCT04431778|Drug|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
79730721|NCT05252650|Behavioral|pain|postoperative pain
80025147|NCT02225366|Other|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
79570786|NCT01784367|Device|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
80025148|NCT03540264|Device|Clearfil Majesty TM|Tooth wear - composite resin
80025149|NCT03540264|Device|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
80025150|NCT00697255|Drug|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
80025151|NCT00697255|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
80025152|NCT00697255|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
80025153|NCT00697255|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
80025154|NCT01957748|Behavioral|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
80025155|NCT00548912|Drug|Spironolactone|
80025156|NCT02161302|Device|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
80025157|NCT02161302|Device|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
80025158|NCT04460300|Other|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
79730722|NCT05252572|Biological|CLL1 CAR T-cells|Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
79730723|NCT00631384|Behavioral|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
79730724|NCT00631384|Behavioral|Individual VCT|Women to receive individual VCT
79865078|NCT02550899|Procedure|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
79865079|NCT02550899|Procedure|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
79865080|NCT00814931|Drug|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
80025159|NCT04460300|Other|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
80025160|NCT05002933|Drug|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
79268785|NCT02170285|Device|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
79304407|NCT05233813|Behavioral|Active Body and Mind|The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
80025161|NCT03487250|Device|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
80025162|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
79268786|NCT02170285|Device|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
79268787|NCT05659082|Device|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
79268788|NCT05141396|Other|Telehealth- enabled support for SAT/SBT adherence|Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.
79570787|NCT01784380|Drug|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
79570788|NCT01784393|Radiation|chemoradiation|
79865081|NCT00814931|Drug|Placebo|matching oral liquid suspension placebo twice a day for 8 days
80025163|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
79268789|NCT05141396|Other|Usual audit and feedback for SAT/SBT adherence|Usual audit and feedback
79268790|NCT04268420|Drug|FMP013|Falciparum Malaria Protein-13
79268791|NCT04268420|Drug|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
79401250|NCT04702672|Dietary Supplement|100% wheat (control)|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
79570789|NCT01784406|Behavioral|Autonomy supportive counselling|
80025164|NCT06161441|Drug|Fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
80025165|NCT06161441|Drug|Cemiplimab|Administered IV Q3W
80025166|NCT06161441|Drug|Pemetrexed|Administered IV Q3W
79268792|NCT02172781|Drug|Ipratropium - unit dose vial|
79268793|NCT02172781|Drug|Tiotropium - inhalation capsule|
79268794|NCT02172781|Drug|Placebo matching tiotropium|
79401251|NCT04702672|Dietary Supplement|100% Lean-baking barley®|"Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou"
79401252|NCT04702672|Dietary Supplement|100% regular barley|"Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
79570790|NCT01784432|Device|Low-level laser therapy and training|
79570791|NCT01784432|Other|Training|
79570792|NCT01784445|Drug|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
79570793|NCT01784471|Device|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
80025167|NCT06161441|Drug|Paclitaxel|Administered IV Q3W
79570794|NCT01784484|Other|No intervention|
79570795|NCT01784510|Procedure|distance of dissection of gastrocolic ligament from pylorus|
79865082|NCT01023087|Drug|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
79865083|NCT01023087|Drug|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
80025168|NCT06161441|Drug|Carboplatin|Administered IV Q3W
80025169|NCT06161441|Drug|Cisplatin|Administered IV Q3W
80025170|NCT06161441|Drug|Placebo|Administered IV Q3W
80025171|NCT06161415|Drug|Laquinimod eye drops|n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
80025172|NCT06161389|Device|Partially inflated mask|Manikin ventilation with a partially inflated mask
80025173|NCT06161389|Device|Fully inflated mask|Manikin ventilation with a fully inflated mask
80025174|NCT06161376|Other|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
80025175|NCT06161363|Other|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
79268795|NCT02172781|Drug|Placebo matching ipratropium|
79268796|NCT05572346|Other|Home-based telerehabilitation program delivered through digital devices|To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
79268797|NCT02172859|Dietary Supplement|lumiVida™|
79268798|NCT02172859|Dietary Supplement|Placebo|
79268799|NCT02172937|Biological|Decidual Stromal Cells thawed in plasma|
79268800|NCT02172937|Biological|Decidual Stromal Cells thawed in human albumin|
79268801|NCT05560568|Other|Sleep parameters data collection|Sleep parameters collected before and after hybrid close-loop pump activation. Data collected with adequate devices (i.e. actigraph and Dreem Band).
79304408|NCT03288467|Procedure|Root canal treatment with 5% NaOCl|
79570796|NCT01784549|Drug|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
79268802|NCT02173015|Other|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
79268803|NCT02173093|Biological|IL-2|Given SC
79268804|NCT02173093|Biological|GD2Bi-aATC|Given IV
80025176|NCT06161350|Combination Product|Structured multi-disciplinary approach|Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
79268805|NCT02173093|Biological|GM-CSF|Given SC
79268806|NCT02173093|Other|laboratory evaluations of immune responses|Correlative studies
79570797|NCT01784562|Drug|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
79570798|NCT01784575|Other|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
79730725|NCT05252494|Other|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
79730726|NCT02691130|Biological|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
80025177|NCT06161324|Other|Pelvic floor muscle exercises|3 intervention arms (telerehabilitation, traditional physiotherapy and control) based on a progressive pelviic floor muscle exercise protocol will be used, including the same execise parameters (endurance, sntrength, positioning etc.) for all patients. However, exercise protocols will be individually presribed based on clinical assessment of PFMs by an experienced physiotherapist.
79268807|NCT04577989|Other|data collection|data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.
79268808|NCT01161992|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
79268809|NCT05142085|Dietary Supplement|nano-PSO|This active treatment will be delivered to 3 out of 5 patients
79401253|NCT04698538|Behavioral|JASPER|JASPER is a naturalistic, developmental, behavioral intervention (NDBI) that focuses on developing social communication and language skills in the context of a play based intervention.
79401254|NCT04696692|Other|Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.|"Blood samples will be collected :~at baseline (before the 1st R-CHOP cycle)~before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~after the 4th administration of the CT~at the end of induction (i.e. end of R-CHOP treatment)~at 24 months after initiation of R-CHOP treatment~at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."
79730727|NCT02691130|Biological|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
79730728|NCT02691130|Biological|Saline|0.9% NaCl in double distilled water
79730729|NCT00916006|Drug|PEP005 Gel|0.015%, three day treatment
79730730|NCT00916006|Drug|Vehicle gel|Vehicle gel, three day treatment
79730731|NCT04606186|Dietary Supplement|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
79730732|NCT04606186|Dietary Supplement|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia)
79268810|NCT05142085|Other|placebo|This treatment will be assigned to 2 out of 5 patients
79268811|NCT00103831|Drug|Oral Taxane|
79268812|NCT03538483|Drug|Bupivacaine Hcl 0.25% Inj|30 ml %0,25 bupivacaine
79268813|NCT03538483|Drug|Bupivacaine HCl Inj 0.25%|20 ml %0,25 bupivacaine
79268814|NCT02173171|Other|Information collection|Q3M Information collection
79268815|NCT02175355|Drug|Low dose of Micardis®|
79268816|NCT02175355|Drug|Medium dose of Micardis®|
79268817|NCT02175355|Drug|High dose of Micardis®|
79268818|NCT02175355|Drug|Hydrochlorothiazide|
79268819|NCT02175355|Drug|Placebo|
79304409|NCT03288467|Procedure|Root canal treatment with 1% NaOCl|
79304410|NCT02446327|Other|Blood sampling for biomarker assessment|
80025178|NCT06161311|Device|DIMS lenses|Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
80025179|NCT06161272|Drug|Fluzoparib|single
80025180|NCT06161272|Drug|Fluzoparib+Apatinib|combination
80025181|NCT06161259|Drug|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
80025182|NCT06161246|Device|Vibrating Beauty Bar|A vibrating beauty bar will be used at the injection site for patient comfort.
80025183|NCT06161233|Device|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
80025184|NCT06161220|Drug|Carbidopa capsule|Dose: 4x 100 mg
80025185|NCT06161220|Drug|Moxifloxacin Tablets, USP|Dose: 400 mg
80025186|NCT06161220|Drug|Placebo|Placebo capsules matching the carbidopa capsules
80025187|NCT06161168|Device|Bootle Blast Play Phase (B)|"Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play."
79570799|NCT01784627|Behavioral|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
79570800|NCT01784640|Drug|Hsp90 inhibitor AUY922|Given IV
79730733|NCT04701814|Other|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
79730734|NCT04589572|Procedure|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
79730735|NCT04589572|Procedure|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
79730736|NCT04669132|Drug|Olanzapine|- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
80025188|NCT06161155|Combination Product|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
80025189|NCT06161142|Diagnostic Test|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
79268820|NCT03538327|Drug|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
79268821|NCT02170597|Drug|BIBR 1048 MS HPMC capsule|
79268822|NCT02170597|Drug|BIBR 1048 MS gelatine capsule|
79570801|NCT01784640|Drug|pemetrexed disodium|Given IV
79570802|NCT01784640|Other|pharmacological study|Correlative studies
79570803|NCT01784640|Other|laboratory biomarker analysis|Correlative studies
79570804|NCT01784653|Behavioral|iMET|Self-completed, computerized motivational enhancement therapy
79401255|NCT04685525|Behavioral|Mycobiome Supporting Diet|MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
79401256|NCT04683003|Biological|TAK-755|TAK-755 IV infusion
79570805|NCT01784653|Behavioral|MET|Clinician-delivered Motivational Enhancement Therapy
79570806|NCT01784692|Dietary Supplement|Immulina|
79570807|NCT01784705|Device|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
80025190|NCT06161142|Diagnostic Test|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
79570808|NCT01784705|Device|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
79570809|NCT01784718|Drug|Buphenyl|
79730737|NCT04669132|Drug|Netupitant|- Netupitanto 300 mg, once daily, on chemotherapy day;
79730738|NCT04669132|Drug|Palonesetron|- Palonosetron 0.56 mg, once daily, on chemotherapy day;
79268823|NCT02170675|Drug|Dabigatran etexilate|
80025191|NCT06161142|Diagnostic Test|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
79570810|NCT01784731|Behavioral|Willingness to pay|
79570811|NCT01784744|Other|Hydroworx Pool at 98 degrees Fahrenheit|
79570812|NCT01784744|Other|Hydroworx Pool at 102 degrees Fahrenheit|
79570813|NCT01784757|Drug|ODM-201 Tablet A|Tablet A formulation of ODM-201
79570814|NCT01784757|Drug|ODM-201 Tablet B|Tablet B formulation of ODM-201
79730739|NCT04701346|Other|Low SAA diet|Diet with low content of methionine and cysteine
80025192|NCT06161142|Diagnostic Test|SF-36|Quality of life questionnaire
80025193|NCT06161142|Diagnostic Test|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
80025194|NCT06161142|Diagnostic Test|Physical examination|A full rheumatological examination will be performed.
80025195|NCT06161142|Diagnostic Test|Recording of vital signs|(including body temperature, blood pressure, heart rate)
80025196|NCT06161142|Diagnostic Test|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis [proportional mass of muscle, water and fat in kg]) will be performed.
80025197|NCT06161142|Diagnostic Test|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
79570815|NCT01784757|Drug|ODM-201 capsule formulation|Capsule formulation of ODM-201
79570816|NCT01784783|Behavioral|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
80025198|NCT06161129|Device|Lenses|The filter lenses will be worn by participants for one month all day.
79570817|NCT01784783|Behavioral|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
79730740|NCT04701346|Other|High SAA diet|Diet with high content of methionine and cysteine
79730741|NCT01168349|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
79268824|NCT02170675|Drug|Ketoconazole|
79268825|NCT02175433|Drug|AGS67E|intravenous (IV) infusion
79268826|NCT04154150|Drug|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
79268827|NCT04154150|Behavioral|Cognitive training|8 sessions of computer-based cognitive training
79268828|NCT04154150|Behavioral|Sham Training|8 sessions of computer-based sham training
79268829|NCT02173249|Drug|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
79570818|NCT01784809|Behavioral|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. ***To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
79730742|NCT00915772|Drug|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
79730743|NCT00915772|Drug|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
79268830|NCT02256085|Device|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
79268831|NCT02256085|Device|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
79268832|NCT02256085|Device|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
79268833|NCT02173327|Device|Continuously helm CPAP|6 hours
79268834|NCT02173327|Device|Intermittent Mask CPAP|10min every 2 hour for 18 hours
79730744|NCT00915772|Drug|Metformin|Metformin 1000 mg tablet bid
79730745|NCT03571828|Drug|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
79730746|NCT04363606|Other|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
79730747|NCT04363606|Biological|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
79730748|NCT04363606|Other|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
79730749|NCT04363606|Device|actigraphy|assessment of sleep quality
80025199|NCT06161103|Procedure|3D Printed Prefabricated Composite Resin Crown Group|3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
80025200|NCT06161103|Procedure|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
80025201|NCT06161090|Biological|CM310|CM310 injection
79730750|NCT04363606|Device|Neuromuscular evaluation|"The maximum isometric force produced by the knee extensors will be measured on the ergometer~the intensity of muscular electrical activity recorded by surface electromyography~Peripheral nerve stimulation~Transcranial magnetic stimulation~Magnetic resonance imaging"
80025202|NCT06161090|Drug|Placebo|subcutaneous injection
79570819|NCT01784809|Behavioral|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
79570820|NCT01784809|Behavioral|Wellness Promotion|
79570821|NCT01784822|Device|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
79730751|NCT04363606|Other|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
79730752|NCT04363606|Other|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
79730753|NCT00632086|Drug|PA32540|
79730754|NCT00632086|Drug|aspirin component of PA32540|The 325 mg aspirin component of PA32540
80025203|NCT06161064|Drug|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
80025204|NCT06161038|Device|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
80025205|NCT06161038|Device|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
80025206|NCT06161038|Drug|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
80025207|NCT06160960|Other|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
80025208|NCT06160947|Other|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as required. All participants will also receive opioid-reduction encouragement as per each CHC's current practices. Due to socioeconomic disadvantages, most CHC patients will be unlikely to access private health care services, including chiropractic care, elsewhere. Nevertheless, the investigators will collect data on other health care utilization and conduct all analyses using an intention-to-treat principle.
80025209|NCT06160947|Other|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, and core muscle strengthening exercises). Primary care providers will also engage participants in a formal collaborative effort with the chiropractic clinicians to reduce opioid use. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 12 chiropractic visits during the active care period, although participants may continue with treatment after the 8-week period (e.g., one visit, every 2-4 weeks) to manage further episodes of exacerbation/flare-up. Aside from the experimental intervention, participants in both study groups will follow the same protocol to minimize non-specific effects.
79570822|NCT01784835|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
79570823|NCT01784835|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
79570824|NCT01784887|Drug|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
79570825|NCT01784900|Drug|Catumaxomab 100µg|
79570826|NCT01784900|Drug|Catumaxomab 140µg|
79268835|NCT02170753|Procedure|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
79570827|NCT01784913|Biological|UV1 synthetic peptide vaccine and GM-CSF|
79730755|NCT00632086|Drug|Ecotrin|325 mg Ecotrin
79730756|NCT00912964|Drug|Mirabegron|Mirabegron tablets
79730757|NCT00912964|Drug|Placebo|Matching mirabegron placebo tablets.
79730758|NCT02647957|Procedure|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
80025210|NCT06160934|Behavioral|T1D Parent Check-in|The Type 1 Diabetes (T1D) Parent Check-in is an innovative, 3-session, T1D-specific intervention for parents of newly diagnosed children and adolescents that can be delivered via telehealth. The T1D Parent Check-in is an adaptation of The Parent Check-In, a brief, prevention-based parenting intervention developed by Grolnick, Levitt, Caruso, & Lerner (2021). The T1D Parent Check-in is designed to promote parenting skills on dimensions of autonomy support, structure and involvement that facilitate children's adjustment and motivation, and integrates skills from cognitive-behavioral therapy, customized to be highly relevant to families with a child 6-12 months from new diagnosis of T1D. The intervention is intended to promote diabetes-related resilience and positive psychological and medical outcomes among families of children with T1D.
80025211|NCT06160921|Other|Standard therapy|Individualized blood pressure reduction program
80025212|NCT06160882|Other|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
79570828|NCT01784952|Dietary Supplement|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
79570829|NCT01784978|Drug|Sunitinib|50 mg pd
80025213|NCT06160882|Procedure|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
79570830|NCT01784978|Drug|Everolimus|10 mg pd
79730759|NCT02641639|Drug|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
79570831|NCT01783652|Behavioral|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
79570832|NCT01785004|Dietary Supplement|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
79570833|NCT01785004|Drug|omega-3 fatty acids (fish oil)|
79730760|NCT02641639|Drug|Placebo|Saline for infusion
79730761|NCT02647723|Dietary Supplement|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
79865084|NCT00815009|Behavioral|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
79570834|NCT01785030|Drug|50% Nitrous oxide|
79730762|NCT02647723|Dietary Supplement|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
79730763|NCT02647567|Other|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
79730764|NCT02647567|Other|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
79865085|NCT00815009|Behavioral|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
79865086|NCT00815009|Behavioral|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
79865087|NCT00381940|Drug|ifosfamide|Given IV
79865088|NCT00381940|Drug|bortezomib|Given IV
79865089|NCT00381940|Drug|vinorelbine tartrate|Given IV
79865090|NCT00381940|Biological|filgrastim|Given IV or SC
79865091|NCT00818597|Device|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
79865092|NCT00818675|Drug|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
79570835|NCT01785043|Drug|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
79570836|NCT01785043|Drug|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
79570837|NCT01785056|Biological|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
79730765|NCT00651469|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
79730766|NCT00651469|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
80025214|NCT06160869|Behavioral|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
80025215|NCT06160869|Combination Product|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
80025216|NCT06160856|Diagnostic Test|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
80025217|NCT06160843|Drug|Pembrolizumab IV infusion Q3W, with daily oral Olaparib.|Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
80025218|NCT06160830|Dietary Supplement|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
80025219|NCT06160830|Other|placebo|Two capsules of placebo containing maltodextrin per day
80025220|NCT06160804|Procedure|Skeletal traction|A pin through the bone with weights attached
80025221|NCT06160804|Procedure|Femoral shaft splinting|A splint of the broken thigh bone
80025222|NCT06160791|Drug|Ruxolitinib|Administered Orally (PO)
79268836|NCT02170753|Procedure|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
79268837|NCT02170831|Drug|BIBR 1048 MS low|
79268838|NCT02170831|Drug|BIBR 1048 MS medium 1|
79268839|NCT02170831|Drug|BIBR 1048 MS medium 2|
79730767|NCT02647489|Biological|PAMVAC|
79730768|NCT02647489|Biological|Alhydrogel|
79730769|NCT02647489|Biological|GLA-SE|
79730770|NCT02647489|Biological|GLA-LSQ|
79730771|NCT02647489|Other|Placebo|
79730772|NCT00653575|Behavioral|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
79730773|NCT00653575|Behavioral|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
79730774|NCT02641171|Other|Specimen sampling|exhaled air samples blood samples fecal samples
80025223|NCT06160791|Drug|Etoposide|Administered IV
80025224|NCT06160791|Drug|Dexamethasone|Administered PO or IV
80025225|NCT06160791|Procedure|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
80025226|NCT06160791|Procedure|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
80025227|NCT06160791|Procedure|Biospecimen Collection|Undergo blood sample collection
79268840|NCT02170831|Drug|BIBR 1048 MS high|
80025228|NCT06160778|Drug|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
79268841|NCT02170831|Drug|BIBR 1048 MS placebo|
79268842|NCT04141670|Drug|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
79268843|NCT03539263|Dietary Supplement|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~Lactobacillus fermentum~Lactobacillus rhamnosus~Lactobacillus plantarum~Bifidobacterium longum"
79268844|NCT03539263|Other|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
79268845|NCT03538249|Other|Aerobic training|
79268846|NCT03538249|Other|Inspiratory muscle training|
79268847|NCT03538249|Other|Resistance Training|
79268848|NCT03538249|Other|Aerobic and Inspiratory training|
79268849|NCT03538249|Other|Combined|Aerobic, inspiratory and resistance training
79570838|NCT01785082|Drug|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
79570839|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg|
79570840|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg X 2|
80025229|NCT06160778|Drug|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
80025230|NCT06160778|Drug|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
80025231|NCT06160778|Drug|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
79730775|NCT00910897|Drug|Velcade-Dexamethasone|
79730776|NCT00910897|Drug|Velcade-Thalidomide-Dexamethasone|
79730777|NCT00913744|Drug|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
79730778|NCT00913744|Drug|Sham injection|Sham injection
80025232|NCT06160739|Drug|Sirolimus 1Mg Oral Tablet|patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam & ultrasound & MRI to compare lesion size before & after use of the drug with observation of potential side effects & after exclusion of it before use of the drug
80025233|NCT06160674|Other|COPD|A vowel segmentation data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques on different segments of a vowel recording.
79401257|NCT04682561|Behavioral|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
79730779|NCT00651547|Drug|budesonide/formoterol|
79730780|NCT00651547|Drug|budesonide|
79730781|NCT00651547|Drug|formoterol|
79730782|NCT04202848|Diagnostic Test|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
79865093|NCT00818675|Drug|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
79865094|NCT00818675|Drug|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
79570841|NCT01785108|Drug|Vitamin D|
79570842|NCT01785108|Drug|Ibuprofen|
79730783|NCT04589260|Drug|TD-1058|Study drug to be administered by oral inhalation
80025234|NCT06160661|Device|mandibular saggital split osteotomy|orthognathic surgery
80025235|NCT06160648|Other|Management according to Mechanical Diagnosis and Therapy|MDT management is based on the patient response to repeated end range movements.
79570843|NCT01785121|Behavioral|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
79730784|NCT04589260|Drug|Placebo|Placebo to be administered by oral inhalation
79730785|NCT02641327|Device|EarlySense (Passive monitoring)|Passive contact-free monitoring
79730786|NCT02644759|Biological|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
79730787|NCT00912808|Drug|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
79730788|NCT00912808|Drug|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
79730789|NCT02647333|Dietary Supplement|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
79730790|NCT02647333|Dietary Supplement|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
79865095|NCT00364156|Drug|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
80025236|NCT06160648|Other|Management according to the Cervical Spine Clinical Practice Guidelines|CPG management is based on clinical research regarding management of people with neck pain.
80025237|NCT06160609|Drug|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
80025238|NCT06160609|Drug|GSK3174998|GSK3174998 will be administered.
79570844|NCT01785121|Behavioral|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
79570845|NCT01785147|Drug|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
79865096|NCT00364156|Drug|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
79865097|NCT00818831|Drug|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
79865098|NCT00452361|Drug|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
80025239|NCT06160596|Genetic|Long term survival multimodal analysis|"To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~To describe global signatures in the overall population (pan-cohort).~To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
79268850|NCT04978064|Behavioral|e-health psychological counselling|"Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study)."
79570846|NCT01785147|Drug|Placebo|
79730791|NCT02641405|Device|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
79865099|NCT00452361|Drug|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~continued for the entire 104-week period of randomized therapy~subsequently discontinued~restarted after discontinuation"
79865100|NCT03334318|Other|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865101|NCT03334318|Other|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865102|NCT03334318|Other|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865103|NCT03334318|Other|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865104|NCT03334318|Other|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865105|NCT03334318|Other|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865106|NCT03334318|Other|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865107|NCT03334318|Other|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865108|NCT03334318|Other|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
79865109|NCT03334318|Drug|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
80025240|NCT06160570|Radiation|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
80025241|NCT06160570|Radiation|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
79730792|NCT02641405|Device|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
79730793|NCT02647255|Procedure|Plasma Exchange (PE)|PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
79730794|NCT02647255|Drug|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
80025242|NCT06160531|Drug|CC-42344|Anti-influenza A agent
79570847|NCT01785173|Procedure|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
79570848|NCT01785173|Procedure|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
79570849|NCT01785199|Procedure|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
79570850|NCT01785212|Device|Stapler|stapler hepatectomy
79730795|NCT04415086|Biological|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
79730796|NCT04329442|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
79865110|NCT03334318|Drug|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
79865111|NCT00640289|Drug|Fibrogammin P|Prophylaxis treatment
79865112|NCT00818909|Other|Systane|Systane prescription
79865113|NCT01049932|Drug|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
79865114|NCT00818987|Other|Open reduction internal fixation; reduction and immobilization|
79865115|NCT01047670|Drug|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
79865116|NCT00819065|Drug|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
80025243|NCT06160531|Drug|Placebo|Matching placebo
80025244|NCT06160518|Behavioral|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
79570851|NCT01785212|Device|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
79730797|NCT04414228|Device|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
80025245|NCT06160505|Device|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
80025246|NCT06160479|Drug|Calcium supplement|Different amount of calcium supplement in pregnancy
80025247|NCT06160440|Drug|SC1011|Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
80025248|NCT06160427|Biological|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
80025249|NCT06160427|Biological|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
80025250|NCT06160401|Drug|Singletine|Singletine orally administered
80025251|NCT06160401|Drug|Placebo|Placebo orally administered
80025252|NCT06160388|Device|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
80025253|NCT06160375|Diagnostic Test|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
80025254|NCT06160362|Biological|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
80025255|NCT06160362|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
80025256|NCT06160362|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
80025257|NCT06160323|Procedure|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
79570852|NCT01785225|Device|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
79570853|NCT01785238|Other|renal echography|renal echography to analyse the kidney
79570854|NCT01785238|Other|Blood sampling|Blood sampling to analyse different parameters of renal function
79570855|NCT01785238|Other|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
79570856|NCT01785238|Other|Blood pressure measurement|
79730798|NCT04414228|Device|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
79570857|NCT01785251|Device|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
79570858|NCT01785264|Procedure|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
79730799|NCT00960531|Biological|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
79401258|NCT04680000|Behavioral|Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)|BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
80025258|NCT06160297|Procedure|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~Knee extension while sitting on a chair~Knee flexion while standing with support from a chair~Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~Standing on tiptoe with support from a chair~Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~Mini squats~Toe walking~Walking on heels~Tandem stance~Tandem walking~Walking backwards (10 steps)~Standing on one leg~Assisted side walking~Side walking without support~Sit and stand on the chair~Figure eight walking"
79730800|NCT00960531|Biological|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
79865117|NCT00819065|Drug|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
80025259|NCT06160297|Procedure|Neuromuscular Exercise|"Proprioceptive stabilization of the knee with ball~Bridging with ball~Stepping forward, sideways and backwards by holding on to a fixed support while standing~Doing the same movements with the support leg on a different surface~Hip abduction-adduction with resistance band~Knee flexion-extension with resistance band~Climbing and descending steps by taking steps~Balancing on the step~Standing up from the chair"
80025260|NCT06160284|Drug|Psilocybin|Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants < 70 kg) or 25 mg (among participants >70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline [11C]-UCB-J PET.
80025261|NCT06160245|Other|exercise therapy|core stabilization exercises
80025262|NCT06160232|Drug|Psilocybin (high dose)|Psilocybin-assisted therapy
80025263|NCT06160232|Drug|Active placebo (low dose of psilocybin)|Placebo-assisted therapy
79730801|NCT00960531|Biological|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
79865118|NCT01047748|Drug|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
79865119|NCT01047748|Drug|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
79865120|NCT01047826|Procedure|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
79865121|NCT01047826|Procedure|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
80025264|NCT06160219|Drug|Hydroxycobalamin|prophylactic to prevent vasoplegia in high risk patients undergoing CABG or valvular surgeries
80025265|NCT06160206|Biological|Bevacizumab|Given IV
80025266|NCT06160206|Procedure|Biospecimen Collection|Undergo blood sample collection
80025267|NCT06160206|Procedure|Computed Tomography|Undergo CT
79730802|NCT04280367|Diagnostic Test|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
79730803|NCT04280367|Diagnostic Test|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
79730804|NCT04280367|Diagnostic Test|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
79730805|NCT02859909|Biological|BT595|
79730806|NCT00652639|Drug|Clonazepam|Tablets, 1 mg, single-dose
79730807|NCT00652639|Drug|Klonopin|tablets, 1 mg, single-dose
80025268|NCT06160206|Other|Electronic Health Record Review|Ancillary studies
80025269|NCT06160206|Radiation|Hypofractionated Radiation Therapy|Undergo radiation therapy
80025270|NCT06160206|Procedure|Magnetic Resonance Imaging|Undergo MRI
80025271|NCT06160206|Biological|Retifanlimab|Given IV
80025272|NCT06160180|Drug|Dexamethasone|Submucosal application
80025273|NCT06160167|Drug|IMiD treatment|Participants with MM treated with IMiDs
80025274|NCT06160167|Drug|No IMiD treatment|Participants with MM not treated with IMiDs
80025275|NCT06160167|Drug|Systemic therapy|Participants with MM treated with systemic therapy
80025276|NCT06160154|Other|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
79730808|NCT02858271|Drug|AKB-9778 subcutaneous injection|
79730809|NCT02644681|Procedure|Aortic Aneurysm, Thoracic surgery|
79730810|NCT02859987|Procedure|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
79730811|NCT02859987|Procedure|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
80025277|NCT06160141|Other|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
80025278|NCT06160115|Device|Flow cytometry|"Profiling of NK cells using flow cytometry on peripheral blood and bone marrow aspirate samples.~Isolation and identification of pathogens causing BSI and bacterial drug susceptibility testing using VITEK compact fully automatic microbial identification instrument."
79570859|NCT01785264|Procedure|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
79730812|NCT02859987|Device|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
79865122|NCT00568451|Drug|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
79865123|NCT00568451|Drug|paclitaxel|100mg/m^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
79865124|NCT00568451|Drug|temozolomide|150mg/m^2 at cycle 1, 200mg/m^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
79268851|NCT02175511|Device|Cloud-based home BP monitoring|"a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network."
79268852|NCT02173483|Procedure|Quadriceps graft|
79268853|NCT05653076|Dietary Supplement|Hibiscus sabdariffa extract|Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
79268854|NCT02173561|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
79268855|NCT02173561|Behavioral|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
79730813|NCT02644915|Drug|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
79730814|NCT02644915|Drug|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg"
79730815|NCT00960375|Behavioral|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
79865125|NCT00459537|Drug|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
79865126|NCT00459537|Drug|amorolfine nail lacquer|5 % amorolfine nail lacquer
79865127|NCT00819299|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
79865128|NCT03850509|Drug|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
79268856|NCT02178319|Procedure|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
79865129|NCT03850509|Drug|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
79865130|NCT00635999|Behavioral|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
79865131|NCT00635999|Other|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
79865132|NCT00635999|Behavioral|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
79865133|NCT03866421|Diagnostic Test|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
79865134|NCT03866421|Diagnostic Test|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
79865135|NCT03866421|Device|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
79268857|NCT02178319|Procedure|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
80025279|NCT06160102|Other|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
79730816|NCT00960375|Behavioral|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
79730817|NCT00651703|Biological|CYT004-MelQbG10 + Montanide|
79730818|NCT00651703|Biological|CYT004-MelQbG10 + Montanide + Imiquimod|
79730819|NCT00651703|Biological|CYT004-MelQbG10 + Imiquimod|
79730820|NCT00651703|Biological|CYT004-MelQbG10 intra nodal injection|
79730821|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
79730822|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
79865136|NCT03866421|Diagnostic Test|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
79865137|NCT03866421|Diagnostic Test|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
79865138|NCT03866421|Radiation|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
79865139|NCT03866421|Biological|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
79865140|NCT03866421|Other|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
80025280|NCT06160089|Other|Isoinertial training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
79730823|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
79865141|NCT00819377|Drug|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
79865142|NCT00819377|Drug|Normal saline|5 ml normal saline by inhalation over 15 min
79865143|NCT01023165|Procedure|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
79268858|NCT02175589|Other|Colchicine Cessation|Colchicine Cessation
79730824|NCT00632242|Drug|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
79865144|NCT01025895|Procedure|acl reconstruction - double bundle technique|
79865145|NCT01025895|Procedure|acle reconstruction - single bundle technique|
79865146|NCT01023243|Other|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
79865147|NCT01023243|Other|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
79865148|NCT01023321|Drug|GLPG0555|single ascending doses, oral solution
79865149|NCT01023321|Drug|placebo|single dose, oral solution
79865150|NCT01023321|Drug|GLPG0555|multiple dose, oral solution, 7 or 14 days
79865151|NCT01023321|Drug|placebo|multiple dose, oral solution, 7 or 14 days
79865152|NCT03762915|Drug|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
79865153|NCT00469209|Drug|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
79865154|NCT00469209|Drug|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
79865155|NCT00469209|Drug|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
79865156|NCT00469209|Drug|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
79268859|NCT05438186|Drug|Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
79268860|NCT02178397|Drug|ERLOTINIB WITH CHEMOTHERAPY|
79268861|NCT02178397|Drug|CHEMOTHERAPY ONLY|
79730825|NCT00632242|Drug|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
80025281|NCT06160089|Other|Gravitational training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
79865157|NCT01322919|Procedure|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
80025282|NCT06160076|Device|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
80025283|NCT06160076|Device|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
80025284|NCT06160063|Behavioral|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
80025285|NCT06160037|Behavioral|Transportation and Developmental Screening|Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
80025286|NCT06160037|Behavioral|Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|"Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life."
80025287|NCT06160024|Behavioral|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
80025288|NCT06160011|Other|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
79268862|NCT04072016|Device|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
80025289|NCT06160011|Other|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
80025290|NCT06160011|Other|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
80025291|NCT06159985|Procedure|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
80025292|NCT06159972|Device|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
80025293|NCT06159959|Drug|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
79268863|NCT02173639|Drug|BI 1356/metformin|fixed dose combination tablet
79730826|NCT02644837|Device|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
79730827|NCT02644837|Device|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
79730828|NCT02644837|Device|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
79730829|NCT02644837|Device|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
79730830|NCT02644837|Device|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
79730831|NCT02644837|Device|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
79865158|NCT00635219|Drug|Placebo|capsules; daily; orally
79268864|NCT02173639|Drug|BI 1356|
79268865|NCT02173639|Drug|Metformin|
79730832|NCT02644837|Device|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
79865159|NCT00635219|Drug|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
79865160|NCT00635219|Drug|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
80025294|NCT06159946|Device|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
79570860|NCT01785264|Procedure|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
79730833|NCT02644837|Device|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
79730834|NCT02964585|Drug|Canagliflozin|100 mg
79730835|NCT02964585|Drug|Placebo|1 tablet daily for 16 weeks
79865161|NCT00635219|Drug|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
79865162|NCT00635219|Drug|Duloxetine|60 mg/day; encapsulated capsules; orally
79865163|NCT03987477|Behavioral|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
80025295|NCT06159920|Diagnostic Test|diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.
79401259|NCT04680000|Other|BCBT-CP Booster|The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
79401260|NCT04677647|Other|OurChild mHealth Digital Platform|The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
79730836|NCT00637936|Drug|Oxygen|Inspiratory fraction during anaesthesia
79730837|NCT02644603|Procedure|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
79730838|NCT02640703|Biological|Infanrix + Prevenar 13|Different time of application
79730839|NCT00630279|Drug|Placebo|Placebo
79865164|NCT03987477|Behavioral|Waiting list|Waiting list procedure for the control group.
79865165|NCT00363766|Drug|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
79865166|NCT00468819|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
79865167|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
79865168|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
79865169|NCT01026129|Drug|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
79865170|NCT01026207|Device|Polysomnography|Sleep study polysomnography compared with portable monitoring
79401261|NCT04665297|Behavioral|International Guide for Monitoring Child Development|Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
79865171|NCT01026285|Drug|Risperidone Long-Acting injectable or oral antipsychotics|According to label
79865172|NCT01026363|Drug|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
79865173|NCT01026363|Drug|Calcitriol|0.25 mcg tablet once daily for 14 days
79865174|NCT01026441|Device|Vela100 (Aesthetic)|6 treatments once a week
79865175|NCT01322997|Device|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
79730840|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
79730841|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
79730842|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
79730843|NCT03850522|Biological|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
79865176|NCT01322997|Behavioral|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
79865177|NCT01322997|Device|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
79865178|NCT01023399|Drug|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
79865179|NCT01026519|Drug|REGN88|Single dose of REGN88 and 43 day follow up.
79865180|NCT01026519|Other|Placebo|Placebo to match REGN88 administration
79865181|NCT00451191|Drug|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
79865182|NCT00451035|Drug|LBH589|
79865183|NCT00468585|Drug|Capecitabine|
79865184|NCT00468585|Drug|Bevacizumab|
79268866|NCT05534906|Other|Blood & Urine Samples|Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time
79268867|NCT05534906|Other|Imaging|MRI & MRE Scans
79268868|NCT05534828|Diagnostic Test|A consultation|A consultation at three months of discharge from the intensive care unit in the population of patients surviving a multivalent intensive care unit stay
79268869|NCT02175667|Procedure|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
79401262|NCT04663750|Procedure|Pars plana vitrectomy|Pars plana vitrectomy
79401263|NCT04663750|Drug|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
79401264|NCT04663750|Drug|subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls|Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
79401265|NCT04663750|Drug|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.
79865185|NCT01021839|Procedure|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
79865186|NCT01026597|Drug|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
79865187|NCT01026597|Drug|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
79865188|NCT00450801|Drug|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
79401266|NCT04648631|Device|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
79401267|NCT04645680|Other|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
79401268|NCT04645680|Other|Dietary Intervention|Whole foods diet
79401269|NCT04645680|Other|Quality-of-Life Assessment|Ancillary studies
79401270|NCT04645680|Other|Questionnaire Administration|Ancillary studies
79401271|NCT04639466|Drug|Placebo Administration|Given IM in the non-dominant upper arm
79401272|NCT04639466|Biological|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
79865189|NCT00450801|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
79865190|NCT00450801|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
79865191|NCT00450801|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
79865192|NCT00450801|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
79865193|NCT00450801|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
79865194|NCT00450801|Drug|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
79865195|NCT00450801|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
79268870|NCT02173717|Drug|Dabigatran etexilate|150 mg Dabigatran etexilate
79268871|NCT02173717|Drug|Rifampicin|600 mg Rifampicin
80025296|NCT06159907|Diagnostic Test|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
80025297|NCT06159881|Procedure|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
79730844|NCT02640781|Procedure|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
80025298|NCT06159855|Other|Intervention group: nurse-led education for bowel preparation of colonoscopy|"PRE-TEST~a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~INTERVENTION~Patients will be given face-to-face training in the clinic training room of the unit.~After face-to-face training is given, an educational brochure will be given to the patient.~If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~LAST TEST~Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale."
80025299|NCT06159842|Combination Product|Aminolevulinic Acid 20% Topical Solution with Blue Light|Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
79268872|NCT04926194|Biological|Decidual stromal cells (DSC)|DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
79730845|NCT02640781|Procedure|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
79401273|NCT04634604|Drug|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
79401274|NCT04634604|Procedure|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
79401275|NCT04631601|Drug|Acapatamab|Acapatamab will be administered as an intravenous (IV) infusion.
79401276|NCT04631601|Drug|Enzalutamide|Enzalutamide will be administered orally.
79865196|NCT00450801|Drug|Thalidomide|Maintenance therapy.
79730846|NCT00651781|Drug|Bortezomib|2 times per week of Velcade administration.
79730847|NCT04166617|Other|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
79730848|NCT04166617|Other|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
79730849|NCT02646787|Behavioral|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
79730850|NCT02646787|Behavioral|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
79865197|NCT00450801|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
79865198|NCT00450801|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
79865199|NCT00450801|Drug|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
79401277|NCT04631601|Drug|Abiraterone|Abiraterone will be administered orally.
79401278|NCT04631601|Drug|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
79865200|NCT00450801|Drug|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
79865201|NCT00450801|Drug|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
79865202|NCT01023555|Other|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
79865203|NCT01023633|Drug|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
79865204|NCT01026675|Procedure|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
79570861|NCT01785290|Drug|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~aged ≥ 80 years~weight ≤ 50 kg~liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
79570862|NCT01785290|Drug|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~aged ≥ 80 years~weight ≤ 50 kg~liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
79570863|NCT01785290|Drug|Placebo|Sodium Chloride 0.9%
79570864|NCT01785303|Behavioral|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
80025300|NCT06159829|Behavioral|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
80025301|NCT06159803|Behavioral|Qualitative Interview|One-to-one semi-structured interviews and Think Aloud interviews
80025302|NCT06159790|Drug|GME751|Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
79865205|NCT00458211|Drug|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
80025303|NCT06159790|Drug|Keytruda-EU|Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
80025304|NCT06159764|Procedure|Cardioneuroablation|radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
79865206|NCT00450723|Drug|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
80025305|NCT06159751|Other|serum albumin level|serum albumin level in gonarthrosis
79401279|NCT04629833|Biological|MC0518|MC0518 will be intravenously infused immediately after thawing.
79865207|NCT00450723|Procedure|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
79865208|NCT00450723|Procedure|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
80025306|NCT06159712|Other|Blood samples|Extra blood samples
79865209|NCT00450723|Procedure|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
79865210|NCT00450723|Procedure|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
79570865|NCT01785303|Procedure|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
80025307|NCT06159686|Drug|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
80025308|NCT06159686|Drug|Placebo|The application of the placebog cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
80025309|NCT06159608|Drug|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
80025310|NCT06159608|Other|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
80025311|NCT06159595|Device|Intracranial electrodes|Surgically-implanted intracranial electrodes.
80025312|NCT06157424|Other|Thread Embedding Acupuncture|Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
79401280|NCT04629833|Biological|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
79401281|NCT04628429|Drug|Erenumab|anti-CGRP-receptor monoclonal anti-body
79401282|NCT04628429|Drug|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
79401283|NCT04628429|Drug|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
79570866|NCT01785329|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
79730851|NCT02646865|Behavioral|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
79730852|NCT02646865|Behavioral|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol
79730853|NCT00957801|Drug|Testosterone injection|100 mg single IM injection
79730854|NCT00957801|Drug|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
79730855|NCT00957801|Drug|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
80025313|NCT06157424|Other|Auricular acupuncture|Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
79730856|NCT02640469|Other|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
79570867|NCT01785355|Other|Dental treatment|"The preliminary stage deals with:~assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~education of the patient regarding correct oral hygiene habits;~Phase I Therapy:~plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~evaluation of response to the treatment~Phase II Therapy - surgical phase:~extraction of hopeless teeth~evaluation of the surgical results.~Maintenance phase:~periodic reevaluation of plaque and calculus and of periodontal conditions."
80025314|NCT06157424|Other|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
80025315|NCT06154525|Other|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
80025316|NCT06154525|Dietary Supplement|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
80025317|NCT06154525|Dietary Supplement|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
79570868|NCT01785368|Other|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
80025318|NCT06153368|Drug|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
80025319|NCT06152913|Behavioral|HANDS-ON treatment|"The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist."
79730857|NCT02640469|Other|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
79865211|NCT00450723|Radiation|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
79865212|NCT01026753|Behavioral|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
79401284|NCT04623515|Other|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
80025320|NCT06152874|Other|consumption of glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
80025321|NCT06152874|Other|consumption of glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
79570869|NCT01785368|Other|Baseline observation|During this period of the study, baseline data will be collected.
79570870|NCT01785381|Other|Added value of coordinator|Added value of coordinator
80025322|NCT06152874|Other|consumption of Bread A and oral processing|bread made with 95% durum wheat fine semolina (< 400 micrometer) + 5% of gluten + 1.2% of yeast + 1% of salt + 59%of water) (portion corresponding to 50 g available carbohydrates) + 250 mL water
80025323|NCT06152874|Other|consumption of Bread B and oral processing|bread made with 80% durum wheat fine semolina (< 400micrometer) + 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
80025324|NCT06152874|Other|consumption of Bread C and oral processing|bread made with 80% durum wheat coarse semolina (> 500micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
79570871|NCT01785394|Drug|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
79570872|NCT01785407|Dietary Supplement|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
79865213|NCT00467961|Combination Product|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
80025325|NCT06152627|Behavioral|Standard of care voice therapy with novice clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
80025326|NCT06152627|Behavioral|Standard of care voice therapy with expert clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
80025327|NCT06152094|Other|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
79401285|NCT04621448|Behavioral|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~repetition with variation (to promote procedural learning);~progressive, functional movements (to improve daily function);~slow pace and step-by-step instruction (to minimize cognitive demands);~participant-centered goal orientation (to enhance personal meaningfulness of movements);~body awareness, mindfulness and breathing (to encourage present-centeredness);~social interaction (to promote meaningful connection); and~positive emotions (to promote feelings of well-being."
79401286|NCT04618172|Other|Exercise|30 minute long exercises twice a week
79730858|NCT02640469|Other|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
79401287|NCT04603066|Drug|Ondansetron 16 mg with Tariquidar|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
79401288|NCT04603066|Drug|Ondansetron 16 mg with Placebo|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
79401289|NCT04602026|Other|Best Practice|Receive standard of care
79401290|NCT04602026|Behavioral|Exercise Intervention|Complete home exercise intervention
79401291|NCT04602026|Procedure|Physical Therapy|Undergo physical therapy
79401292|NCT04602026|Other|Questionnaire Administration|Ancillary studies
79401293|NCT04594291|Procedure|MRI scans|This study does not involve any intervention or new treatment. We will conduct MRI scans of the kidneys, muscles, abdomen and heart at baseline, 12 and 24 months after hospital discharge. The MRI scan will take 60-70 minutes in total.
79401294|NCT04585633|Other|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
79570873|NCT01785446|Drug|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
79570874|NCT01785446|Drug|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
79570875|NCT01785485|Other|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
79570876|NCT01785498|Behavioral|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
79570877|NCT01785511|Radiation|UVA Radiation|UVA radiation exposure for 20 minutes
79570878|NCT01785550|Other|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
79570879|NCT01785576|Behavioral|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
79730859|NCT02640391|Other|colonoscopy|
79730860|NCT02646709|Drug|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
79730861|NCT02646709|Drug|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
79865214|NCT03996213|Other|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
79865215|NCT03996213|Other|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
79865216|NCT04889157|Drug|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
79268873|NCT04067648|Drug|Sufentanil Injection|three doses of sufentanil was intravenously given during anesthesia induction
79865217|NCT04889157|Drug|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
79865218|NCT00457821|Drug|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
80025328|NCT06152094|Other|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
79268874|NCT02173795|Drug|Berodual® Respimat®|
79268875|NCT02173795|Drug|Berodual® MA HFA|
79401295|NCT04585633|Other|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
79401296|NCT04585633|Other|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
79401297|NCT04581200|Behavioral|Lift|The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.
79570880|NCT01785589|Procedure|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
79570881|NCT01785693|Drug|levobupivacaine, clonidine|
79570882|NCT01785732|Procedure|Renal Denervation|Sympathetic renal denervation via renal arteries
79570883|NCT01785745|Other|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
79730862|NCT02646709|Drug|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
79730863|NCT02646709|Drug|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
79730864|NCT00651859|Drug|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
79730865|NCT00651859|Drug|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
79730866|NCT00651859|Drug|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
79730867|NCT02955823|Drug|Rituximab-Dexamethasone-Lenalidomide|"st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~if <PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~if <PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
79730868|NCT02644447|Biological|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
79865219|NCT00457821|Drug|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
79865220|NCT00457821|Drug|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
79865221|NCT00457821|Drug|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
79865222|NCT00633893|Drug|Apixaban|Tablets, Oral, twice daily, 12 months
79865223|NCT00633893|Drug|Placebo|Tablets, Oral, twice daily, 12 months
79865224|NCT02550587|Behavioral|satisfaction|anesthesia satisfaction rates
79865225|NCT02550665|Drug|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
79865226|NCT00819455|Behavioral|Experimental|Active Life style modification-motivation by I.T technology
79865227|NCT00819455|Behavioral|Control arm (usual care/standard care arm)|Life style modification only once
79865228|NCT00819533|Device|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
79865229|NCT00819611|Behavioral|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
80025329|NCT06151873|Diagnostic Test|Adapted sport|control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.
79268876|NCT02175901|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
79268877|NCT02175901|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
79268878|NCT02175901|Drug|Amoxicillin|antibiotic of each quadruple therapy
79268879|NCT02175901|Drug|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
79268880|NCT02175901|Drug|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
79268881|NCT02178631|Behavioral|Deprexis|Online self-help
79268882|NCT02178631|Other|CAU|Care as usual
79268883|NCT02173873|Drug|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
79268884|NCT02176057|Drug|Azithromycin|
79570884|NCT01785745|Other|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
80025330|NCT06151873|Diagnostic Test|Adapted sport|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
80025331|NCT06151613|Device|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
80025332|NCT06150768|Device|Cobalt Chromium Removable Partial Denture|The patient will receive Removable Partial Denture to restore missing teeth in Kennedy Class II cases.
80025333|NCT06150768|Device|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|The patient will receive Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
79268885|NCT02173951|Drug|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6 will start deferiprone 75 mg/kg/d"
79865230|NCT00819611|Behavioral|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
80025334|NCT06150768|Device|Implant-Supported Zirconia Fixed Partial Denture.|The patient will receive Implant-Supported Zirconia Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
79730869|NCT02644447|Biological|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
79730870|NCT02646631|Other|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
79865231|NCT04044677|Device|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
79865232|NCT04044677|Device|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
79865233|NCT00819845|Drug|carvedilol|carvedilol vs ramipril
79730871|NCT02646631|Behavioral|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
80025335|NCT06149247|Drug|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
79268886|NCT02174029|Procedure|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
79268887|NCT02174029|Procedure|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
79268888|NCT02174029|Procedure|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
79268889|NCT01664078|Device|Endovascular AAA repair with InCraft®|
79268890|NCT03537625|Dietary Supplement|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
79730872|NCT02646631|Behavioral|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
79865234|NCT00819845|Drug|ramipril|carvedilol vs ramipril
79865235|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
80025336|NCT06149247|Drug|Mechlorethamine Topical Gel|Valchlor is an FDA-approved drug for the treatment of CTCL.
80025337|NCT06148506|Other|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
79570885|NCT01785758|Drug|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
80025338|NCT06148506|Other|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
79268891|NCT02176135|Drug|Auranofin|3 mg tablets
79268892|NCT02176213|Drug|Pomalidomide|4 mg PO x 21 days
79268893|NCT02176213|Drug|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
79570886|NCT01785784|Drug|rhGM-CSF Gel|
79570887|NCT01785797|Device|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
79865236|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
79865237|NCT00820001|Behavioral|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
80025339|NCT06146582|Behavioral|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
80025340|NCT06145256|Device|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
79730873|NCT02646631|Other|Educational Materials|Printed educational materials on the management of epilepsy
79730874|NCT02535793|Other|blood test (four dry tubes 7ml) and prick tests|
79730875|NCT00957723|Device|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
79730876|NCT02646397|Drug|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
79865238|NCT00820001|Behavioral|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
79268894|NCT02176213|Drug|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
79268895|NCT03537547|Other|GeneSight Psychotropic test|GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
79730877|NCT02646397|Drug|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
79730878|NCT02646397|Drug|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
79268896|NCT03537547|Drug|FDA-approved antidepressant or antipsychotic treatment|Participant is treated with medications included in the GeneSight Psychotropic product.
79268897|NCT04771364|Other|ASAP care's protocol|Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).
79268898|NCT02174107|Radiation|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1*8 Gy; 5*4 Gy and 10*3 Gy
79401301|NCT04575142|Device|CO2 laser|"the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues."
79268899|NCT02174107|Procedure|Percutaneous vertebroplasty|
79401302|NCT04562714|Device|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
79730879|NCT00653731|Behavioral|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
79730880|NCT00653731|Behavioral|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
79730881|NCT00653731|Behavioral|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
79730882|NCT00653731|Behavioral|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
79730883|NCT02646553|Other|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
79730884|NCT04204395|Device|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
79730885|NCT02640079|Behavioral|Cognitive behavioral therapy|
79730886|NCT02859831|Other|water samples|
79730887|NCT04279353|Other|Mindfulness Based Intervention|this intervention is a 4 weeks program with logbook and follow up during intervention
79730888|NCT04282863|Procedure|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
80025341|NCT06140147|Other|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
80025342|NCT06140147|Other|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
80025343|NCT06140030|Behavioral|Mindfulness training|Mindfulness-training mobile health application
80025344|NCT06136793|Behavioral|HomeStyles-China|2-arm ~10 week educational intervention
80025345|NCT06132282|Behavioral|Substance Use and Health Risk Intervention (SUHRI)|Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
80025346|NCT06121271|Drug|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
80025347|NCT06119607|Device|TRIFLO Heart Valve|Surgical Aortic Valve Replacement - Mechanical Valve
79570888|NCT01785823|Other|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
79730889|NCT04282863|Procedure|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
80025348|NCT06119178|Device|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
80025349|NCT06119178|Device|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
80025350|NCT06117345|Behavioral|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
79268900|NCT05425160|Other|Progressive lower limb activities (Chair rise and Step ups)|Progressive lower limb activities (Chair rise and Step ups) were be carried out weekly for upto 6 weeks. Before initiation, cardiopulmonary parameters i.e. Heart rate, oxygen saturation, cardiac output and stroke volume were measured at baseline and later at the termination of activity on each week. Initially, five repeated chair rise were conducted through SPPB and the time was noted to complete the task and step ups through 6MWD for a total period of 30 min. Lastly, fatigue component was assessed via FAS.
79268901|NCT05425160|Other|Standard aerobic exercise i.e. low intensity walking|Standard aerobic exercise i.e. low intensity walking were conducted in both the groups. Follow up phone calls and 1 OPD visit were scheduled accordingly
79268902|NCT02174185|Behavioral|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
79401303|NCT04562714|Other|Diabetes self-management education|"The DSME curriculum is compromised of:~Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~Education modules for both in-person and remote delivery;~Handouts to support the curriculum objectives; and~Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
79401304|NCT04557124|Behavioral|USS|social cognitive training
79730890|NCT00652795|Drug|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
79730891|NCT00652795|Drug|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
79730892|NCT03778021|Behavioral|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
79730893|NCT03778021|Behavioral|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
79268903|NCT04305002|Drug|Exenatide|Injections, 2 mg once weekly for 18 months
79401305|NCT04557124|Behavioral|MovingForward|problem solving training
79570889|NCT01785823|Other|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
79268904|NCT04305002|Drug|Placebo|Injections, once weekly for 18 months
79268905|NCT03367403|Drug|Donanemab|Administered IV
79268906|NCT03367403|Drug|Placebo|Administered IV
79268907|NCT03367403|Drug|LY3202626|Administered orally
79865239|NCT00820001|Other|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
80025351|NCT06105411|Diagnostic Test|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
80025352|NCT06097520|Other|VR Intervention|For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
80025353|NCT06096090|Drug|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
80025354|NCT06096090|Drug|Placebo|Placebo administration
80025355|NCT06095141|Drug|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
80025356|NCT06089135|Device|Intravascular Lithotripsy|Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
80025357|NCT06089135|Device|Cutting Balloon|Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
79401306|NCT04554420|Behavioral|Youth Participatory Action Research-Mental Health Curriculum|The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
79401307|NCT04553770|Drug|Anastrozole|Given PO
79401308|NCT04553770|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79865240|NCT00820001|Other|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
79865241|NCT00457743|Drug|Sunitinib malate (SU011248)|SU011248
79865242|NCT00820079|Drug|ADX10059|oral administration
79865243|NCT00820079|Drug|ADX10059 Matching Placebo|oral administration
80025358|NCT06084845|Procedure|Biospecimen Collection|Undergo blood sample collection
80025359|NCT06084845|Drug|Carboplatin|Given IV
80025360|NCT06084845|Procedure|Chest Radiography|Undergo chest x-ray
80025361|NCT06084845|Drug|Cisplatin|Given IV
80025362|NCT06084845|Procedure|Computed Tomography|Undergo CT and/or PET-CT
79401309|NCT04553770|Biological|Trastuzumab Deruxtecan|Given IV
79730894|NCT00911170|Drug|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
79730895|NCT00911170|Drug|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
79730896|NCT00911170|Biological|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
79730897|NCT00911170|Drug|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
80025363|NCT06084845|Radiation|Image Guided Radiation Therapy|Undergo IGRT
79401310|NCT04547309|Radiation|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
79401311|NCT04544956|Drug|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
79401312|NCT04544956|Drug|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
79865244|NCT00820157|Procedure|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
79865245|NCT00820157|Procedure|TACE|TACE alone or TACE followed by downstage resection for MNHCC
79865246|NCT00820313|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
79865247|NCT04044599|Drug|Gynoflor|VAGİNAL GYNOFLOR
79865248|NCT01023867|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
79865249|NCT00820391|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
79865250|NCT00820391|Behavioral|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
80025364|NCT06084845|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
80025365|NCT06084845|Procedure|Magnetic Resonance Imaging|Undergo MRI
80025366|NCT06084845|Procedure|Positron Emission Tomography|Undergo PET-CT
80025367|NCT06084845|Drug|Xevinapant|Given PO
80025368|NCT06081829|Drug|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
80025369|NCT06081179|Drug|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
80025370|NCT06081179|Drug|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
80025371|NCT06081179|Drug|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
79268908|NCT04743596|Device|High-Definition Videobronchoscopy|Endoscopic inspection and endobronchial biopsy with standard forceps during high-definition videobronchoscopy.
79865251|NCT03696303|Other|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
79730898|NCT02644213|Other|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~simulated road march using a virtual reality environment without additional load~simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~without physical or cognitive load (without march, waiting between performance evaluations) as control."
79730899|NCT00910975|Drug|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
79401313|NCT04543357|Other|Blood Draw|Blood Samples for NAb and ADA to AAV9
79401314|NCT04535323|Other|Quality-of-Life Assessment|Ancillary studies
79570890|NCT01785823|Other|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
79730900|NCT00910975|Drug|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
79268909|NCT04719182|Other|Adjunctive therapies|Determine and compare practice of adjunctive and supportive treatments for COVID-19
79268910|NCT04680728|Other|collection of biological parameters|haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
79401315|NCT04535323|Other|Questionnaire Administration|Ancillary studies
79401316|NCT04535323|Biological|Therapeutic Autologous Platelet-rich Plasma|Given via injection
79401317|NCT04532346|Drug|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
79401318|NCT04529304|Device|Bilateral Bispectral Index and EEG|"raw-EEG and spectrographic EEG-visualization based on the Medtronic Device Bilateral BiSpectral Index"
79730901|NCT04165057|Other|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
79730902|NCT00653887|Other|Biofeedback|4 sessions of biofeedback one session each week
79730903|NCT00653887|Other|Placebo|4 sessions, one each week, of discussion about anorectal disease
79401319|NCT04527146|Other|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
79570891|NCT01785836|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
79570892|NCT01785836|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
79570893|NCT01785836|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
79730904|NCT01167881|Drug|BI 10773|Medium dose once daily
79730905|NCT01167881|Drug|Glimepiride|1-4 mg once daily
79730906|NCT01167881|Drug|Placebo|Placebo matching BI 10773
79730907|NCT01167881|Drug|Placebo|Placebo matching Glimepiride
79730908|NCT02646085|Drug|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
79865252|NCT00820469|Drug|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
79865253|NCT00820469|Drug|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
79865254|NCT00450411|Radiation|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
79865255|NCT00450411|Radiation|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
79865256|NCT00815243|Procedure|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
79865257|NCT00815243|Procedure|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
80025372|NCT06061185|Device|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
79268911|NCT04680728|Other|collection of echographic parameters|echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
79304411|NCT04978233|Other|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
79865258|NCT02551289|Other|Gluten free diet|Patients will follow a gluten free diet
79268912|NCT04680728|Other|collection of clinical parameters|eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
79268913|NCT03297905|Behavioral|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
79401320|NCT04527146|Other|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the PennChart/EPIC electronic medical record dashboard.
79401321|NCT04527146|Other|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
79401322|NCT04520659|Biological|RSV LID/ΔM2-2/1030s|10^5 plaque-forming units (PFU); administered as nose drops
79401323|NCT04520659|Biological|Placebo|Administered as nose drops
79865259|NCT00815321|Biological|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
79570894|NCT01785836|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
79730909|NCT02639767|Drug|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m^2 for pemetrexed in combination with 75 mg/m^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
79730910|NCT02639767|Radiation|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
79730911|NCT02639767|Device|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
79730912|NCT04296136|Other|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
79730913|NCT02646241|Procedure|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
79730914|NCT02646241|Procedure|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB & unroofing biopsy.
79730915|NCT02639689|Device|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
79730916|NCT04829344|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
79730917|NCT04829344|Drug|Placebo|Placebo Topical Ophthalmic Solution
79730918|NCT04166305|Genetic|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
79268914|NCT03297905|Behavioral|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
79304412|NCT03288389|Dietary Supplement|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
79304413|NCT03288389|Dietary Supplement|Placebo|Placebo wafers
79304414|NCT03192631|Other|Financial incentive|Incentive of $15 Canadian
79401326|NCT04508530|Biological|Panzyga|Panzyga 10% IVIG
79401327|NCT04508530|Other|Placebo|Placebo
79570895|NCT01785862|Drug|Ibuprofen 25 mg|Lozenge, Oromucosal administration
79570896|NCT01785862|Drug|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
79570897|NCT01785901|Other|without interventions|without interventions
79730919|NCT04522960|Diagnostic Test|MEG+hdEEG+MRI|"We will perform several tests:~Neuropsychological testing to evaluate evolution of cognition during our study.~Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
79730920|NCT00960063|Drug|Temozolomide|
79730921|NCT00960063|Drug|Vincristine|
80025373|NCT06061172|Other|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~preferences (including a. treatment goals, and b. involvement of other persons in decision making);~activities (including a. activities and participation, and b. social support);~treatment (including a. problems with medication, and b. treatment burden);~complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
80025374|NCT06057454|Drug|R-5280|Modified Superior Starch
79268915|NCT02577146|Device|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
79570898|NCT01785927|Other|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
79570899|NCT01785940|Procedure|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
79730922|NCT00960063|Drug|Ifosfamide|
79730923|NCT00960063|Drug|Irinotecan|
79730924|NCT00960063|Biological|Robatumumab|
79730925|NCT00960063|Drug|Doxorubicin|
79730926|NCT00960063|Drug|Cyclophosphamide|
79730927|NCT00960063|Drug|Etoposide|
79865260|NCT00815399|Drug|Pioglitazone|15-45 mg/die
79865261|NCT00815399|Drug|Metformin|500-2000 mg/die
79865262|NCT00644969|Drug|placebo|Randomization 2:1 treatment to placebo
79865263|NCT00644969|Drug|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
79865264|NCT00815477|Behavioral|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
79865265|NCT00815477|Behavioral|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
79865266|NCT02551445|Behavioral|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
79865267|NCT00815555|Other|There is no intervention - this is an observational study|
79865268|NCT04016909|Procedure|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
80025375|NCT06057454|Other|Placebo|Food Grade Starch
80025376|NCT06053411|Drug|Diclofenac|25 mg capsule
80025377|NCT06053411|Dietary Supplement|curcumin|2,000 mg tablet
80025378|NCT06047301|Behavioral|Pathways|Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
80025379|NCT06047301|Behavioral|Enhanced Usual Care|Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
79268916|NCT02253797|Drug|14C-Tipranavir|
79730928|NCT02646319|Other|Laboratory Biomarker Analysis|Correlative studies
79730929|NCT02646319|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
79730930|NCT02646319|Other|Quality-of-Life Assessment|Ancillary studies
79730931|NCT00653965|Drug|Rosuvastatin|
79730932|NCT00653965|Drug|Atorvastatin|
79730933|NCT02646163|Drug|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
79730934|NCT00959907|Drug|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~Dysport®: 4 units will be injected in the left or right forehead side.~Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
79730935|NCT00912340|Drug|Everolimus|
79730936|NCT00912340|Biological|Trastuzumab|
79865269|NCT00812279|Other|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
80025380|NCT06040463|Behavioral|Diabetes Self-Management Training (DSMT)|The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education & portion control; Session 3 - Tips & Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.
80025381|NCT06040463|Behavioral|Remote Glucose Monitoring (RGM)|Remote Glucose Monitoring (RGM) is an automated process of transmitting glucose levels directly from a personal smartphone device to a healthcare provider using a remote data transmitter. Since 2020, Sinai has worked with Glooko Inc. to provide the RGM platform and technical assistance to patients and for Sinai providers to access data remotely. Via the app, patients can: document their glucose levels; sync data from a meter, insulin pump, pen or continuous glucose monitoring device; track their weight; log food and meals; access educational resources; track steps; and track blood pressure. Remotely uploading data provides patients with a direct line to their provider for regular feedback on progress and answers to questions between clinic visits. Patients also receive one one-hour education session on RGM and the Glooko application.
80025382|NCT06040463|Behavioral|Community Health Worker tailored support|CHWs are frontline public health workers who are trusted members of and/or have an unusually close understanding of the community served. The Center has two bilingual (Spanish/English) CHWs; additional bilingual CHWs will be added to the team to support the proposed study. While approaches will differ slightly depending on the patient and study condition, all patients paired with a CHW will be screened for social needs utilizing a standard social determinants of health (SDoH) screening tool, receive referrals to resources to address unmet social/health needs, and aided in navigating health and social systems.
80025383|NCT06035575|Behavioral|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
79730937|NCT01167257|Drug|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
79730938|NCT01167257|Drug|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
79730939|NCT01119846|Drug|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
79730940|NCT01119846|Drug|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
79730941|NCT01119846|Drug|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
79730942|NCT03775525|Drug|GZ17-6.02|Super enhancer Inhibition
79865270|NCT00812279|Other|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
79865271|NCT00812279|Other|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
79865272|NCT04046081|Drug|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
79865273|NCT00812435|Drug|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
79865274|NCT00812513|Drug|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
79268917|NCT02253797|Drug|Tipranavir|
79268918|NCT02253797|Drug|Ritonavir|
79268919|NCT03285971|Other|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
79730943|NCT03775525|Drug|Capecitabine|antimetabolite
79730944|NCT00654043|Drug|Torsemide|tablets, 20 Mg, single-dose
79730945|NCT00654043|Drug|Demadex|Tablets, 20 mg, single-dose
79730946|NCT02816632|Other|mRI|Neural bases of feedbacks' influence on decision making processes
79865275|NCT00812591|Procedure|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
79865276|NCT00812747|Other|observation|
79865277|NCT00820547|Biological|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
79865278|NCT00820547|Drug|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
79865279|NCT00820547|Drug|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
79268920|NCT02254109|Drug|BEA 2180 BR - rising dose|
79268921|NCT02254109|Drug|Placebo|
79304415|NCT03118141|Procedure|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
79304416|NCT03118141|Procedure|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
79268922|NCT04445753|Other|Tai Chi exercise|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
79268923|NCT04445753|Behavioral|Education (control group)|Individuals in the control group will also be trained on heart failure, which will be applied to individuals in the intervention group. The only attempt to be made to the control group will be education.
79268924|NCT02253875|Drug|Tipranavir (TPV)|
79268925|NCT02253875|Drug|Ritonavir|
79268926|NCT02253875|Drug|Omeprazole|
79730947|NCT02816632|Other|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
79401329|NCT04501666|Drug|Nemolizumab 30 mg|Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.
79730948|NCT04167007|Drug|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
79268927|NCT04408157|Behavioral|Self-management booklet (SWitCh: Stay well during COVID-19)|The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
79268928|NCT03819140|Drug|Yasmin|Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
79401330|NCT04501666|Drug|Placebo|Participants will receive matching placebo as SC injection.
79730949|NCT04167007|Drug|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
79730950|NCT01167179|Behavioral|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
79268929|NCT04406831|Procedure|Blood draw|Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw
79865280|NCT00820547|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
79865281|NCT00820547|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
79865282|NCT00815867|Drug|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
79865283|NCT00820625|Procedure|pulmonary vein isolation|common pulmonary vein isolation procedure
79865284|NCT00820625|Procedure|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
79268930|NCT03546023|Other|Patient Interview|BPI scores will be asked by the Doctor or the Research Nurse
79304417|NCT03118141|Procedure|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
79865285|NCT02550509|Device|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
79865286|NCT02550509|Device|elastography|elastography to patient with stoke
79865287|NCT00815945|Drug|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
79865288|NCT00815945|Drug|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
79865289|NCT00820703|Drug|Nexagon®|
79865290|NCT00820703|Drug|Nexagon® vehicle|
79865291|NCT00820781|Procedure|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
79865292|NCT00820781|Procedure|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
79865293|NCT00644423|Drug|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
79865294|NCT00644423|Drug|Placebo|Matching Placebo
79401331|NCT04497038|Drug|Cabozantinib|Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
79730951|NCT04345120|Drug|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
79730952|NCT04345120|Drug|SY-008 matching placebo|SY-008 matching placebo
79730953|NCT02951455|Behavioral|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
79730954|NCT02951455|Behavioral|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
79865295|NCT00820859|Behavioral|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
79865296|NCT00820859|Behavioral|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
79730955|NCT02951455|Behavioral|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
79730956|NCT02951455|Behavioral|PF|Whether the intervention is delivered by a peer facilitator.
79730957|NCT02951455|Behavioral|LC|Whether the intervention is delivered by a licensed clinician.
79865297|NCT00812825|Drug|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
79865298|NCT00812825|Drug|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
79865299|NCT00812825|Drug|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
79865300|NCT00812825|Drug|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
79865301|NCT00812825|Drug|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
79865302|NCT00820937|Procedure|Single photon emission computed tomography and Magnetic Resonance Imaging|
79865303|NCT00628355|Drug|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
79865304|NCT00628355|Procedure|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
79865305|NCT00627497|Procedure|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
79865306|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
79865307|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
79865308|NCT00627497|Device|Fusion|Posterolateral Interbody Fusion
79865309|NCT00648167|Drug|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
79865310|NCT00812903|Behavioral|Exercise|Training exercises chosen with background in knowledge of intelligent training
79865311|NCT03691623|Drug|EDP-938 Dose 1|Oral suspension for 5 days
79865312|NCT03691623|Drug|EDP-938 Dose 2|Oral suspension for 5 days
79865313|NCT03691623|Drug|Placebo|Oral suspension for 5 days
79865314|NCT03691623|Drug|EDP-938 Dose 3|Oral suspension for 5 days
79865315|NCT03691623|Drug|EDP-938 Dose 4|Oral suspension for 5 days
79865316|NCT03691623|Drug|Placebo|Oral suspension for 5 days
79865317|NCT00647699|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
79865318|NCT00647699|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
79865319|NCT00813059|Drug|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
79865320|NCT01323075|Procedure|Truncal block|Patients will have a truncal block during hand or wrist surgery.
79865321|NCT00467649|Drug|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
79865322|NCT00467649|Drug|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
80025384|NCT06034509|Other|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
80025385|NCT06032156|Dietary Supplement|Low Dose β-OHB|Ingestion of a low dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
80025386|NCT06032156|Dietary Supplement|High Dose β-OHB|Ingestion of a high dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
80025387|NCT06032156|Other|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
79268931|NCT04606238|Other|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
79268932|NCT03756935|Procedure|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
79570900|NCT01785966|Behavioral|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
79268933|NCT04597268|Drug|Dexmedetomidine|intravenous dexmedetomidine 1 mic/kg
79865323|NCT00467649|Drug|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
79268934|NCT04597268|Drug|Ketamine|ketamine 1mg/kg
79268935|NCT04597268|Drug|Midazolam|midazolam 0.05 mg/kg
79268936|NCT04395443|Other|medication reconciliation|the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
79730958|NCT02639611|Other|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
79730959|NCT02639611|Other|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
79730960|NCT01167023|Drug|Prasugrel|Administered orally, once daily for 30 days.
79730961|NCT01167023|Drug|Placebo|Administered orally, once daily for 30 days.
80025388|NCT06032000|Biological|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
79730962|NCT04273126|Behavioral|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
80025389|NCT06032000|Biological|Placebo|0.9% Sodium Chloride Solution
80025390|NCT06027814|Behavioral|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
80025391|NCT06025799|Behavioral|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
80025392|NCT06021808|Procedure|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
80025393|NCT06021808|Drug|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
80025394|NCT06017973|Diagnostic Test|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
79730963|NCT00654121|Drug|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
79730964|NCT04336852|Procedure|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
79865324|NCT01023945|Drug|ASP1941|oral
79865325|NCT01023945|Drug|Placebo|oral
79865326|NCT00450333|Drug|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
79268937|NCT03545555|Dietary Supplement|"Kale Preparation Kale Powder"|Effect of kale preparation kale powder on lipid status
79268938|NCT03545555|Dietary Supplement|"Kale Preparation Kale Extract"|Effect of kale preparation kale extract on lipid status
79268939|NCT03545555|Dietary Supplement|"Kale Preparation Flavonoid Extract"|Effect of kale preparation flavonoid extract on lipid status
79268940|NCT03545555|Dietary Supplement|Placebo|Effect of placebo on lipid status
79865327|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
79865328|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
79865329|NCT00450333|Drug|Dynepo|subcutaneous, Q2W for 24 weeks
80025395|NCT06017973|Diagnostic Test|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
79730965|NCT04336852|Procedure|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
79401332|NCT04481243|Biological|Pneumovax 23- pneumococcal polysaccharide|PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
80025396|NCT06017973|Diagnostic Test|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
79570901|NCT01785979|Drug|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
79730966|NCT04336852|Procedure|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
79730967|NCT03484117|Behavioral|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
79730968|NCT01166945|Drug|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
79865330|NCT00643565|Drug|Standard chemotherapy|As prescribed
79865331|NCT00643565|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
79570902|NCT01785979|Drug|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
79570903|NCT01785992|Drug|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
79730969|NCT01166945|Drug|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
79730970|NCT02639533|Drug|Pregabalin|Pregabalin 150 mg PO, single dose.
79730971|NCT02639533|Other|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
80025397|NCT06015685|Other|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
80025398|NCT06015685|Other|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population [patients who receive routine care (i.e., referral to subspecialty care)], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
80025399|NCT06010420|Device|insoles|Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
80025400|NCT06010407|Other|Survey|"Working Alliance Inventory~Attitude Towards Psychiatry-30 Scale"
80025401|NCT06010394|Other|conventional physiotherapy|ultrasound electrotherapy cold applications
79401333|NCT04481243|Procedure|Blood draw|6 ml blood draw at baseline and 6 months post immunization
79730972|NCT02885987|Device|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
79730973|NCT02646007|Biological|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
79730974|NCT02885675|Other|blood sampling|sample no more than 3ml
79730975|NCT02639377|Drug|Chlorhexidine gluconate|
79730976|NCT02639377|Drug|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
79401335|NCT04475783|Combination Product|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
79401336|NCT04474301|Other|Survey Administration|Complete survey
79865332|NCT00643487|Procedure|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
79865333|NCT00816179|Procedure|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
79865334|NCT02551211|Procedure|blood drawn|blood drawn
79865335|NCT02551211|Procedure|surgical resection of cancer|
79865336|NCT00450255|Biological|ziv-aflibercept|Given IV
80025402|NCT06010394|Other|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
80025403|NCT06010394|Other|payment oriented massage|10 / 15-minute massage treatments to reduce payment
80025404|NCT06006533|Other|taping|Kinesio taping will be applied in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay on the skin for 3 days.
80025405|NCT06006533|Other|massage|Percussive Massage will be applied to the posterior part of the sural fascia, including the plantar flexor muscles, 3 times a week for 5 minutes.
80025406|NCT06006481|Other|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
80025407|NCT06006377|Other|conventional physiotherapy|hotpack electrotherapy ultrasound exercises
80025408|NCT06006377|Other|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
79570904|NCT01786005|Device|Transcranial magnetic stimulation|
79570905|NCT01786018|Drug|Thiotepa|
79730977|NCT02639455|Behavioral|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
79865337|NCT00450255|Other|pharmacological study|Correlative studies
79570906|NCT01786018|Drug|Busulfan|
79570907|NCT01786018|Drug|Fludarabin|
79865338|NCT00816335|Procedure|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
79865339|NCT00816335|Drug|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
80025409|NCT06006364|Other|Survey|"The scales and forms used are respectively:~Demographic Information Form~Nomophobia Scale~Cornell Musculoskeletal Disorder Questionnaire~Smart phone Addiction Scale~Pittsburgh Sleep Quality Index~International Physical Activity Survey~McGill Melzack Pain Questionnaire"
80025410|NCT06005948|Other|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
80025411|NCT06005948|Other|control|No intervention will be made.
80025412|NCT06005922|Other|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
80025413|NCT06005922|Other|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
80025414|NCT06003907|Other|conventional|hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
80025415|NCT06003907|Other|traditional and complementary medicine methods|"The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing."
79268941|NCT04698980|Diagnostic Test|blood samples (venous and capillary at the fingertip)|For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
79570908|NCT01786018|Procedure|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10^7 CD3 cells/kg recipient weight and cryopreserved.
79570909|NCT01786018|Radiation|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
79570910|NCT01786018|Drug|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
79570911|NCT01786018|Drug|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
79570912|NCT01786018|Drug|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
79730978|NCT00910000|Drug|Vorinostat|
79730979|NCT00910000|Drug|Carboplatin|
79730980|NCT00910000|Drug|Gemcitabine|
79730981|NCT02885909|Device|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
79730982|NCT02885909|Procedure|Insulin protocal|Using insulin protocal based on glucose monitor
80025416|NCT06002984|Device|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
80025417|NCT05998330|Behavioral|LiverPAL|The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
80025418|NCT05992506|Diagnostic Test|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
79570913|NCT01786018|Drug|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
79570914|NCT01786018|Procedure|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
79730983|NCT02700945|Device|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
79268942|NCT04578548|Drug|Placebo|Matching placebo capsules administered orally with food
80025419|NCT05992103|Procedure|Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
79865340|NCT00816335|Procedure|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
80025420|NCT05992103|Device|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
79570915|NCT01786031|Other|metastasis biopsy|
80025421|NCT05992103|Device|Apollo ESG|Using only Apollo ESG as approved per label
80025422|NCT05989997|Drug|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
80025423|NCT05989932|Other|Upadacitinib|Real-world on the use of Upadacitinib
80025424|NCT05989308|Behavioral|Email|Email message sent to guardian with proxy information.
80025425|NCT05989308|Behavioral|Text|Text message sent to guardian with proxy information.
80025426|NCT05989308|Behavioral|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
80025427|NCT05984836|Behavioral|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
80025428|NCT05981430|Biological|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
80025429|NCT05981430|Biological|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
79570916|NCT01786044|Behavioral|MasterMed|An online interactive educational program
79570917|NCT01786044|Behavioral|Usual Care|
79570918|NCT01786057|Procedure|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
79570919|NCT01786057|Procedure|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
79570920|NCT01786070|Drug|Budesonide|
79570921|NCT01786070|Drug|placebo|
79730984|NCT05657171|Drug|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
79730985|NCT00652873|Drug|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
79268943|NCT04578548|Drug|GLPG2737|Capsules administered orally with food
80025430|NCT05980091|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
80025431|NCT05980091|Diagnostic Test|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
79268944|NCT04976543|Drug|nadroparin calcium-warfarin sequential anticoagulation|The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
79268945|NCT04565756|Drug|EXN407|EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
79570922|NCT01786083|Behavioral|Application of Problem Solving Technique|
79570923|NCT01786096|Drug|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
79570924|NCT01786122|Other|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
79570925|NCT01786122|Behavioral|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
79570926|NCT01786135|Drug|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
79570927|NCT01786200|Drug|Aspirin|
79570928|NCT01786200|Drug|Ibuprofen|
79570929|NCT01786226|Drug|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
79570930|NCT01786226|Drug|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
79570931|NCT01786278|Radiation|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
79730986|NCT00652873|Drug|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
79730987|NCT02887235|Other|Home Delivered, Medically Tailored Meals (HDTM)|
79730988|NCT00652171|Drug|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
80025432|NCT05980091|Drug|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
80025433|NCT05980091|Drug|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
80025434|NCT05980091|Diagnostic Test|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
80025435|NCT05980091|Procedure|Embryo transfer|Procedure in which embryo is transferred into the uterus
79570932|NCT01786278|Procedure|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
79570933|NCT01786304|Procedure|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
79730989|NCT00652171|Dietary Supplement|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
79865341|NCT00816335|Drug|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
80025436|NCT05974475|Radiation|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
80025437|NCT05974475|Procedure|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
80025438|NCT05973773|Drug|TAS6417|oral tablets/capsules
80025439|NCT05966233|Drug|R-DHAP|"Rituximab 375 mg/m2 IV on D0 or D1~Dexamethasone 40 mg/day IV or PO on D1-4~Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~Cisplatin 100 mg/ m2 IV on D1"
80025440|NCT05966233|Drug|Pola-R-DHAP|"Polatuzumab Vedotin 1.8 mg/kg IV on D1~Rituximab 375 mg/m2 IV on D0 or D1~Dexamethasone 40 mg/day IV or PO on D1-4~Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~Cisplatin 100 mg/ m2 IV on D1"
80025441|NCT05965726|Drug|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
79570934|NCT01786317|Device|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
79570935|NCT01786356|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
79730990|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
80025442|NCT05965726|Drug|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
80025443|NCT05965726|Drug|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
80025444|NCT05936385|Behavioral|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
80025445|NCT05936385|Behavioral|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
80025446|NCT05934175|Behavioral|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
80025447|NCT05934175|Behavioral|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
80025448|NCT05934162|Behavioral|Therapist-supported internet-delivered prolonged exposure|10 weeks of therapist-supported internet-delivered prolonged exposure
80025449|NCT05934162|Behavioral|Therapist-supported internet-delivered CBT|10 weeks of therapist-supported internet-delivered CBT
80025450|NCT05929430|Behavioral|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
80025451|NCT05929430|Behavioral|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
80025452|NCT05925309|Drug|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
79570936|NCT01786356|Other|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B&L MI60 in one eye
79570937|NCT01786382|Drug|PPI-668|
79730991|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
79730992|NCT04281303|Procedure|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
79730993|NCT02885831|Device|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
80025453|NCT05925309|Drug|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
79268946|NCT03232541|Other|Standard care|A) Ordinary nausea treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
79268947|NCT03232541|Device|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
79268948|NCT03232541|Device|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
79865342|NCT00816335|Procedure|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
79570938|NCT01786382|Drug|Midazolam|
80025454|NCT05921812|Diagnostic Test|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
80025455|NCT05919693|Drug|EYE103|EYE103 is a humanized antibody formulated for IVT administration
80025456|NCT05918185|Procedure|Biospecimen Collection|Undergo blood sample collection
79268949|NCT04373759|Other|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
80025457|NCT05918185|Other|Comprehensive Geriatric Assessment|Undergo cGA
79268950|NCT04373759|Other|Modified Rankin score|"0 - no symptoms at all~- no significant disability despite symptoms; able to carry out all usual duties and activities~- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~- Moderate disability; requiring some help, but able to walk without assistance~- Moderately severe disability; unable to walk and attend to bodily needs without assistance~- Severe disability; bedridden, incontinent and requiring constant nursing care and attention~- Dead"
79570939|NCT01786382|Drug|Omeprazole|
79570940|NCT01786382|Drug|Telaprevir|
79570941|NCT01786395|Drug|UF-021|
79570942|NCT01786395|Drug|Placebo|
79570943|NCT01786408|Device|TAP20-C|
79730994|NCT02859363|Genetic|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
79730995|NCT02656953|Other|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
79730996|NCT02656953|Other|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
79730997|NCT02645929|Behavioral|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
79730998|NCT01165307|Drug|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
79730999|NCT01165307|Drug|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
79731000|NCT01165307|Device|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
79731001|NCT02639143|Drug|ticagrelor|
79731002|NCT02639143|Drug|Clopidogrel|
79570944|NCT01786408|Device|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
79570945|NCT01786460|Other|Blood draw at Days 0, 7, 14, and 21|
79570946|NCT01786473|Drug|Testogel 1%|
79570947|NCT01786473|Drug|Placebo|
79570948|NCT01786499|Behavioral|Relaxation Response Training|
79570949|NCT01786525|Behavioral|House Calls|60-minute home based educational intervention which will be administered by a health educator
79570950|NCT01786525|Behavioral|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
80025458|NCT05918185|Other|Electronic Health Record Review|Medical records are reviewed
79570951|NCT01786538|Drug|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
80025459|NCT05918185|Other|Survey Administration|Complete surveys
80025460|NCT05908773|Drug|TTX-MC138-NODAGA-Cu64|TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
80025461|NCT05908669|Diagnostic Test|Deuterium metabolic imaging|MRI after oral administration of 75g of [6,6'-2H2]glucose.
80025462|NCT05905536|Device|Vitalstream|The device will be placed on the subject and monitoring started in the holding room on the morning of surgery. Monitoring will continue postoperatively until the pulmonary artery catheter (PAC) is removed (Standard of Care) or discharged, or at study team discretion. At Intensive Care Unit (ICU) admittance and again 3 hours later a straight leg raise will be done to monitor for changes in hemodynamics.
80025463|NCT05904652|Device|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
79268951|NCT03701828|Procedure|Weight loss surgery|All surgery types will be included. However, only participants scheduled for surgery with collaborating surgeons will be included. Surgery is not provided by study team.
79268952|NCT03546725|Device|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
79570952|NCT01786538|Drug|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
79731003|NCT02536027|Procedure|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
79731004|NCT02645773|Device|non-ablative laser|non-abaltive laser pre, immediate and post wounding
79268953|NCT05534048|Biological|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
80025464|NCT05904652|Device|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
80025465|NCT05903170|Device|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
79570953|NCT01786577|Other|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
79570954|NCT01786577|Behavioral|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
80025466|NCT05903170|Device|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
79731005|NCT02644057|Drug|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
79731006|NCT02644057|Drug|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
80025467|NCT05897385|Drug|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
79268954|NCT05534048|Biological|Comirnaty®|0.45 mL concentrate in a 2 mL clear multidose vial (type I glass) with a stopper (synthetic Bromo-butyl rubber) and a purple flip-off plastic cap with aluminum seal. Each vial contains 6 doses.
79304418|NCT03292445|Procedure|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
79731007|NCT00960999|Radiation|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
80025468|NCT05897385|Drug|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
80025469|NCT05881811|Drug|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1~D4 200mg cimetidine QID from D1~D4
80025470|NCT05878223|Device|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
80025471|NCT05875181|Device|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
80025472|NCT05875181|Device|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
80025473|NCT05871177|Device|Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt|The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight [32 mg (HHA) + 32 mg (LHA) / 2 ml]
80025474|NCT05863884|Behavioral|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
80025475|NCT05863039|Other|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
80025476|NCT05863039|Other|Regular training type 1|Strength training of the lower leg muscles using high loads
79731008|NCT00960999|Radiation|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
79731009|NCT00654277|Drug|Ondansetron|ODT, 8 mg, single-dose
79570955|NCT01786616|Drug|Formoterol|
80025477|NCT05863039|Other|Regular training type 2|Strength training of the lower leg muscles using low loads
79401337|NCT04472260|Procedure|Verticalization and Prone position|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
79570956|NCT01786655|Drug|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
79731010|NCT00654277|Drug|Zofran|ODT, 8 mg, fasting conditions
79731011|NCT01124838|Drug|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
79731012|NCT01124838|Drug|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
79731013|NCT01124838|Drug|Placebo|Administered by subcutaneous injection
79731014|NCT02639221|Drug|PXT002331|
79731015|NCT00959751|Drug|NXN-188|200 mg capsules, 600 mg, PRN
79731016|NCT00959751|Drug|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
80025478|NCT05859295|Device|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
80025479|NCT05849714|Other|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
80025480|NCT05849714|Other|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
79401338|NCT04471779|Other|Disclosure of APOE genotype|Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
79570957|NCT01786655|Drug|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
79570958|NCT01786655|Drug|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
79570959|NCT01786655|Other|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
79570960|NCT01786681|Procedure|Positive pressure|
79570961|NCT01786694|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
79731017|NCT00630435|Drug|Premarin®/MPA formulation A|
79731018|NCT00630435|Drug|Premarin®/MPA formulation B|
80025481|NCT05849090|Drug|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
80025482|NCT05849090|Drug|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
80025483|NCT05847361|Diagnostic Test|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
79570962|NCT01786733|Behavioral|Behavioral Activation|
79570963|NCT01786733|Behavioral|Supportive Therapy|
79570964|NCT01786746|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
79731019|NCT00630435|Drug|Premarin®/MPA formulation C|
79731020|NCT00630435|Drug|Premarin®/MPA currently marketed product|
79731021|NCT02858193|Drug|1.35 g SCMC- lys powder|1.35 g SCMC- lys powder for oral solution
80025484|NCT05846646|Drug|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
80025485|NCT05846646|Drug|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
79731022|NCT02858193|Drug|Fluifort® syrup|SCMC-lys Syrup 90 mg/ml
80025486|NCT05846646|Radiation|PULSAR|1st day of Cycles 1, 2 and 3.
79570965|NCT01786746|Behavioral|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
79731023|NCT02858115|Other|Fluid challenge|100 ml of crystalloid was infused over 1-min
79401339|NCT04468919|Behavioral|BCI-FIT multi-modal access|Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.
79570966|NCT01786759|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
79570967|NCT01786759|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
79731024|NCT02858115|Other|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
79731025|NCT00630591|Behavioral|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
79731026|NCT00630591|Behavioral|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
79731027|NCT00630591|Behavioral|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
79570968|NCT01786772|Other|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
79731028|NCT02581215|Drug|mFOLFIRINOX|"mFOLFIRINOX:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
79731029|NCT02581215|Drug|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
79731030|NCT02581215|Other|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
79731031|NCT04282941|Drug|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
80025487|NCT05846451|Dietary Supplement|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
79731032|NCT04282941|Drug|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
79731033|NCT04280913|Other|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
80025488|NCT05846451|Drug|Oxycodone|Immediate-release oral tablet, 10 mg
80025489|NCT05844033|Other|Screening|Blood tests
79731034|NCT04282707|Procedure|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
79731035|NCT04282707|Other|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
79731036|NCT00910858|Drug|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
79731037|NCT00910858|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
79731038|NCT02859285|Other|Placebo vulvar cream|
79731039|NCT02859285|Other|Estradiol vulvar cream|
80025490|NCT05837884|Diagnostic Test|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
80025491|NCT05836870|Other|Enhanced Usual Care|Participants will receive general recommendations to maintain physical activity.
80025492|NCT05836870|Behavioral|Tele-supervised resistance exercises|Participants will take part in a monitored exercise program.
80025493|NCT05824026|Device|Gelling fiber wound dressing with silver|intervention involving a wound dressing with silver
80025494|NCT05815017|Device|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
80025495|NCT05811065|Device|OPTIVF dosage|Opt-IVF dosage
80025496|NCT05811065|Device|traditional drug treament|Traditional drug treatment
80025497|NCT05805085|Device|Lens A (Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
80025498|NCT05805085|Device|Lens B (Silicone Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
80025499|NCT05805059|Device|Control Contact Lens (stenfilcon A)|one week wear
80025500|NCT05805059|Device|Test Contact Lens (senofilcon A)|one week of wear
79731040|NCT04260412|Device|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
79731041|NCT04260412|Dietary Supplement|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
79865343|NCT00816335|Procedure|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
80025501|NCT05801939|Drug|Cevostamab|Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
80025502|NCT05794126|Device|Soft Multifocal Hydrogel Contact Lens 1|soft multifocal hydrogel contact lens 1 - first period of 15 minutes
80025503|NCT05794126|Device|Soft Multifocal Silicone Hydrogel Contact Lens 2|soft multifocal silicone hydrogel contact lens 2 - second period of 15 minutes.
80025504|NCT05772910|Behavioral|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian…) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
79570969|NCT01786772|Other|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
79570970|NCT01786798|Device|Transvaginal sonography|"Transvaginal sonography will be performed to:~measure the endometrial thickness~detect the endometrial pattern"
79865344|NCT00450177|Drug|Ferrous Sulfate|Iron group
79570971|NCT01786811|Behavioral|Training|"Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
79570972|NCT01786824|Drug|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
79570973|NCT01786824|Drug|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
79570974|NCT01786824|Drug|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
79731042|NCT04260412|Dietary Supplement|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
79731043|NCT02859051|Device|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
79731044|NCT04476550|Drug|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
79731045|NCT00598975|Drug|NKTR-102 100 mg/m2|"NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
79865345|NCT00450177|Drug|Placebo Oral Tablet|Placebo group
79865346|NCT00816569|Device|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
79865347|NCT00813137|Drug|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1~7, D15~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
79570975|NCT01786824|Procedure|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
79731046|NCT00598975|Drug|NKTR-102 125 mg/m2|"NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
79865348|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on saturated fat.
79865349|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
79865350|NCT01024023|Device|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
80025505|NCT05772910|Other|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
80025506|NCT05772910|Other|EDU-EXER|This group will carry out the same two previous interventions together.
80025507|NCT05772910|Other|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
80025508|NCT05766852|Behavioral|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
79731047|NCT00598975|Drug|Cetuximab|Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
80025509|NCT05763628|Device|Control Contact Lens (stenfilcon A Daily Disposable Multifocal Contact Lens)|two weeks of wear
80025510|NCT05763628|Device|Test Contact Lens (senofilcon A Daily Disposable Multifocal Contact Lens)|two weeks of wear
80025511|NCT05754411|Drug|[14C]STI-1558|Fasting oral administration of 600 mg [ 14C ] STI-1558 ( about 100 μCi ) solution.
80025512|NCT05753384|Drug|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
80025513|NCT05753046|Drug|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
80025514|NCT05753046|Drug|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
80025515|NCT05738603|Device|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
80025516|NCT05712694|Drug|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
79570976|NCT01786837|Device|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
79731048|NCT00957021|Device|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
79731049|NCT01124604|Drug|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
79731050|NCT01124604|Drug|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
79731051|NCT00909844|Drug|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
79731052|NCT02645695|Device|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
79865351|NCT00816647|Procedure|Patellofemoral stabilizing surgery|Comparison of surgical techniques
79865352|NCT01024179|Device|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
79865353|NCT00821483|Drug|Frovatriptan|2.5mg, qd
79865354|NCT01021995|Drug|echinacea|drops, 0.9 ml, tid for 4 months
79865355|NCT01021995|Drug|placebo|drops, 0.9 ml tid for 4 months
79865356|NCT02551367|Drug|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
79865357|NCT02551367|Drug|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
79865358|NCT02551367|Drug|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
79865359|NCT00813371|Device|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
79865360|NCT00813371|Device|ARDSnet protocol|ARDSnet protocol
79865361|NCT03848949|Device|Evenup|Orthotic which increases effective leg length.
79865362|NCT00821561|Drug|Nexagon®|
79865363|NCT00821561|Drug|Nexagon® vehicle|
80025517|NCT05712694|Other|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
80025518|NCT05708612|Procedure|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
79268955|NCT04951037|Behavioral|Fully Asynchronous Online Savvy Program|"The intervention is a fully online, self-administered psychoeducational program designed to enhance caregiver mastery for family and friends providing unpaid care for living with Alzheimer's and similar dementia disorders. Participants will be asked to engage with a fully online version of Tele-Savvy for 42 days.~Participants will receive a series of daily video lessons related to caregiving. These lessons are generally 8-15 minutes in length and are emailed to participants. Participants can watch the lessons whenever and as often as they wish over the course of the study. There will also be self-guided learning strategies and exercises to accomplish skill and mastery related to the caregiving role. The lessons cover a variety of topics including:~Facts about dementing Illnesses~Caregiving Strategies - guiding the person through days that are as safe, calm, and pleasant as possible~Self-Care for the Caregiver"
79268956|NCT04691492|Behavioral|Friend-Based Motivational Interview|The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
79268957|NCT02924441|Other|Lidocaine|Applied to breast skin
79268958|NCT02924441|Other|Calming Music|Played during mammography
79401340|NCT04468919|Behavioral|BCI-FIT adaptive signal modeling|Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.
79268959|NCT02924441|Other|No Music|No music played during mammography
79731053|NCT02645695|Device|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
79731054|NCT02882568|Biological|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
79731055|NCT04232020|Diagnostic Test|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
79865364|NCT00821639|Behavioral|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
79865365|NCT00813449|Drug|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
79865366|NCT00813449|Drug|dacarbazine plus placebo (control group)|dacarbazine plus placebo
79268960|NCT04527224|Drug|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
79268961|NCT04933877|Procedure|Fascial plane block|Serratus anterior plane block
79268962|NCT04235699|Other|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
79268963|NCT03754673|Device|MRI|MRI pulmonary with no contrast administration
79268964|NCT03545945|Procedure|Additional office hysteroscopy|Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
79268965|NCT03545945|Procedure|Endometrial biopsy|Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
79268966|NCT02784977|Device|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
79268967|NCT02784977|Device|Intraoral device (IOD)|Treatment of OSA with IOD
79268968|NCT02784977|Procedure|Uvuloplasty|Uvuloplasty
79268969|NCT02784977|Other|Conservative treatment|No active intervention
79268970|NCT03545399|Dietary Supplement|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
79268971|NCT03545399|Dietary Supplement|Placebo|The dose was taken with a glass of water during the evening meal once daily
79731056|NCT00654433|Biological|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
79731057|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
79731058|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
79865367|NCT00816725|Behavioral|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
80025519|NCT05706012|Other|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
80025520|NCT05705024|Biological|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
79268972|NCT00109967|Biological|rituximab|375 mg/m^2 Given IV
79731059|NCT02643745|Procedure|Nephrology Intervention|"pre-operative study:~Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~optimise the patient' s overall condition with a pre-operative strategy:~Obesity control~Control protein, caloric, salt intake~Stop smoking~Good glycemic control~Start ACEI/ARA II if there is proteinuria~Start additional antihypertensive drug if required~Start hypolipemic treatment if required~Start hyperuricemia treatment if required~Start AAS, clopidogrel if it is necessary (prophylaxis)~Phosphate control~Anemia control~Metabolic acidosis correction"
79865368|NCT00821717|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
79865369|NCT00821717|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
79865370|NCT00822029|Drug|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
79865371|NCT00822029|Other|PLACEBO|patient receiving one tablet (oral use) placebo by week
79865372|NCT00816803|Procedure|Autologous bone marrow transplant|
79865373|NCT00816803|Procedure|Physical therapy|
79865374|NCT00467259|Drug|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
79865375|NCT00467259|Drug|Placebo patch|placebo patch, changed twice a week for 52 weeks
79865376|NCT00816881|Device|flutter mucus clearance device|five minutes every session, four sessions per day
79865377|NCT01022151|Drug|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
79268973|NCT00109967|Drug|temsirolimus|25 mg given IV
79268974|NCT02579096|Drug|allopurinol capsule, 100-800 mg by mouth once daily|Patients will be up-titrated up to the dose required to reach target uric acid levels.
79268975|NCT02579096|Drug|febuxostat tablet 40-120 mg by mouth once daily|Patients will be up-titrated to the dose required to reach target uric acid levels.
79268976|NCT02579096|Drug|Placebo, vehicle control (febuxostat-shaped)|Placebo tablets resembling febuxostat will be given with allopurinol.
79268977|NCT02579096|Drug|Placebo, vehicle control (allopurinol-shaped)|Placebo capsules resembling allopurinol will be given with febuxostat.
79268978|NCT04904003|Other|Rehabilitation Intervention|Strength, flexibility, endurance, balance, mobility, (self-efficacy)
79268979|NCT02578940|Drug|18F-Fluciclovine PET CT|Radioligand for PET CT scanning
79268980|NCT02578862|Drug|Propofol|
79268981|NCT02578862|Drug|Sevoflurane|
79401341|NCT04468919|Behavioral|BCI-FIT active querying|Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.
79581484|NCT06071091|Device|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
79731060|NCT02638909|Drug|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
79865378|NCT01022151|Drug|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
79865379|NCT01022151|Drug|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
79865380|NCT01022151|Drug|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
79865381|NCT01022151|Drug|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
79865382|NCT01022151|Drug|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
79268982|NCT02578706|Drug|Clopidogrel|Clopidogrel 75mg
79268983|NCT02578706|Drug|Aspirin|81 mg
80025521|NCT05705024|Other|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
79268984|NCT02578706|Drug|Placebo|
79268985|NCT05533736|Other|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
79865383|NCT01022229|Dietary Supplement|Compound Natural Health Product|"15-35 mg zinc citrate~150-350 mg magnesium lactate~30-70 mg pyridoxine hydrochloride~150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
79268986|NCT05533424|Other|quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
79570977|NCT01786850|Procedure|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
79865384|NCT01022229|Dietary Supplement|Placebo|Placebo
79865385|NCT01027455|Device|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
79268987|NCT05533424|Other|transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
79570978|NCT01786863|Procedure|Neuromuscular blockade|
79731061|NCT01124292|Procedure|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
79865386|NCT01027455|Procedure|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
79865387|NCT01027455|Procedure|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
79401342|NCT04468919|Behavioral|BCI-FIT language modeling|Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
79401343|NCT04468230|Drug|Nicotine Transdermal Patch|Nicotine Treatment Condition
79401344|NCT04467801|Drug|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
79570979|NCT01786889|Biological|blood and urine|Blood collection and urine collection after consent of the patient
79865388|NCT01566045|Procedure|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
79401345|NCT04460937|Drug|Adavosertib|Given PO
79401346|NCT04460937|Radiation|Radiation Therapy|Undergo radiation therapy
79401347|NCT04458194|Other|Standard Care|Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.
79570980|NCT01786889|Behavioral|Questionnaire|The patient complete the questionnaire alone at home
79865389|NCT01566045|Procedure|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
79865390|NCT01566123|Radiation|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
79865391|NCT01566123|Radiation|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
80025522|NCT05702385|Other|Educational Materials for a new diagnostic test|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
79401348|NCT04458194|Behavioral|YOCAS©® yoga|Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
79570981|NCT01786889|Behavioral|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
79570982|NCT01786915|Drug|Bendavia 10mg|
79570983|NCT01786915|Drug|Bendavia 50mg|
79570984|NCT01786915|Drug|Placebo|
79570985|NCT01786928|Other|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
79570986|NCT01786941|Other|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
80025523|NCT05699018|Diagnostic Test|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elstometry ≥ 8 kPa and < 15 kPa)
80025524|NCT05693493|Device|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
79865392|NCT00449865|Drug|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
80025525|NCT05685719|Drug|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
79865393|NCT00449865|Other|placebo|an inactive substance
79865394|NCT00449787|Drug|Sumatriptan 100 mg|Sumatriptan 100mg tablet
80025526|NCT05685719|Drug|Itraconazole|A strong CYP3A4 inhibitor
80025527|NCT05685719|Drug|Rifampin|A strong CYP3A4 inducer
79865395|NCT00449787|Drug|Naproxen|Naproxen 500mg tablet
79268988|NCT05533346|Behavioral|with WISE (Walking Instruction based on Self-Efficacy)|Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
79570987|NCT01786941|Other|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
79865396|NCT01566201|Drug|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
79570988|NCT01787019|Other|Oral feeding|
79570989|NCT01787045|Other|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
79731062|NCT01124292|Device|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
79865397|NCT01566201|Drug|placebo|water for injection
79865398|NCT01566279|Drug|Everolimus|All patients will receive everolimus 10mg q.d.
79865399|NCT00449163|Biological|Bevacizumab|
79865400|NCT00449163|Drug|Floxuridine|
79731063|NCT02645539|Device|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
79865401|NCT00449163|Drug|Irinotecan|
79865402|NCT00449163|Drug|Leucovorin|
80025528|NCT05671055|Other|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
80025529|NCT05665751|Drug|TLC-3595 Dose 1|Tablets administered orally
80025530|NCT05665751|Drug|TLC-3595 Dose 2|Tablets administered orally
80025531|NCT05665751|Drug|Placebo|Tablets administered orally
80025532|NCT05653427|Drug|Amivantamab|Amivantamab will be administered intravenously.
80025533|NCT05650190|Device|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
80025534|NCT05650190|Device|Spectacle lenses|Single vision, impact resistant spectacle lenses
79865403|NCT01026987|Drug|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
79865404|NCT01026987|Drug|AMD3100|
79865405|NCT01026987|Procedure|Leukapheresis|
79865406|NCT01026987|Procedure|Stem Cell Infusion|
79865407|NCT00448539|Drug|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
79865408|NCT01024257|Radiation|beta-irradiation|
79865409|NCT01024257|Procedure|conjunctival autograft|
79865410|NCT00457665|Drug|Nelfinavir|
79865411|NCT00457665|Drug|Efavirenz|
79865412|NCT00447603|Drug|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
79865413|NCT00447603|Drug|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
79865414|NCT00447603|Drug|Placebo for Losartan|
79865415|NCT00447603|Drug|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
80025535|NCT05649995|Other|Pain science education driven physiotherapy program|Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).
79570990|NCT01787045|Other|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
80025536|NCT05649995|Other|Biomedical education driven physiotherapy program|Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
80025537|NCT05645380|Drug|Carboplatin|AUC=6, IV
79570991|NCT01787058|Other|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
79570992|NCT01787071|Other|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
80025538|NCT05645380|Drug|Docetaxel|75 mg/m2, IV
80025539|NCT05645380|Drug|Doxorubicin|60 mg/m2, IV
80025540|NCT05645380|Drug|Cyclophosphamide|600 mg/m2, IV
80025541|NCT05645380|Drug|Pembrolizumab|200 mg, IV
80025542|NCT05641142|Other|monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease|"Monitoring:~hemoglobin and ferritin levels~transfusion or intravenous iron~hospitalization for bleeding or thrombose~digestive bleeding and/or another haemorrhagic accident~severity of epistaxis~quality of life"
80025543|NCT05633537|Procedure|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling & sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
79570993|NCT01787084|Device|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
79570994|NCT01787110|Drug|Oxygen|see arm description
79570995|NCT01787123|Drug|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
79570996|NCT01787123|Drug|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
79731064|NCT02638675|Behavioral|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
79731065|NCT02638675|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
79731066|NCT02638675|Behavioral|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
79731067|NCT02638753|Other|education|Patients will be educated about pain neurophysiology.
79731068|NCT02638753|Other|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
79570997|NCT01787136|Drug|Dextromethorphan|added on therapy
79570998|NCT01787149|Drug|DMARDs|
79570999|NCT01787162|Other|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
79571000|NCT01787214|Dietary Supplement|Full dose|20% of daily energy needs supplied by walnuts
79731069|NCT02643589|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
79731070|NCT02643901|Biological|GW003|single SC injection
79571001|NCT01787214|Dietary Supplement|Half dose|10% of daily energy needs supplied by walnuts
79571002|NCT01787214|Dietary Supplement|Control|Walnut free meals
79571003|NCT01787227|Device|xTAG RPP|
79571004|NCT01787318|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
79571005|NCT01787318|Device|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
79571006|NCT01787344|Drug|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
79571007|NCT01787344|Drug|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
80025544|NCT05633537|Radiation|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
80025545|NCT05633121|Procedure|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
80025546|NCT05627739|Drug|Mycophenolate Mofetil|Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
80025547|NCT05621980|Behavioral|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
79268989|NCT05533346|Behavioral|without WISE (Walking Instruction based on Self-Efficacy)|The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
79268990|NCT03455504|Drug|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
79268991|NCT04475666|Other|Replenish protein group|For patients with Body mass index(BMI) <30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI >=30, use adjusted body weight
79571008|NCT01787357|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
79571009|NCT01787357|Drug|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
79268992|NCT04475666|Other|Standard protein group|For patients with BMI <30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI >=30, use adjusted body weight
79268993|NCT00108953|Drug|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
79731071|NCT02645383|Device|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
79571010|NCT01787357|Drug|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
79865416|NCT00447057|Drug|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
79268994|NCT00108953|Drug|Doxorubicin/Placebo|Chemotherapy plus Placebo
79571011|NCT01787396|Drug|Gemigliptin 50mg|
79571012|NCT01787396|Drug|Placebo(Metformin)|
79571013|NCT01787396|Drug|Metformin|
79571014|NCT01787396|Drug|Placebo(Gemigliptin)|
79571015|NCT01787422|Other|Traditional versus Telemedicine office visit|
79571016|NCT01787435|Drug|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
79865417|NCT00447057|Drug|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
79865418|NCT00447057|Drug|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
79268995|NCT04810520|Other|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
79268996|NCT04810520|Other|Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
79268997|NCT02741531|Other|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
79268998|NCT02741531|Other|saline solution|Saline solution will be used to partially fill patients' bladders
79268999|NCT03545867|Behavioral|Seated control (CON)|Seated rest
79269000|NCT03545867|Behavioral|Moderate intensity continuous (MICT)|Arm cycling at a continuous power output
79571017|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
79571018|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
80025548|NCT05621980|Behavioral|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
80025549|NCT05621668|Drug|Cyclophosphamide|Given by IV (vein)
80025550|NCT05621668|Drug|attIL2-T cells|Given by IV (vein)
80025551|NCT05620342|Biological|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
79571019|NCT01787448|Drug|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
79571020|NCT01787448|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
79269001|NCT03545867|Behavioral|High intensity interval training (HIIT)|Arm cycling at power outputs that vary between high and low intensity intervals
79269002|NCT03545867|Behavioral|Circuit resistance training (CRT)|Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
79401349|NCT04457362|Diagnostic Test|Diagnostic Arthroscopy using the Arthrex NanoScope|"A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~Radial styloid~Proximal scaphoid articular cartilage~Scaphoid fossa~Radioscaphocapitate (RSC) ligament~Long radiolunate (LRL) ligament~Short radiolunate (SRL) ligament~Scapholunate (SL) ligament~Proximal lunate articular cartilage~Lunate fossa~Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment."
79401350|NCT04457362|Diagnostic Test|Diagnostic Arthroscopy using standard arthroscopic instruments|"A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~Radial styloid~Proximal scaphoid articular cartilage~Scaphoid fossa~Radioscaphocapitate (RSC) ligament~Long radiolunate (LRL) ligament~Short radiolunate (SRL) ligament~Scapholunate (SL) ligament~Proximal lunate articular cartilage~Lunate fossa~Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment."
79401351|NCT04456517|Drug|Ranolazine|500 mg tablet
79731072|NCT02645383|Device|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
79731073|NCT02881944|Behavioral|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
79731074|NCT02881944|Behavioral|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
79731075|NCT00652405|Dietary Supplement|alcohol|250 ml of white wine (13% vol; ~25 gram of alcohol per day)
79731076|NCT00652405|Dietary Supplement|Placebo|250 ml of mineral water (Brand name: Vittel)
79731077|NCT02881710|Other|contrast product used to assess biomarkers variations|
79731078|NCT02643823|Biological|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
80025552|NCT05619796|Procedure|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin & isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained & the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points & root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
79269003|NCT03545867|Other|Liquid Meal|A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
79401352|NCT04456517|Drug|Placebo|Ranolazine-matched placebo tablet
79269004|NCT04205435|Biological|β-globin restored autologous HSC|gene edited autologous hematopoietic stem cells with β-globin restoration
79269005|NCT05361044|Biological|Blood samples Donnor|Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
79269006|NCT05130281|Behavioral|Maya mobile app|The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
79571021|NCT01787474|Drug|Cytarabine|Given IV
79571022|NCT01787474|Biological|Filgrastim|Given SC
79571023|NCT01787474|Biological|Filgrastim-sndz|Given SC
79571024|NCT01787474|Drug|Fludarabine Phosphate|Given IV
79571025|NCT01787474|Other|Laboratory Biomarker Analysis|Correlative studies
79571026|NCT01787474|Biological|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
79571027|NCT01787513|Other|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
79571028|NCT01787513|Other|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
79571029|NCT01787526|Drug|ferric carboxymaltose|1 g intravenously per infusion
79731079|NCT02643823|Drug|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
79865419|NCT00447057|Drug|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
79571030|NCT01787526|Drug|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
79269007|NCT05130281|Behavioral|Social Support|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
79571031|NCT01787539|Drug|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
79731080|NCT02638831|Drug|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
79865420|NCT01027533|Other|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
79865421|NCT01027611|Drug|proparacaine HCL 0.5%|
79865422|NCT01027611|Drug|proparacaine HCL 0.5% + 4% lidocaine solution|
79865423|NCT01027611|Drug|3.5% viscous lidocaine gel|
79269008|NCT05130281|Behavioral|Gain Framed|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
79269009|NCT05130281|Behavioral|Loss Framed|Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
79571032|NCT01787552|Drug|LDE225|
79571033|NCT01787552|Drug|INC424|
79571034|NCT01787565|Other|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
79865424|NCT01024413|Drug|erlotinib|study arm.erlotinib 150 mg oral till disease progression
79865425|NCT01024413|Drug|gefitinib|study arm.gefitinib 250 mg oral till disease progression
79269010|NCT02732873|Device|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
79571035|NCT01787565|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
79571036|NCT01787578|Drug|Sobetirome|50 mcg or 100 mcg once-daily oral
79269011|NCT02578316|Drug|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
79571037|NCT01787617|Behavioral|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
79571038|NCT01787617|Behavioral|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
79571039|NCT01787630|Device|Hyaluronic acid|Injection in connection with ultrasound
79571040|NCT01787669|Drug|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
79571041|NCT01787669|Drug|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
79731081|NCT02638831|Drug|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
79731082|NCT01136772|Drug|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
79731083|NCT01136772|Drug|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
79731084|NCT00909532|Drug|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
79731085|NCT00909532|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
79731086|NCT02882490|Behavioral|Parent Training|
79731087|NCT02882490|Other|Supportive Therapy|
79865426|NCT03577587|Dietary Supplement|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
79865427|NCT03577587|Dietary Supplement|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
79865428|NCT00446511|Drug|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
79865429|NCT00446511|Drug|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
79865430|NCT00446511|Drug|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
79865431|NCT00446511|Drug|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
79865432|NCT01024491|Drug|paroxetine|daily dose of paroxetine 15mg for 12 weeks
79865433|NCT01024491|Drug|paroxetine|active daily treatment with paroxetine 20 mg
79865434|NCT01024491|Drug|placebo|active daily treatment with placebo
79865435|NCT00446199|Drug|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
79865436|NCT00446199|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
79865437|NCT00446199|Drug|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
80025553|NCT05619796|Radiation|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
80025554|NCT05619796|Other|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
79571042|NCT01787695|Procedure|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
79269012|NCT05532878|Drug|Apixaban|Apixaban 2.5 mg daily
79731088|NCT04312308|Other|Sample collection|".Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~.Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
79731089|NCT02377570|Device|THERANOVA 400 dialyzer prototype AA|Hemodialysis
79731090|NCT02377570|Device|THERANOVA 400 dialyzer prototype BB|Hemodialysis
79865438|NCT00446199|Drug|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
79865439|NCT01027689|Drug|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
79571043|NCT01787708|Procedure|Red light|
80025555|NCT05617794|Device|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
80025556|NCT05617794|Device|Control Spectacle Lens|Control Spectacles
79269013|NCT05532644|Other|AD drugs|AD drugs
79571044|NCT01787721|Procedure|Ankle manipulation|
79571045|NCT01787721|Other|Sham manipulation|
79571046|NCT01787747|Drug|AVP-786 Dose 1|
79731091|NCT02377570|Device|THERNOVA 400 dialyzer prototype CC|Hemodialysis
79731092|NCT02377570|Device|FX CorDiax 80 dialyzer|Hemodialysis
79731093|NCT01136382|Drug|budesonide|pMDI, inhalation, bid, 6 weeks
79731094|NCT01136382|Drug|placebo|pMDI, inhalation, bid, 6 weeks
79731095|NCT04772326|Other|Questionnaire|Questionnaire
79731096|NCT00912028|Device|senofilcon A|contact lens
79865440|NCT01027689|Drug|alprazolam test sublingual tablet|1 mg tablet, single dose
79865441|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
79865442|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
79865443|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
79865444|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
79865445|NCT01027767|Device|Molecular Breast Imaging|Molecular Breast Imaging
79865446|NCT01027923|Drug|Plerixafor|
79269014|NCT05502614|Device|Neuromodulation|Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
79269015|NCT04405388|Drug|Placebo|Placebo will be given orally as capsule (same size and weight as Spermidine capula)
79269016|NCT04405388|Drug|Spermidine|Spermidine will be given orally as capsule (4mg/day)
79269017|NCT05332340|Drug|BZ371A|Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
79269018|NCT05495360|Dietary Supplement|Oral Nutritional Supplement|twice daily serving of the study product
79269019|NCT05532566|Other|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
79571047|NCT01787747|Drug|AVP-786 Dose 2|
79571048|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 1|
79571049|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 2|
79865447|NCT01027923|Drug|Mitoxantrone|
79865448|NCT01027923|Drug|Etoposide|
79865449|NCT01027923|Drug|Cytarabine|
79865450|NCT01565733|Drug|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
79865451|NCT01565811|Procedure|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
80025557|NCT05611112|Behavioral|Problem Solving Therapy|Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
80025558|NCT05601882|Drug|Upadacitinib|Oral Tablets
80025559|NCT05601882|Drug|Dupilumab|Subcutaneous Injection
80025560|NCT05597137|Dietary Supplement|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
80025561|NCT05590416|Drug|Adalimumab|Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
79865452|NCT01027065|Drug|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
79731097|NCT00912028|Device|lotrafilcon B|contact lens
79731098|NCT00912028|Device|balafilcon A|contact lens
79731099|NCT00912028|Device|methafilcon A|contact lens
79731100|NCT00912028|Device|vifilcon A|contact lens
79865453|NCT01027065|Drug|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
79571050|NCT01787747|Drug|AVP-786 Dose 2/Q Dose 2|
79269020|NCT02576678|Drug|Apremilast|
79269021|NCT05532488|Dietary Supplement|Inulin 20 mg|Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.
79401353|NCT04450342|Device|Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
79401354|NCT04450342|Procedure|Arthroscopic rotator cuff repair|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
79571051|NCT01787747|Drug|AVP-923|
79571052|NCT01787773|Device|Veniti Inferior Vena Cava Filter|
79571053|NCT01787851|Drug|Triheptanoin oil|
79571054|NCT01787903|Device|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
79571055|NCT01787942|Device|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
79571056|NCT01787955|Procedure|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
79731101|NCT00632008|Drug|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
79731102|NCT00632008|Drug|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
79865454|NCT00456495|Drug|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
79865455|NCT00445341|Drug|Flavopiridol|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
79865456|NCT03846453|Biological|HL036 Ophthalmic Solution|HL036 Ophthalmic Solution
79865457|NCT03846453|Biological|Placebo|Placebo vehicle solution
80025562|NCT05578287|Drug|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
80025563|NCT05574478|Behavioral|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications & Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
79269022|NCT05532488|Other|Placebo|Placebo
79571057|NCT01787955|Procedure|conventional PPPD|
79731103|NCT04071730|Dietary Supplement|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
79731104|NCT02731729|Drug|ipilimumab|
79731105|NCT02731729|Drug|nivolumab|
79865458|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
79865459|NCT00444951|Biological|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
79731106|NCT02645461|Drug|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
79865460|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
79269023|NCT04303208|Procedure|Blood sample|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at < - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
79401355|NCT04450342|Device|Arthroscopic rotator cuff repair for revision surgery|The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
79401356|NCT04446650|Drug|Fedratinib|Oral
79731107|NCT02645461|Drug|Riluzole|Riluzole 50 mg twice daily
79731108|NCT00654589|Drug|Deferasirox|
79731109|NCT02645227|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
79865461|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
79865462|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
79865463|NCT00444795|Drug|sunitinib malate|Sunitinib : dosing not pre-determined
79269024|NCT02869646|Procedure|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
79269025|NCT02869646|Procedure|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
79401357|NCT04446299|Drug|Bowel Prep|Orally ingested liquid bowel preparation
79401358|NCT04439227|Drug|Adavosertib|Given PO
79401359|NCT04439175|Drug|Taselisib|Given PO
79401360|NCT04439136|Drug|Afatinib Dimaleate|Given PO
79401361|NCT04416334|Drug|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
79401362|NCT04416334|Drug|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
79401363|NCT04416126|Biological|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
79401364|NCT04416126|Other|Placebo|The placebo for this study is 0.9% sterile saline.
79401365|NCT04415203|Device|Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)|Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
79401366|NCT04415203|Device|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)|Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
79731110|NCT02645227|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
79731111|NCT02645227|Procedure|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
79865464|NCT03846219|Drug|IMU-838 (30 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
79269026|NCT05487404|Drug|ADX-629|3 oral doses of ADX-629 600 milligrams
79269027|NCT05487404|Drug|Placebo|3 oral doses of placebo
79269028|NCT05532332|Drug|Fluoxetine 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
79269029|NCT05532332|Drug|Prozac® 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
79401367|NCT04404777|Procedure|Treatment for local recurrence with surgery or other treatments|All types of treatment for local recurrence will be evaluated
79571058|NCT01787994|Genetic|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
79571059|NCT01788007|Drug|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
79571060|NCT01788007|Drug|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
79571061|NCT01788007|Drug|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
79731112|NCT00652483|Drug|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
79731113|NCT00652483|Drug|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
79571062|NCT01788033|Drug|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
79731114|NCT01119066|Radiation|total body irradiation|dose of 1375-1500 cGy
79269030|NCT05323136|Drug|MT1002 for Injection|single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
79269031|NCT05480540|Behavioral|Serious game|According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
79269032|NCT05532254|Drug|Aripiprazole 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
79269033|NCT05532254|Drug|Abilify® 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
79571063|NCT01788033|Drug|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
79571064|NCT01788059|Other|injection the mesenchymal stem cell in non union site|
79571065|NCT01788072|Drug|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
79571066|NCT01788072|Drug|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
79571067|NCT01788085|Device|Bravo pH monitoring procedure|Bravo pH monitoring procedure
79865465|NCT03846219|Drug|IMU-838 (45 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
79865466|NCT03846219|Drug|Placebo|"Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
79731115|NCT01119066|Drug|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
79731116|NCT01119066|Drug|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
79865467|NCT03846219|Drug|IMU-838 (10 mg/day)|"Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
79865468|NCT00455325|Drug|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
79269034|NCT05532176|Other|Posture standards|Dynamic and static Postural measurements according to four types of tests
79269035|NCT05319626|Other|compression socks|The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
79571068|NCT01788111|Other|Low back exercises 1|Excentric / concentric extension type exercises
79571069|NCT01788111|Other|Low back exercise 2|Traditional low back training
79571070|NCT01788137|Drug|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
79571071|NCT01788137|Drug|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
79571072|NCT01788176|Drug|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
79571073|NCT01788176|Drug|Placebo|one single intravenous infusion of 100ml of saline.
79571074|NCT01788189|Drug|Lenalidomide|
79571075|NCT01788254|Drug|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
79731117|NCT01119066|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
79731118|NCT01119066|Drug|Melphalan|70mg/m2/day x 2
79731119|NCT01119066|Drug|Fludarabine|25mg/m2/ day x 5
79731120|NCT01119066|Drug|Clofarabine|20mg/m2/ day x 5 (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
79731121|NCT01119066|Procedure|(CliniMACS) T-cell depleted PBSC Transplant|
79731122|NCT00910624|Drug|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
79731123|NCT00910624|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
79731124|NCT00910624|Drug|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
79269036|NCT05319626|Other|textured insoles|The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
79731125|NCT00654667|Drug|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
79731126|NCT00654667|Drug|Resveratrol|
79731127|NCT04164511|Dietary Supplement|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
79269037|NCT05319626|Other|smooth socks|The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
79269038|NCT05319626|Other|smooth insoles|The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
79269039|NCT05530850|Behavioral|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training,
79401370|NCT04383639|Other|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
79401371|NCT04381416|Device|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
79571076|NCT01788254|Drug|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
79571077|NCT01788254|Drug|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
79571078|NCT01788254|Drug|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
79571079|NCT01788254|Drug|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
79571080|NCT01788267|Other|scan examination HR-pQCT|
79731128|NCT04066738|Diagnostic Test|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
79865469|NCT00455325|Drug|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
79865470|NCT00455325|Drug|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
79269040|NCT05530850|Other|Thoracic exercise program|Thoracic region focused exercise program
79571081|NCT01788280|Drug|Fluciclitite , PET imaging, and Bevacizumab|[18F] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
79571082|NCT01788293|Other|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports [Cannesson et al., 2008; Zimmermann et al., 2010].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
79731129|NCT04066738|Diagnostic Test|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
79269041|NCT05471648|Drug|420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
79731130|NCT04066738|Diagnostic Test|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
79731131|NCT05095428|Behavioral|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
79731132|NCT05095428|Behavioral|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
79731133|NCT04063150|Biological|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
79269042|NCT05471648|Drug|Perjeta (EU origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
79269043|NCT05471648|Drug|Perjeta (US origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
79269044|NCT04305392|Drug|SHR4640|orally SHR4640
79269045|NCT05532098|Procedure|Dry Needling|Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .
79571083|NCT01788319|Procedure|lasertrabeculoplasty|
80025564|NCT05567731|Drug|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
79865471|NCT00455325|Drug|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
79269046|NCT05532098|Procedure|PRP|Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
79269047|NCT00108745|Other|Clinical Observation|Undergo observation
79571084|NCT01788332|Drug|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
79571085|NCT01788332|Other|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
79571086|NCT01788345|Other|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
79731134|NCT04063150|Biological|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
79865472|NCT01028079|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
79865473|NCT01028079|Drug|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
79269048|NCT00108745|Other|Laboratory Biomarker Analysis|Correlative studies
79269049|NCT00108745|Drug|Paclitaxel|Given IV
79269050|NCT00108745|Drug|Paclitaxel Poliglumex|Given IV
79269051|NCT00108745|Procedure|Quality-of-Life Assessment|Ancillary studies
79269052|NCT05532020|Drug|DCCR (diazoxide choline) extended-release tablets|All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
79269055|NCT05530226|Drug|Traditional Chinese medicine|Traditional Chinese medicine, oral administration, twice daily
79269056|NCT02098343|Drug|APR-246|Intravenous infusion.
79269057|NCT02098343|Drug|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
79731135|NCT04063150|Biological|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
79731136|NCT04063150|Biological|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
79731137|NCT02645071|Behavioral|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
79269058|NCT02176369|Drug|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
79269059|NCT02716805|Drug|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
79571087|NCT01788371|Drug|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
79571088|NCT01788371|Drug|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
79571089|NCT01788384|Drug|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
79731138|NCT04165681|Other|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
79731139|NCT01123980|Drug|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
79731140|NCT01123980|Drug|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
79865474|NCT01028079|Drug|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
79269060|NCT02716805|Drug|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing > 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
79865475|NCT01028157|Behavioral|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
79865476|NCT01028157|Behavioral|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
79865477|NCT01024725|Other|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
79571090|NCT01788384|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
79571091|NCT01788384|Drug|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
79865478|NCT01323231|Behavioral|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
80025565|NCT05567731|Drug|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of >18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
80025566|NCT05567731|Drug|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low estradiol (E2) < 50 and Luteinizing Hormone < 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
80025567|NCT05560230|Drug|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
80025568|NCT05560230|Drug|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
79401372|NCT04377126|Drug|Ghrelin|Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.
79571092|NCT01788397|Behavioral|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
79571093|NCT01788436|Behavioral|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
79269061|NCT02716805|Biological|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
79731141|NCT01123980|Drug|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
79269062|NCT02716805|Drug|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
79269063|NCT02174263|Biological|tocilizumab|Given IV
79731142|NCT01123980|Drug|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
79731143|NCT04037800|Procedure|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
79731144|NCT04037800|Procedure|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
79269064|NCT02174263|Other|laboratory biomarker analysis|Correlative studies
79401373|NCT04377126|Drug|Placebo|Placebo will consist of saline- no active ingredient.
79401374|NCT04375436|Drug|NTRX-07-SDD|NTRX-07-SDD for oral administration
79269065|NCT02174263|Other|quality-of-life assessment|Ancillary studies
79269066|NCT04152473|Drug|Proglumide|oral CCK receptor antagonist
79401375|NCT04373343|Behavioral|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
79865479|NCT01024803|Device|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
79865480|NCT00443781|Procedure|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
79401376|NCT04354961|Drug|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
79401377|NCT04354077|Device|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
79865481|NCT00443781|Procedure|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
79865482|NCT01024881|Procedure|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
80025569|NCT05557552|Radiation|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
80025570|NCT05557552|Radiation|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
79401378|NCT04352972|Device|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
79571094|NCT01788436|Behavioral|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
79571095|NCT01788462|Drug|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
79571096|NCT01788488|Other|Use of procalcitonin as biomarker to guide therapy|
79571097|NCT01788501|Drug|Tacrolimus|D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
79865483|NCT01024881|Procedure|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
79865484|NCT00443703|Drug|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
79865485|NCT00443703|Drug|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
79865486|NCT00443703|Drug|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
79865487|NCT00443703|Drug|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
79865488|NCT00381706|Biological|cetuximab|given IV
79865489|NCT00381706|Drug|ECF|epirubicin and 5-fluorouracil given IV
79865490|NCT00381706|Drug|IC|cisplatin and irinotecan given IV
80025571|NCT05543213|Behavioral|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
80025572|NCT05532410|Device|Fundus Camera|The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
80025573|NCT05519449|Biological|JANX007|JANX007 is dosed via IV weekly in a 21-day cycle
79269067|NCT02143193|Behavioral|Skin-to-Skin Contact|
79269068|NCT03544619|Other|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
79269069|NCT02581982|Other|Laboratory Biomarker Analysis|Correlative studies
79269070|NCT02581982|Drug|Paclitaxel|Given IV
79269071|NCT02581982|Biological|Pembrolizumab|Given IV
79269072|NCT03751397|Other|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
79269073|NCT03751397|Other|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
79865491|NCT00381706|Drug|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
79865492|NCT01045642|Drug|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
79269074|NCT03537469|Device|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
79865493|NCT00535236|Biological|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
79269075|NCT03537469|Device|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
79865494|NCT00535236|Biological|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
80025574|NCT05518617|Other|Positron Emission Tomography (PET) scan using DASB tracer|"DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with [123I]FP-CIT SPECT,"
80025575|NCT05516732|Other|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
80025576|NCT05516732|Other|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
80025577|NCT05516732|Other|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
80025578|NCT05516732|Other|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
80025579|NCT05516732|Other|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
80025580|NCT05516719|Other|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
80025581|NCT05516719|Other|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
79401379|NCT04352972|Other|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
80025582|NCT05516719|Other|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
80025583|NCT05516719|Other|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
79269076|NCT02143271|Drug|KHK7580|Oral administration
79269077|NCT05141617|Procedure|Endoscopic treatment|Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
79401380|NCT04340752|Drug|Indocyanine Green|ICG is an injectable fluorescent pigment that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision. The ICG will not affect the course of the operative or postoperative period, and will be injected intravenously prior to the actual repair
79401381|NCT04332016|Other|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
79401382|NCT04325685|Drug|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
79401383|NCT04325685|Drug|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
79401384|NCT04325685|Drug|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
79865495|NCT05357430|Drug|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
79865496|NCT05357430|Drug|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
79865497|NCT05357430|Drug|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
79865498|NCT00370552|Drug|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
79269078|NCT05141617|Procedure|TIPS|Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
79269079|NCT02143349|Dietary Supplement|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
79269080|NCT02143349|Other|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
79269081|NCT02174653|Drug|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
79269082|NCT02174653|Drug|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
79571098|NCT01788501|Drug|Cyclosporine|D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
80025584|NCT05513352|Device|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
80025585|NCT05513352|Device|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
80025586|NCT05513352|Device|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
80025587|NCT05507723|Other|Treat-to-target|Treatment to achieve urate target using supported self-management approach
79401385|NCT04319276|Drug|Gallium maltolate (500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
79571099|NCT01788501|Drug|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
79571100|NCT01788514|Other|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
79571101|NCT01788527|Device|CGM|Real Time Continuous Glucose Monitoring
79571102|NCT01788540|Drug|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
79865499|NCT00370552|Drug|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
79865500|NCT00370552|Drug|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
79865501|NCT00537030|Drug|Asparaginase|Given IM
79865502|NCT00537030|Other|Laboratory Biomarker Analysis|Correlative studies
79865503|NCT00537030|Other|Pharmacological Study|Correlative studies
79571103|NCT01788579|Behavioral|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
79571104|NCT01788579|Behavioral|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
79571105|NCT01788605|Drug|ramosetron|
79865504|NCT01047904|Device|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
79865505|NCT05357352|Other|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
79865506|NCT00381238|Drug|rosiglitazone|Extended Release Tablets
79865507|NCT04639596|Behavioral|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
79865508|NCT05355714|Device|Sofwave|High-Frequency Non-Focused Ultrasound Device
79865509|NCT05355714|Device|Ultherapy|Microfocused Ultrasound with Visualization
79865510|NCT05260476|Other|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
79865511|NCT04928820|Procedure|Computed Tomography|Undergo PET/CT
79865512|NCT04928820|Other|Gallium Ga 68 Gozetotide|Given IV
79865513|NCT04928820|Procedure|Positron Emission Tomography|Undergo PET/CT
80025588|NCT05507723|Other|Treat-to-flare|Treatment escalation based on reported flares of gout
80025589|NCT05490264|Biological|[68Ga]Ga-NOTA-SNA002|[68Ga]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
80025590|NCT05487040|Drug|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
79571106|NCT01788618|Other|Cognitive exams|"Psychopathological assessment (T0 and T3):~Scale of Spielberger~The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
79865514|NCT03896022|Device|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
80025591|NCT05485701|Diagnostic Test|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
80025592|NCT05483218|Device|Nocturnal wrist orthosis wearing|Nocturnal wearing of one of the 2 wrist orthosis kind
80025593|NCT05469919|Drug|Ceralasertib|Ceralasertib taken orally
80025594|NCT05461508|Biological|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
80025595|NCT05461508|Other|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
80025596|NCT05452902|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
80025597|NCT05452902|Behavioral|Nutrition Education|12 weeks of implementing eating tips and tracking food.
80025598|NCT05449769|Behavioral|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
79865515|NCT03896022|Device|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
79865516|NCT03896022|Device|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
79865517|NCT04430946|Diagnostic Test|Standardized test meal|A test meal of ~700 kcal consisting of protein and fat will be consumed within 10 minutes
79865518|NCT03831880|Drug|Genotropin|Genotropin (dose [mg] at time of enrollment) given subcutaneously once daily
80025599|NCT05440929|Behavioral|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications & Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
79571107|NCT01788618|Other|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
79571108|NCT01788618|Other|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
79865519|NCT03831880|Drug|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
79865520|NCT00924456|Behavioral|Transcendental Meditation program|a natural effortless mental technique
79865521|NCT04429152|Drug|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
79865522|NCT04257552|Behavioral|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
79865523|NCT04257552|Behavioral|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
79865524|NCT04257552|Other|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
79865525|NCT04001400|Drug|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
79865526|NCT04001400|Drug|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
79865527|NCT04219566|Device|VeNS|Non-invasive electrical vestibular nerve stimulation
79865528|NCT04219566|Device|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
79865529|NCT00380692|Drug|Atomoxetine|
79865530|NCT00380692|Drug|Placebo|
79865531|NCT05355636|Behavioral|Fertility Management Counseling|counseling
79865532|NCT04285866|Drug|Durvalumab|Durvalumab after chemoradiotherapy
79865533|NCT01047982|Dietary Supplement|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
80025600|NCT05433415|Behavioral|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
80025601|NCT05433129|Procedure|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
80025602|NCT05433129|Procedure|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
80025603|NCT05433129|Procedure|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
79571109|NCT01788618|Other|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
79865534|NCT01047982|Other|folic acid 400 mcg|2 pills a day
79571110|NCT01788670|Dietary Supplement|Ethanol|
79571111|NCT01788670|Other|Water|
79865535|NCT05355558|Diagnostic Test|[18F]FLT-PET/MRI body scan|"[18F]FLT-PET/MRI body scan will be done at~Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~Obtain vital signs and weight in kg before FLT administration.~Record the dose of FLT received and injected. (**specify dose: 1mCi per 10kg. Maximum injected dose: < 10mCi per patient.)~Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~Perform a saline flush following the FLT injection.~Body PET/MRI will be performed after FLT injection.~Time of injection of FLT and time of scan will need to be recorded."
79865536|NCT00536874|Drug|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
79865537|NCT00536874|Drug|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
79865538|NCT00536874|Genetic|protein expression analysis|
79865539|NCT00536874|Genetic|proteomic profiling|
79401386|NCT04319276|Drug|Gallium maltolate (1,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
79571112|NCT01788696|Radiation|Group A - Early Imaging|Total of 3 scans
79571113|NCT01788696|Radiation|Group B - Delayed Imaging|Total of 2 scans
79571114|NCT01788709|Other|preparation cleaning solution|
79571115|NCT01788722|Drug|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
79571116|NCT01788748|Device|bipolar radiofrequency and infrared|
79571117|NCT01788748|Device|fractional bipolar radiofrequency|
79571118|NCT01788761|Dietary Supplement|Probiotic Supplemented Group|
79571119|NCT01788761|Dietary Supplement|Control Group|
79571120|NCT01788787|Behavioral|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
79865540|NCT00536874|Other|diagnostic laboratory biomarker analysis|
79865541|NCT00536874|Procedure|adjuvant therapy|
79865542|NCT00536874|Procedure|neoadjuvant therapy|
79865543|NCT00536874|Procedure|therapeutic conventional surgery|
79865544|NCT04275102|Other|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
79865545|NCT00991848|Drug|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
80025604|NCT05433129|Procedure|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
80025605|NCT05432934|Drug|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
80025606|NCT05431361|Other|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns [NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
80025607|NCT05429853|Dietary Supplement|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
80025608|NCT05424159|Radiation|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
80025609|NCT05423808|Other|Health Professional Consortium|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
80025610|NCT05423808|Device|Holis Dashboard - Holis Patient App|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
79571121|NCT01788787|Behavioral|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
79865546|NCT05281068|Drug|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
79865547|NCT05281068|Drug|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
79269083|NCT02143427|Behavioral|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
79401387|NCT04319276|Drug|Gallium maltolate (1,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
79571122|NCT01788787|Behavioral|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
79571123|NCT01788787|Behavioral|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
79571124|NCT01788800|Behavioral|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
79571125|NCT01788813|Drug|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
79571126|NCT01788813|Drug|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
80025611|NCT05420064|Behavioral|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
80025612|NCT05400616|Procedure|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
80025613|NCT05400616|Procedure|Placebo|Normal saline.
80025614|NCT05383417|Device|EndoClip|Clip attached to mid portion of the endotracheal tube.
80025615|NCT05377398|Behavioral|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
80025616|NCT05377398|Behavioral|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
79571127|NCT01788826|Procedure|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
79571128|NCT01788826|Procedure|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
79571129|NCT01788865|Device|cSEMS(Covered self-expandable dual-layered metal stent) implant|
79865548|NCT00380068|Drug|Ambrisentan|Oral tablets taken once daily.
79865549|NCT00991926|Drug|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
80025617|NCT05377398|Behavioral|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
79269084|NCT02143427|Behavioral|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
79269085|NCT02176681|Drug|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
79269086|NCT02176681|Drug|Insulin|Insulin
79269087|NCT02143505|Drug|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
79731145|NCT02676973|Procedure|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
79731146|NCT02676973|Procedure|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
79865550|NCT00991926|Other|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
79865551|NCT01048060|Procedure|Bone marrow specimen banking|
79865552|NCT04230954|Drug|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
79865553|NCT04230954|Drug|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
79865554|NCT05265702|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
79401388|NCT04319276|Drug|Gallium maltolate (2,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
79401389|NCT04319276|Drug|Gallium maltolate (2,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
79401390|NCT04319276|Drug|Gallium maltolate (recommended phase 2 dose)|The maximum-tolerated dose (recommended phase 2 dose).
79571130|NCT01788878|Behavioral|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
79731147|NCT02676973|Procedure|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
79401391|NCT04311983|Behavioral|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
79401392|NCT04311983|Behavioral|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
79865555|NCT04127838|Behavioral|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
79401393|NCT04305691|Drug|Ixazomib Citrate|Given PO
79401394|NCT04305691|Other|Quality-of-Life Assessment|Ancillary studies
79731148|NCT04015648|Biological|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10^9 vp, 2.5 x 10^10 vp, 5 x 10^10 vp
79731149|NCT02638441|Other|hospital anxiety and depression scale|Detection of infertility effect on emotional status
79731150|NCT02643511|Radiation|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
79731151|NCT02859207|Drug|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
79731152|NCT05090748|Device|Echocardiographic.|Echocardiographic test.
79731153|NCT02859129|Drug|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
79401395|NCT04305691|Other|Questionnaire Administration|Ancillary studies
79401396|NCT04299880|Drug|Napabucasin|Oral
79865556|NCT04081974|Other|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
79865557|NCT03981432|Behavioral|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79865558|NCT03981432|Behavioral|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79865559|NCT03981432|Behavioral|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
79865560|NCT00536484|Drug|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
79865561|NCT00536484|Drug|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
79865562|NCT00370396|Biological|Synflorix|1 dose injected IM in the right thigh or deltoid.
79865563|NCT00370396|Biological|Prevenar|1 dose injected IM in the right thigh or deltoid.
79401397|NCT04299880|Drug|Nab-paclitaxel|Intravenous
79571131|NCT01788930|Device|CPAP|
79571132|NCT01788956|Device|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
79571133|NCT01788956|Device|Co-Oximeter|
79865564|NCT00370396|Biological|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
79571134|NCT01788969|Drug|Lexapro|Agent + training vs Placebo + training
79571135|NCT01788969|Drug|Placebo|Agent + training vs Placebo + training
79571136|NCT01788982|Drug|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
79269088|NCT02179099|Device|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
79731154|NCT02859129|Drug|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
79731155|NCT02859129|Drug|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
79865565|NCT00992004|Dietary Supplement|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
79865566|NCT00992082|Drug|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
79865567|NCT00992082|Drug|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
79865568|NCT00455013|Drug|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
79865569|NCT00455013|Drug|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
80025618|NCT05377398|Behavioral|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
79269089|NCT02254577|Drug|Endometrin® plus Progesterone in Oil (PIO)|
79269090|NCT02254577|Drug|Progesterone in Oil (PIO) Only|
79401398|NCT04299880|Drug|Gemcitabine|Intravenous
79401399|NCT04299880|Drug|Nivolumab|Intravenous
79731156|NCT02859129|Drug|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
79865570|NCT00455013|Drug|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
79865571|NCT00455013|Drug|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
79865572|NCT00455013|Drug|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
79269091|NCT02176759|Other|Administration of rice fortified with regular FePP|
79269092|NCT02176759|Other|Administration of rice fortified with regular FePP with citrate added during extrusion|
79269093|NCT02176759|Other|Administration of rice fortified with regular FePP and citrate added at consumption|
79269094|NCT02176759|Other|Administration of rice fortified with ferrous sulphate|
79269095|NCT02030275|Drug|RXI-109|surgery.
79269096|NCT02030275|Drug|Placebo|surgery.
79269097|NCT06010667|Drug|Envafolimab|With or without Envafolimab
79269098|NCT06010654|Device|Software as a Medical device|The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
79401400|NCT04299880|Drug|Paclitaxel|Intravenous
79401401|NCT04299880|Drug|Irinotecan|Intravenous
79401402|NCT04299880|Drug|Leucovorin|Intravenous
79401403|NCT04299880|Drug|5Fluorouracil|Intravenous
79401404|NCT04299880|Drug|Bevacizumab|Intravenous
79401405|NCT04284787|Drug|Azacitidine|Given IV or SC
79401406|NCT04284787|Procedure|Biopsy|Undergo biopsy
79401407|NCT04284787|Procedure|Biospecimen Collection|Undergo blood specimen collection
79401408|NCT04284787|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79401409|NCT04284787|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79401410|NCT04284787|Biological|Pembrolizumab|Given IV
79401411|NCT04284787|Drug|Venetoclax|Given PO
79571137|NCT01788982|Drug|Placebo|
79571138|NCT01789021|Device|4 blood glucose monitoring systems|
79571139|NCT01789060|Other|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
79571140|NCT01789073|Dietary Supplement|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
79571141|NCT01789086|Drug|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
80025619|NCT05359848|Other|Diet|Using dietary interventions as an adjuvant tool may represent an effective step toward advancing the treatment options of cancer. Dietary modifications can impact the growth and proliferation of tumors via multiple mechanisms
80025620|NCT05357950|Drug|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
80025621|NCT05357950|Drug|Placebo|Placebo matches active drug in size, color and taste
80025622|NCT05356182|Other|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
79865573|NCT00363298|Drug|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
79269099|NCT06010602|Procedure|Quadratus lumborum block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
79401412|NCT04280848|Drug|UCPVax|"The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum."
79401413|NCT04280848|Drug|Temozolomide|6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
79571142|NCT01789086|Drug|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
79571143|NCT01789099|Biological|UV1 synthetic peptide vaccine and GM-CSF|
79731157|NCT04164823|Device|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
79865574|NCT00363298|Drug|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
79571144|NCT01789112|Other|Blood sample|Taking of blood sample
79731158|NCT04164823|Drug|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
79731159|NCT03976336|Dietary Supplement|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
79731160|NCT03976336|Other|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
79865575|NCT05261412|Other|Standard Consent|Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
79731161|NCT04164589|Device|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
80025623|NCT05354570|Radiation|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
80025624|NCT05350423|Device|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
80025625|NCT05350423|Device|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
80025626|NCT05344235|Other|SBRT|stereotactic radiotherapy of the primary prostate
80025627|NCT05334485|Drug|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
80025628|NCT05334485|Other|Placebo|Oral starch placebo
80025629|NCT05324943|Genetic|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
79269100|NCT06010602|Procedure|İlioinguinal-İliohipogastric nerve block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
79571145|NCT01789125|Drug|Nicotine Patch|
79571146|NCT01789125|Behavioral|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
79571147|NCT01789125|Behavioral|Education-Supportive Psychotherapy|
79571148|NCT01789151|Device|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
79571149|NCT01789177|Device|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
79731162|NCT02857959|Drug|Benzathine Penicillin G|
80025630|NCT05315999|Drug|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II & III)
80025631|NCT05315999|Drug|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II & III)
80025632|NCT05308290|Other|Blood pressure management according to cerebral autoregulation|Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.
80025633|NCT05308290|Other|Blood pressure management according to usual care|Intraoperative blood pressure will be targeted based on usual care.
80025634|NCT05304117|Behavioral|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
80025635|NCT05294978|Diagnostic Test|OCT|Macular optical coherence tomography (OCT)
80025636|NCT05294809|Behavioral|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
79865576|NCT05261412|Other|Digital health education tool (dHET)|Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
79571150|NCT01789177|Other|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
79571151|NCT01789216|Drug|NSAID|
79731163|NCT00632398|Behavioral|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
79731164|NCT00632398|Behavioral|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
79731165|NCT00654979|Device|SafeFlo IVC Filter|SafeFlo IVC Filter
79865577|NCT05254548|Drug|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
79865578|NCT05254548|Drug|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
79865579|NCT05254548|Drug|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
79865580|NCT05254548|Drug|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
79865581|NCT00363142|Drug|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
79401414|NCT04257227|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be)."
79401415|NCT04256421|Drug|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
79401416|NCT04256421|Drug|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
79401417|NCT04256421|Drug|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
79401418|NCT04256421|Drug|Etoposide|Etoposide 100 mg/m^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
79401419|NCT04256421|Drug|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
79571152|NCT01789216|Drug|Gabapentinoids|
79571153|NCT01789216|Drug|placebo|
79571154|NCT01789242|Drug|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
79571155|NCT01789242|Drug|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with <VGPR after 4 cycles.
79571156|NCT01789294|Drug|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
79571157|NCT01789294|Behavioral|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
79731166|NCT04231786|Procedure|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
79731167|NCT02643433|Biological|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
79731168|NCT02643433|Biological|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
79731169|NCT00632476|Other|Placebo|Placebo capsule once a day
79731170|NCT00632476|Dietary Supplement|Vitamin C|A 500-mg vitamin C capsule once a day
79731171|NCT04164745|Drug|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
79731172|NCT04164745|Biological|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
79731173|NCT00655213|Device|Symphony D 2450|
79731174|NCT00655213|Device|Symphony DR 2550|
79865582|NCT00363142|Drug|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
79865583|NCT05246982|Drug|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
79865584|NCT05246982|Drug|HLX07|HLX07 1500mg q3w
79865585|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
79571158|NCT01789307|Dietary Supplement|corn syrup solids|oral ingestion 50 grams, 2 doses
79865586|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
79865587|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
79865588|NCT04002492|Behavioral|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
79865589|NCT00454857|Other|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
80025637|NCT05294809|Behavioral|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
80025638|NCT05294809|Behavioral|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
79269101|NCT06010485|Other|Serial Casting|A short leg cast is applied to the serial casting group by an orthopedic specialist once every three days for three weeks.
79269102|NCT06010485|Other|Exercise|Stretching exercises, strengthening exercises, balance exercises, proprioception exercises, and heel walking exercises are applied to the physical therapy group for 3 weeks with a physiotherapist for 3 sessions a week.
79269103|NCT06010446|Other|No intervention, just retrospective analysis of data.|
79269104|NCT06010433|Device|CERAMENT G|"Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments.~Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing."
79269105|NCT06010381|Other|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
79269106|NCT06010381|Other|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
79571159|NCT01789307|Dietary Supplement|sucrose|oral ingestion 50 grams, 2 doses
79571160|NCT01789359|Other|Blueberry Juice|Dietary intervention
79571161|NCT01789385|Drug|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
79571162|NCT01789398|Drug|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
79571163|NCT01789411|Other|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
79571164|NCT01789411|Device|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
79571165|NCT01789411|Device|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
79865590|NCT00454857|Other|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
79865591|NCT00454857|Other|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
79865592|NCT05243004|Other|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~ensures that the reason for hospitalization is understood~answers the patient's questions."
79865593|NCT02534818|Drug|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
79865594|NCT02534818|Drug|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
79865595|NCT04002024|Other|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
79865596|NCT04002024|Other|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
79865597|NCT01027299|Device|Biventricular pacing|Optimised temporary biventricular pacing.
79865598|NCT05355324|Other|no intervention|no intervention
79865599|NCT01028313|Drug|LBH589|20 mg PO three times weekly
79865600|NCT01028313|Drug|Methylprednisolone|1 mg/kg/day PO continuously
79865601|NCT04001712|Drug|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
80025639|NCT05294367|Drug|Magnesium Chloride-based Lotion|Given topically
80025640|NCT05294367|Other|Quality-of-Life Assessment|Ancillary studies
79865602|NCT03794193|Procedure|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
79865603|NCT05355246|Other|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
79865604|NCT05355246|Other|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
79865605|NCT01028469|Device|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
79865606|NCT01027377|Drug|rFVIIIFc|Single dose
79865607|NCT01027377|Drug|rFVIIIFc|Single dose
80025641|NCT05294367|Behavioral|Special Diet Therapy|Consume magnesium rich foods
80025642|NCT05288452|Behavioral|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
79269107|NCT06010381|Other|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
79401420|NCT04253171|Device|Lithoplasty|"The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.~The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions."
79571166|NCT01789437|Device|Dexamethasone Intravitreal Implant (Ozuredex)|
79571167|NCT01789450|Procedure|Section of Periareolar Dermis in Breast Reduction.|
79571168|NCT01789463|Other|Self rehabilitation|
79571169|NCT01789463|Other|Self rehabilitation plus physiotherapy|
79571170|NCT01789489|Device|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
79571171|NCT01789502|Device|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
79865608|NCT00992160|Drug|GW597599|GW597599 15mg tablet
79865609|NCT00992160|Drug|Placebo|Placebo to match GW597599 15mg tablet
79865610|NCT00379912|Drug|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
79571172|NCT01789502|Device|Plastic stents|Plastic stents were inserted by ERCP
79571173|NCT01789528|Drug|CAZ-AVI|IV infusion
79571174|NCT01789528|Drug|CXL|IV infusion
79571175|NCT01789554|Other|MLS dispatch for bystander CPR|
79571176|NCT01789580|Other|Gambling moderator|
79571177|NCT01789593|Other|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
79865611|NCT00379912|Drug|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
80025643|NCT05288452|Dietary Supplement|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
80025644|NCT05288452|Behavioral|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
80025645|NCT05288452|Behavioral|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
79269108|NCT06010355|Procedure|Discussion|Participate in focus groups
79269109|NCT06010355|Other|Media Intervention|Watch culturally appropriate video
79269110|NCT06010355|Other|Interview|Undergo interview
79269111|NCT06010355|Other|Media Intervention|Watch culturally appropriate video
79269112|NCT06010355|Other|Test|Complete test
79269113|NCT06010342|Drug|TL118 Capsule|Oral administration
79571178|NCT01789619|Drug|Extended release tacrolimus (Advagraf®)|
79571179|NCT01789645|Other|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
79571180|NCT01789645|Procedure|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
79571181|NCT01789658|Other|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
79865612|NCT00379912|Drug|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
79865613|NCT05239650|Drug|HLX07|1000mg
79865614|NCT05239650|Drug|HLX10|200mg
79865615|NCT05239650|Drug|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
79731175|NCT01198522|Drug|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
79731176|NCT02638285|Drug|LH|
79865616|NCT00379834|Drug|Cosopt|Cosopt twice daily in both eyes
79571182|NCT01789671|Behavioral|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
79571183|NCT01789684|Other|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
79731177|NCT02638285|Drug|HCG|
79731178|NCT02638285|Drug|Clomiphene|
79731179|NCT04201210|Other|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
79571184|NCT01789697|Other|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
79865617|NCT04001322|Other|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
80025646|NCT05282654|Behavioral|ePRO Application|The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
80025647|NCT05252988|Drug|Neratinib|Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
80025648|NCT05252988|Drug|Loperamide|Loperamide orally.
80025649|NCT05252988|Drug|Colesevelam|Colesevelam capsules orally, 2 times a day for the first month (28 days).
80025650|NCT05251363|Device|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
80025651|NCT05247333|Other|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
79571185|NCT01789710|Drug|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
79731180|NCT04201210|Other|Matched sibling donor transplantation|10/10 HSCT - matched family donor
79731181|NCT01134250|Drug|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
79731182|NCT03751774|Behavioral|MAMAACT|Post graduate training and health education materials
79731183|NCT03414268|Other|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
79731184|NCT03414268|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
79731185|NCT01118520|Drug|perindopril arginine|10mgs orally daily for the duration of the trial
79865618|NCT04001322|Other|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
80025652|NCT05243563|Device|MonaLisa Touch|3 laser treatments at 6 week intervals for 6 months by a single trained operator
80025653|NCT05243563|Drug|Topical steroid|self-applied topical steroid therapy using clobetasol propionate 0.05%
80025654|NCT05208164|Behavioral|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
80025655|NCT05207462|Behavioral|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
79731186|NCT01118520|Drug|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
79731187|NCT01118520|Drug|placebo|one daily
79731188|NCT04226638|Diagnostic Test|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
79731189|NCT03744832|Diagnostic Test|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
79731190|NCT03744832|Diagnostic Test|Throat culture|Standard bacterial throat culture.
79571186|NCT01789710|Drug|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
79571187|NCT01789710|Behavioral|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
79571188|NCT01789723|Drug|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
79731191|NCT01135992|Drug|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
79731192|NCT01135992|Drug|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
79865619|NCT04001322|Other|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
79269114|NCT06010290|Drug|18F-SMBT-1|Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
79269115|NCT06010277|Drug|Folinic acid|Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
79269116|NCT06010264|Other|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
79269117|NCT06010264|Other|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
79401421|NCT04253171|Device|Conventional|Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
79401422|NCT04252742|Drug|Erenumab|140 mg, 2 consecutive injections of 70 mg
79401423|NCT04252742|Drug|Placebo|2 consecutive injections
79401424|NCT04243044|Device|Transcutaneous spinal stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
79401425|NCT04237623|Drug|Sargramostim|250mcg/m2/day IV starting Day +5
79571189|NCT01789723|Drug|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
79865620|NCT04001322|Other|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
79401426|NCT04237623|Other|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
79571190|NCT01789749|Other|Snare Tip Soft Coagulation|
79571191|NCT01789749|Other|No Snare Tip Soft Coagulation|
79571192|NCT01789762|Biological|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
79571193|NCT01789762|Biological|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
79731193|NCT03734770|Drug|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
79865621|NCT04001322|Other|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
79571194|NCT01789762|Biological|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
79571195|NCT01789788|Drug|Placebo|Matching placebo, multiple doses
79571196|NCT01789788|Drug|RO6811135|multiple ascending doses
79571197|NCT01789801|Procedure|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
79571198|NCT01789801|Procedure|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
79571199|NCT01789827|Other|Laboratory Biomarker Analysis|Correlative studies
79571200|NCT01789827|Procedure|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
79731194|NCT03734770|Drug|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
79731195|NCT00959049|Biological|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
79731196|NCT00959049|Biological|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
79731197|NCT00956943|Drug|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
79731198|NCT00956943|Drug|placebo|placebo patch
79731199|NCT00958893|Drug|25 mg Proellex|one 25 mg capsules
79731200|NCT01135914|Drug|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
80025656|NCT05206279|Drug|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
79731201|NCT01135914|Procedure|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
79731202|NCT04281927|Device|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
79731203|NCT02858973|Drug|Q203|
79731204|NCT02858973|Drug|Placebo|
79865622|NCT04001322|Other|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
80025657|NCT05205291|Drug|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with [11C]PBR28 and four hours before the second PET/MR scan with [11C]PBR28.
80025658|NCT05205291|Radiation|PET/MR with [11C]PBR28|A PET/MR scan using the tracer [11C]PBR28 will be performed to all participants before and four hours after the administration of LPS
80025659|NCT05200468|Other|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
80025660|NCT05200468|Other|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
79401427|NCT04225884|Other|DTx for pain software|Software with active intervention
79401428|NCT04225884|Other|Control software|Software without active intervention
79401429|NCT04225884|Other|Standard care|Pain medication
79401430|NCT04223401|Other|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up & Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~Nutritional intervention~Psychological intervention~Exercise intervention"
79571201|NCT01789827|Biological|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
79571202|NCT01789853|Behavioral|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
79571203|NCT01789853|Behavioral|Conventional Physical Therapy|Regular physical therapy for 8 weeks
79731205|NCT04282005|Procedure|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
79731206|NCT04282005|Other|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
79731207|NCT04280679|Device|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
79571204|NCT01789892|Drug|methylprednisolone|Given IV
79731208|NCT00907738|Drug|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
79731209|NCT04282161|Device|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
79731210|NCT01123356|Drug|Ofatumumab|"Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~Treatment to be administered for up to 6 cycles"
79731211|NCT01123356|Drug|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
79865623|NCT04001322|Other|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
79865624|NCT00992316|Drug|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
79865625|NCT00379210|Behavioral|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
79865626|NCT00379210|Behavioral|Nutrition Education course|8-week course in nutrition
79269118|NCT06010264|Other|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
79571205|NCT01789892|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT scan
79571206|NCT01789892|Procedure|positron emission tomography|Undergo FDG PET/CT scan
79571207|NCT01789892|Procedure|computed tomography|Undergo FDG PET/CT scan
79571208|NCT01789918|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
79571209|NCT01789931|Device|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
79571210|NCT01789944|Behavioral|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
79571211|NCT01789957|Drug|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
79571212|NCT01789996|Procedure|alternative six minute walk test|"Alternate instructions will be given Subjects will~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
79865627|NCT00992472|Drug|Prochlorperazine suppositories, 25mg|
79571213|NCT01789996|Procedure|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
80025661|NCT05200468|Other|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
79571214|NCT01790620|Other|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
79865628|NCT00992472|Drug|Compazine® suppositories, 25mg|
80025662|NCT05197790|Device|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
79269119|NCT06010238|Device|Short term variation|Short term variation in computer software analysis
79269120|NCT06010238|Device|Visual interpretation|Visual interpretation of cardiotocography
79401431|NCT04218331|Behavioral|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
79401432|NCT04218331|Behavioral|PROMPT|PROMPT is a multidimensional oral-motor approach to speech production disorders.
79865629|NCT03453840|Drug|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: <15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; >=35kg, 4 tablets.
79865630|NCT05356650|Other|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
79401433|NCT04208321|Other|Placebo|Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
79401434|NCT04208321|Drug|VT-1598|VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
79571215|NCT01790620|Other|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
79571216|NCT01790711|Procedure|FMT through mid-gut|
79571217|NCT01790854|Drug|Prasugrel dose 5 mg/day|
79571218|NCT01790854|Drug|Prasugrel dose 10 mg/day|
79731212|NCT00630357|Drug|Levetiracetam (Keppra)|
79731213|NCT02858817|Drug|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
79731214|NCT02858817|Biological|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
79731215|NCT02858817|Other|NaCl 0,9%|0.9% NaCl solution for injection
79731216|NCT02883192|Drug|Ondansetron|Zofran 4 mg.
79731217|NCT02883192|Drug|Placebo|Placebo
79269121|NCT06010212|Drug|Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin|"Phase Ib: Patients with advanced ESCC will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 9-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~fruquintinib: 3 mg, 4 mg, or 5 mg qd p.o., 2 weeks and 1 week, every 3 weeks ( dose exploration phases were performed sequentially from the 4 mg group, refer to the study design section for specific protocols); Camrelizumab: 200 mg I.V D1, every 3 weeks for treatment cycles; Paclitaxel liposomes: 135 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles; Nidaplatin: 70 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles. Chemotherapy is used for up to 6 cycles, followed by maintenance therapy with fruquintinib + Camrelizumab until disease progression or intolerable toxicity.~Phase II: Up to a total of 30 patients with advanced ESCC will be enrolled."
79731218|NCT04280835|Behavioral|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
79269122|NCT06010134|Other|Physical Therapy Program|Physical Therapy Program plus Whole Body Vibration
79731219|NCT02883270|Device|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
79269123|NCT06010082|Behavioral|Music Therapy|Music Therapy intervention will be delivered through instructed participants to empty their bladder and then listen to music for 30 min in a semi-fowler's position with their head and shoulders raised 30° in a quiet and dim environment, listening to the music of symphonic music.
79269124|NCT06010069|Diagnostic Test|body temperature measurament|body temperature of every patient was measured with tympanic thermometer during surgical procedure
79731220|NCT02883270|Other|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
79865631|NCT05356650|Other|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
79865632|NCT00378898|Device|BRAVO capsule|
79269125|NCT06010056|Drug|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
79401435|NCT04204902|Drug|Tepotinib 100 mg|Participants received a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in either treatment period 1 or 2.
79401436|NCT04204902|Drug|Tepotinib 250 mg|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in either treatment period 1 or 2.
79401437|NCT04197713|Drug|Adavosertib|Given PO
79401438|NCT04197713|Drug|Olaparib|Given PO
79401439|NCT04195789|Other|Lung sonography|"Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist."
79401440|NCT04191187|Drug|Fludarabine|Fludarabine 30mg/m^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m^2
79401441|NCT04191187|Drug|Melphalan|Melphalan 70 mg/m^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
79401442|NCT04191187|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
79401443|NCT04181463|Drug|Isopropyl Alcohol|Given via nasal inhalation
79401444|NCT04181463|Other|Placebo|Given via nasal inhalation
79401445|NCT04181463|Other|Questionnaire Administration|Ancillary studies
79401446|NCT04176705|Drug|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
79865633|NCT00378898|Procedure|Fluoroscopy|"one time xray to determine evacuation of bravo"
79865634|NCT00378898|Other|sham BRAVO capsule placement|
79865635|NCT01045720|Drug|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
79865636|NCT01045720|Drug|Placebo|Placebo (starch)
79401447|NCT04176705|Drug|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
79401448|NCT04176705|Device|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
79865637|NCT00992550|Drug|Cigarette|
79865638|NCT00992550|Drug|Hookah|
79865639|NCT05354700|Drug|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
79401449|NCT04169542|Other|Questionnaire Administration|Complete questionnaires
79401450|NCT04167358|Drug|Linerixibat|All participants will receive linerixibat.
79865640|NCT05354700|Drug|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
79865641|NCT05354700|Drug|carboplatin and etoposide|chemotherapeutics
80025663|NCT05180695|Drug|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
80025664|NCT05180695|Drug|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
80025665|NCT05176951|Drug|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
80025666|NCT05176951|Drug|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
80025667|NCT05157672|Dietary Supplement|Cinnamon (2 g)|oral capsules, 2 g
80025668|NCT05157672|Drug|Nicotine gum (2.5 mg)|gum, 2.5 mg
79571219|NCT01791270|Device|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~- Respiratory Polygraphy~- Ambulatory Blood Pressure Monitoring~- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~- ß1en subunit expression in peripheral blood leukocytes."
79865642|NCT03339258|Drug|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
80025669|NCT05157672|Drug|Letrozole (2.5 mg)|tablet, 2.5 mg
80025670|NCT05152758|Device|PARx|Prescription Physical Activity Programming Application
80025671|NCT05147454|Other|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
80025672|NCT05147090|Drug|Empagliflozin 10 MG|Empagliflozin 10mg daily
80025673|NCT05147090|Drug|Placebo pills|Identical in appearance to empagliflozin 10mg daily
80025674|NCT05137639|Procedure|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
79865643|NCT03339258|Drug|Placebo|Placebo, or inactive pill.
79865644|NCT04002570|Other|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
79269126|NCT06010056|Drug|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
79401451|NCT04166383|Biological|Vascular Biogenics (VB)-111|1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
80025675|NCT05121012|Other|Study procedures|"All participants will undergo a collection of demographic data, a neurological examination and administration of clinical scales relevant for MSA-P. All participants will undergo a collection of venous blood sample for routine analyses.~Participants will undergo one PET scan with the tracer [11C]UCB-J, and one PET scan with the tracer [18F]FDG. All participants will also undergo one MRI scan.~Participants will also undergo one lumbar puncture (optional).~All procedures will be performed at baseline and after one-year follow-up."
80025676|NCT05115747|Other|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
80025677|NCT05112575|Radiation|Postoperative imaging with magnetic resonance imaging or computed tomography|Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
80025678|NCT05104229|Drug|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
80025679|NCT05104229|Drug|Standard of Care|Standard of Care VTE prophylaxis
80025680|NCT05103436|Other|TENS|Electrical nerve stimulation
79269127|NCT06009978|Device|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
79269128|NCT06009965|Drug|CsA+ATG+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
79731221|NCT02860455|Device|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
79865645|NCT00992628|Device|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
79865646|NCT00992628|Device|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
79865647|NCT00378508|Drug|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
79865648|NCT00378508|Drug|Placebo Arm|
80025681|NCT05076500|Procedure|Biopsy and blood sample collection|"A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy [irradiated site]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected."
79571220|NCT01791387|Drug|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
79571221|NCT01791790|Device|Stimulation|
79571222|NCT01791790|Device|SHAM|no stimulation
79865649|NCT00992706|Drug|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
79865650|NCT00992706|Drug|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
79865651|NCT02534740|Drug|tafamidis|relative bioavailability
79865652|NCT02534740|Drug|tafamidis|fasted
79865653|NCT02534740|Drug|tafamidis|fed
79865654|NCT01580956|Other|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
79865655|NCT01580956|Other|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
80025682|NCT05067777|Procedure|Massage Therapy|Receive SMT
80025683|NCT05067777|Other|Questionnaire Administration|Ancillary studies
80025684|NCT05067777|Procedure|Sham Intervention|Receive light touch control procedure
79269129|NCT06009965|Drug|CsA+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
79269130|NCT06009952|Other|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
79269131|NCT06009913|Other|online teaching|teaching of subject was done using online system only
79269132|NCT06009913|Other|In class teaching|subjects were explained in normal class room
79401452|NCT04166383|Drug|Nivolumab|240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
79571223|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
79571224|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
79865656|NCT00454779|Drug|Cisplatin|chemotherapy arm
79865657|NCT00454779|Drug|Panitumumab|experimental arm
79865658|NCT00454779|Drug|Docetaxel|chemotherapy arm
79865659|NCT00454779|Drug|Cisplatin|experimental arm
79865660|NCT00454779|Drug|Docetaxel|experimental arm
79865661|NCT00992862|Drug|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
79865662|NCT00992862|Drug|Univasc® 15mg Tablets|
79865663|NCT00992940|Procedure|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
79865664|NCT00992940|Procedure|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
79865665|NCT02416206|Drug|BeEAM|BeEAM
79865666|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
79865667|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
79865668|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
79865669|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
79865670|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
79865671|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
79865672|NCT00439569|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
80025685|NCT05057247|Drug|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
80025686|NCT05057247|Drug|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
80025687|NCT05055063|Drug|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
79731222|NCT02860455|Device|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
79865673|NCT00443079|Drug|IdB 1016 (Siliphos)|1 pill 3 times daily x 6 weeks
79865674|NCT00443079|Drug|Matched placebo|1 pill 3 times daily x 6 weeks
79865675|NCT01033929|Biological|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
80025688|NCT05051033|Procedure|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
79401453|NCT04164004|Other|Kansas City Cardiomyopathy Questionnaire-12|Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
79571225|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
79571226|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
79571227|NCT01792063|Drug|Sevoflurane|
79571228|NCT01792063|Drug|Sevoflurane|
79865676|NCT02188836|Device|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
79865677|NCT02188836|Device|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
79269133|NCT06009900|Device|Low intensity laser treatment|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
79865678|NCT00993174|Procedure|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
79865679|NCT00993174|Procedure|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
79865680|NCT02088372|Device|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
79269134|NCT06009900|Drug|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
79401454|NCT04163458|Drug|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
79401455|NCT04163458|Drug|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
79401456|NCT04163458|Other|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
79401457|NCT04163458|Other|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
79571229|NCT01792232|Other|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
79571230|NCT01792232|Other|Saline|Saline will be placed in the lung on day 1 of each triad
79571231|NCT01792258|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
79571232|NCT01792297|Dietary Supplement|Bovine colostrum|
79571233|NCT01792297|Dietary Supplement|Whey protein|
79571234|NCT01792349|Behavioral|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
79571235|NCT01792414|Device|Sham TES|Neuroconn Eldith device
79571236|NCT01792414|Device|Active TES|Neuroconn Eldith device
79571237|NCT01792570|Drug|RPV + DRV/r|Switch to dual HAART
79571238|NCT01792570|Drug|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
79571239|NCT01792622|Other|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
79571240|NCT01792622|Other|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
79731223|NCT00908596|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
79731224|NCT05143593|Diagnostic Test|SSBD(PCR-CRISPR/Cas12a)|Based on 1791 microorganism genomes of 232 species from the public database, we identified species-specific DNA-tags for 12 common pathogenic bacteria, which allowed us to design our Cas12a system for using the trans-cleavage activity and judging whether bacterium infects the patient or not by fluorescence value.
79269135|NCT06009887|Behavioral|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
79865681|NCT05348616|Other|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
79865682|NCT05348616|Other|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
79269136|NCT06009874|Drug|Dapagliflozin 10mg Tab|patients will be treated with DAPA 10 mg once daily for three months
79865683|NCT00993252|Procedure|CT Scan|CT scan
79269137|NCT06009874|Drug|Placebo|patients will be treated with a placebo tab once daily for three months
79571241|NCT01792661|Other|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
79571242|NCT01792661|Other|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
79571243|NCT01792661|Other|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
79571244|NCT01792674|Other|In situ simulation|
79731225|NCT02860689|Other|using questionnaires - International Index Erectile Function|using questionnaires
79865684|NCT02553915|Other|Placebo|Soybean oil placebo
79865685|NCT02553915|Drug|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
79865686|NCT02553915|Drug|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
79865687|NCT02553915|Drug|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
79269138|NCT06009861|Drug|Tislelizumab|Dose: 200 mg Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks
79731226|NCT02590120|Dietary Supplement|Enteral nutrition|
79269139|NCT06009861|Drug|Albumin-Bound Paclitaxel|Dose: 260 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks
79269140|NCT06009861|Drug|Cisplatin|Dose: 60-75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks
79269141|NCT06009848|Drug|Cadonilimab|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days) is a treatment cycle.
79269142|NCT06009835|Other|Recommended treatment plan|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
79269143|NCT06009822|Other|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
79571245|NCT01792674|Other|Off site simulation|
79731227|NCT02860533|Device|cuff device|Measurement of blood pressure during stress testing with cuff device
79865688|NCT04001868|Procedure|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
79571246|NCT01792804|Drug|Trimethoprim-Sulfamethoxazole|study drug 1
79571247|NCT01792804|Drug|Clindamycin|study drug 2
79571248|NCT01792804|Drug|Linezolid|study drug 3
79571249|NCT01792804|Drug|Flucloxacillin|study drug 4
79571250|NCT01792804|Drug|Cloxacillin|study drug 5
79571251|NCT01792804|Drug|Vancomycin|study drug 6
79571252|NCT01792804|Drug|Daptomycin|study drug 7
79571253|NCT01792804|Drug|Cefazolin|study drug 8
79731228|NCT02860533|Device|iphone|Measurement of blood pressure during stress testing with iPhone
79269144|NCT06009809|Diagnostic Test|transesophageal echocardiogram|To measure mean blood velocity at the level of the right renal and superior mesenteric artery
79731229|NCT01118052|Other|Laboratory Biomarker Analysis|Correlative studies
79731230|NCT01118052|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
79731231|NCT02860377|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
79865689|NCT04001868|Procedure|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
79865690|NCT01034007|Combination Product|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
80025689|NCT05051033|Device|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
80025690|NCT05049096|Device|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
80025691|NCT05049096|Device|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
80025692|NCT05042479|Other|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~Application of a patch or anaesthetic cream 1 hour before the treatment~Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~The presence of the parents"
80025693|NCT05042479|Other|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
79269145|NCT06009796|Device|Tooth Tissue Borne Rapid Palatal Expansion|In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
79401458|NCT04149522|Device|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
79571254|NCT01792856|Other|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
79571255|NCT01792856|Other|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
79571256|NCT01793038|Drug|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
79571257|NCT01793038|Drug|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
79571258|NCT01793090|Drug|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
79571259|NCT01793090|Other|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
79571260|NCT01793337|Other|Exposure to cold environmental temperature (-20°C)|
79731232|NCT02860377|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
79731233|NCT03394534|Other|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
79731234|NCT04277949|Device|Erbium:YAG|Treatment with Erbium:YAG laser
79731235|NCT04277949|Drug|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
79731236|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for three months|period of treatment
79731237|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for six months|period of therapy
80025694|NCT05042479|Other|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
79269146|NCT06009796|Device|Tooth Bone Borne Rapid Palatal Expansion|After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
79269147|NCT06009783|Other|ChatGPT Language Model|ChatGPT Language Model - ability to converse with the model and ask questions regarding vasectomies
79269148|NCT06009770|Device|"medical device Homing (TecnoBody); medical device Icone (Heaxel)"|Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.
79269149|NCT06009770|Behavioral|Usual Care|Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
79401459|NCT04146428|Behavioral|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
79571261|NCT01793779|Procedure|cold water immersion|
79401460|NCT04146428|Behavioral|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
79571262|NCT01793779|Dietary Supplement|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
79865691|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
79865692|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
79269150|NCT06009744|Drug|Low-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
79269151|NCT06009744|Drug|High-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
79401461|NCT04144322|Device|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
79571263|NCT01793779|Dietary Supplement|Placebo|
79571264|NCT01793818|Biological|Tat Oyi|Three injections in the arm
79571265|NCT01794104|Drug|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
79571266|NCT01794182|Drug|Glyburide for Injection|Administered as specified in the treatment arm.
79571267|NCT01794182|Drug|Placebo|Administered as specified in the treatment arm.
79571268|NCT01794208|Drug|Follitropin Epsilon|
79571269|NCT01794208|Drug|Follitropin Alfa|
79571270|NCT01794247|Drug|Magnesium sulfate|
79571271|NCT01794247|Drug|Fentanyl|
79571272|NCT01794247|Drug|Lidocaine|
79571273|NCT01794364|Drug|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
79571274|NCT01794364|Other|placebo|Correspondingly, placebo doses will be administered as suspension.
79571275|NCT01794429|Drug|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
79865693|NCT03994107|Drug|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
79865694|NCT03994107|Drug|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
79865695|NCT03994107|Drug|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
79865696|NCT03119766|Drug|Kolofort|Oral administration
79865697|NCT03119766|Drug|Placebo|Oral administration
79865698|NCT03474393|Other|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
79571276|NCT01794429|Drug|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
79571277|NCT01794494|Procedure|Bypass surgery|Patients are treated with femoro-popliteal bypass
79571278|NCT01794494|Procedure|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
79571279|NCT01794754|Other|Care as usual|
79571280|NCT01794754|Other|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
79571281|NCT01794819|Device|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
79571282|NCT01795248|Drug|Liraglutide|1.8 mg liraglutide
79571283|NCT01795248|Drug|Placebo|Liraglutide without the GLP-1 analogue
79571284|NCT01795274|Radiation|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
79571285|NCT01795482|Device|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
79571286|NCT01795872|Procedure|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
79731238|NCT01123200|Device|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
79731239|NCT02857803|Procedure|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
79731240|NCT02857803|Procedure|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
79865699|NCT03469713|Drug|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
79269152|NCT06009705|Drug|toripalimab|JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
79401462|NCT04144322|Device|Zimmer T3 with DCD Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
79731241|NCT02857803|Procedure|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
79401463|NCT04130971|Other|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
79401464|NCT04130464|Drug|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
79401465|NCT04130464|Drug|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
79571287|NCT01796132|Drug|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
79731242|NCT05054088|Device|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
79731243|NCT03335722|Behavioral|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
79865700|NCT00993486|Biological|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
79865701|NCT00427635|Drug|Esomeprazole|
79865702|NCT00993642|Drug|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
79269153|NCT06009692|Other|Upper limb Neuro-dynamics (Slider/ Tensioner Technique)|The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
79401466|NCT04130464|Drug|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
79865703|NCT01564446|Other|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
79865704|NCT01028547|Drug|dexamethasone|single Bolus dose of dexamethasone 8mg
79865705|NCT01028547|Other|normal saline|2 ml 0.9% saline
79571288|NCT01796223|Behavioral|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
79571289|NCT01796223|Behavioral|Control|
79571290|NCT01796314|Behavioral|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~Knowledge of the disease~Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~Crisis situations. Prevention of caregiver's exhaustion~Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
79865706|NCT04001790|Behavioral|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
79865707|NCT01031355|Drug|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
79865708|NCT01031355|Drug|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
79401476|NCT04118348|Behavioral|Best Practice Alert|An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
79401477|NCT04118348|Behavioral|Health Maintenance Topic|An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
79401478|NCT04108988|Behavioral|InvestiDate|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
79571291|NCT01796327|Drug|dacomitinib oral|Dacomitinib 45 mg oral tablet
79571292|NCT01796327|Drug|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
79731244|NCT03335722|Device|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
79865709|NCT01031355|Drug|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
79865710|NCT00993720|Drug|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
79865711|NCT00993720|Drug|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
79865712|NCT00993720|Other|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
79865713|NCT03006666|Behavioral|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
79571293|NCT01796353|Other|sexual rehabilitation|exercise plus psycho-education
79571294|NCT01796353|Other|Usual care|usual care
79571295|NCT01796379|Behavioral|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
80025695|NCT05033184|Behavioral|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
80025696|NCT05033184|Behavioral|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
80025697|NCT05028075|Behavioral|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
79571296|NCT01796379|Behavioral|Moderate Training|
79731245|NCT03335722|Device|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
79731246|NCT04310670|Other|Psychotherapy|The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
79731247|NCT04310670|Behavioral|Physiotherapy|Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
79865714|NCT03006666|Behavioral|Data Only|The teams randomly allocated will not have access to Community Health Workers.
79865715|NCT00427011|Drug|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
79865716|NCT03891264|Drug|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
79865717|NCT00439179|Drug|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
79865718|NCT00439179|Drug|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
79571297|NCT01796418|Drug|Beraprost sodium|
79571298|NCT01796496|Other|Manipulative Therapy Techniques|"Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
79571299|NCT01796496|Other|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
79571300|NCT01796522|Drug|progesterone 200 mg / day vaginally|
79571301|NCT01796522|Drug|nifedipine (60 mg / day orally)|
79731248|NCT04310670|Other|Non-Invasive Brain Stimulation (NIBS)|"Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS)."
79571302|NCT01796717|Drug|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
79731249|NCT00955617|Other|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
79731250|NCT05462860|Other|Suprathel®|Application of standard of care dressing.®
79731251|NCT04277871|Behavioral|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
79865719|NCT00439179|Drug|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
79865720|NCT00439179|Drug|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
80025698|NCT05018273|Biological|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
80025699|NCT05010629|Drug|9-ING-41|Intravenous infusion
80025700|NCT05010629|Drug|Carboplatin|Intravenous infusion
80025701|NCT05010304|Drug|Amoxicillin|Two-dose amoxicillin challenge
80025702|NCT05008523|Behavioral|Opioids and Police Safety Occupational Risk Reduction Training (OPS)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
80025703|NCT05008523|Behavioral|Opioids and Police Safety Occupational Risk Reduction Training (COVID)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
79269154|NCT06009692|Other|Conventional Therapy for Upper limb|Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
79269155|NCT06009679|Drug|Misoprostol 200mcg Tab|Patients in the intervention group with suspected postpartum RPOC will receive 600 micrograms of misoprostol up to 3 times following delivery and followed up by ultrasound and clinical examinations for 6-12 weeks post-partum
79401479|NCT04108988|Other|Non-Health Related Video Game|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
79401480|NCT04108858|Drug|Copanlisib|Given IV
79401481|NCT04108858|Biological|Pertuzumab|Given IV
79401482|NCT04108858|Biological|Trastuzumab|Given IV
79571303|NCT01796717|Drug|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
79571304|NCT01796730|Drug|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
79571305|NCT01796730|Drug|Placebo|
79731252|NCT05331898|Behavioral|Education|the education given increased the rational drug use of the parents.
79731253|NCT03082209|Drug|ABBV-621|Intravenous (IV)
79731254|NCT03082209|Drug|Venetoclax|tablet, oral
79731255|NCT03082209|Drug|Bevacizumab|IV infusion
79731256|NCT03082209|Drug|FOLFIRI|IV infusion
79731257|NCT05423860|Other|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
79731258|NCT02224144|Drug|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
79731259|NCT02224144|Drug|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
79731260|NCT02224144|Drug|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
79731261|NCT00958347|Device|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
79731262|NCT05419180|Drug|Stiripentol|Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
79731263|NCT04281615|Other|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
79865721|NCT01034241|Dietary Supplement|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
79865722|NCT01034241|Dietary Supplement|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
79865723|NCT01034241|Dietary Supplement|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
79865724|NCT01034241|Dietary Supplement|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
79865725|NCT01031511|Behavioral|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
79865726|NCT01031511|Other|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
80025704|NCT05002608|Behavioral|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Session 1- Insurance Plan Basics; Session 2- Your Plan in Relation to Legal Policy; Session 3- Navigating Your Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs; Session 5- Understanding Your Medical Bills.
79865727|NCT00438399|Drug|C. propionate - Corticosteroid 1|Twice daily application
80025705|NCT04992832|Biological|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
79731264|NCT02857647|Behavioral|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
80025706|NCT04992832|Other|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
79401483|NCT04108273|Behavioral|Organizational Skills Training|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
79571306|NCT01796808|Procedure|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
79269156|NCT06009666|Diagnostic Test|Shear Wave Elastography and B Mode Ultrasonography|We evaluated the both upper extremities of the patient and control group with elastography and B mode ultrasonography. Shear wave elastography evaluates tissue deformation caused by acoustic radiation force. A highly focused ultrasound radiation is produced; The propagation speed of the shear wave depends on the stiffness of the tissue. It is a simple, inexpensive, bedside, widely available, non-invasive technique. B mode USG can be used to assess skin and subcutaneous tissue thickness and echogenicity. Skin and subcutaneous thickness were measured with b mode ultrasound. Skin and subcutaneous tissue stiffness was measured by shear wave ultrasonography
79269157|NCT06009666|Diagnostic Test|Quick Dash Questionnare|Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. In the questionnaire, the difficulties of the patients during their daily living activities are questioned with 11 questions. Each answer is scored from 1 to 5 on a Likert scale, from best to worst.
79401484|NCT04108273|Behavioral|Waitlist|Will undergo two magnetic resonance imaging (MRI) sessions separated by a 12 week wait period. Will then undergo OST treatment
79401485|NCT04099615|Procedure|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
79865728|NCT00438399|Drug|C. propionate- Corticosteroid 2|Twice daily application
79865729|NCT00438399|Drug|C. propionate -Corticosteroid 3|Twice daily application
79865730|NCT00438399|Drug|Corticosteroid 1- C. propionate|Twice daily application
79865731|NCT00438399|Drug|Corticosteroid 2 - C. propionate|Twice daily application
79865732|NCT00438399|Drug|Corticosteroid 3 - C. propionate|Twice daily application
79865733|NCT00426231|Behavioral|Navigation by a health worker|Help provided by health worker to navigate medication access programs
80025707|NCT04992169|Behavioral|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
79269158|NCT06009666|Diagnostic Test|The Lymphedema Life Impact Scale|The Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 functional subgroups. Each question is scored from 1 to 5, with higher scores indicating increased seriousness.
79269159|NCT06009666|Diagnostic Test|Questioning lymphedema-related symptoms|Arm pain and feeling of tension, heaviness and stiffness in the arm were evaluated separately by numerical scale. This scale is a 10 cm ruler that writes no pain, no tension, no heaviness, no stiffness on one side, and unbearable pain, tension and heaviness on the other side. Patients were asked to rate their associated symptoms on this scale between 0 and 10.
79401486|NCT04098237|Drug|Pancrelipase|Pancrelipase delayed-release capsules
79865734|NCT00426231|Behavioral|Information control|Information about medication access programs provided to the participant and their healthcare provider
79865735|NCT03386409|Behavioral|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
79401487|NCT04090762|Behavioral|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
79401488|NCT04090762|Behavioral|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
79571307|NCT01796808|Other|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot."
79571308|NCT01796925|Device|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
79571309|NCT01796990|Behavioral|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
79731265|NCT02067052|Procedure|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
79865736|NCT03386409|Behavioral|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
80025708|NCT04982315|Procedure|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
79269160|NCT06009666|Other|Extremity circumference and volume measurement|For the diagnosis of lymphedema, a detailed physical examination and extremity circumference were measured. This measurement was taken from both wrists to arm height with 4 cm intervals. Those with a circumference difference greater than 2 cm and/or no 10% volume difference were considered preclinical (latent) and those with clinical lymphedema.
79269161|NCT06009627|Drug|Dalcelli、Exemestane、Gosserine|"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"
79401489|NCT04088981|Behavioral|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
79401490|NCT04084860|Drug|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
79401491|NCT04084860|Drug|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
79401492|NCT04084860|Behavioral|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
79401493|NCT04084860|Behavioral|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
79401494|NCT04075526|Drug|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
79571310|NCT01796990|Behavioral|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
79571311|NCT01797211|Dietary Supplement|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
79731266|NCT02067052|Procedure|Surgery|Vulvectomy & lymphadenectomy
79731267|NCT05418712|Drug|Placebo|Placebo matched to VX-150 for oral administration.
79731268|NCT05418712|Drug|VX-150|Solution or Suspension for oral administration.
79731269|NCT04280289|Drug|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
79731270|NCT03302728|Drug|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
79865737|NCT00425607|Drug|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
79865738|NCT00437073|Drug|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
79865739|NCT00437073|Drug|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
79865740|NCT00437073|Drug|lapatinib|lapatinib administered 1250mg once daily orally
79865741|NCT00425373|Drug|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
79571312|NCT01797289|Other|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
79865742|NCT00425373|Drug|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
79865743|NCT00425373|Drug|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
79865744|NCT00425373|Drug|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
79571313|NCT01797653|Other|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
79865745|NCT00425373|Drug|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
79865746|NCT00425373|Drug|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
79865747|NCT00425373|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
79865748|NCT00425373|Drug|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
79865749|NCT00425373|Drug|Placebo|4 tablet and 2 capsule placebos taken once daily
79865750|NCT03742479|Device|Restylane® Silk|Injectable Hyaluronic Acid (HA)
79269162|NCT06009627|Drug|Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection|"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"
79571314|NCT01797653|Procedure|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
79401495|NCT04075526|Drug|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
79571315|NCT01797718|Drug|Testosterone|1mg/kg every 4 weeks for 6 months
79571316|NCT01797718|Drug|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
79571317|NCT01797796|Drug|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
79571318|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
79571319|NCT01797796|Drug|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
79571320|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
79731271|NCT03302728|Drug|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
79731272|NCT05331742|Drug|Vaccine|patients who have received vaccine against coronavirus disease infection
79731273|NCT03863236|Dietary Supplement|regular diet|The control group (group 1) will continue their regular diet.
79731274|NCT03863236|Dietary Supplement|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
79731275|NCT00958191|Device|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
79731276|NCT05322382|Procedure|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
79865751|NCT01031589|Drug|TMC278 (Rilpivirine) LA; Placebo|
79865752|NCT03894540|Drug|IPN60090|Oral capsules given daily
79865753|NCT03894540|Drug|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
79865754|NCT03894540|Drug|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
79865755|NCT03894540|Drug|IPN60090 single administration|Oral capsules given once
79865756|NCT00993876|Drug|citalopram|20 to 30 mg per day for 4 weeks
79865757|NCT00993876|Drug|reboxetine|4 to 8 mg per day for 4 weeks
79865758|NCT00993876|Behavioral|interpersonal psychotherapy|
79865759|NCT04002336|Behavioral|Traditional Voice therapy|Traditional method of voice therapy
79865760|NCT04002336|Behavioral|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
79865761|NCT05175612|Device|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
79865762|NCT05088018|Other|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
79571321|NCT01798108|Radiation|Radium-223 dichloride (BAY88-8223)|- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
79865763|NCT05088018|Other|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
79865764|NCT00535626|Device|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
79865765|NCT00994032|Procedure|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
79865766|NCT00994032|Other|Medical treatment|standard antalgic medical treatment
79865767|NCT05252286|Other|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
79865768|NCT05252286|Other|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
79865769|NCT05252286|Other|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
79865770|NCT00994188|Procedure|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
79865771|NCT00995280|Device|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
79865772|NCT00995280|Device|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
79865773|NCT05224518|Behavioral|elastic band training|elastic band training include stretching exercises
79865774|NCT00994266|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
79865775|NCT00994266|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
79865776|NCT05302674|Other|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
79865777|NCT01646814|Drug|PL2200|PL2200, containing 325 mg aspirin active ingredient
79571322|NCT01798329|Dietary Supplement|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~urease faecal activity~faecal pH~inflammatory cytokine"
79865778|NCT01646814|Drug|Aspirin tablets|325 mg aspirin tablets (USP)
79865779|NCT00994344|Drug|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
79865780|NCT00994344|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
79865781|NCT00994500|Drug|vorinostat|Given orally
79865782|NCT00994500|Drug|bortezomib|Given IV
79865783|NCT00994500|Other|pharmacological study|Correlative studies
79865784|NCT00994500|Other|laboratory biomarker analysis|Correlative studies
79865785|NCT01416636|Drug|Treprostinil sodium|
79865786|NCT00995358|Biological|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
79865787|NCT00994578|Behavioral|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
79865788|NCT00994578|Behavioral|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
79865789|NCT00994578|Behavioral|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
79865790|NCT00995592|Behavioral|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
79865791|NCT00994656|Device|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
79865792|NCT00999180|Procedure|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
79865793|NCT00999180|Procedure|Saline and Kinesiotherapy|Saline and Kinesiotherapy
79269163|NCT06009601|Diagnostic Test|Pectus Study Form|"Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives."
79269164|NCT06009601|Diagnostic Test|Adams Test|Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form
79269165|NCT06009601|Diagnostic Test|Scoliosis Graphy|"ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs."
79269166|NCT06009601|Diagnostic Test|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes."
79269167|NCT06009588|Device|type of transcatheter heart valves|patients undergoing TAVR use either self-expandable valves or balloon-expandable valves
79269168|NCT06009575|Dietary Supplement|Iron Supplement Tablets|The intervention group received IST and local culture-based nutrition education
79401496|NCT04075526|Other|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
79401497|NCT04060628|Drug|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
79401498|NCT04054154|Device|Shear Wave Elastography|Undergo shear wave elastography
79571323|NCT01798355|Behavioral|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
79571324|NCT01798355|Behavioral|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
79571325|NCT01798446|Drug|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
79571326|NCT01798680|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
79269169|NCT06009562|Procedure|Laparotomic myomectomy during pregnancy|Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access
79731277|NCT03832972|Other|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
79865794|NCT03889704|Device|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
79401499|NCT04054154|Procedure|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
79401500|NCT04051229|Behavioral|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
79571327|NCT01798680|Other|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
79571328|NCT01798823|Procedure|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
79571329|NCT01798836|Procedure|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
79571330|NCT01798836|Procedure|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
79731278|NCT03051477|Drug|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
79731279|NCT03125356|Other|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
79731280|NCT05314114|Procedure|No axillary surgery|No axillary surgery
79731281|NCT02860299|Drug|citrate 4%|
79731282|NCT02860299|Drug|unfractionated heparin|
79731283|NCT02860299|Biological|blood sample|
79731284|NCT02858739|Device|BIOFREEDOM STENT|
79731285|NCT02858505|Drug|27 mg elemental iron|
79731286|NCT02858505|Drug|54 mg elemental iron|
79731287|NCT05313100|Drug|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
79731288|NCT00960843|Device|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
79731289|NCT00960843|Other|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
80025709|NCT04982315|Procedure|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
80025710|NCT04981470|Device|baroloop System|vagal nerve stimulation
80025711|NCT04977804|Other|Exercise|The interventions are a form or exercise, specifically resistance exercise.
79401501|NCT04051229|Behavioral|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
79401502|NCT04049994|Drug|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
79401503|NCT04049994|Drug|Placebo oral tablet|Placebo oral tablet
79731290|NCT04281693|Diagnostic Test|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
79731291|NCT04281693|Diagnostic Test|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
79731292|NCT02860221|Drug|Tranexamic acid (TXA)|IV and topical administration
79865795|NCT00999258|Drug|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
79865796|NCT05210712|Device|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
79865797|NCT00994734|Drug|Mifepristone|home administration of mifepristone
80025712|NCT04977804|Other|Eccentric plus blood-flow restriction|Eccentric plus blood-flow restriction
79401504|NCT04042259|Device|Abthera|Negative Pressure Wound Therapy Device
79401505|NCT04042259|Procedure|Open adbdomen for post-laparotomy without NPWT device|Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
79571331|NCT01798862|Procedure|Endometrial injury by hysteroscopy or pipelle sampling|
79731293|NCT02860221|Drug|Epinephrine|
79731294|NCT02860065|Drug|CPC-201|solifenacin and donepezil
79731295|NCT02860065|Other|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
79731296|NCT04274829|Procedure|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
79731297|NCT02857881|Procedure|De-epithelization and therapeutic photokeratectomy|
79731298|NCT02857569|Drug|Ipilimumab IT|
79731299|NCT02857569|Drug|Ipilimumab IV|
79731300|NCT02857569|Drug|Nivolumab IV|
79731301|NCT02638363|Behavioral|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
80025713|NCT04969939|Drug|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
80025714|NCT04969939|Drug|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
80025715|NCT04969939|Drug|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
79571332|NCT01798862|Procedure|Proceed to COH directly|
79571333|NCT01798901|Drug|HDAC inhibitor AR-42|Given PO
79571334|NCT01798901|Drug|decitabine|Given IV
79571335|NCT01798901|Other|laboratory biomarker analysis|Correlative studies
79571336|NCT01798901|Other|pharmacological study|Correlative studies
79571337|NCT01799148|Other|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
79571338|NCT01799304|Procedure|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
79571339|NCT01799304|Procedure|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
79731302|NCT04164667|Behavioral|Directed instruction of the combined intervention of physical activity and mindfulness meditation|By using the VA's ANNIE text messaging systems, the participant's will receive detailed guidance on the exercise and mindfulness session.
79731303|NCT04164667|Behavioral|Self-guided practice of the combined intervention of physical activity and mindfulness meditation|The participants will receive the same goals about exercise and mindfulness practice, but without the added text messages where explicit instruction will be provided
80025716|NCT04969939|Drug|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
79401506|NCT04040387|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
79401507|NCT04040387|Device|Sham NightWare|NightWare device not providing interventions
80025717|NCT04967664|Drug|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
80025718|NCT04967664|Drug|capsaicin 0.04% topical system|Low-dose capsaicin control
79865798|NCT00995826|Drug|CS-8958|Inhaled CS-8958
80025719|NCT04949841|Drug|Delgocitinib|Delgocitinib cream 20 mg/g
79269170|NCT06009536|Other|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
79269171|NCT06009497|Drug|Romiplostim|Romiplostim 10 µg/kg, subcutaneous injection, once a week.
79571340|NCT01799304|Procedure|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
79571341|NCT01799304|Procedure|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
79269172|NCT06009497|Drug|Ciclosporin|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
79401508|NCT04037605|Drug|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
79401509|NCT04037605|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
79571342|NCT01799343|Other|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
79865799|NCT00995826|Other|Placebo|Inhaled placebo
79865800|NCT00994812|Drug|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
79865801|NCT00994968|Drug|cyclophosphamide|
79865802|NCT00994968|Drug|docetaxel|
80025720|NCT04947735|Device|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
80025721|NCT04947735|Device|Spectacle lenses|Single vision, impact resistant spectacle lenses
80025722|NCT04937907|Drug|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
80025723|NCT04937907|Drug|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
80025724|NCT04934475|Drug|Isatuximab|treatment with Isa-KRD during induction and consolidation , with revlimid or Iberdomide +isatuximab during maintenance phase
80025725|NCT04934475|Procedure|ASCT|ASCT for ams B, C and D during consolidation
80025726|NCT04930003|Biological|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
80025727|NCT04930003|Other|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
80025728|NCT04928235|Diagnostic Test|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
80025729|NCT04904302|Biological|Nivolumab|Given IV
79269173|NCT06009484|Procedure|Colon resection|Colon cancer resection
79269174|NCT06009471|Other|Routine treatment in Neurology|Routine treatment in Neurology department, including drug treatment,etc.
79269175|NCT06009471|Device|Routine treatment in Neurology and rTMS|Add rTMS to routine treatment. Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability
79304419|NCT03292445|Drug|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover >10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
79401510|NCT04037605|Drug|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
79401511|NCT04037605|Drug|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
79571343|NCT01799512|Device|experimental: real-time continuous glucose monitoring|
79571344|NCT01799512|Device|Active comparator: blinded continuous glucose monitoring|
79571345|NCT01799694|Drug|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
79865803|NCT00994968|Drug|doxorubicin hydrochloride|
80025730|NCT04904302|Other|Quality-of-Life Assessment|Ancillary studies
80025731|NCT04904302|Other|Questionnaire Administration|Ancillary studies
80025732|NCT04904302|Drug|Sitravatinib|Given PO
80025733|NCT04901884|Drug|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
79269176|NCT06009458|Device|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
79865804|NCT00994968|Drug|tegafur-gimeracil-oteracil potassium|
79731304|NCT04164355|Drug|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
79571346|NCT01799863|Drug|Ketorolac trometamol 0.45% with carboxymethylcellulose|
79571347|NCT01799863|Drug|Preservative free artificial tear|
79571348|NCT01800006|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
79571349|NCT01800019|Drug|Nicotine Replacement Therapy (NRT)|
79571350|NCT01800019|Drug|Varenicline|
79571351|NCT01800019|Behavioral|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
79731305|NCT01605253|Drug|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
79731306|NCT01605253|Drug|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
79731307|NCT04164433|Device|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
79731308|NCT00655135|Drug|LDP-02|Each patient in arms 2 & 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
79731309|NCT00655135|Drug|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
79731310|NCT02643121|Other|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
79865805|NCT00994968|Procedure|neoadjuvant therapy|
79865806|NCT00994968|Procedure|therapeutic conventional surgery|
79865807|NCT03887442|Drug|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
79865808|NCT03887442|Drug|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
79865809|NCT00995982|Biological|VRC-FLUDNA056-00VP|
79865810|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
79571352|NCT01800045|Drug|Pitolisant|1 capsule in the morning before breakfast
79571353|NCT01800045|Drug|Placebo|1 capsule in the morning before breakfast
79571354|NCT01800071|Drug|MVA-EBNA1/LMP2 vaccine|
79571355|NCT01800084|Device|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
79571356|NCT01800097|Drug|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
79571357|NCT01800097|Drug|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
79865811|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
79865812|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
79865813|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
79865814|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
79865815|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
79865816|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
79731311|NCT04163965|Device|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
79731312|NCT02643277|Behavioral|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
79269177|NCT06009445|Diagnostic Test|Renal resistive index|"The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity _ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged."
79571358|NCT01800110|Dietary Supplement|pomegranate juice|
79269178|NCT06009432|Other|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.
79571359|NCT01800136|Device|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
79731313|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
79269179|NCT06009419|Other|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
79269180|NCT06009406|Other|Physiotherapy|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
79269181|NCT06009393|Drug|SHR-1918|Three administration
79269182|NCT06009380|Other|Physiotherapy and Rehabilitation|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
79269183|NCT06009367|Procedure|Fascial Manipulation by Stecco method|Fascial Manipulation (FM) is a method carefully developed by members of the Stecco family after many years of research. FM involves deep kneading of the muscle fascia at specific points called centers of coordination (CC) and centers of fusion (CF) along myofascial sequences, diagonals, and spirals. It has been proposed that the friction caused by manipulation creates localized heat and that, due to the thermosensitive characteristics of fascia, this heat facilitates the transition of hyaluronic acid within the extracellular matrix from a condensed state to a more fluid state, thus restoring the gliding properties of fascia.
79304420|NCT02449057|Other|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
79401512|NCT04037605|Drug|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
79731314|NCT02635945|Drug|PBF-680|
79731315|NCT02635945|Drug|Placebo|
79731316|NCT04059991|Biological|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
79865817|NCT00999414|Drug|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
79865818|NCT00999492|Device|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
79865819|NCT00996138|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
80025734|NCT04896385|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
79571360|NCT01800149|Procedure|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
79571361|NCT01800175|Device|Punctum Plug|
79571362|NCT01800188|Procedure|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
79571363|NCT01800188|Procedure|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
79571364|NCT01800188|Procedure|Meal test|A 3 hour standardized liquid meal test without dialysis
79571365|NCT01800227|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
79571366|NCT01800240|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
79571367|NCT01800253|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
79731317|NCT04162249|Other|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
79731318|NCT04162249|Other|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
79571368|NCT01800253|Procedure|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
79571369|NCT01800253|Procedure|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
79401513|NCT04037605|Drug|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
79731319|NCT04162249|Other|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
79571370|NCT01800253|Procedure|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
79269184|NCT06009354|Other|Rehabilitation|The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
79269185|NCT06009341|Other|Rehabilitation|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
79269186|NCT06009328|Other|fundamental movement skills|measured by test of gross motor development
79269187|NCT06009224|Other|ERAS perioperative management|"Epidural analgesia~Fluid balance~Other items are the same as conventional"
79571371|NCT01800253|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
79269188|NCT06009211|Other|QueaseEase|Study participants will participate in one week with aromatherapy treatment and one week without aromatherapy treatment (randomly ordered) to serve as their own control.
79571372|NCT01800266|Behavioral|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
79865820|NCT00995046|Drug|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
79865821|NCT00995046|Drug|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
79865822|NCT00995124|Drug|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
79269189|NCT06009198|Drug|Iron folate tablets|Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
79269190|NCT06009146|Device|Endovascular treatment|Endovascular treatment for infrapopliteal arterial disease.
79731320|NCT04162249|Diagnostic Test|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions <72 hours after ablation.
79865823|NCT00995124|Drug|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
79269191|NCT06009042|Drug|IVIG 20g/d|The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
79269192|NCT06009042|Drug|IVIG 10g/d|The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
79269193|NCT06009029|Radiation|Stereotactic body radiation(SBRT)|"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."
79269194|NCT06009029|Drug|Zimberelimab (GLS-010)|Zimberelimab (GLS-010),240mg d1 iv Q21D
79401514|NCT04037605|Drug|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
79269195|NCT06009016|Diagnostic Test|Inflammatory factors and coagulation factors level in cerebrospinal fluid after subarachnoid hemorrhage|Inflammatory factors and coagulation factors level in cerebrospinal fluid will be tested by ELISA kits.
79269196|NCT06008925|Drug|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
79401515|NCT04037605|Drug|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
79269197|NCT06008925|Drug|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
79269198|NCT06008899|Procedure|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
79401516|NCT04037605|Drug|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
79401517|NCT04037605|Drug|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
79401518|NCT04037605|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
79731321|NCT04164043|Behavioral|Wellness Recovery Program|12-week community-based recreation therapy
79731322|NCT00955305|Biological|Bevacizumab|Given IV
79731323|NCT00955305|Drug|Carboplatin|Given IV
79731324|NCT00955305|Biological|Cixutumumab|Given IV
79731325|NCT00955305|Drug|Paclitaxel|Given IV
79731326|NCT02635789|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
79731327|NCT02635789|Drug|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
79731328|NCT02635711|Behavioral|Adapted Taekwondo training|Adapted Taekwondo training for beginners
79731329|NCT02635711|Behavioral|Control|Daily jogging
79731330|NCT00655291|Drug|XP20B|
79731331|NCT00655291|Drug|Placebo|
79731332|NCT02857725|Drug|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
79731333|NCT02857725|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
80025735|NCT04896385|Drug|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
80025736|NCT04895735|Biological|Pembrolizumab|Given IV
80025737|NCT04895735|Drug|Pemetrexed Disodium|Given IV
80025738|NCT04884724|Other|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
80025739|NCT04879225|Behavioral|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
80025740|NCT04879225|Behavioral|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
79731334|NCT00656695|Drug|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
79269199|NCT06008808|Drug|Ruxolitinib|Ruxolitinib is provided by Incyte Corporation.
79269200|NCT06008769|Behavioral|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
79269201|NCT06008743|Behavioral|Belt Accelerations|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
79269202|NCT06008743|Behavioral|Belt accelerations combined with an exoskeleton|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
79401519|NCT04037605|Drug|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
79401520|NCT04018937|Drug|Alemtuzumab|Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m^2 the second and 20 mg/m^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
79731335|NCT00656695|Drug|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
79401521|NCT04018937|Drug|Fludarabine|Fludarabine will be administered at 30 mg/m^2 IV daily for five days (Days -7 to -3).
79401522|NCT04018937|Drug|Melphalan|Melphalan will be administered at 140 mg/m^2 IV on Day -3 following fludarabine administration.
79401523|NCT04017936|Drug|Anakinra|Active Treatment
79731336|NCT02858427|Behavioral|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
79731337|NCT02858427|Behavioral|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
79731338|NCT02858427|Behavioral|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
79865824|NCT00995124|Drug|Moov Head Lice Solution|Single application for head lice with 10 min application time.
80025741|NCT04879225|Behavioral|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
80025742|NCT04879225|Behavioral|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
80025743|NCT04866303|Diagnostic Test|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
80025744|NCT04865939|Procedure|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
80025745|NCT04865939|Drug|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
80025746|NCT04864899|Diagnostic Test|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
80025747|NCT04864899|Diagnostic Test|Blood test|Blood investigation
80025748|NCT04864899|Diagnostic Test|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
79401524|NCT04016389|Drug|Cisplatin|Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
79401525|NCT04016389|Drug|Carboplatin|Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
80025749|NCT04860570|Device|Double-ring wound-edge protector|Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
79731339|NCT02858427|Behavioral|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
79269203|NCT06008743|Behavioral|Variable Stiffness treadmill|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
79571373|NCT01800279|Other|Physiotherapy Protocol|"Kinesitherapy~Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~Tongue in the palate for all applied exercises.~Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
79731340|NCT02642887|Procedure|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
79571374|NCT01800279|Other|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
79731341|NCT04204083|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
79865825|NCT04001010|Drug|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
79571375|NCT01800292|Drug|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
80025750|NCT04819737|Procedure|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
79865826|NCT04001010|Drug|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
79865827|NCT00999570|Other|Specialty training for knee surgeons|
80025751|NCT04819737|Other|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
79269204|NCT06007157|Behavioral|Hypersodic/Hyposodic diet|Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
79865828|NCT04000542|Other|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
79865829|NCT00999648|Other|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
79865830|NCT00999648|Other|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
79865831|NCT04000698|Drug|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid Condition~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor GVHD prophylaxis~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
80025752|NCT04817969|Device|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
79269205|NCT06006689|Drug|Qishen Yiqi Dripping Pills placebo 3 bags|Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
79401526|NCT04016389|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
79571376|NCT01800305|Drug|Pegylated rhEPO|
79571377|NCT01800305|Drug|EPIAO®|
79571378|NCT01800331|Behavioral|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
79571379|NCT01800344|Device|LMA|
79865832|NCT00996294|Procedure|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
79269206|NCT06006689|Drug|Low dose Qishen Yiqi Dripping Pills 3 bags|Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
79731342|NCT04271865|Other|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
79269207|NCT06006689|Drug|High dose Qishen Yiqi Dripping Pills 3 bags|High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
79269208|NCT06006273|Drug|Eribulin|Given by vein (IV)
79269209|NCT06006273|Drug|Irinotecan|Given by vein (IV)
79269210|NCT06006273|Drug|Temozolomide|Given by PO
79571380|NCT01800344|Device|Ultra|Ultra
79269211|NCT06005792|Biological|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
79269212|NCT06005792|Biological|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
79865833|NCT01004016|Drug|KPS-0373|
79269213|NCT06005597|Combination Product|Combination Therapy|tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
79865834|NCT01004016|Drug|Placebo|
79269214|NCT06005597|Drug|Monotherapy obicetrapib|tablet; 10mg obicetrapib
79571381|NCT01800357|Drug|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
79571382|NCT01800357|Drug|placebo|infusion of plabcebo once a day and for 14 days
79865835|NCT04000932|Drug|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
79865836|NCT04000932|Drug|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
79865837|NCT01004094|Behavioral|simple goal setting|This group will set goals only
79865838|NCT01004094|Behavioral|goal setting plus action intentions|This group will set goals and form action intentions (plans)
79865839|NCT01004094|Behavioral|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
79865840|NCT01004094|Behavioral|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
79865841|NCT00999882|Drug|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
80025753|NCT04805190|Behavioral|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
79269215|NCT06005597|Drug|Monotherapy ezetimibe|capsule; 10mg ezetimibe
79269216|NCT06005597|Other|Combination Therapy placebo|tablet; no active ingredient
79269217|NCT06005597|Other|Obicetrapib Placebo|tablet; no active ingredient
79269218|NCT06005597|Other|Ezetimibe Placebo|capsule; no active ingredient
79269219|NCT06005298|Behavioral|Screening, Brief Intervention, Referral to Treatment (SBIRT)|"SBIRT has been defined by SAMHSA as a comprehensive, integrated, public health approach to the delivery of early intervention for individuals with risky alcohol and drug use and the timely referral to more intensive substance abuse treatment for those who have substance abuse disorders. There is consensus that a comprehensive SBIRT model includes screening, brief intervention/brief treatment, and referral to treatment. In addition there are following characteristics:~It is brief (e.g., typically about 5-10 minutes for brief interventions; about 5 to 12 sessions for brief treatments)~The screening is universal.~One or more specific behaviors related to risky alcohol and drug use are targeted.~The services occur in a public health non-substance abuse treatment setting.~It is comprehensive (comprised of screening, brief intervention/treatment, and referral to treatment).~Strong research or experiential evidence supports the model's effectiveness."
79269220|NCT06005181|Behavioral|Music listening|Daily music listening
79269221|NCT06005181|Behavioral|Piano training|Daily piano practice
79269222|NCT06005142|Dietary Supplement|Eriomin|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
79269223|NCT06005142|Dietary Supplement|Washout|After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
79571383|NCT01800357|Drug|aspirin|infusion of aspirin (100mg) once a day for days
79571384|NCT01800370|Drug|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
79571385|NCT01800370|Drug|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
79731343|NCT04271865|Other|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
79731344|NCT04271865|Other|recipe book|3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
79865842|NCT00996528|Behavioral|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
79865843|NCT05170230|Drug|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
80025754|NCT04805190|Behavioral|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
79865844|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
79865845|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
79865846|NCT01004328|Other|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
79865847|NCT01000116|Procedure|Fibrin glue|Tissucol 2 ml
79865848|NCT01000116|Procedure|Tacks|Protacks
79865849|NCT00996684|Drug|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
79269224|NCT06005142|Dietary Supplement|Placebo|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
79571386|NCT01800370|Other|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
79269225|NCT06004154|Diagnostic Test|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries added to the usual follow-up at 1, 3, 6 and 12 months
79277549|NCT03527563|Behavioral|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
79571387|NCT01800370|Procedure|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
79865850|NCT00996684|Drug|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
80025755|NCT04766749|Other|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
80025756|NCT04761458|Diagnostic Test|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
79571388|NCT01800370|Other|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
79571389|NCT01800396|Dietary Supplement|Milk protein|
79571390|NCT01800396|Dietary Supplement|Milk protein rich in phospholipids|
79571391|NCT01800409|Device|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
79865851|NCT00996762|Drug|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
79865852|NCT05162196|Radiation|SBRT|24Gy/3F
79865853|NCT05162196|Drug|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
79865854|NCT05162196|Drug|Niraparib|200mg qd
79865855|NCT04000464|Behavioral|CLIPP|Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
79865856|NCT01000194|Dietary Supplement|High fat meal|A high fat milkshake containing 55g of fat
79865857|NCT01004484|Other|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
79865858|NCT01004484|Other|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
79865859|NCT01004562|Other|informational intervention|
79269226|NCT06003504|Other|First aid training with blended learning approach|"The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket."
79277550|NCT02364063|Other|urotherapy with or without pharmacotherapy|Individualized
79277551|NCT05300893|Other|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
79731345|NCT04271865|Other|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
79731346|NCT00598585|Drug|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
79731347|NCT00598585|Drug|Placebo|Placebo pills 3X/day for 6 weeks
79731348|NCT04271553|Other|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
79865860|NCT00997074|Drug|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
79865861|NCT01004796|Genetic|cytogenetic analysis|
79731349|NCT00175201|Procedure|Proactive care and rehabilitation|
79865862|NCT01004796|Genetic|microarray analysis|
79401527|NCT04016389|Procedure|Trachelectomy|Surgery to remove the cervix but keep the uterus intact.
79401528|NCT04013841|Other|Oral-agents/Enema|"Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~Enema for mechanical bowel preparation prior to left-side colorectal resection"
79401529|NCT04009681|Drug|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
79401530|NCT04009681|Drug|Checkpoint inhibitor|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
79401531|NCT04009681|Drug|anti-EGFR antibody|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
79401532|NCT04009668|Drug|adalimumab|Adalimumab will be dosed based on weight
79401533|NCT04006990|Behavioral|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
79401534|NCT04003779|Other|Room configuration|Adjust distance, handrails, degrees of turn for participant
79401535|NCT03993561|Other|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
79401536|NCT03987555|Other|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
79731350|NCT00653107|Procedure|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
79731351|NCT00653107|Radiation|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
79865863|NCT01004796|Genetic|mutation analysis|
79865864|NCT01004796|Other|immunohistochemistry staining method|
79865865|NCT01004796|Other|immunologic technique|
79865866|NCT01004796|Other|mass spectrometry|
79865867|NCT00997308|Drug|AZD1446|Solution, oral, for 4 weeks
79865868|NCT00997308|Drug|Placebo|
79865869|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
79865870|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
79865871|NCT01000740|Genetic|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
79865872|NCT01000740|Genetic|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
79865873|NCT05249712|Drug|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
79865874|NCT05249712|Other|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
80025757|NCT04761458|Diagnostic Test|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
80025758|NCT04761458|Diagnostic Test|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
80025759|NCT04761458|Diagnostic Test|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
80025760|NCT04757155|Behavioral|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
80025761|NCT04746833|Behavioral|SUMMIT|multicomponent web-based application focused on pain self-management skills
80025762|NCT04746833|Behavioral|control|My Pain Diary app
79571392|NCT01800422|Drug|telapristone acetate|Given orally
79865875|NCT01005030|Other|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
80025763|NCT04745949|Drug|Brentuximab Vedotin|Given IV
80025764|NCT04745949|Drug|Cyclophosphamide|Given IV
79269227|NCT06003504|Other|First aid training with face-to-face approach|"The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross."
79269228|NCT06003088|Drug|HSK7653(5mg)|Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
79401537|NCT03987555|Other|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
79401538|NCT03987555|Other|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
79401539|NCT03987035|Device|BeGraft Peripheral (BGP) Stent Graft System as bridging stent|BGP Stent Graft System as bridging stent
79401540|NCT03985839|Device|MICRORAPTOR™ REGENESORB™ Suture Anchor|Smith & Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
79401541|NCT03985839|Device|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
79401542|NCT03985839|Device|MICRORAPTOR™ Knotless PEEK Suture Anchor|The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
80025765|NCT04745949|Drug|Doxorubicin|Given IV
80025766|NCT04745949|Biological|Nivolumab|Given IV
79401543|NCT03985592|Behavioral|Education|Intervention description provided in elaboration on arms of the study.
79401544|NCT03985020|Other|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
79401545|NCT03985020|Other|Water Intervention|Bottled Water
79401546|NCT03982940|Device|BGP+ Stent Graft System as bridging stent|BGP+ Stent Graft System as bridging stent
79571393|NCT01800422|Other|placebo|Given orally
79571394|NCT01800422|Procedure|therapeutic conventional surgery|Undergo surgical resection
79571395|NCT01800422|Other|laboratory biomarker analysis|Correlative studies
79571396|NCT01800422|Other|questionnaire administration|Ancillary studies
79571397|NCT01800435|Drug|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
79571398|NCT01800435|Drug|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
79571399|NCT01800461|Other|OPC-Stroke|Occupational therapy coaching intervention
79571400|NCT01800461|Other|Usual care|Usual community care
79571401|NCT01800487|Drug|silymarin|140 mg three times a day for 4 weeks
79571402|NCT01800487|Drug|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
79571403|NCT01800513|Procedure|Endometrial Biopsy|
79571404|NCT01800513|Procedure|Sham Procedure|
79865876|NCT01000896|Drug|AZD0530|film coated tablet, PO, daily
79865877|NCT01000896|Drug|Carboplatin|intravenous, 3 weeks
79865878|NCT01000896|Drug|paclitaxel|intravenous, 3 weeks
79865879|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
79865880|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
79865881|NCT00425061|Other|placebo|placebo
80025767|NCT04745949|Drug|Prednisone|Given PO
80025768|NCT04745949|Other|Quality-of-Life Assessment|Ancillary studies
80025769|NCT04745949|Biological|Rituximab|Given IV
80025770|NCT04735666|Device|TauroPace™|TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.
79865882|NCT04000308|Drug|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
79571405|NCT01800526|Drug|N-Acetylcysteine|Oral and Intravenous administration of NAC
80025771|NCT04721613|Other|Assessment of Melatonin level|Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
80025772|NCT04700111|Device|DOT Pattern|DOT Pattern Spectacle Lens
79269229|NCT06003088|Drug|HSK7653(25mg)|Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
79571406|NCT01800552|Procedure|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
79571407|NCT01800565|Other|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
79571408|NCT01800565|Other|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
79865883|NCT04000308|Drug|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
79865884|NCT01005186|Behavioral|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
79865885|NCT00997542|Drug|Allopurinol|
80025773|NCT04700111|Device|Control Spectacles|Control lens
80025774|NCT04693793|Other|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
80025775|NCT04681625|Behavioral|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~Education about proper urination training in the period without pathological urgency.~Education about conscious urgency suppression through PFMT - suppressive urgency technique.~Education on the principle and effect of PFMT.~Exercises of varying intensity of pelvic floor muscles in different positions.~Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
80025776|NCT04675320|Biological|blood samples|Blood sampling during PARP inhibitor therapy
80025777|NCT04667494|Combination Product|Sonotherapy|Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion
80025778|NCT04654013|Device|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
79269230|NCT06002997|Other|Pregnancy and/or delivery complications|Analysis of post-delivery reports for pregnancy and/or delivery complications.
79401547|NCT03958747|Diagnostic Test|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
79571409|NCT01800578|Device|monitor for depth of hypnosis|"evaluation of depth of hypnosis~--------------------------------------------------------------------------------"
79571410|NCT01800591|Behavioral|Financial incentive|
79571411|NCT01800604|Behavioral|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
79865886|NCT00997542|Drug|Placebo|
79865887|NCT01001130|Drug|fluticasone furoate group|patients who are administered fluticasone furoate at least once
79865888|NCT01005264|Device|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
79269231|NCT06002997|Other|Periodontal disease|Measuring clinical periodontal parameters for assessing presence of periodontal disease.
79269232|NCT06000605|Other|Fed|Participants will eat a light meal prior to testing and be fed a light meal during testing.
79269233|NCT06000605|Other|Fasted|Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
79269234|NCT06000124|Other|Plyometric exercises|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
79865889|NCT01005264|Device|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
79865890|NCT00424827|Drug|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
80025779|NCT04650438|Device|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
80025780|NCT04650438|Device|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
79269235|NCT06000124|Other|Regulation Exercises Program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
79269236|NCT05996159|Device|QDOT MicroTM catheter|Novel high power-short duration ablation catheter for atrial fibrillation
79401548|NCT03958747|Procedure|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
79571412|NCT01800604|Behavioral|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
79731352|NCT00653107|Radiation|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
79731353|NCT02635243|Drug|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
79865891|NCT01001286|Behavioral|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
80025781|NCT04643002|Drug|Isatuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
79269237|NCT05996159|Device|AI-guided ablation only for PVI|Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
79269238|NCT05992467|Behavioral|Wellness Enhancement for Caregivers (WECARE)|WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
79401549|NCT03958747|Other|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
79401550|NCT03958747|Other|Blood draw|12 ml blood sample will be taken
79401551|NCT03958747|Diagnostic Test|Nerve Conduction Study|Sural and tibial nerve assessments
79401552|NCT03958747|Other|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
79401553|NCT03943667|Drug|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
79571413|NCT01800604|Behavioral|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
79731354|NCT02635243|Drug|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
79731355|NCT02635243|Drug|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
80025782|NCT04643002|Drug|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
79731356|NCT00953667|Drug|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
80025783|NCT04643002|Drug|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
79269239|NCT05991843|Behavioral|Instructions of breathing|Breathing normally, slowly and rapidly for 30 seconds with an open and a closed mouth.
79401554|NCT03943667|Drug|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
79401555|NCT03941834|Drug|Rimegepant|BHV3000 (rimegepant) 75mg tablet
79401556|NCT03941834|Drug|Placebo|Placebo
79401557|NCT03939858|Procedure|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
79401558|NCT03939858|Diagnostic Test|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
80025784|NCT04643002|Drug|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
80025785|NCT04643002|Drug|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
80025786|NCT04643002|Drug|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
80025787|NCT04643002|Drug|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
79401559|NCT03939858|Diagnostic Test|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
80025788|NCT04643002|Drug|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
79401560|NCT03930251|Behavioral|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
80025789|NCT04642261|Drug|Empagliflozin 10 MG|Empagliflozin 10mg daily
79571414|NCT01800604|Behavioral|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
79865892|NCT01028625|Behavioral|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
79865893|NCT01028625|Other|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
80025790|NCT04642261|Drug|Placebo pills|Identical in appearance to empagliflozin 10mg daily
80025791|NCT04612621|Diagnostic Test|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
79269240|NCT05988346|Procedure|abdominal plastic intervention|According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
79269241|NCT05981352|Procedure|mineral trioxide aggregate pulpotomy|"After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
79269242|NCT05981352|Procedure|Dehydrated amniotic membrane pulpotomy|"After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber."
79401561|NCT03930251|Behavioral|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
79571415|NCT01800617|Drug|Liothyronine, Sodium|
79571416|NCT01800630|Drug|Gemcitabine HCl Oral Formulation|
79865894|NCT01001364|Drug|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
80025792|NCT04582500|Drug|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
80025793|NCT04555785|Drug|Wilate|Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
80025794|NCT04555785|Other|Placebo|Empty placebo will be given with platelets in cases of severe bleeding.
80025795|NCT04551482|Drug|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
80025796|NCT04551482|Drug|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
80025797|NCT04517851|Biological|Elotuzumab|Given IV
80025798|NCT04517851|Other|Questionnaire Administration|Ancillary studies
80025799|NCT04514705|Other|Exercise|Exercise with treadmil and weight training station
80025800|NCT04499690|Behavioral|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
80025801|NCT04498026|Device|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
80025802|NCT04498026|Device|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
80025803|NCT04495153|Biological|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
80025804|NCT04493164|Drug|Ivosidenib|Given PO
80025805|NCT04493164|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
79731357|NCT04274439|Other|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
79865895|NCT01001364|Drug|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
79865896|NCT03994185|Device|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
79865897|NCT01031667|Drug|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
79865898|NCT03885726|Device|Precision Flow Plus|High velocity nasal insufflation
80025806|NCT04484181|Other|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
80025807|NCT04484181|Other|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
80025808|NCT04473469|Device|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
80025809|NCT04455620|Biological|BNT151|intravenous
80025810|NCT04455230|Genetic|FLT190|FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
79401562|NCT03927833|Device|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
79401563|NCT03923959|Drug|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
79401564|NCT03923959|Other|Placebo|100 cc normal saline
79401565|NCT03923374|Drug|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
79571417|NCT01800643|Other|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
79571418|NCT01800656|Procedure|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
79401566|NCT03923374|Diagnostic Test|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
79401567|NCT03923374|Diagnostic Test|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
79865899|NCT03885726|Device|Treatment as Usual|Conventional therapy per institution
79865900|NCT03995277|Dietary Supplement|Biotin|Daily intake of 10 mg or 50 µg per day
79865901|NCT01034319|Behavioral|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
79865902|NCT01034319|Behavioral|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
79865903|NCT00997776|Other|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
79401568|NCT03923270|Drug|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
79401569|NCT03923270|Drug|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
79401570|NCT03923270|Drug|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
79401571|NCT03923270|Radiation|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
79865904|NCT00997776|Other|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
80025811|NCT04431752|Radiation|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
80025812|NCT04417465|Drug|ABBV-CLS-579|Oral Capsule
80025813|NCT04417465|Drug|PD-1 inhibitor|Intravenous (IV) infusion
79401572|NCT03923270|Drug|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
80025814|NCT04417465|Drug|VEGFR TKI|Oral Tablet
80025815|NCT04405635|Other|No intervention or exposure|No intervention or exposure
80025816|NCT04405180|Drug|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
79269243|NCT05981352|Procedure|Hyaluronic acid pulpotomy|"After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol ."
79401573|NCT03916159|Procedure|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta ~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
79401574|NCT03916159|Procedure|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
79571419|NCT01800656|Procedure|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
79571420|NCT01800682|Drug|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
79865905|NCT01034475|Drug|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
79571421|NCT01800695|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
79571422|NCT01800695|Drug|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
79865906|NCT00997854|Other|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
79865907|NCT04000386|Other|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
79865908|NCT04000386|Other|placebo socks|placebo socks were given to subjects for 2 weeks
79865909|NCT00998088|Other|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
79865910|NCT00998088|Drug|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
80025817|NCT04405180|Drug|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
79571423|NCT01800695|Radiation|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
80025818|NCT04376138|Other|BCI intervention|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
79269244|NCT05978752|Procedure|Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
79269245|NCT05978752|Procedure|Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
79571424|NCT01800708|Drug|Triamcinolone acetonide|
79571425|NCT01800708|Drug|Prednisolone syrup|
79731358|NCT04274439|Other|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
79865911|NCT00998088|Device|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
79865912|NCT00998088|Device|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
79401575|NCT03913117|Biological|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
79401576|NCT03913117|Biological|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
79401577|NCT03911466|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
79401578|NCT03911466|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
79571426|NCT01800721|Behavioral|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
79571427|NCT01800721|Behavioral|SNAP Control|Behavioral: SNAP control 7 group sessions
79731359|NCT02812173|Device|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
79731360|NCT02812173|Device|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
79731361|NCT02812173|Device|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
79731362|NCT00630669|Procedure|Rubber band ligation|placing rubber bands around the internal hemorrhoids
79731363|NCT00630669|Procedure|Bipolar coagulation|using electricity to cauterize
79731364|NCT02857335|Behavioral|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
79865913|NCT00998088|Other|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
80025819|NCT04376138|Other|Conventional Therapy|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
80025820|NCT04359823|Drug|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
80025821|NCT04359823|Drug|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
80025822|NCT04359680|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
80025823|NCT04359680|Drug|Placebo|Placebo administered orally twice daily for six weeks
79269246|NCT05978752|Procedure|Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)|For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
79269247|NCT05969327|Drug|Vitamin D|oral supplementation of two different doses
79269248|NCT05958030|Device|Placebo|The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
79571428|NCT01800734|Other|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
79731365|NCT02857491|Drug|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
79731366|NCT02857491|Drug|sham|sham intravitreal injection before vitrectomy
79269249|NCT05958030|Device|GyroGlove|GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).
79269250|NCT05957627|Procedure|Saleem's protocol|It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
79269251|NCT05952999|Other|Digital Care Solution as supportive personalized care|Patients will need to meet screening and inclusion criteria at time of enrollment. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
79269252|NCT05952999|Other|Traditional Hospital Level Care|Patients will be cared for in the inpatient setting for management of diseases that meet screening and inclusion criteria at time of enrollment for hospital at home. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
79731367|NCT02857491|Procedure|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
79731368|NCT02857179|Procedure|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
79269253|NCT05945901|Drug|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
79269254|NCT05945901|Drug|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
79269255|NCT05943548|Behavioral|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
79731369|NCT00883129|Drug|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
79865914|NCT00998088|Other|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
79865915|NCT00998088|Device|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
80025824|NCT04359680|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
80025825|NCT04359641|Device|CoMET Display|Display and presentation of predictive monitoring score CoMET
79731370|NCT00883129|Drug|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
80025826|NCT04345003|Device|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
79269256|NCT05943548|Behavioral|Control|HIV Testing and referral
79269257|NCT05926609|Dietary Supplement|EB-PA|1 capsule to be taken after breakfast once a day
79269258|NCT05926609|Dietary Supplement|Placebo|1 capsule to be taken after breakfast once a day
79731371|NCT00883129|Drug|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
79731372|NCT02856867|Drug|Nintedanib|
79731373|NCT02856867|Drug|Fluorouracil|
79731374|NCT02856867|Drug|Leucovorin|
80025827|NCT04333966|Behavioral|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
80025828|NCT04333966|Behavioral|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
79731375|NCT02856867|Drug|Oxaliplatin|
79731376|NCT02856867|Drug|Placebo|
79731377|NCT00630513|Drug|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
80025829|NCT04317846|Other|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
79269259|NCT05923164|Diagnostic Test|MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool|It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.
79269260|NCT05923164|Diagnostic Test|Patient And Observer Scar Assessment Scale ( Observer Subscale)|This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
79269261|NCT05920642|Drug|Intrathecal morphine administration|Administration of morphine into the spinal canal.
79269262|NCT05920642|Drug|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
79269263|NCT05920005|Drug|candesartan cilexetil + chlorthalidone + amlodipine|Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
79269264|NCT05920005|Drug|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
79269265|NCT05918796|Drug|Bupivacaine|18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
79269266|NCT05918796|Drug|Dexamethasone|dexamethasone
79269267|NCT05916131|Behavioral|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
79269268|NCT05916131|Behavioral|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
79401579|NCT03910244|Drug|Pomalidomide Oral Product|Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific AE criteria.
79269269|NCT05916131|Behavioral|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
79401580|NCT03910244|Drug|Placebo oral capsule|Matching placebo will be given.
79401581|NCT03907475|Procedure|Biopsy|Undergo tissue biopsy
79401582|NCT03907475|Procedure|Biospecimen Collection|Undergo blood sample collection
79401583|NCT03907475|Drug|Capecitabine|Given PO
80025830|NCT04304625|Drug|Tranexamic Acid / Sodium chloride|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
79571429|NCT01800747|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
80025831|NCT04286022|Other|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
80025832|NCT04286022|Other|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
80025833|NCT04271969|Device|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
80025834|NCT04268550|Drug|Selpercatinib|Given PO
80025835|NCT04259632|Behavioral|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
79269270|NCT05899231|Behavioral|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
79304421|NCT03196141|Diagnostic Test|StO2 and EndoPAT|"StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~The EndoPAT probe will be place on a finger on the same arm.~Pulse oximeter probes will be connected to a finger on each hand."
79401584|NCT03907475|Drug|Carboplatin|Given IV
79401585|NCT03907475|Procedure|Computed Tomography|Undergo CT
79401586|NCT03907475|Biological|Durvalumab|Given IV
79401587|NCT03907475|Procedure|Echocardiography|Undergo ECHO
79401588|NCT03907475|Drug|Gemcitabine Hydrochloride|Given IV
79401589|NCT03907475|Drug|Nab-paclitaxel|Given IV
79401590|NCT03907475|Drug|Paclitaxel|Given IV
79401591|NCT03907475|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79571430|NCT01800773|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
79571431|NCT01800773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
79571432|NCT01800799|Drug|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
79571433|NCT01800799|Drug|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
79571434|NCT01800812|Biological|Injections of OM-174|
80025836|NCT04259632|Behavioral|Caloric Restriction (CR)|15% daily caloric deficient
79269271|NCT05899023|Other|Telehealth Bridge Visits|Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
79401592|NCT03904550|Drug|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
79571435|NCT01800825|Drug|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
79401593|NCT03904550|Drug|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
79571436|NCT01800825|Drug|Placebo|This will be an identical placebo comparator made of starch.
79731378|NCT00630513|Drug|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
79731379|NCT04059211|Diagnostic Test|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
79731380|NCT01278927|Behavioral|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
79401594|NCT03895099|Drug|Desogestrel early follicular phase|Start of ovarian stimulation in early follicular phase
79269272|NCT05899023|Other|Standard of Care|Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.
79401595|NCT03895099|Drug|Desogestrel medium follicular phase|Start of ovarian stimulation in medium follicular phase
79401596|NCT03895099|Drug|Desogestrel ovulatory phase|Start of ovarian stimulation in ate follicular phase
79401597|NCT03895099|Drug|Desogestrel late follicular phase|Start of ovarian stimulation in ovulatory Phase
79865916|NCT03994341|Diagnostic Test|A FLIR Thermovision a320M thermal IR camera|"Clothing removed if necessary~ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~Axillary temperature prior to starting the thermographic imaging.~Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~After surface cooling, thermal imaging will be recorded for ~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~After ~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~Axillary temperature to ensure temperature stability, any clothes will be put back on."
79865917|NCT00377962|Drug|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
79401598|NCT03895099|Drug|Desogestrel luteal phase|Start of ovarian stimulation in luteal phase
79571437|NCT01800851|Other|Energy expenditure evaluation in calorimetric chamber|
79571438|NCT01800864|Other|obesity|
79865918|NCT00377962|Drug|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
79865919|NCT00377962|Drug|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
79865920|NCT00377962|Drug|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
79304422|NCT03292367|Procedure|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
79401599|NCT03893370|Device|RejuvenAir System|RejuvenAir Metered CryoSpray
79401600|NCT03893370|Device|Sham Control Procedure|Sham Control Procedure
79401601|NCT03890614|Other|Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates|Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
79571439|NCT01800929|Device|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
79865921|NCT00424749|Drug|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m^2.
79304423|NCT03196375|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
79401602|NCT03883139|Behavioral|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child.
79571440|NCT01800942|Drug|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
79731381|NCT01278927|Behavioral|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
79731382|NCT01278927|Behavioral|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
79731383|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
79731384|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
79731385|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
79731386|NCT04162483|Device|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
79571441|NCT01800955|Device|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
79731387|NCT04270773|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
79731388|NCT00905632|Drug|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
79731389|NCT00905632|Drug|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
79865922|NCT00424749|Drug|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
79865923|NCT01031745|Behavioral|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
79865924|NCT01031745|Other|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
79865925|NCT01048216|Radiation|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
79865926|NCT01048294|Device|Original Energy Light,|9000 lux, 30 minutes in the morning
79304424|NCT03196375|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
79304425|NCT03292211|Behavioral|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
79571442|NCT01800955|Other|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
79304426|NCT03292211|Behavioral|early standard intervention|Conventional early in-bed activities within three days after stroke
79401603|NCT03883139|Behavioral|DTT (Discrete Trial Training)|"DTT is an adult-led, highly structured, behavioral teaching approach, is considered to have the strongest evidence as a standard of care for young children with autism. DTT emphasizes didactic, adult-led instruction."
79401604|NCT03874065|Other|Medical Chart Review|Collection of data from participant's medical chart
79571443|NCT01801020|Other|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
79571444|NCT01801020|Other|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
79571445|NCT01801046|Drug|mitoxantrone hydrochloride|Given IV
79571446|NCT01801046|Drug|cytarabine|Given IV
79571447|NCT01801046|Procedure|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
79571448|NCT01801046|Other|laboratory biomarker analysis|Correlative studies
79731390|NCT00905632|Drug|Placebo + SOC|Placebo tid +SOC
79731391|NCT00905632|Drug|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
79731392|NCT01213732|Other|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
79731393|NCT05287360|Drug|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
79731394|NCT05333770|Device|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
79731395|NCT05333380|Device|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
79731396|NCT00954447|Drug|Placebo|Placebo, identical to Linagliptin tablet
79731397|NCT00954447|Drug|Linagliptin|intended final marketed dose
79731398|NCT05195320|Behavioral|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
79731399|NCT05186584|Other|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
79731400|NCT05186584|Other|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
79865927|NCT01048294|Device|Original Energy Light prototype|9000 lux 20 minutes in the morning
79571449|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video and brochure
79865928|NCT01048294|Device|Original Energy Light prototype|9000 lux 30 minutes in the morning
79571450|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video
79731401|NCT04735744|Other|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
79731402|NCT00903760|Drug|Decitabine|Decitabine 20 mg/m^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
79401605|NCT03870451|Device|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
79401606|NCT03852550|Other|e-health application|In the first part of this study, an e-health application (MyREADY Transition[TM] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
79731403|NCT00903760|Drug|Clofarabine|Clofarabine 10 mg/m^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
79731404|NCT02969512|Other|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
79731405|NCT02969512|Other|OASIS Online Educational Webinars|2-hour online educational large group sessions
79731406|NCT05177614|Dietary Supplement|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
79731407|NCT05177614|Dietary Supplement|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
79731408|NCT05177614|Dietary Supplement|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
79865929|NCT03246022|Other|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
79731409|NCT04165603|Procedure|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
79865930|NCT00424593|Drug|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
79865931|NCT00424593|Drug|Placebo|every day (QD), by mouth (PO), 13 weeks
79865932|NCT01031823|Behavioral|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
79865933|NCT00369382|Drug|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
79865934|NCT00369382|Drug|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
80025837|NCT04255602|Drug|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
79401609|NCT03839342|Drug|Binimetinib|MEK inhibitor, 45mg oral tablet
79401610|NCT03839342|Drug|Encorafenib|BRAF inhibitor, 450mg oral capsule
79401611|NCT03838978|Device|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
79401612|NCT03831594|Device|Galvanic Vestibular Stimulation|Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
79401613|NCT03831594|Other|Standard Physiotherapy|45 minutes of standard physiotherapy treating impairments and functional problems
79731410|NCT02846272|Procedure|Observation|Observation of MRI changes in subjects
79571451|NCT01801059|Other|questionnaire administration|Ancillary studies
79571452|NCT01801137|Drug|Everolimus (Afinitor®)|
79571453|NCT01801150|Device|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
79571454|NCT01801163|Drug|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
79571455|NCT01801163|Radiation|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
79571456|NCT01801176|Other|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
79401614|NCT03808610|Drug|Cyclophosphamide|Given IV
80025838|NCT04255602|Drug|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
79269273|NCT05877976|Behavioral|Visual Arts Immersion|Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
79571457|NCT01801202|Device|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
79571458|NCT01801228|Drug|Eplerenone|
79571459|NCT01801254|Other|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
79571460|NCT01801254|Other|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
79571461|NCT01801267|Procedure|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
79865935|NCT01324648|Behavioral|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
79865936|NCT01324648|Behavioral|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
79865937|NCT01324648|Other|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
79731411|NCT04202536|Drug|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
79865938|NCT00424515|Drug|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
79571462|NCT01801267|Procedure|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
79571463|NCT01801293|Drug|GS-5806|
79865939|NCT01581112|Biological|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
80025839|NCT04240756|Behavioral|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
80025840|NCT04240756|Drug|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
80025841|NCT04236596|Device|Medtronic Interstim II Model 3058 Neurostimulator|All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
79571464|NCT01801306|Device|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
79571465|NCT01801319|Device|Libra Deep Brain Stimulation System|
79731412|NCT04202536|Drug|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
79731413|NCT02817880|Device|rTMS|
79731414|NCT02817880|Device|tDCS|
79401615|NCT03808610|Drug|Cytarabine|Given IV
79401616|NCT03808610|Drug|Dexamethasone|Given IV or PO
79401617|NCT03808610|Drug|Methotrexate|Given IV
79401618|NCT03808610|Drug|Nelarabine|Given IV
79401619|NCT03808610|Drug|Pegaspargase|Given IV
79401620|NCT03808610|Drug|Prednisone|Given PO
79401621|NCT03808610|Biological|Rituximab|Given IV
79401622|NCT03808610|Drug|Venetoclax|Given PO
79401623|NCT03808610|Drug|Vincristine|Given IV
79401624|NCT03808103|Biological|Placebo|Orally, twice a day, for a period of fifteen days
79401625|NCT03808103|Biological|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
79401626|NCT03792516|Drug|artesunate ointment 40%|artesunate formulated as an ointment to be applied topically to the vulva
79731415|NCT02817880|Device|tsDCS|
79731416|NCT02794402|Drug|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
79731417|NCT02794402|Behavioral|Placebo|Placebo once weekly injections sc
79731418|NCT00883051|Drug|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
79731419|NCT00883051|Drug|Placebo|Placebo
79865940|NCT03994263|Device|ITind device implant|device implanted for 5-7 days
80025842|NCT04229446|Behavioral|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
79865941|NCT00377260|Drug|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
79865942|NCT00377260|Drug|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
79865943|NCT00441441|Drug|fluticasone propionate|fluticasone propionate 100mcg HFA
79865944|NCT00441441|Drug|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
79269276|NCT05853185|Drug|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
79401627|NCT03783442|Drug|Cisplatin|Administered IV
79865945|NCT00436917|Drug|zoledronic acid|zoledronic acid
79865946|NCT00436917|Procedure|Letrozole as adjuvant therapy|standard care
79865947|NCT00436605|Drug|dasatinib|
79401628|NCT03783442|Drug|Oxaliplatin|Administered IV
79401629|NCT03783442|Drug|Fluorouracil (5-FU)|Administered IV
79571466|NCT01801332|Dietary Supplement|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
79571467|NCT01801332|Dietary Supplement|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
79865948|NCT01034787|Drug|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
79571468|NCT01801345|Other|Fatigued|
79401630|NCT03783442|Drug|Capecitabine|Administered orally
79731420|NCT02637739|Device|hysteroscope|Women of PUL with β-hCG > 1000 IU/L or abnormal β-hCG trend (increase < 66% or decrease < 15%) were offered HSC.
79731421|NCT00655525|Dietary Supplement|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
79865949|NCT01323543|Device|Elaspine™|Implantation of device
80025843|NCT04228263|Drug|Hydroxychloroquine|400mg
80025844|NCT04228263|Drug|Folic Acid|5 mg
79401631|NCT03783442|Drug|Paclitaxel|Administered IV
79401632|NCT03783442|Drug|Tislelizumab|Administered IV
79401633|NCT03783442|Drug|Placebo|Placebo to match Tislelizumab
79401634|NCT03773822|Combination Product|Hydrocortisone + Flucortac|Low dose steroids
79401635|NCT03773822|Other|Placebo|Placebo
79401636|NCT03772925|Drug|Belinostat|Given IV
79401637|NCT03772925|Drug|Pevonedistat|Given IV
79401638|NCT03764865|Procedure|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
79401639|NCT03764865|Procedure|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
79401640|NCT03756311|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
79571469|NCT01801345|Other|Rested|
79571470|NCT01801371|Drug|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
79571471|NCT01801397|Drug|osteoanabolic therapy|
79731422|NCT00655525|Dietary Supplement|placebo|placebo administered orally every day for 3 months
79731423|NCT03395587|Biological|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
79731424|NCT03395587|Drug|standard therapy|temozolomide, fractionated radiochemotherapy
79731425|NCT00903682|Drug|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
79865950|NCT01028781|Drug|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
79865951|NCT01031901|Drug|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
79865952|NCT01031901|Drug|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
79865953|NCT01031901|Drug|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
79865954|NCT00368992|Biological|cetuximab|Given IV
79865955|NCT00368992|Drug|paclitaxel|Given IV
79865956|NCT00368992|Biological|bevacizumab|Given IV
79865957|NCT00376246|Drug|Ezetimibe|
79865958|NCT00368836|Device|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
80025845|NCT04228263|Drug|Low-dose aspirin|75 mg
79571472|NCT01801410|Device|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
80025846|NCT04222634|Other|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
79865959|NCT03992716|Drug|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
79865960|NCT03992716|Drug|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
80025847|NCT04205812|Drug|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
80025848|NCT04205812|Drug|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
80025849|NCT04205812|Drug|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
80025850|NCT04205812|Drug|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
80025851|NCT04205812|Drug|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
80025852|NCT04205812|Drug|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
80025853|NCT04205812|Drug|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
79269277|NCT05853185|Drug|EBRRM®|Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
79401641|NCT03756051|Other|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have ~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
79571473|NCT01801410|Drug|Misoprostol|25mcg every 2 hours for maximum of 12 doses
79571474|NCT01801423|Drug|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at ~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
79731426|NCT00903682|Drug|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
79731427|NCT00655603|Other|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
79865961|NCT01050010|Other|MRI|dedicated extremity MRI
79865962|NCT01050088|Dietary Supplement|sucrose solution|5cc 5% sucrose solution P/O
79865963|NCT01050088|Dietary Supplement|Saline|5cc saline p/o
79865964|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
79865965|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
79865966|NCT00375934|Drug|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
79865967|NCT00375934|Drug|Placebo|Oral placebo capsule, every 6 hours
80025854|NCT04201132|Device|Carotid artery stenting with Neuroguard IEP System|Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
80025855|NCT04198870|Device|MitraClip™ device implantation|Transcatheter repair of the mitral valve using MitraClip™ device
80025856|NCT04198870|Procedure|Mitral Valve Repair Surgery|Surgical repair of the mitral valve
80025857|NCT04175886|Drug|Tofacitinib|Patients will be treated with tofacitinib
80025858|NCT04151901|Other|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
80025859|NCT04151901|Other|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
79269278|NCT05851378|Drug|Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)|Given intravenously at time of imaging
79269279|NCT05851378|Procedure|Magnetic Resonance Image (MRI)|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
79269280|NCT05846698|Drug|Luo-Bu-Fu-Ke-Bi-RI Pill|10 pills twice daily
79269281|NCT05846698|Drug|tibolone|2.5 mg once daily
79865968|NCT01052584|Drug|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
79865969|NCT01052584|Drug|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
79865970|NCT01052584|Drug|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
79865971|NCT01050166|Other|Transplantation of labeled islets|
79865972|NCT01050244|Dietary Supplement|Whole soybean soymilk powder|
79865973|NCT01050244|Dietary Supplement|Whole milk powder|
79865974|NCT02534506|Drug|Urelumab|
79865975|NCT02534506|Drug|Nivolumab|
80025860|NCT04151082|Drug|Methylprednisolone|Given IV
80025861|NCT04151082|Drug|Prednisone|Given PO
80025862|NCT04151082|Other|Quality-of-Life Assessment|Ancillary studies
80025863|NCT04151082|Other|Questionnaire Administration|Ancillary studies
80025864|NCT04139499|Procedure|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
80025865|NCT04139499|Procedure|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
79731428|NCT01117428|Drug|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
80025866|NCT04135066|Other|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
79571475|NCT01801462|Other|Simulation-based training|
79401642|NCT03756051|Other|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
79401643|NCT03755401|Other|TFPP|Trauma-Focused Psychodynamic Psychotherapy
79401644|NCT03755401|Other|TAU|treatment as usual at the VA for PTSD
79571476|NCT01801514|Device|Computed Tomography scan|Routine Computed Tomography scan
79571477|NCT01801527|Behavioral|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
79865976|NCT01050322|Drug|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
79571478|NCT01801540|Dietary Supplement|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
79571479|NCT01801553|Other|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
79865977|NCT01050322|Drug|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
79401645|NCT03747757|Behavioral|Cognitive Behavior Therapy|Undergo CBT
79571480|NCT01801553|Other|sham spinal manipulation|
79571481|NCT01801553|Other|Usual medical care|
79865978|NCT01050322|Drug|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
79865979|NCT01048450|Radiation|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
79865980|NCT01048450|Procedure|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
79865981|NCT01048450|Procedure|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
79865982|NCT01048528|Behavioral|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
79865983|NCT03990844|Dietary Supplement|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
79401646|NCT03747757|Other|Quality-of-Life Assessment|Ancillary studies
79401647|NCT03747757|Other|Questionnaire Administration|Ancillary studies
79401648|NCT03745950|Drug|Olaparib Oral Capsule|- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
79401649|NCT03745950|Drug|Placebo oral capsule|- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
79401650|NCT03734016|Drug|Zanubrutinib|160 mg orally twice daily
79401651|NCT03734016|Drug|Ibrutinib|Ibrutinib 420 mg orally once daily
80025867|NCT04135066|Other|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
80025868|NCT04134884|Drug|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
79865984|NCT02534662|Device|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
80025869|NCT04134884|Drug|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
80025870|NCT04133168|Device|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~POLARx™ or POLARx™ FIT Cryoablation Catheter~POLARMAP™ Catheter~POLARSHEATH™~SMARTFREEZE™ Console~Diaphragm Movement Sensor (DMS)~Related Accessories"
80025871|NCT04132960|Drug|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
80025872|NCT04116671|Device|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
80025873|NCT04111094|Diagnostic Test|No intervention|No intervention
79865985|NCT00642941|Drug|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
79269282|NCT05838794|Other|Mckenzie exercise for neck|The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.
79401652|NCT03730922|Procedure|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
79401653|NCT03730922|Procedure|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
79401654|NCT03728972|Drug|Pembrolizumab|200mg IVPB every 3 weeks
79401655|NCT03722680|Drug|Riluzole|Riluzole during chemotherapy (oxaliplatin)
79571482|NCT01801566|Procedure|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
79731429|NCT05223322|Behavioral|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
79731430|NCT04162405|Behavioral|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
79865986|NCT00531960|Drug|Erlotinib|150 mg, PO, daily
80025874|NCT04101357|Drug|BNT411|intravenous
80025875|NCT04101357|Drug|Atezolizumab|intravenous
80025876|NCT04101357|Drug|Carboplatin|intravenous
80025877|NCT04101357|Drug|Etoposide|intravenous
80025878|NCT04069793|Device|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
79401656|NCT03722680|Drug|Placebo Oral Tablet|placebo
79571483|NCT01801605|Procedure|rTMS|Active session with stimulation and placebo session with fictive stimulation
79731431|NCT02637661|Other|earlobe crease positive|
80025879|NCT04069793|Device|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
79401657|NCT03719079|Device|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
79401658|NCT03693300|Drug|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
79401659|NCT03681327|Other|Sensory stimulation during sleep|Sensory stimulation during sleep
79401660|NCT03679468|Other|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
79401661|NCT03679468|Other|Sham Exercise|Sets of balance and stretching exercises
79731432|NCT02637661|Other|earlobe crease negative|
79731433|NCT02715466|Drug|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
79865987|NCT00531960|Drug|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
79865988|NCT00531960|Drug|Standard platinum-based chemotherapy|At the discretion of the investigator
79865989|NCT01001676|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
79865990|NCT01001676|Device|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
80025880|NCT04063592|Procedure|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
79269283|NCT05838794|Other|Stabilization exercise|Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
79401662|NCT03679468|Other|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
79401663|NCT03679468|Other|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
79401664|NCT03671564|Drug|Milademetan|Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
79401665|NCT03671213|Device|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
79401666|NCT03632720|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
79401667|NCT03632720|Biological|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
79401668|NCT03632720|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
79731434|NCT02715466|Drug|Balanced electrolyte solution|Sterofundin ISO
79731435|NCT00655681|Drug|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children < 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
79401669|NCT03632720|Biological|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
79401670|NCT03632720|Biological|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
79401671|NCT03626857|Device|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40& of the contralateral MVIC.
79401672|NCT03626857|Other|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
79571484|NCT01801631|Other|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
79571485|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
79731436|NCT00655681|Other|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
79865991|NCT00816959|Drug|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
79731437|NCT04187586|Other|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
79865992|NCT00816959|Drug|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
79865993|NCT01001754|Drug|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
80025881|NCT04057924|Other|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
80025882|NCT04049825|Drug|OPB-111077|OPB-111077+bendamustine
80025883|NCT04049825|Drug|OPB-111077|OPB-111077+rituximab+bendamustine
80025884|NCT04046224|Biological|ST-920|Single dose of investigational product ST-920
79401673|NCT03626857|Device|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
79401674|NCT03626857|Other|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
79401675|NCT03624790|Biological|rRSV A/Maryland/001/11|10^5 PFU; delivered intranasally
79865994|NCT01001754|Drug|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
79865995|NCT01001754|Drug|Ribavirin|Daily oral administration (400-600 mg BID)
79865996|NCT00825851|Drug|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
79865997|NCT00825851|Drug|Placebo patch|
79865998|NCT00825851|Behavioral|Smoking cessation|
79865999|NCT00825851|Behavioral|Continuous smoking|subjects smoke 20 cigarettes per day
80025885|NCT04040166|Diagnostic Test|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
80025886|NCT04040088|Procedure|Computed Tomography|Undergo PET/CT
79731438|NCT02345356|Genetic|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
79731439|NCT02345356|Other|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
80025887|NCT04040088|Drug|Gallium Ga 68-DOTATATE|Given IV
79269284|NCT05835271|Device|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
79269285|NCT05816798|Device|Photobiomodulation|PBM is a therapeutic technique that uses light at different wavelengths (red or infrared), in a non-invasive way in which non-ionizing irradiation is used to produce a series of photophysical and photochemical effects when applied to biological tissues (humans and animals). Regarding the clinical results, numerous articles have already demonstrated the effect of PBM in improving pain and disability in patients with knee joint pain.
79269286|NCT05816798|Other|Standard Physiotherapy Tretament|standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)
79269287|NCT05816798|Device|Photobiomodulation Placebo|The same interventions described of Photobiomodulation Group bu device will be turned off
79401676|NCT03624062|Drug|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
79269288|NCT05800600|Drug|Venofer|Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
79401677|NCT03607370|Procedure|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
79571486|NCT01801644|Drug|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
79571487|NCT01801670|Procedure|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
79571488|NCT01801670|Procedure|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
79571489|NCT01801683|Other|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
79731440|NCT02635477|Behavioral|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
79731441|NCT02635477|Behavioral|Control|Behavioral: actigraphy device, step count measurement only
79731442|NCT05139550|Device|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
79401678|NCT03606512|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5*10^10 vp.
79401679|NCT03606512|Biological|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
79401680|NCT03606512|Biological|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
79731443|NCT04221568|Drug|Bupivacaine-fentanyl|local anathetic&analgesic drugs
79731444|NCT04221568|Drug|levobupivacaine-fentanyl|local anathetic&analgesic drugs
79866000|NCT00361504|Drug|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
79866001|NCT00361504|Drug|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
80025888|NCT04040088|Procedure|Positron Emission Tomography|Undergo PET/CT
79269289|NCT05798559|Behavioral|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
79269290|NCT05788068|Behavioral|Cognitive behavior therapy|"Participants will receive CBT intervention for smoking cessation via wechat-based mini-program developed by a professional team."
79269291|NCT05774704|Drug|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
79269292|NCT05774704|Drug|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
79277552|NCT04439487|Diagnostic Test|Anthropometric measurements during routine preoperative visit|During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
79731445|NCT02635087|Device|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
79866002|NCT04446611|Diagnostic Test|First antenatal care + test-of-cure|Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
79269293|NCT05772351|Drug|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
79571490|NCT01801696|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
79866003|NCT04446611|Diagnostic Test|First antenatal care + week 30-34 gestation (no test-of-cure)|Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
80025889|NCT04037228|Device|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
79269294|NCT05745233|Drug|Nivolumab|Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
79269295|NCT05745233|Drug|Pembrolizumab|Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
80025890|NCT04019119|Behavioral|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
79269296|NCT05731037|Other|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
79269297|NCT05727215|Biological|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
79269298|NCT05725382|Device|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
79269299|NCT05722288|Procedure|Biospecimen Collection|Undergo collection of blood
79269300|NCT05722288|Other|Informational Intervention|Receive nutritional counseling
79731446|NCT02707198|Drug|kefir|4 ounces of kefir 3 times a day, with or without food.
79731447|NCT04163497|Device|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
79731448|NCT02635165|Device|Thoracic osteosyntheses with Stracos|
79731449|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
79731450|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
79269301|NCT05722288|Other|Quality-of-Life Assessment|Ancillary studies
79269302|NCT05722288|Other|Questionnaire Administration|Ancillary studies
79269303|NCT05722288|Behavioral|Short-Term Fasting|Undergo time-restricted eating
79401681|NCT03604783|Drug|TP-1287|TP-1287 by oral administration
79269304|NCT05721404|Drug|Icodextrin Peritoneal Dialysis Solution|Icodextrin (Extraneal) for long night dwell
79571491|NCT01801696|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
79571492|NCT01801748|Dietary Supplement|oral wheat challenge|
79269305|NCT05721404|Drug|Hypertonic Dextrose solution|Hypertonic Dextrose solution for long night dwell
79269306|NCT05717270|Procedure|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
79571493|NCT01801774|Drug|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
79571494|NCT01801774|Drug|Placebo|
79571495|NCT01801787|Device|tDCS|active vs. sham tDCS left hemisphere
79269307|NCT05710874|Other|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
79731451|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
79731452|NCT04165447|Behavioral|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
79866004|NCT00826085|Drug|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
79866005|NCT01002144|Other|blood sampling|
79866006|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
79866007|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
79571496|NCT01801800|Procedure|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
79866008|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
79866009|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
79731453|NCT00948675|Drug|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
79866010|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
79866011|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
79269308|NCT05710874|Other|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
79269309|NCT05710874|Other|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
79269310|NCT05710874|Other|Conventional|Twice daily use of conventional toothpaste.
79269311|NCT05710744|Behavioral|Shared decision making tip sheet|Physicians will view tip sheets containing best practices for shared decision making with diverse families.
79269312|NCT05710237|Drug|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
79571497|NCT01801813|Other|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
79571498|NCT01801826|Device|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
79571499|NCT01801852|Biological|NKT cells|
79571500|NCT01801878|Biological|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
79571501|NCT01801878|Biological|Normal saline|Normal saline inject to the half of irradiated breast
79571502|NCT01801891|Device|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
79866012|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
79866013|NCT00361270|Behavioral|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
79866014|NCT00826163|Drug|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
79866015|NCT00998166|Drug|Pemetrexed, Cisplatin, Bevacizumab|"Pre-hydration for 1-1/2 hours at 250 ml/hour~Pemetrexed 500 mg/m2 IV over 10 minutes~Return to hydration for 30 minutes at 250 ml/hour~Cisplatin 75mg/m2 IV over 60-120 minutes~Bevacizumab 15mg/kg IV over 90 minutes"
79731454|NCT00948675|Drug|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 [maximum possible dose of 900 milligrams (mg)] intravenously infused over 30 minutes.
80025891|NCT04000672|Procedure|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
80025892|NCT04000672|Procedure|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
80025893|NCT03979170|Procedure|Lung tumor resection|lung tumor resection
80025894|NCT03970304|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
79731455|NCT00948675|Drug|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
79731456|NCT00948675|Biological|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
79731457|NCT02850172|Behavioral|Walk, Eat, & Breathe|"Walking exercise: 3 times per week, 20~30 mins per section~Eat: nutritional assessment and advice weekly~Inspiratory muscle training: twice every day, 7 days a week, 6~8 weeks before surgery"
79731458|NCT02642497|Drug|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
79731459|NCT02642497|Drug|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
79731460|NCT02642497|Drug|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
79731461|NCT00911131|Device|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
79731462|NCT00911131|Procedure|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
80025895|NCT03921008|Drug|Paclitaxel|-Commercial supply
79731463|NCT00911131|Device|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
79731464|NCT02857257|Biological|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
80025896|NCT03921008|Radiation|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
80025897|NCT03921008|Procedure|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
80025898|NCT03915106|Device|Brace|Wear a rigid brace
79269313|NCT05710237|Drug|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
79269314|NCT05710237|Drug|Placebo|The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
79731465|NCT00903370|Procedure|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
79731466|NCT00903370|Device|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
79731467|NCT04273581|Drug|placebo|100mg/d，qn，for 14 days.
79731468|NCT04273581|Drug|Thalidomide|100mg/d，qn，for 14 days.
79731469|NCT01110408|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
79731470|NCT01110408|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
80025899|NCT03915106|Procedure|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
79731471|NCT01110408|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
79866016|NCT03990922|Procedure|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
80025900|NCT03901053|Device|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
79401682|NCT03592238|Other|Aerobic Exercise Intervention|The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.
79866017|NCT03990922|Procedure|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
79866018|NCT03990922|Drug|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
79866019|NCT01005342|Other|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
79866020|NCT01005342|Other|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
79866021|NCT01005342|Other|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
79866022|NCT01005342|Other|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
79866023|NCT01005342|Other|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
79866024|NCT01005342|Other|Control|No fiber was added to control meal (250 g black-currant beverage)
79866025|NCT00822263|Drug|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
79866026|NCT00822263|Drug|Placebo|Control for study
79866027|NCT03992170|Drug|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
79866028|NCT04044755|Other|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
79401683|NCT03592238|Other|Trier Social Stress Test for Children|Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.
79866029|NCT05154474|Other|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
79401684|NCT03592238|Other|Seated Rest|Children will be asked to sit quietly or read a book of their choosing.
79401685|NCT03587311|Biological|Anetumab Ravtansine|Given IV
79401686|NCT03587311|Biological|Bevacizumab|Given IV
79401687|NCT03587311|Drug|Paclitaxel|Given IV
79731472|NCT01110408|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
79866030|NCT00817037|Drug|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
79866031|NCT00817037|Drug|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
79866032|NCT00817037|Drug|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
79866033|NCT00998244|Other|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
79866034|NCT00817115|Device|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
80025901|NCT03901053|Device|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
79866035|NCT00998322|Biological|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
79866036|NCT00998322|Drug|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
80025902|NCT03889613|Other|prospective follow-up with videocapsule|prospective follow-up with videocapsule
80025903|NCT03880344|Device|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
80025904|NCT03880344|Combination Product|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
80025905|NCT03870919|Drug|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~Non-steroidal aromatase inhibitor (letrozole)~Palbociclib~Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
79571503|NCT01801891|Other|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
79571504|NCT01801956|Behavioral|physical activity|free membership of a sport club
80025906|NCT03870919|Other|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
79731473|NCT01110408|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
79731474|NCT02850328|Other|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~Rate of force development~Electromyographic activity~Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~Maximum voluntary activation capacity (%VA): %VA = (1-[torque superimposed twitch/torque resting twitch])*100%."
79866037|NCT04044833|Behavioral|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
79866038|NCT00367744|Drug|Rosiglitazone|Rosiglitazone 4mg BID
79866039|NCT00367744|Drug|Placebo|Placebo for rosiglitazone
79866040|NCT01002222|Drug|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
79866041|NCT01002300|Drug|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
80025907|NCT03867357|Drug|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
79269319|NCT05690373|Dietary Supplement|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from >10 to 40 in Ab titre for seronegative subjects.
79269320|NCT05684289|Drug|BMS-986278|Specified dose on specified days
79401696|NCT03552588|Diagnostic Test|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
79401697|NCT03539302|Drug|Flecainide Acetate|Oral inhalation form using a nebulizer
79401698|NCT03537794|Diagnostic Test|PET scans|PET scans and PHNO scans
79401699|NCT03530709|Other|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
79571505|NCT01801956|Other|Motivational interview|Four motivational interviews by instructors of the local sport club
79571506|NCT01801956|Other|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
79269321|NCT05684289|Drug|Sildenafil|Specified dose on specified days
79269322|NCT05684289|Drug|Placebo|Specified dose on specified days
79269323|NCT05681962|Diagnostic Test|Bronchoscopy|Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
79269324|NCT05681949|Other|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
79401700|NCT03530384|Other|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
79401701|NCT03530384|Other|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
79401702|NCT03525405|Drug|napabucasin|Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
79401703|NCT03513562|Drug|Ibrutinib|Given PO
79401704|NCT03513562|Other|Laboratory Biomarker Analysis|Correlative studies
79571507|NCT01801969|Other|Rehabilitation service|"Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
79571508|NCT01802008|Procedure|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
79571509|NCT01802008|Procedure|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
80025908|NCT03855800|Diagnostic Test|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
80025909|NCT03855800|Procedure|Pancreatic Surgery|Surgical resection of pancreatic cyst
80025910|NCT03855800|Procedure|Endoscopy Exam|Clinically indicated endoscopic ultrasound
80025911|NCT03851198|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
80025912|NCT03850574|Drug|Tuspetinib|Daily (QD), continuous dosing
80025913|NCT03850574|Drug|Venetoclax Oral Tablet|Venetoclax will be given to patients in combo treatment group (Part C) either in 50 mg or 100 mg tablets
79269325|NCT05677126|Drug|Tralement|Tralement with Manganese
79571510|NCT01802021|Drug|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
79269326|NCT05677126|Drug|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
79571511|NCT01802047|Procedure|milk expression with electric pump|
79571512|NCT01802099|Other|Enteral nutrition|
79571513|NCT01802099|Other|Parenteral nutrition|
79571514|NCT01802112|Dietary Supplement|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
79571515|NCT01802112|Other|placebo|15gr placebo
79571516|NCT01802125|Other|laboratory biomarker analysis|Correlative studies
79571517|NCT01802138|Biological|Activated T lymphocyte|intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
79731475|NCT00953043|Drug|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
80025914|NCT03830320|Drug|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
80025915|NCT03830320|Device|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
80025916|NCT03830320|Procedure|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
80025917|NCT03830320|Procedure|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
79269327|NCT05661682|Drug|Tralement|Tralement with Manganese Sulfate
79269328|NCT05661682|Drug|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese Sulfate
79269329|NCT05659004|Behavioral|Qualitative interview|No intervention
79269330|NCT05655078|Radiation|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
79401705|NCT03513562|Drug|Venetoclax|Given PO
79401706|NCT03512314|Drug|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
79571518|NCT01802164|Device|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
79571519|NCT01802177|Procedure|UVB excimer light|
79571520|NCT01802190|Genetic|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
79571521|NCT01802229|Procedure|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
79571522|NCT01802229|Procedure|Fascial suture|The port-site hole is closed with simple suture of the fascia
79571523|NCT01802255|Drug|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
79571524|NCT01802255|Drug|Midazolam|Intravenous sedation.
79571525|NCT01802268|Drug|Conversion from Tacrolimus to Sirolimus|
79731476|NCT00953043|Drug|Placebo|Placebo medication given for three days
79731477|NCT00953043|Other|Bowel preparation|Polyethylene glycol-based bowel preparation
79731478|NCT02850484|Drug|Budesonide|Inhaled corticosteroid
79731479|NCT02850484|Drug|Formoterol|Long Acting Beta Agonist (LABA)
79269331|NCT05642507|Drug|AC01|AC01 microtablets
79269332|NCT05640310|Device|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
79401707|NCT03507257|Drug|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
79571526|NCT01802268|Drug|Maintenance on tacrolimus|
79571527|NCT01802294|Behavioral|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
79571528|NCT01802307|Radiation|Brachytherapy|
79571529|NCT01802359|Drug|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
79571530|NCT01802372|Behavioral|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
79731480|NCT01135134|Drug|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
79731481|NCT01135134|Drug|Placebo|"MF Placebo nasal spray and administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
79571531|NCT01802372|Behavioral|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
80025918|NCT03828357|Other|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
79571532|NCT01802424|Behavioral|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
79571533|NCT01802450|Drug|Dasatinib|
79731482|NCT02850094|Behavioral|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
80025919|NCT03820479|Other|Protocol|Best practice of protocol
80025920|NCT03819764|Behavioral|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
80025921|NCT03819764|Behavioral|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
80025922|NCT03818880|Device|Novel spectacle lens design|Spectacle lens to control progression of myopia
80025923|NCT03800394|Other|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
80025924|NCT03800381|Other|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
80025925|NCT03798301|Biological|CMV-specific T-cells|Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
80025926|NCT03785249|Drug|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
80025927|NCT03785249|Drug|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
80025928|NCT03785249|Drug|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
80025929|NCT03785249|Drug|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
80025930|NCT03773198|Other|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
79401708|NCT03507257|Drug|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
79571534|NCT01802476|Drug|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
79571535|NCT01802476|Drug|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
80025931|NCT03773198|Other|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
80025932|NCT03715946|Drug|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
80025933|NCT03715946|Radiation|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
80025934|NCT03701763|Drug|Apremilast (CC-10004)|Apremilast (CC-10004)
80025935|NCT03701763|Other|Placebo|Placebo
80025936|NCT03700541|Drug|Morphine|Morphine intravenous
80025937|NCT03700541|Drug|Piritramid|Piritramid intravenous
80025938|NCT03700411|Drug|Morphine|Morphine intravenous
79401709|NCT03507257|Drug|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
79401710|NCT03490344|Drug|Daratumumab|"Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
79401711|NCT03490344|Drug|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
79571536|NCT01802489|Drug|Amiloride|
79571537|NCT01802489|Drug|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
79571538|NCT01802502|Drug|Rifampicin intravenous|
79571539|NCT01802502|Drug|Oral rifampicin|
79571540|NCT01802541|Dietary Supplement|diacylglycerol oil|
79571541|NCT01802541|Dietary Supplement|triacylglycerol oil|
79571542|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
79731483|NCT00948441|Drug|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
79866042|NCT01005498|Dietary Supplement|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
80025939|NCT03700411|Drug|Piritramid|Piritramid intravenous
80025940|NCT03700411|Drug|Epidural|Perioperative epidural analgesia
80025941|NCT03651505|Other|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
79731484|NCT00948441|Other|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
79866043|NCT01005498|Dietary Supplement|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
79731485|NCT02849860|Drug|IDP-121 Lotion|Lotion
79571543|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
79866044|NCT00822341|Drug|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
79571544|NCT01802619|Other|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
79571545|NCT01802619|Other|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
79731486|NCT02849782|Drug|Fampridine|Oral intake of 10 mg twice daily
79731487|NCT00630903|Drug|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
79866045|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
79866046|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
79866047|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
79866048|NCT00822419|Drug|lidocaine|lidocaine cream 5%
79866049|NCT00822419|Drug|ketamine|ketamine 5%
79269333|NCT05607147|Device|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
79571546|NCT01802645|Drug|Cetuximab|
79731488|NCT00630903|Drug|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
79731489|NCT02883426|Biological|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
79731490|NCT02883426|Biological|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
79731491|NCT02883426|Biological|Placebo|Administered by nasal spray
79866050|NCT00822419|Drug|non-drug cream|will be put on the skin
79866051|NCT01050400|Genetic|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
79866052|NCT01006044|Biological|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
79571547|NCT01802645|Drug|Bevacizumab|
79571548|NCT01802645|Drug|Irinotecan|
79866053|NCT00817193|Behavioral|Physical Activity|Physical Activity program
79866054|NCT00817193|Behavioral|Wellness|Wellness program
79866055|NCT02534428|Other|wool clothing|superfine merino wool ensembles for baby wear
79571549|NCT01802645|Drug|Oxaliplatin|
79571550|NCT01802645|Drug|5-FU|
79571551|NCT01802645|Drug|Folinic Acid|
79571552|NCT01802658|Drug|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
79571553|NCT01802658|Drug|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
79731492|NCT01238289|Behavioral|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
79731493|NCT01238289|Behavioral|Control|This group continues with standard care at the community health center
79731494|NCT02849314|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
79731495|NCT02849314|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
79731496|NCT05171478|Diagnostic Test|Full-field optical coherence tomography|Sample obtained during bronchoscopy will be imaged using full-field optical coherence tomography
79731497|NCT02857101|Other|dosage of calprotectin|
79731498|NCT02849392|Other|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
79731499|NCT02857023|Behavioral|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
79731500|NCT01207479|Device|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
79866056|NCT01002534|Drug|Vardenafil|Nasal instillation of Vardenafil
79866057|NCT01002534|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
79866058|NCT00817271|Drug|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
80025942|NCT03641378|Other|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
80025943|NCT03641378|Other|Standard Transplant Care|Standard care per hospital guidelines
79731501|NCT02849236|Drug|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
79866059|NCT00817271|Drug|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
79866060|NCT01052896|Drug|Gabapentin|300mg po TID
79866061|NCT01052896|Drug|Placebo|Look-alike of gabapentin 300mg given po tid
79866062|NCT00822497|Behavioral|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
80025944|NCT03633032|Diagnostic Test|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
80025945|NCT03624101|Drug|Trikafta|CFTR modulator
80025946|NCT03624101|Drug|symdeko/Trikafta|CFTR modulator
79401712|NCT03489018|Biological|PCV10|Experimental arms will receive a lower dose of the intervention than the marketed dose.
79731502|NCT02849236|Drug|Placebo|20 mL saline 0.9%
79731503|NCT02856789|Other|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
79571554|NCT01802671|Other|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
79731504|NCT02856789|Other|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
79866063|NCT00822497|Behavioral|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
79866064|NCT01002690|Drug|Etoricoxib|90 mg/day orally for 10-13 days
79866065|NCT01048684|Drug|Mannitol|Variation of mannitol dose
79866066|NCT01048684|Drug|Mannitol|Variation of mannitol dose
80025947|NCT03624101|Drug|Ivacaftor/Trikafta|CFTR modulator
80025948|NCT03623074|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
80025949|NCT03623074|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
80025950|NCT03586661|Drug|Copanlisib|Given IV
79401713|NCT03489018|Biological|PCV13|Experimental arms will receive a lower dose of the intervention than the marketed dose.
79401714|NCT03469986|Device|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
79731505|NCT02856789|Other|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
79731506|NCT02856789|Other|Specialized hemostasis tests|Coagulation factors
79731507|NCT02856711|Behavioral|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
79731508|NCT02848924|Other|No intervention|
79731509|NCT04368676|Other|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
79731510|NCT04368676|Other|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
79731511|NCT01117350|Drug|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
79866067|NCT01002768|Drug|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
79866068|NCT01002768|Drug|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
79866069|NCT01048762|Other|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
79866070|NCT01048762|Other|home training|one instruction in home based exercise training
80025951|NCT03586661|Drug|Niraparib|Given PO
80025952|NCT03575897|Diagnostic Test|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
80025953|NCT03557957|Other|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
80025954|NCT03557957|Other|Standard care|Standard care of hyponatremia
80025955|NCT03493048|Drug|Irinotecan|Irinotecan 130 mg/m²
80025956|NCT03493048|Drug|Cetuximab|Cetuximab, iv, 500mg/m2
80025957|NCT03493048|Drug|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
80025958|NCT03493048|Drug|Oxaliplatin|oxaliplatin 85 mg/m²
79571555|NCT01802671|Behavioral|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~Cognitive restructuring techniques~Behavioural therapy and activity pacing~Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
79731512|NCT01117350|Drug|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
79731513|NCT01117350|Drug|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
79731514|NCT00952731|Drug|oral placebo|Oral placebo taken daily for 4-10 weeks.
79731515|NCT00952731|Drug|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
79731516|NCT00952731|Drug|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
80025959|NCT03493048|Drug|Leucovorin|leucovorin 200 mg/m²
80025960|NCT03449706|Drug|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
80025961|NCT03439748|Behavioral|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
80025962|NCT03439748|Behavioral|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
80025963|NCT03434730|Radiation|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
80025964|NCT03434730|Drug|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
80025965|NCT03434730|Drug|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
80025966|NCT03434730|Drug|Tocilizumab|For participants < 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
80025967|NCT03434730|Drug|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; > 60 kg = 480 mcg subcutaneously daily.
80025968|NCT03433001|Drug|Ixazomib|Ixazomib capsules
80025969|NCT03433001|Drug|Lenalidomide|Lenalidomide capsules
79731517|NCT00952731|Drug|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
79731518|NCT04202224|Drug|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
79731519|NCT04202224|Drug|Glucose|Placebo.
79731520|NCT04202224|Other|No drug|Standard surgical procedure without any preoperative medication.
79731521|NCT02848690|Behavioral|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
79866071|NCT01002846|Procedure|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
79866072|NCT00826397|Procedure|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
79866073|NCT00826397|Procedure|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
80025970|NCT03433001|Drug|Dexamethasone|Dexamethasone tablets
80025971|NCT03432078|Other|Hypnotherapy|Non-pharmacological treatment
80025972|NCT03383575|Drug|Azacitidine|Given IV or SC
80025973|NCT03383575|Drug|Enasidenib|Given PO
80025974|NCT03383575|Other|Quality-of-Life Assessment|Ancillary studies
80025975|NCT03330847|Drug|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
80025976|NCT03330847|Drug|Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
80025977|NCT03330847|Drug|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
80025978|NCT03324893|Diagnostic Test|[F-18]-FCH PET/MRI|Subjects will undergo the [F-18]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
80025979|NCT03314935|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
80025980|NCT03314935|Drug|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
80025981|NCT03314935|Drug|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
79866074|NCT00998478|Other|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
79866075|NCT01050478|Drug|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
80025982|NCT03314935|Drug|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
79866076|NCT01050478|Drug|Benzodiazepine|Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.
79866077|NCT00822575|Device|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
80025983|NCT03314935|Drug|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
80025984|NCT03314935|Drug|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
80025985|NCT03314935|Drug|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
80025986|NCT03299530|Other|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
79866078|NCT00826475|Behavioral|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
80025987|NCT03263351|Behavioral|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
79401715|NCT03455439|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
79401716|NCT03453359|Device|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
79401717|NCT03453359|Device|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
79866079|NCT00826475|Behavioral|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
79866080|NCT00998556|Drug|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
79866081|NCT01052974|Drug|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
79866082|NCT00817427|Other|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
79866083|NCT00817427|Other|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
79866084|NCT00998634|Drug|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
79866085|NCT04044989|Device|Laser|Diode laser device was used for photobiomodulation
79866086|NCT04044989|Device|light-emitting diode (LED)|LED device was used for photobiomodulation
80025988|NCT03263351|Behavioral|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
80025989|NCT03249350|Behavioral|Standard Contingency Management (CM)|"CM utilizes behavior modification & cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
80025990|NCT03249350|Behavioral|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
80025991|NCT03211793|Drug|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
79401718|NCT03450018|Drug|SLC-0111|Oral SLC-0111
79401719|NCT03450018|Drug|Gemcitabine Injection|1000 mg/m^2 IV
79401720|NCT03435718|Drug|Oxfendazole|oral suspension
79401721|NCT03435718|Drug|Albendazole|tablet
79866087|NCT04044989|Device|Placebo|Diode laser device was used for placebo effect
79401722|NCT03434392|Diagnostic Test|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
79731522|NCT02848690|Other|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
79571556|NCT01802671|Behavioral|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
79571557|NCT01802684|Biological|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
79571558|NCT01802697|Drug|IdeS|
79571559|NCT01802697|Drug|Placebo|
79571560|NCT01802736|Behavioral|Motivational intervention counselling plus SPP|
80025992|NCT03211793|Other|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
79571561|NCT01802762|Device|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
79571562|NCT01802801|Other|embryo development|intra- and inter-observator analysis
79571563|NCT01802853|Drug|RO6811135|Single subcutaneous dose
79731523|NCT00947427|Drug|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
80025993|NCT03181100|Drug|Atezolizumab|Given IV
80025994|NCT03181100|Biological|Bevacizumab|Given IV
80025995|NCT03181100|Drug|Cobimetinib|Given PO
80025996|NCT03181100|Drug|Nab-paclitaxel|Given IV
80025997|NCT03181100|Drug|Paclitaxel|Given IV
80025998|NCT03181100|Drug|Vemurafenib|Given PO
79269334|NCT05604989|Drug|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus & Bifidobacterium lactis.
79731524|NCT00947427|Drug|Placebo|Placebo subcutaneous injections
79731525|NCT02848612|Drug|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
79731526|NCT04811404|Drug|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
80025999|NCT03171818|Drug|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
79269335|NCT05604989|Drug|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
79269336|NCT05580406|Behavioral|Outreach messaging|Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.
79269337|NCT05579964|Drug|Dexmedetomidine Hcl 100 Mcg/mL Inj|Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
79401723|NCT03434392|Diagnostic Test|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
79571564|NCT01802853|Drug|RO6811135|Single intravenous dose
79571565|NCT01802892|Drug|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
79571566|NCT01802892|Drug|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
79571567|NCT01802892|Drug|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
79731527|NCT01116882|Procedure|PCI|
79731528|NCT02054013|Procedure|Prostatic artery embolization|
79731529|NCT02054013|Procedure|monopolar transurethral prostatectomy|
79866088|NCT01003002|Drug|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
79866089|NCT01008774|Device|Paxman Cooling Machine|Scalp cooling procedures
79866090|NCT01008774|Device|Cold Caps|Scalp cooling procedures
80026000|NCT03171818|Drug|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
80026001|NCT03169361|Drug|Ixazomib|Ixazomib capsules
80026002|NCT03149861|Procedure|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS >=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
80026003|NCT03149861|Procedure|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
80026004|NCT03108703|Radiation|SBRT|35-40 Gy delivered in 5 fractions
80026005|NCT03101748|Drug|Cyclophosphamide|Given IV
80026006|NCT03101748|Drug|Doxorubicin|Given IV
80026007|NCT03101748|Other|Laboratory Biomarker Analysis|Correlative studies
80026008|NCT03101748|Drug|Neratinib|Given PO
80026009|NCT03101748|Drug|Paclitaxel|Given IV
79269338|NCT05579964|Drug|Placebo|Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
79269339|NCT05567770|Drug|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
79269340|NCT05567770|Radiation|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
79269341|NCT05567770|Drug|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
79269342|NCT05550337|Drug|Trifarotene 0.005 % Topical Cream|Cream
79269343|NCT05550337|Drug|AKLIEF®|Cream
79269344|NCT05550337|Drug|Placebo|Cream
79571568|NCT01802905|Genetic|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
79401724|NCT03434392|Diagnostic Test|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
79571569|NCT01802918|Drug|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
79269345|NCT05549180|Drug|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
79269346|NCT05549180|Drug|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
79731530|NCT02848846|Device|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
79731531|NCT02850562|Behavioral|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
79731532|NCT02850562|Behavioral|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
79731533|NCT02856477|Biological|urine analysis|a sample of urine is collected during 8 hours.
80026010|NCT03101748|Biological|Pertuzumab|Given IV
79269347|NCT05544084|Behavioral|Patient Navigator Approach|Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
79731534|NCT04235062|Drug|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
80026011|NCT03101748|Biological|Trastuzumab|Given IV
79269348|NCT05523505|Device|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
79269349|NCT05523505|Device|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus and left temporal pole using transcranial alternating current stimulation (tACS).
79269350|NCT05523505|Device|CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex using transcranial alternating current stimulation (tACS).
80026012|NCT03054129|Other|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
79269351|NCT05523505|Device|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
79269352|NCT05518825|Dietary Supplement|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
79269353|NCT05514119|Drug|Fenofibrate|160mg once daily orally for 12 weeks
79269354|NCT05500573|Procedure|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
79401725|NCT03426865|Drug|Axumin PET scan|PET scan prior to RPLND
79401726|NCT03417739|Drug|BVD-523|ERK1 and ERK2 inhibitor
79401727|NCT03406338|Procedure|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
79401728|NCT03406338|Drug|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
79571570|NCT01802918|Drug|Placebo|Visually matching GSK2838232
79571571|NCT01802918|Drug|Ritonavir|100mg tablets once daily for 12 days
79571572|NCT01802931|Drug|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
79571573|NCT01802931|Drug|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
79571574|NCT01802944|Drug|Intranasal Insulin|
79571575|NCT01802944|Drug|Placebos|
80026013|NCT03054129|Other|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
79269355|NCT05474534|Device|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
79731535|NCT04235062|Drug|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
80026014|NCT03052114|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
80026015|NCT03031847|Device|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
80026016|NCT03031847|Device|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
80026017|NCT02926404|Device|UNiD Rods|Spinal osteosynthesis
80026018|NCT02831764|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
79731536|NCT02848534|Biological|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
79731537|NCT02848768|Drug|Sunitinib|
79731538|NCT02848456|Procedure|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
79731539|NCT02848456|Procedure|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
79731540|NCT02848456|Procedure|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
79731541|NCT02283255|Other|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
79731542|NCT02283255|Other|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
80026019|NCT02831764|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
79269356|NCT05416229|Drug|Psilocybin|Psilocybin-assisted therapy
79269357|NCT05416229|Drug|Maltodextrin|Placebo-assisted therapy
79269358|NCT05414877|Drug|Ephedrine|vasopressor
79269359|NCT05414877|Drug|Phenylephrine|vasopressor
79731543|NCT02283255|Other|No Exercise Training|Usual care
79731544|NCT02848144|Other|blood samples|
79731545|NCT02848144|Other|Collection of nosocomial infections|
79731546|NCT02848300|Drug|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
79731547|NCT02848300|Drug|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
79731548|NCT00953745|Drug|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
79731549|NCT00953745|Drug|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
79731550|NCT00953745|Drug|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
79731551|NCT00953745|Drug|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
79731552|NCT02847910|Procedure|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
79731553|NCT02847910|Procedure|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
79731554|NCT02848066|Procedure|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
79731555|NCT04202380|Drug|Azithromycin|Patients will receive Azithromycin orally 1000 mg
79731556|NCT04202380|Drug|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
79731557|NCT04202380|Drug|Azithromycin|Azithromycin 500 mg orally once
79731558|NCT04202380|Drug|Azithromycin|Azithromycin 250 mg orally daily for 4 days
79731559|NCT04067674|Biological|Blood sampling|Blood sampling for biomarker measurement
80026020|NCT02831764|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
80026021|NCT02772731|Procedure|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
79401729|NCT03398200|Biological|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
79866091|NCT01008930|Procedure|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
79866092|NCT01003158|Drug|AZD8931|Tablet Oral bid
80026022|NCT02772731|Procedure|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
79401730|NCT03398200|Other|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
79401731|NCT03395236|Combination Product|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
79731560|NCT02847988|Device|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
79866093|NCT01003158|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off
80026023|NCT02754011|Drug|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
79866094|NCT01003236|Drug|placebo|140 mg placebo tablets, 3 times per day for 3 months
79269360|NCT05414877|Drug|Norepinephrine|vasopressor
80026024|NCT02732860|Other|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
80026025|NCT02719847|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
79269361|NCT05413876|Other|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
79269362|NCT05413876|Other|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
79401732|NCT03376880|Other|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
79731561|NCT02847988|Device|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
79269363|NCT05408390|Other|LPD+LED|Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.
79269364|NCT05408390|Other|HPD+LED|High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.
79269365|NCT05408390|Other|LPD+HED|Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.
79401733|NCT03367845|Behavioral|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
79731562|NCT02847832|Other|Standardized transvaginal ultrasound examination|
79866095|NCT01003236|Drug|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
79866096|NCT03883386|Drug|Loratadine|10 mg in a capsule
79866097|NCT03883386|Drug|Placebo|Administered via capsule
79866098|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
79866099|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
79866100|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
79866101|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
79866102|NCT00424047|Drug|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
79571576|NCT01802957|Other|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
79731563|NCT02167048|Drug|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
79731564|NCT02847754|Other|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
79731565|NCT02075710|Other|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
79731566|NCT02075710|Other|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
80026026|NCT02702310|Other|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
80026027|NCT02702310|Other|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
80026028|NCT02678962|Device|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
79731567|NCT02075710|Other|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
79731568|NCT02075710|Other|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
79731569|NCT02075710|Other|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
80026029|NCT02678962|Device|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
80026030|NCT02678962|Device|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
80026031|NCT02678962|Device|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
80026032|NCT02678962|Device|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
80026033|NCT02678962|Device|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
80026034|NCT02653118|Biological|V503|
80026035|NCT02653118|Biological|GARDASIL|
80026036|NCT02567422|Drug|Berzosertib|Given IV
80026037|NCT02567422|Drug|Cisplatin|Given IV
80026038|NCT02567422|Other|Laboratory Biomarker Analysis|Correlative studies
80026039|NCT02567422|Radiation|Radiation Therapy|Undergo radiation therapy
79269366|NCT05408390|Other|HPD+HED|High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
79269367|NCT05389696|Drug|Single subcutaneous administration and Blood collection|Single subcutaneous administration and Blood collection
79731570|NCT02075710|Other|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
79731571|NCT02847442|Drug|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
80026040|NCT02530034|Drug|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
80026041|NCT02530034|Other|Laboratory Biomarker Analysis|Correlative studies
80026042|NCT02530034|Other|Pharmacological Study|Correlative studies
79731572|NCT02847442|Drug|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
79731573|NCT04736602|Drug|Triptorelin pamoate 15mg|Intramuscular injection (IM)
80026043|NCT02528175|Device|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
79731574|NCT02847520|Behavioral|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
80026044|NCT02528175|Radiation|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
80026045|NCT02528175|Drug|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
80026046|NCT02396199|Device|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
80026047|NCT02339532|Drug|FEC100|"3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m²~Epirubicin 100 mg/m²~Cyclophosphamide 500 mg/m²"
80026048|NCT02339532|Drug|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
80026049|NCT02339532|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
79269368|NCT05389696|Drug|Single subcutaneous administration and then IV injection.|Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
79269369|NCT05389696|Drug|MIT-001 20mg and 40mg_Multiple administration|Multiple subcutaneous administration for 7 days and then blood collection
79269370|NCT05387863|Other|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
79571577|NCT01802957|Other|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
79571578|NCT01802957|Other|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
79866103|NCT00424047|Drug|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
79269371|NCT05387863|Other|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
79731575|NCT01698658|Other|ultrasound tomography|Undergo ultrasound tomography using SoftVue
79866104|NCT00530790|Drug|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
79866105|NCT02869971|Device|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
80026050|NCT02339532|Drug|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
80026051|NCT02339532|Drug|Carboplatin|CARBOPLATIN AUC 6 IV q3w
80026052|NCT02284919|Drug|[18F]ISO-1|[18F]ISO-1 PET/CT scan
80026053|NCT02278848|Other|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
80026054|NCT02101944|Drug|Carfilzomib|Given IV
79731576|NCT01698658|Procedure|magnetic resonance imaging|Undergo MRI of the breast
80026055|NCT02101944|Drug|Dexamethasone|Given IV
80026056|NCT02101944|Other|Laboratory Biomarker Analysis|Correlative studies
80026057|NCT02101944|Biological|Pelareorep|Given IV
80026058|NCT02034981|Drug|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~165 mg/m² twice daily for ALCL patients aged from 1 to 17."
80026059|NCT02003222|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
80026060|NCT02003222|Procedure|Biospecimen Collection|Undergo blood sample collection
79269372|NCT05385575|Drug|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
79269373|NCT05385575|Drug|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
79269374|NCT05385575|Drug|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
79269375|NCT05385575|Drug|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
79269376|NCT05385575|Drug|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
79269377|NCT05385575|Drug|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
79269378|NCT05385575|Drug|KN056 (18.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
79277553|NCT04439487|Other|Assesment of intubation parameters during induction of general anaesthesia|During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
79731577|NCT02847676|Procedure|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
79731578|NCT04218292|Device|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
79731579|NCT04710706|Other|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
79866106|NCT02869971|Drug|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
80026061|NCT02003222|Biological|Blinatumomab|Given IV
80026062|NCT02003222|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
80026063|NCT02003222|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
80026064|NCT02003222|Drug|Cyclophosphamide|Given IV
79866107|NCT01032057|Drug|capecitabine|
80026065|NCT02003222|Drug|Cytarabine|Given IT, IV, or SC
80026066|NCT02003222|Drug|Daunorubicin|Given IV
80026067|NCT02003222|Drug|Daunorubicin Hydrochloride|Given IV
80026068|NCT02003222|Drug|Dexamethasone|Given PO
80026069|NCT02003222|Drug|Etoposide|Given IV
79277554|NCT03528967|Drug|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
80026070|NCT02003222|Procedure|Lumbar Puncture|Undergo lumbar puncture
80026071|NCT02003222|Drug|Mercaptopurine|Given PO
80026072|NCT02003222|Drug|Methotrexate|Given PO, IT or IV
80026073|NCT02003222|Drug|Pegaspargase|Given IM or IV
80026074|NCT02003222|Drug|Prednisone|Given PO
80026075|NCT02003222|Biological|Rituximab|Given IV
80026076|NCT02003222|Drug|Vincristine|Given IV
80026077|NCT02003222|Drug|Vincristine Sulfate|Given IV
80026078|NCT02003222|Procedure|X-Ray Imaging|Undergo x-ray imaging
80026079|NCT01897480|Biological|LY2875358|Administered IV
80026080|NCT01897480|Drug|Erlotinib|Administered Orally
79269379|NCT05383846|Other|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
79571579|NCT01802957|Other|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
79269380|NCT05382819|Drug|FRTX-02 Capsule|DYRK-1A Inhibitor
79571580|NCT01802957|Other|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
79731580|NCT02847208|Other|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
79269381|NCT05382819|Drug|Placebo|Matching Placebo
79731581|NCT01551550|Procedure|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
79269382|NCT05359900|Other|Pain neuroscience education|Pain neuroscience education lecture
79731582|NCT01551550|Procedure|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
79269383|NCT05359900|Other|Red Flag Education|Red Flag education lecture
79731583|NCT01551550|Procedure|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
79731584|NCT01478698|Drug|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
79731585|NCT01478698|Drug|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
79731586|NCT04968340|Procedure|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
79731587|NCT04968340|Procedure|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
79731588|NCT00902746|Drug|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
79269384|NCT05356546|Other|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
79269385|NCT05348447|Device|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
79269386|NCT05348447|Other|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
79269387|NCT05345327|Drug|Dapagliflozin|SGLT2 inhibitor
79571581|NCT01802957|Other|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
79571582|NCT01802957|Other|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
79571583|NCT01802957|Other|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
79731589|NCT00632710|Other|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
79269388|NCT05345327|Drug|Metformin|Metformin
79269389|NCT05327257|Device|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
79269390|NCT05325450|Procedure|Program A|Presentation of the sentence to the implant alone
79571584|NCT01802970|Drug|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
79571585|NCT01802996|Drug|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
79571586|NCT01803009|Behavioral|Patient views NCI CRC RAT|
79571587|NCT01803009|Behavioral|View presentation regarding current chance of having an advanced adenoma|
79731590|NCT00632710|Other|phototherapy placebo|disconnected laser (same device - experimental group)
79731591|NCT01199380|Behavioral|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
79731592|NCT01199380|Behavioral|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
79731593|NCT01199380|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
80026081|NCT01736748|Behavioral|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
80026082|NCT01736748|Behavioral|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
80026083|NCT01721343|Behavioral|telephone-based intervention|Undergo telephonic monitoring
79269391|NCT05325450|Procedure|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
79269392|NCT05325450|Procedure|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
79269393|NCT05315505|Other|Maintenance programme|"Continuous educational support, exercise training, behaviour change intervention, and self-management.~Maintenance home-based pulmonary rehabilitation programme for ten months with alternate supervision"
79269394|NCT05315505|Other|Usual Care|No maintenance programme, and the patient has the usual follow-up and medical appointments
79269395|NCT05309018|Other|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
79269396|NCT05305287|Drug|Pioglitazone|An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
79269397|NCT05305287|Other|Placebo|Placebo for pioglitazone
79571588|NCT01803035|Drug|LTX-109 1 %|
79571589|NCT01803035|Drug|LTX-109 2 %|
79269398|NCT05305235|Device|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
79269399|NCT05305235|Device|Relaxation Control|Guides users through relaxation techniques.
79571590|NCT01803035|Drug|Placebo gel|
79731594|NCT02847286|Drug|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
79731595|NCT02847286|Drug|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
79731596|NCT02847286|Drug|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
79731597|NCT00902668|Drug|lovastatin|
79571591|NCT01803061|Behavioral|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
79571592|NCT01803087|Drug|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
79571593|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
79731598|NCT00902668|Other|questionnaire administration|
79731599|NCT00902668|Procedure|adjuvant therapy|
79731600|NCT00902668|Radiation|accelerated partial breast irradiation|
79731601|NCT00902668|Radiation|external beam radiation therapy|
79731602|NCT02846662|Behavioral|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
79731603|NCT00433420|Biological|pegfilgrastim|
79731604|NCT00433420|Drug|cyclophosphamide|
79731605|NCT00433420|Drug|epirubicin hydrochloride|
79731606|NCT00433420|Drug|fluorouracil|
79731607|NCT00433420|Drug|paclitaxel|
79731608|NCT00433420|Procedure|adjuvant therapy|
79731609|NCT02846818|Procedure|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
79866108|NCT01032057|Drug|gemcitabine hydrochloride|
79866109|NCT01032057|Procedure|quality-of-life assessment|
79866110|NCT01032057|Radiation|3-dimensional conformal radiation therapy|
80026084|NCT01721343|Other|case management|Participate in an individualized conditioning program with an RCM
79571594|NCT01803087|Drug|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
79731610|NCT02846584|Biological|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
79731611|NCT04835038|Drug|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
79401734|NCT03367845|Behavioral|Sensitivity Intervention|4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
79571595|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) (CTR)|
79571596|NCT01803100|Other|No intervention|There is no intervention in this trial
79571597|NCT01803113|Device|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
79571598|NCT01803139|Device|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
79571599|NCT01803178|Dietary Supplement|Plant Sterols|
79731612|NCT04835038|Drug|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
79731613|NCT03856918|Procedure|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
79731614|NCT03856918|Procedure|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
79731615|NCT03856918|Procedure|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
79731616|NCT03825094|Device|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
79731617|NCT04201912|Diagnostic Test|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
79866111|NCT01003314|Biological|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later
79866112|NCT01003314|Biological|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
80026085|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
80026086|NCT01721343|Procedure|physical therapy|Participate in an individualized conditioning program with an RCM
79571600|NCT01803178|Dietary Supplement|Placebo Product|
79571601|NCT01803191|Drug|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
80026087|NCT01721343|Other|questionnaire administration|Ancillary studies
80026088|NCT01721343|Procedure|quality-of-life assessment|Ancillary studies
80026089|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care
79277555|NCT03528967|Drug|Aspirin 100 mg Oral Tablet, Enteric Coated|
79571602|NCT01803191|Drug|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
79571603|NCT01803217|Other|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
79571604|NCT01803230|Dietary Supplement|creatine supplementation|creatine supplementation
79571605|NCT01803230|Dietary Supplement|Placebo|
79571606|NCT01803243|Other|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
79571607|NCT01803243|Other|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
79731618|NCT02850952|Other|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
79731619|NCT03678766|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
80026090|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care
80026091|NCT01721343|Other|educational intervention|Participate in an individualized conditioning program with an RCM
80026092|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM
80026093|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM
80026094|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
79866113|NCT00530088|Drug|porfimer sodium|IV
79571608|NCT01803243|Other|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
79571609|NCT01803295|Device|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
79571610|NCT01803295|Other|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
79731620|NCT03678766|Behavioral|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
79571611|NCT01803295|Device|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
79571612|NCT01803308|Drug|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
79571613|NCT01803308|Drug|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
79571614|NCT01803308|Drug|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
79731621|NCT02850796|Behavioral|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
79731622|NCT02850796|Other|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
79866114|NCT00530088|Drug|Photdynamic Therapy (PDT)|
79866115|NCT01009008|Device|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
79866116|NCT01006434|Other|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
79866117|NCT01003470|Other|acupuncture|Xing Nao Kai Qiao Acupuncture
80026095|NCT01661881|Drug|Rituximab|
80026096|NCT01661881|Drug|Bendamustine|
80026097|NCT01661881|Drug|Cytarabine|
80026098|NCT01640652|Biological|MenPF-1.|A new vaccine against meningococcal disease.
79571615|NCT01803321|Drug|rilonacept (IL-1 Trap)|
79571616|NCT01803321|Other|Placebo|
79571617|NCT01803334|Other|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
79571618|NCT01803347|Drug|◦Drug: ASCs. + fibrin glue|Experimental group
79571619|NCT01803347|Drug|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
79731623|NCT04802200|Other|Data collect|Data collect following a vascular closure by MANTA
79731624|NCT03630562|Procedure|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
79866118|NCT01003470|Behavioral|rehabilitation|Kinesitherapy
79866119|NCT01003470|Other|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
79866120|NCT01003548|Device|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
79866121|NCT01003548|Device|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
79866122|NCT01006668|Drug|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
79866123|NCT01006668|Drug|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
79866124|NCT01003626|Procedure|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
79571620|NCT01803360|Drug|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
79571621|NCT01803373|Drug|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
79571622|NCT01803373|Drug|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
79571623|NCT01803373|Drug|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
79571624|NCT01803386|Device|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
79571625|NCT01803399|Drug|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
80026099|NCT01638949|Behavioral|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
80026100|NCT01638949|Biological|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
80026101|NCT01638949|Genetic|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
80026102|NCT01638949|Other|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
80026103|NCT01582269|Drug|LY2157299 monohydrate|Orally administered as tablets
80026104|NCT01582269|Drug|Lomustine|Orally administered as capsules
80026105|NCT01582269|Drug|Placebo|Orally administered as tablets
79866125|NCT01003626|Device|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
80026106|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
80026107|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~10 to < 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
79571626|NCT01803399|Drug|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
79731625|NCT04801030|Behavioral|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
80026108|NCT01474148|Device|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
79731626|NCT04202068|Drug|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
79731627|NCT02850250|Drug|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
79731628|NCT05012644|Drug|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
79731629|NCT05012644|Drug|Aromatase inhibitor|Aromatase inhibitor
79731630|NCT04202302|Procedure|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
79731631|NCT02846506|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
79731632|NCT02846506|Drug|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
79731633|NCT02846506|Drug|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
79731634|NCT02846506|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
79731635|NCT02846428|Drug|5-Fluorouracil|5-FU will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
79571627|NCT01803399|Drug|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
79571628|NCT01803399|Drug|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
79571629|NCT01803425|Other|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
79731636|NCT02846428|Drug|Capecitabine|Capecitabine will be administered at 900 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
79866126|NCT01003704|Procedure|Lower extremity amputation|
79571630|NCT01803438|Device|cryoballoon ablation system|
79571631|NCT01803438|Drug|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
79571632|NCT01803477|Drug|once daily for two consecutive days (Picato)|
79571633|NCT01803503|Drug|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
79571634|NCT01803503|Drug|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
79571635|NCT01803516|Behavioral|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
79269400|NCT05283564|Other|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
79269401|NCT05275140|Other|Physical activity|Combat sports and exercise
79269402|NCT05241834|Drug|LOXO-260|Oral
79269403|NCT05213000|Behavioral|Exercise|90 minute exercise session
79269404|NCT05207267|Device|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
79269405|NCT05188677|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
79571636|NCT01803529|Other|heat-pack with massage|
79571637|NCT01803529|Other|heat-pack only|
79571638|NCT01803568|Other|Exercise|12 weeks of exercise; 4 times pr week
79571639|NCT01803581|Other|X92001327|
79571640|NCT01803581|Other|RID shampoo|
79731637|NCT02846428|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
79731638|NCT02846428|Drug|Docetaxel|Docetaxel will be administered at 100 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
79731639|NCT02846428|Drug|Epirubicin|Epirubicin will be administered at 100 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
79731640|NCT03568084|Other|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
79731641|NCT03568084|Other|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
79731642|NCT04368130|Behavioral|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
79731643|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
79731644|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
79269406|NCT05188677|Biological|Comirnaty Vaccine|intramuscular injection
79571641|NCT01803659|Dietary Supplement|b-carotene|
79269407|NCT05188677|Biological|Vaxzevria Vaccine|intramuscular injection
79269408|NCT05188677|Biological|CoronaVac Vaccine|intramuscular injection
79269409|NCT05177055|Behavioral|Group-based light therapy at gradually advanced timing for DSWPD|Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
79269410|NCT05177055|Behavioral|Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses|Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
79269411|NCT05177055|Other|6-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
79269412|NCT05175404|Diagnostic Test|PET/CT scan F18-PSMA-11|PET/CT scan with F18-PSMA-11
79269413|NCT05170009|Drug|Baloxavir Marboxil|Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing <80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.
79571642|NCT01803659|Dietary Supplement|retinyl palmitate|
79269414|NCT05170009|Drug|Placebo|Placebo at baseline, day 4, and day 7.
79269415|NCT05170009|Drug|Oseltamivir|Oseltamivir 75 mg twice daily for 10 days.
79571643|NCT01803659|Dietary Supplement|placebo|
79571644|NCT01803672|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
79571645|NCT01803672|Behavioral|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
79571646|NCT01803698|Behavioral|Training in the use of IOM charts|
79731645|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
79731646|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
79731647|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
79731648|NCT00947349|Drug|BI 201335 NA low placebo|Placebo
79731649|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
79731650|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
79731651|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
79731652|NCT00947349|Drug|BI 201335 NA low|BI 201335 NA
79731653|NCT00947349|Drug|BI 201335 NA high placebo|placebo
79731654|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
79731655|NCT00947349|Drug|Placebo|
79731656|NCT02846194|Behavioral|brief guided imagery|
79731657|NCT02844556|Procedure|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
79731658|NCT02844556|Other|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
79269416|NCT05168085|Dietary Supplement|Eggs|Providing 1 egg per day fo 6 months to infants
79269417|NCT05159427|Drug|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
79269418|NCT05159427|Drug|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
79269419|NCT05159427|Drug|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
79269420|NCT05159427|Drug|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
79269421|NCT05157958|Biological|ALLO-ASC-SHEET|Weekly administration
79269422|NCT05157958|Other|Vehicle Control|Weekly administration
79269423|NCT05155891|Device|Embosphere Microspheres|The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
79269424|NCT05155891|Procedure|HoLEP Procedure|The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
79269425|NCT05145582|Behavioral|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
79269426|NCT05145582|Behavioral|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
79269427|NCT05134935|Device|Defocus Incorporated Multiple Segment (DIMS) Spectacles|18 months of therapy.
79571647|NCT01803750|Behavioral|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
79571648|NCT01803763|Drug|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
79571649|NCT01803763|Drug|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
79269428|NCT05134935|Device|Orthokerathology lenses (OKL)|18 months of therapy.
79269429|NCT05132699|Drug|Cannabidiol (CBD) oral solution|An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
79571650|NCT01803776|Behavioral|lifestyle counseling|The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
79571651|NCT01803789|Device|Single Kirschner Wire|
79269430|NCT05132699|Drug|Placebo|An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
79269431|NCT05132699|Behavioral|Massed Prolonged Exposure (mPE)|mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
79269432|NCT05129878|Procedure|scaling and OHI|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions
79571652|NCT01803789|Device|Double Kirschner Wire|
79571653|NCT01803802|Behavioral|Expressive writing|Five sessions of 30 minutes of expressive writing
79571654|NCT01803828|Drug|Tadalafil|20 mg/die (1 capsule)
79571655|NCT01803828|Drug|Placebo|Placebo 20 mg/die (1 capsule)
79269433|NCT05129878|Procedure|oral Hygiene instructions|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
79269434|NCT05129878|Procedure|Scaling and oral hygiene instruction|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
79269435|NCT05125991|Procedure|Prepectoral reconstruction|Prepectoral breast reconstruction
79269436|NCT05125991|Procedure|Submuscolar reconstruction|Submuscolar breast reconstruction
79269437|NCT05125679|Drug|Guselkumab|Guselkumab will be administered by subcutaneous injection.
79269438|NCT05107115|Drug|rilzabrutinib|Tablet, oral use
79269439|NCT05107115|Drug|placebo|Tablet, oral use
79269440|NCT05103449|Other|Video Coaching|Video-based coaching sessions after salpingectomy 1 and 2
79269441|NCT05091476|Device|OPTiC System|OPTiC System procedure
79269442|NCT05086757|Behavioral|TRRP|Receive TRRP services
79269443|NCT05086757|Behavioral|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
79571656|NCT01803841|Procedure|Transradial coronary angiography and intervention|
79571657|NCT01803841|Procedure|Transfemoral coronary angiography and intervention|
79571658|NCT01803867|Drug|rHIgM22|Administered via IV infusion
79571659|NCT01803919|Device|Silver Alloy-Coated Urinary Catheters|
79571660|NCT01803919|Device|Conventional Urinary Catheter|
79571661|NCT01803932|Behavioral|Male-focused group violence prevention intervention|
79571662|NCT01803945|Drug|AVE8112|
79571663|NCT01803945|Drug|Placebo|
79866127|NCT04000230|Behavioral|TCIT|"TCIT consists of the following:~CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
79731659|NCT02846116|Other|Prosthetic crown|
79269444|NCT05067764|Procedure|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
79277556|NCT05723965|Other|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
79571664|NCT01803958|Radiation|partial breast irradiation|
79571665|NCT01803958|Radiation|whole breast irradiation|
79571666|NCT01803971|Other|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
79731660|NCT00947193|Drug|Ataluren|Oral powder
79731661|NCT03425812|Drug|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
79571667|NCT01803984|Device|MRI|
79571668|NCT01803984|Device|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
79731662|NCT03425812|Drug|To continue NSAIDs therapy|NSAIDs therapy will be continued.
79731663|NCT00947115|Procedure|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
79731664|NCT00947115|Procedure|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
79731665|NCT02845804|Device|Alpine|
79866128|NCT04000230|Behavioral|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
79571669|NCT01803984|Other|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
79866129|NCT05734326|Device|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA [18].
79866130|NCT00360568|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
79866131|NCT00360568|Device|CADD-Legacy® 1400 ambulatory infusion pump|
79866132|NCT00360568|Device|PEG tube|percutaneous endoscopic gastrostomy tube
79866133|NCT00360568|Device|J-tube|jejunal tube
79866134|NCT00436215|Drug|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
79277557|NCT05723965|Other|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
79277558|NCT02374905|Device|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
79277559|NCT02374905|Behavioral|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
79571670|NCT01803997|Behavioral|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
79571671|NCT01804010|Drug|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
79731666|NCT02845960|Behavioral|rapid recovery|rapid recovery
79731667|NCT02844634|Drug|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
79731668|NCT02844634|Drug|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
79731669|NCT02844634|Drug|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
79731670|NCT02844478|Behavioral|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
79866135|NCT00436215|Drug|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
79866136|NCT03742674|Other|Follow up|No intervention
79866137|NCT01006746|Other|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
79866138|NCT01028859|Drug|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks
79866139|NCT05734248|Procedure|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
79866140|NCT05602974|Radiation|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
79866141|NCT05602974|Other|regular follow-up|regular follow-up
79866142|NCT00441363|Drug|Bromocriptine Mesylate|0.8 mg tablet
79401735|NCT03367845|Behavioral|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
79401736|NCT03367845|Behavioral|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
79571672|NCT01804023|Other|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
79571673|NCT01804127|Drug|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
79731671|NCT02844478|Behavioral|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
79731672|NCT02845648|Drug|anticholinergic|Initial anticholinergic therapy to all patients
79731673|NCT02844166|Other|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
79731674|NCT02844166|Other|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
79401737|NCT03348631|Procedure|Computed Tomography|Undergo CT scan
79401738|NCT03348631|Procedure|Magnetic Resonance Imaging|Undergo MRI
79401739|NCT03348631|Drug|Tazemetostat|Given PO
79401740|NCT03338621|Drug|Pretomanid|200 mg tablets
79401741|NCT03338621|Drug|Bedaquiline|100 mg tablets
79401742|NCT03338621|Drug|Moxifloxacin|400 mg tablets
79571674|NCT01804153|Drug|Adipose-derived expanded stem cells|Intralesional application ASC
79571675|NCT01804192|Other|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
79731675|NCT03337906|Other|Observation|
79731676|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
79731677|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
79731678|NCT00952419|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
79866143|NCT05139186|Device|Artificial Intelligence|Artificial intelligence
79866144|NCT03992248|Behavioral|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
79866145|NCT03992248|Behavioral|Control|Eating for at least 14hrs per day.
79866146|NCT05734170|Dietary Supplement|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
79866147|NCT05734170|Dietary Supplement|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
79401743|NCT03338621|Drug|Pyrazinamide|500 mg tablets
79401744|NCT03338621|Drug|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
79866148|NCT05734170|Dietary Supplement|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
79277560|NCT05723887|Behavioral|Attachment-Based Intervention Program|Attachment-Based Intervention Program
79277561|NCT05723809|Device|Percussive Therapy Device|Same as group description
79277562|NCT05723809|Behavioral|Physical Therapy|Same as group description
79277563|NCT05271565|Dietary Supplement|Oligomeric enteral feeding|Oligomeric enteral formula
79277564|NCT05271565|Dietary Supplement|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
79277565|NCT02374749|Behavioral|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
79277566|NCT02374749|Behavioral|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
79401745|NCT03338621|Drug|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
79401746|NCT03323099|Behavioral|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
79401747|NCT03323099|Behavioral|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
79401748|NCT03323034|Drug|Irinotecan|Given IV
79401749|NCT03323034|Drug|Pevonedistat|Given IV
79401750|NCT03323034|Drug|Temozolomide|Given PO
79866149|NCT01006824|Other|Capsule endoscopy|Capsule endoscopy
80026109|NCT01353313|Drug|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
79731679|NCT02000037|Device|IR Reflexotherapy|"18 IR reflexotherapy sessions :~Once a week for 12 weeks at the beginning of the study~Once a week for 3 weeks, 9 months after the beginning of the study~Once a week for 3 weeks, 15 months after the beginning of the study"
80026110|NCT01353313|Drug|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
79269445|NCT05067764|Procedure|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
79571676|NCT01804205|Drug|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
79571677|NCT01804205|Drug|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
79571678|NCT01804218|Drug|Nadolol|
79731680|NCT02000037|Behavioral|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
79731681|NCT04259541|Diagnostic Test|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
79731682|NCT00902278|Biological|Flulaval|one 0.5-mL dose via intramuscular injection
79866150|NCT01006824|Other|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
79269446|NCT05044299|Device|Isoped|Isoped is a mechanical device allowing movement of lower extremities in a forward and backward motion, with phone-based app to control resistance load
79269447|NCT05033665|Behavioral|Increase water consumption|The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
79269448|NCT05033665|Behavioral|Maintain adequate water consumption|The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
79269449|NCT05026983|Drug|Binimetinib|Given PO
79269450|NCT05026983|Drug|Encorafenib|Given PO
79571679|NCT01804218|Drug|Placebo|
79571680|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
79571681|NCT01804244|Drug|TMC278|1 25-mg tablet [27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
79731683|NCT00902278|Biological|Fluvirin|one 0.5-mL dose via intramuscular injection
79731684|NCT00902278|Biological|Fluzone|one 0.5-mL dose via intramuscular injection
79731685|NCT00902278|Biological|Fluarix|one 0.5-mL dose via intramuscular injection
79866151|NCT05734092|Device|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
80026111|NCT01245712|Radiation|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
79731686|NCT00902278|Biological|Afluria|one 0.5-mL dose via intramuscular injection
79731687|NCT02854293|Other|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
79731688|NCT02845726|Other|Stent examination, urinary analysis, USSQ questionnaire|
79731689|NCT02844322|Drug|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
79731690|NCT02844322|Drug|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
79731691|NCT01998633|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
80026112|NCT01245712|Radiation|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
80026113|NCT01245712|Other|Quality-of-Life Assessment|Ancillary studies
80026114|NCT01209871|Biological|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
80026115|NCT01209871|Other|Laboratory Biomarker Analysis|Correlative studies
79269451|NCT05026983|Other|Questionnaire Administration|Ancillary studies
79571682|NCT01804283|Procedure|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
79866152|NCT05734092|Device|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
79866153|NCT04000074|Behavioral|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
79866154|NCT04000074|Behavioral|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
79866155|NCT00530712|Device|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
79866156|NCT05733858|Device|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
80026116|NCT01083862|Behavioral|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
80026117|NCT01083862|Behavioral|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
80026118|NCT00959452|Behavioral|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
79269452|NCT04993079|Device|Clotild®|Use of Clotild® as neurovascular guidewire
79571683|NCT01804283|Procedure|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
79571684|NCT01804283|Device|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
80026119|NCT00580515|Behavioral|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
79269453|NCT04981132|Behavioral|Pain Neuroscience education + Progressive therapeutic exercise training|The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.
79269454|NCT04981132|Behavioral|Progressive therapeutic exercise training|The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
79269460|NCT04919629|Biological|Bevacizumab|Given IV
79269461|NCT04919629|Biological|Pegcetacoplan|Given IV (only for loading dose) and SC
79731692|NCT02845570|Other|68Ga-DOTANOC PET/MRI|
79269462|NCT04919629|Biological|Pembrolizumab|Given IV
79269463|NCT04919629|Other|Quality-of-Life Assessment|Ancillary studies
79269464|NCT04919629|Other|Questionnaire Administration|Ancillary studies
79269465|NCT04879017|Drug|FHD-286|FHD-286 as a single agent
79731693|NCT02845570|Other|18F-FDG PET/MRI|
79731694|NCT02844400|Device|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
79731695|NCT02844400|Other|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
79731696|NCT03097276|Procedure|blood sample|blood sample will be collected
79731697|NCT03097276|Radiation|CT scan|CT scan
79866157|NCT05733858|Device|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
79866158|NCT05733858|Device|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
79866159|NCT05733858|Behavioral|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
79866160|NCT00626795|Drug|TD1414 2% cream|BID 7 days
79866161|NCT00626795|Drug|TD1414 2% cream|TID 7 days
79866162|NCT00626795|Drug|Bactroban® (mupirocin) 2% cream|BID 7 days
79866163|NCT01007214|Procedure|Prostatectomy|Elective prostatectomy
79866164|NCT00826553|Drug|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
79866165|NCT00826553|Drug|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
79269468|NCT04842448|Drug|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
79401751|NCT03315910|Behavioral|Motivational Interviewing (MI)|two counseling sessions
79401752|NCT03315910|Drug|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
79571685|NCT01804283|Device|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
79571686|NCT01804309|Procedure|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
79571687|NCT01804322|Other|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
79866166|NCT00626639|Drug|Placebo|Administered by intravenous (IV) bolus injection
79866167|NCT00626639|Drug|palifermin|Administered by intravenous (IV) bolus injection
79866168|NCT00626639|Radiation|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation [one fraction per day])
79866169|NCT00626639|Drug|Cisplatin|100 mg/m^2 intravenously (IV) on days 1, 22 and 43.
79866170|NCT00626561|Drug|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
79571688|NCT01804322|Other|usual care|usual care according to the participating Epilepsy Centers
79866171|NCT00626561|Drug|Paclitaxel|60 mg/m^2 IV weekly on days 1, 8, 15, and 22.
79866172|NCT00822653|Device|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
80026120|NCT00580515|Behavioral|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
79269469|NCT04842448|Procedure|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
79269470|NCT04838925|Device|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
79571689|NCT01804335|Drug|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
79866173|NCT00822731|Drug|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
79401753|NCT03315910|Drug|Nicotine Lozenge|6 packs of NRT 2mg lozenge
79401754|NCT03315910|Behavioral|Message Framing|health communication literature and quitting messages
79401755|NCT03315910|Other|saliva sample|saliva samples from those reporting abstinence and analyze samples
79401756|NCT03307252|Drug|Digoxin|Tablet
79401757|NCT03307252|Drug|Furosemide|Oral solution
79401758|NCT03307252|Drug|Metformin|Oral solution
79401759|NCT03307252|Drug|Rosuvastatin|Film-coated tablet
79401760|NCT03307252|Drug|Verapamil|Film-coated tablet
79401761|NCT03307252|Drug|Rifampin|Film-coated tablet
79401762|NCT03307252|Drug|Cimetidine|Tablet
79401763|NCT03307252|Drug|Probenecid|Tablet
80026121|NCT00580515|Behavioral|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
79866174|NCT03859661|Dietary Supplement|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
79866175|NCT00826631|Procedure|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
79571690|NCT01804348|Device|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
79866176|NCT03880266|Drug|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
79866177|NCT03880266|Drug|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
79269471|NCT04830514|Other|Recommended Dietary Allowance of Protein|0.8 g/kg/day protein intake
79269472|NCT04830514|Other|Habitual protein intake|1.0 g/kg/day protein intake
80026122|NCT00319813|Behavioral|Education|
80026123|NCT00151853|Drug|PPSB-SD|
80026124|NCT03487172|Device|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
80026125|NCT03487172|Device|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
79269473|NCT04830514|Other|Optimal Protein Intake|1.5 g/kg/day protein intake
80026126|NCT02167776|Behavioral|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
80026127|NCT04460378|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
79269474|NCT04827927|Procedure|Procedure: INTELLiVENT-ASV|With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.
79269475|NCT04827927|Procedure|Procedure: Conventional ventilation|With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
79269476|NCT04785157|Biological|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
79401764|NCT03286504|Behavioral|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
79571691|NCT01804361|Drug|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
80026128|NCT03069508|Drug|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
80026129|NCT03481478|Diagnostic Test|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
80026130|NCT04995016|Drug|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
80026131|NCT04995016|Drug|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
80026132|NCT03485066|Behavioral|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
79269477|NCT04785157|Biological|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
79269478|NCT04785157|Other|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
79401765|NCT03284385|Drug|Adavosertib|Given PO
79571692|NCT01804361|Drug|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
79571693|NCT01804374|Drug|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
79731698|NCT01987635|Device|MEMO 3D ring|The experimental MEMO 3D ring is placed.
79731699|NCT01987635|Device|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
79731700|NCT01987635|Procedure|3D Echocardiography|
79731701|NCT05337904|Device|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
79731702|NCT05337904|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
79731703|NCT02854137|Drug|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
79731704|NCT02854137|Drug|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
79731705|NCT00630981|Behavioral|Psychotherapy|Specific psychotherapy for dissociative disorders
79731706|NCT00630981|Drug|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
79866178|NCT00423891|Drug|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
79571694|NCT01804374|Drug|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
79269479|NCT04785157|Other|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
79866179|NCT00830609|Drug|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
79866180|NCT00830609|Drug|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
80026133|NCT02764320|Other|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
80026134|NCT02764320|Other|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
79269480|NCT04785157|Behavioral|neurocognitive assessment|multi-domains neurocognitive assessment
79269481|NCT04785027|Drug|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
79571695|NCT01804387|Drug|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
79269482|NCT04785027|Drug|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
79269483|NCT04785027|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
79269484|NCT04784182|Dietary Supplement|probiotic plus prebiotic supplement|Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)
79269485|NCT04784182|Dietary Supplement|placebo|Daily consumption of visually similar placebo pills
79401766|NCT03275168|Behavioral|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
79866181|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 24 weeks
79401767|NCT03275168|Behavioral|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
80026135|NCT04994860|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
79269486|NCT04783064|Procedure|Interscalene brachial plexus block|Interscalene brachial plexus block is performed at ipsilateral side of the affected shoulder.
79269487|NCT04768803|Biological|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
79269488|NCT04755153|Behavioral|Kaiser Bundle|Kaiser Permanente demonstrated that a bundle of evidence-based interventions implemented within a large, integrated health system in Northern California significantly increased blood pressure control rates.
79277567|NCT02363985|Dietary Supplement|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
79401768|NCT03274219|Biological|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
79401769|NCT03270982|Device|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
79571696|NCT01804387|Drug|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
79571697|NCT01804400|Drug|QAW039|
79571698|NCT01804400|Drug|Montelukast|
79866182|NCT00830609|Drug|ribavirin|ribavirin 800 mg/day for 24 weeks
79866183|NCT00830609|Drug|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
79866184|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
79866185|NCT00822809|Drug|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
79866186|NCT00822809|Drug|Prednisolone|25 mg premedication
79866187|NCT00830687|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
79866188|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
79866189|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
79866190|NCT00822887|Drug|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
79866191|NCT00822887|Radiation|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
79866192|NCT02549651|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
80026136|NCT04994860|Drug|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
80026137|NCT03481400|Drug|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
80026138|NCT03481400|Other|Placebo|Isotonic saline
79731707|NCT05243134|Other|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
79731708|NCT02854371|Drug|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
79866193|NCT02549651|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
79866194|NCT02549651|Drug|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
79866195|NCT03999762|Device|sample prep|Effectiveness of a sample preparation protocol
79866196|NCT03999372|Biological|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
79401770|NCT03253081|Behavioral|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
79401771|NCT03253081|Behavioral|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
79866197|NCT03999372|Other|ICSI|Normal ICSI procedure
79866198|NCT00826709|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
79866199|NCT00822965|Other|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
79866200|NCT00822965|Other|Phone Interviews|2 follow-up phone interviews.
79269489|NCT04724694|Behavioral|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
79401772|NCT03247088|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
79401773|NCT03247088|Drug|Busulfan|Given IV
79401774|NCT03247088|Drug|Cyclophosphamide|Given IV
79401775|NCT03247088|Biological|Filgrastim|Given SC
79401776|NCT03247088|Drug|Fludarabine|Given IV
79401777|NCT03247088|Drug|Mycophenolate Mofetil|Given PO
79401778|NCT03247088|Drug|Sorafenib|Given PO
79571699|NCT01804400|Drug|Placebo|
79571700|NCT01804413|Drug|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
79571701|NCT01804413|Drug|Regular insulin|0.1-0.15 units/kg
79571702|NCT01804478|Behavioral|Mild pneumatic compression|
79571703|NCT01804491|Other|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
79571704|NCT01804504|Behavioral|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
79571705|NCT01804530|Drug|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
79571706|NCT01804543|Drug|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
79731709|NCT02854371|Drug|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
79731710|NCT02845180|Procedure|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
79731711|NCT02845414|Drug|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
79866201|NCT00822965|Behavioral|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
79866202|NCT05733468|Drug|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
79866203|NCT05733468|Drug|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
79866204|NCT00830843|Drug|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
79866205|NCT00830843|Drug|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
79866206|NCT00826787|Drug|Levetiracetam|750 mg tablet
79866207|NCT00823121|Procedure|freezing embryos by vitrification|vitrification by Cryotop method
79866208|NCT00823121|Procedure|fresh embryo transfers|fresh embryo transfers
79866209|NCT00823121|Drug|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
79866210|NCT00823121|Drug|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
80026139|NCT02851407|Drug|Defibrotide|
80026140|NCT02851407|Other|Best Supportive Care|
79401779|NCT03247088|Drug|Tacrolimus|Given PO
79401780|NCT03233139|Drug|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
79401781|NCT03233139|Drug|Ipilimumab|To be administered per protocol
79866211|NCT00823121|Drug|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
79866212|NCT00423813|Drug|placebo|Oral Solution
79866213|NCT00423813|Drug|Xyrem®|two doses
79401782|NCT03233139|Drug|Platinum-doublet chemotherapy|To be administered per protocol
79401783|NCT03233139|Drug|Gemcitabine|To be administered per protocol
79401784|NCT03233139|Drug|Pemetrexed|To be administered per protocol
79571707|NCT01804556|Procedure|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 ~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
79571708|NCT01804569|Other|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
79866214|NCT01007604|Device|Peristaltic pulse PCD|Daily use for two hours
80026141|NCT03481322|Dietary Supplement|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
80026142|NCT02167854|Drug|BYL719|
79571709|NCT01804595|Other|Sunscreen|
79571710|NCT01804595|Behavioral|Text-Message Reminders|
79571711|NCT01804595|Other|Sunscreen and Text Message Reminders|
79571712|NCT01804595|Behavioral|Education|
79571713|NCT01804608|Other|Strength|
79571714|NCT01804608|Other|Sensorimotor|
79571715|NCT01804621|Behavioral|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
79866215|NCT01007604|Other|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
79866216|NCT03687372|Drug|A-101|hydrogen peroxide topical solution 45%
79866217|NCT03687372|Other|vehicle|vehicle as a topical solution
79866218|NCT00626405|Biological|bevacizumab|Given IV over 30-90 minutes
79866219|NCT00626405|Drug|carboplatin|Given IV over 30 minutes
80026143|NCT02167854|Drug|LJM716|
80026144|NCT02167854|Drug|TRASTUZUMAB|
80026145|NCT03541122|Diagnostic Test|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
80026146|NCT03071146|Device|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
79269490|NCT04724694|Other|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
79269491|NCT04717804|Other|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
80026147|NCT02759562|Drug|Andecaliximab|Administered via subcutaneous injection
79269492|NCT04717804|Other|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
79269493|NCT04705207|Procedure|reflexology massage|the patient receive only foot reflexology massage
79401785|NCT03233139|Drug|Paclitaxel|To be administered per protocol
79401786|NCT03233139|Drug|Fianlimab|To be administered per protocol
79571716|NCT01804647|Other|No study treatments administered - blood draws only|
79571717|NCT01804660|Other|No study treatments administered|
79571718|NCT01804712|Drug|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
79571719|NCT01804738|Other|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
79571720|NCT01804738|Other|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
79731712|NCT02845492|Other|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
79731713|NCT02845492|Other|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
79731714|NCT00952341|Drug|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
79731715|NCT00952341|Drug|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
79866220|NCT00626405|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
79866221|NCT00626405|Drug|temozolomide|Oral temozolomide on days 1-5
80026148|NCT02759562|Drug|Placebo|Administered via subcutaneous injection
79269494|NCT04705207|Procedure|sham massage|the patient receive only foot traditional massage
79269495|NCT04701307|Biological|Dostarlimab|Given IV
79866222|NCT05454306|Device|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
79731716|NCT00952341|Drug|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
79866223|NCT05733234|Device|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
79269496|NCT04701307|Drug|Niraparib|Given PO
80026149|NCT03604809|Other|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
80026150|NCT02167932|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
80026151|NCT04984954|Drug|MUSK pill|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
80026152|NCT02938377|Behavioral|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
80026153|NCT02938377|Behavioral|CBT4CBT|9 computerized modules delivered at the participant's pace
79401787|NCT03221777|Diagnostic Test|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.[87]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
79401788|NCT03213002|Drug|Capecitabine|Capecitabine at 1500 mg/m2
79731717|NCT00952341|Drug|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
79269497|NCT04693208|Device|Laser therapy|Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
79269498|NCT04683731|Behavioral|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
79269499|NCT04683731|Behavioral|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
79269500|NCT04683731|Behavioral|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
79277568|NCT05723731|Device|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
79401789|NCT03213002|Drug|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
79401790|NCT03209154|Diagnostic Test|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
79401791|NCT03209154|Device|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
79401792|NCT03206047|Drug|Atezolizumab|Given IV
79401793|NCT03206047|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC
79731718|NCT00952341|Drug|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
79731719|NCT02845024|Drug|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
79731720|NCT02845024|Drug|placebo Group|Oral placebo was taken within 15 days
79866224|NCT05733234|Drug|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
79866225|NCT00826865|Drug|Levetiracetam|750 mg tablet
79866226|NCT01007682|Other|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
79269501|NCT04683731|Behavioral|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
79571721|NCT01804777|Drug|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
79571722|NCT01804777|Drug|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
79731721|NCT05242588|Biological|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
79731722|NCT05242588|Biological|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
79731723|NCT02852733|Other|end-of-life emergencies' management|
79866227|NCT00830921|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
79866228|NCT00358150|Drug|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067[active moiety of eliglustat in plasma] trough plasma concentration was greater than or equal to [>=]5 nanogram per milliliter [ng/mL] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than [<] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
79866229|NCT00830999|Behavioral|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
79269502|NCT04675567|Behavioral|Safety-Net Care Team Model|"Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
79269503|NCT04673461|Drug|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
79401794|NCT03206047|Drug|Guadecitabine|Given SC
80026154|NCT02938377|Drug|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
79401795|NCT03206047|Other|Laboratory Biomarker Analysis|Correlative studies
79401796|NCT03206047|Drug|Poly ICLC|Given SC
79731724|NCT02853903|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
79731725|NCT04269525|Biological|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
79866230|NCT00830999|Behavioral|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
79866231|NCT00830999|Behavioral|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
80026155|NCT02161614|Drug|Estradiol valerate|
80026156|NCT02161614|Drug|Placebo|
80026157|NCT04994626|Drug|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
80026158|NCT03604731|Device|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
79731726|NCT05242120|Other|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
79731727|NCT00602277|Other|Laboratory Biomarker Analysis|Correlative studies
79731728|NCT00602277|Biological|Wild-type Reovirus|
79866232|NCT00830999|Behavioral|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
79866233|NCT00830999|Behavioral|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
79866234|NCT00831077|Drug|ORM-14540|i.v.
80026159|NCT02168010|Drug|Analgecine|Analgesic drug under test
80026160|NCT02168010|Drug|Neurotropin|Analgesic drug as positive control
79401797|NCT03191786|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
79571723|NCT01804803|Procedure|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
79866235|NCT00831077|Drug|ORM-12741|i.v.
79866236|NCT01007760|Other|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
80026161|NCT02168010|Drug|Placebo|Blank tablet as placebo.
79269504|NCT04673461|Drug|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
79269505|NCT04673461|Drug|Placebo|Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
79269506|NCT04673175|Drug|Ceftolozane / Tazobactam Injection|Zerbaxa (ceftolozane/tazobactam) for injection is supplied as a white to yellow sterile powder for reconstitution in single-use vials; each vial contains 1 g ceftolozane (equivalent to 1.147 g of ceftolozane sulfate) and 0.5 g tazobactam (equivalent to 0.537 g of tazobactam sodium).
79571724|NCT01804803|Procedure|Use of regular glucometer|
79731729|NCT05241964|Biological|PRP|4~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
80026162|NCT04994314|Drug|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
79866237|NCT00823355|Drug|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
80026163|NCT04994314|Drug|Control primer|Conventional orthodontic primer
80026164|NCT02161692|Drug|Cyclophosphamide|
79269507|NCT04666649|Drug|Venetoclax and pegcrisantaspase|Therapeutic
79269508|NCT04661774|Other|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
79269509|NCT04661774|Other|sham massage|traditional massage of the foot
79269510|NCT04649541|Drug|MRX-8|novel semi-synthetic polymyxin B analog.
79269511|NCT04649541|Drug|Placebo|5% dextrose in water
79269512|NCT04612413|Drug|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
79269513|NCT04612413|Other|Placebo|Solution containing all excipients except for the Allocetra-OTS cells
79269514|NCT04606901|Drug|neostigmine/glycopyrrolate|neuromuscular blockade reversal agents
79401798|NCT03191786|Drug|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
79866238|NCT00823355|Drug|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
79866239|NCT00823355|Drug|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
79866240|NCT00823355|Drug|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
79866241|NCT03999450|Behavioral|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
79269515|NCT04606901|Drug|sugammadex|neuromuscular blockade reversal agent
79401799|NCT03191786|Drug|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
80026165|NCT02161692|Drug|Etoposide|
80026166|NCT02161692|Drug|Cisplatin|
80026167|NCT02161692|Drug|Bleomycin|
79401800|NCT03176394|Device|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
79401801|NCT03176394|Device|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
79401802|NCT03174938|Diagnostic Test|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
80026168|NCT02161692|Drug|Carboplatin|High dose carboplatin
80026169|NCT03070756|Device|Minimal-Intervention - Specification of device settings|- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration <=15 min, softPAP Level is selected based on patient comfort
80026170|NCT02746575|Drug|metoprolol|
80026171|NCT02161770|Drug|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
80026172|NCT02161770|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
80026173|NCT02161770|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
80026174|NCT04989244|Behavioral|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
80026175|NCT03604575|Drug|Insulin Lispro|
80026176|NCT03604575|Drug|Humalog®|
79866242|NCT03999450|Behavioral|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
79866243|NCT01049074|Other|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
79866244|NCT01049074|Other|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
79866245|NCT05427630|Drug|THC ~2.5%|Cannabis flower containing THC ~2.5%
79866246|NCT05427630|Drug|THC ~5%|Cannabis flower containing THC ~5%
79866247|NCT05427630|Drug|THC ~10%|Cannabis flower containing THC ~5%
79866248|NCT05427630|Drug|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
79866249|NCT01050556|Other|Placebo|daily, 24 weeks
80026177|NCT04988932|Drug|Inhaled nitric oxide|Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
80026178|NCT03602313|Device|Body Weight Support Gait Training|
80026179|NCT03602313|Other|Traditional Gait Training|
80026180|NCT03625466|Drug|LUM/IVA|FDC tablets or granules for oral administration.
80026181|NCT03625466|Drug|LUM/IVA|FDC granules for oral administration.
80026182|NCT03625466|Drug|Placebo|Placebo matched to LUM/IVA for oral administration.
80026183|NCT04989010|Drug|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
80026184|NCT03604419|Drug|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
80026185|NCT03604419|Drug|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
80026186|NCT03604419|Drug|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
80026187|NCT03604419|Drug|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
79866250|NCT01050556|Dietary Supplement|folic acid|400 ug/d for 12 or 24 weeks
79866251|NCT01050556|Dietary Supplement|folic acid|800 µg/d for 12 or 24 weeks
80026188|NCT03540654|Other|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
80026189|NCT04994548|Procedure|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
79866252|NCT01050556|Dietary Supplement|creatine|3 mg/d for 12 weeks
80026190|NCT03484988|Dietary Supplement|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
80026191|NCT03484988|Dietary Supplement|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
80026192|NCT03484988|Dietary Supplement|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
80026193|NCT02168166|Behavioral|Executive Function Training|
80026194|NCT02168166|Behavioral|Placebo|Placebo version of executive function training
80026195|NCT02237547|Biological|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
79277569|NCT05723731|Drug|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
79277570|NCT05653791|Diagnostic Test|Intestinal ultrasound|Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
79866253|NCT01050556|Dietary Supplement|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
79866254|NCT05890014|Dietary Supplement|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
80026196|NCT04984720|Behavioral|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
80026197|NCT02168244|Other|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
79866255|NCT05889923|Device|With EDU|using the EDU to perform the procedure
80026198|NCT02168244|Other|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
79866256|NCT05889910|Procedure|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
79866257|NCT05889884|Device|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
80026199|NCT03484832|Device|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
79866258|NCT05889871|Drug|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
79866259|NCT05889832|Diagnostic Test|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
79866260|NCT05889806|Other|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
79866261|NCT05889767|Other|Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)|"All participants will complete two exercise sessions:~VO2 max test on a cycle ergometer~Moderate exercise session (45 minutes at 65% measured VO2 max)"
79866262|NCT05889728|Drug|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for [177Lu]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
79866263|NCT05889676|Diagnostic Test|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
80026200|NCT03484832|Other|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
80026201|NCT03484832|Other|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
79277571|NCT02367495|Device|PCB|PCB with Citrate-based excipient
79401803|NCT03174938|Diagnostic Test|[18F]-RO6958948|PET imaging of Tau aggregates
79401804|NCT03174938|Diagnostic Test|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
79277572|NCT02363829|Drug|Nelfinavir|
79277573|NCT02363829|Biological|Cisplatin|
79277574|NCT03528889|Procedure|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
79277575|NCT03113019|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
79401805|NCT03174938|Diagnostic Test|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
79866264|NCT05889598|Other|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
79277576|NCT03528811|Diagnostic Test|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
79401806|NCT03170518|Drug|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
79401807|NCT03170518|Drug|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
79401808|NCT03170518|Drug|Placebo|Matching placebo tablet will be administered orally once-daily.
79401809|NCT03169075|Behavioral|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
79401810|NCT03169075|Behavioral|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
79401811|NCT03153462|Biological|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
79571725|NCT01804855|Behavioral|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
79571726|NCT01804855|Device|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
79571727|NCT01804868|Other|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
79571728|NCT01804868|Other|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
79866265|NCT05889598|Other|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
79866266|NCT05889455|Drug|Sildenafil|Oral administration of 100mg
79866267|NCT05889455|Other|Placebo|Placebo
79866268|NCT05889442|Drug|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
79866269|NCT05889442|Other|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
79571729|NCT01804907|Behavioral|Cognitive Behavioral Therapy|
79571730|NCT01804907|Behavioral|Behavioral Modification|
79731730|NCT01909089|Drug|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
79731731|NCT02844790|Drug|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
79731732|NCT05337358|Procedure|endocrown|endocrown
80026202|NCT03484832|Drug|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
79866270|NCT05889429|Diagnostic Test|MRI scans|The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.
80026203|NCT04985110|Drug|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
80026204|NCT04985110|Drug|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
80026205|NCT02164812|Drug|Moxifloxacin|
80026206|NCT02164812|Drug|Placebo|
80026207|NCT02164812|Drug|Efavirenz|
80026208|NCT04988776|Other|ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
79269522|NCT04597710|Genetic|utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
79571731|NCT01804920|Dietary Supplement|D-serine|
79571732|NCT01804920|Dietary Supplement|Placebo|
79401812|NCT03145077|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
79571733|NCT01804933|Drug|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
79866271|NCT05889429|Behavioral|clinical assessments|Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
79571734|NCT01804959|Dietary Supplement|Vivomixx probiotics|
79571735|NCT01804972|Other|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
79571736|NCT01804972|Other|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
79571737|NCT01804985|Drug|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
79571738|NCT01804985|Drug|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
79571739|NCT01804985|Drug|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
79571740|NCT01805011|Other|minimum 4 months of breastfeeding|
79571741|NCT01805050|Procedure|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
80026209|NCT04988776|Other|ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block|Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
80026210|NCT02853123|Drug|Tiotropium|fixed dose combination once daily
80026211|NCT02853123|Drug|Olodaterol|fixed dose combination once daily
80026212|NCT02853123|Drug|Tiotropium|
79571742|NCT01805063|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
79731733|NCT02845102|Other|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
80026213|NCT02255370|Drug|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
80026214|NCT04985188|Diagnostic Test|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
80026215|NCT04459832|Procedure|stretch hamstring|Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
80026216|NCT02161848|Other|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
80026217|NCT04984252|Behavioral|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
80026218|NCT04984252|Behavioral|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
79401813|NCT03145077|Other|Questionnaire Administration|Ancillary studies
79731734|NCT01214642|Drug|pegfilgrastim|Administered subcutaneously
79731735|NCT01214642|Drug|LY2523355|Administered intravenously
79731736|NCT02856633|Device|Vitaliti|
79731737|NCT05241652|Other|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
80026219|NCT04984252|Behavioral|Distraction group|Participants will be asked to listen recording on irrelevant topic.
79571743|NCT01805063|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
79731738|NCT05241652|Other|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
79731739|NCT02856243|Drug|new antiviral therapy|
79269523|NCT04577456|Device|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
79269524|NCT04549896|Procedure|CT scan|Surgeon will perform a CT scan before the surgery procedure (CTO PCI) in order to increase the success rate of the surgery.
79269525|NCT04549896|Procedure|No CT scan|The surgery procedure (CTO PCI) will be performed following the standard of care, meaning that the surgeon will not perform a CT scan before the surgery procedure.
79731740|NCT02690740|Other|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
79731741|NCT02852499|Other|Urine sampling|
79731742|NCT02852499|Other|Carry a GPS and BET|
79731743|NCT02852499|Other|Carry pollution sensor|
79731744|NCT02852499|Other|Sampling at the maternity|
79731745|NCT02852499|Other|Self-questionnaires|
79571744|NCT01805115|Drug|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
79571745|NCT01805115|Drug|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
79731746|NCT02852499|Other|Sampling in partum period|Meconium and a strand of hair.
79731747|NCT04410328|Drug|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
79731748|NCT04410328|Other|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
79731749|NCT01214252|Device|Permacol Surgical Implant|Permacol Surgical Implant
79731750|NCT02852577|Drug|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
79731751|NCT02852577|Drug|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
79731752|NCT05234476|Behavioral|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
79731753|NCT05234476|Behavioral|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
80026220|NCT03481166|Other|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
79269526|NCT04547959|Device|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
79269527|NCT04545736|Drug|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants >=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants >= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
79731754|NCT01214174|Drug|IBI-10090|
79731755|NCT04201990|Drug|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
79731756|NCT00901342|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
79731757|NCT00632866|Drug|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
79731758|NCT00632866|Drug|Placebo|Placebo : 2cp/ day since 24 weeks
79269528|NCT04534725|Drug|Interferon alfa|intranasal spray
79269529|NCT04534725|Drug|Selinexor|oral tablet
79269530|NCT04534725|Drug|Lenzilumab|intravenous infusion
79269531|NCT04497805|Biological|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
79571746|NCT01805115|Drug|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
79571747|NCT01805115|Drug|Control|The control group was not given any cervical priming agents or placebo.
79731759|NCT00901186|Drug|RFB002|0.5 mg
79731760|NCT00901186|Procedure|Laser photocoagulation|
79731761|NCT01213472|Biological|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
79731762|NCT05040880|Drug|Telmione plus 80/12.5mg|Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
79731763|NCT05040880|Drug|Micardis plus 80/12.5mg|Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
79731764|NCT00900796|Other|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
79731765|NCT01213082|Drug|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
79731766|NCT01213082|Drug|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
80026221|NCT02161926|Other|dietary restrictions|Dietary restrictions during 8 weeks
80026222|NCT03073642|Other|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
80026223|NCT03073642|Other|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
80026224|NCT03487094|Other|Infant formula|Multi-centered, prospective, randomized clinical trial
80026225|NCT03604029|Device|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
80026226|NCT02168322|Device|collagen membrane|bovine collagen membrane used for selective tissue regeneration
79571748|NCT01805128|Other|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
79571749|NCT01805128|Other|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
80026227|NCT02168322|Device|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
80026228|NCT04984408|Biological|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration: Intramuscular~Storage Conditions: 2 to 8 degree Celsius"
80026229|NCT04984408|Biological|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~Mode of Administration: Intramuscular~Storage Conditions: 2 to 8 degree Celsius"
80026230|NCT03602001|Behavioral|Attentive eating smartphone application.|A smartphone application that encourages a more attentive eating style.
80026231|NCT03602001|Behavioral|Standard dietary advice and text tips.|Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
80026232|NCT02168556|Behavioral|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
80026233|NCT02168556|Behavioral|Video|Subject watches an informational video prior to undergoing urodynamic testing.
80026234|NCT02168556|Other|Standard of care|Standard of care
80026235|NCT03073564|Diagnostic Test|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
80026236|NCT03073564|Diagnostic Test|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
80026237|NCT03484754|Biological|botulinum toxin|injection of botulinum toxina in two different facial sites
79571750|NCT01805128|Other|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
79571751|NCT01805167|Other|Electrophysiological study of the interindividual variability of vocal performance|
79731767|NCT01213082|Drug|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
79731768|NCT04073290|Drug|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
79571752|NCT01805193|Other|Computed tomography myocardial perfusion imaging|
79571753|NCT01805193|Other|Oxygen 15 labelled water positron emission tomography|
79571754|NCT01805206|Other|Assessment of urinary iFABP|
79571755|NCT01805206|Other|Administration of enteral feedings|
79571756|NCT01805219|Other|GPS and accelerometer recording (s) during exercises|
79571757|NCT01805232|Drug|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
79571758|NCT01805232|Drug|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
79731769|NCT04073290|Drug|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
80026238|NCT03601845|Other|Stimuli|Visual stimulation while using additional sequencing
80026239|NCT03601845|Other|No stimuli|Additional sequencing only
80026240|NCT02162004|Procedure|Continuous Correction|
80026241|NCT04459676|Drug|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
80026242|NCT04459676|Drug|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
80026243|NCT03540966|Combination Product|CapulinTM|a kind of camouflage agent
80026244|NCT03540966|Other|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
80026245|NCT04984564|Other|None. As this was an observational study.|Observational study.
80026246|NCT02162082|Device|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
80026247|NCT04984642|Other|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
80026248|NCT02164890|Other|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
80026249|NCT03484676|Device|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
80026250|NCT03603561|Device|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
80026251|NCT03603561|Device|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
80026252|NCT01045226|Procedure|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
80026253|NCT01045226|Other|Quality-of-Life assessment|Quality of Life Assessment
80026254|NCT01045226|Other|Questionnaire Administration|Questionnaire Administration
80026255|NCT02634346|Drug|ALK3831|Daily dosing
79571759|NCT01805245|Behavioral|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
79866272|NCT05889390|Device|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
80026256|NCT02634346|Drug|Olanzapine|Daily dosing
80026257|NCT02634346|Drug|Placebo|Daily dosing
80026258|NCT03601689|Procedure|rectal resection|total mesorectal excision
80026259|NCT00936728|Other|therapeutic nutritional supplementation|Given orally
80026260|NCT00936728|Dietary Supplement|white wine|Given orally
79269532|NCT04463498|Behavioral|Group-based cognitive behavioral therapy for insomnia|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
79269533|NCT04463498|Behavioral|Group-based cognitive behavioral therapy for insomnia and additive bb-glasses|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
79269534|NCT04463498|Other|8-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
79571760|NCT01805258|Drug|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
79571761|NCT01805258|Drug|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
79731770|NCT04073290|Drug|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
79731771|NCT05017558|Diagnostic Test|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~Low risk (maternal VL <1000 cp/ml): NVP for 6 weeks.~virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
79866273|NCT05889390|Drug|Paclitaxel|weekly paclitaxel for 12 weeks
79866274|NCT05889390|Drug|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
79866275|NCT05889390|Drug|Cyclophosphamide/Doxorubicin|according to the AC protocol
79866276|NCT05889390|Procedure|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
79866277|NCT05889377|Procedure|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
80026261|NCT00936728|Other|questionnaire administration|Ancillary studies
80026262|NCT02168634|Drug|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
80026263|NCT02168634|Drug|Placebo|1cc normal saline, local injection
80026264|NCT02237781|Drug|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
80026265|NCT04459208|Device|Manta|plug-based vascular closure
80026266|NCT04459208|Device|ProGlide|suture-based vascular closure
79269535|NCT04443751|Drug|SHR-1702|SHR-1702 monotherapy, administered IV
79401814|NCT03138733|Drug|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
80026267|NCT02168712|Other|Moderate continuous exercise training|
80026268|NCT02168712|Other|Interval exercise training|
80026269|NCT00849147|Biological|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
80026270|NCT00849147|Biological|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~Cy: 50 mg/kg IV on Days 3 and 4~Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm^3 for 3 consecutive days"
80026271|NCT00812240|Drug|Masitinib|
80026272|NCT00812240|Drug|Imatinib|imatinib 400 mg or 600 mg per day, per os
79269536|NCT04385433|Drug|EXPERIMENTAL ARM|"Patients in the experimental arm will receive:~Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
79401815|NCT03138733|Drug|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
79571762|NCT01805310|Other|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
79571763|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
79866278|NCT05889364|Diagnostic Test|"AI-based x-ray analysis and triage (normal/tuberculosis suspected)"|All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
79866279|NCT05889351|Drug|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
79866280|NCT05889351|Drug|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
79866281|NCT05889351|Drug|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
79866282|NCT05889338|Drug|adalimumab and methotrexate|Adult patients (> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
79866283|NCT05889325|Procedure|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
79866284|NCT05889312|Diagnostic Test|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
79866285|NCT05889312|Diagnostic Test|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
79866286|NCT05889299|Drug|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
79571764|NCT01805336|Other|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
79866287|NCT05733156|Radiation|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
79269537|NCT04385433|Other|CONTROL GROUP|"Patients in the standard arm will receive:~Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
79571765|NCT01805336|Other|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
79731772|NCT00632788|Other|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
79731773|NCT04975828|Diagnostic Test|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
79731774|NCT03936790|Other|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
79866288|NCT05889247|Other|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
79866289|NCT05889208|Device|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
79866290|NCT05889169|Other|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
80026273|NCT02165046|Drug|Budesonide|
79401816|NCT03121001|Drug|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
79571766|NCT01805336|Other|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
79731775|NCT03936790|Other|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
79866291|NCT05889143|Drug|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
79866292|NCT05889130|Other|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
79866293|NCT05889091|Other|HRQOL instruments|These instruments include Face Q for Appearance, Eating & drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
79866294|NCT05889091|Other|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
79866295|NCT05889078|Behavioral|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
80026274|NCT02165046|Drug|Procaterol|
80026275|NCT03070678|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
80026276|NCT03070678|Drug|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
79401817|NCT03121001|Drug|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
79401818|NCT03121001|Drug|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
79401819|NCT03121001|Radiation|Total body irradiation|3 Gy on day -1
79731776|NCT04782700|Other|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
79269538|NCT04385433|Radiation|Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)|Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
79269539|NCT04362111|Drug|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
79269540|NCT04362111|Drug|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
79269541|NCT04318132|Device|Nidek Mirante|The Nidek Mirante Optical Coherence Tomography (OCT) including scanning laser ophthalmoscope (SLO) function is an non-contact system for imaging the fundus and for axial cross sectional imaging of anterior and posterior ocular structures.
79269542|NCT04318132|Device|Optovue RTVue XR Avanti|The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
79277577|NCT02363673|Other|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
79731777|NCT04745884|Device|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
79866296|NCT05889065|Procedure|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
79401820|NCT03121001|Procedure|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
79401821|NCT03121001|Drug|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
79401822|NCT03121001|Drug|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
79401823|NCT03077685|Drug|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
79401824|NCT03057054|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
79401825|NCT03057054|Biological|Lactobacillus plantarum strain 299|Given PO or via NJ, NG or G tube
79401826|NCT03057054|Biological|Lactobacillus plantarum strain 299v|Given PO or via NJ, NG or G tube
79401827|NCT03057054|Other|Placebo Administration|Given PO or via NJ, NG or G tube
79401828|NCT03037528|Behavioral|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
79401829|NCT03037528|Behavioral|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
80026277|NCT00101166|Biological|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
79401830|NCT03037528|Behavioral|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
79401831|NCT03037528|Behavioral|dietary tracking|Participants will be asked to track their diet consistently.
79401832|NCT03035292|Diagnostic Test|Red-reflex assessment|The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner
79401833|NCT03035292|Diagnostic Test|Infrared-reflex assessment|The infrared reflex was examined using a modified smart phone camera by a medical student examiner
79731778|NCT05336734|Behavioral|Psychotherapy|see group description
79731779|NCT00885703|Drug|Fluconazole|"Step 1: [For participants randomized to Fluconazole] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: [For participants randomized to Ampho B only] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
79866297|NCT05889065|Procedure|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
79866298|NCT05889026|Device|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
79401834|NCT03026062|Biological|Durvalumab|Given IV
79401835|NCT03026062|Biological|Tremelimumab|Given IV
79401836|NCT03020030|Drug|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
79401837|NCT03020030|Drug|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
79269543|NCT04318132|Device|Optos P200DTx|The P200DTx scanning laser ophthalmoscope (SLO) is indicated for use as a widefield and retinal fluorescence and autofluorescence imaging ophthalmoscope to aid in the diagnosis and monitoring of diseases and disorders that manifest in the retina.
79401838|NCT03020030|Drug|Cyclophosphamide|Standard of Care
79401839|NCT03020030|Drug|CYTARABINE|Standard of Care
79401840|NCT03020030|Drug|DASATINIB|Standard of Care
79571767|NCT01805336|Other|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
79866299|NCT05889026|Procedure|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
80026278|NCT04994236|Drug|Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)|The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
80026279|NCT03601611|Drug|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
80026280|NCT03597945|Procedure|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
80026281|NCT03597945|Procedure|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
79571768|NCT01805336|Other|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
79571769|NCT01805362|Other|Randomization that determine the time of treatment|
79731780|NCT00885703|Drug|Amphotericin B|Step 1: [For participants randomized to Ampho B] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
79731781|NCT04210258|Device|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
79731782|NCT04210258|Device|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
79731783|NCT04554784|Other|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
79866300|NCT05889000|Other|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
79866301|NCT05888818|Other|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
79866302|NCT05888766|Drug|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
80026282|NCT03597945|Procedure|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
80026283|NCT02162160|Device|probiotic creme|Probiotic creme applied
79269544|NCT04293094|Drug|AMG 650|AMG 650 administered orally as a tablet.
79269545|NCT04284761|Combination Product|Bicalutamide implant|Biolen bicalutamide implant
79269546|NCT04275024|Drug|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
79269547|NCT04275024|Drug|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
79401841|NCT03020030|Drug|DEXAMETHASONE|Standard of Care
79401842|NCT03020030|Drug|Dexrazoxane|Standard of Care
79401843|NCT03020030|Drug|Doxorubicin|Standard of Care
79866303|NCT05888740|Device|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
80026284|NCT02162160|Drug|Placebo|Creme without probiotics applied in same manner
80026285|NCT03486782|Device|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
80026286|NCT03486782|Device|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
80026287|NCT03486782|Behavioral|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
80026288|NCT04993846|Diagnostic Test|Dental plaque sampling|Dental plaque sampling
80026289|NCT04993846|Diagnostic Test|qPCR|qPCR
79269548|NCT04275024|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
79269549|NCT04271254|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
79277578|NCT03527329|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
79277579|NCT02367261|Device|SPI implant|SPI implant - the original spiral implant
79401844|NCT03020030|Drug|ETOPOSIDE|Standard of Care
79401845|NCT03020030|Drug|HYDROCORTISONE|Standard of Care
79401846|NCT03020030|Drug|LEUCOVORIN CALCIUM|Standard of Care
79401847|NCT03020030|Drug|MERCAPTOPURINE|Standard of Care
79401848|NCT03020030|Drug|METHOTREXATE|Standard of Care
79401849|NCT03020030|Drug|NELARABINE|Standard of Care
79401850|NCT03020030|Drug|Vincristine|Standard of Care
79401851|NCT03008278|Drug|Olaparib|Give PO
79401852|NCT03008278|Biological|Ramucirumab|Given IV
79571770|NCT01805375|Drug|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
79866304|NCT05888714|Device|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
79866305|NCT05888714|Device|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
80026290|NCT03603483|Procedure|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
80026291|NCT04459910|Procedure|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
80026292|NCT04984018|Drug|chidamide + camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
79401853|NCT02989636|Other|Laboratory Biomarker Analysis|Correlative studies
80026293|NCT02162238|Device|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
80026294|NCT03601533|Drug|Phenol|1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
79571771|NCT01805388|Drug|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
79571772|NCT01805388|Procedure|Control Non-Study Drug Group|Endodontic RTC with no study drug
79571773|NCT01805401|Device|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
79571774|NCT01807507|Device|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
79571775|NCT01807533|Behavioral|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
79866306|NCT05888714|Other|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
79866307|NCT05888649|Behavioral|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
79269550|NCT04259255|Drug|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
79277580|NCT03528733|Device|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
79866308|NCT05888636|Other|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
79866309|NCT05888623|Device|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
79866310|NCT05888584|Other|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
79401854|NCT02989636|Biological|Nivolumab|Given IV
79401855|NCT02989636|Radiation|Stereotactic Radiosurgery|Undergo SRS
79401856|NCT02955290|Other|Laboratory Biomarker Analysis|Correlative studies
79866311|NCT05888558|Device|Body fluid diagnosis|miRNAs derived from exosomes in the serum
79571776|NCT01807533|Behavioral|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
79571777|NCT01807559|Device|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
79571778|NCT01807663|Device|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
79571779|NCT01807663|Device|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
79571780|NCT01807676|Device|ET View Double Lumen Tube|
79571781|NCT01807676|Device|conventional Double Lumen Tube|
79571782|NCT01807702|Drug|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
79571783|NCT01807741|Drug|Asenapine|Available in 5 and 10 mg.
79866312|NCT05888467|Other|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
79571784|NCT01807741|Drug|Placebo|
79866313|NCT05888467|Other|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
80026295|NCT03484598|Device|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
80026296|NCT04983784|Behavioral|walking|walking for 12 weeks at home
80026297|NCT04983784|Other|Routine care|Routine care
80026298|NCT02165280|Behavioral|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
80026299|NCT03486626|Drug|Metformin|Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
80026300|NCT04983550|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
80026301|NCT04983550|Drug|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection 40mg/m ^2 q4w
80026302|NCT02255682|Drug|Simvastatin|
80026303|NCT02255682|Dietary Supplement|Q10|
79571785|NCT01807754|Procedure|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
79866314|NCT05888467|Other|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
80026304|NCT05153486|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
80026305|NCT05153486|Procedure|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
80026306|NCT05153486|Procedure|Surgical ablation|Patients receive surgical ablation.
80026307|NCT03597711|Device|IVcannulation|Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
79571786|NCT01807754|Procedure|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
79866315|NCT05888376|Device|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
80026308|NCT04607096|Behavioral|Intermittent fasting|The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.
80026309|NCT04607096|Behavioral|Control diet|Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
80026310|NCT02261142|Device|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
80026311|NCT03136263|Drug|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
79731784|NCT04554784|Procedure|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
79401857|NCT02955290|Biological|Nivolumab|Given IV
79866316|NCT05888363|Other|No Intervention|Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
79401858|NCT02955290|Biological|Pembrolizumab|Given IV
79866317|NCT05888298|Procedure|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
79866318|NCT05888285|Procedure|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
79401859|NCT02955290|Biological|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
79571787|NCT01807767|Drug|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
79866319|NCT05888285|Procedure|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
79571788|NCT01807767|Drug|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
79866320|NCT05888272|Behavioral|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
79866321|NCT05888259|Other|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
79866322|NCT05888220|Other|warm salt water bath|Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
79571789|NCT01807780|Biological|biological monitoring|
79571790|NCT01807793|Behavioral|Psychoeducation|
79731785|NCT04549480|Drug|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
79731786|NCT04549480|Drug|Bosutinib tablet|100 mg dose of bosutinib tablet
79866323|NCT05888194|Device|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
80026312|NCT03136263|Drug|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
80026313|NCT04988542|Dietary Supplement|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
80026314|NCT03540186|Dietary Supplement|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
80026315|NCT03540186|Procedure|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
80026316|NCT02035449|Device|McGrath MAC|McGrath MAC is a videolaryngoscope
79269551|NCT04226326|Other|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
79269552|NCT04216732|Other|Blood Pressure Measurement|Undergo blood pressure measurement
79269553|NCT04216732|Other|Questionnaire Administration|Complete questionnaires
79269554|NCT04146935|Drug|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
79401860|NCT02924311|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
79401861|NCT02921893|Drug|Dexamethasone|Given PO
79401862|NCT02921893|Drug|Ixazomib Citrate|Given PO
79401863|NCT02921893|Drug|Lenalidomide|Given PO
79571791|NCT01807806|Behavioral|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
79571792|NCT01807832|Other|capsaicin challenge|
79571793|NCT01807845|Dietary Supplement|enriched skimmilk with VD|enriched skimmilk with VD
79571794|NCT01807845|Dietary Supplement|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
79269555|NCT04018677|Behavioral|Use of TOGETHERCare app|TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.
79269556|NCT04011345|Dietary Supplement|Folic Acid Supplement|1 milligram folic acid
79269557|NCT04011345|Dietary Supplement|Placebo|Placebo
79401864|NCT02921893|Other|Questionnaire Administration|Ancillary studies
79401865|NCT02908906|Drug|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
79401866|NCT02905240|Device|nSTRIDE APS|single intra-articular injection
80026317|NCT04988854|Behavioral|Facial expression video|Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
79571795|NCT01807845|Dietary Supplement|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
79571796|NCT01807858|Dietary Supplement|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
79571797|NCT01807858|Dietary Supplement|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
79571798|NCT01807858|Other|Maltodextrin|Maltodextrin
79571799|NCT01807858|Dietary Supplement|İnulin|900 mg inulin per day will be given
79731787|NCT05336578|Other|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
80026318|NCT03601377|Behavioral|Training away from threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
79269558|NCT04007848|Drug|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
79269559|NCT04007848|Drug|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
79269560|NCT03996109|Behavioral|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 6 months. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
79401867|NCT02905240|Device|Saline|single intra-articular injection
79401868|NCT02901275|Drug|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
79401869|NCT02893917|Drug|Cediranib|Given PO
79401870|NCT02893917|Drug|Olaparib|Given PO
79401871|NCT02890329|Drug|Decitabine|Given IV
79401872|NCT02890329|Biological|Ipilimumab|Given IV
79401873|NCT02854527|Drug|Digoxin|single dose
79571800|NCT01807884|Procedure|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
79401874|NCT02854527|Drug|Furosemide|single dose
79401875|NCT02854527|Drug|Metformin|single dose
79401876|NCT02854527|Drug|Rosuvastatin|single dose
79401877|NCT02854527|Drug|Digoxin|0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
79401878|NCT02854527|Drug|Furosemide|1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
79401879|NCT02854527|Drug|Metformin hydrochloride|10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
79401880|NCT02854527|Drug|Rosuvastatin|10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
79401881|NCT02839707|Drug|Atezolizumab|Given IV
79401882|NCT02839707|Biological|Bevacizumab|Given IV
79401883|NCT02839707|Procedure|Computed Tomography|Undergo CT
79401884|NCT02839707|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
79401885|NCT02839707|Other|Quality-of-Life Assessment|Ancillary studies
79571801|NCT01807884|Other|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
79571802|NCT01807910|Drug|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
79269561|NCT03996109|Behavioral|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 6 months. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
79866324|NCT05888181|Other|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
79866325|NCT05888168|Procedure|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
79571803|NCT01807962|Drug|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
80026319|NCT03601377|Behavioral|Training towards threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
80026320|NCT03601377|Behavioral|Placebo|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
80026321|NCT03481088|Procedure|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~Stage- I (pre-treatment),~Stage- II (after pre-functional therapy)~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
80026322|NCT04983706|Procedure|MRI/Ultrasound Fusion Saturation Biopsy|MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
80026323|NCT02165436|Other|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
80026324|NCT02165436|Other|Control|No intervention will be assessed for this group.
80026325|NCT03486548|Drug|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
80026326|NCT03486548|Drug|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
80026327|NCT03486548|Device|Ultrasound|ultrasound
79269562|NCT03993353|Drug|Pembrolizumab|200 mg intravenously every 3 weeks
79269563|NCT03993353|Drug|Tadalafil|10 mg by mouth daily
79269564|NCT03970837|Biological|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
79269565|NCT03970837|Drug|Tofacitinib|Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
79269566|NCT03970837|Drug|Placebo|Placebo matching GSK3196165 and Tofacitinib was administered.
79401886|NCT02830477|Biological|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
79401887|NCT02828592|Drug|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
79401888|NCT02828592|Drug|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 & -5)
79571804|NCT01807962|Drug|sterile saline|Placebo = 5ml of sterile saline solution
79401889|NCT02828592|Radiation|Total Body Irradiation|300 cGy x1 dose (Day -1)
79401890|NCT02828592|Drug|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
79401891|NCT02828592|Drug|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
79401892|NCT02811432|Other|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
79571805|NCT01807975|Other|Forced oscillation|
79571806|NCT01807988|Behavioral|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
79401893|NCT02811432|Other|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
79401894|NCT02800486|Drug|Intra-arterial Cetuximab|
79401895|NCT02800486|Drug|Intra-arterial Mannitol|
79866326|NCT05888142|Behavioral|in clinic pain VR reduction exercises|"During the first two weeks of treatment, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality."
79401896|NCT02800486|Radiation|Hypofractionated re-irradiation|
79866327|NCT05888142|Behavioral|In clinic VRpain reduction exercises + VR homeworks|"During the first two weeks of treatment, participants will use commercially available VR during in clinic physical therapy exercises, and during homeworks to help reduce their pain and improve functionality."
79866328|NCT05888129|Procedure|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
79866329|NCT05888077|Other|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
79866330|NCT05888038|Device|virtual reality|virtual reality
79866331|NCT05888025|Behavioral|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
80026328|NCT03068338|Device|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
79866332|NCT05888012|Device|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
80026329|NCT03068338|Device|Intermittent pneumatic compression|Conventional device used by hospitals
80026330|NCT02255448|Device|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
80026331|NCT02870816|Procedure|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
80026332|NCT02870816|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
80026333|NCT02870816|Procedure|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
80026334|NCT03540108|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
80026335|NCT03540108|Dietary Supplement|Placebo Comparator: Maltodextrin|Please see intervention description above.
80026336|NCT04988230|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
80026337|NCT04988230|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
80026338|NCT02168790|Device|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
80026339|NCT04983160|Drug|Allopurinol|Allopurinol
80026340|NCT04983160|Drug|Placebo|Placebo
80026341|NCT02255526|Device|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
80026342|NCT04455412|Procedure|Laser Assisted ICSI|using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
80026343|NCT03070288|Other|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
80026344|NCT05635942|Drug|optimized quadruple therapy|Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
80026345|NCT05635942|Drug|standard quadruple therapy|Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
80026346|NCT04987684|Diagnostic Test|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
80026347|NCT02759016|Drug|BI 836826|
80026348|NCT02759016|Drug|Ibrutinib|Standard of Care
80026349|NCT02169024|Behavioral|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
80026350|NCT02169024|Other|Standard individual prenatal care|Standard of care- individual prenatal care
80026351|NCT02169102|Other|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
80026352|NCT02169102|Radiation|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
79401897|NCT02779725|Behavioral|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
79866333|NCT05888012|Device|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
80026353|NCT02169102|Radiation|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
80026354|NCT02169102|Radiation|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
80026355|NCT02852967|Drug|Belumosudil|
80026356|NCT02852967|Drug|Placebo|Placebo tablets matching belumosudil
80026357|NCT02162316|Drug|Motilitone®|
80026358|NCT02162316|Drug|A-Cilin®, Clari® and Pantoline®|
80026359|NCT05635864|Procedure|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
80026360|NCT02162394|Device|Observational ambulatory ECG monitoring|
80026361|NCT02169180|Drug|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
80026362|NCT03593044|Drug|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
80026363|NCT03597087|Procedure|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
80026364|NCT03597087|Drug|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
79269567|NCT03945357|Drug|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
79401898|NCT02779725|Behavioral|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
79571807|NCT01808014|Drug|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
79866334|NCT05887973|Behavioral|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~Summer Employment~Social and Emotional Learning~Future Orientation~Adult and Peer Support~Critical Consciousness~Civic Efficacy and Engagement"
79866335|NCT05887960|Other|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
79866336|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 1.8%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
79401899|NCT02779725|Behavioral|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
79571808|NCT01808040|Drug|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
79866337|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 5%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
79866338|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 1.8%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
79866339|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 5%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
80026365|NCT02169258|Procedure|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
80026366|NCT03603327|Drug|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
79269568|NCT03945357|Drug|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
79731788|NCT02642419|Drug|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
79731789|NCT02642419|Drug|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
79731790|NCT00901576|Drug|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
79731791|NCT00901576|Drug|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
79866340|NCT05887921|Procedure|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
79866341|NCT05887908|Drug|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
80026367|NCT05635630|Other|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
80026368|NCT05635630|Other|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
80026369|NCT03596775|Drug|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
80026370|NCT03596775|Drug|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
80026371|NCT03601299|Other|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
80026372|NCT03066466|Drug|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
80026373|NCT03066466|Drug|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
80026374|NCT03066466|Drug|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
80026375|NCT03601221|Other|Sample collection|Collection of one sampling pouch from each blood donor
80026376|NCT03603249|Drug|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in >80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
80026377|NCT03603171|Diagnostic Test|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
80026378|NCT03603171|Diagnostic Test|R-PAct|A Rasch-built Pompe-specific activity scale.
80026379|NCT03603171|Diagnostic Test|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
80026380|NCT03603171|Diagnostic Test|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
80026381|NCT03603171|Diagnostic Test|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
80026382|NCT03603171|Diagnostic Test|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
79401900|NCT02779725|Behavioral|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
79731792|NCT00901576|Drug|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
79731793|NCT00655837|Drug|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
79731794|NCT00655837|Drug|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
79866342|NCT05887908|Drug|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
79866343|NCT05887908|Drug|imipenem/cilastatin|1 g imipenem/1 g cilastatin
79866344|NCT05887869|Behavioral|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
80026383|NCT03603171|Diagnostic Test|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
80026384|NCT03603171|Diagnostic Test|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
80026385|NCT03603171|Diagnostic Test|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
79731795|NCT00655837|Drug|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
79731796|NCT02634931|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
79731797|NCT05336422|Other|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
79866345|NCT05887778|Drug|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
79866346|NCT05887778|Drug|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
79269569|NCT03938636|Drug|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
80026386|NCT03603171|Diagnostic Test|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
80026387|NCT03603171|Diagnostic Test|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference > 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
80026388|NCT03603171|Diagnostic Test|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
79401901|NCT02779725|Behavioral|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
79571809|NCT01808053|Device|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
79571810|NCT01808079|Other|Laboratory Biomarker Analysis|Correlative studies
79571811|NCT01808105|Other|Control Formula|Feeding ad libitum
79731798|NCT00655915|Other|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
79731799|NCT02637271|Other|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
79866347|NCT05887778|Drug|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
79866348|NCT05887674|Behavioral|Diet intervention|Low inflammatory-index diet
79866349|NCT05887674|Behavioral|Exercise|Guided muscle strength training and stretching exercises
80026389|NCT03603171|Diagnostic Test|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
79866350|NCT05887674|Behavioral|Cognitive training|Cognitive training will be implemented in person
80026390|NCT03603171|Diagnostic Test|Quick motor function test|Assessment of proximal motor function.
79866351|NCT05887661|Procedure|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
80026391|NCT03603171|Diagnostic Test|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
80026392|NCT03603171|Diagnostic Test|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
80026393|NCT03603171|Diagnostic Test|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
80026394|NCT03603171|Diagnostic Test|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
79269570|NCT03928509|Other|No intervention|No intervention
79269571|NCT03927885|Other|Placebo Administration|Given open labeled placebo PO
79401902|NCT02772081|Combination Product|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief insertion of a thin catheter into the trachea
79269572|NCT03927885|Other|Quality-of-Life Assessment|Ancillary studies
79269573|NCT03927885|Other|Questionnaire Administration|Ancillary studies
79269574|NCT03927885|Other|Waiting List|Assigned to a waiting list
79304427|NCT03288233|Diagnostic Test|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
79401903|NCT02772081|Drug|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
79571812|NCT01808105|Other|Experimental Formula 1|Feeding ad libitum
79571813|NCT01808105|Other|Experimental Formula 2|Feeding ad libitum
79571814|NCT01808105|Other|Human Milk|Feeding ad libitum
79571815|NCT01808131|Drug|Lesinurad|Tablets, 200 mg QD
79571816|NCT01808131|Drug|Lesinurad|Tablets, 400 mg QD
79571817|NCT01808157|Drug|CT327 ointment|
79571818|NCT01808157|Drug|placebo|
80026395|NCT03603171|Diagnostic Test|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
80026396|NCT03068260|Drug|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
80026397|NCT03068260|Drug|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
80026398|NCT03068260|Drug|Acetaminophen|1 g orally administered postoperatively
80026399|NCT03068260|Drug|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
79269575|NCT03900962|Other|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
79269576|NCT03900962|Other|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
79269577|NCT03896009|Drug|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
79269578|NCT03896009|Drug|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
79571819|NCT01808170|Procedure|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
79571820|NCT01808170|Procedure|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
79731800|NCT02637271|Other|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
79731801|NCT02637349|Behavioral|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
79731802|NCT02637349|Behavioral|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
79731803|NCT04162093|Procedure|uretero ileal anastomosis in single trough|
79866352|NCT05887648|Behavioral|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
79866353|NCT05887622|Dietary Supplement|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
79866354|NCT05887622|Dietary Supplement|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
80026400|NCT03068260|Device|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
80026401|NCT03068260|Drug|Morphine|intravenously administered morphine via PCA-pump
80026402|NCT03068260|Device|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
80026403|NCT02762994|Drug|BCD-085|
80026404|NCT02762994|Other|Placebo|
80026405|NCT05635552|Diagnostic Test|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
79269579|NCT03896009|Drug|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
79269580|NCT03896009|Drug|Placebo|Placebo taken once upon onset of a qualifying migraine.
80026406|NCT05635552|Diagnostic Test|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
79731804|NCT02637193|Drug|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
79731805|NCT02637193|Drug|Moxifloxacin|400 mg single dose moxifloxacin
80026407|NCT05635552|Diagnostic Test|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
80026408|NCT05635552|Diagnostic Test|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
80026409|NCT05635552|Diagnostic Test|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
80026410|NCT03603015|Diagnostic Test|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
80026411|NCT03070834|Device|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
79731806|NCT02637193|Drug|Drug - placebo|Placebo administered for 16 days
79731807|NCT04163575|Biological|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
79866355|NCT05887050|Dietary Supplement|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
79866356|NCT05887050|Dietary Supplement|Placebo|Maltodextrin tablet
79866357|NCT05886283|Procedure|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
79866358|NCT05886283|Procedure|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
79866359|NCT05886283|Procedure|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
80026412|NCT02165514|Procedure|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
80026413|NCT03601065|Other|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
80026414|NCT02166060|Drug|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
80026415|NCT03305614|Procedure|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
80026416|NCT03305614|Procedure|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
80026417|NCT03600987|Behavioral|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
80026418|NCT03600987|Behavioral|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
80026419|NCT03600987|Behavioral|Control|control condition using reading materials without music.
80026420|NCT05635474|Dietary Supplement|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
79269581|NCT03886285|Other|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
79304428|NCT03117829|Behavioral|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
79866360|NCT05885789|Procedure|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
79866361|NCT05885581|Other|Arm A Grow Well|"the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~the feasibility of collecting infant anthropometric data."
80026421|NCT05635474|Dietary Supplement|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
79866362|NCT05885581|Other|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
79866363|NCT05884515|Diagnostic Test|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
79731808|NCT00656773|Drug|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
79731809|NCT00656773|Drug|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
79731810|NCT04017559|Behavioral|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
79731811|NCT04165525|Device|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
79731812|NCT04163263|Drug|BOS-356|topical gel
79731813|NCT04163263|Drug|Vehicle|topical gel
80026422|NCT02237859|Drug|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
80026423|NCT02237859|Dietary Supplement|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
79731814|NCT02634697|Behavioral|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
79731815|NCT00882583|Drug|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
79866364|NCT05883774|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
79571821|NCT01808235|Behavioral|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
79571822|NCT01808261|Drug|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
79866365|NCT05883774|Device|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
79866366|NCT05883072|Behavioral|Exploring AI-Chatbot|All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
79866367|NCT05883007|Radiation|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
79269582|NCT03875781|Drug|Chemotherapy|"Arm A : Experimental~Intervention Type : Drug~Intervention Name : Modified FOLFIRINOX (experimental arm)~Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
79304429|NCT03288155|Dietary Supplement|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
79571823|NCT01808261|Drug|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
79571824|NCT01808274|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
79401904|NCT02742623|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
79401905|NCT02713022|Device|DEXA Scan|
79571825|NCT01808287|Device|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
79571826|NCT01808300|Drug|Pregabalin 300mg, Thioctic acid 600mg|"A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
79731816|NCT00882583|Drug|Dasatinib|Oral Dasatinib Days 8 through 64.
79731817|NCT00882583|Drug|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
79866368|NCT05882617|Other|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
79401906|NCT02713022|Behavioral|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
79731818|NCT00882583|Radiation|Radiation Therapy|Standard Radiation Therapy.
79731819|NCT00656149|Procedure|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
79731820|NCT00656149|Procedure|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
79731821|NCT00900562|Drug|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
79731822|NCT02634775|Other|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
79731823|NCT02636959|Other|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
79401907|NCT02705859|Drug|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
79571827|NCT01808352|Drug|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
79269583|NCT03875781|Drug|Radiochemotherapy|"Arm B: Active comparator~Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."
79866369|NCT05882188|Procedure|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
79269584|NCT03859492|Device|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
79401908|NCT02705859|Drug|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
79571828|NCT01808365|Procedure|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
79571829|NCT01808365|Other|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
79571830|NCT01808378|Drug|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
79731824|NCT04510480|Other|Observational study without specific intervention|Observational study with standard cardiac arrest approach
79731825|NCT04488094|Drug|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of [18F]FSPG.
79731826|NCT02634619|Procedure|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
79866370|NCT05882188|Procedure|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
79866371|NCT05882149|Dietary Supplement|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
79401909|NCT02699697|Radiation|External Beam Radiation Therapy|Undergo EBRT
79401910|NCT02699697|Radiation|Palliative Radiation Therapy|Undergo EBRT
79401911|NCT02699697|Other|Quality-of-Life Assessment|Ancillary studies
79401912|NCT02699697|Other|Questionnaire Administration|Ancillary studies
79401913|NCT02697487|Other|No treatment|This is an observational study with no intervention.
79401914|NCT02664883|Procedure|Computed Tomography|Correlative studies
79401915|NCT02664883|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
79401916|NCT02664883|Other|Laboratory Biomarker Analysis|Correlative studies
79401917|NCT02664883|Procedure|Magnetic Resonance Imaging|Correlative studies
79401918|NCT02639559|Drug|BL-8040|
79401919|NCT02639559|Procedure|Leukapheresis|
79401920|NCT02639559|Procedure|Hematopoietic cell transplant|
79571831|NCT01808404|Behavioral|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
79571832|NCT01808417|Drug|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
79571833|NCT01808430|Procedure|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
79571834|NCT01808443|Other|Cryotherapy|up to a maximum of four treatments every 21-28 days
79571835|NCT01808443|Other|laser|up to a maximum of four treatments every 21-28 days
79571836|NCT01808469|Biological|Monoclonal antibody|
79571837|NCT01808482|Drug|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
79571838|NCT01808482|Drug|Part A: matching placebo|Matching placebo
79571839|NCT01808482|Drug|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
79571840|NCT01808482|Drug|Part B: matching placebo|Matching placebo
79571841|NCT01808482|Drug|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
79571842|NCT01808495|Drug|Mitomycin C|
79571843|NCT01808521|Drug|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
79269585|NCT03836716|Drug|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
79866372|NCT05882149|Dietary Supplement|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
79866373|NCT05881382|Drug|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
79571844|NCT01808586|Procedure|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
79866374|NCT05881382|Drug|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
79269586|NCT03754465|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
79269587|NCT03754465|Procedure|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
79269588|NCT03744975|Drug|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
79269589|NCT03744975|Drug|Placebos|Participants will receive 1oral Placebo capsule
79571845|NCT01808586|Procedure|Dexamethasone|4mg/mL
79571846|NCT01808586|Procedure|Intramuscular Lidocaine|2%
79571847|NCT01808586|Behavioral|Home Exercise|Standardized home exercise program
79731827|NCT02634619|Procedure|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
79866375|NCT05879393|Dietary Supplement|OMNi-BiOTiC® Active|Multistrain probiotic
79866376|NCT05879393|Other|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
79866377|NCT05879094|Other|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
79571848|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
79571849|NCT01808638|Drug|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
79571850|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
79571851|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
79866378|NCT05875415|Other|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
79866379|NCT05875415|Other|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
79731828|NCT04481308|Drug|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
79731829|NCT02634541|Drug|Adalimumab|Biologic drug
79731830|NCT02634541|Other|PET/CT imaging|PET/CT imaging
79866380|NCT05866601|Other|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
79269590|NCT03702556|Device|MRI scan|7.0 tesla functional MRI scan
79269591|NCT03691519|Drug|Omega-3 treatment|"Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day)."
79269592|NCT03691519|Dietary Supplement|Placebo|"The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day)."
79269593|NCT03686215|Combination Product|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
79269594|NCT03665077|Diagnostic Test|Initial blood draw|At baseline, patients will undergo a blood draw.
79269595|NCT03665077|Diagnostic Test|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
79269596|NCT03665077|Diagnostic Test|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
79269597|NCT03665077|Diagnostic Test|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
79269598|NCT03665077|Diagnostic Test|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
79401921|NCT02633137|Drug|Lenalidomide|
79731831|NCT04475848|Drug|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
79269599|NCT03653013|Behavioral|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
79269600|NCT03653013|Behavioral|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
79731832|NCT04475848|Drug|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
79731833|NCT04475848|Drug|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
79731834|NCT04653142|Drug|BI 765063|BI 765063
79731835|NCT04653142|Drug|BI 754091|BI 754091
79731836|NCT00599521|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
79731837|NCT00599521|Drug|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
79269601|NCT03633799|Drug|VeraCept|VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
79866381|NCT05857345|Other|Collection of breastmilk|Collection of breastmilk and other information about the participant
79269602|NCT03612804|Behavioral|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note and unsigned order for the provider about the recommended medication indicated by VA formulary guidelines.
79269603|NCT03612804|Behavioral|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
79866382|NCT05854472|Other|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
79866383|NCT05848817|Device|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
79866384|NCT05845931|Dietary Supplement|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
79866385|NCT05843708|Drug|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
79866386|NCT05843708|Drug|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
79401922|NCT02633137|Drug|R-CHOP|"Rituximab 375 mg/m^2 IVPB with premedications Day 1~Cyclophosphamide 750 mg/m^2 IVPB Day 1~Doxorubicin 50 mg/m^2 IVP Day 1~Vincristine 1.4 mg/m^2 IVP (capped at 2 mg) Day 1~Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
79731838|NCT04201678|Procedure|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
79731839|NCT04201678|Procedure|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
79866387|NCT05843708|Drug|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
79866388|NCT05841563|Drug|PM54|"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"
79269604|NCT03606174|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
79269605|NCT03606174|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
79401923|NCT02633137|Drug|high-dose cytarabine (HIDAC)|
79269606|NCT03606174|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
79269607|NCT03606174|Drug|Enfortumab vedotin|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
79401924|NCT02605512|Other|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
79401925|NCT02584478|Drug|AL3818|Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.
79269608|NCT03581357|Behavioral|Mobile Mindfulness Meditation|It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
79866389|NCT05840991|Device|elastic bandage|3M™ Coban™ elastic bandage
79571852|NCT01808664|Behavioral|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
79866390|NCT05840991|Device|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
79866391|NCT05836844|Device|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
79866392|NCT05836142|Procedure|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
79866393|NCT05835843|Other|In-Person and Remote Disease Assessment|Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
79866394|NCT05833035|Drug|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with [C-14] BI 1291583
79866395|NCT05814822|Behavioral|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
79866396|NCT05814822|Behavioral|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
79866397|NCT05796297|Device|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
79866398|NCT05790590|Diagnostic Test|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
79866399|NCT05790590|Diagnostic Test|Standard dose CT|CT with standard radiation dose and contrast media dose
79866400|NCT05777356|Diagnostic Test|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
79866401|NCT05768607|Procedure|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
79269609|NCT03581357|Behavioral|Mindfulness Coach|It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
79277581|NCT02363751|Drug|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
79277582|NCT03530839|Procedure|Arthrodesis|see study group description
79866402|NCT05768607|Procedure|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
79866403|NCT05768607|Procedure|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
79866404|NCT05768477|Other|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
79866405|NCT05768477|Procedure|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
79866406|NCT05768477|Drug|Baxter therapy|Ketamine or Linisol baxter therapy
79866407|NCT05768477|Behavioral|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
79866408|NCT05754918|Device|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
79866409|NCT05754918|Device|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
79866410|NCT05750160|Other|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
79866411|NCT05743946|Drug|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
79866412|NCT05742789|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
79866413|NCT05742789|Drug|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
79277583|NCT03530839|Procedure|Resection arthroplasty|see study group description
80026424|NCT02166138|Procedure|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
80026425|NCT03594825|Drug|Valsartan|Different time of taking medicine
80026426|NCT05635396|Device|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
80026427|NCT02162550|Drug|Bydureon|once weekly injection
80026428|NCT02162550|Drug|placebo|once weekly injection
80026429|NCT05635318|Device|FDA approved medications for ADHD plus Quantitative EEG Neurofeedback|A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
80026430|NCT05635318|Drug|FDA approved medications for ADHD|Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
79269610|NCT03523143|Other|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
79277584|NCT02367339|Other|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
79277585|NCT02374437|Drug|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
79571853|NCT01808664|Behavioral|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
79731840|NCT04201678|Procedure|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
79866414|NCT05742789|Drug|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
79866415|NCT05729607|Procedure|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
79866416|NCT05729607|Procedure|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
79866417|NCT05723822|Device|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
79866418|NCT05721846|Drug|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
79571854|NCT01808677|Other|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
79731841|NCT00653341|Drug|insulin glargine|
79731842|NCT00653341|Drug|NPH human insulin|
80026431|NCT02162628|Device|Exair Prolapse Repair System|
80026432|NCT02162628|Procedure|Total Native Tissue Repair|
80026433|NCT05306860|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
80026434|NCT02162706|Other|Non intervention study|
80026435|NCT02852265|Drug|Etonogestrel contraceptive implant|Place nexplanon
80026436|NCT02162784|Drug|Budesonide/Procaterol, 180/10mcg X1|one puff
80026437|NCT02162784|Drug|Budesonide/procaterol 180/10 mcg X 2|2 puffs
80026438|NCT02162784|Drug|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
80026439|NCT03602703|Diagnostic Test|Flow cytometry and Western Blot analysis|Diagnostic tests
79269611|NCT03523143|Other|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
79269612|NCT03450707|Drug|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
79571855|NCT01808703|Device|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
79731843|NCT03542812|Drug|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
79731844|NCT02642263|Drug|Carbetocin|Postpartum uterotonic drug
79731845|NCT02637115|Dietary Supplement|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
79731846|NCT02637115|Dietary Supplement|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
79866419|NCT05721846|Drug|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
79866420|NCT05721846|Radiation|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
79866421|NCT05721846|Biological|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
79866422|NCT05715489|Procedure|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
80026440|NCT02166294|Other|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
80026441|NCT02166294|Procedure|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
80026442|NCT03600753|Other|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
80026443|NCT03600753|Other|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
80026444|NCT02166372|Other|Observation of natural course of Diabetes Mellitus Type 2|
80026445|NCT03600675|Other|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
79269613|NCT03450707|Other|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
79269614|NCT03392311|Drug|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
80026446|NCT03539718|Drug|Taurolidine heparin|Taurolock-hep 500 at end of session
80026447|NCT03539718|Drug|Heparin Sodium|Heparin sodium 5000 at end of session
80026448|NCT02166450|Drug|Nystatin|100 000 IU every 6 h as a suspension
80026449|NCT03600519|Device|NOTAL OCT V2.5|AMD Patients
79571856|NCT01808703|Procedure|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
79731847|NCT02637115|Dietary Supplement|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
79731848|NCT02637115|Dietary Supplement|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
80026450|NCT03540498|Dietary Supplement|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
79731849|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
79731850|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
79731851|NCT00656227|Drug|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
79731852|NCT02636803|Drug|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
79731853|NCT02636803|Drug|albendazole|group receives one 400 mg dose of albendazole
79731854|NCT02535871|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
79866423|NCT05715489|Procedure|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
79866424|NCT05704712|Behavioral|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
79866425|NCT05688696|Drug|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
79866426|NCT05688696|Drug|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
80026451|NCT03540498|Dietary Supplement|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
80026452|NCT03600363|Drug|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
80026453|NCT03600363|Drug|Placebos|oral placebos as a maintenance therapy
80026454|NCT02162940|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
79571857|NCT01808716|Device|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
79866427|NCT05688696|Drug|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
79866428|NCT05688254|Behavioral|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
79866429|NCT05671237|Other|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
79866430|NCT05613725|Other|Blood sample collection|Blood sample collection
79866431|NCT05597085|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
79866432|NCT05577481|Combination Product|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
79866433|NCT05577481|Combination Product|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
79269615|NCT03392311|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
79571858|NCT01808742|Device|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
80026455|NCT02162940|Other|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
80026456|NCT03600285|Device|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
80026457|NCT03540888|Other|Deep transverse Friction Massage|The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
80026458|NCT03540888|Other|Dynamic stretching intervention|Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
80026459|NCT03540888|Other|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
80026460|NCT03600207|Other|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
80026461|NCT03600207|Other|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
80026462|NCT04731246|Other|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
80026463|NCT03600129|Procedure|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
80026464|NCT03600129|Drug|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
80026465|NCT03600129|Drug|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
80026466|NCT02169570|Dietary Supplement|Vitamin D|
79571859|NCT01808768|Drug|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
80026467|NCT02169570|Dietary Supplement|Calcium|
80026468|NCT02169570|Dietary Supplement|Placebo Vit D|
80026469|NCT02169570|Dietary Supplement|Placebo Calcium|
79866434|NCT05574634|Behavioral|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
79866435|NCT05574634|Behavioral|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
79866436|NCT05557474|Other|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
79866437|NCT05557474|Other|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
79866438|NCT05544981|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
79866439|NCT05544981|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
79866440|NCT05516069|Other|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
79866441|NCT05499585|Other|Whole Dairy|2 1/2 servings of whole dairy per day
79866442|NCT05486507|Dietary Supplement|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
79866443|NCT05486507|Dietary Supplement|Placebo|Taste matched placebo.
80026470|NCT03600051|Device|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
80026471|NCT03539640|Other|PEEP: 5 cmH2O|During second part of the study (MRI)
79866444|NCT05468515|Diagnostic Test|pulse oxygen saturation|preductal oxygen saturation
80026472|NCT03539640|Other|PEEP: 10 cmH2O|During second part of the study (MRI)
79277586|NCT02374437|Drug|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
79277587|NCT05576623|Biological|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
79571860|NCT01808781|Other|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
79277588|NCT05576623|Biological|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
79571861|NCT01808781|Other|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
79731855|NCT02535871|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
79731856|NCT02634385|Procedure|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
79731857|NCT02634385|Procedure|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
79731858|NCT02634463|Drug|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
79731859|NCT02634463|Other|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
79866445|NCT05465135|Drug|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
79866446|NCT05464342|Behavioral|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
79866447|NCT05464342|Behavioral|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
79866448|NCT05464342|Behavioral|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
79866449|NCT05461157|Device|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
79866450|NCT05461157|Other|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
80026473|NCT03539640|Other|PEEP: 15 cmH2O|During second part of the study (MRI)
80026474|NCT03913143|Drug|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
80026475|NCT03913143|Other|Sham|Sham-Procedure (no experimental drug administered)
80026476|NCT02169648|Drug|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
80026477|NCT03594591|Drug|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
80026478|NCT02170896|Drug|BIBR 1048 MS Capsule A|
80026479|NCT02170896|Drug|BIBR 1048 MS Capsule B|
80026480|NCT02170896|Drug|BIBR 1048 MS Capsule C|
80026481|NCT02170896|Drug|BIBR 1048 MS Capsule D|
80026482|NCT02170896|Drug|BIBR 1048 MS tartaric acid solution|
80026483|NCT02170896|Drug|Pantoprazole|
80026484|NCT03594513|Procedure|MCAF|Periodontal surgical technique to treat gingival recessions.
80026485|NCT03594513|Procedure|PR|Restorative procedure to treat tooth structure loss.
80026486|NCT03594513|Procedure|CTG|Autogenous graft harvested from palate placed in the surgical site.
80026487|NCT03594513|Procedure|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
80026488|NCT03594513|Drug|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
80026489|NCT03594513|Drug|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
80026490|NCT02633800|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
80026491|NCT02633800|Drug|Cetuximab|Cetuximab 400 mg/mg/m^2 IV loading dose, followed by 250 mg/m^2 weekly
80026492|NCT02633800|Drug|Cisplatin|Cisplatin at 100 mg/m^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
79269616|NCT03350464|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
79269617|NCT03337009|Behavioral|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
79571862|NCT01808859|Device|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
79269618|NCT03334656|Biological|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
79269619|NCT03334656|Other|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
79269620|NCT03322865|Drug|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15*~*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
79866451|NCT05442814|Procedure|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
79571863|NCT01808885|Drug|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
79571864|NCT01808885|Drug|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
79571865|NCT01808898|Procedure|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
79571866|NCT01808911|Drug|Steroid + cyclophosphamide|
79866452|NCT05442814|Procedure|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
79866453|NCT05425732|Biological|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
79866454|NCT05425732|Biological|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
79866455|NCT05389514|Drug|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
79866456|NCT05389514|Drug|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
79866457|NCT05389514|Drug|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
79866458|NCT05389514|Biological|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10^9 to 5.0 x 10^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
79866459|NCT05362149|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
79866460|NCT05362149|Drug|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
79866461|NCT05362149|Drug|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
80026493|NCT02633800|Drug|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
80026494|NCT02633800|Drug|Placebo|Placebo to match patritumab
80026495|NCT02169804|Drug|Androxal 25 mg|
80026496|NCT03829657|Drug|ampreloxetine|Oral tablet, QD (Daily)
80026497|NCT03829657|Drug|Placebo|Oral tablet, QD
80026498|NCT02170974|Drug|BIBR 1048 MS polymorph II|
80026499|NCT02170974|Drug|BIBR 1048 MS polymorph I|
80026500|NCT03539250|Radiation|IMRT|IMRT with and without chemotherapy
80026501|NCT03593733|Other|Photobiomodulation Therapy|Photobiomodulation Therapy
80026502|NCT03593733|Other|Cold Water Immersion|Cold Water Immersion
80026503|NCT02174718|Dietary Supplement|Transdermal D Patch|
80026504|NCT02174718|Dietary Supplement|Oral vitamin D3|
80026505|NCT02174718|Dietary Supplement|Placebo patch|
79571867|NCT01808911|Drug|Steroid + rituximab|
79731860|NCT02634463|Drug|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent [eq.] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
79571868|NCT01808976|Other|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
79571869|NCT01808976|Behavioral|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
79731861|NCT02634463|Drug|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
79731862|NCT02535403|Behavioral|ICBT|
79731863|NCT00882115|Drug|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
79731864|NCT00881959|Device|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
80026506|NCT02174718|Dietary Supplement|Oral placebo|
80026507|NCT02238171|Drug|Atrovent® inhalets|
80026508|NCT02174796|Procedure|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
80026509|NCT02174796|Procedure|orthopedic treatment|orthopedic treatment by vacuum bell.
80026510|NCT03069586|Procedure|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
80026511|NCT03069586|Procedure|No pulmonary recruitment|At the end of surgery no intervention was completed
80026512|NCT02237703|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
79571870|NCT01808976|Behavioral|Basic health push app|This is an app that send daily tips for improving your mood.
79571871|NCT01809028|Procedure|EUS FNA with 2 passes|biopsy with 2 passes
79571872|NCT01809028|Procedure|EUS FNA with 4 passes|biopsy with 4 passes
79571873|NCT01809067|Other|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
79571874|NCT01809093|Biological|Blood draw|3-4 tablespoons of blood will be drawn, one time.
79866462|NCT05341882|Behavioral|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
79866463|NCT05341882|Behavioral|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
79866464|NCT05327790|Drug|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
79866465|NCT05327790|Other|Placebo|Placebo
79866466|NCT05327777|Drug|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
79571875|NCT01809119|Procedure|Partial nephrectomy|
79571876|NCT01809145|Other|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
79571877|NCT01809158|Drug|minocycline|
79571878|NCT01809158|Drug|placebo|
79866467|NCT05327777|Behavioral|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
79866468|NCT05326074|Other|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
79866469|NCT05304546|Drug|Pembrolizumab|Solution for IV
79571879|NCT01809171|Drug|Vitamin D3|ampoule
80026513|NCT02169882|Drug|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
80026514|NCT02169882|Drug|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
79571880|NCT01809171|Drug|Placebo|ampoule
79571881|NCT01809184|Drug|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
79571882|NCT01809184|Drug|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
79731865|NCT00653419|Drug|buspirone HCl|Tablets, 30 mg, single-dose
79866470|NCT05304546|Drug|Encorafenib|Oral QD
79866471|NCT05304546|Drug|Binimetinib|Oral BID
79866472|NCT05267340|Behavioral|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
79571883|NCT01809184|Drug|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
79571884|NCT01809223|Drug|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
79571885|NCT01809223|Drug|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
79571886|NCT01809223|Other|sham injection|sham intravitreal injection per month, fixed injection
79571887|NCT01809236|Biological|Conbercept|intravitreal injection of 0.5 mg Conbercept
79571888|NCT01809275|Drug|QBECO|
79571889|NCT01809275|Drug|Placebo|
79731866|NCT00653419|Drug|Buspar|Tablets, 30 mg, single-dose
79731867|NCT00884377|Drug|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
79731868|NCT00884377|Device|ThermoMed|ThermoMed heat treatment device, one treatment
80026515|NCT02169882|Drug|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
79571890|NCT01809301|Drug|Niaspan|
79571891|NCT01809301|Drug|TRIA-662|
80026516|NCT02169882|Drug|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
80026517|NCT03592173|Diagnostic Test|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
80026518|NCT03602547|Drug|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
80026519|NCT02169960|Behavioral|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
80026520|NCT02169960|Behavioral|Breaking Free|Online based intervention for Drug and Alcohol Use
79731869|NCT00656929|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
80026521|NCT02169960|Behavioral|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
80026522|NCT02169960|Behavioral|Resiliency Training|Op Volle Kracht (OVK)
80026523|NCT04277299|Device|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
79571892|NCT01809340|Drug|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
79277589|NCT05576623|Other|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
80026524|NCT03602469|Drug|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
80026525|NCT03602469|Drug|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
80026526|NCT03602469|Drug|Propofol|Using propofol 1.5-2.5 mg/kg
79571893|NCT01809340|Drug|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
79571894|NCT01809340|Drug|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
79277590|NCT02374515|Device|EndoCuff-assisted colonoscopy|Adenoma detection rate
79731870|NCT00656929|Other|Placebo|Placebo tablets
79731871|NCT00656383|Other|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
79731872|NCT00656383|Other|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
79731873|NCT04161937|Behavioral|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
79277591|NCT02374515|Device|Standard Colonoscopy|
79571895|NCT01809353|Drug|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
79571896|NCT01809353|Other|Placebo|Single matching intravenous dose
79571897|NCT01809366|Procedure|seminal plasma insemination|
79571898|NCT01809392|Drug|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
79571899|NCT01809418|Device|keePAP|
79731874|NCT00884221|Drug|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
79731875|NCT00884221|Drug|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
79731876|NCT02634229|Genetic|blood sample|
79731877|NCT02153632|Drug|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
79731878|NCT02153632|Drug|Placebo|subjects are given an identical placebo tablet
79731879|NCT03524326|Drug|Lenvatinib Pill|24 mg oral daily
80026527|NCT03602469|Device|Ultrasound|Ultrasound-guided suprascapular nerve block
80026528|NCT03602469|Drug|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
79571900|NCT01809431|Behavioral|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
79571901|NCT01809444|Drug|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
79731880|NCT03524326|Drug|Lenvatinib Pill|20 mg oral daily
79571902|NCT01809444|Drug|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
80026529|NCT03602469|Drug|Rocuronium|Rocuronium 0.6 mg/kg
79571903|NCT01809457|Other|educational poster|educational poster for dental trauma
79571904|NCT01809470|Behavioral|FIFA2013|Playing FIFA2013 for 1 hour
79571905|NCT01809470|Behavioral|Call of Duty|Playing Call of Duty for 1 hour
79571906|NCT01809470|Behavioral|Watching TV|Watching TV for 1 hour
79571907|NCT01809483|Device|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
79571908|NCT01809483|Device|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
79571909|NCT01809496|Behavioral|Informational Counseling|
79731881|NCT03524326|Drug|Lenvatinib Pill|14 mg oral daily
79731882|NCT03524326|Drug|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
79731883|NCT03524326|Drug|Lenvatinib Pill|10 mg oral daily
79571910|NCT01809496|Behavioral|Patient Centered Counseling|
79866473|NCT05267340|Behavioral|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
79866474|NCT05263544|Other|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
79866475|NCT05263076|Other|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
79866476|NCT05243602|Drug|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
80026530|NCT02174952|Behavioral|Self-help version of the New Forest Parenting Programme|
80026531|NCT02170038|Drug|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
80026532|NCT02170038|Drug|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
80026533|NCT05001373|Biological|Core-g28v2 60mer mRNA Vaccine|100µg, Intramuscularly
79571911|NCT01809509|Procedure|Endometrial biopsy|
79571912|NCT01809522|Procedure|Posterior reconstruction of the rhabdosphincter|
80026534|NCT05001373|Biological|eOD-GT8 60mer mRNA Vaccine|100µg, Intramuscularly
80026535|NCT03591939|Diagnostic Test|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
80026536|NCT02171052|Drug|Dabigatran etexilate|
79571913|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
79571914|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
79571915|NCT01809561|Procedure|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
79571916|NCT01809587|Device|IQP-PO-101|
79571917|NCT01809600|Other|No intervention (observational study)|
79731884|NCT03524326|Drug|Lenvatinib Pill|4 mg oral daily
79731885|NCT01236430|Drug|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
79731886|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
80026537|NCT02171052|Drug|Digoxin|
80026538|NCT03675919|Device|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
79731887|NCT01236430|Drug|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
79731888|NCT01236430|Drug|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
79731889|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
79731890|NCT00726856|Drug|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
79731891|NCT00651274|Drug|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
79731892|NCT00651274|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
79731893|NCT05335330|Other|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the prone position. Measurements will be taken from three different points.
80026539|NCT03675919|Device|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
80026540|NCT03675919|Device|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
79401926|NCT02584478|Drug|Paclitaxel|"Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week"
79401927|NCT02584478|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m^2 intravenously or local standard"
79401928|NCT02584478|Drug|Topotecan|Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard
80026541|NCT03675919|Other|Access to the online portal|self-monitoring of health parameters
80026542|NCT03675919|Other|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
80026543|NCT03591549|Drug|Faslodex|intramuscular injection monthly
80026544|NCT03591549|Drug|Zoladex|intramuscular injection monthly
80026545|NCT02261220|Biological|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
80026546|NCT02261220|Biological|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
80026547|NCT02237937|Drug|Paroxetine|
80026548|NCT02237937|Drug|Sertraline|
80026549|NCT02237937|Drug|Citalopram|
80026550|NCT02237937|Drug|Venlafaxine|
80026551|NCT02237937|Drug|Amitriptyline|
79401929|NCT02584478|Drug|Topotecan|Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard
79401930|NCT02584478|Drug|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
79571918|NCT01809613|Procedure|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
79571919|NCT01809626|Drug|Zolpidem|
79866477|NCT05243602|Drug|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
79866478|NCT05234099|Diagnostic Test|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
79866479|NCT05234099|Diagnostic Test|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
79401931|NCT02584478|Drug|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
79401932|NCT02584478|Drug|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
79571920|NCT01809626|Other|Placebo|
79571921|NCT01809652|Other|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
79571922|NCT01809665|Device|ICD/CRT-P therapy|
79571923|NCT01809665|Other|MRI|
79571924|NCT01809678|Behavioral|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
79571925|NCT01809678|Behavioral|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
79571926|NCT01809678|Other|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
79571927|NCT01809717|Other|Weight Lifting Exercises|
79731894|NCT00351988|Behavioral|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
79731895|NCT00351988|Behavioral|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
79731896|NCT00212836|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
79866480|NCT05234099|Diagnostic Test|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
79866481|NCT05234099|Diagnostic Test|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
80026552|NCT02237937|Drug|Escitalopram|
80026553|NCT02237937|Drug|Amitriptylinoxide|
80026554|NCT02237937|Drug|Nortriptyline|
80026555|NCT02237937|Drug|Trimipramine|
80026556|NCT02238015|Procedure|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
80026557|NCT02170116|Drug|BIBR 1048 MS dose 1|
80026558|NCT02170116|Drug|BIBR 1048 MS dose 2|
80026559|NCT02170116|Drug|BIBR 1048 MS dose 3|
80026560|NCT02170116|Drug|BIBR 1048 MS dose 4|
80026561|NCT02170116|Drug|BIBR 1048 MS dose 5|
80026562|NCT02170116|Drug|Placebo to BIBR 1048 MS|
80026563|NCT03035227|Procedure|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
80026564|NCT03035227|Drug|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
80026565|NCT03591393|Diagnostic Test|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
80026566|NCT02170194|Behavioral|Resilience Enhancement Training via Smart Phone|
80026567|NCT02170194|Behavioral|Daily Text Messages|
80026568|NCT02170272|Behavioral|Home-based Lymphedema Care Program|Undergo HBLCP
80026569|NCT02238405|Other|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
80026570|NCT03539562|Drug|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
80026571|NCT02238249|Drug|Alesion®|Dry Syrup
79731897|NCT00212836|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
80026572|NCT03590769|Drug|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
80026573|NCT03675763|Other|Manual treatment|Craniosacral therapy protocol.
80026574|NCT00394069|Drug|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
80026575|NCT03598959|Drug|tofacitinib|orally 10 mg daily
79277592|NCT03528655|Other|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
79401933|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
79731898|NCT00805324|Drug|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
79866482|NCT05234099|Diagnostic Test|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
79866483|NCT05234099|Diagnostic Test|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
79866484|NCT05192863|Other|No Intervention|This is a non-interventional study.
79866485|NCT05188521|Drug|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
79866486|NCT05188521|Drug|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 16 weeks
79866487|NCT05179577|Drug|Arbaclofen|Arbaclofen Extended Release Tablets
79866488|NCT05179577|Drug|Placebo|Placebo tablets
79401934|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
79401935|NCT02576535|Procedure|Fractionated stereotactic radiosurgery|
79866489|NCT05165095|Device|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
79401936|NCT02576535|Device|Leskell gamma unit|FDA approved device
79866490|NCT05161689|Behavioral|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
79866491|NCT05159713|Behavioral|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
80026576|NCT03598959|Drug|chidamide|orally 20 mg twice weekly
80026577|NCT05634928|Other|collection data|collection data
80026578|NCT03598179|Biological|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10^6 Acute lymphocytic leukemia 2×10^6 Chronic lymphocytic leukemia 10×10^6
80026579|NCT05730478|Device|ASOCT&UBM|glaucoma assesment by ASOCT &UBM
80026580|NCT02238717|Drug|PF-06372865 (65mg)|single oral dose (65 mg)
79277593|NCT02374281|Drug|Glucose sucking|
79277594|NCT02374281|Drug|Water sucking|
79277595|NCT02374281|Other|No sucking|
79401937|NCT02574910|Drug|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
79401938|NCT02574845|Drug|Rosuvastatin|
79731899|NCT00157924|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
79731900|NCT00157924|Drug|atorvastatin|atorvastatin 10mg
79731901|NCT05335642|Procedure|EVAR|Endovascular repair of abdominal aortic aneurysms
79731902|NCT00794794|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
79731903|NCT00794794|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
79731904|NCT03612466|Drug|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 & 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
79401939|NCT02574845|Drug|Metformin HCl|
80026581|NCT02238717|Drug|PF-06372865 (15mg)|single oral dose (15mg)
80026582|NCT02238717|Drug|Pregabalin|single oral dose (300mg)
79269621|NCT03305874|Other|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
79269622|NCT03296527|Drug|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
79269623|NCT03296527|Drug|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
79731905|NCT03612466|Radiation|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
79269624|NCT03267498|Drug|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
79277596|NCT05227573|Procedure|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
79401940|NCT02574845|Drug|Furosemide|
79401941|NCT02530593|Behavioral|There is no intervention, only observation|
79401942|NCT02523534|Procedure|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
79401943|NCT02523534|Procedure|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
79401944|NCT02521844|Drug|ETC-1922159|Oral administration
79401945|NCT02521844|Drug|Pembrolizumab|IV administration
79731906|NCT03612466|Drug|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
79731907|NCT03612466|Drug|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
79731908|NCT03612466|Drug|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
79401946|NCT02498613|Other|18F-Fluoromisonidazole|Correlative studies
79401947|NCT02498613|Drug|Cediranib Maleate|Given PO
79401948|NCT02498613|Other|Laboratory Biomarker Analysis|Correlative studies
79401949|NCT02498613|Drug|Olaparib|Given PO
79731909|NCT00142558|Drug|MK0663; etoricoxib / Duration of Treatment: 5 Days|
79401950|NCT02498613|Procedure|Positron Emission Tomography|Correlative studies
79401951|NCT02496663|Procedure|Biospecimen Collection|Undergo blood sample collection
79401952|NCT02496663|Procedure|Computed Tomography|Undergo CT scan
79401953|NCT02496663|Procedure|Magnetic Resonance Elastography|Undergo MRI
79401954|NCT02496663|Biological|Necitumumab|Given IV
79401955|NCT02496663|Drug|Osimertinib|Given PO
79401956|NCT02445443|Device|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
79571928|NCT01809743|Drug|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
79731910|NCT00142558|Drug|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
79731911|NCT02842606|Other|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
79731912|NCT02842684|Device|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
79731913|NCT00899548|Genetic|DNA methylation analysis|laboratory analysis
79731914|NCT00899548|Genetic|microarray analysis|laboratory analysis
79731915|NCT00899548|Genetic|polymerase chain reaction|laboratory analysis
79731916|NCT00899548|Other|laboratory biomarker analysis|laboratory analysis
79731917|NCT04201366|Other|No intervention|No intervention
79731918|NCT02690818|Behavioral|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
79731919|NCT02842528|Behavioral|Diagnostic Interview for Genetic Studies|
79731920|NCT02842528|Behavioral|Family Informant Schedule and Criteria|
79731921|NCT02842528|Behavioral|Temperament and Character Inventory|
79731922|NCT02842528|Behavioral|Barratt Impulsiveness Scale|
79731923|NCT02842528|Behavioral|Wisconsin Card Sorting Test|
79731924|NCT02842528|Genetic|blood sample withdrawn|
79731925|NCT04201522|Other|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
79731926|NCT04201522|Other|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
79731927|NCT02842450|Device|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
79731928|NCT02842450|Other|definitions only|
79731929|NCT02844088|Other|Meningococcus C conjugate vaccine|
79731930|NCT00899392|Other|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
79731931|NCT02842294|Drug|Bevacizumab|
80026583|NCT02238717|Drug|Placebo|matching oral placebo
80026584|NCT03625453|Drug|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
80026585|NCT03625453|Drug|Placebo|Part 1: 8 weeks with daily administration
80026586|NCT03066388|Other|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
79269625|NCT03267498|Drug|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
79269626|NCT03267498|Radiation|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
79866492|NCT05159713|Behavioral|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
79571929|NCT01809743|Drug|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
80026587|NCT03581955|Other|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
80026588|NCT03581955|Other|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
80026589|NCT03581955|Other|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
79571930|NCT01809743|Drug|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
79731932|NCT05334862|Procedure|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and fixation by usuing 8 plate and screws.
79731933|NCT01176604|Radiation|Yttrium Y 90 Glass Microspheres|Given via catheter
80026590|NCT03568123|Device|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
79269627|NCT03241771|Behavioral|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
79269628|NCT03228680|Drug|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
79269629|NCT03228680|Drug|Follitropin beta|Single daily subcutaneous injection in the abdomen
79269630|NCT03206086|Drug|Eltrombopag|Daily dose - Non-Asian (>=12): 150 mg Non-Asian (6-11): 75 mg Non-Asian (4-5): 2.5 mg/kg East Asian, South East Asian (>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg East Asian, South East Asian (4-5): 1.25 mg/kg
79269631|NCT03194542|Drug|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
79269632|NCT03188094|Other|community health worker (CHW)-led health coaching for patients|Using a stepped-wedge design, investigators will implement the study in 25 NYC PCP sites enrolling 2,840 South Asian patients at- risk for T2DM.
79269633|NCT03160079|Drug|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
79277597|NCT04605211|Behavioral|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
79571931|NCT01809743|Drug|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
79571932|NCT01809743|Drug|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
79731934|NCT02843932|Other|functional brain MRI|functional imagery during motor-perception tasks
79731935|NCT02844010|Other|weighing|
79731936|NCT02842138|Biological|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
79731937|NCT02844244|Behavioral|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
79731938|NCT02841982|Procedure|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
79731939|NCT02841982|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
79731940|NCT02841982|Device|PAJUNK StimuLong|
79731941|NCT02841982|Drug|single dose ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~given immediately after the correct position of the tip of the needle has been verified."
79866493|NCT05154760|Other|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
79866494|NCT05097898|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
79866495|NCT05097898|Procedure|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
79866496|NCT05097898|Procedure|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
80026591|NCT03568123|Device|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
80026592|NCT03558217|Device|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
79269634|NCT03160079|Drug|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
79269635|NCT03101917|Device|The Microtable® Stereotactic System|x
79269636|NCT03098628|Biological|PCV Vaccine|PCV vaccination
79269637|NCT03083808|Drug|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~+~Physician's choice chemotherapy with one of the following every 21 days:~Docetaxel 75mg/m2 IV~Pemetrexed 500mg/m2 IV (non-squamous only)~Gemcitabine 1000mg/m2 IV on days 1 and 8"
79269638|NCT03047330|Drug|Estradiol withdrawal|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
79866497|NCT05097898|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
79269639|NCT03047330|Other|Fragmented sleep|Fragmented sleep will be experimentally induced.
79269640|NCT03005951|Other|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
79269641|NCT03005951|Other|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
79269642|NCT02981407|Biological|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
79269643|NCT02960737|Device|Oral neuromuscular training using an oral device|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
79269644|NCT02860481|Procedure|blood sample for FSHR analysis|
79269645|NCT02860481|Procedure|blood sample for FSHR analysis|
79866498|NCT05097898|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
79866499|NCT05096130|Behavioral|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
79866500|NCT05091593|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
79866501|NCT05091593|Behavioral|Enhanced Usual Care|Usual care from health providers
79866502|NCT05089162|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
79571933|NCT01809756|Other|Caphosol|Caphosol 4 times a day
80026593|NCT03558217|Device|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
79269646|NCT02762266|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79269647|NCT02762266|Procedure|Transarterial Chemoembolization|Undergo TACE
79269648|NCT02762266|Drug|embolic agent|". Acceptable embolic agents include:~Gelatin sponge (gelfoam)~Polyvinyl alcohol (PVA) particles~Microspheres / Embolic beads"
79269649|NCT02762266|Drug|lipiodol|
79269650|NCT02707926|Drug|Anti-HIV Agents|Therapy to treat HIV infection
79269651|NCT02608216|Drug|[18F]FLT|[18F]FLT PET/CT scan, imaging tracer
79269652|NCT02608216|Device|PET/CT|[18F]FLT PET/CT scan
79269653|NCT02608216|Drug|ribociclib|therapeutic
79269654|NCT02608216|Drug|paclitaxel|therapeutic
79269655|NCT02493530|Drug|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
79269656|NCT02493530|Drug|ruxolitinib|
79277598|NCT04605211|Other|Internet-Based Webinars|Attend webinars
79277599|NCT03527251|Drug|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
79277600|NCT03527251|Drug|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
79277601|NCT02363517|Drug|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
79401957|NCT02432326|Drug|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
79401958|NCT02432326|Drug|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
79401959|NCT02404285|Drug|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
79401960|NCT02404285|Drug|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
79866503|NCT05089162|Procedure|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
79866504|NCT05089162|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
79401961|NCT02387905|Procedure|Management of Therapy Complications|Undergo vertebral body cement augmentation
79401962|NCT02387905|Other|Quality-of-Life Assessment|Ancillary studies
79571934|NCT01809769|Biological|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
79731942|NCT02841982|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5~2mg, lock time: 10min, 1h limitation: 6~8mg
79401963|NCT02387905|Other|Questionnaire Administration|Ancillary studies
79401964|NCT02387905|Radiation|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
79571935|NCT01809769|Biological|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
79571936|NCT01809769|Biological|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
79866505|NCT05089162|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
79571937|NCT01809795|Other|Blueberry Smoothie|
79571938|NCT01809795|Other|Sham Smoothie|
79866506|NCT05089162|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
79866507|NCT05089149|Procedure|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
79866508|NCT05089149|Procedure|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
79571939|NCT01809821|Behavioral|Online Sleep Education|
79731943|NCT02841826|Other|IUD|
79866509|NCT05089149|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
79866510|NCT05089149|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
79866511|NCT05089149|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
79277602|NCT04467463|Procedure|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
79277603|NCT02363361|Drug|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
79731944|NCT02841826|Other|Uterine sounding|
79731945|NCT02841826|Radiation|Transvaginal ultrasound|
79731946|NCT00633178|Behavioral|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
79277604|NCT04594915|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics [SmPC]).
79731947|NCT00633178|Behavioral|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
79731948|NCT02841904|Device|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
79571940|NCT01809847|Drug|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
79731949|NCT02841514|Device|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
79731950|NCT02841514|Other|OTC toothpaste and an unoperated Y10 device|
79866512|NCT05073081|Other|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
79866513|NCT05073081|Other|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
80026594|NCT03587259|Diagnostic Test|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
79571941|NCT01809860|Drug|isavuconazole|Oral
79571942|NCT01809860|Drug|sirolimus|Oral
79571943|NCT01809873|Behavioral|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
79269657|NCT02415816|Procedure|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
79571944|NCT01809886|Drug|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
79401965|NCT02344355|Drug|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
79401966|NCT02344355|Radiation|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
79571945|NCT01809886|Drug|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
79571946|NCT01809912|Drug|Recombinant human apolipoprotein(a) Kringle V|
79571947|NCT01809925|Dietary Supplement|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
79866514|NCT05061966|Behavioral|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
80026595|NCT03587259|Diagnostic Test|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
80026596|NCT03470311|Biological|Benralizumab|30mg in 1mL pre-filled syringe
80026597|NCT03470311|Biological|Placebo|Matched placebo (1mL) in pre-filled syringe
79571948|NCT01809925|Dietary Supplement|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
79571949|NCT01809977|Procedure|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
79731951|NCT04533958|Device|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
79731952|NCT02841670|Device|InFo - Instant Focus (c) lens implantation|
79731953|NCT02841592|Other|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
79269658|NCT02328014|Drug|Acalabrutinib|Oral
79269659|NCT02328014|Drug|ACP-319|Oral
79731954|NCT02841592|Other|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
79571950|NCT01809977|Procedure|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
79731955|NCT02841436|Device|Irreversible Electroporation (IRE) System|
79731956|NCT02843776|Other|Questionnaires completion|
79731957|NCT02841358|Biological|Blood sampling|
79866515|NCT05061966|Behavioral|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
79866516|NCT05037734|Device|Persona Partial Knee System|Unicompartmental Knee Replacement
79866517|NCT05027815|Biological|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
79866518|NCT05003856|Other|Quality-of-Life Assessment|Ancillary studies
79866519|NCT05003856|Procedure|Radiofrequency Ablation|Undergo RFA
79866520|NCT04957758|Drug|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
79866521|NCT04957758|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle)
79866522|NCT04951154|Other|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
79866523|NCT04951154|Other|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
79866524|NCT04947176|Dietary Supplement|Supplement|200mg C15:0 once daily
79866525|NCT04947176|Other|Placebo|Matching placebo once daily
79866526|NCT04940000|Other|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
79866527|NCT04920383|Drug|ALPN-202|Various doses
79866528|NCT04920383|Drug|Pembrolizumab|Varies
79866529|NCT04920045|Other|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
79866530|NCT04919967|Behavioral|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
80026598|NCT04051021|Behavioral|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
80026599|NCT04051021|Other|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
80026600|NCT03580707|Drug|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
80026601|NCT03068026|Device|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
80026602|NCT03068026|Other|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
79269660|NCT02316652|Procedure|Scaling and root planing|Mechanical instrumentation
79269661|NCT02316652|Procedure|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
79571951|NCT01809990|Behavioral|Internet-delivered Cognitive Behavior Therapy|
79571952|NCT01810003|Dietary Supplement|High DHA|10 week supplementation period
79571953|NCT01810003|Dietary Supplement|High EPA|10 week supplementation period
79571954|NCT01810003|Dietary Supplement|Placebo|10 week supplementation period
79731958|NCT02841358|Biological|Biopsy|
79731959|NCT02843698|Drug|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
79731960|NCT02843698|Drug|Normal saline|Normal saline
79731961|NCT00690898|Drug|Lanreotide autogel 120 mg|12 months
79731962|NCT02841202|Drug|oral contraceptive pills|
79866531|NCT04919967|Behavioral|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
79866532|NCT04907201|Procedure|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
80026603|NCT03580005|Drug|methylphenidate HCl ERCT|methylphenidate HCl ERCT
80026604|NCT03580005|Drug|Placebo|Placebo to Match Quillichew ERCT
80026605|NCT00293995|Procedure|Repair of unilateral inguinal hernia|
80026606|NCT04412512|Procedure|VATS approach|video-assisted thoracic surgery approach
79866533|NCT04899934|Behavioral|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
80026607|NCT04412512|Procedure|Thoracotomy approach|
80026608|NCT03579927|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
80026609|NCT03579927|Drug|Carmustine|Given IV
80026610|NCT03579927|Drug|Cytarabine|Given IV
80026611|NCT03579927|Drug|Etoposide|Given IV
80026612|NCT03579927|Biological|Filgrastim|Given SC
80026613|NCT03579927|Drug|Melphalan|Given IV
80026614|NCT03579927|Biological|Rituximab|Given IV
80026615|NCT03579927|Biological|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
80026616|NCT05634850|Device|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
80026617|NCT05180890|Drug|Danavorexton|Danavorexton intravenous infusion.
79571955|NCT01810029|Behavioral|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
79571956|NCT01810068|Procedure|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
80026618|NCT05180890|Drug|Placebo|Placebo intravenous infusion.
80026619|NCT00100932|Drug|E7389 28 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
79571957|NCT01810068|Procedure|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
80026620|NCT00100932|Drug|E7389 21 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1 and 8 of a 21 day cycle.
80026621|NCT03579849|Diagnostic Test|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
80026622|NCT05634772|Device|dormia basket|Use of dormia basket in management of proximal stent migration
79269662|NCT02213926|Drug|ACP-196 (acalabrutinib)|
79571958|NCT01810068|Procedure|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
79571959|NCT01810068|Procedure|Diagnostic cystoscopy|Cysto-urethroscopy
79571960|NCT01810094|Device|Fracture Fixation|Thoracolumbar Fracture Fixation
79571961|NCT01810107|Procedure|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
79571962|NCT01810120|Biological|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
79571963|NCT01810146|Other|Digestive functions investigations|
79571964|NCT01810159|Other|Integrated collaborative care|
79571965|NCT01810159|Other|Education and Resources|
80026623|NCT05634772|Device|Extraction biliary ballon|Use of extraction biliary balloon in management of proximal stent migration
79304430|NCT04484233|Device|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
79571966|NCT01810172|Device|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
80026624|NCT03587025|Drug|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
80026625|NCT03587025|Drug|Placebo|Placebo
80026626|NCT02170350|Procedure|Meditation therapy|Use brief mindful meditation practice
80026627|NCT02170350|Other|Quality-of-life assessment|Ancillary studies
80026628|NCT02170350|Other|Questionnaire administration|Ancillary studies
80026629|NCT02171208|Drug|dimethyl fumarate - Reference form|single dose 240 mg
80026630|NCT02171208|Drug|dimethyl fumarate - Test form|single dose 240 mg
80026631|NCT03180307|Drug|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
80026632|NCT03180307|Device|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
80026633|NCT03180307|Procedure|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
80026634|NCT05634694|Other|No interventions.|No interventions.
80026635|NCT05139784|Other|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
80026636|NCT00140881|Drug|MK0476; montelukast sodium|
80026637|NCT00140881|Drug|Comparator: placebo|
80026638|NCT02917213|Other|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
80026639|NCT02917213|Other|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
80026640|NCT02917213|Other|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
80026641|NCT02917213|Other|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
80026642|NCT02917213|Procedure|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
80026643|NCT02917213|Other|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
80026644|NCT02917213|Other|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
79269663|NCT02125786|Radiation|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
79401967|NCT02344355|Drug|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
79401968|NCT02289924|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
79401969|NCT02279537|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
79401970|NCT02270359|Device|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
79401971|NCT02270359|Procedure|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
79866534|NCT04899934|Other|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
79401972|NCT02270359|Drug|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
79401973|NCT02256865|Drug|Ketoconazole|Ketoconazole is taken 4 times a day
79401974|NCT02256865|Drug|Hydrocortisone|Hydrocortisone is taken 3 times a day
79401975|NCT02256865|Drug|Testosterone|Testosterone gel is applied once a day
79866535|NCT04868110|Behavioral|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
79269664|NCT02125786|Procedure|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
79269665|NCT02125786|Drug|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
79269666|NCT02125786|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
79401976|NCT02256865|Drug|Placebo for ketoconazole|Placebo for ketoconazole
79401977|NCT02256865|Drug|Placebo for hydrocortisone|Placebo for hydrocortisone
79401978|NCT02256865|Drug|Placebo for testosterone|Placebo for testosterone
79401979|NCT02193191|Drug|Plerixafor|
79401980|NCT02188264|Drug|Cyclosporine|Given PO
79401981|NCT02188264|Other|Laboratory Biomarker Analysis|Correlative studies
79401982|NCT02188264|Other|Pharmacological Study|Correlative studies
79401983|NCT02188264|Drug|Selumetinib|Given PO
79401984|NCT02162849|Drug|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
79401985|NCT02162849|Drug|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
79401986|NCT02162849|Drug|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
79571967|NCT01810172|Device|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
79571968|NCT01810185|Drug|Low dose naltrexone|4.5 mg daily for 12 weeeks
80026645|NCT02848833|Drug|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
80026646|NCT02848833|Drug|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
80026647|NCT05634616|Device|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
80026648|NCT05634616|Device|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
79269667|NCT02125786|Device|Photon therapy|Participants will receive one or both: Photon or proton therapy.
79269668|NCT02125786|Device|Proton therapy|Participants will receive one or both: Photon or proton therapy.
79269669|NCT02107963|Biological|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
80026649|NCT02170506|Device|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
79269670|NCT02107963|Drug|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
79269671|NCT02107963|Drug|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
79401987|NCT02162849|Drug|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
80026650|NCT03539328|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
79571969|NCT01810185|Drug|Placebo|
80026651|NCT03539328|Drug|Gemcitabine|Chemotherapy medication
80026652|NCT03539328|Drug|Paclitaxel|Chemotherapy medication
79269672|NCT01928589|Radiation|PBI with sequential chemotherapy|270 cGy x15
79571970|NCT01810198|Procedure|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
79571971|NCT01810198|Procedure|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
79571972|NCT01810211|Other|Horizontal Adduction Stretch and Pendulums|
79571973|NCT01810211|Other|Modified Sleeper Stretch and Pendulum|
79571974|NCT01810224|Procedure|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
79571975|NCT01810237|Drug|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
79571976|NCT01810276|Other|Saline|400 mL of Saline will be given intravenously over 2 hours once
79571977|NCT01810276|Other|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
79571978|NCT01810315|Drug|TFV 1% gel|
79571979|NCT01810315|Drug|Estradiol vaginal cream|
79269673|NCT01928589|Other|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
79269674|NCT01892085|Behavioral|Early initiation|Initiation of breast milk expression <1 hour following delivery.
79269675|NCT01892085|Behavioral|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
79269676|NCT01892085|Behavioral|Late initiation|Initiation of milk expression >3-6 hours following delivery.
79269677|NCT00815880|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
79571980|NCT01810328|Other|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
79571981|NCT01810328|Other|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
79269678|NCT00265798|Drug|Sorafenib Tosylate|
79269679|NCT00265681|Behavioral|Phone counseling and written materials|
79269680|NCT03538171|Drug|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
79269681|NCT03538171|Drug|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
79269682|NCT03538171|Drug|Exemestane|Exemestane PO once daily on day 1-28.
79269683|NCT02176915|Behavioral|Group program|
79269684|NCT02176915|Behavioral|Print Materials|
79304431|NCT03288077|Other|Tryptophan|Beverage including tryptophan
79571982|NCT01810354|Drug|Cefazolin|
79571983|NCT01810367|Drug|ABX Combined With Cisplatin|
79571984|NCT01810367|Drug|Gemcitabine Combined With Cisplatin|
79571985|NCT01810393|Drug|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
79571986|NCT01810406|Procedure|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
79571987|NCT01810406|Procedure|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
80026653|NCT03539328|Drug|Liposomal Doxorubicin|Chemotherapy medication
80026654|NCT03361189|Device|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
80026655|NCT03361189|Device|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
80026656|NCT03579537|Other|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
80026657|NCT03579537|Other|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
80026658|NCT02171364|Procedure|Virtual ablation in based 3D CT of patient who diagnosed AF|
79866536|NCT04854967|Other|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
79269685|NCT05529836|Device|electroacupunture|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
80026659|NCT02171364|Procedure|conventional ablation based on physician's personal experience|
79866537|NCT04854967|Behavioral|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
79269686|NCT05529836|Device|sham electroacupuncture|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
79401988|NCT02162849|Behavioral|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
79401989|NCT02162849|Behavioral|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
79401990|NCT02162849|Other|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
79401991|NCT02162849|Other|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
79866538|NCT04854967|Behavioral|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
80026660|NCT05634460|Drug|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
80026661|NCT00111709|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
79401992|NCT02122913|Drug|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
80026662|NCT00111709|Drug|Comparator: placebo / Duration of Treatment - 1 day|
80026663|NCT02171442|Drug|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
80026664|NCT02171442|Drug|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
80026665|NCT02035527|Drug|sorafenib tosylate|Given daily PO in the a.m.
80026666|NCT02035527|Drug|cisplatin|Given IV over 1 hour following Docetaxel administration
80026667|NCT02035527|Drug|docetaxel|Given IV 1 hour prior to cisplatin administration
80026668|NCT02035527|Other|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
80026669|NCT00092131|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
80026670|NCT00092131|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
80026671|NCT05729854|Other|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
79304432|NCT03107065|Device|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
79571988|NCT01810419|Device|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
80026672|NCT02170584|Drug|BIBR 953 ZW IV|
80026673|NCT02170584|Drug|BIBR 1048 MS tablet|
80026674|NCT02170584|Drug|BIBR 1048 MS oral solution|
80026675|NCT02170584|Drug|BIBR 953 ZW IV Placebo|
80026676|NCT03577977|Drug|Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)|Betaferon was injected subcutaneously as prescribed by the treating physician.
80026677|NCT02175264|Genetic|Blood sample|
80026678|NCT02668783|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
79269687|NCT05529836|Device|sham acupuncture|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
79269688|NCT02030197|Behavioral|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
79269689|NCT02030197|Other|Control Group|no treatment
79269690|NCT05312216|Drug|Durvalumab plus Lenvatinib|"Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight < 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events"
79269691|NCT02256319|Drug|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
80026679|NCT02668783|Drug|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
79269692|NCT02256319|Drug|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
79866539|NCT04854967|Behavioral|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
79866540|NCT04854967|Behavioral|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
79269693|NCT04510285|Drug|Trastuzumab|Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).
79269694|NCT04510285|Drug|Pembrolizumab|Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
79269695|NCT05450432|Drug|Ketamine|Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
79269696|NCT05450432|Drug|Esketamine|After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
79401993|NCT02101905|Other|Laboratory Biomarker Analysis|Correlative studies
79401994|NCT02101905|Drug|Lapatinib|Given PO
79401995|NCT02101905|Drug|Lapatinib Ditosylate|Given PO
79401996|NCT02101905|Other|Pharmacological Study|Correlative studies
79401997|NCT02101905|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
79401998|NCT02070549|Drug|Trametinib|Given PO
79401999|NCT02048371|Drug|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
79866541|NCT04848636|Diagnostic Test|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
80026680|NCT02668783|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
80026681|NCT03577899|Biological|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
79402000|NCT02048371|Drug|Placebo|21 days on and 7 days off
79402001|NCT02022514|Other|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
79402002|NCT02022514|Drug|Conventional medical treatment|
79402003|NCT02015117|Other|Laboratory Biomarker Analysis|Correlative studies
79402004|NCT02015117|Other|Pharmacological Study|Correlative studies
79402005|NCT02015117|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
79402006|NCT02015117|Drug|Trametinib|Given PO
79402007|NCT02015117|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
79402008|NCT01957436|Drug|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
79402009|NCT01957436|Radiation|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
79402010|NCT01957436|Other|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
79402011|NCT01957436|Drug|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
79402012|NCT01946139|Procedure|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
79269697|NCT02179255|Drug|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
79269698|NCT02179255|Drug|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
79269699|NCT05529680|Other|Scapular mobilization and Scapular strengthening exercises|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
79402013|NCT01946139|Other|laboratory biomarker analysis|Correlative studies
79402014|NCT01946139|Other|questionnaire administration|Ancillary studies
79402015|NCT01946139|Procedure|quality-of-life assessment|Ancillary studies
79402016|NCT01896973|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
79402017|NCT01886885|Behavioral|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
79866542|NCT04844580|Drug|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
79402018|NCT01860261|Behavioral|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
79571989|NCT01810419|Device|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
79402019|NCT01849146|Drug|Adavosertib|Given PO
79571990|NCT01810458|Device|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
79571991|NCT01810458|Procedure|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
79571992|NCT01810458|Procedure|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
79571993|NCT01810458|Procedure|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
79571994|NCT01810458|Other|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
79731963|NCT02841124|Other|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
79731964|NCT00895414|Drug|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
79731965|NCT00895414|Drug|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
79731966|NCT02843464|Other|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
79731967|NCT02843620|Dietary Supplement|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
79866543|NCT04844580|Drug|Placebo|Aviptadil Placebo will be used for this arm.
79866544|NCT04827134|Drug|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
79269700|NCT05529680|Other|Conventional physical therapy program|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
79269701|NCT04425044|Other|Other|No Intervention
79269702|NCT02182063|Drug|BIBF 1120 low dose|
79269703|NCT02182063|Drug|BIBF 1120 high dose|
79402020|NCT01849146|Radiation|Radiation Therapy|Undergo radiation therapy
79402021|NCT01849146|Drug|Temozolomide|Given PO
79731968|NCT02843620|Other|Placebo|Excipients only
79866545|NCT04827134|Drug|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
79866546|NCT04826276|Other|smoking abstinence|participants will be asked to not smoke for at least 12 hours
79866547|NCT04826276|Other|smoking satiety|participants will be asked to smoke as usual
79866548|NCT04818593|Device|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
79866549|NCT04818593|Other|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
79866550|NCT04811079|Other|419 nm Spectacle Filter|TEST
79402022|NCT01783925|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
79866551|NCT04811079|Other|437 nm Spectacle Filter|TEST
79866552|NCT04811079|Other|456 nm Spectacle Filter|TEST
79866553|NCT04811079|Other|476 nm Spectacle Filter|TEST
79866554|NCT04811079|Other|373 nm Spectacle Filter|CONTROL
80026682|NCT03577899|Biological|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
80026683|NCT03577899|Biological|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
79269704|NCT05444816|Device|Personalised Neurofeedback training at home|"The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed."
79269705|NCT02182141|Drug|BIBF 1120 ES|
79402023|NCT01737619|Procedure|Computed Tomography|Undergo PET/CT
79402024|NCT01737619|Drug|Indocyanine Green Solution|Given via superficial and deep cervical injection
79402025|NCT01737619|Other|Laboratory Biomarker Analysis|Correlative studies
79571995|NCT01810458|Procedure|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
79571996|NCT01810458|Drug|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79866555|NCT04804943|Device|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
79866556|NCT04793516|Other|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
79866557|NCT04736953|Drug|Sirolimus|Sirolimus
79866558|NCT04736953|Other|Placebo|Placebo
79866559|NCT04707911|Behavioral|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
80026684|NCT02175342|Drug|Tiotropium 0.625 mcg/puff|
80026685|NCT02175342|Drug|Tiotropium 1.25 mcg/puff|
79402026|NCT01737619|Procedure|Lymph Node Mapping|Undergo lymph node mapping
79866560|NCT04702737|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
79866561|NCT04685421|Drug|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
80026686|NCT02175342|Drug|Tiotropium 2.5 mcg/puff|
79402027|NCT01737619|Procedure|Lymphadenectomy|Undergo full lymphadenectomy
79402028|NCT01737619|Procedure|Positron Emission Tomography|Undergo PET/CT
79402029|NCT01730781|Radiation|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
79402030|NCT01685008|Drug|MOR00208 (formerly Xmab 5574)|
80026687|NCT02175342|Drug|Tiotropium 5 mcg/puff|
80026688|NCT02175342|Drug|Placebo solution|
80026689|NCT02175342|Drug|Tiotropium-18 lactose powder|
80026690|NCT02175342|Drug|Placebo lactose powder|
80026691|NCT02175342|Drug|Tiotropium 10 mcg/puff|
79731969|NCT05334394|Other|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
79731970|NCT05334394|Other|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
80026692|NCT02175342|Device|Respimat|
79731971|NCT01822288|Drug|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
79731972|NCT01822288|Drug|Estradiol & medroxyprogesterone acetate|Estradiol & medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
79731973|NCT02843542|Device|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
79866562|NCT04683042|Device|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
79866563|NCT04683042|Other|PT only|Routine PT therapy only
79866564|NCT04680975|Drug|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
80026693|NCT02175342|Device|Handihaler|
79269706|NCT04425278|Device|transcranial direct current stimulation with real current|transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
79866565|NCT04680455|Other|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
79866566|NCT04673786|Biological|CT-P43|45mg or 90mg dose subcutaneous administration
79866567|NCT04673786|Biological|Stelara|45mg or 90mg dose subcutaneous administration
79402033|NCT01638533|Other|Pharmacological Study|Correlative studies
79402034|NCT01638533|Drug|Romidepsin|Given IV
79402035|NCT01624805|Biological|Anti-Thymocyte Globulin|Given IV
79402036|NCT01624805|Drug|Cyclosporine|Given PO
79402037|NCT01624805|Biological|Filgrastim|Given SC
79866568|NCT04672798|Behavioral|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
79402038|NCT01624805|Drug|Methylprednisolone|Given IV or PO
79402039|NCT01624805|Biological|Pegfilgrastim|Given SC
79402040|NCT01623167|Drug|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
79731974|NCT02843542|Device|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
79866569|NCT04672798|Behavioral|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
80026694|NCT02504203|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
80026695|NCT04236934|Other|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
79269707|NCT04425278|Device|transcranial direct current stimulation with sham current|transcranial direct current stimulation with sham current is a placebo
79269708|NCT02182219|Drug|BIBF 1120|
79269709|NCT05303480|Drug|Chlormethine|Chlormethine gel 0.016%
79269710|NCT02177149|Device|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
79304433|NCT00777127|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
79402041|NCT01623167|Drug|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
79731975|NCT02811952|Other|without intervention|without intervention
79866570|NCT04670783|Procedure|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
80026696|NCT02171520|Drug|Dabigatran etexilate generation I|
80026697|NCT02171520|Drug|Dabigatran etexilate generation II|
79571997|NCT01810458|Drug|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79571998|NCT01810458|Drug|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79731976|NCT01328626|Drug|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
79571999|NCT01810458|Drug|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79731977|NCT02842918|Procedure|Spinal Manual Therapy|
79731978|NCT02842918|Procedure|Spinal Range of Motion|
79731979|NCT02840812|Drug|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
79731980|NCT01212770|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
79866571|NCT04666792|Drug|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
79269711|NCT02177149|Device|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
79269712|NCT02182297|Drug|BI 201335 NA in single rising doses|
79269713|NCT02182297|Drug|Placebo|
79269714|NCT02182375|Drug|BI 201335 NA|
79269715|NCT02182375|Drug|Raltegravir|
79269716|NCT02179411|Other|tilt test|
79269717|NCT02179567|Drug|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
79269718|NCT02179567|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
79269719|NCT02182453|Drug|BI 10773 - single rising dose|
79269720|NCT02182453|Drug|Placebo|
79269721|NCT02576054|Biological|V501|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
79269722|NCT02182531|Drug|Epinastine|
79269723|NCT02182531|Drug|Pseudoephedrine|
79269724|NCT02182531|Drug|Epinastine + Pseudoephedrine combination|
79731981|NCT01212770|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
79731982|NCT01212770|Drug|Placebo|
79731983|NCT05334316|Drug|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
79731984|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
79731985|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
79731986|NCT00598273|Drug|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
79731987|NCT05334238|Drug|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
79731988|NCT02842840|Behavioral|Patient-based intervention|
79731989|NCT02842840|Behavioral|Family based intervention|
79866572|NCT04647929|Device|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
79866573|NCT04647929|Procedure|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
79731990|NCT02842840|Other|Routine counseling|
79866574|NCT04611399|Behavioral|VR for psychoeducation and relaxation|"Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden)."
80026698|NCT03069118|Behavioral|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
80026699|NCT03069118|Behavioral|Control - Resource List|Tailored list of resources.
80026700|NCT00092053|Drug|Placebo|tablets
80026701|NCT00092053|Drug|ibandronate|50 mg tablets
80026702|NCT03068182|Device|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
79269725|NCT03537313|Procedure|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
79269726|NCT03537313|Procedure|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
79572000|NCT01810458|Drug|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79572001|NCT01810458|Drug|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79572002|NCT01810458|Drug|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
79572003|NCT01810471|Device|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
79572004|NCT01810497|Procedure|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
79866575|NCT04611399|Other|Control (CR)|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
79269727|NCT05531474|Procedure|Bariatric Surgery|Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.
79269728|NCT05531474|Behavioral|Medical Weight Management|The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
79269729|NCT03537235|Device|Libramed|
79269730|NCT03537235|Device|Placebo|
79269731|NCT02177305|Drug|0.02 mcg tiotropium solution|
79269732|NCT02177305|Drug|0.04 mcg tiotropium solution|
79269733|NCT02177305|Drug|0.08 mcg tiotropium solution|
79269734|NCT02177305|Drug|0.16 mcg tiotropium solution|
79269735|NCT02177305|Drug|0.28 mcg tiotropium solution|
79269736|NCT02177305|Drug|0.40 mcg tiotropium solution|
79269737|NCT02177305|Drug|Placebo solution|
79269738|NCT05531396|Other|Agility Training|Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.
79269739|NCT05531396|Other|Health Education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
79866576|NCT04605978|Drug|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
79866577|NCT04605978|Drug|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
79866578|NCT04602533|Drug|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
80026703|NCT03068182|Device|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
80026704|NCT03068182|Other|Exercise|
80026705|NCT00101010|Biological|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
79269740|NCT02182609|Drug|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
79269741|NCT05529368|Behavioral|Conventional Exercise and Tai Chi Exercise interventions|Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
79269742|NCT02182765|Drug|Nevirapine|
79402042|NCT01623167|Drug|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
79572005|NCT01810510|Procedure|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
79731991|NCT04161625|Behavioral|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis&Svettis)"
79866579|NCT04602533|Drug|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
79866580|NCT04597671|Drug|Durvalumab|Durvalumab is used as standard of care
79866581|NCT04597671|Radiation|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
79866582|NCT04584320|Other|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
79866583|NCT04583969|Biological|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
79866584|NCT04583969|Other|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
79866585|NCT04583969|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
79866586|NCT04575857|Drug|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
79866587|NCT04575857|Drug|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
79866588|NCT04569708|Other|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
79866589|NCT04561115|Biological|Gamunex-C|Intravenous infusion.
79866590|NCT04561115|Biological|IVIG-PEG|Intravenous infusion.
79866591|NCT04549779|Procedure|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
79866592|NCT04549779|Procedure|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
79866593|NCT04549779|Procedure|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
79866594|NCT04509245|Behavioral|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
79866595|NCT04502706|Drug|GS-0189|GS-0189 will be administered intravenously.
79866596|NCT04502706|Drug|Rituximab|Rituximab will be administered intravenously.
80026706|NCT00101010|Biological|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
80026707|NCT00101010|Biological|Rituximab|375 mg/m^2 intravenous piggy back (IVPB) on day 1, administered 1st
80026708|NCT00101010|Drug|Cyclophosphamide|750 mg/m^2 IVPB on day 1
80026709|NCT00101010|Drug|Pegylated liposomal doxorubicin hydrochloride|40 mg/m^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
79731992|NCT02641951|Other|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
79731993|NCT02641951|Other|Pecs II block|Ultrasound guided Pecs II block
80026710|NCT00101010|Drug|Prednisone|40 mg/m^2 oral days 1 - 5.
80026711|NCT00101010|Drug|Vincristine Sulfate|2 mg IV, day 1
79269743|NCT02182765|Drug|Amprenavir|
79402043|NCT01623167|Drug|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
79402044|NCT01587352|Other|Laboratory Biomarker Analysis|Correlative studies
80026712|NCT03069040|Procedure|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
80026713|NCT03069040|Procedure|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
79866597|NCT04486833|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
79269744|NCT02182765|Drug|Abacavir|
79269745|NCT02177383|Dietary Supplement|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
79269746|NCT02177383|Dietary Supplement|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
80026714|NCT03539172|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
80026715|NCT05729698|Device|Baby warmer swaddle|Baby Swaddle with Heating System
80026716|NCT05729698|Other|polyethylene bag|polyethylene food bag
79269747|NCT03536689|Diagnostic Test|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
79269748|NCT02179645|Drug|GRC 27864|
79269749|NCT02179645|Drug|Celecoxib|
79269750|NCT02179645|Drug|Placebo|
79269751|NCT03537157|Drug|Rifaximin delayed release tablets|Active intervention
79269752|NCT03537157|Other|Placebo|Comparator placebo
79269753|NCT01606202|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
79402045|NCT01587352|Drug|Vorinostat|Given PO
80026717|NCT02175420|Biological|BCG|
80026718|NCT02175420|Biological|TFV|
80026719|NCT03586011|Behavioral|Predicting factors for increased physical activity|
80026720|NCT02170740|Drug|BIBR 1048 MS - low dose|
80026721|NCT02170740|Drug|BIBR 1048 MS - high dose|
80026722|NCT02170740|Drug|BIBR 1048 MS + Pantoprazole|
80026723|NCT02848599|Drug|morphine|
80026724|NCT02848599|Drug|levobupivacaine|
80026725|NCT02175498|Drug|Homoeopathic medicines|4 pills once a week of the indicated Similimum
80026726|NCT03069274|Behavioral|Intervention|General nutritional recommendations, change drinking habits
80026727|NCT03069274|Behavioral|General nutritional recommendations|Only general nutritional recommendations were given
80026728|NCT02171598|Drug|Clopidogrel|
80026729|NCT02171598|Drug|Dabigatran high dose|
79402046|NCT01556490|Device|TheraSphere|Yttrium 90 microspheres
79731994|NCT04163029|Procedure|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
79866598|NCT04486833|Drug|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
79866599|NCT04486833|Drug|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
79866600|NCT04468776|Drug|Zolpidem|Zolpidem, as prescribed by physician
80026730|NCT02171598|Drug|Dabigatran low dose|
80026731|NCT03579303|Other|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
80026732|NCT03068962|Other|beetroot Juice|Beetroot Juice
80026733|NCT03068962|Other|Buxton water|natural mineral water
80026734|NCT03068962|Other|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
80026735|NCT02171676|Drug|Docetaxel|
80026736|NCT02171676|Drug|BIBW 2992|
79866601|NCT04468776|Behavioral|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
79269754|NCT01606202|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
79572006|NCT01810510|Procedure|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
79866602|NCT04468776|Drug|Trazodone|Trazodone, as prescribed by physician
79866603|NCT04456673|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
80026737|NCT03579225|Device|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
80026738|NCT02170818|Other|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
80026739|NCT02170818|Other|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
80026740|NCT03577743|Drug|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
80026741|NCT04794790|Drug|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
79572007|NCT01810523|Behavioral|Narrative|Narrative form as described above.
80026742|NCT02171754|Drug|BIBW 2992|
80026743|NCT02171754|Drug|Ritonavir|
80026744|NCT02238327|Procedure|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
80026745|NCT02238327|Procedure|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
79572008|NCT01810523|Behavioral|Control|Blank piece of paper
79572009|NCT01810536|Device|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
79572010|NCT01810536|Device|Venturi mask|
79572011|NCT01810549|Drug|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
79572012|NCT01810549|Drug|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
79572013|NCT01810562|Other|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
79572014|NCT01810601|Drug|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
79572015|NCT01810614|Other|ADPKD Diet|Diet specifically designed for people with ADPKD
79572016|NCT01810627|Radiation|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
79866604|NCT04456673|Drug|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
79866605|NCT04456673|Drug|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
79866606|NCT04456673|Drug|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
79866607|NCT04456673|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
80026746|NCT02238327|Procedure|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
80026747|NCT02238327|Procedure|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to <88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
80026748|NCT02238327|Radiation|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
80026749|NCT02238327|Procedure|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
80026750|NCT02238327|Procedure|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
79402047|NCT01453660|Other|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
79731995|NCT04161703|Procedure|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
79572017|NCT01810640|Procedure|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
79572018|NCT01810653|Drug|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
79572019|NCT01810653|Drug|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
79731996|NCT04161703|Procedure|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A & B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
79731997|NCT02636491|Device|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
79866608|NCT04416269|Drug|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
79866609|NCT04416269|Drug|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
79866610|NCT04416269|Drug|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.
80026751|NCT02995369|Device|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
80026752|NCT02995369|Other|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
79572020|NCT01810679|Device|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
79572021|NCT01810731|Biological|Quadrivalent Inactivated Influenza Vaccine (QIV)|
80026753|NCT02171832|Drug|BI 1744 CL, low dose|
80026754|NCT02171832|Drug|BI 1744 CL, high dose|
79572022|NCT01810731|Biological|Inactivated Polio Vaccine|
79572023|NCT01810731|Biological|Double Dose QIV|
79572024|NCT01810744|Other|capillaroscopy|
79572025|NCT01810744|Other|blood pressure measurement|
79572026|NCT01810757|Radiation|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
79572027|NCT01810757|Radiation|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
79866611|NCT04416269|Device|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
79866612|NCT04400292|Other|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
80026755|NCT05633524|Other|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
80026756|NCT05225701|Behavioral|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
80026757|NCT05225701|Behavioral|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
79731998|NCT02636491|Device|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
79731999|NCT00657007|Biological|belimumab|"1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
79866613|NCT04400292|Device|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
80026758|NCT02175654|Drug|Regorafenib|
79732000|NCT00657007|Biological|belimumab|"4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
79866614|NCT04400292|Procedure|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
80026759|NCT02171910|Drug|Doxapram|
79866615|NCT04398017|Procedure|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
79866616|NCT04394351|Drug|Dupilumab|Single-use, prefilled syringe
79866617|NCT04394351|Drug|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
80026760|NCT02171910|Drug|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
80026761|NCT05061355|Procedure|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
80026762|NCT02975167|Other|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
79572028|NCT01810770|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
79732001|NCT00657007|Biological|belimumab|"10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
79732002|NCT00657007|Biological|belimumab|"20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
79572029|NCT01810796|Drug|Ranolazine|Ranolazine versus placebo
79572030|NCT01810809|Procedure|articular lavage with saline injection|Patients will receive articular lavage with saline injection
79572031|NCT01810809|Drug|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
79572032|NCT01810809|Drug|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
79572033|NCT01810809|Drug|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
79572034|NCT01810848|Device|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
79572035|NCT01810848|Other|Control|Control is puncture of the skin at the site of the knee.
79732003|NCT00657007|Biological|Placebo|"IV (in the vein) on Day 0 (Cohorts 1-4).~IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
80026763|NCT02975167|Other|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
80026764|NCT02975167|Procedure|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
79866618|NCT04374461|Drug|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
79866619|NCT04374461|Other|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
80026765|NCT02975167|Behavioral|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
80026766|NCT02975167|Behavioral|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
79402048|NCT01453660|Other|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, & urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure & heart rate, including orthostatics & Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, & urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
79572036|NCT01810874|Procedure|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
79732004|NCT04318652|Drug|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
79732005|NCT04161547|Drug|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
79866620|NCT04366258|Device|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
79866621|NCT04366258|Device|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
79572037|NCT01810874|Procedure|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
79402049|NCT01434316|Drug|Dinaciclib|Given IV
79732006|NCT04161547|Drug|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
79732007|NCT04161547|Drug|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
79732008|NCT04161547|Drug|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
79866622|NCT04343443|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
79269755|NCT05529212|Procedure|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
79269756|NCT05282030|Drug|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
79304434|NCT00777127|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
79402050|NCT01434316|Drug|Veliparib|Given PO
79572038|NCT01810887|Drug|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
79732009|NCT02887898|Device|Automated bolus calculator|
79732010|NCT02887898|Other|Education|
80026767|NCT02975167|Procedure|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
80026768|NCT04518930|Other|Peanuts or plain Greek yogurt|Two different types of dietary snacks
80026769|NCT03068884|Device|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
80026770|NCT03068884|Dietary Supplement|L-Tyrosine|Administration of 2 grams tyrosine
79572039|NCT01810887|Drug|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
80026771|NCT03068884|Device|Transcranial direct current stimulation (sham)|Sham tDCS
80026772|NCT03068884|Dietary Supplement|Cellulose (placebo)|Administration of 2 grams cellulose
79732011|NCT02633995|Procedure|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
79866623|NCT04343443|Procedure|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
80026773|NCT02175732|Behavioral|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
80026774|NCT02175732|Behavioral|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
80026775|NCT04957225|Behavioral|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
80026776|NCT02178306|Drug|Telmisartan low dose|
80026777|NCT02178306|Drug|Telmisartan high dose|patients switch to high dose if mean SBP >= 85 mmHg after 4 weeks of treatment
79732012|NCT02633917|Behavioral|Motor control exercises|exercises to strength the lumbar musculature and control the posture
79732013|NCT02633917|Behavioral|Standard exercises|general exercises
79732014|NCT02633683|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
79402056|NCT01351909|Drug|Cyclophosphamide|Given PO
79402057|NCT01351909|Other|Laboratory Biomarker Analysis|Correlative studies
79402058|NCT01351909|Drug|Veliparib|Given PO
79732015|NCT01211522|Drug|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
79732016|NCT01211522|Drug|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
79732017|NCT01211522|Drug|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
79866624|NCT04343443|Procedure|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
79402059|NCT01351896|Other|Laboratory Biomarker Analysis|Correlative studies
79402060|NCT01351896|Drug|Lenalidomide|Given PO
79402061|NCT01351896|Other|Pharmacological Study|Correlative studies
79402062|NCT01351896|Biological|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
79402063|NCT01347294|Drug|Bleomycin|Intralesional
79402064|NCT01347294|Drug|Fibrovein|Intralesional
79402065|NCT01347294|Drug|Bleomycin + Fibrovein|Intralesional
79572040|NCT01810900|Device|Protescal|
79572041|NCT01810926|Biological|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
79572042|NCT01810926|Drug|Rituximab|single infusion of200 mg/m2 on day -1
79572043|NCT01810926|Drug|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
79572044|NCT01810926|Drug|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
79572045|NCT01810926|Drug|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
79866625|NCT04343443|Procedure|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
79866626|NCT04343443|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
79866627|NCT04343430|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
79866628|NCT04343430|Procedure|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
79572046|NCT01810926|Drug|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
80026778|NCT02178306|Drug|Placebo|Run-in phase
80026779|NCT05729386|Drug|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
80026780|NCT05729386|Drug|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
80026781|NCT05729386|Drug|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
80026782|NCT05729386|Drug|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
80026783|NCT02178384|Procedure|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
80026784|NCT02178384|Device|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
79572047|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
79572048|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
79572049|NCT01810965|Procedure|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
79732018|NCT04161469|Procedure|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
80026785|NCT02178384|Procedure|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
80026786|NCT03068806|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
80026787|NCT05729308|Procedure|caudal epidural block|"The patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound guidance using SonoSite M Turbo(USA).The scanning probe is the linear multi-frequency 6-13 MHz transducer (L25 x 6-13 megahertz linear array)that is covered in sterile plastic bag.Short axis (transverse view) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal view) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.25% bupivacaine will expand the epidural space"
80026788|NCT05729308|Procedure|bilateral erector spinae plane block|The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of T12. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T12 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 15 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side
80026789|NCT05729308|Procedure|general anesthesia with intravenous analgesia.|"Multimodal therapy with acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs) will be used.~Vital data will be monitored as mentioned Intraoperatively, if the pulse rate and/or mean blood pressure increased above 20% of the baseline, IV fentanyl will be administered as an incremental dose of 50 µg.~The patients will be monitored for heart rate and blood pressure at regular 10-minute intervals. If blood pressure decreased more than 20% from baseline, then the patient will receive 500 mL saline infusion; if no response is seen, then 5 mg ephedrine will be administered. If heart rate decreased to 45 beats per minute, an IV injection of 0.1 mg /kg atropine will be administered."
80026790|NCT00778999|Drug|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
80026791|NCT02171988|Drug|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
80026792|NCT02171988|Drug|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
80026793|NCT02171988|Drug|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
80026794|NCT02171988|Drug|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
79402066|NCT01281176|Drug|Carboplatin|Given IV
79402067|NCT01281176|Other|Laboratory Biomarker Analysis|Correlative studies
79572050|NCT01810978|Dietary Supplement|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
79572051|NCT01810978|Dietary Supplement|Maltodextrin|same amount of maltodextrin per day will be given as placebo
79572052|NCT01811017|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
79572053|NCT01811056|Drug|Mifepristone|Mifepristone use outside of the center
79732019|NCT04161469|Procedure|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
79732020|NCT01211288|Device|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
79732021|NCT02641795|Device|Minimally invasive robotic cochlear implantation|
79732022|NCT05404724|Drug|itraconazole、 SHR0302 tablets|Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
79572054|NCT01811069|Procedure|Head up|30˚ reverse trendelenburg body position
79572055|NCT01811082|Drug|Coenzyme A|Coenzyme A 400mg per day.
79572056|NCT01811082|Drug|Pantethine|Pantethine 600mg per day.
79866629|NCT04343430|Procedure|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
79866630|NCT04343430|Procedure|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
80026795|NCT05729230|Behavioral|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
80026796|NCT00725413|Drug|etonogestrel implant (Implanon)|subdermal etonogestrel implant
80026797|NCT02172066|Behavioral|Narrative Exposure Therapy (NET)|
80026798|NCT02631850|Behavioral|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
79572057|NCT01811095|Other|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
80026799|NCT02631850|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
80026800|NCT02631850|Behavioral|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
80026801|NCT02631850|Behavioral|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
80026802|NCT00103038|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
80026803|NCT00103038|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
79402068|NCT01281176|Drug|Paclitaxel|Given IV
79572058|NCT01811121|Drug|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
79572059|NCT01811121|Drug|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
79732023|NCT02636257|Procedure|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
79732024|NCT02636257|Procedure|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
79572060|NCT01811134|Device|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
79572061|NCT01811134|Device|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
79572062|NCT01811160|Drug|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
79402069|NCT01281176|Other|Pharmacological Study|Correlative studies
79402070|NCT01281176|Drug|Vorinostat|Given PO
79572063|NCT01811160|Drug|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
79866631|NCT04343430|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
79866632|NCT04333420|Drug|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
79866633|NCT04333420|Drug|BSC|Phase II study part: BSC
79866634|NCT04333420|Drug|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
79866635|NCT04333420|Drug|Placebo + SOC|Phase III study part: Placebo + SOC
79866636|NCT04332692|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
79866637|NCT04332692|Procedure|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
79866638|NCT04332692|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
79402071|NCT01181947|Device|TEVAR|Thoracic endovascular aneurysm repair
79402076|NCT01133990|Drug|FOLFIRI|FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m^2) and CIV infusion (2400 mg/m^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
79866639|NCT04332692|Procedure|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
79866640|NCT04332692|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
80026804|NCT00103038|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
80026805|NCT00103038|Drug|Ferumoxytol|Given IV
79402077|NCT01133990|Drug|E7820|E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
79402078|NCT01133990|Drug|Bevacizumab|Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
79402079|NCT01115387|Other|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
79572064|NCT01811173|Other|Nurse-physician comprehensive care|"Components of the intervention include:~Complete assessment of the patient's and family's needs conducted by the nurse.~Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~Multimorbid care plan integrating all care aspects.~Action Plan for patients, supporting self management~Proactive monitoring according to the plan."
79732025|NCT00656461|Drug|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
79732026|NCT02633761|Drug|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
79732027|NCT02633761|Drug|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
79732028|NCT02633761|Drug|Misoprostol 200mcg|Buccal misoprostol 200mcg
79732029|NCT04161313|Other|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
79866641|NCT04268485|Diagnostic Test|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
80026806|NCT00103038|Drug|Gadolinium|Given IV
79402080|NCT01115387|Other|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
79402081|NCT01004952|Behavioral|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
79866642|NCT04247165|Drug|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
79866643|NCT04247165|Drug|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
79866644|NCT04247165|Drug|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
80026807|NCT00103038|Procedure|MRI-Based Angiogram|Undergo MRA
80026808|NCT00620035|Drug|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
80026809|NCT03068104|Other|No intervention|
79402082|NCT00910429|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
79402083|NCT00879853|Behavioral|Interpersonal Therapy|
79572065|NCT01811251|Drug|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
79402084|NCT00878163|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
79572066|NCT01811264|Behavioral|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
79732030|NCT04161313|Other|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
79732031|NCT04161313|Other|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
79866645|NCT04247165|Drug|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
79866646|NCT04247165|Radiation|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~Prescription dose shall be according to the following specifications:~A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~Pauses are accepted but the treatment should be delivered within 10 calendar days.~PTV should be covered by 95% isodose (PTV D99% >95%)."
79866647|NCT04234867|Drug|Dapagliflozin|once daily for 5 days
80026810|NCT03068728|Device|Arista|
80026811|NCT03068728|Device|Nexfoam|
80026812|NCT03068728|Device|Nasopore|
80026813|NCT02175888|Dietary Supplement|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
80026814|NCT02175888|Dietary Supplement|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
80026815|NCT05577637|Drug|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
80026816|NCT02176044|Drug|Sodium Nitroprusside infusion|
80026817|NCT02176044|Other|Placebo|
80026818|NCT03067870|Biological|Stem Cell Transplantation|"Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~Transplantation of autologous bone marrow derived stem cells in joints."
80026819|NCT05054491|Behavioral|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
80026820|NCT02176122|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
80026821|NCT02176122|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
80026822|NCT04887064|Drug|Sotorasib|Sotorasib will be administered as an oral tablet.
79269757|NCT05443880|Behavioral|Exercise|The exercise intervention will focus on working the core muscles, starting with low-intensity isometric contraction of the core muscles that stabilize the trunk; increasing intensity by performing functional tasks (phase 1: independent isometric contraction of transversus-abdominis and multifidus, phase 2: co-contraction and functional tasks of the deep trunk muscles; phase 3: functional task with load; phase 4: functional task with unstable surface)
79269758|NCT05443880|Behavioral|Exercise + mindfulness|The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group (using appreciative inquiry) and a Mindfulness practice. Participants will be provided with workbooks, audios with guided meditations, and instructions for practice at home. In addition, the Exercise + mindfulness intervention will include the exercise program described in the exercise intervention.
79269759|NCT05443880|Other|Control group|The control group will be provided with the usual care received in the Physical Medicine and Rehabilitation Service: stretching, breathing and motor control exercises 2 days / week (45 minutes per session) during a period of 8 weeks.
79572067|NCT01811277|Drug|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
79732032|NCT04161313|Other|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
79866648|NCT04234867|Drug|Placebo oral tablet|once daily for 5 days
79269760|NCT01493960|Drug|Cobitolimod|30 mg rectal dose at week 0 and 4
79269761|NCT01493960|Drug|Placebo|Rectal dose at week 0 and 4
79269762|NCT03537079|Other|hypoxia air|Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
79269763|NCT02179723|Device|Leukosan Adhesive|Leukosan adhesive applied to one wound
79572068|NCT01811381|Drug|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
79572069|NCT01811381|Behavioral|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
79732033|NCT04161313|Other|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
79269764|NCT02179723|Device|Transcutaneous suture|Transcutaneous suture applied to one wound
79269765|NCT02179879|Other|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
79269766|NCT05524922|Other|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
79269767|NCT02180035|Dietary Supplement|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
79269768|NCT02180035|Dietary Supplement|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
79269769|NCT02180035|Behavioral|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
79732034|NCT02633605|Device|First Sense Medical®|
79732035|NCT00883753|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
79732036|NCT02641717|Other|vaginal swab|
79732037|NCT04162639|Biological|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
79866649|NCT04234867|Other|Stress|single dose after last administration of experimental drug
79866650|NCT04234867|Other|Placebo Stress|single dose after last administration of experimental drug
79866651|NCT04219280|Drug|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
79866652|NCT04219280|Drug|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
80026823|NCT02967757|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
80026824|NCT05632276|Device|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
80026825|NCT02261298|Drug|ONO-4538|
79402085|NCT00878163|Drug|Erlotinib Hydrochloride|Given PO
79402086|NCT00878163|Drug|Gemcitabine Hydrochloride|Given IV
79732038|NCT01210664|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10^8 cells. The second cohort will receive 0.4 x10^8 cells. The third cohort will receive 3.2 x10^8 cells. The fourth cohort will receive 26 x10^8 cells.
79866653|NCT04186637|Drug|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
80026826|NCT02178618|Device|Deployment of Partially covered biliary self expandable metal stent|
80026827|NCT02178618|Device|Deployment of uncovered biliary self expandable metal stent|
80026828|NCT02176200|Drug|Berodual® Respimat®, low inspiratory flow rate|
80026829|NCT02176200|Drug|Berodual® Respimat®, medium inspiratory flow rate|
80026830|NCT02176200|Drug|Berodual® Respimat®, high inspiratory flow rate|
79572070|NCT01811381|Behavioral|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
80026831|NCT02176200|Drug|Berodual® HFA-MDI, low inspiratory flow rate|
79269770|NCT05531240|Procedure|Prostate Artery Embolization|Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
79732039|NCT02633839|Drug|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
79732040|NCT02633839|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
80026832|NCT02176200|Drug|Berodual® HFA-MDI, medium inspiratory flow rate|
80026833|NCT02176200|Drug|Berodual® HFA-MDI, high inspiratory flow rate|
79732041|NCT02636335|Device|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
79866654|NCT04177693|Dietary Supplement|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
80026834|NCT03577665|Radiation|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
80026835|NCT03537612|Drug|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
80026836|NCT03537612|Other|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
80026837|NCT03579147|Device|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
80026838|NCT02172144|Drug|BI 1744 CL solution for inhalation|
80026839|NCT02172144|Drug|Placebo matching BI 1744 CL|
79269771|NCT05531240|Procedure|Transurethral Prostate Resection (TURP)|Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
79269772|NCT02180113|Device|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
80026840|NCT02172144|Drug|Moxifloxacin (Avalox®)|
80026841|NCT03579069|Other|Ductus venosus Doppler|Ductus venosus Doppler
79269773|NCT05524844|Other|Sample Collection|Saliva, gastric aspirate, and esophageal brushings and biopsies.
79732042|NCT02632903|Drug|Zoledronic acid|
80026842|NCT05729074|Drug|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
80026843|NCT05729074|Drug|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
80026844|NCT05729074|Drug|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
80026845|NCT05729074|Drug|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
80026846|NCT05729074|Drug|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
80026847|NCT05729074|Drug|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
79269774|NCT05524844|Other|Endoscopy results|Results from standard of care endoscopy (scheduled separate of study)
79269775|NCT05524844|Other|Dietary questionnaire|Diet History Questionnaire (II)
79269776|NCT02180191|Other|Comparison of the gut microbiota composition|
79269777|NCT02180269|Drug|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
79572071|NCT01811381|Dietary Supplement|Placebo|Subjects will take 4 capsules x BID of placebo
79572072|NCT01811407|Behavioral|Precommitment announcement|
79572073|NCT01811407|Behavioral|Results announcement|
79572074|NCT01811407|Behavioral|Walking program|
79572075|NCT01811420|Procedure|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
79572076|NCT01811420|Procedure|Conventional method|Dental caries removal using rotatory instrument
79732043|NCT00657397|Drug|Methadone|Methadone sirup once daily
79732044|NCT04160611|Drug|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
79732045|NCT04160299|Behavioral|Dance-based exergaming|Dance sessions
79732046|NCT02535559|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
79866655|NCT04177693|Drug|Clomiphene Citrate|100 mg for 5 days
79866656|NCT04177693|Drug|Letrozole|5 mg for 5 days
79866657|NCT04169009|Biological|Zostavax|Intradermal injection of Zostavax
79866658|NCT04169009|Biological|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
80026848|NCT05729074|Drug|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
80026849|NCT05729074|Drug|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
80026850|NCT02176512|Drug|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
80026851|NCT02176512|Drug|BIBR 277 SE|Treatment B - Monocomponent
80026852|NCT02176512|Drug|HCTZ|Treatment B -Monocomponent
79866659|NCT04146064|Other|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
79269778|NCT02180269|Drug|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
79866660|NCT04129229|Device|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
79866661|NCT04118387|Drug|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
79866662|NCT04118387|Drug|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
79269779|NCT02180269|Drug|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
79269780|NCT02180269|Drug|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
79269781|NCT05531162|Other|Cognition and emotional neuropsychologicl evaluations|Cognitive ans sensory performances during repetitive micro and partial gravity exposure
79269782|NCT03536611|Drug|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
79732047|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
79732048|NCT04161001|Drug|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
79269783|NCT03536611|Drug|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
79572077|NCT01811446|Device|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
79572078|NCT01811459|Drug|Quetiapine|PO
79572079|NCT01811459|Drug|Haloperidol|IV
79732049|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
79732050|NCT02636413|Drug|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
79572080|NCT01811459|Drug|Placebo|PO or IV
79732051|NCT02636413|Dietary Supplement|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
79269784|NCT02630459|Drug|Placebo|placebo via subcutaneous injection
79269785|NCT02630459|Drug|Erenumab|erenumab via subcutaneous injection
79732052|NCT04160767|Drug|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
79732053|NCT04160767|Behavioral|Gluten free diet|Gluten free diet will be encouraged in both arms
79269786|NCT02630459|Drug|Erenumab|erenumab via autoinjector (AI)/pen
79269787|NCT05528354|Drug|VEN and DEC based conditioning regimen|"Patients with age<50 years and HCT-CI<3:~Haploidentical transplantation: AraC 2g/m2 d-10~d-9, BU 0.8mg/kg q6h d-8~-6, CTX 1.8g/m2 d-5~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5~-2, VEN 400mg/d d-15~-9, DEC 20mg/m2 d-15~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7~-4, CTX 60mg/kg d-3~d-2, Meccnu 250mg/m2 d-1, VEN d-12~-8, DEC 20mg/m2 d-12~-6, and ATG for the unrelated donor type.~Patients with age>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10~-5, BU 0.8mg/kg q6h d-7~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4~-1, VEN d-15~-9, DEC 20mg/m2 d-15~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days."
79269788|NCT05528354|Drug|DEC|"In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)>95%.~If the MRD turns positive, DLI can be performed."
79402087|NCT00878163|Drug|Vismodegib|Given PO
79402088|NCT00863681|Drug|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
79572081|NCT01811511|Dietary Supplement|Chungkookjang|
79572082|NCT01811511|Dietary Supplement|Placebo|
79572083|NCT01811537|Device|Artificial Chordae|
79572084|NCT01811550|Other|Glycemic Control|
79572085|NCT01811589|Device|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
79572086|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
79732054|NCT04160767|Other|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
80026853|NCT03578991|Device|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
79269789|NCT03536533|Other|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
79269790|NCT02183077|Drug|Meloxicam gel|
79269791|NCT02183077|Drug|Meloxicam tablet|
79572087|NCT01811602|Other|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
79572088|NCT01811602|Other|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
79572089|NCT01811615|Other|alcohol-free experimental mouth rinse|
79269792|NCT02183155|Drug|Meloxicam - low|
79572090|NCT01811615|Other|alcohol-containing mouth rinsing|
79572091|NCT01811628|Behavioral|Questionnaire|Questionnaire completion taking about 10-15 minutes.
79269793|NCT02183155|Drug|Meloxicam - medium|
79269794|NCT02183155|Drug|Meloxicam - high|
79732055|NCT02633449|Behavioral|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
79732056|NCT02633449|Device|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
79866663|NCT04118387|Drug|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
79866664|NCT04118179|Other|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
79866665|NCT04105335|Drug|MTL-CEBPA|Intravenous administration
79866666|NCT04105335|Drug|Pembrolizumab|Intravenous administration
79269795|NCT02183155|Drug|Placebo|
79269796|NCT02183155|Drug|Extended-release indomethacin|
79269797|NCT02183233|Drug|Eschscholtzia Californica|
79269798|NCT02183233|Drug|Eschscholtzia Californica Placebo|
79269799|NCT02177461|Drug|Telmisartan|
79269800|NCT02177461|Drug|Enalapril|
79269801|NCT02177461|Drug|Clonidine|
79269802|NCT03545243|Drug|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily during 28 days
79269803|NCT03545243|Other|PPI withdrawal|PPI withdrawal for 8 weeks
79269804|NCT02573948|Other|no intervention is assessed|
79572092|NCT01811628|Behavioral|Interview|Audio-recorded interview that will last about 1 hour.
79572093|NCT01811641|Other|season, dietary intake|
79572094|NCT01811667|Drug|Sirolimus|
79572095|NCT01811719|Behavioral|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
79572096|NCT01811719|Behavioral|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
79572097|NCT01811745|Behavioral|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
79572098|NCT01811745|Behavioral|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
79732057|NCT02633449|Device|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
79732058|NCT02535637|Other|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
79866667|NCT04087538|Diagnostic Test|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
79269805|NCT02183311|Drug|BI 1356 BS - single rising dose|
79269806|NCT02183311|Drug|BI 1356 BS - multiple rising dose|
79269807|NCT02183311|Drug|Placebo|
79304435|NCT00761371|Drug|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
79572099|NCT01811758|Behavioral|Culturally Specific CBT|
79572100|NCT01811758|Behavioral|Standard CBT|
79866668|NCT04072952|Drug|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
79572101|NCT01811771|Biological|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
79866669|NCT04072952|Drug|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
79572102|NCT01811784|Behavioral|Ask people not to drink raw sap|
79572103|NCT01811784|Behavioral|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
79866670|NCT04071470|Behavioral|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
79866671|NCT04071470|Drug|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
79866672|NCT04040049|Genetic|FLT190|Gene Therapy product.
79866673|NCT04021784|Device|SDS|The patient is implanted with SDS.
79866674|NCT04021784|Device|NEMOST|The patient is implanted with NEMOST.
80026854|NCT03578991|Other|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
79572104|NCT01811784|Other|No Intervention|
79732059|NCT04162717|Behavioral|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
79866675|NCT04006522|Drug|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
80026855|NCT05632198|Other|Survey|Valid and reliable questionnaires covering perceived uncertainty, self-care behaviors and quality of life will be administered.
79572105|NCT01811784|Other|No Intervention|
79572106|NCT01811797|Device|Low Intensity Shockwave by Renova|
79732060|NCT00911209|Behavioral|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
80026856|NCT03538236|Device|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
80026857|NCT03538236|Behavioral|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
79269808|NCT05518526|Drug|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
79572107|NCT01811797|Device|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
79572108|NCT01811810|Radiation|Radiation therapy (XRT)|
79732061|NCT00881569|Drug|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
79866676|NCT04006522|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
79866677|NCT03961061|Behavioral|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
79866678|NCT03961061|Behavioral|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~a mobile-enabled website,~diet and physical activity tracking apps and physical activity tracker~tailored self-monitoring feedback~caregiver podcasts~animated videos for adolescent patients~social support via social media."
79572109|NCT01811810|Other|Androgen Deprivation Therapy (ADT)|
79572110|NCT01811810|Other|Chemotherapy|
79732062|NCT04017481|Other|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
79572111|NCT01811823|Biological|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
79732063|NCT04017481|Other|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
80026858|NCT03068650|Biological|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
79269809|NCT01464593|Drug|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
79732064|NCT04160143|Procedure|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
79269810|NCT01464593|Other|5% Dextrose Solution|Single 30 minute intravenous infusion
79269811|NCT01464593|Drug|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
79732065|NCT02636179|Other|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
79269812|NCT02183389|Drug|Warfarin|
79269813|NCT02183389|Drug|BI 1356|
79269814|NCT05518448|Dietary Supplement|Ketone - beta-hydroxybutyrate (β-OHB)|Ketone - beta-hydroxybutyrate (β-OHB)
79269815|NCT02180347|Device|Contact lenses|
79269816|NCT02143817|Dietary Supplement|L-citrulline supplementation|
79732066|NCT00657163|Drug|fluoxetine|fluoxetine per os 20 mg daily
79732067|NCT00657163|Drug|placebo|placebo per os daily
79732068|NCT02636101|Drug|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
79732069|NCT04032457|Device|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
79732070|NCT04032457|Device|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
79732071|NCT00657475|Drug|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
79732072|NCT00657475|Drug|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
79732073|NCT02636023|Device|SPhENo-Cardiograph|SPhENo-Cardiograph
79732074|NCT02632981|Other|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
79732075|NCT02632981|Other|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
79732076|NCT04160689|Biological|implantology|placing of implant
79732077|NCT02631889|Device|Transcollation technology|The use transcollation technology for dissection during lung surgery
79732078|NCT02631889|Device|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
79732079|NCT00657319|Drug|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
79732080|NCT00881335|Device|flutter mucus clearance device|five minutes every sessions, three sessions per day
79732081|NCT02632825|Device|Nasal High Flow|Nasal High Flow Therapy
79732082|NCT00657631|Behavioral|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl & Wilson, 1999)."
79732083|NCT04159597|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet.
79732084|NCT00661219|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
79732085|NCT00661219|Drug|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
80026859|NCT02238873|Drug|Pegfilgrastim|
80026860|NCT05141994|Drug|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
80026861|NCT05141994|Drug|4mg of BAT5906|Specification: 4mg of BAT5906
79732086|NCT00665665|Drug|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
79572112|NCT01811836|Dietary Supplement|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
79572113|NCT01811849|Drug|Insulin LISPRO|
80026862|NCT02238951|Other|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
80026863|NCT02238951|Other|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
79732087|NCT00665665|Drug|placebo|Placebo for s.c. injection
79732088|NCT00665665|Drug|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
79732089|NCT00665665|Drug|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
80026864|NCT03034057|Drug|Sayana Press|Sayana Press in the Uniject injection system
79732090|NCT00665665|Drug|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
79277605|NCT05546749|Device|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
79572114|NCT01811849|Drug|Insulin LISPRO|
79732091|NCT00665743|Drug|PN400|naproxen 500 mg /esomeprazole 20 mg
79732092|NCT00665743|Drug|naproxen|naproxen 500 mg tablet
80026865|NCT04630366|Drug|NST-1024|NST-1024
80026866|NCT04630366|Drug|Placebo|Matching placebo to NST-1024
79277606|NCT05546749|Device|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
79277607|NCT03525535|Other|data collection|data from patient included will be collected during the study
79572115|NCT01811849|Drug|Insulin LISPRO|
79572116|NCT01811888|Behavioral|Quantitative sensory testing (QST)|
79572117|NCT01811901|Other|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
79732093|NCT00665743|Drug|naproxen|naproxen 500 mg
79732094|NCT04156711|Procedure|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
79732095|NCT02357992|Radiation|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
79732096|NCT00661297|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
79732097|NCT00661297|Drug|Placebo|Matching placebo
79732098|NCT00665821|Behavioral|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
79732099|NCT00665821|Behavioral|General health education|General health education: a booklet describing general norms for maintaining good health
79732100|NCT02842762|Device|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
79732101|NCT02842762|Procedure|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
79732102|NCT02842762|Device|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
79732103|NCT02842762|Device|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
79732104|NCT02690896|Behavioral|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
79732105|NCT02690896|Behavioral|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
79732106|NCT00879775|Drug|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
79732107|NCT00879775|Drug|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
79732108|NCT02840344|Behavioral|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
79732109|NCT02840344|Behavioral|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
79732110|NCT00665899|Behavioral|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
79572118|NCT01811914|Other|intraoperative TTE|
79269817|NCT02143817|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
79269818|NCT05528276|Procedure|Repair surgery|"a circumscribing skin incision was made 2 mm below the hypospadias meatus,~penile degloving,~the para-urethral plate incision was made,~A vertical midline incision of the urethral plate was made from within the hypospadiac meatus and extended up to the mid-glans.~The urethral plate was tubularised, beginning proximally, and closed in two layers using 6/0 polyglactin 910 suture.~The neomeatus was formed on a catheter 2 F larger than the urethral stent.~A flap was harvested from the prepuce to cover the neourethra and finally glanuloplasty.~A suitable urethral stent was left in situ for 7-10 days, with a compressive dressing applied.~Grafted tubularised incised-plate .~1.Same steps but adding a graft (dorsal inlay) , 2. The graft will be taken from the inner preputial skin . 3. The graft will be sutured to overlying plate incision line from the old meatus to the tip of the glans."
79269819|NCT02177539|Drug|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
79269820|NCT02177539|Drug|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
79269821|NCT05524376|Other|no intervention|no intervention
79269822|NCT06220357|Diagnostic Test|Indocyanine Green|The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.
79269823|NCT06220331|Device|Intra Ocular Lens|Intensity SL Intra Ocular Lens
79269824|NCT06220305|Diagnostic Test|DNA methylation joint AI imaging|DNA were extracted from patients'plasma ,then the DNA was bisulfite converted and tested by DNA methylation assay.The results were combined with AI images to differentiate between benign and malignant lung nodules.
79269825|NCT06220279|Drug|Diclofenac|Each were monitored for pain within 24 hours
79572119|NCT01811927|Device|PRO-Kinetic Energy Stent|Bare-metal stent
79269826|NCT06220253|Procedure|vaginal hysterectomy by bipolar vessels sealing|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
79277608|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
79732111|NCT00665899|Behavioral|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
79732112|NCT00894790|Drug|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
79572120|NCT01811966|Other|Volume|
79732113|NCT00894790|Drug|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
79732114|NCT04156867|Device|Dynesys|discectomy with Dynesys
79732115|NCT04156477|Dietary Supplement|Ketone ester|Intake of weight adjusted drink of a ketone ester
79572121|NCT01811966|Other|Control|
79572122|NCT01811979|Dietary Supplement|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
79572123|NCT01811979|Dietary Supplement|Steril water|steril water plus topical anesthetics
79732116|NCT04156477|Dietary Supplement|Glucose|Isocaloric and - volumetric taste adjusted drink
79732117|NCT04156477|Dietary Supplement|Tap water|Isovolumetric taste adjusted tap water (placebo)
79732118|NCT02840110|Other|ACTR T Cell Product|
79732119|NCT00665977|Drug|Thermosmart & placebo|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
79732120|NCT00665977|Drug|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
79732121|NCT00665977|Device|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
79732122|NCT02840500|Other|No intervention|No intervention
79572124|NCT01811992|Biological|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
79269827|NCT06220253|Procedure|vaginal hysterectomy by traditional technique|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
79866680|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
79866681|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
79866682|NCT03922048|Drug|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
79269828|NCT06220240|Other|Modified Training Programme|Eccentric muscle contractions and 3-minute rest breaks will be used.
79269829|NCT06220240|Other|Routine Training Programme|A routine training program will be used.
79269830|NCT06220227|Procedure|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
79866683|NCT03922048|Drug|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
79269831|NCT06220214|Diagnostic Test|CEDM|Contrast Enhanced Digital Mammography
79269832|NCT06220214|Diagnostic Test|CDBT|Contrast Enhanced Digital Breast Tomosynthesis
79269833|NCT06220175|Drug|Strepsils Intensiv Arm|After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
79269834|NCT06220175|Drug|Xilocaine Spray Arm|After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
79866684|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1.
79269836|NCT06220149|Diagnostic Test|FIT (fecal immunochemical test)|A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
79269837|NCT06220123|Drug|SHR-2004|Investigational product arm: SHR-2004
79269838|NCT06220123|Drug|Enoxaparin Sodium Injection; Rivaroxaban Tablets|Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
79277609|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
79572125|NCT01812018|Drug|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
79572126|NCT01812018|Drug|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
79572127|NCT01812018|Drug|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
79572128|NCT01812031|Other|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
79866685|NCT03922048|Drug|HTX-011|Dose to be determined from Cohorts 1 and 2.
79277610|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
79277611|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
79277612|NCT03527095|Drug|FDL169|CFTR corrector
79277613|NCT02374359|Other|follow-up|
79277614|NCT04512781|Device|Control Cannula - Prosoft Cannula - Unicorn Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
79866686|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1 Part A.
79269839|NCT06220097|Drug|Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells|Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10^6/kg on day 0 and day 1 respectively.
79269840|NCT06220084|Behavioral|Dance for PD®|The intervention consists of 16 60-min adapted to Greek culture DfPD® classes, which will be performed twice weekly for 8 weeks and instructed by a single researcher, who has the approval to use it for research reasons. The intervention will be delivered both live and online in separate periods for each participant.
79572129|NCT01812070|Behavioral|ACT|
79572130|NCT01812070|Behavioral|CBT|
79572131|NCT01812096|Other|Subcutaneous bortezomib|
79572132|NCT01812096|Other|Intravenous bortezomib|
79572133|NCT01812122|Drug|Glimepiride|
79572134|NCT01812122|Drug|Vildagliptin|
79572135|NCT01812135|Biological|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
79572136|NCT01812148|Procedure|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
79572137|NCT01812161|Other|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
79572138|NCT01812161|Other|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of <5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
79572139|NCT01812187|Behavioral|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
79732123|NCT02631811|Other|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
79732124|NCT00666055|Drug|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
79732125|NCT02840734|Other|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
79732126|NCT02839954|Biological|anti-MUC1 CAR-pNK cells|
79866687|NCT03922048|Device|Luer Lock Applicator|Applicator for instillation.
80026867|NCT03578913|Other|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
80026868|NCT03578913|Other|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
79732127|NCT04159285|Behavioral|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
79732128|NCT04159285|Other|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
79866688|NCT03891667|Drug|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
79866689|NCT03871855|Drug|SHR-1702|Administered IV
79866690|NCT03871855|Drug|Camrelizumab|Administered IV
79866691|NCT03866174|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
79866692|NCT03866174|Drug|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
80026869|NCT05628844|Procedure|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
79732129|NCT02690662|Behavioral|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
80026870|NCT05728684|Biological|CM310|CM310 Injection
79732130|NCT02631655|Other|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
79732131|NCT02840188|Other|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
79866693|NCT03866174|Other|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
80026871|NCT05616286|Behavioral|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
80026872|NCT02757768|Drug|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
79269841|NCT06220058|Procedure|"Closure of the midline laparotomy using the small bites technique"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). No Redon drainage system will be left in the subcutaneous tissue."
79277615|NCT04512781|Device|Control Cannula - Unicorn Cannula - Prosoft Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
79572140|NCT01812200|Drug|Dabigatran, Ticagrelor, ASA|
79572141|NCT01812200|Drug|Rivaroxaban, Ticagrelor, ASA|
79572142|NCT01812200|Drug|Phenprocoumon, Ticagrelor, ASA|
79572143|NCT01812213|Drug|[18F]NAV4694|
79866694|NCT03859869|Drug|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
79866695|NCT03859869|Drug|Placebo|Placebo is administered orally as capsules with a meal or snack
80026873|NCT02757768|Drug|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
80026874|NCT02757768|Drug|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
79572144|NCT01812239|Drug|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
79277616|NCT05187793|Drug|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
79402089|NCT00846742|Drug|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
79402090|NCT00846742|Radiation|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
79402091|NCT00802230|Drug|Terbutaline Infusion|
79402092|NCT00795080|Procedure|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
79572145|NCT01812239|Procedure|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
79572146|NCT01812239|Drug|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
79572147|NCT01812265|Drug|PF-06305591|single Dose
79572148|NCT01812265|Drug|PF-06305591|single Dose
79572149|NCT01812265|Drug|Placebo|Single Dose
79572150|NCT01812278|Behavioral|ACT|
79572151|NCT01812278|Behavioral|CBT|
79572152|NCT01812317|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
79572153|NCT01812317|Procedure|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
79572154|NCT01812330|Drug|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
79572155|NCT01812330|Drug|Ticagrelor|90mg Bid
79732132|NCT00661375|Drug|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
79732133|NCT04250974|Other|electroacupuncture|acupuncture with electricity
79732134|NCT00911287|Drug|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
79732135|NCT04154527|Other|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
79732136|NCT02837848|Procedure|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
79732137|NCT02837848|Procedure|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
79732138|NCT02631031|Drug|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
79269842|NCT06220058|Procedure|"Closure of the midline laparotomy using the small bites technique with an absorbable PP mesh"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). A partially absorbable low-density polypropylene suprapubic mesh (Ultrapro®, Ethicon) will be added. Mesh fixation will be done with absorbable staples (Ethicon SecurestrapTM) +/- slow-absorbing resorbable sutures at the discretion of the surgical team.~In the case of a diverting stoma, the prophylactic mesh will not encircle it. A Redon-type drainage will be left at the subcutaneous tissue level. One or two drains will be left at the discretion of the surgical team. Closure of the subcutaneous tissue will be performed with 2/0 or 3/0 absorbable, multifilament, interlocking sutures."
79732139|NCT02839564|Procedure|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
79269843|NCT06220045|Combination Product|Polyvinylidene fluoride mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh."
79402093|NCT00734149|Drug|Bortezomib|
79866696|NCT03822910|Diagnostic Test|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
79866697|NCT03822910|Diagnostic Test|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
79402094|NCT00734149|Drug|Melphalan|
79572156|NCT01812356|Device|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
79572157|NCT01812356|Device|Cryomaze procedure using Argon|Cryomaze procedure using Argon
79572158|NCT01812369|Drug|GEMCITABINE CISPLATINE|
79572159|NCT01812369|Drug|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
79572160|NCT01812382|Drug|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
79732140|NCT02839564|Procedure|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
79732141|NCT00911365|Biological|autologous mesenchymal stem cells|"4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-> Total four times"
79732142|NCT00911365|Biological|normal saline|saline
79866698|NCT03822910|Diagnostic Test|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
79866699|NCT03799458|Device|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
79866700|NCT03799458|Device|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
79866701|NCT03764098|Drug|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
79866702|NCT03764098|Other|Placebo|Placebo
79866703|NCT03763565|Biological|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
79866704|NCT03763565|Other|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
79866705|NCT03740204|Drug|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
79866706|NCT03740204|Drug|Placebo patch and pill|Placebo patch and pill
79866707|NCT03735563|Drug|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
79866708|NCT03735563|Drug|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
79866709|NCT03717402|Behavioral|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
79866710|NCT03715153|Drug|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
79269844|NCT06220045|Combination Product|Prophylactic polypropylene mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
79269845|NCT06220019|Drug|TCM|CAP patients diagnosed with Qi Deficiency Phlegm Dampness Syndrome or Qi Yin Deficiency Phlegm Heat Syndrome after discharge, with traditional Chinese medicine treatment as the exposure factor, will be included in the Traditional Chinese Medicine cohort. Patients who continuously take traditional Chinese medicine (modified by Bu Fei Jian Pi Hua Tan Fang or modified by Yi Qi Yang Yin Qing Fei Fang) for more than 2 months per year, or those who intermittently take medicine for more than 3 months of the total time of the year will be classified.
79402095|NCT00734149|Drug|Prednisone|
79402096|NCT00587431|Drug|GnRh (Leuprolide)|Leuprolide LUPRON
79402097|NCT00587431|Drug|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
79402098|NCT00587431|Drug|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
79572161|NCT01812395|Device|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
79572162|NCT01812395|Procedure|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
79732143|NCT04250272|Procedure|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
79732144|NCT02838160|Behavioral|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
79866711|NCT03715153|Drug|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
79732145|NCT02838160|Behavioral|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
80026875|NCT05615662|Behavioral|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
79732146|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
80026876|NCT05615662|Behavioral|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
80026877|NCT05728606|Procedure|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
80026878|NCT05225389|Drug|300 mg [C14] CT1812|Single dose of 300 mg CT1812 with microtracer dose of [C14]
79269846|NCT06220006|Procedure|Pulmonary vein isolation|Catheter ablation
79277617|NCT05187793|Drug|Standard therapy|"Standard treatment including:~Baricitinib, 4 mg, film coated tablets~Favipiravir, 200 mg, film coated tablets~Dexamethasone IV or IM OR Methylprednisolone IV"
79572163|NCT01812421|Other|Hypertension Health Education Protocol (HHEP)|
79572164|NCT01812434|Drug|Sildenafil|20mg three time daily for 28 days
79572165|NCT01812434|Drug|Placebo|20 mg three times daily for 28 days
79866712|NCT03715153|Drug|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
79572166|NCT01812460|Other|Intervention-training-group|As descriped in Arm Description
79572167|NCT01812486|Radiation|dose de escalation|
79866713|NCT03685773|Drug|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
79866714|NCT03685773|Drug|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
79866715|NCT03685773|Drug|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
79866716|NCT03683277|Drug|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
79866717|NCT03665207|Drug|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
79866718|NCT03660683|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
79866719|NCT03660683|Drug|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
79866720|NCT03660683|Drug|Placebo Oral Tablet|Matching Placebo Tablets
80026879|NCT05552833|Other|High intensity interval training|Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
80026880|NCT03066076|Drug|Antithyroid Drug|Antithyroid drug
79572168|NCT01812486|Radiation|standard dose|
79732147|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
79732148|NCT02839408|Dietary Supplement|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
79732149|NCT02839408|Drug|Azithromycin|Tablet containing 500mg Azithromicyn
79732150|NCT02839408|Other|Talc powder|Sachet containing talc powder and tablet containing talc powder
79732151|NCT02839408|Procedure|Periodontal treatment Scaling and root planning|
79572169|NCT01812512|Behavioral|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
79402099|NCT00514618|Drug|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
80026881|NCT03066076|Procedure|Total thyroidectomy|Operation
79402100|NCT00514618|Dietary Supplement|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
79402101|NCT00496119|Radiation|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
79572170|NCT01812525|Drug|NaCl 3%|NaCl 3%: 4ml QID
79572171|NCT01812525|Other|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
79572172|NCT01812538|Drug|DIC075V|"Four single dose treatments:~Placebo (normal saline)~Moxifloxacin (positive control)~DIC075V 37.5 mg~DIC075V 75 mg~All subjects receive each of the 4 treatments."
79572173|NCT01812551|Drug|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
79732152|NCT02838082|Behavioral|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
79732153|NCT02838082|Behavioral|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
79572174|NCT01812551|Drug|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
79572175|NCT01812564|Biological|Platelet Poor Plasma (PPP)|
79572176|NCT01812564|Biological|Platelet Rich Plasma (PRP)|
80026882|NCT05225077|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
79572177|NCT01812590|Behavioral|Exercise|
79572178|NCT01812629|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
79269847|NCT06219993|Procedure|robot-assisted modified Kasai portoenterostomy|"A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot."
79402102|NCT00496119|Radiation|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
79402103|NCT00283205|Behavioral|Yoga|
79866723|NCT03569293|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
79732154|NCT02838004|Device|IOL MINI WELL READY|IOL MINI WELL READY
79572179|NCT01812642|Drug|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
79732155|NCT05334082|Other|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
79732156|NCT02837614|Drug|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
79732157|NCT02837614|Drug|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
79732158|NCT02837614|Procedure|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
79732159|NCT02837614|Drug|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
79732160|NCT02839486|Other|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
79732161|NCT02839486|Other|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
79866724|NCT03569293|Drug|Upadacitinib|Tablets taken orally once a day
79572180|NCT01812642|Other|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
79732162|NCT05333536|Other|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
79866725|NCT03566511|Drug|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
79866726|NCT03566511|Drug|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
79866727|NCT03525262|Radiation|30Gy (Gray) planning target volume (PTV)|PTV1_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
79866728|NCT03494179|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
80026883|NCT05577286|Other|regular care|the regular medical treatment without change of their daily activity routine
79269848|NCT06219993|Procedure|traditional open Kasai portoenterostomy|Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
79269849|NCT06219980|Combination Product|SBRT+chemoimmunotherapy|All eligible patients will receive SBRT (6Gy*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
79269850|NCT06219967|Drug|Activated Charcoal|Activated charcoal alone
79572181|NCT01812720|Drug|carfilzomib|Given IV
79732163|NCT05333536|Other|No Intervention: Control group|control only participates in their yearly swimming trainings.
79866729|NCT03472404|Procedure|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
79866730|NCT03472404|Procedure|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
79269851|NCT06219967|Drug|Activated Charcoal|Activated charcoal mixed with cola
79269852|NCT06219928|Procedure|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
79269853|NCT06219928|Procedure|Ketamine Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
79269854|NCT06219928|Procedure|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
79269855|NCT06219915|Drug|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
79269856|NCT06219915|Drug|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
79269857|NCT06219915|Drug|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
79269858|NCT06219915|Drug|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
79572182|NCT01812720|Drug|dexamethasone|Given PO
79732164|NCT00879229|Drug|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
79866731|NCT03464136|Biological|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
79866732|NCT03464136|Biological|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
79866733|NCT03464136|Biological|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
79269859|NCT06219902|Drug|Elinzanetant (BAY3427080)|Oral administration of multiple doses of elinzanetant.
79269860|NCT06219902|Drug|Placebo to elinzanetant|Oral administration
79269861|NCT06219902|Drug|Zopiclone|Oral administration
79572183|NCT01812720|Other|laboratory biomarker analysis|Correlative studies
79572184|NCT01812746|Drug|BIND-014|
79572185|NCT01812772|Device|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
79572186|NCT01812772|Device|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
79732165|NCT00879229|Drug|Placebo|Placebo to match ambrisentan administered orally once daily.
79866734|NCT03464136|Biological|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
79866735|NCT03464136|Biological|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
79866736|NCT03427450|Diagnostic Test|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
80026884|NCT05577286|Other|plyometric training|designed plyometric training program for 30 minutes, three times a week for two successive months
79866739|NCT03382587|Drug|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
79866740|NCT04118803|Device|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
79269862|NCT06219902|Drug|Placebo to zopiclone|Oral administration
79269863|NCT06219889|Behavioral|Frequency of neurochecks|the frequency with which a patient is awakened to perform serial examinations
79269864|NCT06219876|Device|low level laser treatment|The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
79269865|NCT06219876|Device|High intensity laser treatment|The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
79402108|NCT00227253|Procedure|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
79402109|NCT00227253|Procedure|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
79572187|NCT01812798|Other|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
79269866|NCT06219876|Other|wrist splint|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
79269867|NCT06219863|Behavioral|Body weight supported harness|A body weight supported harness will be provided to families for one month to set up in their home. Caregivers will be asked to use the harness for their infants for 30 min per day, 5 days a week. Caregivers will complete a daily log describing harness use. At the end of the month, they will complete feasibility and acceptability questionnaires.
79269868|NCT06219850|Other|No intervention|The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
79572188|NCT01812824|Behavioral|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
79732166|NCT02837692|Drug|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
79732167|NCT02837692|Drug|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
79732168|NCT02837692|Drug|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
79732169|NCT02837692|Drug|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
79732170|NCT04249960|Behavioral|Managed transition|Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
79866741|NCT03325972|Drug|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
79866742|NCT03325972|Other|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
79866743|NCT03261362|Dietary Supplement|Branched-chain amino acids reduced intake|
79269869|NCT06219837|Drug|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
79269870|NCT06219811|Device|Two implant -retained overdenture reinforced with Co-Cr framework|The intervention is made from polymethylmethacrylate reinforced with cobalt chromium ( Co-Cr) framework.
79402110|NCT00227253|Procedure|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
79402111|NCT00227253|Procedure|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
79402112|NCT00227253|Procedure|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
79402113|NCT00227253|Procedure|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
79402114|NCT00227253|Procedure|Neurology examination|physical examination including observation of balance, coordination and reflexes.
79402115|NCT00227253|Procedure|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
79402116|NCT00227253|Procedure|Speech pathology evaluation|Standardized speech & language tests and naturalistic assessment procedures.
79402117|NCT00227253|Procedure|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
79732171|NCT04249570|Other|Povidone iodine|
79732172|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
79732173|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
79572189|NCT01812863|Procedure|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
79866744|NCT03247712|Drug|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
79572190|NCT01812889|Drug|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
79402118|NCT00227253|Procedure|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
79572191|NCT01812889|Drug|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
79572192|NCT01812902|Procedure|Radical Prostatectomy|
79572193|NCT01812915|Device|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
79572194|NCT01812915|Device|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
79572195|NCT01812928|Drug|Diclofenac|
79572196|NCT01812941|Other|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
79866745|NCT03247712|Procedure|Surgical Resection|Surgical Resection of Tumor
79572197|NCT01812941|Other|healthy volunteers: blood collection|blood collected at designated time intervals
79572198|NCT01812941|Other|Burn: blood collection|blood collected at designated time intervals
79269871|NCT06219811|Device|Two implant -retained overdenture reinforced with PEEK framework|The intervention is made from polymethylmethacrylate reinforced with Polyetherketoneketone ( PEEK) framework.
79572199|NCT01812954|Drug|Methotrexate|
79572200|NCT01812954|Drug|Cyclosporins|
79572201|NCT01812954|Drug|fumaric acid|
79572202|NCT01812954|Drug|Acitretin|
79572203|NCT01812954|Drug|Infliximab|
79572204|NCT01812954|Drug|etanercept|
79572205|NCT01812954|Drug|Adalimumab|
79572206|NCT01812954|Drug|Ustekinumab|
79572207|NCT01812967|Dietary Supplement|Milk Fat|
79572208|NCT01812967|Dietary Supplement|Milk Protein|
79572209|NCT01812967|Dietary Supplement|Lactose|
79572210|NCT01812967|Other|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
79572211|NCT01812967|Dietary Supplement|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
79572212|NCT01812980|Biological|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
79572213|NCT01812993|Device|Non-invasive ventilatory treatment with auto-BPAP|
79866746|NCT03247712|Radiation|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
79269872|NCT06219798|Diagnostic Test|GFR|Exit of the study due to death, dialysis, or transplantation
79269873|NCT06219785|Device|Low-Intensity Shockwave therapy (LiSWT)|Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
79572214|NCT01813006|Drug|Omega-3|
79572215|NCT01813006|Drug|placebo|
79572216|NCT01813032|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
79572217|NCT01813032|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
79572218|NCT01813045|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
79572219|NCT01813045|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
79572220|NCT01813045|Radiation|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
79572221|NCT01813084|Drug|RV1729 single dose|Safety and tolerability of single escalating doses
79572222|NCT01813084|Drug|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
79572223|NCT01813084|Drug|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
79572224|NCT01813084|Drug|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
79572225|NCT01813123|Behavioral|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
79732174|NCT02837770|Drug|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
79732175|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
79732176|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
79732177|NCT02837770|Drug|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
79732178|NCT02837458|Device|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
79866747|NCT03247712|Radiation|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
79866748|NCT03235076|Drug|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
79732179|NCT02837458|Device|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
79866749|NCT03208049|Behavioral|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Sleep Restriction therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
79866750|NCT03208049|Behavioral|Cognitive Therapy|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
79866751|NCT03196518|Procedure|PET Imaging|PET/CT study immediately after injection
79866752|NCT03196518|Other|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes
79269874|NCT06219746|Diagnostic Test|PSMA-imaging|Subjects undergo additional imaging i.e. PSMA/SPECT/CT and PSMA/PET/CT
79572226|NCT01813136|Drug|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
79866753|NCT03104699|Drug|AGEN2034|Anti-PD-1 Monoclonal Antibody
79866754|NCT03060057|Device|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
79269875|NCT06219733|Drug|Vactosertib|200 mg PO BID 5 days on / 2 days off
79269876|NCT06219733|Drug|Imatinib|Imatinib 400 mg PO QD daily
79269877|NCT06219707|Device|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
79269878|NCT06219694|Device|Laser Acupuncture|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
79269879|NCT06219694|Device|Sham|Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
79572227|NCT01813136|Drug|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
79269880|NCT06219655|Procedure|thoracoscopic sympathectomy|sympathectomy
79866755|NCT03048825|Drug|Colchicine|Colchicine 0.5 mg once daily
79269881|NCT06219642|Behavioral|Mindfulness using virtual reality|"In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?"
79572228|NCT01813162|Drug|Tenofovir 1% gel|
79572229|NCT01813162|Drug|Vaginal product|
79572230|NCT01813175|Other|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
79572231|NCT01813175|Other|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
80026885|NCT04942093|Dietary Supplement|With low-calorie, high-protein diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
79269882|NCT06219616|Diagnostic Test|BKV immune monitoring|Blood will be drawn and investigated for BKV-specific T cell response.
79402119|NCT00227253|Procedure|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
79402120|NCT00227253|Procedure|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
79732180|NCT00878995|Drug|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
79732181|NCT00878995|Drug|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
79732182|NCT02837536|Other|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
79732183|NCT02837536|Other|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
79732184|NCT04250584|Device|iSlpr™|mandibular advancement device
80026886|NCT04942093|Dietary Supplement|Without low-calorie, high-protein diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
80026887|NCT03067558|Diagnostic Test|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
80026888|NCT03067558|Diagnostic Test|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
80026889|NCT04909567|Behavioral|Optimisation|Defined optimisation
80026890|NCT03067792|Drug|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
80026891|NCT03067792|Drug|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
80026892|NCT05224999|Drug|nivolumab|nivolumab 3mg/kg (every 2 weeks)
80026893|NCT03066154|Drug|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
79269883|NCT06219603|Other|survey|questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
79269884|NCT06219590|Procedure|Acetylcholine Iontophoresis|Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
79269885|NCT06219590|Procedure|Shame Acetylcholine Iontophoresis|Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
80026894|NCT03066154|Drug|androgen deprivation therapy|ADT according to the standard of care
79269886|NCT06219577|Drug|Systane Complete Multi-Dose PF|Eyedrop
79269887|NCT06219577|Drug|Walgreen's Lubricant Balance|Eyedrop
79402121|NCT00226174|Drug|Curcuminoids|
79572232|NCT01813175|Other|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
79572233|NCT01813188|Procedure|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
79572234|NCT01813188|Procedure|autologous bone graft|autologous bone graft
79572235|NCT01813201|Drug|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
79572236|NCT01813201|Drug|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
79572237|NCT01813240|Drug|Minocycline|
80026895|NCT03066154|Radiation|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
80026896|NCT05224687|Other|Retroactive review of patient data of those receiving a dose of daptomycin|A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
80026897|NCT02753946|Drug|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
79572238|NCT01813240|Drug|placebo|
79572239|NCT01813253|Drug|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
79572240|NCT01813253|Drug|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
79572241|NCT01813279|Other|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
79572242|NCT01813318|Drug|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
79732185|NCT04250584|Device|SomnoDent® Classic|mandibular advancement device
79732186|NCT02837146|Biological|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
79732187|NCT02837146|Drug|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
79732188|NCT02837068|Device|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
79866756|NCT03048825|Drug|Spironolactone|Spironolactone 25 mg once daily
80026898|NCT02753946|Drug|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
80026899|NCT04959487|Other|Food support|1. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
80026900|NCT04959487|Other|Nutritional Counseling and education|2. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
79277618|NCT03525457|Procedure|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
79572243|NCT01813318|Drug|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
79732189|NCT02837068|Device|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
79732190|NCT02630875|Drug|A4250|A4250
80026901|NCT00431431|Drug|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
79732191|NCT02837224|Device|The Situate Detection System|The Situate Detection System for locating surgical sponges
80026902|NCT00431431|Drug|raloxifen|2 years treatment with raloxifene (60 mg)
80026903|NCT05566210|Device|acupuncture|acupuncture
79732192|NCT00657865|Drug|ramipril|oral intake
79732193|NCT00657865|Drug|placebo|placebo
79732194|NCT00661765|Drug|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
79866757|NCT03048825|Device|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
79866758|NCT03048825|Drug|Colchicine-Placebo|Matching Colchicine-placebo once daily
79269888|NCT06219564|Procedure|Peripartum total abdominal hysterectomy (p-TAH)|"Peripartum total abdominal hysterectomy (cesarean hysterectomy) refers to a surgical procedure in which a woman undergoes both a cesarean section (C-section) and a hysterectomy simultaneously.~Placenta Accreta, Increta, or Percreta: These are conditions where the placenta attaches too deeply to the uterine wall. In cases of severe attachment, it may be difficult to remove the placenta without causing excessive bleeding, and a hysterectomy may be required.~Cesarean hysterectomy is a major surgical procedure involving significant medical expertise and coordination among healthcare professionals, including obstetricians and surgeons. The decision to perform a cesarean hysterectomy is usually made in emergency situations to address life-threatening complications."
79277619|NCT03525301|Radiation|standard treatment|3000 cGy in 10 daily fractions
79277620|NCT03525301|Radiation|short course treatment|1800 cGy in 4 fractions administered twice a day
79277621|NCT03528499|Other|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
79572244|NCT01813383|Other|There is not any intervention|
79572245|NCT01813396|Other|joint mobilization plus massage|
79572246|NCT01813396|Other|joint mobilization/shoulder physical activity guide|
79572247|NCT01813448|Drug|Fidaxomicin|oral
79572248|NCT01813448|Drug|Placebo|oral
79572249|NCT01813461|Drug|14C-labeled prodrug isavuconazonium sulfate|oral
79572250|NCT01813487|Drug|HBsAg vaccine with Entecavir|
79572251|NCT01813500|Other|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
79572252|NCT01813513|Drug|IDX719|50 mg tablet for oral administration
79572253|NCT01813513|Drug|Simeprevir|150 mg capsule for oral administration
79572254|NCT01813526|Other|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
79732195|NCT00661765|Drug|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
79866759|NCT03048825|Drug|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
80026904|NCT05566210|Device|Sham acupuncture|Sham acupuncture
80026905|NCT04945057|Device|Mindpax monitoring system|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns, during the active 12 months of followup.
80026906|NCT03067480|Device|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
80026907|NCT02172222|Drug|BI 10773|
80026908|NCT02172222|Drug|Linagliptin|
80026909|NCT03625219|Drug|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
79732196|NCT02839252|Behavioral|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
80026910|NCT03625219|Drug|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
79732197|NCT00657943|Drug|metformin|metformin tablets 2 g x 2
79732198|NCT00657943|Drug|insulin detemir|insulin as requested
79732199|NCT00657943|Drug|insulin aspart + insulin aspart protamin|insulin as requested
79732200|NCT00657943|Drug|Insulin aspart|insulin as requested
79732201|NCT02837380|Drug|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
79732202|NCT02837380|Drug|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
79866760|NCT03039413|Drug|Copper Cu 64 TP3805|Given IV
79866761|NCT03039413|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
79866762|NCT03039413|Procedure|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
79866763|NCT03026790|Other|Medication management|Individualized management of medications for pain
79866764|NCT03026790|Other|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
80026911|NCT02176590|Behavioral|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
80026912|NCT02176590|Other|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
79572255|NCT01813552|Drug|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
79866765|NCT03026790|Drug|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
79732203|NCT02837302|Drug|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
79732204|NCT04249804|Drug|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
79732205|NCT02630797|Dietary Supplement|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
80026913|NCT02255916|Other|Music|live sound-bed music intervention
80026914|NCT02178852|Device|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
80026915|NCT05536999|Other|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
80026916|NCT05553964|Diagnostic Test|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
80026917|NCT02255994|Device|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
80026918|NCT02255994|Procedure|No mesh.|Patients in this arm had subvesical plication without reinforcement.
79269889|NCT06219564|Procedure|Cesarean Section (C/S)|"A cesarean section (C/S) involves making an incision in the abdominal wall and uterus to deliver a baby when a vaginal delivery is not feasible or safe.~Total placenta previa refers to a condition where the placenta completely covers the opening of the cervix in the uterus. This condition can pose significant risks during pregnancy and childbirth, and it often necessitates a planned cesarean section (C/S) for delivery."
79269890|NCT06219564|Other|Neonatal mortality|"Neonatal mortality refers to the death of a newborn within the first 28 days of life. This period is divided into early neonatal mortality, which covers the first seven days of life, and late neonatal mortality, which extends from the eighth to the 28th day. Neonatal mortality is a critical measure of the health and well-being of infants and is often used to assess a population's overall health and healthcare systems.~To reduce neonatal mortality, efforts are made to improve maternal healthcare, access to prenatal care, skilled attendance during childbirth, and the availability of neonatal healthcare services. Tracking and addressing factors contributing to neonatal mortality are crucial for improving the chances of survival of newborns and overall health outcomes."
79277622|NCT03528499|Other|General Exercises|Strengthening and stretching exercises.
79572256|NCT01813552|Drug|Omeprazole|40 mg delayed-release oral capsules, once daily
79572257|NCT01813552|Drug|Ritonavir|100 mg oral tablets, once daily
79572258|NCT01813565|Drug|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
79572259|NCT01813578|Other|Exercise|Intensive aerobic and muscle endurance exercise
79572260|NCT01813591|Drug|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
79572261|NCT01813604|Biological|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
79572262|NCT01813604|Biological|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
79572263|NCT01813604|Biological|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
79572264|NCT01813604|Biological|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
79572265|NCT01813604|Biological|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
79572266|NCT01813617|Drug|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
79572267|NCT01813630|Drug|DA-3002|
79572268|NCT01813630|Drug|Genotropin®|
79572269|NCT01813643|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
79572270|NCT01813643|Drug|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
79572271|NCT01813656|Drug|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
79572272|NCT01813656|Drug|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
79732206|NCT02630797|Dietary Supplement|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
79866766|NCT03020823|Drug|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
79866767|NCT02969369|Drug|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
79866768|NCT02969369|Drug|Placebo capsule|Placebo once daily
79866769|NCT02948036|Other|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
79269891|NCT06219551|Other|Mobile messages via What's App|The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
79572273|NCT01813682|Other|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
79866770|NCT02777879|Procedure|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
79732207|NCT02630797|Dietary Supplement|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
79269892|NCT06219538|Device|DAISY Uterine Drain|Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery.
79732208|NCT02630797|Dietary Supplement|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
79732209|NCT02836834|Biological|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
79269893|NCT06219525|Dietary Supplement|Higher dose of enteral zinc|Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
79277623|NCT02751827|Other|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
79277624|NCT02374203|Dietary Supplement|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
79572274|NCT01813682|Other|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
79277625|NCT02363049|Procedure|Colectomy|
79572275|NCT01813708|Behavioral|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
79572276|NCT01813708|Behavioral|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
79732210|NCT02631109|Drug|Pegaspargase|2000U/m2 day5
79732211|NCT02631109|Drug|doxorubicin|25mg/m2 day1
79572277|NCT01813747|Device|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
79572278|NCT01813760|Device|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
79732212|NCT02631109|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
79866771|NCT02761499|Device|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
79277626|NCT02363049|Drug|Chemotherapy|
79732213|NCT02631109|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
79732214|NCT02839096|Drug|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
79732215|NCT02839096|Drug|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
79732216|NCT04156321|Dietary Supplement|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
79732217|NCT02838784|Other|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
79732218|NCT02838784|Procedure|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
80026919|NCT03065842|Behavioral|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
80026920|NCT03065842|Behavioral|Usual Standards|Usual standards according to the school curriculum in Kenya.
80026921|NCT04939519|Behavioral|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine."
80026922|NCT04939519|Behavioral|Patient Navigation (PN)|Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
80026923|NCT02176746|Biological|cancer stem cell vaccine|
79269894|NCT06219525|Dietary Supplement|Standard dose of enteral zinc|Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
79572279|NCT01813773|Drug|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
79572280|NCT01813786|Device|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
79572281|NCT01813786|Device|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
79732219|NCT02630485|Behavioral|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
79732220|NCT02630485|Dietary Supplement|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
79732221|NCT02630485|Drug|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
79732222|NCT00666133|Device|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
79269895|NCT06219512|Behavioral|CPET exercise prescription|Exercise mode: walk Frequency: 5 times/week
79269896|NCT06219512|Behavioral|6MWT exercise prescription|Exercise mode: walk Frequency: 5 times/week
79269897|NCT06219512|Behavioral|Regular exercise|Regular exercise
79269898|NCT06219499|Drug|ONC-841|ONC-841 is a humanized monoclonal antibody.
79269899|NCT06219499|Other|Placebo|Placebo
79269900|NCT06219486|Diagnostic Test|D-dimer|The investigators will measure a D-dimer test on participants and randomize on informing the physician on the value.
79269901|NCT06219473|Drug|Fascia lata membrane|novel allogenic derived acellular matrix produced from human fascia lata allograft
79269902|NCT06219473|Drug|Platlet Rich fibrin membrane|Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRF where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue
79269903|NCT06219473|Drug|subepithelial connective tissue graft|The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
79269904|NCT06219460|Other|Ventilation using two types of face masks|ventilation using two types of face mask
79269905|NCT06219447|Device|VRRS Home Tablet or Medico Amico Kids APP|Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
79269906|NCT06219434|Behavioral|Mindfulness Relaxation|Participate in mindfulness program
79572282|NCT01813786|Device|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
79572283|NCT01813799|Drug|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
79269907|NCT06219434|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI
79269908|NCT06219434|Procedure|Biospecimen Collection|Undergo blood sample collection
79269909|NCT06219434|Other|Questionnaire Administration|Ancillary studies
79269910|NCT06219421|Other|Clinical data reuse|Clinical data reuse
79269911|NCT06219395|Procedure|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
79269912|NCT06219382|Device|Neurorehabilitation ecosystem|Over a period of six weeks, the participants will integrate the NEST system into their daily routines, running parallel to their regular neurorehabilitation treatment.
79269913|NCT06219343|Device|Non-invasive vagus nerve stimulation|Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
79269914|NCT06219317|Drug|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
79269915|NCT06219317|Drug|Placebo|standard saline solution
79269916|NCT06219304|Other|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
79572284|NCT01813799|Drug|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
79732223|NCT04159363|Other|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
79269917|NCT06219304|Other|Usual care|Exercises aimed at improving balance and mobility
79269918|NCT06219291|Other|Observational|Observation of the natural course of the disease
79572285|NCT01813799|Drug|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
79572286|NCT01813799|Drug|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
79572287|NCT01813812|Drug|DA-6034|
79572288|NCT01813812|Drug|Rebamipide 300mg|
79572289|NCT01813825|Other|Registry|
79732224|NCT02632513|Device|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
79732225|NCT00661843|Other|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
80026924|NCT05551546|Behavioral|Functional Medicine Health Coaching for Elimination Diet for Elimination Diet|"All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection."
80026925|NCT05551546|Behavioral|Self-guided Elimination Diet|"The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study."
80026926|NCT02178930|Other|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
80026927|NCT02179008|Drug|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
79269919|NCT06219278|Device|Profound Matrix|The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
80026928|NCT02179008|Drug|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
80026929|NCT02179008|Drug|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
79269920|NCT06219265|Behavioral|Dance Therapy|"A single-centre prospective randomised controlled trial will be conducted with a minimum of 48 patients with severe mental disorder (SMD) who will be randomised into two groups, 1 intervention group receiving dance therapy (n=24) and 1 control group receiving no intervention or treatment (n=24).~In addition, there will be an intervention group of healthy people who will receive dance therapy (n=20).~All the tests, will be carried out with patients with SMD and only the EEG for healthy people, in order to determine their baseline state. The dance therapy program will last for 20 sessions over 10 weeks.~The 44 people in the two experimental groups will participate in a 10-week intervention program with 2 sessions per week in which they will work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.~The 24 people in the control group will not receive any type of intervention."
79269921|NCT06219239|Genetic|KL003 cell injection Drug Product|No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
79572290|NCT01813838|Drug|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
79572291|NCT01813838|Drug|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
79572292|NCT01813838|Drug|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
79572293|NCT01813851|Device|Exercise training in addition to nutritional support|
79572294|NCT01813877|Radiation|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
79732226|NCT00879697|Behavioral|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
79732227|NCT00879697|Behavioral|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
80026930|NCT02179008|Drug|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
80026931|NCT02179008|Drug|DE-117 High Dose ophthalmic solution|High Dose DE-117
80026932|NCT02179008|Drug|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
80026933|NCT05545150|Procedure|Intraoperative Imaging|Clarix Imaging Volumetric Specimen Imager
79732228|NCT00894556|Drug|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
79572295|NCT01813903|Behavioral|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
79572296|NCT01813903|Behavioral|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
80026934|NCT05545150|Device|Lumpectomy|Per standard of care (SOC)
80026935|NCT02172300|Drug|Tiotropium inhalation capsules|
80026936|NCT02172300|Drug|Placebo inhalation capsules|
80026937|NCT05223907|Drug|Etomidate|Etomidate will be used for general anesthesia
80026938|NCT05223907|Drug|Propofol|Propofol will be used for general anesthesia
79269922|NCT06219213|Other|Glyceryl Eicosapentaenoate serum|Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.
79269923|NCT06219213|Other|Glyceryl Eicosapentaenoate Cream A|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
79269924|NCT06219213|Other|Glyceryl Eicosapentaenoate Cream B|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
79269925|NCT06219213|Other|Glyceryl Eicosapentaenoate Cream C|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
79572297|NCT01813916|Other|proteomic analysis|
79572298|NCT01813955|Drug|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
79572299|NCT01813981|Dietary Supplement|Low roast coffee|Instant coffee
79572300|NCT01813981|Dietary Supplement|High roast coffee|Instant coffee
79572301|NCT01813981|Dietary Supplement|Control (Caffeine dissolved in water)|Caffeine dissolved in water
79572302|NCT01813994|Drug|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
79572303|NCT01813994|Drug|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
79572304|NCT01814020|Drug|MOB015B|
79732229|NCT00894556|Drug|Comparator: Placebo|Placebo to Rizatriptan
79732230|NCT00894556|Drug|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
79732231|NCT00666367|Drug|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
79732232|NCT00666367|Drug|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
80026939|NCT03537456|Device|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
80026940|NCT04799353|Drug|Budigalimab|Subcutaneous (SC)
80026941|NCT04799353|Drug|Placebo|Subcutaneous (SC)
80026942|NCT04799353|Drug|Budigalimab|Intravenous (IV)
80026943|NCT04799353|Drug|Placebo|Intravenous (IV)
80026944|NCT03065998|Drug|Opipramol|PO
80026945|NCT03065998|Drug|Baclofen|PO
80026946|NCT02172378|Drug|Tiotropium inhalation capsules|
80026947|NCT02172378|Drug|Placebo inhalation capsules|
80026948|NCT05728528|Drug|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
80026949|NCT05728528|Drug|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
80026950|NCT03625375|Other|Exercise|Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
80026951|NCT02176824|Behavioral|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
80026952|NCT02176824|Behavioral|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
80026953|NCT02176824|Other|Treatment as usual|
79732233|NCT01210352|Drug|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
80026954|NCT05728450|Device|Light amplification by stimulated emission of radiation (LASER)|"The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
79269926|NCT06219161|Dietary Supplement|NAD3|NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
79402122|NCT00097786|Drug|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
79572305|NCT01814033|Other|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
79572306|NCT01814033|Other|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
79572307|NCT01814059|Drug|sirolimus|
79269927|NCT06219135|Other|no intervention - Contamination group|there is no intervention for this group of patients
79732234|NCT00661921|Biological|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
79269928|NCT06219135|Biological|blood sample - Bacteraemia group|for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
79277627|NCT05521009|Other|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
79572308|NCT01814085|Drug|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
79572309|NCT01814098|Drug|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
79572310|NCT01814111|Procedure|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
79572311|NCT01814124|Other|Manual therapy plus exercise|
79732235|NCT00661921|Biological|Placebo|AMG 108 volume matching placebo
79732236|NCT04250506|Drug|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
79732237|NCT04250506|Drug|Placebo|Placebo administered as tablets for oral use.
79732238|NCT04250506|Drug|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
79572312|NCT01814124|Other|Advice and home exercise|
79572313|NCT01814163|Drug|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
79572314|NCT01814176|Device|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
79572315|NCT01814189|Drug|Sumatriptan+Promethazine (SPr)|
79572316|NCT01814202|Other|PTM202|
79572317|NCT01814202|Other|Placebo|
79732239|NCT02836912|Other|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
79732240|NCT04158973|Other|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
79732241|NCT04158973|Other|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
79732242|NCT02836678|Biological|Ridge splitting, immediate implant, Nanobone with PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~Alloplast bone graft material (Nanobone)~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
80026955|NCT03625297|Other|shelter cat|families will adopt a shelter cat
80026956|NCT02256228|Drug|Ropivacaine|Active Group
80026957|NCT02256228|Drug|Saline|Placebo Comparator
80026958|NCT03067168|Drug|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
80026959|NCT03067168|Drug|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
80026960|NCT04051177|Behavioral|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
80026961|NCT04051177|Behavioral|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
79572318|NCT01814215|Behavioral|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
79572319|NCT01814228|Procedure|transcatheter ablation of ganglionated plexi in right atrium|
80026962|NCT02176980|Behavioral|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
80026963|NCT02176980|Behavioral|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
80026964|NCT04774237|Drug|BRIMOCHOL™|A single drop in each eye at a visit.
80026965|NCT04774237|Drug|BRIMOCHOL™ F|A single drop in each eye at a visit.
80026966|NCT04774237|Drug|Carbachol|A single drop in each eye at a visit.
79269929|NCT06219122|Behavioral|Creative arts and psychomotor therapies intervention for people with personality disorders|a Group (max of 9 participants) Creative arts and psychomotor therapies (CAPTS) intervention for people with personality disorders. Consisting of 10 sessions, where two CAPTS disciplines and therapists are represented each session. Each session lasts 90 minutes. Sessions are aimed at psychological adativity thru=ough the CAPTS. The sessions cover warming up in one of the CAPTS, short psycho education and a longer assigment focusing on the session goal. The first half of the interventions focusses mainly on listening to body signals, emotions and emotional needs and dealing in a healthy way with these. The second half will be more complex when dealing with challenges and adapting tot he context in a healthy way are goals of the sessions.
79732243|NCT02836678|Biological|Ridge splitting, immediate implantand PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
79732244|NCT00662077|Drug|Ibandronate|Ibandronate endovenous 3 mg every 3 months
79732245|NCT00662077|Behavioral|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
80026967|NCT02172456|Drug|99mTc-radiolabelled tiotropium|
79732246|NCT04250428|Behavioral|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
79732247|NCT04250428|Behavioral|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
79732248|NCT01210118|Behavioral|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
80026968|NCT02172456|Drug|non-radiolabelled tiotropium|
80026969|NCT05223595|Drug|Gentuximab|Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
80026970|NCT03067246|Device|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
79269930|NCT06219096|Procedure|NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration|After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.
79269931|NCT06219096|Procedure|NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration|After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.
79269932|NCT06219070|Other|Core straining|The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
79277628|NCT04199533|Behavioral|RUBI|Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
79277629|NCT04199533|Behavioral|RUBIES|School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
79304436|NCT03287999|Diagnostic Test|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
79304437|NCT03287999|Diagnostic Test|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
79572320|NCT01814267|Other|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~1 hospital consultation at inclusion time, week 0~then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~1 hospital consultation to validate that the wound is well-healed"
79572321|NCT01814267|Other|conventional|"conventional group: iterative diabetes physicians consultations at hospital~1 consultation at inclusion time, week 0~1 consultation 2 weeks after inclusion, week 2~1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~1 consultation to validate that the wound is well-healed"
79572322|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
79572323|NCT01814293|Device|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
79572324|NCT01814306|Device|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
79572325|NCT01814306|Device|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
79572326|NCT01814319|Drug|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
79572327|NCT01814319|Drug|Placebo|Matching placebo oral twice daily
79572328|NCT01814384|Device|prosthesis GMK ® without the ancillary MyKnee ® LBS|
79572329|NCT01814384|Device|Matched patient cutting blocks MyKnee ® LBS|
79572330|NCT01814410|Drug|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
79572331|NCT01814410|Drug|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
79572332|NCT01814410|Drug|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
79732249|NCT01210118|Behavioral|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
79732250|NCT00658099|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
79732251|NCT00658099|Drug|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
79732252|NCT00658177|Drug|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
79732253|NCT00658177|Drug|Placebo|Matching placebo
79572333|NCT01814423|Drug|Chloroquine-base 50 mg|
79572334|NCT01814423|Drug|Chloroquine-base 70 mg|
79572335|NCT01814436|Device|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
79732254|NCT02691104|Device|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
79732255|NCT02691104|Device|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
79732256|NCT00658255|Drug|budesonide/formoterol|
79732257|NCT00658255|Drug|formoterol|
80026971|NCT03067246|Device|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
80026972|NCT02030184|Drug|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
80026973|NCT04235998|Diagnostic Test|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~Sonographic characteristic of effusion~Parietal, diaphragmatic and visceral pleura~Pleural nodules~Lung parenchyma~Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
79732258|NCT04158661|Procedure|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
79732259|NCT04158661|Procedure|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
80026974|NCT02172534|Drug|Tiotropium bromide low|
80026975|NCT02172534|Drug|Tiotropium bromide medium|
80026976|NCT02172534|Drug|Tiotropium bromide high|
79269933|NCT06219057|Behavioral|The Wise Adolescent|The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
79269934|NCT06219044|Procedure|laparoscopic endometrioma laser vaporization|laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
79269935|NCT06219005|Behavioral|ultrasound education and simulation workshop|workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
79269936|NCT06218979|Drug|Risperidone oral solution|See arm/group descriptions
79269937|NCT06218966|Device|intracochlear catheter|intracochlear administration of steroids through the intracochlear catheter INCAT
79572336|NCT01814449|Other|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
79572337|NCT01814449|Drug|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
79572338|NCT01814462|Device|6 months CPAP|
79572339|NCT01814475|Drug|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
79572340|NCT01814475|Drug|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
79572341|NCT01814501|Biological|panitumumab|Given IV
79572342|NCT01814501|Drug|irinotecan hydrochloride|Given IV
79572343|NCT01814501|Drug|fluorouracil|Given IV
79572344|NCT01814501|Drug|leucovorin calcium|Given IV
79572345|NCT01814514|Drug|Timolol-trusopt|
79572346|NCT01814514|Drug|placebo|
79572347|NCT01814527|Dietary Supplement|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
79732260|NCT04158661|Procedure|no thymectomy (control)|routine medical care
79732261|NCT01208870|Behavioral|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
79732262|NCT01208870|Behavioral|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
80026977|NCT02172534|Drug|Placebo|
80026978|NCT02256306|Other|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
79572348|NCT01814527|Drug|Placebo|5 capsules that are identical to the treatment.
79572349|NCT01814579|Device|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
79572350|NCT01814579|Device|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
79732263|NCT02836210|Device|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
80026979|NCT04713631|Drug|Artesunate|Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.
79732264|NCT04249102|Device|Guardian Connect, Medtronic|Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
79269938|NCT06218940|Drug|HY1272|Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
79269939|NCT06218927|Other|QoL monitoring|QoL questionnaire
79402123|NCT00097786|Drug|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
79402124|NCT00097786|Drug|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
79402125|NCT00097786|Drug|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
79572351|NCT01814592|Procedure|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
80026980|NCT04713631|Drug|Curcumin|Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
80026981|NCT04713631|Drug|Placebo A|Artesunate looking placebo
80026982|NCT04713631|Drug|Placebo C|Curcumin looking placebo
80026983|NCT04459078|Drug|Camrelizumab|Intravenous administration of (200mg/3weeks)
79572352|NCT01814592|Procedure|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
79732265|NCT04249102|Device|Abbott Diabetes Care|Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
79732266|NCT00658489|Behavioral|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
79732267|NCT02836288|Drug|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
80026984|NCT04459078|Drug|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
80026985|NCT04459078|Drug|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
79269940|NCT06218901|Drug|immunotherapy|
79269941|NCT06218901|Drug|Targeted Therapy Agent|
79269942|NCT06218888|Drug|Tislelizumab|Tislelizumab 200mg，D1, Q3W
79269943|NCT06218888|Drug|Fruquintinib|Fruquintinib 3mg ,D1-D14, Q3W
79269944|NCT06218888|Drug|Chidamide|Chidamide 30mg
79269945|NCT06218862|Drug|Sivelestat sodium|Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.
79269946|NCT06218862|Drug|Control|Not use Sivelestat sodium
80026986|NCT02179242|Other|Cardiac rehab|
80026987|NCT04693195|Drug|BLU-5937|Oral administration of BLU-5937 tablets
79269947|NCT06218810|Drug|Cadonilimab + bevacizumab + FOLFOX|Cadonilimab + bevacizumab + FOLFOX
79269948|NCT06218797|Other|a routine sedation protocol|In this study group, a routine sedation protocol in our clinic will be applied in the endoscopic unit. Premedication will not be given to the patients.
80026988|NCT04693195|Drug|Placebo|Oral administration of matching placebo for BLU-5937 tablets
79572353|NCT01814605|Procedure|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
79269949|NCT06218797|Drug|Nebulized with dexmedetomidine|Patients will be received nebulisation with dexmedetomidine 2mg/kg 5 cc 20 minute prior to endoscopy. After that routine sedation protocol in our clinic will be applied.
79269950|NCT06218784|Drug|iN1011-N17 HCl Suspension (Part 1)|Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
79402126|NCT01524692|Drug|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
79402127|NCT01277679|Procedure|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
79572354|NCT01814605|Procedure|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
79572355|NCT01814618|Drug|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
79572356|NCT01814631|Other|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
79269951|NCT06218784|Drug|iN1011-N17 HCl Capsule (Part 1)|Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
79269952|NCT06218784|Drug|Placebo Capsule (Part 1)|Dose: b.i.d for 7 days
79269953|NCT06218784|Drug|iN1011-N17 HCl Capsule (Part 2)|Dose: 400 mg QD
79402128|NCT04018105|Other|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
79572357|NCT01814631|Other|image quality and resolution|image quality and resolution will be viewed on the EU-me2
79572358|NCT01814644|Behavioral|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
79572359|NCT01814644|Behavioral|Standard Care|Individual assessment, lifestyle counseling
79572360|NCT01814683|Drug|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
79572361|NCT01814683|Drug|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
79572362|NCT01814683|Drug|Placebo|14 days placebo.
79572363|NCT01814709|Drug|GDC-0032|Oral doses of GDC-0032
79402129|NCT02991417|Biological|CDVAX|
79402130|NCT05366647|Procedure|canaloplasty|canaloplasty ab interno with tensioning suture
79402131|NCT05366647|Procedure|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
79402132|NCT05632549|Drug|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
79402133|NCT05632549|Drug|L-Carnitine 500Mg Oral Tablet|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
79402134|NCT05632549|Drug|Biotin Capsules|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
79572364|NCT01814709|Drug|Itraconazole|Oral doses of Itraconazole
79572365|NCT01814709|Drug|Rifampin|Oral doses of Rifampin
79572366|NCT01814826|Drug|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
79572367|NCT01814826|Drug|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
79572368|NCT01814839|Drug|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
79572369|NCT01814839|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79572370|NCT01814852|Device|Shockwave system|
79572371|NCT01814852|Device|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
79269954|NCT06218784|Drug|iN1011-N17 Mesylate Capsule (Part 2)|Dose: 400 mg QD
79269955|NCT06218784|Drug|iN1011-N17 HCl Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
80026989|NCT03067090|Device|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
79269956|NCT06218784|Drug|iN1011-N17 Mesylate Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
79572372|NCT01814865|Drug|Abiraterone Acetate|1000 mg PO OD x 2 weeks
79732268|NCT02836288|Other|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
79572373|NCT01814865|Drug|Prednisone|5 mg PO OD x 2 weeks
79732269|NCT02632435|Device|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
79732270|NCT02632435|Device|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
79732271|NCT00658645|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
79732272|NCT00658645|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
79732273|NCT00658645|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
79269957|NCT06218784|Drug|Placebo Capsule (Part 3)|Dose: b.i.d for 14 days
79402135|NCT00721539|Device|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
79572374|NCT01814865|Drug|Aromatase Inhibitor|1 mg PO OD x 2 weeks
79572375|NCT01814891|Other|Orange maize feeding|This group was fed orange maize.
79572376|NCT01814891|Other|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
79732274|NCT02836132|Behavioral|Weight Watchers Online|
79732275|NCT02836132|Behavioral|Experience Success Virtual Reality Platform|
79732276|NCT01208402|Drug|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
79732277|NCT00633334|Other|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
79732278|NCT04248946|Other|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
79732279|NCT01208324|Drug|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
80026990|NCT02756832|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
79269958|NCT06218771|Drug|TQB3454 Tablets|TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
79269959|NCT06218680|Drug|Propofol|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
79269960|NCT06218680|Drug|Normal saline|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
79304438|NCT03287921|Drug|mono bronchodilatation|within indication according to current GOLD recommendation
79572377|NCT01814891|Other|Oil only|This group received a small amount of plain oil without vitamin A.
79572378|NCT01814904|Drug|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
79572379|NCT01814904|Drug|colestilan-M|BSAeq 6 g/day
79572380|NCT01814904|Drug|colestilan-H|BSAeq 9 g/day
79572381|NCT01814904|Drug|CBPB|
79572382|NCT01814917|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
79572383|NCT01814917|Drug|CBPB|
79269961|NCT06218667|Drug|Copanlisib|Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
79732280|NCT01208324|Drug|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
79269962|NCT06218667|Drug|Degarelix|Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
79269963|NCT06218667|Procedure|Radical Prostatectomy|Standard treatment
79304439|NCT03287921|Drug|dual bronchodilatation|within indication according to current GOLD recommendation
79304440|NCT03196063|Other|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
79402136|NCT00721539|Procedure|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
79402137|NCT00721617|Other|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
79402138|NCT00721617|Other|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
79732281|NCT01208324|Drug|Placebo Patch|placebo
79402139|NCT00721617|Other|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
79402140|NCT03993613|Biological|human apotransferrin|Intravenous infusions
79572384|NCT01814930|Behavioral|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
79572385|NCT01814956|Drug|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
79732282|NCT01208324|Drug|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
80026991|NCT05728216|Other|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
79572386|NCT01814956|Drug|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
79572387|NCT01814969|Radiation|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
79572388|NCT01814969|Radiation|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
79732283|NCT05333848|Behavioral|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
79269964|NCT06218641|Device|CP - conventional protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~24 hours after the delivery of the first aligner - start of orthodontic treatment;~3 days after the start of orthodontic treatment;~7 days after the start of orthodontic treatment;~24 hours after delivery of the third clear aligner;~3 days after delivery of the third clear aligner;~7 days after delivery of the third clear aligner."
79277630|NCT02366949|Drug|BAY1217389|"BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed."
79572389|NCT01814982|Drug|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
79572390|NCT01814995|Behavioral|Nutrition/Physical Activity Intervention|Please see Arm description.
79572391|NCT01815021|Dietary Supplement|amorphous calcium carbonate|
79572392|NCT01815021|Dietary Supplement|crystalline calcium supplements|
79572393|NCT01815047|Dietary Supplement|Vitamin D3 Supplementation|
79572394|NCT01815073|Biological|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
79572395|NCT01815073|Biological|Live Attenuated Varicella Vaccine|
79572396|NCT01815073|Biological|live attenuated JE vaccine|
79572397|NCT01815086|Biological|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
79572398|NCT01815112|Other|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
79572399|NCT01815112|Other|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
79572400|NCT01815125|Drug|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
79572401|NCT01815125|Drug|PLacebo|placebo
79572402|NCT01815164|Behavioral|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
79572403|NCT01815164|Behavioral|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
79732284|NCT05333848|Behavioral|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
79732285|NCT05333848|Behavioral|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
79866828|NCT02703246|Procedure|abdominal morcellation|patients will be randomized to receive abdominal morcellation
79866829|NCT02703246|Procedure|vaginal morcellation|patients will be randomized to receive vaginal morcellation
79866830|NCT02670837|Device|Cellutome Epidermal Harvesting System|
79866831|NCT02664610|Behavioral|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
79866832|NCT02637973|Drug|Empagliflozin|25 mg once daily
79866833|NCT02637973|Drug|Placebo|once daily
79866834|NCT02583269|Diagnostic Test|Laboratory Biomarker Analysis|Correlative studies
79866835|NCT02583269|Drug|Muscadine Grape Skin Extract|Given PO
79866836|NCT02583269|Procedure|Quality-of-Life Assessment|Ancillary studies
80026992|NCT00108810|Drug|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
80026993|NCT00108810|Drug|Placebo transdermal patch|12 hours application for 28 days
79572404|NCT01815203|Drug|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
79572405|NCT01815203|Drug|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
79572406|NCT01815216|Procedure|Bariatric surgery|Gastric bypass surgery
79572407|NCT01815216|Behavioral|Brain activity in resting state|Measure of activity in brain networks during resting state
79572408|NCT01815216|Behavioral|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
79572409|NCT01815255|Drug|tenofovir (TDF)|
79572410|NCT01815268|Biological|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
79572411|NCT01815268|Biological|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
79572412|NCT01815268|Biological|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
79572413|NCT01815268|Biological|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
79572414|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
79572415|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
79866837|NCT02546921|Drug|MOv18 IgE|The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
79866838|NCT02546921|Drug|MOv18 IgE|The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
79866839|NCT02546921|Drug|MOv18 IgE|The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
79732286|NCT05333848|Behavioral|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
79732287|NCT02838940|Procedure|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
79732288|NCT02838940|Drug|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
79866840|NCT02546921|Drug|MOv18 IgE|The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
79866841|NCT02546921|Drug|MOv18 IgE|The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
79866842|NCT02546921|Drug|MOv18 IgE|The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
79732289|NCT00880399|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
79866843|NCT02546921|Drug|MOv18 IgE|"Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment."
79866844|NCT02527681|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
79866845|NCT02516696|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
79866846|NCT02516696|Drug|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
79866847|NCT02516696|Drug|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
79866848|NCT02513329|Drug|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
79866849|NCT02513329|Drug|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
79866850|NCT02425826|Drug|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
79866851|NCT02425826|Drug|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
79732290|NCT00880399|Other|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
79732291|NCT02835898|Other|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
79732292|NCT02835976|Drug|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
79732293|NCT02838706|Procedure|Surgery for hip fracture|
79732294|NCT02836054|Procedure|lumbar puncture (LP)|
79732295|NCT02836054|Procedure|brain MRI|
79732296|NCT02835742|Drug|Sargramostim|
79732297|NCT02835742|Drug|Placebo|
79866852|NCT02425826|Drug|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
79866853|NCT02406027|Drug|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2*5 mg), orally, once daily.
79866854|NCT02406027|Drug|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
79866855|NCT02406027|Drug|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
80026994|NCT02172612|Other|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
80026995|NCT03067402|Other|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
80026996|NCT03067402|Diagnostic Test|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
80026997|NCT00106080|Behavioral|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
80026998|NCT02177214|Procedure|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
79277631|NCT02366949|Drug|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
79572416|NCT01813669|Behavioral|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
79572417|NCT01815307|Drug|Gemcitabine|1000mg/m2, day 1 every 2 weeks
79572418|NCT01815307|Drug|S-1|80mg/m2/day, day 1-28, every 6 weeks
79732298|NCT05326360|Drug|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
79732299|NCT00666523|Dietary Supplement|phytalgic|3/day
79732300|NCT00666523|Dietary Supplement|placebo|3/Day
79572419|NCT01815320|Procedure|Contrast-enhanced ultrasound (CE-US)|
79732301|NCT02838550|Behavioral|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
79732302|NCT02838550|Behavioral|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
79866856|NCT02406027|Drug|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
79866857|NCT02384434|Device|THOR Laser System for Low Level Laser Therapy (LLLT)|Non-invasive, a cold laser output treatment.
79866858|NCT02278120|Drug|LEE011|LEE011 600 mg daily oral
79866859|NCT02278120|Drug|Tamoxifen|tamoxifen 20 mg daily oral
79866860|NCT02278120|Drug|Letrozole|letrozole 2.5 mg daily oral
79866861|NCT02278120|Drug|Anastrozole|anastrozole 1 mg daily oral
79866862|NCT02278120|Drug|Goserelin|Goserelin 3.6 mg subcutaneous injection
79866863|NCT02278120|Drug|LEE011 Placebo|LEE011 placebo 600 mg daily oral
79866864|NCT02255357|Drug|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
80026999|NCT05588284|Device|AngioJet device|A device can be used for thrombus aspiration and thrombolysis.
80027000|NCT05588284|Other|anticoagulation alone|a medicine for anticoagulation therapy
80027001|NCT02256150|Drug|Mizoribine (MZR)|
80027002|NCT02256150|Drug|Cyclophosphamide (CTX)|
80027003|NCT02179320|Procedure|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
80027004|NCT02179320|Device|acupuncture needle 0,25 x 40mm|
80027005|NCT02177370|Drug|Fenoterol MDI|
80027006|NCT02177370|Drug|DSCG MDI|
80027007|NCT03538080|Device|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
80027008|NCT03538080|Device|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
80027009|NCT03538782|Procedure|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
79732303|NCT00666601|Drug|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
79732304|NCT00666601|Drug|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
79732305|NCT01207388|Drug|Blinatumomab|Continuous intravenous infusion
79732306|NCT02835664|Dietary Supplement|Nicotinamide Riboside (Niagen)|
79732307|NCT02835664|Dietary Supplement|Placebo|
79866865|NCT02255357|Drug|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
79866866|NCT02217943|Procedure|Roux-en-Y gastric bypass|
79866867|NCT02217943|Procedure|Sleeve gastrectomy|
80027010|NCT02172690|Procedure|Laparoscopic Staging|Laparoscopic Staging
79277632|NCT03532919|Diagnostic Test|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
79277633|NCT05503225|Drug|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
79277634|NCT02362893|Other|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
79277635|NCT05261555|Device|NoObesity app|The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.
79277636|NCT04528407|Other|Observation without intervention|This study is a follow-up study without intervention.
79572420|NCT01815320|Device|SonoVue|
79572421|NCT01815346|Procedure|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
79572422|NCT01815346|Behavioral|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
79572423|NCT01815346|Other|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
79572424|NCT01815372|Procedure|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
79572425|NCT01815372|Procedure|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
79572426|NCT01815398|Behavioral|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
79866868|NCT02211131|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
79866869|NCT02211131|Procedure|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
79866870|NCT02155647|Drug|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
79732308|NCT00666913|Other|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
79732309|NCT02838472|Drug|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
79732310|NCT00666991|Drug|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
80027011|NCT03538704|Drug|Metformin|Metformin is given to patients 1-1.5g/d.
80027012|NCT03538548|Behavioral|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
80027013|NCT02633020|Biological|AMG 714|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
80027014|NCT02633020|Biological|Placebo|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
79732311|NCT02835430|Procedure|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
79732312|NCT02835430|Procedure|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
79732313|NCT02835508|Drug|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
79732314|NCT02835508|Drug|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
79732315|NCT02835508|Drug|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
79732316|NCT02838394|Procedure|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
79269965|NCT06218641|Device|DP - delayed protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~24 hours after the delivery of the first aligner - start of orthodontic treatment;~3 days after the start of orthodontic treatment;~7 days after the start of orthodontic treatment;~24 hours after delivery of the third clear aligner;~3 days after delivery of the third clear aligner;~7 days after delivery of the third clear aligner."
79732317|NCT02838394|Other|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
79866871|NCT02134587|Other|Multifaceted educational intervention|"Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~Distribution of educational material~Practical class to explain the correct fill of adverse drug events form~Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
80027015|NCT02172768|Other|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
79269966|NCT06218589|Diagnostic Test|Velacur|Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.
79572427|NCT01815398|Behavioral|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
80027016|NCT02172768|Other|daily dosing|micafungin daily for 8 days
79572428|NCT01815411|Dietary Supplement|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
79732318|NCT00667147|Drug|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
79732319|NCT00667147|Drug|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
80027017|NCT02172768|Drug|micafungin|
79269967|NCT06218589|Diagnostic Test|MRI|Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.
80027018|NCT02172846|Radiation|Proton beam radiation therapy (PBT)|
80027019|NCT02172846|Drug|Paclitaxel|
80027020|NCT02172846|Drug|Carboplatin|
80027021|NCT02172924|Biological|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
80027022|NCT02172924|Biological|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
80027023|NCT02173002|Other|myIBDcoach|
79277637|NCT02203175|Drug|saline|Before the anesthesia induction, 5 ml isotonic saline
79277638|NCT02203175|Drug|fentanyl|before the anesthesia induction 50 mcgr fentanyl
79277639|NCT02203175|Drug|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
79572429|NCT01815437|Dietary Supplement|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
79572430|NCT01815437|Dietary Supplement|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
79572431|NCT01815437|Dietary Supplement|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
79572432|NCT01815437|Dietary Supplement|Mushroom Extract|Same quantity of mushroom extract in a capsule
79732320|NCT02835586|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
79866872|NCT02072772|Behavioral|Positively Smoke Free group treatment|See Arm Description
79866873|NCT02072772|Behavioral|Standard Care|See Arm Description
80027024|NCT02173002|Other|Standard care|
79866874|NCT02057107|Radiation|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
79866875|NCT02057107|Drug|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
79866876|NCT02057107|Drug|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
80027025|NCT00106626|Drug|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
80027026|NCT02179476|Device|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
80027027|NCT03538470|Other|Spa Treatment|"Bath with immersion shower~Overall penetrating shower~Multiple local application cataplasm~Individual physiotherapy~Mobilisation pool"
79269968|NCT06218589|Diagnostic Test|Blood sample collection for biomarkers|Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.
80027028|NCT03537378|Procedure|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
79269969|NCT06218589|Diagnostic Test|Liver biopsy|Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
79572433|NCT01815476|Radiation|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
79866877|NCT01752920|Drug|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
79572434|NCT01815528|Drug|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~10 µg on day 0~20 µg on day 3~50 µg on day 7~150 µg on day 10"
79572435|NCT01815541|Drug|teicoplanin|
79572436|NCT01815593|Device|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
79732321|NCT04154215|Diagnostic Test|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
79866878|NCT01752920|Drug|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
79732322|NCT00911521|Drug|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
79866879|NCT01752920|Drug|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
79866880|NCT01752920|Drug|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
79866881|NCT01728402|Procedure|blood draw, bone marrow procedure, or tissue biopsy|
79866882|NCT01479075|Drug|intransal insulin|4x 40mU intranasal insulin
79866883|NCT01479075|Drug|Placebo|
79866884|NCT01479075|Device|taVNS|
79866885|NCT01479075|Device|sham stimulation|
79866886|NCT01409330|Dietary Supplement|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
79866887|NCT01397279|Biological|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
79866888|NCT01397279|Biological|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
79866889|NCT01327105|Device|TVU|Use of transvaginal ultrasound to determine location of micro-insert
80027029|NCT03538392|Device|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
80027030|NCT02177448|Drug|BIBR277 low dose|
80027031|NCT02177448|Drug|BIBR277 medium dose|
80027032|NCT02177448|Drug|BIBR277 high dose|
80027033|NCT02177448|Drug|Enalapril low dose|
80027034|NCT02177448|Drug|Enalapril medium dose|
80027035|NCT02177448|Drug|Enalapril high dose|
80027036|NCT02177448|Drug|Placebo matching BIBR277|
79269970|NCT06218576|Other|None, purely observational study|None, purely observational study
79269971|NCT06218550|Drug|Delta-9-THC|Acute self-administration of inhaled or oral ∆9-THC by healthy adult research volunteers
80027037|NCT02177448|Drug|Placebo matching enalapril|
79269972|NCT06218550|Drug|Delta-8-THC|Acute self-administration of inhaled or oral ∆8-THC by healthy adult research volunteers
79269973|NCT06218550|Drug|Placebo|Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers
79269974|NCT06218524|Drug|Haloperidol Tablets|Haloperidol tablet 6mg, Oral, Triple/Day
79269975|NCT06218524|Drug|Temozolomide|Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
79269976|NCT06218511|Biological|Peptide-based hepatocellular carcinoma vaccine IMA970A|IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.
79572437|NCT01815606|Procedure|biopsy with 19 gauge needle|biopsy with 19 gauge needle
79572438|NCT01815606|Procedure|biopsy with 25 gauge needle|biopsy with 25 gauge needle
79732323|NCT02835352|Other|Essential oils massages|
79732324|NCT02835352|Other|Oil massages|
79866890|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
79866891|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
79866892|NCT01082679|Drug|Methadone|daily for 12 months
79269977|NCT06218511|Combination Product|Durvalumab|anti-PD-L1
79866893|NCT01082679|Drug|buprenorphine (Suboxone)|daily for 12 months
79866894|NCT00976963|Drug|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
79866895|NCT00976963|Drug|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
79866896|NCT00958633|Drug|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
79866897|NCT00958633|Drug|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
79866898|NCT00911560|Biological|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, & 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), & continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic & bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood & bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or >2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
79269978|NCT06218511|Other|Montanide (Adjuvant)|Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .
79402141|NCT03597997|Drug|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
79572439|NCT01815632|Other|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
79572440|NCT01815632|Other|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
79572441|NCT01815658|Device|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
79572442|NCT01815684|Drug|ASP3652|Oral
79572443|NCT01815684|Drug|Placebo|Oral
79732325|NCT02630407|Biological|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
79732326|NCT02630407|Other|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
79732327|NCT04248790|Behavioral|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
79732328|NCT00667303|Other|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
79866899|NCT00911560|Biological|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
79866900|NCT00902590|Other|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
79572444|NCT01815697|Device|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
79866901|NCT00902590|Other|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
79866902|NCT00748254|Procedure|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
79866903|NCT00748254|Procedure|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
79402142|NCT03597997|Drug|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
80027038|NCT02177526|Device|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
80027039|NCT02179632|Behavioral|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
80027040|NCT02177604|Other|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
80027041|NCT02177604|Other|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
80027042|NCT02177604|Other|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
80027043|NCT02173236|Other|platform-switched implants|
80027044|NCT02173236|Other|platform-matched implant|
80027045|NCT03537300|Behavioral|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
80027046|NCT03537300|Behavioral|conventional exercises|conventional exercises
80027047|NCT03537144|Drug|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If <48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If >7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
80027048|NCT03537144|Drug|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
79402143|NCT01277835|Drug|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
79402144|NCT01277835|Drug|Placebo|Saline Infusion at same rate as experimental arm
79402145|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
79402146|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
79572445|NCT01815710|Other|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
80027049|NCT02632786|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
80027050|NCT02632786|Drug|Placebo|Saline Bag
80027051|NCT02173314|Other|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
79732329|NCT00667303|Other|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
79866904|NCT00591981|Behavioral|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
80027052|NCT02173470|Other|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
79402147|NCT01431287|Drug|tiotropium|low dose or high dose
79402148|NCT01431287|Drug|tiotropium|low dose or high dose
79402149|NCT01431287|Drug|olodaterol|one dose only
79402150|NCT01431287|Device|Respimat|Respimat inhaler
79866905|NCT00393783|Biological|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
79866906|NCT00074269|Biological|anti-thymocyte globulin|
79866907|NCT00074269|Biological|filgrastim|
79866908|NCT00074269|Biological|graft-versus-tumor induction therapy|
79866909|NCT00074269|Biological|therapeutic allogeneic lymphocytes|
79866910|NCT00074269|Drug|cyclosporine|
79866911|NCT00074269|Drug|fludarabine phosphate|
79866912|NCT00074269|Drug|melphalan|
79866913|NCT00074269|Drug|methotrexate|
79866914|NCT00074269|Procedure|peripheral blood stem cell transplantation|
79866915|NCT00423735|Drug|Dasatinib|Given PO
79866916|NCT00423735|Other|Pharmacological Study|Correlative studies
79866917|NCT00626327|Biological|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
79866918|NCT00626327|Biological|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
79866919|NCT00626327|Biological|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
79866920|NCT01032213|Drug|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
79866921|NCT01032213|Drug|normal saline|Group S received the same volume of isotonic saline as same method.
79866922|NCT00357994|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
79866923|NCT00357994|Drug|Placebo gel|
79866924|NCT00357994|Drug|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
79866925|NCT00357994|Drug|Placebo (PBO) oral capsules|
79866926|NCT00357994|Device|CADD-Legacy® 1400 ambulatory infusion pump|
79866927|NCT00357994|Device|PEG tube|percutaneous endoscopic gastrostomy tube
79866928|NCT00357994|Device|J-tube|jejunal tube
79866929|NCT00823433|Drug|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
79866930|NCT00423657|Drug|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
79866931|NCT00423657|Drug|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
79866932|NCT00423657|Drug|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
79866933|NCT00831155|Drug|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
79866934|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
79866935|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
79866936|NCT02533414|Device|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
79866937|NCT02533414|Device|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
79866938|NCT01029015|Procedure|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
79866939|NCT01029015|Procedure|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
79866940|NCT01050712|Drug|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
79866941|NCT01050712|Drug|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
79866942|NCT02550119|Drug|Aprepitant|Given PO
79866943|NCT02550119|Drug|Dexamethasone|Given PO or IV
79866944|NCT02550119|Drug|Dolasetron Mesylate|Given PO or IV
79866945|NCT02550119|Drug|Placebo|Given PO
79866946|NCT02548403|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
79866947|NCT02548403|Drug|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
79866948|NCT00823589|Other|Blood test and clinical test|Blood test and clinical test
79866949|NCT00367432|Drug|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
79866950|NCT01086670|Other|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
79866951|NCT01053052|Device|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
79866952|NCT01050868|Device|Accu-Chek Combo Kit mg DE/de|
79866953|NCT00623363|Drug|piclozotan|piclozotan, intravenous (IV) infusion
79866954|NCT00623363|Drug|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
79866955|NCT00827177|Drug|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If < 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
79572446|NCT01815710|Other|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
79572447|NCT01815723|Drug|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
79572448|NCT01815723|Drug|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
79572449|NCT01815723|Drug|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
79732330|NCT00667303|Other|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
79866956|NCT00823667|Other|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
80027053|NCT02173626|Behavioral|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
79732331|NCT02838238|Drug|Capecitabine|
80027054|NCT03067012|Other|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
80027055|NCT02177682|Drug|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
80027056|NCT03066934|Other|noninvasive ventilation respiratory support|
80027057|NCT03065764|Drug|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
80027058|NCT02755818|Drug|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
80027059|NCT02177760|Drug|Sirolimus|
79269979|NCT06218498|Device|ablative fractional 2940-nm Er: YAG laser|Ablative fractional 2940-nm Er: YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany), the following parameters were used: model of N25%, energy density of 20-30J/cm2, pulse time of 300μs and one to two passes.
79269980|NCT06218498|Device|non-ablative fractional 1565nm|Non-ablative fractional 1565nm (Lumenis, M22): Resur Fx len, energy of 30-35J/cm2, density of 200spot/cm2, overlap ≤10%.
79732332|NCT02838238|Drug|Placebo|
79732333|NCT00667537|Drug|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
79732334|NCT02835040|Other|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
79866957|NCT00823667|Other|medical chart review|Occurs at 1 year post study enrollment
79866958|NCT00823667|Other|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
79866959|NCT00823667|Procedure|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
80027060|NCT05723380|Procedure|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
80027061|NCT02179710|Behavioral|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
80027062|NCT02173782|Drug|Berodual® Respimat ® high dose|
80027063|NCT02173782|Drug|Berodual® Respimat ® low dose|
80027064|NCT02173782|Drug|Berodual® MDI|
80027065|NCT02173782|Drug|Placebo|
79269981|NCT06218498|Drug|5% Minoxidil|topical 5% minoxidil, 1 ml, twice daily
79269982|NCT06218485|Procedure|Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making|"The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR >0.80.~If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area"
79732335|NCT02835040|Other|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
79732336|NCT00667771|Drug|Naltrexone|
79732337|NCT01206764|Drug|RAD001|
79732338|NCT04248400|Other|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
79269983|NCT06218485|Procedure|Fractional flow reserve-guided PCI strategy|"The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~PCI will be performed if FFR ≤0.80 and will be deferred if FFR >0.80.~If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR ([FFR at stent distal edge] - [FFR at stent proximal edge]) < 0.05"
79269984|NCT06218459|Other|Oldpain2go®|OldPain2Go® is a non-medical intervention for the treatment of chronic pain conditions including, but not limited to Chronic Low Back Pain. The underlying premise is rooted in the biopsychosocial model of pain, where the cause of ongoing pain and the development of chronicity, is believed to lie beyond simple tissue damage, injury or malfunction. The intervention draws upon subconscious communication as a means to help patients to re-frame their pain as less threatening and remove old, out of date, pain messages that no longer serve a purpose.
79269985|NCT06218459|Other|Jacobson's progressive relaxation|Jacobson's progressive relaxation is a technique commonly used for eliciting the relaxation response and relieving muscular tension. It involves sequentially relaxing various muscle groups, often starting at the head and moving down the body to the feet.
80027066|NCT02179866|Drug|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) [14C]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
79269986|NCT06218433|Diagnostic Test|Urothelial cancer screening using urine tumor DNA test|Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
79269987|NCT06218433|Diagnostic Test|Urothelial cancer screening using urine cytology (comparator)|Urine cytology sample
79269988|NCT06218420|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
79732339|NCT04248400|Other|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
79269989|NCT06218407|Combination Product|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the medial orbitofrontal regions over long periods of time.
79732340|NCT00667927|Drug|Busulfan|See Detailed Description section for description of treatment plan.
79269990|NCT06218407|Combination Product|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the lateral orbitofrontal regions and networks over long periods of time.
79269991|NCT06218407|Combination Product|Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)|CBOT device enhanced with BCP.
79269992|NCT06218407|Combination Product|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactory stimuli (i.e., not programmed for short or long burst), and without BCP enhancement.
79572450|NCT01815723|Drug|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
79572451|NCT01815762|Other|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
79732341|NCT00667927|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
79732342|NCT00667927|Drug|Mesna|See Detailed Description section for description of treatment plan.
79732343|NCT02835118|Drug|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
79732344|NCT02835118|Drug|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
79732345|NCT00668005|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
79732346|NCT00668005|Drug|Placebo|Matching placebo
79732347|NCT02835196|Device|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
79732348|NCT02835196|Other|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
79732349|NCT05333692|Dietary Supplement|Fresubin® Protein Energy DRINK|1-2 bottles of Fresubin® Protein Energy DRINK per day
79866960|NCT00823667|Procedure|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
80027067|NCT05719948|Procedure|Flouroscopic guidance cervical medial branch radiofrequency ablation|Electromagnetic wave deposition near nerve tissue for pain management
80027068|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
79277642|NCT05792072|Device|rTMS|High-frequency rTMS
79732350|NCT05333692|Dietary Supplement|NEPRO® , Abbott|2-4 cans NEPRO® per day
79866961|NCT00823667|Procedure|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
79866962|NCT00423267|Drug|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
79866963|NCT00423267|Drug|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
79572452|NCT01815775|Other|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
79572453|NCT01815801|Other|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
79732351|NCT04154137|Other|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
79732352|NCT00668161|Behavioral|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
79732353|NCT00668239|Drug|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
79866964|NCT02549261|Drug|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
79866965|NCT02549261|Drug|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
79866966|NCT02549261|Drug|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
79866967|NCT02549261|Radiation|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
79866968|NCT01029093|Other|no intervention, MRI and motor skill test|Two MR Investigations at two different times
80027069|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
80027070|NCT02177916|Other|Education|
79269993|NCT06218394|Procedure|microneedling|The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.
79277643|NCT05792072|Device|Sham rTMS|sham rTMS
79572454|NCT01815801|Other|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
79572455|NCT01815814|Other|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
79732354|NCT00668239|Procedure|laser therapy|pan fotocoaglulation by laser therapy
79866969|NCT01032369|Other|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
80027071|NCT02173860|Procedure|FFR-guided surgical revascularization|
79866970|NCT01032369|Other|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
80027072|NCT02173860|Procedure|Angio-guided surgical revascularization|
80027073|NCT04210336|Device|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
80027074|NCT04210336|Device|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
80027075|NCT02173938|Other|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
80027076|NCT02180022|Drug|Placebo|After randomization, placebo was treated for 12 weeks
80027077|NCT02180022|Drug|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
80027078|NCT05717374|Drug|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
80027079|NCT05717374|Drug|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
80027080|NCT03537768|Drug|Ulipristal Acetate|UPA Tablet
80027081|NCT03537768|Drug|Levonorgestrel|LNG Tablet
79269994|NCT06218394|Procedure|Autologous Concentrated Growth Factor|"27~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15~20 minutes."
79269995|NCT06218394|Drug|5% minoxidil|topical 5% minoxidil, 1 ml, once daily
79572456|NCT01815827|Drug|inclacumab|single intravenous doses
79572457|NCT01815853|Radiation|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
79572458|NCT01815853|Drug|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
79572459|NCT01815853|Procedure|R0 D2 Gastrectomy|
79572460|NCT01815853|Drug|Adjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
79572461|NCT01815866|Procedure|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
79572462|NCT01815892|Drug|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
79866971|NCT02548325|Other|Not apply|None. Just registration epidemiology dates
79866972|NCT00823745|Drug|[14C]-PF-00868554|solution, single dose
79866973|NCT00626093|Device|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
79866974|NCT00357760|Biological|VEGF Trap|Given IV
79866975|NCT02548013|Other|outpatient management|patients if stable will be discharged to continue treatment at home
79866976|NCT02548013|Other|Inpatient management|patients will continue there treatment in hospital till delivery
79866977|NCT01049230|Radiation|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
79866978|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
79866979|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
79866980|NCT03742336|Drug|PF-04965842|Single oral 200 mg dose of PF-04965842
79866981|NCT03742336|Drug|Dabigatran|Single 75 mg dose of dabigatran
79866982|NCT00435825|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
79866983|NCT00824057|Drug|AZD6280|oral
79866984|NCT00824057|Drug|Midazolam|oral
79866985|NCT00824057|Drug|Caffeine|oral
79866986|NCT01053130|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
79866987|NCT01053130|Behavioral|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
79866988|NCT02534272|Other|Stool sampling and sequencing of gut microbiota.|
79866989|NCT00574145|Procedure|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
79866990|NCT00574145|Procedure|fatigue assessment and management|duration
79866991|NCT00574145|Procedure|psychosocial assessment and care|duration
80027082|NCT03537768|Drug|Levonorgestrel|LNG Tablet (x2)
79866992|NCT00574145|Procedure|quality-of-life assessment|duration
79866993|NCT00574145|Procedure|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
79866994|NCT01053208|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
79866995|NCT00831467|Biological|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
79866996|NCT00423189|Drug|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
79866997|NCT00423189|Drug|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
79866998|NCT03991858|Other|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
79866999|NCT03991858|Other|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
79867000|NCT00831545|Drug|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
80027083|NCT02180256|Procedure|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
80027084|NCT02174094|Drug|Clobazam|
80027085|NCT02174094|Drug|Placebo|
79732355|NCT00658801|Radiation|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~Group 2: 5cm <Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
79732356|NCT04156009|Other|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
79732357|NCT04156009|Other|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
79732358|NCT02631499|Procedure|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
79732359|NCT02631499|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
79732360|NCT02631499|Drug|lipiodol|lipiodol is a kind of embolization material used in TACE
80027086|NCT02174172|Drug|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
79269996|NCT06218381|Other|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
79572463|NCT01815892|Drug|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
80027087|NCT02174172|Drug|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
80027088|NCT02174172|Drug|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
79572464|NCT01815905|Other|Mobile program for occupational and speech therapy|
79732361|NCT00662233|Drug|cyclophosphamide|
79732362|NCT00662233|Drug|doxorubicin hydrochloride|
80027089|NCT02174172|Drug|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
79269997|NCT06218355|Other|Intensive Education|Intervention will consist of virtual education and communication through scheduled push notifications
79269998|NCT06218355|Other|Enhanced Virtual Care|"Intervention will utilize a telehealth model consisting of pull approach of patient engagement."
79269999|NCT06218342|Drug|Henagliflozin|Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.
79270000|NCT06218342|Other|Background medication|Participants will only receive lifestyle intervention and background medication.
79572465|NCT01815905|Other|Traditional rehabilitation therapy|
79732363|NCT00662233|Drug|etoposide|
79732364|NCT00662233|Drug|ifosfamide|
79732365|NCT00662233|Drug|vincristine sulfate|
79732366|NCT00662233|Procedure|adjuvant therapy|
79732367|NCT00662233|Procedure|neoadjuvant therapy|
79732368|NCT00662233|Procedure|therapeutic conventional surgery|
79732369|NCT00662233|Radiation|brachytherapy|
79732370|NCT00662233|Radiation|intraoperative radiation therapy|
80027090|NCT02174172|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
79572466|NCT01815944|Drug|0.75% Ropivacaine|
79572467|NCT01815944|Drug|Normal saline|
79572468|NCT01815944|Drug|Dextrose 5%|
79732371|NCT00662233|Radiation|radiation therapy|
79732372|NCT04156243|Biological|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
79732373|NCT00668629|Drug|Lactic acid (Dermacid)|
79732374|NCT02630173|Procedure|Scaling and root planing|Scaling and root planing was done in both the groups
79732375|NCT02630173|Other|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
79732376|NCT02632357|Other|Spinal Manipulation|
79732377|NCT00658957|Drug|gentamicin-collagen sponge|5 × 5 cm sponge
79732378|NCT00658957|Drug|placebo collagen sponge|5 × 5 cm sponge
79572469|NCT01815970|Behavioral|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
79732379|NCT00662467|Drug|aspirin + clopidogrel|Dual therapy
79732380|NCT00662467|Drug|aspirin + clopidogrel + warfarin|Triple therapy
79732381|NCT00668941|Drug|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
79732382|NCT00668941|Drug|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
80027091|NCT02174172|Drug|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
80027092|NCT02180334|Drug|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
79572470|NCT01815996|Other|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
79572471|NCT01814735|Other|Brown rice|
79572472|NCT01814735|Other|White rice|
79572473|NCT01816009|Other|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
79732383|NCT00668941|Dietary Supplement|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
79732384|NCT00668941|Dietary Supplement|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
80027093|NCT02180334|Drug|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
80027094|NCT02180334|Drug|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
79270001|NCT06218316|Drug|botulinum toxin A|Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles, with two injection sites at each head of the gastrocnemius and two sites into the medial hamstring. one vial of BoNT-A in 2 mL of 0.9% sodium chloride solution. followed by a 3-month rehabilitation program. The entire intervention including rTMS, BoNT-A, and rehabilitation training program spanned a period of three months.
79270002|NCT06218316|Device|Transcranial Magnetic Stimulation|Repeated Transcranial Magnetic Stimulation (rTMS) Stimulation coil will strategically place on the primary motor cortex (M1), The patients received 1500 pulses per session, two sessions per week for 3 months, in a combination with 3-month rehabilitation program.
79270003|NCT06218316|Other|Rehabilitation Training Protocol|Rehabilitation Training Protocol: As part of the study protocol, all participating children underwent a comprehensive weekly routine rehabilitation training program. Training Schedule: sessions will conduct for duration of 45 minutes. Training occurred four days a week.
79572474|NCT01816035|Other|Laboratory Biomarker Analysis|Correlative studies
79732385|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
79732386|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
79867001|NCT01051024|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
80027095|NCT03033745|Drug|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
80027096|NCT02174250|Drug|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
79572475|NCT01816035|Other|Pharmacological Study|Correlative studies
79572476|NCT01816035|Biological|Trastuzumab Emtansine|Given IV
79732387|NCT00894322|Other|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
79867002|NCT01051024|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
79867003|NCT02549417|Drug|KHK7580|Oral administration
79867004|NCT00824135|Drug|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
80027097|NCT02174250|Drug|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
80027098|NCT01672294|Other|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
79572477|NCT01816087|Other|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
79572478|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
79270004|NCT06218303|Biological|MUC1 Peptide Vaccine|MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
79270005|NCT06218303|Drug|Hiltonol®|A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
79270006|NCT06218303|Drug|Aromatase Inhibitor|A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
79270007|NCT06218290|Drug|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
79270008|NCT06218277|Diagnostic Test|ASTAR|Rapid AST with ASTAR
79270009|NCT06218264|Dietary Supplement|Ingestion of an amino acid supplement|Oral intake of a supplement containing amino acids
79572479|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
79572480|NCT01816113|Biological|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
79572481|NCT01816113|Biological|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
79572482|NCT01815177|Device|Arthroscopic transosseous fixation|
79572483|NCT01815177|Device|Suture anchors|
79572484|NCT01816178|Behavioral|communication training|Participants were instructed in the use of a voices output communication aid.
79572485|NCT01816191|Drug|Diltiazem Hydrochloride Cream and Oral Diltiazem|
79572486|NCT01816204|Behavioral|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
79572487|NCT01816204|Behavioral|face-to-face individual therapy|weekly individual counseling as usual.
79867005|NCT00824135|Procedure|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
79270010|NCT06218199|Drug|Furosemide|oral administration
79270011|NCT06218199|Drug|Torsemide|oral administration
79270012|NCT06218199|Drug|Bumetanide|oral administration
79270013|NCT06218199|Drug|sacubitril/valsartan|oral administration
79270014|NCT06218199|Drug|Hydralazine|oral administration
79270015|NCT06218199|Drug|Isosorbide Dinitrate|oral administration
79572488|NCT01816217|Device|Intubation with The McGrath Mac videolaryngoscope|
79572489|NCT01816282|Drug|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
79572490|NCT01816321|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
79867006|NCT00824135|Other|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
79867007|NCT00824135|Drug|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
79867008|NCT00824135|Drug|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
79867009|NCT00824135|Drug|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
79572491|NCT01816321|Drug|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
79732388|NCT02631265|Other|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
79867010|NCT00824135|Drug|Rituximab|375 mg/m2 intravenous for 1 dose total
79732389|NCT02631265|Other|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
79732390|NCT02631265|Other|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
79732391|NCT00662623|Behavioral|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
79732392|NCT00662623|Behavioral|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
79867011|NCT00824135|Other|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
79867012|NCT00422799|Drug|Bortezomib|Once weekly for 3 weeks
79867013|NCT00422799|Drug|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
80027099|NCT01672294|Other|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
80027100|NCT02174328|Drug|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
79867014|NCT00827333|Other|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
79867015|NCT00827333|Other|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
80027101|NCT02174328|Drug|Placebo|Placebo once a day until 36 week
80027102|NCT02177994|Drug|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
80027103|NCT02755116|Drug|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
80027104|NCT02755116|Drug|Placebo|placebo by mouth prior to anesthetic induction
80027105|NCT02178150|Dietary Supplement|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
80027106|NCT02178150|Dietary Supplement|Placebo|
80027107|NCT04411030|Drug|ASTX660|Form: capsule; Route of administration: oral
79304441|NCT03196063|Other|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
80027108|NCT04411030|Drug|Midazolam|Form: syrup; Route of administration: oral
80027109|NCT04411030|Drug|Itraconazole|Form: capsule; Route of administration: oral
80027110|NCT03066856|Other|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~reducing high glycemic index food and high insulinemic foods.~reducing sources of saturated fat (red and processed meat, milk and dairy products).~eating mostly food of plant origin, with a wide variety of seasonal products."
80027111|NCT02754492|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
79572492|NCT01816321|Drug|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
79572493|NCT01816321|Drug|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
79572494|NCT01816334|Drug|methylprednisolone|
79572495|NCT01816334|Drug|Ketoprofen|
79572496|NCT01816334|Drug|Sodium Chloride|
79572497|NCT01816347|Procedure|Routine PCI|
79572498|NCT01816360|Other|Olfactory aromatherapy|Inhalation of essential oils.
79572499|NCT01816360|Other|Yogatherapy|Yogatherapy respiratory exercises.
79572500|NCT01816373|Device|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
79572501|NCT01816399|Procedure|Routine coronary angiography|
79572502|NCT01816412|Device|MD02-LDCB Paclitaxel coated balloon catheter|
79572503|NCT01816412|Procedure|Standard Uncoated Balloon Angioplasty Catheter|
79572504|NCT01816425|Device|Thermoplastic partial denture|
79572505|NCT01816425|Device|CoCr partial denture|
79572506|NCT01816464|Biological|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
80027112|NCT04068688|Behavioral|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
80027113|NCT04068688|Behavioral|Telehealth coaching|The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
79572507|NCT01816490|Drug|Intravenous Silibinin (iSIL)|
79867016|NCT00827333|Procedure|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
79572508|NCT01816503|Drug|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
79867017|NCT00827333|Procedure|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
79867018|NCT00827333|Procedure|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
79867019|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
79867020|NCT00827411|Device|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
79867021|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
80027114|NCT02174640|Dietary Supplement|Coffee|Coffee Beverage
80027115|NCT02174640|Dietary Supplement|Water|Water
79270016|NCT06218186|Device|Medical Device: Wesper Lab Home Sleep Test|Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
79270017|NCT06218160|Drug|Hydromorphone combined with ropivacaine|1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block
79270018|NCT06218160|Drug|Ropivacaine|A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
79270019|NCT06218147|Behavioral|Nutrition-behavior lifestyle program|The 15 participants randomized to the intervention group will complete the activities described in the arm/group description.
79270020|NCT06218134|Biological|human Wharton's jelly-derived mesenchymal stem cells|human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)
79572509|NCT01816516|Behavioral|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
79732393|NCT00669097|Drug|TKI258|
79732394|NCT00633412|Drug|Esomeprazole|20mg oral daily
79732395|NCT00633412|Drug|Ranitidine|150mg oral twice daily
79732396|NCT00633412|Drug|Esomeprazole|40mg oral tablet daily
79732397|NCT00596635|Dietary Supplement|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
79732398|NCT00596635|Dietary Supplement|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
79732399|NCT00659113|Drug|cisplatin|
79732400|NCT00659113|Drug|tegafur-gimeracil-oteracil potassium|
79732401|NCT00659113|Other|cytology specimen collection procedure|
79732402|NCT00659113|Procedure|endoscopic biopsy|
79732403|NCT00662701|Procedure|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
79732404|NCT00662701|Procedure|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
79732405|NCT04159051|Device|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
79732406|NCT00662779|Drug|arformoterol|15 mcg arformoterol nebulizer
79732407|NCT00662779|Drug|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
79270021|NCT06218108|Diagnostic Test|Taulí-T1 versus conventional classifications|All the slides of each case will be reviewed, selecting the one that contains the most invasive section, and this will be digitized to take measurements in micrometers with greater precision. To measure the degree of infiltration, the measurement of residual healthy submucosa (hrSB) will be used, which is the distance between the point of greatest infiltration and the muscularis propria. The total thickness of the submucosa in the tumor area will also be measured, taking as a reference the muscularis of the mucosa or, in its absence, the surface of the lesion, to calculate the percentage of infiltration of the submucosa. This percentage will be calculated as the inverse percentage of invasion with respect to the hrSB: (total thickness of the submucosa - hrSB / total thickness of the submucosa) x 100. The qualitative categories will be obtained: sm1 (< 33.3%), sm2 (33.3% - 66.6%) and sm3 (> 66.6%). Measurements will be also taken in micrometers for the conventional classifications.
79270022|NCT06218095|Other|Simulation application|Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
79270023|NCT06218069|Drug|Sasanlimab|6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
79270024|NCT06218069|Radiation|non-ablative radiotherapy|Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
79270025|NCT06218069|Drug|[89Zr]Zr-crefmirlimab berdoxam|Prior to sasanlimab injection and prior to surgery, [89Zr]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
79572510|NCT01816516|Behavioral|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
79572511|NCT01816529|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
79572512|NCT01816529|Drug|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
79572513|NCT01816529|Drug|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
79402151|NCT05632159|Drug|Mg sulphate|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
79402152|NCT05632159|Drug|conventional anaesthesia|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
79402153|NCT00722007|Device|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
79867022|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
79402154|NCT03024931|Other|observational study|No intervention
79402155|NCT04017013|Procedure|Epidural Analgesia|"The epidural infusion will be as follows:~Isobaric Bupivacaine 0.5% 40 cc~Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~Saline solution 0.9% 156 cc.~Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement."
79402156|NCT04017013|Drug|Lidocaine Infusion|2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
79402157|NCT01277913|Drug|Vitamin D3|1000 IU once daily for 12 months
79402158|NCT01277913|Drug|Vitamin D3|500 IU once daily for 12 months
79402159|NCT04385901|Behavioral|Therapy Intervention|Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
79402160|NCT03992677|Other|No intervention|No intervention
79402161|NCT00729807|Drug|pentamidine|
79402162|NCT03590119|Drug|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
79402163|NCT04385511|Device|supraglottic jet ventilation|patients who were randomized into supraglottic jet ventilation group would be placed Wei Nasal Jet Tube after conducted. Then they will get the supraglottic jet ventilation to make sure their pulse oximetry is over 95%. After 3 minutes, endotracheal intubation was performed via mouth approach.
79402164|NCT01272297|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
79732408|NCT00662779|Drug|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
79732409|NCT00669253|Procedure|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
79732410|NCT00669253|Procedure|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
79732411|NCT00669253|Procedure|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
79732412|NCT02630329|Procedure|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
79867023|NCT00827411|Drug|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
80027116|NCT04437654|Drug|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
80027117|NCT05526508|Device|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
80027118|NCT03973918|Drug|Encorafenib|450mg QD 28 day cycle
79732413|NCT02630329|Procedure|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
79732414|NCT00911599|Diagnostic Test|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
79867024|NCT00435045|Drug|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
80027119|NCT03973918|Drug|Binimetinib|45mg BID 28 day cycle
79732415|NCT00662935|Procedure|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
79732416|NCT02630095|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
79732417|NCT02630095|Device|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
79867025|NCT00435045|Drug|atorvastatin|atorvastatin + placebo
79867026|NCT01029171|Behavioral|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
79867027|NCT01029171|Behavioral|control; usual care|Usual care as prescribed by geriatrician.
79867028|NCT00441129|Device|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
79867029|NCT00441129|Device|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
79867030|NCT00622505|Drug|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters [ml]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
80027120|NCT03973918|Biological|Research Bloods|Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
79270026|NCT06218056|Drug|Cannabidiol (CBD) 400 mg or 800 mg|CBD (200 mg or 400 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
79270027|NCT06218056|Drug|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 56 days.
79402165|NCT05366023|Behavioral|BUD1|10 hours of bottom-up driven computerized cognitive training designed to improve processing speed and divided attention
79402166|NCT05366023|Behavioral|BUD2|10 hours of bottom-up driven computerized cognitive training designed to improve divided attention
79867031|NCT02550275|Behavioral|neuropsychological test|
79572514|NCT01816529|Drug|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
79867032|NCT02550275|Radiation|MRI|
79867033|NCT02549183|Device|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
79867034|NCT02550353|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
79867035|NCT02550353|Procedure|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
79402167|NCT05366023|Behavioral|TDD1|10 hours of top-down driven computerized cognitive training designed to improve multiple object tracking
79572515|NCT01816542|Other|patch tests on healthy skin|Patches will be placed on healthy skin.
79572516|NCT01816555|Dietary Supplement|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
79572517|NCT01816568|Procedure|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
79572518|NCT01816568|Procedure|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
79572519|NCT01816581|Drug|Targin|
79572520|NCT01816581|Drug|Oxynorm|
79572521|NCT01816581|Drug|Morphine|
79867036|NCT00827489|Drug|HTC-867|
79867037|NCT00827489|Other|Placebo|
80027121|NCT03973918|Biological|Tumor Tissue|at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
80027122|NCT02185638|Other|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
80027123|NCT02185716|Drug|Levobupivacaine 0.25 %|
80027124|NCT02185716|Drug|Levobupivacaine 0.5%|
80027125|NCT01671748|Device|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
80027126|NCT01671748|Other|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
80027127|NCT02182050|Drug|BIBF 1120 ES low dose|
80027128|NCT02182050|Drug|BIBF 1120 ES high dose|
80027129|NCT02182050|Drug|Placebo to BIBF 1120 ES|
79270028|NCT06218043|Behavioral|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
79270029|NCT06218017|Device|High flow nasal oxygen fist|Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
79572522|NCT01816607|Procedure|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
79572523|NCT01816620|Drug|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
79572524|NCT01816633|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
79572525|NCT01816646|Drug|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
79572526|NCT01816646|Drug|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
79572527|NCT01816659|Drug|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
79732418|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
79732419|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
79732420|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
79732421|NCT00669565|Drug|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
79867038|NCT00831857|Other|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
79867039|NCT00824447|Drug|Oralgen|allergen solution sublingually
79867040|NCT00824447|Other|placebo|placebo control
80027130|NCT02182128|Drug|BIBF 1120|
79270030|NCT06218017|Device|High flow nasal oxygen later|Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
79270031|NCT06218004|Drug|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
79277644|NCT05791994|Procedure|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
79402168|NCT05366023|Behavioral|TDD2|10 hours of top-down driven computerized cognitive training designed to improve executive function
79572528|NCT01816672|Device|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
79572529|NCT01816672|Other|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
79732422|NCT00669643|Drug|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
80027131|NCT02182206|Drug|BIBF 1120|
79572530|NCT01816698|Drug|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
79732423|NCT00669643|Drug|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
79732424|NCT00669643|Drug|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
79732425|NCT00669643|Drug|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
79732426|NCT00669721|Drug|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
80027132|NCT02180490|Drug|UHAC 62 XX tablet|
80027133|NCT02180490|Drug|UHAC 62 XX capsule|
80027134|NCT03963544|Drug|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
80027135|NCT02180568|Procedure|Lipiodol|Lipiodol-guided lung localization technique
80027136|NCT02180568|Procedure|Hookwire|Hookwire-guided lung localization technique
80027137|NCT02180568|Drug|Lipiodol|
80027138|NCT02657889|Drug|niraparib|
80027139|NCT02657889|Biological|pembrolizumab|
80027140|NCT02182284|Drug|low dose BI 201335 NA soft gelatine capsule (SGC)|
80027141|NCT02182284|Drug|high dose BI 201335 NA soft gelatine capsule (SGC)|
80027142|NCT02182284|Drug|low dose BI 201335 NA powder in bottle (PIB)|
80027143|NCT02182284|Drug|high dose BI 201335 NA powder in bottle (PIB)|
80027144|NCT03536286|Behavioral|Encouragement|Households will be visited and encouraged to enroll in Asili
79402169|NCT05366023|Behavioral|CSA10|10 hours of computerized games
79270032|NCT06217991|Procedure|PTST(parachute-tunnel-style technique)for esophagogastrostomy|Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
79270033|NCT06217965|Other|survey|The study will involve patients completing a questionnaire on a secure online platform (such as RedCap)
79572531|NCT01816698|Drug|Placebo|Placebo: 1 package once a day after meals, 12 weeks
79572532|NCT01816750|Device|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
79572533|NCT01816789|Drug|rFSH|
79572534|NCT01816789|Drug|buserelin|
79572535|NCT01816802|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
79572536|NCT01816815|Drug|BAY1002670|
79732427|NCT00669721|Drug|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
79867041|NCT02548169|Biological|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
79867042|NCT04043429|Behavioral|Vision Restoration Training (VRT)|
79867043|NCT04043429|Behavioral|Vision Exploration Training (VET)|
79572537|NCT01816815|Drug|Placebo|
79572538|NCT01816828|Behavioral|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
79867044|NCT04043819|Drug|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
80027145|NCT03536208|Drug|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
80027146|NCT03034915|Drug|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
79270034|NCT06217952|Drug|SPL84|SPL84 solution for nebulization
79270035|NCT06217952|Other|Placebo|Placebo solution for nebulization
79270036|NCT06217939|Drug|Early hydrocortisone|"For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
79402170|NCT05366023|Behavioral|CSA20|20 hours of computerized games
79572539|NCT01816828|Other|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
79572540|NCT01816841|Procedure|fluorescence imaging|Undergo DVFE
79572541|NCT01816841|Procedure|biopsy|Undergo scalpel biopsy
79572542|NCT01816841|Procedure|examination|Undergo COE
79402171|NCT05366023|Behavioral|CSA30|30 hours of computerized games
79402172|NCT05366023|Behavioral|CSA40|40 hours of computerized games
79572543|NCT01816841|Procedure|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
79732428|NCT00669799|Drug|gentamyacin|topical internasal
79732429|NCT00669799|Drug|gentamyacin|intranasal
79732430|NCT04158505|Other|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
79732431|NCT00659347|Drug|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
79732432|NCT00659347|Drug|Placebo|Capsules,25 mg,BID,6weeks
79867045|NCT04016987|Behavioral|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
79867046|NCT00824681|Behavioral|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
80027147|NCT03034915|Drug|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
79572544|NCT01816854|Device|Stenting|
79867047|NCT00824681|Other|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
79572545|NCT01816867|Device|Intramesh T1 implantation|
79572546|NCT01816919|Other|collecting breath samples|
79572547|NCT01816958|Other|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
79732433|NCT00894166|Drug|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
79732434|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
79732435|NCT00894166|Drug|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
79867048|NCT00832013|Drug|Propofol|See detailed description
79867049|NCT00832013|Drug|Propofol|See detailed description
79867050|NCT00824759|Other|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
79867051|NCT00832169|Drug|AZD1386|1 dose of oral solution
79867052|NCT00824837|Other|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
79732436|NCT00894166|Drug|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
79867053|NCT00824837|Other|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
79867054|NCT00832247|Genetic|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
79867055|NCT00832403|Other|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
79867056|NCT02550041|Other|T specific response for diagnostic of aspergillus bronchitis|
79867057|NCT00832481|Drug|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
79867058|NCT00832481|Drug|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
79867059|NCT04044287|Drug|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
79867060|NCT04044287|Drug|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
79867061|NCT00827801|Behavioral|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 & 8.
79867062|NCT02549729|Behavioral|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
79867063|NCT00827879|Behavioral|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
79867064|NCT00827879|Behavioral|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
79572548|NCT01816997|Drug|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
79572549|NCT01816997|Drug|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
79572550|NCT01816997|Drug|Control|placebo
79572551|NCT01817010|Behavioral|Multi-Component Rehabilitation (CMC)|
79572552|NCT01817010|Behavioral|Control (CON)|
79572553|NCT01817023|Radiation|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
79572554|NCT01817023|Drug|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
79572555|NCT01817036|Dietary Supplement|Placebo|placebo
79572556|NCT01817036|Dietary Supplement|Vitamin D|400 IU vitamin D per pill
79572557|NCT01817049|Behavioral|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
79867065|NCT00832559|Biological|CVA21|1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
79867066|NCT02549807|Device|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
79270037|NCT06217939|Drug|Normal saline placebo|"For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
79270038|NCT06217939|Drug|Open-label hydrocortisone|An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
79402173|NCT01278147|Behavioral|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
79572558|NCT01817049|Behavioral|placebo attention control|
79572559|NCT01817088|Procedure|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
79572560|NCT01817088|Procedure|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
79572561|NCT01817101|Dietary Supplement|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
79572562|NCT01817114|Device|Auto Remote Ischemic Conditioning (AutoRIC) device|
79572563|NCT01817153|Drug|hydrocortison hemisuccinate|
79572564|NCT01817153|Drug|placebo followed by hydrocortisone hemisuccinate|
79867067|NCT03856307|Diagnostic Test|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
79867068|NCT00357370|Drug|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
79867069|NCT00357370|Drug|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
79867070|NCT00832715|Procedure|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
79867071|NCT00825071|Drug|Dexamethasone|8 mg, Intravenous
79867072|NCT00825071|Drug|Ondansetron|4 mg, intravenously
79867073|NCT00825071|Drug|normal saline|2 ml, intravenously
79867074|NCT00827957|Device|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
79867075|NCT00827957|Device|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
79867076|NCT03987724|Other|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
79867077|NCT00574847|Drug|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
79277645|NCT05791994|Procedure|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
79572565|NCT01817179|Other|FES neuroprosthesis to dorsiflexors on affected leg|
79572566|NCT01817205|Procedure|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
79572567|NCT01817218|Drug|Platelet Rich Plasma|
79867078|NCT00574847|Drug|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
79867079|NCT00348790|Drug|vatalanib|
79867080|NCT00828035|Procedure|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
79867081|NCT00825149|Drug|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
79867082|NCT00825149|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
79867083|NCT00825149|Drug|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
79867084|NCT00825149|Drug|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
79270039|NCT06217926|Behavioral|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
79270040|NCT06217913|Device|wearable device to monitor the blood pressure|Pregnant women began to establish antenatal examination records (usually before 12 weeks of pregnancy), and were enrolled through randomized grouping. Pregnant women in the intervention group were provided with wearable blood pressure monitoring equipment, and ambulate blood pressure monitoring was conducted for at least 2 24 hours per week from 12 weeks of pregnancy until 28 weeks of pregnancy, after which blood pressure monitoring was carried out according to routine antenatal examination.
79572568|NCT01817218|Device|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
79572569|NCT01817244|Other|care management|6-month care management
79572570|NCT01817257|Drug|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
79572571|NCT01817270|Biological|Live Attenuated Varicella Vaccine|
79270041|NCT06217887|Drug|loxenatide Group|Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
79270042|NCT06217887|Drug|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
79572572|NCT01817283|Drug|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
79572573|NCT01817283|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
79572574|NCT01817283|Drug|placebo|Placebo pills produced the same as Triptolide wilfordii.
79270043|NCT06217874|Other|Non-Interventional Study|Non-interventional study
79270044|NCT06217861|Biological|VGM-R02b|Administered as specified in the treatment arm.
79270045|NCT06217848|Drug|Saxenda|Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
79270046|NCT06217835|Other|To evaluate the response of an orthopedic insole|To evaluate the response of an orthopedic insole of different heights on gait.
79270047|NCT06217835|Other|evaluate activation of musculature|To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.
79572575|NCT01817296|Procedure|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
79572576|NCT01817309|Other|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
79572577|NCT01817322|Drug|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
79572578|NCT01817322|Drug|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
79572579|NCT01817322|Drug|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
79270048|NCT06217809|Behavioral|The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.|The intervention is gender-specific, youth-co-led, and targets minorities through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to sexual health and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
79270049|NCT06217783|Device|Introcan Safety IV Catheter|Given by IV
79270050|NCT06217692|Other|nutrition education|nutrition education
79572580|NCT01817335|Procedure|psychosocial assessment and care|Participate in psycho-educational program
79270051|NCT06217549|Other|ozone therapy|Medical ozone is a mixture of pure ozone gas (0.05-5%) and pure oxygen (99.95-95%). It is produced from pure medical oxygen by medical ozone generators. It is applied to the participants 10 sessions by the intravenous method.
79402174|NCT04248127|Other|Honey sweetened yogurt|2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions
79572581|NCT01817335|Other|educational intervention|Participate in psycho-educational program
79270052|NCT06217276|Other|Respiratory muscle fatigue protocol|It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
79572582|NCT01817335|Other|communication skills training|Participate in psycho-educational program
79270053|NCT06217159|Dietary Supplement|Poikilocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.
79270054|NCT06217159|Dietary Supplement|Normocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
79270055|NCT06217146|Drug|Medical Cannabis|MediCane's balanced T3:C3 medical cannabis oil
79270056|NCT06217146|Drug|Placebo Oil|Placebo Oil
79270057|NCT06216808|Device|HyperQure Renal Denervation System|"The HyperQure RDN System consists of a generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA."
79572583|NCT01817335|Other|questionnaire administration|Ancillary studies
79732437|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
79732438|NCT00894166|Drug|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
79732439|NCT00894166|Drug|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
79867085|NCT00825149|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
79867086|NCT00825149|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
79867087|NCT00825149|Drug|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
79867088|NCT00825383|Other|High Fiber and Moderate Fiber Diets|Dietary
79867089|NCT00360490|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
79732440|NCT00880165|Device|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
79732441|NCT02834650|Other|Cardiac MRI with contrast|Cardiac MRI
79732442|NCT02834650|Other|Cardiac MRI without contrast|Cardiac MRI
79867090|NCT00360490|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
79867091|NCT02549105|Drug|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
79867092|NCT02549105|Drug|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
79867093|NCT00828269|Procedure|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
79867094|NCT00833183|Drug|MAL|80 mg/g cream one administration with incubation for 90 minutes
79867095|NCT00624377|Drug|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
79867096|NCT02549963|Device|WATCHMAN Left Atrial Appendage Occlusion Device|
79867097|NCT02549963|Drug|Rivaroxaban|
79270058|NCT06216704|Diagnostic Test|Magnetic resonance relaxometry|Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
79572584|NCT01817348|Procedure|Lidocaine group|"Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
79572585|NCT01817348|Other|Physiotherapy (PT)|- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
79572586|NCT01817387|Behavioral|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
79572587|NCT01817387|Behavioral|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
80027148|NCT03034915|Drug|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
79572588|NCT01817400|Other|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
79732443|NCT02834650|Other|Blood Test|Hematocrit, Creatinine, Troponin, BNP
79270059|NCT06216704|Diagnostic Test|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
79270060|NCT06216704|Diagnostic Test|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
79270061|NCT06216704|Diagnostic Test|DXA|DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
79270062|NCT06216704|Diagnostic Test|pQCT|pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
79867098|NCT00624065|Drug|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
79867099|NCT00624065|Drug|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
79867100|NCT00360412|Drug|E2007|
79402175|NCT04248127|Other|Sugar sweetened yogurt|sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
79732444|NCT02834650|Other|Heart Rate|Holter Monitor
79402176|NCT05631691|Behavioral|Support for Students exposed to Trauma Program|Support for students exposed to trauma program (SSET) is a school-based intervention program for students who have been exposed to traumatic events and exhibit signs of post-traumatic stress disorder (PTSD). (Jaycox, Langley, & Dean, 2009; Jaycox, Langley, Stein et al., 2009). SSET is specifically designed for school teachers, school counsellors, and other non-clinical staff. SSET program is a series of 10 structured lessons designed to reduce post-traumatic and depressive symptoms and improve functioning in school children exposed to traumatic events. it includes psycho-education, relaxation, cognitive restructuring, social problems solving and behavioral exposure.
79732445|NCT02834650|Other|Pulmonary Function Test|Pulmonary Function Test
79867101|NCT00623831|Biological|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
79402177|NCT03990805|Biological|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection
79402178|NCT03990805|Drug|saline|saline, 1 time injection
79867102|NCT00833339|Drug|mifepristone|600 mg/day x 1 week
79867103|NCT00833339|Drug|placebo|placebo
79867104|NCT02549885|Other|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
79270063|NCT06216652|Other|downhill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the first group performed downhill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
79270064|NCT06216652|Other|uphill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the second group performed uphill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
79270065|NCT06216652|Other|walking with no incline|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the third group performed walking with no incline walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
79732446|NCT02834650|Other|Genetic Testing|Genetic Testing
79732447|NCT02834650|Other|Repeat MRI scan|Repeat MRI scan
79867105|NCT02549885|Other|Static stretching|Static stretching of neck muscles.
79867106|NCT00825617|Drug|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
79732448|NCT04032223|Procedure|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
79732449|NCT00659503|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
79732450|NCT00659503|Drug|Placebo|placebo
79867107|NCT00825695|Dietary Supplement|cocoa|two servings of cocoa daily for one month
79867108|NCT00360334|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
79867109|NCT00360334|Drug|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
80027149|NCT03034915|Drug|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
80027150|NCT03034915|Drug|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
79572589|NCT01817400|Dietary Supplement|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
80027151|NCT02182362|Drug|BI 201335 NA|
79270066|NCT06216600|Behavioral|Acceptance and Commitment Therapy (ACT)|Participants will undergo ACT in combination with exercise and social support.
79270067|NCT06216600|Behavioral|Body weight circuit training|Participants will learn and undergo body weight circuit training in combination with ACT and social support.
79270068|NCT06216600|Behavioral|Empathetic social support|Study participants will participate in empathetic social support
80027152|NCT02182362|Drug|Placebo|
79732451|NCT04248556|Other|Health care product|Health care product (gel) - to be applied on the participant's skin
79867110|NCT00422097|Drug|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
79867111|NCT00422097|Drug|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
79572590|NCT01817400|Drug|Aspirin|
79867112|NCT00422097|Drug|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
80027153|NCT05373459|Biological|Third COVID-19 booster|Third COVID-19 booster
79572591|NCT01817400|Drug|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
79572592|NCT01817413|Procedure|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
79732452|NCT00663013|Other|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
79732453|NCT02834728|Behavioral|telephone interview|
80027154|NCT02180802|Behavioral|motivational interviewing|
80027155|NCT02180802|Behavioral|motivational interviewing with parental involvement|
79732454|NCT04158193|Other|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
80027156|NCT02180802|Behavioral|Control group|
80027157|NCT05141136|Procedure|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
80027158|NCT05141136|Procedure|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
79270069|NCT06216600|Other|Control - list of resources|A local list of resources to access exercise, therapy and social support will be provided.
79270070|NCT06216405|Procedure|Colonoscopy|Colonoscopy
79270071|NCT06216366|Drug|Sodium Chloride 0.9% Inj pre-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure
79572593|NCT01817413|Procedure|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
80027159|NCT03578757|Behavioral|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes…). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
80027160|NCT03577509|Drug|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
79732455|NCT04158193|Other|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
79572594|NCT01817439|Drug|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
79572595|NCT01817465|Drug|Motilitone ®|
79732456|NCT02834572|Behavioral|All About Me|Assessment and algorithm to determine recommended HIV testing approach
79732457|NCT02834572|Behavioral|Control|HIV testing information
79732458|NCT04158115|Other|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
79732459|NCT04158115|Other|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
79732460|NCT00670189|Drug|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
79867113|NCT00422097|Drug|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
79867114|NCT00422097|Drug|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
79867115|NCT00422097|Drug|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
79867116|NCT00422097|Drug|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
79867117|NCT00422097|Drug|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
79270072|NCT06216366|Drug|Sodium Chloride 0.9% Inj post-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure
79572596|NCT01817465|Drug|Pantoline®|
79572597|NCT01817465|Drug|Motilitone® and Pantoline®|
79572598|NCT01817478|Other|microbiologic sample|
79572599|NCT01816386|Other|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
79867118|NCT02534194|Other|Image acquisition|Images of baby's face (including ear) and feet
79270073|NCT06216366|Drug|Recombinant human plasma gelsolin pre-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure
79270074|NCT06216366|Drug|Recombinant human plasma gelsolin post-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure
79270075|NCT06216366|Other|Hyperbaric chamber|High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
79867119|NCT01051102|Drug|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
79572600|NCT01816386|Other|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
79572601|NCT01817543|Device|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
79867120|NCT01051102|Drug|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
79867121|NCT01053364|Device|NL-Prow interspinous spacer implant|Interspinous spacer implant
79572602|NCT01817556|Drug|Stillen Tab.|
79732461|NCT00663091|Drug|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
79867122|NCT00348556|Drug|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
79867123|NCT00434967|Drug|Candesartan cilexetil|32 mg oral tablet
79867124|NCT00434967|Drug|Hydrochlorothiazide|25 mg oral tablet
80027161|NCT02631538|Drug|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
79270077|NCT06215690|Diagnostic Test|Ultrasound measurements|"Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~BPD (Biparietal Diameter)~HC (Head Circumference)~AC (Abdominal Circumference)~FL (Femur Length)~EFW (Estimated Fetal Weight)~Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~Middle Cerebral Artery S/D,PI,RI~Uterine Artery Doppler PI~Anterior Cerebral Artery S/D,PI,RI~CPUR (Cerebral - Placental - Uterin PI Ratio)~CPR (Cerebral - Placental PI Ratio)~The deepest free single vertical pocket in the amnion mai~Cavum Septum Pellucidum: Width - Length Diameters~OFD (Occipitofrontal length)~FAPD (Frontal Anterior Posterior Diameter)~FAPD/OFD ratio~Cerebellar diameter~Lateral ventricle depth~Insular depth~Sylvian fissure depth"
79270078|NCT06215599|Other|Survey|The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
79270079|NCT06215196|Dietary Supplement|Fiber Supplement Group|Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
79270080|NCT06215196|Other|placebo|Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
79270082|NCT06214871|Device|rTMS|Transcranial Magnetic Stimulation
79270083|NCT06214780|Device|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
79270084|NCT06214273|Device|Low level diode laser|diode laser with a wave length range of 800-980 n m and power less than 500 ml
79270085|NCT06214273|Drug|Chamomile|Chamomile 3% mucoadhesive gel
79867125|NCT00434967|Drug|Candesartan/HCT 32/25 mg|
79867126|NCT00825773|Device|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
79867127|NCT00833729|Drug|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
79867128|NCT00837239|Drug|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
79867129|NCT00837239|Drug|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
79867130|NCT00837239|Drug|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
79867131|NCT00833807|Drug|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
79867132|NCT00833885|Device|Masks|Wearing of surgical masks
79867133|NCT00833885|Device|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
80027162|NCT02631538|Drug|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
80027163|NCT02631538|Drug|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
80027164|NCT02631538|Drug|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
80027165|NCT03577353|Behavioral|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
80027166|NCT03577353|Behavioral|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
79270086|NCT06214273|Drug|Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel|Topical anti-inflammatory, topical analgesic and topical antifungal
79270087|NCT06214221|Device|Signos System|The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
79270088|NCT06214221|Other|Standard Lifestyle Education|"In the Standard Lifestyle Education arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight."
79270089|NCT06214130|Drug|Sodium valproate 500 MG|oral intake
79270090|NCT06214130|Drug|Valproic Acid 500 MG|oral intake
79270091|NCT06213636|Biological|CD19/CD22-CAR T cells|"The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
79270092|NCT06213181|Other|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
79572603|NCT01817556|Drug|Mucosta Tab.|
79867134|NCT00833885|Other|Control|General information about virus transmission in households and basic means to prevent it
79572604|NCT01817595|Other|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
79867135|NCT00833963|Drug|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
79867136|NCT00833963|Drug|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
79867137|NCT00833963|Drug|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
79867138|NCT00837317|Dietary Supplement|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
79270093|NCT06212102|Drug|Progestin primed ovarian stimulation|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
79270094|NCT06212102|Drug|GnRH antagonist|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
79572605|NCT01817595|Other|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
79572606|NCT01817621|Behavioral|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
79867139|NCT04043897|Drug|Rifaximin 550mg|Rifaximin 550mg
79867140|NCT00356590|Biological|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
79867141|NCT04043663|Device|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
79867142|NCT04043663|Procedure|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
79867143|NCT00837551|Drug|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
79867144|NCT00834353|Drug|ATT|
79867145|NCT03987334|Other|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
79867146|NCT03987334|Other|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
80027167|NCT03584061|Procedure|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
80027168|NCT03578679|Drug|Ivermectin Oral Product|treatment of pediculosis (head lice)
79270095|NCT06212089|Drug|TR-012001|A single dose of TR-012001 will be administered.
79270096|NCT06212089|Other|Placebo|A single dose of placebo will be administered.
79572607|NCT01817621|Behavioral|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
79867147|NCT02548871|Behavioral|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
79867148|NCT03987256|Other|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
79867149|NCT03987256|Procedure|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
79867150|NCT03987256|Procedure|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
79867151|NCT00828503|Drug|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
79867152|NCT00828503|Drug|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
80027169|NCT04930783|Drug|CDX-301|Administered as an injection given underneath the skin
80027170|NCT04930783|Biological|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
80027171|NCT04930783|Drug|Nivolumab|Administered intravenously (IV)
80027172|NCT03583281|Dietary Supplement|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
80027173|NCT03583281|Dietary Supplement|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
79572608|NCT01817634|Dietary Supplement|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
80027174|NCT05479981|Drug|Placebo|Placebo will be administered by intravenous (IV) infusion.
80027175|NCT05479981|Drug|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
80027176|NCT03583203|Device|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
79572609|NCT01817634|Dietary Supplement|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
79572610|NCT01817634|Dietary Supplement|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
79572611|NCT01817634|Dietary Supplement|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
79572612|NCT01817647|Procedure|Colorectal surgery|
79572613|NCT01817660|Procedure|Open repair of popliteal artery|
79270097|NCT06210828|Behavioral|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
79572614|NCT01817660|Procedure|Endovascular repair of popliteal artery|
79270098|NCT06210828|Behavioral|Control|Receive fall prevention exercise brochure
79402179|NCT03595501|Device|Hematology Analyzer - OLO|Complete blood counts from OLO will be determined from analysis of whole blood samples
79270099|NCT06210685|Device|Automatic Continuous Effusion Shunt implantation|The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
79270100|NCT06210386|Device|Noninvasive ventilation|noninvasive ventilation
79867153|NCT03990220|Dietary Supplement|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
79270101|NCT06209866|Device|PTA|Percutaneous Trans lumenal Angioplasty
79270102|NCT06209632|Behavioral|mirror therapy|30 minutes of intervention, twice a week, and a total of 12 weeks
79270103|NCT06209632|Device|contralaterally controlled functional electrical stimulation|30 minutes of intervention, twice a week, and a total of 12 weeks
79270104|NCT06209632|Behavioral|conventional physiotherapy|50 minutes of intervention, twice a week, and a total of 12 weeks
79270105|NCT06209554|Device|ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser|diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
79572615|NCT01817673|Dietary Supplement|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
79270106|NCT06208488|Drug|Gefurulimab PFS-SD|Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
79270107|NCT06208488|Drug|Gefurulimab AI|Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
79572616|NCT01817673|Dietary Supplement|placebo|
79867154|NCT03990376|Other|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
79867155|NCT00834509|Device|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
79867156|NCT01051180|Procedure|HALO|Ligation of haemorrhoidal arteries
79867157|NCT04322825|Device|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
79867158|NCT03990142|Diagnostic Test|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
79867159|NCT00834665|Biological|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
79867160|NCT00834665|Biological|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
79867161|NCT01051258|Device|AeriSeal System|AeriSeal System for Lung Volume Reduction
79867162|NCT00837707|Drug|aripiprazole|Flexible dose: 5-30 mg/day
79270108|NCT06207981|Drug|induction chemotherapy (mDCF)|"Induction chemotherapy consists of mDCF administered every 2 weeks:~Docetaxel (40 mg/m², day 1),~Cisplatin (40 mg/m², day 1)~5-FU (1200 mg/m²/day IV for 2 days)"
79270109|NCT06207981|Drug|Concomitant chemotherapy (Capecitabin + Mitomycin-C)|Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
79270110|NCT06207981|Radiation|radiotherapy|"Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~49.5 Gy (5 x 1.65 Gy/week) to the pelvis~60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes"
79270111|NCT06207175|Biological|Nonavalent HPV study vaccine|A 3-dose regimen administered at months 0, 2 and 6.
79867163|NCT02548247|Dietary Supplement|Orafti® Inulin|Dietary fiber
79867164|NCT02548247|Dietary Supplement|Placebo|Maltodextrin
79270112|NCT06207175|Biological|GARDASIL® 9|A 3-dose regimen administered at months 0, 2 and 6.
79270113|NCT06206850|Drug|Osimertinib|Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
79270114|NCT06205316|Drug|Antiandrogen Therapy|Receive ADT
79867165|NCT01055938|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
79867166|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally three times a day
79867167|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally twice a day
79867168|NCT00356278|Drug|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
79867169|NCT00356278|Drug|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
79867170|NCT00356278|Behavioral|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
79867171|NCT00356278|Drug|Placebo|Placebo will be administered in the same manner as the active drugs.
79867172|NCT00837863|Drug|Somatropin|ALTU-238 0.3 mg/kg daily
79867173|NCT00837863|Drug|Somatropin|ALTU-238 0.6 mg/kg daily
79867174|NCT00837863|Drug|Somatropin|ALTU-238 0.9 mg/kg daily
79867175|NCT00837863|Drug|Somatropin|Nutropin AQ 0.043 mg/kg daily
79270115|NCT06205316|Procedure|Biospecimen Collection|Undergo blood sample collection
79270116|NCT06205316|Procedure|Bone Scan|Undergo bone scan
79270117|NCT06205316|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79270118|NCT06205316|Procedure|Magnetic Resonance Imaging|Undergo MRI
79867176|NCT00834821|Behavioral|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
79270119|NCT06205316|Procedure|Positron Emission Tomography|Undergo PET scan
79867177|NCT00834821|Behavioral|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
79867178|NCT03991780|Drug|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
79270120|NCT06205316|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
79270121|NCT06205316|Other|Survey Administration|Ancillary study
79270122|NCT06201403|Diagnostic Test|Determination of biomechanical properties of muscles|All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
79867179|NCT02547389|Behavioral|Community support group|
79572617|NCT01817686|Other|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
79867180|NCT02547389|Other|Printed material Supported|
79270123|NCT06201299|Other|Standard Exercise Program|The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
79270124|NCT06201299|Other|Chair-based Exercise Program|The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
79867181|NCT01051336|Device|TARIS Placebo|
79867182|NCT01051336|Procedure|Sham Procedure|
79867183|NCT00837941|Drug|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
80027177|NCT05474287|Procedure|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
80027178|NCT05474287|Procedure|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
80027179|NCT05661214|Other|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
80027180|NCT02035605|Drug|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
79270125|NCT06201182|Drug|FMT via rectal enema|50 grams of FMT via rectal enema
79270126|NCT06201182|Drug|FMT capsules|FMT capsules given twice daily for 2 consecutive days
79270127|NCT06201182|Drug|Placebo via rectal enema|Placebo via rectal enema
79270128|NCT06201182|Drug|Placebo capsules|Placebo capsules given twice daily for 2 consecutive days
79304442|NCT03291977|Drug|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
79867184|NCT00837941|Drug|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
79867185|NCT00837941|Drug|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
79867186|NCT01053442|Dietary Supplement|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
79867187|NCT01053442|Dietary Supplement|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
79867188|NCT00828659|Drug|Placebo|
79867189|NCT00828659|Drug|Active Comparator #1|
79867190|NCT00828659|Drug|Active Comparator #2|
80027181|NCT02035605|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
80027182|NCT03619369|Procedure|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
80027183|NCT03578601|Other|Thyroid surgery|Patient undergoing thyroid surgery
80027184|NCT04421508|Combination Product|INOpulse|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
80027185|NCT04421508|Combination Product|Placebo|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
80027186|NCT03578523|Other|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
80027187|NCT03578523|Other|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
79270129|NCT06201143|Other|BREATHING EXERCISE AND MOBILIZATION TRAINING|After cesarean mobilization and breathing exercise training, the number of breathing exercises performed and the duration of mobilization will be recorded. Thus, the effectiveness of the training will be examined in detail.
79572618|NCT01817686|Other|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
79572619|NCT01817686|Other|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
79572620|NCT01817699|Other|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
79572621|NCT01817699|Dietary Supplement|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
79867191|NCT00828659|Drug|Active Comparator #3|
79867192|NCT00828659|Drug|Lorcaserin Dose #1|
79867193|NCT00828659|Drug|Lorcaserin Dose #2|
79867194|NCT00828659|Drug|Lorcaserin Dose #3|
80027188|NCT03578523|Biological|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
80027189|NCT03578523|Biological|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
79867195|NCT00356200|Drug|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
79867196|NCT00356200|Drug|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
79867197|NCT04044053|Drug|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
79867198|NCT04044053|Drug|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
80027190|NCT03578445|Device|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
80027191|NCT03578445|Diagnostic Test|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
80027192|NCT02185872|Other|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
80027193|NCT02185872|Other|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
80027194|NCT05649982|Behavioral|ALVA|Behavioural digital self-help intervention
80027195|NCT02256462|Drug|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or < 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
80027196|NCT04587271|Dietary Supplement|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
80027197|NCT04587271|Dietary Supplement|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
79270130|NCT06201143|Other|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING|It will be the first study to use kinesiotaping, breathing exercise and mobilization training together.
79270131|NCT06200467|Drug|BI 456906|Solution for injection
79270132|NCT06200467|Drug|Placebo to BI 456906|Solution for injection
79270133|NCT06200467|Drug|Moxifloxacin|Film-coated tablet
79270134|NCT06200467|Drug|Placebo to moxifloxacin|Film-coated tablet
79270135|NCT06197984|Procedure|ERCP|ERCP will serve as the exclusive therapeutic modality, aided by a therapeutic duodenoscope to access the common bile duct using a guidewire.
79304443|NCT03291977|Procedure|White-light surgery|The surgery will be performed under classical conditions
80027198|NCT04587271|Dietary Supplement|Placebo|Mothers and children will receive porridge with placebo.
79270136|NCT06197620|Other|Thread embedding acupuncture and standard therapy|In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
79270137|NCT06197269|Other|Short duration antibiotics|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
79572622|NCT01817738|Biological|CV9104|Intradermal injection of CV9104
79572623|NCT01817738|Biological|Placebo|Intradermal injection of placebo
79572624|NCT01817803|Drug|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
79572625|NCT01817803|Drug|metolazone/no spironolactone|metolazone (add 2.5mg qod)
79572626|NCT01817803|Drug|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
79572627|NCT01817803|Drug|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
79732462|NCT00663091|Drug|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
79867199|NCT04044053|Drug|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
79867200|NCT04044053|Drug|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
79867201|NCT00835289|Dietary Supplement|n-3 polyunsaturated fatty acids|Omax3[TM] (Cenestra Health [TM]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
80027199|NCT02631148|Drug|Melatonin|2mg controlled release melatonin tablet
79270138|NCT06197269|Other|Standard duration antibiotics|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
79572628|NCT01817816|Procedure|Botox_A|
79572629|NCT01817816|Procedure|Botox_B|
79572630|NCT01817829|Drug|paracetamol|500 mg oral tablet
79572631|NCT01817829|Drug|placebo|
79572632|NCT01817842|Behavioral|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
79572633|NCT01817842|Behavioral|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
79572634|NCT01817842|Behavioral|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
79572635|NCT01817868|Other|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
79572636|NCT01817894|Drug|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
79572637|NCT01817920|Behavioral|integrated multidisciplinary fall prevention program|
79572638|NCT01817933|Behavioral|physical therapy|
79867202|NCT00835289|Other|Placebo|3 capsules of matching corn oil placebo
79867203|NCT00838019|Procedure|Intrabone administration of umbilical cord blood|Single administration
79867204|NCT02548091|Other|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
79867205|NCT02548091|Procedure|Non invasive ventilation|
80027200|NCT02631148|Drug|Placebo|placebo tablet identical to circadin
79572639|NCT01817946|Other|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
79572640|NCT01817972|Biological|Certolizumab pegol|Subcutaneous injection
79572641|NCT01817972|Drug|Azathioprine|50mg tablets
79572642|NCT01817985|Drug|GS-5816|
79732463|NCT00663091|Drug|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
79732464|NCT00670345|Drug|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
79572643|NCT01817998|Other|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
79572644|NCT01818011|Drug|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
79732465|NCT00670345|Drug|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
79867206|NCT02548091|Procedure|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
79867207|NCT02548091|Procedure|Computed tomography (CT)|
79867208|NCT00828737|Drug|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
79867209|NCT00356122|Drug|Docetaxel|70 mg/m^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
79867210|NCT00356122|Drug|Oxaliplatin|100 mg/m^2 administered IV on Day 1 for Cycles 1-6
79867211|NCT00356122|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
79867212|NCT01056094|Drug|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
79867213|NCT00838175|Procedure|suture mediated closure|Suture mediated closure of femoral venous access
79867214|NCT03989908|Other|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
79867215|NCT03989908|Other|Control noodle|In this intervention arm, subjects will be served with normal noodle.
79867216|NCT00828815|Drug|TMC125|
79402180|NCT03595501|Device|Hematology Analyzer - Predicate|Complete blood counts from Predicate will be determined from analysis of whole blood samples
79572645|NCT01818011|Drug|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
79732466|NCT04153981|Drug|Insulin Glargine|Administered SC
79732467|NCT02631343|Behavioral|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
79867217|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
79572646|NCT01818011|Drug|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
79572647|NCT01818011|Drug|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
79867218|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
79867219|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
79867220|NCT00838253|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
79867221|NCT00838253|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
79867222|NCT00838253|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
79867223|NCT00838253|Drug|Placebo|Placebo continuous i.v. infusion for 24 hours
79867224|NCT00347932|Drug|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
79867225|NCT00347932|Drug|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
79867226|NCT03990688|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
79867227|NCT03990688|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
79867228|NCT00828893|Device|navigation station|navigation station for gestures (carried out under CT) guidance
79867229|NCT02548793|Other|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
79402181|NCT03592693|Drug|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
79402182|NCT03592693|Drug|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
79402183|NCT02079025|Device|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
79732468|NCT02631343|Other|Essential newborn care|
79732469|NCT04153903|Other|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
79732470|NCT01165229|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
79732471|NCT01165229|Biological|Placebo|Intramuscular injection.
80027201|NCT02030496|Procedure|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
79270139|NCT06197074|Other|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
79270140|NCT06196879|Drug|Verekitug (UPB-101)|Verekitug (UPB-101) formulated solution
79867230|NCT02548793|Other|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
79572648|NCT01818011|Drug|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
79867231|NCT02547701|Drug|P-3058|
79270141|NCT06196879|Drug|Placebo|Verekitug (UPB-101) matching placebo
79270142|NCT06196749|Procedure|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique|This study employs a modified ultrasound-guided dynamic needle tip positioning technique for distal radial arterial cannulation. The technique uses an ultrasound probe with two wires to create an acoustic shadow, improving needle tip visibility. Real-time dynamic tracking assists in precise needle placement within the distal radial artery through the nose-horn region. This method is used for coronary angiography and potential percutaneous coronary interventions, aiming to increase success rates and reduce complications like hematoma, nerve injury, and arterial spasm, thus enhancing safety and efficiency.
79270143|NCT06196749|Procedure|Palpation guided puncture|Perform distal radial arterial cannulation under palpation guidance
79572649|NCT01818011|Drug|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
79572650|NCT01818011|Drug|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
79732472|NCT00596011|Drug|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
79732473|NCT00596011|Drug|Placebo|Matching placebo BID
79867232|NCT00828971|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
79867233|NCT00828971|Drug|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
79270144|NCT06195332|Procedure|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
79270145|NCT06195332|Procedure|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
79732474|NCT00670423|Drug|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
79732475|NCT00670423|Drug|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
79732476|NCT00670423|Drug|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
79732477|NCT04153825|Device|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
79270148|NCT06188312|Other|Health education program|"A pretest questionnaire will be filled out, asking the participants about their knowledge, attitudes, and practices toward chemical hazards and the use of personal protective equipment (PPE) then analysis of the obtained pre-test data will be done.~we will apply a health education program. Development phase: developing the message of the health education program and preparing the materials (slide presentation, brochures, and an educational video).Implementation phase: A group health education session through face-to-face, one hour long, interactive lecture combined with slide presentation will be carried out by the researcher. Evaluation phase: A post-test will be done, after 6 months of the first session, to assess the changes of their knowledge and attitude after the intervention."
79270149|NCT06187194|Device|IRE System|Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy
79270150|NCT06186401|Biological|E-SYNC T Cells|Given IV
79270151|NCT06186401|Drug|Cyclophosphamide (non-investigational)|Given IV
79270152|NCT06186401|Drug|Fludarabine (non-investigational)|Given IV
79270153|NCT06186401|Procedure|Leukapheresis|Undergo leukapheresis
79270154|NCT06186401|Procedure|Surgical resection|Undergo surgical resection of tumor tissue
79572651|NCT01818024|Drug|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
79572652|NCT01818024|Drug|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
79572653|NCT01818024|Drug|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
79867234|NCT02547467|Other|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
79572654|NCT01818024|Drug|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
80027202|NCT02030496|Other|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
79572655|NCT01818024|Drug|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
79572656|NCT01818024|Drug|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
79732478|NCT04153825|Device|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
80027203|NCT02239107|Drug|N-Acetyl cysteine|
80027204|NCT02239107|Procedure|laparoscopic ovarian drilling|
80027205|NCT02182518|Drug|Epinastine|
79572657|NCT01818024|Drug|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
79270155|NCT06185075|Procedure|Implant crown delivery|Dental implant crown will be designed, fabricated by a dental lab, and delivered.
79270156|NCT06179264|Behavioral|ACT Guide for Chronic Health Conditions|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
79304444|NCT02448979|Procedure|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
79572658|NCT01818024|Drug|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
79572659|NCT01818037|Procedure|Cataract surgery|
79572660|NCT01818050|Other|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
79572661|NCT01818089|Device|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
79572662|NCT01818102|Device|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
79732479|NCT04153825|Other|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
79732480|NCT04153825|Device|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
79732481|NCT04153825|Device|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
80027206|NCT02182518|Drug|Pseudoephedrine|
80027207|NCT02182518|Drug|Placebo|Placebo during run-in period
80027208|NCT04339621|Device|LiverMultiscan|The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
80027209|NCT02239185|Procedure|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
79572663|NCT01818102|Device|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
79572664|NCT01818115|Device|Hydrus Implant|
80027210|NCT02239185|Procedure|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
80027211|NCT05486182|Drug|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
79572665|NCT01818115|Procedure|IOL placement|
79572666|NCT01818128|Device|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
79572667|NCT01818128|Device|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
79572668|NCT01818180|Dietary Supplement|URELL|
79572669|NCT01818180|Other|Placebo|
80027212|NCT03574935|Drug|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
79270157|NCT06178380|Other|rehabilitation|"For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed"
79270158|NCT06177639|Device|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
79270159|NCT06177639|Device|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
79270160|NCT06177600|Behavioral|Interactive educational digital platform for transgender and gender-diverse (TGD) youth and caregivers|"Investigators will develop a free mobile- and web-enabled platform for TGD youth and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Youth will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their youth.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked."
79572670|NCT01818206|Other|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
79572671|NCT01818219|Procedure|Records of EADI derived parameters|
79732482|NCT02632201|Biological|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
79732483|NCT02632201|Biological|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
79732484|NCT00659659|Drug|MEDI-563|1.0 mg/kg IV: MEDI-563
79732485|NCT00659659|Drug|MEDI-563|100 mg, 200 mg SC
79732486|NCT00659659|Other|Placebo Comp.|Placebo SC
79732487|NCT00659659|Other|Placebo|Placebo as a single IV infusion (Certain number of subjects)
79732488|NCT00670501|Drug|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
79867235|NCT02548637|Procedure|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
79867236|NCT00835835|Other|Body-weight supported treadmill training +/- Lokomat assistance|walking
79270161|NCT06175923|Biological|Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care|When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
79572672|NCT01818271|Behavioral|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
79572673|NCT01818271|Behavioral|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
79572674|NCT01818310|Biological|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
79732489|NCT00670501|Drug|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
79867237|NCT00835835|Other|Usual Care - no active intervention|No treatment used for comparison
79732490|NCT00670501|Drug|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
79732491|NCT00670501|Drug|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
79732492|NCT00670501|Drug|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
79732493|NCT02631421|Procedure|Blood Sampling|
79732494|NCT02631421|Other|Cardiac MRI|
79867238|NCT00528996|Drug|BEA 2180 BR|Solution
79867239|NCT00528996|Drug|Tiotropium Bromide|Solution
79867240|NCT00528996|Drug|Placebo|Solution
79867241|NCT00838487|Other|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
80027213|NCT03574935|Drug|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
79270162|NCT06171035|Other|3D-printed high-fidelity craniofacial manikin model education|Slide-based presention plus 3D printed model
79572675|NCT01818310|Biological|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
79572676|NCT01818310|Biological|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
79732495|NCT05657093|Dietary Supplement|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
79732496|NCT05657093|Combination Product|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
79572677|NCT01818310|Procedure|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
79572678|NCT01818349|Other|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
79572679|NCT01818349|Other|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
79572680|NCT01818362|Biological|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
79572681|NCT01818362|Biological|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
79572682|NCT01818375|Procedure|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
79572683|NCT01818375|Other|Standard fluid therapy|
79867242|NCT00838487|Other|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
79867243|NCT00359788|Drug|tiotropium|
79867244|NCT00359788|Drug|Combivent (Ipratropium/Albuterol)|
79867245|NCT00838721|Other|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
80027214|NCT02239029|Drug|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
79270163|NCT06171035|Other|Traditional model education|Slide-based presention plus traditional model
79270164|NCT06169410|Drug|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
79572684|NCT01818388|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
79572685|NCT01818401|Device|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
79732497|NCT04153669|Behavioral|Exercise-NMES|Exercise-NMES
79867246|NCT00838877|Drug|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
79867247|NCT00838877|Drug|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
79867248|NCT00836147|Drug|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
80027215|NCT02239029|Drug|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
80027216|NCT03578289|Behavioral|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
80027217|NCT03574857|Drug|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
80027218|NCT03574857|Drug|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
80027219|NCT03578133|Diagnostic Test|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
80027220|NCT02753400|Drug|emixustat hydrochloride|Tablet for oral administration
80027221|NCT02753400|Other|Placebo|Placebo tablets for oral administration contain only inactive ingredients
80027222|NCT03578055|Drug|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
79270165|NCT06169410|Drug|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
79270166|NCT06168929|Drug|SHR4640|SHR4640, 2.5mg*4 - 10mg*1
79270167|NCT06168929|Drug|SHR4640|SHR4640, 10mg*1 - 2.5mg*4
79572686|NCT01818401|Device|Matched patient cutting blocks MyKnee ® LBS|
79572687|NCT01818440|Other|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
79732498|NCT04153669|Behavioral|Exercise-No NMES|Exercise-No NMES
79732499|NCT00663247|Device|Mesalazine|3 grams daily for 3 months
79732500|NCT00663247|Drug|Placebo|3 grams daily for 3 months
79732501|NCT02629939|Behavioral|course for learning CPR|
79732502|NCT04158271|Device|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
79867249|NCT00836147|Drug|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
80027223|NCT03578055|Drug|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
79270168|NCT06168396|Device|Somatosensation Device|The somatosensation device will be worn on the lower limb (either the residual limb for an amputee, or limb with decreased sensation for a participant with diabetic neuropathy) while performing outcome measures.
79270169|NCT06168396|Other|Baseline|Participants will perform outcome measures without wearing the somatosensation device.
79572688|NCT01818440|Other|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
79572689|NCT01818453|Behavioral|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
79732503|NCT04158271|Device|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
79572690|NCT01818479|Biological|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
79732504|NCT04158271|Device|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
79732505|NCT01163747|Biological|tocilizumab|Intravenous repeating dose
79732506|NCT01163747|Drug|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
79732507|NCT01163747|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
79867252|NCT05732922|Device|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
79732508|NCT01163747|Biological|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
79867253|NCT03878160|Other|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
80027224|NCT02185950|Device|ultrasound|
79270170|NCT06167434|Device|Future Cardia™ Insertable Cardiac Monitoring (ICM) System|The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
79270171|NCT06167343|Procedure|ACL reconstruction|In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
79867254|NCT02534116|Procedure|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
79304445|NCT02448979|Procedure|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
79572691|NCT01818479|Procedure|Stem cell transplant|
79572692|NCT01818544|Drug|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
79732509|NCT00663325|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
79732510|NCT00659893|Drug|PEP005 Topical gel|0.05%, two day dose
79732511|NCT02629783|Other|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
79732512|NCT02629783|Other|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
79732513|NCT02629783|Drug|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
79867255|NCT02534116|Procedure|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
79867256|NCT03987490|Behavioral|Text Message|Vaccine reminder notification sent via text
80027225|NCT02185950|Device|paraffin|
80027226|NCT02185950|Device|endermotherapy|
80027227|NCT02238639|Procedure|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
80027228|NCT02186028|Drug|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
80027229|NCT02182596|Drug|Mylotarg|Dose level study
79304446|NCT03287609|Drug|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
79572693|NCT01818544|Drug|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
79572694|NCT01818557|Behavioral|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
79572695|NCT01818570|Drug|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
79732514|NCT01163279|Behavioral|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
79732515|NCT01163279|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
79732516|NCT04155931|Other|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
79732517|NCT02629705|Dietary Supplement|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
79732518|NCT02629705|Dietary Supplement|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
79732519|NCT00670657|Drug|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
79572696|NCT01818570|Drug|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
79732520|NCT01162499|Drug|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
79732521|NCT01162499|Other|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
79732522|NCT04153513|Drug|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
79732523|NCT04153513|Other|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
79732524|NCT00659971|Drug|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
79732525|NCT05657015|Drug|Lepidium Sativum|2 ml of LS in situ gel at baseline
79732526|NCT05657015|Drug|Simvastatin|1.2% of SMV in situ gel at baseline
79732527|NCT04314479|Behavioral|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
79732528|NCT02887313|Drug|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
79867257|NCT03987490|Behavioral|PostCard|Vaccine reminder notification sent via standard mail
79867258|NCT03987490|Behavioral|Standard of Care|No additional information given to parents
79867259|NCT03987490|Behavioral|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
79867260|NCT00623597|Drug|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
79304447|NCT03287609|Drug|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
79572697|NCT01818583|Drug|Potassium chloride|
79572698|NCT01818583|Drug|Glucose 50 MG/ML|
79572699|NCT01818609|Behavioral|Step reduction|taking less than 1500 steps/d
79732529|NCT02887313|Radiation|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
79732530|NCT01206140|Other|Laboratory Biomarker Analysis|Correlative studies
79732531|NCT01206140|Drug|Selumetinib|Given PO
79732532|NCT01206140|Drug|Temsirolimus|Given IV
79867261|NCT00623597|Drug|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
79867262|NCT05732844|Device|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
79867263|NCT05732844|Other|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
79867264|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
79867265|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
79867266|NCT05732766|Biological|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
79732533|NCT01162421|Biological|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
79732534|NCT01162421|Drug|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
79867267|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 16 weeks"
79270173|NCT06155435|Behavioral|solution focused approach training|To the woman; A list of education subjects will be sent in order to determine educational changes for birth, birth and postpartum periods. This list will be; It consists of reproductive organs, pregnancy formations, changes, psychological changes, daily life, nutrition, reproductive monitoring, immunization, frequent problems and solution suggestions, danger signs and what to do. Also included in the list are labor, birth cycle, and postpartum periods.
79270174|NCT06147063|Biological|AZD9838|Intramuscular (IM) injection.
79270175|NCT06147063|Biological|Licensed mRNA vaccine|Intramuscular (IM) injection.
79270176|NCT06145750|Diagnostic Test|Ability to order DELFI lung cancer screening test|The DELFI Lung Cancer Screening Test is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. DELFI Lung Cancer Screening Test is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). DELFI Lung Cancer Screening Test is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.
79270177|NCT06145750|Other|Continuing Medical Education for Lung Cancer|Physician practice will receive standard education on lung cancer screening for CME credit.
79270178|NCT06142773|Device|Tidal Volume set on ventilator|Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
79270179|NCT06141746|Device|Lung ultrasound|Early detection of fluid accumulation in alveolar, interstitial and intracellular compartments of the lung due to intravascular absorption of irrigation fluid of PNL guided by lung ultrasound by detection of sonographic B lines.
79732535|NCT05366387|Device|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
79732536|NCT05366387|Radiation|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
79732537|NCT02885519|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
79867268|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 24 weeks"
79867269|NCT05732688|Diagnostic Test|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
79270180|NCT06138106|Dietary Supplement|Natural Product Supplement|Participants will have blood drawn before and one hour after consuming the natural product supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
79270181|NCT06138106|Dietary Supplement|Placebo control|Participants will have blood drawn before and one hour after consuming the placebo supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
79270182|NCT06131632|Procedure|Breast conserving surgery|Remove only a small part of the breast
79270183|NCT06131632|Procedure|Radical modified mastectomy|Remove all the breast parenchyma, nipple and skin
79402184|NCT02079025|Device|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
79402185|NCT00730353|Drug|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
79572700|NCT01818622|Device|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
79572701|NCT01818622|Device|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
79572702|NCT01818648|Drug|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
79402186|NCT00730353|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
79402187|NCT05631301|Other|Exercise Circuits|Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination
79402188|NCT05631301|Behavioral|Goal Setting|Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities
80027230|NCT03574701|Dietary Supplement|Vitamin A|The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
80027231|NCT02180880|Drug|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
80027232|NCT05471440|Drug|Direct boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
80027233|NCT05471440|Drug|Direct boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
80027234|NCT05471440|Drug|Post-poned boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
80027235|NCT05471440|Drug|Post-poned boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
79572703|NCT01818648|Drug|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
79572704|NCT01818687|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
79572705|NCT01818713|Drug|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
79732538|NCT02885519|Behavioral|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
79270184|NCT06129097|Other|Thyme honey mouthwash|"Thyme honey will be applied as oral rinse.~Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~Patients will be instructed to perform thyme honey rinses in the oral mucosa.~Patients will be instructed not to swallow the thyme honey oral rinse."
79270185|NCT06128265|Behavioral|Sleep Extension|Extending time in bed by 2 hours (going to bed earlier and/or waking up later)
79270186|NCT06128265|Behavioral|Sleep Regularity|Consistent bedtimes (within 30min)
79270187|NCT06123845|Behavioral|static CPAP 8 cmH2O|Set static CPAP or PEEP pressure level at 8 cmH2O
79732539|NCT02885441|Drug|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
79867270|NCT00838955|Drug|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
79867271|NCT00347776|Drug|azithromycin|oral antibiotic
79867272|NCT00347776|Drug|topical tetracycline|
79867273|NCT00839033|Device|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
79867274|NCT00839033|Device|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
79402189|NCT05631301|Behavioral|Psychoeducation-Youth|Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.
80027236|NCT02186106|Drug|Cholecalciferol|
79270188|NCT06123845|Behavioral|static CPAP 5 cmH2O|Set static CPAP or PEEP pressure level at 5 cmH2O
79270189|NCT06123117|Procedure|single transversus abdominis laparoscopy-guided plane block|please see arm/group descriptions
79270190|NCT06123117|Procedure|local trocar site ropivacaine infiltration|please see arm/group descriptions
79270191|NCT06122922|Drug|Hyperpolarized Xe129|Hyperpolarized Xenon Gas
79402190|NCT05631301|Behavioral|Psychoeducation-Caregiver|Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms
79402191|NCT05631301|Other|Waitlist Control Surveys|Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention
79402192|NCT03595423|Procedure|Surgical AVR with bioprosthetic or mechanical prosthesis|Surgical AVR with bioprosthetic or mechanical prosthesis
79402193|NCT01272531|Drug|Mood stabilizer treatment|lithium or valproate
79572706|NCT01818778|Other|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
79572707|NCT01818778|Other|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
79572708|NCT01818791|Behavioral|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
80027237|NCT02181036|Other|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
79402194|NCT03595345|Procedure|Liver transplantation|Liver transplantation
79270192|NCT06120881|Drug|Metformin|Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
79402195|NCT03025685|Procedure|TRUST technique|A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
79402196|NCT03025685|Procedure|Anchoring Technique|A standard endovascular technique of coronary wire support improvement
79402197|NCT03025685|Procedure|Coronary stenting|A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
79402198|NCT01272609|Drug|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
79581485|NCT06071091|Other|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~Nursing~Nursing care~Symptomatic treatments: analgesics for example~Systematic clinical monitoring and control imaging if necessary~Rehabilitation if necessary)"
79732540|NCT04314791|Device|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
79732541|NCT02885597|Drug|Juanbi pill|4g, twice a day, 3month, oral
79732542|NCT02885597|Drug|Juanbi pill placebo|4g, twice a day, 3month, oral
79732543|NCT02885597|Drug|Methotrexate|5mg, once a week, 3 month, oral
79732544|NCT01188551|Drug|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
79732545|NCT01188551|Drug|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
79732546|NCT01188551|Drug|Midazolam|Sedative given pre-op.
79732547|NCT04316429|Other|Egg included vegan phase|: Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. [21] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
79732548|NCT04316429|Other|Vegan Phase|The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
79732549|NCT05293379|Other|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
79732550|NCT01161407|Dietary Supplement|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
79732551|NCT01161407|Dietary Supplement|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
79732552|NCT01161173|Drug|Erlotinib|Erlotinib was provided in the retail versions of the product.
79732553|NCT01159769|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
79867275|NCT00829127|Drug|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
79867276|NCT00829127|Drug|Placebo|Oral suspension
79867277|NCT04452136|Drug|68GA PSMA-HBED-CC|Given IV
79304448|NCT02448745|Device|Insecticide treated wall lining|Polypropylene non-woven fabric.
79304449|NCT03287531|Other|conventional therapy|Exercise therapeutic Ultrasound
79402199|NCT01272609|Device|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
79402200|NCT04489667|Other|+STEP Implementation|All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
79402201|NCT04407091|Drug|14C]AZD4831 Oral Solution|10 mg dose of [14C]AZD4831 Oral Solution
79402202|NCT03595189|Drug|Cilastatin|Dose escalation 3-hour single intravenous administration
79402203|NCT03595189|Drug|Placebo|3-hour single intravenous administration
79402204|NCT00749931|Device|MarginProbe|Device use to assess margin status of the excised specimen surface.
79402205|NCT00749931|Procedure|Lumpectomy|Standard of care lumpectomy procedure
79270193|NCT06120816|Drug|Nitric Oxide|Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
79270194|NCT06119464|Other|Multimodal Intervention: Education|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
79572709|NCT01818791|Behavioral|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
79572710|NCT01818843|Other|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
79572711|NCT01818856|Drug|Ritonavir withdrawal, atazanavir 200 mg/12h|
79572712|NCT01818856|Drug|Telaprevir interactions|
79732554|NCT02885207|Biological|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~Crisis with clinical symptoms indicating focal seizure~& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~No argument for metabolic or neurodegenerative genetic epilepsy.~Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
79572713|NCT01818869|Drug|AZD8848|Multiple doses inhaled IMP via a nebulizer
79867278|NCT00829205|Biological|filgrastim|
79270195|NCT06119464|Other|Multimodal Intervention: Audit and Feedback|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
79572714|NCT01818869|Drug|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
79732555|NCT05280119|Device|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
79867279|NCT00829205|Biological|rituximab|
79867280|NCT00829205|Dietary Supplement|Se-methyl-seleno-L-cysteine|
79867281|NCT00829205|Drug|carboplatin|
79867282|NCT00829205|Drug|etoposide|
79572715|NCT01818882|Other|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
79572716|NCT01818882|Device|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
79572717|NCT01818908|Drug|DA-EPOCH|DA-EPOCH regimen
79572718|NCT01818934|Procedure|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
79867283|NCT00829205|Drug|ifosfamide|
79867284|NCT00829205|Other|laboratory biomarker analysis|
80027238|NCT02239419|Procedure|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
79270196|NCT06119464|Other|Multimodal Intervention: Patient Engagement|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
79270197|NCT06119464|Other|Multimodal Intervention: System Changes|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
79277646|NCT05791955|Behavioral|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
79277647|NCT05791955|Behavioral|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
79572719|NCT01818960|Procedure|IRA-PCI|IRA only PCI at the time of Primary PCI
79572720|NCT01818960|Procedure|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
79572721|NCT01818973|Drug|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
79572722|NCT01818973|Drug|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
79572723|NCT01818973|Drug|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
79572724|NCT01818973|Radiation|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
79572725|NCT01818973|Procedure|surgery|Total Mesorectal Excision (TME)
79572726|NCT01818999|Drug|IXABEPILONE|injection
79867285|NCT00829205|Other|pharmacological study|
79867286|NCT02533882|Behavioral|Movement to Music|
79867287|NCT02533882|Behavioral|Adapted Yoga|
80027239|NCT02239419|Procedure|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
79270198|NCT06115785|Behavioral|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
79867288|NCT00836225|Drug|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
80027240|NCT03943147|Drug|BMS-986165|Specified dose on specified days
80027241|NCT03943147|Drug|Placebo|Specified dose on specified days
79867289|NCT01053754|Biological|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
79867290|NCT03987178|Behavioral|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
79270202|NCT06104202|Other|Early Maladaptive Schemas|"Compare profiles of maladaptive early patterns using scores :~Young Schema Questionnaire Short form~Maslach Burnout Inventory~Montgomery-Asberg depression rating Scale~White Bear Suppression Inventory"
79270203|NCT06103604|Diagnostic Test|latest generation tympanic thermometer|The patient whose core temperature is monitored during hospitalisation has his temperature at tympanic level taken once during the stay. The research nurse will record the core temperature from the monitor on the CRF and, within the next 5 minutes, take the peripheral temperature with the tympanic thermometer three times in a row, recording all three values on the CRF. Subsequently a second operator will always take the temperature 3 times within 5 minutes of the gold standard measurement. Only the first tympanic measurement will then be used to assess accuracy against the gold standard.
79270204|NCT06101511|Procedure|Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs|The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
79270205|NCT06098365|Other|segmental cervical stabilization exercises|Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.
79270206|NCT06098365|Other|cervical isometric exercises|Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
79572727|NCT01818999|Radiation|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
79732556|NCT05280119|Device|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
79732557|NCT05280119|Procedure|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
79732558|NCT04123691|Device|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
79572728|NCT01819012|Drug|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
79572729|NCT01819012|Drug|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
79732559|NCT01157897|Biological|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
79732560|NCT01157897|Other|P. vivax sporozoite challenge|P. vivax sporozoite challenge
79732561|NCT04316507|Procedure|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
79732562|NCT01185821|Drug|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
80027242|NCT03943147|Drug|Mycophenolate Mofetil|Specified dose on specified days
80027243|NCT03536130|Device|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
79270207|NCT06096038|Drug|Cyclophosphamide|cyclophosphamide 300 mg/meter square IV
79270208|NCT06096038|Drug|Fludarabine|fludarabine 30 mg/meter square IV × 3 days
79270209|NCT06096038|Biological|Cell Therapy|the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
79572730|NCT01819012|Drug|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
79572731|NCT01819025|Behavioral|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
79732563|NCT02885285|Behavioral|Spinning Class|Spinning Class twice a week for six weeks.
79732564|NCT02885285|Behavioral|Yoga Class|Yoga Class twice a week for six weeks.
79732565|NCT02885285|Behavioral|Dance Class|Dance Class twice a week for six weeks.
79572732|NCT01819025|Behavioral|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
79867291|NCT03987178|Other|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
79867292|NCT00839111|Drug|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
79572733|NCT01819038|Procedure|continuous renal replacement therapy|
79572734|NCT01819051|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
79867293|NCT00839111|Drug|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
79867294|NCT01053832|Device|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
79867295|NCT00836303|Behavioral|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
79867296|NCT01008228|Procedure|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
79572735|NCT01819077|Procedure|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
79732566|NCT02885285|Other|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
79732567|NCT00893464|Drug|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
79867297|NCT01008228|Procedure|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
79867298|NCT00836381|Drug|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
79867299|NCT00836381|Drug|Placebo|Identical Placebo once daily
79867300|NCT02533336|Drug|abamectin and fenpyroximate|
79867301|NCT00836459|Behavioral|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
79572736|NCT01819090|Device|Elysee 150 ventilator|
79572737|NCT01819090|Device|Elysee 150 ventilator with a ventilation switch control|
79572738|NCT01819142|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
79732568|NCT05318326|Drug|placebo group|placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
79867302|NCT00836459|Behavioral|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
79867303|NCT03991390|Other|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
79867304|NCT03991390|Other|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
79867305|NCT00829361|Other|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
79867306|NCT03829228|Dietary Supplement|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
79867307|NCT00839189|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
79867308|NCT01053910|Drug|Ramipril|tablet of Ramipril once daily
79572739|NCT01819155|Biological|Adjuvanted seasonal trivalent inactivated influenza vaccine|
79572740|NCT01819155|Biological|Seasonal trivalent inactivated influenza vaccine|
79572741|NCT01819155|Biological|Saline (bacteriostatic 0.9% sodium chloride for injection)|
79572742|NCT01819207|Other|blood test by thromboelastography|
79572743|NCT01819220|Drug|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
79732569|NCT05318326|Drug|Yogliptin 400mg group|Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
79732570|NCT05318326|Drug|Yogliptin 200mg group|Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
79732571|NCT02834962|Procedure|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
79732572|NCT02834962|Procedure|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
79732573|NCT04205110|Diagnostic Test|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
79270210|NCT06092814|Device|Active transcranial alternating current stimulation (tACS)|Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.
79732574|NCT02834182|Behavioral|IRMf|
79732575|NCT02834182|Behavioral|Mini International Neuropsychiatric Interview|
79572744|NCT01819220|Drug|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
79270211|NCT06090227|Drug|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
79572745|NCT01819246|Procedure|Aphersis Treatment Arm|
79572746|NCT01819246|Other|Control Arm|
79572747|NCT01819259|Drug|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
79867309|NCT00829517|Other|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
79867310|NCT00829517|Other|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
79572748|NCT01819259|Drug|Placebo|
79867311|NCT03987412|Behavioral|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
79867312|NCT00829595|Biological|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
79867313|NCT01054066|Behavioral|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
79867314|NCT01008384|Dietary Supplement|Vitamin D3|50,000 units taken orally once a week for 8 weeks
79867315|NCT00836771|Dietary Supplement|Infant Formula|
79867316|NCT01008540|Biological|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
79867317|NCT02547155|Procedure|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
79867318|NCT02547155|Procedure|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
79867319|NCT00836849|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
79867320|NCT00836849|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
79867321|NCT03999294|Other|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
79867322|NCT00839345|Drug|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
79867323|NCT00829751|Device|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
79867324|NCT00829751|Device|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
79867325|NCT00839501|Dietary Supplement|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
79572749|NCT01819285|Procedure|Immediate Orchiectomy or depot LHRH|
79572750|NCT01819285|Procedure|Delayed Orchiectomy or depot LHRH|
79270212|NCT06090227|Other|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
79270213|NCT06087601|Drug|0.9% Sodium chloride|us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
79270214|NCT06087601|Drug|95% ethanol|us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
79572751|NCT01819324|Behavioral|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
79572752|NCT01819324|Behavioral|Standardized Lifestyle Management|SLM material (every other week for 4 months)
79732576|NCT02834182|Behavioral|Positive And Negative Syndrom Scale|
79732577|NCT02834182|Behavioral|Young Mania Rating Scale|
79732578|NCT02834182|Behavioral|Hamilton Depression Scale|
79732579|NCT00891904|Biological|cetuximab|Given IV
79732580|NCT00891904|Radiation|stereotactic body radiation therapy|Undergoing Radiotherapy
79572753|NCT01819350|Other|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
79572754|NCT01819350|Other|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
79572755|NCT01819363|Procedure|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
80027244|NCT03617133|Radiation|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of ~20% IB, ~50% IIB, ~20% IIIB and ~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
80027245|NCT03617133|Radiation|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
80027246|NCT03617133|Radiation|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
79572757|NCT01819389|Drug|Imatinib and Nilotinib|
79270218|NCT06086444|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
79270219|NCT06086444|Drug|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
79572758|NCT01819402|Drug|Pioglitazone vs Glimepiride|
79572759|NCT01819428|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
79270220|NCT06086431|Drug|0.9% sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
79572760|NCT01819441|Drug|Azelnidipine|8mg or 16mg
79572761|NCT01819441|Drug|Perindopril|4mg or 8mg
79572762|NCT01819441|Drug|hydrochlorothiazide|12.5mg or 25mg
79572763|NCT01819454|Device|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
79732581|NCT02834338|Device|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
79732582|NCT02837926|Other|questionnaire|
79732583|NCT02837926|Biological|Gardasil vaccine|
79270221|NCT06086431|Drug|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
79270222|NCT06086431|Drug|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
79270223|NCT06086418|Drug|0.9 % Sodium Chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
79270224|NCT06086418|Drug|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
79270225|NCT06086418|Drug|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
79270226|NCT06086392|Drug|Placebo|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
79270227|NCT06086392|Drug|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
79270228|NCT06086392|Drug|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
79270229|NCT06083428|Drug|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
79572764|NCT01819467|Device|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
79572765|NCT01819493|Behavioral|Lifestyle Intervention|Family-based group lifestyle intervention
79572766|NCT01819493|Behavioral|Standard Family-Based intervention|Comparison intervention
80027247|NCT03617133|Radiation|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by ~50%.
79270230|NCT06083428|Drug|Ropivacaine 0.2% Injectable Solution - iliopsoas plane block|ultrasound guided iliopsoas plane block
79270231|NCT06083428|Drug|Control Test|Only spinal anesthesia
79270232|NCT06083298|Procedure|control group|patients will be operated under general anesthesia
79867326|NCT00839501|Drug|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
79572767|NCT01819519|Behavioral|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&A.
79270233|NCT06083298|Procedure|MCP group|patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
79572768|NCT01819532|Procedure|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
79732584|NCT02837926|Biological|Cervarix®|
79270234|NCT06083298|Procedure|ISP group|patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
79270235|NCT06079736|Drug|PGN-EDO51|IV infusion
79270236|NCT06077500|Drug|BI 764532|BI 764532
79572769|NCT01819532|Procedure|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
79732585|NCT02834260|Drug|Dexamethasone implant OZURDEX|
79270237|NCT06077500|Drug|Carboplatin|Carboplatin
79270238|NCT06077500|Drug|Etoposide|Etoposide
79270239|NCT06077500|Drug|Atezolizumab|Atezolizumab
79572770|NCT01819558|Biological|recwt1-A10+AS01B|
79572771|NCT01819571|Drug|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
79732586|NCT02834416|Behavioral|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
79732587|NCT02834416|Behavioral|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
79732588|NCT02831608|Biological|Influenza vaccine|
79732589|NCT02831608|Biological|Placebo|
79732590|NCT01157351|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
79732591|NCT01157351|Drug|risperidone|flexible dosing as prescribed by the study doctor for 15 months
79732592|NCT01157351|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
79270240|NCT06077500|Drug|Durvalumab|Durvalumab
79270241|NCT06077500|Drug|Cisplatin|Cisplatin
79270242|NCT06074133|Procedure|Blood collection|Undergo blood draw
79270243|NCT06074133|Procedure|Chest Computed Tomography|Undergo standard of care chest Computed Tomography
79270244|NCT06071299|Behavioral|FCC|Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
79270245|NCT06071299|Behavioral|CCC|Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
79270246|NCT06069999|Device|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
79270247|NCT06065761|Other|Comprehensive ED heart failure management tool|The investigators plan a regional implementation of an electronic health record-based heart failure decision support tool across 21 EDs of Kaiser Permanente Northern California (KPNC).
79572772|NCT01819610|Drug|SPRIX|
79572773|NCT01819623|Other|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
79572774|NCT01819636|Other|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
79572775|NCT01819649|Dietary Supplement|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
79572776|NCT01819662|Other|Enhanced standard management|Echocardiogram followed by letter to GP about results.
79572777|NCT01819662|Other|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
79572778|NCT01819662|Other|Standard management|Usual care
79732593|NCT01157351|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
79732594|NCT01157351|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
79732595|NCT01157351|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
79867327|NCT00839579|Other|1x4 min interval|Aerobic interval training
79867328|NCT00829907|Drug|ORM-12741|Single dose as a capsule, oral administration
79402206|NCT05631145|Other|MT Combined With XKSA|Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.
79867329|NCT00529542|Drug|Lipitor|40mg caplets per day for six weeks
80027248|NCT03617133|Radiation|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
80027249|NCT03617133|Radiation|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
79867330|NCT00529542|Drug|Placebo|1 placebo caplet per day for six weeks.
80027250|NCT03617133|Radiation|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or >2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
79572779|NCT01819675|Device|Low frequency rTMS|
79572780|NCT01819675|Device|High frequency rTMS|
79732596|NCT01157351|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
79270248|NCT06064214|Procedure|u/s guided intermediate cervical plexus block|The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
79270249|NCT06059599|Other|active informed consent|new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for vertebral or urological surgery.
79277648|NCT05791955|Behavioral|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
79277649|NCT05791890|Drug|Gilteritinib|observational study to evaluate the incidence of infections during therapy with Gilteritinb
79304450|NCT03287531|Other|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
79304451|NCT03195907|Other|Pulmonary physiotherapy|
79304452|NCT03291821|Drug|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
79304453|NCT03291821|Drug|GnRH antagonist|GnRH antagonist subcutaneously
79732597|NCT01157351|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
79867331|NCT04043741|Other|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
79867332|NCT04043741|Other|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
79402207|NCT05631145|Other|MT|Morita therapy (MT) comprised bed rest and light work.
79402208|NCT01274715|Behavioral|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
79402209|NCT03595111|Procedure|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
79402210|NCT01410227|Biological|Recombinant von Willebrand factor (rVWF)|Intravenous administration
79572781|NCT01819675|Device|Sham rTMS|
79572782|NCT01819688|Procedure|laparoscopic liver resection|
79732598|NCT02831686|Drug|Selinexor|
79732599|NCT02831686|Drug|Ixazomib|
79732600|NCT02831686|Drug|Dexamethasone|
79732601|NCT02831530|Drug|Abemaciclib|
79732602|NCT04248478|Other|Eating Behaviours|Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
79867333|NCT00621959|Drug|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
79270250|NCT06055972|Other|Educational Letter Post CT Examination|"Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:~Their calcium score, brief educational content explaining what the calcium score means and how the presence of coronary calcifications is associated with an increased risk of a cardiac event.~Guidance on what actions could be taken to decrease the risk of a heart event, including blood cholesterol management, smoking cessation, weight loss, dieting, exercise, and blood pressure control.~For patients with CAC>0, the letter will encourage the patient to pursue a shared decision- making discussion with his/her primary care physician or cardiologist regarding risk reduction strategies.~Links to American Heart Association (AHA) and phone number for study research coordinator."
79402211|NCT01410227|Drug|Placebo|Syringe supplied with physiologic saline solution for infusion
79732603|NCT04248478|Other|Health Status|The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
79402212|NCT01410227|Biological|Recombinant factor VIIII (rFVIII)|Intravenous administration
79402213|NCT03595033|Device|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
79402214|NCT03989713|Drug|MRD-triggered arm|"Salvage therapy:~Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / >-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~Consolidation therapy:~Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / >-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3~Observation therapy:~No treatment"
79572783|NCT01819701|Dietary Supplement|LC-1000|L-carnitine 1000 mg /d
79572784|NCT01819701|Dietary Supplement|LC-2000|L-carnitine: 2000 mg/d
79572785|NCT01819701|Dietary Supplement|Q10-150|Coenzyme Q10: 150 mg/d
79572786|NCT01819701|Dietary Supplement|Q10-300|Coenzyme Q10: 300 mg/d
79572787|NCT01819701|Other|Placebo|
79732604|NCT00633490|Drug|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
79732605|NCT04247932|Behavioral|Active labor market intervention|Behavior change intervention
79732606|NCT02834026|Other|Cicloergometry training|
79867334|NCT00621959|Drug|placebo|0mg (matching oral tablet)for 14 days
79867335|NCT05702736|Behavioral|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
80027251|NCT03617133|Drug|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
79402215|NCT03989713|Drug|Prophylactic Arm|"Salvage therapy:~Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / >-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~Consolidation therapy:~Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / >-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3;~Maintenance therapy:~Quizartinib: Cycle 1, Days 1-15: 40mg, p.o. and Day 16-28: 60mg, p.o."
79572788|NCT01819714|Other|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
79572789|NCT01819740|Other|"determine the levels of the HEM substance in seminal plasma"|
79572790|NCT01819753|Procedure|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
79572791|NCT01818232|Drug|[14C]-LX4211|
79572792|NCT01819779|Drug|Exforge tab. 10/160mg|
79732607|NCT02834026|Other|No Cicloergometry training|
79732608|NCT02831452|Other|pelvic floor muscle strength evaluation|
79732609|NCT02831374|Drug|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
79867336|NCT00839657|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
79867337|NCT00839657|Behavioral|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
79270251|NCT06051409|Drug|Olverembatinib|Orally, once every other day (QOD).
79270252|NCT06051409|Drug|Imatinib|Orally, once daily (QD).
79572793|NCT01819779|Drug|Lodivixx tab. 5/160mg|
79732610|NCT02831374|Procedure|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
79867338|NCT05261568|Behavioral|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
79867339|NCT02547857|Other|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
79867340|NCT03999528|Diagnostic Test|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
79270253|NCT06050291|Drug|Fixed-Dose Combination (FDC) Tablet|Obicetrapib/Ezetimibe FDC tablet
79270254|NCT06048302|Drug|Obicetrapib|1 single dose of obicetrapib
79572794|NCT01819792|Other|Multiplex respiratory viral PCR|
79572795|NCT01819805|Drug|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
79572796|NCT01819818|Drug|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
79867341|NCT00839813|Behavioral|Yoga|10 weeks of a trauma-sensitive yoga class
79867342|NCT00839891|Drug|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
79867343|NCT00839969|Procedure|Cystoscopy|Saline cystoscopy under general anaesthesia
79867344|NCT00839969|Procedure|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
79867345|NCT00830297|Drug|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
79270255|NCT06043492|Other|High Intensity Interval Training|10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max
79270256|NCT06043492|Other|Coninuous Running|40 min continuous running at lactate threshold
79270257|NCT06043492|Other|Control Trial|The participants will perform only the baseline and post acute-training evaluations, without performing exercise
79270258|NCT06039501|Behavioral|Family Perspective Program|The program involves regular meetings between families and an ICU support counselor. The ICU support counselor is a trained expert in providing culturally competent emotional and/or spiritual support. The ICU support counselor will support families and also learn and summarize family perspectives in a standardized report. ICU care team members will be prompted to perspective take as they review reports prior to regular routine meetings between families and the ICU care team.
79270259|NCT06034652|Device|Integra® Gentrix® Surgical Matrix|Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic & reconstructive surgery.
79270260|NCT06034067|Procedure|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
79270261|NCT06034067|Procedure|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
79270262|NCT06033222|Dietary Supplement|Ricinoleic Acid 750 mg|750 mg administered orally
79270263|NCT06033222|Dietary Supplement|Ricinoleic Acid 1500 mg|1500 mg administered orally
79270264|NCT06033222|Dietary Supplement|Ricinoleic Acid 3000 mg|3000 mg administered orally
79572797|NCT01819857|Drug|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
79867346|NCT00830297|Drug|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
79867347|NCT03877224|Drug|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
79867348|NCT03877224|Other|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
79270265|NCT06033222|Drug|Placebo|Contains no active ingredient.
79304454|NCT03291821|Drug|GnRH analog|GnRH analog subcutaneously
79572798|NCT01819857|Drug|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
79572799|NCT01819857|Drug|Zofran 8 mg|intravenous administration of 8 mg ondansetron
79572800|NCT01819870|Drug|Dilatrend SR capsule 32mg|"1 capsule, oral, once daily, 7days~over the period I&II(crossover)"
79572801|NCT01819870|Drug|Dilatrend IR tablet 25mg|"1 tablet, oral, once daily, 7days~over the period I&II(crossover)"
79867349|NCT00840125|Drug|erlotinib|150mg tablet daily
79867350|NCT00840125|Drug|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
80027252|NCT03617133|Other|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of <=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (>80%) will adhere to the <=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
79867351|NCT02548481|Other|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
80027253|NCT02182674|Drug|Placebo Combivent HFA|
79270266|NCT06033131|Drug|Metformin ER|Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
80027254|NCT02182674|Drug|Combivent HFA|
80027255|NCT02182674|Drug|Combivent (CFC)|
80027256|NCT02182674|Drug|Placebo Combivent (CFC)|
79572802|NCT01819896|Drug|Pacemaker and defibrillator|
79270267|NCT06033131|Drug|Placebo|Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
79270268|NCT06029322|Procedure|Socket seal after alveolar ridge preservation|Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.
79304455|NCT03291821|Procedure|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
79402216|NCT01274559|Drug|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
79402217|NCT01274559|Drug|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
79402218|NCT03594721|Other|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
79732611|NCT02831374|Biological|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
79867352|NCT00840359|Procedure|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
79732612|NCT02831374|Procedure|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
79732613|NCT02831374|Procedure|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
79867353|NCT00840359|Procedure|Cryotherapy|Cryotherapy for 2 times 20 sec
79572803|NCT01819948|Dietary Supplement|PhytoMed™|
79572804|NCT01819961|Drug|MCT/LCT and fish oil|
79572805|NCT01819961|Drug|MCT/LCT|
79572806|NCT01819974|Other|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
79867354|NCT00830453|Procedure|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
79867355|NCT04016597|Device|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
79867356|NCT04016597|Device|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
79867357|NCT00528606|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
80027257|NCT02182752|Drug|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
80027258|NCT02182752|Drug|Ropivacaine|Interscalene block using ropivacaine
80027259|NCT03703258|Behavioral|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
80027260|NCT02186184|Device|Orthokeratology|
80027261|NCT02186184|Device|Spectacle|
80027262|NCT03572439|Diagnostic Test|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
80027263|NCT03572361|Biological|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
79270269|NCT06021613|Behavioral|Randomized instructions|"Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis."
79867358|NCT00528606|Biological|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
79572807|NCT01819987|Behavioral|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
79270270|NCT06018987|Other|No-Treatment Control|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
79270271|NCT06018987|Device|HAC 20L|Subdermal Injections
79572808|NCT01819987|Behavioral|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
79270272|NCT06013839|Drug|talfirastide|TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
79572809|NCT01820000|Procedure|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
79270273|NCT06010901|Drug|TQB2618 injection|TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
79270274|NCT06010901|Drug|Penpulimab injection|Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
79270275|NCT06010901|Drug|Anlotinib hydrochloride capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
79572810|NCT01820013|Device|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
79572811|NCT01820013|Device|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
79270276|NCT06005935|Other|Survey|Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
79572812|NCT01820026|Drug|Imipenem|second line therapy
79572813|NCT01820026|Drug|Vancomycin|Second line therapy
79572814|NCT01820026|Drug|azithromycin|Second line therapy
79572815|NCT01820026|Drug|Cefotaxime|Standard antibiotic therapy
79572816|NCT01820026|Drug|Amoxicillin|Standard therapy
79732614|NCT02831374|Drug|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
79867359|NCT00830531|Drug|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
79867360|NCT00830531|Drug|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
79867361|NCT05014542|Procedure|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
79867362|NCT05014542|Drug|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
79270277|NCT06004895|Device|Actual IPL|Five light pulses along lower lid region of one eye of the participant ranging from 59 to 69 Joules (J) over an area of 2.5cm by 4.5cm for each pulse
79270278|NCT06004895|Device|Sham IPL|Simulated five light pulses along lower lid region of the other eye of the same participant
79270279|NCT06004895|Device|LLLT|Mask with LEDs transferring a total of about 32 J/cm^2 of energy to facial and eyelids region with their eyes closed
79304456|NCT03291821|Diagnostic Test|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
79402219|NCT01409993|Drug|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
79402220|NCT01409993|Drug|Placebo|Matching placebo three times a day for three months
79732615|NCT02833870|Behavioral|Musical intervention|
79732616|NCT02833870|Behavioral|Non-musical (cooking) intervention|
79732617|NCT02833870|Behavioral|Control with no intervention|
79732618|NCT02833558|Device|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
79732619|NCT02833558|Procedure|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
79572817|NCT01820039|Other|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
79867363|NCT00840593|Procedure|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
79867364|NCT00840593|Procedure|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
79270280|NCT06004674|Drug|Lovenox 40mg|Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
79270281|NCT06004362|Behavioral|Complementary and Integrative Medicine online intervention, routine care and book|"The online program takes place in a multiprofessionally guided online group setting once a week for up to 180 minutes (including several breaks) over a period of 10 weeks:~Basic principles of a plant-based whole-food nutrition~Procedures of hydrotherapy according to Kneipp~Self-help strategies (e.g. teas, wraps, compresses etc.)~Methods of mind-body medicine (mindfulness, meditation, breathing, yoga etc.)~Methods of extended Complementary and Integrative Medicine (e.g. acupressure)~It is recommended to practice a part of the taught exercises at home for about 30 minutes daily. In addition, the patients receive a book for the treatment of post-covid syndrome complaints. Group 1 additionally uses the already existing routine care (e.g. general practitioner)."
79572818|NCT01820052|Drug|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
79572819|NCT01820052|Drug|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
79270282|NCT06004362|Behavioral|Routine care and book|Participants in the second study arm receive routine care, e.g. from their general practitioner. In addition, the patients receive the same book as group 1 for the treatment of post-covid syndrome complaints. The participants of the second study arm will be offered to participate in the Complementary and Integrative Medicine online intervention after 4 months within the study.
79270283|NCT05997979|Drug|Capsaicin 8% patch|Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
79304457|NCT03291821|Procedure|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
79572820|NCT01820065|Procedure|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
79732620|NCT02831218|Procedure|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
79732621|NCT02831218|Procedure|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
79867365|NCT00843947|Procedure|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
79867366|NCT04925622|Diagnostic Test|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
79572821|NCT01820078|Drug|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
79572822|NCT01820078|Other|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
79867367|NCT04926324|Drug|Niraparib|Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
79572823|NCT01820091|Drug|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
79572824|NCT01820091|Drug|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
79572825|NCT01820104|Drug|lansoprazole, 30 mg per day for 6 days|
79572826|NCT01820117|Other|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
79732622|NCT02831218|Procedure|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
79867368|NCT04926324|Drug|Dostarlimab|Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
80027264|NCT03730987|Behavioral|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
79270284|NCT05997979|Device|Hydrocolloid dressing|Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
79270285|NCT05997017|Drug|nab-sirolimus|Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
79572827|NCT01820117|Other|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
79572828|NCT01820117|Other|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
79270286|NCT05994911|Behavioral|Mindfulness Training|"The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness."
79270287|NCT05994495|Diagnostic Test|nuclear acid amplification tests|The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)
79270288|NCT05994495|Other|Clinical Syndromic Approach|Physical examination
79270289|NCT05990660|Device|JuxtaFlow System|Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
79867369|NCT04926324|Radiation|Short course radiation|Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
79867370|NCT00621257|Dietary Supplement|ergocalciferol|8000 units/ml
79867371|NCT00621257|Dietary Supplement|Cholecalciferol|400 units per drop
79402221|NCT01409993|Diagnostic Test|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
79402222|NCT01409993|Diagnostic Test|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
79402223|NCT01278381|Procedure|Pancreaticoduodenectomy|Resection of pancreatic lesion
79572829|NCT01820117|Other|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
79732623|NCT02831218|Procedure|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
79732624|NCT02831140|Behavioral|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
79867372|NCT00528840|Biological|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
79867373|NCT02547077|Procedure|Wound Closure with 2-octylcyanoacrylate|
79867374|NCT02547077|Procedure|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
79867375|NCT00840671|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
79270290|NCT05986539|Other|Observational|This study is only observational in nature and will not include an intervention.
79270291|NCT05982054|Procedure|core decompression with local bone marrow mononuclear cells injection|under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
79402224|NCT03988855|Drug|DNV3837|Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
79402225|NCT01273623|Device|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
79270292|NCT05982015|Device|Remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
79270293|NCT05982015|Device|Sham remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
79270294|NCT05978973|Dietary Supplement|Elemental Diet|. Elemental diets contain all daily required vitamins, micronutrients and macronutrients. The ingredients are readily digestible (carbohydrates, amino acids and medium chain fatty acids) and are absorbed within the proximal small bowel. One main disadvantage of elemental diets such as Vivonex is their unpalatability3 which has limited their use.
79572830|NCT01820117|Other|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
79572831|NCT01820117|Other|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
79572832|NCT01820117|Other|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
79572833|NCT01820117|Other|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
79572834|NCT01820117|Procedure|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
79572835|NCT01820117|Other|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
79572836|NCT01820130|Device|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
79732625|NCT02831140|Behavioral|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
79732626|NCT02831140|Behavioral|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
79732627|NCT02831140|Behavioral|commun interventions|"In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~, preservation of Serratus anterior and the front part of Latissimus Dorsi ).~In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
79270295|NCT05977920|Other|Caffeine|s. description
79270296|NCT05977751|Device|FemBloc|Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
79270297|NCT05975632|Device|Device: Self testing Potassium device|"Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test"
79270298|NCT05974384|Device|No Music|No listening to music while intervention is carried out
79270299|NCT05974384|Device|Music|Listening to music while intervention is carried out
79270300|NCT05973825|Procedure|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
79270301|NCT05972278|Drug|Obicetrapib|1 tablet daily
79572837|NCT01820143|Drug|Ilaprazole|
79572838|NCT01820143|Drug|Esomeprazole|
79572839|NCT01820156|Device|Home Respiratory Polygraphy|
79572840|NCT01820156|Device|Standard Polysomnography|
79572841|NCT01820169|Device|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
79572842|NCT01820195|Drug|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
79572843|NCT01820195|Drug|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
79572844|NCT01820195|Drug|Placebo group|The patients in this group will be received both oral placebo and IV placebo
79572845|NCT01820208|Drug|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
79732628|NCT02833480|Drug|Fluticasone group|
79732629|NCT02833480|Drug|Budesonide group|
79732630|NCT02833480|Drug|Formoterol group|
79732631|NCT04248166|Device|Photoacoustic imaging|"Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
79732632|NCT02833636|Procedure|ACEF score|
79732633|NCT04201054|Drug|Fluconazole|50 mg of fluconazole administered orally in a single dose.
79572846|NCT01820208|Drug|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
79270302|NCT05967910|Other|chronic psychological stress|Chronic psychological stress includes symptoms of anxiety and depression.
79270303|NCT05966597|Behavioral|Written persuasive leaflet|Additional written behavioural persuasive technique leaflet and a standard referral leaflet provided at the end of the home-based health screening.
79270304|NCT05966597|Behavioral|Standard referral leaflet|Standard referral leaflet provided at the end of the home-based health screening.
79270305|NCT05966519|Device|Total Knee Replacement (TKR)|Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
79572847|NCT01820221|Procedure|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
79402226|NCT03599401|Other|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
79402227|NCT01409915|Drug|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
79572848|NCT01820234|Other|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
79572849|NCT01820234|Other|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
79572850|NCT01820247|Drug|enteral nutrition|
79270306|NCT05957965|Device|Wii fit|Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.
79402228|NCT01409915|Drug|Saline -- placebo comparator|subcutaneous injection
79402229|NCT01272921|Drug|Bupivacaine|Varying doses to determine the duration of analgesia
79402230|NCT01272921|Drug|Ropivacaine|Varying doses to determine the duration of analgesia
79402231|NCT01409837|Drug|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
79402232|NCT00750165|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
79270307|NCT05957965|Other|Strengthening, proprioceptive exercises.|"-Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion & inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board"
79270308|NCT05957159|Other|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
79270309|NCT05957159|Radiation|PKAB|90 PET Imaging Scan using [11C]LY2795050 (AKA [11C]PKAB)
79270310|NCT05957159|Radiation|CFN|90 Pet Imaging Scan using [11C]-Carfentanil
79402233|NCT01278459|Drug|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
79402234|NCT04407169|Other|no intervention|There will be no intervention. It is only an observationnal study
79402235|NCT00731055|Drug|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
79402236|NCT00731055|Drug|Placebo|1 dose of placebo
79572851|NCT01820247|Drug|Tripterygium glycosides|
79572852|NCT01820286|Behavioral|Positive psychology intervention|
79572853|NCT01820286|Behavioral|Recollection intervention|
79572854|NCT01820299|Drug|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
79572855|NCT01820299|Drug|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
79572856|NCT01820312|Radiation|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
79732634|NCT04247854|Dietary Supplement|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
79732635|NCT04247854|Other|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
79572857|NCT01820325|Drug|Buparlisib|
79572858|NCT01820325|Drug|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
79572859|NCT01820325|Drug|Carboplatin|
79572860|NCT01820325|Drug|Paclitaxel|
79572861|NCT01820338|Behavioral|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
79732636|NCT01157117|Biological|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
79270311|NCT05954832|Diagnostic Test|Echocardiography|Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
79572862|NCT01820338|Behavioral|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
79270312|NCT05951452|Other|Blood samples for testosterone and SHBG measurements|"Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~t0 corresponding to the start of the hospital appointment and before watching the video~t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
79402237|NCT03024463|Procedure|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
79402238|NCT03594565|Drug|Fluticasone Propionate|Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
79402239|NCT01430585|Drug|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
79572863|NCT01820338|Other|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains & carbohydrates. Topics will also include use of vitamin & mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
79572864|NCT01820351|Other|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
79572865|NCT01820377|Behavioral|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
79572866|NCT01820403|Other|portion size kcal of box lunch|
79732637|NCT01157117|Biological|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
79732638|NCT01157117|Drug|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
79732639|NCT04247386|Drug|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
79270313|NCT05951452|Other|Saliva samples for oxytocin measurements|"Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
79270314|NCT05949632|Drug|INCB099280|Administered as specified in the treatment arm description
79270315|NCT05949632|Drug|axitinib|Administered as specified in the treatment arm description
79270316|NCT05945069|Device|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
79277650|NCT05791825|Behavioral|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
79402240|NCT01430585|Drug|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
79402241|NCT01430585|Drug|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
79402242|NCT04005859|Drug|Exparel|"2. Liposomal bupivacaine TAP block (experimental arm)~Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~Adhesive tapes will be applied at the level of the TAP block puncture sites."
79572867|NCT01820442|Drug|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
79572868|NCT01820442|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
80027265|NCT03730987|Behavioral|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
80027266|NCT03730987|Behavioral|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
79572869|NCT01820455|Drug|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
79572870|NCT01820455|Drug|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
79572871|NCT01820468|Behavioral|Adapted critical time intervention team|
79277651|NCT05791799|Drug|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
79572872|NCT01820481|Drug|WIN-901X dose level 1|100mg Bid, PO, 12weeks
79572873|NCT01820481|Drug|WIN-901X dose level 2|200mg Bid, PO, 12weeks
79572874|NCT01820481|Drug|WIN-901X dose level 3|300mg Bid, PO, 12weeks
79572875|NCT01820481|Drug|Placebo|Bid, PO, 12weeks
79732640|NCT04247386|Drug|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
79732641|NCT02833246|Other|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
79732642|NCT02833246|Other|usual care|
79732643|NCT02885051|Procedure|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
79732644|NCT02833324|Behavioral|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
79732645|NCT02833324|Behavioral|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
79732646|NCT02833324|Other|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
79732647|NCT04248088|Behavioral|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
79732648|NCT02833090|Procedure|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
79732649|NCT02833012|Drug|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
79732650|NCT02833012|Drug|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
79732651|NCT02833012|Drug|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
79867376|NCT00840671|Drug|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
79867377|NCT00851123|Behavioral|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
80027267|NCT02186340|Procedure|Inspiratory muscle training|
80027268|NCT03572205|Dietary Supplement|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
80027269|NCT03572205|Dietary Supplement|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
80027270|NCT02181192|Device|PET/CT|PET/CT
80027271|NCT02181192|Radiation|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
79572876|NCT01820494|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
79572877|NCT01820507|Device|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
79572878|NCT01820507|Device|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
79572879|NCT01820520|Drug|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
79572880|NCT01820533|Other|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
79572881|NCT01820598|Device|Multisite NMES training during 6 weeks|
79572882|NCT01820611|Device|Arcos Revision Stem System|Revision Hip System
79572883|NCT01820624|Drug|tretinoin|Given PO
79572884|NCT01820624|Drug|lithium carbonate|Given PO
79572885|NCT01820624|Other|laboratory biomarker analysis|Correlative studies
79572886|NCT01820663|Other|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
79572887|NCT01820663|Other|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
80027272|NCT02181192|Radiation|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
79572888|NCT01820689|Other|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
79572889|NCT01820702|Other|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at ~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against ~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
79572890|NCT01820715|Drug|600㎍ of DA-3030 Injection|
79572891|NCT01820715|Drug|Placebo|
79572892|NCT01820728|Drug|DA-3801 Injection|
79572893|NCT01820728|Drug|Gonal-F®|
79572894|NCT01820767|Drug|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
79572895|NCT01820767|Drug|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
79572896|NCT01820767|Drug|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
79572897|NCT01820780|Other|Natriuretic peptides levels to J7 and J14|
79572898|NCT01820780|Other|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
79572899|NCT01820780|Other|Phone calls in 6 months and 12 months|
79572900|NCT01820780|Other|Natriuretic peptides levels at 6 months|
79732652|NCT02833012|Drug|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
79572901|NCT01820780|Other|Consultation with the general doctor or the cardiologist to J30 with blood results|
79572902|NCT01820793|Drug|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
79572903|NCT01820806|Drug|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
79572904|NCT01820832|Drug|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
79572905|NCT01820871|Other|Self-Management Using Smartphone Application for Type2 DM|
79572906|NCT01820871|Other|self-management using booklet for management type 2 DM|
79867378|NCT00851123|Behavioral|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
79867379|NCT05691114|Biological|hAESCs|human Amniotic Epithelial Stem Cells
79867380|NCT02545985|Device|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
79572907|NCT01820897|Drug|Fosfomycin-Trometamol|
79572908|NCT01820897|Drug|Sulfamethoxazole trimethoprim|
79572909|NCT01820923|Device|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
79867381|NCT00851201|Behavioral|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
79867382|NCT00851201|Behavioral|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
79867383|NCT00844025|Behavioral|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
79867384|NCT02546531|Biological|Defactinib|
79867385|NCT02546531|Biological|Pembrolizumab|
79867386|NCT02546531|Drug|Gemcitabine|
79867387|NCT00840983|Procedure|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
79867388|NCT05205720|Procedure|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
79867389|NCT05205720|Drug|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
79867390|NCT00844103|Drug|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
79867391|NCT00844103|Drug|Placebo|10ml oral solution administered once a day over 10 days.
79867392|NCT00841061|Dietary Supplement|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
80027273|NCT03536598|Drug|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
80027274|NCT03536598|Drug|Amlodipine 10 mg + Valsartan 160 mg|
80027275|NCT03536598|Drug|Valsartan 160 mg + Rosuvastatin 20 mg|
79867393|NCT00841061|Dietary Supplement|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
80027276|NCT03574467|Behavioral|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
80027277|NCT03536988|Procedure|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
79270317|NCT05944497|Procedure|Interscalene brachial plexus block|Using a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).
79572910|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
79402243|NCT04005859|Drug|IV Lidocaine|"1. Intravenous Lidocaine infusion (control arm, current standard of care)~100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~Adhesive tapes will be applied at the presumed level of TAP block puncture sites."
79572911|NCT01820923|Device|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
79572912|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
79572913|NCT01820936|Drug|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
79572914|NCT01820936|Drug|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
79867394|NCT03999060|Device|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
79270318|NCT05940870|Device|Nerivio|Patients with migraine who received the Nerivio device for migraine prevention therapy
79270319|NCT05938387|Biological|CV09050101 mRNA vaccine (CVGBM) 12 μg|CVGBM will be administered as an IM injection.
79270320|NCT05938387|Biological|CV09050101 mRNA vaccine (CVGBM) 25 μg|CVGBM will be administered as an IM injection.
79270321|NCT05938387|Biological|CV09050101 mRNA vaccine (CVGBM) 50 μg|CVGBM will be administered as an IM injection.
79270322|NCT05938387|Biological|CV09050101 mRNA vaccine (CVGBM) 100 μg|CVGBM will be administered as an IM injection.
79572915|NCT01820936|Drug|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
79572916|NCT01820936|Drug|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
79572917|NCT01820936|Drug|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
79270323|NCT05938387|Biological|CV09050101 mRNA vaccine RDE|CVGBM will be administered as an IM injection.
79270324|NCT05938387|Biological|CV09050101 mRNA vaccine (CVGBM) 6 μg|CVGBM will be administered as an IM injection.
79572918|NCT01820962|Procedure|heparin|when not in use CVCs are locked with heparin
79572919|NCT01820962|Procedure|concentrated citrate|when not in use the CVC is locked with concentrated citrate
79572920|NCT01820975|Dietary Supplement|High protein intake|
79572921|NCT01820975|Other|Placebo comparator|No protein intake
79867395|NCT04042805|Biological|Sintilimab|200mg intravenously every 3 weeks
79867396|NCT04042805|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79867397|NCT05643846|Procedure|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
79867398|NCT00841139|Drug|Perhexiline|100mg o bd
79867399|NCT00841139|Drug|Placebo|1 tablet bd
79867400|NCT00841217|Drug|GW501516|2.5mg/day
79867401|NCT00841217|Drug|placebo pill|
79867402|NCT00841295|Drug|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
79867403|NCT00841295|Drug|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
79867404|NCT00851435|Biological|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
79867405|NCT00844337|Drug|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
80027278|NCT03536988|Procedure|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
80027279|NCT03576963|Drug|Guadecitabine|Given SC
80027280|NCT03576963|Biological|Nivolumab|Given IV
80027281|NCT02186496|Drug|CKD-330 8/5mg|
80027282|NCT02186496|Drug|Candesartan 8mg and Amlodipine 5mg|
80027283|NCT05615194|Drug|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
80027284|NCT05615194|Drug|Placebo|Volume equivalent in infusion over 10 minutes
80027285|NCT03572127|Other|Diet|High protein diet derived from either animal or non-animal sources.
80027286|NCT02186574|Drug|Tenofovir disoproxil|
80027287|NCT02186574|Drug|Placebo Oral Tablet|
79572922|NCT01821001|Drug|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
79572923|NCT01821014|Other|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
79572924|NCT01821014|Other|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
79572925|NCT01821027|Drug|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
79867406|NCT00844337|Drug|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
79867407|NCT00844337|Drug|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
79867408|NCT00841373|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
79867409|NCT00841373|Procedure|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
79867410|NCT00841451|Drug|Lovaza (Fish Oils)|Double blinded placebo controlled
79867411|NCT00844493|Biological|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
79867412|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
79572926|NCT01821027|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
79572927|NCT01821040|Drug|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
79572928|NCT01821040|Drug|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
79572929|NCT01821066|Drug|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
79867413|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
79867414|NCT00844493|Biological|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
79867415|NCT00851513|Drug|Lidocaine|local anesthetics
79867416|NCT00851513|Drug|Depmedrol|local steroids
79867417|NCT00851513|Other|physiological serum|important volumes of physiological serum
79867418|NCT00841607|Procedure|pancreaticojejunostomy vs pancreaticogastrostomy|
79867419|NCT00844571|Other|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
79867420|NCT00841841|Drug|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
79867421|NCT02545751|Radiation|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
79867422|NCT02545751|Drug|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
79867423|NCT00841919|Drug|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
79867424|NCT00841919|Drug|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
79270325|NCT05936996|Device|MANTA Vascular Closure Device|The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
79270326|NCT05936580|Drug|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
79402244|NCT03594409|Diagnostic Test|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
79572930|NCT01821066|Drug|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
79572931|NCT01821066|Drug|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
79572932|NCT01821066|Drug|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
79572933|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
79572934|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
79572935|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
79402245|NCT04052945|Procedure|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 )."
79402246|NCT04052945|Procedure|sham acupuncture|"For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6)."
79732653|NCT00891202|Drug|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 [active moiety of ET in plasma] trough plasma concentration >=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration <5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
80027288|NCT04974268|Other|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
80027289|NCT02181270|Other|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
80027290|NCT02181270|Other|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
80027291|NCT03066700|Device|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
79270327|NCT05934136|Behavioral|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
79402247|NCT03594331|Drug|Low-dose PvP001|Low-dose PvP001
79402248|NCT03594331|Drug|Medium-dose PvP001|Medium-dose PvP001
79402249|NCT03594331|Drug|High-dose PvP001|High-dose PvP001
79572936|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
79572937|NCT01821092|Procedure|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
79572938|NCT01821092|Device|osseointegrated implant|Osseointegrated Implant Insertion
80027292|NCT02240901|Device|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
79304458|NCT03291821|Procedure|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
79304459|NCT03291821|Diagnostic Test|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
79402250|NCT03594331|Drug|Placebo|100 mL liquid with no drug
79572939|NCT01821157|Procedure|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
79572940|NCT01821157|Procedure|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
79572941|NCT01821170|Drug|Methylphenidate|Patient will take treatment during two months
80027293|NCT02240901|Device|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
80027294|NCT03066544|Drug|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
79867425|NCT00841919|Drug|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
79572942|NCT01821170|Device|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
79270328|NCT05934136|Behavioral|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
79402251|NCT05633719|Other|Chemotherapy involving cisplatin or carboplatin|Chemotherapy
79402252|NCT03594097|Other|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
79867426|NCT00851669|Behavioral|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
79402253|NCT03594097|Other|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
79402254|NCT01408901|Behavioral|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
79402255|NCT01408901|Other|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
79572943|NCT01821170|Behavioral|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
79572944|NCT01821170|Other|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
79572945|NCT01821196|Procedure|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
79867427|NCT00851669|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
80027295|NCT03066544|Drug|Naratriptan Pill|one pill will be administered twice each day for 5 days
79867428|NCT04214327|Behavioral|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
80027296|NCT03066544|Drug|Dexamethasone|one tablet will be administered twice each day for 3 days
80027297|NCT03066544|Drug|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
80027298|NCT03574311|Drug|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
80027299|NCT03574311|Other|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
79402256|NCT01408901|Drug|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M^2 subcutaneously three times weekly for two weeks.
79402257|NCT04182763|Other|CoA-Z|People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
79402258|NCT04182763|Other|Placebo|The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
79572946|NCT01821209|Procedure|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
79270331|NCT05928403|Other|total knee prosthesis|Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
79270332|NCT05925478|Procedure|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
79572947|NCT01821222|Device|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
79732654|NCT00891202|Drug|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
79867429|NCT04214327|Behavioral|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
79867430|NCT04214327|Behavioral|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
79867431|NCT03849911|Diagnostic Test|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
79867432|NCT03849911|Diagnostic Test|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
79867433|NCT00851981|Other|Placebo|TID
79867434|NCT00851981|Dietary Supplement|SAMe|300 mg TID
79867435|NCT00852059|Drug|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
79270333|NCT05925478|Drug|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
79867436|NCT00852059|Drug|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
79572948|NCT01821235|Drug|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
79572949|NCT01821235|Drug|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
79867437|NCT00844727|Drug|Rofecoxib|
79572950|NCT01821235|Drug|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
79867438|NCT00844727|Drug|placebo|placebo pills
79867439|NCT00844961|Behavioral|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
79867440|NCT00845117|Procedure|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
79867441|NCT00528528|Drug|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
79867442|NCT00528528|Drug|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
79867443|NCT00528528|Drug|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
79867444|NCT00528528|Drug|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
79867445|NCT00528528|Drug|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
79867446|NCT00620555|Drug|gabapentin|Orally administered gabapentin
79867447|NCT00845273|Drug|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
79270334|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
79270335|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
79270336|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
79270337|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
79572951|NCT01821235|Drug|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
79572952|NCT01821248|Drug|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
79572953|NCT01821261|Device|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
79732655|NCT02831062|Other|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
79867448|NCT00845351|Drug|Bexarotene|bexarotene at 300 mg/m2/day
79572954|NCT01821261|Drug|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
79270338|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
79572955|NCT01821261|Drug|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
79270339|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
79402259|NCT05633485|Other|Animation-Supported Education|Expert support was received for the design and preparation of animation videos.
79867449|NCT00529386|Drug|Botox|300 units
79867450|NCT02546141|Other|skimmed milk (UHT)|
79270340|NCT05924594|Drug|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
79402260|NCT05633251|Behavioral|Variable (random) interval|Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
79402261|NCT05633251|Behavioral|Variable (non-random) interval|Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
79402262|NCT05633251|Behavioral|Variable (random) interval with table tents|Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
79402263|NCT05633251|Behavioral|Control|No intervention
79402264|NCT03594019|Procedure|Connective tissue graft|Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
79572956|NCT01821274|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
79732656|NCT02830906|Drug|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
79402265|NCT03594019|Procedure|socket shield technique|The procedure is used to split the teeth and preserve the buccal part
79572957|NCT01821274|Drug|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
79732657|NCT02830906|Drug|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
79867451|NCT02546141|Other|skimmed milk (pasteurized)|
79867452|NCT02546141|Other|skimmed yoghurt|
79270341|NCT05917717|Procedure|Neuroprotective 'bundle of care'|"This includes the 3 devices:~Head up cardiopulmonary resuscitation (HUP-CPR)~Active compression decompression CPR~Impedance threshold device (ITD)"
79270342|NCT05916586|Drug|Prednisone|Prednisone 40 mg orally once a day for 7 days
79270343|NCT05911295|Drug|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks
79270344|NCT05911295|Drug|pembrolizumab|400mg given by IV every 6 weeks
79402266|NCT03594019|Procedure|Immediate implant placement|The implant will be placed in the frest socket immediately after tooth extraction
79572958|NCT01821274|Drug|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
79572959|NCT01821274|Drug|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
79572960|NCT01821287|Other|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
79867453|NCT02546141|Other|full-fat milk (UHT)|
79867454|NCT02546141|Other|non-homogenized full-fat milk (pasteurized)|
79867455|NCT02546141|Other|full-fat cheese (semi-matured)|
79270345|NCT05911295|Drug|gemcitabine|1000 mg/m^2 given by IV on days 1 and 8 of every 3-week cycle
79270346|NCT05911295|Drug|cisplatin|70 mg^2 given by IV on day 1 of every 3-week cycle
79270347|NCT05911295|Drug|carboplatin|Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
79270348|NCT05910970|Drug|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
79572961|NCT01821313|Other|Moderate exercise|
79572962|NCT01821313|Other|High Intensity Interval Exercise|
79572963|NCT01821404|Drug|Atorvastatin|Capsules including 80 mg of atorvastatin
79732658|NCT02832778|Drug|Efavirenz|Efavirenz 400mg
79732659|NCT02832778|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
79732660|NCT02832778|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
79732661|NCT02832778|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
79732662|NCT02832778|Drug|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)
79732663|NCT01185509|Drug|trastuzumab|
79732664|NCT01185509|Drug|vinorelbine|
79732665|NCT02830984|Procedure|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
79867456|NCT02546141|Other|whey protein|
79867457|NCT02546141|Other|micellar casein|
79867458|NCT05213286|Diagnostic Test|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
79867459|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
79867460|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
79572964|NCT01821404|Drug|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
79867461|NCT03875118|Behavioral|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
79867462|NCT03875118|Behavioral|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
79867463|NCT00845819|Drug|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) & nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
79867464|NCT00845819|Drug|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
79867465|NCT02546843|Drug|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
79867466|NCT02546843|Drug|Cisatracurium|cisatracurium 0.15mg/kg intravenously
79867467|NCT02546843|Drug|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
79867468|NCT02546843|Drug|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
79867469|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
79867470|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
79572965|NCT01821430|Drug|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
79867471|NCT00529308|Device|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
79867472|NCT00529308|Device|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
79867473|NCT03999840|Drug|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
79402267|NCT03593863|Behavioral|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
79402268|NCT04748159|Other|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
79867474|NCT03999840|Drug|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
79572966|NCT01821430|Drug|Placebo|Placebo group will follow the same titration as the pregabalin group
79402269|NCT02080195|Drug|Cyclophosphamide|14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
79867475|NCT05000424|Other|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
79867476|NCT05000424|Other|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
79867477|NCT03875508|Drug|Risankizumab|Risankizumab to be injected subcutaneously (SC)
79402270|NCT02080195|Drug|Fludarabine|30 mg/m^2/day on Days -6 through -2.
79867478|NCT03875508|Device|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
79867479|NCT03998982|Drug|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
79867480|NCT03998982|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
79867481|NCT04991766|Drug|[¹⁴C]-LY3484356|Administered orally.
79867482|NCT04991766|Drug|LY3484356|Administered orally.
79867483|NCT04991766|Drug|[¹⁴C]-LY3484356 (IV)|Administered IV.
79402271|NCT02080195|Drug|Tacrolimus|Starting on Day 5. Dose will be adjusted according to blood levels.
79402272|NCT02080195|Drug|Mycophenolate Mofetil|15 mg/kg three times per day from Day 5 to Day 35.
79402273|NCT02080195|Drug|Rabbit antithymocyte globulin|0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
79402274|NCT02080195|Radiation|Total body irradiation|200 centigray on Day -1.
79402275|NCT02080195|Biological|Allogeneic bone marrow transplant|Infusion on Day 0.
79572967|NCT01821443|Other|Stereotactic radiosurgery (SRS)|"Dose & prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% [maximum=100%]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
79270349|NCT05910970|Drug|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
79270350|NCT05906732|Drug|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
79270351|NCT05906732|Drug|Placebo|Matching Placebo
79270352|NCT05906732|Drug|Dofetilide 250 μg Cap|Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker
79402276|NCT04044131|Drug|Metabolic Cofactor Supplementation|Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
79402277|NCT04044131|Drug|Sorbitol|As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
79402278|NCT04748081|Procedure|hepatectomy|hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
79270353|NCT05906511|Drug|Dronabinol 5 MG|Dronabinol 5 mg
79270354|NCT05906511|Drug|Dronabinol 10 MG|Dronabinol 10mg
79867484|NCT00620321|Drug|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
79572968|NCT01821456|Drug|Antiinfectives|To analyze to efficacy of (novel) drug therapies
79270355|NCT05906511|Drug|2mg Purified THC in an ethanolic solution|2mg Purified THC in an ethanolic solution
79572969|NCT01821469|Behavioral|psychoeducation|Bipolar disorders are educated to learn about their pathology
79270356|NCT05906511|Drug|4mg Purified THC in an ethanolic solution|4mg Purified THC in an ethanolic solution
79270357|NCT05906511|Drug|Placebo|Oral placebo and/or vaporized saline
79270358|NCT05904847|Behavioral|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
79732666|NCT02830984|Procedure|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
79732667|NCT02833168|Other|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
79270359|NCT05898841|Drug|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
79732668|NCT02833168|Device|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
79732669|NCT04247230|Drug|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
79732670|NCT04247230|Other|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
79270360|NCT05898841|Drug|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day|TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
79304460|NCT03291821|Procedure|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
79304461|NCT03291821|Diagnostic Test|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
79572970|NCT01821482|Biological|Dendritic and Cytokine-induced Killer Cells|
79572971|NCT01821495|Biological|DC-CIK|
79572972|NCT01821495|Biological|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
79572973|NCT01821508|Other|Clinical Treatment|metabolic surgery for diabetes and weight control
79402279|NCT03024307|Other|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
79572974|NCT01821508|Procedure|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
79732671|NCT04247230|Drug|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
79867485|NCT00620321|Drug|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
79867486|NCT00620321|Drug|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
79867487|NCT00848471|Device|Quark RMR|Quark RMR calorimeter (Cosmed)
79867488|NCT00848471|Device|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
79572975|NCT01821521|Drug|AGSPT_L20|
80027300|NCT02844543|Device|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
79270361|NCT05898841|Drug|Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
79732672|NCT02832934|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
79732673|NCT02832934|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
79867489|NCT00852215|Device|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
79867490|NCT00852215|Device|Vision stent|Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
79867491|NCT00852293|Other|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
79572976|NCT01821521|Drug|Pantoloc 40mg|
79732674|NCT04247776|Combination Product|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
79867492|NCT00621023|Drug|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
80027301|NCT02844543|Other|SCAT-3|The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
80027302|NCT02844543|Device|Desktop Eye-Tracker|Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
80027303|NCT04137562|Biological|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10^8 cells/5mL
79270362|NCT05897216|Drug|CKD-383|QD, PO
79270363|NCT05897216|Drug|CKD-501, D745, D150, D029|QD, PO
79270364|NCT05893147|Other|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic."
79270365|NCT05893147|Other|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime."
79402280|NCT01428713|Drug|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
79402281|NCT01428713|Drug|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
79572977|NCT01821547|Drug|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
80027304|NCT04137562|Other|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
80027305|NCT03063424|Diagnostic Test|Eucapnic voluntary hyperventilation|
80027306|NCT03063424|Diagnostic Test|Exercise challenge on a cycle ergometer|
80027307|NCT03576807|Drug|CD20 CAR-T cells|A total of 1 - 20×10^6 CD20 CAR-T cells/kg will be administered by IV infusions.
79572978|NCT01821573|Drug|botulinum toxin type A|"Experimental arm group:~150 Units in rectus femoris ( 3 ml and 3 points)~70 units in medial gastrocnemius (1.4 ml and 1 point)~70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~60 units in soleus ( 1.2 ml and 3 points)"
79572979|NCT01821573|Drug|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~3 ml of NaCl 0.9% in rectus femoris in 3 points~1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~1.2 ml of NaCl 0.9% in soleus in 3 points"
79572980|NCT01821586|Other|Modified ORS-1|
79572981|NCT01821586|Other|Modified ORS-2 (ReSoMal)|
79572982|NCT01821586|Other|Modified ORS-3 (Benefibre)|
79732675|NCT04247776|Other|ERAS|Enhanced Recovery After Surgery guidelines are applied.
79732676|NCT04247776|Behavioral|Fitbit|Fitbit is worn to monitor step counts.
79732677|NCT02830750|Procedure|Ablation|
79732678|NCT02832700|Dietary Supplement|Casein glycomacropeptide|
79732679|NCT02832700|Dietary Supplement|Placebo|
80027308|NCT03182179|Drug|Ondansetron 4 MG|Ondansetron is taken orally BD
80027309|NCT03182179|Drug|Placebo|Placebo is taken orally BD
80027310|NCT04118452|Behavioral|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
79270366|NCT05893147|Other|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed."
79402282|NCT02985385|Other|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
79402283|NCT01408277|Biological|Santyl|2 mm Santyl applied once daily
79572983|NCT01821599|Other|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
79572984|NCT01821599|Other|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
79572985|NCT01821612|Drug|oxaliplatin|IV
79572986|NCT01821612|Drug|irinotecan|IV
79572987|NCT01821612|Drug|leucovorin|IV
79732680|NCT02832466|Other|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
79732681|NCT05223790|Device|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
79732682|NCT02832232|Other|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
79732683|NCT02832232|Other|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
79867493|NCT02546687|Other|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
79867494|NCT00842465|Biological|blood collection for hormonal status analysis|for hormonal status analysis
79867495|NCT00842465|Procedure|breast Biopsy or surgery|breast Biopsy or surgery
79867496|NCT00842465|Genetic|blood collection|blood collection for prlR gene sequencing
79867497|NCT00842465|Other|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
79270367|NCT05893147|Other|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses"
79867498|NCT00848627|Other|Specimen and questionnaires only|Specimen and questionnaires only
79867499|NCT00842621|Procedure|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
80027311|NCT03576651|Biological|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
80027312|NCT03576651|Biological|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
80027313|NCT03576651|Biological|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
79304462|NCT03291821|Procedure|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
79304463|NCT03291821|Procedure|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
79402284|NCT01408277|Procedure|Control|Standard Care
79572988|NCT01821612|Drug|5-fluorouracil|IV
79572989|NCT01821612|Drug|capecitabine|PO
79402285|NCT01408043|Drug|plerixafor|Given SC
79402286|NCT01408043|Biological|filgrastim|Given SC
79402287|NCT01408043|Drug|etoposide|Given IV
79402288|NCT01408043|Procedure|leukapheresis|Undergo apheresis
79402289|NCT03598855|Other|Ischemic Preconditioning|Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
79572990|NCT01821612|Radiation|radiation|
79572991|NCT01821612|Procedure|surgery|
79572992|NCT01821612|Drug|gemcitabine|IV
79572993|NCT01821651|Device|HeartNavigator|Procedure with software
79572994|NCT01821651|Device|EchoNav|Procedure with software
80027314|NCT03064906|Device|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
80027315|NCT03034135|Drug|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
80027316|NCT03034135|Drug|Temozolomide (TMZ)|TMZ is given per standard of care
80027317|NCT05411458|Other|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
80027318|NCT03574155|Behavioral|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
79867500|NCT00842621|Other|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
79402290|NCT03593785|Drug|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
79402291|NCT03984175|Procedure|Implementation of Processes|Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
80027319|NCT02239731|Drug|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
79732684|NCT02832232|Other|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
79867501|NCT04042883|Procedure|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
79867502|NCT00848705|Behavioral|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
79867503|NCT00848861|Drug|propofol (sedation for outpatient colonoscopy)|
79402292|NCT03023995|Procedure|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
79867504|NCT00848861|Drug|midazolam plus meperidine (sedation for outpatient colonoscopy)|
79402293|NCT03023995|Procedure|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
79402294|NCT03598621|Drug|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
79572995|NCT01821651|Other|Control-Group EN|Procedure without software
79572996|NCT01821651|Other|Control-group HN|Procedure without software
79572997|NCT01821664|Device|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
79572998|NCT01821703|Drug|LY3045697|Administered as oral solution
79572999|NCT01821703|Drug|Placebo|Administered as oral solution
79573000|NCT01821703|Drug|Spironolactone|Administered as capsule
79573001|NCT01821703|Drug|Placebo|Administered as capsule
79573002|NCT01821716|Biological|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
79867505|NCT00852371|Drug|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
79573003|NCT01821742|Other|Ultrasound cardiac output measurement|
79573004|NCT01821755|Behavioral|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
79573005|NCT01821768|Procedure|Sentinel Lymph Node Biopsy|
79573006|NCT01821820|Other|Pistachios|
79732685|NCT02830828|Other|Investigation of precision pinch grip control|
79732686|NCT02830516|Other|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
79732687|NCT04247152|Other|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
79732688|NCT02832310|Procedure|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
79732689|NCT02831920|Other|CEUS and targeted biopsies|
79867506|NCT00852371|Drug|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
80027320|NCT03571893|Behavioral|Weight Watchers Freestyle (Flex)|Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
80027321|NCT03571893|Behavioral|DIY Personal Plan|Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
79732690|NCT02831920|Other|MRI and targeted biopsies|
79867507|NCT00852371|Drug|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
79867508|NCT00852371|Other|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
79867509|NCT00842777|Behavioral|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
79867510|NCT00842777|Behavioral|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
79867511|NCT00528372|Drug|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
79867512|NCT00528372|Drug|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
79867513|NCT00528372|Drug|Metformin|
79867514|NCT01564680|Other|placebo|normal saline
79867515|NCT01564680|Drug|Paracetamol|IV paracetamol infusion
79867516|NCT01564680|Drug|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
79867517|NCT01564836|Behavioral|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
80027322|NCT03064828|Radiation|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
79573007|NCT01821846|Drug|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
79573008|NCT01821872|Drug|Administration of paracetamol|Administration of 1g intravenous paracetamol
79573009|NCT01821885|Behavioral|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
79573010|NCT01821885|Behavioral|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
79573011|NCT01821911|Biological|Zagreb2-1-1|Injection on day 0、7、21
79732691|NCT02830672|Procedure|Surgical release A1 pulley for Trigger finger of the hand|
79867518|NCT00527982|Drug|Celecoxib|600 mg by mouth daily for a total of 12 months.
79867519|NCT04121286|Drug|JAB-3312|JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
80027323|NCT03064828|Radiation|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
80027324|NCT02035683|Procedure|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
80027325|NCT03064594|Procedure|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
79270368|NCT05893147|Other|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
79573012|NCT01821911|Biological|Essen|Injection on day 0、3、7、14、28
79732692|NCT02832076|Procedure|Subcutaneous negative suction drain for 10 days|
79732693|NCT02832076|Procedure|No subcutaneous drain|
79732694|NCT02831842|Drug|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
79732695|NCT02831842|Drug|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
79732696|NCT02831842|Drug|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
79732697|NCT00891046|Drug|Canakinumab|Canakinumab
79732698|NCT02830282|Other|Blood Collection|
79732699|NCT04245982|Procedure|Gingival biopsy|Two gingival biopsies from each participant were collected.
79732700|NCT02830048|Drug|Glibenclamide|
79732701|NCT02830126|Other|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
79732702|NCT04245358|Device|Ainara|1g of gel per administration
80027326|NCT02239809|Procedure|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
80027327|NCT02239809|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
80027328|NCT03571815|Drug|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
80027329|NCT03571815|Other|WATER ON TEETH|control group
80027330|NCT04050358|Dietary Supplement|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
80027331|NCT04050358|Dietary Supplement|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
80027332|NCT02985073|Device|Veritas®|Biologic mesh
79732703|NCT02829892|Device|Light therapy|14-days exposure with an innovative ambient light
79732704|NCT02828800|Other|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith & Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
79732705|NCT02829970|Behavioral|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention & Alcohol Disorders (BAAAD).
79732706|NCT02829970|Behavioral|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
79732707|NCT02828722|Other|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
79867520|NCT00527904|Drug|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
79867521|NCT00527904|Drug|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
79867522|NCT00619619|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
79867523|NCT00852449|Other|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity < 13% and no further increases in SV
79867524|NCT00848939|Drug|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
79867525|NCT00848939|Drug|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
79867526|NCT00842933|Drug|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
79867527|NCT00842933|Drug|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
79867528|NCT00849095|Drug|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
80027333|NCT02985073|Device|TIGR®|Non biologic mesh
80027334|NCT02239887|Device|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
79867529|NCT00849095|Drug|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
79867530|NCT00849095|Drug|placebo|bid inhaled placebo
79867531|NCT00849095|Drug|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
79867532|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
80027335|NCT04096378|Behavioral|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
80027336|NCT04096378|Behavioral|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
80027337|NCT03701815|Behavioral|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
80027338|NCT03571737|Drug|Ibuprofen|Ibuprofen tablet
80027339|NCT03571737|Drug|Lidocaine Patch 4%|Lidocaine patch
80027340|NCT03064672|Device|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
80027341|NCT03571659|Procedure|Laser|
80027342|NCT03705013|Other|Cologuard|Observational
79270373|NCT05879029|Drug|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
79573013|NCT01821950|Behavioral|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
79573014|NCT01821989|Dietary Supplement|Lactoferrin|dose of 100 mg/day
79732708|NCT02828722|Other|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
79732709|NCT04245592|Dietary Supplement|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
79732710|NCT04245592|Dietary Supplement|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
79732711|NCT02828332|Other|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
79732712|NCT02828332|Other|Quality of life|Evaluation of the quality of life and comorbidities
79732713|NCT02828566|Drug|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
79732714|NCT02828566|Drug|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
79732715|NCT02828566|Drug|IN saline 0.9%|Intranasal 0.9% normal saline
79732716|NCT02828566|Drug|IV saline 0.9%|Intravenous 0.9% normal saline
79270374|NCT05879029|Drug|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
79573015|NCT01821989|Dietary Supplement|Lactoferrin|dose of 150 mg/kg/ twice daily
79573016|NCT01821989|Dietary Supplement|Placebo|in form of distilled water
79573017|NCT01822002|Procedure|Canalith repositioning maneuver|
79732717|NCT04245046|Drug|Candesartan, Amlodipine, Atorvastatin|compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
79402295|NCT03598621|Drug|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
79402296|NCT03598621|Drug|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
79573018|NCT01822028|Drug|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
79732718|NCT02828176|Procedure|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
79732719|NCT02828176|Procedure|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
79867533|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
79867534|NCT00843011|Drug|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
79867535|NCT00849329|Drug|lapatinib|1250mg lapatinib
79573019|NCT01822028|Drug|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
79573020|NCT01822041|Drug|ARN-509|Single oral dose of 240 mg ARN-509
79573021|NCT01822080|Drug|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
79573022|NCT01822080|Drug|Placebo|Matching placebo once daily by mouth
79573023|NCT01822093|Biological|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results > 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group"
79732720|NCT02828176|Procedure|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
79732721|NCT02828176|Procedure|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
79573024|NCT01822106|Other|Placebo|
79573025|NCT01822145|Device|ICD|
79573026|NCT01822158|Other|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
79573027|NCT01822171|Other|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
79573028|NCT01822171|Other|Home medication if needed|Patient will be provided with medication to take home, when needed.
79732722|NCT02829580|Procedure|Echocardiography|Measures by Doppler and study of endothelial function
79732723|NCT02828410|Dietary Supplement|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
79732724|NCT04245124|Other|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
79732725|NCT04245124|Other|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
79732726|NCT04246450|Device|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF <35%. In patients in the LVEF <35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
79573029|NCT01822171|Other|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
79573030|NCT01822210|Drug|Botox|injection by gastroscopy (100 Allergen units)
79732727|NCT04244812|Other|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
79867536|NCT00849329|Drug|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
79867537|NCT02545829|Drug|HIP1302|Tenofovir 292mg
79867538|NCT02545829|Drug|HGP1406|Tenofovir 300mg
79867539|NCT02545595|Drug|Sugammadex 1 mg/kg|
79867540|NCT02545595|Drug|Sugammadex 2 mg/kg|
79867541|NCT02545595|Drug|Sugammadex 4 mg/kg|
79573031|NCT01822236|Other|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
79573032|NCT01822236|Other|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
79573033|NCT01822249|Drug|EPI-743|
79573034|NCT01822249|Drug|Placebo|
79573035|NCT01822262|Procedure|minimally invasive cholecystolithotomy with gallbladder reservation|
79573036|NCT01822262|Procedure|laparoscopic cholecystectomy|
79573037|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
79573038|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
79573039|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers earned independent of cocaine use
79573040|NCT01822340|Drug|HM10560A|Once weekly HM10560A
79573041|NCT01822340|Drug|Genotropin|Once daily Genotropin
79573042|NCT01822379|Procedure|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
79573043|NCT01822392|Behavioral|Online Parent Management Training (Interactive)|
79573044|NCT01822392|Behavioral|Online Parent Management Training (Recorded)|
79573045|NCT01822405|Drug|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
79573046|NCT01822405|Other|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
80027343|NCT03576339|Procedure|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
79573047|NCT01822418|Drug|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
80027344|NCT03576339|Device|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
80027345|NCT03576339|Device|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
80027346|NCT03571503|Procedure|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
79573048|NCT01822431|Radiation|metaiodobenzylguanidine scintigraphy|
79573049|NCT01822483|Drug|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
79573050|NCT01822483|Drug|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.
79867542|NCT00843089|Other|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
79867543|NCT00843245|Other|No intervention|No intervention
79270375|NCT05878353|Procedure|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
79270376|NCT05878353|Procedure|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
79573051|NCT01822600|Drug|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels < 25 g/L.
79573052|NCT01822600|Drug|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
79573053|NCT01822613|Drug|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
79573054|NCT01822613|Drug|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
79573055|NCT01822613|Drug|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
79573056|NCT01822613|Drug|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
79573057|NCT01822613|Drug|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
79732728|NCT04244812|Device|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
79732729|NCT02827864|Behavioral|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
79867544|NCT00849563|Other|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
79867545|NCT05027178|Other|Chiropractic Care|Chiropractic care on stroke participants
79867546|NCT04840212|Other|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
80027347|NCT03571503|Drug|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
79867547|NCT01564992|Other|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
79573058|NCT01822626|Behavioral|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
79270377|NCT05863104|Drug|Glycopyrronium Bromide (GPB) Cream|Application of cream to each axilla
79270378|NCT05862272|Drug|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
79402297|NCT03598621|Drug|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
79573059|NCT01822639|Drug|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
79573060|NCT01822639|Drug|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
79573061|NCT01822639|Drug|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
79573062|NCT01822704|Device|Low intensity whole body vibration|
79573063|NCT01822704|Device|High intensity whole body vibration|
79573064|NCT01822704|Behavioral|Leg exercises|
79573065|NCT01822717|Behavioral|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
79573066|NCT01822717|Behavioral|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
79573067|NCT01822730|Drug|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
79573068|NCT01822730|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
79573069|NCT01822769|Other|Cardiopulmonary rehabilitation|See Arm Description
79867548|NCT00855491|Procedure|Phaco|AcrySof Single-Piece IOL
79867549|NCT00849719|Drug|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
79270379|NCT05858996|Behavioral|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
79270380|NCT05858996|Other|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
79402298|NCT03598621|Device|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
79402299|NCT03598621|Device|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
79402300|NCT03598621|Device|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
79402301|NCT03598621|Device|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
79402302|NCT05632783|Drug|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
79402303|NCT05632783|Other|Placebo|Placebo tablets
79402304|NCT01524224|Drug|LY2495655|administered intravenously
79573070|NCT01822769|Other|Standard of care|See Arm Description
79573071|NCT01822782|Biological|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
79573072|NCT01822795|Procedure|Lung volume reduction coïl treatment|
79573073|NCT01822795|Other|Regular medical treatment|
79573074|NCT01822808|Drug|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
79573075|NCT01822808|Drug|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
79573076|NCT01822860|Drug|Chlorthalidone 12.5 mg|
79573077|NCT01822860|Drug|Hydrochlorothiazide 25 mg|
79573078|NCT01822860|Drug|Placebo|
79573079|NCT01822912|Other|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
79573080|NCT01822912|Other|Heart Failure Usual Care|Subjects will receive standard of care.
79573081|NCT01822938|Other|incentive program for physical activity|
79402305|NCT05630443|Procedure|prone position|Ordinary ERAS treatment postoperatvely adding the prone position and voicetraining
79573082|NCT01822951|Drug|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
79867550|NCT00849719|Drug|PCA MO only|When visual analog scale [VAS] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
79867551|NCT04832256|Device|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
79270381|NCT05855135|Device|OPTIMIZER® Integra CCM-D System (Treatment Arm)|"The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years."
79270382|NCT05852444|Device|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
79573083|NCT01822951|Drug|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
79270383|NCT05852444|Device|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
79732730|NCT02827864|Behavioral|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
79867552|NCT02546219|Other|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
79867553|NCT01565070|Drug|Biofreeze|Use of Biofreeze ointment
80027348|NCT03571503|Procedure|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
79270384|NCT05848843|Drug|Durvalumab|Given by vein (IV)
79270385|NCT05848843|Drug|Adagrasib|Given by PO
79573084|NCT01822964|Device|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
79573085|NCT01822964|Device|Placebo - current clinical practice, no cooling|
79573086|NCT01822977|Drug|omeprazole|
79573087|NCT01823003|Radiation|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size < 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
79732731|NCT02827864|Behavioral|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
79270386|NCT05846516|Drug|VSV-GP154|Injection
79732732|NCT00633568|Drug|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
79732733|NCT00633568|Drug|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
79732734|NCT04246294|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
79867554|NCT01565070|Other|Placebo|Use of placebo ointment
79270387|NCT05846516|Drug|ATP150|Injection
79270388|NCT05846516|Drug|ATP152|Injection
79270389|NCT05846516|Drug|Ezabenlimab|Infusion
79270390|NCT05841056|Drug|Amiodarone Hydrochloride 200 MG|200 mg daily for 4 weeks
79270395|NCT05839873|Device|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment.
79402306|NCT00219349|Behavioral|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
79402307|NCT00219349|Drug|escitalopram|10-20 mg per day for 12 weeks
79402308|NCT03593239|Other|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
79402309|NCT03593239|Other|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
79573088|NCT01823003|Radiation|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
79573089|NCT01823003|Radiation|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall < 1 cm, tumour size < 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
79867555|NCT00527748|Device|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
80027349|NCT03571503|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
80027350|NCT03571503|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
80027351|NCT03571503|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
79402310|NCT03593239|Other|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
79573090|NCT01823003|Radiation|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size < 5 cm and distance to the main bronchus < 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
79573091|NCT01823029|Drug|erythropoietin|
79573092|NCT01823029|Drug|enteral nutrition.|
79573093|NCT01823029|Drug|injection of iron|
79573094|NCT01822509|Biological|Ipilimumab|Given IV
79573095|NCT01822509|Other|Laboratory Biomarker Analysis|Correlative studies
79573096|NCT01822509|Biological|Nivolumab|Given IV
79573097|NCT01823042|Drug|azathioprine+enteral nutrition|
79732735|NCT02829658|Behavioral|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
79732736|NCT02829658|Other|No intervention|No intervention
79732737|NCT02827630|Other|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
79867556|NCT00852605|Other|Intermittent Non-Invasive Ventilation|
79573098|NCT01823042|Drug|Azathioprine|
79402311|NCT03593239|Other|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
79573099|NCT01823055|Procedure|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
79732738|NCT02827630|Other|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
79867557|NCT03998280|Device|Assessment|Neck proprioception and postural stability
79867558|NCT00619385|Drug|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
79867559|NCT00855569|Device|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
79402312|NCT03593239|Other|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
79402313|NCT03593239|Other|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
79573100|NCT01823068|Drug|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
79573101|NCT01823081|Drug|Intravitreal injection of bevacizumab (Avastin)|
79573102|NCT01823081|Drug|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
79867560|NCT00852683|Drug|Pregabalin|75 mg twice a day
79867561|NCT00852683|Drug|Placebo|75 mg twice a day
79867562|NCT00855647|Procedure|Hypo-fractionated Radiotherapy|
79867563|NCT04103255|Other|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
79867564|NCT00619307|Drug|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
80027352|NCT03571503|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
80027353|NCT03571503|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
80027354|NCT03571503|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
80027355|NCT04445584|Diagnostic Test|7 Tesla MRI|7 Tesla MRI
79573103|NCT01823120|Other|Supportive and interactive text messages|
79573104|NCT01823133|Drug|gemigliptin only|gemigliptin 50mg qd on day 1~7
79573105|NCT01823133|Drug|rosuvastatin only|rosuvastatin 20mg qd on day 1~7
80027356|NCT03574077|Behavioral|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
79573106|NCT01823133|Drug|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7
79573107|NCT01823159|Drug|retigabine|Single oral administration of a 400 mg tablet.
79867565|NCT00619307|Drug|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
79867566|NCT00850187|Biological|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
79867567|NCT00923897|Radiation|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
79867568|NCT00855725|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
79867569|NCT00855725|Other|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
79867570|NCT00855725|Other|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
79867571|NCT00855725|Other|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
79867572|NCT00855881|Drug|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
79867573|NCT00850265|Device|Volumatic spacer|A spacer is a plastic device to inhaler medication
79867574|NCT00619229|Drug|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
79867575|NCT00619229|Other|Placebo|Placebo/d i.v. for 15 days
79270396|NCT05836259|Genetic|TN-201|TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
79573108|NCT01823159|Drug|placebo|Single oral administration of a tablet
79573109|NCT01823172|Procedure|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
79573110|NCT01823185|Drug|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
79573111|NCT01823185|Drug|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
79573112|NCT01823250|Behavioral|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
79867576|NCT02544971|Behavioral|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
79867577|NCT02544971|Other|Control|Treatment as usual
79867578|NCT02545439|Drug|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
79867579|NCT00619151|Device|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
79867580|NCT00619151|Device|Regent|Implant of the St. Jude Medical Regent mechanical valve
79867581|NCT02546297|Drug|Symbicort|drug are used for 12 months
79867582|NCT02546297|Drug|Spiriva|drug are used for 12 months
79402314|NCT03593239|Other|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
79573113|NCT01823250|Behavioral|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
79573114|NCT01823250|Behavioral|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
79573115|NCT01823250|Behavioral|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
79573116|NCT01823263|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
79270397|NCT05832879|Behavioral|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
79270398|NCT05832658|Device|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
79270399|NCT05832658|Behavioral|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
79270400|NCT05832658|Behavioral|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
79270401|NCT05828810|Drug|surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution|"Patients will be randomized to receive surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution.~Specifically, the first treatment arm will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The second treatment arm will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation."
79270402|NCT05821985|Procedure|The study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
79270403|NCT05821985|Procedure|The Control group|"The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution."
79270404|NCT05816759|Drug|CKD-383|QD, PO
79270405|NCT05816759|Drug|CKD-501, D744, D150|QD, PO
79573117|NCT01823263|Procedure|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
79573118|NCT01823263|Procedure|Interference task|30-minute interference task
79867583|NCT00618995|Drug|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
79867584|NCT00618995|Drug|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
79867585|NCT00618995|Drug|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
79270406|NCT05813925|Drug|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
79270407|NCT05813925|Drug|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
79402315|NCT03593239|Other|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
79573119|NCT01823263|Behavioral|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
79867586|NCT00618995|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
79867587|NCT03685344|Drug|Loncastuximab Tesirine and Durvalumab|intravenous infusion
79867588|NCT00850811|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
79867589|NCT00856115|Other|medical chart review|Patient charts are reviewed to obtain medical data.
79867590|NCT00856115|Other|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
79867591|NCT00856115|Other|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
79270408|NCT05813925|Drug|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
79270409|NCT05811676|Drug|Tranexamic acid|Intravenous administration of 10 mL (1 g of tranexamic acid), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
79270410|NCT05811676|Other|0.9% sodium chloride|Intravenous administration of 10 mL placebo(0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
79402316|NCT03593239|Other|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
79402317|NCT03593239|Other|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
79402318|NCT01523756|Device|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
79402319|NCT01523756|Device|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
79402320|NCT00218257|Drug|Progesterone|200mg progesterone twice daily
79402321|NCT00218257|Other|Placebo|placebo
79402322|NCT01523366|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
79402323|NCT01523366|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
79402324|NCT03024697|Procedure|Pectoral Plane Block|
79402325|NCT03024697|Procedure|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
79270411|NCT05806749|Combination Product|Donor CD34+, CD3+. and belumosudil|"Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24."
80027357|NCT03574077|Behavioral|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
80027358|NCT03574077|Behavioral|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
80027359|NCT03574077|Behavioral|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
79270412|NCT05802797|Other|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
79867592|NCT00856115|Other|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
80027360|NCT03574077|Behavioral|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
80027361|NCT03064516|Procedure|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
79270413|NCT05802797|Dietary Supplement|Algae Oil Capsule|Algae oil capsules with EPA and DHA
79573120|NCT01823263|Behavioral|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
79304464|NCT02445937|Behavioral|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
79573121|NCT01823263|Behavioral|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
79573122|NCT01823276|Other|Tyrosine-Containing Bar|
79573123|NCT01823276|Other|Placebo Bar|
79573124|NCT01823302|Dietary Supplement|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
79573125|NCT01823302|Other|nutritional counseling|nutritional counseling
79573126|NCT01823315|Drug|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
79867593|NCT00856271|Drug|olmesartan medoxomil|oral tablets, once daily for 8 weeks
79867594|NCT00856271|Drug|losartan potassium|capsules, once daily for 8 weeks
79867595|NCT00856427|Radiation|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
79867596|NCT00856427|Procedure|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
79867597|NCT00856505|Drug|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
79573127|NCT01823315|Drug|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)
79573128|NCT01823315|Biological|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
79573129|NCT01823354|Other|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
79867598|NCT02544893|Drug|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
79867599|NCT02544893|Drug|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
79867600|NCT02544893|Drug|serum physiologic|21 ml serum physiologic is applied paravertebral space
79732739|NCT05216692|Procedure|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
79270414|NCT05800353|Procedure|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
79867601|NCT02546063|Other|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
79270415|NCT05799625|Behavioral|StepOne Smartphone Application|This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
79867602|NCT00520572|Drug|AZD9056|
79867603|NCT00520572|Drug|Etanercept|
79270416|NCT05796336|Device|Lip taping|Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
79270417|NCT05795244|Drug|Nivolumab|- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
79270419|NCT05794516|Drug|ZB004|ZB004 single doses administered subcutaneously as solution
79270420|NCT05794516|Drug|Placebo|Placebo single doses administered subcutaneously as solution
79573130|NCT01823354|Other|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
79573131|NCT01823354|Other|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
79573132|NCT01823354|Other|Medical consultation|open questions
79573133|NCT01823367|Behavioral|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
79573134|NCT01823380|Procedure|Blood test|Blood test
79573135|NCT01823393|Drug|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
79573136|NCT01823393|Drug|NaCl|valvuloplasty is performed without heparin (placebo injection)
79270421|NCT05794412|Other|No intervention|No intervention
79304465|NCT03287297|Diagnostic Test|OGTT & HBA1c|oral glucose tolerance test & HBA1c: by measuring glycated hemoglobin
79573137|NCT01823406|Procedure|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
79573138|NCT01823406|Procedure|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
79573139|NCT01823445|Other|Xylitol disk|
79573140|NCT01823458|Behavioral|Lottery Insurance|
79573141|NCT01823458|Behavioral|Standard Lottery|
79867604|NCT00520572|Drug|Placebo|
79867605|NCT00573833|Other|questionnaire administration|
79573142|NCT01823471|Other|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
79573143|NCT01823484|Device|AN 69 ST hemofilter|
79573144|NCT01823484|Device|AN 69 hemofilter|
79867606|NCT00573833|Procedure|quality-of-life assessment|
79867607|NCT00573833|Radiation|brachytherapy|
79867608|NCT00853463|Behavioral|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
79867609|NCT00853619|Other|Service based decision support intervention|Delivering CDS via services
79867610|NCT00853697|Other|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
79270422|NCT05793918|Other|Therapeutic Percutaneous Electrolysis an neuromodulation|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
79270423|NCT05793918|Other|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
79270424|NCT05786326|Device|group 1|Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction
79270425|NCT05786326|Device|group 2|Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
79270426|NCT05786326|Device|group 3|Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
79573145|NCT01823523|Drug|Cefazolin, Cephalexin, Clindamycin|
79573146|NCT01823575|Device|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
79732740|NCT05216692|Procedure|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
79732741|NCT04245826|Other|Change in LCSBs Intake|Effect of changing LCSBs intake
79732742|NCT04245826|Other|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
79732743|NCT02829736|Procedure|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
79732744|NCT02829736|Procedure|Standard post-operative chest tube|A regular chest tube is left in the pleura.
79732745|NCT02829736|Procedure|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
79732746|NCT02829346|Drug|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
79732747|NCT02829346|Drug|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
79732748|NCT05210764|Drug|propofol|General anesthesia is induced and maintained mainly with propofol.
79732749|NCT05210764|Drug|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
79732750|NCT05210764|Drug|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
79732751|NCT00889720|Drug|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
79732752|NCT04244500|Procedure|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
79732753|NCT02827786|Device|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
79732754|NCT02827552|Other|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
79867611|NCT00856817|Drug|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
79270427|NCT05785286|Other|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
79304466|NCT02448901|Drug|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
79573147|NCT01823575|Device|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
79867612|NCT00856817|Drug|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
79867613|NCT00520494|Drug|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
79867614|NCT04041635|Procedure|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
79867615|NCT04041635|Procedure|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
79867616|NCT00853775|Other|No intervention, observational study|
79867617|NCT00861419|Drug|Sorafenib|Sorafenib 400 mg PO (BID)
79867618|NCT00861419|Drug|AMG 706|AMG 706 125 mg PO (QD)
79867619|NCT00861419|Drug|AMG 706|AMG 706 75 mg PO (QD)
79867620|NCT00861419|Drug|AMG 386|AMG 386 10 mg/kg IV (QW)
79867621|NCT00861419|Drug|Sunitinib|Sunitinib 50 mg PO (QD)
80027362|NCT03064516|Procedure|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
79732755|NCT04244734|Other|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
79867622|NCT00861419|Drug|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
80027363|NCT03573999|Drug|Mannitol|4.6 ml/kg will be administered before dura opening
80027364|NCT03573999|Drug|NaCl 7.5%|2 ml/kg will be administered before dura opening
80027365|NCT04863703|Drug|Bulevirtide|Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
80027366|NCT03571425|Other|Oral Placebo|A placebo beverage will be consumed orally
79270428|NCT05784428|Radiation|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
79867623|NCT00861419|Drug|AMG 386|AMG 386 3 mg/kg IV (QW)
79573148|NCT01823588|Behavioral|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
79867624|NCT00527514|Drug|Amlodipine|Tablets
79867625|NCT00527514|Drug|Olmesartan medoxomil plus amlodipine|Tablets
79867626|NCT00861497|Drug|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
79867627|NCT00857051|Other|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
79867628|NCT00857051|Other|Film|A DVD addressing common stressors in the early postpartum.
79867629|NCT03998826|Drug|Piroxicam|20mg piroxicam
79867630|NCT03998826|Drug|Placebo|placebo
80027367|NCT03571425|Other|Oral Protein|A protein beverage will be consumed orally
79867631|NCT00857129|Procedure|Normal Unit|low-risk patients randomised to Normal Unit
79867632|NCT00857129|Procedure|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
79867633|NCT00853853|Device|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
79867634|NCT00853853|Procedure|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
80027368|NCT03571425|Other|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
79309099|NCT02596971|Drug|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
79867635|NCT04607538|Other|No intervention is made|No intervention is made. This i an observational study.
79867636|NCT00853931|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
79867637|NCT00854009|Drug|BLI-489|
79867638|NCT00854009|Drug|Placebo|
80027369|NCT03063190|Drug|Vitamin D|patients will receive vitamin D supplementation according to guidelines
80027370|NCT03063190|Drug|Placebo Oral Tablet|patients will receive placebo oral tablets
80027371|NCT03992638|Procedure|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
80027372|NCT03992638|Procedure|CAF|Completing root coverage by coronally advanced flap technique alone
80027373|NCT03573843|Other|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
80027374|NCT03573843|Other|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
80027375|NCT03573765|Procedure|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
80027376|NCT03573765|Procedure|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
80027377|NCT03573765|Procedure|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
79270429|NCT05784428|Radiation|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
79270430|NCT05784428|Other|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
79270431|NCT05784428|Other|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
79270432|NCT05775458|Diagnostic Test|Blood, CSF and tumor samples|Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
79270433|NCT05773586|Drug|APG-5918|oral tablets 10mg, 50mg.
79270434|NCT05773586|Drug|Placebo|Matching placebo
79573149|NCT01823601|Behavioral|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
79573150|NCT01823601|Behavioral|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
79732756|NCT04244734|Other|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
79732757|NCT02880306|Other|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
79732758|NCT02827318|Dietary Supplement|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
79732759|NCT02827318|Dietary Supplement|Glucose|75g Glucose (high glycaemic load intervention)
79867639|NCT03998592|Biological|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
79867640|NCT03998592|Biological|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
79270435|NCT05773586|Drug|APG-5918|oral tablets 10mg, 50mg.
80027378|NCT03573765|Procedure|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
79732760|NCT02827318|Dietary Supplement|Sweetened water|Sweetened water will be used as a control
79867641|NCT03998592|Biological|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
79867642|NCT03998592|Other|Placebo|Placebo without active component
79867643|NCT00861731|Drug|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
79867644|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
79867645|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
79867646|NCT02544659|Drug|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
80027379|NCT03573765|Procedure|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
80027380|NCT03573765|Procedure|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
80027381|NCT03573765|Procedure|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
80027382|NCT03573765|Procedure|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
80027383|NCT03573765|Procedure|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
80027384|NCT03573765|Procedure|Intra-articular injection|Any intra-articular injection
79270436|NCT05773586|Drug|Placebo|Matching placebo
79270437|NCT05761756|Behavioral|Sleep Deprivation|24 hours sleep deprivation
79573151|NCT01823627|Procedure|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
79573152|NCT01823640|Other|placebo|
79573153|NCT01823640|Other|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
79573154|NCT01823692|Other|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
79867647|NCT00861887|Drug|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
79732761|NCT04309968|Drug|Drug: SYHA1801|Drug: SYHA1801 administered orally
79867648|NCT00861887|Drug|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
79867649|NCT00857441|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
79867650|NCT00857441|Device|Liberté|Bare metal stent
79867651|NCT00857441|Device|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
79573155|NCT01823705|Device|Exilis Implantable Gastric Electrical Stimulation (GES)|
79867652|NCT00857441|Device|Taxus|Paclitaxel eluting stent
80027385|NCT03573687|Dietary Supplement|Micellar Casein Protein|The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
79867653|NCT00857519|Drug|Melphalan, Carboplatin|Intra-arterial chemotherapy.
79867654|NCT00618449|Drug|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 & Day 30 for a total of 2 doses.
80027386|NCT03573687|Other|Resistance Exercise Training|Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
80027387|NCT03576027|Other|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
79270438|NCT05761756|Drug|Caffeine|Oral administration of caffeine
79270439|NCT05761756|Drug|Methylphenidate|Oral administration of methylphenidate
79270440|NCT05761756|Drug|Carbon Dioxide|Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
79270441|NCT05758389|Drug|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
79270442|NCT05758142|Dietary Supplement|Potassium Chloride|Oral administration of potassium chloride tablets
79270443|NCT05758142|Other|Placebo|Oral administration of inert placebo tablets
79270444|NCT05756140|Other|No intervention|No Control
79573156|NCT01823718|Biological|Injection of allogenic CTL EBV specific|
79573157|NCT01823744|Dietary Supplement|micronutrient supplementation|
79573158|NCT01823757|Other|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
79732762|NCT04244578|Device|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
79732763|NCT04244578|Device|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
79732764|NCT02828878|Biological|Allogeneic MPBC transplantation from matched related donor|
79732765|NCT05183464|Biological|saliva samples|Collection of salivary a-amylase during the day (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm) with Salivette.
79867655|NCT00618449|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
79867656|NCT00857597|Procedure|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
79867657|NCT00857597|Drug|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
79867658|NCT00857675|Drug|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
80027388|NCT03571269|Procedure|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
79270445|NCT05755932|Drug|HFO MDI|"Dose formulation: MDI~Unit dose strength(s): Experimental (propellant only)~Dosage level(s): 6 inhalations, BID~Route of administration: Oral inhalation~Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
79573159|NCT01823770|Drug|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
79573160|NCT01823770|Drug|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
79732766|NCT05183464|Behavioral|Stanford sleepiness scale|"The Stanford Sleepiness Scale evaluates sleepiness at the time of the evaluation. The subjects have to choose the statement best representing their level of sleepiness on a scale ranging from 1 to 7: the higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
79867659|NCT00857675|Drug|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
79732767|NCT05183464|Behavioral|Karolinska Sleepiness Scale|"The Karolinska Sleepiness Scale assesses the perceived level of sleepiness at the time of the evaluation on a 9-points scale. The higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
79732768|NCT05183464|Behavioral|Epworth Sleepiness Scale|"The Adapted Epworth Sleepiness Scale for children in which the item falling asleep while in a car stopped in traffic was replaced by falling asleep at school assesses the risk of falling asleep in 8 daily-life situations estimated on a 4-point Likert scale. The total score is the sum of the scores for the 8 items: a higher score represents greater sleepiness and the pathological threshold is higher than 10.~This scale will be submitted to the children one time, at the onset of the hospitalization."
79732769|NCT05183464|Behavioral|BLAST test|"The BLAST (Bron/Lyon Attention Stability Test) is a computerized attention test evaluating brief lapses of attention with 4 measures: reaction times, errors and two composite measures (Stability and Intensity). The subjects have to detect the presence or the absence of a specific stimulus during approximatively 60 trials for 3 minutes. Normative data are available for both children and adults.~This test is part of the neuropsychological evaluation, conducted the afternoon of the first day of hospitalization. The test is realized at 4:00pm."
79867660|NCT00857675|Drug|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
79867661|NCT00861965|Biological|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
79867662|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
79867663|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
79867664|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
79867665|NCT00857753|Drug|Fentanyl patch 25 ug/nr Sandoz|
79573161|NCT01823783|Other|Muscle biopsy|Muscle biopsy
79573162|NCT01823796|Other|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
79867666|NCT00857753|Drug|Duragesic|
80027389|NCT01671280|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
80027390|NCT03573531|Other|Laboratory analysis|Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
79270446|NCT05755932|Drug|HFA MDI|"Dose formulation: MDI~Unit dose strength(s): Reference (propellant only)~Dosage level(s): 6 inhalations, BID~Route of administration: Oral inhalation~Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
79573163|NCT01823796|Other|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
79573164|NCT01823809|Device|adenosine stress Cardiac Magnetic Resonance Imaging|
79867667|NCT03846401|Device|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate & BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~Direct smear by Gram stain and ZeihlNelseen stain~Samples culturedinBact/alert bottle(BioMérieux, France).~Isolation of causative organism from positive cases by:~Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
79867668|NCT00854321|Drug|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
79867669|NCT00854321|Drug|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
79867670|NCT03684642|Drug|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
79573165|NCT01823822|Dietary Supplement|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
79573166|NCT01823822|Dietary Supplement|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
79573167|NCT01823874|Procedure|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
79573168|NCT01823887|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
79867671|NCT03684642|Drug|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
79867672|NCT03684642|Drug|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
80027391|NCT01405963|Drug|Placebo|Administered in a 1-hour intravenous infusion
80027392|NCT01405963|Biological|Tezepelumab|Administered in a 1-hour intravenous infusion
80027393|NCT03571113|Other|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
79573169|NCT01823900|Drug|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
79732770|NCT04244422|Other|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
79867673|NCT04018547|Device|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
80027394|NCT03575715|Device|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
80027395|NCT03065374|Biological|IMM-529|IMM-529
80027396|NCT03065374|Other|Placebo|Matching placebo
80027397|NCT03575637|Drug|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
80027398|NCT03573219|Radiation|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
80027399|NCT04852198|Procedure|OAGB|Simplified gastric bypass procedure
80027400|NCT04852198|Procedure|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
79270447|NCT05753072|Other|Carer Support Nurse|Specialist community nursing role to support unpaid family/carers with complex health-related support needs or unresolved health-related support needs that cannot be met by their usual health care team
79573170|NCT01823900|Drug|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
79270448|NCT05750862|Procedure|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
79270449|NCT05749861|Drug|CKD-348(5)|QD, PO
79402326|NCT04407403|Behavioral|Tai Chi tailored for lowering blood pressure (PRESSURE)|PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.
79573171|NCT01823913|Drug|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
79573172|NCT01823913|Drug|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
79573173|NCT01823926|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
79573174|NCT01823926|Device|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
79573175|NCT01823926|Device|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
79573176|NCT01823939|Drug|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
79732771|NCT02827474|Other|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
79732772|NCT02827474|Other|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
79270450|NCT05749861|Drug|CKD-828, D097, D337|QD, PO
79573177|NCT01823965|Drug|ranibizumab|
79732773|NCT02827396|Behavioral|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
79732774|NCT04243954|Drug|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
79732775|NCT04243954|Drug|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
79867674|NCT00857831|Dietary Supplement|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
79867675|NCT00854399|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
79402327|NCT04407403|Behavioral|Tai Chi tailored for improving balance (BALANCE)|BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
79402328|NCT03593161|Behavioral|Humor therapy|Clown visits
79402329|NCT01427933|Biological|Ramucirumab (IMC-1121B)|Administered intravenously
79573178|NCT01823978|Biological|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
79573179|NCT01824004|Drug|S-1|
79573180|NCT01824017|Other|Blood Draw|
79573181|NCT01824030|Device|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
79573182|NCT01824030|Device|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
79573183|NCT01824056|Drug|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
79732776|NCT04243954|Drug|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
79732777|NCT04244344|Other|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
79732778|NCT02827240|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
79732779|NCT02827942|Drug|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
79732780|NCT02827942|Drug|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
79732781|NCT02827942|Drug|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
79732782|NCT02827942|Drug|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
79867676|NCT00862043|Drug|Sildenafil Citrate|40 mg t.i.d.
79402330|NCT01427933|Drug|Eribulin|Administered intravenously
79402331|NCT03024073|Procedure|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
79867677|NCT00862043|Drug|Placebo|Placebo t.i.d.
79867678|NCT00519636|Drug|FPNS|fluticasone propionate nasal spray
79867679|NCT00519636|Drug|FFNS|fluticasone furoate nasal spray
79867680|NCT00519636|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
79867681|NCT00519636|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
79867682|NCT00857909|Drug|Amiloride|1 tablet twice a day
79867683|NCT00857909|Drug|Spironolactone|1 tablet twice a day
79867684|NCT00857909|Drug|Placebo|Placebo
79867685|NCT00857909|Drug|Placebo and spironolactone|5mg twice daily
79867686|NCT00857909|Drug|Spironolactone|25mg twice daily
79867687|NCT00857987|Drug|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
79867688|NCT00857987|Other|Placebo|Vehicle
80027401|NCT04792255|Procedure|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
79732783|NCT02827942|Drug|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
79270451|NCT05741411|Other|mHealth assisted specialist access|Concussed subjects will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology. A nurse navigator will have access to the symptom data within the electronic health record and will facilitate scheduling an in person or telehealth specialist visit as indicated by the symptom data. Symptoms will continue to be monitored through the acute study period with additional clinical visits occurring according to clinical need.
79732784|NCT00880087|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
79867689|NCT03998514|Drug|CB4211 Dose 1|Administered by subcutaneous injection
79270452|NCT05741385|Drug|Caffeine|Caffeine
79573184|NCT01824069|Other|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
79573185|NCT01824095|Dietary Supplement|Dietary supplement|
79867690|NCT03998514|Drug|CB4211 Dose 2|Administered by subcutaneous injection
79867691|NCT03998514|Drug|CB4211 Dose 3|Administered by subcutaneous injection
79867692|NCT03998514|Drug|CB4211 Dose 4|Administered by subcutaneous injection
79867693|NCT03998514|Drug|CB4211 Dose 5|Administered by subcutaneous injection
79270453|NCT05741385|Drug|Warfarin sodium|Warfarin sodium
79270454|NCT05741385|Drug|Omeprazole|Omeprazole
79270455|NCT05741385|Drug|Metoprolol|Metoprolol
79270456|NCT05741385|Drug|Midazolam|Midazolam
79270457|NCT05737563|Drug|PD-1 Inhibitors|Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.
79270458|NCT05737563|Drug|Irinotecan|Irinotecan: 200mg/m2, injection (For patients who are confirmed to be homozygous for UGT1A1*6 or UGT1A1*28 or UGT1A1*6 and UGT1A1*28 at the same time, the starting dose of CPT-11 is 150 mg/m2).
79270459|NCT05737563|Drug|Capecitabine tablets|Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
79270460|NCT05733936|Other|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
79270461|NCT05727696|Procedure|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
79573186|NCT01824108|Procedure|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
79573187|NCT01824108|Procedure|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
79573188|NCT01824121|Biological|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
79867694|NCT03998514|Drug|CB4211 Dose 6|Administered by subcutaneous injection
79573189|NCT01824134|Other|Klean & Klear The Dandy Day Corp|
79573190|NCT01824134|Other|The Skin Gel Herbal Answers, Inc|
79573191|NCT01824173|Other|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
79573192|NCT01824173|Other|Aerobic exercise|Moderate intensity for 45 minutes
79573193|NCT01824186|Procedure|SILC|Underwent single-incision laparoscopic cholecystectomy
79867695|NCT03998514|Drug|CB4211 Dose TBD|Administered by subcutaneous injection
79867696|NCT03998514|Drug|Placebo|Administered by subcutaneous injection
79867697|NCT00858065|Behavioral|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
79867698|NCT00858065|Behavioral|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
79867699|NCT00854477|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
79732785|NCT00880087|Procedure|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
79732786|NCT02827084|Device|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
79732787|NCT02827084|Device|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
79573194|NCT01824186|Procedure|LC|Underwent conventional 4-port laparoscopic cholecystectomy
79732788|NCT00889252|Device|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
79732789|NCT00889252|Device|contact lens|Placebo contact lens
79732790|NCT00670813|Drug|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
79732791|NCT00670813|Drug|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
79867700|NCT00854555|Other|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
79867701|NCT00854555|Other|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
79732792|NCT01110330|Drug|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
79867702|NCT00854633|Drug|Talactoferrin|Enteral, 150 mg/kg twice per day
79867703|NCT00854633|Drug|Placebo|Oral, twice per day
79867704|NCT00618371|Drug|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
79867705|NCT00858299|Drug|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
79270462|NCT05727696|Procedure|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy & shortening 2.5 mm of capitate, compression by Herpert screw.
79270463|NCT05716529|Other|rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
79270464|NCT05715268|Device|WeB|"Participants will be given WeB devices and trained on the use of these devices for home therapy, including the associated mobile applications. Participants will be given home programs and given a schedule to use the WeB devices at home on their own time. At their standard visit participants will have their WeB device use checked and progressed as the therapist deems appropriate.~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
79732793|NCT01110330|Drug|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
79732794|NCT01110330|Drug|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
79732795|NCT00663481|Drug|CoFactor|
79732796|NCT00663481|Drug|Leucovorin|
79732797|NCT04308954|Drug|[18F]flumazenil|[18F]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
79732798|NCT05016778|Drug|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
79867706|NCT00526890|Dietary Supplement|selenomethionine|Oral Twice daily
79867707|NCT00526890|Drug|carboplatin|Weekly IV
79867708|NCT00526890|Drug|paclitaxel|Weekly IV
79867709|NCT00526890|Other|laboratory biomarker analysis|Correlative Study
79867710|NCT00526890|Radiation|radiation therapy|Undergoing radiation Therapy
79867711|NCT04041167|Drug|alpha lipoic acid|alpha lipoic acid treatment
79867712|NCT04041167|Drug|Saline|No alpha lipoic acid treatment
79867713|NCT03998124|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
79867714|NCT03998124|Other|Usual care|Staff-led social activity
79867715|NCT00858377|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
79867716|NCT00858377|Drug|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
79573195|NCT01824199|Drug|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
79573196|NCT01824225|Drug|Aflibercept|
79573197|NCT01824238|Drug|Anacetrapib|
79573198|NCT01824238|Drug|Placebo for anacetrapib|
79573199|NCT01824251|Drug|NPB-01|
79573200|NCT01824264|Drug|LIK066|Experimental treatment doses
79270465|NCT05715268|Other|Standard pelvic floor physical therapy|"Baseline will consist of a standard PFPT evaluation. Regular visits (tele-video visits or in-person depending on the patients preference) will be scheduled every week for the first 4 weeks and then every other week at the discretion of the therapist. A total of 8-10 visits will be scheduled over the 12 weeks of the study. Participants will be given home exercise programs (as per standard PFPT).~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
79270466|NCT05711823|Drug|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
79732799|NCT02881398|Device|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
79732800|NCT02881398|Other|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
79867717|NCT03864900|Behavioral|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
79270467|NCT05711823|Drug|Granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
79270468|NCT05706506|Drug|Tirzepatide|Administered SC
79573201|NCT01824264|Drug|Sitagliptin|Active comparator treatment dose
79573202|NCT01824264|Drug|Placebo|Placebo comparator dose
79573203|NCT01824277|Other|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
79573204|NCT01824329|Procedure|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
79573205|NCT01824329|Procedure|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
79732801|NCT04243564|Device|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
79732802|NCT05010460|Drug|Roxadustat|orally 100mg every other day for 5-8 days prior to CABG
79732803|NCT05010460|Drug|Placebo|orally 100mg every other day for 5-8 days prior to CABG
79732804|NCT00596947|Drug|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
79867718|NCT00854711|Procedure|inhaled nitric oxide|80 PPM
79867719|NCT00858455|Drug|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
79867720|NCT00858455|Drug|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
79867721|NCT00858455|Drug|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
79867722|NCT00858455|Drug|GSK1349572|A single dose of GSK1349572
79867723|NCT00862355|Drug|SPARC147609|IV infusion
79867724|NCT00862355|Drug|Reference147609|IV infusion
79867725|NCT02544737|Drug|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
79867726|NCT00858533|Behavioral|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
79867727|NCT00526656|Drug|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
79309100|NCT02596971|Drug|Prednisone|Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
79573206|NCT01824368|Procedure|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
79867728|NCT04042649|Behavioral|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
79732805|NCT00596947|Drug|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
79732806|NCT00596947|Drug|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
79732807|NCT00596947|Drug|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
79732808|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
79867729|NCT00858611|Drug|VRC-FLUDNA047-00-VP|
79867730|NCT00858611|Drug|Flulaval (Registered) Seasonal Influenza Vaccine|
80027402|NCT04792255|Procedure|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
80027403|NCT04792255|Diagnostic Test|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
79270470|NCT05695443|Behavioral|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
79867731|NCT00854789|Biological|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
79270471|NCT05695248|Drug|STAR-0215|STAR-0215 will be administered as a subcutaneous bolus injection.
79270472|NCT05674968|Behavioral|Managing Challenging Behaviors in ADHD; Psychosocial program|MCB-ADHD is a brief Behavioral Parent Training (BPT) program delivered to caregivers and children together. THe researchers have specially designed this program to be flexible so that it can be delivered over telehealth and/or in-person. All sessions are guided by web-based tool to provide parent support materials and direct the work to be completed in session. MCB-ADHD combines brief BPT skills modules adapted from an established evidence-based BPT called Helping the Noncompliant Child (HNC; McMahon & Forehand, 2003) with high quality psychoeducation and advocacy training that were developed by the investigators specifically for use in this project. Families receive 4 sessions adapted from HNC focused on behavior management and 2 sessions focused on education and empowerment.
79270473|NCT05673200|Procedure|Biopsy|Undergo biopsy
79270474|NCT05673200|Procedure|Biospecimen Collection|Undergo collection of blood
79270475|NCT05673200|Procedure|Computed Tomography|Undergo CT
79867732|NCT00858767|Dietary Supplement|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
79270476|NCT05673200|Drug|Decitabine and Cedazuridine|Given PO
79270477|NCT05673200|Procedure|Magnetic Resonance Imaging|Undergo MRI
79270478|NCT05673200|Drug|Paclitaxel|Given IV
79270479|NCT05673200|Biological|Pembrolizumab|Given IV
79867733|NCT00858767|Dietary Supplement|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
79867734|NCT00858767|Dietary Supplement|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
79270480|NCT05668741|Drug|VX-522 mRNA therapy|Oral inhalation using nebulizer.
80027404|NCT03575559|Behavioral|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
79270481|NCT05664958|Procedure|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
79732809|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
79270482|NCT05664958|Drug|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
79732810|NCT04155697|Drug|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
79270483|NCT05664958|Drug|bupivacaine|20 ml bupivacaine 0.25% per side.
79270484|NCT05660785|Drug|Herombopag|"Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA."
79270485|NCT05655130|Drug|Dexamethasone|Intraoperative 10 mg IV Dose
79270486|NCT05655130|Drug|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
79573207|NCT01824381|Procedure|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
79573208|NCT01824381|Procedure|Obtaining and Cryopreservation of amniotic membrane|
79732811|NCT04155697|Drug|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
79732812|NCT00663559|Drug|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
79270487|NCT05655130|Other|Standard of Care|standard of care surgery
79270488|NCT05642897|Behavioral|Mind|ACT, mindfulness, and compassion-based intervention
79270489|NCT05642897|Behavioral|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening and a sense of community between participants.
79402332|NCT03024385|Behavioral|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
79573209|NCT01824381|Drug|amniotic membrane|
79573210|NCT01824407|Device|Electrohydraulic-generated shock wave|
79732813|NCT04158349|Drug|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
79732814|NCT04158349|Drug|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
79867735|NCT00617903|Drug|Azelaic acid|15% foam to be applied topically twice daily
79867736|NCT00617903|Drug|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
79867737|NCT00526110|Drug|5-Fluorouracil|2.2 Gm/m^2 IV over 48 hours on Day 1.
79867738|NCT00526110|Drug|Docetaxel|20 mg/m^2 IV over 60 minutes
79573211|NCT01824407|Device|Sham device plus standard of care|
79573212|NCT01824420|Drug|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
79573213|NCT01824420|Drug|Detrusitol 4mg QD|Control group
79573214|NCT01824433|Drug|venlafaxine|venlafaxine 75-225mg qd
79573215|NCT01824433|Drug|fluoxetine|fluoxetine 20-60mg qd
79573216|NCT01824459|Drug|S-1|S-1：40~60mg bid，d1~14 q3W
79573217|NCT01824459|Drug|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
79573218|NCT01824459|Drug|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
79573219|NCT01824485|Drug|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
79573220|NCT01824485|Drug|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
79573221|NCT01824511|Behavioral|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
79573222|NCT01824524|Drug|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
79732815|NCT00670891|Procedure|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~Air or Gas Embolus~Decompression Illness~Carbon Monoxide poising~Clostridial Myonecrosis (Gas Gangrene)~Necrotizing Fasciitis~Crush Injury (Compartment syndromes)~Selected Problem Wounds~Compromised Skin Flaps or Grafts~Refractory Osteomyelitis~Exceptional Anemia due to Blood loss~Osteoradionecrosis~Thermal Burns and Radiation Tissue Damage~Diabetic Wounds~Intra-Cranial Abscess~Brain Injury and other Head Trauma~Cerebral Palsy~High Altitude Sickness~Lyme disease"
79732816|NCT00888940|Drug|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
80027405|NCT03575559|Behavioral|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
80027406|NCT03575559|Behavioral|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
80027407|NCT03062956|Drug|MYK-491 or placebo|Oral suspension
80027408|NCT03704779|Behavioral|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
80027409|NCT03062800|Drug|Thalidomide|100-200mg/d,oral ,qn
80027410|NCT03062800|Drug|pemetrexed|(500mg/m^2) on day 1 of 21-days cycle,ivgtt
80027411|NCT03062800|Drug|cisplatin|(75mg/m^2) on day 1 of 21-days cycle, ivgtt
80027412|NCT03062800|Drug|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
80027413|NCT05709015|Other|Neutral electrolyzed water|Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
80027414|NCT05709015|Drug|Placebo|Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
80027415|NCT05709015|Drug|Chlorhexidine digluconate|Use of mouthwash containing chlorhexidine digluconate twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
80027416|NCT02524041|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
79573223|NCT01824550|Other|home-based exercise training condition|Home based endurance exercise training
79573224|NCT01824563|Other|Observational study|
79732817|NCT00888940|Drug|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
79732818|NCT00595621|Device|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
79732819|NCT02826070|Drug|Telbivudine|Telbivudine, 600mg, oral, daily
79732820|NCT02826070|Drug|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
79732821|NCT02826070|Other|off-treatment follow-up|
80027417|NCT02524041|Other|blood specimen|blood specimen
80027418|NCT03573141|Other|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
79732822|NCT00663637|Device|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
79867739|NCT00526110|Drug|Oxaliplatin|85 mg/m^2 IV over 120 minutes on Day 1.
80027419|NCT03573063|Other|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
79573225|NCT01824615|Drug|Sunitinib|37.5mg everyday from D1-D28
79573226|NCT01824641|Device|Eliminate aspiration catheter|Eliminate aspiration catheter
79573227|NCT01824641|Procedure|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
80027420|NCT03571035|Diagnostic Test|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
80027421|NCT03572907|Other|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
79867740|NCT02544581|Other|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
80027422|NCT03570957|Drug|MT-2990|MT-2990 solution for injection in vial
80027423|NCT03570957|Drug|Placebo|Placebo solution for injection in vial
80027424|NCT04050631|Behavioral|maternal arrest simulation on L&D floor|AFE on L&D
79573228|NCT01824654|Other|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
79573229|NCT01824654|Other|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
79732823|NCT05090488|Behavioral|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
79867741|NCT00858923|Device|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
79867742|NCT00859001|Drug|FM+R|Fludarabine-Mitoxantrone-Rituximab
80027425|NCT03575481|Diagnostic Test|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
80027426|NCT03572829|Drug|Aprepitant|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
80027427|NCT04050787|Procedure|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
79732824|NCT00663715|Other|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
79867743|NCT00859001|Drug|Zevalin (Ibritumomab Tiuxetan)|
79867744|NCT00862511|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
79867745|NCT00862511|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
79867746|NCT00854867|Drug|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
79867747|NCT00854867|Drug|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
79573230|NCT01824667|Dietary Supplement|B-GOS|
79573231|NCT01824667|Dietary Supplement|Maltodextrin|
79573232|NCT01824680|Behavioral|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
79573233|NCT01824706|Procedure|craniectomy|craniectomy
79573234|NCT01824758|Drug|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
79732825|NCT02826226|Device|multiple-breath-washout test|
79732826|NCT02826226|Drug|Bronchodilator Agents|
79732827|NCT00671047|Other|non-interventional|SLE nature history observational
79732828|NCT00671125|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
79732829|NCT00671125|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
79732830|NCT00671125|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
79867748|NCT00859079|Drug|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
79573235|NCT01824758|Drug|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
79573236|NCT01824758|Drug|rocuronium|0.05 mg/kg rocuronium
79573237|NCT01824758|Drug|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
79867749|NCT00859079|Drug|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
79867750|NCT02544425|Drug|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
79867751|NCT02544425|Drug|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
79867752|NCT02544425|Drug|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
79867753|NCT02544425|Drug|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
79573238|NCT01824810|Procedure|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
79867754|NCT02544425|Drug|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
79867755|NCT02544425|Drug|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
79867756|NCT03889548|Other|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
79732831|NCT00671203|Procedure|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
79732832|NCT04157803|Diagnostic Test|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
79867757|NCT00862589|Other|GLP-1 infusion|physiological effect of GLP-1
79867758|NCT04130633|Drug|Placebo|Placebo vapor (distilled water)
79867759|NCT04130633|Drug|THC|Pure THC vapor
79867760|NCT04130633|Drug|Alpha-Pinene|Pure alpha-pinene vapor
79270490|NCT05642832|Device|Throughflow titration phase|"Ventilation with Throughflow will be started at a duty cycle of 20% (TF titration 20%). After 10 minutes measurements will be collected. If Edi is above 5 µV, TF duty cycle will be increased by 20% (TF 40%). Measurements will be collected again after 10 minutes. TF duty cycle will be increased by 10% (TF duty cycle 50% and so on) and measurements collected every 10 minutes until Edi is below 5 µV or TF duty cycle reaches 100%.~Once the Edi target has been met, sedation will be progressively reduced to evaluate the effect of Throughflow on sedation requirements for controlling respiratory effort."
79270491|NCT05638854|Drug|ZB002|ZB002 Single doses administered subcutaneously as solution
79573239|NCT01824810|Procedure|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
79732833|NCT04157959|Drug|SHR4640 dose1|Tablet,dose1,QD
79732834|NCT04157959|Drug|Febuxostat dose2|Tablet,dose2,QD
79867761|NCT00859157|Procedure|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
79867762|NCT00512148|Device|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
79867763|NCT00859235|Drug|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
79867764|NCT00859235|Other|Plain water|Mouth wash prior to procedure
79270492|NCT05638854|Drug|Placebo|Placebo Single doses administered subcutaneously as solution
79270493|NCT05637801|Device|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
79270494|NCT05637801|Device|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
79867765|NCT04523688|Biological|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
79867766|NCT04523688|Drug|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
79867767|NCT00862667|Drug|Treatment A|PF-00241939 300ug using Inhaler A
79867768|NCT00862667|Drug|Treatment B|PF-00241939 300ug using Inhaler B
79867769|NCT00862667|Drug|Treatment C|PF-00241939 300ug using Inhaler C
79867770|NCT02544347|Other|gingival crevicular fluid|gingival crevicular fluid was collected
79867771|NCT02544347|Other|non-surgical periodontal treatment|scaling and root planing were performed
79867772|NCT04041713|Drug|Rett-T|antioxidant cocktail
79867773|NCT04041713|Other|Placebo|Placebo
79867774|NCT00859625|Procedure|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
79867775|NCT00511836|Drug|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
79867776|NCT00511836|Drug|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
79732835|NCT04243408|Other|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
79732836|NCT04243408|Other|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
79732837|NCT00660283|Drug|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
79732838|NCT02826148|Other|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
79732839|NCT00663949|Drug|Captopril|25 mg captopril tablet q8h
79732840|NCT00663949|Drug|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
79732841|NCT00660439|Behavioral|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
79867777|NCT04041245|Device|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
80027428|NCT04050787|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
80027429|NCT03570879|Device|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
79270497|NCT05635929|Combination Product|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
79270498|NCT05625217|Diagnostic Test|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
79270499|NCT05623163|Device|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
79270500|NCT05616910|Drug|inhaled nitric oxide|iNO will be provided by ventilator or nasal cannula for 4 hours each day.
79270501|NCT05596409|Drug|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
79270502|NCT05592990|Drug|NGI226|NGI226 MP
79270503|NCT05592990|Drug|Placebo|Placebo MP
79573240|NCT01824810|Procedure|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
79270504|NCT05591014|Device|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
79270505|NCT05585528|Procedure|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
79270506|NCT05584111|Drug|STC-15|STC-15 oral capsules various dosing regimen in 3-week cycles
79867778|NCT00859703|Drug|Risedronate|35mg oral risedronate once per week for 24 months
80027430|NCT03570879|Procedure|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
79270507|NCT05572632|Behavioral|COPD Wellness|COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
79573241|NCT01824810|Procedure|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
79573242|NCT01824849|Procedure|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
79573243|NCT01824849|Procedure|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
79732842|NCT00888238|Drug|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
79732843|NCT00888238|Drug|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
79732844|NCT05660356|Drug|Growth Hormone|Pfizer provided GH therapy
79867779|NCT00859703|Drug|Placebo|Placebo 35 mg once a week for 24 months
79867780|NCT03998436|Drug|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
79732845|NCT05660356|Drug|Placebo|Pfizer provided placebo
79867781|NCT03998436|Other|Only Standard of Care|Only Standard of Care treatment
79867782|NCT03998436|Other|Vehicle Gel|Vehicle gel application along with Standard of Care
79867783|NCT00855101|Drug|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
79867784|NCT00573755|Drug|anastrozole|given orally
79867785|NCT00573755|Drug|exemestane|given orally
79867786|NCT00573755|Drug|letrozole|given orally
79867787|NCT00573755|Drug|sorafenib tosylate|given orally
80027431|NCT04050475|Dietary Supplement|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
79270508|NCT05572632|Behavioral|COPD Wellness Plus+|Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
79270509|NCT05572632|Behavioral|Usual Care|Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
79573244|NCT01824888|Drug|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
79573245|NCT01824888|Drug|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
79573246|NCT01824914|Device|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
79732846|NCT00595465|Biological|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
79732847|NCT02825914|Dietary Supplement|Casein glycomacropeptide (CGMP)|
79732848|NCT02825914|Dietary Supplement|Placebo|
79732849|NCT00671281|Drug|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
80027432|NCT05367921|Device|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
80027433|NCT02239497|Procedure|Femoral block by ultrasound and neurostimulation|
80027434|NCT02239497|Drug|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
80027435|NCT03572751|Diagnostic Test|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
80027436|NCT03705403|Drug|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
80027437|NCT03705403|Radiation|Radiation|Radiotherapy
80027438|NCT02239653|Behavioral|Physician communication|
79573247|NCT01824927|Procedure|First eye (FE)|Phacoemulsification cataract extraction surgery
79573248|NCT01824927|Procedure|Second eye (SE)|Phacoemulsification cataract extraction surgery
79573249|NCT01824927|Drug|Steroids eye drops|Use steroids eye drops to decrease the pain.
79732850|NCT00671281|Drug|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
79732851|NCT01205438|Drug|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
79732852|NCT01205438|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
79732853|NCT01205438|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
79732854|NCT04155229|Other|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
79867788|NCT00573755|Other|placebo|given orally
79867789|NCT02545361|Drug|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
79867790|NCT02544191|Drug|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
79867791|NCT00859859|Device|Vagus Nerve Stimulation|"Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
79867792|NCT00524316|Drug|doxorubicin hydrochloride|Transarterial chemoembolization
79867793|NCT00524316|Drug|sunitinib malate|Given Orally
79867794|NCT00524316|Other|laboratory biomarker analysis|Correlative Study
80027439|NCT03705325|Device|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
79573250|NCT01824940|Behavioral|Standard care|"Standard Care:~Exclusive breastfeeding promotion for all infants, birth to 6 months~Strengthened PMTCT (prevention of mother to child transmission of HIV) services~Strengthened Village Health Worker system"
79867795|NCT00524316|Procedure|hepatic artery embolization|Surgical procedure
79270510|NCT05571072|Other|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
79270511|NCT05571072|Other|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
79270512|NCT05570994|Drug|177Lu HTK03170|Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
79270513|NCT05570994|Drug|68Ga-HTK03149|68Ga-HTK03149 PET/CT imaging; intravenous during screening
79270514|NCT05567172|Device|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
79270515|NCT05558059|Device|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
79270516|NCT05552755|Drug|REC-4881|REC-4881 4mg capsules
79573251|NCT01824940|Other|WASH|"WASH:~Standard care interventions~Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
79573252|NCT01824940|Dietary Supplement|Infant and young child feeding|"IYCF:~Standard care interventions~Provide 20 g/d Nutributter from 6-18 months~Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
80027440|NCT03575247|Drug|Glucocorticoids|Long-term use of glucocorticoids
80027441|NCT03572673|Device|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
80027442|NCT03572673|Device|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
79270517|NCT05552755|Drug|Placebo|Placebo capsules
79573253|NCT01824940|Other|WASH and Nutrition|"WASH AND IYCF interventions~Standard care interventions~All WASH interventions~All IYCF interventions"
79573254|NCT01824992|Drug|Yallaferon®|
79573255|NCT01825018|Behavioral|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
79573256|NCT01825018|Behavioral|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
79573257|NCT01825031|Drug|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
79573258|NCT01825031|Drug|Fluconazole|100mg once daily for 12 weeks
79573259|NCT01825031|Drug|Azithromycin|500mg once daily for 5 days
79573260|NCT01825031|Drug|Albendazole|a single dose 400mg
79573261|NCT01825031|Drug|Isoniazid|300mg taken immediately in combination with cotrimoxazole
79573262|NCT01825031|Dietary Supplement|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
79573263|NCT01825044|Drug|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
79732855|NCT00664183|Drug|Vitreosolve|Intravitreal injection
79732856|NCT00671359|Drug|TR-701 600mg|TR-701 600mg
79732857|NCT04153201|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing < 60 kg, hydroxychloroquine 400 mg daily for patients weighing >= 60 kg
79732858|NCT05660278|Other|Milk containing A1 and A2 beta-casein|Single dose of milk
79732859|NCT05660278|Other|Milk containing only A2 beta-casein|Single dose of milk
79732860|NCT00664261|Behavioral|smoking cessation intervention|
79732861|NCT00664261|Other|cancer prevention|
79732862|NCT00664261|Other|counseling intervention|
79732863|NCT00664261|Other|educational intervention|
79732864|NCT00664261|Other|laboratory biomarker analysis|
79732865|NCT00664261|Other|questionnaire administration|
79732866|NCT00664261|Other|survey administration|
79732867|NCT00664261|Procedure|study of high risk factors|
79573264|NCT01825044|Drug|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
79732868|NCT04153123|Drug|Epinephrine|
79732869|NCT02825524|Device|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
80027443|NCT04784065|Device|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
79270518|NCT05552118|Procedure|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
79270519|NCT05552118|Procedure|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
79270520|NCT05552118|Device|Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)|CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
79732870|NCT00671593|Biological|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
79732871|NCT00671593|Biological|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
79732872|NCT01104870|Drug|UT-15C|oral
79732873|NCT02887664|Procedure|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
79270521|NCT05549947|Drug|SHR1819|Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，
79270522|NCT05549947|Drug|Placebo|Treatment group D：placebo
79270523|NCT05543278|Drug|Amiodarone|Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
79270524|NCT05539716|Device|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
79270525|NCT05539716|Behavioral|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
79270526|NCT05535088|Device|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
79270527|NCT05533060|Other|No intervention|patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
79573265|NCT01825070|Dietary Supplement|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
79270528|NCT05532319|Combination Product|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
79732874|NCT02825368|Biological|MMR|0.5 mL, subcutaneous
79270529|NCT05528302|Other|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
79309101|NCT02596971|Drug|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
79573266|NCT01825083|Drug|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
79573267|NCT01825083|Drug|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
79573268|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
79573269|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
79573270|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
79732875|NCT02825368|Biological|Tdap|0.5 mL, intramuscular
79732876|NCT02825368|Other|Diphtherinum®|
79732877|NCT02825368|Other|Pertussinum®|
79732878|NCT02825368|Other|Tetanotxicum®|
79732879|NCT02825368|Other|Morbilinum®|
79732880|NCT02825368|Other|Ourlianum®|
79732881|NCT02825368|Other|Sterile saline|0.5 mL, intramuscular
79732882|NCT02825368|Other|Sugar pellets|
79732883|NCT02632279|Dietary Supplement|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
80027444|NCT03575091|Other|Non-individualized|Comparing two experimental interventions with standard care
80027445|NCT03575091|Other|Individualized|Comparing two experimental interventions with standard care
80027446|NCT03704623|Drug|Paracetamol|Paracetamol 1g IV
80027447|NCT03704623|Drug|Parecoxib|Parecoxib 40 mg IV
79732884|NCT02632279|Dietary Supplement|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
79732885|NCT02632279|Device|Stimulator ON|Participants will be tested while their stimulator is turned ON
79732886|NCT02632279|Device|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
79867796|NCT00524316|Procedure|quality-of-life assessment|Correlative Study
79270530|NCT05523947|Drug|YH32367|"Dose Escalation Part: 8 Cohorts (Dose level: 0.3, 0.75, 1.5, 3, 6, 12, 20, and 30 mg/kg). In Dose Escalation part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose of 0.3 mg/kg and the dose being escalated/de-escalated in adjacent dose cohorts will be up to 30 mg/kg.~Dose Expansion Part: 2 Cohorts (Cohort 1: Breast cancer, Cohort 2: Gastric cancer). Upon completion of the Dose Escalation part with the determination of MTD/RP2D, the Dose Expansion part will initiate. Dose Expansion part will consist of multiple cohorts in patients who were treated with three or more prior lines of therapy, HER2-positive breast cancer(Cohort 1); in patients who were treated with two or more prior lines of therapy, HER2-positive gastric or gastroesophageal junction adenocarcinoma(Cohort 2). Approximately 40 patients will be enrolled in each cohort. Additional cohorts may be added, taking into account available non-clinical or clinical data."
79867797|NCT00860093|Other|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
79867798|NCT00860093|Drug|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
79270531|NCT05519345|Behavioral|Operant Conditioning|Active encouragement and feedback to increase motor evoked response during stimulation.
79270532|NCT05519345|Behavioral|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
79270533|NCT05517616|Drug|[14C ]APG-2575|orally, single dose of 400 mg / 200 μCi [14C] APG-2575
79270534|NCT05516862|Other|Dragons acupuncture|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 needles placed in head, upper back, lower back and ankles."
79309102|NCT02596971|Drug|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.
79309103|NCT03205007|Behavioral|Health promotion nutrition program|Health promotion nutrition program
79309104|NCT03204773|Diagnostic Test|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
79309105|NCT03204773|Diagnostic Test|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
79402333|NCT04043273|Behavioral|Characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on PNQ. Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
79402334|NCT03593083|Other|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
79573271|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
79573272|NCT01825135|Device|Neuromuscular electrical stimulation|
79573273|NCT01825135|Device|sham stimulation|sham stimulation will be applied to the quadriceps
79573274|NCT01825148|Other|radiolabeled Exendin|
79573275|NCT01825174|Behavioral|Ball games program|twice a week different ball games 90min
79573276|NCT01825174|Behavioral|Nutrition counseling|9 units of 90min each of nutrition counseling
79732887|NCT02631187|Device|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
79732888|NCT02881476|Other|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
79732889|NCT00664339|Biological|Flu Vaccine|Single dose of Flu vaccine by year (1)
79732890|NCT00664339|Other|Conventional medical therapy for heart failure|According with the international guidelines
79732891|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
79732892|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
79732893|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
79732894|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
79732895|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
79732896|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
79732897|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
79732898|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
79732899|NCT00664417|Biological|Physiological saline|0.5 mL, IM, 2 injections
79573277|NCT01825213|Device|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
79732900|NCT04031755|Drug|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
79732901|NCT04031755|Drug|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
79732902|NCT01104792|Drug|Cariprazine|Cariprazine was supplied in capsules.
79573278|NCT01825226|Other|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
79867799|NCT00862901|Device|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
79867800|NCT00855257|Drug|Acid Nicotinique|
79867801|NCT00855257|Drug|Placebo|
79270535|NCT05516862|Other|Dragons acupressure|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 small acupressure adhesive bandages placed on head, upper back, lower back and ankles."
79309106|NCT03204773|Diagnostic Test|Brief Pain Inventory (BPI)|Testing for pain
79573279|NCT01825239|Other|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
79573280|NCT01825252|Behavioral|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
79573281|NCT01825252|Behavioral|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
79573282|NCT01825304|Device|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
79573283|NCT01825317|Device|NeuroAD|synchronized TMS+COGNITIVE TRAINING
79573284|NCT01825317|Device|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
79573285|NCT01825330|Device|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
79573286|NCT01825330|Device|sham|
79732903|NCT01205126|Drug|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
79732904|NCT01205126|Drug|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
79732905|NCT01205126|Drug|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
79732906|NCT04155307|Device|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
79732907|NCT04155307|Diagnostic Test|Anal Manometry|Anal Manometry done in standard care
79867802|NCT03861936|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
79867803|NCT03861936|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
79867804|NCT02544269|Procedure|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
79867805|NCT02544269|Procedure|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
79867806|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
79867807|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
79867808|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
79867809|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
79867810|NCT00434577|Biological|Placebo|Single intramuscular injection
79867811|NCT04042181|Dietary Supplement|Placebo|standard food grade excipients
79573287|NCT01825369|Drug|IV L-carnitine|See arm description
79573288|NCT01825382|Device|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
79573289|NCT01825395|Drug|3, 4-Diaminopyridine|
79573290|NCT01825421|Other|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
79573291|NCT01825434|Dietary Supplement|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
79573292|NCT01825447|Drug|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
79573293|NCT01825447|Drug|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
79573294|NCT01825447|Drug|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
79867812|NCT04042181|Dietary Supplement|Bifidobacterium longum|Target dose of 1x10^10 CFU/day, plus standard food grade excipients
79732908|NCT04155307|Diagnostic Test|Defecography|Defecographydone in standard care
79867813|NCT00865085|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
79867814|NCT00865085|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
79573295|NCT01825460|Other|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
79867815|NCT00860483|Other|observational|PET Scan
79573296|NCT01825460|Other|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
79732909|NCT04155307|Diagnostic Test|Electromyogram|Electromyogram done in standard care
79867816|NCT00434421|Drug|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters [mL], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose [0.42 mL, 1:10 wt/vol] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
79867817|NCT00434421|Drug|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
80027448|NCT03570723|Procedure|A glove-loaded Foley's catheter tamponade|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
80027449|NCT03570723|Procedure|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
80027450|NCT03701659|Procedure|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
79867818|NCT00421707|Drug|GW876008|
79573297|NCT01825473|Drug|Erythromycin|
79573298|NCT01825473|Device|Multi-channel intra-luminal impedance (MII) pH monitoring|
79573299|NCT01825473|Drug|Placebo (D5W)|
79732910|NCT00664495|Behavioral|Diet Weight Loss|
79732911|NCT00664495|Behavioral|Exercise Weight Loss|
79732912|NCT00664495|Behavioral|Exercise Without Weight Loss|
79732913|NCT00624494|Device|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
79732914|NCT00624494|Device|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
79732915|NCT05137314|Drug|PLG0206|PLG0206 is an engineered antibacterial peptide (EAP)
79732916|NCT02629627|Dietary Supplement|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
79732917|NCT02629627|Drug|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
79732918|NCT02629627|Dietary Supplement|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
80027451|NCT03701659|Drug|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
79573300|NCT01825486|Behavioral|accidental falls|
79732919|NCT02629627|Other|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
79732920|NCT00664729|Behavioral|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
79732921|NCT00664729|Behavioral|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
79867819|NCT00421707|Other|Placebo|
79867820|NCT00796068|Drug|Cyclosporine|Given IV or PO
79867821|NCT00796068|Drug|Fludarabine Phosphate|Given IV
79867822|NCT00796068|Other|Laboratory Biomarker Analysis|Correlative studies
79867823|NCT00796068|Drug|Mycophenolate Mofetil|Given IV
79867824|NCT00796068|Radiation|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
79867825|NCT00796068|Drug|Treosulfan|Given IV
79867826|NCT00796068|Procedure|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
79867827|NCT01032447|Behavioral|Navigator Support|Standard of Care
79867828|NCT01029483|Other|Low carbohydrate diet|Ad libitum low carbohydrate diet (<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
79867829|NCT01029483|Other|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
79573301|NCT01824043|Drug|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
79573302|NCT01825525|Device|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
79573303|NCT01825551|Drug|Granulocyte Colony Stimulating Factor|
79573304|NCT01825551|Drug|Placebo|
80027452|NCT03065296|Behavioral|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
80027453|NCT03065296|Other|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
79304469|NCT03287141|Diagnostic Test|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
79573305|NCT01825590|Other|Dialysate and serum sodium concentration aligned|
79573306|NCT01825616|Dietary Supplement|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
79732922|NCT00664729|Behavioral|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
79732923|NCT00946647|Drug|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
79732924|NCT00946647|Drug|5-Azacytidine|
79867830|NCT01029483|Other|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at ~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
80027454|NCT03572595|Diagnostic Test|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
80027455|NCT03572517|Procedure|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
79867831|NCT03798288|Behavioral|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
79867832|NCT03798288|Other|Usual care|Participants will receive usual care
79867833|NCT00518622|Drug|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
79867834|NCT00518622|Drug|Comparator: Placebo|MK7009 Placebo
79867835|NCT04732182|Device|BrightGo cognitive training|Training on the BrightGo experimental device in the home
80027456|NCT03572517|Procedure|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
80027457|NCT03952546|Device|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
79304470|NCT03287141|Device|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
79304471|NCT03287141|Device|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
79304472|NCT03291353|Drug|pembrolizumab|200 mg IV given every three weeks
79309107|NCT03204773|Diagnostic Test|Becks Depression Inventory (BDI)|Screening for depression
79573307|NCT01825616|Other|Placebo|Mushroom powder without vitamin D2
79573308|NCT01825629|Other|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
79573309|NCT01825629|Other|Placebo|
79573310|NCT01825642|Procedure|nerve-sparing radical prostatectomy|
79573311|NCT01825642|Procedure|seminal vesicle-sparing radical prostatectomy|
79867836|NCT04732182|Drug|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
79867837|NCT01009398|Other|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
79867838|NCT01009476|Drug|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
79573312|NCT01825668|Other|Plant Sterols|
79867839|NCT01009476|Drug|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
79867840|NCT00517296|Procedure|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
79867841|NCT00517296|Drug|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
80027458|NCT03952546|Device|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
79270536|NCT05516862|Other|Dragons placebo|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and the doctor will touch 7 points on head, upper back, lower back and ankles."
79402335|NCT03593083|Other|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
80027459|NCT03570645|Drug|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
79270537|NCT05512598|Drug|HB0034|HB0034, a single dose
79270538|NCT05510284|Other|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
79270539|NCT05509842|Device|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
79270540|NCT05495464|Drug|Acalabrutinib|Given by PO
79270541|NCT05495464|Drug|Rituximab|Given by IV (vein)
79270542|NCT05495464|Other|Brexucabtagene Autoleucel|Given by IV (vein)
79270543|NCT05495464|Drug|Cyclophosphamide|Given by IV (vein)
79402336|NCT00217087|Procedure|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
79402337|NCT00217087|Procedure|Photodynamic Therapy|Porfimer sodium 2mg/kg
79402338|NCT03598543|Other|no intervention|no intervention, this is an obervational study.
79573313|NCT01825668|Other|High cholesterol|
79573314|NCT01825668|Other|Placebo|
79573315|NCT01825681|Behavioral|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
79573316|NCT01825707|Drug|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg (oral) on day1
79573317|NCT01825720|Drug|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
79573318|NCT01825720|Drug|normal saline group|same rate of normal saline
79573319|NCT01825733|Drug|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
79573320|NCT01825733|Drug|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
79573321|NCT01825746|Other|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
79573322|NCT01825759|Drug|danshen dripping pill|
79573323|NCT01825811|Biological|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10^6 cells mixed with fibrin-glue
79573324|NCT01825811|Biological|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10^6 cells mixed with fibrin-glue
79573325|NCT01825824|Radiation|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
79573326|NCT01825850|Drug|Gemigliptin|
79573327|NCT01825850|Drug|Irbesartan|
80027460|NCT03570645|Drug|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
80027461|NCT03570645|Drug|control group|block with only ropivacaine
79573328|NCT01825863|Drug|Ropivacaine|
79573329|NCT01825863|Drug|Saline 9%|
79573330|NCT01825902|Drug|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
79573331|NCT01825902|Radiation|fludeoxyglucose F 18|Undergo 18F-FDG PET
79867842|NCT00517296|Procedure|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
80027462|NCT05354037|Procedure|Enamel matrix derivative application for treatment of intrabony defects|EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
80027463|NCT03705091|Diagnostic Test|Magnetic resonance imaging|ASL and DWI MRI
79270544|NCT05495464|Drug|Fludarabine Phosphate|Given by IV (vein)
79732925|NCT04310514|Dietary Supplement|Fructose/glucose/xylitol/saccharose|"Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
79732926|NCT00671827|Behavioral|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
79867843|NCT00516906|Drug|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
79732927|NCT05117736|Drug|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
79732928|NCT05117736|Drug|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
79573332|NCT01825902|Procedure|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
79573333|NCT01825902|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
79867844|NCT00516906|Drug|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
79867845|NCT01565304|Behavioral|POWER Through Choices|10-session group-based sexual education curriculum
79867846|NCT00523848|Drug|bortezomib|IV
79867847|NCT00523848|Drug|pegylated liposomal doxorubicin hydrochloride|IV
79867848|NCT00523848|Drug|thalidomide|Oral
80027464|NCT03567135|Drug|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
80027465|NCT03567135|Drug|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
80027466|NCT03570567|Device|Piranha Treatment|The piranha device is used with an endoscope to breakup/dislodge the food bolus.
79573334|NCT01825902|Other|laboratory biomarker analysis|Correlative studies
79573335|NCT01825915|Procedure|Laparoscopic Hysterectomy|
79573336|NCT01825915|Procedure|Laparoscopic Supracervical Hysterectomy|
79573337|NCT01825928|Drug|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
79732929|NCT00671905|Procedure|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
79573338|NCT01825928|Drug|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
79573339|NCT01825967|Other|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
79732930|NCT00671905|Procedure|PV isolation|Circumferential PV isolation
79732931|NCT02631967|Procedure|Kono anastomosis|Kono anastomosis
79270556|NCT05485987|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
79270557|NCT05471375|Other|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
79309108|NCT03204773|Diagnostic Test|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
79573340|NCT01825993|Drug|L-BUPIVACAINE ; MORPHINE|
79573341|NCT01825993|Drug|MORPHINE|
79573342|NCT01826006|Device|Excimer laser|
79573343|NCT01826006|Device|Manual Thrombus Aspiration|
79573344|NCT01826019|Other|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
79867849|NCT04711200|Drug|Adipose derived stromal cells intravenously injected|2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
79867850|NCT00617669|Drug|Docetaxel|intravenous infusion given every three weeks
79867851|NCT00617669|Drug|ZD4054|10 mg oral once daily dose
79867852|NCT00617669|Drug|Placebo|placebo oral tablet once daily
79867853|NCT00863135|Device|CPAP|continuous positive airways pressure
79867854|NCT00863135|Device|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
79867855|NCT04018157|Drug|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
79867856|NCT00865241|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
80027467|NCT03624439|Device|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
80027468|NCT03624439|Device|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
80027469|NCT05708937|Behavioral|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body & Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
79573345|NCT01826019|Other|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
79270558|NCT05468736|Biological|Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) (or fractional dose if necessary) on Days 0 and 21 in the Initial Vaccination Period.
79270559|NCT05468736|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 201 and Day 229 for the participants originally randomized to placebo.
79270560|NCT05468736|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
79270561|NCT05468736|Other|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in the Initial Vaccination Period or on Days 201 or Day 229 in the Booster Vaccination Period
79270562|NCT05462990|Drug|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
79270563|NCT05462990|Drug|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
79270564|NCT05456087|Drug|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
79573346|NCT01826032|Device|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
79573347|NCT01826032|Other|Standard care for OSA|sleep higiene and dietary counseling
79573348|NCT01826045|Drug|Poly-gamma Glutamic Acid|
79573349|NCT01826045|Drug|Placebo|
79270565|NCT05452109|Other|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
79270566|NCT05452109|Other|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
79309109|NCT03204461|Diagnostic Test|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
79309110|NCT03204461|Other|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
79309111|NCT04808739|Biological|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
79573350|NCT01826058|Radiation|Stereotactic body radiation therapy|
79573351|NCT01826071|Other|Static Stretch|
79573352|NCT01826071|Other|Active Elongation|
79573353|NCT01826097|Device|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
79573354|NCT01826110|Drug|[11C]PIB|Approximately 15 mCI [11C]PIB IV x1
79573355|NCT01826123|Device|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
79573356|NCT01826123|Device|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
79573357|NCT01826136|Device|Acapella device|
79573358|NCT01826149|Drug|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
79573359|NCT01826149|Drug|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
79573360|NCT01826149|Drug|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
79732932|NCT02631967|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
79732933|NCT04157491|Drug|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
79732934|NCT04157647|Device|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
79573361|NCT01826162|Other|acetate or placebo infusion|
79573362|NCT01826175|Drug|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
79573363|NCT01826175|Drug|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
79573364|NCT01826175|Device|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
79573365|NCT01826188|Drug|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
79573366|NCT01826188|Drug|Placebo|olive oil without cannabis
79573367|NCT01826240|Behavioral|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
79573368|NCT01826253|Drug|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
79270567|NCT05450146|Other|Partner in Balance|"The Partner in Balance intervention (Boots, 2018) consists of 1) a face-to-face intake session with a care professional (casemanagers, dementia nurses or district nurses) to familiarize participants with the program, set goals, and select preferred module themes; 2) tailored online thematic modules, including psychoeducation, behavioral modeling, reflective assignments, set goals, and online messaging feedback with the care professional over 8 weeks; and 3) a face-to-face evaluation session with the care professional evaluating previously set goals."
79270568|NCT05446155|Diagnostic Test|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
79270569|NCT05445804|Drug|300 mg Cannabidiol|300 mg CBD in Medium Chain Triglyceride oil b.i.d.
79270570|NCT05445804|Drug|600 mg Cannabidiol|600 mg CBD in Medium Chain Triglyceride oil b.i.d.
79573369|NCT01826266|Drug|PER977, Placebo|
79270571|NCT05445804|Drug|Placebo|Medium Chain Triglyceride oil
79270572|NCT05443451|Device|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
79270573|NCT05435196|Other|Therapeutic exercise|"The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc."
79270574|NCT05434156|Drug|ELE-101|ELE-101 solution for intravenous infusion
79270575|NCT05434156|Drug|ELE-101 Placebo|ELE-101 placebo matching solution for intravenous infusion
79270576|NCT05432388|Drug|remibrutinib|oral tablets
79573370|NCT01826279|Dietary Supplement|Resveratrol|500mg 3 times daily for 1 month
79573371|NCT01826279|Other|Placebo|1 placebo tablet 3 times daily for 1 month
79573372|NCT01826305|Procedure|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
79270577|NCT05432388|Drug|placebo|oral tablets
79270578|NCT05432375|Drug|Tinostamustine|infusion given over 60 minutes
79270579|NCT05429489|Procedure|Bilevel erector spinae plane block|Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
79270580|NCT05429489|Procedure|Single level erector spinae plane block|Single level erector spinae plane block at 5th thoracic vertebrae
79270581|NCT05429489|Drug|Intravenous morphine|Intravenous morphine 0.1 mg/kg
79270582|NCT05429125|Device|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
79270583|NCT05429125|Device|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
79270584|NCT05428995|Device|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy
79573373|NCT01826305|Procedure|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
79581486|NCT06071078|Behavioral|Training of professionals according to the DISCUSS announcement protocol|"The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure."
79732935|NCT04157647|Device|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
79732936|NCT00671983|Procedure|Neurocognitive Testing|
79732937|NCT02629471|Behavioral|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
79732938|NCT00946101|Biological|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
79732939|NCT00946101|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
79732940|NCT00664885|Other|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
80027470|NCT03698383|Drug|Trastuzumab biosimilars(Herzuma), Gedatolisib|"Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
79573374|NCT01826318|Behavioral|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
79573375|NCT01826331|Behavioral|Incentives for Participation|Participants will receive three smoking cessation programs
80027471|NCT04760782|Drug|Abaloparatide|Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
79270585|NCT05428995|Device|Airtraq videolaryngoscope.|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
79402339|NCT03593005|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
80027472|NCT04760782|Device|Hard collar immobilization|Hard collar immobilization of the cervical spine for 12 weeks
79270586|NCT05427370|Procedure|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
79270587|NCT05427370|Procedure|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
79402340|NCT03593005|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
79402341|NCT01406873|Drug|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
79402342|NCT01406873|Drug|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
79402343|NCT01406795|Device|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
79402344|NCT01406717|Drug|SPIL1033|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
79573376|NCT01826331|Behavioral|Incentives for Cessation|Participants will have access to a smoking cessation program
79573377|NCT01826383|Behavioral|Active-Video|This group will watch an active-video with pain management strategies for parents
79573378|NCT01826383|Behavioral|Placebo Video|This group will watch a placebo-video describing immunization generally.
79573379|NCT01826396|Drug|Irinotecan|Comparison of standard and high dose irinotecan
79573380|NCT01826409|Dietary Supplement|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
79573381|NCT01826409|Dietary Supplement|Placebo|Placebo 2.7g/day for 4 weeks
79581487|NCT06071052|Procedure|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
79581488|NCT06071039|Combination Product|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
79732941|NCT00672061|Drug|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
80027473|NCT03569163|Device|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
80027474|NCT03698305|Drug|ASP5354|Intravenous
80027475|NCT03698305|Drug|Placebo|Intravenous
80027476|NCT03566901|Device|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
80027477|NCT03566901|Other|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
80027478|NCT04743232|Other|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
79573382|NCT01826435|Behavioral|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
79732942|NCT00672217|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
79732943|NCT00672217|Behavioral|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
79573383|NCT01826461|Drug|PDI-192|
79270588|NCT05425745|Drug|Obicetrapib|10 mg Obicetrapib tablet
79270589|NCT05425745|Drug|Placebo|placebo tablet made to resemble active
79270590|NCT05413369|Drug|Insulin glargine/Lixisenatide|solution, by subcutaneous injection
79270591|NCT05413369|Drug|IDegAsp|solution, by subcutaneous injection
79270592|NCT05413369|Drug|Metformin|Tablet, orally
79270593|NCT05413369|Drug|SGLT2 inhibitor|Tablet, orally
79270594|NCT05411133|Drug|Cabotamig (ARB202)|Cabotamig (ARB202), Atezolizumab
79270595|NCT05411107|Procedure|Biospecimen Collection|Undergo collection of sputum sample
79270596|NCT05411107|Procedure|Bronchial Brush Biopsy|Undergo bronchial brush biopsy
79270597|NCT05411107|Procedure|Bronchoscopy|Undergo bronchoscopy
79270598|NCT05411107|Drug|Iloprost|Given PO
79573384|NCT01826461|Drug|Vehicle|
79573385|NCT01826474|Drug|PRO045, 0.15 mg/kg/week|Subcutaneous injection
79270599|NCT05411107|Drug|Placebo Administration|Given PO
79270600|NCT05411107|Other|Questionnaire Administration|Ancillary studies
79270601|NCT05393258|Radiation|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
79270602|NCT05387265|Drug|CX-904|CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.
79270603|NCT05385055|Other|THS use|N/A: No intervention was assigned.
79270604|NCT05385055|Other|Cigarette smoking|N/A: No intervention was assigned.
79270605|NCT05385055|Other|Smoking abstinence|N/A: No intervention was assigned.
79402345|NCT01406717|Drug|Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
79402346|NCT01406015|Drug|Spironolactone|50 mg once daily for 6 weeks.
79573386|NCT01826474|Drug|PRO045, 1.0 mg/kg/week|Subcutaneous injection
79732944|NCT00660751|Drug|Duloxetine|SNRIs
79732945|NCT00664963|Device|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
79732946|NCT00664963|Device|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
79732947|NCT00672295|Drug|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
79270606|NCT05379829|Drug|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
79270607|NCT05379829|Drug|Placebo|Participants will be administered 3 doses s.c. Q4W.
79270608|NCT05376800|Drug|BI 907828 (Brigimadlin)|BI 907828 (Brigimadlin)
79270609|NCT05373758|Other|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
79270610|NCT05373758|Other|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
79270611|NCT05373758|Other|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
79270612|NCT05371587|Other|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
79270613|NCT05371587|Other|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
79309112|NCT03204617|Biological|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
79309113|NCT03204617|Biological|At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
79402347|NCT01406015|Drug|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
79573387|NCT01826474|Drug|PRO045, 3.0 mg/kg/week|Subcutaneous injection
79573388|NCT01826474|Drug|PRO045, 6.0 mg/kg/week|Subcutaneous injection
79573389|NCT01826474|Drug|PRO045, 9.0 mg/kg/week|Subcutaneous injection
79573390|NCT01826474|Drug|PRO045, selected dose|Subcutaneous injection
79573391|NCT01826500|Other|blood test|blood test
79573392|NCT01826526|Device|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
79573393|NCT01826539|Procedure|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
79573394|NCT01826552|Device|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
80027479|NCT04740580|Dietary Supplement|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
79573395|NCT01826552|Device|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
79573396|NCT01826565|Procedure|Rotational technique|90 degree rotation
79573397|NCT01826578|Procedure|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
79867857|NCT00865241|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
79867858|NCT00863213|Procedure|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
79867859|NCT00863213|Drug|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
79867860|NCT00860639|Drug|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
79867861|NCT00860717|Procedure|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
79573398|NCT01826630|Other|CLn BodyWash|Comparing two washes to determine change in bacterial load.
79573399|NCT01826630|Other|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
79867862|NCT00860717|Radiation|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
80027480|NCT04740580|Dietary Supplement|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
80027481|NCT04740580|Dietary Supplement|Alanine|The placebo arm will supplement Alanine
79732948|NCT04154995|Diagnostic Test|Venipuncture|Blood testing at 3, 6 and 12 months
80027482|NCT03704389|Behavioral|Clinical decision support|Clinical decision support nudges within the electronic health record
80027483|NCT03064282|Other|Placebo|observation of skin changes if any
80027484|NCT03064282|Drug|papaverine|observation of symptoms
79573400|NCT01826656|Procedure|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
79573401|NCT01826656|Radiation|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
79732949|NCT04154995|Diagnostic Test|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
79732950|NCT00665041|Drug|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
79732951|NCT04153045|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
79732952|NCT04152655|Drug|Idebenone|30mg tablets three times a day
79573402|NCT01826656|Radiation|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
79732953|NCT04152655|Drug|Placebo oral tablet|placebo tablets three times a day
79867863|NCT03660540|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
79867864|NCT00863291|Drug|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
79867865|NCT00863291|Drug|placebo|Placebo in a manner similar to the active comparator
80027485|NCT04770025|Device|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
80027486|NCT04770025|Device|Sham stimulation|High-density electrode configuration with sham stimulation
80027487|NCT04770025|Behavioral|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
80027488|NCT04440982|Combination Product|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
79309114|NCT03204617|Drug|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
79732954|NCT00672373|Drug|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
80027489|NCT02628418|Other|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
80027490|NCT02628418|Device|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~7 min of a number sequence (counting from one to five);~A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~A sequence of wave-like finger movements (7 min)~A sequence of fist opening/closing (7 min)~A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
80027491|NCT02628418|Other|Specific hand rehabilitation performed by physiotherapist|"The activities were:~Flexion-extension of the fingers (10 min);~Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~Adduction and abduction of the fingers (10 min);~Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
79867866|NCT04689282|Biological|Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).|Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
79867867|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
79867868|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
79867869|NCT00860873|Dietary Supplement|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
80027492|NCT03027609|Drug|AR-105|monoclonal antibody
80027493|NCT03027609|Drug|Placebo|matching placebo (+ SOC antibiotics)
80027494|NCT03704311|Procedure|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
79573403|NCT01826656|Radiation|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
79402348|NCT00215683|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
80027495|NCT03063112|Device|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
80027496|NCT03063112|Drug|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
80027497|NCT03063112|Device|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
80027498|NCT03063112|Drug|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
79402349|NCT00215137|Drug|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
79573404|NCT01826669|Procedure|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
79573405|NCT01826682|Other|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
79573406|NCT01826682|Other|Medical treatment|Standard medical treatment without physiotherapy.
79732955|NCT00672373|Drug|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
79732956|NCT01109940|Biological|AIN457A|
79732957|NCT00595309|Biological|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
79732958|NCT00665119|Drug|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
79867870|NCT00860873|Dietary Supplement|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
80027499|NCT03701503|Behavioral|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
79402350|NCT00215137|Drug|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
79402351|NCT04406779|Device|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
80027500|NCT03704233|Procedure|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
80027501|NCT02752776|Drug|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
79402352|NCT00214201|Drug|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
79402353|NCT03598153|Drug|Shujinjianyao Pill|According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
79732959|NCT00665119|Drug|placebo|NaCl 0.9 %
79732960|NCT05113212|Device|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
79732961|NCT05113212|Device|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
79402354|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
80027502|NCT03704155|Drug|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
79573407|NCT01826695|Other|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
79402355|NCT03598075|Other|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
79402356|NCT03592615|Procedure|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
79402357|NCT03592615|Procedure|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
79402358|NCT03597919|Biological|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
79402359|NCT04001413|Drug|MEDI0457|MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
79402360|NCT04001413|Drug|Durvalumab|Durvalumab is an investigational drug in this study.
79402361|NCT03592459|Device|Macy Catheter|Undergo placement of Macy catheter
79402362|NCT03592459|Procedure|Pain Therapy|Receive opioids via Macy catheter
79573408|NCT01826695|Other|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
79573409|NCT01826708|Biological|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
79732962|NCT00665197|Radiation|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
79573410|NCT01826721|Other|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
79732963|NCT00665197|Radiation|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
79732964|NCT04309890|Other|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
79732965|NCT00672529|Dietary Supplement|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
79732966|NCT02629549|Drug|OTL38|Infusion of OTL38 prior to surgery
79732967|NCT00672607|Drug|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
79732968|NCT00672607|Drug|Placebo|Placebo
79732969|NCT00665509|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
79867871|NCT00865319|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
79309115|NCT04808895|Drug|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
79402363|NCT03592459|Other|Questionnaire Administration|Ancillary studies
79732970|NCT00672685|Dietary Supplement|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
79867872|NCT00865319|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
79867873|NCT00861029|Drug|Pazopanib|Subjects treated with pazopanib
79402364|NCT03592459|Other|Survey Administration|Ancillary studies
79402365|NCT01486784|Drug|Birinapant|IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
79573411|NCT01826747|Drug|crinone (progesterone 8%, vaginal application)|
79867874|NCT00861029|Other|Placebo for pazopanib|Control for comparison with pazopanib
79867875|NCT00861029|Drug|Moxifloxacin|Comparator for pazopanib
79309116|NCT04808895|Drug|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
79309117|NCT04485689|Drug|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
79309118|NCT04485689|Drug|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
79309119|NCT04485689|Drug|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
79270618|NCT05362994|Device|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is >30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis >30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
79270619|NCT05362994|Device|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
79732971|NCT00672685|Behavioral|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
80027503|NCT03704155|Other|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~Passive stretching of lower limbs,~Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~Strengthening of the antagonist muscles with the application of BoNT-A;~Static and dynamic balance training;~Up and down stairs;~Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
79270620|NCT05358470|Other|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
79270623|NCT05354557|Drug|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
79270624|NCT05342753|Device|Restylane Kysse|Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
79270625|NCT05342467|Drug|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
79270626|NCT05342467|Drug|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
79270627|NCT05329155|Drug|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
79270628|NCT05326204|Other|Home blood glucose monitoring|Self monitoring of capillary blood glucose
79867876|NCT00861029|Other|Placebo for moxifloxacin|Placebo for moxifloxacin
79270630|NCT05318534|Drug|GL-0719|Administration route: intravenous infusion and subcutaneous injection
79573412|NCT01826760|Other|Using training and testing groups to construct ANN based on laboratory tests|
79732972|NCT00672685|Drug|Placebo|OMEGA-3 placebo
79270631|NCT05318534|Drug|Placebo|Administration route: intravenous infusion and subcutaneous injection
79270632|NCT05311072|Procedure|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
79270633|NCT05306600|Diagnostic Test|whole exome sequencing analysis|Somatic and germline whole exome sequencing will be analyzed
79309120|NCT04485689|Drug|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
79573413|NCT01826773|Drug|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
79732973|NCT00595075|Drug|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
79732974|NCT00595075|Drug|placebo|placebo identical in appearance to active experimental drug x 1 dose
79867877|NCT00865397|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
79867878|NCT00861107|Biological|AlloStim-7|intradermal injection once a week for 3 weeks
79732975|NCT00887224|Drug|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
79732976|NCT00887224|Drug|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
79573414|NCT01826786|Drug|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
79573415|NCT01826786|Drug|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
79732977|NCT00887224|Drug|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
79732978|NCT00672763|Drug|Colecalciferol D3 (Vigantol Oil)|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
79867879|NCT00861107|Procedure|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
79867880|NCT00861107|Biological|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
79573416|NCT01826864|Biological|sargramostim|Given SC
79573417|NCT01826864|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
79573418|NCT01826864|Other|laboratory biomarker analysis|Correlative studies
79867881|NCT00861107|Biological|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10^8 cell dose and if no toxicity dose escalates to 10^9 cell dose.
79867882|NCT00510510|Drug|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
80027504|NCT03698227|Drug|Olaratumab|iv infusion
80027505|NCT03698227|Drug|Dexrazoxane|iv infusion
80027506|NCT03698227|Drug|Doxorubicin|iv infusion
79732979|NCT00672763|Drug|Medium chain triglycerides|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Migliol Oil 5ml oral fortnightly (2 doses)"
79732980|NCT04154449|Drug|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
79867883|NCT00510510|Drug|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
79573419|NCT01826864|Other|hypertonic saline|Given SC
79573420|NCT01826877|Biological|AdGMCAIX-transduced autologous dendritic cells|Given ID
79573421|NCT01826877|Biological|therapeutic autologous dendritic cells|Given ID
79573422|NCT01826877|Other|laboratory biomarker analysis|Correlative studies
79270634|NCT05298722|Diagnostic Test|Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.|"The images of CT-scans and MRI with DWI shall be processed with specific software to define the direction of diffusion tensors and indicate the direction (red, green, blue coloring for x,y,z, components of the vector) and intensity (anisotropy, brightness of voxels). Further analysis will be performed by fiber tracking which gives a clear indication of functional connectivity of adjacent tissues.~Genetic profilling of liquid biopsies: evolution of the number CTCs in blood samples of patients and subsequent phenotyping of the cells; longitudinal analysis of driver mutations and epigenetic changes in cfDNA; genotyping of germline variations~Questionnaires for patient reported outcomes and health economic analysis~EQ-5D-5L~PAN 26~HADS"
80027507|NCT03697915|Device|Experimental|Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
79573423|NCT01826890|Other|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
79573424|NCT01826916|Drug|DX-88 (ecallantide)|solution for injection 10 mg/mL
79867884|NCT00510510|Drug|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
79270635|NCT05295030|Other|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
79573425|NCT01826929|Other|Therapeutic education|
79573426|NCT01826942|Device|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
79573427|NCT01826942|Device|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
79573428|NCT01826968|Procedure|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
79732981|NCT02629081|Other|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
79732982|NCT00661063|Drug|ketamine|ketamine 150 mcg/g bid
79732983|NCT00661063|Drug|vehicle gel|bid - 12 weeks
79867885|NCT00863525|Drug|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
79402366|NCT03592381|Procedure|Ridge Expansion by ossedensification|Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
79402367|NCT03592381|Procedure|ridge expansion by ridge splitting|using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
79402368|NCT01521884|Other|SC anti-TNF|SC anti-TNF
79573429|NCT01826994|Device|heart type fatty acid binding protein testing|
79732984|NCT00661063|Drug|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
79732985|NCT00661063|Drug|clonidine gel 1%|bid 12 weeks
79732986|NCT00665587|Procedure|Cox-MAZE III|Maze procedure according to standards of the department
79867886|NCT00863525|Drug|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
79867887|NCT05226377|Diagnostic Test|Atherogenic Index of Plasma|- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
79867888|NCT01009632|Behavioral|Resonant voice|4-hr of resonant voice exercise
79867889|NCT01009632|Behavioral|Voice rest|4-hr of complete refrain from any voice use
79732987|NCT02629237|Other|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
79732988|NCT02825446|Procedure|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
79867890|NCT01009632|Behavioral|Spontaneous speech|
79732989|NCT02825446|Procedure|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
79732990|NCT04242706|Device|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
79270636|NCT05295030|Other|Kieember Infant formula, Ruibuen®|Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited
79270637|NCT05295030|Other|Yashili Infant formula, Ruibuen®|Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China
79270638|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
79270639|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
79732991|NCT04242706|Device|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
79270640|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
79270641|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
79573430|NCT01827007|Other|Volume expansion with gelofusine|
79573431|NCT01827020|Drug|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
79573432|NCT01827020|Drug|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
79573433|NCT01827020|Drug|Saline|12 mL saline (0.9% isotonic solution)
79732992|NCT00672919|Drug|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
79732993|NCT01109316|Drug|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
79732994|NCT01109316|Drug|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
79732995|NCT01109316|Drug|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
79732996|NCT02825290|Drug|Choriogonadotropin alfa|
79732997|NCT02825290|Drug|Triptorelin acetate|
79270642|NCT05286762|Drug|Placebo|Subjects will be randomized at Visit 2 to Placebo
79270643|NCT05283577|Other|Electroacupuncture|EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
79270644|NCT05283577|Other|Sham-Electroacupuncture|Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
79270645|NCT05280704|Procedure|Volar digital block with lidocaine|Volar digital block with lidocaine
79270646|NCT05280704|Procedure|Volar digital block with saline|Volar digital block with saline
79270647|NCT05280704|Procedure|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
79732998|NCT00675961|Behavioral|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
79732999|NCT00675961|Drug|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
79733000|NCT00675961|Other|BCI + Naltrexone|Combination of the two previous interventions
79733001|NCT00675961|Behavioral|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
79867891|NCT00863603|Other|oxygen|5 Liter/minute by nasal cannula for 6 wks
79270648|NCT05280704|Procedure|Dorsal digital block with saline|Dorsal digital block with saline
79270649|NCT05279131|Drug|Tirbanibulin ointment 1%|Applied topically for 5 days over a field of approximately 100 cm^2 on the face or balding scalp with AK.
79573434|NCT01827033|Behavioral|meditation training|
79573435|NCT01827059|Drug|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
79573436|NCT01827059|Drug|Placebo|
79573437|NCT01827072|Drug|NPB-01|
79573438|NCT01827085|Device|Conventional Macintosh laryngoscope|
79573439|NCT01827085|Device|Stortz videolaryngoscope|
79573440|NCT01827124|Drug|Carbetocin|
79573441|NCT01827124|Drug|oxytocin|
79573442|NCT01827137|Biological|WT1 Analog Peptide Vaccine|Preparation of a suspension of liquid vaccine drug product preparation (100 mcg of each peptide x 4 WT1 peptides within the GPS mixture; total weight: 400 mcg) 1:1 v/v with Montanide (oil depot emulsifier) to a total volume of ~1 ml, which is then injected s.c. to the patient. GPS is administered subcutaneously with Montanide adjuvant, with the first dose within 22 days of ASCT with melphalan conditioning (200 mg/sq.m.) and biweekly administration thereafter, for a total of 6 initial doses. Subsequently, patients continued to receive booster GPS administrations every 4 weeks, for an additional set of 6 doses, assuming they remain non-progressors per International Myeloma Working Group (IMW) criteria and are also clinically stable.
79733002|NCT00887068|Drug|Azacitidine|32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
79733003|NCT00941031|Drug|AIN457|
79733004|NCT00941031|Drug|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
79733005|NCT00941031|Drug|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
79733006|NCT00941031|Drug|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
79733007|NCT04310436|Behavioral|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
79733008|NCT04310436|Behavioral|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
79733009|NCT00886834|Drug|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
79733010|NCT00886834|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
79573443|NCT01827137|Biological|Sargramostim (GM-CSF)|Granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine®) is administered s.c. at a dose of 70 μg on day -2 and day 0 of each GPS administration.
79867892|NCT00865475|Drug|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
79270650|NCT05275374|Drug|XP-102|XP-102 will be administered orally once or twice daily in a continuous regimen.
79573444|NCT01827137|Drug|lenalidomide|IMiD (lenalidomide; 10 mg p.o. daily) OR -in select patients- proteasome inhibitor (bortezomib; 1.3 mg/sq.m. s.c. every 2 weeks) maintenance starting 3-months post auto SCT.
79733011|NCT00880009|Drug|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
79733012|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
79733013|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
79733014|NCT04242472|Behavioral|SMS-based Mobile Health intervention|Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
80027508|NCT03697837|Behavioral|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
79733015|NCT02827006|Procedure|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
79867893|NCT00865475|Drug|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
79733016|NCT00676039|Drug|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
79733017|NCT00676039|Drug|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
79270651|NCT05275374|Drug|Trametinib|Trametinib will be administered 2mg orally once a day.
79867894|NCT04685694|Drug|Misoprostol|sl 800 mcg misoprostol
79270652|NCT05269706|Drug|Cannabidiol 200mg|Cannabidiol 200mg (twice daily)
79270653|NCT05269706|Drug|Epidiolex|Epidiolex 400mg (twice daily)
79270654|NCT05269706|Drug|Cannabidiol 400mg|Cannabidiol 400mg (twice daily)
79270655|NCT05269706|Drug|Placebo|Matching Placebo (Twice Daily)
79270656|NCT05267613|Drug|Nexium 20mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
79270657|NCT05267613|Drug|Nexium 10mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
79270658|NCT05254457|Biological|EN3835|Treatment or retreatment with up to two doses of EN3835
79867895|NCT00870311|Drug|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
79733018|NCT00676039|Drug|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
79733019|NCT00676039|Drug|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
79733020|NCT01104636|Drug|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
79867896|NCT01564602|Device|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
79867897|NCT00865553|Behavioral|computer-assisted smoking cessation intervention|
79867898|NCT00865553|Other|cancer prevention|
80027509|NCT02186730|Behavioral|Stressbusters|cCBT
80027510|NCT02186730|Behavioral|Websites|Self help websites
79402369|NCT03592147|Other|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
79402370|NCT03592147|Other|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
80027511|NCT01342965|Drug|Erlotinib|Erlotinib was supplied as tablets.
79573445|NCT01827150|Drug|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
79573446|NCT01827176|Other|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
79573447|NCT01827189|Other|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
79867899|NCT00865553|Other|educational intervention|
79867900|NCT00865553|Other|survey administration|
79867901|NCT03560388|Other|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
79573448|NCT01827202|Other|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
80027512|NCT01342965|Drug|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
79573449|NCT01827202|Drug|Aliskiren|
79573450|NCT01827202|Drug|Candesartan|
80027513|NCT02181348|Drug|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
80027514|NCT02181348|Drug|placebo (edible oil)|
80027515|NCT02186886|Drug|Golimumab|Physiological Intermolecular Modification Spectroscopy
79270663|NCT05251233|Drug|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
79270664|NCT05251233|Drug|Pantoprazole|The study will use commercial supply.
79573451|NCT01827215|Behavioral|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
79573452|NCT01827228|Other|Assays|May vary across sites
79573453|NCT01827228|Other|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
79733021|NCT04268511|Procedure|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
79270665|NCT05250011|Drug|Dapagliflozin|Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
79733022|NCT04268511|Procedure|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
79733023|NCT04931602|Diagnostic Test|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
79270666|NCT05247879|Dietary Supplement|Glucose containing Oral Rehydration Solution (ORS)|Oral rehydration solution
79270667|NCT05247879|Dietary Supplement|Sugar free - amino acid and electrolyte ORS|Glucose free oral rehydration solution
79270668|NCT05242965|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
79867902|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
79867903|NCT00865631|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
79270669|NCT05242965|Biological|Sargramostim|Given ID
79270670|NCT05241288|Combination Product|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
79270671|NCT05239169|Drug|Durvalumab|Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.
79270672|NCT05239169|Drug|Tremelimumab|Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.
79402371|NCT03592147|Other|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
79402372|NCT03592147|Other|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
79867904|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
80027516|NCT02186964|Procedure|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
80027517|NCT02186964|Procedure|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
79402373|NCT03592147|Other|Music and Relaxation Light|The music and relaxation lighting were combined.
79573454|NCT01827228|Other|Social network and venue tracing|This is described in Arms 1 and 2
79573455|NCT01827228|Other|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
79573456|NCT01827228|Other|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
79573457|NCT01827228|Behavioral|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
79573458|NCT01827241|Other|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
79573459|NCT01827280|Drug|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
79573460|NCT01827293|Drug|Promethazine|
79573461|NCT01827293|Drug|Lorazepam|
80027518|NCT02186964|Procedure|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
80027519|NCT02182908|Other|PET-Scan|PET-Scan
80027520|NCT02245893|Procedure|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
79733024|NCT04157023|Device|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
79867905|NCT00863759|Procedure|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
79867906|NCT00863837|Drug|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
79867907|NCT00863837|Drug|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
79867908|NCT01009866|Biological|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
79867909|NCT00863915|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
79867910|NCT00863915|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
79867911|NCT01009944|Drug|Lisinopril, Atenolol|once a day for 14 weeks
79867912|NCT01010022|Drug|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
79867913|NCT01010022|Drug|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
79573462|NCT01827345|Dietary Supplement|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
79867914|NCT04672746|Behavioral|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
79867915|NCT04672746|Behavioral|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
79867916|NCT00864071|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
79270673|NCT05239169|Drug|Capecitabine|Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
79573463|NCT01827397|Biological|EN41-UGR7C HIV vaccine|
79573464|NCT01827397|Biological|NaCl|
79270674|NCT05238831|Drug|Alectinib|Given orally (PO)
79733025|NCT04157257|Drug|TDF tablet|TDF tablet 300mg QD
79733026|NCT04157257|Drug|Entecavir Tablet|Entecavir tablet 0.5mg QD
79733027|NCT04157257|Drug|QL-007|QL-007 tablets 200mg BID
79733028|NCT04243174|Behavioral|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
79733029|NCT02852421|Procedure|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
79733030|NCT02852421|Procedure|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
79733031|NCT02825134|Device|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
79733032|NCT02825134|Device|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
79270675|NCT05238831|Drug|Alpelisib|Given PO
79270676|NCT05238831|Drug|Anastrozole|Given PO
79270677|NCT05238831|Biological|Atezolizumab|Given IV
79270678|NCT05238831|Biological|Bevacizumab|Given IV
79270679|NCT05238831|Procedure|Biopsy|Undergo tissue biopsy
79270680|NCT05238831|Procedure|Biospecimen Collection|Undergo collection of blood
79270681|NCT05238831|Drug|Capecitabine|Given PO
79270682|NCT05238831|Drug|Carboplatin|Given IV
79270683|NCT05238831|Drug|Cobimetinib|Given PO
79270684|NCT05238831|Drug|Entrectinib|Given PO
79270685|NCT05238831|Drug|Eribulin|Given IV
79270686|NCT05238831|Drug|Fulvestrant|Given by injection
79270687|NCT05238831|Biological|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given phesgo SC
79270688|NCT05238831|Drug|Irinotecan|Given IV
79270689|NCT05238831|Drug|Letrozole|Given PO
79270690|NCT05238831|Drug|Nab-paclitaxel|Given IV
79270691|NCT05238831|Drug|Niraparib|Given PO
79270692|NCT05238831|Drug|Olaparib|Given PO
79270693|NCT05238831|Drug|Paclitaxel|Given IV
79270694|NCT05238831|Drug|Palbociclib|Given IV
79270695|NCT05238831|Biological|Pertuzumab|Given subcutaneously (SC)
79573465|NCT01827423|Device|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
79573466|NCT01827436|Behavioral|Conventional physical therapy|
79573467|NCT01827436|Behavioral|Asymmetrical gait training|
79573468|NCT01827449|Device|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
79573469|NCT01827501|Device|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
79573470|NCT01827540|Drug|Cenicriviroc|
79270696|NCT05238831|Other|Quality-of-Life Assessment|Ancillary studies
79733033|NCT04152811|Behavioral|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
79733034|NCT04152811|Other|Usual Diabetes Care|Usual Diabetes Care
79733035|NCT04152889|Drug|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
79733036|NCT04152889|Drug|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
79733037|NCT04152889|Drug|Docetaxel|Docetaxel: 40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
79733038|NCT00602511|Drug|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
79733039|NCT00602511|Drug|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
79733040|NCT02826616|Drug|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
79733041|NCT00676117|Drug|Esomeprazole (D961H)|20mg
79270697|NCT05238831|Biological|Trastuzumab|Given SC
79867917|NCT00864071|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
79867918|NCT00870701|Radiation|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
79270698|NCT05238831|Biological|Trastuzumab Emtansine|Given intravenously (IV)
79270699|NCT05238831|Drug|Vemurafenib|Given PO
79270700|NCT05238831|Drug|Vinorelbine|Given IV
79733042|NCT00676117|Drug|Loxoprofen|60mg tablet
79733043|NCT05042986|Drug|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt [0.5 μCi/mg as salt], equivalent to 100 μCi in 142 mg active [0.7 μCi/mg as active]) of [14C]-SKI-O-703 containing approximately 100 μCi of [14C]-SKI-O-703 per capsule after an overnight fast.
79733044|NCT02852187|Device|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
79733045|NCT02852187|Device|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
79733046|NCT00676273|Device|TVT-Obturator (TVT-O)|sub urethral sling
79733047|NCT00676273|Device|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
79733048|NCT01104558|Drug|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
79733049|NCT04242160|Other|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
79733050|NCT04242160|Other|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
79733051|NCT00602589|Drug|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
79867919|NCT00870701|Other|absence of radiotherapy|absence of radiotherapy
79867920|NCT00864149|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
79270701|NCT05238831|Drug|Vismodegib|Given PO
79270702|NCT05230433|Dietary Supplement|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
79270703|NCT05226390|Biological|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
79270704|NCT05224908|Device|EOS|pelvimetry by EOS in standing and sitting position
79270705|NCT05223036|Procedure|Biopsy|Undergo biopsy
79270706|NCT05223036|Procedure|Biospecimen Collection|Undergo collection of blood samples
79270707|NCT05223036|Procedure|Gastrointestinal Endoscopy|Undergo GI endoscopy
79270708|NCT05223036|Biological|Obeticholic Acid|Given PO
79270709|NCT05223036|Drug|Placebo Administration|Given PO
79573471|NCT01827540|Drug|Dolutegravir|
79573472|NCT01827540|Drug|Midazolam|
79573473|NCT01827566|Other|gluten|
79573474|NCT01827566|Other|gluten free flour|
79573475|NCT01827618|Drug|Rapamycin|
79573476|NCT01827631|Drug|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
79573477|NCT01827644|Drug|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
79573478|NCT01827644|Drug|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
79573479|NCT01827644|Drug|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
79573480|NCT01827644|Drug|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
79270710|NCT05223036|Other|Questionnaire Administration|Ancillary studies
79733052|NCT00911755|Procedure|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
79867921|NCT00864149|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
79733053|NCT00911755|Procedure|Endotracheal Intubation|
80027521|NCT02182986|Procedure|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
79270711|NCT05221619|Drug|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
79733054|NCT02826850|Procedure|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
79733055|NCT02826850|Procedure|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
79867922|NCT01010100|Drug|Acarbose (Glucobay, BAYG5421)|50 mg TID
79867923|NCT01010100|Drug|Placebo|50 mg TID
79867924|NCT00870779|Drug|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
79867925|NCT04201470|Other|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
79867926|NCT04201470|Other|MRI|Cervical and cerebral MRI without contrast injection
79867927|NCT04201470|Other|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
79270713|NCT05214989|Behavioral|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
79270714|NCT05208840|Drug|Ocrelizumab|Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
79270715|NCT05199337|Drug|ZN-d5|ZN-d5 will be administered orally
79270716|NCT05198154|Diagnostic Test|ctDNA detection|High-depth sequencing method is used to detecting ctDNA.
79733056|NCT04270071|Drug|Yangxin Shengmai|Yangxin Shengmai Granules
79733057|NCT04270071|Drug|Yangxin Shengmai placebo|Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
79733058|NCT04270071|Drug|nitroglycerin tablets|Be used when angina attack
79733059|NCT04152733|Device|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
79733060|NCT02826538|Device|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
79733061|NCT02826538|Device|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
79733062|NCT04152577|Drug|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
79733063|NCT04152577|Drug|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
79733064|NCT02856087|Drug|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
79733065|NCT02856087|Drug|Naloxone|naloxone infusion
79733066|NCT02856087|Drug|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
79867928|NCT04201470|Other|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
79867929|NCT01010178|Drug|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
79867930|NCT04196634|Other|Risk assessment|People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
79867931|NCT03998904|Procedure|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
80027522|NCT02182986|Drug|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
79270717|NCT05189977|Drug|Propranolol|"Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
79270718|NCT05189977|Drug|Prazosin|"Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
79733067|NCT02856087|Drug|Normal Saline|normal saline infusion
79867932|NCT03998904|Procedure|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
79733068|NCT02881632|Device|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
79867933|NCT01010334|Other|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
79402374|NCT03592147|Other|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
79402375|NCT03027596|Procedure|Remote ischemic conditioning|
79402376|NCT01677858|Drug|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
79402377|NCT01677858|Drug|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
79402378|NCT03027362|Other|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
79402379|NCT03027362|Other|Psychoeducation and medication|
79402380|NCT04198441|Device|Wound dressing|Clean wound, fill wound, dress wound
79402381|NCT03027284|Drug|Merestinib|Administered orally
79733069|NCT02855931|Procedure|Middle turbinate resection|
79733070|NCT00676429|Drug|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
79867934|NCT04643418|Drug|MPB-1734|Administered once daily in a 21-day cycle
79867935|NCT00617591|Drug|Lenalidomide|25 mg orally on days 1-21
79270720|NCT05189535|Drug|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
79270721|NCT05189535|Drug|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
79270722|NCT05189535|Drug|Placebo|placebo
79270723|NCT05186012|Drug|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
79270724|NCT05186012|Drug|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
79270725|NCT05183828|Procedure|Biospecimen Collection|Undergo collection of saliva samples
79402382|NCT03027284|Drug|Cisplatin|Administered IV
79402383|NCT03027284|Drug|Gemcitabine|Administered IV
79733071|NCT00676429|Drug|Placebo|Placebo as oral solution, individually titrated
79733072|NCT02880072|Dietary Supplement|phosphate orally|4 different preparations of phosphate
79733073|NCT02856165|Device|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 > 94%.
79733074|NCT02856165|Device|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 > 94% (up to a maximum of 2l/min).
79733075|NCT02629315|Other|Carnoy's solution|
79733076|NCT02629315|Other|10% neutral buffered formaldehyde|
79733077|NCT04310046|Procedure|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
79733078|NCT04310046|Procedure|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
79733079|NCT02855853|Other|serious game et virtual reality|
79733080|NCT02855853|Other|Nintendo Wii|
79867936|NCT00617591|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated)
79867937|NCT00617591|Drug|Dexamethasone|40 mg orally on days on 1-4
79867938|NCT00865865|Procedure|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
79270726|NCT05183828|Drug|Letrozole|Given PO
79402384|NCT03592069|Drug|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
79402385|NCT03592069|Drug|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
79402386|NCT03027128|Biological|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
79402387|NCT03591991|Drug|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
79402388|NCT03591991|Other|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
79867939|NCT00865865|Procedure|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
79733081|NCT00676507|Biological|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
79733082|NCT00676507|Other|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
79733083|NCT02880150|Other|Stress test|
79867940|NCT00864305|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
79270727|NCT05183828|Other|Questionnaire Administration|Ancillary studies
79270728|NCT05178407|Dietary Supplement|Multiple micronutrient-fortified bouillon cube|Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
79270729|NCT05178407|Dietary Supplement|Control bouillon cube (iodine-only)|Bouillon cube fortified with 30 µg/g Iodine (KIO3)
79270730|NCT05176444|Behavioral|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
79270731|NCT05172960|Device|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
79270732|NCT05163912|Behavioral|Virtual home intervention|Group classes with active videogames and discussions
79270733|NCT05163587|Combination Product|low GI composite flour|low GI composite flour orally in chapati form (3times/day)
79270734|NCT05150405|Drug|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
79402389|NCT03592927|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
79402390|NCT03592927|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
79573481|NCT01827644|Drug|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
79733084|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
79733085|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
79733086|NCT01204658|Biological|Synflorix|Intramuscular injection
79733087|NCT01204658|Biological|Prevenar 13|Intramuscular injection
79733088|NCT01204658|Biological|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
79733089|NCT00951483|Drug|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
79733090|NCT01104246|Drug|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
79733091|NCT00676741|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79733092|NCT00676741|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79733093|NCT00676741|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79733094|NCT01103778|Drug|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
79733095|NCT02855619|Procedure|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
79867941|NCT00864305|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
79867942|NCT00864305|Drug|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
79867943|NCT00870935|Procedure|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
79867944|NCT00870935|Procedure|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
79867945|NCT00510276|Drug|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
79402391|NCT04673058|Procedure|Spinal Manipulation|Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
79573482|NCT01827644|Drug|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
79573483|NCT01827657|Drug|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
79573484|NCT01827683|Other|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
79573485|NCT01827696|Dietary Supplement|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
79573486|NCT01827722|Drug|Ozurdex|Intravitreal injection of Ozurdex
79733096|NCT02855619|Procedure|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
79867946|NCT00510276|Drug|Placebo|twice a day, by mouth for 12 weeks
79867947|NCT00871091|Procedure|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
79573487|NCT01827722|Drug|Ranibizumab|Intravitreal Injection of Ranibizumab
79573488|NCT01827722|Drug|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
80027523|NCT03570411|Diagnostic Test|T-SPOT®.CMV Test|The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
80027524|NCT03536910|Other|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
80027525|NCT05354817|Drug|mFOLFIRINOX|mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
80027526|NCT02181582|Drug|Emapunil|Single peroral administration
80027527|NCT02181582|Device|PET|Positron emission tomography, which creates images by detecting radioactivity.
79573489|NCT01827735|Drug|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
79573490|NCT01827748|Device|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
79733097|NCT02855619|Procedure|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
79733098|NCT00673621|Drug|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
79867948|NCT00871091|Procedure|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
79402392|NCT04673058|Procedure|Sham Manipulation|The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
79402393|NCT03597373|Other|reintubation|Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
79402394|NCT03591913|Drug|Misoprostol|Oral tablets
79867949|NCT00871091|Procedure|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
79867950|NCT00864617|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
79573491|NCT01827748|Device|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
79573492|NCT01827774|Device|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
79573493|NCT01827800|Behavioral|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
79581489|NCT06071013|Drug|Nintedanib, gefitinib, erlotinib, afatinib|"Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells."
79867951|NCT00864617|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
79867952|NCT00865943|Drug|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
79402395|NCT04198519|Other|Weight Loss|The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
79402396|NCT01486316|Device|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
79733099|NCT00673621|Drug|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
79733100|NCT00673621|Drug|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
79573494|NCT01827813|Procedure|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
79573495|NCT01827813|Procedure|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
79402397|NCT01486316|Other|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
79402398|NCT03591835|Other|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
79402399|NCT03591835|Other|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
79573496|NCT01827813|Procedure|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
79733101|NCT01103466|Device|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
79733102|NCT01103466|Device|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
79733103|NCT01103466|Device|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
79733104|NCT02627053|Drug|rivaroxaban|
79733105|NCT00945945|Drug|Duloxetine (DLX)|dose daily by mouth
79733106|NCT00945945|Drug|Placebo (PLA)|Placebo Comparator daily by mouth
79733107|NCT01203956|Device|SmartFlex|Device used with smartflex engaged.
79733108|NCT01203956|Device|Standard|
79733109|NCT04150627|Other|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
79733110|NCT01103232|Procedure|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
79733111|NCT01103232|Procedure|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
79733112|NCT02627287|Device|FlexPen®|For subcutaneously (s.c. under the skin) injection.
79733113|NCT02627287|Device|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
79867953|NCT00865943|Drug|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
79867954|NCT00866021|Drug|Lopinavir/ritonavir|NRTI sparing-regimen
79867955|NCT00866021|Drug|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
79402400|NCT04850898|Biological|SAB-176|Treatment of influenza
79733114|NCT02627287|Drug|placebo|For subcutaneously (s.c. under the skin) injection
79733115|NCT02853669|Procedure|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
79573497|NCT01827826|Behavioral|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
79270735|NCT05147597|Other|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
79733116|NCT02853669|Procedure|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
80027528|NCT05354739|Device|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
79270736|NCT05147467|Drug|APG2575|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
79402401|NCT04850898|Other|Placebo|Placebo Control
79402402|NCT04198285|Procedure|Retrograde bladder filling|The bladder will be filled with a large syringe through the urinary catheter (which is left in place for the surgery) with 200mL of sterile saline, and then the catheter will be removed.
79867956|NCT00866099|Other|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
79867957|NCT00864695|Other|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
79402403|NCT04198129|Drug|Antibiotic treatment (Unasyn or Cleocin)|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
79867958|NCT00871247|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
79270737|NCT05142358|Device|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
79402404|NCT04198129|Drug|Antibiotic treatment (Augmentin or Cleocin)|the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
79402405|NCT04198129|Other|Control Group|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
79270738|NCT05142358|Other|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
79270739|NCT05142358|Other|Free Breath|Regular breathing
79733117|NCT00673699|Procedure|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
79733118|NCT01112982|Other|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
79733119|NCT01112982|Drug|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
79733120|NCT01112982|Drug|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
79867959|NCT00871247|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
79867960|NCT01010412|Device|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
79270740|NCT05136495|Other|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
79867961|NCT01010412|Device|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
79270741|NCT05119881|Behavioral|mirror therapy|a mirror box will be placed in front of the participants with the mirror reflection side toward the non-paretic limb. The paretic arm will be placed behind the mirror, and the mirror box will block the vision of the paretic limb. Through this method, the patients can only view the movement of the non-paretic limb and its mirror reflection from the mirror. The participants will be instructed to move or perform functional tasks with their non-paretic limb and look at the mirror reflection of the non-paretic limb and mentally imagine that it is the paretic arm moving. At the same time, the participants will be encouraged to move the paretic arm along with the mirror reflection of the non-paretic arm. Activities practice during MT will include gross motor movements, fine motor movements, and functional tasks.
79270742|NCT05119881|Device|tDCS|The tDCS will be delivered by a DC-stimulator (Soterix Medical Inc, New York, USA) through 2 saline-soaked surface sponge electrodes (anodal electrode size: 25 cm2; cathode electrode size: 25 cm2). The anodal electrode will be placed over the ipsilesional M1 while the cathodal electrode will be placed over the contralesional M1. The stimulation intensity will be ramped up to 2mA in 15 seconds, and maintained at 2mA throughout the 20-minute stimulation for the MT+tDCS group.
79867962|NCT04137120|Drug|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
79867963|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
79867964|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
79402406|NCT01486238|Drug|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
79270743|NCT05119881|Behavioral|sham mirror therapy|For the sham MT (s-MT) condition, the same mirror box will be used except that the mirror side will be made blurred to view; thus, the participants will not be able to view the mirror reflection of the paretic limb. The participants will perform the same activities as the real MT condition.
79402407|NCT04814394|Diagnostic Test|flowcytometry|The study of CD4,CD25,FOXP3 and PD-1 on peripheral blood sample
79402408|NCT03591757|Drug|Tolcapone|Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
79573498|NCT01827865|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
79573499|NCT01827865|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
79573500|NCT01827878|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
79573501|NCT01827878|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
79573502|NCT01827891|Procedure|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
79573503|NCT01827917|Biological|rabies vaccine|Injection on day 0、7、21
79573504|NCT01827956|Other|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
79573505|NCT01827969|Procedure|ablathermy focused ultrasound|ablathermy focused ultrasound
79573506|NCT01827982|Drug|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
79573507|NCT01827982|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
79573508|NCT01827982|Drug|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
79733121|NCT01203878|Drug|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
79867965|NCT00616655|Drug|Placebo|Placebo total daily dose 0.9 mg
79867966|NCT00510198|Device|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
79867967|NCT00510198|Device|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
79270744|NCT05119881|Device|sham tDCS|For the sham tDCS group, the electrodes will be placed on the brain regions as the real tDCS group. The intensity will first be ramped up to 2mA within 15 seconds and then the stimulator will be turned off gradually within the next 30 seconds.
79270745|NCT05118789|Drug|NVL-520|Oral tablet of NVL-520
79270746|NCT05113017|Other|NO Intervention|NO Intervention
79573509|NCT01827982|Drug|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
79573510|NCT01827982|Drug|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
79573511|NCT01827982|Drug|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
79573512|NCT01827982|Drug|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
79573513|NCT01827982|Drug|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
79573514|NCT01827982|Drug|Placebo|Matching placebo will be given as a single oral dose.
79733122|NCT01203878|Drug|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
79733123|NCT02853825|Behavioral|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
79733124|NCT00676819|Drug|insulin aspart|
79733125|NCT00676819|Drug|human insulin|
79733126|NCT02851953|Device|Aqueduct-100|
79733127|NCT04151797|Other|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~Data collection on comorbidities, medication and laboratory results.~A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~A detailed feedback to the geriatrician.~A written report addressed to the attending physician"
79733128|NCT01112514|Drug|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
79733129|NCT02629003|Drug|[11C]Cimbi-36|
79733130|NCT02629003|Drug|[11C]Cimbi-36-5|
79733131|NCT00625794|Drug|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
79733132|NCT00625794|Behavioral|Smoking cessation counseling|8 weeks or counseling
79867968|NCT00864773|Procedure|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
79733133|NCT02853981|Device|Harmonic scalpel|a method for liver parenchymal transection
79733134|NCT02853981|Device|Kelly clamp crush technique|a method for liver parenchymal transection
79733135|NCT00911911|Procedure|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
79867969|NCT01010490|Procedure|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
79867970|NCT01010490|Procedure|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
79270747|NCT05108337|Procedure|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
79270748|NCT05108337|Other|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
79270749|NCT05100472|Biological|Androgen deprivation therapy (ADT)|ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
79573515|NCT01827995|Other|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
79573516|NCT01827995|Other|Routine assessment|Follow up in the clinic
79733136|NCT00911911|Procedure|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
79733137|NCT00911911|Procedure|SURGERY|Surgery after neoadjuvant chemotherapy
79733138|NCT01203098|Drug|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
79733139|NCT01203098|Drug|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
79733140|NCT01203098|Drug|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
79733141|NCT05032794|Other|Unrestricted diet before colonoscopy|Free diet, without restrictions
79733142|NCT05032794|Other|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
79270750|NCT05100472|Radiation|Brachytherapy|After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
79270751|NCT05100472|Radiation|Hypofractionated pelvic External beam radiation|Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
79573517|NCT01828047|Device|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
79270752|NCT05090943|Other|QOL to be completed by the participant|The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
79733143|NCT05032794|Drug|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
79573518|NCT01828060|Dietary Supplement|Jobelyn™|Sorghum bicolor leaf sheath extract
79573519|NCT01828060|Dietary Supplement|Placebo|Placebo capsules
79733144|NCT00676975|Drug|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
79733145|NCT00676975|Drug|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
79733146|NCT00945555|Drug|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
79867971|NCT01010490|Procedure|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
79867972|NCT00871559|Drug|REGN421(SAR153192)|
79867973|NCT05227859|Procedure|Piezocision|After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
79867974|NCT05227859|Device|Low-level laser|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
79867975|NCT05227859|Device|Conventional treatment|The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
80027529|NCT02181660|Drug|Gilteritinib|oral
79573520|NCT01828086|Biological|CJM112|Monoclonal antibody
79573521|NCT01828086|Biological|Secukinumab|Monoclonal antibody
79573522|NCT01828086|Other|Placebo|Liquid for subcutaneous injection without active drug.
79733147|NCT04318184|Procedure|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
79733148|NCT00673777|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
80027530|NCT03566745|Diagnostic Test|Blood for protein activity|Blood for protein activity
79867976|NCT05227781|Dietary Supplement|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
79867977|NCT05227781|Dietary Supplement|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
79867978|NCT05227469|Behavioral|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
79867979|NCT00516048|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
79867980|NCT00866255|Device|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
79867981|NCT04039997|Device|CPRMeter|teaching resuscitation with application of cpr feedback device
79270753|NCT05090501|Behavioral|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
79867982|NCT04039997|Other|Manual chest compression|Manual chest compression
79867983|NCT04040855|Other|Medication review|Multi-professional medication review
79573523|NCT01828125|Procedure|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
79573524|NCT01828125|Drug|Glucagon|
79733149|NCT01108458|Drug|Pertuzumab|iv, 840 mg, 420 mg
79270756|NCT05079100|Other|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
79867984|NCT00866411|Procedure|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
79867985|NCT00866411|Procedure|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
79867986|NCT05227625|Behavioral|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
79867987|NCT05227625|Behavioral|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
79867988|NCT00871793|Other|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
79309121|NCT04808661|Procedure|Thoracic endovascular aortic repair plus optimal medical therapy|Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
79733150|NCT01108458|Drug|Erlotinib|PO, 150 mg
79733151|NCT00633646|Dietary Supplement|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
79733152|NCT04318262|Biological|Determination of the clinical and biological characteristics|"clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…~biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…"
79733153|NCT04318262|Biological|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
79270757|NCT05076565|Device|Airbag Belt Fall Protection System|Both versions of Airbags features different number of IMU sensors. Participant's will be randomly assigned one of the two versions. The algorithms developed in this project will help the researcher to identify the optimal performance (sensitivity and specificity values for detecting falls). Based on this information the research team will be able to choose a version for home/community deployment portion of the study. Based on the performance of the airbags in detecting true positives (falls) and true negatives (non-falls) accurately one of the airbags will be used in community deployment phase of the study.
79270758|NCT05075408|Drug|Nemolizumab|Participants will receive 2 subcutaneous injections for a total dose of 30 milligrams (mg) of nemolizumab every 4 weeks (Q4W), with a loading dose of 60 mg at baseline for a period of 12 weeks with an 8 week follow-up.
79867989|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
79867990|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
79270759|NCT05075408|Drug|Nemolizumab|Participants will receive 2 subcutaneous injections of 30 mg of nemolizumab Q4W starting at baseline for a period of 12 weeks with an 8 week follow-up.
79270760|NCT05075408|Drug|Placebo|Participants will receive 2 subcutaneous injections of 30 mg of placebo-matched to nemolizumab Q4W for a period of 12 weeks with an 8 week follow-up.
79402409|NCT04438434|Drug|Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
79573525|NCT01828138|Dietary Supplement|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
79573526|NCT01828138|Dietary Supplement|Placebo|Placebo are given in 5 days
79573527|NCT01828151|Device|Noninvasive ventilation mask|
79733154|NCT04318262|Biological|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
79733155|NCT00680485|Drug|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
79867991|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
79867992|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
79733156|NCT02851641|Procedure|"pushed mono-canaliculonasal intubation"|
79733157|NCT04242316|Behavioral|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
79733158|NCT04242316|Behavioral|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
79733159|NCT00680563|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
79867993|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
79867994|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
79867995|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
79270761|NCT05067348|Drug|Tocilizumab Injectable Product|Participants will receive IV tocilizumab
79573528|NCT01828177|Drug|PDI-320|
79573529|NCT01828177|Drug|PDI-320 Monad #1|
79573530|NCT01828177|Drug|PDI-320 Monad #2|
79573531|NCT01828177|Drug|Vehicle|
79573532|NCT01828203|Drug|Minocycline|
79573533|NCT01828203|Drug|Placebo|
79867996|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
79867997|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
79573534|NCT01828203|Procedure|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
79573535|NCT01828203|Procedure|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
79573536|NCT01828229|Behavioral|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
79867998|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
79867999|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
79868000|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
79868001|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
79868002|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
79868003|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
79868004|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
79868005|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
79868006|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
79868007|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
79733160|NCT02887508|Behavioral|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
79270762|NCT05062837|Drug|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
79733161|NCT02887508|Behavioral|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
79733162|NCT02851719|Other|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
79733163|NCT02851719|Other|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
79733164|NCT01108068|Drug|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
79733165|NCT02851875|Other|Registry|
79270763|NCT05061004|Device|Cephea Mitral Valve System|Transcatheter mitral valve replacement
79868008|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
79270764|NCT05057234|Diagnostic Test|FoundationOne liquid CDx|FoundationOne liquid CDx testing
79733166|NCT00680641|Drug|Simvastatin|40mg of Simvastatin once daily
79868009|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
79270765|NCT05057234|Behavioral|Quality of life questionnaires|Quality of life questionnaire - EQ5D
79573537|NCT01828229|Behavioral|inactivity|inactivity for 2 weeks
79573538|NCT01828229|Behavioral|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
79733167|NCT00680641|Drug|Placebo|40mg of placebo once daily
79270766|NCT05048238|Drug|Tofacitinib|10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
79270767|NCT05047978|Other|Cow's milk protein infant formula|A routine cow's milk-based infant formula
79270768|NCT05047978|Other|Partially hydrolyzed protein infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
79868010|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
79868011|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
79573539|NCT01828229|Behavioral|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
79733168|NCT01201850|Drug|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
79270771|NCT05038137|Behavioral|Time restricted feeding|Participants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.
79270772|NCT05038137|Behavioral|Control|Participants will have a daily eating period equal to or greater than 12 hours.
79309122|NCT04808661|Drug|Optimal medical therapy|Optimal medical therapy (strictly control of their blood pressure and heart rate)
79309123|NCT03204227|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
79309124|NCT03204227|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
79573540|NCT01828229|Behavioral|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
79573541|NCT01828242|Behavioral|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
79573542|NCT01828242|Other|Control group following conventional approach|Control group following conventional approach
79573543|NCT01828294|Drug|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
79573544|NCT01828307|Behavioral|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
79573545|NCT01828307|Behavioral|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
79573546|NCT01828307|Behavioral|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
79733169|NCT05660122|Drug|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
79733170|NCT04980144|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
79868012|NCT00866489|Procedure|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
79868013|NCT00872105|Procedure|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
79573547|NCT01828320|Behavioral|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
79573548|NCT01828320|Behavioral|Psychoeducation|
79573549|NCT01828333|Other|No intervention|No intervention
79573550|NCT01828346|Drug|Birinapant|"Dose escalation part: (Drug escalation dose levels)~Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
79573551|NCT01828346|Drug|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
79573552|NCT01828359|Drug|Amosartan® tab|comparison of different combination of anti-hypertension drug
79733171|NCT04980144|Drug|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
79733172|NCT00951171|Procedure|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
79270773|NCT05036304|Other|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
79573553|NCT01828359|Drug|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
79733173|NCT00951171|Procedure|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
79733174|NCT00677131|Other|Reading the package insert of the drug|package insert of the drug
79868014|NCT00872105|Procedure|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
79868015|NCT00876083|Drug|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
80027531|NCT03697759|Other|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
79270774|NCT05036304|Other|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park)
79573554|NCT01828372|Other|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
79573555|NCT01828385|Drug|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
79733175|NCT00677131|Other|Reading the education information provided by the Pharmacy of NTUH|education information
79733176|NCT00677131|Other|Oral education provided by the pharmacist|Oral education provided by the pharmacist
79573556|NCT01828385|Drug|Saline|Saline + rocuronium + sugammadex
79733177|NCT02825056|Drug|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
79733178|NCT02825056|Drug|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
79868016|NCT05225909|Device|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
79868017|NCT00876161|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
79868018|NCT00876161|Drug|Lactose|
79868019|NCT00872417|Drug|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
79573557|NCT01828398|Device|real-tDCS + UE robot-assisted therapy|
79573558|NCT01828398|Device|sham-tDCS + UE robot-assisted therapy|
79573559|NCT01828411|Device|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
79573560|NCT01828411|Device|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
79573561|NCT01828437|Drug|Pyridoxine plus prednisolone|
79868020|NCT00872417|Drug|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
79270775|NCT05035628|Other|Cardiopulmonary exercise training|"Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions."
79733179|NCT02628691|Other|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
79733180|NCT02826772|Drug|GT0918|anti-tumor activity
80027532|NCT03566589|Dietary Supplement|Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
79733181|NCT00677209|Biological|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
79573562|NCT01828437|Drug|Prednisolone|
80027533|NCT03536832|Procedure|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
79733182|NCT02824744|Device|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
79733183|NCT02824744|Device|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
79733184|NCT00674011|Drug|Bevacizumab|Given as part of standard of care or another research protocol
79733185|NCT02824900|Device|Vibration stimuli to neck muscles|
79733186|NCT02824900|Device|Vibration stimuli to hand|
79733187|NCT02824900|Behavioral|conventional physiotherapy|
79733188|NCT00674089|Dietary Supplement|Vitamin A|Vitamin A 50,000 IU
79270776|NCT05028517|Other|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
79573563|NCT01828463|Drug|Nitisinone|doses 1, 2, 4 & 8 mg plus no treatment arm
80027534|NCT03536832|Procedure|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
80027535|NCT03697681|Drug|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
79270777|NCT05028517|Other|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
79573564|NCT01828489|Drug|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
79733189|NCT00674089|Dietary Supplement|Placebo|Vitamin A Placebo
79733190|NCT01200992|Biological|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
79573565|NCT01828489|Drug|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
79573566|NCT01828502|Behavioral|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
79733191|NCT01200992|Biological|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
79733192|NCT02824666|Drug|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
79733193|NCT02824666|Radiation|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of [18F]Fallypride [5-6 mCi being the typical range of injected dose].
79733194|NCT00674167|Drug|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
79733195|NCT00674167|Drug|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
79733196|NCT00674167|Drug|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
79733197|NCT02824588|Behavioral|Working Memory Training|Training mental flexibility
79733198|NCT02824588|Behavioral|Internet use|Used as control for time spent on computer
79733199|NCT00680719|Behavioral|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
79733200|NCT00680719|Behavioral|IBFT|Integrated Behavioral and Family Therapy (IBFT).
79733201|NCT04150471|Other|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
80027536|NCT03697681|Drug|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
80027537|NCT03566355|Radiation|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
79733202|NCT00912145|Drug|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
80027538|NCT02187276|Drug|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
79573567|NCT01828502|Behavioral|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
79270782|NCT05018208|Other|Computer-Assisted Intervention|Use smartphone app
79573568|NCT01828528|Procedure|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
79573569|NCT01828541|Behavioral|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
79573570|NCT01828541|Other|Standard of Care|
79573571|NCT01828580|Device|active laparoscope positioner (AutoLap)|
79573572|NCT01828606|Device|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
79573573|NCT01828606|Device|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
79573574|NCT01828619|Procedure|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
79270783|NCT05018208|Procedure|Patient Monitoring|Wear Biofourmis wearable device(s)
79573575|NCT01828632|Procedure|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
80027539|NCT03697525|Device|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
79573576|NCT01828645|Dietary Supplement|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
79733203|NCT00680875|Behavioral|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
79733204|NCT04243252|Behavioral|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
79733205|NCT04243252|Other|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
79868021|NCT00872573|Device|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
80027540|NCT02183064|Drug|Meloxicam|
80027541|NCT02183064|Drug|NSAID|
80027542|NCT03624907|Radiation|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
79270784|NCT05018208|Other|Questionnaire Administration|Complete questionnaires
79270785|NCT05013138|Behavioral|Training for ACEs and study procedures|"The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic."
79270786|NCT05013138|Behavioral|Training on study procedures|Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
79270787|NCT05012683|Device|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
79270788|NCT05012098|Drug|Bintrafusp alfa / M7824|Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
79270789|NCT04999423|Device|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
79270790|NCT04998006|Drug|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
79270791|NCT04996030|Drug|SY-2101|SY-2101 will be administered per dose and schedule specified in arm description.
79270792|NCT04996030|Drug|Arsenic Trioxide|IV ATO will be administered per dose and schedule specified in arm description.
79270793|NCT04990141|Procedure|Peripheral blood collection in cases group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group
80027543|NCT03624907|Radiation|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
79270794|NCT04990141|Procedure|Peripheral blood collection in control group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group
80027544|NCT03704077|Biological|Relatlimab + Nivolumab|Specified dose on specified days
80027545|NCT03704077|Biological|Nivolumab|Specified dose on specified days
79270795|NCT04988633|Behavioral|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
79270796|NCT04988633|Behavioral|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
79270797|NCT04982133|Dietary Supplement|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
79573577|NCT01828658|Other|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
79573578|NCT01828671|Other|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
79573579|NCT01828671|Other|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
79573580|NCT01828671|Other|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
79573581|NCT01828671|Other|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
79573582|NCT01828671|Other|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
79573583|NCT01828684|Other|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
79573584|NCT01828684|Other|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
79868022|NCT00876317|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
79868023|NCT00876317|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
79868024|NCT00866645|Drug|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
79868025|NCT00866645|Drug|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
79270798|NCT04978519|Procedure|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
79573585|NCT01828723|Biological|SVF|
79868026|NCT00872651|Drug|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
79868027|NCT00872651|Drug|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
79868028|NCT00872807|Behavioral|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
79270799|NCT04972721|Other|No treatment given|The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
79270800|NCT04970355|Biological|Erenumab|Pre-filled syringe; s.c. injection
79270801|NCT04970355|Drug|Placebo|Pre-filled syring; s.c. injection
79270802|NCT04959448|Drug|DUPIXENT®|No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
79573586|NCT01828736|Biological|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
79573587|NCT01828736|Drug|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
79868029|NCT00872807|Behavioral|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
79868030|NCT00876473|Procedure|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
80027546|NCT03704077|Drug|Paclitaxel|Specified dose on specified days
80027547|NCT03704077|Drug|Ramucirumab|Specified dose on specified days
80027548|NCT02256618|Other|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
80027549|NCT04433416|Diagnostic Test|hypertension|If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
80027550|NCT02183142|Drug|Mobic, China, 7.5 mg|
80027551|NCT02183142|Drug|Mobic, Germany, 7.5 mg|
80027552|NCT03568773|Other|High-intensity interval training|HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).
80027553|NCT03568773|Other|Aerobic exercise moderate intensity|The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, <threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).
80027554|NCT03568773|Other|Control Group|The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
79573588|NCT01828736|Drug|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
79573589|NCT01828736|Drug|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
79573590|NCT01828762|Biological|DC-TC+GM-CSF|
79573591|NCT01828775|Other|palliative care|Receive early PCI
79573592|NCT01828775|Other|palliative care|Receive delayed PCI
79573593|NCT01828775|Procedure|quality-of-life assessment|Ancillary studies
79573594|NCT01828775|Other|survey administration|Ancillary studies
80027555|NCT03703999|Device|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
79270803|NCT04956341|Device|Auricular acupuncture|Auricular acupuncture treatments will be utilizing ASP needles. The needles will stay in and fall out on their own (usually 3-10 days). For some patients who are acupuncture naïve, Seirin 15mm needles will be placed and allowed to remain for 45 minutes. This option will be provided to all subjects for their first treatment. Auricular acupuncture treatment possible locations will be as defined as: Master Cerebral/Prefrontal cortex, Amygdala, Hippocampus, Hypothalamus, Point Zero, Shen Men, Insomnia 1,Insomnia 2 OR Prefrontal Cortex, Reticular formation, Pineal gland, Hypothalamus, Point zero. In acupuncture parlance, the patient will be treated with ATP plus sleep I on first visit, then the acupuncturist will continue to use that treatment for each subsequent visit with the potential to add ATP plus sleep II. Both ears will be treated unless the patient requests that one be left open. The acupuncturist may use sleep I in one ear and sleep II in the other.
79270804|NCT04956341|Other|Standard treatment|Standard treatment from Primary Care Manager (PCM) or Mental Health or both
79270805|NCT04950660|Drug|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
79573595|NCT01828788|Drug|Ropivacaine|
79573596|NCT01828788|Drug|placebo|
79573597|NCT01828801|Device|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
79573598|NCT01828827|Drug|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
79573599|NCT01828866|Behavioral|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
79573600|NCT01828866|Behavioral|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~Functional analysis~Communication skills~Problem-solving skills~Sobriety sampling~Social networking~Refusal of substances~Reinforcing activities~Relapse management~Medication monitoring"
79573601|NCT01828879|Drug|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
79573602|NCT01828892|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
79573603|NCT01828892|Procedure|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
79573604|NCT01828892|Drug|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
79733206|NCT04242004|Drug|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
79733207|NCT04242004|Dietary Supplement|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
79733208|NCT04150237|Other|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
79733209|NCT02824510|Other|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
79733210|NCT02824510|Other|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
79733211|NCT02824510|Drug|Insulin aspart, glargine and detemir|
79733212|NCT00674245|Drug|Pantoprazole|40 mg once daily for 4 weeks
79733213|NCT00674245|Drug|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
79733214|NCT00674245|Drug|placebo|40 mg once daily for 4 weeks
79733215|NCT04194190|Drug|Individual Patient TCR-Transduced PBL|
79733216|NCT04242082|Diagnostic Test|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
79733217|NCT00878215|Device|Explorer Liver Image Guided System|
80027556|NCT03701425|Dietary Supplement|Mediterranean diet and exercise plan|"Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%"
80027557|NCT03566277|Behavioral|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
79573605|NCT01828892|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
79868031|NCT00876551|Procedure|Endoscopic vacuum assisted closure|"Endoscopic debridement of wound using a regular biopsy forceps.~Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson & Johnson, St-Stevens-Woluwe, Belgium).~Trimming of the sponge to the specific wound size.~Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~Sponge exchange twice a week until wound grounds are clean and closed"
79868032|NCT00872963|Biological|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
80027558|NCT03566277|Behavioral|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
79270806|NCT04950660|Drug|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
79573606|NCT01828905|Device|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
79573607|NCT01828905|Procedure|Autologous cancellous bone graft|autologous cancellous bone graft
80027559|NCT03566277|Behavioral|Feedback|Participants will receive text message feedback each day about progress towards their goal
79270807|NCT04949100|Device|Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"Duration: 60 minutes.~Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
79573608|NCT01828918|Genetic|microRNAs|
79573609|NCT01828931|Behavioral|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
79573610|NCT01828931|Other|Usual Care|Care as usual
80027560|NCT02181972|Drug|Gingko biloba|
79270808|NCT04949100|Device|PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"Duration: 60 minutes.~Frequency: None~Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~Amperage: None~Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
79270809|NCT04947917|Procedure|SpotTM Tattoo Ink|Ink injection
79573611|NCT01828944|Dietary Supplement|olive oil|
79573612|NCT01828957|Biological|Pneumostem®|
79573613|NCT01828957|Other|Normal Saline|
79573614|NCT01828970|Drug|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
79733218|NCT00878215|Device|Explorer Liver Passive Tracking|
79733219|NCT00878215|Procedure|Liver surgery|-Standard of care
80027561|NCT02181972|Drug|Placebo|
80027562|NCT05708781|Other|Core strengthening exercise|"Isolated lumbar stabilization muscle training:~Bridge track:~Dead bug track:~Quadruped Track:~Supine Track:~Side-support Track:~Prone Track:~Standing Track:"
79270810|NCT04936581|Procedure|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
79270811|NCT04936581|Procedure|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
79270812|NCT04936581|Procedure|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
79573615|NCT01828996|Device|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
79733220|NCT00878215|Procedure|Liver abalation|-Standard of care
79733221|NCT04243018|Behavioral|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
79573616|NCT01828996|Device|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
79573617|NCT01829009|Other|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
79573618|NCT01829022|Procedure|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
79733222|NCT04243018|Behavioral|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
79733223|NCT02628847|Drug|sildenafil citrate|
80027563|NCT05708781|Other|intensive dynamic back exercise|"Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
80027564|NCT05708781|Other|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
79270813|NCT04936581|Procedure|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
79270814|NCT04934540|Procedure|En bloc resection of bladder tumour|En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
79270815|NCT04931134|Device|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
79270816|NCT04931134|Device|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
79270817|NCT04928339|Drug|Bupivacaine Injection|10mL of 0.25% bupivacaine
79573619|NCT01829035|Other|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~Anti-tumor drug:~Unapproved drug/embolization material from each regulatory agency should not be used.~To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
79573620|NCT01829087|Drug|Botox|
79573621|NCT01829087|Drug|placebo|
79573622|NCT01829100|Behavioral|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
79573623|NCT01829152|Device|CHM|
79573624|NCT01829178|Drug|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
79573625|NCT01829178|Drug|Placebo|placebo tablets: 420 mg in 3 divided dose
79733224|NCT02628847|Drug|Placebo|
79733225|NCT04241770|Other|no intervention|no intervention
79733226|NCT00677287|Biological|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
79733227|NCT05660902|Other|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
79868033|NCT05193539|Behavioral|Augmented reality and virtual reality rehabilitation|"This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation."
79270818|NCT04928339|Drug|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
79270819|NCT04928339|Other|Saline|25mL saline control
79270820|NCT04926636|Behavioral|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
79270821|NCT04924660|Drug|TXA127|TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
79270822|NCT04924660|Drug|TRV027|TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
79270823|NCT04924660|Drug|Placebo|"NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses."
79733228|NCT00674401|Procedure|Radiofrequency catheter ablation|"In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~Empirical pulmonary vein antrum circumferential isolation, or~High frequency sites ablation in the LA~In case of Persistent AF, patients will be randomized into one of 2 in the study:~Empirical circumferential PV antrum isolation w/out roof line, or~A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
79573626|NCT01829178|Drug|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
79868034|NCT05193539|Behavioral|Conventional occupational therapy|The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.
79573627|NCT01829256|Behavioral|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
79573628|NCT01829282|Behavioral|Risk Reduction|
79868035|NCT00876629|Device|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
79868036|NCT00617357|Device|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
79868037|NCT05168501|Other|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
79868038|NCT04039685|Other|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
79573629|NCT01829308|Behavioral|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
79573630|NCT01829308|Behavioral|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
79573631|NCT01829321|Drug|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
79573632|NCT01829321|Drug|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
79733229|NCT02824120|Other|Comedy|patients will watch comedy film
79733230|NCT02824120|Other|Documentary|patients will watch a documentary film
79733231|NCT00677443|Drug|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
79868039|NCT04039685|Other|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
79868040|NCT04039685|Other|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
79868041|NCT00876707|Device|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
79868042|NCT00876707|Device|ReSTOR implant|Implant of multifocal IOL ReSTOR
79868043|NCT00876707|Device|ReZoom implant|Implant of multifocal IOL ReZoom
79573633|NCT01829334|Other|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
79573634|NCT01829334|Other|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
79573635|NCT01829334|Other|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
79573636|NCT01829334|Other|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
79573637|NCT01829373|Biological|vaccine 1650-G|
79573638|NCT01829412|Other|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
79573639|NCT01829438|Behavioral|Listening to fast music|
79573640|NCT01829438|Behavioral|Listening to preferred music|
79573641|NCT01829438|Behavioral|Listening to slow music|
79573642|NCT01829451|Other|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------"
79573643|NCT01829490|Biological|ChAdOx1 85A|Intramuscular injection
79733232|NCT00677443|Drug|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
79733233|NCT04913584|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
79573644|NCT01829490|Biological|MVA85A|Intramuscular injection
79573645|NCT01829529|Drug|Amoxicillin|Amoxicillin
79573646|NCT01829542|Dietary Supplement|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
79573647|NCT01829542|Dietary Supplement|Control|Macro- and micro-nutrient matched control in water
79733234|NCT00674557|Drug|SOD1 inhibitor ATN-224|
79733235|NCT00674557|Drug|exemestane|
79733236|NCT00674557|Genetic|protein expression analysis|
79733237|NCT00674557|Genetic|proteomic profiling|
79573648|NCT01829555|Behavioral|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
79573649|NCT01829581|Other|no intervention, only descriptive data analysis|
79868044|NCT00876785|Other|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
79573650|NCT01829594|Other|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
79868045|NCT00876785|Other|wheat bread based breakfast|Reference wheat bread breakfast
79868046|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
79868047|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
79733238|NCT00674557|Other|laboratory biomarker analysis|
79868048|NCT04040543|Dietary Supplement|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
79868049|NCT00873197|Drug|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
79868050|NCT00873353|Drug|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
79733239|NCT00674557|Other|pharmacological study|
79733240|NCT04259242|Procedure|SRP|scaling and root planing with ultrasonic scaler and manual instruments
79733241|NCT04150003|Behavioral|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
80027565|NCT02187510|Procedure|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
80027566|NCT02187510|Procedure|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
80027567|NCT03568695|Diagnostic Test|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
80027568|NCT02183220|Drug|Metamizol|
80027569|NCT02183220|Drug|Acetylsalicylic acid (ASA)|
80027570|NCT02183220|Drug|Metamizol placebo|
80027571|NCT02183220|Drug|ASA placebo|
80027572|NCT03701347|Device|Reeve's model|Reeves, K. O., Young, A. E., & Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
80027573|NCT03701347|Device|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., & Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
79573651|NCT01829607|Other|Functional electrical stimulation of peripheral muscles|
79573652|NCT01829620|Behavioral|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
79733242|NCT04150003|Other|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
79733243|NCT05660824|Device|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
79733244|NCT05660824|Procedure|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 5000 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
79733245|NCT04150159|Dietary Supplement|FMD Arm|ProLon Fasting Mimicking Diet Plan
80027574|NCT03701347|Device|Ida's model|Reusable, portable and modular 3D printed simulator
80027575|NCT03566121|Other|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
80027576|NCT02190084|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
79733246|NCT00677521|Drug|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
79868051|NCT00876941|Behavioral|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
79868052|NCT00876941|Behavioral|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
80027577|NCT03697291|Device|PS wire|The wiring connection used to convey ECG signal from inside the body
80027578|NCT03565965|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
80027579|NCT03565965|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
80027580|NCT03703843|Device|ARTUS MONO|Temporarily implant and activation of the medical device
80027581|NCT02187588|Drug|Eschscholtzia Californica - low dose|
79573653|NCT01829620|Behavioral|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, & 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
79733247|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
79733248|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
79733249|NCT02826304|Procedure|Vaginal hysterectomy|"All the cases were performed by the same surgical team~Incision is made at the anterior cervical lip below the bladder reflection~Anterior peritoneal entry .~Douglas pouch entry.~The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~Uterine artery clamping division and ligation~After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~Hemostasis~The vaginal vault is closed after insertion of intraperitoneal drain and"
80027582|NCT02187588|Drug|Eschscholtzia Californica - high dose|
79573654|NCT01829633|Procedure|Physiotherapy|Shoulder physiotherapy with exercises
80027583|NCT02187588|Drug|Ibuprofen|
80027584|NCT02187588|Drug|Eschscholtzia Californica - low dose Placebo|
80027585|NCT02187588|Drug|Eschscholtzia Californica - high dose Placebo|
80027586|NCT02187588|Drug|Ibuprofen Placebo|
80027587|NCT03568617|Device|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
80027588|NCT03697213|Other|Online study|20 hypothetical patient summaries
80027589|NCT05364489|Drug|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
80027590|NCT02183298|Drug|BI 1356 BS - intravenous|
80027591|NCT02183298|Drug|BI 1356 BS - Tablet|
80027592|NCT02183298|Drug|Placebo|
80027593|NCT03569943|Device|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
80027594|NCT03697135|Behavioral|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
79573655|NCT01829659|Drug|Ticagrelor|
79573656|NCT01829672|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
79573657|NCT01829685|Drug|Entecavir, Adefovir|
79573658|NCT01829698|Drug|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
79733250|NCT02826304|Procedure|Laparoscopic assisted vaginal hysterectomy|"Uterine manipulator was inserted through the cervix to mobilize the uterus~Veress needle was inserted through the base of the umbilicus~creation of pneumoperitoneum~Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~The round and the utero-ovarian ligament are coagulated and divided.~Dissection through the vesico-uterine space to displace bladder away from the cervix.~Uterine artery was coagulated and divided laparoscopically~anterior colpotomy over the cup of the uterine elevator.~Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
79868053|NCT00876941|Behavioral|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
79868054|NCT00877019|Device|Sonicare elite medium brush head|
79733251|NCT00674713|Other|Acupuncture|
80027595|NCT02190162|Drug|Tantum Verde® mouthwash|
80027596|NCT02190162|Other|Placebo mouthwash|Mouthwash with placebo solution
80027597|NCT03565809|Other|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
80027598|NCT03697057|Procedure|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
79733252|NCT00674713|Drug|Ondansetron|
79573659|NCT01829698|Drug|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
79733253|NCT00674713|Drug|Physiological saline solution|
79733254|NCT00674713|Other|Sham acupuncture|
79733255|NCT00674713|Drug|Ondansetron|
79733256|NCT00674713|Other|Acupuncture at P6 point|
79733257|NCT00674713|Drug|Physiological saline solution|
79733258|NCT00674713|Other|Sham acupuncture|
79733259|NCT04241380|Drug|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
79733260|NCT04241380|Other|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
79733261|NCT04241380|Drug|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
79733262|NCT00677677|Biological|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
79868055|NCT00877019|Device|Sonicare elite mini brushhead|
79573660|NCT01829711|Drug|Moxetumomab pasudotox|
79573661|NCT01829711|Drug|IV Bag Protectant for Moxetumomab pasudotox|
79733263|NCT00674791|Biological|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
79733264|NCT02824354|Drug|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
79733265|NCT02824354|Drug|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
79733266|NCT00674869|Other|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
80027599|NCT03701191|Procedure|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
80027600|NCT02183376|Drug|BI 1356|
79573662|NCT01829763|Drug|injection botox|
79573663|NCT01829776|Behavioral|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
79573664|NCT01829789|Behavioral|Group Community Reinforcement Training for Parents|
79573665|NCT01829789|Behavioral|Individual Community Reinforcement Training for Parents|
79868056|NCT00877019|Device|GABA Elmex sensitive extra soft toothbrush|
79868057|NCT00877019|Device|ADA reference toothbrush|
79868058|NCT00877097|Drug|Klodronate and Kliogest|
79868059|NCT00877097|Procedure|Placebo+ Kliogest|
79868060|NCT00877097|Drug|Bonefos|
79868061|NCT00873431|Biological|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
80027601|NCT03696979|Other|Myofascial induction therapy|Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
79733267|NCT04150315|Diagnostic Test|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
79573666|NCT01829802|Drug|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
79573667|NCT01829802|Drug|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
79733268|NCT02823496|Other|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
79733269|NCT02823496|Other|Untreated skin|One site is patched without treatment as control
79733270|NCT00677755|Drug|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
79868062|NCT00877175|Drug|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
79868063|NCT00867347|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
79868064|NCT00867347|Radiation|radiation therapy|Patients undergo radiotherapy
79868065|NCT00420927|Biological|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
79868066|NCT00420927|Drug|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
79868067|NCT00420927|Biological|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
80027602|NCT03696979|Other|Therapeutic pain education|Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
79573668|NCT01829802|Drug|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
79868068|NCT00573443|Drug|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
79270824|NCT04924660|Drug|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
79270825|NCT04919057|Device|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
79270826|NCT04912765|Biological|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
79402410|NCT04438434|Drug|Chlorhexidine mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
79573669|NCT01829815|Behavioral|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
79573670|NCT01829828|Behavioral|No intervention|This is an observational study with no investigational drug administered.
79573671|NCT01829841|Drug|Famitinib|Famitinib 25 mg p.o. qd
79573672|NCT01829841|Drug|Sunitinib|Sunitinib 50 mg p.o. qd
79868069|NCT00573443|Drug|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
79868070|NCT00573443|Drug|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
79270827|NCT04912765|Drug|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
79402411|NCT04438434|Other|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
79573673|NCT01829867|Drug|sNN0031|
79573674|NCT01829893|Drug|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
79573675|NCT01829893|Drug|GL2701 capsule|oral medication with 240 mL water
79573676|NCT01829906|Behavioral|Multidisciplinary outpatient programme|
79573677|NCT01829906|Behavioral|Inpatient lifestyle programme|
79573678|NCT01829932|Dietary Supplement|Factor Altered Diet|
79573679|NCT01829971|Drug|MRX34|micro RNA therapy
79573680|NCT01829984|Other|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~Pre-teaching Evaluation: Caregiver~o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
79270828|NCT04905888|Combination Product|Hyperbaric oxygen therapy|Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
79868071|NCT01029561|Device|CPAP|Treatment with Continuous Positive Airway Pressure
79270829|NCT04903080|Biological|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
79270830|NCT04898543|Biological|M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)|M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
79573681|NCT01829984|Other|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~Post-injection Evaluation: Caregiver~o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~Nurse Evaluation: Control~Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
79573682|NCT01830010|Drug|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
79573683|NCT01830010|Drug|Study Part 2: KRP203 lower dose|
79573684|NCT01830010|Drug|Study Part 2: KRP203 higher dose|
79573685|NCT01830075|Behavioral|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
79573686|NCT01830153|Drug|RAD001|
79733271|NCT00677755|Drug|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
79733272|NCT00674947|Drug|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
79270831|NCT04898543|Biological|N-803 (Cohort 2 part B)|N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.
79270832|NCT04898543|Other|Apheresis collection of MNCs (part A)|Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
79270833|NCT04883658|Drug|CKD-348(2)|QD, PO
79270834|NCT04883658|Drug|CKD-828, D097, D337|QD, PO
79270835|NCT04869982|Biological|RZV|2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
79270836|NCT04869982|Drug|Placebo|2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
79270837|NCT04857632|Drug|Statin|atorvastatin 20mg per day for 7 days
79270838|NCT04854499|Drug|Magrolimab|Administered intravenously
79270839|NCT04854499|Drug|Pembrolizumab|Administered intravenously
79270840|NCT04854499|Drug|Docetaxel|Administered intravenously
79270841|NCT04854499|Drug|5-FU|Administered intravenously
79733273|NCT02628457|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
79733274|NCT02823418|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
79733275|NCT02823418|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
79270842|NCT04854499|Drug|Cisplatin|Administered intravenously
79270843|NCT04854499|Drug|Carboplatin|Administered intravenously
79270844|NCT04854499|Drug|Zimberelimab|Administered intravenously
79270845|NCT04846803|Biological|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
79270846|NCT04846803|Biological|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
79733276|NCT04149379|Drug|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
79733277|NCT02824042|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
79733278|NCT02824042|Drug|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
79733279|NCT02628925|Device|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
79573687|NCT01830231|Drug|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
80027603|NCT03565731|Behavioral|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
79270847|NCT04846101|Other|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
79733280|NCT02628301|Dietary Supplement|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
79868072|NCT01029561|Behavioral|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
79270848|NCT04846101|Other|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
79402412|NCT04198051|Drug|adjuvant chemotherapy|"Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months."
79868073|NCT05225831|Biological|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
79573688|NCT01830231|Drug|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~280 mg/m2 in patients aged >75 - ≤80 years or with PS 1 or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
79270849|NCT04846101|Diagnostic Test|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
79573689|NCT01830244|Drug|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
79270850|NCT04846101|Other|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
79270851|NCT04846101|Other|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
79270852|NCT04835506|Drug|Infliximab|infliximab
79270853|NCT04832685|Device|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
79402413|NCT03596983|Behavioral|Sleep Intervention|"Sleep Diaries (Daily)~Fitbit 24/7~Phone/ video conference calls (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-evening (weekly)"
79573690|NCT01830270|Drug|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
79573691|NCT01830270|Drug|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
79573692|NCT01830270|Drug|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
79868074|NCT05225831|Drug|Cyclophosphamide,Fludarabine|Given
79868075|NCT00873509|Drug|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
79868076|NCT00873509|Drug|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
80027604|NCT02187822|Drug|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
80027605|NCT02187822|Procedure|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
79270854|NCT04827251|Dietary Supplement|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
79270855|NCT04825041|Diagnostic Test|Patency test|Successive flow test, bubble flow test and peristalsis test
79402414|NCT03596983|Behavioral|Week 2 Intervention|"Sleep Diaries (Daily)~Phone Calls (weekly with study team)~Wrist Accelerometry and fitbit 24/7 for 14 days~SAFTEE Questionnaire~ASA24~Behavioral risk factor surveillance system (smoking and alcohol use questions)~Psychological well-being (SF36)~Index of Self Regulation~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)~Epworth Sleepiness Scale (weekly)"
79868077|NCT00873509|Drug|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
79270856|NCT04821635|Device|Rower assisted by electrostimulation (FES-ROW)|"Pre-inclusion visit~Inclusion visit~Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3):~Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week~Interim assessment visit at Month 3 (M3)~Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6):~Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week~Final assessment visit at Month 6 (M6)~End of clinical research visit, 3 months after the end of training (Month 9, M9)"
79573693|NCT01830270|Procedure|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
79270857|NCT04811092|Drug|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
79868078|NCT00873587|Procedure|Chest tube pull on inspiration|Pull chest tube on Inspiration
79868079|NCT00873587|Procedure|Expiration|Pull chest tube on Expiration
79733281|NCT02628301|Other|Normocaloric diet|Normocaloric diet
79733282|NCT00675181|Drug|Melatonin|5mg per os
79868080|NCT00867425|Behavioral|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
79868081|NCT00877253|Drug|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
79573694|NCT01830504|Drug|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
79868082|NCT00877253|Drug|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
79868083|NCT00877253|Drug|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
79868084|NCT05225753|Diagnostic Test|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
79868085|NCT00877331|Behavioral|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
79868086|NCT00873665|Other|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
79868087|NCT00873665|Other|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
79868088|NCT00877409|Drug|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
79733283|NCT00675181|Drug|Placebo|per os
79270858|NCT04811092|Other|Placebo|Placebo
79573695|NCT01830530|Drug|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
79573696|NCT01830530|Drug|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
79573697|NCT01830530|Drug|placebo|two tablets daily in the morning
79573698|NCT01830907|Dietary Supplement|carbohydrates|
79733284|NCT04241458|Drug|BI 703621|BI 703621
79733285|NCT04241458|Drug|Placebo|Placebo
79270859|NCT04785521|Radiation|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
79270860|NCT04785521|Diagnostic Test|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
79270861|NCT04785196|Drug|APG-115|Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
79270862|NCT04785196|Drug|Toripalimab|Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
79573699|NCT01830907|Dietary Supplement|vitamins|
79733286|NCT04241458|Drug|Midazolam|Midazolam
79733287|NCT02823808|Drug|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
79733288|NCT02823808|Drug|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
79733289|NCT04241302|Diagnostic Test|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
79733290|NCT04151719|Drug|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
79733291|NCT02823886|Other|MRI at D7|The infarct size measured on MRI at 7 days.
79733292|NCT02823886|Biological|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
79402415|NCT04462146|Behavioral|Internet-based Self Applied Treatment Program|"It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
79573700|NCT01831037|Other|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
79573701|NCT01831037|Other|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
79573702|NCT01831050|Biological|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
79573703|NCT01831050|Biological|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
79733293|NCT05299255|Drug|Utidelone|Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
79733294|NCT05299255|Drug|Placebo|the placebo as control group.
79733295|NCT02823340|Device|Fractional microneedle RF(United, Peninsula Medical, China)|
79733296|NCT00677911|Behavioral|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
79733297|NCT02823184|Biological|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
79733298|NCT00677989|Procedure|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
79733299|NCT00677989|Procedure|Open appendectomy|open appendectomy: did appendectomy by laparotomy
79733300|NCT02822482|Drug|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
79733301|NCT02822482|Drug|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
79733302|NCT00678067|Dietary Supplement|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
79733303|NCT00678067|Dietary Supplement|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
79733304|NCT00678067|Dietary Supplement|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
79868089|NCT00877409|Drug|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
79733305|NCT00678067|Other|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
79733306|NCT04239898|Other|Red cabbage microgreens|2 cups per day
79733307|NCT04239898|Other|Red beet microgreens|2 cups per day
79733308|NCT02822326|Biological|CD19-CAR-T2 Cells|
79733309|NCT00675337|Procedure|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
79733310|NCT00675337|Procedure|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
79733311|NCT04152265|Procedure|colonoscopy|colonoscopy
79733312|NCT04152265|Other|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
79733313|NCT04152265|Other|demographic data collections|completing the demographic questionnaire
79733314|NCT04152265|Other|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
79733315|NCT04152265|Procedure|Collecte the biological samples|blood and faeces collections
79868090|NCT00873899|Device|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
79573704|NCT01831050|Biological|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
79733316|NCT02822404|Dietary Supplement|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
79573705|NCT01831050|Biological|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
79733317|NCT02822248|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-64-R84-070)
79733318|NCT00675493|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
79733319|NCT04240990|Other|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~TB contact history~Suggestive TB symptoms in the previous 4 weeks~Physical examination~Clinical, anthropometric and biochemical assessment of malnutrition~Clinical assessment for other non-dietary causes of malnutrition~Digitalized CXR~Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~Mycobacterial culture performed on two GAs~Abdominal ultrasonography~QuantiFERON®-TB Gold IGRA~Monocyte-to-Lymphocyte Ratio (MLR)~C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
79733320|NCT02627131|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
79733321|NCT02821936|Procedure|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
79733322|NCT04239664|Other|Acceptance Based Telephone Support (ABS+UC)|Support based on Acceptance and Committment Therapy (Hayes, 1999)
79733323|NCT04240834|Drug|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
79733324|NCT04240834|Drug|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
79733325|NCT01200758|Drug|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
79733326|NCT01200758|Drug|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
79868091|NCT00873977|Device|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
79733327|NCT01200758|Drug|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m^2 IV) administered every 3 weeks.
79868092|NCT00874133|Procedure|Acupuncture|Acupuncture treatment for 12 weeks.
79402416|NCT04462146|Behavioral|Videoconference treatment with a therapist|"It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention."
79733328|NCT01200758|Drug|Doxorubicin|Eight cycles of doxorubicin (50 mg/m^2 IV) administered every 3 weeks.
79733329|NCT01200758|Drug|Vincristine|Eight cycles of doxorubicin (1.4 mg/m^2 IV) administered every 3 weeks.
79733330|NCT01200758|Drug|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
79733331|NCT02823106|Drug|Verapamil and Citicoline|Single dosing strategy will be used.
79733332|NCT02823106|Other|Placebo|Single matching dosing strategy will be used.
79733333|NCT02821858|Drug|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
79733334|NCT02821858|Drug|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
79733335|NCT02821858|Drug|Placebo|Matching placebo will be administered.
79733336|NCT04240600|Dietary Supplement|Experimental group|2 cans or bottles (200ml)per day, orally
79733337|NCT04240600|Dietary Supplement|Control group|2 cans or bottles (200ml)per day, orally
79733338|NCT00876343|Drug|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
79733339|NCT00876343|Drug|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
79733340|NCT00876343|Drug|Placebo|administered orally once daily, 6 weeks
79868093|NCT00874133|Drug|Motilium|20 mg motilium thrice daily
79868094|NCT00867737|Drug|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
79733341|NCT02822014|Other|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
79733342|NCT04151641|Dietary Supplement|MNGDPF|Standardized mangosteen extract in dry powder form
79733343|NCT04151641|Dietary Supplement|MNGEF|Standardized mangosteen extract in encapsulated form
79868095|NCT00867737|Drug|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
79868096|NCT00874211|Procedure|assessment of therapy complications|By dental and medical assessments.
79868097|NCT00877643|Other|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
79270863|NCT04779645|Drug|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
79270864|NCT04779645|Drug|Placebo|12-Week, once weekly subcutaneous injection with placebo
79270865|NCT04760717|Drug|Spironolactone Pill|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
79270866|NCT04743960|Dietary Supplement|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
79270867|NCT04733352|Other|acupuncture|to conduct acupuncture on different acupoints
79270868|NCT04731545|Device|immediate implant placement|Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
79270869|NCT04731480|Drug|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
79270870|NCT04731480|Drug|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
79270871|NCT04731480|Drug|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
79270872|NCT04731480|Drug|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
79733344|NCT02627989|Drug|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
79733345|NCT02627989|Drug|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
79733346|NCT02822170|Other|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
79270873|NCT04725643|Device|Track bleeding patterns before and after implant|Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
79270874|NCT04722770|Device|PhotoniCare OtoSight Middle Ear Scope|PhotoniCare OtoSight imaging using a near-infrared laser
79270875|NCT04720209|Other|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
79270876|NCT04720209|Other|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
79270877|NCT04720209|Other|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
79573706|NCT01831050|Biological|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
79573707|NCT01831050|Biological|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India [SII]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
79733347|NCT02627209|Other|spectrophotometric assay|measurement of enzyme activity in the serum
79733348|NCT02627209|Other|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
79270878|NCT04711161|Drug|GRN-300|A salt-inducible kinase (SIK) inhibitor
79270879|NCT04711161|Drug|Paclitaxel|Microtubule inhibitor
79270880|NCT04707651|Dietary Supplement|Formula diet|Formula diet for 12 weeks
79733349|NCT00675649|Biological|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
79733350|NCT00675649|Biological|placebo|placebo sc injection every 4 weeks from week 0 to week 20
79270881|NCT04700696|Behavioral|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
79733351|NCT00633724|Biological|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
79733352|NCT01107912|Drug|prasugrel|administered orally, daily for 12 days
79733353|NCT01107912|Drug|clopidogrel|Administered orally, daily for 12 days
79733354|NCT01200524|Drug|AZD2423|20 mg tablet
79733355|NCT01200524|Drug|AZD2423|50 mg tablet
79733356|NCT01200524|Drug|Placebo|Placebo
79270882|NCT04700696|Behavioral|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
79270883|NCT04700696|Behavioral|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
79270884|NCT04698746|Procedure|Pericapsular nerve group block|PENG block will be made with 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml NaCl under US-guidance
79270885|NCT04698746|Procedure|Intra-articular local anesthetic injection|Intra-articular local anesthetic injection will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl
79270886|NCT04692597|Device|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
79270887|NCT04692597|Device|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
79270888|NCT04685876|Drug|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
79270889|NCT04685876|Drug|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
79270890|NCT04685876|Drug|Normal saline|placebo (normal saline).
79733357|NCT00678145|Drug|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
79733358|NCT00678145|Dietary Supplement|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
79733359|NCT00678145|Behavioral|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
79733360|NCT00678145|Drug|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
79733361|NCT00678145|Drug|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
79733362|NCT04239742|Diagnostic Test|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
79733363|NCT04239742|Diagnostic Test|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
79733364|NCT05010642|Device|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
79402417|NCT03591679|Drug|Oxytocin|20 units by slow intravenous drip injection
79868098|NCT00877643|Other|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
80027606|NCT03696901|Drug|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration [e.g. hospital, ICU]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
79573708|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
79733365|NCT02626741|Dietary Supplement|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
79868099|NCT00874289|Other|NGAL kit|Kit to test NGAL levels in heart failure patients
79868100|NCT04040465|Drug|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
79868101|NCT03842813|Device|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
79868102|NCT00874445|Device|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
79581490|NCT06071000|Behavioral|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
79733366|NCT02626741|Behavioral|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
79733367|NCT04317950|Other|Vojta|Reflex locomotion stimulus
79733368|NCT04317950|Other|Sham|sham stimulus
79733369|NCT02879916|Drug|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
79733370|NCT02879916|Drug|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
79733371|NCT02690506|Drug|Placebo|
79733372|NCT02690506|Drug|Pregabalin|
79733373|NCT04310280|Drug|Insulin Glargine|Half of the wound surface is injected daily with topical glargine insulin
79733374|NCT04310280|Drug|Saline|Half of the wound surface is injected daily with topical saline solution
79733375|NCT04151407|Drug|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
79733376|NCT04824118|Diagnostic Test|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
79733377|NCT04824118|Diagnostic Test|Clotting Studies|"Standard laboratory tests for clotting:~International normalised ratio (INR)~Prothrombin time (PT)~adjusted partial thromboplastin time (aPTT)~fibrinogen"
79868103|NCT00420849|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
79868104|NCT00420849|Drug|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
79868105|NCT00617279|Device|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
79402418|NCT03591679|Procedure|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
79733378|NCT04824118|Diagnostic Test|Full Blood Count|For platelet count
79733379|NCT04824118|Diagnostic Test|Quantitative hCG|Serum human chorionic gonadotrophin
79733380|NCT04824118|Diagnostic Test|Pregnancy Test|Point of care urinary pregnancy test
79733381|NCT02627911|Device|Diabeloop System|Insulin delivery
79733382|NCT02627911|Device|Continuous Glucose Monitoring|
79733383|NCT02627911|Device|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
79733384|NCT02627911|Dietary Supplement|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
79868106|NCT00617279|Procedure|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
80027607|NCT03063034|Other|PD21864AA|A king size menthol cigarette.
80027608|NCT03063034|Other|PD21864AB|A king size menthol cigarette.
80027609|NCT03565653|Other|High dietary salt|~4,000 mg Na+/day
80027610|NCT03565653|Other|Placebo|dextrose
79868107|NCT00877721|Device|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
79573709|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
79733385|NCT04239586|Drug|Sulfonylurea|Starting treatment with sulfonylurea class of drug
79868108|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
79868109|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
79868110|NCT00874601|Drug|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
79868111|NCT00874679|Drug|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
79733386|NCT02628613|Drug|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
79733387|NCT02628613|Drug|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
79868112|NCT00420381|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
80027611|NCT02187900|Drug|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
79868113|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
79270891|NCT04669678|Drug|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
79270892|NCT04669678|Drug|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
79573710|NCT01831440|Behavioral|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
79868114|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
79270893|NCT04669678|Drug|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
79270894|NCT04669678|Device|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
79733388|NCT04239352|Diagnostic Test|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
79733389|NCT04239352|Diagnostic Test|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
79733390|NCT02627833|Other|observation|Record lung function, Lung clearance index, inflammatory status
79270895|NCT04660370|Drug|CKD-348|QD, PO
79270896|NCT04660370|Drug|CKD-828, D097, D337|QD, PO
79573711|NCT01831440|Drug|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
79733391|NCT01100034|Drug|Etanercept|Expected duration of 24 weeks as one course
79733392|NCT00675727|Biological|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
80027612|NCT02187900|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
80027613|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
80027614|NCT03062644|Drug|MR308|four times daily; Mode of Administration:oral
80027615|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
80027616|NCT03062644|Drug|MR308|given four times daily to maintain the blind; Mode of Administration:oral
79573712|NCT01831648|Other|Blood sample|
80027617|NCT04749355|Drug|BST-236|BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
79868115|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
79270897|NCT04656600|Drug|Cerezyme® / Imiglucerase|Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
79270898|NCT04654234|Device|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
79270899|NCT04646252|Other|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
80027618|NCT02190318|Drug|Losartan|
79270900|NCT04638517|Drug|Danazol|Danazol up to 800mg daily in two-divided doses.
79573713|NCT01831908|Other|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
79573714|NCT01831986|Dietary Supplement|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
79573715|NCT01831986|Other|Placebo|Caps
79573716|NCT01832311|Drug|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
79573717|NCT01832350|Drug|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
80027619|NCT02190318|Drug|spirolactone|
79270901|NCT04638517|Drug|Placebo|Matching placebo.
80027620|NCT02190318|Other|blank control|
79573718|NCT01832389|Device|PiCCO|
80027621|NCT02246361|Procedure|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
80027622|NCT03701113|Dietary Supplement|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
80027623|NCT03701113|Dietary Supplement|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
80027624|NCT03062722|Procedure|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
79270902|NCT04638400|Drug|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
79270903|NCT04638400|Drug|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
79270904|NCT04610112|Device|cochlear implantation|patients receive a cochlear implantation within clinical routine
79402419|NCT03969043|Other|MRI|"The MRI examination will consist of a series of acquisition scans:~Scanning Scan: for positioning the functional volume of interest.~Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~Resting state functional scan: for exploring cerebral activation during a rest activity.~Diffusion Tension Imaging: for measuring structural connectivity.~Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
79402420|NCT04039932|Behavioral|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
79573719|NCT01832545|Other|Aquatic Exercise|
79573720|NCT01832545|Behavioral|Educational Program|Control Group
79573721|NCT01832584|Dietary Supplement|RGC|
79573722|NCT01832584|Dietary Supplement|Placebo|
79573723|NCT01832688|Other|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
79573724|NCT01832740|Device|brain stimulation|oscillating direct current brain stimulation
79573725|NCT01832740|Device|SHAM|no stimulation
79581491|NCT06070974|Diagnostic Test|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
79733393|NCT02822560|Device|pEVAR|percutaneous femoral access using a suture-mediated closure device
79733394|NCT02822560|Procedure|open femoral access|cutdown to femoral artery and surgical closure
79581492|NCT06070948|Drug|Venetoclax|Oral; Tablet
79733395|NCT00675805|Device|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
79733396|NCT00675805|Device|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
79573726|NCT01833104|Behavioral|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills & interoceptive body awareness. 2 exercises: Breathing Meditation & Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, & other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation & Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
79868116|NCT00874835|Device|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
79573727|NCT01833104|Behavioral|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
79573728|NCT01833104|Behavioral|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
79868117|NCT00617201|Drug|atomoxetine|Once daily oral dosing
79868118|NCT00617201|Drug|placebo|Once daily oral dosing - matched placebo
79733397|NCT02880930|Dietary Supplement|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
79868119|NCT00420303|Drug|Etanercept|50 mg injection once weekly
79868120|NCT00420303|Other|Placebo|placebo
79733398|NCT04770766|Other|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
79868121|NCT00617123|Drug|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
79868122|NCT00617123|Drug|Placebo|matching placebo oral tablet
79733399|NCT04148833|Drug|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
79868123|NCT00877955|Drug|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
79270905|NCT04598165|Behavioral|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
79402421|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E10 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
79868124|NCT00877955|Drug|alprazolam sublingual tablet test|0.5 mg tablet, single dose
79868125|NCT00419757|Drug|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
79868126|NCT00419757|Drug|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
79868127|NCT00874913|Device|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
79733400|NCT04148833|Drug|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
79733401|NCT04926246|Drug|R1: Reference Product X|under fasted conditions
79733402|NCT04926246|Drug|T1: Test Product M|under fasted conditions
79733403|NCT04926246|Drug|T2: Test Product N|under fasted conditions
79733404|NCT04926246|Drug|T3: Test Product O|under fasted conditions
79733405|NCT04926246|Drug|T4: Test Product O|under fed conditions
79733406|NCT04926246|Drug|R2: Reference Product Y|under fasted conditions
79868128|NCT00878111|Drug|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min*~Second cohort: iv q3W 80 mcg/sqm over 120 min*~Third cohort: iv q3W 100 mcg/sqm over 120 min*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*~* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
79868129|NCT00867971|Other|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
79868130|NCT00434109|Drug|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
79868131|NCT00434109|Procedure|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
79868132|NCT00875069|Other|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
79733407|NCT04926246|Drug|T5: Test Product P|under fasted conditions
79868133|NCT01029639|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
79868134|NCT00875147|Drug|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
79868135|NCT01566513|Behavioral|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
79270906|NCT04596150|Drug|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
79270907|NCT04596150|Drug|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
79270908|NCT04595994|Drug|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
79573729|NCT01833221|Drug|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
79402422|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E9 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
79573730|NCT01833325|Radiation|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
79573731|NCT01833598|Procedure|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
79573732|NCT01833598|Procedure|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
79573733|NCT01834131|Behavioral|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
79573734|NCT01834300|Behavioral|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
79581493|NCT06070909|Device|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
79733408|NCT04926246|Drug|T6: Test Product P|under fed conditions
79868136|NCT01566513|Behavioral|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
79868137|NCT01566513|Behavioral|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
79270909|NCT04591314|Behavioral|Neurofeedback|The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
79270910|NCT04581421|Other|High Carb Low Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
79270911|NCT04581421|Other|Low Carb High Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
79402423|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E8 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
79402424|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E7 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
79402425|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E6 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
79402426|NCT04197817|Drug|JS002|JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
79402427|NCT04197817|Drug|Placebo|Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
79733409|NCT04926246|Drug|T7: Test Product Q|under fasted conditions
79733410|NCT04926246|Drug|R3: Reference Product Z|under fasted conditions
79733411|NCT04926246|Drug|T8: Test Product S|under fasted conditions
79733412|NCT04926246|Drug|T9: Test Product S|under fed conditions
79733413|NCT04926246|Drug|T10: Test Product U|under fasted conditions
79733414|NCT02821546|Drug|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
79733415|NCT02821702|Device|Vaginal ultrasound|
79733416|NCT02821702|Biological|Blood sample|
79733417|NCT00876265|Device|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
79868138|NCT05226845|Other|prescribed exercise|the therapist chooses the five exercises to do
79868139|NCT05226845|Other|chosen exercise|the patient chooses the five exercises to perform among fifteen possibilities
79733418|NCT00876265|Device|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
79733419|NCT04308018|Procedure|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
79733420|NCT04308018|Procedure|S1 screws|Caudal end of the instrumentation at S1
79573735|NCT01834300|Behavioral|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
79868140|NCT00875225|Behavioral|DVD|Control group will receive usual care DVD from health professionals
79868141|NCT00875225|Behavioral|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
80027625|NCT02183454|Device|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
79733421|NCT02690350|Drug|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
79270912|NCT04573387|Procedure|Operation|All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
79270913|NCT04573387|Procedure|Fixed-time drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. The drainage will be removed after 48 hours.
79733422|NCT02879838|Other|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
79402428|NCT05375682|Other|Integrated care program|Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
79733423|NCT02821468|Drug|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
79733424|NCT02821468|Drug|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
79733425|NCT04964622|Drug|nurofen|tablet
79733426|NCT04769050|Drug|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
79868142|NCT01034943|Procedure|External fixation|Operation with external fixation and optional addition of k-wire
79868143|NCT01034943|Procedure|Volar plate|Operation with a Synthes volar two column plate (TCP)
79868144|NCT00433329|Drug|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
79868145|NCT00433329|Drug|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
79868146|NCT01035021|Drug|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
79868147|NCT01029951|Procedure|manipulation|
79868148|NCT01029951|Procedure|Mobilisation|
80027626|NCT03703687|Behavioral|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
79402429|NCT03591601|Other|Manual Therapy protocol|Treatment based on manual therapy with proven evidence.
79402430|NCT03591601|Other|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
79402431|NCT03591601|Other|Placebo control|Placebo treatment based on the placement of the hands on the head without intention to treat.
79402432|NCT04615338|Other|no intervension|no intervention needed just observation and description
79573736|NCT01834820|Drug|Epinephrine and Dexamethasone|
79573737|NCT01834820|Drug|Hypertonic Saline|
79573738|NCT01834820|Drug|Normal Saline|
79733427|NCT04769050|Drug|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
79733428|NCT04309656|Drug|Pretomanid|"Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~Treatment C (test) = single 50-mg dispersible tablet, orally administered.~Treatment D (test) = single 10-mg dispersible tablet, orally administered."
79733429|NCT02821624|Drug|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
79733430|NCT02821624|Drug|Placebo|Placebo
79868149|NCT01029951|Device|Activator instrument|
79868150|NCT00616421|Biological|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
79868151|NCT00616421|Biological|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
79573739|NCT01834846|Procedure|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
79402433|NCT04197661|Drug|HSK3486|Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
79573740|NCT01834846|Procedure|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
79733431|NCT02879058|Procedure|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
79573741|NCT01834859|Behavioral|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
79733432|NCT02881164|Other|Low glycemic index|Subjects intake a low glycemic index breakfast
79733433|NCT02881164|Other|High glycemic index|Subjects intake a high glycemic index breakfast
79733434|NCT02821390|Drug|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
79733435|NCT02821390|Drug|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
79868152|NCT00616421|Biological|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
79868153|NCT00875303|Behavioral|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
79868154|NCT00875303|Behavioral|Control|Routine primary care.
79868155|NCT05226767|Dietary Supplement|NLC-V|NLC-V
79868156|NCT00878267|Behavioral|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
80027627|NCT03503968|Drug|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
80027628|NCT03503968|Other|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
79573742|NCT01834859|Behavioral|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
79573743|NCT01835002|Device|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
79733436|NCT02821312|Drug|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
79573744|NCT01835028|Other|Echocardiography|Observational Study using Imaging and Biomarkers
79733437|NCT02821312|Drug|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
79868157|NCT00878345|Drug|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
79868158|NCT00878345|Drug|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
79868159|NCT00433017|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of the infusion.
79868160|NCT00433017|Drug|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
80027629|NCT02246829|Procedure|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
80027630|NCT02183532|Drug|BI 1356 BS|single dose
80027631|NCT02183532|Drug|BI 1356 BS|multiple doses
80027632|NCT03569787|Diagnostic Test|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
80027633|NCT04741477|Drug|CBD|CBD will be topically applied
79402434|NCT04197661|Drug|HSK3486|Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
79402435|NCT04197661|Drug|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
79868161|NCT00433017|Drug|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
79868162|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLE494
79573745|NCT01835028|Other|Computed tomography|Observational Study using Imaging and Biomarkers
79573746|NCT01835028|Other|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
79573747|NCT01835028|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
79573748|NCT01835028|Other|Stress echocardiography|Observational Study using Imaging and Biomarkers
79868163|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLF497
79868164|NCT01035411|Drug|AZD9668|2 x 30 mg tablet variant 1
79868165|NCT03726671|Other|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
79868166|NCT03726671|Other|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
79868167|NCT03726671|Other|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
79868168|NCT01030029|Device|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point [2]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
79402436|NCT04197661|Drug|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
79573749|NCT01835054|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
79573750|NCT01835054|Genetic|DNA collection|Observational Study using Imaging and Biomarkers
79573751|NCT01835054|Other|Echocardiography|Observational Study using Imaging and Biomarkers
79573752|NCT01835054|Other|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
79733438|NCT02821078|Other|4D flow imaging sequence|4D flow imaging sequence
79733439|NCT04240132|Other|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
79733440|NCT02821156|Drug||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
79733441|NCT02821234|Other|MRI|
79733442|NCT02820922|Procedure|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
79733443|NCT02822638|Other|STEMI PATIENT Cohort|PCI
79733444|NCT00633958|Drug|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
79733445|NCT00633958|Radiation|PET Imaging|
79868169|NCT01030029|Device|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
79868170|NCT00868127|Drug|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
80027634|NCT04741477|Drug|THC|THC will be topically applied
79402437|NCT04065984|Device|Microstim 2v2 Stimulator|Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
79573753|NCT01835054|Other|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
79573754|NCT01835054|Other|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
79573755|NCT01835054|Other|Holter ECG|Observational Study using Imaging and Biomarkers
79573756|NCT01835197|Drug|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
79573757|NCT01835197|Drug|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
79573758|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
79573759|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
79573760|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
79733446|NCT02820688|Drug|Bupivacaine 0.25%|
79733447|NCT02820688|Drug|Prilocaine 1%|
79733448|NCT02820688|Procedure|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
79733449|NCT02820688|Drug|Bupivacaine 0.167%|
79733450|NCT02820688|Drug|Bupivacaine 0.125%|
79733451|NCT02820688|Drug|Prilocaine 0.66%|
79733452|NCT02820688|Drug|Prilocaine 0.5%|
79733453|NCT02820688|Device|Ultrasound|All nerve blocks will be performed with ultrasound guidance
79733454|NCT02818816|Drug|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
80027635|NCT04741477|Drug|Placebo|a placebo product (without cannabinoids) will be topically applied
80027636|NCT03569709|Behavioral|Aerobic Exercise|Progressive sub-threshold aerobic exercise
80027637|NCT03569709|Behavioral|Rest|No structured exercise.
79573761|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
79573762|NCT01835197|Drug|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
79573763|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
79573764|NCT01835197|Drug|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
79733455|NCT02818816|Other|Carboxymethylcellulose Eye Drops|Ocular lubricants
79573765|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
79733456|NCT02820610|Drug|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
79573766|NCT01835418|Drug|Amlodipine|crossover comparison of amlodipine vs lisinopril
79573767|NCT01835444|Other|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
79733457|NCT02820610|Drug|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
79573768|NCT01835678|Drug|Linagliptin|orally 5 mg/d for 4 weeks
79573769|NCT01835678|Drug|Placebo|orally once a day for 4 weeks
79573770|NCT01835808|Device|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
79573771|NCT01836237|Device|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
79573772|NCT01836354|Behavioral|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
79733458|NCT02820610|Drug|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
79733459|NCT04751266|Procedure|minimally invasive repair of pectus excavatum|substernal insertion of a metal bar
79868171|NCT00868127|Drug|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
79573773|NCT01836614|Drug|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
79868172|NCT00868205|Dietary Supplement|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
80027638|NCT03569709|Behavioral|Stretching|Gentle progressive upper and lower extremity stretching program
80027639|NCT03696823|Procedure|laparoscopic cholecystectomy|treatment of chronic calcular cholecystitis laparoscopically
80027640|NCT03569631|Drug|BPN14770|25 mg BPN14770 capsules
80027641|NCT03569631|Drug|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
80027642|NCT03696745|Other|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
79573774|NCT01836939|Drug|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
79573775|NCT01836939|Drug|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
79733460|NCT02820532|Device|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
79868173|NCT00878423|Drug|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
80027643|NCT03696745|Drug|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
79573776|NCT01837134|Device|telemedical (TM) group|telemedical devices (weighing machine and step counter)
79573777|NCT01837134|Behavioral|telemedical coaching (TMC) group|care calls once per week for 12 weeks
79573778|NCT01837251|Drug|Carboplatin|
79573779|NCT01837251|Drug|PLD|
79573780|NCT01837251|Biological|Bevacizumab|
79573781|NCT01837264|Device|Magellan®|
79733461|NCT04745728|Drug|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
79733462|NCT04745728|Drug|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
79733463|NCT04745728|Drug|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count>5/ul.
79733464|NCT02818660|Drug|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
79733465|NCT05659186|Drug|Tislelizumab|200mg IV Q3W
79733466|NCT05659186|Drug|Anlotinib|12mg PO QD
79733467|NCT05659186|Radiation|Radiotherapy|Multimodal Radiotherapy
79733468|NCT01107444|Drug|Docetaxel|Administered intravenously
79733469|NCT01107444|Drug|LY2181308|Administered intravenously
79573782|NCT01837290|Drug|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
79733470|NCT04238806|Drug|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
79733471|NCT02820454|Drug|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
79868174|NCT00878423|Drug|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
79868175|NCT05202197|Other|Smart cupboard|Development of a memory task with the help of a smart cupboard
79868176|NCT05200949|Procedure|Kidney transplant|Transplant surgery of Kidney
79868177|NCT05195879|Diagnostic Test|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
79868178|NCT00868361|Drug|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
79573783|NCT01837290|Drug|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
79733472|NCT02820454|Radiation|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
79733473|NCT05659108|Behavioral|CPR|HIGH QUALITY CPR
79733474|NCT02878824|Other|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek & Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr & Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
79733475|NCT02878824|Other|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray & Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
79733476|NCT04627558|Other|stroke patients, balance assessment|validity relability dubousset functional test
79868179|NCT04039373|Drug|BMS-986256|specified dose on specified days
79573784|NCT01837290|Drug|saline infusion|Saline infusion to facilitate blinding
79573785|NCT01837290|Drug|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
79733477|NCT02820376|Other|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
79733478|NCT00876187|Biological|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
79868180|NCT04039373|Drug|Mycophenolate Mofetil|specified dose on specified days
79868181|NCT00875537|Other|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
79868182|NCT00875537|Other|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
79868183|NCT00875693|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
79868184|NCT00878579|Device|PDS System|Percutaneous Dynamic Stabilization System
79573786|NCT01837433|Drug|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
79868185|NCT00878579|Device|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
79868186|NCT00875771|Drug|Capecitabine+Irinotecan+Bevacizumab|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
79868187|NCT00875849|Biological|cetuximab|
79868188|NCT00875849|Drug|cisplatin|
79868189|NCT00875849|Radiation|radiation therapy|
79868190|NCT00868595|Biological|BPX-101|Vaccine
79868191|NCT00868595|Drug|AP1903|Activating agent, infusion
79868192|NCT00875927|Other|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
79573787|NCT01837433|Drug|Prednisone 6 weeks|Guidelines recommend
79573788|NCT01837446|Drug|2% morphine solution|
79573789|NCT01837446|Drug|Magnesium aluminum hydroxide|
79573790|NCT01837446|Drug|2% viscous lidocaine|
79573791|NCT01837446|Drug|Diphenhydramine|
79868193|NCT00875927|Other|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
79868194|NCT00875927|Other|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
79868195|NCT00875927|Other|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
79868196|NCT00875927|Other|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
79868197|NCT00878657|Drug|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
79733479|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
79868198|NCT00878657|Radiation|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
79868199|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
79868200|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
79868201|NCT00868673|Dietary Supplement|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
79868202|NCT00868673|Dietary Supplement|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
79270914|NCT04573387|Procedure|Exhaustive drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. If the computed tomography (CT) scan on the first day after surgery indicates that the affected brain region shows sufficient re-expansion, the drainage catheter will be removed when drainage ceases. If subdural collections remain in the hematoma cavity, the participant will be treated with 30,000 U urokinase injection into the hematoma cavity through the catheter. The catheter will be closed and reopened in 1.5-2 hours, and a CT scan will be performed when drainage ceases. If the CT scan shows sufficient re-expansion of the brain, the catheter will be removed. However, if the brain does not show good re-expansion and there is still a residual subdural collection, the above steps will be repeated. If the participant is subjected to urokinase injection for 3 times, the catheter will be removed when drainage ceases.
79868203|NCT00879593|Device|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
79868204|NCT00879671|Dietary Supplement|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
80027644|NCT03568227|Procedure|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
79573792|NCT01837472|Drug|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
79573793|NCT01837472|Drug|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
79573794|NCT01838057|Device|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
79573795|NCT01838057|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
79733480|NCT00876187|Biological|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
79868205|NCT00879671|Dietary Supplement|placebo|Placebo capsules identical in taste and appearance
79733481|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
79733482|NCT00876187|Biological|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
79868206|NCT00868829|Device|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
79868207|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
79868208|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
79868209|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
79270915|NCT04573387|Procedure|Postoperative computed tomography|All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
79733483|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
79733484|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
79733485|NCT00876187|Drug|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
79733486|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
79733487|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
79868210|NCT00868985|Drug|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
79868211|NCT00868985|Drug|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
80027645|NCT03568227|Procedure|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
80027646|NCT03700957|Dietary Supplement|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
80027647|NCT03700957|Other|placebo|placebo
79270916|NCT04567914|Diagnostic Test|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
79270917|NCT04542382|Drug|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
79270918|NCT04542382|Drug|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
79270919|NCT04542382|Drug|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
79573796|NCT01838135|Device|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
79573797|NCT01838278|Behavioral|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
79573798|NCT01838564|Other|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
79573799|NCT01838564|Other|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
79573800|NCT01838733|Other|Observational study|
79573801|NCT01838850|Drug|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
79573802|NCT01838850|Drug|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
79573803|NCT01839201|Other|control|No psychological intervention
79573804|NCT01839201|Other|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
79868212|NCT00869063|Drug|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
80027648|NCT03565419|Device|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
79270920|NCT04531956|Other|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
79868213|NCT00869063|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
79270921|NCT04529070|Behavioral|Nightmare Rescripting and Rehearsal|This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.
79270922|NCT04529070|Behavioral|standard of care|standard of care
79868214|NCT00869219|Drug|Nevanac|1 drop of NEVANAC at random eye
79868215|NCT00869219|Drug|Acular LS|One drop of Acular LS
79868216|NCT00878735|Behavioral|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
79868217|NCT00878813|Procedure|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
79868218|NCT00878813|Procedure|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
79868219|NCT00878891|Device|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
79868220|NCT00418665|Biological|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
79868221|NCT00418665|Drug|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
79733488|NCT04238884|Drug|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
79868222|NCT03994965|Drug|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
79868223|NCT04648059|Diagnostic Test|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
79573805|NCT01839201|Other|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
80027649|NCT03568149|Procedure|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
79573806|NCT01839227|Other|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
79573807|NCT01839305|Other|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
79573808|NCT01839344|Dietary Supplement|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
79573809|NCT01839344|Drug|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
79573810|NCT01839344|Drug|placebo|An oral single dose of a solid, colored empty capsule.
79573811|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~4% trisodium citrate solution~Calcium chloride solution (100 mmol/L)~Dialysate flow rate: 35 ml/kg/h~Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~Blood flow adapted to the acid-base status"
79733489|NCT04238884|Drug|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
79733490|NCT01102374|Drug|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
79868224|NCT01952067|Procedure|line-to-line reaming and cementing technique|
79868225|NCT01952067|Procedure|standard over-reaming with 2 broach sizes|
79270923|NCT04528693|Behavioral|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
79733491|NCT01102374|Drug|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
79733492|NCT01102374|Drug|Placebo|Placebo monthly
79733493|NCT01102374|Dietary Supplement|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
79733494|NCT05658640|Drug|Trametinib|Oral
79733495|NCT05658640|Drug|Dexamethasone|Oral/ Intravenous
79868226|NCT00432237|Drug|MK0974 50 mg|
79868227|NCT00432237|Drug|MK0974 150 mg|
79868228|NCT00432237|Drug|MK0974 300 mg|
79868229|NCT00432237|Drug|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
79868230|NCT00531284|Drug|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
79868231|NCT00531284|Drug|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
79868232|NCT01005446|Device|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
79868233|NCT00531206|Drug|Tipranavir|
79868234|NCT00531206|Drug|Ritonavir|low dose
79868235|NCT00994994|Drug|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
79868236|NCT04000022|Device|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
79868237|NCT00999674|Other|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
79868238|NCT00999752|Drug|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure <140/90
79733496|NCT05658640|Drug|Cyclophosphamide|Intravenous
79573812|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~Standard dialysate for CRRT : Prismasol® K2 solution~Dialysate flow rate: 35 ml/kg/h~Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
79573813|NCT01839669|Device|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
79868239|NCT00999752|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
79868240|NCT00530816|Drug|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
79733497|NCT05658640|Drug|Cytarabine|Intravenous
79733498|NCT05658640|Drug|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
79868241|NCT01005758|Drug|cyclophosphamide|
79868242|NCT01005758|Drug|cytarabine|
79573814|NCT01839669|Procedure|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
79573815|NCT01839669|Device|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
79573816|NCT01839994|Radiation|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
80027650|NCT03568149|Procedure|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~Ovarian vein diameter <4mm~Slow ovarian blood flow (<3cm/sec)~Retrograde blood flow~Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~Standard 2D study, to measure vessels diameter~Vascular doppler study, to evaluate flow direction and blood speed~3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
80027651|NCT03700879|Radiation|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
79573817|NCT01839994|Radiation|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
79573818|NCT01839994|Drug|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
79733499|NCT04238572|Device|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
79733500|NCT04238572|Device|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
79733501|NCT02880696|Behavioral|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
79733502|NCT02880696|Behavioral|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
79733503|NCT02880696|Device|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
79733504|NCT04693702|Device|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
79868243|NCT01005758|Drug|dexamethasone|
79868244|NCT01005758|Drug|doxorubicin hydrochloride|
79868245|NCT01005758|Drug|etoposide phosphate|
79868246|NCT01005758|Drug|hydrocortisone sodium succinate|
79868247|NCT01005758|Drug|imatinib mesylate|
79868248|NCT01005758|Drug|mercaptopurine|
79868249|NCT01005758|Drug|methotrexate|
79868250|NCT01005758|Drug|methylprednisolone|
79868251|NCT01005758|Drug|pegaspargase|
79868252|NCT01005758|Drug|prednisolone|
79868253|NCT01005758|Drug|prednisone|
79868254|NCT01005758|Drug|vincristine sulfate|
79868255|NCT01005758|Other|laboratory biomarker analysis|
79868256|NCT01005758|Radiation|radiation therapy|
79868257|NCT01005836|Behavioral|Cognitive behavioral therapy for youth anxiety|
79868258|NCT01005836|Other|Usual clinic care|
79868259|NCT01005836|Behavioral|Cognitive behavioral treatment for youth depression|
79868260|NCT01005992|Procedure|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
79868261|NCT01005992|Procedure|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
79573819|NCT01840020|Procedure|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
79868262|NCT01008800|Behavioral|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey & Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
79270926|NCT04527185|Drug|Endotoxin|Endotoxin 0.4ng/kg i.v.
79402438|NCT04197895|Procedure|Socket preservation with APRF|Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes
79573820|NCT01840020|Procedure|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
79573821|NCT01840033|Device|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
79573822|NCT01840033|Device|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
79733505|NCT02818504|Other|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
79733506|NCT02818270|Drug|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
79733507|NCT02818270|Drug|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
79733508|NCT02879760|Biological|Ad-MAGEA3|Intramuscular injection
79733509|NCT02879760|Biological|MG1-MAGEA3|Intravenous infusion
79868263|NCT01008800|Behavioral|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy & Grusec, 2001).
79270927|NCT04507074|Device|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
79733510|NCT02879760|Biological|Pembrolizumab|Intravenous infusion
79733511|NCT02818348|Drug|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
79733512|NCT02818348|Drug|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
79733513|NCT04308876|Other|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
79270928|NCT04504500|Behavioral|HSOG guidelines application|In their practice, as regards the mode of delivery, obstetricians are encouraged to conform to the three guidelines and two consent forms published by the Hellenic Society of Obstetrics and Gynecology (HSOG). The members of the appointed Steering Committee and/or local opinion leaders will discuss and disseminate these guidelines among the professional staff in the respective maternity units, providing them with the opportunity to identify specific barriers, overcome them, and develop an implementation timetable.
79402439|NCT04197895|Procedure|natural healing|after atraumatic extraction , the socket will be left for natural healing after suturing
79573823|NCT01840059|Device|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
79733514|NCT04308876|Other|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
79733515|NCT00634192|Drug|tobramycin|1x300mg/d inhaled
79733516|NCT00634192|Drug|tobramycin|2x300mg/d inhaled
79733517|NCT02626897|Device|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
79733518|NCT02626897|Device|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
79868264|NCT01006070|Procedure|kyphoplasty|surgical kyphoplasty
79868265|NCT05092802|Drug|HLX208|450mg bid po
79868266|NCT00615017|Drug|AZD9773 (CytoFab)|intravenous infusions
79573824|NCT01840085|Drug|0.03% DSC127 topical gel|
79573825|NCT01840098|Dietary Supplement|low leucine content drink|
79868267|NCT00615017|Other|Placebo|Placebo
79573826|NCT01840098|Dietary Supplement|high leucine content drink|
80027652|NCT03568071|Drug|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
80027653|NCT03568071|Drug|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
79270929|NCT04504500|Behavioral|Interactive workshops and courses|The workshops and courses will give instruction in indications for cesarean section and clinical scenarios, physiology-based cardiotocography (CTG) interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of the labor ward, as well as launching of regular cesarean section and CTG meetings with review of the patient notes. The workshops will last four days and will be conducted by experienced trainers. The expectation is that the obstetricians will gain very considerable knowledge and skills, which will enable them to subsequently follow these practices safely and competently.
79573827|NCT01840098|Dietary Supplement|low leucine + HMB drink|
79573828|NCT01840098|Dietary Supplement|Control/carbohydrate|
79573829|NCT01840098|Behavioral|36 hour fasting|
79733519|NCT02879214|Radiation|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
79733520|NCT04238182|Other|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
79733521|NCT04238182|Other|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
79270930|NCT04504500|Behavioral|Feedback through follow-up meetings|Regular follow-up meetings with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Feedback with positive phrasing will be incorporated to meet local needs.
79868268|NCT05236244|Other|İntervention group|Diaphragmatic Breathing Exercises
79868269|NCT01006148|Biological|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
79868270|NCT01008878|Behavioral|interdisciplinary intervention|
79270931|NCT04504500|Behavioral|Robson criteria usage|Obstetricians are set to a routine to enable them to use the Robson 10-group classification criteria for cesarean sections and obtain feedback on the unit's cesarean section rates monthly. They thus know which category is higher and can be reduced further.
79573830|NCT01840111|Behavioral|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
79573831|NCT01840111|Behavioral|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
79573832|NCT01840124|Procedure|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
79573833|NCT01840137|Other|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
79573834|NCT01840137|Other|Exercise|Treadmill and muscle exercises.
79573835|NCT01840176|Procedure|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
79573836|NCT01840189|Other|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
79868271|NCT01006226|Drug|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
80027654|NCT02629822|Drug|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
80027655|NCT02247297|Procedure|Blood collection|Diagnostic blood collection
79733522|NCT02627755|Device|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
79733523|NCT02627755|Device|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
79868272|NCT00879047|Drug|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
79868273|NCT00879047|Drug|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
79270932|NCT04504500|Behavioral|Access to live real-time statistics|Live real-time statistics provided by an online platform, on a regular basis, is expected to improve adherence, through regular feedback. Each unit will see other units' statistics by means of an anonymous reporting system. This repetition will create silent signals that will remind the participating obstetricians to remain on task.
80027656|NCT04433104|Biological|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
80027657|NCT04433104|Drug|drug therapy according to Vietnamese MOHS procedure|Salbutamol, Terbutaline
80027658|NCT03565341|Device|PiQo4|PiQo4 Laser System for treatment of Melasma
80027659|NCT03700801|Drug|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
80027660|NCT03700801|Drug|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
79573837|NCT01840189|Other|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
79573838|NCT01840241|Drug|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
79573839|NCT01840241|Drug|normal saline|
79573840|NCT01840254|Drug|dexmedetomidine|
79733524|NCT02817724|Device|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
79733525|NCT02817724|Other|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
79733526|NCT00681421|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
79733527|NCT00684463|Drug|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
80027661|NCT03696667|Device|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
80027662|NCT03700723|Biological|Resusix|spray-dried solvent/detergent treated plasma (blood product)
80027663|NCT03700723|Biological|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
80027664|NCT03696511|Device|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
79868274|NCT01008956|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
79868275|NCT01006304|Drug|JNJ-39439335, Placebo|
80027665|NCT03700645|Drug|Allopurinol|Allopurinol
80027666|NCT03569319|Behavioral|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
79270933|NCT04504500|Behavioral|Attendance of local cesarean section meetings|Local cesarean section meetings will be held weekly, in each unit. The members of the steering committee or local opinion leaders may actively participate in these meetings. Local obstetricians learn to judiciously adapt standard medical practices, thereby avoiding unnecessary medical interventions. This is a way to further enhance compliance, as during the discussions the behavior expected of the obstetricians is clearly stated by the participating opinion leaders.
79270934|NCT04504500|Behavioral|Attendance of local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit, during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings. Obstetricians are encouraged to reflect on their medical practice through judicious physiology-based CTG interpretation."
79573841|NCT01840254|Drug|normal saline|
79573842|NCT01840267|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
79573843|NCT01840332|Drug|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is < 30 after 4 weeks the study continues up to 6 weeks.
79573844|NCT01840358|Other|Observation of hypoglycemias frequency 3 days before and after pump initiation|
79573845|NCT01840371|Drug|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~IV bolus of 1 mg/kg for sedation induction,~Infusion of 60 mcg/min/kg for maintenance of sedation~Additional bolus dose of 10mg as needed for adequate sedation"
79868276|NCT03742700|Behavioral|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
79868277|NCT03742700|Behavioral|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
79733528|NCT02817490|Other|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
79733529|NCT02817568|Other|Drawing Blood|Drawing Blood for genetic analysis
79733530|NCT00678457|Drug|Ondansetron|ondansetron (4 μg/kg b.i.d.)
79733531|NCT00678457|Drug|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
79733532|NCT00678457|Drug|Placebo|placebo
79733533|NCT02817646|Other|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
79733534|NCT02817646|Dietary Supplement|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
79573846|NCT01840371|Drug|Experimental sedation|"Fentanyl~IV bolus of 1 µg/kg for sedation induction~Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~IV bolus of 0.4 mg/kg for sedation induction~Infusion of 30 µg/min/kg for maintenance of sedation~Additional bolus dose of 10mg as needed for adequate depth of sedation"
79733535|NCT00678613|Drug|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
79733536|NCT00678613|Drug|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
79733537|NCT02817334|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
79733538|NCT02626429|Dietary Supplement|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
79573847|NCT01840384|Dietary Supplement|Multi-micronutrients|
80027667|NCT03569319|Behavioral|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
79573848|NCT01840384|Dietary Supplement|Maltodextrin and Lactose|
79868278|NCT03742700|Behavioral|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
79868279|NCT00879749|Biological|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
79868280|NCT00879749|Biological|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
79868281|NCT00879749|Biological|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
79868282|NCT00879749|Biological|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
79868283|NCT00879749|Biological|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
79868284|NCT00879749|Other|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
79868285|NCT00869297|Other|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
79868286|NCT00869297|Other|Control|Fluids titrated at discretion of anesthesiologist.
79733539|NCT02817412|Behavioral|Go/No-Training|
79733540|NCT02817412|Behavioral|Stop-Signal Training|
79733541|NCT02817412|Behavioral|Dot-Probe Paradigm|
79733542|NCT02817412|Behavioral|Generic Response Training|
79733543|NCT04579432|Other|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
79733544|NCT00678769|Drug|Cixutumumab|Given IV
79733545|NCT00678769|Other|Laboratory Biomarker Analysis|Correlative studies
79868287|NCT00999986|Drug|cyclophosphamide|50 mg oral per day for 7 days
79868288|NCT05226611|Other|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
79868289|NCT05178758|Device|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
80027668|NCT03569319|Behavioral|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
79573849|NCT01840423|Drug|ODM-104|ODM-104
79573850|NCT01840423|Drug|Placebo|Placebo
79573851|NCT01840423|Drug|Entacapone|entacapone + levodopa/carbidopa
79573852|NCT01840423|Drug|levodopa/carbidopa|entacapone + levodopa/carbidopa
79573853|NCT01840436|Device|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
79573854|NCT01840436|Device|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
79573855|NCT01840449|Drug|Somatuline Autogel® 60, 90 or 120 mg|
79573856|NCT01840488|Drug|Irosustat (BN83495)|"Three parts (A, B & C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
79868290|NCT01009112|Behavioral|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
79868291|NCT01009112|Behavioral|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
79733546|NCT00678769|Other|Pharmacological Study|Correlative studies
79868292|NCT01000142|Procedure|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
80027669|NCT03567915|Other|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
79270935|NCT04504500|Behavioral|Reminders of proper clinical practice|Effective and reliable reminders concerning optimal obstetric practice will be placed in labor wards, staff rooms, patient notes, vaginal birth packages and above theater hand washers. There will be short messages with positive phrasing regarding the benefits of vaginal birth, thus reminding birth attendants to reduce unnecessary cesarean sections. Relevant SMS (short message service) will be sent to the participating obstetricians' mobiles on a regular basis, so as to motivate them via non-verbal signals.
79573857|NCT01840501|Drug|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
79573858|NCT01840501|Drug|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
79573859|NCT01840501|Drug|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
79573860|NCT01840501|Drug|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
79573861|NCT01840540|Drug|Arterial infusion of autologous mesenchymal stem cells|
79573862|NCT01840553|Drug|oral sodium phosphate tablets|
79573863|NCT01840553|Drug|polyethylene glycol|
79573864|NCT01840618|Device|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
79573865|NCT01840631|Behavioral|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
79573866|NCT01840644|Other|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
79573867|NCT01840670|Drug|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
79573868|NCT01840683|Device|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
79573869|NCT01840696|Drug|Regadenoson|Vasodilator stress testing
79573870|NCT01840709|Behavioral|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
79733547|NCT00678769|Drug|Temsirolimus|Given IV
79733548|NCT02817022|Other|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
79733549|NCT04146883|Drug|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
79868293|NCT01000142|Procedure|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
79868294|NCT01000220|Drug|Omeprazole|
79868295|NCT01000220|Drug|Placebo|
79868296|NCT01006460|Drug|Rhodiola rosea, L|3 Capsules twice a day
79868297|NCT01006460|Drug|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
79868298|NCT01006460|Drug|Panax ginseng|3 capsules twice a day
79868299|NCT01006460|Drug|Placebo - dark brown sugar|3 capsules twice a day
80027670|NCT03624673|Procedure|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
80027671|NCT03624673|Procedure|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
79573871|NCT01840735|Drug|GS-5737|
79573872|NCT01840735|Drug|Placebo|
79573873|NCT01840761|Drug|herbal drug|
79573874|NCT01840761|Drug|placebo|
79573875|NCT01840774|Drug|Low-dose pain medication (Ketalar) and saline placebo|
79573876|NCT01840787|Device|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
79733550|NCT02817256|Dietary Supplement|Vitamins and Minerals|Multivitamins and Minerals supplementation
79733551|NCT00681577|Biological|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
80027672|NCT03064360|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
79868300|NCT01006694|Other|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
79270936|NCT04504500|Other|HSOG guidelines implementation|There will be application in daily practice of three guidelines and two consent forms pertaining to the mode of delivery published by HSOG. Obstetricians are informed on evidence-based medicine in obstetrics and provided with a structured and safe approach to labor management. The members of the appointed Steering Committee and/or local opinion leaders discuss and disseminate the guidelines among the professional staff at the respective maternity units, answer questions, and make available their knowledge and experience. Adoption of guidelines by the participating unit helps to establish clear, consistent rules that are direct and simple, and obstetricians are asked to embrace fully justified medical practice.
79270937|NCT04504500|Other|Interactive workshops and courses training|The workshops and courses will provide instruction in indications for cesarean section and case scenarios, physiology-based CTG interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of labor ward and launching of cesarean section and CTG meetings. This type of formal training provides problem-solving strategies, using mnemonics, that are critical in emergencies and that also aid in learning and retaining the skills being taught. Functional and social skills that directly affect decision-making and effectiveness are addressed. Thus, units adopt a continuous educational procedure for their staff, enhancing their confidence when dealing with labor emergencies and redesigning labor management plans, so as to ensure high-level obstetric services.
79573877|NCT01840787|Device|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
79573878|NCT01840787|Device|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
79733552|NCT02817100|Drug|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
79733553|NCT02817100|Drug|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food [Continental breakfast])
79573879|NCT01840800|Drug|Ropivacaine|
79868301|NCT01006694|Drug|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
79733554|NCT02817100|Drug|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
80027673|NCT03064360|Device|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
80027674|NCT03064360|Behavioral|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
80027675|NCT03565185|Other|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
79573880|NCT01840800|Drug|placebo|
79573881|NCT01840813|Drug|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
79573882|NCT01840813|Drug|Normal saline|It is a placebo group
79733555|NCT00684697|Dietary Supplement|iron|High, intermediate and low iron dosage orally for 2 months
79573883|NCT01840826|Other|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
79573884|NCT01840839|Device|brain stimulation|
79573885|NCT01840839|Device|Sham Stimulation|
79868302|NCT01006772|Other|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
80027676|NCT03565185|Other|placebo|Investigators will use only conventional treatment without robot-assisted gait training
80027677|NCT03703531|Procedure|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
80027678|NCT03564951|Procedure|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
80027679|NCT03564951|Procedure|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
79573886|NCT01840865|Device|brain stimulation|oscillating direct current brain stimulation
79573887|NCT01840865|Device|no stimulation|sham Stimulation
79573888|NCT01840891|Behavioral|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
79573889|NCT01840982|Dietary Supplement|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
79733556|NCT02816944|Procedure|EUS-guided laser ablation for refractory neoplasms|
79733557|NCT00678847|Device|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
80027680|NCT04499053|Drug|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
80027681|NCT04499053|Drug|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
80027682|NCT05353413|Device|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
80027683|NCT05353413|Diagnostic Test|VEP - visual evoked potential|Electrophysiology of the visual pathway.
80027684|NCT05353413|Diagnostic Test|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
80027685|NCT03567681|Drug|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
79270938|NCT04504500|Other|Implementation of Robson criteria classification|Use will be implemented of an online application embedded in the REDCap electronic database questionnaire with Robson 10-group classification criteria and feedback on the unit's cesarean section rates monthly, so as to know which category is higher and can be reduced further. This change in the unit's practice will introduce a new medical reporting and audit system that can detect unjustified medical procedures much more easily.
79868303|NCT04000100|Procedure|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
79868304|NCT01000298|Drug|Placebo|liquid placebo medication given twice per day for 7 days
79868305|NCT01000298|Drug|Amoxicillin|liquid amoxicillin given twice per day for 7 days
79270939|NCT04504500|Other|Live real-time statistics online platform|Live real-time statistics provided on a regular basis by an online platform will provide feedback and essential information. Each unit will see other units' statistics using an anonymous reporting system. This information can trigger self-generative learning strategies and help obstetricians to become more effective learners.
79270940|NCT04504500|Other|Local cesarean section meetings|Local cesarean section meetings will be held weekly in each unit. The members of the Steering Committee or local opinion leaders may actively participate in these meetings. The unit's staff can hear about both justified and unnecessary surgical procedures and draw informed conclusions as to the optimal procedure in similar cases. They will also have the opportunity to actively participate in an elaborative problem-solving discussion. These meetings when routinely conducted, provide feedback and audit resources to help improve performance and further enhance compliance.
79573890|NCT01840982|Dietary Supplement|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
79573891|NCT01840982|Dietary Supplement|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
79573892|NCT01840982|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
79733558|NCT00678847|Device|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
79573893|NCT01840995|Procedure|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
79733559|NCT02816866|Other|empowered primary care model|mode of survivorship care
79733560|NCT02816866|Other|specialty survivor clinic|mode of survivorship care
79573894|NCT01841008|Drug|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
79573895|NCT01841008|Drug|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
79733561|NCT00684853|Drug|bevacizumab|1.25 mg of bevacizumab intravitreal
79733562|NCT00684853|Drug|vetaporfin|full fluence of vetaporfin
79868306|NCT01000298|Drug|Cefdinir|liquid cefdinir given twice per day for 7 days
79868307|NCT00614939|Drug|Saxagliptin|2.5 mg once daily oral dose
79868308|NCT00614939|Drug|Placebo|Placebo
79868309|NCT01009268|Procedure|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
79733563|NCT02816554|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
79733564|NCT02816554|Biological|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
79868310|NCT01006928|Other|Questionaire|Questionaire to mothers
79733565|NCT02816554|Biological|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
79868311|NCT00869453|Other|test meal|Mixed meal containing bread, butter, beef
79868312|NCT00869453|Other|glucose|administration of a glucose meal
79868313|NCT00869453|Other|fat|administration of a lipid meal
79868314|NCT00869453|Other|protein|administration of a protein meal
79733566|NCT02816554|Biological|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
79733567|NCT02816476|Drug|Daratumumab|
79733568|NCT00678925|Dietary Supplement|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
79733569|NCT00678925|Dietary Supplement|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
79733570|NCT00875485|Procedure|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
79868315|NCT00869453|Other|control|no meal
79733571|NCT00875485|Biological|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
79733572|NCT04572802|Procedure|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
79573896|NCT01841034|Drug|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
79573897|NCT01841086|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
79733573|NCT04237870|Device|Active cTBS|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
79733574|NCT04237870|Device|Sham|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
79868316|NCT01007006|Device|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
79868317|NCT00879827|Biological|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
79868318|NCT00879827|Biological|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
79868319|NCT01007084|Drug|Propranolol|40 mg
79868320|NCT01007084|Drug|Propranolol ER|120 mg twice per day
79868321|NCT01007084|Drug|Sugar pills|sugar pill
79868322|NCT01000532|Device|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
79868323|NCT01000532|Device|Pacemaker therapy|Pacemaker therapy
79868324|NCT01000532|Device|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
79868325|NCT00879281|Behavioral|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
79868326|NCT04040309|Biological|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
79573898|NCT01841086|Drug|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
79733575|NCT00684931|Other|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
79868327|NCT04040309|Drug|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
79868328|NCT00869531|Other|wholegrain|wholegrain wheat vs. refined wheat products
79868329|NCT00869531|Other|refined wheat|refined wheat products
79868330|NCT01000688|Drug|vildagliptin + acarbose|4 week treatment
80027686|NCT03462706|Procedure|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
79573899|NCT01841099|Drug|Mesalamine|Mesalamine granules
79573900|NCT01841099|Drug|Placebo granules|Provided by Ferring Pharma
79573901|NCT01841112|Drug|BI 409306|tablet
79573902|NCT01841112|Drug|BI 409306|tablet
79573903|NCT01841112|Drug|BI 409306|tablet
79868331|NCT01000688|Drug|acarbose + vildagliptin|4 week treatment
79573904|NCT01841112|Drug|BI 409306|tablet
79573905|NCT01841112|Drug|placebo|placebo tablet
79573906|NCT01841112|Drug|placebo|placebo tablet
79573907|NCT01841112|Drug|BI 409306|tablet
79733576|NCT04238104|Other|no intervention|it's only observational study. No interventions.
79868332|NCT00879905|Drug|HSP990|
79868333|NCT01007240|Device|polyethylenimine (PEI) nanoparticles.|
79868334|NCT00879983|Drug|azithromycin (Zithromax)|"a single dose of azithromycin ER 2g~3-day regimen of azithromycin tablet 500mg"
79868335|NCT00879983|Drug|azithromycin (Zithromax)|"3-day regimen of azithromycin tablet 500mg~a single dose of azithromycin ER 2g"
79868336|NCT01007318|Procedure|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
79868337|NCT01007318|Procedure|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
79868338|NCT00880061|Drug|IL13-PE38QQR|
79868339|NCT00869687|Device|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
79868340|NCT00869765|Drug|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
79868341|NCT00869765|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
79868342|NCT00530504|Device|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
79868343|NCT00869843|Procedure|RF Ablation|
79733577|NCT04147117|Device|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
79868344|NCT00880139|Procedure|Blood sampling|Determination of cytokine plasma levels (ELISA)
79733578|NCT00679003|Behavioral|SLCBT|Social learning and cognitive behavioral therapy
79868345|NCT00880139|Procedure|Noninvasive measurement of systemic hemodynamics|performed once
79868346|NCT00880139|Procedure|Visual acuity assessment|ETDRS charts
79270941|NCT04504500|Other|Local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings offering coaching and counseling services in decision-making. Through elaborative discussion the staff will improve their knowledge and skills in correct CTG interpretation, thus preventing unnecessary interventions, such as cesarean sections."
79270942|NCT04504500|Other|Follow-up meetings|Regular follow-up meetings of the participating obstetricians with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Establishment of commonly accepted practice augments the homogeneity of clinical action plans and team work in the unit.
79270943|NCT04475250|Device|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
79270944|NCT04474808|Other|L-Arginin containing foot cream|The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
79270945|NCT04474808|Other|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
79270946|NCT04465487|Drug|REGN6569|Administered by intravenous (IV) infusion
79270947|NCT04465487|Drug|Cemiplimab|Administered by IV infusion
79270948|NCT04464876|Device|SATURN TA System|SATURN TA TMVR Device implanted
79573908|NCT01841125|Drug|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
80027687|NCT03462706|Procedure|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
79270949|NCT04462770|Drug|EPX-100 (Clemizole HCl)|Daily dose of EPX100
79573909|NCT01841125|Drug|Placebo|placebo 15mg, QD(once a day), Oral medication
79573910|NCT01841151|Behavioral|SCP training|
79733579|NCT00679003|Behavioral|ES|Education and support (information about nutrition and gastrointestinal system)
79733580|NCT04547140|Biological|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
80027688|NCT03462706|Procedure|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
80027689|NCT03462706|Procedure|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
79733581|NCT04547140|Drug|Placebo|Intravenous infusion
79733582|NCT04547140|Drug|Standard Medical Treatment|SMT
79868347|NCT00880139|Device|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
79868348|NCT00880139|Procedure|Ophthalmic examination and fundus photography|7 + 1 standard fields
80027690|NCT02840253|Device|NIRS|
80027691|NCT03567447|Drug|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
79270950|NCT04462770|Drug|Placebo|Daily dose of Placebo
79270951|NCT04440592|Drug|MT-7117|MT-7117
79270952|NCT04440592|Drug|Placebo|Placebo
79573911|NCT01841151|Behavioral|Live Z-score training|
79573912|NCT01841151|Behavioral|WM training|
79573913|NCT01841164|Drug|Montelukast|
79573914|NCT01841164|Drug|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
79573915|NCT01841164|Other|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
79573916|NCT01841242|Drug|alcoholic povidone iodine|
79573917|NCT01841242|Drug|alcoholic chlorhexidine|
79573918|NCT01841255|Device|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
79573919|NCT01841255|Device|facemask|
79573920|NCT01841294|Drug|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
79573921|NCT01841294|Drug|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
79733583|NCT00679159|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
79733584|NCT00679159|Biological|Prevenar|Streptococcus pneumoniae vaccine
79868349|NCT00880139|Device|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
79868350|NCT00880139|Device|High resolution optical coherence tomography (OCT)|performed once
79868351|NCT03999632|Other|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
79868352|NCT01007474|Device|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
79868353|NCT01007474|Device|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
79868354|NCT01007474|Device|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
80027692|NCT03567447|Other|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
80027693|NCT03567369|Drug|Dexamethasone|Dexamethasone 4,0 mg/mL
80027694|NCT03567369|Drug|Traumeel S|Traummel S 2,2 mg/mL
79270953|NCT04440033|Other|Baseline assessment of demographic, anthropometric and clinical characteristics|"Age~Sex~Height~Body weight~Handedness~Medication use~Blood pressure~Global cognition (Montreal Cognitive Assessment)~Fear of falling (Shortened Iconographical Falls Efficacy Scale)~History of falls (number of falls in the past month)~Time since diagnosis and symptom onset~Disease severity (UPDRS part III, Hoehn and Yahr)~Non-motor symptoms (UPDRS part I)~Motor symptoms (UPDRS part III)~Motor complications (UPDRS part IV)~Disease-dominant side (UPDRS part III)~Freezing of gait (New Freezing of Gait Questionnaire)"
79270954|NCT04440033|Other|Baseline assessment of demographic, anthropometric and clinical characteristics|"Age~Sex~Height~Body weight~Handedness~Medication use~Blood pressure~Global cognition (Montreal Cognitive Assessment)~Fear of falling (Shortened Iconographical Falls Efficacy Scale)~History of falls (number of falls in the past month)"
79270955|NCT04440033|Other|Locomotor assessments|"First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~3 min standing~3 min standing while answering semi-standardized questions~3 min SPTW~3 min SPTW while answering semi-standardized questions (SPTW-Q)~3 min SPTW while verbally describing a VR environment (SPTW-VR1)~6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)"
79573922|NCT01841307|Drug|Cromolyn Sodium|
79573923|NCT01841320|Other|Integrated methadone and antiretroviral therapy (iMART) clinic|
79573924|NCT01841346|Procedure|Procedure: PCI|
79733585|NCT04237714|Behavioral|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
79733586|NCT04146103|Drug|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
79733587|NCT05654038|Biological|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10^6/kg; Dose level two:1-2×10^7/kg; Dose level three:2-5×10^7/kg."
79733588|NCT00685009|Drug|Estrogen hormone therapy|Estrogen pill daily
79733589|NCT00685009|Drug|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
79733590|NCT00685009|Drug|Placebo|Placebo pill daily
79868355|NCT01007474|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
79868356|NCT01007474|Device|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
79868357|NCT00880295|Procedure|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
79733591|NCT02816086|Other|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
79733592|NCT00679237|Behavioral|smoking cessation|NRT and varenicline
79733593|NCT00679237|Drug|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
79733594|NCT00679237|Drug|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
79733595|NCT00679237|Behavioral|training|daily walking
79733596|NCT00679237|Biological|influenza vaccine|vaccine (FLuarix, Influvac etc)
79733597|NCT00679237|Drug|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
79868358|NCT00880295|Procedure|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
79868359|NCT00880373|Drug|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
79868360|NCT00880373|Drug|Placebo|Matching placebo three times daily for 4 days
79868361|NCT00880373|Drug|Diamorphine or Morphine|Diamorphine or Morphine by PCA
79868362|NCT01007630|Drug|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
79868363|NCT01007630|Drug|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
80027695|NCT03397654|Drug|Pembrolizumab|Pembrolizumab solution
79573925|NCT01841372|Other|Second Life|Second Life is an online virtual reality environment.
79573926|NCT01841372|Behavioral|Group Phone Conference Call|
79573927|NCT01841385|Other|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
79573928|NCT01841398|Behavioral|Multimedia Lifestyle Improvement|"Goal setting to improve diet, physical activity or smoking behaviours~Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
79868364|NCT05883384|Other|stool analysis , CBC, specific IgE FOR Cow milk protein allergy|apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
79868365|NCT05883345|Diagnostic Test|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin levels|Endoscopic biopsy
79868366|NCT05883332|Drug|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
79868367|NCT05883332|Other|Oxygen|100% oxygen at 10 Liters/minute
79573929|NCT01841398|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
79868368|NCT05883306|Drug|[14C]LXI-15028|[14C]LXI-15028
79573930|NCT01841411|Drug|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
79868369|NCT05883293|Drug|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
79868370|NCT05883280|Other|Binaural beats|The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
79270956|NCT04440033|Other|Speech assessments|"Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~The Speech Handicap Index (a 15-item self-reported questionnaire)"
79573931|NCT01841411|Drug|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
79573932|NCT01841411|Drug|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
79573933|NCT01841424|Behavioral|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
79573934|NCT01841437|Device|iStent|
79573935|NCT01841450|Device|iStent|Implantation of one iStent in conjunction with cataract surgery
79573936|NCT01841450|Procedure|Cataract surgery|Cataract surgery alone
79573937|NCT01841463|Drug|P1446A-05|- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
79573938|NCT01841463|Drug|Vemurafenib (Zelboraf®)|"In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
79733598|NCT00679237|Behavioral|weight reduction|diet tips
79733599|NCT02816164|Drug|Neupogen|Subcutaneous injections
79733600|NCT02816320|Other|Hospitalization|Patients who were hospitalized in acute care
79733601|NCT00681733|Drug|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
79733602|NCT00681733|Drug|Pioglitazone|30 mg OD
79733603|NCT00681733|Drug|Pentoxifylline|1200 mg/d
79733604|NCT02816008|Behavioral|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
79733605|NCT02816008|Behavioral|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
79733606|NCT04151329|Biological|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
80027696|NCT03397654|Combination Product|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
79270957|NCT04440033|Other|Audiology assessments|"Otoscopy~Tympanometry~Pure tone audiometry~Otoacoustic emissions~Video Head Impuls Test~Cervical Vestibular Evoked Myogenic Potentials~Ocular Vestibular Evoked Myogenic Potentials~Oculomotor function testing~Positional testing~Static visual acuity test~Dynamic visual acuity test~Dizziness Handicap Inventory (a 25-item self-assessment inventory)"
79270958|NCT04434040|Drug|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
79733607|NCT04151329|Biological|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
79573939|NCT01841476|Drug|POL6326|
79733608|NCT02815774|Drug|SP2086|all subjects were given SP2086 50mg only one time.
79733609|NCT00679315|Drug|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
79733610|NCT00679315|Drug|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
79733611|NCT04049773|Procedure|haemodialysis|haemodialysis, thrice weekly in-center
79733612|NCT02626351|Other|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: [1] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; [2] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; [3] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; [4] Follow up.
79270959|NCT04434040|Drug|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
79270960|NCT04397133|Other|inspiratory muscle training|inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
79270961|NCT04397133|Other|sham intervention|in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
79270962|NCT04385940|Dietary Supplement|Ddrops® products, 50,000 IU, Oral|Vitamin D3
79270963|NCT04385940|Dietary Supplement|Vitamin D3|Vitamin D3 1000IU
79270964|NCT04379635|Drug|Tislelizumab|administered via Intravenous (IV) injection
79270965|NCT04379635|Drug|Cisplatin injection|administered via IV infusion
79270966|NCT04379635|Drug|Paclitaxel injection|administered via IV infusion
79270967|NCT04379635|Drug|Pemetrexed Disodium|administered via IV infusion
79270968|NCT04379635|Drug|Placebos|Placebo to match tislelizumab IV infusion
79573940|NCT01841489|Drug|Treatment A|1600 mg GS-9973 (Formulation 1)
79573941|NCT01841489|Drug|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
79573942|NCT01841489|Drug|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
79573943|NCT01841489|Drug|Treatment D|1600 mg GS-9973 (Formulation 2)
79573944|NCT01841489|Drug|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
79573945|NCT01841489|Drug|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
79733613|NCT02626351|Other|Baseline data collection (active comparator)|Endpoint data collection only
79733614|NCT05652400|Other|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
79733615|NCT00679393|Procedure|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
79573946|NCT01841489|Drug|Treatment G|1600 mg GS-9973 (Reference formulation)
79573947|NCT01841489|Drug|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
79573948|NCT01841489|Drug|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
79270969|NCT04379635|Drug|Carboplatin|administered via IV infusion
79304473|NCT03195751|Device|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
79573949|NCT01841489|Drug|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
79573950|NCT01841502|Drug|Paroxetine|paroxetine 20 mg once daily
79573951|NCT01841502|Drug|telaprevir|telaprevir 1125 mg twice daily
79573952|NCT01841515|Drug|Desmopressin administration|
79573953|NCT01841528|Other|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
79733616|NCT00679393|Procedure|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
79733617|NCT02815852|Other|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women <40 years the typical imaging presentation pattern of malignancies observed in women> 40 years are confirmed.
79733618|NCT02816242|Other|concept map teaching|teaching anatomy using concept map to improve critical thinking
79733619|NCT02816242|Other|traditional teaching|teaching anatomy using lecture
79733620|NCT04692298|Other|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
79733621|NCT02815930|Other|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
79733622|NCT04238962|Drug|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
79733623|NCT04238962|Drug|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
79733624|NCT01098474|Biological|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
79733625|NCT01098474|Biological|Tritanrix™ HB+Hib|Intramuscular, 3 doses
79733626|NCT01098474|Biological|Prevnar™|Intramuscular, 3 doses
79733627|NCT01098474|Biological|Polio Sabin™|Oral, 3 doses
79733628|NCT01098474|Biological|Menjugate™|Intramuscular, 3 doses
79733629|NCT04238026|Procedure|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
79733630|NCT00633802|Drug|Risperidone|1 mg/d risperidone for 10 weeks or placebo
79733631|NCT04460248|Drug|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21;~Lenalidomide, 25 mg qd, po, day 2-11;~Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
79733632|NCT02819986|Behavioral|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
79733633|NCT02878902|Other|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
79733634|NCT02819830|Behavioral|Exercise Intervention|Combined strength and aerobic exercise
79733635|NCT02820064|Procedure|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
79733636|NCT04425538|Drug|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
79733637|NCT04309344|Device|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
79733638|NCT04309344|Procedure|control|mechanical debridement
79868371|NCT05883254|Diagnostic Test|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~The method of total RNA extraction: TRIzol and TRIzol LS.~The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
80027697|NCT05354271|Other|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
79270970|NCT04363944|Device|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
79573954|NCT01841528|Other|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
79573955|NCT01841541|Behavioral|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
79573956|NCT01841658|Dietary Supplement|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
79573957|NCT01841671|Biological|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
79573958|NCT01841671|Biological|bOPV|As indicated
79573959|NCT01841671|Biological|mOPV type 2|Administered at 28 weeks of age to all study participants
79573960|NCT01841671|Biological|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
79573961|NCT01841684|Drug|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
79573962|NCT01841684|Drug|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
79733639|NCT02879526|Drug|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
79733640|NCT02815306|Device|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
79733641|NCT04309032|Procedure|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
79573963|NCT01841749|Procedure|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
79573964|NCT01841775|Drug|interferon α 2b + ribavirin|"interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
79733642|NCT04690582|Behavioral|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
79733643|NCT04690582|Behavioral|Crisis Response Plan (CRP)|The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
79868372|NCT05883215|Other|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
80027698|NCT05354271|Other|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
79868373|NCT05883215|Other|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
80027699|NCT05354427|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
80027700|NCT03266146|Drug|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
79573965|NCT01841788|Device|Thermal Adhesion Patch|
79270971|NCT04361487|Device|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
79573966|NCT01841788|Device|Marketed Thermal Adhesion Patch|
79573967|NCT01841788|Device|Placebo Patch|
79573968|NCT01841801|Device|Thermal Adhesive Patch|
79573969|NCT01841801|Device|Marketed Thermal Adhesive Patch|
79304474|NCT03195751|Device|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
79573970|NCT01841801|Device|Placebo Patch|
79733644|NCT04690582|Behavioral|Safety Planning Intervention (SPI)|The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
79573971|NCT01841814|Radiation|Bone densitometry.|
79573972|NCT01841827|Drug|Cilostazol|
79733645|NCT04690582|Behavioral|Narrative Assessment|"The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan."
79733646|NCT02878980|Behavioral|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
79733647|NCT02878980|Other|Laboratory Biomarker Analysis|Correlative studies
79733648|NCT02878980|Other|Quality-of-Life Assessment|Ancillary studies
79733649|NCT02878980|Other|Questionnaire Administration|Ancillary studies
79573973|NCT01841827|Drug|Placebo|
79573974|NCT01841840|Other|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
79573975|NCT01841840|Other|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
79573976|NCT01841853|Behavioral|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
79573977|NCT01841866|Other|LMA removal|
79573978|NCT01841879|Behavioral|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
79573979|NCT01841879|Behavioral|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
79733650|NCT04420156|Other|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
79733651|NCT02627521|Procedure|PRU guided CABG|Coronary Artery Bypass Surgery
79733652|NCT02627521|Procedure|CABG per standard of care|Coronary Artery Bypass Surgery
79868374|NCT05883215|Other|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
80027701|NCT03266146|Drug|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
80027702|NCT03703453|Device|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
80027703|NCT03700489|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
79573980|NCT01841892|Behavioral|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
79573981|NCT01841905|Other|Observational Study|Observational Study
79573982|NCT01841918|Biological|Avian Flu Vaccine|
79573983|NCT01841944|Drug|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
79733653|NCT02627521|Device|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
79733654|NCT02627521|Drug|Ticagrelor|Ticagrelor administration prior to randomization
79733655|NCT02627599|Device|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
79733656|NCT02815228|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-034)
80027704|NCT03695965|Procedure|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
79573984|NCT01841944|Other|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
79868375|NCT05883215|Other|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
79733657|NCT00681967|Drug|Gefitinib|250 mg; oral
79733658|NCT00681967|Drug|Gefitinib|250mg; oral
79733659|NCT00685321|Device|H1 deep TMS coil|20 daily deep rTMS treatment
79733660|NCT00685321|Device|Sham|inactive treatment
79733661|NCT04239118|Combination Product|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
79733662|NCT04239118|Procedure|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
79573985|NCT01841983|Other|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~Motivate individual staff members to engage in targeted health and safety behavior changes;~build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~promote co-worker and supervisor support for targeted health and safety behaviors."
79733663|NCT04139941|Diagnostic Test|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
79733664|NCT02815150|Dietary Supplement|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
79733665|NCT02814994|Behavioral|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
79868376|NCT05883189|Diagnostic Test|Draw blood|Draw blood from human body and make into serum to test
79868377|NCT05883176|Drug|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
79868378|NCT05883111|Diagnostic Test|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
79868379|NCT05883098|Procedure|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
79868380|NCT05883098|Device|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
79868381|NCT05883085|Drug|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
79868382|NCT05883059|Device|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
79304475|NCT03286907|Behavioral|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 & 8.
79573986|NCT01841996|Drug|ME1111 solution|Once a day for 28 days
79573987|NCT01841996|Drug|Vehicle Solution|Once a day for 28 days
79573988|NCT01842009|Device|High Definition transcranial Direct Current Stimulation|
79573989|NCT01842022|Dietary Supplement|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
79573990|NCT01842022|Dietary Supplement|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
79573991|NCT01842022|Dietary Supplement|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
79573992|NCT01842048|Other|Hyperthermia|
79573993|NCT01842048|Radiation|External-beam radiotherapy|
79573994|NCT01842074|Drug|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
79573995|NCT01842087|Other|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
79573996|NCT01842087|Other|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
79573997|NCT01842100|Drug|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
79733666|NCT02814994|Behavioral|low tidal volume|ventilation ventilated with low tidal volume
79733667|NCT00875017|Drug|Lanthanum Carbonate|1 x 1000mg tablet
79733668|NCT00875017|Drug|Sevelamer|3 x 800mg tablets
79733669|NCT02819362|Device|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
79733670|NCT00679705|Drug|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
79733671|NCT00679705|Drug|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
79733672|NCT00679705|Drug|Placebo|Glucose 5%, IV
79868383|NCT05883059|Other|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
80027705|NCT04529824|Device|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
80027706|NCT02800941|Drug|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
80027707|NCT03695887|Drug|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
80027708|NCT03695887|Drug|Placebo|Inactive comparator
79573998|NCT01842100|Other|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
79573999|NCT01842113|Drug|Rifaximin|Rifaximin 550mg by mouth twice a day
79574000|NCT01842113|Drug|Lactulose|Lactulose 30ml by mouth three times a day
79574001|NCT01842113|Drug|Lactulose Placebo|Lactulose Placebo 30ml three times a day
79574002|NCT01842113|Drug|Rifaximin Placebo|Rifaximin Placebo twice a day
79574003|NCT01842126|Biological|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
79574004|NCT01842126|Biological|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
79574005|NCT01842126|Drug|Placebo IV|Ascending Doses intravenous (IV) of Placebo
79574006|NCT01842126|Drug|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
79733673|NCT04672486|Behavioral|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
79868384|NCT05883046|Other|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
79868385|NCT05883046|Other|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
80027709|NCT04432714|Drug|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1~d10# 21days a cycle
79270972|NCT04360018|Other|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
79270973|NCT04360018|Other|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
79270974|NCT04354103|Drug|Atomoxetine|Atomoxetine
79270975|NCT04343079|Diagnostic Test|PET CT|measurement of surgical margins during lumpectomy
79270976|NCT04342585|Drug|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
79574007|NCT01842139|Biological|basiliximab|Given IV
79574008|NCT01842139|Biological|WT1 126-134 peptide vaccine|Given SC
79574009|NCT01842139|Drug|Montanide ISA 51 VG|Given SC
79574010|NCT01842139|Drug|poly ICLC|Given SC
79574011|NCT01842139|Other|laboratory biomarker analysis|Correlative studies
79574012|NCT01842178|Procedure|scratching|"Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control."
79574013|NCT01842191|Dietary Supplement|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
79574014|NCT01842191|Dietary Supplement|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
79574015|NCT01842217|Procedure|FES-PET|
79574016|NCT01842230|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~over the period I & II(cross-over)"
79733674|NCT00685555|Behavioral|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
79868386|NCT05883046|Other|Baseline (Control)|No supplement conditions
79868387|NCT05883033|Device|VAC|Vacuum Assisted Closure device
80027710|NCT04432714|Drug|Rituximab|Rituximab 375 mg/m2，IV, d0
80027711|NCT04432714|Drug|Etoposide|Etoposide 50 mg/m2/day CI24h d1-d4
80027712|NCT04432714|Drug|Doxorubicin|Doxorubicin 10 mg/m2/day CI24h d1-d4
80027713|NCT04432714|Drug|Vincristine|Vincristine 0.4mg/m2/day CI24h d1-d4
80027714|NCT04432714|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2/day IV d5
80027715|NCT04432714|Drug|Prednisone|Prednisone 60 mg/m2/bid oral or IV d1-d5
79270977|NCT04342585|Device|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
79270978|NCT04342260|Other|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
79270979|NCT04342260|Other|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
79270980|NCT04339777|Drug|Busulfan test dose|0.8 mg/kg IV infusion over 2 hours
79574017|NCT01842230|Drug|Telmisartan 80mg and S-amlodipine 5mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~over the period I & II(cross-over)"
79574018|NCT01842243|Procedure|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
79574019|NCT01842243|Procedure|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
79574020|NCT01842243|Device|Pacemaker|MR conditional Pacemaker implanted in all study patients
79574021|NCT01842256|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~oral intake, once in a period~over the period Ⅰ&Ⅱ(crossover)"
79574022|NCT01842256|Drug|atorvastatin 40mg|"1 Tablet (atorvastatin 40mg),~oral intake, once in a period~over the period Ⅰ&Ⅱ(crossover)"
80027716|NCT02752074|Drug|pembrolizumab + epacadostat|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
80027717|NCT02752074|Drug|pembrolizumab + placebo|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~Placebo will be administered orally daily starting at Day 1 (Week 1)"
79868388|NCT05883020|Other|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
79733675|NCT00685555|Behavioral|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
80027718|NCT03564795|Device|KeraStat Gel|Wound dressing for partial thickness burns
80027719|NCT03564795|Device|Silver Sulfadiazine|Wound dressing for partial thickness burns
79868389|NCT05883020|Other|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
80027720|NCT03624595|Drug|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
80027721|NCT03624595|Drug|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
80027722|NCT03063970|Device|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
79868390|NCT05882994|Behavioral|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
79574023|NCT01842269|Drug|Mycophenolate Mofetil 500mg|
79574024|NCT01842269|Drug|Mycophenolate Mofetil 250mg|
79868391|NCT05882968|Diagnostic Test|kidney function tests|using GFR test according to kdigo guide lines
79868392|NCT05882955|Behavioral|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
79868393|NCT05882955|Behavioral|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
79868394|NCT05882942|Dietary Supplement|Matcha green tea|This is the condition with the Matcha green tea
79868395|NCT05882942|Dietary Supplement|Placebo|This is the condition with the placebo
79868396|NCT05882890|Other|cranio sacral therapy|Manual treatment of 5 grams on the whole airwaysystem, the throat, the neck, the meninges, the craniel , nerve sleeves, the visceral cranium, the soft tissue in the mouth
80027723|NCT03063970|Other|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
80027724|NCT03564717|Other|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
80027725|NCT03063892|Drug|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
79868397|NCT05882864|Drug|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
79868398|NCT05882864|Drug|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
79868399|NCT05882851|Behavioral|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
80027726|NCT03063892|Drug|Saline solution|Saline solution is used as the placebo comparator
80027727|NCT05708313|Behavioral|lifestyle modification|Participants will undergo an exercise program designed by AHH
79574025|NCT01842295|Other|Blood and sperm samples|Blood and sperm samples will be done in each visit
79574026|NCT01842321|Drug|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
79574027|NCT01842347|Other|Fecal microbiota|
79574028|NCT01842373|Drug|LMX4|
79574029|NCT01842373|Drug|BLT|
79574030|NCT01841645|Dietary Supplement|CLA depletion-repletion|
79574031|NCT01842412|Behavioral|exercise|one bout of exercise training
79574032|NCT01842477|Procedure|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
79574033|NCT01842503|Drug|GET 73|300 mg tid on 3 days cycle
79574034|NCT01842503|Drug|inactive ingredients capsule|3 capsules tid on 3 days cycle
79574035|NCT01842516|Drug|LCB01-0371 800mg|LCB0-0371 800mg
79574036|NCT01842516|Drug|LCB01-0371 1200mg|LCB01-0371 1200mg
80027728|NCT03063736|Drug|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
79868400|NCT05882838|Other|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
79574037|NCT01842516|Drug|Placebo|Placebo
79270981|NCT04339777|Drug|Fludarabine|40 mg/m2 IV infusion over 30 min once daily for 4 days
79868401|NCT05882825|Other|Dry Needling Therapy Knowledge and Awareness Questionnaire|Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
79868402|NCT05882799|Procedure|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
80027729|NCT03063736|Biological|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
79733676|NCT02815072|Other|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
79270982|NCT04339777|Drug|Busulfan|"AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6)."
79270983|NCT04339777|Drug|Alemtuzumab|Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
79574038|NCT01842529|Biological|botulinum toxin injection|
79574039|NCT01842529|Biological|0.9% normal saline injection|
79574040|NCT01842529|Device|Implantable loop recorder|
79574041|NCT01842542|Device|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
79574042|NCT01842555|Other|Registry|Registry
79574043|NCT01842659|Genetic|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
79270984|NCT04339777|Radiation|Total body Irradiation|200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
79574044|NCT01842685|Procedure|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
79574045|NCT01842698|Device|ultrasoundguided paravertebral catheter|
79733677|NCT04140019|Diagnostic Test|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
79733678|NCT04237948|Device|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
79733679|NCT04237948|Behavioral|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
80027730|NCT03695731|Procedure|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
80027731|NCT03063814|Behavioral|APP|See arm description
80027732|NCT03063814|Behavioral|PHY|see arm description
80027733|NCT02190474|Behavioral|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
79270985|NCT04339777|Procedure|Allogeneic HSCT|Stem cell transplant
79574048|NCT01842737|Procedure|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
79733680|NCT00685633|Drug|bicalutamide|Given orally
79868403|NCT05882799|Procedure|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
79868404|NCT05882786|Procedure|Corticosteroid injection|Subacromial injection of 40mg triamcinolone acetonide.
79270986|NCT04339777|Drug|Tacrolimus (Tacro)|Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5
79402440|NCT03591523|Diagnostic Test|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
79574049|NCT01842737|Procedure|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
79574050|NCT01842750|Device|Endorectal Balloon insertion|
80027734|NCT03703219|Other|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
79868405|NCT05882786|Procedure|Dry Needling|Dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscles tendons.
80027735|NCT05353179|Drug|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
80027736|NCT05353179|Drug|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
79574051|NCT01842802|Device|Diode Laser|Diode Laser for treatment of subcutaneous fat
79574052|NCT01842802|Device|YAG laser|YAG laser for treatment of subcutaneous fat
79574053|NCT01842828|Other|Standard care plus electronic cigarettes|
79574054|NCT01842828|Behavioral|Standard care|
79574055|NCT01842893|Drug|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
79574056|NCT01842919|Other|Kinesthetics tests|
79733681|NCT00685633|Drug|enzastaurin hydrochloride|Given orally
79733682|NCT04206670|Device|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
79868406|NCT05882630|Drug|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
79868407|NCT05882591|Procedure|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
79868408|NCT05882578|Other|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
80027737|NCT03063580|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
80027738|NCT03063580|Drug|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
80027739|NCT03700255|Procedure|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
79270987|NCT04339777|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)
79270988|NCT04339777|Drug|Cyclophosphamide (Cytoxan)|Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
79574057|NCT01842919|Other|Psychological questionnaires|
79574058|NCT01842919|Other|structural Magnetic ResonanceImaging (MRI)|
79574059|NCT01842932|Drug|Phloroglucin|Premedication of colonoscopy
79574060|NCT01842932|Drug|Cimetropium bromide|Premedication of colonoscopy
79574061|NCT01842932|Procedure|Colonoscopy|Diagnostic examination of colon
79574062|NCT01842932|Drug|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
79868409|NCT05882578|Other|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
79868410|NCT05882539|Device|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
79733683|NCT04206670|Device|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
79402441|NCT03591523|Diagnostic Test|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
79868411|NCT05882526|Device|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
79868412|NCT05882513|Drug|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
79868413|NCT05882513|Procedure|surgical resection of lung cancer|radical resection of lung cancer
80027740|NCT02187978|Other|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
80027741|NCT02187978|Other|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
79574063|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
79574064|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
79733684|NCT00685711|Biological|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
79733685|NCT04371952|Drug|Doxycycline|comparison of doxycycline 200 mg/day to placebo
79733686|NCT04371952|Drug|Placebo|Placebo : lactose, 380 mg/gélule
79733687|NCT00682123|Dietary Supplement|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
79733688|NCT04145089|Device|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
79733689|NCT00679861|Behavioral|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
79402442|NCT03785574|Other|Follow up|the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
79402443|NCT03785574|Drug|chemotherapy|First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
79402444|NCT04197427|Device|Experimental Oral Rinse|Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
79402445|NCT04197427|Device|Placebo|Placebo formulation without the active ingredients
79574065|NCT01842971|Procedure|two stage hepatectomy|
79733690|NCT00679861|Behavioral|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
79868414|NCT05882500|Other|No intervention, observation|
79868415|NCT05882487|Genetic|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
79868416|NCT05882474|Device|PaCO2|Level of partial pressure of carbon dioxide
79868417|NCT05882461|Behavioral|90Second Caregiver health letter|Participant receives the weekly health letter via email
79868420|NCT05882435|Other|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
79868421|NCT05882409|Behavioral|Education|Education covers women's education on violence, conflict and awareness.
79733691|NCT02814760|Other|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
79733692|NCT00875797|Dietary Supplement|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
79733693|NCT00875797|Dietary Supplement|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
79733694|NCT04144621|Procedure|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
79733695|NCT04337476|Device|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
79733696|NCT02626195|Dietary Supplement|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~Calories: 30-35Kg, via enteral or parenteral~Protein: 1.2-1.5g/Kg~Lipid : 1-1.5g/Kg~Mineral and vitamins supply~Blood glucose control~Daily monitoring by dietician and specialized nurse"
79733697|NCT02814214|Device|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
79733698|NCT00685789|Device|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
79733699|NCT00685789|Device|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
79733700|NCT04329832|Drug|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min). For patients < 45kg, doses will be halved. For patients with GFR<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
79733701|NCT04329832|Drug|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
79733702|NCT02626273|Radiation|weight loss|
79733703|NCT04237246|Drug|Tacrolimus|"24 hour long acting advegraf"
79733704|NCT00680095|Drug|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
79733705|NCT00680095|Drug|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
79733706|NCT00680095|Drug|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
79733707|NCT00680095|Other|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
79733708|NCT00680095|Other|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
79733709|NCT04237168|Diagnostic Test|IgNGS from circulating tumor DNA|3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
79733710|NCT00685867|Other|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
79733711|NCT00685867|Behavioral|Hand hygiene promotion|"Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~Isolation precautions according to the hospitals' capacity and strategy~Additional basic infection control interventions (if necessary)"
79733712|NCT02814604|Other|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
79733713|NCT00686023|Procedure|internal fixation (DHS - richard nail)|internal fixation
79733714|NCT00686023|Procedure|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
79733715|NCT02814136|Procedure|Ablation|
79733716|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
79733717|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
79733718|NCT00680173|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
79733719|NCT04293016|Behavioral|Support as usual|this group receives current best practice which includes participation in ICU support groups and provision of community support resources
79733720|NCT04293016|Behavioral|problem solving therapy|This group will receive one on one therapy based on identifying stressors and solutions to those stressors
79733721|NCT04293016|Behavioral|ICU diary|This group will provided with a structured written diary that includes identification of stressors and development of solutions to those stressors
79868422|NCT05882396|Other|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
79402446|NCT04585854|Other|Caffeine|Consumption of 3 shots of espresso
79733722|NCT00682279|Drug|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
79402447|NCT04562220|Other|Routine conventional physical therapy plus Vibration session|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
79733723|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
79733724|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
79733725|NCT02811484|Drug|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
79733726|NCT02811484|Behavioral|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
79733727|NCT00686179|Drug|AZD3480|Capsule, oral, single dose, 6 days
79733728|NCT00686179|Drug|Moxifloxacin|Capsule(encapsulated), oral, single dose
79733729|NCT00686179|Drug|PLACEBO|Capsule, oral, single dose
79402448|NCT04562220|Other|Routine conventional physical therapy|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions
79733730|NCT04139707|Device|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
79733731|NCT04139707|Other|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
79733732|NCT02813902|Drug|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
79733733|NCT02813902|Other|Sugar Pill|A pill that appears similar to the supplement
79733734|NCT00922597|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
79733735|NCT02811172|Other|BEhavior of biomarkers during pregnanCy and lactatiOn|
79733736|NCT04151173|Procedure|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
79733737|NCT04151173|Procedure|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
79868423|NCT05882396|Other|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
80027742|NCT05353101|Drug|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
79402449|NCT04471038|Biological|SAB-176|Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
79402450|NCT04471038|Other|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
79402451|NCT03481842|Biological|Linifanib|in a minimally sufficient therapeutic dose
79733738|NCT02627365|Behavioral|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
79733739|NCT02813746|Dietary Supplement|Fitness program|
79733740|NCT02813746|Behavioral|Stop smoking|
79733741|NCT02813746|Procedure|Endometrial fluid collection|
79733742|NCT00874939|Drug|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
79733743|NCT00874939|Drug|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
79733744|NCT00874939|Drug|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
79733745|NCT00874939|Drug|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
79733746|NCT00874939|Drug|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
79733747|NCT04268836|Device|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
79733748|NCT00634348|Drug|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
79733749|NCT00634348|Drug|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
79733750|NCT00680329|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
79733751|NCT00680329|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
79733752|NCT02811016|Drug|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
79733753|NCT02811016|Drug|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
79733754|NCT02811016|Drug|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
79733755|NCT00686413|Drug|AZD3480|single dose, oral
79733756|NCT00686413|Radiation|2-[18F]-F-A85380|Single dose, IV
79733757|NCT02810860|Procedure|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
79733758|NCT04144309|Procedure|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
79574066|NCT01842984|Behavioral|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
79733759|NCT04144309|Procedure|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
79574067|NCT01842997|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
79574068|NCT01843010|Drug|Parecoxib|Parecoxib 40mg will be intravenously infused.
79733760|NCT05592262|Drug|SHR2554|On an empty stomach - after meals
79733761|NCT05592262|Drug|SHR2554|After meals - on an empty stomach
79402452|NCT03481842|Drug|BIBW2992|in a minimally sufficient therapeutic dose
79574069|NCT01843010|Drug|Placebo|Normal saline 5ml will be intravenously infused.
79733762|NCT00690313|Drug|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
79733763|NCT02810938|Device|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
79733764|NCT02626585|Procedure|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
79574070|NCT01843049|Radiation|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
79574071|NCT01843049|Drug|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
79574072|NCT01843075|Drug|Liraglutide|Daily subcutaneous injection
79733765|NCT04237480|Diagnostic Test|serum value 1,25(OH)2 vitamin D|statistical evaluation of the serum values
79733766|NCT04144543|Other|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
79733767|NCT04144543|Other|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
79733768|NCT04144543|Other|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
79733769|NCT04237324|Procedure|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
79304476|NCT03286907|Behavioral|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, & 8.
79733770|NCT04237324|Procedure|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
79733771|NCT02813434|Biological|florbetapir|18F-AV-45 or 18F-Florbetapir
79733772|NCT04139863|Diagnostic Test|aMMP-8 chairside test|No test
79733773|NCT02810782|Drug|Phenobarbital|Phenobarbital per os
79733774|NCT02810782|Drug|Chlorpromazine|Chlorpromazine per os
79733775|NCT02810782|Drug|Morphine|Morphine per os
79733776|NCT02626117|Device|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
79304477|NCT03286907|Behavioral|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
79574073|NCT01843075|Drug|Placebo|Daily subcutaneous injection
79733777|NCT02626117|Device|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
79868424|NCT05882331|Procedure|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes ~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
79868425|NCT05882292|Drug|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal [should be within 1 hour post-meal (fed state)] at approximately the same time each day in a 21-day cycle.
79868426|NCT05882266|Dietary Supplement|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
79868427|NCT05882266|Other|Dietary therapy only|Standard dietary therapy
79270989|NCT04335110|Behavioral|STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)|STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
79270990|NCT04329962|Other|Blueberry Powder Food Product|Consume blueberry powder confection
79270991|NCT04329962|Other|Dietary Intervention|Consume blueberry extract confection
79270992|NCT04329962|Other|Questionnaire Administration|Ancillary studies
79270993|NCT04323839|Other|Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
79270994|NCT04323839|Other|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
79270995|NCT04315168|Device|FRED and FRED JR|Intracranial aneurysm treatment
79270996|NCT04304079|Device|ARssist system|As stated in ARssist system arm description
79402453|NCT03481842|Drug|Axitinib|in a minimally sufficient therapeutic dose
79402454|NCT04197739|Drug|Amikacin|"Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram"
79402455|NCT04197505|Behavioral|FLIR E95 camera|Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
79402456|NCT04197349|Biological|ALD1910|Single Dose IV infusion
79402457|NCT04197349|Biological|Sumatriptan|Single dose subcutaneous injection
79574074|NCT01843088|Drug|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
79868428|NCT05882240|Other|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
79574075|NCT01843088|Drug|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
79574076|NCT01843101|Device|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
79574077|NCT01843114|Device|FDOCT|Measurement of retinal blood velocities
79574078|NCT01843114|Other|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
79574079|NCT01843127|Drug|Ranolazine|
79574080|NCT01843127|Drug|Placebo|
79574081|NCT01843127|Drug|Exenatide|
79270997|NCT04301089|Device|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
79270998|NCT04278924|Drug|Placebo|TAK-079 placebo-matching SC injection.
79270999|NCT04278924|Drug|TAK-079|TAK-079 SC injection.
79271000|NCT04266093|Drug|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have received treatment on an applicable NCI CIO gene therapy protocol.
79574082|NCT01843153|Drug|Ropivacaine|
79574083|NCT01843166|Drug|Premarin vaginal cream|2g at bedtime twice weekly
79574084|NCT01843166|Drug|Placebo cream|2g at bedtime twice weekly
79574085|NCT01843179|Drug|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
79574086|NCT01843179|Drug|Sulindac|Taken orally twice per day at home for 12 months
79574087|NCT01843218|Other|Evaluation of erectile dysfunction|Register R / P and self-administered questionnaire IIEF-5
79733778|NCT02810626|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
79868429|NCT05882227|Behavioral|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
79868430|NCT05882227|Behavioral|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
79868431|NCT05882201|Procedure|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
79868432|NCT05882201|Procedure|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
79574088|NCT01843231|Device|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
79868433|NCT05882201|Procedure|General care|using ordinary technique
79868434|NCT05882123|Other|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
79574089|NCT01843231|Other|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
79868435|NCT05882019|Device|Breast Exam with Bexa|Breast exam with Bexa uses pressure elastography to produce a map of the breast tissue's elasticity.
79271001|NCT04251091|Other|Treadmill walking|Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
79271002|NCT04251091|Other|Overground Walking|Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
79868436|NCT05881980|Drug|Terbinafine Tablets|Terbinafine 250 mg/day
79271003|NCT04248244|Other|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
79868437|NCT05881980|Drug|Itraconazole|Itraconazole 200 mg/day
79868438|NCT05881967|Diagnostic Test|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
79868439|NCT05881954|Procedure|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
79271004|NCT04248244|Other|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
79574090|NCT01843257|Other|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
79574091|NCT01843257|Other|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
79868440|NCT05881941|Device|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
79868441|NCT05881941|Device|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
79868442|NCT05881941|Device|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
80027743|NCT05353101|Drug|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
79574092|NCT01843270|Device|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
79733779|NCT00875563|Device|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
79733780|NCT02810548|Procedure|OFD alone|Periodontal surgical cleaning procedure
79733781|NCT02810548|Drug|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
79733782|NCT02810548|Drug|Nanohydroxyapatite|Synthetic bone graft
79733783|NCT01155869|Drug|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
79271005|NCT04248244|Other|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
79868443|NCT05881902|Behavioral|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
79868444|NCT05881902|Behavioral|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
79868445|NCT05881889|Device|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
79868446|NCT05881889|Device|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
80027744|NCT03700333|Drug|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if<1.5m2; 75mg, twice a day, morning and night,if >1.5m2 )chemotherapy after finishing first-line therapy(>21 days).
80027745|NCT03700333|Drug|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(>21 days).
80027746|NCT03703141|Dietary Supplement|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
80027747|NCT02190630|Device|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
79574093|NCT01843270|Device|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
79574094|NCT01843283|Behavioral|Daily Enhancement Meaningful Activity (DEMA)|
79574095|NCT01843283|Behavioral|Information Support (IS)|
79574096|NCT01843296|Drug|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
79733784|NCT01155869|Drug|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
79733785|NCT05635006|Other||No special intervention, randomly classify the subjects
79733786|NCT02810470|Dietary Supplement|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
80027748|NCT05352555|Device|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~Dix-Hallpike (for posterior canal involvement)~Supine roll (for horizontal canal involvement)~(Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~Epley's and/or Semont's maneuver (for posterior canal involvement)~Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
79574097|NCT01843296|Procedure|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
79574098|NCT01843296|Drug|Bupivacaine|
79574099|NCT01843296|Drug|Fentanyl|
79574100|NCT01843309|Drug|Spironolactone 100mg|
79574101|NCT01843309|Drug|Spironolactone 200mg|
79574102|NCT01843309|Drug|Placebo|
79733787|NCT02810470|Dietary Supplement|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
79733788|NCT00690469|Other|Laboratory Biomarker Analysis|Correlative studies
79733789|NCT00690469|Other|Questionnaire Administration|Ancillary studies
79574103|NCT01843322|Procedure|endoleak repair procedure (navigation technology )|
79733790|NCT02810314|Behavioral|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
79868447|NCT05881824|Behavioral|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
79868448|NCT05881785|Biological|GR1501 low dose|3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly
79868449|NCT05881785|Biological|GR1501 high dose|3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly
80027749|NCT05352555|Other|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~Dix-Hallpike (for posterior canal involvement)~Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~Epley's maneuver (for posterior canal involvement)~Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
80027750|NCT03252340|Drug|ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
79868450|NCT05881785|Biological|placebo|"Core treatment period:placebo~Maintenance treatment period: GR1501 injection"
80027751|NCT03695653|Behavioral|Drink Tracking (MA)|Weekly drink tracking for self-monitoring and assessment
79574104|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
79574105|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
79868451|NCT05881746|Procedure|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
79868452|NCT05881746|Procedure|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
79868453|NCT05881655|Device|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
79868454|NCT05881655|Device|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
79868455|NCT05881642|Procedure|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
79868456|NCT05881642|Procedure|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
79868457|NCT05881629|Behavioral|Maternal position change to side-lying lateral with peanut ball|Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.
80027752|NCT03695653|Behavioral|Adaptive Tailored (TA)|Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress
79304478|NCT03195985|Other|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
79574106|NCT01843400|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
79868458|NCT05881629|Behavioral|Free maternal position|Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
79868459|NCT05881577|Other|Observational|Impact of AR on educational outcomes
79868460|NCT05881525|Biological|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
79868461|NCT05881525|Drug|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
79733791|NCT02810314|Other|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
79733792|NCT02625493|Other|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
79868462|NCT05881525|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
79868463|NCT05881525|Drug|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
79868464|NCT05881525|Drug|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
79868465|NCT05881512|Device|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
79868466|NCT05881434|Other|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
80027753|NCT03695653|Behavioral|Tailored (TO)|Messages are sent more frequently and tailored to some baseline characteristics
79304479|NCT03195985|Other|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
79733793|NCT02813590|Other|Ascitic fluid puncture|
79733794|NCT02813590|Other|Skin swaps from puncture side|
79733795|NCT02813590|Other|Stool samples|
79733796|NCT00690547|Other|muscle activation|activation of the muscle quadriceps femoris
79574107|NCT01843426|Drug|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
79271006|NCT04245423|Behavioral|Collaborative Care for Opioid Use Disorders and Mental Health Conditions|CC is delivered using the investigators' Foundations for Integrated Care model. The first line pharmacotherapy is buprenorphine-naloxone. The second line pharmacotherapy included is extended-release injectable naltrexone. Pharmacotherapy is accompanied by brief problem-solving therapy, cognitive-behavioral therapy, and/or motivational interviewing. The primary care physician, in consultation with the addictions psychiatrist and care manager, also will provide psychotropic medications for psychiatric disorders. In-person and telephone visits consist of the care manager carrying out intervention activities over 6 months. Visits are at baseline (90-minute intake appointment), home or office induction when in moderate opiate withdrawal if buprenorphine is prescribed, twice a week for two weeks with telephone calls in between visits, then weekly, and when stable once a month. There will be a final visit at 6 months. The intervention includes routine collection of urine drug screens.
79574108|NCT01843439|Dietary Supplement|Magnesium|
79733797|NCT02809924|Other|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
79733798|NCT02809924|Other|Video training|Video describing endotracheal intubation
79733799|NCT00690625|Drug|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
79733800|NCT00690625|Drug|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
79733801|NCT02813512|Drug|ADSCs|Autologous ADSCs
79733802|NCT00687037|Drug|Cetylpyridinium chloride|
79733803|NCT02810002|Device|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
79733804|NCT02810002|Device|Control infantry boot|Training: infantry basic training in the control boots
79733805|NCT02625415|Device|Vitamin B6 cream|Topical Vitamin B6 cream
79733806|NCT02625415|Device|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
79574109|NCT01843439|Behavioral|Education for asthma action plan|
79733807|NCT02809768|Drug|Avatrombopag|
79733808|NCT02809768|Drug|Fluconazole|
79733809|NCT02809768|Drug|Itraconazole|
79733810|NCT02809768|Drug|Rifampin|
79733811|NCT02813278|Dietary Supplement|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
79733812|NCT02813278|Other|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra & Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
79733813|NCT04138849|Drug|BBT-877 single dose|Oral capsule, single dose.
79733814|NCT04138849|Drug|Placebo single dose|Oral capsule, single dose.
79733815|NCT00690703|Device|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
79733816|NCT04237090|Drug|Diphenhydramine|Drug identification number : 02369567
79733817|NCT04237090|Drug|Cetirizine|Drug identification number : 02231603
79868467|NCT05881330|Device|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
79868468|NCT05881317|Device|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
79733818|NCT04237090|Drug|Lactose pill|Natural product number : 00501190
79733819|NCT04237090|Drug|Sodium chloride 0.9%|Drug identification number : 00037796
79733820|NCT00690781|Dietary Supplement|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
79304480|NCT02460185|Behavioral|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
79402458|NCT04197349|Biological|ALD1910|Single dose subcutaneous injection
79733821|NCT00690781|Dietary Supplement|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
79733822|NCT00690781|Dietary Supplement|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
79733823|NCT00690781|Dietary Supplement|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
79574110|NCT01843439|Behavioral|hot-lines for acute exacerbation of asthma|
79733824|NCT04187794|Other|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
79868469|NCT05881304|Device|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
80027754|NCT05708391|Drug|Realgar-Indigo Naturalis Formulation|"Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight"
80027755|NCT05708391|Radiation|Radiotherapy|Radiotherapy
80027756|NCT03700177|Drug|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
80027757|NCT03700177|Drug|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
80027758|NCT03700177|Drug|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
80027759|NCT02183610|Drug|[14C] BI 1356 as oral (p.o.) solution|
80027760|NCT02183610|Drug|[14C] BI 1356 solution for i.v. infusion|
80027761|NCT04434352|Device|Storz Duolith Low-Intensity Shockwave Therapy|"A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete."
80027762|NCT03699943|Procedure|CaverStem|
80027763|NCT02183688|Drug|Low dose ASA|
79271007|NCT04245423|Behavioral|Augmented Usual Care|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. All practices will have mental health clinicians to treat mild psychiatric disorders. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD.
79574111|NCT01843439|Behavioral|Inhaler technique training|
79271008|NCT04245423|Behavioral|Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists|This intervention includes the Collaborative Care Intervention plus Certified Recovery Specialist to assist with treatment engagement and retention.
79574112|NCT01843452|Radiation|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
79574113|NCT01843452|Biological|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
79733825|NCT00682669|Behavioral|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
79733826|NCT00682669|Behavioral|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
79868470|NCT05881239|Device|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
79868471|NCT05881187|Drug|Riboflavin|topical application of riboflavin followed by cross linking
79868472|NCT05881187|Drug|Antibotice.g vigamox ED Antifungal e.g Dflucan|topical application of antimicropial therapy
80027764|NCT02183688|Drug|High dose ASA|
80027765|NCT02183688|Drug|Low dose paracetamol|
80027766|NCT02183688|Drug|High dose paracetamol|
80027767|NCT02183688|Drug|Caffeine|
80027768|NCT02183688|Drug|Placebo|
80027769|NCT03695575|Device|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
80027770|NCT02190708|Drug|PQ912|from day2 up to day6 twice daily oral dose of PQ912
80027771|NCT02190708|Drug|Midazolam|single oral dose on day1 and day 6
80027772|NCT02190708|Drug|Omeprazole|single oral dose on day1 and day6
79868473|NCT05881187|Device|pack cross linking|TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
79868474|NCT05881122|Behavioral|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
79868475|NCT05881109|Drug|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
79868476|NCT05881070|Behavioral|Mobile-health self management|Mobile-health self management
80027773|NCT02835495|Behavioral|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
80027774|NCT02835495|Behavioral|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
79271009|NCT04235374|Behavioral|FFC-AC-EIT|The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
79271010|NCT04227717|Diagnostic Test|MRI with custom MRI spine coil|Participants will undergo MRI with custom MRI spine coil
79271011|NCT04226690|Drug|Active CBD/THC Dose 1|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
79271012|NCT04226690|Drug|Active CBD/THC Dose 2|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
79271013|NCT04226690|Drug|matched placebo comparator|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
79271014|NCT04221477|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
79271015|NCT04221477|Drug|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
79271016|NCT04221477|Drug|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
79271017|NCT04221477|Drug|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
79402459|NCT04429854|Biological|Convalescent Plasma|"4 units of convalescent plasma:~2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design."
79402460|NCT04429854|Drug|Standard of care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
79574114|NCT01843452|Drug|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
79574115|NCT01843452|Drug|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
79574116|NCT01843478|Other|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
79574117|NCT01843478|Other|Usual Care|
79574118|NCT01843491|Biological|Ad-PfCA|Vaccine
79733829|NCT00682747|Drug|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
79733830|NCT00682825|Behavioral|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
79733831|NCT00682825|Behavioral|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
79733832|NCT02809612|Behavioral|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
79733833|NCT00682903|Device|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
80027775|NCT02190786|Drug|KUX-1151|
79733834|NCT00912379|Biological|hemoglobin determination|laboratory and non invasive hemoglobin determinations
80027776|NCT04864132|Diagnostic Test|6-minute walk test|This test assesses submaximal exercise capacity.
79271018|NCT04221477|Drug|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
79271019|NCT04221477|Drug|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
79271020|NCT04221477|Drug|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
79271021|NCT04221178|Other|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
79574119|NCT01843543|Other|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
79574120|NCT01843569|Biological|In Vitro maturation|
79574121|NCT01843595|Behavioral|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
79733835|NCT02809378|Drug|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
79733836|NCT02809378|Drug|sevoflurane|Inhalational anesthetics Halogenated.
79271022|NCT04219670|Diagnostic Test|Wearable sensors|Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
79271023|NCT04183205|Diagnostic Test|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
79733837|NCT02809378|Drug|remifentanil|ultra-short acting opioid anesthetics
79733838|NCT02809378|Drug|pentothal sodium|intra-venous anesthetics for anesthesia induction
79733839|NCT02809378|Drug|propofol|intra-venous anesthetics for anesthesia induction and maintenance
79733840|NCT00683059|Drug|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
79733841|NCT02813122|Device|x-ray|x-ray for the detection of leaks and bleeding
79868477|NCT05881044|Other|Psychiatric interview|"Psychiatric interview which include personal identification, present history, past history and family history~Complete physical and Neurological Examination.~Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~Symptom checklist 90(SCL 90)~Quality of life questionnaire.~Hamilton Depression scale.~Hamilton Anxiety scale.~Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
79868478|NCT05881018|Dietary Supplement|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
79868479|NCT05881018|Dietary Supplement|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
79733842|NCT01185353|Drug|LY3009104|Administered orally
79733843|NCT01185353|Drug|Placebo|Administered orally
79733844|NCT01185353|Drug|Methotrexate|Administered orally as background therapy
79733845|NCT02809300|Biological|blood collection|
79733846|NCT04237402|Other|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
79733847|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
79733848|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
79733849|NCT00683137|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
79733850|NCT02809456|Drug|Nicorandil|oral intake
79733851|NCT05576740|Procedure|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
79868480|NCT05881018|Behavioral|Physical activity|Participants will include physical activity units
79868481|NCT05880979|Behavioral|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
80027777|NCT04864132|Diagnostic Test|Incremental shuttle walk test|This test assesses maximal exercise capacity.
80027778|NCT05338983|Drug|Topical anesthetic|20% Benzocaine gel will be applied on the area of infiltration
80027779|NCT05338983|Device|Avent baby bottle warmer|Warming device
80027780|NCT05338983|Drug|Sodium bicarbonate|0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.
80027781|NCT05338983|Device|Buzzy device|"Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic."
80027782|NCT05338983|Drug|Mepivacaine Hydrochloride|Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
80027783|NCT02183766|Dietary Supplement|Galactooligosaccharide prebiotic|6 mL once a day
80027784|NCT02183766|Drug|Maltodextrin|6 mL once a day
79733852|NCT05576740|Procedure|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
79733853|NCT05576740|Procedure|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
79733854|NCT05576740|Procedure|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
79733855|NCT05576740|Procedure|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
79733856|NCT05576740|Device|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
79733857|NCT05576740|Other|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
79733858|NCT05576740|Device|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
79733859|NCT05576740|Procedure|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
79733860|NCT05576740|Procedure|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10^6/μL), hematocrit (%), white blood cells (10^3/μl), platelets (10^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
79733861|NCT05576740|Procedure|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
79733862|NCT05576740|Procedure|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
79733863|NCT05576740|Other|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
79733864|NCT05576740|Procedure|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
79733865|NCT04139473|Procedure|Hepaticojejunostomy / Duct-to-duct anastomosis|
79733866|NCT04139629|Diagnostic Test|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
79733867|NCT04139629|Drug|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
79733868|NCT04222894|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
79733869|NCT04222894|Other|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
79733870|NCT00687349|Behavioral|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
79733871|NCT02813044|Drug|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
79733872|NCT02813044|Drug|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
79733873|NCT02625883|Other|Interview|Interview by validated Quality-of-life-questionnaire
79733874|NCT04236778|Drug|VE303|The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
79733875|NCT04236778|Drug|Oral Vancomycin|Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
79733876|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|"Group A:~Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~Treatment will focus on the patient's needs and in accordance with the physicians requests.~Three months post initial treatment re-assessment will be conducted."
79733877|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
79733878|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
79733879|NCT01098240|Drug|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
79868482|NCT05880979|Behavioral|Regular well child care|Participants will receive their regularly scheduled well-child care
79733880|NCT01098240|Other|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
79733881|NCT02812888|Drug|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
79868483|NCT05880927|Drug|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
80027785|NCT03063658|Drug|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
79868484|NCT05880745|Diagnostic Test|Nine-Hole Peg Test (NHPT)|Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
79733882|NCT00922675|Procedure|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
79733883|NCT00922675|Procedure|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
79733884|NCT04149028|Procedure|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
79868485|NCT05880732|Drug|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
80027786|NCT03063658|Drug|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
80027787|NCT03695263|Behavioral|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
79271024|NCT04183205|Drug|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
79271025|NCT04183205|Drug|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
79271026|NCT04157686|Drug|MT10109L|MT10109L will be injected into either the GL, LCL, or both the LCL and GL.
79574122|NCT01843608|Other|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
79733885|NCT02809222|Other|Samples|Blood samples
79271027|NCT04156620|Drug|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
79271028|NCT04156620|Drug|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
79271029|NCT04146714|Other|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
79271030|NCT04146714|Other|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
79574123|NCT01843647|Drug|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
79733886|NCT02809222|Other|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
79733887|NCT04139785|Other|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
79733888|NCT02812966|Device|Lutonix|Drug Coated Balloons
79733889|NCT02812966|Device|IN.PACT|Drug Coated Balloons
79733890|NCT00687661|Drug|Bisphosphonate|35mg given orally once weekly for 24 months
79733891|NCT00687661|Drug|Placebo|identical placebo pill once weekly for 24 months
79868486|NCT05880732|Drug|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
79868487|NCT05880719|Other|Computer-assisted Music remediation|"These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~15 minutes of music improvisation~20 minutes of harmony and rythm exercices~20 minutes of Lesson about the software and musical interfaces~5 minutes of debrief."
79868488|NCT05880693|Drug|Dexmedetomidine|Group 1 received dexmedetomidine
79868489|NCT05880693|Drug|Magnesium sulfate|the group 2 received magnesium sulfate
79868490|NCT05880680|Device|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
80027788|NCT03535896|Other|HSR|"Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day."
79271031|NCT04138706|Drug|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
79271032|NCT04138706|Drug|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
79271033|NCT04136171|Drug|Eplontersen|Eplontersen by subcutaneous injection
79733892|NCT02809534|Drug|Anlotinib|Anlotinib p.o. qd
79868491|NCT05880654|Procedure|Scaling & root planning|Non Surgical periodontal therapy
79868492|NCT05880589|Dietary Supplement|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
80027789|NCT03535896|Drug|Corticosteroid injection|Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
79868493|NCT05880589|Dietary Supplement|Placebo group|Take 2 tablet 2 times per day for 14 days
80027790|NCT03695107|Drug|Nifedipine controlled released tablets|lower blood pressure
80027791|NCT02835339|Drug|Magnesium sulfate 4g loading dose, 1g/hr infusion|
80027792|NCT02835339|Drug|Magnesium sulfate 6g loading dose, 2g/hr infusion|
79271034|NCT04136171|Drug|Placebo|Eplontersen-matching placebo by subcutaneous injection
79271035|NCT04102774|Device|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
79733893|NCT00687817|Drug|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
79733894|NCT02809144|Procedure|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
79868494|NCT05880563|Drug|[18F]-RoSMA-18-d6|[18F]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
79868495|NCT05880550|Other|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
79868496|NCT05880550|Other|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
79868497|NCT05880511|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires ~ 11.5 minutes in total.
80027793|NCT04473040|Drug|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
80027794|NCT03695029|Drug|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
80027795|NCT02259855|Drug|Tipranavir|
80027796|NCT02259855|Drug|Ritonavir|
79271036|NCT04098718|Drug|Benralizumab|100mg sub cut once only
79271037|NCT04098718|Drug|Prednisolone|30mg tablet daily for 5 days
79271038|NCT04081246|Device|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
79271039|NCT04060082|Other|Telephone Interview|Participants will be asked to answer questions about their experiences with FTD.
79271040|NCT04043689|Device|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
80027797|NCT02259855|Drug|Pegylated interferon|
80027798|NCT02259855|Drug|Ribavirin|
80027799|NCT04465084|Other|Case|Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
79271041|NCT04024696|Drug|Abexinostat|Abexinostat Tosylate Tablets
79733895|NCT02808988|Procedure|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
79733896|NCT02808988|Procedure|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
79733897|NCT02808988|Other|zoledronic acid|5 mg/year zoledronic acid (i.v.)
79733898|NCT02625805|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
80027800|NCT04465084|Other|Withness|Experimental language tasks MRI
79271042|NCT04020978|Diagnostic Test|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
80027801|NCT02188212|Device|NobelProcera Crown Shaded Zirconia|
80027802|NCT03703063|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
80027803|NCT03703063|Drug|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
80027804|NCT03703063|Drug|Onivyde|Administered by intravenous infusion over 90 minutes.
80027805|NCT03703063|Drug|Leucovorin|Administered by intravenous infusion over 30 minutes.
80027806|NCT03703063|Drug|5-fu|Administered by intravenous infusion over 46 hours.
80027807|NCT04094337|Behavioral|Internet-assisted treatment|Internet-assisted treatment
79868498|NCT05880511|Device|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
79574124|NCT01843647|Drug|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
79733899|NCT02625805|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
79733900|NCT02625805|Drug|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
79733901|NCT00687895|Procedure|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~description of signs and symptoms of malaria disease~history taking relevant to malaria and physical examination~identification of danger signs and severe illness for referral~appropriate treatment~counseling patients on the use of drugs.~Malaria microscopy. contents~make thick blood smears from patients with fever and stain with Giemsa~identify and count malaria parasites~maintain the microscope and store blood slides."
79733902|NCT02808910|Behavioral|Nudged to eat less added salt and more other seasonings|
79733903|NCT02808910|Behavioral|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
79733904|NCT02808910|Behavioral|Nudged to eat more vegetables|
79868499|NCT05880511|Device|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires ~ 11.5 minutes in total.
79868500|NCT05880498|Behavioral|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
80027808|NCT02183844|Behavioral|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
79271043|NCT04018456|Other|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
79574125|NCT01843686|Device|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
79733905|NCT02808910|Behavioral|Nudged to eat smaller portions|
79733906|NCT02808910|Behavioral|Nudged to eat less calorie-dense food|
79271044|NCT04018456|Other|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
79733907|NCT00688051|Other|My Life with CF game|Play the game My Life with CF
79271045|NCT04018053|Drug|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
79574126|NCT01843686|Other|Placebo Saline Gel and Usual and Customary Standard of Care|
79574127|NCT01843699|Drug|Topiramate flexible dosage|
79574128|NCT01843699|Drug|Placebo matching tablets|
79574129|NCT01843699|Behavioral|4-session gambling cognitive restructuring|
79574130|NCT01843725|Drug|capecitabine|escalation dose of capecitabine continuously
79574131|NCT01843725|Drug|aflibercept|Intravenous 6mg/kg every 3 weeks
79574132|NCT01843725|Drug|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
79402461|NCT04197271|Procedure|Emergency Hernia Repair|Emergency repair of hernia using method selected by treating surgeon.
79574133|NCT01843738|Radiation|Radiation therapy|Per standard of care
79574134|NCT01843738|Drug|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
79574135|NCT01843764|Device|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
79574136|NCT01843790|Drug|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
79733908|NCT00688129|Behavioral|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
79733909|NCT00688207|Drug|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
79733910|NCT02880462|Dietary Supplement|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
79733911|NCT02880462|Other|placebo|Placebo is made of starch
79733912|NCT00688285|Other|automated clinical alerts|automated clinical alerts in the electronic medical record
79733913|NCT00688285|Other|provider education|PCP education session on CKD
79733914|NCT00688363|Procedure|weekly blood glucose profile|once daily self-control of urinary-glucose
79733915|NCT00688363|Procedure|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
79733916|NCT00688363|Procedure|no blood-glucose self-control|once daily self-control of urinary-glucose
79733917|NCT02812654|Drug|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
79733918|NCT02812654|Drug|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
79868501|NCT05880472|Device|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
80027809|NCT03564249|Device|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
80027810|NCT03702985|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
79574137|NCT01843790|Drug|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
79574138|NCT01843829|Drug|Oxaliplatin|
79574139|NCT01843829|Drug|Capecitabine|
79574140|NCT01843829|Drug|Carboplatin|
80027811|NCT03702985|Drug|Capecitabine|625mg/m2 bid Monday-Friday per week
79574141|NCT01843829|Drug|Paclitaxel|
80027812|NCT03702985|Drug|Irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
80027813|NCT03702985|Drug|Amifostine|400mg/m2 per week
79574142|NCT01843829|Radiation|Radiotherapy|
79574143|NCT01843829|Procedure|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
79402462|NCT04197271|Other|Conservative management|Treatment of hernia without resort to surgery
79574144|NCT01843855|Drug|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
79574145|NCT01843855|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
79733919|NCT02812654|Radiation|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
79574146|NCT01843868|Drug|Standard anti-emetics in conjunction with R-CHOP|
79574147|NCT01843881|Drug|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
79574148|NCT01843881|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
79574149|NCT01843894|Biological|RU-101|Recombinant human serum albumin
79574150|NCT01843907|Behavioral|Empowerment|To give patients the necessary resources to take care of their own health
79574151|NCT01843907|Other|Conversation with nurse|To find out, if the nurse, using her ....
79574152|NCT01843998|Drug|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
79574153|NCT01844011|Other|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
79574154|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
79574155|NCT01844037|Device|OneShot Ablation System|Renal denervation
79574156|NCT01844050|Drug|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
79574157|NCT01844050|Drug|Placebo|
79733920|NCT02809066|Other|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~50 gr kashkaval cheese,~400 ml milk and~150 gr yogurt for each day."
79733921|NCT01097694|Drug|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
79733922|NCT01097694|Drug|Placebo|Placebo
79868502|NCT05880433|Device|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
79868503|NCT05880407|Procedure|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
80027814|NCT02256930|Drug|M518101|
80027815|NCT02256930|Drug|M518101 Vehicle|
80027816|NCT02256930|Other|Sodium lauryl sulfate|
80027817|NCT02256930|Other|Saline|
80027818|NCT04056351|Diagnostic Test|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
80027819|NCT04056351|Other|Questionnaires on patient activity and comorbidities|"Shoulder activity scale (Marx)~Parker Mobility Scale~Barthel index~Charlson Comorbidity Score"
80027820|NCT04056351|Other|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
80027821|NCT04056351|Other|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
80027822|NCT02183922|Dietary Supplement|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
80027823|NCT02183922|Dietary Supplement|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
80027824|NCT02183922|Dietary Supplement|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
79574158|NCT01844063|Genetic|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
79868504|NCT05880407|Procedure|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
80027825|NCT03699787|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
80027826|NCT03564405|Device|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
80027827|NCT03702829|Drug|Inotersen|Open Label Study
79574159|NCT01844063|Genetic|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
79733923|NCT02808754|Procedure|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic > 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
79574160|NCT01844063|Drug|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
79574161|NCT01844102|Device|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
79574162|NCT01844128|Dietary Supplement|weight loss|
79574163|NCT01844141|Drug|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
79733924|NCT00688831|Drug|AZD1305|Solution for iv infusion , single dose
79733925|NCT00688831|Drug|Placebo|NaCl solution for iv infusion, single dose
79733926|NCT02808832|Behavioral|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
79574164|NCT01844141|Drug|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
79733927|NCT00688987|Drug|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
79733928|NCT00688987|Dietary Supplement|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
79733929|NCT02808676|Dietary Supplement|Vitamin D3|Dose: 10000 IU, three times per week, orally.
79733930|NCT02808676|Other|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
80027828|NCT03064984|Other|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
80027829|NCT03064984|Other|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
79868505|NCT05880381|Device|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
79868506|NCT05880381|Other|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
80027830|NCT02184078|Drug|Nevirapine|
80027831|NCT02184078|Drug|Rifabutin|
79868507|NCT05880342|Drug|Reboxetine Pill|8 mg
79868508|NCT05880342|Drug|Methylphenidate Oral Product|20 mg
79868509|NCT05880316|Behavioral|Intermittent Fasting|3:4 regime
79868510|NCT05880290|Procedure|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
79868511|NCT05880277|Diagnostic Test|POCUS|Point of Care Ultrasound
79868512|NCT05880186|Dietary Supplement|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
79868513|NCT05880173|Diagnostic Test|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
79868514|NCT05880121|Diagnostic Test|MRI|brain MRI
79868515|NCT05880082|Drug|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
80027832|NCT03702673|Drug|K-877 CR Tablet A|K-877 Controlled Release Tablet A
79733931|NCT02808676|Other|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
79868516|NCT05880069|Other|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
79868517|NCT05880056|Drug|Nerkardou 5 mg & Nerkardou 10 mg|"(Nerkardou 5 mg) Bisoprolol oral dissolved film ODF: equivalent to 5 mg of bisoprolol fumarate.~(Nerkardou 10 mg) Bisoprolol oral dissolved film ODF: equivalent to 10 mg of bisoprolol fumarate."
79868518|NCT05880030|Drug|Cholecalciferol|cholecalciferol 10000 UI
79868519|NCT05880030|Other|placebo|sunflower oil
80027833|NCT03702673|Drug|K-877 CR Tablet B|K-877 Controlled Release Tablet B
80027834|NCT03702673|Drug|K-877 CR Tablet E|K-877 Controlled Release Tablet E
80027835|NCT03702673|Drug|K-877 IR Tablet|K-877 Immediate Release Tablet
80027836|NCT03694951|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
80027837|NCT03694873|Drug|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
80027838|NCT03694873|Drug|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
80027839|NCT02188446|Behavioral|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
80027840|NCT02191020|Drug|Total glucosides of paeony & Acitretin Capsules|
80027841|NCT02191020|Drug|Acitretin Capsules|
80027842|NCT02832063|Biological|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
79402463|NCT03422094|Biological|NeoVax|At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
79574165|NCT01844167|Procedure|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
79402464|NCT03422094|Biological|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
79733932|NCT02808676|Other|placebo D3|matching placebo for Vitamin D3
79733933|NCT02808676|Other|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
79733934|NCT02808676|Other|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
80027843|NCT02832063|Biological|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
80027844|NCT02188524|Other|Exercise|Tai Chi and Compensatory Stepping
80027845|NCT03694717|Drug|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
80027846|NCT02184234|Drug|Antistax film coated tablets|
80027847|NCT03694639|Other|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
79402465|NCT03422094|Biological|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
79402466|NCT03422094|Procedure|Research blood draw|-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
79402467|NCT03422094|Procedure|Leukapheresis for research|-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
80027848|NCT03564327|Procedure|Wide antrum circle ablation|As standard hospital policy
80027849|NCT03564327|Procedure|External electric cardioversion|Three attempts (200-250 joules)
80027850|NCT05014854|Device|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
80027851|NCT04476199|Combination Product|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
79868520|NCT05880017|Procedure|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
79574166|NCT01844167|Procedure|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
79733935|NCT04138459|Other|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~Qualitative, in-depth interviews with service users and mental health professionals and~Observational fieldwork"
79868521|NCT05880017|Procedure|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
79574167|NCT01844219|Procedure|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
79271046|NCT04018053|Device|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
79271047|NCT04010786|Drug|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
79271048|NCT04010786|Drug|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
79574168|NCT01844245|Procedure|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
79574169|NCT01844258|Procedure|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
79574170|NCT01844258|Procedure|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
79574171|NCT01844271|Device|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
79574172|NCT01844297|Drug|TDF+3TC+EFV|
79574173|NCT01844310|Drug|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
79574174|NCT01844310|Drug|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
79574175|NCT01844323|Other|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
79574176|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
79574177|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
79574178|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
79733936|NCT02878746|Device|Robotic mirror therapy|2-dimensional
79574179|NCT01844336|Device|PBASE system 1.1 + CT100 (active treatment)|
79574180|NCT01844336|Device|PBASE system 1.1 + CT100 (placebo treatment)|
79574181|NCT01844401|Drug|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
79574182|NCT01844401|Drug|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
79733937|NCT02878746|Device|Conventional mirror therapy|2- and 3-dimensional
79733938|NCT00683371|Procedure|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
79733939|NCT00683371|Procedure|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
79733940|NCT04308798|Procedure|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
79574183|NCT01844414|Behavioral|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
79733941|NCT04138693|Device|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
79733942|NCT04138693|Device|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
79868522|NCT05880017|Drug|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
79868523|NCT05880017|Drug|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
79868524|NCT05879900|Other|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
79868525|NCT05879900|Other|Physical Education classes|Physical Education classes according their previously planned contents.
79868526|NCT05879848|Other|VR|virtual reality scenario synchronized with the uterine contractions
79868527|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
79868528|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
79868529|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
79868530|NCT05879796|Drug|cis-platinum|chemotherapeutics
79868531|NCT05879796|Radiation|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
79868532|NCT05879796|Drug|Envafolimab Injection|PD-L1 antibody
79868533|NCT05879796|Drug|Recombinant Human Endostatin Injection|angiogenesis inhibitors
80027852|NCT02188680|Other|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
79574184|NCT01844414|Behavioral|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
79574185|NCT01844414|Behavioral|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
79574186|NCT01844427|Drug|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
80027853|NCT03702595|Other|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
80027854|NCT02191098|Drug|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
79574187|NCT01844427|Drug|Placebo|
79574188|NCT01844440|Procedure|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
79733943|NCT04138693|Device|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
79733944|NCT02812498|Other|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
79733945|NCT02812498|Other|Standard|Group of patients followed in a traditional way
79733946|NCT00689065|Drug|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
79733947|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
79733948|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
79733949|NCT00690937|Drug|Colesevelam Cholestagel|Drug comparator
79733950|NCT00690937|Drug|Placebo|Placebo
79733951|NCT00690937|Drug|Placebo|Placebo
79868534|NCT05879783|Diagnostic Test|Confocal laser endomicroscopy|After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
79868535|NCT05879770|Other|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
79733952|NCT01102140|Drug|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
79733953|NCT01102140|Drug|Sugar Pill|Matching sugar pill
79733954|NCT02690116|Other|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
80027855|NCT04050319|Diagnostic Test|Screening and diagnosis if injured|physical therapy
79271049|NCT03994029|Dietary Supplement|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
79271050|NCT03950336|Dietary Supplement|Prebiotics|Oligofructose-enriched inulin [a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %] 12 g/day for 6 weeks
79271051|NCT03950336|Other|Low n-6 PUFA Diet|The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
79271052|NCT03950336|Dietary Supplement|Maltodextrin|Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment
79271053|NCT03950336|Other|Control Diet|"Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention."
79402468|NCT03596593|Diagnostic Test|SPANOM (identifying MSI status from ctDNA)|SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
79574189|NCT01844453|Procedure|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
79574190|NCT01844466|Procedure|Physiotherapy and speech therapy|
79574191|NCT01844492|Behavioral|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
79574192|NCT01844492|Other|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
79733955|NCT02690116|Other|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
79574193|NCT01844544|Other|inspection of medical records|
79868536|NCT05879705|Other|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
79868537|NCT05879627|Drug|BAT8007 for injection|Intravenous infusion: once every two weeks (Q2W). The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
79868538|NCT05879601|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
79271054|NCT03945240|Procedure|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, ~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
79402469|NCT03225378|Other|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
79868539|NCT05879601|Other|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
79868540|NCT05879588|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
79402470|NCT03225378|Other|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
79574194|NCT01844557|Other|Swallowing Exercises|Participants perform 3 swallowing exercises.
79574195|NCT01844557|Behavioral|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
79574196|NCT01844557|Behavioral|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
79733956|NCT02690116|Other|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
79868541|NCT05879588|Other|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
79733957|NCT00689143|Drug|sargramostim|
79733958|NCT02812810|Device|active rTMS|
79733959|NCT02812810|Device|sham rTMS|
80027856|NCT02188758|Other|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
80027857|NCT02030340|Procedure|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
80027858|NCT02191176|Drug|Dextromethorphan syrup - low dose|
80027859|NCT02191176|Drug|Dextromethorphan syrup - high dose|
80027860|NCT02191176|Drug|Placebo|
80027861|NCT02191254|Drug|Antistax®|
80027862|NCT02191254|Drug|Placebo|
79271055|NCT03945240|Procedure|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, ~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
79733960|NCT02879370|Procedure|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
79733961|NCT04139239|Diagnostic Test|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
79271056|NCT03945240|Procedure|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, ~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
79271057|NCT03940352|Drug|HDM201|Capsule
79271058|NCT03940352|Biological|MBG453|LIVI (Liquid in vial) Concentrate for Solution for infusion
79574197|NCT01844596|Behavioral|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
79574198|NCT01844596|Behavioral|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
80027863|NCT02184312|Drug|Nevirapine XR low dose|
80027864|NCT02184312|Drug|Nevirapine XR medium dose|
80027865|NCT02184312|Drug|Nevirapine XR high dose|
80027866|NCT02184312|Drug|Nevirapine (VIRAMUNE®)|
79271059|NCT03940352|Drug|Venetoclax|Tablet
79271060|NCT03938415|Procedure|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
79402471|NCT03596515|Other|Sensory Integration|Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
79402472|NCT03591367|Diagnostic Test|MicroRNAs-155|Quantitative analysis of cell-free miR-155 using RT-qPCR.
79402473|NCT03591367|Diagnostic Test|Human telomerase reverse transcriptase|Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
79402474|NCT04356534|Other|plasma therapy using convalescent plasma with antibody against SARS-CoV-2|convalescent patient plasma plus routine local standard of care
79402475|NCT04356534|Other|Routine care for COVID-19 patients|local standard of care which include antivirals and supportive care
79402476|NCT03591289|Drug|NMB with rocuronium bromide|Moderate versus deep neuromuscular block Not a device study
79402477|NCT03596437|Device|Ultra High Frequency ultrasound system|Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
79733962|NCT02808442|Biological|UCART19|
79733963|NCT00683527|Drug|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
79733964|NCT02808598|Behavioral|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
80027867|NCT02184390|Other|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
80027868|NCT02184468|Other|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
80027869|NCT02188914|Radiation|Positron emission tomography scan|
80027870|NCT02188914|Other|Magnetic resonance imaging|
80027871|NCT04050241|Device|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
80027872|NCT04050241|Device|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
80027873|NCT02191332|Drug|Viramune|
79574199|NCT01844609|Behavioral|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
79574200|NCT01844609|Behavioral|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
79574201|NCT01844622|Other|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
79271061|NCT03938415|Other|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
79868542|NCT05879562|Diagnostic Test|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
79574202|NCT01844635|Drug|Thymoglobulin|
79271062|NCT03936153|Drug|abexinostat|abexinostat tablet
80027874|NCT03702361|Drug|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
79402478|NCT03023917|Procedure|umbilical cord milking|Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
79574203|NCT01844648|Drug|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
79402479|NCT03023917|Procedure|umbilical cord clamping immediately|umbilical cord was cut immediately after birth
79574204|NCT01844648|Drug|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
79733965|NCT00634426|Procedure|Surgical excision of the metastatic process|Surgical excision of the metastatic process
79402480|NCT03591211|Behavioral|Qigong Training|Eight-Section Brocades; participants were trained individually.
79574205|NCT01844661|Biological|CELYVIR|
79574206|NCT01844674|Drug|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
79574207|NCT01844674|Drug|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
79574208|NCT01844713|Behavioral|Workbook|Subjects will read a workbook about sun protection
79868543|NCT05879536|Drug|Tramadol-ondansetron continuous infusion|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
79868544|NCT05879536|Drug|Ropivacaine via epidural catheter|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
79868545|NCT05879406|Dietary Supplement|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
80027875|NCT02191410|Procedure|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of < 2 L min-1, using a second identical ventilator with low compliant internal circuit
80027876|NCT02191410|Procedure|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
80027877|NCT03699085|Behavioral|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
80027878|NCT02191644|Dietary Supplement|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
79574209|NCT01844739|Drug|NVN1000 4% Gel|Applied topically twice daily
79574210|NCT01844739|Drug|Vehicle Gel|Applied topically twice daily
79574211|NCT01844752|Drug|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
79574212|NCT01844752|Drug|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
79733966|NCT00634426|Radiation|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
79733967|NCT00683683|Behavioral|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
79271063|NCT03935750|Procedure|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
79271064|NCT03935750|Procedure|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
79733968|NCT00683761|Drug|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
79733969|NCT02812732|Behavioral|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3&4. Action Plans are developed in Session 5. Sessions 6&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
79733970|NCT00912457|Drug|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
79271065|NCT03934567|Drug|Abexinostat|Abexinostat tablets
79271066|NCT03931941|Drug|RBX2660|RBX2660 is a microbiota suspension administered as an enema
79271067|NCT03921944|Diagnostic Test|CT scan of the shoulders|studies of both operative and nonoperative shoulders
79402481|NCT03591211|Behavioral|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
79574213|NCT01844752|Drug|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
79574214|NCT01844791|Drug|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
79574215|NCT01844791|Drug|Platinum|Platinum is given as standard chemotherapy each cycle
79574216|NCT01844791|Drug|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
79733971|NCT00912457|Drug|placebo|placebo 1 p/day for 28 days
79402482|NCT03596359|Behavioral|Education with Teach-Back method|
79402483|NCT03596359|Other|Received routine treatment|
79402484|NCT02696382|Behavioral|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
80027879|NCT02191644|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
79402485|NCT02696382|Behavioral|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
79402486|NCT03023761|Device|low level laser|low level laser irradiation
79402487|NCT03023761|Device|laser sham|laser without irradiation
79402488|NCT02471118|Drug|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
79402489|NCT02471118|Drug|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
79271068|NCT03893929|Diagnostic Test|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
79271069|NCT03880435|Device|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
79271070|NCT03877809|Drug|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
79271071|NCT03862781|Procedure|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
79271072|NCT03834688|Drug|Venetoclax|"Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days)."
79271073|NCT03834688|Drug|Bendamustine|Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
79402490|NCT03590977|Other|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
79402491|NCT03590977|Other|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
79574217|NCT01844804|Biological|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
79574218|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
79574219|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
79574220|NCT01844843|Device|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
79574221|NCT01844869|Drug|omacetaxine mepesuccinate|
79574222|NCT01844908|Procedure|Electroacupuncture|
79733972|NCT02808286|Behavioral|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
79733973|NCT02808286|Behavioral|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
79733974|NCT04139161|Procedure|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion >12, indicating a transition to moderate physical activity, or 3) self-reported pain >5.
80027880|NCT02189226|Device|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
80027881|NCT03698929|Other|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
79271074|NCT03834688|Drug|Rituximab|Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
79574223|NCT01844934|Other|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
79574224|NCT01844947|Drug|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance >60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
79574225|NCT01844947|Drug|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
79733975|NCT04093492|Other|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
79271075|NCT03816332|Biological|Ipilimumab|Given IV
79271076|NCT03816332|Biological|Nivolumab|Given IV
79574226|NCT01844960|Procedure|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
79574227|NCT01844960|Procedure|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
79574228|NCT01844973|Drug|M518101|Proper quantity twice a day
79733976|NCT04093492|Other|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
79868546|NCT05879406|Other|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
79574229|NCT01844973|Drug|Vehicle|Proper quantity twice a day
79574230|NCT01844999|Behavioral|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
79868547|NCT05879380|Diagnostic Test|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
79868548|NCT05879380|Diagnostic Test|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
79868549|NCT05879354|Other|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
79868550|NCT05879341|Other|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
79271077|NCT03816332|Drug|Prednisone|Given PO
79271078|NCT03816332|Drug|Tacrolimus|Given PO
79271079|NCT03808961|Dietary Supplement|Niacin|100mg tablets twice daily
79271080|NCT03808961|Dietary Supplement|Niacinamide|100mg tablets twice daily
79271081|NCT03808961|Other|Placebo|Placebo tablet twice daily
79574231|NCT01844999|Behavioral|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
79868551|NCT05879328|Procedure|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
80027882|NCT03698929|Other|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
80027883|NCT02256774|Drug|BILR 355 BS|
80027884|NCT02256774|Drug|Combivir®|
80027885|NCT02256774|Drug|Ritonavir|
80027886|NCT04597164|Other|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
80027887|NCT02191722|Behavioral|reading comics booklet|
80027888|NCT03693859|Behavioral|Cognitive enhancement program|The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
79271087|NCT03783546|Device|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
79271088|NCT03783546|Other|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
79271089|NCT03765736|Other|Genetic Testing|Undergo genetic testing
79271090|NCT03760406|Procedure|Opti-VIM targeting in DBS surgery|DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
79271091|NCT03740724|Genetic|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
79271092|NCT03740724|Drug|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
79271093|NCT03738852|Device|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
79574232|NCT01845012|Other|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
79574233|NCT01845038|Drug|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of ~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
80027889|NCT03693859|Behavioral|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
80027890|NCT02256852|Biological|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
80027891|NCT02189304|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
80027892|NCT02189304|Drug|PT009|PT009 administered as 2 inhalations
80027893|NCT02189304|Drug|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
80027894|NCT02184858|Drug|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
79574234|NCT01845038|Drug|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of ~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
79574235|NCT01845038|Drug|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
79574236|NCT01845064|Drug|DM199|
80027895|NCT02191956|Behavioral|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
80027896|NCT02030652|Procedure|Intermittent nasal positive pressure positive ventilation.|
80027897|NCT02030652|Procedure|CPAP|Nasal continuous positive airway pressure
80027898|NCT03535662|Drug|Orvepitant|Single oral dose
80027899|NCT03535662|Drug|Itraconazole|Once daily dosing for 10 days
80027900|NCT02192034|Behavioral|Navigation|
80027901|NCT03702205|Dietary Supplement|Betaine supplementation|Group taking oral betaine supplementation
80027902|NCT03702205|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
79574237|NCT01845064|Drug|Placebo|
79574238|NCT01845090|Drug|Lanthanum carbonate|the effect on serum FGF23
79574239|NCT01845090|Drug|Calcium Carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
80027903|NCT03624829|Other|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
79271094|NCT03738852|Drug|Insulin|standard insulin regimen
79271095|NCT03716245|Procedure|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
79271096|NCT03716245|Radiation|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
79271097|NCT03704818|Drug|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
79271098|NCT03704818|Drug|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
79271099|NCT03703778|Procedure|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
79574240|NCT01845129|Device|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
79574241|NCT01845129|Device|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
79574242|NCT01845142|Drug|single administration of 100.000 I.U. vitamin D|
79574243|NCT01845142|Drug|Placebo|
79574244|NCT01845168|Other|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
79574245|NCT01845168|Device|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
79733977|NCT04139083|Procedure|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
79733978|NCT04139083|Procedure|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
79733979|NCT04200586|Drug|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
79733980|NCT02807974|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
79733981|NCT02807818|Behavioral|Home visiting Program for Young Pregnant Women|
79733982|NCT04120168|Genetic|Laboratory Tests|"Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
79733983|NCT00874549|Biological|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
79733984|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79733985|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
79733986|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79271100|NCT03703778|Drug|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
79271101|NCT03703778|Drug|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
79271102|NCT03671889|Device|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
79271103|NCT03640208|Behavioral|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
79271104|NCT03637543|Drug|Nivolumab|Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
79271105|NCT03621189|Device|intermittent theta burst stimulation|stimulatory protocol
79271106|NCT03616860|Device|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
79574246|NCT01845168|Device|Computer-alert|
79271107|NCT03604302|Device|fMRI Paradigms|T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
79574247|NCT01845181|Drug|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
79271108|NCT03600441|Drug|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
79574248|NCT01845181|Drug|Placebo|1 or 2 or 3 capsules of placebo.
79574249|NCT01845194|Drug|Codeine|"Treatment period 2:~5 mg Codeine once"
79574250|NCT01845194|Drug|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
79271109|NCT03597399|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
79574251|NCT01845194|Drug|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
79574252|NCT01845194|Drug|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
79574253|NCT01845194|Drug|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
79574254|NCT01845194|Drug|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
79574255|NCT01845194|Drug|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
79733987|NCT04116814|Diagnostic Test|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
79733988|NCT02807740|Other|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
79733989|NCT02807740|Other|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
79733990|NCT02812108|Device|intracranial stent, flow diverter and coils|
79733991|NCT02807896|Other||This study is cohort.
79733992|NCT02812264|Behavioral|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
79271110|NCT03594136|Device|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
79271111|NCT03592472|Drug|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
79574256|NCT01845246|Device|Prospective TDM Arm of colistin|
79733993|NCT02812264|Behavioral|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
79574257|NCT01845259|Drug|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
79574258|NCT01845259|Drug|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
79574259|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
79574260|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
79574261|NCT01845285|Device|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
79574262|NCT01845298|Drug|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
79733994|NCT02812264|Behavioral|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
79733995|NCT02812264|Behavioral|scale|Connected scale that will transfer weight information to app
79733996|NCT04236700|Other|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
79733997|NCT02812030|Other|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
79733998|NCT02625103|Procedure|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
79733999|NCT02625103|Drug|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
79734000|NCT02807662|Behavioral|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
79734001|NCT01155479|Drug|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
79734002|NCT01155479|Drug|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
79734003|NCT01155479|Drug|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
79402492|NCT04197115|Drug|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
79402493|NCT04197115|Drug|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
79574263|NCT01845350|Other|M2 macrophage introduction|"Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~Intrathecal introduction of autologous M2 macrophages"
79734004|NCT01155479|Drug|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
79734005|NCT01155479|Drug|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
79574264|NCT01845363|Drug|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
79271112|NCT03592472|Drug|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
79574265|NCT01845376|Procedure|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
79734006|NCT01155479|Drug|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
79574266|NCT01845376|Procedure|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
79271113|NCT03592472|Other|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
79271114|NCT03583528|Diagnostic Test|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
79271115|NCT03583528|Diagnostic Test|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
79574267|NCT01845376|Procedure|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
79574268|NCT01845389|Device|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
79574269|NCT01845389|Device|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
79574270|NCT01845402|Biological|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
79574271|NCT01845415|Behavioral|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
79574272|NCT01845415|Behavioral|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
79574273|NCT01845428|Drug|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
79574274|NCT01845454|Device|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
79734007|NCT04138303|Other|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
79734008|NCT04138303|Other|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
80027904|NCT02189538|Dietary Supplement|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
79574275|NCT01845480|Behavioral|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
79574276|NCT01845493|Dietary Supplement|Alpha Sprout Homogenate|Alpha Sprout Homogenate
79734009|NCT04138303|Other|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
79271116|NCT03582891|Device|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
79271117|NCT03582891|Diagnostic Test|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
79271118|NCT03582891|Device|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
79574277|NCT01845493|Dietary Supplement|Sulforaphane Homogenate|Active
79271119|NCT03574012|Device|Monitoring Device|Use Fitbit tracker
79574278|NCT01845506|Device|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
79574279|NCT01845506|Device|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
79574280|NCT01845519|Behavioral|Tailored Email|Participants will receive tailored emails.
79574281|NCT01845519|Behavioral|Targeted Email|Participants will receive targeted emails.
79734010|NCT02807584|Device|ELECT|
79734011|NCT04031131|Drug|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
79271120|NCT03574012|Other|Informational Intervention|Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
79271121|NCT03574012|Other|Informational Intervention|Receive general health and fitness information from clinician
79574282|NCT01845532|Drug|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25~0.5% lidocaine, 0.125% bupivacaine)
79574283|NCT01845532|Drug|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
79734012|NCT04031131|Other|KY Gel|Lubricant Gel
79574284|NCT01845545|Other|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
79574285|NCT01845558|Drug|Wobenzym® plus|
79574286|NCT01845558|Other|Placebo|
79734013|NCT00683839|Behavioral|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
79734014|NCT02807272|Drug|Tipifarnib|Oral tablet
79734015|NCT02811796|Other|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
79734016|NCT04138771|Device|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
79734017|NCT01155323|Device|etafilcon A|1-day soft contact lens
79734018|NCT01155323|Device|omafilcon A|1-day soft contact lens
79271122|NCT03574012|Other|Questionnaire Administration|Ancillary studies
79574287|NCT01845584|Drug|NPB-01|
79734019|NCT02807194|Other|spinal anesthesia|
79734020|NCT02807194|Other|general anesthesia|
79734021|NCT02807194|Procedure|lumbar disc herniation|
79734022|NCT00912535|Drug|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
79734023|NCT00912535|Drug|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
79734024|NCT02811718|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
79734025|NCT02811718|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
79734026|NCT04313777|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
79734027|NCT04313777|Device|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
79734028|NCT04313777|Behavioral|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
79574288|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
79868552|NCT05879315|Other|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
79574289|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
79574290|NCT01845623|Drug|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
79574291|NCT01845623|Drug|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
79271123|NCT03551964|Drug|Cangrelor|"Cangrelor: IV bolus 30 μg/kg (application < 1 minute), immediately followed by continuous infusion in the dose of 4 μg/kg/min. To accelerate the initiation of therapy, tables containing calculations of the bolus dose in ml and the speed of infusion therapy for individual weights will be prepared.~Cangrelor therapy will be stopped after circulatory stabilization - when sBP > 100 mmHg persists for one hour / when IABP will be terminated / when vasoactive treatment with norepinephrine, dopamine (in the dose ≥ 5 μg/kg/min) will be stopped, but not later than 4 hours after PCI~30 minutes before stopping Cangrelor infusion, administration of initial dose of crushed Ticagrelor 180 mg and then Ticagrelor maintenance dose 90 mg twice a day for 12 months."
79271124|NCT03551964|Drug|Ticagrelor|Initial dose crushed Ticagrelor 180 mg. Maintenance dose Ticagrelor 90 mg twice daily for 12 months.
79271125|NCT03543813|Drug|CX-2029|CX-2029 Monotherapy
79271126|NCT03532971|Other|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
79574292|NCT01845623|Other|Placebo Concept 1|Placebo administered via the Concept 1 device.
79574293|NCT01845623|Other|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
79271127|NCT03532971|Diagnostic Test|BK polyomavirus PCR|quantitative PCR testing
79271128|NCT03532971|Other|quality of life questionnaires|Standard questionnaires validated for HCT recipients
79734029|NCT02811874|Behavioral|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
79734030|NCT02811874|Behavioral|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
79734031|NCT02625727|Other|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
79734032|NCT02625727|Other|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
79734033|NCT02884739|Other|Data collection|
79734034|NCT04313699|Drug|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
79868553|NCT05879302|Behavioral|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
79271129|NCT03527537|Drug|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
79271130|NCT03520790|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
79271131|NCT03520790|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
79574294|NCT01845662|Other|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
79574295|NCT01845675|Drug|temozolomide or dacarbazine-based chemotherapy, endostatin|
79574296|NCT01845701|Drug|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
79574297|NCT01845701|Drug|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis[1-(7-chloro-4 quinolyl)-4- piperazinyl]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
79734035|NCT01155167|Drug|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
79734036|NCT01155167|Other|Placebo|Placebo
79574298|NCT01845701|Drug|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
79574299|NCT01845714|Procedure|Corneal Cross Linking|
79734037|NCT02807038|Procedure|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
79574300|NCT01845714|Procedure|Corneal Cross Linking combined with topoguided PRK|
79574301|NCT01845727|Drug|Topical Amphotericin B at 3%|
79868554|NCT05879289|Dietary Supplement|A power supplement|A dietary supplement containing vitamins and collagen
79868555|NCT05879276|Drug|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
79868556|NCT05879263|Other|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
79868557|NCT05879263|Other|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
79574302|NCT01845740|Drug|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
79868558|NCT05879237|Drug|Vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
79868559|NCT05879237|Drug|Helicobacter pylori triple therapy|"Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month"
79271132|NCT03520790|Drug|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
79574303|NCT01845740|Drug|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
79574304|NCT01845753|Other|Observation|Observation
79574305|NCT01845766|Other|exercise rehabilitation|
79574306|NCT01845779|Drug|DCF regimen|
79574307|NCT01845844|Drug|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
79868560|NCT05879211|Behavioral|Feedback|Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
79868561|NCT05879172|Device|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
79574308|NCT01845857|Behavioral|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
79574309|NCT01845883|Procedure|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
79574310|NCT01845896|Behavioral|Training|
79574311|NCT01845909|Other|ECG and survey screening|
79574312|NCT01845922|Dietary Supplement|Low sodium diet|Low sodium diet
79574313|NCT01845935|Device|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
79574314|NCT01845948|Behavioral|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
79574315|NCT01845948|Behavioral|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
79574316|NCT01846000|Procedure|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
79574317|NCT01846013|Behavioral|Stand|Stand at least half of the workday at work.
79868562|NCT05879172|Device|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
79868563|NCT05879133|Behavioral|Questionnaires|Survey
79868564|NCT05879133|Other|Fit Bit|measures physical activity
79868565|NCT05879068|Drug|PM8002|IV infusion
79868566|NCT05879068|Drug|Paclitaxel|IV infusion
79868567|NCT05879055|Drug|PM8002|IV infusion
79868568|NCT05879055|Drug|FOLFIRI|IV infusion
79868569|NCT05879003|Behavioral|neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on the two adductors.
79271133|NCT03520790|Other|Placebo|Placebo
79271134|NCT03511391|Drug|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
79271135|NCT03511391|Radiation|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
79271136|NCT03486834|Biological|V160|V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) IM injection.
79868570|NCT05878977|Drug|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
80027905|NCT02189538|Dietary Supplement|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
80027906|NCT03624751|Radiation|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
80027907|NCT02184936|Other|standard of care|
80027908|NCT02192268|Other|PEP|
79271137|NCT03486834|Drug|Placebo|Saline solution administered as a 0.5 mL IM injection
79574318|NCT01846013|Behavioral|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
79574319|NCT01846013|Behavioral|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
79574320|NCT01846026|Drug|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
79574321|NCT01846026|Drug|placebo|
80027909|NCT02192268|Other|HFOO|
79574322|NCT01846078|Device|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
79574323|NCT01846117|Dietary Supplement|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
79574324|NCT01846130|Dietary Supplement|Leucine|
79574325|NCT01846130|Behavioral|Exercise|
79574326|NCT01846130|Dietary Supplement|Whey protein|
79734038|NCT04141111|Device|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
79868571|NCT05878964|Other|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
80027910|NCT02192268|Other|Assisted Coughing|
79868572|NCT05878964|Other|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
79868573|NCT05878964|Other|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
79868574|NCT05878834|Dietary Supplement|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
79868575|NCT05878834|Dietary Supplement|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
79868576|NCT05878756|Other|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
79271138|NCT03482167|Drug|Niagen®|250 mg capsules (4 capsules daily)
79271139|NCT03482167|Other|Placebo|placebo
79271140|NCT03478865|Drug|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
79271141|NCT03356145|Drug|12 mL paracervical block|Injection of 12 mL of lidocaine
79271142|NCT03356145|Drug|20 mL paracervical block|Injection of 20 mL of lidocaine
79271143|NCT03344835|Other|No intervention|
79574327|NCT01846143|Biological|pBCAR3-phosphopeptide|
79574328|NCT01846143|Biological|pIRS2-phosphopeptide|
79574329|NCT01846143|Biological|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
79574330|NCT01846156|Drug|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics & Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
79868577|NCT05878535|Drug|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
79868578|NCT05878535|Drug|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
80027911|NCT02185092|Dietary Supplement|Lactobacillus GG|probiotic supplement
80027912|NCT02185092|Other|Sugar pill|placebo
80027913|NCT02189616|Behavioral|SMS reminder|send weekly mobile phone short message reminders to the intervention group
80027914|NCT02189616|Other|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
80027915|NCT02189616|Other|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
80027916|NCT03693703|Diagnostic Test|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
80027917|NCT03693703|Diagnostic Test|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
80027918|NCT02189694|Device|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
80027919|NCT02189694|Device|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
80027920|NCT02189694|Device|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
80027921|NCT02189772|Drug|Metadoxine extended release|MG01CI
80027922|NCT02189772|Drug|Placebo|Inactive drug
79868579|NCT05877833|Other|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
79574331|NCT01846169|Behavioral|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
79868580|NCT05877651|Biological|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
79868581|NCT05877443|Procedure|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
79868582|NCT05877443|Procedure|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
79868583|NCT05877443|Procedure|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
79868584|NCT05876247|Other|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
79868585|NCT05876104|Behavioral|Behavioral therapy|Behavioral and supportive therapy
79868586|NCT05875506|Drug|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
79868587|NCT05875506|Drug|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
79868588|NCT05875350|Procedure|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
79868589|NCT05874947|Device|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
79868590|NCT05871086|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
79868591|NCT05871086|Other|Placebo|Placebo Capsules
79868592|NCT05871086|Drug|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~Leflunomide - Weight based, 10-20 mg once daily~Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~Etanercept - 0.8 mg/kg/dose once weekly~Adalimumab - Weight based, 10-40 mg every other week"
79868593|NCT05870215|Other|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
79868594|NCT05870215|Other|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
80027923|NCT02192346|Drug|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
80027924|NCT02192346|Drug|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
80027925|NCT02192346|Drug|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
80027926|NCT02192346|Drug|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
79574332|NCT01846247|Other|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
79574333|NCT01846247|Other|Standard care|
79574334|NCT01846273|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
79271144|NCT03312738|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
79574335|NCT01846273|Drug|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
79574336|NCT01846273|Drug|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
79574337|NCT01846312|Other|No treatment given|The participants will not receive any treatment.
79574338|NCT01846325|Dietary Supplement|vitamin E|
79574339|NCT01846325|Dietary Supplement|DHA|
79574340|NCT01846325|Other|placebo|
79574341|NCT01846338|Dietary Supplement|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
79868595|NCT05870215|Other|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
79868596|NCT05870215|Other|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
80027927|NCT02192346|Drug|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
80027928|NCT02192346|Drug|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
80027929|NCT02192346|Drug|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
80027930|NCT02192346|Drug|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
79868597|NCT05870215|Other|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
79868598|NCT05870215|Other|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
80027931|NCT02192346|Drug|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
79402494|NCT04197115|Drug|Complex B|Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
79574342|NCT01846364|Dietary Supplement|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
79574343|NCT01846377|Behavioral|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
79734039|NCT02811406|Procedure|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
79734040|NCT02811406|Biological|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
79734041|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|Low Dose- 70g bar
79734042|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|High Dose- 100g bar
79734043|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
79734044|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|High dose: 100g bar
79734045|NCT00691249|Dietary Supplement|Shredded Wheat|70g bar
80027932|NCT03698773|Other|Access to routine information|Access to routine pain-control information
80027933|NCT03698773|Other|Access to website|Access to informational website: thepainlesspush.com
80027934|NCT02185170|Procedure|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
79574344|NCT01846403|Device|Semi-quantitative urine pregnancy test|
79574345|NCT01846429|Drug|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
79868599|NCT05870215|Other|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
79868600|NCT05866549|Other|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
79868601|NCT05864755|Drug|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
79868602|NCT05864404|Drug|remimazolam-remifentanil|In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
80027935|NCT02185170|Device|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
80027936|NCT02185170|Device|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
79402495|NCT02579850|Drug|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
79574346|NCT01846468|Drug|LHW090|1 mg, 12.5 mg, 100 mg capsules
79574347|NCT01846468|Drug|Placebo|Matching placebo capsules
79574348|NCT01846520|Other|educational intervention|Receive FCPCI home education sessions
80027937|NCT03693469|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
80027938|NCT02192424|Drug|Metformin alone|
80027939|NCT02192424|Drug|Metformin + Intermittent Insulin Therapy|
80027940|NCT04276597|Drug|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
80027941|NCT02257008|Drug|BILR 355 BS|
80027942|NCT02257008|Other|Grapefruit juice|
79868603|NCT05864404|Drug|dexmedetomidine-remifentanil|In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
79868604|NCT05863637|Other|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
79734046|NCT05238155|Drug|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
79868605|NCT05862454|Drug|Magnesium|Magnesium injection therapy
79574349|NCT01846520|Behavioral|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
79868606|NCT05859243|Behavioral|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
79868607|NCT05859243|Behavioral|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
79574350|NCT01846520|Procedure|quality-of-life assessment|Ancillary studies
79868608|NCT05856981|Drug|ADU-1805|anti-SIRPα monoclonal antibody
79868609|NCT05856981|Drug|Pembrolizumab|Keytruda
79734047|NCT01106586|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
79868610|NCT05850572|Drug|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
79868611|NCT05850572|Other|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
80027943|NCT02257008|Drug|Nelfinavir|
80027944|NCT02257008|Drug|Atazanavir|
79734048|NCT01106586|Drug|ATV|Atazanavir 300 mg capsule administered orally once daily
79734049|NCT01106586|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
79734050|NCT01106586|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
80027945|NCT02257008|Drug|Ritonavir|
80027946|NCT04432948|Other|PHQ-9 Depression Scale|It involves a 9-question scale that detects depression
80027947|NCT04432948|Other|GAD-7 General anxiety disorder scale|It involves a 7-question scale that detects general anxiety disorder
80027948|NCT04432948|Other|38-questions questionnaire|It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
80027949|NCT03693391|Drug|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
80027950|NCT03693391|Drug|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) [18F]JNJ-64511070 will be administered.
79271145|NCT03312738|Drug|Exemestane|Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
79574351|NCT01846520|Other|questionnaire administration|Ancillary studies
79574352|NCT01846559|Biological|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
79574353|NCT01846559|Drug|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
79574354|NCT01846559|Drug|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
79574355|NCT01846585|Behavioral|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
79574356|NCT01846585|Behavioral|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
79574357|NCT01846637|Procedure|laparoscopic sleeve gastrectomy|
79574358|NCT01846650|Drug|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
79574359|NCT01846650|Drug|XELODA|Single oral XELODA 2000mg qd
79734051|NCT01106586|Drug|Stribild Placebo|Placebo to match Stribild administered orally once daily
79734052|NCT01106586|Drug|ATV Placebo|Placebo to match ATV administered orally once daily
79734053|NCT01106586|Drug|RTV Placebo|Placebo to match RTV administered orally once daily
79734054|NCT01106586|Drug|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
79868612|NCT05849532|Device|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
79868613|NCT05849103|Other|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
79574360|NCT01846676|Behavioral|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
79868614|NCT05849103|Other|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
80027951|NCT02185248|Behavioral|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
80027952|NCT04433806|Behavioral|Referral to weight loss program|16 weeks Diabetes Prevention Program based weight loss program at a local community partner
79734055|NCT02884583|Other|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
80027953|NCT03693313|Behavioral|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
80027954|NCT02189928|Device|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
80027955|NCT02189928|Other|Usual care|
80027956|NCT04433650|Device|Pictorial support in person-centred care for children (PicPecc)|"Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments."
80027957|NCT02192580|Drug|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
79271146|NCT03312738|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
79574361|NCT01846676|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
79734056|NCT00683995|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
79271147|NCT03297359|Biological|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
79574362|NCT01846689|Drug|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
79574363|NCT01846715|Biological|Implantation of SRC|
79574364|NCT01846767|Other|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton & Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
79734057|NCT02884817|Drug|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
80027958|NCT02193594|Radiation|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
80027959|NCT02193594|Procedure|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
79271148|NCT03284866|Other|Laboratory Biomarker Analysis|Correlative studies
79271149|NCT03284866|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
79271150|NCT03284866|Other|Saline|Given IM
79271151|NCT03268954|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
79868615|NCT05847985|Device|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
79868616|NCT05847790|Device|Invu monitoring belt|INVU monitoring belt used for remote NSTs
79868617|NCT05847790|Other|Standard of care|In-clinic NSTs - standard of care
80027960|NCT02193594|Drug|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
80027961|NCT02185326|Drug|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
79574365|NCT01846780|Procedure|PTA & stenting|PTA & stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
79574366|NCT01846806|Other|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
79574367|NCT01846832|Drug|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
79574368|NCT01846832|Drug|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
80027962|NCT02185482|Behavioral|Physician Supported Care|
80027963|NCT02185482|Other|Usual care|
80027964|NCT03536364|Behavioral|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
80027965|NCT03536364|Behavioral|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
80027966|NCT03536364|Behavioral|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
79574369|NCT01846832|Drug|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is < 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is > or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
79574370|NCT01846845|Device|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
79734058|NCT02884817|Other|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
79734059|NCT02884817|Other|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
80027967|NCT02192736|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
80027968|NCT03535428|Diagnostic Test|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
80027969|NCT02192892|Dietary Supplement|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
80027970|NCT02192892|Dietary Supplement|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
79734060|NCT02806804|Biological|one dose test vaccine|
80027971|NCT02192892|Dietary Supplement|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
79734061|NCT02806804|Biological|one dose commercially available trivalent influenza vaccine|
79734062|NCT02806804|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
79734063|NCT04138537|Other|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
79734064|NCT04138537|Other|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
79868618|NCT05846906|Drug|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
79868619|NCT05846906|Drug|Clomiphene Citrate 50mg|used for ovionulation induct
79868620|NCT05846074|Diagnostic Test|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
80027972|NCT02192892|Dietary Supplement|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
79271152|NCT03268954|Drug|Pevonedistat|Pevonedistat intravenous infusion.
79868621|NCT05845320|Other|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
79868622|NCT05844462|Drug|Tadalafil|Oral Tadalafil
79868623|NCT05844462|Drug|Placebo|Oral Placebo
79868624|NCT05844111|Drug|[14C]-BGB-11417|A single oral dose of liquid formulation
79868625|NCT05841719|Other|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
80027973|NCT02192892|Dietary Supplement|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
80027974|NCT02192892|Dietary Supplement|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
80027975|NCT02192892|Dietary Supplement|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
80027976|NCT02192892|Dietary Supplement|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
80027977|NCT02192892|Dietary Supplement|Commercial porridge flour|Porridge from commercial porridge flour
79574371|NCT01846845|Device|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
79574372|NCT01846910|Behavioral|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
79574373|NCT01846910|Behavioral|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
79868626|NCT05839210|Behavioral|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
79868627|NCT05839210|Behavioral|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
79868628|NCT05839210|Behavioral|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
79868629|NCT05838807|Device|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
80027978|NCT02192892|Dietary Supplement|Commercial porridge bar|Porridge from commercial porridge bar
80027979|NCT02192892|Dietary Supplement|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
79734065|NCT02811562|Device|manikin|
79734066|NCT02811562|Device|fiberoptic bronchoscope|
79734067|NCT02811562|Device|pentax-airwayscope|
79734068|NCT04137991|Device|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
79734069|NCT04137991|Other|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
79734070|NCT04031365|Procedure|Acupuncture|Use of sterile, disposable needles in acupuncture
79734071|NCT04031365|Behavioral|Cognitive Behavioral Therapy|psychotherapy
79734072|NCT01155011|Behavioral|Physical Activity|"MIPARC will focus on 3 physical activity goals:~increasing walking behavior through gradually increasing step goals~increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
79734073|NCT01155011|Behavioral|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
79271153|NCT03242382|Drug|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
79271154|NCT03204513|Device|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
79574374|NCT01846923|Biological|PCV13|
79574375|NCT01846936|Procedure|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
79868630|NCT05838807|Device|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
79402496|NCT02579850|Drug|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
79271155|NCT03204513|Device|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
79574376|NCT01846936|Procedure|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
79402497|NCT02579850|Procedure|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
79271156|NCT03196232|Drug|Epacadostat|Given PO
79574377|NCT01846936|Procedure|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
79734074|NCT01155011|Behavioral|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~health check~step goal check~barrier identification~problem solving~specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
79734075|NCT01155011|Behavioral|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
79734076|NCT01155011|Behavioral|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
79868631|NCT05838807|Device|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
79868632|NCT05838807|Device|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
79868633|NCT05837234|Device|ULF SCS|Ultra low frequency spinal cord stimulation
79868634|NCT05835245|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
79271157|NCT03196232|Drug|Pembrolizumab|Given IV
79868635|NCT05835245|Drug|Sintilimab|a PD-1 immune check inhibitor
79868636|NCT05835245|Drug|Lenvatinib|Lenvatinib capsules
79868637|NCT05827276|Other|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
79868638|NCT05826327|Drug|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
79868639|NCT05826327|Drug|Sufentanil|Sufentanil for labour analgesia in the control group
79868640|NCT05823116|Drug|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
79868641|NCT05823116|Drug|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
79868642|NCT05817721|Drug|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
79868643|NCT05817721|Device|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
79402498|NCT02579850|Other|COPD assessment test|COPD assessment test (CAT) at visit 1
79402499|NCT02579850|Procedure|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
79574378|NCT01846962|Drug|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
79734077|NCT01155011|Behavioral|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
79734078|NCT01155011|Behavioral|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
79868644|NCT05814991|Drug|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
79868645|NCT05814991|Device|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
79868646|NCT05814367|Drug|Blink® Tears eye drops in a multidose bottle|Control
79868647|NCT05814367|Drug|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
79868648|NCT05812248|Diagnostic Test|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
79868649|NCT05800730|Other|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
79868650|NCT05800730|Other|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
79868651|NCT05800730|Other|energy-restricted diet|After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
79868652|NCT05800730|Other|time-restricted diet|After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
79868653|NCT05796479|Drug|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
79868654|NCT05796479|Drug|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
79868655|NCT05794399|Drug|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl >50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
80027980|NCT04762212|Procedure|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
80027981|NCT04412707|Drug|Melphalan|Peripheral versus central administration
79271165|NCT03181256|Procedure|Biospecimen Collection|Undergo collection of sputum
79734079|NCT01155011|Behavioral|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
79734080|NCT01155011|Behavioral|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
79734081|NCT01155011|Behavioral|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
80027982|NCT04412707|Drug|Dexamethasone|Oral tablets
79271166|NCT03181256|Procedure|Biospecimen collection|Undergo collection of nasal epithelium
79271167|NCT03181256|Procedure|Biospecimen collection|Undergo collection of buccal epithelium
79271168|NCT03181256|Procedure|Biospecimen collection|Undergo collection of blood
79271169|NCT03181256|Procedure|Biospecimen collection|Undergo collection of urine
79271170|NCT03181256|Procedure|Pulmonary Function Test|Undergo pulmonary function test
79271171|NCT03181256|Procedure|Computed Tomography (CT)|Undergo chest CT
79271172|NCT03181256|Other|Laboratory Biomarker|Correlative studies
79271173|NCT03122899|Device|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
79271174|NCT03120624|Procedure|Biopsy|Undergo image-guided biopsy
79574379|NCT01846962|Drug|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
79271175|NCT03120624|Procedure|Computed Tomography|Undergo CT
79271176|NCT03120624|Other|Fluorine F 18 Tetrafluoroborate|Given IV
79271177|NCT03120624|Other|Pharmacological Study|Correlative studies
79734082|NCT00689689|Device|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
79734083|NCT00689689|Device|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
79271178|NCT03120624|Procedure|Positron Emission Tomography|Undergo TFB-PET
79271179|NCT03120624|Biological|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
79734084|NCT02879292|Other|Spinal anesthesia|Spinal Anesthesia
79734085|NCT00689767|Device|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
79734086|NCT00689767|Device|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
79734087|NCT04313465|Other|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
79734088|NCT02806648|Drug|Palbociclib|Palbociclib
79734089|NCT04138147|Procedure|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
79734090|NCT04138147|Procedure|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
79734091|NCT04071808|Diagnostic Test|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
79734092|NCT04307784|Dietary Supplement|VD3|VD3 (50.000 IU/week) for 8 weeks
79734093|NCT04307784|Dietary Supplement|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
79734094|NCT04307784|Dietary Supplement|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
79734095|NCT04307784|Other|Control|No intervention is given
79734096|NCT00689845|Biological|bleomycin sulfate|Given IV
79734097|NCT00689845|Biological|filgrastim|Given subcutaneously
79734098|NCT00689845|Biological|rituximab|given IV
79734099|NCT00689845|Drug|cyclophosphamide|Given IV
79271180|NCT03120624|Drug|Ruxolitinib Phosphate|Given PO
79271181|NCT03120624|Drug|Technetium Tc-99m Sodium Pertechnetate|Given IV
79271182|NCT03120624|Procedure|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
79271183|NCT03117933|Drug|Olaparib|Tablet, 100mg and 150mg
79271184|NCT03117933|Drug|Cediranib|Tablet 15mg and 20mg
79271185|NCT03117933|Drug|Paclitaxel|Intravenous (IV)
79271186|NCT03114527|Drug|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
79734100|NCT00689845|Drug|cytarabine|Given subcutaneously
79734101|NCT00689845|Drug|doxorubicin hydrochloride|Given IV
79271187|NCT03114527|Drug|Everolimus|mTOR inhibitor
79271188|NCT03113513|Procedure|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
79271189|NCT03094663|Drug|Bupivacaine with epinephrine|bupivacaine 0.5% with epinephrine 30cc
79271190|NCT03094663|Drug|Methylprednisolone|40 mg/ml, 1 ml
79271191|NCT03094663|Drug|Cefazolin|500 mg in 10 ml
79271192|NCT03094663|Device|8 MHz. Chiba needle|22G/ 4 inches
79271193|NCT03094663|Drug|Bupivacaine with Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
79271194|NCT03094663|Drug|Bupivacaine 25cc|25 cc 0.25% bupivacaine
79734102|NCT00689845|Drug|etoposide phosphate|Given IV
79734103|NCT00689845|Drug|ifosfamide|Given IV
79734104|NCT00689845|Drug|methotrexate|Given IV
79734105|NCT00689845|Drug|prednisolone|Given orally
79734106|NCT00689845|Drug|prednisone|Given orally
79734107|NCT00689845|Drug|vincristine sulfate|Given IV
79734108|NCT00689845|Drug|vindesine|Given IV
79734109|NCT00624767|Drug|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
79734110|NCT00624767|Drug|NovoLog|NovoLog at doses up to 30 IU
79734111|NCT04200820|Diagnostic Test|Trampoline|During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
79734112|NCT04205981|Other|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
79734113|NCT02806492|Other|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP <60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
79734114|NCT02806492|Other|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
79734115|NCT02806492|Other|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
79271195|NCT03094663|Drug|Bupivacaine 20cc|20cc 0.25% bupivacaine
79271196|NCT03094663|Drug|Dexamethasone|2 mg IV dexamethasone.
79271197|NCT03076554|Drug|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
79271198|NCT03065335|Drug|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
79271199|NCT03065335|Other|Placebo|Placebo comparator
79271200|NCT03065335|Device|Cobot TS MV robotic arm for TMS|TMS-Cobot TS MV [Axilum Robotics] robotic arm for spatial positioning and orientation of the TMS coil
79574380|NCT01846962|Behavioral|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
79271201|NCT03065335|Device|NeurOptics PLRTM-30000 Pupillometer|The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
79271202|NCT03022032|Device|Fitbit Zip|Fitbit Zip
79402500|NCT02579850|Other|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
79402501|NCT02579850|Other|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
79734116|NCT02806492|Other|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
79734117|NCT02806492|Other|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
79734118|NCT02884895|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
79868656|NCT05794399|Drug|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
79868657|NCT05790473|Diagnostic Test|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
79402502|NCT04196881|Other|Knowledge Improvement Program about ADHD|This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
79402503|NCT03590665|Other|Hand grip exercise and lower body negative pressure|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
79402504|NCT04196725|Other|Physical therapy treatment|Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
79402505|NCT04196725|Behavioral|Lifestyle treatment|Two weeks rehabilitation programme focusing on physical activity
79402506|NCT03024151|Drug|Comthyroid|T4/T3 combination replacement
79402507|NCT03024151|Drug|Synthroid|T4 mono replacement
79402508|NCT01118676|Drug|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
79574381|NCT01846962|Drug|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
79271203|NCT03022032|Other|HOPE App|HOPE App
79271204|NCT03022032|Other|Standard of Care|Standard of Care
79271205|NCT03022032|Device|Fitbit Charge 2|Fitbit Charge 2
79271206|NCT03022032|Other|SMART Study Intervention|SMART study app + Beiwe study app + Fitbit
79271207|NCT02966145|Other|Observational Study|
79271208|NCT02927262|Drug|Gilteritinib|Oral tablet
79271209|NCT02927262|Drug|Placebo|Oral tablet
79271210|NCT02927236|Device|TMS|TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
79271211|NCT02902211|Device|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
79271212|NCT02902211|Other|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
79271213|NCT02851706|Other|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
79868658|NCT05789563|Other|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
79868659|NCT05789433|Behavioral|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
79868660|NCT05789433|Behavioral|Progressive stretching|Statistic stretching of eight major muscle groups
79868661|NCT05788510|Other|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
79868662|NCT05786846|Drug|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
79271214|NCT02792270|Other|Caloric Restriction Diet|"Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein."
79271215|NCT02763345|Other|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
79574382|NCT01846975|Drug|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
79734119|NCT02884895|Device|Direct Laryngoscopy|Direct Laryngoscopy
79734120|NCT02806258|Radiation|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
79734121|NCT02806258|Drug|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
79734122|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
79868663|NCT05783973|Diagnostic Test|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
79868664|NCT05780203|Behavioral|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
79868665|NCT05780203|Behavioral|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
79868666|NCT05780203|Behavioral|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
79868667|NCT05769322|Device|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
79868668|NCT05765669|Procedure|Percutaneous transiliac - transsacral screw fixation|Surgical intervention in the form of percutaneous transiliac - transsacral screw fixation
79271216|NCT02763345|Other|Standard care|
79271217|NCT02663622|Drug|Efprezimod alfa|Acute GVHD prophylaxis
79868669|NCT05765669|Other|Pain management and physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
79868670|NCT05764395|Drug|Rigosertib|Given by mouth
79271218|NCT02663622|Drug|Methotrexate|Acute GVHD prophylaxis
79574383|NCT01847053|Other|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
79574384|NCT01847053|Other|Oatmeal|Oatmeal control, around 70g; without cinnamon
79868671|NCT05764395|Biological|Pembrolizumab|Given by IV
79868672|NCT05764395|Procedure|Magnetic Resonance Imaging|Undergo MRI
79868673|NCT05764395|Procedure|Biospecimen Collection|Undergo blood sample collection
79868674|NCT05764395|Procedure|Biopsy|Undergo tissue biopsy
79868675|NCT05763888|Other|No drug will given|No intervention will be given to the subject
79574385|NCT01847066|Device|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
79574386|NCT01847066|Device|Erbium 2940 plus cosmetics|laser
79574387|NCT01847079|Other|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
79868676|NCT05763186|Other|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
79868677|NCT05763186|Other|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
79868678|NCT05758571|Drug|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
79868679|NCT05756842|Dietary Supplement|Honey-based gel supplementation|70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
79868680|NCT05755113|Drug|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
79868681|NCT05753462|Drug|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
79868682|NCT05753462|Drug|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
79271219|NCT02663622|Drug|Tacrolimus|Acute GVHD prophylaxis
79271220|NCT02663622|Drug|Placebo|100 ml saline IV infusion.
79271221|NCT02650271|Drug|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
79574388|NCT01847105|Other|RevitaLens|Multi-purpose disinfecting solution
79574389|NCT01847105|Other|OptiFree PureMoist|Multi-purpose disinfecting solution
79868683|NCT05753462|Drug|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
79734123|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
79868684|NCT05753462|Drug|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
79271222|NCT02650271|Drug|Tenofovir|Patients will be received tenofovir before liver resection.
79271223|NCT02649387|Drug|Ibrutinib|Given PO
79574390|NCT01847118|Drug|Sevacizumab|
79574391|NCT01847144|Drug|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
79868685|NCT05735262|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
79868686|NCT05735262|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
79868687|NCT05735171|Procedure|GTR surgery|Gross total resection of the enhancing tumor volume
79868688|NCT05735171|Procedure|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
79868689|NCT05733273|Other|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
79868690|NCT05733273|Other|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
79868691|NCT05733273|Other|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
79868692|NCT05727371|Combination Product|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
79868693|NCT05727371|Device|Hylan G-F 20|Single intra-articular injection at Day 0
79868694|NCT05727371|Drug|Placebo|Single intra-articular injection at Day 0
79868695|NCT05727293|Other|noting|Non intervention
79868696|NCT05715255|Behavioral|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
79868697|NCT05715255|Behavioral|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
79271224|NCT02649387|Other|Laboratory Biomarker Analysis|Correlative studies
79271225|NCT02649153|Drug|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
79868698|NCT05714306|Biological|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
79868699|NCT05714306|Biological|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
79271226|NCT02649153|Drug|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
79271227|NCT02637713|Device|Stretta|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.
79271228|NCT02637713|Procedure|Radiofrequency (RF) Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
79402509|NCT03595969|Diagnostic Test|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
79574392|NCT01847144|Drug|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
79734124|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
79734125|NCT00691405|Drug|Placebo|Placebo inhalation solution BID
79734126|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
79734127|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
79734128|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
79734129|NCT00691405|Drug|Placebo|Placebo inhalation solution QD
79734130|NCT01106430|Drug|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
79271229|NCT02603341|Radiation|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
79734131|NCT01106430|Drug|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
79734132|NCT02804698|Behavioral|Education intervention|13-week educational and physical activity intervention
79868700|NCT05714306|Biological|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
79868701|NCT05714306|Drug|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
79868702|NCT05706259|Dietary Supplement|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
79868703|NCT05706259|Dietary Supplement|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
79734133|NCT01154231|Drug|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
79734134|NCT02806180|Procedure|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
79402510|NCT02467452|Drug|BDP/FF/GB|
79734135|NCT02806180|Procedure|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
79734136|NCT02804776|Drug|Gefitinib|250mg oral daily for 4 weeks
79734137|NCT01154153|Drug|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
79734138|NCT01154153|Drug|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
79868704|NCT05704374|Diagnostic Test|sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)|Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.
79868705|NCT05704374|Drug|Pregabalin 150mg|In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
79868706|NCT05704192|Procedure|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
79868707|NCT05703750|Procedure|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
79868708|NCT05703724|Device|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
79868709|NCT05701709|Drug|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
79402511|NCT02467452|Drug|FlF/VI + Tiotropium|
79402512|NCT03590587|Drug|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
79868710|NCT05696171|Procedure|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
79868711|NCT05696171|Procedure|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
79868712|NCT05690256|Behavioral|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
79271230|NCT02603341|Radiation|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
79271231|NCT02564172|Device|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
79271232|NCT02564172|Other|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~at effective dose, and minimal effective dose on the basis of adverse events and contraindications~as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
80027983|NCT03534882|Other|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
79734139|NCT01154153|Drug|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
80027984|NCT02930850|Device|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
79734140|NCT01154153|Drug|Claritin® Syrup|Children's Claritin® Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
80027985|NCT02193672|Drug|[18F] Fluciclatide|[18F] Fluciclatide given by vein before PET/CT scan.
80027986|NCT02193672|Procedure|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
80027987|NCT02193672|Behavioral|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
79868713|NCT05690256|Behavioral|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
79868714|NCT05680558|Drug|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
80027988|NCT03698695|Drug|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
79868715|NCT05680558|Device|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
80027989|NCT03698695|Drug|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
80027990|NCT03698695|Drug|Placebo|Donepezil placebo and Mefloquine placebo
79402513|NCT03590587|Device|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
79402514|NCT05375526|Device|Magtrace|"In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle."
79574393|NCT01847157|Device|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
79574394|NCT01847157|Drug|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
79574395|NCT01847157|Drug|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
79868716|NCT05679180|Device|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
79868717|NCT05678127|Procedure|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
80027991|NCT03693235|Procedure|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
80027992|NCT02030808|Drug|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
80027993|NCT02030808|Drug|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
80027994|NCT03702049|Behavioral|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
80027995|NCT04729296|Drug|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants <45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
80027996|NCT04729296|Drug|Placebo|Inactive Drug
80027997|NCT03698617|Drug|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
80027998|NCT03698617|Drug|Propofol|For induction of general anesthesia
80027999|NCT02193750|Dietary Supplement|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
79868718|NCT05668728|Other|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
79868719|NCT05668728|Other|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
80028000|NCT02193750|Dietary Supplement|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
80028001|NCT02193750|Dietary Supplement|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
80028002|NCT02193126|Other|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
80028003|NCT02194374|Procedure|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
80028004|NCT02194374|Drug|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
80028005|NCT02194374|Drug|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
80028006|NCT02194374|Drug|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
80028007|NCT02194374|Drug|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
80028008|NCT03693079|Procedure|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~Primary suction; cups are left attached to the skin for 5 minutes.~Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
80028009|NCT02193204|Behavioral|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
80028010|NCT02193204|Behavioral|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
80028011|NCT03693001|Device|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
79271233|NCT02553473|Drug|Doxycycline|
79271234|NCT02553473|Drug|Placebo|
79734141|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
79734142|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
79734143|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
79734144|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
79734145|NCT00691561|Behavioral|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
79734146|NCT00684229|Procedure|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
79734147|NCT00684229|Drug|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
79734148|NCT02887001|Other|Pharmacist consultation|
79868720|NCT05668728|Other|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
79868721|NCT05668221|Behavioral|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
79574396|NCT01847157|Other|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
79574397|NCT01847157|Device|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
79402515|NCT05375448|Other|Neural mobilisation|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
79574398|NCT01847170|Biological|Fecal Microbial Transplantation|
79574399|NCT01847183|Behavioral|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
79574400|NCT01847222|Biological|SANGUINATE™|PEG-bHb-CO
79868722|NCT05667324|Drug|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
79868723|NCT05667324|Drug|Dexamethasone|Plus 4 mg dexamethasone
79868724|NCT05667324|Drug|Placebo|A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
79868725|NCT05663242|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
79868726|NCT05663242|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
79271235|NCT02550366|Drug|MRI Contrast|MRI Contrast
79868727|NCT05661851|Drug|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
79271236|NCT02522611|Drug|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
79868728|NCT05661851|Drug|Blink® Tears eye Drops|Control Product
79868729|NCT05656521|Drug|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
79271237|NCT02520713|Genetic|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
79271238|NCT02470507|Other|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
79574401|NCT01847222|Drug|Normal Saline Solution|Placebo
79271239|NCT02410850|Device|Oral Appliance|Mandibular Advancement Splints
79271240|NCT02398747|Drug|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
79271241|NCT02384473|Procedure|Real-Time CEUS|Undergo real-time CEUS
79271242|NCT02384473|Procedure|SWE|Undergo SWE
79271243|NCT02384473|Drug|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
79574402|NCT01847235|Drug|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
79574403|NCT01847261|Dietary Supplement|Soy Dairy Protein Blend|
79574404|NCT01847261|Dietary Supplement|Positive Control (Dairy Whey Protein)|
79868730|NCT05656521|Drug|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
79868731|NCT05650086|Device|Thermalytix|One-time Thermal imaging is performed for this cohort.
79868732|NCT05646511|Radiation|SCRT|5x5 Gy: 25 Gy
79868733|NCT05646511|Drug|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
79868734|NCT05646511|Drug|CAPOXIRI|Six cycles of CAPOX capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 200 mg/m2 intravenously on day 1, every 3 weeks)
79868735|NCT05644041|Drug|Gemcitabine|Gemcitabine will be administered intravesically at a dose of 2000 mg.
79271244|NCT02384473|Device|Philips Shear Wave Elastography|Type of equipment used for SWE
79271245|NCT02230501|Dietary Supplement|stringent diet regimen|
79271246|NCT02230501|Dietary Supplement|moderate diet regimen|
79271247|NCT02193425|Drug|F-18FDG|18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
79271248|NCT02193425|Device|MRI|Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
79868736|NCT05641207|Device|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients will be assigned to two sessions of treatments with RheOx~Treatment 1 is scheduled at right lung at the first treatment.~And then approximately one month later, treatment 2 is delivered to left lung at the second treatment."
80028012|NCT02193906|Other|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
80028013|NCT02193906|Other|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
80028014|NCT03692923|Other|virtual community|
79868737|NCT05633992|Biological|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
79868738|NCT05633992|Biological|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
79271249|NCT02169310|Device|tDCS|There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
79271250|NCT02169310|Drug|[11C] Raclopride|[11C] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and [11C] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: [11C] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
79271251|NCT02091999|Drug|enfortumab vedotin|intravenous (IV) infusion
79868739|NCT05630430|Procedure|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
79868740|NCT05628623|Drug|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
79271255|NCT02014675|Device|SD01 ICD lead|
79271256|NCT01961869|Other|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
79271257|NCT01961869|Other|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
79402516|NCT03945565|Other|Fraction of inspired oxygen level|A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
79402517|NCT03590431|Dietary Supplement|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
79574405|NCT01847300|Behavioral|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
79574406|NCT01847339|Drug|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
79574407|NCT01847339|Other|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
79574408|NCT01847352|Drug|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
79574409|NCT01847352|Other|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
79574410|NCT01847365|Device|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
79574411|NCT01847378|Procedure|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
79574412|NCT01847391|Drug|GS-6615|GS-6615 tablet(s) administered orally once daily
79574413|NCT01847391|Drug|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
80028015|NCT02193360|Drug|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
79271258|NCT01961869|Other|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
79271259|NCT01915212|Biological|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
79271260|NCT01915212|Other|Placebo|Sodium Chloride 0.9%
79271261|NCT01861106|Procedure|Allogeneic HSCT|Stem cell transplant
79271262|NCT01861106|Drug|Busulfan Test dose|0.8 mg/kg IV infusion over 3 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
79271263|NCT01861106|Drug|Fludarabine (Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
79271264|NCT01861106|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing). If in Arm B and if poor or very poor risk clonal chromosomal abnormalities, busulfan will also be given on day -2.
79271265|NCT01861106|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
79271266|NCT01861106|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
79271267|NCT01861106|Drug|Mycophenolate mofetil (MMF)|15mg/kg IV over 2 hours BID starting on day +5 will continue until day +35 (+/- 2 days)
79402518|NCT03590431|Dietary Supplement|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
79402519|NCT03590431|Dietary Supplement|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
79402520|NCT05102604|Other|Avocado|Subjects will eat one avocado in addition to their usual diet
79402521|NCT05102604|Other|Habitual diet|Subjects will eat their usual diet
79574414|NCT01847404|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
79574415|NCT01847404|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
79574416|NCT01847404|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
79734149|NCT04236622|Other|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
79271268|NCT01861106|Drug|Tacrolimus|0.02mg/kg IV continuous infusion over 24 hours starting on day +5 until day +180
79271269|NCT01861106|Biological|Equine Anti-Thymocyte Globulin|(Deleted this intervention per amendment I): 30mg/kg IV (in the vein)once daily x 3 days on Days -6, -5, -4 (3 doses total)
79271270|NCT01804452|Other|Observational Study|
79271271|NCT01783288|Other|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
79271272|NCT01783288|Other|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured & collected in the supine (lying) and upright position for each participant.
79402522|NCT03980665|Drug|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
79402523|NCT05102526|Behavioral|"Experimental: Young Millie prevention program, active teachers"|"Prevention program: Young Mili, in collaboration with the teacher"
79402524|NCT05102526|Behavioral|"Prevention program: Young Mili, non active teachers"|"Prevention program: Young Mili, without the participation of the teacher"
79402525|NCT04438122|Other|Cabernet Sauvignon|Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
79402526|NCT04438122|Other|Tsipouro|Tsipouro is a greek spirit which contains 38% alcohol vol
79271273|NCT01783288|Procedure|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
79271274|NCT01783288|Other|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
79271275|NCT01722240|Drug|Liraglutide 1.8mg|
79271276|NCT01722240|Drug|Placebo|
79271277|NCT01697397|Device|Recording of Myoelectric Signals|Obtain recordings of the electrical signals of the gut.
80028016|NCT03688321|Dietary Supplement|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
79868741|NCT05628623|Drug|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
79402527|NCT03595813|Procedure|Blood sample collection|Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
79402528|NCT03595813|Procedure|Biopsy collection|Optional biopsy collection at baseline and progression
79402529|NCT03595735|Device|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
79574417|NCT01847404|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
79574418|NCT01847417|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
79574419|NCT01847417|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
79574420|NCT01847417|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
79574421|NCT01847417|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
79574422|NCT01847456|Drug|human insulin as nasal spray|
79574423|NCT01847456|Drug|Placebo|
79574424|NCT01847482|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
79574425|NCT01847495|Drug|Irinotecan|40mg/m2 x 3-5 days
79574426|NCT01847495|Radiation|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
79574427|NCT01847508|Device|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
79574428|NCT01847508|Device|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
79574429|NCT01847521|Dietary Supplement|Luteolin, Quercetin and Rutin combined in a capsule|
79574430|NCT01847534|Other|Supplemental PN|
79574431|NCT01847534|Other|Standard Care|
79574432|NCT01847586|Procedure|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
79574433|NCT01847586|Procedure|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
79734150|NCT04313387|Diagnostic Test|Corneal tomography multivariate index derived from a support vector machine (CTMVI).|MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
79574434|NCT01847599|Other|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
79574435|NCT01847612|Procedure|indocyanine green fluorescent cholangiography|
79734151|NCT02804620|Behavioral|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
79868742|NCT05628623|Drug|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
79868743|NCT05628623|Drug|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
79868744|NCT05622006|Behavioral|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
79868745|NCT05616923|Drug|Trametinib|Topical cream containing 0.1 mg/g trametinib
79868746|NCT05614921|Other|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
80028017|NCT03688321|Dietary Supplement|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
80028018|NCT03692845|Procedure|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
80028019|NCT02194452|Radiation|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
80028020|NCT02194452|Procedure|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
80028021|NCT02194452|Procedure|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
79574436|NCT01847612|Drug|methylene blue|
79574437|NCT01847651|Procedure|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574438|NCT01847651|Drug|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
80028022|NCT02194452|Other|laboratory biomarker analysis|Correlative studies
80028023|NCT04243213|Other|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
80028024|NCT04243213|Other|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
80028025|NCT04243213|Other|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
79271278|NCT01651208|Behavioral|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
79271279|NCT01651208|Behavioral|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
79271280|NCT01524211|Device|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
79271281|NCT01370447|Drug|EPI-743|EPI-743 (oral solution [100 mg/mL] or liquid-filled capsules [100 mg or 200 mg]) will be administered per dose and schedule specified in the arm.
79271282|NCT01266577|Other|NSR MAGNETOM 7T|The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
79271283|NCT01266577|Other|1Tx x 32Rx Head Coil|Used to perform proton imaging and spectroscopy in the human heads.
79271284|NCT01190787|Drug|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
79574439|NCT01847651|Other|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574440|NCT01847651|Other|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574441|NCT01847651|Other|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574442|NCT01847651|Other|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574443|NCT01847651|Other|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574444|NCT01847651|Other|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574445|NCT01847651|Other|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
79574446|NCT01847664|Drug|Rifamycin SV-MMX® 400 mg b.i.d.|
79574447|NCT01847664|Drug|Rifamycin SV-MMX® 600 mg t.i.d.|
79574448|NCT01847664|Drug|Rifamycin SV-MMX® Placebo|
79574449|NCT01847677|Drug|Bevacizumab|
79734152|NCT00690079|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L
79734153|NCT00690079|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
79734154|NCT05251415|Biological|Blood sampling|Blood will be taken in larger quantity.
79734155|NCT02805712|Other|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
79734156|NCT02805712|Other|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
79734157|NCT00874237|Drug|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
79734158|NCT00874237|Drug|Inhaled placebo|Inhaled Staccato placebo single dose
80028026|NCT02193438|Other|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
80028027|NCT02193438|Other|Placebo|Tomato juice intake
80028028|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
80028029|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
80028030|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
80028031|NCT02257164|Procedure|Femoral nerve block|2 mg/ml
80028032|NCT02257164|Procedure|obturator nerve block|
80028033|NCT02257164|Procedure|intraarticular injection|
80028034|NCT02193984|Behavioral|Peer support|
80028035|NCT02194608|Device|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
80028036|NCT02195856|Dietary Supplement|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
80028037|NCT02195856|Dietary Supplement|Placebo|
79574450|NCT01847677|Drug|Paclitaxel|
79574451|NCT01847677|Drug|Carboplatin|
79734159|NCT00874237|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg
79868747|NCT05614921|Other|Wound infiltration|5 ml local anesthetic for each trocar side
79402530|NCT05102448|Drug|Tofacitinib|"Tofacitinib 5mg twice a day for 12 months;~Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until disuse if patients were in inactive status based on the NIH disease activity criteria."
79402531|NCT05102448|Drug|Methotrexate|"Methotrexate (15mg each week) for 12 months~Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until disuse if patients were in inactive status based on the NIH disease activity criteria."
79574452|NCT01847690|Drug|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
79574453|NCT01847703|Procedure|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
79734160|NCT00874237|Drug|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
79574454|NCT01847703|Procedure|Abdominal surgery|Current gold standard
79574455|NCT01847742|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|
79574456|NCT01847768|Biological|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
79574457|NCT01847768|Procedure|Bronchoalveolar Lavage|
79574458|NCT01847768|Drug|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
79574459|NCT01847768|Procedure|Nasal Lavage|
79574460|NCT01847768|Procedure|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
79574461|NCT01847768|Procedure|Bronchial Brushings|
79574462|NCT01847768|Procedure|Lung Mucosal Biopsy|
79574463|NCT01847768|Procedure|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer & glycerol negative control.
79574464|NCT01847768|Procedure|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
79574465|NCT01847768|Procedure|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
79868748|NCT05612932|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
79574466|NCT01847768|Procedure|Spirometry|
79574467|NCT01847781|Biological|Prevenar13|
79574468|NCT01847794|Device|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
79271285|NCT01190787|Drug|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
79271286|NCT01190787|Drug|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
79574469|NCT01847807|Drug|low dose Astragalus|
79574470|NCT01847807|Drug|high dose astagalus|
79574471|NCT01847820|Device|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
79574472|NCT01847833|Other|MRI scan|
79734161|NCT02805946|Drug|posaconazole|iv versus oral
79574473|NCT01847846|Device|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
79574474|NCT01847872|Drug|IPV IM Needle|
79574475|NCT01847872|Drug|IPV ID Needle|
79574476|NCT01847872|Drug|IPV IM Device|
79574477|NCT01847872|Drug|IPV ID Device|
79734162|NCT05544604|Device|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
79734163|NCT04139005|Behavioral|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
79574478|NCT01847898|Procedure|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
79574479|NCT01847898|Procedure|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
79271287|NCT01107717|Drug|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c < 6.5%
79271288|NCT01107717|Drug|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c < 6.5%
79402532|NCT04196647|Other|Home titration|Patients have their initial dosage titration of duodopa done in their own home, supported by one visit from nursing staff, and one video consultation a day
79574480|NCT01847911|Other|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
79574481|NCT01847911|Other|instructor training|a pre-validated OSCE neonatal resuscitation program
79574482|NCT01847924|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
79868749|NCT05612932|Other|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
79868750|NCT05608200|Drug|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
79868751|NCT05608200|Drug|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
79868752|NCT05606692|Drug|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
79868753|NCT05606692|Drug|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
79868754|NCT05606614|Genetic|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
79868755|NCT05602688|Dietary Supplement|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
79868756|NCT05602688|Dietary Supplement|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
79868757|NCT05601336|Drug|Dapagliflozin 5 MG|SGLT2 inhibitor
79868758|NCT05601336|Drug|Metformin Hydrochloride 1000 MG|metformin
79402533|NCT03855696|Biological|MG1113|MG1113
79868759|NCT05601336|Drug|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
79868760|NCT05599672|Behavioral|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
79868761|NCT05599672|Behavioral|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
79868762|NCT05599243|Drug|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
79271289|NCT00978458|Drug|temozolomide|Given orally
79402534|NCT03855696|Other|Placebo of MG1113|Placebo of MG1113
79402535|NCT04196179|Drug|ANG3070|ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
79402536|NCT04196179|Drug|Placebo oral capsule|ANG-3070 placebo capsules visually match the drug product.
79402537|NCT05098158|Other|Non-pharmacological pain treatment|Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
79574483|NCT01847924|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
79574484|NCT01847950|Dietary Supplement|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
79574485|NCT01847950|Dietary Supplement|Maltodextrin|
79574486|NCT01847963|Drug|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
79574487|NCT01847963|Drug|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
79271290|NCT00978458|Radiation|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
79271291|NCT00978458|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
79271292|NCT00882895|Procedure|Stem cell infusion|
79271293|NCT00882895|Procedure|TLI|
79271294|NCT00882895|Drug|Anti-thymocyte globulin|
79271295|NCT00882895|Drug|Solumedrol|
79574488|NCT01847976|Drug|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
79574489|NCT01847989|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
79271296|NCT00882895|Drug|Tacrolimus|
79574490|NCT01847989|Drug|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
79574491|NCT01848002|Drug|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
79574492|NCT01848002|Drug|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
79574493|NCT01848015|Other|detection of CTCs|
79574494|NCT01848080|Behavioral|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
79574495|NCT01848093|Other|sputum collection|collecting of spontaneous sputum from the patient
79574496|NCT01848106|Drug|pegnivacogin/anivamersen|
79574497|NCT01848106|Drug|Bivalirudin|
79574498|NCT01848119|Drug|Gabapentin|
79574499|NCT01848119|Drug|lactose|
79574500|NCT01848132|Drug|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
79574501|NCT01848132|Drug|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
79574502|NCT01848132|Drug|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
79574503|NCT01848132|Drug|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
79574504|NCT01848132|Drug|Prednisone|Prednisone: oral, 100 mg, days 1-5
79574505|NCT01848132|Drug|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
79574506|NCT01848197|Drug|paclitaxel|
79574507|NCT01848236|Dietary Supplement|Vitamin D2|Ergocalciferol vitamin D2
79868763|NCT05599243|Other|Placebo|Vehicle excipient
79868764|NCT05597228|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
79868765|NCT05594264|Behavioral|HBPStories|A 6-week web-based study. Systolic blood pressure, diastolic blood pressure, and medication adherence will be measured at baseline and 6-weeks.
79868766|NCT05592210|Other|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
79574508|NCT01848236|Dietary Supplement|Vitamin D3|Cholecalciferol vitamin D2
79574509|NCT01848262|Procedure|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
79574510|NCT01848262|Procedure|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
79574511|NCT01848275|Device|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
79574512|NCT01848275|Device|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
79574513|NCT01848301|Device|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
79574514|NCT01848301|Drug|Acetylcholine|Infusion in the coronary artery to study endothelial function
79271297|NCT00882895|Drug|Mycophenolate mofetil|
79271298|NCT00819546|Drug|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
79271299|NCT00819546|Drug|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
79271300|NCT00548236|Behavioral|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
79402538|NCT04195711|Diagnostic Test|"objective pediatric vision screen, blinq,"|hand-held birefringent screener for simultaneous foveation
79574515|NCT01848301|Procedure|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
79574516|NCT01848314|Procedure|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
79574517|NCT01848327|Dietary Supplement|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
79574518|NCT01848327|Dietary Supplement|Placebo|Placebo (40 gram packet orally once a day for 90 days)
79574519|NCT01848340|Drug|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
79574520|NCT01848340|Drug|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
79574521|NCT01848340|Drug|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
79574522|NCT01848379|Procedure|ADT+FD|
79271301|NCT05528042|Other|Heart rate and respiratory rate measurement|"Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting"
79868767|NCT05587855|Other|E-group|Participants with Hypertension will be assigned to eCulinary medicine
79271302|NCT05518292|Other|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
80028038|NCT02195934|Other|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
80028039|NCT02195934|Other|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
80028040|NCT02194686|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
79271303|NCT05518292|Other|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
79271304|NCT05518136|Behavioral|exercise-guidance on rehab APP|Training motions included sitting balance, hand support, crawling and squatting training12-14 were scheduled for 1 to 3 months postoperatively, moreover, climbing over obstacles was for 3 to 6 months.
79574523|NCT01848379|Procedure|FD|
79574524|NCT01848444|Other|Breastmilk|to measure levels of contaminants in human breastmilk samples
79574525|NCT01848470|Drug|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
79574526|NCT01848470|Drug|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
79574527|NCT01848470|Drug|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
79574528|NCT01848470|Drug|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
79574529|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
79574530|NCT01848470|Drug|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
79574531|NCT01848470|Drug|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
79574532|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
79574533|NCT01848496|Procedure|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
79868768|NCT05580666|Drug|Azithromycin Oral Tablet|Antimicrobial therapy
79868769|NCT05580666|Drug|Placebo oral tablet|Inert ingredients
80028041|NCT02194686|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
79574534|NCT01848509|Device|With teletransmission|Teletransmission of alerts
80028042|NCT04633681|Dietary Supplement|Sweetener and sweetness enhancer consumption|Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
79574535|NCT01848535|Dietary Supplement|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
79574536|NCT01848535|Dietary Supplement|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
80028043|NCT03692767|Biological|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
80028044|NCT03535038|Diagnostic Test|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
80028045|NCT03535038|Diagnostic Test|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
79734164|NCT04139005|Behavioral|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
79734165|NCT04139005|Behavioral|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
79734166|NCT01153841|Biological|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
79734167|NCT01153841|Biological|Infanrix hexa™|Intramuscular, 3 doses
79734168|NCT02804386|Drug|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
79734169|NCT02805868|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
80028046|NCT04622995|Drug|Benzodiazepine|Benzodiazepine prescribing
80028047|NCT01341639|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
80028048|NCT01341639|Biological|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
80028049|NCT01341639|Biological|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
80028050|NCT01341639|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
80028051|NCT01341639|Biological|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
80028052|NCT03534960|Device|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
80028053|NCT03534960|Device|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
80028054|NCT02196012|Behavioral|Intervention group|
80028055|NCT02196012|Behavioral|attention control condition|
80028056|NCT02628028|Drug|LY3337641|Administered orally
80028057|NCT02628028|Drug|Placebo|Administered orally
80028058|NCT03688087|Device|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
79574537|NCT01848548|Procedure|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
79574538|NCT01848574|Other|standardized multifaceted information procedure to improve patients' comprehension|
79574539|NCT01848587|Other|acupuncture|
79574540|NCT01848587|Other|usual care|
79574541|NCT01848600|Behavioral|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
79574542|NCT01848613|Drug|Vinorelbine|
79574543|NCT01848652|Drug|infusion of MYOCET|
79574544|NCT01848665|Drug|Indomethacin|
79734170|NCT02805868|Other|Laboratory Biomarker Analysis|Correlative studies
79734171|NCT02805868|Biological|Siltuximab|Given IV
79734172|NCT00691639|Other|Blood Collection Only|Blood Collection Only
79734173|NCT02805634|Other|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
79868770|NCT05560737|Behavioral|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~Automated digital counselling resources (educational pages, videos, tools, and trackers)~Chatrooms available 24/7~Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
79868771|NCT05556889|Procedure|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
79868772|NCT05556889|Procedure|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
80028059|NCT03688087|Device|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
80028060|NCT02194764|Drug|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
80028061|NCT02194764|Drug|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
80028062|NCT03692689|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
80028063|NCT02196090|Behavioral|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
80028064|NCT02196090|Device|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
80028065|NCT04619719|Device|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
79574545|NCT01848665|Drug|Placebo|
79574546|NCT01848691|Other|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
79574547|NCT01848704|Behavioral|interpretation of the abstract|
79734174|NCT02805634|Device|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
79734175|NCT00684385|Drug|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration.
79734176|NCT02690038|Drug|Intravenous immunoglobulin (IVIG)|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
79271305|NCT05518058|Other|device and exercises|device and exercises
79271306|NCT05517824|Procedure|microinsulated needle radiofrequency|A single treatment using a microinsulated needle radiofrequency device
79574548|NCT01848717|Device|MINTLIFT®|
79574549|NCT01848730|Drug|CNV2197944|
79574550|NCT01848730|Drug|Placebo|
79574551|NCT01848743|Drug|Tenofovir|
79574552|NCT01848743|Drug|lamivudine|
79734177|NCT02690038|Drug|Normal Saline|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
79734178|NCT00691795|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
79734179|NCT04136821|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
79734180|NCT04136821|Other|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
79868773|NCT05545501|Dietary Supplement|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
79734181|NCT02805556|Drug|BMS-663068|Single oral dose of BMS-663068
79734182|NCT02805556|Drug|BMS-626529|Single intravenous dose of [13C]BMS 626529
79734183|NCT04136977|Device|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
79734184|NCT00694291|Drug|Sorafenib|400 mg orally twice daily
79734185|NCT00694291|Drug|Placebo|Matching Placebo
79868774|NCT05545501|Dietary Supplement|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
79868775|NCT05545501|Dietary Supplement|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
79868776|NCT05541471|Drug|VX-548|Tablets for oral administration.
79574553|NCT01848769|Drug|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
79574554|NCT01848769|Drug|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
79574555|NCT01848769|Drug|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
79574556|NCT01848782|Behavioral|interpretation of the abstract of the systematic review|
79574557|NCT01848795|Device|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
79574558|NCT01848795|Device|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
79402539|NCT03599323|Drug|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
79402540|NCT01602744|Other|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
79574559|NCT01848808|Dietary Supplement|Wobenzym PS|
79574560|NCT01848808|Dietary Supplement|Placebo|
79574561|NCT01848860|Procedure|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
79574562|NCT01848860|Biological|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
79734186|NCT04100902|Drug|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
79734187|NCT04100902|Drug|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
79734188|NCT01153763|Drug|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
79734189|NCT00691873|Drug|Placebo|placebo
79734190|NCT00691873|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
79734191|NCT02805322|Device|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
79734192|NCT02805322|Device|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
79734193|NCT02805322|Device|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
79734194|NCT05538052|Drug|Tramadol hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
79734195|NCT05538052|Drug|Lidocaine Hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
79734196|NCT05298475|Drug|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
79734197|NCT05298475|Drug|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
79734198|NCT05298475|Drug|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
79734199|NCT02884505|Device|Pupillometry|Measures pupillary dynamics in darkness and light conditions
79734200|NCT02884505|Behavioral|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
79734201|NCT02884505|Other|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
79574563|NCT01848873|Drug|Amlodipine|amlodipine 5mg daily
79574564|NCT01848873|Drug|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
79574565|NCT01848873|Drug|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
79574566|NCT01848886|Procedure|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
79574567|NCT01848886|Procedure|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
79271307|NCT04425356|Behavioral|LifeXT Program|The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
79271308|NCT04141904|Drug|Tofacitinib 5 MG [Xeljanz]|Tofacitinib 5mg capsules twice a day for 7-10 days
79271309|NCT04141904|Other|Placebo|Placebo capsules twice a day for 7-10 days
79271310|NCT04622462|Procedure|Standard of Care Histopathology|Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
79574568|NCT01848886|Procedure|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
79271311|NCT04622462|Procedure|STRATICYTE Assessment|Assessment for risk of progression to oral cancer
79271312|NCT01361711|Biological|alemtuzumab|Given SC
79574569|NCT01848886|Procedure|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
79734202|NCT02884505|Behavioral|Hypersomnia Severity Index|Self-report measure of hypersomnolence
79868777|NCT05541471|Drug|Midazolam|Syrup for oral administration.
79868778|NCT05541471|Drug|Digoxin|Tablets for oral administration.
79271313|NCT01361711|Biological|ofatumumab|Given IV
79271314|NCT01361711|Procedure|biopsy|Correlative studies
79574570|NCT01848925|Biological|SANGUINATE™|40 mg/mL intravenous infusion.
79574571|NCT01848925|Drug|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
79734203|NCT02805400|Other|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
79734204|NCT00691951|Drug|budesonide and budesonide/formoterol|
79868779|NCT05540405|Dietary Supplement|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
79868780|NCT05540405|Dietary Supplement|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
79868781|NCT05540405|Dietary Supplement|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
79271315|NCT02144051|Drug|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
79271316|NCT04605848|Diagnostic Test|Infrared themrography|measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
79271317|NCT05517746|Drug|BAY2395840 tablet|tablets, oral administration
79271318|NCT05517746|Drug|BAY2395840 oral solution|solution, oral administration
79271319|NCT05517746|Drug|Placebo oral solution|Placebo matching BAY2395840, oral administration
79574572|NCT01848964|Device|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
79574573|NCT01849003|Drug|GS-6615|GS-6615 tablet(s) administered orally
79574574|NCT01849016|Drug|N-Acetylcysteine|
79574575|NCT01849016|Drug|Placebo|
79574576|NCT01849029|Behavioral|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
79734205|NCT05355233|Other|bebo concept|techniques to remove urinary incontinence
79734206|NCT05355233|Other|diaphragmatic breathing|techniques to remove urinary incontinence
79734207|NCT02805166|Drug|PEG-rhG-CSF|
79734208|NCT02621671|Behavioral|Cognitive interview|
79734209|NCT02621671|Other|Survey|
79868782|NCT05530772|Device|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
80028066|NCT03534414|Dietary Supplement|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~plant sterols (sterol-enriched margarine or supplement)~viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~plant protein (soy products and pulses), and~nuts (tree nuts and peanuts)"
80028067|NCT03534414|Dietary Supplement|NCEP Based Diet|A low saturated fat, low cholesterol diet.
79271320|NCT05517746|Drug|Placebo tablet|Placebo matching BAY2395840, oral administration
79271321|NCT05527340|Drug|Iberdomide|Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
79271322|NCT05527340|Drug|Dexamethasone|Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
79868783|NCT05525312|Procedure|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
79734210|NCT04316351|Drug|Toripalimab + Pemetrexed + Anlotinib|"Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit."
79868784|NCT05525312|Procedure|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
79734211|NCT02805244|Drug|JTZ-951, 14C-JTZ-951|
79734212|NCT00694447|Procedure|Acupuncture|
79734213|NCT02884349|Procedure|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
79734214|NCT02625337|Drug|Pembrolizumab|
79734215|NCT02625337|Drug|Dabrafenib|
79734216|NCT02625337|Drug|Trametinib|
79868785|NCT05504278|Drug|pemetrexed|500mg/m^2, Q3W, day1, i.v.
79868786|NCT05504278|Drug|cis-platinum|75mg/m^2, Q3W, day1, i.v.
79868787|NCT05504278|Drug|Sintilimab|200mg, Q3W, day1, i.v.
79734217|NCT02625337|Procedure|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
79868788|NCT05504278|Drug|IBI351|recommended dose, po
79868789|NCT05504278|Drug|carboplatin|AUC=5, Q3W, day1, i.v.
79868790|NCT05500963|Device|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
79868791|NCT05498792|Drug|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
79868792|NCT05498792|Drug|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
79868793|NCT05498792|Drug|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
79868794|NCT05492214|Procedure|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
79868795|NCT05492214|Procedure|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
79734218|NCT02625337|Procedure|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
79734219|NCT04236310|Drug|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
79868796|NCT05492214|Procedure|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
79868797|NCT05490134|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
79868798|NCT05490134|Drug|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
79868799|NCT05486260|Dietary Supplement|DMB lowest dose|Intake of 150 mg of DMB
79734220|NCT04236310|Drug|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
79734221|NCT04236310|Drug|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
79734222|NCT04236310|Drug|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
79734223|NCT02805478|Other|There is no intervention|This is a prospective observational cohort study without any intervention
79734224|NCT04134949|Behavioral|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
79734225|NCT04134949|Behavioral|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
79734226|NCT02804308|Behavioral|Combined Training|
79734227|NCT02805088|Other|Electroencephalographic recordings|
79734228|NCT02805088|Other|neuropsychological evaluation|
79734229|NCT02805088|Other|clinical evaluation of symptoms|
79734230|NCT02621515|Drug|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
79868800|NCT05486260|Dietary Supplement|DMB highest dose|Intake of 300 mg of DMB
79868801|NCT05486260|Dietary Supplement|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
79868802|NCT05483270|Biological|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
79868803|NCT05476458|Radiation|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
80028068|NCT03534336|Behavioral|Incentive for Education|"A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program"
80028069|NCT03534336|Behavioral|Incentive for Weight Loss|"A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program"
79734231|NCT00912613|Other|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
79734232|NCT02803918|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79734233|NCT02803918|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79574577|NCT01849042|Drug|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
79734234|NCT02803918|Drug|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79734235|NCT02803918|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79734236|NCT04138069|Other|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
79734237|NCT04138069|Other|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
79574578|NCT01849042|Drug|donepezil|
79574579|NCT01849081|Device|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
79271323|NCT05527340|Drug|Daratumumab|Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
79734238|NCT04022356|Device|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
79734239|NCT02621593|Device|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
79868804|NCT05476458|Radiation|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
79868805|NCT05475613|Procedure|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
79271324|NCT05523752|Device|Proseal Laryngeal Mask|insertion of Proseal Laryngeal Mask
79868806|NCT05475613|Procedure|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
79271325|NCT05523752|Device|Classic Laryngeal Mask|insertion of Classic Laryngeal Mask
79271326|NCT05523752|Device|I-gel|insertion of I-gel
79271327|NCT05523752|Device|Suprema Laryngeal Mask|insertion of Suprema Laryngeal Mask
79574580|NCT01849081|Behavioral|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
79574581|NCT01849094|Drug|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
79574582|NCT01849094|Drug|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
79574583|NCT01849094|Drug|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
79574584|NCT01849107|Biological|Plasma citrulline|
79734240|NCT04236466|Device|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
79868807|NCT05463198|Device|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
79868808|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
79271328|NCT02572388|Biological|R21|
79271329|NCT02572388|Biological|Matrix-M1|
79574585|NCT01849120|Device|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
79574586|NCT01849133|Radiation|external fractionated radiotherapy|conventional external beam radiotherapy
79574587|NCT01849133|Radiation|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
79574588|NCT01849159|Biological|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
79574589|NCT01849159|Other|Reference therapy: 400 mL of 0.9% NaCl solution|
79574590|NCT01849185|Other|Food supplement|
79868809|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
79402541|NCT04195867|Drug|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
79402542|NCT05102058|Drug|Magnesium-Dexmedetomidine|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
79574591|NCT01849198|Device|accelerometry m. trapezius and m. adductor pollicis|
79574592|NCT01849211|Drug|rocuronium|
79574593|NCT01849224|Other|Pelvic and lower extremity exercise|
79574594|NCT01849237|Genetic|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
80028070|NCT02967640|Drug|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
79574595|NCT01849237|Drug|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
79574596|NCT01849302|Dietary Supplement|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
79734241|NCT04236466|Device|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
79734242|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
79734243|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
79734244|NCT02805010|Drug|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
79734245|NCT02805010|Other|Placebo|On Day 1, subjects will receive a single SC dose of placebo
79734246|NCT02621437|Other|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
79868810|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
79868811|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
79574597|NCT01849315|Behavioral|AKIDS II|Physically active intervention
79574598|NCT01849341|Drug|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
79868812|NCT05440201|Other|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
79271330|NCT05523518|Device|The Buzzy®|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
79574599|NCT01849341|Drug|Roflumilast 500 mcg per day|
79574600|NCT01849367|Device|Eldith Neuroconn tDCS device|
79574601|NCT01849380|Drug|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
79574602|NCT01849380|Drug|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
79574603|NCT01849393|Other|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
79574604|NCT01849406|Drug|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
79574605|NCT01849406|Drug|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
79574606|NCT01849445|Procedure|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
79574607|NCT01849445|Other|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
79574608|NCT01849471|Other|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
79574609|NCT01849484|Radiation|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
79734247|NCT02621437|Other|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~pain questionnaire with digital scale,~quality of life survey: SF-12~HAD (Hospital and Anxiety Depression) questionnaire"
79734248|NCT02621281|Device|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
79734249|NCT02621281|Device|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
79734250|NCT02803996|Drug|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
79734251|NCT02803996|Drug|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
79734252|NCT04136431|Other|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
79734253|NCT04136431|Other|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
79734254|NCT02800954|Biological|blood samples|
79734255|NCT02800954|Biological|Bone marow samples|
79868813|NCT05426785|Device|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
79868814|NCT05418049|Drug|Baclofen|30mg - Supplied as 10mg and 20mg tablets
79868815|NCT05418049|Drug|Memantine|two 10 mg tablets
79868816|NCT05418049|Drug|Roflumilast|250 mcg capsule
79868817|NCT05418049|Drug|Placebo|Placebo pill
79868818|NCT05414019|Other|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
79868819|NCT05414019|Other|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
80028071|NCT02967640|Drug|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
79734256|NCT00694681|Behavioral|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
79868820|NCT05414019|Other|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
80028072|NCT03692533|Diagnostic Test|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
80028073|NCT02943928|Device|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
80028074|NCT02943928|Device|traditional method by experience|Operator inserted the double lumen tube by experience
80028075|NCT02194920|Procedure|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
79574610|NCT01849484|Radiation|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
79574611|NCT01849510|Radiation|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT & hfSRT
79574612|NCT01849510|Radiation|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
79574613|NCT01849523|Behavioral|Web-based information and support|
79271331|NCT05523518|Device|The AccuVein®|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
79574614|NCT01849536|Device|SENSIMED Triggerfish®|
79574615|NCT01849549|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
79574616|NCT01849549|Other|MRI|Anatomical, diffusion, and/or functional MRI
79574617|NCT01849601|Device|percutaneous transluminal angioplasty balloon catheter|
79868821|NCT05409534|Other|Backward Walking (Exercise group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of backward walking training and 10 minutes of cooling-off exercise. The maximum time to do backward walking training will be 30 minutes. In the backward walking exercise, 1 set will take 5 minutes. The maximum number of sets that can be made will be 6 sets. No more than 6 sets will be made.
79868822|NCT05409534|Other|Forward Walking (Control Group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of forward walking training and 10 minutes of cooling-off exercise as the home exercise programme.
79402543|NCT04195165|Behavioral|SIT|For the SIT and SIT+EX conditions, the subject will be asked to take <3,000 steps. This is meant to achieve ~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.
79574618|NCT01849614|Other|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
79574619|NCT01849640|Drug|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
79574620|NCT01849666|Drug|phenprocoumon|6 mg oral single dose
79574621|NCT01849666|Drug|vemurafenib|960 mg bid orally
79574622|NCT01849679|Other|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
79574623|NCT01849705|Other|No intervention|
79574624|NCT01849731|Other|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
79868823|NCT05409378|Device|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
79868824|NCT05406193|Other|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
79868825|NCT05404529|Drug|Tavapadon|Oral tablets
79271332|NCT05517512|Diagnostic Test|Estimation of Protein 13|"Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22)."
79271333|NCT05162924|Other|Spinal Manipulation|Manual therapy technique applied by a chiropractor in the form of a high-velocity low-amplitude force to the lumbopelvic spine
79271334|NCT05162924|Other|Placebo|Placebo spinal manipulation consisting in the application by a chiropractor of a lower-velocity lower-amplitude force to gluteal muscles in a non-intentional direction
79574625|NCT01849731|Other|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
79271335|NCT05527106|Dietary Supplement|Citicoline|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
79402544|NCT04195165|Behavioral|ACTIVE|For the ACTIVE+EX condition, the subject will be asked to take >10,000 steps for the two intervention days. This is meant to simulate an active lifestyle.
79574626|NCT01849744|Drug|VS-4718|
79574627|NCT01849757|Other|prime crystalloid|used for priming the CPB circuit
79574628|NCT01849757|Other|Human Albumin|Used as a constituent for priming the CPB circuit
79574629|NCT01849757|Other|Voluven|Used as a constituent for priming the CPB circuit
79574630|NCT01849796|Device|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
79574631|NCT01849809|Procedure|Gamma Ventral Capsulotomy|
79574632|NCT01849835|Procedure|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
79574633|NCT01849835|Procedure|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
79734257|NCT02800564|Behavioral|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
79734258|NCT02800564|Behavioral|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
79734259|NCT04236232|Diagnostic Test|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
79734260|NCT02803762|Drug|Pacritinib|400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
79574634|NCT01849861|Drug|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
79574635|NCT01849887|Biological|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
79574636|NCT01849887|Drug|Placebo|Placebo
79734261|NCT00871741|Biological|GSK2202083A vaccine|Intramuscular, three doses
79734262|NCT00871741|Biological|Infanrix hexa|Intramuscular, three doses
79868826|NCT05403554|Biological|NI-1801|All treatments will be administered in 28-day cycles. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given once weekly (QW) in Cycles 1 and 2 (e.g., Days 1, 8, 15, and 22), and once every two weeks (Q2W) in Cycles 3 through 6 (e.g., Days 1 and 15). NI-1801 treatment can extend beyond 6 cycles for those patients who do not have disease progression.
79868827|NCT05398237|Other|Solar Simulated Light (SSL)|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
79271336|NCT05527106|Dietary Supplement|Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
79574637|NCT01849900|Other|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
79574638|NCT01849900|Behavioral|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
79574639|NCT01849913|Other|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
79574640|NCT01849913|Other|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
79574641|NCT01849926|Drug|Ibuprofen|
79574642|NCT01849926|Drug|Mecillinam|
79574643|NCT01849939|Drug|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
79734263|NCT00871741|Biological|Menjugate|Intramuscular, two doses
79734264|NCT02800408|Other|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
79734265|NCT02800408|Other|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
79868828|NCT05395442|Diagnostic Test|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
79868829|NCT05393986|Drug|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
79868830|NCT05393518|Behavioral|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
79868831|NCT05393518|Behavioral|Neuropsychiatric assessment|Screening for depression and anxiety
79271337|NCT05527106|Dietary Supplement|Citicoline and Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
79868832|NCT05391477|Device|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
79868833|NCT05380076|Other|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
79271338|NCT05527106|Dietary Supplement|Vitamin C|Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
79574644|NCT01849965|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
79574645|NCT01849965|Drug|placebo vehicle gel|
79574646|NCT01849965|Drug|Standard of Care gel, Aquasite|
79574647|NCT01849978|Behavioral|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
79734266|NCT02800408|Other|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
79734267|NCT02800720|Behavioral|Meditation Awareness Training|8 Week Meditation Intervention
79734268|NCT02800720|Behavioral|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
79868834|NCT05380076|Other|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
79868835|NCT05380076|Other|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
79868836|NCT05376241|Behavioral|Survey|Identify the prevalence and predictors of negative and positive reactions to evidence about mammography benefits and harms, and consequences for decision-making and trust.
79868837|NCT05369676|Drug|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 ~day5，BID；
79868838|NCT05369676|Drug|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 ~day5，BID；
79868839|NCT05364372|Behavioral|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
79868840|NCT05364372|Behavioral|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
79868841|NCT05363176|Behavioral|Cognitive-Behavioral Therapy for Treatment Seeking|CBT delivered over the course of 1, ~45 minute sessions delivered via telehealth.
79574648|NCT01849978|Behavioral|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
79734269|NCT02625025|Procedure|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
79734270|NCT02625025|Procedure|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
79868842|NCT05363176|Behavioral|Pain treatment education|Pain treatment education describes a variety of pain treatments offered in the VA. It is delivered over the course of 1, ~45 minute session delivered via telehealth
79875900|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
80028076|NCT04855552|Behavioral|Behavioral Weight-loss Program Via Telehealth|Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
80028077|NCT04855552|Behavioral|Behavioral Weight-Loss Program Via Telehealth - Weight Measures|Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
80028078|NCT04855552|Behavioral|Validated Surveys of Patient-Reported Outcomes|"The following surveys will be completed by participants pre- and post-intervention:~COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~International Physical Activity Questionnaire (IPAQ) Short Form~Patient Health Questionnaire (PHQ-9) (Depression)~Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~Mammographic breast density estimated in annual clinical mammogram"
80028079|NCT03701971|Other|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
80028080|NCT02194140|Other|oral iodinated contrast material|diluted in water
79574649|NCT01849978|Behavioral|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
79574650|NCT01849978|Behavioral|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
79734271|NCT02625025|Procedure|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
79734272|NCT00692263|Drug|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
79734273|NCT00692263|Drug|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
79734274|NCT00692263|Drug|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
79734275|NCT00694759|Drug|pioglitazone|30 mg for 2 weeks, then 45 mg daily
79734276|NCT00694759|Drug|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
79734277|NCT00694759|Drug|placebo|capsule twice daily
79734278|NCT02803840|Radiation|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
79734279|NCT00694837|Drug|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
79868843|NCT05360498|Behavioral|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
79868844|NCT05360498|Behavioral|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
79734280|NCT02800252|Drug|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
79868845|NCT06014970|Behavioral|Health and Wellness Curriculum|The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
79574651|NCT01849991|Biological|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
79402545|NCT04195165|Behavioral|EX|The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
79402546|NCT03956797|Device|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
79402547|NCT05327166|Other|ED-LINC|The ED-LINC intervention provides 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
79402548|NCT05101512|Behavioral|Questionnaires on quality of life after surgery|Patient has to answer different questionnaire about quality of life, pain, functional scores
79402549|NCT03598777|Biological|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
79574652|NCT01849991|Biological|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
79734281|NCT02800252|Drug|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
79734282|NCT02800252|Drug|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
79734283|NCT02621359|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily
79868846|NCT06014892|Device|Snoo smart bassinet|Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months
79574653|NCT01850017|Drug|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
80028081|NCT03534648|Drug|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
79402550|NCT03598777|Drug|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
79402551|NCT04192123|Device|HM242|HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
79402552|NCT04195243|Drug|Dapagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
79402553|NCT04195243|Drug|Empagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
79402554|NCT04195243|Drug|Placebo pill|The patient will take one pill, every 24 hr, during 7 days
79402555|NCT04195321|Drug|Norepinephrine|infusion will be started after induction of spinal anesthesia
79402556|NCT04195321|Drug|phenylephrine|infusion will be started after induction of spinal anesthesia
79402557|NCT04195087|Device|Masimo Radical-7® Pulse CO-Oximeter®|The perfusion index and Pleth variability index will be recorded from the device monitor.
79402558|NCT04194931|Biological|Autologous BCMA CAR-T cells and CD19 CAR-T cells|Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5*10^6 cells/kg body weight,separately.
79574654|NCT01850056|Device|drug eluting balloon catheter (trade name: Orchid)|
79574655|NCT01850056|Device|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
79402559|NCT04023643|Other|Ventilation Weaning|Use of different weaning strategies
79402560|NCT06012799|Diagnostic Test|continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System
79574656|NCT01850095|Drug|treatment azelaic acid (azelan)|treatment for 6 months
79574657|NCT01850095|Drug|dorspirenone/ethynil estradiol|
79734284|NCT02621359|Drug|Levofloxacin|Levofloxacin 500 mg once daily
79734285|NCT02621359|Drug|Doxycyclin|Doxycyclin 100 mg twice daily
79734286|NCT02621359|Drug|Omeprazole|Omeprazole 40 mg twice daily
79734287|NCT02800018|Other|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
80028082|NCT03534648|Drug|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
80028083|NCT03534648|Drug|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
80028084|NCT03534648|Drug|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
79868847|NCT06014892|Device|Willow wearable breast pump|Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep
79868848|NCT06014892|Behavioral|Maven Clinic on-demand perinatal consultation|Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.
79868849|NCT06014892|Behavioral|Faculty mentor|After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
80028085|NCT03701893|Dietary Supplement|Lactobacillus PS11610|7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
79734288|NCT01152437|Drug|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
79734289|NCT01152437|Drug|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
79868850|NCT06014879|Behavioral|Teen Videos|All participants in the Teen Videos will create videos about living well with diabetes, which will be used in the upcoming clinical trial of a new behavioral intervention.
79868851|NCT06014840|Other|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
79868852|NCT06014749|Procedure|undergo|regional anesthesia
80028086|NCT02194218|Drug|Nevirapine, low dose|50 mg
79868853|NCT06014749|Device|ultrasound|ultrasound guided
80028087|NCT02194218|Drug|Nevirapine, high dose|100 mg
79574658|NCT01850121|Drug|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
79574659|NCT01850134|Other|Experimental Study Product|
79868854|NCT06014749|Drug|Local anesthetic|local anesthetic
79868855|NCT06014736|Drug|XJ101 for Injection|XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
80028088|NCT02194296|Drug|Ambroxol hydrochloride - lozenge|
80028089|NCT02194296|Drug|Ambroxol hydrochloride - syrup|
80028090|NCT02195076|Other|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
79402561|NCT06012760|Drug|Iron sucrose, Human Erythropoietin Injection, Vitamin C|The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.
79574660|NCT01850134|Other|Control Study Product|
79574661|NCT01850147|Drug|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
79574662|NCT01850160|Drug|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
79574663|NCT01850160|Drug|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
79574664|NCT01850160|Drug|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
79574665|NCT01850173|Device|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
79734290|NCT02800174|Device|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
79734291|NCT02800174|Drug|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
79734292|NCT04137913|Behavioral|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
79868856|NCT06014736|Drug|Placebo|Placebo contains only excipients.
79875901|NCT01322880|Behavioral|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
80028091|NCT02196480|Biological|anti-TNF|Anti-tumor necrosis factor therapy
80028092|NCT03977701|Behavioral|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
80028093|NCT03977701|Behavioral|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
80028094|NCT04224220|Other|Adult Medical Care Coordination|Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
79734293|NCT02800330|Drug|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
79734294|NCT02800330|Drug|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
79734295|NCT02800330|Drug|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
79734296|NCT02799862|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
79734297|NCT02799862|Drug|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
79402562|NCT06012760|Drug|Saline|The participants were administered a placebo regimen consisting of saline three times in the week preceding the surgical procedure.
79402563|NCT06012695|Drug|NBM-BMX Capsule|Each capsule contains 100 mg of the active ingredient.
80028095|NCT04224220|Other|Remote Patient Monitoring|Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
79734298|NCT01151579|Drug|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
79734299|NCT01151579|Drug|Albuterol|Nebulized albuterol 2.5mg
79734300|NCT00694915|Biological|Mycobacterium w|Immunomodulator
79868857|NCT06014710|Other|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
79868858|NCT06014684|Behavioral|Timing of exercise|High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
79868859|NCT06014671|Behavioral|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
79868860|NCT06014645|Other|Rehabilitation|The study group will be given a core stabilization program in addition to education.
79868861|NCT06014645|Other|Control|The control group will receive post-operative cognitive training and will be encouraged to move.
79868862|NCT06014632|Other|Rehabilitation|The study group will be given motor control exercises in addition to the program given to the control group.
79868863|NCT06014632|Other|Control|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
79868864|NCT06014619|Procedure|Mohs surgery|Treatment of a skin disease by Mohs micrographic surgery technique (frozen sections).
79868865|NCT06014619|Procedure|Slow Mohs surgery|Treatment of a skin disease by Slow Mohs technique (formalin fixation and paraffin-embedded sections).
79868866|NCT06014606|Drug|placebo|oral formulation
79868867|NCT06014606|Drug|haloperidol 2mg|oral formulation
79868868|NCT06014606|Drug|propranolol 40mg|oral formulation
80028096|NCT02197026|Drug|Hylan G-F 20|
80028097|NCT02197026|Drug|Standard treatment|Standard drug treatment at the discretion of the investigator
80028098|NCT02197026|Procedure|Physiotherapy|
79574666|NCT01850186|Device|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
79574667|NCT01850186|Drug|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
79734301|NCT00694915|Biological|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
79734302|NCT02800096|Behavioral|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
79868869|NCT06014554|Other|Low-risk subgroup|Self-managed exercise programme.
80028099|NCT02197026|Procedure|Hydrotherapy|
79734303|NCT02800096|Behavioral|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
79734304|NCT00694993|Drug|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
79868870|NCT06014554|Other|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
79868871|NCT06014554|Other|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
79868872|NCT06014554|Other|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
79868873|NCT06014528|Drug|IN10018|100mg QD orally (PO)
79868874|NCT06014528|Drug|Placebo of IN10018|100mg QD orally (PO)
79868875|NCT06014528|Drug|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
79868876|NCT06014476|Other|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
80028100|NCT02197104|Drug|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
79868877|NCT06014450|Radiation|Prophylactic Cranial Irradiation for experiment arm|Prophylactic Cranial Irradiation DT30Gy/10f
79868878|NCT06014437|Drug|PLCL/Fg group|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
79868879|NCT06014437|Drug|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
80028101|NCT03975595|Behavioral|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
79271339|NCT05517434|Biological|Bone Marrow Aspirate Concentrate (BMAC): Minimally manipulated, concentrated autologous cellular preparation|Participants will undergo a bone marrow aspiration to collect 60 mL of bone marrow aspirate (BMA) from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. The components required to collect and process 60 mL of BMA to 9 mL (or less) of BMAC are provided in one BMAC2-60-01 Procedure Pack (Terumo BCT). After processing using the SmartPrep® System, BMAC is injected into the osteoarthritic knee joint (Arm A, Study 1).
79868880|NCT06014398|Diagnostic Test|Dynamic testing of Pituitary Function|"Pituitary Function Assessment:~Baseline assessment of pituitary function by measuring ACTH, cortisol, FSH, LH, oestrogen (in females), testosterone (in males), sex hormone binding globulin, thyroid function tests, prolactin and IGF-1].~Dynamic testing of pituitary function:~Patients will undergo dynamic testing of the ACTH and growth hormone axes using a glucagon stimulation test (GST).~Patients whose GST identifies cortisol deficiency will undergo a short synacthen test to confirm adrenal insufficiency as the GST has a false positive rate of approximately 20% for ACTH deficiency."
80028102|NCT03975595|Behavioral|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
80028103|NCT02197182|Drug|LUXSOL copper containing cream|Active comparator arm
79271340|NCT05517434|Other|Saline (Placebo Comparator for BMAC)|Participants will undergo a bone marrow aspiration to collect 60 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent is injected into the osteoarthritic knee joint (Arm C, Study 1).
79574668|NCT01850199|Other|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
79574669|NCT01850199|Other|Usual management|Usual care will be provided, including face-to-face visits
79574670|NCT01850225|Device|Auditory brainstem implant|
79574671|NCT01850238|Biological|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
79574672|NCT01850238|Other|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
79574673|NCT01850251|Dietary Supplement|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
80028104|NCT02197182|Drug|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
79271341|NCT05517434|Biological|Lipoaspirate + Leukocyte-Poor Platelet-Rich Plasma (LAC + LP-PRP): Minimally manipulated, concentrated autologous cellular preparations|Participants will undergo a lipoaspiration to collect 40 mL of lipoaspirate (LA) from subcutaneous adipose tissue. The components required to process 40 mL of LA to 9 mL (or less) of LAC are provided in one AdiPrep® Adipose Transfer System Procedure Pack (Terumo BCT). Participants will also undergo a blood draw to collect 32 mL of whole blood from the antecubital fossa. The components required to process 32 mL of venous blood to PRP followed by processing to yield 2 mL of LP-PRP are provided in one Platelet Concentrate Procedure Pack and one LP-10 Clear Prep Procedure Pack (Terumo BCT). After processing using the SmartPrep® System, LAC is injected first followed immediately by LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
79271342|NCT05517434|Other|Saline (Placebo Comparator for LAC+LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect 32 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice into the osteoarthritic knee joint (Arm D, Study 2).
79402564|NCT06012695|Drug|Temozolomide|TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
79402565|NCT06012695|Radiation|Standard radiotherapy|A total dose of 60 Gy will be administered in 6 weeks.
79574674|NCT01850251|Dietary Supplement|Standard nutritional supplement|High protein, high calorie nutritional supplement.
79574675|NCT01850264|Device|Application of quadripolar / bipolar LV electrodes|
80028105|NCT03692455|Procedure|Roux-en-Y Gastric Bypass|The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.
80028106|NCT03692455|Procedure|Vertical Sleeve Gastrectomy|VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
79574676|NCT01850277|Drug|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
79734305|NCT00694993|Drug|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
79734306|NCT02803450|Procedure|Epidural needle|Medication administration via epidural needle.
79734307|NCT02803450|Procedure|Catheter Administration|Medication administration via epidural catheter.
79734308|NCT02803450|Procedure|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
79868881|NCT06014281|Behavioral|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~Close your eyes very gently, in a relaxed way, as you do when we go to sleep~Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~Mentally repeat the (chosen) calming word~Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
79271343|NCT05517356|Procedure|Tailored management strategies|"Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved."
79734309|NCT00692497|Behavioral|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
79734310|NCT02803528|Drug|Biodentine|Biodentine is going to be used as the direct pulp capping material
79734311|NCT02803528|Drug|MTA|MTA is going to be used as the direct pulp capping material in the second group
79734312|NCT04136041|Device|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
79868882|NCT06014268|Other|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
79868883|NCT06014216|Other|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
79868884|NCT06014216|Other|Water|Water from tap, one cup given by recovery nurses.
79868885|NCT06014203|Diagnostic Test|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~Midpoint of the upper trapezius muscle~5 cm distal to anterior acromion~5cm distal to lateral acromion~5cm distal to posterior acromion~3cm medial to the axilla~Anterior cubital fossa~Carpal tunnel"
79868886|NCT06014190|Drug|HS-20089|All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
79868887|NCT06014151|Other|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
79868888|NCT06014138|Drug|Propofol|Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
79868889|NCT06014138|Drug|Isoflurane|Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
80028107|NCT02197260|Drug|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
80028108|NCT03688009|Behavioral|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
80028109|NCT03688009|Behavioral|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
79271344|NCT05523128|Genetic|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10^13vg/kg; 2. 6.0×10^13vg/kg.
79734313|NCT01097616|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
80028110|NCT02197338|Other|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
80028111|NCT03687931|Drug|Dexamethasone|Drop
80028112|NCT02814526|Behavioral|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
79734314|NCT01097616|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
79574677|NCT01850277|Procedure|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
79734315|NCT01097616|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
79734316|NCT02799628|Behavioral|intervention|intervention with recommendation and therapist introduction
79734317|NCT02799628|Other|placebo|low back pain education, and physical therapy 3 times per week
79868890|NCT06014034|Other|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
79868891|NCT06013956|Device|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
79271345|NCT05526794|Procedure|Analgesic consumption|1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
79271346|NCT05523050|Procedure|active surgical intervention|two kinds: one is colostomy, and the other one is colonic exclusion
79868892|NCT06013956|Drug|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
79868893|NCT06013904|Procedure|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
79868894|NCT06013904|Procedure|US-trained PEM Fellows|US-trained PEM Fellows
79868895|NCT06013787|Behavioral|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
79734318|NCT00695071|Drug|Itraconazole|Oral
79868896|NCT06013774|Device|IXSI|Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
79868897|NCT06013761|Other|IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm|12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
79868898|NCT06013735|Drug|sodium fluoride solution|sodium fluoride solution mouth rinse (0.2%).
79868899|NCT06013735|Drug|guava leaves aqueous extract|guava leaves aqueous extract mouth rinse (0.5%)
80028113|NCT02814526|Behavioral|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
79868900|NCT06013735|Drug|pomegranate peel aqueous extrac|pomegranate peel aqueous extract mouth rinse (0.5%).
79868901|NCT06013735|Other|Distilled water|placebo distilled water
80028114|NCT04214574|Device|Parasagittal oblique technique (Ultrasound)|the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
79271347|NCT05522894|Drug|AK104|10mg/kg IV every 3 weeks (Q3W)
79271348|NCT05522894|Drug|Cisplatin|75mg/m2 IV every 3 weeks (Q3W)
79271349|NCT05522894|Drug|Paclitaxel|175mg/m2 IV every 3 weeks (Q3W)
79271350|NCT05526638|Radiation|ultraviolet phototherapy|thrice weekly sessions of ultraviolet phototherapy
79271351|NCT05526482|Device|mobile app|preoperative respiratory exercises and thoracic surgery with a mobile application
79271352|NCT05522816|Drug|KX01 0.01% (0.1 mg/g)|Stage 1: 6 patients (KX01 0.01% [0.1 mg/g])
79271353|NCT05522816|Drug|Placebo|
79574678|NCT01850277|Drug|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% >95%
79574679|NCT01850277|Procedure|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
79574680|NCT01850316|Radiation|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
79574681|NCT01850329|Other|computed-assisted information program|
79574682|NCT01850342|Procedure|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
79574683|NCT01850368|Radiation|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
79574684|NCT01850407|Behavioral|Education Counseling|
79868902|NCT06013709|Device|PRESAE CARE|"PRESAGE CARE is a medical device CE marked based on artificial intelligence to prevent and reduce emergency department visits and unplanned hospitalization among frail older adults living at home.~These device is based on the use of a short questionnaire focused on functional and clinical autonomy (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with the home care aides (HAs)or their surroundings. This questionnaire is composed of very simple and easy-to-understand questions, giving a global view of the person's condition. For each of the 27 questions, a yes/no answer was requested. Data recorded by HAs were sent in real time to a secure server to be analyzed by our machine learning algorithm, which predicted the risk level on emergency hospitalization risk and some health clinical situations and displayed it on a web-based secure medical device."
79868903|NCT06013696|Other|Adding household bleach to urine sample|Adding household bleach to urine sample
79868904|NCT06013670|Procedure|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure>90mmHg and heart rate>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
79868905|NCT06013670|Procedure|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
79574685|NCT01850420|Drug|IMC-1|
79734319|NCT04047823|Device|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
79734320|NCT02799550|Biological|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
79734321|NCT00695149|Procedure|Transplantation of bone marrow stromal cell|
79734322|NCT04137679|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
79868906|NCT06013657|Procedure|Liver Resection|Resection of a part of the liver afflicted by hepatocellular carcinoma
79271354|NCT05522816|Drug|KX01 0.1% (1.0 mg/g)|Stage 2: 6 patients (KX01 0.1% [1.0 mg/g])
79271355|NCT05522816|Drug|KX01 1% (10 mg/g) for 5 days|Stage 3: 6 patients (KX01 1% [10 mg/g]) for 5 days
79734323|NCT04137679|Procedure|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
79868907|NCT06013644|Device|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
79868908|NCT06013644|Device|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
79868909|NCT06013644|Drug|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
79271356|NCT05522816|Drug|KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles|Stage 4: 6 patients (KX01 1% [10 mg/g])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
79271357|NCT05010746|Device|Innovalve TMVR system|Innovalve TMVR system
79734324|NCT02621125|Dietary Supplement|Fertilix|daily supplementation
80028115|NCT04214574|Device|Paramedian tranverse technique (Ultrasound)|the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
80028116|NCT02195154|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
79271358|NCT05154500|Other|Iron biofortified potato|A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p>0.05). Based on this study design, every woman is her own control.
79574686|NCT01850433|Behavioral|Internet based CBT for body dysmorphic disorder|
79574687|NCT01850511|Procedure|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
79574688|NCT01850511|Drug|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
79574689|NCT01850537|Device|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
79574690|NCT01850576|Behavioral|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
79574691|NCT01850628|Drug|Paclitaxel|
79574692|NCT01850628|Biological|trastuzumab|
79574693|NCT01850628|Biological|pertuzumab|
79734325|NCT02621125|Other|Placebo|Placebo
79734326|NCT00695227|Diagnostic Test|Screening for Barrett's Esophagus|
79734327|NCT02799394|Other|Activity modification, exercises and gradual return to sport|
79868910|NCT06013631|Other|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic 22 rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
79868911|NCT06013631|Other|Phantom Exercises|The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.
79868912|NCT06013605|Behavioral|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
79868913|NCT06013605|Behavioral|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
80028117|NCT02196636|Drug|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
80028118|NCT02196636|Drug|RO6806127|Administered orally with approximately 240 mL of buffer
79574694|NCT01850654|Genetic|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
79574695|NCT01850654|Genetic|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~CRC study participants diagnosed with CRC <50 years, regardless of tumor studies or family history~CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
79574696|NCT01850654|Behavioral|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
79734328|NCT00692575|Behavioral|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
79734329|NCT00692575|Other|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
79734330|NCT02803294|Procedure|transcatheter aortic valve replacement|
79734331|NCT00871429|Other|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
79734332|NCT02803216|Drug|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
79734333|NCT02803216|Drug|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
79734334|NCT02803216|Drug|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
79574697|NCT01850654|Other|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
79574698|NCT01850654|Behavioral|Questionnaire|
79574699|NCT01850667|Radiation|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
79574700|NCT01850680|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
79574701|NCT01850680|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
79574702|NCT01850680|Drug|methotrexate|Pharmaceutical form:capsule Route of administration: oral
79574703|NCT01850680|Drug|folic acid|Pharmaceutical form:tablet Route of administration: oral
79734335|NCT02624635|Other|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
79734336|NCT02624635|Other|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ [1.0278 - (0.0278 x number of repetitions)] as was used by (Shirazi et al., 2007).
79734337|NCT04308408|Behavioral|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
79868914|NCT06013566|Device|SSVEP|Non-invasive, non-interventional SSVEP EEG device
79868915|NCT06013553|Other|Control Group|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
79868916|NCT06013553|Other|Aerobic Exercises group|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given"
79868917|NCT06013540|Combination Product|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
79868918|NCT06013540|Combination Product|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
79868919|NCT06013527|Other|Supervised Training|"Two different classes over alternate weeks twice per week :~60-minute step aerobics class (Given week 1,3,5,7)~60 minutes circuit training class (Given week 2,4,6,8)~Each class will include warm-up and cool-down periods both lasting 10-15 min. The exercise period of 30 minutes the maximum target RPE would be set at 14-16 on a 20-point BORG scale, a level of exercise that feels somewhat hard or hard and coincides with about 86-92% of maximal heart rate, 76-85% of maximal VO 2 and 5-7 metabolic equivalents (METs) ideal for improving the related domains of QoL and Cardiovascular endurance (12). During the first 3 weeks, the participants would exercise at a lower level of RPE (approximately 11-13), to adapt to the training and so that newly recruited participants could also join the group without difficulty."
79868920|NCT06013527|Other|Individually tailored home program|The type of home training would mainly consist of endurance training such as walking, Nordic walking, or aerobic training, but it would also include jumps and leaps like step aerobics to promote bone health. The Participants will be asked to perform these thrice per week.
79868921|NCT06013514|Device|PERLE Sterile Smooth Opaque gel filled mammary implants|Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs
79868922|NCT06013488|Behavioral|Character Strengths Based Coaching Support|Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks
79868923|NCT06013488|Behavioral|Routine Supervision|Weekly face-to-face supervision by supervisor in groups of ~20 (1 supervisor for ~20 health workers)
79868924|NCT06013436|Drug|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
79868925|NCT06013410|Diagnostic Test|colonoscopy|colonoscopy
79734338|NCT04308408|Behavioral|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
79734339|NCT04308408|Behavioral|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
79734340|NCT04308408|Behavioral|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
79271359|NCT05154500|Other|Zinc biofortified potato|A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
79271360|NCT05153954|Other|Quantitative Indocyanine Green Fluorescence Angiography|Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
79271361|NCT02573870|Drug|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
79271362|NCT02573870|Drug|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
79271363|NCT02573870|Drug|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
79574704|NCT01850719|Procedure|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
79574705|NCT01850719|Other|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
79574706|NCT01850732|Other|Ultrasound of aorta|
79734341|NCT02799316|Other|HBV core antibodies testing. • Real time PCR testing.|"HBV core antibodies testing in HBV surface antigen negative patients.~Real time PCR testing for those having positive HBc antibodies."
79734342|NCT04015999|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
79734343|NCT04015999|Dietary Supplement|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
79734344|NCT04936932|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
79734345|NCT04936932|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
79734346|NCT02803372|Other|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
79734347|NCT02803372|Other|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
79734348|NCT00695383|Behavioral|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
79734349|NCT00695383|Behavioral|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
79271364|NCT02572076|Device|Motus Cleansing System|
79271365|NCT04995458|Procedure|composite-ceramic|To assess the clinical performance of composite-ceramic crowns
79271366|NCT04995458|Procedure|Monolithic zirconia|To assess the clinical performance of monolithic z¡irconia crowns
79574707|NCT01850771|Procedure|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
79574708|NCT01850771|Procedure|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
79574709|NCT01850784|Dietary Supplement|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
79734350|NCT04933890|Device|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
79734351|NCT02803684|Other|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
79734352|NCT00625950|Procedure|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
79734353|NCT02620969|Other|Blood and dialysate sampling|Blood and dialysate sampling
79734354|NCT02799238|Biological|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
79734355|NCT02799238|Radiation|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
79734356|NCT02799238|Drug|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
79734357|NCT00692653|Behavioral|P4|Tailored online decision support system for prostate cancer treatment decision making
79734358|NCT02798926|Device|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
79734359|NCT02620813|Drug|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
79734360|NCT02620813|Drug|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
79868926|NCT06013397|Dietary Supplement|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
79271367|NCT02571452|Behavioral|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
79574710|NCT01850784|Dietary Supplement|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
79868927|NCT06013371|Drug|PF-07038124|topical PDE4 inhibitor
79868928|NCT06013371|Drug|Placebo Ointment|matching placebo
79734361|NCT02803060|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formaulation number- SR15-62 -Z15-038).
79734362|NCT00695461|Dietary Supplement|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
79868929|NCT06013358|Genetic|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
79868930|NCT06013332|Device|PBF PLLA microsphere (injectable poly-L-lactic acid)|Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.
79734363|NCT00695461|Dietary Supplement|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
79868931|NCT06013332|Device|Sculptra®|Sculptra®
79868932|NCT06013293|Procedure|Zinc oxide eugeonal based sealer|Zinc oxide-eugenol (ZOE)- based preparations, which have been used in root canal obturation (RCO) for over a hundered years and are known for their antimicrobial activities.slight microleakage and zinc oxide-eugenol's superior antibacterial property,slight microleakage and concerning the lower cytotoxicity, the zinc oxide-eugenol (ZOE) sealer can be used for root canal obturation as an endodontic sealer.After root canal prepartion , the root canal will be dried with paper points and obturated using gutta-percha cones and zinc oxide eugenol sealer.
79868933|NCT06013293|Procedure|Resin Based Sealer|resin-based sealer used frequently as a gold standard for endodontic sealers, due to its good physicochemical properties and provide satisfactory adhesion interface with dentin radicular surface.After root canal preparation, the root canal will be dried with paper points and obturated using gutta-percha cones and Resin based sealer
79734364|NCT02798848|Device|Tablet computer|iPad
79574711|NCT01850810|Other|Experimental Study Product|
79574712|NCT01850810|Other|Control Study Product|
79574713|NCT01850836|Procedure|repetitive transcranial magnetic stimulation|
79868934|NCT06013215|Other|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
79868935|NCT06013189|Other|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
79868936|NCT06013150|Drug|Epinephrine|"Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.~Participants in the Part 2 of the study will receive multiple doses of the Epinephrine based on MTD of Part 1 of the study."
79868937|NCT06013150|Drug|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
80028119|NCT03534024|Dietary Supplement|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
79734365|NCT00692731|Dietary Supplement|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
79734366|NCT00692731|Other|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
79734367|NCT02624401|Drug|Dexmedetomidine|Intravenous infusion
79734368|NCT02624401|Drug|Propofol|Intravenous infusion
79574714|NCT01850849|Drug|LEO 39652 cream|
79574715|NCT01850849|Drug|cream vehicle|
79574716|NCT01850862|Other|Collective group exercise program in patients with KOA|
79574717|NCT01850862|Other|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
79574718|NCT01850875|Behavioral|Eye-Movement-Desensitization-Reprocessing|
79574719|NCT01850901|Procedure|Renal sympathetic denervation|
79574720|NCT01850927|Procedure|Remote ischaemic preconditioning|
79734369|NCT02624401|Drug|S-ketamine|Intravenous infusion
79734370|NCT02624401|Drug|Sevoflurane|Inhalation
79734371|NCT02624401|Drug|Placebo|Intravenous infusion of saline (Ringer's Acetate)
79734372|NCT02624557|Drug|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
79734373|NCT02802748|Drug|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
79271368|NCT02571452|Behavioral|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
79271369|NCT05526170|Device|Devices for long-term monitoring of objective and subjective parameters of the body|Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
79734374|NCT02802748|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
79271370|NCT05522348|Procedure|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|two patient fitted custom made plates will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
79574721|NCT01850927|Procedure|Control|
79271371|NCT05522348|Procedure|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|one patient fitted custom made plate will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
79734375|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
79734376|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
80028120|NCT03534024|Dietary Supplement|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
79271372|NCT05525936|Diagnostic Test|Echocardiography and central venous pressure|To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
79271373|NCT05148026|Drug|Unfractionated heparin + RCA first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
79271374|NCT05148026|Drug|Unfractionated heparin first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
79574722|NCT01850940|Drug|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
79271375|NCT04991714|Drug|Lactisole|sweet taste inhibitor (decreases sweetness)
79271376|NCT04991714|Drug|Rebaudioside M|Sweetener (increases sweetness)
79271377|NCT04991714|Other|Sucrose|10% Sucrose corresponding to a regular soft drink
79271378|NCT05522270|Procedure|revitalization by concentrated growth factor|modified platelet concentrate
79271379|NCT05522192|Drug|Mitoxantrone liposome|Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
79271380|NCT05522192|Drug|Venetoclax|Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
79574723|NCT01850940|Other|conventional thearpy|conventional therapy with salt limitation ,et al
79574724|NCT01850953|Drug|Varenicline|This is an approved smoking cessation medication.
79574725|NCT01850953|Drug|Placebo|
79734377|NCT02798614|Device|10-day cast|Removal of plaster cast fixation 10 days after reduction
79734378|NCT02620891|Device|helium oxygen mixture|
79734379|NCT02798692|Biological|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
79734380|NCT02798692|Biological|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
79734381|NCT02798692|Biological|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
79734382|NCT02798692|Biological|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
79734383|NCT02620735|Device|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
79734384|NCT02620735|Behavioral|Exercise Only|12 week exercise program
79734385|NCT02620735|Behavioral|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
79734386|NCT02620735|Behavioral|Health Coaching|10 over the phone health coaching sessions.
79734387|NCT02798770|Other|No Intervention Foreseen|
79734388|NCT04235452|Diagnostic Test|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
79271381|NCT05522114|Procedure|TMJ injection using patient specific guide|Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
79868938|NCT06013124|Other|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
79868939|NCT06013098|Drug|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
79868940|NCT06013098|Drug|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
79271382|NCT05516186|Other|Scapular-focused exercise protocol with EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback
79271383|NCT05516186|Other|Control Therapy|manual and exercise therapy
79271384|NCT05516186|Other|Scapular-focused exercise protocol without EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol
79271385|NCT04624490|Drug|Hyperpolarized Xe129|During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
79574726|NCT01850966|Drug|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
79574727|NCT01850979|Drug|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
79734389|NCT01151345|Drug|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
79734390|NCT01151345|Drug|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
79734391|NCT02802904|Other|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
79734392|NCT02802904|Other|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
79734393|NCT02802904|Other|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
79734394|NCT02798302|Other|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
79868941|NCT06013085|Behavioral|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
79271386|NCT05525702|Device|Virtual Reality Treatment|Patients wear virtual reality head-mounted displays and experience immersive virtual environments.
79868942|NCT06013046|Behavioral|Intensity-controlled physical activity training (IPAT)|The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
79271387|NCT05525624|Device|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
79271388|NCT05525624|Other|Control Group|routine neonatal clinic discharge training of the hospital
79271389|NCT05516030|Other|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
80028121|NCT04175574|Other|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
79574728|NCT01850979|Drug|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
79574729|NCT01850992|Device|Active CPAP|Effective CPAP will be administered
79574730|NCT01850992|Device|Sham CPAP|This is placebo CPAP
79574731|NCT01851005|Drug|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
79574732|NCT01851005|Drug|Sevoflurane|Control Vol% to maintain BIS 40~45
79574733|NCT01851005|Drug|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40~45 and changes of vital signs within 20%.
79574734|NCT01851005|Drug|Normal saline|Use as placebo
79574735|NCT01851005|Drug|Rocuronium|0.8 mg/kg for induction
79574736|NCT01851031|Procedure|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
79574737|NCT01851044|Procedure|Platelet Rich Plasma|
79574738|NCT01851044|Procedure|Whole Blood Injection|
79574739|NCT01851044|Procedure|Saline Injection|
79734395|NCT02798146|Other|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
79734396|NCT02802670|Drug|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of [14C]-labeled GDC-0810 on Day 1.
79868943|NCT06013046|Behavioral|Education and Access (EA)|The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
79868944|NCT06013007|Procedure|ICI-guided JINS approach|OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).
79271390|NCT04296812|Behavioral|Self-Love Model|"The model is a visual illustration shaped as a triangle.~The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~At the top of the triangle is a circle with the letter R within for relationship.~Two small lines project horizontally, from the circle, left and right.~At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~Exploring self-esteem strategies.~Importance of self-worth in relationships.~Importance of self-awareness."
79574740|NCT01851057|Behavioral|STAR|Problem-solving and education intervention (8 total sessions)
79734397|NCT02802826|Behavioral|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
79734398|NCT02798068|Drug|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
79734399|NCT02802358|Procedure|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
79868945|NCT06012955|Device|Target-controlled infusion (TCI) systems|Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
79868946|NCT06012916|Drug|Esketamine nasal spray|This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
79868947|NCT06012903|Other|Questionnaire Welbevinden|A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.
79271391|NCT05521724|Procedure|exercise|resistance and strengthening exercises will be applied to a randomized patient group.
79271392|NCT05525234|Drug|Thalidomide|Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
79574741|NCT01851057|Behavioral|Education Only|Education around epilepsy (8 total sessions)
79574742|NCT01851070|Drug|Allogeneic Mesenchymal Precursor Cells|
79574743|NCT01851070|Drug|Normal Saline|
79734400|NCT02802436|Procedure|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
79734401|NCT02797912|Other|No intervention|
79734402|NCT02802280|Other|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
79574744|NCT01851096|Drug|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
79734403|NCT04235842|Other|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
79734404|NCT04235842|Other|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
80028122|NCT02753686|Drug|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
79734405|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
79271393|NCT05525234|Drug|Placebo|Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
79574745|NCT01851109|Behavioral|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~Discuss how the results - positive or negative - affect cancer risk~Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
79734406|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
79574746|NCT01851135|Other|Neuropsychological examination and quality of life measures|
79271394|NCT02574260|Biological|Talimogene Laherparepvec|Administered by intratumoral injection.
79402566|NCT06012682|Drug|Metformin Hydrochloride|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
79574747|NCT01851148|Other|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
79574748|NCT01851148|Other|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
79574749|NCT01851148|Drug|triptans|administration of triptans drug treatment according to international guidelines
79574750|NCT01851161|Procedure|computed tomography|Undergo conventional CT scan in both supine and prone positioning
79574751|NCT01851161|Procedure|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
79574752|NCT01851161|Radiation|radiation therapy|Undergo radiation therapy
79734407|NCT02797834|Procedure|Endometrial fluid collection|
79734408|NCT02797756|Procedure|Esophago-gastro-duodenoscopy (EGD) with biopsy|
79868948|NCT06012903|Other|Questionnaire Vancouver symptom score for dysfunctional elimination syndrome|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.
79868949|NCT06012903|Other|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.
79868950|NCT06012903|Other|Questionnaire concerning LUTS, NDDs and treatment perceptions|Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.
79868951|NCT06012903|Other|Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom|These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
79868952|NCT06012890|Other|Automation of cardiac MRI acquisition|The intervention will consist of the automation of the cMRI examination.
79868953|NCT06012877|Behavioral|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
79868954|NCT06012864|Procedure|PNL|percutaneous extraction of the stones in the kidney
79271395|NCT05521490|Other|Usual Care Control|30 minutes of physical activity on each school day.
79271396|NCT05521490|Behavioral|Physical Activity Enhanced Curriculum|Additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity.
79574753|NCT01851187|Behavioral|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
79574754|NCT01851187|Behavioral|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
79734409|NCT02797756|Procedure|Esophageal Impedance Monitoring (EIM)|
79734410|NCT02797600|Behavioral|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
79574755|NCT01851200|Drug|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
79574756|NCT01851226|Procedure|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
79734411|NCT02797600|Other|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
79734412|NCT04135105|Other|Normal hearing group|Observational
79734413|NCT02797444|Other|semi-structured interviews|
79734414|NCT04136119|Other|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
79868955|NCT06012838|Behavioral|Cause classification of OHCA protocol|training program with cause classification of OHCA protocol
79868956|NCT06010472|Drug|anti-CD19 CAR NK cells (KN5501)|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 3×10^8, 6×10^8, 1.2×10^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
79271397|NCT04295330|Drug|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
79734415|NCT02797366|Radiation|Proton radiotherapy|
79868957|NCT06009172|Other|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
79271398|NCT04295330|Drug|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
79868958|NCT06009133|Procedure|Conservative treatment|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
79271399|NCT05525156|Drug|aspirin enteric coated tablet 75 mg|blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
79734416|NCT00692887|Device|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
79734417|NCT02801890|Biological|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
80028123|NCT02753686|Drug|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
80028124|NCT02195388|Other|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
79574757|NCT01851265|Drug|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
79574758|NCT01851265|Other|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
79574759|NCT01851265|Other|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
79574760|NCT01851265|Other|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
79574761|NCT01851278|Drug|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
79574762|NCT01851278|Drug|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
79574763|NCT01851304|Dietary Supplement|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
79734418|NCT02801812|Device|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
79734419|NCT00695851|Drug|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
79734420|NCT00695851|Drug|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
79734421|NCT02797210|Device|Continuous theta-burst stimulation|
79734422|NCT02624323|Procedure|Real-time ultrasound-guided central vein catheterization.|
79734423|NCT02796820|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
79734424|NCT04135885|Drug|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
79868959|NCT06009133|Procedure|Surgical Treatment|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
79868960|NCT06008210|Behavioral|Decision Support Intervention|The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
80028125|NCT03534258|Device|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
80028126|NCT04216927|Drug|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
79271400|NCT05521334|Device|micropulse transscleral cyclophotocoagulation|glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
79574764|NCT01851304|Dietary Supplement|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
79734425|NCT04135885|Drug|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
79734426|NCT02801968|Procedure|Tap block|
79868961|NCT06008210|Behavioral|Health Coaching|The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
79271401|NCT05512442|Procedure|the centric relation|All participants were recorded the centric relation registrations according to the technique of the gothic tracing method and the neuromuscular method separately.
79271402|NCT05512286|Radiation|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
79271403|NCT05512286|Radiation|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
79271404|NCT02570126|Biological|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
79734427|NCT02801968|Other|intravenous analgesia|
79271405|NCT02570126|Biological|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
79271406|NCT04903184|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.
79271407|NCT04903184|Biological|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo.
79734428|NCT00696865|Drug|AZD2624|oral suspension, 3 doses
79734429|NCT00696865|Drug|Placebo|
79734430|NCT02802046|Radiation|Computed tomographic angiography of coronary artery|
79868962|NCT06007612|Behavioral|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
80028127|NCT04216927|Drug|Oxygen|Oxygen alone will be entrained for placebo arm
80028128|NCT02329834|Drug|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
79574765|NCT01851343|Other|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
79574766|NCT01851408|Drug|sorafenib tosylate|Given orally
80028129|NCT02329834|Drug|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
79734431|NCT02620657|Other|Non interventional study|Non interventional study
79734432|NCT02801734|Other|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
79734433|NCT02624011|Behavioral|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
79734434|NCT02796898|Drug|SM88 (Cohort 1)|"Tyrosine Isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
79271408|NCT05512130|Drug|Empagliflozin 25 mg|Participants will take empagliflozin daily for 2 weeks.
79271409|NCT05512130|Drug|Placebo|Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
79574767|NCT01851408|Drug|temsirolimus|Given IV
79734435|NCT02796898|Drug|SM88 (Cohort 2)|"Tyrosine Isomers - 460 mg (230 mg bid)~Phenytoin - 50 mg qd~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
79734436|NCT00693043|Drug|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
79734437|NCT00695929|Drug|Levosimendan|Intravenous injection
79734438|NCT00695929|Drug|Milrinone|Intravenous injection
79574768|NCT01851460|Device|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of >75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
79574769|NCT01851473|Drug|cocaine|25 mg IV on days 1, 5, and 10
79868965|NCT05997316|Behavioral|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
79574770|NCT01851473|Drug|quinine|80 mg orally on days 7-10
79305869|NCT04430907|Biological|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
79574771|NCT01851473|Drug|acetazolamide|15 mg orally on days 2-5
79734439|NCT04235296|Biological|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
79734440|NCT04235296|Biological|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
79574772|NCT01851486|Drug|Clonidine|Clonidine 0.15 mg
79734441|NCT02624167|Drug|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
79734442|NCT02624167|Drug|Placebo|Patients will be given oral dose of matching Placebo
79734443|NCT02796976|Other|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
79868966|NCT05997004|Drug|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
79868967|NCT05997004|Drug|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
79868968|NCT05995301|Drug|Ropivacaine in Transversus abdominis plane|This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
79868969|NCT05995301|Drug|Ropivacaine in Local infiltration at port site|This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
79868970|NCT05993832|Other|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
79734444|NCT02620501|Drug|Lidocaine|topical lidocaine
79734445|NCT02620501|Drug|Placebo|0.45% Normal Saline
79734446|NCT02796742|Other|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
79734447|NCT00693121|Drug|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
79734448|NCT00693121|Drug|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
79734449|NCT02796586|Other|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
79734450|NCT04134793|Procedure|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
79868971|NCT05876299|Other|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
79868972|NCT05876299|Other|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
79868973|NCT05876299|Other|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
79868974|NCT05871762|Other|Registry study, no specific intervention|Registry study, no specific intervention
79868975|NCT05868044|Device|PRIMUS|Peripheral Nerve Stimulator System
79868976|NCT05858632|Drug|Guselkumab|Guselkumab treatment for ~ 9 months
80028130|NCT02195466|Drug|Tipranavir (TPV)|500 mg bid on days 7-14
80028131|NCT02195466|Drug|Ritonavir (RTV)|200 mg bid on days 7-14
79868977|NCT05843890|Behavioral|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
79271410|NCT05512052|Device|Hannah Cervical Cup (2 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
79271411|NCT05512052|Device|Hannah Cervical Cup (4 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
79574773|NCT01851486|Drug|Naloxone|naloxone 0.15 mg/kg
79734451|NCT02801500|Device|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
79574774|NCT01851486|Drug|placebo|
79574775|NCT01851486|Other|saline|
79574776|NCT01851499|Dietary Supplement|Ultramicronized PEA (Normast)|600 mg
79574777|NCT01851512|Drug|T-R (Test-Reference drug)|
80028132|NCT02195466|Drug|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
79734452|NCT02801500|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
79734453|NCT02801344|Dietary Supplement|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
79868978|NCT05843890|Behavioral|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
79574778|NCT01851512|Drug|R-T (Reference-Test drug)|
79574779|NCT01851525|Device|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
79574780|NCT01851538|Other|Observational study; no intervention.|
79868979|NCT05814783|Behavioral|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
79868980|NCT05814783|Device|digital CBTI|CBTI app
80028133|NCT03692377|Device|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
80028134|NCT02195544|Drug|Synvisc®|
80028135|NCT03687853|Device|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
80028136|NCT02197494|Drug|Valsartan|320mg tablets
79574781|NCT01851551|Drug|Vincristine Sulfate Liposome Injection plus rituximab|
79574782|NCT01851564|Device|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
79574783|NCT01851564|Other|Standard Therapy|Standard Medical and Endoscopic Therapy
79574784|NCT01851577|Behavioral|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
79574785|NCT01851577|Behavioral|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
79574786|NCT01851603|Device|AVL-3288|Drug
79734454|NCT02801344|Dietary Supplement|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
79734455|NCT02801344|Dietary Supplement|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
79734456|NCT02801344|Other|Controlled-diet|the diet containing 0.8 g protein /kg/day
79734457|NCT02620423|Biological|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
79734458|NCT02620423|Drug|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
79734459|NCT02620423|Drug|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
79734460|NCT02620423|Drug|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
79868981|NCT05786794|Behavioral|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
79868982|NCT05785637|Procedure|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
79868983|NCT05785546|Other|usual care|For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
80028137|NCT02710474|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
80028138|NCT02710474|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
80028139|NCT03683017|Device|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
80028140|NCT03683017|Device|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
79271412|NCT05512052|Device|Hannah Cervical Cup (6 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
79271413|NCT02180425|Drug|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
79574787|NCT01851603|Drug|Placebo|Identical diluent to that used for AVL-3288
79574788|NCT01851616|Dietary Supplement|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
79574789|NCT01851616|Dietary Supplement|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
79574790|NCT01851629|Behavioral|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
79574791|NCT01851629|Other|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
79574792|NCT01851681|Drug|Amoxicillin|
79574793|NCT01851707|Drug|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
79734461|NCT02620423|Drug|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
79734462|NCT02620423|Drug|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
79271414|NCT02180425|Drug|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
79271415|NCT02183467|Drug|BI 1356, low dose|
79271416|NCT02183467|Drug|BI 1356, high dose|
79271417|NCT02183467|Drug|Placebo|
79271418|NCT02183467|Drug|Moxifloxacin|
79574794|NCT01851707|Drug|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
79734463|NCT02620423|Drug|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
79868984|NCT05774600|Behavioral|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
79868985|NCT05774600|Behavioral|Minimal Information Control|Provision of online materials for skin cancer prevention.
79574795|NCT01851733|Device|MRI-guided Laser Heat Ablation (MLA)|
79574796|NCT01851733|Drug|Doxorubicin|
79574797|NCT01851733|Other|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~before MLA (up to 3 days before)~2 weeks after MLA~4 weeks after MLA~every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
79574798|NCT01851733|Device|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
79271419|NCT02183545|Drug|BI 1060469|single rising doses given as tablet
79868986|NCT05759442|Drug|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
79868987|NCT05759442|Dietary Supplement|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
79271420|NCT02183545|Drug|Placebo|given as tablet (matching placebo of BI 1060469)
79574799|NCT01851759|Drug|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
79574800|NCT01851759|Drug|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
79574801|NCT01851785|Behavioral|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
79868988|NCT05730218|Drug|ONL1204 Ophthalmic Solution|ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
79868989|NCT05730218|Drug|Sham treatment|Sham injection is performed by touching the eye surface with a syringe without a needle
79868990|NCT05728346|Drug|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
79868991|NCT05728138|Behavioral|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
79868992|NCT05720832|Other|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
80028141|NCT03683017|Device|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
79271421|NCT02755831|Device|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
79271422|NCT02755831|Other|Pre-natal care|Standard Pre-Natal Care
79271423|NCT05515484|Other|prone position with airbags|prone position with airbags
79271424|NCT05515484|Other|prone position without airbags|prone position without airbags
79574802|NCT01851798|Other|Home sleep test administered to all enrolled subjects|
79574803|NCT01851824|Drug|acenocoumarol|4 mg single oral doses on Days 1 and 23
79574804|NCT01851824|Drug|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
79574805|NCT01851837|Other|Exercise time|Continuous training, Interval training
79574806|NCT01851850|Drug|Opicapone|25mg or 50mg once per day
79574807|NCT01851915|Behavioral|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
79574808|NCT01851915|Behavioral|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
79574809|NCT01851941|Drug|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
79734464|NCT02796430|Other|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
79734465|NCT02796430|Other|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
79734466|NCT00696007|Drug|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
79734467|NCT00696007|Other|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
80028142|NCT03683017|Device|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
80028143|NCT01340937|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
79271425|NCT05521100|Procedure|Vascular closure device|Suture of lower extremity veins using the Proglide Vascular Closure Device
79271426|NCT05521100|Procedure|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
79271427|NCT05511974|Diagnostic Test|BASET score|The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
79868993|NCT05701670|Behavioral|Purrble+SSI|"Purrble intervention as described above.~Single Session Intervention (SSI) (~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts."
79868994|NCT05694052|Behavioral|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
79868995|NCT05661721|Other|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
79868996|NCT05661721|Other|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
79868997|NCT05654597|Other|CAPTURE tool|CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
79574810|NCT01851954|Drug|Clarithromycin|IV clarithromycin infusion
79734468|NCT02796508|Behavioral|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
79734469|NCT02796508|Behavioral|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
79734470|NCT02624089|Drug|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
79734471|NCT02624089|Drug|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
79868998|NCT05654597|Other|Spirometry|Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
79868999|NCT05639088|Behavioral|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
79869000|NCT05639088|Other|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
79869001|NCT05632497|Biological|Stool sample|Stool sample
79869002|NCT05631886|Biological|TP53-EphA-2-CAR-DC|5~10 × 10^6 CAR DCs per dose will be administered by intravenous injection.
79869003|NCT05631886|Drug|Abraxane|Intravenous abraxane 125 mg/m^2/day on day-5.
79869004|NCT05631886|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m^2/day on day -4.
79869005|NCT05631886|Drug|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
79869006|NCT05631886|Drug|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
79869007|NCT05601752|Genetic|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
79869008|NCT05601752|Combination Product|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
79869009|NCT05600621|Behavioral|Financial Literacy Training (FLT) Workshops|Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
79271428|NCT02180503|Drug|BI 1356 BS PIB - low dose|
79271429|NCT02180503|Drug|BI 1356 BS tablet - low dose|
79271430|NCT02180503|Drug|BI 1356 BS PIB - high dose|
79574811|NCT01851967|Other|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
79271431|NCT02180503|Drug|BI 1356 BS tablet - high dose|
79271432|NCT02180503|Drug|BI 1356 BS tablet - high dose with food|
79271433|NCT05511896|Other|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
79574812|NCT01851980|Other|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
79574813|NCT01851980|Drug|Furosemide|40 mg and 120 mg
79574814|NCT01851980|Drug|Placebo|0.9% saline
79734472|NCT02801422|Other|fMRI|
79734473|NCT02624245|Other|Conventional Physical Therapy|
79734474|NCT02796196|Other|Medical Chart Review|Review of medical chart
79734475|NCT02796196|Device|Monitoring Device|Wearable physical activity monitoring device
79734476|NCT02796196|Procedure|Physical Therapy|Undergo primarily self-directed physical therapy
79734477|NCT00696943|Drug|([18F]-ML-10)|[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
80028144|NCT01340937|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
80028145|NCT01340937|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
80028146|NCT01340937|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
80028147|NCT01340937|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
80028148|NCT02303470|Behavioral|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
80028149|NCT02303470|Behavioral|Moderate Exercise|
79271434|NCT02177851|Dietary Supplement|Single oral iron dose of 120 mg per day for 3 consecutive days|
79734478|NCT02796040|Device|MRI|
79271435|NCT02177851|Dietary Supplement|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
79271436|NCT05075876|Drug|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
79271437|NCT05075876|Drug|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
79271438|NCT02180581|Dietary Supplement|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 * 10^9 cfu/day) or probiotics for 6 months
79271439|NCT02180581|Dietary Supplement|Placebo|Placebo for 6 months
79271440|NCT02180737|Drug|Dexmeditomedine|
79734479|NCT00693199|Drug|amlodipine|amlodipine 5mg once daily for 28 days
79734480|NCT00693199|Drug|terazosin|terazosin 2 mg once daily for 28 days
79869010|NCT05600621|Behavioral|Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)|"ALHIV will receive a YSA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.~As part of YSA, ALHIV are also trained on investing in income-generating activities (IGA) and are normally allowed to use up to 30% of their matched savings to invest in an IGA to benefit their family. The IGA portion helps promote economic stability for families and enable the ALHIV to afford medical expenses."
79869011|NCT05600621|Behavioral|A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon).|Participants assigned to this component will participate together with her/his caregiving family, in attending sixteen 60 minute sessions hosted within the community over 16 weeks. Each session involves 6-10 families. Participants will learn from the Suubi Cartoon curriculum about their HIV diagnosis and treatment needs, while coping with family loss, stigma, peer relationships, identity, and family functioning.
80028150|NCT03692299|Drug|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
80028151|NCT03692299|Drug|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
80028152|NCT02197650|Drug|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
79271441|NCT05520944|Drug|ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray|Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
79271442|NCT02183623|Drug|Simvastatin|
79271443|NCT02183623|Drug|10 mg BI 1356 BS|
79271444|NCT05511740|Radiation|Afternoon Radiation|Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
79271445|NCT02183701|Drug|Telmisartan|
79271446|NCT02183701|Drug|Losartan + Hydrochlorothiazide|
79271447|NCT02183701|Drug|Placebo|
79574815|NCT01851993|Drug|Ondansetron|
79734481|NCT00693199|Drug|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
79734482|NCT02795962|Other|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
79574816|NCT01851993|Drug|Placebo|0.9% saline
79574817|NCT01852006|Device|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
79574818|NCT01852097|Behavioral|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~Give feedback to individuals on their questionnaire responses.~Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~Provide advice on overcoming practical barriers.~Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
79734483|NCT02623777|Dietary Supplement|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
79734484|NCT02623777|Dietary Supplement|Short chain fatty acids|Short chain fatty acids administered
80028153|NCT03682939|Biological|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
80028154|NCT03682939|Biological|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
80028155|NCT02927184|Drug|VK2809|
80028156|NCT02927184|Drug|Placebo|
80028157|NCT02201992|Other|Clinical Observation|Undergo observation
80028158|NCT02201992|Drug|Crizotinib|Given PO
80028159|NCT02201992|Other|Laboratory Biomarker Analysis|Correlative studies
79574819|NCT01852123|Device|High-sensitivity troponin I assay|
79574820|NCT01852136|Device|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
80028160|NCT03687775|Other|Stability assessment|Qualitative and quantitative stability assessment
80028161|NCT03534492|Drug|Durvalumab|Infusion
80028162|NCT03534492|Drug|Olaparib|P.O.
79875902|NCT01322880|Behavioral|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
79271448|NCT05511662|Other|PRO follow up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
79271449|NCT05141851|Device|Implants with 0,7 mm threads|Implants were placed, with threads of 0.7 mm in the location of premolars and molars.
79574821|NCT01852136|Device|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
79271450|NCT05141851|Device|Implants with 0.3 mm threads|Implants were placed, with threads of 0.3 mm in the location of premolars and molars.
79271451|NCT03537859|Other|Augmented Reality|Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
79271452|NCT03537859|Other|Non Augmented Reality|Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
79271453|NCT05511506|Other|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
79271454|NCT02183779|Procedure|post-occlusive hyperemia|
79271455|NCT02183779|Procedure|cooling box|
79574822|NCT01852136|Device|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
79574823|NCT01852149|Device|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
79574824|NCT01852188|Other|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
79574825|NCT01852253|Procedure|2% chlorhexidine|
79574826|NCT01852253|Procedure|0.12% chlorhexidine|
79574827|NCT01852266|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
79574828|NCT01852266|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
79574829|NCT01852279|Device|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
79271456|NCT02183779|Drug|L-NMMA and Fluconazole dermic injection|
79271457|NCT02183857|Device|Ultrasound|
79271458|NCT02183857|Other|Landmark|
79271459|NCT02183935|Device|Duodena-jejunal liner|
79271460|NCT02180815|Device|ReVENT Sleep Apnea System|
79271461|NCT02256397|Other|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
79574830|NCT01852279|Device|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
79574831|NCT01852305|Other|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI>30) or moderate sleep apnea (AHI>15 to <30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI>5 to <15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
79574832|NCT01852305|Device|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
79574833|NCT01852318|Drug|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
79574834|NCT01852318|Drug|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
79271462|NCT02256397|Other|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
79305870|NCT03054285|Drug|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
79574835|NCT01852318|Drug|placebo|
79574836|NCT01852331|Drug|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
79574837|NCT01852331|Drug|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
79574838|NCT01852357|Other|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
79869012|NCT05600621|Behavioral|Engagement with HIV treatment-experienced role models who share lived experiences of HIV|Participants will be assigned to small groups with an average of 3-4 peers from the same health clinic, and each ALHIV stays in the same group -- for 9 sessions - with the same role model. This is intended to build trust and rapport not only between the role model and mentee, but also between all group members. The 9 sessions, to be conducted over a 6-month period, include activities, videos, scenarios, and role-playing to facilitate discussion and learning. This is intended to promote their self-esteem, improve their HIV care engagement, reduce stigma and stress, encourage hopefulness, build stronger communication skills with their caregivers and/or family members, enhance safe sexual decision-making, and decrease sexual risk-taking behavior.
80028163|NCT03687697|Biological|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
79271463|NCT02573246|Behavioral|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
79271464|NCT02573246|Device|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
79271465|NCT02573246|Device|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
79271466|NCT02256475|Drug|NBI-98854|
79271467|NCT05141773|Device|Computed adenoma detection system (CADe) plus endocuff|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps. An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
80028164|NCT03624283|Drug|Betahistine|Betahistine is used in the treatment of and vertigo.
80028165|NCT03624283|Behavioral|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
80028166|NCT03687619|Other|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
79271468|NCT05141773|Device|Endocuff|An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
79271469|NCT02177929|Other|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
79271470|NCT04293302|Other|No intervention|No intervention
79271471|NCT03537781|Behavioral|Food labelling versus no food labelling|Food labelling availability and satiety status
79271472|NCT02180971|Procedure|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
79305871|NCT04917627|Drug|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
79574839|NCT01852357|Other|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
79574840|NCT01852396|Procedure|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
79574841|NCT01852409|Drug|bevacizumab|
79574842|NCT01852435|Drug|R-CEOP-70|
79574843|NCT01852435|Drug|R-CEOP-90|
79305872|NCT04910451|Other|No Intervention|
79574844|NCT01852435|Drug|R-CHOP-50|
79574845|NCT01852461|Drug|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
79574846|NCT01852461|Drug|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
79574847|NCT01852474|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
79574848|NCT01852487|Dietary Supplement|400mg /day during 6 months|
79574849|NCT01852500|Other|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
79574850|NCT01852500|Other|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
79574851|NCT01852526|Device|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
79574852|NCT01852526|Device|Active Comparator: Plif|monosegmental PLIF
79574853|NCT01852539|Drug|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
80028167|NCT03687619|Other|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
80028168|NCT03687463|Drug|Decitabine|Decitabine for injection
80028169|NCT02197728|Device|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
80028170|NCT03687385|Device|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
79574854|NCT01852539|Drug|propofol|Propofol 2.0 mg/kg was administrated
79574855|NCT01852539|Device|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
80028171|NCT03687385|Device|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
80028172|NCT02031198|Drug|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
80028173|NCT03682861|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
79869013|NCT05600621|Other|Standard of Care (SOC)|SOC consisting of pediatric ART initiation and monitoring outlined by Uganda's Ministry of Health.
79869014|NCT05576454|Drug|Mepolizumab Injection (BAT2606 Injection)|In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.
80028174|NCT03682861|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
80028175|NCT03682783|Diagnostic Test|Fundus Image|Fundus image of optic nerve
80028176|NCT02196948|Other|Electrolysis Percutaneous Therapeutic (EPTE)|
80028177|NCT02196948|Other|Eccentric exercise|
79574856|NCT01852552|Device|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
79574857|NCT01852552|Procedure|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
79574858|NCT01852565|Drug|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
79574859|NCT01852565|Drug|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
79574860|NCT01852578|Drug|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
79574861|NCT01852604|Drug|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
79574862|NCT01852604|Drug|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
79574863|NCT01852604|Drug|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
79574864|NCT01852604|Drug|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
79574865|NCT01852604|Drug|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
79574866|NCT01852604|Biological|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
79574867|NCT01852604|Other|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
80028178|NCT03692143|Drug|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
80028179|NCT03692143|Procedure|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
79869015|NCT05576454|Drug|Mepolizumab Injection (EU-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
79271473|NCT02180971|Procedure|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
79869016|NCT05576454|Drug|Mepolizumab Injection (US-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
79574868|NCT01852617|Behavioral|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
79574869|NCT01852630|Drug|cefepime + Albumin|cefepime + Albumin will be given for 2 days
79574870|NCT01852630|Drug|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
79574871|NCT01852643|Procedure|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
79574872|NCT01852643|Procedure|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
79869017|NCT05565794|Drug|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
79869018|NCT05557747|Other|cervicothoracic junction mobilization in form of Maitland mobilization|Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
79875903|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
79271474|NCT04292912|Drug|GSK2798745|GSK2798745 will be administered.
79271475|NCT02184091|Drug|Nevirapine|
80028180|NCT03692143|Drug|Alendronate|Alendronate Sodium, oral, 70mg, once a week
79271476|NCT02184247|Drug|anhydrous theophylline, 350 mg|
79271477|NCT02184247|Drug|anhydrous theophylline, 300 mg|
79305873|NCT04904133|Other|Low/No Calorie Sweeteners|LNCS powdered and then dissolved in water.
79305874|NCT04904133|Other|Placebo Group|Water
79574873|NCT01852656|Behavioral|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
79869019|NCT05557747|Other|autogenic muscle Energy Technique|"the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold"
79869020|NCT05557747|Other|conventional physical therapy|conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
79734485|NCT04135651|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
79869021|NCT05528835|Procedure|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
80028181|NCT02201004|Drug|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
80028182|NCT02201004|Drug|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
79271478|NCT04292756|Procedure|Subtenon injection of 40 mg triamcinolone acetonide|Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
79574874|NCT01852656|Behavioral|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
79574875|NCT01852656|Behavioral|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
79574876|NCT01852682|Drug|PA21|
79574877|NCT01852695|Behavioral|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
79734486|NCT04135651|Procedure|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
79734487|NCT02796118|Drug|ASP2151|Oral
79734488|NCT02796118|Drug|Placebo|Oral
79734489|NCT02795884|Drug|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
79734490|NCT02795884|Drug|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
79271479|NCT04292756|Procedure|Intravitreal injection of 4 mg triamcinolone acetonide|Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
79271480|NCT04292756|Diagnostic Test|Visometry|Ophthalmic examination
79271481|NCT04292756|Diagnostic Test|Fluorescent angiography|Ophthalmic examination
79271482|NCT04292756|Diagnostic Test|Refractometry|Ophthalmic examination
79734491|NCT02795728|Other|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
79869022|NCT05526521|Drug|Dupilumab|Injection solution Subcutaneous
79869023|NCT05521399|Diagnostic Test|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
79869024|NCT05521399|Diagnostic Test|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
79869025|NCT05521399|Diagnostic Test|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
79875904|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
79271483|NCT04292756|Diagnostic Test|Slit lamp examination|Ophthalmic examination
80028183|NCT02201004|Drug|placebo|Pharmaceutical form:tablet Route of administration: oral
79271484|NCT04292756|Diagnostic Test|Ophthalmoscopy|Ophthalmic examination
80028184|NCT02197884|Drug|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
79271485|NCT04292756|Diagnostic Test|OKT|Ophthalmic examination
79271486|NCT04292756|Diagnostic Test|IOP|Ophthalmic examination
80028185|NCT02197884|Drug|Itraconazole 200 mg|Itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
79734492|NCT02795728|Other|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
79734493|NCT02800798|Other|Preeclampsia positive|
79869026|NCT05501847|Radiation|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
80028186|NCT02197884|Drug|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
80028187|NCT02201082|Procedure|Airway clearance technique|
80028188|NCT02201082|Drug|Amikacin nebulization|
79271487|NCT03537703|Combination Product|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
80028189|NCT02201160|Dietary Supplement|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
80028190|NCT03687229|Diagnostic Test|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
79271488|NCT03537703|Combination Product|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
80028191|NCT03687229|Diagnostic Test|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
80028192|NCT05085054|Drug|Osimertinib Mesylate|Participants will receive targeted therapy followed by salvage surgery
79734494|NCT02795572|Dietary Supplement|Vitamin D|Vitamin D 2000 IU oral once daily
79734495|NCT02795572|Dietary Supplement|Vitamin B6|Vitamin B6 100 mg oral once daily
79734496|NCT02795572|Dietary Supplement|Vitamin B12|Vitamin B12 100 mcg oral once daily
79734497|NCT02795572|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
79734498|NCT02795650|Drug|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
79734499|NCT02795650|Drug|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
79734500|NCT02800876|Other|CT-acquisition|
79402567|NCT06012682|Drug|Placebo|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
79402568|NCT06012630|Diagnostic Test|Ultarsound|Median nerve evaluation of participants with ultrasound
79402569|NCT06012604|Biological|allogeneic mesenchymal stromal stem cells|mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
79734501|NCT02795494|Behavioral|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
79734502|NCT02795494|Behavioral|ASK-P questionnaire at baseline|Patient-reported activity level score
79734503|NCT02795494|Behavioral|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
79734504|NCT02801188|Drug|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
79734505|NCT02801188|Drug|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
79734506|NCT04236076|Device|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
79734507|NCT04236076|Device|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
79734508|NCT04235920|Diagnostic Test|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
79734509|NCT02795260|Biological|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
79869027|NCT05470751|Device|Intermittent self-catheterisation|Self-catheterising with GC Air Male with Feelclean technology
79875905|NCT01028586|Drug|Placebo|matching placebo tablets
80028193|NCT03687151|Other|non intervention / observationnal|non intervention / observationnal
80028194|NCT02257320|Device|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
79869028|NCT05463237|Diagnostic Test|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
79869029|NCT05463237|Diagnostic Test|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
79869030|NCT05453864|Behavioral|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
79869031|NCT05447546|Drug|HT-6184|Oral capsule
79734510|NCT02795260|Biological|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
79869032|NCT05447546|Drug|HT-6184 Placebo|Oral capsule
79869033|NCT05431374|Drug|Measurement Based Care (MBC)|"Patients in both groups will receive either open-label paroxetine (20-50mg/day) or open-label mirtazapine (15-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient."
79869034|NCT05431374|Drug|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
79869035|NCT05415683|Diagnostic Test|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
79402570|NCT06012591|Other|Quality improvement recommendations (action plans)|Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
79574878|NCT01852721|Behavioral|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
79574879|NCT01852721|Behavioral|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
79574880|NCT01852734|Procedure|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
79574881|NCT01852734|Procedure|embolizations|comparison between the two microspheres
79734511|NCT02801032|Drug|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
79734512|NCT02801032|Drug|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
79734513|NCT05442190|Drug|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment.
79734514|NCT05442190|Drug|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
79869036|NCT05411029|Diagnostic Test|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
79869037|NCT05411029|Diagnostic Test|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
79875906|NCT03457350|Procedure|cervical negotiation|trial to bypass severe cervical stenosis
79402571|NCT06012565|Drug|KAND567|2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
79271489|NCT03537703|Combination Product|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
79271490|NCT05520632|Diagnostic Test|Brainstem Auditory Evoked Potentials|Performing Brainstem Auditory Evoked Potentials under sedation
79271491|NCT02178085|Other|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
79271492|NCT04597502|Dietary Supplement|Terminalia Chebula fruit extract|Oral TC fruit extract supplement taken by mouth twice per day
79271493|NCT04597502|Dietary Supplement|Placebo|Oral placebo taken by mouth twice per day
79734515|NCT02795416|Drug|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
79869038|NCT05407194|Dietary Supplement|Collagen + vitamin C|Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
79271494|NCT04597502|Other|Topical Terminalia Chebula|Applied to both forearms and dorsal hands
79574882|NCT01852747|Procedure|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
79869039|NCT05405374|Other|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
79869040|NCT05405374|Device|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
79271495|NCT04597502|Other|Topical Placebo|Applied to both forearms and dorsal hands
79271496|NCT02030353|Behavioral|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
79271497|NCT02030353|Behavioral|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
79271498|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets|
79271499|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
79574883|NCT01852773|Procedure|Open repair of thoracic aorta injury|open surgical management of aortic injury
79734516|NCT02790658|Dietary Supplement|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
79734517|NCT02795026|Procedure|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
79869041|NCT05400564|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
79875907|NCT01065688|Procedure|Roux-en Y reconstruction|surgical procedure
79271500|NCT02184325|Drug|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
79271501|NCT05515172|Other|Mindfulness-based Intervention|"The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks."
79271502|NCT03537001|Other|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
79271503|NCT05074706|Biological|IgG antibodies to Sars-Cov-2|Samples will be collected between 30 and 60 days after second vaccine dose.
79271504|NCT05074706|Biological|QuantiFERON SARS-CoV-2 test|Samples will be collected within 9 months after completion of the vaccination series
79574884|NCT01852773|Procedure|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
79574885|NCT01852786|Other|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
79574886|NCT01852786|Other|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
79875908|NCT01065688|Procedure|Billroth-I reconstruction|surgical procedure
79271505|NCT03536299|Other|Dual-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
79271506|NCT03536299|Other|Single-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
79271507|NCT02181205|Drug|bupivacaine|
79271508|NCT02181205|Drug|placebo|
79305875|NCT04904211|Other|Home-based chemotherapy|To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
79869042|NCT05396443|Behavioral|Black Girls for Wellness|Weekly for 12 weeks, adolescent participants will attend 1) a live stream group Wellness session (90 min/wk), 2) a home cooking experience using ingredients sent to participants' home (60 min/wk), and 3) one live stream group dance classes via Zoom (60 min/wk); participants will also be encouraged to attend 2 other dance classes during the week at their own convenience. Enrolled caregivers and others in the home (e.g., siblings) will be encouraged to participate in activities.
80028195|NCT03969121|Drug|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
79734518|NCT02795026|Procedure|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
80028196|NCT03969121|Drug|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
80028197|NCT02201238|Drug|Diclofenac sodium|Diclofenac sodium
80028198|NCT02201238|Drug|Menthol|Menthol
80028199|NCT03682627|Procedure|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
80028200|NCT03682627|Procedure|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
79271509|NCT05515016|Procedure|chin enhancement with a fatty flap sculpted from the double chin|Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
79271510|NCT02181283|Behavioral|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
79574887|NCT01852864|Drug|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
79574888|NCT01852877|Behavioral|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
79734519|NCT02689960|Drug|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
79734520|NCT01150097|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
79869043|NCT05396443|Behavioral|Black Girls for Wellness Caregivers|Caregivers of adolescents participating in Black Girls for Wellness will be encouraged to participate in the program's activities with their child. For example, they may help adolescent cook, or participate in the dance classes along with their child.
79869044|NCT05368207|Drug|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
79869045|NCT05363020|Drug|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
79305876|NCT04903743|Drug|bupivacaine|group B received 28ml of 0.25% bupivacaine and 2ml normal saline
79869046|NCT05363020|Drug|Placebo|400 mg identically appearing placebo
79869047|NCT05346796|Behavioral|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
79869048|NCT05332600|Other|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
80028201|NCT02257398|Drug|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
79305877|NCT04903743|Drug|magnesium sulfate|group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
79402572|NCT06012565|Drug|Microcrystalline cellulose|Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
79574889|NCT01852903|Dietary Supplement|calcium ascorbate|
79574890|NCT01852903|Dietary Supplement|ascorbic acid|
79574891|NCT01852903|Other|placebo|
79574892|NCT01852916|Device|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
79574893|NCT01852916|Device|NHFOV|Nasal High Frequency Oscillatory Ventilation
80028202|NCT02257398|Drug|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
79734521|NCT01150097|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
79869049|NCT05327543|Behavioral|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
79271511|NCT02181283|Behavioral|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
79271512|NCT02184481|Behavioral|Working memory training|
79402573|NCT06012552|Drug|Tianeptine|Tianesal 12,5mg
79402574|NCT06012552|Drug|Placebo|application as in the control group
79402575|NCT06012526|Diagnostic Test|Polysomnography|Polysomnography is done for patients to find any sleep disordered breathing
79402576|NCT06012500|Drug|Xenon-129|Inhaled contrast for MRI
79574894|NCT01852929|Other|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
79574895|NCT01852981|Behavioral|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
79271513|NCT02184481|Behavioral|Placebo training|
79402577|NCT06012474|Other|Power breath plus|Power breath plus use a variable load calibrated spring. It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O). Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise. patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
79271514|NCT05520242|Other|Use of small animation movies to increase response in a national health survey|Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
79869050|NCT05327543|Behavioral|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
79875909|NCT00450450|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
79875910|NCT00450450|Other|laboratory biomarker analysis|Correlative studies
80028203|NCT02257398|Drug|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
80028204|NCT02257398|Drug|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
79402578|NCT06012474|Other|Incrementing the training load|The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale. If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O. The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
79734522|NCT01150097|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
79734523|NCT01150097|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
79875911|NCT00450450|Biological|filgrastim|Given IV
79271515|NCT02184559|Drug|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
79271516|NCT02184559|Device|The infiltration continues catheter|
79271517|NCT02185651|Drug|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
79271518|NCT02181361|Drug|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
79574896|NCT01852981|Behavioral|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
79271519|NCT02181361|Drug|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
79271520|NCT05520164|Other|Listening the maternal heart sound during the invasive interventions|Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
79574897|NCT01852994|Drug|Testosterone replacement|Application quarterly of Testosterone Undecylate
79734524|NCT01150097|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
79734525|NCT01150097|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
80028205|NCT03533868|Diagnostic Test|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
79869051|NCT05306912|Biological|Blood samples|Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
79869052|NCT05298878|Other|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
79869053|NCT05262855|Drug|[68Ga]FAPI-46|[68Ga]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
79271521|NCT05060276|Biological|STI-3258|Intravenous infusion of STI-3258 will be given (one infusion every three weeks).
79271522|NCT02181439|Device|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
79271523|NCT05511194|Other|Enhanced Recovery After Surgery therapeutic protocol|Feeding and early ambulation, double short IV antibiotic regimen.
79869054|NCT05238324|Biological|Genetic HMI-203|HMI-203 delivered intravenously
79869055|NCT05233228|Drug|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
79271524|NCT05511194|Other|Conventional management|Delayed feeding and ambulation, triple short IV antibiotic regimen.
79869056|NCT05233228|Behavioral|Self-help materials (to support smoking cessation|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
79875912|NCT03440892|Drug|methotrexate|folate antagonist
79875913|NCT03440892|Drug|sulfasalazine|Immunomodulatory
79875914|NCT03440892|Drug|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
79875915|NCT03440892|Drug|tocilizumab|IL-6 receptor antagonist
79271525|NCT02181595|Other|Group reading and discussion|
79875916|NCT03440892|Drug|tofacitinib/baricitinib|JAK inhibitor
79271526|NCT02184637|Drug|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
79271527|NCT02184637|Drug|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
79574898|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
79574899|NCT01853007|Behavioral|COACH Program|
79574900|NCT01853033|Biological|ABT-122|Injection
79574901|NCT01853033|Biological|Placebo|Placebo Injection
79734526|NCT02790190|Other|Radiotherapy dose|
79734527|NCT02794948|Other|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province
80028206|NCT02198742|Device|Miller blade|To participate in the study the subjects must have >500 intubations with the miller blade.
79271528|NCT02184637|Drug|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
79574902|NCT01853098|Behavioral|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
79271529|NCT05510960|Other|Video game & Robotic surgery simulator success|"A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring & Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills."
79271530|NCT02184715|Other|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
79271531|NCT05514704|Other|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3)~Quadriceps strengthening (Level 1-2-3)~Hip abductor/adductor strengthening (Level 1-2-3)~Hamstring stretch~Gastrocnemius stretch"
79271532|NCT05514704|Other|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3)~Quadriceps strengthening (Level 1-2-3)~Hip abductor/adductor strengthening (Level 1-2-3)~Hamstring stretch~Gastrocnemius stretch"
79574903|NCT01853111|Biological|Interleukin-2|
79574904|NCT01853124|Drug|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
79574905|NCT01853124|Drug|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
79574906|NCT01853150|Device|rTMS Motor cortex|
79574907|NCT01853150|Device|rTMS Supplementary motor area|
79574908|NCT01853189|Other|OMT + Usual Care|patients from this group received 6 sessions of OMT
79734528|NCT02794948|Dietary Supplement|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province.
79734529|NCT01149863|Drug|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
79734530|NCT02794792|Drug|Ipragliflozin L-proline|Oral
79574909|NCT01853189|Other|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
79574910|NCT01853202|Behavioral|Supervised aerobic exercise training|
79574911|NCT01853241|Procedure|Single Balloon|All patients in this group will undergo single balloon enteroscopy
79574912|NCT01853241|Procedure|Spirus|All patients in this group will undergo Spirus Enteroscopy
79574913|NCT01853267|Procedure|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
79574914|NCT01853267|Procedure|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
79574915|NCT01853293|Drug|Kudzu extract|
79734531|NCT02794792|Drug|Metformin|Oral
79734532|NCT02794792|Drug|Placebo|Oral
79734533|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
79734534|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
79734535|NCT02790268|Procedure|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
79734536|NCT00872989|Drug|docetaxel|Given IV
79734537|NCT00872989|Drug|vandetanib|Given orally
79734538|NCT02794714|Drug|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
79734539|NCT02794714|Drug|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
79869057|NCT05233228|Behavioral|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
79271533|NCT02185807|Procedure|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
79271534|NCT02185807|Procedure|control group|The control patients receive verbal information and discussion from their physicians.
79271535|NCT05514626|Device|3D Holographic Display|3D holographic visualization of the anatomy during the planned interventional procedure. The HOLOSCOPE-i will be used in addition to and will not replace conventional displays that are currently being used during the procedure.
79271536|NCT05514392|Device|HP Cosmos Torqoalizer|Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.
79869058|NCT05220371|Dietary Supplement|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
79869059|NCT05220371|Other|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
80028207|NCT02198742|Device|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
79734540|NCT02790112|Other|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
79734541|NCT04234750|Biological|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
79734542|NCT01148771|Drug|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
79271537|NCT05126095|Radiation|Radical radiotherapy|Intensity-modulated radiation therapy (IMRT)
79734543|NCT01148771|Drug|ertapenem|1 gram 30 minute infusion q24h for 3 days
79869060|NCT05209438|Device|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
79271538|NCT02030431|Device|Dynaloc|
79271539|NCT02030431|Device|Cancellous screws|
79869061|NCT05193916|Drug|chiglitazar sodium tablets|the drugs will be given orally once a day
79869062|NCT05193916|Drug|Placebo|no active drug contained
79869063|NCT05136053|Drug|Lu AG22515|sterile solution for infusion
79869064|NCT05136053|Drug|Placebo|sterile solution for infusion
79869065|NCT05136053|Drug|Immune System Activator|sterile powder for injection
79271540|NCT02184793|Device|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
79271541|NCT05514314|Drug|Icotinib|Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
79734544|NCT05429008|Drug|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
79869066|NCT05131672|Procedure|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
79869067|NCT05131672|Procedure|cast immobilization|immobilization in a cast without reduction
79869068|NCT05127057|Other|PRIME Parkinson Care|A novel model of care
79869069|NCT05127057|Other|Usual Care|Usual NHS Care
79869070|NCT05119712|Drug|Terbinafine Tablets|500mg oral terbinafine or placebo daily
79869071|NCT05119712|Diagnostic Test|Laboratory Testing|Laboratory testing at screening, baseline, week 8, 16, 24 and 32.
80028208|NCT02198742|Device|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
79271542|NCT04870424|Drug|Colchicine|Colchicine in a loading dosage of 1mg single dose per os the day before TAVI and 1mg single dose at the day of procedure. Thereafter, colchicine 0.5mg once daily per os up to post-procedural day 12.
79574916|NCT01853293|Drug|Placebo|
79734545|NCT01148693|Drug|gentamicin|10mg per 10ml of contrast media
79271543|NCT04870424|Drug|Placebo|Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.
79869072|NCT05119712|Diagnostic Test|Laboratory Testing|Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
79734546|NCT01148693|Drug|Placebo|Distilled water
79869073|NCT05119582|Device|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
79869074|NCT05104047|Other|Moxibustion - Traditional (Active)|Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
79869075|NCT05104047|Other|Moxibustion - Smokeless - (Active)|Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
79869076|NCT05104047|Other|Placebo Moxibustion|Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
79271544|NCT03536845|Drug|Vitamin D 3|oral drops
79271545|NCT02256709|Drug|BIBP 5371 CL tablet|single rising daily doses
79271546|NCT02256709|Drug|BIBP 5371 CL solution|
79271547|NCT02256709|Other|High fat, high caloric breakfast|
79271548|NCT02256709|Drug|Placebo tablet|
79271549|NCT02256709|Drug|BIBP 5371 CL tablet high dose|
79271550|NCT02256709|Drug|Placebo drinking solution|
79574917|NCT01853293|Behavioral|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
79271551|NCT02256709|Drug|BIBP 5371 CL tablet low dose|
79574918|NCT01853306|Drug|Veliparib|veliparib
79574919|NCT01853319|Drug|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
79574920|NCT01853358|Biological|NK Cell infusion|"level 1: 1 x 10e6 NK cells /kg;~level 2: 5 x 10e6 NK cells /kg;~level 3: > 5.10e6 and ≤ 5.10e7 cellules NK/kg"
79734547|NCT00693355|Other|Sodium butyrate|sodium butyrate
79734548|NCT00693355|Other|NaCl|NaCl
79869077|NCT05101629|Drug|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
79869078|NCT05101629|Drug|Lenvatinib Capsules|Lenvatinib 8 mg for BW < 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
80028209|NCT02201316|Drug|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
80028210|NCT02201316|Drug|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
80028211|NCT02201316|Drug|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
79271552|NCT05519930|Other|hereditary high risk pancreatic cancer|Data collection trial for hereditary high risk pancreatic cancer patients.
79271553|NCT05510804|Combination Product|ALISA|assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
79271554|NCT02185885|Procedure|Increased bloodpressure during CPB.|
79271555|NCT05519852|Behavioral|Pilates training|the pilates group (20 patients) will be trained 30 minutes of pilates exercise (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
79271556|NCT02181907|Drug|UH-AC 62 XX tablet|
79271557|NCT02181907|Drug|UH-AC 62 XX capsule|
79271558|NCT02181985|Drug|Full dose TNK-tPA|
79271559|NCT02181985|Drug|Half dose TNK-tPA|
79271560|NCT02181985|Drug|Heparin|
79271561|NCT02181985|Drug|Enoxaparin|
79271562|NCT02181985|Drug|Abciximab|
79271563|NCT05514080|Other|Insulin closed-loop|41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
79271564|NCT02184871|Other|exposure to different risk factors and molecular assessment|
79271565|NCT02184949|Procedure|Percutaneous Coronary Intervention|
79271566|NCT02184949|Procedure|Primary Percutaneous Coronary Intervention|
79574921|NCT01853410|Device|gekoTM|
79574922|NCT01853423|Drug|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
79574923|NCT01853436|Device|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
79734549|NCT04114552|Other|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
80028212|NCT03682549|Diagnostic Test|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
79734550|NCT02620111|Dietary Supplement|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
80028213|NCT02197962|Device|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
80028214|NCT02197962|Device|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
80028215|NCT03533790|Drug|DEP-Ru|"Drug: ruxolitinib~Drug: doxorubicin~Drug: etoposide~Drug: methylprednisolone"
80028216|NCT02198118|Other|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
80028217|NCT02201706|Procedure|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
79271567|NCT02185027|Other|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
80028218|NCT02198196|Behavioral|Weight Talk-Mindfulness|
80028219|NCT02198820|Drug|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
80028220|NCT02198820|Drug|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
80028221|NCT02257476|Drug|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
79271568|NCT05510648|Other|high-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
79271569|NCT05510648|Other|sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
79271570|NCT05519618|Procedure|Epidural veins pressure and flow measurement|"The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine."
79271571|NCT02030509|Other|Quick diagnosis program|
79574924|NCT01853449|Drug|Fentanyl Citrate|
80028222|NCT02257476|Drug|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
79574925|NCT01853449|Other|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
79574926|NCT01853449|Drug|Placebo|0.9% saline
79574927|NCT01853501|Procedure|Autologous fat grafting|ADSC ovary injection
79574928|NCT01853540|Drug|Sildenafil|
79574929|NCT01853566|Drug|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
79734551|NCT02620111|Dietary Supplement|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
80028223|NCT02202018|Other|Active KT intervention|"Provider & patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~Educational white board presentations promoting home dialysis~Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial & national averages~A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
79734552|NCT02883959|Other|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
79734553|NCT00696085|Behavioral|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
80028224|NCT02198898|Device|GUARDIX-SG|
79574930|NCT01853579|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
79734554|NCT02794558|Device|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
79869079|NCT05080179|Behavioral|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
79869080|NCT05080179|Behavioral|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
80028225|NCT03691753|Device|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
80028226|NCT03691753|Device|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
80028227|NCT02198274|Drug|BIBH 1|100 mg/week
80028228|NCT02202096|Other|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
80028229|NCT02202096|Other|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
80028230|NCT02202096|Other|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
79271572|NCT05510570|Genetic|The research does not require interventions|We use Whole-exome sequence (WES) to analyze if there is any gene mutations for DLD(developmantal language disorder) children.
79271573|NCT02185963|Drug|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
79271574|NCT02570750|Behavioral|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
79869081|NCT05080179|Behavioral|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
79869082|NCT05080179|Behavioral|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
79271575|NCT02186041|Device|Sacral Nerve Modulation|
79271576|NCT02186119|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
79574931|NCT01853579|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
79574932|NCT01853657|Other|Virological monitoring|
79574933|NCT01853670|Radiation|concurrent chemo + IGRT|
79734555|NCT00693433|Drug|dexamethasone|Given orally
79869083|NCT05067075|Device|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
79734556|NCT00693433|Drug|temsirolimus|Given IV
79734557|NCT00693433|Other|laboratory biomarker analysis|Correlative studies
79734558|NCT02794090|Behavioral|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
79734559|NCT02794090|Behavioral|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
79734560|NCT05414422|Drug|PCN-101|Concentrate for solution for infusion
79734561|NCT05414422|Drug|Placebo|Concentrate for solution for infusion
79734562|NCT00872599|Drug|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
79734563|NCT00872599|Drug|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
79734564|NCT04233658|Drug|Placebo|3x2 capsules / day
79734565|NCT04233658|Drug|Cynara Scolymus|3x2 capsules / day
79734566|NCT00693511|Behavioral|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
79734567|NCT00693511|Behavioral|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
79734568|NCT02623621|Drug|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
79869084|NCT05042609|Drug|TRS01|TRS01 eye drops Dosed four times a day (QID)
79869085|NCT05042609|Drug|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
79869086|NCT05036720|Behavioral|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
79869087|NCT05036720|Behavioral|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
79869088|NCT05036122|Device|LabClasp|Non-invasive device that estimates blood [lactate] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood [lactate] and return a value to the subject via an accompanying tablet within 20 seconds.
79734569|NCT00693589|Drug|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
79869089|NCT05025345|Device|Tecnis Eyhance|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
79869090|NCT05025345|Device|Tecnis 1 piece IOL|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
79869091|NCT04985344|Drug|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
79869092|NCT04985344|Drug|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
79869093|NCT04985344|Other|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
79271577|NCT02186119|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
79574934|NCT01853670|Radiation|neoadjuvant chemo + IGRT|
79574935|NCT01853683|Procedure|Conservative Management|
79574936|NCT01853683|Procedure|Operative Management|
79574937|NCT01853709|Behavioral|Education|
79574938|NCT01853709|Other|Fiber free diet|
79734570|NCT04233736|Procedure|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
79734571|NCT02620267|Device|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
79869094|NCT04974970|Drug|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
79869095|NCT04946370|Drug|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
79869096|NCT04946370|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
79869097|NCT04946370|Drug|Androgen receptor pathway inhibitor|Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
79574939|NCT01853709|Dietary Supplement|Adjuvants|
79734572|NCT02794168|Drug|VAS203|Treatment
79271578|NCT02186119|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
79271579|NCT02185261|Drug|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
79271580|NCT02186197|Other|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
79734573|NCT02794168|Drug|Saline|Placebo
79869098|NCT04946370|Diagnostic Test|68Ga-PSMA-11|[185 ±74 MBq or 5 ±2 mCi] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
79869099|NCT04941001|Device|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
79271581|NCT02573012|Drug|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
79574940|NCT01853709|Drug|Polyethylene glycol (PEG)|
79574941|NCT01853709|Drug|Bisacodyl|
79574942|NCT01853761|Device|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
79574943|NCT01853761|Device|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
79574944|NCT01853761|Device|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
79869100|NCT04925128|Other|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
79869101|NCT04925128|Other|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
79869102|NCT04924569|Device|Intermittent Catheter|Flexible tubular device used to drain urine from the bladder via the urethra by male, female, and pediatrics.
79869103|NCT04920695|Drug|Nitric Oxide|Pulmonary vasodilator (gas).
79869104|NCT04920695|Drug|Placebo|medical grade normoxic gas (FiO2 = 0.21)
79869105|NCT04918290|Device|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
79869106|NCT04918290|Device|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
79271582|NCT02573012|Drug|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
79271583|NCT02573012|Biological|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
79271584|NCT02185495|Behavioral|Observer nodule detection|Radiologists will detect the nodules.
79574945|NCT01853761|Device|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
79574946|NCT01853761|Device|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
79574947|NCT01853761|Device|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
79734574|NCT02793934|Other|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
79869107|NCT04902417|Other|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
79869108|NCT04885569|Behavioral|Motivational interviewing with CBT (MICBT)|The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
79869109|NCT04885569|Behavioral|Mindfulness based Relapse Prevention (MBRP)|MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
79271585|NCT02185495|Device|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
79271586|NCT03536377|Other|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
79271587|NCT05121727|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
79574948|NCT01853787|Drug|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
79574949|NCT01853787|Drug|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
79574950|NCT01853800|Drug|Rivaroxaban (Xarelto, BAY59-7939)|
79574951|NCT01853813|Drug|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
79869110|NCT04885569|Behavioral|CAMIAB|This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
79574952|NCT01853852|Drug|GR181413A/AT1001 solution|Powder for reconstitution
79574953|NCT01853852|Drug|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
79574954|NCT01853852|Other|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
79574955|NCT01853852|Drug|Placebo capsule|Solution matched
79574956|NCT01853865|Other|Instruction in self-referral|
79875917|NCT00442572|Drug|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
79875918|NCT04898322|Drug|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
79574957|NCT01853891|Other|dim light at night|
79734575|NCT02793934|Other|New model of rehabilitation|
79734576|NCT02793934|Other|Old model of rehabilitation|
79734577|NCT02793934|Other|ICF reader|
79869111|NCT04820400|Other|Immersive VR Video|"The VR-360 video will be custom-made for the burn patient population. Through a review of current evidence for video scenarios/patients surveys, the study team will define and implement the key components appropriate for acute procedural pain such as type, duration and severity in this patient population. Next, patients will be asked about preferred pain relief elements (e.g. individual colours, geographical locations, sounds, etc.) that would help to design a video scenario. Finally, using a Likert pain scale, patients will be asked to rate each individual descriptor that exacerbates or alleviates pain. For instance, the colour red may be associated with 'flames', 'heat' and 'burns', and thus elevated pain, the colour blue may have the opposite effect, representing 'cooling' or 'cold'.~Combined, this information will be used to create a VR-360 video geared towards alleviating acute procedural pain in patients with burn injuries undergoing dressing changes after skin graft."
79574958|NCT01853904|Procedure|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
79869112|NCT04814147|Procedure|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
79869113|NCT04809207|Other|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
79271588|NCT05121727|Procedure|Deep and Superficial Serratus Anterior Plane Block|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
79869114|NCT04785066|Drug|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
79574959|NCT01853904|Procedure|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
79574960|NCT01853917|Other|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
79869115|NCT04778579|Drug|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
79869116|NCT04776356|Device|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
79869117|NCT04751435|Other|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
79869118|NCT04744402|Drug|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm^3 defect
79869119|NCT04737629|Behavioral|Expectancy and Water|In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
79875919|NCT04898322|Drug|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
79271589|NCT05513690|Procedure|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion and intrauterine temperature probe sensor
79574961|NCT01853956|Drug|Alprazolam 0.25 mg|Reference product
79875920|NCT04898322|Drug|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
79271590|NCT02190331|Other|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
79271591|NCT02190331|Other|Control Group physical education classes|Only performed the physical education classes
79574962|NCT01853956|Drug|Alprazolam 0.25 mg|Test product
79574963|NCT01853969|Other|Typing assessment|
79574964|NCT01854008|Other|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index"
79574965|NCT01854008|Other|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
79574966|NCT01854021|Procedure|intravenous anesthesia|intravenous anesthesia
79734578|NCT01148537|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 * 20 mcg/h.
79734579|NCT01148537|Drug|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 * 20.
79734580|NCT01148537|Drug|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
79734581|NCT02794324|Procedure|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
79271592|NCT02190409|Device|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
79271593|NCT05510414|Behavioral|psychological intervention based on psychological capital|Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
79574967|NCT01854021|Procedure|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
79574968|NCT01854021|Procedure|inhalational anesthesia|inhalational anesthesia
79574969|NCT01854073|Drug|Hyoscine butyl bromide|
79574970|NCT01854073|Drug|Normal saline|
79734582|NCT02794324|Procedure|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
79869120|NCT04737629|Behavioral|No Expectancy and Water|Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
79869121|NCT04737629|Behavioral|No Water|Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
79869122|NCT04725721|Behavioral|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
79869123|NCT04725721|Behavioral|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
79869124|NCT04720664|Drug|SM-88|"SM-88, Two 230 mg capsules taken orally twice daily (920 mg daily).~Methoxsalen, One 10 mg capsule taken orally once daily.~Phenytoin, One 50 mg tablet taken orally once daily.~Sirolimus, One 0.5 mg tablet taken orally once daily."
79869125|NCT04718168|Device|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
79869126|NCT04718168|Device|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
79869127|NCT04711343|Drug|BAT2306|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
79869128|NCT04711343|Drug|Cosentyx (US-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
79574971|NCT01854086|Other|Questionnaires about compliance and persistence with bisphosphonates treatment|
79574972|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 1.
79574973|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 2.
79574974|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m^2 x 21 days) with group 3.
79574975|NCT01854125|Biological|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
79574976|NCT01854125|Biological|autologous bone marrow msenchymal stem cells transplantation|
79574977|NCT01854164|Dietary Supplement|HGE (hydrolyzed ginseng extract)|
79574978|NCT01854164|Dietary Supplement|Placebo|
79734583|NCT02794324|Procedure|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
79734584|NCT02794324|Device|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
79734585|NCT02789722|Other|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
79734586|NCT02789722|Other|Placebo|Take 3 capsules, 3 times daily for 28 days.
79875921|NCT04898322|Drug|Placebo|Placebo
79869129|NCT04711343|Drug|Cosentyx (EU-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
79402579|NCT06012474|Other|Diaphragmatic breathing exercises|"Training by using incentive spirometer:~Loosen any tight clothing, especially around neck.~Each patient will be instructed to sit upright with placing incentive spirometer at the same level of his mouth to promote optimal lung expansion while using the spirometer.~The patient will be instructed to exhale letting all the breath out.~patient will asked to close the lips around the mouthpiece of the spirometer.~patient will be instructed to inhale slowly, breathing in until unable to do any more, this would raise the balls to the top of the column.~patient will be asked to hold the breath as long as possible (at least five seconds) then exhale slowly.~Session will be in the form of 30 times in sets, each set consist of 5-6 repetitions with rest 1 minute between sets.~Intensity of exercise will be increased by increasing time of session, time of holding the breath and numbers of repetitions according to patient's status."
79734587|NCT02793778|Drug|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
79869130|NCT04683653|Radiation|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
79271594|NCT04128176|Drug|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
79271595|NCT02186275|Drug|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"Weight at inclusion < 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
79402580|NCT06012448|Drug|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
79402581|NCT06012422|Other|evaluation group|Elderly individuals will be evaluated once, by face-to-face interview method.
80028231|NCT02202096|Other|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
79271596|NCT02186275|Drug|Vitamin D3 800 UI/day then 800 UI/day|"Weight < 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
79271597|NCT05519306|Behavioral|Mental Practice|Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
79271598|NCT02186353|Behavioral|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
79271599|NCT02190565|Dietary Supplement|Food supplement|Randomized double-blind, placebo-controlled
79734588|NCT02793778|Drug|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
79734589|NCT02793544|Drug|Fludarabine|"Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
79869131|NCT04683653|Other|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
79869132|NCT04654949|Other|Horticultural Therapy|The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
79869133|NCT04646707|Drug|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
79869134|NCT04646707|Drug|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
79869135|NCT04646694|Drug|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
80028232|NCT02202096|Other|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
79734590|NCT02793544|Drug|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
79869136|NCT04646694|Other|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
79869137|NCT04636879|Other|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
79869138|NCT04636879|Other|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
79869139|NCT04636879|Other|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
79869140|NCT04629950|Drug|Rimegepant|Active Agent
79869141|NCT04629950|Drug|Placebo|Placebo Comparator
79869142|NCT04612400|Other|Oral amino acid tracer|Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
79869143|NCT04595370|Drug|AZD9977|Participants will receive AZD9977 as per the arms they are randomized.
79869144|NCT04595370|Drug|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized.
79869145|NCT04554966|Drug|ABBV-382|Intravenous (IV) infusion
79869146|NCT04554966|Drug|ABBV-382|Subcutaneous (SC) injection
79869147|NCT04554966|Drug|Placebo for ABBV-382|Intravenous (IV) infusion
79271600|NCT05510336|Procedure|Arthrocentesis|Injection of lactated ringer solution in the TMJ to wash out inflammatory mediators and help reducing anterior disc displacement with reduction
79271601|NCT02185573|Procedure|Bulk fill|This is one of the composite restoration application techniques
79271602|NCT02185573|Procedure|SonicFill|This is the recent intervention under evaluation
79402582|NCT06012396|Behavioral|Stoke complex exercise program|"warm-up(5min) flexibility exercise - neck, triceps brachii, biceps brachii, forearm, back, quadriceps, biceps femoris, ankle~main exercise(40min) aerobic exercise(20min)- use stepper, treadmill, high intensity HRR60%, RPE 11~14 low intensity HRR30%, RPE 9~11 repeated interval training strength and balance exercises(20min)- program1. upper(shoulder press, chest press, biceps curl), lower(hip flexion, knee extension), Core(plank exercise, sit up) program2. upper(seated back row, triceps extension), lower(hip extension, hip abduction, knee flexion, Core(superman exercise, bridge exercise) repeated ever other day program1, program2 clean-up(5min) - same as warm-up"
79574979|NCT01854190|Device|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
79574980|NCT01854203|Drug|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
79734591|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy on Day -1|"200 cGy TBI is administered in a single fraction on Day -1.~Radiation sources, dose rates, and shielding follow institutional practice."
79869148|NCT04543942|Drug|Alcohol|Alcohol will be administered by IV infusion (60mg%). Brain activation during response inhibition (BARI) will be assessed using fMRI during performance of the stop signal task.
79869149|NCT04523714|Behavioral|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
79869150|NCT04523714|Behavioral|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
79869151|NCT04511455|Drug|Cabozantinib|Cabozantinib 60 mg/day peroral
79869152|NCT04506567|Drug|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
79869153|NCT04506567|Diagnostic Test|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
79869154|NCT04506567|Drug|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
79869155|NCT04467866|Behavioral|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
79875922|NCT01322958|Device|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
79271603|NCT05510258|Other|Physiotherapy|TWO GROUPS CONTROL ND EXPERIMENTAL
79271604|NCT05117281|Drug|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
79271605|NCT05117281|Drug|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 0.25 mg/kg
79271606|NCT04424810|Other|High-quality, physician created video|The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
79271607|NCT04424810|Other|Standard of care|Patients in the control group will not be asked to do anything differently prior to their surgery
79271608|NCT02186431|Device|senofilcon A|
79271609|NCT05519072|Drug|Nitrofurantoin|For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
79271610|NCT02190643|Behavioral|Cessation counseling with adherence focus|
79271611|NCT02190643|Behavioral|Cessation counseling without adherence focus|
79271612|NCT02186743|Other|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
79271613|NCT02190799|Biological|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
79402583|NCT06012383|Drug|Bortezomib|Alvocade® was given with a dose of 1.3 mg/m2.
79574981|NCT01854203|Drug|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
79574982|NCT01854216|Drug|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
79574983|NCT01854216|Drug|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
79574984|NCT01854216|Drug|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
79574985|NCT01854307|Procedure|Pneumoperitoneum and SVV/PPV|
79574986|NCT01854320|Behavioral|Acceptance-based treatment|
79574987|NCT01854320|Behavioral|Standard behavioral treatment|
79574988|NCT01854333|Other|ADOS module 1-4 or ADI-R|
79574989|NCT01854346|Behavioral|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
79574990|NCT01854372|Drug|R-HCVAD and R-MC|
79574991|NCT01854398|Device|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
79271614|NCT04411706|Drug|Sintilimab Combined With Apatinib and Capecitabine|"Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;"
79402584|NCT06012370|Procedure|PRP injection|Injection of PRP and hyaluronic acid
79271615|NCT05518994|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
79402585|NCT06012357|Diagnostic Test|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
79402586|NCT06012344|Other|post facilitation stretch|PFS Post-Facilitation Stretch Participants in this arm received the intervention of post-facilitation stretch technique. Post-facilitation stretch involves the application of manual stretching techniques to the targeted muscles after a facilitation phase, which aims to enhance muscle extensibility. The participants underwent a standardized post-facilitation stretch protocol focusing on the hamstring muscles.
79574992|NCT01854398|Device|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
79574993|NCT01854411|Other|analgesic measure|ibuprofen and ketoprofen measured into breast milk
79574994|NCT01854424|Other|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
79574995|NCT01854437|Drug|Mg Oxide|250 mg orally for 4 weeks
79271616|NCT02256943|Drug|Amitriptyline|100 mg single dose
79271617|NCT02256943|Drug|Tolterodine|Placebo 1 mg single dose
79271618|NCT05518916|Other|Nonfarmacology method|Yakson Method and Swaddling
79271619|NCT02193607|Procedure|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
79271620|NCT02193607|Procedure|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
79271621|NCT05059951|Drug|immune checkpoint inhibitor-combined|Pembrolizumab and Sintilimab
79271622|NCT05510102|Device|WHOOP strap 4.0 (full data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
79574996|NCT01854450|Other|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
79574997|NCT01854450|Other|control|usual obstetrical care
79574998|NCT01854463|Drug|Vitamin D3|2000IU per day
79574999|NCT01854463|Drug|placebo|elemental calcium 200mg per day per 24 weeks
79575000|NCT01854476|Device|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
79869156|NCT04467866|Behavioral|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
79875923|NCT01323036|Dietary Supplement|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
79271623|NCT05510102|Device|WHOOP strap 4.0 (partial data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
79875924|NCT01323036|Dietary Supplement|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
79271624|NCT02186899|Other|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
79271625|NCT02186899|Other|General Anesthesia femoral bolus|
79402587|NCT06012344|Other|post isometric relaxation|Participants in this arm of the study received the intervention of post-isometric relaxation technique. Post-isometric relaxation involves the application of isometric contraction followed by a relaxation phase to promote muscle lengthening and improve flexibility. The participants underwent a standardized post-isometric relaxation protocol targeting the hamstring muscles.
79271626|NCT02186899|Other|General anesthesia femoral continuous|
79575001|NCT01854489|Drug|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days [Phase 1 ]
79271627|NCT05510024|Procedure|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy|The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
79271628|NCT05510024|Procedure|SCIT|Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
79402588|NCT06012344|Other|hamstring nordic lower|Participants in this arm received the intervention of hamstring Nordic lower exercise. The hamstring Nordic lower exercise is a challenging eccentric exercise that specifically targets the hamstring muscles. Participants performed the exercise under supervision and followed a standardized protocol for the number of repetitions, sets, and rest intervals.
79575002|NCT01854489|Drug|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
79575003|NCT01854489|Drug|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
79575004|NCT01854502|Behavioral|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
79575005|NCT01854502|Behavioral|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
79575006|NCT01854515|Drug|Budesonide|
79575007|NCT01854515|Drug|Dexamethasone acetate|
79575008|NCT01854567|Biological|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
79734592|NCT02793544|Procedure|Infusion of non-T-cell depleted bone marrow on Day 0|"On Day 0, the harvested bone marrow is infused.~Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
79734593|NCT02793544|Drug|Busulfan|"Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM*min (Perkins et al., 2012))~Busulfan dosing is based on adjusted IBW (Appendix K)"
79734594|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
79734595|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
79734596|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"200cGy TBI is administered in twice daily on Days -3, -2, and -1.~Radiation sources, dose rates, and shielding follow institutional practice."
79271629|NCT05513222|Procedure|flipped autograft|Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
79734597|NCT02793544|Drug|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
79869157|NCT04456478|Procedure|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
79869158|NCT04456478|Procedure|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
79869159|NCT04427228|Radiation|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) < 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
79869160|NCT04427228|Radiation|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
79271630|NCT02030665|Behavioral|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
79271631|NCT02030665|Behavioral|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
79575009|NCT01854567|Biological|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
79575010|NCT01854606|Drug|AEB071|a Protein Kinase C Inhibitor
79575011|NCT01854606|Drug|Everolimus|mTOR inhibitor
79271632|NCT02030665|Behavioral|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
79271633|NCT05512988|Biological|UC-MSC|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10^6/Kg/person."
79575012|NCT01854619|Device|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
79869161|NCT04406818|Drug|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
79869162|NCT04404660|Biological|AUTO1|Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
79271634|NCT05512988|Biological|Saline solution|"Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course"
79271635|NCT02186977|Device|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
79271636|NCT02186977|Drug|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
79271637|NCT02186977|Drug|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
79271638|NCT02752633|Drug|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
79271639|NCT02752633|Drug|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
79575013|NCT01854619|Device|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
79575014|NCT01854671|Other|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
79575015|NCT01854723|Drug|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
79575016|NCT01854723|Drug|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
79575017|NCT01854736|Drug|Grazax|GRAZAX
79575018|NCT01854736|Other|Placebo|Placebo
79575019|NCT01854749|Drug|S1 combined with cisplatin|
79869163|NCT04393623|Behavioral|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
79734598|NCT02793544|Drug|Sirolimus|"Sirolimus dosing is based on adjusted IBW (Appendix K).~Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects < 18 years old:~A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
79734599|NCT02793544|Drug|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
79271640|NCT02191189|Drug|Nevirapine suspension, into Enterion™ capsule|
79271641|NCT02191189|Drug|Nevirapine suspension|
79869164|NCT04393623|Behavioral|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
79869165|NCT04371198|Other|Biopsy|Tissue biopsy
79271642|NCT02187133|Drug|Carfilzomib|"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m^2~Weekly:~DL 1.5: 20,27,27 mg/m^2, DL 2: 20,36,36 mg/m^2, DL 3: 20,56,56 mg/m^2 DL 4: 20,70,70 mg/m^2"
79869166|NCT04361708|Drug|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
79271643|NCT02187133|Drug|Bendamustine|"Given IV; Dose Level (DL)~DL -1: 75 mg/m^2 DL 1,1.5, 2, 3, and 4: 90 mg/m^2"
79575020|NCT01854762|Drug|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
79402589|NCT06012214|Procedure|ROBOTIC-ASSISTED ESOPHAGECTOMY|Comparison between robotic and conventional minimally invasive esophagectomy
79575021|NCT01854762|Drug|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
79575022|NCT01854788|Other|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
79575023|NCT01854788|Other|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
79575024|NCT01854788|Other|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
79575025|NCT01854801|Other|Individual medical Care|Individual medical care in occupational and environmental diseases centers
79575026|NCT01854801|Other|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
79869167|NCT04361708|Drug|Docetaxel|Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
79869168|NCT04361708|Drug|Leucovorin|Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
80028233|NCT02202096|Other|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
79271644|NCT02187133|Drug|Rituximab|Given IV; 375 mg/m^2
79271645|NCT04411862|Dietary Supplement|Phosphatidyl Choline|2.1 g Phosphatidylcholine daily in addition to lifestyle modification
79271646|NCT04411862|Behavioral|Lifestyle modification|Lifestyle modification and health education by Clinical Pharmacist
79402590|NCT06012188|Other|sleep toy|The parents of the children in the experimental group will be given a sleeping companion toy to present to their children. At the end of 15 days, the Children's Sleep Habits scale will be applied as a post-test to evaluate the effect of the sleep companion toy.
79402591|NCT06012123|Procedure|Aortoiliac angioplasty and stenting|Covered endovascular reconstruction of aortic bifurcation (CERAB) in patient with aorto-iliac occlusive disease
79402592|NCT06012097|Drug|Diclofenac gel|using diclofenac as a comparator
79402593|NCT06012097|Drug|Aromatherapy gel|using Aromatherapy gel as an experimetnal treatment
80028234|NCT02202096|Other|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
79575027|NCT01854853|Behavioral|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
79575028|NCT01854853|Behavioral|Health Promotion|Health promotion intervention
79575029|NCT01854866|Other|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
79575030|NCT01854892|Other|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
80028235|NCT02202096|Other|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
80028236|NCT02202096|Other|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
79271647|NCT02187211|Drug|Minocycline|
79271648|NCT02187211|Drug|Placebo (for Minocycline)|
79271649|NCT02752087|Drug|LY900014|Administered SC
79271650|NCT02187289|Device|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
79271651|NCT02187289|Device|Compression Sleeve, daytime wear|
79271652|NCT02187289|Device|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
79575031|NCT01854892|Other|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
79575032|NCT01854892|Other|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
79734600|NCT02793544|Drug|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
79734601|NCT02793544|Drug|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
79734602|NCT02793544|Drug|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
79734603|NCT02793544|Drug|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
79734604|NCT02793544|Drug|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
79271653|NCT02191345|Behavioral|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
79271654|NCT04766996|Behavioral|Guided mindfulness exercises|Guided Meditation twice daily
79271655|NCT04766996|Other|Self-administered aromatherapy|Self-administered aromatherapy every 6 hours and at bedtime
79734605|NCT02793388|Drug|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
79734606|NCT02793388|Drug|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
79869169|NCT04361708|Drug|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
79271656|NCT04766996|Drug|Baby aspirin|Baby aspirin 81mg: Twice daily for 6 weeks after surgery
79271657|NCT04766996|Drug|Tylenol/Acetaminophen|Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
79575033|NCT01854931|Behavioral|Tai Ji Quan|single aim intervention
79575034|NCT01854957|Biological|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
79575035|NCT01854970|Drug|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
79869170|NCT04361708|Drug|5-Fluorouracil|5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
79869171|NCT04345146|Combination Product|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
80028237|NCT02202096|Other|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
79575036|NCT01854996|Drug|PF-05089771|450mg
79575037|NCT01854996|Drug|PF-05089771|450mg
79575038|NCT01854996|Drug|PF-05089771|450mg
79575039|NCT01855009|Dietary Supplement|MannaBears|Subjects will be administered 4 MannaBears daily
79575040|NCT01855009|Dietary Supplement|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
79734607|NCT02793310|Procedure|DMEK|The intervention group will receive cornea transplantation by DMEK
79734608|NCT02793310|Procedure|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
79575041|NCT01855009|Dietary Supplement|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
79734609|NCT02689882|Dietary Supplement|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
79734610|NCT02789644|Drug|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
79575042|NCT01855009|Dietary Supplement|Vitamin D3|Subjects will be administered 800 IU vitamin D3
79869172|NCT04339543|Other|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
79271658|NCT04766996|Drug|Pregabalin|"Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery"
79869173|NCT04336098|Drug|SRF617|SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
79869174|NCT04336098|Drug|Gemcitabine|Gemcitabine as an intravenous (IV) infusion
79869175|NCT04336098|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel as an IV infusion
79869176|NCT04336098|Drug|Pembrolizumab|Pembrolizumab as an IV infusion .
79869177|NCT04316494|Drug|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
79869178|NCT04316494|Drug|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
79271659|NCT04766996|Drug|Prednisone|Prednisone 5mg: Daily for three weeks after surgery
79271660|NCT04766996|Drug|Meloxicam|"Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery"
79271661|NCT04766996|Drug|Prilosec|"Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery"
79869179|NCT04309981|Biological|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
79869180|NCT04288154|Device|EMS Device On|The EMS Device will turned on during exercise as opposed to it being turned off for control group.
79271662|NCT04766996|Drug|Tramadol|Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
79271663|NCT04766996|Drug|Voltaren|Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
79271664|NCT04766996|Drug|Zofran|Zofran 4 mg pre-operative
79271665|NCT04766996|Drug|Pepcid|Pepcid 20 mg pre-operative
79271666|NCT04766996|Drug|Reglan|Reglan 10 mg pre-operative
79271667|NCT04766996|Drug|Versed|Versed 2 mg pre-operative
79271668|NCT04766996|Drug|Lidocaine|Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
79271669|NCT04766996|Drug|Propofol|Propofol 10-125 mcg/kg/min intraoperative
79734611|NCT04234594|Drug|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
79734612|NCT04234594|Drug|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
79734613|NCT02789488|Dietary Supplement|Fenugreek seeds extract 500 mg|Furocyst one caps BID
79734614|NCT02793076|Other|Bollywood Dance|8 week Bollywood Dance Program
79869181|NCT04288154|Other|EMS Device Off|The EMS Device will turned off during exercise as opposed to it being turned off for control group.
79271670|NCT04766996|Drug|Ancef|Ancef 2-3 gm weight-based dosing intraoperative
79271671|NCT04766996|Drug|Tranexamic Acid (TXA)|Tranexamic Acid (TXA) 2 gm intraoperative
79271672|NCT04766996|Drug|Decadron|Decadron 10 mg intraoperative
79869182|NCT04287569|Device|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
79869183|NCT04286594|Drug|CBD|Participants will receive CBD solution during the open-label phase of the trial.
79869184|NCT04280497|Drug|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
79869185|NCT04258579|Behavioral|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
79869186|NCT04231734|Other|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
79271673|NCT04766996|Drug|Bupivacaine hydrochloride|Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
79734615|NCT03806608|Procedure|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
79734616|NCT03806608|Procedure|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
79734617|NCT01148459|Biological|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
80028238|NCT02202096|Other|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
80028239|NCT02202174|Device|Supraglottic Airway Device|
79271674|NCT04766996|Drug|Toradol|Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
79575043|NCT01855022|Behavioral|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
79734618|NCT01148459|Biological|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
79734619|NCT01148459|Biological|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
79869187|NCT04230967|Behavioral|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
79869188|NCT04230967|Behavioral|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
79869189|NCT04203381|Device|GnRH Agonist|Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
79869190|NCT04178434|Behavioral|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
79869191|NCT04138277|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
79869192|NCT04138277|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
79869193|NCT04133909|Drug|Placebo|Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
79869194|NCT04133909|Biological|Mepolizumab|Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
80028240|NCT03943927|Other|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
79575044|NCT01855035|Other|prolonged ECG monitoring|10-day Holter ECG measurement
79575045|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
79575046|NCT01855061|Procedure|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
79575047|NCT01855061|Procedure|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
79575048|NCT01855061|Procedure|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
79575049|NCT01855061|Procedure|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
79575050|NCT01855100|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
79575051|NCT01855113|Device|Invisalign|
79575052|NCT01855139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
79575053|NCT01855152|Other|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
79734620|NCT02789254|Biological|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
79869195|NCT04069052|Drug|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
79869196|NCT04069052|Drug|Placebo|Room air (placebo) flowed into a mask and breathed in.
79271675|NCT04621747|Other|Battery of neurophysiological explorations|"Visit 1: Biometry collection: gender, age, weight, height, eye colour.~Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness."
79575054|NCT01855152|Other|Treatment as usual|Treatment delivered as usual in the care home
79402594|NCT06012045|Behavioral|Enhanced Cue Exposure Therapy|The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. The first session will be used to introduce the rationale and procedures of E-CET to the participant to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. In this session, questions will be asked specifically to assess idiosyncratic CS-US expectancies related to the four categories: positive reinforcement, craving/drive reduction, mood regulation, and disinhibition. An exhaustive list of all idiosyncratic NEE-triggering cues and CSUS expectancies will be generated from this session. These cues and CS-US expectancies will be targeted in the following exposure sessions and in homework exposures with the goal to cover as many of them as possible during the 6-week treatment.
79402595|NCT06012045|Behavioral|Behavioral Lifestyle Intervention|It consists of six weekly sessions of behavioral counseling integrating behavioral strategies for making changes related to diet and exercise. These behavioral strategies will include education about healthy and balanced diets, and ways to attain the minimum level of physical activity for wellbeing (150 minutes moderate-to-vigorous exercise per week), goalsetting, problem-solving, coping, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.
79402596|NCT06012006|Other|constant work-rate cycling exercise test|Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
79402597|NCT06011980|Drug|Growth Inhibitor|growth inhibitors for 250-500μg/h, ivgtt. for 5 days
79402598|NCT06011967|Other|Intubation using C-MAC D blade videolariyngoscope|all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.
79575055|NCT01855165|Behavioral|Advice on DDIs|
79575056|NCT01855178|Device|Emfit Movement Monitor|Factory settings
79734621|NCT03913234|Drug|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
79869197|NCT04045470|Device|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
79869198|NCT04045470|Other|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
79869199|NCT04045470|Other|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
79869200|NCT04013256|Other|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
79575057|NCT01855204|Radiation|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
79271676|NCT02191423|Drug|Oxytocin|administered pre-fMRI assessment
79271677|NCT02191423|Drug|placebo|administered pre-fMRI assessment
79271678|NCT02191423|Behavioral|Dyadic psychotherapy|
79271679|NCT05509946|Drug|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg
79575058|NCT01855217|Drug|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
79575059|NCT01855217|Drug|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
79575060|NCT01855217|Drug|Placebo|0,9% NaCl
79575061|NCT01855230|Drug|ASM-024|ASM-024 b.i.d for 14 days
79575062|NCT01855230|Drug|Placebo|Placebo b.i.d. for 14 days
79271680|NCT05509946|Drug|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
79271681|NCT05509946|Drug|Placebo|Placebo
80028241|NCT03691675|Device|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
79402599|NCT06011941|Procedure|Modified laparoscopic transcystic biliary drainage|First, a needle was passed through a separate skin puncture wound 3 cm below the costal margin on the midaxillary line/posterior axillary line. Second, a lateral incision into the cystic duct was performed medially to allow insertion and embedding of the catheter. Third, a 7-Fr catheter was introduced through the abdominal wall via the cystic duct into the CBD. Fourth, if the position of the catheter inside the CBD was correct (the end of the tube reached the distal CBD but did not pass the papilla), the lateral incision of the cystic duct was closed by a V-Loc closure device using a single-layered, continuous suture in a circling manner to simultaneously cover and anchor the C-tube. After the procedure, an artificial fistula of 3 to 5 mm in length was formed.
79734622|NCT02792842|Drug|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
79271682|NCT04304209|Drug|Oxaliplatin|130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
79734623|NCT02792842|Drug|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
79271683|NCT04304209|Drug|Capecitabine|1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
79869201|NCT04013256|Other|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
79575063|NCT01855256|Drug|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
79869202|NCT04000776|Diagnostic Test|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
79575064|NCT01855256|Drug|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
79869203|NCT04000776|Diagnostic Test|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
79271684|NCT04304209|Drug|Sintilimab|200mg, d1 q3w, intravenous infusion
79734624|NCT02792842|Drug|Placebo|Placebo infusion once daily on days 1-3 in each cycle
79734625|NCT02792998|Drug|IW-1701|IW-1701 Tablet
79575065|NCT01855269|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
79575066|NCT01855269|Dietary Supplement|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
79734626|NCT02792998|Drug|Placebo|Matching Placebo Tablet
79734627|NCT02792920|Device|CoCr-EES|
79734628|NCT02792608|Behavioral|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
79734629|NCT02792686|Drug|ABX464|Single Administration
79734630|NCT02792374|Other|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
79734631|NCT02792530|Other|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
79734632|NCT02792296|Other|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
79734633|NCT02791984|Device|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
79869204|NCT04000776|Diagnostic Test|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
80028242|NCT03533166|Other|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
80028243|NCT03533166|Other|Placebo|Placebo mouth rinse
80028244|NCT03937453|Diagnostic Test|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
80028245|NCT03687073|Drug|Indole-3-Carbinol|Cohorts 2, 3, & 4: 400 mg PO BID
80028246|NCT03687073|Drug|Silibinin|Cohorts 1 & 4: 720mg
80028247|NCT03687073|Drug|Silibin|Cohort 3: 360mg
79271685|NCT04304209|Radiation|radiotherapy|neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.
79271686|NCT04304209|Procedure|total mesorectal excision|total mesorectal excision after neoadjuvant treatment
79271687|NCT04304209|Other|Watch and wait|Watch and wait for cCR patients after neoadjuvant treatment
79271688|NCT05509868|Drug|PBK_L1704 0.35mg|The subject will receive PBK_L1704 0.35mg/ml by PCA
79271689|NCT05509868|Drug|PBK_L1704 0.5mg|The subject will receive PBK_L1704 0.5mg/ml by PCA
79271690|NCT05509868|Drug|Placebo|The subject will receive placebo by PCA
79271691|NCT02187367|Biological|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
79271692|NCT02563028|Device|SightSaver Visual Stimulator|Evoked response photic stimulator
79575067|NCT01855269|Dietary Supplement|placebo sterile water|
79869205|NCT04000776|Other|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
79869206|NCT03974620|Behavioral|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
79869207|NCT03974620|Behavioral|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
79869208|NCT03970343|Device|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~Optimizer Smart or Optimizer Smart Mini~Vesta Charger or Guardio Charger~Two commercially available intravascular leads"
79869209|NCT03963414|Combination Product|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
79869210|NCT03963414|Combination Product|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
79402600|NCT06011837|Device|Altered Auditory Feedback|Mumble Melody is an application that leverages Altered Auditory Feedback (AAF). During AAF, a person's speech is altered in near-real time. Mumble Melody modulates the user's voice and plays it back to them while they are speaking. Included are Unaltered (raw voice), Whisper (voiceless sound), Reverb (cathedral sound), and Harmonized (robotic sound) voice transformations.
79734634|NCT02789332|Drug|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
79869211|NCT03955666|Biological|PRV-3279 or placebo|bi-specific antibody-based molecule
79869212|NCT03952520|Other|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
79869213|NCT03952520|Other|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
79271693|NCT02187445|Drug|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
79575068|NCT01855282|Behavioral|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
79869214|NCT03945214|Behavioral|Meditation|10 minute per day, 8 week digital meditation
79271694|NCT02191501|Procedure|Pyloric restriction|"The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.~However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested."
79402601|NCT06011759|Behavioral|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better [practice]."
79734635|NCT02789332|Drug|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
79734636|NCT02789332|Drug|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
79734637|NCT02789332|Procedure|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
79734638|NCT02789332|Other|Stratification|Hormone-receptor status (HR+ vs HR-) Age < 40 years vs >= 40 years
79734639|NCT02792140|Drug|Naltrexone|one week
79734640|NCT02792140|Other|Placebo|one week
79734641|NCT04234282|Procedure|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
79734642|NCT02791594|Drug|Pembrolizumab|
79869215|NCT03945214|Behavioral|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
79869216|NCT03945214|Behavioral|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
79734643|NCT02791750|Other|questionnary of quality of life|
79575069|NCT01855295|Dietary Supplement|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
79869217|NCT03931538|Diagnostic Test|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
79869218|NCT03931538|Diagnostic Test|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
79869219|NCT03929159|Procedure|Biospecimen Collection|Undergo blood biospecimen collection
79869220|NCT03922646|Behavioral|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
80028248|NCT03691597|Diagnostic Test|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~Images will be analyzed using imageJ software to measure marginal gap.~Gingival health will be measured using G"
79271695|NCT05502848|Behavioral|Internet Cognitive Behavior Therapy|ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
79271696|NCT02187523|Drug|Hydrochlorothiazide|
79271697|NCT02187523|Drug|Telmisartan|
79575070|NCT01855308|Procedure|Single site robotic chole|Cholecystectomy
79271698|NCT02187523|Drug|Telmisartan/HCTZ FDC|
79271699|NCT02187679|Drug|Abobotulinum toxin A|
79271700|NCT05507606|Drug|Osimertinib|osimertinib 80mg/d
79271701|NCT05507606|Drug|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
79402602|NCT06011759|Behavioral|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
79402603|NCT06011759|Behavioral|Usual care|Experimental control sites receiving usual care
79402604|NCT06011720|Other|Improved transition of care.|Evaluation of how early physiatry consultation after acute stroke affects length of stay and resulting outcomes.
79575071|NCT01855308|Device|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
79575072|NCT01855321|Drug|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
79575073|NCT01855321|Drug|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
79575074|NCT01855334|Drug|Spironolactone|
79575075|NCT01855334|Dietary Supplement|L-arginine|
79575076|NCT01855334|Drug|Placebo|
79734644|NCT04234516|Drug|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
79734645|NCT04234516|Drug|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
79734646|NCT02791672|Behavioral|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
79734647|NCT02789566|Drug|Primaquine|Primaquine 30 mg taken after meal in the morning.
79271702|NCT05507606|Drug|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
79271703|NCT05507606|Drug|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
79271704|NCT02191657|Drug|Deferiprone|Oral iron chelator
79271705|NCT05509556|Other|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
79271706|NCT02191735|Device|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
79575077|NCT01855347|Device|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
79734648|NCT03889522|Diagnostic Test|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition [47, 49]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
79734649|NCT03889522|Diagnostic Test|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
79734650|NCT03889522|Diagnostic Test|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
79734651|NCT02791360|Other|Brain MRI|
79869221|NCT03922646|Behavioral|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
79869222|NCT03890679|Diagnostic Test|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
79869223|NCT03867955|Other|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
79869224|NCT03861390|Drug|60 mg Prednisone|Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
79869225|NCT03861390|Drug|Placebo|Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
79869226|NCT03829683|Drug|Vitamin C|200mg/kg/24hours
79869227|NCT03829683|Drug|Dextrose 5% in water|50mL intravenously every 6 hours
79869228|NCT03810456|Behavioral|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
79869229|NCT03810456|Behavioral|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
79271707|NCT02191735|Device|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
79575078|NCT01855373|Dietary Supplement|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
79575079|NCT01855373|Dietary Supplement|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
79869230|NCT03737331|Behavioral|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
79869231|NCT03737331|Behavioral|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
79869232|NCT03737331|Behavioral|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
79869233|NCT03715179|Device|Ostomy Pouching System|An ostomy pouching system is a medical device that provides a means for the collection of effluent from a surgically diverted biological system (colon, ileum, bladder), specifically from a stoma. No intervention is administered during the course of this study.
79869234|NCT03696797|Procedure|Blood Donation|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
79869235|NCT03696797|Procedure|Sham Blood Donation|Participants will have a needle inserted their arm, however, no blood will be drawn.
79869236|NCT03530696|Drug|Palbociclib|Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
79869237|NCT03530696|Drug|T-DM1|The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
79869238|NCT03522961|Drug|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
79869239|NCT03522961|Drug|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
79869240|NCT03514888|Procedure|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
79575080|NCT01855373|Dietary Supplement|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
79575081|NCT01855373|Other|Placebo|Placebo: 2 capsules twice daily on an empty stomach
79869241|NCT03450057|Drug|Daratumumab with dexamethasone|"Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients >75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle."
79869242|NCT03360396|Device|Endobronchial Coils|Endobronchial Coil implants
79869243|NCT03353415|Device|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
79869244|NCT03353415|Device|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
79575082|NCT01855386|Other|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
79575083|NCT01855386|Other|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
79575084|NCT01855438|Behavioral|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
79575085|NCT01855490|Drug|Exenatide|
79734652|NCT00872521|Drug|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 & 11), Doxorubicin 20 mg/m2 i.v. (D1 & 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 & 12)"
79734653|NCT04234438|Device|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
79869245|NCT03270059|Drug|Ferumoxytol|Given IV
79869246|NCT03270059|Drug|Gadolinium|Given IV
79869247|NCT03270059|Procedure|Magnetic Resonance Imaging|Undergo MRI
79869248|NCT03198351|Drug|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
79869249|NCT03160040|Drug|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
79869250|NCT03144583|Biological|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
79869251|NCT03107182|Drug|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
79869252|NCT03107182|Drug|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
79869253|NCT03107182|Drug|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
79869254|NCT03107182|Drug|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
79869255|NCT03107182|Drug|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
79869256|NCT03107182|Drug|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
79869257|NCT03107182|Drug|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
79869258|NCT03107182|Drug|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
80028249|NCT02199210|Other|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
80028250|NCT03686917|Other|CHAT-P|Survey
79575086|NCT01855503|Procedure|Core Biopsy|
79575087|NCT01855516|Drug|Heparin|
79575088|NCT01855529|Drug|Ropivacaine in one arm and placebo (NaCl) in the other arm|
79575089|NCT01855542|Other|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
79575090|NCT01855542|Other|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
79734654|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
79869259|NCT03107182|Drug|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
79869260|NCT03107182|Drug|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
79869261|NCT03107182|Procedure|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
79869262|NCT03107182|Radiation|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
79869263|NCT03107182|Radiation|Chemoradiotherapy|"Patients who have low risk disease with <50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and <30% reduction of tumor, patients who have high risk disease and <50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
79869264|NCT02982070|Behavioral|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
79869265|NCT02879318|Drug|Gemcitabine|
79869266|NCT02879318|Drug|Nab-paclitaxel|
79869267|NCT02879318|Drug|Durvalumab|
79869268|NCT02879318|Drug|Tremelimumab|
79869269|NCT02833701|Dietary Supplement|Ascorbic Acid|Given IV
79869270|NCT02833701|Biological|Bevacizumab|Given intravenously (IV)
79869271|NCT02833701|Other|Laboratory Biomarker Analysis|Correlative studies
79575091|NCT01855555|Drug|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
79734655|NCT02791126|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
79271708|NCT04585256|Other|Trendelenburg positioning|Women positioned in the trendelenburg position prior to external cephalic version
79869272|NCT02833701|Other|Quality-of-Life Assessment|Ancillary studies
79869273|NCT02767999|Drug|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
79869274|NCT02767999|Drug|Placebo|cellulose placebo per day from D0 to D90
79869275|NCT02767999|Radiation|fMRI|functional resting state MRI
80028251|NCT02031354|Dietary Supplement|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
79271709|NCT02191813|Drug|Seresis®|
79271710|NCT02191813|Drug|Placebo|
79271711|NCT02191891|Drug|BI 836845|Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
79734656|NCT02791126|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
79734657|NCT04048213|Other|questionnaire|questionnaire send to the parents
79869276|NCT02675465|Drug|ATB200|
79869277|NCT02675465|Drug|AT2221|
80028252|NCT03682471|Drug|Deoxycholic acid Injection|Solution for subcutaneous injection.
79271712|NCT02191891|Drug|afatinib|Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
79734658|NCT02790814|Device|Moyo strap-on|Continous measurements
79734659|NCT02790814|Device|Hand-held fetoscope|Intermittent measurements
79734660|NCT00693667|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
79869278|NCT02670707|Drug|Cytarabine|Cytarabine 100 mg/m^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
79869279|NCT02670707|Drug|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
79869280|NCT02658890|Drug|BMS-986205|
79869281|NCT02658890|Drug|Nivolumab|
79869282|NCT02658890|Drug|Ipilimumab|
79869283|NCT02597062|Drug|Carfilzomib|
79869284|NCT02597062|Drug|Cyclophosphamide|
79869285|NCT02597062|Drug|Dexamethasone|
80028253|NCT03682471|Drug|Placebo|Placebo, 10 mM sodium phosphate, 0.9% [w/v] sodium chloride in water for subcutaneous injection.
80028254|NCT02198352|Drug|BIBN 4096 BS - in single rising doses|
80028255|NCT02198352|Drug|Placebo|
80028256|NCT03533088|Other|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
79271713|NCT05502536|Other|Traditional rehabilitation programs with Individualized fairytales class|In addition to traditional rehabilitation programs, 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months, to preschool children with Attention Deficit Hyperactivity Disorder and developmental delays in regular traditional rehabilitation programs
79869286|NCT02567292|Other|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants <37 weeks PMA and/or or weight <2,200g or PBCLN-002 for infants >37 weeks PMA and/or weight >2,200g)
79575092|NCT01855568|Procedure|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
79869287|NCT02484417|Biological|RSV A2|Intranasal inoculation of healthy volunteers with 10^5 or 10^6.3 plaque forming units (PFU) of RSV A2.
79869288|NCT02451982|Drug|Cyclophosphamide|200 mg/m2 IV
79271714|NCT05507372|Drug|Pimozide 1 MG|Dopamine Receptor Antagonist - Oral Pimozide
79271715|NCT02193763|Procedure|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
79575093|NCT01855568|Procedure|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
79869289|NCT02451982|Biological|GVAX pancreatic cancer|5x10^8 cells intradermal injection
79869290|NCT02451982|Drug|Nivolumab|480 mg IV
79869291|NCT02451982|Drug|Urelumab|8 mg IV
79869292|NCT02451982|Drug|BMS-986253|2400 mg IV
79869293|NCT02361671|Other|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
79869294|NCT02235623|Procedure|Single-stage Fowler-Stephens orchidopexy (FSO)|
79271716|NCT04571047|Other|Time to treatment|Treatment before or after 4 weeks after diagnosis
79402605|NCT06011707|Behavioral|OPT-IN|Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
79402606|NCT06011707|Other|Psychoeducational control|This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
79402607|NCT06011694|Other|MERCURY test, health questionnaires and annual routine physical exams|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
79402608|NCT06011668|Device|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
79575094|NCT01855581|Drug|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
79575095|NCT01855594|Drug|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
79575096|NCT01855594|Drug|Placebo|placebo tablet, 6 week course of oral administration
79869295|NCT02235623|Procedure|Two-stage Fowler-Stephens orchidopexy (FSO)|
79869296|NCT02122185|Drug|metformin hydrochloride|Given PO
79869297|NCT02122185|Drug|placebo|Given PO
79575097|NCT01855646|Other|Structured Sign Out Form|
79575098|NCT01855672|Device|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
79869298|NCT02122185|Drug|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
79869299|NCT02041663|Biological|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
79869300|NCT01830621|Drug|BBI608|
79869301|NCT01830621|Drug|Placebo|
79869302|NCT01830621|Other|Best Supportive Care|
79869303|NCT01528852|Drug|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
79869304|NCT01528852|Drug|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
79869305|NCT01528852|Other|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
79869306|NCT01248585|Drug|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
79869307|NCT01248585|Drug|Placebo|2 placebo tablets taken once daily for 5 days
79869308|NCT00993655|Drug|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
79869309|NCT00993655|Drug|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
79271717|NCT02191969|Behavioral|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
79869310|NCT00993655|Drug|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
79869311|NCT00338702|Procedure|Autologous Platelet Gel|
79869312|NCT00251251|Device|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
79869313|NCT00251251|Device|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
79869314|NCT00168701|Drug|BG00012|
79575099|NCT01855698|Other|Observation|
79575100|NCT01855711|Drug|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
79869315|NCT05350800|Drug|BMS-986369|Specified dose on specified days
79869316|NCT05346653|Drug|SGLT2i|dapagliflozin (10 mg daily)
79869317|NCT05346653|Other|No SGLT2i|No SGLT2i
79869318|NCT05335889|Device|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
79869319|NCT05335889|Device|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
79869320|NCT05335863|Dietary Supplement|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
79271718|NCT02192047|Other|Palm Olein|8 weeks
79402609|NCT06011642|Diagnostic Test|Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter, digitale Version (Kinder-eDIPS)|The Kinder-eDIPS is a digital, structured interviews which assesses the most frequent psychological disorders. It exists in a parent and a child version. It can be delivered by trained clinicians and takes between 60 and 120 minutes.
79575101|NCT01855724|Drug|Gemcitabine-Pazopanib|
79869321|NCT05335863|Dietary Supplement|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
79271719|NCT02192047|Other|IE Palm olein|8 weeks
79271720|NCT02192047|Other|IE soybean oil-based|8 weeks
79271721|NCT02192125|Device|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:~patient station (PS), which is installed in the home environment of the patient:~Includes:~Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~Includes:~Laptop MySQL- database~station networking (NS), which allows a combination of a several of HS. database"
79271722|NCT02192203|Drug|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
79575102|NCT01855737|Drug|Warfarin|Prescribe warfarin to the patients who are needed.
79575103|NCT01855763|Drug|Metformin|
79575104|NCT01855763|Drug|Insulin|
79734661|NCT02791048|Behavioral|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
79734662|NCT00697021|Drug|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
79271723|NCT02192203|Drug|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
79271724|NCT02192203|Drug|Menthol Only Gel|3% menthol
79271725|NCT02192203|Drug|Placebo Only Gel|0.09% menthol
79402610|NCT06011590|Other|No intervention.|No intervention.
79402611|NCT06011564|Device|Reminder function on Android computer tablet|Computer tablet with reminder function
79575105|NCT01855776|Device|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
79575106|NCT01855776|Behavioral|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
79575107|NCT01855776|Behavioral|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
79575108|NCT01855776|Other|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
79734663|NCT00697021|Drug|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
79734664|NCT02790892|Behavioral|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
79734665|NCT02620345|Drug|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~1tablet/24 hours/day (to 4 weeks after postpartum)"
79271726|NCT02192281|Other|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
79402612|NCT06011538|Other|On-line, multi-media information on a specifically designed website for Same Day Discharge following Laparoscopic Hysterectomy|A patient educational website that provides clear, easily accessible, patient friendly information explaining what SDD after laparoscopic hysterectomy is, why SDD may be beneficial and what to expect from decision for surgery, through to the admission to hospital and immediate, short and long term recovery.
79402613|NCT06011525|Other|standard cold cap|"Standard cold-cap applied throughout anthracycline- and taxane-based chemotherapy treatment.~This device will be supplemented by a compressive bandage in order to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the efficacy of the device."
79402614|NCT06011525|Other|scalp-cooling technique|Scalp-cooling technique applied throughout anthracycline- and taxane-based chemotherapy treatment
79575109|NCT01855841|Drug|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
79575110|NCT01855841|Drug|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
79575111|NCT01855854|Drug|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
79575112|NCT01855893|Other|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
79402615|NCT06011486|Combination Product|Lymphocyte infusion (ImmuneCellVir-I)|Infusion of donor CMV specific cells into patients eligible to the trial
79575113|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
79575114|NCT01855906|Procedure|Gap balanced surgical technique|Gap balanced surgical technique
79575115|NCT01855906|Procedure|Measured resection|Measured resection surgical technique
79869322|NCT05331105|Drug|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
79869323|NCT05328323|Other|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
79869324|NCT05324826|Device|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
79869325|NCT05316493|Behavioral|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
79869326|NCT05316493|Drug|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
79869327|NCT05316493|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
79869328|NCT05316467|Behavioral|Intensive Lifestyle Intervention (ILI)|"dietary guidance~exercise guidance~lifestyle intervention"
79869329|NCT05316467|Drug|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
79271727|NCT02192437|Other|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
79271728|NCT02187757|Dietary Supplement|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
79271729|NCT02187757|Dietary Supplement|Placebo|
79271730|NCT02192515|Drug|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
79271731|NCT02192515|Drug|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
79271732|NCT02192515|Drug|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
79271733|NCT02192515|Drug|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
79271734|NCT02192515|Drug|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
79271735|NCT02192515|Drug|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
79271736|NCT02192515|Drug|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
79575116|NCT01855932|Behavioral|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
79271737|NCT02192515|Drug|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
79271738|NCT02257021|Drug|BILR 355 BS|
79271739|NCT02257021|Drug|Tipranavir|
79271740|NCT02257021|Drug|Low dose of ritonavir|
79271741|NCT02257021|Drug|High dose of ritonavir|
79271742|NCT02187913|Dietary Supplement|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
79869330|NCT05308459|Behavioral|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~A local health profile is conducted among all students~Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~The activities are implemented~A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
79869331|NCT05306652|Other|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
79869332|NCT05306652|Other|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
79869333|NCT05305677|Dietary Supplement|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
79869334|NCT05305677|Other|Placebo|NMN-free placebo capsules for 8 weeks
79869335|NCT05304949|Other|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
79869336|NCT05294341|Drug|Norethindrone Acetate 5 MG|As specified in arm design
79271743|NCT03536065|Behavioral|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
79271744|NCT03536065|Behavioral|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
79271745|NCT02192593|Behavioral|Computer CBT|
79271746|NCT04547491|Device|HPI - hypotension prediction index|treatment of hypotension before the appearance following HPI algorithm
79734666|NCT02620345|Drug|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~Fibroids/ Women of Reproductive age ( discovered fibroids )~1tablet/24 hours/day ( from discovered fibroids through 6 months)"
79734667|NCT02790970|Device|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
79734668|NCT02790970|Other|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
79734669|NCT02623543|Device|OrthoK|
79869337|NCT05294341|Drug|Norethindrone 0.35 MG|As specified in arm design
79869338|NCT05293964|Drug|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
79869339|NCT05293964|Drug|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
79734670|NCT00696163|Drug|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
79734671|NCT02790502|Device|Food Photography Application©|Group testing RFPM as method of recording plate waste
79271747|NCT04547491|Device|GDT|cardiac optimization and treatment of hypotension following standard clinical practice
79271748|NCT02193997|Other|Fiber|
79271749|NCT02193997|Other|Fiber|
79271750|NCT02193997|Other|Placebo|
79734672|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
79734673|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
79734674|NCT00693823|Procedure|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
79734675|NCT00693823|Device|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
79734676|NCT02788864|Drug|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
79271751|NCT02192749|Biological|Umbilical cord mesenchymal stem cells|
79869340|NCT05293964|Drug|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
79869341|NCT05293743|Device|Foot abduction bracing for clubfoot with novel dynamic bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the novel bar.
79271752|NCT03535987|Device|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
79869342|NCT05293743|Device|Foot abduction bracing for clubfoot with standard straight bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the standard bar.
80028257|NCT03533088|Other|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
80028258|NCT02202408|Drug|SKI2670|Oral, Single Dose
79271753|NCT02192827|Drug|Dexamethasone Sodium Phosphate Injection|
79402616|NCT06011460|Drug|Clozapine|"Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old."
79271754|NCT03535909|Diagnostic Test|Noninvasive Hemodynamic Measurement System|Ability of the noninvasive hemodynamic measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
79271755|NCT02188225|Procedure|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
79734677|NCT02788864|Drug|Placebo|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
79271756|NCT02188225|Drug|fluoxetine|10 mg/ daily
79734678|NCT05298787|Drug|RLS-0071|RLS-0071 is administered as an IV infusion
79869343|NCT05292144|Device|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
79869344|NCT05290207|Diagnostic Test|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
79271757|NCT04535089|Drug|Dexmedetomidine injection|receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h
79271758|NCT04535089|Drug|Lidocaine Iv|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
79271759|NCT02188537|Drug|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
79271760|NCT02188537|Drug|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
79271761|NCT02188537|Drug|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
79271762|NCT02193061|Biological|Rotarix|
79271763|NCT02193061|Biological|RotaTeq|
79271764|NCT03535051|Device|fractional carbon dioxide laser|Monthly fractional carbon dioxide laser sessions
79271765|NCT03535051|Drug|Tacrolimus Oint 0.03%|topical daily tacrolimus ointment application
79271766|NCT02188615|Procedure|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
79734679|NCT05298787|Drug|Saline Placebo|Placebo is administered as an IV infusion
79271767|NCT02188615|Drug|Cisplatin|only Radical Chemoradiotherapy
79271768|NCT02188615|Device|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
79402617|NCT06011447|Other|Device to view the skin|Application of device to help view the wound area better
79402618|NCT06011434|Behavioral|Mammography Screening Conversation Aid|"Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points."
79734680|NCT04137055|Drug|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
79734681|NCT04137055|Drug|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
79734682|NCT04137055|Drug|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
79734683|NCT04137055|Drug|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
79734684|NCT04137055|Drug|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
79402619|NCT06011421|Device|Local Anaesthetic Wound Catheter Insertion|Use of the Local Anaesthetic Wound Catheter Insertion during kidney transplant
79402620|NCT06011395|Device|Smartwatch|Activity tracker (step count, calories burned), heart rate monitor
79734685|NCT04137055|Drug|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
79734686|NCT04137055|Drug|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
79869345|NCT05278624|Drug|Roflumilast Cream|Topical Cream
79869346|NCT05271240|Drug|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
80028259|NCT02202408|Drug|Placebo|Same shape as the experimental drug
80028260|NCT02202486|Other|Brain MRI|Brain MRI with gadolinium contrast
80028261|NCT02202564|Procedure|LT|Orthotopic LT
80028262|NCT02202564|Drug|ADV-TK|
80028263|NCT02202564|Drug|ganciclovir|
80028264|NCT02202642|Procedure|collagenase|Cultured limbal stem cells transplantation
80028265|NCT02198508|Drug|DFX(Deferasirox)|
80028266|NCT02198508|Drug|DFP(Deferiprone)|
79869347|NCT05271240|Drug|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
79869348|NCT05268042|Other|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
79869349|NCT05268042|Other|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
80028267|NCT03533634|Procedure|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
80028268|NCT03533634|Procedure|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
80028269|NCT02202720|Drug|Sevoflurane|Short term sedation with sevoflurane in ICU
80028270|NCT02206308|Biological|Chimeric anti-CD20 monoclonal antibody|
80028271|NCT03686839|Behavioral|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
80028272|NCT02202798|Device|Syringe device|
80028273|NCT02202876|Other|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
80028274|NCT02202876|Other|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
79271769|NCT02030743|Other|Visual training|6 training sessions with computerised visual attention paradigm
79271770|NCT02188771|Device|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
80028275|NCT02202876|Other|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
80028276|NCT02202876|Other|Test Soda|Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
79402621|NCT06011395|Device|Imperial Healthy Hearts app|Digital cardiac rehabilitation smartphone application. Represents smart watch data and source of educational materials for cardiac rehabilitiation programme.
79402622|NCT06011382|Device|Advanced Molar Distalization Appliance (amda®)|AMDA is a prefabricated device anchored to the palate by miniscrews and it is a noncompliance appliance for maxillary molar distalization
80028277|NCT02202876|Other|Fruit juice|Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
79402623|NCT06011382|Device|Buccal mini-implants|Buccal mini-implants for maxillary molar distalization
79734687|NCT04137055|Drug|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
79734688|NCT04137055|Drug|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
79734689|NCT04137055|Drug|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
79734690|NCT04137055|Drug|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
80028278|NCT03686761|Procedure|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
80028279|NCT02206386|Other|MHTraining-Net|See Arm Description for more details.
80028280|NCT02206386|Other|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
80028281|NCT03028129|Drug|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
79271771|NCT02188927|Other|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
79271772|NCT02188927|Behavioral|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
79271773|NCT02194075|Drug|Fluvoxamine+Methylphenidate hydrochloride|
79271774|NCT02194075|Drug|Fluvoxamine+sugar pill|
79271775|NCT02030587|Procedure|Radiofrequency Ablation|
79271776|NCT02030587|Procedure|Laparoscopic Adrenalectomy|
79271777|NCT03535285|Procedure|Periodontal ligament distraction|decrease the bony resistant during canine retration
79402624|NCT06011356|Device|Smartwatch|Activity tracker (step count, calories burned), measures heart rate, heart variability and other physiological variables.
79734691|NCT04137055|Drug|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
79734692|NCT02788786|Drug|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
79734693|NCT02788786|Drug|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
79734694|NCT02788786|Drug|Salt and Water|salt and water mix oral rinse
80028282|NCT03028129|Drug|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
79869350|NCT05264883|Drug|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
79869351|NCT05264883|Drug|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
79402625|NCT06011343|Drug|Oral tofacitinib|Association of tofacitinib and meglumine antimoniate
80028283|NCT02202954|Other|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
79575117|NCT01855971|Dietary Supplement|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
79271778|NCT02189005|Dietary Supplement|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
79271779|NCT02189005|Dietary Supplement|Placebo|
79402626|NCT06011343|Drug|Parenteral meglumine antimoniate|Meglumine antimoniate
79402627|NCT06011252|Device|Solia S lead with any BIOTRONIK Pacemaker|"Name: Solia S lead with any BIOTRONIK Pacemaker~Model: Solia S45/S53/S60~Manufacturer: BIOTRONIK SE & Co. KG~Method of use: LBBAP implantation for all bradycardia indications.~Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~Device category and grade: E3610 Cardiovascular devices, Class III"
79402628|NCT06011187|Procedure|Routine care|Fluid administration will be given per routine care MAP between 65 - 70 mmHg
79402629|NCT06011187|Device|AFM|AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg
79402630|NCT06011174|Other|survey application|Participants will only be asked to fill out the questionnaires.
79575118|NCT01855971|Dietary Supplement|Placebo|Same capsules containing rice flour. No active treatment is given.
79734695|NCT00693901|Behavioral|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
79734696|NCT00693901|Behavioral|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
79869352|NCT05263453|Drug|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
79869353|NCT05263453|Drug|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
79869354|NCT05257343|Dietary Supplement|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
79575119|NCT01855971|Other|Cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
79869355|NCT05257343|Dietary Supplement|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
79869356|NCT05249400|Procedure|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
79869357|NCT05245669|Biological|ENZ215|healthy volunteers receive ENZ215 (60mg) once
79305878|NCT02184988|Biological|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
79575120|NCT01855984|Dietary Supplement|Oral mixed tocotrienols|200mg per day
79575121|NCT01855984|Dietary Supplement|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
79575122|NCT01856010|Other|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
79575123|NCT01856010|Other|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
79575124|NCT01856036|Procedure|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
79869358|NCT05245669|Biological|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
79869359|NCT05245669|Biological|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
79869360|NCT05243316|Procedure|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
79869361|NCT05243316|Procedure|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
79575125|NCT01856062|Drug|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
79575126|NCT01856062|Drug|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
79575127|NCT01856088|Device|Inspiron Stent|stent implantation
79271780|NCT02189083|Drug|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
79575128|NCT01856088|Device|Biomatrix Flex Stent|stent implantation
79575129|NCT01856101|Drug|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
79734697|NCT03668236|Drug|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~Fluids used for dehydration: Water or isotonic glucose should be used~Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
79734698|NCT02623465|Drug|Insulin Lispro|Administered subcutaneously (SC)
79734699|NCT00693979|Device|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
79575130|NCT01856127|Drug|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
79575131|NCT01856127|Drug|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
79734700|NCT04232800|Drug|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
79734701|NCT04232800|Other|Placebo|An inert, standard placebo in identical capsules to primary intervention.
79734702|NCT01148225|Drug|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
79734703|NCT02623387|Procedure|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
79734704|NCT02788240|Drug|Peg GCSF|
79734705|NCT02788240|Biological|20% Albumin|
79869362|NCT05233332|Drug|HL-085|12mg BID HL-085
79869363|NCT05233332|Drug|Vemurafenib|720mg BID Vemurafenib
79869364|NCT05232084|Drug|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
79869365|NCT05229783|Procedure|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
79869366|NCT05229783|Procedure|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
80028284|NCT03660384|Procedure|PPV/SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
80028285|NCT03660384|Procedure|PPV/C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
80028286|NCT02206464|Biological|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
79271781|NCT02256787|Drug|BILB 1941 ZW - single rising dose part|
79734706|NCT02788240|Dietary Supplement|Nutrition|
79271782|NCT02256787|Drug|Placebo|
79271783|NCT02256787|Drug|BILB 1941 ZW - solution|
79734707|NCT02788240|Other|Bowel wash|
79271784|NCT02256787|Drug|BILB 1941 ZW - tablet|
79271785|NCT02256787|Other|standardized breakfast|
79271786|NCT02193217|Drug|MT-1303-Low|
79575132|NCT01856153|Dietary Supplement|Before meal|
79575133|NCT01856153|Dietary Supplement|With Meal|
79575134|NCT01856153|Dietary Supplement|After meal|
79575135|NCT01856166|Device|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
79575136|NCT01856166|Device|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
79575137|NCT01856166|Drug|Levobupivacaine|
79575138|NCT01856166|Drug|Sufentanil|
79869367|NCT05224622|Diagnostic Test|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
79734708|NCT02788240|Drug|Terlipressin 1- 4mg,if indicated|
79869369|NCT05218863|Other|No intervention|No intervention
79869370|NCT05217303|Drug|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
79869371|NCT05204537|Procedure|Lung parenchyma resection|Lung parenchyma removal
79271787|NCT02193217|Drug|MT-1303-High|
79869372|NCT05204537|Procedure|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
79869373|NCT05195619|Biological|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
79869374|NCT05195619|Drug|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
79869375|NCT05181475|Drug|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
79869376|NCT05180669|Other|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
79869377|NCT05180669|Other|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
79869378|NCT05164406|Procedure|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
80028287|NCT02206464|Biological|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
79869379|NCT05159362|Other|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
79869380|NCT05158517|Drug|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
79869381|NCT05152459|Drug|Tazemetostat|Given PO
79869382|NCT05152459|Biological|Ublituximab|Given IV
80028288|NCT02203188|Procedure|Lid debridgement scaling|
79271788|NCT02193217|Drug|Fingolimod|
79271789|NCT02193217|Drug|Placebo|
79271790|NCT03534973|Other|Caffeine intake|Cataract surgery in eyes with prior caffeine intake
79271791|NCT03534973|Other|No caffeine intake|Cataract surgery in eyes without prior caffeine intake
79271792|NCT03535207|Radiation|high dose chemoradiotherapy|"Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional."
79402631|NCT06011161|Behavioral|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
79402632|NCT06011135|Other|No intervention|No intervention - qualitative study only using semi-structured interview
79402633|NCT06011122|Procedure|Distal radius fracture ORIF with a specific volar plate|Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate
79402634|NCT06011096|Other|skin-to-skin contact and delayed cord clamping|Placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated with skin-to-skin contact and late cord clamping after delivery.
79734709|NCT02788240|Drug|Meropenem or Imepenem, if indicated|
79734710|NCT02788240|Drug|Placebo|
79734711|NCT02788162|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - X71-144)
79734712|NCT04134715|Drug|PF-06826647|100 mg tablet
79869383|NCT05152459|Drug|Umbralisib|Given PO
80028289|NCT04059679|Drug|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
80028290|NCT04059679|Drug|Aspirin 81 mg|EC aspirin 81 mg qd
80028291|NCT02206542|Device|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
79271793|NCT02189239|Drug|Zeller Entspannung film coated tablet|
79271794|NCT02189239|Drug|Placebo|
79271795|NCT02189239|Other|No Treatment|
79734713|NCT04134715|Drug|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
79734714|NCT04136899|Other|Dukes scale|collection of questionnaires
79734715|NCT00694057|Drug|HE3286|HE3286 10 mg per day (5 mg BID)
79734716|NCT00694057|Drug|Placebo|Placebo capsules BID
79869384|NCT05151887|Other|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
79869385|NCT05151315|Device|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
80028292|NCT02206542|Other|Physical therapy|
80028293|NCT02206542|Device|Electroacupuncture|
80028294|NCT03691363|Behavioral|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes > MVPA at baseline with 2) HR>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR>140 (low end of MVPA). The intervention will be 6 weeks in duration.
80028295|NCT02202330|Other|Video Arm|"5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
79271796|NCT04728061|Drug|Gen1E-1124|Intravenously-infused Gen1E-1124 in vehicle.
79734717|NCT02884115|Drug|benzathine penicillin|
79271797|NCT04728061|Drug|Placebo|Intravenously-infused vehicle.
79575139|NCT01856179|Dietary Supplement|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
79575140|NCT01856205|Drug|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate."
79734718|NCT00696319|Other|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
79734719|NCT00696319|Other|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
79869386|NCT05151315|Device|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
79869387|NCT05142618|Other|Supervised Physical Therapy|The twice-per-week 8-week course of supervised physical therapy begins 2 weeks after surgery. It targets abdominal core function through progressive muscle retraining and strengthening, and patient-specific posture and body mechanics education.
79869388|NCT05142618|Other|Post-operative Precautions|This intervention includes standard of care post-operative instructions typically given to patients undergoing ventral hernia repair across the world. These include limiting strenuous physical activity and a lifting restriction of no more than 10 pounds for 6 weeks. Binder use is also encouraged for 4-6 weeks after the operation.
79869389|NCT05139914|Drug|Dapagliflozin|10 mg/day (in capsule form) of dapagliflozin for 6 weeks
79271798|NCT03534895|Drug|Midazolam Injectable Solution|intravenous
79271799|NCT03534895|Other|Normal saline|intravenous
79271800|NCT03534895|Procedure|Spinal anesthesia|8mg of heavy bupivacaine 0.5% injected in the subarachnoid space, during lateral decubitus
79271801|NCT03534895|Procedure|Surgery|Open inguinal hernia repair, varicose vein stripping, knee arthroscopy or hallux valgus surgery
79575141|NCT01856231|Behavioral|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
79575142|NCT01856244|Behavioral|treadmill walking|
79575143|NCT01856244|Device|Treadmill|
79575144|NCT01856283|Drug|Nilotinib 300mg BID|Nilotinib
79575145|NCT01856296|Procedure|Biopsy|
80028296|NCT03682315|Device|Biphasic phycogenic biomaterial|Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
79575146|NCT01856335|Other|Patient Education|
80028297|NCT03682315|Device|Xenograft bovine hydroxyapatite|Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
80028298|NCT02257710|Device|Orsiro|
79271802|NCT03534895|Drug|Postoperative analgesia|IV acetaminophen 1g + IV ketorolac 30mg
79271803|NCT03534895|Drug|Rescue analgesia|Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS>3.
79271804|NCT03534895|Drug|Wound infiltration|Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
79271805|NCT03534895|Drug|Analgesia at home|Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
79271806|NCT03535753|Drug|Decitabine and R-GDP|Decitabine and R-GDP
79271807|NCT02189395|Drug|NPH and regular insulin|
79271808|NCT02189395|Drug|glargine and humalog|
79271809|NCT03535519|Drug|Methotrexate|standard of care treatment with methotrexate
79575147|NCT01856335|Other|exercise: increase physical activity/goal setting|
79575148|NCT01856348|Drug|Vitamin D|
79575149|NCT01856374|Device|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
79734720|NCT01190891|Procedure|Manual Physical Therapy|Same as arm description
79734721|NCT01190891|Procedure|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
79869390|NCT05139914|Other|Placebo|Placebo capsule for 6 weeks
79869391|NCT05138835|Drug|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
79271810|NCT02193373|Other|Osteopathic Manual Medicine|Osteopathic Manual Medicine
79271811|NCT02193373|Other|Sham|Osteopathic Manual Medicine
79734722|NCT00871975|Device|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
79734723|NCT00694213|Biological|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
79869392|NCT05132231|Biological|Brodalumab|Brodalumab
79869393|NCT05132231|Biological|Matched cohort|Matched cohort
79271812|NCT02189551|Behavioral|Gait training with Lokomat Pro|
79271813|NCT02189551|Behavioral|Gait training with Lokomat Pro FreeD|
79271814|NCT04674631|Other|The effect of neuropathic pain on quality of life, depression and sleep quality|The effect of neuropathic pain on quality of life, depression and sleep quality
79869394|NCT05130853|Behavioral|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
79271815|NCT02194153|Drug|Metalyse weight-adjusted|
79271816|NCT04435873|Other|"Survey using Your Home Dialysis Care Experience tool."|Validation of a new survey instrument to capture the experience of care by home dialysis patients.
79271817|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
79734724|NCT00694213|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
79271818|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
79271819|NCT02189707|Other|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
79271820|NCT02194231|Drug|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
79271821|NCT02562482|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
79271822|NCT02562482|Other|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
79271823|NCT02193451|Procedure|Urodynamics|Diagnostic test for urinary storage and voiding function
79271824|NCT02193451|Procedure|Usual care|
79271825|NCT02190019|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
79734725|NCT00694213|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
79734726|NCT00694213|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
79734727|NCT04134403|Drug|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
79734728|NCT01190813|Drug|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
79734729|NCT01190813|Drug|Placebo|Oral placebo tid
79734730|NCT01190813|Other|Patching|Two hours of daily patching
79869395|NCT05130853|Other|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
79869396|NCT05127252|Diagnostic Test|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
79869397|NCT05121545|Radiation|Pro-GRID|Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
79869398|NCT05112497|Other|No intervention procedure|No intervention procedure
79869399|NCT05100056|Other|No Intervention|This is a non-interventional study.
79734731|NCT03641326|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
79575150|NCT01856374|Device|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
79575151|NCT01856374|Drug|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
79734732|NCT03641326|Device|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
79734733|NCT03721510|Biological|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
79869400|NCT05099107|Drug|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
79734734|NCT03721510|Biological|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
79734735|NCT02788942|Procedure|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
79869401|NCT05099107|Drug|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
79271826|NCT02933671|Procedure|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
79734736|NCT04313309|Other|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
79734737|NCT00870727|Drug|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
79734738|NCT00870727|Drug|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
79734739|NCT02787928|Drug|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
79734740|NCT02617069|Biological|botulinum toxin injection|
79734741|NCT02617069|Biological|0.9% normal saline injection|
79271827|NCT02933671|Procedure|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
79271828|NCT02933671|Drug|Ropivacaine|Local anesthetic (numbing drug)
79271829|NCT02933671|Drug|Saline|Salt water placebo
79271830|NCT05509478|Drug|Lenvatinib|8 mg once daily (QD) oral dosing.
79271831|NCT05509478|Drug|PD-1 inhibitors|Regular dose intravenously every 3 weeks
79271832|NCT05507294|Drug|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
79271833|NCT02194309|Drug|Telmisartan low|
79271834|NCT02194309|Drug|Telmisartan high|
79271835|NCT02194309|Drug|amlodipine|
79271836|NCT02257255|Procedure|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
79271837|NCT02257255|Procedure|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
79575152|NCT01856374|Drug|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
79575153|NCT01856387|Biological|high neutrophil to lymphocyte ratio|
79575154|NCT01856387|Other|normal neutrophil-to Lymphocyte ratio|
79575155|NCT01856413|Drug|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
79575156|NCT01856426|Drug|EDP239|
79575157|NCT01856426|Drug|Placebo|
79575158|NCT01856452|Device|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
79575159|NCT01856452|Device|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
79575160|NCT01856517|Drug|Clonidine|
79575161|NCT01856517|Drug|Placebo|
79575162|NCT01856556|Drug|NRX-1074|Single IV or PO administration
79575163|NCT01856556|Drug|Placebo|Single IV or PO placebo administration
79734742|NCT02617069|Device|Implantable loop recorder|
79869402|NCT05093634|Drug|Setmelanotide|Subcutaneous Injection
79869403|NCT05093634|Drug|Placebo|Subcutaneous Injection
79869404|NCT05091645|Other|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
79869405|NCT05077423|Drug|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
79869406|NCT05077371|Behavioral|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
79869407|NCT05062772|Diagnostic Test|Ultrasound|Intraoperative ultrasound imaging
79575164|NCT01856621|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
79575165|NCT01856621|Drug|Seretide Diskus|2 inhalations as a single dose
79734743|NCT02788630|Behavioral|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
79869408|NCT05058040|Drug|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
79575166|NCT01856621|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
79734744|NCT02619877|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
79402635|NCT06011096|Other|avoiding skin-to-skin contact and early cord clamping|After delivery, placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated without skin-to-skin contact and late cord clamping.
79734745|NCT02619877|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
79869409|NCT05057923|Biological|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
80028299|NCT03682237|Device|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
80028300|NCT03682237|Device|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
79271838|NCT02568254|Device|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
79271839|NCT02568254|Device|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
79271840|NCT02568254|Device|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
79271841|NCT02197117|Device|Remote ischemic conditioning|
79271842|NCT02197117|Device|Control|
79271843|NCT04392505|Drug|Durvalumab Injection|Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start <5 weeks after last radiotherapy dosing.
79869410|NCT05035810|Behavioral|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
79305879|NCT04917939|Other|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
79305880|NCT03055143|Drug|SPARC-08-038|2 mg/ml intravenous infusion
79575167|NCT01856621|Drug|SF Easyhaler|2 inhalations as a single dose
79869411|NCT05035810|Drug|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
79869412|NCT05035810|Behavioral|No Social Incentive applied|No social incentive will be applied
79869413|NCT05035810|Drug|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
79575168|NCT01856634|Drug|100 mg Delamanid|100 mg Delamanid BID for 10 days
79575169|NCT01856634|Drug|50 mg Delamanid|50 mg Delamanid BID for 10 days
79305881|NCT03055143|Drug|Ref-08-038|2 mg/ml intravenous infusion
79575170|NCT01856634|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
79575171|NCT01856634|Drug|10 mg Delamanid Pediatric Formulation|Patients > 10 kg will receive DPF 10 mg BID for 10 days
79575172|NCT01856634|Drug|5 mg Delamanid Pediatric Formulation|"Patients > 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
79575173|NCT01856634|Drug|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
79575174|NCT01856647|Procedure|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.
79734746|NCT02788552|Drug|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
79305882|NCT04753840|Other|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
79402636|NCT06011083|Drug|Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm|using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
79402637|NCT06011083|Device|Fractional carbon dioxide (CO2) laser|fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque
79734747|NCT04135339|Other|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
79575175|NCT01856660|Behavioral|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to > 40 min per day, 5 times/week.
79575176|NCT01856660|Behavioral|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
79575177|NCT01856725|Procedure|Hemodynamic measurements for CRT device programming|
79734748|NCT04135339|Other|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
79869414|NCT05030090|Behavioral|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
79869415|NCT05030090|Dietary Supplement|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
80028301|NCT02203266|Device|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
80028302|NCT02203266|Behavioral|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
80028303|NCT03686527|Procedure|stenosis aortic valve|"The exams to be realized :~a clinical examination with blood pressure~a 12-lead surface electrocardiogram~a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~a cardiac MRI looking for fibrosis myocardial"
80028304|NCT03533556|Dietary Supplement|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
80028305|NCT03533556|Dietary Supplement|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
79271844|NCT05502458|Drug|Desﬂurane|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
79271845|NCT05502458|Drug|Propofol|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
79271846|NCT02197195|Dietary Supplement|Chocolate Milk|
79271847|NCT02197195|Dietary Supplement|Fruit Drink|
79271848|NCT02197195|Behavioral|Exercise|
79271849|NCT05507060|Device|Vibrating MESH nebulizer (Aerogen Ultra)|Medication will be applied with Vibrating MESH nebulizer
79271850|NCT05507060|Device|Jet nebulizers (Philips Respironics)|Medication will be applied with Jet nebulizers
79271851|NCT03534037|Drug|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
79271852|NCT03534037|Drug|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
79271853|NCT03534037|Other|Control|Dietary control only
79271854|NCT02197429|Other|Acupuncture|
79271855|NCT03533959|Drug|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
79575178|NCT01856725|Device|CRT device implant with MultiPoint Pacing|
79575179|NCT01856738|Drug|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
79575180|NCT01856738|Drug|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
79575181|NCT01856777|Device|Semi-quantitative panel test|
79575182|NCT01856777|Device|High sensitivity urine pregnancy test|
79575183|NCT01856803|Drug|anti thymoglobulin|
79271856|NCT05502380|Drug|Standard antibiotic prophylaxis|One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
79271857|NCT02030899|Procedure|Cage fusion|Randomized selection of surgery type
79575184|NCT01856816|Other|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
79575185|NCT01856816|Other|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
79734749|NCT04135339|Other|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
79734750|NCT01147055|Drug|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
79734751|NCT01147055|Drug|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
80028306|NCT03533556|Dietary Supplement|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
79734752|NCT01147055|Drug|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
79734753|NCT03705754|Device|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
79734754|NCT02623231|Drug|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
80028307|NCT03533556|Other|Placebo|Oral administration of 100 ml of water
79869416|NCT05030090|Combination Product|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
79869417|NCT05003726|Procedure|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
80028308|NCT03691285|Procedure|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
80028309|NCT02206854|Drug|R-flurbiprofen|200 mg gelatine capsule once orally
79271858|NCT02030899|Procedure|Plate fusion|Randomized selection of surgery type
79271859|NCT05163145|Other|TPN|early detection of comlications of prolonged TPN on neonatal liver
79402638|NCT06011044|Procedure|Intercostal Nerve Block|The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
79402639|NCT06011005|Other|Ethyl Chloride spray (group A)|Cold test spray
79575186|NCT01856816|Other|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
79575187|NCT01856829|Dietary Supplement|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
79575188|NCT01856829|Other|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
79734755|NCT02623231|Drug|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
79734756|NCT04232878|Drug|CVL-936|CVL-936
80028310|NCT03624205|Device|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
80028311|NCT02206932|Drug|Sofosbuvir + Simeprevir|
80028312|NCT03686449|Procedure|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
80028313|NCT03686449|Procedure|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
79271860|NCT02196025|Device|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
80028314|NCT03686449|Procedure|Split skin graft|Traditional method for treatment of post-burn raw area
79271861|NCT02567708|Drug|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
79271862|NCT02567708|Drug|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
79271863|NCT02196103|Device|Double balloon cervical catheter|
79402640|NCT06011005|Other|Benzocaine gel 20% (group B)|Topical analgesia
79402641|NCT06010992|Drug|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
80028315|NCT02207010|Biological|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
80028316|NCT03686293|Other|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
80028317|NCT05261724|Diagnostic Test|MRI|In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
80028318|NCT03686137|Other|Data collection|Colelction of pre-operative, surgical and post-surgical data
79869418|NCT05003726|Procedure|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
80028319|NCT02203422|Drug|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
80028320|NCT02203422|Drug|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
79575189|NCT01856842|Procedure|Angiography and embolotherapy|
80028321|NCT03686059|Drug|Omega 3|daily intake of 250 mg
80028322|NCT03686059|Device|punctal plug|punctal plug will be inserted in inferior punctum
80028323|NCT03682159|Other|manual lymphatic drainage|The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
80028324|NCT03532854|Drug|Valsartan|Valsartan P.O
80028325|NCT03532854|Drug|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
80028326|NCT03682003|Diagnostic Test|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
79869419|NCT05002868|Drug|RP12146|starting dose of 100 mg QD
79869420|NCT04998786|Drug|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
79869421|NCT04998786|Drug|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
79271864|NCT04283383|Other|Primary Care Clinical Ultrasound Classroom (AECAP)|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
79734757|NCT04232878|Drug|Matching Placebo|Placebo matching CVL-936
79734758|NCT02623153|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
79271865|NCT05509244|Drug|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
79271866|NCT05509244|Drug|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
79271867|NCT02196415|Device|Biplanar Radiography|standard biplanar radiography of the foot
79734759|NCT02623153|Drug|capecitabine|capecitabine of 1000 mg/m2
79734760|NCT02623153|Drug|S1|S1 of 40 mg/m2
79869422|NCT04998786|Drug|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
79869423|NCT04998500|Biological|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
80028327|NCT03591822|Behavioral|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
80028328|NCT03591822|Behavioral|B : Systemic evaluation of the pain|A systematic evaluation of the pain
79271868|NCT05502068|Dietary Supplement|Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion|This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day
79575190|NCT01856881|Drug|AMG 876|Ascending multiple doses of study drug administered SC
79575191|NCT01856920|Biological|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
79734761|NCT02623153|Drug|Docetaxel|docetaxel 40 mg/m2
79869424|NCT04992624|Drug|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
79869425|NCT04992624|Drug|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
79869426|NCT04992624|Drug|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
80028329|NCT03690973|Drug|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
80028330|NCT03690973|Device|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
80028331|NCT03690973|Device|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
80028332|NCT03690973|Drug|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
80028333|NCT04059289|Other|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
80028334|NCT02203500|Drug|Lacidipine|
80028335|NCT02203500|Drug|Telmisartan|
80028336|NCT03681925|Diagnostic Test|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
79869427|NCT04988399|Other|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
79869428|NCT04983225|Drug|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
79869429|NCT04983225|Other|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
79869430|NCT04976569|Device|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
79869431|NCT04975191|Behavioral|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
79869432|NCT04975191|Behavioral|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
80028337|NCT03681847|Procedure|Normal saline|normal saline 0.9% 15 ml/kg over 15-20 minutes.
80028338|NCT03681847|Procedure|hydroxyethyl starch|hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
80028339|NCT03681847|Procedure|Hypertonic saline|hypertonic saline 3% (7ml/kg) over 15-20 minutes.
80028340|NCT03533478|Dietary Supplement|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
80028341|NCT03533478|Dietary Supplement|Placebo|Placebo treatment
80028342|NCT02203656|Drug|Placebo|placebo supplement
80028343|NCT02203656|Dietary Supplement|Nutritional Supplement|protein supplement
80028344|NCT02203656|Behavioral|In-home exercise|In-home exercise program
80028345|NCT02203656|Drug|Testosterone|Testosterone injection
80028346|NCT04436146|Other|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
79271869|NCT02194777|Drug|BIBN 4096 BS - in single rising doses|
79271870|NCT02194777|Drug|Placebo|
79575192|NCT01856946|Dietary Supplement|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
79575193|NCT01856959|Drug|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
80028347|NCT02203734|Procedure|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
79734762|NCT04316195|Diagnostic Test|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
80028348|NCT02203734|Procedure|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
80028349|NCT02203812|Drug|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
80028350|NCT02203812|Drug|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
79271871|NCT02197507|Device|Digitized sensor|Measure of grip strength of the dominant hand
79271872|NCT05506904|Device|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
79271873|NCT02197585|Procedure|Inguinal mesh hernioplasty|
79271874|NCT02030977|Dietary Supplement|Resveratrol|
79271875|NCT02030977|Other|placebo|
79271876|NCT02194855|Drug|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
79271877|NCT02194855|Drug|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
79869433|NCT04975191|Behavioral|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
79869434|NCT04972487|Drug|Tofersen|Administered as intrathecal bolus injection
79869435|NCT04964089|Drug|KSI-301|Intravitreal Injection
79869436|NCT04964089|Drug|Aflibercept|Intravitreal Injection
79575194|NCT01856959|Drug|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
79575195|NCT01856959|Drug|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
79869437|NCT04964089|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
80028351|NCT04431388|Device|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
80028352|NCT04431388|Drug|Levobupivacaine|using the same AL
79575196|NCT01856972|Procedure|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
79575197|NCT01856972|Procedure|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
80028353|NCT02199444|Drug|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
80028354|NCT02199444|Drug|Placebo|
80028355|NCT02199522|Procedure|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
80028356|NCT03532698|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
80028357|NCT03532698|Drug|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
79271878|NCT03534661|Drug|Teduglutide + Normal Saline|Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
79271879|NCT03534661|Drug|Teduglutide + L-NMMA|Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
79271880|NCT03534661|Drug|Placebo + L-NMMA|Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
79271881|NCT02562716|Drug|Fluorouracil|Given IV
79575198|NCT01856972|Other|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
79575199|NCT01856985|Drug|Misoprostol|
79271882|NCT02562716|Drug|Gemcitabine Hydrochloride|Given IV
79271883|NCT02562716|Drug|Irinotecan Hydrochloride|Given IV
79271884|NCT02562716|Drug|Oxaliplatin|Given IV
79271885|NCT02562716|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
79734763|NCT02616913|Other|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
79734764|NCT02616913|Other|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
79734765|NCT02616913|Other|Placebo|Each subject consumes placebo in one of 3 treatment periods
79734766|NCT02884037|Drug|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
79575200|NCT01856985|Drug|Mifepristone|
79575201|NCT01856998|Drug|Propofol|
79575202|NCT01856998|Drug|Diprivan|
79734767|NCT04233502|Drug|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
79734768|NCT04233502|Drug|Placebo|Placebo melatonin
80028358|NCT03685981|Other|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
80028359|NCT02207790|Drug|E2609|
80028360|NCT02207790|Drug|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
80028361|NCT03685903|Device|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
80028362|NCT02203968|Drug|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
80028363|NCT02203968|Drug|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
80028364|NCT03690895|Other|Retrospective survival analysis|Kaplan-Meier model
80028365|NCT02010424|Other|control group|standard IVF protocol
80028366|NCT02010424|Device|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
80028367|NCT02204046|Drug|BIWA 4|
80028368|NCT03063346|Dietary Supplement|Protein hydrolysate high dose|
80028369|NCT03063346|Dietary Supplement|Protein hydrolysate low dose|
80028370|NCT03063346|Dietary Supplement|Placebo|
80028371|NCT03690817|Behavioral|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
80028372|NCT02208102|Procedure|Radio-frequency catheter ablation|
79869438|NCT04963075|Device|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
79869439|NCT04961957|Device|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
80028373|NCT03623971|Device|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
80028374|NCT03063268|Behavioral|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
79575203|NCT01857011|Drug|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
80028375|NCT03063268|Behavioral|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
80028376|NCT03063268|Behavioral|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
79271886|NCT02562716|Procedure|Pancreatectomy|Undergo pancreatectomy
79271887|NCT04286347|Procedure|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
79271888|NCT02197663|Procedure|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
79271889|NCT05509088|Device|high flow nasal cannula|Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
79271890|NCT02031211|Drug|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
79734769|NCT01146665|Behavioral|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
79734770|NCT01146665|Behavioral|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
79734771|NCT00696475|Drug|Diazoxide choline|
79734772|NCT00696475|Drug|Diazoxide choline|
79869440|NCT04961957|Device|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
80028377|NCT02208180|Behavioral|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
80028378|NCT03690739|Drug|Carboplatin|Administration according to investigator's discretion
80028379|NCT03690739|Drug|Gemcitabine|Administration according to investigator's discretion
80028380|NCT03690739|Drug|Bevacizumab|Administration according to investigator's discretion
80028381|NCT03690739|Drug|PLD|Administration according to investigator's discretion
79575204|NCT01857011|Drug|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
79575205|NCT01857024|Drug|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
79575206|NCT01857037|Other|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
79575207|NCT01857076|Procedure|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
79575208|NCT01857076|Procedure|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
79575209|NCT01857076|Other|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
79575210|NCT01857089|Device|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement"
79575211|NCT01857128|Device|Drawtex dressing|
79734773|NCT00696475|Drug|Diazoxide choline|
79734774|NCT00696475|Drug|Placebo|
79734775|NCT03628066|Drug|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
79734776|NCT03628066|Drug|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
79734777|NCT03628066|Drug|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
80028382|NCT03690739|Drug|Paclitaxel|Administration according to investigator's discretion
80028383|NCT03690739|Drug|PLD|Administration 30 mg/m² q21
80028384|NCT03690739|Drug|Trabectedin|Administration 1.1 mg/m² q21
80028385|NCT03690739|Drug|Cisplatin|Administration according to investigator's discretion
80028386|NCT01983748|Biological|Autologous Dendritic Cells loaded with autologous Tumor RNA|
79271891|NCT02031211|Drug|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
80028387|NCT02208258|Device|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
79869441|NCT04959383|Other|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
79869442|NCT04959383|Other|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
80028388|NCT03623815|Other|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
79271892|NCT02195089|Drug|BLS_ILS_E710c 500mg|- 2 capsules per day for 20 days (week 1,2,4 & 8)
79575212|NCT01857128|Device|Negative Pressure Wound Therapy|
80028389|NCT02208336|Other|medical chart review|Ancillary studies
80028390|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
79271893|NCT02195089|Drug|BLS_ILB_710c 1000mg|- 4 capsules per day for 20 days (week 1,2,4 & 8)
80028391|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
79734778|NCT03628066|Diagnostic Test|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
79869443|NCT04959383|Other|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
80028392|NCT03921229|Behavioral|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
80028393|NCT02199678|Drug|Placebo|placebo
79271894|NCT02195089|Drug|BLS_ILS_E710c 1500mg|- 6 capsules per day for 8 weeks (week 1,2,4 & 8)
79271895|NCT05509010|Procedure|CTCA|CTCA is performed as part of routine care procedure.
79575213|NCT01857141|Drug|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
79734779|NCT02616757|Device|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
79734780|NCT00625079|Drug|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
79734781|NCT02788318|Other|Brain samples|Collected in patients died
80028394|NCT02199678|Drug|ketamine 25 mg|ketamine
80028395|NCT02199678|Drug|ketamine 35 mg|ketamine
80028396|NCT02199678|Drug|ketamine 50 mg|ketamine
79271896|NCT02031289|Drug|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
79271897|NCT05506748|Other|pantients undergoing pancreaticoduodenectomy|The study includes all the cases who underwent pancreaticoduodenectomy for carcinoma head of the pancreas, distal cholangiocarcinoma, periampullary and duodenal cancer.
79734782|NCT02788318|Other|Skin samples|Collected in patients died
79271898|NCT02197741|Drug|opiate with bolus|
79271899|NCT02196493|Drug|Azithromycin|250mg azithromycin three times per week for 12 weeks
79271900|NCT02197819|Device|Sling|
79271901|NCT02197819|Device|External Rotation Brace|
79271902|NCT02196571|Other|Structured Exercise|
79271903|NCT02195167|Drug|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
79271904|NCT05506592|Other|dermatological product|cosmetic shampoo
79271905|NCT03533881|Dietary Supplement|Arom Digest Slim|"Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day"
79575214|NCT01857141|Drug|normal saline|patients in the control groups received the equivalent volume of normal saline.
79575215|NCT01857154|Dietary Supplement|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
79734783|NCT02619721|Device|PINS SNS|
79734784|NCT04133389|Other|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
79402642|NCT06010979|Procedure|conventional intrumentation assisted knee arthroplasty|conventional intrumentation assisted knee arthroplasty
79271906|NCT03533881|Behavioral|Nutritional changes|Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
79271907|NCT02195245|Device|memsorb|
79869444|NCT04959383|Other|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
79271908|NCT02257411|Device|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
79271909|NCT02195323|Biological|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
79271910|NCT02197975|Drug|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
79402643|NCT06010979|Procedure|computer navigation assisted knee arthroplasty|computer navigation assisted knee arthroplasty
79402644|NCT06010979|Procedure|robotic system assisted knee arthroplasty|robotic system assisted knee arthroplasty
79402645|NCT06010979|Procedure|patient-spercific assisted knee arthroplasty|patient-spercific assisted knee arthroplasty
79402646|NCT06010940|Dietary Supplement|Dietary supplement|nasogastric tube and oral care
79575216|NCT01857154|Dietary Supplement|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
79575217|NCT01857154|Dietary Supplement|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
79575218|NCT01857167|Dietary Supplement|Fish Oil Supplementation|
79575219|NCT01857167|Dietary Supplement|Flaxseed Oil Supplementation|
79575220|NCT01857167|Dietary Supplement|placebo|
79575221|NCT01857180|Other|Curriculum|
79575222|NCT01857193|Drug|ribociclib (LEE011)|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
79575223|NCT01857193|Drug|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
79575224|NCT01857193|Drug|Everolimus (RAD001)|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
79869445|NCT04943432|Behavioral|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
79869446|NCT04943094|Other|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
79271911|NCT02197975|Drug|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
79271912|NCT02197975|Drug|Placebo MDI|Placebo MDI. Administered as 2 inhalations
79271913|NCT03533803|Drug|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
79271914|NCT03533803|Procedure|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
79271915|NCT02195401|Other|Cleanroom|Cleanroom with air the quality of the pre-industrial age
79271916|NCT02198209|Drug|Liraglutide|"acute study: one injection of 0.6 mg s.c. before IVGTT~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
79402647|NCT06010940|Other|Physical therapy|Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
79402648|NCT06010888|Drug|Fruquintinib+mFOLFOX6/FOLFIRI|Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
79402649|NCT06010771|Other|Listening to fairy tales|Fairy tales by children will be chosen by child psychologists. Tales will be read to the children by the researcher. The researcher has a fairy tale therapy certificate. The tale reading will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Tales will be read to children every other day. This process will continue for 3 weeks.
79402650|NCT06010771|Other|Watching Cartoon Film|The cartoons that children will watch will be preferred by child psychologists. Children will be watched cartoons with the help of tablets. Watching cartoons will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Children will be shown cartoons every other day. This process will continue for 3 weeks.
79402651|NCT06010745|Dietary Supplement|Biotin and silicon|The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
79402652|NCT06010745|Dietary Supplement|Placebo|Inert ingredients only
79575225|NCT01857219|Behavioral|Tai chi|
79575226|NCT01857245|Other|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
79575227|NCT01857284|Drug|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
79575228|NCT01857284|Drug|Ursodeoxycholic Acid Capsules|250mg.tid.po
79575229|NCT01857336|Other|infusion of G-CSF mobilized peripheral harvest|
79575230|NCT01857349|Other|Chlora Prep|Surgical Scrub skin preparation
79575231|NCT01857349|Other|Dura Prep|Surgical Scrub skin preparation
79575232|NCT01857375|Device|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
79575233|NCT01857388|Behavioral|ParentCorps|
79575234|NCT01857401|Other|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
79575235|NCT01857453|Drug|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
79575236|NCT01857453|Drug|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
79575237|NCT01857453|Radiation|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
79869447|NCT04941807|Device|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
80028397|NCT03681613|Other|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
80028398|NCT03681613|Other|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
80028399|NCT02199834|Behavioral|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
80028400|NCT02199834|Behavioral|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
80028401|NCT03690583|Drug|Zinc sulfate|Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
80028402|NCT03690583|Other|Glucose|The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
80028403|NCT03685513|Other|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
79402653|NCT06010537|Drug|polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
79575238|NCT01857466|Procedure|Floseal|
79575239|NCT01857466|Procedure|Bipolar coagulation|
79402654|NCT06010368|Drug|Tranexamic acid injection|In TXA group (n=25): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
79734785|NCT04133389|Other|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
79734786|NCT02787616|Genetic|buccal swab|cheek swab for DNA sampling
79402655|NCT06010368|Drug|Oxytocin|the oxytocin group (n = 25): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
79402656|NCT06010186|Other|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
79402657|NCT06010121|Dietary Supplement|Liposomal Vitamin D|2000 IU of cholecalciferol in liposomal formulation
79575240|NCT01857479|Drug|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
79734787|NCT02787772|Procedure|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
79734788|NCT02616835|Device|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
79734789|NCT02616835|Device|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
79734790|NCT01145885|Drug|BI 6727|PLK-1 inhibitor
79869448|NCT04941807|Device|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
79869449|NCT04941274|Drug|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
80028404|NCT03685513|Other|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
80028405|NCT03685435|Other|Bedside ultrasound|Checking for gastric content using bedside ultrasound
79575241|NCT01857479|Drug|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
79575242|NCT01857492|Device|tDCS|
79575243|NCT01857492|Behavioral|Meditation|Both Active and SHAM groups will receive Meditation.
80028406|NCT03533400|Device|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
79271917|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of [14C]FTD administered as an oral solution on Day 1 (mass balance part)
79271918|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of [14C]TPI administered as an oral solution on Day 1 (mass balance part)
79575244|NCT01857518|Other|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"Visit V1: Diagnostic and clinical assessments~Visit V2: psycho-behavioral assessment and neuroimaging~Visit V3: Diagnostic and clinical assessments~Visit V4: psycho-behavioral assessment and neuroimaging"
79734791|NCT02787538|Behavioral|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
79271919|NCT02031055|Drug|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
79734792|NCT02787538|Behavioral|Control group (Online medication guide)|Standard online medication guide.
79869450|NCT04937504|Behavioral|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
79402658|NCT06010121|Dietary Supplement|Traditional Vitamin D|2000 IU of cholecalciferol in traditional formulation
79734793|NCT02616991|Procedure|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
79734794|NCT02786992|Drug|Misoprostol|
79869451|NCT04937504|Behavioral|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
79869452|NCT04931355|Other|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
79869453|NCT04931355|Other|Western medicine|Western medicine
79271920|NCT02198287|Drug|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
79271921|NCT02198287|Drug|Placebo|
79402659|NCT06010043|Procedure|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
79402660|NCT06010043|Procedure|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
79575245|NCT01857544|Drug|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
79575246|NCT01857557|Other|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
79575247|NCT01857570|Radiation|Volume Computed Tomography of the wrist and carpus|
79575248|NCT01857596|Drug|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
79575249|NCT01857609|Drug|Metformin|
79869454|NCT04924374|Dietary Supplement|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (>30g/day).~anti PD1 therapy every 2-3 weeks"
79869455|NCT04924374|Drug|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
79271922|NCT03534115|Dietary Supplement|NAC|solution containing NAC
79271923|NCT03534115|Dietary Supplement|Placebo|Placebo
79271924|NCT02195557|Drug|Synvisc®|
79271925|NCT02195635|Drug|Telotristat etiprate|500 mg telotristat etiprate
79271926|NCT02195635|Drug|Octreotide acetate|200 µg octreotide acetate three times daily
79305883|NCT04753840|Other|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
79575250|NCT01857609|Drug|Metformin and Pantoprazole|
79575251|NCT01857609|Drug|Metformin and Rabeprazole|
79869456|NCT04918147|Drug|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
79869457|NCT04918147|Drug|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
80028407|NCT03533400|Device|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
79869458|NCT04918147|Drug|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
79869459|NCT04918147|Drug|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
79869460|NCT04918147|Drug|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
80028408|NCT03026257|Device|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
79271927|NCT03534505|Other|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
79271928|NCT03534505|Other|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
79271929|NCT02195791|Drug|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
79271930|NCT02195791|Drug|Placebo|Placebo (oral) 1 tab once daily for 7 days
79575252|NCT01857648|Other|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
79575253|NCT01857661|Device|sound generator|hearing aid with an integrated sound generator
79271931|NCT02196805|Drug|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
79869461|NCT04918147|Drug|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
79271932|NCT02196805|Drug|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
79271933|NCT02196883|Procedure|Transforaminal Epidural Steroid Injection|
79271934|NCT02198443|Drug|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
79734795|NCT02786992|Drug|Oxytocin|
79734796|NCT02786992|Drug|Carbetocin|
79734797|NCT02786992|Drug|Placebo|
80028409|NCT03026257|Device|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
80028410|NCT03026257|Device|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
79271935|NCT02198443|Drug|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
79271936|NCT02201095|Device|Forced air warming|
79271937|NCT02201095|Device|Conduction warming mattress|
79271938|NCT02201173|Behavioral|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
79271939|NCT05262049|Other|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
79575254|NCT01857661|Device|hearing aids with only amplification|
79575255|NCT01857700|Other|Compensation for transport cost|
79575256|NCT01857700|Other|Compensation for lost wages|
79734798|NCT02617303|Procedure|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
80028411|NCT03026257|Device|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
80028412|NCT03026257|Device|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
79575257|NCT01857700|Other|Compensation for transport cost and lost wages|
79575258|NCT01857700|Other|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
79575259|NCT01857726|Drug|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
79575260|NCT01857726|Drug|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
79575261|NCT01857752|Drug|Temozolomide|
79734799|NCT02617303|Procedure|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
79734800|NCT02884193|Procedure|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
79734801|NCT02884193|Procedure|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
79869462|NCT04918147|Drug|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
80028413|NCT03026257|Device|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
79734802|NCT02884193|Procedure|Sham Ice Bag|"Placebo application through an ice bag empty."
79734803|NCT02787460|Behavioral|Behavioral Text Messages|
79575262|NCT01857765|Behavioral|Rehabilitation|Range of motion stretching exercises
79734804|NCT04232644|Drug|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
79734805|NCT04232644|Drug|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
79869463|NCT04914182|Radiation|LASER|Laser will be applied in specific points for perineal lacerations.
80028414|NCT03026257|Device|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
80028415|NCT03026257|Device|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
79869464|NCT04914182|Radiation|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
80028416|NCT02199912|Procedure|Biopsy of adipose and muscular tissue|
79271940|NCT05262049|Other|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~Hot pack /TENS for 10 minutes~Stretching: Hamstring(10x) and calf (10x)~Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
79271941|NCT05262049|Other|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy and intermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
79575263|NCT01857765|Behavioral|Follow-up|Follow-up with surgeon's clinic
79734806|NCT02622529|Other|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
79734807|NCT03557788|Drug|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
79734808|NCT04133155|Drug|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
79271942|NCT03533179|Drug|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
79575264|NCT01857791|Behavioral|multidisciplinary, behavior modification|
79575265|NCT01857804|Drug|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
79575266|NCT01857804|Drug|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
79575267|NCT01857804|Drug|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
79734809|NCT01190267|Drug|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
79734810|NCT02622763|Biological|Tolerogenic Dendritic Cells|Intralesional administration
79734811|NCT02787382|Device|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
79734812|NCT03279874|Other|Interviews|Semi-structured one-on-one interviews
79734813|NCT00869089|Drug|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
79734814|NCT01190189|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
79734815|NCT04232488|Procedure|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
79869465|NCT04912531|Device|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
80028417|NCT02199912|Other|Blood sampling|
80028418|NCT02199912|Other|Calorimetry|
80028419|NCT02199912|Other|Impedance measure|Evaluation of physical composition (non-invasive method)
80028420|NCT02199912|Other|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
80028421|NCT02199912|Other|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
80028422|NCT02199912|Other|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
80028423|NCT02199912|Other|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
80028424|NCT02199912|Other|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
80028425|NCT03681457|Drug|LJN452|Dose A single dose
80028426|NCT02200068|Other|SANOIA Website|
79869466|NCT04912531|Device|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, >97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
80028427|NCT04974502|Procedure|Nonsurgical periodontal treatment|Oral hygiene instructions, scaling and root planning.
79271943|NCT03533179|Drug|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or >25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
79271944|NCT03533179|Drug|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
79271945|NCT03533179|Drug|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
79271946|NCT02198599|Procedure|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
79575268|NCT01857817|Drug|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
79402661|NCT06010030|Device|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
79402662|NCT06010030|Behavioral|Speech Therapy|Participants will receive either semantic or phonological focused speech therapy
79402663|NCT06009640|Device|Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine|Integration of intraoperative neurophysiological monitoring (IONM) into laparoscopic decompression surgery to protect pelvic nerves by continuously monitoring when they are at risk during surgery.
79402664|NCT06009289|Behavioral|Light therapy|One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
79271947|NCT02206321|Procedure|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
79575269|NCT01857817|Drug|Placebo|The placebo capsules will be prepared to match the active drug.
79575270|NCT01857830|Behavioral|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
79575271|NCT01857830|Behavioral|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
79734816|NCT04232488|Procedure|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
79734817|NCT02616367|Drug|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
79734818|NCT02616367|Drug|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
79734819|NCT05347264|Other|gun massager|15 to 20 minutes along with hot pack.
79734820|NCT05347264|Other|transverse friction massage|15 to 20 minutes along with hot pack.
79402665|NCT06009159|Device|Transcutaneous Vagus Nerve Stimulation|30 minutes stimulation, twice per day for 4 weeks
79271948|NCT02206321|Procedure|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
79402666|NCT06008990|Drug|Buprenorphine|Pregnant mother must be taking Buprenorphine
79402667|NCT06008990|Diagnostic Test|Maternal Brain MRI|Maternal Brain MRI obtained between 24-32 week gestation
79402668|NCT06008990|Other|Blood Samples|During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.
79402669|NCT06008990|Behavioral|Questionnaires|Participants will answer questionnaires about their medical history, pregnancy, and substance use.
79734821|NCT04200118|Other|Observational|non intervention
79734822|NCT04200040|Biological|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
79734823|NCT04200040|Drug|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
79734824|NCT00871117|Biological|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
79734825|NCT00871117|Biological|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
79402670|NCT06008002|Procedure|M-TAPA block|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (0.3 ml/kg , %0.25 bupivacaine) will be performed
79734826|NCT00871117|Biological|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
79734827|NCT04232722|Drug|Arsenicals|As4 S4
79734828|NCT02787070|Drug|PQ supervised|
79734829|NCT02787070|Drug|PQ unsupervised|
79402671|NCT06008002|Procedure|EXORA block|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg , %0.25 bupivacaine) will be performed
79271949|NCT02201407|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
79402672|NCT06008002|Drug|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
79402673|NCT06007885|Other|Pathways and Resources to Engagement and Participation (PREP)|Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
79271950|NCT05261971|Drug|Etodolac 400 MG|Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
79575272|NCT01857843|Device|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
79869467|NCT04912531|Device|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
79869468|NCT04905914|Drug|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
79575273|NCT01857843|Device|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
79734830|NCT02622685|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
79869469|NCT04902625|Drug|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
79869470|NCT04888117|Procedure|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
79734831|NCT02622685|Drug|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
79734832|NCT02622685|Drug|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
79734833|NCT02622685|Drug|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
79271951|NCT05261971|Drug|Thiocolchicoside|Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
79734834|NCT02622607|Drug|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
80028428|NCT03690505|Behavioral|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
79271952|NCT02201485|Device|Stent|
79271953|NCT02201485|Device|Balloon|
79271954|NCT02201563|Drug|Minocycline|Oral minocycline (100mg twice a day) for 3 months
79271955|NCT02198677|Procedure|Anterior to posterior pressures|Anterior to posterior pressures
79271956|NCT02198677|Procedure|Lateral glide|Lateral glide
79402674|NCT06007196|Device|non-invasive device (Task Force CORE(R) and Task Force CARDIO(R)|Intraoperative cardiac output will be measured using the non-invasive device (Task Force CORE(R) and Task Force CARDIO(R) and will be compared with the invasive thermodilution method (PiCCO).
79734835|NCT02622841|Procedure|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
79734836|NCT02622451|Behavioral|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
79734837|NCT02622451|Behavioral|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
79734838|NCT02619565|Other|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
79734839|NCT03181750|Behavioral|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
79734840|NCT02616445|Drug|UE2343|"UE2343~10mg, 20, 35mg~twice daily for 9 days"
79271957|NCT02206477|Drug|Dimethyl Sulfoxide|
79271958|NCT02206477|Drug|Saline 0.9%|
79305884|NCT04753840|Behavioral|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
79869471|NCT04888117|Procedure|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
79271959|NCT02201641|Radiation|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
79869472|NCT04885985|Device|DEB catheter|"Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)"
79869473|NCT04884737|Other|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
79734841|NCT02616445|Drug|Placebo|"10mg, 20, 35mg~twice daily for 9 days"
79271960|NCT02201641|Radiation|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
79869474|NCT04892303|Combination Product|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
79869475|NCT04879537|Other|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
79271961|NCT02201641|Device|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
79271962|NCT02201641|Device|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
79575274|NCT01857843|Drug|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~Pravastatin 20mg (mevalotin®, BMS)"
79575275|NCT01857843|Drug|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~Pravastatin 20mg (mevalotin®, BMS)"
79402675|NCT06006312|Diagnostic Test|fecal elastase-1 test|Personal information of the enrolled subjects will be collected and a fecal collection device will be distributed. Fecal elastase-1 levels will be measured after the fecal sample is collected.
79402676|NCT06006312|Diagnostic Test|72-hour fecal fat quantification|Enrolled subjects will eat a standard meal (100g of fat) daily for five consecutive days and collect stool samples for the last 72h. The fat content in the sample will be quantitatively detected and the fat absorption coefficient will be calculated.
79575276|NCT01857856|Drug|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
79575277|NCT01857895|Drug|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
79734842|NCT02616445|Drug|Placebo|"Cross-over study~single dose administered twice (on day 1 and day 8)~study duration 17 days"
79734843|NCT02616445|Drug|UE2343|"Cross-over study~UE2343~single dose administered twice (on day 1 and day 8)~study duration 17 days"
79734844|NCT02616445|Drug|UE2343|"UE2343~twice daily for 3 days~single dose on day 4"
79734845|NCT02622373|Device|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
79734846|NCT02787226|Drug|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
79734847|NCT02787226|Drug|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
79734848|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
79734849|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
79734850|NCT02787148|Behavioral|Cognitive behavioral therapy|
80028429|NCT02200146|Drug|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
79271963|NCT02206555|Drug|emtricitabine/tenofovir disoproxil fumarate|
79271964|NCT02201797|Other|DCE MRI|
79271965|NCT03533647|Other|Observational|none (observational study)
79271966|NCT02198755|Device|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
79271967|NCT02198755|Device|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
79271968|NCT02206633|Device|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
79271969|NCT02206711|Drug|BMS-955176|Single dose of drug on Day 1
79271970|NCT02202187|Drug|GSK2140944|Investigational Study Drug
79271971|NCT02202187|Other|Placebo|Placebo
79271972|NCT02206789|Drug|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
79734851|NCT02616289|Other|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
79869476|NCT04861077|Drug|[18F]FMISO-PET with contrast-enhanced MRI|Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
79869477|NCT04848792|Dietary Supplement|Sulforaphane|Myrosinase-active whole broccoli sprout material
79575278|NCT01857921|Drug|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~Test group:~Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~Control group:~Pravastatin 20mg daily for 12 months after randomization"
79734852|NCT03421756|Drug|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
79734853|NCT03421756|Radiation|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
79734854|NCT03421756|Drug|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
79734855|NCT00870103|Drug|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
79869478|NCT04848792|Dietary Supplement|Placebo capsules|Placebo capsules
79869479|NCT04843306|Behavioral|Biofeedback|Relaxation coaching will be used in this study.
79869480|NCT04843306|Behavioral|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
79869481|NCT04833075|Other|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
79869482|NCT04808206|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
79869483|NCT04805775|Drug|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
79869484|NCT04800744|Other|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
79869485|NCT04800744|Other|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
79869486|NCT04798534|Behavioral|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
79869487|NCT04795817|Device|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
80028430|NCT02200146|Drug|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
80028431|NCT04974190|Device|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
80028432|NCT03690349|Other|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
80028433|NCT02200224|Other|Rapid Testing|
80028434|NCT03685279|Behavioral|Nurtured Heart Approach|Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
79734856|NCT02619487|Other|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
79869488|NCT04758702|Biological|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
80028435|NCT02208492|Drug|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
80028436|NCT02208492|Drug|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
80028437|NCT03685201|Dietary Supplement|Orange Juice1|100% Orange Juice
79575279|NCT01857921|Drug|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~Test group:~Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~Control group:~Pravastatin 20mg daily for 12 months after randomization"
79575280|NCT01857947|Other|AECOPD Mr proADM|
79869489|NCT04758702|Biological|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
79869490|NCT04758702|Device|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
79869491|NCT04755647|Drug|Nitric Oxide-Releasing Solution|Active antimicrobial
79869492|NCT04755647|Drug|Saline solution, hypotonic|Placebo
79869493|NCT04739423|Drug|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
80028438|NCT03685201|Dietary Supplement|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
79271973|NCT02206789|Drug|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
79271974|NCT02202265|Dietary Supplement|Olive oil|30ml a day of olive oil
79869494|NCT04730557|Behavioral|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
80028439|NCT03685201|Dietary Supplement|Raw Orange|Raw Orange
79271975|NCT02202265|Dietary Supplement|Nuts|30g a day of nuts
79271976|NCT02202265|Dietary Supplement|Control diet|Diet based on standard guidelines
79271977|NCT05261737|Procedure|Corticosteroid Injection|Steroid injection effectiveness will be determined by relief of pain scored by patient using Visual Analogue Scale (VAS). Data will be collected during clinic visit and contacting patients in a determined protocol for the following 6 weeks after steroid injection.After approval of the study, data will collected from participants over a period of 6 weeks follow up; the whole study will be conducted over a total of 2 years.Since the study will not conduct any further test to participants and follow up regimen will only state pain related to the specific condition (De Quervain tenosynovitis) and quick-DASH score, it will not result in any anticipated/unanticipated incidental findings, therefore participants will not be recontacted.
79271978|NCT03892369|Other|Ethanol|Ethanol administration
79271979|NCT02206867|Biological|LBAL|Anti-inflammatory agents
79271980|NCT02206867|Biological|Humira|Anti-inflammatory agents
79271981|NCT02202343|Behavioral|school based health and nutrition education|
79271982|NCT03533101|Drug|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
79402677|NCT06006312|Diagnostic Test|blood sample test|The enrolled subjects will undergo oral glucose tolerance test and will be collected blood samples for measurement of plasma glucose, insulin level, C-peptide level, glycosylated hemoglobin and vitamin.
79734857|NCT02619487|Other|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
79734858|NCT03365752|Drug|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
79734859|NCT03365752|Drug|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
79734860|NCT03365752|Drug|General Anesthetics|General anesthetics will be administered intravenously
80028440|NCT01670188|Device|Pneumatic SCD - VenaFlow System (DJO Global)|
80028441|NCT02208570|Other|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
80028442|NCT02208570|Drug|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
79734861|NCT02622217|Behavioral|Sleep deprivation|
79869495|NCT04715438|Biological|mRNA-1273 SARS-CoV-2 vaccine from Moderna|All participants will receive two vaccinations against COVID-19 according to standard of care.
79869496|NCT04704570|Other|Exercise|Spinal stabilization exercise
79869497|NCT04704570|Other|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
80028443|NCT02208570|Other|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
80028444|NCT03685123|Behavioral|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
80028445|NCT03685123|Behavioral|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
80028446|NCT03685123|Behavioral|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
80028447|NCT04982536|Device|VMCore Biopsy System|Prostate Examine
80028448|NCT04982536|Device|Standard of Care Biopsy Needle|Prostate Examine
79402678|NCT06004063|Dietary Supplement|Enteral nutrition (EN)|Given by Nasogastric Tube
79575281|NCT01857960|Behavioral|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
79869498|NCT04699123|Drug|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
79575282|NCT01857999|Drug|Losartan|
79575283|NCT01857999|Drug|Placebo|
79575284|NCT01858025|Radiation|Pencil Beam scanning Radiation|
79575285|NCT01858025|Drug|5-fluorouracil|
79575286|NCT01858025|Drug|Mitomycin-C|
79869499|NCT04699123|Drug|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
79869500|NCT04699123|Drug|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
80028449|NCT02208726|Other|Sucrose pillules|Unmedicated sucrose pillules
80028450|NCT02208726|Other|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
80028451|NCT03690193|Behavioral|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
80028452|NCT02208804|Device|Holmium-166-poly (L-lactic acid) microspheres|
80028453|NCT03684967|Drug|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
80028454|NCT01933048|Drug|FluMist|FluMist Intranasal Vaccine
80028455|NCT02258100|Other|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
80028456|NCT04059367|Drug|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
80028457|NCT04059367|Drug|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
80028458|NCT02208882|Drug|BMS-986120|
79402679|NCT06004063|Other|Standard care parenteral nutrition (PN)|Given by PO or Given by IV (vein)
79402680|NCT06003023|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to participants in both arms.
80028459|NCT02208882|Drug|Placebo|
80028460|NCT02208882|Drug|Midazolam|
79575287|NCT01858038|Device|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
79575288|NCT01858051|Dietary Supplement|Cholecalciferol|
79575289|NCT01858051|Dietary Supplement|Placebo|
79575290|NCT01858064|Drug|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
80028461|NCT04432246|Device|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
80028462|NCT03681301|Other|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
79575291|NCT01858077|Device|ABSORB BVS™|Bioresorbable scaffold
79575292|NCT01858077|Device|XIENCE™|Drug eluting metallic stent
79575293|NCT01858090|Drug|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
79575294|NCT01858090|Drug|Group Fentanyl|
79575295|NCT01858090|Drug|Group sufentanil|
79575296|NCT01858090|Drug|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to <100 mmHg, fluid loading and ephedrine (5 mg) were administered.
79575297|NCT01858090|Drug|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
79575298|NCT01858090|Drug|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
79575299|NCT01858090|Drug|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
79575300|NCT01858090|Drug|Diphenhydramine|for severe pruritus
79575301|NCT01858090|Drug|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
79271983|NCT02751931|Drug|Mirabegron|Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight >=35 kg received mirabegron tablets or body weight <35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became >=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became <35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.
79271984|NCT02561156|Drug|TAK-653 Placebo|TAK-653 placebo-matching tablets.
79271985|NCT02561156|Drug|TAK-653|TAK-653 tablets.
79869501|NCT04698356|Behavioral|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
79869502|NCT04697264|Diagnostic Test|Blood and tissue sample collection from patients with endometrial cancer|Blood and tissue sample collection from patients undergoing surgery for endometrial cancer and blood sample collection only from patients undergoing chemotherapy for endometrial cancer
79271986|NCT02207023|Behavioral|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
79271987|NCT02202421|Behavioral|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
79869503|NCT04696432|Biological|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
79271988|NCT02207101|Dietary Supplement|E-OJ-01 (OXYJUN)|
79271989|NCT02207101|Dietary Supplement|Placebo|
79402681|NCT06003023|Behavioral|Tailored Exercise Prescription|Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
79402682|NCT06003023|Behavioral|Healthy Lifestyle Education|Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
79575302|NCT01858090|Drug|Diclofenac sodium|as additional analgesic among cases in which VAS>3(Postoperatively)
80028463|NCT02208960|Device|Neonatal Kit|"Contents of the neonatal kit:~Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~Sunflower oil emollient (50 mL)~ThermoSpot~Mylar infant sleeve~Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
79869504|NCT04661748|Device|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
79869505|NCT04661501|Device|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
79869506|NCT04661501|Device|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
79869507|NCT04661501|Device|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
79869508|NCT04661501|Device|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
79869509|NCT04652609|Other|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
79869510|NCT04648046|Drug|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
79271990|NCT02198989|Behavioral|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
79271991|NCT05261581|Procedure|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
79271992|NCT05261581|Drug|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
79575303|NCT01858103|Drug|BMN 110|
79575304|NCT01858116|Drug|[68Ga]ABY-025|Intravenous injection followed by PET imaging
80028464|NCT02208960|Behavioral|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~Eye contact and talking to children~Responsive feeding and caregiving~Singing songs, including those with gentle touch"
80028465|NCT04974112|Other|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
79271993|NCT05261581|Behavioral|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
79869511|NCT04648046|Biological|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
79271994|NCT02207179|Device|LumaScan Image Guided Surgery|
79869512|NCT04648046|Biological|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused.
79869513|NCT04648046|Other|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
79869514|NCT04648020|Drug|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
79271995|NCT02199223|Drug|regorafenib + panitumumab|
79271996|NCT02202733|Other|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
79271997|NCT02207335|Drug|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
79869515|NCT04648020|Drug|Placebo Mucoadhesive Buccal Tablet|Placebo
79869516|NCT04637113|Other|This is a non-interventional study|This is a non-interventional study.
79869517|NCT04623398|Drug|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
79869518|NCT04623398|Drug|Placebo|Placebo
79869519|NCT04617756|Drug|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
79271998|NCT02207335|Drug|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
79869520|NCT04615650|Procedure|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
79869521|NCT04615650|Device|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
79869522|NCT04614194|Drug|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
79271999|NCT02202811|Behavioral|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
79272000|NCT03533023|Behavioral|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
79272001|NCT03533023|Behavioral|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
79272002|NCT02561078|Drug|Human regular U-500 insulin (CSII)|Administered SC
79869523|NCT04614194|Drug|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
79869524|NCT04604431|Other|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
79869525|NCT04603313|Other|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
79869526|NCT04602962|Procedure|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
79869527|NCT04594824|Other|No Intervention|no intervention
80028466|NCT02209038|Behavioral|Expanded AD Choice|
80028467|NCT02209038|Behavioral|Expanded Life-sustaining Therapy Choice|
80028468|NCT03681067|Drug|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
80028469|NCT03681067|Drug|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
79272003|NCT02561078|Drug|Human regular U-500 insulin (MDI)|Administered SC
79272004|NCT02202889|Behavioral|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
79272005|NCT04058197|Drug|Deferoxamine Product|Deferoxamine Intradermal Delivery Patch
79272006|NCT04058197|Other|Placebo|Placebo Patch
79272007|NCT02207881|Drug|VDO gel|VDO gel
79272008|NCT02207881|Drug|placebo|matching placebo gel
79272009|NCT03533569|Procedure|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
79272010|NCT02202967|Drug|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
79869528|NCT04593654|Drug|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
80028470|NCT03061708|Drug|AZD2014|mTOR inhibitor
80028471|NCT03680989|Device|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver ~10,000 lux at 22."
79402683|NCT06003023|Behavioral|Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior|Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
79272011|NCT02202967|Drug|Placebo|Placebo contains lactose granules
79869529|NCT04585893|Drug|Rituximab|375 mg/m^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
79869530|NCT04585893|Drug|Etoposide|Subjects with high-risk disease will receive 100 mg/m^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
79869531|NCT04583124|Other|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
79869532|NCT04583124|Other|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
79402684|NCT06001463|Drug|CSMed Dressing|Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
79575305|NCT01858129|Drug|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
79869533|NCT04581603|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 & 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
79575306|NCT01858129|Drug|placebo|
79272012|NCT02203045|Other|Total Knee Arthroplasty|
79272013|NCT04545164|Diagnostic Test|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
79869534|NCT04581603|Behavioral|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
79869535|NCT04573517|Procedure|Amniotomy|Artificial rupture of amniotic membranes
79869536|NCT04573517|Device|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
79869537|NCT04565535|Behavioral|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
79869538|NCT04558346|Drug|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
79272014|NCT04545164|Diagnostic Test|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
79869539|NCT04558346|Drug|Placebo|40ug/kg twice daily by self-injection
79869540|NCT04557436|Drug|PBLTT52CAR19|gene therapy
79869541|NCT04547946|Drug|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
79272015|NCT03532945|Device|Bioactive Glass-Ceramic Spacer|
79272016|NCT03532945|Device|Titanium cage|
79272017|NCT05506514|Other|Water immersion|Comparison of 3 different water temperatures
79272018|NCT05977803|Radiation|MRI with CEST sequence, IVIM and ASL sequence|"Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :~The CEST sequence~The ASL infusion sequence~The IVIM sequence"
79272019|NCT05977777|Diagnostic Test|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
79272020|NCT05977764|Other|Ultrasound|Contrast enhanced ultrasound
79272021|NCT05977712|Other|Questionnaire|The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
79402685|NCT05998369|Behavioral|Empowered Relief for Youth|The Empowered Relief for Youth is a 90-minute class that provides pain science education, as well as cognitive, emotional, and physiologic self-regulation skills for youth with chronic pain. Youth will also develop a personalized plan to use the acquired skills daily. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
79575307|NCT01858142|Behavioral|Parental presence decision tool|
79575308|NCT01858142|Behavioral|Standard preparation|
79575309|NCT01858155|Drug|Melatonin|
79575310|NCT01858181|Biological|ocaratuzumab|
79575311|NCT01858207|Procedure|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
79575312|NCT01858207|Procedure|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
79734862|NCT04133467|Other|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
79734863|NCT02619643|Device|Transcranial Magnetic Stimulation (Magstim)|
79575313|NCT01858207|Drug|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
79575314|NCT01858233|Behavioral|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
80028472|NCT03680989|Device|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver ~500 lux at 22."
79734864|NCT04232410|Diagnostic Test|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
79272022|NCT05977712|Other|Clinical examination|This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
79734865|NCT04232410|Diagnostic Test|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
79575315|NCT01858246|Device|Bonebridge|
79575316|NCT01858246|Device|Bone Anchored Hearing Aid|
79734866|NCT02616133|Other|chart abstraction|abstraction of breast cancer patients with de-identified data
79575317|NCT01858272|Drug|H5.020CMV.PDGF-b and limb compression bandage|
79575318|NCT01858298|Other|Conservative treatment: pulpectomy and composite resin crown|
79734867|NCT02785666|Drug|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
79734868|NCT02785666|Behavioral|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
79734869|NCT01145417|Drug|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
79734870|NCT02622139|Device|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
79869542|NCT04542889|Diagnostic Test|Absolute coronary flow and resistance measurements|Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
79869543|NCT04542889|Diagnostic Test|IMR measurement|IMR measurement by thermodilution using the St Jude pressure guide.
79869544|NCT04535700|Drug|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
79869545|NCT04535700|Other|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
79869546|NCT04531215|Drug|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
79272023|NCT05977712|Other|Accelerometer port|Participants will be wearing an accelerometer for 9 days.
79272024|NCT05977712|Other|Eye examination|Eye fundus photo, OCT and OCT-A exams
79272025|NCT05977647|Drug|Tamsulosin Oral Capsule|Patient will be enrolled in one of study arm through randomization.
79402686|NCT05993000|Other|432 Hertz frequency music|432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
79575319|NCT01858298|Other|Non-conservative treatment: Tooth extraction|
79575320|NCT01858311|Dietary Supplement|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
79575321|NCT01858311|Other|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
79575322|NCT01858324|Other|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
79575323|NCT01858337|Other|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
79575324|NCT01858337|Other|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
79575325|NCT01858337|Other|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
79734871|NCT04232332|Drug|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
79734872|NCT04232332|Drug|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
79734873|NCT04232332|Drug|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
79734874|NCT04135183|Procedure|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
79734875|NCT02785276|Device|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
80028473|NCT03062410|Other|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
79734876|NCT02785276|Drug|Ropivacaine|Commonly used local anaesthetic drug
79869547|NCT04531215|Drug|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
79869548|NCT04515498|Device|CloudCath Monitoring System|The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
79869549|NCT04492020|Drug|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
79869550|NCT04492020|Drug|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
79869551|NCT04491591|Other|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
79869552|NCT04491591|Other|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
79869553|NCT04491591|Other|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
79869554|NCT04479943|Other|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
79869555|NCT04479735|Device|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
79272026|NCT05977608|Behavioral|Telephone Reminiscence Intervention|Participants will receive automatic calls three times a week asking their life experiences and personal memories. They can share as much or as little as they would like. They have up to 10 minutes to record their answer and can end the call at any time by hanging up.They will be able to share the stories online with their families if they want.
79272027|NCT05977569|Other|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
79575326|NCT01858337|Other|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
79734877|NCT02785276|Other|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
79734878|NCT00696553|Other|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
79734879|NCT00696553|Behavioral|Nutrition plus Exercise|Nutrition plus Exercise
79869556|NCT04449328|Device|Computerized Mirror Therapy (CMT)|"Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand."
79869557|NCT04449328|Device|Tendon vibration|Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
79869558|NCT04445597|Other|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
79869559|NCT04439669|Device|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
79869560|NCT04439669|Device|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
79869561|NCT04437225|Dietary Supplement|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
79869562|NCT04437225|Other|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
79869563|NCT04437225|Other|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
79869564|NCT04437225|Other|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
79869565|NCT04429555|Drug|Ibudilast|Ibudilast orally administered, 50 mg twice daily for 7 days.
79869566|NCT04429555|Drug|Placebo|Placebo orally administered, 50 mg twice daily for 7 days.
79734880|NCT04316039|Drug|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
79272028|NCT05977517|Behavioral|Sleep and well-being tracking|This study will track sleep, learning and wellbeing of 500 freshmen under free-living conditions for 20 weeks
79575327|NCT01858350|Other|Active Music Therapy|
79575328|NCT01858350|Other|Passive Music Therapy|
79575329|NCT01858350|Other|Distraction Therapy|
79575330|NCT01858402|Drug|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
79575331|NCT01858402|Drug|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
79575332|NCT01858415|Device|TriPollar|
79575333|NCT01858441|Drug|Abiraterone Acetate|
80028474|NCT02204202|Drug|[18F]FDG|10 millicuries (mCi) of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
80028475|NCT02204202|Drug|[18F]ISO-1|8 mCi of [18F]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
79734881|NCT04316039|Radiation|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
79869567|NCT04419597|Device|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
79869568|NCT04419597|Device|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
79869569|NCT04409444|Diagnostic Test|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
79869570|NCT04409444|Diagnostic Test|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
79869571|NCT04408131|Biological|Blood sample|virological test
80028476|NCT01886794|Drug|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
79869572|NCT04408131|Biological|Blood sample|serological test
80028477|NCT01886794|Drug|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
80028478|NCT02209116|Other|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
80028479|NCT04982380|Drug|Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
79272029|NCT05977491|Diagnostic Test|Health care practitioner is informed of POCT results for CT and NG|Molecular, PCR based near-POCT performed by the research assistant on self -collected urine. The outcome is positive or negative
79272030|NCT05977491|Diagnostic Test|Health care practitioner is informed about POCT result for TV and BV|The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
79575334|NCT01858454|Procedure|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
79575335|NCT01858454|Procedure|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere [Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.].
79869573|NCT04400474|Drug|Cabozantinib 40 mg|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
79869574|NCT04398238|Combination Product|evaluation by transfusion medicine specialist|screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
80028480|NCT04982380|Drug|Siliankang simulating tablets|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
79272031|NCT05977491|Other|Health care practitioner is informed on result for anxiety, depression,domestic violence screening|The research assistant will inform the health care practitioner if screening positive for anxiety, depression or domestic violence.
79272032|NCT05977478|Device|SPECTRA IMDx™|In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
79272033|NCT05977452|Diagnostic Test|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
79575336|NCT01858467|Device|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
79575337|NCT01858467|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
79575338|NCT01858480|Drug|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
79575339|NCT01858480|Other|Placebo|Placebo dosage form designed to mock active.
79575340|NCT01858493|Behavioral|Continence promotion group education workshop|Interactive group education workshop promoting continence
79575341|NCT01858493|Behavioral|Sham health lecture|Interactive group education workshop about general health
79575342|NCT01858506|Procedure|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
79734882|NCT04199416|Device|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
79734883|NCT04199416|Device|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
79869575|NCT04387318|Device|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
80028481|NCT02204358|Procedure|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
79734884|NCT00697645|Device|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
79272034|NCT05977426|Other|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
79272035|NCT05977413|Other|Notification of CAC|Provider and patient are notified of coronary artery calcium present on patient's CT scan. Notification includes a personalized image of CAC from the patient's CT scan performed for lung cancer screening.
79272036|NCT05977413|Other|Usual Care|Patients randomized to Usual Care will receive usual medical care provided by their clinician informed by widely publicized clinical practice guidelines.
79272037|NCT05977400|Drug|Ampicillin|Intravenous Ampicillin
79575343|NCT01858506|Procedure|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
79575344|NCT01858571|Drug|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
79869576|NCT04387318|Device|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
79869577|NCT04387318|Device|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
79734885|NCT00697645|Device|Brainsway Deep TMS|Deep TMS applied over the motor strip
79402687|NCT05993000|Other|TENS|The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
79869578|NCT04387318|Device|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
79869579|NCT04383158|Other|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
79869580|NCT04382911|Drug|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
79869581|NCT04376229|Other|Registry|Registry of cancer patients who receive proton radiation therapy
79869582|NCT04374812|Other|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
79869583|NCT04374812|Other|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
79272038|NCT05977400|Drug|Gentamicin|Intravenous Gentamicin
79272039|NCT05977400|Drug|Placebo|Intravenous Normal Saline
79575345|NCT01858584|Drug|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
79869584|NCT04372238|Behavioral|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
79575346|NCT01858584|Dietary Supplement|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
79869585|NCT04372238|Behavioral|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
79869586|NCT04364386|Device|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
79869587|NCT04362618|Other|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
79869588|NCT04362618|Behavioral|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
79869589|NCT04360564|Other|Recurrent pregnancy loss|As described before.
79869590|NCT04336527|Behavioral|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
79272040|NCT05977374|Other|experimental and conventional group|Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
79575347|NCT01858610|Drug|Irbeasartan/hydrochlorothiazide|
79575348|NCT01858610|Drug|Irbesartan|
79575349|NCT01858610|Drug|Hydrochlorothiazide|
79575350|NCT01858623|Drug|Losartan/hydrochlorothiazide|
79575351|NCT01858623|Drug|Losartan|
79734886|NCT02786680|Behavioral|stroop test in condition DBS off|Patients were evaluated in DBS Off
79869591|NCT04336527|Behavioral|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
80028482|NCT04973644|Device|Remote monitoring devices+Internet management platform|Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
79575352|NCT01858623|Drug|Hydrochlorothiazide|
79575353|NCT01858649|Procedure|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
79575354|NCT01858649|Drug|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
79575355|NCT01858649|Drug|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
79575356|NCT01858649|Drug|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
79575357|NCT01858649|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
79575358|NCT01858662|Procedure|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
79575359|NCT01858662|Drug|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
79575360|NCT01858662|Drug|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
79575361|NCT01858662|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
79575362|NCT01858662|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
79575363|NCT01858662|Drug|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
79575364|NCT01858675|Other|Biomarkers, red blood cells and plasma assessment|
79575365|NCT01858714|Behavioral|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
79575366|NCT01858714|Behavioral|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
79734887|NCT02786680|Behavioral|stroop test in condition DBS on|Patients were evaluated in DBS On
79734888|NCT00697723|Procedure|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
79869592|NCT04327284|Device|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
79869593|NCT04327284|Device|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
79869594|NCT04327115|Procedure|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
79869595|NCT04327115|Procedure|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~High falling risk : out of bed exercise (on a chair for at least 30 min)~Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
79869596|NCT04319627|Drug|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
80028483|NCT02209194|Device|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
80028484|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
80028485|NCT03680833|Procedure|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
80028486|NCT02209350|Procedure|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
79575367|NCT01858714|Behavioral|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
79272041|NCT05977361|Procedure|Resiting Epidural Catheter|After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.
79272042|NCT05977361|Procedure|Intrathecal Catheter Placement|After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
79272043|NCT05977309|Device|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
79272044|NCT05977296|Device|CPAP|To use CPAP
79575368|NCT01858727|Other|forced air warming group|30 minutes before the preoperative will use forced air warming
79272045|NCT05977257|Device|VitaFlow® Transcatheter Aortic Valve Replacement System|This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
79272046|NCT05977244|Other|HGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
79575369|NCT01858727|Other|control group|do not heating group
79575370|NCT01858779|Behavioral|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
79575371|NCT01858779|Device|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
79575372|NCT01858792|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
80028487|NCT02209350|Procedure|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
79734889|NCT01144715|Device|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
79575373|NCT01858792|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
79734890|NCT01144715|Device|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
79734891|NCT00696631|Drug|Dronedarone (SR33589)|oral administration
79869597|NCT04319627|Drug|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
79869598|NCT04308395|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
79734892|NCT00696631|Drug|Placebo|oral administration
79734893|NCT04198324|Procedure|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
79869599|NCT04305613|Other|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
79869600|NCT04305496|Drug|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
79869601|NCT04305496|Drug|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
79869602|NCT04305496|Drug|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
80028488|NCT02209350|Drug|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
79272047|NCT05977244|Other|LGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
79575374|NCT01858792|Other|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
79272048|NCT05977244|Other|HGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
79272049|NCT05977244|Other|LGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
79272050|NCT05977231|Procedure|BT|A program of BT (including exercise and muscle training)
79575375|NCT01858805|Procedure|esophagectomy|
79575376|NCT01858831|Drug|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
79575377|NCT01858831|Drug|Atovaquone|Atovaquone
79734894|NCT04198324|Procedure|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
79734895|NCT02615977|Behavioral|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
79734896|NCT02615977|Behavioral|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
79734897|NCT01189487|Drug|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
79734898|NCT02786602|Genetic|pyrosequencing|
79734899|NCT02621905|Drug|Sporanox|At least 2 capsules twice a day for 3 weeks
79734900|NCT02621905|Drug|Lozanoc|At least 2 capsules twice a day for 3 weeks
79575378|NCT01858844|Other|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
79734901|NCT02785198|Device|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
79869603|NCT04301934|Device|Mona Lisa Touch|Fractional CO2 LASER
79575379|NCT01858870|Drug|lacosamide|routine clinical practice
79869604|NCT04301934|Drug|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
79869605|NCT04301934|Drug|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
79869606|NCT04287192|Other|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
79272051|NCT05977231|Procedure|bPFMT|A bPFMT program at home
79402688|NCT05993000|Other|Mobilization|Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
79869607|NCT04281017|Drug|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
79869608|NCT04281017|Drug|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
80028489|NCT05263128|Other|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
79272052|NCT05977231|Procedure|iVES|An iVES program at home
79272053|NCT05977231|Procedure|BT + bPFMT|Combination of BT and bPFMT
79272054|NCT05977231|Procedure|BT + iVES|Combination of BT and iVES
79272055|NCT05977231|Procedure|bPFMT + iVES|Combination of bPFMT and iVES
79272056|NCT05977218|Other|FoodSwitch|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
79272057|NCT05977205|Other|No interventions, observational study|Not applicable, no interventions, observational study
79402689|NCT05993000|Other|Exercises|The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
79575380|NCT01858909|Drug|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
79575381|NCT01858935|Drug|ND-L02-s0201 Injection|Single IV infusion.
79575382|NCT01858935|Drug|Placebo|Single IV infusion.
79575383|NCT01858961|Drug|BI 201335|Once a day
79575384|NCT01858961|Drug|ribavirin|Twice a day
79575385|NCT01858961|Drug|BI 207127|Twice a day
79575386|NCT01858961|Drug|Telaprevir|Three times a day
79575387|NCT01858961|Drug|ribavirin|Twice a day
79575388|NCT01858961|Drug|Pegylated Interferon|Once a week
79575389|NCT01858987|Procedure|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
79575390|NCT01858987|Procedure|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
79575391|NCT01858987|Device|Ligasure|
79869609|NCT04280003|Other|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
79869610|NCT04280003|Drug|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
79869611|NCT04275791|Other|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
79869612|NCT04267185|Behavioral|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
80028490|NCT02204514|Procedure|Surgery for external snapping hip|
80028491|NCT03680599|Behavioral|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
80028492|NCT03680599|Behavioral|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
79575392|NCT01858987|Other|vascular staple|
79734902|NCT04134247|Drug|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
79734903|NCT04134247|Drug|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
79575393|NCT01859000|Other|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
79734904|NCT04232098|Other|Heat to ankle|Heat administered via hot water to ankle level
79734905|NCT04232098|Other|Heat to calf|Heat administered via hot water to calf level
79734906|NCT01106352|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
79869613|NCT04265768|Procedure|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
79869614|NCT04265768|Procedure|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
79869615|NCT04265768|Procedure|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
79869616|NCT04261036|Drug|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
79869617|NCT04261036|Other|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
79869618|NCT04255407|Device|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
80028493|NCT02209428|Drug|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
80028494|NCT03684733|Diagnostic Test|MRI|Clinical MRI breast screening examination
79575394|NCT01859000|Other|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
79575395|NCT01859039|Biological|Administration of Live attenuated influenza vaccine|
79575396|NCT01859052|Other|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
79575397|NCT01859052|Other|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
80028495|NCT03684577|Behavioral|Hypnotherapy for Agoraphobia|see description of the experimental arm
80028496|NCT03684499|Other|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
79575398|NCT01859052|Other|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
79575399|NCT01859065|Behavioral|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
79575400|NCT01859065|Behavioral|Routine|Routine anticipatory guidance (control)
79734907|NCT01106352|Drug|Docetaxel|Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
79734908|NCT01144403|Drug|Cyclophosphamide|as prescribed, 6 cycles
79734909|NCT01144403|Drug|Fludarabine|as prescribed, 6 cycles
79869619|NCT04255407|Drug|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
79869620|NCT04254861|Procedure|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
79869621|NCT04254861|Procedure|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
79272058|NCT05977166|Device|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
79272059|NCT05977166|Device|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
79402690|NCT05993000|Other|Hotpack|Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
79402691|NCT05992064|Other|Measuring gait|"Measurements are performed by PA trackers. The measurements include:~Lower limb 3D linear accelerations according to gait bouts collected and stored as time-series of linear accelerations with a frequency of 12.5 Hz.~Details on the amount of time spent lying down, sitting, and standing, as well as the number of steps and sit-to-stands completed throughout the day. This information will be stored in 15-minute epochs and then summarized into daily summaries for analysis."
79575401|NCT01859091|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
79402692|NCT05989464|Diagnostic Test|Self-swab for genital HPV|Participants will insert a swab in the vagina to collect a sample for HPV testing.
79402693|NCT05982236|Other|Questionnaire|Questionnaire on WEPI software (secure data), with link sent by e-mail to patients included in the study, including PCOSQOL, HADS, FACT G7 et ASEX scores.
79402694|NCT05982080|Drug|FP002 Injection|Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
79575402|NCT01859104|Behavioral|Use of smartphone app|
79575403|NCT01859117|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
79575404|NCT01859117|Biological|10 x 10^6 cells|10 x 10^6 cells administered on Study Days 1 and 8
79575405|NCT01859117|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
79575406|NCT01859117|Biological|100 x 10^6 cells|100 x 10^6 cells administered on Study Days 1 and 8
79575407|NCT01859169|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
79575408|NCT01859182|Drug|selumetinib|Given PO
79575409|NCT01859182|Drug|Akt inhibitor MK2206|Given PO
79575410|NCT01859182|Other|laboratory biomarker analysis|Correlative studies
79575411|NCT01859182|Other|pharmacogenomic studies|Correlative studies
79575412|NCT01859182|Procedure|quality-of-life assessment|Ancillary studies
79575413|NCT01859234|Drug|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
79575414|NCT01859260|Device|CPAP/autopap|
79575415|NCT01859273|Behavioral|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
79734910|NCT01144403|Drug|Mitoxantrone|as prescribed, 6 cycles
79734911|NCT01144403|Drug|Rituximab|375 mg/m^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
79734912|NCT03071926|Drug|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
79734913|NCT02619331|Procedure|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
79734914|NCT03061552|Diagnostic Test|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
79734915|NCT02883647|Drug|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
79734916|NCT02621827|Other|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
79734917|NCT02615899|Other|Matched: Targeted (specific) balance exercise interventions|
79734918|NCT02615899|Other|Mismatched: Untargeted (non-specific) balance exercise interventions|
80028497|NCT03684499|Other|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.(Bandyopadhyay et al, 2017)
79272060|NCT05977166|Drug|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
79734919|NCT02703922|Other|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
79734920|NCT00625157|Drug|ASF 1096 0.5 % cream|
79869622|NCT04247451|Diagnostic Test|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
79272061|NCT05977153|Procedure|PEEP (positive end-expiratory pressure) - maximum|"Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve."
79402695|NCT05979077|Other|MyChart Questionnaire|Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
79869623|NCT04244929|Procedure|Total knee arthroplasty|Total knee arthroplasty using standard anterior approach.
79869624|NCT04244929|Device|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
79402696|NCT05974449|Drug|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
79869625|NCT04244929|Device|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
79402697|NCT05967637|Other|Whole body vibration|The vibration will be applied for 10 minutes (30 seconds rest, 30 seconds training, 10 reps) in total with a low frequency (20 HZ) and low amplitude (2mm). Participants will be asked to stand in a squatting position by semi-flexing (30°) their knees during the 30-second vibration period.
79869626|NCT04219956|Other|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
79869627|NCT04155190|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
79734921|NCT00625157|Drug|ASF 1096 placebo cream|
79869628|NCT04155190|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
79869629|NCT04129164|Drug|VIB4920|Intravenous Dose 1.
79869630|NCT04129164|Drug|Placebo|Intravenous dose matched to VIB4920.
79869631|NCT04095832|Procedure|Epidural anesthesia|Epidural anesthesia using standardized technique
80028498|NCT02200848|Drug|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
80028499|NCT03684421|Diagnostic Test|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
79734922|NCT01143389|Drug|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
79734923|NCT01143389|Device|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
79734924|NCT00868231|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
79734925|NCT00868231|Drug|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
79869632|NCT04087629|Device|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
80028500|NCT02204670|Other|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
80028501|NCT02204826|Drug|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
80028502|NCT02204826|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
79734926|NCT00868231|Drug|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
79734927|NCT04231864|Biological|Durvalumab|Given intravenously (IV)
79734928|NCT04231864|Drug|Epacadostat|Given orally (PO)
79734929|NCT02786524|Behavioral|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
79734930|NCT02883803|Biological|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
79734931|NCT02883803|Biological|Injection of albumin alone|Injection of albumin alone
79734932|NCT00698347|Device|M2a-Magnum™ Hip System|
79272062|NCT05977153|Procedure|PEEP (positive end-expiratory pressure) - standard|"Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status."
79575416|NCT01859286|Other|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
79575417|NCT01859338|Radiation|cone-beam computed tomography|Undergo CBCT
79575418|NCT01859338|Radiation|magnetic resonance imaging|Undergo MRI
79734933|NCT04130581|Other|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
79734934|NCT02784886|Biological|Women at high risk of MAP|Blood sample
79734935|NCT02614573|Device|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is <2 or >3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is > 4, then verification by venous measure and refer to general practitioner."
79734936|NCT02614495|Drug|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
79575419|NCT01859338|Radiation|computed tomography|Undergo fan beam computed tomography
79734937|NCT01143077|Drug|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
79734938|NCT02786446|Drug|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
79575420|NCT01859351|Drug|WX-037|
79575421|NCT01859351|Drug|WX-554|
79734939|NCT02786446|Drug|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
79869633|NCT04083365|Drug|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
79869634|NCT04083365|Drug|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
79869635|NCT04083365|Drug|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
79869636|NCT04072575|Drug|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
79869637|NCT04072575|Drug|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
80028503|NCT02200926|Other|Loaded breathing training|7 days/weeks, for 8 weeks
80028504|NCT02200926|Other|Unloaded breathing training|7 days/week, for 8 weeks
80028505|NCT02200926|Other|Placebo|7 days/week, for 8 weeks
80028506|NCT03684031|Behavioral|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
79575422|NCT01859377|Drug|V0498 - A mg|Single oromucosal administration
79575423|NCT01859377|Drug|Ibuprofen|Single oral administration
79575424|NCT01859416|Dietary Supplement|Oral nutritional supplement|
79575425|NCT01859429|Other|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
79575426|NCT01859442|Procedure|Structured responsive interval exercise training programme|
79734940|NCT02786446|Drug|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
80028507|NCT03684031|Behavioral|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
80028508|NCT02751450|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
80028509|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
79272065|NCT05977101|Biological|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
79272066|NCT05977101|Other|Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
79272067|NCT05977075|Other|ApisMela protocol|The activities and games proposed by this protocol are offered in a sequence characterized by increasing complexity. The same function is stimulated with varied tasks because the repetitiveness of the same task negatively affects skill generalization. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Language plays a crucial role, participants are encouraged to use speech as a tool for attention regulation and cognitive processing. It's divided into 20 sessions: a weekly group meeting of one hour and thirty.
79402698|NCT05967637|Other|Sham-Whole body vibration|The sham-whole body vibration treatment will follow the same procedures with the vibration machine off.
79402699|NCT05967286|Drug|Alpelisib|Given PO
79402700|NCT05967286|Procedure|Biopsy|Undergo biopsy
79734941|NCT02618941|Biological|AFFITOPE® PD01A|s.c. injection
79869638|NCT04072068|Drug|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
79869639|NCT04071847|Device|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
79869640|NCT04037358|Drug|Radium-223|Radium-223 plus SABR will be within two weeks.
79869641|NCT04037358|Radiation|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
79875925|NCT01023360|Drug|Clopidogrel and proton pump inhibitors|"baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->~1 week washout --> aspirin 100mg PO QD for 1 week"
80028510|NCT03680443|Other|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
79402701|NCT05967286|Procedure|Biospecimen Collection|Undergo collection of blood
79402702|NCT05967286|Procedure|Bone Scan|Undergo bone scans
79402703|NCT05967286|Procedure|Computed Tomography|Undergo CT
79575427|NCT01859442|Other|Sham group|NO intervention in this group, only standard care (no exercise programme)
79575428|NCT01859455|Drug|LGT209 50 mg|Active experimental drug
79734942|NCT02784964|Biological|Elixcyte 8 ml|ADSC 6.4*10^7 cells, allogeneic injection
79402704|NCT05967286|Procedure|Magnetic Resonance Imaging|Undergo MRI
79402705|NCT05967286|Drug|Olaparib|Given PO
79402706|NCT05967286|Procedure|Positron Emission Tomography|Undergo PET
79575429|NCT01859455|Drug|LGT209 300 mg|Active experimental drug
79734943|NCT02784964|Device|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
79734944|NCT02784964|Biological|Elixcyte 4 ml|ADSC 3.2*10^7 cells, allogeneic injection
79734945|NCT02784964|Biological|Elixcyte 2 ml|ADSC 1.6*10^7 cells, allogeneic injection
79734946|NCT02619019|Drug|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
80028511|NCT02204904|Genetic|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
80028512|NCT02209662|Device|APIC-PRP|APIC-PRP
80028513|NCT02209662|Other|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
79869642|NCT04030130|Behavioral|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months).
79869643|NCT04019327|Drug|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
79272068|NCT05977075|Other|"Unstuck and on Target protocol"|The protocol teaches people to be more flexible, skillful in planning and goal-oriented. It is useful for moving more easily from one topic to another and from one task to another, considering new ideas or another person's point of view, generalizing skills learned across contexts so that teachers, parents and therapists can focus more on educational aspects and less on behavioral management. It is divided into 20 sessions: a weekly group meeting of one hour and thirty minutes. A homework sheet is provided for each session to consolidate the skill learned and generalize it outside the work setting. Parents have an active role in performing the task.
79272069|NCT05977062|Other|Self screening|Score ISI (Index de Sévérité de l'Insomnie)
79575430|NCT01859455|Drug|Placebo|Placebo comparator
79575431|NCT01859455|Drug|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
79869644|NCT04019327|Drug|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 & 4 - 100 mg/m2 QD Days 2-8 Level 5 & 6 - 125 mg/m2 QD Days 2-8"
79869645|NCT04014413|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
79869646|NCT03991052|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
79869647|NCT03991052|Device|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
79869648|NCT03985046|Drug|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
79869649|NCT03983369|Device|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
79869650|NCT03983369|Other|Placebo|Placebo
79869651|NCT03973151|Drug|HL-085|HL-085 is one MEK inhibitor.
79869652|NCT03970655|Drug|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1|Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
79869653|NCT03970655|Drug|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2|Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
79869654|NCT03963388|Other|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
79272070|NCT05977062|Other|Phone call|Phone call at the beginning of the program and at the middle and at the end.
79272071|NCT05977062|Other|Online questionnaires|To be completed at week 1, 6, 12 and 24.
79272072|NCT05976997|Drug|Duvelisib, Chidamide|Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
79272073|NCT05976932|Drug|pegylated liposomal doxorubicin|All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
79575432|NCT01859468|Dietary Supplement|Amorphous calcium carbonate|
79575433|NCT01859468|Other|Placebo|
79575434|NCT01859481|Drug|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
79575435|NCT01859481|Drug|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
79734947|NCT02619019|Drug|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
79734948|NCT02619019|Drug|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
79869655|NCT03962868|Procedure|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (<1.5%)
79305885|NCT04903275|Procedure|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
79305886|NCT04903275|Procedure|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
79734949|NCT02615587|Drug|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
79734950|NCT02786368|Behavioral|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
79734951|NCT02786368|Behavioral|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
79734952|NCT02615821|Behavioral|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
80028514|NCT03689881|Device|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
80028515|NCT03689803|Procedure|sleeve gastrectomy|sleeve gastrectomy.
79575436|NCT01859481|Drug|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
79734953|NCT04307160|Procedure|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
79734954|NCT02956798|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
79734955|NCT02947516|Procedure|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
79734956|NCT02947516|Procedure|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
79734957|NCT01096446|Drug|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
79272074|NCT05976906|Biological|Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)|"Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results."
79272075|NCT05976893|Drug|Evolocumab|Evolocuma:420 mg every 4 weeks
79734958|NCT00864721|Drug|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
79869656|NCT03962868|Procedure|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
79869657|NCT03952351|Radiation|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
79734959|NCT05308420|Procedure|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
79272076|NCT05976893|Drug|Statin|The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
79272077|NCT05976802|Drug|High dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
79272078|NCT05976802|Drug|Low dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
79272079|NCT05976802|Drug|Matching placebo rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
79305887|NCT03055299|Other|COMEX intervention|Comprehensive Exercise
79734960|NCT05308420|Procedure|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
79734961|NCT05308420|Drug|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
79869658|NCT03949920|Drug|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
79875926|NCT01023438|Other|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
80028516|NCT03689803|Procedure|gastric bypass|gastric bypass
80028517|NCT02209740|Other|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
80028518|NCT02220582|Other|MRI|Magnetic Resonance Imaging
80028519|NCT02205138|Drug|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
80028520|NCT02257788|Biological|PRO 140|Humanized monoclonal antibody to CCR5
80028521|NCT02220660|Drug|BI 1744 CL|
80028522|NCT02220660|Drug|BI 54903 XX|
79734962|NCT05308420|Procedure|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
79869659|NCT03944538|Behavioral|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
79869660|NCT03944538|Behavioral|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
79869661|NCT03927066|Other|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
79869662|NCT03916627|Drug|cemiplimab|Administered intravenous (IV)
79869663|NCT03916627|Drug|Platinum Doublet|Administered intravenous (IV)
80028523|NCT02220660|Drug|BI 1744 CL + BI 54903 XX FDC|
80028524|NCT02220660|Drug|Placebo|
79272080|NCT05976789|Device|Sound therapy using low-level background sound|"This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief."
79272081|NCT05976789|Behavioral|Remote counseling using HAT-Online|This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
79869664|NCT03916627|Drug|fianlimab|Administered IV
79869665|NCT03912064|Drug|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
79272082|NCT05976789|Other|Sound therapy using successive approximations|This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
79272083|NCT05976776|Behavioral|The Childbirth and Parenthood Preparation Education|"The Childbirth and Parenthood Preparation Education program will be applied to the experimental group for a period of 1 month (each week, once a week in total four sessions)."
79272084|NCT05976737|Drug|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
79402707|NCT05962385|Device|Brain state while receiving TMS|Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
79402708|NCT05935774|Biological|Atezolizumab|Given IV
79402709|NCT05935774|Procedure|Biopsy|Undergo biopsy
79869666|NCT03912064|Biological|CD25hi Treg depleted DLI|Donor lymphocyte product
79869667|NCT03911869|Drug|encorafenib|taken orally
79869668|NCT03911869|Drug|binimetinib|taken orally
80028525|NCT02209818|Radiation|Laser Irradiation One dose|
79272085|NCT05976737|Drug|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
79272086|NCT05976672|Other|PRSS (Peer Recovery Support Specialist)|Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
79402710|NCT05935774|Procedure|Biospecimen Collection|Undergo blood sample collection
79402711|NCT05935774|Procedure|Computed Tomography|Undergo CT
79402712|NCT05935774|Other|Electronic Health Record Review|Ancillary studies
79402713|NCT05935774|Procedure|Magnetic Resonance Imaging|Undergo MRI
79402714|NCT05935774|Drug|Trabedersen (OT-101)|Given IV
79402715|NCT05926440|Biological|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
79734963|NCT05308420|Drug|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
79734964|NCT02615665|Procedure|Hepatic resection|Removal of a part of the liver during surgery
79869669|NCT03911453|Drug|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
79869670|NCT03897088|Drug|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
79869671|NCT03897088|Drug|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
79869672|NCT03896464|Procedure|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
79869673|NCT03896464|Procedure|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
79875927|NCT01023438|Other|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
79875928|NCT00442416|Drug|Epoetin alfa|As prescribed, SC
79875929|NCT00442416|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
80028526|NCT02209818|Radiation|Laser Irradiation Two doses|
80028527|NCT02257944|Behavioral|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
80028528|NCT02257944|Other|Treatment as Usual|treatment as usual
80028529|NCT02220738|Drug|ABT-957|ABT-957 administered twice-daily for 7 days
80028530|NCT02220738|Other|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
79869674|NCT03873272|Device|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
79869675|NCT03873272|Device|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
79869676|NCT03873272|Device|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
79869677|NCT03865290|Drug|Ondansetron 8mg|Oral Ondansetron 8 mg
79869678|NCT03865290|Drug|Placebo|Oral matched placebo
79869679|NCT03843242|Device|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
79875930|NCT01023594|Procedure|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
80028531|NCT03689725|Other|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
80028532|NCT04981990|Procedure|Single lung ventilation by double lumen endotracheal tube|Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
80028533|NCT04981990|Procedure|Two lung ventilation by conventional single lumen endotracheal tube|Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
79272087|NCT05976659|Device|Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)|Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
79402716|NCT05926440|Biological|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
79734965|NCT02897050|Drug|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
80028534|NCT02205216|Device|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
79272088|NCT05976568|Drug|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
79272089|NCT05976568|Drug|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
79272090|NCT05976568|Drug|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
79402717|NCT05912400|Diagnostic Test|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
79402718|NCT05912400|Other|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
79575437|NCT01859520|Procedure|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
79734966|NCT02897050|Drug|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
79734967|NCT02897050|Drug|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
79734968|NCT02897050|Drug|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
79272091|NCT05976568|Drug|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
79734969|NCT02897050|Drug|Epirubicin|Epirubicin 100mg/m2, iv, d1
79734970|NCT02897050|Drug|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
79272092|NCT05976568|Drug|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
79734971|NCT02619097|Drug|Pegol-sihematide injection|single dose
79734972|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
79734973|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
79734974|NCT01095666|Drug|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
79734975|NCT01095666|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
79734976|NCT01095666|Drug|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
79869680|NCT03843242|Device|Pacemaker with VpS® algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
79869681|NCT03843242|Device|Pacemaker with IRSplus algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
79869682|NCT03840291|Drug|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
79869683|NCT03837626|Drug|Placebo - Cap|6 months of 1 pill a day
79869684|NCT03837626|Drug|Amiloride Pill|Max dose of 5 mg a day for 6 months
79869685|NCT03787966|Other|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
79869686|NCT03787966|Other|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
79869687|NCT03781219|Drug|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
79869688|NCT03781219|Drug|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
79869689|NCT03773237|Dietary Supplement|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
79869690|NCT03773237|Dietary Supplement|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
79869691|NCT03731715|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
79869692|NCT03700684|Behavioral|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
79869693|NCT03700684|Device|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
79869694|NCT03700684|Behavioral|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
79575438|NCT01859533|Device|Neopuff|"Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
79575439|NCT01859546|Behavioral|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
79272093|NCT05976516|Diagnostic Test|CXCL2/CXCL8|Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
79272094|NCT05976503|Drug|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
79575440|NCT01859559|Procedure|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
79734977|NCT04132765|Other|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
79734978|NCT04132765|Other|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
79869695|NCT03694808|Drug|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
79869696|NCT03694808|Drug|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
79869697|NCT03691792|Behavioral|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
79272095|NCT05976503|Drug|Placebo|Placebo
79272096|NCT05976503|Other|Alcohol|0.5 g/kg alcohol
79272097|NCT05976438|Drug|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
79575441|NCT01859559|Procedure|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
79575442|NCT01859585|Drug|Parecoxib|Parecoxib 40 mg intravenous
79575443|NCT01859585|Drug|Ketorolac|Ketorolac 30 mg intravenous
79575444|NCT01859624|Drug|Albuterol|Albuterol 4 mg
79869698|NCT03691792|Other|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
79575445|NCT01859650|Other|MR and CT imaging|
79575446|NCT01859689|Radiation|brachytherapy|Undergo image-guided HDR brachytherapy
79575447|NCT01859689|Radiation|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
79869699|NCT03690206|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
79869700|NCT03690206|Drug|Placebo|Placebo for glepaglutide
79869701|NCT03659539|Drug|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
79869702|NCT03659539|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
79869703|NCT03659136|Drug|Xentuzumab|Intravenous infusion
79869704|NCT03659136|Drug|Placebo|Intravenous infusion
79869705|NCT03659136|Drug|Everolimus|Tablet
79869706|NCT03659136|Drug|Exemestane|Tablet
79869707|NCT03629418|Drug|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
79875931|NCT00441792|Drug|Etomidate|Etomidate at induction dose based on weight
79734979|NCT04132765|Other|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
79734980|NCT04132765|Other|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
79575448|NCT01859689|Other|laboratory biomarker analysis|Correlative studies
79869708|NCT03629418|Drug|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
79869709|NCT03615469|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
79869710|NCT03615469|Device|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
79869711|NCT03607474|Other|Questionnaires of life quality for patients|"the WhoQoL~a specific scale of Cushing's syndrome~The Beck II scale~HAD scale~Rosenberg questionnaire~Stunkard, Sorensen and Schlusinger (1983) figurines~Brief Cope scale"
79869712|NCT03607474|Other|Questionnaires of life quality for caregivers|"the WhoQoL~The Beck II scale~HAD scale"
80028535|NCT02205216|Device|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
80028536|NCT02205216|Behavioral|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~cognitive training: attentional strategies (mental counting, mental obstacle)~transfer training: everyday activities~motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
79575449|NCT01859728|Drug|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
79734981|NCT04132765|Other|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
79734982|NCT04132765|Other|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
79734983|NCT04132765|Other|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
79734984|NCT04132765|Other|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
79734985|NCT04132765|Other|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
79869713|NCT03606213|Biological|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
79869714|NCT03606213|Biological|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
80028537|NCT03683953|Other|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
80028538|NCT03683953|Drug|0.9% sodium chloride|0.9% sodium chloride in control group
79575450|NCT01859728|Drug|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
79575451|NCT01859728|Drug|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
79575452|NCT01859728|Drug|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
79575453|NCT01859754|Biological|Octagam 5%|Intravenous immunoglobulin 5%
79575454|NCT01859754|Biological|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
80028539|NCT03061396|Other|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
80028540|NCT03061396|Other|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
80028541|NCT02209896|Device|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
80028542|NCT05262894|Other|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
80028543|NCT03689647|Device|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
80028544|NCT04973722|Drug|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
80028545|NCT04973722|Drug|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
79575455|NCT01859767|Drug|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
79575456|NCT01859780|Other|Visual distractor|
79869715|NCT03606213|Biological|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
79869716|NCT03606213|Device|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
79869717|NCT03603002|Diagnostic Test|Post-SABR Biopsy|Post-SABR Biopsy
79869718|NCT03596476|Procedure|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
79272098|NCT05976438|Drug|Chlortalidone|Chlortalidone 25mg will be one of the study drugs the patients will receive.
79869719|NCT03596476|Procedure|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
79869720|NCT03596476|Procedure|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
79869721|NCT03596476|Procedure|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
79869722|NCT03586739|Procedure|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
79869723|NCT03586739|Procedure|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
79869724|NCT03586739|Device|Duplex-scan|a Duplex-scan will be performed during patient follow up.
79869725|NCT03586739|Device|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
79869726|NCT03586739|Device|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
79869727|NCT03586739|Other|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
80028546|NCT03284034|Device|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
80028547|NCT03284034|Drug|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
80028548|NCT01358175|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
79575457|NCT01859806|Procedure|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
79575458|NCT01859806|Procedure|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
79575459|NCT01859832|Other|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
79869728|NCT03556501|Diagnostic Test|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
79875932|NCT00441792|Drug|midazolam|Midazolam at induction dose based on weight
80028549|NCT01358175|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
80028550|NCT01358175|Drug|Placebo|Placebo
79869729|NCT03555669|Other|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
79402719|NCT05908461|Behavioral|Early Childhood Friendship Project|Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
79575460|NCT01859845|Other|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
79575461|NCT01859871|Behavioral|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
79734986|NCT04132765|Other|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
79734987|NCT04132765|Other|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
79734988|NCT04132765|Other|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
79734989|NCT04231474|Device|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
79869730|NCT03553212|Radiation|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
80028551|NCT03689569|Dietary Supplement|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
80028552|NCT03689569|Behavioral|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
80028553|NCT03689569|Behavioral|Starch|Patients will be given 30 grams of corn starch
80028554|NCT03683797|Other|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
80028555|NCT02209974|Drug|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
80028556|NCT02209974|Drug|Inhaled Placebo|
80028557|NCT03689413|Drug|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
79272099|NCT05976425|Device|ModPG3 Investigational Device|"Connex Vital Sign Monitor with ModPG3~Laptop~Data Collection Software~USB cable~Power strip~Welch Allyn FlexiPort Disposable Blood Pressure Cuffs"
79272100|NCT05976425|Device|Invasive Reference Equipment|"Surveyor S12/S19~Hill-Rom ICU Medical data collection cable DIR 60119852~Hill-Rom Edwards data collection cable DIR 60119853"
79272101|NCT05976386|Drug|Dupilumab (SAR231893)|Injection solution Subcutaneous
79272102|NCT05976373|Drug|Dupilumab (SAR231893)|injection solution subcutaneous
79272103|NCT05976360|Drug|Dupilumab (SAR231893)|Injection solution, subcutaneous
79272104|NCT05976360|Drug|Dupilumab (SAR231893)|Injection solution, subcutaneous.
79402720|NCT05904561|Radiation|low level laser therapy|"comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest"
79402721|NCT05896917|Device|3D Printed Foot Orthosis|3D printed foot orthoses designed and fabricated at the Taibah University
79402722|NCT05896917|Device|Prefabricated Foot Orthosis|Generic foot orthoses available commercially
79402723|NCT05878821|Device|Shockwave|Shockwave therapy session once a week for month 1000shock per session
79734990|NCT02615431|Other|MitraClip Intervention|
79734991|NCT05338840|Other|MULLIGAN ROTATIONAL MOVEMENT|12 sessions over 6 weeks
79734992|NCT05338840|Other|Medial gapping technique|12 sessions over 6 weeks
79734993|NCT02618863|Device|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
79869731|NCT03514108|Drug|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
79869732|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 3 daily
80028558|NCT02220816|Behavioral|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
80028559|NCT02220816|Behavioral|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
80028560|NCT03683641|Device|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
79869733|NCT03514108|Drug|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
79869734|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
79869735|NCT03482791|Radiation|Proton beam therapy|"The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~The Mevion S-250 Proton Radiation Beam Therapy System will be used."
79869736|NCT03482791|Other|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
79869737|NCT03479541|Behavioral|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
79869738|NCT03469362|Procedure|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
79869739|NCT03469362|Procedure|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
79272105|NCT05976282|Other|Fecal Immunochemical Test|The Fecal Immunochemical Test (FIT) is self-administered one-time for participants, per standard of care. This allows participants to obtain their own stool specimens from bowel movements without having a regular colorectal screening procedure in the doctor's office. Participants will use the FIT at the time of their next bowel movement and return their specimens to the laboratory by mail on the same or next day.
79272106|NCT05976282|Other|Septin9 Test|Septin9 (SEPT9) is a blood-based test that will be offered to eligible participants one-time who refused the FIT. Participants will undergo a blood draw collected by a nurse or certified phlebotomist, 90 days after their refusal of the initial offer of FIT.
79272107|NCT05976269|Procedure|Dry needling|Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
79402724|NCT05873478|Other|High Intensity Interval Training|The HIIT sessions ranging from 4-12 minutes in duration for 8 weeks in which three sessions will be conducted each week (weeks 1-3: 4 minutes; weeks 4-6: 8 minutes; weeks 7-8: 12 minutes respectively), with a work to rest ratio of 30sec: 10sec, as mention in table 1. Experimental group/HIT group engaged in their HIIT sessions (inclusive of a short warm-up activity including dynamic exercises i.e., walking/running, 8-10 minutes of HIIT and cool down which include static exercises i.e., shoulder and hip muscle stretches). Session duration and intensity are increased with weekly progression in intervention groups. The high resistance training sessions was be delivered by the researcher to HIT group
79402725|NCT05869162|Drug|SY-3505|A Third-generation ALK TKI
79402726|NCT05853640|Other|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
79575462|NCT01859884|Behavioral|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
79575463|NCT01859910|Procedure|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
79575464|NCT01859910|Procedure|routine preparation for cataract|
79734994|NCT05302180|Other|Pain neuroscience education|"The online pain neuroscience education program will be based on the model proposed by the Pain Research Group, available in http://pesquisaemdor.com.br, which presents the Path of Recovery. In our program we will hold 10 meetings: (1) conversation with the group, (2) acceptance and pain education, (3) continuation about pain education, (4) sleep hygiene, (5) pharmacological assistance, (6) recognizing stress and negative emotions, (7) increasing positive coping in lifestyle, (8) exercises, (9) communication, and (10) prevention of recurrence. The program will be offered by synchronous meetings; asynchronous (videos) and e-book."
79734995|NCT05302180|Other|Usual care|All participants will receive usual care in one of the five physiotherapy clinics accredited to SUS, according to availability of scheduling in the services. The usual care consists of 10 sessions of physical therapy, that is mainly composed by kinesiotherapy and electrothermophototherapy.
79734996|NCT01100658|Drug|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
79869740|NCT03469362|Device|Da Vinci Robot|Da Vinci Robotic Surgical System
79734997|NCT01100658|Drug|Placebo|1 capsule per day for 1 week.
79869741|NCT03419325|Genetic|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
80028561|NCT03683641|Device|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
80028562|NCT05262816|Other|electroacupuncture|electroacupuncture at Sanyinjiao (SP6)
79272108|NCT05976256|Other|Kinesio taping|Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
80028563|NCT03680209|Other|Simulation|pre-training observation training post training observation
79272109|NCT05976256|Other|sham tape (leukotape classic)|leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
79575465|NCT01859936|Device|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
79272110|NCT05976256|Other|standard treatment|standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
79272111|NCT05976191|Behavioral|Patients whose blood glucose is measured intravenously and from the fingertip|A satisfaction survey will be conducted after these patients have previously examined their blood glucose via intravenous route, then fingertip blood glucose will be measured and a satisfaction survey will be applied.
80028564|NCT02207049|Behavioral|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
79272112|NCT05976152|Drug|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months."
79305888|NCT04917003|Other|RIC plus EDAS|Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.
79575466|NCT01860014|Drug|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
79575467|NCT01860014|Drug|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
79734998|NCT02618785|Procedure|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
79869742|NCT03419325|Diagnostic Test|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
79869743|NCT03418792|Other|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head & neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
79575468|NCT01860053|Behavioral|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
80028565|NCT02207049|Behavioral|No Snacking|Caloric needs will be provided to preschoolers within three meals
80028566|NCT02205372|Drug|MT-3995|
80028567|NCT02205372|Drug|Placebo|
80028568|NCT02678793|Drug|CNTX-4975|
80028569|NCT02210442|Behavioral|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
80028570|NCT02210442|Other|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
79575469|NCT01860066|Drug|QVA149|QVA149 via inhaler twice a day
79575470|NCT01860066|Drug|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
79575471|NCT01860105|Drug|MDCO-157|intravenous administration
79575472|NCT01860105|Drug|PLAVIX|oral administration
79734999|NCT02618707|Other|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
80028571|NCT04116229|Procedure|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
80028572|NCT04116229|Behavioral|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
80028573|NCT04116229|Procedure|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
80028574|NCT02210832|Behavioral|Best practices|
80028575|NCT02210832|Behavioral|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
79869744|NCT03411408|Device|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
79272113|NCT05976152|Drug|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 6 months."
79869745|NCT03411408|Radiation|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
79869746|NCT03406741|Behavioral|psychometric evaluation|Wechsler type composite scales (WISC)
79869747|NCT03406741|Behavioral|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
79869748|NCT03390036|Combination Product|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
79869749|NCT03390036|Device|Monovisc|Hyaluronic Acid
79305889|NCT04917003|Other|EDAS|Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
79575473|NCT01860131|Behavioral|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
79575474|NCT01860144|Drug|Bevacizumab|
79575475|NCT01860157|Device|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
79575476|NCT01860157|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
79575477|NCT01860183|Drug|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
79575478|NCT01860196|Drug|Meditoxin|
79869750|NCT03390036|Drug|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
80028576|NCT04981600|Device|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
79575479|NCT01860196|Drug|Normal saline|
79575480|NCT01860209|Procedure|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
79575481|NCT01860222|Procedure|SR|
79575482|NCT01860222|Procedure|PLAT|
79869751|NCT03389685|Biological|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
79869752|NCT03389685|Other|Saline Placebo|saline solution
79869753|NCT03386383|Behavioral|Intervention|Individual session, physical activity tracker, online intervention
79869754|NCT03385798|Procedure|Endowrist|Anastomosis made by Endowrist
79869755|NCT03385798|Procedure|Endo-GIA|Anastomosis made by Endo-GIA
79869756|NCT03379506|Drug|EBR/GZR FDC Tablet|Participants who are 12 to <18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
79869757|NCT03379506|Drug|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
79869758|NCT03379506|Drug|Grazoprevir Oral Granules|Participants 3 to <12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
79575483|NCT01860235|Drug|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
79575484|NCT01860235|Drug|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
79575485|NCT01860235|Drug|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
79869759|NCT03379506|Drug|Elbasvir Oral Granules|Participants 3 to <12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
79869760|NCT03377517|Radiation|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
79869761|NCT03375788|Drug|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
79869762|NCT03375788|Drug|Identical Placebo|Placebo injection daily
79575486|NCT01860235|Drug|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
80028577|NCT04981600|Device|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
79575487|NCT01860248|Drug|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
79575488|NCT01860248|Drug|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
79575489|NCT01860274|Device|External Mesh for vein grafts|
79869763|NCT03368079|Device|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
79869764|NCT03360539|Behavioral|Nurse-Family Partnership|
79869765|NCT03341949|Biological|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
79869766|NCT03341936|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
79869767|NCT03341936|Drug|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
79869768|NCT03328702|Device|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
79869769|NCT03311412|Drug|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
79869770|NCT03311412|Drug|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
79869771|NCT03311412|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
80028578|NCT02212392|Drug|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
80028579|NCT02833077|Device|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.
79272114|NCT05976126|Other|Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements|Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
79575490|NCT01860300|Drug|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
79575491|NCT01860300|Drug|placebo|
79575492|NCT01860313|Behavioral|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
79869772|NCT03310528|Behavioral|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
79869773|NCT03310528|Procedure|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
79869774|NCT03306446|Drug|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
79869775|NCT03292133|Drug|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
79869776|NCT03292133|Drug|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
80028580|NCT03679897|Drug|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
79575493|NCT01860313|Behavioral|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
79575494|NCT01860326|Drug|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
79575495|NCT01860352|Dietary Supplement|Fish OIl|
79575496|NCT01860378|Other|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
79575497|NCT01860378|Other|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
79869777|NCT03289728|Other|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with < moderate ischemia will receive medical treatment only (MT)."
79869778|NCT03289728|Procedure|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
80028581|NCT03679897|Drug|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
80028582|NCT03060070|Drug|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
80028583|NCT03060070|Drug|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
79869779|NCT03284203|Device|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
79869780|NCT03275740|Drug|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
79575498|NCT01860391|Device|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
80028584|NCT03060070|Drug|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
80028585|NCT02212470|Device|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
80028586|NCT02212470|Device|Nitinol stenting|Nitinol stent deployment
79272115|NCT05976113|Other|Observation only|Just obsrevation following standard of care (including surgery, chemotherapy and radiation when appropriate)
79735000|NCT05276908|Procedure|Thoracolumbar interfascial plane block (TLIP)Technique|A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
79869781|NCT03275740|Drug|Placebo intravenous healthy participant|Placebo comparator
79575499|NCT01860417|Biological|Allogenic Mesenchymal Stromal Cells|
79575500|NCT01860417|Drug|Mepivacaine|
79575501|NCT01860443|Other|Telepsychiatry collaborative program|"The intervention includes:~Online training for the health staff~Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~Online supervision in a web platform by specialists~Telephone monitoring"
79575502|NCT01860443|Other|Usual care|"Online training for the health staff~Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
79869782|NCT03275740|Drug|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
79869783|NCT03275740|Drug|Placebo subcutaneous healthy participant|placebo comparator
79869784|NCT03275740|Drug|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
79272116|NCT05976100|Drug|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally|Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
79272117|NCT05976100|Drug|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
79272118|NCT05976100|Drug|NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)|Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
79869785|NCT03275415|Drug|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
79869786|NCT03275415|Drug|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
79875933|NCT00312208|Drug|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
80028587|NCT03683563|Other|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
80028588|NCT03683563|Other|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
80028589|NCT03563625|Procedure|Caudal block|Caudal block/bupivacaine 0.25%
79272119|NCT05976100|Drug|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days|Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
79272120|NCT05976100|Drug|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
79575503|NCT01860469|Procedure|vancomycin-soaked mesh|
79575504|NCT01860469|Procedure|plain mesh|
79575505|NCT01860482|Drug|Newrabell® Tablet 10mg|
79575506|NCT01860495|Procedure|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
79575507|NCT01860495|Procedure|G2|tradetional occlusive collagen membrane
79575508|NCT01860508|Drug|pemetrexed /carboplatin|
79575509|NCT01860547|Dietary Supplement|Bilberries|Frozen bilberries, 100 g/d
79575510|NCT01860547|Dietary Supplement|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
79575511|NCT01860547|Dietary Supplement|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
79575512|NCT01860547|Dietary Supplement|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
79575513|NCT01860599|Behavioral|Exercise|150 minutes of moderate exercise per week
79575514|NCT01860599|Behavioral|Without exercise|Pre-study activity level (i.e. no exercise)
79575515|NCT01860625|Drug|Donepezil patch|
79575516|NCT01860625|Drug|placebo|
80028590|NCT03563625|Procedure|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
80028591|NCT03563625|Drug|Bupivacaine|bupivacaine
79735001|NCT05276908|Procedure|Anesthetic Management|"Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position."
79735002|NCT05276908|Drug|Bupivacaine Injection 10ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
79735003|NCT05276908|Drug|Bupivacaine Injection 20ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
79869787|NCT03269227|Radiation|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
79869788|NCT03233724|Drug|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
79869789|NCT03233724|Drug|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
79869790|NCT03233724|Drug|Pembrolizumab|200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
79869791|NCT03230734|Drug|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
79869792|NCT03230734|Drug|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
79869793|NCT03229408|Drug|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
79869794|NCT03229408|Other|Placebo|Appears identical to experimental drug
79869795|NCT03223922|Radiation|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
79869796|NCT03209050|Device|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
79869797|NCT03183570|Drug|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) [18F]FP-R01-MG-F2 will be administered
79869798|NCT03176420|Procedure|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
79875934|NCT00312208|Drug|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
80028592|NCT04973488|Other|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
79272121|NCT05976100|Drug|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
79272122|NCT05976087|Device|SensoExo|combination of sensory feedback and the use of soft exoskeleton
79575517|NCT01860638|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
80028593|NCT02213016|Device|Transcranial Magnetic Stimulation|
79575518|NCT01860638|Drug|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m^2 PO Q6W, with a cap of 200 mg per dose.
79575519|NCT01860638|Drug|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
79735004|NCT02785978|Drug|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
80028594|NCT02213016|Device|Sham Transcranial Magnetic Stimulation|
80028595|NCT03683485|Procedure|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
80028596|NCT03683485|Procedure|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
80028597|NCT04973878|Procedure|EGD first|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
80028598|NCT04973878|Procedure|Colonoscopy first|In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
80028599|NCT02258178|Biological|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
79305890|NCT04902963|Device|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
79735005|NCT02785978|Other|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
79735006|NCT02785978|Other|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
79735007|NCT02785978|Device|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
79869799|NCT03157713|Behavioral|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
79869800|NCT03157713|Behavioral|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
79869801|NCT03157713|Behavioral|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to <2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to <5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to <5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
80028600|NCT01355679|Device|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
79575520|NCT01860638|Radiation|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
79575521|NCT01860638|Drug|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m^2 per day for the first 5 days of Cycle 1, then 200 mg/m^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
79869802|NCT03146962|Drug|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
79869803|NCT03125564|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
80028601|NCT03062566|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
80028602|NCT02220972|Drug|Perampanel|
80028603|NCT02220972|Drug|Placebo|
79575522|NCT01860638|Drug|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
79575523|NCT01860664|Drug|hydrocortisone ophthalmic ointment 0.5%|"Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~Study medication dosing details:~0.05 grams hydrocortisone per gram of combination product~each application equal to 1/20th of a gram~total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
79735008|NCT02785978|Other|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
79575524|NCT01860664|Drug|placebo|Mineral oil and white petrolatum
79575525|NCT01860690|Drug|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
79575526|NCT01860716|Drug|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
79575527|NCT01860716|Drug|Placebo|
79575528|NCT01860729|Drug|Anacetrapib|
79575529|NCT01860729|Drug|Placebo|
79575530|NCT01860742|Drug|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
79735009|NCT02786056|Other|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
79735010|NCT02786212|Drug|Dexmedetomidine|
79735011|NCT02786212|Drug|Normal Saline|
79735012|NCT05273710|Other|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
79735013|NCT05273710|Other|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
79575531|NCT01860742|Drug|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
79869804|NCT03125564|Procedure|Sham|Infusion of sham
79869805|NCT03125564|Procedure|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
79869806|NCT03085810|Drug|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
79869807|NCT03078452|Device|Power drill|Undergo bone marrow biopsy using power drill
80028604|NCT02205606|Drug|HGP0816 5mg|P.O.
80028605|NCT02205606|Drug|HGP0816 10mg|P.O.
80028606|NCT02205606|Drug|HGP0816 20mg|P.O.
80028607|NCT02205606|Drug|HCP1306 5/10mg|P.O.
80028608|NCT02205606|Drug|HCP1306 10/10mg|P.O.
79575532|NCT01860755|Other|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
79575533|NCT01860755|Other|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
79575534|NCT01860781|Drug|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
79575535|NCT01860794|Drug|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
80028609|NCT02205606|Drug|HCP1306 20/10mg|P.O.
80028610|NCT03629977|Device|CRRT|Continuous Renal Replacement Therapy
79735014|NCT05273710|Other|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
80028611|NCT02832375|Drug|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
80028612|NCT02832375|Drug|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
79575536|NCT01860820|Device|Geko device|
79575537|NCT01860833|Drug|Ibuprofen|time of treatment 14 days
79575538|NCT01860833|Drug|Celecoxib|time of treatment 14 days
79575539|NCT01860833|Drug|Diclofenac|time of treatment 14 days
79575540|NCT01860859|Procedure|Closure of the hysterotomy at the time of primary cesarean|
79575541|NCT01860911|Drug|Insulin|
79575542|NCT01860911|Drug|NG-monomethyl-L-arginine|
79575543|NCT01860924|Behavioral|exercise|vigorous intensity exercise
79575544|NCT01860924|Behavioral|health education|education
79575545|NCT01860963|Procedure|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
79869808|NCT03078452|Device|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
79869809|NCT03065725|Procedure|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
79869810|NCT03043794|Radiation|Stereotactic Body Radiation SBRT|Stereotactic Body Radiation to the breast to 21 Gy
79869811|NCT03026283|Device|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
79869812|NCT02998268|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
80028613|NCT03059680|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
79575546|NCT01861015|Drug|Epinephrine|
79575547|NCT01861015|Drug|Vasopressin|
79575548|NCT01861041|Drug|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
79575549|NCT01861041|Drug|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
79575550|NCT01861067|Procedure|LESS-TLH|
79735015|NCT02784808|Drug|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
79735016|NCT02784808|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
80028614|NCT04964752|Device|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
80028615|NCT02205684|Other|Computer game skills training|Playing Nintendo Wii Sports
80028616|NCT02205684|Other|Physical activity|Aerobic High Intensity Training (HIT)
80028617|NCT03563781|Procedure|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
80028618|NCT03062332|Genetic|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
80028619|NCT02925403|Biological|R21/Matrix-M1|
80028620|NCT02925403|Other|Saline|
80028621|NCT02213640|Device|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
80028622|NCT02213640|Device|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
79575551|NCT01861067|Procedure|LESS-LAVH|
79575552|NCT01861119|Drug|Silicone gel Kelo-cort™;|
79869813|NCT02998268|Drug|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
79869814|NCT02998268|Drug|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
79869815|NCT02993900|Device|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
79869816|NCT02948452|Other|fMRI|fMRI: reward task, anxiety provocation
79869817|NCT02915367|Behavioral|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
79869818|NCT02871882|Radiation|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA [diethylenetriaminepentaacetic acid] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
79869819|NCT02871882|Other|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
79869820|NCT02871882|Drug|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
79869821|NCT02871882|Other|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
80028623|NCT05301387|Procedure|Ganglion Sphenopalatine Block|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL or Block performed with bilaterally inserted q-tips with isotone NaCl
80028624|NCT04973176|Device|Standard Bougie|Standard Bougie for endotracheal intubation
79575553|NCT01861119|Drug|Onion extract gel Contractubex™|
79575554|NCT01861145|Device|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
79575555|NCT01861145|Drug|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
79575556|NCT01861158|Behavioral|Parenting Wisely|Computer-based, online, interactive parenting intervention
79575557|NCT01861171|Dietary Supplement|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
80028625|NCT04973176|Device|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
79575558|NCT01861197|Drug|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
79305891|NCT04902807|Biological|Collection of samples|Blood, Urine and Stool samples will be collected from the participants.
79575559|NCT01861210|Behavioral|Couples Voluntary HIV Counseling and Testing|
79575560|NCT01861210|Behavioral|Individual Counseling and Testing|
79575561|NCT01861223|Drug|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
79575562|NCT01861236|Drug|Firmagon® (degarelix)|Monthly subcutaneous injections
79575563|NCT01861262|Device|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
79575564|NCT01861275|Device|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
79575565|NCT01861327|Drug|CO2|carbon dioxide (CO2) as arterial contrast media
79575566|NCT01861327|Drug|Iodine contrast media|Iodine as arterial contrast media
79575567|NCT01861340|Drug|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
79869822|NCT02838680|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
79869823|NCT02824276|Drug|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
79869824|NCT02824276|Drug|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
79869825|NCT02813135|Drug|Ribociclib|
79869826|NCT02813135|Drug|Topotecan|
79869827|NCT02813135|Drug|Temozolomide|
79869828|NCT02813135|Drug|Everolimus|
79869829|NCT02813135|Drug|Adavosertib|
79575568|NCT01861366|Other|A one year multifaceted implementation strategy|
79869830|NCT02813135|Drug|Carboplatin|
79869831|NCT02813135|Drug|Olaparib|
79869832|NCT02813135|Drug|Irinotecan|
79869833|NCT02813135|Drug|Vistusertib|
79869834|NCT02813135|Drug|Nivolumab|
79869835|NCT02813135|Drug|Cyclophosphamide|
79869836|NCT02813135|Drug|Selumetinib|
79869837|NCT02813135|Drug|Enasidenib|
79869838|NCT02813135|Drug|Lirilumab|
79869839|NCT02813135|Drug|Fadraciclib|
79869840|NCT02813135|Drug|Cytarabine|
79869841|NCT02813135|Drug|Dexamethasone|
79869842|NCT02813135|Drug|Ceralasertib|
79869843|NCT02813135|Drug|Futibatinib|
79869844|NCT02813135|Drug|Capmatinib|
79869845|NCT02812537|Other|patients with conduct disorders|interview with a specialist
79869846|NCT02809196|Behavioral|1: Tailored SMS program implicating friend and mother|
79869847|NCT02809196|Behavioral|2: Standardized SMS program implicating friend and mother|
79272123|NCT05976074|Device|Apple Watch|The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
79735017|NCT02784652|Drug|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
79735018|NCT02784652|Radiation|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions,
79735019|NCT04231630|Other|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
79869848|NCT02809196|Behavioral|3: Tailored SMS program implicating friend, not mother|
79869849|NCT02809196|Behavioral|4: Standardized SMS program implicating friend, not mother|
79869850|NCT02809196|Behavioral|5: Tailored SMS program implicating mother, not friend|
79735020|NCT02784730|Procedure|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
79869851|NCT02809196|Behavioral|6: Standardized SMS program implicating mother, not friend|
79575569|NCT01861366|Other|A three hour lecture about the guidelines|
79575570|NCT01861379|Procedure|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
79869852|NCT02809196|Behavioral|7: Tailored SMS program not implicating mother or friend|
79735021|NCT02784730|Procedure|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
79869853|NCT02809196|Behavioral|8: Standardized SMS program not implicating mother or friend|
79869854|NCT02809196|Behavioral|9: No SMS program|
79869855|NCT02800512|Procedure|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
79869856|NCT02800512|Procedure|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
79869857|NCT02799823|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
79869858|NCT02732288|Dietary Supplement|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
79869859|NCT02712515|Procedure|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
79869860|NCT02712515|Device|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
79869861|NCT02712515|Device|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
79305892|NCT02121262|Drug|Dexamethasone|Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
79575571|NCT01861392|Procedure|sensorio-motor training|
79305893|NCT02121262|Procedure|Laser Photocoagulation|Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
79575572|NCT01861405|Behavioral|neuropsychological testing and quality of life assessments|
79575573|NCT01861405|Radiation|Standard of Care WBRT or SRS|
79575574|NCT01861405|Device|Functional magnetic resonance imaging|
79735022|NCT02786290|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
79735023|NCT04231552|Drug|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
79735024|NCT02785744|Other|Gaucher disease DNA mutation analysis|
79735025|NCT01100502|Drug|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
79735026|NCT01100502|Drug|placebo|Every 21 days by IV infusion
79735027|NCT02784418|Procedure|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
79735028|NCT02784418|Procedure|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
79735029|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone IV drip
79735030|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
79735031|NCT02784340|Drug|Saline (IV fluids)|IV fluids 500 cc saline infusion
79735032|NCT02784340|Drug|Bupivicaine and Fentany|
79735033|NCT02784340|Device|25G spinal needles|
79735034|NCT02785822|Drug|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
79735035|NCT02785822|Drug|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
79735036|NCT02878512|Procedure|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
79735037|NCT02878512|Procedure|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
79575575|NCT01861418|Other|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
79735038|NCT04302246|Genetic|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
79735039|NCT04847856|Behavioral|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
79735040|NCT04306614|Procedure|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
79575576|NCT01861418|Other|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
79735041|NCT04231006|Radiation|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
79735042|NCT01094886|Drug|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
79869862|NCT02687958|Drug|Everolimus|Maintenance therapy
79735043|NCT04231240|Device|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
79735044|NCT02784028|Other|SGM-101|Administration of SGM-101 prior surgery
79869863|NCT02657863|Procedure|Urine collection and blood draw|
79869864|NCT02623712|Other|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
79869865|NCT02623712|Other|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
79869866|NCT02593565|Other|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
79869867|NCT02586090|Behavioral|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
79869868|NCT02586090|Behavioral|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
79869869|NCT02567669|Radiation|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
79305894|NCT03053739|Drug|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
79575577|NCT01861431|Behavioral|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
79575578|NCT01861431|Behavioral|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
79735045|NCT02782234|Behavioral|Contract management|
79735046|NCT01094808|Drug|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
79735047|NCT01094808|Drug|Placebo|Placebo capsules
79735048|NCT01094808|Other|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
79735049|NCT00864253|Drug|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
79735050|NCT00864253|Drug|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
79735051|NCT02782312|Drug|ICS+LABA|Seretide is inhaled for one year
79735052|NCT02782312|Other|routine therapy|routine therapy for one year
79735053|NCT01094730|Device|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
79735054|NCT01094730|Device|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
79869870|NCT02503228|Procedure|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
79575579|NCT01861509|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
79869871|NCT02487524|Other|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
79869872|NCT02487524|Other|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
79869873|NCT02487524|Other|QST|Quantitative sensory testing.
79869874|NCT02478710|Drug|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
79869875|NCT02478710|Drug|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
79869876|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
79869877|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
79402727|NCT05853640|Other|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
79575580|NCT01861535|Drug|Imiquimod|
79575581|NCT01861535|Procedure|Surgery|
79575582|NCT01861561|Drug|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
79575583|NCT01861561|Drug|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
79575584|NCT01861600|Other|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
79575585|NCT01861600|Other|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
79575586|NCT01861600|Other|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
79575587|NCT01861600|Other|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
79575588|NCT01861600|Other|Human Milk|Human Milk
79575589|NCT01861613|Biological|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
79735055|NCT04229758|Drug|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
79402728|NCT05834595|Drug|CKD-828, D064, D701|QD, PO
79735056|NCT04307706|Behavioral|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
79735057|NCT04230538|Device|DJO Walker|
79735058|NCT04230538|Device|Traditional plaster cast|
79735059|NCT02783794|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
79869878|NCT02455505|Behavioral|background questionnaire|
79869879|NCT02455505|Behavioral|bereavement risk screening tool|
79869880|NCT02432482|Behavioral|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
79869881|NCT02432482|Behavioral|Standard care|Brief advice to quit (<5 minutes) Self-help brochure Offer of nicotine patches
79869882|NCT02425865|Drug|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
79869883|NCT02425852|Drug|Azathioprine|Azathioprine alone versus Azathioprine and IFX
79869884|NCT02425852|Drug|Infliximab|
79869885|NCT02425852|Drug|Prednisolone|
79869886|NCT02425852|Drug|Hydrocortisone|
79575590|NCT01861626|Drug|V0057 - A mg|Single oral administration
79575591|NCT01861626|Drug|Isotretinoin|Single oral administration
79575592|NCT01861639|Device|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
79575593|NCT01861639|Device|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
79575594|NCT01861639|Device|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
79575595|NCT01861639|Device|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2*-weighted echo-planar imaging sequence
79575596|NCT01861639|Device|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
79575597|NCT01861639|Device|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
79735060|NCT02783794|Drug|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
79869887|NCT02333188|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
79869888|NCT02333188|Drug|Leucovorin Calcium|Given IV
79869889|NCT02333188|Drug|Irinotecan Hydrochloride|Given IV
79869890|NCT02333188|Drug|Fluorouracil|Given IV
79869891|NCT02333188|Other|Laboratory Biomarker Analysis|Correlative studies
79575598|NCT01861652|Device|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
79735061|NCT00698425|Other|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
79869892|NCT02330601|Procedure|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
79735062|NCT00698425|Drug|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
79735063|NCT02614417|Other|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
79735064|NCT05342506|Drug|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10^9 intravenous reinfusion.
79735065|NCT05242198|Procedure|Robotic prostatectomy|patients who will undergo robotic prostatectomy
79735066|NCT04230616|Procedure|total knee arthroplasty|total knee arthroplasty
79735067|NCT04230616|Radiation|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
79735068|NCT04230850|Other|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
79735069|NCT04230850|Other|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
79735070|NCT04230850|Other|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
79735071|NCT00638092|Drug|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
79869893|NCT02296528|Device|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
79869894|NCT02282358|Drug|Mocetinostat|
79869895|NCT02259413|Behavioral|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
79869896|NCT02242760|Drug|SB204 2%|Applied topically twice daily
79869897|NCT02242760|Drug|SB204 4%|Applied topically daily
79869898|NCT02242760|Drug|Vehicle Gel|Applied topically twice and once daily
79869899|NCT02203695|Drug|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
79869900|NCT02203695|Radiation|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
79272124|NCT05976074|Other|BrainRISE app|The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
79272125|NCT05975996|Drug|Cyclophosphamide added to standard immunosuppressive therapy with eltrombopag|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Eltrombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
79272126|NCT05975944|Drug|Selinexor，Olaparib|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
79575599|NCT01861678|Procedure|High tie of IMA|Conventional technique
79575600|NCT01861678|Procedure|Low tie of IMA|Technique for preserving left colic arterial perfusion
79575601|NCT01861691|Procedure|Open surgery|Conventional technique
79575602|NCT01861691|Procedure|Laparoscopic surgery|New minimum invasive technique
79575603|NCT01861730|Biological|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
79735072|NCT00638092|Drug|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
79735073|NCT04230772|Procedure|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
79735074|NCT04230772|Procedure|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
80028626|NCT04108741|Device|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
79735075|NCT05342272|Drug|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
79869901|NCT02177578|Drug|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
79869902|NCT02177578|Radiation|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
79869903|NCT02177578|Radiation|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
80028627|NCT02205918|Other|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
80028628|NCT02205918|Other|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
80028629|NCT03059836|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
80028630|NCT03059836|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
80028631|NCT03679819|Device|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
80028632|NCT02626780|Device|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
80028633|NCT03683407|Other|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
80028634|NCT02221206|Device|Mini-Screw implant|Mini-screw implants (VectorTASTM8*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
79272127|NCT05975918|Behavioral|Motivational İnterview|Participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.
79272128|NCT05975918|Other|Psychoeducation|2 hours of training on coping with stress and problem solving skills will be provided.
79305895|NCT03053739|Drug|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
79575604|NCT01861730|Biological|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
79869904|NCT02177227|Device|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
80028635|NCT03683329|Other|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
79575605|NCT01861743|Other|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
79869905|NCT02138448|Behavioral|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
79869906|NCT01994954|Other|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
80028636|NCT03683329|Other|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
80028637|NCT05262192|Other|nutrition education|Nutrition education will be given to the patients in the experimental group.
80028638|NCT04981054|Procedure|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
80028639|NCT04972864|Other|Exercise training group|A regular advanced exercise program was given and followed.
79575606|NCT01861743|Other|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
80028640|NCT04972864|Other|Control training group|Basic exercises was given at the beginning and did the same exercises
80028641|NCT03677557|Drug|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
80028642|NCT01363401|Biological|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
80028643|NCT01363401|Other|Control group|No treatment of HYNR-CS inj
80028644|NCT03673020|Biological|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
80028645|NCT04980508|Diagnostic Test|corpus cavernosum electromyography|Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
79869907|NCT01973881|Procedure|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
79869908|NCT01958840|Behavioral|Behavioral Activation for Depression Treatment|
79869909|NCT01958840|Behavioral|Supportive Counseling|
79869910|NCT01892709|Drug|Hydromorphone|
80028646|NCT03679663|Device|Ultrasound|Use of ultrasound to identify pre-puncture site
80028647|NCT02218476|Drug|CoQ10|
80028648|NCT02218476|Drug|Placebo|
80028649|NCT03679507|Procedure|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
80028650|NCT03679507|Other|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
80028651|NCT04972708|Genetic|Cross-sectional genetics study|Cross-sectional genetics study
79272129|NCT05975892|Biological|Transplantation of allogeneic MSCs in periodontal disease|Oral surgery is performed in patients with periodontal disease, under local anesthesia. An incision will be made on the periodontal lesion, A full-thickness flap is elevated on both the buccal and lingual areas and the inner epithelium of the flap removed. Granulation tissue is removed from bone defect area, and a root planning is performed. MSC construct is placed around the bone defect and a collagen membrane is used to cover and close off the bone defect site. The flap will be repositioned and the wound closed by a suture
79272130|NCT05975879|Dietary Supplement|undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)|"Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
79575607|NCT01861769|Other|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
79735076|NCT05342272|Drug|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
79735077|NCT04230460|Drug|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
79735078|NCT04230460|Drug|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
79735079|NCT04230460|Drug|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
80028652|NCT02221440|Device|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
80028653|NCT02221440|Device|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
80028654|NCT04963582|Procedure|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
80028655|NCT02218632|Other|lactose-free diet|standard diet
80028656|NCT02218632|Dietary Supplement|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
80028657|NCT02205996|Drug|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
80028658|NCT02205996|Device|Euglycaemic Hypoglycaemic Insulin clamp|
79735080|NCT04230460|Drug|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
79869911|NCT01873755|Behavioral|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
79869912|NCT01858597|Diagnostic Test|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
79869913|NCT01806571|Drug|Cytarabine|Given IV
79869914|NCT01806571|Drug|Daunorubicin Hydrochloride|Given IV
79272131|NCT05975879|Dietary Supplement|Placebo|Release form: capsules with an average weight of 585 mg. No active ingredients.
79869915|NCT01806571|Other|Laboratory Biomarker Analysis|Correlative studies
79272132|NCT05975866|Dietary Supplement|curcumin|Daily consumption of three 500 mg curcumin capsules with breakfast, lunch, and dinner
79869916|NCT01806571|Drug|Nilotinib|Given PO
79869917|NCT01806571|Other|Pharmacological Study|Correlative studies
79869918|NCT01741311|Behavioral|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
79272133|NCT05975866|Behavioral|Anti-inflammatory diet|The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.
79272134|NCT05975853|Other|Binaural beat music group (BBM group)|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.
79272135|NCT05975853|Other|Control group|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
79869919|NCT01741311|Behavioral|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
79869920|NCT01705899|Drug|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
79869921|NCT01701154|Other|respiratory muscle strength training|
79272136|NCT05975827|Device|Sterile Wound Care Liquid Dressing|Sterile wound care liquid dressing is used in the wound treatment
79272137|NCT05975814|Device|dental implant|dental implants are placed as usual and require a healing abutment. Abutments can be straight or concave, both are equally available on the market.
79272138|NCT05975801|Other|Dry Cupping Therapy|
79272139|NCT05975801|Other|Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound|
79272140|NCT05975762|Procedure|surgical rib fixation|open reduction and internal rib fixation
79272141|NCT05975749|Drug|Serplulimab|Serplulimab: 4.5mg/Kg on day 1
79272142|NCT05975749|Drug|Trastuzuma|Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
79575608|NCT01861769|Other|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
79575609|NCT01861782|Other|Dead Sea Solar and Water Treatment|
79575610|NCT01861782|Other|Sulfur Pool & Medicinal Mud|
79575611|NCT01861795|Other|Preterm Neonates|Preterm Neonates
79575612|NCT01861808|Other|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
79575613|NCT01861821|Device|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
79575614|NCT01861821|Device|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
79735081|NCT02783638|Drug|YHD1119|2 by 2
79735082|NCT02783638|Drug|Lyrica|2 by 2
79869922|NCT01642641|Procedure|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
79869923|NCT01642641|Procedure|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
79869924|NCT01642641|Procedure|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
79869925|NCT01639196|Other|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
79869926|NCT01639196|Other|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
79735083|NCT04229524|Procedure|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least> 30.
80028659|NCT04980586|Diagnostic Test|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
79272143|NCT05975749|Drug|Chemotherapy|Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
79735084|NCT02783326|Other|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
79869927|NCT01633177|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
79272144|NCT05975736|Behavioral|Search only for masses|Participants search the simulated mammogram for simulated masses.
79575615|NCT01861834|Drug|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
79575616|NCT01861860|Device|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
79575617|NCT01861873|Other|measuring liver function by 18-FDGal PET/CT|
79575618|NCT01861886|Device|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
79575619|NCT01861899|Device|SI-LOK|Sacro-iliac joint fusion
79575620|NCT01861912|Device|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities
79735085|NCT02782000|Other|lessons,long-term supervision and message|
79735086|NCT02782000|Other|lessons,short-term supervision and message|
79735087|NCT04230070|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
79735088|NCT04230070|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
79869928|NCT01633177|Drug|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79869929|NCT01633177|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
79869930|NCT01633177|Drug|Fish oil placebo|Fish oil placebo
79869931|NCT01607008|Other|MRI imaging|"3 total MRI imaging studies:~pre standard radiation treatment~during standard radiation treatment~post standard radiation treatment"
79272145|NCT05975736|Behavioral|Search only for calcifications|Participants search the simulated mammogram for simulated calcifications.
79272146|NCT05975736|Behavioral|Search for both together|Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.
79272147|NCT05975736|Behavioral|Search for one after the other|Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
79272148|NCT05975723|Behavioral|MIND diet education|An intensified education program following a localized modified MIND diet for 1 year, which recommends 11 brain healthy food groups (green leafy vegetables, dark red and yellow vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive/tea-seed oil and green tea) and limits intake of 4 unhealthy food groups (red meat and products, animal oil, pastries and sweets, and fried/fast food).
79272149|NCT05975723|Behavioral|Routine follow-up and general advice|Routine follow-up administered by trained staff.
79735089|NCT02782078|Biological|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
79735090|NCT01293682|Drug|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
79735091|NCT02782156|Other|Process evaluation|Adherence to screening and action algorithm
79735092|NCT05342116|Other|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
79735093|NCT05342116|Other|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
79869932|NCT01517451|Radiation|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
79735094|NCT02782936|Other|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
79869933|NCT01517451|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
79869934|NCT01415817|Other|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
79869935|NCT01290835|Radiation|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
79869936|NCT01290835|Radiation|stereotactic radiotherapy|
79869937|NCT01204216|Biological|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
80028660|NCT04980586|Diagnostic Test|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
79272150|NCT05975645|Drug|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death 1 (PD-1).
79272151|NCT05975645|Drug|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).
79272152|NCT05975645|Drug|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
79272153|NCT05975567|Other|Three-dimensional imaging of the collected cardiac specimens|The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
79575621|NCT01861912|Drug|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
79575622|NCT01861912|Drug|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
79575623|NCT01861912|Drug|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
79575624|NCT01861938|Biological|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
79735095|NCT02782936|Device|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
79735096|NCT02782858|Drug|GNbAC1|Monthly IV repeated dose
79735097|NCT02782858|Drug|Placebo|Monthly IV repeated dose
79735098|NCT00864097|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
79735099|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
79735100|NCT00864097|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
79735101|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
79272154|NCT05975528|Drug|SGLT2 inhibitor|"For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered."
79272155|NCT05975528|Drug|Glimepiride|For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
79272156|NCT05975502|Other|Epidemiological study|Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
79735102|NCT00864097|Biological|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
79735103|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
79735104|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
79735105|NCT00864097|Other|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
79735106|NCT04230226|Dietary Supplement|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
79735107|NCT04230226|Other|Placebo|Placebo product consumed prior and after exercise
79735108|NCT02782624|Drug|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
79272157|NCT05974124|Device|Povidone-Iodine 0.66%|Povidone-iodine 0.66% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
79735109|NCT02782624|Drug|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
79735110|NCT02781766|Other|Thrombin generation measurement.|
79735111|NCT02781688|Behavioral|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
79735112|NCT00887536|Drug|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
79735113|NCT00887536|Drug|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
79272158|NCT05974124|Device|Chlorhexidine 0.02%|Chlorhexidine 0.02% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
79272159|NCT05973968|Drug|Surufatinib|Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
79272160|NCT05973799|Other|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
79272161|NCT05973799|Other|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
79575625|NCT01861951|Drug|Pazopanib|
79575626|NCT01861951|Drug|Doxorubicin|
79575627|NCT01861964|Dietary Supplement|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
79735114|NCT00887536|Drug|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
79735115|NCT00887536|Drug|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
79735116|NCT00887536|Drug|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles [filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.]
79735117|NCT02614339|Drug|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
79735118|NCT02614339|Drug|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
79735119|NCT00697333|Procedure|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
79305896|NCT04916925|Drug|Vitamin D|Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
79735120|NCT04132687|Procedure|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
79735121|NCT02618395|Drug|SPARC001A|
80028661|NCT04980586|Diagnostic Test|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
79305897|NCT04916925|Drug|Clomid|CLOMID is adrug used for ovulation induction
79575628|NCT01861964|Dietary Supplement|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
79402729|NCT05819320|Other|observe pattern of mucocutaneous manifestations in chronic kidney disease patients|"To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease"
79575629|NCT01861964|Dietary Supplement|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
79575632|NCT01861990|Drug|Valproic Acid|All participants enrolled on valproic acid arm.
79735122|NCT02618395|Drug|SPARC001B|
79735123|NCT02618395|Drug|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
79272162|NCT05972200|Device|Active HD-tDCS over V5/MT|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V5/MT, whereas the other 4 electrodes return electrical currents that flow away from that area. V5/MT will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
79869938|NCT01204216|Biological|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
79402730|NCT05811936|Behavioral|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
79735124|NCT01183013|Drug|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
79869939|NCT01204216|Behavioral|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
79575633|NCT01862003|Drug|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
79575634|NCT01862003|Drug|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
79575635|NCT01862003|Drug|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
79575636|NCT01862003|Drug|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
79735125|NCT01183013|Drug|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
79869940|NCT01202305|Procedure|Lymph node biopsy|Inguinal lymph node biopsy
79869941|NCT01196312|Behavioral|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
79575637|NCT01862003|Drug|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
79575638|NCT01862016|Procedure|APRV|Pressure ventilation mode allowing early spontaneous breathing
79869942|NCT01161199|Procedure|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
80028662|NCT04980586|Diagnostic Test|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
79575639|NCT01862016|Biological|arterial blood gas measurement each morning|
79735126|NCT01183013|Drug|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
79735127|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
79735128|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
79735129|NCT01183013|Drug|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
79735130|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
80028663|NCT03059914|Device|InterOss|Anorganic bovine bone mineral - Xenograft
80028664|NCT03059914|Device|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
79869943|NCT01107015|Device|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
80028665|NCT04972474|Other|Smartphone app in-app components|Insightful notification text, data visualisation, research team contact details.
80028666|NCT02221518|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
80028667|NCT02206074|Dietary Supplement|Beetroot|
79735131|NCT04129801|Other|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
79272163|NCT05972200|Device|Active HD-tDCS over V1|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V1, whereas the other 4 electrodes return electrical currents that flow away from that area. V1 will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
79402731|NCT05809089|Device|High flow nasal cannula (HFNC)|"High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours."
79402732|NCT05809089|Device|Noninvasive ventilation (NIV)|Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
79575640|NCT01862042|Other|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
79575641|NCT01862068|Other|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
79575642|NCT01862068|Other|Blood sample|Blood sample will be performed at inclusion from all healthy patients
79575643|NCT01862081|Drug|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
79735132|NCT04129801|Other|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
79735133|NCT02618629|Drug|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
79575644|NCT01862081|Drug|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
79575645|NCT01862081|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
79575646|NCT01862120|Drug|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
79735134|NCT04132609|Behavioral|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
79735135|NCT04132609|Behavioral|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
80028668|NCT04972084|Device|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
80028669|NCT04980742|Procedure|acute normovolemic hemodilution|acute normovolemic hemodilution
80028670|NCT02219802|Procedure|Treatment according arm|
80028671|NCT04980664|Other|Integrated intervention strategies|Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
80028672|NCT04972006|Behavioral|Remote, intensive intervention for injection phobia|The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
79575647|NCT01862120|Drug|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
79735136|NCT04132531|Procedure|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
79735137|NCT02615197|Behavioral|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
79735138|NCT02615197|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
79735139|NCT04229212|Device|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
79735140|NCT02618473|Other|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
79735141|NCT00634660|Drug|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
79735142|NCT02886767|Other|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
79735143|NCT00922753|Other|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
79735144|NCT00922753|Other|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
79869944|NCT01107015|Device|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
79869945|NCT01107015|Device|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
79575648|NCT01862120|Drug|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
79735145|NCT00922753|Other|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
79735146|NCT05141500|Device|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|"Reprocessed noninvasive pulse oximeters~1859 & 2329~MAX-A & MAX-N"
79272164|NCT05972200|Device|Sham HD-tDCS over V5/MT or V1|Sham HD-tDCS will be delivered over left V5/MT or left V1. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. .
79575649|NCT01862120|Drug|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
79575650|NCT01862146|Procedure|smoke expose|
79575651|NCT01862172|Other|Additional MRI|
79575652|NCT01862185|Other|semi-quantitative procalcitonin|
79575653|NCT01862198|Device|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
79735147|NCT04312373|Other|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
79735148|NCT02618239|Dietary Supplement|Bimuno Galacto-oligo-saccharide|
79735149|NCT05341102|Drug|LY3556050|Administered orally.
79735150|NCT05341102|Drug|Placebo|Administered orally.
79735151|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
79869946|NCT01104350|Other|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
79735152|NCT02615041|Drug|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
79735153|NCT02615041|Drug|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
79869947|NCT01100892|Drug|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
79869948|NCT01025089|Drug|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
80028673|NCT02220036|Dietary Supplement|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
79575654|NCT01862211|Other|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
79575655|NCT01862237|Other|Intervention|"blood collection~Completion of a pre-operative cardiac MRI.~Completion of a coronary angiography examination~Completion during the surgery d'une myocardial biopsy,~Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~Completion of a cardiac MRI 1 year after surgery."
79575656|NCT01862263|Drug|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
79869949|NCT00999037|Drug|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
79869950|NCT00999037|Other|Placebo|1 inert tablet tid x 12 weeks
79575657|NCT01862263|Drug|Insulin|Long- acting human insulin analog indicated to improve glycemic control
79575658|NCT01862263|Drug|Placebo|Matching placebo of vildagliptin
79735154|NCT04229602|Drug|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
79735155|NCT04229602|Drug|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
79869951|NCT00921856|Other|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
79869952|NCT00900471|Other|biologic sample preservation procedure|
79869953|NCT00900471|Other|medical chart review|
79869954|NCT00833664|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
79869955|NCT00833664|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
79869956|NCT00745355|Behavioral|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
79869957|NCT00696111|Drug|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
79869958|NCT00696111|Drug|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
79869959|NCT00696111|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
79272165|NCT05970458|Other|Quality of life assessment|EQ5D-5L and Stoma QoL
79575659|NCT01862289|Other|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
79575660|NCT01862302|Drug|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
79575661|NCT01862302|Drug|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
79575662|NCT01862341|Dietary Supplement|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
79575663|NCT01862354|Procedure|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
79575664|NCT01862354|Procedure|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
79272166|NCT05969054|Drug|Lacosamide 100 mg|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
79735156|NCT05298163|Drug|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
79735157|NCT05298163|Drug|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
79869960|NCT00380367|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
79272167|NCT05969054|Drug|Levetiracetam 250mg|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
79272168|NCT05957107|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|The drug was administered once every 4 weeks.
79272169|NCT05954637|Device|Optical coherence tomography|Heidelberg Engineering Spectralis
79575665|NCT01862367|Drug|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
79869961|NCT00224393|Drug|Enbrel|
79272170|NCT05953233|Other|Active classroom HEPA cleaner|Commercially available portable HEPA cleaner
79272171|NCT05953233|Other|Sham classroom HEPA cleaner|Commercially available portable HEPA cleaner with filtration device removed
79272172|NCT05943327|Drug|Lu AG06474|Oral Solution
79272173|NCT05943327|Drug|Placebo|Oral Solution
79575666|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
79575667|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
79575668|NCT01862393|Device|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
79575669|NCT01862393|Device|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
79869962|NCT00199862|Drug|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
79869963|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Psycho-educational group
79869964|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Spiritual-Existential Group
79869965|NCT00179348|Procedure|Quality-of-Life Assessment|Ancillary studies
79869966|NCT00179348|Procedure|Yoga|Undergo a yoga-based rehabilitation program
79272174|NCT05943327|Drug|Lu AG06474|Capsule
79272175|NCT05938413|Device|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
79272176|NCT05938413|Behavioral|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
79272177|NCT05932082|Procedure|myomectomy or not|The study group receive myomectomy, while the control group don't receive myomectomy.
79272178|NCT05928559|Other|OMRON BF511 Body Composition Monitor|The OMRON BF511 Body Composition Monitor is a digital scale and participants' body compositions will be evaluated with this device. The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test and the maximum oxygen consumption levels will be calculated with the help of the formula with the data obtained from this test. The trunk extensor muscle endurance of the participants will be evaluated with the Biering-Sorensen Test and the trunk flexor endurance will be evaluated with the Kraus-Weber Test. Participants' M. Quadriceps, M. Hamstring, M. Biceps Brachii and M. Triceps Brachii muscle strengths will be evaluated with MicroFET® 2 hand dynamometer.
79272179|NCT05926635|Device|ATLAS 2030|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
79575670|NCT01862393|Device|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
79575671|NCT01862406|Other|Label|Participants were presented with either a generic label or a brand-name label
79575672|NCT01862432|Other|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
79869967|NCT00128310|Drug|Vinorelbine|
79272180|NCT05925556|Behavioral|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
79272181|NCT05919342|Diagnostic Test|NT-proBNP|Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
79869968|NCT00128310|Drug|Gemcitabine|
79869969|NCT00870077|Dietary Supplement|ProWHEY 94 CFM, SponserR|3 times 20g per day
79869970|NCT04782401|Other|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
79869971|NCT04782401|Device|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
79869972|NCT01007708|Drug|IDP-108|Topical application once a day for 48 weeks
79575673|NCT01862458|Biological|tPA alone|
79575674|NCT01862458|Biological|tPA plus dornase|
79869973|NCT01007708|Drug|Vehicle|Topical application once a day for 48 weeks
79869974|NCT00885443|Drug|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
79869975|NCT00885443|Drug|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
79869976|NCT00882869|Drug|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
79869977|NCT00882869|Drug|Sorafenib|Sorafenib will be administered at 400 mg BID every day
79869978|NCT01001000|Procedure|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
79869979|NCT00882947|Drug|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
79869980|NCT00531050|Drug|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
79869981|NCT00531050|Drug|Placebo|Single dose indacaterol matching placebo via Concept 1 device
79272182|NCT05918081|Other|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
79272183|NCT05909488|Biological|1.5 x 10^6 UC-MSC + CM|1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
79575675|NCT01862471|Device|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
79272184|NCT05909488|Biological|5 x 10^6 UC-MSC + CM|5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
79575676|NCT01862471|Device|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
79575677|NCT01862497|Drug|Carvedilol vs. Prazosin|
80028674|NCT02220114|Drug|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
79869982|NCT00531050|Drug|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
79869983|NCT05231018|Other|Psychotherapy|8-sessions psychotherapy
79272185|NCT05888857|Drug|MEDI5752|A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
79272186|NCT05887583|Behavioral|The Rising New York Road Runners program|The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
79272187|NCT05881538|Other|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
79272188|NCT05869474|Procedure|Iodine125-Seeds implantation|Endoscopic ultrasound-guided intratumoral iodine125-Seeds implantation
79272189|NCT05869474|Drug|Gem/nab-P Chemotherapy|nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
79575678|NCT01862523|Biological|Capsaicin|Thirty-three* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
79575679|NCT01862523|Biological|diluent|diluent
79869984|NCT00530348|Biological|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
79869985|NCT00530348|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
79869986|NCT01001156|Other|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
79575680|NCT01862549|Behavioral|Dialectical Behavior Therapy for children|
79575681|NCT01862549|Behavioral|Treatment as Usual|
79575682|NCT01862562|Procedure|Open surgery|Conventional technique
79575683|NCT01862562|Procedure|Laparoscopic surgery|New minimum invasive technique
79869987|NCT01001312|Other|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
79869988|NCT01001312|Other|Clinical volume status assessment|Volume assessment based on history and physical examination
79869989|NCT03886220|Drug|Elagolix|Oral; Tablet
79869990|NCT03886220|Drug|Placebo|Oral; Tablet
79869991|NCT01007864|Drug|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
79869992|NCT01007864|Drug|pramipexole or ropinirole|continuation of pre-study treatment regimen
79272190|NCT05866536|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
79575684|NCT01862601|Device|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
79575685|NCT01862627|Procedure|Optical coherence tomography|
79869993|NCT05111366|Drug|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
79869994|NCT05111366|Drug|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
79869995|NCT01008020|Dietary Supplement|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
79869996|NCT01008098|Drug|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
79869997|NCT01008176|Behavioral|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
79575686|NCT01862653|Device|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
79869998|NCT00530270|Drug|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
79575687|NCT01862679|Other|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
79272191|NCT05866536|Biological|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
79272192|NCT05847309|Other|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
79272193|NCT05847309|Other|Early extubation|Patients randomized to early extubation, will be extubated < 6 hours after endovascular treatment under general anesthesia.
79272194|NCT05831644|Drug|C21|C21 is an angiotensin II type 2 receptor agonist (ATRAG)
79869999|NCT00530270|Drug|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
79870000|NCT01008254|Behavioral|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
79870001|NCT01008254|Behavioral|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
79870002|NCT01008254|Other|No musical prompt|No intervention.
79272195|NCT05793593|Other|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
79272196|NCT05793593|Other|Colorectal Cancer (CRC) education alone|CRC education alone.
79272197|NCT05790525|Drug|Standard bismuth quadruple|Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
79272198|NCT05780671|Other|oxygen|inhaled oxygen 10L/min with face mask for 1 hour
79272199|NCT05777265|Other|Circuit Training|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
79575688|NCT01862679|Procedure|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
79870003|NCT01008332|Biological|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
79870004|NCT01008332|Biological|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
79870005|NCT01008488|Drug|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
79870006|NCT01001468|Drug|VB-201|Single daily dose of oral VB-201 20 mg
79870007|NCT01001468|Drug|VB-201|Single daily dose or oral VB-201 80 mg
79870008|NCT01001468|Other|Placebo|Single daily dose of oral placebo
79870009|NCT01001624|Other|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
79870010|NCT01001624|Other|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
79870011|NCT01001780|Drug|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
79870012|NCT01001858|Other|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
79870013|NCT01008566|Biological|Cixutumumab|Given IV
79870014|NCT01008566|Other|Laboratory Biomarker Analysis|Correlative studies
79870015|NCT01008566|Drug|Sorafenib Tosylate|Given orally
79870016|NCT01008644|Other|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
79870017|NCT01008644|Other|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
79870018|NCT05733494|Other|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
79870019|NCT05601128|Drug|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
79870020|NCT05593406|Device|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
79272200|NCT05777252|Other|Circuit Training|Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
79870021|NCT05593406|Other|Control Group|NDT treatment 2 sessions per week
80028675|NCT04972240|Other|customization of abutment|we will customize abutment for every patient not ready made
79272201|NCT05763732|Behavioral|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
79870022|NCT01001936|Drug|SKI-606|
79870023|NCT03885596|Drug|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
79272202|NCT05752331|Behavioral|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
79870024|NCT03885596|Drug|Ketorolac|30 mg IV at the onset of anesthesia
79870025|NCT03885596|Drug|Acetaminophen IV|1 g at the onset of anesthesia
79272203|NCT05740501|Procedure|Biospecimen Collection|Undergo collection of blood samples
79870026|NCT03885596|Drug|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
79870027|NCT03885596|Drug|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
79870028|NCT03885596|Drug|Lidocaine HCl|1.5% 12 mL at the end of surgery
79870029|NCT03885596|Drug|Celecoxib|200 mg PO bid each day postoperative
80028676|NCT02221596|Dietary Supplement|vitamin D|50,000IU/wk of vitamin D3
79272204|NCT05740501|Other|Electronic Health Record Review|Medical records are reviewed
79272205|NCT05740501|Other|Questionnaire Administration|Ancillary studies
79305898|NCT04917081|Behavioral|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
79870030|NCT03885596|Drug|Acetaminophen Oral|1 g postoperative
79870031|NCT03885596|Drug|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
79870032|NCT03885596|Drug|Exparel|Bupivacaine liposome injection suspension
79870033|NCT05733338|Other|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
79870034|NCT05733338|Other|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
79870035|NCT01002092|Drug|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
79870036|NCT01002092|Drug|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
79870037|NCT05567510|Drug|BMS-986369|Specified dose on specified days
79870038|NCT03999866|Device|airtraq|airtraq videolaryngoscope
79870039|NCT03999866|Device|mcgrath mac x-blade|mcgarth mac videolaryngoscope
79870040|NCT03999866|Device|storz c-mac|storz c-mac videolaryngoscope
79870041|NCT03999866|Device|storz d-blade|storz d-blade video laryngoscope
79870042|NCT01002326|Behavioral|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
79870043|NCT05733182|Device|3000K Reading lamp|Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
79870044|NCT05733182|Device|4500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
79870045|NCT05733182|Device|6500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
79870046|NCT01002404|Procedure|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
80028677|NCT02221596|Other|aerobic training|7 days of treadmill training during the 13th week of study
79575689|NCT01862692|Behavioral|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
79575690|NCT01862692|Behavioral|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
79870047|NCT00529100|Drug|Pemetrexed Phase 1|300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
79870048|NCT00529100|Drug|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles."
79272206|NCT05667285|Device|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"The investigator will use visual inspection or QCA to assess the diameter of the artery and the length of the lesion during the operation to select the stent. For each lesion, the investigator will determine the number of stents to be used based on the actual situation. The length of the stent should cover from the proximal end of the normal reference vessel to the distal end of the normal reference vessel to ensure full coverage of the lesion.~For each lesion, the investigator will determine the number of stents to be used based on the actual situation. A second stent or more stents can be used when the first stent does not completely cover the lesion. In this case, the second stent or even more stents must be this investigational stent, unless it is clinically contraindicated. Please refer to the IFU operating procedure of the stent.~If the stents are placed overlappingly, the overlapping part should be at least 2 mm."
79272207|NCT05660954|Drug|Cabozantinib|"All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose."
79272208|NCT05642780|Drug|SKB264|be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
79272209|NCT05642780|Drug|Pembrolizumab|be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
79272210|NCT05642741|Other|Response to medical and research questionnaires|Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
79272211|NCT05640063|Other|Enhanced Delivery and Newborn kit|Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
79402733|NCT05802693|Drug|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
79402734|NCT05799521|Drug|Optate|Alkaline Buffer
79402735|NCT05799521|Drug|Placebo|Normal Saline
79402736|NCT05787704|Other|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~Dual-task walking with the auditory stroop task.~Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~Navigational and dual-task walking (condition 1 and 2 together)"
79402737|NCT05784870|Drug|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
79402738|NCT05784870|Drug|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
79575691|NCT01862705|Other|Thoracic spine manipulation|TSM thrust or non-thrust
79575692|NCT01862822|Other|upright position|
79575693|NCT01862835|Drug|Degarelix|
79575694|NCT01862835|Drug|Testosterone|
79575695|NCT01862835|Drug|Anastrozole|
79575696|NCT01862835|Drug|Estrogen patch|
79870049|NCT00529100|Procedure|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
79870050|NCT00529100|Drug|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
79870051|NCT00529100|Drug|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
79575697|NCT01862887|Drug|PH-797804|Tablet, 24 mg, single dose
79575698|NCT01862887|Drug|Moxifloxacin|Tablet, 400 mg, single dose
79575699|NCT01862887|Drug|Placebo|Tablet, PH-797804 matched placebo, single dose
79402739|NCT05767684|Biological|Dendritic Cell Vaccine|Approximately 1.5 x 10^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
79870052|NCT05467280|Other|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
79870053|NCT04976660|Drug|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
79870054|NCT01002638|Other|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
79870055|NCT01002638|Procedure|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
79870056|NCT03878108|Dietary Supplement|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
79870057|NCT03878108|Dietary Supplement|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
79272212|NCT05640050|Other|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
79402740|NCT05767684|Drug|Lenvatinib|Lenvatinib 10mg/day on day 43-77
79575700|NCT01862900|Biological|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
79575701|NCT01862913|Other|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
79870058|NCT01002716|Biological|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
79870059|NCT01002794|Procedure|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital.
79870060|NCT01002794|Other|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training.
79870061|NCT05732714|Behavioral|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
79870062|NCT05388812|Other|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
79870063|NCT05388812|Other|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
79870064|NCT03999398|Procedure|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
79870065|NCT00529958|Procedure|Patellar Tendon|Patellar Tendon autograft
79402741|NCT05767684|Drug|Nivolumab|Nivolumab 3mg/kg on day 43, 57 and 71.
79402742|NCT05762302|Diagnostic Test|MeMed BV test|Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
79575702|NCT01862913|Other|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
79272213|NCT05629117|Behavioral|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
79272214|NCT05629117|Behavioral|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
79272215|NCT05627635|Biological|Balstilimab|Given IV
79575703|NCT01862926|Drug|Rituximab|
79575704|NCT01862926|Drug|Cyclophosphamide|
79870066|NCT00529958|Procedure|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
79870067|NCT00529958|Procedure|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
79870068|NCT00529802|Drug|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
80028678|NCT04971616|Other|Demographic data and range of motion.|The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
79272216|NCT05627635|Biological|Bevacizumab|Given IV
79272217|NCT05627635|Procedure|Biospecimen Collection|Undergo a blood sample collection
79272218|NCT05627635|Biological|Botensilimab|Given IV
79272219|NCT05627635|Procedure|Computed Tomography|Undergo a CT scan
79272220|NCT05627635|Drug|Fluorouracil|Given IV
79272221|NCT05627635|Drug|Leucovorin Calcium|Given IV
79272222|NCT05627635|Procedure|Magnetic Resonance Imaging|Undergo MRI
79575705|NCT01862939|Drug|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
79575706|NCT01862939|Drug|placebo|placebo to match part 2 DS-7309
79575707|NCT01862965|Drug|PredEver|Firstline treatment with prednisone and Everolimus
79575708|NCT01862978|Drug|Heparin|
79575709|NCT01862978|Drug|Nadroparin|
79575710|NCT01862978|Drug|Placebo|
79870069|NCT03742622|Behavioral|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79402743|NCT05758246|Drug|Fisetin-dose 1|20mg/kg once a day for one day.
79575711|NCT01863004|Drug|Bortezomib|
79735158|NCT05133232|Device|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~Preparation for setup (~5 mins)~Instruction video led warm up with active single and multi-joint movements - (~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~Rest break - (~5 mins)~Video led task practice as per the tasks below (any 4 tasks only) - (~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
79870070|NCT03742622|Behavioral|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
80028679|NCT02224794|Device|Ovation® Abdominal Stent Graft Platform|
79402744|NCT05758246|Drug|Fisetin-dose 2|20mg/kg once a day for two days
79402745|NCT05758246|Drug|Placebo|Placebo treatment
79402746|NCT05756829|Other|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
79735159|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
79735160|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
79402747|NCT05751603|Drug|sugammadex|sugammadex is administered just after extubation
79402748|NCT05734794|Drug|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
79575712|NCT01863069|Drug|Interferon beta 1a|
79575713|NCT01863069|Drug|(IM) AVONEX®|
79575714|NCT01863082|Other|exercise|practice of physical exercise
79575715|NCT01863095|Behavioral|Personalized Feedback and Exercise|
79575716|NCT01863108|Biological|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
79575717|NCT01863147|Drug|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
79575718|NCT01863160|Drug|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (0.1%)~Left arm, single treatment area - Placebo cream"
79735161|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
79735162|NCT05340946|Procedure|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
79735163|NCT05340946|Procedure|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
79735164|NCT00863707|Drug|Regadenoson|IV
79735165|NCT00863707|Drug|Placebo|IV
79735166|NCT05340634|Dietary Supplement|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
79735167|NCT05340634|Drug|Oral contraceptive|Drospirenone 4 mg once a day
80028680|NCT02221752|Dietary Supplement|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
80028681|NCT02221752|Dietary Supplement|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
79402749|NCT05734794|Drug|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
79402750|NCT05726721|Other|Treatment as usual, Psychotherapy|The three treament sites will offer psychotherapy as usual. All including elements of cognitive behavioral therapy and some sites also additional elements from either narrative therapy or interpersonal therapy
79575719|NCT01863160|Drug|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
79575720|NCT01863173|Drug|metoprolol|using B blocker in patient group
79735168|NCT02886689|Drug|TNF-alpha antagonist and other biotherapy|
79735169|NCT04181086|Procedure|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
79735170|NCT05367479|Drug|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
79735171|NCT02614105|Procedure|Pelvic floor muscle training|16 weeks of group-based exercise
79735172|NCT02614105|Procedure|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
79735173|NCT02614105|Other|Control|Brief information only
79870071|NCT03742622|Behavioral|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79272223|NCT05627635|Drug|Oxaliplatin|Given IV
79575721|NCT01863173|Drug|placebo|placebo to control group
79870072|NCT01003340|Behavioral|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
79870073|NCT04928456|Other|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
79870074|NCT00528866|Drug|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
79870075|NCT00528866|Drug|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
79870076|NCT00528866|Drug|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
79870077|NCT00528866|Drug|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
79870078|NCT00528866|Radiation|3-dimensional conformal radiation therapy|
79870079|NCT00528866|Radiation|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
79870080|NCT03999008|Drug|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
79272224|NCT05627635|Procedure|Positron Emission Tomography|Undergo a PET scan
79575722|NCT01863199|Drug|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
79272225|NCT05627635|Procedure|X-Ray Imaging|Undergo an x-ray
79272226|NCT05609890|Dietary Supplement|Supplement|"Supplement: a mixture of saffron, tea extract, lemon balm and valerian.~Dose: The participant will take one sachet every day, one hour before going to bed, for six weeks."
79575723|NCT01863199|Drug|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
79575724|NCT01863199|Drug|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
79575725|NCT01863212|Procedure|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
79272227|NCT05609890|Other|Placebo|"Placebo sachet~Dose: The participant will take one sachet everyday, one hour before going to bed, for six weeks."
79272228|NCT05602376|Behavioral|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
79272229|NCT05602376|Behavioral|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
79575726|NCT01863212|Behavioral|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
79575727|NCT01863212|Other|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
79575728|NCT01863225|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
79575729|NCT01863225|Drug|Rosuvastatin|20 mg daily, 28-42 days
79575730|NCT01863225|Drug|Atorvastatin|40 mg daily, 28-42 days
79575731|NCT01863225|Drug|Rosuvastatin|40 mg daily, 28-42 days
79575732|NCT01863225|Drug|Atorvastatin|80 mg daily, 28-42 days
79735174|NCT02780830|Drug|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
79735175|NCT02780830|Drug|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
79735176|NCT04187807|Drug|Melatonin 5 mg|Placebo
79735177|NCT02780752|Drug|hymecromone|Oral Hymecromone
79735178|NCT02781298|Dietary Supplement|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
79735179|NCT02781298|Dietary Supplement|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
80028682|NCT04971382|Drug|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
79735180|NCT04132297|Behavioral|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
79735181|NCT04132297|Behavioral|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
79870081|NCT03999008|Drug|Placebos|Apple Sauce 5 mL+ 1 mL saline
79870082|NCT01003574|Behavioral|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
79272230|NCT05593978|Behavioral|Culinary Medicine|The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
79575733|NCT01863238|Other|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
79575734|NCT01863238|Drug|Ivacaftor Exposed|
79575735|NCT01863251|Drug|Atomoxetine|
79870083|NCT01003574|Behavioral|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
79870084|NCT01003652|Procedure|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
79870085|NCT01003730|Other|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
80028683|NCT02220192|Procedure|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
80028684|NCT04728906|Device|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
79272231|NCT05593978|Behavioral|Control|The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
79272232|NCT05590598|Combination Product|Azelastine + Mometazone, nasal spray|140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
79402751|NCT05705128|Drug|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
79575736|NCT01863264|Other|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
79575737|NCT01863277|Drug|Melatonin|
79575738|NCT01863277|Drug|placebo|
79575739|NCT01863290|Other|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
79575740|NCT01863316|Device|I gel|
79575741|NCT01863316|Device|LMA Supreme|
79575742|NCT01863329|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
79575743|NCT01863342|Procedure|CSI score < 40|
79575744|NCT01863342|Procedure|CSI score ≥ 40|
79575745|NCT01863355|Drug|B0 group: bolus 0.6mcg/kg without background infusion|
79575746|NCT01863355|Drug|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
79575747|NCT01863355|Drug|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
79735182|NCT01094184|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
79870086|NCT04000490|Other|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
79870087|NCT01003808|Biological|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
80028685|NCT02220270|Device|ASD and PDA closure|
80028686|NCT03061162|Radiation|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
80028687|NCT02220348|Drug|linaclotide|
79735183|NCT01094184|Drug|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
79735184|NCT01094184|Drug|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
79735185|NCT00697879|Drug|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
80028688|NCT04151680|Drug|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
80028689|NCT04151680|Drug|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
80028690|NCT02221830|Drug|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
80028691|NCT02221830|Drug|Placebo|This intervention utilizes a Placebo Camparator
80028692|NCT02221908|Device|Mespere Venus 1000 CVP System|
80028693|NCT04151446|Device|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
80028694|NCT02224950|Device|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
79402752|NCT05695092|Behavioral|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
80028695|NCT02224950|Other|Non-medicated Emollient plus Cotton Sleeve|
80028696|NCT02224950|Other|Placebo Sleeve|
80028697|NCT04970524|Procedure|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
80028698|NCT04970524|Procedure|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
80028699|NCT04970758|Other||no intervention
80028700|NCT03039114|Drug|Parsaclisib|Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
80028701|NCT03039114|Drug|Hexal|Bendamustine 90 mg/m^2 administered intravenously at protocol-defined timepoints.
79735186|NCT02780908|Other|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
79735187|NCT02780908|Other|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
79575748|NCT01863381|Device|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
80028702|NCT03039114|Drug|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
80028703|NCT04970602|Drug|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
80028704|NCT02221986|Behavioral|Interdisciplinary rehabilitation|
80028705|NCT02225028|Behavioral|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
80028706|NCT04963114|Behavioral|art therapy|guided art tour and workshop
79402753|NCT05695092|Other|control|control group will not receive any intervention
79402754|NCT05684666|Other|Slow Breathing Exercise (SBE)|"Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks."
79402755|NCT05684666|Other|Progressive Muscle Relaxation (PMR) Technique|"Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks."
79402756|NCT05669053|Behavioral|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
79735188|NCT01134731|Drug|paliperidone|1-5 mg daily (QD)
79735189|NCT01134731|Drug|lithium|300-1500mg QD
79402757|NCT05669053|Behavioral|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
79735190|NCT01134731|Drug|Placebo|1-5 placebo capsules
80028707|NCT04963348|Other|convolutional neural networks (CNNs)|CNN architecture named U-Net architecture
80028708|NCT02831673|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
79575749|NCT01863381|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
79575750|NCT01863394|Other|Screening by mothers|
80028709|NCT02831673|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
79402758|NCT05669053|Behavioral|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
79870088|NCT04932746|Drug|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
79870089|NCT04932746|Drug|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
79870090|NCT00614393|Biological|dalotuzumab|IV infusion
79272233|NCT05590598|Combination Product|Momat Rhino Advance|140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
79272234|NCT05589857|Device|IPAD|Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
79272235|NCT05589857|Device|Augmented Reality|Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
79402759|NCT05650333|Drug|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
79402760|NCT05630859|Biological|NgG low dose investigational vaccine|Two doses of NgG low dose investigational vaccine, administered intramuscularly.
79402761|NCT05630859|Biological|NgG medium dose investigational vaccine|Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
79575751|NCT01863394|Other|Active comparator: Screening by community health workers|
79575752|NCT01863407|Drug|DAM|composed of dexamethasone, allantoin and metronidazole
79272236|NCT05588804|Drug|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
79402762|NCT05630859|Biological|NgG high dose investigational vaccine|Two doses of NgG high dose investigational vaccine, administered intramuscularly.
79402763|NCT05630859|Biological|Placebo|Two doses of placebo, administered intramuscularly.
79575753|NCT01863407|Drug|Normal Saline|Normal Saline 250ml
79575754|NCT01863420|Radiation|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
79575755|NCT01863459|Drug|Lisdexamfetamine Dimesylate|
79575756|NCT01863459|Drug|placebo|
79575757|NCT01863472|Device|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
79575758|NCT01863472|Device|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
79575759|NCT01863485|Drug|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
79272237|NCT05588804|Drug|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
79272238|NCT05582551|Other|Highlighting Patients at Risk for Sensory Screening (HPARSS)|Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
79272239|NCT05554705|Behavioral|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
79272240|NCT05526053|Other|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
79402764|NCT05630859|Biological|NgG HTD investigational vaccine|Two doses of NgG HTD investigational vaccine, administered intramuscularly.
79402765|NCT05630859|Biological|NgG below HTD investigational vaccine|Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
79575760|NCT01863511|Drug|loop diuretic|
79575761|NCT01863511|Drug|tolvaptan|
79575762|NCT01863511|Procedure|ultrafiltration|
79575763|NCT01863537|Behavioral|Multimedia Connect|
79575764|NCT01863537|Behavioral|Traditional Connect|
79575765|NCT01863576|Dietary Supplement|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
79575766|NCT01863576|Dietary Supplement|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
79575767|NCT01863589|Drug|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
79575768|NCT01863602|Drug|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
79575769|NCT01863615|Drug|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
79575770|NCT01863615|Drug|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
79575771|NCT01863628|Other|aerobic exercise|
79575772|NCT01863628|Other|psychoeducation|
79575773|NCT01863641|Drug|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
80028710|NCT02831673|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
80028711|NCT04962802|Behavioral|Manhood 2.0|Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.
79870091|NCT00614393|Drug|irinotecan hydrochloride|IV infusion
80028712|NCT04962802|Behavioral|Post-High School Readiness|Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
80028713|NCT02220504|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
79272241|NCT05507775|Drug|Digoxin tablet|"Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged >70 years or with body weight <55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted."
79272242|NCT05503797|Drug|FORE8394|Oral tablets
79272243|NCT05503797|Drug|Cobicistat|Oral tablets
79305899|NCT04917081|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
79575774|NCT01863641|Drug|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
79735191|NCT04132063|Drug|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
79735192|NCT05340556|Genetic|Blood sample|Blood sample of 12 ml EDTA plasma.
79870092|NCT00614393|Biological|cetuximab|IV infusion
79870093|NCT00614393|Drug|placebo|IV infusion
79870094|NCT00885521|Other|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
79402766|NCT05630118|Behavioral|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
79575775|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Reference product
79575776|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Test product
80028714|NCT02220504|Other|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
80028715|NCT04962958|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
80028716|NCT04962958|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
79870095|NCT00880529|Device|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
79870096|NCT00880529|Drug|IV opioid administration|Patient controlled analgesia with IV narcotics
80028717|NCT04962958|Drug|Donafenib|administration of Donafenib
79870097|NCT00880841|Drug|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
79870098|NCT04503863|Drug|NPC-22|Single administration of middle dose NPC-22
79870099|NCT04503863|Drug|NPC-22|Single administration of high dose NPC-22
79870100|NCT04503863|Drug|NPC-22 Placebo|Single administration of NPC-22 Placebo
79575777|NCT01863706|Drug|Misoprostol|400µg oral misoprostol
79575778|NCT01863706|Drug|Oxytocin|20 IU Oxytocin
79735193|NCT05340556|Genetic|Swap test|receive swab tests for collecting cells from the oral mucosa
79735194|NCT04127071|Procedure|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
79735195|NCT04127071|Procedure|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
79735196|NCT01141205|Biological|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
79735197|NCT01141205|Drug|Saline|1.2 ml saline intramuscularly
79870101|NCT00883259|Drug|Metformin|850 mg twice daily
79870102|NCT00883259|Other|Placebo|Microcristallyne cellulose 1 table twice daily
79575779|NCT01863719|Drug|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
79870103|NCT00885599|Drug|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
79735198|NCT02618317|Drug|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
79272244|NCT05497154|Behavioral|Training Arm|The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
79575780|NCT01863719|Drug|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
79870104|NCT00885599|Drug|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
79870105|NCT00885599|Drug|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
80028718|NCT02031510|Drug|placebo|transversus abdominis plane block with saline 0.9%
79272245|NCT05495945|Device|Low-intensity focused ultrasound pulsation (LIFUP)|LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.
79272246|NCT05495945|Combination Product|Functional Magnetic Resonance Imaging (fMRI) using Propofol|Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations
79575781|NCT01863784|Drug|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
79575782|NCT01863797|Other|Early induction|
79575783|NCT01863797|Other|Expectant mamagement|
79575784|NCT01863810|Drug|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
79575785|NCT01863810|Drug|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
79575786|NCT01863810|Drug|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
79575787|NCT01863810|Drug|Placebo of KW21052|Oral,once a day, for 8 weeks
79575788|NCT01863810|Drug|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
79735199|NCT02618317|Drug|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
79735200|NCT02618317|Drug|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
79735201|NCT02781376|Other|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
79870106|NCT00885599|Drug|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
79870107|NCT00881075|Drug|SeeMore(TM)|single dose intravenous injectable
79870108|NCT04366115|Drug|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
79870109|NCT04366115|Drug|Placebo|Single IV infusion in normal saline over 1 hour to patients.
80028719|NCT02031510|Drug|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
80028720|NCT02031510|Drug|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
80028721|NCT03059758|Other|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
80028722|NCT02230878|Drug|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
80028723|NCT02230878|Drug|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
79575789|NCT01863823|Drug|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
79575790|NCT01863823|Drug|Mouth washing|Two time washing mouth per day
79575791|NCT01863836|Procedure|Fluoroscopy|
79575792|NCT01863836|Procedure|Radial EBUS-guided biopsy|
79575793|NCT01863862|Radiation|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
79575794|NCT01863888|Drug|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
79735202|NCT02781376|Other|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
80028724|NCT02230878|Drug|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
80028725|NCT02230878|Drug|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
80028726|NCT02230878|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
80028727|NCT03059602|Other|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
79575795|NCT01863888|Drug|cholestyramine|Pharmaceutical form:powder Route of administration: oral
79575796|NCT01863888|Drug|charcoal|Pharmaceutical form:granule Route of administration: oral
79735203|NCT02614963|Drug|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
79735204|NCT02614963|Drug|placebo|Irritable bowel syndrome patients treated with placebo
79870110|NCT04712747|Procedure|Ophthalmological examinations|"OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~Color retinophotography~Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
79870111|NCT04712747|Procedure|Blood pressure measurement at rest|At the inclusion visit
79870112|NCT04038125|Drug|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
80028728|NCT02222064|Behavioral|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
80028729|NCT04961788|Drug|Gemox combimed PD1 antibody|"Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
80028730|NCT02222142|Drug|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
79575797|NCT01863914|Drug|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
79575798|NCT01863927|Other|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
79735205|NCT01140503|Drug|Apremilast|Apremilast 20mg PO BID
79735206|NCT02689726|Drug|GTL001+|
79735207|NCT02689726|Drug|Aldara|5% imiquimod cream
79735208|NCT00863317|Drug|montelukast sodium|4mg granules daily for 14 days
79735209|NCT00863317|Other|sucrose|table sugar as placebo daily for 14 days
79735210|NCT02883413|Behavioral|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
79735211|NCT02883413|Behavioral|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
79735212|NCT01200368|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
79870113|NCT00881153|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
80028731|NCT04961710|Drug|Hetrombopag Olamine|Hetrombopag Olamine; once daily
80028732|NCT04961710|Drug|Placebo|Placebo; once daily
80028733|NCT02225262|Radiation|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
80028734|NCT04961866|Dietary Supplement|parenteral protein 1 g/kg|patients received 1 g/ kg of protein
80028735|NCT04961866|Dietary Supplement|Parenteral nutrition 2 g/kg|Patients received 2 g/ kg of protein
79402767|NCT05630118|Behavioral|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
79402768|NCT05603624|Procedure|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
79870114|NCT00881153|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
79870115|NCT00885833|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
79870116|NCT00612677|Drug|Oxaliplatin|Dose Regimen: 120 mg/m^2 on Days 1 every 21 days
79870117|NCT00612677|Drug|Pemetrexed|Dose Regimen: 500 mg/m^2 on Days 1 every 21 days
79735213|NCT01200368|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
79272247|NCT05483582|Device|4-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
80028736|NCT04426084|Other|Hypertension|Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
79575799|NCT01863966|Other|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
79575800|NCT01863966|Procedure|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
79735214|NCT01200368|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
79735215|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
79735216|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
79735217|NCT00697957|Behavioral|Exercise|Progressive impact exercise
79870118|NCT04038749|Drug|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
79870119|NCT04038749|Drug|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
80028737|NCT04426084|Other|Diabetes type 2|"Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.~Exposures will be compared between cases and controls and between cases with different outcomes and controls"
79272248|NCT05483582|Device|2-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
79735218|NCT02878668|Procedure|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
79870120|NCT04038749|Other|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
79870121|NCT00883571|Procedure|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
79870122|NCT00883571|Procedure|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
79870123|NCT00883571|Procedure|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
79870124|NCT00881231|Drug|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
79870125|NCT00881231|Drug|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
79870126|NCT00613925|Device|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
79272249|NCT05474625|Device|High Intensity Laser Therapy|For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
79272250|NCT05474625|Device|Ultrasound|This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
79575801|NCT01864057|Drug|thiamine hydrochloride 100 mg|
79575802|NCT01864070|Other|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
79735219|NCT04125121|Drug|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
79735220|NCT02618083|Device|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
79735221|NCT01079130|Drug|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
79735222|NCT01079130|Drug|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
79735223|NCT01079130|Drug|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
79735224|NCT01079130|Drug|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
79735225|NCT05341570|Drug|BPI-21668|Subjects will receive BPI-21668 until disease progression
79735226|NCT02689414|Procedure|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
79735227|NCT02689414|Procedure|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
79735228|NCT01078974|Drug|pomalidomide|Taken orally once a day
79735229|NCT01078974|Drug|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
79735230|NCT01078974|Drug|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
79272251|NCT05474625|Device|Transcutaneous nerve stimulation (TENS)|TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
79402769|NCT05586958|Drug|Tigulixostat|Xanthine Oxidase Inhibitor
79402770|NCT05586958|Drug|Placebo|Matching placebo
79402771|NCT05575518|Drug|Optimised rifamycin|optimised dose rifampicin with or without moxifloxacin
79575803|NCT01864070|Drug|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
79575804|NCT01864070|Other|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
79735231|NCT04307082|Drug|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
79735232|NCT02877576|Procedure|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
79735233|NCT02877576|Behavioral|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
79735234|NCT02877576|Behavioral|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
79735235|NCT02878200|Biological|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
79870127|NCT00613925|Device|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
79735236|NCT05340088|Procedure|Retrograde intrarenal surgery after DJ stent placement|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
79870128|NCT00881309|Drug|Tripterygium|TW 90mg/d
79870129|NCT00883649|Dietary Supplement|Hydroeye|2 Capsules BID
79870130|NCT00883649|Other|Inactive Capsule|2 Capsules BID
79870131|NCT00883727|Drug|Stem cell|IV infusion of stem cells
79870132|NCT00883727|Drug|Plasmalyte A|IV infusion
79870133|NCT00883805|Biological|Blood draw|Subjects will give blood for analysis of metal ion concentrations
79870134|NCT00883805|Radiation|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
79870135|NCT00881387|Biological|rituximab|Given IV
79870136|NCT00881387|Drug|gemcitabine hydrochloride|Given IV
79870137|NCT00881387|Drug|vinorelbine ditartrate|Given IV
80028738|NCT04426084|Other|Obesity|Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
79272252|NCT05474625|Other|Exercise|A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
79272253|NCT05466383|Behavioral|Exercise|Exercise rehabilitation with Schroth method
79272254|NCT05466383|Device|Brace|Wear an orthopedic brace
79272255|NCT05441592|Drug|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
79402772|NCT05573672|Combination Product|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
79402773|NCT05563415|Behavioral|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
79402774|NCT05558436|Diagnostic Test|Detection of ctDNA methylation|Detection for colorectal tumor-specific plasma ctDNA methylation markers before treatment
79402775|NCT05547022|Procedure|Endovascular revascularisation|Peripheral vascular angioplasty or stenting
79402776|NCT05530213|Device|3D gait analysis on the GRAIL|3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)
79402777|NCT05530213|Other|Weight and height|The subject's body weight and height will be assessed
79402778|NCT05477082|Other|Observational group|Includes blood draws and data collection only
79402779|NCT05472987|Procedure|Ventral Hernia Repair|Patients will undergo retromuscular ventral hernia repair
79575805|NCT01864083|Procedure|Positron Emission Tomography (PET)|
79575806|NCT01864083|Drug|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
79575807|NCT01864083|Procedure|Positron emission mammography (PEM) When available|
79575808|NCT01864083|Procedure|MR|
79575809|NCT01864135|Device|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
80028739|NCT04426084|Drug|Antihypertensive Agents|"Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls"
80028740|NCT04426084|Drug|Statins (Cardiovascular Agents)|Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
80028741|NCT04426084|Other|Chronic kidney disease|Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.
80028742|NCT02830893|Device|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
80028743|NCT02830893|Behavioral|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
80028744|NCT02231112|Radiation|Whole breast RT on prone position|
80028745|NCT04425382|Drug|Darunavir/Cobicistat|Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
80028746|NCT04425382|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
79575810|NCT01864135|Device|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
79575811|NCT01864161|Drug|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
79735237|NCT04302012|Procedure|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
80028747|NCT02231190|Drug|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
80028748|NCT02231190|Drug|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
79272256|NCT05441592|Other|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
79272257|NCT05438199|Device|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
79272258|NCT05437419|Drug|TCK-276|Patients will receive an oral dose of TCK-276 (Dose A, B, C, and D) QD under fed conditions from Day 1 to Day 7.
79272259|NCT05437419|Drug|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo (Dose A, B, C, and D) QD under fed conditions from Day 1 to Day 7.
79575812|NCT01864161|Drug|Liposomal iron|Sideral forte 30 mg/die
79575813|NCT01864187|Drug|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
79575814|NCT01864213|Drug|Ametop cream|
79575815|NCT01864226|Drug|RO5545965|Multiple ascending doses
79735238|NCT04302012|Drug|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
79735239|NCT02780518|Device|Airvo|Applying high flow nasal oxygen
79735240|NCT04306770|Other|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
79735241|NCT00869557|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
79735242|NCT00869557|Drug|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
79735243|NCT02878356|Behavioral|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
79735244|NCT02878356|Behavioral|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
79735245|NCT02878356|Behavioral|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
79735246|NCT02780596|Other|Item1|Does CHILD NAME often wake one or more times during the night?
79735247|NCT02780596|Other|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
79575816|NCT01864226|Drug|placebo|Multiple ascending doses
79575817|NCT01864239|Other|Medicines Advice Service|"The intervention consists of:~Telephone consultations with a pharmacist~Follow-up tailored written information~A medicine reminder chart"
79735248|NCT02780596|Other|Item3|Do you think CHILD'S SLEEP is a problem?
79735249|NCT02780596|Other|Item4|Do you think CHILD NAME has a sleep problem?
79735250|NCT02780596|Other|Item5|Do you have any concerns about CHILD NAME'S sleep?
79735251|NCT02877420|Other|Non-Technical Skills Training Curriculum|
79870138|NCT00883883|Drug|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
79870139|NCT00883883|Drug|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
79870140|NCT00883961|Other|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
79870141|NCT00885989|Drug|SLV338|5 - 1000 mg IV
79870142|NCT00885989|Drug|Placebo|Placebo
79870143|NCT00886067|Drug|AZD1446|Solution, oral, single dose
79870144|NCT00886067|Radiation|2-[18F]-F-A85380|iv, single dose
79870145|NCT00881543|Drug|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
80028749|NCT03563937|Drug|Phenprocoumon|Follow the physician's prescription.
80028750|NCT03563937|Drug|Apixaban|2.5 mg or 5 mg, twice daily
80028751|NCT03563937|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
79402780|NCT05458050|Device|PU sensor|Device to assess microcirculation in sacrum area to find subjects at risk for pressure ulcer
79402781|NCT05442983|Drug|PanCytoVir™ (probenecid)|Active drug
79575818|NCT01864252|Other|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
79575819|NCT01864252|Drug|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
79735252|NCT02877420|Other|Conventional Simulation Training Group|
79735253|NCT01200290|Drug|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
79870146|NCT00881699|Behavioral|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
79870147|NCT00881699|Behavioral|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
79870148|NCT04638569|Procedure|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
79870149|NCT04124861|Drug|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
79870150|NCT00881777|Procedure|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
79870151|NCT00881777|Procedure|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
79870152|NCT02542475|Device|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (< 100x) than those used in ECT and rTMS.
79870153|NCT00881855|Drug|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
79870154|NCT00881855|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
79870155|NCT04015115|Behavioral|Youth Opioid Recovery Support service model|see arm 1 description
79870156|NCT00881933|Other|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight < 10 kg or if age < 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
79870157|NCT03940547|Other|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
79870158|NCT03940547|Other|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
79870159|NCT03929237|Other|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
79870160|NCT00882011|Other|Latest generation chemotherapies for T-LBL + transplant|"Standard doses of one of the following chemotherapies:~Holzer~LSA2-L2 modified~Stanford regimen~Hyper CVAD~Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
79735254|NCT02781142|Other|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
79870161|NCT00884195|Behavioral|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
80028752|NCT03563937|Drug|Edoxaban|30 mg or 60 mg, once daily
79402782|NCT05442983|Drug|Placebo|Matching placebo
79402783|NCT05404945|Drug|Pembrolizumab|Pembrolizumab 400 mg IV
79402784|NCT05404945|Drug|Doxorubicin|Doxorubicin 25mg/m2 IV
79402785|NCT05404945|Drug|Vinblastine|Vinblastine 6mg/m2 IV
79402786|NCT05404945|Drug|Dacarbazine|Dacarbazine 375mg/m2 IV
79402787|NCT05404945|Drug|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg IV
79575820|NCT01864252|Drug|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
79575821|NCT01864265|Drug|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
79575822|NCT01864265|Drug|Placebo|Placebo will be administered according to the label of the biological
80028753|NCT04424992|Other|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
79272260|NCT05414968|Device|Non-pharmacological Heat, Pressure, and Vibration|The innovation central to this approach is in the multifactorial combination of pressure, heat, and vibration stimuli to improve foot sensation. The heat stimuli will be provided with commercially available heating elements. The pressure stimuli will be provided via pneumatic garment. Lastly, the vibrotactile stimuli will be provided with commercially available vibrotactile motors. The non-pharmacological DPN device will be able to safely and consistently control temperature to 100-105°F within 1°F, control pressure to 50 mmHg within 5 mmHg at 0.25 Hz, and provide 5 distinguishable vibrational stimuli to 5 zones on the leg and foot.
79272261|NCT05406505|Drug|Dapagliflozin 10mg Tab|patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
79272262|NCT05406505|Other|Placebo|patients will receive placebo and standard care.
79272263|NCT05399875|Other|Augmented reality virtual ruler|Use of augmented reality virtual ruler to measure catheter length
79272264|NCT05398094|Drug|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
79272265|NCT05371808|Other|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
79272266|NCT05371808|Other|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
79272267|NCT05371808|Other|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
79735255|NCT04131985|Procedure|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
79735256|NCT05052372|Drug|Balversa|BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
79735257|NCT02618005|Dietary Supplement|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
79870162|NCT00884195|Behavioral|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
79870163|NCT02543957|Procedure|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
80028754|NCT02231268|Drug|Gladem|
79575823|NCT01864278|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
79575824|NCT01864317|Device|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
80028755|NCT04961476|Dietary Supplement|1-MNA|1-MNA supplementation
80028756|NCT02231346|Drug|Berodual® Respimat® - inhaler|
80028757|NCT02225418|Drug|Ropivacaine|
79575825|NCT01864317|Other|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
79575826|NCT01864317|Other|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
79575827|NCT01864317|Other|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
79575828|NCT01864317|Other|Humphrey Perimetry|Visual Field Testing
79575829|NCT01864317|Other|Applanation Tonometry|Measurement of Intraocular Pressure
79575830|NCT01864330|Device|Thealoz Duo®|Eye Drops
79575831|NCT01864330|Device|Hyabak®|Eye Drops
79575832|NCT01864330|Device|Hydrabak®|Eye Drops
79575833|NCT01864343|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
79575834|NCT01864356|Drug|NT100|
79575835|NCT01864356|Drug|Placebo|
79575836|NCT01864369|Behavioral|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
79575837|NCT01864382|Other|Core stability|Core stability 5 days a week during 5 weeks
79575838|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
79735258|NCT02781064|Drug|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
79735259|NCT02781064|Drug|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
79735260|NCT04205682|Drug|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
79735261|NCT04205682|Drug|Placebo|Placebo capsules administered BD for 5 days
80028758|NCT02225418|Drug|saline|
79304539|NCT02459639|Other|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
79402788|NCT05344859|Behavioral|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
79402789|NCT05344859|Behavioral|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
79575839|NCT01864395|Procedure|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
79575840|NCT01864395|Procedure|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
79575841|NCT01864395|Procedure|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
79575842|NCT01864408|Other|"Usual practice counseling"|
79735262|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
79870164|NCT00886223|Procedure|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
79870165|NCT00882089|Device|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
80028759|NCT04431856|Behavioral|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
80028760|NCT04431856|Behavioral|SHG|Brochure that details techniques for coping with stress.
80028761|NCT03679429|Device|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
79575843|NCT01864408|Other|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
79575844|NCT01864447|Behavioral|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
79575845|NCT01864473|Other|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
79575846|NCT01864486|Device|Intelligent Retinal Implant System|
79575847|NCT01864499|Procedure|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
79575848|NCT01864551|Drug|Lamotrigine|
80028762|NCT02231424|Drug|Drug: Berodual®|
80028763|NCT04960852|Other|a single shade structurally colored universal resin composite|Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
79575849|NCT01864551|Drug|Olanzapine|
79575850|NCT01864577|Other|Negative Pleural Suction at -20 cm H2O|
79575851|NCT01864577|Other|Water seal|
79575852|NCT01864590|Device|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
79735263|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
79735264|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
79735265|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
79735266|NCT01134263|Biological|Placebo: NaCl 0.9%|0.5 ml, SC
79735267|NCT00626184|Drug|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
79735268|NCT00634738|Procedure|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
79575853|NCT01864590|Device|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
80028764|NCT04431934|Dietary Supplement|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
80028765|NCT04431934|Dietary Supplement|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
80028766|NCT04717128|Other|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
80028767|NCT02231502|Other|Vegetable-based convenience food|
80028768|NCT02231502|Other|Vegetable meal|
79272268|NCT05352451|Behavioral|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
79402790|NCT05344859|Behavioral|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
79575854|NCT01864616|Dietary Supplement|Vitamin D3|
79575855|NCT01864629|Behavioral|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
79575856|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|
79575857|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
79575858|NCT01864655|Drug|saracatinib|oral drug given to experimental group
79575859|NCT01864655|Drug|Placebo|Placebo given to placebo group
79575860|NCT01864681|Drug|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
79735269|NCT02780440|Behavioral|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
79735270|NCT02780440|Behavioral|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
79735271|NCT02780440|Behavioral|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
79735272|NCT01199822|Biological|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
79870166|NCT02543645|Drug|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
79870167|NCT02543411|Drug|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
79870168|NCT02543411|Drug|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
79870169|NCT02543489|Device|Flex IM rod|
79735273|NCT05158816|Procedure|ECMO|Patients undergoing extracorporeal membrane oxygenation
79735274|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
79272269|NCT05351866|Device|CBT-based mobile intervention for depression|SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
79272270|NCT05351866|Device|Mobile control with education about depression|The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
79272271|NCT05331183|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
79272272|NCT05331183|Drug|IVA|Tablets for oral administration.
79402791|NCT05344859|Behavioral|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
79402792|NCT05337852|Other|Emotional Freedom Technique|"To the pregnant women in the experimental group; Emotional freedom technique was applied online with the researcher twice a week. The release protocol of EFT was taught to the participants and it was applied between the interviews made by the researcher. Whether the participant did the application or not was confirmed by phone and a homework schedule was used for smooth follow-up.~PUQE, PRAQ-2 tests will be applied before the intervention,~SUE and PUQE will be applied before and after each session,~After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
79575861|NCT01864681|Drug|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
79575862|NCT01864694|Behavioral|TLC-Diet|Participants receive diet intervention through an automated telephone system
79735275|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
79735276|NCT01096056|Biological|Fluarix|Intramuscular administration, 1 dose
79870170|NCT00882167|Other|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
79870171|NCT00882245|Other|Vehicle ointment|Topical vehicle cream
79870172|NCT00882245|Drug|Ointment|SRD441 Ointment
79870173|NCT02541929|Dietary Supplement|Docosahexaenoic acid|
79870174|NCT00882323|Drug|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
79870175|NCT00884429|Procedure|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
80028769|NCT04960774|Other|Observational study, no intervention|Observational study, no intervention
79870176|NCT00884429|Procedure|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
79575863|NCT01864694|Behavioral|WEB-Diet|Participants receive diet intervention through a web-based system
79870177|NCT00884429|Procedure|3-Airway suction|Airway suction
79870178|NCT00882401|Drug|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
79870179|NCT00882401|Drug|Placebo|Matching placebo at same dose schedule as ergocalciferol
79870180|NCT00886457|Drug|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
79870181|NCT04038671|Device|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
79870182|NCT04038671|Device|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
80028770|NCT02225496|Procedure|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
80028771|NCT02225496|Procedure|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
79272273|NCT05324137|Drug|CM326|CM326 injection
79272274|NCT05324137|Other|Placebo|Placebo
79272275|NCT05317832|Behavioral|WI program|This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
79272276|NCT05317832|Behavioral|WI Program Reminder|Participants will be provided with reminders to use the WI program
79272277|NCT05317832|Behavioral|JITAI Goal Setting|Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
79272278|NCT05317832|Behavioral|JITAI physical activity message|Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
79870183|NCT04038671|Device|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
79575864|NCT01864694|Other|Assessment-only control|Assessment-only control
79575865|NCT01864707|Other|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
80028772|NCT02225496|Behavioral|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
80028773|NCT04960696|Diagnostic Test|OSDI|Change of OSDI in distance education
79272279|NCT05317832|Other|Notification EMA|Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
79272280|NCT05317832|Other|End of day EMA|Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
79272281|NCT05317832|Other|Wake up time EMA|Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
79272282|NCT05317832|Other|Weekly PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
79272283|NCT05317832|Other|Daily PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
79272284|NCT05284058|Other|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
79870184|NCT02543177|Procedure|coronary angiography|
80028774|NCT04960696|Diagnostic Test|tear break up time|Change of tear break up time in distance education
79870185|NCT02543177|Procedure|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
79870186|NCT02543177|Procedure|prior kidney irrigation|
79402793|NCT05321134|Device|Single port robotic colorectal surgical procedure|"After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety & quality event rate for SP platform transabdominal and transanal colorectal operations."
79402794|NCT05318235|Other|No intervention|No intervention
79575866|NCT01864707|Other|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
79575867|NCT01864707|Other|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
79575868|NCT01864733|Other|Physical rehabilitation (exercise).|
79870187|NCT02543099|Drug|policosanol|Patients will receive policosanol 20mg Qd
79870188|NCT02543099|Drug|placebo|Patients will receive placebo 20mg Qd;
79870189|NCT00882635|Drug|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance < 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
80028775|NCT04960696|Diagnostic Test|schirmer|Change of schirmer in distance education
80028776|NCT05057130|Drug|Doxorubicin, Cisplatin, Methotrexate|IV
80028777|NCT05057130|Drug|Doxorubicin, Cisplatin|IV
79272287|NCT05253365|Behavioral|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
79272288|NCT05251116|Device|FreeStyle Libre|FreeStyle Libre 2 continuous Glucose Monitoring System
80028778|NCT04961008|Other|Bottle-PEP|A device that gives positive pressure from a bottle with the help of a non deflating tube
79272290|NCT05226676|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
79272291|NCT05225233|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
79272292|NCT05225233|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
79575869|NCT01864759|Biological|ICOVIR-5|
79575870|NCT01864785|Procedure|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
79575871|NCT01864785|Procedure|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
79575872|NCT01864798|Drug|Denosumab|
79575873|NCT01864811|Behavioral|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
79575874|NCT01864811|Behavioral|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
80028779|NCT04961008|Other|Routine physiotherapy|Routine pulmonary physiotherapy
80028780|NCT03677479|Procedure|socket preservation procedure|socket preservation of post extraction site using bone xenografts
80028781|NCT02222220|Drug|Metoclopramide|30 mg/day during 4 weeks
80028782|NCT02222220|Drug|placebo|
80028783|NCT03059290|Device|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
79735277|NCT00866359|Drug|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
79870190|NCT00882635|Drug|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
80028784|NCT03677323|Device|Virtual reality|"The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete."
80028785|NCT03677323|Drug|Droleptan|Venous administration of 1.25 mg of Droleptan
80028786|NCT03677323|Drug|Propofol|Venous administration of 20 mg of Propofol
79575875|NCT01864824|Drug|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
79870191|NCT02543021|Device|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
79870192|NCT02543021|Procedure|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
79870193|NCT02541539|Dietary Supplement|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
79870194|NCT02541539|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
79870195|NCT00886847|Procedure|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
79870196|NCT00888641|Procedure|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
79272293|NCT05215236|Other|Opiate Sparing|Subjects will receive non-opiate medications for pain control
79272294|NCT05215236|Other|Opiate Based|Subjects will receive opiate based medications for pain control
79575876|NCT01864824|Drug|Placebo|Placebo
79575877|NCT01864863|Drug|HGP1206|One Bosentan 125 mg tablet
79870197|NCT00609947|Device|Endeavor Zotarolimus-Eluting Coronary Stent|
79870198|NCT00609869|Drug|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
79272295|NCT05210920|Other|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
79272296|NCT05182229|Other|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
79575878|NCT01864863|Drug|Traclear|Two Bosentan 62.5 mg tablets
79575879|NCT01864876|Biological|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
80028787|NCT03677323|Drug|Sufentanyl|Venous administration of 5 μg of Sufentanyl.
80028788|NCT02225574|Drug|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
80028789|NCT02225574|Drug|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
79575880|NCT01864876|Biological|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
79575881|NCT01864876|Biological|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
80028790|NCT02225574|Behavioral|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
80028791|NCT02625922|Drug|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
80028792|NCT02625922|Drug|Placebo|Matching placebo i.v infusion
79735278|NCT00866359|Drug|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
79870199|NCT00609869|Drug|Rituximab|Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
80028793|NCT03679273|Dietary Supplement|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
79735279|NCT00634816|Radiation|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
79870200|NCT00529568|Drug|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
79870201|NCT00529568|Drug|placebo|double-blind matched placebo control daily oral administration
80028794|NCT02259192|Device|MED-EL Maestro Cochlear Implant|cochlear implant
80028795|NCT03619291|Other|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
80028796|NCT03619291|Other|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
79575882|NCT01864889|Biological|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
79575883|NCT01864902|Biological|CART33 cells|genetically modified lymphocyte therapy
79870202|NCT00888719|Drug|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
79870203|NCT00888719|Drug|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
79870204|NCT00888719|Drug|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
79870205|NCT04037111|Device|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
79870206|NCT04037111|Device|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
79870207|NCT04037111|Drug|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
80028797|NCT03619291|Other|control|physical inactivity, reading sports science literature, total duration 15 minutes
80028798|NCT02259270|Other|Record review|Record review. No intervention with patient or physician. No effect on outcome.
80028799|NCT02259270|Other|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
80028800|NCT03059212|Device|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
80028801|NCT03059212|Behavioral|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
79272297|NCT05182229|Other|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
79575884|NCT01864902|Biological|anti-CD33 CART|
79575885|NCT01864902|Biological|anti-CD33 CAR T cells|
79870208|NCT00886925|Drug|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
79272298|NCT05179941|Procedure|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
79870209|NCT00886925|Drug|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
79870210|NCT02542709|Device|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
80028802|NCT03688477|Device|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
80028803|NCT02225652|Drug|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
79575886|NCT01864915|Drug|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
79575887|NCT01864915|Procedure|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
79575888|NCT01864941|Procedure|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
79575889|NCT01864941|Device|Catheter venography with balloon venoplasty and balloon|
79575890|NCT01864954|Behavioral|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
79272299|NCT05170178|Behavioral|inclusion and familiarization|"presentation of the study purpose and the protocol to the volunteer~clinical examination to check inclusion and exclusion criteria~Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
79735280|NCT02780986|Behavioral|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
79735281|NCT02780986|Behavioral|Heterosexual men intervention group|"This will be delivered via 3 main activities:~Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
79735282|NCT01199198|Drug|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
79735283|NCT01199198|Drug|Placebo|Placebo by mouth once a day for 14 days.
79575891|NCT01864980|Procedure|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
79575892|NCT01864980|Procedure|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
79575893|NCT01864993|Dietary Supplement|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
79575894|NCT01864993|Dietary Supplement|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
79575895|NCT01865019|Device|mechanical ventilation|
79575896|NCT01865071|Procedure|loop ileostomi|
79575897|NCT01865097|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
79575898|NCT01865097|Behavioral|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
79735284|NCT01095978|Drug|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
79735285|NCT01134107|Drug|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
79735286|NCT01134107|Drug|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
79735287|NCT01199042|Device|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
79735288|NCT02780674|Biological|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
79735289|NCT02780674|Biological|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
79735290|NCT05339620|Procedure|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
79735291|NCT01198574|Dietary Supplement|Iron group|Ferrous fumarate, 60 mg, weekly dose
79735292|NCT01198574|Dietary Supplement|Vitamin A group|Retinol, weekly dose, 15,000 IU
79735293|NCT01198574|Dietary Supplement|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
79735294|NCT01198574|Dietary Supplement|Placebo group|folic acid only as placebo group
79735295|NCT01198028|Drug|Erlotinib|Given PO
79735296|NCT02780362|Drug|Prodactariv|1 tablet contains 60 mg Daclatasvir
79735297|NCT02780362|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
79735298|NCT01197950|Device|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
79735299|NCT01197950|Device|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
79735300|NCT01092780|Drug|MK-7288|one or two 10 mg capsules, orally, single dose
79735301|NCT01092780|Drug|Placebo to MK-7288|one or two capsules, orally, single dose
79735302|NCT01092780|Drug|Modafinil|two 100 mg tablets, orally, single dose
79735303|NCT01092780|Drug|Placebo to modafinil|two 100 mg tablets, orally, single dose
79735304|NCT05338138|Device|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
79735305|NCT04228744|Device|DBS system|"The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation."
80028804|NCT02222298|Procedure|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
80028805|NCT02222298|Procedure|Bascom Cleft lift procedure|
80028806|NCT03059368|Device|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
80028807|NCT03461653|Other|Telemedicine counselling|women on web counselling
79575899|NCT01865123|Behavioral|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
79575900|NCT01865123|Behavioral|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
79870211|NCT02542709|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
79272300|NCT05170178|Behavioral|fMRI acquisition and closure|"Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~debriefing~Protocol ending"
79272301|NCT05165901|Device|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
80028808|NCT04960462|Procedure|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
79870212|NCT00888797|Drug|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
79870213|NCT00888875|Device|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
79870214|NCT00888875|Device|ILMA|Insertion after Induction. Insertion of tracheal tube over device
79870215|NCT00884663|Drug|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
79870216|NCT00884663|Drug|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
79870217|NCT00884663|Drug|placebo|placebo tablets and capsules
79870218|NCT02542553|Procedure|Bilateral BAL|
80028809|NCT02222376|Drug|Pirfenidone|Twice a day topical application
79870219|NCT00887003|Drug|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
80028810|NCT02222376|Procedure|Debridement|Weekly ulcer debridement
79272302|NCT05160558|Drug|BIIB132|Administered as specified in the treatment arm
79870220|NCT00887003|Drug|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
79870221|NCT00887003|Drug|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
80028811|NCT03672799|Behavioral|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
79870222|NCT00887003|Drug|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
80028812|NCT03672799|Other|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
79870223|NCT00887003|Drug|Depo-Medrol|80mg Depo-Medrol
79870224|NCT00887081|Drug|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
79870225|NCT03998696|Drug|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
80028813|NCT04960540|Other|MRI,|"In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data"
80028814|NCT02231658|Drug|Liraglutide|
79272303|NCT05160558|Drug|BIIB132-Matching Placebo|Administered as specified in the treatment arm
80028815|NCT02231658|Drug|Lixisenatide|
79575901|NCT01865123|Behavioral|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
80028816|NCT03677167|Other|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
80028817|NCT04959682|Other|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
80028818|NCT04542408|Drug|Anticoagulation Agents (Edoxaban and/or high dose LMWH)|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
79575902|NCT01865136|Other|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
79575903|NCT01865149|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
79575904|NCT01865175|Drug|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
79735306|NCT05338684|Device|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins & carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck & Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
79870226|NCT03998696|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
79272304|NCT05157971|Drug|Cyclophosphamide|Given IV
79870227|NCT00888953|Other|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
79870228|NCT00888953|Other|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
79870229|NCT04867460|Procedure|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
79272305|NCT05157971|Drug|Cytarabine|Given SC, IV or IT
79272306|NCT05157971|Drug|Daunorubicin Hydrochloride|Given IV
79272307|NCT05157971|Drug|Mercaptopurine|Given PO
79272308|NCT05157971|Drug|Methotrexate|Given IT
79272309|NCT05157971|Drug|Pegaspargase|Given IM or IV
79272310|NCT05157971|Drug|Prednisone|Given PO
79272311|NCT05157971|Drug|Venetoclax|Given PO
79272312|NCT05157971|Drug|Vincristine Sulfate|Given IV
79272313|NCT05143203|Other|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
79272314|NCT05142215|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.
79272315|NCT05142215|Procedure|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.
79735307|NCT04306302|Biological|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
79735308|NCT04306302|Biological|Placebo|Participants will receive single IM injection of matching placebo.
79575905|NCT01865175|Drug|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
79575906|NCT01865188|Drug|LCZ696|Experimental monotherapy doses
79735309|NCT05338606|Drug|Bimatoprost Sustained Release Implant|Intraocular Implant
79575907|NCT01865188|Drug|Amlodipine|Active comparator monotherapy doses
79575908|NCT01865188|Drug|LCZ696 and amlodipine combination|Experimental combination doses
79575909|NCT01865188|Drug|Placebo|Placebo comparator dose
79870230|NCT00889031|Other|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
79870231|NCT05710952|Device|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
79870232|NCT04017923|Diagnostic Test|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
79870233|NCT02542787|Drug|VSN16R|Small molecule
79870234|NCT02542787|Other|Placebo|dummy tablet
79870235|NCT04847882|Behavioral|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
79870236|NCT03999086|Procedure|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
79870237|NCT03999086|Other|Control Group|Laboratory analysis to guide transfusion
80028819|NCT04542408|Drug|Low dose Low molecular weight heparin or Placebo|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
79735310|NCT01092546|Drug|[18F]Flutemetamol|All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
79870238|NCT00611975|Drug|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
79870239|NCT00611975|Drug|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
79870240|NCT05695352|Drug|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
79272316|NCT05141643|Diagnostic Test|PET Scan|Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of [18F]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second [18F]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
79272317|NCT05138991|Procedure|Echocardiogram Recording|Undergo assessment via echo
79272318|NCT05138991|Other|Questionnaire Administration|Ancillary Studies
79870241|NCT05695352|Drug|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
79870242|NCT05695352|Other|Placebo|Each tablet contains Calcium Carbonate 1000 mg
79272319|NCT05138991|Procedure|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
79272320|NCT05138991|Device|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
79870243|NCT00889109|Other|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
79575910|NCT01865201|Drug|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
79575911|NCT01865201|Other|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
79870244|NCT04895306|Drug|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
79575912|NCT01865227|Behavioral|Group Counseling|
79870245|NCT04895306|Drug|Placebo|Weekly intramuscular administration of Placebo
80028820|NCT03623581|Biological|GB226|3mg/kg treat every 2 weeks
80028821|NCT03059134|Drug|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
80028822|NCT04959136|Device|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
79272321|NCT05129280|Drug|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
79272322|NCT05129280|Drug|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants >/= 30 kg or at 12 mg/kg for participants < 30 kg.
79575913|NCT01865240|Device|Renal Denervation|Renal Denervation Catheter
79575914|NCT01865253|Device|Renal Denervation|Renal Denervation
79735311|NCT02779348|Drug|BIA 3-202|Nebicapone tablets 200 mg
79735312|NCT02779348|Drug|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
79735313|NCT02877264|Drug|vapendavir 132 mg capsule|
79575915|NCT01865266|Drug|Ulinaststin for injection|
79575916|NCT01865266|Drug|placebo|
79575917|NCT01865279|Drug|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
79575918|NCT01865279|Drug|placebo|Ascending single doses - 5 dose levels
79575919|NCT01865279|Drug|insulin degludec|A single dose corresponding to that of isophane human insulin
79575920|NCT01865279|Drug|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
79575921|NCT01865292|Drug|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
79575922|NCT01865292|Drug|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
79735314|NCT02877264|Drug|vapendavir 264 mg tablet|
79735315|NCT02877264|Drug|vapendavir 24 mg/mL oral suspension|
80028823|NCT04959214|Behavioral|progressive relaxation egzersize|Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
80028824|NCT03672721|Drug|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
80028825|NCT02225808|Behavioral|CBT for anxiety in autism|
80028826|NCT04959370|Device|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
79272323|NCT05095506|Other|eHealth Intervention|The intervention platform is interactive, and uses multimedia-assisted components. The system uses three SCI-QOL computer-adaptive tests (CATs) to assess depression, anxiety, and resilience; cut scores are used to tailor multi-media content that specifically addresses users' emotional health concerns.
79272324|NCT05095506|Other|Active Control Condition|The active control condition is a static site that displays symptom assessments followed by one educational video each week. These videos, which play in a predetermined order, provide education about managing physical health in individuals with SCI.
79272325|NCT05061823|Drug|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
79870246|NCT02542241|Drug|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
79870247|NCT02542241|Drug|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
79870248|NCT04037891|Drug|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
79272326|NCT05023252|Other|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
79272327|NCT05010005|Drug|Ruxolitinib|Ruxolitinib 20mg BID
79272328|NCT05010005|Drug|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
79575923|NCT01865305|Drug|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
79870249|NCT04037891|Other|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
79870250|NCT00887237|Device|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
79870251|NCT00887237|Device|Conventional cardiac resynchronization|Conventional cardiac resynchronization
79870252|NCT05007158|Other|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
79870253|NCT02541695|Biological|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
79870254|NCT00889343|Drug|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
79870255|NCT00889343|Drug|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
79272329|NCT04972968|Drug|ABBV-154|Subcutaneous Injection
79272330|NCT04972968|Drug|Placebo|Subcutaneous Injection
79272331|NCT04972968|Drug|Glucocorticoid|Oral Tablet
79272332|NCT04972097|Device|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
79575924|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
79575925|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
79735316|NCT02779582|Drug|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
79735317|NCT02779582|Drug|Placebo|pill with no effect
79735318|NCT01197794|Drug|AZD1981|AZD1981 twice daily
79735319|NCT01197794|Drug|AZD1981|AZD1981 once daily
79272333|NCT04963400|Diagnostic Test|Analysis of hs-cTnT serum concentration at hospitalization|Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization
79575926|NCT01865305|Drug|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
79575927|NCT01865305|Drug|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
79735320|NCT01197794|Drug|Placebo|Placebo to match AZD1981
79575928|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
79575929|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
79575930|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
79575931|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
79272334|NCT04963400|Diagnostic Test|Analysis of hs-cTnT serum concentration after discharge|Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)
79272335|NCT04954625|Procedure|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
79272336|NCT04954625|Procedure|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
79870256|NCT00889343|Drug|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
79575932|NCT01865318|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin)
79272337|NCT04953806|Behavioral|Step-CBT|Participants will complete Step-CBT, an integrative 10-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
79272338|NCT04951700|Other|Other|This is not an intervention study
79272339|NCT04945785|Other|No intervention|no intervention
79272340|NCT04928651|Drug|Clonidine|"Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG."
79272341|NCT04923672|Behavioral|Moderate continuous exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
79272342|NCT04923672|Behavioral|High intensity interval exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
79870257|NCT00889343|Drug|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
79870258|NCT00889343|Drug|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
79870259|NCT00884819|Drug|Fenofibrate|fenofibrate 200 mg daily for 6-months
79870260|NCT00884819|Other|Placebo|Placebo match for 6 months
79870261|NCT05229302|Behavioral|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
79870262|NCT05229302|Behavioral|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
79575933|NCT01865331|Drug|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
79575934|NCT01865331|Drug|placebo|Administered subcutaneously (s.c., under the skin)
79575935|NCT01865331|Drug|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
79575936|NCT01865357|Other|Brain MRI - Clinical and cognitive evaluation|"Clinical evaluation (EDSS, MSFC)~Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
79575937|NCT01865357|Other|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
79575938|NCT01865370|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
79575939|NCT01865370|Dietary Supplement|Placebo|Placebo (34.5g/day)
79575940|NCT01865383|Behavioral|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
79575941|NCT01865409|Behavioral|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
79575942|NCT01865422|Other|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
79575943|NCT01865435|Genetic|cord blood sample|
80028827|NCT04959370|Device|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
79870263|NCT04846946|Behavioral|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
80028828|NCT02941237|Device|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
80028829|NCT02222454|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
80028830|NCT04959292|Diagnostic Test|arthroscopy|arthroscopy
80028831|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
80028832|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
79272343|NCT04922762|Behavioral|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
79272344|NCT04922762|Behavioral|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
79272345|NCT04922762|Behavioral|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
79575944|NCT01865474|Drug|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
79575945|NCT01865474|Drug|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
79870264|NCT00573131|Drug|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
79870265|NCT00573131|Drug|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
79870266|NCT00573131|Drug|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
79870267|NCT00573131|Radiation|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
79870268|NCT00573131|Procedure|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
80028833|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
79575946|NCT01865500|Drug|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
79575947|NCT01865500|Drug|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
79575948|NCT01865500|Drug|Metil prednisolone|
79575949|NCT01865526|Dietary Supplement|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~Do not add salt at table and for cooking;~Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~Replace noodle or bread with special no-protein food;~The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~4-5 servings/day of fruits or vegetables are suggested;~Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
79575950|NCT01865526|Dietary Supplement|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
79575951|NCT01865578|Device|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
79575952|NCT01865578|Device|Sham Stimulation|no electrical stimulation
79575953|NCT01865591|Device|Ultrasound-based Renal Denervation|
79575954|NCT01865604|Device|Anodal tDCS|
79870269|NCT01565018|Drug|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
79870270|NCT01565018|Drug|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
79870271|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
79870272|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
79735321|NCT04307316|Other|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
79870273|NCT01565096|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
79870274|NCT01565096|Drug|Glimepiride|Glimepiride at individual dose
79870275|NCT00887393|Other|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (< 15% of total kcaloric intake)
79870276|NCT00887393|Other|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
79870277|NCT00889499|Drug|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
79870278|NCT00889499|Drug|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
79870279|NCT00889499|Drug|Placebo|NHCL 0,9%
79870280|NCT00889655|Drug|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
79870281|NCT00889655|Drug|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
79870282|NCT05002946|Drug|SP-104|single oral dose
79870283|NCT05002946|Drug|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
79870284|NCT04635098|Drug|dexmedetomidine|All participants will be randomly assigned to receive either dexmedetomidine or saline
79870285|NCT04635098|Drug|saline|All participants will be randomly assigned to receive either dexmedetomidine or saline
79870286|NCT00521144|Drug|obatoclax mesylate|Given IV
79870287|NCT00521144|Drug|topotecan hydrochloride|Given IV
79870288|NCT00521144|Other|laboratory biomarker analysis|Correlative studies
79870289|NCT00520676|Drug|pemetrexed|500 mg/m^2, IV, q 21 days x 6 cycles maximum
79870290|NCT00520676|Drug|docetaxel|75 mg/m^2, IV, q 21 days x 6 cycles maximum
79575955|NCT01865604|Device|Cathodal tDCS|
79575956|NCT01865604|Device|sham tDCS|
79575957|NCT01865630|Drug|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
79735322|NCT04307316|Other|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
79870291|NCT00520676|Drug|carboplatin|AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum
79575958|NCT01865643|Device|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
79575959|NCT01865656|Other|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
79575960|NCT01865656|Other|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
79575961|NCT01865656|Other|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
79575962|NCT01865656|Other|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
79735323|NCT02779426|Behavioral|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
79575963|NCT01865656|Other|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
79575964|NCT01865669|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
79870292|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with [18F]-FDOPA
79870293|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with [18F]-FEOBV
79870294|NCT03998852|Device|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the [18F]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
79870295|NCT03998852|Other|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
79870296|NCT04063748|Behavioral|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
79870297|NCT04063748|Behavioral|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
79870298|NCT04063748|Behavioral|Passive Control|No intervention in the passive control group for HA-users.
79870299|NCT00610649|Drug|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
79870300|NCT00610649|Drug|Placebo|Orally administered matching placebo capsules.
79870301|NCT02542085|Procedure|Laparoscopic repair|operative method
79870302|NCT02542085|Procedure|Hybrid repair|operative method
79870303|NCT00885053|Dietary Supplement|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
79870304|NCT00885053|Dietary Supplement|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
79870305|NCT00889733|Drug|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
79870306|NCT00887627|Drug|conivaptan hydrochloride|intravenous
79870307|NCT04037579|Other|Survey|Non-randomised survey
79870308|NCT00889811|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
79870309|NCT00887705|Behavioral|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
79870310|NCT00890123|Dietary Supplement|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
79870311|NCT00885287|Drug|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
80028834|NCT04958980|Behavioral|Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research|"Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home."
80028835|NCT02222532|Drug|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
79735324|NCT04228198|Procedure|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
79735325|NCT04317638|Other|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
80028836|NCT02222532|Drug|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
80028837|NCT04959058|Device|Volunteer|An ultrasound machine will be used to calculate the elastographic value of the brachial plexus in three different positions.
80028838|NCT04958590|Radiation|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
80028839|NCT04958824|Diagnostic Test|Pharmacogenetic test|Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
80028840|NCT02226042|Behavioral|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
79735326|NCT04307472|Behavioral|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
79735327|NCT04307472|Behavioral|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
79735328|NCT02780050|Other|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
79735329|NCT00634894|Drug|Femara|2.5 mg by mouth daily x 12 weeks
79735330|NCT00634894|Drug|Placebo|Placebo capsule by mouth daily x 12 weeks
79735331|NCT02779270|Drug|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
79735332|NCT02779270|Drug|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
79735333|NCT02779894|Other|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
79735334|NCT04228900|Dietary Supplement|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
79272346|NCT04916340|Behavioral|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
79272347|NCT04916340|Behavioral|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
79870312|NCT00923429|Procedure|Stay-active care|No other treatment than the stay-active care
79870313|NCT00923429|Procedure|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
79870314|NCT00923429|Procedure|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
79870315|NCT00923429|Procedure|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
79870316|NCT02542007|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
79870317|NCT02542007|Device|sirolimus-eluting stent system|
79870318|NCT00887861|Drug|Investigational new drug, company code: BGG492|
80028841|NCT03672565|Behavioral|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
79272348|NCT04916327|Dietary Supplement|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
79735335|NCT04228900|Drug|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
79402795|NCT05314361|Behavioral|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
79402796|NCT05307185|Dietary Supplement|Tritordeum-based food|Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
79272349|NCT04916327|Dietary Supplement|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
79402797|NCT05305989|Drug|Belumosudil 200 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
79402798|NCT05305989|Drug|Belumosudil 200 mg BID|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
79735336|NCT01078662|Drug|olaparib|Tablets Oral BID
79402799|NCT05305989|Drug|Belumosudil 400 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
79735337|NCT04227886|Radiation|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
79870319|NCT00887861|Drug|Placebo|
79272355|NCT04887324|Other|no intervention|no intervention
79272356|NCT04881448|Diagnostic Test|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
79272357|NCT04875364|Drug|Eszopiclone|2mg of Eszopiclone just before going to sleep.
79272358|NCT04875364|Other|Supplemental Oxygen|Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
79272359|NCT04875364|Device|Continuous Positive Airway Pressure (CPAP)|A standard CPAP device will be provided using the settings as prescribed by the treating physician.
79402800|NCT05279456|Biological|Advax-CpG55.2 adjuvanted recombinant spike protein|recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
79402801|NCT05276830|Drug|BXCL501|Sublingual film containing 40 Micrograms BXCL501
79402802|NCT05276830|Drug|BXCL501|Sublingual film containing 60 Micrograms BXCL501
79402803|NCT05276830|Drug|Placebo film|Matching Sublingual Placebo film
79402804|NCT05259124|Device|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
79402805|NCT05218109|Device|tVNS|transcutaneous vagus nerve stimulation
79402806|NCT05218109|Behavioral|Mindfulness|Brightmind mobile mindfulness application
79402807|NCT05218109|Device|sham tVNS|sham transcutaneous vagus nerve stimulation
79402808|NCT05218109|Other|Number Puzzle|Control number puzzle task delivered via mobile device
79575965|NCT01865695|Drug|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
79575966|NCT01865695|Other|Placebo|
79575967|NCT01865721|Drug|Entonox|Entonox will be used according to the allocated method
79870320|NCT04037267|Procedure|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
79870321|NCT00892541|Drug|ER OROS paliperidone|
79870322|NCT02541617|Procedure|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
79272360|NCT04858022|Behavioral|Visual Acoustic Biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
79870323|NCT02541617|Procedure|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
79870324|NCT00890279|Drug|Cilnidipine|Cilnidipine up to 20 mg
79575968|NCT01865734|Other|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
79272361|NCT04858022|Other|No treatment - waitlist|10-week period of no treatment
79735338|NCT04227886|Drug|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1*1*1 or 65mg/m2 for UGT1A1*1*28 weekly, followed by a cycle of XELIRI.
79272362|NCT04848116|Drug|Nivolumab|Nivolumab is an investigational drug in this study.
79272363|NCT04848116|Drug|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
79272364|NCT04846829|Drug|Placebo|saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
79735339|NCT02200978|Drug|ATO|Given IV
79735340|NCT02200978|Drug|RIF|Given orally
79735341|NCT02200978|Drug|ATRA|Given orally
79272365|NCT04846829|Device|intermittent theta burst stimulation|"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
79272366|NCT04846829|Drug|intravenous citalopram hydrochloride (CIT)|CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
79735342|NCT02200978|Drug|mitoxantrone|Given IV
79735343|NCT02200978|Drug|Ara-C|Given IV
79272367|NCT04846829|Device|continuous theta burst stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
79735344|NCT02200978|Drug|MTX|Given orally
79735345|NCT02200978|Drug|6MP|Given orally
79735346|NCT02200978|Other|intrathecal injection|Ara-C and dexamethasone
79735347|NCT02779192|Drug|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
79735348|NCT02779192|Drug|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
79870325|NCT00890279|Drug|Imidapril|Imidapril up to 10 mg per day
79870326|NCT00892619|Procedure|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
79735349|NCT02779192|Drug|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
79735350|NCT05020210|Drug|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
79735351|NCT04227808|Drug|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
79870327|NCT00892619|Procedure|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
79870328|NCT00608543|Drug|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
79870329|NCT00890435|Other|questionnaire administration|
79870330|NCT00890435|Procedure|psychosocial assessment and care|
79870331|NCT02541383|Drug|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
79735352|NCT04963426|Behavioral|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
79735353|NCT04963426|Other|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
79735354|NCT01091454|Drug|brostallicin|Given IV
79735355|NCT01091454|Drug|cisplatin|Given IV
79735356|NCT01140347|Biological|Placebo|8 mg/kg IV every 2 weeks
79870332|NCT02541383|Drug|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
79870333|NCT02541383|Drug|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
79272368|NCT04837989|Behavioral|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
79272369|NCT04837989|Behavioral|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
79575969|NCT01865734|Other|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
79575970|NCT01865760|Dietary Supplement|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
79575971|NCT01865760|Dietary Supplement|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
79575972|NCT01865760|Drug|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
79575973|NCT01865773|Procedure|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
79575974|NCT01865825|Radiation|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
79575975|NCT01865838|Device|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
79575976|NCT01865851|Device|Classic Face Mask and NuMask|
79870334|NCT04036643|Radiation|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
79870335|NCT04036487|Drug|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
79870336|NCT04036487|Drug|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
79870337|NCT04036565|Behavioral|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
79272370|NCT04835935|Other|microbiome pattern|microbiome pattern in neonatal period
79870338|NCT02541149|Procedure|blood sample|
79870339|NCT05278793|Drug|Ferrous fumarate|Ferrous fumarate 200mg oral
79870340|NCT00892853|Procedure|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
79870341|NCT00890669|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1),~control condition (conventional physical therapy group) (B). and~treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
79272371|NCT04825704|Drug|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
79272372|NCT04825704|Drug|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
79272373|NCT04815083|Drug|Aminolevulinic Acid Hydrochloride|PD G 506 A for oral solution (aminolevulinic acid [ALA] hydrochloride [HCl] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
79272374|NCT04815083|Device|Eagle V1.2 Imaging System|Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
79272375|NCT04815083|Drug|Placebo|Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
79272376|NCT04798469|Drug|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
79272377|NCT04798469|Drug|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
79272378|NCT04792697|Other|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
79272379|NCT04792697|Other|Decrease evening blue light|Participants will wear blue light blocker goggles for 2 hours before bed
79272380|NCT04792697|Behavioral|Sleep Scheduling|Participants will advance their bedtime by 1.5 hours and regularize their wake time
79735357|NCT01140347|Biological|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
79870342|NCT00892931|Drug|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
79870343|NCT05278325|Other|Telephone intervention|Two planned phone call between clinical controls
79870344|NCT04037657|Drug|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
79870345|NCT04037657|Drug|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
79870346|NCT04037345|Biological|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
79870347|NCT04037345|Biological|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
79870348|NCT04037345|Biological|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)
79575977|NCT01865916|Drug|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
79575978|NCT01865916|Drug|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
79575979|NCT01865929|Device|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
79575980|NCT01865929|Procedure|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
79575981|NCT01865942|Procedure|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
79735358|NCT01140347|Other|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
79735359|NCT02779114|Drug|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
79735360|NCT02779114|Other|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
79575982|NCT01865942|Procedure|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
79735361|NCT02779114|Other|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
79272381|NCT04792697|Behavioral|Monitor sleep, mood, and substance use|Participants will complete smartphone-based sleep, mood, and substance use monitoring
79735362|NCT04227964|Device|Enamel matrix derivative, bone replacement graft, barrier membrane|
79735363|NCT04227964|Procedure|Tooth extraction and replacement|
79735364|NCT02779036|Procedure|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
79735365|NCT02779036|Procedure|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
79735366|NCT02878278|Drug|Chidamide BIW|Chidamide is given 30mg, twice a week
79575983|NCT01865955|Procedure|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
79575984|NCT01865955|Device|The spinal needle|
79575985|NCT01865968|Biological|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
79735367|NCT02878278|Drug|Chidamide QD|Chidamide is given 10mg,QD
79870349|NCT00893009|Drug|Theophylline|100 mg twice a day
79870350|NCT00893009|Drug|Placebo|Placebo
79870351|NCT00888095|Procedure|deep brain stimulation|electrode implantation in either STN or cZI
79870352|NCT00890747|Drug|sunitinib malate|Given PO
79870353|NCT00890747|Other|pharmacological study|Correlative studies
79870354|NCT00890747|Other|laboratory biomarker analysis|Correlative studies
79870355|NCT00888251|Other|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
79870356|NCT00893087|Device|Triggering mode of the ventilator|10 min of each triggering mode
79870357|NCT00893087|Device|Triggering method of the ventilator|Flow triggering
79870358|NCT00893087|Device|Triggering method of the ventilator|Pressure triggering
79870359|NCT00893087|Device|Triggering method of the ventilator|NAVA triggering
80028842|NCT03672565|Behavioral|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
80028843|NCT03672565|Behavioral|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
80028844|NCT02258646|Behavioral|Exercise training at home|
80028845|NCT02258646|Behavioral|Telemonitoring and education/self-management|
80028846|NCT02919163|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
79304540|NCT02459639|Other|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
79735368|NCT02883101|Behavioral|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
79870360|NCT04017845|Diagnostic Test|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
79735369|NCT05209126|Dietary Supplement|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
80028847|NCT02231970|Procedure|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
80028848|NCT02855814|Other|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
80028849|NCT03623425|Drug|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
80028850|NCT03623425|Drug|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
79735370|NCT05224739|Procedure|Minimally Invasive Liver Resection|laparoscopic and robotic liver resections
79735371|NCT04227652|Drug|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
79735372|NCT02883569|Procedure|open or endoscopic discectomy|FDA approved surgical procedures
79735373|NCT02883569|Procedure|epidural block|epidural block
79735374|NCT02883569|Other|exercise|educated exercise
79735375|NCT02883569|Drug|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
79735376|NCT02883569|Procedure|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
79870361|NCT04017845|Procedure|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
80028851|NCT02232048|Other|Transthoracic Echocardiogram|
80028852|NCT04958512|Drug|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
80028853|NCT04958512|Drug|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
80028854|NCT04958512|Other|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
79735377|NCT02883569|Procedure|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
80028855|NCT03672409|Behavioral|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
79735378|NCT02883569|Drug|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
79735379|NCT02883569|Procedure|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
79735380|NCT04306224|Biological|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
80028856|NCT02222766|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
79575986|NCT01865968|Biological|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
80028857|NCT02222766|Behavioral|Control|Minimal attention control- 9 weekly mailed information on general child development
80028858|NCT04957888|Other|none intervention|none intervention.
80028859|NCT03678961|Behavioral|external rotation of leg|external rotation of leg by 45 degrees
80028860|NCT03678961|Behavioral|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
79272382|NCT04782102|Behavioral|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
79272383|NCT04758000|Drug|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI > 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
79575987|NCT01866007|Drug|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
79735381|NCT02883023|Other|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
79735382|NCT02883023|Drug|Intralesional bleomycin injection|Local intralesional injections with bleomycin
79735383|NCT02778958|Drug|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
79735384|NCT02778958|Drug|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
79870362|NCT04017845|Procedure|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions <25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
80028861|NCT04957576|Behavioral|Visuo-tactile stimulation|The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
80028862|NCT03672253|Drug|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
80028863|NCT04957810|Behavioral|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
79735385|NCT01197560|Drug|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
79735386|NCT01197560|Drug|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m^2 IV days 1 and 15 every 28 days for 6 Cycles
80028864|NCT02226354|Dietary Supplement|Ahiflower oil|9.73 ml per day for 28 days
79575988|NCT01866007|Drug|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
79575989|NCT01866007|Drug|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
79575990|NCT01866007|Drug|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
79735387|NCT01197560|Drug|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m^2 IV day 1 for 21 days for 6 Cycles
80028865|NCT02226354|Dietary Supplement|Flaxseed oil|9.73ml per day for 28 days
80028866|NCT04957654|Other|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
79575991|NCT01866033|Drug|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
79735388|NCT01197560|Drug|Rituximab|Suggested starting dose for Rituximab is 375 mg/m^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
79735389|NCT01197560|Drug|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-10 every 28 days for 6 Cycles"
79735390|NCT04227418|Device|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
80028867|NCT04957654|Other|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
79272384|NCT04756141|Device|Continuous Glucose Monitor (CGM)|A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
79272385|NCT04735289|Other|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
79272386|NCT04735289|Other|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~a blood sample for metabolomics analyses~a stool sample for microbiota analysis~Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
79272387|NCT04721145|Device|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
79575992|NCT01866033|Drug|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
79575993|NCT01866033|Drug|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
79575994|NCT01866033|Drug|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
79735391|NCT04227418|Device|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
79575995|NCT01866046|Behavioral|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
79735392|NCT04227418|Device|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
79575996|NCT01866059|Device|Calcium silicate cement|Calcium silicate cement
79870363|NCT04017845|Diagnostic Test|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: >10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
79870364|NCT04017845|Drug|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
79870365|NCT04017845|Drug|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
79272388|NCT04691141|Drug|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
79870366|NCT00893165|Behavioral|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
79272389|NCT04688320|Drug|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
79575997|NCT01866059|Device|Glass Ionomer Cement|Glass Ionomer Cement
79870367|NCT02541773|Device|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
79870368|NCT00891137|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
79870369|NCT00520130|Biological|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
79272390|NCT04688320|Drug|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
79304541|NCT03194347|Diagnostic Test|molecular genetic analyses|molecular genetic analyses
79575998|NCT01866059|Device|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
79575999|NCT01866085|Procedure|AdVance® sling procedure|
79576000|NCT01866085|Procedure|ARGUS Sling procedure|
79576001|NCT01866124|Other|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
79576002|NCT01866176|Device|Stabilizing Knee Brace|Brace with no valgus action
79576003|NCT01866176|Device|Valgus Knee Brace|Valgus brace with traditional three point bending system
79576004|NCT01866176|Device|New Knee Brace|Brace with new mechanism to decrease the knee loading.
79576005|NCT01866189|Other|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
79576006|NCT01866215|Other|exercise|cycling at 100W during 60 min
79576007|NCT01866215|Dietary Supplement|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
79576008|NCT01866215|Dietary Supplement|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
79576009|NCT01866228|Other|Consultation Recording|
79576010|NCT01866241|Drug|Misoprostol|Is a prostaglandin
79576011|NCT01866254|Drug|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
79576012|NCT01866254|Drug|Morphine|Injection of 200 mcg of intrathecal morphine
79870370|NCT00520130|Drug|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
79870371|NCT00520130|Drug|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
79272391|NCT04684576|Device|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
79272392|NCT04684576|Device|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
79272393|NCT04659616|Procedure|Biospecimen Collection|Undergo blood sample collection
79272394|NCT04659616|Procedure|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
79576013|NCT01866267|Drug|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
79576014|NCT01866280|Behavioral|Normal sleep|Normal sleep= sleep 2300-0700
79576015|NCT01866280|Behavioral|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
79735393|NCT04228666|Biological|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
79735394|NCT04196140|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
79735395|NCT05199142|Drug|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
79870372|NCT00520130|Drug|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
79870373|NCT00520130|Drug|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
79735396|NCT05199142|Drug|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
79735397|NCT05320978|Device|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
79735398|NCT05315362|Device|solid microneedle skin patch|intradermal vaccination with a skin patch
79870374|NCT00520130|Drug|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
79870375|NCT00520130|Drug|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
79870376|NCT00520130|Biological|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
79870377|NCT00519896|Drug|sunitinib malate|Given PO
79870378|NCT03998384|Procedure|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
79272395|NCT04659616|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
79272396|NCT04659616|Drug|Cytarabine|Given IV
79735399|NCT05315362|Biological|mRNA-1273|administration of mRNA-1273 vaccine
79272397|NCT04659616|Drug|Daunorubicin|Given IV
79272398|NCT04659616|Procedure|Electrocardiography|Undergo ECHO
79272399|NCT04659616|Drug|Pemigatinib|Given PO
79272400|NCT04645927|Dietary Supplement|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk & soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
79272401|NCT04645927|Dietary Supplement|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
79272402|NCT04645706|Other|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
79272403|NCT04627870|Device|drug (paclitaxel) coated balloon|use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis
79576016|NCT01866280|Behavioral|Late sleep|Late sleep=sleep at 0230-1030 hours
79576017|NCT01866280|Behavioral|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
79735400|NCT05315362|Device|standard needle|intramuscular vaccination with a standard needle
79735401|NCT02778568|Behavioral|Resistance training|Resistance training exercises
79735402|NCT02778568|Behavioral|Control|Stretching exercises
80028868|NCT04957654|Other|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
79735403|NCT04227496|Device|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
80028869|NCT02223000|Drug|BIBV 308 SE solution|
79870379|NCT03998384|Procedure|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
80028870|NCT02223000|Drug|BIBV 308 SE capsule 1|
80028871|NCT02223000|Drug|BIBV 308 SE capsule 2|
79576018|NCT01866332|Other|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
79272404|NCT04627870|Device|PTA balloon|use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
79272405|NCT04625101|Drug|NBI-827104|Triple T-type calcium channel blocker.
79576019|NCT01866332|Device|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
79735404|NCT01133405|Drug|LY2886721|Oral capsules
79272406|NCT04625101|Drug|Placebo|Non-active dosage form.
79576020|NCT01866345|Procedure|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
79576021|NCT01866345|Procedure|Conventional orthodontic treatment|Conventional orthodontic Procedure
79735405|NCT01133405|Drug|Placebo|Oral capsules
79735406|NCT02779816|Device|Pen device|Adaptive pen device
79735407|NCT01196078|Drug|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
79735408|NCT01196078|Drug|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
79735409|NCT05314660|Drug|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
79870380|NCT03941600|Behavioral|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
80028872|NCT04957420|Drug|Neupro|Rotigotine Patches
80028873|NCT03350035|Drug|IV Ganaxolone active|IV
79735410|NCT05314660|Procedure|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
79735411|NCT05314660|Procedure|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
80028874|NCT03350035|Drug|IV Placebo, non-active|IV
80028875|NCT02223078|Biological|G17DT|
80028876|NCT02223078|Biological|Placebo Comparator|
80028877|NCT04957108|Other|Device identification using Xray.|PMIDa and CRMD-f applications were used to identify CIED
80028878|NCT02905188|Genetic|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10^7/m2~DL2: 3x10^7/m2~DL3: 1x10^8/m2~DL4: 3x10^8/m2~DL5: 1x10^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
80028879|NCT02905188|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
80028880|NCT02905188|Drug|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
79735412|NCT05314036|Other|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
79735413|NCT01133171|Behavioral|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
79735414|NCT01133171|Behavioral|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
80028881|NCT03676933|Drug|DS107E|
80028882|NCT03676933|Drug|Vehicle|
80028883|NCT03676933|Drug|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
80028884|NCT04957030|Diagnostic Test|ULDCT group|underwent ultralow-dose chest CT
80028885|NCT02232204|Behavioral|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
80028886|NCT03671941|Drug|D578|D578 Tab.1T single oral administration under fasting condition
80028887|NCT03671941|Drug|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
79576022|NCT01866358|Procedure|Intraosseous infusion|Using intraosseous infusion for resustation in this group
79576023|NCT01866358|Procedure|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
79870381|NCT03941600|Behavioral|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
79576024|NCT01866384|Procedure|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
80028888|NCT03058900|Drug|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
80028889|NCT03058900|Other|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
80028890|NCT03058900|Drug|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
80028891|NCT02226510|Drug|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
80028892|NCT02226510|Drug|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
79272407|NCT04595617|Biological|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
79272408|NCT04586699|Device|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
79272409|NCT04586699|Device|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
79272410|NCT04564742|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
79576025|NCT01866384|Other|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
79576026|NCT01866397|Other|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
79272411|NCT04564742|Drug|Placebo|Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
79272412|NCT04562649|Device|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
79272413|NCT04562649|Behavioral|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
79272414|NCT04508790|Drug|Dexamethasone|Given PO
79272415|NCT04508790|Drug|Leflunomide|Given PO
79272416|NCT04508790|Drug|Pomalidomide|Given PO
79576027|NCT01866436|Other|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
79576028|NCT01866436|Other|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
79576029|NCT01866449|Drug|Cabazitaxel|
79576030|NCT01866462|Other|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
79576031|NCT01866475|Device|EZ-IO|To have an EZ-IO placed up to 48 hours
79576032|NCT01866488|Drug|Misoprostol|
79576033|NCT01866488|Other|Placebo|
79576034|NCT01866501|Procedure|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
79576035|NCT01866501|Device|EZ-IO|
79735415|NCT01195844|Biological|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children < 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
79735416|NCT02883725|Other|data collection|
79735417|NCT04920292|Drug|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
79735418|NCT04920292|Drug|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
79735419|NCT02779972|Other|Echo stress test|Echo stress test
79870382|NCT00527618|Drug|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
79870383|NCT00527618|Drug|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
80028893|NCT03676855|Procedure|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
79272417|NCT04492566|Device|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
79576036|NCT01866514|Procedure|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
79576037|NCT01866514|Drug|2% preservative-free lidocaine|
79272418|NCT04490603|Behavioral|Virtual reality experience|Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
79272419|NCT04469881|Behavioral|VR|"Participants will be asked to do the following things:~Wear VR goggles for the duration of the surgery~Answer questions about their experience with the VR goggles~Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital"
79272420|NCT04468633|Device|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
79576038|NCT01866514|Device|EZ-IO|
79272421|NCT04468633|Device|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
79272422|NCT04466787|Diagnostic Test|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients < 80 kg and 1 mL/kg for patients > 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
79272423|NCT04466787|Diagnostic Test|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients < 80 kg and 1 mL/kg for patients > 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
79304542|NCT03282773|Device|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
79576039|NCT01866553|Drug|Nilotinib|300 mg capsule BID oral use
79576040|NCT01866553|Drug|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
79576041|NCT01866566|Biological|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
79576042|NCT01866566|Biological|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
79576043|NCT01866566|Biological|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
79576044|NCT01866566|Biological|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
79576045|NCT01866605|Drug|Midazolam|Intravenous midazolam 0.3 mg/kg
79576046|NCT01866605|Drug|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
79576047|NCT01866605|Device|Bair Hugger|Forced air warming
79576048|NCT01866644|Drug|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
79576049|NCT01866644|Drug|Saline|Bath saline transplanted liver
79576050|NCT01866670|Behavioral|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
79576051|NCT01866670|Behavioral|relaxation therapy|Relaxation Therapy: deep breathing
79576052|NCT01866683|Behavioral|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
79576053|NCT01866683|Behavioral|1 month waiting period|waiting or detraining period
79576054|NCT01866696|Device|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~Clinical examination~Radiological examination~Guided oral implants insertion~Immediate Prosthetic loading~Follow-up"
79576055|NCT01866722|Behavioral|Usual care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
79735420|NCT04312685|Device|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
79735421|NCT02779738|Drug|Merestinib|Administered orally
79735422|NCT04227262|Other|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
79735423|NCT01132547|Drug|cyproheptadine hydrochloride|Given orally
79735424|NCT01132547|Other|placebo|Given orally
79735425|NCT01194830|Drug|Linagliptin|Active drug 1 tablet PO QD
79735426|NCT01194830|Drug|Placebo|1 Tablet PO QD
79735427|NCT05074888|Drug|Prospekta|Oral administration.
79870384|NCT04622072|Drug|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
80028894|NCT04956874|Behavioral|FL-REACH|The FL REACH intervention is a 6-session intervention designed to facilitate transition to care following delivery of a memory disorders diagnosis by a MDC team. The intervention focused on an approach that used a toolbox of strategies to tailor skills-based learning, knowledge transmission, and self-care strategies to dementia caregivers. This pilot study focuses on adapting the established REACH II intervention for translation to the clinical setting, with a focus not only on implementation of the key components of the program, but also on feasibility and sustainability. This is part of a stepped-care model that is being developed at the AdventHealth-Orlando MDC. Caregivers of patients will be referred to the FL REACH intervention for foundational training and skills-development.
80028895|NCT02225886|Drug|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
80028896|NCT04956328|Drug|Obeticholic Acid Tablets|Obeticholic Acid：Once a day (QD) by mouth (PO).
80028897|NCT04956328|Drug|UDCA|UDCA：continue prestudy dose
80028898|NCT04956328|Drug|Placebo|Placebo
80028899|NCT02223234|Behavioral|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
79272424|NCT04452162|Diagnostic Test|MRI|You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
79272425|NCT04424290|Drug|BI 764524|BI 764524
79272426|NCT04424290|Drug|Sham control of BI 764524|Sham control of BI 764524
79576056|NCT01866722|Behavioral|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
79735428|NCT05074888|Drug|Placebo|Oral administration.
79272427|NCT04393389|Device|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
79272428|NCT04378244|Drug|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
79272429|NCT04298346|Other|no intervention|no intervention
79735429|NCT04228510|Procedure|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
79735430|NCT02778334|Other|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~patients who return home and~patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
79272430|NCT04281472|Biological|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
79272431|NCT04281472|Other|placebo in stage B|Stage A: N/A, stage B: placebo
79272432|NCT04280718|Biological|Efgartigimod PH20 SC|Subcutaneous administration of efgartigimod
79576057|NCT01866722|Behavioral|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
79576058|NCT01866735|Other|Standardized Rehabilitation Therapy|
79576059|NCT01866748|Drug|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
79870385|NCT00527072|Biological|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
79870386|NCT00526994|Other|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
79870387|NCT00526994|Behavioral|universal education|receives referral information
79870388|NCT04743128|Behavioral|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
80028900|NCT02223234|Behavioral|Control|Monthly emails on child health
80028901|NCT02223234|Behavioral|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
79272433|NCT04275310|Behavioral|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
79272434|NCT04273061|Drug|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
79272435|NCT04268992|Other|Long-term exercise|All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
79870389|NCT00519428|Drug|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
79272436|NCT04225871|Drug|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
79576060|NCT01866748|Drug|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
79272437|NCT04157231|Other|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
79272438|NCT04157088|Drug|Darolutamide (Nubeqa, BAY1841788)|600mg, twice daily
79402809|NCT05211596|Behavioral|Deaf Weight Wise intervention|The DWW intervention consists of groups of 5 subjects who meet together for 16 weeks, 2 hours each week. Group meetings will be held virtually on Zoom. A trained, deaf, ASL-fluent counselor will lead the sessions. Each session includes group sharing, problem solving, discussion of a weight management topic, and goal setting and action planning for the next week. A key principle of DWW is motivational interviewing, in which the counselor acts as a facilitator to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The maintenance phase starts immediately after the 16-week intervention, and consists of two meetings of the original group via Zoom; one at month 3 and one at month 6 of the maintenance period. Counselors also email participants bi-weekly to check in and provide additional support.
79402810|NCT05205928|Drug|Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
79402811|NCT05203068|Diagnostic Test|Recombinant tuberculosis allergen (RTA)|Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
79576061|NCT01866748|Drug|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
79576062|NCT01866748|Drug|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
79576063|NCT01866761|Procedure|Periodontal treatment|
79576064|NCT01866774|Other|Fecal calprotectin level|
79576065|NCT01866800|Device|Renal Guard|Renal Guard
79735431|NCT02778178|Drug|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
79735432|NCT02778178|Drug|Placebo|20 mL saline 0.9%, per side
79576066|NCT01866800|Drug|Conventional Treatment|Saline and N-acetylcysteine
79735433|NCT02778178|Device|ultrasound|
79735434|NCT04228432|Other|Dedicated and coordinated monitoring|"Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
79735435|NCT01194440|Drug|letrozole|Given orally
79735436|NCT01194440|Drug|zoledronic acid|Given IV
80028902|NCT03671863|Other|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
79735437|NCT04228588|Drug|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
79735438|NCT04823052|Drug|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
79735439|NCT04823052|Drug|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
79735440|NCT04823052|Drug|Placebo|Placebo Capsule
79735441|NCT04823052|Drug|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
79735442|NCT05048992|Other|ELDOA method|group A will receive
79735443|NCT05048992|Other|Post-facilitation stretching|Group B will receive
79870390|NCT00519428|Drug|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
79870391|NCT00519428|Drug|escitalopram + bupropion|same dosing schedule as for monotherapy
79870392|NCT00432159|Device|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
80028903|NCT03671863|Other|Prenatal management|Prenatal management
80028904|NCT02223312|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
79870393|NCT00432159|Device|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
79870394|NCT00519194|Device|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
80028905|NCT03676699|Diagnostic Test|Ultrasound chest|Ultrasound detection of extravascular lung water
80028906|NCT04426656|Behavioral|Phone application|"The mini-app (used in Part 2) has four main functions:~a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~an asynchronous message function that allows users to chat with a study staff (C.Li); and~a user profile page where users can manage all HIV test orders."
80028907|NCT04955782|Behavioral|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability|"The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer"
80028908|NCT03058822|Drug|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
80028909|NCT04955704|Device|InferRead CT Pneumonia.AI|InferRead CT Pneumonia.AI reads chest CT DICOM images from medical imaging storage devices and triages cases by detecting pneumonia lesions and then flagging suspected cases in the study list. InferRead CT Pneumonia.AI is a tool to assist clinicians and it does not replace the interpretation and diagnosis by clinicians.
80028910|NCT03671707|Behavioral|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~Ask: smokers will be asked about their smoking behaviour~Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~Refer smokers to smoking cessation services if they agree.~Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
79272439|NCT04157088|Drug|Enzalutamide|160mg, once daily
79272440|NCT04149860|Drug|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
79272441|NCT04149860|Drug|Placebo|Concentrate for solution for IV infusion
79272442|NCT04140266|Drug|Dapivirine (DPV) Vaginal Ring (VR)-004|Vaginal ring containing 25 mg of DPV
79272443|NCT04140266|Drug|Truvada Tablet|Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
79272444|NCT04133363|Procedure|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
79272445|NCT04133363|Procedure|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
79272446|NCT04133363|Procedure|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
79576067|NCT01866813|Behavioral|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
79576068|NCT01866878|Device|equipment rehabilitation stereognosis|
79576069|NCT01866878|Device|TENS|
79576070|NCT01866891|Other|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
79576071|NCT01866969|Other|questionnaire administration|Ancillary studies
79576072|NCT01866969|Procedure|quality-of-life assessment|Ancillary studies
79735444|NCT04114474|Diagnostic Test|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
79870395|NCT00519194|Procedure|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
79870396|NCT02363660|Biological|GINI|
79870397|NCT00431847|Procedure|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
79870398|NCT00431847|Procedure|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
79870399|NCT00431067|Drug|BIBW 2992|
79870400|NCT01030107|Behavioral|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
79870401|NCT01030107|Behavioral|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
79272447|NCT04120415|Biological|Vaccine and vedolizumab (Entyvio)|"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
79272448|NCT04120415|Biological|Placebo vaccine and vedolizumab infusion (Entyvio)|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
79272449|NCT04120415|Biological|Placebo vaccine and placebo infusion|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."
79735445|NCT05258500|Other|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
79272450|NCT04093570|Drug|ASTX727|ASTX727 film-coated, immediate-release FDC tablets
80028911|NCT03671707|Drug|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
79870402|NCT01030185|Device|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
79870403|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
79576073|NCT01866982|Procedure|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
79576074|NCT01866982|Procedure|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
79870404|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
79870405|NCT01030263|Other|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
79870406|NCT01030263|Other|Random four-quadrant biopsies.|Random four-quadrant biopsies.
79870407|NCT01035567|Procedure|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
79870408|NCT01035567|Procedure|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
79870409|NCT00430989|Other|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
79870410|NCT00430989|Other|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
79870411|NCT01035645|Drug|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
80028912|NCT03671707|Behavioral|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
80028913|NCT03671707|Behavioral|Very brief advice|Subjects will receive general advice to quit
79576075|NCT01866995|Drug|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
79576076|NCT01866995|Other|standard prostatostasis therapy|
79576077|NCT01867034|Other|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
80028914|NCT03671707|Behavioral|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
80028915|NCT02226588|Drug|Misoprostol|
80028916|NCT04955548|Procedure|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
79576078|NCT01867034|Other|Bare Metal Stent|
80028917|NCT04955548|Procedure|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
80028918|NCT03676621|Drug|Misoprostol|buccal tablets
79735446|NCT05258500|Other|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
79735447|NCT05258500|Other|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
79735448|NCT00951015|Drug|GSK1349572|investigational HIV-1 integrase inhibitor
79870412|NCT00430755|Device|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
79870413|NCT00430755|Procedure|physician taken history|Convential history taking by physicians
79272451|NCT04054453|Combination Product|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
79272452|NCT03977870|Other|vital status determination|consultation of national registries
79272453|NCT03977532|Other|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
79576079|NCT01867060|Device|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
79576080|NCT01867060|Device|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
79576081|NCT01867073|Other|Biomarker|
79576082|NCT01867112|Behavioral|Physical Activity|Physical activity either by individualized program or general guidelines
79576083|NCT01867125|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
79576084|NCT01867125|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
79576085|NCT01867138|Drug|Cefazolin|
79576086|NCT01867138|Drug|Vancomycin|
80028919|NCT03676621|Drug|Oxytocin|intravenous drip
79272454|NCT03971461|Drug|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
79272455|NCT03961854|Drug|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
79576087|NCT01867138|Drug|Amikacin|
79576088|NCT01867151|Dietary Supplement|Gluten Free Diet|
79576089|NCT01867151|Dietary Supplement|Normal Diet|
79576090|NCT01867177|Other|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
79576091|NCT01867177|Other|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
79576092|NCT01867177|Behavioral|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
79735449|NCT00951015|Drug|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
79735450|NCT01139021|Biological|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
79735451|NCT02777866|Drug|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
79870414|NCT00430755|Other|Computer-assisted history taking|
79870415|NCT00518882|Drug|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
80028920|NCT02226666|Drug|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
80028921|NCT02226666|Drug|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
80028922|NCT04419454|Device|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
80028923|NCT03678649|Drug|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
80028924|NCT04955860|Other|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
79870416|NCT00518882|Drug|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
79735452|NCT02777866|Drug|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
79870417|NCT00518336|Procedure|Blood sampling|Blood sampling at Visit 3, 5 and 7.
79870418|NCT00518336|Procedure|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
79870419|NCT00518336|Biological|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
79870420|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
79870421|NCT00518180|Biological|Tdap Vaccine|One dose of vaccine administered intramuscularly
79870422|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
79870423|NCT02352116|Other|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
80028925|NCT02886156|Device|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
80028926|NCT02886156|Dietary Supplement|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
80028927|NCT03678571|Other|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
79576093|NCT01867190|Biological|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
79576094|NCT01867203|Other|Genotyping|DNA extraction from blood
79576095|NCT01867229|Other|observational|standard of care fore patients with non metastatic breast cancer
79576096|NCT01867255|Drug|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
79272456|NCT03961854|Drug|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
79304543|NCT03282773|Device|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
79304544|NCT02445469|Other|MRI exam of the brain|MRI exam of the brain
79304545|NCT03285503|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
79576097|NCT01867268|Drug|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
79576098|NCT01867268|Other|prone positioning|prone positioning the patient for 10 days following the surgery
79576099|NCT01867268|Other|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
79576100|NCT01867281|Drug|aspirin|
79735453|NCT00626262|Drug|Esomeprazole|Oral and Intravenous
79735454|NCT02876796|Drug|GS-0976|Capsule(s) administered orally
79576101|NCT01867437|Drug|Placebo|Sterile solution (vehicle) for subcutaneous infusion
79576102|NCT01867437|Drug|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
79735455|NCT02876796|Drug|Placebo|Capsule(s) administered orally
79735456|NCT02876796|Other|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
79735457|NCT02876796|Other|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
79735458|NCT04980820|Other|No mask|The participant is asked to wear no mask for 10 minutes.
79870424|NCT02352116|Other|Standard of care management|Current standard of care at a major U.S. teaching hospital.
79870425|NCT00525902|Drug|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
79870426|NCT00525824|Drug|Rosuvastatin (Crestor)|10mg and 20 mg
79870427|NCT00525824|Drug|Ezetimibe|10 mg
79870428|NCT00525824|Drug|Simvastatin|40mg and 80 mg
79870429|NCT02260778|Behavioral|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
79870430|NCT00525590|Drug|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
79870431|NCT00430677|Drug|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
79870432|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
79870433|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
79870434|NCT00430677|Drug|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
79870435|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
79735459|NCT04980820|Device|Filtering face mask 2 (FFP2)|The participant is asked to wear a FFP2 mask for 1 hour during work.
79272457|NCT03954678|Behavioral|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
79272458|NCT03954678|Dietary Supplement|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
79870436|NCT02631759|Drug|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
79870437|NCT02631759|Drug|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
79870438|NCT01035801|Drug|IN-105|Prandial Oral Insulin
79870439|NCT01035801|Drug|Insulin Lispro Injection|Insulin Lispro Injection
79272459|NCT03939520|Drug|pirfenidone and nintedanib|The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
79304546|NCT02440087|Dietary Supplement|Refill Bypass|Dietary supplement
79576103|NCT01867463|Biological|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
79576104|NCT01867463|Biological|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
79576105|NCT01867463|Biological|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
79735460|NCT04980820|Device|Filtering face mask 3 (FFP3)|The participant is asked to wear a FFP3 mask for 1 hour during work.
79735461|NCT02876562|Procedure|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
79735462|NCT02779660|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
79735463|NCT02779660|Procedure|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
79870440|NCT00525512|Drug|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
79870441|NCT00525512|Drug|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
79870442|NCT03998306|Dietary Supplement|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
79870443|NCT03998306|Other|No intervention|No intervention
79870444|NCT04501406|Drug|Pioglitazone|An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
79870445|NCT04501406|Other|Placebo|Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
79402812|NCT05200845|Other|Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose|Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79870446|NCT00517634|Drug|FP|Fluticasone Propionate 100 mcg BD
79870447|NCT00517634|Drug|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
80028928|NCT04955392|Other|Osteopathic treatment protocol|"The intervention protocol consists of 4 techniques that will be performed according to the following order:~Inhibition of the suboccipital muscles.~Parietal Lift.~Sutherland Technique of Sphenobasilar Synchondrosis.~Compression technique of the fourth ventricle (CV4)."
79272460|NCT03939520|Drug|pirfenidone or nintedanib|The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
79870448|NCT00517634|Drug|Placebo|Matching Placebo
79870449|NCT02167490|Procedure|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
79272461|NCT03939520|Drug|pirfenidone or nintedanib|The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
79576106|NCT01867476|Other|Automated Adherence Monitoring System|
79870450|NCT03683576|Drug|GB001|film-coated oral tablet
79870451|NCT03683576|Drug|Placebo|film-coated oral tablet
79272462|NCT03926143|Drug|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
79870452|NCT03863834|Device|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
79870453|NCT03998150|Procedure|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
79576107|NCT01867489|Other|No intervention|
79576108|NCT01867502|Drug|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
79576109|NCT01867502|Drug|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
79870454|NCT03998150|Procedure|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
79272463|NCT03876262|Drug|Moxidectin|2mg tablets, encapsulated for blinding
79735464|NCT01193660|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
79735465|NCT01193660|Drug|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
79735466|NCT01193660|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
79735467|NCT01193660|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
79870455|NCT03656666|Drug|Apremilast|Apremilast oral tablets
79870456|NCT03656666|Drug|Placebo|Placebo oral tablets
79870457|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
79735468|NCT01193660|Other|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
79735469|NCT04298814|Other|severe covid-19 pneumonia with ET|severe covid-19 pneumonia undergoing endotracheal intubation
79870458|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
79870459|NCT01036035|Drug|Tolterodine|Comparison of different dosages of drug
79870460|NCT01036035|Drug|Pilocarpine|Comparison of different dosages of drug
80028929|NCT04955392|Other|Sham technique|Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
80028930|NCT02226744|Behavioral|Focused Breathing|
80028931|NCT03671629|Other|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
80028932|NCT04954768|Other||This is a observational study, and there is no interventions.
79272464|NCT03876262|Drug|Ivermectin|3mg tablets, encapsulated for blinding
79272465|NCT03867682|Biological|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
79304547|NCT03282617|Biological|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
79870461|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
79870462|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
79870463|NCT01036035|Drug|placebo capsule|Comparison of different dosages of drug
79870464|NCT01323699|Behavioral|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
79870465|NCT01036659|Drug|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
79870466|NCT01033149|Drug|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
80028933|NCT02845297|Drug|pembrolizumab|Intravenous pembrolizumab
80028934|NCT02845297|Drug|Azacitadine|Intravenous or subcutaneous
80028935|NCT04954534|Biological|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
79272466|NCT03867682|Drug|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
79272467|NCT03867682|Drug|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
79272468|NCT03846505|Drug|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
79272469|NCT03846505|Other|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
79272470|NCT03825692|Drug|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
79272471|NCT03825692|Drug|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
79272472|NCT03821324|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
79272473|NCT03768570|Drug|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
79576110|NCT01867528|Procedure|Laparoscopic adhesiolysis|
79576111|NCT01867528|Procedure|Open adhesiolysis|
79576112|NCT01867554|Genetic|gene analysis|gene analysis
79576113|NCT01867567|Procedure|abdominal bandage|
79576114|NCT01867593|Device|C-11 methionine PET|
79576115|NCT01867645|Drug|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
79576116|NCT01867645|Drug|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
79870467|NCT00429663|Device|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
79870468|NCT00429663|Device|locking periarticular plate|Standard of care device for femur fractures
79870469|NCT00429585|Device|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
79870470|NCT00429585|Device|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
79870471|NCT06051383|Other|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~Introduction to the concept of self-management.~Education/reassurance~Managing fluid intake.~Caffeine abstinence~Alcohol advice~Session 2 :~Adjusting medications~Constipation advice.~Strategies for dribbling. pelvic floor exercise.~Double-voiding.~Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
79870472|NCT06051344|Drug|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
79576117|NCT01867684|Other|Psychotherapy|
79576118|NCT01867697|Drug|Cetuximab|
79576119|NCT01867697|Drug|Irinotecan|
79576120|NCT01867697|Drug|Oxaliplatin|
79576121|NCT01867697|Drug|Folinic Acid|
79576122|NCT01867697|Drug|Calcium Carbonate|
79576123|NCT01867723|Other|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
79576124|NCT01867736|Device|Passeo-18 Lux DRB|
79576125|NCT01867736|Device|Standard PTA (POBA)|
79576126|NCT01867749|Behavioral|Group Interpersonal Psychotherapy (IPT-G)|
79576127|NCT01867749|Behavioral|Coping with Depression (CWD)|
79576128|NCT01867775|Drug|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
79576129|NCT01867814|Procedure|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
79576130|NCT01867827|Other|Neurofeedback and Physical Exercise|
79576131|NCT01867827|Other|Physical Exercise|
79576132|NCT01867853|Device|PLR|passive leg raising test was done before and at the end of SBT
79576133|NCT01867866|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
79576134|NCT01867866|Drug|Trifluridine|35 mg/m2, orally, single dose
79576135|NCT01867879|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
79576136|NCT01867879|Drug|Placebo|Placebo tablets, orally, single dose.
79735470|NCT02778022|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
79870474|NCT06051292|Other|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
79870475|NCT06051292|Other|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
79870476|NCT06051266|Device|Dynamic navigation|Dynamic navigation eliminates the need for a laboratory fabrication process and allows for direct visualisation of the operative area during implant placement. Moreover, it can avoid interfering with water cooling. Navigation-assisted surgery makes it possible to modify the implant system, length, diameter or position in real time, both in the perioperative period and during surgery.
79870477|NCT06051266|Device|Static template|In most clinical situations, a static template can be used to assist in guiding the placement of implants precisely. The static guide has some limitations in that it requires additional fabrication time, has insufficient cooling in the surgical field and is not suitable for simultaneous grafting procedures.
79576137|NCT01867892|Drug|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
79576138|NCT01867892|Drug|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
79272474|NCT03713411|Procedure|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
79870478|NCT06051240|Drug|Lithium|Lithium sulphate, 42 mg (6 mmol lithium)
79272475|NCT03673644|Other|Questionnaires|Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
79272476|NCT03617445|Drug|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
79576139|NCT01867918|Procedure|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
79576140|NCT01867918|Drug|Standard Chemotherapy|
79272477|NCT03617445|Drug|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
79272478|NCT03617445|Drug|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
79272479|NCT03617445|Drug|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
79272480|NCT03512301|Device|CAMCI|CAMCI battery of computerized tasks
79576141|NCT01867944|Behavioral|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
79735471|NCT04306068|Other|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
79870479|NCT06051240|Drug|Placebo|White round tablet, 10 mm. Identical to experimental drug (lithium)
79272481|NCT03480776|Drug|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
79272482|NCT03480776|Other|Placebo|One tablet PO daily
79272483|NCT03421652|Drug|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
79272484|NCT03421652|Radiation|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
79272485|NCT03416933|Other|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
79272486|NCT03409770|Other|Therapeutic hypothermia|Whole body cooling using a servo controlled device
79272487|NCT03318263|Diagnostic Test|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
79272488|NCT03254576|Other|Functional MRI|
79272489|NCT03218241|Biological|PRT064445|Intravenous
79272490|NCT03218241|Drug|Placebo|Intravenous to mimic PRT064445
79272491|NCT03215524|Biological|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
79272492|NCT03215524|Biological|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
79576142|NCT01867944|Behavioral|Educational Control|Education on conventional treatment options for chronic constipation.
79576143|NCT01867957|Biological|Low-dose GC1109|50ug/dose
79576144|NCT01867957|Biological|High-dose GC1109|100ug/dose
79576145|NCT01867957|Biological|Low-dose Placebo|0.9% Saline 0.5 mL
79576146|NCT01867957|Biological|High-dose Placebo|0.9% Saline 1.0 mL
79576147|NCT01867970|Device|Tool|"The It's LiFe! tool consists of three different elements:~the 3D accelerometer (Figure 7-8);~the application (app) on a Samsung Smartphone (Figure 6);~a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
79735472|NCT02777788|Drug|JinFuKang|treated with chemotherapy
79870480|NCT06051214|Biological|thrombogram|blood sampling every month for 12 months
79870481|NCT06051201|Other|ReceptIVFity test (vaginal microbiome swab)|"A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile"
79870482|NCT06051175|Other|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
79870483|NCT06051175|Other|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
79870484|NCT06051175|Other|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
79272493|NCT03045029|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
79272494|NCT03018080|Drug|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
79576148|NCT01867970|Behavioral|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
79576149|NCT01867983|Behavioral|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
79576150|NCT01867983|Behavioral|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
79735473|NCT02777788|Drug|XingZaoRuanJian|treated with chemotherapy
79735474|NCT02777788|Drug|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
79735475|NCT02856009|Other|completion of a quality of life questionnaire|
79735476|NCT01076166|Drug|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
79735477|NCT00631059|Other|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
79272495|NCT03018080|Drug|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
79272496|NCT02869802|Procedure|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
79272497|NCT02869802|Other|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until end of study.
79272498|NCT02799641|Drug|Diazepam|5 mg Diazepam
79272499|NCT02799641|Drug|Lidocaine|2 ml of 2% lidocaine
79735478|NCT02777710|Drug|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
79735479|NCT02777710|Drug|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
79735480|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to < 212 days of age"
79735481|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to < 12 months of age"
79735482|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to < 24 months of age"
79735483|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to < 72 months of age"
79735484|NCT00602901|Other|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
80028936|NCT03678415|Behavioral|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
80028937|NCT04954612|Other|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
79402813|NCT05200845|Other|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose|Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
79272500|NCT02799641|Other|Placebo pill|Placebo pill
79735485|NCT00602901|Other|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
79735486|NCT00602901|Drug|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
79272501|NCT02799641|Other|Placebo injection|Placebo injection
79272502|NCT02782546|Procedure|Graft cell infusion|-Day 0
79735487|NCT04874350|Drug|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
79735488|NCT04874350|Drug|Placebo|Oral matching placebo capsule
79735489|NCT00945477|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
80028938|NCT04954924|Other|standardized physiotherapy program and Kinesio tape|
80028939|NCT04954378|Diagnostic Test|radiomics|
79272503|NCT02782546|Drug|Tacrolimus|-GVHD prophylaxis
79272504|NCT02782546|Drug|Mycophenolate mofetil|-GVHD prophylaxis
79272505|NCT02782546|Drug|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
79272506|NCT02782546|Procedure|CIML NK cell infusion|-Day +7
79272507|NCT02782546|Drug|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
79272508|NCT02782546|Procedure|Leukapheresis|-Day +6
79272509|NCT02781090|Behavioral|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
79272510|NCT02781090|Behavioral|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
79272511|NCT02781090|Drug|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
79272512|NCT02774291|Biological|Aldesleukin|Given IV
79272513|NCT02774291|Biological|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
79402814|NCT05200845|Other|High-Fat Test Meal Inside a Metabolic Chamber|A high-fat test meal (60% fat, 20% carbohydrate) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
79272514|NCT02774291|Drug|Cyclophosphamide|Given IV
79272515|NCT02774291|Biological|Filgrastim|Given SC
79735490|NCT02777398|Procedure|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
79576151|NCT01867996|Drug|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
79576152|NCT01867996|Drug|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
79870485|NCT06051175|Other|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
79870486|NCT06051175|Other|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
79870487|NCT06051136|Behavioral|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
79870488|NCT06051097|Diagnostic Test|sleep study|over-night polysomnography
79870489|NCT06051084|Behavioral|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
79870490|NCT06051084|Behavioral|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
79870491|NCT06051071|Device|Transcranial Direct Current Stimulation (tDCS)|In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
79870492|NCT06051032|Device|Balloon thrombectomy|A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
79870493|NCT06051032|Device|Thromboaspiration system|The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
79576153|NCT01868048|Drug|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
79576154|NCT01868048|Drug|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
79576155|NCT01868061|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
79576156|NCT01868061|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
79576157|NCT01868087|Dietary Supplement|Boost Plus®|
79576158|NCT01868087|Dietary Supplement|Impact Advanced Recovery®|
79576159|NCT01868100|Other|self-completion questionnaire|
79272516|NCT02774291|Drug|Fludarabine Phosphate|Given IVPB
79272517|NCT02774291|Other|Laboratory Biomarker Analysis|Correlative studies
79272518|NCT02734771|Drug|Brentuximab vedotin|
79272519|NCT02734771|Drug|Rituximab|
79272520|NCT02734771|Drug|Cyclophosphamide|
79272521|NCT02734771|Drug|Doxorubicin|
79272522|NCT02734771|Drug|Prednisone|
79272523|NCT02719977|Drug|CX5461|
79272524|NCT02689024|Drug|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
79272525|NCT02689024|Drug|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
79576160|NCT01868113|Drug|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
79735491|NCT02777398|Procedure|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
79576161|NCT01868113|Other|Placebo|Placebo to be administered 12hourly
79272526|NCT02689024|Drug|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
79272527|NCT02689024|Drug|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
79272528|NCT02689024|Drug|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
79272529|NCT02689024|Drug|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
79272530|NCT02689024|Drug|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
79272531|NCT02689024|Drug|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
79272532|NCT02689024|Drug|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
79272533|NCT02689024|Drug|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
79272534|NCT02671448|Behavioral|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
79272535|NCT02671448|Behavioral|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
79272536|NCT02671448|Behavioral|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
79576162|NCT01868126|Drug|DE-117 ophthalmic solution|
79576163|NCT01868126|Drug|latanoprost ophthalmic solution|
79576164|NCT01868126|Other|Placebo|
79272537|NCT02658279|Drug|Pembrolizumab|
79272538|NCT02649686|Drug|Durvalumab|
79272539|NCT02649686|Drug|Trastuzumab|
79272540|NCT02619864|Drug|AZD2014|
79272541|NCT02602691|Other|AlloMap®|
79272542|NCT02602691|Procedure|Endomyocardial biopsies|
79272543|NCT02354079|Genetic|hypobetalipoproteinemia genetic and genotypic screening|
79272544|NCT02144584|Drug|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
79735492|NCT01135719|Procedure|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
79735493|NCT01076088|Drug|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
79735494|NCT01076088|Drug|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
79735495|NCT01076088|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
79272545|NCT02144584|Drug|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
79272546|NCT01897571|Drug|Tazemetostat|Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
79272547|NCT01897571|Drug|Prednisolone|Patients who received 40 mg/m^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
79272548|NCT01897571|Drug|Tazemetostat|Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
79272549|NCT01846390|Drug|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
79272550|NCT01846390|Drug|Dexamethasone|40 mg D1 - D4
79272551|NCT01846390|Drug|Cisplatin|75 mg/m2 D1
79272552|NCT01846390|Drug|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
79272553|NCT01783197|Drug|Paclitaxel|
79272554|NCT01783197|Drug|Carboplatin|
79576165|NCT01868178|Device|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
79576166|NCT01868191|Drug|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
79576167|NCT01868191|Drug|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
79576168|NCT01868256|Other|early discharge (<72 h)|
79576169|NCT01868256|Other|Conventional discharge|
79735496|NCT01076088|Drug|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
79735497|NCT01076088|Drug|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
79870494|NCT06051019|Other|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
79870495|NCT06051019|Other|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
79272555|NCT01783197|Drug|Selumetinib|
79272556|NCT01783197|Drug|Pemetrexed|
79272557|NCT01783197|Drug|Cisplatin|
79272558|NCT01765855|Drug|Betrixaban single oral dose|
79272559|NCT01708993|Drug|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
79272560|NCT01708993|Drug|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
79272561|NCT01708993|Drug|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
79402815|NCT05200845|Other|High-Carbohydrate Test Meal Inside a Metabolic Chamber|A high-carbohydrate test meal (60% carbohydrate, 20% fat) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
79272562|NCT01708993|Drug|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
79735498|NCT05021458|Other|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
79735499|NCT05021458|Other|SNAG|: Ten patients will be treated with SNAGs
79272563|NCT01656538|Drug|Paclitaxel|
79272564|NCT01656538|Drug|Reolysin|
79272565|NCT01652144|Drug|AT7519M|
79272566|NCT01627054|Drug|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
79272567|NCT01619813|Drug|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
79272568|NCT01619813|Drug|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
79272569|NCT01591421|Drug|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
79272570|NCT01591421|Drug|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
79272571|NCT01486368|Drug|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
79272572|NCT01419834|Biological|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over ~30 minutes
79272573|NCT01184274|Drug|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~(starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
79272574|NCT01161810|Other|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
79272575|NCT01147484|Drug|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
79304548|NCT02439931|Behavioral|Remote psychosocial intervention|
79402816|NCT05194735|Biological|Neoantigen specific TCR-T cell drug product|"Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D"
79402817|NCT05194735|Biological|Aldesleukin (IL-2)|To support growth and activation of TCR-T cell drug product
79402818|NCT05182554|Behavioral|Doctor Videos|Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
79735500|NCT02776462|Device|EyeBox CNS|
79735501|NCT02776384|Other|Observational study|
79735502|NCT02777632|Procedure|Living donor liver transplantation|
79735503|NCT02777320|Drug|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
79735504|NCT02777320|Drug|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
79735505|NCT04226560|Device|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
79735506|NCT04226560|Device|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
79735507|NCT04226560|Other|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
80028940|NCT03676387|Other|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation [ETT OD=0.55*(subglottic diameter)+1.16] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
79272576|NCT01145989|Drug|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
79735508|NCT04226560|Other|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
79576170|NCT01868282|Procedure|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
79735509|NCT01193348|Drug|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
79576171|NCT01868282|Procedure|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
80028941|NCT02226900|Procedure|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
79576172|NCT01868282|Procedure|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
80028942|NCT02226900|Procedure|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
80028943|NCT04954456|Drug|QLS31901|QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
80028944|NCT02232360|Drug|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
80028945|NCT02232360|Drug|Rosuvastatin alone|Rosuvastatin 10mg per day
79272577|NCT01140269|Other|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
79272578|NCT01138384|Drug|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
79402819|NCT05182554|Behavioral|Sharing Videos|Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
79576173|NCT01868295|Behavioral|Sleeping with denture|Sleeping with denture at night
79735510|NCT00945321|Drug|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
79402820|NCT05182554|Behavioral|Sharing Videos (Influencers)|Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
79735511|NCT00945321|Drug|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
79735512|NCT00945321|Drug|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
79735513|NCT00945321|Drug|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
79735514|NCT02776228|Drug|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
79735515|NCT02776228|Drug|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
79735516|NCT04990492|Diagnostic Test|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
79272579|NCT01138384|Drug|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
79272580|NCT01112384|Drug|SB939|Given orally 3 times per week
79272581|NCT01079247|Other|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
79272582|NCT01079247|Other|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
79576174|NCT01868347|Other|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
79272583|NCT01075308|Drug|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
79272584|NCT01068587|Drug|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
79272585|NCT01068587|Drug|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
79272586|NCT01068587|Other|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
79272587|NCT00984113|Drug|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
79272588|NCT00917072|Behavioral|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
79272589|NCT00917072|Behavioral|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
79272590|NCT00917072|Behavioral|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
79735517|NCT04990492|Diagnostic Test|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
79272591|NCT00894075|Biological|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
79272592|NCT00869752|Biological|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
79272593|NCT00869752|Drug|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
79272594|NCT00869752|Drug|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
79402821|NCT05182554|Behavioral|Vaccine Ambassador|"Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize."
79402822|NCT05182554|Behavioral|Video framing|"The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video."
79735518|NCT00631215|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
79735519|NCT00945243|Device|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
79735520|NCT01192412|Procedure|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP <100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
79870496|NCT06050993|Other|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
79870497|NCT06050980|Drug|HSK40118|Oral administration, QD
79870498|NCT06050967|Combination Product|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
79870499|NCT06050941|Drug|idarubicin|Idarubicin 6mg/m2 d5-7
79870500|NCT06050941|Drug|Cytarabine|Cytarabine 60mg/m2 d5-9
79870501|NCT06050902|Device|Subclavian venipuncture for catheter placement using the needle-steering device|"Navigation software is implemented in an ultrasound machine.~A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~Real time needle guidance on the ultrasound screen during the puncture."
79870502|NCT06050876|Procedure|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
79402823|NCT05182554|Behavioral|Video order|The order in which videos appear on the vaccine content website will be randomized.
79576175|NCT01868347|Other|control|PEEP after pneumoperitoneum and trendelenburg
79576176|NCT01868360|Drug|Subconjunctival aflibercept|subconjunctival aflibercept injection
79576177|NCT01868360|Other|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
79576178|NCT01868386|Radiation|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
79272595|NCT00836485|Drug|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
79576179|NCT01868412|Device|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
80028946|NCT03676309|Drug|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
80028947|NCT03676309|Drug|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
80028948|NCT04954144|Device|Leap Motion Sensor|As a virtual reality treatment method, leap motion sensor was integrated with laptop computer and participants played object capture, firefly, bee-batting games to improve performance based hand skills.
79576180|NCT01868412|Device|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
79272596|NCT00836485|Drug|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
79272597|NCT00836485|Drug|Olopatadine 0.2%|1 gtt/eye on two separate occasions
79272598|NCT00836485|Drug|Artificial tears|1 gtt/eye on two separate occasions
79272599|NCT00770185|Drug|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
79272600|NCT00770185|Genetic|gene expression analysis|
79272601|NCT00770185|Other|immunohistochemistry staining method|
79272602|NCT00770185|Other|laboratory biomarker analysis|
79735521|NCT01192412|Procedure|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is <80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
79735522|NCT04226092|Device|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
79735523|NCT04226092|Device|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
79870503|NCT06050863|Biological|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
79870504|NCT06050863|Drug|Chlorhexidin|chlorhexidine is used
79870505|NCT06050863|Biological|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
80028949|NCT04954144|Other|Neurodevelopmental Treatment Approach|It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.
79272603|NCT00688246|Other|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture [Lønning 2005]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk [Looker 2000]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
79272604|NCT00688246|Procedure|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
79272605|NCT00658593|Drug|capecitabine|
79272606|NCT00658593|Drug|gemcitabine hydrochloride|
79272607|NCT00658593|Procedure|quality-of-life assessment|
79272608|NCT00651326|Drug|bicalutamide|
79272609|NCT00651326|Drug|buserelin|
79870506|NCT06050837|Other|No intervention|No intervention
79272610|NCT00651326|Drug|flutamide|
79272611|NCT00651326|Drug|goserelin|
79272612|NCT00651326|Drug|leuprolide acetate|
79272613|NCT00651326|Procedure|neoadjuvant therapy|
79272614|NCT00651326|Procedure|quality-of-life assessment|
79402824|NCT05182320|Device|OrthoPath|unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
79735524|NCT04868578|Dietary Supplement|study treatment PPI|patient take PPI every day during 12 months
79735525|NCT04868578|Dietary Supplement|Placebo comparator|patient take PPI placebo every day during 12 months
79870507|NCT06050772|Behavioral|Immersive Virtual Reality Reminiscence|a computer-generated environment using head-mounted displays (HMDs) that provide a fully immersive, completely engaging, and realistic experience so that users feel like they are a part of the virtual world
80028950|NCT02232438|Behavioral|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
80028951|NCT03678337|Other|observational cohort with plasma samples|plasma samples
79272615|NCT00651326|Radiation|radiation therapy|"46 Gy in 23 fractions over < 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over < 3 weeks"
79272616|NCT00651326|Drug|Docetaxel|
79576181|NCT01868464|Biological|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10^6 cfu, 4x10^6 cfu, 8x10^6 cfu and 16x10^6 cfu, respectively.
79870508|NCT06050772|Behavioral|Traditional Reminiscence Therapy|RT is a technique that encourages older adults' positive emotions and coping mechanisms by using the recall of earlier memories and the sharing of life experiences.
80028952|NCT04953676|Procedure|round tunnel technique|Both the femoral tunnel and tibial tunnel were drilled by 8-mm cannulated drill
80028953|NCT04953676|Procedure|flat tunnel technique|Both the femoral tunnel and tibial tunnel were dimension of 5×11-mm rounded-rectangular, which was created by initially drilling a round tunnel with a 5-mm cannulated drill and reshaped by use of a bone rasp and custom-made dilator.
80028954|NCT02226978|Drug|Tipranavir|
80028955|NCT02226978|Drug|Ritonavir|
80028956|NCT02226978|Drug|Valaciclovir|
80028957|NCT02831959|Device|NovoTTF-200M device|
80028958|NCT02831959|Other|Best Standard of Care|
79576182|NCT01868490|Drug|cytokine induced killer cells|at least 10*9 CIK cells, IV on day 0, 14, 28
79735526|NCT02777164|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
79870509|NCT06050759|Diagnostic Test|CRP and Albumin level in blood sample|CRP and Albumin levels will be measured from blood samples of the patients to determine CRP/Albumin Ratio
79870510|NCT06050746|Other|Systematic screening|Included children will be followed prospectively during five years through clinical visits and medical records, where need for additional treatment (casting, braces and/or surgery) is the primary endpoint.
79272617|NCT00640471|Biological|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
79576183|NCT01868529|Drug|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
79576184|NCT01868529|Drug|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
79272618|NCT00640471|Drug|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
79576185|NCT01868555|Drug|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
79576186|NCT01868555|Drug|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
79576187|NCT01868555|Drug|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
79576188|NCT01868555|Drug|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
79735527|NCT01192178|Drug|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
80028959|NCT04953832|Behavioral|Cognitive Training|Participants are asked to remember a series of items while solving puzzles.
80028960|NCT04953520|Procedure|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
80028961|NCT04953520|Procedure|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
80028962|NCT04359030|Diagnostic Test|Multislice CT scanning for aortic wall calcification|Multislice CT scanning for aortic wall calcification
80028963|NCT04359030|Diagnostic Test|Transthoracic stress echocardiography|Transthoracic stress echocardiography
80028964|NCT04953988|Procedure|Robotic TKA|Robotic TKA
80028965|NCT04953988|Procedure|Manual operation|Manual operation
80028966|NCT01358331|Drug|MK-8353|Administered orally twice daily for 28 days for each cycle
79272619|NCT00535353|Drug|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
79576189|NCT01868568|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin).
79735528|NCT01192178|Drug|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
79735529|NCT02777008|Drug|CTP-543|
79735530|NCT02777008|Drug|Placebo for CTP-543|
79735531|NCT02855775|Other|additional blood sample|blood sample every 3 weeks
79735532|NCT02775994|Drug|Canakinumab|interleukin beta (IL-1) antagonist
79735533|NCT01192100|Behavioral|Breakfast Skipping|Participants will continue to skip breakfast each morning.
80028967|NCT04953598|Diagnostic Test|Ultrasonography|Patient undergoes diagnostic ultrasound examination
80028968|NCT03676231|Drug|SGM-1019|Active
80028969|NCT03676231|Drug|Placebo|Inactive
80028970|NCT04937010|Procedure|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
80028971|NCT04952818|Diagnostic Test|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
80028972|NCT03623503|Other|Observational study|
80028973|NCT02227056|Drug|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
80028974|NCT05708157|Drug|concomitant intranasal antihistamine and corticosteroid|concomitant intranasal administration with antihistamine and corticosteroid
80028975|NCT04952662|Genetic|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
79576190|NCT01868568|Drug|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
79576191|NCT01868568|Drug|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
79735534|NCT01192100|Behavioral|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
79576192|NCT01868568|Drug|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
79576193|NCT01868568|Drug|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
79735535|NCT01192100|Behavioral|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
79576194|NCT01868568|Drug|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
79576195|NCT01868568|Drug|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
79735536|NCT04193566|Drug|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
79870511|NCT06050720|Device|Apne-Scan DC1 device|The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
79870512|NCT06050694|Drug|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
79870513|NCT06050655|Device|Lingual aligners|orthodontic treatment with lingual aligners
79870514|NCT06050642|Other|enhanced care model provided by Timkl, a home support provider|A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
79870515|NCT06050603|Device|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
79870516|NCT06050590|Device|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
79870517|NCT06050577|Drug|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
79870518|NCT06050577|Drug|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
79870519|NCT06050564|Other|Treatment recommendations will be based on video documented PBS-Score|Therapeutic recommendations from orthopedic surgeons, will be summarized and described
79870520|NCT06050551|Procedure|uniportal VATS|"elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~(exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
79870521|NCT06050538|Procedure|Transabdominal preperitoneal (TAPP) using polyprolene mesh|Transabdominal preperitoneal (TAPP) approach for recurrent inguinal hernia using polyprolene mesh
80028976|NCT03671317|Behavioral|Medical Clowning|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
80028977|NCT04350840|Behavioral|feedback|feedback of optical diagnosis performance per 3 month
79304549|NCT03285347|Device|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
79576196|NCT01868568|Drug|placebo|A single dose administered subcutaneously (s.c., under the skin).
79576197|NCT01868581|Drug|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
79576198|NCT01868581|Drug|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
79576199|NCT01868620|Device|Iontophoretic CXL|
79576200|NCT01868620|Device|Standard CXL|
79735537|NCT00869401|Drug|dasatinib|Given orally
79735538|NCT00869401|Drug|temozolomide|Given orally
79735539|NCT00869401|Other|placebo|Given orally
79735540|NCT00869401|Radiation|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
79735541|NCT04226482|Device|New Device|Laparoscopic appendectomy using new ultrasonic shears.
79735542|NCT04226482|Device|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
79576201|NCT01868659|Behavioral|Diagnostic checklist|Diagnostic checklist used before patient discharged
79576202|NCT01868659|Behavioral|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
79735543|NCT04823104|Other|Home visitation|Home visitation for pregnancy follow-up
79870522|NCT06050538|Procedure|Total extraperitoneal (TEP) hernioplasty using polyprolene mesh|Total extraperitoneal (TEP) approach for recurrent inguinal hernia using polyprolene mesh
80028978|NCT03058744|Drug|IDP-118 Lotion|Lotion
79576203|NCT01868672|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
80028979|NCT03058744|Drug|HP Monad Lotion|Lotion
80028980|NCT03058744|Drug|Ultravate Cream|Cream
80028981|NCT03058744|Drug|Tazorac Cream|Cream
80028982|NCT02734537|Drug|Cisplatin|Given IV
80028983|NCT02734537|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
80028984|NCT02734537|Other|Laboratory Biomarker Analysis|Correlative studies
79735544|NCT01076010|Drug|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
80028985|NCT03059056|Drug|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
80028986|NCT02227134|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
80028987|NCT00951639|Dietary Supplement|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
80028988|NCT00951639|Procedure|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
80028989|NCT00951639|Dietary Supplement|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
80028990|NCT03058666|Drug|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
80028991|NCT03058666|Device|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
80028992|NCT02223624|Other|walking and light weights|
80028993|NCT02223624|Other|eccentric aerobic exercise|
80028994|NCT02223624|Other|concentric aerobic exercise|
80028995|NCT03563547|Behavioral|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
79272620|NCT00535353|Drug|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
79272621|NCT00526461|Drug|HPPH|IV
79272622|NCT00516828|Drug|cytarabine|subcutaneously twice daily from Day 1 to 10
79402825|NCT05182320|Device|Control|unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
79576204|NCT01868685|Drug|BYM338|BYM338
79576205|NCT01868685|Drug|Placebo|Placebo
79576206|NCT01868698|Other|high-voltage electrical stimulation|
79576207|NCT01868698|Other|Kinesiotherapy|
79576208|NCT01868698|Other|shortwave diathermy|
79576209|NCT01868737|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
79576210|NCT01868737|Dietary Supplement|Placebo|MCT oil
79576211|NCT01868750|Dietary Supplement|Calcitriol|1.0ug twice daily for 7 days before surgery
79735545|NCT01076010|Drug|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
79735546|NCT02775838|Drug|Indocyanine green|perioperative application of Indocyanine green (ICG)
79735547|NCT04122391|Other|sound level volume|Noise level during cardiac arrest
79875935|NCT03979612|Genetic|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
79875936|NCT00297778|Drug|Pramipexole|Dopamine agonist
80028996|NCT03563547|Behavioral|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
79272623|NCT00514085|Biological|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
79272624|NCT00514085|Other|immunohistochemistry staining method|Cycle 1 Day 1 and Cycle 1 Day 29
79272625|NCT00514085|Other|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
79402826|NCT05172791|Behavioral|Antibiotic stewardship messaging|Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
79576212|NCT01868750|Dietary Supplement|Control Pill|placebo pill taken twice daily for 7 days before surgery
79576213|NCT01868763|Device|telemedical devices (weighing machine and step counter)|
79576214|NCT01868763|Behavioral|care calls once per week for 12 weeks|
79870523|NCT06050486|Behavioral|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
79735548|NCT02776852|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: SR15-43-Y65-158)
79735549|NCT02775604|Behavioral|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
79272626|NCT00514085|Other|pharmacological study|Starting dose of 50μg/kg/day as an IV push
79272627|NCT00504296|Drug|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
79576215|NCT01868802|Drug|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
79576216|NCT01868802|Drug|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
79272628|NCT00504296|Other|immunoenzyme technique|
79735550|NCT02775604|Behavioral|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
79870524|NCT06180772|Behavioral|FIT FIRST|High intensity sports drills and games
79272629|NCT00504296|Other|immunohistochemistry staining method|
79272630|NCT00504296|Other|immunologic technique|
79272631|NCT00504296|Other|laboratory biomarker analysis|
79272632|NCT00504296|Other|liquid chromatography|
79272633|NCT00504296|Other|mass spectrometry|
79272634|NCT00504296|Other|pharmacological study|
79272635|NCT00471432|Drug|custirsen sodium|
79272636|NCT00471432|Drug|docetaxel|
79272637|NCT00471432|Other|pharmacological study|
79576217|NCT01868828|Drug|PAD|Induction Therapy of PAD for 4 cycles.
79576218|NCT01868828|Drug|VCD|Induction Therapy of VCD for 4 cycles.
79576219|NCT01868828|Other|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
79576220|NCT01868841|Drug|AdreView|10 millicurie of AdreView (123I-mIBG)
79576221|NCT01868841|Other|Single Photon Emission Computed Tomography|
79576222|NCT01868867|Behavioral|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
79576223|NCT01868906|Drug|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
79576224|NCT01868906|Procedure|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
79272638|NCT00470353|Dietary Supplement|calcium carbonate|
79272639|NCT00470353|Dietary Supplement|cholecalciferol|
79272640|NCT00470353|Other|immunohistochemistry staining method|
79272641|NCT00470353|Other|laboratory biomarker analysis|
79576225|NCT01868906|Device|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
79576226|NCT01868906|Procedure|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
79272642|NCT00470353|Other|pharmacological study|
79272643|NCT00470353|Procedure|biopsy|
79272644|NCT00443976|Drug|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
79272645|NCT00428142|Biological|rituximab|375mg/m2 day 1
79272646|NCT00428142|Drug|bortezomib|1.3mg/m2 days 1 & 8
79272647|NCT00428142|Drug|cyclophosphamide|750mg/m2 day 1
79272648|NCT00428142|Drug|prednisone|40mg/m2 days 1-5
79272649|NCT00428142|Drug|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
79272650|NCT00390117|Drug|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
79272651|NCT00390117|Other|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
79576227|NCT01868906|Radiation|Radiotherapy|Standard radiation therapy
79576228|NCT01868906|Drug|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
79576229|NCT01868919|Behavioral|Positive Parenting Program|Level 3 or 4 of Triple P
79576230|NCT01868932|Other|hypertonic saline|inhaled nebulized 3%NaCl
79576231|NCT01868932|Other|saline|inhaled nebulized 0.9% NaCl
79735551|NCT04305990|Device|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
79735552|NCT04305990|Device|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
79735553|NCT02614651|Procedure|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
79735554|NCT02614651|Procedure|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
79735555|NCT02614651|Procedure|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
79735556|NCT02614651|Procedure|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
79870525|NCT06180759|Drug|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
79870526|NCT06180759|Drug|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
79870527|NCT06180759|Drug|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
80028997|NCT03058510|Procedure|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
79272652|NCT00387400|Drug|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
79272653|NCT00387400|Drug|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
79402827|NCT05131815|Behavioral|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
79576232|NCT01868945|Dietary Supplement|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
79576233|NCT01868945|Dietary Supplement|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
79576234|NCT01868945|Dietary Supplement|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
79576235|NCT01868945|Dietary Supplement|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
79576236|NCT01868971|Device|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation
79735557|NCT02614651|Device|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
79735558|NCT04225780|Drug|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
79870528|NCT06180746|Behavioral|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
79272654|NCT00387400|Genetic|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
79402828|NCT05071027|Other|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
79576237|NCT01868984|Drug|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
79576238|NCT01868984|Procedure|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
79735559|NCT04045171|Drug|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
79875937|NCT00297778|Other|Placebo|
80028998|NCT02227212|Drug|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
80028999|NCT00303849|Drug|Carboplatin|Given IA
80029000|NCT00303849|Drug|Etoposide|Given IV
80029001|NCT00303849|Drug|Etoposide Phosphate|Given IV
80029002|NCT00303849|Other|Laboratory Biomarker Analysis|Correlative studies
80029003|NCT00303849|Drug|Mannitol|Given IA
80029004|NCT00303849|Drug|Melphalan|Given IA
80029005|NCT00303849|Other|Quality-of-Life Assessment|Ancillary studies
79402829|NCT05070364|Drug|Peginterferon Lambda-1a|Immunomodulator
80029006|NCT00303849|Drug|Sodium Thiosulfate|Given IV
79576239|NCT01869010|Other|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
79870529|NCT06180733|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
79870530|NCT06180720|Drug|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
79576240|NCT01869023|Drug|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
79870531|NCT06180720|Drug|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
79576241|NCT01869023|Drug|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
79576242|NCT01869036|Drug|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
79576243|NCT01869036|Drug|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
79870532|NCT06180707|Drug|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
79870533|NCT06180707|Drug|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
80029007|NCT04863846|Other|No intervention, observational study|Exposure of interest: clinical implementation of an algorithm
80029008|NCT03058432|Radiation|Radiotherapy alone|
80029009|NCT03058432|Radiation|Concurrent chemoradiotherapy|
80029010|NCT04649112|Genetic|PBCAR19B|Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused
80029011|NCT04952740|Procedure|IPC+PCI|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
79576244|NCT01869062|Device|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
79870534|NCT06180707|Other|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
79272655|NCT00387400|Other|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
79272656|NCT00377052|Drug|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
79870535|NCT06180681|Behavioral|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
79870536|NCT06180681|Behavioral|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
79875938|NCT03848832|Drug|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
80029012|NCT04952740|Procedure|No IPC|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
80029013|NCT04316832|Behavioral|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
80029014|NCT04316832|Other|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
80029015|NCT02828241|Drug|DFD-04 Ointment|
80029016|NCT02828241|Other|Placebo Ointment|
80029017|NCT04308642|Other|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
80029018|NCT04308642|Other|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
79272657|NCT00377052|Drug|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
79576245|NCT01869062|Device|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
79735560|NCT04816864|Diagnostic Test|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
79735561|NCT02877966|Dietary Supplement|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
79870537|NCT06180668|Procedure|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
79870538|NCT06180655|Behavioral|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
79870539|NCT06180642|Other|Assessment of soft tissue properties|Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
79870540|NCT06180642|Other|Retest assessment of soft tissue properties|Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
79870541|NCT06180629|Behavioral|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
79870542|NCT06180629|Other|normal treatment routine|normal treatment routine
79576246|NCT01869088|Drug|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery
79576247|NCT01869088|Procedure|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
79576248|NCT01869127|Device|Shoes|A unisex canvas slip-on with a sturdy sole.
79870543|NCT06180590|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
79870544|NCT06180577|Device|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
79272658|NCT00372736|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
79272659|NCT00372736|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
79576249|NCT01869140|Device|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
79875939|NCT03848832|Drug|Placebo|Matching placebo oral solution
79875940|NCT00450372|Biological|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
79576250|NCT01869166|Biological|CART-EGFR|
79576251|NCT01869179|Behavioral|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
79272660|NCT00372736|Genetic|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs > 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs > 5 x ULN1
79272661|NCT00372736|Genetic|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
79272662|NCT00372736|Other|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
79272663|NCT00372736|Other|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
79576252|NCT01869179|Behavioral|Wait-list control group|
79576253|NCT01869205|Device|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
79576254|NCT01869231|Dietary Supplement|olive oil|
79576255|NCT01869231|Dietary Supplement|olive oil and chewing gum|
79576256|NCT01869231|Dietary Supplement|chewing gum|
79576257|NCT01869231|Dietary Supplement|water|
79272664|NCT00372736|Other|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
79272665|NCT00372736|Other|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
79735562|NCT02877966|Other|Placebo|
79735563|NCT04226014|Procedure|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
79735564|NCT02618161|Radiation|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
79870545|NCT06180564|Other|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature >3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
79870546|NCT06180551|Diagnostic Test|DKK-3|DKK-3-Urine measurement
79272666|NCT00357747|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
79272667|NCT00357747|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
79272668|NCT00352079|Biological|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
79870547|NCT06180512|Dietary Supplement|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
79870548|NCT06180512|Dietary Supplement|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
79272669|NCT00352079|Drug|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
79272670|NCT00352079|Procedure|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
79304550|NCT03282539|Device|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
79402830|NCT05060068|Drug|S-ketamine (low dose)|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
79402831|NCT05060068|Drug|Placebo|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
79402832|NCT05060068|Drug|S-ketamine (high dose)|Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
79576258|NCT01869257|Device|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
79576259|NCT01869257|Device|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
79576260|NCT01869283|Other|Kinesiotherapy|
79576261|NCT01869283|Other|Ultrasound|
79576262|NCT01869283|Other|Diadynamic currents|
79576263|NCT01869296|Procedure|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
79735565|NCT02618161|Radiation|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
79735566|NCT04226404|Other|CSD1905-11|Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
79735567|NCT04226404|Other|CSD1905-12|Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
79576264|NCT01869296|Procedure|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
79735568|NCT04226404|Other|CSD1905-13|Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
79735569|NCT04226404|Other|CSD1905-14|Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
79735570|NCT04226404|Other|CSD1905-15|Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
79735571|NCT04226404|Other|CSD1905-16|Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
79735572|NCT04226404|Other|CSD1905-17|Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
79735573|NCT00698113|Procedure|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
79870549|NCT06180512|Dietary Supplement|Control group|4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
79870550|NCT06180473|Other|questionnaire|PPQ, TTAQ PTCS
79870551|NCT06180447|Biological|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
79870552|NCT06180408|Other|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
79870553|NCT06180408|Other|lumbar stabilization exercise|core training and myofascial release therapy
79735574|NCT00698113|Other|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
79735575|NCT01075152|Drug|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
79272671|NCT00346320|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
79576265|NCT01869309|Drug|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
79576266|NCT01869309|Drug|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
79576267|NCT01869322|Device|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
79576268|NCT01869322|Device|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
79576269|NCT01869335|Device|radiography|
79272672|NCT00343408|Drug|cediranib maleate|
79272673|NCT00343408|Drug|cisplatin|
79272674|NCT00343408|Drug|fluorouracil|
79272675|NCT00343408|Drug|gemcitabine hydrochloride|
79576270|NCT01869335|Device|MRI (magnetic resonance imaging)|
79272676|NCT00343408|Drug|leucovorin calcium|
79272677|NCT00343408|Drug|oxaliplatin|
79272678|NCT00305812|Drug|dexamethasone|
79272679|NCT00305812|Drug|lenalidomide|
79272680|NCT00305812|Drug|melphalan|
79272681|NCT00265876|Drug|AZD0530|Taken daily every 4 weeks
79272682|NCT00265876|Drug|gemcitabine hydrochloride|1000mg/m2 IV weekly
79272683|NCT00258388|Drug|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
79402833|NCT05056844|Procedure|Contrast Enhanced Digital Mammography|Undergo CESM
79402834|NCT05056844|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
79576271|NCT01869387|Device|Non-invasive ventilation|
79576272|NCT01869426|Dietary Supplement|VSL#3 drops|
79576273|NCT01869426|Dietary Supplement|VSL#3 drops placebo|
79576274|NCT01869452|Behavioral|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
79576275|NCT01869465|Other|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
79576276|NCT01869465|Behavioral|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
79576277|NCT01869491|Drug|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
79272684|NCT00258388|Drug|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
79272685|NCT00258388|Drug|prednisone|5mg PO BID
79576278|NCT01869491|Drug|Matching placebo tablets|2 tablets four times daily
79735576|NCT01075152|Biological|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
79735577|NCT02775526|Procedure|TOT|70 patients
79272686|NCT00258375|Drug|custirsen sodium|
79272687|NCT00258375|Drug|docetaxel|
79272688|NCT00255788|Drug|everolimus|
79272689|NCT00245154|Drug|carboplatin|Given IV
79272690|NCT00245154|Drug|cediranib maleate|Given orally
79272691|NCT00245154|Drug|paclitaxel|Given IV
79272692|NCT00245154|Other|placebo|Given orally
79272693|NCT00095992|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
79272694|NCT00093457|Drug|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
79272695|NCT00084734|Drug|capecitabine|Oral
79272696|NCT00084734|Drug|cisplatin|IV
79272697|NCT00084734|Drug|docetaxel|IV
79272698|NCT00079079|Drug|carboplatin|
79272699|NCT00079079|Drug|cisplatin|
79272700|NCT00079079|Drug|gemcitabine hydrochloride|
79272701|NCT00079066|Biological|cetuximab|
79272702|NCT00079066|Procedure|quality-of-life assessment|
79272703|NCT00079053|Drug|erlotinib hydrochloride|
79272704|NCT00079053|Procedure|adjuvant therapy|
79272705|NCT00075660|Drug|triapine|
79272706|NCT00066443|Biological|pegfilgrastim|Dose escalation schedule A&B = 6mg fixed dose once per cycle on day 2
79402835|NCT05056844|Drug|Iodinated Contrast Agent|Given iodine-based contrast agent IV
79402836|NCT05056844|Other|Questionnaire Administration|Ancillary studies
79402837|NCT05056207|Other|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
79735578|NCT02775526|Procedure|TVT|70 patients
79735579|NCT02775526|Procedure|Burch Colposuspension|70 patients
79735580|NCT04134637|Device|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
79735581|NCT04134637|Drug|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
79735582|NCT04133857|Other|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
79870554|NCT06180395|Other|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
79870555|NCT06180395|Other|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
79576279|NCT01869504|Device|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
79870556|NCT06180382|Drug|Adalimumab|Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
79870557|NCT06180382|Drug|Vedolizumab|Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
80029019|NCT04952428|Behavioral|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom & Richmond test will be conducted."
80029020|NCT04641858|Biological|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
80029021|NCT04641858|Biological|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
80029022|NCT03835143|Procedure|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
80029023|NCT03563703|Device|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
79272707|NCT00066443|Drug|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
79576280|NCT01869517|Other|intrastromal corneal ring segments (Keraring) implantation|
79576281|NCT01869517|Other|Intrastromal corneal continuous ring (Myoring) implantation|
79576282|NCT01869543|Other|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
79576283|NCT01869543|Other|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
79576284|NCT01869556|Drug|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
79272708|NCT00066443|Drug|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
79735583|NCT02877186|Other|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
79272709|NCT00054106|Drug|buserelin|
79272710|NCT00054106|Drug|custirsen sodium|
79272711|NCT00054106|Drug|flutamide|
79735584|NCT02877186|Other|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
79735585|NCT04225858|Procedure|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
79870558|NCT06180369|Other|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissur Sealent application
79870559|NCT06180369|Other|BeutiSealant (Shofu, Kyoto, Japonya)|Fissur Sealent application
79272712|NCT00054106|Procedure|conventional surgery|
79272713|NCT00054106|Procedure|neoadjuvant therapy|
79272714|NCT00053794|Drug|perifosine|
79272715|NCT00053781|Drug|perifosine|
79272716|NCT00030875|Drug|bortezomib|
79272717|NCT02203123|Device|Ultrasound|
79272718|NCT02203123|Drug|normal saline|
79576285|NCT01869556|Drug|Ergot|Ergot 0.25mg IV
79576286|NCT01869556|Drug|Carboprost|Carboprost 0.25mg IM
79304551|NCT03282539|Device|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
79304552|NCT02443909|Procedure|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
79304553|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
79402838|NCT05056207|Other|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
79735586|NCT02617849|Drug|Pembrolizumab|200 mg IV every 3 weeks
79870560|NCT06180317|Other|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
79875941|NCT00450372|Other|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
80029024|NCT03563703|Device|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
80029025|NCT04952272|Combination Product|CpG-ODN|CAR-T cells secreting scFv against OX40
80029026|NCT04295928|Behavioral|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
79576287|NCT01869569|Drug|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
79576288|NCT01869569|Drug|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
79576289|NCT01869608|Procedure|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
79576290|NCT01869621|Drug|Metformin|6 days treatment with metformin to steady-state
79576291|NCT01869660|Behavioral|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
79576292|NCT01869673|Device|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
79576293|NCT01869673|Device|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
79576294|NCT01869712|Other|Cupping therapy|
79576295|NCT01869712|Other|Acupuncture|
80029027|NCT04952116|Other|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
80029028|NCT02227524|Other|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
79272719|NCT03532867|Other|Examination of pressures before stopping the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~Macular and peri-papillary OCT in EDI mode (bilateral examination),~Intraocular pressure (bilateral examination)~Measurement of systolic and diastolic blood pressure~Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
79304554|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
79576296|NCT01869738|Device|MGuard Prime|
79576297|NCT01869738|Device|(BMS/DES)|
79576298|NCT01869751|Drug|Prucalopride|Treatment with prucalopride for slow-transit constipation
79576299|NCT01869790|Other|Different fat types|Saturated, monounsaturated fats
79576300|NCT01869803|Drug|gemtuzumab ozogamicin|Given IV
79576301|NCT01869803|Other|laboratory biomarker analysis|Correlative studies
79576302|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
79576303|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
79576304|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
79576305|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
79735587|NCT02617849|Drug|Carboplatin|AUC=6, every 3 weeks x 4
79735588|NCT02617849|Drug|Paclitaxel|175 mg/m2, every 3 weeks x 4
79735589|NCT02775448|Drug|Carduus marianus 6cH|
79735590|NCT02775448|Drug|Carduus marianus 12cH|
79576306|NCT01869855|Procedure|Subdural Drainage|
79576307|NCT01869855|Procedure|Subperiosteal Drainage|
79576308|NCT01869881|Drug|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
79576309|NCT01869881|Drug|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
79735591|NCT02775448|Drug|Carduus marianus 30cH|
79735592|NCT02775448|Drug|Placebo|
79735593|NCT02775448|Behavioral|Exercise|aerobic exercise, 30 minutes, daily
79735594|NCT02775448|Other|Diet|1600 calories
79735595|NCT00950859|Drug|GSK1349572 (Cohort I)|50 mg once daily
79735596|NCT00950859|Drug|GSK1349572 (Cohort II)|50 mg twice daily
79735597|NCT02775292|Biological|Aldesleukin|Given SC
79735598|NCT02775292|Drug|Cyclophosphamide|Given IV
79735599|NCT02775292|Drug|Fludarabine Phosphate|Given IV
79735600|NCT02775292|Other|Laboratory Biomarker Analysis|Correlative studies
79735601|NCT02775292|Biological|Nivolumab|Given IV
79735602|NCT02775292|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
79272720|NCT03532867|Other|Examination of pressure during the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~Macular and peri-papillary OCT in EDI mode (bilateral examination),~Intraocular pressure (bilateral examination)~Measurement of systolic and diastolic blood pressure~Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
80029029|NCT02227524|Device|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
79402845|NCT05043350|Drug|Loratadine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
79402846|NCT05043350|Drug|Famotidine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
79402847|NCT05023135|Device|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
79402848|NCT05010109|Procedure|6 Minute Walk Functional Test|Participate in 6 MWT
79576310|NCT01869894|Procedure|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
79576311|NCT01869894|Procedure|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
79735603|NCT02775292|Biological|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
79735604|NCT02775292|Procedure|Positron Emission Tomography|Correlative studies
79735605|NCT00862849|Drug|Insulin Lispro|
79735606|NCT00862849|Drug|Regular Human Insulin|
79735607|NCT00862849|Drug|rHuPH20|
79735608|NCT01090050|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
79735609|NCT01090050|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
80029030|NCT02227524|Device|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
80029031|NCT02227524|Device|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
80029032|NCT04951960|Other|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
79304555|NCT02443909|Device|Holmium laser device|
79304556|NCT03285191|Other|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
79402849|NCT05010109|Procedure|Biospecimen Collection|Undergo blood and urine sample collection
79402850|NCT05010109|Procedure|Computed Tomography|Undergo SPECT/CT
79402851|NCT05010109|Procedure|Echocardiography|Undergo echocardiogram
79402852|NCT05010109|Procedure|Exercise Cardiac Stress Test|Undergo stress test
79402853|NCT05010109|Other|Questionnaire Administration|Complete questionnaires
79402854|NCT05010109|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
79402855|NCT04985266|Drug|Palbociclib 125Mg Tab|Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
79402856|NCT04985266|Drug|Fulvestrant injection|Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
79402857|NCT04985266|Drug|Tamoxifen|As per clinical guidelines
79402858|NCT04985266|Drug|Letrozole|As per clinical guidelines
79402859|NCT04985266|Drug|Exemestane|As per clinical guidelines
79402860|NCT04985266|Drug|Anastrozole|As per clinical guidelines
79870561|NCT06180304|Other|Exercise training|The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
79735610|NCT02776618|Procedure|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
79735611|NCT00944229|Drug|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
80029033|NCT04951960|Other|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
79402866|NCT04967274|Procedure|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
79402867|NCT04949776|Diagnostic Test|Mammograms|"In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~In studies with a Score <8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~In studies with a Score> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®."
79402868|NCT04947020|Drug|Metformin|Metformin use before operation due to previously diagnosed diabetes.
79402869|NCT04929288|Drug|Alcohol|Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.
79402870|NCT04896697|Drug|XTX101|XTX101 monotherapy
79402871|NCT04896697|Drug|Atezolizumab|1200 mg administered every 3 weeks in combination with XTX101
79402872|NCT04896697|Drug|XTX101|In combination with Atezolizumab
79402873|NCT04862468|Combination Product|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
79402874|NCT04862468|Combination Product|Perivascular sham|Saline delivery around target vein segment(s)
79402875|NCT04860323|Other|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
79402876|NCT04858451|Drug|RESP301|"A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day."
79576312|NCT01869894|Procedure|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
79576313|NCT01869907|Drug|Minocycline|100 mg once daily by mouth during 14 days
79576314|NCT01869907|Drug|placebo|once daily by mouth during 14 days
79735612|NCT00944229|Drug|Placebo|4 capsules of placebo every 24 hours
79735613|NCT02775370|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
79576315|NCT01869907|Drug|Amitriptyline|25mg once daily by mouth during 14 days
79576316|NCT01869920|Behavioral|Intervention group|Education on breastfeeding
79576317|NCT01869920|Behavioral|Usual care|Usual care
79576318|NCT01869933|Drug|OC-10X|
79576319|NCT01869946|Drug|Ropivacaine|
79576320|NCT01869985|Drug|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
79576321|NCT01870011|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
79576322|NCT01870011|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
79576323|NCT01870024|Drug|Clonazepam|clonazepam 0,015 mg/kg
79735614|NCT00698893|Biological|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
80029034|NCT02223780|Other|early palliative care|the patients will benefit from an early palliative care consultation
80029035|NCT04951882|Biological|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
79735615|NCT04225468|Behavioral|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
79735616|NCT02855307|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
79735617|NCT02855307|Device|Insulin pump|Patient's insulin pump will be used to infuse insulin.
79735618|NCT02855307|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
79735619|NCT02855307|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
79735620|NCT02855307|Other|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
79735621|NCT01077960|Biological|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
79735622|NCT04269369|Drug|5-Fluorouracil|"The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature."
79735623|NCT02776696|Device|Advanced Hybrid Closed Loop System|
79735624|NCT02776696|Device|Hybrid Closed Loop System|
79735625|NCT02776540|Drug|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
79735626|NCT02776540|Drug|Aspirin|there's another group will receive 400 mg Aspirin
79735627|NCT00944697|Drug|Oxycodone Naloxone|Oxycodone Naloxone tablets
79735628|NCT00944697|Drug|Placebo tablets|Placebo Oxycodone Naloxone tablets
79870562|NCT06180291|Other|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~Follow-up organized primarily at home~Monitoring of psychomotor development~Screening for possible cerebral palsy~Comprehensive support for the child's development: weight, diet, sleep...~Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~Creation of equipment if necessary: early seating installation in particular~Parental support and guidance for optimizing early care~Parental psychological support."
79870563|NCT06180278|Other|Blood tests|Participants will have blood tests done at each scheduled visit (approximately every 6 months).
79870564|NCT06180278|Drug|Inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
79870565|NCT06180265|Diagnostic Test|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
79576324|NCT01870024|Drug|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
79576325|NCT01870024|Drug|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
79576326|NCT01870024|Drug|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
79576327|NCT01870037|Drug|Placebo (PBS-20% sucrose)|
79735629|NCT02772796|Drug|SENS-218|Oral Administration
79870566|NCT06180252|Diagnostic Test|PET with 11C MP4|Each subject will undergo a PET exam using 11C MP4 as a tracer. This is a specific ligand for the acetyl-choline esterase enzyme already used abroad both in healthy volunteers and in various patient groups.
79870567|NCT06180226|Diagnostic Test|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
80029036|NCT01355523|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
79576328|NCT01870037|Drug|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
79576329|NCT01870050|Drug|Dapsone gel - verum|
79576330|NCT01870089|Device|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
79576331|NCT01870102|Drug|Pelubiprofen IR (Pelubiprofen 30mg) TID|
79576332|NCT01870102|Drug|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
79576333|NCT01870115|Dietary Supplement|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
79735630|NCT00626652|Drug|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
79735631|NCT02775136|Device|HS-1000 recording|
79735632|NCT02878122|Procedure|Cancer treatment|Chemotherapy and laparoscopic surgery
79735633|NCT04878172|Device|TempSure Firm|The TempSure firm will be used on the abdomen for non-invasive lipolysis.
79272721|NCT03532867|Other|Examination of pressures after stopping the exercise|"In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~Macular and peri-papillary OCT in EDI mode (bilateral examination),~Intraocular pressure (bilateral examination)~Measurement of systolic and diastolic blood pressure~Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
79576334|NCT01870115|Dietary Supplement|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
79735634|NCT04306926|Drug|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
79272722|NCT02207959|Drug|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
79735635|NCT04306926|Radiation|SBRT|Give according to the location of the lesion and clinical condition.
79735636|NCT04807348|Drug|Chiglitazar 32mg|Administrated once daily
79272723|NCT02207959|Procedure|White-light examination|standard white light examination
79272724|NCT02207959|Procedure|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
79576335|NCT01870128|Drug|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
79870568|NCT06180213|Diagnostic Test|FDG PET|Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.
79870569|NCT06180200|Diagnostic Test|PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.
79870570|NCT06180187|Device|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
79870571|NCT06180187|Device|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
79272725|NCT02208115|Dietary Supplement|Meal composition - Low versus high GI.|
79272726|NCT02567552|Drug|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
79735637|NCT04807348|Drug|Chiglitazar 48mg|Administrated once daily
79735638|NCT04807348|Drug|Placebo|Placebo of Chiglitazar
79735639|NCT04807348|Drug|Metformin Hydrochloride|most tolerable dose
79735640|NCT01075074|Procedure|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
79272727|NCT02567552|Drug|Intramuscular progesterone|intramuscular progesterone 50 mg/day
79735641|NCT04224922|Drug|Paclitaxel|
79735642|NCT04224922|Drug|Carboplatinum|
79735643|NCT04224922|Drug|Epirubicin|
79735644|NCT04224922|Drug|Cyclophosphamide|
79735645|NCT00626418|Drug|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
80029037|NCT01355523|Drug|Placebo|6 mg oral placebo daily 1 hour before bedtime
79272728|NCT02208193|Behavioral|Cognitive and psycho-behavioral effects of an artistic dimension|
79272729|NCT02203279|Other|Rebase II Fast|It is going to be used a direct relining material
79272730|NCT02203279|Other|Flexacryl|This is going to be used as a second direct relining material
79272731|NCT02203279|Other|Vertex|This is going to be used as an indirect relining material
79272732|NCT02199301|Procedure|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
79402877|NCT04849975|Other|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
79576336|NCT01870128|Drug|Methotrexate|Methotrexate 15 to 25 mg PO per week
79576337|NCT01870128|Drug|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
79735646|NCT00626418|Drug|Placebo|Placebo tablets
79735647|NCT02877030|Other|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
79735648|NCT02877888|Drug|fluoride varnish 22600ppm|topical application on teeth every 6months
79735649|NCT02772640|Drug|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -> evening evening -> morning"
79735650|NCT02877342|Other|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
79735651|NCT02877810|Other|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
79735652|NCT02877810|Other|Telephone|Consultations will be given over telephone.
79735653|NCT02772484|Device|HS-1000|
80029038|NCT02223936|Other|group exposed|Assessment by Brunet Lezine scale
80029039|NCT02223936|Other|Control|Not exposed group
80029040|NCT04952038|Behavioral|sleep disorder|ALS patients with or without sleep disorder
79870572|NCT06180148|Device|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
79272733|NCT04541654|Genetic|Data and Specimen Collection|"Provide research team and access to relevant medical records~Answer short questionnaires periodically~Consider consenting to other optional parts of the research such as:~Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~Provide a saliva sample (optional).~Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~Consider inviting relatives to join the study (optional)."
79272734|NCT02208427|Drug|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
79870573|NCT06180135|Other|TURKISH COFFEE DRINK|TURKISH COFFEE DRINK
79870574|NCT06180135|Other|FENNEL TEA DRINK|FENNEL TEA DRINK
79576338|NCT01870141|Behavioral|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~self-monitoring~problem solving~goal definition~cognitive restructuring~activation of personal and social resources"
79576339|NCT01870154|Behavioral|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
79870575|NCT06180122|Diagnostic Test|Duplex ultrasound|Vascular ultrasound scan of the left common iliac vein
79870576|NCT06180109|Drug|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
80029041|NCT02227602|Drug|Mango polyphenolics|Frozen mango pack will be provided (200~400g per day).
79272735|NCT02208427|Drug|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
79272736|NCT05506202|Other|Individual basic body awareness therapy|"Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state."
79272737|NCT05506202|Other|Respiratory physiotherapy interventions|Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
79735654|NCT02876952|Other|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
79272738|NCT05508620|Drug|Sirolimus for Injection (Albumin-bound)|Intravenous infusion
79272739|NCT03803605|Biological|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
79576340|NCT01870167|Drug|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
79870577|NCT06180109|Drug|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
79870578|NCT06180070|Drug|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
79870579|NCT06180070|Drug|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
79870580|NCT06180031|Drug|Pericapsular nerve group block using bupivicaine and magnesium sulphate|This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus
79870581|NCT06180018|Other|interrupted sutures|Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
80029042|NCT04951414|Diagnostic Test|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
79272740|NCT03803605|Drug|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
79272741|NCT02208505|Drug|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
79272742|NCT02208505|Drug|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
79576341|NCT01870167|Dietary Supplement|Placebo|Placebo
79576342|NCT01870180|Device|EyeBag|fabric bag of beads which can be heated in a microwave
79576343|NCT01870180|Other|Placebo|
79576344|NCT01870206|Biological|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
79870582|NCT06179979|Diagnostic Test|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
79870583|NCT06179953|Other|NAO intervention|"The protocol is divided into 4 stages:~EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
79870584|NCT06179953|Other|Traditional intervention|"The protocol is divided into 4 stages:~EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
79735655|NCT02876952|Other|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
79735656|NCT02876952|Other|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
79870585|NCT06179940|Other|Pairwise food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The experimental group will conduct the protocol activity in pairs.
79870586|NCT06179940|Other|Individual food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The control group will conduct the activity individually.
79870587|NCT06179927|Other|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
79576345|NCT01870206|Biological|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
79870588|NCT06179927|Other|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
79576346|NCT01870219|Drug|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
79870589|NCT06179901|Procedure|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
79870590|NCT06179901|Procedure|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
79576347|NCT01870219|Drug|Ketamine|ketamine was given to 1mg/kg ıv bolus
79576348|NCT01869582|Device|Fetoscope, Fetal heart rate|
79576349|NCT01869582|Device|Upright Resuscitator, Resuscitation|
79576350|NCT01869582|Device|Doppler, Fetal heart rate|
79576351|NCT01869582|Device|Standard Resuscitator, Resuscitation|
79735657|NCT02876952|Other|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
79735658|NCT02772406|Device|Linked Color Imaging|
79735659|NCT02772406|Device|white light imaging|
79870591|NCT06179888|Procedure|Biospecimen Collection|Undergo collection of blood samples
79272743|NCT05508386|Other|MATLAB-based interface, showing 50 EEG traces, classification of the EEG-pattern as Burst Suppression possible, yes, no.|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
79870592|NCT06179888|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79870593|NCT06179888|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79870594|NCT06179888|Procedure|Computed Tomography|Undergo PET/CT and/or CT
79870595|NCT06179888|Drug|Iberdomide|Given PO
79870596|NCT06179888|Procedure|Magnetic Resonance Imaging|Undergo MRI
79870597|NCT06179888|Procedure|Patient Monitoring|Undergo disease monitoring
79870598|NCT06179888|Procedure|Positron Emission Tomography|Undergo PET/CT
79870599|NCT06179888|Procedure|Skeletal Survey X-Ray|Undergo skeletal survey x-ray
80029043|NCT02227680|Other|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
79272744|NCT02208583|Drug|Docetaxel & Prednisone|Docetaxel & Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
79272745|NCT02208583|Drug|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
79870600|NCT06179875|Drug|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
79870601|NCT06179810|Other|Baduanjin exercise|Baduanjin exercise
79870602|NCT06179797|Device|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
79870603|NCT06179784|Behavioral|Cognitive Behaviour Therapy including third-wave|All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behaviour Therapy including methods from the third wave like Acceptance and Commitment Therapy or Mindful Selfcompassion.
79870604|NCT06179771|Device|HA 380|HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
79870605|NCT06179758|Device|icompanion app|use of the icompanion app as a digital telemonitoring solution
79272746|NCT02208583|Drug|cisplatin & Etoposide|cisplatin & Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
79576352|NCT01870232|Procedure|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
79576353|NCT01870245|Drug|ACHN-975|Intravenous multiple dose
79576354|NCT01870245|Drug|placebo|Intravenous multiple dose
79576355|NCT01870258|Other|ANN prediction of myocardial infarction|
79576356|NCT01870271|Behavioral|Developmentally adapted cognitive processing therapy|
79870606|NCT06179745|Combination Product|EEG-based brain-computer interface|EEG-based brain-computer interface detecting the patient's EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient.
79576357|NCT01870284|Drug|Ixekizumab|Administered SC
79576358|NCT01870284|Drug|Placebo|Administered SC
79576359|NCT01870284|Drug|Adalimumab|Administered SC
79576360|NCT01870310|Procedure|Catheterised renal denervation|
79735660|NCT02772718|Drug|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
79735661|NCT02772718|Drug|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
79735662|NCT02772718|Drug|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
79870607|NCT06179745|Combination Product|Sham EEG-based brain-computer interface|Fake (Sham) EEG-based brain-computer interface which outputs a decision at random about whether EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient are currently detected.
79870608|NCT06179745|Device|Functional Electrical Stimulation|Neuromuscular stimulation of several upper limb muscles (elbow extensors, hand extensors/flexors) to effectuate reach, grasp and release movements of the affected upper limb.
79735663|NCT02772718|Drug|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
79735664|NCT00866281|Drug|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
79576361|NCT01870323|Behavioral|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
79735665|NCT02772016|Drug|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
79870609|NCT06179745|Device|Active hand orthosis|Active hand orthosis effectuating reach, grasp and release movements of the affected uppe r limb.
79735666|NCT04225000|Other|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
79870610|NCT06179732|Combination Product|Mesh - spatial repellent impregnated with transfluthrin (2500mg)|"Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only."
79870611|NCT06179732|Behavioral|Information and Education Campaigns (IEC)|IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
79870612|NCT06179732|Diagnostic Test|test and treat malaria cases|All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
80029044|NCT02227680|Other|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
80029045|NCT04951648|Drug|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
79272747|NCT02208583|Drug|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
79576362|NCT01870323|Behavioral|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
79735667|NCT04225000|Other|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
80029046|NCT04951648|Drug|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
80029047|NCT04185246|Drug|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
80029048|NCT04185246|Diagnostic Test|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
80029049|NCT04164888|Drug|CIVI 007|hypercholesterolemia agent
80029050|NCT04951258|Other|Multicomponent exercise|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
79272748|NCT05501288|Drug|Huashi Baidu granule|Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
79576363|NCT01870336|Device|Combined treatment of medial knee osteoarthritis|
80029051|NCT04951258|Other|Video home exercise group|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
79576364|NCT01870349|Procedure|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
79576365|NCT01870362|Drug|Probiotic (Inersan)|
80029052|NCT02227914|Drug|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
80029053|NCT02227914|Drug|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
79272749|NCT05501288|Drug|compound pholcodine oral solution|Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
79870613|NCT06179719|Drug|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
79870614|NCT06179719|Behavioral|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
79272750|NCT02208739|Procedure|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
79402878|NCT04825015|Device|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
79576366|NCT01870362|Drug|Placebo|
79402879|NCT04814927|Drug|Copper IUD|Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.
79402880|NCT04814927|Drug|Etonogestrel implant|Participants randomized to ETG implant will receive the implant at Visit 2.
79402881|NCT04814927|Drug|Levonorgestrel IUS|Participants randomized to LNG intrauterine system will receive the IUS at Visit 2.
79735668|NCT04121611|Drug|Unfractionated heparin|"Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
79735669|NCT04121611|Drug|Acetylsalicylic Acid (ASA)|"Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose < 2 hours of EVT completion~ASA 81mg PO OD maintenance dose"
79735670|NCT02617615|Drug|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
79735671|NCT02617615|Drug|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
79870615|NCT06179706|Diagnostic Test|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
79870616|NCT06179693|Diagnostic Test|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
79402882|NCT04814927|Drug|DMPA Sub-cutaneous|Participants randomized to DMPA SC will receive the injection at Visit 2.
79576367|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm
79576368|NCT01870427|Drug|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
79576369|NCT01868880|Drug|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
79735672|NCT02772250|Behavioral|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
79735673|NCT02772250|Behavioral|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
79735674|NCT02614885|Device|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
79735675|NCT02772172|Device|Surgical Template|
80029054|NCT04161456|Drug|Apremilast|Apremilast twice daily 30 mg
80029055|NCT04951024|Procedure|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
80029056|NCT04951024|Procedure|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
80029057|NCT04110054|Drug|S-600918|Tablets for oral administration
80029058|NCT04110054|Drug|Placebo to S-600918|Tablets for oral administration
80029059|NCT04950790|Drug|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
80029060|NCT04950790|Drug|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
79870617|NCT06179680|Diagnostic Test|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
80029061|NCT04950790|Drug|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
80029062|NCT04951180|Other|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
80029063|NCT04950478|Other|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
80029064|NCT04950556|Other|Exercise|Pelvic floor muscle exercise will be given to the exercise group
80029065|NCT04950556|Other|Control|No intervention
80029066|NCT02224014|Drug|Lendormin D tablets|
80029067|NCT02224092|Dietary Supplement|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
79272751|NCT02208739|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
79272752|NCT02203825|Biological|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
79272753|NCT03532789|Drug|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
79402883|NCT04772482|Diagnostic Test|Sensitivity Patch Testing|Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
79402884|NCT04747912|Drug|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
79402885|NCT04747912|Drug|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
79576370|NCT01868880|Drug|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
79576371|NCT01870440|Drug|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
79576372|NCT01870466|Drug|Cilostazol|cilostazol bid for 7 days
79576373|NCT01870466|Drug|Simvastatin|simvastatin qd for 7 days
79576374|NCT01870466|Drug|Rosuvastatin|rosuvastatin qd for 7 days
79735676|NCT02772094|Biological|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
79735677|NCT02771860|Drug|denosumab|60mg sc
79735678|NCT02771860|Drug|Placebo|identical syringe
79735679|NCT02771860|Dietary Supplement|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
79735680|NCT02771782|Biological|BCG vaccine (SSI)|
79272754|NCT03532789|Drug|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
79272755|NCT02258035|Other|Blood draw|Sampling of 100-150 ml of blood
79272756|NCT02561000|Drug|PZ-128|
79272757|NCT02561000|Drug|Placebo|
79272758|NCT02258113|Device|Ocusweep|A novel reaction-time based visual field device.
79272759|NCT02258113|Device|Ocusweep OcuRT|Vision based choice reaction time test method
79272760|NCT04539080|Procedure|transversus abdominis plane block|transversus abdominis plane block group
79272761|NCT03533491|Behavioral|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
79735681|NCT02771782|Biological|TDaP-IPV vaccine|
79272762|NCT05501210|Device|WBV|Whole body vibration (WBV) therapy
79402886|NCT04747912|Drug|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
79402887|NCT04747912|Drug|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
79576375|NCT01870479|Other|Live music|
79576376|NCT01870479|Other|Taped music|
79576377|NCT01870492|Drug|Activase|Patients treated with Activase
79576378|NCT01870492|Device|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
79576379|NCT01870518|Device|Bilateral GPi DBS|
79576380|NCT01870518|Device|Bilateral STN DBS|
79735682|NCT02771392|Drug|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
79870618|NCT06179667|Behavioral|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
79870619|NCT06179654|Behavioral|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
80029068|NCT03671161|Device|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
80029069|NCT02258802|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
80029070|NCT03671083|Device|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
79576381|NCT01870544|Dietary Supplement|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
79576382|NCT01870544|Dietary Supplement|Placebo|placebo will be administered daily for 44 days
79576383|NCT01870570|Other|Reference Glucose|
79576384|NCT01870570|Other|Food Product A: Corn Flakes|
79576385|NCT01870570|Other|Food Product B: Ginger Bread|
79576386|NCT01870570|Other|Food Product C:Sandwiched Breakfast Biscuit|
79576387|NCT01870570|Other|Food Product D: Crackers Nature|
79576388|NCT01870570|Other|Food Product E: Breakfast Biscuit|
79576389|NCT01870570|Other|Food Product F: White Bread|
79576390|NCT01870622|Procedure|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
79735683|NCT02771392|Other|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
79735684|NCT02771470|Drug|Probiotics|Microbial composition using probiotic
79735685|NCT02771470|Drug|placebo|Microbiota modulation using placebo
79735686|NCT02696746|Other|Observation|No intervention
80029071|NCT04950088|Other|Hand-held video game device|
80029072|NCT03675997|Other|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
79272763|NCT05501210|Device|PEMF|Pulsed electromagnetic fields (PEMF)
79272764|NCT02208973|Drug|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
79272765|NCT02208973|Drug|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
79272766|NCT02199379|Drug|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
79272767|NCT03532711|Drug|fluorouracil|chemotherapy treated patients
79272768|NCT02209051|Other|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
79272769|NCT02209051|Other|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
79272770|NCT02199457|Device|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
79272771|NCT02199457|Device|SVSS and reference devices|Body temperature taken with infrared thermometer
79576391|NCT01870622|Procedure|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
79576392|NCT01870635|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
79576393|NCT01870635|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
79576394|NCT01870648|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
79576395|NCT01870648|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
79735687|NCT02771704|Other|Silver Diamine fluoride|
79735688|NCT02771704|Other|Potassium iodide|
79735689|NCT02771704|Other|Chlorhexidine|
79735690|NCT02771704|Other|Silver diamine fluoride and potassium iodide|
79735691|NCT02771704|Other|Physiological saline|
79735692|NCT02771548|Procedure|Anterior Cruciate Ligament Reconstruction|
79735693|NCT02771314|Drug|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
79870620|NCT06179615|Other|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
79576396|NCT01870661|Device|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
79870621|NCT06179615|Other|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
79870622|NCT06179589|Dietary Supplement|VS002A|Amino acid based, glucose free ORS
79870623|NCT06179576|Behavioral|Connect to Baby|"To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention."
79735694|NCT02771002|Device|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
79735695|NCT02771158|Drug|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
79870624|NCT06179563|Other|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
79576397|NCT01870661|Device|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
79870625|NCT06179537|Drug|BLU-5937|Single and multiple doses assessment
79870626|NCT06179524|Biological|CAR-T-19 cell injection|The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
79576398|NCT01870674|Drug|YH12852|
79870627|NCT06179498|Behavioral|Partner Navigation Intervention|A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
79870628|NCT06179485|Drug|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
79272772|NCT02199457|Device|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
79576399|NCT01870674|Drug|Prucalopride|
79576400|NCT01870674|Drug|Placebo|
79576401|NCT01870687|Drug|20mg VAC BNO 1095 FCT|
79576402|NCT01870687|Drug|Placebo|
79735696|NCT02771158|Drug|placebo|placebo will be administered to double blind the study
79735697|NCT02771080|Procedure|Cardiac surgery|
79735698|NCT02770924|Device|AT LISA TRI TORIC|phacoemulsification with IOL implantation
79870629|NCT06179485|Drug|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
79870630|NCT06178276|Diagnostic Test|behavior|behavioral measurements will be performed during the oral comprehension testing
79272773|NCT02199457|Device|SVSS and reference devices|Measurement of respiration rate
79272774|NCT04714112|Drug|dexamethasone|Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
79272775|NCT02199613|Drug|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
79272776|NCT02209207|Device|Treadmill|
79272777|NCT02209207|Other|walking training|
79272778|NCT05505812|Biological|HS-IT101|Adoptive transfer of 1x10^9-6x10^10 autologous TIL to patients i.v. in 30-60 minutes.
79576403|NCT01870700|Drug|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
79576404|NCT01870700|Drug|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
79735699|NCT02770924|Device|AT LISA TRI|phacoemulsification with IOL implantation
79735700|NCT02770534|Procedure|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
79576405|NCT01870752|Procedure|Transplantation of previously cryopreserved ovarian tissu|
79576406|NCT01870765|Device|non-invasive ventilation|non-invasive ventilation via face mask
79576407|NCT01870765|Device|high-flow oxygen|high-flow oxygen via nasal cannula
79576408|NCT01870765|Procedure|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
80029073|NCT04950400|Drug|Carrelizumab + chemotherapy + apatinib|Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
79576409|NCT01870791|Drug|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
79870631|NCT06178276|Diagnostic Test|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
79870632|NCT06178276|Diagnostic Test|imaging|central (brain) measurements will be performed during the oral comprehension testing
79576410|NCT01870804|Drug|Rosuvastatin|
79735701|NCT02770768|Drug|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
79735702|NCT02770768|Drug|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
79870633|NCT06176612|Procedure|total hip arthroplasty|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement
79870634|NCT06176066|Procedure|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
79272779|NCT02209285|Behavioral|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
79272780|NCT04710992|Procedure|Isolated needling procedure|The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.
79272781|NCT04710992|Procedure|Low intensity percutaneous electrolysis|Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
79272782|NCT04710992|Procedure|High intensity percutaneous electrolysis|The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
79272783|NCT02209441|Drug|Phase I Dose-finding Study of Sorafenib Study|
79735703|NCT02770690|Drug|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
79735704|NCT02770690|Drug|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
79735705|NCT02770690|Drug|placebo|apply normal saline before propofol iv injection
79870635|NCT06175494|Biological|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
79870636|NCT06175494|Biological|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
79272784|NCT05505656|Diagnostic Test|hysteroscopic guided endomyometrial biopsy|we will obtain hysteroscopic guided endomyometrial biopsy in cases of adenomyosis
79272785|NCT05500898|Drug|DWP16001|Tablets, Oral, multiple doses of DWP16001
79402888|NCT04747912|Drug|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
79402889|NCT04747912|Drug|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
79576411|NCT01870804|Drug|Atorvastatin|
79576412|NCT01870817|Dietary Supplement|Home jejunostomy feeding|
79576413|NCT01870830|Other|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
79576414|NCT01870882|Behavioral|Attentional retraining|
79576415|NCT01870882|Behavioral|Control condition|
79576416|NCT01870895|Drug|YM060|oral
79576417|NCT01870895|Drug|Placebo|oral
79870637|NCT06175494|Biological|Placebo|boost with saline
80029074|NCT02228070|Device|strabismus video goggles|
80029075|NCT02625220|Device|Prototype toric lens senofilcon A|Investigational prototype
79576418|NCT01870908|Drug|tacrolimus|
79576419|NCT01870908|Drug|biological agents|
79576420|NCT01870934|Device|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
79576421|NCT01870947|Behavioral|Exercise on stationary recumbent exercise cycle|
79576422|NCT01870947|Behavioral|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
79576423|NCT01870947|Behavioral|Questionnaires|
79735706|NCT02770378|Drug|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
79735707|NCT02770378|Drug|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
80029076|NCT03623269|Procedure|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
80029077|NCT04046484|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
80029078|NCT04046484|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
80029079|NCT03670927|Other|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
79576424|NCT01870947|Procedure|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
79576425|NCT01870947|Procedure|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
79576426|NCT01870986|Biological|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
79735708|NCT02770378|Drug|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
79735709|NCT02770378|Drug|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
79870638|NCT06174519|Device|Medical device simulation|For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
79272786|NCT05500898|Drug|DWC202204+DWC202205|Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
79272787|NCT05500898|Drug|DWP16001+DWC202204+DWC202205|Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
79272788|NCT02199847|Drug|Pharmaton® Caplets|
79272789|NCT02199847|Drug|Placebo|
79272790|NCT05507762|Biological|UC-MSCs|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively"
79272791|NCT05507762|Biological|Saline solution|Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
79272792|NCT03533413|Procedure|combined CT-fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
79735710|NCT02770378|Drug|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
79870639|NCT06173661|Drug|Fremanezumab|The intervention will be active medication.
79272793|NCT03533413|Procedure|standard fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
79272794|NCT05263531|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
79402890|NCT04747912|Drug|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
79576427|NCT01870986|Biological|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
79576428|NCT01870986|Biological|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
79576429|NCT01871025|Other|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
79735711|NCT02770378|Drug|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
79735712|NCT02770378|Drug|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
79870640|NCT06173661|Other|Placebo|The intervention will be placebo injection.
80029080|NCT04949932|Other|Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
80029081|NCT04949932|Other|Cicer arietinum powder|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
80029082|NCT02826603|Drug|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
80029083|NCT02826603|Drug|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
80029084|NCT02224170|Drug|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
80029085|NCT02224170|Drug|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
80029086|NCT03058120|Other|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
79272795|NCT05479838|Procedure|Percutaneous coronary intervention|Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
79272796|NCT04704908|Drug|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
79272797|NCT05261347|Procedure|mulligan mobilisation|an active mobilisation with movement on elbow according to mulligan's protocol
79272798|NCT05261347|Procedure|sham|a lateral glide
79272799|NCT02204059|Drug|hMAb BIWA 4|
79272800|NCT02204137|Other|Falls Risk Questionnaire|
79576430|NCT01871025|Other|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
79576431|NCT01871064|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
79576432|NCT01871103|Procedure|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
79576433|NCT01871116|Behavioral|POWER-remote|Web-based weight loss program.
79735713|NCT02770378|Drug|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
79870641|NCT06173219|Combination Product|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
79870642|NCT06172790|Other|Training|A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
79870643|NCT06169280|Biological|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
80029087|NCT02224248|Behavioral|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
80029088|NCT02224248|Behavioral|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
79272801|NCT02204137|Other|Cancer and Aging Research Group Geriatric Assessment|
79272802|NCT02204137|Other|Falls Efficacy Scale-International (FES-1)|
79272803|NCT02204137|Other|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
79272804|NCT02204215|Device|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
79272805|NCT02204215|Other|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
79272806|NCT02199925|Drug|Gammaplex 5%|
79576434|NCT01871116|Behavioral|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
79576435|NCT01871129|Drug|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
79576436|NCT01871129|Other|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
79735714|NCT02770378|Drug|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
79735715|NCT02770378|Drug|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
79735716|NCT02770456|Dietary Supplement|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
79576437|NCT01871155|Dietary Supplement|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
79870644|NCT06169280|Dietary Supplement|N-acetylcysteine amide (NACA)|N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
79870645|NCT06167694|Drug|HRS-8080; Dalpiciclib Isethionate Tablets|HRS-8080 combined with Dalpiciclib Isethionate Tablets
79870646|NCT06167668|Other|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
80029089|NCT03670771|Diagnostic Test|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
80029090|NCT02228148|Device|NFS|Cochlear Nucleus Fitting Software
80029091|NCT02228148|Device|CSS|Cochlear Nucleus Custom SoundTM Suite
79272807|NCT02200003|Behavioral|attention bias modification for anxiety|
79272808|NCT03338647|Drug|DEB|Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
79735717|NCT02770456|Dietary Supplement|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
79735718|NCT02770456|Dietary Supplement|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
79735719|NCT02770222|Drug|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
79735720|NCT02770222|Drug|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
79735721|NCT02770222|Drug|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
79272809|NCT03338647|Radiation|SBRT|High precision radiation therapy to the liver tumor(s)
79272810|NCT02209675|Other|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
79272811|NCT02200081|Drug|MGN1703|
79576438|NCT01871168|Procedure|TAP block|Infusion of 0.5-1% lidocaine
79576439|NCT01871168|Procedure|Sham TAP block|Infusion of saline
79576440|NCT01871181|Procedure|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
79576441|NCT01871181|Procedure|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
79576442|NCT01871233|Drug|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
79735722|NCT02770144|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
79735723|NCT02770144|Behavioral|Access to Referral to Social Services|
79735724|NCT00943917|Other|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
79735725|NCT00943917|Drug|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
79735726|NCT00943917|Other|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
79735727|NCT04780620|Other|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
79735728|NCT02876250|Drug|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
79870647|NCT06167668|Other|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
79870648|NCT06166719|Other|No intervention|No intervention
79870649|NCT06166290|Procedure|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
80029092|NCT04949698|Device|plasma exchange|Plasma exchange was performed daily for five times or until platelet level returned to normal
80029093|NCT02258568|Behavioral|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
80029094|NCT05956847|Procedure|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
80029095|NCT05956782|Behavioral|Breathe Easier|See Intervention Group (IG) description.
79272812|NCT02200081|Other|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
79272813|NCT05500742|Dietary Supplement|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
79272814|NCT05500742|Dietary Supplement|Selenium|100 mcg tablets provided by Pharma Nord
79272815|NCT05500742|Dietary Supplement|Resveratrol|350 mg capsules provided by NOW Foods
79735729|NCT02876250|Drug|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
79870650|NCT06166290|Procedure|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
79870651|NCT06164847|Behavioral|AERO Program|HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).
79870652|NCT06164847|Other|Standard Care|home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
79870653|NCT06164821|Drug|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
79870654|NCT06164145|Other|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
79870655|NCT06162806|Procedure|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
79870656|NCT06162806|Procedure|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
79870657|NCT06158841|Drug|ABBV-383|Intravenous (IV) Infusion
80029096|NCT05956743|Other|progressive relaxation exercise sessions|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~week: Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6. week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room. A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
80029097|NCT05956743|Other|Sham|"1. week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~6. week: In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes outpatient training room. Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
79735730|NCT02769910|Drug|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
80029098|NCT05956717|Device|Orthokeratology|The experimental group wore orthokeratology lenses
80029099|NCT05956704|Device|Orthokeratology with aspheric wide inversion zone design in the optical zone|An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
79272816|NCT05500742|Dietary Supplement|TA-65 MD|100 unit capsules provided by TA Sciences
79272817|NCT05500742|Other|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
79272818|NCT05500742|Other|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
79272819|NCT03533335|Other|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
79272820|NCT05505188|Other|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~Neuropathic pain: NPSI in screening~Anxiety/depression: HADS in screening~Quality of life: EORTC (QLQC30 and H&N43)~Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
79272821|NCT02200159|Drug|Sedation with dexmedetomidine|
79735731|NCT02769910|Drug|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
79735732|NCT02769910|Other|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
79735733|NCT02876484|Drug|Colesevelam|
79735734|NCT02876484|Drug|Chenodeoxycholic Acid|
79735735|NCT02876484|Other|Water|
79735736|NCT02851485|Drug|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
79735737|NCT02851485|Drug|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
79735738|NCT02851485|Drug|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
79870658|NCT06158841|Drug|Carfilzomib|IV Infusion
79870659|NCT06158841|Drug|Pomalidomide|Oral Capsule
79870660|NCT06158841|Drug|Elotuzumab|IV Infusion
79870661|NCT06158841|Drug|Selinexor|Oral Tablet
79870662|NCT06158841|Drug|Bortezomib|Subcutaneous or IV Injection
79870663|NCT06158841|Drug|Dexamethasone|Oral Tablet or IV Infusion
80029100|NCT05956704|Device|Orthokeratology with traditional spherical design in the optical zone|Subjects wore the orthokeratology with traditional spherical design in the optical zone
79735739|NCT04779372|Behavioral|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
79870664|NCT06158620|Drug|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
79870665|NCT06158620|Drug|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
79870666|NCT06150170|Other|Proprioceptive training|Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.
80029101|NCT05956678|Behavioral|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
80029102|NCT05956678|Behavioral|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
80029103|NCT05956639|Drug|6-month course of antiandrogen drugs|6-month course of Rezvilutamide and ADT + chemotherapy
79272822|NCT05500664|Drug|Lavender Oil|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
79272823|NCT05263219|Procedure|dTACE-HAIC|"For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination."
79272824|NCT05263219|Procedure|HAIC|"HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter.~The treatment is repeated once every 3 weeks for up to six cycles."
79576443|NCT01871272|Procedure|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
79576444|NCT01871298|Other|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
79735740|NCT04779372|Behavioral|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
79735741|NCT02696668|Other|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
79735742|NCT02696668|Other|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~Limits of stability training with eyes open / eyes closed~Self induced movement strategies with eyes open / eyes closed~Gaze stability exercises in sitting / standing / walking~Sensory integration~Habituation exercises"
79870667|NCT06143670|Drug|Stannous fluoride toothpaste|0.454% w/w SnF2
79870668|NCT06143670|Drug|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
79870669|NCT06131593|Drug|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
80029104|NCT05956639|Drug|Long-term course of antiandrogen drugs|Long-term course of Rezvilutamide and ADT + chemotherapy
80029105|NCT05956613|Procedure|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
79870670|NCT06131593|Drug|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
80029106|NCT05956600|Drug|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
80029107|NCT05956574|Behavioral|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
80029108|NCT05956574|Behavioral|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
79576445|NCT01871324|Behavioral|Lifestyle counseling|group therapy
79870671|NCT06127368|Drug|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
79870672|NCT06127368|Drug|GB-5001D|Depending on the cohort, volume will be varied to administer.
79870673|NCT06127368|Drug|Oral cohort|Single dose of Aricept tablet.
79870674|NCT06126926|Behavioral|group therapy|32 weeks of group therapy
80029109|NCT05956574|Behavioral|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
80029110|NCT05956574|Behavioral|Standard Dietary plan|Receive a standard dietary plan
80029111|NCT05956561|Other|dental implants were placed for all cases while assessing vitamin D levels|vitamin D assessment with measuring implant stability and clinical finding of early failure
80029112|NCT05956548|Procedure|external securement of scs leads during the scs trial period|two groups- one group will have an anchor device used alone to secure the leads, the second group will have an anchor device with a suture to secure the leads
80029113|NCT05956522|Drug|Test Empagliflozin And Linagliptin Tablets|specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
80029114|NCT05956522|Drug|Reference Empagliflozin And Linagliptin tablets|specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH & Co. KG
79735743|NCT04297722|Other|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
79735744|NCT02769598|Device|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
79576446|NCT01871337|Behavioral|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
79735745|NCT04297644|Other|There is no intervention|There is no intervention
79735746|NCT02769676|Other|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
79870675|NCT06126926|Other|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
79576447|NCT01871350|Dietary Supplement|Daily intake for 10 weeks (+/- 2 weeks)|
79576448|NCT01871363|Radiation|chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
79576449|NCT01871376|Drug|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
79576450|NCT01871454|Radiation|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
79576451|NCT01871454|Drug|Pentoxifylline|pentoxifylline
79576452|NCT01871467|Drug|Sargramostim|
79576453|NCT01871480|Drug|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
79576454|NCT01871480|Drug|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
79576455|NCT01871493|Drug|LY2605541|Administered subcutaneous (SQ)
79576456|NCT01871493|Drug|Insulin Lispro|Administered SQ
79576457|NCT01871584|Device|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
79576458|NCT01871597|Device|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
79870676|NCT06124508|Behavioral|Lung Cancer Screening Education|Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
79870677|NCT06124508|Behavioral|Semi-Structured Interview|Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
79576459|NCT01871610|Drug|[18F]AV-45 PET amyloid binding imaging|
79576460|NCT01871623|Procedure|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
79576461|NCT01871623|Procedure|One-piece Le Fort I Osteotomy|conventional approach
79576462|NCT01871636|Procedure|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
79576463|NCT01871636|Procedure|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
79576464|NCT01871636|Device|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
79576465|NCT01871649|Drug|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
79735747|NCT02769676|Other|usual care|Participants in the usual care arm will receive no additional interventions.
79735748|NCT02876094|Drug|celecoxib|dose-response
79735749|NCT00603135|Drug|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
79735750|NCT02769754|Device|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
79735751|NCT02769754|Other|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
79735752|NCT02769286|Drug|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
79735753|NCT02855073|Biological|ReJoinTM|adipose derived mesenchymal progeinitor cells
79735754|NCT02855073|Drug|Sodium Hyaluronate|Sodium Hyaluronate Injection
79272825|NCT05263219|Drug|dTACE-HAIC protocol|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h."
79272826|NCT05263219|Drug|HAIC protocol|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
79304557|NCT03285191|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
79402891|NCT04747912|Procedure|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
79576466|NCT01871649|Drug|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
79576467|NCT01871662|Drug|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
79576468|NCT01871662|Drug|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
79576469|NCT01871662|Drug|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
79735755|NCT01077024|Other|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
79735756|NCT02769130|Drug|Losartan|Losartan is given for 12 months
79870678|NCT06124508|Behavioral|Standard of Care Lung Cancer Screening Program|Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
79304558|NCT02445235|Other|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
79402892|NCT04732780|Other|No intervention|No intervention
79576470|NCT01871675|Drug|IPI-145|
79576471|NCT01871675|Drug|Rituximab|
79576472|NCT01871675|Drug|Bendamustine|
79576473|NCT01871688|Behavioral|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
79735757|NCT02768896|Behavioral|Baseline|Patients will walk naturally with EEG measuring brain waves
79735758|NCT02768896|Behavioral|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
79735759|NCT02768896|Behavioral|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
79735760|NCT02768896|Behavioral|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
79735761|NCT02853357|Other|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
79304559|NCT02439697|Other|Darbepoetin alfa|Conversion from Aranesp® to NESP®
79576474|NCT01871701|Drug|Escitalopram|Escitalopram
79576475|NCT01871701|Drug|Quetiapine|Quetiapine
79576476|NCT01871701|Drug|Moxifloxacin|Moxifloxacin
79576477|NCT01871701|Other|Placebo|Placebo
79576478|NCT01871740|Drug|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
79576479|NCT01871740|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
79576480|NCT01871753|Other|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
79576481|NCT01871779|Other|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
79576482|NCT01871779|Other|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
79576483|NCT01871792|Drug|Pitavastatin|
79576484|NCT01871792|Drug|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
79735762|NCT02853357|Other|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
79304560|NCT03285035|Device|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
79304561|NCT02445313|Device|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
79304562|NCT03284801|Other|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
79402893|NCT04612465|Biological|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10^7 cells of ASC per 1cm^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
79402894|NCT04612465|Drug|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
79402895|NCT04603911|Drug|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
79402896|NCT04603911|Drug|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
79576485|NCT01871818|Behavioral|Combined program|Combined program with physiotherapy, endurance training and resistance training
79576486|NCT01871818|Behavioral|Physiotherapy in private practice|Physiotherapy in private practice
79576487|NCT01871831|Device|6 blood glucose monitoring systems for self-testing|
79402897|NCT04597424|Drug|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
79402898|NCT04597424|Biological|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
79402899|NCT04590703|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
79402900|NCT04590703|Procedure|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
79402901|NCT04569409|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
79402902|NCT04569409|Procedure|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
79402903|NCT04554901|Dietary Supplement|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
79576488|NCT01871844|Drug|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
79576489|NCT01871844|Drug|octreotide 50 mcg tid|
79735763|NCT02853357|Other|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
79870679|NCT06117202|Other|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
79304563|NCT03284645|Drug|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
79576490|NCT01871844|Drug|Placebo|
79576491|NCT01871857|Drug|Hypertonic saline and epinephrine|
79576492|NCT01871857|Drug|Normal saline and epinephrine|
79576493|NCT01871883|Procedure|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
79576494|NCT01871883|Procedure|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
79576495|NCT01871896|Device|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
79576496|NCT01871922|Drug|Placebo|Saline
79576497|NCT01871922|Drug|Atropine|Atropine
79576498|NCT01871935|Drug|Remifentanil|Anaesthesia with remifentanil/propofol.
79576499|NCT01871935|Drug|Sufentanil|Anaesthesia with sufentanil/propofol
79576500|NCT01871948|Other|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
79576501|NCT01871961|Drug|Methotrexate (Metoject® prefilled pen)|
80029115|NCT05956470|Behavioral|Meditation and breathing program : Sudarshan Kriya Yoga (SKY)|The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.
79576502|NCT01871974|Drug|FK949E|oral
79576503|NCT01871987|Drug|FK949E|oral
79576504|NCT01872000|Procedure|Cataract surgery|
79735764|NCT02769208|Device|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
79735765|NCT02769052|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
80029116|NCT05956470|Behavioral|Stress management education|This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
80029117|NCT05956457|Behavioral|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
79402904|NCT04546477|Device|Stent implantation|"Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon."
79576505|NCT01872013|Drug|ASP7991|oral
79735766|NCT02768740|Drug|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
79735767|NCT01089582|Other|No intervention|
80029118|NCT05956457|Device|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
80029119|NCT05956444|Other|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
80029120|NCT05956444|Other|Conventional Physiotherapy|Classical physiotherapy applications for balance.
80029121|NCT05956431|Drug|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
79402905|NCT04501978|Biological|LY3819253|Participants are no longer being randomized to this intervention.
79402906|NCT04501978|Drug|Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion
79402907|NCT04501978|Biological|Remdesivir|Provided to all study participants as SOC unless contraindicated for an individual patient.
79402908|NCT04501978|Biological|VIR-7831|Participants are no longer being randomized to this intervention.
79576506|NCT01872013|Drug|Placebo|oral
79735768|NCT00603213|Procedure|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
79735769|NCT02768974|Drug|OPRX-106|Oral delivery, once daily.
79735770|NCT02851095|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
79735771|NCT02851095|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
79576507|NCT01872026|Drug|ASP7991|oral
79576508|NCT01872039|Drug|Perdipine injection|IV
79576509|NCT01872052|Device|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
79576510|NCT01872065|Drug|ARC-520|
79576511|NCT01872065|Drug|Placebo|
79576512|NCT01872091|Other|cryotherapy by immersion|
79576513|NCT01872091|Other|Control group|
79735772|NCT02851095|Drug|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
80029122|NCT05956431|Drug|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
79735773|NCT04224532|Procedure|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
79735774|NCT04224532|Procedure|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
79870680|NCT06107738|Drug|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
79870681|NCT06107738|Drug|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
79870682|NCT06106191|Behavioral|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
79870683|NCT06106191|Other|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
79870684|NCT06106191|Other|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
79870685|NCT06104605|Other|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
79870686|NCT06104605|Other|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local DCs, information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
79870687|NCT06104605|Other|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
79576514|NCT01872104|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
79576515|NCT01872117|Other|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
79576516|NCT01872117|Other|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
79870688|NCT06098482|Device|the Mobile Research App|"The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the keypad on the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.~Speech material used will be determined by the country/local language and the sub-investigation. For example, sub-investigation A, will use CNC monosyllabic words."
79870689|NCT06098482|Device|SOC/validated delivery of the speech perception test material|Speech material used will be determined by the country/local language and the sub-investigation. For example, sub-investigation A, will use CNC monosyllabic words.
79870690|NCT06096714|Drug|Nicotine|Nicotine will be infused using a pump.
79402909|NCT04501978|Biological|BRII-196/BRII-198|Participants are no longer being randomized to this intervention.
79576517|NCT01872143|Device|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
79402910|NCT04501978|Biological|AZD7442|Participants are no longer being randomized to this intervention.
79735775|NCT02876874|Drug|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
79870691|NCT06096714|Other|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
79402911|NCT04501978|Drug|MP0420|Participants are no longer being randomized to this intervention.
79735776|NCT02768818|Dietary Supplement|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
79735777|NCT02768818|Dietary Supplement|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
79735778|NCT02876016|Device|functional MRI|locate the cerebral bases in functional imaging
79735779|NCT00862459|Drug|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
79870692|NCT06095973|Drug|GB-6002|Depending on the cohort, volume will be varied to administer.
79870693|NCT06095973|Drug|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
79870694|NCT06095973|Drug|Naropin injection|Single dose of Naropin s.c. injection.
79870695|NCT06091007|Dietary Supplement|Magnesium|Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
79402912|NCT04501978|Drug|PF-07304814|250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
79870696|NCT06086093|Dietary Supplement|RespireAid TM/placebo|"Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
79576518|NCT01871311|Drug|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
79735780|NCT00862459|Drug|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
79735781|NCT00862459|Drug|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
80029123|NCT05956418|Drug|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p<0.0001), lactate levels (p=0.0012) and base-deficit (p<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
80029124|NCT05956392|Behavioral|Screen-use reduction + Sleep extension|60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
80029125|NCT05956379|Other|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, >=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
79576519|NCT01872156|Other|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
80029126|NCT05956366|Behavioral|Family-based treatment|Open-end family therapy ad modum The Maudsley model
80029127|NCT05956301|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through Nasal catheter
80029128|NCT05956301|Device|High-flow nasal oxygen|High Flow Nasal Cannula will be administered
80029129|NCT05956301|Device|Supraglottic jet oxygenation and ventilation|Nasal jet tube will be administered
80029130|NCT05956288|Device|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
79304564|NCT03284645|Drug|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
79304565|NCT03284645|Drug|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
79402913|NCT04472442|Procedure|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
79576520|NCT01872156|Other|Control Group|The group control will act according to usual management.
79735782|NCT00862459|Drug|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
79735783|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
79870697|NCT06085664|Drug|REGN5678|Given by IV (vein)
79870698|NCT06085664|Drug|Piflufolastat F18|Given by IV (vein)
79870699|NCT06083571|Drug|Ketorolac|Non-inferiority
80029131|NCT05956275|Drug|Tramadol|ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
79576521|NCT01872182|Drug|ALS-L1023|daily twice for 12 weeks
80029132|NCT05956275|Drug|Morfin|No block was applied to the patients in control
79304566|NCT02445157|Other|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
79735784|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
79735785|NCT02768428|Other|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
79735786|NCT00603369|Behavioral|group intervention|13-session intervention
79735787|NCT00603369|Behavioral|group intervention|2-session intervention
79870700|NCT06083571|Drug|Prochlorperazine|Adjunct
79870701|NCT06083571|Drug|Diphenhydramine|Adjunct
79870702|NCT06077695|Other|therapeutic education|The themes covered concern head trauma in the chronic phase.
79870703|NCT06077695|Other|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
79870704|NCT06077695|Other|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
79870705|NCT06068933|Behavioral|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
79870706|NCT06068933|Device|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
79870707|NCT06064968|Other|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
79870708|NCT06061536|Drug|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
79870709|NCT06061536|Drug|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
79870710|NCT06061536|Drug|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
79870711|NCT06061536|Drug|DTG|DTG +3TC + TDF（once daily）.
79870712|NCT06060587|Drug|Docetaxel|75 mg/m2 via IV
79272827|NCT05504954|Behavioral|IMARA-SA (intervention group)|The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
79402914|NCT04472442|Procedure|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
79576522|NCT01872182|Drug|placebo|daily twice for 12 weeks
79870713|NCT06060587|Drug|ADT|Prior to randomization as part of standard of care.
79870714|NCT06060587|Drug|Abiraterone|1000 mg by mouth
79870715|NCT06055959|Drug|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
79272828|NCT05504954|Behavioral|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
79576523|NCT01872195|Other|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
79576524|NCT01872221|Procedure|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
79576525|NCT01872234|Device|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
79576526|NCT01872286|Device|AKE-1|
79576527|NCT01872286|Device|Pillcam SB2|
79576528|NCT01872351|Drug|Nutraceuticals|
79576529|NCT01872377|Radiation|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
79870716|NCT06053684|Device|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
79870717|NCT06053684|Device|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
79870718|NCT06041373|Device|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
79870719|NCT06041373|Device|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
79870720|NCT06041373|Device|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
79870721|NCT06040502|Behavioral|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
79870722|NCT06037863|Other|Best Practice|Undergo bladder filling prior to CT
79272829|NCT02204527|Dietary Supplement|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
80029133|NCT05956262|Device|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
80029134|NCT05956262|Behavioral|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
79272830|NCT02204527|Dietary Supplement|placebo pill|Placebo
79735788|NCT02853279|Behavioral|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
79576530|NCT01872390|Other|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
79576531|NCT01872390|Other|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
79576532|NCT01872403|Drug|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
79870723|NCT06037863|Procedure|Computed Tomography|Undergo CT
79870724|NCT06037863|Other|Electronic Health Record Review|Ancillary studies
79870725|NCT06037863|Procedure|Imaging Technique|Undergo bladder emptying prior to CT
79870726|NCT06037863|Other|Questionnaire Administration|Ancillary studies
79870727|NCT06037863|Radiation|Radiation Therapy|Undergo radiation therapy
79870728|NCT06032338|Other|CRC screening invitation not including the screening test.|The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
79870729|NCT06032338|Other|Mailing of FIT with invitation|The invitation to CRC-PBOSP will contain the CRC screening test.
79870730|NCT06032338|Other|Information letter before invitation|An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
80029135|NCT05956249|Other|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
80029136|NCT05956249|Other|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
80029137|NCT05956210|Device|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
80029138|NCT05956197|Other|No intervention|No intervention. This is a cohort study
80029139|NCT05956145|Drug|Colchicine 0.5 MG|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
80029140|NCT05956145|Other|Placebo|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
80029141|NCT05956132|Other|retrospective study|data collection from clinical history and medical records
79272831|NCT02209753|Drug|BIRB 796 BS, low dose|
79272832|NCT02209753|Drug|BIRB 796 BS, medium dose 1|
79272833|NCT02209753|Drug|BIRB 796 BS, medium dose 2|
79272834|NCT02209753|Drug|BIRB 796 BS, high dose|
79272835|NCT02209753|Drug|Placebo|
79870731|NCT06027229|Biological|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
79870732|NCT06026033|Drug|Desflurane induction|Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
79870733|NCT06023953|Device|Nerivio device|REN treatment with Nerivio device
80029142|NCT05956080|Diagnostic Test|Allergy testing|University Medicine Greifswald
79272836|NCT05500352|Other|Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
79272837|NCT05500352|Other|Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
79272838|NCT05500352|Other|Rebound hyperglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
79870734|NCT06020846|Other|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
79735789|NCT02853279|Behavioral|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
79576533|NCT01872416|Device|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
79735790|NCT02768116|Procedure|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
79576534|NCT01872442|Drug|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes > 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
79576535|NCT01872442|Drug|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
79576536|NCT01872455|Dietary Supplement|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
79870735|NCT06020846|Other|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
79870736|NCT06019819|Other|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
79272839|NCT05500352|Other|Rebound euglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
79272840|NCT05500352|Other|Hypoglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
79272841|NCT05500352|Other|Hypoglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG < 3.0 mmol/L).
79272842|NCT05500352|Other|Hypoglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG < 3.0 mmol/L).
79272843|NCT05500352|Other|Hyperglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG < 3.0 mmol/L).
79576537|NCT01872455|Dietary Supplement|Usual diet|Usual diet of the patients
79272844|NCT05500352|Other|Hyperglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG < 3.0 mmol/L).
79272845|NCT02204605|Behavioral|Video-based Consensus Opinion|
79272846|NCT02200237|Biological|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
79576538|NCT01872468|Behavioral|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
79735791|NCT02768116|Procedure|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
79735792|NCT02768272|Device|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
79870737|NCT06019819|Other|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
79870738|NCT06017297|Drug|Durvalumab|Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles
79870739|NCT06017297|Drug|Tremelimumab|A single dose of tremelimumab at 300mg IV is given on C1.
79870740|NCT06017297|Drug|Gemcitabine|Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.
79272847|NCT02200237|Biological|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
79870741|NCT06017297|Drug|Cisplatin|Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.
79870742|NCT06017297|Procedure|Surgical Resection|If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.
79870743|NCT06016764|Device|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia and social-emotional impairment in autism
79870744|NCT06016582|Device|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
79272848|NCT02209831|Device|BIBR 796 BS|single dose
79402915|NCT04453475|Behavioral|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
79870745|NCT06015672|Device|Transcranial Magnetic Stimulation (TMS)|Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
79272849|NCT02209831|Drug|Pantoprazole|5 days
79272850|NCT01663532|Drug|Aripiprazole IM Depot|
79870746|NCT06015646|Behavioral|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
79402916|NCT04348591|Behavioral|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
79402917|NCT04348591|Device|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
79870747|NCT06015646|Behavioral|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
80029143|NCT05956067|Other|Green Light stimulation|A portable battery-operated ganzfeld light stimulation device will be used to deliver green light for 2 hours per day for 5 consecutive days.
79272851|NCT01663532|Drug|Placebo|Matching Placebo
79272852|NCT02200315|Other|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
79272853|NCT02200393|Device|Abdominal FES|"Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.~Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm."
79272854|NCT02200471|Device|VeinViewer|
79272855|NCT02200549|Device|Control group|Neither cycle training nor inspiratory muscle training.
79272856|NCT02200549|Device|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
79272857|NCT02200549|Device|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
79272858|NCT02204839|Drug|Basal insulin dose|
79304567|NCT03284567|Behavioral|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors"
79402918|NCT04342819|Drug|SGLT2 inhibitor|Sodium-Glucose Like Transporter 2 Inhibitor
79402919|NCT04320381|Behavioral|Qualitative Interview|2 Semi-Structured Qualitative Interviews
79402920|NCT04280341|Biological|RC48-ADC in combinaton with JS001|"The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg"
79402921|NCT04279223|Procedure|Laparoscopic cholecystectomy|Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy
79402922|NCT04250597|Drug|GNX102|Dose Escalation
79402923|NCT04250597|Drug|GNX102|Expansion Phase
79402924|NCT04250571|Other|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
79576539|NCT01872481|Device|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
79576540|NCT01872481|Device|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
79304568|NCT03190447|Device|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
79576541|NCT01872494|Other|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
79576542|NCT01872494|Other|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
79576543|NCT01872494|Drug|0.33% ropivacaine 250ml|
79576544|NCT01872494|Drug|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
80029144|NCT05956067|Other|Equal Energy White stimulation|A portable battery-operated ganzfeld light stimulation device will be used to deliver white light for 2 hours per day for 5 consecutive days.
80029145|NCT05956067|Other|S-cone modulating white light|A portable battery-operated ganzfeld light stimulation device will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
79576545|NCT01872507|Other|Biofeedback training|usual treatment +12 biofeedback training
79735793|NCT02768272|Procedure|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
79735794|NCT04269681|Device|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher & Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~Titrate the flow up to 60ml / L or up to the maximum tolerated;~Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
79576546|NCT01872533|Other|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at ~ 15% O2 (ca. 2400 m elevation).
79576547|NCT01872546|Drug|HUMIRA 40mg|
79576548|NCT01872559|Other|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
79870748|NCT06009081|Behavioral|postural exercise|The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
79576549|NCT01872572|Drug|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
79576550|NCT01872572|Drug|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
79870749|NCT06009081|Behavioral|aerobic exercise|The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
79870750|NCT06006507|Other|control|no exercise will be given
79870751|NCT06006507|Other|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
80029146|NCT05956054|Other|needle type|straight or curved
80029147|NCT05956028|Procedure|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
79870752|NCT06006494|Other|aerobic|"We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week."
79870753|NCT06006494|Other|resistant|Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
80029148|NCT05956028|Procedure|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
80029149|NCT05955989|Other|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
79272859|NCT04576754|Device|WB001|The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.
79272860|NCT04576754|Device|Educational|The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
79272861|NCT02204995|Procedure|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
79576551|NCT01872572|Drug|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
79576552|NCT01872572|Drug|Subcutaneous RB006 2.0 mg|"Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
80029150|NCT05955963|Other|Abdominal auscultation|spectral analysis of Bowel sounds
80029151|NCT05955950|Behavioral|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
79576553|NCT01872572|Drug|Placebo|Placebo
80029152|NCT05955950|Behavioral|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
80029153|NCT05955833|Diagnostic Test|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
79735795|NCT04269681|Other|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
79576554|NCT01872585|Behavioral|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
79735796|NCT00635284|Drug|ABI-009|nab-rapamycin
79735797|NCT02854839|Biological|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
79735798|NCT02768350|Procedure|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
79735799|NCT02768350|Procedure|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
79735800|NCT04131595|Biological|MVA-BN-WEV Dose 1|1 x 10^7 Inf.U MVA-BN-WEV vaccine
79735801|NCT04131595|Biological|MVA-BN-WEV Dose 2|1 x 10^8 Inf.U MVA-BN-WEV vaccine
79735802|NCT04131595|Biological|MVA-BN-WEV Dose 3|2 x 10^8 Inf.U MVA-BN-WEV vaccine.
79735803|NCT00699049|Drug|Alpha blocker|oral
79870754|NCT06006494|Other|yoga|Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
79870755|NCT06006351|Other|Physiotherapy|manual therapy stretching exercises strengthening exercises electrotherapy applications
80029154|NCT05955820|Device|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
79576555|NCT01872624|Procedure|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
79576556|NCT01872637|Behavioral|Progressive Multi-Component Intervention|
79735804|NCT00699049|Drug|placebo|oral
79735805|NCT00699049|Drug|solifenacin|oral
79735806|NCT04131283|Drug|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
79735807|NCT02768038|Other|Observational|Blood, stool ja biopsy specimens
79735808|NCT04224454|Other|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
79735809|NCT02614027|Other|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
79735810|NCT02614027|Other|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
79735811|NCT02617693|Behavioral|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
79735812|NCT02617693|Other|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
79735813|NCT02696980|Device|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
79735814|NCT02767648|Other|proteomic urine analysis|proteomic urine analysis
79870756|NCT06006351|Other|Hypervolt Device|The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
79870757|NCT06004427|Other|Diet program|A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.
79870758|NCT06004427|Other|Exercise training protocols|calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
80029155|NCT05955820|Device|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
79576557|NCT01872637|Behavioral|Usual Care|
79735815|NCT00943761|Drug|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
79735816|NCT00943761|Drug|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
79576558|NCT01872650|Device|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
79870759|NCT06003894|Other|kegel exercises|Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
79735817|NCT00943761|Drug|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
79735818|NCT00943761|Drug|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (<75 kg or ≥75 kg, respectively), for 48 weeks
79272862|NCT02204995|Procedure|Trapeziectomy|Trapeziectomy
79870760|NCT06003894|Other|360 degree expanded diaphragmatic breathing training|360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
79272863|NCT02205073|Drug|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
79272864|NCT02205073|Drug|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
79272865|NCT02205073|Drug|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
79576559|NCT01872663|Procedure|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
79576560|NCT01872663|Procedure|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
79576561|NCT01872663|Procedure|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
79576562|NCT01872663|Procedure|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
79576563|NCT01872663|Procedure|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
79870761|NCT06003868|Other|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
79272866|NCT02209909|Drug|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
79576564|NCT01872663|Procedure|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
79272867|NCT02209909|Drug|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
79272868|NCT02200783|Device|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
79272869|NCT02200783|Device|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
79304569|NCT03190447|Device|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
79402925|NCT04250571|Other|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
79576565|NCT01872676|Other|Spine manipulation|
79576566|NCT01872676|Other|Manipulation sham|
79576567|NCT01872702|Drug|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
79576568|NCT01872728|Drug|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
79576569|NCT01872741|Procedure|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
79576570|NCT01872741|Procedure|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
79576571|NCT01872754|Drug|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
79735819|NCT02617771|Drug|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
79735820|NCT02696590|Dietary Supplement|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
79735821|NCT02617459|Drug|Levobetaxolol eye drops|one drop per time; twice daily
79870762|NCT06003868|Other|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
79735822|NCT02617459|Drug|Betaxolol eye drops|one drop per time; twice daily
79870763|NCT06002633|Other|Alcohol|Participants will consume beverages containing alcohol.
79870764|NCT06002633|Other|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
79272870|NCT02200783|Device|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
79272871|NCT04502420|Diagnostic Test|Lung function before and after surgery|A diagnostic test
79576572|NCT01872754|Drug|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
79576573|NCT01872780|Drug|Rosiglitazone|single oral administration of 4mg of rosiglitazone
79576574|NCT01872780|Genetic|CYP2C8 genotype|CYP2C8*11.
79576575|NCT01872806|Radiation|a dialing smartphone will be placed on the chest and the ear|
79735823|NCT02854995|Procedure|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
79735824|NCT02854995|Procedure|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.[5] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
79576576|NCT01872832|Drug|RDEA3170 and Placebo|
79576577|NCT01872845|Drug|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
79870765|NCT05998057|Other|exercise|"Exercises:~Lunge to Hamstrings Stretch 3 sets of 30 seconds~Standing Hip Out 3 sets of 30sec~90-90 Hip Stretch 3 sets of 30 seconds~World's Greatest Stretch 3 sets of 30 seconds~Star Excursion 3 sets of 5 reps~Side Jumps+ Balance 3 sets of 10 reps~Forward Hops + Balance 3 sets of 10 reps~Squat 3 sets of 10 reps~Squat Jump 3 sets of 10 reps~Jumping Spider Push-up 3 sets of 10 reps~Double Leg Vertical Jump 3 sets of 10 reps~Broad Jumps 3 sets of 10 reps~Lateral Box Shuffles 3 sets of 10 reps~Plank 3 sets of 30 seconds~Side Plank 3 sets of 30 seconds~Bird Dog 3 sets of 10 reps~Glute Bridge 3 sets of 10 reps~Single Leg Glute Bridge 3 sets of 10 reps~Single Toe Raises 3 sets of 30sec~Nordic Hamstrings 3 sets of 10 reps~Monster Walk 3 sets of 10 reps"
79870766|NCT05998057|Other|control|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
79870767|NCT05996731|Procedure|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
79576578|NCT01872845|Drug|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
79576579|NCT01872858|Drug|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
79870768|NCT05985122|Diagnostic Test|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
79272872|NCT02209987|Drug|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
79272873|NCT02209987|Drug|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
79272874|NCT02205151|Drug|Fimasartan|
79272875|NCT02205151|Drug|Amlodipine|
79272876|NCT02205151|Drug|Fimasartan/Amlodipine combination|
79272877|NCT05500118|Other|Patients Decision Aids|Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
79576580|NCT01872858|Drug|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
79576581|NCT01872871|Drug|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
79576582|NCT01872871|Drug|Topical anaesthetic drop with placebo|
79576583|NCT01872884|Drug|Sevorane Remifentanil|Sevorane Remifentanil
79576584|NCT01872884|Drug|Remifentanil|Remifentanil
79576585|NCT01872897|Drug|Sodium Alginate Double Action Tablets|Four tablets as a single dose
79576586|NCT01872897|Drug|Placebo|4 tablets as a single dose
79576587|NCT01872923|Drug|Amphinex|Photosensitiser
79576588|NCT01872923|Drug|Bleomycin|Anticancer agent
79576589|NCT01872923|Device|Laser|Laser that emits red light at 652 nm.
79576590|NCT01872936|Drug|Miravirsen|
79576591|NCT01872936|Drug|Telaprevir|
79576592|NCT01872936|Drug|Ribavirin|
79735825|NCT04192786|Other|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
79870769|NCT05980507|Drug|ICI201|ICI201 CAR-T cell injection
79870770|NCT05977842|Device|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
79870771|NCT05976230|Drug|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
79870772|NCT05974722|Device|OviTex Mesh|Patient will receive Ovitex Mesh (TELA Bio)
79870773|NCT05974722|Other|Pledgeted sutures|Patient will receive pledgeted sutures
79870774|NCT05969223|Drug|Risankizumab|Subcutaneous injection
80029156|NCT05955794|Other|voice recordings|"Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice [1] and Praat [2]."
80029157|NCT05955781|Procedure|Spinal Mobilization With Leg Movement|spinal mobilization with leg movement is the intervention given to experimental group. This technique involves applying pressure to the relevant spinous process while the patient moves their limb through the previously restricted range of motion. It is assumed that the restriction of movement is due to a spinal issue but it does not always indicate nerve damage as spinal movement is necessary for limb movement beyond a certain point. The goal is to address any spinal mechanical limitations and there may also be potential effects on the nerves.
80029158|NCT05955781|Procedure|Spinal Mobilization|The patients will be given Spinal mobilization transverse glide(kaltenborn glide) on the effected spinous process. The total time duration will be 25-30 minutes.
79272878|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
79272879|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
79576593|NCT01872962|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
79735826|NCT04192786|Other|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
79735827|NCT04192786|Other|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
79735828|NCT02767726|Device|non-invasive multimodal imaging|
79735829|NCT02696512|Drug|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
79735830|NCT02696512|Device|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
80029159|NCT05955781|Procedure|Conventional treatment|Participants will be given Hot pack for 15 minutes, TENS for 10 minutes
80029160|NCT05955742|Device|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
79576594|NCT01872962|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
79576595|NCT01872988|Drug|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
79576596|NCT01872988|Drug|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
79576597|NCT01873001|Drug|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
79735831|NCT02696512|Dietary Supplement|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
79735832|NCT02696512|Other|Standard of Care|Standard of Care treatment
79735833|NCT00949533|Drug|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
79870775|NCT05969223|Drug|Placebo for Risankizumab|Subcutaneous injection
79870776|NCT05968326|Drug|Autogene cevumeran|Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.
79870777|NCT05968326|Drug|Atezolizumab|Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.
79870778|NCT05968326|Drug|mFOLFIRINOX|mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
79870779|NCT05966584|Drug|Benralizumab|Benralizumab 30mg subcutaneously on day -1.
80029161|NCT05955742|Device|ProGlider|The operator prepared the glide path using the ProGlider file.
80029162|NCT05955742|Device|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
80029163|NCT05955716|Device|Virtual reality glasses|Virtual reality glasses are a device suitable for every mobile phone. It is used to watch the 360 degree video selected from the Youtube program.
79272880|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
79870780|NCT05966584|Drug|fulvestrant or AIs) and PI3K inhibition (alpelisib)|SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
80029164|NCT05955703|Behavioral|ppm based training|The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
80029165|NCT05955677|Drug|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of [68Ga]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
80029166|NCT05955677|Drug|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of [68Ga]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
80029167|NCT05955664|Diagnostic Test|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
80029168|NCT05955664|Diagnostic Test|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
80029169|NCT05955599|Other|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
79735834|NCT02767414|Device|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
80029170|NCT05955599|Other|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
80029171|NCT05955560|Device|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
80029172|NCT05955560|Device|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
80029173|NCT05955547|Other|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
80029174|NCT05955521|Procedure|exosome and ctDNA evaluation|Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
80029175|NCT05955404|Other|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
80029176|NCT05955391|Drug|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
79735835|NCT02767414|Device|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
80029177|NCT05955378|Device|DSR Ankle|This is the experimental ankle component used in the overall prosthetic intervention.
80029178|NCT05955378|Device|Predicate Ankle|This is the participant's prescribed ankle/foot complex used in the overall prosthetic intervention.
79576598|NCT01873001|Drug|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
79576599|NCT01873014|Drug|chinese herbs-I|two agent per day, twice a day
79576600|NCT01873014|Drug|chinese herbs-II|two agent per day, twice a day
79735836|NCT02767414|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
79735837|NCT02767258|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
79735838|NCT02767258|Device|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
79870781|NCT05966272|Drug|HRS9531 injection|single dose
79870782|NCT05966272|Drug|HRS9531 injection Placebo|single dose
79576601|NCT01873027|Device|OFDI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
79870783|NCT05964504|Procedure|Blood Specimen|Blood will be drawn via venipuncture
79870784|NCT05962164|Behavioral|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
79576602|NCT01873027|Device|IVUS|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
79870785|NCT05962164|Behavioral|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
80029179|NCT05955313|Drug|Naltrexone Hydrochloride|treatment of vulvodynia
80029180|NCT05955287|Behavioral|Telemonitoring|Text messages of encouragement will be sent to patients and partners. No more than 2 messages will be sent per week to prevent respondent fatigue.
80029181|NCT05955287|Behavioral|Peer Based|Patients and partners will attend OSA virtual support groups led by an African American patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.
80029182|NCT05955287|Behavioral|CPAP Education|Patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners
80029183|NCT05955287|Behavioral|Usual Care|Participants will receive OSA education and CPAP training from providers trained in OSA management.
80029184|NCT05955274|Behavioral|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
79735839|NCT04224376|Device|App based Serious Gaming with the Genu Sport knee trainer|The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
79735840|NCT02854761|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
80029185|NCT05955274|Behavioral|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
79735841|NCT00866047|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
79870786|NCT05960604|Diagnostic Test|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
79735842|NCT01706692|Biological|Adalimumab|all dosages, frequencies and durations prescribed
79870788|NCT05940974|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
79870789|NCT05933824|Drug|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
79870790|NCT05921981|Behavioral|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
80029186|NCT05955248|Dietary Supplement|Mixed-nutriend supplement (NUT)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
79576603|NCT01873040|Behavioral|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
79735843|NCT01706692|Biological|Etanercept|all dosages, frequencies and durations prescribed
79735844|NCT01706692|Biological|Infliximab|all dosages, frequencies and durations prescribed
79735845|NCT01706692|Biological|Ustekinumab|all dosages, frequencies and durations prescribed
79735846|NCT01706692|Drug|Cyclosporine A|all dosages, frequencies and durations prescribed
79735847|NCT01706692|Drug|Fumaric acids|all dosages, frequencies and durations prescribed
79870791|NCT05921981|Behavioral|White Noise|White Noise
79870792|NCT05921253|Device|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
79735848|NCT01706692|Drug|Methotrexate|all dosages, frequencies and durations prescribed
79735849|NCT01706692|Drug|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
79576604|NCT01873040|Behavioral|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
79304570|NCT03190447|Device|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
79576605|NCT01873053|Drug|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
79576606|NCT01873053|Drug|Placebo|
79576607|NCT01873066|Device|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
79576608|NCT01873066|Device|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
79735850|NCT02767336|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
79735851|NCT02617537|Drug|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
79735852|NCT02617537|Drug|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
79304571|NCT03190447|Device|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
79576609|NCT01873079|Drug|Esomeprazole|
79870793|NCT05921253|Device|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
79870794|NCT05904886|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
80029187|NCT05955248|Other|Multimodal Prehabilitation (MM)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
80029188|NCT05955248|Dietary Supplement|Placebo Control (CTRL)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
80029189|NCT05955209|Drug|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
79272881|NCT04664192|Other|Patient Biospecimen Registry (observational and blood sampling)|Clinical data collected at every blood sample collection visit.
80029190|NCT05955196|Procedure|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
80029191|NCT05955144|Device|Picterus JP|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
80029192|NCT05955131|Other|Nutritional acute postprandial intervention: Control bread|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of control bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination
80029193|NCT05955131|Other|Nutritional acute postprandial intervention: bread suppelmented with Chilean beans|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of supplemented bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination.
80029194|NCT05955131|Other|Nutritional acute postprandial intervention: Control glucose|Volunteers will arrive at fasting and capillary blood samples will be obtained before (0 min) and after the intake an amount of control glucose containing 50g of this monosscharide (10 min of intake), capillary slood will be also obtained at 15, 30, 60, 90 and 120 postprandial for glycemia determination.
80029195|NCT05955118|Device|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
80029196|NCT05955105|Drug|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
79272882|NCT04488224|Device|Nano-X Patient Rotation System|"The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired."
79272883|NCT04488224|Radiation|Conventional CBCT scan|A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.
79272884|NCT04488224|Other|Psychometrically validated questionnaires|The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
79272885|NCT05262985|Drug|Durvalumab|In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
79272886|NCT05069636|Other|Lymphatic OMM|Patients receive lymphatic myofascial release and thoracic pump techniques.
79576610|NCT01873079|Other|Standard care|No PPI or other study medication given
79576611|NCT01873105|Other|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
79576612|NCT05855785|Behavioral|dual task exercise|8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks
79576613|NCT05855785|Behavioral|home exercise|60-minute light intensity home exercise, 4 times a week for 8 weeks
79576614|NCT05855772|Device|Extracorporeal shock waves|Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.
80029197|NCT05955105|Drug|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
80029198|NCT05955079|Other|Whole blood|3 samples (before, after surgery and before chemotherapy)
80029199|NCT05955027|Drug|ZX-7101A|a drug to treat influenza, oral
80029200|NCT05955027|Drug|Placebo|placebo control, oral
79272887|NCT05069636|Other|Light Touch|Patients receive a series of light touch techniques.
79870795|NCT05904886|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
79870796|NCT05904886|Drug|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
79870797|NCT05904886|Other|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
79735853|NCT04719442|Behavioral|Building Healthy Families|Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
79870798|NCT05900479|Other|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from two Assistance Dog International (ADI) accredited providers, including K9s For Warriors and Canine Companions for Independence. Both providers have an established track record of training and providing PTSD service dogs, as well as collaborating with the investigative team in research.
79870799|NCT05896748|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
79576615|NCT05855772|Behavioral|Posture Correction Exercise Program|The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
79576616|NCT05855720|Other|FIT model project|Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
79576617|NCT05855707|Biological|WJ-MSC infusion|cellular therapy
79735854|NCT00869323|Biological|rituximab|375 mg/m^2 intravenously on Days 1,8, 15 and 22
79870800|NCT05896748|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
79870801|NCT05894122|Diagnostic Test|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
79870802|NCT05888532|Drug|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
79870803|NCT05888532|Procedure|Positron Emission Tomography (PET)|Imaging procedure
79870804|NCT05877885|Behavioral|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
80029201|NCT05954663|Other|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~Clinical examination carried out 1 month after the operation and more than 6 months after the operation~Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
79272888|NCT02211001|Other|Pilates Group|The exercises were applied once a week during eight weeks.
79272889|NCT02211001|Other|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
79272890|NCT02211001|Other|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
79272891|NCT02212717|Procedure|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
79735855|NCT00869323|Drug|bortezomib|1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
79735856|NCT02775058|Device|synergoss Pxx|dental grafting
79735857|NCT02774980|Behavioral|Recurrent depression|
79735858|NCT02767102|Other|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
79870805|NCT05877885|Behavioral|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
79870806|NCT05876767|Drug|SAR444336|Single or repeated dose subcutaneous injection
79870807|NCT05876767|Drug|Placebo|Single or repeated dose subcutaneous injection
79870808|NCT05870098|Diagnostic Test|All participants|"Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
79870809|NCT05868525|Drug|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
79870810|NCT05864534|Drug|Balstilimab|Balstilimab 450 mg IV over 30 minutes every 3 weeks
79870811|NCT05864534|Drug|Botensilimab|Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
79870812|NCT05864534|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
79870813|NCT05864534|Device|Sonocloud-9 (SC-9)|Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
79870814|NCT05856695|Drug|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
79870815|NCT05844982|Drug|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
79870816|NCT05844982|Drug|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
79870817|NCT05840354|Device|repetitive transcranial magnetic stimulation|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
79870818|NCT05840354|Device|sham repetitive transcranial magnetic stimulation|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
79304572|NCT03190447|Device|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
79576618|NCT05855655|Behavioral|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
79576619|NCT05855629|Dietary Supplement|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10*9, Inulin 25mg, D-chiro-inositol 250mg
79735859|NCT02767102|Other|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
79735860|NCT02774902|Drug|TAK-438|TAK-438 tablets
79870819|NCT05840354|Drug|Steroid Joint Injection|The steroid joint injection will be given 1-4 weeks ahead of active rTMS and sham rTMS commencement. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the facet joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize standard clinical practice without modification.
79870820|NCT05838781|Diagnostic Test|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
79304573|NCT03284489|Other|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
79576620|NCT05855629|Drug|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
79735861|NCT02774902|Drug|Clarithromycin|Clarithromycin tablets
79735862|NCT04662970|Device|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
79735863|NCT02766946|Device|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
79735864|NCT02766946|Device|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
79735865|NCT02766946|Other|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
79870821|NCT05838781|Diagnostic Test|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
80029202|NCT05952440|Other|Tapering and/or discontinuation of treatment based on AI-guidance|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance
80029203|NCT05952440|Other|No tapering and/or discontinuation of treatment based on AI-guidance|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance
80029204|NCT05952440|Other|Tapering and/or discontinuation of treatment based on standard of care|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care
79735866|NCT02766946|Other|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
80029205|NCT05952440|Other|No tapering and/or discontinuation of treatment based on standard of care|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
79272892|NCT02212717|Procedure|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
79576621|NCT05855616|Device|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
79576622|NCT05855616|Other|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
79576623|NCT05855590|Drug|Tranexamic acid|10mg/kg intravenous single dose
79576624|NCT05855590|Other|0.9% isotonic saline solution|100 ml intravenous single dose
79576625|NCT05855564|Behavioral|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
80029206|NCT05952349|Drug|OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)|44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
79735867|NCT02766868|Drug|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
79735868|NCT02774434|Device|JM-105|Measurement of TcB via the JM-105 device
79735869|NCT02767024|Drug|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
80029207|NCT05952349|Drug|Metformin (1000 mg Twice a day)|44 Patients with PCOS receiving Metformin 1000mg (BD)
80029208|NCT05952310|Other|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
79272893|NCT05504720|Drug|Pembrolizumab|200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
79576626|NCT05855551|Other|Base cash transfer|Program beneficiaries will receive a monthly transfer of 800 BDT. A government-to-person (G2P) payment system will be used, which will transfer cash on a monthly basis. Under this new system, beneficiaries will select one of the following payment channels based on convenience: mobile financial services or through a bank transfer (which women in remote areas could access through agent banking). Each month, women will receive a text message from the government informing her that the money has been credited to her account.
79735870|NCT02767024|Drug|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
79735871|NCT02767024|Drug|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
79735872|NCT02766790|Dietary Supplement|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
79735873|NCT02766790|Other|Placebo|Placebo, an inactive formulation
79735874|NCT02774200|Drug|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
79735875|NCT02766712|Procedure|Pace During 1st Half of Lesion|
79735876|NCT02766712|Procedure|Pace During 2nd Half of Lesion|
79735877|NCT01192022|Biological|TachoSil®|Intraoperative application as secondary hemostatic treatment
79735878|NCT01192022|Device|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
80029209|NCT05951920|Procedure|Lymph node aspiration / Blood sampling|Lymph node aspiration / Blood sampling
79272894|NCT05504720|Drug|Trastuzumab|loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
79735879|NCT02766634|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
80029210|NCT05951504|Drug|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
79272895|NCT05504720|Drug|FLOT|Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
79735880|NCT02766634|Biological|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
79272896|NCT02205229|Drug|Multi-ingredient, topical compounded medications|
79576627|NCT05855551|Behavioral|Behavior change communication (BCC)|"The BCC strategy has two different components:~Monthly courtyard meetings: Courtyard sessions (12 to 15 women) will be organized at a place no more than 15 to 20 minutes walking distance from the beneficiary's home. Family members (husband, mother-in-law, …) are invited to join the meeting. Sessions are part of a continuous 4-session cycle. Each session will lasts 1.5 hours and will use different didactic methods. Topics include pregnancy nutrition and care, breastfeeding, importance of different micronutrients, and nutrition and care during lactation. The importance of a healthy diet during pregnancy is repeated in each session. Pregnant women receive a take-home poster that summarizes how to eat a healthy diet during pregnancy.~Home visits: Visits will cover the content of any sessions missed by pregnant women and will reinforce the messages regarding maternal diet on the take-home poster."
79735881|NCT04857190|Device|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
80029211|NCT05951348|Procedure|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
79402926|NCT04250571|Other|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
79402927|NCT04233619|Diagnostic Test|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
79735882|NCT04857190|Device|Conventional Malleable Stylet|Conventional Malleable Stylet
79735883|NCT02774044|Drug|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
80029212|NCT05950386|Other|Lead exposure|The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.
80029213|NCT05950178|Diagnostic Test|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
80029214|NCT05946200|Procedure|Low flow technique in general anesthesia|It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
79272897|NCT05499884|Procedure|Endovaginal ultrasound|"Endovaginal ultrasound will be performed in the operating room by the radiology team to:~to confirm the operative indication for a rectal shaving ;~to confirm the complete removal of the lesion"
79272898|NCT02205385|Procedure|Targeted Muscle Reinnervation|
79272899|NCT02205385|Procedure|Traction Neurectomy|
79735884|NCT02774044|Drug|Survanta|
79402928|NCT04228523|Other|Therapeutic education workshop|"Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~A first round table is organized to know the needs and issues related to drug management of patients.~The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management"
79402929|NCT04228523|Other|Speaking Therapy|Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
79402930|NCT04222569|Procedure|T-piece|Spontaneous breath trial with a T-piece
79402931|NCT04222569|Procedure|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
79735885|NCT00635206|Device|BiPap auto with Fi Flex|"MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)~MaxIPAP = 25 cm H2O~MinPS = 2 cm H2O (cannot be adjusted)~MaxPS = 8 cm H2O~Bi-Flex setting of 3"
79735886|NCT00635206|Device|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
79735887|NCT02766556|Drug|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
80029215|NCT05940688|Behavioral|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
80029216|NCT05940688|Behavioral|Community Health Worker|Health care information delivered via CHW.
80029217|NCT05940688|Behavioral|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
80029218|NCT05939297|Other|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
80029219|NCT05939297|Other|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
80029220|NCT05939297|Other|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
80029221|NCT05937477|Other|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
80029222|NCT05932758|Procedure|Vacuum-assisted excisional biopsy|at least 4g of tissue sampled (excisional biopsy)
80029223|NCT05932758|Procedure|Not excisional biopsy|biopsy with less than 4 g of tissue sampled
80029224|NCT05927753|Device|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
80029225|NCT05925166|Drug|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
79272900|NCT04476992|Drug|Nitric Oxide-Sessions|Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
79272901|NCT04476992|Drug|Nitric Oxide-Continuous and Sessions|"Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm."
79272902|NCT05217511|Behavioral|Neuromuscular Electrical Stimulation|NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
79576628|NCT05855551|Other|Food basket|"The monthly food basket will provide 10 kg micronutrient fortified rice , 3.5 kg of lentils, and 1000 ml of oil, valued at 800 BDT . Assuming a the ration is split equally among the 5 members of an average-sized household in rural Bangladesh and using food composition data for Bangladesh, the food basket is estimated to provide 354 kcal and 11 g of protein per person per day. The food basket will be provided once every month.~The individually packaged foods will be distributed at the Union parishad office, community clinic, or another government facility in the first week of each month. The UDW will inform the beneficiaries of the place and time of the food distribution. Recipients will only receive the food when they present their food card. The card will also be used to record receipt of each ration. If beneficiaries cannot attend the food distribution themselves, a designated nominee can pick up the ration on their behalf."
80029226|NCT05925166|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
80029227|NCT05917795|Procedure|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
79576629|NCT05855551|Other|Top-up cash|"The monthly top-up cash of 1,000 BDT will be added to the base amount that is part of the standard program. For the top-up cash transfer, a person-to-person payment system is used. WFP will contract with one popular mobile banking service (either bKash or Rockets) for the monthly top-up cash transfers. About two weeks after receiving the base cash transfer, women will receive the top-up cash through a mobile account (which can also be used to receive the base cash transfer). A text message will be sent to the beneficiary to inform her that the top-up transfer has been made into her account."
79576630|NCT05855512|Other|Nursing Educational Intervention|Nursing Educational Intervention
79735888|NCT02766556|Procedure|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
80029228|NCT05916404|Other|Upper extremity high-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient."
79870822|NCT05836688|Behavioral|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
80029229|NCT05916404|Other|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
80029230|NCT05914155|Drug|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
80029231|NCT05914155|Drug|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
79272903|NCT02220595|Procedure|Carotid endarterectomy vs. carotid stenting|
79735889|NCT02766556|Drug|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
79735890|NCT01191944|Drug|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
79735891|NCT01191944|Drug|pramipexole extended release tablet|0.375mg-4.5mg, once a day
79272904|NCT05213455|Biological|booster vaccine for COVID 19|The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
80029232|NCT05914155|Drug|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
80029233|NCT05910463|Other|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
80029234|NCT05907395|Drug|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
80029235|NCT05907395|Drug|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
80029236|NCT05896293|Drug|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
80029237|NCT05896293|Drug|GnRH|SC administration of GnRH for approximately six days (pulsatile, every 120 minutes)
79272905|NCT05237557|Behavioral|Preoperative nurse dialogue|Performance of a preoperative nurse dialogue prior major visceral surgery
79272906|NCT05504564|Genetic|The experiment does not required any intervention|The experiment does not required any intervention
79272907|NCT02220673|Drug|BHT 0.1%|
79272908|NCT02220673|Drug|BHT 0.5%|
79272909|NCT02220673|Drug|Placebo for RMT-B|
79272910|NCT02220673|Drug|Placebo for HFA-MDI|
79735892|NCT02774512|Drug|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
79735893|NCT04224844|Other|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
79735894|NCT04224844|Other|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
79870823|NCT05836688|Behavioral|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
79272911|NCT02220751|Drug|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
79735895|NCT02773888|Device|HS-1000|
79870824|NCT05830409|Behavioral|Multisensorial Stimulation|Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
79735896|NCT04223908|Other|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
79735897|NCT01191788|Behavioral|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
79870825|NCT05822921|Behavioral|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
79870826|NCT05822921|Behavioral|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
79870827|NCT05822921|Behavioral|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
80029238|NCT05887388|Behavioral|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
80029239|NCT05886374|Drug|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
80029240|NCT05882006|Other|gallstones|fellow up if the patients have gallstones
79576631|NCT05855499|Device|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
79576632|NCT05855486|Device|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
79272912|NCT02220751|Procedure|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
79272913|NCT02205463|Drug|KD019|
79576633|NCT05855473|Other|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
79576634|NCT05855460|Diagnostic Test|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
79576635|NCT05855434|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
79576636|NCT05855356|Procedure|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
79576637|NCT05855356|Procedure|Standard of Care|Behavioural and Medical management
79735898|NCT01191788|Behavioral|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
79735899|NCT00940875|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
79576638|NCT05855291|Diagnostic Test|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
79576639|NCT05855278|Diagnostic Test|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
79735900|NCT00940875|Drug|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
79735901|NCT00940875|Drug|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
79272914|NCT04858178|Diagnostic Test|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
79272915|NCT04858178|Diagnostic Test|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
79272916|NCT04858178|Diagnostic Test|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
79272917|NCT04858178|Device|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
79272918|NCT02205541|Drug|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
79272919|NCT02205541|Drug|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
79272920|NCT03256435|Behavioral|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
79272921|NCT05499494|Other|Beautifil Flow Plus X F00 injectable composite|bioactive injectable composite
79272922|NCT05499494|Other|Tetric N ceram resin composite|Nano hybrid resin composite
79272923|NCT05193799|Device|Investigational devices must be used 8 hours per day|During 3 consecutive days
79272924|NCT02213965|Device|Peripheral IV catheter|Intravenous access according to Instructions For Use
79402932|NCT04222569|Procedure|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
79576640|NCT05855265|Device|photon therapy face mask|"In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,"
79576641|NCT05855252|Other|No intervention|No intervention
79576642|NCT05855213|Device|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
79576643|NCT05855213|Device|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
79576644|NCT05855187|Drug|Bravamax 200 mg (Modafinil)|Test drug
79576645|NCT05855187|Drug|Vigil 200 mg (Modafinil)|Reference drug
79576646|NCT05855148|Procedure|Enlistment For Lung Transplant|All included patients are enlisted for lung transplantation
79735906|NCT00624572|Drug|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
79735907|NCT02774122|Device|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
79735908|NCT02774122|Device|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
79735909|NCT02851017|Other|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
79735910|NCT05656274|Drug|JS1-1-01|Oral tables
80029241|NCT05881928|Drug|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
80029242|NCT05881928|Drug|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
79576647|NCT05855070|Drug|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
79735911|NCT05656274|Drug|Placebo|Oral tables
79735912|NCT02773810|Other|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
80029243|NCT05881928|Device|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
79576648|NCT05855070|Drug|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
79735913|NCT05656118|Device|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
80029244|NCT05872893|Drug|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
80029245|NCT05872893|Drug|Dexamethasone|Patients will receive dexamethasone 4mg/m2
79272925|NCT02205619|Device|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
79272926|NCT02205619|Device|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
79402933|NCT04187248|Drug|Asparaginase|
79402934|NCT04169243|Behavioral|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
79576649|NCT05855057|Procedure|Flank suspended supine position percutaneous nephrolithotomy|The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
79576650|NCT05855057|Procedure|Supine percutaneous nephrolithotomy group|The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
79735914|NCT02766010|Device|TensorTip|Non Invasive screening of various physiological and hematological parameters.
79735915|NCT04317560|Procedure|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
79735916|NCT04317560|Procedure|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
79735917|NCT04192708|Procedure|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
79870828|NCT05817656|Drug|Sucralfate|3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
79870829|NCT05817539|Procedure|Fluid balance negativation|"During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN > 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN < 0,5 µg/kg/min and without tissue hypoperfusion."
80029246|NCT05869747|Behavioral|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
79870830|NCT05817539|Procedure|Body weight Stabilization|"During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation >5%), the UF net can be increased to 1,5 ml/kg/h.~In case of hemodynamic intolerance (NADN > 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN < 0,5 µg/kg/min."
79870831|NCT05802914|Device|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
79870832|NCT05799599|Behavioral|Stay-Play-Talk Basic|Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
79870833|NCT05799599|Behavioral|Stay-Play-Talk Plus|SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
79870834|NCT05799599|Behavioral|Stay-Play-Talk Advanced|SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
79870835|NCT05796518|Other|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
79870836|NCT05796518|Other|Survey|A brief survey before and after use of the tool will also be completed by participants.
79870837|NCT05796518|Other|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
79870838|NCT05794191|Biological|Vaccine Administration|PCV13 administration
80029247|NCT05869747|Behavioral|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
80029248|NCT05869747|Behavioral|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
80029249|NCT05869747|Behavioral|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
80029250|NCT05869747|Behavioral|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
79272927|NCT02205619|Device|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
79576651|NCT05855057|Procedure|Prone percutaneous nephrolithotomy group|Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
79870839|NCT05785754|Drug|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
80029251|NCT05869539|Drug|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10^9 and up to 2x 10^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
79576652|NCT05855018|Drug|Atropine sulfate eye drops|One drop once daily
79870840|NCT05785754|Drug|Pembrolizumab|Pembrolizumab injection
79870841|NCT05776628|Device|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
79272928|NCT02214823|Device|FES-Cycling|
79272929|NCT02214823|Other|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
79576653|NCT05854979|Diagnostic Test|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
79870842|NCT05766839|Drug|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
80029252|NCT05863026|Behavioral|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
79402935|NCT04169243|Other|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
79576654|NCT05854940|Diagnostic Test|Serum Raman spectroscopy intelligent diagnostic system|Intelligent diagnostic system based on Raman spectrum of serum
79576655|NCT05854901|Diagnostic Test|Procalcitonin|blood test, measuring the concentration of PCT in ug/L
79870843|NCT05763576|Drug|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
79870844|NCT05763576|Other|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
79576656|NCT05854901|Other|Physician's decision|The physician's decided whether the patient will receive antibiotic treatment or not
79870845|NCT05763576|Drug|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
79870846|NCT05761158|Other|questionnaire|patients are asked to complete a questionnaire
80029253|NCT05858359|Behavioral|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~Becoming aware of the patient's core strengths and difficulties~Helping the patient to be optimally responsive to the guidance of the carer, and~Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
79576657|NCT05854888|Procedure|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
79870847|NCT05757817|Procedure|Oropharyngeal or oral cavity reconstruction|"Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers."
79870848|NCT05756179|Drug|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
79870849|NCT05755139|Device|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
79870850|NCT05752201|Biological|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
79870851|NCT05752201|Biological|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
80029254|NCT05855226|Other|OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)|The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
80029255|NCT05826288|Other|BioIntelliSense BioButton Rechargable|This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
80029256|NCT05826288|Other|Memora Health two-way patient engagement platform provided by RC|The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
79576658|NCT05854888|Procedure|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
79870852|NCT05752201|Biological|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
80029257|NCT05826275|Drug|TGN-S11|Small Molecule
80029258|NCT05826275|Drug|Pembrolizumab|PD-1 checkpoint blockade
80029259|NCT05824637|Device|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
80029260|NCT05824637|Diagnostic Test|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
80029261|NCT05818345|Behavioral|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
80029262|NCT05790343|Behavioral|BAPHYC|Nine weekly peer led group meetings
79576659|NCT05854875|Procedure|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
79272930|NCT05504330|Drug|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
79272931|NCT04430972|Procedure|Aortic valve replacement|Open surgical replacement of aortic valve
79272932|NCT02220829|Drug|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
79272933|NCT02220829|Drug|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
79272934|NCT02525939|Drug|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
79272935|NCT02525939|Drug|Placebo|matching placebo tablets
79272936|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D
79576660|NCT05854875|Procedure|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
79735918|NCT04192708|Procedure|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
79735919|NCT04192708|Procedure|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
80029263|NCT05774249|Procedure|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
80029264|NCT05774249|Procedure|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
80029265|NCT05767398|Drug|Zanubrutinib|Administered as a tablet or capsule
79576661|NCT05854849|Drug|Camrelizumab|200mg, D1, Q3W, iv drip.
79576662|NCT05854849|Drug|Gemcitabine|1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
80029266|NCT05759819|Device|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
80029267|NCT05756855|Behavioral|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
79576663|NCT05854849|Drug|Cisplatin|80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
79576664|NCT05854849|Drug|Apatinib|250mg, PO, QD
79576665|NCT05854823|Radiation|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
79735920|NCT05655728|Drug|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose [maximum: 1500 mg/day]).
79735921|NCT05655728|Other|Placebo|The participants will receive treatment of placebo.
79735922|NCT02773654|Other|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
79576666|NCT05854810|Procedure|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
79576667|NCT05854810|Procedure|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
79870853|NCT05752201|Other|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
79870854|NCT05749393|Drug|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
79576668|NCT05854797|Other|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
79576669|NCT05854797|Other|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
79870855|NCT05735119|Device|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
79870856|NCT05733390|Drug|JZP541|Oral suspension
79870857|NCT05733390|Other|Placebo|Oral suspension
79272937|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
79272938|NCT02258269|Other|SQ|
79272939|NCT02258269|Other|Control|
79272940|NCT02205697|Behavioral|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
79272941|NCT02215525|Device|UVA|device uses UVA
79272942|NCT02215525|Dietary Supplement|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
80029268|NCT05754541|Device|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
80029269|NCT05742438|Drug|Lidocaine IV|Continuous intravenous infusion of lidocaine
79272943|NCT04422470|Other|Non-interventional study|Non-interventional study
79272944|NCT04420676|Dietary Supplement|Omnibiotic AAD|Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
79272945|NCT04420676|Dietary Supplement|Placebo|matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
79272946|NCT05262361|Behavioral|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
79272947|NCT02217241|Other|Handoff Workshop|
79272948|NCT02205775|Drug|Atorvastatin|80 + 40 mg pre PCI
79272949|NCT02205775|Drug|Rosuvastatin|40 + 40 mg before PCI
79272950|NCT02205775|Drug|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
79735923|NCT02773654|Other|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
79735924|NCT02887430|Other|foot reflexology therapy|standard care and foot reflexology
79735925|NCT00940485|Drug|entecavir|0.5mg po daily for 8 weeks
79272951|NCT02205775|Drug|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
79272952|NCT02205775|Drug|placebo|twice before PCI
79272953|NCT02205853|Other|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
79272954|NCT02205853|Other|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
79735926|NCT00940485|Drug|entecavir|0.5mg po daily for 48 weeks
79272955|NCT02258347|Device|Echopulse|
79272956|NCT02258425|Behavioral|FEM-CARE|
79272957|NCT02258425|Behavioral|Health Promotion|
79272958|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
79272959|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
79272960|NCT05262283|Other|No intervention|No intervention was made.
79272961|NCT02144129|Other|active Whole Body Electromyostimulation|
79735927|NCT00940485|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
79735928|NCT02696356|Biological|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
79735929|NCT02765932|Procedure|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
79735930|NCT02765932|Procedure|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
79272962|NCT02144129|Other|Passive WB-EMS|
79272963|NCT02144129|Device|WB-EMS application|
79272964|NCT02218411|Other|Exercise training|Exercises routine based on the Otago exercise programme
79272965|NCT02205931|Other|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
79272966|NCT02205931|Drug|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
79272967|NCT02221063|Other|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
79272968|NCT02221063|Other|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
80029270|NCT05742438|Drug|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
80029271|NCT05742438|Drug|intrathecal morphine|intrathecal morphine injection
80029272|NCT05732792|Other|CIPS Survey|"The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period."
80029273|NCT05726188|Procedure|Colonic resection|Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
80029274|NCT05725005|Drug|ASN51|ASN51 formulation for oral capsule
80029275|NCT05719844|Diagnostic Test|Neuropsychological tests|"List of neuropsychological tests:~Matrix reasoning~D2-R~Coding~Symbol search~Digit span~Alertness (computerized TAP battery)~Divided Attention (computerized TAP battery)~Go / No go (computerized TAP battery)~Incompatibility (computerized TAP battery)~Working memory (computerized TAP battery)~16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (< 17 years old)~complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (< 17 years old)"
79272969|NCT02221063|Other|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
79272970|NCT05262127|Behavioral|Flash Version of EMDR|EMDR and the inclusion of a positive engaging focus generated autonomously by participant
79735931|NCT02773186|Other|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
79735932|NCT05655416|Procedure|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
79735933|NCT02854683|Drug|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
79735934|NCT02854683|Dietary Supplement|Oral Rehydration Solution|1 liter of ORS solution given by mouth
79735935|NCT04317248|Drug|Cyclophosphamide|Intravenous drip，250mg/m^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
79735936|NCT04317248|Biological|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, intravenous driptotal 6 times;
79735937|NCT02765776|Other|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
79735938|NCT05655338|Device|antimicrobial photodynamic therapy|
79272971|NCT05236309|Drug|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
79272972|NCT02220049|Drug|Bortezomib|
79272973|NCT01351805|Drug|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
79735939|NCT05655338|Drug|systemic antibiotics|
80029276|NCT05717647|Other|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
80029277|NCT05715138|Procedure|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
79272974|NCT01351805|Dietary Supplement|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
79272975|NCT01351805|Other|placebo pill|placebo
79272976|NCT02206009|Device|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
79735940|NCT00943605|Device|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
79735941|NCT00943605|Device|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
79870865|NCT05717738|Procedure|TACE|Procedure of TACE is standardized.
79870866|NCT05717738|Drug|Lenvatinib|8mg; p.o.; q.d.
79870867|NCT05717738|Drug|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
79272977|NCT05563922|Combination Product|Total Neoadjuvant Chemoradiotherapy|"Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection"
79272978|NCT02206165|Drug|Candesartan 8mg|Once a day, 8 weeks
79870868|NCT05717738|Drug|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
80029278|NCT05715138|Procedure|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
80029279|NCT05715138|Device|GPi-DBS devices|"DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
79735942|NCT02765620|Other|drug&radiation|"Early treatment response assessment: using baseline data and early follow-up data~Evaluate treatment response: using baseline data, early follow-up data and final data~Compare PERCIST to RECIST criteria: correlation analysis~Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
79576670|NCT05854771|Other|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
79576671|NCT05854771|Other|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
79272979|NCT02206165|Drug|Candesartan 16mg|Once a day, 8 weeks
79735943|NCT05655260|Other|Comparison of adjuvant therapies|"Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
79735944|NCT05655260|Other|Comparison of adjuvant therapies|"Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
79735945|NCT02773420|Procedure|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
79735946|NCT05655104|Other|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
79735947|NCT00604227|Other|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
79870869|NCT05717738|Drug|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
79735948|NCT02772874|Other|No intervention|No intervention
79735949|NCT02887352|Other|assessment of problem-solving ability|
79272980|NCT02206165|Drug|Amlodipine 5mg|Once a day, 8 weeks
79272981|NCT02206165|Drug|Amlodipine 10mg|Once a day, 8 weeks
79272982|NCT05503784|Other|BITE Deodorant|BITE natural Deodorant
79272983|NCT04356950|Other|Thrombin generation test assay|lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: [ETP (%)(TM+) / ETP (%)(TM-)].
79272984|NCT04356950|Other|Fibrin generation markers assays|D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)
79735950|NCT00603603|Other|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
79870870|NCT05717738|Drug|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
79272985|NCT02697591|Drug|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
79870871|NCT05717738|Drug|Sorafenib|400mg; p.o. bid
79870872|NCT05717738|Drug|Donafenib|200mg; p.o. bid
79870873|NCT05717738|Drug|Regorafenib|160 mg; p.o.; q.d.
79870874|NCT05715086|Procedure|Ureteroscopy|Upfront ureteroscopy
79870875|NCT05713994|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
79870876|NCT05713994|Drug|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
79735951|NCT00603603|Other|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
79272986|NCT02220127|Radiation|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
79870877|NCT05713994|Drug|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
79870878|NCT05713994|Drug|Lenvatinib|8mg; p.o.; q.d.
79870879|NCT05713994|Drug|Sorafenib|400mg; p.o. bid
79870880|NCT05713994|Drug|Donafenib|200mg; p.o. bid
80029280|NCT05715138|Device|STN-DBS devices|"DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
80029281|NCT05709535|Diagnostic Test|[18F]-PSMA-1007|[18F]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of [18F]PSMA-1007 for PET scan.
80029282|NCT05688059|Other|Absorbable Suture and Permanent Suture|Absorbable Suture and Permanent Suture
79272987|NCT02220127|Radiation|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
79402936|NCT04156087|Drug|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
79402937|NCT04156087|Drug|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
79735952|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
79735953|NCT01132313|Drug|BI 201335|40 weeks, QD
79735954|NCT01132313|Drug|BI 207127|4 weeks, low dose TID
80029283|NCT05678582|Diagnostic Test|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
79402938|NCT04156087|Drug|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
79735955|NCT01132313|Drug|BI 201335|24 weeks, QD
79735956|NCT01132313|Drug|Ribavirin|16 weeks, according to label
79735957|NCT01132313|Drug|Ribavirin|28 weeks, according to label
79735958|NCT01132313|Drug|Ribavirin|28 weeks, according to label
79735959|NCT01132313|Drug|BI 207127|40 weeks, high dose, TID
79304574|NCT03189979|Behavioral|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
79735960|NCT01132313|Drug|BI 207127|24 weeks, very high dose, BID
79735961|NCT01132313|Drug|BI 207127|16 weeks, standard dose, BID
79735962|NCT01132313|Drug|BI 201335|24 weeks, QD
79735963|NCT01132313|Drug|Ribavirin|48 weeks, according to label
79735964|NCT01132313|Drug|Ribavirin|40 weeks, according to label
79735965|NCT01132313|Drug|BI 207127|16 weeks, high dose, TID
79735966|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
79735967|NCT01132313|Drug|BI 201335|28 weeks, QD
79735968|NCT01132313|Drug|BI 201335|16 weeks, QD
79735969|NCT01132313|Drug|Ribavirin|24 weeks, according to label
79735970|NCT01132313|Drug|BI 201335|24 weeks, QD
79735971|NCT01132313|Drug|BI 201335|28 weeks, QD
79735972|NCT01132313|Drug|BI 207127|24 weeks, standard dose, BID
79735973|NCT01132313|Drug|BI 201335|24 weeks, QD
79735974|NCT01132313|Drug|BI 201335|16 weeks, QD
79735975|NCT01132313|Drug|BI 207127|16 weeks, high dose, BID
79735976|NCT01132313|Drug|BI 201335|24 weeks, QD
79735977|NCT01132313|Drug|Ribavirin|16 weeks, according to label
79735978|NCT01132313|Drug|Ribavirin|16 weeks, according to label
79735979|NCT01132313|Drug|BI 207217|28 weeks, high dose BID
79735980|NCT01132313|Drug|BI 201335|16 weeks, QD
79735981|NCT01132313|Drug|BI 207127|24 weeks, high dose, TID
79735982|NCT01132313|Drug|Ribavirin|48 weeks, according to label
79735983|NCT01132313|Drug|BI 207127|4 weeks, high dose, TID
79735984|NCT01132313|Drug|BI 201335|28 weeks, QD
79870881|NCT05713994|Drug|Regorafenib|160 mg; p.o.; q.d.
79870882|NCT05713994|Drug|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
79870883|NCT05713994|Drug|Anti-PD-1 monoclonal antibody|HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
79870884|NCT05709860|Behavioral|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
79735985|NCT01132313|Drug|Ribavirin|24 weeks, according to label
79735986|NCT01132313|Drug|Ribavirin|24 weeks, according to label
79576672|NCT05854758|Other|Core strengthening with conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes."
79735987|NCT00422565|Device|Endeavor, Medtronic|Zotarolimus-eluting stent
79870885|NCT05709860|Behavioral|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
79576673|NCT05854758|Other|Conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval"
79735988|NCT00422565|Device|Cypher, Cordis|Sirolimus-eluting stent
79735989|NCT00422565|Device|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
79735990|NCT04316936|Drug|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
79735991|NCT04316936|Drug|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
79402939|NCT04156087|Procedure|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
80029284|NCT05678491|Other|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
79402940|NCT04140097|Other|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
79402941|NCT04112212|Drug|Fluorescence molecular imaging procedure using vedolizumab-800CW|First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
79402942|NCT04112212|Other|Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW|Fluorescence molecular imaging was performed to enable the visualization and detection of fluorescence signals.
79735992|NCT04316936|Drug|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
79735993|NCT04316936|Drug|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
79735994|NCT02772952|Other|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
79735995|NCT02772952|Other|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
79870886|NCT05703399|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79735996|NCT02850627|Drug|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
79735997|NCT02850627|Drug|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
79735998|NCT02765386|Device|Hybrid fittings for cochlear implant recipients|
79735999|NCT02850861|Device|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
79736000|NCT05658068|Behavioral|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
79736001|NCT00861757|Drug|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
79736002|NCT00861757|Drug|Placebo|PO, QD (30 min after meal) for 12 weeks
79736003|NCT00861757|Drug|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
79870887|NCT05703399|Other|Questionnaire Administration|Complete questionnaire
79870888|NCT05702138|Other|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
79576674|NCT05854732|Other|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
79870889|NCT05695573|Diagnostic Test|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
79272988|NCT04350398|Other|Hippotherapy|The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
79870890|NCT05682326|Drug|Daprodustat|Daprodustat will be administered up to Week 52.
79402943|NCT04112212|Combination Product|Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab|Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
79736004|NCT02762734|Other|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
79272989|NCT04350398|Other|Conventional therapy|Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
79576675|NCT05854732|Other|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
79576676|NCT05854706|Device|Theta Burst Stimulation|Theta Burst Stimulation
79576677|NCT05854693|Device|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
79576678|NCT05854693|Device|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
80029285|NCT05673668|Device|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
79576679|NCT05854589|Drug|Sodium Chloride Granules|Sodium Chloride crystals
79576680|NCT05854589|Other|Water|Plain distilled water
79576681|NCT05854576|Procedure|vascular acess|AVF
79736005|NCT02850783|Procedure|89Zr-nanocoll and Indocyanine Green|
79736006|NCT00604305|Device|Acrysof|Monofocal IOL
79272990|NCT02206243|Drug|Embozene Microspheres|Intraarterial application
79272991|NCT02254187|Drug|Salmeterol capsule - low|
79272992|NCT02254187|Drug|Salmeterol capsule - high|
79402944|NCT04107077|Drug|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
79402945|NCT04107077|Drug|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
79576682|NCT05854563|Other|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
79576683|NCT05854511|Drug|Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets|Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
79576684|NCT05854459|Other|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
79736007|NCT00604305|Device|Acuity's AIOL|Accommodating IOL
79870891|NCT05674487|Device|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
79870892|NCT05674487|Drug|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
79875942|NCT00327340|Drug|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
79576685|NCT05854459|Other|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
79576686|NCT05854446|Other|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
79736008|NCT05657756|Device|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
80029286|NCT05650281|Other|NO INTERVENTION|NO INTERVENTION
80029287|NCT05635812|Other|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
79736009|NCT01131455|Biological|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
80029288|NCT05635812|Other|EEG experimentation|duration: 1 hour
79736010|NCT02765542|Other|Automated disease assessment & self-care support phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
79736011|NCT05657600|Behavioral|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
79736012|NCT05657600|Other|Video-based yoga|Video-based yoga
79736013|NCT05657600|Other|Face-to-face yoga|Face-to-face yoga
79736014|NCT05657600|Other|physical exercise|physical exercise
79736015|NCT02762812|Biological|BCD-055|
79736016|NCT02762812|Biological|Remicade®|
79736017|NCT05657522|Device|Rapid molar intruder|The rapid molar intruder was applied.
79736018|NCT02762890|Drug|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
79736019|NCT02762890|Drug|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
79272993|NCT02254187|Drug|Salmeterol via Serevent® Diskus®|
79272994|NCT02258191|Device|telemonitoring|
79272995|NCT02258191|Device|sham telemonitoring|
79736020|NCT00698191|Biological|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
80029289|NCT05635812|Other|Oculometry experimentation|duration: 30 minutes
80029290|NCT05634174|Drug|Mirabegron|Single dose, 100mg oral mirabegron
79272996|NCT05563610|Drug|Amoxicillin 500mg|Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
79272997|NCT05503706|Other|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
79402946|NCT04080128|Device|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
79272998|NCT03545087|Drug|Lanabecestat|Administered orally
79272999|NCT03545087|Drug|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
79402947|NCT04051320|Drug|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
79402948|NCT04051320|Drug|Estradiol 2 Mg tablet|2 mg estradiol tablet
79402949|NCT04051320|Drug|Micronized progesterone|200 mg micronized progesterone tablets
79402950|NCT04046250|Drug|TK-112690|TK112690 treatment pre-methotrexate treatment
79402951|NCT04046250|Drug|Placebo TK-112690|Placebo
80029291|NCT05632354|Drug|open-label GBT021601|open-label GBT021601
80029292|NCT05619705|Behavioral|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
80029293|NCT05619705|Behavioral|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
79736021|NCT01138007|Drug|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
79870893|NCT05660330|Behavioral|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
79870894|NCT05656508|Biological|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
79576687|NCT05854433|Other|Non-interventional study|No intervention will be administered as part of this study.
79736022|NCT01138007|Drug|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
79736023|NCT04223128|Procedure|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
79736024|NCT05375864|Other|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
79870895|NCT05651594|Procedure|Biopsy|Undergo tissue collection
79870896|NCT05651594|Procedure|Biospecimen Collection|Undergo collection of blood samples
79870897|NCT05651594|Procedure|Computed Tomography|Undergo CT scans
79870898|NCT05651594|Drug|Fluorouracil|Given IV
79870899|NCT05651594|Drug|Leucovorin|Given IV
80029294|NCT05604859|Drug|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone > 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone > 2mg/kg/d) was continued for another 3-5 days.
79736025|NCT02613715|Dietary Supplement|Blackberry juice with 12% ethanol|
79402952|NCT03990961|Drug|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
79576688|NCT05854420|Procedure|Modified anterior Lamellar Recession|ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
79402953|NCT03875729|Biological|teplizumab|Treatment
79736026|NCT02613715|Dietary Supplement|Blackberry juice|
79736027|NCT02762968|Dietary Supplement|Placebo|Placebo capsules similar to the experimental treatments.
79736028|NCT02762968|Dietary Supplement|HMB|Capsules containing calcium HMB.
79736029|NCT02762968|Dietary Supplement|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
79736030|NCT02613559|Biological|TK001|Intravitreal Injection
79736031|NCT02762656|Drug|Lidocaine|Lidocaine drip during surgery
79736032|NCT05657210|Genetic|Mutation|
79736033|NCT02613637|Other|Registry|
79736034|NCT02764996|Device|Acupuncture|
79736035|NCT05657132|Drug|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
79736036|NCT05657132|Drug|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
79402954|NCT03875729|Biological|Placebo|Control
79402955|NCT03861910|Dietary Supplement|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
79402956|NCT03841526|Drug|Glucagon RTU Injection With Insulin Pump Reduction|0.15 mg injection with 50% pump reduction
79402957|NCT03841526|Other|Vehicle for Glucagon RTU Injection With Insulin Pump Reduction|vehicle injection with 50% pump reduction
79736037|NCT02765152|Other|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
79736038|NCT02765152|Other|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
79870900|NCT05651594|Drug|Oxaliplatin|Given IV
79870901|NCT05651594|Biological|Pembrolizumab|Given IV
79870902|NCT05651594|Drug|Propranolol Hydrochloride|Given PO
79870903|NCT05651594|Other|Questionnaire Administration|Perceived Stress Scale
79870904|NCT05649748|Drug|Treprostinil Palmitil|Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
79870905|NCT05649748|Drug|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
79870906|NCT05645432|Drug|Brexanolone|Brexanolone IV infusion
79870907|NCT05642988|Device|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
80029295|NCT05604859|Drug|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
79736039|NCT02765152|Other|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
79576689|NCT05854394|Behavioral|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
79870908|NCT05641987|Behavioral|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
79736040|NCT00865345|Device|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
79870909|NCT05636124|Device|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
80029296|NCT05604859|Drug|Tocilizumab|Tocilizumab:4mg/kg, once
79273000|NCT02224807|Behavioral|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
79273001|NCT02224807|Behavioral|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
79273002|NCT05563532|Behavioral|dental anxiety and oral hygiene|Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
79402958|NCT03841526|Drug|Glugaon RTU Injection Without Insulin Pump Reduction|0.15 mg injection without pump reduction
79402959|NCT03834506|Biological|Pembrolizumab|IV infusion
79402960|NCT03834506|Drug|Docetaxel|IV infusion
79402961|NCT03834506|Drug|Prednisone|Oral tablets
79402962|NCT03834506|Drug|Placebo|IV infusion
79576690|NCT05854355|Other|C-SLAMM Study|The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
79402963|NCT03834506|Drug|Dexamethasone|Oral tablets
79576691|NCT05854342|Other|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
79402964|NCT03808441|Other|ctDNA analysis|Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
79576692|NCT05854290|Behavioral|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
79273003|NCT03545009|Dietary Supplement|Sodium Nitrate|70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
79273004|NCT03545009|Dietary Supplement|Beetroot Juice no Nitrate|70ml Concentrated Beetroot Juice with nitrate removed
79402965|NCT03800108|Procedure|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
79402966|NCT03792659|Other|Blood Sample Draw|Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
79273005|NCT03545009|Dietary Supplement|Beetroot Juice|70ml Concentrated Beetroot Juice
79273006|NCT02224885|Device|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
79576693|NCT05854290|Behavioral|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
79736041|NCT01131299|Other|Placebo|2 tablets PO 3 times a day for 12-14 weeks
79736042|NCT01131299|Drug|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
79736043|NCT02762422|Other|Phlebotomy|Removal of 500 cc of blood via forearm vein
79736044|NCT04316858|Drug|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
79736045|NCT04316858|Dietary Supplement|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
79736046|NCT04316858|Dietary Supplement|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
79870910|NCT05634811|Biological|VLA15|6-valent OspA-based Lyme disease vaccine
80029297|NCT05604859|Drug|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
80029298|NCT05604859|Other|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
79402967|NCT03659123|Behavioral|standardized geriatric intervention|"Nutritional care is based on:~A personalized evaluation of nutritional balance and nutritional needs of the patient~A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~2 to 3 times a week: strength exercise~2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results."
79402968|NCT03637569|Other|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
79402969|NCT03626467|Biological|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
79736047|NCT02614807|Dietary Supplement|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
79736048|NCT04555720|Behavioral|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
79736049|NCT04119895|Other|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
79736050|NCT04119895|Other|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
79736051|NCT02764840|Other|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
79870911|NCT05634811|Other|Normal Saline|0.9% sodium chloride solution for injection
79870912|NCT05631041|Drug|Silymarin|participants in silymarin group will receive silymarin 140 mg once daily.
79870913|NCT05630690|Device|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
79870914|NCT05616221|Biological|AP-PA02|Bacteriophage administered via inhalation
79870915|NCT05616221|Other|Placebo|Inactive Placebo administered via inhalation
79870916|NCT05612490|Drug|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
80029299|NCT05595486|Other|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
79402970|NCT03616431|Diagnostic Test|Pancreo-KIT breath test|"Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive)."
79402971|NCT03610698|Behavioral|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
79870917|NCT05610735|Drug|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
79870918|NCT05610735|Drug|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
79870919|NCT05610735|Drug|Ashwagandha|Administered orally on daily basis twice a day
79870920|NCT05610735|Drug|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
79870921|NCT05597917|Drug|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
80029300|NCT05590234|Drug|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
80029301|NCT05590234|Drug|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
80029302|NCT05590234|Drug|normal saline|20 ml of normal saline 0.9%.
80029303|NCT05584332|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
80029304|NCT05584332|Biological|Placebo|0.5 ml injection in 3 dosing regimen
80029305|NCT05564208|Drug|elafibranor|Oral Tablet
80029306|NCT05564208|Drug|elafibranor|Oral Tablet
80029307|NCT05562635|Combination Product|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
79870922|NCT05597917|Biological|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
79736052|NCT02764840|Other|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
80029308|NCT05562635|Combination Product|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
80029309|NCT05562635|Combination Product|Placebo intervention|Application of placebo without CBD
79870923|NCT05595577|Other|Exercise with Trainerize application|1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise and 10 minute cool down (stretching/toning) with elastic bands.
79870924|NCT05595577|Diagnostic Test|Cardiopulmonary exercise testing|Maximal peak VO2 (to monitor the body's oxygen consumption) and 6-minute exercise walking test.
80029310|NCT05540444|Device|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
80029311|NCT05540223|Device|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
80029312|NCT05540223|Device|Xience DES|Subject undergoes implantation of Xience DES
80029313|NCT05508230|Other|Hyaluronic Nasal Spray|Health care product - nasal application
80029314|NCT05477238|Procedure|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
79273007|NCT02697435|Other|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
79273008|NCT02697435|Other|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
79273009|NCT02031445|Drug|MRX-6|
79273010|NCT02031445|Other|Placebo|
79273011|NCT02399553|Other|Soccer boot intervention|
79870925|NCT05595577|Diagnostic Test|MRI scan|Images of the heart will be taken.
79273012|NCT02174861|Drug|Erenumab|Administered by subcutaneous injection once a month
79273013|NCT02221297|Dietary Supplement|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
79273014|NCT02399631|Other|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
79273015|NCT02221375|Drug|BHT low|
79273016|NCT02221375|Drug|BHT medium|
79402972|NCT03610698|Other|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
79402973|NCT03585660|Procedure|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
79402974|NCT03585660|Procedure|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
79402975|NCT03585660|Device|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
79870926|NCT05595577|Behavioral|Quality of Life Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
80029315|NCT05476172|Drug|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
80029316|NCT05476172|Drug|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
79273017|NCT02221375|Drug|BHT high|
79402976|NCT03558438|Other|No interventions|No interventions
79273018|NCT02221375|Drug|BI 54903 XX low|
79273019|NCT02221375|Drug|BI 54903 XX medium 1|
79273020|NCT02221375|Drug|BI 54903 XX medium 2|
79273021|NCT02221375|Drug|BI 54903 XX high|
79273022|NCT02221375|Drug|Ciclesonide|
79273023|NCT02399709|Drug|simvastatin|
79273024|NCT02399709|Drug|Placebo|
79273025|NCT02220361|Drug|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
79273026|NCT02220361|Drug|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
79736053|NCT00637325|Drug|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
79736054|NCT02762344|Drug|heparin|routinary heparin administration during coronary angiography/PCI
79736055|NCT04316780|Other|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
79736056|NCT02764684|Drug|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
79736057|NCT01130831|Drug|Lanthanum carbonate|
79736058|NCT02764450|Device|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
79736059|NCT02764450|Device|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
79736060|NCT04663282|Drug|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
79736061|NCT04663282|Drug|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
79736062|NCT02764606|Biological|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
79736063|NCT01130597|Drug|patiromer|Active investigational drug
79736064|NCT01130597|Drug|spironolactone|
79736065|NCT02762188|Device|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
79736066|NCT02761876|Behavioral|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
79576694|NCT05854290|Behavioral|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
79576695|NCT05854290|Behavioral|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
79736067|NCT02761876|Behavioral|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
79736068|NCT02761876|Behavioral|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
79736069|NCT02696278|Other|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
79736070|NCT02696278|Other|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
79736071|NCT02696278|Other|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
79736072|NCT00939003|Biological|Adalimumab|40 mg every other week up to Week 12
79736073|NCT00939003|Biological|Placebo|Placebo every other week up to Week 12
79736074|NCT00939003|Biological|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
79736075|NCT01188668|Drug|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
79736076|NCT01188668|Drug|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
79736077|NCT02882945|Other|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
79736078|NCT02882945|Other|Group B|200 cases of type 2 DM without complications were enrolled in the study.
79736079|NCT02882945|Other|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
79736080|NCT04524286|Other|Interviews only.|Interviews will be conducted with childbearing women and midwives.
79736081|NCT04192084|Procedure|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
79736082|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
79273027|NCT02220361|Drug|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
79273028|NCT02144207|Device|Glidescope|
79273029|NCT05175001|Drug|Diprospan|Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
79576696|NCT05854277|Other|educational video|To explain the novel score, a six-minute instructional video was compiled and available to watch, as well as an online tool on the GIEQs website that could be used to grade the image-sets using the score.
79576697|NCT05854264|Dietary Supplement|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
79736083|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
80029317|NCT05444985|Other|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
79870927|NCT05595577|Behavioral|Cognitive and Brain Function Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
79870928|NCT05595577|Other|Blood draws|Approximately 2 teaspoons of blood withdrawn from either a vein in your arm or a currently placed central line port-a-cath. A portion of blood from each visit will be used to collect information about blood cell count.
79870929|NCT05592743|Drug|Vorasidenib|Oral therapy
79870930|NCT05590078|Device|Virtual reality session|The 20-minute virtual reality session, in the outpatient department before surgery, immerses the patient in calm environments combined with music therapy and breathing exercises to relax and reduce anxiety.
79870931|NCT05590078|Other|State Trait Anxiety Inventory|"The State Trait Anxiety Inventory (State anxiety) is a questionnaire given to adults that shows how strong a person's feelings of anxiety are right now, just now. The score is measured on arrival in the outpatient department and just before going into the intervention room (= after the virtual reality session for the experimental group)"
79870932|NCT05590078|Other|Virtual Reality Satisfaction Score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
79870933|NCT05590078|Other|Perioperative care satisfaction score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
79870934|NCT05589610|Drug|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
79870935|NCT05580991|Drug|CAN1012|CAN1012 IT injection (once every 4 weeks)
79870936|NCT05571488|Other|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
79870937|NCT05571488|Other|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
79576698|NCT05854264|Dietary Supplement|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
79576700|NCT05854225|Drug|Thiotepa|Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
79576701|NCT05854212|Behavioral|Behavioral economics-enhanced user interface|The intervention changes the ordering platform visible to food agencies using behavioral economics strategies to promote healthier food choices.
79576702|NCT05854199|Behavioral|Telehealth solution|Telehealth nutrition education platform
79870938|NCT05570565|Procedure|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
79870939|NCT05570565|Procedure|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
79870940|NCT05566756|Other|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
79870941|NCT05553353|Device|repetitive transcranial magnetic stimulation--Active|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
79870942|NCT05553353|Device|repetitive transcranial magnetic stimulation--Sham|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
79870943|NCT05553223|Behavioral|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
80029318|NCT05444062|Behavioral|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
80029319|NCT05433155|Device|Nasotracheal intubation|Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
79576703|NCT05854186|Behavioral|Telehealth solution: video conferencing|Telehealth solution: video conferencing
79273030|NCT05175001|Drug|Ropivacaine|Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
79576704|NCT05854173|Diagnostic Test|Pendulum Exercises|Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
79576705|NCT05854173|Diagnostic Test|Kaltenborn Mobilization|Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
79576706|NCT05854147|Diagnostic Test|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
79576707|NCT05854147|Diagnostic Test|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
79576708|NCT05854134|Diagnostic Test|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
79576709|NCT05854134|Diagnostic Test|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
79870944|NCT05548907|Behavioral|sleep restriction treatment|"Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support"
79870945|NCT05548907|Behavioral|sleep diary monitoring|As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
79870946|NCT05546645|Other|Questionnaire|Hypersecretion questionnaire
80029320|NCT05432518|Drug|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
80029321|NCT05432518|Drug|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
80029322|NCT05432518|Drug|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
79576710|NCT05854121|Diagnostic Test|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
79736084|NCT05301998|Other|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
79870947|NCT05533112|Other|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
79870948|NCT05527379|Device|Virtual reality|"When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events."
79870949|NCT05524883|Drug|DYNE-251|Administered by IV infusion, every 4 weeks
79870950|NCT05524883|Drug|Placebo|Administered by IV infusion, every 4 weeks
79870951|NCT05517044|Other|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
79576711|NCT05854121|Diagnostic Test|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
79576712|NCT05854108|Diagnostic Test|Cervical Traction|Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy
79736085|NCT00865189|Drug|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
79576713|NCT05854108|Diagnostic Test|Snag|Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
79576714|NCT05854082|Drug|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
79870952|NCT05516563|Other|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~Low-load isometric abduction~Functional loading~Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
79870953|NCT05513534|Other|Yoga|A standard yoga program will be provided using Hatha poses.
80029323|NCT05432518|Drug|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
80029324|NCT05432518|Drug|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
80029325|NCT05428709|Behavioral|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
80029326|NCT05426759|Device|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
80029327|NCT05422976|Device|EVI-01|High molecular weight Hyaluronic Acid
80029328|NCT05413096|Combination Product|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
80029329|NCT05413096|Other|placebo|placebo
79576715|NCT05854056|Procedure|Accelerated rehabilitation protocol|See Arms section
79576716|NCT05854056|Procedure|Conservative rehabilitation protocol|See Arms section
79736086|NCT00865189|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m^2) as a 2-hour IV infusion.
79736087|NCT00865189|Drug|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m^2 as a 2-hour infusion.
79736088|NCT00865189|Drug|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m^2 as an IV bolus, then at a dose of 600 mg/m^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
79736089|NCT00865189|Radiation|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
79736090|NCT00865189|Procedure|Surgery|Radical rectal excision based on the TME technique.
79736091|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
80029330|NCT05407987|Drug|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight <50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight >50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
79273031|NCT02224963|Behavioral|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
79273032|NCT02224963|Behavioral|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
79273033|NCT02254343|Device|proximal robot-assisted therapy|
79736092|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
79736093|NCT02762032|Drug|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
79736094|NCT02764372|Behavioral|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
79736095|NCT02764372|Behavioral|Exergames|Participants played exergames existent in the Wii game console
79736096|NCT04311905|Device|Diode laser|Diode laser activated irrigation
80029331|NCT05407987|Drug|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
79273034|NCT02254343|Device|distal robot-assisted therapy|
79273035|NCT02254343|Behavioral|individualized intensive therapy|
79273036|NCT02220517|Device|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
79736097|NCT04311905|Other|Placebo|mock Laser activated irrigation
80029332|NCT05391061|Drug|Abrocitinib|Tablets
79273037|NCT02220517|Device|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
79273038|NCT02231047|Dietary Supplement|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
79273039|NCT02231047|Other|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
79273040|NCT00140855|Biological|ipilimumab|
79273041|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
79273042|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
79273043|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
79273044|NCT02225197|Radiation|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
79273045|NCT02399397|Procedure|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
79273046|NCT02399397|Procedure|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
79736098|NCT00697489|Procedure|correction of POP plus preventive continence procedure|
79736099|NCT00697489|Procedure|POP surgery followed by eventual incontinence procedure|
79736100|NCT02764216|Radiation|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
79736101|NCT00698269|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79736102|NCT00698269|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79736103|NCT00698269|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
79736104|NCT01182194|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
79736105|NCT01182194|Drug|YAZ®|3 mg/0.02 mg Tablets
79736106|NCT02761798|Device|Automated Mobile Interactive Audiometer|iPad game
79736107|NCT04133779|Procedure|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
79736108|NCT04133779|Procedure|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
80029333|NCT05375994|Drug|avutometinib (VS-6766) and adagrasib|The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
79736109|NCT04133779|Procedure|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
79870954|NCT05513534|Other|High-speed Resistance Training|Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
79870955|NCT05513261|Diagnostic Test|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
79273047|NCT02399397|Procedure|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
79273048|NCT02399397|Drug|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
79273049|NCT02399397|Procedure|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
79736110|NCT04268667|Other|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
79273050|NCT02221453|Drug|Triamcinolone Acetonide|
79273051|NCT03106545|Drug|Liposome bupivacaine|
79870956|NCT05513261|Diagnostic Test|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
79273052|NCT02221531|Drug|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
79273053|NCT02221531|Drug|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
79273054|NCT02396355|Device|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
79273055|NCT02396355|Device|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
79273056|NCT02396355|Device|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
79273057|NCT02231125|Drug|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
79273058|NCT02231125|Drug|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
79273059|NCT02396433|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle.
79273060|NCT02396433|Drug|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
79402977|NCT03554785|Behavioral|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
79402978|NCT03535740|Drug|Brigatinib|Brigatinib Tablets
79402979|NCT03518060|Drug|Juluca|Juluca is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
79402980|NCT03477669|Dietary Supplement|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
79402981|NCT03477669|Dietary Supplement|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
79402982|NCT03474744|Drug|Copanlisib|Solution for IV infusion
79736111|NCT02764294|Other|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
79736112|NCT02764294|Other|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
79736113|NCT02764294|Other|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
79736114|NCT04131205|Diagnostic Test|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
79870957|NCT05505214|Drug|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
79402983|NCT03474744|Drug|Rituximab|Solution for IV infusion
79870958|NCT05505214|Drug|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
79870959|NCT05505214|Drug|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
79870960|NCT05496595|Drug|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
80029334|NCT05346523|Device|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
79870961|NCT05495386|Device|Hyposafe hypoglycaemia notification device (H02)|"The H02 device consists of two parts:~An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~The external device receiving signals and storing data from the implant."
79576717|NCT05854043|Other|Modified ERAS protocol|"Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h."
79576718|NCT05854043|Other|routine protocol|Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
79870962|NCT05493566|Biological|Aldesleukin|Given SC
79870963|NCT05493566|Biological|Pembrolizumab|Given IV
79870964|NCT05492513|Behavioral|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 3.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
80029335|NCT05327465|Other|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
80029336|NCT05327465|Other|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
80029337|NCT05309109|Other|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
80029338|NCT05302973|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
80029339|NCT05302973|Other|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
79273061|NCT02396433|Drug|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
79273062|NCT03106467|Procedure|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
79402984|NCT03432481|Procedure|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
79402985|NCT03432481|Device|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
79402986|NCT03370874|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
79402987|NCT03370874|Procedure|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
79402988|NCT03367871|Drug|Pembrolizumab|IV
79870965|NCT05488678|Drug|VNRX-7145|single oral dose
79870966|NCT05488678|Drug|Ceftibuten|single oral dose
79402989|NCT03367871|Drug|Paclitaxel|Administered intravenously (IV) on day 1
79402990|NCT03367871|Drug|Cisplatin|Administered intravenously (IV) on day 1
79870967|NCT05487248|Other|Blood Sample Collection|"For subjects receiving treatments with a 2- or 4-weekly schedule, blood samples for ctDNA testing will be collected at the following timepoints:~Before treatment start (day 1)~2 weeks after treatment start (day 15)~4 weeks after treatment start (day 29)~8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e., at the same time of each imaging tumour assessment)~For subjects receiving treatments with a 3-weekly schedule, blood samples for ctDNA testing will be collected at the following timepoints:~Before treatment start (day 1)~3 weeks after treatment start (day 22)~6 weeks after treatment start (day 43)~8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e., at the same time of each imaging tumour assessment)"
79870968|NCT05482802|Behavioral|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
79870969|NCT05482802|Behavioral|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
79870970|NCT05481879|Drug|DYNE-101|Administered by IV infusion
79870971|NCT05481879|Drug|Placebo|Administered by IV infusion
79870972|NCT05469945|Device|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
80029340|NCT05277077|Other|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
80029341|NCT05277077|Other|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
80029342|NCT05276063|Drug|Linsitinib|Study medication taken twice daily by mouth
80029343|NCT05276063|Drug|Placebo|Placebo taken twice daily by mouth
79273063|NCT03106467|Procedure|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
79273064|NCT02399241|Device|Bluetooth enabled nebuliser device (I-neb)|
79576719|NCT05854030|Diagnostic Test|collect plasma samples and clinical features|8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
79736115|NCT05381571|Other|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
80029344|NCT05270460|Drug|PCS12852|PCS12852 oral tablet administered once daily
80029345|NCT05270460|Drug|Placebo|Placebo comparator oral tablet administered once daily
80029346|NCT05269862|Device|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
80029347|NCT05269862|Device|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
79576720|NCT05854004|Diagnostic Test|Therapeutic Ultrasound|Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
79576721|NCT05854004|Diagnostic Test|Myofascial Release Technique|Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
79576722|NCT05853965|Drug|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
79273065|NCT02231203|Drug|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
79273066|NCT02231203|Drug|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
79736116|NCT02764060|Device|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
79273067|NCT03168165|Other|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
79273068|NCT02231281|Drug|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
79736117|NCT02764060|Device|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
79736118|NCT01181726|Drug|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
79736119|NCT01181726|Drug|Activella®|1 mg/0.5 mg Tablets
79870973|NCT05468359|Drug|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
79870974|NCT05468359|Drug|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
79870975|NCT05468359|Drug|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
79870976|NCT05468359|Drug|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
79870977|NCT05467150|Dietary Supplement|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
79870978|NCT05462613|Other|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
80029348|NCT05260918|Other|Float-REST|Participants will utilize sensory deprivation tanks.
80029349|NCT05260918|Other|Nappod|Participants will utilize nappod.
79870979|NCT05462613|Procedure|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
79870980|NCT05462613|Drug|Regorafenib|"- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
79870981|NCT05462613|Drug|Metronomic chemotherapies|"Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~Cyclophosphamide: 50 mg per os, daily, for two months"
79870982|NCT05462613|Drug|Aspirin|75 mg orally and daily during two months
79870983|NCT05462613|Drug|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
79870984|NCT05462613|Drug|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
79870985|NCT05452668|Device|Laser Therapy|- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
79870986|NCT05452668|Device|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
79870987|NCT05444257|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
79576723|NCT05853952|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
79870988|NCT05438407|Drug|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
79576724|NCT05853952|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
80029350|NCT05260801|Other|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
80029351|NCT05260801|Other|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
79736120|NCT01137071|Biological|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
79736121|NCT04046419|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants.~Second application of the scales to the participants.~Statistical analysis and scaling"
79736122|NCT00603681|Drug|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
79736123|NCT00603681|Drug|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
79273069|NCT02231281|Procedure|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
79402991|NCT03367871|Drug|Carboplatin|Administered intravenously (IV) on day 1
79736124|NCT00699127|Behavioral|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
79736125|NCT02763904|Dietary Supplement|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
79736126|NCT02763904|Other|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
79870989|NCT05407363|Procedure|ABB and ATG with simultaneous implant placement|Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement
79870990|NCT05407363|Procedure|XBB and ATG with simultaneous implant placement|Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement
79870991|NCT05407363|Procedure|ABB and ABG with simultaneous implant placement|Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
79870992|NCT05392946|Drug|Bortezomib|Given SC
79870993|NCT05392946|Biological|Daratumumab|Given SC
79870994|NCT05392946|Drug|Dexamethasone|Given PO
79870995|NCT05392946|Drug|Iberdomide|Given PO
79870996|NCT05378737|Drug|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
79870997|NCT05372497|Other|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~Right / Left Discrimination Training~Localization Training Level 1- Level 2 Training~Visual imagination Training~Visual Imagery Training~Mirror Therapy~Isometric and functional exercises"
79402992|NCT03367871|Drug|Bevacizumab|Administered intravenously (IV) on day 1
79402993|NCT03359889|Drug|PraxbindTM|Drug
79402994|NCT03351049|Device|LAL|Reactive support surface with a low air loss feature
79576725|NCT05853939|Device|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
79273070|NCT03168243|Dietary Supplement|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
79576726|NCT05853926|Diagnostic Test|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
79402995|NCT03351049|Device|Non-LAL|Reactive support surface without a low air loss feature
79402996|NCT03340064|Drug|Levetiracetam|levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
79402997|NCT03304262|Device|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
79402998|NCT03288506|Behavioral|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
79402999|NCT03277638|Drug|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
79576727|NCT05853926|Diagnostic Test|Dry Needling|Dry Needling in Chronic Lower Backache
79576728|NCT05853874|Other|Nutrition intervention (dietary protocol)|The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.
79576729|NCT05853874|Other|Hospital standard of care|The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
79736127|NCT02853045|Drug|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
79736128|NCT02853045|Drug|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
79736129|NCT04131049|Other|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
79736130|NCT04131049|Other|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
79736131|NCT04131049|Other|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
79736132|NCT04131049|Other|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
79736133|NCT00603759|Drug|celecoxib|100 mg qid
79736134|NCT00603759|Drug|placebo|1 cap qid
79736135|NCT04130815|Drug|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
79736136|NCT02761564|Other|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
79576730|NCT05853822|Other|FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey
80029352|NCT05260073|Drug|Tirbanibulin (Klisyri®)|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days
79304575|NCT02445001|Procedure|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
79403000|NCT03277638|Drug|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
79403001|NCT03277638|Drug|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
79403002|NCT03277638|Procedure|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
79403003|NCT03265613|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
79403004|NCT03250351|Other|Neural mobilization group|See arm/group descriptions
79403005|NCT03250351|Other|Control group|See arm/group descriptions
79576731|NCT05853822|Other|Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey
79576732|NCT05853809|Diagnostic Test|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
79576733|NCT05853783|Other|STRATICYTE™ Test|Assessment for risk of progression to oral cancer
79736137|NCT02761564|Other|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
79736138|NCT04256265|Drug|Risdiplam|Risdiplam will be administered orally once daily
79736139|NCT02763982|Other|Physical evaluation|
79736140|NCT04312061|Drug|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
79736141|NCT04312061|Drug|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
79736142|NCT02852811|Other|Group education|Intervention involving two education session with topics common in menopause transition.
79736143|NCT00860743|Drug|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
79576734|NCT05853770|Other|TGfU volleyball intervention|"Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min)."
79576735|NCT05853770|Other|Regular physical education classes|Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
79576736|NCT05853718|Drug|Tenofovir Alafenamide Tablets|Take 25mg TAF daily from week 28-32 of gestation until delivery
79576737|NCT05853692|Device|Zinc Gluconate|Three times a day (spray)
79576738|NCT05853692|Device|Sodium Bicarbonate|Five times a day (rinse)
79304576|NCT03284255|Device|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
79576739|NCT05853666|Behavioral|CNH+|CNH+ is a bundled intervention targeting all four of Bandura's factors associated with improved self-efficacy (i.e., Mastery [evidence-based parent targeted education platform]; Vicarious Experience [observing other families similar to them succeeding in a task i.e., videos and photos]; Verbal Persuasion [in-person/virtual medical rounds and provision of social support]; and Physiological States [notifications and encouragement through mHealth text messaging, parent feedback, and tailored clinical care pathway]).
79576740|NCT05853653|Behavioral|Using dolls in breastfeeding education|Using dolls in breastfeeding education
79576741|NCT05853627|Behavioral|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
79576742|NCT05853627|Drug|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
79576743|NCT05853614|Behavioral|Quality of Life Intervention|Comprised of three components: (1) establishment of clinical research nurse (CRN) and patient relationship, (2) assessment and monitoring of physical, psychological, social, and spiritual well-being and patient-reported outcomes, and (3) weekly, interdisciplinary team meetings led by CRN.
79576744|NCT05853588|Other|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
79576745|NCT05852730|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
79576746|NCT05852730|Drug|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
79870998|NCT05372497|Other|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~Electrotherapy~Scapular mobilization~Passive stretches~Stick Exercises~Pendulum Exercises~Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
79870999|NCT05370391|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
79576749|NCT05851118|Behavioral|Quantified analysis of walking during a crossing task between two walkers|Functional test that reproduce a task of daily living.
79736144|NCT04317170|Other|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
79736145|NCT02761720|Other|No Intervention|
79736146|NCT04311593|Diagnostic Test|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
79736147|NCT01186796|Drug|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~**Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
79576750|NCT05851066|Drug|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
79576751|NCT05851066|Drug|0.9% NaCl|placebo
79576752|NCT05850819|Drug|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
79736148|NCT05383131|Drug|HEC585|Mulltiple doses of HEC585 for up to 10 days
79736149|NCT05383131|Drug|Pirfenidone|Mulltiple doses of Pirfenidone for up to 3 days
79736150|NCT05383131|Drug|Nintedanib|Mulltiple doses of Nintedanib for up to 7 days
79576753|NCT05850819|Drug|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
79576754|NCT05850429|Dietary Supplement|Seaweed protein|Novel protein extracted from seaweed
79576755|NCT05850156|Procedure|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
79871000|NCT05368402|Drug|Ladarixin|The two daily oral doses of ladarixin (400 mg each dose) will be administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules will be swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
79871001|NCT05368402|Other|Placebo|Placebo will be administered with the same ladarixin schedule.
79871002|NCT05360329|Procedure|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
79871003|NCT05354544|Biological|Autologous adipose derived SVF|A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
79871004|NCT05350930|Other|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
79736151|NCT02763670|Other|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~At 6 and 18 months, one cardiology consultation~At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
79871005|NCT05350930|Other|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
79871006|NCT05350930|Other|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
79871007|NCT05350930|Other|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
79871008|NCT05350930|Other|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
79871009|NCT05337696|Procedure|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
79871010|NCT05337696|Device|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
79871011|NCT05320445|Behavioral|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
79871012|NCT05314400|Diagnostic Test|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
79871013|NCT05314400|Diagnostic Test|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
79576756|NCT05850156|Procedure|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
79576757|NCT05850156|Procedure|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
79871014|NCT05309655|Drug|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
79871015|NCT05309655|Diagnostic Test|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
79871016|NCT05309655|Diagnostic Test|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
79871017|NCT05309655|Other|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
79871018|NCT05309655|Behavioral|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
79273071|NCT02221609|Other|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
79304577|NCT03284255|Device|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
79304578|NCT03194113|Behavioral|Trauma-focused treatment|Weekly sessions
79576758|NCT05846347|Drug|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
79871019|NCT05305794|Drug|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
79871020|NCT05305794|Drug|Usual insulin treatment|Usual insulin treatment
79871021|NCT05305794|Biological|Biological check-up|at D0, D90 and D180
79871022|NCT05300724|Other|No intervention|No intervention will be administered in this study.
80029353|NCT05250713|Device|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
80029354|NCT05249192|Device|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
80029355|NCT05249192|Device|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
79403006|NCT03183934|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
79576759|NCT05845684|Other|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
79576760|NCT05845684|Other|Control Group|standard daily applications will be performed on patients
79736152|NCT02763670|Other|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
80029356|NCT05232565|Procedure|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
80029357|NCT05230199|Behavioral|SENSE multisensory program|In order to support parent's ability to implement the daily SENSE program they will be provided with an educational manual reviewing the program, weekly meetings with a therapist, and logs to report their visitation schedule and activities. Parents are able to choose different types of each sensory exposure. All options address the same key principles for that behavior and only include those that have evidence to support their use and are appropriate at each PMA.
79273072|NCT02221609|Other|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
79273073|NCT02399007|Device|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
79273074|NCT02399007|Device|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
79273075|NCT02231359|Drug|Berodual® Respimat® solution for inhalation|
80029358|NCT05230199|Behavioral|Monitored standard of care|Infants who receive sensory exposures only as standard of care but do not recieve the SENSE program
79273076|NCT02399319|Procedure|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
79273077|NCT02399319|Procedure|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
79273078|NCT02225431|Drug|sodium chloride infusion|
79273079|NCT04711525|Behavioral|Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
79273080|NCT04711525|Behavioral|Control Group: Standard health education|The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.
79273081|NCT02780687|Drug|Afatinib|
79273082|NCT02231437|Drug|Berodual®|
79273083|NCT02398851|Behavioral|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
79273084|NCT02398851|Behavioral|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
79304579|NCT03194113|Behavioral|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
79304580|NCT03194113|Behavioral|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
79576761|NCT05845489|Drug|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
79576762|NCT05845489|Other|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
79736153|NCT04119817|Dietary Supplement|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
79736154|NCT04119817|Dietary Supplement|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
79304581|NCT03284177|Drug|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
80029359|NCT05214287|Drug|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
80029360|NCT05183282|Device|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
80029361|NCT05182931|Drug|Dabrafenib 75 MG|Refer arm description
79273085|NCT02225509|Procedure|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
79273086|NCT02147873|Drug|birinapant|
79273087|NCT02147873|Drug|Azacitidine|
79273088|NCT02147873|Drug|Placebo|
79576763|NCT05834894|Other|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
79576764|NCT05834166|Other|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
79576765|NCT05833074|Behavioral|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
79736155|NCT01136915|Drug|Iopamidol 370|one time administration for PCI
79736156|NCT01136915|Drug|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
79736157|NCT02761486|Drug|Aspirin|325mg aspirin per day
80029362|NCT05182931|Drug|Trametinib 2 MG|Refer arm description
80029363|NCT05163067|Behavioral|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
80029364|NCT05157165|Biological|Convalescent plasma|Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more
80029365|NCT05156476|Procedure|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
80029366|NCT05156476|Procedure|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
80029367|NCT05156476|Procedure|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
80029368|NCT05154370|Drug|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
80029369|NCT05139680|Drug|tafamidis|80 or 61 milligrams (mg)
79273089|NCT02398929|Drug|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
79273090|NCT02398929|Drug|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
79273091|NCT02259049|Dietary Supplement|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
79273092|NCT02259049|Dietary Supplement|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
79273093|NCT02396121|Dietary Supplement|Oral nutritional supplement : Renutryl® Booster|
79273094|NCT02221765|Drug|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
79273095|NCT02221765|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
79273096|NCT02398695|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
79273097|NCT05069129|Biological|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
79736158|NCT02761486|Drug|Placebo|placebo in matching capsules
79736159|NCT02617225|Behavioral|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
79736160|NCT02617225|Behavioral|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
79736161|NCT04268589|Other|virtual reality game|routine
79871023|NCT05300152|Procedure|pulpotomy procedure and Histological evaluation|Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days & subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
79871024|NCT05300152|Diagnostic Test|Immunohistochemistry Protocol for Fibronectin Antibody|"Deparaffinization/Rehydration~Slides heated in an oven at 65C for 1 hour.~De-paraffinization~Antigen Retrieval~Immersion of slides into staining dish containing Antigen Retrieval Solution.~Placing the staining dish into rice cooker.~When turned to warm, unplug cooker~Allow to cool down for 20 min~Staining~Wash slides with TBST for 5 min on a shaker.~Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~Block slides with blocking solution for 1 hour.~Dilute primary antibody in blocking buffer~Apply primary antibody to each section and incubate overnight in humidified chamber~Wash slides three times with TBST"
80029370|NCT05135728|Behavioral|Unstuck and On Target: Preschool|Unstuck & On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
79273098|NCT05069129|Biological|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
79736162|NCT02882789|Drug|LCB01-0371|Cohort1 & 3: Placebo-controlled, Single ascending dose administration
80029371|NCT05128383|Drug|Dupilumab|Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
79273099|NCT05069129|Biological|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
80029372|NCT05126836|Drug|Cilostazol 100Mg Tab|Cilostazol Twice a Day
80029373|NCT05126836|Drug|Placebo|Placebo
79736163|NCT02882789|Drug|LCB01-0371 400mg|Cohort 2: Crossover designed administration
79736164|NCT02617381|Other|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
80029374|NCT05109338|Device|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
80029375|NCT05089227|Drug|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
80029376|NCT05089227|Drug|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
80029377|NCT05089227|Biological|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
80029378|NCT05081024|Procedure|Biopsy|Undergo biopsy
80029379|NCT05081024|Procedure|Biospecimen Collection|Undergo collection of blood and/or tissue samples
80029380|NCT05081024|Other|Electronic Health Record Review|Medical records are reviewed
79273100|NCT02147951|Drug|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
79273101|NCT02398461|Drug|rHIgM22|Administered via IV infusion
79273102|NCT02398461|Drug|Placebo|
79273103|NCT02259127|Drug|DTG|
79736165|NCT00940017|Drug|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
79736166|NCT01129583|Drug|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
79273104|NCT03544073|Drug|Saline Solution for Injection|Placebo arm will receive a saline injection
79273105|NCT03544073|Drug|Leuprolide Acetate|Treatment arm will receive a Leuprolide injection
79273106|NCT02140697|Dietary Supplement|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
79273107|NCT02140697|Dietary Supplement|Placebo (3g/day)|Placebo (3g/day), parallel design
79304582|NCT03284177|Drug|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
79304583|NCT03284177|Other|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
79736167|NCT01129583|Drug|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
79736168|NCT00848497|Drug|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
80029381|NCT05075005|Other|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
79273108|NCT02398383|Other|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
79871025|NCT05300152|Diagnostic Test|Immunohistochemistry Protocol for Osteopontin Antibody|will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
80029382|NCT05075005|Other|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
79736169|NCT00848497|Other|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
80029383|NCT05050357|Device|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
80029384|NCT05050357|Drug|Progestins Norethindrone|oral ethisteron twice daily for three months
80029385|NCT05032430|Behavioral|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
79273109|NCT02398383|Other|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
79273110|NCT02398383|Other|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
79273111|NCT02398305|Device|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
79403007|NCT03183661|Biological|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
79403008|NCT03180684|Biological|VGX-3100|One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
80029386|NCT05032430|Behavioral|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
79736170|NCT00848497|Drug|Viagra®|Viagra 25mg was the dose given to the patient which he started.
79273112|NCT02398305|Device|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
79736171|NCT02763592|Drug|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
79736172|NCT02763592|Other|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
79736173|NCT04268043|Device|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
79273113|NCT02259205|Other|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
79273114|NCT02259205|Other|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
79273115|NCT03168087|Other|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
79403009|NCT03180684|Drug|Imiquimod 5% Cream|Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
79403010|NCT03180684|Device|CELLECTRA™ 2000|IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
79736174|NCT04268043|Device|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
79736175|NCT02882867|Other|Injuries in Swedish Youth Athletics. The KLUB-study.|
79736176|NCT02763748|Procedure|Laparoscopic endoscopy combined surgery|
79871026|NCT05296668|Device|Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)|(group C) to receive a cuffed ETT for airway management.
79871027|NCT05296668|Device|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
79871028|NCT05292131|Drug|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
79273116|NCT02221921|Device|MicroPort's Transcatheter Aortic Valve and Delivery System|
79273117|NCT03168009|Procedure|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
79871029|NCT05281718|Drug|Factor IX|Factor IX is on of the substrates of emicizumab.
79871030|NCT05281601|Drug|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
79871031|NCT05265546|Drug|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
79871032|NCT05251285|Procedure|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
79576766|NCT05833074|Behavioral|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
79871033|NCT05245487|Diagnostic Test|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
79576767|NCT05830084|Drug|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~DL1: 82 mg/m^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~DL0 (starting dose): 66 mg/m^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~DL-1: 50 mg/m^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
79576768|NCT05826873|Behavioral|Discharge antibiotic stewardship intervention|Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
79871034|NCT05233891|Procedure|Breast reconstruction|Breast reconstruction after breast cancer.
79576769|NCT05818072|Procedure|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
79871035|NCT05233891|Procedure|Breast reduction|Breast reduction due to breast hypertrophy.
79871036|NCT05216224|Drug|ATI-450|Oral, small molecule MK2 inhibitor
79871037|NCT05216224|Drug|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
79871038|NCT05203510|Drug|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
79871039|NCT05203510|Drug|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
79871040|NCT05191238|Other|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
79871041|NCT05160025|Other|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
79273118|NCT05138887|Drug|Tetrahydrobiopterin|The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
79273119|NCT02231593|Other|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
79576770|NCT05818072|Procedure|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
79576771|NCT05818072|Procedure|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
79576772|NCT05818072|Device|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
79576773|NCT05815602|Drug|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
79871042|NCT05155423|Other|mask for immobilization|mask for immobilization
79871043|NCT05155423|Other|Elekta BodyFix|Elekta BodyFix
79871044|NCT05151744|Drug|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
79871045|NCT05151744|Drug|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
79871046|NCT05151744|Other|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
79871047|NCT05151731|Drug|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
79871048|NCT05151731|Drug|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
79871049|NCT05151731|Other|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
79871050|NCT05141721|Drug|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10^12 viral particles 2 times over the course of the first year.
79871051|NCT05141721|Drug|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
79871052|NCT05141721|Drug|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
79736177|NCT02763748|Procedure|laparoscopic and endoscopic cooperative surgery|
79736178|NCT02763748|Procedure|Single-arch laparoscopic and endoscopic cooperative surgery|
79871053|NCT05141721|Drug|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
79871054|NCT05141721|Drug|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
79576774|NCT05815602|Drug|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
79273120|NCT02698371|Device|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
79273121|NCT02698371|Device|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
79403011|NCT03161652|Drug|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
79403012|NCT03161652|Drug|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
79871055|NCT05141721|Drug|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
79871056|NCT05138068|Drug|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
79576775|NCT05810246|Diagnostic Test|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)|"68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT."
80029387|NCT05008809|Drug|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
80029388|NCT05008809|Drug|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
80029389|NCT04986917|Device|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
79403013|NCT03161652|Drug|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
79403014|NCT03161652|Drug|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
79736179|NCT04268355|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
79736180|NCT00857623|Drug|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
79736181|NCT00857623|Drug|Placebo|Capsule, once daily
79736182|NCT04312607|Diagnostic Test|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
79871057|NCT05138068|Behavioral|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
79871058|NCT05126901|Drug|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to < 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
79871059|NCT05126901|Drug|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
79871060|NCT05119569|Drug|Fenebrutinib|Fenebrutinib will be administered orally.
79871061|NCT05119569|Drug|Placebo|Placebo will be administered orally.
79273122|NCT02698371|Device|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
79871062|NCT05096728|Drug|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~Once daily Nifedipine XL 60mg Vs.~Twice daily Nifedipine XL 30mg"
79273123|NCT02698371|Device|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
79273124|NCT02698371|Device|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
79273125|NCT02698371|Device|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
79403015|NCT03161652|Drug|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
79576776|NCT05807568|Other|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
79736183|NCT02761096|Device|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
79736184|NCT02761096|Other|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
79736185|NCT01185782|Drug|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
79273126|NCT02781311|Drug|Setipiprant|Setipiprant tablets, orally, BID for 24 weeks.
79273127|NCT02781311|Drug|Placebo|Placebo tablets, orally, BID for 24 weeks.
79273128|NCT02781311|Drug|Finasteride|Finasteride tablet, orally, once daily for 24 weeks.
79273129|NCT02225821|Drug|Cephalozin|1000 mg Cephalozin
79403016|NCT03161652|Drug|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
79736186|NCT01185782|Drug|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
79736187|NCT04119349|Behavioral|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
79736188|NCT02761174|Drug|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
79736189|NCT02761174|Other|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
79871063|NCT05094154|Drug|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
79871064|NCT05094154|Drug|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
79871065|NCT05094141|Other|Virtual reality|Virtual reality game
79871066|NCT05076149|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
79871067|NCT05076149|Drug|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
79871068|NCT05076149|Drug|IVA|Tablet for oral administration.
79273130|NCT02225821|Other|Sodium chloride|10 cc of NaCl 0.9%
79273131|NCT02231671|Drug|ALS-008176|
79273132|NCT02231671|Drug|ALS-008112|
79736190|NCT01129115|Behavioral|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
79736191|NCT01129115|Behavioral|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
79871069|NCT05076149|Drug|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
79871070|NCT05076149|Drug|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
79871071|NCT05076149|Drug|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
79576777|NCT05806606|Other|Dyadic empowerment based heart failure management program|The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
79576778|NCT05806606|Other|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
79736192|NCT01129115|Behavioral|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
79736193|NCT01129115|Behavioral|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
79736194|NCT04119583|Device|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
79736195|NCT04119583|Other|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
79736196|NCT04119583|Other|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
79871072|NCT05069610|Biological|AD17002|A recombinant protein
79871073|NCT05069610|Biological|Placebo (Formulation buffer)|Formulation buffer
79273133|NCT02144441|Drug|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
79736197|NCT04222738|Dietary Supplement|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
79736198|NCT04119661|Device|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
79736199|NCT04119661|Device|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
79736200|NCT04315922|Diagnostic Test|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
79736201|NCT04312217|Behavioral|Medical clowning|Medical clowning
79736202|NCT04116307|Dietary Supplement|Polymethylsiloxane|
79736203|NCT04116307|Dietary Supplement|Lactobacillus reuteri|
79736204|NCT02763436|Procedure|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
79736205|NCT04311359|Drug|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
79871074|NCT05066880|Other|Exercise training|Exercise training for 8 weeks
79871075|NCT05059522|Drug|Avelumab|oral
79871076|NCT05059522|Drug|Lorlatanib|oral
79871077|NCT05059522|Drug|Talazoparib|oral
79871078|NCT05059522|Drug|Pemetrexed|IV (intravenous) infusion
79871079|NCT05059522|Drug|Axitinib|oral
79273134|NCT02225977|Drug|Gilenya|
79273135|NCT02148029|Other|Exercise|Upper and Lower extremity exercise
79273136|NCT02148029|Other|Control|Standard care: anticoagulation, compression & ad-lib ambulation
79304584|NCT02439619|Other|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
79871080|NCT05059522|Drug|CMP 001|IT (intratumoral) or SC (subcutaneous)
79871081|NCT05059522|Drug|Utomilumab|IV infusion
79871082|NCT05059522|Drug|PF04518600|IV infusion
79871083|NCT05056857|Procedure|Biospecimen Collection|Undergo collection of blood sample
79871084|NCT05056857|Other|Electronic Health Record Review|Medical charts are reviewed
79871085|NCT05048953|Diagnostic Test|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~Muscle thickness~Muscle echogenicity~Muscle fasciculations"
79871086|NCT05036096|Device|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
79871087|NCT05036096|Device|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
79871088|NCT05035368|Drug|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
79871089|NCT05035368|Other|Placebo|Placebo is administered with the same schedule of Ladarixin.
79871090|NCT05030766|Drug|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
79273137|NCT02226055|Device|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
79403017|NCT03161652|Drug|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
79736206|NCT02882555|Behavioral|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity <10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
79403018|NCT03161652|Drug|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
79403019|NCT03131037|Biological|CAN-2409 + valacyclovir|CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.
79871091|NCT05030766|Behavioral|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
79871092|NCT05030766|Behavioral|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
79871093|NCT05010785|Procedure|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
79403020|NCT03083561|Drug|LY3337641|Administered orally.
79576779|NCT05790369|Behavioral|Resistance training (New ankle machine training)|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
79736207|NCT02882555|Drug|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
79871094|NCT05010785|Procedure|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
79871095|NCT04998721|Behavioral|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
79273138|NCT02810197|Behavioral|Psychopathological assessment|
79273139|NCT02810197|Behavioral|Neuropsychological assessment|
79403021|NCT03083561|Drug|Placebo|Administered orally.
79403022|NCT02992457|Drug|Sofosbuvir|Sofosbuvir 400 mg daily.
79403023|NCT02992457|Drug|Ribavirin|Ribavirin 1000-1200 mg daily
79403024|NCT02992457|Drug|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
79403025|NCT02992457|Drug|Simeprevir|Olysio once daily.
79403026|NCT02992457|Drug|Daclatasvir|Dakla once daily for three months.
79403027|NCT02992457|Drug|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
79403028|NCT02992457|Drug|Sofosbuvir and Ledipasvir|Once daily for three months
79403029|NCT02992457|Drug|Salvage therapy|three months in repeated treatment failure
79403030|NCT02914379|Drug|[¹⁴C]-LY3337641|Administered orally
79403031|NCT02896751|Device|3D printed NIV mask|use of 3D printed mask
79403032|NCT02829424|Drug|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
79403033|NCT02829424|Drug|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
79576780|NCT05790369|Behavioral|Resistance training (Elastic band training )|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
79576781|NCT05784727|Device|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
79736208|NCT02882555|Drug|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
79736209|NCT02761018|Behavioral|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
79736210|NCT02761018|Behavioral|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
80029390|NCT04986917|Diagnostic Test|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
80029391|NCT04986917|Diagnostic Test|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
79871096|NCT04998721|Behavioral|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
79736211|NCT04119427|Device|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
80029392|NCT04986917|Diagnostic Test|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
79403034|NCT02740920|Drug|Pembrolizumab|
80029393|NCT04986917|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
79273140|NCT02810197|Device|Functional magnetic resonance imaging (fMRI)|
79273141|NCT02141009|Biological|Prevnar 13|
79273142|NCT02231827|Other|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
79273143|NCT02564198|Drug|Ramucirumab|Administered IV
79403035|NCT02740920|Procedure|CT Scan|
79403036|NCT02619851|Biological|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
79403037|NCT02619851|Device|Conventional Therapy|Typical therapy conducted for burn injury patients
79403038|NCT02580617|Biological|ALLO-ASC|Infusion for Crohn's disease
79273144|NCT02148185|Drug|MT-1303|
79273145|NCT02398539|Drug|Silver Nitrate|Silver Nitrate Sticks
79403039|NCT02579369|Other|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
79403040|NCT02579369|Device|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
79403041|NCT02515227|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
79403042|NCT02515227|Drug|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
79273146|NCT02398539|Drug|Triamcinolone|0.5% cream
79273147|NCT02226133|Device|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
79403043|NCT02430467|Behavioral|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
79403044|NCT02430467|Behavioral|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
79403045|NCT02369458|Drug|Mitomycin-C|
79403046|NCT02369458|Drug|Pegfilgrastim|
79403047|NCT02316392|Drug|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
79403048|NCT02122172|Drug|afatinib dimaleate|Given PO
79736212|NCT04119427|Device|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
79871097|NCT04992793|Combination Product|Congenital heart surgery|Paediatric congenital heart surgery
79871098|NCT04991116|Drug|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
79871099|NCT04987112|Drug|CAN1012|CAN1012 IT injection (once every 4 weeks)
79871100|NCT04975555|Drug|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
79871101|NCT04933227|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
79871102|NCT04933227|Drug|Tiragolumab|Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
80029394|NCT04986917|Diagnostic Test|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
80029395|NCT04986917|Other|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
80029396|NCT04986917|Other|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
80029397|NCT04986917|Diagnostic Test|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~SAE's and SADE's evaluation of the seroma.~Taking a photograph of the surgery area without disclosing the subject's identity."
79403049|NCT02122172|Other|laboratory biomarker analysis|Correlative studies
79871103|NCT04933227|Drug|Oxaliplatin|Oxaliplatin 130 mg/m^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
79273148|NCT02144753|Dietary Supplement|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
79736213|NCT02763358|Device|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
79736214|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg I.V.
79736215|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
79871104|NCT04933227|Drug|Capecitabine|Capecitabine 1000 mg/m^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
79273149|NCT02144753|Drug|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
79871105|NCT04925479|Drug|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)"
79871106|NCT04925479|Drug|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
79871107|NCT04915950|Drug|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
79871108|NCT04915950|Drug|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
79871109|NCT04899310|Biological|mRNA-3705|A sterile liquid for injection
79871110|NCT04899271|Drug|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
79273150|NCT02231905|Drug|BI-Sifrol®|
79273151|NCT02398071|Device|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
79273152|NCT02141087|Drug|Pirfenidone|
79273153|NCT05563376|Diagnostic Test|Univentricular Hearts|Prevention when factors are recognized
79273154|NCT02231983|Genetic|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
79304585|NCT03192709|Drug|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
79403050|NCT02056132|Other|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
79403051|NCT02052609|Drug|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
79403052|NCT02052609|Drug|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
79403053|NCT02031939|Drug|Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
79736216|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
79736217|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
79736218|NCT01185704|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
79736219|NCT01185704|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
79736220|NCT01128959|Drug|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
79871111|NCT04899271|Other|Placebo|Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
79871112|NCT04897347|Device|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
79871113|NCT04897347|Device|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
79871114|NCT04894370|Biological|Sample collection|"PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection."
79736221|NCT04222582|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
79273155|NCT03544463|Device|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
79871115|NCT04891029|Diagnostic Test|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers
79273156|NCT02698293|Drug|Gliolan|orally, 40 mg/kg 4-6 hours prior to light application
79273157|NCT02698293|Drug|Vitamin D3 cholecalciferol)|Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
79273158|NCT02698293|Other|Photodynamic Therpay|"Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter."
79273159|NCT02258737|Behavioral|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
79273160|NCT02258737|Behavioral|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
79273161|NCT03543917|Combination Product|Perfusion with New Combination Medication|Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
79273162|NCT02226211|Device|Air-Q intubation laryngeal airway|"The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet ."
79304586|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
79304587|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
79403054|NCT02031939|Radiation|standard chemoradiotherapy|All rectal patients in this group will receive standard radiotherapy and surgical resection.
79871116|NCT04889872|Device|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
79871117|NCT04889469|Procedure|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
79871118|NCT04884750|Behavioral|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
79403055|NCT01997190|Biological|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
79403056|NCT01925040|Device|Placement of restoration|Placement of restorations
79403057|NCT01776190|Device|UVA1 radiation treatment|
79403058|NCT01736202|Biological|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
79403059|NCT01447147|Drug|Placebo|Placebo capsules once daily
79403060|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
79736222|NCT04119739|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
79736223|NCT04119739|Drug|Ibuprofen|Oral tablets
79736224|NCT02760706|Device|Computed Tomography scan|
79736225|NCT00625235|Dietary Supplement|VLED followed by a high protein or high carbohydrate diet|
79736226|NCT04206098|Other|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
79736227|NCT02763514|Dietary Supplement|3 g PronovaPure 150:500 EE EU|
79736228|NCT02763514|Dietary Supplement|3 g PronovaPure 500:200 EE EU|
79736229|NCT02763514|Dietary Supplement|3 g Placebo|
79736230|NCT00859573|Drug|Modafinil|400 mg/day
79736231|NCT00859573|Drug|Placebo|inactive substance
79736232|NCT04312295|Behavioral|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
79871119|NCT04882241|Biological|Pembrolizumab|IV infusion
79871120|NCT04882241|Drug|Placebo|IV infusion
79871121|NCT04882241|Drug|Cisplatin|IV infusion
79871122|NCT04882241|Drug|Capecitabine|Oral tablets
79871123|NCT04882241|Drug|5-fluorouracil|IV infusion
79871124|NCT04882241|Drug|Docetaxel|IV infusion
79871125|NCT04882241|Drug|Oxaliplatin|IV infusion
79871126|NCT04882241|Drug|Leucovorin|IV infusion
79871127|NCT04873869|Drug|NBI-921352|Administered orally
79871128|NCT04873869|Drug|Placebo|Administered orally
79871129|NCT04870034|Drug|Binimetinib|Given PO
79736233|NCT02760940|Drug|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
80029398|NCT04976179|Drug|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
79273163|NCT02226211|Device|Ambu-Aura i laryngeal mask|"The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT."
79273164|NCT02141165|Device|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
79273165|NCT02395809|Procedure|lateral internal sphincterotomy|
79273166|NCT02395809|Procedure|TENS|
79736234|NCT01136291|Other|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
79273167|NCT02226289|Drug|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
79273168|NCT04624646|Device|Discontinuous monitoring|Discontinuous ECG monitoring by finger contact every day
79736235|NCT02763280|Dietary Supplement|Ginseng extract 1g|Ginseng extract 1g, parallel design
79736236|NCT02763280|Dietary Supplement|Ginseng extract 3g|Ginseng extract 3g, parallel design
79736237|NCT02763280|Dietary Supplement|Placebo|placebo, parallel design
79871130|NCT04870034|Drug|Palbociclib|Given PO
79871131|NCT04870034|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79871132|NCT04862689|Device|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
79871133|NCT04849169|Device|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
79871134|NCT04845945|Biological|PCV15|Blood draw after the vaccination
79871135|NCT04845178|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
79871136|NCT04845178|Drug|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
79871137|NCT04837248|Other|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
79273169|NCT04624646|Device|Continuous single-lead ECG Patch|Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke
79273170|NCT04624646|Device|24-hour Holter monitoring|Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
79871138|NCT04837248|Other|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
79871139|NCT04817241|Procedure|Biospecimen Collection|Undergo collection of blood samples
79273171|NCT02148341|Other|Community of Practice Facilitation|
79736238|NCT02758444|Dietary Supplement|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
79736239|NCT02758444|Dietary Supplement|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
79273172|NCT02148341|Other|Usual Care|
79273173|NCT04480593|Drug|Brazilian Green Propolis Extract (EPP-AF)|Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
79403061|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
79736240|NCT02758444|Dietary Supplement|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
79736241|NCT02758444|Dietary Supplement|MNP without Zn|Same as above except MNP will not contain Zn
80029399|NCT04976179|Drug|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
80029400|NCT04975334|Drug|kisspeptin, GnRH, naloxone|Six IV doses of kisspeptin 112-121
80029401|NCT04975334|Drug|GnRH|Two IV doses of GnRH
80029402|NCT04975334|Drug|Naloxone|One bolus and one infusion of naloxone
80029403|NCT04966104|Behavioral|ODYSSEE-vCHAT|Automated digital counselling program with social network support
80029404|NCT04964843|Drug|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
80029405|NCT04964843|Drug|Placebo|Placebo
80029406|NCT04950803|Dietary Supplement|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
79736242|NCT02760784|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
79736243|NCT02695966|Procedure|Whipples Surgery|Whipples Surgery
79736244|NCT01185548|Drug|Tolbutamide|Administered orally
79871140|NCT04817241|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
79736245|NCT01185548|Drug|Tasisulam|Administered intravenously
79736246|NCT01128569|Drug|Fluticasone Furoate|FF
79273174|NCT04480593|Other|Standard care|Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
79273175|NCT02148419|Other|no intervention|
79871141|NCT04817241|Drug|Cytarabine|Given IV
79403062|NCT01440699|Biological|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
79736247|NCT01128569|Drug|FF/Vilanterol (VI; GW642444M)|FF/VI
79736248|NCT01128569|Drug|Placebo|Placebo Inhaler
79871142|NCT04817241|Drug|Daunorubicin|Given IV
79871143|NCT04817241|Drug|Decitabine and Cedazuridine|Given PO
79871144|NCT04817241|Drug|Venetoclax|Given PO
79871145|NCT04806347|Biological|TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft|After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
79871146|NCT04806347|Device|CliniMACS® System|The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
79871147|NCT04792385|Drug|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
79871148|NCT04791579|Drug|Ciprofloxacin|Fluoroquinolone antibiotic
79736249|NCT02696044|Drug|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
79871149|NCT04791579|Drug|Placebo|Placebo pill
80029407|NCT04950803|Dietary Supplement|Active placebo|Active placebo contains active vitamin
79736250|NCT04582942|Drug|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
79871150|NCT04781530|Device|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
79871151|NCT04768972|Drug|ION363|ION363 will be administered by IT bolus injection.
79871152|NCT04768972|Drug|Placebo|Placebo will be administered by IT bolus injection.
79871153|NCT04768777|Behavioral|Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach. The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory. Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries. The chats are conducted face-to-face through an online videoconferencing platform. There are a total of 12 chats over 16 weeks. Chats occur on weeks 1-8, 10-11, 13 and16.
79871154|NCT04762953|Drug|Paclitaxel|Intraperitoneal Paclitaxel
79273176|NCT05079217|Biological|High-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
79273177|NCT05079217|Biological|Medium-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
79304588|NCT02460029|Other|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
79736251|NCT04582942|Drug|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
79736252|NCT02883179|Drug|lidocaine injection|anhydrous solution
79736253|NCT02883179|Drug|lidocaine-prilocaine cream|topical cream
79736254|NCT02758366|Drug|Doxorubicin|
79871155|NCT04762953|Drug|Paclitaxel|IV Paclitaxel
79871156|NCT04762953|Drug|Leucovorin|IV Leucovorin
79871157|NCT04762953|Drug|Fluorouracil|IV 5-FU
79871158|NCT04742595|Biological|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
79871159|NCT04735978|Biological|RP3|Genetically modified HSV-1
79871160|NCT04735978|Biological|Nivolumab|anti-PD1 monoclonal antibody
80029408|NCT04946825|Drug|Nicotine replacement therapy patch|The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
80029409|NCT04946825|Drug|Nicotine replacement therapy lozenge|The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
80029410|NCT04946825|Behavioral|Quit electronic cigarettes|Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
79273178|NCT02141243|Procedure|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
79273179|NCT02141243|Procedure|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
79273180|NCT02141243|Procedure|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
79736255|NCT05125601|Other|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
79736256|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
79736257|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
79736258|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - <50 mL/min)
79736259|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr <30 mL/min and not on hemodialysis)
79736260|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
79576782|NCT05784675|Device|MOBI-CPR game|Participants use MOBI-CPR game at home environment.
79736261|NCT02758288|Other|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
79736262|NCT02758288|Other|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
80029411|NCT04946825|Behavioral|Continue electronic cigarettes|Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
79304589|NCT02443753|Device|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
79304590|NCT02443987|Other|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
79403063|NCT01440257|Drug|Placebo|Placebo capsules once daily
79403064|NCT01440257|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
79403065|NCT01370278|Other|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
79576783|NCT05778318|Drug|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
79576784|NCT05778318|Other|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
79576785|NCT05777317|Device|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
79576786|NCT05777317|Other|CMM alone|Conventional medical management alone
79736263|NCT01128413|Device|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
79871161|NCT04719988|Biological|Blood sample collection|"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
79871162|NCT04719988|Procedure|Biopsy|A tumor biopsy will be performed at 2 months after enrollment.
79871163|NCT04700072|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
79871164|NCT04700072|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
79871165|NCT04700072|Drug|Lenvatinib|Administered via oral capsule at a specified dose on specified days
80029412|NCT04907656|Behavioral|dCBT|As per arm of the same name
79871166|NCT04696653|Other|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
79736264|NCT01128413|Device|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
79736265|NCT01128413|Device|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
79736266|NCT01128413|Behavioral|CURVES Questionnaire|The CURVES (CardiovascUlar Response & Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
79576787|NCT05771636|Behavioral|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
79403066|NCT01370278|Other|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
80029413|NCT04901390|Dietary Supplement|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
80029414|NCT04898387|Combination Product|Bimatoprost Timolol (T4030)|Eye drop
80029415|NCT04898387|Combination Product|Bimatoprost Timolol (Ganfort)|Eye drop
79304591|NCT02459873|Behavioral|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
79403067|NCT01242917|Drug|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
79576788|NCT05771636|Behavioral|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
79576789|NCT05767554|Behavioral|Brief modified behavioral activation|The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can jumpstart a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
79736267|NCT01128413|Biological|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, & 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
79736268|NCT01128413|Biological|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
79736269|NCT01128413|Biological|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
79736270|NCT02760628|Behavioral|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
79736271|NCT02760628|Behavioral|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
79736272|NCT01185080|Drug|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
79736273|NCT01185080|Drug|Placebo|Nasal spray solution, intranasal, three times weekly for one month
79871167|NCT04678154|Drug|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
80029416|NCT04874532|Other|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
79304592|NCT02444923|Device|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
79304593|NCT02444923|Device|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
79736274|NCT01185080|Drug|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
79576790|NCT05758441|Behavioral|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
79576791|NCT05758441|Behavioral|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
79736275|NCT00625313|Device|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
79736276|NCT02882399|Other|Shortystrap|
79576792|NCT05755737|Drug|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
79736277|NCT04498156|Other|No intervention|No intervention, observational study
79576793|NCT05755737|Drug|Placebo|Matching placebo identical in appearance.
79736278|NCT02760550|Other|No intervention|Participants of all three groups completed a questionnaire.
79736279|NCT01128179|Drug|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
79736280|NCT01128179|Drug|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
79871168|NCT04678154|Drug|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
79871169|NCT04665856|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
79871170|NCT04665856|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
80029417|NCT04874532|Other|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
80029418|NCT04869189|Device|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
80029419|NCT04848753|Combination Product|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
79871171|NCT04665856|Drug|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
79871172|NCT04665856|Drug|Etoposide|Etoposide 100 mg/m^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
79403068|NCT01242917|Drug|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
79576794|NCT05754554|Procedure|Atlas occipital decompression lateral joint release combined with occipital-neck fusion|A. Chiari malformation combined with type II Basilar invagination showed that the slope spinal canal angle decreased, and the position of the dentition moved up. The yellow fusion device in the picture is C1/2 lateral inter-articular Cage (the patent granted by the applicant for this project); B. After atlanto-occipital decompression, C1/2 lateral inter-articular release is performed, and a fusion device is implanted to move down the position of the tip of the tooth process to reduce the compression of the cervical medulla oblongata; C. Implantation of the posterior neck nail rod system; D. Improve the angle of the sloped spinal canal by posterior compression rod technique (Cantilever) to further reduce the compression on the superior cervical medulla oblongata.
79576795|NCT05746364|Behavioral|Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating|The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
79576796|NCT05741957|Behavioral|Once-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
79736281|NCT02883257|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
79736282|NCT01181102|Drug|edoxaban|
79736283|NCT01181102|Drug|enoxaparin sodium|
79736284|NCT02757820|Device|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
79736285|NCT02757820|Device|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
79736286|NCT02757820|Device|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
79871173|NCT04665856|Drug|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
79871174|NCT04628481|Drug|Ladarixin|Oral ladarixin twice a day for 13 cycles
79871175|NCT04628481|Drug|Placebo|Oral placebo twice a day for 13 cycles
79871176|NCT04622228|Drug|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
79736287|NCT00858637|Drug|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
79273181|NCT02395731|Behavioral|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
79273182|NCT05562986|Diagnostic Test|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.
79273183|NCT02141321|Drug|Misoprostol|
79736288|NCT00858637|Drug|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
79273184|NCT02141321|Drug|Placebo|
79273185|NCT03965078|Drug|topical (eye drop) anti-inflammatories|Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
79273186|NCT02141477|Drug|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
79871177|NCT04622228|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
79576797|NCT05741957|Behavioral|Thrice-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
79576798|NCT05741957|Other|Usual Care Control|Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
79576799|NCT05736952|Drug|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
79576800|NCT05732506|Drug|Edoxaban|There are not intervention.
79736289|NCT00858637|Drug|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
79736290|NCT00858637|Drug|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
79736291|NCT04221646|Device|BTL-899|Treatment with study device.
79736292|NCT02760394|Device|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
79736293|NCT04221334|Device|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
79736294|NCT04221334|Other|oral health care application|phone application that shows the user brushing efficiency real time
79871178|NCT04622228|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
79871179|NCT04622228|Drug|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
79403069|NCT01242917|Drug|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
79576801|NCT05719779|Device|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
79576802|NCT05719155|Drug|CKD-379|1 tablet administration under fed condition
79736295|NCT00699439|Other|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
79736296|NCT04173520|Drug|DDA|Follow up after SVR
79736297|NCT02760316|Drug|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
79736298|NCT02760316|Drug|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
79736299|NCT02760316|Drug|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
79871180|NCT04622228|Radiation|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
79871181|NCT04619472|Device|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
80029420|NCT04848753|Combination Product|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
79576803|NCT05719155|Drug|D759+D745+D150|3 tablet coadministration under fed condition
79736300|NCT02760316|Drug|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
79871182|NCT04597008|Drug|Treatment group|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
79871183|NCT04597008|Drug|Control group|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
79576804|NCT05694442|Other|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
79736301|NCT02760316|Drug|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
79736302|NCT02760316|Drug|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
79736303|NCT02760316|Drug|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
80029421|NCT04833816|Drug|Administration of drug|Administration of ketamin during the 48h after trauma
80029422|NCT04825561|Drug|AD-208|PO, Once daily(QD), 24weeks
80029423|NCT04825561|Drug|AD-2081|PO, Once daily(QD), 24weeks
80029424|NCT04825561|Drug|placebo of AD-208|PO, Once daily(QD), 24weeks
80029425|NCT04825561|Drug|placebo of AD-2081|PO, Once daily(QD), 24weeks
79736304|NCT02760316|Drug|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
79736305|NCT02760316|Drug|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
79736306|NCT00858403|Drug|Dasatinib|Take tablets of Dasatinib by mouth once a day.
79736307|NCT02760472|Drug|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
80029426|NCT04823247|Drug|Tildrakizumab|As provided in real world clinical practice.
80029427|NCT04814329|Other|genetic characteristic|the underlying genetic characteristics that prodicting response
80029428|NCT04795830|Combination Product|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
79273187|NCT02141477|Drug|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
79273188|NCT02397993|Procedure|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
79273189|NCT02397993|Procedure|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
79273190|NCT02397993|Procedure|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
79273191|NCT02232139|Drug|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
79576805|NCT05694429|Other|Product K cleanser and moisturizer|Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
79736308|NCT02760472|Drug|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
79736309|NCT00858247|Dietary Supplement|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
79736310|NCT04222348|Drug|Metformin|850-2550 mg every 24h.
80029429|NCT04795830|Combination Product|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
80029430|NCT04793373|Device|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
80029431|NCT04772222|Drug|Dexmedetomidine Hydrochloride|Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.
80029432|NCT04772222|Drug|Morphine Sulfate|Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.
80029433|NCT04766021|Drug|Mirabegron|Dose-response effect on thermogenesis
80029434|NCT04766021|Drug|Placebo|Placebo control condition
80029435|NCT04764370|Device|WeFlow-Ach Moduler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
79273192|NCT02148497|Procedure|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
79576806|NCT05686967|Dietary Supplement|MitoQ|MitoQ is a biochemically modified form of ubiquinol
79576807|NCT05686967|Dietary Supplement|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
79576808|NCT05686967|Behavioral|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
79736311|NCT04222348|Drug|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
79736312|NCT04222114|Drug|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
79736313|NCT04222114|Drug|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
79871184|NCT04591392|Device|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
79273193|NCT02397681|Other|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
79273194|NCT02226445|Other|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
79273195|NCT02148575|Behavioral|Self-Management Group|
79273196|NCT02148575|Behavioral|Symptom Management Group|
79576809|NCT05685043|Device|perfusion CT|Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients < 80 years or 55 ml in patients > 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
79576810|NCT05674656|Drug|Dolutegravir/Rilpivirine FDC|Dolutegravir/Rilpivirine will be administered.
79273197|NCT02232217|Behavioral|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
79736314|NCT02757976|Device|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
79871185|NCT04581681|Behavioral|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer & Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
80029436|NCT04752644|Biological|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
79273198|NCT02232217|Other|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
79273199|NCT03543761|Device|Dornier Aries 2 device|• Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.
79871186|NCT04581681|Other|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
79871187|NCT04578444|Drug|Zanidatamab|Administered intravenously
80029437|NCT04752644|Drug|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
79273200|NCT03543761|Device|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
79403070|NCT01113268|Other|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
79273201|NCT03543761|Device|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
79273202|NCT02226601|Drug|Aprepitant|3 days perioperative Aprepitant once a day
79273203|NCT02226601|Drug|Placebo|3 days perioperative Placebot once a day
79304594|NCT03283943|Radiation|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
79403071|NCT01028963|Drug|Placebo|Placebo capsules once daily
79403072|NCT01028963|Drug|pioglitazone|pioglitazone 30 mg tablet once daily
79403073|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
79403074|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group D)
79576811|NCT05671354|Device|the auto-wrapping commode chair|The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
79871188|NCT04568902|Drug|H3B-6545|H3B-6545 oral tablets.
80029438|NCT04749511|Behavioral|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
79871189|NCT04568902|Drug|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
79871190|NCT04550923|Combination Product|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
79871191|NCT04550923|Combination Product|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
79871192|NCT04550442|Drug|Azacitidine|Given IV or SC
79273204|NCT03168477|Other|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
79871193|NCT04550442|Drug|Venetoclax|Given PO
79273205|NCT03168477|Other|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
79273206|NCT03168477|Other|mobilization|Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
79871194|NCT04548999|Drug|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight <75 kg) or 1800 mg (participant's body weight >/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.
79871195|NCT04548999|Drug|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
79871196|NCT04548999|Drug|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
79273207|NCT03168477|Other|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
80029439|NCT04748380|Other|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
79273208|NCT03168477|Other|modalities|Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
79273209|NCT02148653|Other|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
79273210|NCT02148653|Other|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
79576812|NCT05664854|Device|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
79576813|NCT05658328|Behavioral|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
79871197|NCT04548999|Drug|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
79871198|NCT04547907|Drug|Albumin binding paclitaxel+ trastuzumab+ patuzumab|Albumin binding paclitaxel 125 mg / m2 (1, 8, 15 days) + trastuzumab (8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.
80029440|NCT04748380|Other|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
80029441|NCT04730336|Device|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
79273211|NCT02232295|Device|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
79273212|NCT02232295|Device|Mirror Box|A resource used for many pain and disability states of the hands and feet.
79273213|NCT02397759|Other|Blood draw and cerebrospinal fluid draw|
79273214|NCT05041361|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
80029442|NCT04728360|Drug|BAT2206|45 mg/0.5 mL
80029443|NCT04728360|Drug|Stelara (EU-sourced)|45 mg/0.5 mL
80029444|NCT04724499|Behavioral|High-Intensity Intervals Training|16 week exercise program with stationary bike.
80029445|NCT04724499|Other|Attention Control|16 week stretching program.
79304595|NCT03283943|Drug|Durvalumab|Durvalumab 1500 mg IV every 28 days
80029446|NCT04682925|Other|skin care arm of where evidence-based practices in the implementation guide|"The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
79304596|NCT02443597|Other|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
79576814|NCT05651633|Drug|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
79576815|NCT05648448|Drug|Drug: Oseltamivir|Oral oseltamivir 75mg BD for 5/7
79576816|NCT05648448|Drug|Drug: Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
79576817|NCT05648448|Drug|Drug: Zanamivir|Inhaled zanamivir 10mg BD for 5/7
79576818|NCT05648448|Drug|Drug: Baloxavir|"Oral baloxavir:~<80kg- single dose of 40mg on D0~≥80kg- single dose of 80mg on D0"
79576819|NCT05648448|Drug|Drug: Molnupiravir|Oral molnupiravir 800mg BD for 5/7
79576820|NCT05648448|Drug|Drug: Peramivir|Intravenous peramivir 600mg once only
79576821|NCT05648448|Drug|Drug: Laninamivir|Inhaled laninamivir 40mg once only
80029447|NCT04682925|Device|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
80029448|NCT04682925|Other|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
80029449|NCT04678167|Diagnostic Test|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
80029450|NCT04678167|Diagnostic Test|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
79576822|NCT05647616|Other|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
79736315|NCT02757976|Device|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
79736316|NCT00838435|Drug|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
80029451|NCT04678167|Diagnostic Test|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
80029452|NCT04678167|Diagnostic Test|Alexander's degree of nystagmus|"there are 3 degrees:~Degree I: nystagmus that exists only when the eyes are turned to the right.~Degree II: also exists when the eyes are to the right or to the front.~Degree Ill: exists when the eyes are on the right, front, or left"
80029453|NCT04678167|Other|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
80029454|NCT04678167|Other|EEV questionnaire|European Vertigo Assessment Questionnaire
80029455|NCT04678167|Other|anxiety VAS|visual analog scale of anxiety
80029456|NCT04648969|Drug|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
80029457|NCT04648969|Drug|GnRH|1 intravenous dose of GnRH
80029458|NCT04622592|Biological|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
80029459|NCT04604093|Device|SMBG Meter|Self Monitoring Blood Glucose Meter
79403075|NCT01027728|Drug|CCX 354-C|"Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
79403076|NCT00899626|Genetic|protein analysis|
79403077|NCT00899626|Genetic|proteomic profiling|
79403078|NCT00899626|Other|biologic sample preservation procedure|
79403079|NCT00899626|Other|laboratory biomarker analysis|
79403080|NCT00899626|Other|medical chart review|
79403081|NCT00899626|Procedure|diagnostic colonoscopy|
79403082|NCT00899626|Procedure|diagnostic endoscopic procedure|
79273215|NCT05041361|Device|Whole-Body Hyperthermia (WBH)|Whole-body hyperthermia (WBH) will be administered by trained research assistants. Preparation for the WBH, the WBH session, and cool down will last 3.5-4 hours, with active WBH lasting up to approximately 140 minutes. WBH will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 101.3 F.
79576823|NCT05645055|Other|treat these patients with biologics|treat these patients with biologics
79576824|NCT05641064|Drug|Placebo|Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
79736317|NCT02760160|Other|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) [114, 217, 343, 500, 619, 848].
79576825|NCT05641064|Drug|Dexmedetomidine 0.5mcg/kg/h|Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
79736318|NCT02757586|Genetic|shRNA|Using shRNA interfered the expression of the gene of CLL
79576826|NCT05641064|Drug|Dexmedetomidine 1 mcg/kg/h|Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
79576827|NCT05634967|Other|Kesimpta|Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
79736319|NCT04111042|Device|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
79736320|NCT02757664|Device|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
79736321|NCT02757664|Other|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
79871199|NCT04547907|Drug|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2 + carboplatin (AUC = 6) + trastuzumab(8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.
80029460|NCT04604093|Device|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
79576828|NCT05627570|Dietary Supplement|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
79576829|NCT05627570|Dietary Supplement|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
79871200|NCT04534218|Drug|Regorafenib|"For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
79871201|NCT04534218|Drug|Cyclophosphamide|50 mg per os, daily, for 6 months
79871202|NCT04534218|Drug|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
79403083|NCT00899626|Procedure|diagnostic endoscopic surgery|
79403084|NCT00899626|Procedure|diagnostic surgical procedure|
79403085|NCT00899626|Procedure|endoscopic surgery|
79576830|NCT05627570|Behavioral|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
79736322|NCT02757664|Device|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
79736323|NCT02757508|Dietary Supplement|protein powder supplement|
79736324|NCT02757508|Dietary Supplement|Vitamins/minerals|
79736325|NCT02760082|Other|Qualitative evaluation|
79871203|NCT04534218|Drug|Aspirin|75 mg orally and daily until progression
79871204|NCT04533763|Behavioral|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
80029461|NCT04558775|Other|Observational|no intervention
80029462|NCT04545866|Drug|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
80029463|NCT04545866|Drug|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
79273216|NCT02226679|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
79403086|NCT00899626|Procedure|screening colonoscopy|
79403087|NCT00754845|Drug|letrozole|Given orally
79403088|NCT00754845|Other|placebo|Given orally
80029464|NCT04529993|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
79736326|NCT04435678|Diagnostic Test|ALEX² test using the MAX 45k automated laboratory system|"The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays."
79871205|NCT04533763|Behavioral|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
79576831|NCT05618093|Device|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
79871206|NCT04530448|Drug|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
79871207|NCT04530448|Other|Standard of Care|Standard of Care treatment
79871208|NCT04511078|Drug|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
79871209|NCT04495452|Drug|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
80029465|NCT04523220|Drug|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
79736327|NCT02757196|Drug|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
79736328|NCT02757196|Drug|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
79736329|NCT04403698|Drug|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
79871210|NCT04476030|Drug|SAGE-217|Oral capsules
79871211|NCT04476030|Drug|Matching Placebo|Oral capsules
79736330|NCT02759770|Other|no intervention|This is a clinical observational study, no intervention was included.
79871212|NCT04476030|Drug|Sertraline|Oral tablets
79871213|NCT04476030|Drug|Escitalopram|Oral tablets
79871214|NCT04476030|Drug|Citalopram|Oral tablets
79871215|NCT04476030|Drug|Duloxetine|Oral capsules
79871216|NCT04476030|Drug|Desvenlafaxine|Oral tablets
79871217|NCT04462042|Radiation|Proton radiotherapy|Proton radiotherapy
79871218|NCT04462042|Radiation|Photon radiotherapy|Conventional photon radiotherapy
80029466|NCT04523220|Drug|Placebo|Subcutaneous administration in the same manner as Osocimab.
80029467|NCT04468906|Procedure|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
79273217|NCT02397369|Other|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
79736331|NCT02759926|Drug|Denatonium benzoate|
79736332|NCT02759926|Drug|Quinine hydrochloride|
79736333|NCT02759926|Drug|Tap water|
79736334|NCT02759536|Radiation|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
79871219|NCT04458831|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79871220|NCT04458831|Drug|Pomalidomide|Pharmaceutical form: oral
79871221|NCT04458831|Drug|Dexamethasone|Pharmaceutical form: oral
79871222|NCT04458831|Drug|Carfilzomib|Pharmaceutical form: solution for infusion
79871223|NCT04450316|Drug|Naltrexone|4.5mg tab (low-dose) nightly
79871224|NCT04450316|Drug|Placebo|1 tab nightly
79871225|NCT04447820|Drug|K-877-ER (Dose A)|Dose A Oral Administration
79871226|NCT04447820|Drug|K-877-ER (Dose B)|Dose B Oral Administration
79871227|NCT04447820|Drug|K-877-IR|K-877-IR Oral Administration
80029468|NCT04468906|Procedure|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
80029469|NCT04446260|Drug|SHR-A1811|be administered via intravenous (IV) infusion
80029470|NCT04407442|Drug|Azacitidine|Given IV
79871228|NCT04443062|Drug|177Lu-PSMA-617|PSMA radioligand therapy
79871229|NCT04438213|Drug|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
80029471|NCT04407442|Biological|Daratumumab|Given SC
80029472|NCT04407442|Drug|Dexamethasone|Given IV or PO
79871230|NCT04438213|Drug|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
79871231|NCT04438213|Drug|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
79576832|NCT05612685|Behavioral|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
79736335|NCT04221256|Drug|Administration of SSRI escitalopram|Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
79736336|NCT04221256|Behavioral|Paired Associative stimulation|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
79736337|NCT04221256|Drug|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
79736338|NCT00838201|Drug|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
79736339|NCT02695888|Behavioral|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
79736340|NCT02695888|Behavioral|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
79736341|NCT02757118|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
79736342|NCT02757118|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
79736343|NCT04222036|Other|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
79871232|NCT04424407|Behavioral|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
79736344|NCT04222036|Other|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
80029473|NCT04372615|Drug|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
80029474|NCT04372615|Drug|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
80029475|NCT04348448|Drug|Canakinumab 150 MG/ML [Ilaris]|COVID-19
79273218|NCT02397369|Behavioral|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
79403089|NCT00751270|Biological|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
79403090|NCT00751270|Drug|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
79576833|NCT05606510|Other|Mindful exercise|In this study, a modified mindful exercise (ME) program based on mindful standing yoga refers to a type of exercise that aims to harmonize the body and mind through the effect of mindfulness meditation and stretching-awareness to carry on the actual moment through body movement and surroundings without any judgement.
79736345|NCT04222036|Other|Reliability|The reliability of the materials will be tested with Cronbach alpha.
79736346|NCT00837967|Drug|Symbicort Turbuhaler|160/4.5μg for 3 days
79736347|NCT00837967|Drug|Terbutaline Turbuhaler|0.4 mg for 3 days
79736348|NCT02759614|Drug|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
79736349|NCT02759614|Drug|Erlotinib|Erlotinib 150mg, orally once a day
79736350|NCT02757040|Drug|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
79576834|NCT05606510|Other|usual care|Routine medicine and nursing care; as well as hospital-recommended movements (physical stretching).
79273219|NCT02397369|Behavioral|Tobacco users:Behavioural therapy Only|"Focus Group discussion:~This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
79736351|NCT02757040|Drug|ibrutinib|ibrutinib
79871233|NCT04402957|Drug|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
79576835|NCT05603923|Behavioral|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
79736352|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
79736353|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
80029476|NCT04345796|Drug|Carvedilol+Empagliflozin|Group A
80029477|NCT04345796|Drug|Carvedilol|Group B
80029478|NCT04345796|Drug|Empagliflozin|Group C
79576836|NCT05603923|Behavioral|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
79576837|NCT05603923|Behavioral|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
79576838|NCT05594706|Other|Measurement of blood levels of 1,5-anhydroglucitol|Measurement of blood levels of 1,5-anhydroglucitol
79736354|NCT02756884|Biological|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
80029479|NCT04345796|Drug|Placebo|Group D
79736355|NCT02756884|Biological|adipose derived stem cells|control arm will only received the adipose derived stem cells.
80029480|NCT04336306|Other|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
80029481|NCT04310267|Device|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
79736356|NCT02759224|Drug|BRI-1501|
79736357|NCT02759224|Drug|Lafutidine|
79736358|NCT02759224|Drug|Irsogladine maleate|
79736359|NCT02756806|Device|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
79736360|NCT02756728|Biological|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
79736361|NCT02756728|Other|High dose melphalan|High dose melphalan (HDM)
79736362|NCT02756728|Other|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
80029482|NCT04288479|Behavioral|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
79736363|NCT02759068|Behavioral|sounds and odors|presentation of sounds and odors
79736364|NCT00638170|Biological|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
79736365|NCT00638170|Biological|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
79736366|NCT00635518|Behavioral|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
79736367|NCT04586920|Drug|LY3509754|Administered orally
79871234|NCT04402957|Drug|Placebo|0.9% saline solution
79871235|NCT04395989|Drug|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79871236|NCT04395989|Drug|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79871237|NCT04395989|Drug|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79273220|NCT02397369|Other|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
79273221|NCT02144909|Behavioral|Partners in Care with Semi-Structured Support Group|
79736368|NCT04586920|Drug|Placebo|Administered orally
79736369|NCT04586920|Drug|Itraconazole|Administered orally
79871238|NCT04395989|Drug|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79871239|NCT04395989|Drug|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
79871240|NCT04395989|Drug|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79273222|NCT02397603|Drug|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
79273223|NCT02397603|Drug|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
79273224|NCT02144987|Biological|Bone Marrow CD133+ Stem Cell Transplantation|"Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~Hysteroscopy will be performed 2-3 months after stem cell transplantation~Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
79273225|NCT04467697|Drug|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
79576839|NCT05592639|Procedure|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
79273226|NCT02395419|Device|Orotracheal intubation with Totaltrack|
79403091|NCT00638612|Biological|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
79576840|NCT05589077|Behavioral|Education on Female Athlete Nutritional Concerns|Visual and audio information presented within the Qualtrics system will cover topics on the Female Athlete Triad, Relative Energy Deficiency in Sport, and eating disorders.
79736370|NCT04586920|Drug|Midazolam|Administered orally
79736371|NCT02756494|Biological|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
79736372|NCT02758990|Dietary Supplement|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
79736373|NCT02758990|Dietary Supplement|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
79871241|NCT04395989|Drug|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
79871242|NCT04395989|Drug|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
79871243|NCT04395989|Drug|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79273227|NCT02395419|Device|Orotracheal intubation with Airtraq|
79273228|NCT05562596|Diagnostic Test|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
79403092|NCT00638612|Drug|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
79871244|NCT04395989|Drug|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
79871245|NCT04382612|Device|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
79736374|NCT02758990|Dietary Supplement|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
79871246|NCT04360941|Drug|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
79273229|NCT02145065|Drug|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
79273230|NCT02145065|Device|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
79736375|NCT02758990|Dietary Supplement|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
79736376|NCT02758990|Dietary Supplement|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
79871247|NCT04360941|Drug|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
79871248|NCT04357275|Other|ICU treatment|ICU treatment according to standard of care
79871249|NCT04336618|Device|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
79871250|NCT04303858|Drug|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
79871251|NCT04303858|Drug|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
79871252|NCT04294810|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
79736377|NCT02758990|Dietary Supplement|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
79736378|NCT02758990|Other|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (~91 grams) per day.
79736379|NCT02758990|Other|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (~30 grams) per day.
79736380|NCT02758990|Dietary Supplement|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
79736381|NCT02758990|Other|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
79736382|NCT02758990|Device|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
79736383|NCT02758990|Other|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
79871253|NCT04294810|Drug|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79871254|NCT04294810|Drug|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79871255|NCT04282785|Diagnostic Test|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
79871256|NCT04273555|Drug|[18F]-FDG|[18F]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
79273231|NCT02226757|Drug|Paclitaxel-trastzumab|"Trastuzumab~Dose:~First dose: 4 mg/kg IV~Subsequent doses: 2 mg/kg every week IV.~The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
79273232|NCT02145221|Other|Music Therapy|
79736384|NCT02756416|Device|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
79736385|NCT02756416|Device|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
79736386|NCT02756416|Device|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
79736387|NCT02758912|Drug|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
79871257|NCT04258722|Other|Resuscitation Personnel|Type of resuscitation team
79273233|NCT02232373|Behavioral|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
79273234|NCT02232373|Dietary Supplement|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
79273235|NCT02232373|Dietary Supplement|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
79273236|NCT04616924|Drug|RHB-204|RHB-204
79273237|NCT04616924|Drug|Placebo|Matching placebo to RHB-204
79273238|NCT02141711|Drug|TAK-438|TAK-438 tablets
79273239|NCT02141711|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
79736388|NCT02758756|Other|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
79273240|NCT02145377|Biological|PXVX0200 10E8|Oral dose of PXVX0200 10E8
79273241|NCT02145377|Biological|PXVX0200 10E9|Oral dose of PXVX0200 10E9
79736389|NCT02758756|Other|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
79736390|NCT02756104|Other|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
79736391|NCT02756104|Other|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
79273242|NCT02145377|Biological|Placebo|Oral dose of sodium bicarbonate buffer
79273243|NCT02145377|Biological|Shanchol|Licensed comparator
79273244|NCT02226913|Drug|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
79273245|NCT02226913|Drug|sodium bicarbonate|8.4% sodium bicarbonate
79736392|NCT02755870|Other|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
79871258|NCT04239794|Drug|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
79871259|NCT04239794|Drug|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
79871260|NCT04225455|Device|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~[Green: 5-15 mmol/L; Amber: 4 to <5mmol/L and >15 to 20mmol/L; Red: <4mmol/L and >20mmol/L]"
79273246|NCT02226913|Drug|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
79403093|NCT00634231|Biological|AdV-tk|
79403094|NCT00634231|Drug|valacyclovir|
79273247|NCT02254655|Drug|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
79736393|NCT02755870|Other|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
79871261|NCT04222556|Behavioral|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
79871262|NCT04222556|Behavioral|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
79871263|NCT04220229|Drug|Cabozantinib S-malate|Given PO
79871264|NCT04220229|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
79273248|NCT02254655|Drug|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
79273249|NCT02226991|Drug|Tipranavir|
79273250|NCT02226991|Drug|Ritonavir|
79273251|NCT02226991|Drug|Efavirenz|
79581494|NCT06070883|Procedure|Amniotic membrane transplantation|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
79736394|NCT02756026|Dietary Supplement|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
79736395|NCT02755714|Drug|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
79871265|NCT04200911|Drug|Rapamune|Sirolimus 1mg capsules
79871266|NCT04164472|Behavioral|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
79871267|NCT04158687|Drug|CTP-692|Administered as powder for oral solution.
79273252|NCT03839576|Behavioral|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
79273253|NCT03839576|Behavioral|Computerized training|Attention, memory, speed of processing, and executive functioning.
79273254|NCT03544385|Drug|Ringers Solution|Treatment vs Placebo
79273255|NCT03544385|Drug|Placebo - Concentrate|treatment vs placebo
79273256|NCT03822338|Procedure|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
79273257|NCT03822338|Procedure|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
79273258|NCT02227069|Drug|M518101|
79273259|NCT02227069|Drug|M518101 Vehicle|
79273260|NCT02227069|Other|sodium lauryl sulfate|
79736396|NCT02755792|Behavioral|Calligraphy Training|
79736397|NCT02755792|Behavioral|iPad Training|
79736398|NCT02758678|Biological|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
79871268|NCT04158687|Drug|Placebo|Administered as powder for oral solution.
79871269|NCT04155125|Drug|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
79871270|NCT04155125|Drug|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
80029483|NCT04265612|Procedure|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
79273261|NCT02227069|Other|saline|
79273262|NCT02148731|Other|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
79736399|NCT02758522|Drug|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
79871271|NCT04153864|Behavioral|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
79273263|NCT02254733|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
79273264|NCT02254733|Other|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
79273265|NCT02227303|Behavioral|lifestyle modification instructional and motivational sessions|
79273266|NCT02254811|Biological|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
79273267|NCT05057143|Device|Implants|3D printed implants
79273268|NCT05057143|Device|Plates|Titanium plates
79273269|NCT05049031|Other|Questionnaire|A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
79576841|NCT05581160|Diagnostic Test|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
79736400|NCT02758522|Drug|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
79736401|NCT02758522|Drug|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
79736402|NCT02758600|Other|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
79736403|NCT00942357|Drug|Carboplatin|Given IV
79736404|NCT00942357|Drug|Cisplatin|Given IV
79871272|NCT04127032|Behavioral|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
79871273|NCT04123418|Biological|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
79871274|NCT04123418|Drug|WHG626|WHG626 will be administered orally in a dose escalation schedule
80029484|NCT04265612|Procedure|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
80029485|NCT04258319|Diagnostic Test|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
80029486|NCT04257877|Procedure|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
79403095|NCT00634231|Radiation|Radiation|
79871275|NCT04098276|Behavioral|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
79736405|NCT00942357|Radiation|Internal Radiation Therapy|Undergo brachytherapy
79736406|NCT00942357|Drug|Paclitaxel|Given IV
79273270|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
79576842|NCT05578755|Behavioral|FutureU|"FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher."
79871276|NCT04094818|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
79871277|NCT04090749|Behavioral|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
79273271|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
79273272|NCT02145455|Device|Unity Total Knee Replacement System|
79273273|NCT02145455|Device|Unity Total Knee Replacement System|
79273274|NCT02222233|Drug|BI 671800 HEA delayed release (enteric coated) tablet|
79273275|NCT02222233|Drug|BI 671800 HEA solution|
79273276|NCT02222233|Drug|BI 671800 HEA particulate|
79576843|NCT05578755|Behavioral|Goal-setting|In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
79736407|NCT00942357|Other|Quality-of-Life Assessment|Ancillary studies
79273277|NCT04609670|Drug|[14C]-ALXN2050|A single dose of 200 milligrams (~85 microcuries) [14C]-ALXN2050 will be administered orally.
79871280|NCT04076059|Drug|Enzalutamide|Oral
79871281|NCT04076059|Drug|Placebo|Oral
79871282|NCT04076059|Drug|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
80029487|NCT04233671|Behavioral|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
79273278|NCT02222311|Other|Blood Samples|
79736408|NCT00942357|Radiation|Radiation Therapy|Undergo radiation therapy
79273279|NCT00705783|Drug|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
79736409|NCT02755402|Device|Xpert HCV Viral load|HCV viral load testing
79736410|NCT02755402|Device|Transient elastography|Evaluation of liver fibrosis
79736411|NCT02755480|Device|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
79736412|NCT02755324|Biological|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
79736413|NCT02755558|Behavioral|Low energy density|Low energy density milk served
79736414|NCT02755558|Behavioral|High energy density|High energy density milk served
79736415|NCT02755558|Behavioral|Small portion|Small portion of milk served
79736416|NCT02755558|Behavioral|Large portion|Large portion of milk served
79736417|NCT02752828|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79736418|NCT02752828|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
79871283|NCT04047420|Drug|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
79871284|NCT04026516|Device|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
79871285|NCT04006457|Drug|PF-06651600|50 mg oral tablets/capsules
80029488|NCT04227145|Behavioral|SexHealth Mobile|"It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with."
79871286|NCT04006457|Biological|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
79736419|NCT02752828|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
80029489|NCT04222088|Drug|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)"
79273280|NCT00705783|Drug|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
79736420|NCT02755636|Behavioral|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
79736421|NCT02755636|Other|Usual care|Primary care as usual
79403096|NCT00555555|Biological|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
79273281|NCT03544931|Procedure|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
79736422|NCT02753062|Drug|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
79736423|NCT00939783|Drug|Dimebon|Tablet for oral administration
79736424|NCT02752594|Biological|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
79736425|NCT02752594|Other|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
79403097|NCT00540657|Drug|CCX282-B|250mg capsule, twice daily, 13 weeks
79273282|NCT03544931|Device|EMD Application|Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
79273283|NCT02222389|Behavioral|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
79736426|NCT02755246|Dietary Supplement|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
79736427|NCT02755246|Dietary Supplement|Placebo supplementation|3 months of placebo intake (3 capsules/day)
79273284|NCT02222389|Behavioral|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
79403098|NCT00540657|Drug|Placebo|Placebo capsule, twice daily, 13 weeks
79736428|NCT04220710|Diagnostic Test|DNA extraction and methylation detection|DNA extraction and methylation detection
79736429|NCT00602199|Drug|ABT-510|
79736430|NCT00602199|Other|immunoenzyme technique|
79736431|NCT00602199|Other|immunohistochemistry staining method|
79871287|NCT04006457|Biological|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
79871288|NCT04003636|Biological|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
79871289|NCT04003636|Drug|Gemcitabine|Gemcitabine by IV infusion
79871290|NCT04003636|Drug|Cisplatin|Cisplatin by IV infusion
79273285|NCT02222389|Behavioral|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
79273286|NCT02222389|Behavioral|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
79736432|NCT00602199|Other|laboratory biomarker analysis|
79736433|NCT00602199|Other|pharmacological study|
79871291|NCT04003636|Drug|Placebo|Placebo to pembrolizumab
79871292|NCT03973814|Device|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
79871293|NCT03958045|Combination Product|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
79871294|NCT03952065|Drug|PD1/PDL1/CTLA4 inhibitors|Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
79736434|NCT00602199|Procedure|biopsy|
79871295|NCT03911271|Drug|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
79871296|NCT03911271|Drug|0.01% atropine|0.01% atropine for 24 months
79576844|NCT05573620|Behavioral|ACT|"Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti."
79736435|NCT02755168|Procedure|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
79736436|NCT02755168|Procedure|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
79871297|NCT03911271|Drug|0.9% Sodium-chloride|Placebo for 24 months
80029490|NCT04222088|Drug|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
79736437|NCT04221100|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
80029491|NCT04222088|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
80029492|NCT04196543|Other|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~Echo-doppler without standard method contrast injection (common practice)~An echo-doppler with Sonovue® ultrasound injection Ultra_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
80029493|NCT04187950|Dietary Supplement|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
80029494|NCT04187950|Dietary Supplement|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
79576845|NCT05573620|Behavioral|In vivo exposure:|The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
79576846|NCT05573620|Behavioral|Virtual Reality|"Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)"
79736438|NCT02754934|Other|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
79736439|NCT04289740|Behavioral|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
79273287|NCT02145611|Drug|Glibenclamide|Glibenclamide
79871298|NCT03904134|Other|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
79871299|NCT03885024|Other|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
79273288|NCT02145611|Drug|Vildagliptin|Vildagliptin
79273289|NCT02222467|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
79273290|NCT02258503|Other|pain in elderly patients|
79273291|NCT02222545|Biological|OMS721|
79403099|NCT00319228|Drug|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
79273292|NCT03745547|Other|Adherence to wearing a Spire wearable health monitor|Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.
79736440|NCT04289740|Behavioral|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
79736441|NCT02754700|Other|Neuromuscular Training|Standardized, comprehensive neuromuscular training
79736442|NCT02754700|Other|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
79736443|NCT02754700|Other|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
79736444|NCT04220788|Other|Enhanced pharmacist service|Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
79736445|NCT04220788|Other|Usual care|Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
79871300|NCT03868475|Procedure|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
79871301|NCT03868475|Procedure|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
79273293|NCT04440579|Procedure|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
79576847|NCT05572372|Behavioral|Acceptance and Commitment Therapy|The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
79273294|NCT04440579|Procedure|Sham Percutaneous Tibial Nerve Stimulation (PTNS)|Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure
79273295|NCT04440579|Procedure|Standard Cystoscopy|Patient will undergo standard cystoscopy
79273296|NCT02222623|Drug|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
79273297|NCT02222623|Drug|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
79273298|NCT02148965|Behavioral|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
79273299|NCT02395263|Drug|Yuxintine|
79576848|NCT05569018|Behavioral|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
79736446|NCT02752360|Procedure|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
79736447|NCT02752360|Procedure|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
79736448|NCT00635596|Biological|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
79871302|NCT03847766|Behavioral|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
79273300|NCT02149043|Device|Thermography|Thermographic imaging of the patient's abdomen surface
79273301|NCT02149043|Procedure|Colonoscopy|Endoscopic examination of the colon
79273302|NCT02397525|Drug|LIPO-202|
79403100|NCT00312039|Drug|Elvucitabine|Elvucitabine 10 mg QD for 14days
79736449|NCT04527796|Other|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
79736450|NCT02752204|Drug|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
80029495|NCT04136340|Other|In-person in clinic follow-up visit|Patient will be seen in-person (i.e. an IR/NV or AFX visit) in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks. Any patients randomized to the in-person group who experience an extraordinary burden and/or are physically unable to attend their in-person visits will be able to be seen by their Supportive Care Service clinician via a home telemedicine visit (patients will return to their original group assignment if possible).
80029496|NCT04136340|Other|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
79273303|NCT03543683|Drug|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
79273304|NCT03543683|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
79273305|NCT02394873|Biological|ALLO-ASC-DFU|Dressing for second-degree burn wound.
79273306|NCT02222935|Behavioral|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
79576849|NCT05569018|Behavioral|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
79576850|NCT05563558|Drug|Pembrolizumab|Included in arm/group description
79576851|NCT05563558|Drug|Carboplatin|Included in arm/group description
79576852|NCT05563558|Drug|Cabazitaxel|Included in arm/group description
79576853|NCT05557890|Behavioral|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
79576854|NCT05557097|Diagnostic Test|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
79576855|NCT05545735|Drug|Standard of Care Antibiotic Therapy|Antibiotics will be administered as per the standard of care orally via tablet
79273307|NCT02222935|Behavioral|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
79576856|NCT05544305|Other|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
79576857|NCT05531994|Drug|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
79576858|NCT05531994|Drug|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
79576859|NCT05530148|Behavioral|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
79736451|NCT02752204|Drug|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
79736452|NCT04220398|Drug|Neoadjuvant chemotherapy combined with hormone therapy|Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
79736453|NCT04220398|Drug|Neoadjuvant hormone therapy|HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
79871303|NCT03847766|Behavioral|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
79871304|NCT03844048|Drug|Venetoclax|oral; film-coated tablets or tablets for oral suspension
79871305|NCT03808584|Other|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
79871306|NCT03806179|Drug|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
79871307|NCT03806179|Drug|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
79273308|NCT02145689|Biological|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
79273311|NCT02145767|Drug|Progesterone|
79273312|NCT02145767|Drug|Placebo|
79581495|NCT06070857|Drug|LV232|"Drug: LV232 1mg Group:~6 subjects will receive LV232 1mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 2mg Group:~6 subjects will receive LV232 2mg, orally; 2 subjects will receive placebo, orally.~Other Names: Placebo~Drug: LV232 4mg Group:~6 subjects will receive LV232 4mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 8mg Group:~6 subjects will receive LV232 8mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 20mg Group:~6 subjects will receive LV232 20mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo"
79871308|NCT03789084|Behavioral|Brief Cognitive-Behavioral Therapy for Health Anxiety|4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
79871309|NCT03789084|Behavioral|Referral to mental health provider|Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
79736454|NCT04220398|Procedure|Radical Prostatectomy (RP)+ extended lymph node dissection|"Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery."
79871310|NCT03788213|Radiation|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
79871311|NCT03788213|Radiation|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
79871312|NCT03783624|Behavioral|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
79871313|NCT03783624|Behavioral|Open label placebo|Ritual intake of 2 placebo capsules twice a day
79871314|NCT03759587|Drug|Niraparib|Niraparib capsule
79736455|NCT02752126|Radiation|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
79736456|NCT02752126|Radiation|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
79736457|NCT04220944|Drug|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
79736458|NCT04220944|Procedure|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
79736459|NCT04220944|Procedure|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
79736460|NCT04221022|Other|Light physical activity|Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
79871315|NCT03752684|Other|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate
79871316|NCT03752684|Other|Moderately high oxalate/low calcium diet|Subjects will be instructed to ingest a controlled diet moderately high in oxalate
79871317|NCT03752684|Other|Oxalobacter formigenes|Subjects will ingest live preparation of O. formigenes
79871318|NCT03748953|Drug|Ixazomib|Ixazomib Capsules
79273313|NCT02227459|Drug|ND-L02-s0201 Injection|
79273314|NCT02395029|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
79273315|NCT02145845|Device|Injectable SIS|Injectable SIS
79273316|NCT02031523|Drug|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
79871319|NCT03746431|Drug|[111In]-FPI-1547 Injection|[111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive [111In]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
79871320|NCT03746431|Drug|[225Ac]-FPI-1434 Injection multi-dose|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of [225Ac]-FPI-1434 Injection. Dose is per cohort assignment.
79871321|NCT03746431|Biological|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
79871322|NCT03746431|Drug|[225Ac]-FPI-1434 Injection single-dose|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of [225]-FPI-1434 Injection. Dose is per cohort assignment.
79871323|NCT03737851|Drug|elezanumab|solution for infusion
79871324|NCT03737851|Drug|placebo|solution for infusion
80029497|NCT04105777|Device|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
80029498|NCT04105777|Device|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
79576860|NCT05530148|Behavioral|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
79576861|NCT05528198|Drug|Montelukast sodium oral thin films without water (A)|Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
79576862|NCT05528198|Drug|Montelukast sodium oral thin films with water (B)|Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
79871325|NCT03737149|Other|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
79871326|NCT03735121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
79576863|NCT05528198|Drug|Montelukast sodium chewable tablets with water (C)|Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
79576864|NCT05518474|Other|Self-proning|Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
79576865|NCT05510596|Other|Magnetic Resonance Imaging with contrast injection|Magnetic Resonance Imaging with contrast injection
79576866|NCT05510596|Other|Blood withdrawal|Blood withdrawal : serum, plasma, cytokine assay
79871327|NCT03735121|Drug|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
79871328|NCT03730194|Dietary Supplement|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
79871329|NCT03730194|Behavioral|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
79871330|NCT03723551|Drug|Afabicin|Administered intravenously and orally.
79871331|NCT03723551|Drug|Standard of Care|Administered with SOC in accordance with local practice and applicable treatment guidelines.
79871332|NCT03689699|Drug|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
79871333|NCT03689699|Drug|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
79871334|NCT03689699|Drug|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
79871335|NCT03669497|Radiation|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
79871336|NCT03655886|Procedure|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
79871337|NCT03655886|Radiation|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
79871338|NCT03655678|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
79871339|NCT03653507|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
79871340|NCT03653507|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
79871341|NCT03653507|Drug|capecitabine|Capecitabine will be administered orally twice daily (bid).
79871342|NCT03653507|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
79871343|NCT03568890|Drug|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 60 days
79871344|NCT03568890|Drug|Clopidogrel -75 mg/day|Duration of treatment: 60 days
79273317|NCT02031523|Drug|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
79273318|NCT02397213|Drug|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
79576867|NCT05510596|Other|Neuropsychological tests|Neuropsychological tests
79576868|NCT05510206|Device|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
79576869|NCT05498519|Drug|SY-4798|FGFR4 selective inhibitor
79576870|NCT05493605|Procedure|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
79576871|NCT05471011|Other|Blood and nasal swab sampling|Blood and nasal swab sampling
79871345|NCT03568890|Drug|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 60 days
79871346|NCT03562364|Other|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
79736461|NCT04221022|Other|Moderate physical activity|Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
79736462|NCT04221022|Other|Vigorous physical activity|Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
79871347|NCT03559400|Drug|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
79576872|NCT05460663|Behavioral|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
79871348|NCT03559400|Drug|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
79871349|NCT03530683|Drug|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
80029499|NCT04104945|Radiation|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
80029500|NCT04063722|Procedure|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
79576873|NCT05458375|Drug|Estradiol vaginal cream|Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
79871350|NCT03530683|Drug|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
79736463|NCT02754622|Other|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
79736464|NCT02752516|Drug|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
79736465|NCT04278352|Behavioral|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
79736466|NCT02751892|Behavioral|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
79736467|NCT02754466|Other|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
79736468|NCT02754466|Other|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
79871351|NCT03530683|Drug|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
80029501|NCT04020458|Procedure|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
79403101|NCT00312039|Drug|Lamivudine|Lamivudine 300 mg QD for 14 days
79403102|NCT00306215|Drug|CCX282-B|CCX282-B or placebo capsules
79403103|NCT00102921|Drug|CCX282-B|
79736469|NCT02754232|Other|Telemedical training|Intervention will involve resistance training and anaerobic training
79736470|NCT04220632|Drug|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
79736471|NCT04220632|Drug|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
79736472|NCT04220632|Drug|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
79736473|NCT02751970|Procedure|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
79736474|NCT02751970|Procedure|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
79736475|NCT02751970|Procedure|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
79736476|NCT02751970|Procedure|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
79871352|NCT03530683|Drug|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
80029502|NCT03978520|Drug|Elsubrutinib|Capsule; Oral
80029503|NCT03978520|Drug|Placebo for elsubrutinib|Capsule; Oral
79273319|NCT02397213|Drug|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
79273320|NCT02145923|Procedure|Peripheral blood stem cell mobilisation and collection|
79871353|NCT03530683|Drug|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
79871354|NCT03530683|Drug|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
80029504|NCT03978520|Drug|Upadacitinib|Film-coated tablet; Oral
80029505|NCT03978520|Drug|Placebo for upadacitinib|Film-coated tablet; Oral
80029506|NCT03968328|Other|Interview|Take part in interview
80029507|NCT03968328|Other|Survey Administration|Respond to survey
80029508|NCT03962127|Other|no intervention|no intervention
80029509|NCT03947957|Diagnostic Test|collection of expectoration, stools and blood|collection of expectoration, stools and blood
79273321|NCT02145923|Drug|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
79273322|NCT02145923|Drug|Bone marrow derived allogeneic MMSCs infusion|
79273323|NCT02145923|Procedure|Autologous peripheral blood stem cells infusion|
79576874|NCT05446064|Behavioral|Stigma-reduction intervention|The intervention is modularized into four weekly 1-hour group sessions, led by a trained facilitator who provides psychoeducation to promote awareness and understanding of HIV stigma and teach CBT-based coping skills. Each group session will last 45-60 minutes. Participants are introduced to the general CBT model of HIV stigma and encouraged to track thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate effective and ineffective coping strategies and practice applying new coping skills to reduce internalized HIV stigma. The interventionist will follow the intervention manual to deliver the intervention and assign homework for group members to practice on their own. In the following sessions, the interventionist will review progress with participants, guide participants through exercises, and identify additional problems to be addressed in subsequent sessions.
79576875|NCT05444725|Other|Stage of Decision Making|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
79736477|NCT02751970|Procedure|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
79736478|NCT02752438|Device|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
79736479|NCT00939627|Biological|cetuximab|Given IV
79736480|NCT00939627|Other|placebo|Given orally
79736481|NCT00939627|Drug|sorafenib tosylate|Given orally
79736482|NCT00939627|Other|laboratory biomarker analysis|Correlative studies
80029510|NCT03941743|Drug|Fingolimod|Given PO
80029511|NCT03941743|Drug|Fingolimod Hydrochloride|Given PO
80029512|NCT03941743|Other|Questionnaire Administration|Ancillary studies
80029513|NCT03929393|Behavioral|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
80029514|NCT03929393|Other|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
79273324|NCT04480281|Drug|Lidocaine Iv|Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
79273325|NCT04480281|Drug|Normal Saline|Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
79273326|NCT03544775|Procedure|Isolated General Anesthesia|No nerve block identified through physician billing codes
79273327|NCT03544775|Procedure|Peripheral Nerve Block|Nerve block identified through physician billing codes
79273328|NCT02227537|Device|Providence Nighttime Bracing System|Providence Nighttime Bracing System
79273329|NCT02227537|Device|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
79273330|NCT02227615|Dietary Supplement|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
79273331|NCT02227615|Dietary Supplement|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
79273332|NCT02149355|Other|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
79273333|NCT02394717|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
79273334|NCT02227771|Device|Percutaneous coronary intervention|
79273335|NCT05745831|Other|Therapeutic decision tool|A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
79403104|NCT00095784|Drug|Decitabine|Given SC
79736483|NCT00939627|Procedure|quality-of-life assessment|Ancillary studies
79736484|NCT02752282|Other|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
80029515|NCT03899259|Drug|Baricitinib|Administered orally
80029516|NCT03899259|Drug|Placebo|Administered orally
80029517|NCT03896685|Drug|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
79736485|NCT02752282|Other|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
80029518|NCT03896685|Drug|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
79273336|NCT02258815|Drug|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
79273337|NCT02149433|Drug|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
79576876|NCT05444725|Other|Choice framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
79576877|NCT05444725|Other|Opportunity Framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
79576878|NCT05420584|Procedure|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
79576879|NCT05420584|Drug|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
79576880|NCT05420584|Drug|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
79576881|NCT05420584|Diagnostic Test|Pelvic MRI|Pelvic MRI to evaluate efficacy
79576882|NCT05420584|Procedure|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
79576883|NCT05416580|Drug|UDCA (Ursodeoxycholic acid)|UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
79576884|NCT05416580|Drug|Placebo|Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
79576885|NCT05416580|Drug|Metformin|Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
79736486|NCT05382741|Drug|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
79871355|NCT03530683|Drug|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
79273338|NCT02149433|Drug|Placebo|
79273339|NCT02394639|Other|video-EEG monitoring|
79273340|NCT02228005|Drug|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
79273341|NCT02146079|Drug|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
79403105|NCT00095784|Other|Laboratory Biomarker Analysis|Correlative studies
79403106|NCT00083174|Drug|exemestane|one 25 mg tablet daily in am
79403107|NCT00070499|Drug|Dasatinib|Given PO
79403108|NCT00070499|Drug|Imatinib Mesylate|Given PO
79403109|NCT00070499|Other|Laboratory Biomarker Analysis|Correlative studies
79576886|NCT05414318|Device|Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis
79736487|NCT05382741|Drug|Regorafenib 30 mg capsules|BAY73-4506
79736488|NCT05090007|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
79736489|NCT05090007|Other|gut microbiota|gut microbiota
79736490|NCT02754076|Drug|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
79871356|NCT03518853|Radiation|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
79871357|NCT03513484|Drug|Azacitidine|Given IV or SC
79871358|NCT03513484|Other|Laboratory Biomarker Analysis|Correlative studies
79871359|NCT03513484|Drug|Nintedanib|Given PO
79871360|NCT03495674|Behavioral|Exercise Intervention|Complete cycling classes
79871361|NCT03495674|Other|Informational Intervention|Receive information about exercise guidelines
79871362|NCT03495674|Device|Monitoring Device|Wear Fitbit
79871363|NCT03495674|Other|Questionnaire Administration|Complete questionnaire
80029519|NCT03896685|Drug|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
80029520|NCT03896685|Drug|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
80029521|NCT03896685|Drug|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
80029522|NCT03874715|Drug|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
79273342|NCT02146079|Drug|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
79576887|NCT05414071|Device|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
79273343|NCT02232451|Device|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
79273344|NCT02232451|Device|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
79576888|NCT05412511|Behavioral|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
79736491|NCT05381415|Other|Inhalation of bronchodilation therapy at FRC|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
79871364|NCT03483012|Drug|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
79576889|NCT05412511|Behavioral|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
79576890|NCT05401578|Drug|Canakinumab|Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
79871365|NCT03483012|Procedure|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
79576891|NCT05401578|Drug|Placebo (0.9% NaCl)|1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
79576892|NCT05391542|Other|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
79576893|NCT05391334|Device|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
79273345|NCT02146157|Dietary Supplement|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
79273346|NCT02146157|Dietary Supplement|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
79273347|NCT02694549|Device|CaveoVasc|
79576894|NCT05387161|Other|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
79576895|NCT05385406|Diagnostic Test|HPV genotyping|Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.
80029523|NCT03874715|Drug|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
80029524|NCT03874715|Drug|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
80029525|NCT03801863|Procedure|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
80029526|NCT03801863|Drug|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
79273348|NCT02228083|Drug|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
79403110|NCT00066573|Drug|anastrozole|Given orally
79403111|NCT00066573|Drug|exemestane|Given orally
79403112|NCT03965845|Drug|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
79403113|NCT03965845|Drug|Palbociclib Oral Capsule or Tablet [Ibrance]|Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
79736492|NCT05381415|Other|Inhalation of bronchodilation therapy at RV|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
79273349|NCT02142179|Behavioral|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
79403114|NCT03594955|Drug|SAR440234|Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
79403115|NCT03593551|Combination Product|five relaxation treatments and one control|Five treatments are relaxation meditation tape, music tape, relaxation lighting, meditation tape plus lighting, and music plus lighting. The control session have no intervention, participants will just be asked to sit comfortably for 10 minutes.
79736493|NCT04220476|Radiation|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
79736494|NCT04220476|Drug|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
79273350|NCT05745753|Other|sample blood|At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.
79273351|NCT02905903|Drug|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
79403116|NCT04194697|Behavioral|Exercise|Exercise program
79403117|NCT04194697|Behavioral|No exercise|No exercise program
79403118|NCT04766359|Drug|Albumin-Bound Paclitaxel|Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal carcinoma.
79403119|NCT04027621|Device|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
79403120|NCT04027621|Device|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
79403121|NCT03023293|Other|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
79403122|NCT03954145|Procedure|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
79403123|NCT03954145|Procedure|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
79576896|NCT05385406|Diagnostic Test|Visual inspection after application of acetic acid|"After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter > 5mm of acetowhite lesion)."
79576897|NCT05377463|Behavioral|Peer support to promote uptake and persistence of medication assisted treatment (MAT)|Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.
79576898|NCT05377463|Behavioral|Behavioral Activation Treatment (BAT) to reduce depression|Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.
79273352|NCT02142257|Procedure|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
79576899|NCT05377463|Behavioral|Patient Navigation to promote linkage and engagement in HIV care|Participants will be assigned to receive patient navigation services. A patient navigator will provide information about the process of obtaining HIV care and provide instrumental support to access care as needed for six months. The navigator will assist with obtaining government sponsored insurance if the participant does not have employer sponsored insurance, including processing needed documents, monetary resources, transportation and clerical support to obtain required documents, such as state ID and birth certificates. Navigators will meet with participants to go over what to expect during their clinic appointment and explain in lay terms medical terminology likely to be discussed by providers to facilitate patient-provider interaction. Other instrumental support provided will be scheduling appointments, providing clean clothing, a place to shower, and transportation to attend medical appointments.
79871366|NCT03455673|Diagnostic Test|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (> 270 ng/ml) = 1"
79273353|NCT02142257|Device|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
79273354|NCT02394483|Drug|F901318 safety|Safety assessments
79576900|NCT05377463|Behavioral|Life Steps educational and skill building session to promote adherence to HIV medication|Participants assigned to this component will participate in a single session that includes one follow-up phone-call or visit. Participants will be exposed to cognitive-behavioral techniques and will learn about the importance of HIV treatment and the strategies and skills needed to take HIV treatment as prescribed. The session consists of strategies for problem solving transportation barriers, skills to improve communication with providers, strategies for dealing with side-effects, reminder cues, and managing lapses.
79576901|NCT05365815|Behavioral|Melanated Group Midwifery Care|Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
79273355|NCT02394483|Drug|F901318 tolerability|Tolerability assessments
79576902|NCT05365607|Device|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
79576903|NCT05365607|Device|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
79576904|NCT05361980|Device|Pediatric orthopaedic implant|Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
79273356|NCT02394483|Drug|F901318 pharmacokinetics|Pharmacokinetic assessments
79576905|NCT05360849|Behavioral|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
79576906|NCT05357547|Drug|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
79273357|NCT02394483|Other|Placebo safety|Safety assessments
79576907|NCT05357547|Drug|Placebo comparator|Lactose-sucrose tablets in opaque capsule
79576908|NCT05344833|Drug|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
79576909|NCT05344833|Drug|Lenalidomide|Lenalidomide 15mg PO Days 1-28 Cycle 4 and can continue until disease progression.
79273358|NCT02394483|Other|Placebo tolerability|Placebo tolerability
79273359|NCT02394483|Other|Placebo pharmacokinetics|Plaacebo pharmacokinetics
79273360|NCT04340323|Other|Pelvic Floor Muscle Training (PFMT)|The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
79273361|NCT02142335|Drug|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 & 3 (days 1 & 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
79273362|NCT02223013|Drug|BIBV 308 SE solution|
79273363|NCT02223013|Drug|BIBV 308 SE capsule L|
79273364|NCT02223013|Drug|BIBV 308 SE capsule S|
79273365|NCT02394249|Behavioral|Physical activity regime|Information already included in arm descriptions
79576910|NCT05342090|Other|Structured Counselling Tool|Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
79576911|NCT05339100|Drug|Anifrolumab|Participants will receive SC doses anifrolumab via AI or APFS.
79273366|NCT02149589|Procedure|Mechanical ventilation|
79273367|NCT02223091|Behavioral|Consultation by a trained physician|
79273368|NCT02223091|Behavioral|Consultation by an untrained physician|
79273369|NCT02394327|Device|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
79273370|NCT02394327|Device|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
79576912|NCT05339100|Device|Autoinjector|Autoinjector will be use to administer single SC dose of anifrolumab.
79871367|NCT03440970|Drug|Lysine Chloride|Patients will receive the study drug twice a day for 5 days.
79871368|NCT03440970|Other|Placebo|Patients will receive the placebo twice a day for 5 days.
79576913|NCT05339100|Device|Accessorized Pre-Filled Syringe|Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
79576914|NCT05337514|Behavioral|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
79576915|NCT05337514|Behavioral|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
79576916|NCT05327153|Behavioral|Acceptance and Commitment Therapy|The theoretical foundation of ACT is Relational Frame Theory (RFT) based on the functional contextualism philosophy, which suggests that the main psychological problem derived verbal and cognitive interaction with environment, leading to behaviors contrary to long-term values and psychological inflexibility. The psychopathological model of ACT includes six core parts: experiential avoidance, cognitive fusion, attachment to the conceptualized self, conceptualized past and feared future, lack of value clarity, inaction.
79576917|NCT05323838|Behavioral|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
79576918|NCT05323838|Procedure|Blood extraction|Blood collection by qualified personnel.
79576919|NCT05323838|Behavioral|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
79576920|NCT05323838|Dietary Supplement|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
79576921|NCT05302999|Drug|Gabapentin|Generic gabapentin
79576922|NCT05302999|Drug|Placebo|Inert cellulose
79576923|NCT05298865|Behavioral|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
79576924|NCT05298865|Behavioral|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
79576925|NCT05298150|Other|Dynamic cycling|The dynamic cycling involves smart bike that changes according to participants' performance.
79576926|NCT05298150|Other|Forced cycling|The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
79576927|NCT05297500|Device|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
79871369|NCT03420833|Device|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
79871370|NCT03379649|Combination Product|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
79273371|NCT02228161|Behavioral|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
79273372|NCT02228239|Drug|Esketamine|Esketamine 84 milligram (mg) [3*1 of spray in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
79273373|NCT02228239|Drug|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
79273374|NCT02228239|Drug|Placebo (Matched to Esketamine)|Placebo [3*1 in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
79273375|NCT02228239|Drug|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
79576928|NCT05295797|Behavioral|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
79576929|NCT05291520|Biological|VH3810109|VH3810109 will be administered.
79576930|NCT05291520|Biological|rHuPH20|rHuPH20 will be administered.
79576931|NCT05285306|Behavioral|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
79736495|NCT04220476|Drug|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
79736496|NCT00937833|Procedure|Prostatectomy|
79736497|NCT00937833|Device|Surgisis Male Sling|
79736498|NCT02695810|Drug|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
79736499|NCT02695810|Drug|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
79736500|NCT02695810|Behavioral|Exercise|Interval training, 5 times per week, 30 min per session
79273376|NCT03167385|Drug|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
79736501|NCT04204161|Biological|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10^5/kg-2.5x10^8/kg .
79871371|NCT03379649|Combination Product|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
79871372|NCT03368950|Other|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
79871373|NCT03363893|Drug|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
79871374|NCT03363893|Drug|Fulvestrant|Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
79871375|NCT03339128|Drug|Eluxadoline|Oral tablets
79403124|NCT04194463|Other|ChemoFit exercise prehabilitation intervention|Exercise intervention consists of walking monitored by wearing a pedometer device. After a baseline measurement of participant's walking activity is done, increase in step count from baseline step count is prescribed. This increase in step count is achieved by walking or jogging at moderate intensity for a target of 30 minutes per day, each day. Participants are also encouraged to perform other physical if they wish and are able to. Patients are regularly contacted by a member of the research team on a weekly basis and given an option to maintain or to increase their step count further. The same approach is used after each week of the intervention. Strengthening exercises will form a further part of the exercise intervention. They are performed every day, 7 days a week. Patients are supplied with resistance bands with handles. They are educated on how to perform two repetitions of 5 simple exercises, each for 1 minute duration.
79576932|NCT05271006|Behavioral|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
79576933|NCT05265806|Drug|Intranasal oxytocin|Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
79273377|NCT03543527|Other|no intervention|no intervention
79576934|NCT05265806|Drug|Oral oxytocin|Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
79576935|NCT05265806|Drug|Placebo|An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
79576936|NCT05256238|Other|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,…~week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
79576937|NCT05255081|Device|Adspray|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
79576938|NCT05255081|Procedure|Placebo-control|Spray with saline would be applied to organs under incision
79736502|NCT02753764|Drug|AZD7624|
79736503|NCT02753764|Drug|prednisone|oral prednisone 20 mg bid for one week
79736504|NCT02753764|Drug|Placebo|
79736505|NCT05382429|Procedure|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
79871376|NCT03339128|Drug|Placebo|Oral tablets
79871377|NCT03325088|Procedure|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
79273378|NCT03167775|Drug|Elemene Injection/Elemene Oral Emulusion|
79736506|NCT05382429|Procedure|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
79736507|NCT02695654|Drug|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
79736508|NCT02695654|Drug|Clonidine|Clonidine 100 mcg
79273379|NCT02228317|Device|Telemedicine consultation|Telemedicine consultation done by telephone or video
79273380|NCT02149745|Procedure|Calling the patient's name|calling the patient's name during anesthesia reversal
79273381|NCT02149745|Procedure|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
79273382|NCT02142569|Drug|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
79273383|NCT02142569|Drug|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
79736509|NCT02751736|Dietary Supplement|CJLP243|Perioperative administration till postoperative weeks 3
79736510|NCT02751736|Dietary Supplement|Placebo|Perioperative administration till postoperative weeks 3
79736511|NCT02751658|Other|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
79736512|NCT00635674|Device|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
79871378|NCT03325088|Procedure|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
79871379|NCT03325088|Procedure|Bronchial alveolar enema|For participants who had signed ancillary research consent
79273384|NCT02142569|Drug|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
79576939|NCT05243017|Genetic|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
79576940|NCT05242419|Drug|Sodium Chloride Injection|0.9% Sodium Chloride Injection
79576941|NCT05242419|Drug|Huperzine A Injection|Huperzine A Injection
79576942|NCT05241301|Other|one to one interviews|one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
79576943|NCT05232227|Drug|Primaquine double dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
79576944|NCT05232227|Drug|Primaquine single dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
79736513|NCT02696122|Procedure|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
79736514|NCT02696122|Procedure|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
79736515|NCT02753608|Other|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
79736516|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
79736517|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
79871380|NCT03251599|Drug|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
79736518|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
79871381|NCT03251599|Drug|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
79871382|NCT03241056|Behavioral|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
79273385|NCT02142569|Device|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
79273386|NCT02394171|Behavioral|Group Cohesion|See description in arm/group above
79273387|NCT02228473|Drug|Glycopyrrolate|Glycopyrrolate will be administered.
79273388|NCT02228473|Drug|Atropine|Atropine will be administered.
79403125|NCT04194619|Other|Questionnaire|Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.
79576945|NCT05225363|Biological|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
79576946|NCT05225363|Drug|Cyclophosphamide|Given IV
79273389|NCT02146235|Behavioral|Psycho-Music Therapy|
79273390|NCT02228551|Other|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
79273391|NCT02146313|Drug|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
79403126|NCT04748029|Other|Systemic immune inflammation index|The systemic immune inflammation index (SII) was calculated using the formula, SII = platelet count x neutrophil count / lymphocyte count. Systemic immune inflammation index (SII) is a new index related to systemic inflammation calculated by the numbers of lymphocytes, neutrophils and platelets in peripheral blood.
79576947|NCT05225363|Drug|Fludarabine|Given IV
79576948|NCT05221229|Drug|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
79736519|NCT01135511|Drug|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
79576949|NCT05215587|Device|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
79736520|NCT01135511|Drug|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
79871383|NCT03241056|Other|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
79871384|NCT03231709|Drug|Trelagliptin|Trelagliptin tablets
79736521|NCT02753140|Drug|Cetuximab|
79871385|NCT03231709|Drug|Alogliptin|Alogliptin tablets
79871386|NCT03199651|Other|Best Practice|Receive usual care
79871387|NCT03199651|Procedure|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
79871388|NCT03199651|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
79736522|NCT02753140|Radiation|radiation|
79871389|NCT03199651|Other|Laboratory Biomarker Analysis|Correlative studies
79576950|NCT05211700|Other|This is an observational study, there is no intervention in this study.|There is no intervention in this study
79871390|NCT03199651|Other|Medical Chart Review|Undergo medical record abstraction
79871391|NCT03199651|Other|Quality-of-Life Assessment|Ancillary studies
79871392|NCT03199651|Other|Questionnaire Administration|Ancillary studies
79871393|NCT03199651|Behavioral|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
79871394|NCT03199469|Genetic|AT132|AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
79871395|NCT03180502|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
79871396|NCT03180502|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
79871397|NCT03180502|Drug|Temozolomide|Chemotherapy drug
79871398|NCT03138863|Device|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio-opaque inclusion
79871399|NCT03138863|Device|Catheter System|100 cm tapered micro-catheter
79871400|NCT03121248|Radiation|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
79871401|NCT03121248|Radiation|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
79871402|NCT03121248|Radiation|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
79273392|NCT02223169|Dietary Supplement|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
79273393|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
79273394|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
79273395|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
79576951|NCT05211063|Dietary Supplement|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
79576952|NCT05211063|Dietary Supplement|Placebo|Daily intake of one tablet for 42 days.
79736523|NCT02753140|Drug|Docetaxel|
79736524|NCT02753140|Drug|Cisplatin|
79736525|NCT02753218|Drug|Midazolam|
79736526|NCT02753218|Drug|LEO 32731|
79736527|NCT05429554|Drug|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
79736528|NCT04220164|Other|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
79736529|NCT05429398|Drug|Linperlisib Tablet|"Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
79871403|NCT03121248|Radiation|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
79871404|NCT03121248|Radiation|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
79871405|NCT03121248|Radiation|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
79871406|NCT03121248|Radiation|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
79871407|NCT03121248|Radiation|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
79871408|NCT03117972|Drug|FOLFOXIRI|12 cycles
79871409|NCT03117972|Drug|FOLFOX|12 cycles
79871410|NCT03117972|Drug|FOLFIRI|12 cycles
79871411|NCT03117972|Drug|Bevacizumab|12 cycles
79871412|NCT03117972|Drug|LV5FU2|Maintenance chemotherapy
79871413|NCT03117972|Drug|Capecitabine|Maintenance chemotherapy
79871414|NCT03108066|Drug|PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment of VHL disease-associated ccRCC.
79871415|NCT03054896|Drug|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
79871416|NCT03054896|Other|DA-EPOCH-R|Intensive chemotherapy regiment
79871417|NCT03054896|Other|R-CHOP|Intensive chemotherapy regiment
79871418|NCT03053193|Diagnostic Test|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
79871419|NCT03043573|Behavioral|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
79736530|NCT04220086|Procedure|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
79736531|NCT04220086|Procedure|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
79736532|NCT04220086|Other|No intervention|No intervention for healthy controls
79576953|NCT05210231|Other|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
79576954|NCT05203120|Radiation|Proton therapy|All patients will receive proton therapy 67.5Gy/15fx
79576955|NCT05195840|Behavioral|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
79736533|NCT04088968|Behavioral|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
79736534|NCT05429086|Drug|Remimazolam combined propofol|Remimazolam combined propofol
79736535|NCT05429086|Drug|Remimazolam|remimazolam only
79736536|NCT05429086|Drug|Propofol|propofol only
79736537|NCT04219930|Diagnostic Test|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
79736538|NCT00638248|Drug|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
79736539|NCT00638248|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
79736540|NCT00638248|Drug|Placebo|Placebo i.v. bolus
79736541|NCT04219306|Other|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
79736542|NCT04219150|Device|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
79736543|NCT04219150|Drug|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
79736544|NCT04220242|Other|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
79736545|NCT04220242|Other|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
79736546|NCT04220242|Other|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
79736547|NCT04468204|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
79736548|NCT04468204|Device|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
79871420|NCT03043573|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
79871421|NCT03032172|Drug|Risdiplam|Risdiplam will be administered orally once daily.
79871422|NCT03028337|Radiation|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
79871423|NCT03028337|Behavioral|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
79871424|NCT03014479|Drug|Trelagliptin|Trelagliptin 100 mg or 50 mg
79871425|NCT03014479|Drug|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
79273396|NCT02142647|Behavioral|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
79273397|NCT02142647|Behavioral|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
79273398|NCT02223247|Drug|TVB-2640|
79273399|NCT03167463|Procedure|flap|Repair choanal atresia with using flap during surgery
79273400|NCT02146391|Drug|Androxal 25 mg Capsules|
79871426|NCT02937818|Drug|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
79871427|NCT02937818|Drug|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
79403127|NCT04193839|Other|Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA)|Computerized provider order entry (CPOE) refers to the process of providers entering and sending treatment instructions - including medication, laboratory, and radiology orders - via a computer application rather than paper, fax, or telephone. The bar Code Medication Administration (BCMA) is a system that consists of a bar code reader, a portable or desktop computer with wireless connection, a computer server, and some software. Before the administration of medications to the patients the patient unique barcode identification is scanned in order to verify the patient's identity.
79403128|NCT04020601|Drug|Ropivacaine|Local anesthetic injection
79576956|NCT05195840|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
79736549|NCT04219462|Device|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
79403129|NCT04020601|Drug|Dextrose|Sham injection
79403130|NCT04198597|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
79403131|NCT04198597|Behavioral|Process-based Cognitive Behavioral Therapy|Please see arm/group descriptions
79871428|NCT02937818|Drug|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
79273401|NCT03115515|Drug|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
79403132|NCT04029805|Combination Product|Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
79273402|NCT02223403|Dietary Supplement|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
79273403|NCT02223403|Dietary Supplement|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
79403133|NCT04029805|Combination Product|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
79273404|NCT02146469|Biological|2 doses with an 3 months interval|varicella vaccination
79736550|NCT04219462|Device|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
79736551|NCT04219852|Other|data collection|data collection
79736552|NCT04467736|Device|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
79736553|NCT04218994|Other|Flossing technique|Subjects instructed on flossing technique
79736554|NCT05428228|Other|TP1|Participants will be administered TP1 during one of the experimental visits.
79736555|NCT05428228|Other|TP2|Participants will be administered TP2 during one of the experimental visits.
79736556|NCT05428228|Other|Placebo|Participants will be administered placebo during one of the experimental visits.
79736557|NCT04219228|Diagnostic Test|Ophthalmic examinations|Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
79736558|NCT04219228|Device|Wearable devices|Physical activity, light intensity, and visual information will be measured with wearable devices.
79736559|NCT00624728|Radiation|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
79871429|NCT02927691|Device|EMST|
79871430|NCT02927691|Behavioral|smTAP|
79871431|NCT02916511|Drug|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5
79871432|NCT02916511|Drug|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw*5
79871433|NCT02916511|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
79871434|NCT02872805|Other|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
79403134|NCT04193995|Behavioral|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
79576957|NCT05194800|Other|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
79736560|NCT01184846|Biological|10% liquid formulation of human immunoglobulin|
79576958|NCT05189106|Drug|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
79576959|NCT05184842|Drug|Venetoclax|Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)
79736561|NCT01180400|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
79403135|NCT04193761|Diagnostic Test|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
79403136|NCT03965221|Behavioral|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
79736562|NCT01180400|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
79576960|NCT05184842|Drug|Decitabine|Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
79736563|NCT04316000|Other|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
79736564|NCT04316000|Procedure|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
79736565|NCT04316000|Other|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
79576961|NCT05149976|Diagnostic Test|Voice recording before and after dietary intake|"A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
79576962|NCT05140018|Procedure|Kidney Transplantation|All participants will receive a kidney transplantation from a living donor or deceased donor
79576963|NCT05140018|Combination Product|Immunosuppression|All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
79736566|NCT04316000|Other|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
79736567|NCT01180244|Device|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
79736568|NCT01180244|Device|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
79736569|NCT01191086|Drug|USL255|
79736570|NCT04316312|Device|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
79273405|NCT02146469|Biological|A second dose with an 1 year interval|varicella vaccine
79273406|NCT02146469|Biological|A second dose with an 3 year interval|varicella vaccine
79273407|NCT02146469|Biological|A second dose with an 5 year interval|varicella vaccine
79736571|NCT01088412|Drug|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
79273408|NCT02146469|Biological|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
79273409|NCT02146469|Biological|1 dose MMR|MMR
79273410|NCT03115593|Procedure|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
79576964|NCT05140018|Procedure|Nephrectomy (kidney donation)|All kidney donors will receive a nephrectomy for kidney donation
79736572|NCT04198714|Procedure|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
79871435|NCT02872805|Behavioral|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
79871436|NCT02864394|Biological|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
79273411|NCT03115593|Procedure|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
79273412|NCT03543449|Other|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
79576965|NCT05135650|Other|Questionnaire Administration|Ancillary studies
79871437|NCT02864394|Drug|Docetaxel|Docetaxel administered IV at 75 mg/m^2 on Day 1 of each 21-day cycle as per the approved product label.
79871438|NCT02836418|Drug|ATYR1940|Concentrate for solution for infusion
79576966|NCT05135650|Biological|Sotrovimab|Given IV
79871439|NCT02823860|Other|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
79403137|NCT03965221|Behavioral|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
79736573|NCT00635752|Other|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
79871440|NCT02773849|Biological|ADSTILADRIN|
79736574|NCT00635752|Other|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
79736575|NCT04218916|Drug|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
79736576|NCT04218916|Drug|Placebo|2 placebo capsules once, three times a day
79871441|NCT02727270|Other|No Intervention - Observational Study|No Intervention - Observational Study
79871442|NCT02684006|Drug|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
79871443|NCT02684006|Drug|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
79871444|NCT02684006|Drug|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
79871445|NCT02654990|Drug|panobinostat capsules|20mg, 10mg or 15mg (for dose reductions only)
79871446|NCT02654990|Drug|bortezomib injection|1.3mg/m^2 sub-cutaneous administration; Cycle 1-4: 2 weeks on/1 week off twice a week for patients ≤ 75 years at time of screening; once a week for patient > 75 years Cycle 5+: once a week for all patients
79871447|NCT02654990|Drug|dexamethasone tablets|pre and 24h after BTZ administration; patients ≤ 75 years at time of screening: 20mg/dose patients > 75 years: 10mg/dose
79871448|NCT02606422|Device|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
79871449|NCT02606422|Device|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
79273413|NCT04319653|Device|Dynamic pelvic MRI with intravaginal probe with pressure sensor|Dynamic pelvic MRI with intravaginal probe and intravaginal and intrarectal opacification gel
79273414|NCT03115281|Device|PCI|PCI
79273415|NCT02142725|Drug|LT-02|four times per day
79273416|NCT02142725|Drug|LT-02|two times per day
79273417|NCT02142725|Drug|Placebo|four times per day
79273418|NCT02228629|Device|CrocsRx Medical Silver cloud clogs|
79403138|NCT04194073|Device|Pulse oximeter calibration population (NightOwl)|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
79576967|NCT05135650|Procedure|Biospecimen Collection|Undergo blood and nasal swab sample collection
79576968|NCT05121688|Other|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
79576969|NCT05111834|Behavioral|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
79576970|NCT05111834|Behavioral|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
79576973|NCT05096936|Other|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
79871450|NCT02583672|Drug|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
79736577|NCT05383924|Procedure|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
79736578|NCT05383924|Procedure|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
79871451|NCT02542839|Device|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
79871452|NCT02542839|Device|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
79576974|NCT05096936|Other|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
79576975|NCT05092100|Behavioral|Visual stimulus similarity|Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
79871453|NCT02542839|Other|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
79736579|NCT04948840|Biological|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
79736580|NCT05318560|Drug|Lidocaine 2% Injectable Solution|for MPS
80029527|NCT03801356|Drug|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
79736581|NCT05318560|Drug|Ozone|for MPS
79576976|NCT05092100|Other|fMRI|fMRI will be used to measure patterns of BOLD activity during learning.
79736582|NCT05318560|Other|stretching exercise|for MPS
79871454|NCT02542839|Other|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
79871455|NCT02542839|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
79736583|NCT04171258|Drug|Botulinum toxin type A injection|Experimental
79871456|NCT02542839|Procedure|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
79871457|NCT02516241|Drug|MEDI4736 (Durvalumab)|IV infusion
79871458|NCT02516241|Drug|Tremelimumab|IV infusion
79871459|NCT02516241|Drug|Cisplatin|IV infusion
80029528|NCT03786003|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
80029529|NCT03786003|Procedure|Thoracotomy|Standard thoracotomy
80029530|NCT03664037|Drug|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
79273419|NCT03744377|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
79273420|NCT04225273|Device|Sculptra Aesthetic 8 ml and Lidocaine|Treatment of nasolabial folds
79273421|NCT02228707|Drug|BIIB061|Participants receive BIIB061
79273422|NCT02228707|Other|Placebo|Matched placebo
79273423|NCT02146547|Drug|Aripiprazole|Administration in once-a-day schedule without regard to meals.
79273424|NCT02146547|Drug|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
79273425|NCT02146547|Drug|Paliperidone|Administration once a day orally standardised in relation to food intake.
79273426|NCT02146547|Drug|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
79273427|NCT02228785|Biological|G17DT|
79576977|NCT05092100|Other|Eye tracking|Eye tracking will be used to measure patterns of eye movements when viewing images.
79576978|NCT05090163|Other|PREP Plus|Group based exercise in addition to PREP exercises
79871460|NCT02516241|Drug|Carboplatin|IV infusion
79871461|NCT02516241|Drug|Gemcitabine|IV infusion
79871462|NCT02491528|Biological|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
80029531|NCT03664037|Drug|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
80029532|NCT03659981|Other|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
79871463|NCT02491528|Biological|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
79871464|NCT02464878|Drug|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
79871465|NCT02464878|Procedure|Islet Transplantation|
79403139|NCT03369444|Biological|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
79403140|NCT04029727|Dietary Supplement|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
79403141|NCT04029727|Dietary Supplement|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
79403142|NCT04193683|Other|Myofascial Release Technique|Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.
79403143|NCT04193683|Other|Sham-Ultrasound|Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
79403144|NCT04029571|Drug|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
79403145|NCT04029571|Other|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
79403146|NCT01677624|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
79403147|NCT03318666|Behavioral|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~adolescents will have access to the website specifically for adolescents: sova.pitt.edu~parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments."
79576979|NCT05090163|Other|PREP|Group based exercise
79273428|NCT02394015|Drug|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
79576980|NCT05082844|Radiation|MRI assessment|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
79576981|NCT05073822|Drug|Tacrolimus|reduction of both standard Tacrolimus & Mycophenolate mofetil does in one arm
79576982|NCT05047952|Drug|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
79273429|NCT05745597|Other|Follow up|Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
79576983|NCT05047952|Drug|Placebo|A placebo pill will be taken once daily.
79576984|NCT05028660|Diagnostic Test|GAG score|blood and urine samples to determine GAG scores
79576985|NCT05009680|Drug|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
79576986|NCT05009680|Drug|Placebo|Placebo is administered orally twice a day
79871466|NCT02464878|Drug|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
79871467|NCT02464878|Drug|Basiliximab|Basiliximab will be used for subsequent transplants.
79576987|NCT05001828|Drug|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
79736584|NCT04171258|Drug|Botulinum Toxin Type A Injection [Botox]|Active Comparator
79736585|NCT04165564|Other|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
79736586|NCT04165564|Other|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
79736587|NCT05247814|Genetic|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
79736588|NCT05247814|Other|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
79403148|NCT03318666|Other|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
79736589|NCT05247814|Other|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
79403149|NCT03913039|Procedure|Transperineal biopsy Protocol|"Transperineal biopsy approach with avoidance of rectal flora~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~Multi-antibiotic prophylaxis~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
79576988|NCT05000866|Behavioral|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
79736590|NCT02695576|Procedure|Lumbar Fusion Surgery|Interbody fusion with fixation
79871468|NCT02464878|Drug|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
79871469|NCT02399995|Behavioral|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~Baseline sociodemographic and clinical variable data sheet (RSA)~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Post surgical follow up disease status and treatment assessment questionnaire~At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
79736591|NCT02695576|Other|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
79736592|NCT02695576|Other|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
79736593|NCT01086384|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
79736594|NCT01086384|Drug|Fluticasone furoate|Inhaled corticosteroid
79736595|NCT00635986|Drug|Fentanyl|100 mcg Fentanyl intravenous or epidural route
79736596|NCT04866784|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
79736597|NCT01127633|Drug|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
79736598|NCT01127633|Drug|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
79736599|NCT04799626|Drug|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
79736600|NCT02751112|Biological|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
79736601|NCT00636064|Drug|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
80029533|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
80029534|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
80029535|NCT03567356|Other|"MAT-PLUS Helping Hands"|"1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
79277652|NCT05791760|Behavioral|Compassion-focused therapy (CFT) for complex PTSD|The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.
80029536|NCT03538457|Drug|Paracetamol|Patients are tested for their normal prescription paracetamol medication
80029537|NCT03535376|Drug|Valsartan|Patients are tested for their normal prescription valsartan medication
80029538|NCT03514485|Behavioral|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
80029539|NCT03514485|Behavioral|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
79273430|NCT04641559|Other|Personalized nutrition group|"A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI."
80029540|NCT03514485|Behavioral|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~Asthma education for school staff/personnel at the start of each school year.~School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
80029541|NCT03502200|Device|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
80029542|NCT03502200|Other|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
79273431|NCT04641559|Other|Personalized Plan group|Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.
79273432|NCT04641559|Other|Control group|The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
79273433|NCT02142881|Other|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of <130 mmHg.
79403150|NCT05097378|Drug|Encorafenib + Binimetinib|"Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity"
79403151|NCT05097378|Drug|Standard Adjuvant Treatment|Standard Adjuvant Treatment
79403152|NCT05097300|Other|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
79736602|NCT00636064|Drug|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
79871470|NCT02372097|Drug|SYR-472|SYR-472 25mg, 50mg
79871471|NCT02309151|Procedure|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
79871472|NCT02212860|Radiation|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
79871473|NCT02162810|Drug|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
80029543|NCT03336242|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
80029544|NCT03334435|Drug|Baricitinib|Administered orally
79871474|NCT02162810|Drug|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
79273434|NCT02142881|Other|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
79273435|NCT05745519|Other|Pittsburgh sleep quality index (PSQI)|The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.
79736603|NCT00636064|Other|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
79736604|NCT01122173|Device|Ablation|Atrial fibrillation ablation procedure
79736605|NCT02751034|Device|Neuramis® Deep Lidocaine|HA filler
79736606|NCT02751034|Device|Restylane® PERLANE-L|HA filler
79736607|NCT02750878|Other|Informational Handout|
79736608|NCT04217668|Drug|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
79736609|NCT01127165|Drug|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1~2 weeks to 3~4mg/kg/day.
79736610|NCT01127165|Drug|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2~4 weeks to 6~8mg/kg/day.
79736611|NCT02750722|Device|Flutter®|Acute exercise with Flutter® breathing therapy.
79273436|NCT05745519|Device|ANSWatch|Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
79576989|NCT05000866|Behavioral|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
79576990|NCT04998734|Diagnostic Test|ASI-SR|Psychometric properties of ASI-SR
79736612|NCT02750722|Device|No Flutter®|Acute exercise without Flutter® breathing therapy.
79736613|NCT04110106|Other|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H&Y scale by a neurologist.
79736614|NCT00941733|Device|IN.PACT Amphirion|Balloon Angioplasty
79736615|NCT00941733|Device|Standard PTA|Balloon Angioplasty
79736616|NCT04278508|Drug|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
79736617|NCT04454242|Other|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
79736618|NCT05382351|Drug|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
79736619|NCT05382351|Drug|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
79273437|NCT02259283|Device|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
79871475|NCT02000089|Drug|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
79273438|NCT02146625|Drug|CJ-40002|
79273439|NCT04832295|Other|photo-supported conversations|"Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs."
79581496|NCT06070857|Drug|Placebo|"Drug: LV232 1mg Group:~6 subjects will receive LV232 1mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 2mg Group:~6 subjects will receive LV232 2mg, orally; 2 subjects will receive placebo, orally.~Other Names: Placebo~Drug: LV232 4mg Group:~6 subjects will receive LV232 4mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 8mg Group:~6 subjects will receive LV232 8mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo~Drug: LV232 20mg Group:~6 subjects will receive LV232 20mg, orally; 2 subjects will receive placebo, orally.~Other Names:Placebo"
79736620|NCT04218760|Drug|Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
79736621|NCT04218760|Other|Blood sample|3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
79736622|NCT02750488|Drug|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
79871476|NCT02000089|Diagnostic Test|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
80029545|NCT03334435|Drug|Placebo|Administered orally
79736623|NCT02750488|Other|Untreated skin|One site is patched without treatment as control
79736624|NCT00604539|Drug|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
79273440|NCT04832295|Other|Care as usual|Medication, psychological treatment
79403153|NCT05097300|Other|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
79403154|NCT05097300|Other|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
79736625|NCT00604539|Drug|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
79736626|NCT02750254|Drug|Fludarabine|
79736627|NCT02750254|Radiation|Fractionated total body irradiation|
79736628|NCT02750254|Drug|Busulfan|
79736629|NCT02750254|Drug|Cyclophosphamide|
79273441|NCT02146703|Drug|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m2 iv on day 1, 8~S-1 60 mg/day po on day 1-14"
79403155|NCT05097300|Other|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
79403156|NCT05085600|Other|Exercise|"Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side."
79576991|NCT04997577|Behavioral|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
79576992|NCT04997577|Behavioral|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
79736630|NCT02750254|Radiation|Single dose total body irradiation|
79273442|NCT04209283|Behavioral|Visuospatial interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
79273443|NCT02228863|Other|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
79736631|NCT02750254|Drug|Melphalan|
79273444|NCT02228863|Other|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
79273445|NCT02228863|Other|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
79273446|NCT02228863|Other|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
79277653|NCT05791747|Other|semi-structured interviews|This is an observational study Patients included in the study will conduct semi-structured interviews to discuss their knowledge and/or experience with supportive care, particularly hypnosis
79736632|NCT02750254|Drug|Granulocyte-colony stimulating factor|
79736633|NCT02750254|Procedure|Stem cell transplant|
79736634|NCT02750254|Drug|Azacitidine|
79736635|NCT00941655|Drug|Oxaliplatin|"Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m^2 over 120 minutes,"
79736636|NCT00941655|Drug|Irinotecan|Irinotecan 165 mg/m^2 IV over 90 minutes
79736637|NCT00941655|Drug|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m^2 continuous intravenous over 48 hours."
79736638|NCT00941655|Drug|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m^2 intravenous over 120 minutes."
79576993|NCT04991792|Other|Intervention Group 1: Infant Formula with synbiotics|Infants will receive infant formula during the first 6 months of life
79576994|NCT04991792|Other|Intervention Group 2: Infant Formula with prebiotics|Infants will receive infant formula during the first 6 months of life
79736639|NCT00941655|Procedure|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
79736640|NCT00605787|Drug|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
79736641|NCT00939393|Device|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
79736642|NCT00939393|Device|Balloon Sinuplasty|Balloon dilatation of sinuses
79871477|NCT02000089|Other|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
79871478|NCT01709435|Drug|Cabozantinib S-malate|Given PO
79871479|NCT01709435|Other|Laboratory Biomarker Analysis|Correlative studies
79871480|NCT01709435|Other|Pharmacological Study|Correlative studies
79403157|NCT05085600|Other|Manual Therapy + Exercise|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
79403158|NCT04199845|Dietary Supplement|PS128|PS128 or placebo will be given twice daily for 8 weeks.
79736643|NCT05382273|Behavioral|T-Break Guide|"The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~The second week focuses on the emotional experience (e.g., anxiety, boredom).~The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy."
79736644|NCT05382195|Other|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
79736645|NCT04441996|Biological|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
79736646|NCT04441996|Other|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
79403159|NCT05084664|Device|electrical stimulation|premodulated current+ exercises
79403160|NCT05084664|Device|electrical stimulation|diadynamic current+ exercises
79576995|NCT04991792|Other|Control Group 1 and 2: Infant Formula without synbiotics|Infants will receive infant formula during the first 6 months of life
79576996|NCT04989881|Device|da Vinci Simulator|Single training session
79576997|NCT04989881|Device|Laparascopic training box|Single training session
79736647|NCT04267965|Procedure|parathyroidectomy plus bilateral thymectomy and autotransplantation|Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
79736648|NCT05380869|Diagnostic Test|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
79736649|NCT02750020|Other|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
79576998|NCT04985422|Behavioral|Smartphone-based Daily Ecological Momentary Intervention|Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.
79576999|NCT04985422|Behavioral|Smartphone-based Weekly-delivered Information|Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
79871481|NCT01585480|Behavioral|Weight Gain Prevention Intervention|"Behavioral Approaches~Distribution of pedometers~Traffic light labeling in worksite cafeteria and vending machines~Informational & Persuasive Messages~Stair use prompts~Posters, pamphlets, table toppers~Website~Social Approaches~a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~Environmental Changes~Traffic light labeling~1/2 portions at 1/2 price~Walking routes~Introduction of healthier foods~Rearrangement of foods in the cafeteria~Adjusting serving spoon size"
79871482|NCT01571895|Drug|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 [CXCL8; formerly interleukin (IL)-8] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
79871483|NCT01358877|Drug|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
79871484|NCT01358877|Drug|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
79871485|NCT01358877|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
79871486|NCT01358877|Drug|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
79273447|NCT02782325|Biological|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
79273448|NCT02782325|Biological|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
79736650|NCT04190836|Behavioral|Self-Managed Exercise Strategy|The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
79736651|NCT00936117|Drug|Posaconazole|200 mg (liquid) by mouth 3 times per day.
79736652|NCT04218682|Behavioral|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
79871487|NCT01358877|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
79273449|NCT02693691|Device|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
79273450|NCT02223481|Drug|Terbogrel low dose|
79403161|NCT04193137|Diagnostic Test|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
79273451|NCT02223481|Drug|Terbogrel high dose|
79403162|NCT05060484|Biological|SCT1000|HPV vaccine
79577000|NCT04970953|Procedure|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
79273452|NCT02223481|Drug|Placebo|
79403163|NCT05060484|Biological|Gardasil®9|HPV vaccine
79577001|NCT04965454|Combination Product|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
79577002|NCT04941924|Procedure|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
79577003|NCT04941924|Device|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
79273453|NCT02146781|Biological|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
79403164|NCT05060484|Biological|Gardasil®|HPV vaccine
79736653|NCT04267653|Drug|Lactoferrin Bovine|treatment for 30 days
79736654|NCT04267653|Drug|Ferrous Sulfate|treatment for 30 days
79736655|NCT04088500|Biological|Nivolumab|Specific dose on specific days
79403165|NCT05060484|Other|placebo|adjuvent
79403166|NCT04193059|Drug|Paclitaxel|paclitaxel 80 mg/m^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
79736656|NCT04088500|Biological|Ipilimumab|Specific dose on specific days
79736657|NCT05379153|Device|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
79736658|NCT05379153|Device|Sham Intervention|Undergo placebo procedure
79871488|NCT01358877|Drug|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
79871489|NCT01358877|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
79871490|NCT01358877|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
79736659|NCT05379153|Other|Questionnaire Administration|Ancillary studies
79871491|NCT01358877|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
79871492|NCT01358877|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
79871493|NCT00670358|Biological|pegfilgrastim|
79277654|NCT05791734|Other|assessing preoperative skin cleanliness|2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
79403167|NCT04193059|Drug|Carboplatin|carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
79403168|NCT04193059|Drug|Epirubicin|epirubicin 90 mg/m^2 ivgtt d1, 21 days per cycle, 4 cycles.
79577004|NCT04939454|Procedure|quadricipital biopsy|The primary endpoint will be evaluated by histological examination only. The technique of percutaneous biopsy using the modified Bergström needle technique is currently considered the best alternative in the context of research, as it allows sufficient material to be obtained for various analyses and is much less invasive than the reference technique (surgical biopsy). Indeed, unlike surgical biopsy which requires an operating room and is a relatively heavy procedure (two suture planes, skin incision of several centimeters, resting for 48 hours after the procedure...), percutaneous biopsy by the modified Bergström technique can be performed in a consultation room, requires only one stitch, and allows resumption of walking 30 minutes after the end of the procedure.
79577005|NCT04937998|Procedure|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
79273454|NCT02146781|Other|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
79273455|NCT04203667|Device|EndoRotor Resection|"The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter."
79273456|NCT02393469|Other|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
79736660|NCT05379153|Other|Quality of Life Assessment|Ancillary studies
79736661|NCT04218214|Other|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
79736662|NCT05379075|Other|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
79871494|NCT00670358|Biological|rituximab|
79871495|NCT00670358|Drug|cyclophosphamide|
79871496|NCT00670358|Drug|doxorubicin hydrochloride|
79871497|NCT00670358|Drug|lenalidomide|
79871498|NCT00670358|Drug|prednisone|
79871499|NCT00670358|Drug|vincristine sulfate|
79871500|NCT00670358|Genetic|polymorphism analysis|
79871501|NCT00670358|Other|laboratory biomarker analysis|
79871502|NCT00643279|Device|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
79871503|NCT00643279|Other|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
79871504|NCT00633087|Drug|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
79871505|NCT00182728|Procedure|surgery|conventional
79871506|NCT00182728|Procedure|therapy|neoadjuvant
79871507|NCT00182728|Radiation|radiation therapy|intraoperative radiation therapy
79871508|NCT00176631|Dietary Supplement|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
79871509|NCT00176631|Drug|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
79871510|NCT00002965|Biological|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
79871511|NCT06050473|Procedure|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
79871512|NCT06050473|Procedure|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
79871513|NCT06050460|Drug|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
79871514|NCT06050460|Other|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
79871515|NCT06050447|Procedure|Right hemicolectomy|Resection of the caecum and ascending colon is appropriate for patients with tumors located anywhere from caecum to the transverse colon
80029546|NCT03333395|Drug|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
79273457|NCT02393469|Other|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
79273458|NCT02782169|Drug|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
79273459|NCT02782169|Drug|Placebo|Matching placebo capsule with excipient to match Pregabalin
79577006|NCT04937998|Procedure|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
79403169|NCT04193059|Drug|Cyclophosphamide|cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle, 4 cycles.
79403170|NCT04193059|Drug|Trastuzumab|trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
79577007|NCT04937309|Device|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
79577008|NCT04937309|Drug|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
79736663|NCT05379075|Other|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
79871516|NCT06050447|Procedure|Left hemicolectomy|Resection of the sigmoid colon is appropriate for patients with tumors located anywhere from the distal transverse colon to the rectosigmoid junction.
79273460|NCT03544151|Device|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
79273461|NCT02393313|Procedure|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
79273462|NCT02393313|Device|Rayner T-flex Toric IOLs|
79273463|NCT04163185|Drug|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
79273464|NCT04163185|Drug|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
79273465|NCT02393391|Device|Neuroelectrics STARSTIM|
79403171|NCT04193059|Drug|Pertuzumab|pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
79403172|NCT04193059|Drug|Docetaxel|docetaxel 100 mg/m^2 ivgtt d1, 21 days per cycle, 4 cycles.
79577009|NCT04937309|Device|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
79736664|NCT02750098|Other|Glucose measurement|"Elective cataract surgery~Blood glucose measurement - glucometer~Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~Perioperative Hemoglobin A1c level - blood laboratory test"
79736665|NCT01082874|Drug|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
79736666|NCT01082874|Drug|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
79871517|NCT06050447|Procedure|Sigmoid colon resection|Resection of the sigmoid colon is appropriate for patients with tumors located in the sigmoid colon
79577010|NCT04933552|Other|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
79871518|NCT06050447|Procedure|Anterior resection of the rectum|AR is appropriate for tumors located in rectosigmoid junction and in the proximal rectum
79871519|NCT06050447|Procedure|Low anterior resection of the rectum|LAR is appropriate for tumors located in the middle and low rectum
79871520|NCT06050447|Procedure|Abdominoperineal resection|APR is appropriate for distal rectal cancers that invade the external sphincter or the levator muscles
79871521|NCT06050447|Procedure|Total Colectomy|Total abdominal colectomy may be indicated for patients with primary multiple cancer tumors
79871522|NCT06050421|Behavioral|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
79273466|NCT02149901|Drug|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
79273467|NCT02149901|Drug|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
79273468|NCT02149901|Other|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
79273469|NCT02149901|Other|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
79577011|NCT04924985|Other|Non-Physiological Feedback CPR|Non-physiologically guided CPR using AV feedback (integrated into defibrillators)
79577012|NCT04924985|Other|Physiological Feedback CPR|Physiological feedback CPR using an optimal regional O2 Saturation (rSO2), End-tidal CO2 (ETCO2) or combined (rSO2/ETCO2) target
79577013|NCT04917484|Drug|Lu-177-DOTA-Octreotide|Lu-177-DOTATOC in standard doses or individualized doses.
79577014|NCT04916613|Drug|Darolutamide 300 mg|600 mg po, b.i.d.
79577015|NCT04916613|Drug|Placebo|po, b.i.d.
79577016|NCT04916613|Drug|Androgen deprivation therapy|Use according to local standard of care
79871523|NCT06050421|Other|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
80029547|NCT03333395|Drug|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
79736667|NCT01082874|Drug|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
80029548|NCT03328104|Drug|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
79736668|NCT01082874|Drug|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
79403173|NCT05289882|Behavioral|PASS Program Condition:|Participants randomized to this condition will be invited to take part in weekly ball hockey games (once per week), that will last approximately 60 minutes, and will be followed by opportunities to socially connect afterwards. The results of our feasibility study indicated that the PASS program acted as an important conduit to direct participants to other support services and resources (e.g., counseling, career transition centre, employment, education). Military veteran men are often reluctant to access such supports, especially if they attach stigma to such services (e.g., mental health services). At each site, a military veteran will be trained as a facilitator to operate as a conduit to refer participants to the relevant support services and agencies.
79403174|NCT04199611|Procedure|Liposuction|This is a type of fat removal procedure used in plastic surgery.
80029549|NCT03328104|Drug|Nelarabine|650 mg/m2 IV daily x Day 1-5
79403175|NCT04199611|Behavioral|Cognitive Behavioral Therapy|This is a psycho-social intervention that aims to improve mental health.
79577017|NCT04916314|Behavioral|Low Carbohydrate diet|Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
79736669|NCT04009408|Device|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
79736670|NCT00933543|Drug|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
79736671|NCT00933543|Drug|Vehicle cream (placebo)|Cream application followed by illumination with red light.
79736672|NCT00933543|Procedure|PDT|Photodynamic Therapy - Light dose 37 J/cm2
79871524|NCT06050421|Other|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
79871525|NCT06050408|Device|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
79871526|NCT06050382|Other|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
80029550|NCT03328104|Drug|Cyclophosphamide|440 mg/m2 IV x Day 1-5
79871527|NCT06050343|Drug|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
79871528|NCT06050343|Drug|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
79871529|NCT06050330|Diagnostic Test|skin biopsy|Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
79871530|NCT06050317|Drug|Sintilimab Plus mFFN and Radiation|Sintilimab Plus mFFN and Radiation
79871531|NCT06050304|Behavioral|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
79871532|NCT06050304|Biological|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
79871533|NCT06050239|Drug|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
80029551|NCT03328104|Drug|Etoposide|100 mg/m2 IV x Day 1-5
80029552|NCT03327519|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
79736673|NCT02749942|Device|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
80029553|NCT03327519|Behavioral|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
80029554|NCT03300284|Behavioral|Questionnaires|Quality of Life Questionnaires
80029555|NCT03260400|Device|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
79577018|NCT04893525|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
79577019|NCT04878679|Other|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
79577020|NCT04878679|Other|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
79871534|NCT06050226|Drug|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
79871535|NCT06050213|Device|Maxillary implant overdenture|maxillary overdenture retained by different number of implants
80029556|NCT03239496|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
80029557|NCT03239496|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
80029558|NCT03183037|Procedure|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
80029559|NCT03183037|Procedure|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
79273470|NCT04440267|Drug|vincristine|acute lymphoblastic leukemia (ALL) -based chemotherapy
79273471|NCT04440267|Drug|daunorubicin|acute lymphoblastic leukemia (ALL) -based chemotherapy
79273472|NCT04440267|Drug|cyclophosphamide|acute lymphoblastic leukemia (ALL) -based chemotherapy
79577021|NCT04878679|Other|Control group|No physical activity
79273473|NCT04440267|Drug|L-Asparaginase|acute lymphoblastic leukemia (ALL) -based chemotherapy
79273474|NCT04440267|Drug|prednisone|acute lymphoblastic leukemia (ALL) -based chemotherapy
79736674|NCT02749942|Device|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
79273475|NCT04440267|Drug|mercaptopurine|acute lymphoblastic leukemia (ALL) -based chemotherapy
79736675|NCT00607503|Drug|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
79736676|NCT04264533|Drug|VC|12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
79736677|NCT04264533|Drug|Sterile Water for Injection|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
79736678|NCT02750176|Other|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
79736679|NCT01082328|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
79736680|NCT04172584|Behavioral|correct use of the contraceptions|know the emergency contraception and how to use
79273476|NCT04440267|Drug|methotrexate|acute lymphoblastic leukemia (ALL) -based chemotherapy
79273477|NCT04440267|Drug|dexamethasone|acute lymphoblastic leukemia (ALL) -based chemotherapy
79273478|NCT04440267|Drug|Tyrosine kinase inhibitor|acute lymphoblastic leukemia (ALL) -based chemotherapy
79273479|NCT02043847|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
79273480|NCT02043847|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant
79577022|NCT04878445|Procedure|Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.|Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
79577023|NCT04877327|Procedure|Ablation|Cryotherapy and radiofrequency
79577024|NCT04875130|Diagnostic Test|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
79577025|NCT04865848|Procedure|Dental local anesthesia|Dental local anesthesia
79736681|NCT03796000|Procedure|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
79736682|NCT02749786|Other|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
79736683|NCT04218058|Procedure|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
79736684|NCT04217434|Procedure|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
79871536|NCT06050200|Procedure|PVE|The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. Embolization is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). After filling the entire volume of the branch of the portal vein, all catheters, guidewires and the vascular sheaths are removed. A dressing is left over the access site and removed the next day. After treatment the patient is given analgesics and antipyretics if necessary.
79871537|NCT06050200|Procedure|LVD|"The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. A similar puncture of the hepatic vein or veins is then performed; sometimes with access via the internal jugular vein. Embolization of the portal branch is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). Embolization of the right hepatic vein or veins begins with the insertion of a vascular plug (Amplatzer) approx. 2 cm from the confluence of the vein(s). The remaining part of the hepatic vein(s) is then filled with a homogeneous mixture of histacryl glue and Lipiodol (volume ratio 1:1).~A dressing is left over the access site and removed the next day; patient is given analgesics and antipyretics if necessary."
79273481|NCT02043847|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
79273482|NCT02043847|Procedure|Autologous transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue
79273483|NCT02043847|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
79273484|NCT02043847|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant
79273485|NCT02043847|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days
79736685|NCT04217434|Procedure|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
79871538|NCT06050200|Procedure|ALPPS|"The ALPPS procedure will be performed in the operating theatre, under general anesthesia, preferably using a minimally invasive (laparoscopic) technique.~The procedure consists of surgical ligation or clipping of the branch of the portal vein with a vascular clip and in partial transection of the parenchyma at the plane of the future resection planned in the second stage (partial transection, approx. 75% of the transection plane)."
80029560|NCT03183037|Other|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
79403176|NCT04028791|Other|Exercise on ergocycle|The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
79403177|NCT04199923|Behavioral|Single leg immobilisation|Immobilisation with single leg suspension immobilisation
79273486|NCT02043847|Procedure|Autologous transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue
79273487|NCT02043847|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
79273488|NCT02043847|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant
79273489|NCT02043847|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days
79273490|NCT02043847|Procedure|Autologous transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue
79273491|NCT02143037|Behavioral|prize contingency management for attending treatment|
79273492|NCT02143037|Behavioral|usual care|
79273493|NCT02564042|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
79273494|NCT02564042|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
79403178|NCT04029103|Other|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
79403179|NCT04028869|Drug|Glycyrrhizic acid preparation|To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
80029561|NCT03183037|Behavioral|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
80029562|NCT03170258|Device|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired ~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
79273495|NCT02564042|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
79736686|NCT04217434|Procedure|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
79273496|NCT05745051|Diagnostic Test|CVAid Flow|CVA-FLOW is a Telestroke mobile software solution that enables the neurologist to remotely assess, on his smartphone, patients suspected with stroke. Real-time, objective, patient-specific data such as images, videos and vocal records of the patient, are acquired by a first responder (CVA-COLLECTOR) at the patient's location. This allows the neurologist to complete the NIH Stroke Scale and independently reach a diagnostic conclusion and treatment plan (CVA-MED).
79277655|NCT05791721|Drug|Etoricoxib 90 Mg Oral Tablet|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
79277656|NCT05791721|Drug|Dexamethasone 4mg|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
79577026|NCT04864808|Behavioral|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
79577027|NCT04859322|Drug|Glucagon|Pancreatic clamp
79871539|NCT06050174|Drug|Azadirachta Indica|"Azadirachtaindica L. is a multipurpose medicinal tree of family Meliaceae.Is also named Nimba, holy tree, Vembu, Arishtha, Indian neem tree, Indian lilac, wonder tree. It occurs in tropical and semitropical regions of the world. Almost all parts of this incredible tree have been used as phytomedicines for more than 4,000 years.~Various pharmacological attributes such as antifungal, antiviral, antibacterial, anti-inflammatory, sterilant, antiscabic, antiallergenic and analgesic are attributed to various parts of the tree."
79871540|NCT06050174|Procedure|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
79871541|NCT06050161|Device|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
79871542|NCT06050161|Device|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
79871543|NCT06050161|Device|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
79871544|NCT06050148|Biological|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
79871545|NCT06050148|Other|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
79871546|NCT06050096|Procedure|PCI|CTO patients treated by DCB
79871547|NCT06050044|Drug|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
79871548|NCT06050044|Drug|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
79871549|NCT06050031|Dietary Supplement|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
79871550|NCT06050018|Other|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
79871551|NCT06050018|Other|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
79871552|NCT06050005|Diagnostic Test|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
79871553|NCT06049992|Device|Pacemaker implantation with conduction system pacing using Lumenless leads|Pacemaker implantation for conduction system pacing will be done using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
79577028|NCT04846647|Behavioral|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
79577029|NCT04846374|Device|PowerPort|The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
79577030|NCT04839666|Drug|Propofol|Perioperatively propofol administration
79736687|NCT04217434|Procedure|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
79871554|NCT06049992|Device|Pacemaker implantation with conduction system pacing using Stylet-driven leads|Pacemaker implantation for conduction system pacing will be done using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE & Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA)
79871555|NCT06049979|Other|Acute gastrointestinal injury|AGIUS score>2
79871556|NCT06049966|Drug|Atezolizumab|TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML
79871557|NCT06049966|Drug|Carboplatin|SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
79871558|NCT06049966|Drug|Etoposide|ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
80029563|NCT03151083|Behavioral|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
79273497|NCT02149979|Device|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
79273498|NCT04156633|Diagnostic Test|conventional identification method: biochemical profiling or MALDI-TOF MS|Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
79577031|NCT04838262|Other|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
79577032|NCT04831957|Diagnostic Test|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
79577033|NCT04827420|Behavioral|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
79577034|NCT04825106|Other|Diagnostic context|A life-threatening situation occurs in 3 different contexts
79577035|NCT04824846|Behavioral|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
79273499|NCT04156633|Diagnostic Test|new identification method: Biofire FilmArray© BCID panel|The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
79273500|NCT04156633|Diagnostic Test|new identification method: metagenomic WGS|shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
79577036|NCT04824846|Other|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
79577037|NCT04818502|Device|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
79736688|NCT04217512|Drug|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
79736689|NCT04217512|Drug|Pantoprazole high dose|Pantoprazole 1.6 mg\kg
79736690|NCT04217512|Other|Standard hydration|Standard hydration alone
79736691|NCT04217512|Drug|Cisplatin|Cisplatin
79875943|NCT00327340|Drug|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
79875944|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
79736692|NCT02749708|Drug|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 [DL1] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
79736693|NCT03632434|Device|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
79871559|NCT06049914|Behavioral|Experimental group|"Exercise interventions~Measuring blood pressure and weight: before starting exercise~Flexibility exercises: 5-10 minutes of stretching~Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~Nutritional interventions~Well nourished: Overall diet check and correction~at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~Confirm compliance and provide feedback once every 2 weeks"
79871560|NCT06049901|Drug|Nitazoxanide|Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
79577038|NCT04814888|Other|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
79273501|NCT02146937|Drug|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
79273502|NCT02229019|Behavioral|Volunteer mealtime assistance|
79581497|NCT06070844|Behavioral|yoga nidra|Yoga Nidra is a guided meditation technique that involves listening to audio readings. Yoga nidra application will be started at the 6th postoperative hour and will be applied one time. Yoga nidra is expressed as yoga sleep or deep relaxation. In this practice, it will be ensured that the mother will mentally visualise all parts of her body with the commands to be given during controlled breathing and emotionally feel the body parts. The Yoga Nidra application will last 30 minutes.
79273503|NCT05744895|Device|Device: Robotic MAKO total knee|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
79736694|NCT04217980|Diagnostic Test|Lung ultrasonography (LUS) or Chest X ray (CXR)|pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
79736695|NCT01079988|Drug|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
79736696|NCT01079988|Drug|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
79736697|NCT01079988|Drug|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
79736698|NCT01079988|Drug|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
79736699|NCT01079988|Drug|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
79871561|NCT06049888|Behavioral|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
80029564|NCT03058588|Genetic|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
80029565|NCT02919449|Biological|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
80029566|NCT02919449|Biological|Atezolizumab|Atezolizumab will be administered every 3 weeks
79273504|NCT05744895|Device|FocusMotion knee brace|Focusmotion knee brace measures range of motion during exercises
80029567|NCT02904291|Drug|Amlodipine|Patients are tested for their normal prescription amlodipine medication
80029568|NCT02874573|Drug|Tocilizumab|Investigational agent
80029569|NCT02874573|Drug|Normal saline|Placebo
79273505|NCT05744895|Device|Fitbit tracking device|Fitbit will measure patients steps, HR, and sleep
79273506|NCT05744895|Device|FocusMotion app|Will survey patients with PROMS
79273507|NCT02143115|Procedure|Optical colonoscopy|Examination of the colon with a colonoscope
79273508|NCT02143115|Radiation|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
79577039|NCT04805216|Procedure|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~T, B & NK cells~Full Blood Count and differential~Serum Immunoglobulins~Antibodies against VZV, CMV, Rubella~Quantiferon assay (T-Cell response)~Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon* if final blood test)~Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon* if final blood test)~Quantiferon assay will be only be performed where possible."
79577040|NCT04804007|Drug|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
79736700|NCT02876718|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
79736701|NCT04217122|Other|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
79736702|NCT04217122|Other|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
79736703|NCT01074216|Drug|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
79871562|NCT06049862|Behavioral|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
79736704|NCT04217044|Diagnostic Test|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
79871565|NCT06049823|Procedure|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
79871566|NCT06049784|Device|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
79871567|NCT06049784|Device|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
79871568|NCT06049771|Other|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
79871569|NCT06049758|Procedure|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
79871570|NCT06049758|Drug|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
79871571|NCT06049758|Drug|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
80029570|NCT02811094|Other|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
79736705|NCT04218136|Biological|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
79736706|NCT01079832|Radiation|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
79736707|NCT01079832|Procedure|quality-of-life assessment|Ancillary studies
79736708|NCT02749630|Drug|Placebo|Matching placebo to UTTR1147A administered intravenously
79736709|NCT02749630|Drug|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
79871572|NCT06049758|Procedure|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
79871573|NCT06049745|Drug|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
79871574|NCT06049719|Other|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
80029571|NCT02806570|Device|Mitral valve repair|
79403180|NCT04028635|Behavioral|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
79403181|NCT04028635|Behavioral|Cognitive behavioral therapy|Usual CBT
79736710|NCT00626730|Procedure|adjuvant therapy|
79736711|NCT00626730|Radiation|radiation therapy|
79875945|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
80029572|NCT02796859|Drug|Siltuximab|Investigational agent
80029573|NCT02796859|Drug|normal saline|Placebo
80029574|NCT02769832|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
80029575|NCT02769832|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
80029576|NCT02735252|Other|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
79736712|NCT03209128|Radiation|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
79273509|NCT02229097|Drug|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
79273510|NCT02229097|Drug|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
79273511|NCT03166995|Other|Low impact aerobic exercise|The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
79736713|NCT04788342|Device|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
79736714|NCT02749318|Genetic|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
79736715|NCT03199144|Drug|Chemotherapy|3 cycles of Gemzar-Abraxane
79736716|NCT03199144|Radiation|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
79871575|NCT06049706|Device|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
79871576|NCT06049706|Device|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
79871577|NCT06049667|Drug|NTQ2494 tablet|"Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle)."
79871578|NCT06049628|Behavioral|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
79871579|NCT06049628|Behavioral|routine program|This program consists of jogging, and stretching exercises.
79871580|NCT06049550|Other|no intervention|no intervention
79871581|NCT06049511|Behavioral|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
79871582|NCT06049511|Behavioral|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
79273512|NCT03166995|Other|Postural exercises|The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
79736717|NCT03199144|Procedure|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
79277657|NCT05791682|Drug|Sealant, Fissure|FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
79277658|NCT05791669|Drug|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
79277659|NCT05791669|Drug|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
79736718|NCT04306536|Dietary Supplement|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
79736719|NCT04304664|Other|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
79871583|NCT06049498|Drug|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
79871584|NCT06049498|Drug|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
80029577|NCT02735252|Device|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
80029578|NCT02706704|Drug|Adalimumab|
80029579|NCT02591472|Procedure|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
80029580|NCT02591472|Procedure|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
80029581|NCT02591472|Other|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
79577041|NCT04801381|Procedure|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
79577042|NCT04801381|Procedure|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
79736720|NCT00636142|Biological|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
79736721|NCT04305522|Dietary Supplement|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
79736722|NCT04305522|Dietary Supplement|Placebo|Placebo comparator with maltodextrin as a carrier.
79871585|NCT06049433|Behavioral|Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
80029582|NCT02591472|Other|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
80029583|NCT02591472|Other|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
80029584|NCT02591472|Other|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
79403182|NCT05101434|Diagnostic Test|Periodontal Probing|with the help Michigan probe, periodontal pocket measurement was done.
79736723|NCT04305522|Dietary Supplement|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
79736724|NCT02499562|Drug|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
79736725|NCT02499562|Drug|Placebo|
79736726|NCT02499562|Drug|Entecavir|
79871586|NCT06049433|Behavioral|On-Demand + Discussion board (DB)|Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
80029585|NCT02591472|Other|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
79577043|NCT04799665|Diagnostic Test|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
79577044|NCT04782180|Drug|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
79577045|NCT04782180|Behavioral|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
79577046|NCT04763499|Other|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
79577047|NCT04762017|Drug|OCS-05 IV administration|Multiple Dose of OCS-05 IV administration for 5 consecutive days
79577048|NCT04762017|Other|Placebo IV administration|Placebo IV administration for 5 consecutive days
80029586|NCT02591472|Other|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
80029587|NCT02591472|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
80029588|NCT02591472|Other|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
79577049|NCT04757584|Drug|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On [A] vs Off [B]) with 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
79871587|NCT06049433|Behavioral|Arm 2|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
80029589|NCT02418156|Device|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for vascular repair.
79577050|NCT04756791|Procedure|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
79871588|NCT06049433|Behavioral|On Demand (OD) + Video Conference (VC)|on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
79871589|NCT06049433|Behavioral|Arm 3|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
79871590|NCT06049433|Behavioral|On Demand (OD) + Video Conference (VC)|Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
80029590|NCT02345005|Device|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
80029591|NCT02326311|Drug|imatinib|Tyrosin kinase inhibitor
79273513|NCT03747107|Behavioral|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
79273514|NCT03166917|Procedure|3D printing implant|3D printing implants in bone defect
79273515|NCT03166917|Procedure|autogenous bone grafting|3D printing implants in bone defect
79273516|NCT02147015|Drug|Glucocorticoids|
79273517|NCT02147015|Drug|Antibiotics|
79273518|NCT02147015|Drug|Inhaled corticosteroid (ICS)|
79273519|NCT02147015|Drug|Long-Acting Muscarinic Antagonists(LAMA)|
79273520|NCT02147015|Drug|Short-acting beta2-agonist (SABA)|
79273521|NCT02147015|Other|Physical treatments|
79577051|NCT04756791|Procedure|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
79577052|NCT04752475|Drug|Furosemide|Furosemide 20 mg pill taken daily for 5 days
79577053|NCT04752475|Other|Placebo|Identical-appearing placebo pill taken daily for 5 days
79577054|NCT04748289|Device|ICU Cockpit software testing|"the ICU Cockpit Software Platform is intended to be used for monitoring of patient characteristics and vital physiological parameters in patients at the Neurointensive Care Unit of the University Hospital Zurich.~Furthermore, three different applications for prognostication and prediction of complications will be tested:~ICU Cockpit COVID-19 for remote monitoring of isolated patients,~ICU Cockpit Stable State for a comprehensive visualization of vital parameters and as additional aid in early detection of imminent critical complications~ICU Cockpit Cerebral Ischemia for the prediction of delayed DCI in patients with subarachnoid hemorrhage (SAH)."
79736727|NCT02877654|Procedure|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
79736728|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
79736729|NCT04304430|Drug|Dapagliflozin|Initiation of dapagliflozin according to clinical indication
79736730|NCT04304430|Drug|DPP-4 inhibitor|Initiation of DPP-4i according to clinical indication
79736731|NCT04216966|Device|Control group|No intervention was given
79736732|NCT04216966|Device|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
79736733|NCT04216966|Device|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
79273522|NCT02147015|Drug|long-acting beta2-agonist (LABA)|
79736734|NCT04216966|Device|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
79871591|NCT06049407|Behavioral|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires. (5) They will answer the follow-up (T3) questionnaires.
79871592|NCT06049368|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
79871593|NCT06049355|Other|Exercise Intervention|Undergo Exercise Together exercise program
79871594|NCT06049355|Procedure|Biospecimen Collection|Undergo collection of blood samples
79871595|NCT06049355|Other|Educational Intervention|Receive educational materials
79577055|NCT04746586|Other|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
79871596|NCT06049225|Behavioral|High-Tech|Access to technological platform and weekly health coaching
79871597|NCT06049225|Behavioral|Low-Tech|Weekly email with educational content and weekly health coaching
79273523|NCT03166683|Other|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
79577056|NCT04740801|Device|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
79577057|NCT04739267|Device|CardioFlux|Not an intervention
79577058|NCT04720885|Procedure|kind of surgery|hysteroscopy, curettage, other
79577059|NCT04719078|Diagnostic Test|MRI of the chest|The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
79577060|NCT04717362|Drug|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
79577061|NCT04706273|Device|GORE® VIABAHN® Endoprosthesis|On Day 1, Participants will receive the GORE® VIABAHN® Endoprosthesis
79577062|NCT04701177|Diagnostic Test|AltoidaML|Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
79577063|NCT04700917|Behavioral|Cognitive Behavioural Therapy|Internet-Based CBT
79577064|NCT04700826|Drug|Direct Oral Anticoagulants|choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
79736735|NCT02875002|Drug|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m^2, is schedule to increase to 100mg/m^2, and be administered on days 1 and 8 of each 28-day cycle.
79736736|NCT02875002|Drug|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m^2 , is scheduled to increase to 1000 mg/m^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
79736737|NCT02749396|Drug|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
79273524|NCT03166683|Other|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
79273525|NCT02229175|Drug|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
79277660|NCT05791630|Other|the labour care guide (LCG)|The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
79736738|NCT02749396|Drug|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
80029592|NCT02326311|Drug|nilotinib|Tyrosin kinase inhibitor
80029593|NCT02326311|Drug|dasatinib|Tyrosin kinase inhibitor
80029594|NCT02324543|Drug|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
80029595|NCT02324543|Drug|Taxotere|IV on days 4 and 11 of a 21 day cycle
79577065|NCT04700189|Device|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
79577066|NCT04693949|Other|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
79577067|NCT04693949|Other|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
79577068|NCT04689256|Device|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
79736739|NCT02749396|Drug|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
80029596|NCT02324543|Drug|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
80029597|NCT02324543|Drug|Cisplatin|IV on days 4 and 11 of a 21 day cycle
80029598|NCT02324543|Drug|Irinotecan|IV on days 4 and 11 of a 21 day cycle
80029599|NCT02279979|Device|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
80029600|NCT02215265|Drug|Cisplatin|Chemotherapy
79736740|NCT02749396|Drug|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
79736741|NCT02749396|Drug|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
79736742|NCT02749396|Drug|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
79736743|NCT02749396|Other|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
80029601|NCT02215265|Radiation|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
80029602|NCT02055638|Drug|SRX246|capsules
80029603|NCT02055638|Drug|Placebo|
79273526|NCT02229175|Device|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
79736744|NCT04305132|Device|Electroconvulsive therapy|Thymatron System IV electroconvulsive therapy device
79871598|NCT06049225|Behavioral|Attention Control|No technology access or health coaching
79736745|NCT00627120|Drug|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
79736746|NCT02749162|Drug|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
79871599|NCT06049186|Behavioral|CRD|During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.
79871600|NCT06049186|Drug|Metformin|After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
79736747|NCT02749162|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
79871601|NCT06049173|Other|novel recruitment maneuver therapy|The use of abdominal compression cardiopulmonary resuscitation apparatus for new recruitment maneuver therapy: the use of autonomous ventilation mode (PSV or CPAP) during mechanical ventilation, followed by abdominal compression recruitment maneuver therapy, the number of times of each compression is 5-10, each time the duration of 30 to 40s, and then adjust to the previous breathing pattern.
79871602|NCT06048874|Procedure|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
79871603|NCT06048874|Drug|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
79871604|NCT06048874|Drug|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
79871605|NCT06048848|Procedure|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
79871606|NCT06048848|Drug|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
79871607|NCT06048848|Drug|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
80029604|NCT01887938|Biological|HGT-1110|Participants will receive IT injection of HGT-1110.
79577069|NCT04688528|Radiation|Dose de-escalation and / or Volume de-escalation|The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
79577070|NCT04687917|Behavioral|The facilitation, training, feedback, and consultation (FTFC) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
79736748|NCT02749162|Drug|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
79577071|NCT04687917|Behavioral|The facilitation, training, feedback, consultation, and pay-for-performance (FTFC+PFP) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and pay-for-performance.
79577072|NCT04678453|Biological|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
79577073|NCT04647032|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
79736749|NCT02749162|Drug|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
79736750|NCT02749162|Drug|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
79736751|NCT02874612|Other|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
79736752|NCT02041234|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
79736753|NCT02041234|Drug|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
79736754|NCT02041234|Drug|Xenical|Xenical: Up to 120 mg tds
79736755|NCT02041234|Drug|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
79736756|NCT02041234|Drug|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
79273527|NCT03544697|Procedure|Skin expansion and repair with flaps|
79273528|NCT04947007|Drug|Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 15 ml +15 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
79273529|NCT04947007|Drug|Bupivacaine HCl 0.025 % in 10+10 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 10 ml +10 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
79577074|NCT04646486|Behavioral|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
79577075|NCT04611191|Other|Team Sports|The intervention involves team sports in sports clubs in local municipalities
79577076|NCT04611191|Other|Control|The intervention involves a control condition with participants continuing their normal way of living
79736757|NCT04305210|Drug|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
79871608|NCT06048640|Dietary Supplement|Dynamine (methylliberine)|Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
79871609|NCT06048614|Procedure|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
80029605|NCT01850524|Drug|Ixazomib|IXAZOMIB capsules.
80029606|NCT01850524|Drug|Placebo|IXAZOMIB matching-placebo capsules.
79403183|NCT05092074|Drug|Vosevi 400/100/100 Oral Tablet|Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks
79403184|NCT02080273|Drug|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
79577077|NCT04608214|Drug|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
79577078|NCT04608214|Other|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
79577079|NCT04601727|Diagnostic Test|16srRNA pyrosequencing analysis of microbiota of saliva and faeces|No intervention in this study
79577080|NCT04571762|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT (a fraction dose adapted to the OAR geometry-of-the-day, 5 fractions) performed on the MR-Linac
79577081|NCT04553289|Other|exercising into pain|the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale
79577082|NCT04553289|Other|exercising with no/slight pain|the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
79577083|NCT04552717|Other|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
79577084|NCT04549207|Drug|Bone modifying agent|Use of bone modifying agent
79577085|NCT04537195|Behavioral|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
79577086|NCT04535492|Behavioral|Decision Making Support Tool|Primary care practices randomized in a stepped wedge cluster design will implement a newly developed predictive model and analytic tool to improve shared decision-making for patients.
79577087|NCT04535193|Drug|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
79577088|NCT04526444|Device|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
79577089|NCT04526444|Other|Online training|Les Mills On Demand
79577090|NCT04526444|Other|Peer support via social media|Facebook group
79577091|NCT04506437|Behavioral|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
79577092|NCT04506437|Behavioral|Standard of care engagement practices|Standard of care engagement practices and services-as-usual
79736758|NCT04305210|Drug|18F-florbetapir|18F-florbetapir
79736759|NCT04217824|Procedure|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
79736760|NCT02749006|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
79736761|NCT02749006|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
79875946|NCT01062724|Other|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
80029607|NCT01850524|Drug|Dexamethasone|Dexamethasone tablets.
80029608|NCT01850524|Drug|Lenalidomide|Lenalidomide capsules.
79403185|NCT02080273|Drug|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
79577093|NCT04505345|Behavioral|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
79577094|NCT04505345|Behavioral|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
79577095|NCT04494711|Behavioral|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
79577096|NCT04439734|Device|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
79577097|NCT04438083|Biological|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
79736762|NCT01072344|Drug|Chamomile (Matricaria recutita)|500 mg 3 times daily
79736763|NCT02695732|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
79273530|NCT04947007|Drug|Bupivacaine HCl 0.025 % in 5+5 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 5 ml +5 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
79403186|NCT02080273|Drug|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
79403187|NCT03131466|Device|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
79736764|NCT02695732|Device|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
79736765|NCT02751268|Drug|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
79577098|NCT04420611|Other|Session 1 (day 1)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
79577099|NCT04420611|Other|Session 2 (day 3)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
79577100|NCT04420611|Other|Session 3 (day 15)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
79736766|NCT02751268|Drug|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
79736767|NCT02751190|Procedure|Totally ExtraPeritoneal (TEP) repair|
79736768|NCT02751190|Procedure|TransAbdominal PrePeritoneal (TAPP) repair|
79736769|NCT02751190|Procedure|Open anterior mesh repair|
79736770|NCT02751190|Procedure|Open Anterior Non Mesh|
79273531|NCT04947007|Drug|Isotonic solution|In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
79273532|NCT02147171|Dietary Supplement|VisionAce|
79273533|NCT02147171|Dietary Supplement|Placebo|
79736771|NCT02751190|Procedure|Combined anterior and posterior repair|
79736772|NCT02751190|Procedure|Open preperitoneal mesh repair|
79736773|NCT02748772|Drug|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
79736774|NCT02748772|Drug|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
79736775|NCT02750956|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
79736776|NCT02748850|Biological|blood sample|a blood sample 20 milliliter
79736777|NCT02748850|Biological|Stem cell donation|The volume of stem cells remained in the tube is recovered
79736778|NCT02747056|Other|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
79736779|NCT02747056|Other|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
79736780|NCT02747056|Other|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
79736781|NCT01071954|Biological|Romiplostim|Administered by subcutaneous injection once a week.
79736782|NCT02746978|Other|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
79273534|NCT04104685|Combination Product|FCD105|Experimental combination
79273535|NCT04104685|Drug|3% Minocycline Foam|Active Comparator
79273536|NCT04104685|Drug|0.3% Adapalene Foam|Active Comparator
79273537|NCT04104685|Other|Vehicle Foam|Placebo
79273538|NCT02147249|Drug|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
79273539|NCT02393235|Other|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
79736783|NCT02746978|Other|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
79871610|NCT06048614|Drug|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
79871611|NCT06048341|Procedure|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
79871612|NCT06048341|Drug|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
79871613|NCT06048341|Drug|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
79871614|NCT06047639|Device|Bone-anchored hearing implants|surgically placed hearing device
80029609|NCT01816256|Procedure|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
80029610|NCT01671696|Other|Cardiac MRI|Cardiac MRI
80029611|NCT01664910|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
80029612|NCT01664910|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
79577101|NCT04420611|Other|Session 4 (day 30)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
79577102|NCT04418453|Other|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
79736784|NCT04216888|Drug|Ketamine Hydrochloride|Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
79871615|NCT06046092|Biological|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
80029613|NCT01664910|Biological|Anti-Thymocyte Globulin|Given IV
79273540|NCT02392845|Drug|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
79273541|NCT03166839|Other|Experiencing PPH|No intervention given
79273542|NCT02229253|Drug|degarelix|
79577103|NCT04345211|Other|Group1, walking group|The walking group includes a weekly walking goal of 75 minutes.
79577104|NCT04345211|Other|Group 2, Walking plus manual therapy|Walking plus self-administered thorax manual therapy
79577105|NCT04345211|Other|Group 3; Walking plus exercises with Theraband|Walking plus thorax exercises with Theraband
79736785|NCT02746744|Drug|Rituximab|Infusion of Mabthera/Rituximab every 6 months
79736786|NCT02746744|Drug|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
79577106|NCT04340531|Other|Best Practice|Receive usual care
79871616|NCT06045884|Procedure|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
79871617|NCT06045884|Drug|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
79871618|NCT06045884|Drug|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
79871619|NCT06045442|Behavioral|Intradialytic exercise training|The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
80029614|NCT01664910|Drug|Bendamustine Hydrochloride|Given IV
80029615|NCT01664910|Drug|Fludarabine Phosphate|Given IV
80029616|NCT01664910|Biological|Inotuzumab Ozogamicin|Given IV
80029617|NCT01664910|Drug|Methotrexate|Given IV
80029618|NCT01664910|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
80029619|NCT01664910|Biological|Rituximab|Given IV
80029620|NCT01664910|Drug|Tacrolimus|Given IV or PO
80029621|NCT01654159|Procedure|Monofocal IOL|Monofocal Intraocular lens will be implanted
79273543|NCT04093765|Diagnostic Test|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~collection of 3x1cm dried blood spots on filter paper~administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
80029622|NCT01654159|Procedure|Multifocal IOL|Multifocal IOL will be implanted
80029623|NCT01654159|Procedure|Toric IOL|Toric IOLS will be implanted
80029624|NCT01609842|Other|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
79871620|NCT06045442|Behavioral|Control|Usual care
79871621|NCT06044805|Drug|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
79871622|NCT06044805|Drug|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
79871623|NCT06044779|Procedure|Transversus Abdominis Plane Block using 0.25% Bupivacaine|TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
80029625|NCT01594580|Other|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
80029626|NCT01594580|Other|Non-impregnated scrubs|
80029627|NCT01569594|Device|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
80029628|NCT01121107|Device|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
80029629|NCT01121107|Device|Patient Advisory Module|Handheld device that provides medication reminders
79403188|NCT03131466|Drug|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
79403189|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|
79403190|NCT04192279|Diagnostic Test|lactate clearance|Lactate clearance rate was monitored within 6 hours after admission
79403191|NCT04199377|Procedure|HIP KNEE REPLACEMENT|HIP KNEE REPLACEMENT
79577107|NCT04340531|Other|Survey Administration|Ancillary studies
79577108|NCT04340531|Other|Tobacco Cessation Counseling|Receive referred to counseling session
79577109|NCT04340531|Other|Tobacco Cessation Counseling|Receive phone counseling
79577110|NCT04340531|Other|Training|Undergo training
79577111|NCT04335214|Other|one to one interview|one to one interviews with older people from moroccon origin in Belgium
79577112|NCT04328038|Other|Survey|Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
79736787|NCT02746744|Drug|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
79736788|NCT02748304|Other|control|just follow up
79577113|NCT04325815|Device|CADDIE- Computer Aided (AI) Device used in Endoscopy|"CADDIE assisted polyp detection~CADDIE assisted polyp characterisation"
79577114|NCT04319328|Drug|Cefazolin|Non-interventional pharmacokinetic evaluation
79577115|NCT04319328|Drug|Ceftazidime|Non-interventional pharmacokinetic evaluation
79736789|NCT02748304|Drug|sorafenib|sorafenib 400mg bid po
79736790|NCT02748304|Drug|aspirin|aspirin 100mg qd po
79577116|NCT04319328|Drug|Ciprofloxacin|Non-interventional pharmacokinetic evaluation
79577117|NCT04317326|Procedure|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 <55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
79577118|NCT04317326|Procedure|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
79736791|NCT02748382|Other|higher chloride crystalloid|Normal saline
79736792|NCT02748382|Other|higher chloride albumin|5% Octalbin
79736793|NCT02748382|Other|lower chloride crystalloid|Ringers Lactate
79736794|NCT02748382|Other|lower chloride albumin|5% Plasbumin
79736795|NCT02746822|Other||
79736796|NCT02746666|Behavioral|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
79736797|NCT02746900|Procedure|Cervical cerclage|McDonald cervical cerclage
79736798|NCT04216654|Diagnostic Test|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
79736799|NCT02748148|Other|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
79736800|NCT02746432|Drug|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
79736801|NCT02746354|Other|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
79871624|NCT06044779|Procedure|Erector Spinae Plane Block using 0.25% Bupivacaine|Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
79273544|NCT04093765|Drug|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
79577119|NCT04317326|Procedure|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
79577120|NCT04317326|Procedure|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
79871625|NCT06043895|Device|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
79871626|NCT06043895|Device|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
79577121|NCT04283903|Diagnostic Test|PICF|PICF collection from 4 sites
79577122|NCT04255160|Drug|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
79577123|NCT04255160|Other|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
79736802|NCT02746276|Drug|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
79871627|NCT06043882|Procedure|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
79871628|NCT06043609|Other|This is an observational cohort study|This is an observational cohort study
79871634|NCT06043128|Other|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
79871635|NCT06042127|Procedure|POEM-F|POEM-F would be performed as described in the arms section
79871636|NCT06042127|Procedure|Conventional POEM|Anterior POEM performed as described in the arms section
79577124|NCT04254562|Behavioral|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
79577125|NCT04254562|Behavioral|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
79577126|NCT04254562|Behavioral|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
79577127|NCT04243512|Behavioral|Time-restricted eating|Restrict food and beverage intake (except water) to a 10-hour window
79577128|NCT04225156|Biological|efgartigimod|Intravenous infusion of efgartigimod
79577129|NCT04184687|Procedure|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
79577130|NCT04184687|Procedure|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
79577131|NCT04179123|Device|Customised PAP interfaces|Customised PAP interfaces
79736803|NCT02746276|Drug|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
79736804|NCT05629936|Other|digital interdisciplinary intervention|Digital medication interview, comprehensive medication review, interdisciplinary patient team discussion followed by a MTO-plan, follow-ups
79871637|NCT06041776|Drug|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
79871638|NCT06041776|Drug|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
79736805|NCT02747602|Drug|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
79736806|NCT02747602|Drug|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
79736807|NCT02747602|Drug|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
79736808|NCT02745964|Device|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
79871639|NCT06040060|Drug|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
79871640|NCT06040060|Other|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
79403192|NCT04199455|Drug|Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)|"Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day."
79577132|NCT04138433|Device|Real tDCS|Anodal tDCS 2 ma
79736809|NCT02745964|Device|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
79736810|NCT02746042|Drug|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
79736811|NCT02746042|Drug|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
79736812|NCT02748226|Procedure|endovascular treatment|endovascular treatment
79736813|NCT02747680|Other|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
79736814|NCT02746198|Other|probiotic dairy drink|
79736815|NCT02746198|Other|acidified milk|
79871641|NCT06040034|Drug|Lidocaine IV|Lidocaine given as bolus or continuous infusion.
79577133|NCT04138433|Device|Sham tDCS|Sham tDCS 2 ma
79577134|NCT04135586|Other|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
79736816|NCT02745886|Drug|metformin 0.85 twice daily for 6 months|
79736817|NCT02745886|Behavioral|Calorie restriction|
79736818|NCT02747446|Dietary Supplement|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
79736819|NCT02745652|Device|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
79736820|NCT02745652|Device|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
79736821|NCT02747524|Other|Vita Mamba peanut butter paste|
79577135|NCT04135586|Other|Control|Yoga + educational program
79577136|NCT04132128|Other|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
79577137|NCT04131491|Procedure|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
79736822|NCT02747212|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
79871642|NCT06038981|Drug|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
79871643|NCT06022185|Diagnostic Test|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
79871644|NCT06022172|Diagnostic Test|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
79871645|NCT06015737|Combination Product|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
79871646|NCT06015737|Other|Placebo|Matching placebo solution for injection in aPFS.
79871647|NCT06015087|Other|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
79871648|NCT06010823|Device|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
79871649|NCT06004700|Other|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
79871650|NCT05998005|Behavioral|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
79736823|NCT02747290|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
79736824|NCT02747368|Device|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
79736825|NCT02745808|Biological|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
79871651|NCT05990400|Drug|Finasteride|finasteride topical 0,1%
79871652|NCT05990400|Drug|Minoxidil|minoxidil topical 5%
79577138|NCT04103346|Other|air filtration with air purifier with hepa filter|long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
79736826|NCT02745808|Biological|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
79736827|NCT02747134|Behavioral|Emotion Regulation and Mindfulness skills|
79736828|NCT02745574|Procedure|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
79736829|NCT02745574|Procedure|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
79736830|NCT02745496|Procedure|TRUS Biopsy|Standard of Care Treatment
79577139|NCT04103346|Other|sham|air purifier running with air filter removed
79736831|NCT02745496|Procedure|TRUS/FUSION Biopsy|Interventional Treatment
79736832|NCT02745730|Other|Glucose|
79736833|NCT02745730|Other|Fructose|
79736834|NCT02745730|Other|Sucralose|
79736835|NCT02745730|Other|Allulose|
79736836|NCT02742142|Other|water as placebo|topical application of water as a placebo in the control arm
79736837|NCT02742142|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
79736838|NCT02742064|Other|Cogito Companion Mobile Phone Application|
79736839|NCT00636298|Drug|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
80029630|NCT00769782|Procedure|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
80029631|NCT00764595|Drug|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
79577140|NCT04101669|Device|EndoBarrier Liner|The EndoBarrier System is provided as a single-use, sterile device and consists of an EndoBarrier Liner preloaded, packaged and sterilized within the EndoBarrier Delivery System. The EndoBarrier Delivery System is utilized to deliver the EndoBarrier Liner to the proximal small intestine. The EndoBarrier Liner is removed using the EndoBarrier Retrieval System. The EndoBarrier System incorporates no pharmacological, biological tissue or blood products.
79871653|NCT05987605|Drug|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
79871654|NCT05985200|Drug|BI 3032950|BI 3032950
79871655|NCT05985200|Drug|Placebo matching BI 3032950|Placebo matching BI 3032950
79871656|NCT05983302|Drug|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
80029632|NCT00628745|Other|None. Observational Study.|
79577141|NCT04101669|Other|Sham|Patient receives upper endoscopy but no treatment
79577142|NCT04099485|Other|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
79577143|NCT04099173|Behavioral|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
79577144|NCT04092387|Other|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarettes
79577145|NCT04092387|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig conditions
79577146|NCT04082416|Biological|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
79871657|NCT05983302|Drug|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
79871658|NCT05983302|Drug|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
79871659|NCT05983302|Other|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
79871660|NCT05976711|Device|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
79871661|NCT05973669|Device|MED-EL Remote Care|Remote cochlear implant support
79875947|NCT05300243|Diagnostic Test|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
80029633|NCT00593840|Radiation|Intensity modulated radiation therapy|
80029634|NCT00576979|Drug|cyclophosphamide|Given IV
80029635|NCT00576979|Drug|etoposide|Given IV
80029636|NCT00576979|Procedure|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
80029637|NCT00576979|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
80029638|NCT00576979|Procedure|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
80029639|NCT00576979|Radiation|intensity-modulated radiation therapy|Undergo IMRT
80029640|NCT00576979|Radiation|tomotherapy|Undergo IMRT using helical tomotherapy
80029641|NCT04949230|Other|No Intervention Used|There is no intervention in this study
79273545|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
79273546|NCT02393001|Other|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
79273547|NCT02393001|Other|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
79273548|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
79403193|NCT04199455|Drug|Placebo|"Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day."
79577147|NCT04082416|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
79736840|NCT05629624|Dietary Supplement|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ > - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
79736841|NCT05629624|Dietary Supplement|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ > - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
79736842|NCT05629624|Dietary Supplement|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ <-2 and ≥-3 z-score, and/or MUAC <12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case & control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
79736843|NCT02741908|Behavioral|Calorie counting diet|
79736844|NCT02741908|Behavioral|Fixed diet plan|
79736845|NCT02745340|Other|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
79871662|NCT05964218|Behavioral|Food-Body-Mind Intervention|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
80029642|NCT03563469|Other|Salivary bacterial and pH level|"Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
79403194|NCT04753242|Other|Online survey questionnaire|Self-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding psychosocial care structures that psychosocial C&L services have established in acute hospitals in the context of the COVID-19 pandemic, the implementation and use of COVID-19-related services for patients, relatives and staff, special challenges, as well as needs and wishes for the future. Thereby the survey is aiming at the creation of a data basis for improving the structural and process quality of psychosocial care services through psychosocial C&L services in the context of pandemics, especially the COVID-19 pandemic.
79577148|NCT04070781|Drug|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
79736846|NCT02745106|Procedure|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
79736847|NCT02745106|Device|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
79871663|NCT05960812|Procedure|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~Semisetting position under GA.~Standard shoulder arthroscopy with standard portals for RC repair.~Inspection of articular surface of rotator cuff and biceps tendon.~Bursectomy, visualization of all rotators.~Mobilization is done for associated rotator tears by shaver and radiofrequency device.~Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~Skillful neglect to the tear.~Rotator repair technique by RC anchors~Biceps Tenotomy will be done in all cases by cutting of LHBT."
80029643|NCT02228538|Device|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system & off-the-shelf standard knee implant system from various manufacturers
79871664|NCT05960812|Procedure|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~Semisetting position under GA.~Standard shoulder arthroscopy with standard portals for RC repair.~Inspection of articular surface of rotator cuff and biceps tendon.~Bursectomy, visualization of all rotators.~Mobilization is done for associated rotator tears by shaver and radiofrequency device.~Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~Skillful neglect to the tear.~Rotator repair technique by RC anchors~Biceps Tenotomy will be done in all cases by cutting of LHBT."
79871665|NCT05951660|Behavioral|Educational intervention|"Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~What is sexuality?~How psychopharmacology influences sexuality~What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences."
79871666|NCT05951179|Biological|TARA-002|"Cohort A: All subjects will receive 6 weekly instillations of TARA-002 at the established recommended Phase 2 dose (RP2D). Subjects who are eligible for reinduction will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period.~Cohort B: All subjects will receive 6 weekly instillations of TARA-002 at the established RP2D. Subjects who are eligible for reinduction will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Subjects confirmed to have a complete response will receive 3 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. All eligible subjects will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18."
80029644|NCT03058042|Other|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
80029645|NCT03058042|Other|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
79403195|NCT04191343|Drug|Toripalimab injection combined with GEMOX|Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
79577149|NCT04070781|Drug|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
79577150|NCT04067765|Behavioral|Alcohol cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor)
79577151|NCT04067765|Behavioral|Neutral cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of neutral beverages (water).
79577152|NCT04066166|Diagnostic Test|Palpation|All healthy subjects palpated
79577153|NCT04064164|Behavioral|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
79577154|NCT04063709|Diagnostic Test|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
79403196|NCT04199143|Drug|Nitrous Oxide-Oxygen|The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
79577155|NCT04062656|Drug|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
79577156|NCT04062656|Drug|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
79577157|NCT04062656|Drug|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
79577158|NCT04062656|Drug|Docetaxel|Docetaxel 50mg/m² IV over 1 h
79577159|NCT04062656|Drug|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
79577160|NCT04062656|Drug|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
79577161|NCT04041050|Drug|Navitoclax|Tablet; Oral
79736848|NCT02745106|Device|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~punction of right jugular vein with Seldinger technique, introducer placement~insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~positioning of swan-ganz catheter in pulmonary artery~direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~calculating of indirect parameters (pulmonary vascular resistance)"
79736849|NCT02741752|Procedure|Decortication|cortical bone perforation
79577162|NCT04041050|Drug|Ruxolitinib|Tablet; Oral
79577163|NCT04041050|Drug|Celecoxib|Capsule; Oral
79577164|NCT04035369|Procedure|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
79736850|NCT02695264|Device|HS-1000 recording|
79736851|NCT02745262|Other|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
79736852|NCT02741674|Procedure|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
79403197|NCT04199143|Device|Tissue Pulsatility Imaging - TPI|Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.
79403198|NCT04199143|Device|Magnetic Resonance Imaging - MRI|Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
79403199|NCT04616274|Drug|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
79403200|NCT04613622|Drug|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
79871667|NCT05941247|Drug|Hemay005 60 mg|"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."
79403201|NCT04022629|Procedure|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
79403202|NCT04022629|Procedure|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
79577165|NCT04035369|Procedure|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
79577166|NCT04018313|Biological|CT-P39|150 mg/mL, Solution for injection in PFS
79577167|NCT04018313|Biological|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
79577168|NCT04018313|Biological|CT-P39|150 mg/mL, Solution for injection in PFS
79577169|NCT04018313|Biological|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
79577170|NCT04018313|Biological|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
79577171|NCT04011332|Other|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
79577172|NCT04006405|Diagnostic Test|GAG score|blood and urine samples to determine GAG scores
79577173|NCT03976518|Drug|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
79577174|NCT03974412|Diagnostic Test|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT [protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes]"
79871668|NCT05941052|Diagnostic Test|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
79577175|NCT03974412|Device|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
79577176|NCT03973203|Dietary Supplement|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
79577177|NCT03930823|Other|Interview|One to one interview
79736853|NCT02741674|Procedure|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
79736854|NCT02741674|Procedure|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
79736855|NCT02695186|Procedure|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
79736856|NCT02744950|Procedure|Pulley stitches|
79871670|NCT05934240|Other|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
79871671|NCT05934240|Other|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
79577178|NCT03916926|Device|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
79577179|NCT03916926|Device|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
79577180|NCT03906370|Diagnostic Test|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
79577181|NCT03899857|Drug|Pembrolizumab|Pembrolizumab will be added to standard of care
79736857|NCT02744950|Procedure|Intermediate Repair|
79736858|NCT02695108|Other|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
79273549|NCT03166293|Behavioral|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
79273550|NCT03166605|Drug|Simethicone|Giving simethicone before and after capsule ingestion.
79403203|NCT04604340|Procedure|transradial access for neuroangiography|The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
79577182|NCT03871491|Drug|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
79736859|NCT02695108|Other|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
79871672|NCT05932368|Other|evaluation|examining files and taking records
79577183|NCT03871491|Drug|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
79871673|NCT05928078|Behavioral|intervention|Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks. The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.
79403204|NCT04604340|Procedure|transfemoral access for neuroangiography|By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
79577184|NCT03853902|Behavioral|Mindfulness Program|Mindfulness Program
79577185|NCT03847324|Other|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors."
79577186|NCT03847324|Other|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
79577187|NCT03847324|Other|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
79577188|NCT03846947|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
79577189|NCT03839914|Drug|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
79577190|NCT03838263|Drug|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
79577191|NCT03838263|Radiation|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
79273551|NCT03699956|Combination Product|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
79273552|NCT03699956|Drug|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
79577192|NCT03808051|Procedure|Physiological-based cord clamping|See Arm description.
79577193|NCT03808051|Procedure|Time-based cord clamping|See Arm description.
79577194|NCT03801642|Drug|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
79736860|NCT02695030|Device|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
79736861|NCT02744716|Drug|Aspirin|low dose of Aspirin after operation
79273553|NCT03166527|Drug|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
79273554|NCT02151383|Drug|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
79273555|NCT02229409|Behavioral|Walkadoo|Walkadoo is a MeYou Health, LLC product.
79273556|NCT03698864|Drug|PCS499|PCS499 900mg twice a day with food
79273557|NCT02392533|Other|Education|Education
79273558|NCT04043923|Drug|Norketotifen|Oral capsule
79273559|NCT04043923|Drug|Placebo|Oral capsule
79273560|NCT02147483|Behavioral|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
79736862|NCT02744716|Device|intrauterine balloon|insert intrauterine balloon after operation
79736863|NCT02741362|Other|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
79736864|NCT02741362|Other|Lipoaspiration|
79736865|NCT00837811|Biological|LY2127399|60 milligrams [(mg) with potential for dose escalation to 120 mg] subcutaneously every 4 weeks for 48 weeks
79736866|NCT02744794|Device|Dermal Cooling System|Treatment with cryotherapy.
79736867|NCT02744872|Drug|Felodipine|Felodipine 10 mg once daily or identical placebo
79736868|NCT02744872|Drug|Placebo|Placebo
79736869|NCT02741206|Behavioral|Bellevue ROSE Intervention|
79736870|NCT02741206|Behavioral|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
79736871|NCT02741206|Behavioral|One Psycho-education session and usual, standard of care Control|
79736872|NCT02744638|Other|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
79736873|NCT02744638|Other|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
79736874|NCT02744638|Drug|Arilin|2 tablets Arilin 500mg for 7 days
79871676|NCT05926193|Dietary Supplement|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
79871677|NCT05925322|Behavioral|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
79273561|NCT02147483|Behavioral|Treatment as usual|Treatment usually provided by clinician
79871678|NCT05925322|Behavioral|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
79273562|NCT02147639|Dietary Supplement|Sodium Nitrate|
79273563|NCT02147639|Dietary Supplement|Sodium Nitrate - double dose|
79875948|NCT05299385|Behavioral|Conventional rehabilition treatment(e.g leaflet) educated by hospital|"Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~method of the conventional rehabilitation treatment~intensity for aerobic exercise and anaerobic exercise"
79577195|NCT03801642|Other|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
79273564|NCT02147639|Dietary Supplement|Placebo|
79577196|NCT03790657|Behavioral|practice of a complex walking task|walking over obstacles
79577197|NCT03790657|Device|Dosage A: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
79577198|NCT03790657|Device|Dosage B: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
79577199|NCT03713645|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant|Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
79577200|NCT03705507|Drug|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
79577201|NCT03705507|Drug|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
79577202|NCT03695848|Device|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
79736875|NCT02744560|Dietary Supplement|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
79736876|NCT00703417|Device|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
79736877|NCT00703417|Device|Computed Tomography|CT scan of the lower back and hip
79736878|NCT00703417|Device|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
79736879|NCT05629078|Device|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
79736880|NCT02744404|Device|POC EID|
80029646|NCT03563391|Other|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
79577203|NCT03686410|Behavioral|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
79577204|NCT03686410|Other|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
79577205|NCT03675308|Biological|Placebo|Placebo for risankizumab administered by subcutaneous injection
79577206|NCT03675308|Biological|Risankizumab|Risankizumab administered by subcutaneous injection
79273565|NCT02147639|Procedure|Increased exercise intensity|
79273566|NCT02147717|Device|Laser stimulation|"Infants will be divided in 2 groups:~Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
79273567|NCT02147717|Device|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
79273568|NCT02695719|Drug|Placebo|Lubiprostone placebo-matching capsules
79273569|NCT02695719|Drug|Lubiprostone|Lubiprostone capsules
79273570|NCT03652454|Device|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
79577207|NCT03667807|Device|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
79577208|NCT03664687|Drug|Zoledronate|Administered intravenously (IV)
79577209|NCT03663504|Other|No Preparation|No preparation before surgery
79577210|NCT03663504|Drug|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
79736881|NCT02744326|Behavioral|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
79736882|NCT02740894|Drug|Gefitinib|
79736883|NCT00857389|Drug|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
79577211|NCT03654066|Drug|Botulinum toxin type A|Botox injection in the LES
79736884|NCT00857389|Drug|Clofarabine|40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
79736885|NCT00857389|Drug|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
79736886|NCT00857389|Procedure|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
79736887|NCT00857389|Drug|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
79736888|NCT00857389|Drug|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
79736889|NCT00857389|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
79736890|NCT00857389|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
79736891|NCT00857389|Drug|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
79736892|NCT00857389|Drug|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
79736893|NCT02741050|Behavioral|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
79736894|NCT02741050|Behavioral|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
79871679|NCT05922618|Device|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
79273571|NCT03652454|Other|conventional fixed appliance treatment|conventional fixed appliance treatment
79577212|NCT03654066|Device|Endoscope balloon dilator|Distal esophageal dilation
79577213|NCT03654066|Other|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
79577214|NCT03654066|Diagnostic Test|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
79736895|NCT03873376|Behavioral|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
79736896|NCT03873376|Behavioral|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
79736897|NCT03873376|Behavioral|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
79273572|NCT02150135|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
79273573|NCT05498168|Genetic|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (~ 1cm3 ) are collected during surgery
79273574|NCT03543059|Drug|GnRH analogue|gonadotrophin releasing hormone analogue
79273575|NCT03166449|Dietary Supplement|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
79577215|NCT03653650|Combination Product|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
79577216|NCT03653650|Combination Product|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
79577217|NCT03653650|Combination Product|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
79577218|NCT03590691|Other|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
79577219|NCT03590691|Other|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
79736898|NCT03868930|Behavioral|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
79871680|NCT05897983|Other|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
79871683|NCT05892081|Biological|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
79871684|NCT05892081|Biological|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
79871685|NCT05891860|Other|Participation in virtual rounds|Virtual participation in daily ICU team rounds
79871686|NCT05876611|Device|New type of self stabilizing atlantoaxial fusion cage|Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
79871687|NCT05875636|Other|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
79871688|NCT05869721|Other|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
79577220|NCT03590691|Behavioral|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
79577221|NCT03590691|Behavioral|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
79871689|NCT05861856|Other|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
79273576|NCT03166449|Dietary Supplement|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
79273577|NCT03741647|Diagnostic Test|sleep study and blood sample|full night polysomnographic study and blood sample to detect some genetic issues
79273578|NCT05498012|Combination Product|placebo dental gel, placebo toothpaste|"Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~Placebo toothpaste; without cannabidiol. For daily use by patient."
79577222|NCT03582488|Drug|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
79736899|NCT03868930|Behavioral|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
79736900|NCT02744482|Drug|risedronate|risedrante tablet (75 mg)
79736901|NCT02744482|Drug|placebo|risedrante placebo tablet (75 mg)
79871690|NCT05861856|Other|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
79871691|NCT05859100|Other|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
79273579|NCT05498012|Combination Product|Cannabidiol dental gel, Cannabidiol toothpaste|"Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient."
79273580|NCT05498012|Combination Product|Placebo toothpaste, Corsodyl dental gel|"Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~Placebo toothpaste; without cannabidiol. For daily use by patient."
79273581|NCT02392689|Other|Procalcitonin|Procalcitonin guided antibiotic therapy
79273582|NCT02150291|Dietary Supplement|Folic acid|
79273583|NCT02150291|Drug|Neurobion|
79273584|NCT02150291|Drug|placebo|
79277661|NCT05791552|Diagnostic Test|Collection of nasal secretion|Standardized collection of nasal secretion in the vicinity of the olfactory cleft
79277662|NCT05791539|Procedure|Erector spinae plane block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
79577223|NCT03580057|Behavioral|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
79736902|NCT02744248|Drug|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
79736903|NCT02744248|Drug|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
79736904|NCT01071798|Drug|Rituximab|As prescribed by physician
79871692|NCT05859100|Other|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
79871693|NCT05855577|Drug|Terazosin|Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
79871694|NCT05832112|Procedure|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
79871695|NCT05829564|Other|virtual reality|The individuals participating in the study will experience virtual reality.
79871696|NCT05829564|Other|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
79871697|NCT05829564|Other|exercise|The individuals participating in the study will performed neck-specific exercises.
79577224|NCT03580057|Behavioral|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
79871698|NCT05829330|Other|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
79871699|NCT05829330|Other|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
79577225|NCT03568552|Behavioral|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
79577226|NCT03553810|Drug|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
79871700|NCT05816031|Dietary Supplement|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
79871702|NCT05809453|Drug|Cocaine|Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
79871703|NCT05809453|Drug|Lidocaine|Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
79871704|NCT05809219|Other|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
79871705|NCT05809219|Other|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
79871706|NCT05809219|Dietary Supplement|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
79871707|NCT05808530|Behavioral|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
79577227|NCT03553810|Drug|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
79736905|NCT02744170|Device|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
79736906|NCT02744170|Device|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
79736907|NCT02744170|Device|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
79736908|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
79736909|NCT00857311|Biological|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
79736910|NCT00857311|Biological|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
79736911|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
79736912|NCT05629000|Procedure|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
80029647|NCT04003974|Drug|Losmapimod|This study includes a 48 week treatment period. Patients will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.
79577228|NCT03546699|Diagnostic Test|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~To describe clinical characteristics and outcomes for these patients.~To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
79736913|NCT05629000|Diagnostic Test|MRI-PWI|Multi-modal MRI before and after surgery.
79736914|NCT05629000|Diagnostic Test|CTA|CTA before and after surgery.
79736915|NCT05629000|Diagnostic Test|PET/MRI|PET/MRI before surgery.
79736916|NCT05629000|Diagnostic Test|Ultrasound|Ultrasound before and after surgery.
79736917|NCT04118881|Other|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
79736918|NCT02875626|Drug|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
79736919|NCT02744014|Behavioral|Add-on Therapy for Axial Spondyloarthritis|
79871708|NCT05803889|Other|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
79871709|NCT05803889|Other|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
79871710|NCT05778448|Device|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
79871711|NCT05773703|Drug|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
79871712|NCT05773703|Drug|PTI-122|Cytoprotective agent
79871713|NCT05772520|Drug|TLL018 tablets|oral tablets administered BID for 12weeks
79871714|NCT05771545|Other|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
79871715|NCT05768789|Dietary Supplement|Buoy Electrolyte|Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.
79871716|NCT05768789|Dietary Supplement|Nuun|Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.
79871717|NCT05768789|Other|Water|Water serves as a control
79871718|NCT05763589|Other|No intervention is involved|No intervention is involved
79871719|NCT05760742|Dietary Supplement|MicAlgae|2 months of supplementation with an innovative microalgae based ingredient
79871720|NCT05760742|Dietary Supplement|Placebo|2 months of supplementation with a placebo (Maltodextrin)
79736920|NCT02874768|Drug|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
79736921|NCT02874768|Drug|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
79736922|NCT04118647|Drug|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
79871721|NCT05756686|Behavioral|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
79871722|NCT05756686|Behavioral|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
80029648|NCT04003974|Drug|Placebo oral tablet|This study includes a 48 week treatment period. Patients will receive Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The placebo tablets are identical to the Losmapimod tablets. Placebo should be taken with food and the date and time of each dose taken recorded in the subject diary.
79736923|NCT02740738|Device|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
79736924|NCT02740738|Device|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
79277663|NCT05791539|Procedure|erector spinae plane block + retrolaminar block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
79871723|NCT05749094|Diagnostic Test|Optic nerve ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
79736925|NCT04118725|Diagnostic Test|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
79736926|NCT05629312|Procedure|Maxillary expansion|The upper jaw is expanded with a removable expansion plate
79871724|NCT05737082|Drug|HCP2201|Take 2 tablets once per period
79871725|NCT05737082|Drug|RLD2205|Take 2 tablets once per period
79871726|NCT05737082|Drug|RLD2206|Take 1 tablet once per period
79871727|NCT05731934|Drug|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
79871728|NCT05730972|Device|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
79871729|NCT05730972|Device|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
79871730|NCT05730972|Drug|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
79875949|NCT05299385|Device|Digital treatment based on Respiratory Rehabilitation Software|"Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise."
79577229|NCT03543865|Behavioral|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
79736927|NCT05629312|Procedure|Extraction of deciduous upper canines|Both deciduous upper canines are extracted in this group
79736928|NCT00857233|Drug|Memantine|20 mg oral tablets once daily
79736929|NCT05628922|Drug|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w * 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w * 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
79736930|NCT05628922|Other|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w * 2 cycles."
80029649|NCT04949386|Drug|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
80029650|NCT04949386|Other|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
80029651|NCT05139693|Device|Respiree|The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval
80029652|NCT05133063|Behavioral|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
79736931|NCT02740426|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
79736932|NCT00856999|Drug|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
79736933|NCT02743624|Procedure|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
79875950|NCT00958139|Other|Permethrin|Permethrin 0.5% treatment of clothing one time
79736934|NCT02743546|Drug|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
80029653|NCT05133063|Behavioral|Control intervention|"Participants receive the following instructions:~Think of the room you are in…. In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
79273585|NCT04907071|Device|Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)|The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
79577230|NCT03543865|Behavioral|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
79736935|NCT02743546|Drug|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
79736936|NCT01071252|Drug|AIN457|
79736937|NCT01071252|Drug|Placebo|
79736938|NCT02743234|Other|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
79736939|NCT02743234|Drug|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
79736940|NCT02743234|Drug|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
79736941|NCT02740270|Drug|GWN323|
79736942|NCT02740270|Drug|PDR001|
79736943|NCT00856843|Drug|BLI800|Solution for oral administration prior to colonoscopy
79736944|NCT00856843|Drug|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
79736945|NCT02875782|Behavioral|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
79736946|NCT02875782|Behavioral|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
80029654|NCT03508765|Diagnostic Test|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
79273586|NCT05744505|Procedure|1565nm Non-ablative Fractional Laser|Every 3 weeks
79871731|NCT05726825|Device|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
80029655|NCT03508765|Diagnostic Test|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
80029656|NCT03508765|Behavioral|Digit Span subtest|Evaluates auditory attention and working memory
79273587|NCT05744505|Procedure|placebo|Every 3 weeks
79273588|NCT04589767|Behavioral|CAPD scale|Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
79273589|NCT02151539|Other|medical chart review|Ancillary studies
79273590|NCT02151539|Other|quality-of-life assessment|Ancillary studies
79273591|NCT03166137|Device|Carbon dioxide laser|Radiation by carbon dioxide laser
79273592|NCT03166137|Device|Cryotherapy|Device using cooling effect
79736947|NCT02740348|Behavioral|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
80029657|NCT03508765|Behavioral|Brief Test of Attention|Assesses selective auditory attention
80029658|NCT03508765|Behavioral|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
79736948|NCT02740348|Behavioral|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
79736949|NCT02743156|Procedure|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
79736950|NCT02743156|Procedure|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
79736951|NCT02743390|Biological|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
79736952|NCT02743390|Other|Saline|Saline for 2 hours (250mL)
79736953|NCT00856609|Drug|Byetta (exenatide)|Exenatide is an injectable medication
79736954|NCT00856609|Behavioral|Weight loss|Because response to weight loss
79871732|NCT05724511|Drug|MIYAIRI 588|In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
80029659|NCT03508765|Behavioral|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
80029660|NCT03508765|Behavioral|Controlled Oral Word Association Test|A timed test of verbal fluency.
79871733|NCT05723549|Drug|HCP1803-3|Take it once per period
79871734|NCT05723549|Drug|RLD2002|Take it once per period
79871735|NCT05723549|Drug|HCP1904-1|Take it once per period
79736955|NCT00856609|Other|Metabolic Chamber|The subject stays in the small room
79871739|NCT05706610|Behavioral|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
79871740|NCT05706610|Behavioral|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
80029661|NCT03508765|Behavioral|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
80029662|NCT03508765|Behavioral|The Center for Epidemiological Study-Depression|assesses perceived depression
79577231|NCT03543865|Other|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
79577232|NCT03516513|Behavioral|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
79736956|NCT00856609|Drug|Placebo|
79871743|NCT05703763|Diagnostic Test|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~Superficial temporal artery to frontal temporal artery~Superficial temporal artery to parietal temporal artery~Common carotid artery to frontal temporal artery~Common carotid artery to parietal temporal artery~Common carotid artery to femoral artery"
79871744|NCT05694819|Drug|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
80029663|NCT03508765|Behavioral|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
80029664|NCT03508765|Other|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
80029665|NCT03563235|Drug|Xulin Jiangu granules|Xulin Jiangu granules tablets
80029666|NCT03563235|Drug|Calcitriol capsules|Calcitriol capsules tablets
80029667|NCT01329900|Drug|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
79577233|NCT03516513|Behavioral|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
79736957|NCT02739958|Drug|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
79736958|NCT02739958|Drug|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
79736959|NCT02740036|Device|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
79871745|NCT05694819|Drug|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
80029668|NCT01329900|Drug|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
80029669|NCT01329900|Drug|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
80029670|NCT01329900|Drug|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
80029671|NCT01329900|Drug|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
80029672|NCT01329900|Procedure|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
79273593|NCT04881877|Device|Synthetic nitrite Condom|The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
79273594|NCT04881877|Device|Latex and graphene Condom|The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
79577234|NCT03483766|Device|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
79577235|NCT03467165|Device|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
79736960|NCT02739802|Drug|Coppertone(BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.Formulation number - SR16-02.
79736961|NCT02739880|Device|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
79736962|NCT01071096|Drug|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
79736963|NCT01071096|Drug|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
79871747|NCT05668988|Drug|DZD9008|orally, 300 mg, once daily until a treatment discontinuation criterion is met.
79871748|NCT05668988|Drug|Pemetrexed+carboplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
79871750|NCT05647213|Biological|iPSC-CL|Autologous IPSCL
79871751|NCT05643105|Procedure|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
79871752|NCT05639036|Device|Image Guided External Ventricular Drain Placement Using the NAV3 System|Nav3 image guidance system used to assist with external ventricular drain placement
79273595|NCT04881877|Device|Standard latex condom|The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
79273596|NCT02229565|Device|Biopsy or prostatectomy|
79273597|NCT02563106|Drug|SYN-004|
79273598|NCT02563106|Drug|Placebo|
79577236|NCT03467165|Device|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
79577237|NCT03453372|Device|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
79577238|NCT03453372|Other|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
79736964|NCT02742844|Biological|APZ2 application|Application of IMP on patients wound.
79736965|NCT02739646|Device|Functional MRI scan|7.0 Tesla functional MRI scan
79736966|NCT02739568|Drug|Pitolisant (BF2.649)|
79736967|NCT02739568|Drug|Placebo|
79736968|NCT02742688|Dietary Supplement|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
79736969|NCT02742688|Dietary Supplement|Placebo|Placebo(4g/day)
79736970|NCT02742610|Behavioral|Mindfulness with Contingency Management|
79871753|NCT05639036|Procedure|Free Hand External Ventricular Drain Placement|External ventricular drain will be placed with the standard free-hand technique
79871754|NCT05635591|Biological|Autologous monocyte - derived DCs pulsed with EBV antigen|Patients will receive approximately （5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
79871755|NCT05628883|Biological|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
79871756|NCT05628883|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
79871757|NCT05628883|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
79875951|NCT00958139|Other|Placebo|water sprayed on clothing one time
79736971|NCT02742610|Behavioral|Active Control|
79871758|NCT05628883|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
79736972|NCT02739724|Procedure|Adnexal surgery|
79736973|NCT00856375|Drug|NKTR-102|IV every 3 weeks
79736974|NCT00856375|Drug|irinotecan|IV every 3 weeks
79577239|NCT03407560|Device|SintLife|"Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage."
79577240|NCT03405129|Behavioral|Phoenix|Phoenix cessation app
79736975|NCT02739490|Procedure|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
79577241|NCT03405129|Behavioral|NRT order button|Ability to order NRT through smartphone app
79577242|NCT03405129|Behavioral|Factoid|Factoid app
79577243|NCT03404596|Drug|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
79577244|NCT03404596|Behavioral|Counseling|Brief counseling sessions, 10-15 minutes each.
79577245|NCT03404596|Behavioral|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
79577246|NCT03404596|Other|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
79577247|NCT03400605|Other|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
79577248|NCT03355456|Procedure|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
79577249|NCT03340220|Drug|XPF-008|Capsule filled with XEN1101
79577250|NCT03340220|Drug|Microcrystalline Cellulose|Placebo capsule
79577251|NCT03340220|Drug|XPF-010|Capsule filled with XEN1101
79871759|NCT05623137|Device|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
79871760|NCT05623137|Device|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy & Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
79577252|NCT03340220|Drug|Itraconazole 400mg|Oral
79577253|NCT03324529|Device|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (<10 breaths/min) with prolonged exhalation.
79577254|NCT03317158|Drug|Durvalumab (Cohort 1-3)|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
79577255|NCT03317158|Radiation|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
79577256|NCT03317158|Biological|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
79577257|NCT03317158|Drug|Gemcitabine|Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
79577258|NCT03317158|Drug|Docetaxel|Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
79736976|NCT01070784|Drug|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
79736977|NCT01070784|Drug|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
79736978|NCT00837577|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
79736979|NCT00837577|Drug|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
79736980|NCT00837577|Drug|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
79875952|NCT00450216|Drug|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
79875953|NCT00450216|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
79875954|NCT00953693|Procedure|Biopsy|Skin biopsy
79736981|NCT02742220|Other|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
79736982|NCT02742220|Other|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
79736983|NCT02742298|Device|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
79577259|NCT03317158|Biological|Tremelimumab|Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
79577260|NCT03317158|Drug|Durvalumab (Cohort 4/5)|Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
79273599|NCT03166059|Device|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
79273600|NCT02155517|Drug|Evaluation of propofol effect|"The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
79736984|NCT02742298|Other|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
79577261|NCT03317158|Other|To be determined|Other regimens to be determined
79871761|NCT05623137|Other|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
79871762|NCT05616247|Behavioral|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
79871763|NCT05616247|Behavioral|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
79871764|NCT05607043|Device|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
79577262|NCT03311997|Procedure|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
79577263|NCT03304223|Diagnostic Test|[18F]FB-IL2 PET scan|[18F]FB-IL2 PET scan procedure
79577264|NCT03293056|Other|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
79736985|NCT01070550|Drug|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
79736986|NCT02742376|Other|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
79736987|NCT02742376|Other|Floor|A marked path on the floor where the subject is instructed to walk.
79736988|NCT02742376|Other|Kyboot shoes|Special shoes will be worn by the subject.
79871765|NCT05591833|Procedure|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
79273601|NCT02155517|Drug|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
79577265|NCT03293056|Other|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
79577266|NCT03274960|Combination Product|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
79577267|NCT03274882|Drug|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
79577268|NCT03263247|Behavioral|Memory Training|
79577269|NCT03263247|Behavioral|Psychoeducation|
79577270|NCT03263247|Behavioral|Alphabet search|
79871766|NCT05591833|Procedure|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
79577271|NCT03246841|Other|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
79871767|NCT05590455|Drug|Adalimumab Injection|one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
79736989|NCT02739178|Other|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
79871768|NCT05589116|Other|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
79871769|NCT05582876|Radiation|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
79577272|NCT03241693|Other|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
79871770|NCT05580003|Drug|PF-07817883|Oral suspension or solid oral formulation(s)
79577273|NCT03241693|Other|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
79273602|NCT03115125|Other|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
79577274|NCT03171064|Behavioral|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
79273603|NCT02155595|Other|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
79736990|NCT04189900|Drug|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
79871771|NCT05580003|Drug|Placebo|Placebo suspension
79273604|NCT02155595|Other|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
79736991|NCT00848107|Drug|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
80029673|NCT03677635|Behavioral|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
79736992|NCT02739334|Behavioral|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
79736993|NCT02739334|Behavioral|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
79736994|NCT00703495|Device|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
80029674|NCT03834597|Device|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
79736995|NCT02739256|Procedure|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
79273605|NCT05497934|Drug|Glycerol|In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
79736996|NCT04030741|Drug|Meronem and flagyl|meronem and flagy
79736997|NCT04030741|Procedure|Appendectomy|Appendectomy as treatment for acute appendicitis
79736998|NCT03689140|Behavioral|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
79736999|NCT03689140|Behavioral|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
79871772|NCT05580003|Drug|Midazolam|midazolam oral solution
79871773|NCT05580003|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet
79871774|NCT05578742|Procedure|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
79273606|NCT02229721|Drug|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
79871775|NCT05578742|Procedure|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
79871776|NCT05574790|Other|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
79871777|NCT05572229|Drug|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
79871778|NCT05572229|Drug|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
79871779|NCT05572229|Drug|Lenalidomide|Lenalidomide will be administered orally
80029675|NCT03834597|Device|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
80029676|NCT04948216|Other|No intervention|No intervention
79737000|NCT03689140|Behavioral|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
79871780|NCT05570825|Procedure|Biopsy|Undergo biopsy
79871781|NCT05570825|Procedure|Biospecimen Collection|Undergo collection of blood samples
79871782|NCT05570825|Procedure|Computed Tomography|Undergo PET/CT or CT
79871783|NCT05570825|Drug|CXCR1/2 Inhibitor SX-682|Given PO
79871784|NCT05570825|Procedure|Magnetic Resonance Imaging|Undergo MRI
79871785|NCT05570825|Biological|Pembrolizumab|Given IV
79871786|NCT05570825|Procedure|Positron Emission Tomography|Undergo PET/CT
79871787|NCT05569408|Drug|EVUSHELD|Tixagevimab (AZD8895) and cilgavimab (AZD1061)
79871788|NCT05567679|Drug|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
79871789|NCT05563818|Other|WinterLight Mobile Phone Speech Analysis|N/A- observational study
80029677|NCT05127993|Device|Passive Talaris Demonstrator|"The amputee will walk with the passive Talaris Demonstrator, a novel prosthetic foot, designed and built by Axiles Bionics."
80029678|NCT03997812|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
79273607|NCT02229721|Drug|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
79273608|NCT04927403|Other|multimodal integrative naturopathic therapy concept|Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
79577275|NCT03171012|Other|Lower limbs CRT|cycle ergometer for lower limbs
79577276|NCT03171012|Other|Upper limbs CRT|cycle ergometer for upper limbs
79737001|NCT04298632|Behavioral|Safety Education Program|this is a pesticide safety education program
79737002|NCT00636376|Procedure|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
79273609|NCT05497700|Drug|Ephedrine|Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
79871790|NCT05558410|Drug|VX-548|Tablets for oral administration.
79871791|NCT05558410|Drug|HB/APAP|Capsules for oral administration.
79273610|NCT05497700|Drug|Norepinephrine|Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
79273611|NCT04866433|Procedure|Real-time binaural sound|Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.
79871792|NCT05558410|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
79871793|NCT05558410|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
79871794|NCT05557032|Procedure|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
79871795|NCT05552781|Drug|H002 capsule|Small molecule, Capsule
79871796|NCT05548543|Drug|HCP2202|Take it once per period.
80029679|NCT03997812|Drug|Placebo|IV infusion of 0 mg of VVZ-149
79273612|NCT04866433|Procedure|Music|Play the same music in both ears through headphones during sedation
79273613|NCT04866433|Procedure|Control|Just wear headphones during sedation
79273614|NCT02155673|Drug|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
79577277|NCT03171012|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
79577278|NCT03171012|Other|respiration|respiration
79577279|NCT03161860|Behavioral|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
79577280|NCT03147859|Biological|Vedolizumab (brand name Entyvio)|IV infusion
79577281|NCT03131219|Biological|Ravulizumab|Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing < 20 kg.
79577282|NCT03103789|Diagnostic Test|single catheter mucosal impedance testing|
79577283|NCT03103789|Diagnostic Test|balloon assembly mucosal impedance testing|
79871797|NCT05548543|Drug|RLD2202|Take it once per period.
79871798|NCT05548543|Drug|RLD2203|Take it once per period.
79871799|NCT05548387|Drug|HCP2202|Take it once per period.
79871800|NCT05548387|Drug|RLD2202|Take it once per period.
79871801|NCT05548387|Drug|RLD2203|Take it once per period.
79871802|NCT05522569|Drug|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
79871803|NCT05512234|Dietary Supplement|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
79871804|NCT05512234|Dietary Supplement|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
79875955|NCT01566006|Drug|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
79875956|NCT05300165|Dietary Supplement|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
79875957|NCT00441480|Dietary Supplement|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
79875958|NCT00441480|Dietary Supplement|placebo|4 gr of corn oil
79577284|NCT03063463|Procedure|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
79871805|NCT05508152|Drug|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
79871806|NCT05508152|Drug|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
79871807|NCT05500378|Other|Head extension and rotation movement|Active exercise of the head
79871808|NCT05492565|Drug|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
79737003|NCT02736760|Drug|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
79871809|NCT05486104|Drug|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
79871810|NCT05486104|Drug|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
79871811|NCT05485168|Other|Sequential Variety|3 different foods served in 3 successive courses
79871812|NCT05485168|Other|Single-Food|1 food served in 3 successive courses
79871813|NCT05485168|Other|Small Portion|Small meal portion size
79871814|NCT05485168|Other|Large Portion|Large meal portion size
79871815|NCT05481411|Drug|Olpasiran|Subcutaneous injection
79871816|NCT05481307|Drug|RLD2202|Take it once a day per period
79871817|NCT05481307|Drug|RLD2203|Take it once a day per period
79871818|NCT05454514|Device|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
79871819|NCT05454514|Device|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
79871820|NCT05454514|Other|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
79871821|NCT05452174|Drug|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
79871822|NCT05448547|Radiation|Radiotherapy or surgery|see arm/ group description
79871823|NCT05448547|Other|initial observation|see arm/ group description
79871824|NCT05448547|Drug|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
79871825|NCT05446779|Diagnostic Test|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
79871826|NCT05446779|Diagnostic Test|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
79871827|NCT05446779|Diagnostic Test|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
80029680|NCT02825043|Device|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
80029681|NCT04948372|Drug|Terlipressin treatment|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
79273615|NCT02691741|Device|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
79577285|NCT03063463|Procedure|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
79577286|NCT03055208|Radiation|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
79577287|NCT02948725|Other|Cross-education + standard rehabilitation|
79577288|NCT02914613|Drug|SF0166 Topical Ophthalmic Solution|
79737004|NCT02736760|Procedure|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
79871828|NCT05434702|Behavioral|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
79871829|NCT05434702|Behavioral|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
79871830|NCT05434702|Behavioral|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
79871831|NCT05434702|Behavioral|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
79871832|NCT05434702|Behavioral|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
80029682|NCT04948372|Drug|Usual care|Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
79577289|NCT02908984|Behavioral|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
79737005|NCT02736838|Device|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
79871833|NCT05434702|Behavioral|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
79871834|NCT05434702|Behavioral|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
79871835|NCT05431166|Behavioral|Virtual Yoga at First 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study
79871836|NCT05431166|Behavioral|Virtual Yoga at Second 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
79871837|NCT05423197|Drug|89Zr-panitumumab IV|Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
79871838|NCT05423197|Drug|Panitumumab|Panitumumab 30mg will be given orally
79871839|NCT05411471|Biological|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
79871840|NCT05399693|Procedure|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
80029683|NCT03960606|Combination Product|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
79273616|NCT02691741|Device|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
79577290|NCT02908984|Other|Standard primary health care|The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
79577291|NCT02793726|Procedure|NMR|NMR
79577292|NCT02781857|Other|No intervention|
79737006|NCT02736838|Device|Laser Doppler|
80029684|NCT03960606|Combination Product|Placebo|PUR1900 placebo
80029685|NCT04947748|Other|Oral versus intravenous administration of antibacterial treatment|Mode of administration of antibacterial treatment
80029686|NCT05184543|Other|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
79277664|NCT05791500|Behavioral|lifestyle intervention|dietary behavior interventions:through a couple of dietary health education lectures physical activity interventions:through at least an offline teaching and jump rope or jog regularly and quantitatively life schedule and habits intervention group: live in a regular and healthy life habit and last at least 4 months
79737007|NCT00856297|Biological|MenACWY-CRM conjugate vaccine|
79737008|NCT00856297|Biological|Licensed comparator|
79737009|NCT02875470|Device|Intensiv Perio Set|Diamond burs for root planing
79737010|NCT02875470|Device|Gracey curette|
79737011|NCT02738944|Behavioral|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
79737012|NCT02738944|Behavioral|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
79737013|NCT04304898|Other|Home spirometry|"Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~Hospital-based spirometry will be performed according to international guidelines.~Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
79871841|NCT05399498|Drug|Psilocybin|Psilocybin 25mg capsule
79871842|NCT05389826|Device|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
79273617|NCT02155751|Behavioral|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
79577293|NCT02753335|Behavioral|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
79577294|NCT02753335|Behavioral|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
79871843|NCT05377008|Behavioral|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
79871844|NCT05371860|Other|Omit breast radiation|Omit breast radiation for 3 years after surgery
79871845|NCT05349591|Biological|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
79871846|NCT05342441|Procedure|QT graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
80029687|NCT05184543|Other|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
79273618|NCT02155751|Behavioral|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
79273619|NCT03993223|Behavioral|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
79577295|NCT02723474|Device|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
79577296|NCT02713945|Drug|Simvastatin|Experimental drug administrated orally
79577297|NCT02713945|Drug|Placebo|Treatment for the control group
79577298|NCT02686229|Other|no interventions|
79577299|NCT02685605|Procedure|Standard surgery|
79737014|NCT02875938|Behavioral|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
79737015|NCT02875938|Behavioral|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
79737016|NCT02875938|Behavioral|Control|control condition using reading materials without music.
79737017|NCT02736604|Drug|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
79737018|NCT02736604|Drug|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
79871847|NCT05342441|Procedure|ST/Gr graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
79871848|NCT05342441|Procedure|BPTB graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar."
79871849|NCT05342428|Drug|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
79871850|NCT05335083|Device|CPAP withdrawal|A negative CPAP intervention
79871851|NCT05323812|Drug|TW001|daily dose of 100 mg TW001/placebo
79871852|NCT05323812|Drug|Placebo|daily dose of 100 mg TW001/placebo
79871853|NCT05323110|Drug|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
79871854|NCT05323110|Drug|Placebo|CBS001 matched placebo
79871855|NCT05301062|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
79273620|NCT02156063|Drug|NT100|
79273621|NCT02156063|Drug|Placebo|
79273622|NCT03106389|Drug|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
79273623|NCT03106389|Device|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
79273624|NCT02258893|Other|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
79273625|NCT02258893|Other|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
79871856|NCT05294159|Other|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
79273626|NCT02258893|Other|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
79273627|NCT03106311|Diagnostic Test|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
79273628|NCT02255045|Drug|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
79273629|NCT02255045|Drug|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
79273630|NCT02255045|Drug|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
79273631|NCT02255045|Drug|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
79273632|NCT02258971|Drug|BEA 2180 BR oral|Oral solution
79577300|NCT02685605|Radiation|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
79577301|NCT02685605|Radiation|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
79577302|NCT02685605|Drug|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
79737019|NCT02736604|Device|laryngeal mask airway (LMA Supreme Size 3/4|
79737020|NCT02736604|Drug|sevoflurane|
79737021|NCT02613013|Device|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
79273633|NCT02258971|Drug|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
79871857|NCT05269303|Device|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
79273634|NCT01257763|Device|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
79577303|NCT02664935|Drug|AZD4547|FGFR Inhibitor
79577304|NCT02664935|Drug|Vistusertib|MTORC1/2 Inhibitor
79577305|NCT02664935|Drug|Palbociclib|CDK4/6 Inhibitor
79273635|NCT01257763|Device|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
79273636|NCT03106233|Procedure|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
79577306|NCT02664935|Drug|Crizotinib|ALK/MET/ROS1 Inhibitor
79577307|NCT02664935|Drug|Selumetinib|MEK Inhibitor
79273637|NCT02229799|Drug|Actilyse|
79273638|NCT02150447|Drug|Proton pump inhibitor|Lansoprazole 30 mg, daily
79273639|NCT02150447|Drug|Placebo|Placebo, daily
79577308|NCT02664935|Drug|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
79577309|NCT02664935|Drug|AZD5363|AKT Inhibitor
79577310|NCT02664935|Drug|Osimertinib|EGFRm+ T790M+ Inhibitor
79273640|NCT03934099|Drug|LC350189 formulated capsule|Xanthine Oxidase Inhibitor
79577311|NCT02664935|Drug|Durvalumab|Anti-PDL1
79577312|NCT02664935|Drug|Sitravatinib|VEGFR Inhibitor
79577313|NCT02664935|Drug|AZD6738|ATR inhibitor
79737022|NCT02613013|Device|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
79273641|NCT03934099|Drug|Placebo|Matching placebo
79273642|NCT02254889|Drug|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
79273643|NCT02150525|Dietary Supplement|omega-3 fatty acid|Given PO (by mouth) daily
79273644|NCT02150525|Other|placebo|Given PO(by mouth)daily
79577314|NCT02658474|Behavioral|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
79577315|NCT02610179|Dietary Supplement|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
79577316|NCT02610179|Dietary Supplement|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
79577317|NCT02586207|Drug|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
79577318|NCT02586207|Drug|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
79737023|NCT02613013|Drug|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
79737024|NCT02613013|Procedure|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
79737025|NCT02613013|Drug|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
79871859|NCT05261009|Drug|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
79871860|NCT05261009|Other|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
79871861|NCT05259059|Other|No intervention is involved|No intervention is involved
79277665|NCT05791487|Other|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
79277666|NCT05791487|Other|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
79577319|NCT02586207|Radiation|Radiation|70 Gy fractionated over 35 days
79577320|NCT02573324|Drug|Temozolomide|Oral Capsule
79577321|NCT02573324|Drug|Depatuxizumab mafodotin|Intravenous (IV) Infusion
79577322|NCT02573324|Radiation|Radiation|
79577323|NCT02573324|Drug|Placebo for ABT-414|IV Infusion (IV)
79577324|NCT02572557|Device|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
79577325|NCT02572557|Drug|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
79577326|NCT02553642|Drug|Nivolumab|"Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
79577327|NCT02553642|Drug|Nivolumab plus Ipilimumab|"Combination Treatment~Ipilimumab 3 mg/kg~Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
79577328|NCT02523092|Drug|Acthar gel|Acthar gel given IM or SQ as per package insert
79273645|NCT02150525|Behavioral|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
79577329|NCT02482350|Behavioral|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
79577330|NCT02450773|Drug|Furosemide|40 mg furosemide on postpartum day 1-6
79577331|NCT02450773|Drug|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
79273646|NCT02229955|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
79273647|NCT03922165|Procedure|Adenotonsillectomy|Routine AT per clinical care.
79273648|NCT02392143|Other|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test [18]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
79277667|NCT05791487|Other|free diet|oral Budeosnide for 6 weeks + free diet
79577332|NCT02450773|Drug|Placebo #1|Placebo (for furosemide)
79577333|NCT02450773|Drug|Placebo #2|Placebo (for KCl)
79577334|NCT02445248|Biological|Tisagenlecleucel|A single infusion of 5 x 10^8 viable CTL019 transduced cells, which will be administered via intravenous infusion.
79577335|NCT02445248|Drug|Lymphodepleting chemotherapy|Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle is planned. The use of any additional chemotherapy prior to the recommended lymphodepleting chemotherapy will be at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy should be started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The proposed lymphodepleting regimen is: Fludarabine (25 mg/m2 intravenously [i.v.] daily for 3 doses) and cyclophosphamide (250 mg/m2 i.v. daily for 3 doses starting with the first dose of fludarabine).
79577336|NCT02420548|Behavioral|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
79737026|NCT02613013|Procedure|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
79737027|NCT04304976|Device|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
79737028|NCT02738710|Procedure|transumbilical incision|incision within umbilicus
79737029|NCT02738710|Procedure|Infra umbilical incision|incision about 1 cm below umbilicus
79737030|NCT02611921|Drug|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
79737031|NCT02611921|Drug|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
79737032|NCT02736448|Drug|Capecitabine|oral low dose of capecitabine
79875959|NCT00958451|Drug|Paricalcitol|"Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
79277668|NCT05791487|Drug|Oral Budesonide|Oral Budesonide 9 mg
79403205|NCT04027933|Behavioral|Education Based on Standard Patient Simulation|"In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups."
79403206|NCT04021303|Dietary Supplement|Experimental cereal|Cereal containing probiotics, prebiotic fiber and low carbohydrates
79403207|NCT04021303|Dietary Supplement|Conventional cereal|Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
79577337|NCT02420548|Behavioral|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
79737033|NCT02736448|Drug|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
79737034|NCT02736448|Drug|SS-LAR|long acting octreotide or lanreotide
79737035|NCT00701077|Drug|3,4-Di-amino-Pyridine|a single 20 mg dosing
79737036|NCT00701077|Drug|placebo|placebo
79737037|NCT02738476|Procedure|Patellofemoral arthroplasty|
79737038|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
79737039|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
79871862|NCT05257928|Behavioral|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
79871863|NCT05254236|Biological|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
79871864|NCT05254236|Biological|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
79871865|NCT05247216|Drug|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
79871866|NCT05247216|Drug|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
79871867|NCT05247216|Drug|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
79871868|NCT05247216|Drug|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
79871869|NCT05243810|Device|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
80029688|NCT05184543|Other|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
79577338|NCT02412566|Drug|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
79577339|NCT02397226|Procedure|Radiofrequency ablation|
79273649|NCT02392143|Other|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
79403208|NCT04021225|Device|Ectoin® Allergy Eye Drops 2%|A one-time application of 1-2 drops in the more affected eye will be investigated.
79577340|NCT02397226|Procedure|High ligation/stripping|
79577341|NCT02397226|Device|Radiofrequency ablation catheter|
79577342|NCT02397226|Procedure|Tumescent anesthesia|
79577343|NCT02397226|Procedure|General anesthesia|
79577344|NCT02397226|Device|Vein stripping catheter|
79577345|NCT02396277|Procedure|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
79577346|NCT02308878|Behavioral|Mobile health cognitive stimulation|
79577347|NCT02296684|Biological|MK-3475 (neoadjuvant)|
79577348|NCT02296684|Procedure|Surgery|Standard of care
79577349|NCT02296684|Radiation|Intensity modulated radiation therapy|Recommended, standard of care
79577350|NCT02296684|Radiation|Image-guided radiation therapy|Recommended, standard of care
79871870|NCT05242042|Drug|JT001|JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
79871871|NCT05242042|Drug|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
79871872|NCT05232942|Other|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
79871873|NCT05221125|Behavioral|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
79871874|NCT05217147|Other|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
79871875|NCT05216081|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
79871876|NCT05199129|Drug|HCP1904-3|Take once daily for 8 weeks orally
79871877|NCT05199129|Drug|RLD2001-1|Take once daily for 8 weeks orally
79871878|NCT05194202|Behavioral|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
79871879|NCT05181917|Behavioral|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
79871880|NCT05179616|Procedure|Transcatheter edge-to-edge tricuspid valve repair|Percutaneous edge to edge repair of tricuspid valve using the TriClip system
79871881|NCT05175014|Biological|PCV10 full dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.
79871882|NCT05175014|Biological|PCV10 fractional dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
79871883|NCT05165823|Behavioral|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
80029689|NCT04947826|Procedure|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
80029690|NCT04947826|Drug|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
80029691|NCT04947826|Drug|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
79403209|NCT04021225|Device|Ectoin® Eye Spray Colloidal|A one-time application of 1-2 drops in the more affected eye will be investigated.
79403210|NCT04021225|Device|Tears Again® eye spray|A one-time application of 1-2 drops in the more affected eye will be investigated.
79577351|NCT02296684|Drug|Cisplatin|Standard of care
79871884|NCT05159245|Drug|Alectinib|ALK
79403211|NCT05097066|Procedure|Neurosurgical procedure|Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
79577352|NCT02296684|Biological|MK-3475 (adjuvant)|
79871885|NCT05159245|Drug|Cobimetinib|MEK1, MEK2
79871886|NCT05159245|Drug|Vismodegib|Hedgehog
79871887|NCT05159245|Drug|Trastuzumab+Pertuzumab|HER2
79871888|NCT05159245|Drug|Entrectinib|NTRK/ ROS1, ALK
79871889|NCT05159245|Drug|Atezolizumab|PD-L1
79577353|NCT02296684|Procedure|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
79577354|NCT02107261|Drug|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
79577355|NCT02107261|Drug|Placebo|matching placebo
79577356|NCT02098265|Device|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
79737040|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
79737041|NCT01046136|Drug|guaifenesin (Mucinex)|bid 7 days
79737042|NCT01046136|Drug|placebo|bid 7 days
79737043|NCT02736682|Drug|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
79871890|NCT05159245|Drug|Vemurafenib|BRAF V600
79871891|NCT05159245|Drug|Regorafenib|KIT/BRAF, RET
79737044|NCT02736682|Drug|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
79737045|NCT02736292|Behavioral|Mindfulness Practices for Healthcare Professionals|
79737046|NCT02874690|Drug|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
79737047|NCT02874690|Drug|Placebo|Placebo pill identical in appearance to methylphenidate
79871892|NCT05159245|Drug|Apalutamide|AR
79871893|NCT05159245|Drug|Abemaciclib|CDK4/6
79871894|NCT05159245|Drug|Selpercatinib|RET
79871895|NCT05159245|Drug|Dabrafenib|RAF
80029692|NCT04947826|Drug|Placebo|Placebo
80029693|NCT04947982|Other|carbon dioxide|carbon dioxide insufflation pressure
80029694|NCT03563079|Other|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
80029695|NCT03563079|Other|Manual Myofascial Release|Myofascial Release Technique
79403212|NCT04021147|Behavioral|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
79871896|NCT05159245|Drug|Trametinib|MEK1, MEK2
79871897|NCT05159245|Drug|Dabrafenib+Trametinib|RAF, MEK1, MEK2
79871898|NCT05159245|Drug|Pralsetinib|RET
79871899|NCT05155995|Drug|HCP2001|Take it once per period.
79871900|NCT05155995|Drug|RLD2007|Take it once per period.
79871901|NCT05155995|Drug|RLD2008|Take it once per period.
80029696|NCT02228616|Drug|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
79577357|NCT02098265|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
79577358|NCT02098265|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
79871902|NCT05155995|Drug|RLD2102|Take it once per period.
79577359|NCT02098265|Other|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
79577360|NCT02098265|Other|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
79737048|NCT02736214|Behavioral|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
79737049|NCT05298007|Device|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
79871903|NCT05142371|Other|Best Practice|Continue current activities of daily living
79871904|NCT05142371|Other|Exercise Intervention|Participate in exercise intervention
79737050|NCT05298007|Device|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
79871905|NCT05142371|Other|Quality-of-Life Assessment|Ancillary studies
79871906|NCT05142371|Other|Questionnaire Administration|Complete questionnaires
79871907|NCT05120830|Biological|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
79871908|NCT05120830|Other|Normal Saline IV Administration|The administration of IV normal saline
79577361|NCT02098265|Other|Delay|10 week delay before intervention
79577362|NCT02098265|Device|BCI-FES|
79577363|NCT02014597|Device|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
79577364|NCT01962324|Radiation|SIB Dose-Escalation Radiotherapy|
79577365|NCT01942954|Other|Mobile health cognitive stimulation|
79577366|NCT01900574|Drug|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
79737051|NCT02738242|Device|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
79871909|NCT05116995|Drug|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
80029697|NCT02228616|Drug|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
80029698|NCT02228616|Drug|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
80029699|NCT04759950|Behavioral|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
79737052|NCT02738632|Drug|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
79737053|NCT02738632|Drug|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
79737054|NCT02738632|Drug|Placebo for Hydrochlorothiazide|
79737055|NCT01070394|Drug|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
79871910|NCT05116995|Drug|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
79871915|NCT05105776|Device|Galvanic stimulation|Galvanic stimulation during physiotherapy sessions
80029700|NCT04759950|Behavioral|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
79273650|NCT02392143|Other|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
79273651|NCT05033327|Behavioral|Nutrition and Exercise app|Personalized, home-based, interactive therapy app
79273652|NCT02230033|Drug|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
79273653|NCT02230033|Drug|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
79273654|NCT02230033|Drug|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
79577367|NCT01582204|Drug|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd & pelvis), 124I-cG250-PET/CT & Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan & 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, & pelvis with contrast after cycles 2, 3, 4 & 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline & week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, & serial blood sampling, following the lst inj of 124I-cG250.
79577368|NCT01558999|Drug|High concentration SI-614|1 drop in each eye 4 times a day
79577369|NCT01558999|Drug|Low concentration SI-614|1 drop in each eye 4 times a day
79577370|NCT01558999|Drug|Vehicle|1 drop in each eye 4 times a day
79737056|NCT00836953|Biological|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
79737057|NCT02736058|Device|Trans- abdominal sonography|
80029701|NCT04759950|Behavioral|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
80029702|NCT05086965|Other|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
79273655|NCT05740371|Drug|Argatroban|"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT > 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
79577371|NCT01491568|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
80029703|NCT04947280|Radiation|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
80029704|NCT03834675|Diagnostic Test|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
79577372|NCT01342367|Drug|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
79577373|NCT01342367|Drug|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
79577374|NCT01342367|Drug|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
79577375|NCT01342367|Radiation|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
79737058|NCT02736058|Device|Trans-vaginal sonography|
79737059|NCT02736058|Procedure|post-operative pathological specimen examination|
79577376|NCT01220908|Device|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
79577377|NCT01220908|Device|Coils|Lung Volume Reduction Coil(s)
79737060|NCT00703807|Drug|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
79737061|NCT00703807|Drug|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
79737062|NCT03649438|Drug|131 I-Metaiodobenzylguanidine|"Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~Dose of > 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
79273656|NCT02230111|Behavioral|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
80029705|NCT03830541|Other|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
79403213|NCT04021147|Behavioral|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
79403214|NCT04021147|Behavioral|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
79577378|NCT01185171|Drug|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance [CC] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
79737063|NCT03649438|Drug|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
79403215|NCT04021147|Behavioral|Exercise|Orofacial exercises
79871916|NCT05097885|Other|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
79871917|NCT05097222|Device|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
79871918|NCT05097222|Device|Sham device|Control
80029706|NCT04946890|Drug|MRX2843|MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
79403216|NCT05096910|Procedure|Uterine Closure with monofilament or polyfilament suture materials|Postoperative 6th-month isthmocele rates
79403217|NCT04027387|Biological|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
79403218|NCT05096676|Drug|Oxytocin: Including placebo|Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
79403219|NCT04027543|Combination Product|Neoadjuvant chemoradiotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
79577379|NCT01106261|Procedure|Metastasectomy|Pulmonary Metastasectomy
79577380|NCT01106261|Procedure|Active monitoring|Active monitoring
79737064|NCT03649438|Drug|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
80029707|NCT04413604|Other|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
80029708|NCT02228772|Drug|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
80029709|NCT02228772|Drug|Vincristine|Standard chemotherapy dosage and duration
79737065|NCT02738554|Other|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
79737066|NCT00701233|Drug|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
80029710|NCT02228772|Drug|Cytarabine|Standard chemotherapy dosage and duration
80029711|NCT02228772|Drug|Doxorubicin|Standard chemotherapy dosage and duration
79737067|NCT00701233|Drug|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
80029712|NCT02228772|Drug|Mercaptopurine|Standard chemotherapy dosage and duration
79403220|NCT04027543|Procedure|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
79871919|NCT05095857|Drug|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
79871920|NCT05095857|Other|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
80029713|NCT02228772|Drug|Cyclophosphamide|Standard chemotherapy dosage and duration
80029714|NCT02228772|Drug|Methotrexate|Standard chemotherapy dosage and duration
80029715|NCT03833037|Other|Soft tissue sarcomas in adults|Adult sinovial sarcoma
79273657|NCT02230111|Behavioral|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
79273658|NCT03543215|Other|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
79737068|NCT03645694|Device|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
80029716|NCT03638466|Diagnostic Test|Functional Magnetic Resonance Imaging (fMRI)|Neural brain activity measured by fMRI
80029717|NCT03638466|Diagnostic Test|Magnetic Resonance Spectroscopy (MRS)|Glutamate and GABA levels measured by MRS
79577381|NCT00987532|Behavioral|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
79577382|NCT00987532|Behavioral|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
79577383|NCT00896493|Drug|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
79577384|NCT00896493|Drug|cyclosporine|5 mg/kg PO or IV
80029718|NCT03638466|Behavioral|Point Subtraction Aggression Paradigm (PSAP) Task|Aggression score measured by the PSAP task
80029719|NCT03638466|Drug|SPN-810|Treatment of SPN-810 36 mg on neuronal brain activity, GABA and Glutamate levels and on the aggression score
80029720|NCT03638466|Drug|Placebo|Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
79273659|NCT02223949|Device|Cook double balloon catheter|
79577385|NCT00896493|Radiation|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
79577386|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
79577387|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
79737069|NCT03633058|Drug|Ketamine|oral ketamine dosed twice daily for 5 days
80029721|NCT03630588|Combination Product|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
80029722|NCT03630588|Combination Product|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
80029723|NCT02228850|Drug|Alprostadil|
80029724|NCT02228850|Other|Placebo|
80029725|NCT02232828|Procedure|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
79273660|NCT02223949|Drug|PGE1 tablet|
79273661|NCT02151617|Drug|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
79273662|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
79273663|NCT02151617|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
79737070|NCT01070316|Drug|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
79737071|NCT02737774|Drug|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
79737072|NCT02737774|Drug|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
79737073|NCT02735590|Drug|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
79871921|NCT05094817|Other|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
79871922|NCT05094817|Other|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
79871923|NCT05094817|Other|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
79871924|NCT05094817|Other|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
79737074|NCT02735590|Drug|Rifapentine|Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
79273664|NCT02151617|Drug|Placebo|Placebo tablet once daily dosing for 14 days
79577388|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
79577389|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
79737075|NCT05626348|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79577390|NCT00695552|Behavioral|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
79273665|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
79577391|NCT00695552|Behavioral|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
79577392|NCT00598026|Other|Tele- follow-up|Remote transmission to the implantation centre every 3 months
79577393|NCT00598026|Other|Conventional follow-up|Visits at the implantation centre every 3 months
79273666|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
79273667|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
79273668|NCT02151617|Drug|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
79737076|NCT05626348|Drug|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79737077|NCT05626348|Drug|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79273669|NCT02151617|Drug|PF-06743649|Tablet, to be decided dose, once daily, 14 days
79273670|NCT02151617|Drug|Placebo|Tablet, once daily, 14 days
79273671|NCT02691507|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
79737078|NCT05626348|Drug|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79737079|NCT05626348|Drug|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
79875960|NCT00958451|Drug|Ergocalciferol|"If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
79273672|NCT02691507|Drug|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
79273673|NCT02150681|Behavioral|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
79577394|NCT00585065|Device|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
79577395|NCT00444093|Drug|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
79577396|NCT00444093|Drug|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
79577397|NCT00316290|Behavioral|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
79577398|NCT00316290|Behavioral|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
79871925|NCT05094817|Other|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
79871926|NCT05094817|Other|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
79871927|NCT05094817|Other|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
79871928|NCT05094817|Other|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
79871929|NCT05094817|Other|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
79871930|NCT05094817|Other|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
79871931|NCT05094817|Other|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
79871932|NCT05086380|Behavioral|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
79273674|NCT02259361|Drug|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
79273675|NCT02259361|Drug|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
79273676|NCT02255201|Dietary Supplement|Master Performance Blend Dose 1|Caffeine content: 200 mg
79273677|NCT02255201|Dietary Supplement|Master Performance Blend Dose 2|Caffeine content: 400 mg
79273678|NCT02255201|Dietary Supplement|Performance Energy Blend|Caffeine content: 175 mg
79577399|NCT00003042|Biological|filgrastim|
79577400|NCT00003042|Drug|cisplatin|
79577401|NCT00003042|Drug|cyclophosphamide|
79577402|NCT00003042|Drug|doxorubicin hydrochloride|
79577403|NCT00003042|Drug|melphalan|
79577404|NCT00003042|Drug|mesna|
79273679|NCT02255201|Dietary Supplement|Energy Blend|Caffeine content: 200 mg
79273680|NCT02255201|Dietary Supplement|Placebo|Caffeine content: 0 mg
79577405|NCT00003042|Drug|paclitaxel|
79737080|NCT02737696|Behavioral|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
79871933|NCT05086380|Device|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
79577406|NCT00003042|Drug|tamoxifen citrate|
79871934|NCT05086380|Behavioral|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
79871935|NCT05086380|Device|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
79871936|NCT05086380|Device|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
79871937|NCT05086380|Device|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
79871938|NCT05086380|Behavioral|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
79871939|NCT05078398|Behavioral|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
79871940|NCT05078398|Behavioral|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
79871941|NCT05056623|Behavioral|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
79273681|NCT02224027|Device|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
79577407|NCT00003042|Procedure|bone marrow ablation with stem cell support|
79577408|NCT00003042|Procedure|conventional surgery|
79871942|NCT05056623|Other|Usual care and pain management pamphlet|Usual care and pain management pamphlet
79871943|NCT05053113|Device|Activity Monitor|Monitor physical activity with FitBit
79273682|NCT02224027|Device|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
79273683|NCT02224027|Device|i-gel|In i-gel group, i-gel is inserted by novices.
79273684|NCT02156141|Other|Supervised high intensity training|8 weeks of supervised training
79273685|NCT02156141|Other|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
79273686|NCT02156141|Other|Control period|8 weeks with no training.
79273687|NCT02156141|Other|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
79871944|NCT05053113|Device|Activity Monitor|Wear accelerometer
79273688|NCT02230267|Other|High intensity exercise and balance training|
79273689|NCT02230267|Other|Usual care arm exercise|
79273690|NCT02151695|Procedure|panretinal photocoagulation|
79273691|NCT02151695|Drug|Aflibercept intravitreal injections|
79273692|NCT03889405|Device|INVU™|The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
79871945|NCT05053113|Other|Educational Intervention|Receive educational newsletter
79871946|NCT05053113|Other|Survey Administration|Ancillary studies
79871947|NCT05053113|Behavioral|Telephone-Based Intervention|Receive phone call from health coach
79871948|NCT05041842|Drug|Tucatinib|300 mg orally twice daily
79273693|NCT03889405|Device|IUPC|The study participants will undergo continuous recording of the uterine contractions by IUPC.
79273694|NCT03889405|Device|TOCO|Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
79403221|NCT04027543|Drug|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
79403222|NCT04497324|Biological|Convalescent plasma|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
79403223|NCT03948763|Biological|V941|V941 administered IM, Q3W for 9 3-week cycles
79577409|NCT00003042|Procedure|peripheral blood stem cell transplantation|
79577410|NCT01873118|Other|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
79577411|NCT01873118|Other|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
79737081|NCT02737696|Behavioral|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
79737082|NCT02738320|Other|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
79737083|NCT02737384|Biological|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
79737084|NCT03512392|Other|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
79871949|NCT05041842|Drug|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
79871950|NCT05041842|Drug|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
79871951|NCT05041842|Drug|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
80029726|NCT02232828|Procedure|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
79871952|NCT05041842|Drug|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
80029727|NCT02232906|Drug|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation >20%)
80029728|NCT03563001|Drug|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
80029729|NCT02228928|Drug|CAPNP, 50 ug/cm2 capsaicin patch|
80029730|NCT02228928|Drug|CAPNP, 100 ug/cm2 capsaicin patch|
79577412|NCT01873118|Other|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
80029731|NCT02228928|Drug|0.075% capsaicin cream|
80029732|NCT02228928|Other|Placebo patch|
80029733|NCT03888378|Drug|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
79577413|NCT01873144|Drug|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
79577414|NCT01873144|Drug|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
79577415|NCT01873144|Device|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
79577416|NCT01873144|Drug|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
79577417|NCT01873157|Drug|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
79577418|NCT01873157|Drug|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
79577419|NCT01873183|Other|Goal directed fluid therapy|
79577420|NCT01873196|Behavioral|Receive extra oil|
79577421|NCT01873196|Behavioral|Receives behavior changed messages on CSB package|
79871953|NCT05039541|Device|Alio Device|Subjects will wear the Alio device over their vasculature.
79871954|NCT05018728|Drug|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
79871955|NCT04998422|Drug|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
79871956|NCT04996004|Drug|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
79871957|NCT04996004|Drug|Doxorubicin|75 mg/m^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
79875961|NCT03372408|Other|Chart review|Retrospective chart review of program participation and socio-demographic & psychosocial characteristics
79875962|NCT05299307|Diagnostic Test|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
80029734|NCT03888378|Drug|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
79403224|NCT03948763|Biological|Pembrolizumab|Pembrolizumab 200 mg, IV for 35 3-week cycles
79737085|NCT03512392|Other|Usual care strategy|Usual care at the discretion of the clinical team
79737086|NCT02735434|Behavioral|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
79737087|NCT02735434|Other|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
79737088|NCT02737228|Drug|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
79871958|NCT04995913|Other|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
79309125|NCT03204149|Device|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
79871959|NCT04995835|Drug|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
79871960|NCT04983511|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
79577422|NCT01873222|Device|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
79577423|NCT01873222|Device|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
79577424|NCT01873248|Drug|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
79577425|NCT01873274|Dietary Supplement|MK-7 containing capsule|
79737089|NCT02737228|Drug|Gemcitabine|1000 mg/m^2 intravenously every week three times per cycle (4 weeks)
79871961|NCT04979104|Procedure|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
79871962|NCT04977167|Drug|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
79871963|NCT04977167|Drug|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
79871964|NCT04973683|Drug|AL101|Given IV
79871965|NCT04973683|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
79871966|NCT04962594|Other|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
79871967|NCT04962594|Other|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
80029735|NCT03888378|Other|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
80029736|NCT03603288|Drug|idebenone 150 mg film-coated tablets|900 mg idebenone/day
80029737|NCT03597360|Radiation|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
79577426|NCT01873274|Dietary Supplement|basic yogurt enriched with MK-7|
79577427|NCT01873274|Dietary Supplement|nutrient-enriched yogurt with MK-7|
79577428|NCT01873300|Procedure|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
79577429|NCT01873313|Drug|Ropivacaine|
80029738|NCT02229006|Radiation|18F-NaF PET-CT|
79577430|NCT01873339|Drug|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
79577431|NCT01873339|Drug|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
79737090|NCT02737228|Drug|Erlotinib|100 mg per oral daily per cycle (4 weeks)
79737091|NCT01126541|Drug|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
79737092|NCT02735278|Other|different test paradigms|
79737093|NCT02737150|Device|CoreValve Evolut R|
79737094|NCT02737150|Device|Edwards Sapien 3|
79737095|NCT02737150|Procedure|Local anesthesia with conscious sedation|
79737096|NCT02737150|Procedure|General anesthesia|
79737097|NCT02736916|Radiation|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
79737098|NCT02736916|Radiation|Conventional PCI|LD-SCLC patients with conventional PCI
79737099|NCT02735356|Drug|Itraconazole|Applied topically
79737100|NCT02735356|Other|Placebo|Applied topically
79871968|NCT04962594|Other|Breast feeding (BF)|Exclusive breast feeding up to 4 months
80029739|NCT03576534|Other|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
80029740|NCT03556956|Drug|Masitinib|Tyrosine kinase inhibitor
80029741|NCT02750592|Drug|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
80029742|NCT03857646|Drug|Intralipid, 20% Intravenous Emulsion|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
80029743|NCT03857646|Drug|SMOF lipid|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
79737101|NCT00625469|Drug|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
79737102|NCT04311125|Procedure|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
79737103|NCT04311125|Procedure|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
79737104|NCT04311125|Procedure|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
79737105|NCT00637481|Drug|atorvastatin calcium|Given orally
79737106|NCT00637481|Other|laboratory biomarker analysis|Correlative studies
80029744|NCT03844074|Biological|bevacizumab|1.25 mg, intravitreal injection
80029745|NCT03844074|Biological|ranibizumab|0.5mg, intravitreal injection
80029746|NCT02624986|Drug|Idasanutlin|Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
80029747|NCT02624986|Drug|Obinutuzumab|Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
80029748|NCT02624986|Drug|Rituximab|Participants received a fixed dose of rituximab, 375 mg/m^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
80029749|NCT04412200|Device|Hyperbaric oxygen chamber (HBOC)|HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
80029750|NCT03058198|Diagnostic Test|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
80029751|NCT04946578|Dietary Supplement|Prebiotic|6 weeks of prebiotic supplementation twice a day
80029752|NCT04946578|Other|Placebo|6 weeks of maltodextrin supplementation twice a day
80029753|NCT04946422|Procedure|Arthroscopy|Discharge diagnosis of patients with sports injury-related injuries
80029754|NCT04945954|Other|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
79737107|NCT00637559|Drug|Esomeprazole Magnesium|
79737108|NCT02736994|Drug|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
79737109|NCT02736994|Drug|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
79871969|NCT04949750|Other|Paper - based cognitive training|Cognitive training
79309126|NCT03204149|Device|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
79737110|NCT02736994|Other|Water|Water
79737111|NCT04310969|Device|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
79737112|NCT04310969|Procedure|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
79737113|NCT04310969|Device|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
79737114|NCT05577208|Device|"Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator (Renal Denervation System)"|Minimally invasive percutaneous interventional therapy aimed to modulate the sympathetic nervous system through endovascular ablation of both renal arteries
79871970|NCT04949243|Behavioral|Behavioral questionaires|Behavioral surveys and questionaires
79871971|NCT04929275|Procedure|Enhanced recovery program|12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
79871972|NCT04929184|Behavioral|Speech and non-speech tasks|Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
79871973|NCT04922034|Drug|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
79871974|NCT04918121|Drug|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
79403225|NCT04896840|Other|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
79304597|NCT03283865|Diagnostic Test|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
79577432|NCT01873352|Procedure|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
80029755|NCT04946188|Device|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
79403226|NCT05096520|Procedure|radiofrequency|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the Baylis brand radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
79737115|NCT04311047|Diagnostic Test|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
79737116|NCT05553730|Behavioral|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
79871975|NCT04894084|Device|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
79871976|NCT04893330|Dietary Supplement|pepticate syneo|follow up of pepticate syneo for one month
79871977|NCT04884685|Biological|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
79871978|NCT04884685|Biological|Placebo|aluminium hydroxide solution only
79871979|NCT04881812|Device|Drug-Coated Balloons|Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).
79871980|NCT04881812|Device|Drug-Eluting-Stent|Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
79871981|NCT04881526|Dietary Supplement|D-beta-hydroxybutyrate|Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.
79871982|NCT04881526|Dietary Supplement|Placebo|Isocaloric flavored water with medium-chain triglyceride oil.
80029756|NCT04945564|Procedure|Oxygen therapy and physical therapy|Patients receive oxygen therapy and physical therapy
79871983|NCT04880226|Device|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
79871984|NCT04857944|Behavioral|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
79875963|NCT03372174|Device|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
80029757|NCT04945564|Device|Oxygen therapy|Patients receive oxygen therapy
80029758|NCT04945252|Diagnostic Test|Signpost caries|Identify carious lesion according to ICCMS visual criteria
80029759|NCT04945096|Drug|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
80029760|NCT04945096|Drug|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
80029761|NCT04945096|Drug|Semustine|Semustine: 250 mg/m2/day on day -9.
79737117|NCT00836875|Drug|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
79737118|NCT02732314|Drug|Investigational OTC Cream|
79871985|NCT04857944|Device|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
79871986|NCT04843917|Diagnostic Test|Immunoglobulin G detection|Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
79871987|NCT04831918|Device|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
79871988|NCT04830449|Drug|HCP1904-2|Take it once daily for 8 weeks orally.
79577433|NCT01873352|Procedure|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
79737119|NCT02732314|Other|Cosmetic Eczema Cream|
79871989|NCT04830449|Drug|RLD2001-2|Take it once daily for 8 weeks orally.
79871990|NCT04820907|Drug|HCP1904-1|Take it once daily for 8 weeks orally.
79871991|NCT04820907|Drug|RLD2001-1|Take it once daily for 8 weeks orally.
79871992|NCT04801446|Device|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
79871993|NCT04801446|Device|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
79871994|NCT04791514|Drug|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
79871995|NCT04789096|Drug|Tucatinib|Oral tablet
79871996|NCT04789096|Drug|Pembrolizumab|Intravenous
79871997|NCT04789096|Drug|Trastuzumab|Intravenous
79871998|NCT04789096|Drug|Capecitabine|Oral tablet
79871999|NCT04782986|Diagnostic Test|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
79872000|NCT04780503|Diagnostic Test|Rapid Shallow Breathing Index|The RSBI is defined as the ratio of respiratory frequency to tidal volume.
79872001|NCT04776239|Drug|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
80029762|NCT04945096|Drug|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
80029763|NCT04945096|Drug|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
80029764|NCT04945096|Drug|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
80029765|NCT04945096|Drug|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
80029766|NCT04945096|Drug|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
79304598|NCT03108053|Procedure|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
79304599|NCT03108053|Device|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
79872002|NCT04776239|Other|Placebo|Placebo delivered via peripheral intravenous infusion
79872003|NCT04769037|Dietary Supplement|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
79872004|NCT04769037|Dietary Supplement|Placebo|Lactose identical in appearance and taste to the active supplement
79872005|NCT04768127|Other|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
79872006|NCT04768127|Other|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
79872007|NCT04720755|Device|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
80029767|NCT04945096|Drug|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
79872008|NCT04697004|Device|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
79737120|NCT02732314|Drug|0.05% Desonide Cream|
79737121|NCT02732314|Other|Placebo Cream|
80029768|NCT04944394|Other|online questionnaire|"Administration of an online questionnaire (Limesurvey platform) at M0~- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected."
80029769|NCT04944394|Other|questionnaire survey|A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
79737122|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
79737123|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
79737124|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
79737125|NCT02732236|Other|Rituximab|Cohort observation study
79737126|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
79737127|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
79737128|NCT02734966|Drug|Tiopronin Injection|Tiopronin Injection 200mg OD
79737129|NCT00847561|Behavioral|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
79737130|NCT00847561|Behavioral|Information Monitoring|Packet providing information on strategies for coping with anxiety
79737131|NCT05569837|Other|Regular meal pattern|6 meals every day
79737132|NCT05569837|Other|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
79737133|NCT01121549|Drug|Aromasin|25 mg daily continuously
79737134|NCT02732002|Procedure|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
79872009|NCT04697004|Device|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
79872010|NCT04668781|Procedure|Analgesia via epidural catheter|Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
79872011|NCT04668781|Procedure|Analgesia via wound catheter|Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
80029770|NCT04823806|Dietary Supplement|Spermidine (spermidineLIFE ®) OR Placebo|21 day of 6mg spermidine OR Placebo supplementation per day
80029771|NCT04944238|Device|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
80029772|NCT04944628|Dietary Supplement|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10^9 cfu/day)
79273695|NCT02156219|Other|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~Control: Surveillance that men do not use cars corresponding to women.~Dosage: Regulation of entry women.~Assignment: Of the women, to the part of the platform where the first wagons stop."
79273696|NCT02151929|Device|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
79737135|NCT00847405|Drug|Sumatriptan Succinate|100 mg Tablets
79737136|NCT00847405|Drug|Imitrex®|100 mg Tablet
79737137|NCT04118413|Other|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
79737138|NCT03268096|Device|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
79737139|NCT02734654|Procedure|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
79872012|NCT04656730|Drug|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
79875964|NCT03372174|Device|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
79875965|NCT05352191|Drug|Beclomethasone|inhaled 800ug
79875966|NCT01028664|Device|SENSIMED Triggerfish|2-hour continuous IOP monitoring
80029773|NCT04411108|Other|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
80029774|NCT04411108|Other|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
79737140|NCT04115995|Diagnostic Test|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
79872013|NCT04649034|Diagnostic Test|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
79872014|NCT04649034|Diagnostic Test|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
79875967|NCT00954005|Drug|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
80029775|NCT04944472|Behavioral|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
79577434|NCT01873365|Other|Data collection|Case report forms (CRFs), logbooks and booklets.
79577435|NCT01873378|Drug|Triptorelin 3.75 mg|
79577436|NCT01873391|Procedure|Diagnostic hysteroscopy|
79577437|NCT01873430|Drug|Melatonin|
79577438|NCT01873443|Drug|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10~25mg/week Folic acid at least 5mg/week
79737141|NCT02881931|Behavioral|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
79737142|NCT02731846|Drug|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
80029776|NCT04944082|Drug|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
80029777|NCT04944004|Other|CogniPlus|The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
79273697|NCT02151929|Device|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
80029778|NCT04944004|Other|Training As Usual (TAU)|Training As Usual (TAU)
80029779|NCT04943692|Drug|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
79273698|NCT03542357|Drug|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
80029780|NCT04943692|Drug|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
80029781|NCT02587598|Drug|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
79273699|NCT03542357|Drug|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79273700|NCT03542357|Drug|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
79273701|NCT02150915|Other|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
79273702|NCT04579393|Drug|Placebo|Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
79273703|NCT04579393|Drug|fostamatinib|The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
79273704|NCT04811001|Drug|Osimertinib|TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
79577439|NCT01873469|Radiation|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
79577440|NCT01873482|Behavioral|Movement to rhythm|Movement to rhythm
79577441|NCT01873508|Drug|RO4917523|Fast release MR capsule, single dose
79577442|NCT01873508|Drug|RO4917523|Target release MR capsule, single dose
79577443|NCT01873508|Drug|RO4917523|Slow release MR capsule, single dose
79577444|NCT01873508|Drug|RO4917523|[13C]-labeled tracer dose i.v.
79577445|NCT01873521|Procedure|Non invasive ventilation|
79577446|NCT01873547|Biological|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
79577447|NCT01873547|Other|rehabilitation|Patients only receive rehabilitation of limb function.
79577448|NCT01873573|Procedure|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
79577449|NCT01873573|Other|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
79737143|NCT02731846|Drug|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
79872015|NCT04649034|Diagnostic Test|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
79273705|NCT04811001|Drug|Dacomitinib|Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
79577450|NCT01873573|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
79577451|NCT01873599|Behavioral|Positive Affect Journaling|
79872016|NCT04649034|Diagnostic Test|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
79577452|NCT01873612|Procedure|Hypoxic ventilatory response|
79403227|NCT05096520|Procedure|control|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
79577453|NCT01873612|Procedure|Hypercapnic ventilatory response|
79872017|NCT04649034|Diagnostic Test|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
79872018|NCT04626466|Other|Biological investigations|(complete blood count, platelet count, renal function evaluation)
79872019|NCT04616495|Procedure|Liver transplantation|Chemotherapy and liver transplantation
79872020|NCT04614129|Diagnostic Test|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
79872021|NCT04611867|Other|Supportive application with integrated weekly PRO|Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.
79872022|NCT04598451|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
79273706|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
79273707|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
79273708|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
79273709|NCT02151071|Device|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
79273710|NCT02151071|Device|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
79577454|NCT01873625|Biological|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
79577455|NCT01873625|Biological|placebo|
79577456|NCT01873638|Procedure|Cholecystectomy|
79577457|NCT01873651|Device|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
79577458|NCT01873664|Behavioral|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
79737144|NCT02731846|Drug|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
79737145|NCT02731846|Device|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
79872023|NCT04598451|Other|Placebo|Subcutaneous injection of placebo
79872024|NCT04598451|Drug|prednisone|Oral prednisone tablets
79273711|NCT04563637|Diagnostic Test|Computer based vision application by video|patients will be tested by computer based analysis of a video as well as by dexa scan.
79872025|NCT04596410|Radiation|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
79403228|NCT05096520|Drug|2% lidocaine|2% lidocaine
79403229|NCT04191109|Other|Observational study|This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
79403230|NCT05269446|Procedure|percutaneous coronary intervention (PCI)|A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA
79403231|NCT05269446|Device|total body PET/CT scan|all participants will receive a total-body PET/CT scan (uExplorer) after enrolment
79577459|NCT01873690|Drug|Ciprofloxacin|Once, 400 mg IV
79577460|NCT01873690|Drug|Placebo|5% Dextrose in water
79577461|NCT01873716|Drug|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
79403232|NCT05269446|Procedure|Coronary Angiography (CAG)|A procedure that uses X-ray imaging to visualize coronary arteries.
79577462|NCT01873768|Drug|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
79577463|NCT01873768|Drug|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
79577464|NCT01873781|Drug|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
79872026|NCT04596410|Radiation|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
79872027|NCT04589611|Drug|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
79872028|NCT04589611|Drug|Placebo (single dose)|One dose of placebo during the initial surgical intervention
79872029|NCT04589611|Drug|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
79872030|NCT04589611|Drug|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
79872031|NCT04565041|Behavioral|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
79872032|NCT04564976|Behavioral|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
79872033|NCT04561466|Drug|Béfizal|600 mf befizal a day for one year
79872034|NCT04553523|Device|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
79872035|NCT04553523|Procedure|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
79872036|NCT04553523|Device|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
79872037|NCT04553263|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
79872038|NCT04553263|Drug|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
79872039|NCT04550221|Behavioral|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
79872040|NCT04549688|Procedure|high-intensity focused ultrasound, HIFU|see above
79872041|NCT04542707|Procedure|joint manipulation|Thrust manipulation to the spine, hand, and foot
79403233|NCT05269446|Drug|TSPO injection|Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
79577465|NCT01873794|Device|Bright white light|
79577466|NCT01873794|Device|Dim red light|
79872042|NCT04542707|Procedure|Exercise|Strength training, bike aerobic training, and yoga exercise
79273712|NCT04563637|Radiation|whole body dual energy x-ray absorptiometry scan|subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
79273713|NCT02776553|Other|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
79273714|NCT02776553|Behavioral|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
79273715|NCT02776553|Behavioral|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
79577467|NCT01873807|Drug|IDA|Idarubicin: 15mg/m2/d: -8->-6d
79304600|NCT02710045|Biological|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
79577468|NCT01873807|Radiation|TBI|TBI: 4.5 Gy/d, -5d, -4d
79577469|NCT01873807|Drug|CTX|CY:60mg/kg/d, -3d, -2d
79577470|NCT01873807|Drug|VP-16|VP-16: 15mg/kg, -2d, -1d
79577471|NCT01873820|Dietary Supplement|Calcium ascorbate|
79577472|NCT01873820|Dietary Supplement|Ascorbic acid|
79577473|NCT01873872|Dietary Supplement|Theralac probiotic|
79872043|NCT04542707|Device|Soft tissue massage|Graston tool
79737146|NCT02731846|Drug|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
79577474|NCT01873872|Dietary Supplement|Culturelle probiotic|
79273716|NCT02230345|Dietary Supplement|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
79872044|NCT04535076|Procedure|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
79872045|NCT04535076|Procedure|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
79872046|NCT04534738|Behavioral|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
79872047|NCT04525365|Procedure|Pleural aspiration|Pleural aspiration
79872048|NCT04525157|Drug|Afamelanotide|
79872049|NCT04525157|Drug|Placebo|
79872050|NCT04515004|Drug|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
79872051|NCT04514107|Other|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
79872052|NCT04514107|Other|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
79577475|NCT01873872|Other|placebo|
79577476|NCT01873885|Drug|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
79872053|NCT04509011|Device|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
79577477|NCT01873885|Drug|Experimental: Single IV Infusion Vasomera (PB1046)|
79872054|NCT04503694|Drug|Nivolumab 10 MG/ML Intravenous Solution|"Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~On day 1 and 15, during the Induction treatment~On day 29, 43 and 57, during the Consolidation treatment"
79872055|NCT04503694|Drug|Regorafenib 40 MG Oral Tablet|"Regorafenib will be administered orally once a day at a dose of 80 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~From day 1 to 14, during the Induction treatment~From day 29 to 49, during the Consolidation treatment"
79273717|NCT02230345|Dietary Supplement|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
79273718|NCT02690727|Drug|RP6530|Single oral dose
79577478|NCT01873898|Device|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
79273719|NCT02224105|Drug|BI 653048 BS|
79273720|NCT02224105|Drug|Prednisolone low|
79273721|NCT02224105|Drug|Prednisolone high|
79273722|NCT02224105|Drug|Placebo|
79273723|NCT02224105|Drug|sodium chloride infusion|
79273724|NCT02224105|Drug|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
79273725|NCT02777333|Behavioral|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
79273726|NCT03857659|Diagnostic Test|Point-of-care ultrasound (POC-US)|POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
79273727|NCT03857659|Diagnostic Test|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
79577479|NCT01873937|Radiation|Red LED|Phototherapy with red LED on temporomandibular area
79737147|NCT00836095|Device|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
79737148|NCT00836095|Device|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
79737149|NCT05564455|Other|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
79737150|NCT05564455|Other|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
79273728|NCT03857659|Diagnostic Test|Formal ultrasound|Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
79304601|NCT02710045|Biological|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
79872056|NCT04503694|Radiation|Radiotherapy|All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.
79872057|NCT04503694|Procedure|Surgery|Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.
80029782|NCT02587598|Drug|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m^2. Cytarabine will be administered as an intravenous (IV) infusion.
80029783|NCT02587598|Drug|Azacitidine|Azacitidine dose will be 75 mg/m^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
80029784|NCT02587598|Drug|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
79872058|NCT04503694|Procedure|Non-operative Management|"Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~Digital rectal examination~Rectal endoscopy~Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch & wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery"
79577480|NCT01873937|Radiation|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
79577481|NCT01873937|Radiation|LASER|Phototherapy with LASER INFRARED on temporomandibular area
79872060|NCT04493151|Drug|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
79872061|NCT04468165|Drug|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
79872062|NCT04463992|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
79872063|NCT04463992|Other|Usual Care|Usual care as provided by local oncologists
79872064|NCT04454476|Drug|Trametinib treatment|1 mg taken by mouth once a day for 14 days
79872065|NCT04454476|Procedure|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
79872066|NCT04452461|Drug|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
79872067|NCT04452461|Drug|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
79872068|NCT04448249|Behavioral|APN intervention|"APN intervention is divided into five main steps:~clinical and paraclinical examinations,~appraisal of patient's knowledge,~health education on hypertension and treatments,~setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
79872069|NCT04424667|Other|donor milk|pasteurized donor milk
80029785|NCT04942990|Other|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
80029786|NCT04943146|Drug|Prednisone 10 MG+aspirin 100MG|Discontinue medication based on early pregnancy outcome
79577482|NCT01874002|Device|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
79577483|NCT01874015|Biological|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
79577484|NCT01874015|Biological|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
79577485|NCT01874028|Drug|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
79872070|NCT04417829|Device|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
79872071|NCT04389242|Other|REST Online（Reduce Stress Tour Online）|Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
80029787|NCT04942444|Other|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
80029788|NCT02485574|Procedure|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
80029789|NCT04942834|Drug|Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone|Class I or III antiarrhythmic drug, including sotalol
80029790|NCT04942834|Device|cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
79737151|NCT02731924|Procedure|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
79872072|NCT04388800|Other|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
80029791|NCT03484286|Device|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
79737152|NCT02731768|Behavioral|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
80029792|NCT03484286|Other|Standard care|Patients in the control group will be subject to standard heart failure care.
80029793|NCT04942756|Device|Continuous Glucose Monitoring|"FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study."
79403234|NCT03948529|Drug|eltrombopag|eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
79737153|NCT02731768|Behavioral|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
79577486|NCT01874041|Other|Massage|
79577487|NCT01874041|Other|Occlusal splint|
79737154|NCT02731768|Device|Fitbit Zip|
79737155|NCT02731768|Device|Digital body weight scale|
79872073|NCT04382963|Other|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
80029794|NCT04942756|Device|Standard Care|"The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center."
79577488|NCT01874080|Drug|Saxagliptin/Metformin|
79577489|NCT01874093|Device|The Ischemic Stroke System|SPG stimulation and standard of care
79577490|NCT01874093|Device|Sham control|Sham stimulation and standard of care
79577491|NCT01874106|Other|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
79403235|NCT04856592|Device|Boston Scientific Vici® Venous Stent System|The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires
79577492|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
79577493|NCT01874171|Drug|Cisplatin|
79577494|NCT01874171|Drug|Cetuximab|
79577495|NCT01874184|Other|counseling intervention|Take part in weekly group counseling sessions
79577496|NCT01874184|Behavioral|behavioral dietary intervention|Set goals for changing dietary habits
79577497|NCT01874184|Behavioral|exercise intervention|Attend group exercise activities
79577498|NCT01874184|Other|questionnaire administration|Ancillary studies
79737156|NCT02694484|Other|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
79737157|NCT04248712|Drug|Famotidine|40 mg tab twice daily by mouth for 12 week duration
79737158|NCT04248712|Drug|Loratadine|10 mg tab once daily by mouth for 12 week duration
79737159|NCT04248712|Drug|Placebo|Contains no active ingredient
79737160|NCT02734732|Drug|Trimethoprim/Sulfamethoxazole|
79872074|NCT04382963|Other|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
79577499|NCT01874184|Other|laboratory biomarker analysis|Correlative studies
79577500|NCT01874197|Device|B-TEVAR device|Creation and implantation of the Branched Thorcoabdominal aortic anerysm device
79737161|NCT02734732|Drug|Ciprofloxacin|
79737162|NCT00835237|Biological|Boostrix®|Intramuscular, single dose.
79737163|NCT00835237|Biological|Decavac™|Intramuscular, single dose.
79577501|NCT01874236|Drug|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
79872075|NCT04382963|Other|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
79872076|NCT04378335|Other|completion of questionnaire|parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
79737164|NCT02731378|Drug|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
79872077|NCT04373902|Procedure|Physiological-based cord clamping|See 'Arm'
79872078|NCT04373278|Other|failure of reconstruction of the mandibule by free fibula flap|description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
79872081|NCT04301323|Drug|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
79872082|NCT04301323|Drug|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
79872083|NCT04301323|Drug|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
79872085|NCT04280575|Procedure|Percutaneous coronary intervention|Coronary artery stenting for stable angina
79872086|NCT04280471|Drug|Fecal Microbiota Transplantation Capsule|Receive OpenBiome FMT Capsule DE PO
80029795|NCT03484052|Other|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
79577502|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
79577503|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
79577504|NCT01874249|Other|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
79577505|NCT01874249|Other|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
79737165|NCT02731378|Drug|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
79737166|NCT02731378|Drug|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
79737167|NCT02731378|Drug|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
79737168|NCT00704119|Drug|RhuDex®|"Treatment A.1: 31.65 mg RhuDex® once N=12~Treatment A.2: 63.33 mg RhuDex® once N=12~Treatment A.3: 126.63 mg RhuDex® once N=12~Treatment A.4: 253.26 mg RhuDex® once N=12~Treatment B.1: 31.65 mg RhuDex® once N=12~Treatment B.2: selected dose of RhuDex® once N=12~Treatment C: selected dose of RhuDex® once N=12~Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
79737169|NCT02731456|Other|altitude exposure|altitude exposure
79872087|NCT04278404|Drug|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
80029796|NCT04942132|Behavioral|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
79577506|NCT01874249|Other|Transient elastography|Transient elastography values greater than 8 kPa
79577507|NCT01874301|Other|High quantity probiotic|The intervention type is food product
79737170|NCT04118335|Other|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
79737171|NCT02731534|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
79872088|NCT04275999|Drug|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
79403236|NCT04856592|Device|Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)|The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
79737172|NCT02731534|Drug|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
79737173|NCT04115917|Device|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
79737174|NCT04115917|Device|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
79577508|NCT01874301|Other|Low quantity probiotic|The intervention type is food product
79872089|NCT04275999|Behavioral|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
79872090|NCT04275999|Device|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
79872091|NCT04243759|Behavioral|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
79872092|NCT04243759|Behavioral|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
79872093|NCT04243759|Behavioral|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
79872094|NCT04193176|Drug|Gefapixant|Administered twice daily as an oral tablet of 45 mg
79872095|NCT04193176|Drug|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
79872096|NCT04190485|Other|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
79872097|NCT04190485|Other|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
79872098|NCT04190485|Other|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
79872099|NCT04174703|Other|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
80029797|NCT04941976|Drug|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
80029798|NCT04941976|Drug|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
79403237|NCT03023605|Behavioral|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~Clinical Update Sessions for staff ED (20 physicians)~training sessions for residents that rotate in ED (60 physicians )~Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~Development of posters, with brief information~Dissemination by e-mail of scientific information~Direct reminder during the working day"
79577509|NCT01874301|Other|placebo|
79577510|NCT01874314|Drug|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
79577511|NCT01874314|Other|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
79577512|NCT01874314|Drug|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
79577513|NCT01874327|Behavioral|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
79737175|NCT02734420|Drug|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
79872100|NCT04166071|Drug|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
79872101|NCT04166071|Drug|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
79273729|NCT02224183|Behavioral|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
79273730|NCT02224183|Behavioral|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
79577514|NCT01874327|Behavioral|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
79737176|NCT02734420|Drug|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
79737177|NCT02734420|Device|Laser|
79577515|NCT01874366|Drug|P11187|"Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
79737178|NCT04117867|Behavioral|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
79577516|NCT01874366|Drug|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
79737179|NCT02731066|Other|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
79737180|NCT02731066|Other|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
79577517|NCT01874379|Other|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
79577518|NCT01874379|Other|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
79577519|NCT01874379|Other|Standard of Care|Normal Procedures, no complementary medicine intervention.
79577520|NCT01874418|Other|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
79577521|NCT01874444|Device|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
79872102|NCT04164277|Behavioral|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
80029799|NCT04942288|Other|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
79273731|NCT05718999|Diagnostic Test|Not intervention|Not having intervention is an observational study
79273732|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
79577522|NCT01874444|Device|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
79737181|NCT02731066|Other|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
79737182|NCT02731066|Other|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
79273733|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
79273734|NCT02230423|Procedure|Nasal surgery|
79737183|NCT04118257|Dietary Supplement|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (~710mL) daily for three weeks, along with their habitual diets.
79737184|NCT04118257|Dietary Supplement|Sugary beverage: Soda|Participants consumed soda (~710mL) daily for three weeks, along with their habitual diets.
79737185|NCT04118257|Dietary Supplement|Control: Water|Participants consumed water (~710mL) daily for three weeks, along with their habitual diets.
79737186|NCT01072500|Behavioral|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
79737187|NCT01072500|Behavioral|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
79737188|NCT02731222|Other|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
79737189|NCT00704275|Drug|0.05% cyclosporin eye drop|bid dosage for 4 months
79872103|NCT04164277|Behavioral|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
79872104|NCT04164277|Behavioral|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat & Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
79737190|NCT02734342|Other|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo & Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
79737191|NCT00847015|Drug|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
79737192|NCT00847015|Drug|Gemcitabine|Gemcitabine 1,000 mg/m^2
79737193|NCT00847015|Drug|cisplatin|cisplatin 35 mg/m^2 will be administered intravenously on days 1 and 8.
79737194|NCT04302792|Behavioral|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
79872105|NCT04142619|Biological|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
79872106|NCT06083285|Other|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
79872107|NCT06083155|Diagnostic Test|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
79872108|NCT06083155|Other|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
79273735|NCT03542279|Procedure|Plasma exchange|PE treatments are performed on an apheresis device (Fresenius MultiFiltrate hemodialysis filtration machine, German). PE volumes of 1 plasma volume per procedure will be used. Treatments will be given every other day with breaks allowed for weekends for most patients. The anticoagulant used is low molecular heparin. The use of high-dose glucocorticoid is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
79309127|NCT04801563|Other|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
79577523|NCT01874444|Device|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
79577524|NCT01874444|Device|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
79577525|NCT01874457|Biological|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
79577526|NCT01874470|Device|renal denervation|
79577527|NCT01874470|Other|standard medication|
79577528|NCT01874483|Drug|Placebo|placebo
79577529|NCT01874483|Drug|BI 187004|BI 187004, dose 2
79577530|NCT01874483|Drug|BI 187004|BI 187004, dose 4
79577531|NCT01874483|Drug|BI 187004|BI 187004, dose 5
80029800|NCT02624284|Device|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
80029801|NCT02738450|Biological|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
79273736|NCT03542279|Drug|IVIG, High-dose glucocorticoid|IVIG is given 0.4 g/kg/d for each course for 5 days. The use of high-dose glucocorticoid is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
79577532|NCT01874483|Drug|BI 187004|BI 187004, dose 6
79273737|NCT03797521|Drug|SXC-2023|SXC-2023 oral capsules
79273738|NCT03797521|Drug|Placebo|Matching Placebo oral capsules
79273739|NCT02230657|Procedure|Same day discharge|
79273740|NCT02230657|Procedure|Next day discharge|
79577533|NCT01874483|Drug|BI 187004|BI 187004, dose 7
79577534|NCT01874483|Drug|BI 187004|BI 187004, dose 1
79577535|NCT01874483|Drug|BI 187004|BI 187004, dose 3
79577536|NCT01874496|Dietary Supplement|GDS, no meal|GDS, no meal
79577537|NCT01874496|Dietary Supplement|GDS, meal|GDS, meal
79737195|NCT04302792|Behavioral|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste & smell alterations) will be expected to evaluate three foods at home over a period of one month.
79737196|NCT00627354|Drug|etoposide|
79872109|NCT06083142|Biological|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules
79872110|NCT06083129|Drug|Grafalon|10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
79273741|NCT02230735|Drug|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
79403238|NCT04020757|Device|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
79737197|NCT00627354|Drug|mitoxantrone hydrochloride|
79737198|NCT00627354|Drug|prednisone|
79403239|NCT04020757|Dietary Supplement|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
79577538|NCT01874496|Dietary Supplement|control, no meal|control, no meal
79872111|NCT06083129|Drug|Thymoglobulin|2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
79872112|NCT06083116|Drug|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
79872113|NCT06083103|Diagnostic Test|18-FDG PET-MRI|For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer
79872114|NCT06083090|Procedure|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
80029802|NCT02738450|Biological|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
79577539|NCT01874496|Dietary Supplement|control, meal|control, meal
80029803|NCT02738450|Biological|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
80029804|NCT04941820|Other|clinical pharmacist intervention|clinical pharmacist intervention
79577540|NCT01874509|Behavioral|Check Your Drinking|
79577541|NCT01874509|Behavioral|Alcohol Help Centre|
79577542|NCT01874522|Drug|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
79577543|NCT01874522|Drug|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
79577544|NCT01874561|Drug|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
79577545|NCT01874561|Drug|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
79577546|NCT01874561|Drug|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
79577547|NCT01874574|Drug|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
79577548|NCT01874574|Drug|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
79577549|NCT01874587|Radiation|adaptative radiotherapy|weekly replanning
79577550|NCT01874600|Device|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
79577551|NCT01874613|Device|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
79577552|NCT01874613|Device|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
79577553|NCT01874639|Device|standard bipolar coagulation|
79737199|NCT00627354|Drug|vinorelbine tartrate|
79737200|NCT02612935|Device|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
79737201|NCT00704431|Drug|SB-480848 (darapladib)|160 mg darapladib
79577554|NCT01874639|Device|Aquamantys® probe for liver hemostasis|
79872115|NCT06083090|Procedure|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
79872116|NCT06083077|Other|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
79872117|NCT06083025|Device|CleaRing|The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
79737202|NCT02734186|Drug|Praziquantel|Anthelminthic
79872118|NCT06082973|Device|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
79872119|NCT06082973|Device|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
79872120|NCT06082934|Drug|Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
79872121|NCT06082869|Drug|Protegera™ toothpaste (NaF)|Plaque Reduction
79872122|NCT06082869|Drug|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
79577555|NCT01874652|Device|Light Weight Breast Implants|Light Weight Breast Implants
79577556|NCT01874678|Drug|TS-1/Cisplatin|
79737203|NCT00704509|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
79737204|NCT00704509|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
79737205|NCT00704509|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
79737206|NCT02730910|Other|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
79872123|NCT06082700|Diagnostic Test|imaging|clinical examination to see missing posterior teeth & vertical measurements by lateral cephalometric x-ray
79872124|NCT06082674|Device|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
79872125|NCT06082674|Device|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
79577557|NCT01874704|Behavioral|Comparison of biomarkers of stress|
79577558|NCT01874717|Other|Conscious sedation for dental care|
79577559|NCT01874717|Drug|midazolam|
79577560|NCT01874730|Other|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
79577561|NCT01874730|Drug|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
79577562|NCT01874730|Other|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
79737207|NCT02730910|Other|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
79737208|NCT02730832|Other|Questionnaires completed at D0|
79737209|NCT02730832|Other|Questionnaires completed at D15 (test-retest for 30 patients)|
79577563|NCT01874743|Drug|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
79737210|NCT02733952|Drug|Tranexamic Acid|
79737211|NCT02733952|Procedure|Pericervical Tourniquet|
79737212|NCT02694796|Behavioral|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
79737213|NCT05435170|Drug|linerixibat|linerixibat will be administered per the treatment sequence
79737214|NCT02733640|Drug|Pantoprazole|pantoprazole 40 mg once-daily
79737215|NCT02733640|Drug|Ranitidine|ranitidine 150 mg twice-daily
79737216|NCT02730520|Other|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
79737217|NCT02730676|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
79737218|NCT02730676|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
79737219|NCT00855595|Drug|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
79403240|NCT05095974|Device|ultrasonography|Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
80029805|NCT04941352|Behavioral|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
80029806|NCT01291004|Drug|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
80029807|NCT01291004|Drug|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
80029808|NCT01291004|Drug|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
80029809|NCT04941118|Drug|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
79577564|NCT01874769|Other|Blood collection|"5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
79577565|NCT01874769|Other|Skin biopsies|"A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
79872126|NCT06082648|Device|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
79872127|NCT06082648|Device|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
80029810|NCT04941118|Drug|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
80029811|NCT05136716|Other|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
80029812|NCT05136716|Device|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
80029813|NCT05388344|Other|Booklet reading|Submission of the questionnaire before and after booklet reading
79403241|NCT05095974|Device|echocardiography|MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
79577566|NCT01874782|Device|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
79737220|NCT00855595|Drug|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
79737221|NCT00855595|Drug|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
79737222|NCT05434858|Other|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
79737223|NCT02733718|Device|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
79737224|NCT05433532|Drug|Azacitidine|Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
79737225|NCT05433532|Drug|Venetoclax|Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
79737226|NCT05433532|Drug|Flumatinib|Flumatinib: 600mg qd, d4-d21, oral
79737227|NCT00855439|Drug|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
80029814|NCT03483974|Diagnostic Test|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
80029815|NCT04940962|Procedure|Sampling of adipose tissue|Removal of less than 1 cm3 of adipose tissue during visceral surgery
79872128|NCT06082635|Drug|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
79872129|NCT06082635|Drug|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
79872130|NCT06082622|Combination Product|laxatives|triple therapy of drugs, behaviour and mental axis
79273742|NCT02230735|Drug|Normal Saline|(placebo for bupivacaine)
79273743|NCT02695329|Device|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
79273744|NCT02258581|Drug|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
79273745|NCT02258581|Drug|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
79577567|NCT01874795|Device|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
79737228|NCT00855439|Drug|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
79872131|NCT06082609|Procedure|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
79872132|NCT06082596|Drug|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
79872133|NCT06082583|Device|Remote Ischemic Conditioning|Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
80029816|NCT03480854|Other|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
79273746|NCT02258581|Drug|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
79403242|NCT05095974|Device|thoracic electrical bioimpedence|EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
79737229|NCT01064856|Biological|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
79737230|NCT01064856|Biological|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
79872134|NCT06082583|Drug|Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)|Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
79273747|NCT03165903|Behavioral|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
79403243|NCT03022669|Behavioral|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
79403244|NCT03022669|Behavioral|Mobile Application|
79403245|NCT03022669|Other|Website|American Heart Association patient education website
79577568|NCT01874795|Device|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
79577569|NCT01874821|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
79577570|NCT01874821|Other|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
79737231|NCT02730442|Drug|F901318|Administration of F901318 intravenously
79737232|NCT02730442|Drug|Fluconazole|Oral administration
79872135|NCT06082570|Drug|c610 injection|Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
79872136|NCT06082557|Drug|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
79872137|NCT06082531|Drug|Sodium hyaluronate injection|The control group was injected into the joint cavity with sodium hyaluronate injection..
79737233|NCT02733874|Drug|Compound Clobetasol Propionate Ointment|
79872138|NCT06082453|Diagnostic Test|Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum|A quantitative polymerase chain reaction (qPCR) assay detects and quantifies DNA in a sample, and the qPCR assay used in this study targets the polA gene of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. qPCR data will only be used to determine testing performance and will not be used in clinical management of study participants.
79872139|NCT06082453|Diagnostic Test|Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum|The Aptima transcription-mediated amplification (TMA) assay used in this study will target RNA of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. TMA data will only be used to determine testing performance and will not be used in clinical management of study participants.
79872140|NCT06082453|Other|Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis|Using the Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines, new born syphilis infection is categorized by clinical providers at birth as follows: confirmed proven/highly probably, possible congenital syphilis (CS), CS less likely, or CS unlikely. These CS categories are determined using neonatal nontreponemal test results, physical exam of the infant, placental pathology, and maternal serologies and treatment history, and comparison of maternal and neonatal nontreponemal tiers. These data will be collected as part of standard clinical care.
79872141|NCT06082427|Device|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
79872142|NCT06082414|Other|no interventions|no interventions because of an observational study
79872143|NCT06082401|Device|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
79577571|NCT01874834|Other|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
79273748|NCT03165903|Behavioral|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
79577572|NCT01874847|Dietary Supplement|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
79577573|NCT01874847|Dietary Supplement|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
79577574|NCT01874873|Drug|Anlotinib|
79577575|NCT01874899|Device|RestoreSensor Neurostimulation|
79577576|NCT01874964|Behavioral|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
79577577|NCT01874964|Behavioral|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
79737234|NCT02733874|Drug|Calcipotriol Betamethasone Ointment|
79737235|NCT02730364|Drug|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
79737236|NCT02730052|Device|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
79737237|NCT02730052|Device|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
79737238|NCT00846391|Drug|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
79577578|NCT01874977|Behavioral|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
79737239|NCT00846391|Drug|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
79737240|NCT00846391|Drug|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
79273749|NCT03167697|Dietary Supplement|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
79273750|NCT03167697|Other|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
79273751|NCT02224417|Behavioral|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
79872144|NCT06082401|Device|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
79872145|NCT06082388|Drug|Comparison of atropine and isoprenaline|Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
79273752|NCT02224417|Behavioral|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
79273753|NCT02224417|Behavioral|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~SGD 2 weekly if one glucose readings falls within the normal range,~SGD 7 weekly if two glucose readings fall within the normal range,~SGD 14 weekly if all three glucose readings fall within the normal range."
79273754|NCT03165825|Drug|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
79737241|NCT00636454|Behavioral|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
79273755|NCT03165825|Drug|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
79737242|NCT00636454|Other|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
79872146|NCT06082375|Dietary Supplement|Vitamin D|Vitamin D3 in the form of cholecalciferol.
79872147|NCT06082375|Dietary Supplement|Placebo|Vegetable oil.
80029817|NCT04940416|Device|Neurofit (oculometric testing)|The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
79273756|NCT03785743|Procedure|TLPD Surgery|TLPD
79273757|NCT03785743|Procedure|OPD Surgery|OPD
79273758|NCT03167853|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
79737243|NCT01042392|Drug|Aliskiren|150 mg Aliskiren as film-coated tablet
79737244|NCT01042392|Drug|Ramipril|Ramipril 5 mg was given in capsule form.
79737245|NCT01042392|Drug|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
79737246|NCT01042392|Drug|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
79737247|NCT00704665|Drug|Relaxin|10 ug/kg/day or 25 ug/kg/day
79737248|NCT00704665|Drug|Relaxin|Placebo
79737249|NCT02694952|Biological|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
79872148|NCT06082362|Other|Collection of clinical and biological material|Collection of clinical and biological material (e.g., samples of semen, stool, urine, blood, buccal swab)
79872149|NCT06082336|Diagnostic Test|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
79872150|NCT06082336|Diagnostic Test|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
79737250|NCT02694952|Biological|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
79737251|NCT00913315|Drug|tolterodine|4 mg of tolterodine ER
79737252|NCT00913315|Drug|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
79872151|NCT06082323|Drug|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
80029818|NCT03483818|Procedure|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
79577579|NCT01874977|Behavioral|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
79872152|NCT06082297|Device|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
79737253|NCT00913315|Drug|placebo|placebo once a day for 8 weeks
79737254|NCT00701857|Drug|cisplatin|Standard weekly dose
79737255|NCT00701857|Drug|Pemetrexed|Biweekly pemetrexed dose escalation
79737256|NCT00701857|Radiation|radiation therapy|Weekly standard dose radiation therapy
79872153|NCT06082245|Procedure|TLIP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"Patients were placed in a prone position;~ultrasound-guided TLIP block: (1) The transducer was positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles. (2) The probe was moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. (3) the TLIP block was performed under real-time ultrasound guidance using an insulated 100-mm 22G echogenic needle which was inserted in-plane lateral to the medial direction. (4) After negative aspiration, 20-mL 0.25% ropivacaine was injected in each side bilaterally in the interface between the MF and LG muscles.~patients received general anesthesia"
79872154|NCT06082245|Procedure|ESP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"Patients were placed in a prone position;~ultrasound-guided ESP block: (1) The 12th rib was identified in the parasagittal plane, and with probe shifted caudad and medial, the L3 transverse process (TP) was identified. (2) Insulated 100-mm 22G echogenic needle was inserted from cranial to caudal direction. (3) The needle tip was identified between the L2 and L3, and 20 mL of 0.25% ropivacaine was injected in each side bilaterally in ESP.~patients received general anesthesia"
80029819|NCT04940728|Other|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
80029820|NCT00374660|Drug|Oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
80029821|NCT00374660|Drug|Irofulven|Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
80029822|NCT04940494|Other|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
80029823|NCT04940260|Diagnostic Test|Renal function|measure eGFR at one year post partum
80029824|NCT04940260|Diagnostic Test|proteinuria|measure urine protein creatinine ratio at one year postpartum
80029825|NCT04463108|Other|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
79273759|NCT02690649|Other|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
79273760|NCT03165357|Dietary Supplement|Sodium bicarbonate supplementation|
79273761|NCT03165357|Dietary Supplement|Placebo treatment|
79273762|NCT05746143|Drug|Zolpidem Tartrate 10 mg|two days preoperatively and five days postoperatively
79737257|NCT02730286|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
79577580|NCT01874977|Behavioral|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
79577581|NCT01874990|Dietary Supplement|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
79577582|NCT01874990|Dietary Supplement|low-salt diet|
79577583|NCT01875003|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
79577584|NCT01875003|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
79737258|NCT02733484|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
79737259|NCT02733484|Dietary Supplement|Placebo|the patients in this arm will receive placebo intervention
80029826|NCT02624050|Drug|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
79273763|NCT05746143|Drug|Placebo|two days preoperatively and five days postoperatively
79273764|NCT03165435|Biological|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
79577585|NCT01875003|Drug|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists [LABAs], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
79577586|NCT01875016|Procedure|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
79577587|NCT01875029|Device|sham-tDCS + back school|sham tDCS + back school
79577588|NCT01875029|Device|real-tDCS + back school|real tDCS + back school
79872155|NCT06082245|Procedure|Lidocaine injection|"patients received general anesthesia~the expected incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery."
80029827|NCT02624050|Drug|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
79273765|NCT03165435|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
79273766|NCT03165591|Biological|V3-P|one tablet of V3-P given once daily for 2 months
79737260|NCT02694640|Behavioral|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
79737261|NCT02694640|Behavioral|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
79737262|NCT02694640|Behavioral|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
79737263|NCT02733328|Procedure|CPB Surgery|
79737264|NCT05420272|Behavioral|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
79273767|NCT03114813|Drug|Carvedilol|Non-selective beta-blocker as per routine clinical care
79273768|NCT03114813|Other|MRI scan|One hour non-invasive MRI scan
79273769|NCT03114813|Procedure|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
79273770|NCT01358864|Drug|BI 201335|BI 201335 once a day (QD) for 24 weeks
79273771|NCT01358864|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
79273772|NCT01358864|Drug|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
79273773|NCT01358864|Drug|Placebo|Placebo to BI201335 for 24 weeks
79273774|NCT02750761|Drug|Tedizolid Phosphate (IV)|200 mg/vial powder for injection
79872156|NCT06082180|Procedure|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
80029828|NCT03486470|Diagnostic Test|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
80029829|NCT05152160|Biological|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
79577589|NCT01875042|Device|TENS|Transcutaneous electrical nerve stimulation
79577590|NCT01875042|Device|Sham TENS|Sham Transcutaneous electrical nerve stimulation
79577591|NCT01875055|Device|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
79577592|NCT01875055|Device|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
79577593|NCT01875068|Behavioral|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
79577594|NCT01875068|Behavioral|versus NPs and PAs who are not required to discuss patient referrals (control group).|
80029830|NCT03483740|Behavioral|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
80029831|NCT03483740|Behavioral|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
79273775|NCT02750761|Drug|Tedizolid Phosphate (oral suspension)|Powder for oral suspension 20 mg/mL following reconstitution
79273776|NCT03165669|Device|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
79273777|NCT03165669|Other|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
79872157|NCT06082128|Behavioral|FOCUSau|"FOCUSau is a self-administered web-based intervention and completed autonomously via the internet by the dyad. Delivery encompasses the completion of four prescribed consecutive FOCUSau sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and family carer, together at a computer. The intervention sessions can be completed at any time within the 12-week timeframe. Participants receive tailored individual and dyadic messages according to the information provided at study enrollment and their responses to questions within the sessions. Dyads are also provided with an online personal workbook containing the results of interactive exercises completed during the internet sessions. Any information sheets that the dyad indicated as 'of interest to them' during the internet sessions are included as a hyperlink in their personal workbook which also contains evidence-based local advanced cancer related resources."
79872158|NCT06082115|Other|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L & L.L (U.L & L.L approximation, U.L & L.L weight bearing exercises), stretching exercises for U.L & L.L muscles, strengthening exercises for antispastic group of U.L & L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
79872159|NCT06082115|Other|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
79872160|NCT06082115|Other|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
79872161|NCT06082089|Behavioral|Divorce Adjustment Program (DAP)|This is a brief group intervention program for divorced women. It consists of 6 sessions for participants with children and 5 sessions for participants without children. Each session lasts approximately 2.5-3 hours focusing on one of the difficulties experienced by women after divorce (i.e., self-perception, emotions and emotion regulation, social problems, family-related problems, problems with ex-spouse and children (for participants with children)). In this study, the DAP will be implemented in online format.
79872162|NCT06082076|Drug|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
79872163|NCT06082076|Drug|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
79872164|NCT06082076|Drug|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
79872165|NCT06082063|Drug|Aspirin tablet|Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
79872166|NCT06082063|Drug|Semaglutide|GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c >53 mmol/mol or BMI>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
79872167|NCT06082063|Drug|Sotagliflozin|SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR >30 mg/g and eGFR < 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
79872168|NCT06082063|Drug|Finerenone|Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (>30 mg/g) despite RAS blockade.
79273778|NCT02814019|Drug|Idebenone 150 mg film-coated tablets|
79872169|NCT06082050|Drug|YOLT-201|Infusion of YOLT-201 at Day 1。
79872170|NCT06082011|Device|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
79872171|NCT06081985|Device|Transcranial Magnetic Stimulation with double-cone coil|Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
79872172|NCT06081985|Device|Transcranial Magnetic Stimulation with sham coil|Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
79872173|NCT06081959|Drug|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
79872174|NCT06081959|Drug|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
79872175|NCT06081959|Drug|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
79872176|NCT06081959|Drug|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
79872177|NCT06081959|Drug|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
79872178|NCT06081933|Drug|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
79872179|NCT06081933|Drug|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
79872180|NCT06081868|Behavioral|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
79273779|NCT02814019|Drug|placebo|
79273780|NCT02224495|Behavioral|Structured exercise training|
79304602|NCT02710045|Biological|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
79304603|NCT03283631|Biological|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
79304604|NCT04483375|Biological|SCTA01|recombinant humanized anti-SARS-CoV-2 monoclonal antibody
79872181|NCT06081868|Behavioral|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
80029832|NCT04940104|Drug|Botox Injectable Product|Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A &B, are available for medical and cosmetic uses.
79273781|NCT03364244|Drug|Sildenafil|"[REVATIO® Tablets / REVATIO® OD Film] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~[REVATIO® Dry Syrup for Suspension] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily."
79403246|NCT05095896|Other|ITP patients|ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
79403247|NCT03832465|Drug|Levofloxacin film-coated tablet|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
79872182|NCT06081855|Diagnostic Test|CT|Measuring aortic root diameter by CT
79872183|NCT06081842|Other|Contraceptive counseling strengthening intervention package|Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.
79872184|NCT06081816|Other|carie|Caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. The assessment of oral health related quality of life by Oral Health impact Profile questionary (OHIP-14), applied as an interview. The evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of Pell and Gregory and Winter
79872185|NCT06081803|Drug|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
79872186|NCT06081764|Other|Exercise|Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
79872187|NCT06081751|Behavioral|Pretest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
80029833|NCT03483428|Behavioral|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
80029834|NCT03483428|Behavioral|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
79403248|NCT03832465|Drug|Levofloxacin intravenous solution|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
80029835|NCT03057886|Device|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
79273782|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
79577595|NCT01875081|Biological|Livercellgram|"Livercellgram~Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃~Injection Method: Directly inject into liver through hepatic artery"
79577596|NCT01875094|Other|Self-Management / MTM using Health IT|
79577597|NCT01875107|Drug|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
79577598|NCT01875133|Other|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
80029836|NCT03131882|Drug|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
79273783|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
79273784|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
79304605|NCT04483375|Other|Placebo|Placebo
79577599|NCT01875146|Other|4x4 min HIT|Conventional 4x4 min high-intensity interval training
79577600|NCT01875146|Other|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
79577601|NCT01875146|Other|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
79577602|NCT01875146|Other|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
79577603|NCT01875172|Drug|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
79577604|NCT01875172|Drug|placebo|
80029837|NCT03131882|Drug|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
80029838|NCT04938934|Behavioral|Lipids infusion|Lipids infusion via intestinal tube
80029839|NCT04938934|Behavioral|Sham infusion|Sham infusion via intestinal tube
80029840|NCT04460534|Diagnostic Test|diagnostic|The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
80029841|NCT04938700|Drug|probiotics|Probiotics as granules can be used for infants and adolescents
79872188|NCT06081751|Behavioral|Posttest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
79273785|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
79273786|NCT03165513|Behavioral|mhGAP-IG|psychosocial interventions
79872189|NCT06081738|Drug|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
79273787|NCT03165123|Drug|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
79872190|NCT06081738|Drug|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
79872191|NCT06081712|Drug|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
79872192|NCT06081712|Drug|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
79872193|NCT06081699|Drug|TNP-2198|Oral
80029842|NCT04938700|Drug|conventional medical treatment|Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
80029843|NCT04837508|Drug|MRG002|Administrated intravenously
80029844|NCT04938622|Other|Sedentary Control|Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
79577605|NCT01875172|Behavioral|smoking cessation counseling|
79577606|NCT01875185|Drug|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
79577607|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy with Splenectomy|
79577608|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
79273788|NCT03165123|Drug|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
79273789|NCT03167931|Other|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
79577609|NCT01875224|Drug|Belatacept|
79577610|NCT01875224|Drug|Tacrolimus|Standard administration of tacrolimus
79577611|NCT01875263|Drug|Cloxacilin|2g/4 hours i.v., 5 days
79577612|NCT01875263|Drug|Cloxacillin|2g/4h 14 days Standard therapy
79577613|NCT01875263|Drug|Levofloxacin|500 mg v.o./24h, 9 days
79577614|NCT01875289|Procedure|obturator nerve block|
80029845|NCT04938622|Other|Exercising control|Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
80029846|NCT04938622|Other|15 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
80029847|NCT04938622|Other|30 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
79577615|NCT01875315|Other|Diagnostic Cardiac Imaging|
79577616|NCT01875328|Other|Telemedicine|Post stroke follow up in home using telemedicine.
79577617|NCT01875328|Other|Clinic|Post stroke clinic group follow up
79577618|NCT01875341|Device|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
79872194|NCT06081699|Drug|TNP-2198 Placebo|The placebo for TNP-2198 active drug
79872195|NCT06081686|Drug|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of [177Lu] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
79577619|NCT01875341|Device|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
79577620|NCT01875354|Dietary Supplement|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
79577621|NCT01875354|Dietary Supplement|Placebo and Low Fat Eating Plan|
79872196|NCT06081686|Drug|Phase II:[177Lu]Lu-XT033 Injection|Patients received [177Lu]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
80029848|NCT04938622|Other|30 percent energy deficit (15/15)|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
80029849|NCT04938622|Other|60 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
80029850|NCT04709822|Behavioral|Visuospatial Interference|"Two remote intervention sessions with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) alongside accompanying information.~Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions)."
80029851|NCT04938310|Procedure|sleeve gastrectomy|sleeve gastrectomy
80029852|NCT04938310|Device|support garment|A custom made support garment
80029853|NCT03483350|Drug|Granisetron|Ampoule
79403249|NCT04437966|Behavioral|Enhanced Chronic Disease Self-management program|CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
79577622|NCT01875380|Drug|Regorafenib|
79577623|NCT01875393|Drug|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
79577624|NCT01875406|Other|diagnostic exercises|
79577625|NCT01875419|Device|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
79577626|NCT01875419|Behavioral|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
79872197|NCT06081673|Drug|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
79872198|NCT06081673|Drug|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
79872199|NCT06081673|Drug|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
79872200|NCT06081660|Behavioral|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
79872201|NCT06081647|Device|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
79872202|NCT06081647|Device|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
79872203|NCT06081634|Behavioral|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
80029854|NCT03483350|Drug|Midazolam|Ampoule
80029855|NCT03057730|Biological|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
79872204|NCT06081634|Other|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
79872205|NCT06081621|Biological|REGEND001|REGEND001: 1-1.5×10^6 bronchial basal cells/kg administrated by bronchoscopy.
79872206|NCT06081621|Biological|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
79872207|NCT06081608|Diagnostic Test|kidney function test|blood sample for kidney function test
80029856|NCT03480308|Drug|Fentanyl|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
79872208|NCT06081595|Drug|Fluzoparib|Fluzoparib 100mg bid
79872209|NCT06081595|Drug|Apatinib|Apatinib 375mg qd
79872210|NCT06081582|Drug|Toripalimab|"This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
79273790|NCT03167931|Other|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
79872211|NCT06081569|Diagnostic Test|gait video; speech video; facial expression video;|The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
79872212|NCT06081556|Diagnostic Test|ultrasonic testing|mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
79872213|NCT06081543|Dietary Supplement|Ketogenic diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
79872214|NCT06081543|Dietary Supplement|Low-fat Mixed diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
79872215|NCT06081517|Behavioral|Social Determinants of Health and toxicity questionnaires|Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.
79577627|NCT01875497|Dietary Supplement|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
79577628|NCT01875523|Drug|Serelaxin|
79273791|NCT05497622|Diagnostic Test|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
79872216|NCT06081504|Other|Wii fit exercises program|Wii fit exercises for balance training and lower limb strengthening for 30 minutes. In addition to warming up and cooling down, 10 minutes each in the form of a range of motion exercises and stretching.
80029857|NCT03480308|Drug|Dexamethasone|Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
80029858|NCT03480308|Drug|Bupivacaine|Bupivacaine
79273792|NCT05497622|Diagnostic Test|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~Tissue Texture abnormality~Asymmetry~Restriction of Motion~Tenderness"
79273793|NCT05497622|Procedure|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
79273794|NCT04601870|Other|No Financial Incentive|No monetary incentive to participate in quit planning and quit counseling with a tobacco cessation specialist.
79273795|NCT04601870|Other|Financial Incentive (100 dollars)|Financial incentive (100 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
79273796|NCT04601870|Other|Financial Incentive (50 dollars)|Financial incentive (50 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
79577629|NCT01875536|Device|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
79304606|NCT03283475|Procedure|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
79737265|NCT02729662|Drug|Tolvaptan|"Before administration of tolvaptan~TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~24-hour urine collection・Hematology/urinalysis: Once/year~Physical findings: Blood pressure and medical interview at ambulatory visit~Hospitalization for education and examination at the start of tolvaptan administration~24-hour urine collection・Hematology/urinalysis・Inulin clearance~Physical findings: Body weight, blood pressure~Adverse Events~After administration of tolvaptan~TKV・Liver capacity・inulin clearance: Once/year~24-hour urine collection: Once/6 months~Hematology/urinalysis: Once/month in principle~Physical findings: Blood pressure and medical interview at ambulatory visit~Adverse Events"
79304607|NCT02444767|Drug|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
79577630|NCT01875536|Behavioral|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
79577631|NCT01875549|Device|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
79737266|NCT03195244|Other|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
79304608|NCT02459717|Other|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
79577632|NCT01875549|Procedure|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
79737267|NCT03194854|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
79872217|NCT06081504|Other|Pilates exercises program|Selected pilates exercises for balance training and lower limb strengthening: Articulating bridge, Spine stretch, Single leg stretch, Double leg stretch, Criss-cross, One leg kick, Side kick, Hip twist, and Standing footwork for 30 minutes, 10 repetitions each. In addition to the warming up and the cooling down exercises before and after the pilates exercises, 10 minutes each in the form of a range of motion exercises and stretching, and deep friction massage for scar management.
80029859|NCT03057418|Drug|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
79273797|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
79304609|NCT02459717|Other|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
79737268|NCT02733250|Biological|Pembrolizumab|200mg IV Day 1 of each 21 cycles
79737269|NCT02733250|Drug|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
79403250|NCT04190407|Behavioral|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
79737270|NCT02733094|Drug|Secukinumab|
79872218|NCT06081504|Other|Standard physical therapy program|All patients will receive the standard physical therapy program consisting of 45 minutes per session of a supervised and individualized exercise program for three sessions per week for eight weeks which will include: Stretching exercises for lower limb muscles, each stretch will be maintained for 45 seconds, 3 repetitions, strengthening exercises for lower limb muscles starting from 50 to 60% of 1 repetition maximum and the intensity will be increased gradually until 80 to 85 % through the treatments weeks.
79872219|NCT06081491|Diagnostic Test|diagnosis|Pediatric patients within the inclusion criteria will be diagnosed for MIH by the primary investigator and the questionnaire will be filled with face to face interviews with their parents
79577633|NCT01875562|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
79737271|NCT03188068|Drug|Sirolimus|Oral administration
79737272|NCT03188068|Drug|Prednisolone|Oral administered with sirolimus
79737273|NCT03304600|Device|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
79737274|NCT03304600|Device|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
79737275|NCT02729506|Procedure|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
79737276|NCT02729506|Procedure|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
79737277|NCT02732782|Other|Isometric exercise|
79872220|NCT06081478|Drug|CD19/CD22-bispecific CAR-T cells|CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
80029860|NCT03480230|Drug|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
80029861|NCT04938076|Device|Transcranial direct current stimulation|Transcranial direct current stimulation on motor cortex
79304610|NCT02439541|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10^7)
79304611|NCT03282149|Biological|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
79577634|NCT01875575|Dietary Supplement|Placebo|
79577635|NCT01875575|Dietary Supplement|Glucose 25g|
79577636|NCT01875575|Dietary Supplement|Glucose 10g|
79577637|NCT01875627|Dietary Supplement|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
79577638|NCT01875627|Dietary Supplement|Carbohydrate and Konjac Noodles|
79577639|NCT01875627|Dietary Supplement|Carbohydrate noodles|
79577640|NCT01875653|Biological|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
79737278|NCT02732782|Other|Eccentric exercise|
79872221|NCT06081413|Procedure|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
79403251|NCT04605432|Drug|PEG-FFI|"Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher."
79577641|NCT01875653|Biological|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
79577642|NCT01875666|Drug|Trastuzumab|8 mg/kg IV, single dose
79737279|NCT02729428|Device|MRI|Participants will undergo an MRI scan
79737280|NCT02732548|Other|Negative Pressure Wound Therapy (NPWT)|
79872222|NCT06081400|Procedure|Cryoablation|Percutaneous imaging-guided cryoablation
79872223|NCT06081400|Drug|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
79872224|NCT06081387|Dietary Supplement|Vitamin D|Oral capsules containing 5,000 international units of vitamin D every two weeks for four months. The tablets will be taken with 250 ml of water at lunch.
79872225|NCT06081387|Other|Resistance training|Sarcoplasm stimulating training system. This program will run for 15 weeks and three sessions a week. This exercise plan is designed in three 5-week periods.
79872226|NCT06081387|Drug|placebo|Capsules made of paraffin oil, designed as a placebo. They will be indistinguishable in shape and colour from vitamin D capsules. The tablets will be taken with 250 ml of water at lunch.
79872227|NCT06081374|Device|simulation implication|Breastfeeding education is planned by dressing pregnant women with simulation models.
79872228|NCT06081322|Drug|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
79872229|NCT06081296|Procedure|Control group|Control Group (Ctl): alveolus closure with total flap elevation and simple suture; and socket sealing with mixed free gingival tissue graft.
79872230|NCT06081296|Procedure|Mixed free gingival graft group|closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual's own palate, which will be properly sutured. This graft is a combination of epithelialized-subepithelial connective tissue graft, which will be taken from the hard palate of the regions.
80029862|NCT04937842|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
79304612|NCT02444689|Behavioral|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
79577643|NCT01875666|Drug|pertuzumab|840 mg IV single dose
79577644|NCT01875666|Drug|lapatinib|1000 mg daily for 7 days
79577645|NCT01875679|Other|Comprehensive Surgical Coaching|
79577646|NCT01875679|Other|Conventional Surgical Training|Surgical training as per participant's residency program
79577647|NCT01875705|Drug|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
79577648|NCT01875705|Drug|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
79577649|NCT01875718|Drug|UC1010|
79577650|NCT01875718|Drug|Placebo|
79737281|NCT02732548|Other|MIRODERM Application(s)|
79737282|NCT02732548|Other|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
79872231|NCT06081296|Procedure|Bone+ mixed free gingival graft group|closure of the socket without flap elevation, placement of a freeze-dried bone graft and sealing of the socket with a mixed free gingival tissue graft.
79872232|NCT06081296|Procedure|Bone + Titanium Seal group|socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
80029863|NCT05151614|Drug|Colchicine 0.5 MG|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
80029864|NCT03483194|Device|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
79304613|NCT02444689|Behavioral|Standard of care education|
79304614|NCT03281993|Other|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
79304615|NCT03281915|Procedure|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
79304616|NCT03281915|Procedure|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
79577651|NCT01875744|Drug|Polyethylene glycol 4000|
79577652|NCT01875757|Drug|Vitamin D3|
79577653|NCT01875757|Drug|Placebo|
79577654|NCT01875796|Behavioral|Cognitive-Behavioral Therapy|
79577655|NCT01875796|Behavioral|Motivation Enhancement Therapy|
79577656|NCT01875796|Behavioral|Integrated Cannabis and Anxiety Reduction Treatment|
79737283|NCT03303664|Other|IMPROVE Protocol|Comprehensive pain management protocol
79737284|NCT02729272|Procedure|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
79737285|NCT02729272|Procedure|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
79737286|NCT02729272|Device|Monopolar ESD|
79737287|NCT02729272|Device|Ultrasonic ESD|
80029865|NCT03483194|Drug|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
80029866|NCT04937530|Drug|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
79577657|NCT01875796|Behavioral|False Safety Behavior Elimination Therapy|
79577658|NCT01875822|Dietary Supplement|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
79737288|NCT02732470|Other|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
80029867|NCT04937530|Drug|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
80029868|NCT04937608|Diagnostic Test|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
79273798|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
79577659|NCT01875835|Device|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
79577660|NCT01875835|Device|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
79577661|NCT01875887|Procedure|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
79577662|NCT01875900|Other|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
79737289|NCT03170362|Other|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
79737290|NCT02732158|Other|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
79872233|NCT06081270|Other|Liquid biopsy|Blood withdrawal for each patient is performed (i) at the time of treatment initiation with tyrosine kinase inhibitors (TKI); (ii) at the time of the first planned instrumental re-evaluation according to clinical practice regardless of the type of response to the TKI employed (9-12 weeks); (iii) at the time of radiological progression according to RECIST 1 criteria. 1 at computerized tomography scan with contrast or metabolic progression at 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose during TKI therapy; (iv) at the time of the change of therapeutic strategy decided by the investigator when used beyond progression and not coinciding with point iii. The ctDNA is extracted from plasma and analyzed with Illumina sequencing method.
79872234|NCT06081218|Other|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
79872235|NCT06081205|Other|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
79273799|NCT02688933|Drug|HOE901-U300 (Insulin Glargine 300 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
79273800|NCT02688933|Drug|Lantus (Insulin Glargine 100 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
79872236|NCT06081192|Procedure|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
79577663|NCT01875900|Other|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
79577664|NCT01875913|Behavioral|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
79577665|NCT01875913|Behavioral|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
79577666|NCT01875926|Biological|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
79577667|NCT01875926|Biological|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
79577668|NCT01875926|Biological|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
79737291|NCT02727166|Dietary Supplement|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
79737292|NCT02727166|Dietary Supplement|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
79737293|NCT03112408|Behavioral|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
80029869|NCT04937218|Behavioral|Egg demand creation campaign|Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
80029870|NCT04937140|Diagnostic Test|14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients|assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
80029871|NCT04409548|Other|All of the spatial and Temporal Gait parameters|
80029872|NCT04649840|Diagnostic Test|Humoral and cellular immunity|Humoral (IgG) and cellular (antigen-specific cells) immunity
80029873|NCT03482960|Drug|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~Administration: By mouthpiece attached to a single use Tedlar bag.~Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~Frequency: 10-minute interval between doses."
79273801|NCT02688933|Drug|Mandated back ground therapy|Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
79577669|NCT01875939|Drug|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
79273802|NCT05497544|Behavioral|Exercise recommendation group|A verbal exercise recommendation will be provided. This recommendation will be reported also in the hospital resignation letter.
79273803|NCT05497544|Behavioral|Exercise recommendation plus guidebook group|This group will receive the exercise (verbal and written) recommendation. Additionally, the oncologist hand the patient a guidebook about exercise, specifically designed for cancer patients.
79577670|NCT01875939|Drug|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
79577671|NCT01875952|Drug|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
79577672|NCT01876004|Drug|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
79577673|NCT01876004|Drug|Placebo|Prescribed Placebo IM (intramuscularly), single dose
79577674|NCT01876017|Biological|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
79577675|NCT01876030|Device|FES|
79577676|NCT01876056|Behavioral|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
79577677|NCT01876069|Device|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
79577678|NCT01876069|Device|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
79577679|NCT01876095|Procedure|Multidisciplinary medication review|"Consists of the following steps:~1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~5. Execution of pharmaceutical care plan according to agreed schedule."
79577680|NCT01876108|Drug|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
79577681|NCT01876121|Drug|Celecoxib|oral
79577682|NCT01876160|Other|Transcutaneous electrical nerve stimulation|
79737294|NCT03112408|Behavioral|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
79737295|NCT03112408|Behavioral|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
79737296|NCT03112408|Behavioral|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
79737297|NCT02727088|Procedure|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
79737298|NCT02727088|Procedure|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
79872237|NCT06081140|Dietary Supplement|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
79273804|NCT05502926|Diagnostic Test|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
79273807|NCT02688621|Behavioral|Internet Only|18 month behavioral weight loss intervention delivered online
79273808|NCT02688621|Behavioral|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
79273809|NCT00882505|Dietary Supplement|vitamin D|Subject will receive vitamin d supplements
79273810|NCT00882505|Other|Placebo|Subject will receive a placebo.
79273811|NCT04480359|Drug|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
79577683|NCT01876173|Behavioral|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
79577684|NCT01876186|Drug|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
79577685|NCT01876186|Drug|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
79577686|NCT01876199|Behavioral|intense follow up|
79577687|NCT01876225|Behavioral|Forced coughing during cervical punch biopsy|
79577688|NCT01876238|Other|T-PAT|
79577689|NCT01876238|Other|Surveys|Pre-test and posttest surveys and questionnaires
79577690|NCT01876264|Procedure|Extended resection|
79577691|NCT01876264|Procedure|Conventional resection|
79737299|NCT02727244|Procedure|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
79273812|NCT04480359|Drug|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
79403252|NCT04605432|Drug|PEG-nonFFI|"All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse."
79403253|NCT04190173|Drug|Prucalopride|1-2 mg once daily enteral feeding for 5 consecutive days
79872238|NCT06081127|Other|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~Three in-person visits for clinical measurements~Enhanced usual care (EUC)~Pre-hab (pre-treatment PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~Teach Back (HEP, post-op movement precautions)~Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
80029874|NCT03482960|Drug|PFP|"Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
79737300|NCT02728960|Procedure|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
79273813|NCT04480359|Drug|Meloxicam|7.5mg, once a day, 3 month, oral
79577692|NCT01876290|Drug|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
79577693|NCT01876290|Drug|Placebo|Placebo
79577694|NCT01876303|Other|laboratory biomarker analysis|Correlative studies
79577695|NCT01876303|Other|questionnaire administration|Ancillary studies
79577696|NCT01876316|Drug|Moxifloxacin|single oral administration of 400mg of moxifloxacin
79577697|NCT01876316|Drug|Placebo|single oral administration of 400mg of placebo
79577698|NCT01876342|Procedure|open repair|2-0 sutures
80029875|NCT05259644|Device|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
79273814|NCT03724825|Diagnostic Test|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
79577699|NCT01876342|Procedure|endoscopic TEP repair|mesh
79577700|NCT01876394|Other|Coconut Oil|Shake with 50 g Coconut oil
79577701|NCT01876394|Other|Canola Oil|Shake with 50 g Canola oil
79737301|NCT02726932|Other|No intervention, merely observational|
79737302|NCT02728882|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
79737303|NCT01064310|Drug|pazopanib|oral anti-angiogenic treatment
79872239|NCT06081127|Other|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have ONLY EUC consisting of~Three in-person visits for clinical measurements~Planned oncology treatment (surgery, chemotherapy, radiation)~Nursing education on surgical site and drain care, post-operative movement precautions, pain management~If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~Monthly monitoring with PROMIS-PF surveys beginning at baseline with alerts from scores = or < 45 (indicating moderate or severe impairment) for physical therapy referral"
80029876|NCT05259644|Other|conservative treatment of obesity|Diet and exercise
80029877|NCT05259644|Device|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
80029878|NCT05151224|Diagnostic Test|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
80029879|NCT04936672|Behavioral|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
79273815|NCT03724825|Diagnostic Test|Total testosterone|blood samples will be collected after 10 hours fasting
79273816|NCT03724825|Diagnostic Test|Adropin|blood samples will be collected after 10 hours fasting
79273817|NCT03724825|Diagnostic Test|Adiponectin|blood samples will be collected after 10 hours fasting
79273818|NCT02232841|Device|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
79403254|NCT04190173|Drug|Placebo|1/2-1 tablet once daily enteral feeding for 5 consecutive days
79403255|NCT04190095|Device|Motion Tracking in VR|Participant will wear motion sensors and VR devices
79403256|NCT04190095|Behavioral|VR Interaction|Participant will perform VR interaction task
79577702|NCT01876394|Other|Grapeseed Oil|Shake with 50 g Grapeseed oil
79577703|NCT01876394|Other|Chia Oil|Shake with 50 g Chia oil
79577704|NCT01876394|Other|Butter|Shake with 50 g Butter
79577705|NCT01876407|Device|Low intensity laser for oral mucositis|
79577706|NCT01876407|Device|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
79577707|NCT01876433|Drug|Mirabegron|
79577708|NCT01876433|Drug|Placebo|
79577709|NCT01876459|Other|MRI|
79577710|NCT01876459|Procedure|lumbar puncture|
79577711|NCT01876459|Behavioral|neuropsychological tests|
79577712|NCT01876472|Behavioral|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
79577713|NCT01876498|Procedure|Xiaflex surgery|Xiaflex surgery
79577714|NCT01876537|Device|Hardware wound healing|
79737304|NCT01064310|Drug|sunitinib|oral anti-angiogenic treatment
79737305|NCT00627276|Dietary Supplement|omega-3 fatty acid|Oral, 3 times daily
79737306|NCT00627276|Other|placebo|Oral, 3 times daily
79872240|NCT06080672|Other|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
80029880|NCT05259488|Dietary Supplement|immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
79872241|NCT06080360|Other|Patient-Reported Outcome Measures|Functional Independence Measurement-FIM, Barthel Index and European Quality of Life-5 Dimensions Questionnaire-EQ-5D, which are self-report based evaluation methods, were applied to patients who received routine treatment and met the inclusion criteria.To determine the patients' level of participation in the treatment, Hopkins was scored by the physiotherapist applying the treatment.
80029881|NCT03479996|Drug|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
79872242|NCT06079840|Device|mindfulness-based stress reduction app|mobile application (app) for caregivers
80029882|NCT05151068|Behavioral|traditional nursing method|"①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support."
80029883|NCT05151068|Behavioral|Precise acupoint application combined with ear acupoint embedding nursing program|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
80029884|NCT02524184|Drug|sildenafil|sildenafil 100 mg per day for 7 days.
79577715|NCT01876537|Device|Usual Surgery|
79577716|NCT01876550|Drug|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
79577717|NCT01876550|Drug|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
79577718|NCT01876550|Drug|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
79872243|NCT06079242|Device|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
79872244|NCT06078384|Drug|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
80029885|NCT02524184|Drug|placebo|an identical placebo per day for 7 days
79577719|NCT01876563|Dietary Supplement|vitamin D|one tab 4000 IU/day vitamin D
79273819|NCT02232841|Device|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
79273820|NCT02232919|Device|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
79577720|NCT01876563|Dietary Supplement|placebo|one tab per day placebo
79577721|NCT01876576|Other|Clear liquids|Clear liquids
79577722|NCT01876576|Other|Low residue breakfast and lunch|Low residue
79577723|NCT01876589|Device|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
79577724|NCT01876589|Device|Xience Prime|Drug eluting metallic stent
79577725|NCT01876602|Behavioral|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
79577726|NCT01876615|Drug|YH4808|experimental drug
79577727|NCT01876615|Drug|Diclofenac|Depain tablet 25mg
79577728|NCT01876615|Drug|YH4808+Diclofenac|
79577729|NCT01876641|Drug|Vemurafenib + Cobimetinib, Decitabine|
79577730|NCT01876654|Device|TruMatch® patient specific cutting guide|
79737307|NCT02726854|Drug|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
79737308|NCT04724928|Radiation|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
79737309|NCT04724928|Drug|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
79737310|NCT04724928|Procedure|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
80029886|NCT03486236|Drug|VX-440|VX-440 was administered in TC with TEZ and IVA.
80029887|NCT03486236|Drug|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
80029888|NCT03486236|Drug|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
80029889|NCT03486236|Drug|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
79737311|NCT02728570|Other|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
79577731|NCT01876667|Other|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
79273821|NCT02234401|Device|Bi level pressure support|
79737312|NCT02728570|Other|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
79577732|NCT01876667|Other|Placebo|Usual Care
79577733|NCT01876680|Other|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
79577734|NCT01876680|Other|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
79737313|NCT02728492|Drug|Quisinostat|
79872245|NCT06078384|Drug|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
79872246|NCT06078358|Other|Resistance exercise training|Traditional linear periodization resistance training.
79872247|NCT06078215|Combination Product|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset
79872248|NCT06077903|Biological|GT101|Autologous tumor infiltrating lymphocyte injection
79872249|NCT06077149|Biological|RSV vaccine|"All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally"
79872250|NCT06076551|Diagnostic Test|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
79872251|NCT06076408|Other|SNAGS with Pilates|Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient
79872252|NCT06076408|Other|SNAGS|Patients will Receive Sustained Natural Apophyseal glides
79872253|NCT06076356|Other|Foam Rolling|Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
79872254|NCT06076356|Other|Kinesio Taping|Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
79872255|NCT06071702|Device|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
79273822|NCT02234401|Other|Standard Care|
79872256|NCT06071195|Diagnostic Test|Prostate Cancer Patients|see arm/group description
79273823|NCT04227704|Drug|Ketamine 50 MG/ML|Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
79577735|NCT01876693|Procedure|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
79737314|NCT02728492|Drug|Paclitaxel|
79273824|NCT04227704|Drug|Control|Administration of 0.9% Sodium Chloride (N/S)
79273825|NCT03608371|Drug|BTRX-246040|oral capsule 40 mg
79273826|NCT03608371|Drug|Placebo|oral capsule matching BTRX-246040 40 mg capsule
79273827|NCT03720613|Drug|Naldemedine|0.2 mg tablet once a day at any time with or without food
79273828|NCT03720613|Drug|Lubiprostone|0.024 mg twice a day [adjust dose based on liver function]
79273829|NCT03720613|Drug|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
79273830|NCT02709512|Drug|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
79273831|NCT02709512|Other|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
79273832|NCT03664921|Drug|Omnitram Oral Tablet|Administered three times daily for 28 consecutive days.
79737315|NCT02728492|Drug|Carboplatin|
79737316|NCT02728492|Drug|Gemcitabine|
79737317|NCT02728492|Drug|Cisplatin|
79737318|NCT02726776|Other|Suspension in a harness|
79737319|NCT02726776|Other|Climbing|
79737320|NCT02726152|Procedure|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
79273833|NCT03664921|Drug|Placebo Oral Tablet|Administered three times daily for 28 consecutive days.
79273834|NCT03530293|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
79737321|NCT02726152|Procedure|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
79403257|NCT04020679|Behavioral|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
79403258|NCT01272219|Drug|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
79577736|NCT01876745|Drug|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
79737322|NCT02726308|Drug|Dexamethasone|5 mg I.V. Dexamethasone just before induction
79577737|NCT01876758|Behavioral|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
79577738|NCT01876758|Behavioral|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
79577739|NCT01876797|Drug|ticagrelor/prasugrel|
79577740|NCT01876836|Device|i-gel|i-gel placed after induction
79577741|NCT01876836|Device|C-LMA|placed after induction
79577742|NCT01876849|Drug|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
79737323|NCT02726308|Drug|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
79872257|NCT06071065|Behavioral|Pharmacist counselling|Counselling session with Pharmacist about disease and medication therapy.
79872258|NCT06069973|Other|No intervention, observational study|No intervention
79273835|NCT03530293|Drug|Placebo oral capsule|non-active dosage form
79273836|NCT03516487|Drug|SYNB1618|SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
79577743|NCT01876862|Other|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
79737324|NCT02726308|Drug|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
79737325|NCT02728414|Dietary Supplement|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
79273837|NCT03516487|Drug|Placebo|Subjects receive placebo orally in a chilled buffered solution (100 mL).
79737326|NCT02728414|Dietary Supplement|placebo|the patients in this arm will receive placebo intervention
79273838|NCT00510055|Procedure|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
79273839|NCT00510055|Procedure|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
79273840|NCT03659929|Drug|Amphetamine Sulfate|active experimental AR19
79273841|NCT03659929|Drug|Placebo|Matching placebo
79737327|NCT01037244|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
79737328|NCT01037244|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
79737329|NCT00833989|Drug|GSK249320|I.V. infusion
79737330|NCT00833989|Drug|PLACEBO|Placebo
79737331|NCT02728180|Drug|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
79273842|NCT03505957|Device|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
79273843|NCT03658759|Procedure|Extracorporeal Cardiopulmonary Resuscitation|local ECPR clinical pathway, including transport with mechanical chest compression device and rapid response VA-ECMO
79273844|NCT03500263|Drug|PTI-808|Active
79737332|NCT02728180|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
79737333|NCT02873832|Biological|Blood sample|
79737334|NCT02873832|Other|Flow cytometry|
79872259|NCT06069076|Diagnostic Test|cathepsin S and chromogranin A|Diagnostic value of serum Cathepsin S and Chromogranin A
79872260|NCT06067269|Drug|Apalutamide|Given PO
79273845|NCT03500263|Drug|Placebo|Placebo
79273846|NCT03500263|Drug|PTI-801|Active
79273847|NCT03500263|Drug|PTI-428|Active
79273848|NCT03500263|Drug|Placebo|Placebo
79273849|NCT02811679|Drug|Blinatumomab|Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia
79273850|NCT02232529|Drug|MIN-101|
79273851|NCT02232529|Drug|Placebo|
79273852|NCT03448081|Drug|SNA-120|SNA-120 (0.5%) active ointment
79872261|NCT06067269|Procedure|Biospecimen Collection|Undergo collection of blood samples
79872262|NCT06067269|Procedure|Computed Tomography|Undergo PSMA-PET/CT
79872263|NCT06067269|Other|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
79872264|NCT06067269|Radiation|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
79872265|NCT06067269|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
79872266|NCT06067269|Procedure|Positron Emission Tomography|Undergo PSMA-PET/CT
79872267|NCT06067269|Other|Questionnaire Administration|Ancillary studies
80029890|NCT04935892|Behavioral|Slippers|Patients in the intervention group wear slippers when out of bed
79872268|NCT06066411|Other|Massage Ball|The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
79872269|NCT06063941|Drug|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
80029891|NCT03486158|Device|CalproSmart™ system|Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
80029892|NCT03479918|Drug|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
79737335|NCT02873832|Other|western blot|
79737336|NCT02728024|Other|Missing items, Errors in Completion, Difficulties|
79737337|NCT00627432|Drug|gemcitabine hydrochloride|
79737338|NCT00627432|Drug|oxaliplatin|
79737339|NCT02726230|Behavioral|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
79737340|NCT02727946|Other|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
79737341|NCT01037088|Drug|Mild dose cannabis|3.53% THC by weight
79737342|NCT01037088|Drug|Low dose cannabis|1.29% THC by weight
79737343|NCT01037088|Drug|Cannabis|0.00% THC by weight
79737344|NCT02727790|Device|Stimulator|
80029893|NCT03479918|Drug|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
80029894|NCT03479918|Drug|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
80029895|NCT03479918|Drug|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
80029896|NCT04936048|Behavioral|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
80029897|NCT04936048|Behavioral|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
80029898|NCT03482804|Other|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
80029899|NCT04935970|Diagnostic Test|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
79273853|NCT03448081|Drug|Placebo|Vehicle Ointment
79273854|NCT03448081|Drug|Calcipotriene|Calcipotriene ointment (0.005%)
80029900|NCT04935970|Diagnostic Test|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
80029901|NCT03479840|Procedure|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
79872270|NCT06063941|Drug|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
80029902|NCT03482726|Behavioral|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
80029903|NCT04935346|Other|no intervention group|The awareness of medical and nursing students were evaluated. there is no intervention
80029904|NCT04935502|Other|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
79273855|NCT04792879|Diagnostic Test|Peripheral veins Doppler ultrasound|Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
79273856|NCT02232607|Drug|Lacidipine, low dose|
79273857|NCT02232607|Drug|Lacidipine, medium dose|
79273858|NCT02232607|Drug|Lacidipine, high dose|
79273859|NCT02232607|Drug|Placebo|
79273860|NCT04638049|Other|Collection of human biofluids|Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT
79872271|NCT06054984|Drug|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10^8±20%,5×10^9±20%,5×10^10±20%.
79872272|NCT06054464|Drug|PC14586|Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
79872273|NCT06054464|Drug|Rabeprazole|Part 1: Daily oral dose of rabeprazole on days 11-14.
79872274|NCT06054464|Drug|Famotidine|Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
79872275|NCT06054308|Other|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
79872276|NCT06052462|Drug|[14C]-LY3556050|Administered orally
79872277|NCT06051669|Device|iLivTouch|The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
79872278|NCT06051669|Device|FibroScan|The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.
79872279|NCT06047938|Radiation|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children[11]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
79872280|NCT06047704|Other|No intervention|No intervention
79872281|NCT06045104|Dietary Supplement|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
79872282|NCT06045104|Dietary Supplement|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
79872283|NCT06042725|Procedure|Biospecimen Collection|Undergo optional collection of blood samples
79872284|NCT06042725|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
79872285|NCT06042725|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
79403259|NCT01272219|Drug|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
79737345|NCT04189120|Procedure|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
79737346|NCT02725996|Biological|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
79872286|NCT06042725|Procedure|Chest Radiography|Undergo chest x-ray
79872287|NCT06042725|Procedure|Computed Tomography|Undergo PET/CT
79872288|NCT06042725|Biological|Daratumumab|Given SC
79872289|NCT06042725|Drug|Dexamethasone|Given PO
79872290|NCT06042725|Drug|Lenalidomide|Given PO
79872291|NCT06042725|Procedure|Low Dose Computed Tomography of the Whole Body|Undergo WBLDCT
79737347|NCT02725996|Other|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
79872292|NCT06042725|Procedure|Magnetic Resonance Imaging|Undergo MRI
79872293|NCT06042725|Procedure|Positron Emission Tomography|Undergo PET/CT
79872294|NCT06042725|Drug|Venetoclax|Given PO
79872295|NCT06042725|Procedure|X-Ray Imaging|Undergo x-rays
79872296|NCT06036082|Other|Conventional physical therapy|"Standing with feet together .~Step standing .~High step standing and trying to keep balanced.~Single leg stance unilateral standing with assistance.~Standing on a declined surface by using wedge.~Standing with manual locking of the knees.~Changing position.~Gait training.~Static and dynamic muscle contraction."
79872297|NCT06036069|Other|Conventional physical therapy|"Standing with feet together while the therapist was sitting behind and manually locking the child knees.~Step standing with the therapist behind the child.~High step standing and trying to keep balanced. The child stood on exercise mattress.~Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~Standing with manual locking of the knees.~Changing position.~Gait training.~Static and dynamic muscle contraction."
80029905|NCT04935502|Other|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
80029906|NCT03482648|Drug|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
79737348|NCT02725762|Device|LT-300 Active (PBM)|
79737349|NCT02725762|Device|LT-300 Inactive (Sham)|
79872298|NCT06034288|Drug|Xeomin 100 UNT Injection|intravesical injection
79872299|NCT06034288|Drug|Botox 100 UNT Injection|intravesical injection
79872300|NCT06025565|Diagnostic Test|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
79872301|NCT06012175|Dietary Supplement|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
79872302|NCT06012175|Dietary Supplement|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
80029907|NCT03482648|Drug|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
80029908|NCT03482648|Drug|Placebo|Placebo matched to BBT-401-1S, oral capsule
79304617|NCT02443285|Drug|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
79304618|NCT02443285|Drug|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
79304619|NCT02445079|Other|This is an observational study only|Observational study only
79304620|NCT03284099|Drug|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
79304621|NCT03281837|Device|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
79304622|NCT03281837|Other|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
80029909|NCT04935190|Diagnostic Test|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
80029910|NCT05150834|Other|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
79577744|NCT01876875|Dietary Supplement|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
79577745|NCT01876875|Dietary Supplement|Usual diet|The patients of this group were randomized to continue their usual diet
79872303|NCT06008938|Genetic|HEMGENIX|HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
79577746|NCT01876927|Other|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
79577747|NCT01876927|Other|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
79577748|NCT01876940|Device|air-Q, followed by fiberoptic intubation|
79577749|NCT01876940|Device|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
79577750|NCT01876966|Drug|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
79577751|NCT01876966|Drug|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
79872304|NCT06008938|Biological|Factor IX (FIX)|FIX prophylaxis therapy
79872305|NCT06003348|Dietary Supplement|OHCit- standard dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
79872306|NCT06003348|Drug|Potassium Citrate|10 mEq Extended-release tablets for oral use
79577752|NCT01876966|Drug|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets [20/120 mg] at 0, 8, 24, 36, 48, and 60 hours)
79577753|NCT01877005|Drug|Ruxolitinib|
79577754|NCT01877018|Behavioral|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
79577755|NCT01877031|Device|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
79872307|NCT06003348|Drug|Placebo|Placebo
79872308|NCT06003348|Dietary Supplement|OHCit- low dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
80029911|NCT04934644|Procedure|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
80029912|NCT03486080|Drug|Dutogliptin Tartrate|Active treatment
80029913|NCT03486080|Drug|Filgrastim Injectable Product|Active treatment
80029914|NCT03486080|Drug|Placebos|placebo control
79273861|NCT04638049|Other|Patient reported outcome measures|EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
79273864|NCT02310464|Drug|OBI-833/OBI-821|
79273865|NCT03365947|Drug|ARO-HBV Injection|Single or multiple doses of ARO-HBV Injection by subcutaneous (sc) injection
79273866|NCT03365947|Other|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
79273867|NCT02260466|Other|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
79577756|NCT01877031|Device|Ultrasound|Standard of Care - Ultrasound guided intervention
79872309|NCT06000891|Drug|ZP7570|13 once-weekly subcutaneous injections
79872310|NCT06000891|Drug|Placebo|13 once-weekly subcutaneous injections
79872311|NCT05998070|Other|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
80029915|NCT04934878|Biological|Referral information|first visit to our hospital/transfer from another hospital
80029916|NCT03131258|Procedure|Donor Nephrectomy|48 Donor Nephrectomy Patients
80029917|NCT03057262|Device|Repositioning splint|Application of repositioning splint in the study group.
79577757|NCT01877044|Dietary Supplement|NAXUS|
79577758|NCT01877044|Dietary Supplement|Placebo|
79577759|NCT01877057|Dietary Supplement|Saturn|
80029918|NCT03479450|Drug|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
80029919|NCT03477344|Drug|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
80029920|NCT03477344|Drug|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
79273868|NCT02232685|Device|18F-Choline PET/CT|18F-Choline PET/CT
79577760|NCT01877096|Behavioral|Motivational Interviewing|A brief motivational interviewing session
79872312|NCT05998044|Other|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~Arm Circles~Toe Touch~bridge~Shoulder Bridge~Chest Lift~Hundred~Roll Up~Leg Circles~Chris Cross~Side Kick~Side Leg Circles~one leg kick~double leg kick~Swan~Single leg Stretch~Double leg Stretch~saw~Spine Stretch"
79577761|NCT01877096|Behavioral|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
79577762|NCT01877122|Device|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
79577763|NCT01877122|Device|Marlex® Mesh Implant|
79872313|NCT05998044|Other|control|They will be asked not to participate in any regular exercise for 8 weeks.
79872314|NCT05994638|Dietary Supplement|Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)|Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3
79872315|NCT05979233|Procedure|staged managment|staged management
79872316|NCT05979233|Procedure|one session ERCP then LC|one session ERCP then LC
79872317|NCT05979233|Procedure|one session LC then ERCP|one session LC then ERCP
79737350|NCT02727712|Procedure|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4)program
79872318|NCT05975021|Drug|Istaroxime|IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 1.0 or 0.5 µg/kg/min for 18 hours, 0.5 µg/kg/min for 24 hours. Total duration 48 hours.
79872319|NCT05975021|Drug|Placebo|IV infusion via a syringe pump. Total duration 48 hours.
79872320|NCT05974735|Behavioral|Wellness trail|"Setting up wellness trails based on four distinct themes:~Food, Nutrition and Micronutrition~Physical activity~Sleep~Stress and well-being"
79872321|NCT05967520|Drug|JMKX000189|JMKX000189 will be administered orally once a day
79872322|NCT05967520|Drug|Placebo|Placebo will be administered orally once a day
79872323|NCT05948644|Drug|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
79872324|NCT05947162|Behavioral|extinction training (nicotine cues)|extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
79872325|NCT05947162|Behavioral|extinction training (neutral cues)|extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
80029921|NCT04933864|Drug|Methylene Blue and Photodynamic Therapy|"Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm^2 energy dose were performed."
80029922|NCT03477266|Drug|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
80029923|NCT03477266|Drug|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
80029924|NCT04933318|Other|TENS|Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
80029925|NCT04933318|Other|shamTENS|shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
79872326|NCT05947162|Behavioral|Time-restricted smoking cessation|Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
79872327|NCT05947162|Behavioral|Time-restricted fasting|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
80029926|NCT04933318|Other|IFC|Interferential current therapy (IFC)- analgesic current therapy
80029927|NCT04933318|Other|shamIFC|shamInterferential current therapy (shamIFC)- analgesic current therapy
80029928|NCT03479372|Drug|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
79273871|NCT02232763|Drug|Losartan|12 weeks of losartan or placebo with crossover to the other
79273872|NCT02232763|Drug|Placebo|12 weeks of losartan or placebo with crossover to the other
79273873|NCT03335371|Drug|TTP399|Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
79273874|NCT03335371|Drug|TTP399|Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
79577764|NCT01877174|Device|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
79577765|NCT01877174|Procedure|transcarotid stenting|
79577766|NCT01877200|Other|No treatment given|Patients will fill out a questionnaire by interview.
79577767|NCT01877213|Behavioral|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
79737351|NCT02727712|Device|Transesophageal Echocardiography（TEE）|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~Goal-directed fluid management"
79737352|NCT02727712|Device|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6~7ml/kg, joint use of PEEP)
80029929|NCT03131336|Drug|PeproStat|solution for local application
80029930|NCT03131336|Drug|Saline|solution for local application
79273875|NCT03335371|Drug|Placebo Oral Tablet|Phase 2: Participants will receive Placebo oral tablets for 12 weeks
79577768|NCT01877226|Drug|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
79577769|NCT01877252|Procedure|Surgical revascularization|
79577770|NCT01877252|Procedure|Endovascular revascularization|
79577771|NCT01877252|Other|No vascular intervention|
79577772|NCT01877304|Device|AKITA|
79577773|NCT01877317|Device|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
79577774|NCT01877330|Procedure|Interscalene block for shoulder arthroscopy|
79577775|NCT01877356|Procedure|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
79737353|NCT02727712|Drug|Anesthesia drugs during the surgery|"Bilateral thoracic paravertebral block before induction of anesthesia;~Fast channel anesthesia • Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01~0.04ug/kg•min, Sevoflurane 0.5~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
79737354|NCT02727712|Procedure|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml*2)program
79737355|NCT04118101|Drug|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
79737356|NCT04118101|Other|control|no ESPB will be given.
79273876|NCT04294784|Drug|Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
79577776|NCT01877356|Procedure|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
79737357|NCT01042236|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
79737358|NCT02725918|Drug|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
79737359|NCT02725918|Drug|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
79737360|NCT02727634|Other|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
79273877|NCT04294784|Drug|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
79872328|NCT05947162|Behavioral|Time-restricted fasting with food supplemnet|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
79577777|NCT01877382|Drug|Milademetan|DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
79577778|NCT01877382|Drug|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
79737361|NCT02725606|Biological|Pegylated Recombinant Human G-CSF|subcutaneous
79737362|NCT02725606|Biological|GW003|subcutaneous
79737363|NCT02725684|Other|Observational study, no intervention|Observational study, no intervention
79872329|NCT05945680|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
79872330|NCT05945680|Drug|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
79872331|NCT05943795|Drug|SI-B001|Administration by intravenous infusion
79872332|NCT05943795|Drug|Docetaxel|Administration by intravenous infusion
79872333|NCT05941728|Other|Avocado|The intervention treatment will contain avocado
79273878|NCT02262559|Drug|BIBR 277 tablet|
79273879|NCT02262559|Drug|BIBR 277 capsule|
79273880|NCT04293458|Device|EsoGuard|EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
79273881|NCT05491460|Drug|Apixaban 5 MG Tab|oral intake
79273882|NCT05491460|Drug|Dabigatran 150 MG Tab|oral intake
79273883|NCT05491460|Drug|Edoxaban 60Mg Tab|oral intake
79577779|NCT01877434|Procedure|Reversed shoulder arthroplasty|
79577780|NCT01877447|Device|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
79577781|NCT01877460|Other|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
79577782|NCT01877473|Procedure|Ablation|
79273884|NCT05491460|Drug|Rivaroxaban 20 MG Tab|oral intake
79273885|NCT03311269|Device|ClariVein RES|ClariVein system
79577783|NCT01877486|Procedure|Ablation|Pulmonary vein isolation following dofetilide
79737364|NCT02725450|Behavioral|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
79273886|NCT03311269|Drug|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
79273887|NCT03311269|Drug|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
79273888|NCT04286906|Other|Questionnaire|MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
79737365|NCT02725450|Behavioral|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
79737366|NCT02725294|Other|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
79737367|NCT00592501|Radiation|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
79737368|NCT00592501|Drug|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
79273889|NCT02762929|Drug|HTX-011A|HTX-011A (bupivacaine/meloxicam), via injection.
79273890|NCT02762929|Biological|Saline Placebo|Saline placebo via injection.
79273891|NCT02762929|Drug|HTX-011B|HTX-011B (bupivacaine/meloxicam), via injection or instillation.
79737369|NCT00592501|Drug|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
79737370|NCT02727556|Behavioral|visual images|
79737371|NCT03097666|Device|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
79872334|NCT05941728|Other|Oil + Fiber|The active comparator will contain a snack with oils and fibers that mimic an avocado
79872335|NCT05941728|Other|Average American Diet|The sham comparator will contain foods/beverages that mimic a standard American Diet
79872336|NCT05939739|Biological|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
79872337|NCT05939739|Other|Consultation for results delivery|at 4 months
79872338|NCT05939739|Other|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
79872339|NCT05938959|Drug|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
79872340|NCT05938959|Drug|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
79273892|NCT02762929|Drug|HTX-002|HTX-002, via injection.
79273893|NCT02762929|Drug|Bupivacaine HCl|Bupivacaine HCI, via injection.
79273894|NCT02762929|Drug|HTX-009|HTX-009, via injection.
79273895|NCT01209182|Device|Testing a new device (LS BioPath TOUCH) on excised tissue|Measurements are obtained with test device on excised tissue.
79273896|NCT02262637|Drug|Micardis®|
79273897|NCT02262637|Drug|MicardisPlus®|
79273898|NCT03301051|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
79273899|NCT03301051|Biological|Placebo|Single dose of a Placebo
79273900|NCT00467233|Procedure|Laser Treatment|Laser treatment to half of the face at each study visit
79273901|NCT00467233|Procedure|Acid Peel|Acid peel to half of the face at each study visit
79273902|NCT01662986|Drug|tiotropium bromide|18 mcg once a day (QD)
79273903|NCT01662986|Drug|Placebo|Once a day (QD)
79273904|NCT05497232|Procedure|simultaneous pancreas-kidney transplantation|"Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases."
79737372|NCT02721628|Procedure|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
79737373|NCT02721628|Procedure|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
79872341|NCT05937230|Device|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
79273905|NCT04204850|Drug|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
79273906|NCT00054158|Drug|dexamethasone|
79273907|NCT00054158|Drug|doxorubicin hydrochloride|
79273908|NCT00054158|Drug|thalidomide|
79273909|NCT00054158|Drug|vincristine sulfate|
79273910|NCT01337167|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
79872342|NCT05937230|Device|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
79872343|NCT05932615|Device|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
79872344|NCT05932615|Device|Any Commercially Available Transcatheter Aortic Valve (CAV) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
79872345|NCT05932459|Drug|Deuremidevir Hydrobromide for Suspension 100mg|Take it with 240ml water in fasted condition.
79872346|NCT05932459|Drug|Deuremidevir Hydrobromide for Suspension 300mg|Take it with water in fasted condition or after taking infant formula.
80029931|NCT03057340|Biological|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
80029932|NCT02523950|Procedure|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
80029933|NCT02523950|Procedure|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
79577784|NCT01877499|Other|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~Treatment time (up to 4 hours per session);~Blood flow rate (up to 400 mL/min;~Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
79577785|NCT01877512|Drug|Change in daily dosage of Growth Hormone|
79577786|NCT01877525|Procedure|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
79872347|NCT05932459|Drug|Deuremidevir Hydrobromide for Suspension 25mg|Take it with 240ml water on an empty stomach.
79872348|NCT05932459|Drug|Deuremidevir Hydrobromide tablets 100mg|Take it with 240ml water in fasted condition.
79872349|NCT05914649|Other|IV normal saline (1500mL infusion)|1500mL of IV normal saline will be infused intravenously
79872350|NCT05914649|Other|IV normal saline (50mL infusion)|50mL of IV normal saline will be infused intravenously as a placebo control.
79872351|NCT05914090|Procedure|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
79872352|NCT05903209|Device|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
79872353|NCT05899595|Other|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~Subjective fatigue (Rate of Fatigue scale)~Heart rate variability with a holter ECG~Muscle pain with a visual analogue scale~Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
79872354|NCT05894876|Other|No treatment is given|No treatment is provided to the participants as part of this study.
79872355|NCT05892835|Other|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
79872356|NCT05880849|Drug|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast & 4 capsules with dinner) x 180 days
80029934|NCT02523950|Device|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
80029935|NCT03482570|Device|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
79273911|NCT01337167|Biological|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
79273912|NCT01337167|Biological|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
79304623|NCT02439463|Procedure|Below-knee amputation|Patients with traumatic below-knee amputation.
79737374|NCT02721628|Device|Femtosecond laser|Use in the epic-keratoplasty surgery
79737375|NCT02721472|Procedure|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
79737376|NCT02721472|Procedure|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
80029936|NCT03477188|Behavioral|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
80029937|NCT03477188|Behavioral|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
79577787|NCT01877577|Dietary Supplement|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
79872357|NCT05878015|Drug|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
79577788|NCT01877590|Drug|alpha-lipoic acid|
80029938|NCT03482492|Drug|Tramadol|Tramadol iv
79273913|NCT01337167|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
79273914|NCT01337167|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
79273915|NCT01337167|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
79273916|NCT01337167|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
79273917|NCT01337167|Biological|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
79577789|NCT01877616|Other|diagnostic test|Polysomnography
79872358|NCT05872477|Drug|Ruxolitinib Topical|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
80029939|NCT03482492|Drug|Paracetamol|Paracetamol iv
79273918|NCT05496764|Drug|Dexamethasone|we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A
79273919|NCT05496764|Drug|Glucose Injection|inject10 ml glucose 5% into the carpal tunnel in group B
79273920|NCT05491070|Device|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
79273921|NCT05496608|Procedure|L-PRF|a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.
79273922|NCT05496608|Procedure|OFD|Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
79273923|NCT05496608|Procedure|CM|Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
79273924|NCT04424732|Radiation|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
79273925|NCT05496530|Drug|Suprachoroidal triamcinolone acetonide injection|Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
79577790|NCT01877616|Other|Diagnostic test|overnight polysomnography
79577791|NCT01877629|Drug|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
79577792|NCT01877629|Drug|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
79577793|NCT01877681|Procedure|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
79577794|NCT01877681|Procedure|Active comparator|Usual care as specified in the PU practice guideline
79577795|NCT01877694|Drug|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
79577796|NCT01877694|Drug|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
79577797|NCT01877707|Other|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
79577798|NCT01877733|Other|Maximal strength training|
79577799|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
79577800|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
79577801|NCT01877746|Other|No intervention|No intervention, only standard medical therapy
80029940|NCT03477032|Biological|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
80029941|NCT03874286|Diagnostic Test|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
79273926|NCT04280198|Behavioral|Triple P Parenting Videos|Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
79273927|NCT04280198|Behavioral|Activity Boxes|There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
79577802|NCT01877759|Biological|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .
79577803|NCT01877785|Drug|MHAA4549A|Single-ascending dose of MHAA4549A
79577804|NCT01877785|Drug|Placebo|Placebo to MHAA4549A
79577805|NCT01877798|Procedure|volume resuscitation, vasoactive drug|
79577806|NCT01877811|Drug|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
79577807|NCT01877824|Other|Fast-track training|
79577808|NCT01877850|Procedure|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
79872359|NCT05872477|Drug|Placebo|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
79273928|NCT05499260|Drug|CB03-154|CB03-154 tablet once daily.
79403260|NCT01272219|Drug|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
79872360|NCT05870930|Other|Carob beverage|Volunteers will consume 2 tablespoons of carob powder in 200mL drinking water.
79872361|NCT05870930|Other|Sucrose beverage|Volunteers will consume a beverage with sucrose equal to this contained in carob beverage (approx. 5g) prepared in 200mL drinking water.
79872362|NCT05867875|Other|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
79872363|NCT05867875|Other|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
79273929|NCT05499260|Drug|Placebo|Placebo tablet once daily.
79273930|NCT02744833|Drug|GMI-1271|
79273931|NCT02744833|Drug|Enoxaparin Sodium (Lovenox®)|
79577809|NCT01877863|Other|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
79577810|NCT01877889|Drug|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 [treatment period 2] or Sequence 2 [treatment period 1]).
80029942|NCT03482414|Other|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
80029943|NCT03482414|Other|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
79403261|NCT01272219|Drug|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
79403262|NCT05230836|Other|High-frequency alternating current stimulation|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group"
79577811|NCT01877889|Drug|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 [treatment period 1] or Sequence 2 [treatment period 2]).
79737377|NCT02721394|Behavioral|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
79737378|NCT01040832|Drug|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
79737379|NCT01040832|Drug|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
79737380|NCT02721550|Drug|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
79737381|NCT02721238|Biological|20% Albumin|
80029944|NCT03482414|Other|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
79273932|NCT02234635|Other|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
79273933|NCT04065386|Device|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
79273934|NCT04065386|Device|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
79273935|NCT04477057|Drug|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
79872364|NCT05854602|Behavioral|Component A|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component A focusses on making parents aware of the process of avoidance in children with anxiety, and helps them to identify situations in which they accommodate to the anxiety of their children. Subsequently, a first step that parents can take to reduce accommodation is discussed."
79872365|NCT05854602|Behavioral|Component B|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component B tries to increase parents empathetic reactions to their anxious child. This is done by teaching parents to label the emotion of their children, empathize with the emotion, and communicate confidence in the abilities of their child to face the situation."
79273936|NCT02234869|Drug|Interferon Beta|Subcutaneous injection
79273937|NCT02234869|Drug|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
79577812|NCT01877928|Device|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
79577813|NCT01877928|Device|standard CPAP|Standard of care postoperative treatment for OSA.
79577814|NCT01877954|Drug|Extra-fine hydrofluoroalkane beclometasone dipropionate|
79273938|NCT05499104|Device|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
79273939|NCT05499104|Device|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
79273940|NCT05499104|Device|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
79273941|NCT05499026|Drug|Chenodeoxycholic Acid|Bile acid
79304624|NCT02459405|Procedure|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
79304625|NCT02459405|Device|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
79577815|NCT01877954|Drug|Fluticasone propionate|
79577816|NCT01877967|Dietary Supplement|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
79577817|NCT01877967|Dietary Supplement|placebo|
79737382|NCT02721238|Other|Plasmalyte|
79737383|NCT02721004|Drug|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
79737384|NCT04302090|Other|Regulated expiratory method|This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
79577818|NCT01878058|Other|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
79577819|NCT01878110|Behavioral|COMB|
79577820|NCT01878123|Biological|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
79577821|NCT01878123|Other|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
79577822|NCT01878136|Drug|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
79577823|NCT01878188|Drug|BC-819/PEI|Intravesical instillation
79577824|NCT01878188|Drug|BCG Vaccine|intravesical instillations
80029945|NCT03479294|Drug|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
80029946|NCT03482336|Other|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
80029947|NCT03476720|Device|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
80029948|NCT03482258|Dietary Supplement|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
79577825|NCT01878201|Drug|Fimasartan|Fimasartan 30 mg
79577826|NCT01878201|Drug|Valsartan|Valsartan 80 mg
79577827|NCT01878227|Drug|Coenzyme A|Coenzyme A 400mg per day
79577828|NCT01878227|Drug|Fenofibrate 200mg|Fenofibrate 200mg per day
79577829|NCT01878240|Procedure|EVAR without coils embolization/ Coils embolization during EVAR|
79577830|NCT01878266|Radiation|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
79577831|NCT01878266|Radiation|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
79577832|NCT01878266|Radiation|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
79577833|NCT01878279|Other|Underlying medical illness|
79577834|NCT01878305|Device|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
79577835|NCT01878318|Drug|methotrexate|stable dose
79577836|NCT01878318|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
79872366|NCT05854602|Behavioral|Component C|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component C consists of cognitive restructuring of parental maladaptive cognitions concerning their child's anxiety. Parents are taught to recognize their own cognitions about the anxiety of their child, challenge this thought and come up with an alternative, helpful thought."
79872367|NCT05844657|Other|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
80029949|NCT03482258|Dietary Supplement|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
80029950|NCT05259098|Drug|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
80029951|NCT05259098|Drug|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
79577837|NCT01878357|Drug|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
80029952|NCT05259020|Combination Product|ID140009|Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
80029953|NCT05259020|Combination Product|ID1803+ID1805|(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)
79577838|NCT01878357|Drug|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
79577839|NCT01878370|Other|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
79577840|NCT01878370|Other|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
79577841|NCT01878396|Drug|Anti-B-RAF|
79577842|NCT01878422|Drug|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
79577843|NCT01878422|Drug|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
79577844|NCT01878422|Drug|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
79577845|NCT01878422|Drug|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
79577846|NCT01878448|Drug|Anlotinib|
80029954|NCT03482180|Drug|KI1106 4g, QD|KI1106 4 Capsules
80029955|NCT03482180|Drug|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
80029956|NCT04459442|Procedure|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
79577847|NCT01878474|Drug|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
79577848|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
79577849|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
79577850|NCT01878474|Drug|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
79577851|NCT01878474|Drug|Placebo|Single ascending dose in Caucasian men
79577852|NCT01878474|Drug|Placebo|Age-effect in Caucasian men
79577853|NCT01878474|Drug|Placebo|Gender-effect in Caucasian women
79577854|NCT01878474|Drug|Placebo|Single ascending dose in Japanese men
79577855|NCT01878487|Device|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~At baseline~After thrombus aspiration with a thrombus extraction catheter~After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
80029957|NCT04689932|Drug|Triferic AVNU|Ferric Pyrophosphate Citrate
79273942|NCT05496218|Diagnostic Test|Blood samples|At study entry, we will collect morning blood samples from fasting women. participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS). In addition, women will be asked to report about their usual weekly food consumption in the previous year. Information on the diet will be based on a reproducible and valid food frequency questionnaire. Energy and mineral and macro-and micronutrient intakes will be estimated using the most recent update of an Italian Food Consumption Database.
79577856|NCT01878513|Drug|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
79577857|NCT01878539|Device|coagulometer|
79872368|NCT05844657|Other|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
79872369|NCT05844657|Other|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
80029958|NCT03479060|Procedure|Wet Cupping|cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
79273943|NCT04001582|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
79577858|NCT01878539|Behavioral|training programme|
79872370|NCT05844657|Other|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
80029959|NCT03478748|Other|Dental health education|Anticipatory guidance given to mothers to promote their children's oral health.
80029960|NCT03481946|Drug|BAY1093884|0.3 mg/kg given intravenously
80029961|NCT03481946|Drug|BAY1093884|1 mg/kg given intravenously
80029962|NCT04334408|Drug|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
80029963|NCT04334408|Drug|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
79577859|NCT01878565|Drug|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
79577860|NCT01878565|Drug|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
79577861|NCT01878578|Drug|Eslicarbazepine acetate|Tablets containing ESL 600 mg
79577862|NCT01878578|Drug|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
79577863|NCT01878578|Drug|Placebo|Tablets containing matching placebo
79577864|NCT01878630|Device|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~weighing scale (Seca 861 with bluetooth, seca gmbh & co. kg.)~blood pressure device (UA767PBT with bluetooth, A&D Ltd.)~ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)"
79577865|NCT01878630|Other|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
79577866|NCT01878643|Drug|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
79577867|NCT01878643|Drug|Placebo|normal saline administered to patient via nebulization
79577868|NCT01878695|Drug|IV/oral n-acetylcysteine|
79577869|NCT01878708|Drug|PEG-L-asparaginase|
79577870|NCT01878708|Drug|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
79577871|NCT01878721|Radiation|PET/CT|positron emission tomography/computed tomography
79273944|NCT05498714|Drug|PEG+lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
79577872|NCT01878734|Dietary Supplement|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
80029964|NCT04294550|Other|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
80029965|NCT02523560|Other|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
79872371|NCT05844657|Other|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
79872372|NCT05844657|Other|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
79872373|NCT05844657|Other|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
79872374|NCT05844657|Other|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
79872375|NCT05844657|Other|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
80029966|NCT03476564|Drug|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
80029967|NCT03476564|Drug|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
80029968|NCT05258708|Biological|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
80029969|NCT05258552|Procedure|enema|preoperative enema
80029970|NCT05258474|Drug|controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)|single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
79273945|NCT05498714|Drug|CSP＋lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
79577873|NCT01878747|Behavioral|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
79577874|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------"
79577875|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
79577876|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
79577877|NCT01878864|Drug|Bupivacaine lozenge|
79577878|NCT01878864|Drug|Lidocaine-adrenalin injection|
80029971|NCT05258474|Drug|Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
80029972|NCT05258474|Drug|Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)|single- and multiple-ascending dose (SAD/MAD)
80029973|NCT05258474|Drug|Placebo Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
80029974|NCT05258396|Other|MRI without injection of contrast product|MRI without injection of contrast product
80029975|NCT03478436|Drug|Doxycycline|Doxycycline 40 mg capsules
79273946|NCT05490836|Biological|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.
79273947|NCT05490836|Biological|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
79273948|NCT01338025|Drug|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
79577879|NCT01878903|Other|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
79577880|NCT01878929|Drug|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
79273949|NCT01338025|Drug|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
79273950|NCT05498636|Combination Product|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
79403263|NCT05230836|Other|Sham current stimulation|"Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
79403264|NCT04190017|Other|Cranial MRI|Cranial MRI
79403265|NCT01510028|Biological|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
79403266|NCT05104164|Other|Self-myofascial release|At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
79403267|NCT05104086|Device|ultrasound elastography|strain ratio and resistivity index
79577881|NCT01878942|Drug|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
79577882|NCT01878942|Drug|LSD|200µg per os, single dose
79872376|NCT05844657|Other|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
79577883|NCT01878955|Genetic|AMH level difference between patient with PCOS and multicystic ovaries.|
79577884|NCT01878968|Other|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
79577885|NCT01878994|Behavioral|Counselling group|
79577886|NCT01878994|Behavioral|Nereu group|
79577887|NCT01879007|Drug|Factive® Tab / Factive IV|
79872377|NCT05844657|Other|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
79872378|NCT05844657|Other|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
79273951|NCT05498558|Other|No intervention.|No intervention.
79273952|NCT02262715|Drug|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
79273953|NCT02262715|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
79273954|NCT02262715|Other|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
79273955|NCT04314362|Drug|AZR-MD-001 ointment/semi-solid drug|AZR-MD-001 (1.0%) and suitable excipient
79273956|NCT04127864|Procedure|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
79273957|NCT02235025|Other|Cardio-pulmonary exercise testing|
79273958|NCT02235103|Other|Sperm Chromatin Dispersion Test|
79577888|NCT01879020|Drug|TA-8995|Drug: TA-8995 1mg
79577889|NCT01879020|Drug|TA-8995|Drug: TA-8995 2.5mg
79577890|NCT01879020|Drug|TA-8995|Drug: TA-8995 5mg
79577891|NCT01879020|Drug|TA-8995|Drug: TA-8995 10mg
79577892|NCT01879020|Drug|TA-8995|Drug: TA-8995 25mg
79577893|NCT01879020|Drug|Placebo|Placebo (TA-8995 1mg)
79577894|NCT01879020|Drug|Placebo|Placebo (TA-8995 2.5mg)
79577895|NCT01879020|Drug|Placebo|Placebo (TA-8995 5mg)
79577896|NCT01879020|Drug|Placebo|Placebo (TA-8995 10mg)
79577897|NCT01879020|Drug|Placebo|Placebo (TA-8995 25mg)
79577898|NCT01879033|Other|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
79872379|NCT05844657|Other|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
79872380|NCT05844657|Other|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
79872381|NCT05844657|Other|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
80029976|NCT03476486|Procedure|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
80029977|NCT01338987|Procedure|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
80029978|NCT01338987|Drug|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients <18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18 years and as a 3 month injection (adult preparation) for patients < 18 years
79273959|NCT05490758|Other|sensorimotor training|sensorimotor training include activities like play with dough, peg games, puzzles for 5 days a week for 4 week.
79273960|NCT05490758|Other|constraint induced movement therapy|constraint induced movement therapy in which arm was constraint for 6 hours a day for 5 days a week for 4 week.
79577899|NCT01879033|Other|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
79577900|NCT01879046|Procedure|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
79577901|NCT01879111|Other|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
79872382|NCT05844657|Other|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
79872383|NCT05844657|Other|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
79273961|NCT04424420|Drug|Paracetamol|Paracetamol oral tablet
79273962|NCT04424420|Drug|Ibuprofen|Ibuprofen oral tablet
79273963|NCT04424420|Drug|Placebo oral tablet|Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
79273964|NCT00457951|Drug|Open-Label|ODSH administered open-label
79403268|NCT04020991|Diagnostic Test|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
79403269|NCT05104008|Other|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
79577902|NCT01879150|Device|Cyclaplex bone anchor|Device implantation
79577903|NCT01879163|Biological|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
79577904|NCT01879163|Biological|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
79273965|NCT00457951|Drug|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
79577905|NCT01879189|Behavioral|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
79577906|NCT01879202|Drug|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
79577907|NCT01879202|Drug|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
79577908|NCT01879215|Procedure|Intramedullary nailing of the tibia|Standard care surgery
80029979|NCT01338987|Drug|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):[18F]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
80029980|NCT01338987|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults > 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric </= 22 years)
80029981|NCT01338987|Drug|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
80029982|NCT01338987|Drug|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
79273966|NCT00457951|Drug|ODSH|Randomized, Blinded, ODSH Arm
79577909|NCT01879254|Device|Deep Brain Stimulation|
79737385|NCT04304196|Other|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
79737386|NCT04304196|Other|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
79737387|NCT02832856|Behavioral|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
79737388|NCT02832856|Behavioral|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
79737389|NCT02720770|Drug|norditropine simplex|
79737390|NCT02733406|Other|Target Controlled Infusion|
79737391|NCT02733406|Other|Velocity Controlled Infusion|
79737392|NCT02720926|Drug|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
79737393|NCT02720926|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
79737394|NCT02720926|Drug|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
79872384|NCT05844657|Other|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
79872385|NCT05844657|Other|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
79872386|NCT05844657|Other|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
79872387|NCT05844657|Other|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
79872388|NCT05844657|Other|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
79872389|NCT05844657|Other|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
79872390|NCT05838755|Drug|GSK3858279|GSK3858279 will be administered
80029983|NCT01338987|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
80029984|NCT01338987|Drug|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
79309128|NCT03119051|Behavioral|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
79577910|NCT01879267|Behavioral|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
79577911|NCT01878162|Other|Exercise|
79577912|NCT01879098|Dietary Supplement|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
79577913|NCT01879098|Dietary Supplement|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
79577914|NCT01879098|Dietary Supplement|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
79737395|NCT00854581|Biological|PEG-interferon alfa-2b|Administered subcutaneously.
79872391|NCT05838755|Drug|Placebo|Placebo will be administered
79872392|NCT05838313|Behavioral|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
80029985|NCT01338987|Drug|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
79737396|NCT00854581|Biological|Interferon alfa-2b|Administered intravenously.
80029986|NCT01338987|Procedure|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
80029987|NCT04234100|Other|Orange juice rich in hesperidin and narirutin|The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
80029988|NCT03476408|Other|Correlation / Observational|correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
79737397|NCT00854581|Drug|Valproic Acid|Administered orally.
80029989|NCT03131180|Other|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
79737398|NCT00854581|Drug|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
79737399|NCT02720458|Other|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
79737400|NCT02720458|Behavioral|Short-term simple self-help program|"The short-term simple self-help program consists in:~Restriction of time in bed~Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
79737401|NCT02720614|Radiation|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
79872394|NCT05821465|Device|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
79872395|NCT05816226|Drug|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
79872396|NCT05816226|Drug|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
79737402|NCT02720380|Other|Buteyko|Intervention will be held twice a week during 3 weeks.
79737403|NCT02720380|Other|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
79737404|NCT00833911|Drug|Tramadol Once A Day|
79737405|NCT02719756|Drug|Metformin|Metformin tablets 1000 mg
79737406|NCT02719756|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets
79737407|NCT02719756|Drug|Metformin up-titration|
79872397|NCT05793801|Other|Dressing change|"The patient circuit corresponds to that of usual care.~Not part of usual patient management:~The rhythm of PICCline dressing changes, which differed between the two groups.~The collection of pain on a visual analog scale at each dressing change."
79872398|NCT05792956|Behavioral|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
80029990|NCT03478280|Drug|Brodalumab|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
80029991|NCT03478280|Drug|Placebos|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
80029992|NCT04856007|Drug|Dapagliflozin/metformin XR FDC 5/500 mg|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
80029993|NCT04856007|Drug|Dapagliflozin/metformin XR FDC 10/1000 mg|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
79737408|NCT02719678|Other|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
79737409|NCT01125293|Drug|Everolimus|
79737410|NCT01125293|Drug|Rituximab|
79737411|NCT01125293|Drug|Bortezomib|
79737412|NCT02702986|Procedure|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
79737413|NCT02702986|Device|Laser|
80029994|NCT04856007|Drug|Dapagliflozin 5 mg + Metformin 500 mg XR|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
80029995|NCT04856007|Drug|Dapagliflozin 10 mg + Metformin 1000 mg XR|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
80029996|NCT04936906|Behavioral|Extra Care (EC) Intervention|The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
79737414|NCT02719912|Device|mitral valve replacement|transcatheter mitral valve replacement
79737415|NCT05111483|Other|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~Repositioning with diastasis rehab splint :~Protect the connective tissue~Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~Diastasis safe exercises program to maintain the gains"
79737416|NCT05111483|Other|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~Tie a scarf around abdomen while performing exercises~Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~Respiratory rehabilitation manoeuvre"
79737417|NCT02719834|Drug|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
79737418|NCT02719834|Other|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
79872399|NCT05787483|Behavioral|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
79872400|NCT05787483|Behavioral|active control group|business as usual; regular wellness or SEL classes
79403270|NCT05104008|Other|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors & abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
79872401|NCT05771779|Biological|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
79872402|NCT05771779|Biological|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
79872403|NCT05771779|Biological|Measles and Rubella (MR)|Live attenuated vaccine
79577915|NCT01879098|Dietary Supplement|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
79577916|NCT01879280|Procedure|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
79872404|NCT05753670|Drug|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
79872405|NCT05753670|Drug|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
80029997|NCT04936906|Other|Usual Care (UC)|Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
80029998|NCT02523794|Other|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
80029999|NCT02523794|Other|Placebo|Purified Drinking Water
79273968|NCT05495672|Procedure|Local treatment|"Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany)."
79273969|NCT02233075|Drug|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
79273970|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
79273971|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
79273972|NCT02583919|Drug|Placebo|once weekly dosing for 26 weeks
79872406|NCT05746468|Behavioral|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
79872407|NCT05746468|Behavioral|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
79403271|NCT04020211|Device|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
79577917|NCT01879280|Procedure|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
79577918|NCT01879293|Drug|Metformin|
79577919|NCT01879293|Drug|placebo|
79577920|NCT01879358|Device|Drug-eluting stent|
79577921|NCT01879384|Device|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
79577922|NCT01879397|Device|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~ARFI based images of the carotid artery and plaque~Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
79577923|NCT01879423|Drug|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
79577924|NCT01879423|Drug|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
79577925|NCT01879462|Drug|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
79577926|NCT01879462|Drug|Placebo|Visually matching GSK2878175
79577927|NCT01879475|Device|032-11|Topical haemostat
79737419|NCT04311203|Behavioral|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
79737420|NCT02719600|Behavioral|Virtual reality|Evaluation of observational motor learning using virtual reality
79872408|NCT05744765|Other|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
79737421|NCT02719288|Other|CLARIX® CORD 1K graft|
79737422|NCT02719210|Biological|High Volume Plasma Exchange|
79737423|NCT02719210|Drug|Hypertonic 3% saline|
79273973|NCT02581657|Drug|PE0139 Injection|PE0139 Injection
79273974|NCT02581657|Drug|Placebo Injection|Placebo Injection
79273975|NCT04300244|Biological|UV1 vaccine + leukine|The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
79273976|NCT04300244|Biological|ipilimumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
79273977|NCT04300244|Biological|nivolumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
79403272|NCT04577820|Drug|garetosmab|Repeated doses administered intravenously (IV) every four weeks (Q4W)
79403273|NCT04097600|Drug|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
79403274|NCT04020367|Procedure|biopsy of mucosa's olfactory|intervention under general or local anesthesia
79403275|NCT04096820|Biological|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
79577928|NCT01879475|Device|Floseal (R)|Topical haemostat
79577929|NCT01879488|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
79577930|NCT01879488|Device|Vibrating-mesh nebulizer|
79577931|NCT01879488|Other|Gamma scintigraphy|
79577932|NCT01879488|Other|Preoperative spirometry|
79577933|NCT01879501|Behavioral|Low Vision Self-Management Program|The program has been describe above.
79577934|NCT01879514|Drug|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
79577935|NCT01879514|Drug|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
80030000|NCT04736979|Drug|amoxicillin clavulanate|dosage according to Shariff score and creatinine clearance
80030001|NCT03706430|Device|Pulse CO-Oximeter sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
80030002|NCT03651050|Behavioral|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
80030003|NCT03651050|Behavioral|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
80030004|NCT03562923|Drug|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
80030005|NCT03562923|Drug|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
79577936|NCT01879527|Drug|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
79577937|NCT01879527|Drug|Sugar pill|containing placebo
79577938|NCT01879566|Other|No intervention will be done. The study is observational|
79577939|NCT01879605|Drug|Docusate natrium and sorbitol|
79577940|NCT01879605|Drug|Bisacodyl|
79577941|NCT01879631|Procedure|radial keratotomy|
79577942|NCT01879644|Behavioral|NF|
79577943|NCT01879644|Behavioral|SM|
79577944|NCT01879644|Behavioral|PE|
79577945|NCT01879644|Behavioral|SU|
79577946|NCT01879670|Device|CircuLite Synergy left ventricular assist device|
79577947|NCT01879696|Device|ECSPRESS catheter with active vacuum|
79577948|NCT01879709|Behavioral|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
79577949|NCT01879709|Behavioral|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
79577950|NCT01879709|Other|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
80030006|NCT03562923|Drug|Placebo|Placebo Product
79577951|NCT01879748|Drug|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~placebo (8 Japanese and 8 Caucasian subjects)"
79872409|NCT05742698|Drug|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
79872410|NCT05742698|Drug|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
80030007|NCT03476252|Diagnostic Test|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
80030008|NCT03593252|Drug|Senna|Laxative,used for bowel preparation
80030009|NCT03593252|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
79273978|NCT02578771|Drug|ZuraPrep with 70% IPA|Apply topically
79273979|NCT02578771|Drug|ZuraPrep without 70% IPA|Apply topically. 0% IPA
79273980|NCT02578771|Drug|ChloraPrep CHG/IPA Teal Tint|Apply topically
79577952|NCT01879748|Drug|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~placebo (8 Japanese and 8 Caucasian subjects)"
79737424|NCT02719210|Drug|Mannitol|
79737425|NCT02719210|Device|Elective positive pressure ventilation|
79737426|NCT02719132|Drug|Dapagliflozin|Dapagliflozin, 10 mg
79737427|NCT02719132|Drug|Metformin|Metformin, up to 2500 mg
79872411|NCT05731960|Drug|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
79872412|NCT05731960|Drug|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
79872413|NCT05726812|Behavioral|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
80030010|NCT03593252|Drug|Metronidazole Oral|Oral antibiotic
80030011|NCT03593252|Drug|Neomycin|Oral non-absorbable antibiotic
80030012|NCT03593252|Drug|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
80030013|NCT03593252|Drug|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
80030014|NCT03593252|Other|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for >=8 hours, no formula milk/full liquids >= 4hours; no breast milk or clear fluids >=2hours.
80030015|NCT03593252|Other|Clear fluids the day before surgery|As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
79577953|NCT01879787|Other|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
79737428|NCT02719054|Behavioral|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
79872414|NCT05723679|Combination Product|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
79737429|NCT02718976|Procedure|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
79872415|NCT05723679|Combination Product|Room air gas mixture|Normal room air
79872416|NCT05714696|Behavioral|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
79872417|NCT05714696|Behavioral|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
79872418|NCT05705739|Procedure|retrolaminar block|curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
79872419|NCT05705739|Procedure|ESPB|curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
80030016|NCT03476174|Drug|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
80030017|NCT03476174|Drug|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
79273981|NCT02578771|Other|Normal Saline|Apply topically
79273982|NCT05498246|Procedure|laparoscopic partial nephrectomy|Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
79273983|NCT03128827|Device|RAM sensor|Acoustic Respiration Monitor
79273984|NCT02259595|Drug|HPN-07|500-1,500 mg oral capsules administered in a single dose
79577954|NCT01879813|Dietary Supplement|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
79577955|NCT01879813|Dietary Supplement|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
79273985|NCT02259595|Drug|NAC|1,200mg NAC administered via oral capsule in single dose
79273986|NCT02259595|Drug|Placebo|placebo oral capsule
79577956|NCT01879839|Dietary Supplement|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
79577957|NCT01879865|Other|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
79737430|NCT02718976|Procedure|Ultrasound guided lumbar plexus block (Shamrock)|
80030018|NCT04725045|Device|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
80030019|NCT03478202|Dietary Supplement|GOLO RELEASE|GOLO RELEASE plus Diet
79577958|NCT01879865|Other|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
80030020|NCT02259933|Drug|KUC 7483 CL|
80030021|NCT02259933|Drug|Placebo|
79577959|NCT01879878|Dietary Supplement|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
79577960|NCT01879878|Dietary Supplement|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
79872421|NCT05688436|Drug|Diroximel Fumarate|Administered as specified in the treatment arm.
79872422|NCT05688436|Biological|Alemtuzumab|Administered as specified in the treatment arm.
79577961|NCT01879891|Other|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
79577962|NCT01879904|Procedure|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
79577963|NCT01879917|Drug|Liraglutide|
79577964|NCT01879917|Drug|Placebo|Saline
79577965|NCT01879930|Drug|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
79872423|NCT05688436|Drug|Fingolimod|Administered as specified in the treatment arm.
79872424|NCT05688436|Drug|Glatiramer acetate|Administered as specified in the treatment arm.
79872425|NCT05688436|Biological|Interferon beta|Administered as specified in the treatment arm.
79872426|NCT05688436|Biological|Natalizumab|Administered as specified in the treatment arm.
79872427|NCT05688436|Biological|Ocrelizumab|Administered as specified in the treatment arm.
79872428|NCT05688436|Biological|Ofatumumab|Administered as specified in the treatment arm.
79872429|NCT05688436|Drug|Ozanimod|Administered as specified in the treatment arm.
79872430|NCT05688436|Biological|Peginterferon beta-1a|Administered as specified in the treatment arm.
79872431|NCT05688436|Drug|Ponesimod|Administered as specified in the treatment arm.
79872432|NCT05688436|Drug|Siponimod|Administered as specified in the treatment arm.
79872433|NCT05685758|Other|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
79872434|NCT05679622|Other|Fecal Microbiota Transplantation|In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
79872435|NCT05676450|Diagnostic Test|cell-free DNA|Given by IV (vein)
80030022|NCT05258318|Procedure|DK crush|Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).
80030023|NCT05258318|Procedure|DR crush|Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
80030024|NCT03562689|Other|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
80030025|NCT05258162|Other|Mobilization|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation~Lock and key exercises.~Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~Elbow flexion and extension~Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second."
80030026|NCT05258162|Other|Muscle Energy Technique|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~Elbow flexion and extension~Wrist flexion and extension~Forearm supination and pronation~Lock and key exercises.~Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~Elbow flexion and extension~Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~3 days per week for 3 weeks."
80030027|NCT04459520|Behavioral|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
79872436|NCT05650606|Other|High Intensity Gait Training|Physical therapy intervention for improving gait in patients post Cerebral Vascular Accident.
79273987|NCT02259673|Other|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
80030028|NCT04459520|Behavioral|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
79577966|NCT01879930|Drug|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
79273988|NCT02259673|Other|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
79273989|NCT05490524|Device|GATEKEEPER|The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
79577967|NCT01879943|Device|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
79577968|NCT01879943|Procedure|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
79872437|NCT05650606|Other|Conventional Therapy|Standard inpatient rehabilitation physical therapy treatments for Cerebral Vascular Accident.
79872438|NCT05637515|Biological|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
79577969|NCT01879956|Other|Craft Activities|There is no intervention method used to perform the task.
79577970|NCT01879956|Behavioral|OGI Method|metacognitive approach to assess executive functions.
79577971|NCT01879969|Procedure|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
79577972|NCT01879969|Procedure|computer assisted orthognathic planning and surgery of asymmetric patients|
79577973|NCT01879995|Procedure||
79577974|NCT01880034|Other|Lipid Emulsion Survey|
79577975|NCT01880112|Drug|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
79273990|NCT02571907|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
79577976|NCT01880125|Drug|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
79737431|NCT02718976|Drug|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
79872439|NCT05637515|Biological|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg [2 × 40 mg]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~Humira (40 mg every other week) at Week 16 and Week 18, and~Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
79872440|NCT05635162|Drug|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
79872441|NCT05635162|Drug|Rituximab|Rituximab 375 mg/m2 intravenous (IV)* on day 1 (+/-3 days) of each 28-day cycle
79273991|NCT02571907|Device|Atrium iCAST™|Implantation of Atrium iCAST
79273992|NCT02571907|Device|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
79577977|NCT01880138|Other|watching animated cartoon before general anesthesia|
79577978|NCT01880138|Other|not watching animated cartoon beofre general anaesthesia|
79577979|NCT01880151|Device|EEG|EEG recorded during a resting condition and during an episodic memory task condition
79577980|NCT01880190|Other|Ringer's Lactate|
79577981|NCT01880190|Other|HES 130/0.4 and Ringer's Lactate|
79577982|NCT01880203|Procedure|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
79577983|NCT01880216|Drug|Bemiparin sodium|subcutaneous application daily for 7±2 days
79737432|NCT02718664|Other|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
79737433|NCT02718742|Other|Laboratory Biomarker Analysis|Correlative studies
80030029|NCT04459520|Behavioral|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
79577984|NCT01880216|Drug|Enoxaparin sodium|subcutaneous for 7±2 days
79577985|NCT01880255|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
79737434|NCT02718742|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
80030030|NCT04459754|Drug|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
80030031|NCT03481868|Biological|Collection of blood and bone marrow|Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
80030032|NCT02523638|Drug|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
79737435|NCT02718742|Other|Quality-of-Life Assessment|Ancillary studies
79577986|NCT01880268|Device|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
80030033|NCT03478124|Behavioral|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
79577987|NCT01880268|Behavioral|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
79577988|NCT01880281|Other|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
79577989|NCT01880294|Drug|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
79577990|NCT01880307|Drug|Azathioprine|
79577991|NCT01880307|Drug|Infliximab|
79577992|NCT01880307|Drug|Prednisolon|
79577993|NCT01880333|Other|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
79737436|NCT02718508|Behavioral|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
79737437|NCT02718430|Drug|VXM01|Oral immunotherapy targeting VEGFR2
79872442|NCT05620264|Diagnostic Test|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
79872443|NCT05614544|Drug|HSK3486|HSK3486 for induction of general anesthesia
80030034|NCT03478046|Other|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
80030035|NCT05257148|Drug|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
79737438|NCT02718352|Other|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
79737439|NCT02718274|Device|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
79737440|NCT02718274|Other|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
79872444|NCT05614544|Drug|Propofol|Propofol for induction of general anesthesia
79273993|NCT05486000|Device|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
79273994|NCT02259751|Drug|KUC 7483 CL|
79737441|NCT02717884|Drug|tranylcypromine|"TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)~**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
79872445|NCT05614544|Drug|Placebo|Intralipid
79273995|NCT02259751|Drug|Placebo|
79273996|NCT05495516|Genetic|without Intervention|without Intervention
79273997|NCT02804035|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
79273998|NCT00345943|Other|MRI|Magnetic Resonance Imaging scans
79273999|NCT00345943|Behavioral|Neuropsychological Testing|Neuropsychological tests
79274000|NCT02262793|Drug|telmisartan|
79872446|NCT05604443|Other|retrospective analyze|retrospective analyze of MS39 and Pentacam images
79872447|NCT05547412|Device|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
79872448|NCT05533372|Drug|IA-14069|IA-14069 for oral administration.
79872449|NCT05533372|Drug|Placebo|Placebo for oral administration.
79274001|NCT02262793|Drug|ASA/ER-DP|
79274002|NCT02559206|Drug|Linaclotide|Oral, once daily
79274003|NCT02559206|Drug|Matching Placebo|Oral, once daily
79403276|NCT04766203|Behavioral|Treatment of REDS using a holistic treatment arm|This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
79403277|NCT04409756|Other|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
79403278|NCT01272765|Other|Placebo|Placebo
79403279|NCT01272765|Dietary Supplement|IHBG-10|500 mg IHBG-10
79577994|NCT01880346|Dietary Supplement|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
79577995|NCT01880346|Dietary Supplement|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
79577996|NCT01880372|Dietary Supplement|Alpha Lipoic Acid|Same as Arm description
79872450|NCT05533372|Drug|Methotrexate|Methotrexate for oral administration.
79872451|NCT05527938|Other|web-based intervention|"Establishing management teams.~Establishment of a nursing intervention team.~Daily uploading of health intervention records~Regularly delivering related health knowledge.~Home visiting~Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
79872452|NCT05525078|Behavioral|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
79403280|NCT05103852|Procedure|Cardiac MRI|vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
79577997|NCT01880385|Biological|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
80030036|NCT05257148|Drug|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
80030037|NCT05257148|Drug|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
79403281|NCT04020133|Procedure|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
79577998|NCT01880385|Drug|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
79577999|NCT01880385|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
79578000|NCT01880385|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
79578001|NCT01880385|Drug|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
79578002|NCT01880385|Biological|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
79578003|NCT01880398|Other|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
79578004|NCT01880411|Biological|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
79737442|NCT02717884|Drug|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
79737443|NCT02717884|Drug|cytarabine|40mg s.c. (days 1-10)
79737444|NCT02718196|Behavioral|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
79737445|NCT04100512|Device|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
79737446|NCT04100512|Device|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
79737447|NCT02717572|Radiation|Fludeoxyglucose F 18|
79737448|NCT02717572|Device|Positron Emission Tomography|
79737449|NCT02717572|Device|Computerized Tomography|
79737450|NCT02717572|Device|Magnetic Resonance Imaging|
79737451|NCT05041192|Dietary Supplement|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
79872453|NCT05525078|Other|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
79872456|NCT05519007|Other|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
79403282|NCT04020133|Procedure|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
79578005|NCT01880450|Behavioral|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
79578006|NCT01880450|Behavioral|TEEN|Control condition the promote communication, decision-making skills etc.
79578007|NCT01880463|Drug|Omega-3 fatty acids (fish oil)|
79578008|NCT01880463|Dietary Supplement|Vitamin D3|
79578009|NCT01880463|Dietary Supplement|Vitamin D3 placebo|
79578010|NCT01880463|Drug|Fish oil placebo|
79578011|NCT01880476|Other|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
79737452|NCT05041192|Dietary Supplement|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
79737453|NCT02717806|Behavioral|PATHway|Patients will use the PATHway platform for 6 months
79737454|NCT02717026|Device|Optical coherence tomography|Sections including the retinal vasculature will be taken.
79872457|NCT05519007|Other|Saline irrigation|The surgical site will be irrigated with Saline
79872458|NCT05498038|Behavioral|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
79872459|NCT05493657|Drug|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
79872460|NCT05493657|Drug|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
79403283|NCT04020133|Drug|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
79403284|NCT04020133|Drug|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
79737455|NCT02717026|Device|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
79737456|NCT02717026|Device|Fundus photography|30 and 50 degree fundus images
79737457|NCT01121393|Drug|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
79872461|NCT05489575|Device|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
79872462|NCT05489575|Device|Sham CPAP|Sham continuous positive airway pressure applied at <4 cm H2O
79872463|NCT05489575|Other|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
79872464|NCT05477602|Procedure|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
79403285|NCT04565574|Drug|E7090|Oral tablet.
79403286|NCT04565574|Drug|Rabeprazole 20 mg|Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
79578012|NCT01880489|Behavioral|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
79578013|NCT01880502|Drug|Belviq 10mg|Belviq 10mg single dose administration
79578014|NCT01880502|Drug|Belviq 20mg|Belviq 20mg single dose administration
79578015|NCT01880502|Drug|Placebo|Placebo single dose administration
79737458|NCT01121393|Drug|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
79872465|NCT05476094|Drug|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
79872466|NCT05466916|Behavioral|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
79872467|NCT05444790|Diagnostic Test|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
79872468|NCT05440058|Device|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
79872469|NCT05439902|Drug|Tamsulosin|One 0.4mg Tamsulosin capsule taken per day for 30 days
79872470|NCT05439902|Drug|Placebo|one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
79872471|NCT05439148|Drug|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
79872472|NCT05424757|Drug|PEG 3350|"Data and biospecimens will be collected from two groups of children:~Children who have taken PEG 3350 daily for at least 30 days.~Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
79872473|NCT05422599|Dietary Supplement|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
79737459|NCT02717338|Behavioral|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
79737460|NCT02717338|Behavioral|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
79737461|NCT02717338|Behavioral|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
79274004|NCT04478539|Device|Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter|"Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF)."
79274005|NCT02262871|Device|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
79578016|NCT01880606|Procedure|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
79578017|NCT01880619|Drug|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
79737462|NCT02717260|Device|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
79737463|NCT02717182|Other|interviews|interviews
79737464|NCT02882477|Drug|Deferiprone|
79737465|NCT02882477|Drug|Acetylcysteine|
79737466|NCT02882477|Drug|Sitagliptin and Metformin|
79737467|NCT04081168|Device|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
79737468|NCT04081168|Device|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
79872474|NCT05422599|Dietary Supplement|Placebo|300mg Maltodextrin capsules
79737469|NCT02716870|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
79872475|NCT05419427|Drug|Denosumab|Denosumab 60 MG/ML
79872476|NCT05419427|Drug|Denosumab-Ref|Denosumab 60 MG/ML
79872477|NCT05414305|Drug|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
79872478|NCT05412290|Drug|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
79872479|NCT05384834|Behavioral|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
79872480|NCT05362929|Device|Sciton Halo|Laser treatment
79872481|NCT05358444|Behavioral|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
80030038|NCT03481790|Drug|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
80030039|NCT03481790|Drug|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
80030040|NCT03475862|Drug|PTI-821 capsule Manipulated|PTI-821 (oxycodone) 40 mg extended release capsule
79403287|NCT04565574|Drug|Rifampin 600 mg|Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
79578018|NCT01880619|Drug|Solifenacin|Patients in the arm will receive Solifenacin
79578019|NCT01880619|Drug|Control|Patients in this are will receive placebo
79578020|NCT01880632|Drug|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
79578021|NCT01880645|Procedure|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
79578022|NCT01880645|Procedure|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
79737470|NCT04163224|Device|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
79578023|NCT01880645|Procedure|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
79578024|NCT01880658|Drug|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
79578025|NCT01880671|Device|Inactive Migraine Medical Device|
79872482|NCT05358444|Behavioral|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
79274006|NCT02262871|Device|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
79274007|NCT02235181|Device|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
79578026|NCT01880671|Device|Migraine Medical Device|
79578027|NCT01880749|Drug|RAD001|
79578028|NCT01880775|Drug|Prilocaine|experimental
79578029|NCT01880775|Drug|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
79578030|NCT01880814|Behavioral|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
79872483|NCT05356897|Biological|Trastuzumab|Given IV
79274008|NCT02233153|Other|Elder-Friendly Surgical Unit|
79274009|NCT04476667|Behavioral|e-Psychotherapy|Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
79737471|NCT02716792|Drug|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
79872484|NCT05356897|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
79872485|NCT05356897|Drug|Tucatinib|Given PO
79872486|NCT05346757|Diagnostic Test|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
79872487|NCT05345847|Other|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
79737472|NCT02716636|Procedure|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
79872488|NCT05345847|Other|Early initiation|Immediate start of high-dose steroids
80030041|NCT03475862|Drug|PTI-821 Non-manipulated|PTI-821 (oxycodone) 40 mg capsule extended release capsule
79274010|NCT04432675|Drug|hydroxyethl starch|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
79403288|NCT00731211|Drug|Pazopanib|800 mg of pazopanib orally each day continuously
80030042|NCT03475862|Drug|OxyContin|Crushed OxyContin (oxycodone) extended-release 40 mg tablet
79403289|NCT04192513|Drug|J. lividum|Investigational Product
79403290|NCT01521494|Drug|PA21|
79403291|NCT01521494|Drug|PA21|
79578031|NCT01880814|Behavioral|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
79578032|NCT01879241|Drug|Rasagiline|
79578033|NCT01879241|Drug|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
79737473|NCT02694016|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
79872489|NCT05345041|Behavioral|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
79872490|NCT05345041|Behavioral|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
80030043|NCT03475862|Other|Placebo|Matching placebos for PTI-821 and oxycodone IR
79578034|NCT01880827|Procedure|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
79578035|NCT01880827|Drug|GIP-infusion|Blood flow and volume during infusion
79578036|NCT01880827|Drug|GLP-1|Blood flow and volume during infusion
79578037|NCT01880827|Drug|MMS|Blood flow and volume after meal solution
79578038|NCT01880827|Procedure|Sleeve gastrectomy|as in RYGS group
79578039|NCT01880853|Other|mammography|participants were screened by mammography alone every year
79578040|NCT01880853|Other|ultrasound|participants were screened by ultrasound alone every year
79578041|NCT01880853|Other|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
79578042|NCT01880866|Drug|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
79578043|NCT01880879|Device|helios stent|the group with helios stent implanted
79578044|NCT01880905|Procedure|Measure of uteroovarian ligament length during gynecological surgery|
79578045|NCT01880931|Drug|Remifentanil|The effect site concentration of remifentanil
79737474|NCT02359318|Procedure|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
80030044|NCT03475862|Drug|Oxycodone|Crushed oxycodone 40 mg immediate release tablet
80030045|NCT03481712|Diagnostic Test|Diagnostic tests|"Head-to-head comparison between:~CADScor and Diamond-Foster score~Rb PET and 3T CMRI~QFR and ICA-FFR"
80030046|NCT03477968|Other|Plasma sampling|Additional blood draw or additional volume during blood draw
80030047|NCT03430934|Combination Product|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
80030048|NCT03477812|Device|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
80030049|NCT03475784|Drug|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
79403292|NCT01521494|Drug|PA21|
79403293|NCT01521494|Drug|PA21|
79403294|NCT01521494|Drug|Placebo|
79403295|NCT04192045|Other|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
79578046|NCT01880944|Other|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
79578047|NCT01880970|Other|starter infant formula with pro and prebiotics|
79578048|NCT01880970|Other|Placebo comparator|
79578049|NCT01880996|Other|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
79578050|NCT01881022|Behavioral|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
79578051|NCT01881035|Procedure|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
79578052|NCT01881074|Drug|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
79274011|NCT04432675|Drug|Lactated Ringer's solution|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
79872491|NCT05337930|Device|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
79872492|NCT05329935|Biological|Cultured Thymus Tissue|Product will be surgically administered into the quadriceps
79578053|NCT01881074|Drug|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
79578054|NCT01880710|Procedure|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
79578055|NCT01880710|Procedure|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
79737475|NCT02359318|Procedure|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
79737476|NCT02716558|Other|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
79872493|NCT05320887|Other|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
79872494|NCT05320887|Other|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
79872495|NCT05320887|Other|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
79872496|NCT05320887|Other|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
79872497|NCT05312177|Other|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
79872498|NCT05312177|Other|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
79872499|NCT05312177|Other|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
79872500|NCT05312177|Other|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
79872501|NCT05312177|Other|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
79872502|NCT05312177|Other|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
79872503|NCT05312177|Other|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
79872504|NCT05312177|Other|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
79403296|NCT04026919|Other|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
79403297|NCT01270971|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
79737477|NCT02716558|Other|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
79274014|NCT05490212|Other|Single Molecule Array (SiMoA)|The Single Molecule Array (SiMoA), capable of quantifying multiple salivary cytokines from a single sample source at a femtoscale level. The SiMoA platform has been adapted to detect up to nine inflammatory biomarkers, including CRP, PCT, tumor necrosis factor α (TNF α) and ILs 1ß, 6, and 8 in neonatal saliva.
79274015|NCT04402723|Drug|Donafenib|In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
79274016|NCT02262949|Device|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
79737478|NCT02716402|Radiation|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
79578056|NCT01881100|Other|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
79872505|NCT05311956|Device|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
79872506|NCT05311956|Device|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
79872507|NCT05307783|Device|EmboCube Embolization Gelatin|EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
79872508|NCT05304962|Drug|RGT-419B|oral capsules
79872509|NCT05304962|Drug|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
79872510|NCT05298371|Behavioral|Corrected Sitting postures|Change after being in Corrected Sitting postures
79872511|NCT05298371|Behavioral|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
79872512|NCT05298371|Behavioral|Corrected Standing posture|Change after being in Corrected Standing posture
79872513|NCT05298371|Behavioral|Natural / relaxed standing postures|Change after being in relaxed standing postures
79872514|NCT05294016|Device|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
79872515|NCT05287464|Drug|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
79872516|NCT05275907|Drug|Amlodipine Besylate|10 mg capsule once daily for 6 weeks
79872517|NCT05275907|Drug|Chlorthalidone|25mg capsule once daily for 6 weeks
79872518|NCT05274048|Drug|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
79872519|NCT05274048|Drug|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
79872520|NCT05269316|Drug|IMP9064|IMP9064 Monotherapy administered for 21 days
79872521|NCT05265429|Genetic|Data and Specimen Collection|"Provide research team access to relevant medical records~Answer two (2) short questionnaires at time of consent~Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~Consider consenting to other optional parts of the research such as:~Providing additional blood or tissue samples in the future (optional)~Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
79872522|NCT05250843|Procedure|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
79872523|NCT05250843|Drug|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight <60kg, or 12mg for patients weight more than 60Kg.
79872524|NCT05250843|Drug|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
79872525|NCT05250843|Procedure|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
80030050|NCT03475784|Drug|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
79403298|NCT01270971|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
79403299|NCT05103774|Diagnostic Test|T3-T4-TSH|thyroid function tests
79403300|NCT04026841|Drug|PD-1 antibody Sintilimab|Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
79872526|NCT05230043|Other|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
79872527|NCT05230043|Other|functional MRI|"Two 8s sequences of spin echo field map with phase encoding AP and PA~A 12:00min bold sequence for resting-state~A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~A 6:38min T1w MPR sequence~A 7:40min T1w MPR sequence~A 5:57min T2w SPC sequence~A 8:24min T2w SPC sequence~A 8:32min FLAIR T2w sequence~Two 8:26min Multi-echo GRE sequence~A 8:29min high resolution multi-echo GRE sequence~Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~Two 6:03min diffusion weighted images with phase encoding AP and PA"
80030051|NCT03368066|Drug|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
79274017|NCT05490056|Other|no intervention|the study will not apply on intervention
79274018|NCT02235337|Drug|Riboflavin 400mg daily|
79274019|NCT05485454|Device|Aria Health Aria Free|An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
79274020|NCT05485454|Device|A Traditional PCD|An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
79274021|NCT02233231|Drug|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
79274022|NCT02233231|Drug|Placebo|similar tabl
79578057|NCT01881100|Other|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
79578058|NCT01881139|Behavioral|exercise training|
80030052|NCT02481986|Behavioral|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
80030053|NCT02481986|Behavioral|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
79578059|NCT01881152|Other|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
79872528|NCT05223725|Biological|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
79872529|NCT05205343|Other|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
79872530|NCT05205343|Other|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
79872531|NCT05197842|Drug|BDB-001 injection|Intravenously administered
79872532|NCT05197842|Drug|Cyclophosphamide|Intravenously administered
79872533|NCT05197842|Drug|Glucocorticoids|Orally administered
79872534|NCT05176145|Device|VisioCyt®|"Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~Urine collection for conventional cytology and VisioCyt® test"
79872535|NCT05152940|Drug|Ertugliflozin|Treatment with Ertugliflozin 5 mg oral once per day for one month
79872536|NCT05152940|Drug|Placebo|Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
79403301|NCT04128774|Drug|Dexamethasone|The case group receives dexamethasone based on the clinical indication.
79578060|NCT01881152|Other|Usual care|Information on stroke usually delivered at the community level.
79578061|NCT01881165|Drug|Cranberry|
79578062|NCT01881165|Drug|Placebo|
79578063|NCT01881178|Dietary Supplement|NOPALEA|
79578064|NCT01881191|Other|MRI|
79872537|NCT05131087|Device|Cadence implant|CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
79872538|NCT05107219|Procedure|Biopsy|Undergo biopsy
79872539|NCT05107219|Procedure|Biospecimen Collection|Undergo collection of luminal fluid
79872540|NCT05107219|Procedure|Esophagogastroduodenoscopy|Undergo EGD
79872541|NCT05107219|Drug|Linaclotide|Given PO
79872542|NCT05107219|Drug|Plecanatide|Given PO
79274023|NCT02263027|Biological|Vaccine|Licensed trivalent inactivated influenza vaccine
79274024|NCT05485298|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
79578065|NCT01881204|Dietary Supplement|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
79578066|NCT01881204|Dietary Supplement|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
79578067|NCT01881204|Dietary Supplement|Control|Cookies without Hesperidin or Calcilock added.
79578068|NCT01881217|Drug|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
79578069|NCT01881282|Drug|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
79578070|NCT01881282|Drug|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
79578071|NCT01881295|Dietary Supplement|Placebo control|
79578072|NCT01881295|Dietary Supplement|Low dose potassium gluconate|
79578073|NCT01881295|Dietary Supplement|Medium dose potassium gluconate|
79578074|NCT01881295|Dietary Supplement|High dose potassium gluconate|
79872543|NCT05101486|Biological|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
79872544|NCT05100706|Drug|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
79872545|NCT05100706|Drug|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
79872546|NCT05091372|Drug|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
79872547|NCT05091372|Drug|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
79872548|NCT05089474|Device|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
79872549|NCT05087563|Device|Neurolens spectacle lens|spectacle lens
79872550|NCT05087563|Device|Placebo spectacle lens|spectacle lens for refractive correction
80030054|NCT03475628|Drug|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
80030055|NCT03477734|Device|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
80030056|NCT05234294|Other|Survey|We will investigate symptoms through monthly surveys.
79578075|NCT01881295|Dietary Supplement|Low dose potato|
79274025|NCT05485220|Other|Aerobic exercise|Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.
79578076|NCT01881295|Dietary Supplement|Medium dose potato|
79578077|NCT01881295|Dietary Supplement|High dose potato|
79578078|NCT01881295|Dietary Supplement|High dose French fries|
79737479|NCT02716480|Behavioral|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
79737480|NCT02716480|Behavioral|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
79737481|NCT04964596|Diagnostic Test|colonoscopy|colonoscopy
79737482|NCT04964596|Diagnostic Test|FIT test|faecal immunochemical test
79872551|NCT05085301|Diagnostic Test|Rapid diagnostic test|The performance of three index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
79872552|NCT05083585|Biological|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
79872553|NCT05081219|Drug|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
79872554|NCT05081219|Drug|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
79872555|NCT05081219|Device|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
79274026|NCT05485220|Other|High-intensity interval training|High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
79403302|NCT04027855|Procedure|collection of peripheral blood mononuclear cells from healthy volunteers|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
79578079|NCT01881295|Dietary Supplement|Basal diet control|
79578080|NCT01881321|Behavioral|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
79578081|NCT01881347|Dietary Supplement|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
79578082|NCT01881347|Dietary Supplement|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
79737483|NCT04964596|Diagnostic Test|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
79737484|NCT04964284|Biological|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
79737485|NCT04964284|Radiation|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
79872556|NCT05081219|Drug|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
79872557|NCT05081219|Drug|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
79872558|NCT05071313|Biological|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as single IM injection.
79872559|NCT05071313|Biological|Quadrivalent High-dose Influenza Vaccine|Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.
79872560|NCT05071313|Biological|Placebo|Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
79872561|NCT05048797|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan administered by intravenous infusion
79872562|NCT05048797|Drug|Cisplatin|Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion
79872563|NCT05048797|Drug|Carboplatin|Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion
79274027|NCT02263105|Drug|CDDP|
79578083|NCT01881360|Other|Gluten-free diet|A diet that is free of the gluten component
79578084|NCT01881360|Other|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
79578085|NCT01881386|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
79578086|NCT01881399|Device|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
79578087|NCT01881399|Other|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
79578088|NCT01881399|Procedure|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
79578089|NCT01881464|Device|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
79872564|NCT05048797|Drug|Pembrolizumab|Pembrolizumab administered by intravenous infusion
79872565|NCT05048797|Drug|Pemetrexed|Pemetrexed administered by intravenous infusion
80030057|NCT05231564|Other|hybrid training|The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
79737486|NCT02716168|Other|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
80030058|NCT02738138|Drug|ABT-493 coformulated with ABT-530|Tablet
80030059|NCT03018860|Procedure|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
79737487|NCT04896346|Other|Punch biopsy|punch biopsies will be used for histologic analysis and biochemical assays
80030060|NCT03018860|Procedure|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
79274028|NCT02263105|Drug|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
79274029|NCT05485064|Drug|fentanyl|The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
79274030|NCT05485064|Procedure|eletroacupuncture(transcutaneous electrical acupuncture point stimulation )|The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam
79737488|NCT04896346|Other|non-invasive photography, assessments, and measurements|photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
79578090|NCT01881464|Drug|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
79578091|NCT01881477|Procedure|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
79737489|NCT02716090|Drug|Adapalene and Benzoyl peroxide Dalap Duo®|
79737490|NCT02716090|Drug|Adapalene and Benzoyl peroxide Epiduo®|
79872566|NCT05019729|Drug|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
79872567|NCT05019729|Other|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
79872568|NCT05007080|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as intramuscular (IM) injection.
79737491|NCT02715934|Other|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
79737492|NCT02715934|Other|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
79737493|NCT01227616|Drug|Ferumoxytol|IV Ferumoxytol
79872569|NCT04975607|Behavioral|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
79274031|NCT05485064|Drug|placebo needle|The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
79737494|NCT01227616|Drug|Iron Sucrose|IV Iron Sucrose
79737495|NCT02715544|Other|Healthy lifestyle|The families will receive a designed for these purposes intervention
79737496|NCT02715544|Other|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
80030061|NCT05195450|Drug|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
79274032|NCT05485064|Drug|remimazolam|The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
79274033|NCT05626153|Other|Routine anesthesia care|• Implementing anesthesia management according to current routine practice.
80030062|NCT03477656|Procedure|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
80030063|NCT03477656|Procedure|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
80030064|NCT03477578|Other|freezers|neuropsychological evaluation
80030065|NCT03477578|Other|non freezers|neuropsychological evaluation
79872572|NCT04906980|Drug|JNJ-64281802|JNJ-64281802 will be administered orally.
80030066|NCT03477422|Drug|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
80030067|NCT03477422|Drug|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
80030068|NCT03920384|Behavioral|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
80030069|NCT03920384|Behavioral|Active control arm|Standard psychological therapy for psychosis without new therapy components
80030070|NCT01355289|Drug|Avatrombopag|
80030071|NCT01355289|Drug|Placebo|
79578092|NCT01881490|Device|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
80030072|NCT01355289|Drug|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
79274034|NCT05626153|Other|Improved anesthesia care|"Encourage regional anesthesia or combined regional-general anesthesia.~Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~Encourage extubation in the operating room at the end of surgery.~Encourage multimodal analgesia after surgery.~Encourage strict indication for ICU admission after surgery."
79274035|NCT02553343|Biological|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
79274036|NCT02553343|Biological|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
79274037|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
79578093|NCT01881503|Biological|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
79578094|NCT01881516|Device|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
79578095|NCT01881516|Device|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
79872573|NCT04906980|Drug|Placebo|Matching placebo (PEG400) will be administered orally.
79872574|NCT04891406|Other|A|Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes
79274038|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
79274039|NCT02235415|Drug|Motens® (lacidipine)|
79872575|NCT04891406|Other|B|Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes
79872576|NCT04891406|Other|C|Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes
79737497|NCT04189276|Biological|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
79737498|NCT04189276|Biological|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
79737499|NCT04189276|Biological|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
79274040|NCT03995017|Drug|Rucaparib|Rucaparib tablet
79578096|NCT01881555|Procedure|invasive coronary angiography|
79872577|NCT04891406|Other|D|Use of product D (Nicotine pouch, 10.6 mg/pouch) for 20 minutes
79872578|NCT04891406|Other|E|Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
79872579|NCT04890236|Drug|Duvelisib|Given PO
79872580|NCT04890236|Biological|Tisagenlecleucel|Given via infusion
79872581|NCT04885998|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
79872582|NCT04885998|Drug|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
79578097|NCT01881555|Procedure|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
79872583|NCT04867954|Other|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
80030073|NCT01355289|Drug|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
80030074|NCT01355289|Drug|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
80030075|NCT04680741|Behavioral|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
80030076|NCT03473288|Behavioral|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
79578098|NCT01881568|Drug|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
79578099|NCT01881568|Drug|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
79578100|NCT01881581|Biological|Saline Solution|Saline Solution is used as control in all arms.
79578101|NCT01881581|Biological|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
79578102|NCT01881581|Biological|M-GPE|M-GPE is used in Arm D,E,F,G and H
79737500|NCT04189276|Biological|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
80030077|NCT03473288|Behavioral|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
79737501|NCT00956488|Behavioral|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
79737502|NCT02714998|Drug|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
79737503|NCT02714998|Procedure|salpingectomy|Laparoscopic unilateral salpingectomy
79737504|NCT04162054|Other|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
80030078|NCT03473210|Drug|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
80030079|NCT03473210|Drug|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
80030080|NCT03473210|Procedure|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
80030081|NCT05177432|Device|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
80030082|NCT05161520|Procedure|phacoemulsification combined with IOL and CTR implantation|Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.
80030083|NCT05161520|Procedure|phacoemulsification combined with IOL implantation|Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
79274041|NCT03995017|Drug|Ramucirumab|Ramucirumab intravenous solution
79274042|NCT03995017|Drug|Nivolumab|Nivolumab intravenous solution
79737505|NCT00765310|Dietary Supplement|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
79274043|NCT02263183|Dietary Supplement|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
79274044|NCT02263183|Dietary Supplement|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
79274045|NCT02528539|Other|ITP|"The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.~Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points"
79274046|NCT02558894|Drug|MEDI4736 monotherapy|MEDI4736 via IV infusion.
79274047|NCT02558894|Drug|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
79274048|NCT02235571|Behavioral|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
79274049|NCT02235649|Behavioral|Social Cognition therapy ( Psychological Therapy)|
79274050|NCT02235727|Drug|GBR 900|
79274051|NCT02235727|Drug|Placebo|
79737506|NCT00765310|Dietary Supplement|Placebo|two capsules once daily in morning on empty stomach
79737507|NCT02715154|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
79737508|NCT02715154|Drug|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
80030084|NCT03473132|Drug|four factor prothrombin complex concentrate|After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
80030085|NCT02899754|Behavioral|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
80030086|NCT02899754|Behavioral|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
80030087|NCT03475238|Procedure|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
79872584|NCT04867954|Other|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
80030088|NCT02737592|Device|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
80030089|NCT02720432|Other|CIMT|Constraint-induced movement therapy
80030090|NCT02720432|Other|HABIT|hand-arm bimanual intensive training
79578103|NCT01881594|Procedure|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
79578104|NCT01881607|Behavioral|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
79578105|NCT01881633|Drug|ISU302|
79578106|NCT01881633|Drug|Placebo|
79578107|NCT01881646|Radiation|Positron emission tomography (PET) using [11C]PBR28|
79737509|NCT02715232|Drug|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
79737510|NCT02715232|Drug|Lynestrenol|2-3 tablets/day, if menstruation still occurs
79737511|NCT02715232|Drug|Cyproterone Acetate|25mg daily
79737512|NCT02715232|Drug|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
80030091|NCT02720432|Other|baby-massage|instructions for baby-massage
80030092|NCT03475160|Drug|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
80030093|NCT03475160|Drug|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
79274052|NCT02233387|Other|injection with [18F] HX4 and PET imaging|"A standard clinical [18F]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline [18F]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) [18F]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of [18F]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i"
79274053|NCT02233465|Procedure|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
79737513|NCT02715232|Drug|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
80030094|NCT03475160|Procedure|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
80030095|NCT03475160|Procedure|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
79578108|NCT01881698|Other|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
79578109|NCT01881711|Device|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
79737514|NCT02714608|Drug|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
79737515|NCT02714608|Drug|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
79737516|NCT02714608|Drug|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
79274054|NCT04251182|Drug|15mg T3D-959|Oral administration once daily in the morning
79274055|NCT04251182|Drug|30 mg T3D-959|Oral administration once daily in the morning
79578110|NCT01881711|Device|Imaging|Imaging of ventricle size
79578111|NCT01881724|Behavioral|Sleep education|
79578112|NCT01881815|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
79578113|NCT01881841|Behavioral|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
79578114|NCT01881880|Device|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
79578115|NCT01881893|Behavioral|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
80030096|NCT03475082|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (>50Hz), low frequency (<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
80030097|NCT02694068|Other|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
79578116|NCT01881906|Other|Usual care|
79737517|NCT00643864|Behavioral|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
79737518|NCT02693860|Drug|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute.
79737519|NCT02693860|Drug|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
79737520|NCT02721160|Other|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~nb of cases screened and referred to HC for acute malnutrition (AM)~nb of classes promoting good nutrition~HC level~nb of cases screened and cared for severe and moderate AM~nb of growth follow-ups~Hospital level~nb of treated severe AM cases with complications~length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
79737521|NCT02714686|Behavioral|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
79737522|NCT02714842|Drug|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
79737523|NCT02714842|Drug|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
79737524|NCT02714842|Drug|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
79737525|NCT02714842|Drug|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
79872585|NCT04867954|Other|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 dose of GBCA will be administered, if required."
80030098|NCT02694068|Other|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
79578117|NCT01881906|Other|Exercise|
79578118|NCT01881919|Dietary Supplement|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
79737526|NCT02714530|Drug|Erlotinib|Tarceva daily during radiotherapy course
79737527|NCT02714530|Radiation|Radiation|Radiotherapy
79578119|NCT01881919|Dietary Supplement|Control|Address: Fagron GmbH&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
79578120|NCT01881945|Other|Non-invasive physiological signal recording on healthy volunteer|
79578121|NCT01881958|Drug|DiaPep277®|
79578122|NCT01881971|Drug|Placebo|suger pill manufactured to mimic crestor pills
79578123|NCT01881971|Drug|Rouvastatin calcium|
79578124|NCT01881997|Drug|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
79578125|NCT01881997|Drug|Normal Saline|IM normal saline
79578126|NCT01882010|Drug|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
79403303|NCT04192669|Device|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
79872586|NCT04867954|Other|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
79274056|NCT04251182|Drug|45 mg T3D-959|Oral administration once daily in the morning
79578127|NCT01882010|Drug|placebo|saline solution daily subcutaneous injection 56 days
79737528|NCT02714452|Behavioral|Person-centred care|Person-centred and thriving promoting care
79737529|NCT02714296|Drug|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
79737530|NCT02714296|Dietary Supplement|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
79737531|NCT02714374|Biological|GL-ONC1|"Dose and Regimen:~Single dose group: Cohort 1 dose is 1 × 109 pfu~Multiple dose groups:~Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
79274057|NCT04251182|Drug|Placebos|Oral administration once daily in the morning
79737532|NCT02714140|Behavioral|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
79737533|NCT02714140|Behavioral|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
79737534|NCT02714140|Behavioral|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
79737535|NCT02714140|Behavioral|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
79274058|NCT02510599|Drug|solithromycin|
79274059|NCT05484986|Other|A questionnaire with 47 items|A form consisted of questions on introductory characteristics (age, sex, and class, among others), Big Five Inventory (BFI) to evaluate personality traits, and Management of Workplace Violence Competence Scale for Nursing Students in Areas of Clinical Practice.
79274060|NCT02235805|Dietary Supplement|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
79274061|NCT02235805|Dietary Supplement|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
79274062|NCT05484908|Other|DPMAS+LPE|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
79274063|NCT05484908|Other|PE|Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
79274064|NCT05484908|Other|Comprehensive internal medical treatment|Patients will receive comprehensive internal medical treatment.
79274065|NCT04227769|Drug|Anakinra Prefilled Syringe|Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
79403304|NCT00732225|Device|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
79403305|NCT00732225|Device|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
79403306|NCT00732225|Device|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
79578128|NCT01882010|Diagnostic Test|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
79578129|NCT01882049|Device|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
79578130|NCT01882075|Drug|Open loop|
79578131|NCT01882075|Device|Closed-loop|
79578132|NCT01882101|Procedure|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
79872587|NCT04799171|Other|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
79872588|NCT04799171|Other|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
79872589|NCT04799171|Other|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
79872590|NCT04764799|Procedure|Rapid sequence induction|Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
79872591|NCT04747054|Drug|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
79737536|NCT02714140|Behavioral|SMS Reminder|Participants will receive an SMS reminder to test.
79737537|NCT02713906|Device|X-Ray Knee Guide group|
79737538|NCT02713984|Biological|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
79872592|NCT04747054|Radiation|Loco-regional radiotherapy|The loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) (if delayed, RT should be started no later than three weeks after the first administration of pembrolizumab, i.e. before the second administration of pembrolizumab if possible), with 54 Gy/18 fractions in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary.
79872593|NCT04747054|Drug|Chemotherapy|If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles
79274066|NCT02508337|Drug|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
79274067|NCT02508337|Drug|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
79872594|NCT04740515|Other|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
79872595|NCT04692181|Biological|SYN-004, Ribaxamase or Placebo|SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
79872596|NCT04682834|Drug|Sulopenem Etzadroxil/Probenecid|Individual Patients
79274068|NCT05484752|Device|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at knee joint 1 session
79274069|NCT05484752|Behavioral|Education|Conventional exercise and life style modification
79309129|NCT03119051|Behavioral|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
79578133|NCT01882101|Procedure|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
79578134|NCT01882127|Drug|All-Trans Retinoid Acid(ATRA)|patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
79578135|NCT01882127|Drug|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
79737539|NCT02713672|Other|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
79737540|NCT02713750|Other|reversible contraceptive methods|"Consistent male condom use only~Consistent female condom use only~Hormonal contraception, combined oral contraceptive pills and male/female condom~Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~Hormonal contraception , progestin only hormonal implant and male/female condom~Intrauterine device and male/female condom"
79578136|NCT01882140|Other|Electrical Stimulation by Capacitive Field|
79578137|NCT01882140|Other|Electrical Stimulation by Capacitive Field Placebo Sham|
79578138|NCT01882166|Drug|fostimon|
79578139|NCT01882166|Drug|puregon|
79578140|NCT01882179|Drug|Mineralocorticoid receptor antagonist potassium-canrenoate|
79274070|NCT05557435|Other|breast milk odor|"The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water."
79274071|NCT05557435|Other|Placebo|Placebo
79274072|NCT05484674|Procedure|Deroofing and laser|Deroofing and laser to axilla
79274073|NCT02263261|Other|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
79737541|NCT04000906|Drug|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
79274074|NCT02688387|Drug|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
79274075|NCT02688387|Drug|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
79274076|NCT05489900|Drug|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
79274077|NCT02476201|Device|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
79737542|NCT04000906|Drug|Cisplatin|10.5 mg/m2
79872599|NCT04643574|Biological|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
79274078|NCT05484362|Other|D-Glucose beverage as reference food|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
79309130|NCT03119207|Behavioral|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
79309131|NCT03204071|Drug|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
79403307|NCT00732225|Device|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
79403308|NCT00732225|Device|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
79578141|NCT01882179|Drug|placebo|
79578142|NCT01882192|Behavioral|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
79578143|NCT01882205|Device|Virtual chromoendoscopy|
79737543|NCT00636766|Drug|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
79737544|NCT00636766|Drug|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
79872600|NCT04643574|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
79872601|NCT04643574|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
79872602|NCT04643574|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
79872603|NCT04643574|Radiation|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
79872604|NCT04642105|Device|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
79872605|NCT04626791|Drug|Acalabrutinib|Given PO
79872606|NCT04626791|Drug|Bortezomib|Given SC
80030099|NCT04458896|Behavioral|Stand When You Can|"Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, & the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility"
80030100|NCT03473054|Other|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
80030101|NCT02541188|Genetic|Genetic analysis|
80030102|NCT03474926|Procedure|Routine Template-based lymphadenectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
80030103|NCT03474926|Procedure|LND only for lymph nodes enlargement found in preoperative image or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
80030104|NCT03474848|Other|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
80030105|NCT03474848|Other|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
79274079|NCT05484362|Other|15mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
79309132|NCT03204071|Drug|Aloevera|Oral prophylaxis followed by placement of aloevera gel
79578144|NCT01882205|Procedure|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
79578145|NCT01882218|Drug|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
79578146|NCT01882218|Drug|Standard Treatment|Standard liver surgery.
79737545|NCT00636766|Drug|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
79737546|NCT00636766|Drug|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
79309133|NCT03204071|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
79578147|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
79578148|NCT01882244|Behavioral|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
79578149|NCT01882244|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
79578150|NCT01882283|Dietary Supplement|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
79578151|NCT01882283|Dietary Supplement|Placebo|
79578152|NCT01882296|Drug|AGSPT_10|AGSPT 10mg for 7days administration
79578153|NCT01882296|Drug|AGSPT_20|AGSPT 20mg for 7days administration
79578154|NCT01882296|Drug|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
79578155|NCT01882296|Drug|Pantoprazole_20|Pantoprazole 20mg for 7days administration
79578156|NCT01882296|Drug|Pantoprazole_40|Pantoprazole 40mg for 7days administration
79578157|NCT01882322|Drug|Prograf|oral
79578158|NCT01882322|Drug|Advagraf|oral
79872607|NCT04626791|Drug|Cyclophosphamide|Given IV
80030106|NCT00308516|Drug|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
80030107|NCT00308516|Drug|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
80030108|NCT00308516|Procedure|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
80030109|NCT00308516|Drug|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
80030110|NCT00308516|Drug|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
80030111|NCT03471494|Other|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
79578159|NCT01882335|Behavioral|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
79578160|NCT01882348|Behavioral|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
79737547|NCT02713360|Behavioral|Cognitive Therapy|
80030112|NCT02523404|Procedure|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
79737548|NCT02713282|Drug|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
79737549|NCT00611104|Dietary Supplement|standardized freeze-dried table grape powder|
79737550|NCT00611104|Other|laboratory biomarker analysis|
80030113|NCT04331366|Device|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
80030114|NCT05155592|Biological|reduction or discontinuation of Adalimumab|For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.
80030115|NCT03474614|Drug|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
79274080|NCT05484362|Other|30mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
79578161|NCT01882361|Drug|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
79578162|NCT01882361|Drug|placebo comparator|this placebo has no specific pharmacological activity
79737551|NCT00611104|Other|pharmacological study|
79737552|NCT02713516|Other|Virtual Reality|Use of virtual reality to deliver exposure therapy
79872608|NCT04626791|Drug|Cytarabine|Given IV
80030116|NCT03474614|Genetic|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
79578163|NCT01882374|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
79737553|NCT02713048|Other|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
79872609|NCT04626791|Drug|Doxorubicin Hydrochloride|Given IV
79872610|NCT04626791|Drug|Prednisone|Given PO
80030117|NCT05155514|Procedure|Mobil-O-Graph PWA|After resting in a quiet room preoperatively, blood pressure was measured on the right arm using an oscillometric method.
80030118|NCT05154812|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
80030119|NCT05154812|Drug|Routine medical care|Routine medical care
80030120|NCT03474380|Behavioral|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
79737554|NCT00611260|Behavioral|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
79872611|NCT04626791|Biological|Rituximab|Given IV
79872612|NCT04626791|Biological|Rituximab and Hyaluronidase Human|Given IV
79872613|NCT04589663|Drug|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
79872614|NCT04589663|Drug|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
79274081|NCT05489666|Dietary Supplement|Nature Made Vitamin D3 5,000 IU, 125mcg|Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
80030121|NCT03215342|Behavioral|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
79578164|NCT01882387|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
80030122|NCT03215342|Behavioral|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
80030123|NCT03088202|Other|Educational program|E-learning lectures, group exercises, skills training
80030124|NCT03088202|Other|Standardized care pathways|Pathways for systematic follow-up
80030125|NCT03088202|Other|Early palliative care|Compulsory referral to palliative care at inclusion
80030126|NCT03063164|Device|Intralase IFS150|Intralase flap creation
80030127|NCT03063164|Device|Visumax|Visumax flap creation
79274082|NCT05489666|Dietary Supplement|Placebo|Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
79274083|NCT04152499|Drug|SKB264|SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
79309134|NCT03203915|Dietary Supplement|Chardonnay grape marc marc high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
79309135|NCT03203915|Dietary Supplement|Chardonnay grape marc powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
79578165|NCT01882400|Drug|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
79578166|NCT01882426|Other|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
79737555|NCT00611260|Other|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
79737556|NCT02712970|Procedure|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of <1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
79737557|NCT02712970|Procedure|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
79578167|NCT01882426|Other|Usual Care|usual step care practice
79872615|NCT04589663|Drug|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
79872616|NCT04585295|Dietary Supplement|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
79872617|NCT04585295|Dietary Supplement|BCAA Big 6|1 level scoop (~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
79872618|NCT04585295|Dietary Supplement|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
79872619|NCT04562233|Behavioral|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
79578168|NCT01882452|Behavioral|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
79737558|NCT02712970|Procedure|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
79737559|NCT02712970|Procedure|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
80030128|NCT02737358|Drug|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
80030129|NCT02737358|Other|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
80030130|NCT03474302|Behavioral|Physical Activity|Aerobic, strength training, balance, flexibility
80030131|NCT03474302|Other|Successful Aging|Healthy aging education
80030132|NCT05052710|Drug|AZD4831|Subjects will receive oral doses once daily from Days 2-11.
80030133|NCT05052710|Drug|Midazolam|Subjects will receive oral single doses on Day 1 and Day 11.
80030134|NCT02866838|Drug|Tranexamic acid|intravenous
80030135|NCT02866838|Drug|Saline 0.9%|intravenous
80030136|NCT03474146|Other|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
80030137|NCT03474146|Other|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
79578169|NCT01882452|Behavioral|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
79578170|NCT01882491|Drug|Placebo|Solution for subcutaneous injection
80030138|NCT03474146|Other|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
80030139|NCT04458350|Behavioral|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
80030140|NCT04458662|Procedure|Interval running protocol / eccentric-based resistance exercise protocol|
80030141|NCT01090154|Drug|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
80030142|NCT05159024|Diagnostic Test|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
79578171|NCT01882491|Drug|gevokizumab|Solution for subcutaneous injection
79309136|NCT03203915|Dietary Supplement|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
79309137|NCT04801017|Drug|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
79578172|NCT01882504|Drug|gevokizumab|
79578173|NCT01882517|Dietary Supplement|Yogurt that contains plant stanol esters|
79578174|NCT01882517|Dietary Supplement|Placebo yogurt|
79578175|NCT01882530|Drug|Paracetamol|
79872620|NCT04562233|Behavioral|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
79872621|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
79872622|NCT04549662|Dietary Supplement|Active A|Powdered formula containing whey protein and arginine
79872623|NCT04549662|Dietary Supplement|Active B|Powdered formula containing whey protein
79872624|NCT04549662|Dietary Supplement|Lipid bolus|Omega-3 fatty acids
79872625|NCT04549662|Dietary Supplement|Placebo oil|Control placebo oil that does not contain omega-3 fatty acids
79872626|NCT04544475|Device|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
79872627|NCT04544475|Drug|Estrace|Vaginal estrogen cream, estradiol: 100mcg
79578176|NCT01882530|Drug|Nefopam|
79578177|NCT01882530|Drug|Ketoprofen|
79578178|NCT01882530|Drug|Morphine|
79578179|NCT01882556|Drug|onabotulinumtoxinA|
79578180|NCT01882556|Drug|Placebo|
79578181|NCT01882595|Other|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
79578182|NCT01882595|Other|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
79578183|NCT01882608|Other|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
79872628|NCT04507438|Drug|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
79872629|NCT04507438|Drug|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
80030143|NCT05158868|Diagnostic Test|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
79578184|NCT01882621|Drug|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
79578185|NCT01882621|Drug|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
79578186|NCT01882634|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
80030144|NCT03473990|Other|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
79578187|NCT01882673|Behavioral|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
79578188|NCT01882673|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
79578189|NCT01882686|Other|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
79578190|NCT01882712|Drug|CD07805/47 Gel 0.5%|
79578191|NCT01882712|Drug|CD07805/47 Gel Placebo|
79578192|NCT01882777|Behavioral|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
79578193|NCT01882842|Procedure|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
79578194|NCT01882842|Device|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
79578195|NCT01882881|Other|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
79578196|NCT01882881|Other|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide ~33% of calories from fat. The SFA (~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (~9g).
79578197|NCT01882881|Other|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide ~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing ~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
79737560|NCT03987568|Other|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
79737561|NCT03987568|Diagnostic Test|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
79737562|NCT02712892|Genetic|Non Interventional Study|
79737563|NCT02693782|Dietary Supplement|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
79737564|NCT02693782|Dietary Supplement|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
79872630|NCT04459273|Procedure|Computed Tomography|Undergo PET/CT
79737565|NCT00611338|Behavioral|HIV Skills-based Prevention|
79737566|NCT04188886|Other|Practice survey|Practice survey on
79872631|NCT04459273|Drug|Gallium Ga 68 FAPi-46|Given IV
79872632|NCT04459273|Procedure|Positron Emission Tomography|Undergo PET/CT
79872633|NCT04459273|Radiation|18F-FDG|Given IV
79872634|NCT04457973|Device|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
79309138|NCT04801017|Drug|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
79737567|NCT02712580|Device|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
79737568|NCT02712580|Device|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
79872635|NCT04457973|Device|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
79872636|NCT04457232|Procedure|Computed Tomography|Undergo PET/CT imaging
79872637|NCT04457232|Other|Gallium Ga 68 FAPi-46|Given IV
79872638|NCT04457232|Procedure|Positron Emission Tomography|Undergo PET/CT imaging
79872639|NCT04441775|Other|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
79872640|NCT04440358|Device|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
80030145|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
80030146|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
80030147|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
80030148|NCT05019872|Behavioral|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
80030149|NCT05004272|Procedure|Massage|20-minute manual full-body massage
80030150|NCT05004272|Procedure|Gymnastics|20-minute moderate body workout
79872641|NCT04440358|Drug|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
80030151|NCT05004272|Other|Lecture|20-minute lecture on medicinal herbs
80030152|NCT04940234|Behavioral|Exposure to a Photo|We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
79737569|NCT02712580|Device|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
80030153|NCT02736578|Drug|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
80030154|NCT02736578|Drug|Cetuximab|Administered as a 100 mg IV loading dose
80030155|NCT05158400|Radiation|Ultrasound|Ultrasound examination on the hand
80030156|NCT04366856|Behavioral|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
80030157|NCT04366856|Behavioral|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
79737570|NCT02712580|Device|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
79737571|NCT00611416|Dietary Supplement|green tea|different catechin combinations
79737572|NCT00611416|Dietary Supplement|Mix of catechins and caffeine|3 tablet a day
79737573|NCT00611416|Dietary Supplement|EGCG|3 tablets a day
79737574|NCT00611416|Dietary Supplement|EGC|3 tablets a day
79737575|NCT00611416|Dietary Supplement|Caffeine|3 tablets a day
79737576|NCT00611416|Dietary Supplement|Placebo|3 tablets a day
79737577|NCT02712658|Drug|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
79737578|NCT02712658|Drug|Placebo|
79737579|NCT02712736|Other|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
79737580|NCT00611494|Drug|MMF|Gradual optimization of drug dosage, as clinically tolerated.
79737581|NCT00611494|Drug|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
79737582|NCT02712502|Drug|Levofloxacin|"Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
79737583|NCT02712502|Drug|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
79737584|NCT02712346|Drug|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
79737585|NCT02712346|Drug|Placebo|One inactive pill daily for twelve weeks
79737586|NCT02712190|Device|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
79737587|NCT02712268|Other|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
79737588|NCT02712034|Behavioral|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~Advice on where to go for help and on how to make the best use of health and human services; and~A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
79737589|NCT02712034|Other|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
79872642|NCT04417088|Drug|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
79872643|NCT04417088|Device|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
79872644|NCT04381897|Drug|N-acetyl cysteine|Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
79872645|NCT04381897|Other|Placebo|NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
80030158|NCT05157776|Drug|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
80030159|NCT02479568|Dietary Supplement|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
80030160|NCT02479568|Dietary Supplement|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
80030161|NCT02479568|Dietary Supplement|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
79578198|NCT01882881|Other|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at ~34-35% and the SFA will match that of the Almond Diet at ~8-9%. The fiber content of this diet will be highest (~35g); cholesterol will remain ≤200 mg/day.
79578199|NCT01882894|Device|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
80030162|NCT02479100|Diagnostic Test|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
80030163|NCT03473834|Other|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
80030164|NCT03473834|Behavioral|Medication|The control group will be received the normal medication from their doctor.
79578200|NCT01882894|Other|Faux orthosis|Foam cut out
80030165|NCT03473678|Dietary Supplement|Nitrate-rich beetroot juice|concentrated beetroot juice
80030166|NCT03473678|Dietary Supplement|Nitrate-depleted beetroot juice|concentrated beetroot juice
80030167|NCT04312412|Procedure|Controlled active motion (CAM)|Rehabilitation, post-surgery protocol
80030168|NCT05157542|Drug|Durvalumab|Day 1 and 22, 1500mg
80030169|NCT05157542|Drug|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
80030170|NCT05157542|Radiation|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
79274084|NCT05489276|Drug|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
79309139|NCT04801017|Drug|Placebo|0.9% sodium chloride injection
79309140|NCT03203837|Other|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
79309141|NCT04801251|Diagnostic Test|Echocardiographic examination|Each patient included will undergo full cardiac physical examination and echocardiographic examination
79309142|NCT03233165|Procedure|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
79309143|NCT03233165|Procedure|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
79872646|NCT04381689|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Teratect Prefilled Syringe Inj. 0.5mL
79872647|NCT04381689|Biological|Fluarix Tetra Pre-filled Syringe|Fluarix Tetra Pre-filled Syringe 0.5mL
79578201|NCT01882920|Drug|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) <2.5 l/min/m2, stroke volume index (SVI) < 35 SVI ml/m2 and stroke volume variation (SVV)> 15%. In the case of CI <2.5 l/min/m2 and SVI <35 ml/m2 with SVV < 15%, an infusion with dopamine was initiated.
79578202|NCT01882920|Drug|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
79872648|NCT04362501|Biological|dupilumab|300mg dupixent SC every two weeks for six months
79872649|NCT04362501|Drug|placebo|placebo SC injection every two weeks for six months
79872650|NCT04360213|Device|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
79872651|NCT04350268|Device|Wearable sensor|Wireless sensor
79872652|NCT04330690|Drug|Artesunate|2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
79872653|NCT04330690|Drug|Imatinib|400 mg enterally daily for 14 days plus standard of care
79872654|NCT04330690|Drug|Infliximab|5 mg/kg IV given one time, over 2 hours plus standard of care
80030171|NCT03472976|Other|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
80030172|NCT03472976|Drug|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
80030173|NCT03472976|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
79309144|NCT04800705|Other|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
79309145|NCT03203759|Other|Home hospitalization|See above
79737590|NCT02711722|Device|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~Blood gas analysis~Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
79872655|NCT04330690|Drug|Dexamethasone|6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
79872656|NCT04330690|Drug|LSALT Peptide|5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
80030174|NCT04457726|Biological|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
80030175|NCT04457570|Other|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
80030176|NCT04216394|Procedure|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
80030177|NCT03471104|Other|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
80030178|NCT04608578|Behavioral|Silver|A serious game to improve mental health in youth
79274085|NCT05484284|Procedure|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
79737591|NCT02711722|Device|PScli1|Pressure support set by clinicians prior to inclusion
79274086|NCT05484128|Dietary Supplement|Gastrus|"Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475.~Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus."
79737592|NCT02711722|Device|PScli2|Pressure support at the same level as prior to the study
79737593|NCT04161742|Device|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
79872657|NCT04304872|Behavioral|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
80030179|NCT03473600|Procedure|Cryotherapy|Liquid Nitrogen spray
79274087|NCT05484128|Other|Placebo|placebo has an identical preparation to Gastrus
79274088|NCT05484050|Other|Immunohistochemistry analysis|Estimation of VEGF through Immunohistochemistry
79737594|NCT02711566|Device|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
79737595|NCT02711566|Device|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
79737596|NCT02711488|Behavioral|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
79737597|NCT02711410|Drug|Clopidogrel|
80030180|NCT03473600|Drug|Triamcinolone acetonide injection|Intralesional Triamcinolone Acetonide injection
80030181|NCT03473522|Device|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
79274089|NCT05483894|Drug|Atorvastatin 10mg|Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
79274090|NCT05483894|Drug|Placebo|Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
79737598|NCT02711176|Drug|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
79578203|NCT01882946|Biological|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
80030182|NCT03473522|Behavioral|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
79578204|NCT01882959|Other|Radiofrequncy Denervation|
79578205|NCT01882972|Behavioral|Exercise|
79737599|NCT02711176|Drug|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
79737600|NCT02711176|Drug|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
79737601|NCT02711176|Drug|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
80030183|NCT02523326|Device|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
79274091|NCT01621243|Drug|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
79274092|NCT01621243|Drug|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
79274093|NCT01621243|Drug|placebo|Placebo will be dosed daily
79578206|NCT01882972|Behavioral|Meditation|
79578207|NCT01882998|Behavioral|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
79578208|NCT01883011|Drug|Piracetam|
79578209|NCT01883011|Other|Placebo|
79578210|NCT01883037|Other|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
79578211|NCT01883050|Device|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
79578212|NCT01883063|Device|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
79578213|NCT01883063|Device|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
79737602|NCT02711176|Drug|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
79737603|NCT02711176|Drug|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
79737604|NCT02711098|Biological|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
79737605|NCT02711098|Biological|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
79737606|NCT00611650|Drug|defined green tea catechin extract|Given orally
79737607|NCT00611650|Other|placebo|Given orally
79274094|NCT01621243|Drug|Necuparanib|Necuparanib will be dosed daily
79309146|NCT03203759|Other|Traditional inpatient hospitalization|See above
79737608|NCT02711332|Other|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
79737609|NCT02711332|Other|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
80030184|NCT04457882|Behavioral|Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube|No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
80030185|NCT04457882|Behavioral|Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube|Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
79309147|NCT03203213|Procedure|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
79309148|NCT04786665|Other|Strawberry|Freeze dried strawberry powder
79309149|NCT04786665|Other|Placebo group|Comparative placebo powder
79309150|NCT03232853|Other|Elearning|Elearning
79309151|NCT04800549|Other|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
79309152|NCT03203369|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
79309153|NCT04794855|Diagnostic Test|laboratory tests|routine laboratory tests and biomarkers tests
79578214|NCT01883076|Biological|autologous cell-based delivery|"autologous cells (derived from self)"
79578215|NCT01883089|Behavioral|Motivational Enhancement Therapy|
79578216|NCT01883102|Drug|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
80030186|NCT04457804|Behavioral|Virtual ACT Workshop for Emotional Eating|"This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
80030187|NCT04457648|Device|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
79274095|NCT05483816|Combination Product|VR+TENS|The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
79274096|NCT04076761|Drug|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
79274097|NCT05494112|Dietary Supplement|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
79274098|NCT05489198|Procedure|cataract surgery with Centurion phacoemulsification system|Cataract surgery performed with the Centurion phacoemulsification system
79403309|NCT05103462|Behavioral|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
79737610|NCT02711020|Behavioral|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
79737611|NCT02711020|Behavioral|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
79737612|NCT02710942|Behavioral|SPHERE|
79872658|NCT04304872|Behavioral|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
79403310|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79403311|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79403312|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79737613|NCT02710942|Behavioral|PRISM|
79737614|NCT02710708|Drug|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
79737615|NCT02710552|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
79737616|NCT02710552|Drug|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
79737617|NCT02710396|Drug|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
79737618|NCT02710396|Drug|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
79737619|NCT02710396|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
79737620|NCT02710396|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
79872659|NCT04280757|Procedure|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
79872660|NCT04276064|Device|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
79872661|NCT04276064|Device|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
79872662|NCT04276064|Device|Sham stimulation|Sham stimulation
79872663|NCT04268199|Drug|Bortezomib Injection|Subcutaneous injection
80030188|NCT04457648|Device|systane eye drops|systane lubricant eye drops
80030189|NCT05004584|Other|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
80030190|NCT05004584|Other|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
80030191|NCT05004584|Other|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
80030192|NCT05004584|Other|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
80030193|NCT05004584|Other|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
79403313|NCT04026763|Procedure|prostate biopsy|standard of care
79578217|NCT01883102|Drug|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
79578218|NCT01883128|Device|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
79578219|NCT01883128|Procedure|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
79578220|NCT01883128|Procedure|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
79578221|NCT01883167|Drug|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
79578222|NCT01883167|Drug|Febuxostat 40 mg|Febuxostat 40 mg qd
79578223|NCT01883167|Drug|placebo|placebo qd
79737621|NCT04564768|Behavioral|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
79737622|NCT02710318|Behavioral|Electronic immunization alert|Immunization alert in the electronic health record
79872664|NCT04255303|Other|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
79872665|NCT04252794|Procedure|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
79872666|NCT04252794|Other|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
79872667|NCT04223310|Drug|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Preselect drug with optimal antiarrhythmic effects in the patient.~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
79872668|NCT04223310|Drug|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
79872669|NCT04198116|Drug|Varenicline|Varenicline 2mg/day
79872670|NCT04198116|Drug|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
79872671|NCT04172844|Drug|Azacitidine|75mg/m^2 Days 1-7 given IV
79872672|NCT04172844|Drug|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
79872673|NCT04172844|Drug|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
79872674|NCT04147494|Procedure|Computed Tomography|Undergo PET/CT scan
79872675|NCT04147494|Radiation|Gallium Ga 68 FAPi-46|Given IV
79872676|NCT04147494|Radiation|Gallium Ga 68-labeled PSMA-11|Given IV
79872677|NCT04147494|Procedure|Positron Emission Tomography|Undergo PET/CT scan
79872678|NCT04147494|Radiation|18F-FDG|Given IV
79872679|NCT04144413|Drug|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
79872680|NCT04144413|Drug|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
79872681|NCT04144413|Other|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
79309154|NCT02450357|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
79309155|NCT02450357|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
79309156|NCT04794309|Other|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
79309157|NCT04794309|Dietary Supplement|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
79309158|NCT03107429|Drug|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
79309159|NCT03107429|Drug|Placebo|Placebo was a sugar based placebo placed in a capsule.
79309160|NCT03107429|Other|Trendelenburg Position|Placed in Trendelenburg Position
79309161|NCT04794231|Other|Standard dressing|a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 [8.5 x 10.5cm] or 1633 [7 × 8.5 cm] depending on patient size; 3M, Neuss, Germany)
79578224|NCT01883180|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
79274099|NCT05489198|Procedure|cataract surgery with Quatera 700 phacoemulsification system|Cataract surgery performed with the Quatera 700 phacoemulsification system
79578225|NCT01883193|Dietary Supplement|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
79578226|NCT01883219|Drug|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
79578227|NCT01883232|Device|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
79578228|NCT01883232|Device|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
79737623|NCT02710162|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
79578229|NCT01883245|Device|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
79578230|NCT01883245|Device|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
79737624|NCT02710162|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
79872682|NCT04124939|Drug|OnabotulinumtoxinA 100 Units|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
79872683|NCT04124250|Other|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
79872684|NCT04078698|Device|Immunoadsorber GLOBAFFIN®|Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease
79872685|NCT04047251|Drug|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
79872686|NCT04045613|Drug|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
79872687|NCT04045613|Drug|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
79872688|NCT04045613|Drug|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
79872689|NCT04045613|Drug|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
79872690|NCT04045613|Drug|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
79872691|NCT04045613|Drug|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
79872692|NCT04045613|Drug|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
79872693|NCT04042831|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
79872694|NCT04042831|Procedure|Computed Tomography|Undergo CT
79274100|NCT02235961|Drug|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
79274101|NCT02235961|Drug|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
79274102|NCT02235961|Drug|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
79274103|NCT01612039|Drug|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
79274104|NCT01612039|Drug|Placebo|Matching placebo tablets
79274105|NCT05483738|Diagnostic Test|Clinical assessment, blood samples, bone marrow and bone biopsy|Assessment of blood samples, bone marrow and bone biopsy
79737625|NCT02710162|Device|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
79872695|NCT04042831|Procedure|Magnetic Resonance Imaging|Undergo MRI
79872696|NCT04042831|Drug|Olaparib|Given PO
79872697|NCT03964207|Drug|Tiotropium Respimat® (T1)|inhalation solution
79872698|NCT03964207|Drug|Tiotropium Handihaler® (T2)|Inhalation Powder
79872699|NCT03947255|Drug|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
79872700|NCT03930147|Procedure|ASV ventilation|Ventilation on ASV mode
79872701|NCT03929757|Biological|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
79872702|NCT03929757|Biological|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
79872703|NCT03929757|Biological|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
80030194|NCT04993976|Other|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs [eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises], one to three sets each) for 20-60 minutes five days a week.
79578231|NCT01883258|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
80030195|NCT04993976|Other|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
79578232|NCT01883258|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
79872704|NCT03919773|Drug|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
79872705|NCT03919773|Drug|Albumin|This will be the matching placebo used in the study.
79578233|NCT01883271|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
79578234|NCT01883271|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
79578235|NCT01883284|Other|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
80030196|NCT02622724|Drug|Interferon beta-1a|Investigational drug
80030197|NCT02622724|Drug|Placebo|Placebo for investigational drug
80030198|NCT03471026|Diagnostic Test|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
80030199|NCT03710720|Behavioral|TIPS app|Psycho-educational electronic application
80030200|NCT03710720|Behavioral|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
79274106|NCT02236039|Procedure|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
79274107|NCT02688153|Device|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR & CABG.
79737626|NCT02710162|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
79737627|NCT02710162|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
79737628|NCT02710162|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
79737629|NCT02710162|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
79737630|NCT02710162|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
79737631|NCT02710162|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
79737632|NCT02710162|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
79872706|NCT03904147|Device|Tricuspid valve repair|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
80030201|NCT03690596|Other|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
80030202|NCT03690596|Other|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
79274108|NCT02688153|Device|Stented aortic bioprostheses|In comparison to control valves available on the market.
80030203|NCT03690596|Other|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
80030204|NCT04933396|Diagnostic Test|ultrasound diagnostic criteria|evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW <10th percentile according to the Hadlock growth standard).
80030205|NCT04932928|Device|FreeStyle Libre|Flash glucose monitoring + Education on lifestyle modification
80030206|NCT04932928|Device|Blood glucose meter|Self monitoring of blood glucose + Education on lifestyle modification
79578236|NCT01883310|Device|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
79737633|NCT02710162|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
79274109|NCT05493956|Radiation|chemoradiation|Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
79737634|NCT02710162|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
80030207|NCT04932772|Other|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
80030208|NCT04932772|Other|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
79737635|NCT02709928|Drug|TD-0714|
79737636|NCT02709928|Drug|Placebo|
79872707|NCT03877653|Device|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
79872708|NCT03845829|Procedure|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
79872709|NCT03789786|Diagnostic Test|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
79872710|NCT03789786|Diagnostic Test|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
79872711|NCT03789786|Behavioral|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
79872712|NCT03770858|Drug|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
79872713|NCT03770858|Device|Scratch sensor|advanced, flexible and wearable skin sensor
79872714|NCT03761641|Other|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics & eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face &cushion between the skin & eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, & dilation velocity. Total pupil dilation testing time is < 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position & movement velocity during these tests. Total saccade-tracking testing takes < 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
79872715|NCT03754803|Other|HIV Symptom Distress Module Questionnaire|The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
79274110|NCT02236117|Other|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week-1; intensity, >80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
79274111|NCT01610245|Drug|Nitazoxanide|
79274112|NCT01610245|Drug|Oseltamivir|
79274113|NCT01610245|Drug|Placebo Oral Tablet|
79737637|NCT02710006|Procedure|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
79872716|NCT03754803|Other|HIV treatment satisfaction questionnaire|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
79872717|NCT03748823|Combination Product|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
79872718|NCT03748823|Biological|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
79274114|NCT01610245|Drug|Placebo Oral Capsule|
79274115|NCT04138628|Drug|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
79274116|NCT05493878|Diagnostic Test|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
79309162|NCT04794231|Other|Chlorhexidine gluconate -impregnated dressing group|A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R [7 x 8.5 cm] or [11.5 x 8.5 cm] depending on patient size; 3M, Neuss, Germany).
79309163|NCT02450201|Drug|Pyruvate|
79872719|NCT03741400|Device|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
79872720|NCT03716167|Device|Summus Laser|infrared laser treatment
79872721|NCT03716167|Device|Summus Laser Sham|non-infrared light
79872722|NCT03690154|Drug|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
79872723|NCT03665831|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
79872724|NCT03622606|Diagnostic Test|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
79872725|NCT03617497|Diagnostic Test|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
79872726|NCT03617497|Diagnostic Test|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
79872727|NCT03598699|Drug|AXR-159|AXR-159 Ophthalmic Solution
79872728|NCT03598699|Drug|Vehicle|AXR-159 Ophthalmic Solution Vehicle
79872729|NCT03588754|Drug|Propranolol|Propranolol Extended Release (160mg/day).
79872730|NCT03588754|Drug|Placebo|Placebo pill administered orally.
79872731|NCT03573089|Drug|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
79872732|NCT03573089|Drug|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
79872733|NCT03565913|Drug|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
79872734|NCT03565913|Other|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
79872735|NCT03548558|Behavioral|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
79872736|NCT03548558|Behavioral|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
79872737|NCT03548558|Behavioral|Booster sessions|After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
79872738|NCT03548558|Behavioral|Fathers invited|During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
79872739|NCT03535883|Drug|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
80030209|NCT04932304|Device|Transcranial direct current stimulation (tDCS)|
79872740|NCT03523156|Drug|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
79872741|NCT03523156|Drug|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
79872742|NCT03517657|Behavioral|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
79872743|NCT03517657|Behavioral|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
79872744|NCT03503058|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
79274117|NCT03162471|Diagnostic Test|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
79274118|NCT03162315|Procedure|Freeze all|
79274119|NCT02687919|Other|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
79737638|NCT00611728|Drug|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle."
79737639|NCT04497610|Diagnostic Test|Breath sample|Patient will blow into a tube 5 times.
79737640|NCT02709850|Drug|IONIS ANGPTL3-LRx|
79737641|NCT02709850|Drug|Placebo|0.9%NaCl, water, riboflavin
79737642|NCT02709772|Behavioral|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
79737643|NCT02709304|Drug|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
79737644|NCT02709304|Drug|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
79872745|NCT03503058|Biological|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
79872746|NCT03503058|Other|Normal Saline|0.9% Sodium chloride
79872747|NCT03503058|Drug|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
79872748|NCT03502993|Diagnostic Test|Validation of biomarker|
79872749|NCT03482349|Procedure|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
79872750|NCT03459534|Drug|Radotinib HCl|"Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~Storage conditions: Store in an airtight light proof container at room temperature."
79872751|NCT03456817|Drug|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 & -2, ATG will be infused after fludarabine & busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 & over at least 4 hrs on days -3, -2, -1 & 0. Dose is based on actual body wt, & rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in >5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 & 10 mg/m2 on days +3, +6 & +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
79872752|NCT03456817|Drug|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
79872753|NCT03435705|Behavioral|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
79872754|NCT03428633|Drug|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
79872755|NCT03428633|Drug|Morphine|Morphine intraoperatively and postoperatively
80030210|NCT04932304|Device|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
80030211|NCT01354353|Drug|LY2140023|Administered orally
79309164|NCT04800081|Drug|Sacubitril/Valsartan|Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
79737645|NCT04189666|Drug|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
79737646|NCT04189666|Drug|Melatonin|compare the ability of the drug in preventing postoperative delirium
79872756|NCT03419832|Other|NEAT Form|The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
79274120|NCT02263339|Behavioral|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
79274121|NCT02263339|Behavioral|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
79309165|NCT04800081|Drug|Valsartan|Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
79578237|NCT01883310|Device|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
79578238|NCT01883323|Drug|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
79578239|NCT01883323|Drug|Fludarabine|i.v., 25mg/m2 per day for 5 days
79578240|NCT01883323|Biological|Tumor-Infiltrating Lymphocytes|i.v., 1x10^10 - 1.6x10^11 cells
79737647|NCT04160338|Device|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
79737648|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation I
79737649|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation II
79872757|NCT03419832|Other|Standard Form|The regular IRB approved version.
79872758|NCT03367247|Behavioral|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
79872759|NCT03367247|Other|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
79872760|NCT03364673|Other|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
79872761|NCT03364673|Other|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
79872762|NCT03330405|Drug|Avelumab Phase 1b|Avelumab
79872763|NCT03330405|Drug|Talazoparib Phase 1b|Talazoparib
80030212|NCT01354353|Drug|Aripiprazole|Administered orally
80030213|NCT04932538|Other|Kİnesio Taping|Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
79737650|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation III
79737651|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation IV
79737652|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation V
79737653|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation VI
79737654|NCT00937521|Biological|Control|Control
79737655|NCT00937521|Biological|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
79872764|NCT03330405|Drug|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
79872765|NCT03330405|Drug|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
79872766|NCT03222869|Diagnostic Test|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
79872767|NCT03207958|Drug|Belimumab|-Given over 1 hour
79872768|NCT03176927|Diagnostic Test|magnetogastrogram|
79872769|NCT03164928|Drug|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
80030214|NCT02622568|Drug|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
79872770|NCT03164928|Other|Placebo|SC Q6M placebo
79872771|NCT03153280|Drug|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
79872772|NCT03153280|Drug|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
79872773|NCT03153280|Drug|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
79872774|NCT03150797|Drug|Melatonin|Melatonin
79872775|NCT03150797|Drug|Placebo oral capsule|Placebo
79872776|NCT03096418|Drug|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
80030215|NCT02622568|Procedure|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
80030216|NCT04932460|Procedure|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
80030217|NCT04932460|Procedure|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
80030218|NCT04932070|Dietary Supplement|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
80030219|NCT03070899|Drug|OBE2109|OBE2109 100mg tablets for oral administration once daily
79274122|NCT02263339|Behavioral|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
79274123|NCT05489042|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
79578241|NCT01883323|Biological|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
79578242|NCT01883349|Procedure|Kidney Transplant|Kidney Transplant Surgery
79737656|NCT02709460|Procedure|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
79737657|NCT02709460|Procedure|Cervical occlusion|Cervical occlusion of the uterine artery
79737658|NCT02709382|Drug|Cefepime and Tazobactam combination|
79872777|NCT03074513|Drug|Atezolizumab|Given IV
79872778|NCT03074513|Biological|Bevacizumab|Given IV
79872779|NCT03074513|Other|Laboratory Biomarker Analysis|Correlative studies
79872780|NCT03074513|Other|Pharmacological Study|Correlative studies
79872781|NCT03070106|Dietary Supplement|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
79872782|NCT03054909|Biological|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
79872783|NCT03054909|Biological|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
80030220|NCT03070899|Drug|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
80030221|NCT03070899|Drug|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
79274124|NCT05489042|Device|sham rTMS|10 sessions of sham rTMS
79403314|NCT04026763|Procedure|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
79578243|NCT01883375|Behavioral|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
79578244|NCT01883375|Behavioral|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
79578245|NCT01883401|Dietary Supplement|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
79578246|NCT01883401|Dietary Supplement|Dietary fiber|4g or 8g dietary fiber blended in water
79737659|NCT02708992|Drug|Azithromycin|
79737660|NCT02708992|Drug|Cefixime|
79737661|NCT02709070|Procedure|resection|hepatectomy for HCC
79737662|NCT02709070|Procedure|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
79737663|NCT02709148|Device|Activa PC+S|DBS
79872784|NCT03044392|Other|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
79872785|NCT03014414|Behavioral|Fun First|Learn key enjoyable maintenance skills before losing weight
79872786|NCT03014414|Behavioral|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
79872787|NCT02835443|Device|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
79872788|NCT02817698|Drug|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
79872789|NCT02756897|Drug|Ibrutinib|Given PO
79872790|NCT02756897|Other|Laboratory Biomarker Analysis|Correlative studies
79872791|NCT02756897|Drug|Venetoclax|Given PO
79872792|NCT02754830|Drug|LY3303560 - IV|Administered IV
79872793|NCT02754830|Drug|Saline Solution - IV|Administered IV
79872794|NCT02754830|Drug|LY3303560 - SC|Administered SC
80030222|NCT03070899|Drug|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
80030223|NCT04931680|Other|Data collection|During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
80030224|NCT04931992|Other|No intervention|Retrospective analysis
79737664|NCT00611962|Drug|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
79274125|NCT03162237|Other|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo-latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
79274126|NCT03162237|Other|Autologous Treg|Autologous Treg: 2x10^6/Kg
79872795|NCT02732171|Other|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
79872796|NCT02683239|Drug|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
79872797|NCT02683239|Drug|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
79872798|NCT02608411|Drug|ARQ197|
79872799|NCT02551237|Radiation|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
79872800|NCT02551237|Drug|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
79872801|NCT02551237|Radiation|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
79872802|NCT02437214|Other|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
79872803|NCT02407808|Drug|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
79872804|NCT02407808|Drug|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
79872805|NCT02299921|Other|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
79872806|NCT02228343|Other|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
79274127|NCT02741791|Drug|AXS-05|AXS-05 taken daily for 6 weeks.
79274128|NCT02741791|Drug|Bupropion|Buproprion taken daily for 6 weeks.
79274129|NCT05483660|Other|Lactobacillus plantarum|1.5×10^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
79274130|NCT05483660|Other|Bacillus coagulans|1.5×10^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
79274131|NCT05483660|Other|Lactobacillus plantarum + Bacillus coagulans|1.5×10^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
79274132|NCT05483660|Other|Placebo|Adult milk powder 15 g pertime, three times daily and half an hour before meal.
79274133|NCT04119518|Device|CSEM Pulse Watch|Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
79274134|NCT05438173|Dietary Supplement|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
79274135|NCT05438173|Dietary Supplement|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
79578247|NCT01883414|Device|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
79737665|NCT05380791|Other|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
79737666|NCT00606099|Drug|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
79737667|NCT00606099|Drug|adefovir dipivoxil|Active Comparator
79737668|NCT02708602|Genetic|β2AR polymorphism|
79872807|NCT02097134|Drug|Melphalan|Given IA
79872808|NCT01961375|Drug|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
79872809|NCT01954992|Drug|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
79872810|NCT01954992|Drug|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
79872811|NCT01946854|Behavioral|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
79872812|NCT01927744|Drug|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
79872813|NCT01927744|Drug|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
79872814|NCT01927744|Other|Placebo|150 mg by mouth daily continuously until the day before surgery.
79872815|NCT01927744|Behavioral|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
79872816|NCT01927744|Behavioral|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
79872817|NCT01927744|Drug|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
79872818|NCT01891981|Drug|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
80030225|NCT04931524|Drug|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
79274136|NCT05483504|Drug|F61 injection|Colorless or slightly yellow liquid, may be slightly opalescent
79274137|NCT05483504|Drug|F61 Placebo|Colorless or slightly yellow liquid, may be slightly opalescent
79872819|NCT01859130|Device|Zimmer Persona Total Knee System|
79872820|NCT01750892|Behavioral|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
79872821|NCT01750892|Behavioral|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
79274138|NCT05493644|Other|Remedial treatment within 3 months|Remedial therapy was performed within 3 months
79274139|NCT05493644|Other|Remedial treatment within 3 to 6 months|Remedial therapy was performed within 3 to 6 months
79274140|NCT05493644|Other|Remedial treatment within 6 to 12 months|Remedial therapy was performed within 6 to 12 months
79274141|NCT05493644|Other|Remedial treatment after 12 months|Remedial therapy was performed after 12 months
79274142|NCT04275518|Drug|APG-115|APG-115 orally once daily from Days 1 to 7 every 28 days.
79274143|NCT04275518|Drug|Azacitidine|75 mg/m^2 SC QD on Days 1- 7 (28-day cycle)
79274144|NCT04275518|Drug|Cytarabine|1g/m^2 IV QD on Days 3-7 (28-day cycle)
79274145|NCT05410171|Device|early warning platform|High risk inpatients will be evaluated by early warning platform
79274146|NCT02263495|Drug|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
79274147|NCT02263495|Drug|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
79274148|NCT02263495|Drug|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
79274149|NCT02687451|Drug|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
79737669|NCT00935883|Drug|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
79737670|NCT00935883|Drug|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
79737671|NCT02708446|Drug|Mifepristone|200mg oral mifepristone to both study arms
79737672|NCT02708446|Drug|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
79737673|NCT02708446|Drug|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
79274150|NCT02687451|Drug|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
79274151|NCT03908281|Behavioral|Fasted Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
79274152|NCT03908281|Behavioral|Postprandial Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
79274153|NCT02263573|Other|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE * 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC * 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
79274154|NCT02263573|Other|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
79737674|NCT02708056|Drug|Sugammadex|
79737675|NCT04426708|Drug|HMS5552|single dose of HMS5552 25mg
79737676|NCT05305209|Other|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
79737677|NCT05305209|Other|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
80030226|NCT04431310|Other|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
80030227|NCT04931446|Procedure|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
80030228|NCT03562611|Drug|Nalbuphine|Nalbuphine administration during surgery
80030229|NCT03562611|Drug|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
79274155|NCT02557646|Biological|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
79274156|NCT02557646|Drug|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
79274157|NCT02263651|Procedure|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
79737678|NCT05378919|Radiation|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
79737679|NCT05378919|Drug|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
79274158|NCT02263651|Procedure|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
79274159|NCT02679573|Drug|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
79274160|NCT02679573|Drug|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
79578248|NCT01883466|Other|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
79578249|NCT01883479|Behavioral|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
79578250|NCT01883479|Behavioral|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
79274161|NCT02679573|Drug|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
79274162|NCT02236273|Behavioral|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
79578251|NCT01883518|Biological|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
79578252|NCT01883531|Drug|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
79578253|NCT01883531|Drug|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
79737680|NCT05378919|Drug|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
79737681|NCT05378919|Radiation|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
79737682|NCT00607581|Drug|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
79737683|NCT00607581|Drug|lenalidomide|lenalidomide: 15 mg orally on days 1-21
79737684|NCT00607581|Drug|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
79872822|NCT01750892|Other|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
79872823|NCT01628536|Dietary Supplement|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
79872824|NCT01534299|Device|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
79872825|NCT01335308|Behavioral|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
80030230|NCT03562611|Drug|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
80030231|NCT04930120|Other|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
79274163|NCT02236273|Behavioral|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
79274164|NCT05493410|Other|TREATMENT GROUP (TG)|In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
79274165|NCT05493410|Other|CONTROL GROUP (CG)|"For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate."
79274166|NCT05338957|Drug|MRG002+HX008|Administrated intravenously
79274167|NCT05493332|Procedure|HAIC(FOLFOX)|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
79274168|NCT05493332|Drug|Oxaliplatin|85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
79274169|NCT05493332|Drug|Leucovorin|400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
79578254|NCT01883544|Drug|ALXN1007|
79872826|NCT01335308|Behavioral|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
79872827|NCT01335308|Behavioral|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
79872828|NCT01174043|Drug|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
79872829|NCT00954226|Drug|Erlotinib Hydrochloride|Given PO
79872830|NCT00954226|Other|Laboratory Biomarker Analysis|Correlative studies
79872831|NCT00575549|Other|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
79872832|NCT00494728|Behavioral|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
79872833|NCT00494728|Drug|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
79872834|NCT00494728|Behavioral|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
79872835|NCT00488072|Drug|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
79872836|NCT00488072|Drug|Placebo|One placebo tablet by mouth daily.
79872837|NCT00398034|Drug|Testosterone Gel|
79872838|NCT00389350|Drug|Extract of Green and Black Tea|
79872839|NCT00329043|Drug|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
79872840|NCT00329043|Drug|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
79872841|NCT00329043|Procedure|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
79872842|NCT00254384|Drug|Cisplatin|Given IV
79872843|NCT00254384|Drug|Docetaxel|Given IV
79872844|NCT00254384|Drug|Erlotinib|Given PO
79872845|NCT00254384|Drug|Erlotinib Hydrochloride|Given PO
79872846|NCT00254384|Other|Laboratory Biomarker Analysis|Correlative studies
79872847|NCT00253318|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
79872848|NCT00253318|Drug|RAD001|30 mg orally on Days 1 and 8.
79872849|NCT00253318|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
79872850|NCT00081874|Drug|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
79872851|NCT04119674|Drug|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
79872852|NCT04119674|Drug|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
79872853|NCT04119674|Radiation|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
79872854|NCT04109365|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
79872855|NCT04089566|Drug|Nusinersen|Administered as specified in the treatment arm
79872856|NCT04086524|Other|Binocular cartoon treatment at home|see arm description.
79872857|NCT04086524|Other|Patching|see arm description
79274170|NCT05493332|Drug|Fluorouracil|400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
79274171|NCT05493332|Drug|Toripalimab|240mg IVdrip，D3, Q3W
79578255|NCT01883570|Other|training in visual search strategy|
79872858|NCT04086524|Other|Binocular cartoon treatment in office|see arm description.
79737685|NCT02707900|Drug|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
79872859|NCT04050982|Device|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
79274172|NCT05493332|Drug|Donafenib|0.1g. P.O, BID, continuously
79274173|NCT01591447|Drug|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
79274174|NCT01591447|Drug|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
79274175|NCT04239326|Diagnostic Test|targeted Next Generation Sequencing (tNGS)|The index tests used in this trial will include up to three end-to-end, targeted next generation sequencing (tNGS) solutions for diagnosis of DR-TB. Each solution will include all of the equipment, reagents, and software necessary for handling the entire sequencing workflow, including DNA extraction from processed sputum samples (i.e. sediment), library preparation, sequencing, and data analysis/interpretation for clinical result reporting.
79274176|NCT01578655|Drug|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
79274177|NCT01578655|Drug|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
79578256|NCT01883570|Other|access to a library of chest x-rays without search strategy|
79872860|NCT04050982|Behavioral|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
79872864|NCT04032847|Biological|ATL001|ATL001 infusion
79578257|NCT01883583|Device|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
79578258|NCT01883596|Drug|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
79578259|NCT01883596|Drug|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
79578260|NCT01883609|Biological|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
79737686|NCT02707900|Biological|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
79872865|NCT04032847|Drug|Pembrolizumab|Checkpoint inhibitor
79872866|NCT04031430|Device|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
79872867|NCT04031430|Other|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
79578261|NCT01883609|Biological|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
79872868|NCT04031430|Other|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
79872869|NCT04013126|Diagnostic Test|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
79872870|NCT03990571|Drug|Avelumab|Given IV
79872871|NCT03990571|Drug|Axitinib|Given PO
79872872|NCT03948139|Device|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
80030232|NCT04930276|Other|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
80030233|NCT04442763|Device|Densah Burs|osseodensification method
80030234|NCT04442763|Device|Standard drills|conventional drilling
79274178|NCT01578655|Drug|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
79578262|NCT01883609|Biological|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
79872873|NCT03948139|Device|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
80030235|NCT03057574|Drug|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
79578263|NCT01883648|Drug|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
79737687|NCT05380479|Drug|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
79737688|NCT05380479|Drug|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
80030236|NCT04929964|Procedure|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
79309166|NCT03202979|Drug|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
79578264|NCT01883648|Other|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
79578265|NCT01883661|Biological|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
79737689|NCT02707822|Other|Clinical and genetic factors|
79737690|NCT00936975|Radiation|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
79737691|NCT02707978|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
79737692|NCT00604929|Dietary Supplement|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
80030237|NCT03056950|Device|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
80030238|NCT03057028|Drug|Anakinra|
80030239|NCT04406961|Procedure|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
80030240|NCT04406961|Device|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
79309167|NCT03202979|Drug|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
79578266|NCT01883674|Other|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
79578267|NCT01883687|Procedure|Septoplasty|
79737693|NCT04410718|Other|Glycaemic levels|Glycaemic levels during admission for COVID-19
79737694|NCT02707510|Other|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
79872874|NCT03944434|Drug|Ribociclib|ribociclib 600 mg/day orally
79872875|NCT03944434|Drug|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
79872876|NCT03944434|Drug|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
79872877|NCT03918096|Other|Questionnaire|Questionnaire to the parents after the hospital discharge
79274179|NCT04781049|Procedure|Trans-Perineal Laser Ablation of Prostate|"TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance."
79872878|NCT03905265|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
79578268|NCT01883700|Other|Boiled Pasta|
79578269|NCT01883700|Other|Boiled Chickpeas with Oil|
79578270|NCT01883700|Other|Instant Mashed Potatoes|
79578271|NCT01883700|Other|Instant Mashed Potatoes with Egg Whites|
79578272|NCT01883713|Device|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
79872879|NCT03899350|Other|No intervention|No intervention
79872880|NCT03898596|Diagnostic Test|ECG|An ECG collects superficial readings of heart activity
79872881|NCT03869476|Diagnostic Test|Non-invasive diagnosis score|"spleen fibrosis by elastography~plasma cytokines levels~mutationnal landscape by NGS~CD34 circulating cells"
79872882|NCT03859752|Biological|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
79872883|NCT03852784|Other|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
79872884|NCT03850860|Other|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
79872885|NCT03848845|Drug|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
79872886|NCT03848845|Drug|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
79872887|NCT03827434|Device|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
79872888|NCT03827434|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
79872889|NCT03781440|Procedure|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
79872890|NCT03781440|Procedure|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
79872891|NCT03771989|Biological|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
79872892|NCT03771989|Other|Saline|The placebo is an injection with saline
79872893|NCT03762044|Other|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"Health education / patient empowerment.~Neurodynamic activities oriented to ADL.~Proprioceptive neuromuscular facilitation exercises oriented to ADL.~Self-adherent self-adhesive antiedema of low compression."
79578273|NCT01883726|Device|Grayson's presurgical nasoalveolar molding|Grayson NAM
79578274|NCT01883726|Device|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
79578275|NCT01883739|Other|Parental Presence at Handover Rounds|
79578276|NCT01883752|Procedure|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
79578277|NCT01883765|Behavioral|Neurofeedback active|
79578278|NCT01883765|Behavioral|Neurofeedback sham|
79578279|NCT01883765|Behavioral|Metacognitive Training|
79578280|NCT01883791|Behavioral|SBIRT|See above Arm description.
79578281|NCT01883791|Behavioral|Health Education|See Arm Description.
79578282|NCT01883830|Device|gaming therapy (Xbox)|
79578283|NCT01883830|Device|Dynamic balance platform (Biodex)|
79872894|NCT03762044|Other|Complete Decongestive Therapy (CDT)|"Skin care.~Kinesitherapy~Manual lymphatic drainage (MLD)~Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
79872895|NCT03742037|Drug|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
79872896|NCT03742037|Drug|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
79872897|NCT03742037|Drug|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
79872898|NCT03742037|Drug|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
79872899|NCT03742037|Drug|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
79872900|NCT03742037|Drug|cenerimod 2 mg (ex-4 mg)|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
79872901|NCT03714815|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
79872902|NCT03713229|Diagnostic Test|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
79872903|NCT03712943|Drug|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
79872904|NCT03712943|Drug|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
80030241|NCT04406961|Procedure|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
79274180|NCT04781049|Procedure|Trans-Urethral Resection of Prostate|TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
79578284|NCT01883843|Device|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
79578285|NCT01883843|Device|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
79578286|NCT01883869|Drug|ticagrelor|
79578287|NCT01883869|Drug|placebo|placebo
79578288|NCT01883882|Behavioral|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
79578289|NCT01883921|Other|Immunoglobulin Therapy|
79578290|NCT01883934|Other|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
79578291|NCT01883934|Other|Control|
79578292|NCT01883947|Procedure|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
79578293|NCT01883947|Other|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
79578294|NCT01884012|Procedure|long term oxygen therapy|
79737695|NCT02707354|Device|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
79872905|NCT03710915|Drug|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
79872906|NCT03707938|Drug|Brigatinib|Given PO
79872907|NCT03707938|Procedure|Local Consolidation Therapy|Undergo local consolidative therapy
79274181|NCT05361447|Drug|Diazepam|5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
79737696|NCT04335682|Drug|Darolutamide|Patients randomized to darolutamide.
79737697|NCT04335682|Drug|Enzalutamide|Patients randomized to enzalutamide.
79274182|NCT05483426|Other|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
79274183|NCT03963596|Procedure|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
79274184|NCT01577173|Drug|MEHD7945A|1100 mg iv every 2 weeks
79274185|NCT01577173|Drug|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
79737698|NCT02707120|Drug|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
79872908|NCT03686488|Drug|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
79872909|NCT03686488|Drug|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
79872910|NCT03646760|Behavioral|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
79872911|NCT03646760|Behavioral|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
80030242|NCT04406961|Device|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
79274186|NCT03165201|Device|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
79274187|NCT01573351|Drug|Asunaprevir|
79274188|NCT01573351|Drug|Daclatasvir|
79274189|NCT01573351|Drug|Peg-interferon Alfa-2a|
79274190|NCT01573351|Drug|Ribavirin|
79578295|NCT01884090|Behavioral|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
79274191|NCT03162159|Other|Collection of growth and bone maturation data|
79274192|NCT05483348|Procedure|Endometrial Ablation|Thermal endometrial ablation
79274193|NCT05483348|Procedure|Repeated gynecological procedure|subsequent gynecological procedures such as hysterectomy for any benign indication, D&C or repeat ablation.
79274194|NCT02685033|Drug|Dalbavancin|
79872912|NCT03640312|Drug|QUARTET LDQT|Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
79274195|NCT02685033|Drug|Comparator|
79274196|NCT01559701|Drug|PF-00345439|5-80 mg twice-a-day for 12 months
79274197|NCT05488730|Diagnostic Test|passive leg raising test and fluid challenge|"Shocked patients were subjected to echocardiographic examination if (EF <52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness)."
79274198|NCT03135613|Procedure|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
79274199|NCT04052048|Diagnostic Test|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
79274200|NCT02684097|Drug|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
79274201|NCT02684097|Drug|Placebo|Matching placebo given every two weeks for 24 weeks
79309168|NCT03202979|Drug|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
79309169|NCT04799925|Drug|Febuxostat|uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
79309170|NCT03232775|Other|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
79578296|NCT01884116|Drug|NSAID patch|
79578297|NCT01884116|Drug|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
79578298|NCT01884116|Drug|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
79578299|NCT01884116|Drug|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
79872913|NCT03640312|Drug|Candesartan|Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
79872914|NCT03625388|Drug|Dasatinib|Film coated tablet contains dasatinib monohydrate
79578300|NCT01884142|Other|Aerobic Exercise Training|
79578301|NCT01884155|Procedure|Allogeneic umbilical cord blood therapy|
79578302|NCT01884168|Biological|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
79578303|NCT01884207|Other|MRI|
79872915|NCT03622879|Behavioral|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
79274202|NCT05483192|Dietary Supplement|Oral Dyglomera|"Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin."
79274203|NCT02555618|Biological|TAK-850|TAK-850 subcutaneous injection
79274204|NCT02555618|Biological|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
79578304|NCT01884220|Other|There are no interventions in this study.|
79872916|NCT03622879|Device|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
79578305|NCT01884233|Behavioral|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
79274205|NCT00258427|Biological|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
79274206|NCT00258427|Biological|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10^9/L)
79274207|NCT00258427|Drug|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if <4 years old)
79274208|NCT00258427|Drug|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
79274209|NCT00258427|Drug|fludarabine phosphate|35 mg/m^2 intravenously (IV) on Days -5 through -2.
79578306|NCT01884233|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
79872917|NCT03622879|Behavioral|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
79274210|NCT00258427|Drug|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
79274211|NCT00258427|Biological|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
79274212|NCT03135457|Procedure|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
79578307|NCT01884246|Behavioral|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
79737699|NCT02707120|Drug|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
79872918|NCT03614962|Device|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
79274213|NCT03135457|Procedure|Saline transfusion|Saline transfusion 300ml 10ml/min
79274214|NCT05483114|Procedure|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
79274215|NCT05483114|Procedure|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
79274216|NCT02782117|Device|Luminopia One|Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
79274217|NCT05488418|Other|Clinical, cognitive and biological tests|"Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit."
79274218|NCT01531699|Drug|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
79274219|NCT01531699|Other|saline control|single application for up to 6 hours
79274220|NCT01531699|Drug|Betadine ophthalmic prep solution|single application for up to 6 hours
79274221|NCT02233621|Other|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with [18F]FES before coelioscopy
79274222|NCT02233699|Drug|XEN-D0501|
79274223|NCT02233699|Drug|Placebo|
79274224|NCT02557100|Drug|Abatacept|
79274225|NCT02557100|Drug|Adalimumab|
79274226|NCT02557100|Drug|Methotrexate|
79274227|NCT02233777|Drug|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
79274228|NCT02233777|Drug|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
79737700|NCT02706808|Dietary Supplement|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
79737701|NCT02706808|Dietary Supplement|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
79274229|NCT02236507|Device|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
79274230|NCT02261545|Dietary Supplement|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
79274231|NCT02261545|Dietary Supplement|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
79578308|NCT01884246|Other|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
79578309|NCT01884272|Drug|lesinurad 400 mg|
79274232|NCT01528111|Drug|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
79274233|NCT01528111|Drug|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
79274234|NCT01528111|Drug|LX7101 Vehicle|Subjects will receive vehicle
79274235|NCT02634853|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
79309171|NCT03232775|Other|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
79578310|NCT01884272|Drug|naproxen 250 mg|
79578311|NCT01884272|Drug|indomethacin 25 mg|
79578312|NCT01884285|Drug|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
79578313|NCT01884285|Drug|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
79737702|NCT02693470|Drug|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
79737703|NCT00936897|Drug|Ibandronate|Ibandronate 150mg PO QM (tablet)
79737704|NCT00936897|Drug|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
79872919|NCT03614962|Device|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
79872920|NCT03614962|Device|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
79872921|NCT03614962|Device|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
79274236|NCT02634853|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
79274237|NCT01520545|Drug|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
79274238|NCT01520545|Device|SynchroMed® II Programmable Pump|Intrathecal programmable pump
79274239|NCT02624947|Biological|RSV F vaccine with adjuvant|
79403315|NCT04026763|Device|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
79737705|NCT02706418|Procedure|Clinical Massage Therapy|
79737706|NCT00607659|Other|No intervention, only observational|No intervention, only observational
79872922|NCT03614962|Device|control|No warmth pad and TENS electrodes presented in the cap.
79274240|NCT02624947|Biological|Formulation buffer|
79274241|NCT05488184|Dietary Supplement|Flavoured Oral Nutritional Supplement (ONS)|Sensory analysis of different ONS of sweet (pineapple, tropical, brownie) and acid flavoured (tomato, ham)
79274242|NCT02261623|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
79274243|NCT02261623|Device|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
79274244|NCT02261623|Device|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
79274245|NCT05488106|Dietary Supplement|Placebo|Placebo
79274246|NCT05488106|Dietary Supplement|Riboflavin 1.6mg/d|Riboflavin 1.6mg/d
79403316|NCT04026685|Drug|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
79578314|NCT01884285|Drug|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
79578315|NCT01884285|Drug|Part D1: AZD2014 combination with AZD8186|Dose & schedule finding of AZD8186 in combination with AZD2014
79578316|NCT01884285|Drug|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
79578317|NCT01884285|Drug|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
79578318|NCT01884298|Drug|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
79578319|NCT01884298|Drug|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
79274247|NCT05488106|Dietary Supplement|Riboflavin 5mg/d|Riboflavin 5mg/d
79274248|NCT05488106|Dietary Supplement|Riboflavin 20mg/d|Riboflavin 20mg/d
79274249|NCT02233933|Other|Hemospray|hemospray is used after argon coagulation to stop bleeding
79274250|NCT05492318|Drug|ITF2357 Givinostat 10mg/mL|Dose: 10 mg/mL; Dosage form: oral suspension
79274251|NCT05492318|Drug|Midazolam 1Mg/Ml (Pf) Inj Syringe 5Ml|Dose: 1 mg/ml; Dosage form: solution for injection/infusion or rectal administration
79274252|NCT05492318|Drug|Midazolam Oral Liquid Product|Dose: 2.5 mg; Dosage form: oromucosal solution
79274253|NCT05492318|Drug|Dabigatran Etexilate 75 MG [Pradaxa]|Dose: 75 mg; Dosage form: hard capsules
79274254|NCT05492318|Drug|Clarithromycin 500Mg Tab|Dose: 500 mg; Dosage form: immediate-release film-coated tablets
79274255|NCT01337635|Drug|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
79274256|NCT02264041|Drug|Cilobradine, low dose|
79578320|NCT01884324|Other|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
79578321|NCT01884363|Other|Once ounce per day of walnuts|
79274257|NCT02264041|Drug|Cilobradine, high dose|
79274258|NCT02264041|Drug|Itraconazole|
79274259|NCT02234089|Drug|Degarelix|According to medical practice
79274260|NCT02234089|Drug|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
79274261|NCT05488028|Procedure|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
79274262|NCT05488028|Procedure|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
79274263|NCT02234167|Behavioral|Risk behaviour and infectious diseases|through counselling, testing vaccination
79403317|NCT04026685|Drug|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
79578322|NCT01884376|Device|Neuromaix|
79872923|NCT03580213|Other|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
79274264|NCT05492084|Other|without Intervention|without Intervention
79274265|NCT02261701|Other|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
79403318|NCT04024033|Dietary Supplement|pine cone extract|pine cone extract capsule
79403319|NCT04024033|Other|placebo|placebo capsule
79403320|NCT04026061|Behavioral|FMA group|A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
79578323|NCT01884389|Other|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
79578324|NCT01884402|Drug|Peginterferon alfa-2a|Treatment as usual clinical practice
79274266|NCT02261701|Other|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
79274267|NCT02261779|Drug|Tranylcypromine|
79578325|NCT01884402|Drug|Ribavirin|Treatment as usual clinical practice
79737707|NCT02706340|Other|No intervention - observational study only|
79737708|NCT04266561|Other|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
79737709|NCT02706184|Drug|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
79274268|NCT02261779|Drug|Tretinoin|
79274269|NCT05487872|Behavioral|Mindfulness skills training to reduce experiential avoidance and anxiety symptoms|The intervention aimed to increase participants' mindfulness skills which may be critical in decreasing general experiential avoidance and anxiety symptoms
79274270|NCT02261857|Device|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
79274271|NCT02261935|Other|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
79403321|NCT04026061|Behavioral|Control group|Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
79578326|NCT01884415|Biological|HBV vaccine|Patients receive a second cycle of vaccination
79737710|NCT02706184|Drug|Placebo|Placebo
79737711|NCT04264689|Procedure|serratus anterior block|ultrasound guided block
79737712|NCT04264689|Procedure|thoracic epidural|thoracic epidural
79737713|NCT04264689|Procedure|erector spinae block|ultrasound guided block
79737714|NCT05265676|Drug|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
79274272|NCT02261935|Other|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
79274273|NCT02556710|Biological|4 mL injection of AMPION™|4 mL Injection of Ampion
79274274|NCT02556710|Drug|4 mL injection of Placebo|4 mL Injection of Placebo
79274275|NCT02262013|Behavioral|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
79274276|NCT02262013|Behavioral|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
79274277|NCT01515241|Drug|CER-001|Weekly injection
79578327|NCT01884415|Biological|HBV vaccine|Patients receive vaccination according to the guidelines.
79274278|NCT05157685|Drug|Azithromycin Oral Tablet|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
79274279|NCT05157685|Drug|Placebo|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
79274280|NCT02556632|Drug|Curcumin-based Gel|Applied topically
79274281|NCT02556632|Procedure|Dermatologic Complications Management|Apply HPR Plus topically
79274282|NCT02556632|Other|Laboratory Biomarker Analysis|Correlative studies
79578328|NCT01884428|Drug|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
79872924|NCT03580213|Other|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
79274283|NCT02556632|Other|Placebo|Apply placebo gel topically
79274284|NCT02556632|Other|Questionnaire Administration|Ancillary studies
79274285|NCT05135611|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
79737715|NCT05265676|Drug|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
79872925|NCT03576417|Drug|Cisplatin|Intravenous
79872926|NCT03576417|Drug|Nivolumab|Intravenous
79872927|NCT03576417|Radiation|RT|IMRT 66 Gy / 6.5 weeks
79274286|NCT05132803|Drug|HPV 16 TA-CIN|No dose escalation or reduction
79274287|NCT05482490|Procedure|Maintenance protocol for the hygiene of implant supported prosthesis|Sequence of phases that include the hygiene and cleaning of the prosthesis and the implants, the motivation of the patients and reinforcement of oral hygiene.
79274288|NCT02262091|Dietary Supplement|Food fibers|
79274289|NCT02262091|Dietary Supplement|Maltodextrin|
79872928|NCT03570827|Drug|Androgen Suppression|Given androgen suppression therapy
79872929|NCT03570827|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
79274290|NCT02262091|Biological|Influenza vaccine (incl. criterion)|
79274291|NCT05491928|Drug|Tempol|Tempol will be given as an adjunct to chemotherapy.
79274292|NCT02613949|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
79274293|NCT05487716|Behavioral|High-intensity interval training (HIIT)|Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
79578329|NCT01884428|Drug|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
79578330|NCT01884428|Drug|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
79578331|NCT01884428|Drug|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
79578332|NCT01884428|Drug|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
79872930|NCT03570827|Other|Quality-of-Life Assessment|Ancillary studies
79872931|NCT03570827|Other|Questionnaire Administration|Ancillary studies
79872932|NCT03529019|Drug|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
79872933|NCT03529019|Drug|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
79872934|NCT03404310|Dietary Supplement|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
79872935|NCT03404310|Other|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
80030243|NCT04929652|Drug|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"Dose climbing stage design (n=12) :~Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed > DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with > developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~Dose expansion phase design(n=36):~Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~Irinotecan: 200mg/㎡, iv, D1, 3w;~GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
80030244|NCT04929574|Diagnostic Test|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
79274294|NCT02611609|Biological|MultiStem|
79274295|NCT02611609|Biological|MultiStem|
79274296|NCT02611609|Biological|Placebo|
79274297|NCT05487638|Other|Nursing Education and Counseling Service Provided to Patients by Video Calling on the Phone|Nursing Education and Counseling Services were provided to the patients by video calling on the phone for the problems they may encounter in the postoperative period.
79274298|NCT02610283|Drug|QPI-1002|IV injection
79274299|NCT02610283|Drug|Placebo|isotonic saline
79274300|NCT05491850|Other|Moderate Physical Activity for Peripheral Diabetic Neuropathy|Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
79403322|NCT00751179|Drug|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
79403323|NCT00751179|Drug|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
79403324|NCT00751179|Drug|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
79403325|NCT04766281|Dietary Supplement|MLC901|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
79578333|NCT01884441|Drug|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
79578334|NCT01884441|Drug|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
79737716|NCT00606333|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
79578335|NCT01884441|Drug|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
79737717|NCT00606333|Device|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
79872936|NCT03399721|Device|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
79872937|NCT03399721|Device|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
79872938|NCT03387553|Biological|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
80030245|NCT04394949|Behavioral|Center for Independent Living SEEKS Team|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
79274301|NCT01515007|Drug|Ciprofloxacin dispersion for inhalation|
79274302|NCT01515007|Drug|Placebo|
79274303|NCT05482178|Behavioral|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (>25g per day)."
79274304|NCT05482178|Behavioral|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (>25g per day).
79274305|NCT05487560|Drug|Esomezol Cap|Esomezol Cap, Once daily administered per the locally approved product information
79578336|NCT01884454|Behavioral|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
79578337|NCT01884467|Drug|Gentamicin|Comparison of Gentamicin versus placebo
79578338|NCT01884467|Drug|Placebo|
79578339|NCT01884493|Device|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
79578340|NCT01884493|Device|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
79274306|NCT05482100|Diagnostic Test|Patients monitored with OmniGraf testing|This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.
79737718|NCT04264611|Other|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
79578341|NCT01884506|Dietary Supplement|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
79274307|NCT02262169|Drug|Omeprazole|2 Omeprazole capsules 20 mg, once daily
79274308|NCT02262169|Drug|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
79578342|NCT01884506|Dietary Supplement|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
79737719|NCT04264611|Other|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
79737720|NCT05265442|Drug|Methadone|titration of Zoryon (methadone): increase of posology untill pain relieved is reached
79737721|NCT05265130|Drug|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
79274309|NCT02262169|Drug|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
79737722|NCT05265130|Drug|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
79737723|NCT02691117|Drug|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
79737724|NCT02693626|Behavioral|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
79872939|NCT03387553|Drug|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
79274310|NCT02262169|Drug|Placebo capsule of Omeprazole|2 placebo capsules of Omeprazole, once daily
79274311|NCT05491694|Drug|Toripalimab|Toripalimab 240mg
79274312|NCT05491694|Drug|Epirubicin|90mg/m2，IVD，q3w
79274313|NCT05491694|Procedure|High Intensity Focused Ultrasoun|HIFU treatment at lesion site
79274314|NCT05491694|Drug|Cyclophosphamide|600mg/m2，IVD，q3w
79737725|NCT02693626|Behavioral|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
79737726|NCT04266405|Dietary Supplement|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
79737727|NCT04266405|Dietary Supplement|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
79737728|NCT05264662|Drug|Adacel (Tdap)|Administer Adacel to hiv infected and hiv uninfected pregnant mothers
79737729|NCT00606411|Drug|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
79274315|NCT05491694|Drug|Carboplatin|AUC 5，IVD，q3w
79274316|NCT05491694|Drug|Nab-paclitaxel|260mg/m2，IVD，q3w
79274317|NCT05487482|Other|Ageing Safe from the Risk (ASRi) Model of safety culture|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.
79872940|NCT03387553|Procedure|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
79872941|NCT03367533|Drug|Ketamine|Intravenous ketamine
79872942|NCT03367533|Drug|Perampanel|Oral perampanel (6 mg)
79274320|NCT01499563|Drug|ITI-007|Capsules containing ITI-007 for 28 days
79274321|NCT01499563|Drug|Placebo|Capsules containing inactive placebo for 28 days
79578343|NCT01884532|Device|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
79578344|NCT01884558|Drug|isavuconazole|oral
79578345|NCT01884558|Drug|metformin|oral
79737730|NCT00631293|Dietary Supplement|lactisole|administration of lactisole followed by placebo
79737731|NCT00631293|Other|placebo|administration of placebo followed by lactisole
79737732|NCT00612196|Drug|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
79737733|NCT00612196|Drug|Placebo|
79737734|NCT00607737|Drug|insulin detemir|3 cutaneous injections
79737735|NCT00607737|Drug|saline|3 cutaneous injections
79737736|NCT05264428|Dietary Supplement|Honey|Participants need to drink honey every day for four weeks.
79737737|NCT05264428|Dietary Supplement|Water|Participants need to drink water every day for four weeks.
79872943|NCT03367533|Drug|Placebo|Oral placebo
79872944|NCT03340896|Drug|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
79872945|NCT03340896|Drug|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
79872946|NCT03340896|Drug|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
79274322|NCT01499563|Drug|Risperidone|Capsules containing risperidone for 28 days
80030246|NCT04394949|Other|Usual Care|Consumers will get same CIL services they would get if they were not enrolled in the study.
79737738|NCT05264272|Other|Prospective serological assays|"Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
80030247|NCT04929418|Other|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
80030248|NCT04929418|Other|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
80030249|NCT04929340|Other|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
79274323|NCT05481944|Diagnostic Test|MRI in patients|Injected MRI
79274324|NCT05481944|Diagnostic Test|MRI in healthy volunteers|non injected MRI
79274325|NCT01491529|Drug|AFQ056|"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
79274326|NCT01491529|Drug|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
79274327|NCT05481866|Other|Oropharyngeal administration of colostrum|The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours.
79274328|NCT05481866|Other|Oropharyngeal administration of sterile water|The control group will be given 0.2ml sterile water for oropharyngeal administration every 3 hours.
79274329|NCT03922880|Drug|ADI PEG20|ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
79274330|NCT03922880|Drug|Nivolumab|Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
79274331|NCT03922880|Drug|Ipilimumab|Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
79274332|NCT02262403|Other|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
79578346|NCT01884584|Drug|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
79737739|NCT05264272|Other|Retrospective serological assays|"Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
79274333|NCT02264119|Drug|Lefradafiban tablet|
79274334|NCT02264119|Drug|Pantoprazole tablet|
79274335|NCT02264119|Device|Lefradafiban double chamber sachet|
79872947|NCT03340896|Radiation|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
79872948|NCT03299088|Biological|Pembrolizumab|Given IV
79872949|NCT03299088|Drug|Trametinib|Given PO
79872950|NCT03290079|Drug|Pembrolizumab|200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
79274336|NCT05481632|Other|Endoangel assisted the process of colonoscopy|Endoangel assisted doctors to detect polyps
79274337|NCT05481632|Other|Colonoscopy was performed without endoangel assistance|Polyps were detected without ENDOANGEL assistance
79274338|NCT02262481|Drug|dydrogesterone|
79274339|NCT02262481|Drug|placebo|
79872951|NCT03290079|Drug|Lenvatinib|20 mg Lenvatinib by mouth every day of each 3 week cycle
79274340|NCT02264197|Drug|BIBX 245 CL - fed|
79274341|NCT02264197|Drug|BIBX 245 CL- fasted|
79274342|NCT01437787|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
79274343|NCT01437787|Drug|Placebo|"Pharmaceutical form:capsule~Route of administration: oral"
79274344|NCT01435369|Drug|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
79274345|NCT01257607|Drug|MIM-D3 Ophthalmic Solution|28 Days, BID
79274346|NCT01257607|Drug|Placebo Ophthalmic Solution|28 Days, BID
79578347|NCT01884636|Drug|isavuconazole|oral
79578348|NCT01884636|Drug|methotrexate|oral
79578349|NCT01884662|Behavioral|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
79578350|NCT01884662|Behavioral|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
79578351|NCT01884701|Device|ENABLER-P Catheter System|
79872952|NCT03272464|Drug|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
79872953|NCT03272464|Drug|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
80030250|NCT04929340|Other|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
80030251|NCT04929106|Device|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
79274347|NCT02264275|Behavioral|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
79274348|NCT01487083|Drug|Pomaglumetad methionil|Administered orally
79274349|NCT01662440|Biological|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
79403326|NCT04766281|Genetic|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
79578352|NCT01884714|Other|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
79737740|NCT01120691|Drug|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
79737741|NCT01120691|Drug|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
79872954|NCT03272464|Drug|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
79403327|NCT01273233|Biological|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
79403328|NCT01273233|Other|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
79737742|NCT01120691|Drug|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
79737743|NCT01120691|Drug|Salbutamol/albuterol|As needed throughout the study
79737744|NCT00612274|Drug|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
79872955|NCT03263481|Procedure|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
79872956|NCT03162536|Drug|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
80030252|NCT01353963|Drug|desvenlafaxine succinate|50 mg tablet once daily
80030253|NCT04928404|Procedure|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
80030254|NCT04927936|Biological|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
80030255|NCT04927936|Biological|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
79274350|NCT01662440|Biological|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
79274351|NCT01662440|Other|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
79274352|NCT01253629|Drug|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
79274353|NCT01253629|Drug|Placebo|Placebo medication identical in appearance to active medication was provided
79403329|NCT01278693|Drug|L-carnitine|500 mg,twice daily, 16 weeks
79578353|NCT01884727|Dietary Supplement|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
80030256|NCT04927936|Biological|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
79403330|NCT01278693|Drug|placebo|500 mg,twice daily, 16 weeks.
79403331|NCT01277211|Drug|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
80030257|NCT04927936|Biological|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
79737745|NCT00612274|Drug|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
79274354|NCT01252693|Drug|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
79274355|NCT01252693|Drug|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
79578354|NCT01884727|Dietary Supplement|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
79578355|NCT01884792|Other|Sitting OGTT|
79578356|NCT01884792|Other|Standing OGTT|
79578357|NCT01884792|Other|Sitting CGM|
79578358|NCT01884792|Other|Standing CGM|
79737746|NCT00612274|Drug|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
79737747|NCT05263882|Drug|Gemcitabine combined with eribulin|"Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
79872957|NCT03155737|Other|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
79872958|NCT03155737|Other|Knee health education|A course regarding knee health will be offered to the subjects in this group.
79872959|NCT03128151|Behavioral|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
79274356|NCT05481554|Biological|Stool sample|Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
79872960|NCT03110224|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
79872961|NCT03082248|Other|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
79274357|NCT05486936|Radiation|hypofractionated radiation|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
79274358|NCT01433497|Drug|Masitinib|
79274359|NCT01433497|Drug|Placebo|
79274360|NCT01662362|Device|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
79274361|NCT05481476|Drug|Surufatinib|250mg, qd, po, 21 days for a cycle
79578359|NCT01884805|Device|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
79737748|NCT02725138|Dietary Supplement|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
79737749|NCT02725138|Other|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
80030258|NCT04928248|Other|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
80030259|NCT04167813|Drug|Ondansetron 8mg or matched placebo tablets|"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"
79578360|NCT01884818|Other|Manipulation vs. TNS thoracic pain|
79872962|NCT03082248|Procedure|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
79872963|NCT03079011|Drug|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
79872964|NCT03079011|Drug|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
79872965|NCT03079011|Drug|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
79872966|NCT03038828|Biological|Leukocyte Interleukin, Injection|Immunotherapy
80030260|NCT04928638|Behavioral|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
80030261|NCT04928638|Behavioral|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
80030262|NCT04928716|Other|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
79274362|NCT05481476|Drug|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
79274363|NCT05481476|Drug|AG|nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
79403332|NCT01277211|Drug|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
79737750|NCT05261230|Behavioral|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
79737751|NCT05261230|Behavioral|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
79737752|NCT05261152|Drug|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
79872967|NCT02964624|Other|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
80030263|NCT04928560|Diagnostic Test|SMI|ULTRASOUND
80030264|NCT03562533|Drug|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
80030265|NCT03562533|Drug|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
80030266|NCT04927858|Drug|Empagliflozin|Empagliflozin
79274364|NCT01486849|Drug|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
79274365|NCT01486849|Drug|Placebo|Matching placebo tablets BID for 21 days
79274366|NCT01486849|Drug|Riluzole 50 MG|
79274367|NCT01484119|Drug|ACT-129968|daily tablets
79274368|NCT01484119|Drug|Placebo|matching placebo tablets and capsules
79274369|NCT01484119|Drug|Cetirizine|daily capsules
79274370|NCT05486858|Other|MSK ultrasonograpy|MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
79274371|NCT05486858|Other|sitting Functional and Lateral Reach Test|Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
79274372|NCT02265055|Procedure|transfer early cleavage embryos|transfer early cleavage embryos
79274373|NCT02265055|Procedure|transfer non early cleavage embryo|
79274374|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
79274375|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
79274376|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 24 weeks
79274377|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 48 weeks
79403333|NCT04022161|Drug|Nitrogen Gas for Inhalation|See arm description
79403334|NCT04022161|Other|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
79403335|NCT04022161|Drug|Nitric Oxide|See arm description
79403336|NCT01676220|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
79737753|NCT05261074|Other|No intervention|No intervention (retrospective study)
79737754|NCT05260996|Other|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
79737755|NCT02724904|Procedure|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
79737756|NCT02724904|Drug|Fludarabine|Standard Treatment
79737757|NCT02724904|Drug|Thiotepa|Standard Treatment
79737758|NCT02724904|Drug|Methotrexate|IV Bolus
79737759|NCT00935493|Drug|Guanfacine|Guanfacine 0.1 mg po qhs
80030267|NCT03821727|Procedure|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
80030268|NCT04927624|Procedure|transversus abdominis plane block|The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
80030269|NCT04927624|Procedure|quoadratus lumborum block|quoadratus lumborum block
80030270|NCT02820597|Device|ClariFix device|
80030271|NCT04927546|Behavioral|Exercise|Thirty minutes of aerobic exercise in a treadmill.
79274378|NCT01482403|Drug|boceprevir|800 mg three times a day for 24 weeks
79274379|NCT01482403|Drug|boceprevir|800 mg three times a day for 48 weeks
79274380|NCT01482403|Drug|mericitabine|1000 mg twice daily for 24 weeks
79274381|NCT01482403|Drug|mericitabine placebo|mericitabine placebo
79274382|NCT01482403|Drug|boceprevir placebo|boceprevir placebo
79737760|NCT00935493|Drug|Guanfacine|Guanfacine 0.5 mg po qhs
79872968|NCT02866383|Drug|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
80030272|NCT04927468|Procedure|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
80030273|NCT04927468|Procedure|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
79274383|NCT01482403|Drug|boceprevir|800 mg three times a day for 44 weeks
79274384|NCT05486780|Behavioral|Digital Window|For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. Data collection will be completed by the researcher completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the experimental group who are in the field of view of the digital window.
79274385|NCT01481077|Drug|Latanoprost-PPDS|Sustained release for 12 weeks
79274386|NCT02265211|Behavioral|Self-Help App|
79274387|NCT05481398|Other|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
79274388|NCT02268331|Other|Active Surveillance|
79274389|NCT02268331|Other|Passive Surveillance|
79274390|NCT05486702|Other|Time Restricted Eating|Time restricted eating (TRE) can be divided into early TRE (eTRE) and late TRE (lTRE), depending on the time of day of the eating window.
79274391|NCT05486624|Other|Reiki|Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
79578361|NCT01884831|Biological|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
79578362|NCT01884857|Drug|Metoprolol Succinate ER Tablets 50 mg|1* 50 mg tablet once a day
79578363|NCT01884857|Drug|'TOPROL-XL®' ER Tablets 50 mg|1 * 50 mg tablet per day
79578364|NCT01884870|Procedure|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
79274392|NCT02268409|Drug|ACE-536|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
79274393|NCT02268487|Drug|Sertraline|Treatment
79274394|NCT02265289|Drug|Lefradafiban|
79274395|NCT02265289|Drug|Clopidogrel|
79274396|NCT04271228|Device|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
79274397|NCT02265445|Drug|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
79274398|NCT02265445|Drug|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
79274399|NCT04476121|Procedure|PRF application|PRF application into post-operative wound.
79274400|NCT04476121|Drug|Nipas application|Nipas application into post-operative wound.
79274401|NCT01234519|Drug|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
79274402|NCT01234519|Drug|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
79274403|NCT01474135|Drug|0.25% AR-12286 / 0.004% travoprost|
79274404|NCT01474135|Drug|0.5% AR-12286, 0.004% travoprost|
79274405|NCT01474135|Drug|0.004% Travoprost|
79274406|NCT02554682|Behavioral|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.
79578365|NCT01884883|Device|PROTEOR Internal unicompartmental knee brace|
79578366|NCT01884896|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
79578367|NCT01884896|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
79737761|NCT00935493|Drug|Placebo|Placebo po qhs
79737762|NCT05380245|Drug|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
79737763|NCT05380245|Drug|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
79737764|NCT03856996|Biological|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
79578368|NCT01884909|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
79578369|NCT01884909|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
79578370|NCT01884935|Biological|Natalizumab|As specified in the treatment arm
79578371|NCT01884948|Drug|Omegaven™|
79737765|NCT03856996|Biological|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
79872969|NCT02866383|Drug|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
79872970|NCT02866383|Radiation|Radiotherapy|15 Gy x 1 fraction given on day 1
79872971|NCT02841215|Drug|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
79872972|NCT02841215|Drug|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
79737766|NCT03856996|Biological|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
79274407|NCT02554682|Behavioral|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
79274408|NCT02554682|Behavioral|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
79274409|NCT02268565|Drug|Aspirin|81mg aspirin daily at bedtime over a 2 week period
79578372|NCT01884961|Other|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
79578373|NCT01884974|Other|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
79578374|NCT01884987|Drug|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
79578375|NCT01885013|Drug|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
79578376|NCT01885013|Drug|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
79578377|NCT01885026|Behavioral|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
79578378|NCT01885026|Behavioral|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
79737767|NCT05378685|Procedure|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
79872973|NCT02807571|Procedure|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
79403337|NCT01676220|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
79274410|NCT02268565|Drug|Placebo|pill that looks like aspirin without the effects of aspirin
79403338|NCT04027231|Other|analysis of the synovial fluid|Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
79403339|NCT04026997|Drug|CIN-102 Dose 1|CIN-102 Dose 1
79578379|NCT01885026|Behavioral|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
79578380|NCT01885052|Behavioral|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
79578381|NCT01885052|Behavioral|Low Contact|
79578382|NCT01885065|Other|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
79737768|NCT03853252|Other|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
79737769|NCT02724826|Behavioral|Qigong therapy|Medical qigong
79737770|NCT02724826|Behavioral|Exercise therapy|Regular exercise
79737771|NCT00605241|Drug|GSK598809|Drug
79737772|NCT04266171|Behavioral|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
79872974|NCT02804542|Other|Observational|
79403340|NCT04026997|Drug|CIN-102 Dose 2|CIN-102 Dose 2
79578383|NCT01885091|Other|Kinerase|
79274411|NCT02268643|Other|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
79578384|NCT01885143|Radiation|Digital Breast Tomosynthesis|
79872975|NCT02804542|Other|Retrospective review|
79872976|NCT02798601|Other|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
79872977|NCT02793466|Drug|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
79872978|NCT02767557|Drug|Tocilizumab|Intravenous infusion
79872979|NCT02767557|Drug|Gemcitabine|Intravenous infusion
79872980|NCT02767557|Drug|nab-Paclitaxel|Intravenous infusion,
79872981|NCT02594917|Procedure|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
79872982|NCT02594917|Other|Blood draw|Test and control group will be asked to give 20 ml of blood samples
79872983|NCT02463708|Behavioral|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
79872984|NCT02461368|Procedure|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
80030274|NCT03056716|Procedure|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
79274412|NCT01420783|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
79274413|NCT05479448|Other|Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness)|Biological material will be sampled at three time-points. The first time-point will be when patients have been treated with 15 mg of prednisone per day for at least 5 days. A second time-point will be after prednisone was successfully tapered and maintained at 5 mg per day for at least 5 days, a third time point will be 4 weeks after the stop of prednisone. Biosampling is done for cellular analyses, pharmacokinetics and hormone measurements.
79274414|NCT05479448|Other|Data collection for exploratory analyses of endogenous steroid hormones|Concentrations of GC, MC, androgens and progestins will be determined and the suppression of cortisol and cortisone upon prednisone treatment will be analyzed.
79274415|NCT05479448|Other|Data collection for correlation between clinical defined and lab defined GC responsivness|The time to first relapse, the cumulative steroid dose at 1 year after diagnosis, the need for treatment with steroid sparing agents and the GTI after 1 year will be correlated to the percentage of in vitro inhibition of cytokine concentration by dexamethasone treatment, to the prednisone/prednisolone ratio in plasma, to the percentage of endogenous GC suppression (plasma and urinary cortisol and cortisone) by prednisone treatment. Furthermore, correlations of steroid sensitivity with Mineralocorticoid (MC) and androgens will be investigated.
79274416|NCT05479448|Other|Data collection for Prednisone metabolism|Plasma concentrations of prednisone and its active metabolite prednisolone will be quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). If changes on prednisone/prednisolone are observed, the quantification of the 6-hydroxylated prednisone/prednisolone metabolites in 24 h urine samples will be performed to estimate their metabolism as well as the ratio of inactive to active GC.
79274417|NCT02265523|Other|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
79274418|NCT05475626|Procedure|Arthroereisis-|Surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.
79578385|NCT01885169|Biological|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
79578386|NCT01885221|Behavioral|Multimedia Support Intervention|
79737773|NCT04266171|Behavioral|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
79737774|NCT00935259|Drug|Simvastatin|40 mg once daily for 2 weeks
79737775|NCT00935259|Drug|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
79737776|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
79737777|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
79737778|NCT02724748|Behavioral|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
79274419|NCT01472887|Drug|SAR3419|"Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous"
79274420|NCT05479292|Other|Sars-CoV-2 outbreak|Sars-CoV-2 pandemic's impact on provision of healthcare for cancer patients
79274421|NCT05481008|Device|transcatheter aortic valve implantation|All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
79578387|NCT01885234|Other|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
79578388|NCT01885234|Other|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
79578389|NCT01885273|Procedure|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
79578390|NCT01885273|Procedure|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
79578391|NCT01885286|Procedure|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
79578392|NCT01885312|Behavioral|Adaptive Tailored Intervention|Adaptive
79737779|NCT05260450|Device|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
79737780|NCT00606567|Other|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
79737781|NCT04267419|Diagnostic Test|salivary biomarker|MDA and NO as salivary biomarkers
80030275|NCT03056560|Behavioral|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
80030276|NCT04927000|Drug|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
80030277|NCT02822235|Other|No Intervention|
79737782|NCT05378451|Procedure|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
79274422|NCT02268721|Device|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
79274423|NCT05480852|Other|Bis-GMA Free dental resin composite|Restorative Material
79274424|NCT02264509|Procedure|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
79274425|NCT01466725|Drug|CC-930|
79274426|NCT01466725|Drug|Placebo|Placebo
79274427|NCT05475548|Device|powerscope|The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
79274428|NCT04423562|Other|No intervention|No intervention
79274429|NCT02264587|Drug|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
79274430|NCT02264587|Drug|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
79274431|NCT05475470|Procedure|finger-blade technique|laparoscopic access technique for group a
79274432|NCT05475470|Procedure|Hasson's technique|laparoscopic access technique for group b
79578393|NCT01885312|Behavioral|Consequence-based Intervention|Loss Framed
79578394|NCT01885312|Behavioral|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
79578395|NCT01885312|Other|Assessment only|EMA only
79737783|NCT00606645|Biological|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
79872985|NCT02461368|Procedure|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
79274433|NCT05475470|Procedure|veress needle technique|laparoscopic access technique for group c
79274434|NCT01229215|Drug|FCFD4514S|Repeating intravitreal injection
79274435|NCT01229215|Drug|sham|Repeating sham injection
79274436|NCT05475080|Drug|Antiplatelet Drug|Any antiplatelet drug or combination
79274437|NCT05475080|Drug|Anticoagulant|Any anticoagulante
79403341|NCT04026997|Drug|CIN-102 Dose 3|CIN-102 Dose 3
79403342|NCT04026997|Drug|Placebo|Placebo
79737784|NCT02724670|Radiation|IGRT|MR-based IGRT
79872986|NCT02400190|Other|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
79872987|NCT02373072|Drug|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
79274438|NCT05475080|Procedure|Endovascular|Angioplasty +- stent
79274439|NCT05475080|Procedure|Surgery|Endarterectomy
79274440|NCT01228513|Drug|ZK245186|Daily topical application
79274441|NCT01228513|Drug|Placebo (vehicle without active ingredient)|Daily topical application
79274442|NCT04563572|Device|PPG Smartwatch|Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
79403343|NCT01275105|Drug|Vehicle|one drop in each eye at designated visits
79403344|NCT01275105|Drug|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
79403345|NCT01275105|Drug|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
79578396|NCT01885325|Other|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
79578397|NCT01885338|Drug|N-acetylcysteine (NAC)|
79578398|NCT01885338|Drug|Inactive placebo capsule|
79578399|NCT01885351|Behavioral|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
79872988|NCT02373072|Drug|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
79274443|NCT04269434|Other|No Screening|the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
79737785|NCT04267341|Other|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
79737786|NCT04267341|Other|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
79737787|NCT04267341|Other|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
79737788|NCT02724514|Other|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
79737789|NCT05260372|Diagnostic Test|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
79274444|NCT05474300|Other|mechanical ventilation|Pressure controlled ventilation mode on mechanical ventilation
79274445|NCT03782402|Drug|Cannabinoids|Cannabinoids with THC and CBD versus placebo cannabinoids
79274446|NCT05478668|Other|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
79274447|NCT00154063|Drug|E2007|
79737790|NCT04264377|Procedure|Bronchoscopy|Bronchoscopy for retrieval of airway cells
79737791|NCT05260294|Procedure|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
79737792|NCT00606723|Biological|Hematopoietic stem cells from bone marrow or peripheral blood|> = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
79737793|NCT03826576|Behavioral|Multicomponent intervention|"The multicomponent intervention will be consist of:~Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~Nutritional and food allergen analysis of the menu of the restaurant~Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~Marketing campaign about healthy and food allergen adapted menus in the restaurants"
79737794|NCT00607971|Drug|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
79737795|NCT02724436|Procedure|TACE|
79737796|NCT02724436|Procedure|radioembolization with Y-90|radioembolization with Y-90
79737797|NCT01120379|Device|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
79872989|NCT02373072|Drug|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
79872990|NCT02303678|Drug|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
79872991|NCT02292004|Device|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
79872992|NCT02292004|Procedure|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
79872993|NCT02285140|Drug|Cefazolin|administration as outlined
79274448|NCT00154063|Other|Placebo|
79274449|NCT02683941|Drug|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
79274450|NCT02683941|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
79274451|NCT02683941|Drug|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator
79274452|NCT01463059|Biological|Placebo|Placebo solution for injection, administered as subcutaneous injections
79274453|NCT01463059|Biological|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
79274454|NCT01463059|Biological|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
79274455|NCT01463059|Biological|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
79274456|NCT01401985|Drug|TD-1211|Capsules
79274457|NCT01401985|Drug|Placebo|Capsules
79274458|NCT01225393|Drug|MLTA3698A|Subcutaneous repeating dose
79403346|NCT01275105|Drug|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
79737798|NCT02724358|Procedure|TACE|iodized oil (5ml) + Pirarubicin (20mg)
79737799|NCT02724358|Drug|Rg3|20mg, BID, maintained though Month 12.
79737800|NCT02724358|Other|TACE + Rg3|
79274459|NCT01225393|Drug|adalimumab|Subcutaneous repeating dose
79274460|NCT01225393|Drug|leflunomide|Stable dose if not on methotrexate
79872994|NCT02285140|Drug|Vancomycin|administration as outlined
79872995|NCT02254278|Drug|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
79872996|NCT02254278|Radiation|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
79274461|NCT01225393|Drug|methotrexate|Stable dose if not on leflunomide
79274462|NCT01225393|Drug|placebo|Subcutaneous repeating dose
79274463|NCT02678247|Device|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
79578400|NCT01885351|Behavioral|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
79578401|NCT01885364|Drug|Normal saline|intravenous injection with normal saline before injection of propofol
79274464|NCT02678247|Device|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
79274465|NCT01225315|Drug|Placebo|Matching placebo administered orally twice daily
79274466|NCT01225315|Drug|Setipiprant|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
79274467|NCT01223911|Drug|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
79274468|NCT01223911|Drug|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
79274469|NCT01457677|Drug|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
79274470|NCT01457677|Drug|RO4995819|5 mg oral once daily for 6 weeks
79274471|NCT01457677|Drug|RO4995819|15 mg oral once daily for 6 weeks
79274472|NCT01457677|Drug|RO4995819|30 mg oral once daily for 6 weeks
79274473|NCT02683785|Drug|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
79274474|NCT02683785|Drug|Placebo|Matching placebo will be administered as above.
79274475|NCT02264743|Drug|Femoston Conti|Ultra-low-dose oral E2/D [Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg] oral Femoston Conti 0.5mg Estradiol&Dydrogesterone vs Oestradiol&Norethisterone acetate
79274476|NCT02264743|Drug|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
79274477|NCT01220947|Drug|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
79403347|NCT01273389|Drug|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
79403348|NCT01273389|Drug|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
79737801|NCT02724358|Procedure|protective therapy|standard liver protective therapy
79274478|NCT01220947|Drug|Danoprevir|Danoprevir 50 mg BID
79274479|NCT01220947|Drug|Danoprevir|Danoprevir 100 mg BID
79403349|NCT03951337|Drug|64Cu-ATSM|64 Cu-ATSM PET/CT scan
79737802|NCT05260138|Other|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
79872997|NCT02254278|Radiation|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
79872998|NCT02174549|Drug|Tirapazamine|Intra-arterial injection into the tumor feeding artery
79274480|NCT01220947|Drug|Danoprevir|Danoprevir 200 mg BID
79274481|NCT01220947|Drug|Pegasys|Pegasys 180 microgram sc qw
79274482|NCT01220947|Drug|Ritonavir|Ritonavir 100 mg
79274483|NCT02265679|Drug|BIIL 284 BS, low dose, pediatric patients|
79274484|NCT02265679|Drug|BIIL 284 BS, medium dose, pediatric patients|
79274485|NCT02265679|Drug|BIIL 284 BS, high dose, pediatric patients|
79274486|NCT02265679|Drug|BIIL 284 BS, low dose, adult patients|
79274487|NCT02265679|Drug|BIIL 284 BS, medium dose, adult patients|
79274488|NCT02265679|Drug|BIIL 284 BS, high dose, adult patients|
79274489|NCT02265679|Drug|Placebo|
79274490|NCT01397227|Biological|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
79274491|NCT01397227|Biological|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
79274492|NCT01397227|Biological|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
79274493|NCT01396213|Drug|Larazotide Acetate|gelatin capsule
79274494|NCT01396213|Drug|placebo|gelatin capsule
79274495|NCT01393639|Drug|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
79274496|NCT01393639|Drug|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
79274497|NCT01393639|Drug|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
79274498|NCT01393639|Drug|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
79274499|NCT01393639|Drug|prednisone|5 mg capsule once daily for 8 weeks
79578402|NCT01885364|Drug|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
79578403|NCT01885364|Drug|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
80030278|NCT04927078|Other|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
79578404|NCT01885364|Drug|propofol|intravenous injection after pretreatment
80030279|NCT04926532|Drug|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
80030280|NCT04926532|Drug|Sorafenib|Sorafenib is a multi-kinase inhibitor
80030281|NCT04925674|Drug|HEC53856|"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."
80030282|NCT04925596|Behavioral|ePrimaPrescribe online educational program|online training program aiming to change general practitioners' benzodiazepine prescription
80030283|NCT04925596|Behavioral|ComunicaSaudeMental online educational program|online training program aiming to improve general practitioners' communication with mentally ill patients
80030284|NCT02035995|Other|Pregnant volunteers with GDM|
80030285|NCT04925518|Device|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
80030286|NCT04925518|Device|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
80030287|NCT04925362|Other|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~added for the research : blood, urine, stools~collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
79578405|NCT01885390|Device|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
79737803|NCT05260138|Other|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
79737804|NCT00608049|Behavioral|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
79737805|NCT00608049|Behavioral|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
79737806|NCT00608049|Behavioral|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
80030288|NCT04925362|Other|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
80030289|NCT04924894|Other|no intervention|no intervention
80030290|NCT03842709|Drug|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
80030291|NCT03842709|Other|Placebo|Administration of placebo
79578406|NCT01885403|Device|non-invasive respiratory parameter measurements|
79578407|NCT01885416|Other|consumption of test meal based on dairy products|
79578408|NCT01885416|Other|consumption of high fat test meal without dairy products|
79578409|NCT01885416|Other|consumption of high fat test meal with dairy products|
79578410|NCT01885429|Dietary Supplement|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
79578411|NCT01885429|Dietary Supplement|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
80030292|NCT04924816|Procedure|Awake prone position|The prone position in awake patients consists of asking the patient to voluntarily change to prone position, in a swimmer's posture
80030293|NCT05707533|Procedure|TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
80030294|NCT03056482|Drug|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
80030295|NCT03056482|Drug|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
80030296|NCT03056482|Drug|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
80030297|NCT02817555|Drug|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin > 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
80030298|NCT02817555|Drug|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin >150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
80030299|NCT04924738|Behavioral|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
79274500|NCT01393639|Other|prednisone|10 mg capsule once daily for 8 weeks
79274501|NCT01393639|Other|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
79274502|NCT02265757|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
79274503|NCT02265757|Behavioral|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
79274504|NCT02265757|Behavioral|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
79274505|NCT02265757|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
79274506|NCT02265757|Behavioral|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
79274507|NCT02265835|Other|no intervention|no intervention
79737807|NCT00608049|Behavioral|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
79274508|NCT02265991|Procedure|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
79403350|NCT04026139|Other|Elastic Band Resistance Exercise|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
79737808|NCT05259748|Behavioral|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
79737809|NCT02724202|Drug|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
79737810|NCT02724202|Drug|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
79872999|NCT02174549|Procedure|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
79873000|NCT02145000|Biological|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
79873001|NCT02145000|Biological|Placebo|
79873002|NCT02059499|Drug|imiquimod|Given intra-anally
79873003|NCT02059499|Drug|fluorouracil|Given intra-anally
80030300|NCT04924192|Drug|TQB3616 capsules|A CDK4/6 kinase inhibitor
80030301|NCT04924192|Drug|Anlotinib Hydrochloride capsules|A multi-target receptor tyrosine kinase inhibitor
79873004|NCT02059499|Other|questionnaire administration|Ancillary studies
79873005|NCT02059499|Other|laboratory biomarker analysis|Correlative studies
79873006|NCT01998841|Drug|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
79873007|NCT01998841|Drug|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
80030302|NCT04924192|Drug|Irinotecan Hydrochloride for Injection|An inhibitor of DNA topoisomerase Ⅰ
80030303|NCT02036073|Drug|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
80030304|NCT03793803|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
80030305|NCT04924426|Procedure|TTC immersion|TTC immersion
80030306|NCT02036229|Drug|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
80030307|NCT03056404|Other|additional blood sample|
79274509|NCT01382797|Drug|ALKS 37|Capsules for oral administration
79737811|NCT04265859|Behavioral|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
79274510|NCT01382797|Drug|Placebo|Capsules for oral administration
79274511|NCT01379209|Drug|RGI-2001|A single administration of RGI-2001 on Day 0 post AHSCT.
79737812|NCT04265859|Behavioral|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
79274512|NCT01379209|Drug|Calcineurin Inhibitors|GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
79737813|NCT01120067|Behavioral|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
79873008|NCT01864850|Radiation|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
79274513|NCT01379209|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|According to institutional guidelines.
80030308|NCT03056404|Other|respiratory functional exploration|
79274514|NCT01379209|Drug|Conditioning Regimen|Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
79274515|NCT01379209|Procedure|Allogeneic Bone Marrow Transplantation|According to institutional guidelines
79274516|NCT01379209|Drug|Methotrexate|
79274517|NCT01379209|Drug|Mofetil Mycophenolate|
79403351|NCT04026139|Other|active joint range-of-motion exercises and isometric contraction exercises|The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
79873009|NCT01864850|Radiation|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
79873010|NCT01607879|Drug|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
80030309|NCT02817087|Device|repetitive Transcranial Magnetic Stimulation -On|Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
80030310|NCT02817087|Device|repetitive Transcranial Magnetic Stimulation -Off|Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
80030311|NCT02036307|Dietary Supplement|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
80030312|NCT02036307|Dietary Supplement|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
79737814|NCT01120067|Behavioral|Treatment as Usual|Treatment as Usual.
79737815|NCT02724280|Device|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
80030313|NCT03056326|Drug|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
79274518|NCT01379209|Drug|sirolimus|Administered for GVHD prophylaxis as per institutional guidelines
79274519|NCT01204099|Drug|Docetaxel|
79274520|NCT01204099|Drug|PX-866|
79274521|NCT01203943|Drug|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
79274522|NCT01203943|Other|Placebo|Placebo
79274523|NCT01203943|Drug|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
79274524|NCT01203943|Drug|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
79274525|NCT01203631|Drug|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
79274526|NCT01203631|Drug|Placebo|A single dose administered subcutaneously (s.c., under the skin)
79274527|NCT01201837|Drug|Placebo|Weekly injection
79274528|NCT01201837|Drug|CER-001|Weekly injection
79403352|NCT00734409|Device|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
79737816|NCT02724280|Device|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
79737817|NCT05282043|Other|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
79873011|NCT01607879|Other|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
79873012|NCT01561612|Behavioral|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
80030314|NCT03056326|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
80030315|NCT03056326|Drug|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
80030316|NCT03056326|Drug|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
79274529|NCT05473676|Device|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
79274530|NCT01192867|Drug|Placebo|Placebo will be administered orally QD for 56 weeks
79274531|NCT01192867|Drug|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
80030317|NCT03056170|Device|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
79274532|NCT01192867|Drug|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
79578412|NCT01885429|Dietary Supplement|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
79578413|NCT01885429|Dietary Supplement|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
80030318|NCT04923022|Other|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
80030319|NCT04923022|Other|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
80030320|NCT04923490|Behavioral|state and trait anxiety scale levels|"While the STAI-I anxiety level is scored as (1) never, (2) somewhat, (3) frequently, and (4) almost always, the scoring options in STAI-II are (1) almost never, (2) sometimes, (3) most of the time, and (4) almost always."
79578414|NCT01885429|Dietary Supplement|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
79578415|NCT01885442|Device|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
79403353|NCT04026373|Behavioral|modified Prolonged Exposure|
79403354|NCT04026373|Behavioral|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
79578416|NCT01885455|Other|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
79578417|NCT01885455|Other|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
79578418|NCT01885481|Drug|Dexamethasone|epidural steroid injection using dexamethasone
79873013|NCT01336933|Drug|prednisone|Given PO
79873014|NCT01336933|Drug|cyclophosphamide|Given IV
79873015|NCT01336933|Drug|etoposide|Given PO or IV
79873016|NCT01336933|Drug|Vincristine|Given IV
79873017|NCT01336933|Drug|pralatrexate|Given IV
79578419|NCT01885481|Drug|Betamethasone|epidural steroid injection using betamethasone
79578420|NCT01885507|Other|Pass recommendations on ventilation factors and extubation|"the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
79578421|NCT01885520|Dietary Supplement|fasting condition|eperisone SR tablet 75mg administrated under fasting
79578422|NCT01885520|Dietary Supplement|fed condition|eperisone SR tablet 75mg administrated fed condition
79578423|NCT01885546|Device|AgaMatrix Blood Glucose Monitor|
79578424|NCT01885572|Device|TiLOOP Bra|Titaniferously coated polypropylene mesh
79578425|NCT01885585|Drug|Apixaban|
79578426|NCT01885598|Drug|Apixaban|
79873018|NCT01336933|Other|laboratory biomarker analysis|Correlative studies
79873019|NCT01336933|Genetic|comparative genomic hybridization|Correlative studies
79274533|NCT02543294|Device|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
79274534|NCT02543294|Device|Electrocardiogram|Electrocardiogram performed at baseline.
79403355|NCT05102838|Other|Anti-virus treatment|Anti-virus treatment
79403356|NCT04029649|Drug|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
79578427|NCT01885611|Other|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
79578428|NCT01885611|Dietary Supplement|Virgin Coconut Oil|cold-processed VCO
79578429|NCT01885624|Biological|TAB08|monoclonal antibody
79873020|NCT01336933|Genetic|gene expression analysis|Correlative studies
79873021|NCT01336933|Genetic|nucleic acid sequencing|Correlative studies
79873022|NCT01336933|Genetic|mutation analysis|Correlative studies
79873023|NCT01336933|Other|immunohistochemistry staining method|Correlative studies
79873024|NCT01336933|Genetic|microarray analysis|Correlative studies
79873025|NCT01336933|Genetic|RNA analysis|Correlative studies
79873026|NCT01107522|Drug|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
79873027|NCT01107522|Drug|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
79873028|NCT01107522|Drug|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
79578430|NCT01885650|Other|Airway Clearance Techniques|
79737818|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
79274535|NCT02543294|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
79578431|NCT01885663|Procedure|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
80030321|NCT02813577|Device|Lutonix® 035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
80030322|NCT04922788|Biological|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
80030323|NCT04922788|Biological|Placebo|0,5 mg Aluminum adjuvant
79578432|NCT01885676|Device|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
79578433|NCT01885676|Other|Saline Solution|Saline Solution mesotherapy micro injection
79737819|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
79873029|NCT01087619|Procedure|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
79873030|NCT00756379|Other|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
79873031|NCT00352027|Drug|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
79873032|NCT00352027|Drug|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
79873033|NCT00352027|Drug|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
79873034|NCT00352027|Drug|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
80030324|NCT02815293|Drug|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
80030325|NCT02815293|Drug|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
80030326|NCT04922398|Biological|platelet rich plasma|blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
80030327|NCT04922398|Drug|Normal saline|0.9% normal saline will be injected in each ovary
79274536|NCT02543294|Behavioral|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
79274537|NCT01188187|Drug|Custirsen|
80030328|NCT04922086|Procedure|Conventional aesthetic crown lengthening surgery|The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
79274538|NCT01188187|Drug|Docetaxel|
79274539|NCT01188187|Drug|Prednisone|
79274540|NCT01188187|Drug|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
79274541|NCT05478356|Drug|low-dose atropine eye drops|low-dose atropine eye drops
79274542|NCT05478356|Device|orthokeratology|orthokeratology, ortho-K lenses
79578434|NCT01885715|Drug|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
79578435|NCT01885728|Dietary Supplement|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
79578436|NCT01885741|Device|IPBS|
79578437|NCT01885780|Device|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
79578438|NCT01885793|Device|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
79737820|NCT00625547|Drug|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
79737821|NCT00625547|Drug|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
79737822|NCT05241340|Drug|Sasanlimab|Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
79873035|NCT00352027|Drug|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
79873036|NCT00352027|Drug|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
79873037|NCT00352027|Drug|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
79873038|NCT00352027|Drug|Prednisone|Given PO every other day of weeks 1-12.
79873039|NCT00352027|Biological|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
79873040|NCT00352027|Procedure|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
79737823|NCT05241340|Radiation|Stereotactic Body Radiation Therapy|This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
79403357|NCT04029649|Drug|Placebo|Placebo capsule three times daily for 90 days
79274543|NCT01186861|Drug|OSI-906|Tablet administered with food and with up to 200 mL of water
79274544|NCT01186861|Drug|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
79274545|NCT01186861|Drug|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
79578439|NCT01885806|Device|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
79274546|NCT01180465|Drug|LIPO-102|LIPO-102 High dose
79274547|NCT01180465|Drug|LIPO-102 Low|LIPO-102 Low dose
79274548|NCT01180465|Drug|LIPO-102, Placebo|Placebo
79578440|NCT01885806|Device|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
79737824|NCT05241340|Procedure|Radical Cystectomy + pelvic lymph node dissection + urinary diversion|"This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis."
79737825|NCT04265469|Other|Diabetic foot education|Give Diabetic foot education via mobile phone
79873041|NCT00285259|Biological|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
79274549|NCT01175785|Procedure|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood transplant
79274550|NCT01175785|Drug|fludarabine phosphate|Given IV
79274551|NCT01175785|Drug|cyclophosphamide|Given IV
79274552|NCT01175785|Biological|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
79274553|NCT01175785|Radiation|total-body irradiation|Undergo TBI
79578441|NCT01885819|Biological|Autologous stromal vascular fraction cells|
79873042|NCT00285259|Other|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
79274554|NCT01175785|Drug|cyclosporine|Given IV
79274555|NCT01175785|Drug|mycophenolate mofetil|Given IV and PO
79274556|NCT01175785|Other|laboratory biomarker analysis|Correlative studies
79403358|NCT01270347|Drug|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
79403359|NCT01270347|Drug|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
79578442|NCT01885832|Biological|Autologous adipose tissue stromal vascular fraction|
79873043|NCT00262470|Drug|Acetazolamide|250 mg PO x 1
79873044|NCT00262470|Drug|Atomoxetine|10-40 mg PO x 1 dose
79274557|NCT05478044|Drug|Ascorbic acid|Ascorbic acid IV ampoules (20%).
79274558|NCT05478044|Other|saline|saline (0.9%)
79274559|NCT05472506|Drug|IK-175 + nivolumab|IK-175 + nivolumab
79403360|NCT03608436|Procedure|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
79403361|NCT03608436|Drug|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
79403362|NCT03947281|Other|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
79578443|NCT01885845|Device|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
79274560|NCT01445899|Drug|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
79274561|NCT01445899|Drug|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
79274562|NCT01445899|Drug|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
79274563|NCT05459090|Other|ex-vivo study|ex-vivo experiments in tissue slices obtained from biopsies
79274564|NCT04474951|Dietary Supplement|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.
79274565|NCT04474951|Dietary Supplement|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.
79274566|NCT04474951|Dietary Supplement|Peppermint|Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
79274567|NCT02269033|Behavioral|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
79873045|NCT00262470|Other|NO Drug|No intervention - just monitoring
79873046|NCT00262470|Drug|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
79873047|NCT00262470|Drug|Entacapone|Entacapone 200-400 mg PO x 1 dose
79873048|NCT00262470|Drug|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
80030329|NCT04922086|Procedure|Guided dual aesthetic crown lengthening surgery|The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
80030330|NCT02813421|Device|CGM Informed|
80030331|NCT04922008|Drug|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR<10%, T≤2cm or ER and/or PR ≥10% 1cm<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
80030332|NCT04922008|Drug|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR<10%, T≤2cm or ER and/or PR ≥10% 1cm<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
80030333|NCT03056092|Drug|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
80030334|NCT04921852|Procedure|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
79274568|NCT02269033|Behavioral|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
79274569|NCT02269111|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
79274570|NCT02269111|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
79737826|NCT05240326|Other|exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.
79737827|NCT05240326|Other|control training group|The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
79737828|NCT02881853|Drug|XmAb7195|
79737829|NCT02881853|Drug|Placebo|
79737830|NCT02724046|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
79873049|NCT00262470|Drug|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
79873050|NCT00262470|Drug|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
79873051|NCT00262470|Drug|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
79873052|NCT00262470|Drug|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
79274571|NCT02269111|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
79274572|NCT02269111|Procedure|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
79274573|NCT02269189|Drug|BIIL 284 BS, high dose|
79274574|NCT02269189|Drug|BIIL 284 BS, low dose|
79274575|NCT02269189|Drug|Placebo|
79274576|NCT02266069|Other|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
79274577|NCT03649724|Drug|Placebo|Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
79274578|NCT03649724|Drug|Eligard 22.5Mg Suspension for Injection|Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
79737831|NCT05379621|Other|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
79737832|NCT02724124|Other|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
79737833|NCT02724124|Other|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
79873053|NCT00262470|Dietary Supplement|Melatonin|melatonin 3 mg PO x 1 dose
79873054|NCT00262470|Drug|Midodrine|midodrine 2.5-10 mg PO x 1 dose
79873055|NCT00262470|Drug|Modafinil|modafinil 100-200 mg PO x 1 dose
79873056|NCT00262470|Drug|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
79873057|NCT00262470|Radiation|Placebo|lactose tablet x 1 pill
79873058|NCT00262470|Drug|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
79873059|NCT00262470|Drug|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
79873060|NCT00262470|Drug|Sertraline|sertraline 25-50 mg PO x 1 dose
79873061|NCT00262470|Procedure|IV Saline|1 liter IV over 2 hours
79873062|NCT00262470|Other|Drinking Water|16 fluid ounces
79873063|NCT00262470|Device|Breathing Device|Breathing through a dead space tube
79873064|NCT00262470|Drug|memantine|memantine 5-20 mg PO x 1 dose
79873065|NCT00262470|Device|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
79274579|NCT04474873|Procedure|erector spinae block|we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
79274580|NCT04474639|Device|echocardiographic examination|conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
79274581|NCT05477966|Other|Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
79274582|NCT05626933|Procedure|Buccinator myomucosal flap with Furlow palatoplasty|Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
79274583|NCT01358695|Biological|ANT-1207|The interventions differ by dose of investigational product applied.
79274584|NCT01358695|Biological|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
79274585|NCT01358695|Biological|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
80030335|NCT04921852|Procedure|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
79274586|NCT02266303|Other|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
79274587|NCT03135223|Behavioral|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
79274588|NCT01163227|Drug|Placebo (single and multiple doses)|
79274589|NCT01163227|Drug|AQW051 2 mg (single and multiple doses)|
79578444|NCT01885845|Other|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
79578445|NCT01885858|Behavioral|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
79274590|NCT01163227|Drug|AQW051 15mg (single and multiple doses)|
79578446|NCT01885858|Behavioral|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
79578447|NCT01885884|Behavioral|Embedded Supportive Care|
79578448|NCT01885923|Device|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
80030336|NCT04921540|Procedure|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
80030337|NCT04921540|Procedure|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
79274591|NCT01163227|Drug|AQW051 100mg (single dose), and 50mg (multiple doses)|
79274592|NCT02551874|Drug|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
79274593|NCT02551874|Drug|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
79274594|NCT02551874|Drug|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
79274595|NCT02551874|Drug|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
79274596|NCT01162681|Drug|A-623|High dose given subcutaneously once a week for up to 52 weeks
79274597|NCT01162681|Drug|A-623|Low dose given subcutaneously once a week for up to 52 weeks
79274598|NCT01162681|Drug|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
79274599|NCT01162681|Other|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
79274600|NCT02269345|Other|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
79274601|NCT02269345|Other|Standard Treatment|Standard Treatment alone.
79578449|NCT01885962|Behavioral|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
79578450|NCT01885988|Drug|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
80030338|NCT04921306|Drug|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
80030339|NCT04921306|Drug|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
79578451|NCT01885988|Drug|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
79737834|NCT02724124|Other|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
79737835|NCT02724124|Other|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
79274602|NCT03646604|Drug|Upadacitinib (ABT-494)|Upadacitinib will be administered orally.
79274603|NCT02269501|Other|Exercise treatment|
79274604|NCT05477732|Dietary Supplement|Bifidobacterium longum OLP-01|Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.
79737836|NCT02724124|Other|Control|No intervention
79274605|NCT05477732|Other|Placebo|Subjects in placebo group will supplement with placebo powder per day for 12 weeks.
79274606|NCT01354717|Drug|Brand Carac|treatment of actinic keratosis
79274607|NCT01354717|Drug|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
79274608|NCT01354717|Other|Placebo cream|treatment of actinic keratosis
79737837|NCT00608127|Device|LupusorbTM|Single treatment
79737838|NCT04265547|Behavioral|Breast Cancer Risk Reduction Household Intervention|This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
79737839|NCT01124045|Drug|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
79737840|NCT01124045|Drug|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
79737841|NCT04265391|Dietary Supplement|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
79737842|NCT01123889|Biological|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
79737843|NCT01123889|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
79274609|NCT02266459|Device|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is < 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
79274610|NCT01072981|Biological|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
79274611|NCT01072981|Drug|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
79578452|NCT01886001|Drug|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
79274612|NCT01072981|Radiation|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
79274613|NCT02706626|Drug|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
79274614|NCT03347708|Biological|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
79274615|NCT03347708|Drug|Saline Solution|Sodium Chloride Solution
79274616|NCT03347708|Drug|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
79274617|NCT02269579|Drug|CPX-351|
79274618|NCT05455970|Other|Rhythmic auditory stimulation (RAS)|A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
79578453|NCT01886001|Drug|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
79274619|NCT01159249|Drug|Vildagliptin|
79274620|NCT01156753|Drug|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
79578454|NCT01886001|Drug|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
79578455|NCT01886001|Other|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
79578456|NCT01886014|Drug|Oxytocin|
79578457|NCT01886014|Other|placebo|
79873066|NCT00082641|Biological|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
79873067|NCT00440271|Drug|tipranavir|
79873068|NCT00440271|Drug|ritonavir|
79873069|NCT00440271|Drug|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
79873070|NCT00346216|Drug|celecoxib|100 to 200 mg twice daily, taken by mouth
79873071|NCT00346216|Drug|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
79274621|NCT01156753|Drug|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
79274622|NCT03324464|Behavioral|Central Executive Training: Working Memory|Computerized working memory training
79274623|NCT03324464|Behavioral|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
79274624|NCT01345045|Drug|ABT-639|ABT-639 Twice Daily for six weeks.
79274625|NCT01345045|Drug|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
79274626|NCT01345045|Drug|Placebo|Placebo twice daily for 6 weeks.
79274627|NCT05477654|Diagnostic Test|Extensive motor-cognitive testing protocol|Screening of their functional performance while monitoring brain and muscle activity
79578458|NCT01886027|Behavioral|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
79578459|NCT01886027|Behavioral|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
79737844|NCT05226208|Diagnostic Test|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
79873072|NCT00346216|Drug|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
80030340|NCT04921462|Procedure|Septoplasty surgery|septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
79274628|NCT05626699|Device|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
80030341|NCT04921150|Other|standardization management|Apply standardization management to improve the outcomes of pregnancy
79274629|NCT01344187|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
79274630|NCT01344187|Drug|placebo solution|0.0% riboflavin ophthalmic solution
79274631|NCT01344187|Device|KXL System|30 mW/cm2
79274632|NCT01342315|Drug|33525|Daily dosing
79274633|NCT01342315|Drug|Placebo|Daily dosing
79274634|NCT01338883|Drug|Cenicriviroc 100 mg|100 mg CVC plus Truvada
79578460|NCT01886053|Drug|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
79578461|NCT01886053|Drug|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
79578462|NCT01886053|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
79578463|NCT01886066|Biological|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (~8mm) in the cervical stroma for a total injection volume of 2 mL.
79578464|NCT01886079|Drug|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
79274635|NCT01338883|Drug|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
79274636|NCT01338883|Drug|Sustiva + Truvada|Sustiva plus Truvada
79274637|NCT05625919|Drug|Sirolimus for Injection (Albumin Bound)|Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
79274638|NCT04423952|Other|COMQ-12 questionnaire|Subjects respond to COMQ-12 questionnaire twice at 15 days apart. COMQ-12 : quality of life measurement questionnaire related to chronic otitis media.
79274639|NCT01338805|Drug|BGG492|
79578465|NCT01886079|Drug|Saline|0.4 mcg/kg/h, IV
79737845|NCT05226208|Diagnostic Test|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
79737846|NCT05379543|Other|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
79737847|NCT02723968|Other|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
79737848|NCT02723968|Procedure|HGPIV diagnosis test|
79873073|NCT01030419|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
79274640|NCT02266537|Drug|Tamsulosin|
79274641|NCT02266537|Drug|Alfuzosin|
79274642|NCT02266537|Drug|Doxazosin|
79274643|NCT02266537|Drug|Placebo|
79274644|NCT02269735|Drug|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
79274645|NCT02269735|Biological|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
79274646|NCT02269735|Drug|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
79737849|NCT02723968|Procedure|HOMAR-IR diagnosis test|
79737850|NCT00606879|Drug|SGX523 Capsules|This is a dose escalation study
79873074|NCT01030419|Behavioral|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
79578466|NCT01886092|Device|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
79274647|NCT02269735|Biological|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
79274648|NCT02269735|Drug|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
79274649|NCT05477498|Drug|Ferric carboxymaltose|Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
79274650|NCT05477498|Drug|Placebo|Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
79578467|NCT01886092|Device|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
79578468|NCT01886092|Device|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
79578469|NCT01886092|Device|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
79737851|NCT00605631|Device|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
79737852|NCT02723890|Device|Tyto Device|
79737853|NCT00606957|Dietary Supplement|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
79873075|NCT01325116|Behavioral|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
79873076|NCT01051648|Drug|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy
79873077|NCT00417963|Device|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
79873078|NCT00429273|Drug|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
79873079|NCT00429273|Drug|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
79873080|NCT00359632|Drug|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
79873081|NCT00359632|Drug|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
79873082|NCT01324960|Drug|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
79873083|NCT01324960|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
79873084|NCT00417885|Drug|exemestane|25 mg, oral, daily dosing
79873085|NCT00417885|Drug|sunitinib malate|37.5 mg, oral, continuous dosing, daily
79873086|NCT01056250|Procedure|SILS cholangiography|intraoperative
79873087|NCT03989596|Radiation|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
79403363|NCT03947281|Other|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
79578470|NCT01886118|Procedure|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
79578471|NCT01886118|Other|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
79737854|NCT02723656|Behavioral|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
79873088|NCT03989596|Other|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
79873089|NCT01036893|Drug|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
79274651|NCT05471102|Procedure|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
79274652|NCT05471102|Procedure|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
79274653|NCT05477342|Behavioral|Board Game|The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
79274654|NCT05477342|Behavioral|Tobacco Cesseation Education|The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
79274655|NCT05477342|Behavioral|Combined İntervention|"The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale."
79274656|NCT05231733|Biological|SPX-101|Subjects will receive SPX-101 on Day 1 of the first cycle, and will be evaluated for DLTs in the following 3 weeks. After the first cycle, subjects will continue treatment at dosing intervals as determined by safety and PK results. All patients will continue treatment until disease progression, development of unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion (maximum duration: 2 years).
79737855|NCT02723656|Behavioral|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
79737856|NCT05192512|Drug|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
79737857|NCT00934947|Drug|Propranolol|40 mg
79274657|NCT01038739|Drug|Mesalazine|3 g per day
79274658|NCT01038739|Drug|Mesalazine|1.5 g per day
79274659|NCT01038739|Drug|Placebo|0 g per day
79274660|NCT02269813|Other|MammaPrint|
79274661|NCT02269813|Other|BluePrint|
79274662|NCT02269813|Other|TargetPrint|
79274663|NCT05231967|Other|Cardioversion|In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
79737858|NCT00934947|Drug|Placebo|sugar pill
79737859|NCT00934947|Drug|Propanolol|120 mg twice per day
79873090|NCT01056406|Behavioral|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
79274664|NCT05487339|Procedure|Erector spinae plane block|fascial plane injection guided by fluoroscopy device
79274665|NCT02269891|Dietary Supplement|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
79737860|NCT05191810|Behavioral|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
79737861|NCT02723578|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
79274666|NCT02269891|Other|Placebo|
79274667|NCT02550938|Device|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
79274668|NCT01336465|Drug|placebo|Repeating subcutaneous injection
79274669|NCT01336465|Drug|rhuMAb Beta7|Repeating subcutaneous injection
79737862|NCT02723578|Drug|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
79737863|NCT04267263|Behavioral|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
79737864|NCT01123655|Drug|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
79737865|NCT01123655|Drug|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
79737866|NCT05379465|Other|No intervention|No intervention was done.
79737867|NCT04189198|Drug|Articaine|Supraclavicular block with 30 ml articaine 2%
79737868|NCT04189198|Drug|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
79737869|NCT04253535|Other|questionnaries|Study on questionnaries
79737870|NCT00608361|Drug|Dasatinib|Given PO
79873091|NCT01856439|Drug|ProSavin|Long term follow up of patients who received ProSavin in a previous study
79873092|NCT01051726|Other|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
79873093|NCT01051726|Other|None essential oil|Baby oil
79873094|NCT04488770|Drug|GSK3882347|Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
80030342|NCT04920760|Dietary Supplement|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children > 1 or for infants of < 1 year of age, respectively).
80030343|NCT03056248|Drug|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
80030344|NCT03056248|Drug|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
80030345|NCT04920604|Other|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
79274670|NCT03164733|Other|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
79274671|NCT03161691|Procedure|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
79737871|NCT00608361|Other|Pharmacological Study|Correlative studies
79737872|NCT04311281|Biological|[F-18]FDDNP-PET|[F-18]FDDNP, or 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
79274672|NCT05470088|Other|Neuroimaging (MRI)|Multimodal magnetic resonance imaging
79274673|NCT03161769|Procedure|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
79873095|NCT04488770|Drug|Placebo|Matching strength placebo capsules will be provided
80030346|NCT04920604|Other|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
79274674|NCT03161769|Device|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
79274675|NCT02769065|Drug|TAK-071|TAK-071 capsules
79274676|NCT02769065|Drug|Donepezil|Donepezil over-encapsulated tablet
79737873|NCT02694406|Device|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
79737874|NCT00934791|Drug|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
80030347|NCT04920526|Drug|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
80030348|NCT04920448|Drug|N-Acetyl cysteine|Administered as specified in the treatment arm
80030349|NCT04969900|Other|Placebo oil|The placebo group will receive placebo oil.
80030350|NCT04969900|Other|Lavender oil.|Investigational Product. This group will receive Lavender oil.
80030351|NCT04969666|Drug|IPED2015|Active treatment
80030352|NCT04969666|Drug|Placebo|Placebo
80030353|NCT04969588|Diagnostic Test|Microsoft Azure Kinect Developer Kit|3D images and 3D joint coordinates are obtained.
80030354|NCT04969588|Diagnostic Test|Bioelectrical impedance analyzer|Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
79578472|NCT01886118|Other|Conventional media culture|embryos are cultured in conventional media
79578473|NCT01886131|Other|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
80030355|NCT04969588|Diagnostic Test|Dual Energy X-ray Absorptiometry|Skeletal length and body composition are estimated.
79274677|NCT02769065|Drug|TAK-071 Placebo|TAK-071 placebo-matching capsules
79274678|NCT02769065|Drug|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
79274679|NCT03164811|Procedure|goal directed fluid therapy|pulse pressure variation will be used to as a goal to guide fluid administration in this group
79274680|NCT03164811|Other|Controlled|standard fluid treatment by an anesthesiologist
79274681|NCT02681523|Drug|Eribulin|
79578474|NCT01886144|Device|Knee OA Brace|
79737875|NCT00934791|Drug|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
79737876|NCT00934791|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
79737877|NCT00934791|Drug|Prednisone|Prednisone tapered to 5 mg/day by day 92
79873096|NCT00525044|Drug|Ambroxol|
79873097|NCT00525044|Drug|Placebo|
79873098|NCT00355342|Drug|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
79873099|NCT00355342|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
79873100|NCT00355342|Device|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
79873101|NCT03573362|Device|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
79873102|NCT03573362|Device|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
80030356|NCT04432168|Procedure|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
79274682|NCT02540954|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
79274683|NCT05265975|Drug|ATG-010|Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
79274684|NCT05265975|Drug|Lenalidomide|Oral administration,QD, Days 1-21 of each cycle
79274685|NCT05265975|Drug|Rituximab|Intravenous injection Days 1 of each cycle, Cycles 1-6
79274686|NCT03542201|Other|PLS|Participants will have to read standard textual information about the conducted systematic review (approximately 500 words)
79274687|NCT03542201|Other|Blogshot|Participants will have to read the blogshot information about the results of the Cochrane systematic review (approximately 100 words)
79737878|NCT02882165|Other|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
79737879|NCT02723812|Biological|GCFLU® Influenza vaccine (Split virion, Inactivated)|
79873103|NCT01051804|Other|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
79873104|NCT01051804|Other|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
79873105|NCT01051882|Biological|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
79873106|NCT01051882|Biological|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
79873107|NCT01573754|Drug|Hydroxychloroquine|100 mg by mouth twice weekly
79873108|NCT01573754|Procedure|Phlebotomy|450 mL every 2 weeks
79274688|NCT03164577|Behavioral|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
79274689|NCT03164577|Other|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
79274690|NCT04411316|Combination Product|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
79274691|NCT04411316|Drug|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
79274692|NCT05245773|Other|Automated SMS program to support post-discharge transitions of care|The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
79274693|NCT02151305|Drug|Propofol, remifentanil|
79274694|NCT02151305|Drug|Sevoflurane|
79274695|NCT03164499|Behavioral|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
79578475|NCT01886157|Procedure|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
79578476|NCT01886157|Procedure|Corticosteroid injection|Standard trigger finger corticosteroid injection.
79578477|NCT01886170|Other|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
79578478|NCT01886183|Other|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
79737880|NCT05268159|Other|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
79873109|NCT03989674|Dietary Supplement|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
79873110|NCT03986788|Other|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
79873111|NCT03989830|Drug|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
79873112|NCT03989830|Drug|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
79873113|NCT03989518|Behavioral|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
79737881|NCT02723422|Procedure|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
79274696|NCT03164499|Behavioral|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
79403364|NCT03486678|Drug|SHR-1210+GEMOX|28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
79403365|NCT03652285|Device|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
79403366|NCT03652285|Device|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
79274697|NCT05477030|Device|Medtronic MiniMed 780G with SmartGuard activation|Insulin pump implemented with alghoritm for automatic modulation of insulin delivery (to increase time in glucose range 70-180 mg/dl)
79274698|NCT05477030|Device|Medtronic MiniMed 780G without SmartGuard activation|Insulin pump implemented with alghoritm for low glucose insulin suspension (to reduce hypoglycemia rate)
79274699|NCT02152319|Device|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
79274700|NCT02152319|Procedure|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
79403367|NCT04154046|Procedure|Tenotomy(cutting) of flexor tendons is performed with needle|"Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge."
79737882|NCT02723422|Procedure|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
79274701|NCT03164421|Drug|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
79274702|NCT03164421|Drug|L-carnitine|L-carnitine in clomiphene resistant pcos women
79274703|NCT04472702|Procedure|cRFA|cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
79403368|NCT04025671|Device|Nasal Spray Naloxone|Nasal spray naloxone device.
79403369|NCT04025671|Device|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
79403370|NCT04025671|Device|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
79578479|NCT01886183|Other|Physical Therapy|Patients of the control group will be trained with balance exercises.
79578480|NCT01886196|Drug|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
79578481|NCT01886196|Other|placebo|placebo designed to mimic experimental drug (ibuprofen)
79578482|NCT01886196|Behavioral|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
79578483|NCT01886196|Behavioral|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
79578484|NCT01886209|Drug|Prednisone|
79578485|NCT01886209|Drug|VX-509|
79578486|NCT01886209|Drug|Methylprednisolone|
79737883|NCT00605709|Drug|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
79737884|NCT02882009|Drug|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
79274704|NCT03164343|Device|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
79274705|NCT03542123|Device|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
79578487|NCT01886222|Other|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
79873114|NCT03989518|Behavioral|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
79873115|NCT03989518|Behavioral|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
79274706|NCT03164187|Drug|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
79274707|NCT02152397|Behavioral|Therapist-led brief intervention (TBI)|
79274708|NCT05228613|Biological|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
79737885|NCT02882009|Drug|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
79274709|NCT05228613|Biological|SARS-CoV-2 inactivated vaccine|active control manufactured by Sinovac Life Sciences Co.Ltd
79274710|NCT02156453|Procedure|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
79274711|NCT05476874|Procedure|Open Mini-Laparotomy|A 5-cm paraumbilical skin is made, and the abdominal wall is incised in layers. The distal catheter tip is inserted into the peritoneal cavity in a craniocaudal direction, and the abdominal wound is sutured in layers.
79274712|NCT05476874|Procedure|Abdominal Puncture|An about 0.5-cm paraumbilical incision made to allow introduction of a splitable trocar. The trocar is pierced through the abdominal wall into the abdominal cavity. Pull out the puncture cone, and adjust the trocar towards the pelvis. The distal catheter tip is inserted into the peritoneal cavity through the puncture cannula. Then the splitable puncture cannula is split apart and removed. The skin incision requires only one stitch.
79873116|NCT03989284|Behavioral|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
79274713|NCT02159417|Other|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~Knowledge of the disease~Food~Physical Activity and care of feet~The therapeutics"
79403371|NCT01273467|Drug|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
79274714|NCT05221827|Diagnostic Test|C2i Test|The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
79274715|NCT03542981|Device|Interferential Current|
79274716|NCT03542981|Device|Sham Interferential Current|
79403372|NCT01273467|Drug|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
79578488|NCT01886222|Other|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
79578489|NCT01886248|Drug|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
79737886|NCT00636688|Behavioral|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
79737887|NCT00636688|Behavioral|Control - general information|General information about healthy food choices and exercise
79737888|NCT00607035|Drug|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
79737889|NCT00607035|Drug|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
79873117|NCT00355264|Drug|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
79578490|NCT01886274|Device|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
79873118|NCT01054378|Procedure|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
79873119|NCT02533648|Drug|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
79873120|NCT02533648|Drug|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
79578491|NCT01886326|Other|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
79873121|NCT01056796|Device|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
79274717|NCT04440111|Other|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
79274718|NCT04440111|Other|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
79274719|NCT02658812|Other|Laboratory Biomarker Analysis|Correlative studies
79274720|NCT02658812|Biological|Talimogene Laherparepvec|Given IT
79274721|NCT02156531|Behavioral|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
79274722|NCT02156531|Behavioral|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
79578492|NCT01886339|Other|SNIF test (Sniff Nasal Inspiratory Force)|
79578493|NCT01886352|Drug|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
79578494|NCT01886352|Drug|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
79737890|NCT05060081|Other|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
79737891|NCT05060081|Other|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
79873122|NCT02533492|Device|vicryl|wound closure with vicryl suture
79403373|NCT03412188|Drug|Eltrombopag|Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
79403374|NCT03412188|Drug|conventional|Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
79873123|NCT02533492|Device|Vicryl plus|wound closure with vicryl plus suture
79403375|NCT01273545|Drug|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
79578495|NCT01886352|Drug|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~Each subdiaphragmatic area 0.05 ml/kg~Dome of abdomen then settling onto bowel 0.05 ml/kg~Surgical dissection site 0.05 ml/kg~At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
79578496|NCT01886365|Device|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
79578497|NCT01886365|Other|Conventional therapy with a fixed insulin dosing scheme|Routine care
79873124|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose
79873125|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
79873126|NCT01056874|Drug|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
79873127|NCT01056952|Procedure|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 > 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
79578498|NCT01886430|Other|Functional electrical stimulation|Functional electrical stimulation for 10 days
79578499|NCT01886430|Other|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
79578500|NCT01886443|Drug|Antithrombin-III|
79578501|NCT01886443|Drug|Infliximab|
79578502|NCT01886443|Drug|Apotransferrin|
79578503|NCT01886443|Drug|Human recombinant erythropoietin|
79578504|NCT01886443|Drug|C1-Inhibitor|
79578505|NCT01886443|Drug|Glutathione|
79578506|NCT01886443|Drug|Alfa-tocopherol|
79578507|NCT01886443|Drug|Melatonin|
79578508|NCT01886443|Drug|Epoprostenol|
79578509|NCT01886456|Device|Laser trabeculoplasty|
79578510|NCT01886469|Drug|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
79578511|NCT01886469|Drug|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
80030357|NCT04432168|Other|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
80030358|NCT04969354|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
80030359|NCT04969432|Other|Client-centered|Rehabilitation
80030360|NCT04969042|Device|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
79578512|NCT01886469|Drug|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
79873128|NCT01056952|Procedure|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 > 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
79873129|NCT01056952|Procedure|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 > 90%
79737892|NCT02723266|Behavioral|STOPPING-GDM|Educational counseling and skills building Intervention
79578513|NCT01886482|Other|nutrition intervention|high protein diet
80030361|NCT04968730|Other|Postoperative rehabilitation nursing|Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
80030362|NCT04968262|Other|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
80030363|NCT04968262|Other|Sepsis-related acute kidney injury therapy|Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
80030364|NCT03061006|Drug|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
80030365|NCT03061006|Drug|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
79274723|NCT03164031|Device|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
79578514|NCT01886495|Other|nutrition intervention|
79578515|NCT01886508|Procedure|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
79578516|NCT01886508|Procedure|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
79578517|NCT01886521|Procedure|Lumbar drain|
79737893|NCT00608439|Drug|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
79737894|NCT00608439|Other|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
79737895|NCT02693236|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
79873130|NCT00355030|Drug|somatropin|0.05 mg/kg/day
79873131|NCT00355030|Drug|leuprorelin|11.25 mg/3 months
79873132|NCT01057030|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
80030366|NCT03060928|Procedure|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
80030367|NCT03060928|Procedure|Micro-perforations|Biological stimulation with micro-perforations
80030368|NCT03060928|Procedure|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
79578518|NCT01886521|Procedure|Ventricular drain|
79578519|NCT01886534|Other|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
79873133|NCT01057030|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
80030369|NCT03061240|Device|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
80030370|NCT03055702|Other|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
80030371|NCT04980274|Other|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
80030372|NCT04920214|Diagnostic Test|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
80030373|NCT04919902|Procedure|Electric cardioversion|Electric cardioversion in short sedation according to established clinical practice and indications
79274724|NCT03164031|Device|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
79274725|NCT02628704|Drug|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
79403376|NCT00734799|Behavioral|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
79578520|NCT01886534|Behavioral|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
79578521|NCT01886534|Other|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
79578522|NCT01886534|Other|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
79274726|NCT02628704|Drug|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
79578523|NCT01886534|Other|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
79578524|NCT01886547|Other|Prostate health screening|
79578525|NCT01886560|Drug|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
79578526|NCT01886560|Drug|Placebo|Tablets placebo one PO per day for 12 weeks
79578527|NCT01886573|Drug|Azacitidine|Given SC
79578528|NCT01886573|Drug|Entinostat|Given PO
79274727|NCT02628704|Drug|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
79274728|NCT02628704|Drug|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
79578529|NCT01886573|Other|Laboratory Biomarker Analysis|Correlative studies
79578530|NCT01886573|Other|Pharmacological Study|Correlative studies
79578531|NCT01886573|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79578532|NCT01886586|Behavioral|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
79578533|NCT01886586|Behavioral|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
79737896|NCT04265313|Other|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
80030374|NCT04967794|Other|Teleorientation and Tooth Brushing Orientation|Guide children in toothbrushing with a preventive purpose during the COVID-19 pandemic
80030375|NCT04967638|Procedure|tumor resection and mandible reconstruction|The patients who underwent primary ablative tumor resection with segmental mandibulectomy and immediate VFF reconstruction were retrieved from the database
80030376|NCT04919746|Other|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
79403377|NCT01278849|Drug|ASA404|
79274729|NCT02152475|Drug|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
79274730|NCT02152475|Device|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
79274731|NCT02152553|Drug|Hydrocortisone|
79274732|NCT02152553|Drug|Placebo|
79403378|NCT04146805|Drug|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
79737897|NCT02722954|Drug|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
79737898|NCT02722954|Drug|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
79578534|NCT01886586|Other|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
79403379|NCT04146805|Drug|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
79274733|NCT04411394|Other|Questionnaire|Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale
79578535|NCT01886599|Drug|Asunaprevir|
79737899|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
79737900|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
79873134|NCT03991546|Behavioral|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
79578536|NCT01886612|Device|Duo-STIM neuromuscular electrical stimulator|
79578537|NCT01886612|Device|AV Impulse System Model 6000|
79578538|NCT01886625|Procedure|unilateral single-port VATS sympathicotomy|
79578539|NCT01886638|Drug|Abacavir|
79578540|NCT01886664|Drug|sevoflurane|
79578541|NCT01886664|Drug|Desflurane|
79873135|NCT03986632|Behavioral|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
79737901|NCT04262973|Other|education|six-hour dementia care course
79737902|NCT04262973|Other|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
79274734|NCT03161457|Biological|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
79274735|NCT03161457|Biological|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
79274736|NCT02159573|Biological|natalizumab|Administered as per routine clinical practice
79274737|NCT02159573|Drug|dimethyl fumarate|Administered as per routine clinical practice
79578542|NCT01886677|Behavioral|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
79274738|NCT04468256|Other|COVID-19 experience surveys|Serial online surveys recording experiences of the COVID-19 pandemic.
79274739|NCT03163953|Behavioral|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
79578543|NCT01886677|Behavioral|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
79578544|NCT01886703|Behavioral|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
79578545|NCT01886729|Other|transcranial direct current stimulation (tDCS)|
79578546|NCT01886742|Drug|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
79578547|NCT01886742|Drug|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
79578548|NCT01886755|Dietary Supplement|ORS rehydration solution|
79578549|NCT01886755|Dietary Supplement|placebo|
79737903|NCT00625859|Drug|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
79737904|NCT00625859|Drug|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
79737905|NCT00625859|Drug|Placebo|Placebo tablets will be given to subjects.
79737906|NCT02723110|Other|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
79737907|NCT02723110|Other|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
79737908|NCT04262739|Drug|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
79737909|NCT04262739|Drug|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
79737910|NCT04262739|Drug|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
79737911|NCT02691195|Drug|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
79873136|NCT03989128|Other|Medical Chart Review|Undergo medical chart review
79274740|NCT03163953|Behavioral|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
79274741|NCT03163953|Other|Control|No intervention
79274742|NCT02152709|Biological|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
79274743|NCT02152709|Biological|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
79274744|NCT03164109|Drug|GC4419 IV|50mg infused IV over 15 minutes
79274745|NCT03164109|Drug|Placebo|Infused IV over 15 minutes
79274746|NCT03164109|Drug|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
79274747|NCT02152787|Drug|Injection of propofol 1.0mg/kg|
79403380|NCT04007094|Other|ViviGen Cellular Bone Matrix|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
79873137|NCT03989128|Other|Survey Administration|Complete survey
79873138|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg BID
79873139|NCT01057108|Other|FOSTRAP Chewing Gum|40 mg BID
79873140|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
79737912|NCT02691195|Drug|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
79737913|NCT02723032|Device|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
79873141|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
79873142|NCT01057108|Other|Placebo chewing gum|
79873143|NCT01057186|Dietary Supplement|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
79873144|NCT01057186|Drug|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
79873145|NCT03986476|Dietary Supplement|Probiotics|5x10^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
79873146|NCT03986476|Other|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
79873147|NCT01057264|Drug|HAI Abraxane|Starting dose: 120 mg/m^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
79873148|NCT01057264|Drug|Gemcitabine|Starting dose: 600 mg/m^2 by IV on Days 1 and 8 of 21 day cycle
79274748|NCT02152787|Drug|propofol 0.5mg/kg|
79274749|NCT02152787|Drug|normal saline|
79274750|NCT03163875|Other|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
79274751|NCT00154375|Drug|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
79873149|NCT01057264|Drug|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
79873150|NCT01057264|Drug|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
79873151|NCT03991312|Drug|itraconazole|Participants will receive an oral solution as described in the arm description.
79873152|NCT03991312|Drug|rifampin|Participants will receive oral capsule(s) as described in the arm description.
79873153|NCT03991312|Drug|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
79873154|NCT03988972|Device|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
79274752|NCT00154375|Drug|Hydroxyurea|
79873155|NCT03988972|Device|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
79274754|NCT03163719|Diagnostic Test|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
79274755|NCT03160989|Other|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
79274756|NCT02765399|Drug|Liraglutide|
79274757|NCT02765399|Drug|Placebo|
79578550|NCT01886768|Device|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
79737914|NCT02722876|Other|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
79737915|NCT02722876|Other|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
79737916|NCT04131946|Other|Community-Based (Intervention Arm)|Community dispensed FIT
79737917|NCT03808090|Other|Normal Individuals|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
79274758|NCT02266693|Behavioral|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
79873156|NCT01057342|Drug|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
79578551|NCT01886768|Device|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
79578552|NCT01886820|Drug|[18F]NAV4694|
79578553|NCT01886898|Other|Infant formula|infant formula
79873157|NCT01057342|Drug|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
79578554|NCT01886898|Other|Breastfeeding|
79578555|NCT01886911|Other|Attention Training Intervention Game|
79578556|NCT01886911|Other|Prosocial Training Intervention Game|
79737918|NCT03808090|Other|Calcium Oxalate Kidney Stone Formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
79737919|NCT03808090|Other|Type 2 Diabetes|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
79737920|NCT03808090|Other|Type 2 diabetic kidney stone formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
79873158|NCT01057342|Drug|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
79873159|NCT01054534|Procedure|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
79873160|NCT01057420|Drug|oxygen inhalation|Inhalation of 80% oxygen via face mask
79274759|NCT03163641|Device|Acuvue Oasys|Bandage Contact Lens
79873161|NCT01054612|Other|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
79873162|NCT01054690|Device|Bactiguard Infection Protection (BIP) Cathter.|
79873163|NCT01054690|Device|Silicone Urinary Catheter|
79873164|NCT01057498|Drug|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
79274760|NCT03163641|Device|Ocular Bandage Gel|0.75% crosslinked HA
79578557|NCT01886911|Other|Control for Attention Intervention|
79274761|NCT01037179|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
79274762|NCT05476640|Genetic|NGS|In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
79274763|NCT02269969|Drug|Tobramycin|
79578558|NCT01886911|Other|Control for Prosocial Intervention|
79578559|NCT01886924|Behavioral|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
79578560|NCT01886924|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
79578561|NCT01886976|Biological|CART-138 cells|
79578562|NCT01886989|Dietary Supplement|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
79578563|NCT01887015|Device|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
79578564|NCT01887054|Device|Tower of Hanoi|
79578565|NCT01887054|Other|Placebo group - non use of Tower of Hanoi|
79578566|NCT01887080|Other|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
79578567|NCT01887080|Device|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
79737921|NCT02722642|Biological|Bronchial basal cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
79873165|NCT01057498|Drug|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
79873166|NCT03742258|Drug|Cyclophosphamide|Given IV
79873167|NCT03742258|Drug|Doxorubicin Hydrochloride|Given IV
79873168|NCT03742258|Drug|Prednisone|Given PO
79873169|NCT03742258|Biological|Rituximab|Given IV
79873170|NCT03742258|Drug|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
79873171|NCT03742258|Drug|Vincristine Sulfate|Given IV
79873172|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
79873173|NCT01057576|Other|Placebo|capsule, daily dosage
79873174|NCT00354172|Biological|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
79737922|NCT02722720|Procedure|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
79274764|NCT02520986|Device|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
79274765|NCT02520986|Device|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
79274766|NCT03163797|Diagnostic Test|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
79274767|NCT02266771|Device|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
79274768|NCT02266771|Device|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
79274769|NCT01033357|Device|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
79274770|NCT01033357|Device|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
79274771|NCT05469308|Other|questionary|When the patients renew their treatment in community pharmacy, they have an adherence record with a pharmacist who calculates the PDC score, and perform questionaries on adherence to the DOACs, and collects data about clinical history and pharmacological information on the prescribed DAOCs, demography.
79274772|NCT05450666|Other|mobility exercises|Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
79274773|NCT04265846|Device|bifocal IOL|The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.
79578568|NCT01887080|Other|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
79578569|NCT01887093|Behavioral|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
79578570|NCT01887106|Drug|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
79578571|NCT01887106|Drug|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
79578572|NCT01887106|Drug|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
79578573|NCT01887106|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
79578574|NCT01887119|Drug|Eplerenone|
79578575|NCT01887119|Other|Placebo|Eplerenone-matched placebo
79274774|NCT04265846|Device|mix bifocal IOL|The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.
79274775|NCT04265846|Device|trifocal IOL|The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.
79578576|NCT01887145|Procedure|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
79873175|NCT00354172|Biological|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
79274776|NCT04265846|Device|EDOF IOL|The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.
79274777|NCT04265846|Device|different IOLs|The patients will undergo phacoemulsification and different IOLs implantation bilaterally.
79274778|NCT04265846|Device|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
79274779|NCT04265846|Device|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
79274780|NCT05144685|Device|OTX-202|Experimental Pscyhoeducation and Intervention App
79274781|NCT05144685|Device|OTX-000|Other Pscyhoeducation App
79274782|NCT05140863|Drug|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
79274783|NCT05140863|Drug|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
79274784|NCT05140863|Drug|Placebo BID|Placebo, orally twice a day, treatment period; 12-weeks fixed dose
80030377|NCT04980196|Diagnostic Test|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
79274785|NCT03232424|Device|NovoTTF-200A|"Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
79274786|NCT03232424|Drug|Temozolomide|"Concomitant phase:~75 mg/m2 per day for 42 days concomitant with radiotherapy.~Begins 1 day prior to XRT start.~Maintenance phase:~Begins 4 weeks after concomitant phase completion (+/- 1 week).~Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
79274787|NCT03232424|Radiation|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
79578577|NCT01887145|Procedure|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
79578578|NCT01887158|Drug|Polyethylene glycol|
79578579|NCT01887158|Drug|Bisacodyl|
79274788|NCT02676765|Drug|allergen extract tablet|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
80030378|NCT04980118|Behavioral|Control group|A nutritional intervention program that consisted of two individual nutritional consults.
79274789|NCT02676765|Drug|Placebo tablet|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
79274790|NCT05476406|Other|äKwä skincare system products|The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
79274791|NCT05476406|Other|competitor products (control)|Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
79578580|NCT01887184|Drug|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranassaly
79578581|NCT01887197|Other|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
79578582|NCT01887197|Drug|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
79578583|NCT01887197|Drug|mannitol inhalation powder|mannitol inhalation powder
79578584|NCT01887223|Procedure|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
79578585|NCT01887223|Drug|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
79578586|NCT01887236|Behavioral|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
79578587|NCT01887236|Behavioral|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
79578588|NCT01887249|Drug|Clarithromycin|
79578589|NCT01887249|Drug|metronidazole|
79578590|NCT01887249|Drug|esomeprazole|
79578591|NCT01887262|Device|BCM-guided fluid management|
79578592|NCT01887262|Procedure|Fluid management based on the clinical information alone|
79578593|NCT01887275|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
79737923|NCT02722720|Procedure|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
80030379|NCT04980118|Behavioral|Nutrition and physical activity group|A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
80030380|NCT03672188|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
80030381|NCT03672188|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
79274792|NCT05450120|Other|Functional Rehabilitation|Functional rehabilitation protocol
79274793|NCT05450120|Other|Neuromuscular Electrical Stimulation|Neuromuscular electrical stimulation protocol
79274794|NCT03163563|Device|Easywarm|Warming blanket
79274795|NCT03163563|Device|BairHugger|Patient warming mattress with continuous warm air.
79274796|NCT02680041|Drug|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
79578594|NCT01887275|Drug|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
79578595|NCT01887314|Dietary Supplement|Standardized Ginger extract|
79578596|NCT01887340|Drug|Carboplatin|"- carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
79578597|NCT01887340|Drug|Etoposide|100 mg/m2 D1 to D5
79578598|NCT01887340|Drug|Cisplatin|20 mg/m2 de D1 to D5
79578599|NCT01887379|Drug|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
79578600|NCT01887392|Other|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
79737924|NCT01111019|Drug|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
79873176|NCT00354172|Biological|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
79274797|NCT03163407|Drug|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
79274798|NCT03163407|Drug|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
79737925|NCT02883400|Drug|Spironolactone|spironolactone 25 mg up to 50 mg
79737926|NCT01119287|Drug|Dexamethasone 0.1% ophthalmic suspension|Maxidex
79737927|NCT01119287|Drug|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
79737928|NCT01119287|Other|Inactive ingredients, used as placebo|Tears Naturale II
79737929|NCT02694172|Other|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
80030382|NCT04980352|Other|real world treatment by doctors|real world treatment by doctors
80030383|NCT04919668|Behavioral|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
79274799|NCT03163485|Device|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
79274800|NCT03163485|Device|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
79578601|NCT01887405|Drug|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
79578602|NCT01887431|Other|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
79578603|NCT01887431|Other|Conventional therapy|3-month routine clinic visits
79737930|NCT01110707|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day [mg/day]).
79737931|NCT01110707|Drug|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
79737932|NCT03772600|Device|Dexcom G6 CGM|Use of Dexcom G6
79737933|NCT04931368|Drug|Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix|De-escalated induction treatment with R/HD-MTX and two courses of MATRix
79737934|NCT04931368|Drug|Control intervention: four courses of MATRix|Patients receive four courses of MATRix as induction treatment.
79274801|NCT03163251|Behavioral|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
79274802|NCT02547974|Biological|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
79274803|NCT02547974|Biological|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
79274804|NCT02547974|Biological|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
79274805|NCT02547974|Drug|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
79274806|NCT00154297|Drug|Everolimus (RAD001)|
79274807|NCT02679729|Drug|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
79578604|NCT01887444|Dietary Supplement|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
79737935|NCT02694250|Device|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
79274808|NCT02679729|Drug|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
79274809|NCT02679729|Other|Placebo|inactive substance
79737936|NCT01119131|Drug|Vitamin D3|Vitamin D3 at 10,000 IU a day
79737937|NCT01119131|Dietary Supplement|calcium|1000mg calcium daily
79274810|NCT01327183|Procedure|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
79274811|NCT01327183|Drug|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
79274812|NCT01327183|Drug|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
79578605|NCT01887444|Other|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
79274813|NCT01327183|Drug|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
79274814|NCT05449964|Procedure|SCALING AND ROOT PLANING (SRP)in single sitting|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
79274815|NCT05449964|Procedure|SCALING AND ROOT PLANING (SRP)in two sittings|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
80030384|NCT04919434|Other|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
79274816|NCT02270281|Drug|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
79274817|NCT03163329|Procedure|TAVR|Transcatheter Aortic Valve Replacement
79274818|NCT03163329|Procedure|SAVR|Surgical Aortic Valve Replacement
79274819|NCT01033123|Drug|BSI-201|IV infusion, 5.6 mg/kg
79737938|NCT01119131|Other|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
79274820|NCT05449262|Other|functional resistance training GROUP A|"Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
79274821|NCT05449262|Other|functional resistance training GROUP B|"Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
79274822|NCT03163173|Drug|GC4419|30 mg (~100 μCi) dose of [14C]GC4419
79578606|NCT01887457|Drug|VFEND|voriconazole will be administered in iv form
79737939|NCT00636922|Drug|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
79274823|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
79578607|NCT01887483|Dietary Supplement|Vetal Laban active|Dairy product with probiotic
79578608|NCT01887483|Dietary Supplement|Placebo|Dairy product without probiotic
79578609|NCT01887509|Device|Probe-based confocal laser endomicroscopy|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE~Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
79737940|NCT02722096|Drug|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
79873177|NCT00354172|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
79873178|NCT00354172|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
80030385|NCT03060694|Other|diabetes|"a history of diabetes and using anti-diabetic medicines.~fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
80030386|NCT03239990|Behavioral|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
79274824|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
80030387|NCT03060850|Drug|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
80030388|NCT04432558|Diagnostic Test|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
80030389|NCT04432558|Other|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
80030390|NCT04432558|Drug|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
79873179|NCT00354172|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
79274825|NCT01323205|Drug|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
79578610|NCT01887509|Procedure|Rectoscopy|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
79578611|NCT01887509|Procedure|EUS|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
79578612|NCT01887509|Procedure|Biopsy and resection|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE~Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
79274826|NCT01323205|Drug|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
79578613|NCT01887535|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
79578614|NCT01887535|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
79578615|NCT01887535|Drug|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
79274827|NCT03162861|Drug|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
79578616|NCT01887535|Drug|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
79873180|NCT00354172|Drug|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
80030391|NCT04770428|Drug|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
80030392|NCT04770428|Drug|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
80030393|NCT04919278|Procedure|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
79578617|NCT01887535|Drug|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
79578618|NCT01887535|Drug|Placebo|Matching placebo will be administered as an oral suspension formulation.
79737941|NCT02722096|Drug|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
80030394|NCT04979650|Drug|Methylprednisolone succinate|1 gram of methylprednisolone succinate within 500 ccs of normal saline
80030395|NCT04979650|Drug|Normal saline|500 g of normal saline without methylprednisolone succinate
79274828|NCT03162861|Drug|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
80030396|NCT04919044|Other|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
80030397|NCT04919200|Diagnostic Test|the single-breath helium dilution method and Whole-body plethysmography|The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
79274829|NCT01322269|Drug|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
79274830|NCT03114579|Device|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
79274831|NCT03114579|Device|NEXFIN HD|
79274832|NCT03114423|Other|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
79274833|NCT03114423|Other|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
79274834|NCT02765165|Drug|USL311|Administered once weekly in a 21-day cycle
79274835|NCT02765165|Drug|USL311|Administered once daily in a 21-day cycle
79274836|NCT02765165|Drug|USL311|Administered once daily in a 42-day cycle
79274837|NCT02765165|Drug|Lomustine|Administered once every 6 weeks in a 42-day cycle
79274838|NCT02156843|Drug|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
79578619|NCT01887548|Other|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
79578620|NCT01887561|Drug|dasatinib|
79578621|NCT01887574|Other|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
79578622|NCT01887613|Drug|Regnite|oral
79737942|NCT04893538|Diagnostic Test|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
80030398|NCT04967716|Other|basic information|Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
79274839|NCT02156843|Drug|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
79274840|NCT02675907|Drug|N1539|
79274841|NCT02675907|Drug|Intravenous Placebo|
79274842|NCT02156921|Other|App-based training|
79274843|NCT02675517|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
80030399|NCT04967716|Other|venous blood test|The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
80030400|NCT04703738|Procedure|Soft tissue flap + Connective Tissue Graft|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
79274844|NCT02152865|Drug|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
79274845|NCT02152865|Drug|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
79274846|NCT02152943|Drug|Everolimus|Given PO
79274847|NCT02152943|Other|Laboratory Biomarker Analysis|Correlative studies
79274848|NCT02152943|Drug|Letrozole|Given PO
79274849|NCT02152943|Biological|Trastuzumab|Given IV
79274850|NCT02156999|Device|Ibandronic acid, vitamin D|
79274851|NCT03162393|Procedure|nerve transfer|
79274852|NCT02153021|Radiation|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
79274853|NCT02157155|Biological|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
79274854|NCT02157233|Behavioral|Rest|
79274855|NCT02157233|Behavioral|Exercise|
79274856|NCT02159651|Drug|tacrolimus|oral
79578623|NCT01887626|Drug|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
79578624|NCT01887626|Drug|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
79578625|NCT01887626|Drug|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
79578626|NCT01887665|Behavioral|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
79737943|NCT04893538|Diagnostic Test|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
79737944|NCT04862962|Drug|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
80030401|NCT04703738|Device|Soft tissue flap + Geistlich Fibro-Gide®|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
79578627|NCT01887691|Drug|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
79578628|NCT01887704|Device|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
79578629|NCT01887704|Procedure|conventional angioplasty|Conventional angioplasty was used in both arms.
79578630|NCT01887704|Procedure|stenting|Stenting was implanted in both arms.
79578631|NCT01887704|Device|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
79578632|NCT01887704|Drug|Aspirin|Aspirin will be administrated in participants in both arms.
79578633|NCT01887704|Drug|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
79578634|NCT01887704|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
79737945|NCT01118975|Drug|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
79737946|NCT01118975|Drug|Lapatinib|1,250 mg once daily
79873181|NCT00354172|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L)."
79274857|NCT04996641|Procedure|Root canal treatment and crown|Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients
79274858|NCT02764775|Device|Headpod|Adaptive equipment to assist with active head movements
79274859|NCT03160833|Drug|HMPL-453|oral administrative
79274860|NCT02159885|Other|Telemonitoring|
79274861|NCT02774681|Procedure|Cognitive Assessment|Ancillary studies
79578635|NCT01887704|Device|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
79578636|NCT01887704|Device|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
79578637|NCT01887704|Device|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
79578638|NCT01887730|Behavioral|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
79737947|NCT02722018|Drug|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
79737948|NCT02722018|Drug|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
79737949|NCT04310111|Procedure|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
79737950|NCT02721940|Procedure|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
79274862|NCT02774681|Drug|Palbociclib|Given PO
79737951|NCT02721940|Biological|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
79873182|NCT00354172|Procedure|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
79873183|NCT00354172|Radiation|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
79873184|NCT03986242|Device|rolling|use non- vibration rolling and the total time is 20 minutes.
79274863|NCT02774681|Procedure|Quality-of-Life Assessment|Ancillary studies
79274864|NCT02774681|Biological|Trastuzumab|Given IV
79274865|NCT03113799|Device|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
79274866|NCT02157311|Drug|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
79578639|NCT01887730|Behavioral|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
79578640|NCT01887730|Behavioral|Control|
79578641|NCT01887743|Drug|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
79578642|NCT01887756|Device|Tele Rehabilitation|
79578643|NCT01887782|Device|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
79578644|NCT01887782|Device|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
79578645|NCT01887795|Drug|Erlotinib|
79578646|NCT01887795|Drug|WBRT|
79578647|NCT01887821|Drug|Chloroquine|
79578648|NCT01887821|Drug|Dihydroartemisinin/Piperaquine|
79873185|NCT03986242|Device|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
79873186|NCT03986242|Other|static stretching|static stretching and the total time is 20 minutes.
80030402|NCT04967404|Dietary Supplement|Phosphatidylserine|800 mg per day for 10 days
79274867|NCT03542903|Device|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
79403381|NCT01273701|Behavioral|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
79274868|NCT02157389|Other|Administration of a pharmacological placebo|
79274869|NCT04784039|Diagnostic Test|Transesophageal echocardiography|Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE
79274870|NCT04784039|Diagnostic Test|D-Dimer analysis|Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
79274871|NCT02159963|Other|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
79274872|NCT02159963|Other|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
79737952|NCT02721940|Biological|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
79737953|NCT02721940|Drug|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
80030403|NCT04650152|Drug|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
80030404|NCT04967950|Drug|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
79274873|NCT02159963|Other|Optional training|8 weeks of optional home based, unsupervised training.
79274874|NCT02159963|Other|Control|8 weeks of control period. Participants are doing daily living.
79274875|NCT02547428|Drug|CTN SR|CTN SR tablets, daily, Orally.
79274876|NCT02547428|Drug|Matching placebo|Matching-placebo tablets daily, orally.
79274877|NCT02157467|Drug|BMS-955176|
79274878|NCT02157467|Drug|Ortho Cyclen|
79403382|NCT01273701|Behavioral|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
79274879|NCT01374087|Drug|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
79274880|NCT01374087|Radiation|Brachytherapy|Brachytherapy: Low or high dose rate.
79274881|NCT02153333|Procedure|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
79274882|NCT00152971|Drug|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
79274883|NCT00152971|Drug|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
79274884|NCT00152971|Drug|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
79274885|NCT00152971|Drug|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
79274886|NCT00152971|Drug|Enoxaparin|30 mg subcutaneously twice daily
79274887|NCT02157701|Dietary Supplement|Polyherbal capsule|
79274888|NCT02157701|Dietary Supplement|Placebo capsule|
79274889|NCT02538614|Drug|Idelalisib|Tablets administered orally twice daily
79274890|NCT02538614|Drug|BI 836826|Intravenous administration as a rate-controlled infusion
79578649|NCT01887834|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|
79578650|NCT01887834|Dietary Supplement|Kyodophilus Matching Placebo Capsules|
79578651|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
79274891|NCT02160119|Other|MRI-based techniques|fMRI, DTI
79274892|NCT02160119|Other|EEG|ERP
79578652|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
79578653|NCT01887873|Device|Hyaluronan Thiomer i.o. implant|
79578654|NCT01887899|Device|transcranial direct current stimulation|
79578655|NCT01887899|Device|sham stimulation|
79578656|NCT01887951|Drug|Penthrox Inhaler|
79578657|NCT01887951|Drug|Tramadol Injection|
79274893|NCT03734939|Other|None intervention is planned.|None intervention is planned, just a survey.
79578658|NCT01887964|Other|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
79274894|NCT05447078|Dietary Supplement|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
79737954|NCT02721940|Drug|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
79737955|NCT04851340|Other|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
79737956|NCT04851340|Other|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
79873187|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
79737957|NCT04829422|Drug|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
79737958|NCT04094350|Other|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
79274895|NCT05447078|Dietary Supplement|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
79274896|NCT02160197|Device|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
79274897|NCT02160197|Device|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
79274898|NCT04475575|Device|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
79274899|NCT03160599|Other|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.
79274900|NCT04475341|Biological|BMS + Bone Marrow Aspirate Concentrate|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
79403383|NCT04020289|Behavioral|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
79403384|NCT04949412|Diagnostic Test|Vitamin D|serum vitamin D level
79578659|NCT01887964|Other|Control flour|Wheat flour without resistant starch (type-4)
79578660|NCT01887977|Other|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
79578661|NCT01888016|Other|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
79737959|NCT04094350|Other|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
79873188|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
80030405|NCT04967950|Drug|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
80030406|NCT04967950|Drug|Methotrexate|methotrexate
79873189|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
79873190|NCT01052506|Drug|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
80030407|NCT04967326|Drug|Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)|
79578662|NCT01888016|Other|standard physiotherapies treatment|"10 standard treatments in 2 weeks~Deltoid and infraspinatus muscles electrotherapy~Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~Scar massage~Upper limb, cervical spine and scapula massages~Passive and assisted/active shoulder mobilization exercises~Scapula micro-mobilizations~Gleno-humeral decoaptation~Elbow, wrist and hand active mobilization~Proprioceptive exercise with and without the aid of the mirror"
79737960|NCT04094350|Other|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
79737961|NCT04094350|Other|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
79737962|NCT01110239|Procedure|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
79737963|NCT02721862|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
79737964|NCT02721862|Drug|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
79737965|NCT02721862|Radiation|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
79873191|NCT01052506|Drug|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
79873192|NCT03988816|Drug|Roflumilast|500Mcg Tab, once daily
80030408|NCT03145142|Procedure|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
80030409|NCT03145142|Procedure|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
80030410|NCT03062176|Drug|Anakinra|Anakinra (Kineret)
79274901|NCT04475341|Procedure|BMS alone|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
79274902|NCT03504644|Other|Laboratory Biomarker Analysis|Correlative studies
79274903|NCT03504644|Drug|Venetoclax|Given PO
79274904|NCT03504644|Drug|Vincristine Liposomal|Given IV
79578663|NCT01888029|Device|transcranial direct current stimulation|
79578664|NCT01888029|Device|sham stimulation|
79578665|NCT01888042|Drug|Everolimus|10 mg (1 tablet of 10 mg)
79578666|NCT01888055|Device|transcranial direct current stimulation|
79578667|NCT01888055|Device|sham stimulation|
79274905|NCT04620135|Drug|Netarsudil ophthalmic solution 0.02%|Topical sterile ophthalmic solution Other Name: Rhopressa®
79737966|NCT00612898|Drug|apricitabine|800mg BID apricitabine orally for 48 weeks
79873193|NCT03988816|Drug|Placebo oral tablet|once daily
79873194|NCT00353704|Drug|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
79873195|NCT00353704|Drug|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
79873196|NCT00353704|Drug|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
79873197|NCT03742180|Drug|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
80030411|NCT03472820|Other|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
80030412|NCT03472820|Other|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
80030413|NCT03472820|Other|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
80030414|NCT03472820|Other|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
80030415|NCT03472820|Other|PhytoGanix (tropical fruit flavor)|Organic Superfruits & Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
80030416|NCT03472820|Other|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
79274906|NCT04620135|Drug|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|Other Name: Glanatec®
79274907|NCT02160275|Device|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
79274908|NCT02160275|Device|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
79578668|NCT01887652|Other|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
79274909|NCT03126968|Drug|Topical epinephrine|Prophylactic topical epinephrine
79274910|NCT03126968|Drug|Placebos|Topical placebo (normal saline)
79578669|NCT01887652|Other|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
79274911|NCT05676879|Other|Ice massage was applied to the SP6 points|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.
79578670|NCT01888081|Drug|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
79274912|NCT02266849|Drug|Loperamide|12 mg Loperamide each day for three days
79274913|NCT02266849|Drug|Placebo|6 tablets daily for three days
79274914|NCT02552966|Device|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
79274915|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
79274916|NCT01309945|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
79578671|NCT01888081|Radiation|Ionizing Radiation|
79578672|NCT01888094|Other|Ultrasound-guided cannulation and examination|
79578673|NCT01888107|Drug|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
79873198|NCT03742180|Drug|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
79274917|NCT01309945|Drug|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
79578674|NCT01888107|Drug|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
79274918|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
79274919|NCT01309945|Drug|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
79578675|NCT01888107|Drug|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
79578676|NCT01888120|Drug|Ziconotide|
79578677|NCT01888133|Behavioral|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
79578678|NCT01888133|Behavioral|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
79873199|NCT00512252|Drug|AMD3100|
79274920|NCT02552888|Drug|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
79274921|NCT02552888|Dietary Supplement|Isoquercetin|Isoquercetin 225 mg by mouth once per day
79274922|NCT02552888|Other|placebos|placebos
79873200|NCT00512252|Drug|Mitoxantrone|
79873201|NCT00512252|Drug|Etoposide|
79873202|NCT00512252|Drug|Cytarabine|
80030417|NCT04967014|Drug|HIP2101|Test drug
80030418|NCT04967014|Drug|RLD2101|Reference drug
79274923|NCT02153567|Drug|Escitalopram|Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
79274924|NCT02153567|Other|Placebo|Placebo will be given for the next 10 weeks.
79274925|NCT03541967|Device|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
79274926|NCT01023685|Biological|CAD106|
79274927|NCT02160431|Behavioral|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
79274928|NCT02441660|Drug|Capsaicin 8% Patch|Applied topically for 1 hour
79274929|NCT02441660|Drug|Low Dose Capsaicin 0.025% Well Patch|
79274930|NCT02160509|Device|IPhone based realtime remote ultrasound interpretation|
79578679|NCT01888146|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
79578680|NCT01887028|Device|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
79578681|NCT01888159|Procedure|Bilateral Salpingectomy|
79578682|NCT01888159|Procedure|Tubal sterilization with bipolar energy|
79578683|NCT01888172|Behavioral|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
79578684|NCT01888172|Device|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
79737967|NCT00612898|Drug|lamivudine|150mg BID lamivudine orally for 48 weeks
79737968|NCT01118663|Drug|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
79737969|NCT01118663|Drug|Acetadote|Acetadote [old formulation] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
79274931|NCT01303783|Drug|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
79274932|NCT01303783|Drug|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
79274933|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
79274934|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
79274935|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
79274936|NCT01303783|Drug|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
79274937|NCT01303783|Drug|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
79403385|NCT04385355|Device|Conventional transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
79578685|NCT01888172|Behavioral|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
79274938|NCT01303783|Drug|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
79274939|NCT02153801|Procedure|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
79873203|NCT03988894|Device|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
79873204|NCT00516386|Drug|RhIGF-1|35-40 mcg/k/dose twice daily SC
79403386|NCT04385355|Device|Narrow transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
79578686|NCT01888211|Dietary Supplement|Omega 3 fatty acid supplementation|2 grams Omacor daily
79578687|NCT01888211|Dietary Supplement|Olive Oil|2 grams olive oil daily
79274940|NCT02160587|Drug|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
79274941|NCT02160587|Drug|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
79274942|NCT02160587|Other|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
79274943|NCT02153879|Drug|Fenofibrate|fenofibrate 145/day for 12 weeks
79274944|NCT02153879|Drug|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
79578688|NCT01888224|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
79403387|NCT04023175|Other|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
79403388|NCT04023175|Other|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
79403389|NCT04914858|Other|Education|Its validity and reliability is a reliable scale in Turkey
79403390|NCT04022473|Drug|Bafiertam|Over-encapsulated capsule to mask treatment
79403391|NCT04022473|Drug|Tecfidera|Over-encapsulated capsule to mask treatment
79403392|NCT05375058|Other|Observational Study|Observational Study; the study did not involve any interventions
79737970|NCT02721706|Other|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h <50%, serum albumin <3 g/dl, body mass index <18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
79737971|NCT02721784|Device|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
79737972|NCT02721784|Radiation|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
79737973|NCT01118351|Drug|sunitinib malate|Given orally
79737974|NCT01118351|Other|immunohistochemistry staining method|Correlative studies
79737975|NCT01118351|Other|TdT-mediated dUTP nick end labeling assay|Correlative studies
79403393|NCT03972696|Radiation|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
79578689|NCT01888237|Drug|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
79578690|NCT01888237|Drug|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
79578691|NCT01888250|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
79578692|NCT01888263|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
79737976|NCT01118351|Other|light microscopy|Correlative studies
79737977|NCT01118351|Other|laboratory biomarker analysis|Correlative studies
79737978|NCT04188496|Other|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
79873205|NCT00524420|Device|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
79578693|NCT01888276|Other|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~The test of Stroop that assesses selective attention~During the session 2:~The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~The task of the casino (Iowa Gambling Test)~The task of landing~The test of Stroop"
79274945|NCT03541421|Other|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
79737979|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
79737980|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
79737981|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
80030419|NCT03055286|Drug|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
79873206|NCT00524420|Device|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
79873207|NCT00512096|Drug|Ifosfamide|1200 mg/m^2 By Vein Over 2 Hours on Days 1-3
80030420|NCT03470948|Other|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
79274946|NCT01373931|Drug|LY2216684|Administered orally
79274947|NCT01373931|Drug|Ortho Cyclen|35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
79274948|NCT01373931|Drug|Placebo|Administered orally
79274949|NCT01147939|Drug|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
79274950|NCT01147939|Drug|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
79274951|NCT02160743|Dietary Supplement|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
79274952|NCT02158013|Other|Levorag Emulgel|
79737982|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
79737983|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
79737984|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
79737985|NCT02693314|Dietary Supplement|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
79274953|NCT02158013|Drug|Diltiazem|
79274954|NCT05676021|Behavioral|motivational interview|motivational interview-based health education
79274955|NCT01147003|Drug|Investigational new drug, company code: BGG492|
79274956|NCT01147003|Drug|Placebo|
79274957|NCT01147003|Drug|Investigational new drug, company code: BGG492|
79274958|NCT01023295|Drug|fosbretabulin|single dose, intravenous infusion
79274959|NCT01023295|Drug|Saline|single dose, intravenous infusion
79274960|NCT05468138|Drug|SOX|"Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1."
79274961|NCT05468138|Drug|XELOX|Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
79274962|NCT05468138|Other|Observation|follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
79274963|NCT05468138|Drug|PD-1 antibody|Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
79737986|NCT02693392|Drug|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea based oral hypoglycemic agents~Metformin based oral hypoglycemic agents~Metformin plus Sulfonylurea based oral hypoglycemic agents"
79873208|NCT00512096|Drug|Paclitaxel (Taxol)|175 mg/m^2 By Vein Over 3 Hours on Day 1
79274964|NCT02154113|Device|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
79274965|NCT02154113|Device|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
79274966|NCT02158325|Procedure|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0~3.9, 4.0~5.0, 5.1~6.0 mm in diameter)
79578694|NCT01888289|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
79578695|NCT01888302|Drug|Cisplatin|Given IV
79578696|NCT01888302|Drug|Gemcitabine Hydrochloride|Given IV
79578697|NCT01888302|Other|Quality-of-Life Assessment|Ancillary studies
79873209|NCT00512096|Drug|Cisplatin|25 mg/m^2 By Vein Over 2 Hours on Days 1-3
80030421|NCT04918498|Behavioral|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
80030422|NCT04918498|Behavioral|routine treatment|provide routine nursing and rehabilitation program
79578698|NCT01888302|Drug|Sirolimus|Given PO
79737987|NCT02693392|Dietary Supplement|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
79737988|NCT04175626|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
79737989|NCT00613054|Drug|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate & hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs & 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate & that such doses are safe & well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety & pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate & hydroxyurea for 28 days for purpose of scheduling evaluations."
79737990|NCT04687696|Other|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
79737991|NCT04687696|Other|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
79737992|NCT04687696|Other|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
79737993|NCT04167436|Other|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
79403394|NCT02705911|Other|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
79873210|NCT01565252|Dietary Supplement|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
79873211|NCT04462796|Dietary Supplement|Magnesium Citrate|Magnesium Citrate 200 mg daily
79274967|NCT01140217|Drug|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
79274968|NCT02552732|Device|NHF with or without Oxygen|NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
79274969|NCT02160821|Procedure|Caudal Epidural|Ultrasound Guided Caudal Block
79274970|NCT02160821|Procedure|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
79274971|NCT01297543|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
79274972|NCT01297543|Drug|G-CSF|Background therapy
79274973|NCT04488068|Procedure|Sham Magnetic stimulation|Sham Magnetic stimulation for comparison.
79274974|NCT02154191|Procedure|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
79274975|NCT04439955|Drug|CBD|300 mg CBD
79274976|NCT03113877|Other|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
79274977|NCT03541265|Drug|Exparel|long-acting Bupivacaine extended release liposome compound
79274978|NCT03541265|Procedure|Adductor block protocol|Adductor block using Exparel
79274979|NCT03541265|Procedure|peri-articular injection protocol|peri-articular injection using Exparel
79274980|NCT02547038|Drug|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
79403395|NCT02705911|Other|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
79403396|NCT03845946|Behavioral|angioedema|electronic tracking book
79403397|NCT01485614|Drug|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
79578699|NCT01888315|Device|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
79578700|NCT01888315|Device|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
79578701|NCT01888315|Device|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
79578702|NCT01888315|Device|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
79578703|NCT01888328|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
79274981|NCT02547038|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
79274982|NCT05620537|Other|observation|There are no interventions.
79274983|NCT02161055|Drug|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = [fasting blood glucose (mmol/L) × 18-100] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
79274984|NCT01131013|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
79274985|NCT01131013|Drug|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
79274986|NCT01131013|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
79274987|NCT02764697|Drug|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
79274988|NCT05467904|Other|Xltranplus, Xltran|Xltranplus and Xltran are full hemp flower formulations
79274989|NCT02266927|Drug|Flovent HFA|
79274990|NCT02266927|Drug|OPTINOSE™ FLUTICASONE|
79578704|NCT01888341|Drug|Isotretinoin|Isotretinoin Capsules,20 mg
79274991|NCT02397668|Device|CorMatrix Cor TRICUSPID ECM Valve|CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
79873212|NCT00524030|Drug|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
79274992|NCT02158481|Dietary Supplement|A capsule containing both polyphenols and carotenoids|
79274993|NCT02158481|Dietary Supplement|Placebo intervention|Placebo intervention
79274994|NCT02267005|Dietary Supplement|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
79274995|NCT02267005|Dietary Supplement|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
79274996|NCT02158559|Drug|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
79403398|NCT01485614|Drug|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
79873213|NCT00524030|Drug|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
79274997|NCT02158559|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
79403399|NCT01485614|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
79403400|NCT01485614|Drug|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
79403401|NCT01485614|Drug|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
79873214|NCT00523718|Drug|riluzole|50 mg PO bid, 12 weeks
79873215|NCT00523718|Drug|placebo|placebo, 1 capsule PO bid, 12 weeks
79873216|NCT00523640|Drug|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
79873217|NCT00345358|Biological|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
79274998|NCT05612191|Drug|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
79274999|NCT02673489|Drug|DCV|
79275000|NCT02673489|Drug|SOF|
79275001|NCT02673489|Drug|RBV|
79275002|NCT03738995|Biological|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
79275003|NCT05445362|Device|Diode laser disinfection|- Disinfection with parameter of Power: 1.5 watt, Mode: pulse: SP: Ton=10ms; Toff10ms 50Hz (50% pulse mode), for 5 seconds in spiral movement in apical to coronal direction no stop with non-initiated endodontic tip 200 micron diameter and 15 mm length three times. Irrigation with NaOCl, irradiation with the laser, then irrigation with E.D.T.A and irradiation with the laser, for three times then final rinse with distilled water with paper point dryness in between irrigations.
79403402|NCT01485614|Biological|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
79403403|NCT00722553|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
79578705|NCT01888354|Drug|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
79578706|NCT01888380|Procedure|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
79578707|NCT01888380|Procedure|Conventional autopsy|
79578708|NCT01888393|Drug|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
79578709|NCT01888406|Behavioral|Guided Self-Help|
79578710|NCT01888406|Behavioral|Pure Self-Help|
79578711|NCT01888419|Other|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
79578712|NCT01888445|Drug|roxadustat|oral
79275004|NCT05445362|Device|Diode Laser bio-stimulation.|"- The diode laser bio-stimulation with Wiser Diode Laser, Irradiation of the periapical area from the labial mucosal surface, day after day day on-day off for one week, two sessions will be applied at the same day with two hours interval, first session immediately after filing (blood induction), with flat top hand piece , diameter 1cm at a distance between 0 and 105 cm, at 1 watt power for 50s with CW continues mode in order to obtain the 5 J/cm2 fluence."
79737994|NCT00613132|Drug|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
79737995|NCT03712852|Procedure|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
79737996|NCT03712852|Procedure|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
79737997|NCT03712852|Procedure|CAF treated patients|Patients will be treated by coronally advanced flap
79403404|NCT00722553|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
79403405|NCT00722553|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
79403406|NCT03022747|Drug|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
79403407|NCT03022747|Drug|Standard treatment|Oral 6-mercaptopurine and methotrexate
79737998|NCT00613444|Device|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
79737999|NCT04143100|Other|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
79738000|NCT04558216|Drug|Vonoprazan|20 mg tablets administered orally
79738001|NCT04558216|Drug|Rifampin|600 mg (Two 300 mg capsules)
79738002|NCT04132180|Other|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
79403408|NCT04853082|Drug|Limonene capsule|All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
79873218|NCT00345358|Biological|Infanrix IPV/Hib|4 intramuscular injections
79873219|NCT03869684|Drug|MT-0814|Randomly assigned dose
79873220|NCT03869684|Drug|Placebo|Placebo manufactured to mimic MT-0814
79738003|NCT04132180|Other|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
79738004|NCT04120870|Drug|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
79738005|NCT04120870|Drug|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
79738006|NCT01118117|Device|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
79738007|NCT00613522|Other|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
79738008|NCT04310657|Diagnostic Test|mNGS|Metagenomics second generation sequencing technology
79873221|NCT01058746|Other|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
80030423|NCT02915432|Biological|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
79403409|NCT04853082|Drug|Limonene capsules(Placebo)|Limonene capsules(Placebo)
79403410|NCT03928015|Drug|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
79403411|NCT03928015|Drug|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
79873222|NCT01058746|Other|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
79275005|NCT05445362|Drug|Triple antibiotic paste disinfection|-The root canals will be copiously and slowly irrigated with 20 ml of 1.5% (17) sodium hypochlorite (NaOCl) solution for 5 minutes alternatively with 20 ml of 17% ethylene diamine tetra acetic acid (E.D.T.A) solution for 5 minutes with intermediated rinse of distilled water with paper point dryness in between irrigations. The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline . The doxycycline capsule content will be evacuated in a sterile mortar; a tablet of metronidazole and a tablet of ciprofloxacin will be crushed and ground into homogenous powder in the same mortar using a pestle. Saline drops will be added and mixed using the pestle until a creamy paste achieved . The canals Will be dried with paper points and medicated with triple antibiotic paste; the access cavity will be sealed with intermediate restorative material (I.R.M) .
79873223|NCT00516074|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
79275006|NCT05445362|Procedure|"revascularization using the standard method Blood Clot"|"- The root canal Will be over-instrumented using finger plugger size #25 to encourage bleeding up to cemento-enamel junction. The sterile finger plugger size # 25 will be used with sharp strokes into the periapical tissue beyond the apex until bleeding becomes evident at the cervical portion of the canal. Blood column will be left 10 minutes to clot covered by sterile cotton, a collagen orifice plug Collagen plugs will be used as matrix against mineral trioxide aggregate (M.T.A) condensation, M.T.A will be mixed according to the manufacturer's instructions and carried to the cavity with M.T.A carrier (Dovgan M.T.A Carrier) , and then compacted using wet cotton roll on pluggers (S- Kondenser) . Finally the cavity will be restored with a glass ionomer base and light cure composite resin ."
79275007|NCT05611099|Device|Dreem 3 System vs WatchPAT One|Dreem 3 System and WatchPAT One will be worn simultaneously during 3 nights by each study participant, in order to compare the TST automatically outputted by both devices.
79873224|NCT00516074|Drug|placebo|subcutaneous injection, volume equivalent to active, twice a day
79873225|NCT01057654|Drug|Pravastatin|Pravastatin 40 mg
79403412|NCT03831906|Diagnostic Test|Xpert MTB/RIF Ultra (Ultra)|"The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available."
79403413|NCT00735969|Drug|Peginterferon|
79578713|NCT01888445|Drug|darbepoetin alfa|iv
79578714|NCT01888458|Drug|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
79578715|NCT01888471|Procedure|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
79578716|NCT01888471|Other|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
79873226|NCT01057654|Drug|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
79403414|NCT00735969|Drug|Ribavirin|
79873227|NCT00515294|Drug|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
79403415|NCT03022591|Other|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
79578717|NCT01888510|Procedure|computed tomography|Undergo conventional free breathing CT
79578718|NCT01888510|Procedure|4-dimensional computed tomography|Undergo 4D CT
79578719|NCT01888510|Procedure|computed tomography|Undergo ABC CT
79578720|NCT01888510|Procedure|cone-beam computed tomography|Undergo ABC CBCT
79738009|NCT03747562|Drug|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
79738010|NCT03747562|Other|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
79873228|NCT00515294|Other|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
79578721|NCT01888510|Procedure|cone-beam computed tomography|Undergo free breathing CBCT
79873229|NCT00515294|Drug|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
79873230|NCT00515294|Other|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
79873231|NCT00345046|Drug|Pred Forte|Four drops daily decreasing to once daily over four weeks.
79873232|NCT00345046|Drug|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
79403416|NCT04792164|Procedure|Ultra sound guided nerve block|Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
79873233|NCT00345046|Drug|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
79578722|NCT01888523|Behavioral|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
79578723|NCT01888523|Behavioral|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
79873234|NCT01055002|Biological|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
79873235|NCT00515216|Drug|5-fluorouracil|
79578724|NCT01888536|Drug|Limaprost|
79873236|NCT00515216|Drug|Oxaliplatin|
79873237|NCT00515216|Drug|Leucovorin|
79873238|NCT00522626|Device|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
79578725|NCT01888536|Drug|Pregabalin|
79275008|NCT05611099|Other|Usability Questionnaire|After having undergone the 3 nights of measurement, an end of Study Questionnaire will be performed on a separate day to obtain Usability feedback from participants who have undergone simultaneous recordings with the Dreem 3 + WatchPAT devices.
79275009|NCT02772809|Device|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
79275010|NCT01020565|Drug|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
79578726|NCT01888536|Drug|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
79578727|NCT01888536|Drug|Placebo(for Limaprost)|mimic Limaprost tablet
79578728|NCT01888549|Drug|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
79578729|NCT01888549|Drug|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
79873239|NCT00440193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
79873240|NCT00440193|Drug|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
79275011|NCT05475938|Other|Painting therapy and psychoanalysis|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
79275012|NCT01020097|Drug|fluorine F18 EF5|Given IV
79275013|NCT01020097|Procedure|immunohistochemistry staining method|Correlative study
79275014|NCT01020097|Procedure|biopsy|Correlative study
79275015|NCT01020097|Procedure|Positron Emission tomography|Undergo scan
79275016|NCT02154269|Drug|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
79275017|NCT02154269|Drug|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
79275018|NCT01002235|Biological|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
79403417|NCT04792164|Procedure|Usual infiltration|Usual infiltration by lidocaine before open inguinal hernia repair.
79403418|NCT04386213|Device|coronary artery in-stent restenosis|treat the petients with coronary artery in-stent restenosis
79304626|NCT02439073|Behavioral|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
79403419|NCT04025437|Procedure|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
79578730|NCT01888549|Drug|placebo|
79578731|NCT01888562|Drug|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
79578732|NCT01888575|Drug|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
79578733|NCT01888588|Drug|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
79873241|NCT00511472|Drug|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
79873242|NCT00511472|Drug|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
79873243|NCT00511472|Drug|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
79873244|NCT01033305|Drug|CyCol™|Orally, once per day for 4 weeks
79873245|NCT01033305|Drug|Placebo|Orally, once per day for 4 weeks
79873246|NCT01037049|Other|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
79873247|NCT00514904|Biological|Nimenrix|Single dose, intramuscular injection
79873248|NCT00514904|Biological|Mencevax|Single dose, subcutaneous injection
79873249|NCT00440115|Behavioral|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
80030424|NCT02915432|Biological|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
79403420|NCT04025437|Radiation|Neoadjuvant radiotherapy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
79403421|NCT03229512|Drug|Sildenafil|Topical 1% Sildenafil Cream
79873250|NCT00440115|Behavioral|Low intensity disease management|Health education mailings, one motivation interview/counseling
79873251|NCT00440115|Behavioral|Comparison group|Health education mailings
79873252|NCT00440115|Drug|Bupropion|Buproprion or Nicotine Replacement Therapy
79873253|NCT04384328|Other|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
80030425|NCT02915432|Biological|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
80030426|NCT03062098|Device|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
80030427|NCT02178332|Other|Yhteispeli, whole school programme|
80030428|NCT02178332|Other|Two theoretical lectures|
79873254|NCT01037205|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
79873255|NCT01037205|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
80030429|NCT02620384|Drug|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
79403422|NCT01279083|Drug|DE-112|Topical ocular solution
79873256|NCT00440037|Biological|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
79403423|NCT01279083|Drug|DE-112|Topical ocular solution
79403424|NCT01279083|Drug|DE-112|Topical ocular solution
79873257|NCT01037283|Behavioral|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
79873258|NCT01033461|Dietary Supplement|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
79403425|NCT01279083|Drug|DE-112|Topical ocular solution
79403426|NCT01279083|Drug|DE-112 Vehicle Solution|Topical ocular solution
79403427|NCT01279083|Drug|Timolol Maleate Solution|Topical ocular solution
79873259|NCT01033461|Dietary Supplement|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
79873260|NCT01033461|Other|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
79873261|NCT01033539|Other|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
79403428|NCT03022201|Drug|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
79403429|NCT03022201|Drug|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
79403430|NCT03022201|Drug|Placebo domperidone|
79403431|NCT03022201|Drug|Placebo DA-9701|
79403432|NCT04716114|Drug|SKLB1028|SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
79403433|NCT04716114|Drug|Salvage Chemotherapy|Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
79403434|NCT00752973|Drug|MALG (malathion) Treatment|MALG applied for 30 minutes
79403435|NCT04025593|Drug|Cyclophosphamide|750mg/m2 day 1
79873262|NCT01037439|Device|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
79873263|NCT01033617|Procedure|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
79403436|NCT04025593|Drug|Rituximab|375mg/m2 day 0
79403437|NCT04025593|Drug|Doxorubicin|50mg/m2 day 1
79578734|NCT01888627|Other|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
79738011|NCT04510246|Behavioral|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~Further testing advice~Awareness that treatment can be prescribed by the general practitioner~Conducting pre-treatment work-up assessment~DAA prescription guidelines, including linkage to specialist consultation~Providing treatment support~Advising on testing process for cure~Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
79738012|NCT01109849|Behavioral|behavior therapy|combination of individual and group parent training plus school consultation
79578735|NCT01888679|Procedure|Head movement|Head movement in extension, flexion, right and left rotation
80030430|NCT02620384|Drug|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
80030431|NCT03470870|Other|Comparative analysis of the characteristics|"Predictive nomogram of short-term hospitalization (less than two days after surgery)~Factors influencing the variations of average stay lenght~Morbidity of the ERAS program"
80030432|NCT04918576|Drug|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
80030433|NCT04918576|Drug|Normal Saline|40 mL topical of 0.9% normal saline
80030434|NCT04214756|Procedure|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
80030435|NCT04403308|Biological|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
79738013|NCT01109849|Drug|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
79403438|NCT04025593|Drug|Vincristine|1.4mg/m2, max 2mg day 1
79578736|NCT01888718|Drug|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
79578737|NCT01888731|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
79738014|NCT01109849|Other|monitoring|monthly weight, height and BMI checks
79578738|NCT01888744|Drug|GnRH agonist|
79738015|NCT01109849|Other|drug holiday|switch from seven day a week dosing to medication only on school days
79738016|NCT01109849|Dietary Supplement|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
79738017|NCT04094662|Drug|Mirogabalin|Mirogabalin tablets for oral administration
79738018|NCT04094662|Drug|Placebo|Matching placebo tablets for oral administration
79738019|NCT01061736|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79738020|NCT01061736|Drug|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
79738021|NCT01061736|Drug|Methotrexate|Same weekly dose as received prior to enrollment
79738022|NCT01061736|Drug|Folic Acid|According to local standard
80030436|NCT02523170|Device|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
80030437|NCT03472508|Drug|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
79304627|NCT03190135|Behavioral|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
79304628|NCT03190135|Behavioral|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
79304629|NCT03281759|Device|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
79403439|NCT04025593|Drug|Prednisone|60mg/m2, max 100mg day 1-5
79403440|NCT04025593|Drug|Ibrutinib|420mg/day qd
79403441|NCT04025593|Drug|Lenalidomide|25mg day1-10
79403442|NCT04025593|Drug|chidamide|20mg day 1,4,8,11
79403443|NCT04025593|Drug|decitabine|decitabine 10mg/m2 day-5 to day-1
79403444|NCT02709967|Other|Material support|Writing materials
79578739|NCT01888744|Drug|GnRH antagonist|
79738023|NCT04083820|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
79578740|NCT01888744|Drug|hP-hMG|
79578741|NCT01888744|Drug|Human chorionic gonadotropin|induction of final oocyte maturation
79578742|NCT01888744|Drug|Progesterone|
79578743|NCT01888757|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
79578744|NCT01888783|Other|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
79578745|NCT01888796|Drug|Linagliptin|
79578746|NCT01888796|Drug|placebo|
79738024|NCT02881463|Other|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
80030438|NCT03472508|Drug|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
80030439|NCT03472508|Drug|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
80030440|NCT04966780|Procedure|acute abdominal surgery|Acute surgery for acute abdominal disease
80030441|NCT03470792|Device|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
79275019|NCT03541811|Diagnostic Test|3-d gait examination (level walking)|"Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured."
79275020|NCT03541811|Diagnostic Test|Anthropometrics and body composition assessment|Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
79403445|NCT02709967|Other|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
79578747|NCT01888809|Behavioral|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
80030442|NCT04966936|Other|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
79304630|NCT03281759|Device|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
79304631|NCT03193957|Drug|Etanercept|Etanercept PFS and Autoinjector
79304632|NCT03193957|Device|Autoinjector|Autoinjector
79403446|NCT02709967|Behavioral|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
79403447|NCT01279707|Biological|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
79578748|NCT01888809|Behavioral|Screening and referral|
79578749|NCT01888822|Drug|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
79738025|NCT02881541|Procedure|Enhanced support|
79403448|NCT01279707|Biological|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
79403449|NCT01279707|Biological|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
79578750|NCT01888822|Drug|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
79578751|NCT01888822|Drug|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
79578752|NCT01888835|Drug|Mirtazapine|
79578753|NCT01888835|Drug|Placebo|
79578754|NCT01888848|Dietary Supplement|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
79578755|NCT01888848|Dietary Supplement|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
79578756|NCT01888861|Dietary Supplement|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
79578757|NCT01888861|Drug|placebo|the patients in this arm were received 900mg placebo through NG tube.
79578758|NCT01888939|Other|Walking on a Treadmill|
79738026|NCT02881541|Procedure|Usual care|
79738027|NCT04058782|Other|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
79738028|NCT01117337|Procedure|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
79738029|NCT04465162|Other|Radiation Therapy|Undergo radiation therapy
79738030|NCT05033873|Other|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
80030443|NCT04966936|Other|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
79738031|NCT05033873|Other|Sling Exercise Therapt (SET)|"The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
79738032|NCT05033873|Other|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~Active and passive joint movement~Muscle strength training~Bridging exercises~Balance training in sitting and standing positions, according to the patients' functional state.~Weight bearing exercises on affected Limbs"
79738033|NCT02874378|Drug|Dexmedetomidine|
79275021|NCT03541811|Diagnostic Test|Biomarkers|"Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method)."
79275022|NCT03541811|Diagnostic Test|Clinical examination|Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
79275023|NCT03541811|Diagnostic Test|Habitual physical activity tracking (accelerometer based)|Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
79738034|NCT02874378|Drug|0.9%NaCl solution|
79275024|NCT04475965|Other|Isometric exercise for shoulder external rotators|The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).
79275025|NCT03738683|Drug|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
79275026|NCT04475887|Drug|Iron Carboxymaltose|see above
79578759|NCT01888939|Other|Sedendary Activities Only|
79738035|NCT01108523|Device|HP828-101|
79738036|NCT01035606|Behavioral|training in goal-directed attention regulation|training in goal-directed attention regulation
79738037|NCT01035606|Behavioral|brain health education|brain health education workshops
79738038|NCT01035606|Behavioral|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
79873264|NCT02562963|Biological|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment.
79873265|NCT02561559|Radiation|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
79275027|NCT04475887|Drug|Placebo|see above
79275028|NCT02537678|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
79578760|NCT01888978|Drug|Gem-OX|
79873266|NCT03055611|Drug|ELOCTA|Extended half-life factor VIII product
79873267|NCT03055611|Drug|ALPROLIX|Extended half-life factor IX product
79873268|NCT01030731|Drug|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
79578761|NCT01888978|Drug|Gem-5FU|
79578762|NCT01888978|Drug|Gem-Tax|
79578763|NCT01888978|Drug|Modified FOLFOX-6|
79578764|NCT01888978|Drug|Ox-Tax|
79578765|NCT01888978|Drug|FOLFIRI|
79578766|NCT01888978|Drug|Tax-Iri|
79578767|NCT01888991|Other|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
79578768|NCT01889004|Drug|Dexmedetomidine|Escalating concentrations until loss of responsiveness
79578769|NCT01889004|Drug|Propofol|Escalating concentrations until loss of responsiveness
79578770|NCT01889017|Other|patient questionnaire (tablet pc based)|
79578771|NCT01889056|Drug|Erythropoietin (Epoetin beta)|
79873269|NCT00417027|Procedure|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
80030444|NCT04966936|Other|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
79275029|NCT02537678|Behavioral|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
80030445|NCT04966312|Other|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
80030446|NCT04966312|Other|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
79873270|NCT00416949|Device|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
79275030|NCT02267239|Drug|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (I-EO).
79275031|NCT02267239|Drug|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
79275032|NCT02267239|Drug|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (M-EO).
79275033|NCT02267239|Drug|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
79275034|NCT02267239|Procedure|professional oral cleaning|scaling and polishing teeth of the volunteers
79275035|NCT02267239|Procedure|Plaster cast|Taking a plaster cast of the volunteers' mouth
79403450|NCT02976714|Other|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
79403451|NCT04146415|Diagnostic Test|Spect scan with mTc99-PYP|. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
79403452|NCT00736125|Device|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
79403453|NCT00736125|Device|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
79578772|NCT01889056|Drug|Placebo|0.9% sodium chloride solution
79578773|NCT01889082|Behavioral|Behavioral Weight Loss Intervention for Young Adults|
79873271|NCT03993483|Behavioral|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
79873272|NCT00416715|Drug|letrozole|Given PO
79275036|NCT02267239|Device|IDODS|Specific intraoral device which carries six glass disks
79275037|NCT04408677|Device|Zilia Ocular|Measurement of the oxygen saturation in the eye fundus
79275038|NCT02267395|Other|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
79275039|NCT02267395|Other|(2) scapular dyskinesis test|Test to determine scapular control
79275040|NCT02267395|Other|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
79275041|NCT02766023|Biological|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
79275042|NCT02766023|Drug|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
79275043|NCT02766023|Other|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
79275044|NCT04354935|Device|rTMS basic|1 session per day, for 4 or 6 weeks.
79275045|NCT04354935|Device|rTMS VIIT|5 sessions per day, for 2 weeks.
79578774|NCT01889095|Drug|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
79578775|NCT01889095|Drug|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
79578776|NCT01889121|Behavioral|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
79578777|NCT01889134|Drug|Sedron (alendronate)|
79578778|NCT01889134|Procedure|Parathyroidectomy|
79873273|NCT00416715|Dietary Supplement|calcium carbonate|Given PO
79873274|NCT00416715|Other|laboratory biomarker analysis|Optional correlative studies
79873275|NCT00416715|Dietary Supplement|calcium citrate|Given PO
79873276|NCT00416715|Dietary Supplement|calcium glucarate|Given PO
79873277|NCT00416715|Drug|calcium gluconate|Given PO
79873278|NCT00416715|Dietary Supplement|cholecalciferol|Given PO
79873279|NCT00416715|Procedure|assessment of therapy complications|Ancillary studies
79275046|NCT04354935|Device|rTMS SAINT modified|8 sessions per day, for 1 week.
79275047|NCT04354935|Device|rTMS SAINT|10 sessions per day, for 1 week.
79403454|NCT02957292|Drug|Levonorgestrel (13,5 mg) intrauterine device|
79403455|NCT02957292|Device|Cooper (380mm2) intrauterine device|
79403456|NCT04146181|Drug|PD-1|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
79738039|NCT01117181|Drug|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
79275048|NCT05466500|Procedure|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
79403457|NCT03021889|Behavioral|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
79403458|NCT03021889|Behavioral|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
79578779|NCT01889147|Biological|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
79578780|NCT01889147|Biological|Placebo|
79738040|NCT01117181|Drug|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
79873280|NCT00416715|Procedure|musculoskeletal complications management/prevention|Correlative studies
79873281|NCT01037517|Drug|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
79873282|NCT01037517|Other|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
79873283|NCT01323933|Drug|AB0024|Comparison of different dosages of drug
79873284|NCT00406029|Drug|Preladenant|1 mg BID capsules
79873285|NCT00406029|Drug|Preladenant|2 mg BID capsules
79873286|NCT00406029|Drug|Preladenant|5 mg BID capsules
79873287|NCT00406029|Drug|Preladenant|10 mg BID capsules
79873288|NCT00406029|Drug|Placebo|BID capsules
79873289|NCT00406029|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
79873290|NCT00406029|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
79873291|NCT00514514|Drug|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
79873292|NCT00514514|Drug|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
79873293|NCT00514514|Drug|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
79873294|NCT00514514|Drug|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
79873295|NCT00405639|Drug|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
79873296|NCT00405639|Drug|Placebo|Normal saline will be used for placebo.
79275049|NCT05466500|Procedure|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
79275050|NCT05628493|Behavioral|Gut microbiota Analysis|fecal samples were collected per patient on days 1,3 and 7 after ICU admission. All eligible patients were given antibiotics therapy, actively control infection source by puncture drainage or surgery if necessary, as well as other supportive therapy to maintain organ function.
79304633|NCT03281681|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
79403459|NCT00753363|Other|Weight Loss|6 months of weight loss
79403460|NCT00753363|Other|Aerobic Exercise Training|6 months of aerobic exercise training
79578781|NCT01889160|Drug|AZD4721 Solution|1-9 mg/mL liquid solution
79578782|NCT01889160|Drug|AZD4721 Placebo|Liquid solution
79578783|NCT01889160|Drug|AZD4721 Suspension|9 mg/g liquid suspension
79578784|NCT01889173|Drug|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
79578785|NCT01889173|Drug|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
79873297|NCT03993795|Other|A19010-W|A snus product
79873298|NCT03993795|Other|B19010-F|A snus product
80030447|NCT03472430|Device|Transcutaneous electrical nerve stimulation|The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
80030448|NCT03472430|Device|TENS machine with electrodes not emitting any impulses.|TENS machine with electrodes not emitting any impulses.
79873299|NCT01030809|Other|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
79873300|NCT00439725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
80030449|NCT04966234|Drug|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
80030450|NCT04966234|Drug|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
80030451|NCT03472352|Biological|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
80030452|NCT04018820|Other|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
80030453|NCT04979026|Device|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
80030454|NCT04979026|Device|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
80030455|NCT03927794|Other|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
79738041|NCT01117181|Other|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~Review and adjustment of the patient and caregiver supportive care plans~Emotional support and opportunity to ventilate feelings~Counseling regarding specific caregiving skills~Assistance with problem solving of specific issues that the caregiver brings to the sessions~Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
79275051|NCT05675553|Device|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
79275052|NCT05675553|Other|treatment as usual|Both groups will receive treatment as usual, including medication, exercise, and psychological education.
79275053|NCT05628259|Behavioral|Motivational Interviewing with WhatsApp video call|The individuals in the intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interview will be applied every two weeks, 6 times in total.
79275054|NCT04475107|Drug|Pyronaridine-Artesunate|Pyramax
79403461|NCT04437420|Drug|injection of BEP 800|injection of BEP 800
79738042|NCT04302714|Procedure|Hysteroscopic injection|Hysteroscopic injection
79275055|NCT04475107|Drug|Placebo|Placebo
79275056|NCT02254967|Drug|Fidaxomicin|oral tablets administered in an extended pulsed regimen
79275057|NCT02254967|Drug|Vancomycin|oral capsule
79403462|NCT04437420|Other|Control|no injection of BEP 800
79403463|NCT02984917|Procedure|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
79403464|NCT02984917|Procedure|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
79275058|NCT05444036|Drug|Ketamine|compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
79403465|NCT01273779|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
79738043|NCT04302714|Procedure|Cervical injection|Cervical injection
79873301|NCT00439725|Drug|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
79873302|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
79873303|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
79873304|NCT00515502|Drug|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
79275059|NCT04423640|Other|Active COVID-19 disease|Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
79275060|NCT05475860|Device|implantable cardiac electronic device recipients|implantable cardiac electronic device recipients for any clinical indication
79578786|NCT01889173|Drug|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
79578787|NCT01889173|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
79738044|NCT02881619|Drug|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
79403466|NCT01273779|Drug|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
79403467|NCT01485536|Drug|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
79403468|NCT02658630|Device|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
79578788|NCT01889212|Other|11C-erlotinib PET/CT|
79578789|NCT01889264|Other|Observational|Observational, Translational non-treatment study
79578790|NCT01889277|Drug|MT-3995-Low|
79578791|NCT01889277|Drug|MT-3995-High|
79578792|NCT01889277|Drug|Placebo|
79578793|NCT01889290|Drug|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
79738045|NCT02881619|Drug|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
79873305|NCT00515502|Drug|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
79873306|NCT03997734|Drug|AB001|single and repeated dosing
79275061|NCT02161367|Drug|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
79738046|NCT04303806|Drug|rosuvastatin|receive rosuvastatin orally once daily.
79275062|NCT02161367|Drug|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
79275063|NCT03542825|Drug|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
79275064|NCT03542825|Drug|Iron Supplement|Iron Sulphate 150 mg once daily
79275065|NCT03542825|Drug|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
79275066|NCT03478826|Other|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
79578794|NCT01889316|Device|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
79578795|NCT01889316|Device|AN24|
79578796|NCT01889342|Behavioral|Metacognitive therapy|
79578797|NCT01889342|Behavioral|Cognitive behavioral therapy|
79578798|NCT01889368|Dietary Supplement|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
79578799|NCT01889368|Dietary Supplement|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
79578800|NCT01889394|Procedure|secondary wound healing|secondary wound healing
79578801|NCT01889394|Procedure|primary wound closure using a limberg flap|primary wound closure using a limberg flap
79578802|NCT01889407|Drug|Idarubicin|8 mg/m2, iv drip on days 1-3
79578803|NCT01889433|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
79578804|NCT01889433|Drug|Pegasys|180 µg subcutaneously, once a week
79578805|NCT01889446|Dietary Supplement|Calcium propionate|
79578806|NCT01889472|Device|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
79578807|NCT01889498|Drug|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:~250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~One tablet to take two hours before surgery~500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
79738047|NCT02882087|Drug|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
79738048|NCT02882087|Drug|RC18 160 mg plus MTX|
79738049|NCT04303884|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
79738050|NCT00625625|Drug|isosulfan blue|
79738051|NCT00625625|Genetic|polymerase chain reaction|
79738052|NCT00625625|Other|diagnostic laboratory biomarker analysis|
79738053|NCT00625625|Other|immunohistochemistry staining method|
79873307|NCT03997734|Drug|oral capsule|single dose
79873308|NCT03997734|Drug|positive comparative patch|single and repeated dosing
79873309|NCT03997734|Drug|Placebos|single and repeated dosing
79873310|NCT03997890|Procedure|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
79873311|NCT03997344|Behavioral|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
79738054|NCT00625625|Procedure|diagnostic lymphadenectomy|
79275067|NCT03478826|Other|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
79403469|NCT01484912|Drug|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
79275068|NCT03478826|Other|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
79275069|NCT02161445|Device|the acoustic cardiographic parameters were calculated|STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
79275070|NCT02764229|Drug|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
79275071|NCT05628025|Other|Organ phantom of prostate|Participants will operate on a 3D printed model of the prostate.
79275072|NCT02537522|Device|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
79275073|NCT02537522|Device|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
79275074|NCT01001923|Drug|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
79275075|NCT01001923|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
79738055|NCT00625625|Procedure|therapeutic conventional surgery|
79403470|NCT01484912|Drug|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
79738056|NCT00625625|Procedure|therapeutic lymphadenectomy|
79738057|NCT05032547|Behavioral|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
79738058|NCT05032547|Behavioral|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
79738059|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
79738060|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
79738061|NCT01040130|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
79738062|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high dose
79738063|NCT01040130|Drug|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
79738064|NCT05012969|Device|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
79873312|NCT03997344|Behavioral|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
79738065|NCT00932451|Drug|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
79738066|NCT02874456|Other|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
79738067|NCT05297682|Device|anesthesia with propofol|General anesthesia with propofol
79738068|NCT01108055|Drug|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
79738069|NCT01108055|Drug|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
79873313|NCT01010646|Drug|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
79275076|NCT02158715|Device|Site of smartphone on chest compressor' arm|
79275077|NCT02154503|Device|topical 5% Minoxidil (Microneedling)|
79275078|NCT05442632|Drug|Hetrombopag|The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
79275079|NCT05442632|Drug|Placebo|The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
79738070|NCT00609375|Drug|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
79873314|NCT01010646|Drug|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
79873315|NCT01010646|Drug|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
79873316|NCT00439647|Drug|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
79304634|NCT03281603|Device|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
79403471|NCT03022123|Drug|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
79403472|NCT04024969|Diagnostic Test|T2* MRI|Research T2* weighted MRI sequence
79403473|NCT04024969|Diagnostic Test|Lumbar puncture to test for presence of unmatched oligoclonal bands|Current clinical standard practice
79403474|NCT01520870|Drug|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
79403475|NCT02907762|Device|Endovascular aneurysm repair EVAR|
79738071|NCT00609375|Drug|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
79738072|NCT01107899|Drug|clopidogrel|taken orally, day one, single dose
79738073|NCT01107899|Drug|prasugrel|taken orally, day one, single dose
79738074|NCT04264299|Procedure|T tube drainage|closure of common bile duct over T tube
79738075|NCT04264299|Procedure|Primary closure|Primary closure of common bile duct
79738076|NCT04264299|Procedure|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
79738077|NCT04265157|Procedure|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
79738078|NCT01115933|Device|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
79873317|NCT00439647|Drug|Placebo|Placebo intravenous (i.v.) once a year
79873318|NCT00515112|Drug|AndroGel|Androgel 1%, 10g daily
79873319|NCT00515112|Drug|placebo|placebo
79873320|NCT03034785|Device|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
79873321|NCT01030887|Behavioral|Exercise programme|Moderate intensity exercise
79873322|NCT03742557|Drug|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
79873323|NCT01324011|Behavioral|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
79873324|NCT01324089|Dietary Supplement|Resveratrol|Resveratrol 2.5 grams
79873325|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
79873326|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
79403476|NCT05100576|Device|Telemedicine system users|Telemonitoring by medical devices connected to a software system with a router.
79403477|NCT01520714|Device|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
79403478|NCT05100498|Device|Web-based oncofertility support tool|The website structure was developed to satisfy the needs of reproductive-age women was investigated based on four domains of social support, as developed by Cohen and Syme (1985). The important needs of patients can be classified as emotional, informational, appraisal, and instrumental support.
79403479|NCT00722865|Drug|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
79403480|NCT02700529|Drug|ubenimex|
79873327|NCT00404547|Drug|Ciclesonide|Asthma Care with Alvesco
79873328|NCT00404547|Drug|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
79873329|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
79873330|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
79873331|NCT00515034|Drug|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
79873332|NCT00515034|Drug|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
79275080|NCT03897049|Behavioral|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
79275081|NCT03897049|Behavioral|General Health App|The control group will download a mobile app that addresses general health behaviors and concerns, including sexual health topics.
79275082|NCT03731351|Procedure|Mechanical Thrombectomy|Acute Ischemic Stroke patient with Large Vessel Occlusion and NIHSS less than or equal to 5 will have a standard of care mechanical thrombectomy. Mechanical thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Some patients may be candidates for this procedure using an angiogram or a catheterization and a device that grabs clots and removes them, to reestablish blood flow to the brain.
79738079|NCT01107743|Drug|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
79403481|NCT02700529|Other|placebo|
79275083|NCT01282255|Drug|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
79403482|NCT02659098|Drug|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
79275084|NCT01282255|Drug|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
79738080|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
79738081|NCT01059864|Drug|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
79738082|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
79738083|NCT01059864|Drug|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
79873333|NCT01012518|Device|Standard PCT|The standard technique, performed without video guidance
79275085|NCT02536976|Drug|mirabegron|
79873334|NCT01012518|Device|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
79873335|NCT00404235|Drug|carboplatin|
79275086|NCT02536976|Drug|Placebo|
79275087|NCT02672553|Device|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
79275088|NCT02672553|Device|Stented Aortic Bioprostheses|In comparison to control valves available on the market undergoing FS-AVR
79275089|NCT01281631|Drug|NP001|Low dose of NP001
79275090|NCT01281631|Drug|NP001|High dose of NP001
79403483|NCT02659098|Device|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
79873336|NCT00404235|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
79873337|NCT00404079|Drug|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
79873338|NCT00404079|Drug|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
79873339|NCT00403845|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
79403484|NCT00723099|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
79873340|NCT00403845|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
79873341|NCT00403845|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
79873342|NCT00509262|Drug|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
79873343|NCT00509262|Drug|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
79275091|NCT01281631|Drug|Placebo|normal saline
79403485|NCT00723099|Drug|Cyclophosphamide|Given IV
79403486|NCT00723099|Drug|Cyclosporine|Given IV
79403487|NCT00723099|Drug|Fludarabine Phosphate|Given IV
79275092|NCT05556577|Drug|investigational medicine product (IMP)|Investigational medicine product (IMP) received at SURMOUNT-CN trial
79403488|NCT00723099|Other|Laboratory Biomarker Analysis|Correlative studies
79403489|NCT00723099|Drug|Mycophenolate Mofetil|Given IV or PO
79403490|NCT00723099|Radiation|Total-Body Irradiation|Undergo TBI
79873344|NCT00509262|Drug|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
79873345|NCT00509262|Drug|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
79275093|NCT05556577|Other|placebo|Placebo received at SURMOUNT-CN trial
79738084|NCT04310033|Other|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
80030456|NCT04966468|Device|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
80030457|NCT04966468|Other|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
80030458|NCT03130946|Device|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
79275094|NCT01270945|Drug|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
79275095|NCT01270945|Procedure|Standard of Care|
79275096|NCT05526703|Drug|D064, D701, placebo of D012|Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
79403491|NCT00723099|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
79403492|NCT01508936|Drug|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
79403493|NCT01508936|Drug|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
79403494|NCT04146259|Drug|calcium carbonate and alphacalcidol|treatment for hypocalcemia
79403495|NCT04437342|Other|PHQ-9 (Patient Health Questionnaire) Depression Scale|9 question questionnaire for assessment of depression
79403496|NCT04437342|Other|GAD-7 (General Anxiety Disorder) scale|7 question questionnaire for assessment of General Anxiety Disorder
79403497|NCT04437342|Other|38 questions questionnaire|38 questions questionnaire
79403498|NCT04437342|Other|EPDS (Edinburgh Postnatal Depression Scale)|10 questions scale for detection of postpartum depression
79873346|NCT00607997|Drug|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
79873347|NCT00509106|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
79873348|NCT00509106|Drug|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
80030459|NCT03130946|Device|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
80030460|NCT04978714|Procedure|Cystocele repair|Fascial repair for endopelvic fascia and anterior colporrhaphy
79403500|NCT05100186|Drug|Dexamethasone 0.4 MG [Dextenza]|Dextenza
79403501|NCT04323462|Drug|Insulin Glargine|Three times bolus insulin with regular or Shorter acting insulin
79403502|NCT04323462|Drug|Diabetic DM|Previously receiving OADs and/or basal insulin
79403503|NCT00723177|Drug|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
79403504|NCT00723177|Drug|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
79403505|NCT04318392|Other|Breath Analysis|Breath analysis using the ReCIVA device will take place during each study visit.
79738085|NCT04309955|Procedure|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
79738086|NCT02880917|Device|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
79738087|NCT02880917|Device|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
80030461|NCT03061942|Other|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
80030462|NCT03061942|Other|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
80030463|NCT03915860|Drug|Trifarotene|Topical Cream
79578808|NCT01889511|Behavioral|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
79738088|NCT02880917|Other|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
79738089|NCT01035138|Drug|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
79738090|NCT03739840|Drug|Padsevonil|Padsevonil in different dosages.
80030464|NCT04965922|Behavioral|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
80030465|NCT03470714|Other|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
80030466|NCT03470714|Other|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
79403506|NCT04318392|Other|Pulmonary Function Tests|Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
79738091|NCT03739840|Drug|Placebo|Placebo will be provided matching padsevonil.
79738092|NCT04301700|Behavioral|mindfullness and relaxation|three arms: mindfullness and relaxation
79738093|NCT02875236|Drug|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
79738094|NCT02875236|Drug|Ringer-acetat|Crystalloid used as standard of care.
79738095|NCT01039428|Dietary Supplement|HS219|Chewing for 30 min three time a day far after meal
79738096|NCT01039428|Dietary Supplement|Placebo|Chewing for 30 min three times a day far after meal
79403507|NCT04318392|Other|Blood sampling and storage for genetic analysis|Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
79403508|NCT04318392|Other|Blood sampling and storage of plasma for metabolomic analysis|Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
80030467|NCT04170998|Drug|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
80030468|NCT04170998|Drug|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
80030469|NCT04170998|Drug|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
79403509|NCT04318392|Other|Bronchoalveolar lavage|Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
80030470|NCT04170998|Drug|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
79403510|NCT04318392|Other|Sputum Culture|Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
79403511|NCT04318392|Other|Spirometry|Spirometry will be performed on all healthy controls prior to enrolment into the study
79403512|NCT04698434|Drug|Esketamine|each group was given a single intravenous dose of the corresponding esketamine.
79403513|NCT04146025|Behavioral|Nature Coach Intervention|"Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
79738097|NCT00613600|Dietary Supplement|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
79738098|NCT00613600|Dietary Supplement|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
79738099|NCT03962608|Device|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
79738100|NCT03962608|Device|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
79738101|NCT01034358|Biological|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
79275097|NCT05526703|Drug|D012, placebo of D064, placebo of D701|Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
79738102|NCT03470818|Other|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
79275098|NCT02267551|Other|Mimic dv-Trainer|
79275099|NCT02267551|Other|daVinci Skills Simulator|
79578809|NCT01889524|Other|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
79578810|NCT01889524|Other|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
79738103|NCT03470818|Other|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
79738104|NCT04302402|Drug|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
79738105|NCT04302402|Drug|Placebo|Similar looking placebo
79738106|NCT03935620|Behavioral|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
79738107|NCT04408300|Procedure|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
79873349|NCT00509106|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
80030471|NCT04458740|Other|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
80030472|NCT03055780|Device|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
79275100|NCT00992563|Drug|AL-39324 ophthalmic suspension|
79275101|NCT00992563|Drug|Ranibizumab 10 mg/mL|
79275102|NCT02267707|Drug|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
79275103|NCT02267707|Drug|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
79275104|NCT02267785|Other|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
79275105|NCT02267785|Other|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
79304635|NCT02439151|Device|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
79304636|NCT02439151|Device|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
79275106|NCT02267785|Other|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
79275107|NCT01373229|Drug|Lenalidomide + Plerixafor (+ Rituximab)|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~Cohort 1: 0.24 mg/kg~Cohort 2: 0.32 mg/kg~Cohort 3: 0.42 mg/kg~Cohort 4: 0.54 mg/kg~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~Subjects will then continue single agent lenalidomide until disease progression."
79275108|NCT01112527|Drug|PF-00299804|Taken orally once a day
79275109|NCT02267941|Other|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
79275110|NCT02671461|Drug|BMS-986141|
79275111|NCT02671461|Drug|Aspirin|
79578811|NCT01889524|Other|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
79738108|NCT03931408|Drug|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
79873350|NCT03997656|Behavioral|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
80030473|NCT03130868|Other|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
80030474|NCT04966078|Procedure|liposuction|suction-assisted liposuction
79275112|NCT02671461|Other|Placebo|
79403514|NCT04024735|Diagnostic Test|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
79403515|NCT04142749|Drug|Oltipraz|Total 90mg, By mouth, TID
79403516|NCT04142749|Drug|Placebos|Total 90mg, By mouth, TID
79403517|NCT01508702|Drug|lesinurad|Tablets, 400 mg QD
79873351|NCT03997656|Other|usual care|standard health education from primary care providers in the clinic
79275113|NCT05467033|Drug|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
79873352|NCT00607919|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
79873353|NCT00607919|Drug|Placebo|oral, daily, for 16 weeks
79873354|NCT00344968|Drug|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
80030475|NCT04966078|Procedure|surgical excision|periareolar surgical excision
80030476|NCT04965532|Drug|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
80030477|NCT04965532|Drug|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
80030478|NCT04965610|Other|Preoxygenation with High Flow Nasal Cannula|Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
80030479|NCT04965610|Other|Preoxygenation via face mask|Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
80030480|NCT03055546|Drug|Oxytocin|intranasal administration of oxytocin
79275114|NCT05467033|Drug|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
79275115|NCT04196283|Drug|ABBV-368|Intravenous (IV) infusion
79275116|NCT04196283|Drug|Tilsotolimod|Intratumoral (IT) injection
79275117|NCT04196283|Drug|Nab-paclitaxel|Intravenous (IV) infusion
79275118|NCT04196283|Drug|ABBV-181|Intravenous (IV) infusion
79275119|NCT02268019|Procedure|tourniquet application|
79275120|NCT02268019|Drug|epinephrine injection|
79275121|NCT02268097|Procedure|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
79275122|NCT02268097|Procedure|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
79403518|NCT01508702|Drug|Placebo|Tablets, Placebo QD
79403519|NCT05100108|Behavioral|Dog-assisted therapy|The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
79738109|NCT03931408|Other|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
79275123|NCT03114111|Drug|aminolevulinic acid (ALA)|
79873355|NCT00344968|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
79403520|NCT05099796|Procedure|Transforaminal epidural steroid injection|
79578812|NCT01889537|Behavioral|Virtual Reality|The patient will receive virtual reality during a burn care procedure
79578813|NCT01889550|Behavioral|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
79578814|NCT01889550|Behavioral|Access to the website www.ouh.dk|Access to the usual information from the hospital website
79873356|NCT00344968|Procedure|Standard of care laser photocoagulation|Laser photocoagulation
79873357|NCT02541461|Procedure|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
80030481|NCT03055546|Drug|Placebo|intranasal administration of placebo
79275124|NCT03114111|Drug|Placebo|
79275125|NCT04475653|Behavioral|Physical Activity using an Activity Tracker|
79275126|NCT04475419|Procedure|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
79275127|NCT01110889|Drug|Agomelatine (AGO178C)|
79275128|NCT01110889|Drug|Agomelatine (AGO178C)|
79403521|NCT05099796|Procedure|Caudal epidural steroid injection|
79578815|NCT01889576|Dietary Supplement|Magnesium Oxide|
79873358|NCT00509028|Drug|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
79873359|NCT00509028|Drug|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
79873360|NCT01055080|Dietary Supplement|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
79873361|NCT00893321|Procedure|Inferior Oblique Muscle Recession and Myectomy|
79873362|NCT01012752|Biological|modified allergen extract|subcutaneous injections
79873363|NCT01012752|Biological|Placebo|subcutaneous injections
79873364|NCT00352846|Drug|Zoledronic Acid|4 mg/m^2 by vein over 30 Minutes at baseline and 6 months.
79873365|NCT00352846|Drug|Vitamin D|400 mg by mouth daily
79873366|NCT00352846|Drug|Calcium Carbonate|1200 mg by mouth daily
79873367|NCT00508872|Drug|5-Fluorouracil|400 mg/m^2 IV over 15 minutes, followed by 2400 mg/m^2 IV Over 46 Hours
79873368|NCT00508872|Drug|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
79873369|NCT00508872|Drug|Leucovorin|400 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
79873370|NCT00508872|Drug|Oxaliplatin|85 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
79873371|NCT00508482|Other|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
79873372|NCT00508482|Drug|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
79275129|NCT01110889|Drug|Placebo|
79275130|NCT01108705|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
79275131|NCT01108705|Drug|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
79275132|NCT01106989|Drug|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
79275133|NCT00975091|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
79275134|NCT00975091|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
79403522|NCT04022395|Diagnostic Test|stress cardiac MRI|pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
79403523|NCT04142593|Other||
79403524|NCT02337270|Biological|Ad5Ag85A|Aerosol administration of Ad5Ag85A
79578816|NCT01889589|Other|Surveillance|
79578817|NCT01889615|Other|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
79578818|NCT01889628|Dietary Supplement|Liquid-based Nutritional Formulae and liquid glucose|
79578819|NCT01889654|Other|Venous blood sampling|
79578820|NCT01889680|Drug|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
79578821|NCT01889680|Drug|LV|400 mg/m2 IV day 1 every 14 days until disease progression
79578822|NCT01889680|Drug|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
79578823|NCT01889680|Drug|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
79578824|NCT01889719|Biological|MVA-CMDR|injections of MVA-CMDR vaccine
79578825|NCT01889732|Device|ROTEM|
79873373|NCT00508482|Other|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
79873374|NCT00344500|Behavioral|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~Be given a 7% weight loss goal~Be assisted in obtaining a 500 calorie reduction per day~Exercise for at least 30 min/day, at least 5 days a week~Maintain weekly food and exercise diaries~Be quizzed on their knowledge of healthy eating habits and nutrition"
79873375|NCT00344032|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
79738110|NCT03931408|Other|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
79873376|NCT00344032|Biological|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
79275135|NCT05627401|Procedure|Modified multiple orbital wall decompression|Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.
79873377|NCT00607373|Drug|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
79275136|NCT02535416|Drug|ARC-520|
79403525|NCT01484834|Behavioral|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
79403526|NCT01484834|Behavioral|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
79403527|NCT01484834|Behavioral|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
79578826|NCT01889745|Drug|HX-1171|Anti-oxidatant, Anti-inflamation
79578827|NCT01889758|Drug|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
79578828|NCT01889758|Drug|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
79578829|NCT01889758|Drug|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
79578830|NCT01889771|Drug|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
79873378|NCT00607373|Drug|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
79403528|NCT01484834|Other|Control Company|No intervention was applied for the participants of this group
79738111|NCT03398824|Drug|metformin HCl|Receive metformin HCl
79873379|NCT00508404|Drug|Panitumumab|Administered by intravenous infusion
79873380|NCT00508404|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
79275137|NCT02535416|Drug|cetirizine|
79738112|NCT01033734|Drug|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
79738113|NCT03792256|Drug|Palbociclib|Given PO (or via NG- tube)
79873381|NCT00888407|Behavioral|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
79275138|NCT02535416|Drug|diphenhydramine|
79275139|NCT00912691|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
79275140|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
79275141|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
79275142|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
79403529|NCT04024813|Drug|Seladelpar|Capsule(s) administered orally once daily
79403530|NCT04024813|Drug|Placebo to match Seladelpar|Capsule(s) administered orally once daily
79738114|NCT03792256|Drug|Cytarabine|Given intrathecally (IT)
79738115|NCT03792256|Drug|Methotrexate|Given intrathecally (IT)
79738116|NCT03792256|Drug|Hydrocortisone|Given IT
79738117|NCT03792256|Drug|Doxorubicin|Given intravenously (IV)
79304637|NCT02443363|Other|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
79738118|NCT03792256|Drug|Prednisolone|Either prednisone or prednisolone is given PO
79738119|NCT03792256|Drug|Vincristine|Given IV
79738120|NCT03792256|Drug|Pegaspargase|Given IV
79738121|NCT03792256|Drug|Hydrocortisone|Given intrathecally (IT)
79738122|NCT03792256|Drug|Prednisone|Either prednisone or prednisolone is given PO
79738123|NCT04301856|Drug|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
79873382|NCT00888407|Behavioral|Nutrition - Small group educational session|Small group session with diet & nutrition focused, topic related resources provided.
80030482|NCT04918264|Drug|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
79275143|NCT00911443|Biological|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
80030483|NCT04918264|Other|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
80030484|NCT04918264|Behavioral|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil <16 vs Uracil ≥16).
79738124|NCT00613288|Drug|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~Placebo (hypogonadism after leuprorelide injection)~Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~No treatment."
79738125|NCT03711838|Dietary Supplement|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
79738126|NCT03711838|Dietary Supplement|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
80030485|NCT04978558|Other|Continuous assessment of cerebrovascular autoregulation with NIRS and TCD|Continuous monitoring of MAP, cerebral oxygenation, and cerebral blood flow velocity before, during, and after surgery to calculate two cerebrovascular autoregulation indices Cox and Mx.
79738127|NCT00613678|Behavioral|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
80030486|NCT04917718|Drug|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
79275144|NCT00911443|Drug|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
79738128|NCT00613678|Behavioral|Education|The health education program is based on educational materials from the Arthritis Foundation.
79738129|NCT03656848|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
80030487|NCT04917952|Device|Blood Flow Restriction (BFR)|"Exercise: Bilateral knee extension at range 90ο-0ο~Load: 30% 1RM~BFR: Yes, 80% at both legs~Sets: 4~Reps: 30-15-15-15~Rest: 30'' between sets~Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
79275145|NCT03949478|Drug|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
79275146|NCT03949478|Drug|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
79275147|NCT03949478|Drug|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
79275148|NCT03856411|Drug|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
79738130|NCT03656848|Diagnostic Test|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
79738131|NCT04275778|Drug|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
79738132|NCT04275778|Drug|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
79738133|NCT04260880|Other|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
79738134|NCT04260880|Other|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
79873383|NCT00352690|Drug|Paclitaxel poliglumex|
79873384|NCT00352690|Drug|Carboplatin|
79873385|NCT00352690|Radiation|External beam radiation therapy|
79873386|NCT00888485|Behavioral|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
79873387|NCT03294408|Diagnostic Test|multimodal imaging|
79873388|NCT00895505|Drug|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
79873389|NCT00895505|Drug|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
79873390|NCT03988738|Other|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
79275149|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
79738135|NCT04260880|Other|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
79578831|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
79738136|NCT01115855|Drug|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
79873391|NCT03268824|Device|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
79738137|NCT01115855|Drug|Placebo|Placebo once daily or every once daily
79738138|NCT03669094|Dietary Supplement|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
79738139|NCT03669094|Dietary Supplement|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
79873392|NCT03268824|Device|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
79873393|NCT03268824|Other|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
79873394|NCT03249012|Other|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
79873395|NCT03249012|Other|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
79873396|NCT01565460|Other|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
79873397|NCT03194880|Device|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~The laboratory component: For each test we will evaluate:~The percentage of assays completed~The percentage of assays incomplete (i.e. invalid result on two attempts)~Reasons for incomplete assays, e.g.~The sample could not be delivered to the strip or cartridge correctly~Invalid control~Results could not be interpreted~Others"
79873398|NCT00893477|Biological|rituximab|
79873399|NCT00893477|Biological|sargramostim|
79873400|NCT00893477|Genetic|gene expression analysis|
79873401|NCT00893477|Genetic|gene rearrangement analysis|
79873402|NCT00893477|Genetic|polymerase chain reaction|
79873403|NCT00893477|Genetic|polymorphism analysis|
79873404|NCT00893477|Other|laboratory biomarker analysis|
79873405|NCT01010724|Drug|bIAP|
79873406|NCT01010724|Drug|Placebo|
79873407|NCT00609245|Drug|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
79873408|NCT00609245|Drug|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
79873409|NCT01010802|Drug|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
79873410|NCT04036253|Biological|Erythropoietin alfa|Prefilled syringes of erythropoietin
79873411|NCT00343642|Drug|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
79738140|NCT03615508|Drug|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
79738141|NCT05331976|Diagnostic Test|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
79873412|NCT00343642|Drug|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
79873413|NCT00343642|Dietary Supplement|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
79873414|NCT00893555|Drug|voriconazole|TDM (through level of 2-5mg/L).
79873415|NCT00893555|Drug|voriconazole (dosing according to the SPC)|No serum concentrations are determined
79873416|NCT02541071|Behavioral|Stress Film|
79873417|NCT02541071|Drug|Yohimbine|
79873418|NCT02541071|Drug|Clonidine|
79873419|NCT02541071|Drug|placebo|
79873420|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
79873421|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
79873422|NCT00895739|Biological|alemtuzumab|
79873423|NCT00895739|Drug|cyclosporine|
79873424|NCT01325038|Procedure|Isometric exercise|Isometric exercise several times/week for three months
79738142|NCT05288296|Device|dynamic taping|"The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
79738143|NCT00614068|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
79738144|NCT00614068|Behavioral|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
79873425|NCT03988660|Diagnostic Test|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
79738145|NCT05274802|Drug|ALS-4|Single dose of ALS-4 before Breakfast
79738146|NCT05274802|Drug|Placebo|Single dose of placebo before Breakfast
79873426|NCT03986320|Device|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
79873427|NCT03986398|Other|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
79275150|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
79738147|NCT05274802|Drug|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
79738148|NCT05274802|Drug|ALS-4|Multiple dose of ALS-4 up to two times daily
79275151|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
79873428|NCT03988348|Procedure|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
79738149|NCT05274802|Drug|Placebo|Multiple dose of placebo up to two times daily
79738150|NCT02880995|Device|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
79738151|NCT02880995|Behavioral|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
79738152|NCT02880995|Drug|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
79738153|NCT03522064|Drug|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
79275152|NCT00973141|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
79275153|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
79275154|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
79738154|NCT03522064|Drug|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
79738155|NCT01115309|Device|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
79738156|NCT04310579|Drug|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
79873429|NCT03988348|Procedure|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
79275155|NCT00909649|Procedure|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
79275156|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
79275157|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
79275158|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
79275159|NCT00971035|Drug|placebo|Subcutaneous repeating dose
79275160|NCT05238571|Procedure|Re-surgery|Re-surgery with meshectomy and selective neurectomy
79275161|NCT04787965|Drug|Opicapone|Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
79275162|NCT04776811|Device|Continuous glucose monitoring system|Medtronic Guardian Connect with Guardian Sensor 3
79738157|NCT04310579|Drug|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
79275163|NCT00968851|Drug|EVP-6124|Arms: 1
79738158|NCT04188340|Behavioral|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
79738159|NCT05244538|Device|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
79738160|NCT05244538|Drug|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
79738161|NCT05175742|Biological|PTX-COVID19-B|Sterile solution for injection
79738162|NCT05175742|Biological|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
79275164|NCT00968851|Drug|Placebo|Arm: 3
79403531|NCT05374902|Other|Providing procedural informational animation video|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
79578832|NCT01889784|Device|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
79738163|NCT05175742|Biological|Placebo|0.9% sodium chloride (normal saline) injection
79738164|NCT03638128|Drug|Denosumab|Solution for injection
79738165|NCT03638128|Drug|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
79738166|NCT00614146|Device|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
79873430|NCT03988582|Biological|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
79275165|NCT00968851|Drug|EVP-6124|Arms: 2
79275166|NCT02670915|Drug|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
79275167|NCT02670915|Drug|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
79275168|NCT02670915|Drug|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
79275169|NCT05382793|Dietary Supplement|Control|No iodine
79275170|NCT05382793|Dietary Supplement|Iodide (150 μg/day)|A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide
79275171|NCT05382793|Dietary Supplement|Iodine (300 μg/day)|Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
79275172|NCT00907387|Drug|RT001|Dose A RT001
79275173|NCT00907387|Drug|RT001|Dose B RT001
79275174|NCT00907387|Other|Placebo|Dose C Placebo
79275175|NCT04474561|Other|Reduced sulfur diet|A reduced sulfur diet includes reducing foods, food additives (e.g., carrageenan) and beverages high in sulfate/sulfur, limiting sulfur containing supplements, and consuming omega-3 fatty acid supplements to potentially help control overgrowth of sulfur-reducing bacteria in the colon. Omega-3 fatty acid intake for cardiovascular disease prevention should be around 500 mg/d23. After dietary assessment if patients are not meeting their required daily intake of 500 mg/d of Omega-3, the RD will recommend increased fish consumption to 200 g per week or 1 g/d of an Omega-3 supplement. This will ensure the daily recommended intake of 500 mg/d is being met to reduce the chances of a deficiency; however, a therapeutic dose for UC will not be recommended (i.e., > 4 g/d18).
79275176|NCT02545868|Biological|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
79275177|NCT02545868|Biological|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
79275178|NCT02545868|Biological|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
79275179|NCT02545868|Biological|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
79403532|NCT05374902|Device|Buzzy|Buzzy® was placed on the injection site and it was turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
79403533|NCT05374902|Combination Product|Multiple interventions|Watching procedural informational animation video prior to venipuncture, and Buzzy application during venipuncture
79403534|NCT04145791|Other|Ice|ice packs
79403535|NCT01484132|Procedure|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
79738167|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
79738168|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
79873431|NCT01058902|Drug|Aspirin 75 mg|Aspirin 75 mg
79275180|NCT02545868|Drug|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
79275181|NCT02545868|Biological|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
79275182|NCT00821977|Drug|Vildagliptin|
79738169|NCT03555838|Other|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
79275183|NCT00821977|Drug|Vildagliptin|
79738170|NCT03555838|Other|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
79738171|NCT05108194|Behavioral|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
79738172|NCT03529630|Other|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
79738173|NCT04940026|Drug|amcenestrant|Tablet Oral
79738174|NCT04940026|Drug|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
79738175|NCT04940026|Drug|[14C]-SAR439859|Powder for oral solution Oral
79873432|NCT01058902|Other|no aspirin|nothing
79275184|NCT00821977|Drug|Placebo|
79738176|NCT03448120|Procedure|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
79738177|NCT03448120|Procedure|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
79738178|NCT00614224|Behavioral|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
79738179|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
79873433|NCT01055158|Behavioral|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
79873434|NCT01055158|Behavioral|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
79738180|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
79738181|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
79873435|NCT00609167|Drug|bortezomib|"First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 & 11~Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 & 22"
79873436|NCT00609167|Drug|cyclophosphamide|300mg/m^2 PO days 1, 8, 15 & 22
79873437|NCT00609167|Drug|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
79873438|NCT01055236|Drug|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
79873439|NCT04036955|Other|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
79873440|NCT00895973|Other|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
79873441|NCT00896129|Other|HRQOL Survey Packet|Questionnaires
79873442|NCT00606281|Drug|Aripiprazole|oral, 24mg/day
79873443|NCT00606281|Drug|placebo|oral, 0mg(4tablets)/day
79873444|NCT00506142|Drug|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
79873445|NCT01010880|Drug|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
79275185|NCT03114267|Other|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
79275186|NCT04474327|Drug|Montelukast Sodium|Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
79275187|NCT05376787|Device|Medline NE Grounding Pad|Split Universal Grounding Pads
79275188|NCT02764151|Drug|PF-06840003|Daily Oral PF-06840003
79275189|NCT05675475|Other|Exposure|Higher education students from health technologies field exposed to digital devices.
79275190|NCT05675475|Diagnostic Test|Orthoptic assessment (Outcome measure)|The orthoptic assessment is a non-invasive assessment that will last for 30 min to determine visual parameters related to binocular vision. It will be carried out by the research team in the orthoptics and vision sciences laboratories of the Lisbon School of Health Tecnology.
79873446|NCT00891605|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
79578833|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
79578834|NCT01889784|Device|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
80030488|NCT04917952|Device|Sham Blood Flow Restriction (sham BFR)|"Exercise: Bilateral knee extension at range 90ο-0ο~Load: 30% 1RM~BFR: Yes, Sham BFR, 10mm Hg at both legs~Sets: 4~Reps: 30-15-15-15~Rest: 30'' between sets~Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
79275191|NCT05675475|Diagnostic Test|Tear film Break Up Time (BUT) test (Outcome measure)|The BUT test is a tear film rupture assessment test that allows the stability of the tear film to be evaluated. To perform these tests, it is necessary to instill fluorescein and then it is observed in the slit lamp under illumination with a cobalt blue filter, to count the break-up time.
79275192|NCT05375773|Other|PVP-I Nasal Irrigation and gargling|The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
79275193|NCT00961675|Drug|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4 gtt BID (twice a day)
79275194|NCT00961675|Drug|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID (twice a day)
79275195|NCT00819169|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
79275196|NCT00819169|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
79275197|NCT05442086|Behavioral|Music and Theta Auditory Beat Stimulation|Participants will listen to calm music with theta auditory beat stimulation for 24 minutes
79873447|NCT00891605|Drug|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
79873448|NCT00891683|Drug|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
79873449|NCT00893711|Other|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
79873450|NCT00893711|Other|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
79873451|NCT00893711|Dietary Supplement|L.reuteri + Vit D|
79873452|NCT00893711|Dietary Supplement|Vit D placebo|
79873453|NCT00514020|Drug|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
79873454|NCT00514020|Drug|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
80030489|NCT03060538|Drug|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
80030490|NCT03060538|Other|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
80030491|NCT06016595|Diagnostic Test|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
80030492|NCT06016569|Diagnostic Test|Exhaled breath condensate sampling|Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
80030493|NCT06016569|Diagnostic Test|Blood sampling|A venous blood sample will be taken for further biomarker analysis.
80030494|NCT06016569|Procedure|LDCT|LDCT scan will be performed.
79275198|NCT05442086|Behavioral|Pink Noise (control)|Participants will listen to pink noise for 24 minutes
79275199|NCT02161601|Procedure|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
79304638|NCT02443363|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
79304639|NCT03281447|Other|Nurse navigation|
79873455|NCT00514020|Drug|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
79873456|NCT00514020|Genetic|gene expression analysis|Blood collection
79873457|NCT00514020|Genetic|polymorphism analysis|Blood collection
79873458|NCT00514020|Genetic|protein expression analysis|Blood collection
79275200|NCT05221723|Behavioral|High Intensity Interval Exercise Training Group|Participants will participate in a maximum of twice weekly exercise classes (90 minutes each class) for a total of 6 months. While participants will be encouraged to attend as many classes as able, there is no minimum requirement for class attendance. During the exercise classes, participants will participate in a 10-minute warm up, followed by 30-60 minutes of aerobic, resistance and/or balance training up to a maximum intensity of 8/10 on the rating of perceived exertion scale. Participants will finish each class with a 10-minute cool-down consisting of lower intensity exercise.
79275201|NCT02161679|Drug|IMMU-132 infusion is administered to participants in one arm for the study|
79275202|NCT02161679|Drug|IMMU-132 plus Carboplatin infusion|
79275203|NCT03541109|Drug|Polypill|fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
79275204|NCT02545322|Radiation|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
79275205|NCT05675397|Dietary Supplement|donor human milk|Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
79403536|NCT01276041|Drug|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
79275206|NCT00955981|Drug|RDEA594|Uricosuric agent for the treatment of gout
79403537|NCT04150770|Drug|infliximab|
79403538|NCT03717961|Drug|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
79403539|NCT03717961|Drug|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
79578835|NCT01889823|Other|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
79578836|NCT01889823|Other|Hyperoxia|Subjects will be breathing 100% oxygen
79578837|NCT01889836|Biological|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
79578838|NCT01889836|Biological|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
79578839|NCT01889849|Drug|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
79578840|NCT01889849|Drug|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
79578841|NCT01889875|Drug|"ALK Grazax 75,000 SQ-T Phleum pratense"|
79738182|NCT03261076|Behavioral|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
79738183|NCT03221218|Other|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
79738184|NCT00614302|Drug|TPV|
79738185|NCT05345236|Drug|Aflibercept|Intravitreal (IVT) injection
79738186|NCT02692690|Device|Stimulette r4x|
79873459|NCT00514020|Other|pharmacological study|Blood collection
79873460|NCT03560531|Drug|ZN-c5|ZN-c5 is a study drug
79873461|NCT03560531|Drug|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
79275207|NCT00955981|Drug|Placebo|Matching placebo
79275208|NCT02154659|Device|24hr pH monitoring|
79275209|NCT02381990|Procedure|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
79275210|NCT04439721|Drug|γδT Cell infusion agent|γδT
79304640|NCT03281447|Other|Current care coordination|
79304641|NCT02444611|Drug|BCG Vaccine|intradermal vaccination
79403540|NCT04026438|Drug|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
79578842|NCT01889875|Drug|"ALK AluTard 225 Phleum pratense"|
79578843|NCT01889888|Other|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
79578844|NCT01889914|Drug|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
79738187|NCT02692534|Other|Urine cocaine negative|Preoperative urine cocaine negative
79738188|NCT02692534|Other|Urine cocaine positive|Preoperative urine cocaine positive
79873462|NCT00513708|Behavioral|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
80030495|NCT06016569|Diagnostic Test|Vital signs|Blood pressure, weight, height, pulse, oxygen saturation will be measured.
80030496|NCT06016569|Diagnostic Test|Spirometry|Spirometry will be performed.
79403541|NCT01275339|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
79873463|NCT00513708|Behavioral|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
79873464|NCT00896207|Drug|Akt inhibitor SR13668|Given orally as a single dose
79275211|NCT03541031|Dietary Supplement|Micronutrient & Fish oil|Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).
79403542|NCT01275339|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
79873465|NCT00896285|Other|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
79873466|NCT00896285|Other|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
79873467|NCT00896285|Other|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
79403543|NCT05104320|Procedure|MICS-CABG|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
79578845|NCT01889927|Other|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
79738189|NCT04153318|Device|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
79873468|NCT00896285|Other|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
79873469|NCT00891761|Drug|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
79403544|NCT05104320|Procedure|sternotomy CABG|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
79578846|NCT01889940|Behavioral|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients & families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
79578847|NCT01889953|Other|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~Rendezvous technique~Direct transluminal access transesophageal technique~Direct transluminal access transduodenal technique~or direct transluminal access using transgastric approach"
79738190|NCT04413370|Diagnostic Test|Dry eye diagnostic test|The artificial intelligent dry eye screening platform
79578848|NCT01889966|Drug|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
79738191|NCT05344768|Other|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
79738192|NCT05344768|Other|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
79275212|NCT03541031|Dietary Supplement|Olive oil & Safflower oil|Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
79738193|NCT05344768|Other|resistance exercise training|resistance exercise training will be applied
79738194|NCT00613912|Other|Magnetic Resonance Imaging|"Morphological sequences~Arterial Spin Labelling (Perfusion)~Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
79738195|NCT05344612|Radiation|CT Coronary Angiography|Upfront ct-coronary angiography
79738196|NCT00614536|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
79873470|NCT00891761|Drug|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
79873471|NCT00891761|Drug|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
79873472|NCT00891761|Drug|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
79873473|NCT00891761|Drug|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
79873474|NCT01012830|Drug|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
79304642|NCT02444611|Drug|Hepatitis B Vaccine|intramuscular vaccination
79304643|NCT03545477|Other|Novel locomotion treatment: curved-walking training|"Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)"
79738197|NCT05344222|Device|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
79578849|NCT01889979|Drug|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
79578850|NCT01889979|Drug|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
79738198|NCT05344222|Device|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
79738199|NCT04333654|Drug|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
79275213|NCT03731273|Behavioral|portion size|"Smaller than normal portion size - the intervention is the meal size perceived as 'smaller than normal' that participants are provided with during a lunchtime session in the laboratory.~'Small-normal' portion size - the intervention is the meal size perceived as 'small normal' that participants are provided with during a lunchtime session in the laboratory.~'Large normal' portion size - the intervention is the meal size perceived as 'large normal' that participants are provided with during a lunchtime session in the laboratory."
79578851|NCT01890018|Behavioral|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
79578852|NCT01890018|Behavioral|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
79738200|NCT04333654|Drug|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
79738201|NCT01059630|Drug|Obinutuzumab|IV infusion.
79738202|NCT01059630|Drug|Bendamustine|IV infusion.
79738203|NCT05344144|Other|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
79738204|NCT05344144|Other|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
79738205|NCT04314700|Device|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
79738206|NCT04226170|Drug|DAS-001|ondansetron + pyridostigmine
80030497|NCT06016530|Behavioral|Sleep Deprivation|During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
79275214|NCT05433350|Drug|Acoziborole|"Two different formulations will be used during the study depending on the body weight and on the step of the study:~Tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1 Granules in bottle of 160 mg for paediatric patients weighing 10 to 40 kg in step 2"
79873475|NCT04036175|Device|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2>= 92%
79873476|NCT02540603|Device|F&P Jupiter Full Face Mask|Investigative F&P Jupiter full face mask to be used for OSA therapy
79275215|NCT04982003|Other|exercise|10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
79578853|NCT01890018|Behavioral|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
79578854|NCT01890278|Radiation|Whole Brain IMRT|
79738207|NCT05343910|Other|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
79873477|NCT00513474|Drug|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
79873478|NCT00513474|Drug|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
79873479|NCT00513474|Drug|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
80030498|NCT06016530|Drug|Dexamethasone Supplementation|"Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs)."
80030499|NCT06016517|Drug|Adalimumab|40 mg subcutaneously every 2 weeks with oral placebo once daily
79578855|NCT01890278|Radiation|Conventional Whole Brain RT|
79578856|NCT01890317|Procedure|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
79578857|NCT01890330|Other|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
80030500|NCT06016517|Drug|Sarilumab|200 mg subcutaneously every 2 weeks with oral placebo once daily
80030501|NCT06016517|Drug|Upadacitinib|15 mg orally once daily with subcutaneous placebo injection every 2 weeks
79578858|NCT01890330|Other|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
79578859|NCT01890538|Drug|Administration of 100 mg dimenhydrinate intravenous|
79578860|NCT01890538|Drug|2 g piracetam intravenous|
79578861|NCT01890681|Behavioral|Baby NAP SACC|
79578862|NCT01890681|Behavioral|Back to Sleep|
79873480|NCT00513474|Drug|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
79275216|NCT05675241|Diagnostic Test|Clinical examination of a dental implant|Clinical examination includes bleeding on probing, pocket depth, gingival biotype, suppuration, gingival index
79738208|NCT05343676|Device|ultrasonography|"For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
79873481|NCT00513474|Drug|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
79873482|NCT00513474|Drug|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
79873483|NCT00513474|Drug|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
79873484|NCT00513474|Drug|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
79873485|NCT00513474|Procedure|allogeneic hematopoietic stem cell transplantation|
80030502|NCT06016491|Behavioral|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
79275217|NCT05675241|Diagnostic Test|Radiological Examination|A standardized periapical radiograph in parallax technique will be taken.
79275218|NCT05675241|Diagnostic Test|Peri-implant crevicular fluid sample collection|A sample of the peri-implant crevicular fluid will be collected using paper strip for 60 seconds. The sample of the fluid will be a resultant of inserting six different strips at the same time in six sites of the implant including mesiobuccal, midbuccal, distobuccal, distopalatal/distolingual, midpalatal/midlingual, mesiopalatal/mesiolingual sites of the implant.
79275219|NCT05465018|Device|Happy Flow / Baseline|Baseline (without make-up or mask)
79578863|NCT01891123|Device|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
79578864|NCT01891123|Drug|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
79873486|NCT00513474|Procedure|peripheral blood stem cell transplantation|
79403545|NCT01520402|Drug|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
79403546|NCT04145557|Device|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
79403547|NCT04145557|Device|scaling root planing|scaling and root planing
79578865|NCT01891279|Other|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
79578866|NCT01891279|Other|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
79578867|NCT01891292|Drug|Enalapril|0.25-0.35 mg/kg/day
79873487|NCT00513474|Radiation|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
79873488|NCT00513474|Drug|fludarabine|Fludarabine 40 mg/m^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
79873489|NCT00513474|Drug|allopurinol|Allopurinol per institutional guidelines
79873490|NCT00891917|Dietary Supplement|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
79873491|NCT00891917|Dietary Supplement|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
80030503|NCT06016491|Behavioral|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
79275220|NCT05465018|Device|Make-up|To test device on participant who is wearing facial make-up
79275221|NCT05465018|Device|Sunglasses|To test device on participant who is wearing sunglasses
79578868|NCT01891292|Drug|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
79873492|NCT00893867|Drug|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
79873493|NCT00893867|Drug|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
79873494|NCT01010958|Drug|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
79873495|NCT04036877|Other|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
79873496|NCT00896519|Biological|rituximab|
79873497|NCT00896519|Biological|sargramostim|
79873498|NCT00896519|Drug|cyclophosphamide|
79873499|NCT00896519|Drug|doxorubicin hydrochloride|
79275222|NCT05465018|Device|Face mask|To test device on participant who is wearing a facial mask
79275223|NCT05465018|Device|Minimum requirements camera|To test the minimum requirements of the camera
79873500|NCT00896519|Drug|prednisone|
79873501|NCT00896519|Drug|vincristine sulfate|
79578869|NCT01891448|Other|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
79578870|NCT01891448|Other|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
79578871|NCT01891487|Drug|Track A|Bimatoprost 0.03% solution applied to eyebrow
79578872|NCT01891487|Drug|Track B|Refresh Tears applied to eyebrows
79578873|NCT01892033|Behavioral|Aerobic Exercise|12 weeks of brisk walking
79578874|NCT01892280|Behavioral|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
79578875|NCT01892280|Behavioral|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
79578876|NCT01892319|Drug|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
79578877|NCT01892319|Drug|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
79738209|NCT04200976|Behavioral|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
79738210|NCT04200976|Behavioral|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
79873502|NCT00896519|Genetic|gene expression analysis|
79873503|NCT00896519|Genetic|gene rearrangement analysis|
79873504|NCT00896519|Genetic|polymerase chain reaction|
79873505|NCT00896519|Other|R-CHOP regimen|
79873506|NCT00896519|Other|laboratory biomarker analysis|
79873507|NCT00896597|Drug|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
79873508|NCT00505752|Drug|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
79873509|NCT00505752|Drug|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
79873510|NCT00505752|Drug|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
79873511|NCT00505752|Drug|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
79873512|NCT00505752|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to [>=] 18 millimeter [mm], two or more additional follicles with a diameter of >= 16 mm, and Estradiol [E2] levels will approximately 150 picogram per milliliter [pg/mL] per mature follicle).
79873513|NCT01011036|Drug|clobazam|test substance
79873514|NCT01011036|Drug|clonazepam|positive control
79873515|NCT01011036|Drug|tolterodine|active placebo
79873516|NCT03601637|Drug|LUM|Fixed Dose Combination (FDC) granules (LUM/IVA).
79873517|NCT03601637|Drug|IVA|FDC granules (LUM/IVA).
79873518|NCT00896675|Other|proteomic profiles|blood samples analysis
79873519|NCT00896675|Other|proteomic profiles|blood samples analysis
79873520|NCT00893945|Drug|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
79873521|NCT00893945|Drug|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
79873522|NCT00893945|Drug|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
79873523|NCT00894023|Drug|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
79873524|NCT00894023|Drug|IV abciximab|IV abciximab + infusion
79738211|NCT04192240|Other|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
79738212|NCT04192240|Other|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
79738213|NCT05343520|Behavioral|Pelvic floor muscle exercises|Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
79738214|NCT04672980|Drug|RTX-321|RTX-321 monotherapy
79738215|NCT04143958|Drug|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
79738216|NCT04143958|Drug|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
79873525|NCT00892073|Drug|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
79873526|NCT00892073|Drug|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
79275224|NCT05465018|Device|Worst case hardware|To test if software still works with an older smartphone
79275225|NCT05465018|Device|Damaged lens|To test if software is still working when the lens of the smartphone is damaged
79275226|NCT05465018|Device|Face or chest outside test frame|To test software if the participants face or chest is outside the test frame
79275227|NCT02161835|Other|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
79275228|NCT04739527|Biological|DCP-001|allogeneic dendritic cell vaccine
79738217|NCT04303338|Procedure|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
79275229|NCT02154737|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
79738218|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
79275230|NCT02154737|Drug|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
79275231|NCT04474171|Behavioral|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
79275232|NCT02161913|Behavioral|Multi-Family Group Treatment|
79738219|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
79738220|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
79738221|NCT04142086|Biological|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
79873527|NCT00894101|Drug|[F-18] FLT|10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.
79873528|NCT00896831|Drug|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
79873529|NCT00896831|Drug|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
79873530|NCT00896909|Genetic|gene expression analysis|
79873531|NCT00896909|Genetic|mutation analysis|
79275233|NCT02161913|Behavioral|SCI Education Control Group|
79275234|NCT00813163|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
79275235|NCT02154815|Other|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, and 24 months
79275236|NCT00812383|Device|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
79275237|NCT05430932|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
79738222|NCT04643184|Other|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
79873532|NCT00896909|Genetic|polymerase chain reaction|
79873533|NCT00896909|Other|diagnostic laboratory biomarker analysis|
79873534|NCT02541227|Drug|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
79275238|NCT02158871|Behavioral|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
79304644|NCT03545477|Other|Standard locomotion treatment: straight-walking training|It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
79873535|NCT00896987|Drug|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
79873536|NCT00896987|Drug|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)
79873537|NCT00897065|Genetic|microarray analysis|
79873538|NCT00897065|Genetic|polymerase chain reaction|
79873539|NCT00897065|Genetic|protein expression analysis|
79873540|NCT00897065|Other|diagnostic laboratory biomarker analysis|
79873541|NCT00897065|Other|fluorescent antibody technique|
79873542|NCT00897065|Other|immunohistochemistry staining method|
79873543|NCT00897065|Other|immunologic technique|
79873544|NCT00897143|Genetic|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
79873545|NCT00897143|Genetic|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
79873546|NCT00897143|Other|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
79738223|NCT05343442|Procedure|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
79275239|NCT02158871|Behavioral|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
79275240|NCT00812305|Drug|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
79578878|NCT01892579|Behavioral|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
79578879|NCT01892579|Other|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
79873547|NCT00897143|Other|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
79578880|NCT01892800|Procedure|Lung resection|
79578881|NCT01893008|Other|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
79578882|NCT01893112|Behavioral|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training & Education Center for health).
79873548|NCT04035863|Device|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
79873549|NCT00343252|Drug|teriparatide|20 ug/day, subcutaneous, 18 months
79578883|NCT01893112|Behavioral|Breast Cancer Screening|
79578884|NCT01893229|Drug|Lithium|Lithium is used as a mood stabiliser
79578885|NCT01893229|Drug|Valproate|Valproate is used as a mood stabiliser
79578886|NCT01893229|Drug|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
79578887|NCT01893229|Drug|Quetiapine|Quetiapine is used as a mood stabiliser
79578888|NCT01893229|Drug|Olanzapine|Olanzapine is used as a mood stabiliser.
79873550|NCT00343252|Drug|risedronate|35 mg/once weekly, oral, 18 months
79873551|NCT00343252|Drug|placebo|once weekly, oral, 18 months
79873552|NCT00343252|Drug|placebo|daily, subcutaneous, 18 months
79873553|NCT00892229|Drug|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
79873554|NCT00892229|Drug|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
79873555|NCT00897221|Drug|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
79873556|NCT00897221|Drug|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
79275241|NCT00812305|Drug|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
79275242|NCT04968197|Device|Vestibular Intervention via Portable Electrical Stimulator (VIPES) system|A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
79738224|NCT02874222|Other|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
79738225|NCT05333302|Biological|CD19 CAR-T-cells|One dose of CD19 CAR-T cells (1*10e6 CAR+ T-cells/kg) by intravenous infusion.
79873557|NCT02540525|Device|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
79275243|NCT00901693|Drug|AL-46383A Ophthalmic Solution|
79275244|NCT00901693|Drug|AL-46383A Ophthalmic Solution Vehicle|
79578889|NCT01893229|Drug|Ziprasidone|Ziprasidone is used as a mood stabiliser
79275245|NCT05440760|Device|The Oculus Quest 2 Virtual Reality Headset|"The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~Nature Treks VR published by Greener Games (Ironbridge, England, UK)"
79275246|NCT04474093|Other|Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)|
79578890|NCT01893645|Device|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
79578891|NCT01893749|Behavioral|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
79578892|NCT01893775|Biological|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
79578893|NCT01894269|Drug|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
79578894|NCT01894347|Other|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
79578895|NCT01894789|Drug|Ticagrelor|Blinded administration of ticagrelor for 10 days
79578896|NCT01894789|Drug|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
79578897|NCT01894815|Drug|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
79578898|NCT01894815|Device|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
79738226|NCT05333302|Drug|Tocilizumab|Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
79738227|NCT05343208|Diagnostic Test|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
79738228|NCT03456778|Procedure|Ultrasound-guided Percutaneous Tenotomy with Platelet-Rich Plasma (PRP)|Using an aseptic procedure, 7 cubic centimeters (cc) of blood will be collected and processed for the PRP injection. The site to be injected will be prepared with isopropyl alcohol and then sprayed with ethyl chloride to achieve cutaneous anesthesia. Next, with continuous sonographic visualization, the skin and subcutaneous tissues overlying the tendon will be infiltrated with 0.5% bupivacaine and 1% sodium bicarbonate (50 milliequivalents (mEq)/50 mL) via a 25-gauge hypodermic needle. Once adequate anesthesia is achieved, a 20-gauge needle will be used to repeatedly fenestrate the tendinotic portion of the tendon along the long plane. Any calcifications within the substance of the tendon will be mechanically fragmented. When the region of interest has been treated, a PRP injection (5 cc) will be delivered.
80030504|NCT06016426|Other|Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.|the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
79275247|NCT02154893|Device|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
79275248|NCT02154893|Device|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
79275249|NCT02154893|Device|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
79578899|NCT01894815|Other|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
79578900|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
79578901|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
79578902|NCT01895751|Procedure|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
79738229|NCT03664882|Drug|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
79873558|NCT02540525|Device|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
79275250|NCT05642949|Drug|MHB036C|MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
79275251|NCT05464706|Dietary Supplement|Synchrolevels|Supplement therapy to model the recovery after liver surgery
79275252|NCT00899977|Drug|Placebo|Matching placebo
79578903|NCT01896024|Behavioral|Psychiatric Management|
79275253|NCT00899977|Drug|TC-5214|
79275254|NCT02159027|Drug|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
79275255|NCT02159027|Drug|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
79275256|NCT05674461|Other|WhatsApp Group|"Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, WHOQOL-BREF-TR and Healthy Lifestyle Behaviors Scale II.~Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form, WHOQOL-BREF-TR and Healthy Lifestyle Behaviors Scale II."
79275257|NCT05674461|Other|Face-to-face Group|"Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, WHOQOL-BREF-TR and Healthy Lifestyle Behaviors Scale II.~The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form, WHOQOL-BREF-TR and Healthy Lifestyle Behaviors Scale II."
79275258|NCT05674461|Other|Control Group|"Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, WHOQOL-BREF-TR and Healthy Lifestyle Behaviors Scale II.~No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form, WHOQOL-BREF-TR and Healthy Lifestyle Behaviors Scale II."
79738230|NCT03664882|Drug|Placebo|Pharmaceutical form: tablet Route of administration: oral
79578904|NCT01896024|Behavioral|Motive-oriented therapeutic relationship/Plan Analysis|
79578905|NCT01896570|Procedure|Catheter ablation of subsequent atrial tachycardia|
79578906|NCT01896622|Drug|Ritonavir|Impact on dabigatran PK/PD
79738231|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79873559|NCT00892307|Radiation|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
79873560|NCT00897299|Genetic|microarray analysis|
79275259|NCT02161991|Drug|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
79275260|NCT02161991|Drug|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
79275261|NCT04473859|Drug|FSR Peptide 20μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
79275262|NCT04473859|Drug|FSR Peptide 50μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
79275263|NCT04473859|Drug|FSR Peptide 100μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
79275264|NCT04473859|Drug|FSR Peptide 200μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
79578907|NCT01896622|Drug|Cobicistat|Impact on dabigatran PK/PD
79578908|NCT01897051|Drug|Rifaximin + propranolol|"Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
79738232|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
79873561|NCT00897299|Genetic|protein expression analysis|
79275265|NCT04473859|Drug|Placebo|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
79275266|NCT02162069|Device|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
79275267|NCT05438966|Other|No intervention|No intervention
79578909|NCT01897051|Drug|Propranolol + Placebo|"Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
79578910|NCT01897090|Other|Elimination Diet|
79578911|NCT01897090|Other|Dietary Guidelines for Americans|
80030505|NCT06016413|Drug|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
79275268|NCT04473703|Drug|renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor|Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
79275269|NCT04473937|Radiation|Radiotherapy|Radiotherapy at pre-determined dose and schedule
79275270|NCT02763215|Drug|Standard of Care Medications|Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
79275271|NCT00948961|Biological|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
80030506|NCT06016413|Drug|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
79275272|NCT00948961|Biological|CDX-1401|
79578912|NCT01897142|Biological|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
79578913|NCT01897142|Drug|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
79275273|NCT00948961|Biological|Resiquimod|
79578914|NCT01897142|Biological|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
79578915|NCT01897142|Drug|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
79873562|NCT00897299|Other|immunohistochemistry staining method|
79873563|NCT00897299|Other|laboratory biomarker analysis|
79873564|NCT00342628|Biological|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
79873565|NCT00342628|Biological|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
79873566|NCT00342628|Biological|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
79873567|NCT00897377|Radiation|Radiation therapy|
79873568|NCT00897377|Drug|Temozolomide|
79873569|NCT00505284|Drug|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
79873570|NCT00505284|Drug|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
79873571|NCT00505284|Drug|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
79873572|NCT00505284|Drug|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
79873573|NCT00505284|Drug|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
80030507|NCT06016413|Drug|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
80030508|NCT06016400|Drug|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
80030509|NCT06016400|Drug|Placebo|Placebo
80030510|NCT06016374|Other|telerehabilitation|"During this study, the patient will be asked to use the TeleRé programme at least 5 times a week for 30 minutes for one month. Through the programme, they will have access to exercises in video format and thus self-rehabilitation as well as serious therapeutic games. The self-education games and videos target the functional and motor recovery of the upper limb. In addition, cognitive functions (attention, memory, etc.) will also be stimulated via the programme. Therapeutic education modules and PROMS assessments will also be available."
79275274|NCT00948961|Biological|poly-ICLC|
79275275|NCT02159105|Device|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
79275276|NCT00803413|Behavioral|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
79275277|NCT00803413|Behavioral|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
79578916|NCT01897142|Biological|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
79578917|NCT01897142|Drug|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
79578918|NCT01897142|Biological|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
79578919|NCT01897142|Drug|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
79578920|NCT01897142|Biological|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
79873574|NCT00894569|Drug|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
80030511|NCT06016361|Other|VS-200Cr|Topical cream with moisturizing factors.
80030512|NCT06016361|Other|Standard of care|AAD recommended course of care.
79873575|NCT00894569|Drug|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
80030513|NCT06016309|Other|There is no intervention.|There is no intervention.
80030514|NCT06016296|Other|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
79578921|NCT01897142|Drug|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
79578922|NCT01897142|Biological|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
79578923|NCT01897142|Drug|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
79578924|NCT01897298|Behavioral|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
79578925|NCT01897649|Dietary Supplement|NUTRIOSE FB06|15g/day NUTRIOSE FB06
79738233|NCT03571750|Behavioral|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
79738234|NCT03571750|Behavioral|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
79873576|NCT00337168|Drug|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
79873577|NCT00337168|Drug|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
79873578|NCT00892385|Drug|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
79873579|NCT00892385|Drug|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
79873580|NCT00892463|Drug|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
79873581|NCT01011114|Drug|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
79873582|NCT01011114|Drug|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
79873583|NCT00606905|Biological|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
79873584|NCT00606905|Other|normal saline|equivalent volume of normal saline
79873585|NCT01055392|Drug|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
79578926|NCT01897649|Dietary Supplement|GLUCIDEX 21|15g/day GLUCIDEX 21
79578927|NCT01897662|Dietary Supplement|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
79578928|NCT01897662|Dietary Supplement|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
79578929|NCT01897740|Drug|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
79578930|NCT01897753|Drug|growth hormone|36 months
79578931|NCT01897870|Behavioral|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
79578932|NCT01898065|Drug|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
79578933|NCT01898221|Drug|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
79578934|NCT01898221|Procedure|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
79578935|NCT01898338|Drug|Fosfomycin 2gr/6h iv|
79578936|NCT01898338|Drug|Daptomycin 10mg/kg/24h iv|
80030515|NCT06016231|Device|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
80030516|NCT06016166|Device|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
79275278|NCT00803413|Behavioral|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
79275279|NCT00803413|Behavioral|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
79578937|NCT01898572|Other|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
79578938|NCT01898897|Procedure|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
79873586|NCT01055392|Drug|Placebo|Identical placebo tablets were administered twice-a-day for two years.
79275281|NCT05673213|Other|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
79873587|NCT03063762|Drug|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
79873588|NCT03063762|Drug|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
79738235|NCT03521362|Device|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
79738236|NCT03521362|Device|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
79738237|NCT03514732|Drug|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
79873589|NCT03063762|Drug|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
79275282|NCT02770547|Device|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
79275283|NCT02770547|Device|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
79738238|NCT03800836|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
79873590|NCT00897455|Genetic|DNA analysis|
79873591|NCT00897455|Genetic|mutation analysis|
79275284|NCT00800605|Biological|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
79578939|NCT01898897|Procedure|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
79873592|NCT00897455|Genetic|polymorphism analysis|
79873593|NCT00897455|Other|laboratory biomarker analysis|
79873594|NCT00897455|Procedure|evaluation of cancer risk factors|
79873595|NCT03985228|Dietary Supplement|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
79738239|NCT03800836|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
80030517|NCT06016101|Other|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~Pill counting~Morisky questionnaire"
79738240|NCT03800836|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
79738241|NCT03800836|Drug|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m^2 on Days 1, 8, and 15 of each 28 day cycle.
79738242|NCT03800836|Drug|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m^2 and 600 mg/m^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
80030518|NCT06016101|Other|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~Evaluation of user experience~Evaluation of the report produced by the application"
79275285|NCT00800605|Biological|Placebo: Phosphate-buffered saline|Single intramuscular injection
79275286|NCT02159261|Drug|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
79275287|NCT05231499|Other|nasal irrigation|regular saline nasal rinse
79275288|NCT00890305|Drug|CT-011|
79275289|NCT00890305|Drug|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
79275290|NCT01661972|Drug|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
79275291|NCT04650659|Diagnostic Test|6-minute walk test part one|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
79738243|NCT00932373|Drug|trastuzumab-MCC-DM1|Intravenous escalating dose
79873596|NCT03985228|Dietary Supplement|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
79873597|NCT01058980|Procedure|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
79275292|NCT04650659|Diagnostic Test|6-minute walk test part two|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
79275293|NCT04650659|Diagnostic Test|1-minute sit-to-stand test|Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
79275294|NCT04650659|Diagnostic Test|4-meters gait speed test|Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
79275295|NCT04650659|Diagnostic Test|Nailfold videocapillaroscopy|"Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands."
79275296|NCT04650659|Diagnostic Test|HR-pQCT|Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
79275297|NCT04650659|Diagnostic Test|Hand x-ray|Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
79738244|NCT03511690|Behavioral|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
79738245|NCT04265235|Other|Home-based exercise program|see 'arm' section
79738246|NCT03509506|Behavioral|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~The vital signs show undesired readings~The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
79738247|NCT04265001|Drug|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
79738248|NCT03488290|Behavioral|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
79738249|NCT03488290|Other|Treatment as Usual|The Treatment as Usual group will receive routine care
80030519|NCT06016062|Drug|RC148|RC148 is a bispecific antibody, targeting programmed death-1(PD-1) and Vascular endothelial growth factor(VEGF).
80030520|NCT06016049|Other|EMLA® adjuvant|cutaneous forearm deafferentation
79578940|NCT01898936|Procedure|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
80030521|NCT06016049|Behavioral|Sensory training|Sensibility training of the median nerve
80030522|NCT06016036|Drug|SAL-0951|"SAL-0951：~initial phase：4mg QD for 8 weeks~subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
80030523|NCT06016036|Drug|Placebo|"SAL-0951 placebo：~initial phase：4mg QD for 8 weeks~subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
80030524|NCT06015984|Behavioral|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
80030525|NCT06015971|Dietary Supplement|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
80030526|NCT06015971|Dietary Supplement|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
80030527|NCT06015958|Other|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
79578941|NCT01898936|Device|Only photodynamic therapy|
79738250|NCT04263753|Procedure|Bladder conservative surgery in placenta accretta|"After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20"
79738251|NCT03463486|Behavioral|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
79578942|NCT01899001|Behavioral|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
79738252|NCT00607347|Other|Glucose|Oral Glucose Tolerance Test
79738253|NCT00608595|Drug|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
79738254|NCT00608595|Genetic|gene expression analysis|not noted
79873598|NCT01058980|Procedure|No additional ablation|Presence of dormant PV conduction, no additional ablation.
79738255|NCT00608595|Genetic|protein expression analysis|Not noted
79873599|NCT01058980|Procedure|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
79873600|NCT01058980|Procedure|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
80030528|NCT06015958|Other|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
80030529|NCT06015932|Behavioral|Cognitive Behavior Therapy|Participate in CBCSM group sessions
80030530|NCT06015932|Other|Questionnaire Administration|Complete questionnaires
80030531|NCT06015919|Behavioral|dash diet|"Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
80030532|NCT06015919|Device|Acupuncture|acupuncture
80030533|NCT06015854|Biological|Vvax001 therapeutic cancer vaccine|Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
79275298|NCT04650659|Diagnostic Test|DEXA|Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
80030534|NCT06015828|Dietary Supplement|bovine lactoferrin|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
80030535|NCT06015802|Other|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
79873601|NCT00894725|Procedure|laparoscopic left colonic resection|laparoscopic colonic resection
79275299|NCT00947557|Drug|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
79275300|NCT00947557|Drug|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
79873602|NCT00894725|Procedure|open left colonic resection|conventional open colonic resection
79275301|NCT03542747|Device|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
79578943|NCT01899001|Behavioral|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
79578944|NCT01899105|Drug|lumacaftor|
79873603|NCT05278637|Drug|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
79578945|NCT01899105|Drug|ivacaftor|
79578946|NCT01899456|Device|Catheter-based renal denervation|
79578947|NCT01899469|Procedure|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
79873604|NCT05278637|Drug|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
79873605|NCT00897533|Genetic|gene mapping|
79873606|NCT00897533|Genetic|polymorphism analysis|
79873607|NCT00897533|Other|diagnostic laboratory biomarker analysis|
80030536|NCT06015776|Other|Gender|Differences between men and women will be observed
80030537|NCT06015763|Procedure|Endoscopy|Endoscopic biopsy
79275302|NCT03542747|Device|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
79275303|NCT05464238|Other|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
79738256|NCT00608595|Other|immunohistochemistry staining method|not noted
79738257|NCT00608595|Other|laboratory biomarker analysis|not noted
79738258|NCT00608595|Other|mass spectrometry|
79738259|NCT00608595|Procedure|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
79738260|NCT00608595|Procedure|neoadjuvant therapy|not noted
79738261|NCT00608595|Procedure|therapeutic conventional surgery|not noted
79738262|NCT00614770|Procedure|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
79873608|NCT00897533|Other|immunohistochemistry staining method|
79873609|NCT00897611|Procedure|DNA methylation analysis|
79873610|NCT00897611|Procedure|polymerase chain reaction|
80030538|NCT06015711|Drug|Maxigesic administration|Preoperative Maxigesic IV administration
79275304|NCT05464238|Other|Standard treatment|Standard treatment during study duration
79275305|NCT02162225|Drug|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
79275306|NCT02163005|Drug|Gadolinium|-agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
79275307|NCT02155049|Drug|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
79738263|NCT00614770|Procedure|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
79873611|NCT00897611|Procedure|computed tomography|
79873612|NCT00897611|Procedure|magnetic resonance imaging|
79873613|NCT00900965|Device|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
79873614|NCT00900965|Device|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
79873615|NCT00901043|Dietary Supplement|Walnut supplementation|Eight weeks of walnut supplementation
79275308|NCT03540953|Drug|Endoscopic injection of Mitomycin C|administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
79275309|NCT00888355|Drug|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
79275310|NCT00888355|Drug|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
79873616|NCT00901043|Dietary Supplement|Ad lib diet|Eight weeks without walnut supplementation
79873617|NCT00901121|Device|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
79275311|NCT03542591|Other|"Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet"|No active intervention, only survey as mentioned above.
80030539|NCT06015698|Procedure|Laparoscopic tubal disconnection|"The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~Then, the tube is severed in the middle of the burn area with laparoscopic scissors~Ensure adequate hemostasis"
79275312|NCT02155127|Behavioral|walking|
79873618|NCT00901121|Device|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
80030540|NCT06015698|Procedure|Laparoscopic salpingectomy|"The tube will be removed from its anatomical attachements by progressive bipolar coagulation~Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~Removal of the tube through one of the ancillary ports using artery forceps~Ensure adequate hemostasis"
80030541|NCT06015633|Other|No intervention|Observational only
80030542|NCT06015594|Drug|Metformin|Patients treated with metformin
80030543|NCT06015568|Drug|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
80030544|NCT06015568|Drug|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
80030545|NCT06015555|Behavioral|TAMO|TAMO therapy
80030546|NCT06015555|Behavioral|Postural Control exercises|Postural Control exercises
80030547|NCT06015503|Drug|PLB1004|PLB1004 is a capsule in the form of 80mg and 40mg.
79275313|NCT00794677|Drug|ezetimibe|Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
79275314|NCT00794677|Drug|placebo|Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
79275315|NCT00792727|Drug|ketoprofen Patch|2 topical patches applied once daily for 28 days
79738264|NCT00614770|Procedure|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
79873619|NCT04017377|Drug|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
79873620|NCT02539901|Behavioral|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
79873621|NCT02539901|Behavioral|Free hearing test categorization|Free hearing test categorization evaluation
80030548|NCT06015477|Drug|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
80030549|NCT06015477|Drug|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
80030550|NCT06015464|Drug|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
80030551|NCT06015451|Other|Sub-symptom threshold exercise|Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
80030552|NCT06015412|Diagnostic Test|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
80030553|NCT06015399|Procedure|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
79275316|NCT00792727|Other|Placebo Patch|2 topical placebo patches applied once daily for 28 days
79275317|NCT00945763|Drug|N1539|30 mg
79275318|NCT00945763|Drug|placebo|tablets
79275319|NCT00945763|Drug|N1539|15 mg
79275320|NCT00945763|Drug|N1539|60 mg
79275321|NCT00945763|Drug|Motrin|400 mg
79738265|NCT03761134|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
79738266|NCT03761134|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
79738267|NCT03761134|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
79738268|NCT03761134|Drug|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
79873622|NCT02539901|Behavioral|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
80030554|NCT06015399|Procedure|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
80030555|NCT06015386|Other|inclined plane|2 parallel groups one treated with clear aligner and other treated using inclined plane
79738269|NCT05241717|Behavioral|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
79738270|NCT01055496|Drug|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
79873623|NCT02539901|Behavioral|psychomotor infancy development scale|
80030556|NCT06015386|Other|clear aligner|2 parallel groups one treated with clear aligner and other treated using inclined plane
80030557|NCT06015373|Drug|supress the night dose of carvedilol|already described
79275322|NCT03135145|Device|Lite Run Gait Trainer|"Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient."
79275323|NCT03135145|Other|Usual Treatments|The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
79275324|NCT02770391|Drug|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
79578948|NCT01899469|Procedure|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
79873624|NCT02539901|Behavioral|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
79873625|NCT00897845|Genetic|RNA analysis|
79578949|NCT01899469|Procedure|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
79873626|NCT00897845|Genetic|microarray analysis|
79873627|NCT00897845|Other|immunohistochemistry staining method|
79873628|NCT00897845|Other|laboratory biomarker analysis|
79873629|NCT00897923|Procedure|radionuclide imaging|
79873630|NCT00897923|Radiation|indium In 111-labeled autologous peripheral blood mononuclear cells|
79873631|NCT00897923|Radiation|indium In 111-labeled autologous polymorphonuclear leukocytes|
79873632|NCT00894881|Procedure|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
79873633|NCT00901277|Behavioral|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
79873634|NCT00901277|Behavioral|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
79873635|NCT04035785|Drug|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
79873636|NCT00898079|Other|Cytology Specimen Collection Procedure|Correlative studies
79873637|NCT04035707|Drug|Rocuronium|using rocuronium as a relaxants during general anaesthesia
79873638|NCT04035707|Drug|general volatile anaesthesia|method of anaesthesia
79873639|NCT00901433|Device|Personal WheezoMeter|pulmonary sounds analyzer
79873640|NCT00898157|Other|laboratory biomarker analysis|
80030558|NCT06015334|Procedure|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
80030559|NCT06015321|Drug|Enzalutamide|enzalutamide 160 mg PO daily
80030560|NCT06015295|Diagnostic Test|18F-Fluciclovine (Axumin)|Given by Injection
80030561|NCT06015295|Diagnostic Test|Pet Scan|Scans
80030562|NCT06015269|Drug|DC cells|At a single arm, 1x107cells dose
80030563|NCT06015243|Drug|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
80030564|NCT06015230|Biological|low dose GR1603 in phase Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
80030565|NCT06015230|Biological|high dose GR1603 in phaseⅠb|6 subjects in GR1603 high dose，2 subjects in placebo
80030566|NCT06015230|Biological|low dose GR1603 in phase Ⅱ|low dose GR1603 monthly
80030567|NCT06015230|Biological|high dose GR1603 in phase Ⅱ|high dose GR1603 monthly
80030568|NCT06015230|Biological|Placebo in phase Ⅱ|Placebo
79275325|NCT02770391|Drug|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
79275326|NCT02770391|Procedure|Radical prostatectomy|
79275327|NCT00881023|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
79873641|NCT02539745|Other|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
79873642|NCT02539745|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
79275328|NCT00881023|Device|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
79873643|NCT00894959|Biological|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
79873644|NCT00894959|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
79275329|NCT02155205|Drug|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
79275330|NCT02155205|Drug|Placebo|Matching placebo
79275331|NCT02155205|Drug|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
79275332|NCT02155361|Drug|Topical Citrullus colocynthis fruit oil (1%)|
79275333|NCT02155361|Drug|Topical vehicle oil|
79275334|NCT02162303|Drug|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
79578950|NCT01899547|Procedure|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
79578951|NCT01899547|Procedure|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
79873645|NCT04035395|Other|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
79873646|NCT04035395|Other|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
79275335|NCT02162303|Drug|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
79578952|NCT01899599|Drug|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
79275336|NCT05430308|Procedure|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
79275337|NCT05430308|Procedure|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
79275338|NCT00877903|Drug|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
79275339|NCT00877903|Drug|Placebo|Intravenous infusion of excipients of Prochymal®
79275340|NCT00877279|Device|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
80030569|NCT06015217|Drug|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
80030570|NCT06015152|Drug|Tazarotene 0.045% Topical Application Lotion [ARAZLO]|[ARAZLO]
80030571|NCT06015139|Device|cotton roll-coated viscoelastic polymer pads|relton-hall frame cotton roll-coated viscoelastic polymer pads
79275341|NCT00877279|Device|Belotero Soft|Dermal Filler
79275342|NCT04726033|Drug|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
79275343|NCT04707703|Drug|Isavuconazonium Injection [Cresemba]|Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days
79275344|NCT04707703|Drug|Placebo|Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
79275345|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose
79275346|NCT00936871|Drug|Placebo|Placebo single dose
79275347|NCT00936871|Drug|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
79275348|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
79275349|NCT00936871|Drug|Placebo|Placebo single dose
79275350|NCT00936871|Drug|Moxifloxacin|Moxifloxacin 400 mg single dose
79275351|NCT02536508|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
79275352|NCT02536508|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
79275353|NCT02536508|Drug|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
79304645|NCT03545477|Other|Standard physical therapy|It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
79578953|NCT01899599|Drug|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
79578954|NCT01899664|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
79578955|NCT01899716|Other|Exercise|
80030572|NCT06015139|Device|viscoelastic polymer pads|relton-hall frame viscoelastic polymer pads
79578956|NCT01900015|Drug|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
80030573|NCT06015126|Drug|metronomic oral vinorelbine plus anlotinib|To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
80030574|NCT06015113|Drug|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
80030575|NCT06015100|Drug|Inetetamab plus pyrotiniband and capecitabine|Inetetamab plus pyrotiniband and capecitabine
80030576|NCT06015074|Drug|Propofol|patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
80030577|NCT06015074|Drug|Ciprofol|patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
80030578|NCT06015061|Diagnostic Test|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
80030579|NCT06015035|Drug|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
80030580|NCT06014177|Behavioral|STIckER|"STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk."
80030581|NCT06014177|Other|Control|"After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor."
79738271|NCT01055496|Drug|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
79738272|NCT03436498|Drug|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79873647|NCT04035395|Other|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
80030582|NCT06014060|Procedure|24 Months DAPT|All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization.
80030583|NCT06014060|Procedure|12 Months DAPT|All subjects will receive aspirin (100 mg/day) monotherapy without co-administration of clopidogrel for 12 months after randomization.
80030584|NCT06013280|Other|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
79275354|NCT04663867|Device|AngioSafe Peripheral CTO Crossing System|The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
79578957|NCT01900015|Drug|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
79738273|NCT03436498|Drug|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79304646|NCT03281213|Other|Thoracotomy|
79578958|NCT01900028|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
79578959|NCT01900028|Drug|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
79578960|NCT01900028|Drug|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
79578961|NCT01900041|Drug|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
79578962|NCT01900041|Drug|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
79738274|NCT00609453|Behavioral|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
79738275|NCT01055262|Device|Heatwrap 1|8 hours continuous topically-applied heat
79873648|NCT04035395|Other|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
80030585|NCT06013267|Other|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
79403548|NCT05099406|Device|Transcranial electrical stimulation|"By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session."
79403549|NCT00738543|Other|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
79403550|NCT03924973|Behavioral|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
79738276|NCT00609531|Drug|Citalopram|Pill, 5-20mg once a day for twelve weeks
79738277|NCT00609531|Drug|Placebo|Placebo pill once a day for twelve weeks
79403551|NCT01520324|Device|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
79873649|NCT04035395|Other|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
80030586|NCT06013202|Other|Nigella Sativa Oil Mouth Rinse|Nigella Sativa Oil Mouth Rinse
80030587|NCT06013202|Other|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
80030588|NCT06010550|Radiation|Magnetic resonance imaging|Brain magnetic resonance imaging
79578963|NCT01900080|Other|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
79403552|NCT03832231|Device|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
79578964|NCT01900080|Other|Standard ART Initiation|Standard ART Initiation
79873650|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
79578965|NCT01900080|Other|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
79403553|NCT01279473|Drug|Nilotinib|
79578966|NCT01900080|Other|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count >500 cells/mm3
79578967|NCT01900093|Drug|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
79578968|NCT01900106|Drug|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
79578969|NCT01900106|Drug|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
79738278|NCT03414736|Drug|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
79738279|NCT04301466|Drug|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
79738280|NCT04301466|Drug|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
79738281|NCT04264923|Other|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
79738282|NCT03406000|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
79873651|NCT00901589|Dietary Supplement|thistle oil|four capsules a day
79873652|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
79873653|NCT00901589|Dietary Supplement|Thistle oil|Four capsules daily
79578970|NCT01900158|Drug|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
79873654|NCT04035083|Device|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
79738283|NCT02874300|Other|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
79873655|NCT04035083|Device|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
79578971|NCT01900171|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
79578972|NCT01900171|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
79578973|NCT01900184|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
79578974|NCT01900184|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
79578975|NCT01900197|Drug|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
79873656|NCT00895115|Dietary Supplement|vitamin E|Given once daily
79275355|NCT04638361|Other|Questionnaires|To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
79578976|NCT01900210|Behavioral|WaySafe|
79578977|NCT01900236|Behavioral|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
79578978|NCT01895179|Other|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
79578979|NCT01895179|Other|Grazing|Grazing involves eating meals spread out over the course of the day.
79873657|NCT00895115|Procedure|sham intervention|No supplementation
79873658|NCT02540759|Dietary Supplement|Buglossoides oil|
79873659|NCT02540759|Dietary Supplement|High Oleic Sunflower Oil|
79275356|NCT00934921|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
79275357|NCT00934921|Drug|Zofran®|1 x 8 mg ODT
79275358|NCT00930163|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
79578980|NCT01900262|Other|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
79578981|NCT01900262|Other|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
79578982|NCT01900262|Other|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
79578983|NCT01900275|Other|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
79873660|NCT00901745|Drug|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
79873661|NCT00901745|Drug|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
79873662|NCT02540837|Drug|Bupivacaine|Obturator nerve block
79275359|NCT00930163|Drug|placebo|Subcutaneous repeating dose
79275360|NCT00929539|Drug|JTT-130|Tablets
79275361|NCT00929539|Drug|JTT-130 Placebo|Tablets
79275362|NCT05429450|Drug|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
79275363|NCT05429450|Drug|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
79275364|NCT00103259|Drug|bortezomib|Given IV
79275365|NCT00103259|Drug|irinotecan hydrochloride|Given IV
79275366|NCT00103259|Other|laboratory biomarker analysis|Optional correlative studies
79304647|NCT02438761|Drug|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
79578984|NCT01900288|Behavioral|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
79578985|NCT01900288|Behavioral|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
79578986|NCT01900301|Drug|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
79873663|NCT02540837|Drug|Saline|Obturator nerve block with saline(placebo)
79873664|NCT00898391|Other|laboratory biomarker analysis|Correlative studies
79873665|NCT00898391|Genetic|polymerase chain reaction|Correlative studies
79873666|NCT00898391|Genetic|polyacrylamide gel electrophoresis|Correlative studies
79873667|NCT00898391|Genetic|DNA analysis|Correlative studies
79873668|NCT00901823|Drug|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
79578987|NCT01900301|Drug|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
79738284|NCT02874300|Other|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
79275367|NCT05437016|Behavioral|HUBER exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises. HUBER exercises require the synergistic activation of various muscle groups of the lower limbs, trunk and upper limbs to develop low-high force levels against the handles.
79738285|NCT04262037|Diagnostic Test|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
79275368|NCT05437016|Behavioral|Standard exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises.
79275369|NCT02162381|Drug|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
79738286|NCT01052844|Drug|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
79275370|NCT02162381|Other|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
79275371|NCT00782431|Biological|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
79275372|NCT00782431|Biological|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
79275373|NCT05258617|Device|LLLT Photobiomodulation|Treatment with red LED light using UltraSlim device.
79275374|NCT02155439|Drug|5-fluorouracil|antimitotic drug
79275375|NCT02155439|Drug|Triamcinolone|
79275376|NCT03542435|Drug|SXC-2023|Oral capsule
79403554|NCT05111730|Device|The Shock wave Therapy.|Shockwave therapy is a multidisciplinary device used in orthopedics, physiotherapy, sports medicine, urology and veterinary medicine. Its main assets are fast pain relief and mobility restoration. Together with being a non-surgical therapy with no need for painkillers makes it an ideal therapy to speed up recovery and cure various indications causing acute or chronic pain. Shockwave is an acoustic wave which carries high energy to painful spots and myoskeletal tissues with sub-acute, sub-chronic and chronic conditions. The energy promotes regeneration and reparative processes of the bones, tendons and other soft tissues. Shockwaves are characterized by jump change in pressure, high amplitude and non-periodicity. The kinetic energy of the projectile, created by compressed air, is transferred to the transmitter at the end of the applicator and further into the tissue.
79403555|NCT04145713|Dietary Supplement|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
79403556|NCT04145713|Other|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
79578988|NCT01900327|Radiation|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
79403557|NCT05108220|Dietary Supplement|Cannabidiol (CBD)- containing consumer products|Oils or capsules containing CBD which could be purchased commercially within the U.S.
79403558|NCT04145479|Behavioral|physical activity|exercise
79403559|NCT05107986|Procedure|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
79403560|NCT01484054|Device|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
79873669|NCT00901823|Drug|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
79873670|NCT00898469|Genetic|polymorphism analysis|
79275377|NCT03542435|Drug|Placebo|Placebo
79275378|NCT02544152|Drug|Lubiprostone|8 mcg administered orally twice daily (BID)
79275379|NCT02544152|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
79275380|NCT02162537|Drug|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
79275381|NCT02162537|Drug|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
79578989|NCT01900327|Drug|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
79578990|NCT01900327|Procedure|Surgery|Upfront pancreato-duodenectomy
79578991|NCT01900327|Drug|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
79578992|NCT01900340|Dietary Supplement|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
79738287|NCT01052844|Drug|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
79738288|NCT04261881|Dietary Supplement|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
79873671|NCT00606593|Drug|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79275382|NCT02162537|Drug|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
79275383|NCT02162537|Radiation|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
79873672|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
80030589|NCT06005766|Behavioral|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
80030590|NCT06005766|Other|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
79275384|NCT02534324|Drug|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
79578993|NCT01900340|Drug|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
79873673|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79873674|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79873675|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79873676|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79275385|NCT02761733|Behavioral|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
79275386|NCT00864175|Drug|INCB007839|100 mg BID
79403561|NCT01484054|Device|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
79403562|NCT03711799|Behavioral|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
79403563|NCT03027674|Drug|10% nifedipine cream|Topical treatment for Raynaud
79403564|NCT03027674|Drug|5% sildenafil cream|Topical treatment for Raynaud
79403565|NCT03945799|Drug|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
79403566|NCT04024345|Diagnostic Test|Barratt Simplified Measure of Social Status (BSMSS)|Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
79403567|NCT04024345|Diagnostic Test|Global Assessment of Functioning scale (GAF)|Used to measure overall levels of functionality of an individual
79403568|NCT04024345|Diagnostic Test|General Self-Efficacy Scale (GSES)|Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
79873677|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79873678|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
80030591|NCT06004102|Other|reminder text message|The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
80030592|NCT05999773|Drug|SGLT2 inhibitor|Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
79275387|NCT00864175|Drug|INCB007839|200 mg BID
79275388|NCT00864175|Drug|INCB007839|300 mg BID
79275389|NCT00864175|Drug|INCB007839|300 mg BID
79403569|NCT04024345|Diagnostic Test|Perceived Stress Scale (PSS)|To assess the perceived stress
79403570|NCT04024345|Diagnostic Test|Coping Orientation to Problems Experienced (Brief COPE),|It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
79578994|NCT01900340|Dietary Supplement|Saline|IV saline infusion and intraduodenal administration of nutrients
79578995|NCT01900340|Drug|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
79578996|NCT01900353|Other|brushing methods|
79578997|NCT01900366|Procedure|Fat Biopsy|Fat biopsy
79873679|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79578998|NCT01900379|Procedure|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
79873680|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
79275390|NCT00864175|Drug|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
79403571|NCT04024345|Diagnostic Test|Multidimensional Scale of Perceived Social Support (MSPSS)|to explore the subject's social support system
79275391|NCT00864175|Drug|Docetaxel|
79275392|NCT00861211|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
79275393|NCT00861211|Drug|Placebo|Placebo comparator
79275394|NCT02166593|Drug|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
79275395|NCT02166593|Drug|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
79275396|NCT00858871|Drug|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
79578999|NCT01900379|Other|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
79579000|NCT01900405|Drug|Dexmedetomidine|
79579001|NCT01900418|Behavioral|Walk with Ease|An evidence-based walking program
79579002|NCT01900457|Other|electromyography|
79738289|NCT04261881|Dietary Supplement|ATP-II|3 capsules daily with breakfast
79275397|NCT00858871|Drug|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
79275398|NCT00858871|Drug|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
79275399|NCT00858871|Drug|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
79275400|NCT02163083|Procedure|ICG|Improvement of detection of positive lymphnodes
79275401|NCT02162693|Biological|Mesenchymal progenitor cells|Administrated for intra-articular injection
79738290|NCT04261881|Dietary Supplement|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
79738291|NCT05319795|Behavioral|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
79738292|NCT04261647|Other|kinesio-taping techniques.|
79275402|NCT02162693|Biological|Sodium Hyaluronate|
79275403|NCT02162927|Dietary Supplement|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
79275404|NCT02162927|Dietary Supplement|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
79738293|NCT04261647|Other|Pelvic floor exercise|
79738294|NCT04261647|Other|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
79738295|NCT03679936|Diagnostic Test|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
79738296|NCT04261803|Biological|salivary sample|spit of saliva in a tube
79738297|NCT04261803|Biological|blood test|2millilitter blood test
79738298|NCT01049412|Drug|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
79738299|NCT01049412|Drug|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
79873681|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
79275405|NCT02166671|Biological|HBV booster vaccination 1dose|
79275406|NCT02163161|Drug|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
79275407|NCT02163161|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
79275408|NCT02163161|Drug|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
79275409|NCT00917293|Drug|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
79275410|NCT00917293|Drug|Placebo|Placebo 2 pills, po bid.
79275411|NCT02166749|Procedure|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
79275412|NCT02166827|Device|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
79403572|NCT04436874|Device|endoscopy|transplant infusion of feces from healthy donors into affected subjects
79579003|NCT01900457|Other|electroencephalography|
79579004|NCT01900457|Other|approaches from psychophysics|
79738300|NCT02692378|Drug|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
79738301|NCT02692456|Device|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
79873682|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 3mcg
79873683|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 15mcg
79873684|NCT00902057|Drug|placebo|saline subcutaneous
79873685|NCT00895349|Procedure|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
79873686|NCT00895349|Procedure|CT Abdomen and Pelvis scan|Pre-treatment scan
79873687|NCT00898547|Other|immunoenzyme technique|
79275413|NCT02166827|Device|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
79275414|NCT00845299|Drug|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
79275415|NCT00845299|Drug|artificial tears preserved with Benzalkonium Chloride|
79275416|NCT02255591|Drug|Lidocaine-adrenaline added gadolinium.|
79275417|NCT04473391|Device|Cycle-ergometer training assisted by FES for lower extremities|The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
79275418|NCT02170883|Other|Interactive SMS|
79738302|NCT02692456|Device|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
79738303|NCT04302480|Other|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
79738304|NCT04302480|Other|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
79738305|NCT04302480|Other|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
79738306|NCT04302480|Other|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
79738307|NCT02873988|Other|bronchial epithelial cell culture|
79738308|NCT05494918|Drug|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
79873688|NCT00898547|Other|laboratory biomarker analysis|
79873689|NCT04035941|Behavioral|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
79873690|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
79275419|NCT02170883|Other|Usual care|
79275420|NCT00913393|Drug|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
79275421|NCT00913393|Drug|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
79275422|NCT00913393|Drug|Placebo|Placebo IV every 2 weeks for 22 weeks
79275423|NCT02166983|Other|computer-assisted cognitive training|Complete Lumosity cognitive exercises
79275424|NCT02166983|Other|cognitive intervention|Complete Active Journaling cognitive exercises
79275425|NCT02166983|Procedure|mind-body intervention procedure|Complete relaxation exercises
79275426|NCT02166983|Other|memory intervention|Complete compensatory strategies
79275427|NCT02166983|Other|questionnaire administration|Ancillary studies
79275428|NCT04486963|Drug|Sanhuangjingshimingwan|Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
79275429|NCT04486963|Drug|Sanhuangjingshimingwan Placebo|Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
79275430|NCT03539237|Other|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
79738309|NCT04593498|Diagnostic Test|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
79738310|NCT04593498|Diagnostic Test|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
79738311|NCT04593498|Diagnostic Test|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
79738312|NCT04593498|Diagnostic Test|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
79738313|NCT02584426|Device|Ultrasonic Distribution of Cefazolin|
79738314|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
79738315|NCT00934089|Drug|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
79738316|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
79738317|NCT00934089|Drug|latanoprost|Topical ocular solution, once-daily for 14 days
79738318|NCT05333068|Procedure|PCI revascularization strategy based on combined FFR and OCT assessment|PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with > 70 % AS or MLA < 2.5 mm2.
79275431|NCT02167061|Drug|DA-1229_01|complex single administration
79275432|NCT02167061|Drug|E+M|co-administration of 2 drugs
79275433|NCT02167061|Drug|DA-1229_01 fast|
79275434|NCT02167061|Drug|DA-1229_01 fed|
79579005|NCT01900470|Behavioral|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
79579006|NCT01900496|Biological|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
79579007|NCT01900496|Biological|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m^2 IV. Additional doses are given at three and six months post week 27.
79579008|NCT01900509|Drug|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
79579009|NCT01900509|Drug|Clofarabine|Route of administration: IV days 1-5.
79579010|NCT01900509|Drug|Etoposide|Route of administration: IV days 1-5.
79579011|NCT01900509|Drug|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
79873691|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
79873692|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
79873693|NCT00898703|Other|flow cytometry|
79873694|NCT00898703|Other|immunoenzyme technique|
79873695|NCT00898703|Other|laboratory biomarker analysis|
79403573|NCT02080507|Device|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
79873696|NCT02539589|Behavioral|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
79873697|NCT02539589|Behavioral|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
79873698|NCT00902213|Behavioral|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
79275435|NCT03715465|Drug|Melatonin 0.5 MG|Melatonin tablet
79275436|NCT03715465|Other|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
79275437|NCT02163239|Device|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
79275438|NCT04657523|Device|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
79275439|NCT00781339|Drug|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
79275440|NCT02171039|Drug|Dabigatran|
79873699|NCT00902213|Behavioral|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
79873700|NCT02540369|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
79873701|NCT00902369|Drug|AK106-001616|Part1: Dose escalation Part2: Dose expansion
79873702|NCT00902369|Drug|Placebo|
79873703|NCT00902369|Drug|Active comparator|
79873704|NCT02540135|Other|fluorescein|fluorescein and conventional neuro-navigation
79873705|NCT02540135|Other|intraoperative MRI|conventional neuro-navigation and iMRI
79873706|NCT00905879|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
79873707|NCT02539433|Procedure|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
79275441|NCT02171039|Drug|Atorvastatin|
79275442|NCT03540407|Dietary Supplement|Oncoxin-Viusid®|Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
79275443|NCT03540407|Dietary Supplement|Placebo|Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
79275444|NCT00840073|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
79275445|NCT00840073|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
79403574|NCT02080507|Device|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
79403575|NCT04023721|Drug|Inarigivir soproxil|Inarigivir soproxil 200 mg tablets
79403576|NCT04023721|Drug|Nucleoside/nucleotide (NUC) analogue inhibitors|Continuation of prestudy NUC therapy
79403577|NCT04023877|Drug|E2027|E2027 oral capsule.
79738319|NCT05333068|Procedure|PCI revascularization strategy based FFR assessment|PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
79873708|NCT00605267|Drug|Tamoxifen|20 mg once daily oral dose
79873709|NCT00605267|Drug|Anastrazole (Arimidex)|1 mg once daily oral dose
79873710|NCT00605267|Drug|Goserelin acetate (Zoladex)|3.6mg/month depot injection
79579012|NCT01900509|Drug|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
79275446|NCT02261207|Drug|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
79873711|NCT02539355|Other|Diet A|12-week diet
79275447|NCT03697447|Procedure|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
79275448|NCT02163473|Procedure|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
79275449|NCT02163473|Procedure|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
79579013|NCT01900522|Drug|ITI-214 Dose A|ITI-214 Dose A Oral Solution
79579014|NCT01900522|Drug|ITI-214 Dose B|ITI-214 Oral Solution Dose B
79579015|NCT01900522|Drug|ITI-214 Dose C|ITI-214 Dose C Oral Solution
79579016|NCT01900522|Drug|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
79579017|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
79579018|NCT01900522|Drug|ITI-214 Dose E|ITI-214 Dose E Oral Solution
79579019|NCT01900522|Drug|ITI-214 Dose F|ITI-214 Dose F Oral Solution
79738320|NCT01032174|Drug|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
79738321|NCT01032174|Drug|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
79738322|NCT03344146|Behavioral|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
79738323|NCT03344146|Behavioral|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
79403578|NCT03870204|Diagnostic Test|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
79275454|NCT02167373|Other|Cogito Companion Intervention|
79275455|NCT02167373|Device|mobile phone application|
79275456|NCT00838591|Drug|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
79275457|NCT00838591|Drug|Placebo|
79275458|NCT02163629|Behavioral|Stress management|
79275459|NCT00838279|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
79275460|NCT00838279|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
79275461|NCT02163707|Drug|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
79275462|NCT00772525|Drug|Nerispirdine|"form: tablet~Route: oral"
79275463|NCT00772525|Drug|Placebo|"form: tablet~Route: oral"
79403579|NCT04023955|Behavioral|Twitter|Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
79579020|NCT01900522|Drug|ITI-214 Dose G|ITI-214 Dose G Oral Solution
79579021|NCT01900522|Drug|ITI-214 Dose H|ITI-214 Dose H Oral Solution
79579022|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
79579023|NCT01900548|Dietary Supplement|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
79579024|NCT01900548|Dietary Supplement|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
79579025|NCT01900548|Dietary Supplement|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
79579026|NCT01900548|Other|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
79579027|NCT01900587|Drug|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
79579028|NCT01900587|Drug|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
79579029|NCT01900600|Other|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
79579030|NCT01900600|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
79579031|NCT01900613|Behavioral|Ninos Sanos Familia Sana|
79579032|NCT01900639|Behavioral|change time of intake of aspirin|
79579033|NCT01900678|Device|VytronUS Ablation System|Pulmonary vein isolation.
79579034|NCT01900717|Drug|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
79579035|NCT01900717|Drug|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
79738324|NCT02704780|Drug|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
79873712|NCT02539355|Other|Diet B|12-week Diet
79873713|NCT00902525|Drug|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
79873714|NCT00902603|Drug|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
79873715|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
79873716|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
79873717|NCT00906113|Drug|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
79579036|NCT01900743|Drug|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
79579037|NCT01900743|Drug|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
80030593|NCT05995678|Behavioral|STEP-Home-SP|This group will meet for ~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
80030594|NCT05995678|Behavioral|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
80030595|NCT05995678|Behavioral|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
80030596|NCT05994339|Drug|Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
80030597|NCT05993338|Diagnostic Test|right heart catheterization (RHC).|Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC).
80030598|NCT05965869|Other|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
80030599|NCT05963932|Drug|BMS-986419 DR Capsule|Specified dose on specified days
79579038|NCT01900756|Behavioral|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
79579039|NCT01900769|Drug|Blood Volume Dilution|
79579040|NCT01900782|Biological|Intervention A|Prefilled syringe.
80030600|NCT05963932|Drug|BMS-986419 IR Tablet|Specified dose on specified days
80030601|NCT05949437|Other|Yuga|Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks
80030602|NCT05949437|Other|Aerobic exercises|in form of treadmill according to the target exercise heart rate for 12 weeks
79275464|NCT02171117|Procedure|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
79275465|NCT02171117|Biological|HLA-mismatched donor peripheral stem cell infusion|
79275466|NCT00769795|Drug|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
79873718|NCT00906113|Drug|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
79873719|NCT00906191|Drug|SAM-531|
79873720|NCT00902759|Other|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
79873721|NCT04035317|Drug|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
79873722|NCT04035317|Drug|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
79275467|NCT00769795|Drug|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
79275468|NCT00769795|Drug|Goserelin|10.8 mg subcutaneous once
79275469|NCT02171273|Behavioral|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
79579041|NCT01900782|Biological|Intervention B|Prefilled syringe.
79579042|NCT01900782|Biological|Placebo|Prefilled syringe to match experimental drug and active comparator.
79579043|NCT01900795|Drug|V117957|V117957 4.5 mg suspension taken orally after surgery.
79579044|NCT01900795|Drug|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
79579045|NCT01900795|Drug|Placebo|Placebo taken orally after surgery.
79579046|NCT01900808|Device|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
79579047|NCT01900808|Device|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
79579048|NCT01900808|Device|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
79579049|NCT01900834|Other|No treatment given|The participants will not receive any treatment
80030603|NCT05924360|Other|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
79275470|NCT02171273|Behavioral|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
79275471|NCT02171273|Behavioral|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
79275472|NCT02167607|Dietary Supplement|Active Comparator|Purple Potato
79873723|NCT00902837|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
79738325|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
79873724|NCT00902837|Drug|oxycodone prolonged release tablet|
79873725|NCT00902837|Drug|oxycodone naloxone tablet|
79275473|NCT02167607|Dietary Supplement|Placebo Comparator|Placebo Comparator
79403580|NCT02412540|Behavioral|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
79403581|NCT04145245|Drug|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
79403582|NCT04145323|Diagnostic Test|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
79403583|NCT01483118|Drug|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
79873726|NCT00899015|Other|pharmacological study|
79873727|NCT00605813|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
79873728|NCT00899093|Other|Cytology Specimen Collection Procedure|Correlative studies
79275474|NCT02163785|Procedure|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
79275475|NCT00767299|Drug|arzoxifene|20 mg, QD, PO,24 weeks
79403584|NCT01483118|Dietary Supplement|Placebo|Placebo capsules containing ground cereal.
79403585|NCT05106972|Drug|UC-MSC infusion|UC-MSC infusion by introvenus
79873729|NCT00899093|Other|Laboratory Biomarker Analysis|Correlative studies
79873730|NCT00906269|Drug|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
79275476|NCT00767299|Drug|Placebo|QD, PO, 24 weeks
79275477|NCT03134677|Drug|Bupivacaine|2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
79403586|NCT04146337|Biological|FMT|Fecal microbiota in frozen capsules
79403587|NCT05111652|Other|observational|observational electromiographic musculature activation
79403588|NCT04094948|Drug|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
79403589|NCT04094948|Drug|Placebos|dextrose-filled capsules
79738326|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
79738327|NCT02704546|Drug|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
79738328|NCT02704546|Drug|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
79738329|NCT01032018|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
79275478|NCT03134677|Drug|Sevoflurane|General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
79304648|NCT03536429|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79304649|NCT03536429|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79403590|NCT04023565|Drug|perindopril + moxonidine|"After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses)."
79275479|NCT02759939|Other|Video + Prompt Card|"A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
79579050|NCT01900860|Dietary Supplement|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
79738330|NCT01032018|Drug|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
79275480|NCT02759939|Other|Decision Aids + Training|"Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
79275481|NCT03577483|Procedure|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
79579051|NCT01900873|Device|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
79579052|NCT01900873|Device|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
79738331|NCT01032018|Other|Standard care|Participants will receive standard of care from the current physicians
79738332|NCT05332912|Behavioral|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
79275482|NCT02163863|Device|Femoropopliteal stenting|
79579053|NCT01900886|Other|Peginterferon alfa-2a|Treatment as usual clinical practice
79579054|NCT01900886|Drug|Ribavirin|Treatment as usual clinical practice
79579055|NCT01900912|Other|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
79579056|NCT01900925|Procedure|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
79738333|NCT04264221|Behavioral|New management mode|"New management mode intervention: Pharmaceutical care~SMS text messages and Phone Calls~Behavioural Educational leaflet~Self-Administered Therapy A financial incentive for mobile use"
79873731|NCT00906269|Drug|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
79873732|NCT02538653|Other|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
79873733|NCT02538653|Other|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
79873734|NCT00902915|Drug|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
79873735|NCT02538575|Other|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
79873736|NCT02540057|Procedure|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
79275483|NCT02163941|Behavioral|Compassion Training|
79275484|NCT00762541|Device|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
79275485|NCT03540329|Device|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
79275486|NCT03540329|Device|External Osteogenesis distractor|External distraction osteogenesis in mandible
80030604|NCT05924360|Other|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
79579057|NCT01900925|Procedure|Pragmatic low back pain treatment|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
79275487|NCT00722917|Drug|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
79275488|NCT00722917|Drug|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
79275489|NCT00722917|Drug|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
79275490|NCT00722917|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
79275491|NCT00722917|Drug|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
79579058|NCT01900938|Procedure|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
79275492|NCT02164097|Drug|ODSH|
79738334|NCT00609687|Procedure|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
79738335|NCT00614848|Device|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
79738336|NCT01031706|Drug|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
79738337|NCT01031706|Drug|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
79738338|NCT04260165|Procedure|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
79738339|NCT04260165|Procedure|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
79738340|NCT00627510|Other|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
79873737|NCT02540057|Procedure|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
79873738|NCT00902993|Drug|AZD1446|Solution, oral single and multiple dose
79873739|NCT00902993|Drug|Placebo|Placebo
79873740|NCT00922493|Other|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
79873741|NCT00899171|Genetic|DNA analysis|
79275493|NCT00717457|Drug|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
79873742|NCT00899171|Genetic|DNA methylation analysis|
79873743|NCT00899171|Genetic|RNA analysis|
79873744|NCT00899171|Genetic|gene expression analysis|
80030605|NCT05924360|Other|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
79275494|NCT00717457|Drug|taspoglutide|10mg once weekly
79275495|NCT00717457|Drug|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
79275496|NCT02171507|Drug|Dabigatran etexilate|
79873745|NCT00899171|Genetic|reverse transcriptase-polymerase chain reaction|
79873746|NCT00899171|Other|laboratory biomarker analysis|
79275497|NCT02171507|Drug|Diclofenac|
79275498|NCT03539159|Other|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
79304650|NCT02438683|Drug|BI 409306|medium dose, single dose, oral administration
79579059|NCT01900938|Procedure|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
79579060|NCT01900938|Drug|Midazolam|
79873747|NCT00604721|Drug|selumetinib|Given orally
79873748|NCT00604721|Other|pharmacological study|
79873749|NCT04034771|Drug|Melatonin 10 MG Oral Tablet|Melatonin tablets
79873750|NCT04034771|Drug|Propofol|propofol amp
79873751|NCT04034771|Drug|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
79873752|NCT00906581|Behavioral|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
80030606|NCT05924360|Device|TENS|TENS application will be administered for 20 minutes at 100Hz
80030607|NCT05920226|Device|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
80030608|NCT05920226|Diagnostic Test|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
79275499|NCT03539159|Other|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
79275500|NCT05142683|Other|Treatment As Usual|Various typical interventions for adolescents with depression.
79579061|NCT01900938|Drug|Propofol|
79579062|NCT01900951|Drug|Temozolomide|
79579063|NCT01900964|Procedure|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
79579064|NCT01900964|Procedure|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
79579065|NCT01900990|Device|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
79579066|NCT01901003|Drug|Lorazepam|
79579067|NCT01901003|Other|no premedication|
79579068|NCT01901003|Drug|Placebo (microcrystalline celluloses)|
79738341|NCT05484934|Procedure|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
79738342|NCT05118243|Other|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
79873753|NCT00899327|Genetic|DNA methylation analysis|
80030609|NCT05918406|Combination Product|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
80030610|NCT05903820|Drug|Estradiol patch|Transdermal patch of estradiol
80030611|NCT05903820|Drug|Progesterone|Oral progesterone capsules 100mg/day
79873754|NCT00899327|Genetic|RNA analysis|
79275501|NCT05142683|Other|CARIBOU-2|Integrated Care Pathway intervention for adolescents with depression.
79873755|NCT00899327|Genetic|cytogenetic analysis|
79873756|NCT00899327|Genetic|gene expression analysis|
79873757|NCT00899327|Genetic|mutation analysis|
79873758|NCT00899327|Genetic|polymerase chain reaction|
79275502|NCT00758953|Drug|Danazol Once Weekly|semi-solid
79275503|NCT00758953|Drug|Danazol Twice Weekly|semi-solid
79275504|NCT00758953|Drug|Placebo Once Weekly|semi-solid
79275505|NCT00758953|Drug|Placebo Twice Weekly|semi-solid
79579069|NCT01901016|Behavioral|Jacobson progressive muscular relaxation|PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
79579070|NCT01901016|Behavioral|Schultz's autogenic training|AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas [28]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
79579071|NCT01901042|Dietary Supplement|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
79579072|NCT01901042|Dietary Supplement|Maltodextrin|Control patients will receive sachets containing maltodextrin
79579073|NCT01901068|Device|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
79738343|NCT05118243|Other|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
79738344|NCT02873910|Dietary Supplement|IQP-AS-119|
79738345|NCT02873910|Dietary Supplement|Placebo|
79738346|NCT00927069|Drug|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
79738347|NCT00927069|Drug|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
79738348|NCT01031628|Drug|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
79738349|NCT01031628|Drug|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
79873759|NCT00899327|Genetic|protein expression analysis|
79873760|NCT00899327|Other|laboratory biomarker analysis|
79873761|NCT00899483|Drug|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
79873762|NCT02539121|Device|Acupuncture|Acupuncture needles
79873763|NCT02539199|Drug|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
79873764|NCT02539199|Drug|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
79873765|NCT00903227|Drug|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
79873766|NCT00903227|Drug|Placebo|1 puff of inhaled Placebo twice a day
79873767|NCT00903227|Drug|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
80030612|NCT05901675|Other|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
80030613|NCT05901675|Other|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
80030614|NCT05888402|Drug|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
80030615|NCT05888402|Radiation|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
80030616|NCT05888207|Drug|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
80030617|NCT05888207|Drug|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
80030618|NCT05887843|Drug|Mometasone + Azelastine|Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
80030619|NCT05887843|Drug|Mometasone Furoate|Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
79275506|NCT02167685|Drug|CMX001|
79579074|NCT01901081|Device|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
79579075|NCT01901107|Drug|Kiklin capsules|oral
80030620|NCT05887843|Drug|Azelastine Hydrochloride|Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
80030621|NCT05883163|Device|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
79275507|NCT00758563|Drug|Fluoride|Brush twice daily
79275508|NCT00758563|Drug|Triclosan/Fluoride|Brush twice daily
79579076|NCT01901120|Drug|Betanis|oral
79579077|NCT01901133|Drug|MDV3100|Oral
79579078|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (tablet)
79873768|NCT00903227|Drug|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
79873769|NCT00903227|Drug|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
79873770|NCT00605657|Drug|Valproic Acid|Oral administration of valproic acid
79873771|NCT00605657|Procedure|CT Scan|CT scans were done before and after treating the patient with valproic acid
79873772|NCT00605657|Procedure|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
79873773|NCT04034849|Radiation|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
79873774|NCT04034849|Radiation|Placebo|Device turned off
79275509|NCT02171585|Drug|Dabigatran etexilate|
79579079|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (capsule)
79738350|NCT01031628|Drug|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
79275510|NCT02171585|Drug|Clarithromycin|
79275511|NCT03540251|Other|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
79275512|NCT03134443|Drug|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
79738351|NCT02704468|Other|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
79738352|NCT00609843|Other|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
79873775|NCT00903305|Other|medical chart review|
79873776|NCT00903305|Other|questionnaire administration|
79304651|NCT02438683|Drug|BI 409306|low dose, single dose, oral administration
79579080|NCT01901172|Drug|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
79738353|NCT02691988|Other|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
80030622|NCT05880784|Other|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
80030623|NCT05880784|Other|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
80030624|NCT05878405|Other|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
80030625|NCT05878405|Other|Methylene Blue Oral Rinse|Given PO
80030626|NCT05871385|Device|rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
79275513|NCT03134443|Drug|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
79579081|NCT01901172|Drug|RO5503781|Daily for 5 days followed by 23 days rest per cycle
79579082|NCT01901172|Drug|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
79873777|NCT00903305|Procedure|fatigue assessment and management|
79873778|NCT00903305|Procedure|psychosocial assessment and care|
79873779|NCT00903305|Procedure|quality-of-life assessment|
79873780|NCT00899795|Genetic|cytogenetic analysis|
79873781|NCT00899795|Genetic|fluorescence in situ hybridization|
80030627|NCT05871385|Device|placebo rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
80030628|NCT05866367|Drug|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
79275514|NCT02171663|Drug|BIBW 2992|
79304652|NCT02438683|Drug|Placebo|single dose, oral administration
79304653|NCT02444455|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10^5/kg) once a day,a total of three times.
79403591|NCT05106504|Drug|Medical Cannabis|Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
79403592|NCT04149847|Procedure|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
79738354|NCT02691988|Other|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
79738355|NCT01031004|Device|narafilcon B|contact lens
79738356|NCT01031004|Device|etafilcon A|contact lens
79738357|NCT01904656|Behavioral|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
79738358|NCT01904656|Behavioral|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
79738359|NCT00608673|Drug|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
79738360|NCT00608673|Drug|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
79873782|NCT00899795|Other|flow cytometry|
79873783|NCT00899795|Procedure|biopsy|
79873784|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
80030629|NCT05866367|Drug|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
80030630|NCT05859347|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
80030631|NCT05859191|Biological|Blood sample|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
79304654|NCT03281135|Other|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
79304655|NCT03193645|Drug|Degarelix|Injection
79403593|NCT05111496|Radiation|Gafchromic film|Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
79403594|NCT04144855|Drug|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
79403595|NCT01506908|Drug|oral nicotine|oral nicotine replacement product
79403596|NCT01506908|Drug|Placebo|no active
79403597|NCT04144777|Dietary Supplement|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
79579083|NCT01901172|Drug|RO5503781|Single doses Days 1 and 11
79579084|NCT01901172|Drug|posaconazole|Multiple doses Days 8-14
79579085|NCT01901198|Biological|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
79579086|NCT01901198|Biological|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
79275515|NCT05010967|Other|High intensity interval training|"HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches."
79275516|NCT05010967|Other|Yoga Training|Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
79275517|NCT02164175|Device|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
79275518|NCT04438603|Drug|Intervention for incipient patients at low risk of disease progression|Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of < 130/80 mm Hg
79275519|NCT04438603|Drug|Intervention for patients at high risk of disease progression|"BP-lowering goal of < 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~If GFR>60 ml/min/1.73m^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~If GFR is 30-60 ml/min/1.73m^2, intravenous cyclophosphamide (CTX) 750 mg per month per m^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks."
79275520|NCT02167841|Behavioral|Knee-Chest Position|
79275521|NCT02171741|Drug|BIBW 2992|continuous daily dosing for 20 or 13 days
79275522|NCT02171741|Drug|Docetaxel|single infusion on day 1
79579087|NCT01901237|Behavioral|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
79275523|NCT04438291|Other|MDL-SHPVP|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
79275524|NCT04438291|Other|30-minute educational video|A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
79403598|NCT04164654|Behavioral|Loneliness Intervention|28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
79403599|NCT04149769|Device|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
79403600|NCT01519778|Drug|TR701 FA|1 tablet 200 mg once daily
79403601|NCT05106660|Procedure|Ambulatory Laparoscopic Sleeve Gastrectomy|Same-day discharge
79579088|NCT01901263|Behavioral|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
79579089|NCT01901276|Drug|Omeprazole 40 mg bid|As above.
79738361|NCT01622062|Biological|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
79738362|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
79738363|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
79738364|NCT02873676|Behavioral|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
79275525|NCT02167919|Device|Microspheres|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
79275526|NCT00835705|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
79275527|NCT00835705|Drug|Augmentin®|400 mg-57 mg chewable tablet
79275528|NCT02171897|Procedure|Osteosynthesis|
79275529|NCT02171897|Procedure|Total hip replacement|
79275530|NCT02759471|Device|comfilcon A sphere lens (control)|contact lens
79275531|NCT02759471|Device|comfilcon A asphere lens (test)|contact lens
79403602|NCT05106660|Procedure|Conventional Laparoscopic Sleeve Gastrectomy|Next-day discharge
79738365|NCT02873676|Behavioral|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
79738366|NCT02873676|Behavioral|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
79579090|NCT01901315|Procedure|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
79275532|NCT00713401|Drug|Tecadenoson|Tecadenoson administered intravenously (i.v.)
79275533|NCT00713401|Drug|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
79579091|NCT01901315|Procedure|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
79403603|NCT04023097|Device|Toothwave toothbrush|Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
79403604|NCT05111340|Behavioral|Perioperative score|Creation and validation of a perioperative walk score. The patient has to answer different items.
79738367|NCT02873676|Behavioral|control|The intervention involve dietary pattern modification and protein intake standardization
79738368|NCT04263519|Drug|Tacrolimus|Oral Immunosuppressant
79738369|NCT04215718|Procedure|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\0 sutures
79738370|NCT04215718|Procedure|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
79738371|NCT00609921|Drug|ARQ197|treatment
79738372|NCT02704078|Device|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
79738373|NCT02704078|Device|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
79738374|NCT00637650|Procedure|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
79873785|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
79738375|NCT00637650|Procedure|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
80030632|NCT05852613|Device|high power laser therapy (HPLT)|high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
80030633|NCT05852613|Combination Product|selected physical therapy program|hot pack, US for 5 min, exercise for 20 min.
79403605|NCT04149067|Drug|Dapagliflozin|Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
79403606|NCT04149067|Drug|Sitagliptin|Evaluation of the effectiveness and safety of the Sitagliptin treatment.
79579092|NCT01901354|Other|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
79579093|NCT01901354|Other|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
79738376|NCT00637767|Drug|melphalan|
79738377|NCT00637767|Procedure|autologous hematopoietic stem cell transplantation|
79738378|NCT00637767|Radiation|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
79738379|NCT03570190|Other|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~Determination of the status quo~Dedicated reflection and training followed by implementation of tailored changes~Determination of the effect"
79738380|NCT01280500|Behavioral|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
79304656|NCT03280979|Drug|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
79304657|NCT03280979|Drug|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
79403607|NCT05066022|Biological|CT0590 CAR T Cells|Dose-escalated CAR T cells infusion
79738381|NCT01280500|Other|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
79738382|NCT01280500|Other|usual care|No EMR
79403608|NCT04148755|Procedure|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
79403609|NCT05111106|Device|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
79738383|NCT01280500|Other|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
80030634|NCT05852314|Behavioral|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
79275534|NCT02171975|Procedure|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
79275535|NCT02171975|Procedure|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
79738384|NCT01280500|Other|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
79579094|NCT01901367|Dietary Supplement|nutritional intervention|Receive nutritional intervention
79275536|NCT00835549|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
79579095|NCT01901367|Behavioral|exercise intervention|Receive exercise intervention
79275537|NCT00835549|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
79275538|NCT02164253|Drug|Deferiprone|30 mg/kg per day, oral use
79275539|NCT02172053|Other|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
79579096|NCT01901367|Other|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
79579097|NCT01901367|Behavioral|counseling intervention|Receive phone counseling with a trained health coach
79738385|NCT05100849|Procedure|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
79738386|NCT05100849|Procedure|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
79738387|NCT01221688|Procedure|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
79738388|NCT01221688|Procedure|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
79873786|NCT00903461|Biological|EGFR Antisense DNA|"Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
79579098|NCT01901367|Other|quality-of-life assessment|Ancillary studies
79579099|NCT01901367|Other|laboratory biomarker analysis|Correlative studies
79579100|NCT01901367|Other|questionnaire administration|Ancillary studies
79579101|NCT01901380|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|
79579102|NCT01901432|Drug|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
79579103|NCT01901445|Behavioral|Educational action with focal group|
79579104|NCT01901458|Device|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
79738389|NCT00609999|Drug|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
79579105|NCT01901458|Device|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
79738390|NCT00951652|Behavioral|CBT|
79738391|NCT00951652|Other|Interpersonal and emotional processing therapy|
79738392|NCT00951652|Behavioral|supportive listening|
79738393|NCT00608751|Radiation|IMRT|
79738394|NCT00931515|Device|NuBac|NuBac device implanted at the L4/5 level.
79738395|NCT00931515|Device|Prodisc-L|Prodisc-L implanted at the L4/5 level.
79738396|NCT02703766|Behavioral|overfeeding induced weight gain|
79738397|NCT00823108|Drug|GIK|12 hour infusion of GIK solution
79738398|NCT04259619|Device|Low-Level Laser Therapy|The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
79738399|NCT04259619|Device|Placebo Therapy|The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
79873787|NCT00604565|Drug|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
79275540|NCT02172053|Other|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
79738400|NCT00627250|Drug|Amantadine|Amantadine 100 mg every morning and 12 noon
79738401|NCT05330949|Diagnostic Test|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
79873788|NCT00604565|Other|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
79873789|NCT00903539|Device|SecurAcath Securement System|Subcutaneous catheter securement system
79873790|NCT00899873|Genetic|cytogenetic analysis|
79275541|NCT00755287|Drug|insulin glargine|starting dose 10 IU daily
79275542|NCT00755287|Drug|metformin|As prescribed
79275543|NCT00755287|Drug|taspoglutide|10 mg once weekly
79738402|NCT04301232|Other|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg > preanesthetic level, 20 - 50 mm Hg > preanesthetic level, 50 mm Hg > preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 > 92% on room air, Supplemental O2 required to maintain SpO2 > 90%,SpO2 < 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
79738403|NCT04301232|Other|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)<15%, Blood pressure 15-30%, Blood pressure>30%, Level of consciousness,(Awake&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value>90% on room air, Requires supplemental oxygen, Saturation<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score<1 in any individual category)would be required for a patient after general anesthesia
79403610|NCT04022941|Drug|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
79403611|NCT04022941|Other|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
79738404|NCT04301232|Other|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and < 180, HR > 50 and < 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and < 180, HR > 50 and < 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in room air Y/N, Pain Control (VAS < 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
79873791|NCT00899873|Other|flow cytometry|
79873792|NCT00899873|Other|fluorescence activated cell sorting|
79873793|NCT00899873|Other|immunoenzyme technique|
79873794|NCT00899873|Other|laboratory biomarker analysis|
80030635|NCT05847647|Other|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
80030636|NCT05847647|Other|Retrograde Filling+L-PRF Group|2. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
79275544|NCT00755287|Drug|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
79275545|NCT02164331|Behavioral|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
79275546|NCT02168075|Drug|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
79579106|NCT01901471|Drug|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
79403612|NCT05087862|Procedure|Ultrasound-guided pericapsular nerves group of the hip block|After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.
79579107|NCT01901471|Drug|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
79738405|NCT02692144|Other|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
79579108|NCT01901484|Drug|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
79579109|NCT01901497|Device|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
79579110|NCT01901510|Drug|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
79738406|NCT04300374|Other|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
79738407|NCT02703376|Drug|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
79738408|NCT04259697|Other|Clinical pilates|Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.
79873795|NCT00899951|Drug|fentanyl citrate|
79873796|NCT00899951|Other|pharmacological study|
79873797|NCT00900107|Procedure|Exercise|
79873798|NCT00900185|Genetic|mutation analysis|
79873799|NCT00900185|Genetic|polymerase chain reaction|
79873800|NCT00900185|Genetic|polymorphism analysis|
79873801|NCT00900263|Genetic|cytogenetic analysis|
79873802|NCT00900263|Genetic|microarray analysis|
79873803|NCT00900263|Other|biologic sample preservation procedure|
79873804|NCT00900263|Other|laboratory biomarker analysis|
79873805|NCT00900341|Genetic|DNA analysis|
79873806|NCT00900341|Genetic|gene expression analysis|
79873807|NCT00900341|Genetic|protein expression analysis|
79873808|NCT00900341|Genetic|reverse transcriptase-polymerase chain reaction|
79873809|NCT00900341|Genetic|western blotting|
79873810|NCT00900341|Other|immunohistochemistry staining method|
79275547|NCT02168075|Drug|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
79275548|NCT02168075|Drug|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
79275549|NCT02168075|Drug|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
79403613|NCT05087862|Procedure|Pericapsular local anesthetic infiltration of the hip|Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
79403614|NCT04022863|Diagnostic Test|TEP|Tumor Educated Platelets
79873811|NCT00900341|Other|laboratory biomarker analysis|
79873812|NCT02539979|Drug|Paracetamol|
79873813|NCT02539979|Drug|Placebo - Normal Saline|Normal Saline 100cc
79873814|NCT00906737|Device|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
79873815|NCT00906737|Other|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
79275550|NCT02164409|Procedure|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
79579111|NCT01901510|Other|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
79275551|NCT00712699|Drug|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
80030637|NCT05847647|Other|(Orthograde Filling Group / OG Group).|3. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
79275552|NCT00712699|Drug|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
79738409|NCT04259697|Other|Whole body vibration|Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
79275553|NCT03945825|Drug|AF03|A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
79579112|NCT01901523|Behavioral|Reporting of discrepancy to journal|
79275554|NCT03945825|Biological|Delta Inulin-CpG55.2|A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
79275555|NCT03945825|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
79275556|NCT03945825|Biological|Quadrivalent Recombinant Seasonal Influenza Vaccine|2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
79738410|NCT04301388|Procedure|Transvaginal ultrasound|Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
79738411|NCT00615394|Procedure|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
79738412|NCT02873442|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
79275557|NCT00706537|Drug|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
79275558|NCT00706537|Drug|Placebo|Placebo as two tablets once daily for three weeks
79275559|NCT05008159|Behavioral|3 month community-based mobility and health intervention|"12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~socialization to foster peer and community connections, co-learning, and decrease social isolation~skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support"
79275560|NCT04987333|Drug|Efavaleukin alfa|Administered as a single dose SC injection.
79275561|NCT02759315|Drug|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
79275562|NCT02759315|Drug|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
79579113|NCT01901536|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
79579114|NCT01901549|Procedure|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
79579115|NCT01901549|Drug|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
79579116|NCT01901549|Drug|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
79738413|NCT02873442|Biological|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
79738414|NCT04261179|Drug|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
79738415|NCT04261179|Drug|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
79738416|NCT00610077|Drug|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
79403615|NCT04022863|Diagnostic Test|ctDNA|circulating tumor DNA
79579117|NCT01901601|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
79738417|NCT00610077|Drug|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
79738418|NCT00823576|Drug|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
79579118|NCT01901601|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
79873816|NCT00906893|Procedure|18F]-FMISO PET-CT|pretherapy([18F]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe [18F]-FMISO uptake will be used.
79873817|NCT00903773|Drug|telaprevir|
79275563|NCT05461898|Other|Inpatient Rehabilitation|Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.
79275564|NCT05461898|Other|Inspiratory muscle training|Inspiratory muscle training protocol during 6 weeks with a electronic-controlled valve device
79275565|NCT00699517|Drug|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
79275566|NCT00699517|Drug|Placebo|I.V. infusion followed by administration of cisplatin
79403616|NCT05111028|Biological|Autologous Room Temperature stored Platelet transfusion|An autologous transfusion of platelets stored at 22°C for 7 days.
79403617|NCT05111028|Biological|Autologous Cold Stored Platelet transfusion|An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
79579119|NCT01901601|Drug|Retrobulbar Block or General Anesthesia|
79403618|NCT04022707|Other|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
79403619|NCT04022707|Other|Educational control|Lectures on health and fitness
79579120|NCT01901601|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
79403620|NCT05110716|Behavioral|Bundle-size 1|In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
79738419|NCT01028352|Drug|Duloxetine|"Patients will be treated with open-label duloxetine:~30 mg daily x 7 days, then~60 mg daily x 3 weeks, then~If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
79738420|NCT03172780|Drug|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
79738421|NCT03172780|Drug|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
79738422|NCT03172780|Drug|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
79738423|NCT00929643|Other|no intervention|success of the initial empiric treatment
79403621|NCT05110716|Behavioral|Bundle-size 3|In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
79738424|NCT05011617|Device|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
80030638|NCT05847647|Other|(Orthograde Filling+L-PRF Group|4. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
80030639|NCT05838482|Device|CT Photon-Counting|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
79275567|NCT03540719|Procedure|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
79275568|NCT05633433|Drug|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
79275569|NCT05633433|Drug|Placebo|Placebo
79275570|NCT00697099|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
79275571|NCT00697099|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
79738425|NCT02703298|Drug|TRX-818 capsules|
79579121|NCT01901601|Drug|Topical Anesthesia|
79579122|NCT01901601|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
79579123|NCT01901640|Drug|DA-8159 (Udenafil)|
79579124|NCT01901666|Drug|Growth Hormone|"All GH deficient patients with bone age <14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
79275572|NCT00697099|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection"
79873818|NCT05277701|Drug|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
79873819|NCT00900653|Drug|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
80030640|NCT05836272|Drug|Norepinephrine Bitartrate|"The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion."
79275573|NCT02172131|Drug|BI 1744 CL|
79275574|NCT02172131|Drug|Placebo|
79579125|NCT01901692|Radiation|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
79579126|NCT01901692|Drug|Sorafenib|Sorafenib 800 mg/day orally
79579127|NCT01901705|Drug|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
79738426|NCT04259385|Behavioral|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
79738427|NCT04259385|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
79738428|NCT04261101|Other|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
79738429|NCT03101488|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
79738430|NCT00926367|Drug|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
79738431|NCT00926367|Drug|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
79738432|NCT02703142|Procedure|Patients after esophagectomy|postoperative endoscopic evaluation
79738433|NCT04261023|Drug|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
79873820|NCT00605345|Drug|Darbepoetin alfa|As prescribed
79873821|NCT00605345|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
79579128|NCT01901705|Drug|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake [Blue #32] and 45.2% Allura Red AC aluminum lake [Red #40] powders), Vaseline, microcrystalline wax, and olive oil.
79873822|NCT00903851|Drug|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
79873823|NCT00900887|Drug|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
79275575|NCT05631951|Procedure|bone transport through induced membrane|Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport
79275576|NCT05631951|Procedure|bone transport|Debridement done then external fixator was applied then bone transport started.
79579129|NCT01901731|Procedure|transjugular coil embolisation of pelvic veins|
79579130|NCT01901731|Procedure|endovenous treatment of leg varicose veins|
79275577|NCT02168231|Procedure|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
79275578|NCT05435768|Drug|Denosumab|Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days
79579131|NCT01901744|Procedure|Cataract Surgery|
79579132|NCT01901757|Drug|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
79579133|NCT01901757|Drug|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
80030641|NCT05836272|Other|Placebo|For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
79275579|NCT00835081|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
79738434|NCT05086341|Device|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
79275580|NCT00835081|Drug|DURICEF® capsules 500 mg|1 x 500 mg
79275581|NCT02543918|Drug|Ixekizumab|Administered by SQ injection
79275582|NCT02543918|Drug|Boostrix®|Administered by IM injection
79275583|NCT02543918|Drug|Pneumovax®23|Administered by IM injection
79275584|NCT03539003|Drug|sevoflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
79275585|NCT03539003|Drug|desflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of desflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
79275586|NCT03539003|Drug|propofol and remifentanil|anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
79275587|NCT02164565|Drug|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
79275588|NCT02164565|Drug|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
79275589|NCT04265534|Drug|Telaglenastat|Oral Glutaminase Inhibitor
79403622|NCT05110716|Behavioral|Bundle-size 9|In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
79403623|NCT05106114|Other|Intensive gait training rehabilitation protocole|6 weeks of intensive gait training : 4 weeks at the center and 2 weeks of home-based telerehabilitation
79403624|NCT01519700|Drug|EP2006|Eligible patients will be teated with EP2006
79579134|NCT01901783|Procedure|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
79579135|NCT01901783|Procedure|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
79738435|NCT01114529|Drug|Everolimus|Early CNI to everolimus conversion
79738436|NCT01114529|Drug|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
79738437|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
79738438|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
80030642|NCT05835024|Device|Acorai Sensor Data Collection (ASDC) system 1.0|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation."
80030643|NCT05821387|Drug|Lucid-21-302|A small molecule inhibitor of hypercitrullination
80030644|NCT05821387|Drug|Placebo|Product containing excipients with no active ingredients
79275590|NCT04265534|Drug|Carboplatin Chemotherapy|IV infusion
79275591|NCT04265534|Drug|Pemetrexed Chemotherapy|IV infusion
79275592|NCT04265534|Biological|Pembrolizumab Immunotherapy|IV infusion
79275593|NCT04265534|Drug|Placebo|Oral placebo
79403625|NCT01519700|Drug|Filgrastim|Eligible patients will be teated with Filgrastim
79403626|NCT04144075|Behavioral|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
79579136|NCT01901796|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
80030645|NCT05814198|Diagnostic Test|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
79275594|NCT04265534|Dietary Supplement|Folic acid 400 -1000 μg|Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
79403627|NCT04144075|Behavioral|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
79403628|NCT04144075|Other|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
79579137|NCT01901822|Procedure|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
79579138|NCT01901822|Procedure|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
79738439|NCT00926289|Drug|Hydrochlorothiazide|Hydrochlorothiazide25mg
79579139|NCT01901835|Procedure|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
80030646|NCT05795504|Other|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
79275595|NCT04265534|Dietary Supplement|Vitamin B12 1000 μg|Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
79275596|NCT04265534|Drug|Dexamethasone 4 mg|For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
79275597|NCT00750685|Device|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
79403629|NCT04143997|Diagnostic Test|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
79579140|NCT01901835|Other|survey administration|Ancillary studies
79579141|NCT01901835|Procedure|quality-of-life assessment|Ancillary studies
79738440|NCT02707276|Device|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
79579142|NCT01901887|Drug|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
79579143|NCT01901887|Drug|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
79275598|NCT02168465|Behavioral|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
79275599|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79275600|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79579144|NCT01901913|Device|MD-bolus calculator for pre-meal bolus|
79579145|NCT01901913|Device|No MD-bolus calculator for pre-meal bolus|
79579146|NCT01901926|Procedure|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
79275601|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79275602|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79275603|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79403630|NCT05110560|Behavioral|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
79403631|NCT04143685|Drug|Misoprostol|Oral administration of cytotec every 4 hours until a maximum of 6 doses
79579147|NCT01901939|Other|exercise|daily tailored low level pedaling exercise at bedside
79579148|NCT01901952|Behavioral|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
79579149|NCT01901952|Behavioral|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
79873824|NCT00900887|Drug|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
80030647|NCT05795504|Other|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
79579150|NCT01901978|Behavioral|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
79275604|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79579151|NCT01901991|Procedure|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
79579152|NCT01901991|Procedure|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
79579153|NCT01902017|Drug|Ketotifen|5 mg PO bid
79579154|NCT01902017|Drug|Placebo|5 mg placebo PO bid
79579155|NCT01902056|Procedure|One layer allograft|The acellular dermal matrix was placed on the facial surface.
79738441|NCT02707276|Device|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
79738442|NCT02699398|Behavioral|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
79579156|NCT01902056|Procedure|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
80030648|NCT05795504|Dietary Supplement|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
79275605|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
79275606|NCT02172209|Drug|BI 10773|
79275607|NCT02168543|Drug|Alendronate|
79403632|NCT04143685|Drug|Oxytocin|Intravenous infusion of Pitocin through an IVAC until delivery
79403633|NCT05082090|Procedure|Spinal Surgery|Implanted with Orthofix Spinal products
79403634|NCT04148599|Drug|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
79403635|NCT04148599|Drug|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
79579157|NCT01902069|Dietary Supplement|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
79403636|NCT04148599|Drug|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
79403637|NCT04143763|Other|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
79738443|NCT02699398|Behavioral|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
79579158|NCT01902069|Dietary Supplement|Placebo|Placebo consists of rice flour
79579159|NCT01902082|Drug|Mesenchymal stem cells|
79275608|NCT02168543|Drug|Placebo|
79275609|NCT01372995|Drug|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
79275610|NCT01372995|Drug|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
79275611|NCT01372995|Other|Inactive substance|Inactive substance given enterally for 5 days.
79579160|NCT01902082|Drug|Placebo|
79579161|NCT01902095|Device|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
79579162|NCT01902095|Device|Tooth paste (control)|Active Comparator
79738444|NCT04309643|Drug|CTP-543|Investigational Drug
79275612|NCT00748501|Drug|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
79275613|NCT02168621|Procedure|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
79579163|NCT01902108|Drug|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
79579164|NCT01902108|Drug|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
79579165|NCT01902121|Drug|Technosphere® Insulin 10U + 20U|Inhaled Insulin
79579166|NCT01902121|Drug|Technosphere® Insulin 30U|Inhaled Insulin
79579167|NCT01902147|Other|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
79579168|NCT01902160|Drug|Brentuximab Vedotin|Given IV
79403638|NCT04143841|Device|Viveye OMNS treatment|The Viveye OMNS treatment ( ~30 min) will be applied once, during the treatment visit only
79403639|NCT04143841|Device|Viveye OMNS sham treatment|The Viveye OMNS sham treatment ( ~30 min) will be applied once, during the treatment visit only
79579169|NCT01902160|Other|Laboratory Biomarker Analysis|Correlative studies
79579170|NCT01902160|Drug|Temsirolimus|Given IV
79579171|NCT01902186|Drug|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
79579172|NCT01902186|Drug|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
79579173|NCT01901861|Drug|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
79579174|NCT01901861|Drug|Placebo|Placebo is given before meal ingestion
79738445|NCT04309643|Drug|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
79738446|NCT02881073|Other|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
79738447|NCT03208036|Device|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
79275614|NCT02168621|Procedure|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
79275615|NCT04239859|Biological|secukinumab|Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
79275616|NCT04239859|Drug|Methotrexate|Oral tablet up to 15mg per week
79275617|NCT04239859|Drug|Cyclosporin A|Oral capsule up to 200mg per day
79275618|NCT04239859|Drug|Acitretin|Oral capsule up to 25mg per day
79738448|NCT03208036|Device|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
79738449|NCT03208036|Behavioral|Cognitive Remediation|Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
79738450|NCT03208036|Behavioral|Bridging Group|Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
79738451|NCT04259307|Drug|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
79738452|NCT00926211|Device|ARTAS™ System|Hair harvest using a computer-assisted system
79738453|NCT00926211|Procedure|Manual Hair Harvest|Hair harvesting via the manual technique
79873825|NCT00900887|Drug|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
79275619|NCT03875157|Biological|IBI318|0.3 mg intravenous infusion, C1D1 and afterwards Q2W
79403640|NCT04930458|Other|Nanosilver fluoride|Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months
79403641|NCT04930458|Other|Sodium fluoride with casein phosphopeptides amorphous calcium phosphate|Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months
79403642|NCT04930458|Other|Sodium fluoride varnish|Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
79403643|NCT03021811|Device|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
79403644|NCT03021733|Procedure|Operative management|Rotator cuff surgery
79403645|NCT04917588|Combination Product|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
79579175|NCT01902199|Behavioral|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
79579176|NCT01902212|Other|Oral Nutritional Supplement|
79579177|NCT01902225|Drug|Istodax|
79579178|NCT01902225|Drug|Doxil|
79579179|NCT01902238|Procedure|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
79579180|NCT01902251|Drug|Enzalutamide tablet|Oral
79275620|NCT03875157|Biological|IBI318|1 mg intravenous infusion, C1D1 and afterwards Q2W
79275621|NCT03875157|Biological|IBI318|3 mg intravenous infusion, C1D1 and afterwards Q2W
79579181|NCT01902251|Drug|Enzalutamide capsule|Oral
79275622|NCT03875157|Biological|IBI318|10 mg intravenous infusion, C1D1 and afterwards Q2W
79275623|NCT03875157|Biological|IBI318|30 mg intravenous infusion, C1D1 and afterwards Q2W
79275624|NCT03875157|Biological|IBI318|100 mg intravenous infusion, C1D1 and afterwards Q2W
79275625|NCT03875157|Biological|IBI318|300 mg intravenous infusion, C1D1 and afterwards Q2W
79275626|NCT03875157|Biological|IBI318|600 mg intravenous infusion, C1D1 and afterwards Q2W
79275627|NCT03875157|Biological|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
79275628|NCT03875157|Biological|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
79275629|NCT03875157|Biological|IBI318|Intravenous infusion Q3W
79275630|NCT02255903|Other|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
79275631|NCT04923919|Drug|Anti-CLL1 CART cells|In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
79275632|NCT03114189|Procedure|footbath|
79275633|NCT03114189|Behavioral|care of sleep|
79275634|NCT02168699|Other|Ultrasound examination of the axilla|
79579182|NCT01902264|Drug|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
79579183|NCT01902329|Drug|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
79738454|NCT04310813|Diagnostic Test|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
79873826|NCT02539277|Drug|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
79579184|NCT01902329|Drug|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
79275635|NCT02757521|Drug|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
79275636|NCT02757521|Drug|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
79579185|NCT01902342|Drug|Oseltamivir 75 mg 1 cap|
79738455|NCT03188146|Drug|Ursodeoxycholic Acid|Standard care of PBC patients
79738456|NCT00610233|Procedure|deep brain stimulation ON|deep brain stimulation in the ON state
79579186|NCT01902355|Procedure|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
79579187|NCT01902355|Procedure|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
79579188|NCT01902368|Other|gluten free diet|
79579189|NCT01902394|Other|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
79579190|NCT01902394|Other|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
79738457|NCT00610233|Procedure|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
79738458|NCT02880839|Device|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
79873827|NCT02539277|Drug|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
79873828|NCT02539277|Drug|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
79275637|NCT00744367|Drug|metformin|>1500 mg/day or maximum tolerated dose (MTD)
79275638|NCT00744367|Drug|pioglitazone|>= 30 mg/day
79275639|NCT00744367|Drug|placebo|sc once weekly
79275640|NCT00744367|Drug|taspoglutide|10 mg sc once weekly;
79738459|NCT02880839|Device|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
79738460|NCT02880839|Device|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
79738461|NCT02699320|Other|Complications|Not involved
79738462|NCT04259073|Drug|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
79738463|NCT04259073|Drug|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
79738464|NCT04259073|Drug|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
79738465|NCT04303793|Device|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
79738466|NCT00609063|Drug|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
79738467|NCT00609063|Drug|Placebo|Placebo capsules taken daily for 6 months
79738468|NCT02703064|Dietary Supplement|Furocyst|Furocyst caps BD
79873829|NCT02539277|Drug|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
79873830|NCT00904085|Drug|Oxymorphone IR|5 mg
79873831|NCT00908453|Drug|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
79275641|NCT00744367|Drug|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
79275642|NCT02172287|Drug|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
79275643|NCT02172287|Drug|Salmeterol|Inhalation aerosol twice daily
79275644|NCT02172287|Drug|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
79275645|NCT02172287|Drug|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
79275646|NCT02255669|Device|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
79275647|NCT02255669|Device|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
79579191|NCT01902433|Procedure|Astym|
79873832|NCT02538497|Behavioral|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
79579192|NCT01902446|Drug|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
79579193|NCT01902485|Other|Timing of Contraceptive Initiation in Medical Abortion|
79579194|NCT01902498|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
79738469|NCT01114373|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
79738470|NCT01114373|Drug|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
79738471|NCT02699476|Behavioral|Psycho-Social Therapy|
79738472|NCT02699476|Device|Cognitive Behavioral Computer Training|
79275648|NCT00695305|Drug|rilapladib|250 mg oral dose once daily
79579195|NCT01902498|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
79579196|NCT01902498|Drug|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
79579197|NCT01902511|Drug|G-CSF+Erythropoetin|
79579198|NCT01902511|Drug|G-CSF|
79738473|NCT02699476|Behavioral|Interactive Trainer-Subject Sessions|
79738474|NCT02699476|Device|Active Control Games|
79738475|NCT00925899|Drug|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
79738476|NCT00925899|Drug|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
79738477|NCT02601586|Drug|PR Oxycodone|PR Oxycodone
79873833|NCT02538497|Behavioral|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
79579199|NCT01902524|Drug|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
79579200|NCT01902537|Drug|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
79579201|NCT01902550|Drug|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
79579202|NCT01902550|Drug|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
79579203|NCT01902550|Drug|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
79738478|NCT02601586|Drug|Levodopa|Levodopa
79738479|NCT02601586|Drug|Oxycodone Placebo|Placebo of PR Oxycodone
79738480|NCT02601586|Drug|Levodopa placebo|
79738481|NCT00609141|Biological|cixutumumab|Given IV
79738482|NCT00609141|Other|pharmacological study|Correlative studies
79275649|NCT00695305|Drug|placebo|placebo
79275650|NCT00695305|Other|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
79275651|NCT02261129|Drug|Telmisartan film-coated tablet|
79275652|NCT02261129|Drug|Telmisartan uncoated tablet|
79579204|NCT01902563|Other|Osteopathic Manipulative Treatment|
79579205|NCT01902589|Other|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
79738483|NCT00609141|Other|laboratory biomarker analysis|Correlative studies
79738484|NCT00615862|Other|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
79738485|NCT05330715|Other|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
79738486|NCT02702830|Other|Cardiopulmonary Exercise Testing|Undergo CPET
79738487|NCT02702830|Device|Magnetic Resonance Imaging|Undergo MRI
79738488|NCT05208957|Other|No intervention|No intervention
79579206|NCT01902641|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
79403646|NCT04917588|Combination Product|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
79403647|NCT03021577|Device|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
79579207|NCT01902641|Drug|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
79738489|NCT02702908|Other||Historical Reference group.
79738490|NCT00610389|Biological|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
79738491|NCT01114217|Drug|Ferumoxytol|IV Ferumoxytol
79275653|NCT00694135|Drug|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
79275654|NCT00694135|Drug|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
79275655|NCT00694135|Drug|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
79738492|NCT01030536|Drug|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
79275656|NCT00694135|Drug|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
79275657|NCT03540095|Drug|Erector Spinae Plane Block|See arm description
79738493|NCT01030536|Drug|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
79738494|NCT01030536|Drug|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
79738495|NCT01030536|Drug|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
79738496|NCT01030536|Drug|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
79738497|NCT01030458|Drug|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
79275658|NCT03540095|Drug|Paravertebral Nerve Block|See arm description
79275659|NCT03071185|Procedure|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
79275660|NCT02169011|Procedure|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
79738498|NCT01030458|Drug|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
79738499|NCT02692222|Other|Calculation of PPV and CO with two methods|
79738500|NCT02702674|Drug|propranolol|propranolol 20 mg given before induction of labor
79738501|NCT02702674|Drug|placebo|starch tablet containing no active drug material given before induction of labor
79738502|NCT02702674|Drug|Oxytocin|intravenous infusion of oxytocin
79738503|NCT00930969|Device|ICD|Subjects implanted with an ICD.
79738504|NCT02702752|Other|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
79738505|NCT01114139|Drug|Ferumoxytol|IV Ferumoxytol
79738506|NCT01114139|Other|Placebo|IV Placebo
79738507|NCT02699242|Device|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
79738508|NCT01027884|Drug|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
79738509|NCT01027884|Drug|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
79738510|NCT02699164|Device|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
79738511|NCT02699164|Other|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
79738512|NCT02699164|Other|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
79579208|NCT01902641|Drug|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
79579209|NCT01902654|Other|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
79738513|NCT02699008|Drug|Clopidogrel|Antiplatelet agent
79738514|NCT02699008|Drug|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
79275661|NCT02169011|Procedure|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
79579210|NCT01902654|Other|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
79579211|NCT01902654|Other|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
79873834|NCT04034537|Diagnostic Test|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
79579212|NCT01902667|Procedure|Magnetic Resonance Imaging|
79579213|NCT01902680|Radiation|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
79579214|NCT01902719|Behavioral|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
79579215|NCT01902719|Behavioral|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
79579216|NCT01902719|Behavioral|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
79873835|NCT00907127|Behavioral|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
79579217|NCT01902732|Device|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
79579218|NCT01902745|Behavioral|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
79579219|NCT01902771|Biological|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
79579220|NCT01902771|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
79579221|NCT01902771|Other|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
79873836|NCT02538731|Procedure|dilation-assisted stone extraction|
79873837|NCT02538731|Device|Spyglass Guided Laser Lithotrips|
79275662|NCT00741715|Drug|AVE5530|oral administration once daily in the evening with dinner
79275663|NCT00741715|Drug|atorvastatin|oral administration once daily in the evening with dinner
79738515|NCT00627666|Biological|anti-thymocyte globulin|
79275664|NCT00741715|Drug|placebo|oral administration once daily in the evening with dinner
79304658|NCT02714153|Device|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
79738516|NCT00627666|Drug|busulfan|
79873838|NCT00908531|Drug|letrozole (Femara)|tablet 2.5 mg daily
79304659|NCT02438527|Behavioral|Chart for CPR guidance|
79738517|NCT00627666|Drug|fludarabine phosphate|
79873839|NCT02538263|Device|Volume-targeted noninvasive ventilation|
79873840|NCT00904319|Other|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
79738518|NCT00627666|Drug|leucovorin calcium|
79738519|NCT00627666|Drug|methotrexate|
79738520|NCT00627666|Procedure|allogeneic bone marrow transplantation|
79738521|NCT00627666|Procedure|allogeneic hematopoietic stem cell transplantation|
79738522|NCT00627666|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79275665|NCT02169167|Device|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
79738523|NCT03387514|Drug|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~PET2A - Post-surgery and prior to start of standard of care systemic therapy~PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~PET3A - Prior to start of additional anti-angiogenesis therapy~PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
79275666|NCT02169167|Device|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
79579222|NCT01902771|Procedure|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
79275667|NCT02172443|Drug|tiotropium inhalation powder capsules|
79275668|NCT02172443|Drug|Atrovent|
79403648|NCT03021577|Device|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
79403649|NCT03021577|Procedure|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
79403650|NCT04022317|Biological|Biocon Insulin R|Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
79579223|NCT01902784|Behavioral|Storytelling Interview|
79579224|NCT01902797|Other|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
79579225|NCT01902810|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization
79579226|NCT01902810|Drug|Placebo|Placebo by mouth given daily throughout hospitalization
79579227|NCT01902823|Behavioral|Services from a Nurse Navigator|Services from a Nurse Navigator
79738524|NCT01022580|Drug|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
79403651|NCT04022317|Biological|Humulin®R|Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
79403652|NCT05105724|Biological|PRP|PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
79403653|NCT04021849|Other|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
79403654|NCT04021849|Other|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
79738525|NCT01022580|Drug|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
79738526|NCT02698930|Drug|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
79738527|NCT02698930|Drug|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
79738528|NCT02880683|Device|NeuroTronik CANS Therapy System|
79738529|NCT04215094|Diagnostic Test|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
79738530|NCT02698852|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
79738531|NCT01107353|Drug|Imipramine Pamoate|75 mg capsule
79738532|NCT02702206|Drug|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
79738533|NCT02702206|Drug|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
79738534|NCT02702206|Drug|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
79738535|NCT01107197|Dietary Supplement|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
79738536|NCT01107197|Dietary Supplement|Control formula|Isonitrogenous isocaloric oral formula
79738537|NCT04216186|Drug|Atomoxetine|Atomoxetine once daily
79275669|NCT02172443|Drug|placebo to Atrovent|
79275670|NCT02172443|Drug|placebo to tiotropium inhalation capsules|
79275671|NCT00740623|Drug|Carisbamate|800 mg/day for 14 weeks
79738538|NCT04216186|Drug|Coenzyme Q|Coenzyme Q once daily
79275672|NCT00740623|Drug|placebo|placebo for 14 weeks
79579228|NCT01902836|Biological|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
79579229|NCT01902836|Biological|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
79579230|NCT01902849|Other|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~T0- before the induction of anesthesia (venous cannula insertion time)~T1- after induction but before starting surgery~In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~T2, T3- at 2 and 24 hours after surgery"
79579231|NCT01902862|Drug|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
79579232|NCT01902862|Drug|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
79579233|NCT01902875|Drug|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
79579234|NCT01902875|Biological|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
79579235|NCT01902914|Procedure|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
79579236|NCT01902927|Other|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
79579237|NCT01902940|Other|Natural History|Assessment of natural history in IBM and CCFDN
79579238|NCT01902979|Behavioral|Lifestyle intervention|
79275673|NCT00740623|Drug|Carisbamate|1,200 mg/day for 14 weeks
79275674|NCT03540641|Device|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
79579239|NCT01902992|Drug|Depiquick Birch (DPG103)|
79579240|NCT01902992|Drug|Placebo|
79873841|NCT00604175|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
79275675|NCT00834613|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
79275676|NCT00834613|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
79579241|NCT01903018|Drug|P276-00|
79579242|NCT01903018|Radiation|Radiation Therapy|
79275677|NCT02172521|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
79275678|NCT03037411|Device|Peripheral stenting|stent implantation during the index procedure
79275679|NCT02169245|Other|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
79579243|NCT01903018|Drug|Cisplatin|
79579244|NCT01903044|Procedure|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
79579245|NCT01903057|Drug|azithromycin|
79579246|NCT01903057|Drug|ivermectin|
79579247|NCT01903057|Drug|albendazole|
79579248|NCT01903057|Drug|placebo|
79579249|NCT01903070|Drug|Linagliptin|
79579250|NCT01903083|Drug|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
79579251|NCT01903083|Drug|Gemcitabine|Three doses of gemcitabine (1000 mg / m^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
79579252|NCT01903083|Radiation|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
79873842|NCT00605189|Device|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
79873843|NCT00605189|Device|Powered Suction Pump|continuous gauze based negative pressure wound therapy
79873844|NCT00605189|Device|MWT|moist wound therapy
79275680|NCT00834535|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
79275681|NCT00834535|Drug|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
79275682|NCT02169323|Other|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
79275683|NCT02169401|Device|Implantation with the commercially available Axium Neurostimulator|
79275684|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
79275685|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
79275686|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
79275687|NCT00691717|Other|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
79275688|NCT03036319|Device|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
80030649|NCT05780008|Behavioral|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
80030650|NCT05777798|Device|Hyalistil Bio PF|Moisturizing and lubricating ophthalmic solution
79275689|NCT03036319|Device|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
79275690|NCT03036319|Behavioral|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
79275691|NCT03036319|Device|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
79579253|NCT01903083|Procedure|Pancreaticoduodenectomy|Surgical resection.
79579254|NCT01903096|Behavioral|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
79579255|NCT01903096|Drug|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
79579256|NCT01903109|Drug|Cevimeline|
79579257|NCT01903122|Drug|Cevimeline|
79579258|NCT01903135|Procedure|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
79579259|NCT01903135|Procedure|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
79579260|NCT01903161|Procedure|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
79738539|NCT02702440|Other|Liquid calories from sugars|
79579261|NCT01903161|Procedure|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
79873845|NCT00904397|Drug|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
79873846|NCT00904397|Drug|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
80030651|NCT05757128|Behavioral|Optimal Health Program|The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook, all accessed virtually through a web based digital portal. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
80030652|NCT05748184|Device|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
79275692|NCT03036319|Device|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
79275693|NCT03036319|Device|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
79275694|NCT03036319|Device|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
79304660|NCT03192085|Diagnostic Test|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
79579262|NCT01903174|Device|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
79579263|NCT01903200|Drug|FK949E|Oral
79579264|NCT01903213|Drug|bixalomer|Oral
79579265|NCT01903226|Other|High intensity training|
79579266|NCT01903226|Other|Moderate intensity training|
79738540|NCT02881697|Other|Adipose tissue sampling|
79579267|NCT01903239|Procedure|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
79579268|NCT01903278|Drug|PEG-IFN-SA /RBV|
79579269|NCT01903278|Drug|Pegasys /RBV|
79579270|NCT01903291|Drug|dimethyl fumarate|As described in the treatment arm
79579271|NCT01903304|Other|Olive Oil|3 months intervention
79738541|NCT02698540|Other|Nutritional Supplement|High calorie, high protein peptide based
79738542|NCT02698696|Other|ECo program|
79738543|NCT02698696|Other|CRT program|
79738544|NCT02698696|Other|Supportive psychotherapy|
79738545|NCT01989598|Other|Laboratory Biomarker Analysis|Correlative studies
79738546|NCT01989598|Other|Pharmacological Study|Correlative studies
79738547|NCT01989598|Drug|Trametinib|Given PO
79738548|NCT01989598|Drug|Uprosertib|Given PO
79738549|NCT04214938|Other|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
79873847|NCT02538887|Device|Radio Frequency Surgical Detection|
79873848|NCT00907205|Drug|SF1126|Dose Escalating with 3+ patients in each cohort
79403655|NCT05099250|Drug|Bupivacain|local anesthetic agent
79403656|NCT05099250|Drug|magnesium sulfate|In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
79579272|NCT01903317|Other|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
79579273|NCT01903317|Other|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B [UVB] or ultraviolet A and psoralen [PUVA]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
79275695|NCT03539939|Procedure|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
79579274|NCT01903317|Other|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
79738550|NCT02702050|Other|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
79738551|NCT02702050|Other|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
79275696|NCT00688441|Drug|Nasal CO2|Twice daily during the 14 day Treatment Period
79275697|NCT00688441|Drug|Placebo|Use of the study drug dispenser at the same frequency as the active arm
79579275|NCT01903343|Device|shear wave elastography|ultrasound
79738552|NCT00615160|Drug|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
79738553|NCT00615160|Drug|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
79738554|NCT02702362|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
79275698|NCT02172599|Behavioral|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
79738555|NCT02702284|Behavioral|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
79738556|NCT02702284|Behavioral|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
79738557|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
79873849|NCT00908765|Behavioral|Exercise|"High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
79873850|NCT00903071|Behavioral|Real PPL|See above arm description
79275699|NCT00834067|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
79403657|NCT05099250|Other|saline|medical solution
79579276|NCT01903369|Device|Shear Wave Elastography|Shear wave elastography
79579277|NCT01903395|Behavioral|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
79738558|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Medical management
79873851|NCT00903071|Behavioral|Sim PPL|See above arm description
79738559|NCT04215484|Diagnostic Test|serum BNP assessment|serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
79738560|NCT02698618|Procedure|Diagnostic|"Pre-PCI and treatment:~At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
79275700|NCT00834067|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
79275701|NCT00682981|Drug|Obatoclax|IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
79275702|NCT00682981|Drug|Carboplatin/etoposide|Carboplatin/etoposide combination
79275703|NCT02758613|Drug|Baricitinib|Administered orally.
79403658|NCT03942913|Other|an observational study|this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
79403659|NCT04764006|Drug|Surufatinib|Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
79403660|NCT04143451|Biological|Vaxigrip tetra|quadrivalent influenza vaccine
79403661|NCT04143451|Biological|Fluzone high-dose|high-dose trivalent influenza vaccine
79403662|NCT04143451|Drug|Aldara 5% Topical Cream|imiquimod cream
79403663|NCT04143451|Drug|Aqueous cream BP|inactive aqueous cream
79403664|NCT05105646|Procedure|Knee Arthroplasty, knee revision arthoplasty|Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
79738561|NCT02698618|Drug|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.
79873852|NCT00908843|Other|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
79275704|NCT02758613|Drug|Placebo|Administered orally.
79275705|NCT02758301|Device|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
79275706|NCT00833521|Drug|Zolpidem 10 mg tablets|1 x 10 mg
79275707|NCT00833521|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
79275708|NCT02669667|Drug|MEDI9314|single dose of MEDI9314
79275709|NCT02669667|Drug|placebo|single dose of placebo
79403665|NCT04143529|Behavioral|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
79403666|NCT04143529|Behavioral|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
79738562|NCT02698618|Procedure|PCI|"Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
79873853|NCT00908843|Other|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
79873854|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
80030653|NCT05748184|Device|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
79403667|NCT05080062|Behavioral|Requirements and functional Schedule|An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program
79579278|NCT01903447|Drug|SSRI|
79579279|NCT01903447|Behavioral|CBT|
79275710|NCT00832507|Drug|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
79275711|NCT00832507|Drug|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
79275712|NCT02172677|Behavioral|Episodic memory task|
79275713|NCT02172677|Device|fMRI|
79275714|NCT02169557|Drug|Fexinidazole|
79275715|NCT03538847|Other|Numerical rating scale|Measure of postoperative pain
79275716|NCT03538769|Other|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
79275717|NCT04187209|Device|Use of the Atalante exoskeleton|A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
79275718|NCT02802943|Biological|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A*01, A*02, A*03, A*24, B*07, B*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
79275719|NCT02802943|Drug|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
79275720|NCT02164877|Drug|pectin|Patients allocated to experiment group will receive 15g pectin each day
79275721|NCT02169635|Procedure|macular buckle|macular buckle with a three-armed silicone capsule
79275722|NCT00735085|Drug|SLV334|1000mg SLV334 as a single dose
79275723|NCT00735085|Drug|SLV334|1000mg SLV334 b.i.d. for one day
79275724|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for one day
79275725|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for three days
79275726|NCT00735085|Drug|Placebo|SLV334 Placebo arm
79579280|NCT01903499|Other|Other: Bean patty|
79579281|NCT01903499|Other|Other: Beef patty|
79579282|NCT01903512|Procedure|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
79579283|NCT01903538|Device|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
79579284|NCT01903538|Device|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
79579285|NCT01903551|Device|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
79579286|NCT01903577|Other|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
79579287|NCT01903577|Other|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
79579288|NCT01903590|Procedure|TVT surgery TOT surgery|
79579289|NCT01903629|Device|MCE|MCE first, followed by standard gastroscopy
79579290|NCT01903629|Device|Standard gastroscopy|
79579291|NCT01903642|Other|proteomic analysis|
79275727|NCT02165033|Drug|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
79275728|NCT00734461|Drug|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
79873855|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
79873856|NCT00908921|Drug|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
79275729|NCT02169713|Drug|Mirabegron|Oral
79275730|NCT02169713|Drug|Solifenacin succinate|Oral
79275731|NCT02169713|Drug|Tamsulosin HCl|Oral
79275732|NCT02169713|Drug|Placebo|Oral
79579292|NCT01903655|Other|telomere length|
79579293|NCT01903681|Drug|Circadin 2 mg|First arm lower dose
79579294|NCT01903681|Drug|Circadin 10 mg|Second arm higher dose
79579295|NCT01903694|Drug|Sorafenib + Pravastatin|
79579296|NCT01903694|Drug|Sorafenib|
79579297|NCT01903707|Other|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
79738563|NCT02698462|Other|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
79873857|NCT00904631|Device|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
79275733|NCT03980041|Drug|IPI-549 (eganelisib)|IPI-549 (40mg QD) administered orally in 28-day cycles
79275734|NCT03980041|Drug|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
79738564|NCT02698150|Device|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
79873858|NCT00909077|Drug|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
79275735|NCT03980041|Drug|Placebos|Placebo administered orally in 28-day cycles
79275736|NCT04800835|Device|Gastric Balloon|implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months
79275737|NCT02669433|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
79275738|NCT02669433|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
79275739|NCT02669433|Drug|Placebo|once daily, oral, matching tablets
79275740|NCT02756819|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
79275741|NCT00829309|Drug|Pravastatin|80 mg Tablet
79275742|NCT00829309|Drug|Pravastatin|80 mg Tablets
79275743|NCT02169947|Behavioral|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
79275744|NCT02169947|Behavioral|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
79304661|NCT03192085|Diagnostic Test|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
79579298|NCT01903707|Other|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
79579299|NCT01903759|Other|Blood samples|
79579300|NCT01903772|Other|Inspiratory Muscle Training|
79579301|NCT01903785|Drug|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
79579302|NCT01903785|Drug|Placebo|
79579303|NCT01903824|Drug|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
79579304|NCT01903824|Drug|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
79579305|NCT01903824|Drug|modafinil|modafinil 200 mg tablet, over-encapsulated
79579306|NCT01903824|Drug|Placebo|Placebos formulated to match each active drug
79579307|NCT01903850|Device|spray cryotherapy|spray cryotherapy
79579308|NCT01903889|Other|clinic based intervention|counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
79579309|NCT01903889|Other|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
79579310|NCT01903902|Device|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length < 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
79579311|NCT01903928|Biological|ASP0113|injection
79579312|NCT01903941|Behavioral|Aerobic Exercise|
79579313|NCT01903941|Behavioral|Only Counseling|
79579314|NCT01903980|Other|No intervention. It is a retrospective study|No intervention. It is a retrospective study
79738565|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
79579315|NCT01904006|Procedure|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
79579316|NCT01904006|Procedure|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
79579317|NCT01904045|Other|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
79579318|NCT01904045|Other|tacrolimus Prograf|intake of Prograf twice daily for 3 months
79275745|NCT04796935|Device|Tactile Imaging (VerTouch)|VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
79275746|NCT04796935|Other|Control (palpation)|Control, palpation used to identify and mark an insertion site.
79275747|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
79579319|NCT01904084|Device|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
79873859|NCT00909077|Drug|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
79275748|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
79275749|NCT02165189|Drug|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram ([kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
79579320|NCT01904084|Device|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
79579321|NCT01904097|Drug|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
79579322|NCT01904097|Other|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
79579323|NCT01904097|Other|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
79275750|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
79275751|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
79275752|NCT00725881|Drug|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
79275753|NCT00725881|Drug|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
79275754|NCT02669121|Biological|NoV Placebo-matching Saline|NoV placebo-matching saline (0.9% sodium chloride).
79579324|NCT01904110|Drug|Risedronate/Cholecalciferol combination(montly)|once a month
79579325|NCT01904110|Drug|Risedronate/Cholecalciferol combination(weekly)|once a week
79579326|NCT01904162|Drug|400 mg finafloxacin (2 x 200 mg tablets)|
80030654|NCT05748184|Device|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
79579327|NCT01904214|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
79579328|NCT01904227|Behavioral|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
79579329|NCT01904227|Behavioral|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
79275755|NCT02669121|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
79275756|NCT02165267|Biological|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
79403668|NCT05080062|Behavioral|No intervention|a pain rehabilitation-program
79579330|NCT01904253|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
79579331|NCT01904253|Drug|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
79579332|NCT01904253|Drug|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
79738566|NCT01112267|Drug|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
79738567|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
79275757|NCT02165267|Biological|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
79275758|NCT02165267|Biological|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
79275759|NCT00725803|Drug|GS-9450|GS-9450 capsules administered orally once daily
79275760|NCT00725803|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
79275761|NCT05653063|Other|A web-based artificial intelligence (AI) auto-planning tool|"The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.~In this study patients will not be treated with the AI tool but the manual plan created by the local teams."
79403669|NCT05105412|Drug|Lenalidomide and Gemcitabine (Dose level 11)|lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
79403670|NCT05105412|Drug|Lenalidomide and Gemcitabine (Dose level 21)|lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
79403671|NCT05105412|Drug|Lenalidomide and Gemcitabine (Dose level 31)|lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
79403672|NCT05105412|Drug|Lenalidomide and Gemcitabine (Dose level 41)|lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
79403673|NCT04766047|Drug|Dexmedetomidine|Administration of dexmedetomidine intraoperatively
79579333|NCT01904266|Procedure|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
79579334|NCT01904266|Procedure|GA + sham block|Injection of 1 cc saline subcutaneously
79579335|NCT01904279|Drug|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
80030655|NCT05747846|Procedure|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
79579336|NCT01904292|Drug|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
79579337|NCT01904318|Drug|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
79579338|NCT01904318|Drug|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
79579339|NCT01904318|Drug|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
79579340|NCT01904318|Drug|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
79579341|NCT01904318|Drug|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
79579342|NCT01904318|Drug|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
79579343|NCT01904318|Drug|Placebo|Placebo single dose administration
79579344|NCT01904344|Device|Sensor testing and validation|
79579345|NCT01904357|Drug|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
79275762|NCT03750513|Radiation|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Given LET optimized IMPT
79403674|NCT04662294|Biological|CD70 CAR T-cells|Each subject receive CD70 CAR T-cells by intravenous infusion
79579346|NCT01904357|Drug|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
79579347|NCT01904396|Drug|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
79579348|NCT01904422|Procedure|conventional periodontal treatment|
79579349|NCT01904461|Device|Vacuum device|
79579350|NCT01904461|Procedure|Conventional surgery|
79579351|NCT01904474|Other|Next.Step - e-therapeutic intervention program|
79579352|NCT01904474|Other|Standard treatment protocol|
79579353|NCT01904487|Radiation|[11C]flumazenil|[11C]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
79579354|NCT01904487|Drug|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
79579355|NCT01904500|Drug|Pre-operative cefazolin|
79579356|NCT01904513|Dietary Supplement|Pasteurized Whole Milk|
79579357|NCT01904513|Dietary Supplement|Lactobacillus rhamnosus GR-1|
79579358|NCT01904539|Drug|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
79579359|NCT01904552|Device|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
79579360|NCT01904565|Radiation|Hyperthermia and Proton Beam|"Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
79738568|NCT01112267|Drug|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
79738569|NCT04216030|Other|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
79738570|NCT04216030|Other|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
79738571|NCT00616096|Procedure|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
79275763|NCT03750513|Other|Quality-of-Life Assessment|Ancillary studies
79275764|NCT03750513|Other|Questionnaire Administration|Ancillary studies
79579361|NCT01904578|Other|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
79873860|NCT00904709|Drug|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
79275765|NCT02165423|Behavioral|myFAMI iPad application|
79275766|NCT04473001|Other|Continuous vital signs and glucose monitoring|"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~Glucose measurements (quasi-continuous, every 5 minutes)~Heart rate~Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~Respiration rate~Oxygen saturation of arterial hemoglobin (%SpO2)~Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~Blood pressure (quasi-continuous; every 30-60 minutes)~Skin temperature~Electrodermal activity~Ambulatory activity (accelerometry)"
79275767|NCT00825955|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
79403675|NCT04021927|Device|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
79403676|NCT04021615|Other|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
79403677|NCT04021615|Other|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
79579362|NCT01904578|Other|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
79579363|NCT01904591|Dietary Supplement|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
79873861|NCT05277389|Other|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
80030656|NCT05747846|Procedure|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
80030657|NCT05738811|Other|TENS treatment protocol|The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
79275768|NCT00825955|Other|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
79275769|NCT00825955|Procedure|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
79275770|NCT02292225|Drug|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
79275771|NCT02292225|Drug|Obinutuzumab|1000mg/40mL single-use vials
79275772|NCT02247453|Other|screening|"All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT."
79579364|NCT01904591|Dietary Supplement|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
79579365|NCT01904617|Other|Dextrose|
79579366|NCT01904617|Other|Normal Saline|
79579367|NCT01904630|Genetic|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
79579368|NCT01904643|Drug|lenalidomide|Given PO
79579369|NCT01904643|Drug|mitoxantrone hydrochloride|Given IV
79579370|NCT01904643|Drug|etoposide|Given IV
79579371|NCT01904643|Drug|cytarabine|Given IV
79579372|NCT01904682|Drug|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
79579373|NCT01904695|Drug|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
79275773|NCT02743117|Biological|Monovalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
79579374|NCT01904695|Drug|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
79275774|NCT02743117|Other|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
79275775|NCT00677053|Drug|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
79738572|NCT00925587|Drug|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
79275776|NCT00677053|Drug|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
79275777|NCT00677053|Drug|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
79275778|NCT00677053|Drug|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
79403678|NCT05061498|Diagnostic Test|Additional Pacing maneuvers|In order to determine the optimal setting for pacemapping in all participants additional pacing maneuvers (output and cycle length) are performed
79403679|NCT03940261|Other|High Intensity Interval Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 10, 1-minute cycling intervals at 90% of peak power output, each separated by 1-min at 10% peak power output.
79403680|NCT03940261|Other|Continuous Moderate Intensity Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 30-50 minutes of cycling at 60% peak power output.
79403681|NCT04633668|Behavioral|CBT for parasomnias (CBT-p)|Psychoeducation, sleep hygiene, imagery re-scripting, scheduled awakenings, safety planning, cognitive therapy, and stress management for 6 weeks
79403682|NCT04633668|Behavioral|Self-Monitoring|Monitoring of sleep quality through sleep diary, actigraphy, nightmare experiences for 6 weeks
79275779|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
79275780|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
79403683|NCT04874220|Device|Deep Brain Stimulation|Deep brain stimulation will be used
79403684|NCT04596228|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
79403685|NCT04747951|Combination Product|Concurrent Chemoradiotherapy|"50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
79275781|NCT00677053|Drug|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
79275782|NCT00677053|Drug|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
79275783|NCT00677053|Drug|Placebo|Stages I, II & III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
79275784|NCT00644839|Drug|CP-945,598|Administration of CP-945,598 alone in period 1
79275785|NCT00644839|Drug|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
79275786|NCT00643669|Drug|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
79275787|NCT00674635|Drug|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
79275788|NCT00674635|Drug|Placebo|matching placebo
79275789|NCT03875053|Diagnostic Test|Monitoring Device|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
79275790|NCT03875053|Other|Quality-of-Life Assessment|Ancillary studies
79275791|NCT03875053|Other|Questionnaire Administration|Ancillary studies
79275792|NCT01950403|Drug|linaclotide acetate|Given PO
79275793|NCT01950403|Other|placebo|Given PO
79403686|NCT04747951|Procedure|TME|Total mesorectal excision
79403687|NCT04747951|Drug|consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
79579375|NCT01904708|Other|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
79275794|NCT01950403|Other|pharmacological study|Correlative studies
79579376|NCT01904734|Drug|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
79579377|NCT01904747|Drug|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
79579378|NCT01904747|Drug|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
79579379|NCT01904747|Drug|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
79579380|NCT01904747|Drug|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
79579381|NCT01904786|Drug|Melatonin|
79579382|NCT01904786|Drug|placebo|
79579383|NCT01904799|Other|Cognitive Assessment test|
79579384|NCT01904812|Other|Questionnaire about quality of life and satisfaction|
79738573|NCT02698306|Drug|Dexamethasone|Dexamethasone
79738574|NCT02698306|Drug|Diclofenac Sodium|Diclofenac Sodium
79738575|NCT02698228|Drug|Bupivacaine (femoral nerve block)|0.5% bupivacaine
79738576|NCT02698228|Drug|Morphine|Intravenous injection of 0.1mg/kg of morphine
79738577|NCT02698228|Device|Ultrasound|
79738578|NCT02698072|Other|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
79738579|NCT02698072|Device|Dry needling|Dry needling needle AGUPUNT®
79738580|NCT02698072|Device|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
79275795|NCT01950403|Other|laboratory biomarker analysis|Correlative studies
79275796|NCT03607539|Drug|Sintilimab|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
79579385|NCT01904877|Behavioral|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
79275797|NCT03607539|Drug|Pemetrexed|500mg/m^2; Q3W (qualer 3 weeks), day1, I.V.
79275798|NCT03607539|Drug|Platinum|Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
79275799|NCT03607539|Drug|Placebos|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
79738581|NCT00616174|Procedure|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
79304662|NCT03280901|Other|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
79403688|NCT04747951|Drug|adjuvant chemotherapy|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
79403689|NCT04148677|Dietary Supplement|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
79403690|NCT04515888|Other|PFDI-20 / PFIQ-7 questionnaires|PFDI-20 / PFIQ-7 questionnaires (one shot)
79403691|NCT04148053|Diagnostic Test|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
79403692|NCT04147975|Diagnostic Test|RaPID/BSI Test|RaPID/BSI Test
79403693|NCT02656680|Behavioral|FB + Friends|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
79738582|NCT02702128|Drug|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
79738583|NCT02702128|Drug|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
79579386|NCT01904890|Behavioral|CRC Prevention and Screening Education|Refer to Arm Description
79579387|NCT01904890|Behavioral|Nutrition Education|Refer to Arm Description
79579388|NCT01904916|Procedure|Histological biopsy procedure|
79738584|NCT05194683|Behavioral|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
79873862|NCT05277389|Other|Sham Control|Practice of Movement task without START
80030658|NCT05738811|Other|EMS treatment protocol|The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
80030659|NCT05738811|Other|Exercises|Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
80030660|NCT05738135|Drug|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
80030661|NCT05738135|Drug|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
80030662|NCT05734261|Procedure|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
79579390|NCT01904981|Drug|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
79579391|NCT01904981|Drug|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
79738585|NCT00610545|Drug|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
79738586|NCT00610545|Drug|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
79738587|NCT00193414|Drug|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
79738588|NCT00193414|Drug|Gemcitabine|1500mg/m2, 30min IV
79873863|NCT00340834|Drug|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
79873864|NCT00340834|Drug|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
79275800|NCT04472923|Procedure|Traditional Treatment|"Patients belonging to the control group received conventional physical therapy program in the form of:~Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months."
79275801|NCT04472923|Device|Biofeedback|"Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months."
79275802|NCT02151669|Behavioral|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
79275803|NCT00629941|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
79403694|NCT02656680|Behavioral|FB Only|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
79403695|NCT04148209|Drug|PF-07081532|Participants will receive single ascending doses PF-07081532
79579392|NCT01904994|Procedure|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
79579393|NCT01904994|Procedure|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
79738589|NCT05330559|Other|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
79403696|NCT04148209|Drug|Placebo|Participants will receive placebo
79738590|NCT02701972|Device|BACE Device|Implanted BACE device
79873865|NCT00340834|Drug|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
79873866|NCT03986554|Procedure|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
79873867|NCT03986554|Procedure|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
79873868|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
79275804|NCT02404779|Drug|cisatracurium besilate|
79738591|NCT02701816|Device|innova stent (Boston scientific)|
79738592|NCT04260711|Drug|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
79738593|NCT00610623|Drug|azithromycin|300 mg/day, IV from day 1 to 20
79738594|NCT00610623|Drug|placebo|once per day, IV from day 1 to 20
79738595|NCT02701660|Device|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
79738596|NCT04214782|Diagnostic Test|Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm|AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
79275805|NCT02404779|Other|Placebo|
79275806|NCT00629551|Drug|saredutant (SR48968)|oral administration,capsules
79275807|NCT00629551|Drug|paroxetine|oral administration, capsules
79275808|NCT00629551|Drug|placebo|oral administration, capsules
79275809|NCT05231577|Procedure|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
79275810|NCT05231577|Procedure|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
79579394|NCT01904994|Behavioral|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
79275811|NCT00625651|Drug|Placebo|Inactive dummy AMG 655 (to maintain blind)
79275812|NCT00625651|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
79275813|NCT00625651|Drug|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)] administered by intravenous infusion once every 14 days (+3 days)
79275814|NCT00625651|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
79275815|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
79579395|NCT01904994|Behavioral|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
79275816|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
79275817|NCT02280733|Other|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
79275818|NCT02669043|Drug|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
79579396|NCT01904994|Other|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
79579397|NCT01905007|Device|Defibrillation testing|Defibrillation testing at initial ICD implantation
79579398|NCT01905020|Other|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
79579399|NCT01905020|Other|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
79275819|NCT02283385|Behavioral|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
79275820|NCT02283463|Device|Intrauterine device (IUD) insertion|
79275821|NCT02283463|Procedure|Endometrial biopsy|
79579400|NCT01905059|Drug|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
79275822|NCT02283541|Behavioral|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
79275823|NCT02283619|Other|None - no intervention, observational study|No intervention, observational study
79275824|NCT02280967|Behavioral|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
79275825|NCT02404857|Device|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
79275826|NCT02281045|Device|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
79275827|NCT02281045|Device|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
79275828|NCT03514329|Device|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
79275829|NCT04472689|Drug|Lidocaine|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
79275830|NCT04472689|Drug|Normal saline|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
79275831|NCT02405013|Drug|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
79403697|NCT04147897|Device|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
79275832|NCT02405013|Drug|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
79403698|NCT04458792|Other|Paraffin tissue samples|Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue
80030663|NCT05732259|Other|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
80030664|NCT05732259|Other|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
80030665|NCT05732246|Other|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
80030666|NCT05730595|Procedure|lymph node dissection|The extent of lymph node dissection varies between groups
80030667|NCT05724797|Drug|NRS-033|A single dose of NRS-033 will be administered
79403699|NCT04458792|Other|blood sample|MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
79403700|NCT04765891|Other|Positional release therapy|Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.
79738597|NCT02697994|Other|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
79738598|NCT02697994|Other|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
80030668|NCT05724797|Drug|Placebo|A single dose of matching placebo will be administered
80030669|NCT05716815|Diagnostic Test|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
79275833|NCT02405013|Drug|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
79275834|NCT02405013|Drug|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
79304663|NCT03189823|Device|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
79738599|NCT02697838|Drug|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
79873869|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
79403701|NCT04765891|Other|Therapeutic Massage|Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
79403702|NCT05104944|Radiation|Serial MRIs|Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
79403703|NCT02080819|Drug|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
79403704|NCT05104788|Drug|Icotinib|Oral
79403705|NCT05104788|Drug|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
79873870|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
79873871|NCT01058044|Other|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
79403706|NCT05104788|Drug|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
79403707|NCT05104788|Drug|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
79403708|NCT04405843|Drug|Ivermectin Oral Product|Ivermectin oral suspension, 6 mg/mL
79403709|NCT04405843|Drug|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
79873872|NCT01058122|Procedure|Collection of adverse drug events|
79873873|NCT00603941|Drug|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
79873874|NCT00603941|Drug|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
79873875|NCT00340678|Drug|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
79873876|NCT00340678|Drug|Placebo|Treatment with placebo corresponding to each dose of losartan.
79873877|NCT01055470|Drug|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
79873878|NCT01055470|Drug|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
79275835|NCT02283697|Behavioral|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
79579401|NCT01905059|Drug|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
79579402|NCT01905072|Other|Education Home Visits|"Intervention will include educational home visits on:~Growth monitoring and feedback~Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
79579403|NCT01905085|Device|No intervention|
79579404|NCT01905098|Other|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
80030670|NCT05716815|Diagnostic Test|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
80030671|NCT05708625|Drug|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
79403710|NCT04316364|Drug|SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
79403711|NCT04316364|Drug|SHR-1316、Chemotherapeutic|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
79579405|NCT01905098|Other|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
79579406|NCT01905111|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
79873879|NCT00904787|Drug|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
79873880|NCT02533102|Drug|E7050|100 mg tablet administered orally
79873881|NCT00907361|Device|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
80030672|NCT05708625|Procedure|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
80030673|NCT05708625|Drug|Intralesional Voriconazole|Weekly intralesional Voriconazole
80030674|NCT05708625|Drug|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
79275836|NCT02283697|Other|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
79403712|NCT04316364|Drug|Placebo、Chemotherapeutic|Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
79873882|NCT02533024|Other|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
79579407|NCT01905124|Drug|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
79579408|NCT01905124|Drug|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
79579409|NCT01905137|Drug|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
79579410|NCT01905137|Drug|placebo|
79873883|NCT05277311|Drug|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
79873884|NCT05277311|Drug|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
79873885|NCT03986008|Drug|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
79275837|NCT02173145|Drug|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
79275838|NCT02173145|Drug|placebo|Placebo will be given 3 times a wek over a period of 3 months.
79275839|NCT04472455|Diagnostic Test|HRME|
79403713|NCT04142671|Other|Individualised gait modification intervention|An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
80030675|NCT05698602|Device|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~store the measurements in the embedded memory~extract from the measurement basic respiratory markers:~detect if and when a patient is using the respiratory assist device,~calculate leakage~calculate respiratory frequency~transmit the measured values via the NivolisBox component to NivolisPortal"
79403714|NCT04282122|Radiation|Radiotherapy|curative-intent radiotherapy
79275840|NCT02404701|Dietary Supplement|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79275841|NCT02404701|Dietary Supplement|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79403715|NCT04142827|Device|High Flow Humidification|myAirvo2 gives at home for long therapy treatment
79403716|NCT04147741|Dietary Supplement|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
79403717|NCT04147741|Other|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
79403718|NCT04147741|Other|Endurance Training|- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
79403719|NCT04972500|Dietary Supplement|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
79403720|NCT04142359|Biological|BCG in Combination with N-803|BCG in Combination with N-803
79403721|NCT04142359|Drug|N-803 alone|N-803 alone
79579411|NCT01905150|Drug|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin
79579412|NCT01905150|Drug|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
79579413|NCT01905150|Dietary Supplement|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
79579414|NCT01905163|Procedure|Tumor Debulking Surgery by laparoscopy|
79579415|NCT01905176|Other|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
79304664|NCT03270839|Drug|Bonine 25Mg Chewable Tablet|Motion sickness drug
79304665|NCT03270839|Drug|Kwells|Motion sickness drug
79275842|NCT02404701|Dietary Supplement|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79275843|NCT02404701|Dietary Supplement|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79579416|NCT01905176|Other|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
79275844|NCT02404701|Dietary Supplement|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79403722|NCT04184154|Other|Questionnaires|The self-questionnaire of 104 questions collected personal and socio-demographics data, global and sexual quality of life characteristics (European Organisation for Research and Treatment of Cancer [EORTC] quality of life questionnaires: QLQ-C30 and gynecologic and cervical cancer specific-questionnaire QLQ-CX24), vaginal dilatators and moisturizers use, and barriers and facilitators of their use. Clinical data were extracted from the patients' medical files. Vaginal stenosis was evaluated at 6 weeks after the end of brachytherapy and after 1-year follow-up by in-town gynecologists or in our Institute, and censored in case of complete vaginal obliteration
79738600|NCT02697838|Drug|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~other paclitaxel-based regimens"
79579417|NCT01905176|Other|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 & 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 & 2
79579418|NCT01905189|Procedure|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
79579419|NCT01905202|Drug|Secretrol|
79579420|NCT01905215|Biological|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79579421|NCT01905215|Biological|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79579422|NCT01905215|Biological|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79579423|NCT01905215|Biological|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79579424|NCT01905215|Biological|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79579425|NCT01905215|Biological|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79738601|NCT02697682|Biological|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
79579426|NCT01905215|Drug|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
79579427|NCT01905228|Drug|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
79579428|NCT01905280|Procedure|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
79579429|NCT01905280|Procedure|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
79579430|NCT01905293|Other|Feeding Study|
79579431|NCT01905306|Procedure|computer guided implant planning|
79579432|NCT01905306|Procedure|free hand implants placement|
79579433|NCT01905319|Other|Blood collecting for storage of samples|
79738602|NCT02697526|Other|Terumo|
79738603|NCT02697526|Other|Tensoplast|
79579434|NCT01905332|Other|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
79275845|NCT02404701|Dietary Supplement|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79403723|NCT04406155|Procedure|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
79403724|NCT04406155|Procedure|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
79403725|NCT04918212|Device|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
79403726|NCT04781478|Other|Application of Biorepair Gel|Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).
79403727|NCT04781478|Other|Irrigation of Chlorhexidine 1.00% gel|Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).
79579435|NCT01905332|Other|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
79873886|NCT03986008|Drug|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
79579436|NCT01905345|Procedure|Training|
79873887|NCT00909233|Drug|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
79579437|NCT01905371|Drug|Dextroamphetamine|
79873888|NCT03985774|Procedure|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
79873889|NCT00904865|Procedure|SPA cholecystectomy|SPA cholecystectomy
79873890|NCT00904865|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
79873891|NCT03986086|Drug|MPH966|RP2D tablet
79873892|NCT03986086|Drug|Placebo|MPH966 placebo table
79873893|NCT03313895|Behavioral|ACT|ACT stands for combined aerobic exercise and cognitive training.
79873894|NCT03313895|Behavioral|Cycling Only|Cycling on a recumbent stationary cycle
79873895|NCT03313895|Behavioral|Cognitive Training Only|Engage in cognitive training on a computer
79873896|NCT03313895|Behavioral|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
79873897|NCT01058200|Device|iCup|new vacuum extractor: sterile disposable plastic cup
79873898|NCT01058200|Device|reference cup|reference cup of the obstetrical ward: metallic cup
79873899|NCT00909311|Drug|ABT-450|capsules, QD, 1 dose in each cross-over period
79873900|NCT00909311|Drug|ritonavir|capsule, QD, 1 dose in each cross-over period
79873901|NCT00907595|Drug|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
79873902|NCT00907595|Drug|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
79873903|NCT05277467|Other|no intervention|no intervention
79873904|NCT00907673|Device|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
79873905|NCT00907751|Drug|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
79403728|NCT04436562|Drug|[14C]-Poziotinib|Single oral administration of 8 mg (as the hydrocholoride salt) of [14C]-poziotinib
79873906|NCT00909467|Other|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
79873907|NCT00905333|Drug|Candesartan (test)|16 mg oral tablet, single dose
79873908|NCT00905333|Drug|Felodipine (test)|5 mg oral extended release tablet, single dose
79873909|NCT00905333|Drug|Candesartan Cilexetil|16 mg oral tablet, single dose
79275846|NCT02404701|Dietary Supplement|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79738604|NCT02690428|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
79275847|NCT02404701|Dietary Supplement|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
79275848|NCT03538379|Behavioral|Bleeding Control Basic (B-Con) Course|The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
79873910|NCT00905333|Drug|Felodipine|5 mg oral extended release tablet, single dose
79275849|NCT00670033|Drug|Travoprost ophthalmic solution (new formulation)|
79275850|NCT00670033|Drug|Travoprost ophthalmic solution, 0.004%|
79275851|NCT00670033|Drug|Vehicle|Inactive ingredients used as a placebo
79304666|NCT03270839|Drug|Placebo Oral Tablet|No active substance in the tablet
79304667|NCT02458547|Drug|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8~1.0
79304668|NCT02458547|Drug|Propofol|Total intravenous anesthesia with propofol target controlled infusion
79304669|NCT02458547|Drug|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
79403729|NCT05104398|Device|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
79579438|NCT01905371|Other|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
79304670|NCT02459561|Device|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
79579439|NCT01905371|Drug|Placebo|
79738605|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
79738606|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
79738607|NCT02706106|Device|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
79873911|NCT00907829|Drug|lidocaine|comparison of the effect of the drug to help improve finger function
79403730|NCT04141969|Dietary Supplement|RLP|RLP nutraceutical
79403731|NCT04141969|Other|Placebo|Inert brown powder
79403732|NCT03935113|Other|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
79579440|NCT01905410|Drug|VVZ-149 Injection|VVZ-149 in water for injection
79579441|NCT01905410|Drug|placebo|water for injection
79579442|NCT01905449|Behavioral|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
79873912|NCT00907829|Device|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
79873913|NCT00905411|Behavioral|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
79403733|NCT04018872|Drug|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
79579443|NCT01905462|Other|Data Collection|Analyses of data collected within the CPRD GOLD database.
79738608|NCT02697760|Radiation|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
79738609|NCT04956705|Dietary Supplement|Vitamin D and calcium|Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
79873914|NCT00336544|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
79873915|NCT00336544|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
79873916|NCT01059058|Procedure|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
80030676|NCT05698602|Device|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 & tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
80030677|NCT05697276|Drug|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
80030678|NCT05697276|Drug|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
79275852|NCT02170259|Other|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
79275853|NCT02170259|Other|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
79403734|NCT04141735|Diagnostic Test|ultrasound|no intervention
79403735|NCT03978078|Other|Biological collection|- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
79403736|NCT04147429|Behavioral|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
79579444|NCT01905462|Biological|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
79579445|NCT01905475|Drug|POL6326|
79579446|NCT01905475|Drug|Placebo|
79579447|NCT01905501|Drug|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
79873917|NCT01059058|Procedure|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
79873918|NCT01059058|Procedure|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
79873919|NCT00605033|Drug|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
79873920|NCT00605033|Drug|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
79579448|NCT01905501|Drug|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
79873921|NCT03988114|Drug|Abemaciclib|Administered orally
79873922|NCT03988114|Drug|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
79579449|NCT01905514|Device|internet mobile application|
79873923|NCT00905723|Drug|estradiol|1 mg daily for 6 months
79579450|NCT01905527|Other|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
79579451|NCT01905527|Other|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
79873924|NCT00905723|Drug|isoflavone|150 mg isoflavone daily for 6 months
79873925|NCT00905723|Drug|Placebo|sugar pill daily for six months
79579452|NCT01905527|Other|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
80030679|NCT05674500|Other|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
79579453|NCT01905579|Procedure|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
79275854|NCT02170259|Other|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
79275855|NCT03170973|Other|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
79403737|NCT04147507|Other|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
79403738|NCT04147507|Behavioral|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
79579454|NCT01905605|Drug|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
79579455|NCT01905605|Drug|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
79579456|NCT01905566|Drug|Clopidogrel|75mg once a day
79738610|NCT04260633|Device|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
79738611|NCT02705950|Drug|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
79738612|NCT02705950|Other|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
79738613|NCT04951323|Drug|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
79275856|NCT02283775|Drug|Isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
79275857|NCT02283775|Drug|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
79275858|NCT02283775|Drug|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
79579457|NCT01905566|Drug|Ticagrelor|90mg twice a day
79579458|NCT01905618|Behavioral|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
79738614|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
79738615|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
79738616|NCT04215016|Biological|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
79738617|NCT02701894|Dietary Supplement|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
79738618|NCT02706028|Device|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
80030680|NCT05674500|Other|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
80030681|NCT05672784|Procedure|genicular nerve block plus standard analgesia|In supine position with a pillow under the popliteal fossa, a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) will be placed parallel to the shaft of long bones of the legs. The target points will be next to superior lateral, superior medial, and inferior medial genicular arteries to block the superior lateral, superior medial, and inferior medial branches of genicular nerve. Identification will be done using color Doppler near the periosteal areas (the junctions of the epicondyle and the shafts of the femur and tibia, accordingly). The needle will be inserted in the plane of the ultrasound probe in the long-axis view. After confirming the placement of the needle-tip next to the genicular arteries, a 2.5 mL of bupivacaine (5%) will be injected at each target points.
79275859|NCT00505219|Biological|Ixmyelocel-T|Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
80030682|NCT05672784|Procedure|genicular nerve block plus infiltration Between Popliteal Artery and Capsule of Posterior Knee plus standard analgesia|IPACK block will be performed in supine position with flexion of the knee in 45o. low frequency transducer at a depth of 3.5-4 cm will be placed transversely over the medial aspect of the knee, 2-3 cm above the patella, with sliding the transducer proximally and distally to identify the distal part of the shaft of the femur and the popliteal artery ( If the two femoral condyles appear first, proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared). Advance the needle in plane toward the space between the popliteal artery and the femur then 15 ml of bupivacaine 0.5% will be injected plus genicular nerve block
79275860|NCT00505219|Other|Standard of Care Only|Core decompression of the femoral head to remove necrotic tissue
80030683|NCT05672784|Drug|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm thrice daily and meloxicam (15 mg) every 24).
80030684|NCT05661253|Drug|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
79403739|NCT03915691|Procedure|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
79403740|NCT03915691|Procedure|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
79579459|NCT01905618|Behavioral|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
80030685|NCT05661253|Drug|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
79579460|NCT01905618|Behavioral|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
79738619|NCT02706028|Device|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
79738620|NCT02701348|Other|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
79738621|NCT02701348|Drug|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
79738622|NCT02701348|Procedure|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
79738623|NCT02701348|Other|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
79738624|NCT02701426|Behavioral|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
79304671|NCT02459561|Other|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
79304672|NCT02458625|Dietary Supplement|Iron sucrose 500 mg|
79304673|NCT02458625|Dietary Supplement|Iron bisglycinate 60 mg|
79579461|NCT01905618|Behavioral|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
79738625|NCT00615706|Other|No intervention|no intervention
79275861|NCT02165579|Other|1 cohort, standard care, observational|This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
79275862|NCT04479891|Drug|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
79275863|NCT04479891|Drug|Itraconazole capsule|200 mg itraconazole QD
79275864|NCT02281123|Other|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
79275865|NCT02173223|Drug|Rho-Kinase Inhibitor|
79403741|NCT04141345|Diagnostic Test|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
79579462|NCT01905644|Procedure|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
79579463|NCT01905670|Device|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
79738626|NCT02700880|Device|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
79738627|NCT00930813|Device|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
79738628|NCT00930813|Device|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
79738629|NCT05324800|Dietary Supplement|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
79738630|NCT05324800|Dietary Supplement|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
79738631|NCT04216108|Device|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
79738632|NCT04216108|Device|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
79738633|NCT04215796|Device|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
79738634|NCT02700958|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
79738635|NCT02700958|Procedure|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
79738636|NCT04215328|Dietary Supplement|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
79873926|NCT04034069|Device|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
79275866|NCT03113565|Behavioral|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
79275867|NCT02281201|Biological|BE1116 (Prothrombin Complex Concentrate)|
79275868|NCT02170337|Drug|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
79275869|NCT02170337|Drug|Placebo|Contains no active drug
79275870|NCT01726257|Device|Nellix System|Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
79275871|NCT02281279|Biological|rituximab|Given IV
79275872|NCT02281279|Drug|lenalidomide|Given PO
79275873|NCT02281279|Drug|romidepsin|Given IV
79403742|NCT04140877|Device|Visu|An experimental (test) virtual reality display
79403743|NCT05581459|Other|63 Hz Vibration|Vibrations of 63 Hz were applied with handheld vibration device.
79403744|NCT05581459|Other|42 Hz Vibration|Vibrations of 42 Hz were applied with handheld vibration device.
79579464|NCT01905696|Drug|Oral N-acetylcysteine|
79579465|NCT01905709|Biological|Human fecal matter|
79579466|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
79738637|NCT04215328|Dietary Supplement|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
79738638|NCT04258527|Drug|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
80030686|NCT05656001|Other|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
79275874|NCT02281279|Other|laboratory biomarker analysis|Correlative studies
79275875|NCT02173457|Drug|Chiglitazar|Take orally
79403745|NCT05581459|Other|Sham vibration|Handheld device was applied to the participants without any vibrations.
79579467|NCT01905722|Other|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
79403746|NCT03896035|Behavioral|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
79579468|NCT01905735|Drug|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
79579469|NCT01905735|Drug|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
79579470|NCT01905748|Other|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
79579471|NCT01905774|Drug|Deferasirox|
80030687|NCT05656001|Other|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
79738639|NCT00615238|Behavioral|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
80030688|NCT05639192|Biological|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
79275876|NCT02173457|Drug|Sitagliptin|Take orally
79738640|NCT00615238|Behavioral|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
79275877|NCT05652855|Drug|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
79275878|NCT05604885|Drug|AP1189, 60 mg|AP1189 tablets for oral use
79275879|NCT05604885|Drug|AP1189, 80 mg|AP1189 tablets for oral use
79275880|NCT05604885|Drug|AP1189, 100 mg|AP1189 tablets for oral use
79275881|NCT05604885|Drug|Placebo|Matching placebo tablets for oral use
79275882|NCT02165657|Device|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
79275883|NCT00805129|Drug|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
79403747|NCT04868136|Behavioral|Exercise|30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
79403748|NCT04141189|Procedure|weekly|fetal surveillance frequency
79403749|NCT04141189|Procedure|bi-weekly|fetal surveillance frequency
79579472|NCT01905800|Device|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
79579473|NCT01905878|Drug|DLBS1033|
79738641|NCT00615238|Behavioral|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
79738642|NCT04946799|Behavioral|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
79403750|NCT05078268|Behavioral|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
79873927|NCT04034069|Behavioral|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
79873928|NCT03987646|Procedure|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
79275884|NCT03375723|Other|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
79275885|NCT03375723|Other|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
79403751|NCT05078268|Behavioral|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
79873929|NCT00907985|Drug|Placebo|Single dose of placebo will be provided.
79403752|NCT05076786|Drug|Chidamide|20mg, administered orally. Week 1/2: twice a week (d0, d4, d7, d11); Week 3: stop. Repeat every 3 weeks for 4-6 cycles.
79579474|NCT01905891|Procedure|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
79873930|NCT00907985|Drug|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
79579475|NCT01905904|Drug|sevorane|Sevorane 4% Sevorane 7%
79579476|NCT01905917|Other|Tele-rehabilitation|
79579477|NCT01905930|Device|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
79579478|NCT01905930|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
79579479|NCT01905982|Procedure|reflectory breathing therapy|duration:2x60 minutes
79579480|NCT01905982|Procedure|conventional breathing therapy|duration:4x30 minutes
79579481|NCT01906021|Procedure|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
79873931|NCT00907985|Drug|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
79873932|NCT03987880|Procedure|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
79873933|NCT03987880|Procedure|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
79873934|NCT01325194|Drug|liposomal cytarabine|50 mg intrathecally three times
79873935|NCT00908063|Drug|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
79873936|NCT00908063|Drug|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
79873937|NCT00909701|Dietary Supplement|PreOP Booster|1 serving of 400 ml per study arm
79873938|NCT00909701|Dietary Supplement|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
79873939|NCT01058278|Procedure|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
79873940|NCT00905801|Other|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
79275886|NCT00501709|Drug|Belatacept and Raptiva|immunosuppressant agent to prevent rejection in transplant recipients
79275887|NCT02165891|Drug|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
79275888|NCT02165891|Procedure|primary video-assisted thorascopic surgery|
79275889|NCT05572827|Behavioral|Breathing exercises|Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
79275890|NCT02273635|Drug|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
79275891|NCT02273635|Drug|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
79579482|NCT01906021|Procedure|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
79579483|NCT01906034|Behavioral|Exercise with supervision|
79738643|NCT04946799|Behavioral|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
79738644|NCT04946799|Behavioral|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
79738645|NCT00610779|Dietary Supplement|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
79738646|NCT00610779|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
79738647|NCT02700724|Other|Immediate Surgery|
79738648|NCT02700724|Other|Observation|
79738649|NCT02700724|Procedure|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
79738650|NCT04258371|Drug|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
79738651|NCT04258371|Drug|Placebo oral tablet|Placebo once daily for 12 weeks
79275892|NCT03539471|Diagnostic Test|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
79275893|NCT02404467|Device|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
79275894|NCT00622765|Drug|placebo|Placebo capsule twice daily
79275895|NCT00622765|Drug|R256918|5 mg capsule twice daily
79275896|NCT00622765|Drug|R256918|10 mg capsule twice daily
79275897|NCT00622765|Drug|R256918|15 mg capsule twice daily
79403753|NCT05076786|Drug|Etoposide + Cisplatin/Carboplatin|"Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (75mg/m2; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (25mg/m2; intravenous infusion; d1-3). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Carboplatin (AUC=5; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles."
79403754|NCT04141033|Diagnostic Test|assessment of neopterin levels|neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
79738652|NCT00609219|Biological|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 2 x 10^7 cells/m2~Group Two:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 1 x 10^8 cells/m2~Group Three:~Day 0 - 1 x 10^8 cells/m2 Day 14 - 2 x 10^8 cells/m2"
79873941|NCT00908219|Drug|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
79873942|NCT00927173|Device|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
80030689|NCT05639192|Other|Placebo|Placebo will be administered once per week as an i.v. infusion
80030690|NCT05620576|Drug|LY3857210|Administered orally
80030691|NCT05620576|Drug|Placebo|Administered orally
79275898|NCT02170415|Drug|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
79275899|NCT02170415|Other|Pain education|Participant will receive a pain education leaflet
79275900|NCT02170415|Behavioral|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
79275901|NCT02170415|Procedure|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
79275902|NCT02170415|Other|Daily visits from pain team whilst in hospital|
79275903|NCT02668185|Drug|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
79275904|NCT02668185|Drug|Placebo|Placebo
79403755|NCT03588949|Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
79579484|NCT01906034|Behavioral|Home-based without supervision|
79579485|NCT01906060|Device|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
79579486|NCT01906073|Drug|intranasal fentanyl spray|
79579487|NCT01906073|Drug|slow release morphine|
79579488|NCT01906086|Other|nutritional intervention|
79579489|NCT01906086|Other|life style intervention|
79579490|NCT01906099|Other|nutritional intervention|
80030692|NCT05619081|Behavioral|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
79275905|NCT02165969|Procedure|endoscopic endonasal surgery with UPSIT|
79579491|NCT01906099|Other|life style modification|
79579492|NCT01906112|Procedure|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
79579493|NCT01906125|Drug|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
79579494|NCT01906125|Drug|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
79579495|NCT01906125|Drug|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
79579496|NCT01906138|Device|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
79579497|NCT01906151|Device|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
79579498|NCT01906164|Drug|ALS-008176|
79873943|NCT00927173|Device|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
79873944|NCT02538185|Device|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
79579499|NCT01906164|Drug|Placebo|
80030693|NCT05617885|Drug|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
80030694|NCT05617885|Drug|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
79275906|NCT00622063|Drug|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
79275907|NCT03134365|Other|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
79579500|NCT01906190|Biological|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
79579501|NCT01906203|Device|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
79579502|NCT01906216|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
79579503|NCT01906216|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
79579504|NCT01906242|Other|water|
79579505|NCT01906242|Other|sodium hypochlorite|
79579506|NCT01906242|Other|sodium bicarbonate|
79579507|NCT01906242|Other|chlorhexidine|
79579508|NCT01906268|Other|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
79579509|NCT01906268|Other|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
79579510|NCT01906281|Other|Blood analyse, arthrocentesis, ultrasound examination|
79579511|NCT01906294|Drug|antidiabetic treatment (ATC A10B)|
79579512|NCT01906307|Drug|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
79738653|NCT00930579|Drug|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
79738654|NCT00609297|Other|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
79738655|NCT00609297|Other|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
79873945|NCT02538185|Device|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
79873946|NCT02538185|Device|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
79873947|NCT02538185|Drug|Vaccin rabique Pasteur®|
79275908|NCT03134365|Other|Combined meal|Combined meal.
79275909|NCT02166125|Procedure|Endosuturing|Endoscopic suturing
79275910|NCT02173691|Drug|Tiotropium inhalation powder capsules|
80030695|NCT05617885|Drug|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
80030696|NCT05617885|Drug|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
79579513|NCT01906320|Behavioral|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
80030697|NCT05617885|Drug|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
80030698|NCT05616338|Other|Blood sample|"A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS."
79579514|NCT01906333|Other|Exercise|
79579515|NCT01906333|Other|Glucose|
79579516|NCT01906333|Other|Fasted|
79579517|NCT01906359|Other|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
79579518|NCT01906359|Other|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
79579519|NCT01906359|Other|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
80030699|NCT05614570|Device|SSVEP Device|Non-invasive, non-interventional SSVEP sensor device
80030700|NCT05614570|Other|SCAT5|The Sport Concussion Assessment Tool version 5
80030701|NCT05601271|Drug|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
79403756|NCT03588949|Dietary Supplement|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
79403757|NCT03476317|Drug|Vancomycin|Oral suspension 4 times daily (Day 1-14)
79403758|NCT03476317|Drug|Neomycin|Oral three times daily (Days 1-3)
79403759|NCT03476317|Drug|Ciprofloxacin|Oral twice daily (Days 4-14)
79403760|NCT03476317|Drug|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
79403761|NCT03476317|Drug|Fluconazole|Orally once daily (Day 1-14)
79403762|NCT02658084|Drug|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
79579520|NCT01906398|Other|ketogenic diet|KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction
79579521|NCT01906411|Dietary Supplement|Dopamine depletion vs. Balanced aminoacid drink|
79738656|NCT00609297|Other|survey administration|Given to patient and caregivers throughout the study
79738657|NCT04257981|Device|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
79738658|NCT04257981|Other|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
79738659|NCT04260555|Drug|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
79738660|NCT04260555|Drug|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
79738661|NCT04260555|Drug|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
79738662|NCT04260321|Device|AI|Artificial intelligence colonoscopy
79738663|NCT02700568|Drug|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
79738664|NCT00925353|Drug|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
79738665|NCT02700646|Behavioral|Developmental recommendations|
79738666|NCT02700646|Behavioral|Standard care|standard care
79738667|NCT02705560|Other|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
79738668|NCT02705560|Other|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
80030702|NCT05593198|Procedure|Khoury technique|the bone block will be used following the principles of the Khoury technique to augment the bone volume.
80030703|NCT05593198|Procedure|Guided bone regeneration|the membrane and the bone granules will be used to perform the guided bone regeneration technique.
79275911|NCT02173691|Drug|Salmeterol inhalation aerosol|
79275912|NCT02173691|Drug|Placebo inhalation aerosol|
79275913|NCT02173691|Drug|Placebo inhalation powder capsules|
79275914|NCT02274259|Drug|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
79275915|NCT02274259|Drug|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
79275916|NCT05571111|Drug|FE 999302|Subcutaneous injection as a single dose. 3 different doses
79275917|NCT05571111|Drug|Ovitrelle|Subcutaneous injection as a single dose. 250 µg (0.5 mL)
79579522|NCT01906424|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
79579523|NCT01906437|Device|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
79579524|NCT01906450|Drug|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
79579525|NCT01906450|Drug|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
79579526|NCT01906502|Device|Sensimed Triggerfish|
79579527|NCT01906528|Drug|Mivacurium|Effect of Mivacurium in males vs females
79579528|NCT01906541|Genetic|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
79738669|NCT02705560|Other|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
79738670|NCT04203615|Device|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
79738671|NCT04203615|Device|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
79738672|NCT02705482|Biological|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
79738673|NCT02705482|Biological|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
79738674|NCT02705482|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
79738675|NCT00615316|Drug|Guaraná|Guaraná extract 75mg/day
79579529|NCT01906554|Other|Egg Dose|Different quantities of eggs
79579530|NCT01906580|Drug|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
79738676|NCT00615316|Drug|Placebo|Placebo 1tab/d
79738677|NCT00611013|Device|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
79738678|NCT04215172|Drug|Macrolides|administration of azithromycin three times weekly for six months
79579531|NCT01906580|Drug|Entecavir|0.5mg,oral administration every day
79579532|NCT01906606|Behavioral|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
79738679|NCT02700490|Behavioral|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
79738680|NCT04260399|Other|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
79403763|NCT02658084|Drug|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
79403764|NCT03588871|Other|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
79579533|NCT01906632|Biological|DC-CIK Immunotherapy|
79579534|NCT01906645|Other|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
79579535|NCT01906671|Drug|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
79579536|NCT01906671|Drug|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
79579537|NCT01906684|Drug|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
79579538|NCT01906697|Procedure|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
79579539|NCT01906697|Procedure|middle turbinate resection|middle turbinate resection
79579540|NCT01906697|Procedure|middle turbinate medialization|middle turbinate medialization
79579541|NCT01906710|Other|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
79579542|NCT01906723|Device|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
79738681|NCT04260399|Other|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
79738682|NCT02705638|Drug|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
79738683|NCT02705638|Drug|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
79738684|NCT04877223|Other|No intervention|No intervention
79738685|NCT02705170|Procedure|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
79738686|NCT04260009|Drug|Brigatinib|Brigatinib tablets
80030704|NCT05565495|Drug|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
79275918|NCT05571111|Drug|Novarel|Subcutaneous injection as a single dose. 10,000 IU (1 mL)
79403765|NCT03588871|Other|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
79403766|NCT03588871|Other|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
79403767|NCT03588871|Other|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
79403768|NCT03588871|Other|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
79403769|NCT03588871|Other|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
79403770|NCT04548882|Device|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
79403771|NCT04140643|Device|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
79403772|NCT04140643|Behavioral|Oral hygiene instructions|Oral Hygiene instructions
79403773|NCT03021655|Behavioral|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
79403774|NCT03021655|Behavioral|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
79403775|NCT03021655|Behavioral|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
79403776|NCT03588793|Other|Two Point Discrimination|Validity of mechanism in phantom limb pain i.e. cortical reorganisation to be tested using comparison of data from interventions above
79403777|NCT03345186|Other|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
79403778|NCT03588715|Drug|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
79579543|NCT01906749|Drug|Colchicine|0.5mg once daily orally
79579544|NCT01906749|Drug|Placebo|
79579545|NCT01906762|Drug|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
79738687|NCT04260009|Drug|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
79738688|NCT02705092|Other|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
79738689|NCT02705092|Other|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
79738690|NCT04257825|Device|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
79738691|NCT02700256|Behavioral|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
79579546|NCT01906762|Drug|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
79738692|NCT02692066|Biological|varicella vaccine|
79738693|NCT02691910|Drug|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
79738694|NCT02691910|Drug|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
79738695|NCT04215250|Other|andropulous method|Counts the CVC depth using specific equation
79738696|NCT04215250|Device|ECG|Using ECG to monitor the insertion of the CVC
79738697|NCT02705326|Device|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
79873948|NCT02538185|Drug|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
79873949|NCT00908297|Dietary Supplement|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~300 mg for two weeks~600 mg for two weeks~1200 mg for two weeks~1800 mg for final two weeks"
79873950|NCT00927329|Biological|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
79873951|NCT00931541|Drug|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
79873952|NCT00931541|Drug|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
79275919|NCT02404623|Dietary Supplement|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
79275920|NCT00618319|Drug|BIIB021|Dose, schedule, and duration specified in protocol
79275921|NCT02170571|Drug|Dabigatran etexilate|
79275922|NCT05570799|Other|Augmented Reality and Kahoot game learning|"An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password."
79275923|NCT00618007|Drug|PF-00734200 30 mg QD|30 mg QD
79275924|NCT00618007|Drug|PF-00734200 20 mg QD|20 mg QD
79738698|NCT02700802|Other|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
79738699|NCT02705014|Drug|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
79275925|NCT00618007|Drug|Placebo|Placebo
79738700|NCT02700178|Other|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
79873953|NCT00927407|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
79275926|NCT02256059|Procedure|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
79275927|NCT02388399|Procedure|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex> cap thickness, spotty calcification)
79275928|NCT02388399|Procedure|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
79403779|NCT03588715|Drug|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
79738701|NCT02704624|Dietary Supplement|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
79738702|NCT02704624|Other|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
79738703|NCT02701114|Procedure|Proximal Adductor Canal Block|Continuous Nerve Block
79738704|NCT02701114|Procedure|Distal Adductor Canal Block|Continuous Nerve Block
79873954|NCT00927407|Drug|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
79873955|NCT00339040|Biological|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
79873956|NCT00339040|Other|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
79275929|NCT02173847|Procedure|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
79275930|NCT02173847|Device|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
79275931|NCT02173847|Device|Diode laser|Low power, near infrared diode laser for welding the surgical wound
79275932|NCT04481841|Drug|oryzanol + vitamin B2 (riboflavin) + vitamin E|"1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
79275933|NCT00493441|Drug|AVN944|150, 200, 250, 300, or 400 mg q12h
79275934|NCT02388477|Drug|Doxycycline|antibiotic used to treat infection
79275935|NCT02388477|Drug|sugar pill|placebo with no pharmacologic effect
79873957|NCT03743519|Dietary Supplement|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
79873958|NCT03743519|Dietary Supplement|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
79275936|NCT02166359|Drug|Extraneal (Icodextrin)|
79275937|NCT02166359|Drug|Glucose solution|
79275938|NCT00488839|Drug|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
79275939|NCT00488839|Drug|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
79275940|NCT00488839|Drug|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
79275941|NCT00488839|Drug|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
79275942|NCT00488839|Drug|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
79275943|NCT00488839|Drug|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
79275944|NCT00488839|Drug|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
79275945|NCT00488839|Drug|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
79275946|NCT00488839|Drug|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
79403780|NCT03588559|Diagnostic Test|Blood Pressure Measurement|Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
79403781|NCT04528758|Drug|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
79873959|NCT04015193|Procedure|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
79873960|NCT00931697|Drug|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
79873961|NCT00931697|Drug|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
79738705|NCT02700100|Device|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect (VSD)~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
79275947|NCT03539315|Behavioral|ARCHES|Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
79873962|NCT00931697|Drug|Placebo|Over-encapsulated placebo to maintain blinding
79873963|NCT00927797|Drug|Cyclophosphamide, Pentostatin, Rituximab|
79275948|NCT04479501|Other|Asthma exacerbation related hospitalization|Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
79275949|NCT03115671|Dietary Supplement|Vayarin|Vayarin capsule
79275950|NCT02255747|Drug|Lactulose|
79275951|NCT01654731|Drug|Bezafibrate|
79873964|NCT00338962|Drug|paroxetine|paroxetine (40mg/day)
79275952|NCT01654731|Drug|placebo|
79275953|NCT00485563|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
79275954|NCT00485563|Biological|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
79579547|NCT01906775|Other|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
79873965|NCT00338962|Drug|desipramine|200 mg per day
79873966|NCT00338962|Drug|Naltrexone|50 mg per day
79275955|NCT00485563|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
79275956|NCT00485563|Drug|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
79275957|NCT00485563|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
79275958|NCT02174705|Drug|Sucrose|Sucrose 24% orally prior to vaccine injections
79403782|NCT04140409|Drug|Sandostatin|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
79403783|NCT04452474|Drug|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL
79403784|NCT04452474|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
79873967|NCT00338962|Drug|Placebo|placebo
79873968|NCT00931775|Drug|Pindolol|Pill orally administered. 15 mg/day t.i.d.
79403785|NCT04527510|Diagnostic Test|Conventional-reading|Two radiologists interpret at least three views of each breast without AI independently.
79579548|NCT01906788|Drug|Artemether Lumefantrine|
79579549|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
79579550|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
79873969|NCT00927875|Drug|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
79403786|NCT04527510|Diagnostic Test|Second-reading|One radiologist reads AB US images without AI first, then combines the indications of AI marks to make the final decision.
79579551|NCT01906801|Drug|Glucosamine sulfate|
79873970|NCT00927875|Drug|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
79579552|NCT01906801|Drug|Diacerein|
79579553|NCT01906801|Drug|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
79579554|NCT01906840|Drug|Turmeric|
79579555|NCT01906840|Drug|placebo|
79873971|NCT00927875|Drug|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, & 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
79873972|NCT00924599|Behavioral|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
79873973|NCT00924599|Behavioral|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
79873974|NCT00924677|Procedure|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
79738706|NCT04213846|Behavioral|Experimental: Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
79738707|NCT02700022|Drug|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
79738708|NCT02699944|Device|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
79579556|NCT01906879|Drug|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
79275959|NCT02174705|Drug|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
79275960|NCT02255825|Genetic|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
79275961|NCT02255825|Procedure|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
79275962|NCT02255825|Other|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
79275963|NCT03134287|Procedure|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
79579557|NCT01906892|Other|Group drumming (participatory)|Active participation in group drumming workshops
79579558|NCT01906892|Other|Group drumming (live)|Listening to live performances of group drumming
79275964|NCT02388243|Behavioral|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
79275965|NCT02388243|Behavioral|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
79579559|NCT01906892|Other|Group drumming (recorded)|Listening to recorded performances of group drumming
79579560|NCT01906892|Other|Comparative activity|Taking part in a literary-based activity
79738709|NCT02699788|Device|Multifunction Cardiogram|
79738710|NCT02699710|Drug|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
79738711|NCT02699710|Drug|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
79738712|NCT02699710|Drug|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
79873975|NCT00924677|Procedure|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
79579561|NCT01906918|Procedure|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
79579562|NCT01906931|Device|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
79579563|NCT01906931|Device|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
79579564|NCT01906944|Drug|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
79579565|NCT01906944|Drug|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
79579566|NCT01906983|Other|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
79579567|NCT01906996|Procedure|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
79579568|NCT01906996|Procedure|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
79579569|NCT01907022|Device|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
79873976|NCT00568061|Drug|Nitric Oxide|Nitric oxide for inhalation
79579570|NCT01907035|Behavioral|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
80030705|NCT05561400|Device|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
79579571|NCT01907035|Other|Usual care|
80030706|NCT05561400|Other|Placebo|sham tDCS to the right cerebellum
80030707|NCT05557825|Radiation|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
80030708|NCT05547503|Drug|AFA-281|Part 1: AFA-281 will be administered as a single dose at 5 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 days at 3 dose levels (TBD)
79275966|NCT02388243|Behavioral|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
79579572|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
79579573|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
79304674|NCT04978155|Diagnostic Test|Duplex ultrasound performed by the surgeon after locoregional anesthesia|Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
79403787|NCT04527510|Diagnostic Test|Concurrent-reading|One radiologist identifies CAD marks first, then quickly browses the entire AB US examination to make the final decision.
79403788|NCT04527510|Diagnostic Test|Tow views-reading|Two radiologists interpret only two views of each breast without AI independently.
79403789|NCT04527510|Diagnostic Test|Handheld US-screening|One radiologist screens the breast cancer using Handheld US and interprets images immediately.
79403790|NCT03588403|Radiation|TOMO|Tomotherapy
79403791|NCT03588403|Radiation|IMRT|Intensity modulated radiotherapy
79403792|NCT05580835|Diagnostic Test|PET MRI with PSMA|A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent
79403793|NCT04436718|Diagnostic Test|Daily pocus exam|Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
79579574|NCT01907061|Drug|N-acetylcysteine|drug will be administered via IV,NG
79579575|NCT01907061|Drug|Placebo|placebo or NAC will be given
79579576|NCT01907126|Behavioral|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
79579577|NCT01907126|Behavioral|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
79579578|NCT01907139|Behavioral|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
79738713|NCT02699710|Drug|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
79738714|NCT00618670|Behavioral|Walking Exercise|Three times per week for 3 months
79738715|NCT00618670|Behavioral|Control--Resistance Training|Three times per week for 3 months
79738716|NCT04212520|Other|No intervention|No intervention
79873977|NCT00568061|Drug|Placebo|Nitrogen gas (placebo) for inhalation
79873978|NCT00931853|Drug|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
79873979|NCT00931931|Biological|HSV1716|
79873980|NCT03547427|Other|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
80030709|NCT05542394|Dietary Supplement|Curcumin|"water soluble version of turmeric extract standardized to 10% curcuminoids~."
80030710|NCT05539742|Dietary Supplement|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
80030711|NCT05539742|Dietary Supplement|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
80030712|NCT05531734|Device|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
80030713|NCT05531734|Behavioral|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
79403794|NCT04879290|Other|FiO2 0.5|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 0.5 (50%)
79275967|NCT02388243|Behavioral|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
79738717|NCT05119348|Other|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
79738718|NCT00618904|Dietary Supplement|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
79403795|NCT04879290|Other|FiO2 1|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 1 (100%)
79403796|NCT03912805|Biological|botulinum toxin, Type A|topical liniment
79403797|NCT03912805|Biological|Vehicle|Vehicle Formulation
79403798|NCT03909685|Behavioral|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
79403799|NCT04642950|Drug|Sargramostim|250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.
79403800|NCT04642950|Drug|Placebo|2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
79403801|NCT03588325|Diagnostic Test|CBC-DIFF with MDW, PCT, CRP|Tests will be run to determine early identification of sepsis and added value of the combination of tests. Results will not be used to manage patients
79403802|NCT05110092|Behavioral|leg resistance combined with breathing exercise training|The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
79403803|NCT05109936|Drug|Adenuric|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
79403804|NCT04472208|Device|Ambulatory monitoring solution|Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
79403805|NCT04522440|Other|to relieve the pain of inpatients in the hospice Ward|This study will use pain scale, distress thermometer and POMS to understand whether the patient's pain status have changed.
79738719|NCT00618904|Dietary Supplement|Placebo|Placebo administered bid for 6 weeks.
79403806|NCT04427982|Behavioral|dance|Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.
79403807|NCT04427982|Behavioral|diabetes education|The dance classes will be followed by a brief diabetes education and discussion session.
79403808|NCT04374240|Genetic|AdNRGM|"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide]"
79403809|NCT05109468|Other|Quality of life questionnaire|to assess the quality of sexual life of patients treated for anal cancer treated with radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after cancer diagnosis.
79403810|NCT05109390|Drug|Danicopan|Oral tablet.
79403811|NCT05109390|Drug|Cyclosporine|Oral capsule.
79403812|NCT05109390|Drug|Tacrolimus|Oral capsule.
79403813|NCT05109390|Drug|Calcium Carbonate|Chewable tablet.
79403814|NCT05109390|Drug|Aluminum/Magnesium Hydroxide/Simethicone|Chewable tablet.
79403815|NCT05109390|Drug|Omeprazole|Oral, delayed-release capsule.
79738720|NCT05324722|Other|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
79738721|NCT05324722|Other|cross body stretch|crossbody stretch performed by an individual
79738722|NCT05324644|Behavioral|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
79738723|NCT04214704|Device|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
79403816|NCT04783974|Device|Dental implants|Treatment of total or partial edentulism through the placement of osseointegrated dental implants
79403817|NCT04030182|Diagnostic Test|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
79403818|NCT04782414|Procedure|Hot AXIOS® prosthesis|endoscopic trans digestive drainage using of the Hot AXIOS prosthesis in the treatment of pancreatic collections (incompletely fluid or necrotic)
79738724|NCT04214704|Device|Conventional lancing device|Conventional lancing device
79579579|NCT01907139|Behavioral|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
79579580|NCT01907139|Behavioral|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
79738725|NCT03140488|Drug|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
79738726|NCT00616408|Drug|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
79738727|NCT03093610|Procedure|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
79738728|NCT03093610|Procedure|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
79738729|NCT05323942|Other|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
79738730|NCT03088150|Procedure|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
79738731|NCT03088150|Procedure|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
79738732|NCT02691754|Other|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
79738733|NCT02691676|Drug|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
79738734|NCT02691676|Drug|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
79738735|NCT00616486|Device|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
79275968|NCT02275741|Biological|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
79738736|NCT00616486|Device|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
79738737|NCT05321602|Drug|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
79738738|NCT05321602|Drug|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
79738739|NCT05321602|Drug|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
79579581|NCT01907152|Other|Protein enriched yoghurt drink and bread|
79275969|NCT02170805|Drug|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
79403819|NCT05109000|Drug|Sodium Chloride 0.9% Inj|10 mL subcutaneous injection into one randomized anterior thigh of subject
79403820|NCT05109000|Drug|Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)|10 mL subcutaneous injection into the contralateral anterior thigh of subject
79579582|NCT01907165|Drug|Temozolomide|
79579583|NCT01907165|Drug|Disulfiram|
79579584|NCT01907165|Dietary Supplement|Copper gluconate|
79579585|NCT01907204|Drug|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
79579586|NCT01907204|Drug|Budesonide|Budesonide by metered dose inhaler
79579587|NCT01907204|Drug|Budesonide|Budesonide by nebulization
79275970|NCT02170805|Drug|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
79275971|NCT02170805|Drug|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
79275972|NCT02170805|Drug|Pantoprazole|Pantoprazole 40 mg
79275973|NCT00606697|Drug|GR205171|10 milligrams (mg)
79275974|NCT00606697|Drug|GW597599|15 mg
79304675|NCT03270449|Other|Multidisciplinary intervention|10 week multidisciplinary education and exercise
79738740|NCT05321602|Drug|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
79738741|NCT05318872|Device|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
79738742|NCT01106651|Drug|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
79738743|NCT01106651|Drug|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
79738744|NCT01106651|Drug|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.
79579588|NCT01907230|Drug|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
79738745|NCT01106651|Drug|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
79738746|NCT00637078|Other|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
79579589|NCT01907243|Procedure|spreader flap|producing of upper lateral cartilage flap as a spreader flap
79579590|NCT01907256|Procedure|inverted V incision|It is a type of incision
79579591|NCT01907256|Procedure|stair step incisions|It is a type of incision
79738747|NCT05323162|Other|encapsulated autologous fecal microbiota transplantation|Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
79738748|NCT05323006|Other|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
79738749|NCT04214470|Other|No intervention|There is no intervention for this study
79738750|NCT00616564|Drug|GM-CSF|Concomitant Priming with GM-CSF
79738751|NCT04214314|Behavioral|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
79873981|NCT03547427|Other|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at ~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
79873982|NCT03547427|Other|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
79579592|NCT01907282|Behavioral|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
79579593|NCT01907282|Behavioral|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
79579594|NCT01907308|Drug|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
79873983|NCT03547427|Other|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
79873984|NCT03547427|Other|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
79275975|NCT05560893|Behavioral|Relational Savoring Intervention|Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
79403821|NCT05108610|Other|Shi-style manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
79403822|NCT05108610|Other|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
79579595|NCT01907308|Drug|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
79579596|NCT01907373|Drug|olmesartan medoxomil|
79579597|NCT01907373|Drug|olmesartan medoxomil+probenecid|
79738752|NCT05003609|Other|Early Rehabilitation|The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
79738753|NCT00625781|Drug|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
79738754|NCT02867644|Other|standard care|Patients coming for preoperative breast assessment will have standard care.
80030714|NCT05522023|Procedure|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
80030715|NCT05522023|Procedure|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
80030716|NCT05519579|Drug|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
80030717|NCT05519579|Drug|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
80030718|NCT05485142|Procedure|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
79275976|NCT02174003|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
79275977|NCT00605449|Drug|GSK376501|
79275978|NCT00604123|Drug|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
79579598|NCT01907386|Other|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
79403823|NCT03876990|Diagnostic Test|Multiplex PCR|Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
79579599|NCT01907399|Other|Blood samples|
79579600|NCT01907464|Other|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
79579601|NCT01907464|Other|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
79579602|NCT01907464|Other|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
79579603|NCT01907464|Other|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
79579604|NCT01907477|Other|Samples taken at the clinical hematology unit|
79579605|NCT01907503|Procedure|Evaluation of the balance of force platform|
79579606|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
79579607|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
79738755|NCT02867644|Other|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
79738756|NCT02880449|Behavioral|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
80030719|NCT05470608|Drug|SL-1002|SL-1002 injectable solution
80030720|NCT05470608|Drug|Placebo|Matching placebo injectable solution
79275979|NCT00604123|Drug|Placebo|Placebo nasal spray twice daily for 2 weeks.
79275980|NCT02404077|Drug|Clonidine|
79275981|NCT02174783|Other|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
79738757|NCT01027650|Drug|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
79738758|NCT01027650|Drug|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
79873985|NCT03547427|Other|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
79873986|NCT00932087|Procedure|Blood sample|Blood sample for lipidomic study
79873987|NCT00928109|Behavioral|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
79873988|NCT00928109|Behavioral|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
79873989|NCT00928265|Device|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
79738759|NCT02880527|Other|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
79738760|NCT05322772|Device|ECG|ii. 12 leads ECG: 12 leads ECG will be done to all infants & children using (FUKUDA DENSHI, CARDIMAX, model FCP 7101). The electrocardiograms will be reviewed through the creation of descriptive reports and determination of the following variables: heart rate, QRS duration, The QT interval was measured from the onset of the QRS complex to the end of the T wave, defined by the return of the terminal T wave to the isoelectric T-P baseline. When U waves were present, the end of the T wave will be taken as the nadir between the T and U waves. Then QT interval will be corrected for heart rate using Bazett's formula Interpretation of every ECG paper
79873990|NCT00928343|Drug|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
79275982|NCT02174783|Other|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
79275983|NCT02174783|Other|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
79403824|NCT03876990|Diagnostic Test|Current strategy alone|Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
79579608|NCT01907542|Procedure|stapled skin closure|as above
79579609|NCT01907542|Procedure|monocryl skin suture|as above
79579610|NCT01907581|Other|Quality of life questionnaires|
79403825|NCT03799380|Dietary Supplement|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
79403826|NCT03799380|Dietary Supplement|Standard of care nutritional support|Standard of care nutritional support
79579611|NCT01907594|Drug|D-cycloserine|
79579612|NCT01907594|Drug|Nicotine Replacement Therapy (patch)|
79579613|NCT01907594|Behavioral|Smoking Cue Exposure|
79579614|NCT01907594|Behavioral|Progressive Muscle Relaxation|
79579615|NCT01907594|Drug|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
79403827|NCT03952494|Genetic|Genomind®Professional PGx Express TM|The current test includes the analysis of fifteen pharmacodynamic genes and nine pharmacokinetic genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, Posttraumatic Stress Disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
79403828|NCT05098314|Other|Personalized interventions regarding the Cicat-Occitanie network|"First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature."
79579616|NCT01907620|Other|blood sample|
79579617|NCT01907633|Drug|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
79579618|NCT01907646|Device|bladder training|vescical catheter
79873991|NCT00928343|Drug|Placebo|Matching subcutaneous or oral placebo
79579619|NCT01907646|Procedure|No bladder training|
79873992|NCT00338884|Drug|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
79579620|NCT01907659|Other|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
79579621|NCT01907672|Procedure|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
79579622|NCT01907685|Drug|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
79579623|NCT01907685|Drug|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
79579624|NCT01907698|Behavioral|Vaginal intercourse|vaginal intercourse at least twice a week
79873993|NCT00338806|Behavioral|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
79873994|NCT00338806|Behavioral|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
79579625|NCT01907711|Device|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
79579626|NCT01907724|Drug|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
79579627|NCT01907724|Drug|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
79275984|NCT04744311|Other|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
79738761|NCT05000567|Other|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
79738762|NCT04214548|Other|No Intervention|There is no intervention for this study
79738763|NCT04309331|Dietary Supplement|Motion|Amino acid based protein substitute
79738764|NCT00616876|Drug|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
79275985|NCT02174939|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
79275986|NCT02174939|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
79579628|NCT01907724|Drug|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
79579629|NCT01907724|Drug|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
79579630|NCT01907750|Device|biliary drainage tube|
79579631|NCT01907763|Drug|SOTB07 200mg|
79579632|NCT01907763|Drug|SOTB07 400mg|
79275987|NCT02404233|Drug|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
79403829|NCT03680196|Drug|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
79403830|NCT05094960|Diagnostic Test|Blood samples|5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine
79403831|NCT04814472|Drug|BLD-0409|Randomized to active product.
79579633|NCT01907763|Drug|SOTB 200mg placebo|Placebo of SOTB07 200mg
79738765|NCT00616876|Dietary Supplement|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
79738766|NCT01106027|Drug|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
79738767|NCT00616954|Drug|ATG-F|ATG-f
79403832|NCT03661632|Drug|BMS-986310|Specified dose on specified days
79403833|NCT03661632|Biological|Nivolumab|Specified dose on specified days
79579634|NCT01907763|Drug|SOTB 400mg placebo|Placebo of SOTB07 400mg
79873995|NCT03038100|Drug|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle
79738768|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738769|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738770|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738771|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738772|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738773|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79275988|NCT02404233|Drug|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
79275989|NCT00603577|Drug|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
79275990|NCT00603577|Drug|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
79275991|NCT02178215|Other|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
79275992|NCT02178215|Other|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
79275993|NCT02388087|Device|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
79403834|NCT04748250|Device|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
79579635|NCT01907776|Drug|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
79579636|NCT01907776|Drug|ME1100 placebo inhalation solution|Vehicle placebo
79579637|NCT01907802|Drug|Dabrafenib|Given PO
79579638|NCT01907802|Other|Laboratory Biomarker Analysis|Correlative studies
79579639|NCT01907802|Other|Pharmacogenomic Study|Correlative studies
79579640|NCT01907802|Other|Pharmacological Study|Correlative studies
79579641|NCT01907841|Other|Ischemic Preconditioning|
79579642|NCT01907867|Drug|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
79579643|NCT01907880|Drug|Pamidronate|90mg IV once every 4 weeks for 3 cycles
79579644|NCT01907880|Drug|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
79579645|NCT01907880|Drug|placebo|
79579646|NCT01907893|Behavioral|Trauma Collaborative Care Plus Treatment as Usual|
79873996|NCT03038100|Drug|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles
79275994|NCT02388087|Procedure|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
79738774|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738775|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
79738776|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
79403835|NCT04748250|Dietary Supplement|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
79403836|NCT04726878|Procedure|Erector spinae plane block|Ultrasound-guided the erector spinae plane block with 0.375% ropivacaine, 0.4 mL per KG, up to 40 mL (maximum dose).
79403837|NCT04726878|Procedure|Sham block|Ultrasound-guided the erector spinae plane block with 0.9% saline, 0.4 mL per KG, up to 40 mL (maximum dose).
79275995|NCT02178293|Drug|Benzidamine hydrochloride|
79403838|NCT04726878|Procedure|General anesthesia|"Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl."
79579647|NCT01907932|Device|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
79579648|NCT01907945|Behavioral|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
79579649|NCT01907945|Behavioral|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
79579650|NCT01907984|Drug|Diclofenac|
79738777|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
79738778|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
79738779|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
79738780|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
79738781|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
79738782|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
79403839|NCT04726878|Procedure|Patient-controlled analgesia|All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
79403840|NCT04726878|Drug|Oxycodone|Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
79275996|NCT02178293|Drug|Ketoprofen lysine salt|
79275997|NCT03170895|Drug|Sorafenib|Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
79403841|NCT04726878|Drug|paracetamol|intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
79403842|NCT04525638|Drug|177Lu-Dotatate|7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
79403843|NCT04525638|Drug|Nivolumab|240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
79403844|NCT04164342|Other|surveys|Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
79403845|NCT04701216|Drug|SHR8735|SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
79403846|NCT04663230|Diagnostic Test|cardiac magnetic resonance imaging|right atrial late gadolinium enhancement in % and cm2
79403847|NCT04706364|Behavioral|Neuropsychological Testing|Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
79579651|NCT01907984|Drug|Midazolam|
79579652|NCT01907997|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
79579653|NCT01907997|Drug|normal saline infusion|In group C, the patients receive same volume of normal saline
79275998|NCT03170895|Drug|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
79579654|NCT01908010|Drug|ABT-354|ABT-354 Low Dose
79579655|NCT01908010|Drug|ABT-354|ABT-354 High Dose
79579656|NCT01908010|Drug|Placebo|Placebo
79738783|NCT04257513|Diagnostic Test|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
79738784|NCT01027416|Drug|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
79738785|NCT04259931|Diagnostic Test|microbiome analysis|gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
79738786|NCT04300842|Device|smart bracelet|to measure the stress, fatigue, and activity.
79873997|NCT03038100|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
79738787|NCT05331495|Device|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
79738788|NCT02873520|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
79275999|NCT02277847|Drug|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
79276000|NCT02277847|Drug|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
79579657|NCT01908023|Behavioral|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
79276001|NCT02174237|Drug|LNP1892|Tablets of two strengths (5 and 25 mg)
79276002|NCT02174237|Drug|Placebo|Matching placebo
79276003|NCT03171207|Device|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
79403848|NCT04706364|Genetic|(Optional) Saliva Collection|"The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes.~Genetic testing is funded by Boston Children's Hospital."
79579658|NCT01908049|Dietary Supplement|Probiotic.|
79579659|NCT01908049|Dietary Supplement|Placebo|
79738789|NCT02873520|Biological|Precision Cell Immunotherapy|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
79738790|NCT05026203|Drug|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
79738791|NCT05026203|Drug|Midazolam|Midazolam
79738792|NCT00923559|Other|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
79873998|NCT03038100|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
79873999|NCT03038100|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
79874000|NCT00338728|Drug|Imatinib Mesylate|Given PO
79276004|NCT03171207|Device|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
79276005|NCT04471753|Behavioral|Coma Recovery Scale-Revised|Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
79276006|NCT02178371|Procedure|mCIMT|affected upper limb use with constraint of the healthy hand
79276007|NCT02178371|Procedure|Unimanual therapy without constraint UTWC|affected upper limb use without constraint of healthy hand
79276008|NCT01457781|Combination Product|Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 1: 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
79403849|NCT04706364|Device|Sensory Testing|"Three different tests will be completed:~the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold).~Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist).~The second sensory visit will be another version of the PPI testing involving hearing and sound."
79403850|NCT04706364|Device|Electroencephalogram (EEG)|A cap will be placed on the participants head that will be filled with electrodes (small discs). The EEG will allow investigators to measure how the brain reacts to the sensory testing.
79874001|NCT00338728|Drug|Letrozole|Given PO
79403851|NCT04706364|Device|Transcranial Magnetic Stimulation|"Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex.~There will be two - four identical TMS testing visits."
79403852|NCT01482962|Drug|Alisertib|Alisertib enteric coated tablets
79403853|NCT01482962|Drug|Pralatrexate|Pralatrexate IV infusion
79403854|NCT01482962|Drug|Gemcitabine|Gemcitabine IV infusion
79403855|NCT01482962|Drug|Romidepsin|Romidepsin IV infusion
79579660|NCT01908075|Drug|FP/SAL|
79579661|NCT01908075|Drug|BDP/FOR|
79579662|NCT01908088|Biological|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
79579663|NCT01908114|Behavioral|Enhanced Community mobilization|
79579664|NCT01908114|Biological|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
79579665|NCT01908166|Procedure|ultrasound elasticity imaging|Undergo ultrasound elastography
79276009|NCT01457781|Combination Product|Placebo delivered via INOpulse DS Device|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%) delivered via INOpulse DS Device and INOpulse DS nasal cannula
79276010|NCT01457781|Combination Product|Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L [4880 ppm] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
79738793|NCT00923559|Other|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
79276011|NCT00664573|Biological|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
80030721|NCT05470517|Drug|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
79579666|NCT01908192|Drug|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
79579667|NCT01908192|Drug|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
79579668|NCT01908244|Other|Music|Pentatonic music
79738794|NCT01015638|Drug|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
79738795|NCT01015638|Drug|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
79738796|NCT04257591|Other|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
79738797|NCT01022502|Drug|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
79738798|NCT01022502|Drug|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
79874002|NCT01059136|Drug|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
79874003|NCT01061242|Behavioral|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
79874004|NCT03985618|Procedure|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
79579669|NCT01908257|Drug|lesinurad 400 mg|
80030722|NCT05470517|Procedure|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
80030723|NCT05465122|Procedure|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arterotomy followed by removal of plaque and reconstruction of the vessel.
79276012|NCT03537677|Behavioral|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
79276013|NCT02281435|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
79403856|NCT04701060|Drug|Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
79403857|NCT05116098|Combination Product|zinc 50 mg + Epigallocatechin gallate|ZINC 50 MG and EGCG 200mg oral daily for 1 month
79403858|NCT04464408|Drug|Favipiravir|1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
79403859|NCT04464408|Drug|Placebo|(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
79403860|NCT04587570|Procedure|Infiltration with PRP|Infiltration with 1.5 ml PRP
79579670|NCT01908257|Drug|ranitidine 150 mg|
79579671|NCT01908257|Drug|lesinurad 400 mg + ranitidine 150 mg|
79579672|NCT01908270|Behavioral|Yoga|
79579673|NCT01908270|Other|Usual care|
79403861|NCT04587570|Procedure|Infiltration with Fat|Infiltration with 1.5 ml Fat
79403862|NCT04587570|Procedure|Infiltration with PRP and Fat|Infiltration with 0.75 ml PRP and 0.75 ml Fat
79403863|NCT04587570|Procedure|Infiltration with NaCl|Infiltration with 1.5 ml NaCl
79403864|NCT04585620|Drug|Onabotulinum Toxin A|Series of subcutaneous injections
79403865|NCT04585620|Drug|Normal saline|Series of subcutaneous injections
79579674|NCT01908283|Biological|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
79579675|NCT01908296|Drug|FK949E|Oral
79579676|NCT01908296|Drug|fluvoxamine|Oral
79579677|NCT01908309|Drug|Iobitridol 350|
79579678|NCT01908309|Drug|Iodixanol 320|
79276014|NCT02174393|Drug|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
79276015|NCT02174393|Procedure|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
79738799|NCT04907877|Dietary Supplement|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
79579679|NCT01908322|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
79579680|NCT01908335|Drug|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
79579681|NCT01908335|Drug|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
79276016|NCT02174393|Drug|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~Gentle Antioxidant Soothing Cleanser daily~Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~AM: Physical sheer sunscreen and recovery ointment~PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~AM: BD Hydrating Day/Night Cream~PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
79579682|NCT01908335|Drug|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
79738800|NCT04907877|Dietary Supplement|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
79738801|NCT02872506|Drug|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
79579683|NCT01908335|Drug|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
79276017|NCT02174393|Drug|Post-Universal Peel Skin Care|"Gentle Antioxidant Soothing Cleanser daily~Physical Sunscreen daily~Soothing recovery ointment fortified with silver only when peeling occurs~After completely peeling, vitamin c product in the morning and the retinol in the evening"
79276018|NCT00468403|Biological|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
79403866|NCT04581096|Other|no intervention|just descriptive analysis of clinical data
79579684|NCT01908348|Dietary Supplement|Erythritol|
79579685|NCT01908361|Behavioral|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
79579686|NCT01908361|Behavioral|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
79579687|NCT01908361|Behavioral|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
79738802|NCT02872506|Procedure|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
79738803|NCT05331417|Diagnostic Test|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
79738804|NCT00627744|Drug|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
79579688|NCT01908374|Dietary Supplement|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
79579689|NCT01908387|Drug|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
80030724|NCT05465122|Procedure|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arterotomy followed by removal of plaque and reconstruction of the vessel.
79738805|NCT01105091|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
79738806|NCT01105091|Drug|Flolan®|Per Prescribing Information
79738807|NCT04257435|Behavioral|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, & Parks, 2006; Rashid, 2015).
79738808|NCT04257435|Behavioral|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
79738809|NCT04253301|Device|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
80030725|NCT05465122|Other|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
80030726|NCT05460494|Behavioral|RELOAD-C|RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
80030727|NCT05449119|Biological|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
80030728|NCT05449119|Other|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
79579690|NCT01908400|Biological|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
79874005|NCT03985618|Procedure|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
79874006|NCT03983278|Other|School Model|Free delivery of glasses at the school within two weeks after screening
80030729|NCT05449119|Other|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
80030730|NCT05449119|Other|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
80030731|NCT05449119|Other|Measurement of muscle mass by bioelectrical impedance analysis|at T0, T3 months, T6 months, T9 months and T12 months
80030732|NCT05449119|Other|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
80030733|NCT05449119|Other|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
79403867|NCT05115708|Procedure|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group
79579691|NCT01908413|Drug|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
79738810|NCT00628056|Drug|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
79738811|NCT00924729|Drug|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
79874007|NCT03983278|Other|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
79874008|NCT03983278|Other|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
80030734|NCT05448144|Other|Collect stool and blood samples from patients|Collect stool and blood samples from patients
80030735|NCT05428566|Dietary Supplement|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
79579692|NCT01908439|Other|whole-body vibration|High amplitude whole-body vibration
79579693|NCT01908452|Drug|Pyridoxine|1200 mg/d during 12 weeks
79579694|NCT01908478|Drug|Veliparib|
79579695|NCT01908478|Drug|Gemcitabine|
79579696|NCT01908478|Radiation|Intensity modulated radiation therapy|
79738812|NCT00924729|Drug|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
79738813|NCT01099709|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
79738814|NCT01099709|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
79874009|NCT00336856|Drug|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
80030736|NCT05428566|Dietary Supplement|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
80030737|NCT05427799|Dietary Supplement|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
80030738|NCT05427799|Dietary Supplement|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
80030739|NCT05419635|Drug|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
79579697|NCT01908491|Device|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
79579698|NCT01908491|Device|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
79579699|NCT01908504|Other|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
80030740|NCT05402384|Drug|AVTX-801|Medical grade D-galactose
79579700|NCT01908517|Behavioral|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
79579701|NCT01908556|Drug|Letrozole|
79579702|NCT01908569|Other|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
79738815|NCT04257357|Behavioral|8-weeks supervised exercise program|Please refer to group description
80030741|NCT05402384|Drug|Placebo|Placebo
80030742|NCT05394506|Procedure|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
80030743|NCT05394506|Procedure|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
80030744|NCT05393219|Other|Cardiac biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit
80030745|NCT05393219|Other|Mindfulness|6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.
80030746|NCT05393219|Other|Resources mobilization|6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.
79403868|NCT05115708|Procedure|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
79738816|NCT04257357|Behavioral|Active control|Please refer to group description
79738817|NCT01099397|Other|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
80030747|NCT05393219|Other|Control|6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
80030748|NCT05390515|Drug|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
80030749|NCT05387980|Drug|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
79738818|NCT04907019|Drug|rifampicin，SY-004|"On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22."
79738819|NCT01022424|Drug|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
79874010|NCT00336856|Drug|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
79276019|NCT00468403|Biological|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
79403869|NCT04339218|Device|Cryoablation|"Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly."
79579703|NCT01908569|Other|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
79403870|NCT04339218|Drug|Pembrolizumab|Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
79403871|NCT04339218|Drug|Pemetrexed|Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
79579704|NCT01908621|Drug|G-CSF (filgrastim)|
79579705|NCT01908621|Drug|Cytosine arabinoside + G-CSF (filgrastim)|
79579706|NCT01908647|Behavioral|RT fMRI|Real-time fMRI with neurofeedback.
79579707|NCT01908647|Behavioral|Cognitive Training|Computer based attention training.
79579708|NCT01908647|Behavioral|Control RT fMRI|Control condition for real-time fMRI.
79579709|NCT01908647|Behavioral|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
79579710|NCT01908660|Drug|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
79579711|NCT01908673|Behavioral|HRV biofeedback|
79579712|NCT01908673|Behavioral|ASTM|
79579713|NCT01908686|Behavioral|Pivotal Response Training|Behavioral intervention for autism
79738820|NCT05329857|Drug|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
79738821|NCT01026948|Drug|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
79738822|NCT01026948|Device|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
79738823|NCT04951089|Device|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
79738824|NCT04951089|Device|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
79874011|NCT02532868|Drug|MK-0457|
79579714|NCT01908764|Drug|AL-60371 otic suspension|
79874012|NCT01059370|Procedure|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
79874013|NCT00566501|Drug|Donepezil|Donepezil SR 23 mg once daily orally.
79874014|NCT00504894|Drug|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
79403872|NCT04339218|Drug|Carboplatin|Carboplatin will be prescribed and administered at the dose recommended by market authorization.
79579715|NCT01908790|Device|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
79579716|NCT01908790|Device|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
79738825|NCT05033652|Other|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
79579717|NCT01908855|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
79738826|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
79874015|NCT00504894|Drug|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
79874016|NCT00504894|Drug|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
79874017|NCT03743441|Other|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
79874018|NCT03743441|Other|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
79874019|NCT03743441|Other|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
79874020|NCT03743441|Other|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
79874021|NCT00924755|Device|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
79874022|NCT01011348|Dietary Supplement|Coenzyme Q10|100mg/day for three months
79579718|NCT01908855|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
79579719|NCT01908868|Other|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
79874023|NCT01011348|Dietary Supplement|Coenzyme Q10|300mg/day for three months
79738827|NCT01104779|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
79738828|NCT00918957|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
79738829|NCT00918957|Drug|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
79738830|NCT04308161|Drug|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
79738831|NCT04308161|Drug|Miconazole Topical Gel|topical anti fungal agent
79738832|NCT04308161|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
79874024|NCT01011348|Dietary Supplement|Placebo|Three month period
79874025|NCT00924911|Drug|GSK1322322|Four different formulations of 1000mg of GSK1322322
80030750|NCT05381675|Other|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
80030751|NCT05381675|Other|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
80030752|NCT05378243|Device|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
80030753|NCT05378243|Behavioral|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
79579720|NCT01908868|Other|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
79579721|NCT01908868|Other|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
79738833|NCT04308161|Drug|Oracure gel|Topical analgesic gel
79738834|NCT04308161|Other|Alkamisr sachets|Sodium bicarbonate mouthwash
79738835|NCT04939467|Drug|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
79874026|NCT00924911|Drug|GSK1322322|GSK1322322 1000mg
79874027|NCT00928655|Drug|acetazolamide|acetazolamide 250mg 1/0/2
79874028|NCT00928655|Procedure|nocturnal continuous positive airway pressure|continuous positive airway pressure
79874029|NCT00928655|Drug|placebo|placebo capsules
79874030|NCT03743363|Other|Exergame 2/week|virtual training 2 times a week(8 week-long)
79874031|NCT03743363|Other|Exergaming 3/week|virtual training 3 times a week(8 week-long)
79874032|NCT03743363|Other|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
79874033|NCT01011426|Drug|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
79874034|NCT01011426|Drug|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
80030754|NCT05377593|Device|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
79579722|NCT01908881|Behavioral|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
79738836|NCT04939467|Drug|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
79579723|NCT01908881|Behavioral|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
79579724|NCT01908894|Drug|BIOD-123|
79276020|NCT00468403|Biological|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
79276021|NCT00468403|Drug|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
79276022|NCT00468403|Drug|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
79579725|NCT01908894|Drug|BIOD-125|
79738837|NCT04939467|Drug|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
79738838|NCT01015560|Drug|anti-CCR2 monoclonal antibody MLN1202|
79579726|NCT01908894|Drug|Humalog|
79738839|NCT01015560|Genetic|polymorphism analysis|
79738840|NCT01015560|Other|laboratory biomarker analysis|
80030755|NCT05372588|Drug|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
79276023|NCT00468403|Procedure|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant[s]) will occur intraportally.
79276024|NCT02175017|Drug|ONO-4538|
79738841|NCT02878889|Drug|S-1|
79738842|NCT04581174|Diagnostic Test|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
79738843|NCT02879045|Other|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
79738844|NCT04253223|Biological|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
80030756|NCT05372588|Drug|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
80030757|NCT05372588|Drug|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
79276025|NCT02388009|Biological|Flexyn2a|Intramuscular doses of 0.5 mL
79276026|NCT02388009|Biological|Placebo|Intramuscular doses of 0.5 mL
79276027|NCT02388009|Biological|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
79276028|NCT02178449|Drug|Dexamethasone acetate|
79579727|NCT01908920|Other|Osteopathic manipulative treatment|
79579728|NCT01908920|Other|SHAM|
79579729|NCT01908920|Other|CONTROL|
79579730|NCT01908933|Device|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
79579731|NCT01908946|Behavioral|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
79579732|NCT01908959|Behavioral|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
79738845|NCT00918879|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
79738846|NCT00918879|Drug|Placebo|Oral tablet, once daily for 24 weeks
80030758|NCT05372588|Drug|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
79276029|NCT02178449|Drug|Placebo|
79276030|NCT02178449|Drug|Ropivacaine|
79276031|NCT02387775|Device|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
79276032|NCT02278705|Other|Attention to BMI|Evidence (using electronic health record data) denoting provider attention to about high BMI.
79276033|NCT02278705|Other|Attention to high-BMI-related Medical Risk|Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
79276034|NCT02278705|Other|No attention to high BMI or high-BMI-related medical risk|Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
79276035|NCT05142137|Dietary Supplement|Drinkable solution|The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
79276036|NCT02387931|Dietary Supplement|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
79276037|NCT02387931|Dietary Supplement|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
79403873|NCT04253808|Behavioral|Carbohydrate-restricted, high-fat diet|"Diet composition was ~45% fats, ~30% carbohydrates, and ~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided."
79579733|NCT01908985|Procedure|high intensity focused ultrasound for cyclodestruction in the eye|
79579734|NCT01908998|Other|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
79579735|NCT01909024|Procedure|Coil embolisation|transjugular coil embolisation of pelvic veins
79579736|NCT01909024|Procedure|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
79738847|NCT04874805|Other|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
79738848|NCT01026792|Drug|Temsirolimus|Given IV
79738849|NCT01026792|Other|Laboratory Biomarker Analysis|Correlative studies
79738850|NCT01026324|Drug|dinaciclib|Given IV
80030759|NCT05372588|Drug|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
79276038|NCT02387931|Other|Placebo|Placebo capsule, 2 taken daily
79276039|NCT02281669|Drug|Pentostam|Intralesional injection of Pentostam
79579737|NCT01909037|Dietary Supplement|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
79579738|NCT01909063|Dietary Supplement|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
79579739|NCT01909063|Dietary Supplement|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
79738851|NCT01026324|Other|pharmacological study|Correlative studies
79738852|NCT01026324|Other|laboratory biomarker analysis|Correlative studies
79276040|NCT00466765|Device|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
79276041|NCT02178527|Other|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
79276042|NCT02178527|Other|Usual Care|Usual general podiatry care provded by UK National Health Service
79276043|NCT00662389|Device|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
79276044|NCT02178605|Procedure|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
79276045|NCT03170583|Device|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
79738853|NCT04300686|Biological|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
79874035|NCT00925067|Procedure|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
79874036|NCT00925067|Device|lightweight TiMesh|
79874037|NCT00925067|Device|lightweight VyproII|
79874038|NCT00925067|Device|Heavyweight Marlex|
79874039|NCT02808156|Other|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
79579740|NCT01909063|Dietary Supplement|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
79738854|NCT04300686|Biological|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
80030760|NCT05363267|Dietary Supplement|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
80030761|NCT05352776|Device|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
80030762|NCT05338593|Other|Outcome|Mortality rate of prolonged therapy.
79403874|NCT04253808|Behavioral|Regular composition diet|The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
79738855|NCT04299282|Device|CanGaroo|CIED ECM envelope
79738856|NCT01098539|Biological|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
79874040|NCT02808156|Other|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
79738857|NCT01098539|Drug|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
79738858|NCT02880215|Behavioral|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
80030763|NCT05335798|Device|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
80030764|NCT05335798|Device|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
80030765|NCT05330312|Device|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
80030766|NCT05326633|Combination Product|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
80030767|NCT05297747|Diagnostic Test|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
80030768|NCT05297747|Diagnostic Test|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
80030769|NCT05282797|Drug|ANEB-001|Experimental Treatment
79276046|NCT02178683|Drug|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
79276047|NCT03170739|Drug|Dexmedetomidine|Dexmedetomidine given during surgery.
79276048|NCT03170739|Drug|Dopamine|Dopamine given during surgery.
79276049|NCT04514159|Drug|ZN-c5|ZN-c5 is the study drug.
79276050|NCT04514159|Drug|Abemaciclib|Abemaciclib (VERZENIO®) is an approved drug.
79403875|NCT05115318|Drug|Medical Cannabis|Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
79579741|NCT01909076|Behavioral|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
79579742|NCT01909076|Behavioral|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
79738859|NCT02880215|Behavioral|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
79738860|NCT01098461|Biological|albiglutide|subcutaneous injection of albiglutide
79738861|NCT01098461|Biological|placebo|subcutaneous injection of placebo to match albiglutide
79738862|NCT01098305|Drug|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
79738863|NCT01098305|Behavioral|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
79874041|NCT00932555|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
79874042|NCT00928733|Device|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
79874043|NCT01012908|Dietary Supplement|Norzyme - Bergamo|2 - 8 tablets per day.
79874044|NCT01012908|Dietary Supplement|Creon|2 - 8 tablets pet day
80030770|NCT05282797|Drug|Placebo|Placebo comparator
80030771|NCT05281952|Procedure|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
80030772|NCT05281952|Procedure|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
79276051|NCT00459745|Drug|Pravafen|
79276052|NCT00459745|Drug|Pravastatin|
79276053|NCT00459745|Drug|Fenofibrate|
79874045|NCT00932711|Behavioral|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
79738864|NCT00833833|Drug|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
80030773|NCT05276492|Drug|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
79579743|NCT01909076|Behavioral|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
80030774|NCT05276492|Drug|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
80030775|NCT05276492|Other|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
79403876|NCT05115162|Other|Exercise|The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
79738865|NCT00833833|Drug|Dexamethasone|oral dexamethasone
79738866|NCT00833833|Drug|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
79738867|NCT04308083|Procedure|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
80030776|NCT05276492|Drug|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
79738868|NCT02878733|Drug|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
79738869|NCT01098071|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
80030777|NCT05269732|Behavioral|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
80030778|NCT05268731|Procedure|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
80030779|NCT05268731|Procedure|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
79276054|NCT02175095|Drug|Regorafenib|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy).
79276055|NCT03170505|Procedure|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
79738870|NCT04307771|Behavioral|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
79738871|NCT02612545|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
79738872|NCT02612545|Drug|Mefloquine (MQ)|ACT partner drug
79276056|NCT02284087|Device|PAS|
79276057|NCT02178761|Device|drug-eluting balloon|angioplasty completed with drug-eluting balloons
79738873|NCT02878577|Device|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
79738874|NCT00704743|Device|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
79874046|NCT04014959|Combination Product|TMS/ fMRI Stimulation|"The study uses a modified repetitive TMS stimulation protocol. Participants receive active TMS on five separate days: a baseline TMS/ fMRI scan, three mini TMS sessions, and a final TMS/ fMRI scan.~Again, this level of stimulation is considered to be sub-threshold for that of a TMS treatment protocol."
79874047|NCT01012986|Other|Assessment of reading skills|
79276058|NCT02178761|Device|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
79276059|NCT02178761|Device|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
79276060|NCT02178761|Device|Stent System|stenting with either bare-metal stents or drug-eluting stents
79579744|NCT01909076|Behavioral|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
79874048|NCT00513240|Drug|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
79579745|NCT01909076|Behavioral|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
80030780|NCT05268731|Procedure|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
80030781|NCT05255887|Other|Informing Patients With Video|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
80030782|NCT05238415|Diagnostic Test|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
79276061|NCT02742181|Drug|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
79276062|NCT02742181|Other|Control Group|Standard postoperative care
79276063|NCT02175329|Device|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
79276064|NCT02175329|Device|Manually layered veneering|
79276065|NCT02175407|Drug|ASP1707|oral
79276066|NCT02175407|Drug|itraconazole|oral
79276067|NCT02182193|Drug|BIBF 1120 capsules charge 1|
79874049|NCT00513240|Drug|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
79874050|NCT00925145|Procedure|Single Incision Laparoscopic Appendectomy|
79874051|NCT00928811|Drug|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
79874052|NCT00928811|Drug|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
79874053|NCT00932867|Drug|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
79874054|NCT00928967|Drug|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
79874055|NCT00932945|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
79276068|NCT02182193|Drug|BIBF 1120 capsules charge 2|
79276069|NCT02182193|Drug|BIBF 1120 drinking solution|
79276070|NCT02178839|Dietary Supplement|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
79276071|NCT02178839|Dietary Supplement|Maltodextrin|8.5 g/d Maltodextrin
79276072|NCT02182271|Drug|BI 201335 ZW - single rising dose|
79276073|NCT02182271|Drug|Placebo|
79276074|NCT02742103|Biological|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
79276075|NCT02742103|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
79276076|NCT02175485|Drug|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
79276077|NCT04575779|Drug|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
79276078|NCT02178917|Other|Neurofeedback therapy|
79276079|NCT02178917|Other|No neurofeedback therapy|
79276080|NCT02387697|Device|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
79874056|NCT00504426|Drug|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
79276081|NCT02182349|Drug|BI 201335 NA soft gelatin capsule|
79579746|NCT01909115|Drug|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
79579747|NCT01909115|Drug|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
79276082|NCT02182349|Drug|[14C]-BI 201335 NA radiolabelled drug|
79579748|NCT01909128|Dietary Supplement|fermented milk|fermented milk with Lactobacillus CBA-L74
79579749|NCT01909128|Dietary Supplement|fermented rice|fermented rice wit Lactobacillus CBA-L74
79579750|NCT01909193|Behavioral|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
79874057|NCT00933023|Drug|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
79874058|NCT00933023|Drug|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
79579751|NCT01909193|Behavioral|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
79579752|NCT01909219|Drug|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
79579753|NCT01909258|Other|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
79579754|NCT01909258|Other|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
79579755|NCT01909258|Other|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
79579756|NCT01909271|Behavioral|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
79579757|NCT01909271|Other|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
79276083|NCT02741713|Procedure|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
79276084|NCT02741713|Procedure|Interscalene Block|An interscalene block will be performed on the subjects.
79276085|NCT02741713|Procedure|Sham Block|
79579758|NCT01909284|Device|Acupuncture|"BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
79276086|NCT02741713|Drug|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
79276087|NCT02741713|Drug|Solution for Injection in Sham Block|Lidocaine 1%
79579759|NCT01909284|Procedure|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
79579760|NCT01909297|Device|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
79579761|NCT01909297|Device|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
79579762|NCT01909297|Device|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
79874059|NCT00933179|Drug|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
79276088|NCT02741713|Drug|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
79276089|NCT03170427|Device|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
79276090|NCT03170427|Diagnostic Test|Sensory levels|Sensory levels are checked using ice test cold
79276091|NCT03170427|Diagnostic Test|Motor block|motor block is measured by modified Bromage scale
79874060|NCT00933179|Drug|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
79874061|NCT00504348|Drug|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
79874062|NCT00929123|Procedure|neural mobilization|manual therapy technique known to directly stress the median nerve
79874063|NCT00929123|Procedure|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
79874064|NCT00929123|Other|healthy controls|People without carpal tunnel syndrome for comparison
79874065|NCT00507546|Drug|Ramelteon|8 mg nightly
79874066|NCT00507546|Drug|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
79738875|NCT00704743|Device|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
79579763|NCT01909310|Procedure|head extension|the lungs are ventilated with the patient´s head extended
79579764|NCT01909310|Procedure|neutral position|the lungs are ventilated with the patient´s head in neutral position
79738876|NCT00704743|Device|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
79738877|NCT01097057|Drug|Carboplatin|Given IV
79738878|NCT01097057|Drug|Etoposide|Given IV
79874067|NCT00925457|Other|No Intervention|Neither current domperidone nor current PPI
80030783|NCT05190315|Drug|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
79738879|NCT01097057|Biological|Filgrastim|Given SC
79276092|NCT03170427|Diagnostic Test|Sensory level|Sensory levels are checked using touch with alcohol puffs
79276093|NCT03537521|Procedure|Urgent surgery which can not be postponed to the next 24 hrs|The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
79579765|NCT01909310|Procedure|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
79579766|NCT01909323|Other|maltitol 85% / FOS15%|
79579767|NCT01909323|Other|maltitol alone|
79738880|NCT01097057|Drug|Ifosfamide|Given IV
79738881|NCT01097057|Procedure|Leukapheresis|Given through catheter
79738882|NCT01097057|Drug|Plerixafor|Given SC
79738883|NCT01097057|Biological|Rituximab|Given IV
79738884|NCT02612701|Other|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
79738885|NCT02612701|Other|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
79276094|NCT00459277|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
79276095|NCT02175563|Device|Audiovisual feedback from smartphone based app|
79276096|NCT00602329|Biological|bevacizumab|Given IV
79738886|NCT02612701|Other|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
79738887|NCT02612701|Other|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
79738888|NCT05065463|Drug|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
79403877|NCT01506596|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
79579768|NCT01909323|Other|maltitol 68% / FOS 32%|
79276097|NCT00602329|Drug|fluorouracil|Given IV
79276098|NCT00602329|Drug|leucovorin calcium|Given IV
79276099|NCT00602329|Drug|oxaliplatin|Given IV
79579769|NCT01909323|Other|maltitol 50% / FOS 50%|
79579770|NCT01909323|Other|FOS alone|
79579771|NCT01909323|Other|Placebo|
79579772|NCT01909349|Behavioral|self-regulation|Web-based support for behavior change regarding physical activity and fruit & vegetable consumption
79579773|NCT01909388|Radiation|MRI-TRUS fusion guided real time HDR|
79579774|NCT01909401|Drug|boceprevir|
79579775|NCT01909440|Behavioral|exercise intervention|Receive whole body RT
79738889|NCT02878811|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
79738890|NCT01022112|Drug|TA-7284-Low|TA-7284-Low
79738891|NCT01022112|Drug|TA-7284-Low-middle|TA-7284-Low-middle
79738892|NCT01022112|Drug|TA-7284-High-middle|TA-7284-High-middle
79738893|NCT01022112|Drug|TA-7284-High|TA-7284-High
79738894|NCT01022112|Drug|Placebo|Placebo
79738895|NCT04299204|Procedure|Percutaneous nephrolitotomy|Pediatric PCNL
79738896|NCT01096667|Drug|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
79738897|NCT01096667|Drug|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
79738898|NCT01096667|Drug|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
79738899|NCT01096667|Drug|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
79738900|NCT01096667|Drug|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
79738901|NCT01096667|Drug|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
79738902|NCT01096667|Drug|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
79874068|NCT00925457|Drug|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
79874069|NCT00925457|Drug|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
79874070|NCT04522674|Biological|Autologous platelet rich plasma|0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
79874071|NCT00933257|Drug|LACTIC ACID(ND)|Treatment duration 5 weeks
79874072|NCT04015271|Behavioral|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
79874073|NCT04015271|Behavioral|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
80030784|NCT05190315|Drug|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events > grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
80030785|NCT05190315|Radiation|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
80030786|NCT05177575|Procedure|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
79874074|NCT00925613|Device|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
79276100|NCT02391831|Other|Strength, function and activity measurements|
79579776|NCT01909440|Dietary Supplement|nutritional supplementation|Given whey protein supplementation PO
79579777|NCT01909440|Procedure|quality-of-life assessment|Ancillary studies
80030787|NCT05160961|Procedure|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
80030788|NCT05160961|Procedure|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
80030789|NCT05157789|Other|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
80030790|NCT05145153|Procedure|Thoracic surgery application|The chronic pain findings of the patients who underwent thoracic surgery will be questioned at the postoperative 3rd and 6th months.
80030791|NCT05143840|Drug|Asciminib|Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).
80030792|NCT05143840|Drug|Ascimininb + Nilotinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, once daily, with the goal of attaining MR4.5.
80030793|NCT05143840|Drug|Asciminib + Imatinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of imatinib 300mg, once daily, with the goal of attaining MR4.5.
80030794|NCT05143840|Drug|Asciminib + Dasatinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of dasatinib 50mg, once daily, with the goal of attaining MR4.5.
80030795|NCT05134974|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
80030796|NCT05134974|Drug|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
80030797|NCT05134922|Drug|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
80030798|NCT05109442|Drug|AFM24|intravenous infusion
80030799|NCT05109442|Drug|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
79276101|NCT02391831|Other|Muscle MRI|
79276102|NCT02391831|Other|Electrophysiology measurements|
79276103|NCT02391831|Other|Blood sampling for biomarker analysis|
79276104|NCT02182505|Drug|Berodual® Respimat®, low dose|
79276105|NCT02182505|Drug|Berodual® Respimat®, high dose|
79579778|NCT01909440|Other|questionnaire administration|Ancillary studies
79579779|NCT01909440|Other|pharmacological study|Correlative studies
79579780|NCT01909440|Other|laboratory biomarker analysis|Correlative studies
79579781|NCT01909544|Other|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
80030800|NCT05108870|Drug|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
80030801|NCT05108870|Drug|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
80030802|NCT05108870|Drug|Carboplatin|Chemotherapy drug.
80030803|NCT05108870|Drug|Paclitaxel|Chemotherapy drug.
80030804|NCT05108870|Procedure|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
79276106|NCT02182505|Drug|Berodual® MDI|
79276107|NCT02281903|Device|The TrueCPR feedback device|feedback devices
79276108|NCT02281903|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
79579782|NCT01909557|Drug|Acetyl-L-carnitine|
79579783|NCT01909557|Drug|placebo|
79579784|NCT01909583|Other|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
79579785|NCT01909596|Other|Without orthoses|Condition control
79874075|NCT00925613|Device|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
79874076|NCT00929279|Drug|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
80030805|NCT05107401|Behavioral|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
80030806|NCT05099276|Drug|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
80030807|NCT05099276|Drug|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
80030808|NCT05095948|Procedure|Discussion|Undergo audio recording of clinic conversations
80030809|NCT05095948|Other|Electronic Health Record Review|Review of medical records
80030810|NCT05095948|Other|Questionnaire Administration|Complete questionnaires
79276109|NCT02276521|Biological|Cervarix®|All groups will received one dose of Cervarix® vaccine
80030811|NCT05093855|Drug|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
80030812|NCT05083832|Procedure|Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block|Two different catheter techniques with same doses local anesthetic infusion
80030813|NCT05080439|Other|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
80030814|NCT05080439|Other|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
80030815|NCT05070650|Drug|Acetylcysteine|200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
79276110|NCT02387619|Drug|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
79276111|NCT02387619|Drug|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
79276112|NCT02387619|Drug|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
79276113|NCT02175797|Device|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
79403878|NCT04474860|Diagnostic Test|gene sequencing|Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
79276114|NCT00599989|Procedure|adjuvant therapy|
79276115|NCT00599989|Procedure|conventional surgery|
79276116|NCT00599989|Radiation|3-dimensional conformal radiation therapy|
79276117|NCT00599989|Radiation|brachytherapy|
79276118|NCT00599989|Radiation|intracavitary balloon brachytherapy|
79276119|NCT00599989|Radiation|proton beam radiation therapy|
79276120|NCT02391753|Device|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
79276121|NCT03537443|Dietary Supplement|Cholecalciferol (vitamin D3)|Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
79276122|NCT00595699|Drug|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
79403879|NCT03895801|Drug|IFX-1|intravenously administered
79579786|NCT01909596|Device|6° lateral wedge insoles|Insoles with a lateral inclination set at 6°
79579787|NCT01909596|Device|10° lateral wedge insoles|Insoles with a lateral inclination set at 10°
79579788|NCT01909596|Device|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
80030816|NCT05070650|Drug|Paracetamol|500 mg/10 mg granules for oral solution: one sachet three times per day
80030817|NCT05070650|Drug|Phenylephrine|500 mg/10 mg granules for oral solution
80030818|NCT05056766|Behavioral|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
79276123|NCT00595699|Drug|placebo|Placebo
79276124|NCT05268705|Other|7-day diet|The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
79403880|NCT03895801|Drug|Placebo-IFX-1|intravenously administered
79403881|NCT03895801|Drug|Glucocorticoid (GC)|orally administered
79403882|NCT03895801|Drug|Placebo-Glucocorticoid (Placebo-GC)|orally administered
79403883|NCT04469478|Other|Survey and interview|Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
79403884|NCT05115084|Other|no intervention|no intervention
79579789|NCT01909596|Device|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
79579790|NCT01909596|Device|7° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 7°
80030819|NCT05056324|Device|Online vestibular rehabilitation tool|For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)
79579791|NCT01909596|Device|8° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 8°
80030820|NCT05056324|Other|Standard care (written instructions leaflet)|For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet
80030821|NCT05047211|Drug|Ferrous sulfate|one tablet 325 milligrams three times a day
80030822|NCT05047211|Drug|Iron dextran|1000 mg intravenous infusion
79579792|NCT01909596|Device|9° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 9°
80030823|NCT05040893|Behavioral|Physiotherapy|"Interventions will include:~Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises)."
79579793|NCT01909596|Device|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
79579794|NCT01909596|Device|Orthotist integrated lateral customized foot orthoses|Foot orthoses with arch support and integrated lateral inclination set according to orthotist experience
79579795|NCT01909596|Device|Orthotist lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set according to orthotist experience
79579796|NCT01909609|Other|AAP Documents|
79579797|NCT01909609|Other|Parent Survival Guide|
80030824|NCT04977310|Device|CardioMEMS|Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
80030825|NCT04958642|Drug|Adrabetadex|Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
80030826|NCT04956432|Drug|SHR4640|SHR4640 Dose 1 ,tablets, QD
79579798|NCT01909622|Dietary Supplement|Vitamin D|
79738903|NCT01014624|Drug|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
79738904|NCT01014624|Drug|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
79738905|NCT01021878|Other|icodextrin|glucose sparing dialysis solution
79738906|NCT01021878|Other|Dianeal|glucose based dialysis solution
80030827|NCT04956432|Drug|Allopurinol|Allopurinol 300mg, tablets, QD
79579799|NCT01909622|Dietary Supplement|No vitamin D|
79579800|NCT01909635|Behavioral|Food Feelings|
79579801|NCT01909635|Behavioral|Other Feelings|
79579802|NCT01909648|Other|Blood withdrawal|
79738907|NCT02872428|Drug|Valproic Acid|By infusion over 1 hour
79738908|NCT02872428|Drug|Isotonic saline solution|By infusion over 1 hour
79738909|NCT02873364|Drug|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
79738910|NCT02873364|Drug|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
80030828|NCT04950010|Behavioral|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be ~30 minutes in length. Indoor cycling is the primary mode of exercise.
80030829|NCT04950010|Behavioral|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
79579803|NCT01909648|Genetic|Blood withdrawal|
79579804|NCT01909661|Other|Damira/Celia peptide hydrolyzed casein|
79579805|NCT01909661|Other|Picot riz/Celia rice/Sanutri arroz|
79579806|NCT01909687|Device|Blood glucose monitoring systems|
79579807|NCT01909700|Device|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
79579808|NCT01909726|Other|ScreenPlay|Interactive technology
79579809|NCT01909739|Drug|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
79579810|NCT01909739|Drug|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
79579811|NCT01909752|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
79579812|NCT01909752|Biological|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
79738911|NCT02872740|Procedure|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
79874077|NCT00929279|Drug|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
79738912|NCT02872740|Procedure|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
80030830|NCT04935762|Drug|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
79276125|NCT05268705|Other|7-day diet|The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
79738913|NCT02871960|Procedure|Robotic and Laparoscopic Colectomy|
79276126|NCT05268705|Other|7-day diet|The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
79276127|NCT05141591|Other|Anxiety level assessment|To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
79276128|NCT02256215|Drug|Vitamin D|
79579813|NCT01909752|Drug|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
79579814|NCT01909752|Drug|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
79579815|NCT01909752|Biological|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
79579816|NCT01909765|Other|Dorsal slit|Skin and mucosa incision made together
79579817|NCT01909765|Other|Double incision|Skin and mucosa incision made separately
79738914|NCT00628290|Drug|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
79579818|NCT01909817|Procedure|Routine coronary angiogram|
80030831|NCT04920084|Other|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
80030832|NCT04914832|Biological|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
80030833|NCT04912492|Behavioral|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
79579819|NCT01909830|Drug|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
79579820|NCT01909843|Biological|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
79579821|NCT01909856|Drug|Palonosetron|Palonosetron 0.25mg d1,d3
79579822|NCT01909856|Drug|Granisetron|Granisetron 3mg d1-3
79874078|NCT00567593|Drug|Rosiglitazone|8mg tablet once a day for 14 days
79874079|NCT00335764|Drug|sorafenib tosylate|given orally
79874080|NCT00335764|Drug|erlotinib hydrochloride|given orally
79874081|NCT00335764|Drug|tipifarnib|given orally
79276129|NCT00591799|Device|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
79276130|NCT00587275|Drug|AST-120|Oral, sachet, 2 grams daily for 4 weeks
79874082|NCT00335764|Drug|temsirolimus|IV administration
79276131|NCT00587275|Drug|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
79276132|NCT02182583|Drug|Ba253MDI|
79276133|NCT02182583|Drug|Ba253BINEB|
79276134|NCT03133975|Drug|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
79276135|NCT03133975|Other|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
79579823|NCT01909856|Drug|Dexamethasone|Dexamethasone 10mg d1-3
79579824|NCT01909856|Drug|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
79738915|NCT00628290|Drug|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
79738916|NCT04559412|Device|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
79738917|NCT04559412|Drug|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
79738918|NCT00854113|Drug|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
79738919|NCT00854113|Drug|Placebo|Placebo to match EGT0001474
79738920|NCT02872584|Drug|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
79738921|NCT00704821|Drug|PTC299|Oral
79874083|NCT03743285|Device|AID System|AID system
79874084|NCT03743285|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
79874085|NCT00933413|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
79874086|NCT03981562|Drug|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
79874087|NCT03981562|Drug|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
80030834|NCT04912492|Behavioral|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
80030835|NCT04912492|Behavioral|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
79874088|NCT03981484|Biological|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
79276136|NCT02282137|Drug|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
79276137|NCT02182661|Drug|Ba253BINEB|
79276138|NCT00586651|Drug|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
79579825|NCT01909869|Device|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
79579826|NCT01909882|Other|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
79579827|NCT01909908|Device|ECM|ECM in saline applied to wound
79579828|NCT01909908|Biological|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
79738922|NCT00704821|Drug|Docetaxel|Intravenous infusion
79738923|NCT00704899|Procedure|Physiotherapy|Structured exercise regimen
79874089|NCT03981484|Biological|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
79874090|NCT03983200|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
80030836|NCT04912492|Behavioral|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
80030837|NCT04912492|Behavioral|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
80030838|NCT04906278|Device|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
79738924|NCT00704899|Drug|Amitryptiline|Amitryptiline 25mg once daily
79738925|NCT00845845|Drug|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
79738926|NCT00845845|Drug|Placebo|Daily placebo with dietary counseling for 24 weeks.
79738927|NCT01104701|Drug|exenatide once weekly|subcutaneous injection, 2 mg, once a week
80030839|NCT04906278|Procedure|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
79738928|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
79738929|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
79276139|NCT02663271|Drug|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
79276140|NCT02663271|Device|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
79276141|NCT02663271|Other|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
79738930|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
79874091|NCT03983200|Drug|Mecobalamin|mecobalamine 0.5mg,tid
79874092|NCT00567359|Drug|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
79874093|NCT01063582|Other|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
79874094|NCT01063582|Procedure|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
79874095|NCT04014725|Device|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
79874096|NCT01063660|Drug|Treosulfan|14 g/m²/d day -6 to -4
79874097|NCT00933569|Drug|LACTIC ACID(ND)|treatment period: 21 consecutive days
80030840|NCT04906278|Drug|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
80030841|NCT04895670|Behavioral|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
80030842|NCT04895475|Behavioral|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
79276142|NCT02663271|Other|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
79276143|NCT02256293|Behavioral|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
79276144|NCT00659191|Drug|GSK1265744|
79579829|NCT01909908|Device|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
79738931|NCT00833755|Drug|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
79276145|NCT02182739|Drug|Meloxicam|tablets or injectable solution
79579830|NCT01909947|Other|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~A 60-minute period while the infant receives any mode of conventional mechanical ventilation~A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
79579831|NCT01909960|Other|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
79579832|NCT01909986|Drug|[14C]ONO-4053|Single dose [14C]ONO-4053
79579833|NCT01909999|Procedure|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
79579834|NCT01909999|Procedure|Clinical parameters evaluation|"The following parameters were assessed:~Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
79738932|NCT00833755|Drug|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
79738933|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
79738934|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
79738935|NCT00704977|Procedure|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
79738936|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
79874098|NCT00925847|Drug|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
79874099|NCT00492726|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
79874100|NCT00492726|Drug|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
79874101|NCT00925925|Other|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
79874102|NCT00933647|Dietary Supplement|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
79874103|NCT00933647|Dietary Supplement|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
79874104|NCT00933647|Dietary Supplement|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
80030843|NCT04895202|Other|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
80030844|NCT04878458|Procedure|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
79738937|NCT00923091|Drug|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
80030845|NCT04878458|Procedure|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
79738938|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
80030846|NCT04864587|Diagnostic Test|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
79276146|NCT02175953|Behavioral|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
79579835|NCT01909999|Procedure|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
79579836|NCT01909999|Procedure|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
79276147|NCT00583609|Drug|PEG3350|PEG3350
79579837|NCT01909999|Procedure|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
79579838|NCT01909999|Drug|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
79738939|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
79738940|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
79738941|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
79738942|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
79738943|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
79738944|NCT04030819|Behavioral|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
79276148|NCT03170115|Drug|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
79738945|NCT04115683|Other|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
79874105|NCT00933725|Other|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
79874106|NCT00933725|Other|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
79874107|NCT00309946|Drug|cediranib maleate|Given orally
79874108|NCT00492648|Procedure|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
79874109|NCT00929591|Drug|cyclophosphamide|
79874110|NCT00929591|Drug|doxorubicin hydrochloride|
79276149|NCT03170115|Drug|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
79579839|NCT01910038|Drug|corticoids+ tocilizumab 8mg/Kg/4 weeks|
79874111|NCT00929591|Drug|endocrine therapy|
79874112|NCT00929591|Drug|endocrine-modulating drug therapy|
79874113|NCT00929591|Drug|fluorouracil|
79874114|NCT00929591|Drug|tamoxifen citrate|
79874115|NCT00929591|Radiation|brachytherapy|
79874116|NCT00929591|Radiation|low-LET electron therapy|
79874117|NCT00929591|Radiation|low-LET photon therapy|
79874118|NCT00929591|Radiation|radiation therapy|
79276150|NCT02179229|Dietary Supplement|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
79403885|NCT05114928|Procedure|Transepithelial Corneal Collagen Cross-linking|Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
79403886|NCT05114928|Diagnostic Test|Scheimpflug camera|Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
79579840|NCT01910077|Drug|Tacrobell capsule 1mg|1 capsule, oral, over the period I&II(crossover)
79738946|NCT04115683|Other|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
79874119|NCT01063738|Dietary Supplement|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
79874120|NCT01063738|Other|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
79874121|NCT01063738|Other|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
79874122|NCT01063738|Dietary Supplement|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
79874123|NCT00929747|Device|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
79874124|NCT00929747|Procedure|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
79874125|NCT03997500|Drug|normal saline|a bolus of normal saline was given followed by normal saline infusion
79874126|NCT03997500|Drug|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
79738947|NCT04299126|Device|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
79738948|NCT04299126|Device|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
79276151|NCT02179229|Dietary Supplement|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
79738949|NCT00853957|Drug|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
79874127|NCT00933881|Other|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
79276152|NCT00583531|Drug|AST-120|Oral, 2 grams TID in sachets for 4 weeks
79403887|NCT05114772|Diagnostic Test|Measuring Serum bio-markers|ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
79403888|NCT03021421|Procedure|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
79738950|NCT00853957|Drug|Amlodipine|Amlodipine 5 mg titrated to 10mg
79874128|NCT01013064|Drug|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
79874129|NCT00933959|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
79874130|NCT00933959|Behavioral|Sleep Hygiene|Treatment as usual
79403889|NCT03021421|Procedure|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
79738951|NCT04571034|Procedure|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
79738952|NCT04571034|Procedure|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
79874131|NCT01011660|Drug|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
79874132|NCT04014881|Biological|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
79874133|NCT04015505|Behavioral|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
79874134|NCT01015248|Drug|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
79579841|NCT01910077|Drug|Prograf capsule 1mg|1 capsule, oral, over the period I&II(crossover)
79579842|NCT01910090|Drug|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
79579843|NCT01910090|Drug|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
79579844|NCT01910142|Dietary Supplement|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
79579845|NCT01910142|Dietary Supplement|calcium|
79579846|NCT01910155|Drug|Ciprofloxacin/Dexamethasone|
79579847|NCT01910155|Drug|Ciprodex (R)|
79579848|NCT01910155|Drug|Placebo|
79579849|NCT01910194|Drug|Luyxumia versus Lantus|
79579850|NCT01910220|Drug|REGN1033 (SAR391786)|
79579851|NCT01910220|Other|placebo|
79738953|NCT04571034|Procedure|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
79738954|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
79276153|NCT03169959|Drug|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
79276154|NCT03169959|Drug|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
79738955|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
79874135|NCT00926081|Behavioral|Supervised exercise training|A standardized supervised exercise training program
79276155|NCT03169959|Drug|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
79276156|NCT03169959|Drug|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
79276157|NCT03169959|Drug|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
79276158|NCT03169959|Drug|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
79276159|NCT02176187|Drug|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
79276160|NCT02176187|Drug|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
79579852|NCT01910246|Drug|Metformin|
79579853|NCT01910259|Drug|Amiloride|Comparison with placebo
79579854|NCT01910259|Drug|Riluzole|Comparison with placebo
79579855|NCT01910259|Drug|Fluoxetine|Comparison with placebo
79579856|NCT01910259|Drug|Placebo|Placebo comparator
79579857|NCT01910272|Device|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
79738956|NCT01021020|Drug|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
79738957|NCT04256187|Other|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
79874136|NCT00929825|Device|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
79874137|NCT00929825|Procedure|TENS|transcutaneous electrical stimulation
79874138|NCT01013142|Drug|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
79579858|NCT01910285|Drug|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
79738958|NCT00833053|Drug|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
79738959|NCT00833053|Drug|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
79738960|NCT02873130|Behavioral|Telepractice Global Voice Prevention Model|
79738961|NCT02873130|Behavioral|In-person Global Voice Prevention Model|
79738962|NCT02873130|Behavioral|Telepractice, Vocal Hygiene and Vocal Education|
79738963|NCT04299984|Procedure|Open Conversion after EVAR|"See Open Conversions group description."
79738964|NCT04299984|Procedure|SemiConversion after EVAR|"See SemiConversions group description."
79874139|NCT01013142|Drug|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
79874140|NCT01013142|Drug|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
79874141|NCT00934037|Procedure|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
79874142|NCT00934037|Other|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
79874143|NCT01013220|Other|Depression Product Detailing|"two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~technical assistance in purchasing high quality depression management products"
79874144|NCT01013220|Other|Depression HEDIS detailing|"academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~technical assistance"
79874145|NCT04014569|Device|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
79874146|NCT00506922|Drug|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m^2~Group 3 - Pentostatin 1 mg/m^2~Group 4 - Pentostatin 1.5 mg/m^2~Group 5 - Pentostatin 2 mg/m^2"
79276161|NCT03169803|Device|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
79276162|NCT02279251|Behavioral|VÅG|Low-intensity CBT intervention
79276163|NCT02279251|Behavioral|CHILLED|Standard length CBT intervention
79403890|NCT04521582|Drug|Amlodipine|The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times [including baseline and end of the study] in the active municipality and 3 times [including baseline and end of the study] in the control municipality).
79738965|NCT05329467|Other|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
79276164|NCT02176265|Device|Qvanteq bioactive coronary stent|PCI
79276165|NCT02176499|Drug|Telmisartan, low dose|
79579859|NCT01910285|Drug|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
79579860|NCT01910324|Behavioral|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
79579861|NCT01910324|Behavioral|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
79738966|NCT04256031|Other|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
79738967|NCT04245735|Diagnostic Test|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
79403891|NCT04521582|Behavioral|Lifestyle counselling|Female Community Health Volunteer will provide lifestyle counseling at the participant's home
79738968|NCT04253067|Device|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
79738969|NCT04253067|Device|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
79276166|NCT02176499|Drug|Telmisartan, high dose|
79276167|NCT02176499|Drug|Placebo|
79738970|NCT04252989|Other|data collection|"Demographic data: age, sex~Ophthalmological history: refraction of parents, previous refractions~Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~Potential undesirable events (halos, photophobia...)"
79276168|NCT02176577|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
79738971|NCT01020786|Drug|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
79276169|NCT05141981|Device|dexa scan|measure muscle mass
79579862|NCT01910337|Device|Use the Polar Cardiac rate meter|
79579863|NCT01910350|Behavioral|Kin KeeperSM Cancer Prevention Intervention|
79579864|NCT01910350|Other|Standard of care|
79874147|NCT00506922|Drug|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
79874148|NCT00506922|Drug|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
79276170|NCT05219253|Biological|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
79276171|NCT05219253|Drug|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) administered intramuscularly, one each at Day 1 and Month 2.
79276172|NCT02176733|Drug|cyclosporine|
79276173|NCT03536741|Procedure|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
79276174|NCT03536741|Drug|General Intravenous Anesthetic|General Intravenous Anesthetic
79276175|NCT02403609|Other|BPT, Computerized Assessment|
79276176|NCT02403687|Drug|baclofen 2%|compound topical cream
79276177|NCT02403687|Drug|Bupivacaine hydrochloride 1%|compound topical cream
79276178|NCT02403687|Drug|Cyclobenzaprine hydrochloride 2%|compound topical cream
79276179|NCT02403687|Drug|Diclofenac Sodium 3%|compound topical cream
79276180|NCT02403687|Drug|Flurbiprofen 10%|compound topical cream
79276181|NCT02403687|Drug|Gabapentin 6%|compound topical cream
79276182|NCT02403687|Drug|Ketamine 10%|compound topical cream
79276183|NCT02403687|Drug|Lidocaine 2%|compound topical cream
79276184|NCT02403687|Drug|Prilocaine 2.5%|compound topical cream
79276185|NCT02403687|Drug|Meloxicam 0.09%|compound topical cream
79579865|NCT01910363|Drug|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
79403892|NCT03588169|Dietary Supplement|semi-structured interviews|"About 30 minutes and touching on the following subjects:~perception of hospital meals~patient representation of ONS~taking ONS and feelings about it"
79276186|NCT02403687|Drug|Sumatriptan 5%|compound topical cream
79276187|NCT02403687|Drug|Tizanidine 0.1%|compound topical cream
79276188|NCT02403687|Drug|Topiramate 2.5%|compound topical cream
79276189|NCT02403687|Drug|Capsaicin, USP 0.0375%|compound topical cream
79276190|NCT02403687|Drug|Menthol, NF 5.00 %|compound topical cream
79276191|NCT02742649|Drug|Fixed Combination|Continuous elution from the ocular insert.
79276192|NCT02742649|Drug|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
79276193|NCT02742649|Drug|Timolol|Continuous elution from the ocular insert. This is an active control arm.
79276194|NCT02742649|Device|Placebo Segment|One segment of placebo (no drug product)
79276195|NCT02742649|Drug|Timolol 0.5%|0.5% timolol drops twice daily.
79403893|NCT01482884|Drug|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
79738972|NCT01020786|Drug|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
79276196|NCT02183051|Drug|Meloxicam 7.5 mg|
79738973|NCT00918645|Drug|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
79738974|NCT04255719|Procedure|DBS|Unilateral DBS for treatment of patients with PD
79276197|NCT02183051|Drug|Meloxicam 3.75 mg|
79276198|NCT02183051|Drug|Meloxicam 1.875 mg|
79276199|NCT02183051|Drug|Ibuprofen 200 mg|
79276200|NCT02183051|Drug|Placebo|
79738975|NCT00922935|Device|Cresco|Cresco components loading 10 days post surgery
79738976|NCT00922935|Device|Cresco|Cresco loading at 6-8 weeks post surgery
79738977|NCT00922935|Device|Straumann components|Straumann components loading 6-8 weeks post surgery
79874149|NCT00929903|Drug|pazopanib hydrochloride|Given orally
79276201|NCT02183051|Drug|Meloxicam 15 mg|
79276202|NCT02183051|Drug|Ibuprofen 400 mg|
79276203|NCT02391285|Device|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
79276204|NCT05200767|Other|completing surveys|"The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results."
79276205|NCT02179307|Behavioral|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
79276206|NCT00453271|Drug|NB-002|
79403894|NCT01482884|Drug|placebo|2 sc injections of every 2 weeks for 12 weeks.
79276207|NCT00453271|Drug|Vehicle control|
79276208|NCT03169725|Biological|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
79276209|NCT03169725|Biological|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
79276210|NCT02176889|Dietary Supplement|Lactospore|Bacillus coagulans MTCC 5856
79276211|NCT02176889|Other|Placebo|
79276212|NCT02403531|Drug|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
79276213|NCT02403531|Drug|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
79276214|NCT02403531|Radiation|Radiotherapy|definitive radiotherapy
79276215|NCT02279953|Drug|Vortioxetine 10-20 mg|
79276216|NCT02279953|Drug|Placebo|
79276217|NCT02279953|Drug|SSRI|escitalopram, citalopram or sertraline
79276218|NCT02183207|Procedure|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
79276219|NCT02391207|Procedure|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
79276220|NCT02179385|Behavioral|Health Coaching|
79276221|NCT00578773|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79276222|NCT00578773|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
79276223|NCT00578773|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
79403895|NCT03588091|Drug|Pyrotinib|pyrotinib: 400mg orally daily;
79403896|NCT03588091|Drug|Placebo Oral Tablet|placebo: 400mg orally daily;
79403897|NCT03588091|Drug|Trastuzumab|trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
79738978|NCT01020474|Drug|placebo|matching placebo capsules twice daily.
79738979|NCT01020474|Drug|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
79738980|NCT02872818|Drug|17β estradiol hemihydrate|4mg/kg/day for 20 days
79738981|NCT02872818|Drug|Metformin|50 mg/kg/day last 10 days
79874150|NCT00929903|Other|pharmacological study|Correlative studies
79579866|NCT01910363|Drug|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
79579867|NCT01910415|Drug|Lumacaftor|
79874151|NCT01013298|Device|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
80030847|NCT04845399|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
79738982|NCT02872818|Drug|medroxyprogesterone acetate|1mg/kg/day last 10 days
79579868|NCT01910415|Drug|Lumacaftor Placebo|
80030848|NCT04841317|Combination Product|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
80030849|NCT04826614|Other|optimized treatment|early adjust dose or change drug
80030850|NCT04807374|Device|Control IQ|We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
80030851|NCT04799106|Behavioral|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
79276224|NCT02387307|Drug|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
79579869|NCT01910415|Drug|Ivacaftor|
79579870|NCT01910415|Drug|Ivacaftor Placebo|
79579871|NCT01910415|Drug|moxifloxacin hydrochloride|
79579872|NCT01910428|Drug|L-asparaginase encapsulated in RBC|"50 IU/kg IV~100 IU/kg IV~150 IU/kg IV~200 IU/kg IV"
79738983|NCT00922779|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
79738984|NCT00922779|Drug|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
79874152|NCT00934193|Drug|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
79874153|NCT00934193|Drug|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
79874154|NCT01013376|Drug|MC-1101|MC-1101 1.0%
79738985|NCT04205448|Behavioral|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
79738986|NCT04532892|Dietary Supplement|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 & V4) and calls for antistress advices and adverse events, concomitant medication reporting & compliance (V1 & V3)
79738987|NCT04532892|Dietary Supplement|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 & V4) and calls for antistress advices and adverse events, concomitant medication reporting & compliance (V1 & V3)
79738988|NCT00924651|Behavioral|exercise|home based walking and progressive resistance training exercise
79738989|NCT04570410|Procedure|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
79738990|NCT04570410|Drug|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
79738991|NCT04570410|Drug|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
79738992|NCT04203771|Dietary Supplement|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum [now Lactoplantibacillus plantarum] KABP051 (CECT7481) and Lactobacillus brevis [now Levilactobacillus brevis] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
79738993|NCT04203771|Other|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
79738994|NCT04203771|Procedure|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
79738995|NCT04203771|Drug|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
79874155|NCT01013376|Drug|Vehicle|Vehicle
80030852|NCT04766853|Drug|Dexamethasone|Dexamethasone 5mg/ml
80030853|NCT04766853|Drug|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
80030854|NCT04765605|Device|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
80030855|NCT04755218|Other|Vaginal Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States"
80030856|NCT04755218|Other|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current labor induction protocol
79579873|NCT01910454|Behavioral|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
79874156|NCT01011972|Drug|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
79738996|NCT04256733|Biological|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
79874157|NCT04014491|Procedure|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
79874158|NCT04014491|Procedure|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
79874159|NCT04014491|Other|No intervention|No intervention
79874160|NCT01012050|Device|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
79874161|NCT01012050|Other|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
79874162|NCT00930137|Other|isocaloric for week diet|"Consumption of the 2 experimental diets~a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
80030857|NCT04732845|Biological|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10^5 cells/kg) Level 1 [Starting Dose] (5 x 10^5 cells/kg) Level 2 (1 x 10^6 cells/kg) Level 3 (2 x 10^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
80030858|NCT04732845|Drug|Fludarabine|25 mg/m2 daily from day -5 to -3
80030859|NCT04732845|Drug|Cyclophosphamide|60mg/Kg on day -6
80030860|NCT04693585|Behavioral|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
79276225|NCT02177045|Drug|Sonovue, Bracco|Intravenous injection
79276226|NCT02403375|Device|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
79276227|NCT00578695|Drug|lixivaptan|Oral Capsule
79874163|NCT01015404|Drug|Trafermin|Administered to the bone defect during flap operation
79874164|NCT00934271|Radiation|fractionated stereotactic radiotherapy|Audit of outcome
79874165|NCT00492024|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
79874166|NCT00492024|Drug|Placebo|Placebo - 380 mg Microcrystalline Cellulose
79874167|NCT00934427|Drug|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
80030861|NCT04693585|Behavioral|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
80030862|NCT04670536|Device|PASS LP implants|Thoraco lumbar arthrodesis
79874168|NCT00934427|Drug|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
79874169|NCT00926315|Drug|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
79874170|NCT00926315|Drug|Calcitriol|calcitriol 0.25 mcg PO bid
80030863|NCT04670536|Device|PASS DEGEN|Thoraco lumbar arthrodesis
80030864|NCT04670536|Device|PASS TULIP PRIME|Thoraco lumbar arthrodesis
80030865|NCT04634435|Combination Product|CIML NK Cells plus KP1237 and low dose IL-2|Single dose infusion of CIML NK Cells plus KP1237 followed by low dose IL-2
80030866|NCT04614610|Drug|Lidocaine Iv|Lidocaine 1.5mg/kg (Max dose: 200mg) in Dextrose 5% 100mL over 10 minutes
80030867|NCT04614610|Drug|Placebo|Dextrose 5% 100mL over 10 minutes
80030868|NCT04613453|Drug|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
80030869|NCT04613453|Drug|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
79276228|NCT00578695|Drug|Placebo|Oral Capsule
79276229|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 soft gelatine capsules|
79276230|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 film-coated tablets|
79276231|NCT02183285|Dietary Supplement|Placebo film-coated tablets (fct)|
79276232|NCT02183285|Dietary Supplement|Placebo soft gelatine capsules|
79276233|NCT02183363|Drug|BI 1356 - Tablet TFII|
79276234|NCT02183363|Drug|BI 1356 - Tablet iFF|
79276235|NCT02183363|Drug|BI 1356 - Tablet TFIIb|
79276236|NCT02387151|Drug|mesenchymal stromal cells|2 doses of 1-2x10^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
80030870|NCT04562740|Device|ABLUMINUS DES drug eluting stent|Following successful plain balloon angioplasty of the arterial lesion, (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.
79403898|NCT03588091|Drug|Docetaxel|docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
79874171|NCT01013454|Drug|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload [drug amount loaded in each patch]) will be applied to the upper back over a single 24 hour period
79874172|NCT00930215|Drug|D961H|Oral gelatin capsule
79403899|NCT04422756|Diagnostic Test|Seated intravenous saline infusion test|"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels <140 pmol/L will be considered as negative, levels >280 pmol/L as positive, and levels in between classified as indeterminate."
79874173|NCT00930215|Drug|D961H|Oral HPMC capsule
79874174|NCT00926471|Behavioral|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
80030871|NCT04535219|Other|Exercise|60 minutes of moderate-intensity treadmill exercise (70% of maximal heart rate determined from the maximal graded exercise test)
79403900|NCT04422756|Diagnostic Test|Ultra low-dose ACTH stimulation test|"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone >2200 pmol/L and ARR >220 pmol/L/mIU/L following stimulation."
79403901|NCT04140253|Behavioral|Pelvic floor muscle training (PFMT) with lumbopelvic stabilization|"Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~Educating of probands about anatomy, physiology, and pelvic floor muscles functions~Training of pelvic floor muscles in different position~Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist."
79738997|NCT04256733|Biological|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
79738998|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
79738999|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
79739000|NCT00922623|Device|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
79739001|NCT01025232|Drug|Ranibizumab|Intravitreal Injection of 2.0mg formulation
79739002|NCT04300452|Drug|Carbetocin|Administration of Carbetocin after placental detachment
79739003|NCT04300452|Drug|Ergometrine Maleate|Administration of ergometrin after placental detachment
79739004|NCT04252755|Behavioral|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
79739005|NCT01025154|Drug|Clofarabine|Induction Cycle: 20 mg/m^2 IV over approximately 1 hour daily for 5 days (days 1-5)
79739006|NCT01025154|Drug|Idarubicin|Induction Cycle: 10 mg/m^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
79739007|NCT01025154|Drug|Cytarabine|Induction Cycle: 1 g/m^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
79739008|NCT04252833|Drug|CT-044|CT-044 HCl is a reactive species decomposition accelerant
79739009|NCT04252911|Other|Bispectral index score|Bis value from two sites gives similar results
79739010|NCT04252365|Drug|Sintilimab|Given i.v.
79739011|NCT04252365|Drug|Pembrolizumab|Given i.v.
79739012|NCT04256499|Procedure|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
79739013|NCT04256577|Diagnostic Test|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
79739014|NCT04252443|Other|Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital|Interventions involving nurses' pharmacological level
79739015|NCT00832819|Drug|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
79739016|NCT00832819|Drug|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
79739017|NCT00832819|Drug|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
79739018|NCT00832819|Drug|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
79739019|NCT04820361|Drug|Cannabis sativa L., folium cum flore|Muscle Relaxation
79874175|NCT00491556|Procedure|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
80030872|NCT04535219|Other|Supervised Total Sleep Deprivation|Laboratory-monitored total sleep deprivation
80030873|NCT04499924|Drug|tucatinib|300 mg given twice daily orally
80030874|NCT04499924|Drug|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
79739020|NCT04820361|Drug|Placebo|Muscle Relaxation
79874176|NCT00491556|Procedure|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
79874177|NCT04015037|Combination Product|placebo or drug|Group A and B (medicated or placebo)
79579874|NCT01910454|Behavioral|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
79579875|NCT01910467|Device|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
79874178|NCT00926549|Device|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
79579876|NCT01910467|Device|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
79579877|NCT01910480|Drug|NBI-98854 50 mg capsule once daily|
79874179|NCT00926627|Drug|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
79579878|NCT01910480|Drug|Ketoconazole 400 mg (200 mg twice daily)|
79874180|NCT00926627|Drug|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
79874181|NCT00934583|Behavioral|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
79874182|NCT00934739|Drug|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
79874183|NCT00934739|Drug|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
79874184|NCT00930371|Other|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
80030875|NCT04499924|Drug|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
80030876|NCT04499924|Drug|paclitaxel|60 or 80 mg/m^2 IV on Days 1, 8, and 15 of each cycle
80030877|NCT04499924|Other|tucatinib placebo|Given twice daily orally
79403902|NCT05114304|Other|Evaluation of co-morbid psychiatric disorders|"Added scales :~Mini Internationnal Neuropsychiatric Interview~Fagerström test~DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
79403903|NCT01518374|Drug|Florbetapir F 18|370 MBq (10 mCi)
80030878|NCT04499924|Other|trastuzumab placebo|IV on Days 1 and 15 of each cycle
79403904|NCT04359654|Drug|Dornase Alfa Inhalation Solution [Pulmozyme]|Nebulised Dornase alfa 2.5mg bd for 7 days
79739021|NCT04256655|Drug|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
79739022|NCT04256655|Drug|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
79739023|NCT04256655|Drug|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
80030879|NCT04481555|Drug|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
79874185|NCT00930371|Other|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
79874186|NCT01015482|Drug|Remifentanil|Remifentanil Infusion
79874187|NCT01015482|Drug|Midazolam|Midazolam Infusion
80030880|NCT04481555|Drug|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
80030881|NCT04453020|Device|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
80030882|NCT04437511|Drug|Donanemab|Given IV
80030883|NCT04437511|Drug|Placebo|Given IV
79739024|NCT05320497|Device|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
79739025|NCT00853723|Drug|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
79739026|NCT00853723|Drug|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
79579879|NCT01910493|Behavioral|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
79579880|NCT01910506|Drug|RDEA3170 10 mg|
80030884|NCT04434768|Biological|UMSC01|There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
80030885|NCT04370587|Biological|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
79403905|NCT03588013|Other|Nutritional education|4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ < -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
79739027|NCT00853723|Drug|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
79739028|NCT01104545|Drug|MK-3614|
79739029|NCT01104545|Drug|Comparator: Placebo|
79874188|NCT03760679|Device|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
80030886|NCT04370587|Combination Product|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
79403906|NCT03588013|Dietary Supplement|Ready to Use Therapeutic Food|If child remains WHZ < -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
79579881|NCT01910532|Drug|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
79579882|NCT01910545|Drug|OTS167IV|
79579883|NCT01910558|Dietary Supplement|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
79579884|NCT01910558|Dietary Supplement|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
79739030|NCT04117789|Behavioral|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
79739031|NCT04117789|Behavioral|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
79739032|NCT04117789|Other|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
79739033|NCT00918255|Biological|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
79739034|NCT00918255|Drug|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
79403907|NCT03588013|Procedure|Upper gastrointestinal endoscopy with biopsy|If child remains at WHZ < -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
79579885|NCT01910558|Dietary Supplement|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
79739035|NCT04252131|Drug|cassia seed tablet|traditional Chinese herbs
79739036|NCT04252053|Other|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
79739037|NCT04252053|Other|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
79739038|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
79739039|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
79874189|NCT03760679|Device|i-gel evaluation|Device: i-gel evaluation
79874190|NCT00934817|Drug|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
79874191|NCT00934817|Drug|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
79874192|NCT01013532|Drug|Cilostazol|Cilostazol 100mg bid
79874193|NCT01013532|Drug|Probucol|Probucol 250mg bid
79874194|NCT01013532|Drug|Aspirin|Aspirin 100mg qd
80030887|NCT04357353|Biological|Platelet rich plasma|PRP will be used in the experimental arm.
80030888|NCT04357353|Other|Placebo Sham Injection|sham injection
80030889|NCT04347447|Other|Exercise training|All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
80030890|NCT04321343|Drug|PXL065|PXL065 oral tablet
80030891|NCT04321343|Drug|Placebo oral tablet|Placebo oral tablet
80030892|NCT04318938|Drug|Brigatinib|Treatment with Brigatinib
80030893|NCT04318938|Drug|Tyrosine kinase inhibitor|Treatment with any TKI
80030894|NCT04298255|Other|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
80030895|NCT04298255|Other|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
79579886|NCT01910571|Drug|P7435|
79739040|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
79739041|NCT01096589|Device|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
79739042|NCT04252521|Drug|metoclopramide|10 mg Metpamid in 100 ml normal saline solution
79579887|NCT01910571|Other|Placebo|
79739043|NCT04252521|Drug|dexketoprofen trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution
79579888|NCT01910584|Procedure|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
79579889|NCT01910597|Drug|SBG|
79579890|NCT01910610|Biological|FOLFIRI-cetuximab|
79579891|NCT01910610|Biological|mFOLFOX6-bevacizumab|
79579892|NCT01910610|Biological|OPTIMOX-bevacizumab|
79874195|NCT01013532|Drug|placebo of cilostazol|same shape and size of active cilostazol
79579893|NCT01910610|Biological|irinotecan-based chemo + bevacizumab|
79874196|NCT01013532|Drug|placebo of aspirin|same size and shape of active aspirin 100mg
79874197|NCT01013532|Device|ankle-brachial index (ABI)|measurement of ABI every years during follow up
79874198|NCT01013532|Device|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
79579894|NCT01910610|Biological|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
79579895|NCT01910610|Biological|XELOX + bevacizumab|
79579896|NCT01910623|Other|Health Related Quality of Life (HRQOL) measures|
79739044|NCT04252521|Drug|metoclopramide+dexketoprofen trometamol|10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
79739045|NCT04819659|Device|Pharyngeal packing|Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
79739046|NCT04918745|Device|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~A - Baseline stimulation, no modulation stimulation~B - Baseline stimulation, modulated stimulation~C - Reduced baseline stimulation, modulated stimulation"
79874199|NCT01013532|Device|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
79874200|NCT01013532|Device|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
79874201|NCT01012206|Behavioral|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
79874202|NCT00926705|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
79874203|NCT00926705|Drug|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
79874204|NCT00930449|Other|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
79874205|NCT00930449|Other|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
79874206|NCT00930449|Other|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
79874207|NCT00506454|Drug|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
79874208|NCT00506454|Drug|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
79579897|NCT01910649|Drug|Drisapersen|Subcutaneous and Intravenous
79579898|NCT01910662|Other|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
79874209|NCT03415139|Drug|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
79874210|NCT03415139|Drug|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
79579899|NCT01910662|Other|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
79579900|NCT01910662|Other|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
79579901|NCT01910662|Other|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
79579902|NCT01910675|Drug|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
79579903|NCT01910675|Drug|FFP|4 units Octaplas. Additional fibrinogen if needed.
79579904|NCT01910701|Behavioral|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
79739047|NCT00845065|Drug|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
79874211|NCT03415139|Drug|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
79874212|NCT01012284|Drug|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
79874213|NCT00930527|Dietary Supplement|Omega-3 Fatty Acid|4g per day for 3 weeks
79874214|NCT00934973|Drug|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
80030896|NCT04292717|Behavioral|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
79403908|NCT04436172|Procedure|spinal anesthesia|The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
79579905|NCT01910714|Behavioral|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
79579906|NCT01910714|Behavioral|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
79739048|NCT00845065|Other|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
79739049|NCT00845065|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
79739050|NCT00845065|Drug|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
79874215|NCT00934973|Drug|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
80030897|NCT04274153|Biological|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
79874216|NCT00934973|Drug|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
79874217|NCT00934973|Behavioral|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
79874218|NCT00934973|Behavioral|No website|No CBT website
80030898|NCT04238754|Drug|Epidiolex|Epidiolex 100 mg/mL Oral Solution
80030899|NCT04238754|Drug|Placebo|Cherry syrup oral solution
79874219|NCT00934973|Behavioral|CBT website with minimal support|
79874220|NCT00485472|Drug|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
79874221|NCT00485472|Other|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
79874222|NCT00930605|Drug|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
79874223|NCT00930605|Drug|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
79874224|NCT01018836|Drug|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
79874225|NCT01018836|Radiation|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
80030900|NCT04232358|Drug|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
79874226|NCT00935051|Other|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
79874227|NCT04015661|Drug|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
79874228|NCT00491400|Drug|Fenofibrate|140 mg/day for 8 weeks
79874229|NCT00491400|Drug|Atorvastatin|20 mg/day for 8 weeks
80030901|NCT04232358|Drug|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
79874230|NCT04015583|Behavioral|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
79874231|NCT00491322|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
80030902|NCT04225234|Other|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
79276237|NCT02179541|Other|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
79739051|NCT04772001|Drug|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
79739052|NCT04772001|Drug|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
79739053|NCT04772001|Radiation|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
79874232|NCT00491322|Dietary Supplement|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
79874233|NCT00930683|Drug|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
79276238|NCT02387073|Other|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
79276239|NCT02179619|Device|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
79276240|NCT02179619|Device|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
79874234|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
79579907|NCT01910727|Behavioral|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
79276241|NCT02183441|Drug|BI 1356|
79579908|NCT01910740|Other|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
79579909|NCT01910740|Other|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
79579910|NCT01910740|Other|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
79739054|NCT02880059|Device|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
79739055|NCT00702091|Drug|Ramipril|10 mg capsule
79739056|NCT00626171|Procedure|Allergen Challenge|Allergen challenge
79739057|NCT00832585|Drug|Alefacept|Alefacept 15mg IM every week for 12 weeks
79739058|NCT00918567|Drug|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
79739059|NCT00918567|Behavioral|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
79739060|NCT04255797|Behavioral|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
79739061|NCT05252325|Device|hyaluronic acid plus lidocaine|local injection for correction of nasolabials fold
79739062|NCT05252325|Device|hyaluronic acid without lidocaine|local injection for correction of nasolabial folds
79874235|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
79874236|NCT00930683|Drug|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
79874237|NCT00930683|Drug|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
79874238|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
79874239|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
79874240|NCT00930683|Drug|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
79874241|NCT00930683|Drug|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
79874242|NCT00926861|Device|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
79276242|NCT02183441|Drug|Ritonavir|
79874243|NCT00926861|Device|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
79579911|NCT01910753|Procedure|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
80030903|NCT04223570|Device|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
79579912|NCT01910766|Drug|Coenzyme Q10|no more details
79579913|NCT01910766|Drug|clomiphene citrate|
80030904|NCT04220190|Biological|RAPA-501 Autologous T cells|TREG/Th2 cells
80030905|NCT04213820|Device|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
79739063|NCT04255641|Other|time lapse analysis|grading of the embryos before freezing using time lapse/
79739064|NCT04770051|Procedure|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
79739065|NCT05252091|Drug|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
79739066|NCT01024920|Drug|BIBF 1120|VEGF inhibitor
79276243|NCT02403219|Drug|Botulinum toxin type A injection|Injection of botulinum toxin type A
79739067|NCT01024920|Drug|sunitinib|VEGF inhibitor
79739068|NCT00832117|Drug|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
79874244|NCT00935129|Device|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
79874245|NCT00935129|Device|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
79874246|NCT00930839|Drug|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
79276244|NCT02403219|Other|Saline solution injection|Injection of saline solution
79276245|NCT03537287|Drug|17 alpha hydroxyprogestrone caproate|250 mg of 17 alpha hydroxyprogestrone caproate weekly
79579914|NCT01910779|Procedure|100 joule as first biphasic shock energy|
79579915|NCT01910779|Procedure|120 joule as first biphasic shock energy|
79579916|NCT01910805|Behavioral|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
79579917|NCT01910844|Drug|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
79874247|NCT00935207|Other|Pediatric Pain Diary|Pain diary designed for pediatric patients
79276246|NCT03537287|Drug|Vaginal progesterone|200 mg of vaginal progesterone daily
79276247|NCT03537287|Drug|Oral dydrogesterone|2 tablets of dydrogesterone daily
79276248|NCT02280031|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
79579918|NCT01910844|Drug|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
79579919|NCT01910857|Behavioral|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
79579920|NCT01910870|Drug|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
79739069|NCT00832117|Drug|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
79739070|NCT00832117|Drug|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
79276249|NCT02280031|Drug|Placebo|Capsule containing placebo pill with lactose
79276250|NCT02386761|Drug|Single Ascending Dose (SAD)|
79739071|NCT00832117|Drug|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
79739072|NCT02873052|Device|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
79874248|NCT01013610|Drug|LNK-754|Escalating dose
79874249|NCT01013610|Drug|Placebo|Escalating dose
79874250|NCT00926939|Behavioral|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
79874251|NCT00926939|Behavioral|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
79739073|NCT02611843|Behavioral|Peer-Supported Web CBT|
79276251|NCT02386761|Drug|Multiple Ascending Dose (MAD)|
79276252|NCT00449605|Drug|Rimonabant|Tablet, oral administration
79874252|NCT01015716|Behavioral|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
79874253|NCT01015716|Behavioral|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
79579921|NCT01910870|Drug|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
79579922|NCT01910883|Drug|Finafloxacin i.v. solution 200 mg|
79579923|NCT01910883|Drug|Finafloxacin i.v. solution 400 mg|
79579924|NCT01910883|Drug|Finafloxacin i.v. solution 600 mg|
79579925|NCT01910883|Drug|Finafloxacin i.v. solution 800 mg|
80030906|NCT04213820|Behavioral|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
80030907|NCT04213820|Behavioral|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
80030908|NCT04212143|Other|there is no intervention|There is no intervention in this study. It is observational only.
80030909|NCT04208958|Biological|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
80030910|NCT04208958|Drug|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
80030911|NCT04208958|Drug|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
79579926|NCT01910883|Drug|Finafloxacin i.v. solution 1000 mg|
79579927|NCT01910883|Drug|Placebo i.v. solution|
79739074|NCT02611843|Behavioral|Self-Managed Web CBT|
79739075|NCT02872272|Drug|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
79874254|NCT00927017|Other|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
79874255|NCT00927017|Other|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
79874256|NCT03997032|Dietary Supplement|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
80030912|NCT04205955|Other|Best Practice|Receive healthy living education via phone call
79579928|NCT01910896|Device|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
79739076|NCT02872896|Procedure|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
79874257|NCT00930917|Device|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
79874258|NCT00930917|Device|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
80030913|NCT04205955|Dietary Supplement|Dietary Intervention|Receive diet modification coaching via phone call
79276253|NCT00449605|Drug|Glimepiride|Tablet, oral administration
79276254|NCT00449605|Drug|Metformin|Metformin continued at stable dose as background therapy
79276255|NCT02403297|Device|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
79276256|NCT02774239|Drug|Human normal immunoglobulin G (IgG)|"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."
79276257|NCT02179697|Other|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
79579929|NCT01910935|Behavioral|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
79874259|NCT00930917|Other|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
79874260|NCT01015794|Drug|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
79874261|NCT01015794|Drug|ephedrine hydrochloride|single dose of 1 mg/kg body weight
79874262|NCT01015872|Device|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
79874263|NCT00935363|Drug|glyburide|single oral dose
79874264|NCT00935363|Drug|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
79874265|NCT00935363|Drug|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
79579930|NCT01910948|Drug|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
79579931|NCT01910961|Procedure|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
79579932|NCT01910974|Procedure|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
79874266|NCT00935363|Drug|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
79874267|NCT00930995|Drug|Candesartan|16mg po daily
79874268|NCT00930995|Drug|Placebo|once daily
79874269|NCT00935441|Behavioral|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
80030914|NCT04205955|Other|Message|Receive motivational messages via email and/or text message
80030915|NCT04205955|Other|Quality-of-Life Assessment|Ancillary studies
79739077|NCT02612467|Other|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
79874270|NCT00935441|Behavioral|usual case management|telephone contact with a case manager
79276258|NCT02179697|Procedure|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
79276259|NCT02386683|Other|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
79579933|NCT01910987|Drug|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
79579934|NCT01910987|Drug|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
79579935|NCT01910987|Drug|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
79874271|NCT01015950|Dietary Supplement|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
79579936|NCT01910987|Drug|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
79579937|NCT01911000|Radiation|RT and hyperthermia after TACE|
79579938|NCT01911026|Other|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
79579939|NCT01911039|Biological|Regulatory T Cells|
79579940|NCT01911052|Other|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
79579941|NCT01911052|Other|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
79579942|NCT01911078|Procedure|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
79579943|NCT01911078|Device|EnligHTN™ Renal Denervation System.|
79739078|NCT02612467|Other|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
80030916|NCT04205955|Other|Questionnaire Administration|Ancillary studies
80030917|NCT04183179|Behavioral|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
80030918|NCT04175444|Diagnostic Test|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
79276260|NCT02280109|Drug|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
79276261|NCT02280109|Drug|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
79276262|NCT02403141|Other|Questionnaire|
79276263|NCT02183753|Other|wood smoke|
79276264|NCT02183753|Other|clean air|
79276265|NCT00576667|Drug|Rimonabant|Tablet, oral administration
79276266|NCT00576667|Drug|Placebo (for Rimonabant)|Tablet, oral administration
79739079|NCT04205292|Procedure|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
79874272|NCT01015950|Dietary Supplement|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
79874273|NCT01015950|Dietary Supplement|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
80030919|NCT04175444|Diagnostic Test|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
79276267|NCT02403063|Drug|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
79276268|NCT02403063|Drug|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
79276269|NCT02403063|Drug|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
80030920|NCT04150068|Drug|Oral Lenacapavir|Tablets administered without regard to food
80030921|NCT04150068|Drug|Oral Lenacapavir Placebo|Tablets administered without regard to food
79276270|NCT02177279|Other|Visit A high wheat bran|
79276271|NCT02177279|Other|Visit B normal wheat bran|
79276272|NCT02177279|Other|Follow up normal (8days) and high (1day) bran consumption|
79276273|NCT04472221|Procedure|Arterioarterial synthetic graft|Synthetic poly tetraflouroethylene graft
79276274|NCT02177357|Drug|Pramipexole|
79276275|NCT02177357|Drug|Placebo|
79276276|NCT02391051|Radiation|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
79276277|NCT04471831|Other|Rehabilitation exercise protocol|"The exercise package will then be sent to them after securing video contact with the prospective participant. Only participants with smart phone that can receive the video package will be selected for this study.~Physiotherapy-Patients' Engagements At every morning after their prescribed drugs might have been served in the ward, the physiotherapist will call the participant for the exercises. The patient will be connected to the physiotherapist who is in his clinic (not in the isolation ward with the patients) through a WhatsApp or zoom video call. The physiotherapist will control the rhythm and pace of the exercises through the video interactions."
79276278|NCT02030093|Behavioral|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
79276279|NCT02386449|Drug|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
79579944|NCT01911156|Drug|Continue NA treatment|Prescribed NA during the 72 week study period
79579945|NCT01911156|Drug|Discontinue NA Treatment|Discontinue NA Treatment
79874274|NCT01015950|Dietary Supplement|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
79403909|NCT03446989|Behavioral|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
79579946|NCT01911182|Other|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
79579947|NCT01911208|Behavioral|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
79579948|NCT01911208|Behavioral|Control|Non-intervention control.
79579949|NCT01911234|Biological|TNF-Kinoid|IM administration
79579950|NCT01911234|Other|Placebo|IM administration
79579951|NCT01911247|Drug|Metformin|Metformin 850 mg once daily
79739080|NCT01104311|Procedure|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
79739081|NCT01104311|Procedure|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
79739082|NCT02612389|Other|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
79739083|NCT04205214|Behavioral|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
79739084|NCT00702247|Procedure|Hematopoietic Stem Cell Transplantation|
79739085|NCT00831493|Radiation|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
79739086|NCT00831493|Drug|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
79739087|NCT00853567|Drug|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
79739088|NCT00853567|Other|placebo|Placebo
79739089|NCT00853489|Device|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
79739090|NCT00853489|Procedure|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
79874275|NCT00931073|Drug|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
80030922|NCT04150068|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
79276280|NCT02386449|Drug|mannitol|
79276281|NCT02386449|Drug|Bisacodyl|
79276282|NCT00656539|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
79276283|NCT02391129|Procedure|Operation for Periprosthetic fractures of the hip with stem loosening|
79276284|NCT02179775|Drug|propranolol|
79276285|NCT02179775|Drug|Quince's oxymel|
79276286|NCT02179775|Drug|placebo|
79276287|NCT00566449|Drug|Placebo|one dose daily for 4 weeks
79276288|NCT00566449|Drug|JNJ-31001074|10 mg daily for 4 weeks
79276289|NCT00566449|Drug|JNJ-31001074|30 mg daily for 4 weeks
79276290|NCT02390973|Procedure|Sleeve Gastrectomy|
79276291|NCT02390973|Procedure|Roux-en-Y Gastric Bypass|
79276292|NCT02390973|Procedure|Biliopancreatic Diversion with Duodenal Switch|
79276293|NCT02390973|Other|Medical management|
79276294|NCT02177435|Drug|Telmisartan|
79276295|NCT02177435|Drug|Telmisartan/Hydrochlorothiazide|
79276296|NCT02177435|Drug|Placebo|
79276297|NCT02402829|Procedure|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
79276298|NCT02183831|Device|Insertion of the capsular tension ring|
79276299|NCT02284477|Other|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
79579952|NCT01911286|Procedure|Apnea test - Standard|
79579953|NCT01911286|Procedure|Apnea test - CPAP|
79579954|NCT01911299|Dietary Supplement|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
79579955|NCT01911299|Dietary Supplement|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
79276300|NCT02284477|Other|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
79403910|NCT04740060|Other|Augmented Feedback without Virtual Reality(VR|"For Walking Speed:One-minute fast walking with visual augmented feedback without VR interface (we ask participants to look at a screen where their walking speed and distance are tracked and increase their speed).~For Step Length: Maximum step length with visual augmented feedback without VR interface in which we ask participants to look at a screen where their step length is displayed and attempt to increase their step length up."
79739091|NCT00705445|Dietary Supplement|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
79874276|NCT00931073|Drug|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
79276301|NCT02402985|Other|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
79276302|NCT02402985|Other|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
79276303|NCT02280265|Drug|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
79276304|NCT02179931|Drug|Flupentixol/melitracen film-coated tablet|
79276305|NCT02179931|Drug|Flupentixol/melitracen coated tablet (Deanxit®)|
79403911|NCT04740060|Other|Augmented Feedback with Non-Game based VR|"For Walking Speed:One-minute fast walking with basic VR interface (we ask participants to look at a screen where their avatar walker representative will be represented in a virtual walking environment and try to make the avatar walk faster).~For Step Length: Maximum step length with basic VR interface in which we ask participants to look at their avatar feet in a virtual stepping environment and step with the avatar foot as far as possible."
79579956|NCT01911312|Device|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
79579957|NCT01911312|Device|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
79579958|NCT01911325|Drug|Buparlisib|
79579959|NCT01911325|Drug|Buparlisib matching placebo|
79579960|NCT01911325|Drug|Docetaxel|
79579961|NCT01911338|Device|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
79739092|NCT00705445|Dietary Supplement|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
79874277|NCT00931073|Drug|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
79874278|NCT01016028|Behavioral|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
79276306|NCT00655369|Drug|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
79276307|NCT00655369|Drug|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
79276308|NCT00655369|Drug|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
79276309|NCT00655369|Drug|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
79739093|NCT00705445|Other|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
79739094|NCT02879981|Drug|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
79739095|NCT02879981|Drug|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
79276310|NCT00655369|Drug|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
79276311|NCT00655369|Drug|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
79276312|NCT02184065|Drug|Meloxicam|
79276313|NCT03538067|Procedure|Percutaneous coronary intervention (PCI)|Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
79276314|NCT03537989|Drug|Saline|To reduce the volume of saline administered during surgery of the colon and the rectum
79276315|NCT00564421|Drug|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
79276316|NCT00564421|Other|placebo nasal spray|2 sprays in each nostril, dosed twice a day
79276317|NCT00564421|Drug|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
79276318|NCT00564421|Drug|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
79276319|NCT00564421|Drug|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
79276320|NCT00653185|Drug|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
79276321|NCT00653185|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
79276322|NCT00653185|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
79276323|NCT00653185|Drug|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
79579962|NCT01911338|Device|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
79579963|NCT01911364|Drug|BDP/FF/GB|Superiority over Tiotropium
79579964|NCT01911364|Drug|Tiotropium|Superiority of CHF5993 over Tiotropium
80030923|NCT04150068|Drug|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
79276324|NCT00653185|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
79276325|NCT02665689|Drug|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
79276326|NCT02386293|Drug|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
79276327|NCT02386293|Other|Placebo|Sugar pill made to look identical to irbesartan intervention.
79579965|NCT01911364|Drug|BDP/FF + Tiotropium|non inferiority vs CHF5993
79579966|NCT01911377|Drug|Botulinum Toxin Type A|
79579967|NCT01911377|Drug|Normal Saline for Injection|
79579968|NCT01911416|Drug|LDE225|
79579969|NCT01911455|Drug|acamprosate|
79579970|NCT01911455|Drug|Placebo|
79739096|NCT02879981|Drug|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
79739097|NCT04307693|Drug|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
79874279|NCT01016028|Behavioral|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
79874280|NCT01016028|Behavioral|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
79276328|NCT00563563|Drug|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
79276329|NCT00563563|Behavioral|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
79579971|NCT01911468|Drug|metformin|
79579972|NCT01911468|Drug|liraglutide|
79739098|NCT04307693|Drug|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
79739099|NCT02878421|Device|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
79579973|NCT01911468|Drug|metformin and liraglutide|
79579974|NCT01911481|Other|hydration|
79579975|NCT01911494|Behavioral|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
79739100|NCT02878421|Other|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
79874281|NCT00935597|Biological|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
80030924|NCT04150068|Drug|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
80030925|NCT04144153|Combination Product|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
80030926|NCT04144153|Combination Product|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
79276330|NCT02184221|Device|High frequency stimulation|The parameter of DMS: alpha frequency
79276331|NCT02184221|Device|Low frequency stimulation|The parameter of DMS: 0.5Hz
79579976|NCT01911494|Device|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
79579977|NCT01911494|Drug|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
79579978|NCT01911494|Drug|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
79579979|NCT01911507|Drug|INC280|Given PO
79579980|NCT01911507|Drug|erlotinib hydrochloride|Given PO
79579981|NCT01911520|Drug|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
79579982|NCT01911520|Drug|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
79579983|NCT01911520|Procedure|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
79579984|NCT01911520|Procedure|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
79579985|NCT01911559|Device|standing-frame|
79739101|NCT02878421|Other|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
79276332|NCT05149365|Drug|Sitagliptin + Standard Prophylaxis|Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
79276333|NCT05149365|Drug|Standard Prophylaxis|Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
79579986|NCT01911585|Behavioral|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
79579987|NCT01911598|Drug|5-FU|5-FU will be administered as per schedule specified in the respective arm.
79579988|NCT01911598|Drug|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
79579989|NCT01911598|Drug|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
79579990|NCT01911598|Drug|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
79579991|NCT01911598|Drug|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
79579992|NCT01911611|Drug|RO6870868|Single ascending doses
79579993|NCT01911611|Drug|placebo|Single ascending doses
79739102|NCT02878187|Device|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
79739103|NCT04307303|Device|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
79739104|NCT02879903|Procedure|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
79739105|NCT02879903|Procedure|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
79739106|NCT02879903|Procedure|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
79739107|NCT04307459|Other|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
79739108|NCT01019694|Drug|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
79739109|NCT01019694|Drug|Combivent Respimat 20/100 mcg|Open label randomized parallel
79276334|NCT02180087|Drug|Ketoprofen|
79276335|NCT02390583|Behavioral|CBT treatment of internet dependence|CBT treatment of internet dependence
79276336|NCT02390583|Behavioral|CBT treatment of sleep disorders|CBT treatment of sleep disorders
79276337|NCT02280343|Other|evaluated lung function|lung function tests
79276338|NCT02402751|Procedure|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
79276339|NCT02402751|Device|MRI|
79276340|NCT02184299|Drug|Nevirapine|
79276341|NCT02184299|Drug|Prednisone|
79276342|NCT00651079|Drug|GSK1247303|
79276343|NCT02402673|Other|Temporary activity modification and graded exercises|
79403912|NCT04740060|Other|Augmented Feedback with Game based VR|"For Walking Speed: One-minute fast walking with the VR Racing exergame (we ask participants to look at a screen where their avatar walker representative present in a virtual racing environment with other avatar racers and try to beat the avatar racers).~For Step Length: Maximum step length with the VR Stepping Exergame (we ask participants to look at their avatar legs and avatar animals in a virtual stepping environment and try to step over the avatar animals without touching the animal."
79579994|NCT01911624|Drug|direct thrombin inhibition|
79579995|NCT01911624|Drug|enoxaparin|
79579996|NCT01911637|Drug|VBY-036|Study drug VBY-036
79579997|NCT01911637|Drug|Placebo|Placebo
79579998|NCT01911650|Other|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
79579999|NCT01911650|Other|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
79580000|NCT01911650|Other|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
79580001|NCT01911702|Other|Standard fluidic resuscitation.|"Goals:~arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~diuretic rhythm ≥ 1 ml / Kg / h~venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~BE> - 3~Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
79739110|NCT01019694|Drug|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
79739111|NCT00831415|Drug|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
79739112|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
79580002|NCT01911702|Other|Volemic small treatment|"Goals of the treatment:~arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~diuretic rhythm ≥ 0.5 ml / kg / h~venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~BE> - 5~PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be > 10-15 ml / kg / h an infusion of furosemide should be initiated"
79874282|NCT00931151|Dietary Supplement|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
79874283|NCT00936689|Procedure|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
79874284|NCT00936689|Procedure|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
79580003|NCT01911715|Drug|MDV3100|Oral
79739113|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
79739114|NCT01095653|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
79739115|NCT01095653|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
79874285|NCT01018914|Drug|Prograf|oral
80030927|NCT04128995|Procedure|Advanced Medical Therapy and Bariatric Surgery|Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
79276344|NCT03537053|Behavioral|A plan to Move a Little and Often|"The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993)."
79580004|NCT01911728|Drug|MDV3100|Oral
79580005|NCT01911728|Drug|Pioglitazone|Oral
79580006|NCT01911728|Drug|Warfarin|Oral
79580007|NCT01911728|Drug|Omeprazole|Oral
79580008|NCT01911728|Drug|Midazolam|Oral
79580009|NCT01911741|Drug|MDV3100|Oral
79580010|NCT01911754|Biological|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
79580011|NCT01911806|Device|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
79580012|NCT01911806|Procedure|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
79874286|NCT01018914|Drug|Advagraf|oral
79739116|NCT00913159|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
79580013|NCT01911832|Procedure|esophagojejunostomy after total gastrectomy|
79739117|NCT00920907|Biological|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
79874287|NCT01018914|Drug|Myfortic|oral
79874288|NCT01019070|Drug|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
79874289|NCT00936767|Drug|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
79874290|NCT00936767|Drug|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
79874291|NCT00931229|Drug|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
79874292|NCT01013688|Procedure|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
79874293|NCT00936923|Drug|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
79874294|NCT01019382|Drug|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
79874295|NCT04014023|Drug|DWP16001|DWP16001 tablets
79874296|NCT04014023|Drug|Placebo|DWP16001 placebo-matching tablets
80030928|NCT04128995|Drug|Advanced Medical Therapy|Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
80030929|NCT04128995|Procedure|Bariatric Surgery|Vertical Sleeve Gastrectomy for youth without type 2 diabetes
80030930|NCT04126577|Biological|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
80030931|NCT04114175|Other|Exercise BE|Basic exercises related to amputation will be applied
79580014|NCT01911832|Procedure|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
79580015|NCT01911832|Procedure|wide tube reconstruction after subtotal gastrectomy|
79580016|NCT01911832|Procedure|narrow tube reconstruction after subtotal gastrectomy|
79580017|NCT01911858|Device|Askina Calgitrol Paste|
79874297|NCT03997188|Device|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
79580018|NCT01911871|Biological|Blood sample|a blood sample was taken on the day of inclusion
79874298|NCT00935675|Drug|Escitalopram|Escitalopram 10 mg once a day
79874299|NCT01016184|Dietary Supplement|Vitamin D|Oral vitamin D 100,000 IU
79874300|NCT01016184|Dietary Supplement|Placebo|Placebo
79276345|NCT00549679|Drug|GSK256066|PDE4 inhibitor
79276346|NCT00549679|Drug|Placebo|Placebo
79580019|NCT01911884|Behavioral|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
79580020|NCT01911923|Procedure|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
79580021|NCT01911923|Procedure|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
79580022|NCT01911936|Drug|LM716|
79580023|NCT01911949|Drug|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
79739118|NCT00705601|Procedure|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
79739119|NCT01103141|Device|Micropuncture needle set|Groin access for vascular intervention
79739120|NCT01103141|Device|Standard gauge-18 needle set|Groin access for vascular intervention
79276347|NCT02386137|Device|Contrast-enhancement ultrasound with Sonovue|
79276348|NCT04481763|Drug|Camrelizumab|Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
79276349|NCT04481763|Radiation|radiotherapy|radiotherapy
79403913|NCT03587935|Other|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
79580024|NCT01911962|Procedure|transvaginal laparoscopic surgery|
79580025|NCT01911975|Drug|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
79580026|NCT01911975|Drug|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
79874301|NCT00502320|Drug|Ramelteon|one 8 mg tablet at bed for up to 4 months
79874302|NCT00502320|Drug|Placebo|one tablet at bedtime for up to 4 months
79874303|NCT02567825|Device|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
79739121|NCT00700297|Drug|Colchicine|100 mg Colchicine per day for 4 months
79739122|NCT00700297|Drug|Placebo|One tablet placebo per day for 4 months
79739123|NCT04307147|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
79276350|NCT02282371|Drug|Cetuximab|
79276351|NCT02282371|Drug|BYL719|
79739124|NCT04307147|Drug|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
79739125|NCT00844831|Drug|Lubiprostone|24 mcg bid for 28 days
79739126|NCT02878343|Behavioral|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
79739127|NCT02878343|Behavioral|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
79739128|NCT04117633|Device|Laparoscopy|Laparoscopic Procedures for Rectopexy
79739129|NCT00920829|Drug|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
79739130|NCT00920829|Drug|Placebo|placebo
79739131|NCT04306835|Behavioral|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
79276352|NCT02282371|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
79276353|NCT02402595|Drug|AVP-923|
79276354|NCT02402595|Drug|AVP-786|
79276355|NCT02402595|Drug|Itraconazole|
79276356|NCT02177513|Drug|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
79276357|NCT02177513|Drug|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
79276358|NCT02177513|Drug|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
79276359|NCT02177513|Drug|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
79403914|NCT03587935|Other|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
79580027|NCT01912001|Other|Telephone follow-up|
79580028|NCT01912001|Other|Sympton Assessment|
79580029|NCT01912014|Behavioral|Psychosocial support and counselling|
79580030|NCT01912027|Procedure|Open Latarjet technique|
79580031|NCT01912027|Procedure|Arthroscopic Latarjet techniques|
79739132|NCT05010876|Drug|C1 Inhibitor Human|standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
79874304|NCT02567825|Drug|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
79739133|NCT05010876|Drug|Icatibant Injection|a single injection of 30 mg subcutaneously
79874305|NCT02567825|Drug|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
79874306|NCT00490776|Drug|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
80030932|NCT04114175|Other|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
79276360|NCT02177513|Drug|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
79276361|NCT00548587|Drug|E5555|
79276362|NCT00548587|Drug|Placebo|
79276363|NCT00548119|Biological|NeoCart|autologous tissue implant
79276364|NCT00548119|Procedure|microfracture|microfracture
79580032|NCT01912053|Radiation|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
79580033|NCT01912066|Drug|Stillen|
79580034|NCT01912066|Drug|Cytotec (reference drug)|
79580035|NCT01912066|Drug|NSAID (Aceclofenac)|
79580036|NCT01912092|Device|Askina Calgitrol paste|
79580037|NCT01912105|Device|Airway medix closed suction system|
79580038|NCT01912105|Device|standard closed suctioning systems|
79874307|NCT00935753|Drug|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
79874308|NCT01019460|Procedure|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
79874309|NCT00935831|Drug|GSK1278863A|50mg, 150mg
80030933|NCT04106154|Behavioral|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
80030934|NCT04056247|Other|Plasma sample collection|Collect at least two plasma samples
79580039|NCT01912118|Drug|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
79276365|NCT02180321|Drug|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
79276366|NCT02180321|Drug|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
79276367|NCT00547651|Drug|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
79276368|NCT00547651|Drug|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
79276369|NCT02665455|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
79276370|NCT03537911|Behavioral|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
79276371|NCT02177669|Other|quick Contrast Sensitivity Function test|
79276372|NCT05479461|Other|Digital Hypertension Management System|Mobile health technology using physician- directed, semi-automated management of hypertension
79580040|NCT01912118|Drug|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
79580041|NCT01912131|Behavioral|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
79580042|NCT01912131|Behavioral|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
79580043|NCT01912131|Behavioral|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences,
79580044|NCT01912131|Behavioral|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
79580045|NCT01912131|Behavioral|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
79580046|NCT01912144|Other|Coffee|
79580047|NCT01912157|Behavioral|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
79580048|NCT01912170|Dietary Supplement|Fish oil|
79580049|NCT01912170|Dietary Supplement|Flaxseed oil|
79580050|NCT01912183|Behavioral|Communication through PHR outside clinic|
79739134|NCT05010876|Other|Placebo|The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
79739135|NCT04307069|Drug|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
79739136|NCT02878265|Dietary Supplement|Vitamin A|Vitamin A supplements
79739137|NCT02878265|Dietary Supplement|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
79739138|NCT02878265|Dietary Supplement|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
79739139|NCT00831181|Drug|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
79739140|NCT00831181|Drug|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
79739141|NCT00831181|Drug|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
79276373|NCT05479461|Other|Usual Care|The participants will receive usual care
79580051|NCT01912183|Behavioral|Monitoring device in PHR|
79580052|NCT01912183|Device|Physical activity and sleep monitor|
80030935|NCT04045184|Other|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
80030936|NCT04003896|Drug|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
79874310|NCT00935831|Drug|Placebo|matching placebo
79580053|NCT01912183|Other|PHR|Access to their PHR
80030937|NCT03996005|Procedure|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
80030938|NCT03952156|Genetic|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
79276374|NCT02386215|Behavioral|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~One standard OraQuick ADVANCE I/II test kit~Written pre-test information including test instructions in written and pictorial form~A phone number that participants can call to obtain additional information~Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
79580054|NCT01912196|Drug|MSI-195|
79580055|NCT01912196|Drug|Placebo|
79874311|NCT01019538|Other|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
79874312|NCT00566735|Drug|Razadyne|The starting dose of study medication is 4 mg twice a day
79874313|NCT00566735|Drug|Placebo|4 mg, 2 times a day
79874314|NCT03653273|Other|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
79874315|NCT03653273|Drug|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
79874316|NCT00936143|Drug|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
79874317|NCT00937079|Other|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
79874318|NCT04013633|Other|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
80030939|NCT03952156|Genetic|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
79580056|NCT01912209|Behavioral|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
79580057|NCT01912235|Other|2-15N glutamine|Glutamine with N15 isotope tracer
79580058|NCT01912235|Other|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
79580059|NCT01912235|Other|1-13C glutamine|Glutamine carbon isotope tracer
79580060|NCT01912248|Other|strength training|strength training, lower limb.
79580061|NCT01912261|Drug|Placebo|one capsule orally daily times 84 days
79580062|NCT01912261|Drug|Polysaccharide iron complex|150 mg daily orally times 84 days
79580063|NCT01912300|Behavioral|experimental condition: Passvice Video game; Avtive Video game; Exercise|
79580064|NCT01912326|Device|Pacemaker Implantation|Implantation of a dual chamber pacemaker
79739142|NCT00831181|Procedure|mesorectal excision|mesorectal excision
79739143|NCT01023672|Drug|Armodafinil|150-250 mg armodafinil by mouth daily
79739144|NCT04251429|Other|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
79739145|NCT05252013|Other|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
79739146|NCT05252013|Other|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
79874319|NCT04013633|Other|Face-to-face training|Short face-to-face CPR training
79874320|NCT00566111|Drug|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
79874321|NCT00566111|Drug|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
79276375|NCT00546793|Biological|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
79403915|NCT04080986|Procedure|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
79276376|NCT02385981|Device|Stivax|
79874322|NCT00937313|Other|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
79276377|NCT02390661|Device|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
79580065|NCT01912365|Procedure|Above Elbow Cast|
79874323|NCT00514046|Drug|Vandetanib|once daily continuously (28 day cycles)
79276378|NCT05128799|Other|3 Wishes Program (3WP)|"The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds."
79276379|NCT02402283|Drug|Metronidazole benzoate oral granules|Single oral dose of 400 mg
79276380|NCT02402283|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
79276381|NCT02184533|Drug|sodium selenite|Given PO
79403916|NCT04080986|Procedure|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
79403917|NCT03587779|Drug|Sevoflurane|Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
79403918|NCT03587779|Drug|Desflurane|Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
79403919|NCT05580211|Device|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive ~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
79580066|NCT01912365|Procedure|Long Arm Splint|
79580067|NCT01912378|Drug|Oxytocin|
79580068|NCT01912378|Drug|Placebo nasal spray|
79580069|NCT01912391|Drug|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
79580070|NCT01912391|Drug|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
79739147|NCT00705835|Biological|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
79739148|NCT01094171|Biological|Poliorix TM|Intramuscular administration, 3 doses
79739149|NCT01094171|Biological|Infanrix TM|Intramuscular administration, 3 doses
79739150|NCT00702637|Drug|Modafinil|
79739151|NCT05251935|Other|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
79739152|NCT05251935|Combination Product|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
79276382|NCT02184533|Radiation|radiation therapy|Undergo radiation therapy
79276383|NCT02184533|Other|laboratory biomarker analysis|Correlative studies
79276384|NCT02184533|Other|pharmacological study|Correlative studies
79276385|NCT02184533|Other|questionnaire administration|Ancillary studies
79276386|NCT04470739|Diagnostic Test|chest x-ray|First Chest X-ray in the first 6 hours of infants
79276387|NCT02402205|Behavioral|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
79276388|NCT02386059|Drug|PLACEBO|received normal saline, intravenously
79276389|NCT02386059|Drug|Dexamethasone|4 mg, intravenously, at the start of surgery
79276390|NCT02386059|Drug|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
79276391|NCT02386059|Drug|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
79276392|NCT02184689|Drug|fexinidazole|
79276393|NCT00443287|Drug|ataciguat (HMR1766)|oral administration
79276394|NCT00443287|Drug|placebo|oral administration
79276395|NCT00443287|Drug|cilostazol|oral administration
79276396|NCT02385747|Procedure|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
79276397|NCT02962895|Biological|VAY736|VAY736
79403920|NCT05580211|Device|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive ~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
79739153|NCT01093625|Device|Narafilcon B Contact Lens|
79739154|NCT01093625|Device|Spectacles|spectacle wearers
79739155|NCT01023516|Drug|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
79739156|NCT01023516|Drug|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
79739157|NCT00844753|Drug|atomoxetine|atomoxetine
79739158|NCT00844753|Drug|Placebo|Placebo + parent management treatment
79739159|NCT00844753|Behavioral|Parent Management Training|
79739160|NCT02878109|Device|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
79276398|NCT02962895|Other|Placebo|Placebo control
79276399|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing < 20 kg
79580071|NCT01912417|Other|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
79276400|NCT00442039|Drug|Lithium Carbonate|"The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability"
79874324|NCT00937469|Behavioral|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
79580072|NCT01912430|Behavioral|ICC (Integrated Care Coaching) Intervention Group|
80030940|NCT03925675|Drug|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
79276401|NCT00442039|Drug|Lithium Carbonate|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
79276402|NCT00442039|Drug|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
79874325|NCT00937469|Other|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
79276403|NCT04481217|Other|Self-questionnaires battery|"Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, & Handelsman, 1997; Bernstein et al., 2003)~The Young schema questionnaire short form (SQ-SF ; Cottraux & Black, 2006; Young, 1998).~Dissociative experiences scale (Laroi et al., 2013).~Launay-Slade hallucination scale (Bentall & Slade, 1985; Launay & Slade, 1981)~Cardiff Anomalous Perceptions Scale (Bell et al., 2006)"
79874326|NCT00937625|Biological|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
79276404|NCT04481217|Other|Socio-demographic screening|age; gender; education; highest diploma; job; marital status; living place
79276405|NCT00546247|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
79580073|NCT01912443|Drug|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
79276406|NCT02956265|Device|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
79276407|NCT02390739|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
79580074|NCT01912469|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
79580075|NCT01912469|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
79739161|NCT02878109|Device|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
79739162|NCT05525611|Drug|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
79739163|NCT05525611|Other|Placebo|Placebo once a week in 12 weeks
79739164|NCT04309175|Device|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
79739165|NCT00830947|Device|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
79739166|NCT00830947|Device|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
79276408|NCT02390739|Drug|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
79276409|NCT02390739|Drug|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
79276410|NCT02390739|Biological|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
79276411|NCT02177747|Other|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
79276412|NCT02177747|Device|Smartphone|
79276413|NCT00544297|Drug|PEP005 gel|Two day application, 0.05%
79276414|NCT02385825|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
79276415|NCT02755805|Behavioral|CO-OP|
80030941|NCT03920293|Biological|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams [mg]/milliliter [mL]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
79403921|NCT05580133|Procedure|anterior cruciate ligament reconstruction|Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
79403922|NCT04688502|Other|High intensity interval training|High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
79580076|NCT01912482|Other|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
79580077|NCT01912482|Other|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
79580078|NCT01912521|Behavioral|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
79580079|NCT01912534|Drug|Valsartan|40, 80 and 160 mg tablets of Valsartan
79874327|NCT04014101|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
79874328|NCT04014101|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor.
79874329|NCT04014257|Drug|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
79874330|NCT00936533|Drug|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
79403923|NCT04688502|Other|Continuous exercise training|5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
79403924|NCT03587545|Other|Probiotic nasal spray|Total daily nasal administration of 2*10^8 CFU of probiotic bacteria delivered via 2 servings.
79580080|NCT01912534|Drug|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
79580081|NCT01912547|Procedure|Blood draw for TEG analysis|Blood drawn for TEG analysis
79580082|NCT01912573|Drug|Intranasal (IN) naloxone|
79874331|NCT00936533|Drug|Placebo|Placebo preparation without active compound, administered as the active drug.
79874332|NCT04618250|Other|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
80030942|NCT03920293|Drug|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
79276416|NCT02755805|Behavioral|Attention Control|
79276417|NCT02286349|Device|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
79276418|NCT02286349|Device|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
79276419|NCT03169647|Behavioral|Listening-based intervention|Participants will listen to pre-specified material on a CD
79403925|NCT03587545|Other|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
79403926|NCT04188756|Other|Exercise|High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
79403927|NCT03587467|Other|collect fecal specimens|collect fresh fecal specimens of participants
79403928|NCT04405921|Drug|Hydroxychloroquine 200 Mg Oral Tablet|orally or via gastric tube
79403929|NCT04405921|Drug|Azithromycin 250 MG|orally or via gastric tube
79403930|NCT05113836|Biological|Deep nasopharyngeal swab|On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
79580083|NCT01912573|Drug|Intravenous (IV) naloxone|
79580084|NCT01912573|Drug|Intramuscular (IM) naloxone|
79580085|NCT01912573|Drug|Intraosseus (IO) naloxone|
79276420|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
79276421|NCT00542035|Drug|Placebo; oral|dose 1, dose 2
79276422|NCT00542035|Drug|Placebo; oral|dose 1
79276423|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
79276424|NCT02177825|Drug|Imatinib Mesylate|oral administration
79276425|NCT02402049|Drug|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
79276426|NCT02402049|Drug|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
79276427|NCT02402049|Drug|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
79403931|NCT05113836|Biological|Blood sample at D1, D3 and D7|"Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total)."
79276428|NCT02402049|Drug|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
79580086|NCT01912586|Other|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
79580087|NCT01912638|Device|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
80030943|NCT03912376|Diagnostic Test|Quest Hyperspectral Imaging System|In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
79276429|NCT02402049|Drug|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
79276430|NCT02402049|Drug|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
79580088|NCT01912638|Drug|Provisc|Provisc is an cohesive viscoelastic.
79276431|NCT02402049|Drug|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
79276432|NCT02402049|Drug|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
79276433|NCT02402049|Drug|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
79276434|NCT02402049|Drug|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
79403932|NCT05583565|Other|sensory integration approach|Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment
79580089|NCT01912677|Drug|Nifedipine|
79580090|NCT01912677|Drug|Labetalol|
79580091|NCT01912677|Drug|Methyldopa|
79739167|NCT05524129|Other|rehabilitation exercise|Conventional rehabilitation exercise.
79580092|NCT01912690|Other|aerobic training|
79580093|NCT01912690|Other|aerobic and strength training|
79580094|NCT01912703|Other|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
79580095|NCT01912742|Behavioral|Very-low calorie diet (VLCD)|
79276435|NCT02402049|Drug|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
79739168|NCT05524129|Other|electrotherapy|A middle frequency electro-therapy
80030944|NCT03910387|Drug|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
80030945|NCT03910387|Drug|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
79580096|NCT01912742|Behavioral|Low calorie diet (LCD)|
79580097|NCT01912755|Drug|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
79580098|NCT01912755|Drug|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
79580099|NCT01912794|Other|Sensory Intervention|"full sensory information, whose participants will practice balancing tasks without constraint sensory body;~sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~control, whose participants will exercise activities involving cognitive and upper limbs."
79739169|NCT01018992|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
80030946|NCT03910387|Drug|Telotristat Ethyl|Given PO
80030947|NCT03882229|Device|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
80030948|NCT03871712|Behavioral|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
79276436|NCT02402049|Drug|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
79276437|NCT00539929|Drug|E6201 0.005%|
79276438|NCT00539929|Drug|E6201 0.01%|
79276439|NCT00539929|Drug|E6201 0.03%|
79276440|NCT00539929|Drug|Placebo|
79276441|NCT05141825|Radiation|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
79276442|NCT02180477|Drug|UHAC 62 XX - TF1 tablet|
79276443|NCT02180477|Drug|UHAC 62 XX - TF2 tablet|
79580100|NCT01912820|Dietary Supplement|green tea extract|Given PO
79580101|NCT01912820|Drug|quercetin|Given PO
79580102|NCT01912820|Other|placebo|Given PO
79580103|NCT01912820|Procedure|therapeutic conventional surgery|Undergo prostatectomy
79580104|NCT01912820|Other|laboratory biomarker analysis|Correlative studies
79580105|NCT01912846|Behavioral|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
79739170|NCT01018992|Drug|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
79739171|NCT00628368|Genetic|gene expression analysis|
79739172|NCT00628368|Genetic|mutation analysis|
79739173|NCT00628368|Genetic|polymorphism analysis|
79739174|NCT00628368|Other|laboratory biomarker analysis|
79739175|NCT00628368|Procedure|biopsy|
79739176|NCT00628368|Procedure|endoscopic biopsy|
79739177|NCT02872350|Device|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
79276444|NCT02180477|Drug|UHAC 62 XX - capsules|
79580106|NCT01912846|Behavioral|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
79276445|NCT02390817|Drug|Sugammadex|Administration of Sugammadex
79276446|NCT02390817|Drug|Neostigmine|Administration of Neostigmine
79580107|NCT01912859|Behavioral|Nutrition/physical activity intervention|Nutrition/physical activity intervention
79580108|NCT01912885|Device|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
79874333|NCT04264052|Diagnostic Test|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
79276447|NCT00537043|Drug|SK&F-105517 (COREG CR FDC)|
79276448|NCT02177903|Device|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
79580109|NCT01912885|Device|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
79580110|NCT01912885|Device|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
79580111|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
79580112|NCT01912885|Device|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
79580113|NCT01912898|Device|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
79739178|NCT00917553|Drug|doxycycline monohydrate|50 mg
79739179|NCT00917553|Drug|Placebo|Cellulose Placebo Capsule
79739180|NCT04809909|Procedure|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
79739181|NCT04809909|Procedure|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
79739182|NCT05251857|Behavioral|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
79739183|NCT04747509|Other|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
79276449|NCT02180555|Other|Oral glucose tolerance test|
79276450|NCT00387907|Drug|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
79276451|NCT00387907|Drug|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
79580114|NCT01912924|Device|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
79580115|NCT01912937|Device|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
79739184|NCT04747509|Other|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
79739185|NCT04255251|Drug|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
79874334|NCT00564629|Drug|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
79874335|NCT00564629|Drug|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
79276452|NCT02184845|Device|Implant NobelActive 3.0|
79276453|NCT02282449|Device|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
79276454|NCT02282449|Device|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
79276455|NCT02180633|Other|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
79276456|NCT02286427|Device|Amniotic Membrane|
79276457|NCT05125133|Other|ITENs + ITWS|A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
79580116|NCT01912976|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
79276458|NCT00533377|Drug|CP-533, 536|Active study drug
79276459|NCT00533377|Drug|Placebo|Placebo vehicle
79276460|NCT00533377|Procedure|Standard of Care|Standard surgical procedure
79739186|NCT04255251|Drug|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
79580117|NCT01912976|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
79276461|NCT00533377|Drug|CP-533,536|Active study drug
79874336|NCT00564629|Biological|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
79874337|NCT00564395|Drug|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
79874338|NCT00564395|Drug|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
79874339|NCT00937703|Device|placebo|paper support for glycaemia face to face visit at T4mounths
79874340|NCT00937703|Device|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
79276462|NCT00533377|Drug|CP-533,536|Active study drug
79276463|NCT00533377|Drug|CP-533,536|Active study drug
79276464|NCT03537755|Other|Observation|Examine thoughts and behaviors
79276465|NCT02180789|Drug|Tamsulosin OCAS|oral
79276466|NCT02286505|Device|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
79276467|NCT02286505|Other|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
79403933|NCT05583565|Other|traditional physical therapy program|"conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs )."
79276468|NCT00434473|Drug|A-001|A-001
79276469|NCT00434473|Other|Placebo|Placebo
79403934|NCT04516902|Drug|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
79276470|NCT02286583|Device|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
79403935|NCT04516902|Drug|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
79403936|NCT04516902|Other|LSD Placebo|Pure alcohol instead of an alcoholic solution containing LSD
79403937|NCT04516902|Other|MDMA Placebo|Mannitol capsules instead of capsules containing MDMA
79403938|NCT03581149|Drug|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
79403939|NCT03581149|Drug|2L polyethylene glycol/ascorbic acid|"First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
79739187|NCT04859439|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
79739188|NCT04855851|Procedure|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
79739189|NCT04855851|Procedure|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
79276471|NCT00427219|Drug|Ozarelix|Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
79276472|NCT00427219|Drug|Placebo|Placebo will be administered IM on Day 0 and Day 14.
79276473|NCT02282683|Drug|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
79276474|NCT02755649|Drug|Dupilumab|
79276475|NCT02755649|Drug|Matching Placebo|
79276476|NCT02183909|Other|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
79276477|NCT02183909|Behavioral|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
79403940|NCT05113602|Device|URGOnight|EEG dry electrodes portable device
79580118|NCT01911663|Dietary Supplement|KRG|500 mg Korea red ginseng (KRG)
79580119|NCT01911663|Dietary Supplement|Placebo|500 mg placebo
79874341|NCT00937703|Device|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
79276478|NCT02183909|Other|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
79580120|NCT01912989|Behavioral|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
79276479|NCT02183909|Drug|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
79403941|NCT05113602|Device|Enobio|EEG wet electrodes portable device
79276480|NCT02286661|Procedure|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
79276481|NCT02286661|Procedure|Casting (short arm)|
79403942|NCT05113134|Procedure|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
79403943|NCT04406077|Device|Ligasure|Using ligasure to treat hydrocele
79403944|NCT05112978|Diagnostic Test|MRI|MRI genu non contrast
79403945|NCT04405531|Other|task-oriented training (TOT)|The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
79403946|NCT04405531|Other|conventional occupational therapy (COT)|The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
79276482|NCT02282839|Dietary Supplement|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
79580121|NCT01913002|Drug|LX4211 800 mg|
79580122|NCT01913002|Drug|LX4211 2000 mg|
79580123|NCT01913002|Drug|moxifloxacin 400 mg|
79580124|NCT01913002|Drug|LX4211 Placebo|
79580125|NCT01913015|Drug|abiraterone acetate|Given PO
79580126|NCT01913015|Dietary Supplement|dietary intervention|Receive low fat breakfast
79580127|NCT01913015|Dietary Supplement|dietary intervention|Receive high fat breakfast
79580128|NCT01913015|Other|pharmacological study|Correlative studies
79580129|NCT01913015|Other|questionnaire administration|Ancillary studies
79580130|NCT01913015|Other|laboratory biomarker analysis|Correlative studies
79580131|NCT01913028|Drug|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
79580132|NCT01913028|Drug|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
79580133|NCT01913054|Drug|Fentanyl Injection|
79276483|NCT02282839|Dietary Supplement|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
79276484|NCT02286739|Device|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA 510K clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
79403947|NCT02487420|Behavioral|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
79580134|NCT01913054|Drug|Etomidate Fat Emulsion Injection|
79580135|NCT01913054|Drug|Propofol Injection|
79580136|NCT01913067|Drug|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
79874342|NCT00937781|Genetic|RNA analysis|
79874343|NCT00937781|Genetic|gene expression analysis|
79276485|NCT02286739|Procedure|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
79403948|NCT05583409|Radiation|SBRT+Osimertinib|Received SBRT after three months of Osimertinib treatment
79403949|NCT05583409|Drug|Osimertinib 80 MG|Osimertinib 80mg, po, Qd
79403950|NCT04405453|Procedure|trapezius muscle injection|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.
79874344|NCT00937781|Genetic|microarray analysis|
79874345|NCT00937781|Genetic|polymerase chain reaction|
79403951|NCT04405453|Procedure|erector spina plane block|1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
79580137|NCT01913067|Procedure|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
79580138|NCT01913080|Other|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~Personal information and emergency contact(s)~Physician names and contact information~Insurance information~Medications, vitamins and supplements~Surgeries~Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
79739190|NCT01018680|Drug|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
79739191|NCT01018680|Drug|Placebo|Taken by mouth, once daily for 10 weeks
79739192|NCT04255017|Drug|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
79739193|NCT04255017|Drug|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
79739194|NCT04255017|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
80030949|NCT03871712|Behavioral|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
79403952|NCT05112588|Behavioral|Intervention|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
79276486|NCT00421525|Biological|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
79276487|NCT00375193|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
79276488|NCT02177981|Procedure|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
79276489|NCT02177981|Procedure|Control|The cuff will be placed around the arm but not inflated.
80030950|NCT03851445|Drug|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
79580139|NCT01913106|Drug|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
79580140|NCT01913119|Drug|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
79276490|NCT02284711|Device|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
79403953|NCT03020953|Other|Exercise + Estrogen|12 weeks resistance training and estrogen patches
79580141|NCT01913145|Device|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
79580142|NCT01913171|Other|Exercise|
80030951|NCT03844815|Drug|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
79739195|NCT04255173|Diagnostic Test|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
79403954|NCT03020953|Other|Exercise + Placebo|12 weeks resistance training and placebo patches
79403955|NCT03893539|Device|Ion Endoluminal System™|The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
80030952|NCT03844815|Drug|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
79403956|NCT05112510|Other|Observing whether developing distant metastasis or recurrence|The study is a observational study and has no intervention.
79276491|NCT02284711|Device|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
79276492|NCT02184923|Other|presentation of visual vertical|
79403957|NCT03903523|Device|Lumen apposing metal stent (LAMS)|Stent positioning
79276493|NCT05208385|Procedure|video-assisted umbilical closure|video-assisted umbilical closure
79276494|NCT02185001|Procedure|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
79276495|NCT02185001|Procedure|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
79276496|NCT02256371|Behavioral|Hypnosis sessions|1 session per week during 8 weeks
79276497|NCT02256371|Behavioral|Relaxation group|1 relaxation session per week during 8 weeks
79580143|NCT01913184|Device|AKITA|
79580144|NCT01913197|Other|An MRI-based technique to identify prostate cancer|
79580145|NCT01913210|Dietary Supplement|Ginseng|
79580146|NCT01913223|Device|Nestis® jet injector system with a bi-functional catheter|
79739196|NCT04255173|Diagnostic Test|waist circumference|waist circumference is measured as cm
79739197|NCT04255173|Diagnostic Test|hip circumference|hip circumference is measured as cm
79739198|NCT04255173|Diagnostic Test|height|height is measured as cm
79739199|NCT04255173|Diagnostic Test|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
79739200|NCT04255173|Diagnostic Test|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2].
79874346|NCT00937781|Other|immunohistochemistry staining method|
79874347|NCT00937781|Other|laboratory biomarker analysis|
79276498|NCT00151411|Drug|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
79276499|NCT00151411|Drug|Placebo|Placebo
79276500|NCT00151411|Behavioral|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
79276501|NCT02185079|Behavioral|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
79276502|NCT02185079|Behavioral|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
79276503|NCT04471441|Drug|Everolimus Tab.|After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/mL.
79276504|NCT04471441|Drug|Mycophenolate mofetil Tab./Cap.|Up to 1.5g BID(total 3g daily), PO
79276505|NCT05141045|Dietary Supplement|omega-3 PUFA supplement|participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
79874348|NCT00939419|Other|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
79874349|NCT00939419|Other|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
79874350|NCT00939419|Other|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
79874351|NCT04013243|Drug|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
79874352|NCT04013243|Drug|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
79276506|NCT05141045|Dietary Supplement|placebo|placebo
79874353|NCT00940277|Behavioral|Group Counseling|Group counseling
79580147|NCT01913236|Other|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
79276507|NCT02662569|Biological|Evolocumab|Administered by subcutaneous injection
79580148|NCT01913249|Procedure|LIFT|Ligation of intersphincteric fistula tract
79739201|NCT04255173|Diagnostic Test|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
79739202|NCT04255173|Diagnostic Test|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
79739203|NCT04255173|Diagnostic Test|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
79739204|NCT04255095|Procedure|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
79739205|NCT04255095|Procedure|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
79874354|NCT03160547|Other|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
79874355|NCT03160547|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
79276508|NCT02662569|Drug|Atorvastatin|Administered orally once a day
79276509|NCT02662569|Other|Placebo|Placebo to evolocumab administered by subcutaneous injection
79276510|NCT00374413|Device|Artificial disk|Implant
79276511|NCT00374413|Device|Artificial disc|Implant
79580149|NCT01913262|Behavioral|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
79276512|NCT02185157|Other|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
79276513|NCT02185157|Other|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
79276514|NCT02178137|Drug|Diacerien|
79276515|NCT02178137|Drug|Glucosamine/Chondroitin|
79276516|NCT02178137|Drug|Placebo|
79580150|NCT01913288|Other|Biological Maternal Sounds|
79580151|NCT01913301|Drug|Alagebrium|
79580152|NCT01913366|Behavioral|CM-PST|
79580153|NCT01913366|Behavioral|SG-PST|
79580154|NCT01913379|Drug|MDV3100|Oral
79739206|NCT04592991|Diagnostic Test|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
79580155|NCT01913379|Drug|Gemfibrozil|Oral
79580156|NCT01913379|Drug|Itraconazole|Oral
79739207|NCT04592991|Diagnostic Test|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
79739208|NCT01012440|Device|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
79739209|NCT01012440|Device|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
79739210|NCT00916929|Device|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
79739211|NCT04299750|Procedure|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
79874356|NCT00938093|Behavioral|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
79874357|NCT00938093|Behavioral|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
79276517|NCT02284789|Other|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
79276518|NCT02185313|Other|visual stimulus to follow|
79276519|NCT02741635|Device|New Nasal Pillows Mask|Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
79276520|NCT02185391|Procedure|Audience Response System|patients use during oral presentations an audience response system
79580157|NCT01913392|Procedure|laparoscopic sleeve gastrectomy|
79580158|NCT01913418|Drug|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
79580159|NCT01913418|Drug|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
79580160|NCT01913431|Drug|Baracle Tab.®|
79739212|NCT04299750|Procedure|Tooth extraction|Tooth extraction and socket natural healing
79739213|NCT04299516|Procedure|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
79739214|NCT04299516|Procedure|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
79739215|NCT02872194|Drug|BAY987516, Y55-170|10 uL in one eye
79739216|NCT02872194|Drug|BAY987516, X72-151|10 uL in one eye
79739217|NCT02872194|Drug|BAY987516, Y49-034|10 uL in one eye
79276521|NCT02185391|Behavioral|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
79276522|NCT02286817|Drug|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
79276523|NCT02181023|Drug|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
79276524|NCT02181023|Drug|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
79276525|NCT02185469|Procedure|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
79580161|NCT01913431|Drug|Baraclude Tab.®|
79580162|NCT01913444|Drug|Recombinant Antithrombin|
79580163|NCT01913496|Other|ebalance|using the ebalance application for 14 weeks
79580164|NCT01913509|Device|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
79580165|NCT01913509|Device|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
79580166|NCT01913522|Procedure|Pulmonary Vein Isolation|
79580167|NCT01913561|Device|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
79874358|NCT00938171|Procedure|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
79739218|NCT02872194|Drug|Standard shampoo mixture (control)|10 uL in one eye
79580168|NCT01913561|Device|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
79739219|NCT04298736|Procedure|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
79739220|NCT04298736|Behavioral|Lifestyle modification|guided low-calorie diet and physical activity.
79874359|NCT00938171|Procedure|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
79874360|NCT00938249|Dietary Supplement|Monascus Garlic Fermented Extract|
79874361|NCT00938249|Dietary Supplement|Placebo|
79874362|NCT00939497|Drug|Risperidone|
80030953|NCT03841669|Behavioral|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
79276526|NCT02185469|Procedure|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
79874363|NCT00940355|Behavioral|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
80030954|NCT03841669|Behavioral|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
79276527|NCT02185469|Drug|sulfur hexafluoride (SF6)|
79276528|NCT02185469|Device|5/8-in 25-gauge needle|
79874364|NCT00940433|Procedure|open properitoneal hernia repair|suprapubic retro-inguinal approach
79874365|NCT00940433|Procedure|Lechtestien hernia repair|onlay mesh repair
79276529|NCT02185469|Device|laser|intraoperative laser retinopexy
79276530|NCT02286973|Drug|Tranexamic Acid|
79276531|NCT02181101|Drug|FEC-DocGemzar adjuvant chemotherapy|
79580169|NCT01913613|Device|IASD|IASD device implantation
79580170|NCT01913626|Behavioral|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
79580171|NCT01913652|Drug|Cabazitaxel|
79874366|NCT00940433|Procedure|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
79874367|NCT00940433|Procedure|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
79276532|NCT02181101|Drug|FEC-Doc adjuvant chemotherapy|
79276533|NCT02181101|Drug|Zoledronic acid i.v. 2 years|
79580172|NCT01913665|Other|B.lactis|
79580173|NCT01913665|Other|Inulin|
79276534|NCT02181101|Drug|Zoledronic acid i.v. 5 years|
79276535|NCT02390349|Other|Placebo|
79580174|NCT01913665|Other|B.Lactis +Inulin|
79580175|NCT01913665|Other|Placebo|
79580176|NCT01913678|Other|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
79580177|NCT01913678|Other|Complete diet|The participants will be given all dietary items in their diet with no additional products.
79739221|NCT02871336|Other|Data collection|
79739222|NCT00844597|Drug|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
79739223|NCT01017120|Drug|Tazarotene Foam|Tazarotene foam once a day application to the face
79739224|NCT01017120|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
79739225|NCT04297410|Radiation|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
79739226|NCT04298580|Procedure|PVB block|PVB block before surgery versus after surgery
79739227|NCT02872038|Drug|Cefepime|Cefepime intraperitoneal continuous dosing
79739228|NCT02872038|Drug|Cefazolin plus Ceftazidime|
79874368|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
79874369|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
79874370|NCT00938405|Drug|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
79874371|NCT00938405|Drug|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
80030955|NCT03838445|Device|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
80030956|NCT03837899|Drug|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
80030957|NCT03820830|Drug|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
80030958|NCT03820830|Drug|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
79276536|NCT02390349|Dietary Supplement|Curamin|
79739229|NCT02871804|Procedure|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
79580178|NCT01913678|Other|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
79739230|NCT02871804|Procedure|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
79739231|NCT04298424|Other|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
79739232|NCT01016964|Device|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
79739233|NCT01016964|Device|Sham Device|Sham Device
79276537|NCT02390349|Dietary Supplement|CuraMed|
79276538|NCT00413725|Biological|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
79276539|NCT00413725|Other|Placebo|Placebo
79276540|NCT03536351|Behavioral|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
79580179|NCT01913691|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
79580180|NCT01913704|Device|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
79580181|NCT01913756|Dietary Supplement|Gamalost (Norwegian traditional cheese)|
79580182|NCT01913756|Dietary Supplement|Gouda-type cheese|
79739234|NCT00627900|Device|bare metal stent|implantation of a bare metal stent
79739235|NCT00627900|Device|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
79276541|NCT02383095|Behavioral|Art therapy|
79276542|NCT02383095|Behavioral|metacognitive therapy|
79276543|NCT02185703|Device|Chordate System S020 in treatment mode|
79580183|NCT01913769|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
79739236|NCT04299360|Device|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
79739237|NCT02996110|Biological|Nivolumab|Specified Dose on Specified Days
79739238|NCT02996110|Biological|Ipilimumab|Specified Dose on Specified Days
79739239|NCT02996110|Biological|Relatlimab|Specified Dose on Specified Days
79739240|NCT02996110|Drug|BMS-986205|Specified Dose on Specified Days
79739241|NCT02996110|Drug|BMS-813160|Specified Dose on Specified Days
79739242|NCT04213768|Procedure|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
79874372|NCT00938483|Other|Nutramigen Lipil (Infant formula)|
79874373|NCT00938561|Drug|Inulin|
80030959|NCT03791619|Device|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
80030960|NCT03791619|Device|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
80030961|NCT03791567|Biological|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
79276544|NCT02185703|Device|Chordate System S020 in placebo mode|
79276545|NCT02385903|Other|Flammacerium|
79276546|NCT02385903|Other|Standard dressing procedure|
79276547|NCT02181179|Behavioral|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
79276548|NCT02284945|Procedure|Open fixation|
79276549|NCT02284945|Procedure|Keyhole surgery|
79276550|NCT02390271|Other|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
79739243|NCT04213768|Procedure|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
79276551|NCT02256683|Drug|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
79276552|NCT02256683|Drug|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
79276553|NCT00411385|Drug|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
79403958|NCT05112354|Drug|systemic and intratympanic injection of steoid|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."
79739244|NCT00916617|Drug|bapineuzumab|5 mg/week subcutaneous bapineuzumab
80030962|NCT03770572|Genetic|Low dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose
79276554|NCT00411385|Drug|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
79276555|NCT00411385|Drug|Ribavirin|800mg/day for 24 weeks
79276556|NCT02390193|Procedure|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study."
79276557|NCT03536273|Other|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
79276558|NCT02385513|Biological|10-valent pneumococcal conjugate vaccine|
79276559|NCT02185547|Drug|Zoloft|Sertraline treatment 25 mg
79276560|NCT02185547|Behavioral|ICBT|Internet behavioral cognitive therapy only
79276561|NCT02382861|Device|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
79739245|NCT04214236|Device|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
79739246|NCT04214236|Other|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
79874374|NCT03045653|Drug|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
80030963|NCT03770572|Genetic|High dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at high dose
79874375|NCT03972137|Behavioral|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
79874376|NCT03972137|Behavioral|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
79874377|NCT03972137|Drug|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
79874378|NCT00940511|Behavioral|Coordinated care|
79874379|NCT00490698|Drug|Zoledronate|4 mg IV Once Every 4 Weeks
79874380|NCT00490698|Drug|Atorvastatin|20 mg PO Daily
79874381|NCT04492254|Drug|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
79874382|NCT01013766|Drug|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
79874383|NCT01013766|Drug|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
80030964|NCT03756792|Behavioral|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
80030965|NCT03756792|Behavioral|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
80030966|NCT03696433|Dietary Supplement|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
79874384|NCT03855228|Drug|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
79580184|NCT01913808|Drug|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
80030967|NCT03696433|Dietary Supplement|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
79580185|NCT01913808|Drug|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
80030968|NCT03672331|Other|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
79580186|NCT01913834|Drug|Forsteo|Subcutaneous administration 20 micrograms
80030969|NCT03672331|Other|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
80030970|NCT03672331|Other|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
80030971|NCT03672331|Other|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
80030972|NCT03659565|Behavioral|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
79276562|NCT02382861|Device|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
79276563|NCT02385591|Behavioral|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
79403959|NCT03580993|Diagnostic Test|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
79403960|NCT03580915|Behavioral|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
79580187|NCT01913834|Drug|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
79739247|NCT01103063|Drug|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
79739248|NCT01103063|Drug|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
79739249|NCT04214158|Other|Assessment|Assessment
79739250|NCT02987998|Drug|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
79276564|NCT02385591|Behavioral|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
79276565|NCT02030483|Drug|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
79403961|NCT03580915|Behavioral|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
79580188|NCT01913847|Drug|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
79580189|NCT01913847|Drug|Placebo|Oral placebo TID for 12 weeks
79580190|NCT01913860|Behavioral|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
79739251|NCT02987998|Drug|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
79739252|NCT02987998|Drug|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
80030973|NCT03659565|Behavioral|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
80030974|NCT03546049|Procedure|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
79580191|NCT01913873|Other|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
79580192|NCT01913886|Procedure|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
79580193|NCT01913899|Other|Occupational/ physical therapy|
79580194|NCT01913899|Other|Mirror therapy|- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
79580195|NCT01913925|Other|Tyrosine-Containing Food Bar|
79580196|NCT01913925|Other|Placebo Bar|
79739253|NCT02987998|Drug|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
79874385|NCT03855228|Drug|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
79874386|NCT03855228|Drug|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
79874387|NCT03855228|Drug|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
79874388|NCT04013165|Behavioral|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
79739254|NCT04141306|Other|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
79739255|NCT04141306|Other|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
79276566|NCT02030483|Drug|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
79276567|NCT02030483|Drug|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
79874389|NCT04013165|Behavioral|Village-based intervention|"Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
79874390|NCT04013477|Drug|DA-5207|DA-5207 Transdermal Delivery System
79276568|NCT00528697|Drug|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
79276569|NCT00528697|Drug|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
79276570|NCT00528697|Drug|placebo|Subject will take a tablet once daily for 8 weeks
79276571|NCT02385435|Drug|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
79276572|NCT02385435|Drug|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
79276573|NCT02385435|Drug|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
79580197|NCT01913964|Drug|Acetylcarnitine|
79580198|NCT01913964|Drug|Placebo|(sugar pill)
79580199|NCT01913990|Drug|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
79739256|NCT04141306|Other|Histological data|Evaluation of Pathology report of thyroid surgery
79739257|NCT04141306|Other|Imaging data|Evaluation of scintigraphy, MRI, scan
79739258|NCT04141306|Other|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
79874391|NCT04013477|Drug|Donepezil Hydrochloride|donepezil HCl 10mg QD
79874392|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
79874393|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
79276574|NCT00526045|Drug|AUY922 2 mg/m2|
79276575|NCT02287207|Device|transcranial direct current stimulation (tDCS)|
79276576|NCT02382783|Other|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
79276577|NCT02753075|Device|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
79276578|NCT02753075|Device|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
79403962|NCT05109624|Procedure|prolonged prone position ventilation|patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
79739259|NCT04141306|Other|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
79739260|NCT04213378|Device|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
79739261|NCT04213378|Device|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
79739262|NCT02879591|Other|Social Skills training with Avatar therapist|
79739263|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
79739264|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
79739265|NCT00617032|Genetic|tgAAC94 placebo|Single dose
79276579|NCT02753075|Other|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
79276580|NCT02753075|Drug|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
79276581|NCT03133897|Drug|Dexamethasone|experimental group will receive 2 day treatment
79276582|NCT03133897|Drug|Prednisone|control group will receive 4 day treatment
79276583|NCT02390115|Other|Elastic tape application in shoulder|
79276584|NCT05443425|Drug|Cholestyramine|Given PO
79276585|NCT05443425|Drug|Leflunomide|Given PO
79276586|NCT05443425|Drug|Steroid Therapy|Given steroid therapy
79276587|NCT00370981|Drug|pagoclone|
79276588|NCT03536975|Other|Platform|"The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it"
79580200|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
79580201|NCT01914016|Other|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
79580202|NCT01914042|Drug|Morphine|
79739266|NCT02877953|Behavioral|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
79874394|NCT00940667|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
79874395|NCT00940667|Drug|Amlodipine|amlodipine 5mg q.d.
79874396|NCT04013087|Dietary Supplement|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
79874397|NCT04013087|Dietary Supplement|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
79874398|NCT04013087|Dietary Supplement|Breast feeding|Breast feeding of human milk for 16 weeks
79874399|NCT01019772|Biological|LBVH0101 (Hib vaccine)|
79276589|NCT02385357|Dietary Supplement|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
79403963|NCT05105334|Device|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.
79580203|NCT01914042|Drug|Milnacipran|
79580204|NCT01914055|Device|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
79580205|NCT01914055|Device|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
79580206|NCT01914068|Other|Supervised exercise in hospital|
79580207|NCT01914081|Other|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
79580208|NCT01914081|Other|Placebo|Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
79739267|NCT04213924|Drug|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
79739268|NCT04213924|Drug|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
79874400|NCT01019772|Biological|Hiberix™ Vaccine|
79874401|NCT00940745|Device|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
79874402|NCT00940745|Drug|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
79874403|NCT01014000|Device|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
79739269|NCT00616720|Biological|aldesleukin|
79874404|NCT01014000|Device|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
79874405|NCT00513500|Drug|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
79874406|NCT00513500|Drug|Coartem|Give Coartem without RDT and refer fast breathing
79874407|NCT03969719|Drug|Placebo|Placebo
79874408|NCT03969719|Drug|PF-06835919|150 mg once daily
79874409|NCT03969719|Drug|PF-06835919|300 mg once daily
79276590|NCT03134053|Device|extracorporeal shock-wave|to treat painful and retracting scars
79276591|NCT03134053|Other|massage|to treat painful and retracting scars
79276592|NCT02185625|Device|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
79580209|NCT01914107|Procedure|real-time monitoring and instruction of cancer pain|as description in arm
79580210|NCT01914107|Procedure|standard cancer pain care|as description in arm
79580211|NCT01914133|Drug|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
79580212|NCT01914133|Drug|Placebo|Placebo given prior to meal the standardized meal
79580213|NCT01914146|Other|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
79580214|NCT01914146|Other|No Insulin|Study session will occur prior to initiation of insulin therapy.
79580215|NCT01914172|Other|online questionairres|see group descriptions
79739270|NCT00616720|Biological|idiotype-pulsed autologous dendritic cell vaccine APC8020|
79739271|NCT00616720|Biological|recombinant interferon gamma|
79739272|NCT00616720|Genetic|polymerase chain reaction|
79403964|NCT05105334|Device|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA)|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. This will be alternated with radiofrequency microneedling treatment will include 3 passes each at a depth of 2 mm, 1.5 mm, and 0.8 mm, treatment level 5 (32 w, 50 ms)-7 (40 w, 60 ms), monopolar setting with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions (2 of each modality) at 4-week intervals.
79403965|NCT03639324|Drug|Dose combination 1-1|100 mg QD of idelalisib + 100 mg QD of venetoclax
79276593|NCT02190149|Biological|ADVATE (Antihemophilic Factor [Recombinant])|
79276594|NCT02190149|Biological|RIXUBIS (Coagulation Factor IX [Recombinant])|
79739273|NCT00616720|Genetic|reverse transcriptase-polymerase chain reaction|
79276595|NCT00366145|Biological|Prochymal®|2 infusions of 2 million cells/kg per week for 4 weeks
79276596|NCT00366145|Drug|Placebo|2 infusions per week for 4 weeks
79403966|NCT03639324|Drug|dose combination 1-2|100 mg QD of idelalisib + 200 mg QD of venetoclax
79403967|NCT03639324|Drug|Dose combination 1-3|100 mg BID of idelalisib + 200 mg QD of venetoclax
79403968|NCT03639324|Drug|dose combination 1-4|150 mg BID of idelalisib + 200 mg QD of venetoclax
79580216|NCT01914185|Other|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
79580217|NCT01914198|Other|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
79580218|NCT01914211|Drug|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
79739274|NCT00616720|Other|flow cytometry|
79739275|NCT00616720|Other|laboratory biomarker analysis|
79874410|NCT03998072|Other|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
79874411|NCT00511004|Drug|Albendazole|Comparing 400 mg to 800 mg dose
79276597|NCT00366145|Drug|Standard of Care for GVHD|Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
79403969|NCT03639324|Drug|Sub-Trial: Dose combination 2-1|100 mg BID of idelalisib + 100 mg QD of venetoclax
79403970|NCT03639324|Drug|Sub-Trial: Dose combination 2-2|150 mg BID of idelalisib + 100 mg QD of venetoclax
79403971|NCT05583253|Procedure|Vitrectomy|Small gauge pars-plana vitrectomy for management of retinal detachment.
79580219|NCT01914211|Procedure|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If > 5Kg draw 20% of circulating blood volume without PRBC replacement)
79580220|NCT01914224|Behavioral|dietary education of low sodium and high potassium consumption|
79580221|NCT01914224|Behavioral|dietary education of low sodium consumption only|
79580222|NCT01914237|Device|Castor Stent Graft|Endovascular Repair of Aortic Dissection
79739276|NCT01091675|Drug|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
79739277|NCT00620230|Drug|NVP-VAK694|
79739278|NCT00620230|Drug|NVP-VAK694|
79739279|NCT00617110|Other|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
79739280|NCT00617110|Other|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
79739281|NCT04140370|Other|There is no intervention|There is no intervention
79739282|NCT02739412|Biological|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
79739283|NCT04213612|Drug|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
79739284|NCT01091519|Other|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
79739285|NCT01091519|Other|Toviaz(fesoterodine) without educational materials|No educational materials
79874412|NCT00511004|Drug|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
79874413|NCT02550197|Biological|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
79874414|NCT02550197|Biological|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
79276598|NCT02190227|Device|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
79276599|NCT02382471|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
79276600|NCT02382471|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
79276601|NCT02185859|Drug|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
80030975|NCT03546049|Procedure|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
80030976|NCT03530189|Drug|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
80030977|NCT03530189|Drug|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
80030978|NCT03485391|Behavioral|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
80030979|NCT03438747|Device|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
80030980|NCT03438747|Other|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
80030981|NCT03434769|Drug|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
80030982|NCT03434769|Drug|Fludarabine|Fludarabine 25mg/m^2 IV on days -5 to -3
80030983|NCT03434769|Biological|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 [Starting dose] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
79276602|NCT02185859|Drug|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
79276603|NCT02185859|Drug|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
79276604|NCT02332720|Drug|Grazoprevir|Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
79739286|NCT00620308|Drug|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
79739287|NCT00620308|Drug|Placebo|Dextrose 5% in water (the vehicle)
79739288|NCT02878031|Drug|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age <12 months (4 - <10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age <3 years (10 kg - <14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children <5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
79739289|NCT00572962|Procedure|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
79874415|NCT02959502|Other|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
80030984|NCT03425500|Procedure|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
80030985|NCT03425500|Procedure|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
79276605|NCT02332720|Drug|Uprifosbuvir|Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
79403972|NCT03571386|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
79403973|NCT03571386|Behavioral|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
79739290|NCT02879669|Biological|ONCOS-102|
79739291|NCT02879669|Drug|Pemetrexed/cisplatin (carboplatin)|
79739292|NCT02879669|Drug|Cyclophosphamide|
79739293|NCT04213690|Other|No Intervention|There is no intervention for this study
79739294|NCT05339321|Genetic|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
79739295|NCT05339321|Biological|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
79739296|NCT00620386|Device|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
79739297|NCT00620386|Device|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
80030986|NCT03425500|Device|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
80030987|NCT03404492|Other|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
79580223|NCT01914250|Drug|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
79874416|NCT02959502|Other|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
79874417|NCT01009424|Drug|R7103|escalating inhaled dose
79580224|NCT01914263|Biological|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10^9 cord blood-derived cytokine indued killer cells.
79580225|NCT01914289|Procedure|Resection|
79580226|NCT01914289|Radiation|Radiotherapy|
79580227|NCT01914302|Device|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79580228|NCT01914302|Device|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79580229|NCT01914302|Device|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79580230|NCT01914302|Device|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79739298|NCT00918333|Drug|panobinostat|Given PO
79874418|NCT00938795|Other|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
79874419|NCT00938795|Other|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
80030988|NCT03398070|Other|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~delivery of a rule-in diagnosis~providing educational materials~referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~referring to FND-related cognitive behavioral therapy (CBT)~psychotropic medication management based on standard psychiatric care"
80030989|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
79276606|NCT02332720|Drug|Elbasvir|Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
79276607|NCT02332720|Drug|Ruzasvir|Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
79276608|NCT02332720|Drug|MK-3682B|Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
79276609|NCT02332720|Drug|Ribavirin (RBV)|Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
79276610|NCT02283151|Dietary Supplement|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
79739299|NCT00918333|Drug|everolimus|Given PO
79739300|NCT00918333|Other|laboratory biomarker analysis|Correlative studies
79739301|NCT00918333|Other|pharmacological study|Correlative studies
79580231|NCT01914302|Device|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79580232|NCT01914302|Device|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79874420|NCT00939887|Drug|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
79874421|NCT00938873|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
79874422|NCT00939965|Drug|isotretinoin|
79874423|NCT00939965|Genetic|DNA analysis|
79874424|NCT00939965|Genetic|polymerase chain reaction|
79874425|NCT00939965|Other|laboratory biomarker analysis|
79580233|NCT01914302|Device|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79580234|NCT01914302|Device|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
79739302|NCT04929730|Other|Nephrology care bundle|Nephrology care bundle
79739303|NCT01091363|Behavioral|Standard|10 minute brief cessation counseling
79739304|NCT01091363|Behavioral|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
79276611|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
79276612|NCT02382315|Behavioral|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
79276613|NCT05089175|Drug|Low-dose aspirin|FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin ~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
79403974|NCT05099562|Device|Acupuncture|Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
79276614|NCT02181335|Drug|Respimat® Budesonide low dose|
79403975|NCT03542994|Other|EDP1066|EDP1066 is an orally administered monoclonal microbial
79403976|NCT03542994|Drug|Placebo oral capsule|placebo
79580235|NCT01914315|Behavioral|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
79739305|NCT04910542|Other|Epi-Net Intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
79739306|NCT04306757|Device|Evone|Airway ventilation device
79739307|NCT04306757|Device|Primus|Airway ventilation device
79276615|NCT02181335|Drug|Respimat® Budesonide high dose|
79874426|NCT00939965|Other|pharmacological study|
79739308|NCT00617266|Other|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
79874427|NCT04012541|Procedure|active dental procedure|scaling and root planing
79276616|NCT02181335|Drug|Turbohaler® Budesonide|
79874428|NCT04012541|Drug|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
79276617|NCT02181335|Drug|Placebo|
79276618|NCT04945317|Other|ROSE (presence of cytotech)|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure
79739309|NCT00617266|Other|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
79276619|NCT04945317|Other|NO-ROSE (absence of cytotech)|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure
79276620|NCT02185937|Dietary Supplement|cola|imatinib intake with coca-cola
79276621|NCT00517543|Drug|GW856553|
79403977|NCT03586843|Drug|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
79403978|NCT05582863|Other|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
79403979|NCT03580681|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
79403980|NCT03580681|Dietary Supplement|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
79403981|NCT03580603|Other|Visualization tool|Visual representation of past microbiological culture data
79403982|NCT03437616|Behavioral|Tulppa rehabilitation|The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
79403983|NCT03586765|Other|Female urinary incontinence|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
79403984|NCT03580447|Dietary Supplement|Citrus extract|Citrus extract
79403985|NCT03580447|Dietary Supplement|Placebo|Maltodextrin
79739310|NCT00617266|Other|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
79739311|NCT00617266|Other|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
79874429|NCT04012541|Radiation|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
79874430|NCT02877134|Drug|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
79874431|NCT02877134|Drug|Placebo|Participants will receive placebo Subcutaneously.
79874432|NCT02877134|Drug|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
79874433|NCT00563381|Drug|Tiotropium bromide|18 mcg/daily
79874434|NCT00563381|Drug|Salmeterol|100 mcg/daily
79874435|NCT00563381|Drug|Placebo Salmeterol|Placebo identical to Salmeterol device
79874436|NCT00563381|Drug|Placebo Tiotropium|Placebo identical to Tiotropium device
79874437|NCT00512798|Drug|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~Level -1 0.7 mg/m2~Level 1 1.0 mg/m2~Level 2 1.0 mg/m2~Level 3 1.3 mg/m2~Level 4 1.5 mg/m2"
79874438|NCT00512798|Drug|temozolomide|"Temozolomide (day 8)~Level - 1 50 mg/m2~Level 1 50 mg/m2~Level 2 75/mg/m2~Level 3 75 mg/m2~Level 4 75 mg/m2"
79276622|NCT00517153|Drug|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
79403986|NCT03177421|Other|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
79276623|NCT02384811|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
79580236|NCT01914315|Other|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
79276624|NCT02285101|Biological|PEG-BCT-100|
79276625|NCT02382237|Device|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
79403987|NCT03177421|Other|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
79403988|NCT03100578|Device|WOPN TRANSMURAL DRAINAGE: PLASTIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT"
79580237|NCT01914341|Other|Music|Live music played on the pentatonically tuned children's harp
79580238|NCT01914380|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
79739312|NCT01090973|Drug|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
79580239|NCT01914419|Drug|Oxytocin|
79739313|NCT04755933|Behavioral|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
79580240|NCT01914432|Drug|YH16410|
79580241|NCT01914432|Drug|Rosuvastatin|
79739314|NCT02607904|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
79874439|NCT00512798|Other|immunoenzyme technique|Not noted
79874440|NCT00512798|Drug|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
79874441|NCT00512798|Drug|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
79739315|NCT04604925|Behavioral|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
79739316|NCT05295394|Drug|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
79874442|NCT03998930|Other|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
79580242|NCT01914432|Drug|Telmisartan|
79580243|NCT01914432|Drug|YH16410 placebo|
79580244|NCT01914432|Drug|Rosuvastatin placebo|
79276626|NCT00359437|Drug|Satavaptan|oral administration once daily
79276627|NCT00359437|Drug|placebo|oral administration once daily
79276628|NCT02382393|Other|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
79276629|NCT02382393|Other|Computerized Assessment|a validated, computerized cognitive assessment tool
79276630|NCT02190383|Behavioral|Habit Reversal Training|awareness training, competing response training
79276631|NCT02331394|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
79276632|NCT02283307|Other|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
79276633|NCT02283307|Other|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
79276634|NCT02384733|Radiation|Loco-regional RT|
79276635|NCT02181491|Other|[11C]-P943|
79276636|NCT02287285|Drug|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
79276637|NCT02190461|Procedure|Early Respiratory Rehabilitation Program|
79276638|NCT02190461|Procedure|Conventional Respiratory Rehabilitation Program|
79580245|NCT01914432|Drug|Telmisartan placebo|
79276639|NCT04471129|Other|HFO/O2C/NIV|High-flow oxygen therapy + O2C + Non invasive ventilation
79580246|NCT01914445|Drug|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
79276640|NCT04471129|Other|NIV/O2C/HFO|Non invasive ventilation + O2C + High-flow oxygen therapy
79276641|NCT02382003|Behavioral|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
79276642|NCT02382003|Behavioral|50/50 Cognitive Bias Modification - Interpretation|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.
79276643|NCT02382003|Behavioral|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
79580247|NCT01914458|Procedure|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
79580248|NCT01914471|Behavioral|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
79580249|NCT01914484|Drug|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
79580250|NCT01914484|Drug|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
79403989|NCT03100578|Device|WOPN TRANSMURAL DRAINAGE: METALLIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT"
79580251|NCT01914497|Device|Acutus Medical System Mapping|
79580252|NCT01914523|Device|Macintosh|Laryngeal exposure and tracheal intubation using that device
79580253|NCT01914523|Device|King Vision|Laryngeal exposure and tracheal intubation using that device
79276644|NCT02382003|Behavioral|Neutral Imagery Prime|At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
79403990|NCT03069300|Drug|N-acetyl cysteine (NAC)|
79580254|NCT01914523|Device|Glidescope|Laryngeal exposure and tracheal intubation using that device
79580255|NCT01914523|Device|AirTraq|Laryngeal exposure and tracheal intubation using that device
79580256|NCT01914562|Drug|OCA 10 mg|OCA 10 mg tablet oral
79580257|NCT01914562|Drug|OCA 25 mg|OCA 25 mg tablet oral
79580258|NCT01914575|Device|Mapping with the Acutus Medical System followed by Ablation|
79580259|NCT01914588|Procedure|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
79580260|NCT01914588|Other|Standard care|"Detailed instruction about medical therapy and lifestyle counseling~Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~Follow-up visits"
79739317|NCT01090739|Device|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
79276645|NCT00401011|Drug|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
79276646|NCT00401011|Drug|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
79276647|NCT00401011|Drug|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
79276648|NCT02381769|Dietary Supplement|Soybean based lipid emulsion|
79276649|NCT02287363|Other|No intervention involved|No interventions will be involved since it is an observational study
79276650|NCT02382081|Procedure|Patient-initiated shared care|
79403991|NCT05582317|Drug|Biodentine|Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
79403992|NCT05582317|Drug|Simvastatin|3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
79580261|NCT01914601|Device|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
79739318|NCT02871648|Drug|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
79739319|NCT02871648|Drug|Fludrocortisone|Fludrocortisone 0.1 mg
79739320|NCT02871648|Drug|Eplerenone|Epleronone 100 mg
79739321|NCT04873024|Device|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
79739322|NCT00637845|Drug|Esomeprazole Magnesium|40mg once daily
79739323|NCT00637845|Drug|Lansoprazole|30mg twice daily
79403993|NCT03977064|Behavioral|Life style change and weight reduction|Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
79403994|NCT03891355|Drug|Carfilzomib|Carfilzomib
79580262|NCT01914601|Device|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
79874443|NCT03743207|Other|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
79276651|NCT02190539|Other|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
79874444|NCT03743207|Other|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
79874445|NCT00940121|Drug|mirabegron|oral tablet
79403995|NCT03891355|Drug|Lenalidomide|Lenalidomide
79403996|NCT03891355|Drug|Dexamethasone|Dexamethasone
79580263|NCT01914627|Drug|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
79580264|NCT01914627|Drug|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
79874446|NCT00940121|Drug|mirabegron|IV solution
79874447|NCT00565721|Drug|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
79874448|NCT00940979|Procedure|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
79403997|NCT03954132|Drug|Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist|LAMA+LABA
79403998|NCT03954132|Drug|Triple combination of Free or fixed Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist + inhalative corticosteroids|(LAMA+LABA+ Inhalative Corticosteroids (ICS)
79403999|NCT05582005|Device|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children 3 year old and younger, scheduled for elective MRI, that are not intubated or require higher oxygen support and with no parents/guardians refusal will be placed on an electrocardiogram during post-anesthesia recovery. The NIPE monitor will be connected to the patients monitor in the PACU. Values will be recorded from the time of patient awaking until the patient meets the discharge criteria from PACU not before 1 hour.
79276652|NCT02389491|Dietary Supplement|normal density formula (Necocate)|In control group,there are 32 infants
79404000|NCT03580291|Other|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10^6/kg body weight
79404001|NCT03580291|Drug|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
79404002|NCT03580291|Other|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
79874449|NCT00938951|Other|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
79874450|NCT04012619|Drug|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
79404003|NCT03580291|Drug|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
79404004|NCT03898284|Diagnostic Test|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
79404005|NCT05028738|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.
79580265|NCT01914653|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
79580266|NCT01914692|Drug|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
79580267|NCT01914705|Procedure|Landmark Procedure|Using Landmarks to guide SCVC placement
79874451|NCT00561977|Behavioral|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
79874452|NCT00561977|Behavioral|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
79276653|NCT02389491|Dietary Supplement|high density formula(Infatrini)|In intervention group,there are 32 infants
79580268|NCT01914705|Procedure|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
79276654|NCT00397345|Biological|Trovax|1ml IM injection 2-8 weeks apart.
79276655|NCT00397345|Biological|Placebo|Placebo
79874453|NCT00561977|Behavioral|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
79580269|NCT01914718|Drug|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
79874454|NCT00941057|Drug|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
79276656|NCT00397345|Biological|Standard of care therapy|subcutaneous low dose IL-2, interferon-α or sunitinib
79580270|NCT01914731|Drug|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
79874455|NCT00941057|Drug|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
79580271|NCT01914744|Drug|Entecavir|entecavir 0.5 mg/day PO
79874456|NCT00941057|Drug|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
79874457|NCT00561821|Drug|Esmirtazapine|one tablet daily
79874458|NCT00561821|Drug|Placebo|one tablet daily
79874459|NCT00558701|Device|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
79874460|NCT00558701|Device|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
79874461|NCT03684044|Drug|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
79580272|NCT01914744|Drug|Lamivudine|lamivudine 100 mg/day PO
79874462|NCT03684044|Other|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
79874463|NCT01009502|Drug|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
79874464|NCT00510692|Drug|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
79874465|NCT00510692|Procedure|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
79874466|NCT00510692|Procedure|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
79874467|NCT00510692|Drug|Placebo|2 x 500mg placebo capsules twice daily for 6 months
79874468|NCT00335452|Drug|Clopidogrel|oral administration
79874469|NCT00335452|Drug|acetylsalicyclic acid (ASA)|oral administration
79874470|NCT00522548|Drug|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
79874471|NCT00522548|Drug|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
79404006|NCT03586375|Other|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
79404007|NCT02936388|Procedure|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
79404008|NCT02936388|Procedure|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
79580273|NCT01914770|Drug|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
79739324|NCT04297878|Dietary Supplement|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
79739325|NCT04209712|Biological|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
79874472|NCT00522392|Drug|bortezomib|Given IV
79874473|NCT00522392|Drug|lenalidomide|Given PO
79874474|NCT00522392|Drug|dexamethasone|Given PO
79874475|NCT04346264|Diagnostic Test|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
79739326|NCT02497300|Drug|Spironolactone|
79739327|NCT02497300|Drug|Amiloride|
79739328|NCT04254471|Drug|AL3810|5mgQD, 7.5mgQD, 10mgQD
79739329|NCT04254471|Drug|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
79739330|NCT04254471|Drug|Placebo|Placebo
79739331|NCT04299672|Procedure|Postural reconstruction|Interventions are described in group descriptions
79580274|NCT01914770|Drug|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
79580275|NCT01914770|Drug|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
79580276|NCT01914783|Other|ultrafine particles|exposure to ultrafine particles
79580277|NCT01914783|Other|ultrafine particles and ozone|exposure to ultrafine particles and ozone
79276657|NCT02181647|Behavioral|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
79580278|NCT01914783|Other|clean air|Exposure to clean air.
79580279|NCT01914796|Drug|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
79580280|NCT01914796|Drug|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
79580281|NCT01914809|Other|samples blood|
79580282|NCT01914809|Other|biopsy placentaire|
79580283|NCT01914822|Drug|methylphenidate hydrochloride|
79580284|NCT01914822|Drug|Sugar pill (placebo)|
79580285|NCT01914835|Behavioral|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
79404009|NCT03586141|Diagnostic Test|Pronto® hemoglobin measurement tool|All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
79580286|NCT01914848|Other|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
79874476|NCT01061320|Drug|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
79874477|NCT01061320|Drug|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
79874478|NCT01061398|Procedure|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
79404010|NCT03020563|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine
79276658|NCT01645930|Drug|Ixazomib|Ixazomib capsules
79276659|NCT01645930|Drug|Lenalidomide|Lenalidomide capsules
79276660|NCT01645930|Drug|Dexamethasone|Dexamethasone tablets
79276661|NCT02389413|Drug|PQ912 oral|
79580287|NCT01914848|Other|Control Group|A routine care discharge planning with the social service
79580288|NCT01914874|Behavioral|Mindfulness Meditation|
79580289|NCT01914887|Drug|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
79580290|NCT01914913|Biological|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
79580291|NCT01914939|Drug|Oxytocin|
79580292|NCT01914939|Behavioral|Social Skills focused CBT|
79580293|NCT01914939|Behavioral|Stress management/relaxation training|
79580294|NCT01914939|Drug|placebo drug|
79580295|NCT01914952|Dietary Supplement|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
79580296|NCT01914952|Dietary Supplement|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
79874479|NCT01061398|Procedure|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
79276662|NCT02389413|Other|Placebo|
79404011|NCT03020563|Drug|Bupivacaine|Bupivacaine
79404012|NCT04591626|Drug|Dulaglutide|Administered SC
79404013|NCT04591626|Drug|Placebo|Administered SC
79404014|NCT04591626|Drug|Insulin Glargine|Administered SC
79404015|NCT05702203|Other|Creative Music Therapy|Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
79404016|NCT03586063|Other|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
79276663|NCT02190617|Behavioral|Enhanced Clinic+ Unified Plan + CHW|"Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
79739332|NCT00631527|Drug|Leuprolide|Injections given through a needle in the muscle every 3 months.
79739333|NCT00631527|Drug|Goserelin|Subcutaneous injections given once every 3 months.
79404017|NCT03580135|Drug|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
79404018|NCT03580135|Drug|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
79580297|NCT01914952|Dietary Supplement|HMB free acid mixed in water|0.8 g HMB free acid in water
79580298|NCT01914952|Dietary Supplement|CaHMB in water|1.0 g CaHMB powder mixed in water
79404019|NCT03379272|Device|GOLDSTANDARD|RECORDING WITH EEG GOLDSTANDARD
79404020|NCT03379272|Device|NEURONAUTE|RECORDING WITH NEURONAUTE
79580299|NCT01914952|Dietary Supplement|HMB free acid|0.8 g HMB free acid
79404021|NCT01890252|Device|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
79580300|NCT01914965|Drug|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
79739334|NCT00631527|Drug|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
79739335|NCT00631527|Drug|Casodex|Once a day by mouth for 2 weeks.
79739336|NCT00631527|Radiation|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
79874480|NCT01565408|Drug|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
79580301|NCT01914965|Drug|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
79580302|NCT01914978|Other|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
79874481|NCT01565408|Drug|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
79580303|NCT01914978|Other|Food allergy treatment as usual|
79580304|NCT01914991|Procedure|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
79739337|NCT00620620|Drug|Inhaled placebo|Inhaled Staccato Placebo
79739338|NCT00620620|Drug|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
79739339|NCT00620620|Drug|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
79739340|NCT00620620|Drug|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
79739341|NCT00620620|Drug|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
79874482|NCT03985306|Procedure|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
79874483|NCT01012544|Drug|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
79739342|NCT04209556|Drug|PF-06826647 100 mg QD|Investigational Product
79739343|NCT04209556|Drug|PF-06826647 300 mg QD|Investigational Product
79739344|NCT04209556|Drug|PF-06826647 600 mg QD|Investigational Product
79739345|NCT04209556|Drug|Placebo|Matched Placebo
79739346|NCT04209556|Drug|PF-6826647 400 mg QD|Investigational Product
79739347|NCT00916383|Drug|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
79739348|NCT00916383|Drug|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
79276664|NCT02190617|Behavioral|Enhanced Clinic+ Unified Management Plan|"Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
79276665|NCT02190617|Behavioral|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
79276666|NCT02389569|Procedure|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
79404022|NCT01890252|Drug|saline solution|saline solution of 5% NaCl
79404023|NCT04765579|Behavioral|visual analogy scala|We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
79874484|NCT01012700|Drug|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
79874485|NCT01012778|Behavioral|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
79874486|NCT01565486|Device|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
79404024|NCT04369482|Device|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
79580305|NCT01914991|Procedure|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
79580306|NCT01915004|Other|Educational Intervention|Bladder Training Video
79739349|NCT00617500|Other|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
79739350|NCT00617500|Other|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
79739351|NCT00617500|Other|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
79276667|NCT02389569|Procedure|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
79276668|NCT02181725|Behavioral|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
79276669|NCT02181725|Behavioral|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
79276670|NCT02190695|Drug|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
79276671|NCT02190695|Drug|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
79404025|NCT04369482|Device|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
79739352|NCT00617500|Drug|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
79874487|NCT01565486|Device|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
79874488|NCT01565720|Drug|Isavuconazole|oral
79874489|NCT01565720|Drug|Placebo|oral
79874490|NCT01565720|Drug|Moxifloxacin|oral
79874491|NCT00309244|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
79874492|NCT00309244|Drug|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
79874493|NCT00483756|Drug|Cyclosporine|Standard of care
79874494|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
79874495|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
79404026|NCT03585985|Procedure|Standard patient monitor|Measurement of reference data: heart rate, heart rate variability and respiratory rate
79404027|NCT03585985|Procedure|Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)|Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
79404028|NCT03585907|Dietary Supplement|MAD|A high fat, low carbohydrate diet
79404029|NCT03585907|Dietary Supplement|MIND|A combination of the Mediterranean and DASH diets
79404030|NCT03585829|Drug|Hydrocortisone|at a substitutive dosage
79404031|NCT03585829|Drug|Prednisolone|at a substitutive dosage
79404032|NCT03587389|Biological|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
79276672|NCT02190695|Drug|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
79276673|NCT00514267|Drug|YM 155|IV
79276674|NCT00514267|Drug|Docetaxel|IV
79404033|NCT03585751|Procedure|Pulpectomy for primary molars + triple antibiotic mix|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with a triple antibiotic mix mixed with a Carrier ( MP) as an obturating material
79404034|NCT03585751|Procedure|Pulpectomy for primary molars + 3mixstatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with 3mixstatin (triple antibiotic mix + simvastatin) as an obturating material mixed with a Carrier ( MP) as an obturating material
79404035|NCT03585751|Procedure|Pulpectomy for primary molars + simvastatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with simvastatin as mixed with a Carrier ( MP) as an obturating material
79404036|NCT03583333|Drug|IMI/REL FDC|500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
79404037|NCT03583333|Drug|PIP/TAZ FDC|4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
79404038|NCT03583333|Drug|Linezolid|Open-label 600 mg Linezolid
79404039|NCT03585673|Drug|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
79404040|NCT03585673|Drug|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
79404041|NCT01602510|Drug|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
79404042|NCT01602510|Drug|Placebo|Placebo
79404043|NCT04952142|Other|minimal water exchange|Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
79404044|NCT03887533|Drug|VTS-270|Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
79580307|NCT01915017|Behavioral|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
79580308|NCT01915017|Behavioral|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
79739353|NCT04845555|Other|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
79739354|NCT04254003|Device|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
79874496|NCT00309166|Biological|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
79874497|NCT00309166|Biological|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
79874498|NCT01063816|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
79276675|NCT00514267|Drug|Prednisone|Oral
79276676|NCT02384967|Drug|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
79276677|NCT02287441|Other|Tomato|Tomato Products (tomato)
79276678|NCT02287441|Other|Raw|Vegetables Prepared Raw (raw).
79276679|NCT02186249|Drug|Nivolumab|
79276680|NCT02186249|Drug|Ipilimumab|
79276681|NCT02287519|Behavioral|Group Session|
79276682|NCT02287519|Behavioral|Telephone Coaching Session|
79276683|NCT02287519|Behavioral|Webinar|
79276684|NCT00511459|Drug|AMG 386 Placebo|AMG 386 Placebo [blinded]
79276685|NCT00511459|Drug|AMG 386|AMG 386 3mg/kg IV QW [blinded]
79276686|NCT00511459|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
79276687|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [Open-Label]
79276688|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [blinded]
79276689|NCT00511459|Drug|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
79276690|NCT02381847|Procedure|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
79276691|NCT02384889|Drug|Difluoromethylornithine|Active Therapy with DFMO
79276692|NCT02384889|Drug|Placebo|Placebo Comparitor
79404045|NCT04511754|Behavioral|Experiential Psychotherapy Skill Training|The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.
79404046|NCT04511754|Behavioral|Standard Psychotherapy Skill Training|Standard didactic training with research support, examples, and opportunities to ask questions.
79580309|NCT01915017|Behavioral|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
79739355|NCT04254003|Device|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
79276693|NCT02186327|Behavioral|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
79739356|NCT04703998|Procedure|Arthroscopic rotator cuff repair|A double-row rotator cuff repair will be performed.
79739357|NCT04703998|Biological|platelet rich plasma|A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
79739358|NCT04209478|Drug|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
79276694|NCT02381691|Other|maternal breast milk odor|
79276695|NCT02381691|Other|no odor|
79276696|NCT02256527|Other|Observational|compare data
79276697|NCT00510133|Biological|GRNVAC1|Autologous dendritic cell vaccine
79276698|NCT02186405|Drug|LEVOTHYROXINE|administration of levothyroxine
79874499|NCT01063816|Drug|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
79874500|NCT01063816|Drug|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
79874501|NCT00501852|Drug|NVA237|single-dose dry-powder inhaler (SDDPI)
79276699|NCT02299336|Drug|Aflibercept|pro re nata (PRN)
79276700|NCT02299336|Procedure|Focal Laser|Focal laser administered based on pre-specified criteria
79404047|NCT03585439|Procedure|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
79404048|NCT04945512|Procedure|Epidural Analgesia|In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
79404049|NCT04934982|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1~2 cm of the parametrium and 1~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
79580310|NCT01915017|Other|Treatment as Usual|Standard medication follow up and limited case management
79580311|NCT01915030|Other|High protein diet|controlled feeding trail. Both arms are caloric restricted
79580312|NCT01915030|Other|standard protein diet|
79580313|NCT01915043|Other|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
79580314|NCT01915056|Other|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
79580315|NCT01915069|Drug|Cilostazol|
79739359|NCT05252715|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
79739360|NCT05252715|Biological|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
79874502|NCT00501852|Drug|Placebo|single-dose dry-powder inhaler (SDDPI)
79874503|NCT00501852|Drug|Tiotropium|Handihaler inhaler
79874504|NCT03981250|Behavioral|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
79874505|NCT00482274|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
79874506|NCT03985462|Biological|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
79276701|NCT02384655|Drug|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
79276702|NCT00395317|Other|Placebo|placebo tablet
79276703|NCT00395317|Drug|Firategrast 150 mg|150 mg tablet
79276704|NCT00395317|Drug|Firategrast 300 mg|300 mg tablet
79276705|NCT02186483|Drug|Metformin|Metformin,1000mg, once daily
79276706|NCT02186483|Drug|Rosuvastatin|Rosuvastatin, 20 mg, once daily
79276707|NCT02186483|Drug|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
79276708|NCT02381613|Other|Baked beef|A meal based on baked beef
79276709|NCT02381613|Other|Baked herring|A meal based on baked herring
79276710|NCT02381613|Other|Pickled herring|A meal based on pickled herring
79276711|NCT02190851|Device|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
79404050|NCT04934982|Other|Total Abdominal Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1~2 cm of the parametrium and 1~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
79404051|NCT03581071|Drug|TS-143|
79276712|NCT02190851|Device|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
79276713|NCT03133819|Device|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
79580316|NCT01915082|Drug|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
79580317|NCT01915082|Drug|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
79580318|NCT01915121|Behavioral|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
79580319|NCT01915121|Behavioral|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
79874507|NCT03983122|Procedure|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
79874508|NCT00490542|Drug|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
79874509|NCT00490542|Drug|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
79276714|NCT02256995|Device|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
79276715|NCT02381301|Biological|Venous blood sampling prior to CCTA.|
79276716|NCT02256605|Dietary Supplement|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D [259OH)D] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
79276717|NCT00393991|Drug|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
79276718|NCT00393991|Drug|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
79276719|NCT00393991|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
79276720|NCT00393991|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
79874510|NCT03982966|Dietary Supplement|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
79874511|NCT01016418|Dietary Supplement|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
79874512|NCT01059604|Drug|Sumatriptan|Sumatriptan
79276721|NCT02181959|Drug|Pharmaton® with DMAE|
79276722|NCT02181959|Drug|Pharmaton® without DMAE|
79276723|NCT02181959|Drug|Placebo|
79276724|NCT05726071|Device|Holter|24 hour electrocardiography
79276725|NCT02664441|Drug|Exenatide|Weekly injections of active drug.
79276726|NCT02664441|Drug|placebo|Weekly placebo injections
79276727|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
79276728|NCT02191007|Drug|Calcipotriol Betamethasone ointment|
79276729|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Urea Cream|
79404052|NCT04306458|Procedure|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
79404053|NCT04306458|Device|daVinci Xi system|robot assisted minimally invasive esophagectomy
79404054|NCT04161378|Diagnostic Test|Cardiac imaging|"Transthoracic echocardiography~Late gadolinium enhancement CMR"
79404055|NCT04161378|Diagnostic Test|Laboratory analysis|"complete blood count~biochemistry~hs-CRP, MMPs, IL6, NT-pro-BNP"
79739361|NCT00617578|Device|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
79276730|NCT04470271|Other|Patients with hepatitis C lost follow up|Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
79276731|NCT02182037|Drug|Single rising doses of BIBT 1011 BS|
79276732|NCT02182037|Drug|BIBT 1011 BS placebo|
79404056|NCT05701813|Dietary Supplement|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
79580320|NCT01915134|Drug|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
79404057|NCT05701813|Dietary Supplement|CELLULOSE|4.3 grams of cellulose once a day for 90 days.
79404058|NCT03586921|Behavioral|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
79404059|NCT03586921|Other|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
79404060|NCT03586219|Behavioral|Opioid-specific educational patient pamphlets|See prior description
79404061|NCT01675596|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
79580321|NCT01915134|Drug|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
79580322|NCT01915147|Drug|OXN PR followed by OxyPR tablets|
79580323|NCT01915147|Drug|OxyPR followed by OXN PR tablets|
79580324|NCT01915160|Behavioral|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
79580325|NCT01915160|Behavioral|TF-CBT|Treatment as usual.
79580326|NCT01915186|Dietary Supplement|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
79580327|NCT01915199|Other|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
79580328|NCT01915264|Drug|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
79580329|NCT01915277|Drug|Dexmedetomidine|
79580330|NCT01915316|Other|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
79580331|NCT01915329|Device|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
79580332|NCT01915329|Device|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
79874513|NCT01059604|Drug|Naratriptan|Naratriptan
79874514|NCT01059604|Drug|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
79874515|NCT02532634|Drug|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
79874516|NCT02532634|Drug|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
79739362|NCT00617578|Device|ATP One Shot OFF|Standard defibrillation shock delivery
79739363|NCT05252637|Procedure|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
79739364|NCT04209244|Dietary Supplement|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
79874517|NCT03981172|Behavioral|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
79276733|NCT04470193|Other|MyChildCMC app|Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
79874518|NCT00501540|Drug|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
79276734|NCT02298946|Drug|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
79276735|NCT02298946|Radiation|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
79276736|NCT02298946|Drug|Cyclophosphamide|200mg/m(2) IV on day 0.
79276737|NCT02389257|Device|MINIMAG / MEG|
79276738|NCT02389257|Device|MINIMAG / ECG|
79276739|NCT02186717|Dietary Supplement|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
79276740|NCT04470115|Other|General anesthesia|Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.
79404062|NCT03585361|Behavioral|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
80030990|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
80030991|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
79404063|NCT03585361|Behavioral|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
79580333|NCT01915342|Device|Focal muscular vibration|
79580334|NCT01915355|Device|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
79580335|NCT01915368|Behavioral|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
79739365|NCT04209244|Dietary Supplement|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
79739366|NCT05251623|Other|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
79874519|NCT01014156|Drug|epoprostenol|titration up to 4 ng/kg/min
79739367|NCT04209166|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
79874520|NCT00322348|Drug|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
80030992|NCT03326310|Drug|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
79404064|NCT03585361|Behavioral|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
79739368|NCT04209166|Drug|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
79739369|NCT04209166|Drug|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
79739370|NCT04209166|Drug|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
79739371|NCT00916305|Other|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
79874521|NCT00322348|Drug|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
79874522|NCT01014234|Drug|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
79874523|NCT01014234|Drug|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
79580336|NCT01915368|Behavioral|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
79580337|NCT01915368|Behavioral|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
79580338|NCT01915381|Other|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
79739372|NCT00916305|Other|Unmodified audio video|An audio video with unaltered music
79739373|NCT04253925|Other|Kegel exercises|global postural correction exercises
79739374|NCT04766008|Drug|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
79739375|NCT00916149|Drug|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
79874524|NCT00501228|Drug|Filgrastim|5 mg/kg ID Once Daily x 1 Week
79874525|NCT00308620|Drug|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
79874526|NCT00308620|Drug|Placebo|Placebo once daily for 8 weeks
79276741|NCT04470115|Other|Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks|The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
79276742|NCT02384343|Drug|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
79580339|NCT01915433|Other|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
79580340|NCT01915433|Other|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
79276743|NCT02384343|Drug|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
79580341|NCT01915459|Biological|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
79580342|NCT01915459|Biological|Botulinum toxin type A(Botox®)|
79580343|NCT01915472|Drug|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
79580344|NCT01915485|Radiation|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
79874527|NCT01014312|Behavioral|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
79276744|NCT05033639|Drug|Melatonin 6 MG|Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
79874528|NCT01014312|Behavioral|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
79276745|NCT05033639|Other|Breast Milk|Naturally occurring milk from the mother of the infant.
79874529|NCT01016496|Other|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
79874530|NCT01016496|Other|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
79874531|NCT00492752|Drug|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
79874532|NCT00492752|Drug|Placebo|Matching placebo (orally) twice daily
79276746|NCT02193581|Device|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
79580345|NCT01915524|Biological|CV9202|Intradermal injection of CV9202
79580346|NCT01915524|Radiation|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
79580347|NCT01915537|Drug|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
79874533|NCT01016574|Device|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
80030993|NCT03326310|Drug|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
80030994|NCT03317496|Drug|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
80030995|NCT03317496|Drug|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
80030996|NCT03317496|Drug|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
80030997|NCT03317496|Drug|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
79276747|NCT02328040|Drug|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
79276748|NCT02328040|Drug|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
79874534|NCT01009658|Dietary Supplement|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
79874535|NCT01009658|Dietary Supplement|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
79276749|NCT02285335|Dietary Supplement|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
79874536|NCT00308308|Drug|Technosphere Insulin|Inhalation, 15U/30U
79874537|NCT00308308|Drug|Active comparator|sc injectable insulin
79276750|NCT02191085|Procedure|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
79276751|NCT00355849|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
79276752|NCT00355849|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
79580348|NCT01915537|Drug|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
79580349|NCT01915550|Drug|Metformin|
79580350|NCT01915550|Drug|Humulin Insulin Mixtard|
79580351|NCT01915576|Drug|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
79874538|NCT00505934|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily).~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
79874539|NCT02532790|Drug|Prednisone|1.5mg/kg/d
79874540|NCT02532790|Drug|ACEI|0.2-0.3mg/kg/d
79874541|NCT03981406|Behavioral|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
79874542|NCT03981406|Behavioral|Standard of Care|Control group will receive standard of care treatment for IPF.
79874543|NCT00505778|Drug|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
79276753|NCT02191163|Drug|Antistax®|
79276754|NCT02191163|Drug|Placebo|
79276755|NCT02384499|Biological|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
79276756|NCT02384499|Drug|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
79276757|NCT01647958|Device|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
79580352|NCT01915576|Drug|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
79580353|NCT01915576|Drug|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
79580354|NCT01915589|Drug|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
79580355|NCT01915602|Drug|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
79874544|NCT00505778|Drug|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
79874545|NCT01061554|Dietary Supplement|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
80030998|NCT03308474|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
79276758|NCT01647958|Drug|PPI|Control Arm participants will take maximum standard dose of PPI during Initial Study period
79276759|NCT02186951|Drug|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
79580356|NCT01915602|Drug|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
79580357|NCT01915628|Device|BioMatrix Flex|Percutaneous coronary intervention
79874546|NCT01061554|Dietary Supplement|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
79276760|NCT02186951|Drug|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
79404065|NCT03585361|Behavioral|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
79580358|NCT01915641|Device|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
79580359|NCT01915654|Procedure|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
79580360|NCT01915667|Drug|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
79580361|NCT01915667|Drug|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
79874547|NCT01063894|Other|breakfast cereal|breakfast cereal and milk
79874548|NCT01063894|Other|water|water
79874549|NCT01064050|Device|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
79874550|NCT00308074|Drug|Aripiprazole|open-label, flexible-dosing
80030999|NCT03242174|Other|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
80031000|NCT03236441|Device|RIPC|Remote ischemic preconditioning
80031001|NCT03236441|Device|Sham-RIPC|Control
79276761|NCT02384109|Behavioral|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
79276762|NCT02384109|Other|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
79580362|NCT01915667|Drug|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
79580363|NCT01915693|Radiation|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
79580364|NCT01915706|Procedure|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
79580365|NCT01915719|Procedure|Early non invasive ventilation|
79276763|NCT02285413|Biological|DC vaccination|DC vaccination without cisplatinum
79276764|NCT02285413|Biological|DC vaccination with cisplatinum|DC vaccination with cisplatinum
79580366|NCT01915719|Procedure|Oxygen therapy only|
79580367|NCT01915745|Other|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
79580368|NCT01915758|Drug|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
79580369|NCT01915758|Drug|vehicle gel|vehicle gel
79580370|NCT01915784|Device|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
79874551|NCT01059838|Behavioral|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
79580371|NCT01915784|Device|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
79580372|NCT01915836|Other|web-based video game (Quit IT)|
79580373|NCT01915836|Behavioral|Questionnaires|
79580374|NCT01915836|Behavioral|Evaluation Interview|
79580375|NCT01915875|Other|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
79874552|NCT03997058|Other|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
79874553|NCT03997058|Drug|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
80031002|NCT03228667|Drug|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
80031003|NCT03228667|Drug|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
80031004|NCT03228667|Drug|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
80031005|NCT03228667|Drug|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
80031006|NCT03228667|Drug|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
79276765|NCT02193659|Dietary Supplement|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
80031007|NCT03228667|Drug|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
80031008|NCT03228667|Drug|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
79739376|NCT00916149|Drug|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
79276766|NCT02381379|Drug|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
79276767|NCT02187107|Drug|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
79276768|NCT02187107|Drug|rtv|100 mg tablet of Norvir®
79276769|NCT02285491|Drug|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
79404066|NCT03585361|Behavioral|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
79739377|NCT04742920|Device|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
79739378|NCT04742920|Procedure|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
79739379|NCT00631761|Other|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
79874554|NCT01061632|Procedure|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
79404067|NCT05118984|Drug|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
79580376|NCT01915888|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
79580377|NCT01915901|Drug|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
79580378|NCT01915901|Drug|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
79739380|NCT00631761|Other|no intervention (usual resident activities)|usual activities
79739381|NCT00620932|Behavioral|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
79739382|NCT00175162|Device|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
79874555|NCT01061632|Procedure|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
79874556|NCT00500760|Drug|Cisplatin|Administered intravenously (IV; in a vein)
79874557|NCT00500760|Radiation|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
79874558|NCT00500760|Drug|Panitumumab|Administered intravenously
79874559|NCT00505622|Drug|Perampanel|
79874560|NCT01009736|Dietary Supplement|tomato-soy juice|
79874561|NCT01009736|Other|laboratory biomarker analysis|
79874562|NCT01009736|Other|pharmacological study|
79874563|NCT01009736|Procedure|therapeutic conventional surgery|
79276770|NCT02285491|Drug|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
79276771|NCT02298868|Drug|Baclofen|
79276772|NCT02381067|Other|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
79404068|NCT05118984|Drug|Placebo|A treatment that has no active properties
79580379|NCT01915901|Drug|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
79580380|NCT01915927|Drug|MSC-AFP|
79580381|NCT01915966|Dietary Supplement|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
79580382|NCT01915966|Dietary Supplement|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
79580383|NCT01915979|Biological|Plasma rich in growth factors (PRGF)|
79580384|NCT01915979|Drug|Celestone cronodose (Bethametasone)|
79580385|NCT01915992|Other|blood samples|
79580386|NCT01916018|Other|Clinical and radiologic exams and blood samples|
79276773|NCT02187185|Other|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
79276774|NCT02187185|Other|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
79580387|NCT01916031|Behavioral|Education|
79739383|NCT04690660|Other|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
79874564|NCT03852576|Drug|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
79739384|NCT04690660|Other|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
79276775|NCT02389179|Drug|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
79580388|NCT01916044|Other|Ultrasound|Measure of Uterine Segment by Ultrasound
79276776|NCT02285647|Drug|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
79739385|NCT04690660|Other|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
79874565|NCT01012856|Behavioral|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
79874566|NCT01012856|Behavioral|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
79276777|NCT02285647|Drug|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
79874567|NCT03851094|Behavioral|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
79874568|NCT01016730|Drug|Bortezomib|Given IV
79874569|NCT01016730|Other|Laboratory Biomarker Analysis|Correlative studies
79874570|NCT01016730|Other|Questionnaire Administration|Ancillary studies
79874571|NCT00505076|Drug|MK-0777|MK-0777 GEM, 8 mg BID
79580389|NCT01916057|Device|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
79874572|NCT00505076|Drug|MK-0777|MK-0777 GEM, 3 mg BID
79874573|NCT00505076|Drug|placebo|2 tablets placebo BID
79874574|NCT01012934|Drug|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
79874575|NCT01012934|Drug|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
79276778|NCT02388867|Procedure|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
79276779|NCT02388867|Procedure|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
79276780|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
79580390|NCT01916096|Device|Delica Device|
79580391|NCT01916135|Radiation|[18F]-SKI-249380|
79580392|NCT01916135|Procedure|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
79580393|NCT01916135|Other|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic & metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
79580394|NCT01916161|Other|Questionnaire|
79580395|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
79874576|NCT04334330|Drug|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
79874577|NCT01015196|Drug|Zavedos|
79874578|NCT01015196|Drug|Cerubidine|
79874579|NCT01009892|Drug|Codeine Sulfate|Tablet
79874580|NCT00307684|Drug|double blind placebo|matching placebo tablets once daily for 4 weeks
79874581|NCT00307684|Drug|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
79580396|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
80031009|NCT03228667|Drug|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
79276781|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
79580397|NCT01916187|Drug|Imetelstat|
79739386|NCT04690660|Other|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
79739387|NCT04690660|Other|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
79739388|NCT00621010|Drug|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
79404069|NCT03585283|Other|Myofascial Group|Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
79739389|NCT00621088|Procedure|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
79739390|NCT04213222|Drug|Bevacizumab|bevacizumab combined with chemotherapy
79874582|NCT00307684|Drug|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
79874583|NCT00489918|Drug|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
79874584|NCT00489918|Drug|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
80031010|NCT03228667|Drug|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
80031011|NCT03228667|Drug|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
79580398|NCT01916200|Drug|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
80031012|NCT03212404|Drug|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
80031013|NCT03206736|Other|Loop DS surgery|these patients will receive a loop DS bariatric procedure
80031014|NCT03181048|Procedure|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
80031015|NCT03181048|Procedure|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
80031016|NCT03127215|Drug|Olaparib|Olaparib 150 mg tablet
80031017|NCT03127215|Drug|Physician's choice|treatment according to current guidelines
80031018|NCT03127215|Drug|Trabectedin|Trabectedin 1.1mg/m² infusional solution
80031019|NCT03125811|Other|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
79276782|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
79580399|NCT01916213|Procedure|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
80031020|NCT03125811|Drug|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
80031021|NCT03087396|Device|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
80031022|NCT03081195|Behavioral|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
79276783|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
79276784|NCT02187341|Dietary Supplement|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
80031023|NCT02962401|Drug|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
79580400|NCT01916239|Dietary Supplement|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
79874585|NCT01061788|Drug|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
80031024|NCT02962401|Drug|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
80031025|NCT02920996|Drug|Merestinib|Oral, predetermined dosage per protocol, once daily per 28 day treatment cycle
80031026|NCT02898181|Device|Neuromodulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
80031027|NCT02880319|Drug|Stereotactic Body Radiation Therapy (SBRT)|
79276785|NCT02187341|Dietary Supplement|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
79276786|NCT02327260|Behavioral|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
79276787|NCT02327260|Behavioral|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
79276788|NCT02388945|Other|APD|PDGO APD machines used in the PD patients for 8 weeks
79874586|NCT00307294|Drug|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
79874587|NCT00307294|Drug|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
79874588|NCT03981094|Drug|BMS-986278|suspension
80031028|NCT02880319|Device|Stereotactic Linear Accelerator|
80031029|NCT02836249|Drug|TAF|TAF 25 mg tablet administered orally once daily
80031030|NCT02836249|Drug|TDF|TDF 300 mg tablet administered orally once daily
80031031|NCT02836249|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
79276789|NCT02388945|Other|CAPD|CAPD used in the PD Patients for 8 weeks
79276790|NCT00113191|Drug|Veronate|
79580401|NCT01916239|Dietary Supplement|Pomegranate extract formulation-1|New pomegranate extract formulation-1
79580402|NCT01916239|Dietary Supplement|Pomegranate extract formulation-2|New pomegranate extract formulation-2
79580403|NCT01916252|Drug|bortezomib (Velcade ®)|
79580404|NCT01916252|Drug|lenalidomide (Revlimid®)|
79580405|NCT01916252|Drug|busulfan (Busilvex ®)|
79580406|NCT01916252|Drug|Dexamethasone acetate|
79580407|NCT01916252|Drug|Melphalan|
79580408|NCT01916265|Drug|Glucagon|
79580409|NCT01916291|Drug|Propess insertion group|
79580410|NCT01916343|Procedure|Study Laparoscopic Curriculum|
79874589|NCT03981094|Drug|Pirfenidone|capsule
79874590|NCT01064128|Procedure|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
79580411|NCT01916356|Other|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
79874591|NCT01064128|Procedure|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
79874592|NCT03963401|Drug|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
80031032|NCT02836249|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
79739391|NCT00621166|Drug|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
79739392|NCT04563832|Other|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
79739393|NCT04563832|Other|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
79276791|NCT02187419|Other|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
79276792|NCT02389023|Other|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
79276793|NCT02389023|Other|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
79739394|NCT04555798|Drug|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
79276794|NCT02187497|Drug|Low dose of BIBR 277|
79580412|NCT01916369|Biological|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
79874593|NCT03963401|Other|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
79874594|NCT04410965|Drug|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
79874595|NCT04012775|Biological|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
80031033|NCT02827344|Biological|blood sample collection for CTC and MDSC analysis|"Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
80031034|NCT02769416|Other|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
79276795|NCT02187497|Drug|Medium dose of BIBR 277|
79276796|NCT02187497|Drug|High dose of BIBR 277|
79276797|NCT04195750|Drug|Belzutifan|Oral tablets
79276798|NCT04195750|Drug|Everolimus|Oral tablets
79276799|NCT02256761|Drug|BIRT 2584 XX - multiple escalating dose|
79276800|NCT02256761|Drug|Placebo|
79404070|NCT03585283|Other|Sham Group|Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
79739395|NCT04555798|Device|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
79874596|NCT04012775|Biological|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
79874597|NCT00944723|Dietary Supplement|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
79874598|NCT00944723|Dietary Supplement|Zinc supplement|Liquid supplement with zinc
79874599|NCT00944723|Dietary Supplement|Non-fortified bread|Daily consumption of non-fortified bread
80031035|NCT02700841|Drug|Melphalan|Given IV
79276801|NCT02256761|Drug|BIRT 2584 XX - single dose|
79580413|NCT01916382|Drug|Nitisinone|drug
79580414|NCT01916395|Drug|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
79874600|NCT00944723|Dietary Supplement|Placebo supplement|Daily intake of placebo supplement
79874601|NCT00944801|Drug|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
79874602|NCT00334282|Drug|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
80031036|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
79580415|NCT01916408|Drug|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
79580416|NCT01916408|Drug|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
79580417|NCT01916421|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
79404071|NCT03583645|Behavioral|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
79580418|NCT01916434|Other|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
79580419|NCT01916434|Other|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
79874603|NCT00334282|Drug|placebo|matching placebo (800 mg tablet) once daily
80031037|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
80031038|NCT02700841|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
79580420|NCT01916434|Other|No salmon|The placebo group will continue to consume their habitual diet.
79580421|NCT01916447|Drug|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
80031039|NCT02700841|Biological|Tetanus Toxoid Vaccine|Given IM
80031040|NCT02688985|Drug|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
79580422|NCT01916447|Drug|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
80031041|NCT02688985|Procedure|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
79739396|NCT04549090|Drug|QL (quadratus lumborum) block administration|Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
79739397|NCT00617812|Biological|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
79739398|NCT04515550|Diagnostic Test|lumbar puncture|Some participants will have an optional lumbar puncture
79739399|NCT00617968|Drug|DOCETAXEL|
80031042|NCT02688985|Drug|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
79739400|NCT00621400|Drug|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
79874604|NCT03982420|Procedure|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
79874605|NCT01060228|Drug|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
80031043|NCT02688985|Drug|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
80031044|NCT02672826|Procedure|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
79276802|NCT02256761|Other|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
79276803|NCT00099853|Drug|Vildagliptin|Vildagliptin 50 mg tablets
79276804|NCT00099853|Drug|pioglitazone|pioglitazone 45 mg qd
79276805|NCT00099853|Drug|Placebo|Vildagliptin matching placebo
79580423|NCT01916447|Drug|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
79580424|NCT01916460|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
79580425|NCT01916473|Other|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
79580426|NCT01916473|Other|Continuous wound infusion|Continuous wound infusion via catheter
79739401|NCT00621400|Drug|Melphalan|0,18mg/Kg/day from day 1- 4
79739402|NCT00621400|Drug|Dexamethasone|40mg/day from day 1- 4.
79739403|NCT04208932|Drug|SSRIs|Selective Serotonin Reuptake Inhibitors
79739404|NCT02691364|Procedure|Blood withdrawal|
79874606|NCT01060228|Drug|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
79874607|NCT00306670|Drug|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
79874608|NCT00306670|Drug|prednisone|<30 mg/day
79874609|NCT00306592|Biological|BG00002 (natalizumab)|
79874610|NCT03982732|Biological|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
80031045|NCT02669186|Drug|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
79739405|NCT04208854|Drug|Vinorelbine|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
79739406|NCT01090427|Drug|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
79874611|NCT00321646|Drug|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
79874612|NCT00321646|Drug|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
79874613|NCT03982654|Device|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
80031046|NCT02669186|Drug|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
80031047|NCT02602145|Other|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
79276806|NCT02381145|Dietary Supplement|EGCG+RSV-supplementation|Teavigo (~300mg/d) Resveratrol (~80mg/d)
79276807|NCT02381145|Dietary Supplement|Placebo|
79276808|NCT02187575|Drug|UHAC 62 XX tablet|
79580427|NCT01916486|Behavioral|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
79276809|NCT02187575|Drug|UHAC 62 XX capsule|
79580428|NCT01916486|Behavioral|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
79739407|NCT01090427|Drug|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
79276810|NCT00097357|Drug|Apixaban|Tablets, Oral, 12 +/- 2 days
79739408|NCT01090427|Other|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
79739409|NCT04208776|Drug|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
80031048|NCT02568566|Other|Laboratory Biomarker Analysis|Correlative studies
80031049|NCT02568566|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
80031050|NCT02548104|Other|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
79276811|NCT00097357|Drug|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
79276812|NCT00097357|Drug|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
79276813|NCT00097357|Drug|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
79276814|NCT00097357|Drug|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
79276815|NCT02191241|Drug|Red Vine Leaf Extract|
79276816|NCT03535493|Behavioral|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
79276817|NCT03535493|Behavioral|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
79276818|NCT03535493|Behavioral|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
79276819|NCT02296840|Drug|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
79276820|NCT02296840|Drug|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
79276821|NCT02191319|Drug|Viramune®|
79276822|NCT00336973|Drug|efalizumab|Subcutaneous repeating dose
79276823|NCT02191475|Drug|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
79580429|NCT01916486|Behavioral|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
79580430|NCT01916499|Other|3 tesla magnetic resonance imaging findings; coronary artery status|
79580431|NCT01916499|Other|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
79580432|NCT01916525|Behavioral|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
79580433|NCT01916564|Other|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
79580434|NCT01916564|Other|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
79580435|NCT01916577|Drug|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
79580436|NCT01916603|Behavioral|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
79404072|NCT03583645|Other|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
79276824|NCT02191475|Drug|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
79404073|NCT04514952|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
79580437|NCT01916616|Behavioral|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
79580438|NCT01916642|Drug|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
79580439|NCT01916642|Drug|Lidocaine 1.5mg/kg|same as other
79580440|NCT01916642|Drug|Lidocaine 2mg/kg|same as other
79276825|NCT02191553|Behavioral|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
79739410|NCT04208776|Drug|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
79276826|NCT02191553|Behavioral|Loving-kindness meditation|Following Kristin Neff protocol
79276827|NCT02191553|Behavioral|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
79276828|NCT02191553|Behavioral|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
79276829|NCT02287753|Other|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
79580441|NCT01916642|Drug|Lidocaine 2.5mg/kg|same as other
79874614|NCT00403767|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
79580442|NCT01916694|Device|Blue tooth enabled glucose meter with smart phone application|
79874615|NCT00403767|Drug|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
79580443|NCT01916694|Behavioral|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
79580444|NCT01916707|Drug|Dosing of enoxaparin for VTE prophylaxis|
79580445|NCT01916720|Drug|SB-480848 40 mg|Study Drug
79580446|NCT01916720|Drug|SB-480848 80 mg|Study Drug
79580447|NCT01916720|Drug|Placebo|Study Drug
79580448|NCT01916733|Drug|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
79739411|NCT02879435|Drug|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
79739412|NCT02879435|Other|Placebo|pre-operative wound infiltration with 10 ml of sterile water
79739413|NCT05662774|Diagnostic Test|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
79739414|NCT02879513|Drug|Paclitaxel|
79739415|NCT02879513|Drug|Cisplatin|
79739416|NCT02879513|Drug|Epirubicin|
79874616|NCT00403767|Drug|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
79739417|NCT02879513|Drug|Cyclophosphamide|
79739418|NCT02879513|Drug|5-fluoruracil|
80031051|NCT02548104|Other|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
79276830|NCT02384031|Device|Traumatic needle|Lumbar puncture is performed with a traumatic needle
79276831|NCT02384031|Device|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
79276832|NCT02191631|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
79276833|NCT02285803|Device|transcranial direct current stimulation (tDCS)|
79874617|NCT00403767|Drug|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
79874618|NCT00492284|Drug|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
79276834|NCT02191709|Drug|Dextromethorphan syrup|
79874619|NCT00492284|Drug|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
79276835|NCT02191709|Drug|Dextromethorphan soft pastilles|
79276836|NCT02285881|Behavioral|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
79874620|NCT00492284|Drug|ranibizumab|0.5 mg intravitreal injection
79874621|NCT00492284|Drug|dexamethasone|0.5 mg intravitreal injection
79874622|NCT01013012|Drug|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
79874623|NCT01013012|Drug|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
79874624|NCT01009970|Drug|Rituximab|375 mg/m2 day 1
79874625|NCT01009970|Drug|Cyclophosphamide|750 mg/m2 day 2
79874626|NCT01009970|Drug|Vincristine|1,4 mg/m2 (max 2 mg) day 2
79874627|NCT01009970|Drug|Prednisone|40 mg/m2 day 2-6
79874628|NCT01009970|Drug|Doxorubicin|50 mg/m2 day 2
79874629|NCT01013090|Drug|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
79874630|NCT01013090|Drug|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
79874631|NCT01015352|Drug|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
79874632|NCT01015352|Drug|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
79874633|NCT01043757|Behavioral|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
79874634|NCT00510458|Device|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
79874635|NCT03563157|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
79874636|NCT03563157|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]
79874637|NCT03563157|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79874638|NCT03563157|Biological|ETBX-021|Ad5 [E1-, E2b-]-[HER2]
79874639|NCT03563157|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79874640|NCT03563157|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
79874641|NCT03563157|Biological|GI-4000|RAS yeast
79874642|NCT03563157|Biological|GI-6207|CEA yeast
79874643|NCT03563157|Biological|GI-6301|Brachyury yeast
79874644|NCT03563157|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
79874645|NCT03563157|Drug|Avelumab|BAVENCIO® injection
79874646|NCT03563157|Drug|Capecitabine|XELODA® tablets
79874647|NCT03563157|Drug|Cetuximab|ERBITUX® injection
79874648|NCT03563157|Drug|Cyclophosphamide|Cyclophosphamide Capsules
79874649|NCT03563157|Drug|5-Fluorouracil|5-FU; Fluorouracil Injection
79874650|NCT03563157|Drug|Leucovorin|Leucovorin Calcium
79874651|NCT03563157|Drug|Nab-paclitaxel|ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
79874652|NCT03563157|Drug|Oxaliplatin|ELOXATIN® injection
79874653|NCT03563157|Drug|Regorafenib|STIVARGA® tablets
79874654|NCT03563157|Procedure|SBRT|Stereotactic body radiation therapy
79874655|NCT01010048|Drug|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
79874656|NCT01013168|Procedure|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
79874657|NCT01013246|Other|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
79874658|NCT00414765|Drug|Aldesleukin|
79874659|NCT03997292|Drug|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
79874660|NCT03997292|Drug|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
79874661|NCT01013402|Drug|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
79874662|NCT01013402|Drug|Human Insulin|0.1U/kg IV pulse.
79276837|NCT02383797|Biological|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
79276838|NCT02191787|Drug|Seresis®|
79276839|NCT02191787|Drug|Placebo|
79276840|NCT00326287|Drug|Ceftobiprole medocaril|
79276841|NCT00326287|Drug|Ceftriaxone with or without Linezolid|
79276842|NCT02191943|Device|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
79276843|NCT02191943|Device|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
79404074|NCT03585127|Behavioral|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
79404075|NCT03585127|Behavioral|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
79404076|NCT04514328|Device|cerebral 18F-FDG PET-CT|cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
79739419|NCT00621478|Drug|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
79404077|NCT03115723|Procedure|Percutaneous coronary intervention|
79874663|NCT01013480|Drug|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
79874664|NCT00500682|Drug|Placebo|9g /day (3 times a day)
79404078|NCT03115723|Procedure|Coronary angiography|
79874665|NCT00500682|Drug|AST-120|9g /day (3 times a day)
79404079|NCT02802852|Device|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
79404080|NCT02802852|Drug|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
79404081|NCT04405609|Device|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~First phase: 5 weeks.~Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
79404082|NCT01236456|Drug|Cyclophosphamide|
79404083|NCT00886548|Procedure|Ultrasound performed|Nurse-driven ultrasound performed
79404084|NCT03159325|Behavioral|Healing Circles|See description in the arm description.
79404085|NCT00409266|Device|Computer assisted navigation|
79404086|NCT05118048|Diagnostic Test|Lactate, Hemoglobin, Hematocrit|Compare diagnostic tests to reference methods
79874666|NCT00500370|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
79874667|NCT00500370|Drug|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
79739420|NCT00621556|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
79739421|NCT00618046|Drug|Oxcarbazepine|
79739422|NCT04308551|Drug|Indobufen|Indobufen Tablets
79874668|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
79874669|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
79276844|NCT02663895|Drug|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
79276845|NCT04441333|Device|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
79276846|NCT02257151|Drug|BMS-986142|
79404087|NCT04405375|Drug|gemcitabin|1.25g/㎡ d1, repeated every 21 days
79404088|NCT04405375|Drug|Pegaspargase|2500IU/㎡ d1, total dose=<3750IU, repeated every 21 days
79404089|NCT04405375|Drug|Etoposide|75mg/㎡ d1-3, repeated every 21 days
79404090|NCT04405375|Drug|Dexamethasone|20mg d1-4
79739423|NCT04308551|Drug|Aspirin|Aspirin Tablets
79874670|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
79874671|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
80031052|NCT02536365|Behavioral|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
79276847|NCT02257151|Drug|Placebo|
79739424|NCT04209010|Procedure|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
79404091|NCT05118438|Other|Health Promotion Nursing Intervention|A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
80031053|NCT02536365|Behavioral|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
80031054|NCT02536183|Device|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
79404092|NCT03583801|Other|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
79404093|NCT03583801|Other|without aromatherapy|no intervention
79404094|NCT05106348|Diagnostic Test|Aerobic Fitness Test|aerobic fitness test to assess wheelchair rugby players capacity
79404095|NCT03584503|Other|Suction Above Cuff Endotracheal Tube|Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
79404096|NCT03587857|Other|Mobile Health Application|This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
79404097|NCT02776488|Drug|Sodium Lactate|Infusion of exogenous sodium lactate
79404098|NCT02776488|Drug|Placebo|Infusion of normal saline
79404099|NCT03158857|Drug|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
79404100|NCT03584425|Diagnostic Test|Rasch modified version of the Fugl-Meyer Motor assessment|All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
80031055|NCT02536183|Drug|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
80031056|NCT02317874|Drug|Carboplatin|Given IV
80031057|NCT02317874|Drug|Paclitaxel|Given IV
80031058|NCT02317874|Drug|Talazoparib|Given PO
79276848|NCT00074425|Drug|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
79276849|NCT00074425|Drug|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
79276850|NCT00074425|Drug|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
79404101|NCT03584425|Diagnostic Test|Anatomical image acquisition|High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
79404102|NCT03584425|Diagnostic Test|Functional MRI task and acquisition|Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
79404103|NCT03029611|Drug|Carboplatin|Given IV
80031059|NCT02255383|Device|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
79404104|NCT03029611|Procedure|Gynecological Surgical Procedure|Undergo cytoreductive surgery
79404105|NCT03029611|Other|Laboratory Biomarker Analysis|Correlative studies
79739425|NCT04306991|Device|Auscultation using an electronic stethoscope (EKO CORE 4)|"Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~Measurement of cardiac output using echocardiography."
79739426|NCT04212988|Procedure|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
79739427|NCT04306913|Drug|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
79739428|NCT04306913|Drug|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
80031060|NCT02253251|Genetic|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
80031061|NCT02221999|Drug|Paclitaxel|
80031062|NCT02221999|Drug|Cisplatin|
80031063|NCT02221999|Drug|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
80031064|NCT02221999|Drug|Letrozole|
80031065|NCT02038140|Device|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
80031066|NCT01849562|Drug|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
79276851|NCT02192255|Behavioral|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
79580449|NCT01916746|Procedure|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
79580450|NCT01916759|Drug|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
79276852|NCT02663817|Device|CT Scan|
79276853|NCT00325507|Biological|TroVax|TroVax 1 x 10E9 TCID 50mL
79276854|NCT00325507|Drug|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
79276855|NCT02193737|Procedure|Early oral fluid recovery.|
79276856|NCT02193737|Procedure|Delayed oral fluid recovery.|
79580451|NCT01916772|Other|no interventions|no interventions
79580452|NCT01916785|Drug|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
79874672|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
79874673|NCT03996798|Other|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
79276857|NCT03106155|Drug|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
79874674|NCT03996486|Drug|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
79874675|NCT01014468|Drug|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
79874676|NCT01014468|Drug|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
79276858|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
79276859|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
79276860|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
79276861|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
79276862|NCT02188043|Behavioral|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
79276863|NCT03105687|Behavioral|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
79874677|NCT03980782|Other|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
79874678|NCT00503984|Drug|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
79874679|NCT00503984|Drug|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
79874680|NCT00503984|Drug|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
80031067|NCT01849562|Drug|ACH-3102|Nonstructural protein 5A inhibitor.
80031068|NCT01849562|Drug|Ribavirin|
80031069|NCT01849562|Drug|Placebo|
80031070|NCT01700179|Drug|ACH-0143102|
80031071|NCT01700179|Drug|Ribavirin|
80031072|NCT01474200|Device|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
80031073|NCT01474200|Drug|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
80031074|NCT01171131|Other|Blood/saliva sampling|one-time blood sample (~ 1 TBS) and saliva sample (~ 1 tsp)
79739429|NCT02299414|Drug|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
80031075|NCT00913471|Other|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
80031076|NCT00698854|Device|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
80031077|NCT00698854|Device|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
80031078|NCT00665223|Drug|ACR16|Capsules will be swallowed whole with water.
80031079|NCT00665223|Drug|Placebo|Capsules will be swallowed whole with water.
80031080|NCT00500123|Procedure|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
79276864|NCT00071461|Drug|bosentan|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
79276865|NCT00071461|Drug|Placebo|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
79276866|NCT02192333|Procedure|Management of Therapy Complications|Receive survivorship care
79276867|NCT02192333|Other|Quality-of-Life Assessment|Ancillary studies
79276868|NCT02192333|Other|Questionnaire Administration|Ancillary studies
79404106|NCT03029611|Drug|Paclitaxel|Given IV
79404107|NCT03029611|Biological|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
79404108|NCT03584347|Behavioral|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
79580453|NCT01916798|Drug|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up & another dose at the day of embryo Transfer.
79580454|NCT01916837|Other|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
79580455|NCT01916837|Other|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
79580456|NCT01916837|Procedure|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
79580457|NCT01916850|Drug|LX4211 400 mg|
79739430|NCT02299414|Other|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains <160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
79874681|NCT00503984|Genetic|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
79874682|NCT00503984|Drug|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
79874683|NCT00503984|Drug|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
79874684|NCT03981016|Other|Biological collection|"blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
79874685|NCT03996564|Device|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
79276869|NCT02192333|Behavioral|Telephone-Based Intervention|Receive phone-based booster intervention
79276870|NCT00069745|Drug|Satraplatin|
79580458|NCT01916850|Drug|LX4211 800 mg|
79580459|NCT01916850|Drug|LX4211 Placebo|
79580460|NCT01916863|Drug|LX4211 400 mg|
79580461|NCT01916863|Drug|canagliflozin 300 mg|
79739431|NCT02877875|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
79276871|NCT00069745|Drug|Prednisone|
79874686|NCT03996564|Drug|Acetaminophen|Acetaminophen 500mg-1000mg,
79874687|NCT03996564|Drug|Diclofenac|Diclofenac 50mg-75 mg orally
79874688|NCT03996564|Drug|Diazepam|Diazepam 5mg-10 mg intravenous or oral
79874689|NCT03996564|Drug|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
79874690|NCT03996564|Drug|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
79874691|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
80031081|NCT00178659|Other|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
79276872|NCT02192411|Drug|Lidocaine|1/4 dose lidocaine
79404109|NCT03020173|Other|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
79404110|NCT05701579|Procedure|"ACL decompression"|"The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue."
79580462|NCT01916863|Drug|LX4211 Placebo|
80031082|NCT03060226|Diagnostic Test|blood sample|Search of blood predictive marker (s)
79580463|NCT01916876|Other|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~On day 3 they will be contacted telephonically to:~i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~Reminders via SMS to attend there OPD appointment(s)~Medical out-patient review at 2-weeks and 6 weeks if required~Medical telephonic hot-line for advice"
79276873|NCT01372605|Other|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
80031083|NCT03786380|Drug|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
80031084|NCT03055234|Drug|Oral Treprostinil|Extended-release oral tablet for TID administration
80031085|NCT03055234|Drug|Placebo|Matching placebo for TID administration
80031086|NCT03055312|Drug|TPC|"Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 & days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 & days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 & days 8) every 3 weeks"
80031087|NCT03055312|Drug|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
79276874|NCT01372605|Other|Enhanced Usual Care|
79404111|NCT03159949|Other|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
79404112|NCT03159949|Other|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
79874692|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
80031088|NCT03055468|Behavioral|Peer support|Peer support and antidepressant medications
80031089|NCT04977544|Device|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
80031090|NCT04977544|Drug|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
80031091|NCT04917640|Radiation|Radiation Therapy|Either SBRT or IMRT radiation therapy
79580464|NCT01916889|Other|RACY test|
80031092|NCT03470636|Device|HeartLight X3|Pulmonary vein isolation
80031093|NCT05157074|Behavioral|Group Drumming Music Therapy|"All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit."
80031094|NCT02626000|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
80031095|NCT02626000|Biological|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
79276875|NCT02192489|Drug|CC-220 0.3 mg Daily|
79580465|NCT01916902|Drug|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
79276876|NCT02192489|Drug|CC-220 0.6mg Daily|
79276877|NCT02192489|Drug|Placebo|
79276878|NCT02193893|Other|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
79276879|NCT02193893|Other|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
79580466|NCT01916902|Drug|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
79580467|NCT01916902|Procedure|Optical Coherence Tomography|
79580468|NCT01916915|Drug|Tramadol infusion via wound catheter|
79874693|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
79276880|NCT02380989|Device|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
79276881|NCT02380989|Device|Placebo|
79276882|NCT04863209|Other|Upper cervical manipulation|The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
79276883|NCT04863209|Other|Sphenopalatine ganglion manipulation|The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
79580469|NCT01916915|Drug|Levobupivacaine|
79580470|NCT01916954|Drug|3-day artemether-lumefantrine|
79580471|NCT01916954|Drug|5-day artemether-lumefantrine|
79874694|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
79580472|NCT01916993|Drug|NBI-98854 50 mg capsule|
79580473|NCT01917019|Drug|Placebo|matching placebo tablets
79276884|NCT02383875|Behavioral|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
79874695|NCT00565409|Drug|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
79276885|NCT02380911|Other|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
79404113|NCT04765501|Other|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
79276886|NCT02192567|Drug|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
79580474|NCT01917019|Drug|BIIB041 (fampridine)|fampridine prolonged-release tablets
79739432|NCT02877875|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
79874696|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
79739433|NCT02877875|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
79739434|NCT04309097|Behavioral|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
79739435|NCT04309097|Behavioral|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
79739436|NCT01016262|Drug|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
79739437|NCT01016262|Drug|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
79739438|NCT01016262|Drug|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
79739439|NCT00625937|Drug|cisplatin|
79739440|NCT00625937|Drug|docetaxel|
79874697|NCT03980860|Other|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
79874698|NCT00394251|Drug|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
80031096|NCT03769376|Device|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
80031097|NCT03769376|Device|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
80031098|NCT03060460|Diagnostic Test|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
80031099|NCT03744494|Procedure|Bilateral simple orchidectomy (BSO)|
80031100|NCT03744494|Procedure|Bilateral Subcapsular Orchidectomy|
79276887|NCT02192645|Drug|Sanfujiu|
79404114|NCT03584035|Behavioral|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right & left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
79404115|NCT03584035|Behavioral|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
79580475|NCT01917032|Dietary Supplement|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
79580476|NCT01917032|Dietary Supplement|placebo|
79580477|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
79580478|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
79580479|NCT01917045|Drug|Morphine|morphine 0. 5mg/ml
79739441|NCT00625937|Drug|tegafur-gimeracil-oteracil potassium|
79874699|NCT00394251|Drug|ABI-007|260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
79874700|NCT00394251|Drug|Taxol|175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
79874701|NCT00394251|Drug|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
80031101|NCT03744494|Procedure|Bilateral Epididymal-sparing Orchidectomy|
80031102|NCT03060382|Device|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
80031103|NCT03060382|Biological|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
79276888|NCT02192645|Drug|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
79276889|NCT02388711|Other|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
79580480|NCT01917058|Drug|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
79874702|NCT00394251|Drug|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
79874703|NCT02532400|Drug|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d*7 plus exemestane: 25mg, po, qd*24w, or anastrozole: 1mg, po, qd*24w
80031104|NCT05156450|Drug|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
79276890|NCT02257073|Behavioral|Cognitive-behavioral treatment|
79739442|NCT00625937|Radiation|radiation therapy|
79276891|NCT02257073|Behavioral|Waiting List|
79276892|NCT02384187|Drug|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
79276893|NCT02384187|Drug|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
79739443|NCT00621634|Dietary Supplement|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
79739444|NCT00621634|Dietary Supplement|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
79276894|NCT02286115|Behavioral|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
79276895|NCT02192723|Drug|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day), twice per day, 8 weeks
79580481|NCT01917058|Drug|placebo|
79739445|NCT05662696|Other|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
79739449|NCT04308629|Other|Transcranial direct current stimulation|
79739450|NCT00621712|Device|GamCath® central venous catheter|choice of catheter type
79874704|NCT02532400|Drug|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w*6, Epirubicin 75mg/m2, d1, q3w*6 and Cyclophosphamide: 500mg/m2, d1, q3w*6
80031105|NCT03060304|Drug|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
80031106|NCT03060304|Drug|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
80031107|NCT03665636|Drug|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
79276896|NCT02192723|Drug|Risperidone|2~6mg/day, twice per day, 8 weeks
79276897|NCT02192723|Drug|Olanzapine|Olanzapine, 400~750mg/day, twice per day, 8 weeks
79276898|NCT02192723|Drug|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
79276899|NCT02192723|Device|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
79276900|NCT02192723|Drug|Ziprasidone|Ziprasidone 80~160mg/day, twice per day, 8 weeks
79276901|NCT02388789|Other|active movement|same as arm description
79276902|NCT00319969|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
79739451|NCT00621712|Device|GamCath Dolphin® Protect central venous catheter|choice of catheter type
79874705|NCT03980704|Drug|IMPACT|Administration of oral immunostimulating oral supplement
79874706|NCT03980704|Drug|resource protein|Administration of oral high-protein oral supplement
79276903|NCT00319969|Drug|Topotecan|Topotecan 1.5mg/m<2> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
79276904|NCT02388555|Procedure|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
79276905|NCT02380599|Other|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
79404116|NCT03159637|Procedure|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
79404117|NCT03583723|Radiation|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
79580482|NCT01917071|Other|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
79580483|NCT01917097|Drug|Dexmedetomidine|
79739452|NCT04308317|Drug|Tetrandrine|Tetrandrine 60mg QD for 1week
79739453|NCT04212208|Device|IV cannulation|IV cannulation in the preoperative period
79874707|NCT03980548|Procedure|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
79874708|NCT00394095|Drug|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
79874709|NCT00394095|Drug|Placebo|Matched placebo to Experimental arm
79874710|NCT00503906|Drug|Avastin|
79874711|NCT00503906|Drug|Gemcitabine|
79404118|NCT03589495|Drug|N Acetyl L Cysteine|100 mg/kg n acetyl cysteine dissolved in dextrose5%
79580484|NCT01917110|Device|omafilcon A|
79580485|NCT01917110|Device|Spectacle|
79580486|NCT01917123|Drug|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
79580487|NCT01917149|Drug|Benazepril|
79276906|NCT02380599|Other|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
79276907|NCT02380599|Other|Sham Ultrasound|Sham ultrasound to T3-5 region
79276908|NCT00317395|Drug|Otamixaban (XRP0673)|intravenous administration
79404119|NCT03589495|Other|dextrose 5%|
79404120|NCT03589417|Other|Assessments with Biodex Balance System®|Postural Stability, limits of stability and fall risk tests will be applied with the Biodex Balance System®
79404121|NCT03159559|Drug|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
79580488|NCT01917149|Drug|Valsartan|
79580489|NCT01917149|Drug|Metoprolol|
79580490|NCT01917162|Device|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
79580491|NCT01917162|Device|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
79739454|NCT04212130|Other|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
79739455|NCT01009554|Device|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
79739456|NCT01009554|Drug|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
79739457|NCT04211896|Drug|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
79739458|NCT04211896|Drug|Nivolumab|Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
79739459|NCT02012374|Behavioral|Intensive Language Action Therapy|
79739460|NCT04188184|Drug|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
79739461|NCT04188184|Drug|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
79874712|NCT00503906|Drug|Abraxane|
79874713|NCT00305110|Drug|2 mg IV hydromorphone|
79874714|NCT03984760|Drug|Ferric Citrate|Take the capsules with meals or immediately after meals.
79874715|NCT03984760|Drug|Sevelamer Carbonate|Take the tablets with meals.
79874716|NCT01060462|Drug|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
79874717|NCT00491894|Drug|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
79874718|NCT01060618|Other|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
79874719|NCT03984604|Drug|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
79874720|NCT03984604|Drug|Placebo|Placebo is a vehicle oil will match CHI-921
79874721|NCT00491504|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
79874722|NCT00491504|Other|Placebo|Placebo: 2 sprays in each nostril
80031108|NCT04432402|Drug|Lenalidomide|Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
79874723|NCT04326452|Device|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
79580492|NCT01917201|Procedure|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
79580493|NCT01917201|Procedure|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
80031109|NCT03663764|Drug|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
79580494|NCT01917227|Behavioral|Video|
79580495|NCT01917240|Other|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
79580496|NCT01917253|Device|Standard Device for peripheral vein cannulation|
79874724|NCT01015508|Other|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
79874725|NCT01015508|Other|Weight maintenance|10 months
79874726|NCT00500292|Drug|Vandetanib|once daily oral tablet two dose strengths
79874727|NCT00500292|Drug|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
79874728|NCT01013558|Drug|Remifentanil|0.15 microgram/kg/min continuous infusion.
80031110|NCT03663764|Radiation|hypofractionated radiotherapy|HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
79874729|NCT01013558|Drug|saline|continuous infusion
80031111|NCT03663764|Drug|concurrent chemoradiotherapy|All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
80031112|NCT03060148|Device|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
80031113|NCT04432324|Biological|Intravenous Immune Globulin|IVIG Intravenous infusion
80031114|NCT04432324|Drug|Standard Medical Treatment|SMT
79276909|NCT00317395|Drug|unfractionated heparin|intravenous administration
79276910|NCT00317395|Drug|eptifibatide|intravenous administration
79276911|NCT02383563|Drug|metformin extended release|
79276912|NCT03535961|Drug|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
79276913|NCT02380755|Drug|Clomiphene Citrate|50 mg orally daily during 12 weeks
79276914|NCT02380755|Drug|Placebo|1 pill orally daily during 12 weeks
79404122|NCT03159403|Drug|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
79874730|NCT01013636|Procedure|Blood sampling|"Anaplasma diagnosis test : serology and PCR~If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
79874731|NCT00499746|Drug|tramadol|oral dose, once per day
79874732|NCT00499746|Drug|placebo|oral dose, once per day
79874733|NCT00499746|Drug|Hydromorphone|oral dose, once per day
79874734|NCT00499746|Drug|Methylphenidate|oral dose, once per day
80031115|NCT02736890|Drug|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
80031116|NCT02736890|Drug|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
80031117|NCT04977388|Drug|Droxidopa|Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
80031118|NCT04977388|Other|Placebo|Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
79874735|NCT01010516|Drug|High-dose rosuvastatin|40 of rosuvastatin daily
79874736|NCT01010516|Drug|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
79874737|NCT01010516|Drug|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
80031119|NCT04965376|Procedure|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
79276915|NCT02188277|Drug|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
79276916|NCT02188277|Drug|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
79276917|NCT00316771|Drug|P38 Inhibitor (4) 150mg|150mg po qd
79404123|NCT03583567|Drug|Chlorpheniramine and ranitidine|Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
79404124|NCT03583567|Drug|0.9% Normal Saline|Patient will receive normal saline as placebo.
79404125|NCT03583489|Drug|APD421|10 mg IV
79580497|NCT01917253|Device|Long Catheters for peripheral vein cannulation|
79580498|NCT01917279|Drug|Docetaxel plus Capecitabine|"Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase."
79580499|NCT01917279|Drug|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
79739462|NCT04016662|Device|Tandom t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
79739463|NCT04495218|Biological|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
79874738|NCT01020162|Drug|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
79874739|NCT01020162|Procedure|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
79874740|NCT00489216|Biological|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
79874741|NCT01016886|Drug|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
79874742|NCT00499590|Drug|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
79874743|NCT00499590|Drug|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
79276918|NCT00316771|Drug|P38 Inhibitor (4) 25mg|25mg po bid
79580500|NCT01917279|Drug|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
79580501|NCT01917292|Procedure|One-Stage Full-Mouth Disinfection|"Basic oral hygiene instructions~Dental extractions will be performed (only in cases of teeth that could not be saved)~Standard cycle of supragingival ultrasonic scaling and polishing~Scaling and root planning after the administration of local anesthesia, four quadrants in one session~Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
80031120|NCT04965376|Procedure|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
79276919|NCT00316771|Drug|P38 Inhibitor (4) 300mg|300mg po qd
79276920|NCT00316771|Drug|P38 Inhibitor (4) 50mg|50mg po qd
79276921|NCT00316771|Drug|P38 Inhibitor (4) 75mg|75mg po bid
79276922|NCT00316771|Drug|Placebo|po bid
79404126|NCT03583489|Drug|Placebo|IV
79404127|NCT03583489|Drug|Ondansetron|4 mg IV
79874744|NCT00510146|Drug|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
79874745|NCT00510146|Drug|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
79874746|NCT00480636|Drug|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
79874747|NCT01017198|Drug|BIIB021 and Food|Assessing the effect of food use on BIIB021
79404128|NCT03159871|Device|Stratafix suture|Stratafix barbed sutures during C-Sections.
79404129|NCT03159871|Device|Vicryl suture|Standart Vicryl suture during C- Sections.
79404130|NCT03589261|Device|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
79580502|NCT01917292|Procedure|Periodontal care|"Basic oral hygiene instructions~Standard cycle of supragingival ultrasonic scaling and polishing"
79580503|NCT01917305|Device|platform-shifted implant|
79580504|NCT01917318|Drug|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
79276923|NCT02380833|Behavioral|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
79580505|NCT01917318|Drug|Placebo|During 8 weeks subjects will receive oral placebo
79404131|NCT03583411|Other|Epidemiological data collection|To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
79874748|NCT01017198|Drug|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
79874749|NCT01013948|Other|Non-Interventional|Non-Investigational Product (Survey Study)
79874750|NCT00499122|Drug|Cyclophosphamide|
79580506|NCT01917331|Drug|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
79580507|NCT01917331|Drug|Beclometasone/Formoterol|Active comparator
80031121|NCT03472196|Device|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
80031122|NCT03470480|Device|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
79580508|NCT01917357|Biological|Quinvaxem in Uniject|
79739464|NCT05093764|Device|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
80031123|NCT03470480|Device|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
80031124|NCT03470480|Behavioral|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
80031125|NCT03470480|Behavioral|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
79739465|NCT01006590|Drug|Saxagliptin|5 mg, oral tablet, once daily
79874751|NCT00499122|Drug|Docetaxel|
79874752|NCT00499122|Drug|Doxorubicin|
79874753|NCT00499122|Drug|NOV 002|
79874754|NCT01017276|Drug|ASP1585|oral
79874755|NCT00393939|Drug|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
79739466|NCT01006590|Drug|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
79874756|NCT00393939|Drug|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
79874757|NCT00488982|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days
79874758|NCT00488982|Drug|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
80031126|NCT04958018|Dietary Supplement|Almonds|almond (Prunus dulcis) consumption
80031127|NCT04958018|Dietary Supplement|Snack bars|324 calories/day, Nutri-Grain cereal bars, 120 kcal each
80031128|NCT04976998|Diagnostic Test|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
79276924|NCT02380833|Behavioral|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
79276925|NCT02380833|Behavioral|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
79276926|NCT02380833|Behavioral|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
79404132|NCT03020485|Other|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
79404133|NCT03020485|Other|Sucrose|Sucrose is normal table sugar
79404134|NCT03159169|Device|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
79580509|NCT01917357|Biological|Quinvaxem in single dose vials|
79580510|NCT01917370|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
79580511|NCT01917396|Drug|Fleet enema|
79580512|NCT01917409|Device|conventional laryngoscopy|the device is to assist nasotracheal intubation
79580513|NCT01917409|Device|video-stylet|the device is to guide the nasotracheal tube into trachea
79580514|NCT01917435|Device|video-stylet|
79874759|NCT00488826|Biological|7-valent pneumococcal conjugate vaccine|
79874760|NCT00488826|Biological|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
79874761|NCT01017354|Drug|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
79874762|NCT01017354|Dietary Supplement|ViDe3 (CH)|60000 vitamin D3 orally and once per month
79276927|NCT02380521|Drug|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg"
79276928|NCT00315757|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
79580515|NCT01917435|Device|fiberoptic bronchoscope|
79276929|NCT00315757|Biological|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
79276930|NCT00315757|Drug|Bortezomib|1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
79276931|NCT02377401|Drug|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
79276932|NCT02383485|Behavioral|Exercise|Heart rate monitors worn by each child at each session
79739467|NCT02010112|Other|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
79276933|NCT02383485|Behavioral|After-school program|Supervised recreational program with token economy
79276934|NCT00312091|Drug|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
79739468|NCT00619138|Behavioral|individual cognitive-behavioural therapy|1 session per week for 12 weeks
79276935|NCT00312091|Drug|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
79276936|NCT00312091|Drug|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
79739469|NCT00619138|Behavioral|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
79739470|NCT04212832|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
79739471|NCT04212832|Other|Standard pain|Standard pain follow up and monitorization
79739472|NCT04211974|Diagnostic Test|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
79739473|NCT00621790|Drug|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
79739474|NCT00621790|Drug|placebo|placebo
79739475|NCT00618124|Drug|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
79739476|NCT02252380|Device|Transcranial ExAblate System|MR Guided Focused Ultrasound
79739477|NCT05067946|Biological|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
79739478|NCT05067946|Other|Placebo|GX-19N formulation buffer
79739479|NCT00621868|Drug|ipragliflozin|Oral
79739480|NCT00621868|Drug|Placebo|Oral
79580516|NCT01917448|Drug|Morphine|spinal morphine 0.15 mg
79580517|NCT01917448|Other|control|Patient receive only local infiltration without spinal analgesia
79580518|NCT01917474|Dietary Supplement|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
79580519|NCT01917474|Dietary Supplement|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
79580520|NCT01917539|Device|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
79739481|NCT02246374|Device|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
79739482|NCT01882660|Drug|Decitabine|
79739483|NCT05662618|Procedure|Percutaneous selective arteriography of peripheral arteries|Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
79739484|NCT05662618|Procedure|Percutaneous selective arteriography of peripheral arteries|Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
79739485|NCT02216500|Dietary Supplement|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
79874763|NCT01017354|Dietary Supplement|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
79874764|NCT00393861|Drug|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
79874765|NCT01020240|Behavioral|Avolition|- avolition for cesarean discomforts
79874766|NCT01020240|Behavioral|Orientation|"avolition of cesarean discomfort~physiotherapy orientation"
79874767|NCT01020240|Behavioral|Guide|"avolition of cesarean discomfort~physiotherapy orientation~guide orientation"
79874768|NCT03993639|Drug|Pegfilgrastim|Single dose of SC administration
79276937|NCT00312091|Drug|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
79276938|NCT02383329|Dietary Supplement|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
79276939|NCT00389779|Drug|Darusentan|Darusentan capsules administered orally once daily
79580521|NCT01917539|Device|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
79580522|NCT01917578|Device|Ultrasound|"Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size refers to WHO standards."
79739486|NCT01001832|Drug|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
79404135|NCT03158935|Drug|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
79874769|NCT01040559|Drug|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
79874770|NCT03996954|Device|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
80031129|NCT05156294|Device|NovoMatrix|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
80031130|NCT05156294|Other|Control|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
80031131|NCT03469856|Drug|Prasugrel monotherapy|A multicenter, single arm, open-label trial of in patients with chronic stable angina
79276940|NCT00389779|Drug|Guanfacine|Guanfacine capsules administered orally once daily
79276941|NCT00389779|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
79276942|NCT02377323|Other|MACFIMS|Cognitive evaluation of 50 participants
79276943|NCT02377323|Other|MSQoL-54|Quality of life questionnaires
79276944|NCT02380365|Device|Electrocardiography|"Duration of intervention per patient/subject:~5 min, observation 6 months"
79404136|NCT03158935|Drug|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
79404137|NCT03158935|Procedure|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
79404138|NCT03158935|Biological|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10^10 - 1.6x10^11 cells
79404139|NCT03158935|Biological|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
79739487|NCT01001832|Drug|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
79739488|NCT01873456|Other|multifactorial nutritional intervention|
79739489|NCT01851694|Drug|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
79739490|NCT01851694|Drug|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
79739491|NCT01001598|Drug|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
79739492|NCT04208620|Drug|Placebo|Placebo administered subcutaneously
79739493|NCT04208620|Drug|Cotadutide|Cotadutide administered subcutaneously
79739494|NCT01006356|Drug|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
79404140|NCT04965168|Procedure|phacoemulsification of the lens|all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
79404141|NCT03158623|Biological|Platelet Rich Plasma|
79739495|NCT03836092|Procedure|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
79739496|NCT04213066|Device|Portable tablet|Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
79874771|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
79874772|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
79874773|NCT01014702|Device|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
79874774|NCT01014702|Device|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
79874775|NCT00480324|Biological|Rotarix|Two-dose oral vaccination.
79276945|NCT02372019|Behavioral|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
79404142|NCT03158623|Biological|Cellerate|
79404143|NCT03158467|Other|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
79404144|NCT05117580|Device|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
79404145|NCT03583177|Diagnostic Test|No intervention|No intervention
79404146|NCT02653326|Device|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
79580523|NCT01917578|Procedure|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
79404147|NCT02653326|Procedure|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
79580524|NCT01917578|Procedure|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
79580525|NCT01917578|Device|Pathologic Large Tissue Selected Table|"Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~Each piece of breast tissues by cutting with the table has 3mm thickness."
79580526|NCT01917578|Device|Leica TP1020|"Procedure:~Alcohol 70 % 1h~Alcohol 80 % 1h~Alcohol 85 % 1h~Alcohol 90 % 1h~Alcohol 95 % 1h~Alcohol Ⅰ 100 % 1h~Alcohol Ⅱ 100 % 1h~Xylene Ⅰ 2h~Xylene Ⅱ 2h~Xylene Ⅲ 2h~Paraffin 6h~Paraffin 6h"
79404148|NCT02653326|Behavioral|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
79404149|NCT02653326|Other|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
79404150|NCT02653326|Drug|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
79580527|NCT01917578|Device|Pathologic Large Tissue Embedded Table|"The table is made of brass .It is applying for a chinese patent.~The table can simultaneously embed 8 piece of breast tissues."
79580528|NCT01917578|Device|Leica SM2000 R|Each of paraffin section has 4 um thickness.
79580529|NCT01917578|Procedure|HE Stain|"Procedure:~Xylene Ⅰ 60℃ 15-20 minutes~Xylene Ⅱ 60℃ 15-20 minutes~Alcohol 100% Ⅰ 3-5 minutes~Alcohol 100% Ⅱ 3-5 minutes~Alcohol 95% Ⅱ 3-5 minutes~Alcohol 90% Ⅱ 3-5 minutes~Wash in running tap water for 3 minutes~Hematoxylin 5-10 minutes~Wash in running tap water for 3 minutes~Differentiate in 1% acid alcohol for 30 seconds~Wash in running tap water for 1 minute~Bluing in 0.2% ammonia water for 30-60 seconds~Wash in running tap water for 3 minutes~Counterstain in eosin Y solution for 30-60 seconds~Wash in running tap water for 1 minute~Alcohol 90% Ⅱ 2-3 minutes~Alcohol 95% Ⅱ 2-3 minutes~Alcohol 100% Ⅱ 3-5 minutes~Alcohol 100% Ⅱ 3-5 minutes~Xylene Ⅲ 5-10 minutes~Xylene Ⅳ 5-10 minutes~Mounting with neutral resin"
79580530|NCT01917578|Device|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
79580531|NCT01917578|Device|Epson V600|"Each slice that has been microscopically outlined is scanned by Epson V600.~Every image by scanning should be saved as JPG."
79874776|NCT00480324|Biological|Placebo|Two-dose oral administration.
79874777|NCT00488592|Biological|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
79874778|NCT00488592|Biological|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
79874779|NCT00488592|Drug|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
79276946|NCT02372019|Behavioral|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
79580532|NCT01917578|Device|MRI|"Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size refers to WHO standards.~The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
79580533|NCT01917578|Procedure|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~Observe the shrinkage modes in three-dimensional space.~According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
79276947|NCT02372019|Behavioral|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
79276948|NCT00389155|Drug|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
79739497|NCT01089725|Biological|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
79276949|NCT00389155|Drug|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
79276950|NCT00389155|Other|Placebo|
79739498|NCT01089725|Biological|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
79739499|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
79276951|NCT02380209|Other|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
79276952|NCT02188433|Behavioral|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
79276953|NCT02380443|Biological|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
79276954|NCT02380443|Procedure|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
79276955|NCT02188511|Other|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to < 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
79276956|NCT02188511|Other|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
79276957|NCT02188511|Other|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
79276958|NCT02188511|Other|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
79739500|NCT01089725|Biological|Placebo IV|1 ml placebo administered IV every 8 weeks
79739501|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
79739502|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
79739503|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
79739504|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
79739505|NCT01089725|Biological|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
79739506|NCT01089725|Biological|Placebo SC|1ml placebo administered SC every 8 weeks
79739507|NCT00622102|Behavioral|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
79739508|NCT00622102|Behavioral|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
79739509|NCT00619216|Drug|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
79874780|NCT00488592|Biological|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
79276959|NCT02188511|Other|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
79276960|NCT02380131|Drug|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
79276961|NCT02380131|Drug|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
79276962|NCT03535103|Drug|Gonal-F®|A single Subcutaneous injection, 225IU
79580534|NCT01917578|Device|Mammography|"Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size and calcification extent refers to WHO standards.~Calcification extent is not only measured in mammography image but also under microscope."
79739510|NCT00619372|Drug|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
79580535|NCT01917578|Drug|TAC,TC,TA,CAF,CEF|"TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
79276963|NCT03535103|Drug|LM001|A single Subcutaneous injection, 225IU
79276964|NCT00389077|Drug|Perifosine|Perifosine 50 mg tablets
79276965|NCT02188667|Other|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
79276966|NCT02188667|Other|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
79276967|NCT00388609|Drug|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
79580536|NCT01917578|Drug|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
79739511|NCT00619372|Drug|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
79739512|NCT00619372|Drug|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
79874781|NCT04244760|Behavioral|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
79276968|NCT00388609|Drug|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
79276969|NCT04551365|Behavioral|Lifestyle changes|Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
79276970|NCT04551365|Dietary Supplement|Chitosan|Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks
79276971|NCT04551365|Other|Placebo|Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
79276972|NCT00304525|Drug|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
79276973|NCT02377167|Procedure|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
79276974|NCT02188823|Behavioral|Low carbohydrate diet|
79276975|NCT05725681|Other|High protein ramen|Participants will be served one portion of high-protein instant ramen noodles [CHEF WOO Roasted Chicken Flavor Ramen Cup Noodles, Borealis Foods; 71 g]
79276976|NCT05725681|Other|Standard ramen|Participants will be served one portion of standard instant ramen noodles [RAMEN EXPRESS Chicken Flavor Ramen Cup Noodle Chef Woo, Borealis Foods; 71 g]
79739513|NCT00619372|Drug|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
79739514|NCT00619372|Drug|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
79739515|NCT00619372|Drug|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
79276977|NCT02377011|Behavioral|Problem solving cognitive behaviour therapy (PS CBT)|
79276978|NCT02188901|Other|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) [GE healthcare]
79276979|NCT00028639|Drug|bortezomib|
79276980|NCT02751983|Behavioral|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
79580537|NCT01917591|Device|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
79404151|NCT03158545|Dietary Supplement|Olive oil Placebo|olive oil
79404152|NCT03158545|Dietary Supplement|EPA-rich|EPA-rich omega-3 oil
79580538|NCT01917591|Device|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
79580539|NCT01917617|Drug|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
79580540|NCT01917617|Drug|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
79580541|NCT01917630|Drug|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
79580542|NCT01917630|Drug|placebo|
79580543|NCT01917695|Drug|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
79739516|NCT02879279|Device|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
79739517|NCT02879279|Other|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
79874782|NCT04244760|Behavioral|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
79874783|NCT00488514|Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
79874784|NCT00320710|Drug|Zoledronic acid|4mg IV
79276981|NCT02751983|Other|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
79276982|NCT00298987|Drug|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
79404153|NCT03158545|Dietary Supplement|DHA-rich|DHA-rich omega-3 oil
79404154|NCT04818372|Drug|CM313-Dose escalation|Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
79404155|NCT04818372|Drug|CM313|Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
79404156|NCT04818372|Drug|Dexamethasone|dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
79404157|NCT04818372|Drug|Lenalidomide|25 mg/day lenalidomide 21 of 28 days cycle
79404158|NCT01462578|Drug|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
79404159|NCT04601844|Drug|Pozelimab|Single dose administered subcutaneously
79404160|NCT04601844|Drug|Cemdisiran|Single dose administered SC
79404161|NCT03059173|Dietary Supplement|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
79580544|NCT01917695|Radiation|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
79580545|NCT01917695|Radiation|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
79580546|NCT01917695|Procedure|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
79580547|NCT01917708|Drug|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
79580548|NCT01917721|Drug|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
79739518|NCT00618202|Drug|Balsalazide|
79739519|NCT02877719|Other|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
79874785|NCT00320710|Drug|Placebo|Placebo to zoledronic acid
79874786|NCT00320398|Drug|Fondaparinux|
79874787|NCT00498186|Drug|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
80031132|NCT04153786|Other|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
80031133|NCT04912232|Device|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
80031134|NCT04917016|Diagnostic Test|Plasma B-HCG levels|Blood sample
80031135|NCT04917250|Drug|Gemcitabine|1000mg/㎡，d1,4 ivdrip
80031136|NCT04917250|Drug|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
79276983|NCT02380053|Drug|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
79276984|NCT02380053|Drug|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
79276985|NCT02192957|Device|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
79276986|NCT02371707|Drug|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
79580549|NCT01917721|Drug|Placebo|Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
79580550|NCT01917734|Other|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
79580551|NCT01917786|Device|ECG|
79874788|NCT01017510|Device|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
79874789|NCT01017510|Device|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
79874790|NCT00333970|Behavioral|cognitive remediation|individual cognitive training
79874791|NCT01017588|Device|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
79874792|NCT03984526|Drug|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
79874793|NCT03984526|Drug|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
79874794|NCT03984526|Drug|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
79874795|NCT01017666|Drug|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
79874796|NCT01017666|Drug|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
79276987|NCT02371707|Drug|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
79276988|NCT02193971|Device|BS-DES (Biostable polymer drug-eluting stent)|
79276989|NCT02193971|Device|BD-DES (Biodegradable polymer drug-eluting stent)|
79276990|NCT02193971|Drug|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
79276991|NCT00004915|Drug|raloxifene|
79276992|NCT02379975|Procedure|Non-surgical Periodontal Therapy|
79276993|NCT03530605|Device|Optune TTF device|portable device which produces electrical fields
79276994|NCT02193035|Other|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
79276995|NCT02379897|Other|Diet|
79276996|NCT02287987|Procedure|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
79276997|NCT02287987|Procedure|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
79580552|NCT01917799|Drug|Aspirin|75mg tab of LDA once daily for 7 months
79580553|NCT01917799|Drug|Heparin|0.4 mL/day of the Enoxaparin
79580554|NCT01917838|Behavioral|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
79874797|NCT03984370|Drug|ZP4207|Abdominal SC administration
79874798|NCT03984370|Other|Placebo (saline)|Abdominal SC administration
79874799|NCT01017744|Device|Anesthetic Conserving Device|"Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
79874800|NCT03984292|Procedure|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
80031137|NCT04917250|Drug|Etoposide|100mg/㎡，d1-3 ivdrip
80031138|NCT04917250|Drug|Dexamethasone|20mg/d d1-4 ivdrip
80031139|NCT05156138|Other|no interventions as it is a case control observational study|no interventions as it is a case control observational study
80031140|NCT05155748|Other|Continuous education and knowledge exchange|The intervention is educational and directed at the complete nursing home care team.
80031141|NCT04977076|Other|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
80031142|NCT04977076|Other|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
80031143|NCT03469778|Device|Robotic Therapy|Robotic Therapy
80031144|NCT04976764|Other||
80031145|NCT04859582|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
79580555|NCT01917864|Behavioral|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
79580556|NCT01917890|Dietary Supplement|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
79874801|NCT01064596|Other|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
79580557|NCT01917890|Dietary Supplement|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
79874802|NCT03980392|Other|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
79874803|NCT03980236|Device|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
79276998|NCT03535415|Drug|Recombinant Human Growth Hormone Injection (rhGH)|rhGH 0.05mg/kg/d by subcutaneous injection
79580558|NCT01917942|Device|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
79276999|NCT02379741|Biological|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
79277000|NCT00289549|Drug|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
79277001|NCT02030717|Drug|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
79277002|NCT02030717|Drug|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
79404162|NCT03059173|Drug|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
79739520|NCT00619450|Other|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
79739521|NCT00626015|Biological|PEP-3-KLH conjugate vaccine|Given intradermally
79739522|NCT00626015|Biological|daclizumab|Given IV
79739523|NCT00626015|Drug|temozolomide|Given by mouth.
79404163|NCT03059173|Dietary Supplement|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
79580559|NCT01917942|Other|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
79739524|NCT00626015|Other|placebo|Given IV
79739525|NCT00626015|Biological|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
79739526|NCT03787498|Drug|PLX2853|Tablets
79739527|NCT00618280|Drug|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
79739528|NCT01101191|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
79739529|NCT01101191|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
79739530|NCT04212754|Other|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
79739531|NCT02879357|Behavioral|Training|"Clinician training~System for patient selection~System of triggering and tracking conversations~Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
79739532|NCT00622258|Drug|Everolmus|
79739533|NCT01812616|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
79739534|NCT01812616|Drug|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
79739535|NCT00618358|Device|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
79739536|NCT00618358|Other|Gelfoam/Thrombin|
79580560|NCT01917981|Device|Personal Heart Rhythm Monitor|
79739537|NCT04212676|Other|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
80031146|NCT04859582|Drug|Cisplatin|Administered as an IV infusion on Day 1 Q3W
79404164|NCT05117268|Procedure|SDF Application for caries arrest|Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
80031147|NCT04859582|Drug|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
80031148|NCT04859582|Drug|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
80031149|NCT04859582|Drug|Capecitabine|Administered orally BID on Days 1 to 14 Q3W
80031150|NCT04859582|Drug|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
80031151|NCT03469700|Other|general anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
79277003|NCT02371473|Drug|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
79277004|NCT02371473|Drug|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
79277005|NCT04301661|Other|Blood collection|Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
79580561|NCT01917994|Behavioral|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
79277006|NCT04301661|Drug|Abacavir/lamivudine|Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
79277007|NCT04301661|Drug|Tenofovir alafenamide/emtricitabine|Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
79580562|NCT01917994|Behavioral|Appointment Reminders|
79739538|NCT04212676|Other|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
79739539|NCT01178762|Drug|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
79739540|NCT03629236|Other|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
79739541|NCT03629236|Other|Control|Debridement, dressing application, standard compression therapy
79874804|NCT00477594|Drug|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
79874805|NCT00475722|Behavioral|1 Healthy Eating|6 months telephone counseling
79874806|NCT00475722|Behavioral|2 Mediterranean|6 months telephone counseling
79874807|NCT00304954|Drug|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
79580563|NCT01918020|Behavioral|Go Wild with Fruits and Veggies!|Fruits and Vegetables
79580564|NCT01918020|Behavioral|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
79580565|NCT01918059|Procedure|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
79874808|NCT00304954|Drug|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
79874809|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
79874810|NCT00304954|Drug|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
79874811|NCT00475176|Drug|Peginterferon alfa-2a|
79874812|NCT00475176|Drug|Ribavirin|
79874813|NCT00475176|Drug|S-adenosyl methionine for Chronic Liver Disease|
79277008|NCT04301661|Drug|Switch|Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
80031152|NCT03469700|Other|Paravertebral block|Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
80031153|NCT03469700|Other|Placebo PVB|Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
80031154|NCT03062020|Device|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
79277009|NCT03530527|Procedure|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
80031155|NCT03469622|Device|EndoRings|EndoRings-assisted colonoscopy
79277010|NCT03530527|Procedure|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
79404165|NCT05117268|Procedure|Glass ionomer restoration|The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.
79580566|NCT01918059|Procedure|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
79739542|NCT03563560|Drug|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
79277011|NCT02189057|Other|AssureRx GeneSight genotyping results|
79277012|NCT02189057|Other|Treatment as usual|
79277013|NCT02371551|Other|Blood/urine sampling|Routine chemistry profile
79277014|NCT02371551|Other|Conventional routine CT examination|Standard diagnostic examination
79277015|NCT02371551|Other|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
79404166|NCT05117268|Procedure|Hall technique|In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
79404167|NCT05122338|Drug|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
79404168|NCT05122338|Drug|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
79739543|NCT03563560|Drug|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
79739544|NCT03563560|Drug|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
79739545|NCT03563560|Drug|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
79739546|NCT03563560|Drug|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
79739547|NCT01178294|Biological|OBI-1|Intravenous infusion
79874814|NCT01062022|Behavioral|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
79874815|NCT01062022|Behavioral|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
79874816|NCT01064674|Other|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
79874817|NCT01062100|Device|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
79874818|NCT00414609|Drug|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
79277016|NCT02371551|Other|Functional MRI|Study-specific diagnostic examination
79277017|NCT02194049|Drug|BKM120|Given PO
79277018|NCT02194049|Drug|cisplatin|Given IV
79277019|NCT02194049|Drug|etoposide|Given IV
79277020|NCT02371317|Behavioral|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
79277021|NCT02371317|Behavioral|Stress Management Education|Patients are randomized to an intervention
79277022|NCT02371317|Other|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
79739548|NCT01799044|Device|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
79874819|NCT00414609|Drug|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
79874820|NCT00393705|Drug|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
79874821|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
79874822|NCT00393705|Drug|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
80031156|NCT03469622|Device|Standard colonoscopy|Standard colonoscopy without any additional devices
80031157|NCT04912726|Drug|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
80031158|NCT03130712|Drug|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
79580567|NCT01918059|Procedure|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
79739549|NCT00619606|Device|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
79739550|NCT00619606|Device|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
79739551|NCT00619606|Device|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
79874823|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
79874824|NCT00303628|Drug|oxaliplatin|Given IV
80031159|NCT04912882|Diagnostic Test|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
80031160|NCT03472118|Device|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
80031161|NCT04976842|Device|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
80031162|NCT04976842|Drug|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
80031163|NCT02779556|Other|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
79404169|NCT05122338|Drug|Compound lidocaine|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
79404170|NCT05122338|Drug|Esketamine|Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
79404171|NCT03157843|Drug|low-molecular-weight heparin|
79739552|NCT00619606|Device|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
80031164|NCT02779556|Other|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
79739553|NCT01178138|Drug|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
79739554|NCT04211428|Other|No intervention|There is no intervention for this study
79874825|NCT00303628|Drug|fluorouracil|Given IV
80031165|NCT05133206|Other|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
79739555|NCT00618592|Dietary Supplement|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
79874826|NCT00303628|Drug|leucovorin calcium|Given IV
79874827|NCT00303628|Drug|bevacizumab|Given IV
80031166|NCT05106998|Device|nailfold capillaroscopy|Nailfold capillaroscopy (NFC) is a non-invasive easily repeatable technique and the best method for morphological analysis of nutritional capillaries in the nailfold area
80031167|NCT03470402|Other|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
80031168|NCT03470402|Other|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
79404172|NCT04386174|Other|Neurofeedback|Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
79404173|NCT03157921|Radiation|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
79580568|NCT01918098|Drug|Oxycodone/naloxone prolonged release tablets|
79580569|NCT01918111|Procedure|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
79580570|NCT01918111|Drug|adenosine infusion treatment|Continue hypertensive medication
79874828|NCT00414453|Drug|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
79874829|NCT00414453|Drug|Extended-release oxycodone|extended-release oxycodone titrating schedule
79874830|NCT00414453|Drug|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
79874831|NCT00414453|Drug|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
79874832|NCT01040715|Biological|TNFa Kinoid|TNFa kinoid
80031169|NCT03470402|Other|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
79404174|NCT03157921|Diagnostic Test|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
79404175|NCT04014894|Drug|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
79404176|NCT05121870|Biological|UC-MSCs|3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.
79580571|NCT01918124|Radiation|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
79580572|NCT01918124|Drug|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
79580573|NCT01918124|Drug|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
79739556|NCT04206254|Biological|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
79874833|NCT01040715|Biological|TNF kinoid|IM administration 2 or 3 injections within 28 days
79874834|NCT01037595|Drug|turmeric|turmeric 500 md tid orally for 8 weeks
79404177|NCT05121870|Biological|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo intravenously at week 0, week 4, week 8.
79739557|NCT04206410|Dietary Supplement|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
79739558|NCT04206410|Dietary Supplement|Maltodextrin|Maltodextrin as placebo
79739559|NCT05662150|Diagnostic Test|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
80031170|NCT03470402|Other|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
80031171|NCT03470402|Other|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
80031172|NCT02603900|Drug|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
80031173|NCT02603900|Drug|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
80031174|NCT02603900|Device|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
80031175|NCT02603900|Device|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
79277023|NCT02189135|Device|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
79277024|NCT02379663|Drug|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
79404178|NCT03589027|Drug|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
79404179|NCT03589027|Drug|Rilpivirine|Oral ripilvirine 25mg once daily
79739560|NCT02558530|Other|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
79404180|NCT03589027|Drug|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
79404181|NCT03918486|Device|Caretaker|Application of Caretaker device to subjects that are scheduled for elective surgeries.
79580574|NCT01918124|Drug|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
79580575|NCT01918137|Dietary Supplement|chocolate bar|
79580576|NCT01918137|Dietary Supplement|Porridge|
79580577|NCT01918150|Device|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
79580578|NCT01918150|Device|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
79580579|NCT01918163|Dietary Supplement|Pomegranate pills|
79580580|NCT01918176|Drug|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
79739561|NCT04208542|Drug|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
79874835|NCT01037595|Drug|placebo|placebo 3 time orally for 8 weeks
79874836|NCT01037595|Drug|turmeric|500 mg tid orally for 8 weeks
79874837|NCT01037673|Procedure|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
79874838|NCT01037673|Procedure|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
80031176|NCT01669798|Drug|BIBF 1120|PO 200mg BID
80031177|NCT03055078|Biological|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
80031178|NCT02334722|Drug|Levetiracetam|
79404182|NCT03156673|Biological|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
79580581|NCT01918176|Drug|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
79404183|NCT03874494|Drug|Brexpiprazole|Brexpiprazole 2-4 mg/day
79404184|NCT03874494|Drug|Aripiprazole|Aripiprazole 10-20 mg/day
79404185|NCT03156439|Drug|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
79404186|NCT05113992|Other|aromatherapy massage|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
79580582|NCT01918202|Drug|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
79580583|NCT01918202|Drug|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
79580584|NCT01918202|Drug|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
79580585|NCT01918228|Behavioral|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
79580586|NCT01918241|Drug|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
79739562|NCT01190228|Biological|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
79739563|NCT01190228|Biological|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
79277025|NCT02379663|Drug|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
79404187|NCT05113992|Other|classic massage|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
79404188|NCT04436328|Procedure|Surgical treatment|Surgical treatment of native vertebral osteomyelitis consisting of debridement, spinal decompression and instrumentation using hardware. Additional standard antimicrobial therapy, according to the pathogen and its antimicrobial susceptibility (intravenous route during first 2 weeks, followed by oral route for additional 4 weeks).
79580587|NCT01918241|Drug|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
79739564|NCT01009086|Drug|Placebo|SC injections
79277026|NCT02379663|Other|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
79739565|NCT01009086|Drug|Ustekinumab 45 mg|SC injections
80031179|NCT04916626|Behavioral|OPUS YOUNG|OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.
80031180|NCT04916626|Behavioral|Treatment as Usual|The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
80031181|NCT05035784|Drug|Fecal supernatant|Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
80031182|NCT05035784|Drug|Placebo|a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
79277027|NCT02288065|Drug|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
79739566|NCT01009086|Drug|Ustekinumab 90 mg|SC injections
79277028|NCT02189291|Procedure|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
79277029|NCT02189291|Procedure|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
79580588|NCT01918241|Drug|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
79580589|NCT01918241|Drug|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
79739567|NCT05662072|Behavioral|Motor imagery|Mental imagery of respiratory exercises
79277030|NCT02379507|Other|DEC033 Study Product|Apply twice daily
79580590|NCT01918254|Drug|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
79580591|NCT01918254|Drug|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
79580592|NCT01918254|Drug|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
79580593|NCT01918280|Procedure|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
79580594|NCT01918293|Device|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
79739568|NCT05662072|Behavioral|Action observation|Action observation of respiratory exercises
79404189|NCT04436328|Other|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only, bed rest or temporary external immobilization of affected spinal segment with orthopedic orthesis. Antimicrobial therapy will be administrated according to the pathogen type and antimicrobial susceptibility, with initial intravenous administration for 2 weeks, followed by oral antibiotics for 4 weeks to complete 6 weeks of total therapy.
79874839|NCT01040949|Behavioral|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
80031183|NCT04976062|Diagnostic Test|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
80031184|NCT04534400|Radiation|thoracic CT-scan|Automated measurement
80031185|NCT04975984|Diagnostic Test|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
79580595|NCT01918319|Behavioral|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
79580596|NCT01918358|Drug|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
79580597|NCT01918358|Drug|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
79580598|NCT01918358|Drug|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
79580599|NCT01918358|Drug|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
79580600|NCT01918358|Drug|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
80031186|NCT03469544|Other|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
80031187|NCT02204462|Drug|FBnTP|A PET imaging radiotracer
79580601|NCT01918358|Drug|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
79874840|NCT01040949|Behavioral|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
80031188|NCT03062254|Drug|radium-223 dichloride|6 doses of Radium-223
80031189|NCT02125136|Drug|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
79277031|NCT02288143|Drug|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~Oral clomiphene citrate: 100 mg/day until the day of the triggering.~Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~1-2 days after the identification of one follicle ≥ 17 mm~0-1 days after the identification of one follicle ≥ 19 mm."
79277032|NCT02379351|Device|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
79277033|NCT03535805|Behavioral|Mind My Mind (MMM)|"Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks."
79404190|NCT04223466|Procedure|Subxiphoid surgery procedure|Subxiphoid procedure for thymectomy
79404191|NCT04223466|Procedure|VATS surgery procedure|VATS procedure for thymectomy
79404192|NCT03156283|Behavioral|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
79739569|NCT05662072|Other|Placebo Intervention|Placebo observation
79739570|NCT01190150|Drug|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
79874841|NCT00332488|Drug|Technosphere Insulin|Inhalation, 15U/30U, prandial
79874842|NCT00332488|Drug|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
79874843|NCT00332488|Drug|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
79874844|NCT00332332|Biological|etanercept|etanercept subcutaneous injection
79874845|NCT00392925|Drug|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
79874846|NCT00392925|Drug|metreleptin|subcutaneous injection, twice a day, 5mg
79874847|NCT00392925|Drug|placebo-pramlintide 600 uL|twice a day
79874848|NCT00392925|Drug|placebo-metreleptin 1 mL|twice a day
79277034|NCT03535805|Behavioral|Treatment as Usual (TAU)|The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
79874849|NCT00392925|Drug|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
79874850|NCT03979846|Other|Best Practice|Receive usual care
80031190|NCT02125136|Drug|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
80031191|NCT04912258|Drug|Trans arterial chemoembolization with Irinotecan Drug-eluting Beads|preoperative chemoembolization with Irinotecan Drug-eluting Beads
79277035|NCT04469647|Diagnostic Test|Serology Test|"Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test."
79277036|NCT04691271|Procedure|Stellate ganglion block|"After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care."
79404193|NCT03156283|Other|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
79404194|NCT05044806|Other|Ultrasound-guided remote ischemic conditioning|Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
79580602|NCT01918384|Drug|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
79580603|NCT01918384|Drug|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
79580604|NCT01918410|Device|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
79580605|NCT01918410|Device|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
79739571|NCT04211662|Behavioral|Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).|Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
79874851|NCT03979846|Other|Computer Application|Use computer-based symptom reporting system
79874852|NCT03979846|Other|Questionnaire Administration|Ancillary studies
79874853|NCT03979846|Other|Quality-of-Life Assessment|Ancillary studies
79874854|NCT00474786|Drug|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
79874855|NCT00474786|Drug|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
79874856|NCT00392769|Drug|Cetuximab|Initial Dose = 400 mg/m^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m^2 IV Over 60 Minutes.
80031192|NCT01952288|Drug|simvastatin|simvastatin 40 mg/day for 12 months
79277037|NCT02030639|Drug|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
79277038|NCT00004897|Biological|recombinant interferon alfa|
79277039|NCT00004897|Drug|cisplatin|
79404195|NCT05044806|Other|Traditional remote ischemic conditioning|The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
79580606|NCT01918423|Behavioral|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
79580607|NCT01918436|Behavioral|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
79580608|NCT01918436|Other|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
79580609|NCT01918449|Other|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
79580610|NCT01918475|Drug|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
79580611|NCT01918475|Drug|Placebo|1ml of NaCl 0.9% is administered intravenously
79580612|NCT01918488|Dietary Supplement|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
79580613|NCT01918488|Drug|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
79580614|NCT01918501|Procedure|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
79580615|NCT01918514|Drug|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
79874857|NCT03532893|Other|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
79874858|NCT01041183|Drug|intravenous ramosetron|0.3 mg IV ramosetron (group I)
80031193|NCT01952288|Drug|Placebo Oral Tablet|placebo comparator
79874859|NCT01041183|Drug|oral ramosetron|0.1 mg oral ramosetron (group II)
79874860|NCT01041183|Drug|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
79874861|NCT01041261|Dietary Supplement|BariatrX Essentials 360 Treatment|Medical food
80031194|NCT04912414|Behavioral|Brief Family Therapy (BFT)|Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
79277040|NCT00004897|Drug|fluorouracil|
79277041|NCT00004897|Drug|hydroxyurea|
79277042|NCT00004897|Drug|leucovorin calcium|
79277043|NCT00004897|Procedure|conventional surgery|
79277044|NCT00004897|Radiation|radiation therapy|
79277045|NCT00004231|Biological|aldesleukin|
79277046|NCT00004231|Biological|filgrastim|
79277047|NCT00004231|Biological|recombinant interferon alfa|
79277048|NCT00004231|Drug|busulfan|
79277049|NCT00004231|Drug|cyclophosphamide|
79277050|NCT00004231|Drug|cytarabine|
79277051|NCT00004231|Drug|doxorubicin hydrochloride|
79277052|NCT00004231|Drug|leucovorin calcium|
79277053|NCT00004231|Drug|methotrexate|
79277054|NCT00004231|Drug|prednisone|
79277055|NCT00004231|Drug|teniposide|
79277056|NCT00004231|Drug|vincristine sulfate|
79277057|NCT00004231|Procedure|allogeneic bone marrow transplantation|
79277058|NCT00004231|Procedure|autologous bone marrow transplantation|
79277059|NCT00004231|Procedure|peripheral blood stem cell transplantation|
79277060|NCT02189369|Other|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
79874862|NCT03764943|Dietary Supplement|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
79874863|NCT00319696|Drug|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
79874864|NCT00319696|Drug|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
79874865|NCT01037751|Behavioral|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
80031195|NCT03054532|Drug|Durvalumab|Durvalumab intravenous 1500 mg
79739572|NCT04315688|Drug|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
80031196|NCT03054532|Drug|Lenali|Lenalidomide oral 20 mg/day
79874866|NCT01037751|Behavioral|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
79874867|NCT00474630|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
79277061|NCT02189369|Other|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
79277062|NCT02189447|Procedure|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
79874868|NCT00474630|Drug|Placebo|
80031197|NCT04975360|Dietary Supplement|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
79277063|NCT02288299|Device|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
79580616|NCT01918540|Procedure|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
79277064|NCT02189603|Biological|Recombinant (E. Coli) Hepatitis E Vaccine|
79277065|NCT03530449|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
79277066|NCT03530449|Device|Color Fundus Photography|Non-contact white light photography
79277067|NCT03530449|Device|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
79277068|NCT02376855|Other|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
79277069|NCT02030795|Other|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
79580617|NCT01918540|Procedure|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
79580618|NCT01918540|Device|MS-30 femoral stem|This is the stem used in the study.
79580619|NCT01918553|Other|clinical parameters|
79580620|NCT01918553|Other|visual acuity exams|
79580621|NCT01918553|Other|retinophotography|
79580622|NCT01918553|Other|SD-OCT|
79580623|NCT01918553|Other|Intra ocular Pressure (IOP)|
79580624|NCT01918553|Other|retinal imaging (OPTOMAP)|
79580625|NCT01918553|Other|axial length (IOL master)|
79874869|NCT00474630|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
79874870|NCT01043835|Procedure|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
79874871|NCT01043835|Procedure|Open gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
79874872|NCT01064752|Drug|Minocycline|100 mg po bid for 8 weeks
79874873|NCT01043913|Drug|Guarana extract|Guarana extract 50mg q12 hours for 21 days
79874874|NCT00392379|Drug|Nicotine Lozenges|Nicotine lozenges, 4 mg
79874875|NCT00392379|Drug|Placebo lozenge|Placebo lozenge
79874876|NCT01037829|Other|Non-intervention observational study|Non-intervention observational study
79874877|NCT01020552|Other|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
80031198|NCT04975360|Other|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
80031199|NCT00812708|Device|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
80031200|NCT03054454|Procedure|Podiatry|Podiatry treatments and care from the multidisciplinary team.
79277070|NCT02030795|Other|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
79277071|NCT03133585|Device|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
79277072|NCT02376777|Other|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
79580626|NCT01918566|Dietary Supplement|tap water|
79580627|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
79580628|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
79580629|NCT01918566|Dietary Supplement|25g Fructose in 300ml tap water|
79580630|NCT01918566|Dietary Supplement|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
79580631|NCT01918566|Dietary Supplement|300ml tap water with 450ppm lactisole|
79580632|NCT01918579|Procedure|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
79277073|NCT00004171|Drug|busulfan|
79580633|NCT01918592|Device|MRI/acetate-PET imaging|
79277074|NCT00004171|Drug|cyclophosphamide|
79277075|NCT00004171|Procedure|peripheral blood stem cell transplantation|
79580634|NCT01918605|Device|Diluted spacer|
79580635|NCT01918605|Device|Non-diluted spacer|
79580636|NCT01918631|Drug|tenofovir disoproxil fumarate|
79580637|NCT01918631|Drug|Entecavir|
79580638|NCT01918657|Drug|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
79580639|NCT01918657|Drug|walnut powder|escalating doses of walnut powder
79580640|NCT01918670|Procedure|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
79739573|NCT05210062|Other|Iterative exposure to suxamethonium during ECT sessions|"The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase."
79874878|NCT01038063|Drug|Artemether-lumefantrine combination|
79874879|NCT00497874|Behavioral|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
79874880|NCT01043991|Drug|Darbepoetin alfa|
79874881|NCT01043991|Drug|Placebo|
79874882|NCT01044147|Behavioral|VLM-S|Online program for weight loss - standard
79874883|NCT01044147|Behavioral|VLM-M|Online program for weight loss - modulated
79277076|NCT02030873|Other|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
79277077|NCT00004165|Biological|filgrastim|
79277078|NCT00004165|Drug|melphalan|
79277079|NCT00004165|Procedure|peripheral blood stem cell transplantation|
79277080|NCT02193113|Drug|KVD001 Injection|A novel plasma kallikrein inhibitor
79277081|NCT00004093|Drug|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
79277082|NCT00004093|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
79277083|NCT00004093|Drug|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
79277084|NCT00004093|Drug|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
79277085|NCT00004093|Radiation|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
79277086|NCT00004093|Drug|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
79580641|NCT01918696|Behavioral|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
79580642|NCT01918696|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
79580643|NCT01918696|Behavioral|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
79580644|NCT01918709|Drug|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
79580645|NCT01918709|Drug|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
79580646|NCT01918709|Drug|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
79580647|NCT01918709|Drug|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
79580648|NCT01918709|Drug|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
80031201|NCT00563576|Drug|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
80031202|NCT00563576|Drug|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
79874884|NCT01044147|Behavioral|OGR|Online program for weight loss - resources
79874885|NCT01020630|Drug|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
79580649|NCT01918709|Drug|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
79277087|NCT00004093|Drug|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
79874886|NCT01020630|Drug|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
79277088|NCT02193269|Drug|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
79874887|NCT00403455|Drug|Paroxetine|SSRI
80031203|NCT04911946|Other|Questionnaire|After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
79277089|NCT02193269|Drug|Minocycline|you will receive 200 mg as a single daily dose for 4 days
79277090|NCT02371239|Behavioral|Physical activity intervention|
79277091|NCT00002479|Drug|tretinoin|
79277092|NCT02194127|Drug|Anthocyan capsules|
79277093|NCT02194127|Drug|Placebo|
79874888|NCT04923282|Biological|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
79277094|NCT02371083|Other|Extended timing of pessary care|
79874889|NCT04923282|Biological|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
79580650|NCT01918722|Drug|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
79874890|NCT04923282|Biological|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
79874891|NCT04923282|Biological|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
79874892|NCT04923282|Biological|Placebo|Intravenous infusion
79874893|NCT00318370|Drug|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
79874894|NCT00318370|Drug|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
79874895|NCT03996408|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
79874896|NCT03996408|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
79874897|NCT01064908|Device|OxyMask|Novel vortex oxygen delivery mask
79874898|NCT00510068|Drug|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
79874899|NCT00510068|Drug|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
80031204|NCT04912102|Device|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
79277095|NCT00002371|Drug|Indinavir sulfate|
79277096|NCT00002371|Drug|Lamivudine|
79277097|NCT00002371|Drug|Stavudine|
79277098|NCT00002371|Drug|Zidovudine|
79277099|NCT02189681|Procedure|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
79277100|NCT02189681|Procedure|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
79277101|NCT02189681|Device|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
79580651|NCT01918722|Drug|placebo|placebo herbal medicine, one dose,bid, for 10 days
79580652|NCT01918722|Drug|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
79580653|NCT01918748|Device|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
79874900|NCT00509600|Drug|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
80031205|NCT04390178|Biological|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
80031206|NCT04911218|Device|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
80031207|NCT04911218|Device|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
79277102|NCT04188639|Drug|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
79874901|NCT04485026|Radiation|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
80031208|NCT04904744|Other|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
80031209|NCT04904744|Other|No message|No reminders are sent
79277103|NCT05715385|Procedure|laser photocoagulation|"Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.~Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.~Duration of about 0.05-0.1 sec is used Number of spots- 100-500"
79277104|NCT05715385|Drug|eye drop bromfenac 0.09%|twice daily e/d bromfenac 0.09% for 6 weeks
79277105|NCT05715385|Drug|Placebo|Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
80031210|NCT04904744|Other|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
80031211|NCT04342286|Genetic|Organoid culture|Organoid culture
80031212|NCT04975282|Device|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
79277106|NCT04182633|Combination Product|vancomycin, Miralax, intestinal microbiota|vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
79277107|NCT04182633|Combination Product|placebo vancomycin, Miralax, placebo intestinal microbiota|placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
79277108|NCT03133507|Behavioral|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
79739574|NCT01001520|Drug|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
79874902|NCT04485026|Drug|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
79874903|NCT01014026|Other|Screening test|Two Vaginal self sampling devices and HPV test
79874904|NCT01014104|Drug|Methylprednisolone|Administration of Methylprednisolone
79277109|NCT03133507|Behavioral|Reassurance Condition|Children will be reassured by the experimenter .
79739575|NCT01001520|Drug|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
79874905|NCT01014104|Drug|Control|Normal salin injection
79874906|NCT00402987|Drug|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
79874907|NCT00402987|Drug|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
79874908|NCT00402987|Drug|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
79874909|NCT00402987|Drug|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
80031213|NCT04975282|Device|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
80031214|NCT03109574|Device|BioFlo DuraMax Chronic Hemodialysis Catheter|
80031215|NCT03109574|Device|Standard of Care Catheter|
80031216|NCT04911712|Dietary Supplement|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
80031217|NCT04911712|Dietary Supplement|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
80031218|NCT03469466|Diagnostic Test|bedside ultrasound|bedside ultrasound imaging of the lungs
80031219|NCT04975126|Other|CatInfo tool|Presentation about cataract surgery
80031220|NCT04316156|Device|Uincare Homeplus|Interactive digital healthcare system
80031221|NCT04316156|Other|Brochure|Brochure
79580654|NCT01918787|Device|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
79580655|NCT01918813|Drug|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
79739576|NCT00619840|Drug|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
79874910|NCT01015664|Drug|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
79874911|NCT01015664|Drug|cisplatin|75 mg/m2 IV over 60 minutes on day 1
79874912|NCT01015664|Drug|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
79874913|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
79874914|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment.
80031222|NCT04975750|Behavioral|Problem solving intervention|The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified
80031223|NCT04975750|Behavioral|Care as usual|The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
80031224|NCT05161052|Device|Corvis ST (dynamic Scheimpflug technology)|"Measurement of corneal stiffness parameters { Deformation Amlitude (DAR1), Integrated radius, Stress parameter (SP A1), Stress strain index (SSI) and Corvis biomechanical index (CBI) } in keratoconic corneas before and after 3 and 6 months CXL using Corvis ST.~Measurement of demarcation line depth using anterior segment OCT and correlate between corneal stiffness following CXL and demarcation line depth"
80031225|NCT03061864|Behavioral|Periviable Birth Plan|
79580656|NCT01918826|Device|TENS|
79739577|NCT00619840|Drug|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
79874915|NCT01015742|Drug|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
79277110|NCT03133507|Behavioral|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
79580657|NCT01918852|Drug|Capecitabine|
79580658|NCT01918852|Drug|Teysuno|
79874916|NCT00501644|Drug|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
79874917|NCT00501644|Drug|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
79874918|NCT00501644|Drug|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
79277111|NCT02194205|Drug|COMBIVENT HFA|
79580659|NCT01918852|Drug|Bevacizumab|
79580660|NCT01918865|Drug|ISIS-PTP1BRx|
79580661|NCT01918865|Drug|Placebo|
79580662|NCT01918865|Drug|daily OAD (metformin and/or sulfonylurea)|
79739578|NCT02871258|Device|The MetaNeb® System|
79739579|NCT04463082|Procedure|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
79739580|NCT02344108|Device|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
79739581|NCT04415658|Drug|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
79277112|NCT02194205|Drug|Placebo HFA|
79277113|NCT02194205|Drug|COMBIVENT CFC|
79277114|NCT02194205|Drug|Placebo CFC|
79277115|NCT03133663|Other|Electrocardiogram group|Experimental
79277116|NCT03133663|Other|Pulse oximeter and auscultation group|Control
79277117|NCT02194361|Drug|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
79277118|NCT02194361|Drug|Placebo|
79277119|NCT03133741|Other|GIP-A|GIP-A (GIP receptor antagonist)
79277120|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
79277121|NCT03133741|Other|Placebo|Saline (9mg/mL)
79277122|NCT03133741|Other|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
79277123|NCT02371005|Radiation|Cone Beam Computed Tomography (CBCT)|
79580663|NCT01918878|Drug|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
79580664|NCT01918891|Behavioral|Nurse Practitioner Only|
79580665|NCT01918891|Behavioral|Nurse Practitioner + Health Coach|
79580666|NCT01918904|Drug|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
79580667|NCT01918904|Drug|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
79580668|NCT01918917|Drug|Levobupivacaine|intraarticular
79580669|NCT01918917|Drug|Dexmedetomidine|intraarticular 1 ml (100 mcg)
79580670|NCT01918917|Drug|Morphine|intravenously, patient-controlled analgesia
79580671|NCT01918943|Device|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
79580672|NCT01918956|Biological|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
79580673|NCT01918995|Drug|Regadenoson|Intravenous (IV)
79580674|NCT01918995|Drug|Placebo|Intravenous (IV)
79874919|NCT03997214|Device|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
79874920|NCT01014260|Drug|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
79277124|NCT02288455|Device|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
79277125|NCT02194517|Device|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
79277126|NCT02371161|Drug|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~R-DHAP~Rituximab 375 mg/m2, e.v. day 1~Desamethasone 40 mg days 1-4~cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~R-ICE~Rituximab 375 mg/m2, e.v. day 1~Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
79277127|NCT03532633|Procedure|cord blood|collection of cord blood
79277128|NCT03532633|Procedure|blood sample infant|collection of remnant of clinically indicated blood sample
79277129|NCT03532633|Procedure|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
79277130|NCT03532633|Procedure|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
79739582|NCT04415658|Drug|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
79739583|NCT02871024|Device|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
79580675|NCT01919008|Drug|FK949E|Oral
79580676|NCT01919021|Other|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
79580677|NCT01919021|Other|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
79277131|NCT02195843|Other|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
79580678|NCT01919021|Procedure|Assessment of Gastric motor and sensory function|
80031226|NCT05160818|Radiation|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
79580679|NCT01919047|Drug|Betanis|Oral
79277132|NCT02195843|Other|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
79580680|NCT01919073|Behavioral|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
79580681|NCT01919073|Behavioral|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
79580682|NCT01919125|Drug|IDX719|IDX719 supplied as 50 mg tablets.
79739584|NCT01189604|Drug|Placebo|Infusion of placebo, same infusion rates as for arm 2
79739585|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
79739586|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
79580683|NCT01919177|Dietary Supplement|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
79580684|NCT01919177|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
79580685|NCT01919203|Drug|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
79580686|NCT01919242|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
79739587|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
79739588|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
79739589|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
79739590|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
79739591|NCT02697058|Biological|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
79874921|NCT01014260|Drug|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
79277133|NCT02195843|Device|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
79277134|NCT04439565|Genetic|movement|aortic dissection or aneurysm patients this is an observation cohort study about a Non-syndromic Familial Aortic Dissection without intervention.
79277135|NCT00266461|Drug|Daikenchuto Extract Granules (TU-100)|
79277136|NCT02194283|Drug|Ambroxol - in single rising doses|
79277137|NCT02194283|Drug|Placebo|
79277138|NCT02376543|Device|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
79277139|NCT02376543|Device|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
79277140|NCT00263341|Combination Product|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
79580687|NCT01919255|Drug|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
79580688|NCT01919255|Drug|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
79580689|NCT01919268|Device|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
79580690|NCT01919268|Device|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
79739592|NCT02697058|Drug|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
79874922|NCT01010672|Drug|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
79874923|NCT01014338|Drug|Fosinopril|10mg od
79874924|NCT01014338|Other|lactose|placebo
79874925|NCT01014416|Drug|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
79874926|NCT00497796|Drug|maribavir|100mg twice a day for 14 weeks.
79277141|NCT02195999|Other|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
79277142|NCT02195999|Other|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
79277143|NCT02195999|Other|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
79277144|NCT02195999|Other|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
79277145|NCT02370771|Procedure|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
79580691|NCT01919281|Behavioral|strength training|
79580692|NCT01919281|Behavioral|interval training|
79580693|NCT01919294|Drug|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
79580694|NCT01919320|Device|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
79277146|NCT02370771|Device|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
79277147|NCT05725447|Other|Validity and reliability study|Face-to-face questionnaire study
79739593|NCT04294524|Other|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
79739594|NCT05661994|Dietary Supplement|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
79580695|NCT01919320|Device|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
79874927|NCT00497796|Drug|ganciclovir|1000mg three times per day for 14 weeks.
79580696|NCT01919346|Drug|Eculizumab|
79580697|NCT01919346|Drug|Normal Saline|
79580698|NCT01919359|Dietary Supplement|Multizyme Cellular Vitality Cyruta Plus SHEP|
79580699|NCT01919372|Device|Telemedic assistance with a technological system|
79580700|NCT01919372|Other|Standard care|
79739595|NCT04294602|Other|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
79874928|NCT01017822|Biological|conatumumab|
79874929|NCT01017822|Drug|capecitabine|
79874930|NCT01017822|Drug|gemcitabine hydrochloride|
79874931|NCT01017822|Radiation|3-dimensional conformal radiation therapy|
79874932|NCT04449822|Procedure|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
79404196|NCT05044806|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
79874933|NCT04449822|Procedure|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
79277148|NCT02376621|Dietary Supplement|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
79580701|NCT01919385|Device|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
79404197|NCT03156517|Device|Deep Brain Stimulation|
79404198|NCT03156361|Drug|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
79580702|NCT01919424|Drug|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
79580703|NCT01919424|Device|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
79580704|NCT01919424|Device|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
79580705|NCT01919437|Device|Web-Enabled Cognitive Neuropsychological Evaluation System|
79580706|NCT01919463|Behavioral|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
79580707|NCT01919463|Device|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
80031227|NCT04915222|Other|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
79277149|NCT02376621|Dietary Supplement|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
79277150|NCT02376621|Dietary Supplement|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
79277151|NCT02376621|Dietary Supplement|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
79404199|NCT03156361|Drug|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
79404200|NCT05690035|Drug|Tislelizumab & Fruquintinib|combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
79739596|NCT04294602|Other|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
79739597|NCT04294602|Other|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
79739598|NCT04294602|Other|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
79739599|NCT02696824|Behavioral|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
79580708|NCT01919476|Other|Bagel|
79739600|NCT04296786|Drug|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
79739601|NCT04296786|Drug|Chidamide|20mg po per week continuously
79739602|NCT00622414|Biological|ziv-aflibercept|Given IV
79739603|NCT01008696|Drug|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
79580709|NCT01919476|Other|Cream Cheese|
79580710|NCT01919476|Other|Almond Butter|
79580711|NCT01919502|Device|Semi-quantitative urine pregnancy test|
79580712|NCT01919515|Device|ZR Crown|This is an esthetic primary molar crown.
79580713|NCT01919515|Device|Stainless Steel Crown|This is a conventional stainless steel crown.
79580714|NCT01919528|Procedure|ultrasound|catheterization of the axillary vein under ultrasound guidance
79277152|NCT02376621|Dietary Supplement|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
79277153|NCT02288533|Device|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
79404201|NCT03156049|Procedure|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
79404202|NCT03156049|Procedure|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
79404203|NCT03156127|Drug|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
80031228|NCT04915222|Other|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
80031229|NCT03471962|Other|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
80031230|NCT04911556|Dietary Supplement|Bifidobacterium longum|types of intestinal flora
79404204|NCT05002530|Drug|Aerosolized 13 cis retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79404205|NCT05002530|Drug|Aerosolized All trans retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
79404206|NCT05002530|Other|Standard therapy|Standard therapy
79580715|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
79404207|NCT05700487|Other|PELVIC FLOOR EXERCISES|Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
79580716|NCT01919541|Device|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
79580717|NCT01919541|Device|hyperinsulinemic euglycemic hyperaminoacid clamp|
79580718|NCT01919541|Dietary Supplement|whey protein supplementation|
80031231|NCT04911556|Dietary Supplement|A placebo made of starch|placebo
80031232|NCT03470324|Device|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
80031233|NCT03470324|Device|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
79739604|NCT01008696|Drug|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
79739605|NCT01955980|Drug|Budesonide|Inhalation
80031234|NCT03470324|Behavioral|Swallowing therapy|Swallowing therapy with speech therapist
80031235|NCT03470246|Behavioral|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
79739606|NCT01955980|Drug|Budesonide|Nasal Spray
79739607|NCT02870478|Drug|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
79739608|NCT00622492|Other|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
79739609|NCT05661838|Procedure|transfusion|transfusion
79739610|NCT04296162|Drug|Vinorelbine|Vinorelbine chemotherapy (oral)
79739611|NCT04296162|Drug|Capecitabine|Capecitabine chemotherapy (oral)
80031236|NCT03470246|Behavioral|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
80031237|NCT03470246|Behavioral|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
80031238|NCT04915066|Other|Medical data collection|Collection of medical data from patients'medical records
79580719|NCT01919541|Other|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
79580720|NCT01919554|Biological|SLIT tablets of HDM allergen extracts|
79580721|NCT01919593|Drug|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
79580722|NCT01919593|Drug|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
79580723|NCT01919632|Behavioral|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
79739612|NCT04296162|Drug|Trastuzumab|Trastuzumab target therapy
79739613|NCT00619996|Drug|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
79739614|NCT00619996|Drug|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
79739615|NCT02870790|Drug|TDF/FTC|one pill daily
79874934|NCT00496782|Drug|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
80031239|NCT04911010|Behavioral|Prolonged Exposure|In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
80031240|NCT03998540|Diagnostic Test|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
80031241|NCT03998540|Other|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
80031242|NCT03998540|Other|Mass Spectometry|samples previously used for western blotting will be subjected to mass spectrometry analysis
80031243|NCT03998540|Other|RNA seq|analyze muscle gene expression in patients with titinopathies in our cohort by RNAseq
80031244|NCT03782636|Drug|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
80031245|NCT03782636|Other|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
80031246|NCT04911244|Diagnostic Test|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
80031247|NCT04910620|Drug|Placebo|Placebo only
80031248|NCT04910620|Drug|TCI378|TCI378 (Lactobacillus plantarum TCI378)
79308576|NCT03041493|Behavioral|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
79580724|NCT01919645|Other|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
79580725|NCT01919658|Procedure|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
79580726|NCT01919671|Drug|Tongxinluo capsule|for 90 days
79580727|NCT01919671|Drug|placebo capsule|for 90 days
79580728|NCT01919684|Drug|LGD-6972|
79580729|NCT01919684|Drug|Placebo (Captisol®)|
79580730|NCT01919710|Drug|rHSA/GCSF|for treatment of neutropenia
79739616|NCT05028400|Device|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
79739617|NCT05661526|Other|Bloodpoly board game|Blood transfusion training given by Bloodpoly board game
79739618|NCT05661526|Other|Text-to-speech group|Blood transfusion training given by text-to-speech
80031249|NCT04910620|Drug|TCI507|TCI507 (Lactobacillus plantarum TCI507)
80031250|NCT03761810|Drug|S6G5T-3|Once a day topical cream
79404208|NCT03583021|Drug|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
79277154|NCT04347941|Procedure|Prone Positioning|Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 <94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 >94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula
79404209|NCT03583021|Drug|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
80031251|NCT03761810|Drug|S6G5T-8|Once a day topical cream
79580731|NCT01919736|Behavioral|Gait Retraining|
79874935|NCT00496782|Procedure|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
79874936|NCT01017900|Procedure|local excision|surgical excision by orthopaedic surgeon under local anesthesia
79874937|NCT01020708|Drug|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
79874938|NCT01020708|Drug|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
80031252|NCT04915456|Drug|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
79874939|NCT01020708|Drug|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
79874940|NCT01020864|Drug|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
79874941|NCT01020864|Drug|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
79874942|NCT01020864|Drug|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
80031253|NCT04915456|Other|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
79404210|NCT05113914|Diagnostic Test|Cardio-pulmonary exercise test|An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
79874943|NCT01020942|Procedure|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
80031254|NCT04575740|Device|PAP|Positive airway pressure to treat sleep apnea
79404211|NCT04937322|Procedure|Interventional Endoscopy procedures|• All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.
79404212|NCT04903548|Procedure|SIRT with Y-90 resin microspheres|Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC
79404213|NCT03582787|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
79404214|NCT03582787|Device|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
79580732|NCT01919788|Drug|Insulin (Insuman Rapid)|
79580733|NCT01919788|Drug|Glucose|
79580734|NCT01919788|Other|Saline|
79580735|NCT01919827|Biological|Endobronchial infusion of adult mesenchymal stem cells|
79874944|NCT01020942|Procedure|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
79874945|NCT01017978|Procedure|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
79874946|NCT00402831|Biological|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
80031255|NCT04853836|Combination Product|co-ultraPEALut|Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
80031256|NCT04853836|Procedure|Olfactory Rehab|Olfactory Rehabilitation10 minutes twice a day for all the observation period
80031257|NCT04853836|Drug|PEA-LUT 1 sachet|Only 1 sachet day of PEA-LUT no olfactory training
80031258|NCT04853836|Drug|PEA-LUT 2 sachet day|2 sachets day of PEA-LUT no olfactory training
80031259|NCT04498130|Behavioral|12-Week Home Exercise Group|12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
79580736|NCT01919827|Biological|Autologous mesenchymal stem cells derived from bone marrow|
79580737|NCT01919840|Procedure|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
80031260|NCT04498130|Behavioral|Education Comparison Group|12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
79277155|NCT04347941|Procedure|Standard of care.|Standard of care. Prone positioning may be administered as a rescue therapy
79277156|NCT05725369|Behavioral|Combined Lifestyle Intervention (CLI)|In the Netherlands, the combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie (GLI)) is available for all Dutch citizens with a BMI ≥ 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease. The CLI aims to realize health benefits for people with a moderate weight-related health risk and consists of a two-year program with advice and counseling to improve health-related behavior such as physical activity and diet.
79277157|NCT02378727|Device|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
79277158|NCT02378727|Device|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
79277159|NCT03534869|Procedure|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
79277160|NCT03534869|Drug|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
79277161|NCT03532321|Other|NA : non interventional study|NA : non interventional study
79277162|NCT02370849|Drug|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
79277163|NCT02370849|Drug|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
79580738|NCT01919840|Other|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
79580739|NCT01919853|Behavioral|Mindfulness-Based Stress Reduction|
80031261|NCT04841668|Drug|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
80031262|NCT03469388|Diagnostic Test|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
80031263|NCT04492904|Other|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
80031264|NCT03469310|Drug|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
80031265|NCT03469310|Drug|Tylenol #3 Oral Tablet|Narcotic medication first
80031266|NCT03469310|Drug|Tramadol|non-narcotic medication first with narcotic as second choice
80031267|NCT04910854|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
80031268|NCT04839874|Other|No intervention|Semi-structured qualitative interviews
79277164|NCT02370849|Drug|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
79277165|NCT03532243|Procedure|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
79277166|NCT02194673|Other|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
79277167|NCT02194673|Other|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
79580740|NCT01919853|Behavioral|Attention Control|
79580741|NCT01919866|Other|Transplantation of CD3/CD19 depleted stem cells|
79580742|NCT01919879|Drug|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
79580743|NCT01919879|Drug|Cetuximab|Cetuximab administered intravenously
79739619|NCT00622570|Drug|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
79739620|NCT00622570|Drug|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
79739621|NCT04208308|Dietary Supplement|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
79277168|NCT02194673|Other|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
79277169|NCT03532165|Diagnostic Test|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
79277170|NCT02197091|Other|questionnaire administration|Ancillary studies
79277171|NCT02197091|Other|medical chart review|Ancillary studies
79277172|NCT02378649|Drug|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
79277173|NCT02378649|Drug|Placebo|Placebo comparator concomitant with best practice usual care
79277174|NCT03534791|Other|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
79580744|NCT01919892|Drug|Lithium|
79580745|NCT01919905|Dietary Supplement|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
79277175|NCT02378571|Behavioral|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
80031269|NCT03469232|Drug|Huanglian-Jiedu Decoction|Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
79277176|NCT03530137|Behavioral|Healthy Home|An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
79739622|NCT04208308|Dietary Supplement|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
79739623|NCT04208308|Dietary Supplement|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
79739624|NCT04208308|Dietary Supplement|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
79580746|NCT01919918|Drug|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
79580747|NCT01919944|Drug|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
79580748|NCT01919944|Drug|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
79580749|NCT01919957|Other|No intervention|
79739625|NCT01473004|Device|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
79739626|NCT05368792|Dietary Supplement|Complex Carbohydrate (PREcovery)|Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
79739627|NCT04141072|Diagnostic Test|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
79874947|NCT03996642|Behavioral|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
79874948|NCT01038141|Procedure|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
79277177|NCT03530137|Behavioral|Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).|ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
79277178|NCT03530137|Behavioral|HealthySteps|Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
79404215|NCT04235244|Other|Thermo mechanical device|The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
79404216|NCT04235244|Other|local coolant spray|Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.
79739628|NCT00925678|Drug|DSP-3025|
79739629|NCT00925678|Drug|Placebo|
79739630|NCT00890266|Procedure|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
79739631|NCT04208152|Drug|anle138b|capsule containing excipient and anle138b
79874949|NCT01014858|Drug|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
79874950|NCT00496626|Biological|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
79874951|NCT00496626|Biological|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
79874952|NCT01018212|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
80031270|NCT04904224|Device|Panintestinal video capsule endoscopy|Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
79739632|NCT04208152|Drug|Placebo|matching placebo capsule containing excipient
80031271|NCT04904224|Device|Colonoscopy|Performing a standard colonoscopy using the colonoscope available in the study center
80031272|NCT03527186|Drug|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
80031273|NCT05159882|Drug|THR-1442 and Dapagliflozin placebo|THR-1442 tablets 20mg and Dapagliflozin tablets placebo
80031274|NCT05159882|Drug|Dapagliflozin 10mg and THR1442 placebo|Dapagliflozin tablets 10mg and THR-1442 tablets placebo
80031275|NCT04910698|Drug|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
80031276|NCT04461236|Dietary Supplement|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
80031277|NCT04461236|Dietary Supplement|Placebo|Placebo
79580750|NCT01920009|Behavioral|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
79580751|NCT01920022|Drug|Mifepristone|Day one of medical abortion
79874953|NCT01015014|Drug|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
80031278|NCT04914442|Diagnostic Test|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
79580752|NCT01920022|Drug|etonorgestrel|
79580753|NCT01920074|Drug|Nitroglycerin Ointment 0.4%|
79580754|NCT01920165|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
79874954|NCT01015014|Drug|Placebo|0.9% sodium chloride for injection
79874955|NCT04052958|Device|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
80031279|NCT04904146|Diagnostic Test|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
80031280|NCT04455464|Drug|Midodrine Oral Tablet|Midodrine will be given 10 mg for one time only.
79580755|NCT01920360|Other|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
79874956|NCT00471276|Drug|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
79874957|NCT00470262|Drug|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
79874958|NCT00470262|Drug|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
80031281|NCT04914598|Drug|ENDOSTAR，cisplatin|After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
80031282|NCT04914598|Drug|Placebo , cisplatin|Placebo , cisplatin
80031283|NCT04312256|Device|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
80031284|NCT04903990|Other|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
79404217|NCT04235244|Other|ıce battery|abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
79580756|NCT01920360|Other|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
79739633|NCT00622804|Procedure|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
79739634|NCT00622804|Procedure|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
79874959|NCT04034862|Drug|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
79874960|NCT00496470|Drug|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
79874961|NCT00496470|Drug|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
79874962|NCT01021176|Other|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
79580757|NCT01920360|Other|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
79580758|NCT01920412|Device|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
79580759|NCT01920516|Drug|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
79580760|NCT01920698|Device|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
79277179|NCT02197169|Drug|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
79404218|NCT05659693|Behavioral|digital literacy education specific to menopause|Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
79580761|NCT01920698|Other|control|
79580762|NCT01920750|Biological|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
79739635|NCT00622804|Procedure|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
79739636|NCT05661760|Behavioral|interdisciplinary multimodal pain treatment|A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
79739637|NCT04210960|Radiation|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
79580763|NCT01920750|Biological|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
79739638|NCT04210960|Radiation|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
80031285|NCT03470168|Device|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
79277180|NCT02197169|Drug|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
79874963|NCT01021176|Drug|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
79874964|NCT00496080|Device|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
79874965|NCT01018368|Drug|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
79874966|NCT01018368|Drug|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
79874967|NCT00487578|Drug|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
79277181|NCT02376309|Behavioral|Inactivity|Inactivity
79277182|NCT02376309|Drug|ND|1 nandrolone decanoate injection
79580764|NCT01920750|Other|Mock Antigen|Physiological saline
79580765|NCT01920763|Other|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
79580766|NCT01920984|Drug|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
79874968|NCT00495612|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
80031286|NCT03470168|Device|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
80031287|NCT04904380|Other|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
79277183|NCT02376309|Dietary Supplement|Leu|Leucine supplements
79277184|NCT05165849|Drug|GFS101A|GFS101A will be administrated intravenously Q3W.
79277185|NCT05165849|Drug|Toripalimab|Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
79277186|NCT02376231|Device|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
79404219|NCT03156205|Behavioral|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
79404220|NCT03156205|Behavioral|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
79404221|NCT03156205|Behavioral|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
79580767|NCT01921283|Device|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
79580768|NCT01921283|Drug|no- BIS sensor attachment|
79580769|NCT01921374|Biological|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
79580770|NCT01921374|Biological|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
79580771|NCT01921374|Biological|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
79404222|NCT04885608|Other|PReGe|There will be two weekly sessions of 45 minutes, outdoors in outdoor fitness parks. The components of balance, gait, resistance, strength and elasticity will be worked on and breathing exercises will be performed. The sessions will be guided and dosed by physiotherapists, considering the level of perception of effort. Indications will be given to carry out other sessions of 60 to 120 minutes of therapeutic walking (minimum speed of 4 km/hour) during the week, to complete the 150-300 minutes per week of physical activity recommended by the WHO.
79404223|NCT03155971|Device|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
79874969|NCT00495612|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
79874970|NCT01021488|Drug|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
79874971|NCT01021488|Drug|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
79580772|NCT01921374|Biological|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
79580773|NCT01921374|Biological|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
79580774|NCT01921972|Drug|Galantamine CR|24 mg/day with dose-titration over twelve weeks
79580775|NCT01921972|Drug|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
79739639|NCT04211038|Device|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
79874972|NCT00487188|Drug|Enfuvirtide|90 mg subcutaneous injection twice a day
79874973|NCT00487188|Drug|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
80031288|NCT04913974|Procedure|Uni-condylar knee arthroplasty|Surgical replacement of medial compartment of arthritic knee with an implant
80031289|NCT03099746|Behavioral|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
80031290|NCT03099746|Behavioral|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
80031291|NCT03099746|Behavioral|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
79580776|NCT01921972|Drug|Placebo|Placebo will be similar in appearance to Memantine
79739640|NCT04187638|Dietary Supplement|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
79874974|NCT00509366|Drug|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
79277187|NCT00232141|Drug|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
79277188|NCT00232141|Drug|Placebo|Placebo
79277189|NCT02378415|Drug|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
79277190|NCT02378415|Drug|Placebo|Normal Saline Infusion
79277191|NCT02197325|Device|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
79404224|NCT03157765|Procedure|endometrial biopsy|endometrial biopsy
80031292|NCT04903912|Diagnostic Test|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
80031293|NCT04903912|Diagnostic Test|Laboratory tests|Metabolic profile and platelet reactivity
80031294|NCT04903912|Drug|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
80031295|NCT04903912|Procedure|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
79580777|NCT01922362|Device|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
79580778|NCT01922362|Device|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
79580779|NCT01922414|Device|Laser|Patients will undergo laser lithotripsy durin PNL
79874975|NCT00509366|Drug|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
80031296|NCT03054220|Drug|Dextromethorphan 5 MG|
80031297|NCT03054220|Drug|Tramadol 10 mg|
80031298|NCT03054220|Drug|Duloxetine 60mg|
80031299|NCT03054220|Drug|Paroxetine 20 mg|
80031300|NCT05388188|Drug|sublingual sufentanil|Dsuvia in patients with SCD VOC as a bridging medication.
79874976|NCT00509366|Drug|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
80031301|NCT04903834|Diagnostic Test|Soton hyperinflammation score|Score for hyperinflammation defined by blood parameters and other physiological measurements
80031302|NCT04903834|Diagnostic Test|HScore|Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
80031303|NCT03470090|Behavioral|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
80031304|NCT03470090|Behavioral|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
80031305|NCT03053908|Procedure|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
79404225|NCT03582319|Other|Biodentine|Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
79580780|NCT01922414|Device|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
79580781|NCT01922830|Dietary Supplement|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
79580782|NCT01922830|Dietary Supplement|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
79580783|NCT01922882|Behavioral|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
79580784|NCT01923168|Drug|alpelisib|BYL719 + Letrozole
79580785|NCT01923168|Drug|buparlisib|BKM120 + Letrozole
79874977|NCT00509366|Drug|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
79874978|NCT01015898|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
80031306|NCT03053908|Procedure|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
80031307|NCT04203836|Drug|LEO 152020 Tablet|film-coated tablet
80031308|NCT04118036|Drug|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
80031309|NCT04118036|Drug|Abemaciclib|Oral 2 times a day
80031310|NCT05159336|Device|tACS for auditory hallucinations via single arm|a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
80031311|NCT04914130|Other|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
80031312|NCT05159258|Other||
80031313|NCT04903600|Dietary Supplement|Probiotics fruit vegetable fiber powder product|Eat 16 g for once, and twice a day
80031314|NCT04903600|Dietary Supplement|Placebo|Eat 16 g for once, and twice a day
80031315|NCT03471884|Procedure|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
80031316|NCT03471884|Procedure|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
80031317|NCT04909918|Drug|Dexamethasone|Baseline laboratory & clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
80031318|NCT04909918|Drug|Methylprednisolone|Baseline laboratory & clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
80031319|NCT04903444|Device|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
79874979|NCT03997682|Other|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
80031320|NCT03054688|Device|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
80031321|NCT04903678|Drug|Melphalan|Melphalan is performed for intrathecal chemotherapy
80031322|NCT04903366|Drug|Timolol Maleate|timolol maleate 0.5% gel-forming solution
80031323|NCT03054610|Drug|Betamethason Sodium Phosphate|
79580786|NCT01923168|Drug|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
79580787|NCT01923454|Procedure|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
80031324|NCT03054610|Drug|Ropivacaine|
79580788|NCT01923454|Drug|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
79874980|NCT01016054|Biological|AGS-8M4|IV infusion
79874981|NCT01016054|Drug|Pegylated liposomal doxorubicin (PLD)|IV infusion
79874982|NCT01016054|Drug|gemcitabine|IV infusion
79874983|NCT01016054|Drug|carboplatin|IV infusion
79874984|NCT00500318|Drug|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
79277192|NCT02370459|Other|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
80031325|NCT03054610|Drug|Botulinum Toxins, Type A|
79404226|NCT03582319|Other|Formocresol|Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
79580789|NCT01923454|Procedure|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
79580790|NCT01923519|Procedure|bronchofiberscopy|
79580791|NCT01923688|Other|Informatics Alert/Nurse/physician responders|
79874985|NCT00500318|Drug|Placebo|Dose matched placebo, once daily oral inhalation.
79874986|NCT00508820|Biological|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
80031326|NCT03053752|Procedure|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
80031327|NCT04909762|Other|Early Rehabilitation and Mobilisation (ERM)|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
80031328|NCT04902742|Procedure|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
80031329|NCT04902742|Procedure|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
80031330|NCT03053830|Drug|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
80031331|NCT04913740|Other|Ointment and dressing for external use|"pay attention to the protection of exposed skin, so that it is local dry.~Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
80031332|NCT04913896|Drug|PD-1 inhibitor|SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
80031333|NCT04913662|Procedure|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
80031334|NCT04913506|Other|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
80031335|NCT04913506|Device|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
80031336|NCT04913506|Other|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
80031337|NCT04913428|Other|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
80031338|NCT04913428|Other|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
80031339|NCT04902586|Device|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
80031340|NCT03053674|Other|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
79580792|NCT01923701|Behavioral|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
79580793|NCT01923935|Drug|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
79874987|NCT00499694|Biological|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
80031341|NCT03053674|Other|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
80031342|NCT03053596|Device|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
79277193|NCT02370459|Other|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
79580794|NCT01923935|Drug|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)
79580795|NCT01923974|Drug|Melatonin 10 mg|
79580796|NCT01923974|Drug|Melatonin 100 mg|
79277194|NCT02378337|Other|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
79580797|NCT01923974|Drug|Placebo|
79580798|NCT01924013|Dietary Supplement|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
79580799|NCT01924013|Dietary Supplement|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
79580800|NCT01924208|Biological|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
79874988|NCT00499694|Drug|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
79874989|NCT01014494|Device|Adaprev|Class III Medical Device
79874990|NCT00486954|Drug|Lapatinib|6 pills at 250 mg each once daily
79874991|NCT00486954|Drug|Paclitaxel|Infusion at 80 mg/m2 weekly
79874992|NCT00494676|Device|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
79580801|NCT01924208|Biological|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
79580802|NCT01924208|Procedure|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
79580803|NCT01924507|Device|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
79580804|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
79580805|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
79580806|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
79739641|NCT04187638|Dietary Supplement|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
79277195|NCT02194751|Biological|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
79874993|NCT00494676|Device|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
79874994|NCT00486720|Drug|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
79874995|NCT00486720|Drug|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
79874996|NCT00486330|Drug|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
79874997|NCT04010682|Other|urine sample collection|no drug/devise intervention. sample collection study only
79874998|NCT01021566|Device|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
79874999|NCT01021566|Drug|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
79875000|NCT01021644|Behavioral|aerobic exercise-training|3 times per week for 6 months
79277196|NCT02378493|Biological|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
79739642|NCT04211116|Device|Central venous line insertion|Pediatric patients indicated to central venous line insertion
79739643|NCT02691832|Device|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
79277197|NCT02197403|Drug|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion
79277198|NCT02197403|Drug|Propofol|25~75mcg/kg/min continuous infusion
79580807|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
79875001|NCT01021644|Behavioral|stretch exercise|3 times per week for 6 months
79580808|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
79739644|NCT01176968|Drug|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
79739645|NCT01176968|Drug|Placebo|Matching placebo tablets
79875002|NCT01021722|Procedure|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
79875003|NCT00486252|Other|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
79277199|NCT02196389|Device|Nasal dilator Nasanita|Nasal Dilator
79277200|NCT02196389|Device|Nasal dilator Nozovent|
79277201|NCT02196389|Device|Nasal dilator Breath Right|
79277202|NCT02196389|Device|Nasal dilator Airmax|
79580809|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
79580810|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
79580811|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
79580812|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
79580813|NCT01924741|Procedure|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
79580814|NCT01925066|Drug|Vancomycin|
79580815|NCT01925235|Procedure|remote ischemic preconditioning|
79739646|NCT04211584|Device|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
79739647|NCT02697370|Drug|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
79875004|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
79875005|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
79875006|NCT01021800|Biological|MIS|Cell infusion
79875007|NCT03851016|Behavioral|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
79875008|NCT03851016|Behavioral|Usual Care|Three weeks of Usual Care with no visits from research team
79875009|NCT00493974|Drug|Zileuton|Zyflo tablets, 600 mg, 4 times a day
79875010|NCT00493974|Drug|Placebo|Placebo 4 x daily
79580816|NCT01925365|Dietary Supplement|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
79580817|NCT01925365|Dietary Supplement|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
79404227|NCT03157375|Device|Intraocular Lens Implantation|
79739648|NCT02691442|Drug|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
79875011|NCT01018446|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
79875012|NCT01018524|Procedure|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
79875013|NCT01018602|Drug|vildagliptin|100 mg per day over 24 months
80031343|NCT03053284|Drug|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
80031344|NCT03053284|Drug|Saline Solution|Saline Solution injection will be given once per study visit
80031345|NCT04894318|Behavioral|Low-fat and low-cholesterol diet|Low-fat (<30% of total energy) and low-cholesterol (<200mg/day) diet total of 12 weeks
79580818|NCT01925625|Biological|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
79404228|NCT00307242|Drug|Adefovir Dipivoxil|
79580819|NCT01925807|Behavioral|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
79580820|NCT01926262|Behavioral|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
79580821|NCT01926457|Other|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
79580822|NCT01926522|Device|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
79739649|NCT02691442|Drug|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
79580823|NCT01926522|Other|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
79875014|NCT01018602|Drug|inactive pill|1 pill per day over 24 months
79875015|NCT01018758|Drug|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
79875016|NCT00469092|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
79580824|NCT01926535|Procedure|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
79580825|NCT01926535|Device|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
79739650|NCT02691442|Drug|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
79739651|NCT00622648|Drug|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
79739652|NCT00622648|Drug|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
79739653|NCT04316234|Other|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
80031346|NCT03053128|Device|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
80031347|NCT03053128|Other|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
79277203|NCT02197559|Procedure|DES group|all the participants in this group will be performed with drug -eluting stents
79875017|NCT00469092|Drug|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
79404229|NCT05120778|Behavioral|exercise training|as appear in arm description.
79404230|NCT05120778|Other|conventional medical treatment|participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
79404231|NCT03157297|Device|MARVEL algorithm|Software download into implanted Micra device
79875018|NCT00469092|Drug|metformin|Tablets, 2550 mcg. Administered once daily.
79404232|NCT05120700|Biological|Synovial Tissue and Fat Pad Stromal Vascular Fraction|Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
80031348|NCT03053206|Drug|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
79277204|NCT02197559|Procedure|BMS group|all the participants in this group will be performed with bare-metal stents
79875019|NCT00469092|Drug|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
79875020|NCT03997110|Radiation|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
79875021|NCT03997110|Radiation|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
79875022|NCT00499616|Drug|carboplatin|Given IV
79875023|NCT00499616|Drug|cyclophosphamide|Given IV
79875024|NCT00499616|Drug|doxorubicin hydrochloride|Given IV
79875025|NCT00499616|Drug|etoposide|Given orally
79277205|NCT02196467|Biological|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
79875026|NCT00499616|Drug|topotecan hydrochloride|Given IV
79875027|NCT00499616|Drug|Isotretinoin|Given orally
79277206|NCT02196467|Procedure|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
79404233|NCT04512768|Behavioral|Transdiagnostic Internet-delivered Cognitive Behaviour Therapy|All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
79580826|NCT01926561|Other|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
79580827|NCT01927003|Procedure|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
79875028|NCT00499616|Procedure|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
79875029|NCT00499616|Drug|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy & continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
79875030|NCT01016210|Drug|Leuveris|IV
79580828|NCT01927016|Procedure|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
79580829|NCT01927185|Device|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
79580830|NCT01927185|Device|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
79580831|NCT01927237|Other|HLR|
79580832|NCT01927237|Other|EHR|
79875031|NCT01016210|Drug|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
80031349|NCT04893928|Other|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
79875032|NCT00402597|Drug|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
79875033|NCT00402597|Drug|Placebo|1 placebo tablet twice daily for 6 months.
79739654|NCT04208386|Drug|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
80031350|NCT04893928|Other|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
79277207|NCT02370147|Behavioral|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
79580833|NCT01927276|Other|Gluten Free Flour|
79580834|NCT01927276|Other|Wheat Flour|
79580835|NCT01927302|Behavioral|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
79739655|NCT02886806|Other|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
79875034|NCT00402597|Drug|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
79875035|NCT00402363|Drug|omega-3-acid ethyl esters|
79739656|NCT02886806|Other|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
79739657|NCT02687854|Drug|Apixaban|As prescribed by treating physicians
79739658|NCT02687854|Drug|Vitamin K antagonist|As prescribed by treating physicians
79875036|NCT00402363|Drug|Placebo|
79875037|NCT00469014|Drug|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m^2 intravenous (IV) Daily; Arm 2 = 20 mg/m^2 IV Daily; Arm 3 = 30 mg/m^2 IV Daily; Arm 4 = 40 mg/m^2 IV Daily
79875038|NCT00469014|Drug|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily; Arm 4: 40 mg/m^2 IV Daily.~Test dose Day -8 32 mg/ m^2 IV over 45 min, rest on Day -7."
79875039|NCT00469014|Drug|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily
79875040|NCT00469014|Other|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
79875041|NCT00469014|Drug|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
79277208|NCT02370147|Behavioral|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
79580836|NCT01927302|Behavioral|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
79580837|NCT01927302|Behavioral|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
79580838|NCT01927302|Behavioral|No Treatment|No treatment will be administered.
79739659|NCT03991468|Diagnostic Test|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
79739660|NCT03991468|Diagnostic Test|Light Microscopy|Use of traditional light microscopy per institutional standard practice
79875042|NCT00469014|Drug|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
79875043|NCT00493038|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
79875044|NCT00493038|Drug|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
79875045|NCT01024998|Biological|AAV2-sFLT01|2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
79875046|NCT01024998|Biological|AAV2-sFLT01|2 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
79580839|NCT01927380|Other|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
79580840|NCT01927445|Other|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
79580841|NCT01927549|Procedure|Immediate multivessel PCI|
79875047|NCT01024998|Biological|AAV2-sFLT01|6 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
79875048|NCT01024998|Biological|AAV2-sFLT01|2 x 10^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
79404234|NCT04512768|Behavioral|Brief Internet-Delivered Cognitive Behaviour Therapy for Insomnia|A new sleep lesson will replace the existing resource, developed using a patient-oriented process, that provides information and skills to aid with insomnia. The sleep lesson includes psychoeducation on the nature of sleep problems and factors that affect sleep, such as circadian rhythm. Two key behavioural strategies are introduced: sleep restriction, which requires the patient to avoid napping and sleep on a strict schedule for several weeks until they begin to feel naturally sleepy at night; and stimulus control, which asks the participant to only spend time in bed when prepared to sleep and avoid other activities (e.g., work, TV) in bed. Patients will record how much they sleep each night and provide ratings of sleep quality and fatigue each week. Therapists will support patients in adjusting their sleep schedule. Patients are encouraged to apply skills they learn during the Wellbeing Course to sleep problems, for example, by applying thought challenging to beliefs about sleep.
79875049|NCT00392223|Drug|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
79875050|NCT00392223|Drug|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
79875051|NCT00392223|Drug|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
79875052|NCT00392223|Drug|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
79875053|NCT00402285|Dietary Supplement|lycopene supplement|
79875054|NCT00402285|Dietary Supplement|fish oil supplement|
79875055|NCT00402285|Other|Placebo|placebos for lycopene and fish oil.
79875056|NCT01038375|Behavioral|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
79277209|NCT04247009|Other|Meal based on red meat, fish products or vegan products|Three meals will be served
79277210|NCT04247009|Other|Meal based on red meat|Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
79277211|NCT02370069|Biological|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
79580842|NCT01927549|Procedure|Culprit Lesion only PCI|
79739661|NCT01006122|Drug|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
79875057|NCT01324479|Drug|INC280|
79875058|NCT00413283|Biological|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
79875059|NCT00413283|Drug|Placebo|Placebo subcutaneous injection.
79875060|NCT00413283|Drug|Gemcitabine|Intravenous infusion
79875061|NCT00413283|Drug|Carboplatin|Intravenous infusion
79875062|NCT00413283|Drug|Cisplatin|Intravenous infusion
79875063|NCT00402051|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
79875064|NCT00402051|Drug|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
79875065|NCT00402051|Drug|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
79875066|NCT00468858|Other|Placebo|"Lyophilized, single dose vials and sterile water for~> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
79875067|NCT00468858|Biological|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
79875068|NCT00468858|Biological|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
79875069|NCT00401973|Drug|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
79875070|NCT00401973|Drug|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
79875071|NCT00401973|Drug|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
79875072|NCT00401973|Drug|zonisamide|Zonisamide, 100-400mg, oral, daily.
79875073|NCT00401973|Behavioral|Wellness education|weight management
79875074|NCT01038453|Dietary Supplement|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
79277212|NCT02196545|Behavioral|Exercise|
79580843|NCT01927640|Drug|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
79580844|NCT01927640|Drug|Normal Saline|Normal saline infusion (10 cc)
79580845|NCT01927640|Drug|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
79580846|NCT01927679|Drug|Vitamin E|
79580847|NCT01927679|Drug|Eucerin|Control
79580848|NCT01927965|Drug|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
79580849|NCT01928004|Device|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
79580850|NCT01928004|Procedure|Conventional reline|conventional reline of the existing mandibular complete denture
79580851|NCT01928108|Behavioral|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
79580852|NCT01928108|Behavioral|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
79580853|NCT01928407|Drug|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
79580854|NCT01928407|Drug|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
79580855|NCT01928875|Device|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
79580856|NCT01928875|Device|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
79580857|NCT01929486|Biological|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
79580858|NCT01929551|Other|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
79739662|NCT01006122|Drug|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
79739663|NCT02687698|Other|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
79875075|NCT01038453|Other|placebo tablet|placebo 2 tablet, once a day,
79875076|NCT01038453|Dietary Supplement|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
79875077|NCT00401193|Drug|Tranexamic acid tablets|3900 mg/Day
79875078|NCT00401193|Drug|Tranexamic acid tablets|1950 mg/Day
79875079|NCT00401193|Drug|Placebo tablets|
79875080|NCT00400569|Drug|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
79580859|NCT01929551|Other|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
79580860|NCT01929551|Other|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
79580861|NCT01929551|Other|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
79739664|NCT02689570|Other|observational|no interventions; observational study
79739665|NCT00639028|Other|Ankle echography|Ankle echography
79739666|NCT00639028|Other|Ankle echography + stress radiography|Ankle echography + stress radiography
79739667|NCT00639028|Other|stress radiography|ankle stress radiography
79739668|NCT04186156|Drug|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
79739669|NCT01005966|Drug|Sodium Fluoride Toothpaste|Test product
79580862|NCT01929551|Other|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
79739670|NCT01005966|Drug|Amine Fluoride Toothpaste|Test product
79739671|NCT01005966|Drug|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
79739672|NCT01005966|Drug|Placebo|placebo and washout treatment
79739673|NCT01005966|Drug|675 ppmf toothpaste|dose response
79739674|NCT03937960|Other|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
79580863|NCT01929551|Other|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
79739675|NCT03937960|Other|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
79739676|NCT01005732|Device|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and <5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
79875081|NCT03993015|Other|Help to diagnosis software|Help to diagnosis software
79875082|NCT01038531|Other|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
79875083|NCT01038531|Other|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
79875084|NCT00413049|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
79875085|NCT00413049|Drug|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
80031351|NCT04893928|Other|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~Frequency of use of ten different ICTs for personal purposes;~Frequency of use of ten different ICTs for IBD-related purposes;~A free question about others ICTs that the patient uses for IBD-related purposes;~Eight specific IBD-related purposes ICTs are used to;~Assessment of ICTs for eight IBD-related purposes;~Eight Features an IBD-related App must comprehend."
79739677|NCT00628680|Device|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
80031352|NCT04893928|Other|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
79404235|NCT02653170|Other|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~Biopsychosocial assessment of patient and caregiver needs.~Set up appointments.~Assist scheduling appointments with primary care physician and other medical providers.~Promote medication adherence through medication tool kits, pill organizers and other aids.~Facilitate patient and caregiver engagement and activation.~Facilitate access to social and community services."
79580864|NCT01929551|Other|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
80031353|NCT04908982|Drug|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
79277213|NCT02370225|Other|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
79580865|NCT01929590|Drug|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
79277214|NCT02196623|Other|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
79277215|NCT02196623|Other|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
79277216|NCT02375919|Other|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
79277217|NCT02369991|Procedure|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
79277218|NCT03530059|Other|Home-based rehabilitation|Observational study
79277219|NCT02194907|Behavioral|Brain activity training - anterior insula|training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain
79277220|NCT02194907|Behavioral|Brain activity training - medial prefrontal cortex|training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
79277221|NCT00226759|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
79277222|NCT00226759|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
79580866|NCT01929590|Drug|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
79580867|NCT01929590|Drug|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
79580868|NCT01930006|Drug|MGCD265|
79580869|NCT01930019|Drug|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
79580870|NCT01930071|Device|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
79580871|NCT01930084|Other|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
79580872|NCT01930084|Other|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
79580873|NCT01930084|Behavioral|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
79580874|NCT01930084|Other|Non-cash Financial Incentives|Non-cash Financial Incentives
79739678|NCT00628680|Drug|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
79739679|NCT00603382|Drug|GW685698X|GW685698X
79739680|NCT00603382|Drug|Placebo|placebo comparator
79739681|NCT01176266|Drug|asfotase alfa|
79739682|NCT01182428|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
80031354|NCT04893850|Behavioral|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
80031355|NCT04893850|Behavioral|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
80031356|NCT02811159|Drug|Telapristone acetate|Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
79875086|NCT03732495|Drug|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
79580875|NCT01930097|Other|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
80031357|NCT04901650|Diagnostic Test|Survey|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
80031358|NCT04412356|Procedure|Tracheotomy|Surgical procedure to secure airway
80031359|NCT04893304|Device|co2 laser|types of laser
79875087|NCT01041729|Drug|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
79875088|NCT01041729|Drug|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
80031360|NCT04901026|Other|An in-house manikin|Participants obtain an in-house manikin
79580876|NCT01930110|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
80031361|NCT04892992|Behavioral|DFG|
79580877|NCT01930110|Other|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
79739683|NCT01182428|Device|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
80031362|NCT04430998|Drug|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
80031363|NCT04430998|Drug|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
79739684|NCT00603304|Drug|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
80031364|NCT04430998|Other|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
79580878|NCT01930149|Behavioral|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
79580879|NCT01930201|Procedure|Caudal epidural block|
79580880|NCT01930201|Other|General anesthesia|
79875089|NCT01324245|Drug|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
79875090|NCT00454194|Drug|pemetrexed disodium|given IV
79875091|NCT00454194|Drug|sorafenib tosylate|given orally
79875092|NCT00412971|Drug|Hexvix|Single installation, TURB
80031365|NCT03052894|Device|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
80031366|NCT03052894|Device|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
80031367|NCT03051958|Behavioral|Internet mindfulness&exposure treatment|"See description under Arm."
79580881|NCT01930227|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
79580882|NCT01930227|Other|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
79739685|NCT00603304|Drug|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
79739686|NCT00603304|Drug|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
79277223|NCT04469335|Device|mobile neurofeedback|"to maximize usability and effectiveness, we would like to conduct a study that regulates theta/beta ratio using mobile app-based Neurofeedback Training Equipment (OmniCNS).~The actual Neurofeedback training allows you to download and use the omnifit brain_Game, an application with an audio guide. After the pre-assessment, the researcher will provide guidance to subjects and carers on how to use the application, and demonstrate how to use it in practice. For 2 weeks, 4 weeks and 6 weeks, phone calls are conducted to check whether they are used or not and for any inconvenience. After 12 weeks of Neurofeedback training, the device is returned and post-evaluated.~The application is equipped with four types of games and is instructed to use the three-day-a-week application. For Neurofeedback attention and cognitive training, use a headset with left and right frontal lobe 2 channel-EEG sensors to perform the game through feedback to see if it is concentrating well."
79404236|NCT02653170|Other|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~Biopsychosocial assessment of patient and caregiver needs.~Set up appointments.~Assist scheduling appointments with primary care physician and other medical providers.~Promote medication adherence through medication tool kits, pill organizers and other aids.~Facilitate patient and caregiver engagement and activation.~Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~Contact list of care team members.~Access to hospital patient portal.~Stroke education materials, resources, and guidelines.~Access to Michigan 2-1-1 services.~Medication information and adherence tools.~Patient and Caregiver support networks."
79404237|NCT03582007|Drug|Murepavadin|Murepavadin + ertapenem
79404238|NCT03582007|Drug|One anti-pseudomonal antibiotic|Either meropenem or piperacillin-tazobactam
79580883|NCT01930240|Drug|TRIA-662|1-MNA Chloride
79739687|NCT00603304|Drug|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
79739688|NCT00603304|Drug|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
79739689|NCT00603304|Drug|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
79739690|NCT01176032|Drug|Aliskiren|Aliskiren 300 mg film coated tablets
79739691|NCT01176032|Drug|Losartan|Losartan 100 mg tablets
79739692|NCT01176032|Drug|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
79739693|NCT01176032|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (<140/90 mmHg) had not been reached.
79875093|NCT00412971|Other|Standard white light cystoscopy|
79739694|NCT02691598|Drug|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
79875094|NCT00303472|Drug|Romiplostim|
79739695|NCT01008618|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
79875095|NCT00468546|Drug|MabThera/Rituxan|1
79739696|NCT01008618|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
79875096|NCT00468546|Drug|Methotrexate|2
79875097|NCT00468546|Other|Placebo|3
79875098|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
79875099|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
79875100|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
79875101|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
80031368|NCT03051958|Other|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
79580884|NCT01930240|Drug|Placebo|Double-blind placebo
79580885|NCT01930266|Dietary Supplement|Experimental|
79580886|NCT01930266|Behavioral|Active comparator|
79580887|NCT01930279|Other|Blood withdrawal|Blood withdrawal
79580888|NCT01930292|Drug|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
79580889|NCT01930292|Drug|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
79580890|NCT01930292|Drug|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
79875102|NCT01064986|Biological|Placebo|Saline vehicle (placebo)
79875103|NCT01064986|Biological|Hydrocortisone|Hydrocortisone
79875104|NCT00468312|Drug|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
79875105|NCT00468312|Drug|Placebo|Two sprays in each nostril in the morning
80031369|NCT04908124|Device|Lubricant A|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
80031370|NCT04908124|Device|Lubricant B|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
80031371|NCT04908124|Device|Lubricant C|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
80031372|NCT04908124|Device|Lubricant D|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
80031373|NCT04908124|Device|Lubricant E|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
79277224|NCT04469335|Device|Sham mobile neurofeedback|"It uses the sham devices and programs as the Neurofeedback, but it is not usually possible to obtain the expected effects of the Neurofeedback by providing random feedback regardless of actual brain waves.~In case of Sham control group, parental education is conducted the same for each clinical evaluation, and in case of Sham control group, actual Neurofeedback is applied if patients and parents want it after the end of the study."
79277225|NCT04469335|Device|medication + mobile neurofeedback|The mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
79277226|NCT04469335|Device|medication + Sham mobile neurofeedback|The sham mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
79580891|NCT01930292|Drug|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
80031374|NCT04430764|Procedure|non-surgical periodontal treatment|Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.
80031375|NCT04892836|Other|Training|Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
79580892|NCT01930318|Drug|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
79580893|NCT01930331|Drug|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
79739697|NCT01001208|Drug|Methotrexate|Methotrexate tablets over-encapsulated for blinding
79739698|NCT01001208|Drug|Etanercept|1 mL for subcutaneous injection
79739699|NCT01001208|Drug|Placebo|Matching placebo to methotrexate capsules
80031376|NCT04901182|Diagnostic Test|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
79277227|NCT02195141|Radiation|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
79277228|NCT02195141|Radiation|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
79277229|NCT02376075|Drug|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
79277230|NCT02376075|Drug|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
79277231|NCT04469257|Behavioral|Sunbathing|the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
79580894|NCT01930331|Drug|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
79739700|NCT04296708|Other|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
79739701|NCT04296630|Other|Social media message #1|Social media message promoting colorectal cancer screening
79739702|NCT04296630|Other|Social media message #2|A different social media message promoting colorectal cancer screening
79739703|NCT04296630|Other|Social media message #3|A different social media message promoting colorectal cancer screening
79739704|NCT04296630|Other|Tailored social media messages|Tailored social media messages promoting colorectal cancer screening.
79277232|NCT02197637|Drug|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
79277233|NCT02377869|Other|No intervantion|
79277234|NCT04469413|Drug|Paracetamol Infusion|Continuous and Standard Intermittent Boluses Paracetamol Infusion
79277235|NCT02369913|Other|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
79277236|NCT04374149|Procedure|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
79277237|NCT04374149|Drug|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
79277238|NCT02377713|Drug|KHK6640|Single ascending dose administration
79277239|NCT02377713|Drug|Placebo|Single ascending dose administration
79277240|NCT02288611|Dietary Supplement|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
79277241|NCT02288611|Dietary Supplement|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
79277242|NCT02257307|Procedure|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
79277243|NCT02369757|Behavioral|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
80031377|NCT04900948|Drug|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
80031378|NCT04900948|Drug|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
79277244|NCT00207025|Drug|BMS-275183|
79404239|NCT02895373|Drug|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
79404240|NCT02895373|Drug|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
79277245|NCT02195219|Procedure|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
79404241|NCT05087784|Combination Product|Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps|Patient-centered, technology-supported integrated survivorship- and care management
80031379|NCT04892368|Other|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
79277246|NCT02195219|Other|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
80031380|NCT04901104|Drug|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
80031381|NCT04900324|Device|MRI guidance|Injections of botulinum toxin performed using MRI guidance
80031382|NCT04900324|Device|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
80031383|NCT04892680|Behavioral|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
80031384|NCT04907812|Drug|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
79277247|NCT02377791|Genetic|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5*1/*1 vs CYP3A5*1/*3 or CYP3A5*3/*3
79277248|NCT00166543|Drug|TAS-108|
79404242|NCT03157141|Procedure|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
79580895|NCT01925976|Behavioral|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
79580896|NCT01930344|Device|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
79580897|NCT01930344|Device|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
80031385|NCT04907812|Procedure|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints <50 contracture ii. PIP joints <40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints >50 degree contracture ii. PIP Joints >40 degrees contracture b. >2 fingers involved
79739705|NCT04295460|Drug|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
80031386|NCT04907734|Other|Caliper|Description of the sample adipose tissue and skinfolds using different calipers.
79277249|NCT02369601|Other|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
79580898|NCT01930370|Drug|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
79277250|NCT03533933|Device|Collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
79277251|NCT03533933|Other|autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
79277252|NCT02288689|Device|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
79277253|NCT02375997|Other|Palliative care|Early nutrition intervention and psychological intervention
79277254|NCT02195297|Other|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
79277255|NCT03532087|Drug|Denosumab 120 mg|Denosumab 120 mg every 3 weeks.
79277256|NCT03532087|Drug|Denosumab 60 mg|Denosumab 60 mg every 6 months.
79277257|NCT02376153|Device|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
79277258|NCT02376153|Device|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
80031387|NCT04892290|Other|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
79277259|NCT04348019|Behavioral|Fasting|Fasting was defined as no foods or caloric beverages.
79277260|NCT02288767|Device|Conventional arterial blood pressure monitoring|
79277261|NCT02288767|Device|Stroke volume variation monitoring with arterial blood pressure monitoring|
79277262|NCT02369679|Device|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
79404243|NCT03157141|Procedure|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
79404244|NCT05230056|Behavioral|PG|Shoulder Digital therapy
79580899|NCT01930370|Drug|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
79404245|NCT05230056|Behavioral|CTRL|Shoulder non-digital therapy
79404246|NCT05698771|Dietary Supplement|nicotinamide riboside|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6-10 healthy individuals (3-5 men and 3-5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using HPLC-MS. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans. Based on these results we will determine the optimal dosing frequency of NRT in healthy individuals.
79277263|NCT02369679|Device|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
79277264|NCT02197715|Behavioral|Computer-adaptive SAFE|
79277265|NCT02197715|Behavioral|Face-to-face SAFE|
79277266|NCT02197715|Behavioral|Usual Care|
79277267|NCT02031185|Behavioral|FitBit only|Participants will use the FitBit device
79277268|NCT02031185|Behavioral|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
79277269|NCT04181879|Behavioral|Intervention|"GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste')."
79277270|NCT02288923|Procedure|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
79404247|NCT05698771|Dietary Supplement|nicotinamide mononucleotide|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6-10 healthy individuals (3-5 men and 3-5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using HPLC-MS. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans. Based on these results we will determine the optimal dosing frequency of NRT in healthy individuals.
79580900|NCT01930396|Drug|Tinzaparin|
79580901|NCT01930396|Drug|Unfractionated Heparin|
79580902|NCT01930396|Drug|Placebo (for Tinzaparin)|0.9% Normal Saline
79580903|NCT01930396|Drug|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
80031388|NCT01889186|Drug|ABT-199 (Main Cohort)|Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
80031389|NCT01889186|Drug|ABT-199 (Safety Expansion Cohort)|Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
80031390|NCT04900558|Procedure|Radical Cystectomy|All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
80031391|NCT04892212|Drug|Sirolimus|The daily dose of sirolimus is divided twice.
80031392|NCT04892056|Other|Friction Mechanics|anterior segment retraction using elastomeric power chains
79404248|NCT04207320|Device|αβ+ T-cell depletion with Miltenyi CliniMACS system|Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
80031393|NCT04892056|Other|Frictionless Mechanics|anterior segment retraction using closing loops
79875106|NCT03980002|Drug|FCR and Ibrutinib|"Induction treatment:~Patients <65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count <10×10^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~Ibrutinib:420mg/d"
79875107|NCT03980002|Drug|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or <65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
79875108|NCT03980002|Drug|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
80031394|NCT03052582|Other|Milk type|
79404249|NCT03581929|Dietary Supplement|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
79580904|NCT01930409|Behavioral|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~Health Status~Medication Management~Activity/Exercise Prescription and Goal-Setting~Falls Prevention~Clarification of Appointments~Coordination of Post-Discharge Home Services~What To Do If a Problem Arises"
79580905|NCT01930409|Behavioral|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
79739706|NCT02871102|Procedure|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
80031395|NCT01510184|Drug|Zevalin|Zevalin administered intravenous infusion.
80031396|NCT01510184|Drug|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
80031397|NCT01510184|Drug|Rituximab|Rituximab administered by intravenous infusion.
79404250|NCT03581929|Other|Placebo|Placebo comparator
79404251|NCT04205604|Drug|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
79404252|NCT03156907|Drug|Buprenorphine|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
79404253|NCT03156829|Other|Splint|Custom made splint
79404254|NCT03156829|Drug|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
79404255|NCT03156829|Combination Product|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
80031398|NCT01510184|Drug|In-111 Zevalin|In-111-Zevalin administered by intravenously.
80031399|NCT04907422|Diagnostic Test|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
80031400|NCT04907422|Diagnostic Test|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
80031401|NCT04900090|Other|Epidemiological study|"Clinical phenotypic assessment and neurosensory measures~Biological, genetic and metabolomic evaluation~Questionnaires (quality of life, gout, life habit, comorbidities)~Morphological evaluation by Dual-energy CT scan"
80031402|NCT04906954|Other|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
80031403|NCT04907344|Drug|Camrelizumab|IV infusion
80031404|NCT04907344|Drug|Nab-Paclitaxel|IV infusion
80031405|NCT04907344|Drug|Carboplatin|IV infusion
79404256|NCT03156751|Diagnostic Test|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
79277271|NCT02288923|Procedure|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
79277272|NCT02288923|Procedure|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
79404257|NCT03581851|Device|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
79580906|NCT01930422|Device|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
79580907|NCT01930422|Device|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
79580908|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
79580909|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
79739707|NCT01000974|Biological|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
79739708|NCT01000974|Biological|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
79739709|NCT01000974|Biological|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
79875109|NCT03938220|Device|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
79739710|NCT01000974|Biological|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
79739711|NCT01000974|Biological|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
79739712|NCT01000974|Biological|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
79875110|NCT00331864|Drug|Ranibizumab|
79875111|NCT03984136|Behavioral|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
79875112|NCT03984136|Behavioral|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
79875113|NCT00331630|Drug|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
79404258|NCT03581851|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
79580910|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
79580911|NCT01930461|Biological|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
79580912|NCT01930500|Behavioral|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
79739713|NCT01000974|Biological|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
79739714|NCT01000974|Biological|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
79580913|NCT01930500|Behavioral|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
80031406|NCT03877484|Device|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
79277273|NCT02288923|Procedure|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
79277274|NCT02288923|Drug|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
79580914|NCT01930526|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
79580915|NCT01930552|Drug|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
79580916|NCT01930552|Drug|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
79580917|NCT01930552|Drug|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
79580918|NCT01930552|Drug|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
79580919|NCT01930565|Other|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
79739715|NCT04295616|Device|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
79875114|NCT00331630|Drug|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
79875115|NCT00331552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
79875116|NCT00331552|Drug|cyclophosphamide|Given orally
79875117|NCT00331552|Biological|trastuzumab|Given IV
79875118|NCT01062178|Drug|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
79875119|NCT03983746|Device|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
80031407|NCT04907266|Other|Structured Questionnaire|A structured proforma to assess outcome
79580920|NCT01930565|Other|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
79580921|NCT01930578|Other|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
79580922|NCT01930578|Other|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
79580923|NCT01930578|Other|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
79580924|NCT01930591|Drug|Ticagrelor|180 mg bolus followed by 90 mg BID
79580925|NCT01930591|Drug|Clopidogrel|300 mg bolus followed by 75 mg OD
79580926|NCT01930604|Drug|Botox (onabotulinumtoxinA)|
79580927|NCT01930604|Drug|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
79580928|NCT01930604|Drug|NaCl (placebo)|
79875120|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
79875121|NCT03980080|Drug|Placebo|Vehicle study drug
80031408|NCT04906876|Drug|Gemcitabine|Gemcitabine as a 90-minute IV infusion
80031409|NCT04906876|Drug|Docetaxel|Docetaxel as a 60-minute IV infusion
80031410|NCT04906876|Drug|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
79404351|NCT04310748|Drug|Total Intravenous Anesthesia(TIVA)|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded"
79404352|NCT04310748|Drug|Inhalation Anesthesia|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded."
79404353|NCT03154645|Drug|Ibuprofen|non-steroidal anti-inflammatory drug
79404354|NCT03154645|Drug|Acetazolamide|a diuretic
79739846|NCT04204824|Other|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
79739847|NCT04186702|Procedure|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
79902192|NCT03423121|Drug|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
79404355|NCT01671631|Other|Measurement of intracoronary pressure|
79404356|NCT01671709|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
79404357|NCT01189422|Drug|teplizumab or placebo|infusion or injection
79432790|NCT05581628|Diagnostic Test|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
79739848|NCT04187014|Drug|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
79739849|NCT04187014|Drug|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
79760926|NCT05373342|Device|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
79760927|NCT05344066|Other|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
79760928|NCT05344066|Other|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
79760929|NCT05339412|Behavioral|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
79760930|NCT05337540|Device|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
79760931|NCT05337540|Device|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
79760932|NCT05336123|Behavioral|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
79760933|NCT05336123|Behavioral|Health Education|Weekly health education classes lasting 10 weeks.
79760934|NCT05323149|Other|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
79760935|NCT05323149|Drug|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
79760936|NCT05322577|Drug|Bemarituzumab|Intravenous (IV) infusion
79760937|NCT05322577|Drug|CAPOX|CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
79760938|NCT05322577|Drug|SOX|SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.
79760939|NCT05322577|Drug|Nivolumab|IV infusion.
79760940|NCT05316532|Device|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
79760941|NCT05294991|Behavioral|Calm Meditation|This is the active intervention group.
79760942|NCT05294991|Behavioral|Health Education Podcast|This is the active comparator/control group.
79277669|NCT05791461|Behavioral|MARS (Measures Against Work-related Stress)|"The stress management intervention is based on cognitive behavioral therapy and aims to change the way patients perceive and cope with stressful situations at work.~It is group sessions over 3 months with approximately 9 participants. Participants meet 9 times (once a week the first 3 weeks and once every second week the last 5 times) and for a follow-up session 3 months after the intervention has ended. Each session lasts for 3 hours and is led by a trained psychologist. The participants perform tasks at home between the sessions. In the first session the rationale behind the intervention is introduced. In session 2 and 3 the patients work with enhancing self-regulation. In session 4 and 5 the focus is on modifying intermediate beliefs. In session 6 the focus is on improving interaction. Session 7 and 8 focuses on consolidation of learning and strategies to prevent relapse, and session 9 is a follow-up session 3 months after the intervention has ended."
79404358|NCT04302636|Dietary Supplement|Low glycemic index diet|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
79739850|NCT02686840|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
79760943|NCT05293080|Other|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
79760944|NCT05293080|Other|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
79760946|NCT05273762|Device|FlowTriever|Mechanical thrombectomy for pulmonary embolism
79404359|NCT05222256|Drug|Levosimendan|Patients in this group will receive levosimendan
79277670|NCT05791409|Drug|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
79404360|NCT05222256|Drug|Adrenaline|Patients in this group will receive Adrenaline
79404361|NCT01671787|Drug|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
79288968|NCT04255511|Device|Twin Block|Functional appliance
79404362|NCT01671787|Drug|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
79609676|NCT05771324|Other|Baby-Led Weaning (BLW)|BLW trainings given to mothers for 6-12 month old babies
79609677|NCT05771324|Other|Traditional Complementary Feeding (TCF)|TCF trainings given to mothers for 6-12 month old babies
79609678|NCT05771311|Device|KTP|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
79609679|NCT05771311|Device|PDL|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
79609680|NCT05771298|Device|532nm KTP|one to three treatment sessions
79609681|NCT05771298|Device|585nm PDL|one to three treatment sessions
79609682|NCT05771285|Other|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
79760947|NCT05270759|Diagnostic Test|Estimated absolute blood volume|Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.
79760948|NCT05270759|Diagnostic Test|Modified VExUS evaluation|The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
79760949|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760950|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760951|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760952|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760953|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760954|NCT05262400|Drug|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
79760955|NCT05262400|Drug|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
79760956|NCT05262400|Drug|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
79760957|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760958|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760959|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
79760960|NCT05253677|Device|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
79277671|NCT05791409|Drug|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
79739851|NCT02686840|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
79739852|NCT00638482|Drug|Hydrochlorothiazide|Hydrochlorothiazide
79739853|NCT00639964|Other|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
79739854|NCT00639964|Other|diet questionnaire|questions about nutrition before and during pregnancy
79739855|NCT00639964|Other|umbilical cord blood collect|collected at the delivery
79739856|NCT00639964|Other|placenta collect|collected at the delivery
79739857|NCT02684968|Procedure|Colorectal surgery|
79739858|NCT04034290|Biological|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
79277672|NCT05791396|Biological|Donor - FMT|this intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
79581498|NCT06070831|Device|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
79739859|NCT04034290|Other|Placebo|Placebo
79739860|NCT04105894|Device|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
79739861|NCT04105894|Diagnostic Test|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
79739862|NCT04105894|Drug|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
79739863|NCT02688946|Other|Not provided|
79739864|NCT04184596|Other|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
79739865|NCT00638560|Dietary Supplement|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
79739866|NCT00638560|Dietary Supplement|Antioxidant treatment|no treatment
79739867|NCT04405648|Behavioral|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
79288969|NCT04255511|Device|Fixed orthodontic appliance|Braces
79739868|NCT02685124|Dietary Supplement|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
79739869|NCT00638638|Drug|Abciximab|"Abciximab: 0.25 mg/Kg bolus~Abciximab placebo bolus~Abciximab infusion 10 µg/Kg/min"
79739870|NCT00638638|Drug|Abciximab placebo|"Abciximab placebo Bolus~Abciximab: 0.25 mg/Kg bolus~Abciximab infusion 10 µg/Kg/min"
79739871|NCT02684812|Drug|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
79739872|NCT04185376|Other|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
79739873|NCT02686216|Drug|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
79739874|NCT02686294|Drug|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
79739875|NCT02686294|Drug|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
79739876|NCT02688478|Other|Phthalate|Delivered by inhalation on day 1 of the triad
79739877|NCT02688478|Other|Filtered Air|Delivered by inhalation on day 1 of the triad
79739878|NCT02688478|Other|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
79760961|NCT05253677|Device|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
79739879|NCT01004250|Drug|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
79902193|NCT03423121|Drug|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
79432870|NCT05580224|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
79739880|NCT01004250|Drug|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
79739881|NCT01004250|Drug|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
79739882|NCT02688634|Drug|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
79739883|NCT00639496|Drug|n-acetylcysteine|600 mg x 3, for 12 months
79739884|NCT00639496|Drug|placebo|Placebo
79739885|NCT04186624|Drug|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
79739886|NCT00639574|Drug|Néfopam|"There are two groups :~a group N : néfopam~a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
79739887|NCT04184752|Diagnostic Test|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position [14]. A 20-minute pad test for each woman was also performed [15, 16]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS [3]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
79581499|NCT06070831|Device|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
79739888|NCT02685046|Drug|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
79739889|NCT01004172|Drug|carboplatin|
79739890|NCT01004172|Drug|bevacizumab|
79739891|NCT01004172|Drug|herceptin|
79739892|NCT02688244|Procedure|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
79739893|NCT02688244|Procedure|No irrigation|Suction only, using suction device
79739894|NCT02688322|Drug|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
79739895|NCT02870400|Drug|REGN2477|Participants will receive ascending doses of REGN2477
79739896|NCT02870400|Drug|Placebo|Participants will receive matching placebo
79739897|NCT02685904|Biological|ENIA11|
79739898|NCT02685904|Biological|Placebo|
79739899|NCT00638794|Device|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
79739900|NCT03098290|Procedure|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
79739901|NCT03098290|Procedure|Bypass-Surgery|Venous or alloplastic or comparable Bypass
79739902|NCT03098290|Procedure|Endarterectomy|Endarterectomy, Patchplasty
79739903|NCT04184986|Diagnostic Test|dry blood test|screening test for Fabry disease
79739904|NCT00639652|Procedure|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
79739905|NCT00639652|Procedure|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
79902194|NCT03413423|Behavioral|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
79432791|NCT05581628|Diagnostic Test|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
79739906|NCT04186234|Radiation|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
79739907|NCT02685748|Drug|Aspirin|1000 mg pd in two doses
79739908|NCT02685748|Drug|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
79739909|NCT02685748|Drug|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
79739910|NCT04112992|Procedure|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
79581500|NCT06070818|Other|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
79581501|NCT06070805|Other|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
79581502|NCT06070792|Other|NEURO LINGUISTIC PROGRAM|NEURO LINGUISTIC PROGRAM
79581503|NCT06070792|Other|PROGRESSIVE MUSCLE RELAXATION EXERCISES|PROGRESSIVE MUSCLE RELAXATION EXERCISES
79581504|NCT06070766|Drug|Ketamine|The use of ketamine in chronic conditions.
79581505|NCT06070753|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
79739911|NCT04104802|Device|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
79739912|NCT04186312|Behavioral|ACCESS - Accessing Campus Connections & Empowering Student Success|Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
79739913|NCT04184440|Dietary Supplement|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
79739914|NCT04184440|Dietary Supplement|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
79739915|NCT04184440|Dietary Supplement|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
79739916|NCT02685982|Device|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
79739917|NCT04184908|Drug|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
79739918|NCT04184908|Other|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
79739919|NCT00639730|Dietary Supplement|modified Atkins diet|High fat, low carbohydrate diet
79739920|NCT02684500|Device|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
79739921|NCT02685670|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
79432871|NCT05580146|Dietary Supplement|Zynamite® 15% 150mg|leaves of the mango food plant
79432872|NCT05580146|Dietary Supplement|Zynamite® 15% 300mg|leaves of the mango food plant
79432873|NCT05580146|Dietary Supplement|Zynamite® 15% 600mg|leaves of the mango food plant
79739922|NCT02685670|Drug|Fludarabine|
79739923|NCT02685670|Drug|Cyclophosphamide|
79739924|NCT02684656|Procedure|Hemodialysis|Hemodialysis >/=4h
79739925|NCT02684656|Procedure|Hemodiafiltration|Hemodiafiltration >/=4h, > 20l convection
79739926|NCT00640120|Device|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
79739927|NCT02688010|Behavioral|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
79739928|NCT00638872|Drug|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
79739929|NCT00638872|Other|0.9% NaCl|same as PDRN
79739930|NCT00638950|Dietary Supplement|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
79739931|NCT00638950|Dietary Supplement|Placebo|The placebo products were commercial dairy products with comparable fat contents.
79739932|NCT00639808|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
79739933|NCT00639808|Drug|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
79739934|NCT02687932|Drug|LCZ696|
79739935|NCT02687932|Drug|Valsartan|
79739936|NCT00641602|Drug|Esomeprazole|40mg once daily
79739937|NCT00641602|Drug|Lansoprazole|30mg once daily
79739938|NCT04183972|Procedure|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
79739939|NCT01161524|Drug|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
79739940|NCT01161524|Drug|Placebo|Matching Placebo taken once daily.
79739941|NCT02681224|Other|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
79739942|NCT02681224|Other|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
79739943|NCT02681224|Other|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
79739944|NCT02681224|Other|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
79739945|NCT04182646|Device|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
79739946|NCT02683096|Other|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
79739947|NCT02680990|Behavioral|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
79739948|NCT02680990|Other|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
79739949|NCT04184128|Diagnostic Test|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position [14]. A 20-minute pad test for each woman was also performed [15, 16]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS [3]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
79739950|NCT02682940|Device|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
79739951|NCT01000506|Biological|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
79739952|NCT01000506|Biological|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
79739953|NCT01000506|Biological|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
79739954|NCT01000506|Drug|Placebo saline|Placebo saline every four weeks by i.v.
79739955|NCT02682862|Drug|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
79739956|NCT02682862|Drug|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
79739957|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
79739958|NCT00640198|Behavioral|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
79739959|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
79739960|NCT00640198|Drug|placebo|Placebo
79739961|NCT04296552|Other|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
79739962|NCT04293822|Drug|Cetirizine|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF)."
79760964|NCT05230914|Other|Simplified imaging strategy|NCCT and CTA will be used to screen patients for endovascular treatment
79760965|NCT05230914|Other|Standard imaging strategy|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
79760966|NCT05229900|Drug|SGN-ALPV|Given into the vein (IV; intravenously)
79739963|NCT04293822|Drug|Minoxidil|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel"
79739964|NCT02680600|Drug|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
79739965|NCT02680600|Other|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
79739966|NCT02680600|Other|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
79739967|NCT02680600|Other|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
79739968|NCT02680600|Other|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
79739969|NCT02680600|Other|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
79739970|NCT02680600|Other|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
79739971|NCT02680678|Other|Colloid Preload|preload infusion
79739972|NCT02680678|Other|colloid co-load|co-load infusion
79739973|NCT02680678|Other|Crystalloid preload|preload infusion
79739974|NCT02680678|Other|Crystalloid Co-load|co-load infusion
79739975|NCT04182724|Drug|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
79739976|NCT02680912|Device|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
79739977|NCT02680912|Device|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
79739978|NCT02682628|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
79739979|NCT04183816|Other|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
79739980|NCT04183816|Other|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
79739981|NCT04184518|Drug|Cediranib Maleate|Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
79739982|NCT04184518|Drug|Durvalumab|Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
79277673|NCT05791396|Other|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through colonoscopy
79432874|NCT05580146|Dietary Supplement|Placebo|Sunflower oil matched for appearance
79739983|NCT02680522|Other|Exercise|exercise training with virtual reality in videogame
79432875|NCT03021044|Other|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
79432876|NCT03021044|Other|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
79432877|NCT01797679|Other|Strength Training|
79432878|NCT01797679|Other|Aerobic Exercise|
79739984|NCT01174238|Drug|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
79739985|NCT01174238|Drug|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
79875968|NCT01023750|Drug|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
79875969|NCT05300009|Combination Product|topical methotrexate hydrogel 1% coupled with microneedling.|Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
79875970|NCT05300009|Other|Liquid nitrogen|"The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions."
79875971|NCT05352113|Drug|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
79875972|NCT05352113|Procedure|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
79875973|NCT05352113|Procedure|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
79581506|NCT06070740|Drug|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
79875974|NCT05352113|Drug|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
79875975|NCT00547703|Drug|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
79875976|NCT00547703|Drug|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
79875977|NCT00297232|Drug|Natalizumab|
79581507|NCT06070727|Other|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
79875978|NCT00954083|Behavioral|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
79875979|NCT00954083|Behavioral|Routine care|Routine care
79875980|NCT05351957|Procedure|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
79875981|NCT05351645|Behavioral|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
79875982|NCT01062802|Drug|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
79875983|NCT01062802|Other|Placebo|Placebo given once daily for 4 weeks.
79581508|NCT06070675|Device|Minze Diary Pod|The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
79581509|NCT06070675|Other|Paper bladder diary|The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).
79739986|NCT01174238|Drug|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
79739987|NCT04315532|Other|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
79739988|NCT04315532|Other|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
79739989|NCT04315532|Other|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
79739990|NCT02682472|Other|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
79875984|NCT00954161|Other|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
79739991|NCT00640900|Behavioral|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
79739992|NCT00640900|Behavioral|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
79739993|NCT02680444|Behavioral|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
79875985|NCT00954161|Other|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
79875986|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
79875987|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
79875988|NCT00954317|Procedure|epidural placed low|epidural placed low
79875989|NCT00954317|Procedure|high epidural|high epidural
79875990|NCT01062880|Behavioral|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
79875991|NCT03938909|Genetic|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
79875992|NCT03867383|Drug|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
79875993|NCT03867383|Drug|Placebo|60 milliliters normal saline
79739994|NCT02680444|Behavioral|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
79875994|NCT05351567|Other|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
79875995|NCT03855215|Diagnostic Test|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
79875996|NCT05351411|Other||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
79875997|NCT00954395|Other|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
79875998|NCT05351177|Other|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
79875999|NCT00954473|Other|laboratory biomarker analysis|Correlative studies
79277674|NCT05791383|Device|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
79277675|NCT05791370|Dietary Supplement|A 12-week parallel dietary intervention|Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
79739995|NCT02680444|Behavioral|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
79739996|NCT02928406|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
79739997|NCT01174160|Drug|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
79739998|NCT01174160|Drug|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
79739999|NCT04313894|Biological|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
79740000|NCT02683798|Dietary Supplement|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
79277676|NCT05791357|Diagnostic Test|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
79277677|NCT05791331|Other|Surfactant administration following lung mechanics assessment in addition to clinical assessment|Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L
79277678|NCT05791331|Other|Surfactant administration following clinical assessment|Surfactant is administered following oxygenation-based criteria
79277679|NCT05791292|Other|Evaluation|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
79277680|NCT05791266|Device|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
79740001|NCT02683798|Dietary Supplement|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
79277681|NCT05791214|Other|score|Creation and validation of new nurse' score in ICU
79277682|NCT05791175|Device|Teeth scan with intraoral scanner (Trios, 3 Shape, Denmark)|Intraoral scanner will be use to monitor the changes of the teeth over time. Intraoral scanners are devices that capture three-dimensional images of teeth and are used as an alternative to conventional dental impressions.
79740002|NCT04315454|Drug|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
79740003|NCT02683720|Dietary Supplement|ONS|randomized clinical trial involving different ONS strategies
79740004|NCT02885480|Behavioral|questionnaires|
79740005|NCT02682550|Procedure|blood drawing|blood drawing
79760967|NCT05220956|Behavioral|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
79760968|NCT05220956|Behavioral|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
79760969|NCT05213936|Device|Scalp cooling with hairstyle|Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
79760970|NCT05213936|Device|Scalp cooling with conditioner and water emulsion|Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
79760971|NCT05209867|Drug|CBD oil|"Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc ~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration"
79760972|NCT05201547|Drug|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
79760973|NCT05201547|Drug|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
79760974|NCT05196815|Other|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
79760975|NCT05196815|Procedure|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
79760976|NCT05196815|Procedure|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
79760977|NCT05196815|Radiation|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
79760978|NCT05196815|Drug|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
79760979|NCT05177484|Drug|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
79760980|NCT05164458|Drug|IBI 308 injection|IBI308 IV 200mg Q3W Day1
79760981|NCT05164458|Drug|IBI 389 Injection|IBI 389 IV Q2~Q3W Day 1
79760982|NCT05155865|Device|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
79760983|NCT05155865|Device|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
79760984|NCT05149638|Diagnostic Test|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
79760985|NCT05136170|Drug|Oxervate|One drop of the test product will be instilled in both eyes TID
79740006|NCT01161446|Behavioral|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
79740007|NCT01161446|Device|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
79277683|NCT05791149|Diagnostic Test|saliva tube|1 tube of saliva (~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
79277684|NCT05791136|Radiation|Radiotherapy|95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
79277685|NCT05791136|Drug|Toripalimab|Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
79277686|NCT05791123|Procedure|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
79288970|NCT03465553|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
79581510|NCT06070662|Diagnostic Test|Coronary microvascular disease testing during coronary angiography|During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
79581511|NCT06070662|Diagnostic Test|Cardiac magnetic resonance scan including exercise|Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
79740008|NCT02680210|Other|Questionnaires and cognitive measures|
79740009|NCT00641680|Drug|Budesonide|
79740010|NCT00641680|Drug|Fluticasone propionate|
79740011|NCT00641680|Drug|Placebo|
79740012|NCT04183582|Behavioral|Behavioural Activation|"Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well"
79740013|NCT04033588|Device|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
79740014|NCT01174004|Drug|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
79740015|NCT01174004|Drug|placebo|placebo, tablet, once daily by mouth for 6 weeks
79740016|NCT02680288|Drug|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
79740017|NCT02680288|Drug|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
79740018|NCT02680288|Other|Oral Placebo|Oral inert treatment
79740019|NCT02885402|Other|MRI Sodium ( 23Na )|
79740020|NCT04184206|Behavioral|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
79740021|NCT04184206|Behavioral|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
79740022|NCT04184206|Behavioral|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
79740023|NCT01173692|Drug|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
79740024|NCT01173692|Drug|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
79740025|NCT00641758|Drug|Pycnogenol|Pycnogenol 100mg twice daily
79740026|NCT00641758|Drug|Placebo|Placebo 100mg twice daily
79740027|NCT00640276|Drug|pitavastatin|Pitavastatin 2mg daily once
79740028|NCT00640276|Behavioral|Lifestyle Modification|conducting mainly exercises and diet
79740029|NCT00640354|Device|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
79740030|NCT00640354|Device|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
79740031|NCT02680132|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
79740032|NCT02680132|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
79740033|NCT02790346|Procedure|arthrodesis talonavicular|
79740034|NCT02790346|Procedure|tendon gestures|
79740035|NCT02683564|Drug|BOW015|monoclonal antibody against TNF-alpha
79740036|NCT02683564|Drug|Remicade|monoclonal antibody against TNF-alpha
79740037|NCT01101035|Drug|Febuxostat|Febuxostat tablets
79740038|NCT01101035|Drug|Allopurinol|Allopurinol tablets
79760986|NCT05136170|Other|Vehicle|One drop of the placebo will be instilled in both eyes TID
79760987|NCT05118724|Drug|Atezolizumab|Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
79760988|NCT05097820|Device|Placement of testicular prosthesis|The surgical implantation of one or two testicular prostheses on request of the patient
79760989|NCT05093868|Device|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
79288971|NCT03488381|Device|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
79581512|NCT06070662|Diagnostic Test|Additional analysis of already acquired CT scan|Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
79581513|NCT06070636|Procedure|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
79740039|NCT04306679|Other|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
79288972|NCT05230849|Device|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
79740040|NCT04306679|Other|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
79740041|NCT01100567|Device|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
79740042|NCT01160822|Biological|Canakinumab|Intra-articular injection
79740043|NCT01160822|Drug|Placebo to canakinumab|Intra-articular injection
79740044|NCT01160822|Drug|Naproxen|Tablets for oral administration
79740045|NCT01160822|Drug|Placebo to Naproxen|Tablets for oral administration
79740046|NCT01006980|Drug|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
79740047|NCT01006980|Drug|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
79740048|NCT00887926|Biological|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
79740049|NCT04182178|Other|10 years follow up|Questionnaires
79740050|NCT02679898|Other|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
79740051|NCT02679898|Other|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
79740052|NCT04296240|Drug|Oxaliplatin and capecitabine|Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
79740053|NCT04296240|Procedure|Total Mesorectal Excision|Patient receive total mesorectal excision after neoadjuvant chemotherapy
79740054|NCT04205058|Dietary Supplement|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
79740055|NCT04205058|Dietary Supplement|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
79740056|NCT04205058|Dietary Supplement|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
79740057|NCT04183738|Drug|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
79740058|NCT04183738|Drug|Darunavir|800mg tablet by mouth once daily for 96 weeks.
79740059|NCT04183738|Drug|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
79581514|NCT06070636|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
79581515|NCT06070636|Drug|Sintilimab|200mg intravenously every 32 weeks
79581516|NCT06070623|Device|US|We use elastography and color Doppler from US machine and compare results with CT
79740060|NCT04183738|Drug|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
79740061|NCT02870322|Behavioral|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
79740062|NCT02870322|Behavioral|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
79740063|NCT02682160|Other|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
79740064|NCT04033666|Other|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
80031756|NCT04894552|Procedure|Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma|Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.
79740065|NCT04033666|Other|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
79740066|NCT02871414|Behavioral|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
79740067|NCT02871414|Behavioral|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
79740068|NCT00641134|Other|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
79740069|NCT02682082|Procedure|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
79740070|NCT02682082|Drug|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
79740071|NCT02870946|Procedure|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
79740072|NCT02870946|Procedure|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
79581517|NCT06070571|Drug|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
79740073|NCT00640432|Drug|Diclofenac|75 mg oral capsule twice daily for 7 days
79581518|NCT06070558|Device|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
79581519|NCT06070545|Other|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
79581520|NCT06070532|Biological|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
79581521|NCT06070519|Diagnostic Test|CPET and related variables evaluation|"At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed:~Echocardiography (LVEF)~Blood sample (Na+, MDRD, Hb)~Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)"
79740074|NCT00640432|Drug|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
79740075|NCT02870244|Biological|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10^7/kg TIL 1383I TCR transduced T cells."
79740076|NCT02679664|Drug|Rosuvastatin|20 mg tablet of rosuvastatin
79740077|NCT02871180|Dietary Supplement|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
79740078|NCT02871180|Other|No late night snack|Patient consumed no nutrients at late night.
79740079|NCT02679742|Dietary Supplement|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
80031757|NCT04880356|Other|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
79288973|NCT05230849|Other|convencional treatment|is a physiotherapy treatment for neurological patients
79288974|NCT04461431|Procedure|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
79740080|NCT02679742|Dietary Supplement|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
80031758|NCT04880512|Drug|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
80031759|NCT04880512|Drug|Placebo|Matching placebo, oral tablets, in fasted state
80031760|NCT04885270|Drug|cisplatin i.p.|paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
79581522|NCT06070493|Other|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
79277687|NCT05791084|Other|mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.|The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
79277688|NCT05791058|Procedure|ultrasound guided pericapsular nerve group shoulder block|The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected
79581523|NCT06070493|Other|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
79740081|NCT04295226|Other|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
79740082|NCT02679586|Device|Diffusion weighted MRI|
79288975|NCT04461119|Drug|Evenamide|oral capsules for 4 weeks of treatment
79581524|NCT06070480|Other|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
79581525|NCT06070480|Other|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
79740083|NCT04295070|Biological|CodaVax-RSV|Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
79740084|NCT04295070|Biological|Normal saline|Saline (0.9%) administered via dropper
79740085|NCT00641836|Procedure|Transplantation of autologous endothelial progenitor cells|
79740086|NCT02870010|Biological|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
79740087|NCT02870010|Radiation|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
79740088|NCT02870712|Procedure|Suture of perineum|suture of the tear to obtain hemostasis
79740089|NCT02870712|Procedure|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
79740090|NCT02537782|Device|Cardiac resynchronisation therapy|
79740091|NCT02537782|Other|Echocardiography|
79740092|NCT02537782|Other|Magnetic Resonance Imaging|
79740093|NCT02537782|Other|Positron Emission Tomography|
79740094|NCT00998400|Behavioral|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
79740095|NCT00641212|Drug|Budesonide|
79740096|NCT00641212|Drug|Placebo|
79740097|NCT02869776|Behavioral|Questionnaire|Behavioral questionnaires
79740098|NCT02869776|Procedure|Rapid finger stick|HIV and HCV testing through rapid finger stick
79740099|NCT02869776|Procedure|Venipuncture|HIV and HCV testing through venipuncture
79740100|NCT04293900|Other|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79740101|NCT04293900|Other|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79740102|NCT04293900|Other|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79740103|NCT04293900|Other|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79740104|NCT04293900|Other|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79581526|NCT06070480|Other|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
79876000|NCT03814889|Device|Vibration pattern|"PHASE 1 and PHASE 2 are pilot studies not included in the clinical trial.~Phase 2b: All participants try on several wearable prototypes in our laboratory that provide vibration to the arm. Sensors or electrodes taped onto the arm and hand will sense muscle activity and record any changes during periods of vibration and periods with vibration turned off.~PHASE 3: Patients will be given a wearable device to take home. The patient will wear the device daily. At the beginning and end of the phase, arm function will be tested.~PHASE 4: This study takes 3 or 6 months. 1) If the patient gets Botox injections in their hand and arm, their arm function will be measured for three months during this standard care. 2) Next, all patients will be given a wearable device to take home. The patient will wear the device while feeling vibrations for 3 hours during the day while awake for two months. During this time and 1 month after this intervention, arm function will be tested."
79581527|NCT06070467|Other|Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools|"A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~Semi-directive interviews,~Focus groups,~Field observation."
79581528|NCT06070454|Diagnostic Test|vaginitis panel|vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
79740105|NCT04293900|Other|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79876001|NCT03814889|Device|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
79876002|NCT03741101|Drug|Trametinib|treatment
79876003|NCT05350787|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
79876004|NCT00449670|Biological|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
79876005|NCT00449670|Biological|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
79277689|NCT05791058|Procedure|ultrasound guided suprascapular and axillary nerve block|The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space
79277690|NCT05791058|Other|general anesthesia without nerve block|this group will receive general anesthesia without nerve block
79277691|NCT05791045|Procedure|single vs double|we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
79277692|NCT05791006|Behavioral|Neuropsychological tests|"Neuropsychological assessment with:~NADL-F~Frontal Assessment Battery (FAB)~functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)~Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients~Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients"
79277693|NCT05790980|Device|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
79277694|NCT05790941|Combination Product|Latanoprost and Minoxidil|Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
79581529|NCT06070402|Device|DIAL, a voice-controlled virtual assistant|Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
79740106|NCT04293900|Other|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79876006|NCT00449670|Biological|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
79876007|NCT04011449|Device|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
79876008|NCT04010903|Diagnostic Test|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
79876009|NCT05350709|Other|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
79876010|NCT04010513|Behavioral|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
79876011|NCT04010513|Other|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
79876012|NCT00954629|Drug|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
79581530|NCT06070337|Device|H-Guard|A novel Haemodialyser primer used for one treatment only
80031761|NCT03048994|Dietary Supplement|Glutamine|"Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
79876013|NCT00954629|Drug|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
79740107|NCT04293900|Other|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
79740108|NCT04183192|Biological|Mepolizumab|Mepolizumab 3 mg administered SC
79876014|NCT00296374|Drug|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
79876015|NCT00296374|Drug|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
79876016|NCT00296374|Drug|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
79876017|NCT03839082|Other|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
79876018|NCT03839082|Other|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
79876019|NCT05350475|Radiation|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
79277695|NCT05790902|Drug|Silodosin|The patients used Silodosin for Medical expulsive therapy of ureteric calculi
79277696|NCT05790902|Drug|Tamsulosin|The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
79581531|NCT06070324|Procedure|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
79581532|NCT06070324|Device|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
79581533|NCT06070311|Combination Product|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
79740109|NCT04183192|Biological|Mepolizumab|Mepolizumab 6 mg administered SC
79876020|NCT05350475|Radiation|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
79876021|NCT05350241|Other|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
79876022|NCT05350241|Other|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
79876023|NCT05304923|Procedure|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
79876024|NCT05304923|Procedure|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
79876025|NCT01060774|Drug|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
79277697|NCT05790876|Procedure|SSO2 therapy|SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
79277698|NCT05790863|Device|Ergometer cycling|Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
79740110|NCT04183192|Biological|Mepolizumab|Mepolizumab 12 mg administered SC
79740111|NCT04183192|Biological|Mepolizumab|Mepolizumab 24 mg administered SC
79740112|NCT04183192|Biological|Reslizumab|Reslizumab 0.1 mg/kg administered IV
79740113|NCT04183192|Biological|Reslizumab|Reslizumab 0.2 mg/kg administered IV
79740114|NCT04183192|Biological|Reslizumab|Reslizumab 0.4 mg/kg administered IV
79740115|NCT04183192|Biological|Reslizumab|Reslizumab 0.8 mg/kg administered IV
79876026|NCT01060774|Drug|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
79876027|NCT04011059|Biological|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
79876028|NCT00954785|Device|Ankle brace|Sports Stirrup ankle brace (Aircast)
79876029|NCT00954785|Drug|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
79581534|NCT06070155|Other|Aerobic Exercise three time a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
79876030|NCT00954785|Drug|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
79581535|NCT06070129|Procedure|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
80031762|NCT03048994|Dietary Supplement|Placebo|"Nutritional support will be continued as per managing ICU team discretion.~Management of severe sepsis will be continued as per managing ICU team discretion.~Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
79581536|NCT06070064|Other|Effect of music on the manifestation of strength|"After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test."
79581537|NCT06070038|Behavioral|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
79581538|NCT06070012|Drug|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
79740116|NCT04183192|Biological|Placebo|Placebo (administered either IV or SC)
79581539|NCT06069986|Procedure|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
79581540|NCT06069960|Procedure|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
79581541|NCT06069947|Procedure|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
79581542|NCT06069908|Other|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
79581543|NCT06069908|Other|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
79740117|NCT02681848|Drug|Varenicline|Smoking cessation medication
79740118|NCT02681848|Drug|Nicotine replacement therapy|
79740119|NCT00997386|Drug|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
79740120|NCT02394574|Other|Clean Cookstove|Ethanol
79740121|NCT02394574|Other|Traditional Cookstove|Firewood / Kerosene
79876031|NCT00326950|Drug|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
79876032|NCT03981874|Other|telephonic interview|Telephonic interview
79876033|NCT00548717|Drug|Sirolimus|
79876034|NCT00548717|Drug|Mycophenolate mofetil|
79876035|NCT00548717|Drug|Bortezomib|
80031763|NCT04885426|Drug|low-dose metformin|Metformin Pill 250mg/day
79288976|NCT04461119|Drug|Placebo|oral capsules for 4 weeks of treatment
79288977|NCT03465397|Diagnostic Test|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
79740122|NCT02870088|Behavioral|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
79876036|NCT00441168|Drug|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
79876037|NCT00441168|Drug|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
79876038|NCT00441168|Drug|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
79876039|NCT00441168|Drug|vincristine|vincristine: 0.4mg IV push on days 1 to 4
79876040|NCT00296140|Behavioral|self management of PSD symptoms|
79876041|NCT00296140|Procedure|screening and treatment of PSD|
80031764|NCT04885426|Drug|high-dose metformin|Metformin Pill 500mg/day
80031765|NCT04885426|Drug|Placebo|Placebo
80031766|NCT04879888|Biological|Peptide pulsed Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
79876042|NCT03669432|Radiation|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
79876043|NCT03669432|Procedure|Surgery alone|This intervention is of no interest
79876044|NCT03958331|Behavioral|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
79581544|NCT06069908|Other|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
79581545|NCT06069908|Other|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
79876045|NCT03958331|Behavioral|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
79876046|NCT03958331|Behavioral|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
79876047|NCT01062958|Other|Neevo® (a medical food)|
79876048|NCT01062958|Other|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
79876049|NCT01566318|Behavioral|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
79876050|NCT03956615|Other|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
79876051|NCT01028976|Dietary Supplement|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
79876052|NCT01028976|Dietary Supplement|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
79876053|NCT01024140|Drug|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
79876054|NCT03956225|Device|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
79876055|NCT03956225|Device|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
79404363|NCT04074876|Device|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~0: normal pattern (A-lines)~1: multiple B lines (at least 3 for field), well defined.~2: B lines coalescent~3: consolidation of any dimension"
79404364|NCT05229510|Drug|50 mg/mL Virazole Inhalant Product|50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
79876056|NCT01024218|Device|NovoFine® needle 8 mm|
79876057|NCT01024218|Device|autocover needle|
79876058|NCT01027026|Other|Early discharge|The patients are discharged the same day as coronary angiography.
79404365|NCT05229510|Drug|100 mg/mL Virazole Inhalant Product|100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
79581546|NCT06069830|Drug|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
79581547|NCT06069830|Drug|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
79581548|NCT06069830|Drug|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
79581549|NCT06069804|Drug|The TR group|Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
79760990|NCT05066165|Genetic|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
79760991|NCT05066165|Genetic|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
79760992|NCT05044286|Other|no intervention|no intervention
79760993|NCT05018507|Other|Data collection only|No intervention, just data collection from system machines
79760994|NCT04994613|Other|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
79876059|NCT01027026|Other|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
79876060|NCT05178329|Behavioral|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
79876061|NCT05178329|Behavioral|Standard exercise|Standard exercise program after mastectomy
79740123|NCT02870088|Behavioral|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
79876062|NCT02936609|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
79876063|NCT00457626|Drug|Valsartan|Extemporaneous suspension of valsartan, orally.
79876064|NCT02748707|Drug|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
79876065|NCT02748707|Drug|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
79404366|NCT05229510|Drug|Placebo|Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
79876066|NCT02748707|Drug|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
79404367|NCT04372381|Device|Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro|Treatment of aortic valve stenosis using transcatheter aortic valve replacement
79876067|NCT02748707|Other|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
79876068|NCT05177861|Diagnostic Test|EMG|Electromyelography
79876069|NCT05175209|Diagnostic Test|EMG|Electromyelography
79740124|NCT04182256|Device|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
79740125|NCT02869620|Other|Data collection|
79876070|NCT05131061|Diagnostic Test|68Ga-Pentixafor PET/CT imaging|68Ga-Pentixafor PET/CT imaging
79876071|NCT04010279|Procedure|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
79876072|NCT05050487|Procedure|PENG block|"The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . .~The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly .~After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane."
79876073|NCT05050487|Procedure|lumbar erector spinae plane block|"The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle."
79876074|NCT02249975|Device|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~Device malfunctions~Adverse events~Patient Pain~Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
79404368|NCT01671943|Device|Ice-Sense3TM|Ice-Sense Cryoprobe
79404369|NCT01672021|Procedure|PET/MRI|PET/MRI
79740126|NCT02679820|Device|Copper T intrauterine device|
79740127|NCT02683330|Behavioral|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
79404370|NCT01362348|Drug|pazopanib eye drops|10 mg/mL (1 drop) four times daily
79404371|NCT03154489|Other|acenocoumarol|medication review with follow-up in acenocoumarol treatment
79740128|NCT00641914|Drug|budesonide|
79740129|NCT00641914|Drug|Placebo|
79277699|NCT05790798|Other|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
79288978|NCT03461575|Drug|HU007|cyclosporine 0.02%, trehalose 3%
79288979|NCT03461575|Drug|Restasis|cyclosporine 0.05%
79288980|NCT03461575|Drug|Moisview|trehalose 3%
79288981|NCT03131843|Drug|Alcohol|Alcohol cleansing swab/wipe
79404372|NCT03154489|Other|control|group
79740130|NCT02683408|Other|placebo|inactive placebo
79740131|NCT02683408|Dietary Supplement|diosmiplex|diosmiplex is an FDA regulated medical food product
79740132|NCT00640588|Drug|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
79740133|NCT00640588|Drug|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
79740134|NCT05663398|Drug|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
79404373|NCT05607979|Drug|Lavior Diabetic Wound Gel|Daily application of hydrogel treatment for 60 days.
79404374|NCT05607979|Drug|Smith & Nephew Solosite Gel Hydrogel Wound Dressing|Daily application of hydrogel treatment for 60 days.
79740135|NCT05663398|Drug|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
79740136|NCT02683252|Other|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
79740137|NCT02681926|Procedure|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
79740138|NCT00640666|Behavioral|Exercise Behavior Change|Multidisciplinary
79740139|NCT02679352|Device|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
79740140|NCT00640744|Drug|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
79740141|NCT02678026|Device|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
79288982|NCT03131843|Drug|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
79740142|NCT05663008|Procedure|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
79740143|NCT02678104|Procedure|Tooth extraction|Tooth removal
79288983|NCT03461341|Other|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
79288984|NCT04125173|Other|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
79288985|NCT04125173|Other|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
79288986|NCT04125173|Other|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
79404375|NCT04248036|Behavioral|Circle of Security - Parenting, COS-P|Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
79740144|NCT02678104|Drug|Chlorhexidine mouth wash|Chlorhexidine mouth wash
79740145|NCT02678104|Drug|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
79740146|NCT04183036|Procedure|Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
79740147|NCT02681536|Drug|Triptorelin|
79740148|NCT02681536|Drug|Combined oral contraceptive pills|
79740149|NCT02681536|Drug|HMG|
79740150|NCT04183114|Biological|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
79740151|NCT04183114|Biological|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
79760995|NCT04991480|Drug|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
79760996|NCT04991480|Drug|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
79760997|NCT04991480|Drug|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
79760998|NCT04991467|Behavioral|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
79760999|NCT04991467|Behavioral|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
79761000|NCT04991467|Behavioral|CARE Program|Participant will take part in 12 week CARE program.
79761001|NCT04991467|Behavioral|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
79761002|NCT04991467|Behavioral|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
79761003|NCT04975698|Biological|HST-NEETs|HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10^7/m^2 cells between 3 Days and 7 Days post-ASCT.
79761004|NCT04975698|Biological|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
79761005|NCT04972123|Drug|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
79761006|NCT04972123|Diagnostic Test|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
79761007|NCT04972123|Drug|Placebo|Placebo for CPC
79761008|NCT04965909|Other|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
79761009|NCT04958239|Drug|BI 765179|BI 765179
79761010|NCT04958239|Drug|Ezabenlimab|Ezabenlimab
79761011|NCT04925752|Drug|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
79761012|NCT04925752|Drug|F/TDF|Tablets administered orally
79876075|NCT01841957|Procedure|ISBCS|same-day cataract surgery
79876076|NCT01841957|Procedure|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
79876077|NCT05014061|Drug|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
79876078|NCT05001503|Device|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
79876079|NCT04977245|Other|Mindfulness-Based Stress Reduction|Eight MBSR sessions of 1.5 hours per week
79876080|NCT04977245|Other|Self-Guided Mindfulness eCourse|Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
79876081|NCT00373113|Drug|Capecitabine|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
79876082|NCT00373113|Drug|Sunitinib malate|37.5 mg daily, continuous dosing
79876083|NCT01045941|Drug|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
79876084|NCT01045941|Procedure|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
79876085|NCT00407511|Drug|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
79876086|NCT00384189|Drug|Ciclesonide|inhaled Ciclesonide
79876087|NCT00384189|Drug|Placebo|Ciclesonide placebo-matching inhaler
79876088|NCT00384189|Drug|Salbutamol|Salbutamol inhalation powder
79876089|NCT00326716|Drug|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
79876090|NCT01063192|Drug|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
79876091|NCT01063192|Drug|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
79876092|NCT03983356|Other|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
80031767|NCT03048682|Device|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
80031768|NCT03048682|Device|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
79404376|NCT04371055|Other|7-day Holter ECG|7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
79404377|NCT04371055|Other|Implantable cardiac monitor|Continuous rhythm monitoring using an implantable cardiac monitor
79404378|NCT04371055|Other|Standard of care|Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
79404379|NCT04228848|Other|new triple hop test|New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
79404380|NCT04052724|Behavioral|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
79404381|NCT04336033|Other|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
79404382|NCT04336033|Other|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
79404383|NCT04336033|Other|Printed Nutrition Pamphlet|"After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions."
79404384|NCT00698022|Drug|Risperidone|risperidone daily for 28 days
79404385|NCT00698022|Drug|Mifepristone|mifepristone daily for 28 days
79404386|NCT00698022|Drug|Risperidone-matched placebo|risperidone-matched placebo daily for 28 days
79876093|NCT03978910|Other|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
79876094|NCT01066078|Other|Echocardiography and SonR recording|
79876095|NCT01063426|Drug|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
79876096|NCT01063426|Drug|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
79277700|NCT05790798|Other|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
79277701|NCT05790759|Other|No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait|Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
79277702|NCT05790694|Drug|HBM9378 (SKB378) Injection|Strength: 225 mg (1.5 mL)/vial
79404387|NCT00698022|Drug|Mifepristone-matched placebo|mifepristone-matched placebo daily for 28 days
79404388|NCT01672099|Dietary Supplement|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
79581550|NCT06069804|Drug|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
79740152|NCT02681692|Device|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
79761013|NCT04925752|Drug|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
79761014|NCT04925752|Drug|Placebo SC LEN|Administered via SC injections
79761015|NCT04925752|Drug|PTM F/TDF|Tablets administered orally
79404389|NCT01672099|Dietary Supplement|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
79404390|NCT01672177|Behavioral|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
79404391|NCT02570503|Drug|Ropivacaine|Ropivacaine (5mg/ml)-50ml
79404392|NCT02570503|Drug|Ketorolac|ketorolac (30mg/ml)- 1 ml
79404393|NCT02570503|Drug|Clonidine|clonidine (0.1mg/ml)- 0.8ml
79404394|NCT02570503|Drug|Epinephrine|epinephrine (1mg/ml)-1ml
79404395|NCT02570503|Drug|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
79761016|NCT04925752|Drug|PTM Oral LEN|Tablets administered orally
79761017|NCT04925752|Drug|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
79404396|NCT01672333|Drug|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
79404397|NCT02492269|Drug|Dexmedetomidine|
79404398|NCT02492269|Drug|Placebo|
79761018|NCT04917796|Device|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
79761019|NCT04917796|Device|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
79761020|NCT04896008|Drug|Sotatercept|Sotatercept is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
79761021|NCT04896008|Other|Placebo|Placebo
79761022|NCT04872738|Other|Survey|Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
79761023|NCT04857476|Diagnostic Test|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
79761024|NCT04846400|Device|ssNPA|The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
79761025|NCT04839497|Combination Product|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
79761026|NCT04835233|Drug|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
79761027|NCT04827953|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
79876097|NCT00548405|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
79876098|NCT00548405|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
79277703|NCT05790694|Drug|Placebo|Strength: 225 mg (1.5 mL)/vial
79876099|NCT00548405|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
79876100|NCT00958529|Dietary Supplement|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
79876101|NCT00958607|Behavioral|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care & by telephone during inpatient rehabilitation and community discharge. SSP provides support, information & guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
79277704|NCT05790655|Other|oPRP|Prepared sample from patient's own blood collected and processed
79277705|NCT05790629|Procedure|endo-sequence putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
79277706|NCT05790629|Procedure|neo-MTA putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
79277707|NCT05790616|Procedure|Arterial blood draw|"For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values."
79277708|NCT05790616|Other|Oxygen reduction|Volunteers undergo an ambient oxygen decrease from 21% to 10%
79876102|NCT00958607|Behavioral|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
80031769|NCT04880122|Diagnostic Test|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
80031770|NCT04879576|Other|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
80031771|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
80031772|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
79876103|NCT00958685|Dietary Supplement|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
79581551|NCT06069739|Behavioral|Guided physical activity|To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.
79581552|NCT06069739|Behavioral|Standard physical activity|"Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline."
79761028|NCT04827953|Drug|Nab paclitaxel|Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
79761029|NCT04827953|Drug|NLM-001|NLM-001 will be administered three cycles consecutively followed by two rest cycles.
79761030|NCT04827953|Drug|Zalifrelimab|Zalifrelimab administration each 6 weeks.
79761031|NCT04758533|Biological|AloCELYVIR|Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
79761032|NCT04756232|Drug|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
79761033|NCT04756232|Other|Placebo Comparator Challenge|Matching placebo oral pill administered once
79876104|NCT00958685|Dietary Supplement|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
79876105|NCT00958763|Behavioral|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
79740153|NCT00996996|Biological|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
79876106|NCT00958763|Behavioral|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
79277709|NCT05790603|Device|Experimental: Low pressure group of quantitative pressure patent hemostasis|The compression pressure was 120% of upper SBP. Pressure will be released by 4% hourly until the bleeding is stopped.
79876107|NCT00958763|Other|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
79876108|NCT00958997|Drug|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
79277710|NCT05790603|Device|Experimental: Medium pressure group of quantitative pressure patent hemostasis|The compression pressure was 125% of upper SBP. Pressure will be released by 5% hourly until the bleeding is stopped.
79876109|NCT00958997|Biological|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
79876110|NCT00959075|Dietary Supplement|Vitamin B1|100 mg Twice a day
79277711|NCT05790603|Device|Experimental: High pressure group of quantitative pressure patent hemostasis|The compression pressure was 130% of upper SBP. Pressure will be released by 5% hourly until the bleeding is stopped.
79277712|NCT05790603|Device|Active Comparator: Conventional radial artery hemostat device|Radial artery hemostatic device. Pressure will be released hourly based on medical staff's experiences until the bleeding is stopped.
79277713|NCT05790564|Other|Almond|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
79581553|NCT06069700|Other|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. *Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. *Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. *Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
79876111|NCT00959075|Dietary Supplement|Placebo|Sugar pill
79876112|NCT05299775|Diagnostic Test|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
79876113|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
79876114|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
79277714|NCT05790564|Other|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
79277715|NCT05790538|Procedure|Assessment of Therapy Complications|Complete clinic assessments
79277716|NCT05790538|Other|Electronic Health Record Review|Medical records are reviewed
79404400|NCT01672567|Dietary Supplement|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
79740154|NCT04182568|Drug|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
79876115|NCT00295750|Drug|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
79876116|NCT04910321|Other|diet, physical activities, sleep|lifestyle factors
79277717|NCT05790538|Other|Medical Device Usage and Evaluation|Wear instrumented socks
79277718|NCT05790538|Other|Medical Device Usage and Evaluation|Wear activity monitor
79277719|NCT05790538|Other|Survey Administration|Complete surveys
79902195|NCT03413423|Behavioral|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
79277720|NCT05790447|Drug|Thymalfasin|loading dose with thymalfasin based on the amounts of T lymphocyte
79581554|NCT06069700|Other|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
79581555|NCT06069674|Diagnostic Test|Serum dosage of GFAP and UCH-L1|blood test execution as per usual care in the ED
79277721|NCT05790447|Radiation|Radiotherapy|hypofractionated radiotherapy/SBRT
79277722|NCT05790447|Drug|PD-1/PD-L1 inhibitor|The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
79277723|NCT05790447|Drug|GM-CSF|subcutaneous injection daily for 7 consecutive days
79740155|NCT04182568|Drug|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
79876117|NCT04850963|Device|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
79876118|NCT04850963|Device|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
79876119|NCT04850963|Device|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
79876120|NCT00959153|Device|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
79404401|NCT01672567|Dietary Supplement|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
79740156|NCT02681380|Other|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
79876121|NCT00959231|Drug|cyclophosphamide|
79876122|NCT00959231|Drug|cyclosporine|
79876123|NCT00959231|Drug|fludarabine phosphate|
79277724|NCT05790434|Diagnostic Test|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
79277725|NCT05790434|Diagnostic Test|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
79277726|NCT05790434|Diagnostic Test|biopsy|including arthrocentesis culture，and frozen section
79277727|NCT05790395|Other|Theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
79404402|NCT01672567|Dietary Supplement|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
79404403|NCT00617994|Drug|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
79404404|NCT04405219|Other|The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain|Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
79404405|NCT03153943|Device|HIP Mobile e-Monitoring support|3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
79404406|NCT03153943|Other|Workbook support|Printed material support
79581556|NCT06069661|Device|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
79581557|NCT06069648|Behavioral|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
79581558|NCT06069648|Behavioral|a leaftlet|a leaflet containing information about healthy lifestyles
79581559|NCT06069648|Behavioral|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
79740157|NCT02681380|Other|Control group|No session will be planned for the participants.
79740158|NCT02681068|Other|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
79740159|NCT02870868|Behavioral|Slow breathing|Slow breathing techniques from yoga
79404407|NCT05561179|Procedure|Hyaluronic acid injection|"Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
79740160|NCT04283682|Behavioral|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
79404408|NCT05561179|Procedure|Sodium chloride injection (control group)|"Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
79740161|NCT04033744|Procedure|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
79740162|NCT00628836|Device|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
79740163|NCT02679196|Drug|KA2237|PI3 Kinase p110β/δ inhibitor
79740164|NCT00641368|Behavioral|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
79740165|NCT00641368|Other|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
79740166|NCT00641446|Drug|budesonide|
79876124|NCT00959231|Drug|mycophenolate mofetil|
79876125|NCT00959231|Other|laboratory biomarker analysis|
79876126|NCT00959231|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
79404409|NCT03154021|Combination Product|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
79404410|NCT03154021|Combination Product|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
79404411|NCT05456425|Drug|CBT-001|A multi-kinase inhibitor
79404412|NCT05456425|Drug|Vehicle|Formulation without drug
79404413|NCT03754309|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
79581560|NCT06069635|Other|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
79740167|NCT00641446|Drug|varicella zoster virus|
79740168|NCT02677948|Drug|Pacritinib|
79876127|NCT00959231|Procedure|umbilical cord blood transplantation|
79876128|NCT00959231|Radiation|total-body irradiation|
79404414|NCT03754309|Drug|Placebo|Matched placebo
79404415|NCT05409937|Other|Water-saturated Improved Hot Weather Combat Uniform|Water-saturated Improved Hot Weather Combat Uniform
79404416|NCT05409937|Other|Water-saturated Army Combat Uniform|Water-saturated Army Combat Uniform
79740169|NCT02677948|Drug|Ibrutinib|
79740170|NCT02869854|Behavioral|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
79740171|NCT02869854|Behavioral|PAP|Physical Activity on Prescription, after 3 months a new prescription
79740172|NCT02681146|Other|Multimodal intervention|Educational advice + physiotherapist treatment
79876129|NCT03948581|Drug|Vedolizumab SC|Vedolizumab SC liquid.
79876130|NCT00548327|Drug|Atomoxetine|Comparison between Atomoxetine and Placebo
79876131|NCT00548327|Procedure|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
79404417|NCT05409937|Other|Water-saturated Army Combat Uniform + Silk Weights|Water-saturated Army Combat Uniform + Silk Weights
79404418|NCT03153397|Other|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
79404419|NCT03153397|Other|Osmolite|non-prebiotic fiber containing formula (Osmolite)
79404420|NCT03153241|Other|No intervention|No intervention
79876132|NCT00548327|Procedure|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
79876133|NCT00548327|Drug|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
79740173|NCT02679118|Device|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
79277728|NCT05790395|Other|health-risk behaviors|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
79876134|NCT00959309|Behavioral|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
79876135|NCT00959309|Behavioral|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
79581561|NCT06069635|Other|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
79876136|NCT04720547|Drug|Zolpidem|A nonbenzodiazepine hypnotic
79404421|NCT02467153|Other|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
79404422|NCT02467153|Dietary Supplement|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
79581562|NCT06069622|Diagnostic Test|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
79581563|NCT06069622|Dietary Supplement|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
79876137|NCT04720547|Other|No Treatment|The Control condition in which participants do not receive medication.
79876138|NCT00959387|Drug|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
79876139|NCT00959387|Radiation|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
79277729|NCT05790382|Drug|NM-101|"In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts)."
79277730|NCT05790382|Drug|Placebo|Placebo solution for infusion
79277731|NCT05790356|Drug|Fecal Microbial transplant|Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
79277732|NCT05790356|Other|Placebo capsules|The placebo capsules will not contain FMT but will have the same appearance.
79581564|NCT06069609|Device|Kalifilcon a Contact Lens for Astigmatism|Kalifilcon A Daily Disposable Toric Contact Lens for Astigmatism
79581565|NCT06069609|Device|Acuvue Oasys 1-Day for Astigmatism|Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism
79876140|NCT00959465|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
79277733|NCT05790330|Drug|Methotrexate|As per usual standard of care
79277734|NCT05790317|Procedure|Surgical Procedure with ERAS Protocol|It covers the period before, during and after the surgery.
79277735|NCT05790291|Other|Checklist|the experimental group will practice using the checklist
79277736|NCT05790265|Device|ANNE One|Chest sensor for single lead ECG and finger sensor for pulse oximetry.
79277737|NCT05790239|Drug|3,4-methylenedioxymethamphetamine|Initial doses per Experimental Session include 68 mg or 100 mg MDMA (equivalent to 80 mg or 120 mg MDMA HCl), followed 1.5 to 2 hours later by a supplemental dose of 34 mg or 50 mg MDMA (equivalent to 40 mg or 60 mg MDMA HCl).
79277738|NCT05790239|Drug|d-amphetamine|Initial dose per experimental session will be 5 mg or 10 mg d-amphetamine, followed 1.5 to 2 hours later by supplemental dose of 2.5 mg or 5 mg d-amphetamine.
79740174|NCT00641524|Procedure|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
79740175|NCT02677636|Drug|MSRD-100|MSRD-100 is a topical gel.
79740176|NCT02677636|Drug|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
79740177|NCT05663164|Drug|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
79581566|NCT06069583|Behavioral|Support platform|"The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D."
79581567|NCT06069505|Diagnostic Test|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
79404423|NCT02467153|Dietary Supplement|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
79581568|NCT06068075|Other|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
79581569|NCT06067594|Diagnostic Test|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
79581570|NCT06067113|Procedure|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
79581571|NCT06066918|Drug|Pregabalin 75mg|Pregabalin 75 mg twice a day
79581572|NCT06066866|Other|endoscopic sampling of luminal fluid|We will collect luminal fluid via endoscopic sampling
79740178|NCT05663164|Drug|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
79740179|NCT02677558|Other|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
79404424|NCT03719521|Other|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
79404425|NCT04933903|Drug|Ipilimumab|1mg/kg IV on day 1 (1 dose total)
79404426|NCT04933903|Drug|Nivolumab|3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
79581573|NCT06066775|Other|Observation study without intervention|Observation study without intervention
79581574|NCT06066489|Other|educational program about VAP|An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
79581575|NCT06066307|Other|Olfactory training|Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
79581576|NCT06066294|Biological|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
79581577|NCT06066294|Biological|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
79581578|NCT06066281|Behavioral|Neuropsychological assessment|All participants who will meet the inclusion criteria will be adminstered a pencil-paper neuropsychological tests battery including: the Digit Span Backward Task, the Brief Repeatable Battery of Neuropsychological Tests and the CST. After 15 days from the baseline evaluation the CST will be re-administrated to all subjects.
79581579|NCT06065592|Drug|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
79761034|NCT04755127|Procedure|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
79761035|NCT04755127|Drug|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
79761036|NCT04738942|Drug|Vedolizumab|Vedolizumab 300 mg, IV infusion
79761037|NCT04731298|Drug|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
79761038|NCT04676412|Biological|Pembrolizumab|IV infusion
79761039|NCT04676412|Drug|Lenvatinib|oral capsule
79761040|NCT04676412|Drug|Placebo for lenvatinib|oral capsule
79761041|NCT04657120|Procedure|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level <1.0 μg/mL (<1000ng/mL), and in patients with ≥1 items and a D-dimer level <0.5 μg/mL (<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
79761042|NCT04657120|Procedure|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
79876141|NCT04718285|Drug|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
79305115|NCT04965441|Procedure|Computer-assisted surgery|Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
79876142|NCT04718285|Drug|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
79581580|NCT06065592|Drug|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
79876143|NCT04718285|Drug|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
79404427|NCT04933903|Radiation|SBRT|1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
79404428|NCT03153163|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
79404429|NCT03153085|Biological|TBI-1401(HF10)|"1x10^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
79404430|NCT03153085|Drug|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
79404431|NCT03463525|Drug|Osimertinib|Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
79404432|NCT03463525|Drug|[11C]osimertinib|Patients will receive 3 single IV microdose administrations of [11C]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
79404433|NCT04880239|Procedure|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
79404434|NCT01673269|Other|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
79404435|NCT03438643|Diagnostic Test|Blood samples|Blood samples (42mL) will be taken before and during treatment.
79404436|NCT03438643|Diagnostic Test|skin biopsy|skin biopsy will be taken before and during treatment.
79404437|NCT01675128|Drug|ISIS 183750|
79404438|NCT01675128|Drug|Irinotecan|
79404439|NCT02626507|Drug|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
79404440|NCT02626507|Drug|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
79581581|NCT06065592|Genetic|SNP|diagnostics of patients' carriers or not of the risk allele(s)
79581582|NCT06062602|Drug|TAK-676|Intratumoral microdose injection by the CIVO device.
79581583|NCT06062602|Drug|Carboplatin|Intratumoral microdose injection by the CIVO device.
79581584|NCT06062602|Drug|5-FU|Intratumoral microdose injection by the CIVO device.
79581585|NCT06062602|Drug|Paclitaxel|Intratumoral microdose injection by the CIVO device.
79581586|NCT06062602|Combination Product|TAK-676 + Carboplatin|Intratumoral microdose injection by the CIVO device.
79581587|NCT06062602|Combination Product|Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
79581588|NCT06062602|Combination Product|Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
79581589|NCT06062602|Combination Product|TAK-676 + Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
79581590|NCT06062602|Combination Product|TAK-676 + Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
79581591|NCT06062472|Dietary Supplement|Probiotics|Both live and heat-treated of Lactobacillus paracasei will be used in this study
79581592|NCT06062446|Procedure|Modified Lumbar Puncture|The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
79581593|NCT06062290|Device|Electromyography (EMG)|Measurement of the compound muscle action potential for the assessment of neuromuscular function
79581594|NCT06062290|Device|Kinemyography (KMG)|Measurement of the muscle velocity for the assessment of neuromuscular function
79581595|NCT06061393|Drug|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
79581596|NCT06061393|Drug|Ferinject|ferinject 500 mg, once a week for 2 weeks
79761043|NCT04646473|Behavioral|SweetGoals app|App offers goal setting and feedback
79761044|NCT04646473|Behavioral|Coaching|Web health coaching
79761045|NCT04646473|Behavioral|Incentives|Financial incentives for meeting goals
79761046|NCT04641975|Drug|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight < 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
79761047|NCT04641975|Drug|Placebo|Oral/ Oral Suspension
79876144|NCT05299619|Device|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
79581597|NCT06061107|Behavioral|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
79876145|NCT00959543|Other|MRI|MRI and clinical investigation
79876146|NCT00959621|Drug|Aspirin|ASA 100 mg once daily per os
79876147|NCT00959621|Drug|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
79876148|NCT00959621|Drug|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
79876149|NCT05299541|Dietary Supplement|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~All dishes will be photographed at the end of the meal by Android camera, iPhone~A NUTRITION DAY success photo form will be completed and collected ."
79876150|NCT05299541|Diagnostic Test|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
79876151|NCT05299541|Diagnostic Test|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
79876152|NCT05299541|Behavioral|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
79876153|NCT05299541|Dietary Supplement|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~All dishes will be photographed at the end of the meal by Android camera, iPhone~A NUTRITION DAY success photo form will be completed and collected ."
79876154|NCT00959777|Drug|DA-3031|
79876155|NCT00959777|Drug|Filgrastim|
79876156|NCT04450745|Behavioral|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
79876157|NCT04450745|Behavioral|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
79876158|NCT03953183|Other|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
79876159|NCT03953183|Other|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
79277739|NCT05790239|Behavioral|Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
79305116|NCT03260075|Other|cat|Cat living at the ward
79404441|NCT02626507|Drug|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
79404442|NCT02626507|Drug|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
79902196|NCT03364530|Drug|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
79581598|NCT06060938|Other|Risk stratified arm|"Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~Measurement of height and weight (baseline)~Complete a mammography (baseline and every 1-4 years according to the risk-group)~Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~Receive a screening schedule recommendation."
79404443|NCT03243175|Drug|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
79404444|NCT03243175|Device|left atrial appendage closure|left atrial appendage closure
79581599|NCT06060938|Other|Control arm|"Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~Measurement of height and weight (baseline)~Complete a mammography (baseline and every second year)~Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)"
79581600|NCT06060171|Procedure|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
79581601|NCT06059196|Behavioral|ARCHES (Addressing Reproductive Coercion in Health Settings)|ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
79876160|NCT00959855|Other|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
79581602|NCT06059196|Behavioral|BCS+ (Balanced Counseling Strategy Plus)|BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
79876161|NCT00961883|Biological|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 ^7 PFU
79581603|NCT06058182|Diagnostic Test|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
79876162|NCT00961883|Biological|Placebo|Sodium Chloride for injection, delivered intramuscularly
79876163|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^10 PFU
79876164|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^9 PFU
79876165|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^8 PFU
79876166|NCT00959933|Drug|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
79876167|NCT00959933|Drug|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
79876168|NCT00960089|Device|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
79876169|NCT00960167|Radiation|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
79277740|NCT05790226|Device|Sentry System|any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
79432879|NCT03587324|Drug|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
79581604|NCT06056869|Drug|hyoscine butylbromide|will be given during first stage of labor intravenously
79876170|NCT00962195|Dietary Supplement|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
79876171|NCT00960245|Drug|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
79876172|NCT00960245|Drug|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
79876173|NCT00962273|Behavioral|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
79876174|NCT00962273|Behavioral|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
79876175|NCT00406653|Drug|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
79277741|NCT05790200|Drug|Cadonilimab|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
79277742|NCT05790187|Other|Presentation of differents face pictures|Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
79876176|NCT00406653|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
79876177|NCT00406653|Drug|abatacept|"~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
79277743|NCT05790148|Device|3Shape|original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
79277744|NCT05790135|Device|shear wave elastography|Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
79581605|NCT06056869|Other|normal saline|placebo
79876178|NCT03381651|Radiation|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
79876179|NCT03381651|Radiation|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
79876180|NCT00547157|Drug|Panitumumab|Arm 2 consists of panitmumab plus RT
79876181|NCT00547157|Drug|Cisplatin|Cisplatin
79876182|NCT00960479|Drug|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
79876183|NCT00960479|Drug|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
79876184|NCT00960557|Drug|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
79876185|NCT00960635|Drug|1,25-dihydroxy-vitamin D3 (calcitriol)|
79876186|NCT00960635|Drug|placebo|pill without agent
79740180|NCT00643318|Radiation|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
79740181|NCT02537470|Drug|Biphasic Remogliflozin Etabonate|Experimental Drug
79740182|NCT02537470|Other|Placebo|Placebo Comparator
79740183|NCT02678728|Drug|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
79740184|NCT02678728|Drug|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
79876187|NCT00960713|Drug|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
79277745|NCT05789823|Procedure|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 5 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
79876188|NCT04009889|Dietary Supplement|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
79876189|NCT04009889|Other|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
79876190|NCT00962351|Procedure|Total Hip Replacement|
79432792|NCT05581628|Diagnostic Test|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
79876191|NCT00962507|Drug|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
79277746|NCT05789823|Procedure|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
79876192|NCT00962507|Drug|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
79876193|NCT00962507|Other|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
79876194|NCT00962507|Other|pharmacological study|Pre-study, day 1 and day 26
79876195|NCT00960791|Device|AZD1656|Oral single dose
79876196|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
79876197|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
79876198|NCT00384033|Drug|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
79432793|NCT03558373|Drug|Immunosuppressive|Immunosuppressive therapies
79432794|NCT04064957|Biological|HB-adMSCs|
79432795|NCT05581550|Radiation|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
79581606|NCT06050707|Radiation|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
79876199|NCT00384033|Drug|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
79581607|NCT06050707|Radiation|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
79581608|NCT06050707|Radiation|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
79581609|NCT06050707|Radiation|Radiotherapy - High risk group|35 fractions completed in 7 weeks
79581610|NCT06048328|Behavioral|Game Changers for Family Planning|Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 7 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
79876200|NCT00962663|Drug|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
79740185|NCT04180072|Drug|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
79876201|NCT00962663|Drug|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
79876202|NCT00962663|Drug|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
79876203|NCT00962819|Biological|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
79876204|NCT00961025|Drug|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
79876205|NCT00961025|Drug|Placebo|placebo
79876206|NCT00962897|Procedure|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
79876207|NCT00962897|Procedure|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
79876208|NCT00962975|Drug|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
79432796|NCT05581550|Radiation|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
79581613|NCT06046300|Diagnostic Test|Investigation of the relationship between trunk position sense and muscle activation, balance and quality of life in individuals with transtibial amputation.|It is aimed to investigate whether the trunk position sense, including the trunk right and left sides of the individuals with transtibial amputation, is affected and the relationship between trunk position sense and muscle activation, balance and quality of life.
79740186|NCT04180072|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
79740187|NCT02678806|Radiation|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
79761048|NCT04633200|Other|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
79761049|NCT04625153|Biological|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
79761050|NCT04625153|Biological|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
79761051|NCT04617002|Drug|ONC201 (dordaviprone)|ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
79581614|NCT06041282|Procedure|manipulation under anesthesia|After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.
79581615|NCT06041282|Procedure|supervised home rehabilitation|The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.
79581616|NCT06038032|Behavioral|My Viva Plan (www.myvivaplan.com)|A web-based platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
79581617|NCT06038032|Behavioral|Online healthcare professional support|Individual and group sessions with a Registered Dietitian, Qualified Exercise professional, and Mental Health Professional for 16 weeks.
79581618|NCT06037135|Drug|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
79761052|NCT04616365|Procedure|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
79761053|NCT04603560|Behavioral|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
79761054|NCT04603560|Behavioral|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
79761055|NCT04578041|Device|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~Modality: Excitatory stimulation~Frequency: 5 Hz~Interval between stimulus: 100 ms~Duration of each stimulus: 25 ms~Duration of stimulation: 40 minutes~Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
79761056|NCT04578041|Other|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
79761057|NCT04578041|Other|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
79761058|NCT04558840|Procedure|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
79761059|NCT04557462|Drug|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
79761060|NCT04550260|Drug|Durvalumab|Durvalumab intravenous infusion
79761061|NCT04550260|Drug|Placebo|Durvalumab matching placebo for intravenous infusion
79761062|NCT04550260|Drug|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
79761063|NCT04550260|Drug|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
79404445|NCT04995510|Other|Observational|To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
79581619|NCT06037135|Drug|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
79581620|NCT06031974|Behavioral|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
79404446|NCT04764877|Other|Osteopathic Manipulative Medicine|Provided 15-20 minute long OMT session for patients in the OMT arm
79404447|NCT04764955|Dietary Supplement|Placebo|This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
79740188|NCT02678806|Drug|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 ~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
79581621|NCT06030050|Behavioral|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
79581622|NCT06024486|Diagnostic Test|fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)|measurement of serum albumin, fibrinogen and CRP
79404448|NCT04764955|Dietary Supplement|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
79581623|NCT06016907|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
79404449|NCT04511208|Device|Cooling Vest|Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
79581624|NCT06016907|Behavioral|In-person cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
79581625|NCT06012149|Behavioral|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
79581626|NCT06012149|Behavioral|Structured advice on physical activity|A 12 week program where participants are encouraged to engage in physical exercise
79581627|NCT06001762|Drug|Abemaciclib|CDK4 and CDK6 inhibitor, tablet taken orally
79581628|NCT06001762|Drug|Tamoxifen|Selective estrogen receptor modulator, taken orally per institutional standard of care
79581629|NCT06001762|Drug|Anastrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
79404450|NCT04511208|Device|Without cooling vest|Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
79404451|NCT01673581|Other|Survey|
79404452|NCT03152851|Procedure|Pressure stimulus group|
79581630|NCT06001762|Drug|Letrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
79581631|NCT06001762|Drug|Exemestane|Steroidal aromatase inhibitor, taken orally per institutional standard of care
79581632|NCT06001762|Drug|LHRH Agonist|Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
79581633|NCT06001671|Drug|BEBT-109|"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"
79581634|NCT05994482|Other|adenoma vs no adenoma|For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
79581635|NCT05994482|Other|colonoscopy vs no colonoscopy|For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
79740189|NCT02676076|Drug|CHF 5993 100/6/12.5 µg|
79740190|NCT02676076|Drug|CHF 1535 100/6 µg|
79404453|NCT01770067|Drug|CITA-RNPT|
79404454|NCT01770067|Procedure|Extraction of infected CIED|
79404455|NCT03152695|Device|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
79740191|NCT02537626|Device|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
79761064|NCT04550260|Radiation|Radiation|50-64Gy in total
79761065|NCT04542031|Other|Questionnaire|Questionnaire to be completed at 6 and 12 months
79761066|NCT04527432|Other|Survey|Survey at baseline, 6 and 12 months
79761067|NCT04527432|Diagnostic Test|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
79761068|NCT04522895|Drug|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
79761069|NCT04512131|Procedure|dialysis mode|intermittent hemodialysis or continuous renal replacement therapy
79404456|NCT03028597|Behavioral|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
79404457|NCT03028597|Behavioral|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
79404458|NCT03152461|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79404459|NCT04404673|Procedure|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
79581636|NCT05994482|Other|survey and expert panel|The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
79740192|NCT02537626|Device|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
79404460|NCT03150121|Procedure|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
79404461|NCT03150121|Procedure|Blood sample|5-10mL of blood will be drawn from participants.
79404462|NCT03150121|Device|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
79876209|NCT01046097|Biological|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
79876210|NCT01046175|Procedure|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
79277747|NCT05787405|Other|Artificial Intelligence methods|The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.
79277748|NCT05787353|Other|Exercise programme|Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
79876211|NCT01046175|Procedure|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
79740193|NCT04181554|Other|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
79740194|NCT02678650|Drug|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
79876212|NCT04009655|Other|music|music selected by musician
79876213|NCT00075387|Drug|Carboplatin|Given IA
79876214|NCT00075387|Drug|Cyclophosphamide|Given IV
79876215|NCT00075387|Drug|Etoposide Phosphate|Given IV
79740195|NCT02678650|Drug|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
79876216|NCT00075387|Other|Quality-of-Life Assessment|Ancillary studies
80031773|NCT04879108|Other|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
79740196|NCT04180150|Drug|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
79740197|NCT04180150|Drug|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
79876217|NCT00075387|Drug|Sodium Thiosulfate|Given IV
79876218|NCT00963131|Drug|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
79876219|NCT00963209|Drug|tamoxifen citrate|
79876220|NCT00963209|Other|laboratory biomarker analysis|
79876221|NCT00963209|Other|pharmacological study|
79876222|NCT00963287|Drug|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
79876223|NCT00961337|Biological|Trivalent inactivated influenza vaccine|one dose
79876224|NCT00963365|Drug|AZD6765|Single oral dose and single IV infusion of AZD6765
79876225|NCT00963365|Drug|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
79876226|NCT00963443|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
79876227|NCT00963443|Drug|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
79876228|NCT00963443|Drug|Placebo|Matching Placebo
79876229|NCT00963521|Biological|therapeutic autologous dendritic cells|
79876230|NCT00961493|Behavioral|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
79876231|NCT00961493|Behavioral|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
79876232|NCT00961727|Other|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; [1] an expert derived, multi-centre validated severity of illness score, [2] an inter-professionally developed documentation record into which the severity of illness score is embedded, [3] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and [4] an educator-developed education-implementation program.
79876233|NCT00963833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
79876234|NCT00964067|Other|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
79404463|NCT02081365|Behavioral|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
79581637|NCT05994313|Dietary Supplement|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
79581638|NCT05994313|Dietary Supplement|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
79581639|NCT05988164|Other|Eye Mask|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
79581640|NCT05986149|Behavioral|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
79581641|NCT05984524|Behavioral|Gamma-Music Based Intervention|Gamma or Control lights with Music-Based Intervention for 8 week period
79581642|NCT05982184|Other|Music|Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.
79581643|NCT05979519|Behavioral|Fresh Funds for Mom's|"Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks."
79581644|NCT05979519|Behavioral|Standard Medical care|Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.
79581645|NCT05979519|Behavioral|Medically Tailored Frozen Meals|Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
79581646|NCT05977023|Drug|NMDAE|Use of an NMDA enhancer for the treatment of bipolar depression
79581647|NCT05977023|Drug|Placebo Cap|Use of placebo as a comparator.
79581648|NCT05968586|Other|Body positioning|Body positioning of infants prone vs supine.
79581649|NCT05946824|Radiation|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
79581650|NCT05946824|Radiation|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
79581651|NCT05945940|Other|no intervention|no intervention
79581652|NCT05945641|Behavioral|Low Load Resistance training|Performing single leg knee extension exercise with using equivalent to ~30%1-RM to failure,
79581653|NCT05945641|Behavioral|Sprint/High Intensity Interval Training|Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
79581654|NCT05944133|Other|No intervention, observational retrospective study|No intervention
79581655|NCT05936632|Other|Discrete Choice Experiment (DCE)|DCE survey experiment
79876235|NCT00967655|Biological|panitumumab|
79581656|NCT05936177|Other|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
79581657|NCT05936008|Behavioral|Exercise MICT|Standard of care, exercise recommendations for people with stroke
79404464|NCT01674049|Dietary Supplement|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
79404465|NCT01674049|Dietary Supplement|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
79404466|NCT01674049|Other|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
79404467|NCT01674127|Drug|Methyldopa|
79404468|NCT01674127|Drug|Placebo|
79277749|NCT05786235|Other|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
79277750|NCT05786235|Other|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
79277751|NCT05781165|Other|Augmented reality|Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
79581658|NCT05936008|Behavioral|Exercise HIIT|The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
79581659|NCT05934331|Drug|LM302+Toripalimab|LM-302 in combination with Toripalimab.
79581660|NCT05931380|Drug|Orforglipron|Administered orally
79581661|NCT05931380|Drug|Placebo|Administered orally
79581662|NCT05928910|Device|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
79581663|NCT05928910|Other|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
79581664|NCT05925608|Combination Product|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
79581665|NCT05918692|Drug|BMF-500|Investigational Product
79581666|NCT05916560|Drug|LY3437943|Administered SC.
79581667|NCT05907616|Behavioral|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
79581668|NCT05906706|Drug|dupilumab|Subcutaneous (SC) administration
79404469|NCT02081443|Drug|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
79581669|NCT05903885|Other|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the DMV site by the research staff.
79581670|NCT05903885|Other|Mailed Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly by mailing without any personal (face-to-face) contact.
79581671|NCT05900401|Other|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
79876236|NCT00967655|Drug|capecitabine|
79581672|NCT05900401|Procedure|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
79581673|NCT05900401|Drug|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
79581674|NCT05900401|Drug|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
79581675|NCT05900401|Drug|Rituximab|Rituximab on study day -6
79581676|NCT05900401|Drug|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
79581677|NCT05898594|Procedure|Low-dose Computed Tomography|Per standard care
79581678|NCT05893082|Device|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
79581679|NCT05888506|Dietary Supplement|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
79581680|NCT05888506|Dietary Supplement|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
79581681|NCT05883358|Drug|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
79581682|NCT05882916|Device|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
79876237|NCT00967655|Drug|irinotecan hydrochloride|
79876238|NCT00967655|Procedure|neoadjuvant therapy|
79581683|NCT05882916|Behavioral|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
79740198|NCT04180150|Drug|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
79876239|NCT00967655|Procedure|therapeutic conventional surgery|
79876240|NCT00967655|Radiation|radiation therapy|
79876241|NCT01563419|Device|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
79876242|NCT00546377|Biological|filgrastim|
79876243|NCT00546377|Biological|pegfilgrastim|
79581684|NCT05881473|Diagnostic Test|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
79740199|NCT00643396|Radiation|thoracic radiotherapy|
79740200|NCT02678338|Drug|Hu5F9-G4|
79740201|NCT00642226|Procedure|Grid Laser|ETDRS Grid Laser
79740202|NCT00642226|Procedure|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
79740203|NCT02675608|Biological|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
79277752|NCT05775744|Other|Tight postpartum blood pressure control|The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
79740204|NCT02678494|Other|Neurofeedback training|
79740205|NCT02677402|Other|immersion|
79740206|NCT02677480|Dietary Supplement|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
79277753|NCT05774548|Other|In-depth interviews (IDI)|In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
79404470|NCT02081443|Drug|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
79581685|NCT05875129|Device|VAVA prototype|Cognitive behavioral therapy for insomnia
79740207|NCT02677480|Dietary Supplement|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
79740208|NCT00996918|Drug|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
79740209|NCT00996918|Drug|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
79740210|NCT02675530|Drug|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
79740211|NCT04179994|Other|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
79404471|NCT03725449|Other|Best Practice|Receive standard of care
79404472|NCT03725449|Behavioral|mySmartCheck|Receive access to mySmartcheck program
79404473|NCT03725449|Other|Survey Administration|Ancillary studies
79404474|NCT01674205|Biological|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
79404475|NCT01674205|Biological|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
79404476|NCT01674205|Biological|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
79404477|NCT01674205|Biological|Vaccine placebo (Leibovitz-15 [L-15])|
79404478|NCT01674205|Biological|Vaccine placebo (FluMist®)|
79581686|NCT05872022|Other|No Intervention|This is a non-interventional study, therefore no intervention is used.
79581687|NCT05870176|Behavioral|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
79581688|NCT05870176|Behavioral|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
79740212|NCT04179994|Other|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
79740213|NCT04179994|Other|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
79761070|NCT04509427|Behavioral|Instructional handouts|Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program
79761071|NCT04509427|Behavioral|Physical therapist instruction and monitoring via teleconferencing|The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.
79761072|NCT04509427|Behavioral|Web-based instructional videos|Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.
79761073|NCT04509427|Behavioral|Posture training|Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
79761074|NCT04509427|Behavioral|Marching in place|Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
79876244|NCT00546377|Biological|rituximab|
79876245|NCT00546377|Biological|sargramostim|
79876246|NCT00546377|Drug|cyclophosphamide|
79876247|NCT00546377|Drug|mitoxantrone hydrochloride|
79876248|NCT00546377|Drug|pentostatin|
80031774|NCT04879108|Other|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
79277754|NCT05774548|Other|Focus group discussion (FGD)|Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
79277755|NCT05763706|Device|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
79277756|NCT05760027|Other|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
79277757|NCT05760027|Other|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
79404479|NCT03157063|Diagnostic Test|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
79404480|NCT03154411|Drug|ABY-029|A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
79581689|NCT05867186|Behavioral|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
79581690|NCT05866315|Drug|Remimazolam|Administer remimazolam
79581691|NCT05866315|Drug|Desflurane|administer desflurane
79876249|NCT00546377|Genetic|fluorescence in situ hybridization|
79876250|NCT00546377|Genetic|gene rearrangement analysis|
80031775|NCT04884880|Drug|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
79404481|NCT03151057|Drug|Idelalisib 100 MG|100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
79404482|NCT03151057|Drug|Placebo Oral Tablet|placebo
79404483|NCT01674283|Drug|Glucagon|
79404484|NCT01674283|Drug|placebo|
79404485|NCT04404517|Drug|Adalimumab|Monoclonal antibody used in IBD treatment
79581692|NCT05866315|Drug|Remifentanil|administer remifentanil
79581693|NCT05863052|Biological|Immunotherapy|immunotherapy
79581694|NCT05860504|Diagnostic Test|Echocardiography|All patients in the study will be examined with echocardiography
79581695|NCT05860504|Diagnostic Test|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
79581696|NCT05860504|Diagnostic Test|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
79581697|NCT05843799|Drug|ILB-202|Single i.v. infusion
79876251|NCT00546377|Genetic|polymerase chain reaction|
79876252|NCT00546377|Genetic|protein expression analysis|
79876253|NCT00546377|Other|flow cytometry|
79876254|NCT00546377|Procedure|biopsy|
79876255|NCT00967889|Genetic|gene expression analysis|
79876256|NCT00967889|Genetic|protein analysis|
79876257|NCT00967889|Other|biologic sample preservation procedure|
79876258|NCT00967889|Other|laboratory biomarker analysis|
79876259|NCT00964301|Other|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
79876260|NCT00964301|Other|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
79876261|NCT00967967|Drug|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
79876262|NCT00968045|Drug|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
79876263|NCT00964379|Procedure|intraperitoneal or extraperitoneal colostomy|creation of colostomy
79876264|NCT00964457|Drug|cetuximab|cetuximab 500mg per meter square every second week
79876265|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
79876266|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
80031776|NCT04884880|Drug|The placebo 10g|Placebo 10g，once daily，4 weeks
80031777|NCT04872244|Device|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
80031778|NCT04872244|Drug|Levonorgestrel Drug Implant Product|intrauterine administration
80031779|NCT04872322|Drug|Ropivacaine 0.5% Injectable Solution|Participants will receive the nerve block preoperatively using 0.5% ropivacaine
80031780|NCT04872322|Drug|Ropivacaine 0.25% Injectable Solution|Participants will receive the nerve block preoperatively using 0.25% ropivacaine
79277758|NCT05747534|Drug|Larazotide Acetate|AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
79277759|NCT05747534|Drug|Placebo|Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
79581698|NCT05843799|Drug|Placebo|Single i.v. infusion
80031781|NCT04872322|Drug|Percocet Pill|After surgery participants will be given a prescription for Percocet to be taken as needed for pain
79404486|NCT04688905|Diagnostic Test|Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion|Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.
79404487|NCT01674517|Drug|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
79581699|NCT05841212|Other|DBT for ADHD|See information included in arm/group description.
80031782|NCT04872322|Drug|Norco Pill|After surgery participants will be given a prescription for Norco to be taken as needed for pain
80031783|NCT04872322|Procedure|Foot/Ankle Surgery|Participant will undergo foot or ankle surgery and receive a popliteal nerve block
80031784|NCT04879264|Diagnostic Test|self-rating scale for severity of sleep disorders|Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
80031785|NCT04879264|Diagnostic Test|self-rating scale for distress caused by sleep disorders|Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
79404488|NCT03159793|Behavioral|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
79404489|NCT03159793|Behavioral|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
79581700|NCT05839119|Drug|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
79581701|NCT05839119|Combination Product|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
79581702|NCT05832086|Behavioral|Fasting Mimicking Diet (FMD)|Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.
79581703|NCT05832086|Behavioral|Standard Anti-Cancer Diet|Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
79581704|NCT05831735|Behavioral|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
79876267|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
79876268|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
79876269|NCT00964691|Drug|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
79876270|NCT00964691|Drug|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
79277760|NCT05746234|Behavioral|Emotion Regulation Course|"Each module contains a) the session outline, b) review of previous session's homework, c) theoretical background and module's rationale, d) skills activities, and e) homework assignment.~Each group will attend five 1.5-hour sessions with their allocated instructor. Participants in both groups will receive the same training modules in the same chronological order. For consistency across modalities, participants will receive an instructor's manual containing the core material for facilitating the ER4ALL training, and a companion students' workbook with supporting information and activities."
79277761|NCT05735886|Dietary Supplement|Softgel containing placebo|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
79581705|NCT05831735|Behavioral|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
79581706|NCT05824767|Drug|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
80031786|NCT04871932|Biological|Recently Vaccination|
79277762|NCT05735886|Dietary Supplement|Softgel containing 250mg of Urolithin A (Mitopure)|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
79277763|NCT05727605|Behavioral|Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test|"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
79277764|NCT05727605|Diagnostic Test|MRI|"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI & ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
79277765|NCT05727605|Behavioral|Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI|Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
79277766|NCT05727605|Other|Toxicity scoring|During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
79277767|NCT05713110|Drug|tazemetostat|"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
79581707|NCT05824351|Device|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
79740214|NCT04179916|Diagnostic Test|stimulation in virtual reality|"HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
79740215|NCT02675374|Drug|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
79581708|NCT05824351|Device|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
79740216|NCT02675374|Drug|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
79876271|NCT00964769|Biological|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
79876272|NCT00964847|Behavioral|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
80031787|NCT03048526|Device|NovaTears®|Topical eye drops for lubrication of the ocular surface
79581709|NCT05824351|Device|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
79581710|NCT05823688|Device|Electrical Impedance Tomography|Measure of regional ventilation by Electrical Impedance Tomography (EIT) before and during pneumoperitoneum
79740217|NCT05662930|Behavioral|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
80031788|NCT03048526|Device|Hydrabak®|Eye drops
80031789|NCT04871620|Diagnostic Test|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
80031790|NCT04879186|Procedure|Peripheral endovascular angioplasty|Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
80031791|NCT04879030|Drug|Beta-Lactams|The patient was randomized to use beta-lactams antibiotic
80031792|NCT04879030|Drug|Fluoroquinolone|The patient was indicated to use a combination of beta-lactams and fluoroquinolones
79876273|NCT00964847|Behavioral|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
79740218|NCT05662930|Behavioral|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
79740219|NCT05662930|Behavioral|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
79740220|NCT05662930|Behavioral|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
79740221|NCT05662930|Behavioral|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
79740222|NCT05662930|Behavioral|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
79740223|NCT02678260|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
79740224|NCT02677168|Device|cNEP|continuous negative external pressure
79277768|NCT05713110|Drug|HMPL-689|"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
79277769|NCT05709106|Drug|Rimegepant 75 MG|Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
79581711|NCT05823376|Drug|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10^9/L; Drug administration will be stopped when PLT≥100×10^9/L.
79581712|NCT05822791|Diagnostic Test|Prolonged cardiac monitoring|Prolonged cardiac monitoring
79277770|NCT05702047|Behavioral|Nose-only breathing|Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.
79277771|NCT05702047|Behavioral|Mouth-only breathing|Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
79277772|NCT05687578|Diagnostic Test|Diagnostic Only|This is an observational study only using non-invasive diagnostic testing
79277773|NCT05687370|Procedure|Modified dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
79404490|NCT01923649|Drug|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
79277774|NCT05687370|Procedure|Long-axis technique|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
79277775|NCT05683444|Drug|Octreotide infusion|Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
79277776|NCT05683444|Drug|Saline infusion|Saline Infusion
79277777|NCT05671692|Drug|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
79404491|NCT01923649|Drug|Placebo|Placebo for somatuline slow release 90 mg
79404492|NCT01670071|Drug|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
79277778|NCT05671692|Drug|Placebo|Same as active comparator, except placebo dispensed.
79404493|NCT01670071|Drug|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
79581713|NCT05822791|Diagnostic Test|ECG|Electrocardiogram
79581714|NCT05819242|Diagnostic Test|Angulus|Smartphone app
79581715|NCT05816655|Drug|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
79581716|NCT05816655|Drug|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
79581717|NCT05811039|Device|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
79740225|NCT04181398|Diagnostic Test|Anthropometry|"Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio will be calculated from measured height and waist circumference."
79740226|NCT04181398|Diagnostic Test|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
79277779|NCT05669274|Other|Milk containing A1 and A2 beta-casein|Milk dose for 2 weeks
79581718|NCT05802004|Device|Acoustic Stimulation (STIM)|During the in-lab overnight, the Dreem 2 Headband will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power). Tones are phase-locked to the up-phase of the delta wave. Tone delivery is paused when an arousal is detected.
79581719|NCT05802004|Device|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear the Dreem 2 Headband, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
79740227|NCT04181398|Diagnostic Test|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
79277780|NCT05669274|Other|Milk containing only A2 beta-casein|Milk dose for 2 weeks
79876274|NCT00968357|Drug|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
79876275|NCT00968435|Other|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
79277781|NCT05667090|Other|Vitamin D|Oral supplementaiton of 576,000 IU once a week of vitamin D3 for 4 weeks
79404494|NCT01674751|Other|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
79404495|NCT01427309|Biological|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
79404496|NCT01427309|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
79740228|NCT04181398|Other|Questionnaire|General questionnaire on cardiovascular risk factors
79404497|NCT04747093|Biological|CAR-ITNK cells|CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
79404498|NCT01674985|Biological|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
79404499|NCT01426373|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
79404500|NCT04763785|Device|Corneal tomography with Eyestar 900|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
79581720|NCT05802004|Device|Daily acoustic stimulation (STIM2)|During the ~2 weeks at home, the Dreem 2 Headband will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power). Tones are phase-locked to the up-phase of the delta wave. Tone delivery is paused when an arousal is detected.
79740229|NCT04181398|Diagnostic Test|Blood sample|Blood sample for hs-CRP
79740230|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
79740231|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
79740232|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Coleman technique
79740233|NCT02677012|Procedure|Reconstructive Surgery|Undergo reconstructive surgery
79740234|NCT02677090|Drug|Placebo (including Maltodextrin)|
79740235|NCT02677090|Drug|Dose 1 - Promitor®|
79740236|NCT02677090|Drug|Dose 2 - Promitor®|
79740237|NCT02677090|Drug|Dose 3 - Promitor®|
79876276|NCT00965003|Procedure|MRI scan|Standard of Care
79876277|NCT05253287|Drug|Growth Hormone|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
79876278|NCT00968513|Behavioral|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
79277782|NCT05667090|Other|Placebo|Oral supplementaiton of placebo once a week for 4 weeks
79277783|NCT05663606|Combination Product|Happy Bob|Application, which gives stars when subject reachs Time In Range
79277784|NCT05663606|Device|CGM|Dexcom CGM
79404501|NCT04763785|Device|Corneal tomography with Pentacam|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
79404502|NCT04763785|Device|Biometry with IOL-Master|Non-invasive biometry for presurgical intraocular lens calculation
79404503|NCT04763785|Other|retrospective analysis, no intervention|retrospective analysis of 4500 existing, fully anonymised picture data
79432880|NCT00604045|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
79876279|NCT00968513|Behavioral|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
79876280|NCT00968513|Behavioral|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
79876281|NCT00968591|Drug|Everolimus|
79876282|NCT00968903|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
79876283|NCT00969059|Drug|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
79876284|NCT00969059|Drug|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
79876285|NCT00969137|Drug|saline|intravenous saline
79876286|NCT00969137|Drug|Nicotine|Intravenous nicotine
79876287|NCT00965315|Drug|Rosuvastatin,SFC fenofibrate|"Rosuvastatin 10 mg once daily~Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
79876288|NCT00969215|Device|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
79876289|NCT00969293|Drug|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
79876290|NCT00969371|Device|posterior chamber IOL implantation|
80031793|NCT04871386|Behavioral|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
80031794|NCT04871386|Behavioral|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
79277785|NCT05628740|Drug|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
79404504|NCT04043117|Other|Body Image evaluation|"Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves."
79581721|NCT05802004|Device|No daily acoustic stimulation (SHAM2)|During the ~2 weeks at home, the participant will wear the Dreem 2 Headband, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
79581722|NCT05799209|Device|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
79581723|NCT05799209|Device|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
79277786|NCT05628740|Drug|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
79277787|NCT05628740|Drug|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
79876291|NCT00969371|Device|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
79876292|NCT00969449|Drug|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
79876293|NCT00969449|Drug|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
79876294|NCT00965393|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
79876295|NCT00965393|Drug|Placebo|Systemic infusion of placebo (saline)
79876296|NCT00965393|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
79876297|NCT00965471|Drug|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
79876298|NCT00965471|Drug|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
79876299|NCT00965549|Drug|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
79876300|NCT00965549|Drug|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
79876301|NCT00965549|Drug|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
79876302|NCT00969527|Dietary Supplement|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
79581724|NCT05787379|Behavioral|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete ~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered ~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
79404505|NCT04043117|Other|Self esteem evaluation|"Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false."
79876303|NCT00969527|Dietary Supplement|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
80031795|NCT04878796|Diagnostic Test|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
79581725|NCT05787379|Behavioral|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
79581726|NCT05787119|Other|Conventional therapy|The CT consists of 1 session of 30 minutes of physical therapy (type of re-education established according to the pain at rest and during movement assessed every day) and 1 session of 30 minutes of occupational therapy (type of re-education established according to the pain at rest and during movement assessed every day). CT is performed 5 days a week.
79740238|NCT04179682|Procedure|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
79740239|NCT04179604|Drug|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
79876304|NCT00969605|Procedure|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
79876305|NCT00969683|Device|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
79404506|NCT03885817|Behavioral|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
79404507|NCT03885817|Other|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
79404508|NCT03858751|Drug|Placebo oral capsule|Placebo capsule before bedtime
79404509|NCT03858751|Drug|LTM1201AZ|LTM1201AZ oral capsule before sleep
79404510|NCT03858751|Drug|LTM1201AT|LTM1201AT oral capsule before sleep
79404511|NCT03858751|Drug|LTM1201AG|LTM1201AG oral capsule before sleep
79404512|NCT03858751|Drug|LTM1201AD|LTM1201AD oral capsule before sleep
79404513|NCT01426217|Device|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
79404514|NCT01675375|Device|Eye Shield|one application following refractive surgery
79404515|NCT04042415|Other|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
79876306|NCT00969683|Device|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
79876307|NCT00965705|Behavioral|Therapy|Individual Therapy and Group Therapy
79876308|NCT00965783|Other|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
79876309|NCT00965783|Other|Extension|Bedtime is extended by 2 hours per night for 4 nights
79404516|NCT04042415|Other|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
79404517|NCT03884647|Device|DELPhI system|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
79740240|NCT04179604|Drug|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
79740241|NCT05277142|Other|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
79277788|NCT05628740|Drug|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
79277789|NCT05628740|Drug|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
79876310|NCT00969839|Device|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
79277790|NCT05628740|Drug|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) [2x Placebo capsules] in a parallel fashion according to a prespecified randomization schedule
79277791|NCT05622981|Behavioral|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
79876311|NCT00965861|Other|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
79277792|NCT05619614|Device|eye-tracking glasses|endoscopists wear eye-tracking glasses during real-time colonoscopy
80031796|NCT04870996|Device|tDCS|tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
79277793|NCT05604937|Other|Shi's traumatology osteopathic manipulation|Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.
79277794|NCT05604937|Drug|Merislon|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
79404518|NCT03856099|Drug|TTAC-0001|"Investigational product (IP): TTAC-0001~Treatment groups: 3 dose groups~Dose group A : TTAC-0001 16 mg/kg on D1 and D15~Dose group B : TTAC-0001 20 mg/kg on D1 and D15~Dose group C : TTAC-0001 24 mg/kg on D1 and D15~Cycle: 4 weeks (28 days per cycle)"
79404519|NCT01425749|Biological|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
79581727|NCT05787119|Other|ARMT|The ARMT consists of 1 session of 30 minutes (type of rehabilitation established according to the pain at rest and during movement evaluated daily). ARMT is performed 5 days a week for 1 month.
79404520|NCT03852901|Drug|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
79404521|NCT01675687|Behavioral|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
79581728|NCT05787119|Other|cortical reactivity|An electroencephalogram was taken at the start and end of the study to study cortical reactivity during the performance of 3 different tasks repeated 30 times: a resting task (consisting of looking at a cross on a screen), a motor imagery task (consisting of imagining performing wrist flexions/extensions) and a motor execution task (consisting of performing wrist flexions/extensions).
79581729|NCT05787119|Other|Fluidity of movement|Motion capture at the start and end of the study to study the fluidity of movement during 3 different tasks repeated 30 times: a resting task (looking at a cross on a screen), a motor imagery task (imagining wrist flexions/extensions) and a motor execution task (performing wrist flexions/extensions).
79740242|NCT05277142|Device|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
79740243|NCT02673580|Other|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
79740244|NCT02673580|Other|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
79740245|NCT02675218|Other|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
79740246|NCT02673502|Dietary Supplement|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
79740247|NCT02673502|Dietary Supplement|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
79740248|NCT04179370|Other|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
79404522|NCT01403987|Behavioral|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
79404523|NCT01403987|Behavioral|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
79404524|NCT01403987|Other|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
79876312|NCT04009187|Behavioral|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
79876313|NCT04009187|Behavioral|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
79277795|NCT05592808|Device|Extracorporeal Shockwave Therapy (ESWT)|Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
79581730|NCT05760521|Other|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
79876314|NCT00969917|Drug|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
79277796|NCT05592808|Other|Low-Dye Taping|After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
79581731|NCT05754398|Behavioral|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
79740249|NCT00643474|Device|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
79277797|NCT05592808|Other|Kinesio Taping|After ESWT application, Kinesio Taping will be applied 3 times, once a week.
79277798|NCT05583032|Device|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
79581732|NCT05741502|Drug|Clozapine|We will assess inflammatory/immune marker labs
79581733|NCT05741502|Drug|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
79740250|NCT00643474|Device|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
79740251|NCT02537704|Behavioral|Group Lifestyle Balance Program|
79740252|NCT02673658|Behavioral|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
79277799|NCT05553392|Device|StrataXRT|"StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel.~When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns."
79404525|NCT01403987|Behavioral|Pager|"The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure."
79404526|NCT01675843|Procedure|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
79404527|NCT01675921|Other|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
79404528|NCT01675999|Other|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
79404529|NCT01675999|Other|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
79581734|NCT05729022|Device|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
79581735|NCT05729022|Radiation|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
79581736|NCT05725070|Drug|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
79740253|NCT02673658|Behavioral|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
79404530|NCT01675999|Other|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
79277800|NCT05553392|Drug|Aquaphor|"Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather."
79404531|NCT01425359|Drug|Ranolazine|
79581737|NCT05716217|Other|Arm training|Daily arm training program
79581738|NCT05706727|Drug|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
79277801|NCT05530421|Drug|Selinexor|Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
80031797|NCT04870996|Behavioral|Cognitive Training|All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
80031798|NCT04871230|Diagnostic Test|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
80031799|NCT04871230|Diagnostic Test|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
79277802|NCT05530421|Drug|Venetoclax|Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
79277803|NCT05530421|Drug|Dexamethasone|Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
79277804|NCT05518734|Drug|VX-708|Solution for intravenous (IV) administration.
79277805|NCT05518734|Drug|Itraconazole|Solution for oral administration.
79277806|NCT05518734|Drug|Midazolam|Solution for oral administration.
79277807|NCT05518734|Drug|Placebo|Placebo matched to VX-708 for IV administration.
79404532|NCT01425359|Drug|Ranolazine placebo|
79404533|NCT02082145|Device|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
79404534|NCT03846895|Device|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
79404535|NCT04764409|Procedure|Chemoembolization|Transarterial Chemoembolization (TACE)
79404536|NCT04764409|Procedure|Chemoinfusion|Transarterial Infusion (TAI)
79404537|NCT04764565|Dietary Supplement|Nuun Instant|Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).
79404538|NCT04764565|Other|Water|water
79581739|NCT05706727|Drug|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
79432881|NCT00604045|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
79432882|NCT05582954|Behavioral|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
79432883|NCT05582954|Behavioral|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
79432884|NCT05246683|Other|observational|registry
79581740|NCT05705648|Dietary Supplement|medium chain triglyceride oil|Medium chain triglyceride oil
79581741|NCT05705648|Dietary Supplement|Safflower oil|Safflower oil
79581742|NCT05701280|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
79581743|NCT05701280|Other|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
79581744|NCT05700032|Diagnostic Test|high MI impulses|patients will receive intermittent high MI impulses(>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
79581745|NCT05700032|Diagnostic Test|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
79581746|NCT05695742|Other|Active Smoking|Being active smoker
79581747|NCT05695742|Other|Passive smoker|Being exposed to secondhand smoke
79581748|NCT05695742|Other|Non-smoker|Not being an active or passive smoker.
79581749|NCT05679388|Drug|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
79581750|NCT05679388|Drug|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
79581751|NCT05679388|Drug|Itraconazole|A drug used to treat fungal infections.
79581752|NCT05678101|Device|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
79581753|NCT05678101|Device|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
79581754|NCT05655182|Biological|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10^6 PFU
79581755|NCT05655182|Biological|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10^7 PFU
80031800|NCT04871230|Diagnostic Test|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
79740254|NCT04178356|Other|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
79277808|NCT05515679|Behavioral|The BRAIN App|The BRAIN App will be the first-ever artificial intelligence enabled cognitive stimulation therapy app, specifically designed for PWD. The goal of the app is to foster positive relationships between the care triad.
79404539|NCT04764565|Dietary Supplement|Nuun Electrolyte|Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
79740255|NCT04178356|Other|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
79277809|NCT05513365|Drug|Goserelin 10.8 mg|Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
79740256|NCT02675140|Drug|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
79404540|NCT04404751|Combination Product|Iodised salt with Iron, Folic acid and Vitamin B12|Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
79740257|NCT02675140|Drug|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
79277810|NCT05513365|Drug|Bicalutamide 50 mg|Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
79404541|NCT01403051|Drug|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
79404542|NCT01403051|Drug|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
79404543|NCT01403051|Drug|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
79404544|NCT01403051|Drug|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
79581756|NCT05655182|Drug|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU).
79740258|NCT00642538|Drug|MKC253 Inhalation Powder|Inhalation Powder, prandial
79740259|NCT00642538|Drug|Technosphere Inhalation Powder|Inhalation Powder, prandial
79277811|NCT05513365|Drug|Dutasteride 0.5 mg|Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
79404545|NCT01403051|Drug|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
79404546|NCT03873337|Behavioral|Persistence Targeted Smoking Cessation in SMI (PTSC-S)|All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
79404547|NCT03873337|Drug|Nicotine patch|All participants will receive 10 weeks of nicotine patch
79404548|NCT04404829|Other|Manual Therapy|"The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM."
79581757|NCT05634447|Drug|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
79581758|NCT05628038|Drug|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
79581759|NCT05628038|Drug|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
79740260|NCT00642538|Drug|subcutaneous injection|10µg Exenatide, prandial
79740261|NCT00644254|Procedure|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
79740262|NCT02674906|Drug|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
79740263|NCT02674906|Drug|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
80031801|NCT04582318|Biological|NGM621|NGM621 will be administered via IV infusion
80031802|NCT04582318|Biological|Placebo|Placebo will be administered via IV infusion
80031803|NCT04878718|Biological|Fecal Microbiota Transplant; Vancomycin|Subject will be treated with vancomycin followed by fecal microbiota transplant
79404549|NCT04747639|Other|500 ml glucose-depleted apple juice|
79404550|NCT04747639|Other|500 ml conventional apple juice|
79404551|NCT04747639|Other|250 ml glucose-depleted apple juice|
79404552|NCT04747639|Other|250 ml conventional apple juice|
79581760|NCT05628038|Drug|5FU|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
79581761|NCT05628038|Drug|folinic acid|400 mg/m2 q2w
79581762|NCT05628038|Drug|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
79581763|NCT05628038|Drug|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
79740264|NCT02674672|Device|VenaTech® (VenaTech Retrievable Filter)|
79740265|NCT02673268|Procedure|Mastectomy|
79740266|NCT02673268|Device|Da Vinci Robot Xi|
79740267|NCT04179214|Other|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
79876315|NCT05246969|Other|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
79876316|NCT05194163|Drug|MW150|oral-delivered capsule of study drug
79876317|NCT05194163|Drug|Placebo|oral delivered capsule matched to study drug capsule
79876318|NCT00966173|Device|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
79277812|NCT05497518|Other|Observational study - registry|The Network is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
79277813|NCT05492604|Other|Clinical examination|Cinical examination carried out during a consultation for the follow-up of the patient
79277814|NCT05492604|Other|Functional scales|The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department
79277815|NCT05492604|Diagnostic Test|Walking test|Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
79277816|NCT05487313|Procedure|Erector spinae plane block|fascial plane injection guided by fluoroscopic device after ultrasound guidance
79404553|NCT03873259|Device|Burst Wave Lithotripsy|Fragment upper urinary tract stones
79404554|NCT03871231|Device|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
79404555|NCT04115748|Drug|Filgotinib|Tablets administered orally once daily with or without food
79404556|NCT04115748|Drug|Adalimumab|Injection administered subcutaneously once every 2 weeks
79581764|NCT05628038|Drug|Raltitrexed|2 mg/m² q2w and 3 mg/m² q3w
79581765|NCT05628038|Radiation|Radiation|"25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor."
79277817|NCT05473455|Procedure|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
79277818|NCT05454735|Procedure|coronary artery bypass surgery|coronary artery bypass surgery
79404557|NCT04115748|Drug|Placebo to match filgotinib|Tablets administered orally once daily with or without food
79404558|NCT04115748|Drug|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
79404559|NCT04747015|Drug|Oxytocin|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation
79404560|NCT04747015|Drug|Oxytocin|5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
79404561|NCT04747015|Procedure|cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus. Meanwhile (CCT ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end
79404562|NCT03755713|Drug|ASP0892|Intradermal
79581766|NCT05626829|Drug|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
79581767|NCT05626088|Other|No Intervention|This is a non-interventional study.
79581768|NCT05621018|Device|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
79740268|NCT04179214|Other|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
79876319|NCT00966251|Drug|CT-011|CT-011
79876320|NCT00966329|Drug|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
79876321|NCT00966329|Drug|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~or ATV/unboosted (in a regimen without tenofovir)~or 1 NNRTI (nevirapine or efavirenz)."
79876322|NCT00970229|Drug|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not > 10% of 8 mCi limit)of [123I]MNI-420, followed by SPECT imaging.
79876323|NCT00970385|Drug|CHOP21|"CHOP regimen:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
80031804|NCT03048916|Other|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
79740269|NCT00641290|Device|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
79740270|NCT00643630|Device|Tetrix|Twice daily topical application
79740271|NCT00643630|Device|Tetrix|Twice daily topical application
79876324|NCT00970385|Drug|VIP/ABVD|"VIP regimen:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D"
79876325|NCT00970385|Radiation|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
79277819|NCT05454735|Procedure|aortic valve replacement surgery|aortic valve replacement surgery
79277820|NCT05442879|Behavioral|Knowledge Translation Intervention|The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.
79277821|NCT05442879|Behavioral|Educational handout|Educational handout describing a commonly cited ACL-IPP.
79277822|NCT05442749|Drug|Niraparib|"Eligible patients will receive niraparib once daily, per os, continuously until loss of clinical benefit, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.~300 mg/day, continuously for patients with TB >1.5- 3 ULN and/or ASAT/ALAT ≤5ULN.~Or 200mg/day initial dosing for patients with TB >1.5 ULN and up to 3ULN and/or ASAT/ALAT > 2.5 ULN and up to 5 ULN with increase to 300mg/day if 1) liver safety lab tests improve to Grade 1 according to NCI criteria (based on total bilirubin and AST/ALT) with bilirubin < 1.5ULN) and 2) no grade >1 related AE are reported."
79277823|NCT05441488|Drug|Placebo|treatment per os
79277824|NCT05441488|Drug|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
79277825|NCT05437120|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
79404563|NCT03755713|Drug|Placebo|Intradermal; normal saline solution
79404564|NCT04403815|Procedure|vascular access for coronary procedures|comparison of x-rays exposition of interventional cardiologist according to vascular access used
79740272|NCT01160744|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
79740273|NCT01160744|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
79740274|NCT01160744|Drug|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
79740275|NCT01160744|Drug|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
79740276|NCT01160744|Drug|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
79740277|NCT01160744|Drug|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
79740278|NCT02677246|Drug|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
79277826|NCT05404633|Device|Ergogycle prototype testing for acceptability|The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.
79277827|NCT05361655|Drug|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
79277828|NCT05361655|Drug|Aromatase inhibitor|Aromatase inhibitor therapy
79404565|NCT04747171|Drug|intrathecal Magnesium|intrathecal adjuvants to bupivacaine
79876326|NCT00966485|Drug|80 mg ASA dosing|
79404566|NCT04747171|Drug|intrathecal dexamthasone|intrathecal adjuvants to bupivacaine
79404567|NCT04747171|Drug|intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
79404568|NCT02082769|Drug|Febuxostat|
79404569|NCT02082769|Drug|Allopurinol|
79404570|NCT03751423|Drug|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
79740279|NCT02673112|Behavioral|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
79740280|NCT02673112|Behavioral|Light stretching (LS)|Brief daily stretching routine.
79740281|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
79740282|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
79740283|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
79740284|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
79740285|NCT04181164|Other|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
79876327|NCT00966485|Drug|500 mg ASA dosing|
79876328|NCT00966563|Drug|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
79876329|NCT00966563|Drug|Placebo|
79876330|NCT00970541|Dietary Supplement|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
79876331|NCT00970541|Dietary Supplement|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
79740286|NCT04181164|Other|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
79902197|NCT03364530|Procedure|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
79277829|NCT05359003|Behavioral|12-week physical activity program|Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
79277830|NCT05355740|Drug|Corsodyl|Corsodyl (a chlorhexidine mouthwash) will be used to rinse the mouth for one minute with 10 ml twice daily during ten days after oral surgery
79277831|NCT05348395|Other|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
79404571|NCT03751423|Drug|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
79404572|NCT03751423|Drug|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
79404573|NCT03751423|Drug|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
79404574|NCT03751423|Drug|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
79740287|NCT04181164|Biological|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
79740288|NCT02672800|Behavioral|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
79740289|NCT04180774|Biological|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
79740290|NCT02674828|Behavioral|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
79740291|NCT02674828|Other|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
79740292|NCT01160354|Drug|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
79404575|NCT04972188|Drug|ZYIL1 Capsule|NLRP3 inflammasome inhibitor
79404576|NCT01676623|Behavioral|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
79404577|NCT01676623|Behavioral|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
79404578|NCT01676623|Behavioral|Mass media campaign|Alive & Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
79404579|NCT03746509|Device|Laryngeal Vibration (Treatment)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
79404580|NCT03746509|Device|Laryngeal Vibration (Comparator)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
79404581|NCT03745729|Drug|allopurinol sustained-release capsules|allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
79404582|NCT03745729|Drug|placebo capsules|placebo sustained-release capsules, once a day, one pill at a time
79404583|NCT04904952|Drug|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
79277832|NCT05333003|Drug|Semaglutide|The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
79404584|NCT04904952|Drug|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
79740293|NCT01160354|Drug|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
79876332|NCT04083287|Other|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
79277833|NCT05333003|Other|Placebo|Placebo will be provided to participants
79277834|NCT05316831|Biological|PCV13|Pneumococcal polysaccharides conjugated to CRM197 carrier protein
79740294|NCT00643786|Drug|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
79277835|NCT05316831|Biological|PPSV23|Pneumococcal polysaccharides
79404585|NCT04763863|Other|Body Assessment Tool|Assessment tool to evaluate stoma to find proper ostomy products
79404586|NCT03661411|Drug|Aspirin|100mg qd
79404587|NCT03661411|Drug|Clopidogrel 75mg|75mg（after first dose of 300mg）qd
79404588|NCT03661411|Drug|Alteplase|Iv at 0.9 milligrams per kilogram (mg/kg)
79404589|NCT04756596|Diagnostic Test|DDVIT testing|One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
79740295|NCT00643786|Drug|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
79740296|NCT04178512|Drug|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
79404590|NCT04756596|Diagnostic Test|ETDRS testing|The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
79404591|NCT03827941|Other|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
79404592|NCT03827941|Other|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
79581769|NCT05619146|Device|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
79581770|NCT05617625|Drug|Busulfan|0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
79740297|NCT02674360|Behavioral|SDM Training|
79876333|NCT04083287|Other|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
79876334|NCT00970619|Device|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
79876335|NCT00970697|Drug|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
79581771|NCT05617625|Drug|Melphalan|70 mg/m^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
79581772|NCT05617625|Drug|Fludarabine|25 mg/m^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
79581773|NCT05617625|Device|CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)|CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
80031805|NCT03048916|Other|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
79277836|NCT05315635|Other|Questionnaire|"Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)"
79277837|NCT05308056|Device|Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)|The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
79277838|NCT05308017|Device|Richard Wolf 24F Laser scope|24F Laser with HoLEP
79277839|NCT05308017|Device|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
79432885|NCT03587246|Diagnostic Test|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
79432886|NCT01798459|Drug|Methylphenidate|
79432887|NCT03587090|Diagnostic Test|echocardiography|echocardiography by subcostal and transhepatic views
79740298|NCT04179292|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
79740299|NCT04179292|Other|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
79432888|NCT04143308|Other|Simultaneous training of walking and cognitive group|"Device:~SWATCH system (App & controller)~Wearable technology Fitness wristband & APP"
79740300|NCT01160198|Drug|ferrous ascorbate|100 mg elemental iron
79740301|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
79581774|NCT05612061|Behavioral|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
79876336|NCT00970697|Drug|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
79876337|NCT00970775|Drug|AZD2423|oral solution, single dose
79432889|NCT04143308|Other|Cognitive training group|"Device:~SWATCH system (App)~Wearable technology Fitness wristband & APP"
79740302|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
79740303|NCT02676934|Device|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
79876338|NCT00970775|Drug|Placebo|oral solution,single dose
79876339|NCT00967031|Drug|capecitabine|
79876340|NCT00967031|Drug|lapatinib ditosylate|
79876341|NCT00967031|Other|circulating tumor cell analysis|
79876342|NCT00967031|Other|laboratory biomarker analysis|
79876343|NCT00967109|Other|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
79876344|NCT00967109|Other|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
79876345|NCT00545753|Drug|Spinosad|10 minute topical application product, following by a complete rinse off.
79876346|NCT00545753|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
79876347|NCT00545753|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
79876348|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
79876349|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
79876350|NCT00970931|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
79876351|NCT00970931|Drug|placebo|Oral placebo once a day, for 18 months
80031806|NCT04878250|Drug|Bintrafusp alfa|4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
79740304|NCT05277220|Device|Thermal Camera Thermo Malin TC|"Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images."
79404593|NCT04706520|Dietary Supplement|Study Beverage Consumption|All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
79581775|NCT05597748|Device|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
79740305|NCT05351086|Drug|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
79876352|NCT00971009|Behavioral|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
79876353|NCT00971009|Behavioral|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
80031807|NCT04877938|Behavioral|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
80031808|NCT04877548|Other|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
79277840|NCT05306717|Other|Questionnaire|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
79277841|NCT05293730|Behavioral|eFRIEND|eFRIEND is a 6-month CWH-led intervention. All CHW will be part of the research team to ensure successful recruitment and interaction with patients, and all CHW will be certified and have participated in the North Carolina Community Health Worker Standardized Core Competency Training.
79404594|NCT03742297|Drug|Lenalidomide.|Lenalidomide
79404595|NCT03742297|Drug|Carfilzomib|Carfilzomib
79581776|NCT05597748|Device|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
79581777|NCT05595551|Behavioral|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
79581778|NCT05593770|Drug|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
79277842|NCT05293730|Other|Usual Care|Routine treatment in primary care
79277843|NCT05285267|Behavioral|Behavioral Parent Support|Parent training on effective child management strategies
79277844|NCT05285267|Behavioral|Shared Parent-Child Activities|Structured parent-child activities
79277845|NCT05285267|Behavioral|COACHES|This intervention involves practice of parenting strategies with facilitator monitoring and support.
79277846|NCT05277805|Other|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
79277847|NCT05276284|Combination Product|Atezolizumab, 6-mercaptopurine, 6-thioguanine|Combination therapy with Atezolizumab, 6-mercaptopurine and 6-thioguanine
79404596|NCT03742297|Drug|Bortezomib|Bortezomib
79404597|NCT03742297|Drug|Daratumumab|Daratumumab
79404598|NCT03742297|Drug|Dexamethasone|Dexamethasone
79404599|NCT03742297|Drug|Prednisone|Prednisone
79404600|NCT03742297|Drug|Melphalan|Melphalan
79404601|NCT01677403|Drug|Tobramycin|Nebulised 80mg twice daily
79404602|NCT01677403|Drug|Saline|Nebulised 5mls 0.9% Saline twice daily
79404603|NCT03629652|Other|head-down position treatment|In the head-down position, the body is in the supine position with the head lowered to 30 degrees
79404604|NCT03629652|Other|Conventional Rehabilitation|The body is in the supine position without lowered head
80031809|NCT04877548|Other|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
79277848|NCT05259605|Other|Observational|The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
79404605|NCT03441750|Drug|metformin|Metformin tablets will be administrated in the experimental arm.
79740306|NCT05351086|Drug|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
79404606|NCT03441750|Other|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~Moderate intensity physical activity (150 minutes per week) is recommended.~Smoking cessation is encouraged for the smoker.~Excessive alcohol intake is encouraged to avoid."
79404607|NCT04527744|Procedure|the injection of onabotulinumtoxinA at different point|For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
79404608|NCT04976010|Other|No intervention|There will be no intervention in the separate goups, as this is an observational study
79277849|NCT05258656|Behavioral|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
79277850|NCT05258656|Behavioral|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
79581779|NCT05593770|Drug|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
80031810|NCT04877548|Other|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
79277851|NCT05251753|Device|K-Lock|Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
79581780|NCT05555017|Procedure|PSMA-radioguided surgery|Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
80031811|NCT04871152|Drug|OnabotulinumtoxinA|To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
80031812|NCT02808429|Drug|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
79277852|NCT05251194|Device|video laryngoscope at thyroid surgical position|After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.
79277853|NCT05245799|Behavioral|Speech Language Therapy|Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.
79404609|NCT04503954|Other|Chronic disease self-management program|The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.
79432890|NCT04143308|Other|Treatment as usual group|Keep treatment as usual
79432891|NCT00555321|Drug|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term [ST]), in accordance with local practice and the package insert, 4 years (Long-Term Extension [LTE])
80031813|NCT02808429|Drug|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
79432892|NCT00555321|Drug|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
79581781|NCT05555017|Drug|ADT|Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
79581782|NCT05540275|Drug|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
79432893|NCT00555321|Drug|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension [LTE])"
79581783|NCT05539391|Other|Data patient|Medical History and characteristic of patient
80031814|NCT02808429|Drug|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
79277854|NCT05245799|Behavioral|Digital Software Application|The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.
79581784|NCT05539391|Other|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
79876354|NCT00971087|Device|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
79876355|NCT00406419|Drug|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
79876356|NCT00406419|Drug|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
79876357|NCT00406419|Drug|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
79876358|NCT00967265|Behavioral|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
79876359|NCT00967265|Other|Usual care|Usual care
79876360|NCT00967421|Drug|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
79876361|NCT00967421|Drug|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
79876362|NCT00967421|Other|Placebo drink|Placebo drink containing no alcohol + placebo pill
79876363|NCT00971165|Drug|losartan|Oral losartan up to 100 mg daily fo 18 months
79876364|NCT00971165|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
79876365|NCT00971399|Drug|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
79876366|NCT00971399|Drug|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
79876367|NCT01049295|Dietary Supplement|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
79277855|NCT05243082|Device|Radio frequency ablation|Radio frequency ablation of pancreatic neuroendocrine tumors
79277856|NCT05237960|Procedure|Biopsy|Undergo biopsy
79277857|NCT05237960|Procedure|Biospecimen Collection|Correlative studies
79404610|NCT04503954|Other|General psychiatric intervention|General psychiatric intervention contains the activities in psychiatric center.
79404611|NCT03198468|Device|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).
79277858|NCT05237960|Drug|Extended Release Metformin Hydrochloride|Given PO
79404612|NCT03741751|Device|rTMS|Participants will receive either active or sham bilateral rTMS over the dorsolateral prefrontal cortex (DLPFC) for 12.5 min per side.
79581785|NCT05539391|Procedure|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
79581786|NCT05539391|Procedure|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
79581787|NCT05535257|Device|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
79277859|NCT05237960|Drug|Placebo Administration|Given PO
79277860|NCT05236803|Behavioral|Testing of general motor skills, fine motor skills and occulomotricity|"Recording of participant's performance during eye, fine motor and gross motor tests; Children's gross motor skills will be assessed through a biomechanical analysis.~Eye movements will be recorded using the eye-tracking system (Tobii Pro TX300). The technique used is the corneal reflection technique."
79581788|NCT05534750|Drug|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
79581789|NCT05534750|Drug|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
79581790|NCT05534750|Drug|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
79581791|NCT05526924|Radiation|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
79581792|NCT05526924|Drug|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
79740307|NCT05351086|Other|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
79740308|NCT05351086|Other|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
79740309|NCT02885168|Drug|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
79740310|NCT02885168|Device|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
79740311|NCT02885168|Drug|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
79876368|NCT01049295|Other|corn oil pearls|corn oil pearls 3 times a day
79876369|NCT00973505|Drug|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
79876370|NCT00971477|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
79277861|NCT05236803|Behavioral|Questionnaires|Passing self and hetero questionnaires.
79277862|NCT05220345|Device|colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)|All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly
79404613|NCT03741751|Behavioral|Computerized cognitive training|All participants will receive computerized cognitive training for 40 min after each rTMS session.
79581793|NCT05526924|Drug|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
79581794|NCT05526924|Drug|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
79740312|NCT02885168|Biological|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
79740313|NCT05657002|Other|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
79876371|NCT00971477|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
79581795|NCT05526924|Drug|Tislelizumab|An anti-cancer drug.
79581796|NCT05522244|Diagnostic Test|extended CTA|Extending the standard CTA 6 cm below the carina.
79581797|NCT05517122|Dietary Supplement|Nicotinamide (NAM)|500 mg a day
79581798|NCT05517122|Dietary Supplement|Nicotinamide Riboside (NR)|1000 mg a day
79581799|NCT05517122|Dietary Supplement|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
79581800|NCT05517122|Dietary Supplement|Microcrystalline cellulose|500 mg a day
79581801|NCT05516940|Other||
79581802|NCT05515991|Other|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
79581803|NCT05515991|Other|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
79581804|NCT05515575|Drug|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
79581805|NCT05501366|Dietary Supplement|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) & 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
79581806|NCT05501366|Behavioral|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
79876372|NCT00973583|Dietary Supplement|vitamin D|vitamin D3 400 IU daily
79876373|NCT00973583|Dietary Supplement|placebo|placebo
79876374|NCT00971711|Biological|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
79876375|NCT04008953|Device|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
80031815|NCT03047200|Biological|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
80031816|NCT04870372|Drug|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
80031817|NCT02048319|Drug|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
79876376|NCT00973661|Behavioral|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
79876377|NCT00973895|Biological|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
79404614|NCT03179748|Drug|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
80031818|NCT02048319|Procedure|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
80031819|NCT02048319|Drug|Placebo|Saline solution, injected as placebo
79277863|NCT05206630|Other|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
79277864|NCT05204004|Device|Sunrise|"Sunrise (Sunrise SA, Belgium) is a novel integrated digital medicine solution for the diagnosis of OSA allowing the detection of respiratory disorders from the analysis of mandibular movements optimised by an artificial intelligence algorithm machine learning. It is composed of a unique innovative sensor, placed on the chin during the night, connected via Bluetooth to a mobile application which guides the patients for the implementation and allows the transfer of the data collected by the sensor to a certified health host guaranteeing the security and confidentiality of medical data. The analysed data is integrated and automatically transferred into a detailed report made available to doctors via a secure website the day after the test."
79404615|NCT03740191|Other|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
79404616|NCT03740191|Radiation|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
79876378|NCT00972101|Radiation|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
79876379|NCT00972101|Drug|Melphalan|140 mg/m^2 by vein over 30 minutes as a single dose on Day -8
80031820|NCT01594762|Drug|Topical pexiganan cream 0.8%|14 days of treatment
80031821|NCT01594762|Drug|Topical placebo cream|14 days of treatment
80031822|NCT01594762|Other|Standard wound care|14 days of treatment
80031823|NCT03561987|Procedure|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
79404617|NCT03740191|Radiation|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
79404618|NCT04868292|Drug|SPR206|Three 100 mg SPR206 intravenous doses administered every 8 hours
79404619|NCT03657433|Dietary Supplement|Ferrous sulfate 325mg|Oral tablets supplied for home use
79404620|NCT03657433|Drug|Ferumoxytol|Ferumoxytol will be administered in two infusions, one week apart
79404621|NCT04351386|Device|AF Detection|Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
79404622|NCT01676935|Drug|ABT-126|See arm description
79404623|NCT03821155|Other|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
79404624|NCT03821155|Drug|Corticosteroid|Prednisolone
79404625|NCT04803552|Device|Overnight sleep study with Sleepiz One and a respiratory polygraphy|"Participants will undergo a screening night with Sleepiz One. and with a cardiorespiratory polygraphy device (Miniscreen, Heinen-Löwenstein).~Measurements (Miniscreen, Heinen-Löwenstein)~Thoracic respiratory effort: respiration frequency (BR), respiration curve~Airflow: respiration frequency (BR), respiration curve~Body movement: body position~Blood oxygen saturation (SpO2)~Pulse~Measurements (Sleepiz One):~• Movement originating from breathing and heart contractions"
79876380|NCT00972101|Drug|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
79876381|NCT00972101|Drug|Fludarabine|40 mg/m^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
79876382|NCT00972101|Drug|Rituximab|"Regimen 1:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
79876383|NCT00972101|Drug|Etoposide|60 mg/m^2 by vein over 1-2 hours as a single dose on Day -3.
79876384|NCT00972101|Drug|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
80031824|NCT02048397|Other|Pulmonary Rehabilitation|
80031825|NCT02048397|Dietary Supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
79581807|NCT05501366|Biological|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
79740314|NCT05657002|Other|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
79277865|NCT05204004|Device|Polygraphy|Polygraphy (Apnoealink-Air, ResMed, Australia) is a commercially available, limited-channel sleep study device which can be used in the home. Many sleep services in the UK already use the ApneaLink Air for routine screening. It is a portable device which consists of a nasal cannula to measure nasal flow and snoring, oximeter to measure pulse and blood oxygen levels, and a chest band to measure respiratory effort. It contains software which allows for the scoring of apnoeas, hypopnoea and arousals.
79277866|NCT05201924|Behavioral|Bedtime routine|a regular routine conducted around bedtime includes brush, book reading and regular bedtime
79277867|NCT05201924|Behavioral|Control|a healthy control checklist
79404626|NCT03819283|Diagnostic Test|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
79581808|NCT05501366|Other|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
79740315|NCT05657002|Other|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
79740316|NCT05657002|Other|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
79740317|NCT02674282|Procedure|ACL reconstruction|ACL reconstruction with hamstrings autograft.
79740318|NCT02672722|Drug|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
79740319|NCT02672722|Other|Exercise|
79740320|NCT02672722|Other|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
79740321|NCT00643942|Other|No intervention required|
79740322|NCT02672878|Device|Bioresorbable vascular scaffold|
79581809|NCT05501366|Other|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
79581810|NCT05501366|Other|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day
79581811|NCT05501366|Radiation|DXA|Lean Body Mass will be assessed once via DXA
79740323|NCT01159574|Drug|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
79740324|NCT01159574|Drug|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
79740325|NCT01159574|Drug|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
79876385|NCT00972101|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
79876386|NCT00972101|Drug|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
79876387|NCT00972101|Procedure|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
79277868|NCT05192057|Device|Hypertonic Saline inhalation|Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
79876388|NCT00972101|Drug|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e^9/L.
79277869|NCT05183542|Drug|Bone scan|Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including a score of neuropathique pain scale < 4, see non-inclusion criteria), will be proposed to participate in the study neuropathic pain If they give their oral agreement to the neurosurgeon, a request for a bone scan will be sent to the nuclear medicine department of the Nancy-Brabois Hospital. The patients will fill pain scales before and after surgery (ODI and NS)
79277870|NCT05167500|Drug|Lorlatinib|"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
79404627|NCT03651895|Drug|Metformin|Drug
79581812|NCT05501366|Other|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting <1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
79581813|NCT05496491|Radiation|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
79740326|NCT00910156|Device|Airtraq laryngoscope|Airtraq intubation
79740327|NCT00910156|Device|Glidescope laryngoscope|glidescope intubation
80031826|NCT03935308|Radiation|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
79277871|NCT05148871|Biological|Spikogen/Covax-19|Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
79277872|NCT05144698|Biological|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
80031827|NCT02048475|Other|desflurane|changing concentration
80031828|NCT02048553|Device|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
80031829|NCT02048553|Procedure|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
79277873|NCT05144698|Drug|Chemotherapy Prior to RAPA-201 Therapy|Carboplatin + Paclitaxel Regimen (CP Regimen)
79404628|NCT03651895|Drug|Placebo|Placebo
79404629|NCT04760184|Other|Autologous stem cell transplantation|The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
79404630|NCT03650491|Drug|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
79404631|NCT03867396|Device|CROS|Advanced Bionics CROS
79404632|NCT03867396|Device|Hearing Aid|Advanced Bionics Naida hearing aid
79404633|NCT03867396|Other|Cochlear Implant Alone|No hearing device on contralateral ear
79404634|NCT02398656|Drug|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
79581814|NCT05496491|Drug|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
79740328|NCT00910156|Device|Macintosh laryngoscope|Macintosh intubation
79740329|NCT04179058|Other|Follow-up|Clinical data, radiological data and laboratory tests follow-up
79740330|NCT01158950|Drug|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
79740331|NCT01158950|Other|Placebo|Placebo (200mg) administered at study visit
79740332|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3*10^8/kg/once.
79740333|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3*10^8/kg/once.
79740334|NCT02676856|Drug|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
79740335|NCT02676856|Drug|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
79740336|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
79876389|NCT00972101|Procedure|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e^5 T cells/kg on Day 14+.
79876390|NCT00325468|Drug|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
79876391|NCT00972257|Drug|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
79404635|NCT02398656|Drug|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
79404636|NCT00003469|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
79404637|NCT04748640|Procedure|Gamma Knife VIM thalamotomy|Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
79404638|NCT04670484|Other|Wearing Mask|Participants wearing masks as per federal guidelines to prevent Coronavirus spread
79876392|NCT00972257|Drug|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
79876393|NCT00311584|Drug|irinotecan hydrochloride|Given IV
79876394|NCT00311584|Drug|temozolomide|Given IV
79277874|NCT05142150|Other|Questionaire|"Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying."
79876395|NCT03021681|Other|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
79876396|NCT03992859|Procedure|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
79277875|NCT05123391|Radiation|External beam image guided radiotherapy|Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
79277876|NCT05067127|Drug|Pegcetacoplan|Complement (C3) Inhibitor
79277877|NCT05067127|Other|Placebo|Sterile solution of equal volume to active arm
79277878|NCT05048472|Diagnostic Test|Abbott HIV-1/2 VL Point of care Device|Point of care viral load monitoring
79277879|NCT05032326|Drug|Follow-up study of the treated cohort|follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
79404639|NCT03648463|Procedure|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
79876397|NCT00383331|Drug|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
79277880|NCT05032326|Other|Follow-up study of the untreated cohort|follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
79277881|NCT04993300|Device|transcranial magnetic stimulation (TMS)|The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
79277882|NCT04986345|Other|High-intensity interval training (HIIT)-4|4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.
79404640|NCT04657926|Drug|APPA|APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) & 2-hydroxy-4-methoxyacetophenone (2H4MA).
79404641|NCT04657926|Drug|Placebo|Placebo capsules
79404642|NCT04070898|Procedure|Remove urinary catheter after surgery|Remove bladder catheter after surgery
79404643|NCT04000620|Procedure|surgery|treatment intent surgery
79404644|NCT04000620|Procedure|punture|diagnostic punture
79404645|NCT03807037|Dietary Supplement|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
79581815|NCT05496491|Drug|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
79581816|NCT05488522|Biological|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
79581817|NCT05480605|Behavioral|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
79876398|NCT00383331|Drug|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
79404646|NCT03807037|Drug|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
79404647|NCT03638791|Behavioral|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
79404648|NCT03805399|Drug|Pyrotinib with Capecitabine|If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
79404649|NCT03805399|Drug|AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
79581818|NCT05469204|Drug|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
79581819|NCT05469204|Drug|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
79876399|NCT03934541|Biological|MPER-656 Liposome Vaccine|Administered by intramuscular injection
79876400|NCT03934541|Biological|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
79404650|NCT03805399|Drug|anti PD-1 with nab-paclitaxel|If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
79404651|NCT03805399|Drug|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
79277883|NCT04986345|Other|High-intensity interval training (HIIT)-10|10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.
79876401|NCT00325234|Drug|Pemetrexed|600 mg/m^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
79277884|NCT04986345|Other|Rest|Participants are to stay seated for 30 minutes while reading or watching television.
79581820|NCT05469204|Drug|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
79876402|NCT00325234|Drug|Carboplatin|AUC 5 mg*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
79277885|NCT04969133|Drug|Levobupivacaine Hydrochloride 2.5 MG/ML|To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
79277886|NCT04931095|Drug|Cannabis|Cannabis will be orally ingested via a brownie
79277887|NCT04931095|Drug|Alcohol|Alcohol will be orally ingested via a flavored drink
79277888|NCT04921800|Procedure|Anterior Cervical Discectomy & Fusion|Participants are undergoing previously scheduled anterior cervical discectomy & fusion for single level or multiple level cervical disease
79277889|NCT04921800|Device|Application of ADAM mechanoacoustic skin sensor|Applying the ADAM sensor to the suprasternal notch following surgery to allow for collection of the anatomical data
79404652|NCT03805399|Drug|BLIS with anti-VEGFR included therapy|"If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w"
79581821|NCT05469204|Drug|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
79740337|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
79740338|NCT00910234|Drug|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
79740339|NCT04315220|Other|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
79876403|NCT00325234|Drug|Gemcitabine|1200 mg/m^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
79876404|NCT00325234|Drug|Vinorelbine|30 mg/m^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
79404653|NCT03805399|Drug|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
79404654|NCT03805399|Drug|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
79404655|NCT02652624|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
79404656|NCT02652624|Drug|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
79404657|NCT02652624|Drug|ATV|ATV 300 mg capsules administered orally once daily with food
79404658|NCT02652624|Drug|RTV|RTV 100 mg tablets administered orally once daily with food
79404659|NCT02652624|Drug|FTC/TDF|200/300 mg tablet administered orally once daily with food
79740340|NCT04315220|Other|No Intervention|No Intervention
79740341|NCT05652322|Drug|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
79277892|NCT04910061|Dietary Supplement|Nicotinamide mononucleotide (NMN-C)|Daily supplementation with NMN-C at 400 mg for 29 days in total
79277893|NCT04896593|Behavioral|Smartphone App|Smartphone app teaching suicide prevention skills.
79277894|NCT04887610|Procedure|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
79277895|NCT04887610|Procedure|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
79277896|NCT04887610|Dietary Supplement|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
79277897|NCT04887610|Dietary Supplement|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
79740342|NCT05652322|Drug|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
79740343|NCT05652322|Drug|Furosemide Injection|change from intravenous to oral furosemide
79740344|NCT01172288|Drug|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
79740345|NCT01172288|Drug|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
79876405|NCT01063504|Drug|teriparatide|
79876406|NCT00366249|Drug|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
79876407|NCT00366249|Drug|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
79876408|NCT00325156|Biological|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
79876409|NCT01066234|Radiation|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
79581822|NCT05456958|Other|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
79581823|NCT05456958|Other|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
79581824|NCT05454488|Other|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
79740346|NCT02676622|Drug|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
79740347|NCT02676622|Other|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
79740348|NCT02676622|Drug|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
79740349|NCT02676622|Other|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
79876410|NCT01066234|Drug|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
79740350|NCT02676622|Drug|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
79740351|NCT04313816|Other|questionnaire|no intervention at all apart from filling a brief questionnaire
79876411|NCT03927911|Drug|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
79876412|NCT03927911|Drug|Standard of Care|Standard of Care
79876413|NCT00383019|Drug|Xalatan|latanoprost 0.005%, one rop once daily in evening
79876414|NCT00383019|Drug|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
79876415|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
79876416|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
79876417|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
79876418|NCT00310804|Biological|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
79277898|NCT04887467|Drug|Apomorphine|"Assigned Interventions:~blood sampling~blood collection~systolic, diastolic, mean blood pressure and heart rate measure"
79404660|NCT02652624|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
79581825|NCT05454488|Other|Standard of Care|Participants will receive a prostate biopsy.
79277899|NCT04878393|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
79277900|NCT04867642|Drug|UCB0022|Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.
79876419|NCT01046409|Other|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
79277901|NCT04867642|Other|Placebo|Study participants will receive placebo comparator in a pre-specified sequence during the Treatment Period of Part A, B and C.
79277902|NCT04864535|Diagnostic Test|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
79404661|NCT03852966|Behavioral|CBT-i/ADHD|Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
79581826|NCT05454488|Other|Quality-of-life Questionnaires|Participants will fill out questionnaires.
79581827|NCT05445726|Device|CPM Device|CPM device used in tangent with reference ECG for validation
79876420|NCT01060852|Behavioral|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
79876421|NCT00590187|Drug|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
79876422|NCT00590187|Drug|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
79876423|NCT00590187|Drug|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
79876424|NCT00590187|Drug|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
79876425|NCT00590187|Drug|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
79876426|NCT00590187|Drug|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
79876427|NCT00590187|Drug|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
79876428|NCT00590187|Drug|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
79876429|NCT00590187|Drug|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
79876430|NCT03978364|Drug|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
79277903|NCT04861064|Drug|Sirolimus|Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
79740352|NCT00644020|Drug|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
79740353|NCT04178980|Drug|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
79581828|NCT05445492|Device|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
79581829|NCT05445206|Device|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
79581830|NCT05433025|Device|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
79581831|NCT05396794|Behavioral|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
79581832|NCT05396794|Behavioral|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
79740354|NCT02674048|Other|Metvix|
79740355|NCT02674126|Behavioral|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
79876431|NCT03978364|Drug|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
79876432|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
79277904|NCT04846335|Drug|Doxycycline Hcl|tablets of DOXY hydrocloride (Bassado)
79277905|NCT04846335|Drug|Placebo|tablets of placebo
79581833|NCT05392608|Drug|Alpelisib 150 MG Oral Tablet [Piqray]|Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
79581834|NCT05392608|Drug|Fulvestrant|Fulvestrant 300mg 1x/four weeks
79740356|NCT02674126|Behavioral|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
79740357|NCT04178902|Drug|ABBV-467|Intravenous (IV) Infusion
79740358|NCT02672566|Drug|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
79277906|NCT04827875|Drug|AIV001|Intradermal
79581835|NCT05368025|Device|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
79581836|NCT05360160|Drug|SNDX-5613|Given by PO
79581837|NCT05360160|Drug|Venetoclax|Given by PO
79581838|NCT05360160|Drug|ASTX727|Given by PO
79581839|NCT05356936|Dietary Supplement|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
79581840|NCT05356936|Dietary Supplement|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
79581841|NCT05355051|Drug|Azacytidine|Given by Vein (IV)
79581842|NCT05355051|Drug|Pembrolizumab|Given by Vein (IV)
79581843|NCT05353738|Biological|Blood sample for research of anti-xoprs netralizing anti spike|"The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group)."
79581844|NCT05353738|Other|Questionnaire|Evaluation of vaccine efficacy in real life by filling out questionnaires
79581845|NCT05339451|Diagnostic Test|Blood biomarkers|Blood biomarkers in plasma and serum.
79740359|NCT02672566|Other|Usual care|Patients will all benefit from the usual care
79740360|NCT02672488|Drug|Sorafenib|Standard treatment for advanced HCC
79740361|NCT02672488|Drug|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
79740362|NCT02673892|Other|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
79277907|NCT04826094|Biological|Env-C Plasmid DNA|2 mg per dose. Administered by intramuscular injection.
79277908|NCT04826094|Biological|HIV Env gp145 C.6980 protein|100 µg per dose. Administered by intramuscular injection.
79277909|NCT04826094|Drug|Rehydragel®|Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
79277910|NCT04826094|Biological|ALF43|Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
79277911|NCT04826094|Biological|dmLT|Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
79277912|NCT04826094|Drug|Placebo (IM)|0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
79277913|NCT04826094|Drug|Placebo (TCl)|Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
79277914|NCT04797052|Device|Prefrontal EEG (VEEGix by NeuroServo)|Prefrontal EEG reading
79277915|NCT04796220|Drug|Gemcitabine|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.
79277916|NCT04796220|Device|Focused Ultrasound|Focused ultrasound will be applied to up to 2 breast lesions on day 8.
79740363|NCT00644098|Dietary Supplement|soluble fibre complex and medium chain triglycerides|
79740364|NCT00644098|Dietary Supplement|cellulose and soybean oil|
79277917|NCT04796220|Other|Gemcitabine and Focused Ultrasound|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
79740365|NCT02537392|Dietary Supplement|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
79740366|NCT02537392|Dietary Supplement|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
79740367|NCT02537392|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid.
79740368|NCT05613712|Other|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
79740369|NCT05613712|Other|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
79740370|NCT02676700|Behavioral|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
79740371|NCT02676700|Behavioral|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
79740372|NCT02676544|Device|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
79277918|NCT04777045|Drug|Diltiazem Hydrochloride|"Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm."
79740373|NCT04178278|Diagnostic Test|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
79740374|NCT04178278|Diagnostic Test|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
79740375|NCT04178278|Diagnostic Test|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
79740376|NCT00642928|Drug|Placebo|1 capsule per day during 4 weeks
79277919|NCT04777045|Drug|Placebo|Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
79404662|NCT03724903|Procedure|Ductal lavage|The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
79404663|NCT03724903|Drug|Corticosteroid therapy|Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
79581846|NCT05337826|Device|Continuous Glucose Monitor|Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
79581847|NCT05329792|Drug|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
79581848|NCT05322343|Other|Questionnaires|"Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer):~A general questionnaire, with collection of general health history and exposure data~A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits.~An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
79740377|NCT00642928|Drug|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
79740378|NCT00642928|Drug|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
79740379|NCT00642928|Drug|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
79277920|NCT04771455|Behavioral|Behavioral weight loss|Participants will receive behavioral weight loss intervention
79277921|NCT04771455|Behavioral|Intervention component: Decrease overvaluation of weight and shape|Participants will receive an intervention component to decrease overvaluation of weight and shape
79740380|NCT00642928|Drug|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
79740381|NCT02676232|Behavioral|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
79740382|NCT02673814|Biological|durvalumab|
79740383|NCT02673814|Biological|bavituximab|
79740384|NCT00644176|Drug|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
79740385|NCT00644176|Other|placebo|placebo
79404664|NCT03722017|Other|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
79740386|NCT00644176|Drug|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
79740387|NCT00644176|Other|placebo|placebo
79740388|NCT02673424|Procedure|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
79740389|NCT02673424|Procedure|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)"
79740390|NCT02673736|Drug|PLX73086|
79740391|NCT04178200|Drug|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
79740392|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
79740393|NCT04178200|Drug|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
79740394|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
79740395|NCT00644410|Biological|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
79740396|NCT00644410|Biological|Saline|12 injection with 0.2 ml saline
79740397|NCT02537158|Drug|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
79740398|NCT02537158|Procedure|TACE|TACE group patients will accept TACE therapy once at a month after resection.
79277922|NCT04771455|Behavioral|Intervention component: Decrease unhealthy weight control practices|Participants will receive an intervention component to decrease unhealthy weight control practices
80031830|NCT03046888|Procedure|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
80031831|NCT03046498|Behavioral|Evidence-Based Program|DSMP and DPP
79740399|NCT04177420|Device|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
79404665|NCT04348279|Device|propylene mesh|propylene mesh as a palatal stent for palatal wound
79404666|NCT03637075|Other|intranasal insulin|intranasal administration of insulin (160 IU)
79404667|NCT03637075|Other|Placebo|placebo intranasal administration
79740400|NCT04177420|Device|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
79277923|NCT04771455|Behavioral|Intervention component: Decrease negative affect|Participants will receive an intervention component to decrease negative affect
79277924|NCT04770116|Device|Auditory Stimulation|The device records biosignals and precisely plays tones to enhance sleep slow waves.
79277925|NCT04751786|Drug|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
80031832|NCT03046576|Diagnostic Test|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
80031833|NCT03049384|Other|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
79277926|NCT04746612|Drug|HH30134|HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
79404668|NCT04403503|Drug|Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
79740401|NCT04177420|Device|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
79740402|NCT04177420|Device|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
79740403|NCT02676154|Drug|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
79740404|NCT02676310|Drug|Bimatoprost|
79740405|NCT04180618|Other|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
79740406|NCT04177888|Device|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
79740407|NCT00643084|Procedure|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
79740408|NCT00643084|Procedure|standard bowel preparation|standard bowel preparation
79581849|NCT05322343|Other|Fasting blood sampling.|In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.
79740409|NCT02676388|Procedure|Freeze-dried, Capsulized FMT|
79876433|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
79277927|NCT04729231|Procedure|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
79277928|NCT04729231|Procedure|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
79277929|NCT04705324|Procedure|Operative Hysteroscopy|Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy
79277930|NCT04705324|Procedure|D&C|Separation of the non-viable gestational sac from the uterine wall through dilation and curettage
79277931|NCT04705324|Procedure|Operative Hysteroscopy - safety and feasibility|Operative hysteroscopy - safety and feasibility phase
79277932|NCT04681404|Procedure|Knee Arthroplasty|Comparison of TKA, UKA and healthy controls in relation to balance, function and QOL
80031834|NCT03049384|Other|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
79277933|NCT04679935|Biological|Brolucizumab|Intravitreal injection
79277934|NCT04668066|Drug|PF-07242813|PF-07242813 given intravenously or subcutaneous
79277935|NCT04668066|Drug|Placebo|Placebo given intravenously or subcutaneous
79277936|NCT04628715|Device|RSA biofeedback|Biofeedback intervention based on breathing at resonance frequency
79277937|NCT04614896|Diagnostic Test|Transoral ultrasound of tongue tumors|A transoral ultrasound scan of tongue tumors will be performed to assess the depth of invasion of the tumor
80031835|NCT03561909|Other|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
80031836|NCT03562143|Dietary Supplement|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
79277938|NCT04601272|Behavioral|Decision aid|Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
79404669|NCT04403503|Drug|Cyanoacrylate, Isobutyl|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
79740410|NCT02676388|Procedure|Fresh FMT|
79277939|NCT04591860|Device|Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet|Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
79277940|NCT04551092|Device|NEVR|a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
79277941|NCT04539158|Device|Direct Current Cardioversion|The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
79277942|NCT04527614|Diagnostic Test|qRT-PCR and serology|qRT-PCR and serology
79404670|NCT00249795|Drug|Irbesartan|oral administration (tablets) once daily
79404671|NCT00249795|Drug|placebo|oral administration (tablets) once daily
79404672|NCT04404127|Drug|Basiliximab 20 milligram [Simulect]|Basiliximab
79404673|NCT04404127|Other|Normal Saline|No-Induction
79404674|NCT04763629|Other|Physical exercise|Patients of both arms will undergo two different modalities of exercise during the 12 weeks study period.
79404675|NCT04763473|Dietary Supplement|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
79404676|NCT04763473|Dietary Supplement|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
79404677|NCT02651220|Drug|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
79581850|NCT05322343|Other|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
79740411|NCT04094974|Device|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
79404678|NCT02651220|Drug|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
79404679|NCT02651220|Drug|placebo gel|vehicle used as placebo
79740412|NCT04177186|Other|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
79740413|NCT04177186|Combination Product|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
79740414|NCT04094194|Other|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
79740415|NCT02672020|Biological|omics identity card|
80031837|NCT03562143|Dietary Supplement|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
79277943|NCT04517799|Drug|Epidiolex|"While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
79581851|NCT05322343|Other|Urine samples|During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.
79581852|NCT05322343|Other|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope
79581853|NCT05322343|Other|Nasal microbiota|Nasal or nasopharyngeal swab
79581854|NCT05322343|Other|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
79581855|NCT05322343|Other|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
79581856|NCT05322343|Other|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
79581857|NCT05313204|Other|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
79581858|NCT05311904|Other|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
79740416|NCT04096846|Diagnostic Test|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
79740417|NCT04092244|Diagnostic Test|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
79277944|NCT04517799|Drug|placebo oral solution|"GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
79277945|NCT04513444|Other|Relaxation with music listening and medical hypnosis during radiotherapy treatment:|"Music listening (According to the patient's wishes),~Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session,~Self-hypnosis during the 4th and 5th radiotherapy session,~Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
79277946|NCT04513444|Other|Relaxation with music listening during radiotherapy treatment:|"Music listening (According to the patient's wishes),~Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
79277947|NCT04509648|Radiation|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral chest wall or whole breast and regional lymph regions and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast
79277948|NCT04496518|Device|Intrinsic Antitachycardia Pacing (iATP) Therapy|iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
79277949|NCT04495296|Drug|TST001|TST001 will be administered by specified doses on specified day
79277950|NCT04495296|Drug|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
79277951|NCT04495296|Drug|Capecitabine|Capecitabine will be administered by specified doses on specified day
79277952|NCT04495296|Drug|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
79277953|NCT04495296|Drug|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
79277954|NCT04495296|Drug|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
79277955|NCT04495296|Drug|Nivolumab|Nivolumab will be administered by specified doses on specified day
79277956|NCT04429308|Procedure|Photodynamic Therapy|Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
79277957|NCT04429308|Drug|Chemical Peels|Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
79740418|NCT04180384|Drug|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
79740419|NCT04091776|Radiation|CT scan|"Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~Assessment of fixation failure in fixed fractures if occurred.~Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
79277958|NCT04404062|Diagnostic Test|Membrane-based immunoassay kit|The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
79277959|NCT04404062|Diagnostic Test|Quantitative antibody Tests|Antibody titres will be measured from whole blood samples taken from volunteers.
79277960|NCT04404062|Diagnostic Test|PCR Test|PCR tests will be conducted on throat swabs taken from volunteers.
79277961|NCT04350515|Other|Cyberball: Other Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
79581859|NCT05305144|Procedure|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~Measurement of central arterial pressure,~Measurement of arterial stiffness,~Continuous blood pressure measurement (beat-to-beat),~Heart rate measurement,~24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~Auto-refractometry~Measurement of the axial length of the globe~Color retinophotography of the retina,~Adaptive Optics Exam~SS-OCT-A exam"
79277962|NCT04350515|Other|Cyberball: Player Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
79277963|NCT04350515|Other|Mindfulness: Emotion Regulation Task|In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen & Sturm (2018). It takes around 14 minutes to complete the whole task.
79277964|NCT04350515|Other|Mindfulness: Word Recognition Task|"In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task."
79277965|NCT04348630|Other|Simulated heatwave exposure|Older adults are exposed to a 8-hour simulated exposure
79277966|NCT04339374|Device|Photoacoustic imaging, photoacoustic microscopy|"Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise~The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers~The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)~The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants"
80031838|NCT03049228|Diagnostic Test|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
79277967|NCT04339374|Device|Endorectal photoacoustic imaging probe|"Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively.~The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants"
79277968|NCT04338503|Diagnostic Test|Partial IVC occlusion|Partial balloon occlusion of the inferior vena cava.
79277969|NCT04330742|Drug|lactated ringers|the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
79581860|NCT05298709|Other|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
79581861|NCT05294081|Behavioral|Exposure therapy|10 sessions based on an individualized pain hierarchy
79581862|NCT05294081|Behavioral|Cognitive behavioral therapy|10 sessions with graded activity, relaxations techniques and cognitive interventions
79581863|NCT05291923|Other|no intervention|no intervention
79277970|NCT04295044|Dietary Supplement|high protein diet|receive 1.8g protein/kg
80031839|NCT03049228|Diagnostic Test|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
80031840|NCT03049228|Diagnostic Test|Blood analysis|To determine blood glucose metabolism and renal function.
79277971|NCT04295044|Dietary Supplement|normal protein diet|receive 1g protein/kg
79740420|NCT02672254|Radiation|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
79740421|NCT04177732|Diagnostic Test|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
79277972|NCT04238598|Procedure|Pulse Radiofrequency|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.
79277973|NCT04238598|Procedure|Standard of Care Intra- Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.
79404680|NCT00724347|Behavioral|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
79404681|NCT04271943|Behavioral|Computer Based Exercises|For 8 weeks 3 days a week for 45 minutes See-ME Virtual Rehabilitation system with the physical therapist will perform cognitive and physical activity exercises
79404682|NCT04271943|Dietary Supplement|Aerobic Exercises|For 8 weeks 3 days a week exercise bike with 5 min warm-up 35 min constant speed exercise 5 min cooling, a total of 45 min prescribed by the physiotherapist to the maximum heart rate will do aerobic exercise work. Cardiac values will also be monitored throughout the session
79581864|NCT05280600|Other|Not applicable - non-interventional study|Not applicable - non-interventional study
79581865|NCT05252442|Other|Pre-COVID-19|Pre-COVID-19 period
79277974|NCT04238598|Procedure|Placebo Intra-Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
79740422|NCT04177732|Diagnostic Test|Probing depth|Williams SE manual probe will be used to measure the probing depth
79277975|NCT04224324|Procedure|Tonsillectomy and Adeniodectomy|pediatric patients undergoing tonsillectomy and adenoidectomy
79404683|NCT04580004|Other|Med Optimization Arm|An evidence-based medication recommendation website that is provided to the patients.
79404684|NCT01279551|Drug|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
79404685|NCT01279551|Drug|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
79404686|NCT00780403|Drug|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
79404687|NCT00780403|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
79404688|NCT01274091|Other|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
79404689|NCT01274091|Other|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
79581866|NCT05252442|Other|COVID-19|COVID-19 period
79277976|NCT04218643|Other|Ultrasound-guided technique|IV inserted via ultrasound guidance
79277977|NCT04218643|Other|Standard technique|IV inserted via standard technique
79277978|NCT04202900|Other|phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
79432894|NCT00555321|Drug|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
79432895|NCT00555321|Drug|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term [ST]), ≤ 1 g/day, 4 years (Long-term extension [LTE])
79581867|NCT05252442|Other|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out period
79581868|NCT05245500|Drug|MRTX1719|MRTX1719 is a potent PRMT5-MTA inhibitor
79581869|NCT05243641|Drug|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
79581870|NCT05243641|Drug|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
79581871|NCT05229679|Diagnostic Test|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
79581872|NCT05224336|Drug|Psilocybin|25mg oral psilocybin
79581873|NCT05224336|Drug|Placebo Niacin|100mg oral niacin
79581874|NCT05222620|Other|Questionnaire Administration|Ancillary studies
79581875|NCT05222620|Radiation|Stereotactic Radiosurgery|Undergo single fraction SRS
79581876|NCT05222620|Radiation|Stereotactic Radiosurgery|Undergo fractionated SRS
79581877|NCT05191719|Procedure|Botox injection|Comparator, current gold standard
79740423|NCT04177732|Diagnostic Test|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
79740424|NCT04177732|Diagnostic Test|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
79740425|NCT04177732|Diagnostic Test|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
79740426|NCT02671942|Drug|Roflumilast|
79740427|NCT02671942|Drug|Placebo|
79277979|NCT04197856|Other|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
79277980|NCT04197856|Other|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
79277981|NCT04169139|Device|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
79404690|NCT04436094|Procedure|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
79581878|NCT05191719|Procedure|Neurotomy|Surgical procedure
79404691|NCT04436094|Procedure|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
79404692|NCT01677013|Other|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
79581879|NCT05179785|Device|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
80031841|NCT03049228|Diagnostic Test|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
79277982|NCT04162938|Other|Patient-Centered Electronic App|The coordinator will enter lab information to generate the patient's Fibrosis-4 score for liver fibrosis staging. With the information of liver fibrosis staging and survey responses, the app will generate individualized reports of the participant's comprehensive HCV disease progression, knowledge, and level of interest in receiving HCV care. The app will then deliver a streamlined, tailored, brief education message and include information regarding services and assistance for receiving HCV care.
79277983|NCT04159831|Drug|LTI-01|single-chain urokinase plasminogen activator, scuPA
79277984|NCT04159831|Drug|Placebo|normal saline
79277985|NCT04158752|Drug|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
79277986|NCT04153240|Device|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
79277987|NCT04151693|Behavioral|Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)|Adaptation (support own agency), rehabilitation and improvement of functional capacity.
79277988|NCT04147546|Diagnostic Test|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
79277989|NCT04147546|Drug|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
79277990|NCT04147546|Other|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
79277991|NCT04141579|Drug|Evolocumab 140 MG/ML [Repatha]|Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
79277992|NCT04103671|Procedure|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
79277993|NCT04103671|Procedure|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
79740428|NCT00643240|Radiation|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
79277994|NCT04097977|Other|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
79277995|NCT04089046|Behavioral|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
80031842|NCT03049228|Diagnostic Test|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
79277996|NCT04089046|Behavioral|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
79277997|NCT04070924|Other|Bandaid|Bandaid dressing
79404693|NCT00741273|Drug|Proellex|Proellex 25 mg capsule, single dose
79404694|NCT03630601|Procedure|Photoacoustic Imaging|Undergo PAI
79404695|NCT01979796|Device|Ecig 24 mg nicotine|Cigalike
79404696|NCT01979796|Device|Ecig 0 mg nicotine|Cigalike
79404697|NCT01979796|Device|Nicotine free inhalator|Plastic CIG a Like
79581880|NCT05179785|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
79277998|NCT04070924|Other|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
79404698|NCT03797989|Biological|P. vivax infected inoculum (parasitised red blood cells)|In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
79404699|NCT00247611|Behavioral|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
79404700|NCT00247611|Other|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
79404701|NCT04532190|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS)
79432896|NCT05583500|Other|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
79432897|NCT03587012|Other|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
79581881|NCT05166499|Dietary Supplement|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
79581882|NCT05166499|Dietary Supplement|Balanced Amino Acids|Balanced Amino Acids
79581883|NCT05160675|Other||No intervention
79581884|NCT05157100|Drug|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
79581885|NCT05149937|Other|interprofessional, person-centered care concept|interprofessional, person-centered care concept
79581886|NCT05143619|Other|Survey Administration|Complete surveys
79581887|NCT05134142|Other|Electronic Health Record Review|Undergo medical record review
79581888|NCT05134142|Other|Physical Performance Testing|Undergo physical performance testing
79740429|NCT00643240|Radiation|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
79740430|NCT00644488|Drug|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
79740431|NCT02675920|Drug|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
79740432|NCT02671474|Other|4-dimensional volume-rendered computed tomography|
79740433|NCT02671630|Other|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
79740434|NCT02671552|Drug|Perflutren Protein-Type A Microspheres|Given IV
79277999|NCT03987451|Drug|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
79581889|NCT05134142|Other|Quality-of-Life Assessment|Complete assessments
79581890|NCT05134142|Other|Questionnaire Administration|Complete questionnaire
79278000|NCT03987451|Drug|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
79278001|NCT03977493|Drug|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
79581891|NCT05133804|Drug|Methylphenidate|Ritalin 10mg
79278002|NCT03977493|Drug|Placebo - Concentrate|One injection in each muscle.
79278003|NCT03971162|Drug|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
79278004|NCT03971162|Drug|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
79278005|NCT03968744|Drug|Safinamide|Safinamide taken per Os for 12 weeks
79278006|NCT03965091|Drug|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm description.
79432898|NCT03587012|Other|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
79581892|NCT05133804|Drug|Reboxetine|Reboxetine 4mg
79581893|NCT05133804|Drug|Placebo|Placebo matched to Reboxetine
79581894|NCT05133804|Drug|Placebo|Placebo matched to Ritalin
79581895|NCT05131321|Procedure|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
79278007|NCT03965091|Drug|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
79740435|NCT02671552|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
79740436|NCT05277064|Other|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
79278008|NCT03956030|Other|Contraception Handout|Handout covering contraception options
79278009|NCT03956030|Other|Nutritional Handout|Handout covering nutrition
79278010|NCT03949556|Other|Videos and/or SMS|Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
79278011|NCT03927508|Drug|r-tPA|Pulse spray and infusion
79278012|NCT03927508|Device|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
79278013|NCT03907345|Behavioral|Exposure|The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
79740437|NCT02671006|Other|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
79581896|NCT05131321|Procedure|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
79740438|NCT00644566|Other|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
79740439|NCT04176328|Drug|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
79740440|NCT04178044|Biological|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
79740441|NCT04178044|Biological|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
79740442|NCT04178044|Biological|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
79278014|NCT03867175|Radiation|Stereotactic Body Radiation Therapy|Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)
79278015|NCT03867175|Biological|Pembrolizumab|Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
79278016|NCT03852433|Drug|Bulevirtide|Administered via subcutaneous injections
79581897|NCT05127421|Drug|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
79581898|NCT05127421|Drug|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
79581899|NCT05126797|Other|Questionnaire Administration|Ancillary studies
79581900|NCT05126797|Device|Stent Device|Wear customized 3D printed oral stent
80031843|NCT02615470|Behavioral|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
79278017|NCT03852433|Drug|Peginterferon Alfa-2a (PEG-IFN alfa)|Administered via subcutaneous injections
79278018|NCT03849469|Biological|XmAb®22841|Monoclonal bispecific antibody
79278019|NCT03849469|Biological|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
79278020|NCT03843554|Other|Standard of Care Oral Hygiene|Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
79432899|NCT03904316|Biological|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
79581901|NCT05117931|Drug|Amivantamab|Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (<80kg) or 1400mg (>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh <80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
79581902|NCT05115656|Behavioral|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
79581903|NCT05115656|Behavioral|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
79740443|NCT04178044|Biological|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
79740444|NCT04178044|Biological|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
79740445|NCT04175860|Behavioral|The intervention with the patient (Chronic Patient Care Group and his family.)|"Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
79740446|NCT02671396|Behavioral|Virtual reality based intervention|Virtual reality based balance training
79740447|NCT02671396|Behavioral|Conventional intervention|Conventional balance training
79278021|NCT03843554|Procedure|Oral mucosal deterging and dental prophylaxis|Subjects will receive a professional dental prophylaxis including periodontal surface debridement [a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum] and deterging of the oral mucosal surfaces.
79278022|NCT03837522|Diagnostic Test|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
79278023|NCT03837522|Diagnostic Test|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
79432900|NCT03904316|Other|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
79432901|NCT02133235|Procedure|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
79432902|NCT02133235|Procedure|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
79432903|NCT05583266|Drug|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
79581904|NCT05112133|Dietary Supplement|Mulberry leaf extract|Oral administration
79581905|NCT05112133|Dietary Supplement|Water|Oral administration
79740448|NCT04177342|Drug|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
79740449|NCT04177342|Drug|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
79740450|NCT02671786|Other|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories & 15-17 gms of proteins.
79740451|NCT00644644|Other|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
79740452|NCT04016506|Other|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
79740453|NCT02668276|Other|Standard NCCN counseling|
80031844|NCT02615470|Other|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
80031845|NCT05674227|Procedure|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
80031846|NCT05674227|Procedure|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
79432904|NCT05583266|Drug|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
79278024|NCT03805607|Drug|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
79581906|NCT05109364|Drug|Terazosin therapy|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
79740454|NCT02668276|Other|Standard NCCN counseling and Oncotype DX results|
79278025|NCT03805607|Drug|Placebos|Normal Saline
79278026|NCT03744013|Device|Fortiva® 1mm|Post mastectomy immediate reconstruction
79278029|NCT03678194|Device|Smartphone Support System|6 weeks smartphone application with daily evaluations
79278030|NCT03670368|Behavioral|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
79278031|NCT03670368|Behavioral|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
80031847|NCT05674227|Procedure|Open surgery|Surgical treatment of operable lung cancers using open surgery
79278032|NCT03646383|Procedure|Radiofrequency ablation|The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
79278033|NCT03643848|Behavioral|Sleep with Sound Cues|Experimental manipulation to observe effects on memory for learned material.
79740455|NCT04175158|Biological|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
79740456|NCT04175158|Biological|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
79740457|NCT02671318|Drug|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
79740458|NCT02671318|Drug|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
79278034|NCT03643848|Behavioral|Sleep with Sham Cues|Sham manipulation
79278035|NCT03496766|Drug|Tipifarnib|Tipifarnib 600 mg will be administered until progression
79740459|NCT02668510|Biological|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
79278036|NCT03418909|Procedure|Primary Trans Oral Robotic Surgery (TORS)|In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).
80031848|NCT03046654|Diagnostic Test|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
79740460|NCT02668510|Drug|Normal saline|placebo injection of normal saline immediately following shockwave therapy
80031849|NCT03046654|Diagnostic Test|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
80031850|NCT03046654|Diagnostic Test|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
80031851|NCT02048709|Drug|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
80031852|NCT03048448|Drug|Fevipiprant|Single 450mg dose
80031853|NCT02050815|Drug|MEK162|
80031854|NCT02048787|Drug|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
79278037|NCT03418909|Radiation|Radio(chemo)therapy|As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
79278038|NCT03406715|Drug|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
79432905|NCT04405856|Device|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
79432906|NCT00607243|Biological|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
79740461|NCT00644722|Device|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
80031855|NCT04374448|Procedure|Sinonasal Benign or Malignant Tumor Resection|During sinus tumor resection, margins will initially be estimated with the naked eye. Then the dye, Indocyanine Green (ICG), will be injected through the intravenous line to identify tumor margins and be compared to estimated margins.
79581907|NCT05106257|Behavioral|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
79740462|NCT00644722|Device|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
79740463|NCT02668588|Drug|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
79740464|NCT02668588|Drug|extended release of placebo|1 intramuscular injection of extended release of placebo
79740465|NCT02668042|Biological|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
79278039|NCT03406715|Drug|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
79278040|NCT03406715|Biological|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
79278041|NCT03385720|Procedure|modified neck dissection|Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
79278042|NCT03385720|Procedure|traditional neck dissection|traditional neck dissection without preservation of submandibular gland
80031856|NCT04374448|Procedure|Skull Base Surgery (Assessment of Nasoseptal Flap)|In this surgery, a piece of individuals septum will be used for the reconstruction. The amount of time for the flap to fluoresce Indocyanine Green (ICG) will be measured. It will be ensured that the it is still lighting up at the end of the surgery, indicating it is still receiving a good supply and ensures longevity of the flap.
80031857|NCT04374448|Procedure|Endoscopic Sinus Surgery|During the surgery, the timing of Indocyanine Green (ICG) administration to fluorescence of anterior and posterior ethmoidal artery and of the internal carotid artery will be measured.
79740466|NCT04174690|Device|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
79740467|NCT02671084|Drug|sevoflurane|compare effect of sevoflurane when administered before PCI
79278043|NCT03363763|Drug|Sirolimus 0.2%|Ointment for topical administration hs x 12 weeks
79278044|NCT03363763|Drug|Sirolimus 0.4%|Ointment for topical administration hs x 12 weeks
79404702|NCT04202874|Procedure|Surgeon-administered transversus abdominis plane (TAP)|Prior to fascial closure, the rectus muscle is gently elevated superiorly and the surgeon identifies its lateral border; the nerves that supply the anterior abdominal wall travel through the myofascial plane between internal oblique and transversus abdominis muscles, 2 fingerbreadths above the iliac crest. Access to this plane can easily be achieved by inserting a blunted needle through the parietal peritoneum; there is an appreciable loss of resistance ('one pop') and the correct plane is entered. After careful aspiration to ensure no vascular injury has occurred, 20 mL 0.25% bupivacaine or 20 mL of normal saline is injected slowly. The same procedure is repeated on the other side.
79404703|NCT00742053|Device|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
79404704|NCT03628339|Drug|Midazolam|Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.
79278045|NCT03363763|Drug|Placebo ointment|Placebo ointment comparator for topical administration hs x 12 weeks
79404705|NCT03628339|Drug|Tepotinib|Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.
79404706|NCT03433950|Other|No Intervention|Observational
79404707|NCT04412694|Drug|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
79740468|NCT02671162|Drug|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
79740469|NCT02671162|Drug|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
79902198|NCT03335475|Behavioral|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
79902199|NCT03335475|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
79902200|NCT03316391|Other|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
79902201|NCT03303066|Drug|FG-4592|Oral
79902202|NCT03303066|Drug|Placebo|Oral
79902203|NCT03289910|Drug|Carboplatin|Given IV
79902204|NCT03289910|Drug|Topotecan|Given IV
79902205|NCT03289910|Drug|Topotecan Hydrochloride|Given IV
79902206|NCT03289910|Drug|Veliparib|Given PO
79404708|NCT04412694|Drug|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
79404709|NCT04412694|Diagnostic Test|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
79581908|NCT05106257|Behavioral|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
80031858|NCT04374448|Procedure|Posterior Epistaxis Management (SPA Ligation)|During surgery timing of Indocyanin Green (ICG) administration to fluorescence of the sphenopalatine artery will be measured.
80031859|NCT02048865|Drug|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
80031860|NCT02048865|Drug|Placebo drug|placebo drug 2.5mg BID for 6 months
80031861|NCT03663946|Other|Non-Interventional|Non-Interventional
79581909|NCT05106257|Behavioral|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
79740470|NCT04175782|Procedure|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
79740471|NCT04176796|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
79740472|NCT04176484|Other|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
79740473|NCT02667964|Other|spiroergometry|Spiroergometry on a bicycle ergometer
79404710|NCT04412694|Diagnostic Test|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
79404711|NCT04412694|Diagnostic Test|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
79740474|NCT05276986|Other|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
79740475|NCT00644800|Drug|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
79740476|NCT04083586|Other|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
79740477|NCT02670616|Drug|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
79740478|NCT02670616|Drug|Rituximab|375 mg/m2 IV, day 1
79740479|NCT02670616|Drug|Cyclophosphamide|750 mg/m2 IV day 1
79740480|NCT02670616|Drug|Doxorubicin|50 mg/m2 IV day 1
79740481|NCT02670616|Drug|vincristine|1.4 mg/m2 IV on day 1
79740482|NCT02670616|Drug|Prednisolone|100mg per day on day 1-5
79740483|NCT00996840|Drug|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
79740484|NCT00996840|Drug|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
79740485|NCT00996840|Drug|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
79740486|NCT00996840|Drug|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
79740487|NCT00996840|Other|Placebo|Placebo to match intervention
79740488|NCT00645502|Drug|risperidone|
80031862|NCT02048943|Drug|dovitinib lactate|Given PO
80031863|NCT02048943|Drug|gemcitabine hydrochloride|Given IV
80031864|NCT02048943|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
80031865|NCT02048943|Other|pharmacological study|Correlative studies
80031866|NCT02048943|Other|laboratory biomarker analysis|Correlative studies
79278046|NCT03359096|Device|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
79278047|NCT03359096|Device|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
79404712|NCT04412694|Diagnostic Test|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
79404713|NCT04412694|Procedure|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
79581910|NCT05106257|Behavioral|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
79740489|NCT04174768|Procedure|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
79740490|NCT00644956|Drug|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
79740491|NCT00644956|Drug|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
79740492|NCT04175002|Drug|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
79740493|NCT04174846|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
79740494|NCT04174846|Dietary Supplement|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
79740495|NCT02670772|Drug|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
79740496|NCT02670772|Drug|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
80031867|NCT02049021|Device|MECTA SPECTRUM 5000Q ECT|
79740497|NCT02667808|Other|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
79740498|NCT02667808|Other|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
79740499|NCT02667184|Dietary Supplement|Low FODMAP Oral Nutrition Supplement|
79740500|NCT04294992|Drug|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
79740501|NCT02670460|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
79740502|NCT00628914|Drug|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
79740503|NCT00628914|Drug|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
79740504|NCT00628914|Drug|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
79740505|NCT02670850|Other|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
79740506|NCT02870634|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
79740507|NCT02537236|Dietary Supplement|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
80031868|NCT02049021|Procedure|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
79278048|NCT03330158|Device|ASTS|Implantation of a motorized spinal distraction rod
79404714|NCT04412694|Other|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
79404715|NCT04412694|Other|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
79404716|NCT04412694|Other|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
79404717|NCT04412694|Other|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
79404718|NCT04412694|Other|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
79404719|NCT04412694|Other|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
79404720|NCT04412694|Other|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
79404721|NCT04412694|Other|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
79278049|NCT03314155|Diagnostic Test|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer ([18F]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
79278050|NCT03313128|Other|Sanitation|Improved sanitation facility
79278051|NCT03309683|Device|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
79278052|NCT03306485|Other|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
80031869|NCT04430296|Procedure|Cyclophotocoagulation|"High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye."
79404722|NCT03628261|Device|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
79404723|NCT03628261|Other|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
79404724|NCT03613038|Behavioral|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
79404725|NCT03627715|Drug|Propagermanium|Immediate release capsule
79404726|NCT03627715|Drug|Placebo|Placebo capsule
79404727|NCT04298268|Device|CUSA Clarity Ultrasonic Surgical Aspirator System use|Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal
79581911|NCT05106257|Behavioral|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
79581912|NCT05097716|Drug|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
79740508|NCT02537236|Behavioral|TLC nutritional intervention|nutritional orientation.
79740509|NCT02537236|Dietary Supplement|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
79740510|NCT04174066|Other|blood sample|blood sample during planned in the follow-up of patients.
79404728|NCT00246753|Drug|lapatinib ditosylate|1500 mg, daily until disease progression
79581913|NCT05097716|Drug|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
79581914|NCT05086016|Device|Catheterized Stenting|Catheterized stenting of vascular narrowings.
80031870|NCT02050893|Drug|sedatives(Midazolam and Propofol)|
79581915|NCT05084963|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
79581916|NCT05084963|Drug|Placebo|Matching placebo for IRL201104
79581917|NCT05071703|Drug|Trilaciclib|"Carboplatin combined with Etoposide (ES-SCLC patients)~plus Topotecan (second/third line ES-SCLC patients)"
79581918|NCT05071300|Drug|Eplontersen|Eplontersen will be administered by SC injection.
79740511|NCT04174066|Other|tissue sample|tissue sample during planned in the follow-up of patients.
79740512|NCT04174066|Other|excreta|urine sample during planned in the follow-up of patients.
79740513|NCT00645580|Drug|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
79740514|NCT02666872|Behavioral|Motivational interviewing|
79740515|NCT02670304|Drug|letrozole|letrozole from the day of oocyte retrieval for 5 days
79740516|NCT02670304|Drug|Aspirin|aspirin from the day of oocyte retrieval for 5 days
79740517|NCT02671708|Drug|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
79740518|NCT02671708|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
80031871|NCT02050971|Biological|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
80031872|NCT02050971|Biological|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
80031873|NCT05257330|Diagnostic Test|CSF Examination|Lumbar puncture for CSF Examination
80031874|NCT03551782|Drug|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
80031875|NCT03551782|Drug|Apalutamide 240 mg|Apalutamide 240 mg (4*60 mg) tablets per day will be administered orally.
80031876|NCT02806947|Drug|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
79278053|NCT03182751|Drug|Tranexamic Acid (TXA)|Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
80031877|NCT02806947|Drug|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
80031878|NCT03046732|Other|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
80031879|NCT03442114|Behavioral|Hydroxyurea SDM Toolkit|Implementation tools and visit decision aids
80031880|NCT03442114|Behavioral|Clinician Pocket Guide|current hydroxyurea protocol and ASH pocket guide
79278054|NCT03182751|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient
79278055|NCT03139149|Procedure|Adhesiolysis|"Method of video laparoscopic operation:~Open access in the left upper quadrant of the anterior abdominal wall,~Installation of trocars, depending on the prevalence of the adhesion process~Assessment of the peritoneal adhesion index~Detection of the asleep gut~Detection of obstacle area~Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
79278056|NCT03139149|Radiation|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
79404729|NCT02083861|Device|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
79278057|NCT03139149|Radiation|Computer tomography|Computer tomography of abdomen with iv contrast
79278058|NCT03139149|Procedure|Ultrasound|Ultrasound of the abdomen (2 times)
79581919|NCT05058989|Diagnostic Test|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
79740519|NCT02671708|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
79278059|NCT03139149|Other|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
79278060|NCT03121989|Drug|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
79278061|NCT03121989|Other|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
79740520|NCT05060458|Other|No intervention|No intervention
79278062|NCT03121989|Drug|NAC|Participants will be receiving NAC as part of their clinical treatment.
79278063|NCT03105245|Other|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
79278064|NCT03090646|Other|Financial Incentive|Up to three gift cards to a major online retailer.
79581920|NCT05058989|Other|Clinical interventions and procedures|"First trimester (0-13 weeks):~Consent~Clinical data collection~Blood samples (genomic+ hormonal)~Duplex ultrasound~Vector flow imaging (advanced ultrasound software)~Truncated cone tool (measuring leg circumference using a tape measure)~PPG~AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~Clinical data collection~Blood sample (hormonal only)~DUS~VFI~Truncated cone tool~PPG~AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
79581921|NCT05055843|Procedure|Magnetic Resonance Imaging|Undergo 3D MRI
79581922|NCT05054998|Radiation|Fludeoxyglucose F-18|Given IV
79740521|NCT00998946|Drug|Pralatrexate|Pralatrexate injection administered as intravenous (IV) push
79740522|NCT00998946|Dietary Supplement|Vitamin B12|1 mg intramuscular (IM) injection
79740523|NCT00998946|Dietary Supplement|Folic Acid|Oral 1 mg tablet
79740524|NCT05146180|Device|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
79278065|NCT03075397|Other|blood sample|A sample of HIV-1 infected patients's blood is collected
79740525|NCT01158404|Drug|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
80031881|NCT03562065|Biological|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
79278066|NCT03075397|Other|sperm sample|A sample of HIV-1 infected patients's sperm is collected
79278067|NCT03019588|Biological|Pembrolizumab|IV infusion
79278068|NCT03019588|Drug|Paclitaxel|IV infusion
79278069|NCT02959944|Drug|ibrutinib|Ibrutinib capsules administered orally daily
79278070|NCT02959944|Drug|Placebo|Placebo capsules administered orally daily
79278071|NCT02959944|Drug|Prednisone|Prednisone administered daily
79278072|NCT02823002|Procedure|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
79278073|NCT02823002|Procedure|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
80031882|NCT04870684|Other|thromboelastometry test|This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
80031883|NCT02037399|Drug|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
79581923|NCT05054998|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
80031884|NCT02037399|Drug|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
80031885|NCT03561753|Drug|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
79740526|NCT01158404|Drug|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
79581924|NCT05054998|Procedure|Positron Emission Tomography|Undergo PET/MRI
79581925|NCT05053555|Device|high dose rate brachytherapy|diagnostic workup, staging, and treatment per the institution standard of care
79278074|NCT02823002|Procedure|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
79581926|NCT05053555|Device|high dose rate brachytherapy|reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
79740527|NCT02670070|Drug|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
79740528|NCT00645034|Drug|placebo|placebo by mouth as a single dose
79740529|NCT00645034|Drug|sildenafil|sildenafil 100 mg by mouth as a single dose
79740530|NCT02885090|Procedure|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
79278075|NCT02823002|Procedure|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
79278076|NCT02823002|Procedure|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
79278077|NCT02823002|Procedure|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
79581927|NCT05047302|Device|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
79278078|NCT02823002|Drug|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
79278079|NCT02823002|Drug|Buffer|Sodium Bicarbonate
79278080|NCT02806687|Drug|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
79278081|NCT02806687|Drug|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
79581930|NCT05041153|Drug|Lenvatinib|Given by PO
79581931|NCT05041153|Biological|Pembrolizumab|Given by IV
79581932|NCT05035706|Procedure|Biopsy|Undergo biopsy
79581933|NCT05035706|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
79581934|NCT05035706|Other|Electronic Health Record Review|Medical records reviewed
79581935|NCT05035706|Other|Photography|Photographs taken
79581936|NCT05035667|Other|Questionnaire Administration|Complete questionnaires
79740531|NCT04173832|Drug|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
79278082|NCT02774668|Other|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
79278083|NCT02774668|Other|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
79278084|NCT02761668|Procedure|ParS+Ortho 4W|Orthodontics 4 weeks post surgical
79278085|NCT02761668|Procedure|ParS+Ortho 6M|Orthodontics 6 months post surgical
79278086|NCT02698449|Procedure|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
79278087|NCT02698449|Procedure|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
79278088|NCT02698449|Procedure|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
80031886|NCT03561753|Drug|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
80031887|NCT02260089|Drug|Low dose of telmisartan|
80031888|NCT02260089|Drug|High dose of telmisartan|
80031889|NCT02260089|Drug|Placebo|
80031890|NCT03805815|Device|tunable crack sensor|blood pressure monitoring via crack sensor
79581937|NCT05032105|Device|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
80031891|NCT02049255|Drug|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
79581938|NCT05006248|Device|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
79581939|NCT05006248|Device|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
79278089|NCT02698449|Procedure|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
79278090|NCT02698449|Radiation|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
79278091|NCT02633891|Behavioral|Balance exercise|tailored balance exercise program
79278092|NCT02633891|Behavioral|Standard care|general health education and fall prevention classes
79278093|NCT02596568|Device|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
79740532|NCT04173832|Drug|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
79740533|NCT04173910|Procedure|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
79740534|NCT00998790|Device|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
79278094|NCT02596568|Other|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
79278095|NCT02589821|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
79278096|NCT02589821|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
79278097|NCT02588170|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
79740535|NCT02537002|Drug|PF-05230907|A single intravenous dose of 3 μg/kg
79740536|NCT02537002|Drug|PF-05230907|A single intravenous dose of 5 μg/kg
79740537|NCT02537002|Drug|Placebo|A single intravenous dose of matched placebo
79740538|NCT00645658|Drug|Testim (1% testosterone gel)|Subjects apply contents of gel packet to skin daily.
79740539|NCT01001988|Other|Blood sample|Blood sample for immunogenicity assessment
79404730|NCT03600480|Drug|NNC0174-0833|Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous [s.c.], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
79581940|NCT05006248|Device|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
79581941|NCT04989959|Drug|[18F]PT2385|[18F]PT2385 infusion
79581942|NCT04989959|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after [18F]PT2385 infusion
79581943|NCT04989959|Procedure|Biopsy|CT-guided tumor biopsy
79278098|NCT02588170|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
79740540|NCT01001988|Biological|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
79740541|NCT02667340|Dietary Supplement|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game & at halftime)
79740542|NCT02667340|Other|Placebo|0.7 g glucose per kg body mass in two ingestions (before game & at halftime)
79740543|NCT04293354|Procedure|Serratus Plane Block|Serratus Plane Block was performed
79278099|NCT02559180|Drug|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
79278100|NCT02539966|Device|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
80031892|NCT02049255|Drug|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
80031893|NCT02049333|Procedure|Phacoemulsification|
80031894|NCT02049333|Procedure|Endoscopic Cycloplasty (ECPL)|
80031895|NCT02806713|Drug|Phenazopyridine|
80031896|NCT02806713|Other|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
79404731|NCT03600480|Drug|Semaglutide|Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
79404732|NCT03600480|Drug|Placebo (NNC0174-0833)|Participants will receive once weekly injections of NNC0174-0833 matched placebo.
79404733|NCT03624361|Device|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
79404734|NCT00246129|Drug|Campath|Monoclonal antibody induction therapy
80031897|NCT02037711|Drug|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
80031898|NCT02037711|Drug|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
80031899|NCT03561675|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
80031900|NCT03561675|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
80031901|NCT02049411|Drug|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
80031902|NCT02049411|Drug|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
80031903|NCT02807493|Device|Occlusal Support Device|Bite plate
80031904|NCT02807493|Other|Control|Control group
80031905|NCT02051127|Other|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
79404735|NCT00246129|Drug|Daclizumab|Monoclonal antibody induction therapy
79404736|NCT04131972|Device|REGENERA|REGENERA breast implant
79404737|NCT02980848|Other|Screening digital mammography|Screening with digital mammography alone
79581944|NCT04973852|Device|Ekso|Exoskeleton walking
79581945|NCT04971200|Drug|Tildrakizumab|2 100mg subcutaneous injections Q4W
79740544|NCT04293354|Procedure|Control|No block was performed
79740545|NCT02666170|Drug|Alpha-lipoic acid|
79740546|NCT02670148|Procedure|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
79740547|NCT02667262|Other|Algorithm to identify patients experiencing opioid abuse/addiction|
79740548|NCT04077268|Other|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
79740549|NCT00645736|Other|No intervention|No intervention
80031906|NCT02049489|Biological|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
79278101|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
79278102|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
79404738|NCT02980848|Other|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
79278103|NCT02455557|Other|Laboratory Biomarker Analysis|Correlative studies
79876434|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
80031907|NCT02051751|Drug|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
79740550|NCT02666404|Other|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
80031908|NCT02051751|Drug|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
79404739|NCT02980848|Other|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
79404740|NCT02980848|Other|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
79581946|NCT04931225|Drug|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
79876435|NCT01046487|Procedure|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
79581948|NCT04906512|Device|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
79740551|NCT00646126|Drug|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
79740552|NCT00646126|Drug|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
79740553|NCT02670226|Other|Samples|Blood samples, muscle biopsy
79740554|NCT02537080|Drug|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
80031909|NCT02049567|Device|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
80031910|NCT02049567|Procedure|Cataract Surgery|Performed using standard microsurgical techniques
79278104|NCT02455557|Drug|Montanide ISA 51 VG|Given SC
79278105|NCT02455557|Biological|Sargramostim|Given SC
79278106|NCT02455557|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
79278107|NCT02455557|Drug|Temozolomide|Given PO or IV
79404741|NCT02980848|Other|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
79404742|NCT01676779|Biological|Dendritic cell therapy|Dendritic cell therapy IV and ID
79740555|NCT02537080|Drug|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
79740556|NCT02667496|Drug|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
79740557|NCT02667496|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
79740558|NCT02667496|Drug|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
79740559|NCT00645112|Drug|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
79740560|NCT00645112|Drug|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
79740561|NCT02666482|Behavioral|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
79278108|NCT02443961|Biological|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
79278109|NCT02401139|Drug|Ketamine|
79278110|NCT02401139|Drug|Placebo|
79404743|NCT04345575|Device|PainCare VR|Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
79404744|NCT04345575|Other|Audio content|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
79740562|NCT02667106|Drug|RX0041-2|Pharmacokinetic study
79740563|NCT02666092|Other|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
79876436|NCT01069276|Other|No intervention in this study|No intervention in this study
79876437|NCT01066390|Biological|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
79876438|NCT03978286|Drug|Vortioxetine|10 mg per day
79278111|NCT02367846|Drug|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
79581949|NCT04906512|Device|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
79581950|NCT04905277|Drug|Atenolol 50 MG|50 mg Atenolol daily
79278112|NCT02367846|Drug|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
79876439|NCT03978286|Drug|Sertraline|75 mg per day
79876440|NCT03826186|Device|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
79581951|NCT04905277|Drug|Placebo|one placebo daily
79278113|NCT02270450|Procedure|therapeutic conventional surgery|Undergo abdominal surgery
79278114|NCT02270450|Procedure|gastrointestinal complications management/prevention|Undergo non-surgical management
80031911|NCT02051829|Other|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
80031912|NCT02051907|Device|KAM1403 Gel|
80031913|NCT02051907|Device|aloevera gel|
80031914|NCT02049801|Drug|MEK inhibitor MEK162|Given PO
80031915|NCT02049801|Drug|idarubicin|Given IV
79581952|NCT04893278|Other|Virtual reality|Use of Virtual reality goggles during procedure
80031916|NCT02049801|Drug|cytarabine|Given IV
80031917|NCT02049801|Other|pharmacological study|Correlative studies
80031918|NCT02049801|Other|laboratory biomarker analysis|Correlative studies
79278115|NCT02270450|Other|quality-of-life assessment|Ancillary studies
79278116|NCT02241109|Other|no intervention|progression monitoring by echocardiography
79278117|NCT02195895|Drug|Alendronate|Weekly oral alendronate 70 mg for 12 months
79278118|NCT02195895|Dietary Supplement|Calcium|Daily oral 1000 mg Calcium
79278119|NCT02195895|Dietary Supplement|Vitamin D|Daily oral 1000 IU
79278120|NCT02194842|Drug|Ra223|
79278121|NCT02194842|Drug|Enzalutamide|
79581953|NCT04892472|Device|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
79581954|NCT04892472|Drug|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
79581955|NCT04889911|Behavioral|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
79581956|NCT04889911|Other|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
79581957|NCT04888312|Biological|CD40 agonist mitazalimab in combination with chemotherapy|Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.
79581958|NCT04880083|Dietary Supplement|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
79581959|NCT04857671|Drug|Botulinum Toxin Type A in saline water|"100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points."
79581960|NCT04857671|Drug|Isotone saline water|2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
79581961|NCT04856046|Procedure|Biospecimen Collection|Undergo collection of blood sample
79876441|NCT03826186|Device|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
79876442|NCT01069432|Other|No Intervention|No Intervention
79876443|NCT00382863|Device|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
79876444|NCT00382863|Drug|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
80031919|NCT02049879|Drug|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
80031920|NCT02051283|Other|RFA|RFA
80031921|NCT02053311|Drug|Orteronel|300mg orteronel
80031922|NCT02053311|Drug|Placebo|Placebo
79278122|NCT02185781|Other|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
79740564|NCT02666092|Biological|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
79404745|NCT02848716|Procedure|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
79278123|NCT01970722|Drug|Carboplatin|Given IP or IV
79278124|NCT01970722|Drug|Cisplatin|Given IP
80031923|NCT02051439|Procedure|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
79404746|NCT02848716|Radiation|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
79278125|NCT01970722|Drug|Gemcitabine Hydrochloride|Given IP or IV
79404747|NCT02848716|Radiation|chemoradiation|
79404748|NCT01274247|Drug|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
79404749|NCT02738034|Other|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
79581962|NCT04856046|Other|Electronic Health Record Review|Review of medical records
79581963|NCT04855864|Other|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
79581964|NCT04855864|Other|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
79581965|NCT04855864|Other|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
79740565|NCT02669524|Drug|LY2409021|
79740566|NCT02669524|Drug|LY2409021 placebo|
79740567|NCT02669524|Procedure|OGTT|
79278126|NCT01970722|Other|Laboratory Biomarker Analysis|Correlative studies
79278127|NCT01970722|Drug|Paclitaxel|Given IP or IV
79278128|NCT01970722|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IP or IV
79278129|NCT01970722|Other|Quality-of-Life Assessment|Ancillary studies
79278130|NCT01970722|Procedure|Therapeutic Conventional Surgery|Undergo surgery
79740568|NCT02669524|Procedure|IIGI|
79581966|NCT04853004|Diagnostic Test|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
79740569|NCT02669524|Procedure|Standardised liquid meal|
79740570|NCT04071496|Other|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
79740571|NCT04076566|Device|alfapump system|active implantable device for treatment of malignant ascites
79740572|NCT00996606|Drug|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
79740573|NCT00996606|Drug|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
79740574|NCT00645814|Drug|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
79740575|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
79740576|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
79740577|NCT02669836|Procedure|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
79740578|NCT02669836|Procedure|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
79740579|NCT04174378|Drug|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
79740580|NCT02669446|Device|Medical devices|
79278135|NCT01913951|Drug|vosaroxin|Given IV over 10 minutes on Day 1 and 4
79278136|NCT01913951|Drug|Azacitidine|Given SC or IV over 15 minutes on days 1-7
79278137|NCT01885702|Biological|DC vaccination|DC vaccination
79278138|NCT01867320|Drug|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
79278139|NCT01709136|Drug|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
79278140|NCT01630850|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
79278141|NCT01630850|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
79278142|NCT01565499|Drug|Nab-paclitaxel|
79278143|NCT01435668|Behavioral|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
79278144|NCT01435668|Behavioral|Simple written advice|Patients receive an information leaflet.
79581967|NCT04836637|Dietary Supplement|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
79581968|NCT04836637|Dietary Supplement|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
79740581|NCT02669446|Device|traditional household remedy|
79740582|NCT00645892|Drug|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
79740583|NCT00645892|Drug|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
79740584|NCT00645190|Drug|Galantamine HBr|
79740585|NCT04293120|Other|Training with weighted ball|Participants will stop or catch a weighted ball
79740586|NCT04174456|Diagnostic Test|FDG PET|baseline and 6-month follow-up FDG PET
79740587|NCT02870166|Other|blood sample|
79740588|NCT02869308|Drug|stannous pyrophosphate|Injection of 1ml Angiocis
79740589|NCT02869308|Drug|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
79740590|NCT02869308|Device|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
79740591|NCT02869308|Device|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
79740592|NCT00910390|Other|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
79740593|NCT00910390|Other|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
79876445|NCT03933449|Biological|pembrolizumab|IV infusion
79876446|NCT03933449|Drug|paclitaxel|IV infusion
79876447|NCT03933449|Drug|docetaxel|IV infusion
80031924|NCT02807259|Behavioral|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
79278145|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
79278146|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
79278147|NCT01036087|Drug|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
79278148|NCT01036087|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
79278149|NCT01036087|Drug|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
79278150|NCT01036087|Drug|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
79404750|NCT01279629|Drug|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
79404751|NCT04762849|Procedure|Laparoscopic one anastomosis gastric bypass|Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
79581969|NCT04836637|Dietary Supplement|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
79278151|NCT01036087|Drug|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
79278152|NCT01036087|Drug|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
79740594|NCT00910390|Other|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
79404752|NCT04762849|Device|A shape-memory ring for adjustable gastric banding|A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
79740595|NCT02869698|Procedure|Spectral Dynamic Imaging|
79278153|NCT00794001|Behavioral|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
79278154|NCT00783367|Drug|Lenalidomide|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study
79278155|NCT00783367|Drug|Dexamethasone|Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study;
79278156|NCT00783367|Drug|Rituximab|Rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
79404753|NCT01274325|Drug|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
79278157|NCT00572156|Drug|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
79278158|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
79404754|NCT01274325|Drug|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
79404755|NCT04502394|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
79404756|NCT04502394|Drug|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
79278159|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
79278160|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
79278161|NCT00447772|Biological|Botulinum toxin type A|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
79278162|NCT00255216|Drug|Policosanol supplement (oral capsule) vs. placebo|
79404757|NCT02984839|Device|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
79404758|NCT00746187|Device|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
79581970|NCT04836637|Dietary Supplement|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
79581971|NCT04828083|Drug|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
79740596|NCT02869698|Device|Hybride electrode|
79740597|NCT02869698|Device|Macro electrode|
79740598|NCT02665936|Drug|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
79740599|NCT02665936|Drug|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
79740600|NCT02665936|Drug|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
79740601|NCT04292262|Other|Observational|Observational
79740602|NCT02665858|Other|OCT Imaging|
79581972|NCT04828083|Drug|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
80031925|NCT02053389|Behavioral|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
80031926|NCT02053389|Behavioral|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
79278163|NCT02199353|Other|Stimulation of Activities Daily Living|"Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
79404759|NCT00746187|Device|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
79404760|NCT01677091|Other|Cervical vibration|Vibration of neck muscles during 10 minutes
79404761|NCT01677091|Other|Prism adaptation|Prism adaptation during 10 minutes
79404762|NCT01677091|Other|Conventional rehabilitation|conventional rehabilitation
80031927|NCT03805893|Procedure|Moderate heat pain|To apply a sensory challenge that can be applied over longer periods required for PET imaging and that is also compatible with high magnetic fields during MRI scanning, we will use a well-established thermal challenge of the lower extremity. To apply mildly painful heat to the patient, the right leg (from the foot up to the knee) will be wrapped in a blanket that incorporates a network of small-diameter plastic tubing through which hot water (45 - 55 oC) is circulated from a temperature-controlled reservoir.
79278164|NCT02199353|Other|Conventional ADLOccupational Therapy|"Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
79404763|NCT01274403|Drug|Melphalan, Prednisone and Thalidomide|
79581973|NCT04826068|Behavioral|Emotional Processing|Processing Emotions of others based on photographs of faces
79404764|NCT03182868|Device|PAS Goggle|PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
79404765|NCT03700099|Drug|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
79404766|NCT03700099|Drug|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
79581974|NCT04825678|Drug|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
79581975|NCT04808713|Behavioral|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
79581976|NCT04808700|Other|Follow-up of Episealer implant|Follow-up and radiographic evaluation in patients who received an Episealer implant
79581977|NCT04808505|Biological|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
79581978|NCT04808505|Drug|Miglustat|65 mg oral capsules
79581979|NCT04805346|Device|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
79581980|NCT04788654|Drug|Celebrex, acetaminophen, and dexamethasone|Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
79581981|NCT04788654|Procedure|Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum|Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
79581982|NCT04781647|Drug|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
79581983|NCT04781647|Drug|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
79581984|NCT04781647|Biological|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
79876448|NCT03933449|Drug|irinotecan|IV infusion
79876449|NCT00974285|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
79876450|NCT00974285|Drug|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
79876451|NCT03932045|Device|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
79876452|NCT03932045|Device|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
79876453|NCT00972413|Radiation|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
79876454|NCT00972413|Radiation|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
79876455|NCT00972413|Radiation|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
80031928|NCT02053467|Other|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
79278165|NCT04504773|Behavioral|Virtual Reality Exposure Therapy|Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
79404767|NCT01274481|Drug|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
79581985|NCT04777084|Drug|IBI318|IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 20 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
79278166|NCT02207309|Drug|Pazopanib|
79278167|NCT02207309|Drug|Placebo (for Pazopanib)|
79404768|NCT03782467|Biological|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
79404769|NCT00754377|Other|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
79581986|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
79581987|NCT04770246|Drug|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
79278168|NCT02374125|Device|Diacutaneous Fibrolysis|Applied only around teres major muscle.
79278169|NCT02374125|Other|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
79278170|NCT02374125|Other|Protocolized physiotherapy|Exercises, TENS and cryotherapy
79278171|NCT02257697|Drug|Mizoribine (MZR)|
79278172|NCT02257697|Drug|Cyclophosphamide (CTX)|
79278173|NCT04468555|Other|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
79278174|NCT02366793|Other|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
79278175|NCT02366793|Other|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
79278176|NCT02257775|Genetic|n/a - observational|
79278177|NCT04468711|Drug|Vitamin D|Vitamin D plus topical 1% hydrocortisone cream twice daily
79278178|NCT04468711|Drug|Placebo|placebo plus topical 1% hydrocortisone cream twice daily
79278179|NCT02207387|Drug|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
79278180|NCT02207387|Behavioral|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
79278181|NCT02207387|Other|Music|
79278182|NCT03528421|Biological|IM19|CAR-T cells
79404770|NCT03779269|Other|meditation|meditation effect assessment using assessment tools.
79404771|NCT00245583|Drug|Topiramate|minimum does of 50mg/day
79404772|NCT00245583|Drug|Placebo|matching tablet
79404773|NCT01379989|Drug|Carboplatin|Carboplatin AUC 5
79404774|NCT01379989|Drug|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
79404775|NCT01379989|Drug|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
79404776|NCT04129320|Biological|enoblituzumab|anti-B7-H3 antibody
79581988|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
79581989|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
79581990|NCT04768569|Drug|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
79581991|NCT04768569|Drug|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
79581992|NCT04759664|Drug|LUT014 Gel (Dose 1)|Topical gel
79581993|NCT04759664|Drug|LUT014 Gel (Dose 2)|Topical gel
79581994|NCT04759664|Drug|Placebo|LUT014 matching placebo topical gel
79581995|NCT04743791|Drug|Dupilumab|Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
79278183|NCT03528421|Drug|Fludarabine|Two days before cell infusion, all patients will be treated with fludarabine for 3 days
80031929|NCT02053545|Drug|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
79278184|NCT03528421|Drug|Cyclophosphamide|Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
79278185|NCT04059939|Other|Reading|Small group reading instruction
79278186|NCT04059939|Behavioral|Anxiety Management|small group anxiety management skills instruction
79278187|NCT04059939|Other|Classroom Business as Usual|Classroom Business as Usual
79404777|NCT04129320|Biological|MGA012|anti-PD-1 antibody
79404778|NCT04129320|Biological|MGD013|PD-1 X LAG-3 bispecific DART protein
79740603|NCT02869386|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
79740604|NCT02869386|Procedure|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
79278188|NCT04059939|Other|Attention Control (math practice)|Attention Control (math practice)
79404779|NCT04053426|Other|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
79404780|NCT04012242|Diagnostic Test|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
79404781|NCT04762303|Other|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
79404782|NCT04348903|Behavioral|Virtual Reality Distraction|The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
79740605|NCT02665780|Procedure|Periodontal debridement|teeth cleaning
79740606|NCT02665780|Other|Cetylpyridium chloride|mouthrinse
79740607|NCT02869464|Other|Imaging-Ultrasound|Abdominal Ultrasound
79740608|NCT02869464|Other|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
79740609|NCT02869464|Genetic|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
79740610|NCT00646360|Dietary Supplement|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
79278189|NCT02207543|Other|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
79278190|NCT02374047|Drug|CAT-2054|
79278191|NCT02374047|Drug|Placebo|
79278192|NCT02374047|Drug|CAT-2054-C|
79278193|NCT02374047|Drug|Atorvastatin|
79278194|NCT02203253|Drug|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
79404783|NCT04348903|Behavioral|Positive Pre-Visit Imagery Intervention|Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
79404784|NCT03775291|Diagnostic Test|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
79432907|NCT04143074|Behavioral|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
79278195|NCT02203253|Drug|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
79278196|NCT02203253|Drug|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
79278197|NCT03528343|Drug|Non-narcotic pain control|Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
79432908|NCT04142918|Other|Immunostaining|Immunostaining of oral mucosa/gingiva samples
79740611|NCT00646360|Dietary Supplement|Placebo|2 tablets daily during pregnancy
79740612|NCT04293510|Procedure|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
79278198|NCT02207699|Drug|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
79581996|NCT04743791|Other|Placebo|Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
79278199|NCT02207699|Drug|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
79278200|NCT02207699|Drug|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
79278201|NCT02207699|Drug|Placebo|8 placebo perles given by mouth once
79278202|NCT02296138|Drug|olodaterol|fixed dose combination
79740613|NCT04174300|Procedure|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
79740614|NCT00995436|Device|Extraoral anchorage|Extra oral anchorage
79278203|NCT02296138|Drug|tiotropium|fixed dose combination
80031930|NCT02051985|Other|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
80031931|NCT02051985|Other|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
80031932|NCT02802345|Drug|Nintedanib|
79278204|NCT02296138|Drug|tiotropium|
79278205|NCT01306942|Drug|Dasatinib|
79278206|NCT01306942|Drug|Trastuzumab|
79432909|NCT00607321|Device|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
79432910|NCT04142840|Drug|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
79581997|NCT04737330|Drug|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
79581998|NCT04737330|Drug|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
79278207|NCT01306942|Drug|Paclitaxel|
79278208|NCT02203487|Drug|BIIF 1149 BS - single rising dose|
79278209|NCT02203487|Drug|Placebo|
79278210|NCT03528265|Device|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
79278211|NCT02366715|Device|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. [3] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
79278212|NCT02207855|Drug|Chloroprocaine|
79581999|NCT04734210|Drug|0.02% Betamethasone Sodium Phosphate|topical corticosteroid solution
79278213|NCT03532841|Drug|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
79278214|NCT03532841|Drug|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
79278215|NCT02199431|Drug|Lu AF11167|
79278216|NCT02199431|Drug|Itraconazole|
79278217|NCT02207933|Procedure|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
79278218|NCT02207933|Procedure|Gait training|Gait training only for 3 times a week for 6 weeks.
79278219|NCT02199587|Behavioral|Presence of medical clown during endocrine test|
79278220|NCT02208167|Biological|HXTC infusion|
79278221|NCT03532763|Dietary Supplement|Tocotrienol-rich fraction|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
79278222|NCT03532763|Dietary Supplement|Placebo|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
79278223|NCT02208245|Device|Ultrasound: Axillary block|Ultrasound guided axillary block
79278224|NCT02208245|Device|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
79278225|NCT02208245|Drug|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
79278226|NCT03532685|Procedure|Bariatric|withdrawing a part of the stomach and may or may not be combined with bowel deviation
79278227|NCT02199821|Dietary Supplement|Formula with soybean oil, medium-chain triglycerides|
79432911|NCT04142840|Drug|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
79432912|NCT04142762|Drug|ABI-H2158|ABI-H2158 tablets
79432913|NCT04142762|Drug|Itraconazole|Itraconazole capsules
79432914|NCT04142762|Drug|Rifampin|Rifampin capsules
79432915|NCT04142762|Drug|Midazolam|Midazolam syrup
79432916|NCT04142762|Drug|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
79432917|NCT04142762|Drug|Esomeprazole|Esomeprazole capsules
79432918|NCT04142762|Drug|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
79582000|NCT04734210|Drug|0.04% Betamethasone Sodium Phosphate|topical corticosteroid solution
79582001|NCT04734210|Drug|Placebo|topical vehicle solution
79582002|NCT04732130|Behavioral|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
79740615|NCT00995436|Device|Miniscrews|Intraoral skeletal anchorage using mini screws
80031933|NCT02802345|Drug|Placebo|
80031934|NCT02802345|Drug|Sildenafil|
80031935|NCT02052063|Device|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
80031936|NCT02052063|Device|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
79278228|NCT02199821|Dietary Supplement|Soybean oil formula commonly used in the hospital|
79740616|NCT00995436|Device|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
80031937|NCT02053779|Drug|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
79432919|NCT00607867|Other|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
79740617|NCT04173598|Behavioral|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
79740618|NCT04173598|Behavioral|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
79740619|NCT02667028|Procedure|PCI|percutaneous coronary intervention
79740620|NCT04292886|Drug|Tamoxifen and femoston|oral
79740621|NCT04292886|Drug|Vitamin C and femoston|Vitamin C and femoston
79740622|NCT02669134|Other|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
79740623|NCT04292418|Drug|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
79740624|NCT02666716|Drug|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
79740625|NCT04292028|Other|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
79740626|NCT04292028|Other|Home exercises|Control group were given a home-based exercise program.
79740627|NCT04064476|Drug|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
79740628|NCT02869230|Procedure|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
79740629|NCT02869230|Procedure|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
80031938|NCT02801877|Behavioral|IntelliCare|
79278229|NCT03514901|Other|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
80031939|NCT02801877|Behavioral|Hub App with the Recommender System|
80031940|NCT02801877|Behavioral|Coaching|
80031941|NCT02056041|Procedure|Hepatectomy|
79278230|NCT03514901|Drug|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
79432920|NCT00607867|Other|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
79432921|NCT03020264|Device|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
79432922|NCT03445520|Behavioral|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
79432923|NCT03586778|Other|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
79432924|NCT03586778|Other|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
79582003|NCT04732130|Behavioral|Alternate Day Fasting|Participants are instructed to fast every other day.
79582004|NCT04727528|Drug|Sodium zirconium cyclosilicate|Investigational medicinal product
79582005|NCT04727528|Drug|Placebo|Plabeco comparator
79582006|NCT04724980|Drug|PRGN-2012|"In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10^11 and 5x10^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D."
79582007|NCT04716998|Biological|MesenCure|Three administrations of MesenCure in addition to standard care
79582008|NCT04714450|Behavioral|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
80031942|NCT02053857|Dietary Supplement|RUTF|
80031943|NCT02053857|Dietary Supplement|RUTF-P|
80031944|NCT02053857|Drug|Amoxicillin|
80031945|NCT02053935|Drug|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
80031946|NCT02037867|Device|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
79582009|NCT04711837|Drug|HSK3486|HSK3486 for induction of general anesthesia.
79278231|NCT02203877|Dietary Supplement|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
79278232|NCT02203877|Dietary Supplement|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
79740630|NCT02669290|Other|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
79278233|NCT03526783|Procedure|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
79404785|NCT02652156|Drug|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
79432925|NCT03586778|Other|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
79432926|NCT04142528|Device|ParkinPal|Wear and periodic recording of motion data during daily wear
79582010|NCT04711837|Drug|Propofol|Propofol for induction of general anesthesia.
79582011|NCT04693377|Procedure|Cryosurgery|Undergo cryoablation
79740631|NCT02669290|Other|Non-guided|LV lead placement will be conventional posterolateral placement
79582012|NCT04693377|Other|Quality-of-Life Assessment|Ancillary studies
79582013|NCT04693377|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
79582014|NCT04682678|Procedure|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
79740632|NCT02868840|Behavioral|Tai Chi exercise|exercise twice a week each for one hour
79740633|NCT02868840|Behavioral|symptom management|sending text message weekly to manage symptoms related to stroke
79740634|NCT02669368|Drug|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
79740635|NCT02669368|Drug|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
79278234|NCT03526783|Procedure|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
79278235|NCT02203955|Drug|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
79278236|NCT02203955|Drug|Maltodextrin|4 chews (maltodextrin) daily for 12 months
79278237|NCT02208323|Device|Bubble CPAP|Respiratory assistance
79278238|NCT05263661|Procedure|LIFT|Ligation of fistula tract between external and internal sphincter
79278239|NCT05263661|Procedure|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
79278240|NCT04468477|Device|6 Lead ECG|Patients will be assessed with the Kardiamobile device.
79278241|NCT05058313|Device|Photobiomodulation|Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
79740636|NCT02669368|Drug|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
79740637|NCT02669368|Drug|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
79740638|NCT00645268|Drug|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
79278242|NCT02199899|Drug|BIIF 1149 BS - single rising doses|
79740639|NCT00645268|Drug|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
79278243|NCT02199899|Drug|Placebo|
79278244|NCT04441021|Other|Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
79278245|NCT02208401|Procedure|conventional cold snare polypectomy|conventional cold snare polypectomy
79278246|NCT02208401|Procedure|Cold snare polypectomy with suction|Cold snare polypectomy with suction
79278247|NCT02208479|Other|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
79278248|NCT04440787|Procedure|Three point cuff palpation technique|the ETT is finally positioned according to the Three point cuff technique.
79278249|NCT02199977|Other|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
79278250|NCT02199977|Other|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
79278251|NCT02199977|Other|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
79278252|NCT04440709|Device|Brain/neural hand exoskeleton (B/NHE)|The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
79278253|NCT03533387|Drug|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
79278254|NCT04235023|Other|myeloid PTP1B expression analysis|peripheral blood macrophage PTP1B expression
79278255|NCT02324842|Drug|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
79278256|NCT02324842|Drug|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
79582015|NCT04680611|Other|no study intervention. Patients receive standard clinical care|no intervention. observational study
79278257|NCT02208557|Procedure|Reinforcement with Absorbable Mesh|
79278258|NCT02208557|Radiation|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
79278259|NCT02208557|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
79278260|NCT04467385|Other|VR training + Sensory Integration therapy + conventional therapy|"After the baseline assessment,~Coconut ShootersVR - 5 min/day~Ninja flipVR - 5 min/day.~Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~Conventional exercises include:~passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
79278261|NCT04467385|Other|VR training + conventional therapy|"After the baseline assessment,~The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~Coconut ShootersVR - 8 min/day~Ninja flipVR - 8 min/day~Conventional Therapy - 20 min per day~Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
79278262|NCT02295280|Drug|Metoclopramide|IV
79740640|NCT00645268|Drug|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
79876456|NCT00387075|Procedure|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
79278263|NCT02295280|Drug|Diphenhydramine|iv
79278264|NCT02295280|Drug|Codeine|PO
79278265|NCT05263505|Drug|Baricitinib 2 MG [Olumiant]|Two tabs daily
79278266|NCT05263505|Drug|Methotrexate|Target dose: 20mg weekly
79278267|NCT05263505|Drug|Azathioprine|Target dose: 2mg/kg daily
79278268|NCT05263505|Drug|Mycophenolate|Target Dose: 1g twice daily
79582016|NCT04676425|Drug|MK-8189|Administered at a dose of 4 mg via oral tablet
79582017|NCT04674189|Biological|CVnCoV Vaccine|Intramuscular injection
79582018|NCT04674189|Drug|Placebo|Intramuscular injection
79582019|NCT04670198|Behavioral|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
79278269|NCT04467307|Device|Rigit bronchoscopy|After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
79278270|NCT02208635|Other|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (~30 µg Zn/g).
79278271|NCT02208635|Other|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
79278272|NCT02208635|Other|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
80031947|NCT02054091|Dietary Supplement|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
79278273|NCT04881214|Other|Pulmonary rehabilitation|pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
79278274|NCT04467151|Drug|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
79278275|NCT04467151|Other|Placebo|Administration of placebo (albumin 5%)
79278276|NCT02204033|Drug|99mTc - labelled hMAb BIWA 4|
79278277|NCT02204033|Drug|186 Re - labelled hMAb BIWA 4|
79278278|NCT02204033|Drug|unlabelled hMAb BIWA 4 - low dose|
79278279|NCT02204033|Drug|unlabelled hMAb BIWA 4 - medium dose|
79278280|NCT02204033|Drug|unlabelled hMAb BIWA 4 - high dose|
79278281|NCT03526705|Device|NB-UVB|Phototherapy
79278282|NCT03533309|Procedure|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
79582020|NCT04670198|Behavioral|Waiting-list control|Usual care for 6 months, followed by the YES programme.
80031948|NCT02056197|Other|Placebo|Shortwave
80031949|NCT02056197|Other|Stable surface exercises|Stable surface exercises
79278283|NCT03533309|Procedure|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
79278284|NCT02200133|Other|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
79582021|NCT04661891|Other|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
79740641|NCT00646438|Drug|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
79278285|NCT02208713|Biological|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
79404786|NCT02652156|Drug|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
79278286|NCT04189159|Behavioral|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
79278287|NCT02204111|Other|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
79278288|NCT02204189|Drug|TongFuSan|TongFuSan 1g
79278289|NCT02204267|Other|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
80031950|NCT02056197|Other|Unstable surface exercises|
80031951|NCT02056275|Other|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
79278290|NCT02204267|Device|ECG|
79278291|NCT05263271|Drug|Gentulizumab|Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
79278292|NCT02204423|Procedure|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
79278293|NCT02917187|Drug|BIIB074|Administered as specified in the treatment arm
79278294|NCT02917187|Drug|Placebo|Matched placebo
79278295|NCT02204501|Drug|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
79278296|NCT02204501|Drug|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
79404787|NCT02652156|Drug|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
79404788|NCT03699865|Other|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
79740642|NCT02666014|Drug|Sugammadex|Reversal of neuromuscular blockade
79278297|NCT02204501|Drug|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
79278298|NCT05471089|Device|Diathermy by emission of Radiofrequency|Applied only to experimental group
79404789|NCT00754923|Drug|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
79404790|NCT03698149|Device|PMT/Blackrock Combination Device|PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
79740643|NCT02666014|Drug|Neostigmine|Reversal of neuromuscular blockade
80031952|NCT02056275|Other|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
80031953|NCT02038101|Behavioral|Education and Feedback|"Formal Rounds on AUC for TTE~Appropriate Use for TTE Application for Smartphone~Individualized Feedback Reports provided by email"
80031954|NCT02056353|Device|LOGIC-Insulin algorithm|
80031955|NCT02056353|Device|Paper protocol|
79740644|NCT02665702|Drug|NVB|25mg/m2 ，D1，8
79740645|NCT02665702|Drug|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
79278299|NCT05471089|Other|Therapeutic exercise|Applied to both arms/groups
79278300|NCT02204735|Behavioral|Eat majority of calories in the morning|
79278301|NCT02204735|Behavioral|Eat the majority of calories in the evening|
79278302|NCT02204813|Drug|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
79278303|NCT02204813|Drug|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
79278304|NCT02204813|Drug|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
79278305|NCT02204813|Drug|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
79278306|NCT02294734|Drug|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
79278307|NCT02294734|Drug|Placebo|Dry powder for inhalation via DISKUS 'device'
79278308|NCT03581383|Behavioral|PREP-C|The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.
79582022|NCT04661891|Other|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
79740646|NCT02665702|Drug|Endostar|15mg/d，d1-d7 civ
79740647|NCT04173676|Drug|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
79740648|NCT02665156|Procedure|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
79278309|NCT03581383|Behavioral|Modified ECHO|The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.
79278310|NCT03581383|Behavioral|Patient Telemedicine Questionnaire|The patient questionnaire includes questions about patient experiences with telemedicine visits with providers
79278311|NCT02204891|Dietary Supplement|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
79278312|NCT02204891|Dietary Supplement|Probiotics|One capsule twice daily for 30 days
79278313|NCT03533231|Combination Product|Canal Disinfection Triple Antibiotic Paste (TAP)|"Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity."
79278314|NCT03533231|Combination Product|Ciprofloxacin + Propolis Paste|
79278315|NCT03533231|Combination Product|Ciprofloxacin + Metronidazole Paste|
79740649|NCT04173130|Device|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
79740650|NCT04173286|Procedure|antibiotherapy|< 7 days
79278316|NCT03533231|Combination Product|Propolis + Metronidazole paste|
79278317|NCT02200601|Device|Seipher Wellness|
79404791|NCT00746421|Drug|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
79582023|NCT04661891|Device|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
79740651|NCT00646750|Drug|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
79740652|NCT00646516|Drug|budesonide/formoterol (Symbicort)|
79740653|NCT04033198|Procedure|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
79740654|NCT02665624|Drug|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
79740655|NCT02665624|Drug|Senna alone|comparison of bowel cleansing and patient comfort.
79740656|NCT05258266|Drug|ZX-101A|Q.D., oral dosing
79876457|NCT00387075|Drug|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
79876458|NCT00974441|Drug|Divalproex Sodium|500 mg Extended Release Tablet
79278318|NCT04172623|Behavioral|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
80031956|NCT03636633|Other|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
80031957|NCT03636633|Other|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
80031958|NCT03603951|Drug|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
80031959|NCT02052219|Drug|Blisibimod|Blisibimod administered subcutaneously
79582024|NCT04661891|Device|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
79582025|NCT04661891|Device|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
79740657|NCT02668744|Behavioral|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
79876459|NCT00974441|Drug|Depakote®|500 mg Extended Release Tablet
79278319|NCT04172623|Behavioral|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
79278320|NCT02200757|Drug|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
79278321|NCT02200757|Drug|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
79278322|NCT03525067|Other|Bile sampling for bacterial examination|At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
80031960|NCT02052219|Drug|Placebo|Placebo administered subcutaneously
80031961|NCT03561519|Other|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
80031962|NCT03561519|Other|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
80031963|NCT02056587|Drug|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
79278323|NCT02200913|Other|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
79278324|NCT02200913|Other|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
79278325|NCT02208791|Drug|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
79278326|NCT02208791|Drug|No intervention|
79278327|NCT05223101|Drug|Telminone 80 mg|Single administration of telmisartan 80 mg
79278328|NCT05223101|Drug|Drug: Micardis 80 mg|Single administration of telmisartan 80 mg
79278329|NCT05448391|Drug|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
79404792|NCT00746421|Drug|Placebo|200mg, 300mg or 400mg
80031964|NCT02038335|Drug|DMPA|Depot medroxyprogesterone acetate
80031965|NCT02038335|Drug|NET-EN|Norethisterone enantate
80031966|NCT02038335|Drug|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
80031967|NCT02038335|Device|LNG-I|Levonorgestrel subdermal implant
80031968|NCT02038335|Device|ENG-I|Etonogestrel subdermal implant
80031969|NCT02038335|Device|Cu-IUD|Copper IUD
80031970|NCT02056665|Drug|MINOCYCLINE|Pill Minocycline 50 mg capsule
80031971|NCT02056665|Drug|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
80031972|NCT02056743|Drug|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
80031973|NCT02056743|Drug|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
80031974|NCT02056743|Dietary Supplement|Red ginseng|During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
80031975|NCT02056743|Dietary Supplement|Fermented-red ginseng|During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
80031976|NCT02805309|Behavioral|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
79278330|NCT02204969|Dietary Supplement|Lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
80031977|NCT02805309|Behavioral|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
80031978|NCT02805309|Behavioral|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
79582026|NCT04661891|Other|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
79582027|NCT04660539|Drug|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
79740658|NCT02668900|Behavioral|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
79582028|NCT04660539|Drug|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
79582029|NCT04660539|Drug|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
79740659|NCT00910546|Device|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
79740660|NCT00646594|Drug|budesonide/formoterol (Symbicort)|
79740661|NCT00646594|Drug|fluticasone/salmeterol (Advair)|
79740662|NCT00646984|Drug|Standard continuous antiretroviral therapy|
79740663|NCT00646984|Drug|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
79740664|NCT00646984|Drug|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
80031979|NCT02804763|Drug|Placebo|Solution for infusion, 0,9% saline
80031980|NCT02804763|Drug|Dapirolizumab pegol (DZP)|Solution for infusion
79278331|NCT02204969|Device|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
79278332|NCT02258087|Radiation|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
79278333|NCT02258087|Radiation|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
79278334|NCT02852057|Drug|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
79278335|NCT04132999|Behavioral|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
79278336|NCT04132999|Behavioral|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
79278337|NCT04020445|Other|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
79278338|NCT05203523|Device|transcranial alternative current stimulation (tACS)|A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.
79404793|NCT00755235|Other|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
79404794|NCT02117076|Drug|Gabapentin immediate release|up to 1200 mg per day
79404795|NCT02117076|Drug|Gabapentin enacarbil extended release|up to 1200 mg per day
80031981|NCT02052297|Other|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
79404796|NCT00724477|Drug|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
79278339|NCT05203523|Other|cognitive exercises|"Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant."
79278340|NCT03524833|Drug|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
79278341|NCT03524833|Drug|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
79278342|NCT02220647|Drug|Linagliptin/Metformin FDC|
79404797|NCT01274793|Drug|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
79582030|NCT04660539|Drug|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
79582031|NCT04652765|Drug|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
79582032|NCT04652765|Drug|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
79582033|NCT04642430|Drug|Apixaban|Refer to Apixaban group
80031982|NCT02052375|Drug|ASP2408|subcutaneous injection
79278343|NCT02220647|Drug|Linagliptin|
79582034|NCT04642430|Drug|Rivaroxaban|Refer to Rivaroxaban group
79740665|NCT00910468|Procedure|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
79740666|NCT04173052|Device|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
79740667|NCT04172896|Procedure|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
79740668|NCT04172896|Procedure|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
79740669|NCT02665390|Procedure|Percutaneous cryoablation|Percutaneous cryoablation
79740670|NCT04172818|Behavioral|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
79740671|NCT02668978|Device|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
79740672|NCT02668978|Procedure|Standard surgical technique|Lung resuturing or restapling
79740673|NCT00647140|Other|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
79740674|NCT04172428|Diagnostic Test|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
79740675|NCT00647218|Drug|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
79740676|NCT00647218|Drug|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
79740677|NCT00647218|Procedure|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
79740678|NCT00647218|Radiation|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
79740679|NCT00647218|Drug|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
80031983|NCT02052375|Drug|Placebo|subcutaneous injection
80031984|NCT03561363|Behavioral|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
79278344|NCT02220647|Drug|Metformin|
79404798|NCT01274793|Device|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
79404799|NCT01274793|Device|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
79404800|NCT03763578|Other|Licorice|Natural herbal product
79404801|NCT00746889|Drug|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
79582035|NCT04630431|Other|Best Practice|Undergo standard of care follow-up
79582036|NCT04630431|Other|Educational Intervention|Undergo clinical trial education via a video and educational booklet
79582037|NCT04630431|Other|Electronic Health Record Review|Review of medical record
79582038|NCT04630431|Behavioral|Patient Navigation|Undergo clinical trial navigation
79404802|NCT00746889|Drug|saline|Single intraarticular injection of 1 ml of 0.9% saline
79404803|NCT01675050|Drug|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
79404804|NCT01675050|Drug|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
79404805|NCT00756093|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
79404806|NCT00756093|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
79404807|NCT00756093|Other|Blink Tears|Blink Tears one drop each eye one time
79404808|NCT00756093|Other|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
79582039|NCT04630431|Other|Questionnaire Administration|Complete questionnaire
79582040|NCT04627948|Diagnostic Test|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
80031985|NCT02054559|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
79582041|NCT04624750|Drug|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to < 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to < 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
80031986|NCT02054559|Radiation|Radiotherapy|
80031987|NCT02054637|Drug|Lanreotide|
80031988|NCT02056977|Other|Titration|Individualized PEEP according to PEEP titration monitored by EIT
80031989|NCT02056977|Other|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
80031990|NCT02057055|Other|Soap 300000027003|
80031991|NCT02057055|Other|Soap 300000029240|
79404809|NCT00816582|Procedure|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
79582042|NCT04614467|Biological|CLBS16|GCSF-mobilized autologous CD34+ cells
79582043|NCT04614467|Biological|Placebo|isotonic solution (no CD34+ cells)
79740680|NCT00994890|Drug|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
80031992|NCT02057211|Biological|autologous mesenchymal stem cell transplantation|
80031993|NCT02057211|Procedure|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
79740681|NCT00994890|Drug|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
79278345|NCT02205203|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
79278346|NCT02205203|Other|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
79278347|NCT04155385|Other|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
79404810|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
79582044|NCT04604509|Drug|Bupropion Hydrochloride Controlled-release|Given PO
79582045|NCT04604509|Drug|Nicotine Replacement|Given via nicotine patch, lozenges, or gum
79582046|NCT04604509|Other|Questionnaire Administration|Ancillary studies
79740682|NCT00994890|Drug|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
79740683|NCT02663830|Drug|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
79740684|NCT02663830|Drug|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
79740685|NCT00910702|Device|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
79876460|NCT01049451|Drug|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
79876461|NCT01049451|Drug|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
79876462|NCT00974519|Drug|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
79582047|NCT04604509|Other|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
79876463|NCT00974519|Drug|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
79582048|NCT04604509|Drug|Varenicline|Given PO
79582049|NCT04595422|Other|Educational Intervention|Undergo training consisting of a 60-minute educational session
79582050|NCT04595422|Other|Educational Intervention|Receive lung cancer screening educational materials
79582051|NCT04595422|Other|Questionnaire Administration|Complete questionnaire
79582052|NCT04595422|Other|Survey Administration|Ancillary studies
80031994|NCT02052531|Drug|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
80031995|NCT02052531|Other|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
80031996|NCT02054793|Drug|Itraconazole|100 mg 200 mg 300 mg
80031997|NCT02054793|Drug|Orteronel|300 mg
80031998|NCT02052687|Drug|LFX453 H1|LFX453 high dose cream 1
79278348|NCT04155385|Other|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
79582053|NCT04594005|Drug|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
79582054|NCT04591977|Device|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
79582055|NCT04580732|Device|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
79582056|NCT04578665|Behavioral|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
79609683|NCT05771272|Diagnostic Test|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
79740686|NCT02665078|Other|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
79740687|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablet
79740688|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablets
79740689|NCT00645346|Biological|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
79740690|NCT00645346|Biological|Placebo|Subjects will receive one dose of placebo
79740691|NCT00647374|Other|this is an observational study|
79740692|NCT04175314|Other|Clinical examination of gingival tissues|Measure of the periodontal recession
79740693|NCT00648622|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
79740694|NCT00648622|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
79740695|NCT00994422|Drug|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
79740696|NCT00994422|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
79740697|NCT00647452|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
79740698|NCT00648700|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
79740699|NCT00648700|Drug|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
79740700|NCT04172662|Behavioral|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
79278349|NCT02208947|Behavioral|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
79740701|NCT00648778|Drug|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
79740702|NCT00648778|Drug|Loxitane® Capsules 25 mg|25mg, single dose fasting
79740703|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
79740704|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
79740705|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
79740706|NCT04172740|Device|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
79876464|NCT00974519|Drug|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
79404811|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
79740707|NCT04172350|Other|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
79278350|NCT02208947|Behavioral|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
79278351|NCT03544567|Drug|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
79278352|NCT02209025|Dietary Supplement|Theobromine|Theobromine a compound for cocoa
79609684|NCT05771272|Diagnostic Test|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
79740708|NCT04172350|Other|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
79740709|NCT02664844|Behavioral|Physical activity|
79278353|NCT02209025|Dietary Supplement|Placebo drink|
79278354|NCT03526471|Device|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
79278355|NCT03524755|Other|Exercise|
79278356|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid|
79278357|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid formulation|
79740710|NCT02665000|Procedure|Structured training programme|Participants will undergo 5-days training sessions
80031999|NCT02052687|Drug|LFX453 L1|LFX453 low dose cream 1
80032000|NCT02052687|Drug|LFX453 H2|LFX453 high dose cream 2
79278358|NCT02209103|Dietary Supplement|Identical looking placebo|
79278359|NCT02205281|Behavioral|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
80032001|NCT02052687|Drug|LFX453 L2|LFX453 low dose cream 2
80032002|NCT02052687|Drug|Imiquimod|Imiquimod cream
80032003|NCT02052687|Drug|Placebo 1|Placebo cream 1
80032004|NCT02052687|Drug|Placebo 2|Placebo cream 2
80032005|NCT02052765|Device|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
80032006|NCT02057289|Drug|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
79278360|NCT03524677|Diagnostic Test|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
79278361|NCT02323204|Behavioral|Link for Injured Kids|Psychological First Aid
79278362|NCT02323204|Other|So you've been in an accident|Educational materials
79278363|NCT02220803|Drug|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
79278364|NCT02220803|Device|nasal Continuous Positive Airway Pressure (nCPAP)|
79278365|NCT02258321|Drug|PPI-668 tablet|
79278366|NCT02258321|Drug|PPI-668 capsule|
79278367|NCT02258399|Behavioral|Exercise|Moderate intensity exercise
79278368|NCT02258399|Dietary Supplement|Breakfast|Breakfast consumption
79278369|NCT02209337|Device|SRS|
79278370|NCT02220881|Device|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
79278371|NCT02220881|Other|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
79278372|NCT02322892|Drug|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
79404812|NCT01279785|Drug|123I-MIP-1072|Single IV dose
79609685|NCT05771259|Other|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
79609686|NCT05771233|Other|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
79740711|NCT02663596|Drug|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
79740712|NCT04171336|Behavioral|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
79278373|NCT02322892|Drug|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
79278374|NCT03274375|Drug|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
79278375|NCT03274375|Drug|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~at least 1 day before each IA session~the last injection will occur after the last session IA (minimum one day after)"
79278376|NCT02220959|Other|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
79278377|NCT03526393|Device|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
79278378|NCT03526393|Device|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
79278379|NCT03526393|Device|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
79278380|NCT04466839|Other|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
79278381|NCT04467073|Behavioral|Online RIT|"Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log)."
79278382|NCT04466605|Other|Tele-yoga therapy|Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.
79582057|NCT04578665|Device|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
79582058|NCT04578665|Behavioral|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error [difference of the desired trajectory and actual trajectory] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
79582059|NCT04578665|Device|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
79582061|NCT04574193|Device|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
79740713|NCT00647530|Biological|panitumumab|
79740714|NCT00647530|Drug|capecitabine|
79740715|NCT00647530|Drug|fluorouracil|
79740716|NCT00647530|Drug|oxaliplatin|
79740717|NCT00647608|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
79278383|NCT04466605|Other|Primary care|Patients will follow standard care provided by primary care physicians including analgesics and self care management.
79278384|NCT03916081|Drug|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
79278385|NCT03916081|Drug|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
79582062|NCT04574193|Other|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
79740718|NCT00647608|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fed
79740719|NCT02663440|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
79740720|NCT02663440|Biological|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
79740721|NCT02663440|Drug|Temozolomide|Temozolomide
79740722|NCT04171180|Drug|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
79278386|NCT03916081|Drug|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
79278387|NCT04961827|Behavioral|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
79278388|NCT04961827|Behavioral|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
79278389|NCT04865263|Device|Digital Pain-Management Tool|Self management digital tool for chronic pain
79278390|NCT03524599|Other|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
79278391|NCT04467229|Behavioral|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
79278392|NCT03524521|Behavioral|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
79278393|NCT03524521|Behavioral|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
79278394|NCT03116113|Biological|BIIB112|Administered as specified in the treatment arm.
79278395|NCT04468009|Biological|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
79278396|NCT03766555|Procedure|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
79278397|NCT03766555|Procedure|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
79582063|NCT04570761|Device|Dreem headband|acoustic stimulation
79582064|NCT04570761|Device|Dreem headband|acoustic stimulation
79278398|NCT02739997|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
79278399|NCT02739997|Drug|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
79278400|NCT04467931|Drug|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
79278401|NCT04467931|Drug|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
79582065|NCT04560595|Behavioral|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
79582066|NCT04537429|Drug|Eptinezumab|up to four iv infusions of eptinezumab
79582067|NCT04528719|Biological|mRNA-1345|Formulation for injection
79582068|NCT04528719|Drug|Placebo|0.9% sodium chloride (normal saline) injection
79582069|NCT04521764|Biological|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
79582070|NCT04517643|Other|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
79740723|NCT02660008|Drug|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
79740724|NCT02660008|Drug|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
79740725|NCT02664766|Behavioral|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
80032007|NCT02057367|Drug|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
79582071|NCT04512911|Procedure|Endocardial ablation|Endocardial ablation of VT
79582072|NCT04512911|Procedure|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
79582073|NCT04512911|Drug|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
79404813|NCT05128188|Other|No intervention will be given in this study|No intervention will be given in this study
79582074|NCT04501133|Device|Peripheral electrical stimulation|Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
79740726|NCT02664688|Other|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
79740727|NCT02664688|Other|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
79740728|NCT00649168|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
79740729|NCT00649168|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
79740730|NCT02659774|Behavioral|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
79740731|NCT02659774|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
79740732|NCT02659774|Behavioral|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
79740733|NCT02659774|Behavioral|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
79278402|NCT04467931|Drug|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
79278403|NCT04467931|Drug|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
79278404|NCT03524443|Behavioral|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
79278405|NCT04744129|Drug|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
79278406|NCT04744129|Drug|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
79582075|NCT04501133|Device|Single pulse TMS|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
79582076|NCT04492540|Other|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
79740734|NCT02659774|Behavioral|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
79740735|NCT02659774|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
79740736|NCT02663206|Procedure|peroral endoscopic myotomy|peroral endoscopic myotomy
79740737|NCT02663206|Procedure|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
79740738|NCT02663284|Drug|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
79740739|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
79740740|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h|single application
79740741|NCT04172272|Drug|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
79740742|NCT04172272|Procedure|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
79278407|NCT03133117|Radiation|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
79404814|NCT05127798|Other|Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.|Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
79404815|NCT00244881|Drug|cediranib maleate|Given orally
79404816|NCT00244881|Other|laboratory biomarker analysis|Correlative studies
80032008|NCT02057367|Drug|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
79278408|NCT03524287|Procedure|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
79404817|NCT03701958|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
79278409|NCT03522883|Dietary Supplement|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
79278410|NCT03522805|Device|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
79278411|NCT03522727|Behavioral|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
79278412|NCT03522727|Behavioral|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
79582077|NCT04492540|Other|MIND diet program|control group will receive diet program for 12 weeks
79582078|NCT04489589|Drug|Midodrine|10mg PO/NG q8h
79582079|NCT04489589|Drug|Placebo|10mg PO/NG q8h
79278413|NCT03522727|Behavioral|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
79876465|NCT01049529|Dietary Supplement|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
79278414|NCT03522649|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
79278415|NCT03522649|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion.
79278416|NCT03522649|Drug|Leucovorin|Irinotecan 180 mg/m^2 followed by or concurrent with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
79278417|NCT03522649|Drug|Irinotecan|Irinotecan 180 mg/m^2 followed by or concurrent with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
79278418|NCT02366481|Dietary Supplement|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
79278419|NCT02366481|Dietary Supplement|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
79278420|NCT02366481|Dietary Supplement|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
79278421|NCT02373891|Drug|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
79278422|NCT02373891|Drug|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
79404818|NCT04763395|Other|No intervention|No intervention
79404819|NCT03446508|Device|Active frontal|1) active HD-tDCS will be administered
79740743|NCT04172272|Other|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
79278423|NCT05353231|Behavioral|Attention Feedback Awareness and Control Training (A-FACT)|"A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial."
79404820|NCT03446508|Device|Active parietal|2) active HD-tDCS will be administered
79404821|NCT03446508|Device|Sham|3) sham HD-tDCS - no current
79404822|NCT03767491|Device|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
79404823|NCT00530517|Device|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
79404824|NCT05404698|Other|Aerobic exercise|EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
79404825|NCT05404698|Other|Control|CONT: participants will receive hemodialysis treatment only (usual care)
79582080|NCT04471987|Drug|IL12-L19L19|"Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications."
79278424|NCT05353231|Behavioral|Mindful Disengagement from Thoughts Training (MDTT)|MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.
79278425|NCT05353231|Behavioral|Placebo-Control|The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
79278426|NCT02366247|Drug|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
79278427|NCT02366247|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
79404826|NCT01274949|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
79404827|NCT03686605|Other|Thai version of the Edmontom Symptom Assessment System (ESAS)|Screening and diagnostic questionaire for depression
79278428|NCT02366247|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
79278429|NCT02373735|Other|crystalloid|Group A (SVV <10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
79404828|NCT05404620|Other|Schroth exercises|9 participants will perform Schroth exercises with 2 mint rest between each exercise. + Hot pack (10 mint) +static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be provided.
79404829|NCT05404620|Other|PNF technique|9 participants will perform PNF techniques followed by a hot pack for 10 minutes and static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be given.
79404830|NCT05404464|Other|Different baseline characteristics and clinical management|Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
79404831|NCT03683095|Procedure|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
79278430|NCT02373735|Other|colloid|Group A (SVV <10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is > 20%
79278431|NCT02373735|Other|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is < 10%
79278432|NCT02373735|Other|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is < 10%
79404832|NCT04435938|Radiation|Stereotactic Body Radiotherapy (SBRT)|45 Gy in 5 fractions delivered once every 3-4 days
79404833|NCT02820012|Other|Scoliosis|Questionnaires, radiography
79404834|NCT03765853|Other|Physiotherapy|Usual prevention methods (ergonomic education) and Stretching Postural® postures.
79404835|NCT04366362|Procedure|Individualised ACL reconstruction|ACL reconstruction based on anatomical and functional distinctiveness of each patient separately
79404836|NCT04366362|Procedure|Conventional ACL reconstruction|ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
79404837|NCT05123976|Drug|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
79404838|NCT05123976|Drug|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
79278433|NCT03526315|Other|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
79404839|NCT03762421|Behavioral|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
79404840|NCT03762421|Behavioral|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
79404841|NCT05127096|Diagnostic Test|FirstSight blood test|FirstSight blood test for colorectal cancer screening
79740744|NCT02663050|Other|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
79740745|NCT02663050|Drug|NSAID's|twice a daily
79278434|NCT03526315|Other|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
79278435|NCT03526315|Other|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
79582081|NCT04471987|Drug|IL12-L19L19|Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
79404842|NCT03762343|Drug|ultrasound guided Greater occipital nerve block|ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
79404843|NCT03762343|Drug|control group C|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
79404844|NCT05126940|Diagnostic Test|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis|Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
79404845|NCT04246164|Device|HD-tDCS combined with CT|HD-tDCS treatments will be administered during a cognitive training session.
79582082|NCT04466371|Other|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
79582083|NCT04464785|Device|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
79582084|NCT04464473|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
79582085|NCT04460352|Radiation|Neoadjuvant radiotherapy (arm A)|1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
79582086|NCT04460352|Drug|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
79582087|NCT04460352|Procedure|Esophagectomy|Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
79740746|NCT00648856|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
79740747|NCT00648856|Drug|Zoloft® Tablets 100 mg|100mg, single dose fed
79740748|NCT01171976|Drug|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
79404846|NCT04246164|Device|sham HD-tDCS combined with CT|sham-HD-tDCS treatments will be administered during a cognitive training session.
79404847|NCT02724072|Device|Thoraflex™ Hybrid Device|Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
79740749|NCT00996216|Drug|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
79740750|NCT00996216|Drug|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
79740751|NCT00647764|Drug|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
79740752|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
79740753|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h|single application
79740754|NCT02662972|Drug|Botulinum Toxin Type A|
80032009|NCT02057445|Drug|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
80032010|NCT02057445|Other|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
79278436|NCT03524131|Other|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
79404848|NCT00005803|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
79404849|NCT00005803|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
79404850|NCT00005803|Drug|Carmustine|Given IV
79404851|NCT00005803|Drug|Cyclophosphamide|Given IV
79404852|NCT00005803|Drug|Cyclosporine|Given PO
79740755|NCT04291716|Device|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
79740756|NCT02662894|Drug|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
79740757|NCT02662894|Drug|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
79740758|NCT02662894|Drug|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
79278437|NCT03524131|Other|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
79278438|NCT03524131|Other|current national leaflet|4-sided leaflet
79404853|NCT00005803|Drug|Cytarabine|Given IV
79404854|NCT00005803|Drug|Etoposide|Given IV
79404855|NCT00005803|Drug|Fludarabine Phosphate|Given IV
79740759|NCT02662894|Drug|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
79582088|NCT04460352|Radiation|Neoadjuvant radiotherapy (arm B)|"Two alternative schemes:~1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy."
79740760|NCT04291794|Drug|Propofol|2mg/kg single bolus
79740761|NCT04291794|Drug|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
79740762|NCT02662660|Drug|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
79740763|NCT02662660|Drug|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
80032011|NCT02054871|Procedure|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
80032012|NCT02054949|Drug|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
80032013|NCT02748057|Drug|Ezetimibe|
79278439|NCT03112551|Drug|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
79278440|NCT03133351|Device|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
79582089|NCT04460352|Drug|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
79582090|NCT04460352|Drug|Cisplatin, paclitaxel|Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
79582091|NCT04460352|Drug|Oxaliplatin, calcium folinate, 5-fluorouracil|FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
79582092|NCT04460352|Procedure|Esophagectomy|Esophagectomy only in case of residual or recurrent locoregional cancer.
79582093|NCT04445831|Biological|ACI-35.030|Administration of a Low dose of ACI-35.030
79582094|NCT04445831|Biological|ACI-35.030|Administration of a Medium dose of ACI-35.030
79740764|NCT02662660|Drug|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
80032014|NCT02748057|Drug|Rosuvastatin|
80032015|NCT02057601|Drug|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
80032016|NCT02052843|Behavioral|Steps to Success|
80032017|NCT02052843|Behavioral|Traditional Healthy Families|
80032018|NCT02055027|Other|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
80032019|NCT02057679|Drug|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
80032020|NCT02057679|Drug|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
80032021|NCT02055105|Procedure|miRNA in Sepsis|miRNA in Sepsis
80032022|NCT02038491|Procedure|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
80032023|NCT02055183|Drug|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
80032024|NCT02055261|Device|Low frequency DBS of the pedunculopontine nucleus|
80032025|NCT02055339|Device|Fisher & Paykel heated humidified high flow nasal cannula|
80032026|NCT02055339|Device|InfantFlow/RAM nasal continuous positive airway pressure|
80032027|NCT02052921|Procedure|Rectal resection|Surgical rectal resection
80032028|NCT02052921|Other|Observation|
79278441|NCT02366325|Drug|EPO-018B|
79404856|NCT00005803|Other|Laboratory Biomarker Analysis|Correlative studies
79404857|NCT00005803|Drug|Melphalan|Given IV
79582095|NCT04445831|Biological|ACI-35.030|Administration of a High dose of ACI-35.030
79582096|NCT04445831|Other|Placebo|Administration of Placebo
79582097|NCT04445831|Biological|JACI-35.054|Administration of a Low dose of JACI-35.054
79582098|NCT04445831|Biological|JACI-35.054|Administration of a Medium dose of JACI-35.054
79582099|NCT04419181|Drug|Docetaxel|Dose: 75 mg/m2 q3w
80032029|NCT02055417|Behavioral|Personal Approaches to Treatment Choices for HIV|
80032030|NCT02055417|Behavioral|Stress Reduction Skills Program|
80032031|NCT02052999|Drug|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
80032032|NCT02052999|Other|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
80032033|NCT02052999|Drug|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
80032034|NCT02055573|Other|Ready To Learn (RTL)|See arm description
80032035|NCT02055573|Other|All Babies Cry (ABC)|See arm description
80032036|NCT03561285|Diagnostic Test|antiphospholipid Abs|Laboratory test
80032037|NCT02055651|Behavioral|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
80032038|NCT02057913|Drug|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
79582100|NCT04419181|Drug|Carboplatin|Dose: area under the concentration-time curve [AUC] 6 q3w
80032039|NCT02055729|Biological|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
79740765|NCT00628992|Other|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
80032040|NCT02055729|Biological|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 & 28)
80032041|NCT02055729|Biological|Stool sample|Stool samples will be collected on days 0 and 28.
80032042|NCT02055729|Biological|Urine sample|Urine samples will be collected on days 0 and 28.
80032043|NCT02057991|Other|educational intervention|Watch an educational video
79278442|NCT02366169|Device|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
79278443|NCT03522571|Behavioral|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
79278444|NCT05373433|Drug|SSD8432 750mg|Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
79278445|NCT05373433|Drug|SSD8432 placebo|Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
79582101|NCT04419181|Drug|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
79582102|NCT04419181|Drug|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
79740766|NCT00628992|Other|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
79740767|NCT00628992|Other|Cycloergometer training|Muscular rehabilitation of the leg
79740768|NCT00628992|Other|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
79740769|NCT02868606|Other|Physiologic Insulin Therapy|
79404858|NCT00005803|Drug|Mycophenolate Mofetil|Given PO
79404859|NCT00005803|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
79740770|NCT02868606|Other|Sliding-Scale Insulin Therapy|
79404860|NCT00005803|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
79404861|NCT00005803|Biological|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
79582103|NCT04419181|Drug|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
79582104|NCT04396340|Biological|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
79582105|NCT04388852|Biological|Ipilimumab|Given IV
79582106|NCT04388852|Drug|Valemetostat|Given PO
79582107|NCT04387435|Other|A change or titration in the current or frequency settings of the VNS therapy system.|The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
79740771|NCT02659852|Procedure|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
79740772|NCT02659852|Procedure|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
79740773|NCT02662738|Dietary Supplement|Natural fruit extract|
79740774|NCT02662738|Other|Placebo|
79740775|NCT02662738|Other|Glucose solution|
79740776|NCT00647920|Biological|adalimumab|40 mg adalimumab sc, every other week
79740777|NCT00647920|Biological|placebo|placebo sc, every other week
79876466|NCT01049529|Dietary Supplement|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
79876467|NCT00972491|Procedure|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
79876468|NCT01045395|Dietary Supplement|Corn starch|90mg/d
79876469|NCT01045395|Dietary Supplement|Unique Marine Algae Concentrate (UMAC)|90mg/d
79876470|NCT01045395|Dietary Supplement|Golden brown algae|90mg/d
79876471|NCT00972569|Drug|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
79876472|NCT00972569|Drug|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
79876473|NCT01324557|Procedure|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
79876474|NCT00972647|Procedure|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
79876475|NCT00974597|Device|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
79876476|NCT00974753|Drug|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
79876477|NCT00974753|Other|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
80032044|NCT02057991|Procedure|CAM exercise therapy|Watch a mindfulness exercise video
79740778|NCT02664454|Other|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
79278446|NCT02363127|Drug|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
79278447|NCT02363127|Drug|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
79278448|NCT03522493|Device|"Yaalom Katom"|Full face Gas mask
79582108|NCT04386317|Drug|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
79740779|NCT04172116|Device|Continuous glucose monitoring|see arm/group descriptions
79740780|NCT02662816|Device|Proton magnetic resonance spectroscopy (1H MRS)|
79278449|NCT02362737|Behavioral|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be ~16 weekly meetings of ~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
79278450|NCT03524053|Other|Exercise induced bronchoconstriction|Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
79278451|NCT03524053|Other|Inhibited EIB|Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
79404862|NCT00005803|Radiation|Total-Body Irradiation|Undergo radiotherapy
79404863|NCT05123898|Procedure|Soft tissue augmentation|"Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~Modeling of sterile collagen matrix according to the shape of the recipient bed~Fixation of the collagen matrix to the vestibular flap~Suturing the wound tightly"
79740781|NCT02662816|Other|a protein rich breakfast at home|
79740782|NCT02662816|Other|a protein rich lunch at the Clinical Investigation Center|
79740783|NCT00830869|Drug|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
79740784|NCT02662504|Device|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
79740785|NCT02662504|Procedure|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
79740786|NCT02662504|Drug|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
79278452|NCT02362815|Other|Apple juice|Intervention consists in allowing drinks during labour
79278453|NCT04467541|Biological|Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)|Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
79278454|NCT02373423|Other|Advocacy|See above for description
79278455|NCT03526237|Behavioral|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
79278456|NCT03526237|Behavioral|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
79278457|NCT02373501|Procedure|Intra-abdominal repair|Intra abdominal repair of uterine incision
79404864|NCT03760315|Diagnostic Test|blood mNGS (IDSeqTM Ultra); blood Culture|take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.
79582109|NCT04380857|Drug|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
79582110|NCT04380857|Drug|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
79278458|NCT02373501|Procedure|Extra-abdominal repair|Extra abdominal repair of uterine incision
79876478|NCT04008719|Other|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
79278459|NCT02373657|Behavioral|instruction in soap-making and hygiene education|
79404865|NCT03680131|Drug|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
79404866|NCT03680131|Drug|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
79404867|NCT03680131|Drug|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
80032045|NCT02057991|Other|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
80032046|NCT02057991|Other|questionnaire administration|Ancillary studies
79404868|NCT03680131|Drug|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
79582111|NCT04327570|Other|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
79404869|NCT03679195|Dietary Supplement|NO Ultra|6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
79740787|NCT04061902|Other|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
79278460|NCT02723799|Behavioral|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
79278461|NCT02723799|Other|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
80032047|NCT02057991|Other|laboratory biomarker analysis|Correlative studies
80032048|NCT02053155|Behavioral|Computer based patient education|
80032049|NCT02055807|Other|PEEP and recruitment maneuvers|
79740788|NCT00648934|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
80032050|NCT02055807|Other|ZEEP (no PEEP nor recruitment maneuver)|
80032051|NCT02260167|Other|A mix of natural treatments and medications|
80032052|NCT02748213|Drug|Xeloda|Participants will receive oral Xeloda, 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle.
79404870|NCT03679195|Dietary Supplement|Placebo|"6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group."
80032053|NCT02748213|Drug|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
80032054|NCT02748213|Drug|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
79582112|NCT04307836|Device|Renal Denervation|Renal Denervation: DENEX system
79582113|NCT04307485|Drug|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
79582114|NCT04299620|Device|Digital Image Analysis|Analysis of images
79582115|NCT04299620|Procedure|Radical Prostatectomy|Undergo standard of care radical prostatectomy
79582116|NCT04299620|Procedure|Transrectal Ultrasound|Undergo transrectal ultrasound
79582117|NCT04284267|Device|Transcranial Magnetic Stimulation|TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
79740789|NCT00648934|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
79740790|NCT04170868|Other|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
79582118|NCT04271488|Drug|Tasurgratinib|Tasurgratinib oral tablet.
79582119|NCT04271488|Drug|Tasurgratinib|Tasurgratinib oral capsule.
79740791|NCT02659228|Device|EEG recording|EEG recording with anesthetic (DIPRIVAN)
79278462|NCT03526159|Drug|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
79278463|NCT03523741|Drug|Clozapine|Clozapine is administered orally according to individual prescribed dosing regimens.
79278464|NCT02362347|Device|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
79404871|NCT03593629|Combination Product|6-month PrEP + blood-based HIV self-test|Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.
79404872|NCT03593629|Combination Product|6-month PrEP + oral fluid HIV self-test|Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
79404873|NCT00244725|Drug|Odiparcil|
79404874|NCT00244725|Drug|Warfarin|
79404875|NCT00244725|Drug|Coumadin|
79582120|NCT04265274|Drug|Disulfiram|dosing 400mg daily
79740792|NCT02659228|Drug|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
79876479|NCT04008719|Other|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
79876480|NCT04008719|Other|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
79876481|NCT00974831|Other|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
79876482|NCT00974831|Other|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
79278465|NCT02362347|Other|exercise|exercise
79582121|NCT04265274|Drug|Vinorelbin|25mg/m2 day 1 and 8,
79582122|NCT04265274|Drug|Cisplatin|75mg/m2 day 1
79740793|NCT00844519|Drug|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
79740794|NCT00844519|Drug|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
79740795|NCT02664376|Other|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~Walking speed measurement~Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
79278466|NCT03522337|Other|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
79278467|NCT03522337|Other|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
79740796|NCT02659462|Other|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
79278468|NCT02362581|Other|prophylaxis treatment, on demand treatment|
79278469|NCT03526081|Other|Chamomile Tea|Chamomile Tea in 300mL hot water
79278470|NCT03526081|Other|Parsley based drink|3.2 g dried parsley in 300mL hot water
79278471|NCT03526081|Other|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
79278472|NCT03526081|Other|Apigenin|Apigenin capsule mixed with 300mL hot water
79278473|NCT03526081|Other|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
79278474|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
79278475|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
79278476|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
79278477|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
79582123|NCT04265274|Drug|Copper|2 mg of elementary Copper daily
79278478|NCT03526003|Diagnostic Test|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
79404876|NCT03757741|Diagnostic Test|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
79404877|NCT03757741|Diagnostic Test|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
79278479|NCT02362113|Other|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
79278480|NCT03525925|Drug|Ibrutinib|Given PO
79432927|NCT02138227|Behavioral|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
79432928|NCT02138227|Behavioral|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
79278481|NCT03525925|Other|Laboratory Biomarker Analysis|Correlative studies
79278482|NCT03525925|Biological|Nivolumab|Given IV
79278483|NCT02373579|Drug|Omega-3 Fatty Acids|"study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
79278484|NCT02373579|Drug|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
79278485|NCT02221037|Drug|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
79278486|NCT02221037|Drug|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
79432929|NCT03586700|Drug|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
79432930|NCT03586700|Radiation|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
79432931|NCT03586700|Drug|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
79432932|NCT02275923|Device|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
79582124|NCT04264260|Drug|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
79582125|NCT04255199|Behavioral|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
79432933|NCT02139007|Drug|Alendronate|
79582126|NCT04255199|Behavioral|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over ~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
79582127|NCT04254094|Other|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
79278487|NCT02365857|Drug|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine & Bupivacaine.
79582128|NCT04240392|Behavioral|Collaborative Care (CC)|"The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner."
79582129|NCT04240392|Behavioral|Extension for Community Healthcare Outcomes (ECHO)|The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
79582130|NCT04225806|Device|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
79582131|NCT04218708|Other|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
79582132|NCT04218708|Behavioral|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
79278488|NCT02365857|Drug|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
79582133|NCT04218708|Behavioral|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
79740797|NCT00702793|Drug|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
79740798|NCT04170166|Procedure|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
79740799|NCT04170166|Procedure|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
79740800|NCT01171820|Device|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
79740801|NCT01171820|Device|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
79278489|NCT03523507|Device|Active: rTMS|Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
80032055|NCT05257096|Behavioral|Medical clown|The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
80032056|NCT03804099|Drug|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
80032057|NCT03048604|Device|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
79740802|NCT02658916|Drug|BIIB092|Same dose as corresponding CN002003 study panel.
79740803|NCT05518747|Dietary Supplement|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.
79432934|NCT03833115|Other|vaginal gel containing or not sodium lauryl sulfate|Prevention
79432935|NCT04142138|Other|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
79432936|NCT01590277|Drug|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
79278490|NCT03523507|Device|Sham: rTMS|Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
79404878|NCT03592849|Procedure|UC-MSCs therapy|After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
79404879|NCT02649894|Device|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
79404880|NCT02649894|Device|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
79404881|NCT03591055|Other|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
79740804|NCT05518747|Dietary Supplement|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
79740805|NCT02662426|Drug|Lingdancao granules|4 packs per time (3g/pack), three times per day
79740806|NCT02662426|Drug|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
79740807|NCT02662426|Drug|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
79740808|NCT02662426|Drug|analogous Lingdancao granules|4 packs per time, three times per day
79740809|NCT00994110|Drug|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
79740810|NCT00994110|Other|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
79876483|NCT00972803|Drug|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
79876484|NCT00972803|Drug|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
79876485|NCT00972803|Drug|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
79876486|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
80032058|NCT02058303|Drug|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
79582134|NCT04218708|Behavioral|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
79582135|NCT04218708|Other|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver >300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
80032059|NCT02058303|Drug|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
79278491|NCT00592293|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
79404882|NCT01279941|Behavioral|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
79404883|NCT03556969|Other|Observation|no intervention
79404884|NCT01275027|Dietary Supplement|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
79404885|NCT04185012|Biological|Benralizumab|Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
79404886|NCT04185012|Biological|Placebo|Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
79278492|NCT04640155|Behavioral|Low FODMAP Diet|Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.
79278493|NCT04640155|Behavioral|Regular Diet|Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
79278494|NCT02365935|Procedure|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
79278495|NCT02365935|Procedure|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
80032060|NCT05256862|Other|Data collection|"Data collection~on the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022)~on the performance of three novel tests as triage tool in the screening algorithm, QG-MPH, Prevo-check® and PT Monitor®"
79278496|NCT02365935|Drug|Cisplatin|
79278497|NCT02365935|Drug|Paclitaxel|
79278498|NCT02205593|Behavioral|Control|Regular follow-up and treatment WITHOUT behavioural intervention
79278499|NCT02365701|Drug|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
79278500|NCT02365701|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
79278501|NCT02209415|Behavioral|standard follow-up|Outpatient clinic visits
79278502|NCT02209415|Procedure|PET/CT and EUS|PET/CT and EUS
79404887|NCT01276899|Procedure|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
79404888|NCT01276899|Procedure|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
79404889|NCT05126706|Behavioral|Digital lifestyle management|Digital lifestyle management for Weight Loss Control after Thyroidectomy
79740811|NCT04315376|Behavioral|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
79404890|NCT01275183|Drug|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
80032061|NCT02058381|Drug|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
79404891|NCT05126628|Drug|Proxalutamide|Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
79404892|NCT05126628|Drug|Placebo|Placebo 3 tablets q.d. for 14 days
79278503|NCT02365623|Drug|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
79278504|NCT02365623|Drug|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS], para-aminosalicylic acid [PAS], amikacin [AMK], levofloxacin [LVFX] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
79278505|NCT05262647|Diagnostic Test|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
79278506|NCT02361957|Dietary Supplement|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
79278507|NCT02361957|Dietary Supplement|Placebo|Placebo
79278508|NCT02221115|Device|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
79278509|NCT02221193|Other|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
79404893|NCT05126394|Procedure|ultrasound guided serratus anterior plane block|the patients receive local anesthetic (20 ml of Bupivacaine 0.25 %), injected superficial to the serratus muscle under ultrasound guidance.
79404894|NCT03676543|Procedure|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
79404895|NCT01677169|Dietary Supplement|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
79740812|NCT04315376|Behavioral|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
79582136|NCT04189588|Drug|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
79740813|NCT02662348|Drug|Recombinant Human Interleukin-2|Given SC
79740814|NCT02662348|Drug|HER2Bi-Armed T Cells|Given IV
79740815|NCT02868372|Drug|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
79740816|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
79740817|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
79740818|NCT02662192|Other|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
79740819|NCT02662192|Other|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
79740820|NCT00993954|Procedure|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
79740821|NCT02662114|Other|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
79740822|NCT01157234|Drug|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of < 140/ 90.
79740823|NCT01157234|Drug|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure < 140/90.
79740824|NCT04170712|Other|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
79404896|NCT01677169|Dietary Supplement|Placebo|
79404897|NCT05126160|Diagnostic Test|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
79582137|NCT04189588|Drug|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
79582138|NCT04189588|Drug|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
79740825|NCT02661802|Other|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
79740826|NCT00991302|Behavioral|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
80032062|NCT02058381|Drug|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
79278510|NCT03927261|Drug|PRGN-3006 T Cells|Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
79740827|NCT04170790|Drug|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
79740828|NCT04170790|Drug|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
79278511|NCT02209493|Behavioral|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
79278512|NCT02209493|Behavioral|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
79278513|NCT02365779|Procedure|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
79278514|NCT02365779|Device|endomicroscopy Cellvizio® system|
79278515|NCT02221271|Drug|NPB-01|
79278516|NCT02205671|Behavioral|Building Better Caregivers Small-group Workshop|
79404898|NCT04762615|Diagnostic Test|AMH level measurement|AMH level measurement using ELISA test from blood samples
79740829|NCT02661958|Drug|S6G5T-3|once a day topical cream
79740830|NCT02661958|Drug|S6G5T-1|once a day topical cream
79740831|NCT02661958|Drug|S6G5T-5|once a day topical cream
79740832|NCT02661958|Drug|S6G5T-6|once a day topical cream
79740833|NCT02661958|Drug|S6G5T-7|once a day topical cream
79740834|NCT02661958|Drug|S6G5T-8|once a day topical cream
79740835|NCT04291872|Other|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
79740836|NCT04171648|Other|Roasted Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of roasted in shell peanuts a day for two weeks.
79740837|NCT04171648|Other|Boiled Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of boiled peanuts a day for two weeks.
79404899|NCT05126004|Drug|Azacitidine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
79404900|NCT05126004|Drug|N Acetyl L Cysteine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
79404901|NCT05125926|Biological|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
79404902|NCT05125926|Biological|Placebo|Aluminum hydroxide
79740838|NCT00995670|Drug|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
79404903|NCT01278615|Other|Laboratory Biomarker Analysis|Correlative studies
79740839|NCT00995670|Drug|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
79740840|NCT00995670|Drug|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
79278517|NCT03112707|Drug|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
79740841|NCT00995670|Drug|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
79740842|NCT02661724|Behavioral|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
79740843|NCT02658838|Drug|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
79740844|NCT02658838|Drug|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
79740845|NCT02658838|Drug|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
79740846|NCT02658838|Drug|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
79740847|NCT04293588|Diagnostic Test|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
79740848|NCT02536534|Other|Correlation assessment|
79278518|NCT03112707|Drug|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
79278519|NCT02209571|Other|Venous blood markers|Routine venous blood sampling
79278520|NCT05262413|Drug|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
80032063|NCT02053233|Device|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
79278521|NCT02704429|Drug|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
79404904|NCT01278615|Drug|Selumetinib|Given PO
79404905|NCT05125770|Biological|New crown vaccine|New Coronavirus vaccine
79740849|NCT00648076|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
79278522|NCT02209649|Drug|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
79278523|NCT02209649|Drug|Lacidipine|
79278524|NCT02209649|Drug|Telmisartan|
79278525|NCT02361567|Drug|Tramacet|Pain medication commonly used post-operatively
79278526|NCT02361567|Drug|Percocet|Pain medication commonly used post-operatively
79404906|NCT05123430|Procedure|Monitoring of the pressure of the middle left atrium|During the MitraClip surgery, additional catheter is installed in order to monitoring the ppressure of the middle left atrium
79278527|NCT02205749|Behavioral|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
79278528|NCT02205749|Behavioral|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
79278529|NCT02205749|Behavioral|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
79404907|NCT00350701|Drug|androgel|androgel 5g
79404908|NCT00350701|Drug|androgel 10g|androgel 10g
79404909|NCT00350701|Drug|placebo|placebo
79404910|NCT01275261|Behavioral|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
79404911|NCT05123352|Other|collection of biological samples and clinical data|blood and feces samples
79404912|NCT01677325|Drug|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
79404913|NCT04384887|Behavioral|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
79278530|NCT03112785|Device|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
79404914|NCT04435860|Other|Truncal flexion-extension muscle power|Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
79278531|NCT02205827|Other|Single-arm|collection of blood for assessment of whole blood clotting time
79582139|NCT04176419|Drug|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
79582140|NCT04176419|Drug|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
79278532|NCT02361879|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
79404915|NCT04435860|Other|Truncal extension muscle power|Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
79404916|NCT04435860|Other|Cervical flexion muscle power|Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
79404917|NCT04435860|Other|Cervical extension muscle power|Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
79740850|NCT00648076|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fed
79278533|NCT02361879|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
79278534|NCT03133429|Device|MER|carotid artery stenting
79278535|NCT02361645|Drug|Ketorolac 0.5% eyedrops|
79278536|NCT02361645|Drug|Indomethacin 0.5% eyedrops|
79278537|NCT02361645|Drug|Bromfenac 0.09% eyedrops|
79278538|NCT02361645|Drug|Nepafenac 0.1% eyedrops|
79278539|NCT03525769|Diagnostic Test|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
79278540|NCT02205905|Drug|14C PER977|Open-label, single dose
79404918|NCT04435860|Other|Cervical lateral flexion muscle powers|Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
79404919|NCT04435860|Other|Shoulder flexion muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
79404920|NCT04435860|Other|Shoulder extension muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
79404921|NCT04435860|Other|Shoulder internal rotation muscle power|Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
79278541|NCT03522181|Other|saline|saline
79278542|NCT03522181|Other|Insulin|
79278543|NCT02359461|Device|Combination pulsatile Stendo3|
79278544|NCT03695783|Other|Online decision aid called IBD&me|Patients randomized to IBD&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
79278545|NCT03695783|Other|Standardized educational material|Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
79582141|NCT04176419|Drug|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
79582142|NCT04176419|Drug|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
79740851|NCT02868294|Device|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
79740852|NCT02869152|Other|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
79582143|NCT04176419|Drug|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
79582144|NCT04176419|Drug|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
79582145|NCT04176419|Drug|Gabapentin|600 mg orally at time of check in to the preoperative unit
79582146|NCT04176419|Drug|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
79582147|NCT04176419|Drug|Celecoxib|200 mg orally at time of check in to the preoperative unit
79740853|NCT02869152|Other|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
79740854|NCT02869152|Other|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
79740855|NCT02869152|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
79740856|NCT02869152|Procedure|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
79740857|NCT02869152|Procedure|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
79404922|NCT04435860|Other|Shoulder external rotation muscle power|Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
79278546|NCT02290015|Other|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
79278547|NCT02373033|Other|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
80032064|NCT02053233|Device|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
79582148|NCT04176419|Drug|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
80032065|NCT04147156|Procedure|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
79404923|NCT04435860|Other|Shoulder abduction muscle power|Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
79404924|NCT04435860|Other|Hip flexion muscle power|Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
79404925|NCT04435860|Other|Hip extension muscle power|Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
79404926|NCT04435860|Other|Hip abduction muscle power|Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
79404927|NCT04435860|Other|Hip internal rotation muscle power|Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
80032066|NCT04147156|Procedure|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
80032067|NCT04147156|Procedure|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
79876487|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
79404928|NCT04435860|Other|Hip external rotation muscle power|Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
79404929|NCT04435860|Other|Bath Ankylosing Spondylitis Functional Index (BASFI)|"This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10."
79404930|NCT04435860|Other|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
79432937|NCT01590277|Drug|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
79432938|NCT01590277|Drug|Placebo|Control: no alcohol, administered for a total of 90 minutes.
79876488|NCT02908269|Biological|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
79582151|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
79582152|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
79740858|NCT00629070|Other|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
79740859|NCT00629070|Other|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
79582153|NCT04162210|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered.
79582154|NCT04162210|Drug|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide and Dexamethasone will be administered.
79876489|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system
79278548|NCT02373033|Other|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
79278549|NCT02373033|Other|Apple juice|Received apple juice containing no folate or folic acid.
79278550|NCT05186129|Drug|Clopid® 75 mg Tablet|Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
79740860|NCT00649012|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
79876490|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
79876491|NCT00974987|Radiation|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
79740861|NCT00649012|Drug|Actos® Tablets 45 mg|45mg, single dose fed
79740862|NCT02869542|Other|Data collection|
80032068|NCT04869904|Procedure|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
80032069|NCT04870060|Drug|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
80032070|NCT04870294|Device|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
80032071|NCT04870294|Device|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
80032072|NCT02613910|Drug|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
80032073|NCT02613910|Drug|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
79278551|NCT05186129|Drug|Plavix® 75mg Tablet|Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
79404931|NCT04435860|Other|The Health assessment questionnaire (HAQ)|The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
79404932|NCT04435860|Other|Bath Ankylosing Spondylitis Metrology Index (BASMI)|Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
79432939|NCT01590277|Drug|Placebo|Control: no iomazenil, administered for a total of 10 minutes
79432940|NCT03586622|Dietary Supplement|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
79740863|NCT04293432|Drug|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
79432941|NCT03586622|Dietary Supplement|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum* BL03, B. infantis* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus** BD08; *Recently reclassified as B. animalis subsp. lactis ** Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
79740864|NCT02661334|Dietary Supplement|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
79740865|NCT02661334|Dietary Supplement|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
79740866|NCT04274712|Diagnostic Test|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
79740867|NCT04291248|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
79740868|NCT04291248|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
79740869|NCT04170088|Drug|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
80032074|NCT02613910|Drug|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
79278552|NCT02361723|Drug|BGB-290|
80032075|NCT02613910|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
80032076|NCT02802735|Drug|Apremilast|Tablet for oral administration
80032077|NCT02802735|Drug|Placebo|Tablet for oral administration
79278553|NCT02361723|Drug|BGB-290|
79278554|NCT02361723|Drug|BGB-290|
79278555|NCT02361723|Drug|BGB-290|
79278556|NCT02361723|Drug|BGB-290|
79278557|NCT03596281|Drug|Pembrolizumab|200mg Q3W IV
79278558|NCT03596281|Drug|Bevacizumab|400 or 300 mg Q3W IV
79278559|NCT03596281|Drug|pegylated liposomal doxorubicin (PLD)|15 or 20 or 30 mg/m² Q3W IV
79278560|NCT02221505|Drug|LOP628|
79278561|NCT05172167|Diagnostic Test|Levels of IgG and IgM SARS-CoV-2 antibodies blood test.|0,1,2 months
79278562|NCT05172167|Diagnostic Test|RT-PCR SARS-CoV-2 nasopharyngeal swab|0,1,2 months
79278563|NCT03583879|Other|Exoskeleton exercise|Functional exercise with a robotic exoskeleton
79278564|NCT03583879|Other|Standard exercise|Functional exercise without a robotic exoskeleton
79278565|NCT03583879|Other|No treatment|Wait-list control
79432942|NCT03586466|Device|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
79432943|NCT03586466|Drug|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
79432944|NCT03586466|Other|MEMS|Subjects will receive their medication in a MEMS pill bottle.
79582155|NCT04157101|Behavioral|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
79740870|NCT04170088|Drug|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
79278566|NCT02361489|Device|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
79278567|NCT02209727|Drug|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
79278568|NCT02359149|Procedure|intravitreal injections given by a nurse|
79404933|NCT04277247|Drug|Botulinum toxin type A|A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
80032078|NCT04869748|Other|Perfetti method|"Participant was blindfolded, while lying flat in a quiet and comfortable room.~Participants received a 15-minute session of Perfetti method on affected elbow flexor.~Participants were asked to concentrate on the position of their elbows.~Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
80032079|NCT04869748|Other|passive stretching|"Participant was blindfolded, while lying flat in a quiet and comfortable room.~Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
79278569|NCT02359149|Procedure|intravitreal injections given by a physician|
79278570|NCT02359149|Procedure|Intravitreal injections|
79278571|NCT02359149|Drug|Anti-VEGF agents|
79278572|NCT05168891|Procedure|Surgical therapy|Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.
79278573|NCT05168891|Procedure|Non-surgical therapy of peri-implantitis|Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
79278574|NCT03113097|Other|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
79278575|NCT02209805|Drug|BIRB 796 BS, low dose|
79278576|NCT02209805|Drug|BIRB 796 BS, high dose|
79404934|NCT04277247|Drug|Placebo|0.9% saline placebo injection
79740871|NCT02867670|Device|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
79740872|NCT00648154|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
79740873|NCT00648154|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fed
79740874|NCT02869074|Genetic|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
79740875|NCT02664142|Procedure|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
79740876|NCT02664142|Procedure|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
79740877|NCT02664142|Drug|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
79740878|NCT04291638|Behavioral|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
79278577|NCT02209805|Drug|Placebo|
79278578|NCT02290093|Drug|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
79278579|NCT02290093|Drug|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
79278580|NCT02290093|Drug|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
79278581|NCT02221583|Drug|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
79404935|NCT03541213|Procedure|myocardial biopsy|Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.
79404936|NCT03541213|Procedure|sternal bone marrow biopsy|Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
79432945|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
79432946|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
79432947|NCT00570349|Drug|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
79278582|NCT02221583|Drug|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
79740879|NCT04291638|Behavioral|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
79740880|NCT02664064|Behavioral|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
79278583|NCT02221583|Drug|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
79278584|NCT03112941|Procedure|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
79278585|NCT03112941|Other|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
79278586|NCT02361333|Behavioral|Teaching Intervention|Patients will be taught how to install and use a remote monitor
79278587|NCT02290171|Behavioral|Activity groups|Children attend to activity groups weekly during the intervention periode.
79278588|NCT02290171|Behavioral|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
79404937|NCT03541213|Biological|blood sample|blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
79278589|NCT02290171|Behavioral|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
79278590|NCT02751359|Drug|Cannabidiol|200, 400, or 800 mg Cannabidiol
79740881|NCT04291482|Behavioral|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
79740882|NCT04291482|Behavioral|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
79740883|NCT04169854|Drug|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
79278591|NCT02751359|Drug|Placebo|0 mg Cannabidiol
79278592|NCT04465825|Behavioral|HITT: intermittent high intensity exercise|Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
79278593|NCT02358993|Drug|methenamine hippurate|A urinary antiseptic used for prevention of UTI
79278594|NCT02358993|Drug|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
79278595|NCT05262179|Drug|CTO0101|1 drop/ once or three times a day/ for 17 days divided into stage2
79278596|NCT05262179|Other|Placebo (vehicle)|1 drop/ once or three times a day/ for 17 days divided into stage2
79278597|NCT03523195|Behavioral|Exercise Intervention|Complete exercise program
79278598|NCT03523195|Other|Informational Intervention|Receive written information on healthy exercise and diet recommendations
79278599|NCT03523195|Other|Laboratory Biomarker Analysis|Blood tests
79278600|NCT03523195|Device|Monitoring Device|Wear Fitbit
79278601|NCT03523195|Other|Questionnaire Administration|Ancillary studies
79278602|NCT03523195|Other|Physical Performance Testing|Performance of physical tests
79278603|NCT04059445|Device|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
79278604|NCT04059445|Drug|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
79278605|NCT02361099|Other|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
79278606|NCT02361255|Other|no intervention|
79278607|NCT02290249|Device|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
79404938|NCT01505114|Drug|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
79404939|NCT01505114|Drug|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
79404940|NCT01505114|Drug|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
79404941|NCT01505114|Other|Maraviroc placebo|Once daily from Week 0 through Week 48
79404942|NCT01505114|Other|Emtricitabine placebo|Once daily from Week 0 through Week 48
80032080|NCT03048214|Procedure|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
80032081|NCT03048214|Procedure|General anaesthesia|Usual practice for upper limb surgeries.
80032082|NCT02058615|Behavioral|Male Spouse Transition Toolkit|
80032083|NCT02058927|Drug|Measles vaccine|measles revaccination administered at 12 months from start of ART
80032084|NCT02059083|Behavioral|Heart rate variability biofeedback|
80032085|NCT02059083|Behavioral|CBT|
80032086|NCT02060955|Biological|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
80032087|NCT02060955|Drug|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
80032088|NCT02273362|Drug|Erlotinib|Given PO
80032089|NCT02273362|Drug|Erlotinib Hydrochloride|Given PO
79404943|NCT01505114|Other|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
79404944|NCT04276077|Other|High-frequency electrical muscle stimulation training|High-frequency electrical muscle stimulation training with 50 Hertz during 8 weeks
79404945|NCT04276077|Other|Low-frequency electrical muscle stimulation training|Low-frequency electrical muscle stimulation training with 10 Hertz during 8 weeks
79740884|NCT04169854|Drug|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
79740885|NCT02536768|Behavioral|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
79740886|NCT02661100|Drug|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
79740887|NCT02661100|Biological|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
79278608|NCT02290249|Device|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
80032090|NCT02273362|Other|Laboratory Biomarker Analysis|Correlative studies
80032091|NCT02273362|Other|Quality-of-Life Assessment|Ancillary studies
79278609|NCT02224859|Device|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
79740888|NCT02661100|Biological|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
79876492|NCT00974987|Radiation|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
79278610|NCT02224859|Other|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
79278611|NCT03160677|Other|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 130 mm Hg
79278612|NCT03160677|Other|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 185 mm Hg
79278613|NCT02221895|Other|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
79278614|NCT02221895|Other|Postpartum follow up 6-8wk after delivery|control arm
79404946|NCT04177524|Device|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
79404947|NCT04177524|Device|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
79404948|NCT04177524|Device|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
79404949|NCT05116488|Diagnostic Test|ECG(electrocardigraph)|Detection of electrocardiographic Brugada patterns using high precordial leads positioning as placing the precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.
79404950|NCT00006151|Behavioral|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
79404951|NCT00747747|Biological|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
79876493|NCT00974987|Drug|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
79876494|NCT00975065|Drug|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
79876495|NCT00975065|Drug|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
79876496|NCT00972881|Biological|cetuximab|
79876497|NCT00972881|Drug|capecitabine|
79876498|NCT00972881|Drug|irinotecan hydrochloride|
79876499|NCT00972881|Procedure|neoadjuvant therapy|
79278615|NCT02358915|Device|FastStart neuromuscular electrical stimulator|
79278616|NCT02221973|Dietary Supplement|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
79278617|NCT02359071|Other|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
79278618|NCT02358759|Procedure|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
79278619|NCT05092841|Drug|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
79278620|NCT05092841|Drug|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
79404952|NCT00747747|Device|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
79404953|NCT05125692|Procedure|vaginal surgical repair of isthmocele|after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
79740889|NCT00648232|Behavioral|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
79740890|NCT00648232|Behavioral|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
79278621|NCT02358525|Behavioral|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
79278622|NCT02358447|Procedure|TKR|non-navigated versus computer-navigated total knee replacement
79278623|NCT02224937|Drug|Melatonin|
79404954|NCT04761757|Other|Booklet of Scripts of Doctors|"The Booklet of Scripts for Doctors was used in the control arm. This tool was developed and tested to encourage shared decision-making in prescribing antidepressants within the Malaysian context."
79278624|NCT02224937|Drug|Placebo|
79278625|NCT02210429|Procedure|Elbow Fracture Fixation|
79278626|NCT02373111|Dietary Supplement|Isoflavone|
79278627|NCT02373111|Dietary Supplement|Astaxanthin|
79278628|NCT02373111|Dietary Supplement|Placebo|
79278629|NCT02225015|Behavioral|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
79278630|NCT02358291|Procedure|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
79278631|NCT02358291|Procedure|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
79404955|NCT04761757|Other|Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)|"The Booklet of Scripts for Doctors along with the Antidepressant Decision Aid for Major depressive disorder patients, ADAM, was used in the intervention arm. The decision aid was developed as per the International Patient Decision Aid Standards (IPDAS) criteria to enhance patient understanding of risks and benefits of different antidepressants available within the Malaysian context."
79404956|NCT01275573|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
79404957|NCT01275651|Other|laboratory biomarker analysis|Correlative studies
79740891|NCT00648232|Behavioral|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
79740892|NCT00648232|Behavioral|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
79740893|NCT00601354|Behavioral|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
79278632|NCT02358291|Procedure|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
79278633|NCT02290327|Drug|Pantoprazole|Proton pump inhibitor
79278634|NCT02290327|Drug|Placebo|50 ml of 0.9% normal saline
79278635|NCT02750813|Device|Delefilcon A contact lenses|
79278636|NCT02750813|Device|Senofilcon A contact lenses|
79278637|NCT02358213|Procedure|Ultrasound|Ultrasound examinations are done 5 times
79278638|NCT02290561|Procedure|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
79278639|NCT02290561|Device|MRI|
79278640|NCT02290561|Device|high intensity focused ultrasound (HIFU)|
79278641|NCT02373267|Biological|Technozyme|determination of ADAMTS13 activity
79278642|NCT02222051|Behavioral|Tai Chi|traditional chinese martial art meditative movement technique
79278643|NCT02222051|Behavioral|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
79278644|NCT02372955|Drug|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
79278645|NCT02372955|Drug|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
79278646|NCT02211053|Drug|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
79278647|NCT02211053|Drug|placebo|
79278648|NCT02358057|Drug|Dexmedetomidine|
79404958|NCT05111184|Behavioral|Education groupe|Education
79278649|NCT02358057|Drug|Alfentanil|
79278650|NCT02225093|Drug|Caffeine|Oral
79278651|NCT02225093|Drug|Dextromethorphan|Oral /.L
79404959|NCT03582631|Procedure|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
79278652|NCT02225093|Drug|Enzalutamide|Oral
79278653|NCT02225093|Drug|Enzalutamide Placebo to Match (PTM)|Oral
79278654|NCT02212535|Drug|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
79278655|NCT02372487|Drug|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
79278656|NCT02372487|Dietary Supplement|fluid therapy|2 liters of fluid per day
79278657|NCT02588885|Behavioral|Trauma-sensitive Care|"Psychological intervention~education~empowerment~desensitization~relaxation tools~Physical therapy intervention~techniques to address muscular tension~empowerment~comfort~encouragement of trauma-related coping skills"
79404960|NCT01277757|Drug|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
79404961|NCT01277757|Other|Laboratory Biomarker Analysis|Correlative studies
79404962|NCT01277757|Other|Pharmacological Study|Correlative studies
79404963|NCT00245271|Drug|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
79278662|NCT02213861|Drug|SHAPE|topical gel
79278663|NCT04478799|Device|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
79404964|NCT00245271|Drug|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
79404965|NCT00243867|Drug|Taxoprexin|6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
79404966|NCT01679899|Drug|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
79404967|NCT01679899|Drug|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
79404968|NCT01276821|Drug|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
79404969|NCT01276821|Drug|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
79404970|NCT03461419|Procedure|Microcannula Harvest Adipose Stroma|Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells
79404971|NCT03461419|Device|Centricyte 1000|Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
79404972|NCT03461419|Procedure|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
79404973|NCT04403269|Drug|IgIV|2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
79404974|NCT00245037|Biological|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
79876500|NCT00972881|Procedure|therapeutic conventional surgery|
79876501|NCT00972881|Radiation|radiation therapy|
79876502|NCT00290758|Drug|placebo|Given orally
79876503|NCT00290758|Drug|genistein|Given orally
79876504|NCT00290758|Other|laboratory biomarker analysis|Correlative studies
79876505|NCT00975299|Drug|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
79876506|NCT00975299|Drug|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
79404975|NCT00245037|Drug|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
79404976|NCT00245037|Drug|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
79404977|NCT00245037|Drug|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~Monitoring: Fludarabine level is not monitored.~Dose Adjustments: There are no provisions for fludarabine dose adjustments."
79278664|NCT04478799|Device|Sham Transcutanous Posterior Tibial Nerve Stimulation|Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
79278665|NCT05057195|Radiation|Interstitial radiation therapy|From 30 to 50 Gy,
79582156|NCT04157101|Behavioral|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
79278666|NCT05057195|Radiation|Postoperative external beam therapy|50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
79278667|NCT02361177|Drug|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
79278668|NCT05055713|Procedure|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
79278669|NCT05055713|Procedure|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
79582157|NCT04154488|Drug|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
79740894|NCT00601354|Drug|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
79740895|NCT02660866|Drug|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
79902207|NCT03253133|Drug|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 * 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~* Start level"
79278670|NCT05055713|Procedure|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
79902208|NCT03253133|Drug|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
79902209|NCT03253133|Drug|Oxycodone|Oxycodone
79902210|NCT03252756|Other|Placebo|Saline taken by mouth (PO)
79902211|NCT03252756|Drug|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
79278671|NCT05055713|Procedure|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
79278672|NCT05055713|Procedure|Endoscopic therapy+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
80032092|NCT02059317|Other|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
80032093|NCT02059317|Other|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
79278673|NCT05055713|Procedure|Endoscopic therapy+PSE+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
80032094|NCT02059317|Other|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
80032095|NCT04429906|Device|Huami smart wearable device|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
80032096|NCT03561129|Other|Embryo transfer|all the fresh embryo transfers, performed between January 1997 and December 2016 at Humanitas Fertility Center after IVF-ICSI cycles, divided per operator
80032097|NCT02060175|Device|Cilotax drug-eluting stents implantation|
80032098|NCT02060175|Device|DESyne drug-eluting stents implantation|
80032099|NCT03048760|Other|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans & 1 after approx. 2 weeks of radiotherapy treatment.
80032100|NCT01027858|Behavioral|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
79278674|NCT02360865|Other|Exercise|
79278675|NCT02361021|Other|- Weaning from mechanical ventilation|
79404978|NCT00245037|Drug|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
79582158|NCT04149171|Drug|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
79582159|NCT04149171|Drug|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
79582160|NCT04147585|Other|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
79582161|NCT04144894|Diagnostic Test|Shear Wave Elastography|Advanced ultrasound technique
79582162|NCT04111822|Drug|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
79740896|NCT02660866|Drug|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
79278676|NCT02225327|Biological|Fluad alone|Fluad
79278677|NCT02225327|Biological|Fluad and PPV23 on the different arms|Fluad and Prodiax
79278678|NCT02225327|Biological|Fluad and PPV23 on the same arm|Fluad and Prodiax
79278679|NCT02225327|Biological|PPV23 alone|Prodiax
79278680|NCT02357745|Procedure|Non surgical periodontal therapy|scaling and root planing
79278681|NCT02214641|Behavioral|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
79278682|NCT02214641|Behavioral|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
79278683|NCT02360787|Behavioral|Energy restriction|
79278684|NCT02360787|Behavioral|Almonds (15% kcal/day)|
79740897|NCT04169932|Biological|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 ^ 6 cells/kg,2 × 10 ^ 6 cells/kg,4 × 10 ^ 6 cells/kg,8 × 10 ^ 6 cells/kg).
80032101|NCT01027858|Behavioral|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
79278685|NCT02225561|Procedure|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
79404979|NCT00245037|Procedure|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~In autologous transplants, patients receive their own stem cells.~In syngeneic transplants, patients receive stem cells from their identical twin.~In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
79278686|NCT02225561|Procedure|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
79278687|NCT02357823|Other|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
79278688|NCT02357823|Other|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
79278689|NCT02222285|Other|Medical Food : Vayarin_005|
79278690|NCT02222285|Other|Placebo|
79278691|NCT04439097|Other|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
79278692|NCT04439097|Other|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
79404980|NCT00245037|Radiation|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
79404981|NCT00245037|Drug|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
79582163|NCT04111822|Drug|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
79582164|NCT04086264|Drug|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
79582165|NCT04086264|Drug|IMGN632|Study formulation given intravenously (IV)
79582166|NCT04086264|Drug|Venetoclax|Commercially available formulation administered orally
79582167|NCT04082520|Radiation|Gallium Ga 68-DOTATATE|Given IV
79278693|NCT02214797|Device|Etafilcon A, Lotrafilcon B , Senofilcon A|
79278694|NCT02357589|Procedure|2D laparoscopic cholecystectomy|
79902212|NCT03225417|Drug|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
79902213|NCT03225417|Drug|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
79278695|NCT02357589|Procedure|3D laparoscopic cholecystectomy|
80032102|NCT02059473|Procedure|Rotator cuff repair|Physiotherapy & Surgery
79582168|NCT04082520|Drug|Lutetium Lu 177 Dotatate|Given IV
79582169|NCT04082520|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
79582170|NCT04082520|Procedure|Positron Emission Tomography|Undergo PET/MRI
79902214|NCT03225417|Drug|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
79902215|NCT03225417|Drug|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
79902216|NCT03209609|Device|VEST|External support for vein grafts, cobalt chrome braid
79902217|NCT03209609|Procedure|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
80032103|NCT02059473|Procedure|Physiotherapy|
80032104|NCT03048838|Behavioral|Risk reduction behavioral intervention|
79278696|NCT02357511|Device|Study Monitor used|
79278697|NCT02225639|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
79278698|NCT02225639|Drug|Placebo|Oral placebo capsule
79278699|NCT02225639|Drug|PRC-063 35 mg|Oral 35 mg capsule - active
80032105|NCT03048838|Behavioral|Wellness Promotion Intervention|
79278700|NCT02225639|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
79740898|NCT04169620|Other|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
79278701|NCT02225639|Drug|PRC-063 55 mg|Oral 55 mg capsule - active
79278702|NCT02225639|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
79278703|NCT02225639|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
79404982|NCT00245037|Drug|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
79278704|NCT02225639|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
79278705|NCT05231109|Other|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
79876507|NCT01060930|Drug|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
79876508|NCT00973037|Drug|Tamoxifen|Tamoxifen 20mg qd
79876509|NCT00973115|Drug|Simvastatin CR|
79278706|NCT03159975|Drug|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
79278707|NCT03159975|Drug|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
79278708|NCT03159975|Drug|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
79278709|NCT02222363|Drug|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
79902218|NCT03164356|Device|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
80032106|NCT03046810|Device|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
80032107|NCT02059629|Device|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
80032108|NCT02059629|Device|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
79278710|NCT02360709|Device|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
79305159|NCT03252509|Procedure|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
79404983|NCT00245037|Drug|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
79582171|NCT04082520|Other|Quality-of-Life Assessment|Ancillary studies
79582172|NCT04082520|Other|Questionnaire Administration|Ancillary studies
79582173|NCT04079465|Device|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
79582174|NCT04066114|Biological|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
79582175|NCT04066114|Biological|antithymocyte globulin (rabbit)|1.5 mg/kg intravenously (IV) on Day 0 (day of transplantation) and the day following (Day 1)
79582176|NCT04066114|Drug|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
79582177|NCT04066114|Biological|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
79902219|NCT03091660|Biological|BCG Solution|Given intravesically
79902220|NCT03091660|Biological|BCG Tokyo-172 Strain Solution|Given intravesically
79902221|NCT03091660|Biological|BCG Tokyo-172 Strain Vaccine|Given ID
79902222|NCT03091660|Other|Laboratory Biomarker Analysis|Correlative studies
79278711|NCT02215421|Behavioral|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
79278712|NCT05030519|Drug|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
79278713|NCT02372643|Other|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
79278714|NCT02215577|Procedure|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
79582178|NCT04066114|Drug|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~Days 4 through 10: 30 mg daily~Days 11 through 17: 20 mg daily~Days 18 through 24: 10 mg daily~After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
79278715|NCT02215577|Procedure|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
79278716|NCT02357277|Drug|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
79278717|NCT02357277|Other|Placebo Inhaler|inhaled placebo
79278718|NCT02217293|Device|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
79278719|NCT02372175|Biological|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
79278720|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
79278721|NCT02222441|Drug|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
79278722|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
79278723|NCT02222441|Drug|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
79305160|NCT04965051|Drug|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
79305161|NCT04965051|Drug|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
79582179|NCT04066114|Drug|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
79582180|NCT04066114|Biological|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
79876510|NCT00975377|Procedure|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
79876511|NCT00973193|Drug|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
79876512|NCT00975533|Device|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
79876513|NCT00975533|Drug|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
79876514|NCT00372567|Drug|sunitinib malate|37.5 mg daily
79876515|NCT00372567|Drug|imatinib mesylate|800mg daily
79876516|NCT04008251|Genetic|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
79876517|NCT00973271|Drug|290 mg DCCR|290 mg diazoxide choline
79876518|NCT00973271|Drug|435 mg DCCR|435 mg diazoxide choline
79876519|NCT00973271|Drug|135 mg fenofibric acid|135 mg fenofibric acid
79876520|NCT00973271|Drug|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
79876521|NCT00973271|Drug|atorvastatin|20 mg atorvastatin
79876522|NCT00975767|Drug|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
79876523|NCT00975767|Drug|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
79876524|NCT00975845|Other|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
79876525|NCT00365547|Biological|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
79876526|NCT00365547|Drug|topotecan hydrochloride|Topotecan 4 mg/m^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
79582181|NCT04066114|Drug|mycophenolate mofetil|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolate mofetil 1000 mg administered orally twice daily or~mycophenolic acid"
79582182|NCT04066114|Drug|mycophenolic acid|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolic acid 720 mg taken orally twice daily or~mycophenolate mofetil"
79876527|NCT00545441|Device|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
79876528|NCT00545441|Device|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
79876529|NCT03991767|Other|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
79404984|NCT04402879|Procedure|Prone Positioning (PP)|"The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is > 8 hours per day for up to 60 days, or until oxygen requirements are < 2 L per minute or < 2 L per minute above baseline home oxygen requirements."
79404985|NCT00241839|Drug|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
79582183|NCT04060862|Drug|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
79582184|NCT04060862|Drug|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
79740899|NCT04169620|Other|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
79740900|NCT02663986|Behavioral|Organizational Skills Training (OST) Intervention|
79740901|NCT00853099|Biological|adalimumab|
79740902|NCT00853099|Drug|placebo|
79740903|NCT00648310|Drug|Tolterodine 4 mg|
79876530|NCT03991767|Diagnostic Test|Serology HIV|Realization of HIV serology for included patients.
79404986|NCT00241839|Drug|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
79582185|NCT04060862|Drug|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
79740904|NCT00648310|Drug|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
79740905|NCT00702871|Drug|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
79740906|NCT00702871|Drug|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
79740907|NCT00700453|Behavioral|Control group with no video game play|Subjects will abstain from all video game play during study participation.
79740908|NCT00700453|Behavioral|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
79740909|NCT00700453|Behavioral|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
79740910|NCT00700453|Behavioral|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
79740911|NCT00992784|Biological|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
79740912|NCT00992784|Biological|FluarixTM|Single dose, intramuscular injection
79740913|NCT00830167|Drug|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
79740914|NCT00830167|Drug|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
79740915|NCT02611531|Behavioral|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
79740916|NCT02611531|Behavioral|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
79876531|NCT00976001|Other|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
79876532|NCT00976001|Other|As the general practitioner wants to do|
79902223|NCT03091595|Drug|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
79902224|NCT03091595|Drug|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
79902225|NCT03089541|Behavioral|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
79902226|NCT03028402|Procedure|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
79278724|NCT02290639|Behavioral|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
79278725|NCT02290639|Behavioral|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
79278726|NCT02372565|Behavioral|Facebook and text Message|Culturally-relevant physical activity promotion program
79278727|NCT02372565|Behavioral|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
79404987|NCT00241839|Drug|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
79404988|NCT00241839|Drug|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
79404989|NCT03529903|Behavioral|Health Coaching|Our trained health coaches will use the Way To Health platform to track patient health behaviors, and will communicate with patients via both SMS text messaging (up to four messages per week) and biweekly phone calls (up to one hour). During these interactions, health coaches will connect the patient to helpful resources and to help them reflect on previous goals and to set realistic, achievable goals for the upcoming weeks.
79404990|NCT03529435|Behavioral|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
79582186|NCT04060862|Drug|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
79582187|NCT04040881|Behavioral|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
79609687|NCT05771220|Combination Product|ESWT+ traditional physical therapy treatment|"Participants will receive one session per week for 6 weeks on the affected tissue region which will be achieved by a sequence of 2000 shock wave pulses fired with a repetition frequency of 2 pulses per second. Energy level or intensity will be set at a tolerable level by patient (0.2mJ/mm2).~The usual physical therapy care consists of hot pack (10min), stretching, pendulum exercises, isometrics exercises of shoulder one per week, and for 12 weeks. home exercises program (HEP)"
79609688|NCT05771220|Combination Product|Placebo shockwave + traditional physical therapy treatment|"Participants will be treated one time a week over a six-week period. Placebo shockwave treatment (apply low intensity with low dose and frequency: intensity 0.1, freq 1, dose 200 shocks).~The usual physical therapy care consists of hot pack (10min), stretching, pendulum exercises, isometrics exercises of shoulder one per week, and for 12 weeks. home exercises program (HEP)"
79609689|NCT05771207|Dietary Supplement|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
79278728|NCT02225717|Procedure|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
79609690|NCT05771207|Dietary Supplement|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
79876533|NCT00979589|Drug|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
79876534|NCT00979589|Drug|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
80032109|NCT03046420|Other|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
80032110|NCT04877626|Drug|Artemeter plus lumefantrina vs artesunato plus amodiquina|"Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)"
79305162|NCT02455427|Device|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
79305163|NCT02455427|Other|Physical Therapy|Physical therapy will be administered for 60 minutes
79609691|NCT05771207|Dietary Supplement|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
79278729|NCT02372331|Other|ERAS perioperative management|"Preop Counseling~Preop biliary drainage (X) when Serum Total bilirubin < 14.62mg/dl and cholangitis (-)~Preop enteral nutrition~Oral bowel preparation (mechanical bowel preparation ) (X)~Preop fasting < 6 hours~Prevention of postoperative nausea and vomiting (PONV) (O)~Nasogastric intubation (X)~Near-zero fluid balance~Somatostatin analogues (X)~Postop routine artificial nutrition (X), soft diet at POD #2~Audit~Other items are same as conventional"
79278730|NCT02290717|Device|Fractional CO2 laser|
79278731|NCT02290717|Other|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
79278732|NCT02290717|Drug|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
79278733|NCT02225795|Other|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~6 r-ATG 2 mg/kg~5 r-ATG3 2 mg/kg~4 r-ATG3 2 mg/kg~3 Cyclophosphamide with Mesna~2 Cyclophosphamide with Mesna~1 REST 0 PBSC infusion~3 Cyclophosphamide with Mesna~4 Cyclophosphamide with Mesna~6 Start GCSF"
79278734|NCT02360553|Behavioral|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
79278735|NCT02360553|Behavioral|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
79582188|NCT04040569|Radiation|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
79582189|NCT04010461|Device|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
79582190|NCT04010461|Behavioral|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
79582191|NCT03995108|Drug|Mavorixafor|Mavorixafor provided as 100 mg capsules.
79740917|NCT00992394|Drug|etanercept|etanercept 50 mg once weekly as requested.
79740918|NCT00992394|Drug|etanercept|etanercept 25 mg or 50 mg as requested.
79740919|NCT04291170|Other|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
79740920|NCT04291170|Other|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
79740921|NCT00829933|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
79740922|NCT00829933|Drug|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
79278736|NCT02290795|Other|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
79876535|NCT00294658|Procedure|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
79876536|NCT00294658|Drug|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
79876537|NCT00979667|Drug|Oseltamivir|75 mg twice daily for 5 days
79278737|NCT02360241|Device|Robot|Use of the robot to locate the fictional needle
79278738|NCT02225873|Other|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
79582192|NCT03995108|Drug|Placebo|Placebo matching to mavorixafor capsules
79740923|NCT01170962|Drug|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
79740924|NCT01170962|Drug|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
79740925|NCT01170962|Drug|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
79740926|NCT01170962|Drug|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
79740927|NCT01170962|Drug|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
79740928|NCT00843193|Drug|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
79740929|NCT00843193|Drug|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
79876538|NCT00979667|Drug|Zanamivir|10 mg twice daily for 5 days
79876539|NCT00979667|Drug|Placebo of Oseltamivir|twice daily for 5 days
79876540|NCT00976079|Device|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
79876541|NCT00976079|Device|Placebo TENS|Placebo TENS use
79902227|NCT03025971|Device|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
79902228|NCT02926391|Device|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
79902229|NCT02923232|Device|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
79902230|NCT02914808|Other|Patients will undergo a lower limb MRI and blood tests|
79902231|NCT02861781|Other|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
79902232|NCT02626312|Other|Laboratory Biomarker Analysis|Correlative studies
79902233|NCT02626312|Procedure|Magnetic Resonance Imaging|Correlative studies
79582193|NCT03985423|Drug|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day [SD] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
79740930|NCT00843193|Drug|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
79740931|NCT00829621|Other|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
79740932|NCT00829621|Other|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
79740933|NCT01157078|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
79740934|NCT01157078|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
79740935|NCT00591721|Behavioral|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
79740936|NCT04117399|Other|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
79740937|NCT01156844|Drug|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
79278739|NCT02225873|Other|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
79278740|NCT02294149|Drug|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
79582194|NCT03978793|Device|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
79582195|NCT03971734|Drug|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
79740938|NCT01156844|Drug|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
79740939|NCT00853021|Biological|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
79740940|NCT00853021|Biological|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
79740941|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
79740942|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
79740943|NCT05367284|Drug|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
79740944|NCT00843115|Other|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
79278741|NCT02294149|Drug|placebo|
79278742|NCT02360163|Procedure|Traditional Landmark Technique (TLT)|
79278743|NCT02360163|Device|ultrasound guided peripheral intravenous access (USGPIVA)|
79278744|NCT02217449|Other|Prediction of histology|
79305164|NCT02455427|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
79582196|NCT03971734|Drug|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
79582197|NCT03971734|Drug|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
79582198|NCT03971734|Drug|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
79582199|NCT03971734|Drug|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
79582200|NCT03971734|Drug|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
79582201|NCT03971734|Drug|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
79582202|NCT03875092|Biological|Pembrolizumab|IV infusion
79582203|NCT03875092|Drug|Paclitaxel|IV infusion
79582204|NCT03875092|Drug|Nab-paclitaxel|IV infusion
79582205|NCT03875092|Drug|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
79582206|NCT03875092|Drug|Saline placebo for pembrolizumab|IV infusion
79582207|NCT03863041|Other|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
79582208|NCT03862833|Drug|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
79740945|NCT01156376|Device|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
79740946|NCT01156376|Device|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
79902234|NCT02626312|Radiation|Radiation Therapy|Undergo radiation therapy
79902235|NCT02626312|Other|Survey Administration|Ancillary studies
79902236|NCT02386553|Drug|Nusinersen|Solution for intrathecal injection
79902237|NCT02307058|Radiation|LEAD RT|The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
79278745|NCT02291107|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
79582209|NCT03862833|Drug|Zoledronic Acid|4 mg at day +15 post graft
79582210|NCT03859063|Behavioral|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
79582211|NCT03859063|Behavioral|Control|Community based follow-up as usual
79740947|NCT01156376|Device|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
79740948|NCT00700531|Device|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
79740949|NCT00700531|Procedure|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
79740950|NCT00829387|Behavioral|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
79740951|NCT00829387|Behavioral|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
79740952|NCT00705913|Device|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
79582212|NCT03856892|Other|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
79582213|NCT03856892|Other|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
79740953|NCT00705913|Device|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
79740954|NCT01156142|Drug|doxepin hydrochloride|Oral rinse
79740955|NCT01156142|Other|placebo|Oral rinse
79740956|NCT00842257|Drug|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
79740957|NCT00705991|Procedure|ROTEM|
79740958|NCT05603377|Diagnostic Test|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
79740959|NCT00706069|Drug|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
79740960|NCT00706069|Drug|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
79740961|NCT00700609|Behavioral|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
79740962|NCT02884622|Other|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
79740963|NCT02884622|Other|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
79740964|NCT04188002|Behavioral|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
79740965|NCT04188002|Other|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
79740966|NCT00852475|Dietary Supplement|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
80032111|NCT03046030|Other|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
79278746|NCT02291107|Other|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
79278747|NCT02357355|Device|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
79582214|NCT03847467|Drug|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
79582215|NCT03847467|Other|Placebo|Dextrose
79582216|NCT03829319|Biological|Pembrolizumab|IV infusion Q3W
79582217|NCT03829319|Drug|Carboplatin|IV infusion Q3W
79278748|NCT02218229|Device|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
79278749|NCT02360007|Drug|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~Buprenorphine (BUP)~Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~HIV+Hepatitis Education delivered via iPad"
79278750|NCT02294305|Drug|Vortioxetine|
79740967|NCT00852475|Dietary Supplement|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
79582218|NCT03829319|Drug|Cisplatin|IV infusion Q3W
79582219|NCT03829319|Drug|Pemetrexed|IV infusion Q3W
79582220|NCT03829319|Drug|Lenvatinib|Oral capsule once daily
79278751|NCT02294305|Drug|Placebo|
79740968|NCT01155284|Drug|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
79740969|NCT01155284|Drug|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
79582221|NCT03829319|Drug|Placebo matching lenvatinib|Oral capsule once daily
79582222|NCT03824652|Other|walnuts|2 ounces of walnuts daily for 4-10 weeks
79582223|NCT03824652|Other|usual diet|Subject continues usual diet
79582224|NCT03824652|Other|phone counseling with dietitian|Weekly calls with dietitian
79740970|NCT00852397|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
79278752|NCT02225951|Dietary Supplement|Nutritional product|
79278753|NCT02225951|Other|Standard breakfast according to ADA recommendations|
80032112|NCT03046030|Other|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles [20, 35, 104-106]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling [20, 35, 104]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
79278754|NCT02357199|Other|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
79582225|NCT03800823|Behavioral|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
79278755|NCT03133039|Procedure|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
79582226|NCT03800823|Behavioral|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
79582227|NCT03800823|Behavioral|Standard care|Standard care for overweight and obesity.
79582228|NCT03776318|Drug|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
79740971|NCT00852397|Drug|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
79740972|NCT00852397|Other|Placebo|Placebo tablet for 24 weeks
79278756|NCT05013983|Biological|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
79582229|NCT03774485|Device|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
79582230|NCT03771716|Behavioral|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
79740973|NCT00841321|Drug|Ginkgo biloba|120 mg orally twice a day for 12 weeks
79740974|NCT00841321|Drug|Placebo|One capsule orally twice a day for 12 weeks
79740975|NCT00986232|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
79740976|NCT00986232|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
79278757|NCT05013983|Other|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
79740977|NCT00986232|Biological|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
79582231|NCT03771716|Behavioral|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
79740978|NCT00852241|Drug|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
79278758|NCT02357433|Device|High Doses CPFA|
79278759|NCT02222519|Drug|Rocuronium|Rocuronium 0.6mg/kg iv single dose
79278760|NCT02357121|Device|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
79740979|NCT00852241|Drug|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
79740980|NCT02612233|Drug|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
79278761|NCT02220023|Drug|INOmax Inhalation|
79278762|NCT02352909|Other|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
80032113|NCT03046030|Other|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
79740981|NCT01169636|Drug|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
79278763|NCT02352909|Other|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
79278764|NCT02352909|Other|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
79278765|NCT03132961|Other|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
79278766|NCT02222597|Device|infrascanner|
80032114|NCT03046030|Other|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
80032115|NCT02059707|Device|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
79278767|NCT02356965|Drug|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
79278768|NCT02356965|Drug|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
79582232|NCT03755388|Device|Episealer|Placing Episealer device
79582233|NCT03747159|Drug|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
79740982|NCT01169636|Drug|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
79740983|NCT01169636|Drug|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
79740984|NCT01169636|Drug|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
79740985|NCT01169636|Drug|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
79740986|NCT01169636|Drug|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
79278769|NCT02222675|Procedure|Sonography assisted breast surgery|
79278770|NCT02222675|Procedure|Conventional breast surgery|
79278771|NCT04478955|Diagnostic Test|Schirmer test|Tear tests Meibomian gland grading test
79278772|NCT02359695|Drug|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
79278773|NCT02294539|Drug|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
79278774|NCT02294539|Drug|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
79278775|NCT02294539|Drug|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
79278776|NCT02294539|Drug|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
79582234|NCT03735628|Drug|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
79582235|NCT03735628|Drug|Nivolumab|Nivolumab: concentrate for solution for infusion
79582236|NCT03727100|Combination Product|Clonidine Micropellets|Injection
79582237|NCT03727100|Other|Sham|Injection
79740987|NCT00706225|Drug|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
79740988|NCT00703105|Biological|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
79740989|NCT00706303|Behavioral|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
79740990|NCT04117009|Drug|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
79740991|NCT04117009|Diagnostic Test|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
79740992|NCT04117243|Drug|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
79740993|NCT04117243|Drug|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
79740994|NCT04117243|Drug|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
79740995|NCT01169558|Drug|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
79740996|NCT01169558|Drug|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
79740997|NCT00700687|Drug|PA32540|aspirin/omeprazole
79740998|NCT00700687|Drug|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
79740999|NCT00700687|Drug|aspirin and [NSAID]|aspirin and [NSAID]
79741000|NCT00706459|Device|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
79741001|NCT04314908|Procedure|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
79741002|NCT04314908|Procedure|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
80032116|NCT05255848|Drug|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
80032117|NCT04877704|Other|Symprove (probiotic)|Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
80032118|NCT04877704|Other|Placebo|Matched placebo to Symprove probiotic
80032119|NCT04430062|Procedure|Surgical procedures performed under general anesthesia|Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
79582238|NCT03720275|Genetic|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
79582239|NCT03694938|Device|Magnetic resonance imaging|Annually magnetic resonance imaging
79582240|NCT03694691|Diagnostic Test|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
79582241|NCT03685331|Drug|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
79582242|NCT03685331|Drug|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
79278777|NCT02356809|Drug|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
79278778|NCT02359617|Drug|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
79404991|NCT03529435|Behavioral|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
79582243|NCT03685331|Drug|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
79582244|NCT03634488|Drug|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
79741003|NCT04314908|Procedure|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
79741004|NCT04314908|Procedure|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
79404992|NCT05347381|Drug|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
79582245|NCT03634488|Dietary Supplement|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeautic food
79582246|NCT03634072|Procedure|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
79582247|NCT03621540|Device|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
79582248|NCT03621540|Device|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
79582249|NCT03621540|Behavioral|Adaptive working memory training|Adaptive spatial n-back training.
79582250|NCT03605719|Drug|Carfilzomib|Given IV
79582251|NCT03605719|Drug|Dexamethasone|Given IV
79582252|NCT03605719|Biological|Nivolumab|Given IV
79876542|NCT03978052|Dietary Supplement|EGCG|"Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up).~Participants that weight <50kg intake one oral dose in the morning for breakfast (266 mg/EGCG, 49 of Font-up"
79876543|NCT03978052|Dietary Supplement|Placebo EGCG|Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up)
79404993|NCT02651688|Drug|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
79876544|NCT03978052|Other|Personalized intervention|A personalized intervention include a physical activity plan,dietary intervention, mental health promotion interventions,
79404994|NCT02651688|Drug|Enclomiphene|Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
79876545|NCT03978052|Other|Lifestyle recommendations|The recommendations are to balance caloric intake and physical activity to achieve and maintain a healthy body weight; consume a diet rich in vegetables and fruits;
79876546|NCT03923933|Drug|Chlorthalidone|Chlorthalidone
79404995|NCT05347615|Procedure|IOL Implantation:EDOF lens|A EDOF lens is implanted in the dominant eye
80032120|NCT02799381|Drug|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
80032121|NCT02799381|Drug|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
80032122|NCT02799381|Device|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
80032123|NCT02799381|Device|Percutaneous endoscopic gastrostomy tube|(PEG tube)
79582253|NCT03605719|Biological|Pelareorep|Given IV
79876547|NCT03923933|Drug|Bumetanide|Bumetanide
80032124|NCT02799381|Device|Jejunal extension tube|(J-tube)
80032125|NCT04877158|Behavioral|Self-Blame and Perspective-Taking Intervention|The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
80032126|NCT04387942|Drug|IL-2|For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
80032127|NCT04877002|Diagnostic Test|Sona Saliva C-19 Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
80032128|NCT01333059|Drug|Midazolam|
80032129|NCT01333059|Drug|Normal saline|
80032130|NCT01333059|Drug|Fentanyl|
80032131|NCT03046186|Diagnostic Test|Mixed meal test with double tracer technique|
79278779|NCT02359617|Device|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
79582254|NCT03602391|Behavioral|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
79741005|NCT02884778|Diagnostic Test|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
79278780|NCT02359539|Procedure|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
79278781|NCT02291263|Biological|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
79741006|NCT00840463|Drug|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
79741007|NCT00840463|Other|Placebo|Sugar pill
79741008|NCT00706615|Biological|Ad-sig-hMUC-1/ecdCD40L vaccine|
79741009|NCT00703183|Drug|ACU-4429|administered as a single dose, orally
79741010|NCT00703183|Drug|matching placebo|administered as a single dose, orally
79741011|NCT00706693|Dietary Supplement|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
79741012|NCT00706693|Dietary Supplement|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
79741013|NCT00706693|Dietary Supplement|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
79741014|NCT02613325|Device|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
79741015|NCT02613325|Procedure|Standard of care surgical excision|
79741016|NCT02613325|Device|Single cell photoacoustic microscopy|
79741017|NCT00700765|Drug|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
79741018|NCT02611999|Behavioral|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
79741019|NCT02611999|Behavioral|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
79278782|NCT02291263|Biological|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
79278783|NCT02291263|Biological|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
79404996|NCT05347615|Procedure|IOL Implantation: Monofocal lens|A monofocal lens is implanted in the non dominant eye.
79404997|NCT03528109|Behavioral|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
79404998|NCT01276353|Drug|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
79404999|NCT01276353|Drug|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
79741020|NCT04030897|Behavioral|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
79741021|NCT04030897|Behavioral|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
79741022|NCT04030897|Behavioral|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
79741023|NCT04117165|Diagnostic Test|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
79741024|NCT04117165|Drug|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
79278784|NCT02226029|Other|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~13C-markers will be mixed with emulsions"
79278785|NCT03154125|Drug|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
79405000|NCT03578029|Drug|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
79405001|NCT03578029|Drug|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
79405002|NCT03525847|Diagnostic Test|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
79405003|NCT03807921|Drug|Warfarin|Oral anticoagulation
79741025|NCT00828451|Biological|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
79741026|NCT00839917|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
79278786|NCT02226107|Behavioral|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
79741027|NCT00839917|Biological|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
79741028|NCT00839527|Drug|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
79741029|NCT00839527|Biological|albiglutide|albiglutide weekly subcutaneous injection
79741030|NCT00839527|Drug|metformin|metformin
79741031|NCT00839527|Drug|glimepiride|glimepiride
79741032|NCT00839527|Drug|pioglitazone|pioglitazone
79405004|NCT03807921|Drug|Aspirin|Antiplatelet treatment
79278787|NCT02226107|Behavioral|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
79278788|NCT02294617|Other|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
79278789|NCT02294617|Other|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
79278790|NCT03112161|Other|Eucaloric Feeding Period|
79278791|NCT03112161|Other|Overfeeding Feeding Period|
79405005|NCT00762021|Device|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
79405006|NCT00762021|Device|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
79278792|NCT03112161|Other|Underfeeding Feeding Period|
79278793|NCT02226185|Drug|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
79405007|NCT01675609|Drug|Placebo|1 drop in each eye daily for up to 35 days
79405008|NCT01675609|Drug|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
79405009|NCT01673659|Drug|Mometasone furoate|
79405010|NCT01673659|Drug|Nasonex Nasal Spray|
79405011|NCT01673659|Drug|Placebo nasal spray|
79405012|NCT00762177|Drug|Fluoride|Brush twice a day for 14 days
79405013|NCT00762177|Drug|Fluoride, Triclosan|Brush twice daily for 14 days
79405014|NCT00762177|Drug|Stannous Fluoride|Brush twice daily for 14 days
79405015|NCT04403659|Device|Telemedicine/telemonitoring (TM) suite|"The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily.~The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured."
79405016|NCT02536794|Biological|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
79405017|NCT02536794|Other|Laboratory Biomarker Analysis|Correlative studies
79405018|NCT02536794|Other|Pharmacological Study|Correlative studies
79405019|NCT02536794|Biological|Tremelimumab|Given IV
79741033|NCT00839527|Drug|placebo to match pioglitazone|pioglitazone matching placebo
79741034|NCT00706771|Drug|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
79741035|NCT00706771|Drug|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
79741036|NCT04031053|Other|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
79741037|NCT00706927|Drug|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
79741038|NCT00706927|Drug|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
79741039|NCT00707083|Drug|dexamethasone|Given oral
79741040|NCT00707083|Drug|mercaptopurine|Given orally
79741041|NCT00707083|Drug|methotrexate|Given orally
79741042|NCT00707083|Drug|vincristine sulfate|Given IV
79741043|NCT05500261|Drug|Dexmedetomidine|intranasal administration of dexmedetomidine
79741044|NCT04116931|Drug|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
79741045|NCT00600886|Drug|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
79741046|NCT00600886|Drug|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
79741047|NCT00649324|Drug|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
79741048|NCT00649324|Drug|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
79741049|NCT00648388|Drug|Cilostazol Tablets 100 mg|100mg, single dose fasting
79741050|NCT00648388|Drug|Pletal® Tablets 100 mg|100 single dose fasting
79741051|NCT02658760|Drug|Dexmedetomidine|dexmedetomidine plus placebo
79741052|NCT02658760|Drug|Bupivacaine|dexmedetomidine and Bupivacaine
79741053|NCT02536690|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
79278794|NCT02226185|Drug|placebo|supplement of placebo two times per day for 2-3 years
79582255|NCT03593993|Procedure|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
79582256|NCT03547050|Other|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
79582257|NCT03547050|Other|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
79741054|NCT02536690|Drug|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
79741055|NCT02536690|Drug|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
79741056|NCT02660632|Other|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
79741057|NCT02660632|Other|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
79741058|NCT00649090|Drug|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
79741059|NCT00838903|Biological|albiglutide|albiglutide
79741060|NCT00838903|Drug|sitagliptin|sitagliptin
79741061|NCT00838903|Drug|glimepiride|Glimepiride
79741062|NCT00838903|Drug|metformin|Metformin
79741063|NCT00838903|Biological|placebo albiglutide|placebo to match albiglutide
79741064|NCT00838903|Drug|placebo sitagliptin|placebo to match sitagliptin
79741065|NCT00838903|Drug|placebo glimepiride|placebo to match glimepiride
79741066|NCT02660398|Procedure|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
79741067|NCT00648466|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
79741068|NCT00648466|Drug|Imitrex® Tablets 100 mg|100mg, single dose fasting
79278795|NCT02291341|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
79278796|NCT02291341|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
79278797|NCT02258633|Other|Interactive interview and tailored family centered seatbelt safety intervention|
79278798|NCT03112317|Other|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
79405020|NCT00749073|Device|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
79582258|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
79741069|NCT04170322|Device|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
79741070|NCT04170322|Device|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
79741071|NCT00649402|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
79741072|NCT00649402|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
79741073|NCT00649480|Drug|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
79278799|NCT02258711|Device|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
79278800|NCT02220179|Behavioral|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
79405021|NCT00777855|Drug|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
79405022|NCT00777855|Drug|warfarin|warfarin 7.5mg po x 1
79405023|NCT05125536|Other|Music therapy|rutin
79582259|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
79741074|NCT00649480|Drug|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
79741075|NCT02656108|Procedure|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
79741076|NCT02656108|Procedure|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
79741077|NCT02656342|Drug|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
79741078|NCT02656342|Drug|Placebo|Predicted to have no enhancing effect
79741079|NCT04116385|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
79741080|NCT02656186|Dietary Supplement|Pre-intervention|First 2-weeks : keeping routine dietary habit
79741081|NCT02656186|Dietary Supplement|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
79741082|NCT04169464|Drug|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
79741083|NCT02656030|Other|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
79741084|NCT02656030|Other|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
79741085|NCT02656030|Other|usual care|usual care, 2 time per week, 6 weeks duration
79741086|NCT00650416|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
79278801|NCT02352987|Drug|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
79405024|NCT03523429|Drug|blinatumomab|Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
79741087|NCT00650416|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
79741088|NCT00649948|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
79741089|NCT00649948|Drug|Glucophage XR 500 mg|500mg, single dose fed
79741090|NCT04254328|Device|Nintendo Wii Fit|Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.
79741091|NCT04254328|Device|Threshold IMT|Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
79741092|NCT04167982|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
79741093|NCT04167982|Drug|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
79741094|NCT04167982|Drug|Oral low-dose isotretinoin|low-dose isotretinoin
79741095|NCT02651974|Behavioral|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
79741096|NCT02651974|Behavioral|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
79741097|NCT02651974|Behavioral|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
79741098|NCT00649558|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
79741099|NCT00649558|Drug|Actos® Tablets 45 mg|45mg, single dose fasting
79741100|NCT02658604|Other|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
79741101|NCT02658682|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
79741102|NCT02658682|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
79741103|NCT04169308|Drug|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
79741104|NCT02658526|Behavioral|anesthesia - surgery|
79741105|NCT02655718|Other|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
79741106|NCT02655718|Device|MRI|
79741107|NCT02651818|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
79876548|NCT00372489|Drug|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
79278802|NCT02352987|Drug|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
79278803|NCT02226263|Dietary Supplement|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 [CFU] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
79741108|NCT02651896|Radiation|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
79741109|NCT02658370|Device|animated home-based exercises (Wii-fit)|
79741110|NCT02658370|Procedure|conventional home-based exercise program|
79741111|NCT00650494|Drug|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
79876549|NCT01066468|Drug|Gleevec/Glivec|
79876550|NCT00979823|Other|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
80032132|NCT02060253|Drug|ganetespib|Given IV
79741112|NCT00650494|Drug|Valtrex® 1000 mg|1000mg, single dose fed
79278804|NCT04439019|Other|Lifestyle and dietary modification program|"The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date.Patients are encouraged to attend sessions with a family member. Improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation will be shown."
79582263|NCT03471182|Behavioral|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
79582264|NCT03471182|Drug|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
79741113|NCT02655874|Biological|Influenza vaccine|Administered at day 1
79741114|NCT02655874|Biological|Influenza vaccine|Administered at day 180
79741115|NCT02655874|Biological|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
79741116|NCT00828139|Biological|ziv-aflibercept|Given IV
79741117|NCT00828139|Drug|topotecan hydrochloride|Given IV
79741118|NCT02655796|Device|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
79741119|NCT04222192|Other|Epidural block|Epidural catheter insertions
79741120|NCT04169386|Drug|AK102|AK102 single dose administered subcutaneously
79741121|NCT04169386|Drug|Placebo|Placebo single dose administered subcutaneously
79741122|NCT02658214|Drug|paclitaxel + carboplatin|IV infusion
79741123|NCT02658214|Drug|carboplatin + etoposide|IV infusion
79741124|NCT02658214|Drug|gemcitabine + carboplatin|IV infusion
79741125|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
79741126|NCT02658214|Drug|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
79278805|NCT03521947|Diagnostic Test|Complete blood picture|Iaboratory investigation
79582265|NCT03471182|Radiation|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of [18F]FPEB.
79582266|NCT03471182|Other|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
79741127|NCT02658214|Biological|durvalumab|IV infusion
79741128|NCT02658214|Biological|tremelimumab|IV infusion
79741129|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
79741130|NCT02658214|Drug|cisplatin + 5-fluorouracil (5FU)|IV infusion
79741131|NCT04169230|Drug|Citalopram|Single dose administration of citalopram (20mg)
79741132|NCT04169230|Drug|Placebo oral tablet|Single dose administration lactose placebo tablet
79741133|NCT02655952|Drug|Foxy-5|
79741134|NCT02655640|Other|Questionnaires|Questionnaires will be provided to patients
79741135|NCT02658058|Other|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
79741136|NCT02658058|Other|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
79741137|NCT02658058|Other|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
79741138|NCT02655484|Device|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
80032133|NCT02060253|Drug|paclitaxel|Given IV
79278806|NCT02226341|Drug|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
79405025|NCT03802851|Procedure|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
79405026|NCT04403035|Diagnostic Test|ID NOW vs. Accula|Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
79405027|NCT03807609|Other|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79405028|NCT03807609|Other|EX -30. Condition with an acute exercise set 30 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79582267|NCT03467919|Biological|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
79582268|NCT03467919|Biological|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
79582269|NCT03467789|Drug|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is < 31 ng/mL, and 5 days if the D3 level is > 31 ng/mL
79582270|NCT03467789|Radiation|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
79582271|NCT03467789|Drug|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
79582272|NCT03455725|Device|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
79582273|NCT03455725|Other|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
79876551|NCT00979823|Other|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
79278807|NCT02226341|Drug|ACTHar gel|Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
79876552|NCT01581190|Dietary Supplement|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
79278808|NCT02226341|Drug|ACTHar gel|Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
79876553|NCT00976157|Procedure|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
79278809|NCT02291575|Other|Training|(please see Arm Description)
79876554|NCT00976235|Device|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
80032134|NCT02060253|Biological|trastuzumab|Given IV
80032135|NCT02060253|Biological|pertuzumab|Given IV
80032136|NCT03560973|Drug|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
80032137|NCT03560973|Drug|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
80032138|NCT02059785|Drug|Pinocembrin for Injection|
80032139|NCT04383574|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
79278810|NCT02291575|Other|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
79278811|NCT04465903|Other|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
79278812|NCT02222987|Drug|Terbogrel|
79278813|NCT02222987|Drug|Clopidogrel|
79278814|NCT03147573|Diagnostic Test|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
79405029|NCT03807609|Other|EX-180. condition with an acute exercise set 180 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
79582274|NCT03454646|Drug|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
79278815|NCT03147573|Diagnostic Test|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
79278816|NCT03147573|Diagnostic Test|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
79278817|NCT03147573|Diagnostic Test|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
79582275|NCT03441061|Biological|Inotuzumab Ozogamicin|Given IV
79741139|NCT02651506|Procedure|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
79741140|NCT02651506|Procedure|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
79278818|NCT03521245|Other|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
79741141|NCT02655250|Other|Microbiome|
79741142|NCT04201756|Drug|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
79876555|NCT03977740|Other|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
79876556|NCT03977740|Other|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
79278819|NCT03521245|Other|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
79278820|NCT03521245|Drug|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
79278821|NCT03521245|Drug|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
79278822|NCT04479033|Other|Multidisciplinary collaborative model of community care management|An individualised care plan is developed for PLWDs-caregiver dyads who meet/communicate weekly with various members of the HMDCS team depending on the nature of their needs. Each dyad's care plan involves the diagnosis of problems (eg: memory problems, family conflicts, poor nutrition, fall risk, medication compliance, lack of long-term care arrangements), establishment of treatment goals (eg: caregiver education, awareness of long-term care planning, stabilising medical care at home, improving emotional support), and indicating specific interventions (eg: referrals to counsellors, specialist doctors, day rehabilitation centres; consultations at GP clinic; coordination of advanced care planning; installation of home safety devices; training caregivers to detect acute deterioration in PLWDs). Monitoring of the dyads' statuses and updating of care plans are performed throughout the duration of the programme.
79278823|NCT03521869|Device|Compression bandage|Compression bandage placed after total knee replacement
79278824|NCT03521869|Device|Gauze dressing|standard of care gauze dressing placed after total knee replacement
79405030|NCT02403193|Drug|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
79405031|NCT02403193|Drug|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
79405032|NCT02403193|Drug|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
79876557|NCT00976313|Procedure|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
79405033|NCT02403193|Drug|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
79405034|NCT02403193|Drug|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
79405035|NCT02403193|Drug|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
79405036|NCT02403193|Drug|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
79405037|NCT02403193|Drug|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
79582276|NCT03407469|Behavioral|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
79741143|NCT02651350|Drug|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
79876558|NCT00976313|Other|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
79876559|NCT03921047|Procedure|Biospecimen Collection|Undergo collection of blood samples
79876560|NCT03921047|Other|Laboratory Biomarker Analysis|Correlative studies
79278825|NCT02481245|Drug|Bezafibrate|30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
79405038|NCT02403193|Drug|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
79405039|NCT03807297|Drug|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
79405040|NCT03807297|Drug|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
79405041|NCT03807297|Other|sevoflurane|inhalational anaesthetic agent
79278826|NCT02352597|Drug|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
79876561|NCT00980135|Device|Sinecort cream|Application over 29 days
79278827|NCT02352597|Drug|estradiol valerate|2mg from cycle day 7 to day 11
79405042|NCT03807297|Other|nitrous oxide|inhalational anaesthetic agent
79405043|NCT05387148|Drug|Cannabidiol (CBD)|Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
79405044|NCT05387148|Drug|Placebo|The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
79405045|NCT03807219|Dietary Supplement|Magnox Comfort|Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).
79405046|NCT03807219|Other|Placebo|placebo
79582277|NCT03401762|Behavioral|MCI|EMG-controlled game
79582278|NCT03401762|Behavioral|Sham MCI|Sham control game
79741144|NCT02651350|Drug|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
79741145|NCT02658292|Drug|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
79741146|NCT02658292|Drug|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
79876562|NCT00980135|Drug|Hydrocortison cream|Application over 29 days
79876563|NCT00980135|Other|Untreated skin|
79876564|NCT00980213|Drug|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
79278828|NCT02352597|Drug|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
79278829|NCT02294851|Drug|BMS-986168|
79278830|NCT02294851|Drug|BMS-986168 Placebo|
79876565|NCT04986527|Procedure|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
79876566|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
79876567|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
79876568|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
79278831|NCT02352675|Other|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
79278832|NCT02226419|Dietary Supplement|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
79405047|NCT03569917|Other|Rectal swab collection|Rectab swab collection will be performed at inclusion and 5 and 30 days later.
79405048|NCT03807375|Other|CPAP preoxygenation|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
79405049|NCT05076084|Procedure|QUICK questionnaire and 6 additional questions|QUICK questionnaire and 6 additional questions
79278833|NCT02294929|Procedure|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
79278834|NCT02226497|Device|Health Telemonitoring|Use home telemonitoring device
79278835|NCT02226497|Other|Quality-of-Life Assessment|Ancillary studies
79278836|NCT02226497|Other|Questionnaire Administration|Ancillary studies
79278837|NCT02226497|Procedure|Supportive Care|Receive standard outpatient supportive care
79405050|NCT05076084|Other|Retrospective collection of clinical data from the patients' medical records|Retrospective collection of clinical data from the patients' medical records
79582279|NCT03336268|Behavioral|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
79876569|NCT00976469|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
79582280|NCT03328026|Biological|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
79741147|NCT02657824|Other|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
79741148|NCT02655328|Other|blood sample|blood sample
79741149|NCT02655328|Other|urine sample|urine sample
79741150|NCT04169152|Procedure|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
79741151|NCT04168840|Diagnostic Test|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
79876570|NCT00976469|Biological|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
79876571|NCT00372411|Device|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
79876572|NCT00372411|Other|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
79876573|NCT00372411|Other|Usual Care|The usual chronic stroke care as delivered at each participating medical center
79876574|NCT00976625|Procedure|Aortic Valve Replacement|Surgical valve replacement of the aorta
79278838|NCT03521167|Drug|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
79278839|NCT03521167|Drug|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
79278840|NCT03521167|Drug|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
79278841|NCT03521167|Drug|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for >65y or if patient having significant sedation/dizziness
79278842|NCT03521167|Drug|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if <70kg
79278843|NCT03521167|Drug|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients >65y or with GFR < 50 Consider dose reduction in patients with sleep apnea
79278844|NCT03521167|Drug|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if <70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
79278845|NCT02352519|Procedure|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
79876575|NCT00980603|Drug|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
79741152|NCT02655172|Other|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
79741153|NCT02655172|Other|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
79876576|NCT00980603|Drug|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
79876577|NCT00980603|Drug|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
79876578|NCT00955097|Drug|Definity®|Definity® injections given both pre-ablation and post-ablation
79278846|NCT02352519|Procedure|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
79278847|NCT02226575|Behavioral|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
79876579|NCT00955175|Radiation|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
79278848|NCT02291653|Device|McGrath|video-laryngoscopy
79876580|NCT00980759|Radiation|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
79278849|NCT02291653|Device|MIL|direct-laryngoscopy
79278850|NCT02356419|Drug|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
79278851|NCT02220335|Procedure|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
79278852|NCT02220335|Drug|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
79278853|NCT02291731|Drug|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
79278854|NCT03147339|Other|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
79405051|NCT03809637|Drug|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
79405052|NCT03513445|Drug|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
79278855|NCT02223221|Procedure|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
79405053|NCT03513445|Drug|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
79405054|NCT03513445|Drug|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
79405055|NCT03802071|Drug|Durvalumab+doxorubicin cobination|Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
79278856|NCT02223221|Genetic|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
79278857|NCT02223221|Other|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
79278858|NCT03521011|Device|MSCT|Non enhanced MSCT Abdomen
79278859|NCT02223299|Dietary Supplement|L-tyrosine|6g/d daily for 30 days
79278860|NCT02223299|Dietary Supplement|L-Tryptophan|2g/d daily for 30 days
79405056|NCT05124756|Device|Bioelectric stimulation|The sessions will include 20 minutes for stimulation of the thigh muscles and 45 minutes for stimulation of the kidneys. The electrodes will be placed on the motor point of the quadriceps muscle in both lower limbs. The neuromuscular electric stimulation will be applied by symmetrical biphasic pulsed current, at an 80 Hz frequency, 400 ms pulse width, 10 s contraction time, rest time decreasing as the protocol advanced, at reciprocal mode. The intensity will be individually adjusted to produce visible muscle contraction. Concomitant, two electrodes will be placed in the abdominal corresponding to the kidney anatomical site and two electrodes on the dorsal region at the level of the 10th thoracic vertebra. The stimulation of the kidneys will include in addition to Klotho, precise signals for several pro-regenerative proteins. The intensity of the electric current will be individually adjusted to sensory stimulation.
79405057|NCT00758667|Drug|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
79876581|NCT00980759|Radiation|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
79278861|NCT02223299|Drug|deplin|15mg daily for 30 days
79278862|NCT02223299|Other|Placebo A|a sugar-pill that looks like a real medication
79405058|NCT04412772|Drug|Tocilizumab|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
79405059|NCT04412772|Drug|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
79582281|NCT03328026|Drug|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
79582282|NCT03328026|Drug|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites ~2 days after SV-BR-1-GM inoculation.
79278863|NCT02223299|Other|Placebo B|a sugar-pill that looks like a real medication
79278864|NCT02356341|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
79278865|NCT02295007|Behavioral|text message|
79305165|NCT03253601|Behavioral|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
79305166|NCT04953195|Drug|Levothyroxine Sodium Tablets|Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
79582283|NCT03328026|Drug|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
79582284|NCT03324932|Drug|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
79582285|NCT03297645|Behavioral|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
79741154|NCT02657980|Device|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79741155|NCT02657980|Device|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
79741156|NCT04168996|Behavioral|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
79741157|NCT00650572|Drug|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
79741158|NCT02651038|Drug|Micafungin|Measurement of PK
79741159|NCT00650026|Biological|adalimumab|40 mg adalimumab every other week
79741160|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail|
79741161|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
79741162|NCT02536924|Behavioral|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
79741163|NCT02536924|Behavioral|Treatment as usual.|The patient will receive treatment as usual.
79741164|NCT02657746|Other|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
79741165|NCT02657668|Behavioral|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
79741166|NCT04033042|Device|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
79741167|NCT02650882|Procedure|Device POWERbreathe|
79741168|NCT00838513|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
79741169|NCT04032886|Other|kinesio tape|This is a taping method used for correction of rounded shoulders.
79741170|NCT04032886|Other|exercise|Exercises include basic postural exercises.
79741171|NCT02536222|Other|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
79741172|NCT00649636|Drug|Fluoxetine Capsules 40 mg|40mg, single dose fasting
79741173|NCT00649636|Drug|Prozac Pulvules 40 mg|40mg, single dose fasting
79741174|NCT04030663|Drug|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
79741175|NCT04030663|Drug|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
79741176|NCT04030663|Drug|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
79741177|NCT02654938|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
79741178|NCT02654938|Drug|Placebo|5% infusion solution of dextrose
79741179|NCT00700921|Drug|Lovastatin|40mg po once daily
79741180|NCT00700921|Drug|Placebo|One capsule, once daily
79741181|NCT00600106|Drug|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
79741182|NCT00600106|Drug|Placebo|1 mg placebo
79305167|NCT03253523|Procedure|Occipital neurolysis|Surgical occipital nerve decompression
79305168|NCT03252119|Device|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
79741183|NCT04168918|Behavioral|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
79582286|NCT03297645|Behavioral|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
79582287|NCT03297645|Behavioral|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
79741184|NCT02650726|Dietary Supplement|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
79741185|NCT02650726|Other|Placebo|placebo 320mg daily for 24 weeks
79741186|NCT00850993|Drug|Stannsoporfin|Stannsoporfin administered as a single IM injection
79741187|NCT00850993|Other|Placebo|Placebo (sterile saline solution) administered as a single IM injection
79741188|NCT00850993|Other|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
79741189|NCT04168762|Other|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
79741190|NCT02657512|Drug|rivaroxaban|rivaroxaban 40 mg/day (1 day)
79278866|NCT05256121|Other|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
79278867|NCT02355873|Device|AN69ST hemofilter|
79876582|NCT00976859|Behavioral|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
79876583|NCT00976859|Behavioral|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
79278868|NCT02355873|Device|AN69 hemofilter|
79278869|NCT02226731|Device|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
79582288|NCT03297645|Behavioral|Informational mail|Family will be mailed publicly available asthma information every 3 months.
79582289|NCT03266783|Drug|Apixaban|Refer to Apixaban group
79582290|NCT03266783|Drug|Rivaroxaban|Refer to Rivaroxaban group
79278870|NCT02226731|Device|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
79582291|NCT03242343|Device|VasQ|An external support device for AV fistula
79582292|NCT03231735|Device|Mid frequency ventilation|Mechanical ventilator used at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
79582293|NCT03231735|Device|Standard frequency ventilation|Mechanical ventilator used at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
79582294|NCT03219359|Procedure|Autologous stem cell transplant|Hematopoietic stem cell transplantation
79741191|NCT02657512|Drug|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
79582295|NCT03219359|Drug|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ >20x104/ml then leukapheresis daily to collection goal
79582296|NCT03219359|Drug|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
79741192|NCT00818779|Drug|Aliskiren|150 - 300 mg once daily for 6 weeks
79741193|NCT00818779|Drug|Amlodipine|5-10 mg once daily for 6 weeks
79741194|NCT02654548|Other|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
79741195|NCT02657278|Procedure|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
79741196|NCT00850759|Device|virtual pedestrian environment|a computer-driven virtual pedestrian environment
79741197|NCT00850759|Device|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
79741198|NCT00850759|Behavioral|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
79741199|NCT02657200|Other|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
79582297|NCT03219359|Drug|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
79582298|NCT03219359|Drug|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
79582299|NCT03219359|Drug|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
79741200|NCT02650492|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
79876584|NCT04011293|Biological|CNCT19|0.5 to 4 x 10^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10^8 autologous CNCT19 transduced cells via intravenous infusion.
79876585|NCT03958019|Other|RESTORE II Program|Detailed in arm description
79405060|NCT03509857|Device|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
79582300|NCT03180034|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
79582301|NCT03180034|Other|Questionnaire Administration|Ancillary studies
79582302|NCT03180034|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
79582303|NCT03180034|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
79741201|NCT00827827|Other|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
79741202|NCT00827827|Other|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
79741203|NCT00650728|Procedure|placing gastric tube|
79741204|NCT02654704|Biological|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
79741205|NCT02650336|Drug|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
79741206|NCT00649714|Drug|Zonisamide Capsules 100 mg|100mg, single dose fed
79741207|NCT00649714|Drug|Zonegran® Capsules 100 mg|100mg, single dose fed
79741208|NCT02654392|Dietary Supplement|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
79741209|NCT02654392|Dietary Supplement|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils) every day for 5 weeks
79741210|NCT02654158|Drug|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
79741211|NCT02654158|Drug|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
79741212|NCT02657122|Drug|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
79741213|NCT02657122|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
79741214|NCT02657122|Drug|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
79876586|NCT00372255|Biological|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
79876587|NCT00977015|Drug|Treatment A|Inhaled, 750/150, single dose
79876588|NCT00977015|Drug|Treatment B|Inhaled, 750/150, single dose
79582304|NCT03169712|Behavioral|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
79582305|NCT03169712|Behavioral|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
79582306|NCT03158805|Drug|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
79582307|NCT03158805|Other|Placebo|Placebo injection
79741215|NCT02657122|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
79876589|NCT00274456|Drug|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
79876590|NCT00274456|Drug|Docetaxel|Docetaxel dosed q3w at 100 mg/m^2
79876591|NCT01045629|Other|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
79876592|NCT01049607|Procedure|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
79876593|NCT01049607|Procedure|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
79582308|NCT03126331|Drug|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
79582309|NCT03126331|Drug|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
79582310|NCT03121352|Drug|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
79278871|NCT02291809|Biological|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
79278872|NCT02226809|Device|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
79278873|NCT02352441|Other|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
79278874|NCT02291887|Drug|Ranibizumab|Intravitreal injection of Ranibizumab
79278875|NCT02291887|Drug|Aflibercept|Intravitreal injection of Aflibercept
79278876|NCT02352285|Drug|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
79876594|NCT00977093|Other|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
80032140|NCT04383574|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
79278877|NCT02352285|Drug|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
79278878|NCT02220491|Radiation|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
79278879|NCT02220491|Radiation|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
79582311|NCT03121352|Drug|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
79741216|NCT00600028|Drug|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
79741217|NCT00600028|Drug|Placebo|Placebo 50-100 mg by mouth per day
79278880|NCT03521713|Drug|EPORON|"Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~Formulation : Solution in PFS"
79278881|NCT03521713|Drug|EPREX|"Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~Formulation : Solution in PFS"
79278882|NCT02355717|Other|Observational Study|
79405061|NCT03509857|Other|No Intervention|No intervention
79405062|NCT00758745|Device|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
79741218|NCT02650102|Drug|Risperidone|a kind of antipsychotics
79741219|NCT02650102|Drug|Olanzapine|a kind of antipsychotics
79741220|NCT02650102|Drug|Quetiapine|a kind of antipsychotics
79876595|NCT00977093|Other|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
79876596|NCT00977249|Behavioral|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
79278883|NCT02226887|Procedure|MESH|"Pre-operative :~It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~Surgical technique:~Peristomal incision with electrocautery~Release the handle of ileum~Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~We add the mesh between the edges of the defect during fascia closure.~The skin is sutured purse string style.~Post-Op~Hospital discharge after verification of normal digestive transit."
79278884|NCT02226887|Procedure|NO MESH|"Pre-operative :~It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~Surgical technique:~Peristomal incision with electrocautery~Release the handle of ileum~Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit"
79405063|NCT00758745|Device|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
79405064|NCT05124600|Device|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
79405065|NCT05041920|Drug|famitinib、omeprazole|famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
79582312|NCT03121352|Drug|Pembrolizumab|200 mg IV every 21 days
79582313|NCT03114501|Behavioral|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
79582314|NCT03114501|Behavioral|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
79741221|NCT02650102|Drug|Aripiprazole|a kind of antipsychotics
79741222|NCT02650102|Drug|Ziprasidone|a kind of antipsychotics
79741223|NCT02657044|Procedure|EMR|
79741224|NCT02657044|Procedure|ESD|
79741225|NCT00650182|Drug|fentanyl; naltrexone|
79741226|NCT02650180|Device|Soberlink Cellular Device|Alcohol Breath Analyzer
79876597|NCT00977249|Drug|varenicline|
79876598|NCT00977249|Drug|placebo|
79876599|NCT01069822|Drug|AZD6765|IV solution
79876600|NCT01069822|Drug|midazolam|
79876601|NCT00977327|Device|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
79876602|NCT00977327|Device|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
79876603|NCT03977974|Drug|LY3526318|Administered orally
79876604|NCT03977974|Drug|Placebo|Administered orally
79741227|NCT02653924|Other|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
79278885|NCT02226887|Radiation|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
79278886|NCT02226887|Radiation|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
79741228|NCT02653924|Other|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
79741229|NCT02653924|Other|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
79741230|NCT02653924|Other|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
79876605|NCT00955565|Procedure|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
79278887|NCT02226887|Other|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
79405066|NCT03802461|Biological|Fecal Microbiota Transplantation (FMT)|Feces from healthy donor
79405067|NCT03984786|Behavioral|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
79876606|NCT00955565|Procedure|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
80032141|NCT04383574|Biological|Two doses of placebo at the schedule of day 0,28|The placebo was manufactured by Sinovac Research & Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
79405068|NCT03984786|Behavioral|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
79405069|NCT03984786|Behavioral|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
79582315|NCT03114501|Behavioral|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
79582316|NCT03113929|Radiation|MRI|Research MRI
79582317|NCT03108456|Device|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
79582318|NCT03108456|Device|Balloon|Vessel preparation with conventional and/or specialty balloons
79582319|NCT03086421|Behavioral|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
79582320|NCT03073577|Drug|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
79582321|NCT03069469|Drug|DCC-3014|CSF1R inhibitor
79582322|NCT03066206|Drug|Poziotinib|Given PO
79582323|NCT03051659|Drug|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
79741231|NCT00650884|Device|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
79741232|NCT00910780|Drug|Aripiprazole|via oral tablets, everyday
79741233|NCT00910780|Drug|Zyprexa|via oral tablets, taken once daily
79741234|NCT00910780|Drug|Risperdal|via oral tablets, taken once daily
79741235|NCT02649712|Device|biliary stent|Self-expandable biliary nitinol alloys stent
79741236|NCT02656888|Drug|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
79741237|NCT02656888|Drug|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
79278888|NCT04465513|Dietary Supplement|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
79278889|NCT04465513|Dietary Supplement|Best Standard of Care|Combination of placebo with clinical care
79278890|NCT02355795|Behavioral|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
79278891|NCT02355795|Behavioral|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
79278892|NCT02355795|Behavioral|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
79278893|NCT02355951|Other|blood draw|
79278894|NCT03517501|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
80032142|NCT04383574|Biological|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
79741238|NCT02656966|Device|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
80032143|NCT04876768|Procedure|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
79278895|NCT03517501|Drug|Placebo Comparator - Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
80032144|NCT03046108|Device|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
80032145|NCT03046108|Drug|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
79278896|NCT02295163|Procedure|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
79278897|NCT02295163|Procedure|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
79278898|NCT02223533|Device|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
79278899|NCT02223533|Drug|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
79278900|NCT02231021|Drug|alogliptin|alogliptin 25 mg add-on background medication metformin
79278901|NCT02231021|Drug|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
79278902|NCT02231021|Drug|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
79278903|NCT02295241|Other|No intervention|This is an observational trial, no interventions are being used.
79405070|NCT03508219|Device|BiOSS LIM C|"The BiOSS LIM C (Bifurcation Optimization Stent System, Balton, Warsaw, Poland). The BiOSS LIM C is a dedicated bifurcation stent covered with a mixture of a biodegradable polymer and the antiproliferative substance sirolimus. BiOSS LIM C will be used for treatment of the Left-Main bifurcation, according to its instructions for use.~The Alex-Plus cobaltchromium sirolimus eluting stent (Balton, Warsaw, Poland) will be used for treatment of distal left-main side branches according to its instructions for use (i.e. proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel is part of a trifurcation).~All other lesions (other than left-main bifurcations) will be treated with XIENCE family everolimus-eluting coronary stent systems."
79405071|NCT05032716|Other|Balance exrcises|the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights
79582324|NCT03051659|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
79582325|NCT03051074|Behavioral|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
79582326|NCT03051074|Behavioral|Comparison|Watching a relaxing film for up to 90 minutes
79582327|NCT03050671|Device|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
79741239|NCT02656810|Drug|Teriparatide|Single subcutaneous injection
79741240|NCT02536612|Other|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
79741241|NCT02536612|Other|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
79741242|NCT02653846|Procedure|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
79278904|NCT04465123|Drug|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels >4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
79278905|NCT04465123|Drug|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels >4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
79278906|NCT04658303|Drug|Pimonidazole|Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
79741243|NCT02653846|Procedure|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
79405072|NCT05032716|Other|Balance exrcises and Treadmill training|the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
79405073|NCT03807453|Other|Microbiota|The scalp microbiota
79741244|NCT02649478|Drug|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
79741245|NCT02649478|Drug|Placebo|
79405074|NCT03506113|Drug|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
79741246|NCT02649478|Drug|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
79741247|NCT00650962|Other|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
79741248|NCT00650962|Other|Rhythm analysis|Rhythm analysis as soon as AED is ready
79741249|NCT02653612|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
79741250|NCT04167592|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
79741251|NCT04167592|Drug|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
79741252|NCT02656732|Biological|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
79741253|NCT02656732|Procedure|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
79278907|NCT04465279|Device|Trifocal diffractive intraocular lens|Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
79278908|NCT02231099|Procedure|Prolift + M|prolapse surgery with mesh
79278909|NCT02231099|Procedure|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
79405075|NCT03506113|Drug|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
79405076|NCT04413084|Other|Gaze stability exercises|Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
79741254|NCT04168294|Drug|Propofol|patients in sedation group will be intravenous injected propofol in bolus
79741255|NCT04168294|Device|endoscopy|endoscopy system
79741256|NCT02653534|Behavioral|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
79278910|NCT02292043|Drug|HTEA|HTEA
79876607|NCT03976180|Device|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
79278911|NCT02401347|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
79278912|NCT02295319|Other|Individual discharge|"See previous description in Arms"
79278913|NCT02231255|Drug|Sifrol®|
79278914|NCT02352051|Drug|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
79278915|NCT02352051|Drug|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
79582328|NCT03050671|Device|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
79582329|NCT02975882|Drug|Irinotecan Hydrochloride|Given PO
79741257|NCT02656576|Procedure|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
79741258|NCT02656576|Procedure|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
79741259|NCT04167202|Procedure|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
79741260|NCT04167202|Procedure|RICE|RICE protocol
79741261|NCT02649244|Behavioral|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
79582330|NCT02975882|Other|Laboratory Biomarker Analysis|Correlative studies
79582331|NCT02975882|Other|Pharmacological Study|Correlative studies
79582332|NCT02975882|Drug|Sirolimus Albumin-bound Nanoparticles|Given IV
79582333|NCT02975882|Drug|Temozolomide|Given PO
79741262|NCT02653378|Behavioral|DIET|25% Energy Depletion by Diet only for 3 Days
79876608|NCT03976180|Device|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
79278916|NCT04465981|Diagnostic Test|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
79405077|NCT04413084|Other|Brandt-Daroff Exercises|"Brandt-Daroff Exercises~Start sitting upright on the edge of the bed.~Turn your head 45 degrees to the left, or as far as is comfortable.~Lie down on your right side.~Remain in this position for 30 seconds or until any dizziness has subsided.~Sit up and turn head back to center.~Turn your head 45 degrees to the right, or as far as is comfortable.~Lie down on your left side.~Remain in this position for 30 seconds or until any dizziness has subsided.~Sit up and turn head back to center."
79432948|NCT03586388|Other|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
79582334|NCT02965755|Other|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
79582335|NCT02938130|Other|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
79741263|NCT02653378|Behavioral|EX|25% Energy Depletion by Exercise only for 3 Days
79741264|NCT04168138|Drug|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
79432949|NCT04141826|Dietary Supplement|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
79741265|NCT02653222|Procedure|Renal sympathicolysis|
79741266|NCT02653222|Procedure|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
79582336|NCT02916550|Behavioral|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
79741267|NCT02653222|Radiation|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
79741268|NCT02653222|Biological|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
79741269|NCT02656498|Drug|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
79741270|NCT02653066|Other|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
80032146|NCT03046108|Drug|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
80032147|NCT03046108|Device|ultrasound guided injection|Introduction of a needle based guided by ultrasound
80032148|NCT03046108|Drug|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
80032149|NCT03046108|Drug|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
79582337|NCT02911064|Behavioral|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
79278917|NCT02227277|Drug|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL > 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
80032150|NCT01370733|Device|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
80032151|NCT01370733|Device|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
79278918|NCT03147183|Drug|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
79278919|NCT02292121|Procedure|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
79278920|NCT02292121|Other|a solution of mannitol and lactitol|
79278921|NCT03147105|Behavioral|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
79278922|NCT02223611|Drug|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)<1.25 m2 40mg twice a day, 1.25 m2≤BSA<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
79741271|NCT02653066|Other|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
79741272|NCT00649870|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
79741273|NCT00649870|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fed
79741274|NCT02536144|Procedure|magnetic-controlled capsule endoscopy system|"A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
80032152|NCT03048292|Other|Acute Endovascular Stroke Treatment|
79278923|NCT02223611|Drug|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
79278924|NCT03520777|Other|Art Intervention|Type of artist intervention will be determined by the subject and the assigned artist.
79278925|NCT03147027|Procedure|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
79741275|NCT02536144|Procedure|Colonoscopy|"Bowel preparation should be well done before the examination.~A tube with illumination and camera system would insert into colon from anus.~From the pictures captured by the camera ,the doctor would see the mucous of the colon."
79741276|NCT04167280|Drug|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
79741277|NCT04167280|Drug|placebo metered dose inhaler|matched MDI to deliver inactive drug
79741278|NCT02652910|Drug|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
79741279|NCT04167046|Procedure|Erector spinae block|Preoperative erector spinae block.
79741280|NCT02652832|Device|non invasive brain stimulation|non invasive brain stimulation
79741281|NCT02652988|Other|Active-tDCS|Active home-based tDCS applied at home.
79741282|NCT02652988|Other|Sham-tDCS|Sham home-based tDCS applied at home.
79741283|NCT04166968|Device|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
79741284|NCT04166968|Device|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
79741285|NCT04166968|Device|Sham stimulation (sham-tDCS)|placebo stimulation
79278926|NCT03147027|Other|medication|medication to prevent sustained VT and ICD therapies
79278927|NCT03517345|Dietary Supplement|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
79278928|NCT03517345|Dietary Supplement|Control|The only yogurt consumed as 200 g/d without prebiotic.
79278929|NCT02355561|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
79582338|NCT02908672|Drug|Atezolizumab|Will be administered as per the schedule described in individual arm.
79582339|NCT02908672|Drug|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
79582340|NCT02908672|Drug|Cobimetinib|Will be administered as per the schedule described in individual arm.
79876609|NCT03976180|Device|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
79876610|NCT03976180|Device|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
79876611|NCT00364923|Drug|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
79876612|NCT01066702|Biological|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
79278930|NCT02355561|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
79582341|NCT02908672|Drug|Vemurafenib|Will be administered as per the schedule described in individual arm.
79582342|NCT02908672|Drug|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
79876613|NCT01066702|Procedure|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
79278931|NCT02355561|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
79278932|NCT02231333|Drug|S-adenosylmethionine (SAMe)|
79278933|NCT02231333|Drug|pentoxiphylline (PTX)|
79432950|NCT04141826|Dietary Supplement|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
79432951|NCT04141826|Dietary Supplement|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
79432952|NCT05582486|Behavioral|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
79432953|NCT05582330|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
79432954|NCT00608491|Drug|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
79582343|NCT02871921|Behavioral|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
79582344|NCT02827032|Device|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
79741286|NCT04166968|Behavioral|Neuromotor training|conventional neuromotor treatment
79741287|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
79741288|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
79741289|NCT02649010|Device|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
79741290|NCT02649088|Device|Microscan|It allows to look at sublingual microcirculation
79741291|NCT02649088|Device|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
79876614|NCT00381849|Drug|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
79876615|NCT00381849|Drug|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
79876616|NCT00273052|Drug|Carvedilol Phosphate modified release formulation|
79278934|NCT03517267|Diagnostic Test|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
79582345|NCT02818283|Dietary Supplement|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
79278935|NCT02348229|Procedure|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
79582346|NCT02818283|Other|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
79876617|NCT00273052|Drug|metoprolol succinate|
79876618|NCT01046721|Drug|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
79876619|NCT01046721|Drug|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
79582347|NCT02811133|Drug|Inositol|Subjects will receive inositol
79582348|NCT02790021|Procedure|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
79741292|NCT04281160|Device|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
79876620|NCT02808351|Drug|Berberine|
79876621|NCT02535195|Dietary Supplement|Ginger supplement|
79741293|NCT02652598|Drug|Tolcapone|
79876622|NCT02535195|Dietary Supplement|Placebo (starch)|
79876623|NCT01046799|Drug|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
79278936|NCT02348229|Procedure|ERAS protocols|No bowel preparation
79278937|NCT02348229|Procedure|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
79876624|NCT00290290|Drug|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
79876625|NCT00290290|Drug|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
79278938|NCT02348229|Procedure|ERAS protocols|Vasoactive drugs used if need be
79741294|NCT02648776|Drug|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
79876626|NCT01049685|Drug|First-line Antiretroviral Therapy|"Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~Efavirenz: 01 capsules day, plus NRTI background"
79876627|NCT01580943|Drug|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
79876628|NCT01580943|Drug|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
79876629|NCT02534961|Drug|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
79876630|NCT01046955|Drug|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
79876631|NCT00272038|Drug|Tarceva|150mg QD
79876632|NCT01047033|Behavioral|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
79278939|NCT02348229|Procedure|ERAS protocols|Temperature management
79278940|NCT02348229|Procedure|ERAS protocols|Intra-abdominal drains not to be used
79278941|NCT02348229|Procedure|ERAS protocols|Intraperitoneal Ropivicaine infusion
79582349|NCT02784119|Procedure|temporary porto-caval shunt|temporary porto-caval shunt
79582350|NCT02775435|Biological|Pembrolizumab|IV infusion
79582351|NCT02775435|Drug|Paclitaxel|IV infusion
79582352|NCT02775435|Drug|Nab-paclitaxel|IV infusion
79582353|NCT02775435|Drug|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
79741295|NCT02648464|Drug|Hydroxychloroquine|
79741296|NCT02648464|Drug|Placebo|
79741297|NCT02648542|Other|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
79741298|NCT02648542|Device|transcranial direct current stimulation|Low-current electrical brain stimulation
79876633|NCT01047033|Other|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
79741299|NCT02648542|Other|Combined CAS and tDCS|Combined auditory and electrical stimulation
79278942|NCT02348229|Procedure|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
79278943|NCT02348229|Procedure|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
79278944|NCT02348229|Procedure|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
79278945|NCT02348229|Procedure|ERAS protocols|On the5-6th postoperative day Check discharge criteria
79278946|NCT02348229|Procedure|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
79741300|NCT02648542|Other|Sham stimulation|Sham stimulation
79278947|NCT02348229|Procedure|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
79278948|NCT02348229|Procedure|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
79876634|NCT00271024|Drug|Naltrexone (drug)|50 mg q.d. for 13 weeks
79278949|NCT02348229|Procedure|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
79278950|NCT02348229|Procedure|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
79278951|NCT02348229|Procedure|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
79278952|NCT02227433|Drug|Brentuximab Vedotin|
79876635|NCT00271024|Drug|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
79278953|NCT03517189|Procedure|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
79278954|NCT02351973|Drug|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
79278955|NCT02351973|Drug|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
79305169|NCT03253445|Behavioral|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
79405078|NCT04412850|Drug|Magnesium Sulfate|"Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge."
79405079|NCT00778167|Biological|cixutumumab|Given IV
79405080|NCT00778167|Drug|erlotinib hydrochloride|Given PO
79405081|NCT00778167|Other|laboratory biomarker analysis|Correlative studies
79741301|NCT02652754|Drug|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
79741302|NCT02652520|Procedure|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
79741303|NCT02645110|Device|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
79741304|NCT02645110|Device|Tap water|Washing hand with water alone in comparison to hand washing with soap
79741305|NCT02645188|Other|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
79741306|NCT02645032|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
79741307|NCT02645032|Biological|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
79876636|NCT00381693|Drug|azacitidine|
79876637|NCT00545363|Drug|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
79876638|NCT04011215|Other|wool clothing|superfine merino wool ensembles for baby/child wear
79741308|NCT02645032|Biological|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
79278956|NCT02351973|Drug|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg & + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
79582354|NCT02775435|Drug|Saline placebo for pembrolizumab|IV infusion
79278957|NCT03520621|Other|No intervention|no intervention
79278958|NCT04831619|Drug|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
79741309|NCT02536066|Behavioral|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
79278959|NCT02295397|Other|food|food provocation, skin testing, blood sampling
79278960|NCT02231411|Procedure|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
79582355|NCT02685826|Drug|Durvalumab|single use vials administered via intravenous infusion
79876639|NCT04011215|Other|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
79582356|NCT02685826|Drug|Lenalidomide|capsules for oral administration
79582357|NCT02685826|Drug|Dexamethasone|tablets for oral administration
79582358|NCT02684162|Biological|Donor Lymphocytes|Given IV
79582359|NCT02684162|Drug|Guadecitabine|Given SC
79582360|NCT02684162|Other|Laboratory Biomarker Analysis|Correlative studies
79582361|NCT02662907|Procedure|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
79582362|NCT02662907|Behavioral|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
79582363|NCT02662907|Device|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
79582364|NCT02662907|Device|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
79582365|NCT02662907|Behavioral|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
79582366|NCT02662907|Drug|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
79582367|NCT02659800|Other|Laboratory Biomarker Analysis|Correlative studies
79876640|NCT00955643|Other|oxygen|
79582368|NCT02659800|Biological|NT-I7|Given IM
79876641|NCT00955643|Other|other|
80032153|NCT02061189|Other|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
80032154|NCT02613364|Behavioral|Behavioral Intervention|Undergo yoga intervention
80032155|NCT02613364|Other|Cognitive Intervention|Undergo CBT-I intervention
79582369|NCT02659800|Other|Placebo|Given IM
80032156|NCT02613364|Other|Educational Intervention|Receive health education
79582370|NCT02658981|Biological|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
79582371|NCT02658981|Biological|Anti-PD-1|Given IV
79741310|NCT02644954|Drug|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
79741311|NCT02644954|Drug|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
80032157|NCT02613364|Other|Laboratory Biomarker Analysis|Correlative studies
80032158|NCT02613364|Device|Monitoring Device|Correlative studies
79582372|NCT02658981|Other|Pharmacological Study|Correlative Studies
79582373|NCT02658981|Other|Laboratory Biomarker Analysis|Correlative Studies
79582374|NCT02658981|Biological|Anti-CD137|Given IV
79582375|NCT02592291|Device|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
79582376|NCT02575794|Drug|Terameprocol|Given PO
79582377|NCT02575794|Other|Pharmacological Study|Correlative studies
79582378|NCT02481349|Other|Best Practice|Undergo standard of care
79582379|NCT02481349|Other|Informational Intervention|Receive DVD for home practice
79582380|NCT02481349|Other|Quality-of-Life Assessment|Ancillary studies
79582381|NCT02481349|Other|Questionnaire Administration|Ancillary studies
79582382|NCT02481349|Other|Yoga|Complete couple-based Hatha yoga program
79582383|NCT02419339|Procedure|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
79582384|NCT02403505|Biological|9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use|"By the percutaneous route with the multiple puncture device~9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix"
79741312|NCT02644954|Drug|Topical Coal tar|Topical coal tar to be applied once daily
79741313|NCT02644954|Drug|Topical calcipotriol|Topical calcipotriol to be applied once daily
79741314|NCT02652286|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
79741315|NCT00650338|Drug|DE-104 ophthalmic solution, low concentration|Topical ocular application
80032159|NCT02613364|Other|Quality-of-Life Assessment|Ancillary studies
80032160|NCT02061267|Dietary Supplement|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
79278961|NCT02231411|Procedure|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
79582385|NCT02240472|Procedure|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
79278962|NCT02231411|Procedure|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
79278963|NCT02355405|Device|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
79278964|NCT02355405|Radiation|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
79405082|NCT05124444|Genetic|High throughput DNA and RNA sequencing|High throughput DNA and RNA sequencing
79405083|NCT03807141|Other|Modified Atkins diet|This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
79405084|NCT03806907|Radiation|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
79741316|NCT00650338|Drug|DE-104 ophthalmic solution, medium concentration|Topical ocular application
79278965|NCT03520543|Drug|[11C]Yohimbine|Each subject will receive an intravenous (IV) bolus injection of [11C]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of [11C]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of [11C]Yohimbine.
79582386|NCT02236910|Other|Lu-DOTA-TATE|
79582387|NCT02140021|Procedure|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
79582388|NCT02140021|Other|Laboratory Biomarker Analysis|Correlative studies
79582389|NCT02107105|Other|Quality-of-Life Assessment|Complete quality of life questionnaire
79582390|NCT02107105|Other|Questionnaire Administration|Complete quality of life questionnaire
79741317|NCT00650338|Drug|DE-104 ophthalmic solution, high concentration|Topical ocular application
79741318|NCT00650338|Drug|Placebo|placebo
79278966|NCT03520543|Drug|[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)|"Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following [11C]Yohimbine PET scan (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after [11C]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of [11C]Yohimbine (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of [11C]Yohimbine obtained at baseline (part A)."
79278967|NCT02227511|Dietary Supplement|Fruits|Randomization to extra fruit or nuts as snacks
79582391|NCT02046057|Procedure|PNB of SLN|Percutaneous biopsy of sentinel node
79278968|NCT02227511|Dietary Supplement|Nuts|
79278969|NCT02355483|Device|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
79582392|NCT01993810|Drug|Carboplatin|Given IV
79582393|NCT01993810|Drug|Cisplatin|Given IV
79582394|NCT01993810|Biological|Durvalumab|Given IV
79582395|NCT01993810|Drug|Etoposide|Given IV
79741319|NCT00650338|Drug|0.005% latanoprost|Topical ocular application
79278970|NCT02231489|Drug|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
79405085|NCT03957330|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend ~15 mins. per week/per client.
79582396|NCT01993810|Drug|Paclitaxel|Given IV
79582397|NCT01993810|Drug|Pemetrexed Disodium|Given IV
79582398|NCT01993810|Radiation|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
79582399|NCT01993810|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
79741320|NCT02644720|Procedure|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
79741321|NCT02644720|Procedure|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
79876642|NCT05059457|Device|Blood source: single and pooled capillary and venous blood|"A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
80032161|NCT02061267|Dietary Supplement|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
79582400|NCT01993810|Other|Quality-of-Life Assessment|Ancillary studies
79582401|NCT01993810|Other|Questionnaire Administration|Ancillary studies
79582402|NCT01962415|Drug|Hydroxyurea|Oral administration at 30 mg/kg/day.
79405086|NCT03809559|Device|MRCP+|Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
79741322|NCT02644720|Drug|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
79405087|NCT05124366|Procedure|dental prophylaxis + oral hygiene instructions|Follow up: 2 weeks and 4 weeks
79582403|NCT01962415|Drug|Alemtuzumab|"Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only."
79278971|NCT02231489|Drug|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
79278972|NCT02231489|Drug|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
79582404|NCT01962415|Drug|Fludarabine|IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
79582405|NCT01962415|Drug|Melphalan|IV administration at 70 mg/m2/dose.
79582406|NCT01962415|Drug|Thiotepa|IV administration at 200 mg/m2/dose
79278973|NCT02355639|Drug|Clobetasol propionate 0.05 % ointment|
79582407|NCT01950351|Other|Laboratory Biomarker Analysis|Correlative studies
79278974|NCT02355639|Drug|Betamethasone dipropionate 0.064 % ointment|
79278975|NCT02355639|Drug|Petrolatum ointment|
79278976|NCT02355249|Procedure|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
79582408|NCT01950351|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
79741323|NCT02644720|Device|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
79278977|NCT02355249|Procedure|OE|Patients will be treated with traditional three incisions esophagectomy.
79278978|NCT03520465|Device|DynaMesh®-CICAT longitudinal measure 10x35 cm|
79278979|NCT02227589|Behavioral|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
79278980|NCT02227589|Behavioral|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
79278981|NCT02227589|Other|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
79278982|NCT02259101|Behavioral|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
79278983|NCT02259101|Behavioral|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
79405088|NCT03916848|Procedure|Combined Micro-Macro SEEG Electrodes|The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
79582409|NCT01950351|Other|Quality-of-Life Assessment|Ancillary studies
79582410|NCT01919619|Biological|Ipilimumab|Given IV
79582411|NCT01919619|Drug|Lenalidomide|Given PO
79405089|NCT00778869|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
79582412|NCT01918527|Drug|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
79741324|NCT02644720|Device|monofocal intraocular lens (IOL) (Tecnis ZCB)|
79741325|NCT03542266|Drug|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
79741326|NCT03542266|Drug|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
79741327|NCT02648386|Procedure|Laparoscopic surgery|Completely resected rectal tumor.
79876643|NCT05059457|Device|Blood source: single capillary and venous blood|"A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
79278984|NCT02351895|Other|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
79582413|NCT01918527|Drug|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
79582414|NCT01851369|Drug|TRC102|TRC102 has been shown to potentiate the activity of temozolomide by preventing BER and allowing cleavage of TRC102 bound DNA, which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with TMZ and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
79278985|NCT00503035|Drug|Celecoxib|400 mg by mouth twice daily x 6 months
79876644|NCT05059457|Device|Blood source: pooled capillary and venous blood|"Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
79876645|NCT00977405|Device|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
79278986|NCT00503035|Procedure|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
79876646|NCT00977639|Procedure|Pathwork TOO test|
79278987|NCT02227745|Drug|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
79278988|NCT02227745|Drug|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
79876647|NCT00981383|Dietary Supplement|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
79582415|NCT01792531|Behavioral|Parent training group|The More & Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More & Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
79405090|NCT05118594|Behavioral|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
79405091|NCT05008536|Biological|Anti-BCMA CAR-NK Cells|1-3×10^6 /KG, 3-6×10^6 /KG, 0.6-1.2×10^7/KG Treatment follows a lymphodepletion
79405092|NCT05008536|Drug|Fludarabine|recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.
79405093|NCT05008536|Drug|Cytoxan|recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.
79582416|NCT01792531|Behavioral|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
79405094|NCT00779103|Drug|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
79582417|NCT01792531|Behavioral|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
79876648|NCT00981383|Other|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
79876649|NCT00977795|Drug|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
79876650|NCT00977873|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
79876651|NCT00977873|Dietary Supplement|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
79876652|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
79278989|NCT02348073|Drug|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
79278990|NCT02348073|Drug|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
79278991|NCT03517033|Drug|Torrent's Nebivolol Tablets|
79278992|NCT03517033|Drug|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
79278993|NCT02355327|Device|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
79278994|NCT02355327|Behavioral|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
79278995|NCT02223845|Other|Music|Self-selected music played via headphones
79278996|NCT03516955|Drug|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
79278997|NCT02348151|Other|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
79278998|NCT02348151|Other|Corridor|The volunteers will perform the shuttle walk test on the corridor
79278999|NCT02259179|Drug|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
79279000|NCT02259179|Drug|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
79279001|NCT03520153|Procedure|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
79876653|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
79876654|NCT00977951|Drug|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
79876655|NCT00977951|Drug|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
79876656|NCT00981539|Procedure|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
79405096|NCT05373420|Other|Education level|Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.
79279002|NCT03520153|Procedure|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
79405097|NCT05373420|Other|Household net income|Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.
79582418|NCT01731236|Dietary Supplement|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
79876657|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
79876658|NCT00457392|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
79405098|NCT05373420|Other|Gender|Male or female. This variable is obtained from the Belgian national registry.
79279003|NCT03520153|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
79582419|NCT01731236|Dietary Supplement|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
79582420|NCT01731236|Drug|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
79582421|NCT01731236|Drug|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
79582422|NCT01731236|Drug|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
79582423|NCT01627093|Other|Medical Chart Review|Review of medical records
79741328|NCT02648386|Device|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
79405099|NCT05373420|Other|Migration background|Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
79741329|NCT02648386|Biological|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
79279004|NCT02355093|Procedure|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
79305170|NCT03253445|Other|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
79305171|NCT04952259|Drug|Shexiang Tongxin Dropping Pills + routine treatment|oral+percutaneous coronary intervention
79405100|NCT05373420|Other|Household type|Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
79582424|NCT01627093|Other|Questionnaire Administration|Complete questionnaires
79582425|NCT01590069|Biological|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
79582426|NCT01590069|Other|Laboratory Biomarker Analysis|Optional correlative studies
79741330|NCT02648386|Biological|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
79876659|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
79876660|NCT00457392|Drug|placebo|Placebo daily by oral capsules in a continuous regimen
79876661|NCT00545051|Drug|Placebo|po monthly for 12 months
79876662|NCT00545051|Drug|ibandronate|150mg po monthly for 12 months
79876663|NCT00381615|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
79279005|NCT02355093|Procedure|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
79405101|NCT05373420|Other|Health literacy|Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
79582427|NCT01529593|Drug|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
79279006|NCT02355093|Drug|ropivacaine|
79582428|NCT01529593|Drug|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
79279007|NCT03516799|Other|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
79876664|NCT00381615|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
79279008|NCT03146949|Device|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
79279009|NCT03146949|Device|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
79279010|NCT02227901|Drug|Tipifarnib|Given PO
79582429|NCT01504789|Behavioral|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
79741331|NCT02641600|Device|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
79741332|NCT02641600|Device|Placebo stockings|Placebo stocking with pressure applied to the legs
79279011|NCT02227901|Radiation|External Beam Radiation Therapy|Undergo EBRT
79279012|NCT02227901|Drug|Temozolomide|Given PO
79279013|NCT02227901|Other|Laboratory Biomarker Analysis|Correlative studies
79279014|NCT03146715|Other|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
79405102|NCT04345419|Drug|Remdesivir|Remdesivir as antiviral drug
79876665|NCT00381615|Biological|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
79876666|NCT00381615|Biological|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
79305172|NCT04952259|Procedure|routine treatment|percutaneous coronary intervention
79405103|NCT04345419|Other|Standard of care treatment|Standard of care treatment
79405104|NCT04841070|Other|Ages & Stages Questionnaires®, Third Edition (ASQ3)|Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.
79405105|NCT01480076|Drug|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
79405106|NCT04830774|Device|ILR, PMK, ICD|"Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions"
79405107|NCT00759525|Drug|Glycyrrhetic Acid|130 mg daily for fourteen days
79405108|NCT00759525|Drug|Placebo|Placebo daily for fourteen days
79582430|NCT01504789|Behavioral|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
79582431|NCT01504789|Behavioral|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
79741333|NCT02648308|Behavioral|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
79741334|NCT02644876|Drug|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
79876667|NCT00381615|Biological|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
79876668|NCT00381615|Biological|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
79279015|NCT03160053|Device|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
79279016|NCT02227979|Behavioral|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
79741335|NCT02644876|Drug|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
79279017|NCT02227979|Behavioral|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
79279018|NCT03146793|Drug|Sodium Thiosulfate|25g intravenously 3 times per week
79279019|NCT03133195|Drug|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
79279020|NCT03133195|Drug|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
79582432|NCT01504789|Behavioral|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
79582433|NCT01446133|Drug|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
79582434|NCT01446133|Drug|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
79582435|NCT01349881|Drug|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
79741336|NCT00652600|Drug|Propranolol|ER Capsules, 160 mg, single-dose
79741337|NCT00652600|Drug|Inderal-LA|ER Capsules, 160 mg, single-dose
79741338|NCT02644642|Other|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
79741339|NCT03520504|Radiation|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
79741340|NCT04166578|Drug|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
79741341|NCT04166578|Procedure|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
79279021|NCT03133195|Dietary Supplement|Calcium supplement|1000 mg/day of elemental calcium
79279022|NCT03133195|Dietary Supplement|Vitamin D|20,000 IU/week of vitamin D2
79876669|NCT00381615|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
80032162|NCT02061267|Dietary Supplement|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
79279023|NCT02258789|Other|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
79279024|NCT02292199|Device|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
79279025|NCT02292199|Device|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
79279026|NCT02292199|Device|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
79279027|NCT02231567|Other|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
79279028|NCT02231567|Other|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
79279029|NCT03153033|Behavioral|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
79582436|NCT01349881|Drug|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
79582437|NCT01349881|Drug|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
79741342|NCT04166578|Procedure|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
79279030|NCT02224001|Procedure|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
79279031|NCT02039037|Device|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
79582438|NCT01349881|Drug|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
79582439|NCT01340742|Procedure|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
79741343|NCT04166578|Behavioral|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
79741344|NCT04166578|Behavioral|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
79876670|NCT00978107|Biological|MVA-FCU1, flucytosine|"TG4023: single IT injection; possibility to re-administer once,~Percutaneous IT injections, under radiological or ultrasound imaging guidance~Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~MTD injected to up to 3 different lesions (Cohort #4)~5-FC (5-fluorocytosine)/flucytosine~Dose and dosing schedule:~Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~Duration: 2 weeks.~Possible routes of administration:~PO: 500 mg tablets, qid~IV: 1% 250 mL vials, 45-minute infusions."
79876671|NCT00978185|Other|medical chart review|
79876672|NCT00978185|Other|questionnaire administration|
79279032|NCT02039037|Device|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
79279033|NCT02295631|Device|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
79279034|NCT02295631|Device|ETView VivaSight SL|ETI with ETView VivaSight SL
79279035|NCT02224079|Drug|BIIB 722 CL|
79279036|NCT02224079|Drug|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
79279037|NCT03159741|Other|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
79279038|NCT03159741|Other|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
79876673|NCT00978185|Procedure|acupressure therapy|
79876674|NCT00978185|Procedure|quality-of-life assessment|
79876675|NCT00978185|Procedure|sham intervention|
79876676|NCT00978185|Procedure|standard follow-up care|
79876677|NCT01029132|Drug|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
79876678|NCT00981695|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
79279039|NCT03159741|Other|Placebo + GIP|Placebo and GIP are used as study tools.
79279040|NCT03159741|Other|Placebo + Saline|Placebo
79279041|NCT03516721|Other|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
79279042|NCT02231645|Device|STN DBS|The DBS device is turned on and off by the physician.
79279043|NCT03159585|Drug|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
79279044|NCT02292277|Drug|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
79279045|NCT02292355|Other|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
79279046|NCT03152799|Procedure|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
79582440|NCT01340742|Procedure|Control|Cuff placed on arm uninflated for 30 minutes.
79582441|NCT01295645|Drug|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
79582442|NCT01295645|Other|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
79741345|NCT04166578|Diagnostic Test|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
79279047|NCT03152799|Other|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
79876679|NCT04008017|Diagnostic Test|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
79876680|NCT01049763|Drug|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
79876681|NCT00981773|Drug|Maraviroc|Maraviroc 150 mg bid
79876682|NCT00981773|Drug|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
79876683|NCT04007549|Behavioral|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
79279048|NCT02231801|Behavioral|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
79279049|NCT03516643|Other|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
79279050|NCT02228135|Drug|Dexamethasone|
79279051|NCT03152877|Drug|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
79279052|NCT03152877|Drug|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
79279053|NCT02295709|Procedure|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
79279054|NCT02295709|Procedure|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
79279055|NCT02295709|Drug|Dexamethasone|One of the most efficient steroids
79279056|NCT02295709|Device|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
79279057|NCT02295709|Radiation|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
79741346|NCT04166578|Diagnostic Test|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
79279058|NCT02228213|Biological|MIS416|Intravenous administration weekly for 52 weeks
79279059|NCT02228213|Drug|Saline|Intravenous administration weekly for 52 weeks
79279060|NCT02354937|Drug|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
79582443|NCT01254903|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
79582444|NCT01234025|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
79582445|NCT01234025|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
79582446|NCT01234025|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
79582447|NCT01234025|Drug|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
79582448|NCT01234025|Drug|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
79582449|NCT01187199|Drug|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
79582450|NCT01187199|Drug|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
79582451|NCT01187199|Drug|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
79582452|NCT01187199|Drug|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
79582453|NCT01187199|Drug|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
79279061|NCT02289001|Behavioral|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
79582454|NCT01177683|Drug|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
79876684|NCT00371865|Behavioral|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
79876685|NCT00371865|Behavioral|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
79279062|NCT03152331|Behavioral|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
79279063|NCT02295787|Drug|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
79279064|NCT02295787|Drug|Placebo|
79279065|NCT02228291|Dietary Supplement|Capsule containing citrus flavonoid|
79279066|NCT02228291|Dietary Supplement|Placebo|
79279067|NCT02292511|Behavioral|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
79279068|NCT03152487|Other|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
79279069|NCT03152487|Other|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
79279070|NCT04464967|Biological|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
79279071|NCT04464967|Drug|Trastuzumab|HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
79741347|NCT02647996|Procedure|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
79741348|NCT04166734|Drug|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
79876686|NCT05057585|Behavioral|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
80032163|NCT02061267|Dietary Supplement|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
79279072|NCT04464967|Drug|Cetuximab|EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
79279073|NCT02228369|Drug|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
79279074|NCT02228369|Drug|AZD9291|AZD9291 160mg once daily
79279075|NCT03146871|Drug|Azacitidine|Given IV or SC
79279076|NCT03146871|Drug|Decitabine|Given IV
79582455|NCT01177683|Drug|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
79405109|NCT03606876|Drug|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
79405110|NCT00759603|Drug|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
79279077|NCT03146871|Other|Laboratory Biomarker Analysis|Correlative studies
79405111|NCT00759603|Drug|Rituximab|Dose of 375 mg/m^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
79876687|NCT03935867|Behavioral|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
79876688|NCT01049841|Drug|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
79405112|NCT03599934|Other|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
79405113|NCT03599934|Other|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
79279078|NCT03146871|Other|Pharmacological Study|Correlative studies
79876689|NCT00978263|Drug|metformin-based Oral Antidiabetic Drugs|
79876690|NCT00978263|Drug|Glargine|
79876691|NCT00981851|Drug|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
79876692|NCT00981851|Drug|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
79876693|NCT00978575|Drug|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
79279079|NCT03146871|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
79876694|NCT00978575|Drug|Ferrosulfate|200mg daily for 12 weeks
79876695|NCT00978575|Drug|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
79279080|NCT02289235|Drug|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
79582456|NCT01177683|Drug|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
79582457|NCT01177683|Drug|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
79582458|NCT01177683|Drug|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000"
79876696|NCT04007315|Device|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
79876697|NCT04007315|Behavioral|Usual care|6-weeks of usual NHS care
79876698|NCT00981929|Drug|Tramadol|50 mg single oral dose
79279081|NCT02289235|Drug|Placebo|Placebo powder 2 capsules twice daily for 3 months
79279082|NCT03519841|Device|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
79279083|NCT02354625|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
79279084|NCT02228447|Behavioral|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
79279085|NCT03516565|Other|Saliva collection|
79279086|NCT03516565|Other|GCF collection|
79279087|NCT02351661|Other|There was no intervention|observational study, no intervention
79279088|NCT02258555|Drug|GS-9901|GS-9901 tablets administered orally
79279089|NCT02295943|Other|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
79582459|NCT01084252|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79582460|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
79582461|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
79741349|NCT04166734|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
79741350|NCT00653536|Device|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
79741351|NCT00651352|Drug|4 mg nicotine lozenge|marketed formulation
79741352|NCT00651352|Drug|2 mg nicotine lozenge|marketed formulation
79741353|NCT00651352|Drug|2 mg nicotine prototype|2 mg
79741354|NCT00651352|Drug|4 mg nicotine prototype|4 mg
79876699|NCT00981929|Drug|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
79876700|NCT00981929|Drug|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
80032164|NCT02060409|Genetic|spliceosome|spliceosome mutations
80032165|NCT01370655|Drug|MK-7145|
79741355|NCT02641678|Device|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
79582462|NCT00993044|Drug|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
79279090|NCT02354391|Drug|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
79741356|NCT02641444|Procedure|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
79582463|NCT00993044|Drug|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
79741357|NCT02641444|Procedure|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
79741358|NCT02641444|Procedure|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
79741359|NCT02644564|Other|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
79741360|NCT02648074|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
79741361|NCT02648074|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
79741362|NCT02641210|Procedure|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
79279091|NCT02354391|Drug|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
79405114|NCT03809325|Drug|Paliperidone Palmitate 3-Month Formulation (PP3M)|No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
79405115|NCT04759014|Other|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life
79405116|NCT03510390|Drug|Metformin|850 mg, oral, twice daily, 9-14 days
79741363|NCT02641210|Drug|Albendazole|All participants took Albendazole 400 mg before the intervention.
79741364|NCT02641366|Device|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
79741365|NCT02641366|Procedure|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
79741366|NCT02641366|Procedure|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
79279092|NCT02354391|Procedure|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
79741367|NCT02644330|Procedure|transthoracic device closure|minimally invasive transthoracic device closure
79741368|NCT02644330|Procedure|surgical repair|surgical repair with cardiopulmonary bypass
79741369|NCT02644408|Drug|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
79741370|NCT02644408|Radiation|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
79741371|NCT02644408|Other|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
79741372|NCT02644486|Drug|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
79741373|NCT02644486|Drug|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
79741374|NCT02644486|Drug|Irbesartan|Irbesartan 300mg/d
80032166|NCT01370655|Drug|Hydrochlorothiazide (HCTZ)|
79279093|NCT02231957|Other|educational text message reminders|
79279094|NCT02231957|Other|conventional text message reminders|
79279095|NCT03519763|Diagnostic Test|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
79279096|NCT04478253|Device|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
79279097|NCT02228603|Behavioral|high-intensity exercise training|
79279098|NCT02228603|Behavioral|web-based follow-up program|
79279099|NCT02228603|Behavioral|usual care|
79405117|NCT03505099|Biological|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
79741375|NCT00652756|Device|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
79279100|NCT02354547|Genetic|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
79876701|NCT00364845|Drug|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
79279101|NCT02354547|Drug|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
79279102|NCT02354547|Drug|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
79279103|NCT02232035|Drug|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
79279104|NCT02296021|Drug|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
79279105|NCT02296021|Drug|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
79279106|NCT02296021|Drug|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
79405118|NCT03806829|Other|Water|250 ml
79405119|NCT03806829|Other|Red Wine|250 ml
79405120|NCT03806829|Other|Green Tea|250 ml
79405121|NCT03806829|Other|Orange Juice|250 ml
79741376|NCT00652756|Other|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
79741377|NCT00827359|Drug|Everolimus|Tablet form taken orally once a day
79741378|NCT02641288|Drug|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
79876702|NCT00364845|Drug|Placebo|Prefilled syringe placebo, to match active arm
79876703|NCT00978653|Drug|allopurinol|150 mg once a day
79876704|NCT00982241|Dietary Supplement|water|drinking water / normal dietary fluids for oral intake
79876705|NCT00978809|Other|Epley maneuver|
79405122|NCT03806673|Drug|marcaine|epidural block
79405123|NCT04925778|Drug|monomethyl fumarate|Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,
79405124|NCT03807063|Biological|Rivogenlecleucel|Given IV
79405125|NCT03807063|Drug|Rimiducid|Given IV
79405126|NCT04553562|Device|Acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads by the needles (0.30mm in diameter, 40 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 25-30mm. Yintang (GV4) will be inserted through the pads by the needle (0.30mm in diameter, 25mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 10-15mm. The needles at all points will be lightly lifting, thrusting, and twirling every 10 minutes during each session with the sensation of sourness, achiness, heaviness and numbness (deqi). The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
79405127|NCT04553562|Device|Sham acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Needles (0.30 mm in diameter, 25 mm in length) with a blunt tip will be inserted at the Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) without penetrating the skin. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
79405128|NCT03809871|Biological|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
79405129|NCT03291990|Drug|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
79405130|NCT03806595|Drug|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
79876706|NCT00978809|Other|Semont maneuver|
79876707|NCT00978887|Other|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
80032167|NCT01370655|Drug|Placebo to MK-7145|
79876708|NCT00978887|Other|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
80032168|NCT01370655|Drug|Placebo to HCTZ|
79279107|NCT02296021|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
79279108|NCT02296021|Drug|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
79279109|NCT03516409|Dietary Supplement|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~DHA + EPA: >1mg per sachet~Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
79279110|NCT03516409|Dietary Supplement|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
79279111|NCT02232113|Drug|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
79279112|NCT02289391|Drug|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
79279113|NCT02289391|Drug|Anesthesia maintenance|"Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3~8mg/(kg•h).~Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30~40 mmHg and bispectral index (BIS) to 45~60."
79279114|NCT02289391|Drug|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
79279115|NCT02354313|Drug|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
79279116|NCT02224547|Radiation|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
79582464|NCT00993044|Drug|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
79741379|NCT02641288|Drug|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
79741380|NCT04165174|Drug|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
79405131|NCT03806595|Drug|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
79582465|NCT00993044|Drug|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
79582466|NCT00955045|Drug|istradefylline|
79582467|NCT00887302|Procedure|Gastric Band|Places a band over the upper portion of the stomach.
79582468|NCT00887302|Procedure|Gastric Sleeve|Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
79582469|NCT00887302|Procedure|Gastrostomy Tube|Tube is inserted into the stomach that delivers nutrition directly into the stomach.
79741381|NCT04165174|Radiation|SBRT|6-10Gy/F,5-8F
79741382|NCT02613247|Device|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
79741383|NCT02641132|Drug|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
79741384|NCT02641132|Procedure|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
80032169|NCT02059863|Behavioral|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
80032170|NCT02612194|Drug|Crizotinib|Crizotinib was administered orally at 250mg twice daily
79741385|NCT02647840|Behavioral|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
79279117|NCT02292667|Procedure|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
79279118|NCT02292667|Drug|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
79279119|NCT02292667|Drug|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
79582470|NCT00761618|Procedure|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
79876709|NCT04891445|Behavioral|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
79876710|NCT04891445|Behavioral|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
79876711|NCT04007237|Drug|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
79582471|NCT00761618|Procedure|IPC Placement|IPC placed in chest cavity to drain excess fluid
79582472|NCT00761618|Radiation|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
79741386|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
79741387|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
79741388|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
79741389|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
79741390|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
79741391|NCT00653614|Drug|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
79741392|NCT00653614|Drug|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
79741393|NCT00653614|Drug|Placebo|Placebo administration in each arm
79279120|NCT02228759|Procedure|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
79876712|NCT00293722|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
79902238|NCT02307058|Radiation|HEIGHT RT|The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
79902239|NCT02245048|Other|Carotid Intima-Media Thickness (CIMT)|
79279121|NCT02354157|Other|no intervention|no intervention
79279122|NCT02296177|Behavioral|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
79741394|NCT02647762|Drug|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
79741395|NCT02647762|Drug|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
79279123|NCT02232269|Other|Black Coffee|
79902240|NCT01981993|Biological|Urinary proteomic analysis|
79279124|NCT02232269|Other|Grapefruit Juice|
79279125|NCT02232269|Other|Water|
79279126|NCT02232269|Drug|Felodipine|
79279127|NCT04478331|Behavioral|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
79279128|NCT02292745|Radiation|stereotactic radiotherapy|
79279129|NCT02031575|Behavioral|Interactive Treatment|Mobile phone text messaging service about reproductive health
79741396|NCT02647762|Drug|Placebo|Placebo tablets, 1mg BID for 12 weeks
79279130|NCT02031575|Behavioral|Basic Treatment|Mobile phone text messaging service about reproductive health
80032171|NCT03044860|Procedure|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every ~30 cm of the small intestine and specific locations in the large intestine
80032172|NCT03044626|Drug|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
79279131|NCT02031575|Other|Control, comparator arm|
79279132|NCT04478565|Other|Indirect Calorimetry|"RMR was calculated by breath oxygen consumption (O2 in mL·min-1), minute by minute, using a portable device (Breezing®, Arizona, USA), and the Weir equation (1949), while participants remained in a sitting position for ≈15 to 20 minutes.~The anthropometric measurements were performed by certified level 3 anthropometrists following the guidelines of the International Society for the Advancement of Kinanthropometry, ISAK"
79582473|NCT00579644|Drug|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
79582474|NCT00579644|Drug|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
79741397|NCT02647762|Drug|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
79582475|NCT00116272|Drug|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
79582476|NCT00080886|Biological|rituximab|
79582477|NCT00080886|Drug|carmustine|
79582478|NCT00080886|Drug|cytarabine|
79582479|NCT00080886|Drug|etoposide|
79582480|NCT00080886|Drug|melphalan|
79582481|NCT00080886|Procedure|autologous bone marrow transplantation|
79582482|NCT00080886|Procedure|peripheral blood stem cell transplantation|
79582483|NCT01936571|Other|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
79582484|NCT01936584|Procedure|TAPP repair for inguinal hernias|
79582485|NCT01936584|Procedure|TEP repair for inguinal hernia|
79741398|NCT02644252|Drug|Day 1: Cisplatin 75 mg/m2|
79279133|NCT03516331|Drug|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
79279134|NCT04486313|Drug|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
79741399|NCT02644252|Drug|Day 1: Vinorelbine 25 mg/m2|
79741400|NCT02644252|Drug|Day 8: Capsule vinorelbine 50 mg/m2|
79741401|NCT02644252|Drug|Day 1: Carboplatin AUC=5|
79582486|NCT01936584|Other|EuraHS-QoL questionnaire|questionnaire administration
79582487|NCT01936584|Other|Carolina Comfort Scale|questionnaire administration
79741402|NCT02644252|Drug|Day 1: Vinorelbine 30 mg/m2|
79741403|NCT02644252|Drug|Day 8: Capsule vinorelbine 60 mg/m2|
79741404|NCT02644252|Dietary Supplement|Tocotrienol 300 mg x 3 daily until progression|
79741405|NCT02644252|Drug|Placebo 1 capsule x 3 daily until progression|
79582488|NCT01936597|Other|Therapeutic and preventive strategies|Single set (control Arm)
79582489|NCT01936597|Other|Therapeutic and preventive strategies|Controller
79582490|NCT01936597|Other|Therapeutic and preventive strategies|Audio
79741406|NCT00818389|Drug|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
79741407|NCT00818389|Drug|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
79902241|NCT01925131|Drug|cyclophosphamide|Given IV
79902242|NCT01925131|Drug|vincristine sulfate|Given IV
79902243|NCT01925131|Drug|prednisone|Given PO
79902244|NCT01925131|Biological|inotuzumab ozogamicin|Given IV
79902245|NCT01925131|Other|laboratory biomarker analysis|Correlative studies
79902246|NCT01767311|Drug|Lecanemab 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
79902247|NCT01767311|Drug|Lecanemab 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
80032173|NCT03044626|Drug|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
79902248|NCT01767311|Drug|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
79279135|NCT04486313|Drug|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
79279136|NCT04486313|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
79279137|NCT02354001|Drug|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
79582491|NCT01936610|Other|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
79582492|NCT01936610|Other|lecture|Describe advantages and disadvantages in one 90-min session
79582493|NCT01936636|Drug|Fentanyl|
79582494|NCT01936675|Other|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
79582495|NCT01936701|Procedure|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
79279138|NCT02354001|Drug|Placebo|1 capsule daily for 12 week trial - lactose
79279139|NCT03516253|Dietary Supplement|Fish oil + EPO|Supplementation with both fish oil and EPO
79279140|NCT02228837|Dietary Supplement|Pear|
79279141|NCT02228837|Dietary Supplement|Placebo|
79279142|NCT02347839|Procedure|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
79279143|NCT02289547|Drug|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
79279144|NCT02292823|Device|MGuard™ Prime Embolic Protection Stent System|
79279145|NCT02353923|Dietary Supplement|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
79279146|NCT03516175|Device|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
79279147|NCT03516175|Device|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
79279148|NCT04461275|Other|ERAS 2.0|ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
79582496|NCT01936714|Procedure|cataract surgery|
79582497|NCT01936727|Procedure|cataract surgery|
79582498|NCT01936740|Procedure|cataract surgery|
79582499|NCT01936753|Behavioral|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
79582500|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
79582501|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
79582502|NCT01936805|Drug|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
79279149|NCT02292901|Device|Macintosh laryngoscope|
79279150|NCT02292901|Device|McGrath Mac videolaryngoscope|
79279151|NCT02347449|Other|Questionnaires, Oncotype Dx Assay|"Physician pre-assay questionnaire~Patient pre-assay questionnaire~Oncotype DX® Assay~Physician post- assay questionnaire~Patient post-assay questionnaire"
79279152|NCT02289625|Other|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
79279153|NCT02351427|Drug|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
79279154|NCT02351427|Drug|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
79405132|NCT04539834|Other|electrolytes|measuring level of electrolytes
79582503|NCT01936922|Device|GaitAid®|Provides visual and auditory cues for walking.
79582504|NCT01936961|Drug|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
79582505|NCT01936961|Radiation|Hypofractionated Radiotherapy|
79582506|NCT01937013|Drug|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
79582507|NCT01937013|Drug|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
79582508|NCT01937065|Other|No treatment|
79609692|NCT05771194|Drug|Routine preoperative and postoperative anti-infection therapy|received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
79741408|NCT00818389|Drug|placebo|an inactive substance
79741409|NCT02640976|Drug|Human menopausal gonadotrophin (HMG)|[Merional® 75 IU ampoules, IBSA institut]
79741410|NCT02640976|Drug|GnRH antagonist Cetrorelix|[Cetrotide® 0.25 mg syringes, Merck Serono]
79741411|NCT02640976|Drug|Human chorionic gonadotrophin (hCG)|[Choriomon® 5000 IU ampoules, IBSA institut]
79741412|NCT04166344|Behavioral|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online & offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
79279155|NCT04437563|Behavioral|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
79279156|NCT02293057|Behavioral|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
79279157|NCT02293057|Behavioral|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
79279158|NCT03149835|Other|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
79279159|NCT02296255|Biological|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
79279160|NCT02229071|Drug|Donafenib(200mg)|Donafenib 200mg,bid,po
79279161|NCT02229071|Drug|Donafenib(300mg)|Donafenib 300mg,bid,po
79279162|NCT03150147|Other|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
79279163|NCT03150147|Other|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
79279164|NCT03516097|Behavioral|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
79582509|NCT01937078|Drug|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
79582510|NCT01937104|Drug|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60"
79582511|NCT01937104|Drug|Remifentanil|"Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%"
79609693|NCT05771194|Drug|artificial tear therapy|given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
79741413|NCT04116463|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
79279165|NCT03516097|Device|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
79279166|NCT03519607|Behavioral|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
79741414|NCT04116463|Behavioral|Financial Self-Management Program (FSMP)|
79741415|NCT02644018|Drug|Imidazolyl ethanamide pentandioic acid|
79741416|NCT02644018|Drug|placebo|
79279167|NCT02232971|Drug|Glucagon|Glucagon is given in three different doses according to three research days.
79279168|NCT02232971|Other|Isotonic saline solution|Placebo
79279169|NCT02347293|Other|High levels of indigestible carbohydrates|
79279170|NCT02347293|Other|Low levels of indigestible carbohydrates|
79741417|NCT02647684|Behavioral|Self-Directed Triple P|10 Week Triple P Self directed workbook
79741418|NCT00850135|Device|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
79741419|NCT02647918|Drug|Sotagliflozin|Single dose
79741420|NCT02647918|Drug|Sotagliflozin|2 single doses
79741421|NCT02644174|Procedure|Bariatric Surgery|
79741422|NCT02647450|Other|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
79279171|NCT03146637|Biological|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
79279172|NCT03146637|Biological|CIK|Traditional CIK were infused for 3 days
79279173|NCT02296333|Drug|ondansetron|8 mg intravenous in the skin closure
79279174|NCT02296333|Drug|isotonic|8 mg intravenous in the skin closure
79902249|NCT01767311|Drug|Lecanemab 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
79279175|NCT04409561|Device|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
79279176|NCT03149913|Device|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
79279177|NCT03149913|Device|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
79405133|NCT03808935|Drug|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
79279178|NCT02289703|Drug|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
79279179|NCT02232347|Drug|Ketamine|
79741423|NCT02640898|Radiation|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
79279180|NCT02232347|Drug|Sufentanil|
79876713|NCT01070056|Behavioral|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
79279181|NCT03521557|Behavioral|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
79279182|NCT03521557|Behavioral|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
79279183|NCT03545321|Behavioral|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
79279184|NCT03158961|Procedure|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
79279185|NCT03542669|Drug|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
79279186|NCT03542669|Drug|Doxorubicin|Subjects will be adminitered 4~6 cycles of chemotherapy (Doxorubicin, 30 mg/m^2 IV on Day 1 of every cycle)
79279187|NCT03146481|Drug|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
79279188|NCT03146481|Other|Placebo|Placebo tablet given one hour before starting the root canal treatment
79279189|NCT03521401|Behavioral|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
79279190|NCT02353767|Procedure|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
79279191|NCT03541655|Drug|Bupivacaine HCl|0.25% Bupivacaine HCl
79279192|NCT03541655|Drug|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
79279193|NCT02296411|Drug|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
79279194|NCT02296411|Drug|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
79279195|NCT02353689|Dietary Supplement|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
79279196|NCT02353689|Dietary Supplement|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
79279197|NCT02353689|Dietary Supplement|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
79279198|NCT02229305|Behavioral|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
79279199|NCT02229305|Behavioral|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita & Weisz, 2010).
79279200|NCT02347137|Other|step-reduction|reduce daily physical activity to less than 1500 steps per day
79279201|NCT02347137|Other|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
79279202|NCT03516019|Other|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
79279203|NCT03516019|Other|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
79279204|NCT03516019|Other|am notices|notifications sent at 7 am.
79279205|NCT03516019|Other|pm notices|notifications sent at 7 pm.
79279206|NCT03516019|Other|weekday notices|notifications sent on Wednesday
79582512|NCT01937104|Device|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
79279207|NCT03516019|Other|weekend notices|notifications sent on Saturday
79582513|NCT01937104|Procedure|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
79582514|NCT01937104|Procedure|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
79876714|NCT01070056|Behavioral|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
79876715|NCT03976414|Other|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
79876716|NCT00381303|Drug|darunavir|600mg bid for 48 wks
79876717|NCT00381303|Drug|ritonavir|100mg bid for 48 wks
79279208|NCT02293135|Device|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
79279209|NCT02293135|Device|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
79876718|NCT00448812|Device|Bronchial Thermoplasty with the Alair System|Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
79279210|NCT02293213|Behavioral|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
79279211|NCT02293213|Behavioral|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
79876719|NCT00364689|Drug|Rifaximin|
79876720|NCT00364689|Drug|Lactulose|
79876721|NCT00364689|Other|Placebo|
79876722|NCT00545129|Drug|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
79876723|NCT00545129|Drug|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
79876724|NCT05279339|Other|Exercise|Upper limb exercises using an elastic band.
79279212|NCT02293213|Behavioral|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
79876725|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
79279213|NCT02293213|Behavioral|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
79279214|NCT02293213|Behavioral|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
79279215|NCT02293213|Behavioral|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
79279216|NCT02229617|Drug|Subcutaneous testosterone|
79582515|NCT01937104|Procedure|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
79582516|NCT01937143|Behavioral|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
79582517|NCT01937143|Behavioral|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
79582518|NCT01937143|Behavioral|Control|General information about infant immunizations at birth of a newborn infant
79582519|NCT01937169|Behavioral|Motor Task|A motor task executed for 30 minutes after drug adminidtration
79582520|NCT01937169|Drug|Levodopa tablet|
79279217|NCT02347059|Drug|L-dopa|Antiparkinsonian medication
79279218|NCT02347059|Drug|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
79279219|NCT02296489|Device|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
79279220|NCT02353611|Other|6% hydrogen peroxide|
79279221|NCT02353611|Other|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
79582521|NCT01937169|Behavioral|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
79582522|NCT01937169|Drug|Placebo pill|
79279222|NCT02258867|Drug|Placebo|Solution for subcutaneous injection
79279223|NCT02258867|Drug|Gevokizumab|Solution for subcutaneous injection
79582523|NCT01937182|Drug|Citalopram|Citalopram 10-40 mg per day administered orally
79582524|NCT01937182|Drug|Placebo|1/2-2 tablets per day with no intrinsic drug activity
79582525|NCT01937208|Radiation|intensity modulated radiation therapy in both arms|
79279224|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
79279225|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
79582526|NCT01937208|Drug|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
79582527|NCT01937221|Other|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
79582528|NCT01937234|Drug|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
79582529|NCT01937234|Drug|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
79279226|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
79279227|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
79279228|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
79876726|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
79279229|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
79741424|NCT02640898|Radiation|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
79279230|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
79279231|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
79279232|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
79582530|NCT01937325|Drug|ivacaftor|active arm
79582531|NCT01937325|Drug|placebo|active arm
79582532|NCT01937338|Drug|AZD7624|nebuliser solution; 20 mg/mL for inhalation
79741425|NCT02647606|Procedure|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
79279233|NCT02296567|Other|Control Group|Control group Subjects will no previous anti-VEGF treatment
79279234|NCT02351193|Other|transvaginal Ultrasound|
79876727|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
79876728|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
79876729|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
79279235|NCT02353533|Device|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
79279236|NCT02353533|Device|EMR|Standard endoscopic mucosal resection using a resection snare
79279237|NCT02296723|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
79279238|NCT03158649|Other|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
79279239|NCT02289859|Procedure|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
79279240|NCT02289859|Procedure|Wound Closure without Undermining|One side of the wound will remain un-undermined.
79582533|NCT01937338|Drug|Placebo|nebuliser solution for inhalation
79582534|NCT01937416|Biological|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
79582535|NCT01937429|Device|Colonoscopy with blue Indigo Carmin®|
79741426|NCT02647606|Device|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
79279241|NCT03519139|Other|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
79582536|NCT01937429|Device|Standard colonoscopy with insufflation of air|
79582537|NCT01937442|Drug|Thalidomide Celgene™|200mg once daily and by mouth
79582538|NCT01937455|Biological|rAAV1-PG9DP|4x10^12 vg administered intramuscularly
79582539|NCT01937455|Biological|rAAV1-PG9DP|4x10^13 vg administered intramuscularly
79582540|NCT01937455|Biological|rAAV1-PG9DP|8x10^13 vg administered intramuscularly
79582541|NCT01937455|Biological|rAAV1-PG9DP|1.2x10^14 vg administered intramuscularly
79741427|NCT02647606|Device|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
79741428|NCT02647606|Device|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
79741429|NCT02535910|Dietary Supplement|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
79741430|NCT02535910|Dietary Supplement|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
79741431|NCT02535910|Dietary Supplement|Control|Subjects are asked to consume a breakfast without vitamin D
79279242|NCT02346981|Behavioral|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
79741432|NCT01154816|Drug|Alisertib|Given orally
79279243|NCT02289937|Drug|Ropivacaine|
80032174|NCT04875832|Behavioral|Eye Movement Desensitization and Reprocessing - EMDR|"EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences"
79279244|NCT02289937|Drug|Placebo|
79279245|NCT02289937|Device|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
79279246|NCT03146559|Device|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
79279247|NCT03146559|Device|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
79582542|NCT01937481|Behavioral|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
79582543|NCT01937494|Drug|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
79582544|NCT01937533|Procedure|Magnetic Resonance Imaging using an endovaginal receiver coil|
79741433|NCT01154816|Other|Laboratory Biomarker Analysis|Correlative studies
79741434|NCT01154816|Other|Pharmacological Study|Correlative studies
79279248|NCT03446807|Drug|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
79279249|NCT03446807|Drug|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
79279250|NCT03158181|Other|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
79279251|NCT03521323|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
79279252|NCT03521323|Drug|Placebos|Placebos: Saline，Sham operation
79279253|NCT03158259|Other|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
79582545|NCT01937546|Procedure|Primary delivery of anterior shoulder|
79582546|NCT01937546|Procedure|Primary delivery posterior shoulder|
79279254|NCT03519061|Drug|Budesonide|Nasal saline irrigations with budesonide
79279255|NCT02229773|Drug|BIBB 1464 MS low dose|
79279256|NCT02229773|Drug|Placebo|
79279257|NCT02229773|Drug|Pravastatin|
79279258|NCT02229773|Drug|BIBB 1464 MS medium dose|
79279259|NCT02229773|Drug|BIBB 1464 MS high dose|
79279260|NCT02296879|Genetic|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
79279261|NCT03515863|Genetic|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
79279262|NCT03515863|Device|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
79582547|NCT01937572|Other|Visionaire system (Knee MRI)|
79741435|NCT03057808|Behavioral|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
79876730|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
79876731|NCT00956111|Biological|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
79279263|NCT03515863|Other|Collection of life style data|Collection of life style data using quality of life questionnaire
79279264|NCT02346669|Procedure|gastroscopy|as detailed in arm description
79582548|NCT01937572|Other|No Knee MRI|
79876732|NCT00978965|Genetic|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
79876733|NCT00982475|Procedure|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
79279265|NCT02346669|Drug|Fecal Microbiota Transplantation|as detailed in arm description
79279266|NCT02346669|Other|high fat low fiber diet|as detailed in arm description
79279267|NCT02346669|Other|sham diet|as detailed in arm description
79876734|NCT00979355|Device|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
79876735|NCT00979433|Device|Bubble CPAP|Bubble CPAP will be delivered using Fischer & Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
79279268|NCT02346669|Other|low fat high fiber diet|as detailed in arm description
79405134|NCT03808935|Drug|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
79582549|NCT01937585|Behavioral|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
79582550|NCT01937585|Behavioral|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
79582551|NCT01937611|Drug|Dexmedetomidine|Dexmedetomidine
79582552|NCT01937611|Drug|Midazolam|Midazolam
79582553|NCT01937637|Behavioral|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
79279269|NCT03357029|Device|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
79279270|NCT03357029|Device|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
79279271|NCT02293291|Dietary Supplement|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
79582554|NCT01937650|Drug|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
79582555|NCT01937663|Drug|KWA-0711|
79279272|NCT03157557|Behavioral|Lifestyle treatment|Lifestyle treatment
79279273|NCT04305275|Drug|SAGE-324|SAGE-324 oral tablet
79279274|NCT04305275|Drug|SAGE-324 Placebo|SAGE-324 matched placebo oral tablet
79279275|NCT05231031|Behavioral|Aerobic exercise|continuous aerobic exercise on a treadmill
79876736|NCT00979433|Device|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
79902250|NCT01767311|Drug|Lecanemab 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
79902251|NCT01767311|Drug|Placebo|biweekly (once every 2 weeks) administered as i.v. infusion
79902252|NCT01767311|Drug|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
79279276|NCT05231031|Behavioral|breathing exercise|continuous aerobic exercise plus breathing exercise (Mindfulness)
79279277|NCT05231031|Behavioral|Relaxation training|continuous aerobic exercise plus relaxation training
79279278|NCT02347215|Other|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
79405135|NCT05170698|Procedure|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
79582556|NCT01937689|Drug|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
79582557|NCT01937702|Other|0.9% NaCl (sodium chloride)|
79582558|NCT01937728|Drug|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA < 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
79582559|NCT01937728|Drug|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
79582560|NCT01937728|Drug|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
79582561|NCT01937728|Drug|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
79279279|NCT02347215|Procedure|Stress imaging|Stress imaging
79279280|NCT03337451|Drug|OPN-305|Patients will receive study drug every 4 weeks
79279281|NCT03515707|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
79279282|NCT03515707|Drug|Busulfan|Given IV or oral
79279283|NCT03515707|Drug|Etoposide|Given IV
79582562|NCT01937728|Drug|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
79582563|NCT01937728|Drug|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
79582564|NCT01937754|Dietary Supplement|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
79582565|NCT01937754|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
79582566|NCT01937767|Drug|Remimazolam|
79741436|NCT03057808|Behavioral|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
79876737|NCT00982631|Drug|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
79582567|NCT01937767|Drug|Propofol|
79741437|NCT00849901|Drug|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
79279284|NCT03515707|Other|Laboratory Biomarker Analysis|Correlative studies
79279285|NCT02346513|Device|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
79279286|NCT02346513|Device|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
79279287|NCT02296957|Procedure|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
79279288|NCT02346591|Behavioral|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
79279289|NCT02346591|Behavioral|Online stress management information|Online educational information about stress management
79279290|NCT02298205|Other|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
79582568|NCT01937767|Drug|Sevoflurane|
79582569|NCT01937767|Drug|Remifentanil|
79582570|NCT01937767|Drug|Fentanyl|
79582571|NCT01937767|Drug|Rocuronium|
79582572|NCT01937793|Other|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
79582573|NCT01937793|Other|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
79582574|NCT01937806|Drug|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
79582575|NCT01937806|Drug|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
79582576|NCT01937819|Device|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
79582577|NCT01937832|Drug|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
79741438|NCT00849901|Drug|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
79741439|NCT00849901|Drug|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
79279291|NCT02298205|Other|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
79279292|NCT03307577|Drug|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
79279293|NCT03307577|Other|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
79279294|NCT03514771|Device|Fraxel DUAL 1550/1927|
79279295|NCT03514771|Drug|oral isotretinoin|oral isotretinoin
79279296|NCT03514771|Drug|oral valacyclovir|Oral valacyclovir
79279297|NCT02346279|Other|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
79279298|NCT02298283|Drug|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
79279299|NCT02298283|Drug|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
79279300|NCT02298283|Drug|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
79279301|NCT02298283|Drug|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
79279302|NCT02298283|Drug|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
79741440|NCT04313660|Drug|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
79279303|NCT02298283|Drug|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
79279304|NCT02298283|Drug|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
79279305|NCT02298283|Drug|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
79279306|NCT02298283|Drug|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
79279307|NCT02298283|Radiation|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
79876738|NCT00364611|Drug|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~On Day 1 of the 1st cycle over 120 minutes~On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
79279308|NCT02346357|Procedure|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% [local anesthetic]) 30 minutes prior to induction of anesthesia.
79279309|NCT02346357|Drug|Ropivacaine|
79279310|NCT02346357|Drug|Placebo Saline|
79279311|NCT03146247|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
79876739|NCT00364611|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
79279312|NCT03263273|Drug|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
79279313|NCT03263273|Drug|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
79876740|NCT00364611|Drug|Trastuzumab|"A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
79279314|NCT03263273|Other|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
79279315|NCT02293369|Procedure|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
79279316|NCT02293369|Procedure|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
79279317|NCT03146325|Drug|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
79279318|NCT03146325|Drug|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
79279319|NCT03518905|Device|Radiofrequency ablation|Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
79582578|NCT01937832|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
79582579|NCT01937897|Other|Bi-lateral massage|Unilateral massage on the left side of the body.
79279320|NCT03518905|Procedure|esophagoscopy|Patients receive an esophagoscopy without radiofrequency ablation under sedation
79279321|NCT03518749|Other|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
79279322|NCT03518749|Other|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
79279323|NCT03518749|Behavioral|Cognitive control training|cognitive control training with the PASAT
79279324|NCT02346123|Genetic|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
79279325|NCT03514693|Procedure|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
79582580|NCT01937910|Behavioral|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
79582581|NCT01937936|Behavioral|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
79741441|NCT02641054|Drug|CVXL-0107|
79741442|NCT02641054|Drug|Placebo|
79741443|NCT02641054|Drug|Levodopa|
79741444|NCT02643784|Drug|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
79741445|NCT02643784|Other|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
79279326|NCT03514693|Procedure|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
79279327|NCT02233049|Drug|Erlotinib|
79279328|NCT02233049|Drug|Everolimus|
80032175|NCT04865692|Other|BFRT|Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
79279329|NCT02233049|Drug|Dasatinib|
79279330|NCT02350725|Drug|Furosemide injection solution for subcutaneous administration (80 mg)|
79741446|NCT04166890|Drug|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
79741447|NCT02610907|Other|Buffer|The sleeve contains phosphate buffered saline buffer
80032176|NCT04865692|Other|Routine Physical Therapy|knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
79279331|NCT02350725|Drug|Oral Furosemide tablets (80 mg)|
79279332|NCT02297035|Behavioral|Behavioural testing|
79279333|NCT02297035|Other|Brain imaging|MRI, PET
79279334|NCT02297035|Genetic|Genetic screening|APOE, Progranulin
79279335|NCT02350959|Drug|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
79279336|NCT02350959|Drug|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
79279337|NCT04088357|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
80032177|NCT03045952|Procedure|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
79279338|NCT04088357|Drug|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
79279339|NCT02297113|Device|Macintosh blade|conventional endotracheal intubation
79279340|NCT02297113|Device|C-MAC videolaryngoscope|
79405136|NCT05170698|Procedure|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
80032178|NCT03045796|Device|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
79279341|NCT02350803|Device|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
79279342|NCT03202901|Dietary Supplement|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
79279343|NCT03202901|Dietary Supplement|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
79582582|NCT01937936|Behavioral|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
79582583|NCT01937988|Other|Doula Arm|
79582584|NCT01938027|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
79582585|NCT01938053|Other|Call when test results are ready|Patients are called when the test results are ready
79582586|NCT01938053|Other|Text message when test results are ready|Patients receive a text message when results are ready
79741448|NCT02610907|Other|Own output|The sleeve contains the subject own ileal effluent
79741449|NCT02610907|Other|simulated output|The sleeve contains simulated output
79741450|NCT02640820|Drug|Sensitizing DPCP Ointment|Sensitization
79741451|NCT02640820|Drug|Treatment DPCP Ointment|Treatment
79741452|NCT02610985|Device|3-D laparoscopy|3-D laparoscopy
79741453|NCT02610985|Device|2-D laparoscopy|2-D laparoscopy
79582587|NCT01938053|Other|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
79582588|NCT01938092|Drug|Diazepam|
79582589|NCT01938092|Drug|Placebo|
79741454|NCT00652912|Drug|Clonazepam|ODT, 1 mg
79279344|NCT03518593|Other|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
79279345|NCT02350335|Drug|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
79279346|NCT02297191|Procedure|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~Ultrasound images will be saved using the nomenclature TLIP Anatomy~Photos will only include surface anatomy of the low-to-mid back.~Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
79279347|NCT02297191|Drug|Ropivicaine|
79279348|NCT02350413|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
79279349|NCT03189173|Device|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
79582590|NCT01938105|Other|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~--------------------------------------------------------------------------------"
79582591|NCT01938118|Behavioral|Obesity Prevention Group|
79741455|NCT00652912|Drug|Klonopin Wafers|ODT, 1 mg
79741456|NCT01168232|Drug|Ixabepilone|Given IV
79279350|NCT03189173|Drug|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
79279351|NCT03189173|Other|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
79741457|NCT01168232|Other|Laboratory Biomarker Analysis|Correlative studies
79741458|NCT02647528|Device|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
79741459|NCT02647528|Device|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
79741460|NCT02640430|Device|standard treatment|20 minutes, twice a day for 10 sessions
79741461|NCT02640430|Device|Free Aspire|20 minutes, twice a day for 10 sessions
79741462|NCT00817531|Drug|Dasatinib|pill form, 100 mg daily
79741463|NCT00651586|Drug|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
79582592|NCT01938118|Behavioral|Injury Prevention Group|
79582593|NCT01938131|Device|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
79741464|NCT00651586|Drug|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
79741465|NCT02640508|Drug|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
79741466|NCT02640508|Drug|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
79741467|NCT05312606|Other|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
79741468|NCT05312606|Other|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
79741469|NCT02647372|Procedure|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
79741470|NCT02647372|Procedure|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
79741471|NCT02643550|Biological|Monalizumab|
79741472|NCT02643550|Biological|Cetuximab|
79279352|NCT03189173|Other|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
79279353|NCT03514615|Procedure|Incision|A skin incision will be made on the medial aspect of the upper arm.
79582594|NCT01938144|Drug|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
79582595|NCT01938144|Drug|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
79582596|NCT01938144|Drug|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
79741473|NCT02643550|Biological|Anti-PD(L)1|
79741474|NCT00817063|Drug|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
79741475|NCT00817063|Drug|Placebo|Patients receive matching placebo for up to 24 weeks
79279354|NCT03514615|Drug|Active gel|The incision site on one arm will be dosed with the active gel.
79279355|NCT03514615|Drug|Placebo gel|The incision site on the other arm will be dosed with placebo gel.
79279356|NCT02293447|Drug|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
80032179|NCT04876144|Device|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~CBT - vicious circle, progressive muscle relaxation, peer support content~Cognitive distortions, relaxation in imagination, peer support content~Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
79279357|NCT02293447|Drug|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
79279358|NCT02353455|Procedure|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
79279359|NCT02345967|Device|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
79279360|NCT04464811|Diagnostic Test|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
79405137|NCT03455959|Procedure|Bronchoscopy/BAL|Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
79582597|NCT01938157|Procedure|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
79582598|NCT01938183|Procedure|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
79582599|NCT01938183|Drug|Metronidazole tablet|750 mg metronidazole tablets
79582600|NCT01938183|Drug|placebo gel|semi-solid suspension containing carbopol
79582601|NCT01938183|Drug|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
79582602|NCT01938196|Drug|KWA-0711|
79582603|NCT01938196|Drug|Placebo|
79582604|NCT01938209|Other|seated thoracic manipulation|seated general thoracic spine manipulation
79582605|NCT01938209|Other|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
79741476|NCT02640352|Dietary Supplement|Probi Defendum|
79741477|NCT02640352|Dietary Supplement|Placebo|
79741478|NCT04166188|Procedure|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
79741479|NCT04165876|Device|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
79741480|NCT04165876|Device|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
79741481|NCT04165876|Device|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
79741482|NCT04165876|Device|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
80032180|NCT04875598|Procedure|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
79279361|NCT03155451|Diagnostic Test|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
79279362|NCT02293525|Device|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
79279363|NCT02293525|Drug|Ropivacaine|
79279364|NCT02293525|Drug|Saline|
79279365|NCT02293525|Drug|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
79279366|NCT02293525|Drug|Oxycodone|10mg every 4-6 hours
79279367|NCT02346045|Procedure|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~After femoral puncture guiding catheter is engaged in renal artery~Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
79279368|NCT02298517|Procedure|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
79279369|NCT02298517|Procedure|inspiratory load equipment|Threshold and Power breathe
79279370|NCT02293603|Biological|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
79279371|NCT02345499|Procedure|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
79279372|NCT02345499|Procedure|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
79279373|NCT03137381|Drug|CTP-543|Administered as tablets.
79279374|NCT03137381|Drug|CTP-543 matching placebo|Administered as tablets.
79279375|NCT02298595|Drug|cisplatin|75 mg/m2 IV day 1 of each cycle
79876741|NCT00979511|Other|milk and exercise|"milk fortified with 1000mg calcium or low-calcium milk~weight-bearing exercise or passive exercise"
79876742|NCT00956189|Drug|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
79876743|NCT00956189|Drug|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
79279376|NCT02298595|Drug|Cetuximab|XXXX day 1, 8, and 15 of each cycle
79279377|NCT02298595|Drug|BYL719|200, 250, 300, or 350 mg/day by mouth every day
79876744|NCT00984581|Drug|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
79876745|NCT00984581|Drug|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
79279378|NCT03155139|Diagnostic Test|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
79405138|NCT03455959|Procedure|Airway Brushing|After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
79405139|NCT03807999|Drug|Nab-paclitaxel|
79405140|NCT03807999|Drug|Gemcitabine|
79405141|NCT05403918|Other|conventional physiotherapy|Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.
79582606|NCT01938222|Procedure|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
79582607|NCT01938235|Drug|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
79582608|NCT01938235|Drug|Placebo|Intravenous bolus and 24-hour infusion of placebo
79582609|NCT01938274|Other|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
79582610|NCT01938287|Device|SENSIMED Triggerfish|
79741483|NCT01166750|Behavioral|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
79876746|NCT00984581|Drug|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
79876747|NCT00956267|Drug|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
79876748|NCT00956267|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
79876749|NCT04007003|Behavioral|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
79279379|NCT03155139|Diagnostic Test|Confirmatory tests|Captopril challenge test, Saline infusion test
79279380|NCT02297269|Device|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
79582611|NCT01938300|Drug|Magnesium Sulfate|
79876750|NCT00982709|Behavioral|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
79279381|NCT02297269|Device|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
79582612|NCT01938300|Drug|Normal saline|
79876751|NCT04007081|Procedure|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
79876752|NCT04007081|Diagnostic Test|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
79876753|NCT04007081|Other|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
79876754|NCT04007081|Other|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
79876755|NCT00364533|Drug|Tapentadol IR (CG5503)|Fixed Dose 50, 75, & 100 mg BID for 3 days
79876756|NCT00364533|Drug|Placebo|Fixed Dose Matching placebo for 3 days
79876757|NCT00364533|Drug|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
79876758|NCT00364533|Drug|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
79876759|NCT00982787|Drug|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
79279382|NCT02353143|Drug|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
79279383|NCT03518515|Other|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
79279384|NCT03518515|Other|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
79279385|NCT03518515|Other|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
79876760|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
79279386|NCT02345343|Drug|Apixaban|
79279387|NCT01541345|Device|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
79279388|NCT01541345|Drug|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
79279389|NCT01541345|Procedure|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
79279390|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
79279391|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
79279392|NCT02297425|Drug|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
79279393|NCT02345109|Device|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT."
79279394|NCT02345109|Device|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
79279395|NCT03146169|Behavioral|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
79279396|NCT03515473|Device|cochlear implant|cochlear implant surgery
79279397|NCT03122405|Device|RAM sensors|Noninvasive acoustic monitoring device
79582613|NCT01938313|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery~No Bowel preparation~Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Fluid restriction & Management by pulse contour analysis or transesophageal doppler~Early mobilization~Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~Epidural patient controlled analgesics (no opioids analgesics)~Postoperative Nausea Active Control~Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~Perioperative High content Oxygen therapy~No drain insertion~No Levin tube~Patients will be discharged at POD#4 if there's no problem."
79582614|NCT01938313|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery~Bowel preparation~No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~Conventional Mobilization~Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~IV PCA~Postoperative Nausea Control if needed~No Thromboembolism prophylaxis~No or Low Content Oxygen therapy~Routine drain insertion~Levin tube insertion if needed"
79741484|NCT01166750|Behavioral|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
79741485|NCT02640196|Device|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
79876761|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
79279398|NCT02350491|Other|Collection of biological samples|collection of biologic samples ( blood and urine) befor and after woman pregnacy
79279399|NCT02298751|Behavioral|Cue Exposure Treatment|
79279400|NCT02350257|Behavioral|Internet-based CBT|12 weeks of internet-based CBT
79279401|NCT05196295|Drug|Hydrogen|Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
79279402|NCT02353065|Procedure|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
79279403|NCT02353065|Radiation|Bedside x-ray|Portable x-ray of fracture post-reduction
79279404|NCT02298829|Drug|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
79876762|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
79876763|NCT01047423|Drug|Simvastatin|40mg encapsulated once daily for 12 weeks
79582615|NCT01938339|Device|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
79876764|NCT01047423|Drug|Placebo|Encapsulated oral once daily for 12 weeks
79876765|NCT00984737|Drug|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
79405142|NCT05403918|Other|scapular stabilization exercises along with conventional physiotherapy|Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
79405143|NCT03808857|Biological|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
79405144|NCT03558451|Other|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
79405145|NCT03558451|Other|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
79405146|NCT04427280|Diagnostic Test|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
79405147|NCT04427280|Diagnostic Test|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5mL) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
79405148|NCT04427280|Diagnostic Test|Blood collection|Approximately 30mL of blood will be taken at each study visit.
79405149|NCT03808701|Drug|SCT200|Recombinant Anti-EGFR Monoclonal Antibody
79741486|NCT02640196|Device|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
79876766|NCT01047579|Drug|Rivastigmine transdermal|
79876767|NCT04006847|Drug|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
79405150|NCT03499951|Behavioral|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
79405151|NCT03499951|Behavioral|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
79405152|NCT03498625|Diagnostic Test|Colonoscopy|Colonoscopy for CD patients in clinical remission
79405153|NCT04372056|Behavioral|Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic|Health care professionals
79405154|NCT04762147|Drug|paracetamol, the group P|The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
79582616|NCT01938352|Biological|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
79582617|NCT01938352|Biological|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
79582618|NCT01938404|Biological|Octaplas|Octoplas infusion solution for IV administration
79741487|NCT02640196|Device|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
79741488|NCT02640196|Device|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
79741489|NCT04311242|Other|Diet|Ketogenic diet
79876768|NCT04006847|Drug|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
79876769|NCT00984893|Drug|zoledronic acid|
79876770|NCT00984893|Drug|Any oral bisphosphonates marketed in Canada|
79582619|NCT01938404|Drug|Standard Plasma|Plasma given as replacement fluid
79582620|NCT01938417|Drug|tobramycin|
79582621|NCT01938443|Drug|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
79876771|NCT02502747|Drug|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
79876772|NCT02502747|Drug|optimal standard of care|Optimal standard of care
79876773|NCT02502747|Procedure|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
79876774|NCT00983021|Drug|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
79876775|NCT00983021|Drug|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
79876776|NCT00983021|Drug|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
79876777|NCT00983021|Drug|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
79876778|NCT00984971|Drug|Tenofovir|Topical gel applied rectally
79876779|NCT00984971|Drug|HEC Placebo|Placebo gel applied rectally
79876780|NCT00984971|Drug|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
79876781|NCT00544817|Radiation|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
79279405|NCT02350179|Drug|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
79582622|NCT01938443|Drug|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
79582623|NCT01938456|Drug|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
79582624|NCT01938456|Drug|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
79582625|NCT01938456|Drug|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter^2 or 75 mcg/body
79582626|NCT01938469|Other|Liquid Meal|
79582627|NCT01938469|Other|Solid Meal|
79876782|NCT00544817|Drug|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
79582628|NCT01938482|Drug|0.3% GSK1940029 gel|Will be supplied as gel for topical application
79741490|NCT02640274|Behavioral|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
79741491|NCT02640274|Other|Usual care|
79741492|NCT04313270|Drug|Evolocumab|12 weeks of treatment with Evolocumab
79876783|NCT00544817|Drug|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
79876784|NCT00983099|Drug|Neramexane|single and multiple dose, tablets, oral
79876785|NCT04661423|Other|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
79876786|NCT04812899|Behavioral|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
79876787|NCT04005833|Diagnostic Test|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
79279406|NCT02350179|Drug|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
79279407|NCT03515395|Behavioral|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
79279408|NCT03146013|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
79279409|NCT04464889|Drug|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
79876788|NCT00289978|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
79582629|NCT01938482|Drug|1% GSK1940029 gel|Will be supplied as gel for topical application
79582630|NCT01938482|Drug|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
79582631|NCT01938508|Drug|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
79582632|NCT01938521|Dietary Supplement|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
79582633|NCT01938521|Dietary Supplement|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
79582634|NCT01938534|Drug|Helicobacter pylori eradication|
79582635|NCT01938560|Other|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
79582636|NCT01938586|Other|Steri-Strip|
79582637|NCT01938586|Other|Superficial sutures|
79741493|NCT02640118|Drug|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
79876789|NCT00289978|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
79876790|NCT00289978|Drug|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
79876791|NCT00983177|Drug|Colchicine|0.5 mg twice daily for 4 months
79876792|NCT00983177|Drug|lactose|lactose capsules twice daily
79279410|NCT04464889|Drug|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
79582638|NCT01938612|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
79582639|NCT01938612|Drug|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
79582640|NCT01938638|Drug|BAY1143572|
79741494|NCT02640118|Drug|Lixisenatide-Placebo|
79279411|NCT04464889|Drug|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
79279412|NCT04464889|Drug|MDG1021 optimal dose|20 patients to receive the selected optimal dose
79279413|NCT02233205|Device|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
79279414|NCT02233205|Drug|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
79405155|NCT04762147|Drug|fentanyl, group-F administered as an active comparator|The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
79405156|NCT05005338|Drug|BIIB122 (DNL151)|Oral doses
79405157|NCT05005338|Drug|[14C] BIIB122 ([14C] DNL151)|Intravenous doses
79405158|NCT05403840|Procedure|Mitral valve surgery|Surgical mitral valve repair or replacement
79582641|NCT01938651|Procedure|high field strength magnetic resonance imaging|Undergo 7T MRI
79582642|NCT01938651|Procedure|magnetic resonance spectroscopic imaging|Undergo 31P MRS
79582643|NCT01938651|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
79582644|NCT01938651|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
79582645|NCT01938651|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
79741495|NCT02640118|Other|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
79741496|NCT02643316|Drug|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
79741497|NCT02643316|Drug|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
79741498|NCT02647138|Other|white noise|exposure to white noise
79741499|NCT02647216|Behavioral|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
79582646|NCT01938690|Device|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
79582647|NCT01938729|Procedure|Liver resection and placement of hepatic artery infusion pump|
79582648|NCT01938729|Drug|FLOXURIDINE|
79741500|NCT02647216|Behavioral|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
79741501|NCT00653770|Biological|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10^7 pfu)
79741502|NCT00653770|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10^7 pfu)
79741503|NCT00910936|Behavioral|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
79582649|NCT01938729|Drug|DEXAMETHASONE|
79582650|NCT01938729|Drug|GEMCITABINE|
79741504|NCT02640040|Device|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
79741505|NCT02640040|Device|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
79741506|NCT02640040|Procedure|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
79741507|NCT02643160|Other|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
79741508|NCT04165642|Other|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
79876793|NCT00985283|Behavioral|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
79279415|NCT03145311|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|
79279416|NCT02843633|Device|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
79279417|NCT02843633|Drug|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
79279418|NCT02293681|Drug|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
79279419|NCT02293681|Drug|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
79405159|NCT05403840|Procedure|Transcatheter mitral valve intervention|Transcatheter mitral valve repair or replacement
79405160|NCT04273737|Drug|Amantadine Hydrochloride|6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
79405161|NCT02963064|Biological|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
79582651|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 60 mg dextrose
79582652|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 80 mg dextrose
79582653|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 100 mg dextrose
79582654|NCT01938781|Drug|entecavir|antiviral therapy
79582655|NCT01938781|Drug|Peg-IFN|antiviral and antifibrosis therapy
79582656|NCT01938807|Behavioral|CareCoach mobile application to assist in diabetes management|
79279420|NCT02293681|Drug|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
79279421|NCT03145935|Diagnostic Test|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
79582657|NCT01938820|Drug|entecavir|anti-viral therapy
79582658|NCT01938820|Drug|Thymosin-α|antiviral and antifibrosis therapy
79582659|NCT01938859|Drug|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
79582660|NCT01938859|Drug|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
79582661|NCT01938859|Drug|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
79582662|NCT01938872|Procedure|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
79582663|NCT01938898|Other|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~Male & Study & Confidentiality~Male & Study~Male & Project & Confidentiality~Male & Project~Female & Project & Confidentiality~Female & Project~Female & Study & Confidentiality~Female & Study~Neutral & Study & Confidentiality~Neutral & Study~Neutral & Project & Confidentiality~Neutral & Project"
79582664|NCT01938911|Drug|Syntocinon-Spray|Intranasal oxytocin (24 IU)
79741509|NCT00826267|Drug|lapatinib|lapatinib tablets 1500 mg daily
79741510|NCT00826267|Drug|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
79741511|NCT00826267|Drug|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
79741512|NCT02639962|Radiation|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
79582665|NCT01938911|Drug|Placebo of syntocinon|Intranasal administration
79279422|NCT03145935|Diagnostic Test|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
79279423|NCT02297659|Procedure|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
79279424|NCT02297659|Device|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
79279425|NCT02259491|Other|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
79279426|NCT05255523|Drug|pyrotinib|After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
79279427|NCT02297737|Behavioral|Tai Chi|
79279428|NCT02297737|Other|Health Education|
79279429|NCT02259335|Device|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
79279430|NCT03149679|Drug|Cyclophosphamide|Chemotherapy
79279431|NCT02298985|Drug|Curcumin|3 g/day (3 capsules/day) for 6 months
79279432|NCT02298985|Drug|placebo|3 g/day (3 capsules/day) for 6 months
79279433|NCT03926117|Biological|Ziltivekimab|human IgG1k anti-human IL-6 monoclonal antibody
79876794|NCT00985283|Behavioral|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
79582666|NCT01938911|Behavioral|Social support|Social support from the best friend
79582667|NCT01938924|Device|GekoTM|electrical neuromuscular stimulation
79582668|NCT01938937|Device|Transcranial bright light device|
79582669|NCT01938937|Device|Transcranial sham device|
79582670|NCT01938950|Other|Aerobic Exercise|
79582671|NCT01938950|Other|Resistance Exercise|
79582672|NCT01938950|Other|Aerobic and Resistance Exercise|
79582673|NCT01938963|Behavioral|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
79582674|NCT01938976|Behavioral|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
79582675|NCT01939015|Device|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
79741513|NCT00653848|Drug|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
79741514|NCT00707551|Drug|Ketoconazole|Tablet, administered as repeated doses.
79741515|NCT00707551|Drug|Verapamil|Extended Release tablet, administered as repeated doses.
79741516|NCT00707551|Drug|AZD1305|Extended Release tablet, administered as a single dose.
79741517|NCT02535754|Behavioral|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
79405162|NCT03808779|Procedure|Radiofrequency Ablation|Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
79432955|NCT00608491|Device|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
79582676|NCT01939015|Device|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
79582677|NCT01939041|Device|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
79741518|NCT02535754|Behavioral|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
79741519|NCT02535754|Behavioral|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
79741520|NCT02642926|Procedure|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
79741521|NCT02642926|Procedure|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
79741522|NCT00986154|Drug|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
79741523|NCT00986154|Drug|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
79741524|NCT00986154|Drug|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
79741525|NCT02611375|Other|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
79741526|NCT02611375|Other|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
79741527|NCT02611375|Other|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
79876795|NCT03977428|Other|standard of care|No intervention, this a patient registry and is purely an observational study
79902253|NCT01698918|Drug|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
79279436|NCT03514537|Procedure|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
79279437|NCT03514537|Device|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
79279438|NCT03514537|Procedure|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
79279439|NCT03514537|Drug|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
79432956|NCT02985086|Drug|Cefoxitin|
79432957|NCT02985086|Drug|oxytocin/misoprostol|
79432958|NCT04143542|Procedure|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
79279440|NCT03514537|Drug|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
79279441|NCT02293759|Procedure|HoLEP|Holmium laser enucleation of the prsotate
79279442|NCT02293759|Procedure|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
79279443|NCT02345187|Dietary Supplement|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
79279444|NCT02345187|Dietary Supplement|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
79279445|NCT02299063|Drug|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
79876796|NCT00983255|Drug|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 & 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
79279446|NCT02299063|Drug|0.9% NaCl|
79279447|NCT03149289|Drug|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
79279448|NCT05624801|Drug|D3 VitaCaps®|Gelatine free soft capsules containing 24'000 IU cholecalciferol per capsule
79741528|NCT00653926|Drug|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
79741529|NCT00653926|Drug|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
79279449|NCT03515239|Procedure|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
79279450|NCT04478097|Drug|CKD-330 Tab. and D086 Tab.|1T
79279451|NCT04478097|Drug|CKD-333 Tab.|1T
79405163|NCT03808779|Procedure|Conventional Surgery|Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
79741530|NCT02613091|Drug|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
79741531|NCT00653146|Behavioral|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
79741532|NCT00653146|Behavioral|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
79741533|NCT02642848|Procedure|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
79741534|NCT02642848|Procedure|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
79741535|NCT02642848|Procedure|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
79876797|NCT00983255|Drug|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
79876798|NCT05279261|Procedure|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
79279452|NCT01161641|Drug|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
79279453|NCT01161641|Drug|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
79279454|NCT01161641|Drug|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
79279455|NCT03518281|Dietary Supplement|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing >50% Beta Glucan
79432959|NCT03586310|Device|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
79432960|NCT03586232|Dietary Supplement|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
79432961|NCT03586232|Dietary Supplement|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
79902254|NCT01698918|Drug|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
79279456|NCT03518281|Dietary Supplement|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
79279457|NCT03897257|Drug|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A [low dose]). Drug A is an antifungal agent.
79279458|NCT03897257|Drug|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A [low dose]). Drug A is an antifungal agent.
79279459|NCT03897257|Drug|UHE-103B cream|Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
79279460|NCT03897257|Drug|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A [low dose antifungal] + drug B [keratolytic]).
79582678|NCT01939041|Device|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
79582679|NCT01939041|Behavioral|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
79279461|NCT03897257|Drug|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A [high dose antifungal] + drug B [keratolytic]).
79279462|NCT05255211|Drug|Remimazolam tosilate|IV before procedure
79582680|NCT01939054|Drug|Nimotuzumab|
79582681|NCT01939054|Drug|docetaxel|
79582682|NCT01939054|Drug|capecitabine|
79741536|NCT02646904|Drug|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
79741537|NCT02646904|Drug|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
79741538|NCT00848965|Drug|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
79741539|NCT00848965|Drug|Placebo|Placebo comparator
79741540|NCT02642770|Device|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
79741541|NCT00654082|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
79741542|NCT00654082|Drug|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
79741543|NCT02639416|Dietary Supplement|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
79741544|NCT02639416|Dietary Supplement|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
79741545|NCT02639416|Other|Standard management|Standard management with F-100 and/or RUTF
79741546|NCT00654160|Drug|fluorouracil|
79741547|NCT00654160|Drug|irinotecan hydrochloride|
79876799|NCT00983333|Device|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
79279463|NCT05255211|Drug|Propofol|IV before procedure
79279464|NCT05255211|Other|saline solution|IV before procedure
79279465|NCT02297893|Behavioral|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
79279466|NCT02297893|Behavioral|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
79741548|NCT00654160|Drug|leucovorin calcium|
79279467|NCT03149367|Procedure|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
79741549|NCT00654160|Other|pharmacogenomic studies|
79741550|NCT00654160|Other|pharmacological study|
79761075|NCT04494958|Drug|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
79279468|NCT03149367|Procedure|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
79279469|NCT02233283|Other|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
79761076|NCT04492033|Drug|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
79279470|NCT02233283|Other|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
79279471|NCT02233283|Other|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
79279472|NCT02233283|Other|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
79279473|NCT02343471|Dietary Supplement|20 g whey protein|
79279474|NCT03514381|Drug|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~Cycle 1 (Day 1-Day 2-Day 3)~Cycle 2 (Day 1-Day 2-Day 3)"
79582683|NCT01939067|Device|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
79741551|NCT02639572|Biological|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
79279475|NCT02233361|Behavioral|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
79405164|NCT04183062|Drug|Chemotherapy (gemcitabine & docetaxel) plus BIO-11006|"BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8."
79405165|NCT04325880|Drug|Mirabegron 50 MG|Patients in this arm will receive Mirabegrone 50 MG once daily
79405166|NCT04325880|Drug|Tamsulosin|Patients in this arm will receive Tamsulosin o.4 MG once daily
79582684|NCT01939067|Device|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
79582685|NCT01939080|Procedure|Exercise training with supervised sessions|
79582686|NCT01939093|Drug|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
79279476|NCT02343393|Drug|Hydralazine|
79582687|NCT01939093|Dietary Supplement|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
79761077|NCT04492033|Drug|Paclitaxel|Paclitaxel will be administered weekly.
79279477|NCT02343393|Drug|Isosorbide Dinitrate|
79876800|NCT00983411|Other|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
79279478|NCT03514303|Diagnostic Test|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
79279479|NCT02344875|Drug|FYU-981, (Oral single dosing)|
79279480|NCT02293915|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
79761078|NCT04492033|Drug|Irinotecan|Irinotecan will be administered biweekly.
79761079|NCT04483505|Drug|Combination, Rogaratinib + palbociclib + fulvestrant|"Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression."
79876801|NCT00988403|Dietary Supplement|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
79279481|NCT02293915|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
79279482|NCT03145623|Drug|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
79279483|NCT02343315|Device|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~Equipment- TENS (CEFAR Basic TENS Machine)~Electrodes- Four channel electrode to cover the site of pain~Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~Frequency- 5 Hertz~Duration- 30 minutes"
79279484|NCT02343315|Other|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
80032181|NCT04865224|Diagnostic Test|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
80032182|NCT04865380|Drug|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
80032183|NCT04865068|Diagnostic Test|Echocardiography measures on SSA participants|"Upon SSA Subject is admitted to the hospital for an echocardiography,~Information about this study process,~Participants will receive an information note ;~Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~Performing and recording the echocardiographic examination according to routine protocol~delivery of the results according to the usual management;~deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards"
79582688|NCT01939093|Drug|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
79582689|NCT01939132|Drug|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
79582690|NCT01939171|Drug|Thymoglobulin|
79582691|NCT01939210|Other|Educational Intervention|Participate in breathing training sessions
79741552|NCT02639572|Biological|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
79741553|NCT02639104|Radiation|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
79876802|NCT00988403|Dietary Supplement|Fructan - 10|Subjects will consume 10 grams of fructan
79876803|NCT00988403|Dietary Supplement|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
79876804|NCT00988403|Dietary Supplement|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
79876805|NCT00988481|Drug|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
79876806|NCT03720821|Behavioral|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
79582692|NCT01939210|Other|Meditation Therapy|Participate in breathing training sessions
79582693|NCT01939210|Other|Questionnaire Administration|Ancillary studies
79582694|NCT01939236|Drug|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
79405167|NCT04325880|Drug|Solifenacin Succinate 10 MG|Patients in this arm will receive Solifenacin Succinate 10 MG once daily
79582695|NCT01939236|Drug|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
79582696|NCT01939106|Device|One Piece Drainable Pouch|
79405168|NCT04325880|Drug|Placebo oral tablet|Patients in this arm will receive placebo oral tablet once daily
79405169|NCT00780741|Procedure|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
79432962|NCT03586232|Other|Placebo|A pharmacologically inert preparation
79432963|NCT04186767|Dietary Supplement|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
79432964|NCT03586076|Biological|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
79582697|NCT01939249|Device|Abbott Laboratories Xience|
79582698|NCT01939249|Device|Biotronik Orsiro|
79405170|NCT00780741|Procedure|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
79405171|NCT02943954|Procedure|Angiography guided PCI|
79582699|NCT01939262|Other|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
79582700|NCT01939262|Other|Control|Participants assigned to the control group will be instructed to follow their usual diets.
79582701|NCT01939327|Drug|Lenalidomide/Rituximab|
79405172|NCT02943954|Device|Fractional Flow Reserve (FFR)|
79405173|NCT04385043|Other|plasma hyperimmune|patients will receive this as add on therapy
79582702|NCT01939379|Drug|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
79582703|NCT01939379|Drug|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
79582704|NCT01939392|Device|Renal Denervation (OneShot™ Renal Denervation System)|
79582705|NCT01939418|Drug|RAD001|Afinitor 5mg qd. po.
79582706|NCT01939418|Drug|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
79582707|NCT01939418|Drug|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
79582708|NCT01939444|Drug|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
79582709|NCT01939444|Drug|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
79582710|NCT01939457|Drug|Misoprostol|
79582711|NCT01939483|Drug|irinotecan hydrochloride|Given IV
79582712|NCT01939483|Other|laboratory biomarker analysis|Correlative studies
79582713|NCT01939509|Drug|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
79582714|NCT01939509|Drug|Bisoprolol|
79741554|NCT02639104|Other|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
79741555|NCT04274556|Other|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
79741556|NCT02642380|Drug|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
79741557|NCT02642380|Drug|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
79405174|NCT04385043|Drug|standard therapy|patients will receive only standard therapy for Covid-19 infection
79405175|NCT04862442|Other|Qigong exercises|Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves
79405176|NCT02758236|Other|No Intervention|No Intervention
79741558|NCT02642692|Procedure|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
79741559|NCT02642692|Procedure|Hamstring Graft|Acl reconstruction with hamstring graft
79405177|NCT03808623|Device|MAC with NOVOCART Basic|"NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.~NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue."
79405178|NCT04846608|Other|Observation|Observation
79876807|NCT00983567|Other|teen web|Min web
79876808|NCT00542321|Other|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
79876809|NCT00542321|Device|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
79876810|NCT00289900|Drug|MK-0524A|
79876811|NCT00289900|Drug|Atorvastatin|
79876812|NCT00289900|Drug|Simvastatin|
79876813|NCT01067014|Device|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
79876814|NCT00543725|Drug|TMC278|25 mg tablet once daily for 96 weeks
79876815|NCT00543725|Drug|efavirenz|600 mg tablet once daily for 96 weeks
79405179|NCT04846218|Drug|hCG|
79405180|NCT04846218|Drug|Progesterone|
79405181|NCT04846218|Drug|Triptorelin|
79405182|NCT03808233|Other|ACTIVE mini|the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
79432965|NCT03586076|Biological|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
79432966|NCT04167579|Device|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
79582715|NCT01939522|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|
79582716|NCT01939535|Other|No intervention|Evaluation of an imaging technique ic MRI
79582717|NCT01939561|Drug|Lamotrigine|
79582718|NCT01939561|Drug|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
79741560|NCT02642302|Behavioral|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
79876816|NCT00985361|Dietary Supplement|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
79876817|NCT00985361|Dietary Supplement|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
79876818|NCT00984035|Other|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
79741561|NCT02642302|Behavioral|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
79279485|NCT02343315|Other|UHEP|"All the participants will receive the following treatments:~Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
79279486|NCT02298049|Other|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
79279487|NCT02298049|Device|MRI|
79279488|NCT02343237|Procedure|Osteopathic treatment|osteopathic sessions of 20 minutes
79582719|NCT01939574|Other|Chemoradiation Therapy|"Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
79582720|NCT01939574|Other|Adjuvant Therapy|"Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
79582721|NCT01939587|Drug|PBF-680 5 mg|
79582722|NCT01939587|Drug|PBF-680 20 mg|
79582723|NCT01939587|Drug|Placebo|
79582724|NCT01939600|Other|Starch-free breakfast|Starch-free breakfast alone
79582725|NCT01939600|Other|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
79741562|NCT02642302|Behavioral|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
79279489|NCT02343237|Procedure|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
79582726|NCT01939600|Other|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
79582727|NCT01939600|Other|Amioca|Starch-free breakfast plus 56.4g amioca starch
79741563|NCT01154036|Drug|ezetimibe 10 mg|
79741564|NCT01154036|Drug|atorvastatin|
79279490|NCT03885011|Drug|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
79876819|NCT00984035|Other|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
79876820|NCT00984035|Other|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
79876821|NCT00269152|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 4 cycles
79279491|NCT03885011|Drug|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
79279492|NCT03885011|Drug|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
79279493|NCT02294071|Drug|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
79279494|NCT02294071|Drug|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
79279495|NCT03145389|Procedure|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
79279496|NCT03515161|Device|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
79582728|NCT01939613|Drug|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
79582729|NCT01939626|Device|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
79582730|NCT01939626|Device|Standard culture medium|This culture system needs media change on day 3 of culture.
79582731|NCT01939639|Drug|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
79741565|NCT01154036|Drug|Comparator: rosuvastatin|
79741566|NCT00816595|Biological|bevacizumab|Given IV
79741567|NCT00816595|Biological|pegfilgrastim|Given subcutaneously
79741568|NCT00816595|Biological|rituximab|Given IV
79741569|NCT00816595|Drug|cyclophosphamide|Given IV
79741570|NCT00816595|Drug|pentostatin|Given IV
79741571|NCT02886026|Device|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
79279497|NCT02344797|Procedure|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures >185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
79279498|NCT02233439|Dietary Supplement|Herbal galactagogue|
79582732|NCT01939639|Drug|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
79582733|NCT01939652|Procedure|Restrictive VS Standard Fluid Regime|
79582734|NCT01939652|Drug|Drag: Crystalloids and Colloids|
79582735|NCT01939691|Drug|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
79582736|NCT01939691|Drug|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
79279499|NCT02233439|Dietary Supplement|Placebo|
79582737|NCT01939691|Drug|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
79582738|NCT01939704|Other|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
79582739|NCT01939704|Other|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
79741572|NCT02886026|Device|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
79279500|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
79279501|NCT02350023|Drug|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
79279502|NCT02350023|Drug|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
79279503|NCT03514147|Other|Experimental|"Profile of participants: an anamnesis file was used to collect personal data;~To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
79279504|NCT03514147|Other|Control|"Profile of participants: an anamnesis file was used to collect personal data;~To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
79279505|NCT02342925|Other|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
79279506|NCT02342925|Drug|RG1662|Oral administration twice daily
79279507|NCT02342925|Drug|metformin|Single 850 mg dose of metformin
79876822|NCT00269152|Drug|cisplatin|75 mg/m^2, intravenous (IV), every 21 days x 4 cycles
79876823|NCT00269152|Drug|carboplatin|area under the curve (AUC) 5 milligrams per milliliter*minute (mg/ml*min), intravenous (IV), every 21 days x 4 cycles
79741573|NCT00922909|Behavioral|Simon task|Reaction time task
79741574|NCT01166438|Drug|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
79741575|NCT01166438|Drug|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
79279508|NCT03518047|Drug|risankizumab|rizankizumab subcutaneous (SC) infusion
79279509|NCT03518047|Drug|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
79279510|NCT03879863|Drug|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
79279511|NCT03879863|Drug|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
79279512|NCT03879863|Drug|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
79279513|NCT03879863|Drug|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
79582740|NCT01939717|Other|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
79582741|NCT01939730|Drug|Rituximab|375 mg/m^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
79582742|NCT01939730|Drug|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
79582743|NCT01939743|Drug|Diclofenac suppository plus lidocaine gel|
79582744|NCT01939743|Drug|Lidocaine gel only|
79741576|NCT01166438|Drug|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
79876824|NCT00988715|Biological|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
79279514|NCT02344641|Drug|Exenatide|
79876825|NCT00988715|Drug|Cyclosporine|Given IV
79279515|NCT03513991|Other|Infant formula|
79876826|NCT00988715|Drug|Mycophenolate Mofetil|Given PO
79876827|NCT00988715|Radiation|Total-Body Irradiation|Undergo total-body irradiation
79582745|NCT01939756|Device|Intravesical baobab oil|Intravesical baobab oil
79741577|NCT01166438|Drug|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
79741578|NCT00707707|Drug|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
79741579|NCT00707707|Drug|Paclitaxel|Intravenous infusion over 1 hour
79741580|NCT02611297|Procedure|Cryoprobe|
79741581|NCT01153958|Drug|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
79741582|NCT01153958|Drug|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
79741583|NCT00707785|Dietary Supplement|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
79741584|NCT00599638|Drug|pregabalin|75mg bid titrating to 150mg bid on day 4
79741585|NCT00599638|Drug|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
79876828|NCT00988715|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
79876829|NCT00988715|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
79279516|NCT03853343|Dietary Supplement|Seaweed extract|1 capsule 3 times per day
79279517|NCT03853343|Dietary Supplement|Placebo|1 capsule 3 times per day
79279518|NCT02344719|Drug|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
79279519|NCT02344719|Procedure|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
79279520|NCT02344719|Procedure|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
79582746|NCT01939769|Other|Exercise - Low-intensity exercise|
79741586|NCT00599638|Drug|Placebo|Placebo
79741587|NCT00654316|Biological|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
79741588|NCT04165252|Diagnostic Test|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
79876830|NCT00988715|Drug|Fludarabine Phosphate|Given IV
79876831|NCT00988715|Other|Pharmacological Study|Correlative studies
79876832|NCT00988715|Other|Laboratory Biomarker Analysis|Correlative studies
79582747|NCT01939769|Other|Exercise - High-intensity exercise|
79741589|NCT02642146|Drug|Calcium Channel Blockers|
79741590|NCT02642146|Drug|Phosphodiesterase Inhibitors|
79741591|NCT02642146|Drug|Endothelin receptor blocker|
79741592|NCT02642146|Drug|Prostanoids|
79741593|NCT02642146|Drug|Other vasodilator|
79741594|NCT02646514|Device|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
79876833|NCT01325740|Drug|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
79876834|NCT03975166|Drug|Test Product|2 inhalations in one study period
79876835|NCT03975166|Drug|Reference Product|2 inhalations in one study period
79876836|NCT01067092|Behavioral|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
79876837|NCT01067092|Behavioral|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
79876838|NCT03976024|Other|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
79582748|NCT01939782|Other|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
79741595|NCT02646514|Device|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
79741596|NCT00654394|Drug|Rosuvastatin|
79741597|NCT00911014|Other|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
79741598|NCT00653302|Drug|Lantus (insulin glargine) + Glucophage (Metformin)|
79876839|NCT03976024|Other|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
79279521|NCT02344719|Drug|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
79279522|NCT03515005|Behavioral|Lay Health Advisor|Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
79279523|NCT03798743|Drug|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
79279524|NCT02302417|Procedure|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
79279525|NCT02302417|Other|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
79876840|NCT01067170|Device|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
79279526|NCT03796637|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
79582749|NCT01939782|Other|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
79741599|NCT02638870|Drug|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
79741600|NCT02641990|Drug|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
79741601|NCT02641990|Drug|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
79876841|NCT01325818|Drug|pravastatin, rosuvastatin|"Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
79876842|NCT00379899|Drug|cinacalcet|Low dose vitamin D with cinacalcet
79876843|NCT02535039|Drug|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg * d for application to the third day after surgery
79279527|NCT02342769|Drug|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
79279528|NCT03514927|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
79876844|NCT02535039|Other|Physiological saline|The same volume of physiological saline will be given in Placebo group
79876845|NCT02535117|Procedure|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
79279529|NCT03514927|Device|High-Intensity Focused Ultrasound|Under go HIFU
79279530|NCT03514927|Other|Laboratory Biomarker Analysis|Correlative studies
79876846|NCT02535117|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
79876847|NCT00371787|Device|Soft contact lens|Soft contact lens
79876848|NCT00363129|Dietary Supplement|vitamin E|Given orally
79279531|NCT03514927|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
79279532|NCT03514927|Procedure|Radical Prostatectomy|Undergo prostatectomy
79279533|NCT02298127|Other|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
79279534|NCT02342847|Other|N/A (non-interventional study)|
79279535|NCT03514849|Procedure|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
79279536|NCT03514849|Procedure|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
79741602|NCT00653380|Drug|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
79876849|NCT00363129|Other|placebo|Given orally
79876850|NCT00268996|Drug|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
79582750|NCT01939795|Other|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
79582751|NCT01939808|Other|Splint Neutral|
79582752|NCT01939808|Other|Splint Extended|
79741603|NCT00653380|Drug|Monodox|Capsules, 100 mg, single-dose
79741604|NCT02646592|Drug|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
79876851|NCT00268996|Drug|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
79876852|NCT00371397|Behavioral|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
79876853|NCT00371397|Behavioral|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
79876854|NCT00379587|Drug|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
79876855|NCT00379587|Drug|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
79279537|NCT03514849|Drug|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
79876856|NCT00289276|Device|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
79876857|NCT03975244|Behavioral|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
79876858|NCT03977506|Diagnostic Test|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
79876859|NCT00289198|Drug|FF|fluticasone furoate 110 μg nasal spray
79876860|NCT00289198|Drug|Placebo|placebo nasal spray
79279538|NCT03766295|Drug|Masitinib|
79279539|NCT03766295|Drug|Gemcitabine|
79279540|NCT03766295|Drug|Placebo|
79279541|NCT02344563|Drug|Meropem|
79279542|NCT02344563|Drug|Mepem|
79279543|NCT03513913|Procedure|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
79279544|NCT02349945|Drug|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage > 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
79279545|NCT03513835|Diagnostic Test|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
79279546|NCT02350101|Device|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
79279547|NCT02299219|Behavioral|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
79279548|NCT02299219|Behavioral|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
79279549|NCT03759197|Drug|188-0551 Spray|Topical Spray containing active drug
79279550|NCT03759197|Drug|Vehicle Spray|Topical Spray containing no active drug
79741605|NCT02646592|Drug|sevoflurane or propofol|
79876861|NCT01067404|Biological|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
79741606|NCT02646670|Drug|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
79741607|NCT02646670|Drug|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
79741608|NCT02646670|Drug|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
79741609|NCT02646670|Drug|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
79741610|NCT00651976|Drug|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
79741611|NCT00651976|Other|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
79741612|NCT00651976|Procedure|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
79741613|NCT02638792|Behavioral|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
79876862|NCT03741712|Drug|SHR3680|Tablet. Specifications of 80mg
79279551|NCT02302495|Drug|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
79279552|NCT02342457|Device|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
79279553|NCT02342301|Behavioral|Standing Desk|Participants will be provided with a standing desk for 3 months
79876863|NCT03741712|Drug|SHR2554|Tablet. Specifications of 50mg and 200mg
79876864|NCT00363051|Drug|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
79279554|NCT02342301|Behavioral|Traditional Desk|Participants will use a traditional seated desk for 3 months
79876865|NCT00363051|Drug|Octreotide Depot|
79279555|NCT02306395|Procedure|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
79279556|NCT02813447|Drug|Sertraline|
79876866|NCT00379353|Drug|Thalidomide|100 mg capsules orally, once a day for 14 days.
79279557|NCT02813447|Drug|Placebo|
79279558|NCT02342145|Drug|Basiliximab,|Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
79876867|NCT00379353|Drug|Placebo|Two placebo capsules orally, once a day for 14 days.
79279559|NCT02342145|Drug|cyclosporine A|Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
79279560|NCT02342145|Drug|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
79279561|NCT02342145|Drug|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
79876868|NCT03992391|Behavioral|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
79876869|NCT01047657|Behavioral|Low caloric diet plus orlistat and sibutramine|All subjetcs
79876870|NCT00378573|Drug|docetaxel|
79876871|NCT00378573|Drug|gemcitabine|
79876872|NCT00378573|Drug|bevacizumab|
79876873|NCT01581099|Procedure|Digestive Adaptations III surgery|
79876874|NCT01047891|Drug|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
79876875|NCT02534571|Device|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 <=150g once
79876876|NCT02534571|Device|Hemo-clipping|Hemo-clipping <=20 clips
79876877|NCT02534571|Drug|Epinephrine|epinephrine injection endoscopically <20 mls
79876878|NCT02534571|Device|thermo-coagulation|contact thermo-coagulation < = 4 pulses
79876879|NCT03831945|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
79279562|NCT02302573|Drug|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
79279563|NCT03746015|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Tetravalent Dengue Vaccine (TDV) subcutaneous injection
79279564|NCT02349321|Behavioral|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
79279565|NCT02349321|Behavioral|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
79279566|NCT03507985|Other|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
79876880|NCT03831945|Biological|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
79876881|NCT03831945|Biological|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
79876882|NCT00457002|Drug|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
79876883|NCT00457002|Drug|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
79279567|NCT02349399|Drug|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
79279568|NCT02306473|Drug|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
79279569|NCT02232503|Genetic|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
79876884|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
79279570|NCT02349555|Dietary Supplement|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
79279571|NCT03507907|Other|Mulligan Mobilization for Study Group|Mulligan Mobilization techniques were applied to the older adults who included in study group.
79279572|NCT03507907|Other|Conventional therapy for Control Group|Conventional therapy was applied to the older adults who included in control group.
79279573|NCT02344329|Device|Topical wound dressing|Topical Wound Dressing
79582753|NCT01939821|Behavioral|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
79741614|NCT02638792|Behavioral|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
79741615|NCT02638636|Behavioral|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
79279574|NCT02344329|Biological|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
79279575|NCT02344329|Other|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
79279576|NCT03513679|Procedure|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
79279577|NCT03709121|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
79279578|NCT03709121|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
79279579|NCT03709121|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
79279580|NCT02344095|Drug|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
79279581|NCT02344095|Drug|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
79279582|NCT02344095|Device|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
79279583|NCT00157339|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
79279584|NCT00157339|Drug|injected insulin|patient specific dose, injected, before meals, 12 months.
79741616|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
79741617|NCT02646436|Other|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
79741618|NCT02638714|Biological|Stem Cells|Intervention: Transplantation of autologous purified stem cells
79741619|NCT00654550|Drug|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
79741620|NCT00652054|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
79741621|NCT04164862|Device|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
79741622|NCT02646358|Drug|Vepoloxamer|
79876885|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
79876886|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
79876887|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
79876888|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
79876889|NCT00362115|Drug|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
79876890|NCT00362115|Drug|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
79876891|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
79279585|NCT02342067|Drug|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
79582754|NCT01939821|Behavioral|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
79741623|NCT02642224|Behavioral|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
79741624|NCT01166282|Biological|adalimumab|Adalimumab solution for subcutaneous injection.
79741625|NCT01166282|Biological|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
79741626|NCT02884700|Biological|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
79405183|NCT04152486|Biological|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
79405184|NCT02512692|Device|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
79741627|NCT01153724|Drug|BI 1744|10 mcg solution for oral inhalation
79741628|NCT01153724|Drug|Fluconazole|400 mg capsule
80032184|NCT04869046|Drug|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
80032185|NCT04430530|Biological|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
80032186|NCT04875910|Other|Home-based exercise program|"The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week."
80032187|NCT04385680|Drug|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
80032188|NCT04864756|Other|Simulation based learning|Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
80032189|NCT04868422|Device|Telemonitoring via wireless internet-based system|
80032190|NCT02798211|Drug|Secukinumab 300 mg|150 mg x 2 s.c. injection
80032191|NCT02798211|Drug|Secukinumab 150 mg|150 mg s.c. injection
79279586|NCT02342067|Drug|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
79279587|NCT02750501|Device|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
79876892|NCT00485264|Drug|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
79876893|NCT00485264|Drug|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
79876894|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet.
79876895|NCT00293254|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
79876896|NCT00293254|Drug|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
79876897|NCT01018784|Drug|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
80032192|NCT02798211|Other|Placebo|Placebo
79279588|NCT02750501|Other|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
79279589|NCT02344017|Drug|ODM-204|co-administered with prednisone, orally daily
79279590|NCT02344017|Drug|Prednisone|ODM-204 is co-administered with oral prednisone
79279591|NCT02343861|Behavioral|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
79279592|NCT02343861|Behavioral|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
79279593|NCT03676751|Drug|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
79279594|NCT03676751|Drug|Placebo|Oral suspension of placebo for azithromycin
79279595|NCT02302651|Device|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
79582755|NCT01939834|Device|AAA control|"AAA control is a method to determine insulin dosing to keep glucose in range. AAA control is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the AAA control and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.~AAA control will be tested in 40 hours sessions and 5 consecutive overnight sessions."
79741629|NCT02884388|Procedure|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
79741630|NCT02884388|Procedure|general anesthesia|Patients in this group were assigned to receive general anesthesia.
79741631|NCT02885870|Procedure|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
79741632|NCT04314596|Other|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
79741633|NCT04314596|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
79741634|NCT02885948|Drug|Naloxone|used to block the effects of opioids, especially in overdose
79279596|NCT02343783|Other|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
79279597|NCT02302729|Dietary Supplement|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
79279598|NCT02302729|Behavioral|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
79279599|NCT02302729|Dietary Supplement|Placebo|Riboflavin Vitamin B2
79279600|NCT02343705|Device|Latella Knee Implant System|
79279601|NCT03513601|Drug|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
79405185|NCT02512692|Drug|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
79279602|NCT03513601|Drug|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
79279603|NCT03648827|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
79279604|NCT03149133|Other|Heavy hypertrophy training|Training with 75-80 % of 1-RM
79405186|NCT02512692|Drug|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
79405187|NCT03933072|Procedure|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
79582756|NCT01939834|Other|CGM + insulin pump at home|The subject will be on their home insulin pump and using a CGM per their usual care.
79741635|NCT02885948|Drug|Placebo|Placebo, ineffective control arm
79741636|NCT01152788|Drug|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
79741637|NCT01152788|Drug|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
79741638|NCT01165424|Drug|mometasone furoate|"MFNS 50 μg spray device~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
79741639|NCT01152554|Drug|TC-5214|Tablet, oral, twice daily for 52 weeks
79741640|NCT01152554|Drug|Placebo|Tablet, oral, twice daily for 52 weeks
79405188|NCT03933072|Biological|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
79405189|NCT03933072|Procedure|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
79279605|NCT03149133|Other|Light hypertrophy training|Training with 35-50 % of 1-RM
79279606|NCT03513523|Dietary Supplement|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
79279607|NCT03513523|Dietary Supplement|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
79279608|NCT03513523|Other|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
79876898|NCT01047969|Drug|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
79279609|NCT03148977|Procedure|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
79279610|NCT03507829|Drug|Human insulin isophane, Humulin N (Eli Lilly)|Human insulin isophane, Humulin N (Eli Lilly)
79279611|NCT03507829|Drug|Standard of care|Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
79582757|NCT01939847|Other|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
79582758|NCT01939860|Other|Written and verbal patient education on hypertension and its treatment|
79582759|NCT01939873|Behavioral|KRISTELLER|
79876899|NCT01047969|Procedure|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
79876900|NCT01019018|Device|subtenon block|subtenon block with stevens cannula
79876901|NCT01019018|Device|subtenon block|subtenon block with Olive tip cannula cannula
79876902|NCT03977350|Device|EEG monitoring|EEG monitoring under general anesthesia
79279612|NCT03507829|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|Insulin lispro, Humalog (Eli Lilly) in insulin pump
79876903|NCT04498611|Diagnostic Test|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
79279613|NCT02232581|Drug|Alovudine - low|
79279614|NCT02232581|Drug|Alovudine - medium|
79279615|NCT02232581|Drug|Alovudine - high|
79279616|NCT02232581|Drug|Placebo|
79279617|NCT02341833|Drug|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
79279618|NCT04464499|Diagnostic Test|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
79279619|NCT02232659|Device|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
79876904|NCT03975010|Drug|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
79876905|NCT01050075|Other|acupuncture therapy|acupuncture therapy
79279620|NCT02337231|Dietary Supplement|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
80032193|NCT04874896|Dietary Supplement|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
80032194|NCT04874896|Dietary Supplement|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
79279621|NCT02341677|Procedure|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
79279622|NCT02306629|Biological|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
79279623|NCT02306629|Biological|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
79405190|NCT04499664|Device|Monitoring of the autonomic nervous system|Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
79582760|NCT01939886|Drug|Mefloquine - Artesunate|
79582761|NCT01939886|Drug|Artemether-lumefantrine combination|
79582762|NCT01939912|Drug|Adenosine|Antiarrhythmic agent.
79582763|NCT01939925|Other|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
79876906|NCT01050075|Other|questionnaire administration|Ancillary study
79279624|NCT03513367|Other|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
79279625|NCT03513367|Other|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
79876907|NCT01050075|Other|management of therapy complications|To be determined by the treating physician
79876908|NCT04534010|Device|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
79876909|NCT01070134|Behavioral|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
79876910|NCT01070134|Behavioral|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
79279626|NCT01337297|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
79405191|NCT03458988|Device|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
79405192|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
79582764|NCT01939925|Other|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
79582765|NCT01939951|Dietary Supplement|Activation Energy Serum|7 drops or 21 drops twice daily
79582766|NCT01939964|Other|Activation Mist|Activation Mist topical spray
79582767|NCT01939990|Drug|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
79741641|NCT00598702|Drug|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
80032195|NCT04868344|Drug|MRG003|Administered intravenously
79405193|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
79405194|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
79405195|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
79405196|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
79582768|NCT01939990|Drug|Nebivolol|5 to 10mg per day
79741642|NCT01148810|Drug|BAF312|
79741643|NCT01148810|Drug|Placebo|
79741644|NCT00624962|Dietary Supplement|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
79741645|NCT00624962|Dietary Supplement|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
79741646|NCT04313426|Other|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
79741647|NCT02884310|Drug|Remifentanil adapted to SPI|
79741648|NCT02884310|Drug|Remifentanil fixed|
79876911|NCT01016990|Drug|valproic acid|
79876912|NCT01016990|Genetic|western blotting|
79876913|NCT01016990|Other|laboratory biomarker analysis|
79876914|NCT01016990|Other|pharmacological study|
79876915|NCT01048047|Drug|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
79876916|NCT01011686|Biological|ANT-SM|autologous adipose-derived stem cell
79876917|NCT01324635|Drug|Panobinostat|Given PO
79876918|NCT01324635|Radiation|Stereotactic body radiation therapy|Undergo SBRT
79876919|NCT01324635|Procedure|Quality-of-life assessment|Ancillary studies
79876920|NCT01324635|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
79876921|NCT01017068|Drug|OME|4g/100ml) dose: п gutt tid x 1/52
79876922|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
79876923|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
79876924|NCT01017068|Drug|OME|(4g/100ml) dose: п gutt tid x 1/52
79876925|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
79876926|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
79279627|NCT03510793|Drug|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
79279628|NCT03510793|Drug|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
79876927|NCT04178564|Behavioral|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
79876928|NCT04170608|Device|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
79405197|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
79582769|NCT01940003|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
79582770|NCT01940016|Behavioral|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
80032196|NCT03045640|Other|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
79279629|NCT02336997|Procedure|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
79582771|NCT01940016|Behavioral|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
79582772|NCT01940042|Behavioral|CO2 was removed by means of trandelenburg positions|
79582773|NCT01940055|Behavioral|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
79582774|NCT01940055|Behavioral|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
79582775|NCT01940068|Dietary Supplement|Amino acid based formula|
79279630|NCT02336997|Procedure|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
79279631|NCT02336997|Procedure|PLACEBO|Saline will be injected into expanded skin.
80032197|NCT04868266|Other|end tidal carbon dioxide monitoring|We will monitor end tidal carbon dioxide with capnography during minimal sedation
79279632|NCT02299453|Behavioral|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
79405198|NCT04682106|Drug|LY3493269|Administered orally.
79405199|NCT04682106|Drug|Placebo|Administered orally.
79405200|NCT05403606|Device|GASPARD®|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
79405201|NCT00782379|Drug|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
79405202|NCT00782379|Drug|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
79582776|NCT01940081|Other|Transthoracic echocardiography|
79582777|NCT01940081|Other|Exercise test|
79582778|NCT01940081|Other|24-hour Holter electrocardiogram|
79582779|NCT01940081|Other|Contrast-enhanced magnetic resonance imaging|
79582780|NCT01940081|Other|123-iodine metaiodobenzylguanidine imaging|
79582781|NCT01940081|Other|Blood samples|
79582782|NCT01940081|Genetic|Genetic analysis|
79582783|NCT01940081|Procedure|Invasive electrophysiological study|
79582784|NCT01940081|Procedure|Endomyocardial biopsy|
79582785|NCT01940081|Procedure|Intraoperative biopsy|
79582786|NCT01940081|Procedure|Intraoperative mapping and/or ablation|
79582787|NCT01940107|Other|evaluations|Only evaluations
79582788|NCT01940107|Procedure|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
79876929|NCT00456846|Drug|ABI-007|100 mg/m^2 ABI-007 weekly for 3 weeks followed by 1 week rest
79279633|NCT02341443|Procedure|Implants|"Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
79582789|NCT01940133|Drug|PQR309|Dosing will be orally, once a day for the duration of the trial.
79582790|NCT01940159|Drug|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
79582791|NCT01940159|Drug|Placebo|single oral dose placebo
79582792|NCT01940172|Drug|Birinapant|"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
79876930|NCT01011764|Behavioral|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
79876931|NCT03324282|Drug|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
80032198|NCT03045718|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
79582793|NCT01940172|Drug|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
79741649|NCT01151618|Device|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
79582794|NCT01940224|Drug|Pregabalin|Preoperative administration of pregabalin 300mg
80032199|NCT02060019|Drug|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
80032200|NCT04864600|Other|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
79582795|NCT01940224|Drug|Placebo|Preoperative administration of placebo
79876932|NCT03324282|Drug|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
79876933|NCT00448344|Behavioral|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
79876934|NCT00448344|Behavioral|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
79876935|NCT00484094|Drug|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
80032201|NCT04864600|Other|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
80032202|NCT02061501|Other|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
79279634|NCT02299531|Other|Varying meal energy density and portion size|
79279635|NCT02234375|Drug|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
79582796|NCT01940224|Drug|Morphine|Postoperative administration of morphine via PCA pump for 48h
79582797|NCT01940237|Behavioral|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
79582798|NCT01940250|Drug|Magnesium Sulphate|MgSO4 IV infusion
79582799|NCT01940250|Drug|Sterile water|H2O IV infusion
79582800|NCT01940263|Dietary Supplement|Anthocyanin|
79582801|NCT01940263|Dietary Supplement|Placebo|
79582802|NCT01940289|Device|Algometric meter readings for perception of pain|
79582803|NCT01940302|Dietary Supplement|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
79582804|NCT01940315|Biological|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
79741650|NCT01164956|Drug|methylphenidate|
79741651|NCT01164956|Other|Placebo|
79741652|NCT02884232|Procedure|Nasofibroscopy|
79741653|NCT01164722|Other|clinical observation|Patients undergo observation
79741654|NCT01164722|Device|infrared photocoagulation therapy|Anal infrared coagulator ablation
79741655|NCT04314830|Device|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
79876936|NCT01029288|Other|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
79876937|NCT01029288|Other|Statin Choice Decision Aid|Statin Choice Cards
79876938|NCT01029288|Other|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
79876939|NCT01029288|Other|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
80032203|NCT02061501|Other|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
80032204|NCT05654415|Other|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
80032205|NCT05654415|Other|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
79279636|NCT02341521|Drug|OC000459|Taken orally for 8 days
79582805|NCT01940315|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
80032206|NCT03044548|Other|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
79582806|NCT01940328|Device|Transchoracic ultrasound Doppler|
79279637|NCT02234453|Device|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
79279638|NCT05230797|Drug|Zinc oxide Propolis|antibacterial and anti-inflammatory
79279639|NCT05230797|Drug|Zinc Oxide-Eugenol Cement|Antimicrobial and antiseptic
79279640|NCT02039349|Drug|PF-05190457|
79279641|NCT02234609|Device|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
80032207|NCT03044938|Drug|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
79741656|NCT04314830|Device|Gait training without perturbation|Walking on a treadmill with steady belt speed
79279642|NCT02341365|Other|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
79741657|NCT01151540|Drug|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
79741658|NCT02884466|Behavioral|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
79741659|NCT02883998|Other|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
79279643|NCT02299609|Other|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
79741660|NCT02883998|Other|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
79741661|NCT01163786|Drug|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
79279644|NCT04899999|Behavioral|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
79279645|NCT04899999|Behavioral|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
79279646|NCT04899999|Behavioral|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
79582807|NCT01940367|Device|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
79582808|NCT01940367|Device|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~Mode: Burst~Cycle: 10 seconds~Frequency: 10 Hz~Pulse Width: 250 µs~Intensity: to subject comfort level"
79582809|NCT01940393|Drug|Cetirizine|Drug administration
79582810|NCT01940393|Drug|Desloratadine|Drug Administration
79582811|NCT01940393|Drug|Fexofenadine|Drug administration
79582812|NCT01940393|Drug|Ebastine|Drug administration
79582813|NCT01940393|Drug|Bilastine|Drug administration
79582814|NCT01940406|Procedure|Stimulation procedure|Device
79582815|NCT01940419|Drug|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
79582816|NCT01940419|Drug|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
79279647|NCT04899999|Behavioral|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
80032208|NCT03044938|Drug|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
80032209|NCT03045484|Drug|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
80032210|NCT03045484|Other|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
80032211|NCT04874506|Drug|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
80032212|NCT04867876|Behavioral|Physical Therapy|Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
80032213|NCT04429672|Behavioral|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
79279648|NCT02299687|Drug|Omeprazole|
79279649|NCT02349243|Drug|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
79279650|NCT02349243|Drug|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
79279651|NCT03513289|Other|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
79279652|NCT02341131|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
79279653|NCT02341131|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
79741662|NCT00984282|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
79279654|NCT02341209|Drug|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
79876940|NCT01029444|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
79876941|NCT01024452|Device|DAWN AC|computerized dosing management system for anticoagulation clinics
79876942|NCT01024452|Device|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
79279655|NCT02349165|Procedure|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
79279656|NCT02349165|Drug|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
79279657|NCT02349165|Drug|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
79279658|NCT02302963|Device|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
79279659|NCT02302963|Device|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
79279660|NCT03112005|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
79279661|NCT03112005|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
79279662|NCT02341053|Other|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
79279663|NCT02303197|Drug|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
79876943|NCT03995394|Other|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
79876944|NCT01029522|Drug|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
79876945|NCT01029522|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
79279664|NCT03111849|Other|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
79405203|NCT00782379|Drug|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
79741663|NCT00984282|Drug|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
79741664|NCT01147874|Procedure|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
79741665|NCT04292184|Drug|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
79876946|NCT00447876|Biological|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
79876947|NCT00447876|Drug|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
79876948|NCT01029600|Procedure|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
79279665|NCT03507361|Other|HRV-BASED MUSIC|Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
79876949|NCT01029600|Procedure|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
79876950|NCT01565772|Radiation|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
79279666|NCT03111771|Procedure|carcinological surgery|carcinological surgery for Group K +
79279667|NCT03111771|Procedure|cervical surgery|cervical surgery for Group K-
79405204|NCT00782379|Drug|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
79741666|NCT01147640|Drug|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
79876951|NCT01565772|Drug|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
79876952|NCT01565772|Drug|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
79876953|NCT03995550|Drug|LEO 142397|A compound in development by LEO Pharma A/S
79876954|NCT03995550|Drug|Placebo|Placebo
79279668|NCT02306785|Drug|TP05 Coating D|One radio-labelled tablet given to subjects
79279669|NCT02306785|Drug|TP05 Coating E|One radio-labelled tablet given to subjects
79279670|NCT02306785|Drug|TP05 Coating H|One radio-labelled tablet given to subjects
79279671|NCT03148587|Behavioral|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
79405205|NCT00782379|Drug|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
79741667|NCT01147640|Drug|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
79876955|NCT00456612|Procedure|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
79741668|NCT02867982|Procedure|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
79741669|NCT02867982|Procedure|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
79876956|NCT00456300|Drug|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
79876957|NCT00456300|Drug|Insulin|Each subject received a baseline study with insulin alone
79876958|NCT00267748|Drug|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
79876959|NCT00267748|Drug|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
79876960|NCT00267202|Drug|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
79876961|NCT00267202|Drug|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
79902255|NCT01698918|Drug|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
79902256|NCT01698918|Drug|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
79902257|NCT01698918|Drug|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
79902258|NCT01495403|Drug|Hydroxychloroquine|daily dosing
79902259|NCT01347697|Procedure|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
79902260|NCT01347697|Procedure|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
79902261|NCT01208974|Procedure|Nipple-Sparing Mastectomy|Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
79902262|NCT01208974|Procedure|Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
79902263|NCT01208974|Procedure|Axillary Surgery|Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
79902264|NCT01208974|Radiation|Prophylactic Nipple-Areolar Complex RT|Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
79902265|NCT00897117|Genetic|gene expression analysis|Blood and lung tissue collection
79902266|NCT00897117|Genetic|microarray analysis|Blood and lung tissue collection
79902267|NCT00897117|Genetic|protein expression analysis|Blood and lung tissue collection
79902268|NCT00897117|Other|biologic sample preservation procedure|Blood and lung tissue collection
79902269|NCT00897117|Other|laboratory biomarker analysis|Blood and lung tissue collection
79741670|NCT02867982|Drug|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
79279672|NCT03148587|Behavioral|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
79279673|NCT02306863|Device|vibrating chair|vibration provided via physioacoustic method
79279674|NCT02306863|Device|sham treatment|simulated whole-body vibration
79582817|NCT01940432|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
79741671|NCT02867982|Device|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
79405206|NCT00782379|Procedure|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
79876962|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
80032214|NCT04429672|Behavioral|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
80032215|NCT04874428|Drug|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
80032216|NCT04874428|Drug|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
80032217|NCT04863976|Other|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
79741672|NCT02867982|Radiation|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
79741673|NCT02884154|Device|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
79405207|NCT00782379|Procedure|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
79876963|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
80032218|NCT04863976|Other|Passive stretching|passive stretching of the quadriceps muscle
80032219|NCT04863976|Other|Self-stretching|Self-stretching of the quadriceps muscle
80032220|NCT04864288|Device|Shear Wave Elastography|is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves
80032221|NCT04867720|Drug|Everolimus|- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~8mg/mL.
80032222|NCT02799069|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
80032223|NCT02799069|Drug|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
79405208|NCT04637334|Procedure|Superior vena cava reconstruction|Endovascular therapy with percutaneous transluminal angioplasty (PTA) and, in recent years, with stenting of the SVC, has been performed with increasing frequency. An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because long-term durability of this treatment method remains to be assessed.
79741674|NCT01121900|Drug|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
79741675|NCT01121900|Drug|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
79741676|NCT00625040|Other|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
79279675|NCT03112239|Device|Light-Emitting Diode Therapy (LEDT)|Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
79279676|NCT02340741|Procedure|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
79279677|NCT02340741|Procedure|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
79279678|NCT02340741|Procedure|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
80032224|NCT02799069|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
79741677|NCT01121666|Drug|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
79279679|NCT02299765|Drug|Gefitinib|patients in arm A will be given gefitinib as target therapy
79279680|NCT02299765|Drug|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
79279681|NCT02299765|Drug|carboplatin|patients in arm A will be given carboplatin chemotherapy
79582818|NCT01940432|Behavioral|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
79405209|NCT04572828|Procedure|Paracervical Block|Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.
79582819|NCT01940445|Device|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
79582820|NCT01940445|Device|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
79741678|NCT00984126|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
79741679|NCT00984126|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
79741680|NCT02867748|Procedure|TVT-Abbrevo|
79741681|NCT02867748|Procedure|Serasis|
79741682|NCT02867514|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
79279682|NCT03112395|Device|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
79741683|NCT02868060|Drug|Romiplostim|
79741684|NCT02868996|Drug|Recombinant human tissue kallikrein|Intravenous DM199
79741685|NCT04290702|Procedure|regional analgesia for labor|three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
79741686|NCT00629226|Biological|cetuximab|Given IV
79279683|NCT02299843|Procedure|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
79279684|NCT02299843|Procedure|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
79279685|NCT03510559|Drug|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
79279686|NCT03510559|Drug|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
79279687|NCT04771923|Drug|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
79279688|NCT04771923|Drug|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
79405210|NCT04572828|Drug|550 mg Naproxen Sodium 60 minutes before the procedure|550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
79582821|NCT01940536|Drug|Tranexamic Acid|antifibrinolytic
79582822|NCT01940536|Drug|Placebo|Placebo
79741687|NCT00629226|Drug|bortezomib|Given IV
79741688|NCT00629226|Drug|cisplatin|Given IV
79741689|NCT00629226|Radiation|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
79741690|NCT04291326|Diagnostic Test|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
79741691|NCT00979602|Biological|GSK2340274A|One intramuscular injection
80032225|NCT01669174|Drug|Placebo|
80032226|NCT01669174|Drug|BYM338|BYM338
80032227|NCT02060097|Dietary Supplement|Cocoa flavanol beverage|
80032228|NCT02060097|Dietary Supplement|Placebo beverage|
79582823|NCT01940549|Device|Trauma Focused Therapy + tDCS|
79582824|NCT01940562|Drug|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children < 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
80032229|NCT03045562|Drug|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
79876964|NCT01067638|Drug|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
79876965|NCT03977116|Drug|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
80032230|NCT03045562|Drug|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
80032231|NCT02062047|Procedure|FMSRP|FMSRP in a maximum of 24 hours.
80032232|NCT02062047|Drug|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
79582825|NCT01940575|Device|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
79582826|NCT01940575|Device|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
79582827|NCT01940588|Behavioral|Neuropsychoanalytic therapy|Psychotherapy, medication management
79582828|NCT01940601|Drug|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
79741692|NCT00979602|Biological|GSK2340273A|One intramuscular injection
79876966|NCT03977116|Drug|Placebo|These patients will receive placebo therapy after catheter ablation.
79876967|NCT01067794|Drug|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
80032233|NCT02062047|Procedure|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
80032234|NCT02062047|Other|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
80032235|NCT03047902|Other|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
80032236|NCT03047902|Other|Group 2- Parents will not be present for the Questionnaire|
80032237|NCT03045406|Drug|Apixaban|Tablets
80032238|NCT03045406|Drug|Dalteparin|Injections
79279689|NCT02306941|Behavioral|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
79876968|NCT00267046|Drug|Palifermin|180 mcg/kg 3 days prior to chemotherapy
79279690|NCT04631549|Drug|SHR3680|SHR3680, PO, single dose
79279691|NCT02303275|Behavioral|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
79405211|NCT04572828|Procedure|The capped needle|The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
79405212|NCT05316597|Behavioral|Forest bathing|Participants will be seated in a forest environment for an hour-long exposure to the forest
79279692|NCT02303275|Behavioral|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
79405213|NCT05318391|Diagnostic Test|Gene expression profile|"Diagnostic Test:~The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)"
79405214|NCT05134350|Drug|LOXO-305|Oral LOXO-305
79876969|NCT00267046|Drug|Placebo|Single dose 3 days prior to chemotherapy
79876970|NCT00267046|Drug|Adriamycin (Doxorubicin)|30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).
79405215|NCT05134350|Drug|Omeprazole|Oral omeprazole
79405216|NCT05129826|Behavioral|the association between periodontitis and malnutrition status|be determine the association between periodontitis and malnutrition status in older adult.
80032239|NCT02798835|Drug|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
80032240|NCT02798835|Drug|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
79582829|NCT01940601|Drug|Filgrastim|Filgrastim 5 μg/kg
79741693|NCT02866734|Other|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
79741694|NCT02866734|Other|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
79741695|NCT02866734|Other|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
79741696|NCT00629304|Device|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
79741697|NCT00629304|Device|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
79741698|NCT00629304|Device|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
79279693|NCT02307019|Other|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
79279694|NCT02307019|Other|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
79279695|NCT04616573|Device|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
79741699|NCT00816361|Drug|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
79582830|NCT01940614|Other|Water deprivation test|Classical water deprivation test alone
79741700|NCT05297929|Drug|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
79741701|NCT00826111|Drug|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
79741702|NCT00826111|Drug|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
79741703|NCT00982644|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
79279696|NCT04616573|Device|iStent inject|Trabecular meshwork implantation
79279697|NCT02300155|Drug|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
79741704|NCT00982644|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
79741705|NCT00815659|Drug|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
79741706|NCT02867904|Drug|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
79279698|NCT02300155|Drug|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
79741707|NCT02867904|Drug|Marcaine (4ml 0.5%, injection)|Control
79279699|NCT03510403|Device|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
79279700|NCT02234765|Other|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
79279701|NCT02234765|Other|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
79279702|NCT03513133|Behavioral|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
79279703|NCT05254899|Drug|Anti-PD-1 monoclonal antibody|200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
79741708|NCT00825175|Behavioral|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
79741709|NCT00825175|Device|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
79741710|NCT04290936|Drug|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
79741711|NCT04290936|Drug|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
79741712|NCT00707941|Drug|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
79741713|NCT00707941|Drug|Placebo|"Children < 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
79741714|NCT02866890|Device|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
79741715|NCT04038931|Other|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
79279704|NCT05254899|Drug|Pegaspargase|3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
79279705|NCT05254899|Drug|Gemcitabine|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
79279706|NCT05254899|Drug|Oxaliplatin|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
79582831|NCT01940614|Other|Water deprivation test|classical water deprivation test plus plasma copeptin cut-off levels
79582832|NCT01940614|Other|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
79582833|NCT01940627|Dietary Supplement|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
79582834|NCT01940627|Dietary Supplement|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
79741716|NCT04290312|Other|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing ~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
79741717|NCT02867826|Device|Cap|Cap-assisted endoscopy
79279707|NCT05254899|Radiation|Involved site radiotherapy|Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
79582835|NCT01940640|Dietary Supplement|DHA|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
79279708|NCT02307097|Procedure|Cognitive-Behavioural Bibliotherapy|
79279709|NCT02307097|Procedure|Cognitive-Behavioural Therapy|
79279710|NCT02307097|Other|WAIT|
79279711|NCT03148509|Drug|risperidone|DA receptor-mediated drugs
79279712|NCT03148509|Drug|aripiprazole|DA receptor-mediated drugs
79279713|NCT03148509|Drug|bupropion|DA receptor-mediated drugs
79279714|NCT03148431|Drug|LY3002815|Administered IV
79279715|NCT03148431|Drug|Placebo|Administered IV
79279716|NCT04464343|Other|no intervention|This is an observation study, with no intervention
79405217|NCT05134194|Drug|Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
79405218|NCT05134194|Drug|Capecitabine/eribulin/gemcitabine/vinorelbine|Capecitabine or eribulin or gemcitabine or vinorelbine
79582836|NCT01940640|Dietary Supplement|control|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
79741718|NCT02867358|Drug|KT07 Capsule|
79741719|NCT02867358|Other|Placebo|
79741720|NCT00824473|Drug|Placebo|Placebo
79741721|NCT00824473|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
79741722|NCT04291092|Drug|Immunotherapy|Immunotherapy for brain metastasis
80032241|NCT02798835|Drug|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
80032242|NCT02798835|Drug|Bupivacaine|Used in spinal anesthetic
79741723|NCT04291092|Radiation|WBRT|local therapy for brain metastasis
79741724|NCT04291092|Drug|Chemotherapy|Chemotherapy for brain metastasis
79741725|NCT04041037|Device|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
79279717|NCT02039271|Other|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
79279718|NCT03507283|Procedure|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
79279719|NCT05254665|Drug|Docetaxel Polymeric Micelles for Injection|Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
80032243|NCT02798835|Drug|Fentanyl|May or may not be used in spinal anesthetic
79741726|NCT02867436|Other|Gluten-free diet|
79741727|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
79741728|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
79279720|NCT03513055|Other|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
79279721|NCT03148353|Procedure|Subacromial injection|"Modified ultrasound guided corticosteroid subacromial injection~Standardized ultrasound guided corticosteroid subacromial injection"
79279722|NCT03512977|Procedure|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
80032244|NCT02798835|Drug|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
79279723|NCT03512977|Drug|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
79405219|NCT04498728|Other|Mobile Health Application for Remote Monitoring|The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
79405220|NCT05129514|Other|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
79405221|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
79405222|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
79405223|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
79405224|NCT00761007|Drug|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
79741729|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
80032245|NCT02798835|Drug|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
79279724|NCT03148119|Drug|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a 5 amino acid linker [Gly-Gly-Gly-Ser-Lys] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
79876971|NCT00267046|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.
79279725|NCT03148119|Device|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
79279726|NCT03132727|Other|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
79279727|NCT02336919|Behavioral|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
79582837|NCT01940653|Drug|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
79582838|NCT01940679|Dietary Supplement|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
79582839|NCT01940692|Drug|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
79582840|NCT01940692|Drug|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
79741730|NCT02867280|Drug|Sorafenib|red round tablet
79741731|NCT00815191|Device|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
79279728|NCT02349009|Drug|C-82 Topical Gel, 1%|active
79741732|NCT00815191|Device|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
79741733|NCT04290390|Drug|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
79741734|NCT04290390|Drug|Rifampin|CYP3A inducer
79279729|NCT02349009|Drug|C-82 Topical Gel, Placebo|placebo
79741735|NCT04290390|Drug|Itraconazole|CYP3A inhibitor
79741736|NCT00708253|Device|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
79876972|NCT00267046|Drug|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
79876973|NCT00267046|Drug|Cisplatin|120 mg/m^2 on day 0, for patients receiving the AP Regimen.
79876974|NCT00441090|Drug|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
79279730|NCT03507205|Device|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
79876975|NCT00441090|Drug|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
79902270|NCT00897117|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
79279731|NCT03507205|Device|Xience Prime|Durable polymer-coated everolimus-eluting stents
79279732|NCT03507205|Device|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
79279733|NCT03507205|Device|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
79279734|NCT03507205|Device|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
79279735|NCT03507439|Device|AVIVO Mobile Patient Management (MPM) System|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
79279736|NCT03507439|Device|VitalPatch biosensor|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
79279737|NCT03507439|Device|DynaPort Move Monitor|Wearable device for ambulatory monitoring of physical activity, used by participants for 2 monitoring periods of 7 days each in the study
79279738|NCT03510325|Drug|Olanzapine|Commonly used oral antipsychotics intervention therapy.
79279739|NCT03510325|Drug|Risperidone|Commonly used oral antipsychotics intervention therapy.
79279740|NCT03510325|Drug|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
79279741|NCT03510325|Drug|Amisulpride|Commonly used oral antipsychotics intervention therapy.
79279742|NCT03510325|Drug|Paliperidone long-acting injection|long-acting injection
79902271|NCT00840177|Drug|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
79902272|NCT00840177|Drug|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
79902273|NCT00840177|Drug|pravastatin sodium|1,280 mg/day given orally on days 1-8
79902274|NCT00114985|Device|Prostate Immobilization Device|Device placed during radiation treatment
79902275|NCT01049867|Procedure|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
79902276|NCT01347580|Drug|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
79902277|NCT01347580|Drug|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
79902278|NCT00398411|Drug|moxifloxacin|400 mg p.o. per day
79876976|NCT03305406|Other|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
80032246|NCT03044236|Procedure|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
79279743|NCT02337075|Behavioral|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
79279744|NCT02337075|Device|Activity Mentor|
79582841|NCT01940718|Drug|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
79582842|NCT01940731|Drug|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
79582843|NCT01940744|Procedure|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
79741737|NCT00708253|Device|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
79741738|NCT04119960|Device|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
79741739|NCT00708331|Device|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
79741740|NCT04007952|Procedure|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
79876977|NCT03305406|Other|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
79876978|NCT00441012|Biological|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 & 12 months of age. Duration of treatment is 11 months.
79876979|NCT00441012|Biological|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
79876980|NCT01029678|Drug|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
79876981|NCT01029678|Drug|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
79279745|NCT03507127|Drug|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
79279746|NCT03507127|Drug|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
79279747|NCT02340351|Device|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
79279748|NCT02340351|Procedure|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
79279749|NCT02307409|Other|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
79279750|NCT02336841|Other|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
79279751|NCT02336841|Other|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
79876982|NCT01029678|Radiation|Radiotherapy|66Gy, 33 fractions, 6 week
79876983|NCT01323426|Procedure|Periurethral injection|Periurethral injection of autologous muscle fibers
79279752|NCT03512821|Drug|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
79279753|NCT03512821|Drug|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
79279754|NCT02336529|Drug|Bupivacaine|
79279755|NCT02336529|Drug|NaCl|
79279756|NCT04658433|Dietary Supplement|300 mg of omega3-FA|The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
79279757|NCT02307487|Drug|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
79279758|NCT02307487|Drug|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
79279759|NCT02307487|Drug|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
79279760|NCT02307487|Drug|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
79279761|NCT02307487|Drug|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
79279762|NCT02307487|Drug|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
79279763|NCT03148041|Other|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
79279764|NCT02349087|Device|Acute EEG with fast applicable EEG electrode|
79279765|NCT02307565|Drug|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
79279766|NCT02307565|Drug|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
79279767|NCT02340429|Device|DE500 Digital Video Otoscope|
79279768|NCT02307643|Drug|MT-1303 Low dose|
79405225|NCT00761085|Drug|Morphine|Standard of care for pain management of acute episode of pain
79582844|NCT01940744|Procedure|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
79582845|NCT01940783|Radiation|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
79279769|NCT02307643|Drug|MT-1303 High dose|
79279770|NCT02348931|Device|Use of customized nasal brace (Nasella) for nose deformities|
79279771|NCT02348931|Procedure|corrective surgery|
79279772|NCT05253885|Device|Smartphone use|"Smartphone addiction scale (short version) higher than 33~Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159*79*9 mm."
79279773|NCT02300389|Radiation|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
79279774|NCT02300389|Radiation|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
79279775|NCT02348853|Behavioral|Healthy Weight for Living (HWL)|
79279776|NCT02348853|Behavioral|Current Best Practice (CBP)|
79279777|NCT02300467|Drug|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
79279778|NCT04477551|Procedure|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
79279779|NCT04477551|Procedure|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
79405226|NCT00761085|Drug|Methadone|Compare to standard of care for pain management of acute episode of pain
79432967|NCT05582252|Other|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
79582846|NCT01940783|Device|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
79279780|NCT03510013|Procedure|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
79279781|NCT03510013|Drug|Sevoflurane|Drug used for wash-in protocol
79876984|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
80032247|NCT02061579|Behavioral|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
80032248|NCT03044470|Other|cryotherapy|Role of cryotherapy in reduction of post operative pain
80032249|NCT02061657|Drug|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
79405227|NCT02650128|Device|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
79405228|NCT02145039|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
79405229|NCT02145039|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
79405230|NCT02145039|Radiation|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
79405231|NCT02145039|Biological|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
79582847|NCT01940796|Drug|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
79582848|NCT01940848|Drug|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
79741741|NCT02866968|Procedure|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
79876985|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
79279782|NCT05253729|Device|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
79279783|NCT05253729|Behavioral|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
79279784|NCT03512665|Dietary Supplement|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
79876986|NCT00286468|Drug|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
79876987|NCT00507026|Drug|IV Diclofenac|IV Diclofenac q6h
79876988|NCT00507026|Drug|IV ketorolac|IV ketorolac q6h
79279785|NCT03512665|Dietary Supplement|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
79582849|NCT01940848|Drug|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
79876989|NCT00507026|Drug|Placebo|Placebo q6h
79279786|NCT03512665|Other|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
79876990|NCT00446550|Drug|afegostat tartrate|
79279787|NCT02340507|Other|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
79279788|NCT02340507|Other|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
79279789|NCT02307721|Drug|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
79405232|NCT03806205|Other|regular follow-up|we give a regular follow-up and supervision on the study group
79405233|NCT03806049|Drug|Niraparib|given orally once daily
79405234|NCT03806049|Drug|Bevacizumab|given as iv infusion every three weeks
79405235|NCT03806049|Drug|TSR042|Given as IV infusion every three weeks
79405236|NCT03806049|Drug|Carboplatin|given as iv infusion every three weeks
79405237|NCT03806049|Drug|Paclitaxel|given as iv infusion every three weeks
79582850|NCT01940913|Dietary Supplement|Probiotic capsules|
79582851|NCT01940913|Dietary Supplement|Placebo capsules|
79582852|NCT01940926|Drug|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
79582853|NCT01940952|Drug|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
79582854|NCT01940952|Drug|Placebo + Donepezil 5mg or 10mg|
79582855|NCT01940952|Drug|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
79741742|NCT04145310|Drug|BOL-DP-o-04 + SCO|sublingual drops
79741743|NCT04145310|Drug|Placebo + SCO|sublingual drops
79876991|NCT01029756|Device|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
79876992|NCT01029756|Device|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
79876993|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
79876994|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
79405238|NCT05133960|Other|Questionnaire assessment|Validity and reliability of the Turkish Version of the Activity Diversity Questionnaire
79405239|NCT04397562|Drug|Levilimab|Levilimab 324 mg
79582856|NCT01940965|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
80032250|NCT02061657|Drug|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
79876995|NCT01017224|Other|18F-FAZA|PET scan
79876996|NCT03847974|Drug|LIB003|300 mg SC Q4W
80032251|NCT03048136|Drug|Nivolumab|Specified dose on specified days
79876997|NCT01011842|Procedure|Radiotherapy|Standard of care
79876998|NCT01011842|Procedure|Align RT|Standard of care
79279790|NCT02307721|Drug|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
79279791|NCT02307721|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
79279792|NCT02307721|Device|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
79279793|NCT02348541|Device|CollaGUARD|
79279794|NCT03506815|Drug|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
79279795|NCT02348697|Biological|NOVOCART 3D|Autologous Chondrocyte Implantation
79582857|NCT01940965|Drug|biguanide|Pharmaceutical form:tablet Route of administration: oral
79582858|NCT01940965|Drug|TZD|Pharmaceutical form:tablet Route of administration: oral
79582859|NCT01940965|Drug|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
79582860|NCT01940965|Drug|glinide|Pharmaceutical form:tablet Route of administration: oral
79582861|NCT01940978|Drug|Methylphenidate ER|Watson generic, starting dose 18mg QD
79582862|NCT01940978|Drug|Cyproheptadine|cyproheptadine hydrochloride
79582863|NCT01941004|Drug|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
79582864|NCT01941004|Drug|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
79405240|NCT04397562|Drug|Placebo|Placebo
79405241|NCT02147301|Device|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
79405242|NCT01362270|Device|Verum Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
79405243|NCT01362270|Device|Sham Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
79405244|NCT04902612|Device|HM242-Solution|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
79582865|NCT01941056|Biological|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
79582866|NCT01941056|Other|laboratory biomarker analysis|Correlative studies
79876999|NCT01011920|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
79877000|NCT01011920|Drug|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
79877001|NCT01011920|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
79877002|NCT01011920|Drug|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
79902279|NCT00398411|Drug|placebo|one tablet per day p.o.
79902280|NCT03352414|Drug|Alvimopan|alvimopan pill
79902281|NCT03352414|Drug|Placebo|placebo pill
79902282|NCT00364793|Drug|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
79902283|NCT03351478|Drug|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
79902284|NCT03351478|Drug|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
79902285|NCT03351478|Drug|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
79902286|NCT03351478|Drug|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
79902287|NCT04572737|Behavioral|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
79902288|NCT00363545|Biological|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
79902289|NCT00363545|Biological|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
79902290|NCT01042301|Other|Blood samplings|
79902291|NCT03351244|Drug|BI 409306|28 week treatment period
79902292|NCT03351244|Drug|Placebo|28 week treatment period
79741744|NCT04290858|Drug|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
79279796|NCT03509935|Other|Intervention Ultrasound Group|"Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
79279797|NCT02336061|Behavioral|Evaluation of gender differences on the psychosocial and economic impact.|
79279798|NCT03506737|Other|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
79279799|NCT03506737|Other|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
79279800|NCT02442973|Procedure|Control group (CG): standard practice|Standard practice group
79279801|NCT02442973|Procedure|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
79279802|NCT02442973|Device|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
79279803|NCT02348463|Drug|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
79279804|NCT03512509|Other|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
79279805|NCT03512509|Other|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
79877003|NCT01011920|Radiation|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
79877004|NCT01011920|Drug|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
79582867|NCT01941069|Behavioral|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
79279806|NCT02340273|Device|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
80032252|NCT03048136|Drug|Ipilimumab|Specified dose on specified days
80032253|NCT03797859|Procedure|Apneic ventilation|Ventilation by THRIVE
79582868|NCT01941069|Behavioral|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
79582869|NCT01941082|Drug|RO6867461|Single or multiple ascending dose by intravitreal injection
79279807|NCT02340273|Device|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
79877005|NCT01011920|Other|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
80032254|NCT02062203|Drug|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
79279808|NCT02300623|Drug|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
79741745|NCT02866656|Other|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
79741746|NCT02866656|Device|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
79741747|NCT00812929|Drug|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
79877006|NCT01017302|Drug|Placebo|Subcutenaous once weekly for 4 weeks
79877007|NCT01017302|Drug|Placebo|Single subcutaneous dose in week 5
79877008|NCT01017302|Drug|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
79279809|NCT02300623|Drug|Antiretroviral therapy alone|Standard antiretroviral therapy
79877009|NCT01017302|Drug|RO5095932|Single subcutenaous dose in week 5
79279810|NCT04463953|Drug|Zanubrutinib,Ixazomib and Dexamethasone|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15；Ixazomib and dexamethasone every 4 weeks of a cycle, with induction of 6 cycles, and then maintain every 12 weeks, up to 6 cycles (96 cycles in total). Zanubrutinib is taken orally twice a day for up to 96 cycles, with a reduction in the last ID cycle. ZID regimen will continue 6 cycles after reaching the maximum response after introduction section.
79279811|NCT02340039|Dietary Supplement|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
79877010|NCT01019330|Other|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
80032255|NCT02062203|Drug|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
80032256|NCT02062203|Drug|Placebo|Single oral dose of placebo
80032257|NCT02062203|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
80032258|NCT04863820|Diagnostic Test|cutaneous silent period|form of Nerve conduction studies
79279812|NCT02336295|Other|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
79279813|NCT02307955|Device|firefly|
79279814|NCT02307955|Other|Standard of care|
79405245|NCT04902612|Device|Saline|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
79279815|NCT03147963|Drug|Docetaxel|Docetaxel will be given until progression or patient intolerance
79405246|NCT02147613|Other|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
79405247|NCT02147613|Other|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
79741748|NCT00812929|Drug|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
79741749|NCT04034017|Other|no intervention|descriptive study, no intervention
79741750|NCT05326555|Diagnostic Test|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
79741751|NCT00824161|Drug|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
79279816|NCT03512431|Diagnostic Test|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
79405248|NCT04413006|Behavioral|Self-Compassion for Chronic Pain Virtual Group Treatment Program|6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
79741752|NCT02610829|Dietary Supplement|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
79741753|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
79741754|NCT00979134|Drug|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
79741755|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
79741756|NCT00824005|Biological|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
79741757|NCT00824005|Biological|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
79741758|NCT04289844|Other|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
79741759|NCT04289844|Other|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
79741760|NCT05756647|Device|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
79741761|NCT05756647|Combination Product|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
79877011|NCT01019330|Other|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
79279817|NCT02348307|Drug|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
79279818|NCT02348307|Drug|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
79279819|NCT02303509|Drug|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
79279820|NCT02303509|Drug|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
79279821|NCT02303509|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
79405249|NCT02147769|Device|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
79405250|NCT04940676|Drug|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
79405251|NCT04940676|Drug|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
79405252|NCT00089479|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
79405253|NCT00089479|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
79405254|NCT00089479|Drug|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
79405255|NCT05057052|Drug|Sintilimab|Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
79405256|NCT05057052|Drug|Regorafenib|Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
79405257|NCT05057052|Combination Product|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
79741762|NCT05758051|Procedure|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
79877012|NCT03976102|Biological|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
79877013|NCT03976102|Other|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
79877014|NCT00506948|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
79279822|NCT02340117|Genetic|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
79279823|NCT02340117|Drug|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
79279824|NCT02340117|Drug|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
80032259|NCT04863742|Drug|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
80032260|NCT04863742|Drug|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
79582870|NCT01941121|Behavioral|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
79582871|NCT01941134|Drug|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
80032261|NCT02611882|Drug|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
79279825|NCT02300701|Drug|Xolair|According to manufacturer's instructions
79279826|NCT02300701|Drug|Placebo|Placebo
79279827|NCT02336139|Drug|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
79741763|NCT04290468|Device|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
79279828|NCT02300779|Dietary Supplement|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
80032262|NCT02611882|Device|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
79279829|NCT02300779|Dietary Supplement|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
79279830|NCT02340195|Drug|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
79279831|NCT02300857|Behavioral|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
80032263|NCT02611882|Device|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
79279832|NCT02300857|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
79279833|NCT02300857|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
79279834|NCT02339961|Radiation|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
79279835|NCT04464733|Drug|HRS9950|Group A to Group E: dose 1-dose 5, single dose Group F: dose 2, multiple doses Group C-: dose 3 food effect Group G to Group J: dose 2-dose4, multiple doses
80032264|NCT02060877|Other|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
79279836|NCT04464733|Drug|Placebo|Group A to Group J
79582872|NCT01941147|Device|pulsed ELF-MF|(75 Hz, 1,8 mT)
79582873|NCT01941160|Dietary Supplement|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
79582874|NCT01941160|Dietary Supplement|Placebo|Placebo capsule twice daily
79582875|NCT01941173|Biological|ziv-aflibercept|Given IV
79582876|NCT01941173|Drug|leucovorin calcium|Given IV
79741764|NCT04289610|Device|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
79741765|NCT00814879|Drug|Raltegravir|400 mg BID
79741766|NCT00814879|Drug|Atazanavir|300 mg BID
79741767|NCT00814879|Other|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
79279837|NCT02335827|Procedure|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
79741768|NCT04289532|Drug|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
79279838|NCT04465045|Procedure|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
79279839|NCT04421703|Behavioral|Med-South Lifestyle Program|The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
79279840|NCT02300935|Drug|trametinib|
79279841|NCT02300935|Drug|nab-paclitaxel|
79582877|NCT01941173|Drug|irinotecan hydrochloride|Given IV
79582878|NCT01941173|Drug|fluorouracil|Given IV
79582879|NCT01941199|Drug|DA-1229|
79741769|NCT02866422|Other|No Intervention|Observational Study: No intervention
79582880|NCT01941199|Drug|metformin|
79582881|NCT01941199|Drug|DA-1229 + metformin|
79582882|NCT01941212|Behavioral|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
79582883|NCT01941225|Drug|Inhaled iloprost 5.0 mcg|Single administration
79741770|NCT00708409|Procedure|Cardiac valve surgery|Different autograft implantation techniques.
79582884|NCT01941225|Drug|Placebo|Single administration
79582885|NCT01941264|Other|community based screening and treatment|Already described in intervention arm description.
79582886|NCT01941316|Drug|Carfilzomib|20/36 * mg/m2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
79582887|NCT01941316|Drug|Irinotecan|125 mg/m2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
79582888|NCT01941329|Procedure|Panretinal Photocoagulation (PRP)|
79582889|NCT01941329|Drug|Intravitreous injection of ranibizumab|
79582890|NCT01941342|Procedure|Pancreatoduodenectomy|
7958289